<?xml version="1.0" encoding="UTF-8" standalone="no" ?><xml><records><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40001</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sirisinha,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailand</style></auth-address><titles><title><style face="normal" font="default">The potential impact of gut microbiota on your health:Current status and future challenges</style></title><secondary-title><style face="normal" font="default">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="264" start="249">249-264</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clostridium</style></keyword><keyword><style face="normal" font="default"> Clostridium difficile</style></keyword><keyword><style face="normal" font="default"> Communication</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> diversity</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Engineering</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Fungi</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> Genome</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> Gut microbiota</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human health</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Lifestyle</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbes</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> mood</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parasites</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> Personalized medicine</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Probiotics</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutics</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Viruses</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">Our health and probably also our behaviors and mood depend not only on what we eat or what we do (lifestyle behaviors), but also on what we host. It is well established for decades that all vertebrates including humans are colonized by a wide array of bacteria, fungi, eukaryotic parasites and viruses, and that, at steady state (homeostasis), this community of microbes establishes a friendly mutual relationship with the host. The term microbiota was originally meant to represent an ecological community of commensals and potentially pathogenic microbes that live within our bodies, but it is now used interchangeably with the term microbiome which was initially meant to represent a collective genome of the microbiota. Although the number of microbes that live in or on our body was previously estimated to outnumber that of their hosts by 10 to 1, the latest estimate put the ratio to be closer to 1:1. On the other hand, their collective genomes (microbiome) outnumber those of the host by 100-200 times. It is not surprising therefore that these microbes not only provide the host with a variety of metabolic impact, but can also modulate tissue integrity and immune defense, all of which lead to a healthy ecosystem (symbiosis) that is unfavorable for colonization and invasion of pathogens. Microbiota is well known for its role in development and education of immune system. However, its link with diseases is less known and it is only recently that there is a surge of interest in the potential impact of microbiota on human health and disease. The diversity and composition of microbiota (healthy microbiota profile) are dynamics, depending not only on the host physical status, genotype and immune phenotype, but also on the environmental factors like diet, antibiotic usage and lifestyle behaviors. These environmental factors may adversely alter gut ecosystem (dysbiosis) that is frequently associated with increased susceptibility to infections as well as to non-communicable diseases like obesity, metabolic syndromes (e.g., diabetes and cardiovascular diseases), allergy and other inflammatory diseases. Emerging evidence from more recent studies also demonstrate the existence of a bidirectional communication route linking gut and microbiota with brain, thus suggesting that these microbes may play a role in neurological disorders as well as in host perception, behavior and emotional response. However, whether the observed alteration of the microbiota profile in these diverse conditions is the cause or the consequence of the disease remains to be established. These observations imply that it may be possible to design new strategies for the management of diseases by manipulating gut microbiota. The common practice now available is the use of probiotics to rehabilitate gut ecosystem. The microbiota-based therapeutics like fecal transplantation for the treatment of recurrent antibiotic-resistant Clostridium difficile infection is now under clinical trial and reported to be highly successful. In the next decade, we will probably see even more exciting approaches, for example, using advanced microbiota engineering technologies to create "intelligent" or "smart" bacteria for use in diagnosis, prevention, prediction and treatment of inflammatory diseases and possibly of some gastrointestinal cancers. The microbiota-based therapeutics together with personalized medicine may be the most accurate and optimal strategy for the future treatment of some difficult-to-manage diseases. However, many challenges remain to be solved before the translational potential of this new knowledge can be implemented clinically. In this review, I highlight some important recent developments and advances that contribute to our understanding in the role of microbiota in human health and disease and on how to best manipulate the microbiome to promote greater human health</style></abstract><notes><style face="normal" font="default">DA - 20170102IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="default">10.12932/AP0803</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28042926">PM:28042926</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2016-34-249-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2016-34-249-64.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170102, Sirisinha S</style></custom2><misc3><style face="normal" font="default">10.12932/AP0803</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40002</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Abdul Razak,M.R.</style></author><author><style face="normal" font="default"> Chirakalwasan,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary and Critical Care Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand</style></auth-address><titles><title><style face="normal" font="default">Obstructive sleep apnea and asthma</style></title><secondary-title><style face="normal" font="default">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="271" start="265">265-271</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Apnea</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Obstructive sleep apnea</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Sleep apnea</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">Both asthma and obstructive sleep apnea (OSA) are common conditions involving the adults and children population, and have significant impact on the healthcare system. For the last few decades a lot of data emerged in terms of the prevalence between asthma and OSA. The prevalence ranges from 38% up to as high as 70%. Based on the current concepts of bidirectional relationship of OSA and asthma, it is sensible to assume that treating one disorder will result in the other's better control and vice versa. This review will look into the pathogenesis of concomitant OSA and asthma and whether the first line OSA therapy will result in better control of asthma in patients with concomitant OSA. There is growing evidence that continuous positive airway pressure (CPAP) in adults and adenotonsillectomy in children which are recommended as first line treatment of OSA can improve their asthma symptoms. However, further confirmation is necessary with larger randomized control trials to further evaluate both conditions and the treatment effects</style></abstract><notes><style face="normal" font="default">DA - 20170102IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="default">10.12932/AP0828</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28042927">PM:28042927</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2016-34-265-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2016-34-265-71.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170102, Abdul Razak MR</style></custom2><misc3><style face="normal" font="default">10.12932/AP0828</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40003</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Min,H.J.</style></author><author><style face="normal" font="default"> Hong,Y.H.</style></author><author><style face="normal" font="default"> Yang,H.S.</style></author><author><style face="normal" font="default"> Kim,K.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology-Head and Neck Surgery, Chung-Ang University College of Medicine, 224-1, Heukseok-dong, Dongjak-gu, Seoul, Korea 156-755</style></auth-address><titles><title><style face="normal" font="default">The correlation of serum eosinophil cationic protein level with eosinophil count, and total IgE level in Korean adult allergic rhinitis patients</style></title><secondary-title><style face="normal" font="default">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="294" start="290">290-294</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> allergen sensitization</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> cationic protein</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> ECP</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Granules</style></keyword><keyword><style face="normal" font="default"> House dust</style></keyword><keyword><style face="normal" font="default"> house dust mite</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Nonallergic rhinitis</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pollen</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Eosinophil cationic protein (ECP) is present in eosinophil granules. It has been associated with eosinophil-associated disorders. OBJECTIVE: We compared serum ECP levels in allergic and non-allergic rhinitis patients and evaluated the association with the eosinophil count and the total IgE level. METHOD: We retrospectively reviewed medical records and categorized enrolled patients into the allergic (AR) and non-allergic rhinitis (NAR) groups. ECP, eosinophil count, and total IgE levels were reviewed in both groups. The association between ECP and the eosinophil count and total IgE level was further evaluated according to commonly detected specific antigens. RESULTS: Six hundred and ten adults were included in the study. In the AR group (n=349), the median age was 27.0(23.0-42.0) years and the female:male ratio was 0.26:1. In the NAR group (n=261), the median age was 32.0(24.0-45.5) years and the female:male ratio was 0.33:1. We found that ECP (AR: 18.8(9.9-31.4), NAR: 14.8(8.2-24.9), p=0.003), eosinophil count (AR: 191.0(112.0-308.5), NAR: 149.0(91.0-249.0), p=0.002) and total IgE (AR: 166.0(58.4-422.5), NAR: 68.8(24.5-141.0), p&lt;0.001) were higher in AR than in NAR patients. The ECP level was associated with the eosinophil count in both the AR (p&lt;0.001) and NAR groups (p&lt;0.001). A significant correlation between the ECP level and eosinophil count was demonstrated in AR patients who were skin test positive against house dust mite, animal and pollen allergens. CONCLUSIONS: We suggest that ECP could be an important mediator in the pathogenesis of AR. The level of serum ECP was positively correlated with eosinophilia in AR patients regardless of the type of allergen sensitization. However, further study is warranted to verify the role of ECP in the clinical management of allergic rhinitis</style></abstract><notes><style face="normal" font="default">DA - 20160630IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.12932/AP0739</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27362405">PM:27362405</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2016-34-290-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2016-34-290-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160630, Min HJ</style></custom2><misc3><style face="normal" font="default">10.12932/AP0739</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40004</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Steiner,M.</style></author><author><style face="normal" font="default"> Huber,S.</style></author><author><style face="normal" font="default"> Harrer,A.</style></author><author><style face="normal" font="default"> Himly,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy &amp; Immunology, Department of Molecular Biology, University of Salzburg, Salzburg, Austria</style></auth-address><titles><title><style face="normal" font="default">The Evolution of Human Basophil Biology from Neglect towards Understanding of Their Immune Functions</style></title><secondary-title><style face="normal" font="default">Biomed Res Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Biomed Res Int</style></abbr-1></periodical><pages end="" start="82328300">82328300-</pages><volume><style face="normal" font="default">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adaptive</style></keyword><keyword><style face="normal" font="default"> Adaptive immunity</style></keyword><keyword><style face="normal" font="default"> adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Austria</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic test</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evolution</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> IgE binding</style></keyword><keyword><style face="normal" font="default"> IgE-binding</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Molecular Biology</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Recombinant</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Being discovered long ago basophils have been neglected for more than a century. During the past decade evidence emerged that basophils share features of innate and adaptive immunity. Nowadays, basophils are best known for their striking effector role in the allergic reaction. They hence have been used for establishing new diagnostic tests and therapeutic approaches and for characterizing natural and recombinant allergens as well as hypoallergens, which display lower or diminished IgE-binding activity. However, it was a long way from discovery in 1879 until identification of their function in hypersensitivity reactions, including adverse drug reactions. Starting with a historical background, this review highlights the modern view on basophil biology</style></abstract><notes><style face="normal" font="default">DA - 20170112IS - 2314-6141 (Electronic)LA - engPT - ReviewPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="default">10.1155/2016/8232830</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28078302">PM:28078302</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biomed Res Int\2016-2016-82328300.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biomed Res Int\2016-2016-82328300.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170112, Steiner M</style></custom2><misc3><style face="normal" font="default">10.1155/2016/8232830</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40005</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Han,K.T.</style></author><author><style face="normal" font="default"> Bae,H.C.</style></author><author><style face="normal" font="default"> Lee,S.G.</style></author><author><style face="normal" font="default"> Kim,S.J.</style></author><author><style face="normal" font="default"> Kim,W.</style></author><author><style face="normal" font="default"> Lee,H.J.</style></author><author><style face="normal" font="default"> Ju,Y.J.</style></author><author><style face="normal" font="default"> Park,E.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Public Health, Graduate School, Yonsei University, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Are sleep disorders associated with increased mortality in asthma patients?</style></title><secondary-title><style face="normal" font="default">BMC Pulm Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Pulm Med</style></abbr-1></periodical><pages end="" start="154">154-</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> COX</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Increased prevalence</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Sleep Disorders</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="17" Month="11" Year="2016">2016/11/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: South Korea has experienced problems regarding poor management of symptoms of asthma patients and remarkable increases in sleep disorders. However, few studies have investigated these issues. We examined the relationship between sleep disorders and mortality in asthma patients to suggest effective alternatives from a novel perspective. METHODS: We used data from the National Health Insurance Service (NHIS) National Sample Cohort 2004-2013, which included medical claims filed for 186,491 patients who were newly diagnosed with asthma during the study period. We performed survival analyses using a Cox proportional hazards model with time-dependent covariates to examine the relationship between sleep disorders and mortality in asthma patients. RESULTS: There were 5179 (2.78%) patients who died during the study period. Sleep disorders in patients previously diagnosed with asthma were associated with a higher risk of mortality (hazard ratio [HR]: 1.451, 95% confidence interval [CI]: 1.253-1.681). In addition, significant interaction was found between sleep disorders and Charlson comorbidity index. CONCLUSIONS: Our findings suggest that an increased prevalence of sleep disorders in asthma patients increases the risk of mortality. Considering the worsening status of asthma management and the rapid growth of sleep disorders in South Korea, clinicians and health policymakers should work to develop interventions to address these issues</style></abstract><notes><style face="normal" font="default">DA - 20161118IS - 1471-2466 (Electronic)IS - 1471-2466 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1186/s12890-016-0313-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27855675">PM:27855675</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Muskuloskelet Disord\2016-16-154.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Muskuloskelet Disord\2016-16-154.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161118, Han KT</style></custom2><misc3><style face="normal" font="default">10.1186/s12890-016-0313-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40006</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Murdoch,B.</style></author><author><style face="normal" font="default"> Carr,S.</style></author><author><style face="normal" font="default"> Caulfield,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Health Law Institute, University of Alberta, Edmonton, Alberta, Canada</style></auth-address><titles><title><style face="normal" font="default">Selling falsehoods? A cross-sectional study of Canadian naturopathy, homeopathy, chiropractic and acupuncture clinic website claims relating to allergy and asthma</style></title><secondary-title><style face="normal" font="default">BMJ Open</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Open</style></abbr-1></periodical><pages end="" start="e014028">e014028-</pages><volume><style face="normal" font="default">6</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Advertising</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> British Columbia</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Columbia</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Homeopathy</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Marketing</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Ontario</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="16" Month="12" Year="2016">2016/12/16</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To identify the frequency and qualitative characteristics of marketing claims made by Canadian chiropractors, naturopaths, homeopaths and acupuncturists relating to the diagnosis and treatment of allergy and asthma. DESIGN: Cross-sectional study. SETTING: Canada. DATA SET: 392 chiropractic, naturopathic, homeopathic and acupuncture clinic websites located in 10 of the largest metropolitan areas in Canada, as identified using 400 Google search results. Duplicates were not excluded from data analysis. MAIN OUTCOME MEASURES: Mention of allergy, sensitivity or asthma, claim of ability to diagnose allergy, sensitivity or asthma, claim of ability to treat allergy, sensitivity or asthma, and claim of allergy, sensitivity or asthma treatment efficacy. Tests and treatments promoted were noted as qualitative examples. RESULTS: Naturopath clinic websites have the highest rates of advertising at least one of diagnosis, treatment or efficacy for allergy or sensitivity (85%) and asthma (64%), followed by acupuncturists (68% and 53%, respectively), homeopaths (60% and 54%) and chiropractors (33% and 38%). Search results from Vancouver, British Columbia were most likely to advertise at least one of diagnosis, treatment or efficacy for allergy or sensitivity (72.5%) and asthma (62.5%), and results from London, Ontario were least likely (50% and 40%, respectively). Of the interventions advertised, few are scientifically supported; the majority lack evidence of efficacy, and some are potentially harmful. CONCLUSIONS: The majority of alternative healthcare clinics studied advertised interventions for allergy and asthma. Many offerings are unproven. A policy response may be warranted in order to safeguard the public interest</style></abstract><notes><style face="normal" font="default">DA - 20161217IS - 2044-6055 (Electronic)IS - 2044-6055 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1136/bmjopen-2016-014028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27986744">PM:27986744</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Open\2016-6-e014028.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Open\2016-6-e014028.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161217, Murdoch B</style></custom2><misc3><style face="normal" font="default">10.1136/bmjopen-2016-014028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40007</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Newhouse,N.</style></author><author><style face="normal" font="default"> Martin,A.</style></author><author><style face="normal" font="default"> Jawad,S.</style></author><author><style face="normal" font="default"> Yu,L.M.</style></author><author><style face="normal" font="default"> Davoudianfar,M.</style></author><author><style face="normal" font="default"> Locock,L.</style></author><author><style face="normal" font="default"> Ziebland,S.</style></author><author><style face="normal" font="default"> Powell,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Nuffield Department of Primary Care Health Sciences, Health Experiences Research Group, University of Oxford, Oxford, UK</style></auth-address><titles><title><style face="normal" font="default">Randomised feasibility study of a novel experience-based internet intervention to support self-management in chronic asthma</style></title><secondary-title><style face="normal" font="default">BMJ Open</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Open</style></abbr-1></periodical><pages end="" start="e013401">e013401-</pages><volume><style face="normal" font="default">6</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic asthma</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Data Collection</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> England</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Feasibility Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> General practice</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Status</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Internet</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Self efficacy</style></keyword><keyword><style face="normal" font="default"> Self-management</style></keyword><keyword><style face="normal" font="default"> Sequence</style></keyword><keyword><style face="normal" font="default"> trends</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="12" Year="2016">2016/12/28</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To determine the feasibility of a randomised controlled trial (RCT) assessing the effects of an experience-based website as a resource for the self-management of chronic asthma. DESIGN AND SETTING: Feasibility, single-blind RCT in 2 regions of England. Randomisation used computer-generated random number sequence in a 1:1 ratio, after baseline data collection, to website access for 2 weeks. PARTICIPANTS: Adults (age >/=18 years), with clinically diagnosed asthma as coded in their primary care electronic record, prescribed inhaled corticosteroids for at least 3 months in the previous year, were recruited from 9 general practices. INTERVENTION: The EXPERT asthma intervention is an interactive PC/laptop/tablet/smartphone compatible website designed with extensive input from adults with asthma. It provides experience-based information and aims to support subjective perception of self-efficacy, self-management and improve health status. OUTCOME MEASURES: Primary outcomes were consent/recruitment, website usage and completion of outcome measures. Secondary outcomes included Partners in Health (PIH) questionnaire, the Chronic Disease Self-Efficacy Scale, the SF36 and the E-Health Impact Questionnaire. Participant blinding postrandomisation was not possible. The analysis was blind to allocation. RESULTS: Recruitment target exceeded. 148 participants randomised (73 intervention group). Age range 19-84 years; 59% female. 121 of 148 (84%; 62 intervention group) followed up. The median number of logins was 2 (IQR 2-3, range 1-48). Minimal differences of change from baseline between groups; both showed improvement in health state or management of their condition with no significant differences between arms. No adverse events. CONCLUSIONS: Recruitment and retention confirmed feasibility. The trends towards improved outcomes suggest that further research on digital interventions based on exposure to others' personal experiences may be of value in the self-management of chronic asthma. TRIAL REGISTRATION NUMBER: ISRCTN29549695; Results</style></abstract><notes><style face="normal" font="default">DA - 20161229IS - 2044-6055 (Electronic)IS - 2044-6055 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1136/bmjopen-2016-013401</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28031210">PM:28031210</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Open\2016-6-e013401.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Open\2016-6-e013401.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161229, Newhouse N</style></custom2><misc3><style face="normal" font="default">10.1136/bmjopen-2016-013401</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40008</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Apfelbacher,C.J.</style></author><author><style face="normal" font="default"> Jones,C.J.</style></author><author><style face="normal" font="default"> Frew,A.</style></author><author><style face="normal" font="default"> Smith,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Primary Care and Public Health, Brighton and Sussex Medical School, Brighton, UK</style></auth-address><titles><title><style face="normal" font="default">Validity of three asthma-specific quality of life questionnaires: the patients' perspective</style></title><secondary-title><style face="normal" font="default">BMJ Open</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Open</style></abbr-1></periodical><pages end="" start="e011793">e011793-</pages><volume><style face="normal" font="default">6</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Interviews</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> QOL</style></keyword><keyword><style face="normal" font="default"> Qualitative study</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Restaurants</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="22" Month="12" Year="2016">2016/12/22</year></dates><abstract><style face="normal" font="default">OBJECTIVES: It is not known which of the many asthma-specific quality of life (QoL) questionnaires best capture the lived experience of people with asthma. The objective of this study was to explore patients' views of three commonly used asthma-specific QoL questionnaires. DESIGN: Qualitative study using semistructured interviews. SETTING: Primary and secondary care in Brighton and Hove, UK. PARTICIPANTS: 30 adult people with a physician-diagnosis of asthma who were asked to complete the Juniper Asthma Quality of Life Questionnaire (AQLQ-J), the Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and the Living with Asthma Questionnaire (LWAQ) to elicit their views on the content validity of these. RESULTS: Thematic content analysis revealed a lack of congruence between the concerns of people with asthma and the questionnaire content in terms of missing (eg, allergies) and irrelevant (eg, smoky restaurants) content. The AQLQ-J was perceived as a 'narrow', 'medical' questionnaire focused on symptoms, the environment and functional ability. In contrast, the LWAQ and the AQLQ-S were perceived to be 'non-medical'. The LWAQ was described as a 'test' and as a wide-ranging, embracing and holistic questionnaire. Its strong emotional focus was irritating to some. The AQLQ-S was described as a simple, quick and easy questionnaire, although there was a perception that it was lacking in depth. CONCLUSIONS: Patient interviews highlighted strengths and shortcomings in the content validity of these three asthma-specific questionnaires. For patients, the AQLQ-S content seemed to be the most pertinent in its adequacy of coverage of medical, social and emotional aspects of health-related QoL in asthma</style></abstract><notes><style face="normal" font="default">DA - 20161223IS - 2044-6055 (Electronic)IS - 2044-6055 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1136/bmjopen-2016-011793</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28007706">PM:28007706</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Open\2016-6-e011793.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Open\2016-6-e011793.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161223, Apfelbacher CJ</style></custom2><misc3><style face="normal" font="default">10.1136/bmjopen-2016-011793</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40009</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Diepgen,T.L.</style></author><author><style face="normal" font="default"> Ofenloch,R.</style></author><author><style face="normal" font="default"> Bruze,M.</style></author><author><style face="normal" font="default"> Cazzaniga,S.</style></author><author><style face="normal" font="default"> Coenraads,P.J.</style></author><author><style face="normal" font="default"> Elsner,P.</style></author><author><style face="normal" font="default"> Goncalo,M.</style></author><author><style face="normal" font="default"> Svensson,A.</style></author><author><style face="normal" font="default"> Naldi,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Social Medicine, Occupational and Environmental Dermatology, University Hospital Heidelberg, Thibautstrasse 3, 69115, Heidelberg, Germany</style></auth-address><titles><title><style face="normal" font="default">Prevalence of fragrance contact allergy in the general population of five European countries: a cross-sectional study</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="1419" start="1411">1411-1419</pages><volume><style face="normal" font="default">173</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Age Distribution</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Fragrance allergy</style></keyword><keyword><style face="normal" font="default"> Fragrance mix</style></keyword><keyword><style face="normal" font="default"> Fragrances</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lactones</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Multicenter Studies</style></keyword><keyword><style face="normal" font="default"> Multicenter study</style></keyword><keyword><style face="normal" font="default"> Myroxylon</style></keyword><keyword><style face="normal" font="default"> Myroxylon pereirae</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Perfume</style></keyword><keyword><style face="normal" font="default"> Petrolatum</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Sesquiterpene lactones</style></keyword><keyword><style face="normal" font="default"> Sex Distribution</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="12" Year="2015">2015/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Contact allergy to fragrances is assessed mostly in clinical populations of patients. Studies in the general population are scarce and vary in their methodology across countries. OBJECTIVES: To determine the prevalence of fragrance contact allergy in the European general population and to assess the clinical relevance of positive patch test reactions to different fragrances. METHODS: In five European countries (Germany, Italy, the Netherlands, Portugal and Sweden) a random sample from the general population aged 18-74 years was drawn. In total, 12 377 subjects were interviewed in this cross-sectional study and a random sample (n = 3119) was patch tested using the TRUE Test and Finn Chamber techniques. Patch test procedures were harmonized by mandatory training before the study and monitoring during the study. RESULTS: The highest prevalence for contact allergy of 2.6% [95% confidence interval (CI) 2.1-3.2] was found for fragrance mix (FM) I in petrolatum, with a high content of atranol and chloratranol, followed by 1.9% (95% CI 1.5-2.4) for FM II in petrolatum. The conservatively estimated prevalence of fragrance contact allergy was 1.9% (95% CI 1.5-2.5). This is defined as the existence of a positive patch test to FM I or FM II; any of their individual materials; Myroxylon pereirae; sesquiterpene lactones or 3- and 4-hydroxyisohexyl 3-cyclohexene carboxaldehyde that show clinical relevance, defined conservatively as lifetime avoidance of scented products and an itchy skin rash lasting > 3 days in a lifetime. Using the reported lifetime prevalence of any contact dermatitis instead of the lifetime prevalence of any itchy skin rash, the prevalence is 0.8% (95% CI 0.5-1.2). The prevalence rates of contact allergy to fragrances in women are about twice those in men. CONCLUSIONS: This study helps to identify targets for prevention of fragrance allergy</style></abstract><notes><style face="normal" font="default">DA - 20151228IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - ENGPT - Journal ArticlePT - Multicenter StudyRN - 0 (Allergens)RN - 0 (Perfume)SB - IMCO - Italy -CO - Sweden -CO - Netherlands -CO - Germany -CO - Portugal -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.14151</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26332456">PM:26332456</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\2015-173-1411-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\2015-173-1411-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20151228, Diepgen TL</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.14151</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40010</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bennike,N.H.</style></author><author><style face="normal" font="default"> Zachariae,C.</style></author><author><style face="normal" font="default"> Duus,J.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Allergy Research Centre, Department of Dermatology and Allergy, Herlev-Gentofte Hospital, University of Copenhagen, 2900, Hellerup, DenmarkDepartment of Dermatology and Allergy, Herlev-Gentofte Hospital, University of Copenhagen, 2900, Hellerup, DenmarkNational Allergy Research Centre, Department of Dermatology and Allergy, Herlev-Gentofte Hospital, University of Copenhagen, 2900, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Trends in contact allergy to fragrance mix I in consecutive Danish eczema patients over three decades; a cross-sectional study from 1986 to 2015</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Fragrance mix</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> trends</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="18" Month="11" Year="2016">2016/11/18</year></dates><abstract><style face="normal" font="default">BACKGROUND: For more than 30 years, fragrance mix I (FMI) has been the most important screening marker for fragrance contact allergy. Meanwhile, governmental and corporate initiatives have been implemented, aimed at reducing sensitization to fragrance allergens, including the single constituents of FMI. OBJECTIVES: To examine trends in contact allergy to FMI from 1986 to 2015 in dermatitis patients, and test the hypothesis that sensitization to the fragrance screening marker has decreased within recent years. METHODS: Cross-sectional registry study on patch test results to FMI among consecutively tested dermatitis patients from a single university clinic across three 10-year periods. From 2006-2015, data on eczema location according to MOAHLFAA, clinical relevance of sensitization, and cosmetic exposures were available. RESULTS: Of 24,168 patients, 7.8% (95% CI: 7.4-8.1%) were sensitized to FMI. For women, a significant trend (p=0.004) was observed for an increase in sensitization to FMI across the three decades. From 2011-2015, the prevalence of contact allergy to FMI increased significantly for both women (8.0% versus 10.4%, p=0.002) and men (4.4% versus 7.3%, p=0.002) compared to the previous 5-year period. From 2006-2015, clinical relevance was established in 78.2% of FMI positive patients with no differences over time. An increase (28.6% versus 36.1%, p=0.05) in FMI positive patients suffering from facial dermatitis was observed for the period 2011-2015 compared to 2006-2010. CONCLUSIONS: The prevalence of contact allergy to FMI has been increasing within recent years. No effect of previous preventive initiatives could be demonstrated. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161118IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15180</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27861735">PM:27861735</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20161118-BennikeNH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20161118-BennikeNH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161118, Bennike NH</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15180</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40011</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Diepgen,T.L.</style></author><author><style face="normal" font="default"> Ofenloch,R.</style></author><author><style face="normal" font="default"> Bruze,M.</style></author><author><style face="normal" font="default"> Cazzaniga,S.</style></author><author><style face="normal" font="default"> Coenraads,P.J.</style></author><author><style face="normal" font="default"> Elsner,P.</style></author><author><style face="normal" font="default"> Goncalo,M.</style></author><author><style face="normal" font="default"> Svensson,A.</style></author><author><style face="normal" font="default"> Naldi,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Social Medicine, Occupational and Environmental Dermatology, University Heidelberg, Thibautstrasse 3, 69115, Heidelberg, Germany</style></auth-address><titles><title><style face="normal" font="default">Colophony as a marker for fragrance allergy in the general European population</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="696" start="695">695-696</pages><volume><style face="normal" font="default">174</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse effects</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Fragrance allergy</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Perfume</style></keyword><keyword><style face="normal" font="default"> Plant</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Resins,Plant</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2016">2016/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20160323IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - LetterRN - 0 (Perfume)RN - 0 (Resins, Plant)RN - 88S87KL877 (rosin)SB - IMCO - Germany -CO - Sweden -CO - Netherlands -CO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.14297</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26581543">PM:26581543</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\2016-174-695-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\2016-174-695-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160323, Diepgen TL</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.14297</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40012</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhao,C.Y.</style></author><author><style face="normal" font="default"> Hao,E.Y.</style></author><author><style face="normal" font="default"> Oh,D.D.</style></author><author><style face="normal" font="default"> Daniel,B.S.</style></author><author><style face="normal" font="default"> Martin,L.K.</style></author><author><style face="normal" font="default"> Su,J.C.</style></author><author><style face="normal" font="default"> Rodrigues,M.</style></author><author><style face="normal" font="default"> Murrell,D.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">St George Hospital, Sydney, Australia</style></auth-address><titles><title><style face="normal" font="default">A comparison study of clinician-rated atopic dermatitis outcome measures for intermediate to dark skin patients</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Iga</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="23" Month="12" Year="2016">2016/12/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis (AD) assessment is more difficult in patients with skin of colour (SOC). We sought to compare the reliability of commonly used outcome measures for assessing AD in SOC patients and evaluated a novel greyscale in this population. METHOD: Twenty-five AD patients each attended a one-day scoring exercise based in either Sydney or Melbourne, Australia. Each patient was scored by the same five physicians using the Eczema Area Severity Index (EASI), objective-Scoring Atopic Dermatitis score (oSCORAD), Investigator's Global Assessment (IGA) and a novel greyscale. Patients also completed the Patient-Oriented Eczema Measure (POEM) and quality of life measures. A mexameter was used for measuring baseline melanin indices. Ten random patients were re-scored to test intra-rater reliability. RESULTS: We included 11 light skinned patients (melanin index &lt;/=200) and 14 SOC patients (melanin index >200) in the cohort. The inter-rater ICCs were: EASI 0.827 (95% CI 0.658-0.941) for light skin and 0.774 (95% CI 0.598-0.906) for SOC; oSCORAD 0.680 (95% CI 0.441-0.880) for light skin and 0.736 (95%CI 0.544-0.889) for SOC; IGA 0.803 (95%CI 0.618-0.932) for light skin and 0.696 (95%CI 0.490-0.868) for SOC; the greyscale had an ICC of 0.776 (95%CI: 0.601-0.907) when replacing the EASI's erythema scale for SOC patients. All scores showed excellent intra-rater reliability for all skin types. Erythema component analysis showed that erythema did not contribute to variability. CONCLUSIONS: EASI showed excellent reliability for patients of all skin colours, and is recommended as the optimal core measure for patients with all skin colours. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161224IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15271</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28012183">PM:28012183</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20161224-ZhaoCY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20161224-ZhaoCY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161224, Zhao CY</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15271</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40013</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gonzalez-Lopez,G.</style></author><author><style face="normal" font="default"> Ceballos-Rodriguez,R.M.</style></author><author><style face="normal" font="default"> Gonzalez-Lopez,J.J.</style></author><author><style face="normal" font="default"> Feito,R.M.</style></author><author><style face="normal" font="default"> Herranz-Pinto,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: a systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Bandages</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="8" Month="11" Year="2016">2016/11/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Wet wrap therapy (WWT) consists of topical steroids administered under a layer of wet cotton bandages or garments. Several trials with WWT have reported promising results in atopic dermatitis (AD). However, no systematic review and meta-analysis on its efficacy and safety has been published. OBJECTIVES: To systematically review the literature on WWT in AD to assess its efficacy and safety. METHODS: We included randomized controlled trials among patients of all ages with a diagnosis of AD based on predefined criteria or performed by a dermatologist. Electronic searches were performed from 1970 to March 30, 2016, in the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and the WHO International Clinical Trials Registry. Selection of studies and data extraction was performed independently by two researchers, and discrepancies were resolved by consensus. RESULTS: 6 trials comparing WWT against topical steroids in children or adults with AD were included. Sample sizes ranged from 19 to 51 patients. Results on clinical severity and quality of life were reported incompletely and proved heterogeneous across studies. A nonsignificant tendency to increased risk of mild skin infections was observed in those treated with WWT (pooled relative risk 6.35; 95% confidence interval 0.83 to 48.55). The overall grade of quality of evidence for the efficacy and safety outcomes was low. CONCLUSIONS: The evidence that WWT is more effective than conventional treatment with topical steroids in AD is of low quality. Further clinical trials should establish the efficacy of WWT in AD. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161118IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15165</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27861727">PM:27861727</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20161118-GonzalezLopezG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20161118-GonzalezLopezG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161118, Gonzalez-Lopez G</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15165</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40014</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Strom,M.A.</style></author><author><style face="normal" font="default"> Fishbein,A.B.</style></author><author><style face="normal" font="default"> Paller,A.S.</style></author><author><style face="normal" font="default"> Silverberg,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Feinberg School of Medicine at Northwestern University, Suite 1600, 676 N. St. Clair St, Chicago, IL, 60611, U.S.A</style></auth-address><titles><title><style face="normal" font="default">Association between atopic dermatitis and attention deficit hyperactivity disorder in U.S. children and adults</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="929" start="920">920-929</pages><volume><style face="normal" font="default">175</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Itch</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis (AD) is associated with chronic itch, allergic disease and sleep disturbance, all of which might increase the risk of attention deficit (hyperactivity) disorder (ADD/ADHD). Previous analyses have found a consistent association between AD and ADD/ADHD, although the underlying factors contributing to such an association remain underexplored. Additionally, the relationship has been underexplored in adults. OBJECTIVES: To determine if childhood and adult AD and AD severity are associated with ADD/ADHD and to delineate the factors contributing to such an association. METHODS: We analysed data on 354 416 children aged 2-17 years and 34 613 adults age 18+ years from 19 U.S. population-based surveys, including the National Health Interview Survey 1997-2013 and the National Survey of Children's Health 2003/4 and 2007/8. RESULTS: In multivariate models adjusting for age, sex, sociodemographics, allergic disease and healthcare utilization, AD was associated with ADD/ADHD in both children [adjusted odds ratio (95% confidence interval), 1.14 (1.03-1.26)] and adults [1.61 (1.25-2.06)]. Children with both severe AD and only 0-3 nights of adequate sleep per week had much higher odds of ADD/ADHD [16.83 (7.02-40.33)] than those with 0-3 nights of adequate sleep per week [1.83 (1.47-2.26)] or mild-moderate AD alone [1.56 (1.22-1.99)]. AD was most strongly associated with severe ADHD. AD unaccompanied by other allergic disease was also associated with increased risk of ADD/ADHD in children. Among children with AD, history of anaemia, headaches and obesity were associated with even higher odds of ADD/ADHD. Asthma, insomnia and headaches increased the odds of ADHD in adults with AD, although underweight body mass index was protective. CONCLUSIONS: Atopic dermatitis is associated with increased odds of ADD/ADHD in adults and children. Several factors increase the risk of ADHD in adults and children with AD</style></abstract><notes><style face="normal" font="default">DA - 20160829IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - ENGPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.14697</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27105659">PM:27105659</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\2016-175-920-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\2016-175-920-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160829, Strom MA</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.14697</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40015</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Taylor,K.</style></author><author><style face="normal" font="default"> Swan,D.J.</style></author><author><style face="normal" font="default"> Affleck,A.</style></author><author><style face="normal" font="default"> Flohr,C.</style></author><author><style face="normal" font="default"> Reynolds,N.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Policy, Ethics and Life Sciences Research Centre, Newcastle University</style></auth-address><titles><title><style face="normal" font="default">Treatment of moderate-to-severe atopic eczema in adults within the UK: results of a national survey of dermatologists</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic eczema</style></keyword><keyword><style face="normal" font="default"> Azathioprine</style></keyword><keyword><style face="normal" font="default"> bias</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Decision Making</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ethics</style></keyword><keyword><style face="normal" font="default"> Flare</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Methotrexate</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral corticosteroids</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Recall</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic therapy</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="12" Year="2016">2016/12/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Little is known about UK dermatologists' treatment approaches towards adult patients with recalcitrant moderate-to-severe atopic eczema. OBJECTIVES: We wanted to learn about the i) treatment approaches used for this disease in the UK; ii) factors that influence treatment decisions; and iii) perceived gaps in evidence on treatment safety and efficacy and priorities for future trials. METHODS: We conducted an online survey of consultant-level dermatologists in the UK. RESULTS: 61 respondents from at least 35 centres reported on management of moderate-to-severe atopic eczema in adults, outwith the context of an acute flare. Phototherapy/PUVA was the most common therapeutic modality chosen as first-line (46%), and this was usually narrowband UVB. Systemic therapy was chosen as a first-line approach by 36% of dermatologists, with most using azathioprine (46%), followed by oral corticosteroids (43%), ciclosporin (37%) and methotrexate (25%). Methotrexate was the most common second-line treatment, chosen by 49% of respondents. The key factors that influenced decision-making on the use of phototherapy and systemic agents were: respondent's clinical experience, results of baseline tests (systemic agents), and knowledge of both efficacy and acute and chronic side-effect profiles. The most important evidence gaps identified were: the relative effectiveness of treatments, the alternatives to current approaches and the safety of long-term maintenance treatment. With regard to future trials, respondents suggested that priority should be given to studies involving methotrexate. CONCLUSIONS: While survey study designs have limitations, including the possibility of selection and recall bias, we found that phototherapy, in particular narrow-band UVB, was respondents' preferred first-line treatment for adults with recalcitrant moderate-to-severe atopic eczema, perhaps reflecting access to, and clinical experience of, this approach. Azathioprine is widely used as a longer-term maintenance treatment. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161212IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15235</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27943248">PM:27943248</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20161212-TaylorK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20161212-TaylorK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161212, Taylor K</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15235</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40016</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bensefa-Colas,L.</style></author><author><style face="normal" font="default"> Stocks,S.J.</style></author><author><style face="normal" font="default"> McNamee,R.</style></author><author><style face="normal" font="default"> Faye,S.</style></author><author><style face="normal" font="default"> Pontin,F.</style></author><author><style face="normal" font="default"> Agius,R.M.</style></author><author><style face="normal" font="default"> Lasfargues,G.</style></author><author><style face="normal" font="default"> Telle-Lamberton,M.</style></author><author><style face="normal" font="default"> Momas,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Occupational Diseases Department, University Hospital of Centre of Paris HOTEL DIEU, AP-HP, Paris, France</style></auth-address><titles><title><style face="normal" font="default">Effectiveness of the European Chromium VI Directive for cement implementation on occupational allergic contact dermatitis occurrence: Assessment in France and UK</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Chromium</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational disease</style></keyword><keyword><style face="normal" font="default"> Occupational Diseases</style></keyword><keyword><style face="normal" font="default"> Occupational Health</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Regulations</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="23" Month="12" Year="2016">2016/12/23</year></dates><abstract><style face="normal" font="default">Hexavalent chromium is the main sensitizer in wet cement and a common cause of occupational allergic contact dermatitis (OACD), especially among workers in the construction industry.1,2 The European Chromium VI directive3 transposed into national regulations in France and UK respectively on May and January 2005, prohibits selling or using of hydrated cement with more than 0.0002% of chromium. This was achieved through the addition of ferrous sulphate to the dry product, allowing to reduce chromium VI to chromium III which is less sensitizing. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161223IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - LetterCO - France -CO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15261</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28008593">PM:28008593</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20161223-BensefaColasL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20161223-BensefaColasL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161223, Bensefa-Colas L</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15261</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40017</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Roekevisch,E.</style></author><author><style face="normal" font="default"> Leeflang,M.M.</style></author><author><style face="normal" font="default"> Schram,M.E.</style></author><author><style face="normal" font="default"> Campbell,L.E.</style></author><author><style face="normal" font="default"> Irwin McLean,W.H.</style></author><author><style face="normal" font="default"> Kezic,S.</style></author><author><style face="normal" font="default"> Bos,J.D.</style></author><author><style face="normal" font="default"> Spuls,P.I.</style></author><author><style face="normal" font="default"> Middelkamp-Hup,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Academic Medical Center, Department of Dermatology, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Atopic dermatitis patients with filaggrin loss-of-function mutations show good but lower responses to immunosuppressive treatment</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Azathioprine</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Filaggrin</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Methotrexate</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="19" Month="11" Year="2016">2016/11/19</year></dates><abstract><style face="normal" font="default">Filaggrin (FLG) mutations are a strong risk factor to develop atopic dermatitis (AD). However, the relationship between FLG mutations and treatment outcome in AD has not been thoroughly studied. To investigate whether FLG mutations influence immunosuppressive treatment outcome in AD, we studied the effect of FLG mutations in patients with severe AD participating in a single blinded randomized controlled trial (RCT) with methotrexate (MTX) or azathioprine (AZA) during a 24 weeks treatment regimen.(1) Two years after randomization buccal mucosa swabs were collected from 36 of the 42 RCT patients (86%) to determine the FLG genotype status (R501X, 2282del4, R2447X, S3247X and 3321delA mutations). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161119IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - LetterCO - Netherlands -CO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15191</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27864930">PM:27864930</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20161119-RoekevischE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20161119-RoekevischE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161119, Roekevisch E</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15191</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40018</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jurado-Roman,A.</style></author><author><style face="normal" font="default"> Lopez-Lluva,M.T.</style></author><author><style face="normal" font="default"> Sanchez-Perez,I.</style></author><author><style face="normal" font="default"> Piqueras-Flores,J.</style></author><author><style face="normal" font="default"> Maseda,R.n</style></author><author><style face="normal" font="default"> Lozano-Ruiz-Poveda,F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Bioresorbable vascular scaffold to treat malignant in-stent restenosis in a patient with nickel allergy</style></title><secondary-title><style face="normal" font="default">Cardiovascular Revascular Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cardiovascular Revascular Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Alloys</style></keyword><keyword><style face="normal" font="default"> Bioresorbable vascular scaffold</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Nickel allergy</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Restenosis</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Stents</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutic alternative</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1553-8389</style></isbn><abstract><style face="normal" font="default">Abstract Nickel is the most frequent allergen in patients with allergic contact dermatitis and nickel allergy has been associated with recurrent in-stent restenosis. However, it is often misdiagnosed because of a low suspicion threshold. It should be discarded in patients with recurrent in-stent restenosis, especially if their medical history reveals prior contact dermatitis. It is also noteworthy and rarely specified that even newer generation stents that use novel metal alloys also contain low amounts of nickel. To avoid the implantation of new stents containing this metal, when percutaneous coronary intervention is indicated, drug eluting balloons or bioresorbable vascular scaffolds associated with small doses of steroids could provide good alternatives of treatment. To the best of our knowledge, this is the first description of this therapeutic alternative in such an exceedingly rare clinical scenario</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.carrev.2016.12.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28089777">PM:28089777</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cardiovascular Revascular Med\20170116-JuradoRomanA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cardiovascular Revascular Med\20170116-JuradoRomanA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170116, Jurado-Roman A</style></custom2><misc3><style face="normal" font="default">10.1016/j.carrev.2016.12.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40019</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Abraham,T.</style></author><author><style face="normal" font="default"> McGarry,D.P.</style></author><author><style face="normal" font="default"> Frith,J.</style></author><author><style face="normal" font="default"> Casselman,J.</style></author><author><style face="normal" font="default"> Tcheurekdjian,H.</style></author><author><style face="normal" font="default"> Hostoffer,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy and Immunology, University Hospitals, Regional Hospitals, Richmond Heights, OH, USA</style></auth-address><titles><title><style face="normal" font="default">Pure Cold-Induced Cholinergic Urticaria in a Pediatric Patient</style></title><secondary-title><style face="normal" font="default">Case Reports Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Case Reports Immunol</style></abbr-1></periodical><pages end="" start="7425601">7425601-</pages><volume><style face="normal" font="default">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Cold</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Cold urticaria and cholinergic urticaria are two distinct entities. The presentation of exclusive cold-induced cholinergic urticaria is very rare. The patient described herein had experienced urticaria in the exclusive setting of exercising in a cold environment. Urticarial testing including laboratory and in-office testing was all negative. The patient has prevented urticaria symptoms with oral antihistamine therapy. Pure cold-induced cholinergic urticaria is rarely described in literature. This form of urticaria has yet to be described in a pediatric patient</style></abstract><notes><style face="normal" font="default">DA - 20161227IS - 2090-6609 (Print)IS - 2090-6617 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1155/2016/7425601</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28025628">PM:28025628</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Case Reports Immunol\2016-2016-7425601.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Case Reports Immunol\2016-2016-7425601.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161227, Abraham T</style></custom2><misc3><style face="normal" font="default">10.1155/2016/7425601</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40020</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Erbas,B.</style></author><author><style face="normal" font="default"> Shrestha,S.K.</style></author><author><style face="normal" font="default"> Dharmage,S.C.</style></author><author><style face="normal" font="default"> Katelaris,C.</style></author><author><style face="normal" font="default"> Davies,J.</style></author><author><style face="normal" font="default"> Abramson,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Psychology and Public Health, La Trobe University, Melbourne, Vic., Australia</style></auth-address><titles><title><style face="normal" font="default">The effects of Air Pollution on asthma Hospital admissions in Adelaide, South Australia, 2003-2013: time series and case-crossover analysis</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="1624" start="1623">1623-1624</pages><volume><style face="normal" font="default">46</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> psychology</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time series</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161031IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12847</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27797423">PM:27797423</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\2016-46-1623-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\2016-46-1623-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161031, Erbas B</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12847</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40021</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jones,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy UK, Sidcup, Kent, UK</style></auth-address><titles><title><style face="normal" font="default">Allergy UK, a national patient organisation, response to the BSACI guideline: prescribing an adrenaline auto-injector</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="1620" start="1619">1619-1620</pages><volume><style face="normal" font="default">46</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adrenaline</style></keyword><keyword><style face="normal" font="default"> Adrenaline auto-injector</style></keyword><keyword><style face="normal" font="default"> Adrenaline autoinjector</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161128IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12854</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27893939">PM:27893939</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\2016-46-1619-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\2016-46-1619-20.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161128, Jones C</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12854</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40022</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Regent,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Anaphylaxis Campaign, Farnborough, Hampshire, UK</style></auth-address><titles><title><style face="normal" font="default">Response to the BSACI auto-injector guideline in Clinical &amp; Experimental Allergy</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="1618" start="1617">1617-1618</pages><volume><style face="normal" font="default">46</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161128IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12852</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27893942">PM:27893942</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\2016-46-1617-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\2016-46-1617-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161128, Regent L</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12852</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40023</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,K.</style></author><author><style face="normal" font="default"> Glonek,G.</style></author><author><style face="normal" font="default"> Hansen,A.</style></author><author><style face="normal" font="default"> Williams,S.</style></author><author><style face="normal" font="default"> Tuke,J.</style></author><author><style face="normal" font="default"> Salter,A.</style></author><author><style face="normal" font="default"> Bi,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Public Health, University of Adelaide, Adelaide, SA, Australia</style></auth-address><titles><title><style face="normal" font="default">Reply to 'Comments on the effects of air pollution on asthma hospital admissions in Adelaide, South Australia, 2003-2013: time series and case-crossover analyses'</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="141">141-</pages><volume><style face="normal" font="default">47</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time series</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161028IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12841</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27790759">PM:27790759</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\2017-41-141.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\2017-41-141.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161028, Chen K</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12841</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40024</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Harnan,S.E.</style></author><author><style face="normal" font="default"> Essat,M.</style></author><author><style face="normal" font="default"> Gomersall,T.</style></author><author><style face="normal" font="default"> Tappenden,P.</style></author><author><style face="normal" font="default"> Pavord,I.</style></author><author><style face="normal" font="default"> Everard,M.</style></author><author><style face="normal" font="default"> Lawson,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Health Economics and Decision Science, ScHARR, University of Sheffield</style></auth-address><titles><title><style face="normal" font="default">Exhaled nitric oxide in the diagnosis of asthma in adults: a systematic review</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> economics</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To identify and synthesise evidence on the diagnostic accuracy of FE NO for asthma in adults. MATERIALS AND METHODS: Systematic searches (nine key biomedical databases and trial registers) were carried out to November 2014. Records were included if they: recruited patients with the symptoms of asthma; used a single set of inclusion criteria; measured FE NO50 in accordance with American Thoracic Society guidelines, 2005 (off-line excluded); reported/allowed calculation of true positive, true negative, false positive and false negative patients as classified against any reference standard. Study quality was assessed using QUADAS II. Meta-analysis was planned where clinical study heterogeneity allowed. Rule-in and Rule-out uses of FE NO were considered. RESULTS: 4861 records were identified originally and 1312 in an update. 27 studies were included. Heterogeneity precluded meta-analysis. Results varied even within subgroups of studies. Cut-off values for the best sum of sensitivity and specificity varied from 12ppb to 55ppb, but did not produce high accuracy. 100% sensitivity or 100% specificity were reported by some studies indicating potential use as a rule-in or rule-out strategy. CONCLUSIONS: FE NO50 had variable diagnostic accuracy even within subgroups of studies with similar characteristics. Diagnostic accuracy, optimal cut-off values and best position for FE NO50 within a pathway remain poorly evidenced. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161201IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12867</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27906490">PM:27906490</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20161201-HarnanSE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20161201-HarnanSE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161201, Harnan SE</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12867</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40025</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mitchell,P.D.</style></author><author><style face="normal" font="default"> Salter,B.M.</style></author><author><style face="normal" font="default"> Oliveria,J.P.</style></author><author><style face="normal" font="default"> El-Gammal,A.</style></author><author><style face="normal" font="default"> Tworek,D.</style></author><author><style face="normal" font="default"> Smith,S.G.</style></author><author><style face="normal" font="default"> Sehmi,R.</style></author><author><style face="normal" font="default"> Gauvreau,G.M.</style></author><author><style face="normal" font="default"> Butler,M.</style></author><author><style face="normal" font="default"> O'Byrne,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Firestone Institute of Respiratory Health, Department of Medicine, Michael G DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="default">Glucagon Like Peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> agonists</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> allergen challenge</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Glucagon</style></keyword><keyword><style face="normal" font="default"> Glucose</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hormones</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Indications</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Ireland</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> LPS</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> Ontario</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Glucagon Like Peptide-1 (GLP-1) and its receptor are part of the incretin family of hormones the regulate glucose metabolism. GLP-1 also has immune modulatory roles. OBJECTIVES: To measure the expression of the GLP-1 receptor (GLP-1R) on eosinophils and neutrophils in normal and asthmatic subjects and evaluate effects of a GLP-1 analog on eosinophil function. METHODS: Peripheral blood samples were taken from 10 normal and 10 allergic asthmatic subjects. GLP-1R expression was measured on eosinophils and neutrophils. Subsequently, the asthmatic subjects underwent allergen and diluent inhalation challenges and GLP-1R expression was measured. Purified eosinophils, collected from mild asthmatic subjects, were stimulated with LPS and a GLP-1 analog to evaluate eosinophil cell activation markers CD11b and CD69 and cytokine (IL-4, IL-5, IL-8 and IL-13) production. RESULTS: GLP-1R is expressed on human eosinophils and neutrophils. Eosinophil, but not neutrophil, expression of GLP-1R is significantly higher in normal controls compared to allergic asthmatics. The expression of GLP-1R did not change on either eosinophils or neutrophils following allergen challenge. A GLP-1 analog significantly decreased the expression of eosinophil surface activation markers following LPS stimulation and decreased eosinophil production of IL-4, IL-8 and IL-13, but not IL-5. CONCLUSION &amp; CLINICAL RELEVANCE: GLP-1R is expressed on human eosinophils and neutrophils. A GLP-1 analog attenuates LPS-stimulated eosinophil activation. GLP-1 agonists may have additional adjunctive indications in treating persons with concomitant Type 2 diabetes mellitus and asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161208IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - Ireland -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12860</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27928844">PM:27928844</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20161208-MitchellPD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20161208-MitchellPD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161208, Mitchell PD</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12860</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40026</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cugno,M.</style></author><author><style face="normal" font="default"> Tedeschi,A.</style></author><author><style face="normal" font="default"> Nussberger,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Internal Medicine, IRCCS Maggiore Hospital, University of Milan, Milan, ItalyInternal Medicine, Fatebenefratelli Hospital, Milan, ItalyInternal Medicine, University Hospital, Lausanne, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Bradykinin in idiopathic non-histaminergic angioedema</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="140" start="139">139-140</pages><volume><style face="normal" font="default">47</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">angioedema</style></keyword><keyword><style face="normal" font="default"> Bradykinin</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161201IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - Italy -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12869</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27906489">PM:27906489</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\2017-41-139-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\2017-41-139-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161201, Cugno M</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12869</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40027</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Raap,U.</style></author><author><style face="normal" font="default"> Gehring,M.</style></author><author><style face="normal" font="default"> Kleiner,S.</style></author><author><style face="normal" font="default"> Rudrich,U.</style></author><author><style face="normal" font="default"> Eiz-Vesper,B.</style></author><author><style face="normal" font="default"> Haas,H.</style></author><author><style face="normal" font="default"> Kapp,A.</style></author><author><style face="normal" font="default"> Gibbs,B.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dept. of Dermatology and Allergy, Hannover Medical School, Germany</style></auth-address><titles><title><style face="normal" font="default">Human Basophils are Differentially Activated by and are a Source of IL-31</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anti-IgE</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> CD203c</style></keyword><keyword><style face="normal" font="default"> CD63</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Chemotaxis</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Histamine Release</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-3</style></keyword><keyword><style face="normal" font="default"> IL-31</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Oncostatin M</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Basophils are important effector cells involved in the pathogenesis of inflammatory skin diseases including chronic urticaria which is associated by increased IL-31 serum levels. So far the effects of IL-31 on human basophils are unknown. OBJECTIVE: To analyse the functional role of IL-31 in basophil biology. METHODS: IL-31 expression was evaluated in skin samples derived from chronic spontaneous urticaria patients. Oncostatin M receptor (OSMR), IL-31 receptor A (RA) and IL-31 protein expressions were analysed on human basophils from healthy donors. Basophil responses to IL-31 were assessed for chemotaxis, externalization of CD63 and CD203c as well as the release of histamine, IL-4 and IL-13. RESULTS: IL-31RA and OSMR were expressed on human basophils. IL-31 was strongly expressed in the skin of patients with chronic spontaneous urticaria and was released from isolated basophils following either anti-IgE, IL-3 or fMLP stimulation. IL-31 induced chemotaxis and the release of IL-4 and IL-13 which was specifically inhibited by anti-IL-31RA and anti-OSMR. Conversely, IL-31 had no effect on CD63 and CD203c externalization or histamine release. CONCLUSIONS AND CLINICAL RELEVANCE: Human basophils are a source of -and are activated by- IL-31 with the release of pro-inflammatory cytokines and the induction of chemotaxis indicating an important novel function of IL-31 in basophil biology. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161221IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cea.1287</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28000952">PM:28000952</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20161221-RaapU.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20161221-RaapU.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161221, Raap U</style></custom2><misc3><style face="normal" font="default">10.1111/cea.1287</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40028</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Porter,L.M.</style></author><author><style face="normal" font="default"> Cowburn,A.S.</style></author><author><style face="normal" font="default"> Farahi,N.</style></author><author><style face="normal" font="default"> Deighton,J.</style></author><author><style face="normal" font="default"> Farrow,S.N.</style></author><author><style face="normal" font="default"> Fiddler,C.A.</style></author><author><style face="normal" font="default"> Juss,J.K.</style></author><author><style face="normal" font="default"> Condliffe,A.M.</style></author><author><style face="normal" font="default"> Chilvers,E.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke's and Papworth Hospitals, Cambridge, UK</style></auth-address><titles><title><style face="normal" font="default">Hypoxia causes IL-8 secretion, Charcot Leyden crystal formation, and suppression of corticosteroid-induced apoptosis in human eosinophils</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Apoptosis</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical Medicine</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dexamethasone</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> fluticasone furoate</style></keyword><keyword><style face="normal" font="default"> GC</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Glucocorticoids</style></keyword><keyword><style face="normal" font="default"> glucocorticosteroids</style></keyword><keyword><style face="normal" font="default"> Glucose</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Staining</style></keyword><keyword><style face="normal" font="default"> suppression</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Up-Regulation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Inflamed environments are typically hypercellular, rich in pro-inflammatory cytokines, and profoundly hypoxic. While the effects of hypoxia on neutrophil longevity and function have been widely studied, little is known about the consequences of this stimulus on eosinophils. OBJECTIVE: We sought to investigate the effects of hypoxia on several key aspects of eosinophil biology; namely secretion, survival, and their sensitivity to glucocorticosteroids (GCS), agents which normally induce eosinophil apoptosis. METHODS: Eosinophils derived from patients with asthma/atopy or healthy controls were incubated under normoxia and hypoxia, with or without glucocorticoids. Activation was measured by flow cytometry, ELISA of cultured supernatants and F-actin staining; apoptosis and efferocytosis by morphology and flow cytometry, and GCS efficacy by apoptosis assays and qPCR. RESULTS: Hypoxic incubation (3 kPa) caused: (i) stabilisation of HIF-2alpha and up-regulation of hypoxia regulated genes including BNIP3 (BCL2/adenovirus E1B 19 kDa protein-interacting protein 3) and GLUT1 (glucose transporter 1), (ii) secretion of pre-formed IL-8, and Charcot Leyden crystal (CLC) formation, that was most evident in eosinophils derived from atopic and asthmatic donors, (iii) enhanced F-actin formation, (iv) marked prolongation of eosinophil lifespan (via a NF-kappaB and Class I PI3-kinase-dependent mechanism), and (v) complete abrogation of the normal pro-apoptotic effect of dexamethasone and fluticasone furoate. This latter effect was evident despite preservation of GCS-mediated gene transactivation under hypoxia. CONCLUSION AND CLINICAL RELEVANCE: These data indicate that hypoxia promotes an eosinophil pro-inflammatory phenotype by enhancing eosinophil secretory function, delaying constitutive apoptosis and importantly, antagonising the normal pro-apoptotic effect of GCS. Since eosinophils typically accumulate at sites that are relatively hypoxic, particularly during periods of inflammation, these findings may have important implications to understanding the behaviour these cells in vivo. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161221IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12877</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28000962">PM:28000962</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20161221-PorterLM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20161221-PorterLM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161221, Porter LM</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12877</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40029</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Esnault,S.</style></author><author><style face="normal" font="default"> Johansson,M.W.</style></author><author><style face="normal" font="default"> Kelly,E.A.</style></author><author><style face="normal" font="default"> Koenderman,L.</style></author><author><style face="normal" font="default"> Mosher,D.F.</style></author><author><style face="normal" font="default"> Jarjour,N.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Wisconsin-Madison School of Medicine and Public Health, Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine</style></auth-address><titles><title><style face="normal" font="default">IL-3 Up-regulates and Activates Human Eosinophil CD32 and alphaMss2 Integrin Causing Degranulation</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Affinity</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> allergen challenge</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Igg</style></keyword><keyword><style face="normal" font="default"> IL-3</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Eosinophils contribute to the pathogenesis of multiple diseases, including asthma. Treatment with antibodies targeting IL-5 or IL-5 receptor alpha reduces the frequency of asthma exacerbations. Eosinophil receptors for IL-5 share a common ss-chain with IL-3 and GM-CSF receptors. We recently reported that IL-3 is more potent than IL-5 or GM-CSF in maintaining the ERK/p90S6K/RPS6 ribosome-directed signaling pathway, leading to increased protein translation. OBJECTIVE: We aimed to determine disease-relevant consequences of prolonged eosinophil stimulation with IL-3. METHODS: Human blood eosinophils were used to establish the impact of activation with IL-3 on IgG-driven eosinophil degranulation, which was then compared to IgG-mediated degranulation of freshly isolated (unstimulated) airway eosinophils activated in vivo by segmental allergen challenge. RESULTS: When compared to IL-5, continuing exposure to IL-3 further induced degranulation of eosinophils on aggregated IgG via increased production and activation of both CD32 (low affinity IgG receptor) and alphaMss2 integrin. In addition, unlike IL-5 or GM-CSF, IL-3 induced expression of CD32B/C (FCGRIIB/C) subtype proteins, without changing CD32A (FCGRIIA) protein and CD32B/C mRNA expression levels. Importantly, these in vitro IL-3-induced modifications were recapitulated in vivo on airway eosinophils. CONCLUSIONS: We observed for the first time upregulation of CD32B/C on eosinophils, and identified IL-3 as a potent inducer of</style></abstract><notes><style face="normal" font="default">DA - 20161221IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12876</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28000949">PM:28000949</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20161221-EsnaultS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20161221-EsnaultS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161221, Esnault S</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12876</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40030</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Robinson,D.</style></author><author><style face="normal" font="default"> Humbert,M.</style></author><author><style face="normal" font="default"> Buhl,R.</style></author><author><style face="normal" font="default"> Cruz,A.A.</style></author><author><style face="normal" font="default"> Inoue,H.</style></author><author><style face="normal" font="default"> Korom,S.</style></author><author><style face="normal" font="default"> Hanania,N.A.</style></author><author><style face="normal" font="default"> Nair,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Severe Asthma Service, UCLH NHS Foundation Trust, London, UK</style></auth-address><titles><title><style face="normal" font="default">Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="175" start="161">161-175</pages><volume><style face="normal" font="default">47</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adaptive</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Characterization</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Endotypes</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Periostin</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> sputum eosinophil</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Asthma is a complex respiratory disorder characterized by marked heterogeneity in individual patient disease triggers and response to therapy. Several asthma phenotypes have now been identified, each defined by a unique interaction between genetic and environmental factors, including inflammatory, clinical and trigger-related phenotypes. Endotypes further describe the functional or pathophysiologic mechanisms underlying the patient's disease. Type 2-driven asthma is an emerging nomenclature for a common subtype of asthma and is characterized by the release of signature cytokines IL-4, IL-5 and IL-13 from cells of both the innate and adaptive immune systems. A number of well-recognized biomarkers have been linked to mechanisms involved in Type 2 airway inflammation, including fractional exhaled nitric oxide, serum IgE, periostin, and blood and sputum eosinophils. These Type 2 cytokines are targets for pharmaceutical intervention, and a number of therapeutic options are under clinical investigation for the management of patients with uncontrolled severe asthma. Anticipating and understanding the heterogeneity of asthma and subsequent improved characterization of different phenotypes and endotypes must guide the selection treatment to meet individual patients' needs. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161230IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - France -CO - Germany -CO - Brazil -CO - Japan -CO - Switzerland -CO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12880</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28036144">PM:28036144</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20161230-RobinsonD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20161230-RobinsonD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161230, Robinson D</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12880</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40031</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Akoto,C.</style></author><author><style face="normal" font="default"> Davies,D.E.</style></author><author><style face="normal" font="default"> Swindle,E.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, University Hospital Southampton, Southampton, UK</style></auth-address><titles><title><style face="normal" font="default">Mast cells are permissive for rhinovirus replication: potential implications for asthma exacerbations</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial epithelium</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> epithelia</style></keyword><keyword><style face="normal" font="default"> Epithelium</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate immunity</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinovirus</style></keyword><keyword><style face="normal" font="default"> Rhinoviruses</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Human rhinoviruses (HRVs) are a major trigger of asthma exacerbations, with the bronchial epithelium being the major site of HRV infection and replication. Mast cells (MCs) play a key role in asthma where their numbers are increased in the bronchial epithelium with increasing disease severity. OBJECTIVE: In view of the emerging role of MCs in innate immunity and increased localisation to the asthmatic bronchial epithelium, we investigated whether HRV infection of MCs generated innate immune responses which were protective against infection. METHODS: The LAD2 MC line or primary human cord blood-derived MCs (CBMCs) were infected with HRV or UV-irradiated HRV at increasing multiplicities of infection (MOI) without or with IFN-beta or IFN-lambda. After 24 h, innate immune responses were assessed by RT-qPCR and IFN protein release by ELISA. Viral replication was determined by RT-qPCR and virion release by TCID50 assay. RESULTS: HRV infection of LAD2 MCs induced expression of IFN-beta, IFN-lambda and IFN-stimulated genes. However, LAD2 MCs were permissive for HRV replication and release of infectious HRV particles. Similar findings were observed with CBMCs. Neutralisation of the type I IFN receptor had minimal effects on viral shedding suggesting that endogenous type I IFN signalling offered limited protection against HRV. However, augmentation of these responses by exogenous IFN-beta, but not IFN-lambda, protected MCs against HRV infection. CONCLUSION AND CLINICAL RELEVANCE: MCs are permissive for the replication and release of HRV which is prevented by exogenous IFN-beta treatment. Taken together these findings suggest a novel mechanism whereby MCs may contribute to HRV-induced asthma exacerbations. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161223IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12879</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28008678">PM:28008678</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20161223-AkotoC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20161223-AkotoC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161223, Akoto C</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12879</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40032</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hamann,C.R.</style></author><author><style face="normal" font="default"> Brankov,N.</style></author><author><style face="normal" font="default"> Hamann,D.</style></author><author><style face="normal" font="default"> Hamann,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Loma Linda University School of Medicine, Loma Linda, CA, USALoma Linda University School of Medicine, Loma Linda, CA, USADepartment of Internal Medicine, Division of Dermatology, The Ohio State University, Columbus, OH, USAContact Dermatitis Institute, Phoenix, AZ, USA</style></auth-address><titles><title><style face="normal" font="default">Chronic areolar dermatitis due to methylisothiazolinone-containing bodywash</style></title><secondary-title><style face="normal" font="default">Clin Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Dermatol</style></full-title></periodical><pages end="115" start="114">114-115</pages><volume><style face="normal" font="default">41</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disinfectants</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Ohio</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Soaps</style></keyword><keyword><style face="normal" font="default"> Thiazoles</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="1" Year="2016">2016/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20160115IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - ENGPT - Case ReportsPT - Journal ArticleRN - 0 (Disinfectants)RN - 0 (Soaps)RN - 0 (Thiazoles)RN - 229D0E1QFA (2-methyl-4-isothiazolin-3-one)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/ced.12712</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26189328">PM:26189328</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Dermatol\2016-41-114-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Dermatol\2016-41-114-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160115, Hamann CR</style></custom2><misc3><style face="normal" font="default">10.1111/ced.12712</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40033</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kasperska-Zajac,A.</style></author><author><style face="normal" font="default"> Grzanka,A.</style></author><author><style face="normal" font="default"> Mazur,B.</style></author><author><style face="normal" font="default"> Gwozdz,A.</style></author><author><style face="normal" font="default"> Zamlynski,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Diseases, Dermatology and Allergology, Medical University of Silesia in Katowice, Zabrze, Poland.Medical Center, Zabrze, Poland</style></auth-address><titles><title><style face="normal" font="default">Lower serum B12 vitamin concentrations are not accompanied by hyperhomocysteinaemia in chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default">Clin Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Dermatol</style></full-title></periodical><pages end="40" start="36">36-40</pages><volume><style face="normal" font="default">42</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergology</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Lower serum vitamin B12 concentrations have been observed in patients with chronic spontaneous urticaria (CSU). It is known that vitamin B12 deficiency is closely related to hyperhomocysteinaemia, which is associated with a proinflammatory state. AIM: To assess the relationship between vitamin B12 status and concentrations of homocysteine (Hcy) with acute phase response in patients with CSU. METHODS: Circulating concentrations of vitamin B12, Hcy and C-reactive protein (CRP) were measured in 42 patients with CSU of varying severity, and compared with 19 healthy controls (HCs). RESULTS: Significantly lower concentrations of vitamin B12 and higher concentrations of CRP were observed in the serum of the patients with CSU compared with HCs (P &lt; 0.01 and P &lt; 0.001, respectively). However, there were no significant differences in plasma Hcy concentrations between the investigated groups. In addition, no correlations were found between the concentrations of vitamin B12, Hcy and CRP. CONCLUSIONS: Lower values of vitamin B12 concentration in patients with CSU were not associated with higher Hcy concentrations, suggesting that such patients do not have functional vitamin B12 deficiency</style></abstract><notes><style face="normal" font="default">DA - 20161017IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Poland -</style></notes><work-type><style face="normal" font="default">10.1111/ced.12985</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27747917">PM:27747917</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Dermatol\2017-42-36-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Dermatol\2017-42-36-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161017, Kasperska-Zajac A</style></custom2><misc3><style face="normal" font="default">10.1111/ced.12985</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40034</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Smolkova,B.</style></author><author><style face="normal" font="default"> Tulinska,J.</style></author><author><style face="normal" font="default"> Palkovicova,M.L.</style></author><author><style face="normal" font="default"> Buocikova,V.</style></author><author><style face="normal" font="default"> Liskova,A.</style></author><author><style face="normal" font="default"> Rausova,K.</style></author><author><style face="normal" font="default"> Kuricova,M.</style></author><author><style face="normal" font="default"> Patayova,H.</style></author><author><style face="normal" font="default"> Sustrova,M.</style></author><author><style face="normal" font="default"> Neubauerova,S.E.</style></author><author><style face="normal" font="default"> Ilavska,S.</style></author><author><style face="normal" font="default"> Szabova,M.</style></author><author><style face="normal" font="default"> Nemessanyi,T.</style></author><author><style face="normal" font="default"> Jahnova,E.</style></author><author><style face="normal" font="default"> Dusinska,M.</style></author><author><style face="normal" font="default"> Ciznar,P.</style></author><author><style face="normal" font="default"> Fuortes,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia</style></auth-address><titles><title><style face="normal" font="default">Impact of IL13 Genetic Polymorphism Arg130Gln on Total Serum IgE Levels and IFN-gamma Gene Expression</style></title><secondary-title><style face="normal" font="default">Clin Exp Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> Biomedical Research</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> early childhood</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic susceptibility</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Norway</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> serum IgE levels</style></keyword><keyword><style face="normal" font="default"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> Slovakia</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Up-Regulation</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="5" Month="1" Year="2017">2017/1/5</year></dates><abstract><style face="normal" font="default">This cross-sectional study was designed to investigate the extent of genetic susceptibility by targeting variants in IL-4/IL-13 signalling pathways leading to atopic disease in early childhood. We evaluated involvement of five single nucleotide polymorphisms IL4 C-590T, IL13 C-1055T, IL13 Arg130Gln, IL4RA Ile50Val and IL4RA Ser478Pro, in the control of serum total and antigen-specific IgE levels. Furthermore, we analyzed their association with changes in gene expression of five cytokines having key roles in inflammatory and anti-inflammatory immune response (IL-4, IL-13, IFN-gamma, IL-8 and IL-10). Total and antigen-specific IgE levels in serum and gene expression of selected cytokines in peripheral blood were measured in 386 children aged 1 to 8 years. TaqMan allelic discrimination, ARMS-PCR and RFLP methods validated by sequencing were used for genotyping. All genotypes for children with total and antigen-specific IgE levels in the normal range were in Hardy-Weinberg equilibrium. Gene expression analyses were carried out using TaqMan Gene Expression Assays. We found elevated total IgE levels in carriers of IL13Arg130Gln variant allele (OR 1.84; 95% CI 1.16-2.93). This effect was more apparent for boys (OR 2.31; 95% CI 1.25-4.28). However, no significant association was observed for the other 4 variants examined. We found up-regulation of IFN-gamma in children with elevated serum total IgE levels carrying Arg130 allele (P=0.005). No differences were found for IL4, IL8 or IL10 while IL13 gene expression was under detection limit. IL13 Arg130Gln genotypes can play a role in genetic susceptibility to allergy via regulation of serum total IgE levels and affecting IFN-gamma gene expression. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1365-2249 (Electronic)IS - 0009-9104 (Linking)LA - engPT - Journal ArticleCO - Slovakia -CO - Norway -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/cei.12923</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28054352">PM:28054352</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Immunol\20170105-SmolkovaB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Immunol\20170105-SmolkovaB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, SMolkova B</style></custom2><misc3><style face="normal" font="default">10.1111/cei.12923</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40035</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Han,N.R.</style></author><author><style face="normal" font="default"> Moon,P.D.</style></author><author><style face="normal" font="default"> Ryu,K.J.</style></author><author><style face="normal" font="default"> Jang,J.B.</style></author><author><style face="normal" font="default"> Kim,H.M.</style></author><author><style face="normal" font="default"> Jeong,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Republic of KoreaDepartment of Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Republic of KoreaDepartment of Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Republic of KoreaDepartment of Pharmaceutical Engineering and Inflammatory, Disease Research Center, Hoseo University, Asan, Chungnam, 31499, Republic of KoreaDepartment of Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul, 02447, Republic of KoreaDepartment of food science &amp; technology, hoseo university, asan, chungnam, 31499, republic of korea</style></auth-address><titles><title><style face="normal" font="default">beta-eudesmol suppresses allergic reactions via inhibiting mast cell degranulation</style></title><secondary-title><style face="normal" font="default">Clin Exp Pharmacol Physiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Exp Pharmacol Physiol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> anti-allergic drug</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cell Degranulation</style></keyword><keyword><style face="normal" font="default"> Cell Line</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Engineering</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Histidine</style></keyword><keyword><style face="normal" font="default"> Histidine Decarboxylase</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE-dependent</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Passive Cutaneous Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> rat</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> VEGF</style></keyword></keywords><dates><year Day="14" Month="11" Year="2016">2016/11/14</year></dates><abstract><style face="normal" font="default">The regulatory effect of beta-eudesmol, which is an active constituent of Pyeongwee-San (KMP6), is evaluated for allergic reactions induced by mast cell degranulation. Phorbol 12-myristate 13-acetate (PMA) plus calcium ionophore A23187-stimulated human mast cell line, HMC-1 cells, and compound 48/80-stimulated rat peritoneal mast cells (RPMCs) are used as the in vitro models; mice models of systemic anaphylaxis, ear swelling, and IgE-dependent passive cutaneous anaphylaxis (PCA) are used as the in vivo allergic models. The results demonstrate that beta-eudesmol suppressed the histamine and tryptase releases from the PMA plus calcium ionophore A23187-stimulated HMC-1 cells. beta-eudesmol inhibits the expression and activity of histidine decarboxylase in the activated HMC-1 cells. In addition, beta-eudesmol inhibits the levels of histamine and tryptase released from the compound 48/80-stimulated RPMCs. Furthermore, beta-eudesmol decreases the intracellular calcium level in the activated RPMCs. beta-eudesmol also decreases the compound 48/80-induced mortality and ear swelling response. beta-eudesmol suppresses the serum levels of histamine, IgE, IL-1beta, IL-4, IL-5, IL-6, IL-13, and VEGF under PCA mice as well as PCA reactions. Therefore, the results from this study indicate the potential of beta-eudesmol as an anti-allergic drug with respect to its pharmacological properties against mast cell-mediated allergic reactions. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161118IS - 1440-1681 (Electronic)IS - 0305-1870 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1111/1440-1681.12698</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27862161">PM:27862161</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Pharmacol Physiol\20161118-HanNR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Pharmacol Physiol\20161118-HanNR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161118, Han NR</style></custom2><misc3><style face="normal" font="default">10.1111/1440-1681.12698</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40036</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tomazic,P.V.</style></author><author><style face="normal" font="default"> Graessel,A.</style></author><author><style face="normal" font="default"> Silva,D.</style></author><author><style face="normal" font="default"> Eguiluz-Gracia,I.</style></author><author><style face="normal" font="default"> Guibas,G.V.</style></author><author><style face="normal" font="default"> Grattan,C.</style></author><author><style face="normal" font="default"> Bousquet,J.</style></author><author><style face="normal" font="default"> Tsilochristou,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of General Otorhinolaryngology, H&amp;NS, Medical University of Graz, Graz, Austria</style></auth-address><titles><title><style face="normal" font="default">A mutually beneficial collaboration between the European Academy of Allergy and Clinical Immunology Junior Members and Clinical and Translational Allergy</style></title><secondary-title><style face="normal" font="default">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Transl Allergy</style></full-title></periodical><pages end="" start="43">43-</pages><volume><style face="normal" font="default">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Austria</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Publishing</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">The European Academy of Allergy and Clinical Immunology (EAACI) Junior Members (JM) comprise the largest EAACI section with around 4000 clinicians and scientists under 35 years of age working in the field of allergy and clinical immunology. The Junior Member collaboration with Clinical and Translational Allergy Journal is a mutually beneficial relationship providing Junior Members of EAACI with excellent opportunities to publish their work in the Journal, enhance their visibility in their respective field, and get involved with Journal-related activities and processes. In the future, this collaboration will grow, not only by the consolidation of these activities, but also by the implementation of new initiatives, such as a platform for discussing and/or publishing Junior Members' dissertations in the Journal. From the CTA perspective, the collaboration presents an opportunity to promote a new generation of allergists with experience of conducting and presenting research, with improved skills in critical review</style></abstract><notes><style face="normal" font="default">DA - 20161213IS - 2045-7022 (Linking)LA - engPT - EditorialCO - Austria -CO - Portugal -CO - Spain -CO - United Kingdom -CO - France -</style></notes><work-type><style face="normal" font="default">10.1186/s13601-016-0133-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27957322">PM:27957322</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Transl Allergy\2016-6-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Transl Allergy\2016-6-43.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161213, Tomazic PV</style></custom2><misc3><style face="normal" font="default">10.1186/s13601-016-0133-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40037</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bousquet,J.</style></author><author><style face="normal" font="default"> Hellings,P.W.</style></author><author><style face="normal" font="default"> Agache,I.</style></author><author><style face="normal" font="default"> Bedbrook,A.</style></author><author><style face="normal" font="default"> Bachert,C.</style></author><author><style face="normal" font="default"> Bergmann,K.C.</style></author><author><style face="normal" font="default"> Bewick,M.</style></author><author><style face="normal" font="default"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="default"> Bosnic-Anticevitch,S.</style></author><author><style face="normal" font="default"> Bucca,C.</style></author><author><style face="normal" font="default"> Caimmi,D.P.</style></author><author><style face="normal" font="default"> Camargos,P.A.</style></author><author><style face="normal" font="default"> Canonica,G.W.</style></author><author><style face="normal" font="default"> Casale,T.</style></author><author><style face="normal" font="default"> Chavannes,N.H.</style></author><author><style face="normal" font="default"> Cruz,A.A.</style></author><author><style face="normal" font="default"> De Carlo,G.</style></author><author><style face="normal" font="default"> Dahl,R.</style></author><author><style face="normal" font="default"> Demoly,P.</style></author><author><style face="normal" font="default"> Devillier,P.</style></author><author><style face="normal" font="default"> Fonseca,J.</style></author><author><style face="normal" font="default"> Fokkens,W.J.</style></author><author><style face="normal" font="default"> Guldemond,N.A.</style></author><author><style face="normal" font="default"> Haahtela,T.</style></author><author><style face="normal" font="default"> Illario,M.</style></author><author><style face="normal" font="default"> Just,J.</style></author><author><style face="normal" font="default"> Keil,T.</style></author><author><style face="normal" font="default"> Klimek,L.</style></author><author><style face="normal" font="default"> Kuna,P.</style></author><author><style face="normal" font="default"> Larenas-Linnemann,D.</style></author><author><style face="normal" font="default"> Morais-Almeida,M.</style></author><author><style face="normal" font="default"> Mullol,J.</style></author><author><style face="normal" font="default"> Murray,R.</style></author><author><style face="normal" font="default"> Naclerio,R.</style></author><author><style face="normal" font="default"> O'Hehir,R.E.</style></author><author><style face="normal" font="default"> Papadopoulos,N.G.</style></author><author><style face="normal" font="default"> Pawankar,R.</style></author><author><style face="normal" font="default"> Potter,P.</style></author><author><style face="normal" font="default"> Ryan,D.</style></author><author><style face="normal" font="default"> Samolinski,B.</style></author><author><style face="normal" font="default"> Schunemann,H.J.</style></author><author><style face="normal" font="default"> Sheikh,A.</style></author><author><style face="normal" font="default"> Simons,F.E.</style></author><author><style face="normal" font="default"> Stellato,C.</style></author><author><style face="normal" font="default"> Todo-Bom,A.</style></author><author><style face="normal" font="default"> Tomazic,P.V.</style></author><author><style face="normal" font="default"> Valiulis,A.</style></author><author><style face="normal" font="default"> Valovirta,E.</style></author><author><style face="normal" font="default"> Ventura,M.T.</style></author><author><style face="normal" font="default"> Wickman,M.</style></author><author><style face="normal" font="default"> Young,I.</style></author><author><style face="normal" font="default"> Yorgancioglu,A.</style></author><author><style face="normal" font="default"> Zuberbier,T.</style></author><author><style face="normal" font="default"> Aberer,W.</style></author><author><style face="normal" font="default"> Akdis,C.A.</style></author><author><style face="normal" font="default"> Akdis,M.</style></author><author><style face="normal" font="default"> Annesi-Maesano,I.</style></author><author><style face="normal" font="default"> Ankri,J.</style></author><author><style face="normal" font="default"> Ansotegui,I.J.</style></author><author><style face="normal" font="default"> Anto,J.M.</style></author><author><style face="normal" font="default"> Arnavielhe,S.</style></author><author><style face="normal" font="default"> Asarnoj,A.</style></author><author><style face="normal" font="default"> Arshad,H.</style></author><author><style face="normal" font="default"> Avolio,F.</style></author><author><style face="normal" font="default"> Baiardini,I.</style></author><author><style face="normal" font="default"> Barbara,C.</style></author><author><style face="normal" font="default"> Barbagallo,M.</style></author><author><style face="normal" font="default"> Bateman,E.D.</style></author><author><style face="normal" font="default"> Beghe,B.</style></author><author><style face="normal" font="default"> Bel,E.H.</style></author><author><style face="normal" font="default"> Bennoor,K.S.</style></author><author><style face="normal" font="default"> Benson,M.</style></author><author><style face="normal" font="default"> Bialoszewski,A.Z.</style></author><author><style face="normal" font="default"> Bieber,T.</style></author><author><style face="normal" font="default"> Bjermer,L.</style></author><author><style face="normal" font="default"> Blain,H.</style></author><author><style face="normal" font="default"> Blasi,F.</style></author><author><style face="normal" font="default"> Boner,A.L.</style></author><author><style face="normal" font="default"> Bonini,M.</style></author><author><style face="normal" font="default"> Bonini,S.</style></author><author><style face="normal" font="default"> Bosse,I.</style></author><author><style face="normal" font="default"> Bouchard,J.</style></author><author><style face="normal" font="default"> Boulet,L.P.</style></author><author><style face="normal" font="default"> Bourret,R.</style></author><author><style face="normal" font="default"> Bousquet,P.J.</style></author><author><style face="normal" font="default"> Braido,F.</style></author><author><style face="normal" font="default"> Briggs,A.H.</style></author><author><style face="normal" font="default"> Brightling,C.E.</style></author><author><style face="normal" font="default"> Brozek,J.</style></author><author><style face="normal" font="default"> Buhl,R.</style></author><author><style face="normal" font="default"> Bunu,C.</style></author><author><style face="normal" font="default"> Burte,E.</style></author><author><style face="normal" font="default"> Bush,A.</style></author><author><style face="normal" font="default"> Caballero-Fonseca,F.</style></author><author><style face="normal" font="default"> Calderon,M.A.</style></author><author><style face="normal" font="default"> Camuzat,T.</style></author><author><style face="normal" font="default"> Cardona,V.</style></author><author><style face="normal" font="default"> Carreiro-Martins,P.</style></author><author><style face="normal" font="default"> Carriazo,A.M.</style></author><author><style face="normal" font="default"> Carlsen,K.H.</style></author><author><style face="normal" font="default"> Carr,W.</style></author><author><style face="normal" font="default"> Cepeda Sarabia,A.M.</style></author><author><style face="normal" font="default"> Cesari,M.</style></author><author><style face="normal" font="default"> Chatzi,L.</style></author><author><style face="normal" font="default"> Chiron,R.</style></author><author><style face="normal" font="default"> Chivato,T.</style></author><author><style face="normal" font="default"> Chkhartishvili,E.</style></author><author><style face="normal" font="default"> Chuchalin,A.G.</style></author><author><style face="normal" font="default"> Chung,K.F.</style></author><author><style face="normal" font="default"> Ciprandi,G.</style></author><author><style face="normal" font="default"> de Sousa,J.C.</style></author><author><style face="normal" font="default"> Cox,L.</style></author><author><style face="normal" font="default"> Crooks,G.</style></author><author><style face="normal" font="default"> Custovic,A.</style></author><author><style face="normal" font="default"> Dahlen,S.E.</style></author><author><style face="normal" font="default"> Darsow,U.</style></author><author><style face="normal" font="default"> Dedeu,T.</style></author><author><style face="normal" font="default"> Deleanu,D.</style></author><author><style face="normal" font="default"> Denburg,J.A.</style></author><author><style face="normal" font="default"> De Vries,G.</style></author><author><style face="normal" font="default"> Didier,A.</style></author><author><style face="normal" font="default"> Anh-Xuan,A.T.</style></author><author><style face="normal" font="default"> Dokic,D.</style></author><author><style face="normal" font="default"> Douagui,H.</style></author><author><style face="normal" font="default"> Dray,G.</style></author><author><style face="normal" font="default"> Dubakiene,R.</style></author><author><style face="normal" font="default"> Durham,S.R.</style></author><author><style face="normal" font="default"> du Toit,G.</style></author><author><style face="normal" font="default"> Dykewicz,M.S.</style></author><author><style face="normal" font="default"> Eklund,P.</style></author><author><style face="normal" font="default"> el-Gamal,Y.</style></author><author><style face="normal" font="default"> Ellers,E.</style></author><author><style face="normal" font="default"> Emuzyte,R.</style></author><author><style face="normal" font="default"> Farrell,J.</style></author><author><style face="normal" font="default"> Fink,Wagner A.</style></author><author><style face="normal" font="default"> Fiocchi,A.</style></author><author><style face="normal" font="default"> Fletcher,M.</style></author><author><style face="normal" font="default"> Forastiere,F.</style></author><author><style face="normal" font="default"> Gaga,M.</style></author><author><style face="normal" font="default"> Gamkrelidze,A.</style></author><author><style face="normal" font="default"> Gemicioglu,B.</style></author><author><style face="normal" font="default"> Gereda,J.E.</style></author><author><style face="normal" font="default"> van Wick,R.G.</style></author><author><style face="normal" font="default"> Gonzalez,D.S.</style></author><author><style face="normal" font="default"> Grisle,I.</style></author><author><style face="normal" font="default"> Grouse,L.</style></author><author><style face="normal" font="default"> Gutter,Z.</style></author><author><style face="normal" font="default"> Guzman,M.A.</style></author><author><style face="normal" font="default"> Hellquist-Dahl,B.</style></author><author><style face="normal" font="default"> Heinrich,J.</style></author><author><style face="normal" font="default"> Horak,F.</style></author><author><style face="normal" font="default"> Hourihane,J.O.</style></author><author><style face="normal" font="default"> Humbert,M.</style></author><author><style face="normal" font="default"> Hyland,M.</style></author><author><style face="normal" font="default"> Iaccarino,G.</style></author><author><style face="normal" font="default"> Jares,E.J.</style></author><author><style face="normal" font="default"> Jeandel,C.</style></author><author><style face="normal" font="default"> Johnston,S.L.</style></author><author><style face="normal" font="default"> Joos,G.</style></author><author><style face="normal" font="default"> Jonquet,O.</style></author><author><style face="normal" font="default"> Jung,K.S.</style></author><author><style face="normal" font="default"> Jutel,M.</style></author><author><style face="normal" font="default"> Kaidashev,I.</style></author><author><style face="normal" font="default"> Khaitov,M.</style></author><author><style face="normal" font="default"> Kalayci,O.</style></author><author><style face="normal" font="default"> Kalyoncu,A.F.</style></author><author><style face="normal" font="default"> Kardas,P.</style></author><author><style face="normal" font="default"> Keith,P.K.</style></author><author><style face="normal" font="default"> Kerkhof,M.</style></author><author><style face="normal" font="default"> Kerstjens,H.A.</style></author><author><style face="normal" font="default"> Khaltaev,N.</style></author><author><style face="normal" font="default"> Kogevinas,M.</style></author><author><style face="normal" font="default"> Kolek,V.</style></author><author><style face="normal" font="default"> Koppelman,G.H.</style></author><author><style face="normal" font="default"> Kowalski,M.L.</style></author><author><style face="normal" font="default"> Kuitunen,M.</style></author><author><style face="normal" font="default"> Kull,I.</style></author><author><style face="normal" font="default"> Kvedariene,V.</style></author><author><style face="normal" font="default"> Lambrecht,B.</style></author><author><style face="normal" font="default"> Lau,S.</style></author><author><style face="normal" font="default"> Laune,D.</style></author><author><style face="normal" font="default"> Le,L.T.</style></author><author><style face="normal" font="default"> Lieberman,P.</style></author><author><style face="normal" font="default"> Lipworth,B.</style></author><author><style face="normal" font="default"> Li,J.</style></author><author><style face="normal" font="default"> Lodrup Carlsen,K.C.</style></author><author><style face="normal" font="default"> Louis,R.</style></author><author><style face="normal" font="default"> Lupinek,C.</style></author><author><style face="normal" font="default"> MacNee,W.</style></author><author><style face="normal" font="default"> Magar,Y.</style></author><author><style face="normal" font="default"> Magnan,A.</style></author><author><style face="normal" font="default"> Mahboub,B.</style></author><author><style face="normal" font="default"> Maier,D.</style></author><author><style face="normal" font="default"> Majer,I.</style></author><author><style face="normal" font="default"> Malva,J.</style></author><author><style face="normal" font="default"> Manning,P.</style></author><author><style face="normal" font="default"> De Manuel,K.E.</style></author><author><style face="normal" font="default"> Marshall,G.D.</style></author><author><style face="normal" font="default"> Masjedi,M.R.</style></author><author><style face="normal" font="default"> Mathieu-Dupas,E.</style></author><author><style face="normal" font="default"> Maurer,M.</style></author><author><style face="normal" font="default"> Mavale-Manuel,S.</style></author><author><style face="normal" font="default"> Melen,E.</style></author><author><style face="normal" font="default"> Melo-Gomes,E.</style></author><author><style face="normal" font="default"> Meltzer,E.O.</style></author><author><style face="normal" font="default"> Mercier,J.</style></author><author><style face="normal" font="default"> Merk,H.</style></author><author><style face="normal" font="default"> Miculinic,N.</style></author><author><style face="normal" font="default"> Mihaltan,F.</style></author><author><style face="normal" font="default"> Milenkovic,B.</style></author><author><style face="normal" font="default"> Millot-Keurinck,J.</style></author><author><style face="normal" font="default"> Mohammad,Y.</style></author><author><style face="normal" font="default"> Momas,I.</style></author><author><style face="normal" font="default"> Mosges,R.</style></author><author><style face="normal" font="default"> Muraro,A.</style></author><author><style face="normal" font="default"> Namazova-Baranova,L.</style></author><author><style face="normal" font="default"> Nadif,R.</style></author><author><style face="normal" font="default"> Neffen,H.</style></author><author><style face="normal" font="default"> Nekam,K.</style></author><author><style face="normal" font="default"> Nieto,A.</style></author><author><style face="normal" font="default"> Niggemann,B.</style></author><author><style face="normal" font="default"> Nogueira-Silva,L.</style></author><author><style face="normal" font="default"> Nogues,M.</style></author><author><style face="normal" font="default"> Nyembue,T.D.</style></author><author><style face="normal" font="default"> Ohta,K.</style></author><author><style face="normal" font="default"> Okamoto,Y.</style></author><author><style face="normal" font="default"> Okubo,K.</style></author><author><style face="normal" font="default"> Olive-Elias,M.</style></author><author><style face="normal" font="default"> Ouedraogo,S.</style></author><author><style face="normal" font="default"> Paggiaro,P.</style></author><author><style face="normal" font="default"> Pali-Scholl,I.</style></author><author><style face="normal" font="default"> Palkonen,S.</style></author><author><style face="normal" font="default"> Panzner,P.</style></author><author><style face="normal" font="default"> Papi,A.</style></author><author><style face="normal" font="default"> Park,H.S.</style></author><author><style face="normal" font="default"> Passalacqua,G.</style></author><author><style face="normal" font="default"> Pedersen,S.</style></author><author><style face="normal" font="default"> Pereira,A.M.</style></author><author><style face="normal" font="default"> Pfaar,O.</style></author><author><style face="normal" font="default"> Picard,R.</style></author><author><style face="normal" font="default"> Pigearias,B.</style></author><author><style face="normal" font="default"> Pin,I.</style></author><author><style face="normal" font="default"> Plavec,D.</style></author><author><style face="normal" font="default"> Pohl,W.</style></author><author><style face="normal" font="default"> Popov,T.A.</style></author><author><style face="normal" font="default"> Portejoie,F.</style></author><author><style face="normal" font="default"> Postma,D.</style></author><author><style face="normal" font="default"> Poulsen,L.K.</style></author><author><style face="normal" font="default"> Price,D.</style></author><author><style face="normal" font="default"> Rabe,K.F.</style></author><author><style face="normal" font="default"> Raciborski,F.</style></author><author><style face="normal" font="default"> Roberts,G.</style></author><author><style face="normal" font="default"> Robalo-Cordeiro,C.</style></author><author><style face="normal" font="default"> Rodenas,F.</style></author><author><style face="normal" font="default"> Rodriguez-Manas,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Montpellier University Hospital, Montpellier, France ; MACVIA-France</style></auth-address><titles><title><style face="normal" font="default">ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle</style></title><secondary-title><style face="normal" font="default">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Transl Allergy</style></full-title></periodical><pages end="" start="47">47-</pages><volume><style face="normal" font="default">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Africa</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Alergia</style></keyword><keyword><style face="normal" font="default"> Algeria</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergic Rhinitis and its Impact on Asthma</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Argentina</style></keyword><keyword><style face="normal" font="default"> ARIA</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Austria</style></keyword><keyword><style face="normal" font="default"> Bangladesh</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Bulgaria</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Chile</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical decision support system</style></keyword><keyword><style face="normal" font="default"> Colombia</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Croatia</style></keyword><keyword><style face="normal" font="default"> Czech Republic</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Egypt</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Georgia</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Hungary</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> Ireland</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Language</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mexico</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Norway</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pakistan</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatric Pneumology</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Peru</style></keyword><keyword><style face="normal" font="default"> Philippines</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Romania</style></keyword><keyword><style face="normal" font="default"> Russia</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Serbia</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Slovakia</style></keyword><keyword><style face="normal" font="default"> Slovenia</style></keyword><keyword><style face="normal" font="default"> socioeconomic status</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> tablet</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Venezuela</style></keyword><keyword><style face="normal" font="default"> Vietnam</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword><keyword><style face="normal" font="default"> World Health</style></keyword><keyword><style face="normal" font="default"> World Health Organization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease</style></abstract><notes><style face="normal" font="default">DA - 20170104IS - 2045-7022 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - France -CO - United Kingdom -CO - United States -CO - Germany -CO - Singapore -CO - Greece -CO - Italy -CO - Finland -CO - Philippines -CO - Belgium -CO - Slovenia -CO - China -CO - Argentina -CO - South Africa -CO - Pakistan -CO - Cyprus -CO - Sweden -CO - Netherlands -CO - Spain -CO - Austria -CO - Kyrgyzstan -CO - Brazil -CO - Norway -CO - Paraguay -CO - Switzerland -CO - Venezuela -CO - Israel -CO - Portugal -CO - Poland -CO - Bulgaria -CO - Croatia -CO - Denmark -CO - South Korea -CO - Czechia -CO - Burkina Faso -CO - Mozambique -CO - Congo -CO - Japan -CO - Hungary -CO - Russia -CO - Latakia -CO - Serbia -CO - Romania -CO - Iran -CO - Ireland -CO - Dubai -CO - Vietnam -CO - Canada -CO - Turkey -CO - Ukraine -CO - Chile -CO - Mexico -CO - Peru -CO - Georgia -CO - Egypt -CO - Algeria -CO - Macedonia -CO - Colombia -CO - Bangladesh -CO - South Africa -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1186/s13601-016-0137-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28050247">PM:28050247</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Transl Allergy\2016-6-47.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Transl Allergy\2016-6-47.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170104, Bousquet J</style></custom2><misc3><style face="normal" font="default">10.1186/s13601-016-0137-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40038</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pinho,A.</style></author><author><style face="normal" font="default"> Marta,A.</style></author><author><style face="normal" font="default"> Coutinho,I.</style></author><author><style face="normal" font="default"> Goncalo,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Department, Hospitais da Universidade de Coimbra, Centro Hospitalar e Universitario de Coimbra, 3000-045, Coimbra, Portugal</style></auth-address><titles><title><style face="normal" font="default">Long-term reproducibility of positive patch test reactions in patients with non-immediate cutaneous adverse drug reactions to antibiotics</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acute Generalized Exanthematous Pustulosis</style></keyword><keyword><style face="normal" font="default"> adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Aminopenicillin</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> beta-Lactams</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Betalactams</style></keyword><keyword><style face="normal" font="default"> Clindamycin</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Cutaneous adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity Syndrome</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exanthema</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity syndrome</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nonimmediate</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillins</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Reproducibility</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Vancomycin</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: As in contact allergy, T cell-mediated hypersensitivity in non-immediate (NI) cutaneous adverse drug reactions (CADRs) to antibiotics is considered to be lifelong, but, in this setting, patch tests have rarely been repeated after long time intervals. OBJECTIVE: To evaluate the long-term reproducibility of positive patch test reactions to antibiotics in patients with NI CADRs. METHODS: Fifty-six patients with NI CADRs to antibiotics who had relevant positive reactions during patch testing were invited to repeat patch tests with a similar antibiotic series 2-15 years thereafter. RESULTS: Twenty patients were included (9 males and 11 females; mean age 54.6 years): 18 with maculopapular exanthema, 1 with drug hypersensitivity syndrome, and 1 with acute generalized exanthematous pustulosis. Results were reproducible in 17 of 20 patients after a mean interval of 6.0 years (range 2-14.7 years). Concerning beta-lactams, 7 of 8 patients remained positive for aminopenicillins, 4 of 4 for isoxazolyl penicillins, and 1 for cefoxitin. Patch test results were also reproducible for clindamycin in 5 of 7 patients, for vancomycin in 1 patient, and for spiramycin in 1 patient. Reproducibility was not affected by the time interval between tests, sex, or age at testing. CONCLUSIONS: In the context of NI CADRs, we showed high reproducibility of positive patch test reactions to various antibiotics, even after several years</style></abstract><notes><style face="normal" font="default">DA - 20161202IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12720</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27910104">PM:27910104</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20161202-PinhoA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20161202-PinhoA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161202, Pinho A</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12720</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40039</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Heede,N.G.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author><author><style face="normal" font="default"> Thuesen,B.H.</style></author><author><style face="normal" font="default"> Linneberg,A.</style></author><author><style face="normal" font="default"> Szecsi,P.B.</style></author><author><style face="normal" font="default"> Stender,S.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, The National Allergy Research Centre, Copenhagen University Hospital Herlev-Gentofte, 2900, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Health-related quality of life in adult dermatitis patients stratified by filaggrin genotype</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Filaggrin</style></keyword><keyword><style face="normal" font="default"> Fingers</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand eczema</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> Heel</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Keratosis</style></keyword><keyword><style face="normal" font="default"> Life quality</style></keyword><keyword><style face="normal" font="default"> Mental Disorders</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Information concerning health-related quality of life (HRQoL) and comorbidities of adult dermatitis patients stratified by loss-of-function mutations in the filaggrin gene (FLG) is limited. OBJECTIVE: To investigate HRQoL, skin symptoms and comorbidities in adult FLG mutation carriers. METHODS: This cross-sectional study included patients diagnosed with atopic dermatitis and/or hand eczema (n = 520). Patients completed questionnaires about dermatitis, skin symptoms, HRQoL, and comorbidities, including actinic keratosis, and atopic and mental disorders. RESULTS: FLG mutations (R501X, 2282del4, and R2447X) were identified in 16.9% of patients, and were significantly associated not only with atopic dermatitis, but also independently with skin fissures on the fingers and heels, and self-reported actinic keratosis. Although FLG mutations were significantly associated with reduced HRQoL, as measured by use of the Dermatology Life Quality Index (DLQI), no association with self-reported anxiety or depression was identified. Notably, the highest median DLQI score, reflecting greater impairment, was reported by patients with both FLG mutations and atopic dermatitis. Overall, 19.7% of patients with both atopic dermatitis and FLG mutations reported a 'large or extremely large' impact on their lives; this represents twice the prevalence seen in patients with atopic dermatitis and wild-type FLG (9.6%). CONCLUSION: Patients with both atopic dermatitis and common FLG mutations are more frequently affected by reduced HRQoL</style></abstract><notes><style face="normal" font="default">DA - 20161220IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12731</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27995642">PM:27995642</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20161220-HeedeNG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20161220-HeedeNG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161220, Heede NG</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12731</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40040</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Warburton,K.L.</style></author><author><style face="normal" font="default"> Uter,W.</style></author><author><style face="normal" font="default"> Geier,J.</style></author><author><style face="normal" font="default"> Spiewak,R.</style></author><author><style face="normal" font="default"> Mahler,V.</style></author><author><style face="normal" font="default"> Crepy,M.N.</style></author><author><style face="normal" font="default"> Schuttelaar,M.L.</style></author><author><style face="normal" font="default"> Bauer,A.</style></author><author><style face="normal" font="default"> Wilkinson,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Chapel Allerton Hospital, Leeds, LS7 4SA, UK</style></auth-address><titles><title><style face="normal" font="default">Patch testing with rubber series in Europe: a critical review and recommendation</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">additives</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact allergens</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Occupation</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Health</style></keyword><keyword><style face="normal" font="default"> Occupations</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rubber</style></keyword><keyword><style face="normal" font="default"> Rubber additives</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Rubber additives constitute an important group of contact allergens, particularly in certain occupations. OBJECTIVES: To collect information regarding the current practice of using a 'rubber series' in Europe, and discuss this against the background of evidence concerning the prevalence of allergy in order to derive a recommendation for a 'European rubber series'. METHODS: The following were performed: (i) a survey targeting all members of the COST action 'StanDerm' consortium, (ii) analysis of rubber contact allergy data in the database of the European Surveillance System on Contact Allergies, and (iii) a literature review. RESULTS: Information from 13 countries was available, from one or several departments of dermatology, and occasionally occupational health. Apart from some substances tested only in single departments, a broad overlap regarding important allergens was evident, but considerable variation existed between departments. CONCLUSIONS: An up-to-date 'European rubber series' is recommended, with the exclusion of substances only of historical concern. A 'supplementary rubber series' containing allergens of less proven importance, requiring further analysis, is recommended for departments specializing in occupational contact allergy. These should be continually updated as new evidence emerges</style></abstract><notes><style face="normal" font="default">DA - 20161229IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Germany -CO - Poland -CO - France -CO - Netherlands .</style></notes><work-type><style face="normal" font="default">10.1111/cod.12736</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28032352">PM:28032352</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20161229-WarburtonKL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20161229-WarburtonKL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161229, Warburton KL</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12736</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40041</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Uter,W.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author><author><style face="normal" font="default"> Goncalo,M.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Informatics, Biometry and Epidemiology, University of Erlangen/Nurnberg, 91054, Erlangen, GermanyContact Allergy Unit, Department of Dermatology, University Hospital K.U. Leuven, 3000, Leuven, BelgiumDepartment of Dermatology, University Hospital and Faculty of Medicine, University of Coimbra, 3000-075, Coimbra, PortugalDepartment of Dermato-Allergology, National Allergy Research Centre, Gentofte Hospital, University of Copenhagen, 2900, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Guidelines for the presentation of contact allergy case reports</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="113" start="107">107-113</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Biometry</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Informatics</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Publications</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Suggestion</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Case reports constitute a classic publication format that is being increasingly appreciated, for example because of its educational value. In the field of contact dermatitis research, case reports often serve as sentinel publications concerning new allergens, or new exposures to known allergens, or regarding other conditions leading to contact dermatitis. The CARE guideline published in 2013 addresses standardized and complete reporting of case reports in all fields of medicine. The present article takes up the CARE suggestions, and further specifies these in terms of application to case reports in the field of contact dermatitis. The objective of this structured guidance is to provide junior or inexperienced doctors and researchers with an annotated list, against which the fulfilment of essential or optional items of a complete, high-quality case report to be submitted to Contact Dermatitis or other journals can be checked</style></abstract><notes><style face="normal" font="default">DA - 20161205IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Belgium -CO - Portugal -CO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12709</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27917498">PM:27917498</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-107-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-107-13.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161205, Uter W</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12709</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40042</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jamil,W.N.</style></author><author><style face="normal" font="default"> Lindberg,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, School of Medical Sciences, Orebro University Hospital, 701 85, Orebro</style></auth-address><titles><title><style face="normal" font="default">Effects of time and recall of patch test results on quality of life (QoL) after testing. Cross-sectional study analyzing QoL in hand eczema patients 1, 5 and 10 years after patch testing</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand eczema</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> Life quality</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> QOL</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Recall</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patch testing can improve health-related quality of life (HRQoL). OBJECTIVES: To study the impact on HRQoL of elapsed time after patch testing (1-10 years), and how the outcome of testing and patients' recall affects HRQoL. PATIENTS/MATERIALS/METHODS: The Dermatology Life Quality Index (DLQI) questionnaire was sent to all patients (aged 18-65 years) who were patch tested for suspected contact allergy in 2009, 2005 and 2000 at the Department of Dermatology in Orebro. RESULTS: The response rate was 51% (n = 256). The DLQI score was significantly lower at 10 years after patch testing (mean DLQI = 5.5) than at 1 year (mean DLQI = 7.7). Work was the most impaired aspect. A binary logistic model showed that only time (10 years after testing) was associated with no effect, a light effect or a moderate effect (DLQI &lt; 10) on HRQoL. No such association was seen for patients with negative or positive test results concerning full recall, partial recall or no recall of diagnosed allergens. CONCLUSIONS: Although there was an improvement in HRQoL over time, the work aspect remained a major problem. The improvement was not affected by the outcome of testing and patients' recall of test results</style></abstract><notes><style face="normal" font="default">DA - 20161229IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12734</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28032351">PM:28032351</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20161229-JamilWN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20161229-JamilWN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161229, Jamil WN</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12734</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40043</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schwensen,J.F.</style></author><author><style face="normal" font="default"> Uter,W.</style></author><author><style face="normal" font="default"> Bruze,M.</style></author><author><style face="normal" font="default"> Svedman,C.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author><author><style face="normal" font="default"> Wilkinson,M.</style></author><author><style face="normal" font="default"> Gimenez-Arnau A.</style></author><author><style face="normal" font="default"> Goncalo,M.</style></author><author><style face="normal" font="default"> Andersen,K.E.</style></author><author><style face="normal" font="default"> Paulsen,E.</style></author><author><style face="normal" font="default"> Agner,T.</style></author><author><style face="normal" font="default"> Foti,C.</style></author><author><style face="normal" font="default"> Aalto-Korte,K.</style></author><author><style face="normal" font="default"> McFadden,J.</style></author><author><style face="normal" font="default"> White,I.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermato-Allergology, National Allergy Research Centre, Gentofte Hospital, University of Copenhagen, 2900, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">The epidemic of methylisothiazolinone: a European prospective study</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Cosmetic products</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Eyelid</style></keyword><keyword><style face="normal" font="default"> Eyelids</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Occupational Health</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: The use of methylisothiazolinone (MI) in cosmetic products has caused an unprecedented epidemic of MI contact allergy. Current data concerning exposures at a European level are required. OBJECTIVES: To describe demographics and MI exposures for European patients with MI contact allergy. METHODS: Eleven European dermatology departments from eight European countries prospectively collected data between 1 May and 31 October 2015 among consecutive patients who had positive patch test reactions to MI (2000 ppm aq.). RESULTS: A total of 6.0% (205/3434; range 2.6-13.0%) of patients had positive patch test reactions to MI. Dermatitis most frequently affected the hands (43.4%), face (32.7%), arms (14.6%), and eyelids (11.7%); 12.7% had widespread dermatitis. For 72.7% (149/205), MI contact allergy was currently relevant mainly because of exposure to cosmetic products (83.2%; 124/149). Of these 124 patients, 19.5% were exposed to leave-on and rinse-off cosmetic products, 24.8% only to leave-on cosmetic products and 38.9% only to rinse-off cosmetic products containing MI or methylchloroisothiazolinone/MI. The majority of these (79%) noted onset of their dermatitis between 2013 and 2015. Fifteen patients (7.3%) had previously experienced allergic reactions when they were in newly painted rooms. CONCLUSION: Clinically relevant MI contact allergy remains prevalent across European countries, mainly because of exposure to rinse-off and leave-on cosmetic products</style></abstract><notes><style face="normal" font="default">DA - 20161229IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - Germany -CO - Sweden -CO - Belgium -CO - United KIngdom -CO - Spain -CO - Italy -CO - Finland -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12733</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28032337">PM:28032337</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20161229-SchwensenJF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20161229-SchwensenJF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161229, Schwensen JF</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12733</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40044</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Deza,G.</style></author><author><style face="normal" font="default"> Garcia-Bravo,B.</style></author><author><style face="normal" font="default"> Silvestre,J.F.</style></author><author><style face="normal" font="default"> Pastor-Nieto,M.A.</style></author><author><style face="normal" font="default"> Gonzalez-Perez,R.</style></author><author><style face="normal" font="default"> Heras-Mendaza,F.</style></author><author><style face="normal" font="default"> Mercader,P.</style></author><author><style face="normal" font="default"> Fernandez-Redondo,V.</style></author><author><style face="normal" font="default"> Niklasson,B.</style></author><author><style face="normal" font="default"> Gimenez-Arnau,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Hospital del Mar, Institut Mar d'Investigacions Mediques, Universitat Autonoma de Barcelona (UAB), 08003 Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default">Contact sensitization to limonene and linalool hydroperoxides in Spain: a GEIDAC* prospective study</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="80" start="74">74-80</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Haptens</style></keyword><keyword><style face="normal" font="default"> Hygiene</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Limonene</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Terpenes</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Limonene and linalool are common fragrance terpenes widely used in cosmetic, household and hygiene products. Their primary oxidation products formed after air exposure, the hydroperoxides, have been recognized as important contact haptens. OBJECTIVES: To investigate the prevalence of contact allergy to hydroperoxides of limonene (Lim-OOHs) and hydroperoxides of linalool (Lin-OOHs) in Spain, and to define the optimal concentration for screening in consecutive patients. METHODS: Three different concentrations of Lim-OOHs (0.1%, 0.2% and 0.3% pet.) and Lin-OOHs (0.25%, 0.5% and 1.0% pet.) were simultaneously tested in 3639 consecutive patients at 22 departments of dermatology in Spain. RESULTS: Lim-OOHs at 0.1%, 0.2% and 0.3% yielded positive patch test reactions in 1.4%, 3.4% and 5.1% of the tested patients, respectively; and Lin-OOHs at 0.25%, 0.5% and 1.0% yielded positive reactions in 1.3%, 2.9% and 4.9% of the tested patients, respectively. Few irritant (1.5-1.9%) and doubtful reactions (0.4-0.5%) to both terpene hydroperoxides were registered at the highest concentrations tested. CONCLUSIONS: Lim-OOHs and Lin-OOHs can actually be considered as common causes of contact allergy, and their inclusion in an extended baseline patch test series therefore seems to be appropriate. The patch test preparations of Lim-OOHs 0.3% pet. and Lin-OOHs 1.0% pet. are useful tools for screening of contact sensitization</style></abstract><notes><style face="normal" font="default">DA - 20161129IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12714</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27896835">PM:27896835</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-74-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-74-80.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161129, Deza G</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12714</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40045</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martina,E.</style></author><author><style face="normal" font="default"> ROSA,L.</style></author><author><style face="normal" font="default"> Postacchini,V.</style></author><author><style face="normal" font="default"> Simonetti,O.</style></author><author><style face="normal" font="default"> Cataldi,I.</style></author><author><style face="normal" font="default"> Offidani,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Clinic, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, 60100 Torrette-Ancona, Italy</style></auth-address><titles><title><style face="normal" font="default">Photoprotection and photodermatitis: a case</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="55" start="54">54-55</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Clinical</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161213IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12644</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27957757">PM:27957757</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-54-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-54-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161213, Martina E</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12644</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40046</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Meysman,T.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, K.U. Leuven University Hospital, 3000 Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="default">Occupational allergic contact dermatitis caused by benzisothiazolinone in printing ink and soap</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="53" start="51">51-53</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Benzisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Ink</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Printing</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161213IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1111/cod.1264</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27957753">PM:27957753</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-51-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-51-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161213, Meysman T</style></custom2><misc3><style face="normal" font="default">10.1111/cod.1264</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40047</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oiso,N.</style></author><author><style face="normal" font="default"> Tatebayashi,M.</style></author><author><style face="normal" font="default"> Kawada,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Faculty of Medicine, Kindai University, Osaka-Sayama, 589-8511, Japan</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by efinaconazole: positive patch test reactions up to 0.1% pet</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="54" start="53">53-54</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161213IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12643</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27957750">PM:27957750</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-53-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-53-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161213, Oiso N</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12643</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40048</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Linauskiene,K.</style></author><author><style face="normal" font="default"> Malinauskiene,L.</style></author><author><style face="normal" font="default"> Blaziene,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Vilnius University Hospital, Santariskiu Klinikos, Center of Pulmonology and Allergology, 08661, Vilnius, Lithuania</style></auth-address><titles><title><style face="normal" font="default">Time trends of contact allergy to the European baseline series in Lithuania</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy prevention</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Formaldehyde</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Fragrance mix</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> methylchloroisothiazolinone</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Myroxylon</style></keyword><keyword><style face="normal" font="default"> Myroxylon pereirae</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Potassium</style></keyword><keyword><style face="normal" font="default"> Potassium Dichromate</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> trends</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Monitoring trends of positive patch test reactions is useful for epidemiological surveillance and contact allergy prevention, and has not previously been reported in Lithuania. OBJECTIVES: To examine and compare changes in the prevalence of contact allergy to European baseline series allergens in adults with suspected contact dermatitis during a 9-year period. METHODS: In this retrospective study, patch test results of 297 consecutive patients, tested with the European baseline series in 2014-2015, were analysed and compared with the data published earlier in Lithuania. RESULTS: The most common allergens were nickel sulfate (30.6%), methylisothiazolinone (MI) (13.5%), methylchloroisothiazolinone (MCI)/MI (7.4%), potassium dichromate (6.1%), cobalt chloride (6.1%), Myroxylon pereirae resin (5.4%), p-phenylenediamine (5.4%), fragrance mix I (4.7%), formaldehyde (4.4%), and methyldibromo glutaronitrile (3.7%). Increases in the prevalence of sensitization to MCI/MI (2.3% in 2006-2008 and 7.4% in 2014-2015; p &lt; 0.0001) and nickel sulfate (16.4% in 2006-2008 and 30.6% in 2014-2015; p &lt; 0.0001) and decreases in the prevalence of sensitization to paraben mix (3.2% in 2006-2008 and 0.3% in 2014-2015; p = 0.006) were observed. Prevalences for the other allergens remained stable or showed a decreasing trend (Myroxylon pereirae resin; p = 0.06). CONCLUSION: This study provides current information on the prevalence of contact allergy in Lithuania. Changing trends in sensitivity to some allergens probably reflect changes in exposure</style></abstract><notes><style face="normal" font="default">DA - 20161205IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Lithuania -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12726</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27917496">PM:27917496</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20161205-LinauskieneK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20161205-LinauskieneK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161205, Linauskiene K</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12726</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40049</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ochi,H.</style></author><author><style face="normal" font="default"> Cheng,S.W.</style></author><author><style face="normal" font="default"> Leow,Y.H.</style></author><author><style face="normal" font="default"> Goon,A.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Skin Centre, Singapore 308205, Singapore</style></auth-address><titles><title><style face="normal" font="default">Contact allergy trends in Singapore - a retrospective study of patch test data from 2009 to 2013</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="50" start="49">49-50</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> trends</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161213IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12629</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27957752">PM:27957752</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-49-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-49-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161213, Ochi H</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12629</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40050</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Millelid,R.</style></author><author><style face="normal" font="default"> Isaksson,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Solvesborgs Health Centre, Blekinge County Hospital, 294 32, Solvesborg, Sweden</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by exfoliating socks</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="60" start="59">59-60</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161213IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12662</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27957756">PM:27957756</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-59-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-59-60.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161213, Millelid R</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12662</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40051</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yamaguchi,Y.</style></author><author><style face="normal" font="default"> Hoshina,D.</style></author><author><style face="normal" font="default"> Furuya,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Hakodate Central General Hospital, Hakodate 040-8585, Japan</style></auth-address><titles><title><style face="normal" font="default">Onychomadesis caused by efinaconazole</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="58" start="57">57-58</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161213IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12658</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27957751">PM:27957751</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-57-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-57-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161213, Yamaguchi Y</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12658</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40052</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Opstrup,M.S.</style></author><author><style face="normal" font="default"> Sorensen,H.B.</style></author><author><style face="normal" font="default"> Zachariae,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermato-Allergology, Copenhagen University Hospital Gentofte, 2900, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Occupational allergic contact dermatitis caused by tetracaine in an otorhinolaryngologist</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="57" start="55">55-57</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Tetracaine</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161213IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.1264</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27957755">PM:27957755</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-55-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-55-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161213, Opstrup MS</style></custom2><misc3><style face="normal" font="default">10.1111/cod.1264</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40053</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Perez-Novo,C.</style></author><author><style face="normal" font="default"> Pezato,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">aDepartment Biomedical Sciences, University Antwerp; Laboratory of Proteinchemistry, Proteomics Epigenetic Signaling, Wilrijk, Belgium</style></auth-address><titles><title><style face="normal" font="default">Dendritic cell subset expression in severe chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="4" start="1">1-4</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> adaptive</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immunomodulation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> nasal polyposis</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> plasmacytoid dendritic cell</style></keyword><keyword><style face="normal" font="default"> Polyposis</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Proteomics</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Two main pillars are implicated in nasal polyposis development: a severe imbalance in immunomodulation and a mechanical dysfunction because of an abnormal remodeling process. Dendritic cells play a crucial role in the link between innate and adaptive immune response and orchestrating the T-cell response and are implicated in the severe inflammatory process found in nasal polypoid tissue. This review summarizes the existent knowledge about dendritic cells in nasal polyposis. RECENT FINDINGS: Dendritic cells are found increased in nasal polyposis, regardless of subset. Of interest, plasmacytoid dendritic cells are decreased in patients with a more severe Th2 profile, suggesting an important role of the cytokines milieu in their functional response or that plasmacytoid dendritic cell could act mitigating the inflamed process found in polypoid tissue. SUMMARY: Understanding the dendritic cell subset expression in different environments, as well as the effect of these subsets on T-cell differentiation will greatly improve the development of new therapies in nasal polyposis</style></abstract><notes><style face="normal" font="default">DA - 20161121IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000328</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27870663">PM:27870663</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-1-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-1-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161121, Perez-Novo C</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000328</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40054</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Serrano-Pariente,J.</style></author><author><style face="normal" font="default"> Plaza,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">aPneumology Department, Hospital Comarcal d'Inca, Inca, Islas Baleares</style></auth-address><titles><title><style face="normal" font="default">Near-fatal asthma: a heterogeneous clinical entity</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="35" start="28">28-35</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Alternaria</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Biological Markers</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cluster Analysis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Menstrual Cycle</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: The aims of the present review were to describe the heterogeneous nature of near-fatal asthma (NFA) and to summarize the distinctive phenotypes identified in this subtype of asthma. RECENT FINDINGS: Clinical, physiological, and histological studies have shown a large number of triggers, pathological mechanisms, and risk factors associated with NFA. Based on the demographic and clinical characteristics of the patients, the circumstances surrounding the asthma exacerbation and some distinctive features of the disease, several clinical profiles of asthma patients with NFA have been described. Recent data show new associations between some gene expression patterns and fatal asthma, as well as with some biological markers related to inflammatory or immunologic mechanisms in the airways. Also, the use of statistical methods, such as cluster analysis, allowed identifying and confirming different phenotypes of life-threatening asthma patients. SUMMARY: NFA is a heterogeneous clinical entity, in which different patients' clinical profiles may coexist [e.g. rapid-onset NFA, NFA in patients with dyspnea hypoperception or sensitized to certain pneumoallergens (Alternaria alternata, soybean), NFA related to the menstrual cycle, brittle asthma]. Knowledge of these phenotypes as well as adequate and specific management strategies can reduce morbidity and mortality in patients suffering from NFA</style></abstract><notes><style face="normal" font="default">DA - 20161121IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000333</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27870665">PM:27870665</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-28-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-28-35.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161121, Serrano-Pariente J</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000333</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40055</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Smith,K.A.</style></author><author><style face="normal" font="default"> Rudmik,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Otolaryngology - Head and Neck Surgery, Department of Surgery; University of Calgary, Calgary, Alberta, Canada</style></auth-address><titles><title><style face="normal" font="default">Medical therapy, refractory chronic rhinosinusitis, and productivity costs</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="11" start="5">5-11</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">anti-IgE</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium Channel Blockers</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Decision Making</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Irrigation</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Otolaryngology</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> sinus</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: The purpose of this review is to address the most recent advances in the medical therapy for chronic rhinosinusitis (CRS), define recalcitrant and refractory CRS, and discuss the productivity costs associated with CRS. RECENT FINDINGS: Recent studies evaluating anti-IL-4 receptor alpha antibodies and calcium channel blockers have demonstrated promising early results during management of CRS. Recent appropriateness criteria have been developed to assist clinicians with defining which patients have 'refractory' CRS and may be considered candidates for endoscopic sinus surgery. Productivity costs appear to be associated with disease severity and can be reduced with appropriate interventions. SUMMARY: Topical corticosteroid therapy and high volume saline irrigation continue to be the cornerstone to medical therapy, whereas use of systemic corticosteroids and antibiotics depends on CRS phenotype and presence of acute exacerbation. More research is needed before routine use of novel immunomodulatory therapies such as anti-IL5, anti-IgE, anti-IL4, and calcium channel blockers. Clinicians should apply an appropriate definition for refractory CRS when discussing role of sinus surgery. Assessing the degree of work productivity impairment can assist in treatment decision-making and may help predict treatment outcomes</style></abstract><notes><style face="normal" font="default">DA - 20161201IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000329</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27906696">PM:27906696</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-5-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-5-11.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161201, Smith KA</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000329</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40056</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rodrigo,G.J.</style></author><author><style face="normal" font="default"> Neffen,H.</style></author><author><style face="normal" font="default"> Plaza,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">aDepartamento de Emergencia, Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay</style></auth-address><titles><title><style face="normal" font="default">Asthma-chronic obstructive pulmonary disease overlap syndrome: a controversial concept</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="41" start="36">36-41</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Argentina</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Characterization</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutics</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: To illustrate the scant evidence and the shortcomings of the concept of 'asthma-COPD overlap syndrome' (ACOS) in terms of clinical utility. RECENT FINDINGS: Asthma and chronic obstructive pulmonary disease (COPD) are considered as two distinct and heterogeneous diseases. For many years, physicians have been aware that asthma and COPD can coexist in some patients. Recently, the term ACOS has been applied when a person has clinical features of both asthma and COPD. However, the lack of an accurate diagnosis has led to inconsistent data regarding reported prevalence, prognosis and therapeutics. Even today, it has not been possible to establish a phenotypic characterization of ACOS, although it is part of the overall complexity and heterogeneity of COPDs. No high quality data exist on which to base treatment recommendations for ACOS. Consequently, in clinical practice, treatment is extrapolated from the available evidence on asthma and COPD. SUMMARY: The current concept of ACOS seems clinically irrelevant because it has no influence on the prognosis and treatment of these patients. The authors concluded that the term ACOS should be avoided in the case of patients with features of both asthma and COPD</style></abstract><notes><style face="normal" font="default">DA - 20161114IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Uruguay -CO - Argentina -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000326</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27841767">PM:27841767</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-36-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-36-41.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161114, Rodrigo GJ</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000326</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40057</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gorska,M.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">aNational Jewish Health, Denver bUniversity of Colorado, Aurora, Colorado, USA</style></auth-address><titles><title><style face="normal" font="default">Natural killer cells in asthma</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="54" start="50">50-54</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> allergic sensitization</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Pollutants</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Killer Cells</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Maternal Exposure</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Natural Killer cells</style></keyword><keyword><style face="normal" font="default"> NK cells</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pollutants</style></keyword><keyword><style face="normal" font="default"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="default"> Respiratory viruses</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> suppression</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral infection</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> Viruses</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: This review article discusses current knowledge on natural killer (NK) cells in asthma. RECENT FINDINGS: It is now well accepted that NK cell activities go beyond cancer immune surveillance and antiviral defense. Recent reports indicate that NK cells are activated in response to allergens in vivo. NK cells promote allergic sensitization, type-2 immune response, development of eosinophilic inflammation, and airway hyperresponsiveness. NK cells are activated by respiratory syncytial virus and other respiratory viruses. When infection occurs in the setting of active allergic inflammation, NK cells augment its magnitude and contribute to asthma exacerbations. Proasthma activities of NK cells can be programmed during embryogenesis through maternal exposure to environmental pollutants. Prenatally programmed NK cells produce type-2 and type-3 cytokines and mediate asthma predisposition. NK cells can also act as asthma antagonists. NK cells contribute to the resolution of inflammation through suppression of antigen-specific CD4+ T cells and type-3 immunity. When viral infection occurs in naive mice prior to allergic sensitization, NK cells antagonize type-2 immunity and prevent development of asthma. SUMMARY: NK cells are nonredundant participants of allergic inflammation. The environmental context determines whether NK cells act as protagonists or antagonists</style></abstract><notes><style face="normal" font="default">DA - 20161114IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000327</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27841766">PM:27841766</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-50-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-50-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161114, Gorska MM</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000327</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40058</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,M.</style></author><author><style face="normal" font="default"> Kim,D.W.</style></author><author><style face="normal" font="default"> Shin,H.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Obstructive Upper airway Research (OUaR) Laboratory, Department of Pharmacology, Seoul National University College of Medicine bDepartment of Biomedical Sciences, Seoul National University College of Medicine cDepartment of Otorhinolaryngology-Head and Neck Surgery, Boramae Medical Center dClinical Mucosal Immunology Study Group eDepartment of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital fIschemic/Hypoxic Disease Institute, Seoul National University College of Medicine gCancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Targeting IL-25 as a novel therapy in chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="22" start="17">17-22</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate lymphoid cells</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="default"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disorder with a poorly understood pathophysiology. Recent findings show that epithelial-derived cytokines, including thymic stromal lymphopoietin, IL-33, and IL-25, can exacerbate Th2 immune responses, ultimately leading to recalcitrant chronic rhinosinusitis and nasal polyps. Although IL-25 is increased in CRSwNP, the targeting of IL-25 as a therapeutic strategy remains largely unexplored. In this review, we outline the many recent advances in our understanding of the association between IL-25 and CRSwNP. RECENT FINDINGS: Recently, we demonstrated that IL-25, produced primarily by sinonasal epithelial cells and infiltrating mast cells, plays an important role in the pathogenesis of CRSwNP in Asian patients. Furthermore, IL-25 and IL-25R are elevated in nasal polyps. This cytokine has roles in the pathogenesis of CRSwNP via modulating group 2 innate lymphoid cells (ILC2s). Similarly, ILC2 enrichment has been reported in CRSwNP patients, and a positive correlation has been shown between ILC2s and CRSwNP. Clinical trials blocking thymic stromal lymphopoietin and IL-33 pathways are ongoing using monoclonal antibodies, AMG157 and AMG282, against CRSwNP, respectively. SUMMARY: Studies on the role played by IL-25 in the pathogenesis of CRSwNP are accumulating and suggest the possibility of a novel therapeutic strategy for treating CRSwNP</style></abstract><notes><style face="normal" font="default">DA - 20161121IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000332</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27870664">PM:27870664</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-17-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-17-22.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161121, Lee M</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000332</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40059</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Braido,F.</style></author><author><style face="normal" font="default"> Baiardini,I.</style></author><author><style face="normal" font="default"> Puggioni,F.</style></author><author><style face="normal" font="default"> Garuti,S.</style></author><author><style face="normal" font="default"> Pawankar,R.</style></author><author><style face="normal" font="default"> Canonica,W.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">aRespiratory and Allergy Diseases Clinic, Department of Internal Medicine, University of Genoa, Genoa bRespiratory and Allergy Diseases, Department IRCCS Humanitas Research and Clinical Center-Humanitas University, Rozzano, Milan, Italy cDepartment of Pediatrics, Nippon Medical School, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">Rhinitis: adherence to treatment and new technologies</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="27" start="23">23-27</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Nonadherence to treatment is a major issue in approximately 50% of patients suffering from chronic diseases. The availability of new technologies could represent a possible way to improve patients' engagement and adherence in a real-life setting. Research and technology tools made available or in process of being made available to patients with allergic diseases and their physicians could potentially improve the management of these disease in daily life by improving adherence. In this review, we sought to outline many of the recent advances in these technological approaches. RECENT FINDINGS: Short Message Service (SMS) reminder, social networks, wearable devices, mobile applications (Apps), monitoring systems of inhaled device use, often presented as 'serious game' are changing the way of approaching to chronic disease, such as rhinitis, management. SUMMARY: Studies of the role played by various technologies in improving adherence to treatment in rhinitis are still limited as compared with other diseases such as asthma, but the results are encouraging. Further studies in this area may lead to the discovery of novel management approaches that is easy to be integrated in patients' daily life</style></abstract><notes><style face="normal" font="default">DA - 20161122IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Japan -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000331</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27875376">PM:27875376</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-23-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-23-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161122, Braido F</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000331</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40060</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Teo,W.Z.</style></author><author><style face="normal" font="default"> Schalock,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Surgery (Dermatology), Geisel School of Medicine at Dartmouth, Hanover, NH, USA</style></auth-address><titles><title><style face="normal" font="default">Metal Hypersensitivity Reactions to Orthopedic Implants</style></title><secondary-title><style face="normal" font="default">Dermatol Ther (Heidelb)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Dermatol Ther (Heidelb)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Hip</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Knee</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> LTT</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metal allergies</style></keyword><keyword><style face="normal" font="default"> Metal allergy</style></keyword><keyword><style face="normal" font="default"> metal hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Recovery</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="19" Month="12" Year="2016">2016/12/19</year></dates><abstract><style face="normal" font="default">Total hip and knee replacement surgery using metal alloy devices is common. Type IV allergic reactions to these implants occur, though infrequently. While uncommon, peri-implant metal allergic reactions may cause significant morbidity for the affected individual-including aseptic loosening, pseudotumor formation and frank device failure. It is challenging to predict who will have these reactions, even in those with established pre-implant metal allergy. At this time, the scientific literature clearly supports few conclusions. Despite this, we believe several conclusions can be made: routine pre-implant testing in asymptomatic individuals is not indicated; listen to patient's concerns about metal allergy if the concern arises; patch testing is probably the best pre- and post-implant screening test; post-implantation testing is controversial and even positive LTT or patch test does not definitively diagnose morbidity from a metal allergy; and complete recovery following revision placement of an immunologically inert device is diagnostic. More research is needed to scientifically approach this issue</style></abstract><notes><style face="normal" font="default">DA - 20161220IS - 2193-8210 (Print)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s13555-016-0162-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27995484">PM:27995484</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatol Ther (Heidelb)\20161220-TeoWZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatol Ther (Heidelb)\20161220-TeoWZ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161220, Teo WZ</style></custom2><misc3><style face="normal" font="default">10.1007/s13555-016-0162-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40061</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Megna,M.</style></author><author><style face="normal" font="default"> Napolitano,M.</style></author><author><style face="normal" font="default"> Patruno,C.</style></author><author><style face="normal" font="default"> Villani,A.</style></author><author><style face="normal" font="default"> Balato,A.</style></author><author><style face="normal" font="default"> Monfrecola,G.</style></author><author><style face="normal" font="default"> Ayala,F.</style></author><author><style face="normal" font="default"> Balato,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Naples Federico II, Naples, Italy.</style></auth-address><titles><title><style face="normal" font="default">Systemic Treatment of Adult Atopic Dermatitis: A Review</style></title><secondary-title><style face="normal" font="default">Dermatol Ther (Heidelb)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Dermatol Ther (Heidelb)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Calcineurin</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic therapy</style></keyword><keyword><style face="normal" font="default"> Systemic treatment</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> topical treatment</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="26" Month="12" Year="2016">2016/12/26</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a common chronic inflammatory skin disease that predominantly affects children. However, it can persist in adulthood and/or start at older ages. Due to its chronic nature and frequently occurring relapses, AD has a substantial effect on patients' quality of life, often requiring long-term systemic treatment, especially in adult patients, who are more frequently refractory to adequate topical treatment with mid- to high-potent corticosteroids and/or calcineurin inhibitors. Therefore, treatment with systemic therapies is often needed to take control of the disease, prevent exacerbations and improve quality of life. However, data regarding systemic treatment effectiveness and long-term safety in adult patients with AD are insufficient. Indeed, standardized international guidelines are lacking, and the treatment approach widely differs among diverse countries. This review focuses on the use of systemic treatments in adult AD patients analyzing published literature</style></abstract><notes><style face="normal" font="default">DA - 20161227IS - 2193-8210 (Print)LA - engPT - ReviewPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1007/s13555-016-0170-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28025775">PM:28025775</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatol Ther (Heidelb)\20161227-MegnaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatol Ther (Heidelb)\20161227-MegnaM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161227, Megna M</style></custom2><misc3><style face="normal" font="default">10.1007/s13555-016-0170-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40062</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bilal,A.I.</style></author><author><style face="normal" font="default"> Tilahun,Z.</style></author><author><style face="normal" font="default"> Osman,E.D.</style></author><author><style face="normal" font="default"> Mulugeta,A.</style></author><author><style face="normal" font="default"> Shekabdulahi,M.</style></author><author><style face="normal" font="default"> Berhe,D.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmaceutics and Social Pharmacy, College of Health Sciences, School of Pharmacy, Addis Ababa University, Addis Ababa, Ethiopia.</style></auth-address><titles><title><style face="normal" font="default">Cosmetics Use-Related Adverse Events and Determinants Among Jigjiga Town Residents, Eastern Ethiopia</style></title><secondary-title><style face="normal" font="default">Dermatol Ther (Heidelb)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Dermatol Ther (Heidelb)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse events</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> Cosmetic products</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Cosmetovigilance</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> Ethiopia</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Herbal</style></keyword><keyword><style face="normal" font="default"> Hirsutism</style></keyword><keyword><style face="normal" font="default"> Interviews</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Saliva</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword></keywords><dates><year Day="23" Month="11" Year="2016">2016/11/23</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Non-medicated cosmetics use is very common among the Ethiopian population. However, little is known about these products' related adverse events. The aim of this study was to assess the prevalence and determinants of cosmetics-related adverse events among Jigjiga Town residents, Eastern Ethiopia. METHODS: A community-based cross-sectional study design was conducted in May and June 2014. Semi-structured interviews were used to collect cosmetics use pattern and related adverse events. For assessing determinants, logistic regression was used and statistical significance was set at p &lt; 0.05. RESULTS: Overall, 600 participants were approached with a 93% response rate. Ninety-three percent (n = 521) of them reported the use of cosmetics at least once within 2 weeks prior to this study, and of these, 229 (44%) used traditional herbal cosmetics along with modern cosmetics. A total of 342 (61%) reported experiencing adverse events of which the most common reported were: allergic reactions, 149 (36%); the appearance of acne, 66 (16%); and hirsutism, 52 (12.5%). The occurrence of cosmetics-related adverse events were significantly associated with the number of cosmetics used per day, the frequency of use, mixing of different types of cosmetics together, and mixing of cosmetics with water or saliva. CONCLUSION: A higher proportion of cosmetic users reported experiencing at least one adverse event. The number of cosmetic products and frequency of use were important predictors for experiencing adverse events. This implies the need to consider safety concerns related to cosmetic use. Approaches to address such issues may include awareness creation programs and promoting the concept of cosmetovigilance among cosmetic sellers, users, and other stakeholders</style></abstract><notes><style face="normal" font="default">DA - 20161124IS - 2193-8210 (Print)LA - engPT - Journal ArticleCO - Ethiopia -</style></notes><work-type><style face="normal" font="default">10.1007/s13555-016-0157-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27882506">PM:27882506</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatol Ther (Heidelb)\20161124-BilalAI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatol Ther (Heidelb)\20161124-BilalAI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161124, Bilal AI</style></custom2><misc3><style face="normal" font="default">10.1007/s13555-016-0157-y</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40063</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shen,S.</style></author><author><style face="normal" font="default"> Li,J.</style></author><author><style face="normal" font="default"> You,H.</style></author><author><style face="normal" font="default"> Wu,Z.</style></author><author><style face="normal" font="default"> Wu,Y.</style></author><author><style face="normal" font="default"> Zhao,Y.</style></author><author><style face="normal" font="default"> Zhu,Y.</style></author><author><style face="normal" font="default"> Guo,Q.</style></author><author><style face="normal" font="default"> Li,X.</style></author><author><style face="normal" font="default"> Li,R.</style></author><author><style face="normal" font="default"> Ma,P.</style></author><author><style face="normal" font="default"> Yang,X.</style></author><author><style face="normal" font="default"> Chen,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hubei Key Laboratory of Genetic Regulation and Integrative Biology, School of Life Sciences, Central China Normal University, Wuhan 430079, Hubei, China</style></auth-address><titles><title><style face="normal" font="default">Oral exposure to diisodecyl phthalate aggravates allergic dermatitis by oxidative stress and enhancement of thymic stromal lymphopoietin</style></title><secondary-title><style face="normal" font="default">Food Chem Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Food Chem Toxicol</style></full-title></periodical><pages end="69" start="60">60-69</pages><volume><style face="normal" font="default">99</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Melatonin</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oxidative Stress</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> ROS</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="18" Month="11" Year="2016">2016/11/18</year></dates><abstract><style face="normal" font="default">Diisodecyl phthalate (DIDP) is extensively used as an environmentally friendly plasticizer. However, little is known about the adverse effects and the underlying mechanisms of DIDP exposure on immunological diseases. We aimed to determine the role and mechanisms of DIDP exposure in allergic contact dermatitis-like skin lesions. We show that oral DIDP exposure can aggravate allergic dermatitis in mice. Moreover, an increase of ROS, total serum IgE and IL-4 levels were concomitant with this deterioration. We detected the expression of Thymic stromal lymphopoietin (TSLP) and the activation of STATs and NF-kappaB signal pathways. The data indicated that DIDP in combination with FITC triggers TSLP production. Our results also suggested that DIDP exacerbated the activation of NF-kappaB signal pathways, with an enhancement in TSLP expression, which potentiated the activation of STATs and the degranulation of mast cells in the skin, and finally exacerbated allergic dermatitis. The study also suggested that melatonin enhanced the expression of Nrf2, up-regulated the antioxidant genes HO-1 and NQO1, reduced the levels of oxidative stress and TSLP, and alleviated allergic dermatitis. The results demonstrated that DIDP exacerbated allergic dermatitis through oxidative stress and enhanced TSLP production</style></abstract><notes><style face="normal" font="default">DA - 20161122IS - 1873-6351 (Electronic)IS - 0278-6915 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.fct.2016.11.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27871981">PM:27871981</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Food Chem Toxicol\2016-99-60-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Food Chem Toxicol\2016-99-60-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161122, Shen S</style></custom2><misc3><style face="normal" font="default">10.1016/j.fct.2016.11.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40064</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ma,Y.</style></author><author><style face="normal" font="default"> Zhang,J.X.</style></author><author><style face="normal" font="default"> Liu,Y.N.</style></author><author><style face="normal" font="default"> Ge,A.</style></author><author><style face="normal" font="default"> Gu,H.</style></author><author><style face="normal" font="default"> Zha,W.J.</style></author><author><style face="normal" font="default"> Zeng,X.N.</style></author><author><style face="normal" font="default"> Huang,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, the First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu 210029, China</style></auth-address><titles><title><style face="normal" font="default">Caffeic acid phenethyl ester alleviates asthma by regulating the airway microenvironment via the ROS-responsive MAPK/Akt pathway</style></title><secondary-title><style face="normal" font="default">Free Radic Biol Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Free Radic Biol Med</style></abbr-1></periodical><pages end="175" start="163">163-175</pages><volume><style face="normal" font="default">101</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> AKT</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic asthma</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> Collagen</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Hyperplasia</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Intercellular Adhesion Molecule-1</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> lung cancer</style></keyword><keyword><style face="normal" font="default"> Malondialdehyde</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Matrix Metalloproteinase 9</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> mitogen-activated protein kinase</style></keyword><keyword><style face="normal" font="default"> Monocyte</style></keyword><keyword><style face="normal" font="default"> Monocyte Chemoattractant Protein-1</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Ovalbumin</style></keyword><keyword><style face="normal" font="default"> oxidant</style></keyword><keyword><style face="normal" font="default"> Oxidative Stress</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Propolis</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> ROS</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> Transforming Growth Factor beta1</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="13" Month="10" Year="2016">2016/10/13</year></dates><abstract><style face="normal" font="default">In the pathophysiology of asthma, structural cell dysfunction and concomitant microenvironment changes in airways are crucial to pathological progression, which involves oxidative stress. Caffeic acid phenethyl ester (CAPE) is an active anti-oxidative component obtained from propolis, and has been shown to have beneficial effects on several respiratory disorders, such as chronic obstructive pulmonary disease and lung cancer. However, the impact of CAPE on asthma is not well understood. Therefore, this study investigated the advantages of using CAPE to treat asthma and demonstrated the roles of CAPE in the regulation of airway microenvironments. In ovalbumin (OVA)-sensitized mice, CAPE treatments notably reduced airway hyperresponsiveness, attenuated extensive inflammatory cell infiltration and inhibited goblet cell hyperplasia and collagen deposition and fibrosis. In addition, CAPE improved the airway microenvironment in a dose-dependent manner by inhibiting OVA-induced increases in immunoglobulin E, tumor necrosis factor alpha (TNF-alpha), transforming growth factor-beta1 (TGF-beta1), interleukin (IL)-4 and IL-13 and suppressing matrix metalloproteinase-9 and alpha-smooth muscle actin expression as well as malondialdehyde production. To determine the underlying mechanisms responsible for these effects, we used TNF-alpha-stimulated BECs and TGF-beta1-challenged human ASMCs to explore the impacts of CAPE on pro-inflammatory proteins and ASMC proliferation. The results indicated that CAPE significantly limited the secretion of eotaxin-1, monocyte chemoattractant protein-1, IL-8 and intercellular adhesion molecule-1 and dramatically inhibited the proliferation of ASMCs. These effects were shown to be associated with decreased reactive oxidant species (ROS) levels. The phosphorylation of Akt and Mitogen-Activated Protein Kinase (MAPK) caused by increased ROS was significantly decreased by CAPE, which implied a contribution of ROS-MAPK/Akt signaling to the attenuation of asthma. Our findings indicated for the first time that CAPE alleviates airway inflammation and remodeling in chronic asthma by balancing the airway microenvironment, which highlights a novel profile of CAPE as a potent agent for asthma management</style></abstract><notes><style face="normal" font="default">DA - 20161017IS - 1873-4596 (Electronic)IS - 0891-5849 (Linking)LA - ENGPT - ReviewPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.freeradbiomed.2016.09.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27746262">PM:27746262</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Free Radic Biol Med\2016-101-163-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Free Radic Biol Med\2016-101-163-75.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161017, Ma Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.freeradbiomed.2016.09.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40065</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lin,T.H.</style></author><author><style face="normal" font="default"> Cheng,C.C.</style></author><author><style face="normal" font="default"> Su,H.H.</style></author><author><style face="normal" font="default"> Huang,N.C.</style></author><author><style face="normal" font="default"> Chen,J.J.</style></author><author><style face="normal" font="default"> Kang,H.Y.</style></author><author><style face="normal" font="default"> Chang,T.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University , Kaohsiung , Taiwan</style></auth-address><titles><title><style face="normal" font="default">Lipopolysaccharide Attenuates Induction of Proallergic Cytokines, Thymic Stromal Lymphopoietin, and Interleukin 33 in Respiratory Epithelial Cells Stimulated with PolyI:C and Human Parechovirus</style></title><secondary-title><style face="normal" font="default">Front Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Immunol</style></abbr-1></periodical><pages end="" start="440">440-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> activation</style></keyword><keyword><style face="normal" font="default"> adaptive</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway epithelial cell</style></keyword><keyword><style face="normal" font="default"> airway epithelial cells</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic response</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dexamethasone</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Epidemiological studies</style></keyword><keyword><style face="normal" font="default"> epithelia</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> Epithelium</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Hygiene</style></keyword><keyword><style face="normal" font="default"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate immunity</style></keyword><keyword><style face="normal" font="default"> Interferon</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Interleukin-33</style></keyword><keyword><style face="normal" font="default"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> LPS</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Taiwan</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> TLR</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Epidemiological studies based on the "hygiene hypothesis" declare that the level of childhood exposure to environmental microbial products is inversely related to the incidence of allergic diseases in later life. Multiple types of immune cell-mediated immune regulation networks support the hygiene hypothesis. Epithelial cells are the first line of response to microbial products in the environment and bridge the innate and adaptive immune systems; however, their role in the hygiene hypothesis is unknown. To demonstrate the hygiene hypothesis in airway epithelial cells, we examined the effect of lipopolysaccharide (LPS; toll-like receptor 4 ligand) on the expression of the proallergic cytokines thymic stromal lymphopoietin (TSLP) and interleukin 33 (IL33) in H292 cells (pulmonary mucoepidermoid carcinoma cells). Stimulation with the TLR ligand polyI:C and human parechovirus type 1 (HPeV1) but not LPS-induced TSLP and IL33 through interferon regulatory factor 3 (IRF3) and NF-kappaB activity, which was further validated by using inhibitors (dexamethasone and Bay 11-7082) and short hairpin RNA-mediated gene knockdown. Importantly, polyI:C and HPeV1-stimulated TSLP and IL33 induction was reduced by LPS treatment by attenuating TANK-binding kinase 1, IRF3, and NF-kappaB activation. Interestingly, the basal mRNA levels of TLR signaling proteins were downregulated with long-term LPS treatment of H292 cells, which suggests that such long-term exposure modulates the expression of innate immunity signaling molecules in airway epithelial cells to mitigate the allergic response. In contrast to the effects of LPS treatment, the alarmin high-mobility group protein B1 acts in synergy with polyI:C to promote TSLP and IL33 expression. Our data support part of the hygiene hypothesis in airway epithelia cells in vitro. In addition to therapeutic targeting of TSLP and IL33, local application of non-pathogenic LPS may be a rational strategy to prevent allergies</style></abstract><notes><style face="normal" font="default">DA - 20161109IS - 1664-3224 (Linking)LA - ENGPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.3389/fimmu.2016.00440</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27826297">PM:27826297</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Immunol\2016-7-440.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Immunol\2016-7-440.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161109, Lin TH</style></custom2><misc3><style face="normal" font="default">10.3389/fimmu.2016.00440</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40066</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lourenco,O.</style></author><author><style face="normal" font="default"> Fonseca,A.M.</style></author><author><style face="normal" font="default"> Taborda-Barata,L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Human CD8+ T Cells in Asthma: Possible Pathways and Roles for NK-Like Subtypes</style></title><secondary-title><style face="normal" font="default">Front Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Immunol</style></abbr-1></periodical><pages end="" start="638">638-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial inflammation</style></keyword><keyword><style face="normal" font="default"> CD8+ T cells</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Characterization</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Repair</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> subtypes</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="default">1664-3224</style></isbn><abstract><style face="normal" font="default">Asthma affects approximately 300 million people worldwide and is the most common chronic lung disease, which usually is associated with bronchial inflammation. Most research has focused upon the role of CD4+ T cells and relatively few studies have addressed the phenotypic and functional roles of CD8+ T cell types and subtypes. Human NK-like CD8+ T cells may involve cells that have been described as CD8+CD28-, CD8+CD28-CD57+, CD8+CD27-, or CD8+ effector-memory (TEM) cells, among other. However, most of the data which is available regarding these various cell types were obtained in murine models, did not thoroughly characterize these cells with phenotypically or functionally or did not involve asthma-related settings. Nevertheless, one may conceptualize three principal roles for human NK-like CD8+ T cells in asthma: disease-promoting, regulatory and/or tissue repair. Although evidence for some of these roles is scarce, it is possible to extrapolate some data from overlapping or related CD8+ T cell phenotypes, with caution. Clearly, further research is warranted, namely in terms of thorough functional and phenotypic characterization of human NK-like CD8+ T cells in human asthma of varying severity</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.3389/fimmu.2016.00638</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.3389/fimmu.2016.00638</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Immunol\2016-7-638.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Immunol\2016-7-638.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170115, Lourenco O</style></custom2><misc3><style face="normal" font="default">10.3389/fimmu.2016.00638</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40067</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Thompson,M.D.</style></author><author><style face="normal" font="default"> Capra,V.</style></author><author><style face="normal" font="default"> Clunes,M.T.</style></author><author><style face="normal" font="default"> Rovati,G.E.</style></author><author><style face="normal" font="default"> Stankova,J.</style></author><author><style face="normal" font="default"> Maj,M.C.</style></author><author><style face="normal" font="default"> Duffy,D.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Biochemical Genetics and Metabolomics Laboratory, Department of Pediatrics, University of California, San Diego, La JollaCA, USA</style></auth-address><titles><title><style face="normal" font="default">Cysteinyl Leukotrienes Pathway Genes, Atopic Asthma and Drug Response: From Population Isolates to Large Genome-Wide Association Studies</style></title><secondary-title><style face="normal" font="default">Front Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Pharmacol</style></abbr-1></periodical><pages end="" start="299">299-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">5-Lipoxygenase</style></keyword><keyword><style face="normal" font="default"> Acids</style></keyword><keyword><style face="normal" font="default"> activation</style></keyword><keyword><style face="normal" font="default"> ALOX5</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> Arachidonic Acid</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> association studies</style></keyword><keyword><style face="normal" font="default"> association study</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma risk</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic asthma</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Ca2+</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> CysLT</style></keyword><keyword><style face="normal" font="default"> cysteinyl leukotriene</style></keyword><keyword><style face="normal" font="default"> cysteinyl leukotrienes</style></keyword><keyword><style face="normal" font="default"> cysteinyl-leukotrienes</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drug therapy</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Enzymes</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic Loci</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Genome-wide</style></keyword><keyword><style face="normal" font="default"> genome-wide association</style></keyword><keyword><style face="normal" font="default"> genome-wide association studies</style></keyword><keyword><style face="normal" font="default"> genome-wide association study</style></keyword><keyword><style face="normal" font="default"> Glutathione</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Intracellular signaling</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Leukotriene C4</style></keyword><keyword><style face="normal" font="default"> Leukotrienes</style></keyword><keyword><style face="normal" font="default"> Lipoxygenase</style></keyword><keyword><style face="normal" font="default"> LTE4</style></keyword><keyword><style face="normal" font="default"> metabolomics</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Sequence</style></keyword><keyword><style face="normal" font="default"> Sequences</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> Tandem Repeat Sequences</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Genetic variants associated with asthma pathogenesis and altered response to drug therapy are discussed. Many studies implicate polymorphisms in genes encoding the enzymes responsible for leukotriene synthesis and intracellular signaling through activation of seven transmembrane domain receptors, such as the cysteinyl leukotriene 1 (CYSLTR1) and 2 (CYSLTR2) receptors. The leukotrienes are polyunsaturated lipoxygenated eicosatetraenoic acids that exhibit a wide range of pharmacological and physiological actions. Of the three enzymes involved in the formation of the leukotrienes, arachidonate 5 lipoxygenase 5 (ALOX5), leukotriene C4 synthase (LTC4S), and leukotriene hydrolase (LTA4H) are all polymorphic. These polymorphisms often result in variable production of the CysLTs (LTC4, LTD4, and LTE4) and LTB4. Variable number tandem repeat sequences located in the Sp1-binding motif within the promotor region of the ALOX5 gene are associated with leukotriene burden and bronchoconstriction independent of asthma risk. A 444A > C SNP polymorphism in the LTC4S gene, encoding an enzyme required for the formation of a glutathione adduct at the C-6 position of the arachidonic acid backbone, is associated with severe asthma and altered response to the CYSLTR1 receptor antagonist zafirlukast. Genetic variability in the CysLT pathway may contribute additively or synergistically to altered drug responses. The 601 A > G variant of the CYSLTR2 gene, encoding the Met201Val CYSLTR2 receptor variant, is associated with atopic asthma in the general European population, where it is present at a frequency of approximately 2.6%. The variant was originally found in the founder population of Tristan da Cunha, a remote island in the South Atlantic, in which the prevalence of atopy is approximately 45% and the prevalence of asthma is 36%. In vitro work showed that the atopy-associated Met201Val variant was inactivating with respect to ligand binding, Ca2+ flux and inositol phosphate generation. In addition, the CYSLTR1 gene, located at Xq13-21.1, has been associated with atopic asthma. The activating Gly300Ser CYSLTR1 variant is discussed. In addition to genetic loci, risk for asthma may be influenced by environmental factors such as smoking. The contribution of CysLT pathway gene sequence variants to atopic asthma is discussed in the context of other genes and environmental influences known to influence asthma</style></abstract><notes><style face="normal" font="default">DA - 20161219IS - 1663-9812 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -CO - Italy -CO - Grenada -CO - Canada -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.3389/fphar.2016.00299</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27990118">PM:27990118</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Pharmacol\2016-7-299.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Pharmacol\2016-7-299.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161219, Thompson MD</style></custom2><misc3><style face="normal" font="default">10.3389/fphar.2016.00299</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40068</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Amo,G.</style></author><author><style face="normal" font="default"> Cornejo-Garcia,J.A.</style></author><author><style face="normal" font="default"> Garcia-Menaya,J.M.</style></author><author><style face="normal" font="default"> Cordobes,C.</style></author><author><style face="normal" font="default"> Torres,M.J.</style></author><author><style face="normal" font="default"> Esguevillas,G.</style></author><author><style face="normal" font="default"> Mayorga,C.</style></author><author><style face="normal" font="default"> Martinez,C.</style></author><author><style face="normal" font="default"> Blanca-Lopez,N.</style></author><author><style face="normal" font="default"> Canto,G.</style></author><author><style face="normal" font="default"> Ramos,A.</style></author><author><style face="normal" font="default"> Blanca,M.</style></author><author><style face="normal" font="default"> Agundez,J.A.</style></author><author><style face="normal" font="default"> Garcia-Martin,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departamento de Farmacologia, Universidad de Extremadura Caceres, Spain</style></auth-address><titles><title><style face="normal" font="default">FCERI and Histamine Metabolism Gene Variability in Selective Responders to NSAIDS</style></title><secondary-title><style face="normal" font="default">Front Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Pharmacol</style></abbr-1></periodical><pages end="" start="353">353-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Diclofenac</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Etofenamate</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic Association</style></keyword><keyword><style face="normal" font="default"> Genetic Markers</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Ibuprofen</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> Indomethacin</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Ketoprofen</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Naproxen</style></keyword><keyword><style face="normal" font="default"> NSAID</style></keyword><keyword><style face="normal" font="default"> NSAID hypersensitivity</style></keyword><keyword><style face="normal" font="default"> NSAIDs</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paracetamol</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Piroxicam</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> selective responders</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Subunit</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">The high-affinity IgE receptor (Fcepsilon RI) is a heterotetramer of three subunits: Fcepsilon RIalpha, Fcepsilon RIbeta, and Fcepsilon RIgamma (alphabetagamma2) encoded by three genes designated as FCER1A, FCER1B (MS4A2), and FCER1G, respectively. Recent evidence points to FCERI gene variability as a relevant factor in the risk of developing allergic diseases. Because Fcepsilon RI plays a key role in the events downstream of the triggering factors in immunological response, we hypothesized that FCERI gene variants might be related with the risk of, or with the clinical response to, selective (IgE mediated) non-steroidal anti-inflammatory (NSAID) hypersensitivity. From a cohort of 314 patients suffering from selective hypersensitivity to metamizole, ibuprofen, diclofenac, paracetamol, acetylsalicylic acid (ASA), propifenazone, naproxen, ketoprofen, dexketoprofen, etofenamate, aceclofenac, etoricoxib, dexibuprofen, indomethacin, oxyphenylbutazone, or piroxicam, and 585 unrelated healthy controls that tolerated these NSAIDs, we analyzed the putative effects of the FCERI SNPs FCER1A rs2494262, rs2427837, and rs2251746; FCER1B rs1441586, rs569108, and rs512555; FCER1G rs11587213, rs2070901, and rs11421. Furthermore, in order to identify additional genetic markers which might be associated with the risk of developing selective NSAID hypersensitivity, or which may modify the putative association of FCERI gene variations with risk, we analyzed polymorphisms known to affect histamine synthesis or metabolism, such as rs17740607, rs2073440, rs1801105, rs2052129, rs10156191, rs1049742, and rs1049793 in the HDC, HNMT, and DAO genes. No major genetic associations with risk or with clinical presentation, and no gene-gene interactions, or gene-phenotype interactions (including age, gender, IgE concentration, antecedents of atopy, culprit drug, or clinical presentation) were identified in patients. However, logistic regression analyses indicated that the presence of antecedents of atopy and the DAO SNP rs2052129 (GG) were strongly related (P &lt; 0.001 and P = 0.005, respectively) with selective hypersensitivity to ibuprofen. With regard to patients with selective hypersensitivity to ASA, men were more prone to develop such a reaction than women (P = 0.011), and the detrimental DAO SNP rs10156191 in homozygosity increased the risk of developing such hypersensitivity (P = 0.039)</style></abstract><notes><style face="normal" font="default">DA - 20161017IS - 1663-9812 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="default">10.3389/fphar.2016.00353</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27746735">PM:27746735</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Pharmacol\2016-7-353.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Pharmacol\2016-7-353.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161017, Amo G</style></custom2><misc3><style face="normal" font="default">10.3389/fphar.2016.00353</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40069</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yao,Y.S.</style></author><author><style face="normal" font="default"> CHANG,W.W.</style></author><author><style face="normal" font="default"> He,L.P.</style></author><author><style face="normal" font="default"> Jin,Y.L.</style></author><author><style face="normal" font="default"> Li,C.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Environment and Health, School of Earth and Environment, Anhui University of Science and Technology, Huainan 232001, Anhui, China</style></auth-address><titles><title><style face="normal" font="default">An updated meta-analysis of transforming growth factor-beta1 gene: Three well-characterized polymorphisms with asthma</style></title><secondary-title><style face="normal" font="default">Hum Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Hum Immunol</style></abbr-1></periodical><pages end="1291" start="1291">1291-1291</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma risk</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Homozygote</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Transforming Growth Factor beta1</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="10" Year="2016">2016/10/4</year></dates><abstract><style face="normal" font="default">The association between TGF-beta1 polymorphisms and asthma risk has been widely reported, but results were controversial. We performed this meta-analysis based on the Preferred Reporting Items for Systematic Reviews and meta-analyses statement (PRISMA). Electronic database of Pub Med, Web of Science, CBM, and CNKI were searched for eligible articles published up to September, 2013. The effect summary odds ratio (OR) and 95% confidence intervals were obtained. Finally, a total of 20 articles were identified, 17 studies with 3694 cases and 5613 controls for C-509T polymorphism, 7 studies with 1109 cases and 1098 controls for T869C polymorphism and 5 studies with 849 cases and 829 controls for G915C polymorphism. For C-509T, significant associations with asthma were found in Asians (TT+TC vs. CC: P=0.004, OR=1.43, 95%CI=1.12-1.81, Pheterogeneity=0.001) and in Caucasians (P=0.05, OR=1.16, 95%CI=1.00-1.34, Pheterogeneity=0.36). With respect to T869C, a small significant association was observed in overall analysis of allele contrasts(C vs. T: OR=1.14, 95%CI: 1.01-1.29, P=0.03) and homozygote comparison (CC vs. TT: OR=1.29, 95%CI: 1.00-1.65, P=0.05), but no significant risks were found among Caucasian population and Asian population. For G915C polymorphism, no significant association with asthma risk was demonstrated in overall analysis and subgroup analyses according to ethnicity for all genetic models. This meta-analysis suggested that TGF-beta1 C-509T and T869C polymorphisms may be risk factors for asthma</style></abstract><notes><style face="normal" font="default">DA - 20161008IS - 1879-1166 (Electronic)IS - 0198-8859 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.humimm.2016.09.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27717847">PM:27717847</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Hum Immunol\2016-77-1291-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Hum Immunol\2016-77-1291-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161008, Yao YS</style></custom2><misc3><style face="normal" font="default">10.1016/j.humimm.2016.09.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40070</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ke,X.</style></author><author><style face="normal" font="default"> Song,S.</style></author><author><style face="normal" font="default"> Wang,X.</style></author><author><style face="normal" font="default"> Shen,Y.</style></author><author><style face="normal" font="default"> Kang,H.</style></author><author><style face="normal" font="default"> Hong,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China</style></auth-address><titles><title><style face="normal" font="default">Associations of single nucleotide polymorphisms of PTPN22 and Ctla4 genes with the risk of allergic rhinitis in a Chinese Han population</style></title><secondary-title><style face="normal" font="default">Hum Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Hum Immunol</style></abbr-1></periodical><pages end="231" start="227">227-231</pages><volume><style face="normal" font="default">78</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Increased prevalence</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Protein-Tyrosine-Phosphatase</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> T lymphocyte</style></keyword><keyword><style face="normal" font="default"> T-lymphocyte</style></keyword><keyword><style face="normal" font="default"> Tyrosine</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic rhinitis (AR) is an inflammatory disorder of the upper airway. Protein tyrosine phosphatase non-receptor 22 encoded by PTPN22 gene and cytotoxic T-lymphocyte associated 4 encoded by Ctla4 gene are associated with autoimmune diseases. PURPOSE: This study was performed to evaluate the potential association of PTPN22 and Ctla4 single nucleotide polymorphisms (SNPs) with AR in a Chinese Han population. METHODS: A case-control study was performed in 783 Chinese AR patients and 811 healthy controls. Three SNPs in PTPN22 gene (rs2488457, rs1310182, and rs3789604) and 6 SNPs in Ctla4 gene (rs3087243, rs231779, rs11571302, rs11571315, rs231725, and rs35219727) were detected using a polymerase chain reaction-restriction fragment length polymorphism assay (PCR-RFLP). RESULTS: For PTPN22 gene, a significantly decreased prevalence of the rs2488457 CC genotype and C allele was found in AR patients. The frequencies of the rs1310182 CC genotype, CT genotype, and C allele were significantly associated with the risk of AR. For Ctla4 gene, a significantly increased prevalence of the rs11571302 AA genotype, CA genotype and A allele was noted in AR patients. CONCLUSION: SNPs of PTPN22 and Ctla4 genes are significantly associated with the risk of AR in the Chinese Han population</style></abstract><notes><style face="normal" font="default">DA - 20161126IS - 1879-1166 (Electronic)IS - 0198-8859 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.humimm.2016.11.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27888068">PM:27888068</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Hum Immunol\2017-78-227-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Hum Immunol\2017-78-227-31.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161126, Ke X</style></custom2><misc3><style face="normal" font="default">10.1016/j.humimm.2016.11.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40071</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kordulewska,N.K.</style></author><author><style face="normal" font="default"> Kostyra,E.</style></author><author><style face="normal" font="default"> Cieslinska,A.</style></author><author><style face="normal" font="default"> Matysiewicz,M.</style></author><author><style face="normal" font="default"> Fiedorowicz,E.</style></author><author><style face="normal" font="default"> Sienkiewicz-Szlapka,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Warmia and Mazury in Olsztyn, Olsztyn, Warminsko-Mazurskie, Poland.</style></auth-address><titles><title><style face="normal" font="default">Changes in gene expression induced by histamine, fexofenadine and osthole: Expression of histamine H1 receptor, COX-2, NF-kappaB, CCR1, chemokine CCL5/RANTES and interleukin-1beta in PBMC allergic and non-allergic patients</style></title><secondary-title><style face="normal" font="default">Immunobiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunobiology</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> COX-2</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Fexofenadine</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> H1 receptor</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> histamine H1 receptor</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Interleukin-1beta</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Fexofenadine (FXF) is a third-generation antihistamine drug and osthole is assumed as a natural antihistamine alternative. This paper compares results of histamine, FXF and osthole impact on HRH-1, COX-2, NF-kappaB-p50, CCR1 mRNA expression. We also measured mRNA expression of IL-1beta and CCL5/RANTES in incubated peripheral blood mononuclear cells (PBMC) to compared how histamine, FXF and osthole had influence on expression level and interacts on product secretion. OBJECTIVE: The purpose was to investigate expression pattern in asthma PBMC. METHODS: The cultures were treated 72h with FXF and osthole. We measured mRNA expression of histamine HRH-1, COX-2, NF-kappaB-p50, CCR1, IL-1beta and CCL5/RANTES with Real-Time PCR (RT-PCR). RESULTS: The present study suggest that osthole may be a potential inhibitor of histamine H1 receptor activity. We also demonstrated that cells cultured with histamine increase COX-2 mRNA expression and osthole reduce it. CONCLUSION: Allergy remains one of the most common chronic diseases in Europe and it is rapidly approaching epidemic proportions; with current predictions estimating that the number of allergy-afflicted will equal the healthy population by 2020. It is therefore paramount to find new pharmaceuticals which successfully combat allergic disease</style></abstract><notes><style face="normal" font="default">DA - 20161115IS - 1878-3279 (Electronic)IS - 0171-2985 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.imbio.2016.11.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27843000">PM:27843000</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunobiology\20161115-KordulewskaNK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunobiology\20161115-KordulewskaNK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161115, Kordulewska NK</style></custom2><misc3><style face="normal" font="default">10.1016/j.imbio.2016.11.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40072</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">D'Auria,E.</style></author><author><style face="normal" font="default"> Barberi,S.</style></author><author><style face="normal" font="default"> Cerri,A.</style></author><author><style face="normal" font="default"> Boccardi,D.</style></author><author><style face="normal" font="default"> Turati,F.</style></author><author><style face="normal" font="default"> Sortino,S.</style></author><author><style face="normal" font="default"> Banderali,G.</style></author><author><style face="normal" font="default"> Ciprandi,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, San Paolo Hospital, Department of Health Sciences, University of Milan, Milan, ItalyDepartment of Medicine, IR</style></auth-address><titles><title><style face="normal" font="default">Vitamin D status and body mass index in children with atopic dermatitis: A pilot study in Italian children</style></title><secondary-title><style face="normal" font="default">Immunol Lett</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immunol Lett</style></abbr-1></periodical><pages end="35" start="31">31-35</pages><volume><style face="normal" font="default">181</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adaptive</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetic factors</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pilot study</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="11" Year="2016">2016/11/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Vitamin D (vitD) is involved in important regulatory functions of the innate and adaptive immune system. So, it has been hypothesized that vitD might influence the course of atopic dermatitis (AD). Also obesity may have impact on immune system. The aim of our study was to investigate vitamin D status and body mass index (BMI) in urban children with AD. METHODS: 52 children with AD and 43 healthy children were enrolled. SCORAD, BMI and serum vitD levels were evaluated. RESULTS: There was an association between vitamin D and the AD occurrence but neither between vitamin D and the AD severity, nor between vitamin D and BMI. A positive correlation was observed between BMI and the AD severity in males. CONCLUSIONS: This study highlights the complex inter-relationships among atopic dermatitis severity, vitamin D and body mass index and suggests the need to investigate the role of genetic factors and/or gender-related differences to possibly identify new prevention strategies</style></abstract><notes><style face="normal" font="default">DA - 20161113IS - 1879-0542 (Electronic)IS - 0165-2478 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.imlet.2016.11.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27838470">PM:27838470</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Lett\2016-181-31-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Lett\2016-181-31-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161113, D'Auria E</style></custom2><misc3><style face="normal" font="default">10.1016/j.imlet.2016.11.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40073</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bhat,Y.J.</style></author><author><style face="normal" font="default"> Hassan,I.</style></author><author><style face="normal" font="default"> Akhter,S.</style></author><author><style face="normal" font="default"> Rasool,F.</style></author><author><style face="normal" font="default"> Mubashir,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Sexually Transmitted Diseases and Leprosy, Government Medical College, University of Kashmir, Srinagar, Jammu and Kashmir, India</style></auth-address><titles><title><style face="normal" font="default">Patch testing in children: An experience from Kashmir</style></title><secondary-title><style face="normal" font="default">Indian J Dermatol Venereol Leprol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Indian J Dermatol Venereol Leprol</style></full-title></periodical><pages end="188" start="186">186-188</pages><volume><style face="normal" font="default">82</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Government</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Leprosy</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2016">2016/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20160229IS - 0973-3922 (Electronic)IS - 0378-6323 (Linking)LA - engPT - LetterSB - IMCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/0378-6323.168938</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26585851">PM:26585851</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Dermatol Venereol Leprol\2016-82-186-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Dermatol Venereol Leprol\2016-82-186-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160229, Bhat YJ</style></custom2><misc3><style face="normal" font="default">10.4103/0378-6323.168938</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40074</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Choudhary,B.</style></author><author><style face="normal" font="default"> Kumari,S.</style></author><author><style face="normal" font="default"> Dhingra,B.</style></author><author><style face="normal" font="default"> Jhaj,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India</style></auth-address><titles><title><style face="normal" font="default">A clinically suspected case of Anaphylactoid reaction to vitamin K injection in a child - a case report and review of literature</style></title><secondary-title><style face="normal" font="default">Indian J Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Indian J Pharmacol</style></abbr-1></periodical><pages end="457" start="455">455-457</pages><volume><style face="normal" font="default">48</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">anaphylactoid reaction</style></keyword><keyword><style face="normal" font="default"> Cardiopulmonary Resuscitation</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Commercial</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Resuscitation</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Vitamin K</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="default">Vitamin K is commonly indicated in pediatric patients with coagulopathies. Its commercial preparations are available in the market since long. Minor complications are very well-known, but life-threatening events are rarely reported in children. We present a case of 8-year-old child who developed life-threatening event following intravenous Vitamin K injection. She was survived after cardiopulmonary resuscitation. The reaction was most probably due to anaphylactoid reaction to Vitamin K</style></abstract><notes><style face="normal" font="default">DA - 20161019IS - 1998-3751 (Electronic)IS - 0253-7613 (Linking)LA - ENGPT - JOURNAL ARTICLECO - India -</style></notes><work-type><style face="normal" font="default">10.4103/0253-7613.186216</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27756962">PM:27756962</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Pharmacol\2016-48-455-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Pharmacol\2016-48-455-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160109, Choudhary B</style></custom2><misc3><style face="normal" font="default">10.4103/0253-7613.186216</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40075</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mahatme,M.S.</style></author><author><style face="normal" font="default"> Dakhale,G.N.</style></author><author><style face="normal" font="default"> Tadke,K.</style></author><author><style face="normal" font="default"> Hiware,S.K.</style></author><author><style face="normal" font="default"> Dudhgaonkar,S.D.</style></author><author><style face="normal" font="default"> Wankhede,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacology, Indira Gandhi Government Medical College, Nagpur, Maharashtra, India</style></auth-address><titles><title><style face="normal" font="default">Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial</style></title><secondary-title><style face="normal" font="default">Indian J Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Indian J Pharmacol</style></abbr-1></periodical><pages end="653" start="649">649-653</pages><volume><style face="normal" font="default">48</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Cost-effectiveness</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Health</style></keyword><keyword><style face="normal" font="default"> Government</style></keyword><keyword><style face="normal" font="default"> H1-antihistamine</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Intranasal corticosteroid</style></keyword><keyword><style face="normal" font="default"> intranasal corticosteroids</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> montelukast</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Allergic rhinitis (AR) is a global health problem. Almost 10%-25% of population worldwide is affected by AR. Oral/intranasal H1-antihistamine, decongestants, leukotriene receptor antagonists, and intranasal corticosteroids are the pillars in the management of AR. The combination therapy of montelukast with antihistaminic provides enhancing and complimentary effects, thereby reducing the symptoms effectively, but there are scanty data regarding the comparisons of combinations. Therefore, we aimed to compare the efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine combination in patients of AR. MATERIALS AND METHODS: Seventy patients with AR participated in a prospective, randomized, double-blind, parallel, active-controlled, comparative 4-week trial. The patients between the age group of 18-65 years of either gender having moderate-severe intermittent or mild persistent AR were included in the study. The study inclusion criteria required the patients with total nasal symptom score (TNSS) of 5 or higher. The patients were randomly divided into two treatment groups with montelukast-levocetirizine (10 mg and 5 mg) in one group and montelukast-fexofenadine (10 mg and 120 mg) in another group. TNSS parameter was the main effectiveness parameter. RESULTS: Evaluation of TNSS revealed significant difference (P &lt; 0.05) when compared from baseline to 4th week in both groups. The mean change of TNSS, i.e., 9.46 was significant (P &lt; 0.05) in montelukast-fexofenadine group. The cost-effectiveness ratio was less in montelukast-levocetirizine group than in montelukast-fexofenadine group. CONCLUSION: The decrease in TNSS was more in montelukast-fexofenadine group, but the cost-effectiveness is more with montelukast-levocetirizine combination</style></abstract><notes><style face="normal" font="default">DA - 20170109IS - 1998-3751 (Electronic)IS - 0253-7613 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/0253-7613.194854</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28066101">PM:28066101</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Pharmacol\2016-48-649-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Pharmacol\2016-48-649-53.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170109, Mahatme MS</style></custom2><misc3><style face="normal" font="default">10.4103/0253-7613.194854</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40076</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Linneberg,A.</style></author><author><style face="normal" font="default"> Gonzalez-Quintela,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Centre for Prevention and Health, The Capital Region of Denmark, Glostrup, Denmark</style></auth-address><titles><title><style face="normal" font="default">The Unsolved Relationship of Alcohol and Asthma</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="157" start="155">155-157</pages><volume><style face="normal" font="default">171</style></volume><number><style face="normal" font="default">3-4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Alcohol</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword></keywords><dates><year Day="14" Month="12" Year="2016">2016/12/14</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161213IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1159/000454809</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27960176">PM:27960176</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2016-171-155-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2016-171-155-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161213, Linneberg A</style></custom2><misc3><style face="normal" font="default">10.1159/000454809</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40077</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Marone,G.</style></author><author><style face="normal" font="default"> Varricchi,G.</style></author><author><style face="normal" font="default"> Loffredo,S.</style></author><author><style face="normal" font="default"> Galdiero,M.R.</style></author><author><style face="normal" font="default"> Rivellese,F.</style></author><author><style face="normal" font="default"> de Paulis,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Translational Medical Sciences (DiSMeT), University of Naples Federico II, Naples, Italy</style></auth-address><titles><title><style face="normal" font="default">Are Basophils and Mast Cells Masters in HIV Infection?</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="165" start="158">158-165</pages><volume><style face="normal" font="default">171</style></volume><number><style face="normal" font="default">3-4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Glycoprotein</style></keyword><keyword><style face="normal" font="default"> Glycoproteins</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hiv</style></keyword><keyword><style face="normal" font="default"> HIV infection</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human mast cells</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> Viruses</style></keyword><keyword><style face="normal" font="default"> World Health</style></keyword><keyword><style face="normal" font="default"> World Health Organization</style></keyword></keywords><dates><year Day="14" Month="12" Year="2016">2016/12/14</year></dates><abstract><style face="normal" font="default">The World Health Organization AIDS epidemic update estimates that more than 37 million people are living with HIV infection. Despite the unprecedented success of antiretroviral treatments, significant challenges remain in the fight against HIV. In particular, how uninfected cells capture HIV and transmit virions to target cells remains an unanswered question. Tissue mast cells and peripheral blood basophils can be exposed to virions or HIV products during infection. Several HIV proteins (i.e., envelope glycoproteins gp120 and gp41, Tat, and Nef) can interact with distinct surface receptors expressed by human basophils and mast cells and modulate their functional responses at different levels. Additionally, several groups have provided evidence that human mast cells can be infected in vitro, as well as in vivo, by certain strains of HIV. Recently, it has been demonstrated that basophils purified from healthy donors and intestinal mast cells can efficiently capture HIV on their cell surface and, cocultured with CD4+ T cells, they can transfer the virus to the cocultured cells leading to infection. Direct contact between human basophils or intestinal mast cells and CD4+ T cells can mediate viral trans-infection of T cells through the formation of viral synapses. Thus, basophils and mast cells can provide a cellular basis for capturing and then spreading viruses throughout the body. Collectively, these findings suggest that human basophils and mast cells play a complex and possibly distinct role in HIV infection, warranting further investigations</style></abstract><notes><style face="normal" font="default">DA - 20161213IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1159/000452889</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27960171">PM:27960171</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2016-171-158-65.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2016-171-158-65.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161213, Marone G</style></custom2><misc3><style face="normal" font="default">10.1159/000452889</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40078</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pichler,W.J.</style></author><author><style face="normal" font="default"> Hausmann,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">ADR-AC GmbH, Bern, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Classification of Drug Hypersensitivity into Allergic, p-i, and Pseudo-Allergic Forms</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="179" start="166">166-179</pages><volume><style face="normal" font="default">171</style></volume><number><style face="normal" font="default">3-4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> cross reactivity</style></keyword><keyword><style face="normal" font="default"> Cross-reactivity</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Enzymes</style></keyword><keyword><style face="normal" font="default"> HLA</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune-mediated</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Pseudoallergy</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword></keywords><dates><year Day="14" Month="12" Year="2016">2016/12/14</year></dates><abstract><style face="normal" font="default">Drug hypersensitivity reactions (DHR) are clinically and functionally heterogeneous. Different subclassifications based on timing of symptom appearance or type of immune mechanism have been proposed. Here, we show that the mode of action of drugs leading to immune/inflammatory cell stimulation is a further decisive factor in understanding and managing DHR. Three mechanisms can be delineated: (a) some drugs have or gain the ability to bind covalently to proteins, form new antigens, and thus elicit immune reactions to hapten-carrier complexes (allergic/immune reaction); (b) a substantial part of immune-mediated DHR is due to a typical off-target activity of drugs on immune receptors like HLA and TCR (pharmacological interaction with immune receptors, p-i reactions); such p-i reactions are linked to severe DHR; and (c) symptoms of DHR can also appear if the drug stimulates or inhibits receptors or enzymes of inflammatory cells (pseudo-allergy). These three distinct ways of stimulations of immune or inflammatory cells differ substantially in clinical manifestations, time of appearance, dose dependence, predictability, and cross-reactivity, and thus need to be differentiated</style></abstract><notes><style face="normal" font="default">DA - 20161213IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1159/000453265</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27960170">PM:27960170</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2016-171-166-79.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2016-171-166-79.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161213, Pichler WJ</style></custom2><misc3><style face="normal" font="default">10.1159/000453265</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40079</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shimoda,T.</style></author><author><style face="normal" font="default"> Obase,Y.</style></author><author><style face="normal" font="default"> Matsuse,H.</style></author><author><style face="normal" font="default"> Asai,S.</style></author><author><style face="normal" font="default"> Iwanaga,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical Research Center, Fukuoka National Hospital, Fukuoka, Japan</style></auth-address><titles><title><style face="normal" font="default">The Pathogenesis of Alcohol-Induced Airflow Limitation in Acetaldehyde Dehydrogenase 2-Deficient Mice</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="284" start="276">276-284</pages><volume><style face="normal" font="default">171</style></volume><number><style face="normal" font="default">3-4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acetaldehyde</style></keyword><keyword><style face="normal" font="default"> airflow</style></keyword><keyword><style face="normal" font="default"> Airflow limitation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Alcohol</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Constriction</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Ethanol</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Stem Cells</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: In Japanese patients, alcohol-induced asthma is attributed to elevated plasma concentrations of acetaldehyde following alcohol consumption because of an acetaldehyde dehydrogenase 2 gene (ALDH2) polymorphism. The resulting increase in plasma histamine concentrations seems to trigger the onset of asthma symptoms. However, the specific pathogenic mechanism underlying this response remains unclear. ALDH2-deficient mice were therefore generated to investigate the pathogenesis of alcohol-induced asthma. METHODS: ALDH2-deficient mice were generated using embryonic stem cells that were derived from C57BL/6 mice. The resulting mice were backcrossed into the BALB/c mice background. Exon 1 of ALDH2 was replaced with the Neo cassette. Pure ethanol was orally administered to ALDH2-deficient and wild-type mice, and the plasma concentrations of ethanol, acetaldehyde, and histamine, in addition to enhanced pause (Penh) values, were determined and compared between the 2 groups. RESULTS: We established an ALDH2-deficient mouse line to compare responses between wild-type and ALDH2-deficient mice receiving orally administered ethanol. The results showed that the plasma concentrations of acetaldehyde (p &lt; 0.0001) and histamine (p &lt; 0.005) were significantly higher, and the Penh values (p &lt; 0.01) were significantly greater in the ALDH2-deficient mice, although plasma ethanol levels were not different. CONCLUSIONS: We studied the pathogenesis of alcohol-induced asthma using ALDH2-deficient mice. The results demonstrated that alcohol intake resulted in an increase in acetaldehyde levels, and a subsequent increase in histamine levels, which induced airway constriction. Alcohol consumption is known to be an important factor that exacerbates bronchial asthma, and studies investigating this factor are useful for the treatment of patients with alcohol-induced asthma</style></abstract><notes><style face="normal" font="default">DA - 20170103IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1159/000452709</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28049208">PM:28049208</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2016-171-276-84.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2016-171-276-84.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170103, Shimoda T</style></custom2><misc3><style face="normal" font="default">10.1159/000452709</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40080</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rebelo Gomes,E.</style></author><author><style face="normal" font="default"> Geraldes,L.</style></author><author><style face="normal" font="default"> Gaspar,A.</style></author><author><style face="normal" font="default"> Malheiro,D.</style></author><author><style face="normal" font="default"> Cadinha,S.</style></author><author><style face="normal" font="default"> Abreu,C.</style></author><author><style face="normal" font="default"> Chambel,M.</style></author><author><style face="normal" font="default"> Almeida,E.</style></author><author><style face="normal" font="default"> Faria,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunoallergology Department, Centro Hospitalar do Porto EPE, Porto, Portugal</style></auth-address><titles><title><style face="normal" font="default">Hypersensitivity Reactions to Nonsteroidal Anti-Inflammatory Drugs among Adults: Clinical Features and Risk Factors for Diagnosis Confirmation</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="275" start="269">269-275</pages><volume><style face="normal" font="default">171</style></volume><number><style face="normal" font="default">3-4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Gold</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> immediate reactions</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> NSAID</style></keyword><keyword><style face="normal" font="default"> NSAIDs</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> Pyrazolones</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDS) are among the most common causes of drug hypersensitivity (HS) reactions. The diagnosis is based on a careful clinical history, and provocation tests are considered the gold standard for diagnosis. Skin tests have some value to study reactions to pyrazolones. Laboratory investigations are mostly used for research purposes. Different phenotypes have been described. OBJECTIVE AND METHODS: Our aim was to describe the most common clinical manifestations of NSAID HS in a large population of adult patients, the drugs involved, the association with previously described risk factors, and the outcome of diagnostic procedures. The classification of reactions proposed by the European Academy of Allergy and Clinical Immunology (EAACI) Drug Allergy Interest Group was adopted. RESULTS: Acetylsalicylic acid was the drug most often involved in reactions (34%), isolated cutaneous symptoms were the most reported (60%), and immediate reactions (58%) were the most common. There was an overall female predominance (64%) and 35% of the patients were atopic. HS to NSAIDs was confirmed in 21% of the patients. The most common phenotypes encountered among HS patients were NSAID-induced urticaria/angioedema and single-NSAID-induced urticaria/angioedema or anaphylaxis. Logistic regression analysis showed that gender and atopy were not significant risk factors for HS confirmation, but diagnosis depended on the number of previous reactions, the type of reaction, and the time interval between drug intake and reaction. CONCLUSION: Only 21% of suspected HS reactions were confirmed after diagnostic workup. Patients describing >1 previous reaction and suffering immediate reactions had a higher probability of a positive investigation</style></abstract><notes><style face="normal" font="default">DA - 20170103IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.1159/000452627</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28049210">PM:28049210</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2016-171-269-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2016-171-269-75.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170103, Rebelo Gomes E</style></custom2><misc3><style face="normal" font="default">10.1159/000452627</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40081</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cesana,P.</style></author><author><style face="normal" font="default"> Scherer,K.</style></author><author><style face="normal" font="default"> Bircher,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Hospital Basel, Basel, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Immediate Type Hypersensitivity to Heparins: Two Case Reports and a Review of the Literature</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="289" start="285">285-289</pages><volume><style face="normal" font="default">171</style></volume><number><style face="normal" font="default">3-4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> cross reactivity</style></keyword><keyword><style face="normal" font="default"> Cross-reactivity</style></keyword><keyword><style face="normal" font="default"> Dalteparin</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fondaparinux</style></keyword><keyword><style face="normal" font="default"> Heparin</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> LMWH</style></keyword><keyword><style face="normal" font="default"> Low molecular weight heparin</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="1" Year="2017">2017/1/4</year></dates><abstract><style face="normal" font="default">Immediate type hypersensitivity reactions due to heparins are rare, and the exact immunologic pathomechanism has not been identified so far. In our 2 case reports, we describe first a 50-year-old female who received dalteparin (Fragmin(R)) and developed signs of an immediate type hypersensitivity reaction. The personal history revealed a previous application of dalteparin (Fragmin(R)). Evaluation with a skin prick test showed positive results for dalteparin. The second case deals with a 73-year-old female with a suspected immediate type reaction after the administration of dalteparin (Fragmin(R)). A skin prick test was negative but intracutaneous tests showed a positive reaction to the causative agent. Both cases indicated cross-reactivity reactions for low-molecular-weight heparin (LMWH) but not for unfractioned heparin (UFH) or fondaparinux. In conclusion, our case reports including a review of published cases of immediate type hypersensitivity reactions after the application of heparins illustrate this rare complication. Mostly, the causative agent can be identified with a skin test, which is highly suggestive of an IgE-mediated reaction. Therapeutic alternatives for patients with sensitization to an LMWH are UFH and fondaparinux. Both agents have a small risk of cross-reactivity compared to heparins of the same substance class</style></abstract><notes><style face="normal" font="default">DA - 20170103IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1159/000453525</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28049195">PM:28049195</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2016-171-285-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2016-171-285-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170103, Cesana P</style></custom2><misc3><style face="normal" font="default">10.1159/000453525</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40082</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mozafari,O.</style></author><author><style face="normal" font="default"> Shorofi,S.A.</style></author><author><style face="normal" font="default"> Yousefi,S.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dept. of Traditional Persian Medicine, School of Medicine, Student Research Committe, Mazandaran University of Medical Sciences, Sari, Iran</style></auth-address><titles><title><style face="normal" font="default">First Report on Infant Acute Urticaria after Mother's Parenteral Use of Meglumine Antimoniate (Glucantime): A Case Report</style></title><secondary-title><style face="normal" font="default">Iran J Public Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Iran J Public Health</style></abbr-1></periodical><pages end="1219" start="1217">1217-1219</pages><volume><style face="normal" font="default">45</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> Leishmaniasis</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Meglumine</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="default">Pentavalent antimonials are still the first drug of choice for the treatment of cutaneous leishmaniasis (CL). Like other treatments, they can cause adverse reactions including musculoskeletal pain, gastrointestinal disturbances, and mild to moderate headaches. In this paper, we report the first case of an infant who developed acute urticaria after her mother's parenteral use of meglumine antimoniate (glucantime)</style></abstract><notes><style face="normal" font="default">DA - 20161213IS - 2251-6085 (Print)IS - 2251-6085 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27957467">PM:27957467</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Iran J Public Health\2016-45-1217-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Iran J Public Health\2016-45-1217-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161213, Mozafari O</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40083</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Platt,C.D.</style></author><author><style face="normal" font="default"> Massaad,M.J.</style></author><author><style face="normal" font="default"> Cangemi,B.</style></author><author><style face="normal" font="default"> Schmidt,B.</style></author><author><style face="normal" font="default"> Aldhekri,H.</style></author><author><style face="normal" font="default"> Geha,R.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA</style></auth-address><titles><title><style face="normal" font="default">JAK3 deficiency caused by a homozygous synonymous exonic mutation that creates a dominant splice site</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Amino acid</style></keyword><keyword><style face="normal" font="default"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Saudi Arabia</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Sequence</style></keyword><keyword><style face="normal" font="default"> Siblings</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="9" Month="12" Year="2016">2016/12/9</year></dates><abstract><style face="normal" font="default">Two siblings were found to have JAK3 deficiency due to a synonymous exonic mutation. The mutation does not change the predicted JAK3 amino acid sequence, though it is pathogenic as it creates a new donor splice site that disrupts protein expression</style></abstract><notes><style face="normal" font="default">DA - 20161213IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Saudi Arabia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.09.057</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27956217">PM:27956217</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161213-PlattCD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161213-PlattCD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161213, Platt CD</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.09.057</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40084</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jean,T.</style></author><author><style face="normal" font="default"> Pourang,D.</style></author><author><style face="normal" font="default"> Gabikian,P.</style></author><author><style face="normal" font="default"> Lim,J.Y.</style></author><author><style face="normal" font="default"> Samant,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy and Immunology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, Calif.</style></auth-address><titles><title><style face="normal" font="default">Unilateral Nasal Congestion and Headache: Renal Cell Carcinoma Metastasis to the Sinuses</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1124" start="1122">1122-1124</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Headache</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Los Angeles</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161227IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.11.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28024970">PM:28024970</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1122-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1122-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161227, Jean T</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.11.028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40085</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vignesh,P.</style></author><author><style face="normal" font="default"> Gupta,A.</style></author><author><style face="normal" font="default"> Dogra,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Allergy Immunology Unit, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, IndiaPediatric Allergy Immunology Unit, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, IndiaDepartment of Dermatology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Electronic address: sundogra@hotmail.com</style></auth-address><titles><title><style face="normal" font="default">Malar Rash in a Child with Chronic Granulomatous Disease</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="474" start="473">473-474</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic granulomatous disease</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161226IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.11.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28017630">PM:28017630</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-5-473-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-5-473-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161226, Vignesh P</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.11.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40086</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Draijer,C.</style></author><author><style face="normal" font="default"> Boorsma,C.E.</style></author><author><style face="normal" font="default"> Robbe,P.</style></author><author><style face="normal" font="default"> Timens,W.</style></author><author><style face="normal" font="default"> Hylkema,M.N.</style></author><author><style face="normal" font="default"> Ten Hacken,N.H.</style></author><author><style face="normal" font="default"> van den Berge,M.</style></author><author><style face="normal" font="default"> Postma,D.S.</style></author><author><style face="normal" font="default"> Melgert,B.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Groningen, Department of Pharmacokinetics, Toxicology, and Targeting, Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Asthma is characterized by more IRF5+ M1 and CD206+ M2 macrophages and less IL10+ M2-like macrophages around airways compared to healthy airways</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> pharmacokinetics</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Toxicology</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="19" Month="12" Year="2016">2016/12/19</year></dates><abstract><style face="normal" font="default">In asthma, macrophage polarization is altered from a state associated with anti-inflammatory responses to a state associated with inflammation as compared to control. Macrophage polarization states is linked to disease severity, sex and ICS treatment</style></abstract><notes><style face="normal" font="default">DA - 20161223IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28007476">PM:28007476</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161223-DraijerC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161223-DraijerC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161223, Draijer C</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40087</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martin,M.A.</style></author><author><style face="normal" font="default"> Press,V.G.</style></author><author><style face="normal" font="default"> Nyenhuis,S.M.</style></author><author><style face="normal" font="default"> Krishnan,J.A.</style></author><author><style face="normal" font="default"> Erwin,K.</style></author><author><style face="normal" font="default"> Mosnaim,G.</style></author><author><style face="normal" font="default"> Margellos-Anast,H.</style></author><author><style face="normal" font="default"> Paik,S.M.</style></author><author><style face="normal" font="default"> Ignoffo,S.</style></author><author><style face="normal" font="default"> McDermott,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Illinois at Chicago, Chicago, Ill.</style></auth-address><titles><title><style face="normal" font="default">Care transition interventions for children with asthma in the emergency department</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="1525" start="1518">1518-1525</pages><volume><style face="normal" font="default">138</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Communication</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health care utilization</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Illinois</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> Self-management</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">The emergency department (ED) is a critical point of identification and treatment for some of the most high-risk children with asthma. This review summarizes the evidence regarding care transition interventions originating in the ED for children with uncontrolled asthma, with a focus on care coordination and self-management education. Although many interventions on care transition for pediatric asthma have been tested, only a few were actually conducted in the ED setting. Most of these targeted both care coordination and self-management education but ultimately did not improve attendance at follow-up appointments with primary care providers, improve asthma control, or reduce health care utilization. Conducting any ED-based intervention in the current environment is challenging because of the many demands on ED providers and staff, poor communication within and outside of the medical sector, and caregiver/patient burden. The evidence to date suggests that ED care transition interventions should consider expanding beyond the ED to bridge the multiple sectors children with asthma navigate, including health care settings, homes, schools, and community spaces. Patient-centered approaches may also be important to ensure adequate intervention design, enrollment, retention, and evaluation of outcomes important to children and their families</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931533">PM:27931533</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2016-138-1518-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2016-138-1518-25.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161209, Martin MA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40088</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chinen,J.</style></author><author><style face="normal" font="default"> Notarangelo,L.D.</style></author><author><style face="normal" font="default"> Shearer,W.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunology, Allergy and Rheumatology Section, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, Tex.</style></auth-address><titles><title><style face="normal" font="default">Advances in clinical immunology in 2015</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="1540" start="1531">1531-1540</pages><volume><style face="normal" font="default">138</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Therapy</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic mutations</style></keyword><keyword><style face="normal" font="default"> Hematopoietic Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> Texas</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">Advances in clinical immunology in the past year included the report of practice parameters for the diagnosis and management of primary immunodeficiencies to guide the clinician in the approach to these relatively uncommon disorders. We have learned of new gene defects causing immunodeficiency and of new phenotypes expanding the spectrum of conditions caused by genetic mutations such as a specific regulator of telomere elongation (RTEL1) mutation causing isolated natural killer cell deficiency and mutations in ras-associated RAB (RAB27) resulting in immunodeficiency without albinism. Advances in diagnosis included the increasing use of whole-exome sequencing to identify gene defects and the measurement of serum free light chains to identify secondary hypogammaglobulinemias. For several primary immunodeficiencies, improved outcomes have been reported after definitive therapy with hematopoietic stem cell transplantation and gene therapy</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931534">PM:27931534</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2016-138-1531-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2016-138-1531-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161209, Chinen J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40089</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Anise,A.</style></author><author><style face="normal" font="default"> Hasnain-Wynia,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Addressing Disparities Program, Patient-Centered Outcomes Research Institute, Washington, DC.</style></auth-address><titles><title><style face="normal" font="default">Patient-centered outcomes research to improve asthma outcomes</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="1510" start="1503">1503-1510</pages><volume><style face="normal" font="default">138</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> African American</style></keyword><keyword><style face="normal" font="default"> African Americans</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma education</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Comparative effectiveness</style></keyword><keyword><style face="normal" font="default"> DC</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> General practice</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Washington</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">The Patient-Centered Outcomes Research Institute is funding 8 comparative effectiveness research projects to improve patient-centered outcomes for African American and Hispanic/Latino patients with uncontrolled asthma. These projects aim to compare multilevel interventions with known efficacy at the community, home, and health system levels to enhance patient and clinician uptake of the National Heart, Lung, and Blood Institute's National Asthma Education Prevention Program guidelines and improve outcomes. The National Asthma Education Prevention Program guidelines provide clinicians with a range of acceptable approaches for the diagnosis and management of asthma and define general practices that meet the needs of most patients. Yet disparities in asthma care and outcomes remain pervasive for African Americans and Hispanics/Latinos. The National Heart, Lung, and Blood Institute AsthmaNet consortium has identified several top research priorities for pediatric and adult populations, including a recommendation to examine tailored approaches based on race/ethnicity. In addition, the guidelines emphasize the need for studies that focus on multicomponent interventions recognizing that single interventions are generally ineffective. This article will describe the Patient-Centered Outcomes Research Institute-funded asthma projects and how they are individually and collectively addressing evidence gaps in asthma care by focusing on multicomponent and tailored approaches for improving outcomes and reducing disparities for African American and Hispanic/Latino patients</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931532">PM:27931532</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2016-138-1503-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2016-138-1503-10.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161209, Anise A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40090</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hansel,K.</style></author><author><style face="normal" font="default"> Bellini,V.</style></author><author><style face="normal" font="default"> Bianchi,L.</style></author><author><style face="normal" font="default"> Brozzi,J.</style></author><author><style face="normal" font="default"> Stingeni,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Section of Clinical, Allergological and Venereological Dermatology, Department of Medicine, University of Perugia, Perugia, Italy</style></auth-address><titles><title><style face="normal" font="default">Drug reaction with eosinophilia and systemic symptoms from ceftriaxone confirmed by positive patch test: An immunohistochemical study</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="810" start="808">808-810</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Ceftriaxone</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161207IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.10.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27923648">PM:27923648</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-808-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-808-10.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161207, Hansel K</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.10.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40091</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Naeem,A.S.</style></author><author><style face="normal" font="default"> Tommasi,C.</style></author><author><style face="normal" font="default"> Cole,C.</style></author><author><style face="normal" font="default"> Brown,S.J.</style></author><author><style face="normal" font="default"> Zhu,Y.</style></author><author><style face="normal" font="default"> Way,B.</style></author><author><style face="normal" font="default"> Willis Owen,S.A.</style></author><author><style face="normal" font="default"> Moffatt,M.</style></author><author><style face="normal" font="default"> Cookson,W.O.</style></author><author><style face="normal" font="default"> Harper,J.I.</style></author><author><style face="normal" font="default"> Wl,D.</style></author><author><style face="normal" font="default"> Brown,S.J.</style></author><author><style face="normal" font="default"> Reinheckel,T.</style></author><author><style face="normal" font="default"> O'Shaughnessy,R.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunobiology and Dermatology, UCL Institute of Child Health; Livingstone Skin Research Centre, UCL Institute of Child Health</style></auth-address><titles><title><style face="normal" font="default">An mTORC1/AKT1/Cathepsin H axis controls filaggrin expression and processing in skin, a novel mechanism for skin barrier disruption in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cell Culture</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Filaggrin</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Keratinocytes</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Protease</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> Skin barrier function</style></keyword><keyword><style face="normal" font="default"> Subunit</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Up-Regulation</style></keyword></keywords><dates><year Day="29" Month="11" Year="2016">2016/11/29</year></dates><abstract><style face="normal" font="default">BACKGROUND: Filaggrin, encoded by the FLG gene, is an important component of the skin's barrier to the external environment and genetic defects in FLG strongly associate with Atopic Dermatitis (AD). However, not all AD patients have FLG mutations. OBJECTIVE: We hypothesised that these patients may possess other defects in filaggrin expression and processing, contributing to barrier disruption and AD, and therefore present novel therapeutic targets for this disease. RESULTS: We describe the relationship between the mTORC1 protein subunit RAPTOR, the serine/threonine kinase AKT1 and the protease cathepsin H, for which we establish a role in filaggrin expression and processing. Increased RAPTOR levels correlated with decreased filaggrin expression in AD. In keratinocyte cell culture, RAPTOR up-regulation or AKT1 shRNA knockdown reduced the expression of the protease cathepsin H. Skin of cathepsin H-deficient mice and CTSH shRNA knockdown keratinocytes showed reduced filaggrin processing and the mouse showed both impaired skin barrier function and a mild proinflammatory phenotype. CONCLUSION: Our findings highlight a novel, potentially treatable, signalling axis controlling filaggrin expression and processing which is defective in AD</style></abstract><notes><style face="normal" font="default">DA - 20161203IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.09.052</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27913303">PM:27913303</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161203-NaeemAS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161203-NaeemAS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161203, Naeem AS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.09.052</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40092</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Haahtela,T.</style></author><author><style face="normal" font="default"> Herse,F.</style></author><author><style face="normal" font="default"> Karjalainen,J.</style></author><author><style face="normal" font="default"> Klaukka,T.</style></author><author><style face="normal" font="default"> Linna,M.</style></author><author><style face="normal" font="default"> Leskela,R.L.</style></author><author><style face="normal" font="default"> Selroos,O.</style></author><author><style face="normal" font="default"> Reissell,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, Finland.</style></auth-address><titles><title><style face="normal" font="default">The Finnish experience to save asthma costs by improving care in 1987-2013</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> and primary</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Cost Savings</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> health care use</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The Finnish National Asthma Program 1994-2004 markedly improved asthma care in the 1990s. We evaluated the changes in costs during 26 years from 1987 to 2013. Direct and indirect costs were calculated by using data from national registries. Costs from both the societal and patient perspectives were included. The costs were based on patients with persistent, physician-diagnosed asthma verified by lung function measurements. We constructed minimum and maximum scenarios to assess the effect of improved asthma care on total costs. The number of patients with persistent asthma in the national drug reimbursement register increased from 83,000 to 247,583. Improved asthma control reduced health care use and disability, resulting in major cost savings. Despite a 3-fold increase in patients, the total costs decreased by 14%, from euro222 million to euro191 million. Costs for medication and primary care visits increased, but overall annual costs per patient decreased by 72%, from euro2656 to euro749. The theoretical total cost savings for 2013, comparing actual with predicted costs, were between euro120 and euro475 million, depending on the scenario used. The Finnish Asthma Program resulted in significant cost savings at both the societal and patient levels during a 26-year period</style></abstract><notes><style face="normal" font="default">DA - 20161216IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.12.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27979429">PM:27979429</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161216-HaahtelaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161216-HaahtelaT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161216, Haahtela T</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.12.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40093</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Haapaniemi,E.M.</style></author><author><style face="normal" font="default"> Fogarty,C.L.</style></author><author><style face="normal" font="default"> Keskitalo,S.</style></author><author><style face="normal" font="default"> Katayama,S.</style></author><author><style face="normal" font="default"> Vihinen,H.</style></author><author><style face="normal" font="default"> Ilander,M.</style></author><author><style face="normal" font="default"> Mustjoki,S.</style></author><author><style face="normal" font="default"> Krjutskov,K.</style></author><author><style face="normal" font="default"> Lehto,M.</style></author><author><style face="normal" font="default"> Hautala,T.</style></author><author><style face="normal" font="default"> Eriksson,O.</style></author><author><style face="normal" font="default"> Jokitalo,E.</style></author><author><style face="normal" font="default"> Velagapudi,V.</style></author><author><style face="normal" font="default"> Varjosalo,M.</style></author><author><style face="normal" font="default"> Seppanen,M.</style></author><author><style face="normal" font="default"> Kere,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden; Folkhalsan Institute of Genetics, Folkhalsan Research Center, Helsinki, Finland; Research Programs Unit, Molecular Neurology, University of Helsinki, Folkhalsan Institute of Genetics, Folkhalsan Research Center, Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="default">To the Editor: Combined immunodeficiency and hypoglycemia associated with mutations in hypoxia up-regulated 1</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Hypoglycemia</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">We describe recessive mutations in hypoxia up-regulated 1 (HYOU1) in a patient that presented with generalized susceptibility to bacterial and herpetic infections as well as hypoglycemic episodes</style></abstract><notes><style face="normal" font="default">DA - 20161203IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Finland -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.09.050</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27913302">PM:27913302</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161203-HaapaniemiEM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161203-HaapaniemiEM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161203, Haapaniemi EM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.09.050</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40094</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Van Roey,G.A.</style></author><author><style face="normal" font="default"> Vanison,C.C.</style></author><author><style face="normal" font="default"> Wu,J.</style></author><author><style face="normal" font="default"> Huang,J.H.</style></author><author><style face="normal" font="default"> Suh,L.A.</style></author><author><style face="normal" font="default"> Carter,R.G.</style></author><author><style face="normal" font="default"> Norton,J.E.</style></author><author><style face="normal" font="default"> Shintani-Smith,S.</style></author><author><style face="normal" font="default"> Conley,D.B.</style></author><author><style face="normal" font="default"> Welch,K.C.</style></author><author><style face="normal" font="default"> Peters,A.T.</style></author><author><style face="normal" font="default"> Grammer,L.C.</style></author><author><style face="normal" font="default"> Harris,K.E.</style></author><author><style face="normal" font="default"> Hulse,K.E.</style></author><author><style face="normal" font="default"> Kato,A.</style></author><author><style face="normal" font="default"> Stevens,W.W.</style></author><author><style face="normal" font="default"> Kern,R.C.</style></author><author><style face="normal" font="default"> Schleimer,R.P.</style></author><author><style face="normal" font="default"> Tan,B.K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Classical Complement Pathway Activation in the Nasal Tissue of Patients With Chronic Rhinosinusitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Autoantibodies</style></keyword><keyword><style face="normal" font="default"> Basement Membrane</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Complement</style></keyword><keyword><style face="normal" font="default"> Complement Activation</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Igg</style></keyword><keyword><style face="normal" font="default"> Igm</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulins</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laminin</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Tissue Extracts</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Complement plays a major role in inflammatory diseases but its involvement and mechanisms of activation in chronic rhinosinusitis (CRS) are not known. OBJECTIVES: Following earlier studies discovering autoantibodies in CRS, we sought to investigate the nature, extent, and location of complement activation in nasal tissue of patients with CRS. Specifically, we were interested in whether antibody-mediated activation via the classical pathway was a major mechanism for complement activation in CRS. METHODS: Nasal tissue was obtained from patients with CRS and control patients. Tissue homogenates were analyzed for complement activation products (ELISA-C5b-9, C4d, activated C1 and C5a) and major complement fixing antibodies (Luminex). Tissue sections were stained for C5b-9, C4d, and laminin. Antibodies were purified using protein A/G columns from nasal polyps (NP), matching patient serum and control serum, and assayed for basement membrane binding via ELISA. RESULTS: C5b-9 was significantly increased in NP tissue compared to UT (uncinate tissue) of CRS with NP (CRSwNP) and CRS without NP (CRSsNP) (p&lt;0.01). Similarly, C4d was increased in NP compared to UT of CRSwNP, CRSsNP and control (p&lt;0.05). Activated C1 was also increased in NP tissue compared to UT of CRSsNP and control (p&lt;0.05) and was correlated with C5a (p&lt;0.01), local immunoglobulins, especially IgM (p&lt;0.0001) and anti-dsDNA IgG (p&lt;0.05). Immunofluorescence showed that C5b-9 and C4d deposition occurred linearly along the epithelial basement membrane. NP tissue extracts had significantly more anti-basement membrane antibodies than sera from CRSwNP and control patients (p&lt;0.0001). CONCLUSION: C5b-9, C4d and activated C1 were significantly increased locally in NP tissue. C5b-9 and C4d were almost universally deposited linearly along the basement membrane of NP tissue. Furthermore, activated C1 was best correlated with local immunoglobulin levels and C5a levels. Together, these data suggest that the classical pathway plays a major role in complement activation in CRS</style></abstract><notes><style face="normal" font="default">DA - 20161216IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27979430">PM:27979430</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161216-VanRoeyGA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161216-VanRoeyGA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161216, Van Roey GA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40095</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tabellini,G.</style></author><author><style face="normal" font="default"> Vairo,D.</style></author><author><style face="normal" font="default"> Scomodon,O.</style></author><author><style face="normal" font="default"> Tamassia,N.</style></author><author><style face="normal" font="default"> Ferraro,R.M.</style></author><author><style face="normal" font="default"> Patrizi,O.</style></author><author><style face="normal" font="default"> Gasperini,S.</style></author><author><style face="normal" font="default"> Soresina,A.</style></author><author><style face="normal" font="default"> Giardino,G.</style></author><author><style face="normal" font="default"> Pignata,C.</style></author><author><style face="normal" font="default"> Lougaris,V.</style></author><author><style face="normal" font="default"> Plebani,A.</style></author><author><style face="normal" font="default"> Dotta,L.</style></author><author><style face="normal" font="default"> Cassatella,M.A.</style></author><author><style face="normal" font="default"> Parolini,S.</style></author><author><style face="normal" font="default"> Badolato,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy</style></auth-address><titles><title><style face="normal" font="default">Impaired NK cell functions in patients with STAT1 gain-of-function mutations</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Bacterial Infections</style></keyword><keyword><style face="normal" font="default"> Candidiasis</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cell Proliferation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> IL-2</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> NK cells</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Promoter</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> signal transducer and activator of transcription 1</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> STAT1</style></keyword><keyword><style face="normal" font="default"> TH17</style></keyword><keyword><style face="normal" font="default"> TH17 cells</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword></keywords><dates><year Day="6" Month="1" Year="2017">2017/1/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Gain-of-function (GOF) mutations affecting the coiled-coil domain or the DNA-binding domain of the Signal Transducer and Activator of Transcription 1 (STAT1) cause chronic mucocutaneous candidiasis disease (CMCD). This condition is characterized by fungal and bacterial infections due to impaired generation of Th17 cells; meanwhile some CMCD patients may also develop viral or intracellular pathogens infections. OBJECTIVE: To Investigate the effect of GOF-STAT1 mutations on functioning of Natural Killer (NK) cells. METHODS: Since STAT1 is involved in the signaling response to several cytokines, we studied NK cell functional activities and STAT1 signaling in eight patients with STAT1-GOF mutations. RESULTS: Functional analysis of NK cells shows a significant impairment of cytolytic and degranulation activities in patients with STAT1-GOF mutations. Moreover, NK cells from these patients display lower production of IFN-gamma in response to IL-15 and reduced proliferation after stimulation with IL-2 or IL-15, suggesting that STAT5 signaling is affected. In addition, signaling studies demonstrate that the increased phosphorylation of STAT1 in response to IFN-alpha is associated with detectable activation of STAT1 and increased STAT1 binding to IFIT1 promoter in response to IL-15, while STAT5 phosphorylation and DNA binding to IL2RA are reduced or not affected in response to the same cytokine. CONCLUSION: These observations suggest that persistent activation of STAT1 might affect NK cell proliferation and functional activities</style></abstract><notes><style face="normal" font="default">DA - 20170110IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.051</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28069426">PM:28069426</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170110-TabelliniG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170110-TabelliniG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170110, Tabellini G</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.051</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40096</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sun,Q.</style></author><author><style face="normal" font="default"> Liu,L.</style></author><author><style face="normal" font="default"> Wang,H.</style></author><author><style face="normal" font="default"> Mandal,J.</style></author><author><style face="normal" font="default"> Khan,P.</style></author><author><style face="normal" font="default"> Hostettler,K.E.</style></author><author><style face="normal" font="default"> Stolz,D.</style></author><author><style face="normal" font="default"> Tamm,M.</style></author><author><style face="normal" font="default"> Molino,A.</style></author><author><style face="normal" font="default"> Lardinois,D.</style></author><author><style face="normal" font="default"> Lu,S.</style></author><author><style face="normal" font="default"> Roth,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biochemistry and Molecular Biology, Key Laboratory of Environment and Genes Related to Diseases (Ministry of Education), Xi'an Jiaotong University Health Science Center, Xi'an, China</style></auth-address><titles><title><style face="normal" font="default">Constitutive high expression of protein arginine methyltransferase 1 in asthmatic airway smooth muscle cells is caused by reduced microRNA-19a expression and leads to enhanced remodeling</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway remodeling</style></keyword><keyword><style face="normal" font="default"> airway smooth muscle</style></keyword><keyword><style face="normal" font="default"> airway smooth muscle cells</style></keyword><keyword><style face="normal" font="default"> Arginine</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Biochemistry</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Cell Proliferation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Collagen</style></keyword><keyword><style face="normal" font="default"> Collagen Type I</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="default"> fibronectin</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> MicroRNAs</style></keyword><keyword><style face="normal" font="default"> mitogen-activated protein kinase</style></keyword><keyword><style face="normal" font="default"> Molecular Biology</style></keyword><keyword><style face="normal" font="default"> Muscle Cells</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> Platelet-Derived Growth Factor</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> rat</style></keyword><keyword><style face="normal" font="default"> Rats</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Rna</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> STAT1</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="1" Year="2017">2017/1/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: In asthma remodeling airway smooth muscle cells (ASMCs) contribute to airway wall thickness through increased proliferation, migration, and extracellular matrix deposition. Previously, we described that protein arginine methyltransferase 1 (PRMT1) participates in airway remodeling in pulmonary inflammation in E3 rats. OBJECTIVE: We sought to define the asthma-specific regulatory mechanism of PRMT1 in human ASMCs. METHODS: ASMCs from healthy subjects and asthmatic patients were activated with platelet-derived growth factor (PDGF)-BB. PRMT1 was localized by means of immunohistochemistry in human lung tissue sections and by means of immunofluorescence in isolated ASMCs. PRMT1 activity was suppressed by the pan-PRMT inhibitor AMI-1, signal transducer and activator of transcription 1 (STAT1) was suppressed by small interfering RNA, and extracellular signal-regulated kinase (ERK) 1/2 mitogen-activated protein kinase (MAPK) was suppressed by PD98059. MicroRNAs (miRs) were assessed by using real-time quantitative PCR and regulated by miR mimics or inhibitors. RESULTS: PRMT1 expression was significantly increased in lung tissue sections and in isolated ASMCs of patients with severe asthma. PDGF-BB significantly increased PRMT1 expression through ERK1/2 MAPK and STAT1 signaling in control ASMCs, whereas in ASMCs from asthmatic patients, these proteins were constitutively expressed. ASMCs from asthmatic patients had reduced miR-19a expression, causing upregulation of ERK1/2 MAPK, STAT1, and PRMT1. Inhibition of PRMT1 abrogated collagen type I and fibronectin deposition, cell proliferation, and migration of ASMCs from asthmatic patients. CONCLUSIONS: PRMT1 is a central regulator of tissue remodeling in ASMCs from asthmatic patients through the pathway: PDGF-BB-miR-19a-ERK1/2 MAPK and STAT1. Low miR-19a expression in ASMCs from asthmatic patients is the key event that results in constitutive increased PRMT1 expression and remodeling. Therefore PRMT1 is an attractive target to limit airway wall remodeling in asthmatic patients</style></abstract><notes><style face="normal" font="default">DA - 20170113IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - China -CO - Switzerland -CO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28081849">PM:28081849</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170113-SunQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170113-SunQ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170113, Sun Q</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40097</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Han,Y.Y.</style></author><author><style face="normal" font="default"> Forno,E.</style></author><author><style face="normal" font="default"> Celedon,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pediatric Pulmonary Medicine, Allergy, and Immunology, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh, Pittsburgh, Pa</style></auth-address><titles><title><style face="normal" font="default">Vitamin D Insufficiency and Asthma in a US Nationwide Study</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="796" start="790">790-796</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Income</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> National Health and Nutrition Examination Survey</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Medicine</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Vitamin D insufficiency (a serum 25-hydroxy vitamin D level of &lt;30 ng/mL) has been associated with asthma morbidity. OBJECTIVE: To examine vitamin D insufficiency, asthma, and lung function among US children and adults. METHODS: Using data from the National Health and Nutrition Examination Survey from 2001 to 2010, we examined vitamin D insufficiency and (1) current asthma or wheeze in 10,860 children (6-17 years) and 24,115 adults (18-79 years) and (2) lung function in a subset of participants. Logistic or linear regression was used for the multivariable analysis, adjusting for age, sex, race/ethnicity, income, body mass index, smoking, and C-reactive protein level. RESULTS: Vitamin D insufficiency was associated with current asthma (odds ratio, 1.35; 95% CI, 1.11-1.64) and current wheeze in children, as well as with current wheeze in adults (odds ratio, 1.17; 95% CI, 1.04-1.31). After stratifying the analysis by race/ethnicity and (in adults) current smoking, vitamin D insufficiency was associated with current asthma and wheeze in non-Hispanic white children only; in adults, vitamin D insufficiency was associated with current wheeze in non-Hispanic whites and blacks. Vitamin D insufficiency was also associated with lower FEV1 and forced vital capacity in children and adults. When analyzing each National Health and Nutrition Examination Survey wave separately, vitamin D insufficiency prevalence was 72% to 76% from 2001 to 2006, and then decreased from 2007 to 2010 (64%-65%); interestingly, asthma prevalence decreased for the first time from the period 2007 to 2008 (8.2%) to the period 2009 to 2010 (7.4%). CONCLUSIONS: We show racial/ethnic-specific associations between vitamin D insufficiency and current asthma or wheeze in children and adults. Moreover, we report parallel recent decrements in the prevalence of vitamin D insufficiency and asthma</style></abstract><notes><style face="normal" font="default">DA - 20161203IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.10.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27913247">PM:27913247</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-790-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-790-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161203, Han YY</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.10.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40098</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sverrild,A.</style></author><author><style face="normal" font="default"> Kiilerich,P.</style></author><author><style face="normal" font="default"> Brejnrod,A.</style></author><author><style face="normal" font="default"> Pedersen,R.</style></author><author><style face="normal" font="default"> Porsbjerg,C.</style></author><author><style face="normal" font="default"> Bergqvist,A.</style></author><author><style face="normal" font="default"> Erjefalt,J.S.</style></author><author><style face="normal" font="default"> Kristiansen,K.</style></author><author><style face="normal" font="default"> Backer,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">University Hospital Bispebjerg, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default">Eosinophilic airway inflammation in asthma is associated with an altered airway microbiome</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> diversity</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> induced sputum</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Mannitol</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> Neisseria</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Non-eosinophilic</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Subjects with asthma have higher microbiome diversity, and an altered composition with more Proteobacteria and less Bacteroidetes compared to healthy controls. Studies comparing airway inflammation and airway microbiome are sparse, especially in subjects not on anti-inflammatory treatment. OBJECTIVE: To describe the relationship between the airway microbiome and patterns of airway inflammation in steroid-free subjects with asthma and healthy controls. METHODS: Broncho-alveolar lavage was collected from 23 steroid-free, non-smoking subjects with asthma and 10 healthy controls. Bacterial DNA was extracted from and subjected to Illumina MiSeq sequencing of the 16S rDNA V4 region. Eosinophils and neutrophils in submucosa were quantified by immunohistochemical identification and computerized image analysis. Induced sputum was performed, and Airway hyperresponsiveness to mannitol and Fractional Exhaled Nitric Oxide were measured. Relationships between airway microbial diversity and composition, and inflammatory profiles were analyzed. RESULTS: In patients with asthma, airway microbial composition was associated with airway eosinophilia and AHR to mannitol, but not airway neutrophilia. The overall composition of the airway microbiome of asthmatics with the lowest levels of eosinophils, but not asthmatics with the highest levels of eosinophils deviated significantly from that of healthy individuals. Asthmatics with the lowest levels of eosinophils had an altered bacterial abundance profile with more Neisseria, Bacteroides and Rothia, and less Sphingomonas, Halomonas and Aeribacillus compared to asthmatics with more eosinophils and healthy controls. CONCLUSION: The level of eosinophilic airway inflammation correlates with variations in microbiomes across subjects with asthma, whereas neutrophilic airway inflammation does not. This warrants further investigation on molecular pathways involved in eosinophilic as well as non-eosinophilic asthma</style></abstract><notes><style face="normal" font="default">DA - 20170102IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28042058">PM:28042058</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170102-SverrildA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170102-SverrildA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170102, Sverrild A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.046</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40099</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stein,J.V.</style></author><author><style face="normal" font="default"> Gonzalez,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Theodor Kocher Institute, University of Bern, Bern, SwitzerlandInstitute for Research in Biomedicine, Universita della Svizzera Italiana, Bellinzona, Switzerland.</style></auth-address><titles><title><style face="normal" font="default">Dynamic intravital imaging of cell-cell interactions in the lymph node</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="20" start="12">12-20</pages><volume><style face="normal" font="default">139</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">area</style></keyword><keyword><style face="normal" font="default"> B-Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Biomedicine</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> imaging</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> Microscopy</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">In the last decade, the application of 2-photon intravital microscopy as a tool to study cell interactions in different areas of the immune system has offered an unprecedented opportunity to understand the complexity of cell behavior in relation to immune functions. In this review we describe the latest advances in the field of live imaging in the lymph nodes, grouping the different cell populations in 2 compartments according to their motility: the sessile compartment, which is formed by resident cells of stromal origin, macrophages, and resident dendritic cells, and the motile compartment, which is mainly formed by T and B lymphocytes. Here we review how the use of in vivo imaging has contributed to our understanding of the role of these cells in the initiation of the immune response in the draining lymph nodes</style></abstract><notes><style face="normal" font="default">DA - 20170109IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28065277">PM:28065277</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-12-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-12-20.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170109, Stein JV</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40100</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Perez,E.E.</style></author><author><style face="normal" font="default"> Orange,J.S.</style></author><author><style face="normal" font="default"> Bonilla,F.</style></author><author><style face="normal" font="default"> Chinen,J.</style></author><author><style face="normal" font="default"> Chinn,I.K.</style></author><author><style face="normal" font="default"> Dorsey,M.</style></author><author><style face="normal" font="default"> el-Gamal,Y.</style></author><author><style face="normal" font="default"> Harville,T.O.</style></author><author><style face="normal" font="default"> Hossny,E.</style></author><author><style face="normal" font="default"> Mazer,B.</style></author><author><style face="normal" font="default"> Nelson,R.</style></author><author><style face="normal" font="default"> Secord,E.</style></author><author><style face="normal" font="default"> Jordan,S.C.</style></author><author><style face="normal" font="default"> Stiehm,E.R.</style></author><author><style face="normal" font="default"> Vo,A.A.</style></author><author><style face="normal" font="default"> Ballow,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Associates of the Palm Beaches, North Palm Beach, Fla.</style></auth-address><titles><title><style face="normal" font="default">Update on the use of immunoglobulin in human disease: A review of evidence</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Egypt</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> humoral</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Indications</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> subcutaneous</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Human immunoglobulin preparations for intravenous or subcutaneous administration are the cornerstone of treatment in patients with primary immunodeficiency diseases affecting the humoral immune system. Intravenous preparations have a number of important uses in the treatment of other diseases in humans as well, some for which acceptable treatment alternatives do not exist. We provide an update of the evidence-based guideline on immunoglobulin therapy, last published in 2006. Given the potential risks and inherent scarcity of human immunoglobulin, careful consideration of its indications and administration is warranted</style></abstract><notes><style face="normal" font="default">DA - 20170102IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Egypt -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.09.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28041678">PM:28041678</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170102-PerezEE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170102-PerezEE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170102, Perez EE</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.09.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40101</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">May,S.M.</style></author><author><style face="normal" font="default"> Motosue,M.S.</style></author><author><style face="normal" font="default"> Park,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary, Critical Care, Sleep &amp; Allergy, University of Nebraska Medical Center, Omaha, Neb.</style></auth-address><titles><title><style face="normal" font="default">Dapsone is often tolerated in HIV-infected patients with history of sulfonamide antibiotic intolerance</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="833" start="831">831-833</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Dapsone</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161230IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.11.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28034550">PM:28034550</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-831-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-831-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161230, May SM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.11.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40102</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cogne,Y.</style></author><author><style face="normal" font="default"> Mouton-Faivre,C.</style></author><author><style face="normal" font="default"> Cavasino,T.</style></author><author><style face="normal" font="default"> Teychene,A.M.</style></author><author><style face="normal" font="default"> de Pontual,L.</style></author><author><style face="normal" font="default"> Dewachter,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Service de Pediatrie Generale, Groupe Hospitalier de Paris-Seine-Saint-Denis, Assistance Publique-Hopitaux de Paris, Hopital Jean Verdier, Bondy and Universite Paris 13, France</style></auth-address><titles><title><style face="normal" font="default">Chlorhexidine-induced IgE-mediated allergy in a 6-year-old child</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="838" start="837">837-838</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170102IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.11.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28042002">PM:28042002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-837-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-837-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170102, Cogne Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.11.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40103</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gupta,M.</style></author><author><style face="normal" font="default"> Gomes,J.M.</style></author><author><style face="normal" font="default"> Irizarry,J.</style></author><author><style face="normal" font="default"> DaVeiga,S.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pediatric Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY</style></auth-address><titles><title><style face="normal" font="default">The use of standardized drug desensitization protocols at a pediatric institution</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="836" start="834">834-836</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drug desensitization</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161230IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.11.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28034551">PM:28034551</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-834-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-834-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161230, Gupta M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.11.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40104</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nyenhuis,S.M.</style></author><author><style face="normal" font="default"> Krishnan,J.A.</style></author><author><style face="normal" font="default"> Berry,A.</style></author><author><style face="normal" font="default"> Calhoun,W.J.</style></author><author><style face="normal" font="default"> Chinchilli,V.M.</style></author><author><style face="normal" font="default"> Engle,L.</style></author><author><style face="normal" font="default"> Grossman,N.</style></author><author><style face="normal" font="default"> Holguin,F.</style></author><author><style face="normal" font="default"> Israel,E.</style></author><author><style face="normal" font="default"> Kittles,R.A.</style></author><author><style face="normal" font="default"> Kraft,M.</style></author><author><style face="normal" font="default"> Lazarus,S.C.</style></author><author><style face="normal" font="default"> Lehman,E.B.</style></author><author><style face="normal" font="default"> Mauger,D.T.</style></author><author><style face="normal" font="default"> Moy,J.N.</style></author><author><style face="normal" font="default"> Peters,S.P.</style></author><author><style face="normal" font="default"> Phipatanakul,W.</style></author><author><style face="normal" font="default"> Smith,L.J.</style></author><author><style face="normal" font="default"> Sumino,K.</style></author><author><style face="normal" font="default"> Szefler,S.J.</style></author><author><style face="normal" font="default"> Wechsler,M.E.</style></author><author><style face="normal" font="default"> Wenzel,S.</style></author><author><style face="normal" font="default"> White,S.R.</style></author><author><style face="normal" font="default"> Ackerman,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, University of Illinois at Chicago, Chicago, Ill; University of Illinois Hospital &amp; Health Sciences System, Chicago, Ill.</style></auth-address><titles><title><style face="normal" font="default">Race is associated with differences in airway inflammation in patients with asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">African American</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> confounding factors</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> cytology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Illinois</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory phenotypes</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> race</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> sputum eosinophil</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: African American subjects have a greater burden from asthma compared with white subjects. Whether the pattern of airway inflammation differs between African American and white subjects is unclear. OBJECTIVE: We sought to compare sputum airway inflammatory phenotypes of African American and white subjects treated or not with inhaled corticosteroids (ICSs; ICS+ and ICS-, respectively). METHODS: We performed a secondary analysis of self-identified African American and white subjects with asthma enrolled in clinical trials conducted by the National Heart, Lung, and Blood Institute-sponsored Asthma Clinical Research Network and AsthmaNet. Demographics, clinical characteristics, and sputum cytology after sputum induction were examined. We used a sputum eosinophil 2% cut point to define subjects with either an eosinophilic (>/=2%) or noneosinophilic (&lt;2%) inflammatory phenotype. RESULTS: Among 1018 participants, African American subjects (n = 264) had a lower FEV1 percent predicted (80% vs 85%, P &lt; .01), greater total IgE levels (197 vs 120 IU/mL, P &lt; .01), and a greater proportion with uncontrolled asthma (43% vs 28%, P &lt; .01) compared with white subjects (n = 754). There were 922 subjects in the ICS+ group (248 African American and 674 white subjects) and 298 subjects in the ICS- group (49 African American and 249 white subjects). Eosinophilic airway inflammation was not significantly different between African American and white subjects in either group (percentage with eosinophilic phenotype: ICS+ group: 19% vs 16%, P = .28; ICS- group: 39% vs 35%, P = .65; respectively). However, when adjusted for confounding factors, African American subjects were more likely to exhibit eosinophilic airway inflammation than white subjects in the ICS+ group (odds ratio, 1.58; 95% CI, 1.01-2.48; P = .046) but not in the ICS- group (P = .984). CONCLUSION: African American subjects exhibit greater eosinophilic airway inflammation, which might explain the greater asthma burden in this population</style></abstract><notes><style face="normal" font="default">DA - 20170110IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28069248">PM:28069248</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170110-NyenhuisSM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170110-NyenhuisSM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170110, Nyenhuis SM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40105</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Khullar,G.</style></author><author><style face="normal" font="default"> Vignesh,P.</style></author><author><style face="normal" font="default"> Lau,Y.L.</style></author><author><style face="normal" font="default"> Rudramurthy,S.M.</style></author><author><style face="normal" font="default"> Rawat,A.</style></author><author><style face="normal" font="default"> De,D.</style></author><author><style face="normal" font="default"> Handa,S.</style></author><author><style face="normal" font="default"> Singh,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.</style></auth-address><titles><title><style face="normal" font="default">Chronic Mucocutaneous Candidiasis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1121" start="1119">1119-1121</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Candidiasis</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hong Kong</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword></keywords><dates><year Day="5" Month="1" Year="2017">2017/1/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170109IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - India -CO - Hong Kong -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.11.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28065688">PM:28065688</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1119-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1119-21.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170109, Khullar G</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.11.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40106</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Druey,K.M.</style></author><author><style face="normal" font="default"> Parikh,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Allergic Diseases, NIAID/NIH, Bethesda, MD 20892.</style></auth-address><titles><title><style face="normal" font="default">Idiopathic Systemic Capillary Leak Syndrome (Clarkson disease)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> Capillaries</style></keyword><keyword><style face="normal" font="default"> Capillary Leak Syndrome</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> rat</style></keyword><keyword><style face="normal" font="default"> Rats</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">In 1960, Dr. Bayard Clarkson described a woman experiencing sporadic, recurrent episodes of shock and anasarca. Plasma from an acute attack induced a "shock"-like syndrome when injected into rats. The enigmatic "Systemic Capillary Leak Syndrome" (SCLS) named for Dr. Clarkson is characterized by transient and severe, but reversible, hemoconcentration and hypoalbuminemia due to leakage of fluids and macromolecules into tissues. Although &lt; 500 cases of SCLS have been reported in the literature since 1960, the condition is probably under-diagnosed due to lack of awareness and a high mortality without treatment. Allergists should be vigilant of this diagnosis since its presentation can resemble more common plasma leakage syndromes including angioedema or systemic anaphylaxis. Although the precise molecular etiology of SCLS remains unknown, substantial advances over the last five years have increased our understanding of SCLS pathogenesis</style></abstract><notes><style face="normal" font="default">DA - 20161225IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28012935">PM:28012935</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161225-DrueyKM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161225-DrueyKM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161225, Druey KM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.042</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40107</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,W.</style></author><author><style face="normal" font="default"> Wang,T.</style></author><author><style face="normal" font="default"> Pino-Yanes,M.</style></author><author><style face="normal" font="default"> Forno,E.</style></author><author><style face="normal" font="default"> Liang,L.</style></author><author><style face="normal" font="default"> Yan,Q.</style></author><author><style face="normal" font="default"> Hu,D.</style></author><author><style face="normal" font="default"> Weeks,D.E.</style></author><author><style face="normal" font="default"> Baccarelli,A.</style></author><author><style face="normal" font="default"> Acosta-Perez,E.</style></author><author><style face="normal" font="default"> Eng,C.</style></author><author><style face="normal" font="default"> Han,Y.Y.</style></author><author><style face="normal" font="default"> Boutaoui,N.</style></author><author><style face="normal" font="default"> Laprise,C.</style></author><author><style face="normal" font="default"> Davies,G.A.</style></author><author><style face="normal" font="default"> Hopkin,J.M.</style></author><author><style face="normal" font="default"> Moffatt,M.F.</style></author><author><style face="normal" font="default"> Cookson,W.O.</style></author><author><style face="normal" font="default"> Canino,G.</style></author><author><style face="normal" font="default"> Burchard,E.G.</style></author><author><style face="normal" font="default"> Celedon,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pediatric Pulmonary Medicine, Allergy, and Immunology, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh, Pittsburgh, PA</style></auth-address><titles><title><style face="normal" font="default">An epigenome-wide association study of total serum immunoglobulin E in Hispanic children</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> association studies</style></keyword><keyword><style face="normal" font="default"> association study</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Blood Cells</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Genome-wide</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Latino</style></keyword><keyword><style face="normal" font="default"> Lifestyle</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Methylation</style></keyword><keyword><style face="normal" font="default"> Monocyte</style></keyword><keyword><style face="normal" font="default"> Monocytes</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Medicine</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="6" Month="1" Year="2017">2017/1/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Total immunoglobulin E (IgE) is a therapeutic target in allergic diseases. DNA methylation in white blood cells (WBCs) was associated with total IgE in an epigenome-wide association study (EWAS) of Caucasians. Whether DNA methylation of eosinophils explains those findings is insufficiently understood. METHODS: We tested for association between genome-wide DNA methylation in WBCs and total IgE in two studies of Hispanic children: the Puerto Rico Genetics of Asthma and Lifestyle Study (PR-GOAL, n = 306) and the Genes-environments and Admixture in Latino Americans (GALA II, n = 573). Whole-genome methylation of DNA from WBCs was measured using the Illumina Infinium HumanMethylation450 BeadChip. Total IgE was measured using the UniCAP 100 system. In PR-GOAL, WBC types (i.e. neutrophils, eosinophils, basophils, lymphocytes, and monocytes) in peripheral blood were measured using Coulter-Counter techniques. In GALA II, WBC types were imputed. Multivariable linear regression was used for the analysis of DNA methylation and total IgE, which was first conducted separately for each cohort, and then combining results from the two cohorts in a meta-analysis. RESULTS: CpG sites in multiple genes, including novel findings and results previously reported in Caucasians, were significantly associated with total IgE. However, adjustment for WBC types resulted in markedly fewer significant sites. Top findings from this adjusted meta-analysis were in genes ZFPM1 (P=1.5x10-12), ACOT7 (P=2.5x10-11), and MND1 (P=1.4x10-9). CONCLUSIONS: In an EWAS adjusted for WBC types (including eosinophils), methylation changes in genes enriched in pathways relevant to asthma and immune responses were associated with total IgE among Hispanic children</style></abstract><notes><style face="normal" font="default">DA - 20170110IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -CO - United Kingdom -CO - Puerto Rico -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28069425">PM:28069425</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170110-ChenW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170110-ChenW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170110, Chen W</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.030</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40108</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Press,V.G.</style></author><author><style face="normal" font="default"> Kelly,C.A.</style></author><author><style face="normal" font="default"> Kim,J.J.</style></author><author><style face="normal" font="default"> White,S.R.</style></author><author><style face="normal" font="default"> Meltzer,D.O.</style></author><author><style face="normal" font="default"> Arora,V.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Section of General Internal Medicine, Department of Medicine, University of Chicago, Chicago, Ill.</style></auth-address><titles><title><style face="normal" font="default">Virtual Teach-To-Goal Adaptive Learning of Inhaler Technique for Inpatients with Asthma or COPD</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1039" start="1032">1032-1039</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adaptive</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> African American</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> health literacy</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Inpatients</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Learning</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Self efficacy</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="5" Month="1" Year="2017">2017/1/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma and chronic obstructive pulmonary disease (COPD) result in more than 1 million hospitalizations annually. Most hospitalized patients misuse respiratory inhalers. This misuse can be corrected with in-person education; however, this strategy is resource intensive and skills wane quickly after discharge. OBJECTIVE: The objective of this study was to develop and pilot a virtual teach-to-goal (V-TTG) inhaler skill training module, using innovative adaptive learning technology. METHODS: Eligible adults with asthma or COPD completed a V-TTG metered-dose inhaler session with tailored rounds of narrated demonstration and self-assessments. The primary outcome was the proportion of participants with inhaler misuse post- versus pre-V-TTG; secondary analyses tested mastery, self-efficacy, and perceived versus actual inhaler skills. Analyses were tested with McNemar's chi2 test (P &lt; .05). RESULTS: Among 90 enrolled participants, the majority were African American (94%), female (62%), and had asthma (68%), with a mean age of 48 years. Among those completing both pre- and post-V-TTG (n = 83), misuse was significantly lower post- versus pre-V-TTG (24% vs 83%, P &lt; .001). Mastery and confidence both improved significantly (46% vs 7%, P &lt; 0.001; 83% vs 67%, P &lt; .001) post- versus pre-V-TTG. After V-TTG, there was greater congruence between perceived versus actual inhaler skills (P &lt; .01). No differences were seen in subgroup analyses for age, health literacy level, or diagnosis. CONCLUSIONS: This study is the first to demonstrate the efficacy of adaptive V-TTG learning to teach the inhaler technique. V-TTG improved most participants' technique to an acceptable level, reached mastery for half, and also increased self-efficacy and actualized skill. V-TTG has potential to improve health care across care transitions</style></abstract><notes><style face="normal" font="default">DA - 20170109IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.11.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28065689">PM:28065689</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1032-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1032-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170109, Press VG</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.11.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40109</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">DeVries,A.</style></author><author><style face="normal" font="default"> Wlasiuk,G.</style></author><author><style face="normal" font="default"> Miller,S.J.</style></author><author><style face="normal" font="default"> Bosco,A.</style></author><author><style face="normal" font="default"> Stern,D.A.</style></author><author><style face="normal" font="default"> Lohman,I.C.</style></author><author><style face="normal" font="default"> Rothers,J.</style></author><author><style face="normal" font="default"> Jones,A.C.</style></author><author><style face="normal" font="default"> Nicodemus-Johnson,J.</style></author><author><style face="normal" font="default"> Vasquez,M.M.</style></author><author><style face="normal" font="default"> Curtin,J.A.</style></author><author><style face="normal" font="default"> Simpson,A.</style></author><author><style face="normal" font="default"> Custovic,A.</style></author><author><style face="normal" font="default"> Jackson,D.J.</style></author><author><style face="normal" font="default"> Gern,J.E.</style></author><author><style face="normal" font="default"> Lemanske,R.F.,Jr.</style></author><author><style face="normal" font="default"> Guerra,S.</style></author><author><style face="normal" font="default"> Wright,A.L.</style></author><author><style face="normal" font="default"> Ober,C.</style></author><author><style face="normal" font="default"> Halonen,M.</style></author><author><style face="normal" font="default"> Vercelli,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Arizona Respiratory Center, University of Arizona, Tucson, AZ 85724; Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ 85724</style></auth-address><titles><title><style face="normal" font="default">Epigenome-wide Analysis Links SMAD3 Methylation at Birth to Asthma in Children of Asthmatic Mothers</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Arizona</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> Asthma risk</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cord Blood</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Methylation</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> Neonate</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Recovery</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Trajectory</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: The timing and mechanisms of asthma inception remain imprecisely defined. Although epigenetic mechanisms likely contribute to asthma pathogenesis, little is known about their role in asthma inception. OBJECTIVE: To assess whether the trajectory to asthma begins already at birth and epigenetic mechanisms, specifically DNA methylation, contribute to asthma inception. METHODS: We used Methylated CpG Island Recovery Assay (MIRA)-chip to survey DNA methylation in cord blood mononuclear cells (CBMC) from 36 children (18 non-asthmatic, 18 asthmatic by age 9) from the Infant Immune Study (IIS), an unselected birth cohort closely monitored for asthma for a decade. SMAD3 methylation in IIS (n=60) and in two replication cohorts (The Manchester Asthma and Allergy Study, n=30, and the Childhood Origins of ASThma Study, n=28) was analyzed by bisulfite sequencing or Illumina 450K arrays. CBMC-derived IL-1beta was measured by ELISA. RESULTS: Neonatal immune cells harbored 589 differentially methylated regions (DMRs) that distinguished IIS children who did and did not develop asthma by age 9. In all three cohorts, methylation in SMAD3, the most connected node within the network of asthma-associated DMRs, was selectively increased in asthmatic children of asthmatic mothers and was associated with childhood asthma risk. Moreover, SMAD3 methylation in IIS neonates with maternal asthma was strongly and positively associated with neonatal production of IL-1beta, an innate inflammatory mediator. CONCLUSIONS: The trajectory to childhood asthma begins at birth and involves epigenetic modifications in immunoregulatory and pro-inflammatory pathways. Maternal asthma influences epigenetic mechanisms that contribute to the inception of this trajectory</style></abstract><notes><style face="normal" font="default">DA - 20161224IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Australia -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28011059">PM:28011059</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161224-DeVriesA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161224-DeVriesA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161224, DeVries A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.041</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40110</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cicardi,M.</style></author><author><style face="normal" font="default"> Zanichelli,A.</style></author><author><style face="normal" font="default"> Suffritti,C.</style></author><author><style face="normal" font="default"> Wu,M.A.</style></author><author><style face="normal" font="default"> Machnig,T.</style></author><author><style face="normal" font="default"> De Silvestri,A.</style></author><author><style face="normal" font="default"> Regazzi,M.</style></author><author><style face="normal" font="default"> Tinelli,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan and ASST Fatebenefratelli Sacco, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="default">Catabolism of C1 inhibitor influences the response to replacement therapy in hereditary angioedema</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">angioedema</style></keyword><keyword><style face="normal" font="default"> C1 INH</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor deficiency</style></keyword><keyword><style face="normal" font="default"> C1-INH</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> C1Inh</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Complement</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pharmacokinetics</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE) is a disabling and life-threatening disease for which plasma-derived C1 inhibitor (pdC1-INH) is an effective treatment. Poor responses to pdC1-INH are rare. The aim of this prospective study was to evaluate the pharmacokinetics and pharmacodynamics of C1 inhibitor (C1-INH) in a C1-INH-HAE patient with poor response to treatment to investigate the mechanism underlying poor response to pdC1-INH. Seventeen C1-INH-HAE patients with normal responses to treatment served as retrospective controls. In the poor response patient, higher than standard doses of pdC1-INH did not change the PK but led to normalization of PD parameters and symptoms disappeared, recurring upon dose reduction. Therefore, we conclude that hyperactivation of the complement and contact systems in highly symptomatic C1-INH-HAE patients does not account for interpatient variability in response to pdC1-INH, which may be connected to differences in hepatic clearance of infused pdC1-INH</style></abstract><notes><style face="normal" font="default">DA - 20161227IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28025012">PM:28025012</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161227-CicardiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161227-CicardiM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161227, Cicardi M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.044</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40111</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Giavina-Bianchi,P.</style></author><author><style face="normal" font="default"> Galvao,V.R.</style></author><author><style face="normal" font="default"> Picard,M.</style></author><author><style face="normal" font="default"> Caiado,J.</style></author><author><style face="normal" font="default"> Castells,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass</style></auth-address><titles><title><style face="normal" font="default">Basophil Activation Test Is a Relevant Biomarker of the Outcome of Rapid Desensitization in Platinum Compounds-Allergy</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="736" start="728">728-736</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophil activation test</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> BAT</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> CD203c</style></keyword><keyword><style face="normal" font="default"> CD63</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic tool</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drug desensitization</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Platinum</style></keyword><keyword><style face="normal" font="default"> Platinum Compounds</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Rapid desensitization</style></keyword><keyword><style face="normal" font="default"> Rapid drug desensitization</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum tryptase</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe reactions</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Rapid drug desensitization (RDD) has become a cornerstone in the management of immediate drug hypersensitivity reactions (DHRs) to chemotherapeutic agents. Because of the inherent risk of anaphylaxis during RDD, biomarkers to predict patients at risk of developing such severe reactions are needed. The basophil activation test (BAT) has been used in DHRs as a diagnostic tool. OBJECTIVE: We evaluated basophil CD63 and CD203c expression (BAT) as a biomarker to assess the safety and effectiveness of RDD in platinum compounds-allergic patients. METHODS: Patients allergic to platinum compounds (n = 15) undergoing RDD were assessed through clinical history, skin testing, serum tryptase levels, and BAT. BAT was performed immediately before RDD, assessing CD203c and CD63 expression on basophils. BAT was also performed in 6 patients tolerant to platinum compounds and in 6 healthy volunteers. RESULTS: BAT was positive to CD203c or CD63 in 11 out of 15 patients allergic to platinum compounds (73%), with increased expression of CD203c and CD63 in 11 (73%) and 6 (40%) patients, respectively. Increased CD63 expression tended to be associated with more severe initial reactions. All controls had negative test results. Reactions during RDD were associated with BAT positivity and increased tryptase levels. Only 1 of 4 patients with negative BAT had a mild reaction during RDD. BAT remained positive in multiple sequential RDD. CONCLUSIONS: BAT identified patients allergic to platinum compounds with an increased risk of reactions during desensitization and higher CD63 expression was observed in severe reactions. Multiple RDDs to platinum compounds did not induce persistent hyporesponsiveness on basophils. BAT is a potential biomarker for RDD</style></abstract><notes><style face="normal" font="default">DA - 20161230IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - Brazil -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.11.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28034549">PM:28034549</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-728-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-728-36.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161230, Giavina-Bianchi P</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.11.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40112</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Engebretsen,K.A.</style></author><author><style face="normal" font="default"> Bager,P.</style></author><author><style face="normal" font="default"> Wohlfahrt,J.</style></author><author><style face="normal" font="default"> Skov,L.</style></author><author><style face="normal" font="default"> Zachariae,C.</style></author><author><style face="normal" font="default"> Nybo Andersen,A.M.</style></author><author><style face="normal" font="default"> Melbye,M.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Allergy Research Centre, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Prevalence of atopic dermatitis in infants by domestic water hardness and season of birth</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Hardness</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Interviews</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword><keyword><style face="normal" font="default"> water hardness</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis (AD) appears to be more common in regions with hard domestic water and in children with a fall/winter birth. However, it is unknown whether a synergistic effect exists. OBJECTIVE: To evaluate the association between domestic water hardness and season of birth, respectively, with onset of AD within the first 18 months of life in a large Danish birth cohort. METHODS: 52,950 children from the Danish National Birth Cohort were included. History of physician-diagnosed AD and population characteristics were obtained from interviews. Birth data was obtained from the Civil Registration System, and domestic water hardness data from the Geological Survey of Denmark and Greenland. The relative prevalence (RP) of AD was calculated using log-linear binomial regression. RESULTS: The prevalence of AD was 15.0% (7,942 of 52,950). The RP of AD was 5% (RPtrend 1.05; 95% CI 1.03-1.07) higher for each 5 degrees increase in domestic water hardness (range 6.60-35.90 degrees dH (118-641 mg/L)). While the RP of AD was higher in children with a fall (RP 1.24; 95% CI 1.17-1.31) or winter (RP 1.18; 95% CI 1.11-1.25) birth, no significant interaction was observed with domestic water hardness. The population attributable risk of hard domestic water on AD was 2%. CONCLUSION: We observed that early exposure to hard domestic water and a fall/winter birth was associated with an increase in the relative prevalence of AD within the first 18 months of life. While the two exposures did not interact synergistically, a dose-response relationship was observed between domestic water hardness and AD</style></abstract><notes><style face="normal" font="default">DA - 20161226IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28017882">PM:28017882</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161226-EngebretsenKA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161226-EngebretsenKA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161226, Engebretsen KA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40113</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pothoven,K.L.</style></author><author><style face="normal" font="default"> Norton,J.E.</style></author><author><style face="normal" font="default"> Suh,L.A.</style></author><author><style face="normal" font="default"> Carter,R.G.</style></author><author><style face="normal" font="default"> Harris,K.E.</style></author><author><style face="normal" font="default"> Biyasheva,A.</style></author><author><style face="normal" font="default"> Welch,K.</style></author><author><style face="normal" font="default"> Shintani-Smith,S.</style></author><author><style face="normal" font="default"> Conley,D.B.</style></author><author><style face="normal" font="default"> Liu,M.C.</style></author><author><style face="normal" font="default"> Kato,A.</style></author><author><style face="normal" font="default"> Avila,P.C.</style></author><author><style face="normal" font="default"> Hamid,Q.</style></author><author><style face="normal" font="default"> Grammer,L.C.,III</style></author><author><style face="normal" font="default"> Peters,A.T.</style></author><author><style face="normal" font="default"> Kern,R.C.</style></author><author><style face="normal" font="default"> Tan,B.K.</style></author><author><style face="normal" font="default"> Schleimer,R.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill</style></auth-address><titles><title><style face="normal" font="default">Neutrophils are a major source of the epithelial barrier disrupting cytokine Oncostatin M in mucosal airways disease</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Airways disease</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> allergen challenge</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> BAL</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> epithelia</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelium</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> induced sputum</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Oncostatin M</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> specific antibodies</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> Staining</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: We have previously shown that Oncostatin M (OSM) is elevated in nasal polyps of chronic rhinosinusitis (CRS) patients, as well as in bronchoalveolar lavage (BAL) fluids after segmental allergen challenge in allergic asthmatics. We also showed in vitro that physiological levels of OSM impair barrier function in differentiated airway epithelium. OBJECTIVE: We sought to determine which hematopoietic or resident cell type(s) were the source of the OSM expressed in mucosal airways disease. METHODS: Paraffin-embedded NP sections were stained with fluorescence-labeled specific antibodies against OSM, GM-CSF and hematopoietic cell specific markers. Live cells were isolated from NP and matched blood samples for flow cytometric analysis. Neutrophils were isolated from whole blood, cultured with the known OSM inducers GM-CSF and FSTL1, and levels of OSM were measured in the supernatants. Bronchial biopsy sections from controls, moderate asthmatics and severe asthmatics were stained for OSM and neutrophil elastase. RESULTS: OSM staining was observed in NP, showed co-localization with neutrophil elastase (n=10), and did not co-localize with markers for eosinophils, macrophages, T cells or B cells (n=3-5). Flow cytometric analysis of NP (n=9) showed that 5.1+/-2% of CD45+ cells were OSM+, and of the OSM+ cells, 56+/-7% were CD16+Siglec8-, indicating neutrophil lineage. Only .6+/-.4% of CD45+ events from matched blood samples (n=5) were OSM+, suggesting that elevated OSM in CRS was locally stimulated and produced. A majority of OSM+ neutrophils expressed Arginase 1 (72.5+/-12%), suggesting a N2 phenotype. GM-CSF was elevated in nasal polyp tissue compared to control, and was sufficient to induce OSM production (p&lt;.001) in peripheral blood neutrophils in vitro. OSM+ neutrophils were also observed at elevated levels in biopsies from patients with severe asthma. Additionally, OSM protein was elevated in induced sputum from asthmatic patients compared to controls (p&lt;.05). CONCLUSIONS: Neutrophils are a major source of OSM producing cells in CRS and severe asthma</style></abstract><notes><style face="normal" font="default">DA - 20161220IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27993536">PM:27993536</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161220-PothovenKL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161220-PothovenKL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161220, Pothoven KL</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.039</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40114</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Litonjua,A.A.</style></author><author><style face="normal" font="default"> Weiss,S.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA.</style></auth-address><titles><title><style face="normal" font="default">JACI Editorial: Vitamin D status through the first 10 years of life: A vital piece of the puzzle in asthma inception</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161220IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27993535">PM:27993535</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161220-LitonjuaAA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161220-LitonjuaAA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161220, Litonjua AA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40115</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kuijpers,T.W.</style></author><author><style face="normal" font="default"> Tool,A.T.</style></author><author><style face="normal" font="default"> van der Bijl,I.</style></author><author><style face="normal" font="default"> de Boer,M.</style></author><author><style face="normal" font="default"> van Houdt,M.</style></author><author><style face="normal" font="default"> de Cuyper,I.</style></author><author><style face="normal" font="default"> Roos,D.</style></author><author><style face="normal" font="default"> van Alphen,F.</style></author><author><style face="normal" font="default"> van Leeuwen,K.</style></author><author><style face="normal" font="default"> Cambridge,E.</style></author><author><style face="normal" font="default"> Arends,M.J.</style></author><author><style face="normal" font="default"> Dougan,G.</style></author><author><style face="normal" font="default"> Clare,S.</style></author><author><style face="normal" font="default"> Ramirez-Solis,R.</style></author><author><style face="normal" font="default"> Pals,S.T.</style></author><author><style face="normal" font="default"> Adams,D.J.</style></author><author><style face="normal" font="default"> Meijer,A.B.</style></author><author><style face="normal" font="default"> van den Berg,T.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric Hematology, Immunology and Infectious Diseases, Emma Children's Hospital, Academic Medical Center (AMC), University of Amsterdam, Amsterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Combined immunodeficiency with severe inflammation and allergy caused by ARPC1B deficiency</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hematology</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161214IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.09.061</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27965109">PM:27965109</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161214-KuijpersTW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161214-KuijpersTW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161214, Kuijpers TW</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.09.061</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40116</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yin,Y.</style></author><author><style face="normal" font="default"> Mitson-Salazar,A.</style></author><author><style face="normal" font="default"> Wansley,D.L.</style></author><author><style face="normal" font="default"> Singh,S.P.</style></author><author><style face="normal" font="default"> Prussin,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</style></auth-address><titles><title><style face="normal" font="default">Rapamycin Preferentially Inhibits Human IL-5+ Th2 Cell Proliferation via an mTORC1/S6 Kinase-1 Dependent Pathway</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Cell Proliferation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161207IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27923564">PM:27923564</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161207-YinY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161207-YinY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161207, Yin Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40117</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shusterman,D.</style></author><author><style face="normal" font="default"> Baroody,F.M.</style></author><author><style face="normal" font="default"> Craig,T.</style></author><author><style face="normal" font="default"> Friedlander,S.</style></author><author><style face="normal" font="default"> Nsouli,T.</style></author><author><style face="normal" font="default"> Silverman,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of California San Francisco, San Francisco, Calif.</style></auth-address><titles><title><style face="normal" font="default">Role of the Allergist-Immunologist and Upper Airway Allergy in Sleep-Disordered Breathing</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="639" start="628">628-639</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Apnea</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hypertrophy</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyposis</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Obstructive sleep apnea</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> Polyposis</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> San Francisco</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Sleep apnea</style></keyword><keyword><style face="normal" font="default"> Snoring</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Sleep-disordered breathing in general and obstructive sleep apnea in particular are commonly encountered conditions in allergy practice. Physiologically, nasal (or nasopharyngeal) obstruction from rhinitis, nasal polyposis, or adenotonsillar hypertrophy are credible contributors to snoring and nocturnal respiratory obstructive events. Nevertheless, existing practice parameters largely relegate the role of the allergist to adjunctive treatment in cases of continuous positive airway pressure intolerance. OBJECTIVES: To survey active American Academy of Allergy, Asthma &amp; Immunology members regarding their perceptions and practices concerning sleep-disordered breathing in adult and pediatric patients with rhinitis, and to review the medical literature concerning this connection to identify therapeutic implications and research gaps. METHODS: Members of the Work Group on Rhinitis and Sleep-disordered Breathing composed and distributed a Web-based clinically oriented survey to active American Academy of Allergy, Asthma &amp; Immunology members in mid-2015. The group, in addition, conducted an English-language literature review using PubMed and other sources. RESULTS: Survey results were returned by 339 of 4881 active members (7%). More than two-third of respondents routinely asked about sleep problems, believed that sleep-disordered breathing was a problem for at least a "substantial minority" (10%-30%) of their adult patients, and believed that medical therapy for upper airway inflammatory conditions could potentially help ameliorate sleep-related complaints. Literature review supported the connection between high-grade nasal congestion/adenotonsillar hypertrophy and obstructive sleep apnea, and at least in the case of pediatric patients, supported the use of anti-inflammatory medication in the initial management of obstructive sleep apnea of mild-to-moderate severity. CONCLUSIONS: Clinical allergy practice and the medical literature support a proactive role for allergists in the diagnosis and management of sleep-disordered breathing</style></abstract><notes><style face="normal" font="default">DA - 20161207IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.10.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27923646">PM:27923646</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-628-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-628-39.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161207, Shusterman D</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.10.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40118</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kelly,H.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics and College of Pharmacy, University of New Mexico Health Sciences Center, Albuquerque, NM.</style></auth-address><titles><title><style face="normal" font="default">Assessing the therapeutic index of inhaled corticosteroids in children: Is knemometry the answer?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Children</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Mexico</style></keyword><keyword><style face="normal" font="default"> New Mexico</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170114IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28087225">PM:28087225</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170114-KellyHW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170114-KellyHW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170114, Kelly HW</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40119</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hershko,A.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Allergy and Clinical Immunology, Department of Medicine, Meir Medical Center, Kfar Saba, Israel</style></auth-address><titles><title><style face="normal" font="default">Insights into the mast cell-microbiome connection in the skin</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170114IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - Israel -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28087228">PM:28087228</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170114-HershkoAY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170114-HershkoAY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170114, Hershko AY</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40120</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jabbal,S.</style></author><author><style face="normal" font="default"> Poli,G.</style></author><author><style face="normal" font="default"> Lipworth,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Scottish Centre for Respiratory Research, Ninewells Hospital &amp; Medical School, Dundee UKGlobal Clinical Development, Chiesi Farmaceutici S.p.A., Parma, ItalyScottish Centre for Respiratory Research, Ninewells Hospital &amp; Medical School, Dundee UK. Electronic address: b.j.lipworth@dundee.ac.uk</style></auth-address><titles><title><style face="normal" font="default">Does size really matter- relationship of particle size to lung deposition and exhaled fraction</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Particle Size</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="default">CAPSULE SUMMARY: We demonstrate that extra-fine particles are not associated with an appreciably higher exhaled fraction, hence explaining their efficacy profile in asthma</style></abstract><notes><style face="normal" font="default">DA - 20170114IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28087325">PM:28087325</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170114-JabbalS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170114-JabbalS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170114, Jabbal S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.036</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40121</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">van den Heuvel,D.</style></author><author><style face="normal" font="default"> Jansen,M.A.</style></author><author><style face="normal" font="default"> Nasserinejad,K.</style></author><author><style face="normal" font="default"> Dik,W.A.</style></author><author><style face="normal" font="default"> van Lochem,E.G.</style></author><author><style face="normal" font="default"> Bakker-Jonges,L.E.</style></author><author><style face="normal" font="default"> Bouallouch-Charif,H.</style></author><author><style face="normal" font="default"> Jaddoe,V.W.</style></author><author><style face="normal" font="default"> Hooijkaas,H.</style></author><author><style face="normal" font="default"> van Dongen,J.J.</style></author><author><style face="normal" font="default"> Moll,H.A.</style></author><author><style face="normal" font="default"> van Zelm,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands</style></auth-address><titles><title><style face="normal" font="default">Effects of nongenetic factors on immune cell dynamics in early childhood: The Generation R Study</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> CD8+ T cells</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cytomegalovirus</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> early childhood</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetic factors</style></keyword><keyword><style face="normal" font="default"> Helicobacter pylori</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Immune-mediated</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Leukocytes</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Subsets</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Membranes</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Modeling</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> premature</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: . Numbers of blood leukocyte subsets are highly dynamic in childhood and differ greatly between individuals. Inter-individual variation is only partly accounted for by genetic factors. OBJECTIVE: Determine which nongenetic factors affect the dynamics of innate leukocytes, and naive and memory lymphocyte subsets. METHODS: . We performed six-color flow cytometry and linear mixed effect modeling to define the dynamics of 62 leukocyte subsets from birth to 6 years of age in 1,182 children with one to five measurements per individual. Subsequently, we defined the impact of prenatal maternal lifestyle-related or immune-mediated determinants, birth characteristics and bacterial/viral exposure-related determinants on leukocyte subset dynamics. RESULTS: . Functionally similar leukocyte populations were grouped by unbiased hierarchical clustering of patterns of age-related leukocyte dynamics. Innate leukocyte numbers were high at birth and were predominantly affected by maternal low education level. Naive lymphocytes peaked around 1 year, while most memory lymphocyte subsets more gradually increased during the first 4 years of life. Dynamics of CD4+ T cells were predominantly associated with gender, birth characteristics, and persistent infections with cytomegalovirus (CMV) or Epstein Barr virus (EBV). CD8+ T cells were predominantly associated with CMV and EBV infections, and TCRgammadelta+ T cells with premature rupture of membranes and CMV infection. B-cell subsets were predominantly associated with gender, breastfeeding and Helicobacter pylori carriership. CONCLUSIONS: . Our study identifies specific dynamic patterns of leukocyte subset numbers, as well as nongenetic determinants that affect these patterns, thereby providing new insights into the shaping of the childhood immune system</style></abstract><notes><style face="normal" font="default">DA - 20161203IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27913304">PM:27913304</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161203-vandenHeuvelD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161203-vandenHeuvelD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161203, van den Heuvel D</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40122</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Straka,B.T.</style></author><author><style face="normal" font="default"> Ramirez,C.E.</style></author><author><style face="normal" font="default"> Byrd,J.B.</style></author><author><style face="normal" font="default"> Stone,E.</style></author><author><style face="normal" font="default"> Woodard-Grice,A.</style></author><author><style face="normal" font="default"> Nian,H.</style></author><author><style face="normal" font="default"> Yu,C.</style></author><author><style face="normal" font="default"> Banerji,A.</style></author><author><style face="normal" font="default"> Brown,N.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Nashville, TN 37232, USA</style></auth-address><titles><title><style face="normal" font="default">Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> African American</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> Bradykinin</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor deficiency</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Eyelid</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Icatibant</style></keyword><keyword><style face="normal" font="default"> Lip</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharynx</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> subcutaneous</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Tongue</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: The B2 receptor antagonist icatibant is approved for treatment of attacks of hereditary angioedema. Icatibant has been reported to decrease time-to-resolution of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema in one study of European patients. METHODS: Patients with ACE inhibitor-associated angioedema (defined as swelling of lips, tongue, pharynx or face during ACE inhibitor use and no swelling in the absence of ACE inhibitor use) were enrolled at Vanderbilt University Medical Center from October 2007 through September 2015 and at Massachusetts General Hospital in 2012. C1 inhibitor deficiency and patients with bowel edema only were excluded. Patients were randomized within six hours of presentation to subcutaneous icatibant 30 mg or placebo at zero and six hours later. Patients assessed severity of swelling using a visual analog scale serially following study drug administration or until discharge. RESULTS: Thirty-three patients were randomized and 31 received treatment, with 13 receiving icatibant and 18 receiving placebo. One patient randomized to icatibant did not complete the visual analog scale and was excluded from analyses. Two-thirds of patients were African American and two-thirds were women. Time-to-resolution of symptoms was similar in placebo and icatibant treatment groups (p=0.19 for the primary symptom and p>0.16 for individual symptoms of face, lip, tongue, or eyelid swelling). Frequency of administration of H1 and H2 blockers, corticosteroids, and epinephrine was similar in the two treatment groups. Time-to-resolution of symptoms was similar in black and white patients. CONCLUSIONS: This study does not support clinical efficacy of a bradykinin B2 receptor antagonist in ACE inhibitor-associated angioedema</style></abstract><notes><style face="normal" font="default">DA - 20161203IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.09.051</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27913306">PM:27913306</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161203-StrakaBT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161203-StrakaBT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161203, Straka BT</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.09.051</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40123</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rutkowski,K.</style></author><author><style face="normal" font="default"> Taylor,C.</style></author><author><style face="normal" font="default"> Wagner,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default">HLA B62 as a possible risk factor for drug reaction with eosinophilia and systemic symptoms to piperacillin/tazobactam</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="830" start="829">829-830</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drug reaction with eosinophilia and systemic symptoms</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> HLA</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161204IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.10.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27914818">PM:27914818</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-829-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-829-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161204, Rutkowski K</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.10.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40124</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chang,E.H.</style></author><author><style face="normal" font="default"> Willis,A.L.</style></author><author><style face="normal" font="default"> McCrary,H.C.</style></author><author><style face="normal" font="default"> Noutsious,G.T.</style></author><author><style face="normal" font="default"> Le,C.H.</style></author><author><style face="normal" font="default"> Chiu,A.G.</style></author><author><style face="normal" font="default"> Mansfield,C.J.</style></author><author><style face="normal" font="default"> Reed,D.R.</style></author><author><style face="normal" font="default"> Brooks,S.G.</style></author><author><style face="normal" font="default"> Adappa,N.D.</style></author><author><style face="normal" font="default"> Palmer,J.N.</style></author><author><style face="normal" font="default"> Cohen,N.G.</style></author><author><style face="normal" font="default"> Stern,D.A.</style></author><author><style face="normal" font="default"> Guerra,S.</style></author><author><style face="normal" font="default"> Martinez,F.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology, University of Arizona, Tucson, AZ.</style></auth-address><titles><title><style face="normal" font="default">Association between the CDHR3 rs6967330 risk allele and chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Arizona</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Multicenter Studies</style></keyword><keyword><style face="normal" font="default"> Multicenter study</style></keyword><keyword><style face="normal" font="default"> Otolaryngology</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">A retrospective, multi-center study of adults with and without chronic rhinosinusitis (CRS) identifies a significant association between rs6967330 in the viral receptor CD</style></abstract><notes><style face="normal" font="default">DA - 20161207IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27923563">PM:27923563</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161207-ChangEH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161207-ChangEH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161207, Chang EH</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40125</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,A.R.</style></author><author><style face="normal" font="default"> Qureshi,A.A.</style></author><author><style face="normal" font="default"> Drucker,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Alpert Medical School of Brown University, Providence, RI</style></auth-address><titles><title><style face="normal" font="default">Insight into the patient experience of eczema through a crowdsourcing approach</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="863" start="861">861-863</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Dermatology</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161204IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.10.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27914819">PM:27914819</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-861-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-861-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161204, Wang AR</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.10.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40126</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ricciardolo,F.L.</style></author><author><style face="normal" font="default"> Sorbello,V.</style></author><author><style face="normal" font="default"> Folino,A.</style></author><author><style face="normal" font="default"> Gallo,F.</style></author><author><style face="normal" font="default"> Massaglia,G.M.</style></author><author><style face="normal" font="default"> Favata,G.</style></author><author><style face="normal" font="default"> Conticello,S.</style></author><author><style face="normal" font="default"> Vallese,D.</style></author><author><style face="normal" font="default"> Gani,F.</style></author><author><style face="normal" font="default"> Malerba,M.</style></author><author><style face="normal" font="default"> Folkerts,G.</style></author><author><style face="normal" font="default"> Rolla,G.</style></author><author><style face="normal" font="default"> Profita,M.</style></author><author><style face="normal" font="default"> Mauad,T.</style></author><author><style face="normal" font="default"> Di Stefano,A.</style></author><author><style face="normal" font="default"> Ciprandi,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical and Biological Sciences, University of Torino, AOU San Luigi Hospital, Orbassano (Torino), Italy.Health Science Department, University of Genova, Italy</style></auth-address><titles><title><style face="normal" font="default">Identification of IL-17F/frequent exacerbator endotype in asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Microscopy</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophilic asthma</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> ROC</style></keyword><keyword><style face="normal" font="default"> Roc Curve</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> TH17</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Severe asthma might be associated with neutrophil recruitment and Th17 cytokines over-expression in bronchial biopsies. OBJECTIVE: To study IL-17-related cytokines in nasal/bronchial biopsies from controls and mild (MA)-to-severe (SA) asthmatics in relation to exacerbation rate. METHODS: Inflammatory cells and IL-17A+, IL-17F+, IL-21+, IL-22+ and IL-23+ cells were examined by immunohistochemistry (IHC) in cryostat sections of bronchial/nasal biopsies obtained from 33 SA (21 frequent exacerbators (FE)), 31 MA (3 FE) and 14 controls. IL-17F protein was also measured by ELISA in bronchial/nasal lysates and by IHC in bronchial tissue obtained from subjects died for fatal asthma. Immunofluorescence/confocal microscopy was used for IL-17F co-localization. RESULTS: Higher number (p&lt;0.05) of neutrophils, IL-17A+, IL-17F+ and IL-21+ cells in bronchial biopsies and higher number (p&lt;0.01) of IL-17F+ and IL-21+ cells in nasal biopsies were observed in SA compared to MA. Bronchial IL-17F+ cells correlated with bronchial neutrophils (r=0.54), exacerbation rate (r=0.41) and FEV1 (r=-0.46). Nasal IL-17F+ cells correlated with bronchial IL-17F (r=0.35), exacerbation rate (r=0.47) and FEV1 (r=-0.61). FE showed increased number of bronchial neutrophils/eosinophils/CD4+/CD8+ cells and bronchial/nasal IL-17F+ cells. ROC curve analysis evidenced predictive cut-off values of bronchial neutrophils and nasal/bronchial IL-17F for discriminating between asthmatics and controls, between MA and SA and between FE and non-FE. IL-17F protein increased in bronchial/nasal lysates of SA and FE and in bronchial tissue of fatal asthma. IL-17F co-localized in CD4+/CD8+ cells. CONCLUSIONS: IL-17-related cytokines expression was amplified in bronchial/nasal mucosa of neutrophilic asthma prone to exacerbation suggesting a pathogenic role of IL-17F in frequent exacerbators</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931975">PM:27931975</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161209-RicciardoloFL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161209-RicciardoloFL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161209, Ricciardolo FL</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.034</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40127</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jans,J.</style></author><author><style face="normal" font="default"> Pettengill,M.</style></author><author><style face="normal" font="default"> Kim,D.</style></author><author><style face="normal" font="default"> van der Made,C.</style></author><author><style face="normal" font="default"> de Groot,R.</style></author><author><style face="normal" font="default"> Henriet,S.</style></author><author><style face="normal" font="default"> de Jonge,M.I.</style></author><author><style face="normal" font="default"> Ferwerda,G.</style></author><author><style face="normal" font="default"> Levy,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Pediatric Infectious Diseases, Department of Pediatrics, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, the Netherlands</style></auth-address><titles><title><style face="normal" font="default">Human newborn B cells mount an IFNAR-dependent humoral response to RSV</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> humoral</style></keyword><keyword><style face="normal" font="default"> Igm</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> neutralizing</style></keyword><keyword><style face="normal" font="default"> newborn</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> RSV</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">This study provides evidence of a first line of human humoral defense against RSV infection in early life including the presence of natural neutralizing anti-RSV IgM as well as an IFN-beta-mediated newborn B cell activation</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931976">PM:27931976</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161209-JansJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161209-JansJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161209, Jans J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.032</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40128</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jorgensen,S.F.</style></author><author><style face="normal" font="default"> Macpherson,M.E.</style></author><author><style face="normal" font="default"> Bjoro,K.</style></author><author><style face="normal" font="default"> Karlsen,T.H.</style></author><author><style face="normal" font="default"> Reims,H.M.</style></author><author><style face="normal" font="default"> Grzyb,K.</style></author><author><style face="normal" font="default"> Fosby,B.</style></author><author><style face="normal" font="default"> Fevang,B.</style></author><author><style face="normal" font="default"> Aukrust,P.</style></author><author><style face="normal" font="default"> Nordoy,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Rikshospitalet, Oslo, Norway</style></auth-address><titles><title><style face="normal" font="default">Liver transplantation in patients with primary antibody deficiency</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Liver Failure</style></keyword><keyword><style face="normal" font="default"> Liver Transplantation</style></keyword><keyword><style face="normal" font="default"> Norway</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Patients with primary antibody deficiency and liver failure should be considered for liver transplantation and not rejected because of their immunodeficiency alone. Improved anti-fungal prophylaxis may further improve their prognosis</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Norway -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931972">PM:27931972</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161209-JorgensenSF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161209-JorgensenSF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161209, Jorgensen SF</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40129</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Avershina,E.</style></author><author><style face="normal" font="default"> Cabrera-Rubio,R.</style></author><author><style face="normal" font="default"> Lundgard,K.</style></author><author><style face="normal" font="default"> Perez-Martinez,G.</style></author><author><style face="normal" font="default"> Collado,M.C.</style></author><author><style face="normal" font="default"> Storro,O.</style></author><author><style face="normal" font="default"> Oien,T.</style></author><author><style face="normal" font="default"> Dotterud,C.K.</style></author><author><style face="normal" font="default"> Johnsen,R.</style></author><author><style face="normal" font="default"> Rudi,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Chemistry, Biotechnology and Food Science, University of Life Sciences, As, Norway</style></auth-address><titles><title><style face="normal" font="default">Effect of probiotics in prevention of atopic dermatitis is dependent on the intrinsic microbiota at early infancy</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> Bifidobacterium</style></keyword><keyword><style face="normal" font="default"> Biotechnology</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> Gut microbiota</style></keyword><keyword><style face="normal" font="default"> Infancy</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Norway</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Probiotics</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Although a link between probiotic intervention and reduction in atopic disease has been documented, no consistent associations with microbiota has yet been established. Here we have conducted an extensive analysis of the microbiota from more than 250 mother child pairs from a probiotic intervention cohort, where we previously have shown 40 % reduction in atopic dermatitis. Within the probiotic intervention group at the age of 10 days we found that the atopic children had a deviating microbiota (p = 0.028, BH-FDR corrected Kruskal Wallis) with high levels (> 10 %) of a bacterium related to Bifidobacterium dentium (p=0.039, BH-FDR corrected Chi-square). Based on these findings, we propose a model with two groups of children where the group responding to probiotic intervention, has gut microbiota related to that of non-atopic children; while the non-responding group has a divergent microbiota at the age of 10 days with overrepresented amounts of B. dentium. In conclusion, our results support the importance of early colonization for prevention of diseases developing later in life, with potential intervention effects being dependent on the intrinsic microbiota</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Norway -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.09.056</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931973">PM:27931973</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161209-AvershinaE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161209-AvershinaE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161209, Avershina E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.09.056</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40130</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Doherty,T.A.</style></author><author><style face="normal" font="default"> Broide,D.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, University of California, San Diego, La Jolla</style></auth-address><titles><title><style face="normal" font="default">Pathways to limit group 2 innate lymphoid cell activation</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170114IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.12.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28087226">PM:28087226</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170114-DohertyTA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170114-DohertyTA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170114, Doherty TA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.12.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40131</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hoshino,A.</style></author><author><style face="normal" font="default"> Okada,S.</style></author><author><style face="normal" font="default"> Yoshida,K.</style></author><author><style face="normal" font="default"> Nishida,N.</style></author><author><style face="normal" font="default"> Okuno,Y.</style></author><author><style face="normal" font="default"> Ueno,H.</style></author><author><style face="normal" font="default"> Yamashita,M.</style></author><author><style face="normal" font="default"> Okano,T.</style></author><author><style face="normal" font="default"> Tsumura,M.</style></author><author><style face="normal" font="default"> Nishimura,S.</style></author><author><style face="normal" font="default"> Sakata,S.</style></author><author><style face="normal" font="default"> Kobayashi,M.</style></author><author><style face="normal" font="default"> Nakamura,H.</style></author><author><style face="normal" font="default"> Kamizono,J.</style></author><author><style face="normal" font="default"> Mitsui-Sekinaka,K.</style></author><author><style face="normal" font="default"> Ichimura,T.</style></author><author><style face="normal" font="default"> Ohga,S.</style></author><author><style face="normal" font="default"> Nakazawa,Y.</style></author><author><style face="normal" font="default"> Takagi,M.</style></author><author><style face="normal" font="default"> Imai,K.</style></author><author><style face="normal" font="default"> Shiraishi,Y.</style></author><author><style face="normal" font="default"> Chiba,K.</style></author><author><style face="normal" font="default"> Tanaka,H.</style></author><author><style face="normal" font="default"> Miyano,S.</style></author><author><style face="normal" font="default"> Ogawa,S.</style></author><author><style face="normal" font="default"> Kojima,S.</style></author><author><style face="normal" font="default"> Nonoyama,S.</style></author><author><style face="normal" font="default"> Morio,T.</style></author><author><style face="normal" font="default"> Kanegane,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan</style></auth-address><titles><title><style face="normal" font="default">Abnormal hematopoiesis and autoimmunity in human subjects with germline IKZF1 mutations</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">abnormalities</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Age of Onset</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="default"> Autoimmunity</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Bone Marrow</style></keyword><keyword><style face="normal" font="default"> candidate gene</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Dysgammaglobulinemia</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Hematopoiesis</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Iga</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Leukemia</style></keyword><keyword><style face="normal" font="default"> Lupus</style></keyword><keyword><style face="normal" font="default"> Lupus erythematosus</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mutant</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Purpura</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Sequence</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vasculitis</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Ikaros, which is encoded by IKZF1, is a transcriptional factor that play a critical role in hematopoiesis. Somatic IKZF1 alterations are known to be involved in the pathogenesis of leukemia in human subjects. Recently, immunodeficiency caused by germline IKZF1 mutation has been described. OBJECTIVE: We sought to describe the clinical and immunologic phenotypes of Japanese patients with heterozygous IKZF1 mutations. METHODS: We performed whole-exome sequencing in patients from a dysgammaglobulinemia or autoimmune disease cohort and used a candidate gene approach in 4 patients. Functional and laboratory studies, including detailed lymphopoiesis/hematopoiesis analysis in the bone marrow, were performed. RESULTS: Nine patients from 6 unrelated families were identified to have heterozygous germline mutations in IKZF1. Age of onset was 0 to 20 years (mean, 7.4 years). Eight of 9 patients presented with dysgammaglobulinemia accompanied by B-cell deficiency. Four of 9 patients had autoimmune disease, including immune thrombocytopenic purpura, IgA vasculitis, and systemic lupus erythematosus. Nonautoimmune pancytopenia was observed in 1 patient. All of the mutant Ikaros protein demonstrated impaired DNA binding to the target sequence and abnormal diffuse nuclear localization. Flow cytometric analysis of bone marrow revealed reduced levels of common lymphoid progenitors and normal development of pro-B to pre-B cells. CONCLUSIONS: Germline heterozygous IKZF1 mutations cause dysgammaglobulinemia; hematologic abnormalities, including B-cell defect; and autoimmune diseases</style></abstract><notes><style face="normal" font="default">DA - 20161212IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.09.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27939403">PM:27939403</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161212-HoshinoA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161212-HoshinoA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161212, Hoshino A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.09.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40132</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gibson,A.</style></author><author><style face="normal" font="default"> Faulkner,L.</style></author><author><style face="normal" font="default"> Wood,S.</style></author><author><style face="normal" font="default"> Park,B.K.</style></author><author><style face="normal" font="default"> Naisbitt,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">MRC Centre for Drug Safety Science, Department of Clinical and Molecular Pharmacology, Sherrington Building, Ashton Street, The University of Liverpool, Liverpool, L69 3GE, England</style></auth-address><titles><title><style face="normal" font="default">Identification of drug- and drug-metabolite immune responses originating from both naive and memory T-cells</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> England</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Haptens</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> peptide</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="default">Both naive and memory T-cells from drug-naive donors can be stimulated by parent drug and drug haptens. Thus, drug-derived antigens can stimulate naive T-cells alongside pre-existing memory T-cells through proposed heterologous immunity with an as yet undetermined peptide antigen</style></abstract><notes><style face="normal" font="default">DA - 20170114IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28087328">PM:28087328</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170114-GibsonA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170114-GibsonA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170114, Gibson A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.032</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40133</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dominguez-Huttinger,E.</style></author><author><style face="normal" font="default"> Christodoulides,P.</style></author><author><style face="normal" font="default"> Miyauchi,K.</style></author><author><style face="normal" font="default"> Irvine,A.D.</style></author><author><style face="normal" font="default"> Okada-Hatakeyama,M.</style></author><author><style face="normal" font="default"> Kubo,M.</style></author><author><style face="normal" font="default"> Tanaka,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Bioengineering, Imperial College London, London SW7 2AZ, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Mathematical Modeling of Atopic Dermatitis Reveals "Double switch" Mechanisms Underlying Four Common Disease Phenotypes</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> activation</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> dysregulation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune dysregulation</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mexico</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Modeling</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: The skin barrier acts as the first line of defense against constant exposure to biological, microbial, physical and chemical environmental stressors. Dynamic interplay between defects in the skin barrier, dysfunctional immune responses, and environmental stressors are major factors in the development of atopic dermatitis (AD). A systems-biology modeling approach can yield significant insights into these complex and dynamic processes through integration of prior biological data. OBJECTIVE: To develop a multi-scale mathematical model of AD pathogenesis that describes the dynamic interplay between the skin barrier, environmental stress and immune dysregulation, and use it to achieve a coherent mechanistic understanding of onset, progression and prevention of AD. METHODS: We mathematically investigated synergistic effects of known genetic and environmental risk factors on the dynamic onset and progression of the AD phenotype, from a mostly asymptomatic mild phenotype to a severe treatment-resistant form. RESULTS: Our model analysis identified a "double switch", with two concatenated bistable switches, as a key network motif that dictates AD pathogenesis: The first switch is responsible for the reversible onset of inflammation; The second switch is triggered by long-lasting or frequent activation of the first switch, causing the irreversible onset of systemic Th2 sensitization and worsening of AD symptoms. CONCLUSIONS: Our mathematical analysis of the bistable switch predicts that genetic risk factors lower the threshold of environmental stressors to trigger systemic Th2 sensitization. This analysis predicts and explains four common clinical AD phenotypes from a mild and reversible phenotype through to severe and recalcitrant disease and provides a mechanistic explanation for clinically-demonstrated preventive effects of emollient treatments against development of AD</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Mexico -CO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931974">PM:27931974</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161209-DominguezHuttingerE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20161209-DominguezHuttingerE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161209, Dominguez-Huttinger E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.026</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40134</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yin,H.S.</style></author><author><style face="normal" font="default"> Gupta,R.</style></author><author><style face="normal" font="default"> Mendelsohn,A.L.</style></author><author><style face="normal" font="default"> Dreyer,B.P.</style></author><author><style face="normal" font="default"> van Schaick,L.</style></author><author><style face="normal" font="default"> Brown,C.R.</style></author><author><style face="normal" font="default"> Encalada,K.</style></author><author><style face="normal" font="default"> Sanchez,D.</style></author><author><style face="normal" font="default"> Warren,C.</style></author><author><style face="normal" font="default"> Tomopoulos,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatrics , NYU School of Medicine / Bellevue Hospital Center , New York , NY</style></auth-address><titles><title><style face="normal" font="default">Use of a Low Literacy Written Action Plan to Improve Parent Understanding of Pediatric Asthma Management: A Randomized Controlled Study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Albuterol</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> health literacy</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> rescue medication</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="3" Month="1" Year="2017">2017/1/3</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To determine whether parents who use a low literacy, pictogram- and photograph-based written asthma action plan have a better understanding of child asthma management compared to parents using a standard plan. METHODS: Randomized controlled study in 2 urban pediatric outpatient clinics. INCLUSION CRITERIA: English/Spanish-speaking parents of 2-12 year old asthmatic children. Parents were randomized to receive a low literacy or standard asthma action plan (American Academy of Allergy, Asthma and Immunology) for a hypothetical patient on controller and rescue medications. A structured questionnaire was used to assess whether there was an error in knowledge of 1)medications to give everyday and when sick, 2)need for spacer use, and 3)appropriate emergency response to give albuterol and seek medical help. Multiple logistic regression analyses performed adjusting for parent age, health literacy (Newest Vital Sign); child asthma severity, medications; site. RESULTS: 217 parents were randomized (109 intervention;108 control). Parents who received the low literacy plan were 1)less likely to make an error in knowledge of medications to take everyday and when sick compared to parents who received the standard plan (63.0 vs. 77.3%, p = 0.03; adjusted odds ratio [AOR] = 0.5[95% CI: 0.2-0.9]) and 2)less likely make an error regarding spacer use (14.0 vs. 51.1%, p&lt;0.001; AOR = 0.1[0.06-0.3]). No difference in error in appropriate emergency response was seen (43.1 vs. 48.1%, p = 0.5). CONCLUSIONS: Use of a low literacy written asthma action plan was associated with better parent understanding of asthma management. Further study is needed to assess whether use of this action plan improves child asthma outcomes</style></abstract><notes><style face="normal" font="default">DA - 20170103IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1277542</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28045551">PM:28045551</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170103-YinHS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170103-YinHS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170103, Yin HS</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1277542</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40135</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ginis,T.</style></author><author><style face="normal" font="default"> Akcan,F.A.</style></author><author><style face="normal" font="default"> Capanoglu,M.</style></author><author><style face="normal" font="default"> Toyran,M.</style></author><author><style face="normal" font="default"> Ersu,R.</style></author><author><style face="normal" font="default"> Kocabas,C.N.</style></author><author><style face="normal" font="default"> Civelek,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric Allergy and Immunology , Ankara Children's Hematology Oncology Training and Research Hospital , Ankara , Turkey</style></auth-address><titles><title><style face="normal" font="default">The frequency of sleep-disordered breathing in children with asthma and its effects on asthma control</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> C-ACT</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Control level</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="default"> Hematology</style></keyword><keyword><style face="normal" font="default"> Hypertrophy</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tonsil</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="6" Month="1" Year="2017">2017/1/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: The presence of sleep-disordered breathing (SDB) in children with asthma may cause difficult to control asthma. OBJECTIVES: The aim of this study was to determine the frequency of SDB in children with asthma, to evaluate its effects on asthma control and to assess the risk factors associated with the presence of SDB. METHODS: Parents of children who Sleep Questionnaire (PSQ) and the Childhood Asthma Control Test (C-ACT). Asthma control level was assessed according to Global Initiative for Asthma (GINA). Same ear-nose-throat (ENT) specialist evaluated all patients. A 4-point tonsil grading method and adenoid-nasopharynx ratio were used to categorize tonsil and adenoid size, respectively. RESULTS: A total of 408 children (275 male, 67.4%) with a mean age of 8.1 +/- 3.2 years were included. Nearly 40% of asthmatic children were not-well-controlled according to GINA and 34.6% of all patients had SDB according to PSQ. Multivariate logistic regression analysis revealed that coexistence of SDB [OR: 6.62, 95% CI (4.21-10.41); p &lt; 0.001)] and tonsillar hypertrophy [OR: 3.47; 95% CI (1.05-11.5); p &lt; 0.041] were independent risk factors for not-well-controlled asthma in asthmatic children after other established contributors to asthma control were adjusted. CONCLUSIONS: Our study showed that SDB is a strong risk factor for not-well-controlled asthma in asthmatic children independent of other confounders. In addition, tonsillar hypertrophy may have a role in the association between SDB and not-well-controlled asthma in childhood</style></abstract><notes><style face="normal" font="default">DA - 20170106IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1220012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28060556">PM:28060556</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170106-GinisT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170106-GinisT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170106, Ginis T</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1220012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40136</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bellinger,C.</style></author><author><style face="normal" font="default"> Bleecker,E.R.</style></author><author><style face="normal" font="default"> Peters,S.P.</style></author><author><style face="normal" font="default"> Pascual,R.M.</style></author><author><style face="normal" font="default"> Krings,J.</style></author><author><style face="normal" font="default"> Smith,R.V.</style></author><author><style face="normal" font="default"> Hasties,A.</style></author><author><style face="normal" font="default"> Moore,W.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Genomics and Personalized Medicine Research, Wake Forest University School of Medicine , Winston-Salem , NC</style></auth-address><titles><title><style face="normal" font="default">Effects of bronchoscopy on lung function in asthmatics</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Albuterol</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Bronchoscopy</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Genomics</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Compliance</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral corticosteroids</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Personalized medicine</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Prednisolone</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Recovery</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="5" Month="1" Year="2017">2017/1/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: To better understand changes in pulmonary physiology related to asthma severity following bronchoscopy, we performed scheduled pre- and post-procedure spirometry on all subjects undergoing bronchoscopy in our research program. METHODS: Control subjects and asthma subjects of all severity were recruited for bronchoscopy. On the day of bronchoscopy, subjects underwent spirometry when they arrived, after pre-bronchoscopy treatment with albuterol and then up to three sets within two hours following completion of the bronchoscopy. A subset of patients had a second bronchoscopy after two weeks of treatment with oral prednisolone (40 mg daily). RESULTS: A total of 92 subjects had at least one bronchoscopy [12 control subjects, 56 nonsevere asthma (NSA), 24 severe asthma (SA)]. The SA and NSA groups had similar decreases in FEV1 (-20+/-13% vs -19+/-16%, p = 0.92) and FVC (-20+/-12% vs -20+/-14%, p = 0.80), but no change in FEV1/FVC ratio. The control and NSA group had more rapid recovery of both FEV1 and FVC by 2 hours compared to the SA group (p = 0.01). In the subset of 36 subjects (22 NSA, 14 SA) who underwent a second bronchoscopy following administration of oral prednisolone for 14 days, steroids resulted in more rapid recovery of lung function(p&lt;0.04). CONCLUSION: Following bronchoscopy control subjects and asthma subjects demonstrated similar concurrent decreases in FEV1 and FVC, but not FEV1/FVC. Nonsevere asthma subjects recovered lung function more quickly than severe asthma subjects. Treatment with oral corticosteroids was associated with quicker recovery of FEV1 which may suggest an inflammatory mechanism for these changes in lung compliance</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1276587</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28055281">PM:28055281</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170105-BellingerC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170105-BellingerC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Bellinger C</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1276587</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40137</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Park,Y.A.</style></author><author><style face="normal" font="default"> Park,H.B.</style></author><author><style face="normal" font="default"> Kim,Y.H.</style></author><author><style face="normal" font="default"> Sul,I.S.</style></author><author><style face="normal" font="default"> Yoon,S.H.</style></author><author><style face="normal" font="default"> Kim,H.R.</style></author><author><style face="normal" font="default"> Kim,K.W.</style></author><author><style face="normal" font="default"> Kim,K.E.</style></author><author><style face="normal" font="default"> Sohn,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatrics , Severance Children's Hospital, Institute of Allergy, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine , Seoul , Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Airway Hyperresponsiveness to Mannitol and Methacholine and Exhaled Nitric Oxide in Children with Asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Mannitol</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="5" Month="1" Year="2017">2017/1/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1255751</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28055271">PM:28055271</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170105-ParkYA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170105-ParkYA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Park YA</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1255751</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40138</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rhee,H.</style></author><author><style face="normal" font="default"> McQuillan,B.</style></author><author><style face="normal" font="default"> Chen,D.G.</style></author><author><style face="normal" font="default"> Atis,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">LMSW Roberts Wesleyan College</style></auth-address><titles><title><style face="normal" font="default">Perceptions about Interpersonal Relationships and School Environment Among Middle School Students with Asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> race</style></keyword><keyword><style face="normal" font="default"> Rural</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> Students</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="5" Month="1" Year="2017">2017/1/5</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To examine interpersonal relationships involving peers and teachers and perceptions about school environment among middle school students with asthma in comparison to their healthy counterparts. The study also assesses asthma prevalence in a large sample of middle school students representing different geographic locations. METHODS: Cross-sectional data were collected from 1059 middle school students in grades 6-8 enrolled in schools in a northeastern region of the U.S. Students reported their chronic health conditions including asthma and completed questionnaires measuring perceptions about their relationships with peers and teachers as well as school environment. ANCOVAs were used to compare students with asthma and their healthy counterparts in the study variables. RESULTS: Asthma was reported by 16.5% of the sample (n = 169). The rate was higher among minority students (23%) than their white counterparts (15%). Greater proportion of urban students (28%) reported asthma than rural (18%) and suburban (14%) students. Students with asthma reported significantly poorer relationships with peers (B = -1.74, p&lt;.001) and teachers (B = -1.41, p = .009), and their perceptions about overall school environment (B = -1.30, p = .009) were also lower than their healthy counterparts. Race showed no significant effects on school factors. CONCLUSION: Overall asthma prevalence was substantially higher than the national average of adolescent asthma, particularly those residing in the urban area. Poor perceptions of interpersonal relationships with peers and teachers among students with asthma may indicate compromised quality of life. Suboptimal interpersonal relationships and school environment need to be identified and adequately addressed given their implications for asthma management at the school setting among middle school students</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1277540</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28055268">PM:28055268</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170105-RheeH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170105-RheeH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Rhee H</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1277540</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40139</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sabar,M.F.</style></author><author><style face="normal" font="default"> Shahid,M.</style></author><author><style face="normal" font="default"> Bano,I.</style></author><author><style face="normal" font="default"> Ghani,M.U.</style></author><author><style face="normal" font="default"> Akram,M.</style></author><author><style face="normal" font="default"> Iqbal,F.</style></author><author><style face="normal" font="default"> Kousar,S.</style></author><author><style face="normal" font="default"> Iqbal,Z.</style></author><author><style face="normal" font="default"> Altaf,S.</style></author><author><style face="normal" font="default"> Husnain,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Applied Molecular Biology, University of the Punjab , Lahore , Pakistan</style></auth-address><titles><title><style face="normal" font="default">rs12603332 is associated with male asthma patients specifically in urban areas of Lahore, Pakistan</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> B-Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Molecular Biology</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pakistan</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Saudi Arabia</style></keyword><keyword><style face="normal" font="default"> Software</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="5" Month="1" Year="2017">2017/1/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: rs12603332, an important regulatory site variant, is known to alter the regulatory motif E2A that is involved in maturation of B-lymphocytes. The study was designed to check whether different environmental exposures alter its risk allele association with asthma or not. METHODS: 200 Physician diagnosed asthma patients and 108 healthy individuals were enrolled from hospitals of Lahore. After quantitation of DNA extracted from their peripheral blood samples, amplification of genomic region with rs12603332 was performed followed by single base extension. Allele and frequencies were calculated by SHEsis and Haploview softwares. Statistical analyses on PLINK were also performed taking different factors as covariates. HaploReg analysis was done to predict effect of risk allele on different regulatory motifs. RESULTS: Risk allele for rs12603332 i.e., 'C' allele was found to be significantly associated with male patients residing in urban localities. CONCLUSION: The finding suggests that on exposure with urban environment, risk allele carriers tend to develop asthma symptoms via epigenetic regulation of motif associated with maturation of B-lymphocytes</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Pakistan -CO - Saudi Arabia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1277539</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28055272">PM:28055272</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170105-SabarMF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170105-SabarMF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Sabar MF</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1277539</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40140</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oyana,T.J.</style></author><author><style face="normal" font="default"> Podila,P.</style></author><author><style face="normal" font="default"> Wesley,J.M.</style></author><author><style face="normal" font="default"> Lomnicki,S.M.</style></author><author><style face="normal" font="default"> Cormier,S.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Preventive Medicine, College of Medicine, The University of Tennessee Health Science Center, Department of Environmental Sciences , Louisiana State University</style></auth-address><titles><title><style face="normal" font="default">Spatiotemporal patterns of childhood asthma hospitalization and utilization in Memphis Metropolitan Area from 2005 to 2015</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">African American</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Louisiana</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Preventive Medicine</style></keyword><keyword><style face="normal" font="default"> race</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Tennessee</style></keyword><keyword><style face="normal" font="default"> Trajectory</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> white</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="5" Month="1" Year="2017">2017/1/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To identify key risk factors and explain spatiotemporal patterns of childhood asthma in the Memphis Metropolitan Area (MMA) over an 11-year period (2005 to 2015). We hypothesize that in the MMA region this burden is more prevalent among urban children living south, downtown, and north of Memphis than other areas. METHODS: We used a large-scale longitudinal electronic health record database from an integrated healthcare system, GIS, statistical, and space-time models to study spatiotemporal distributions of childhood asthma at census-tract level. RESULTS: We found statistically significant spatiotemporal clusters of childhood asthma in the south, west, and north of Memphis city after adjusting for key covariates. Results further show a significant increase in temporal gradient in frequency of emergency department visits and inpatient hospitalizations from 2009 to 2013; and an upward trajectory from 4 per 1,000 children in 2005 to 16 per 1,000 children in 2015. The multivariate logistic regression identified age, race, insurance, admit source, encounter type, and frequency of visits as significant risk factors for childhood asthma (p&lt;0.05). We observed a greater asthma burden and healthcare utilization for African American (AA) patients living in a high-risk area than those living in a low-risk area in comparison to the White patients: AA vs. White [Odds Ratio (OR) = 3.03, 95% Confidence Interval (CI): 2.75-3.34]; and Hispanic vs. White (OR = 1.62, 95% CI: 1.21-2.17). CONCLUSIONS: These findings provide a strong basis for developing geographically-tailored population health strategies at the neighborhood level for young children with chronic respiratory conditions</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1277537</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28055280">PM:28055280</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170105-OyanaTJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170105-OyanaTJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Oyana TJ</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1277537</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40141</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Celebi,S.Z.</style></author><author><style face="normal" font="default"> Aydin,O.</style></author><author><style face="normal" font="default"> Demirel,Y.S.</style></author><author><style face="normal" font="default"> Soyyigit,S.</style></author><author><style face="normal" font="default"> Cerci,P.</style></author><author><style face="normal" font="default"> Kendirlinan,R.</style></author><author><style face="normal" font="default"> Bavbek,S.</style></author><author><style face="normal" font="default"> Celik,G.E.</style></author><author><style face="normal" font="default"> Misirligil,Z.</style></author><author><style face="normal" font="default"> Sin,B.A.</style></author><author><style face="normal" font="default"> Kelesoglu,A.</style></author><author><style face="normal" font="default"> Mungan,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Ankara University School of Medicine, Department of Chest Diseases , Division of Allergy and Clinical Immunology</style></auth-address><titles><title><style face="normal" font="default">Does the Medical Diagnosis of Occupational Asthma Coincide With the Legal Diagnosis?</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchial Hyperreactivity</style></keyword><keyword><style face="normal" font="default"> Bronchial Provocation Tests</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic test</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> occupational asthma</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword><keyword><style face="normal" font="default"> Workplace</style></keyword></keywords><dates><year Day="5" Month="1" Year="2017">2017/1/5</year></dates><abstract><style face="normal" font="default">Objective The incidence of occupational asthma(OA) is increasing worldwide. In this study, we first aimed to document the rate of diagnosis of OAamong patients who were referred to our clinic from Social Security Institution and factors that affected diagnosis, and secondly, we aimed to assess the consistency of the medical diagnosis and the legal diagnosis. Methods The study involved 132 consecutive patients who were referred to our clinic for evaluation of OA between 2010 and 2015. Detailed workplace history,the tools used in the diagnosis such as peak expiratory flow(PEF) monitoring and bronchial provocation tests and final medical diagnosis were recorded from case files. Results Asthma was diagnosed in 75% (n = 99) of the patients. Among them, 22.2% were diagnosed as having OA. The diagnosis was confirmed by serial PEF measurement (45.5%), non specific bronchial hyperreactivity (NSBHR) assessment (22.7%) and both tests (27.2%) at work and off-work periods. OA diagnosis was mostly established in workers who were actively working (72.7%). The legal diagnosis period was completed in 54.5% of these 22 patients, and 50% (n = 11) were officially diagnosed as having OA with an 91.6% concordance with medical diagnosis. Conclusion This study verifies the importance of correct diagnosis of asthma in the evaluation of OA as first step. Diagnostic tests other than specific provocation tests could be preferential in patients who still work in the same field. We believe that cooperation with the patient's occupational physician and adequate recognition of the work environment will improve the consistency of legal and medical diagnosis</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1277541</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28055274">PM:28055274</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170105-CelebiSZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170105-CelebiSZ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Celebi SZ</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1277541</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40142</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kotsiou,O.S.</style></author><author><style face="normal" font="default"> Douras,A.</style></author><author><style face="normal" font="default"> Makris,D.</style></author><author><style face="normal" font="default"> Mpaka,N.</style></author><author><style face="normal" font="default"> Gourgoulianis,K.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Respiratory Medicine , University Hospital of Larissa, Faculty of Medicine, University of Thessaly, BIOPOLIS , 41500 , Larissa , Greece</style></auth-address><titles><title><style face="normal" font="default">Takotsubo cardiomyopathy: a known unknown foe of asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">abnormalities</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Status Asthmaticus</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Takotsubo Cardiomyopathy</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="5" Month="1" Year="2017">2017/1/5</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Patients with uncontrolled asthma are at a greater risk of asthma attacks requiring emergency room visits or hospital admissions. Takotsubo cardiomyopathy is potentially a significant complication in a course of status asthmaticus. CASE STUDY: We present a 43-year-old female patient who presented with status asthmaticus further complicated with takotsubo cardiomyopathy. RESULTS: Recognizing apical ballooning syndrome is challenging in patients with a history of respiratory disease because the symptoms of the last entity may complicate the diagnostic approach. It is difficult to distinguish clinically apical ballooning syndrome from the acute airway exacerbation itself. Both asthma and takotsubo cardiomyopathy share the same clinical presentation with dyspnea and chest tightness. In our patient, the electrocardiographic abnormalities, the rapidly reversible distinctive characteristics of echocardiography and the modest elevation of serum cardiac biomarkers levels, in combination with the presence of a stress trigger (severe asthma attack), strongly supported the diagnosis of broken heart syndrome. CONCLUSION: Clinicians should re-evaluate asthma management and be aware of the complications associated with asthma attacks such as stress-induced cardiomyopathy</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1276586</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28055270">PM:28055270</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170105-KotsiouOS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170105-KotsiouOS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Kotsiou OS</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1276586</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40143</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Monteiro,F.P.</style></author><author><style face="normal" font="default"> Sole,D.</style></author><author><style face="normal" font="default"> Wandalsen,G.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Federal University of Sao Paulo (UNIFESP) - Master of Pediatrics and Sciences applied to pediatrics</style></auth-address><titles><title><style face="normal" font="default">Quality of Life of Asthmatic Children and Adolescents: Portuguese Translation, Adaptation and Validation of the Questionnaire "Pediatric Quality of Life (PedsQL) Asthma Module</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> C-ACT</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="5" Month="1" Year="2017">2017/1/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To translate, validate and verify the psychometric properties of the Portuguese version of the instrument "Pediatric Quality of Life Asthma Module" (PedsQL Asthma) culturally adapted for the Brazilian culture. METHODS: After being translated to Portuguese and culturally adapted, the questionnaire was answered by 200 asthmatic children and adolescents (ages 2 to 18) as well as the adults responsible for them. Validation required the use of the following instruments, PedsQL Asthma Children (applied to children and adolescents), PedsQL Asthma Parents (applied to adults responsible for children and adolescents), Pediatric Asthma Quality of Life (PAQLQ), Asthma Control Test (ACT) or Childhood Asthma Control Test (C-ACT), as well as socio-economic and personal information questionnaires. A group of 45 clinically stable children repeated the questionnaires 15 to 60 days after answering the first questionnaire. RESULTS: Correlations between the scores of PedsQL Children and PedsQL Parents (r = 0.67), PedsQL Children and PAQLQ (r = 0.66) and PedsQL Parents and PAQLQ (r = 0.64) were moderate and significant. Correlations were higher for males (r = 0.72) when analyzing the children's and parents' answers to PedsQL according to gender. The 5- to 7-year old age group had the strongest correlations with PAQLQ (r = 0.79). Cronbach's Alpha coefficient for PedsQL Children and Parents had values of 0.85 and 0.87, respectively. A high concordance was observed in both tests' at different times, with Kappa values of 0.89 and 0.87 for PedsQL Children and Parents, respectively. CONCLUSION: The instrument used in this study was considered valid, consistent and reproducible and has acceptable psychometric proprieties for the Brazilian population</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1277543</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28055276">PM:28055276</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170105-MonteiroFP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170105-MonteiroFP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Monteiro FP</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1277543</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40144</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,F.P.</style></author><author><style face="normal" font="default"> Mao,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Respiratory Medicine , West China Hospital, Sichuan University , Chengdu 610041 , Chinaa Department of Respiratory Medicine , West China Hospital, Sichuan University , Chengdu 610041 , China</style></auth-address><titles><title><style face="normal" font="default">Respiratory comorbidities cannot be neglected</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="671">671-</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">China</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161208IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1266652</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27929685">PM:27929685</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20161208-WangFP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20161208-WangFP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161208, Wang FP</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1266652</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40145</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zipkin,R.</style></author><author><style face="normal" font="default"> Schrager,S.M.</style></author><author><style face="normal" font="default"> Nguyen,E.</style></author><author><style face="normal" font="default"> Mamey,M.R.</style></author><author><style face="normal" font="default"> Banuelos,I.</style></author><author><style face="normal" font="default"> Wu,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Children's Hospital Los Angeles</style></auth-address><titles><title><style face="normal" font="default">Association Between Pediatric Home Management Plan of Care Compliance and Asthma Readmission</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> intensive care unit</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Los Angeles</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of care</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective cohort study</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">OBJECTIVES: In 2007, The Joint Commission implemented three children's asthma care (CAC) measures to help improve the quality of care for patients admitted with asthma. Due to lack of consistent evidence showing a relationship between home management plan of care (HMPC) compliance and readmission rates, CAC-3 was retired in 2016. We aimed to understand the relationship between HMPC compliance and revisits to the hospital, and investigate which components of the HMPC, if any, were driving the effect. METHODS: This was a retrospective cohort study at a quaternary care freestanding children's hospital, including patients between 2 and 17 years of age admitted with a primary diagnosis of asthma between January 1, 2006 and July 1, 2013. Bivariate and multiple logistic regression analyses examined effects of HMPC provider compliance on hospital readmission and emergency department utilization for asthma within 180 days of initial discharge, controlling for admission to the intensive care unit, age, gender, ethnicity, insurance type and whether inhaled corticosteroids were prescribed. RESULTS: 1,176 patients were included. Patients discharged with an HMPC (n = 756, of which 84% were fully compliant) were found to have significantly lower readmission rates (7% vs. 11.9%; aOR = 0.63; 95% CI, 0.41-0.95) and ED revisit rates (aOR = 0.73; 95% CI, 0.56-0.96) within 180 days of discharge. CONCLUSIONS: Providing an HMPC upon discharge was found to be associated with decreased asthma readmission and ED utilization rates. This suggests that although HMPC is no longer a required measure, there may still be utility in continuing this practice</style></abstract><notes><style face="normal" font="default">DA - 20161208IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1263651</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27929691">PM:27929691</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20161208-ZipkinR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20161208-ZipkinR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161208, Zipkin R</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1263651</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40146</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oh,S.</style></author><author><style face="normal" font="default"> Du,R.</style></author><author><style face="normal" font="default"> Zeiger,A.M.</style></author><author><style face="normal" font="default"> Mcgarry,M.E.</style></author><author><style face="normal" font="default"> Hu,D.</style></author><author><style face="normal" font="default"> Thakur,N.</style></author><author><style face="normal" font="default"> Pino-Yanes,M.</style></author><author><style face="normal" font="default"> Galanter,J.M.</style></author><author><style face="normal" font="default"> Farber,H.J.</style></author><author><style face="normal" font="default"> Eng,C.</style></author><author><style face="normal" font="default"> Nishimura,K.K.</style></author><author><style face="normal" font="default"> Huntsman,S.</style></author><author><style face="normal" font="default"> Meade,K.</style></author><author><style face="normal" font="default"> Avila,P.</style></author><author><style face="normal" font="default"> Serebrisky,D.</style></author><author><style face="normal" font="default"> Bibbins-Domingo,K.</style></author><author><style face="normal" font="default"> Lenoir,M.A.</style></author><author><style face="normal" font="default"> Ford,J.G.</style></author><author><style face="normal" font="default"> Brigino-Buenaventura,E.</style></author><author><style face="normal" font="default"> Rodriguez-Cintron,W.</style></author><author><style face="normal" font="default"> Thyne,S.M.</style></author><author><style face="normal" font="default"> Sen,S.</style></author><author><style face="normal" font="default"> Rodriguez-Santana,J.R.</style></author><author><style face="normal" font="default"> Williams,K.</style></author><author><style face="normal" font="default"> Kumar,R.</style></author><author><style face="normal" font="default"> Burchard,E.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">a University of California San Francisco, Medicine , Box 2911, San Francisco , 94143-2911 United States</style></auth-address><titles><title><style face="normal" font="default">Breastfeeding associated with higher lung function in African American youths with asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> African American</style></keyword><keyword><style face="normal" font="default"> African Americans</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Infancy</style></keyword><keyword><style face="normal" font="default"> Latino</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Poisson</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Puerto Rican</style></keyword><keyword><style face="normal" font="default"> San Francisco</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> youth</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Objective In the United States, Puerto Ricans and African Americans have lower prevalence of breastfeeding and worse clinical outcomes for asthma compared with other racial/ethnic groups. We hypothesize that history of breastfeeding is associated with increased forced expiratory volume in 1 second (FEV1) % predicted and reduced asthma exacerbations in Latino and African American youths with asthma. Methods As part of Study A and Study B, we conducted case-only analyses in children and adolescents aged 8-21 years old with asthma from four different racial/ethnic groups: African Americans (n = 426), Mexican Americans (n = 424), mixed/other Latinos (n = 255), and Puerto Ricans (n = 629). We investigated the association between any breastfeeding in infancy and FEV1% predicted as well as asthma exacerbations using multivariable linear and Poisson regression models, respectively. Results Prevalence of breastfeeding was lower in African Americans (59.4%) and Puerto Ricans (54.9%) compared to Mexican Americans (76.2%) and mixed/other Latinos (66.9%; p&lt;0.001). After adjusting for covariates, breastfeeding was associated with a 3.58 percentage point increase in FEV1% predicted (p = 0.01) and a 21% reduction in asthma exacerbations (p = 0.03) in African Americans only. Conclusion Breastfeeding was associated with higher FEV1% predicted in asthma and reduced number of asthma exacerbations in African American youths, calling attention for continued support for breastfeeding</style></abstract><notes><style face="normal" font="default">DA - 20161208IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Puerto Rico -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1266496</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27929698">PM:27929698</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20161208-OhS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20161208-OhS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161208, Oh S</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1266496</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40147</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Merianos,A.L.</style></author><author><style face="normal" font="default"> Dixon,C.A.</style></author><author><style face="normal" font="default"> Mahabee-Gittens,E.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a University of Cincinnati, School of Human Services, University of Cincinnati , PO Box 210068, Cincinnati , OH , USA</style></auth-address><titles><title><style face="normal" font="default">Secondhand Smoke Exposure, Illness Severity and Resource Utilization in Pediatric Emergency Department Patients with Respiratory Illnesses</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> Bronchiolitis</style></keyword><keyword><style face="normal" font="default"> Cessation</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Documentation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Influenza</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> Intubation</style></keyword><keyword><style face="normal" font="default"> Magnesium</style></keyword><keyword><style face="normal" font="default"> Magnesium Sulfate</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Oxygen</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pneumonia</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> secondhand smoke</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Smoke</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Hospital-based data reveal that children who have secondhand smoke exposure (SHSe) experience severe respiratory illnesses and greater resource utilization. Our objective was to assess the relationship between SHSe and illness severity/resource utilization among children presenting to the pediatric emergency department (PED) with three common respiratory conditions - asthma, bronchiolitis, and pneumonia. METHODS: A retrospective review of a yearlong consecutive sample of PED patients with SHSe status documentation and asthma, bronchiolitis, or pneumonia diagnoses was performed. PED illness severity/resource utilization variables included: triage categorization, initial oxygen saturation, evaluation/testing (influenza A &amp; B, respiratory syncytial virus, chest x-ray), procedures/interventions performed (supplemental oxygen, suctioning, intubation), medications administered and disposition. Logistic and linear regression models were conducted to determine differences in each diagnosis group while controlling for sociodemographics, medical history, seasonality, and insurance type. RESULTS: There were 3,229 children with documentation of SHSe status and an asthma (41%), bronchiolitis (36%), or pneumonia (23%) diagnosis. Across diagnosis groups, approximately 1/4 had positive documentation of SHSe. Asthmatic children with SHSe were more likely to receive corticosteroids (OR = 1.71, 95%CI = 1.19, 2.44) and/or receive magnesium sulfate (OR = 1.66, 95%CI = 1.14, 2.40). Children with SHSe and bronchiolitis were more likely to receive racemic epinephrine (OR = 2.48, 95%CI = 1.21, 5.08), have a chest x-ray (OR = 1.36, 95%CI = 1.00, 1.85), and/or be admitted (OR = 1.46, 95%CI = 1.09, 1.95). No differences in illness severity/resource utilization were identified for children with pneumonia. CONCLUSIONS: SHS exposed children with asthma or bronchiolitis have greater illness severity/resource utilization. Our findings highlight the importance of SHSe assessment, cessation and research efforts in the PED setting</style></abstract><notes><style face="normal" font="default">DA - 20161208IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1265127</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27929695">PM:27929695</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20161208-MerianosAL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20161208-MerianosAL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161208, Merianos AL</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1265127</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40148</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ding,B.</style></author><author><style face="normal" font="default"> DiBonaventura,M.</style></author><author><style face="normal" font="default"> Karlsson,N.</style></author><author><style face="normal" font="default"> Ling,X.</style></author></authors></contributors><auth-address><style face="normal" font="default">AstraZeneca , Molndal , Sweden</style></auth-address><titles><title><style face="normal" font="default">A cross-sectional assessment of the prevalence and burden of mild asthma in urban China using the 2010, 2012, and 2013 China National Health and Wellness Surveys</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> QOL</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To estimate the prevalence of mild asthma in urban China and to measure the association between asthma severity and quality of life (QOL), work productivity, and healthcare resource use. METHODS: Data were from the China National Health and Wellness Surveys (NHWS) conducted between 2010 and 2013 (N = 59,935), Internet-based surveys of adults in urban China. Patients were categorized by asthma severity according to self-report and Global Initiative for Asthma (GINA2014) guidelines via self-reported medication use (mild [GINA 1-2] vs moderate/severe [GINA 3-4]). Propensity scores were used to identify matched controls without asthma. These three groups (mild vs. moderate/severe vs. matched control) were compared with respect to QOL (revised Short Form-12/36), work productivity (WPAI questionnaire), and healthcare use using generalized linear models. RESULTS: 1,191 respondents reported an asthma diagnosis (1.99%). 455 (0.77% and 76.86% of the total sample and asthma sample which could be categorized based on GINA2014 guidelines, respectively) and 897 (1.50% and 75.31% of the total and asthma sample, respectively) had mild asthma based on GINA2014 guidelines and self-report, respectively. Compared with matched controls, mild patients based on GINA2014 guidelines reported worse QOL (Physical Component Summary = 44.67 vs. 48.97), more overall work impairment (54.51% vs. 34.35%), and more all-cause emergency room visits in the past 6 months (1.95 vs. 0.63 visits) (all p&lt;.05). Similar results were observed using self-reported severity. CONCLUSIONS: Most patients with asthma in the China NHWS are mild according to either definition. Asthma patients experience significant burden to QOL, work productivity, activity impairment, and healthcare resource use</style></abstract><notes><style face="normal" font="default">DA - 20161221IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1255750</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28001469">PM:28001469</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20161221-DingB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20161221-DingB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161221, Ding B</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1255750</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40149</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chan,M.A.</style></author><author><style face="normal" font="default"> Ciaccio,C.E.</style></author><author><style face="normal" font="default"> Gigliotti,N.M.</style></author><author><style face="normal" font="default"> Rezaiekhaligh,M.</style></author><author><style face="normal" font="default"> Siedlik,J.A.</style></author><author><style face="normal" font="default"> Kennedy,K.</style></author><author><style face="normal" font="default"> Barnes,C.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Division of Allergy, Asthma &amp; Immunology, Children's Mercy Hospital , 2401 Gillham Rd, Kansas City , MO 64108 , USA</style></auth-address><titles><title><style face="normal" font="default">DNA Methylation Levels Associate with Race and Childhood Asthma Severity</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">African American</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Cockroach</style></keyword><keyword><style face="normal" font="default"> Cockroaches</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Housing</style></keyword><keyword><style face="normal" font="default"> Immunoassay</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Income</style></keyword><keyword><style face="normal" font="default"> indoor</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Kansas</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> low income</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Methylation</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> Mites</style></keyword><keyword><style face="normal" font="default"> molds</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> race</style></keyword><keyword><style face="normal" font="default"> Rodent</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> socioeconomic status</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Asthma is a common chronic childhood disease worldwide. Socioeconomic status, genetic predisposition and environmental factors contribute to its incidence and severity. A disproportionate number of children with asthma are economically disadvantaged and live in substandard housing with potential indoor environmental exposures such as cockroaches, dust mites, rodents and molds. These exposures may manifest through epigenetic mechanisms that can lead to changes in relevant gene expression. We examined the association of global DNA methylation levels with socioeconomic status, asthma severity and race/ethnicity. METHODS: We measured global DNA methylation in peripheral blood of children with asthma enrolled in the Kansas City Safe and Healthy Homes Program. Inclusion criteria included residing in the same home for a minimum of 4 days per week and total family income of less than 80% of the Kansas City median family income. DNA methylation levels were quantified by an immunoassay that assessed the percentage of 5-methylcytosine. RESULTS AND CONCLUSIONS: Our results indicate that overall, African American children had higher levels of global DNA methylation than children of other races/ethnicities (p = 0.029). This difference was more pronounced when socioeconomic status and asthma severity were coupled with race/ethnicity (p = 0.042) where low-income, African American children with persistent asthma had significantly elevated methylation levels relative to other races/ethnicities in the same context (p = 0.006, Hedges g = 1.14). Our study demonstrates a significant interaction effect among global DNA methylation levels, asthma severity, race/ethnicity, and socioeconomic status</style></abstract><notes><style face="normal" font="default">DA - 20161208IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1265126</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27929694">PM:27929694</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20161208-ChanMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20161208-ChanMA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161208, Chan MA</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1265126</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40150</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kondo,T.</style></author><author><style face="normal" font="default"> Tanigaki,T.</style></author><author><style face="normal" font="default"> Yokoyama,H.</style></author><author><style face="normal" font="default"> Hibino,M.</style></author><author><style face="normal" font="default"> Tajiri,S.</style></author><author><style face="normal" font="default"> Akazawa,K.</style></author><author><style face="normal" font="default"> Yamada,Y.</style></author><author><style face="normal" font="default"> Cassan,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Respiratory Medicine , Shonan Fujisawa Tokushukai Hospital , 1-5-1 Kandai, Tsujido, Fujisawa, Kanagawa 251-0041 Japan</style></auth-address><titles><title><style face="normal" font="default">Impact of holding position during inhalation on drug release from a reservoir-, a blister-, and a capsule- type dry powder inhaler</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Blister</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Dry Powder Inhalers</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To determine whether drug release may be impaired by tilting some dry powder inhalers (DPIs). METHODS: Using an inhalation simulator, we measured drug release from Turbuhaler(R) (TBH), Diskus(R) (DKS) and Breezhaler(R) (BZH) at several peak inhaled flow rates (PIFs) while the DPIs were held level and tilted (80 degrees). Drug release was then measured from all three DPI's at 0, 30, 60 and 90 degrees of tilt, and capsule rotation was also recorded. RESULTS: Drug release from TBH was flow-dependent while that from DKS and BZH was flow-independent. With TBH, the plot of drug release vs PIF either at level or tilted position scattered along almost the same regression lines. With DKS and BZH drug release at tilted position was significantly lower than that while level. With DKS the decrease was almost 20%, while with BZH drug release frequently failed. With BZH, significant reductions in drug release were observed while the device was tilted 30-90 degrees. CONCLUSION: The position in which the DPI is held may impact drug delivery especially using BZH</style></abstract><notes><style face="normal" font="default">DA - 20161208IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1266497</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27929704">PM:27929704</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20161208-KondoT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20161208-KondoT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161208, Kondo T</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1266497</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40151</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martin-Lazaro,J.</style></author><author><style face="normal" font="default"> Nunez-Orjales,R.</style></author><author><style face="normal" font="default"> Battikhi-Precedo,N.</style></author><author><style face="normal" font="default"> Lopez-Freire,S.</style></author><author><style face="normal" font="default"> Carballada-Gonzalez,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hospital Universitario Lucus Augusti, Lugo, Spain</style></auth-address><titles><title><style face="normal" font="default">Allergy to Blue Dye</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="383" start="381">381-383</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0101</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996948">PM:27996948</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161220, Martin-Lazaro J</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0101</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40152</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cano-Mollinedo,M.</style></author><author><style face="normal" font="default"> Rodriguez del Rio,P.</style></author><author><style face="normal" font="default"> Sanchez-Garcia,S.</style></author><author><style face="normal" font="default"> Escudero,C.</style></author><author><style face="normal" font="default"> Ibanez,M.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy, Nino Jesus University Hospital, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Serious Adverse Reaction to Timolol Eye Drops in a 7-Year-Old Boy With Glaucoma and Asthma</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="381" start="379">379-381</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Glaucoma</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Timolol</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0099</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996947">PM:27996947</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161220, Cano-Mollinedo M</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0099</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40153</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Prados,M.</style></author><author><style face="normal" font="default"> Labella,M.</style></author><author><style face="normal" font="default"> Baynova,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergology, University Hospital Virgen del Rocio, Seville, Spain</style></auth-address><titles><title><style face="normal" font="default">Accelerated-type Reactions to High Parenteral Doses of Metamizole in Patients Who Tolerated Therapeutic Doses of Oral Metamizole and Other NSAIDs</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="379" start="378">378-379</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergology</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> NSAID</style></keyword><keyword><style face="normal" font="default"> NSAIDs</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0098</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996946">PM:27996946</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161220, Prados M</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0098</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40154</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Unal,D.</style></author><author><style face="normal" font="default"> Coskun,R.</style></author><author><style face="normal" font="default"> Demir,D.</style></author><author><style face="normal" font="default"> Gelincik,A.</style></author><author><style face="normal" font="default"> Colakoglu,B.</style></author><author><style face="normal" font="default"> Buyukozturk,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Immunology and Allergic Diseases, Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="default">Successful Desensitization to Vitamin D in a Patient With Vitamin D Deficiency</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="393" start="392">392-393</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> Vitamin D Deficiency</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0108</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996953">PM:27996953</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161220, Unal D</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0108</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40155</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Palacios Castano,M.I.</style></author><author><style face="normal" font="default"> Venturini,D.M.</style></author><author><style face="normal" font="default"> Lobera,L.T.</style></author><author><style face="normal" font="default"> Gonzalez,M.I.</style></author><author><style face="normal" font="default"> del Pozo Gil,M.D.</style></author><author><style face="normal" font="default"> Blasco Sarramian,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Servicio de Alergologia, Hospital San Pedro, Logrono, Spain</style></auth-address><titles><title><style face="normal" font="default">Anaphylaxis Due to the Excipient Polysorbate 80</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="396" start="394">394-396</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0109</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996954">PM:27996954</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161220, Palacios Castano MI</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0109</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40156</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Caballero,T.</style></author><author><style face="normal" font="default"> Maurer,M.</style></author><author><style face="normal" font="default"> Longhurst,H.J.</style></author><author><style face="normal" font="default"> Aberer,W.</style></author><author><style face="normal" font="default"> Bouillet,L.</style></author><author><style face="normal" font="default"> Fabien,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Department, Hospital La Paz Institute for Health Research (IdiPaz), Biomedical Research Network on Rare Diseases (CIBERER, U754), Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Triggers and Prodromal Symptoms of Angioedema Attacks in Patients With Hereditary Angioedema</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="386" start="383">383-386</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Austria</style></keyword><keyword><style face="normal" font="default"> Biomedical Research</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Rare Diseases</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Germany -CO - United KIngdom -CO - Austria -CO - France -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0102</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996949">PM:27996949</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161220, Caballero T</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0102</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40157</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Romano,R.</style></author><author><style face="normal" font="default"> Cirillo,E.</style></author><author><style face="normal" font="default"> Giardino,G.</style></author><author><style face="normal" font="default"> Gallo,V.</style></author><author><style face="normal" font="default"> Mollica,C.</style></author><author><style face="normal" font="default"> Pignata,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Translational Medical Sciences, Unit of Immunology, Federico II University, Naples, Italy</style></auth-address><titles><title><style face="normal" font="default">A Bronchovascular Anomaly in a Patient With 22q11.2 Deletion Syndrome</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="392" start="390">390-392</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161220IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0107</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996952">PM:27996952</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2016-26-374-402.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161220, Romano R</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0107</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40158</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martin-Navarro,J.A.</style></author><author><style face="normal" font="default"> Gutierrez-Sanchez,M.J.</style></author><author><style face="normal" font="default"> Petkov-Stoyanov,V.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hypersensitivity to synthetic hemodialysis membranes</style></title><secondary-title><style face="normal" font="default">Nefrologia</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nefrologia</style></abbr-1></periodical><pages end="808" start="807">807-808</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse effects</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> analogs &amp; derivatives</style></keyword><keyword><style face="normal" font="default"> Bronchial Spasm</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Cellulose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity,Immediate</style></keyword><keyword><style face="normal" font="default"> instrumentation</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Membranes</style></keyword><keyword><style face="normal" font="default"> Membranes,Artificial</style></keyword><keyword><style face="normal" font="default"> Methacrylate</style></keyword><keyword><style face="normal" font="default"> Polymers</style></keyword><keyword><style face="normal" font="default"> Polymethyl Methacrylate</style></keyword><keyword><style face="normal" font="default"> Povidone</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Renal Dialysis</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Sulfones</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="17" Month="11" Year="2014">2014/11/17</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20141122IS - 1989-2284 (Electronic)IS - 0211-6995 (Linking)LA - engLA - spaPT - Case ReportsPT - LetterRN - 0 (Membranes, Artificial)RN - 0 (Polymers)RN - 0 (Sulfones)RN - 25667-42-9 (polyether sulfone)RN - 9003-39-8 (Povidone)RN - 9004-34-6 (Cellulose)RN - 9011-14-7 (Polymethyl Methacrylate)RN - 9012-09-3 (cellulose triacetate)SB - IMCO - Spain -</style></notes><work-type><style face="normal" font="default">10.3265/Nefrologia.pre2014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="25415584">PM:25415584</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nefrologia\2014-34-807-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nefrologia\2014-34-807-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20141122, Martin-Navarro JA</style></custom2><misc3><style face="normal" font="default">10.3265/Nefrologia.pre2014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40159</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Alvarez-de Lara,M.A.</style></author><author><style face="normal" font="default"> Martin-Malo,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hypersensitivity reactions to synthetic haemodialysis membranes an emerging issue?</style></title><secondary-title><style face="normal" font="default">Nefrologia</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nefrologia</style></abbr-1></periodical><pages end="702" start="698">698-702</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acrylic Resins</style></keyword><keyword><style face="normal" font="default"> Acrylonitrile</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> analogs &amp; derivatives</style></keyword><keyword><style face="normal" font="default"> Anaphylatoxins</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Complement Activation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Fluorocarbons</style></keyword><keyword><style face="normal" font="default"> haemodialysis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity,Immediate</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> instrumentation</style></keyword><keyword><style face="normal" font="default"> Leukostasis</style></keyword><keyword><style face="normal" font="default"> Membranes</style></keyword><keyword><style face="normal" font="default"> Membranes,Artificial</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Polymers</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Renal Dialysis</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Sulfones</style></keyword></keywords><dates><year Day="17" Month="11" Year="2014">2014/11/17</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20141122IS - 1989-2284 (Electronic)IS - 0211-6995 (Linking)LA - engLA - spaPT - EditorialRN - 0 (Acrylic Resins)RN - 0 (Anaphylatoxins)RN - 0 (Fluorocarbons)RN - 0 (Membranes, Artificial)RN - 0 (Polymers)RN - 0 (Sulfones)RN - 25135-51-7 (polysulfone P 1700)RN - 60650-36-4 (AN-69)RN - MP1U0D42PE (Acrylonitrile)SB - IMCO - Spain -</style></notes><work-type><style face="normal" font="default">10.3265/Nefrologia.pre2014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="25415569">PM:25415569</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nefrologia\2014-34-698-702.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nefrologia\2014-34-698-702.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20141122, Alvarez-de Lara MA</style></custom2><misc3><style face="normal" font="default">10.3265/Nefrologia.pre2014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40160</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guvenir,H.</style></author><author><style face="normal" font="default"> Misirlioglu,E.D.</style></author><author><style face="normal" font="default"> Aydin,F.</style></author><author><style face="normal" font="default"> Ece,D.</style></author><author><style face="normal" font="default"> Cakar,N.</style></author><author><style face="normal" font="default"> Kocabas,C.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Ankara Children's Hematology Oncology Training and Research Hospital,Department of Pediatric Allergy and Immunology, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="default">Successful Methyl-prednisolone Desensitization In a Pediatric Patient</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hematology</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Methyl prednisolone</style></keyword><keyword><style face="normal" font="default"> Methylprednisolone</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword></keywords><dates><year Day="31" Month="12" Year="2016">2016/12/31</year></dates><abstract><style face="normal" font="default">Corticosteroids (CS) have anti-inflammatory and immuno-suppressive effects and which they are widely used for allergic diseases, autoimmune and immune-related diseases. CS cause rarely immediate type hypersensitivity reactions after administration of oral and parenteral. Incidence of reaction has been reported 0.3-0.5% (1, 2). Methyl-prednisolone (MPZ) is one of the most common corticosteroids that caused allergic reactions (3, 4). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161231IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12693</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28039896">PM:28039896</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161231-GuvenirH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161231-GuvenirH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161231, Guvenir H</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12693</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40161</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Westergren,T.</style></author><author><style face="normal" font="default"> Berntsen,S.</style></author><author><style face="normal" font="default"> Carlsen,K.C.</style></author><author><style face="normal" font="default"> Mowinckel,P.</style></author><author><style face="normal" font="default"> Haland,G.</style></author><author><style face="normal" font="default"> Fegran,L.</style></author><author><style face="normal" font="default"> Carlsen,K.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Health and Sport Sciences, University of Agder.</style></auth-address><titles><title><style face="normal" font="default">Perceived exercise limitation in asthma: the role of disease severity, overweight and physical activity in children</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> exercise-induced bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Norway</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> overweight</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Socioeconomic Factors</style></keyword><keyword><style face="normal" font="default"> Sport</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Children with asthma may be less physically active than their healthy peers. We aimed to investigate if perceived exercise limitation (EL) was associated with lung function or bronchial hyperresponsiveness (BHR), socio-economic factors, prenatal smoking, overweight, allergic disease, asthma severity or physical activity (PA). METHODS: The 302 children with asthma from the 10-year examination of the Environment and Childhood Asthma birth cohort study underwent a clinical examination including perceived EL (structured interview of child and parent(s)), measure of overweight (body mass index by sex and age passing through 25kg/m2 or above at18 years), exercise-induced bronchoconstriction (forced expiratory volume in one second (FEV1 ) pre- and post-exercise), methacholine bronchial challenge (severe BHR; provocative dose causing >/=20% decrease in FEV1&lt;/=1mumol) and asthma severity score (dose of controller medication and exacerbations last 12 months). Multivariate logistic regression analyses were conducted to assess associations with perceived EL. RESULTS: In the final model explaining 30.1%, asthma severity score (OR 1.49, (1.32, 1.67)) and overweight (OR 2.35 (1.14, 4.82)) only were significantly associated with perceived EL. Excluding asthma severity and allergic disease, severe BHR (OR 2.82 (1.38, 5.76)) or maximal reduction in FEV1 post exercise (OR 1.48 (1.10, 1.98)) and overweight (OR 2.15 (1.13, 4.08) and 2.53 (1.27, 5.03)) explained 9.7% and 8.4% of perceived EL, respectively. CONCLUSIONS: Perceived EL in children with asthma was independently associated with asthma severity and overweight, the latter doubling the probability of perceived EL irrespectively of asthma severity, allergy status, socio-economic factors, prenatal smoking or PA. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161013IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Norway -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12670</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27734537">PM:27734537</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161013-WestergrenT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161013-WestergrenT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161013, Westergren T</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12670</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40162</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">James,A.</style></author><author><style face="normal" font="default"> Stenberg,H.K.</style></author><author><style face="normal" font="default"> Reinius,L.</style></author><author><style face="normal" font="default"> Konradsen,J.R.</style></author><author><style face="normal" font="default"> Dahlen,S.E.</style></author><author><style face="normal" font="default"> Soderhall,C.</style></author><author><style face="normal" font="default"> Hedlin,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Experimental Asthma and Allergy Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. anna.james@ki.seCentre for Allergy Research, Karolinska Institutet, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default">A longitudinal assessment of circulating YKL-40 levels in preschool children with wheeze</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Leukocytes</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> preschool children</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Remission</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Schoolchildren</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: The chitinase-like protein YKL-40 (CHI3L1) is elevated in the circulation of adults and schoolchildren with chronic severe asthma. It is unknown whether YKL-40 is altered in younger, preschool children with wheeze, acute or chronic. We therefore examined YKL-40 in preschool children during an acute episode of wheeze and during remission, in comparison to healthy controls. METHODS: Blood was obtained from 128 children (aged 6 to 44 months) at the emergency department during an acute episode of wheeze, and at two follow-up visits (approximately 3 months and 1 year later), as well as from 100 age-matched healthy controls on one occasion. Plasma YKL-40 levels were examined in relation to CHI3L1 rs4950928 genotype and clinical characteristics including Asthma Predictive Index, medication use, time spent with respiratory symptoms, atopic status and blood leukocytes. RESULTS: Children with wheeze had higher median YKL-40 levels at the acute visit (14.7 (11.5-22.6) ng/ml, p&lt;0.001) and 3-month follow-up (15.9 (11.5-20.2), p&lt;0.001) compared to the 1-year follow-up (11.9 (9.5-17.2)). YKL-40 levels in healthy controls (13.6 (11.0-17.0) tended to be lower than those during acute wheeze (p=0.07) and 3-month follow-up (p=0.04), but were no different at the 1-year follow-up. CHI3L1 rs4950928 affected YKL-40 in all subjects, with highest levels present in those with the CC genotype (p&lt;0.001). Genotype frequency was similar in the two subject groups. YKL-40 levels showed a positive correlation with blood neutrophil counts but no consistent relationships with clinical characteristics of relevance to continuous wheeze. CONCLUSION: YKL-40 levels were elevated during acute wheeze in preschool children, a finding which may be related to current neutrophilic inflammation, but YKL-40 was not associated with characteristics of persistent wheeze in this young cohort. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161012IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12669</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27732738">PM:27732738</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161012-JamesA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161012-JamesA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161012, James A</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12669</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40163</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Drummond,D.</style></author><author><style face="normal" font="default"> Monnier,D.</style></author><author><style face="normal" font="default"> Tesniere,A.</style></author><author><style face="normal" font="default"> Hadchouel,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Ilumens Simulation Department, Paris Descartes University, 45 rue des Saint Peres, 75006, Paris, France</style></auth-address><titles><title><style face="normal" font="default">A Systematic Review of Serious Games in Asthma Education</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma education</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Control Groups</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Learning</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Serious games may be useful tools for asthma education. The objectives of this systematic review were to identify the available articles on serious games designed to educate patients and the general public about asthma and to assess their impact on patient's knowledge, behavior and clinical outcomes related to asthma. METHODS: PubMed, Embase, Cochrane Library, PsychInfo, and Web of Science were systematically searched from January 1980 to December 2015 for studies investigating serious games in asthma education. Two investigators independently assessed studies against inclusion criteria and rated those included on indicators of quality. Investigators extracted data on serious games' content and learning objectives, and on outcomes following Kirkpatrick classification. RESULTS: A total of 12 articles were found to be relevant, describing a total of 10 serious games. All serious games were directed towards children, with eight games for children with asthma and two for school-based intervention. The average Medical Education Research Study Quality Instrument (MERSQI) score was 13.9 of 18, which is high. Most of the serious games were associated with high rates of satisfaction and improvement in children's knowledge. Seven studies evaluated the impact of serious games on clinical outcomes, and found no significant difference relative to control groups. CONCLUSIONS: Although serious games designed for asthma education have evolved with advances in technology, results of their evaluation remained similar across studies, with clear improvements in knowledge but little or no change in behaviors and clinical outcomes. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161219IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12690</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27992659">PM:27992659</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161219-DrummondD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161219-DrummondD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161219, Drummond D</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12690</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40164</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hadizadeh,H.</style></author><author><style face="normal" font="default"> Salehi,M.M.</style></author><author><style face="normal" font="default"> Khoramnejad,S.</style></author><author><style face="normal" font="default"> Vosoughi,K.</style></author><author><style face="normal" font="default"> Rezaei,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="default">The association between parental consanguinity and primary immunodeficiency diseases: a systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> and primary</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: We aimed to establish the prevalence of parental consanguinity among patients with primary immunodeficiency diseases (PID), and compare the prevalence with the general population. METHOD: We searched PubMed, EMBASE, and Scopus for studies mentioning parental consanguinity prevalence in PID patients and calculated the prevalence odds ratio (POR) of parental consanguinity in each study, compared to a matched healthy population. RESULTS: We identified 21 eligible studies with a total population of 18091 accounting for sample overlap. The POR among studies on a sample of mixed PID patients ranged from 0.6 to 21.9 with the pooled POR of 3.0 (P&lt;0.001; I2 =89%, 95% CI 2.5-3.7). CONCLUSION: PIDs with an autosomal recessive pattern of inheritance had significant odds of parental consanguinity compared to the healthy population; a phenomenon not observed in other inheritance patterns. Determining the extent of the impact that consanguinity impose upon the progeny paves the way for convincing healthcare policy makers in highly consanguineous communities to act more diligently in informing the masses about the consequences of practicing inbreeding. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161128IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12685</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27893166">PM:27893166</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161128-HadizadehH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161128-HadizadehH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161128, Hadizadeh H</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12685</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40165</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cifaldi,C.</style></author><author><style face="normal" font="default"> Angelino,G.</style></author><author><style face="normal" font="default"> Chiriaco,M.</style></author><author><style face="normal" font="default"> Di Cesare,S.</style></author><author><style face="normal" font="default"> Claps,A.</style></author><author><style face="normal" font="default"> Serafinelli,J.</style></author><author><style face="normal" font="default"> Rossi,P.</style></author><author><style face="normal" font="default"> Antoccia,A.</style></author><author><style face="normal" font="default"> Di Matteo,G.</style></author><author><style face="normal" font="default"> Cancrini,C.</style></author><author><style face="normal" font="default"> de Villartay,J.P.</style></author><author><style face="normal" font="default"> Finocchi,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Systems Medicine, "University of Rome Tor Vergata", Rome, Italy</style></auth-address><titles><title><style face="normal" font="default">Late-onset combined immune-deficiency due to LIGIV mutations in a 12 years old patient</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Dna</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Repair</style></keyword><keyword><style face="normal" font="default"> Rome</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The non-homologous end joining (NHEJ) pathway is involved in the repair of the DNA double-strand breaks. Defects in NHEJ factors result in IR sensitivity, and in defects in V(D)J recombination leading to immunodeficiency. DNA Ligase IV is an essential component that performs the final 'end processing' step of NHEJ. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161128IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12684</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27893162">PM:27893162</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161128-CifaldiC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161128-CifaldiC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161128, Cifaldi C</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12684</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40166</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Barnish,M.S.</style></author><author><style face="normal" font="default"> Tagiyeva,N.</style></author><author><style face="normal" font="default"> Devereux,G.</style></author><author><style face="normal" font="default"> Aucott,L.</style></author><author><style face="normal" font="default"> Turner,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Child Health, University of Aberdeen, Aberdeen, UK.</style></auth-address><titles><title><style face="normal" font="default">Changes in the relationship between asthma and associated risk factors over fifty years</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> parental asthma</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> socioeconomic status</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Childhood asthma is a common condition whose prevalence is changing. We hypothesised that the relationship between asthma and associated risk factors has changed over a 50-year period. METHODS: An ecological study design was used. Children aged 8-13 attending schools in Aberdeen city were surveyed on seven occasions between 1964 and 2014. The following were determined: history of asthma, history of eczema, parental smoking, parental asthma, sex and socioeconomic status. Analysis was by a structural change model with two knots. The outcome reported was the change in odds ratio between asthma and a given risk factor during a given period. RESULTS: There were 23,241 questionnaires distributed and 17,439 returned (75%). The odds ratio (OR) for a child with asthma to have eczema increased between 1989 and 1999 by 1.031 [95% CI 1.028, 1.035] and by 1.042 between 2004 and 2014 [1.038, 1.047].The OR for a child with asthma to have a parent who smoked rose by 1.032 [1.028, 1.036] between 1989 and 1999 and by 1.043 [1.038, 1.047] between 2004 and2014), and to have a parent with asthma (1.027 [1.022, 1.031] for 1994-99 and 1.042 [1.037, 1.048] for 2004-2014). The OR for a child with asthma being male and being from the most deprived communities also rose between 1989-1999 and 2004-2014. CONCLUSIONS: The relationship between asthma prevalence and particular risk factors changed over the 50 year period of study and this might reflect changes in children's environment and/or susceptibility. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161025IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12674</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27779796">PM:27779796</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161025-BarnishMS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161025-BarnishMS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161025, Barnish MS</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12674</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40167</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lundelin,K.</style></author><author><style face="normal" font="default"> Poussa,T.</style></author><author><style face="normal" font="default"> Salminen,S.</style></author><author><style face="normal" font="default"> Isolauri,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Paediatrics, Turku University Hospital and the Department of Clinical Sciences, Faculty of Medicine, University of Turku, Turku, Finland.</style></auth-address><titles><title><style face="normal" font="default">Long-term safety and efficacy of perinatal probiotic intervention: evidence from a follow-up study of four randomized, double-blind, placebo-controlled trials</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> Bifidobacterium</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immune-mediated</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Lactobacillus</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nurses</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> paediatrics</style></keyword><keyword><style face="normal" font="default"> Perinatal</style></keyword><keyword><style face="normal" font="default"> Physical Examination</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Probiotics</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Societies worldwide are faced with a progressive increase in immune-mediated health problems such as allergic, autoimmune and inflammatory diseases, as well as obesity. Perinatal administration of specific probiotic bacteria is an attractive approach in reducing the risk of these conditions, but long-term efficacy and safety data are lacking. The aim here was to evaluate the clinical benefit and long-term safety of specific probiotics administered during the perinatal period. METHODS: The probiotic strains used were Lactobacillus rhamnosus GG, Bifidobacterium lactis Bb-12, Lactobacillus paracasei ST11 and Bifidobacterium longum BL999. The children involved have subsequently undergone prospective long-term follow-up. In addition to physical examination, data were collected by structured questionnaires on non-communicable diseases and continued probiotic use, and growth data from welfare clinics and school nurses. RESULTS: Altogether 303 mother-infant pairs were included in the analysis. Seventy-six out of 163 (47%) children receiving perinatal probiotics had developed allergic disease compared with 79 out of 140 (56%) receiving placebo (OR 0.67, 95% CI 0.43-1.06, p=0.09). Fifty-nine out of 133 (44%) children receiving Lactobacillus rhamnosus GG perinatally had developed allergic disease, OR 0.62, 95% CI 0.38-0.99, p=0.047, as compared to placebo. We found no differences in growth or non-communicable disease prevalence between children receiving perinatally probiotics or placebo. CONCLUSIONS: Perinatal probiotic administration is safe in long-term follow-up. Children receiving Lactobacillus rhamnosus GG perinatally tended to have decreased allergy prevalence. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161025IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12675</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27779809">PM:27779809</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161025-LundelinK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161025-LundelinK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161025, Lundelin K</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12675</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40168</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gallo,V.</style></author><author><style face="normal" font="default"> Dijk,F.N.</style></author><author><style face="normal" font="default"> Holloway,J.W.</style></author><author><style face="normal" font="default"> Ring,S.M.</style></author><author><style face="normal" font="default"> Koppelman,G.H.</style></author><author><style face="normal" font="default"> Postma,D.S.</style></author><author><style face="normal" font="default"> Strachan,D.P.</style></author><author><style face="normal" font="default"> Granell,R.</style></author><author><style face="normal" font="default"> de Jongste,J.C.</style></author><author><style face="normal" font="default"> Jaddoe,V.W.</style></author><author><style face="normal" font="default"> den Dekker,H.T.</style></author><author><style face="normal" font="default"> Duijts,L.</style></author><author><style face="normal" font="default"> Henderson,A.J.</style></author><author><style face="normal" font="default"> Shaheen,S.O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Primary Care and Public Health, Barts and The London School of Medicine and Dentistry, London, UK</style></auth-address><titles><title><style face="normal" font="default">TRPA1 gene polymorphisms and childhood asthma</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Dentistry</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Paracetamol</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Animal data have suggested that the transient receptor potential ankyrin-1 (TRPA1) ion channel plays a key role in promoting airway inflammation in asthma and may mediate effects of paracetamol on asthma, yet confirmatory human data are lacking. To study associations of TRPA1 gene variants with childhood asthma and total IgE concentration, and interactions between TRPA1 and prenatal paracetamol exposure on these outcomes. METHODS: We analysed associations between 31 TRPA1 single nucleotide polymorphisms (SNPs) and current doctor-diagnosed asthma and total IgE concentration at 7.5 years in the Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort. We sought to confirm the most significant associations with comparable outcomes in the Prevention and Incidence of Asthma and Mite Allergy (PIAMA) and Generation R birth cohorts. In ALSPAC we explored interactions with prenatal paracetamol exposure. RESULTS: In ALSPAC there was strong evidence for association between six SNPs and asthma: rs959974 and rs1384001 (per allele odds ratio for both: 1.30 (95% CI: 1.15-1.47), P=0.00001), rs7010969 (OR 1.28 (1.13-1.46), P=0.00004), rs3735945 (OR 1.30 (1.09-1.55), P=0.003), rs920829 (OR 1.30 (1.09-1.54), P=0.004) and rs4738202 (OR 1.22 (1.07-1.39), P=0.004). In a meta-analysis across the three cohorts the pooled effect estimates confirmed that all six SNPs were significantly associated with asthma. In ALSPAC, TRPA1 associations with asthma were not modified by prenatal paracetamol, although associations with IgE concentration were. CONCLUSION: This study suggests that TRPA1 may play a role in the development of childhood asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161025IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12673</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27779810">PM:27779810</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161025-GalloV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161025-GalloV.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161025, Gallo V</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12673</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40169</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Minshall,E.</style></author><author><style face="normal" font="default"> Patel,H.</style></author><author><style face="normal" font="default"> Francis,N.</style></author><author><style face="normal" font="default"> Hansel,T.</style></author><author><style face="normal" font="default"> Warner,J.O.</style></author><author><style face="normal" font="default"> Boyle,R.J.</style></author><author><style face="normal" font="default"> Fell,J.</style></author><author><style face="normal" font="default"> Epstein,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Paediatric Allergy, Cambridge University Hospitals NHS Foundation Trust</style></auth-address><titles><title><style face="normal" font="default">Local chemokine profiling in eosinophilic esophagitis: the Synthetic Absorptive Matrix test</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default"> Esophagitis</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">We describe a novel method of sampling the esophageal lining fluid in children and show that levels of eotaxin-1 and MCP-4 differentiate those children with a histological diagnosis of EoE from those without. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20160929IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - LETTERCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12664</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27685893">PM:27685893</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20160929-MinshallE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20160929-MinshallE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160929, Minshall E</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12664</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40170</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Baiardini,I.</style></author><author><style face="normal" font="default"> Fasola,S.</style></author><author><style face="normal" font="default"> Montalbano,L.</style></author><author><style face="normal" font="default"> Cilluffo,G.</style></author><author><style face="normal" font="default"> Malizia,V.</style></author><author><style face="normal" font="default"> Ferrante,G.</style></author><author><style face="normal" font="default"> Braido,F.</style></author><author><style face="normal" font="default"> La Grutta,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy &amp; Respiratory Diseases Clinic - D</style></auth-address><titles><title><style face="normal" font="default">RHINASTHMA-Children: A new Quality of Life tool for patients with respiratory allergy</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Respiratory allergies</style></keyword><keyword><style face="normal" font="default"> Respiratory allergy</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Respiratory diseases</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Recent research has focused on measuring the Health Related Quality of Life (HRQoL) impact (physical, psychological, and social) on children suffering from respiratory allergy. The burden of the disease has been evaluated by mean of different questionnaires specifically validated for asthma or allergic rhinitis. Several studies demonstrated that these two conditions often coexist, being seen in half to three quarter of children (1). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161012IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - ENGPT - LETTERCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12667</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27732756">PM:27732756</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161012-BaiardiniI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161012-BaiardiniI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161012, Baiardini I</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12667</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40171</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Emons,J.A.</style></author><author><style face="normal" font="default"> Flokstra-de Blok,B.M.</style></author><author><style face="normal" font="default"> de Jong,C.</style></author><author><style face="normal" font="default"> van der Molen,T.</style></author><author><style face="normal" font="default"> Brand,H.K.</style></author><author><style face="normal" font="default"> Arends,N.J.</style></author><author><style face="normal" font="default"> Amaral,R.</style></author><author><style face="normal" font="default"> Fonseca,J.A.</style></author><author><style face="normal" font="default"> van Wijk,R.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Department, Erasmus Medical Center, Rotterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default">Use of the Control of Allergic Rhinitis and Asthma Test (CARATkids) in children and adolescents; validation in Dutch</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> VAS</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic rhinitis and asthma are common and closely related diseases. Recently, a Portugese questionnaire has been developed 'The Control of Allergic Rhinitis and Asthma Test' (CARATkids) that measures disease control of both diseases in children. This study aims to validate the CARATkids in Dutch children and for the first time in adolescents. In addition, to calculate the minimal clinically important difference (MCID). METHODS: A prospective observational study was conducted in an outpatient clinic. After translation of the CARATkids from Portuguese to Dutch, patients (6-18 years) with asthma or asthma and allergic rhinitis completed the CARATkids, Asthma Control Test (ACT) and visual analog scale (VAS) questionnaire three times. Baseline characteristics, mean scores, internal consistency, test-retest reliability, cross-sectional and longitudinal validity, discriminative properties, responsiveness and MCID of the CARATkids were assessed. RESULTS: 111 patients were included. 86% and 79% respectively completed the questionnaires at the second and third visit. All children had asthma and 85% had concomitant allergic rhinitis. The internal consistency was good with all expected a priori correlations met. CARATkids scores were higher in patients with uncontrolled asthma and patients with moderate-severe rhinitis compared to better controlled subjects. Patients with a variable asthma control had significantly higher scores during periods of uncontrolled asthma. Also the Guyatt's responsiveness index was good. The MCID was 2.8. CONCLUSIONS: The CARATkids questionnaire is a reliable and valid tool to assess allergic rhinitis and asthma control among Dutch children. The tool can be used in adolescents. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161101IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Portugal -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12678</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27801950">PM:27801950</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161011-EmonsJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161011-EmonsJA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161101, Emons JA</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12678</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40172</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Davies,G.I.</style></author><author><style face="normal" font="default"> Davies,D.</style></author><author><style face="normal" font="default"> Charles,S.</style></author><author><style face="normal" font="default"> Barnes,S.L.</style></author><author><style face="normal" font="default"> Bowden,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Alfred Health, Melbourne, Australia.</style></auth-address><titles><title><style face="normal" font="default">Successful Desensitisation to Deferasirox in a Paediatric Patient with beta Thalassemia Major</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Australia</style></keyword><keyword><style face="normal" font="default"> beta-Thalassemia</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> desensitisation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Erythema Multiforme</style></keyword><keyword><style face="normal" font="default"> Ferritin</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Iron</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin reaction</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">To our knowledge, this is the first case and protocol in the literature of paediatric desensitisation to deferasirox following the adverse skin reaction of erythema multiforme major. Thalassemia is one of the most common genetic conditions globally (1, 2). beta thalassemia major results in severe anaemia requiring monthly, life-long red blood cell transfusions with life-long iron chelator therapy required to control ferritin levels (1, 3). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161031IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12677</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27797415">PM:27797415</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161031-DaviesGI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20161031-DaviesGI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161031, Davies GI</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12677</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40173</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nakamoto,K.</style></author><author><style face="normal" font="default"> Watanabe,M.</style></author><author><style face="normal" font="default"> Sada,M.</style></author><author><style face="normal" font="default"> Inui,T.</style></author><author><style face="normal" font="default"> Nakamura,M.</style></author><author><style face="normal" font="default"> Honda,K.</style></author><author><style face="normal" font="default"> Wada,H.</style></author><author><style face="normal" font="default"> Mikami,Y.</style></author><author><style face="normal" font="default"> Matsuzaki,H.</style></author><author><style face="normal" font="default"> Horie,M.</style></author><author><style face="normal" font="default"> Noguchi,S.</style></author><author><style face="normal" font="default"> Yamauchi,Y.</style></author><author><style face="normal" font="default"> Koyama,H.</style></author><author><style face="normal" font="default"> Kogane,T.</style></author><author><style face="normal" font="default"> Kohyama,T.</style></author><author><style face="normal" font="default"> Takizawa,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Kyorin University School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">Serum Reactive Oxygen Metabolite Levels Predict Severe Exacerbations of Asthma</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0164948">e0164948-</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Airway Obstruction</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Hydrogen</style></keyword><keyword><style face="normal" font="default"> Hydrogen Peroxide</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Oxygen</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> pulmonary function test</style></keyword><keyword><style face="normal" font="default"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> ROS</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">BACKGROUND AND PURPOSE: Bronchial asthma (BA) is a chronic airway disease characterized by airway hyperresponsiveness and remodeling, which are intimately linked to chronic airway inflammation. Reactive oxygen species (ROS) such as hydrogen peroxide are generated by inflammatory cells that are involved in the pathogenesis of BA. However, the role of ROS in the management of BA patients is not yet clear. We attempted to determine the role of ROS as a biomarker in the clinical setting of BA. SUBJECTS AND METHODS: We enrolled patients with BA from 2013 through 2015 and studied the degrees of asthma control, anti-asthma treatment, pulmonary function test results, fractional exhaled nitric oxide (FeNO), serum reactive oxygen metabolite (ROM) levels, and serum levels of interleukin (IL)-6 and IL-8. RESULTS: We recruited 110 patients with BA. Serum ROM levels correlated with white blood cell (WBC) count (rs = 0.273, p = 0.004), neutrophil count (rs = 0.235, p = 0.014), CRP (rs = 0.403, p &lt; 0.001), and IL-6 (rs = 0.339, p &lt; 0.001). Serum ROM levels and IL-8 and CRP levels negatively correlated with %FEV1 (rs = -0.240, p = 0.012, rs = -0.362, p &lt; 0.001, rs = -0.197, p = 0.039, respectively). Serum ROM levels were significantly higher in patients who experienced severe exacerbation within 3 months than in patients who did not (339 [302-381] vs. 376 [352-414] CARR U, p &lt; 0.025). Receiver-operating characteristics analysis showed that ROM levels correlated significantly with the occurrence of severe exacerbation (area under the curve: 0.699, 95% CI: 0.597-0.801, p = 0.025). CONCLUSIONS: Serum levels of ROM were significantly associated with the degrees of airway obstruction, WBC counts, neutrophil counts, IL-6, and severe exacerbations. This biomarker may be useful in predicting severe exacerbations of BA</style></abstract><notes><style face="normal" font="default">DA - 20161024IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="default">    10.1371/journal.pone.0164948</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27776186">PM:27776186</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2016-11-e0164948.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2016-11-e0164948.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161024, Nakamoto K</style></custom2><misc3><style face="normal" font="default">    10.1371/journal.pone.0164948</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40174</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zheng,H.</style></author><author><style face="normal" font="default"> Liang,H.</style></author><author><style face="normal" font="default"> Wang,Y.</style></author><author><style face="normal" font="default"> Miao,M.</style></author><author><style face="normal" font="default"> Shi,T.</style></author><author><style face="normal" font="default"> Yang,F.</style></author><author><style face="normal" font="default"> Liu,E.</style></author><author><style face="normal" font="default"> Yuan,W.</style></author><author><style face="normal" font="default"> Ji,Z.S.</style></author><author><style face="normal" font="default"> Li,D.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Key Laboratory of Reproduction Regulation of NPFPC, SIPPR, IRD, Fudan University, Shanghai 200032, China</style></auth-address><titles><title><style face="normal" font="default">Altered Gut Microbiota Composition Associated with Eczema in Infants</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0166026">e0166026-</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Bifidobacterium</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Clostridium</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> diversity</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> Gut microbiota</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Reproduction</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Streptococcus</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Eczema is frequently the first manifestation of an atopic diathesis and alteration in the diversity of gut microbiota has been reported in infants with eczema. To identify specific bacterial communities associated with eczema, we conducted a case-control study of 50 infants with eczema (cases) and 51 healthy infants (controls). We performed high-throughput sequencing for V3-V4 hypervariable regions of the 16S rRNA genes from the gut fecal material. A total of 12,386 OTUs (operational taxonomic units) at a 97% similarity level were obtained from the two groups, and we observed a difference in taxa abundance, but not the taxonomic composition, of gut microbiota between the two groups. We identified four genera enriched in healthy infants: Bifidobacterium, Megasphaera, Haemophilus and Streptococcus; and five genera enriched in infants with eczema: Escherichia/Shigella, Veillonella, Faecalibacterium, Lachnospiraceae incertae sedis and Clostridium XlVa. Several species, such as Faecalibacterium prausnitzii and Ruminococcus gnavus, that are known to be associated with atopy or inflammation, were found to be significantly enriched in infants with eczema. Higher abundance of Akkermansia muciniphila in eczematous infants might reduce the integrity of intestinal barrier function and therefore increase the risk of developing eczema. On the other hand, Bacteroides fragilis and Streptococcus salivarius, which are known for their anti-inflammatory properties, were less abundant in infants with eczema. The observed differences in genera and species between cases and controls in this study may provide insight into the link between the microbiome and eczema risk</style></abstract><notes><style face="normal" font="default">DA - 20161104IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - ENGPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="default">    10.1371/journal.pone.0166026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27812181">PM:27812181</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2016-11-e0166026.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2016-11-e0166026.pdf</url></text-urls><related-urls><url ppv-ref="no">xls in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20161104, Zheng H</style></custom2><misc3><style face="normal" font="default">    10.1371/journal.pone.0166026</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40175</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Han,R.T.</style></author><author><style face="normal" font="default"> Back,S.K.</style></author><author><style face="normal" font="default"> Lee,H.</style></author><author><style face="normal" font="default"> Lee,J.</style></author><author><style face="normal" font="default"> Kim,H.Y.</style></author><author><style face="normal" font="default"> Kim,H.J.</style></author><author><style face="normal" font="default"> Na,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Neuroscience Research Institute &amp; Department of Physiology, Korea University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Formaldehyde-Induced Aggravation of Pruritus and Dermatitis Is Associated with the Elevated Expression of Th1 Cytokines in a Rat Model of Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0168466">e0168466-</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Capsaicin</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Formaldehyde</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-17A</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> indoor</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> rat</style></keyword><keyword><style face="normal" font="default"> Rats</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> serum IgE levels</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> TH2 cytokines</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urbanization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Atopic dermatitis is a complex disease of heterogeneous pathogenesis, in particular, genetic predisposition, environmental triggers, and their interactions. Indoor air pollution, increasing with urbanization, plays a role as environmental risk factor in the development of AD. However, we still lack a detailed picture of the role of air pollution in the development of the disease. Here, we examined the effect of formaldehyde (FA) exposure on the manifestation of atopic dermatitis and the underlying molecular mechanism in naive rats and in a rat model of atopic dermatitis (AD) produced by neonatal capsaicin treatment. The AD and naive rats were exposed to 0.8 ppm FA, 1.2 ppm FA, or fresh air (Air) for 6 weeks (2 hours/day and 5 days/week). So, six groups, namely the 1.2 FA-AD, 0.8 FA-AD, Air-AD, 1.2 FA-naive, 0.8 FA-naive and Air-naive groups, were established. Pruritus and dermatitis, two major symptoms of atopic dermatitis, were evaluated every week for 6 weeks. After that, samples of the blood, the skin and the thymus were collected from the 1.2 FA-AD, the Air-AD, the 1.2 FA-naive and the Air-naive groups. Serum IgE levels were quantified with ELISA, and mRNA expression levels of inflammatory cytokines from extracts of the skin and the thymus were calculated with qRT-PCR. The dermatitis and pruritus significantly worsened in 1.2 FA-AD group, but not in 0.8 FA-AD, compared to the Air-AD animals, whereas FA didn't induce any symptoms in naive rats. Consistently, the levels of serum IgE were significantly higher in 1.2 FA-AD than in air-AD, however, there was no significant difference following FA exposure in naive animals. In the skin, mRNA expression levels of Th1 cytokines such as TNF-alpha and IL-1beta were significantly higher in the 1.2 FA-AD rats compared to the air-AD rats, whereas mRNA expression levels of Th2 cytokines (IL-4, IL-5, IL-13), IL-17A and TSLP were significantly higher in 1.2 FA-naive group than in the Air-naive group. These results suggested that 1.2 ppm of FA penetrated the injured skin barrier, and exacerbated Th1 responses and serum IgE level in the AD rats so that dermatitis and pruritus were aggravated, while the elevated expression of Th2 cytokines by 1.2 ppm of FA in naive rats was probably insufficient for clinical manifestation. In conclusion, in a rat model of atopic dermatitis, exposure to 1.2 ppm of FA aggravated pruritus and skin inflammation, which was associated with the elevated expression of Th1 cytokines</style></abstract><notes><style face="normal" font="default">DA - 20161222IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0168466</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28005965">PM:28005965</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2016-11-e0168466.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2016-11-e0168466.pdf</url></text-urls><related-urls><url ppv-ref="no">suppl. video in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20161222, Han RT</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0168466</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40176</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Manousek,J.</style></author><author><style face="normal" font="default"> Stejskal,V.</style></author><author><style face="normal" font="default"> Kubena,P.</style></author><author><style face="normal" font="default"> Jarkovsky,J.</style></author><author><style face="normal" font="default"> Nemec,P.</style></author><author><style face="normal" font="default"> Lokaj,P.</style></author><author><style face="normal" font="default"> Dostalova,L.</style></author><author><style face="normal" font="default"> Zadakova,A.</style></author><author><style face="normal" font="default"> Pavlusova,M.</style></author><author><style face="normal" font="default"> Benesova,K.</style></author><author><style face="normal" font="default"> Kala,P.</style></author><author><style face="normal" font="default"> Miklik,R.</style></author><author><style face="normal" font="default"> Spinar,J.</style></author><author><style face="normal" font="default"> Parenica,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine and Cardiology, University Hospital Brno, Brno, Czech Republic</style></auth-address><titles><title><style face="normal" font="default">Delayed-Type Hypersensitivity to Metals of Environmental Burden in Patients with Takotsubo Syndrome - Is There a Clinical Relevance?</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0164786">e0164786-</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Arthritis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Catecholamines</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Czech Republic</style></keyword><keyword><style face="normal" font="default"> delayed-type hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Transformation</style></keyword><keyword><style face="normal" font="default"> Lymphocyte transformation test</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mercury</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Transformation</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Takotsubo syndrome (TS) is a heart condition characterised by a sudden transient left ventricular dysfunction; its pathophysiology is probably associated with elevated levels of catecholamines but the exact mechanism is not known as yet. Literature and clinical experience suggest that TS affects persons with various comorbidities. This pilot work aims to evaluate the frequency of comorbidities with potential pathological immune reactivity, and to evaluate the potential association between TS and hypersensitivity to metals assessed by LTT-MELISA(R). METHODOLOGY, RESULTS: A total of 24 patients (23 women, 1 man) with a history of TS attack and 27 healthy controls were evaluated. Hypersensitivity was evaluated by a lymphocyte transformation test (LTT-MELISA(R)); a questionnaire of environmental burden was used to select evaluated metals. A total of 19 patients (79%) had at least one condition that might potentially be associated with pathological immune reactivity (autoimmune thyroid disease, drug allergy, bronchial asthma, cancer, contact dermatitis, rheumatoid arthritis). Hypersensitivity to metals was identified significantly more frequently in TS patients than in healthy controls (positive reaction to at least one metal was identified in 95.8% of TS patients and in 59.3% of controls; p = 0.003); the difference was statistically significant for mercury (45.8% and 14.8%, respectively; p = 0.029). CONCLUSION: Our work shows that conditions with pathological immune reactivity occur frequently in TS patients, and our data suggest a possible association between TS and hypersensitivity to metals (mercury in particular) evaluated by LTT-MELISA(R). We also suggest that apart from the triggering stress factor, potential existence of other serious conditions should be considered when taking medical history of TS patients</style></abstract><notes><style face="normal" font="default">DA - 20161108IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Czechia -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0164786</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27824862">PM:27824862</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2016-11-e0164786.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2016-11-e0164786.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161108, Manousek J</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0164786</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40177</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Al-Garawi,A.</style></author><author><style face="normal" font="default"> Carey,V.J.</style></author><author><style face="normal" font="default"> Chhabra,D.</style></author><author><style face="normal" font="default"> Mirzakhani,H.</style></author><author><style face="normal" font="default"> Morrow,J.</style></author><author><style face="normal" font="default"> Lasky-Su,J.</style></author><author><style face="normal" font="default"> Qiu,W.</style></author><author><style face="normal" font="default"> Laranjo,N.</style></author><author><style face="normal" font="default"> Litonjua,A.A.</style></author><author><style face="normal" font="default"> Weiss,S.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts, United States of America</style></auth-address><titles><title><style face="normal" font="default">The Role of Vitamin D in the Transcriptional Program of Human Pregnancy</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0163832">e0163832-</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic sensitization</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma risk</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> differentially expressed gene</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microarray</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Notch</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Randomized clinical trial</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Rna</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> transcription factor</style></keyword><keyword><style face="normal" font="default"> Transcriptome</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patterns of gene expression of human pregnancy are poorly understood. In a trial of vitamin D supplementation in pregnant women, peripheral blood transcriptomes were measured longitudinally on 30 women and used to characterize gene co-expression networks. OBJECTIVE: Studies suggest that increased maternal Vitamin D levels may reduce the risk of asthma in early life, yet the underlying mechanisms have not been examined. In this study, we used a network-based approach to examine changes in gene expression profiles during the course of normal pregnancy and evaluated their association with maternal Vitamin D levels. DESIGN: The VDAART study is a randomized clinical trial of vitamin D supplementation in pregnancy for reduction of pediatric asthma risk. The trial enrolled 881 women at 10-18 weeks of gestation. Longitudinal gene expression measures were obtained on thirty pregnant women, using RNA isolated from peripheral blood samples obtained in the first and third trimesters. Differentially expressed genes were identified using significance of analysis of microarrays (SAM), and clustered using a weighted gene co-expression network analysis (WGCNA). Gene-set enrichment was performed to identify major biological pathways. RESULTS: Comparison of transcriptional profiles between first and third trimesters of pregnancy identified 5839 significantly differentially expressed genes (FDR&lt;0.05). Weighted gene co-expression network analysis clustered these transcripts into 14 co-expression modules of which two showed significant correlation with maternal vitamin D levels. Pathway analysis of these two modules revealed genes enriched in immune defense pathways and extracellular matrix reorganization as well as genes enriched in notch signaling and transcription factor networks. CONCLUSION: Our data show that gene expression profiles of healthy pregnant women change during the course of pregnancy and suggest that maternal Vitamin D levels influence transcriptional profiles. These alterations of the maternal transcriptome may contribute to fetal immune imprinting and reduce allergic sensitization in early life. TRIAL REGISTRATION: clinicaltrials.gov NCT00920621</style></abstract><notes><style face="normal" font="default">DA - 20161006IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0163832</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27711190">PM:27711190</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2016-11-e0163832.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2016-11-e0163832.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161006, Al-Garawi A</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0163832</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40178</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Griffiths,C.</style></author><author><style face="normal" font="default"> Bremner,S.</style></author><author><style face="normal" font="default"> Islam,K.</style></author><author><style face="normal" font="default"> Sohanpal,R.</style></author><author><style face="normal" font="default"> Vidal,D.L.</style></author><author><style face="normal" font="default"> Dawson,C.</style></author><author><style face="normal" font="default"> Foster,G.</style></author><author><style face="normal" font="default"> Ramsay,J.</style></author><author><style face="normal" font="default"> Feder,G.</style></author><author><style face="normal" font="default"> Taylor,S.</style></author><author><style face="normal" font="default"> Barnes,N.</style></author><author><style face="normal" font="default"> Choudhury,A.</style></author><author><style face="normal" font="default"> Packe,G.</style></author><author><style face="normal" font="default"> Bayliss,E.</style></author><author><style face="normal" font="default"> Trathen,D.</style></author><author><style face="normal" font="default"> Moss,P.</style></author><author><style face="normal" font="default"> Cook,V.</style></author><author><style face="normal" font="default"> Livingstone,A.E.</style></author><author><style face="normal" font="default"> Eldridge,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Asthma UK Centre for Applied Research, Centre for Primary Care and Public Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Effect of an Education Programme for South Asians with Asthma and Their Clinicians: A Cluster Randomised Controlled Trial (OEDIPUS)</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0158783">e0158783-</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> and primary</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dentistry</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> General practice</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Minority Groups</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Nurses</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Self efficacy</style></keyword><keyword><style face="normal" font="default"> Self-management</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">BACKGROUND: People with asthma from ethnic minority groups experience significant morbidity. Culturally-specific interventions to reduce asthma morbidity are rare. We tested the hypothesis that a culturally-specific education programme, adapted from promising theory-based interventions developed in the USA, would reduce unscheduled care for South Asians with asthma in the UK. METHODS: A cluster randomised controlled trial, set in two east London boroughs. 105 of 107 eligible general practices were randomised to usual care or the education programme. Participants were south Asians with asthma aged 3 years and older with recent unscheduled care. The programme had two components: the Physician Asthma Care Education (PACE) programme and the Chronic Disease Self Management Programme (CDSMP), targeted at clinicians and patients with asthma respectively. Both were culturally adapted for south Asians with asthma. Specialist nurses, and primary care teams from intervention practices were trained using the PACE programme. South Asian participants attended an outpatient appointment; those registered with intervention practices received self-management training from PACE-trained specialist nurses, a follow-up appointment with PACE-trained primary care practices, and an invitation to attend the CDSMP. Patients from control practices received usual care. Primary outcome was unscheduled care. FINDINGS: 375 south Asians with asthma from 84 general practices took part, 183 registered with intervention practices and 192 with control practices. Primary outcome data were available for 358/375 (95.5%) of participants. The intervention had no effect on time to first unscheduled attendance for asthma (Adjusted Hazard Ratio AHR = 1.19 95% CI 0.92 to 1.53). Time to first review in primary care was reduced (AHR = 2.22, (1.67 to 2.95). Asthma-related quality of life and self-efficacy were improved at 3 months (adjusted mean difference -2.56, (-3.89 to -1.24); 0.44, (0.05 to 0.82) respectively. CONCLUSIONS: A multi-component education programme adapted for south Asians with asthma did not reduce unscheduled care but did improve follow-up in primary care, self-efficacy and quality of life. More effective interventions are needed for south Asians with asthma</style></abstract><notes><style face="normal" font="default">DA - 20161228IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0158783</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28030569">PM:28030569</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2016-11-e0158783.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2016-11-e0158783.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161228, Griffiths C</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0158783</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40179</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fulcher,Y.G.</style></author><author><style face="normal" font="default"> Fotso,M.</style></author><author><style face="normal" font="default"> Chang,C.H.</style></author><author><style face="normal" font="default"> Rindt,H.</style></author><author><style face="normal" font="default"> Reinero,C.R.</style></author><author><style face="normal" font="default"> Van,Doren,Sr.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biochemistry, 117 Schweitzer Hall, University of Missouri, Columbia, MO, 65211, United States of America</style></auth-address><titles><title><style face="normal" font="default">Noninvasive Recognition and Biomarkers of Early Allergic Asthma in Cats Using Multivariate Statistical Analysis of NMR Spectra of Exhaled Breath Condensate</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0164394">e0164394-</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acetone</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Biochemistry</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> cat</style></keyword><keyword><style face="normal" font="default"> Cats</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Columbia</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Discriminant Analysis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic asthma</style></keyword><keyword><style face="normal" font="default"> Exhaled Breath</style></keyword><keyword><style face="normal" font="default"> exhaled breath condensate</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Missouri</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Principal Component Analysis</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Transformation</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Asthma is prevalent in children and cats, and needs means of noninvasive diagnosis. We sought to distinguish noninvasively the differences in 53 cats before and soon after induction of allergic asthma, using NMR spectra of exhaled breath condensate (EBC). Statistical pattern recognition was improved considerably by preprocessing the spectra with probabilistic quotient normalization and glog transformation. Classification of the 106 preprocessed spectra by principal component analysis and partial least squares with discriminant analysis (PLS-DA) appears to be impaired by variances unrelated to eosinophilic asthma. By filtering out confounding variances, orthogonal signal correction (OSC) PLS-DA greatly improved the separation of the healthy and early asthmatic states, attaining 94% specificity and 94% sensitivity in predictions. OSC enhancement of multi-level PLS-DA boosted the specificity of the prediction to 100%. OSC-PLS-DA of the normalized spectra suggest the most promising biomarkers of allergic asthma in cats to include increased acetone, metabolite(s) with overlapped NMR peaks near 5.8 ppm, and a hydroxyphenyl-containing metabolite, as well as decreased phthalate. Acetone is elevated in the EBC of 74% of the cats with early asthma. The noninvasive detection of early experimental asthma, biomarkers in EBC, and metabolic perturbation invite further investigation of the diagnostic potential in humans</style></abstract><notes><style face="normal" font="default">DA - 20161020IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0164394</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27764146">PM:27764146</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2016-11-e0164394.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2016-11-e0164394.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161020, Fulcher YG</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0164394</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40180</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Alves de Medeiros,A.K.</style></author><author><style face="normal" font="default"> Speeckaert,R.</style></author><author><style face="normal" font="default"> Desmet,E.</style></author><author><style face="normal" font="default"> Van Gele,M.</style></author><author><style face="normal" font="default"> De Schepper,S.</style></author><author><style face="normal" font="default"> Lambert,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Ghent University Hospital, Ghent, Belgium</style></auth-address><titles><title><style face="normal" font="default">JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0164080">e0164080-</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Alopecia</style></keyword><keyword><style face="normal" font="default"> Alopecia Areata</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidermis</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Formulation</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Keratinocytes</style></keyword><keyword><style face="normal" font="default"> Lichen Planus</style></keyword><keyword><style face="normal" font="default"> Lupus</style></keyword><keyword><style face="normal" font="default"> Lupus erythematosus</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> Pyoderma</style></keyword><keyword><style face="normal" font="default"> Pyoderma Gangrenosum</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> topical treatment</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">The recent interest and elucidation of the JAK/STAT signaling pathway created new targets for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical formulations have shown beneficial results in psoriasis and alopecia areata. Patients suffering from other ISDs might also benefit from JAK inhibition. Given the development of specific JAK inhibitors, the expression patterns of JAKs in different ISDs needs to be clarified. We aimed to analyze the expression of JAK/STAT family members in a set of prevalent ISDs: psoriasis, lichen planus (LP), cutaneous lupus erythematosus (CLE), atopic dermatitis (AD), pyoderma gangrenosum (PG) and alopecia areata (AA) versus healthy controls for (p)JAK1, (p)JAK2, (p)JAK3, (p)TYK2, pSTAT1, pSTAT2 and pSTAT3. The epidermis carried in all ISDs, except for CLE, a strong JAK3 signature. The dermal infiltrate showed a more diverse expression pattern. JAK1, JAK2 and JAK3 were significantly overexpressed in PG and AD suggesting the need for pan-JAK inhibitors. In contrast, psoriasis and LP showed only JAK1 and JAK3 upregulation, while AA and CLE were characterized by a single dermal JAK signal (pJAK3 and pJAK1, respectively). This indicates that the latter diseases may benefit from more targeted JAK inhibitors. Our in vitro keratinocyte psoriasis model displayed reversal of the psoriatic JAK profile following tofacitinib treatment. This direct interaction with keratinocytes may decrease the need for deep skin penetration of topical JAK inhibitors in order to exert its effects on dermal immune cells. In conclusion, these results point to the important contribution of the JAK/STAT pathway in several ISDs. Considering the epidermal JAK3 expression levels, great interest should go to the investigation of topical JAK3 inhibitors as therapeutic option of ISDs</style></abstract><notes><style face="normal" font="default">DA - 20161006IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0164080</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27711196">PM:27711196</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2016-11-e0164080.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2016-11-e0164080.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161006, Alves de Medeiros AK</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0164080</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40181</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kartha,G.K.</style></author><author><style face="normal" font="default"> Li,I.</style></author><author><style face="normal" font="default"> Comhair,S.</style></author><author><style face="normal" font="default"> Erzurum,S.C.</style></author><author><style face="normal" font="default"> Monga,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, United States of America</style></auth-address><titles><title><style face="normal" font="default">Co-Occurrence of Asthma and Nephrolithiasis in Children</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e01688133">e01688133-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Increased prevalence</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Kidney</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> urine</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">It has been proposed that epithelial dysfunction and inflammation may predispose patients to kidney stone formation. Asthma is another chronic condition related to epithelial dysfunction and inflammation. We hypothesized that pediatric patients with asthma would have an increased prevalence of nephrolithiasis. Furthermore, we investigated if asthma patients with nephrolithiasis have clinical characteristics and urine profiles that point to mechanisms of stone formation. We evaluated 865 pediatric patients who had a diagnosis of nephrolithiasis. Clinical/demographic data and 24 hour urine samples were compared between asthma + stone (n = 142) and stone only patients. Data from asthmatics without stone were also available for evaluation of medication differences among asthma + stone and asthma only patients. The prevalence of nephrolithiasis in the pediatric population at our institution was 0.08% vs. 0.31% in our pediatric asthmatic population. The prevalence of asthma in our pediatric population was 6.8% vs. 26.7% in our pediatric stone patients. Asthma + stone patients were more likely to be on a combination inhaled corticosteroid + long acting beta agonist inhaler as compared to age/gender/BMI matched asthma patients without stone (29.7% vs. 13.7%, p = 0.0012). 259 kidney stone patients had 24 hour urine samples for comparison. There was no difference in 24 hour urine profiles between asthma + stone and stone only patients. Children with asthma have a 4-fold greater prevalence of kidney stones than the general pediatric population. Similarly, children with kidney stones have a 4-fold greater prevalence of asthma. This correlation may suggest a mechanistic link between asthma and nephrolithiasis. Further investigation is needed to elucidate the pathophysiologic origin of this relationship</style></abstract><notes><style face="normal" font="default">DA - 20170112IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">    10.1371/journal.pone.0168813</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28081237">PM:28081237</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2016-11-e01688133.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2016-11-e01688133.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170112, Kartha GK</style></custom2><misc3><style face="normal" font="default">    10.1371/journal.pone.0168813</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40182</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Singhania,A.</style></author><author><style face="normal" font="default"> Rupani,H.</style></author><author><style face="normal" font="default"> Jayasekera,N.</style></author><author><style face="normal" font="default"> Lumb,S.</style></author><author><style face="normal" font="default"> Hales,P.</style></author><author><style face="normal" font="default"> Gozzard,N.</style></author><author><style face="normal" font="default"> Davies,D.E.</style></author><author><style face="normal" font="default"> Woelk,C.H.</style></author><author><style face="normal" font="default"> Howarth,P.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Altered Epithelial Gene Expression in Peripheral Airways of Severe Asthma</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0168680">e0168680-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> Peripheral airways</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Repair</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Management of severe asthma remains a challenge despite treatment with glucocorticosteroid therapy. The majority of studies investigating disease mechanisms in treatment-resistant severe asthma have previously focused on the large central airways, with very few utilizing transcriptomic approaches. The small peripheral airways, which comprise the majority of the airway surface area, remain an unexplored area in severe asthma and were targeted for global epithelial gene expression profiling in this study. Differences between central and peripheral airways were evaluated using transcriptomic analysis (Affymetrix HG U133 plus 2.0 GeneChips) of epithelial brushings obtained from severe asthma patients (N = 17) and healthy volunteers (N = 23). Results were validated in an independent cohort (N = 10) by real-time quantitative PCR. The IL-13 disease signature that is associated with an asthmatic phenotype was upregulated in severe asthmatics compared to healthy controls but was predominantly evident within the peripheral airways, as were genes related to mast cell presence. The gene expression response associated with glucocorticosteroid therapy (i.e. FKBP5) was also upregulated in severe asthmatics compared to healthy controls but, in contrast, was more pronounced in central airways. Moreover, an altered epithelial repair response (e.g. FGFBP1) was evident across both airway sites reflecting a significant aspect of disease in severe asthma unadressed by current therapies. A transcriptomic approach to understand epithelial activation in severe asthma has thus highlighted the need for better-targeted therapy to the peripheral airways in severe asthma, where the IL-13 disease signature persists despite treatment with currently available therapy</style></abstract><notes><style face="normal" font="default">DA - 20170103IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0168680</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28045928">PM:28045928</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2016-11-e0168680.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2016-11-e0168680.pdf</url></text-urls><related-urls><url ppv-ref="no">xls in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20170103, Singhania A</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0168680</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40183</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Czarnecka-Operacz,M.</style></author><author><style face="normal" font="default"> Jenerowicz,D.</style></author><author><style face="normal" font="default"> Szulczynska-Gabor,J.</style></author><author><style face="normal" font="default"> Teresiak-Mikolajczak,E.</style></author><author><style face="normal" font="default"> Szyfter-Harris,J.</style></author><author><style face="normal" font="default"> Bowszyc-Dmochowska,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Prof. Magdalena Czarnecka-Operacz, MD, PhD, Department of Dermatology, 49 Przybyszewski Str., 60-355 Poznan, Poland</style></auth-address><titles><title><style face="normal" font="default">Vesicular Contact Reaction May Progress into Erythema Multiforme</style></title><secondary-title><style face="normal" font="default">Acta Dermatovenerol Croat</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Acta Dermatovenerol Croat</style></full-title></periodical><pages end="309" start="307">307-309</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Abdomen</style></keyword><keyword><style face="normal" font="default"> Acyclovir</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> Back</style></keyword><keyword><style face="normal" font="default"> Buttocks</style></keyword><keyword><style face="normal" font="default"> Ceftriaxone</style></keyword><keyword><style face="normal" font="default"> Cesarean Section</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous reaction</style></keyword><keyword><style face="normal" font="default"> Cyclosporine</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dermis</style></keyword><keyword><style face="normal" font="default"> Dexamethasone</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostics</style></keyword><keyword><style face="normal" font="default"> Disinfectants</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Epidermis</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Erythema Multiforme</style></keyword><keyword><style face="normal" font="default"> Evolution</style></keyword><keyword><style face="normal" font="default"> Extremities</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> herpes</style></keyword><keyword><style face="normal" font="default"> Herpes Simplex</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Igg</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Injections</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Leukocytosis</style></keyword><keyword><style face="normal" font="default"> Lymphopenia</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Remission</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Textiles</style></keyword><keyword><style face="normal" font="default"> Thigh</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Type IV hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">Dear Editor, Erythema multiforme is considered an acute skin condition, characterized by a self-limiting and sometimes recurrent course. It is regarded as a type IV hypersensitivity reaction associated with certain infections, medications, and other various triggers. Allergic contact dermatitis is in turn a delayed type of induced allergy as a result of cutaneous contact with a specific allergen to which the patient develops specific sensitivity. This type of cutaneous reaction is associated with inflammation manifesting with erythema, edema, and vesicles. A 27-year old female patient presented with a 3-day history of erythematous and vesicular lesions which developed 24 hours after cesarean section. Initially the lesions were localized in the area of surgery (mainly the abdomen and upper thighs) and on the next day progressed to the buttocks and lumbar area. The patient was referred to the Outpatient Clinic and was treated with antihistamines, but her dermatological state deteriorated rapidly. At the day of admission to the Department of Dermatology, numerous erythematous and vesicular lesions were present on the skin of the abdomen, thighs, and back (Figure 1, a), but the skin of the neck, chest, and extremities was also covered with erythematous and edematous patches. On the second day of hospitalization, we observed the evolution of lesions localized within the chest and extremities into an erythema multiforme-like targetoid eruption (Figure 1, b). Initially the patient was treated with intravenous injections of dexamethasone and ceftriaxone and orally with second-generation antihistamines (in four-fold doses), followed by intravenous metyloprednisolone pulse-therapy (total dose of 3 g). As the new vesicobullous lesions started to appear on the face and arms, we introduced cyclosporine A orally 400 mg daily. We could then observe gradual remission, but on the seventh day of hospitalization the patient developed a massive labial herpes simplex infection and had to be treated with acyclovir intravenously. Eight days after admission, we switched from intravenous metyloprednisolone to its oral formula. Diagnostic methods included: laboratory analyses (leukocytosis, neutrophilia, lymphopenia could be observed, and also serum CRP elevation). Pemphigoid gestationis was excluded on the basis of a direct immunofluorescence from perilesional skin and on the basis of indirect immunofluorescence and also serum analysis using ELISA for serum IgG antibodies to BP180-NC16A (courtesy of Prof. Marian Dmochowski). Histopathological examination revealed: massive edema of dermal papillae, leading to the formation of sub-epidermal vesicles; individual cell necrosis was observed in the upper epidermis. Within the dermis, a dense, perivascular inflammatory infiltrate was detected: the clinical picture suggested erythema multiforme. Another histopathological examination was performed at the University Clinic of Dermatology and Venereology in Magdeburg, courtesy of Prof. Dr. Harald Gollnick and Dr. Med. I. Franke; it also suggested the bullous form of erythema multiforme (dermal type). Three months after remission, the patient was hospitalized again to perform allergological diagnostics. Patch tests were performed with the European Baseline Series (Chemotechnique Diagnostics) supplemented with disinfectants and textiles used during surgical procedure. For patch testing, Finn Chambers on Scanpor were used. Results were recorded at 48 and 72 hour time points. According to the ICDRG (International Contact Dermatitis Research Group), reactions evaluated as ++ and +++ pluses were considered as positive and reaction evaluated as + plus was considered as doubtful. Patch testing revealed polyvalent contact allergy (Table I), (Figure 2a). The patient also reacted to Kodan Tinctur forte used as a skin disinfectant (contains brown dye LF 1</style></abstract><notes><style face="normal" font="default">DA - 20170127IS - 1847-6538 (Electronic)IS - 1330-027X (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28128086">PM:28128086</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Acta Dermatovenerol Croat\2016-24-307-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Acta Dermatovenerol Croat\2016-24-307-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170127, Czarnecka-Operacz M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40184</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,Y.Y.</style></author><author><style face="normal" font="default"> Je,I.G.</style></author><author><style face="normal" font="default"> Kim,M.J.</style></author><author><style face="normal" font="default"> Kang,B.C.</style></author><author><style face="normal" font="default"> Choi,Y.A.</style></author><author><style face="normal" font="default"> Baek,M.C.</style></author><author><style face="normal" font="default"> Lee,B.</style></author><author><style face="normal" font="default"> Choi,J.K.</style></author><author><style face="normal" font="default"> Park,H.R.</style></author><author><style face="normal" font="default"> Shin,T.Y.</style></author><author><style face="normal" font="default"> Lee,S.</style></author><author><style face="normal" font="default"> Yoon,S.B.</style></author><author><style face="normal" font="default"> Lee,S.R.</style></author><author><style face="normal" font="default"> Khang,D.</style></author><author><style face="normal" font="default"> Kim,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">CMRI, Department of Pharmacology, Daegu 700-422, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">2-Hydroxy-3-methoxybenzoic acid attenuates mast cell-mediated allergic reaction in mice via modulation of the FcepsilonRI signaling pathway</style></title><secondary-title><style face="normal" font="default">Acta Pharmacol Sin</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Acta Pharmacol Sin</style></abbr-1></periodical><pages end="99" start="90">90-99</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Affinity</style></keyword><keyword><style face="normal" font="default"> AKT</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cell Line</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Histamine Release</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> oral administration</style></keyword><keyword><style face="normal" font="default"> OVA</style></keyword><keyword><style face="normal" font="default"> Ovum</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> rat</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Syk</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> Vasodilation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Mast cells are important effector cells in immunoglobulin (Ig) E-mediated allergic reactions such as asthma, atopic dermatitis and rhinitis. Vanillic acid, a natural product, has shown anti-oxidant and anti-inflammatory activities. In the present study, we investigated the anti-allergic inflammatory effects of ortho-vanillic acid (2-hydroxy-3-methoxybenzoic acid, o-VA) that was a derivative of vanillic acid isolated from Amomum xanthioides. In mouse anaphylaxis models, oral administration of o-VA (2, 10, 50 mg/kg) dose-dependently attenuated ovalbumin-induced active systemic anaphylaxis and IgE-mediated cutaneous allergic reactions such as hypothermia, histamine release, IgE production and vasodilation; administration of o-VA also suppressed the mast cell degranulator compound 48/80-induced anaphylaxis. In cultured mast cell line RBL-2H3 and isolated rat peritoneal mast cells in vitro, pretreatment with o-VA (1-100 mumol/L) dose-dependently inhibited DNP-HSA-induced degranulation of mast cells by decreasing the intracellular free calcium level, and suppressed the expression of pro-inflammatory cytokines TNF-alpha and IL-4. Pretreatment of RBL-2H3 cells with o-VA suppressed DNP-HSA-induced phosphorylation of Lyn, Syk, Akt, and the nuclear translocation of nuclear factor-kappaB. In conclusion, o-VA suppresses the mast cell-mediated allergic inflammatory response by blocking the signaling pathways downstream of high affinity IgE receptor (FcepsilonRI) on the surface of mast cells</style></abstract><notes><style face="normal" font="default">DA - 20161128IS - 1745-7254 (Electronic)IS - 1671-4083 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1038/aps.2016.112</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27890918">PM:27890918</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Acta Pharmacol Sin\2017-38-90-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Acta Pharmacol Sin\2017-38-90-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161128, Kim YY</style></custom2><misc3><style face="normal" font="default">10.1038/aps.2016.112</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40185</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Panaszek,B.</style></author><author><style face="normal" font="default"> Pawlowicz,R.</style></author><author><style face="normal" font="default"> Lindner,K.</style></author><author><style face="normal" font="default"> Dobek,R.</style></author><author><style face="normal" font="default"> Panaszek,K.</style></author><author><style face="normal" font="default"> Obojski,A.</style></author><author><style face="normal" font="default"> Rosinczuk,J.</style></author><author><style face="normal" font="default"> Ichnowski,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine and Allergology, Wroclaw Medical University, Poland</style></auth-address><titles><title><style face="normal" font="default">Impact of Birth Weight and Smoking on Lung Function in Patients with Asthma, COPD, and Healthy Volunteers</style></title><secondary-title><style face="normal" font="default">Adv Clin Exp Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Adv Clin Exp Med</style></abbr-1></periodical><pages end="1213" start="1207">1207-1213</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Birth Weight</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Respiratory System</style></keyword><keyword><style face="normal" font="default"> smokers</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword><keyword><style face="normal" font="default"> youth</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Birth weight (BW) is an important factor for determining the development of the respiratory system. The majority of research analyzed the impact of BW on lung function in youth. BW influence and smoking on lung function in adults with asthma and COPD is an interesting issue. OBJECTIVES: The aim of the study was to investigate relationships between BW, smoking, and lung function in adult healthy individuals and diagnosed with asthma or COPD. MATERIAL AND METHODS: Four hundred seventy-nine subjects were divided into 5 groups: 123 healthy non-smokers, 180 healthy smokers, 72 non-smoking asthmatics, 57 smoking asthmatics, and 47 COPD patients. Relationships between 4 BW quartiles and lung function was analyzed with respect to smoking. RESULTS: Impact analyzes of BW, smoking, and asthma on FVC% revealed that asthma is the only significant differentiating factor in this spirometric parameter (p &lt; 0.01). FEV1% was significantly influenced by asthma and BW, and FEV1/ FVC% was exclusively influenced by asthma. Spirometric parameters increased proportionally to particular BW quartiles in healthy non-smokers group; however optimal BW quartile predicting increase of parameters was 2751-3250 g. In asthma, BW quartile predicting the increase of spirometric parameters was 3251-3750 g, but BW quartile predicting decrease of FEV1/FVC% was 2751-3250 g. The comparison of results between COPD group and results from other 4 groups showed that values of all parameters in patients with COPD did not change proportionally to all quartiles of BW. In terms of FEV1/FVC%, the proportional increase of parameter in BW quartile 2751-3250 g was observed. CONCLUSIONS: BW, as independent factor influences on spirometric parameters of healthy individuals, patients with asthma, COPD in a differentiated manner depending on quartile of BW rather than on simple linear increase of BW, regardless of smoking</style></abstract><notes><style face="normal" font="default">DA - 20161228IS - 1899-5276 (Print)IS - 1899-5276 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.17219/acem/62455</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28028975">PM:28028975</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Adv Clin Exp Med\2016-25-1207-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Adv Clin Exp Med\2016-25-1207-13.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161228, Panaszek B</style></custom2><misc3><style face="normal" font="default">10.17219/acem/62455</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40186</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yadav,S.</style></author><author><style face="normal" font="default"> Dogra,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dr Yadav is an Assistant Professor, Department of Dermatology and Venereology, All India</style></auth-address><titles><title><style face="normal" font="default">A Cutaneous Reaction to Microneedling for Postacne Scarring Caused by Nickel Hypersensitivity</style></title><secondary-title><style face="normal" font="default">Aesthet Surg J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Aesthet Surg J</style></abbr-1></periodical><pages end="NP170" start="NP168">NP168-NP170</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acne Vulgaris</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Cicatrix</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Cosmetic Techniques</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous reaction</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Equipment Design</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> instrumentation</style></keyword><keyword><style face="normal" font="default"> Miniaturization</style></keyword><keyword><style face="normal" font="default"> Needles</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20160310IS - 1527-330X (Electronic)IS - 1090-820X (Linking)LA - engPT - Case ReportsPT - LetterRN - 7OV03QG267 (Nickel)SB - IMCO - India -</style></notes><work-type><style face="normal" font="default">10.1093/asj/sjv229</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26961992">PM:26961992</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Aesthet Surg J\2016-36-NP168-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Aesthet Surg J\2016-36-NP168-70.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160310, Yadav S</style></custom2><misc3><style face="normal" font="default">10.1093/asj/sjv229</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40187</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wedi,B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Dermatitis update: clinical manifestations, pathogenesis and current therapeutic approaches</style></title><secondary-title><style face="normal" font="default">Allergo J Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergo J Int</style></abbr-1></periodical><pages end="232" start="219">219-232</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostics</style></keyword><keyword><style face="normal" font="default"> Epidermis</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Keratinocytes</style></keyword><keyword><style face="normal" font="default"> Kinetics</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> Neurodermatitis</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic therapy</style></keyword><keyword><style face="normal" font="default"> T lymphocyte</style></keyword><keyword><style face="normal" font="default"> T lymphocytes</style></keyword><keyword><style face="normal" font="default"> T-lymphocyte</style></keyword><keyword><style face="normal" font="default"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="default">2197-0378</style></isbn><abstract><style face="normal" font="default">Dermatitis affects up to 10 % of the population, and yet its nomenclature still remains inconsistent. Classifications can be made according to morphology, localization, triggers, kinetics, or pathophysiology. The eczematous inflammatory reaction involves the migration of activated T-lymphocytes into the epidermis (epidermotropismus) and pathological changes to the epidermal keratinocytes occur, with spongiosis, acanthosis, and parakeratosis. Dermatitis is characterized by a polymorphous clinical picture. Contact dermatitis (toxic irritant and allergic) and atopic dermatitis (neurodermatitis) account for the majority of dermatitis cases. Seborrheic dermatitis and nummular (dysregulatory microbial) dermatitis are also common. A qualified overall assessment of the targeted patient history and clinical picture are crucial to correctly diagnosing the type of dermatitis. This is followed by further diagnostics to confirm the dermatitis type, identify potential triggers, and exclude differential diagnoses. Since most forms of dermatitis can be caused by allergy, a qualified allergy diagnostic work-up is often necessary. Dermatitis management primarily comprises avoiding/dealing with the causes, alongside symptomatic treatment. In terms of treatment, local and systemic therapies with an anti-inflammatory, immunosuppressant, antipruritic, hydrating, keratolytic, antiproliferative, antimicrobial, antifungal, or dehydrating/astringent effect are available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1007/s40629-016-0133-1</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-016-0133-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergo J Int\2016-25-219-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergo J Int\2016-25-219-32.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170206, Wedi B</style></custom2><misc3><style face="normal" font="default">10.1007/s40629-016-0133-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40188</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Turker,S.</style></author><author><style face="normal" font="default"> Dogru,M.</style></author><author><style face="normal" font="default"> Yildiz,F.</style></author><author><style face="normal" font="default"> Yilmaz,S.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Zeynep Kamil Woman and Children's Diseases Training and Research Hospital, Department of Pediatrics, Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="default">The effect of nebulised magnesium sulphate in the management of childhood moderate asthma exacerbations as adjuvant treatment</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adjuvant</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Magnesium</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Methylprednisolone</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="30" Month="1" Year="2017">2017/1/30</year></dates><abstract><style face="normal" font="default">BACKGROUND: After the bronchodilator effect of magnesium was shown, the use of magnesium in treatment of asthma exacerbations became common. With the results of recent studies, the use of intravenous magnesium in severe asthma exacerbations took its place. We aimed to examine the effects of adding isotonic magnesium sulphate instead of isotonic saline into nebulised salbutamol on the Modified Pulmonary Index Score (MPIS) and the hospitalisation rate in moderate asthma exacerbations. METHODS: Our study population included 100 children age between 3 and 15 years with asthma admitted to emergency department due to moderate asthma exacerbations. The patients were randomised to placebo or magnesium, with 50 patients in each arm. All patients received 1mg/kg of systemic methylprednisolone at the beginning of treatment and thereafter received either nebulised salbutamol (0.15mg/kg/dose) and 1ml magnesium sulphate (15%)+1.5ml isotonic saline on three occasions at roughly 20min intervals (Magnesium group) or nebulised salbutamol (0.15mg/kg/dose) and 2.5ml isotonic saline mixture on three occasions at roughly 20min intervals (Placebo group). The MPIS of patients on 0th min, 20th min, 40th and 120th min were calculated and compared. The primary outcome was to compare MPIS values at the end of 120th min. RESULTS: Both groups have similar demographic, allergic characteristics and baseline MPIS scores. When the MPIS scores in the 120th min and admission rates in the 200th min, there was no significant difference between the two groups. CONCLUSIONS: The use of nebulised magnesium sulphate in moderate asthma exacerbation as adjuvant treatment showed no benefit to standard treatment in our study</style></abstract><notes><style face="normal" font="default">DA - 20170203IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2016.10.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28153353">PM:28153353</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170203-TurkerS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170203-TurkerS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170203, Turker S</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2016.10.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40189</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gupta,D.</style></author><author><style face="normal" font="default"> Deshmukh,L.</style></author><author><style face="normal" font="default"> Gupta,R.</style></author><author><style face="normal" font="default"> Sandhu,S.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Fungal Biotechnology and Invertebrate Pathology Laboratory, Department of Biological Science, R.D. University, Jabalpur, 482001 M.P., India.</style></auth-address><titles><title><style face="normal" font="default">Allergy genuflection? It's surmount with special focus on ear, nose and throat</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Biotechnology</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Chest Pain</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Cold</style></keyword><keyword><style face="normal" font="default"> Common Cold</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Nose</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Tonsillitis</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="2" Year="2017">2017/2/1</year></dates><abstract><style face="normal" font="default">The system that protects body from infectious agents is immune system. On occasions, the system seldom reacts with some foreign particles and causes allergy. Allergies of the ear, nose and throat (ENT) often have serious consequences, including impairment and emotional strain that lowers the quality of life of patients. This is further responsible for the common cold, cough, tonsillitis, dermal infection, chest pain and asthma-like conditions which disturb one's day to day life. The present review enlightens some common ENT allergies which one can suffer more frequently in one's lifetime, and ignorance leads to making the condition chronic. Information regarding pathophysiology and the management of ENT allergy by this review could help clinicians and common people to better understand the circumstances and treatment of ENT allergy</style></abstract><notes><style face="normal" font="default">DA - 20170205IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - India -</style></notes><work-type><style face="normal" font="default"> 10.1016/j.aller.2016.10.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28161280">PM:28161280</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170205-GuptaD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170205-GuptaD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170205, Gupta D</style></custom2><misc3><style face="normal" font="default"> 10.1016/j.aller.2016.10.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40190</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Asher,I.</style></author><author><style face="normal" font="default"> Haahtela,T.</style></author><author><style face="normal" font="default"> Selroos,O.</style></author><author><style face="normal" font="default"> Ellwood,P.</style></author><author><style face="normal" font="default"> Ellwood,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Paediatrics: Child and Youth Health, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.</style></auth-address><titles><title><style face="normal" font="default">Global Asthma Network survey suggests more national asthma strategies could reduce burden of asthma</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Interpretation</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> New Zealand</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> paediatrics</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword><keyword><style face="normal" font="default"> youth</style></keyword></keywords><dates><year Day="1" Month="2" Year="2017">2017/2/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Several countries or regions within countries have an effective national asthma strategy resulting in a reduction of the large burden of asthma to individuals and society. There has been no systematic appraisal of the extent of national asthma strategies in the world. METHODS: The Global Asthma Network (GAN) undertook an email survey of 276 Principal Investigators of GAN centres in 120 countries, in 2013-2014. One of the questions was: "Has a national asthma strategy been developed in your country for the next five years? For children? For adults?". RESULTS: Investigators in 112 (93.3%) countries answered this question. Of these, 26 (23.2%) reported having a national asthma strategy for children and 24 (21.4%) for adults; 22 (19.6%) countries had a strategy for both children and adults; 28 (25%) had a strategy for at least one age group. In countries with a high prevalence of current wheeze, strategies were significantly more common than in low prevalence countries (11/13 (85%) and 7/31 (22.6%) respectively, p&lt;0.001). INTERPRETATION: In 25% countries a national asthma strategy was reported. A large reduction in the global burden of asthma could be potentially achieved if more countries had an effective asthma strategy</style></abstract><notes><style face="normal" font="default">DA - 20170205IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - New Zealand -CO - FInland -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2016.10.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28161283">PM:28161283</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170205-AsherI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170205-AsherI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170205, Asher I</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2016.10.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40191</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Suarez-Castanon,C.</style></author><author><style face="normal" font="default"> Modrono-Riano,G.</style></author><author><style face="normal" font="default"> Solis-Sanchez,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cabuenes Universitary Hospital, Gijon, Regional Health Service of Asturias, Spain.</style></auth-address><titles><title><style face="normal" font="default">Use of anti-allergic drugs in children</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> anti-allergic drug</style></keyword><keyword><style face="normal" font="default"> anti-allergic drugs</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Budesonide</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Corticoids</style></keyword><keyword><style face="normal" font="default"> desloratadine</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Habits</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Mometasone</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="1" Month="2" Year="2017">2017/2/1</year></dates><abstract><style face="normal" font="default">Allergic rhinitis is one of the most frequent chronic diseases in children. We have analysed the prescriptions habits of anti-allergic medications in children (&lt;14 years old) in 2011. We calculated the DHD (N degrees DDD/1000 children/day) for oral antihistamines and intranasal therapies (corticoids and antihistamines) in the region (sanitary districts I-VIII) and specifically in sanitary district V (health centres 1-15). We also reviewed the clinical records in six health centres in sanitary district V to know more details about age and diagnosis and to value if these prescriptions are adequate. We observed a use of 8.78 DHD in the group of oral antihistamines, with a predominance of desloratadine (3.48 DHD), a 3rd generation drug of this group, and in second place the intranasal therapy with a preference of corticoids (budesonide 3.5 DHD and mometasone 2.25 DHD). We think that it is necessary to improve the knowledge of anti-allergic drugs in children</style></abstract><notes><style face="normal" font="default">DA - 20170205IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2016.10.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28161282">PM:28161282</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170205-SuarezCastanonC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170205-SuarezCastanonC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170205, Suarez-Castanon C</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2016.10.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40192</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ishii,S.</style></author><author><style face="normal" font="default"> Iikura,M.</style></author><author><style face="normal" font="default"> Hojo,M.</style></author><author><style face="normal" font="default"> Sugiyama,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default">Use of 3D-CT airway analysis software to assess a patient with severe persistent bronchial asthma treated with bronchial thermoplasty</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Bronchial thermoplasty</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Health</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Software</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="16" Month="1" Year="2017">2017/1/16</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170123IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2016.12.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28110895">PM:28110895</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170123-IshiiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170123-IshiiS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170123, Ishii S</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2016.12.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40193</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ichiyama,S.</style></author><author><style face="normal" font="default"> Funasaka,Y.</style></author><author><style face="normal" font="default"> Yamashita,H.</style></author><author><style face="normal" font="default"> Tamura,H.</style></author><author><style face="normal" font="default"> Inokuchi,K.</style></author><author><style face="normal" font="default"> Saeki,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Nippon Medical School, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default">Leukocytoclastic vasculitis with eosinophilic infiltration associated with thalidomide therapy for multiple myeloma: A case report</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Case Report</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Multiple Myeloma</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> Vasculitis</style></keyword></keywords><dates><year Day="16" Month="1" Year="2017">2017/1/16</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170123IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2016.12.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28110897">PM:28110897</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170123-IchiyamaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170123-IchiyamaS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170123, Ichiyama S</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2016.12.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40194</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arakawa,H.</style></author><author><style face="normal" font="default"> Hamasaki,Y.</style></author><author><style face="normal" font="default"> Kohno,Y.</style></author><author><style face="normal" font="default"> Ebisawa,M.</style></author><author><style face="normal" font="default"> Kondo,N.</style></author><author><style face="normal" font="default"> Nishima,S.</style></author><author><style face="normal" font="default"> Nishimuta,T.</style></author><author><style face="normal" font="default"> Morikawa,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Gunma University Graduate School of Medicine, Gunma, Japan.</style></auth-address><titles><title><style face="normal" font="default">Japanese guidelines for childhood asthma 2017</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescence</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Control level</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> early intervention</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infancy</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Step down</style></keyword><keyword><style face="normal" font="default"> Step-down</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="default">The Japanese Guideline for the Diagnosis and Treatment of Allergic Diseases 2017 (JAGL 2017) includes a minor revision of the Japanese Pediatric Guideline for the Treatment and Management of Asthma 2012 (JPGL 2012) by the Japanese Society of Pediatric Allergy and Clinical Immunology. The section on child asthma in JAGL 2017 provides information on how to diagnose asthma between infancy and adolescence (0-15 years of age). It makes recommendations for best practices in the management of childhood asthma, including management of acute exacerbations and non-pharmacological and pharmacological management. This guideline will be of interest to non-specialist physicians involved in the care of children with asthma. JAGL differs from the Global Initiative for Asthma Guideline in that JAGL emphasizes diagnosis and early intervention of children with asthma at &lt;2 years or 2-5 years of age. The first choice of treatment depends on the severity and frequency of symptoms. Pharmacological management, including step-up or step-down of drugs used for long-term management based on the status of asthma control levels, is easy to understand; thus, this guideline is suitable for the routine medical care of children with asthma. JAGL also recommends using a control test in children, so that the physician aims for complete control by avoiding exacerbating factors and appropriately using anti-inflammatory drugs (for example, inhaled corticosteroids and leukotriene receptor antagonists)</style></abstract><notes><style face="normal" font="default">DA - 20170121IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2016.11.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28108245">PM:28108245</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170121-ArakawaH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170121-ArakawaH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170121, Arakawa H</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2016.11.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40195</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Taura,M.</style></author><author><style face="normal" font="default"> Asai,J.</style></author><author><style face="normal" font="default"> Wakabayashi,Y.</style></author><author><style face="normal" font="default"> Masuda,K.</style></author><author><style face="normal" font="default"> Katoh,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan</style></auth-address><titles><title><style face="normal" font="default">Drug eruption caused by esomeprazole: A case report and mini-review</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Case Report</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug eruption</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2016.12.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28094107">PM:28094107</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170117-TauraM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170117-TauraM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Taura M</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2016.12.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40196</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tanaka,T.</style></author><author><style face="normal" font="default"> Hiragun,M.</style></author><author><style face="normal" font="default"> Hide,M.</style></author><author><style face="normal" font="default"> Hiragun,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Tanaka Dermatology and Allergy Clinic, Hiroshima, Japan</style></auth-address><titles><title><style face="normal" font="default">Analysis of primary treatment and prognosis of spontaneous urticaria</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> office</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Remission</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: The prognosis of spontaneous urticaria in association with early treatment remains unclear. In this study, we retrospectively studied the prognosis of acute spontaneous urticaria in relation to age and treatments in a local clinic of dermatology. METHODS: Out of 5000 patients who visited an office dermatology clinic, clinical records of patients with spontaneous urticaria were extracted. Their prognosis and the relation to age and treatments were analyzed by the Kaplan-Meier method and generalized Wilcoxon test. RESULTS: Among 386 patients diagnosed with spontaneous urticaria, 284 patients (73.6%) began treatments within a week after the onset. Their non-remission rates after one week, four weeks and one year from the onset were 26.8%, 15.0% and 6.7%, respectively. The non-remission rates of patients who were 20-years-old or younger by one year after the onset of urticaria, were significantly lower than those of patients older than 20-years-old. No apparent relationship between remission rates and sex or the use of steroids was detected. However, the non-remission rates of urticaria treated with a standard dose of antihistamine were lower than that treated with additional medications. CONCLUSIONS: Most patients who began treatments within one week from the onset remitted quickly. However approximately 7% of them continued to suffer from symptoms for more than a year. Such prolongation tended to be seen among patients who required other medications in addition to a standard dose of antihistamine</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2016.12.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28094108">PM:28094108</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170117-TanakaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170117-TanakaT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Tanaka T</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2016.12.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40197</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ryan,D.</style></author><author><style face="normal" font="default"> Angier,E.</style></author><author><style face="normal" font="default"> Gomez,M.</style></author><author><style face="normal" font="default"> Church,D.</style></author><author><style face="normal" font="default"> Batsiou,M.</style></author><author><style face="normal" font="default"> Nekam,K.</style></author><author><style face="normal" font="default"> Lomidze,N.</style></author><author><style face="normal" font="default"> Gawlik,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Honorary Clinical Research Fellow, Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, UKGP and Clinical Assistant Department of immunology and Allergy, Northern General Hospital, Herries Road, Sheffield, S5 7A,, UKAllergy &amp; Asthma Unit, Hospital San Bernardo, Salta, ArgentinaBath Lodge Practice, Commercial Road, Southampton, SO18 6BT, UKRiRL, 5 Coles Lane, Oakington, Cambridge, CB24 3BA, UKHospital of the Order of the Hospitaller Brothers, Budapest, 1277 Budapest 23, ., POB 98, HungaryCenter of Allergy and Immunology, Tbilisi, GeorgiaDept. and Clinic of Internal Medicine, Allergy and Clinical Immunology, Silesian University of Medicine, Katowice, Poland</style></auth-address><titles><title><style face="normal" font="default">Results of an Allergy educational needs questionnaire for Primary Care</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Argentina</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Commercial</style></keyword><keyword><style face="normal" font="default"> Computer</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Georgia</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hungary</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Learning</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="25" Month="1" Year="2017">2017/1/25</year></dates><abstract><style face="normal" font="default">BACKGROUND: It is well recognized that knowledge of allergic conditions is sub-optimal in primary care. The Primary Care Interest Group of the European Academy of Allergy and Clinical Immunology undertook an educational needs survey to better understand what they were and how best to meet them, in the primary care environment. METHOD: an electronic questionnaire was devised and distributed as widely as possible. RESULTS: 2226 people from 63 countries opened the e-questionnaire of which 692 provided evaluable responses. 81% were medical doctors with 299 possessing additional qualifications. Self-declared gaps in knowledge were expressed most manifestations of allergy with a correspondingly high self-expressed educational need. The preferred learning modalities were: Online guidelines (69.6%) and courses (68.8%) followed closely by workshops (68%), structured online modules (63.9%) and small local working groups (59.75%). Podcasts and webinars scored poorly with only 25% expressing these as preferred learning modes although there was an age gradient. The preferred electronic platform was the personal computer (82.6%). CONCLUSION: A better understanding of the needs of primary care should help guide the design of educational initiatives to meet those needs. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170125IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Argentina -CO - Uruguay -CO - Georgia -CO - Poland -</style></notes><work-type><style face="normal" font="default">10.1111/all.13134</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28122131">PM:28122131</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170125-RyanD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170125-RyanD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170125, Ryan D</style></custom2><misc3><style face="normal" font="default">10.1111/all.13134</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40198</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kortekaas,K.I.</style></author><author><style face="normal" font="default"> Bobic,S.</style></author><author><style face="normal" font="default"> Dooley,J.</style></author><author><style face="normal" font="default"> Lan,F.</style></author><author><style face="normal" font="default"> Zhang,N.</style></author><author><style face="normal" font="default"> Bachert,C.</style></author><author><style face="normal" font="default"> Steelant,B.</style></author><author><style face="normal" font="default"> Bullens,D.</style></author><author><style face="normal" font="default"> Liston,A.</style></author><author><style face="normal" font="default"> Ceuppens,J.L.</style></author><author><style face="normal" font="default"> Seys,S.F.</style></author><author><style face="normal" font="default"> Hellings,P.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Clinical Immunology, Dpt. Microbiology &amp; Immunology, KU Leuven, Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="default">PD-1 expression correlates with disease severity and IL-5 in Chronic Rhinosinusitis with Nasal Polyps</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">association</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Cell Death</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Ligands</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="25" Month="1" Year="2017">2017/1/25</year></dates><abstract><style face="normal" font="default">BACKGROUND: Programmed cell Death 1 (PD-1) is a negative regulator of T cell responses. Expression of PD-1 and its ligands PD-L1 and PD-L2 in chronic rhinosinusitis with nasal polyps (CRSwNP) is poorly studied. METHODS: Expression of PD-1, PD-L1, PD-L2, TGF-beta, IL-5 and IL-10 mRNA was measured by RT-PCR on tissue homogenates of patients with CRSwNP (n=21) and healthy controls (n=21) and on primary epithelial cells. Disease severity was scored using the Lund-Mackay scores of maxillo-facial CT scans. PD-1 and PD-L1/L2 expression were evaluated at the cellular and tissue level (n=6) by flow cytometry and immunohistochemistry. RESULTS: PD-1 mRNA expression was increased in tissue homogenates from patients with CRSwNP compared to controls, irrespectively of the atopy status. Importantly, expression of PD-1 correlated with the total CT scan scores (r=0.5, p= 0.02). Additionally, a significant association was found between PD-1 mRNA and expression of IL-5 mRNA in control nasal tissue (r=0.95, p&lt;0.0001) and in CRSwNP (r=0.63, p=0.002). PD-1 was expressed on different subsets of T cells and CD11b- dendritic cells. Both PD-1 and its ligands were expressed on primary epithelial cells from control nasal tissue and nasal polyp tissue. CONCLUSIONS: Higher PD-1 expression was found in CRSwNP than in nasal tissue from controls. This was associated with disease severity and tissue IL-5 expression but unrelated to the patients' atopy status. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170125IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/all.13136</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28122135">PM:28122135</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170125-KortekassKI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170125-KortekassKI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170125, Kortekass KI</style></custom2><misc3><style face="normal" font="default">10.1111/all.13136</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40199</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aron,J.L.</style></author><author><style face="normal" font="default"> Akbari,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, 1450 Biggy Street NRT 5509, Los Angeles, California, 90033, USA</style></auth-address><titles><title><style face="normal" font="default">Regulatory T Cells and Type 2 Innate Lymphoid Cell Dependent Asthma</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate lymphoid cells</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Los Angeles</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> persistence</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> regulatory T cell</style></keyword><keyword><style face="normal" font="default"> regulatory T cells</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> Tregs</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="default">Group two innate lymphoid cells (ILC2s) are a recently identified group of cells with the potent capability to produce Th2-type cytokines such as interleukin (IL)-5 and IL-13. Several studies suggest that ILC2s play an important role in the development of allergic diseases and asthma. Activation of pulmonary ILC2s in murine models lacking T and B cells induces eosinophilia and airway hyperreactivity (AHR), which are cardinal features of asthma. More importantly, numerous recent studies have highlighted the role of ILC2s in asthma persistence and exacerbation among human subjects and thus, regulation of pulmonary ILC2s is a major area of investigation aimed at curbing allergic lung inflammation and exacerbation. Emerging evidence reveals that a group of regulatory T cells, induced Tregs (iTregs), effectively suppress the production of ILC2-driven, pro-inflammatory cytokines IL-5 and IL-13. The inhibitory effects of iTregs are blocked by preventing direct cellular contact or by inhibiting the ICOS-ICOS-ligand (ICOSL) pathway, suggesting that both direct contact and ICOS-ICOSL interaction are important in the regulation of ILC2 function. Also, cytokines such as IL-10 and TGF-beta1 significantly reduce cytokine secretion by ILC2s. Altogether, these new findings uncover iTregs as potent regulators of ILC2 activation and implicate their utility as a therapeutic approach for the treatment of ILC2-mediated allergic asthma and respiratory disease. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170204IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.13139</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28160290">PM:28160290</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170204-AronJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170204-AronJL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, Aron JL</style></custom2><misc3><style face="normal" font="default">10.1111/all.13139</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40200</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sengupta,S.</style></author><author><style face="normal" font="default"> Haczku,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Children's Hospital of Philadelphia, Philadelphia, PA</style></auth-address><titles><title><style face="normal" font="default">Targeting IkappaBNS in allergic asthma: Where it resides, matters</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Airways disease</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Philadelphia</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> transcription factor</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="default">The activity NF-kappaB, a pro-inflammatory transcription factor, and its complex modulation play a central role in in inflammatory airways disease such as allergic airway hyperresponsiveness. In a new study, Yokota and colleagues investigated Ikappa</style></abstract><notes><style face="normal" font="default">DA - 20170118IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.13126</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28100002">PM:28100002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170118-SenguptaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170118-SenguptaS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170118, Sengupta S</style></custom2><misc3><style face="normal" font="default">10.1111/all.13126</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40201</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Drucker,A.M.</style></author><author><style face="normal" font="default"> Thompson,J.M.</style></author><author><style face="normal" font="default"> Li,W.Q.</style></author><author><style face="normal" font="default"> Cho,E.</style></author><author><style face="normal" font="default"> Li,T.</style></author><author><style face="normal" font="default"> Guttman-Yassky,E.</style></author><author><style face="normal" font="default"> Qureshi,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Warren Alpert Medical School, Providence, RI, USA</style></auth-address><titles><title><style face="normal" font="default">Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses' Health Study 2</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Alopecia</style></keyword><keyword><style face="normal" font="default"> Alopecia Areata</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Nurses</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Vitiligo</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="19" Month="1" Year="2017">2017/1/19</year></dates><abstract><style face="normal" font="default">We aimed to determine the risk of alopecia areata (AA) and vitiligo associated with atopic dermatitis (AD) in a large cohort of US women, the Nurses' Health Study 2. We used logistic regression to calculate age- and multivariate-adjusted odds ratios to determine the risk of incident AA and vitiligo associated with AD diagnosed in or before 2009. A total of 87 406 and 87 447 participants were included in the AA and vitiligo analyses, respectively. A history of AD in 2009 was reported in 11% of participants. There were 147 incident cases of AA and 98 incident cases of vitiligo over 2 years of follow-up. AD was associated with increased risk of developing AA (OR 1.80, 95% CI 1.18-2.76) and vitiligo (OR 2.14, 95% CI 1.29-3.54) in multivariate models. In this study of US women, AD was associated with increased risk of incident vitiligo and AA in adulthood</style></abstract><notes><style face="normal" font="default">DA - 20170119IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.13128</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28101886">PM:28101886</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170119-DruckerAM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170119-DruckerAM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170119, Drucker AM</style></custom2><misc3><style face="normal" font="default">10.1111/all.13128</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40202</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Blom,L.H.</style></author><author><style face="normal" font="default"> Martel,B.C.</style></author><author><style face="normal" font="default"> Larsen,L.F.</style></author><author><style face="normal" font="default"> Hansen,C.V.</style></author><author><style face="normal" font="default"> Christensen,M.P.</style></author><author><style face="normal" font="default"> Juel-Berg,N.</style></author><author><style face="normal" font="default"> Litman,T.</style></author><author><style face="normal" font="default"> Poulsen,L.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Allergy Clinic, Copenhagen University Hospital Herlev and Gentofte, Denmark</style></auth-address><titles><title><style face="normal" font="default">The immunoglobulin superfamily member CD200R identifies cells involved in type 2 immune responses</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> PBMCs</style></keyword><keyword><style face="normal" font="default"> Peanut</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> Th2 Cells</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="1" Year="2017">2017/1/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: The pathology of allergic diseases involves type 2 immune cells, such as Th2, ILC2, and basophils exerting their effect by production of IL-4, IL-5, and IL-13. However, surface receptors that are specifically expressed on type 2 immune cells are less well documented. The aim of this investigation was to identify surface markers associated with type 2 inflammation. METHODS: Naive human CD4+ T-cells were short-term activated in the presence or absence of IL-4, and analysed for expression of >300 cell-surface proteins. Ex vivo isolated PBMCs from peanut and non-allergic allergic subjects, were stimulated (14-16h) with peanut extract to detect peanut-specific CD4+ CD154+ T-cells. Biopsies were obtained for transcriptomic analysis from healthy controls and patients with extrinsic or intrinsic atopic dermatitis and psoriasis. RESULTS: Expression analysis of >300 surface proteins enabled identification of IL-4 up-regulated surface proteins, such as CD90, CD108, CD109, and CD200R (CD200R1). Additional analysis of in vitro differentiated Th0, Th1, and Th2 cultures, identified CD200R as up-regulated on Th2 cells. From ex vivo isolated PBMCs, we found high expression of CD200R on Th2 and ILC2 cells and basophils. In peanut-allergic subjects the peanut-specific Th2 (CD154+ CRTh2+ ) cells expressed more CD200R than the non-allergen specific Th2 (C</style></abstract><notes><style face="normal" font="default">DA - 20170120IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/all.13129</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28106273">PM:28106273</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170120-BlomLH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170120-BlomLH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170120, Blom LH</style></custom2><misc3><style face="normal" font="default">10.1111/all.13129</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40203</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Flayer,C.H.</style></author><author><style face="normal" font="default"> Haczku,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of California, DavisUniversity of California, Davis</style></auth-address><titles><title><style face="normal" font="default">The Th2 gene cluster unraveled: Role of RHS6</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> RAD50</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> transcription factor</style></keyword><keyword><style face="normal" font="default"> Transcription Factors</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="1" Year="2017">2017/1/20</year></dates><abstract><style face="normal" font="default">Although the transcription factors that regulate T helper (Th) type 2 cytokine production (IL-4, IL-5, and IL-13) are possible novel therapeutic targets, we lack a detailed understanding of the mechanisms that regulate the transcription of these cytokines. In this issue of Allergy, Hwang et al. studied the role of a specific DNA region (a cis-acting element called Rad50 hypersensitive site 6) RHS6, in the development of allergic airway inflammation. RHS6 is found in the Th2 cytokine "locus control region" but its role in activation of the IL-4, IL-5, and IL-13 genes was unknown. The authors here showed that RHS6 recruited the transcription factors GATA3, SATB1, and IRF4, each of which are involved in transcription of all three Th2 cytokine genes. Indeed genetic deficiency in RHS6 inhibited expression of IL-4, IL-5, and IL-13 and reduced allergic airway inflammation in a murine model of ovalbumin-induced sensitization. Deletion of RHS6 also inhibited formation of the transcription factor complex of GATA3, SATB1, and IRF4 that reduced the transcription of IL-4, IL-5, and IL-13. This study suggests that RHS6 is critical for the development of allergic airway inflammation and that the GATA3, SATB1, IRF4 and RHS6 complex maybe a potential therapeutic target for the treatment of asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170121IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.13130</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28108985">PM:28108985</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170121-FlayerCH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170121-FlayerCH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170121, Flayer CH</style></custom2><misc3><style face="normal" font="default">10.1111/all.13130</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40204</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jindal,N.L.</style></author><author><style face="normal" font="default"> Harniman,E.</style></author><author><style face="normal" font="default"> Prior,N.</style></author><author><style face="normal" font="default"> Perez-Fernandez,E.</style></author><author><style face="normal" font="default"> Caballero,T.</style></author><author><style face="normal" font="default"> Betschel,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">grid.415502.7Division of Clinical Immunology and Allergy, St. Michael's Hospital, Bond Street, 4 CC Specialty Clinics, Toronto, ON M5B 1W8 Canada</style></auth-address><titles><title><style face="normal" font="default">Hereditary angioedema: health-related quality of life in Canadian patients as measured by the SF-36</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Clin Immunol</style></full-title></periodical><pages end="" start="4">4-</pages><volume><style face="normal" font="default">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> C1 INH</style></keyword><keyword><style face="normal" font="default"> C1-INH</style></keyword><keyword><style face="normal" font="default"> C1Inh</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hereditary angioedema (HAE) is a rare but serious condition characterized by recurrent spontaneous attacks of angioedema affecting superficial tissues of upper respiratory and gastrointestinal tracts. The potentially fatal and disfiguring nature of HAE impacts the health-related quality of life (HRQoL) of patients with this condition. OBJECTIVES: To assess the health-related quality of life of Canadian patients with HAE using the 36-item Short-Form Health Survey (SF-36v2). METHODS: Twenty-one patients living in Canada over age 18 with known diagnosis of hereditary angioedema due to C1-INH deficiency (HAE), completed the SF-36v2 (generic HRQoL questionnaire). Results were compared to Canadian normative data by converting the SF-36 scores into z scores. RESULTS: The SF-36v2 showed a significant reduction in general health (p = 0.0063) in patients with HAE when compared with healthy Canadians. Percentage of patients with z scores below 0.8 (large effect) was 47.6% for general health subscale, 33.3% for bodily pain and vitality subscales and 28.6% for physical component scores. Mean scores of eight dimensions ranged from 57.7 to 88.9. Mean Physical and mental component scores were 49.1 and 50.4. Internal consistency of evaluation was demonstrated by Cronbach's alpha value above 0.7 for all scales. General perception of health was significantly different in these patients, compared to Canadian normative data. CONCLUSIONS: This study of Canadian patients with HAE shows that General Health is most frequently affected followed by Bodily Pain and Vitality, as measured by SF-36v2. The SF-36v2 offers valuable insight to assess quality of life in patients with HAE, however a larger number of Canadian patients and specific tools for assessment are needed for better evaluation</style></abstract><notes><style face="normal" font="default">DA - 20170124IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1186/s13223-016-0176-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28115964">PM:28115964</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170124, Jindal NL</style></custom2><misc3><style face="normal" font="default">10.1186/s13223-016-0176-3</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40205</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Inada,N.</style></author><author><style face="normal" font="default"> Shoji,J.</style></author><author><style face="normal" font="default"> Yamagami,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">0000 0001 2149 8846grid.260969.2Department of Visual Sciences, Division of Ophthalmology, School of Medicine, Nihon University, 30-1, Oyaguchi-Kamicho, Itabashi-ku, Tokyo 173-8610 Japan</style></auth-address><titles><title><style face="normal" font="default">Atopic keratoconjunctivitis complicated by Kocuria koreensis keratitis: the first case</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Clin Immunol</style></full-title></periodical><pages end="" start="6">6-</pages><volume><style face="normal" font="default">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AKC</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> Atopic diseases</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> Conjunctiva</style></keyword><keyword><style face="normal" font="default"> Cornea</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> herpes</style></keyword><keyword><style face="normal" font="default"> Herpes Simplex</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hyperemia</style></keyword><keyword><style face="normal" font="default"> Immunosuppressive Agents</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Keratitis</style></keyword><keyword><style face="normal" font="default"> Keratoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Ophthalmology</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Scraping</style></keyword><keyword><style face="normal" font="default"> Sequence</style></keyword><keyword><style face="normal" font="default"> Sequence Analysis</style></keyword><keyword><style face="normal" font="default"> Staphylococcus</style></keyword><keyword><style face="normal" font="default"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Ulcer</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> virus infection</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patients with atopic dermatitis have a predisposition to Staphylococcus aureus and a Herpes simplex virus infection. The treatment of atopic diseases with steroid and immunosuppressive agents induces opportunistic infection. However, there is a concern regarding visual prognosis in patients with atopic keratoconjunctivitis (AKC) complicated with infectious keratitis. We report an unusual case of an atopic shield ulcer with Kocuria keratitis. CASE PRESENTATION: A 51-year-old Japanese man presented with a 14-day history of eye pain and visual loss in his left eye. At the initial examination, a shield ulcer was observed in the upper-central cornea of the left eye, and the conjunctiva in both eyes had a velvety appearance due to papillary formation, as well as hyperemia and swelling in the palpebral area. The shield ulcer showed white stromal opacification in the marginal zone with a coral-like appearance. Samples were obtained by corneal scraping, and Kocuria sp. was identified by microbiological examination including culture and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. The 16S rRNA gene sequence analysis was performed using isolated Kocuria strain from the patient. The obtained DNA sequence showed 99% homology with Kocuria koreensis. The combination of corneal scraping and instillation of cefmenoxime antibiotic ophthalmic solution was considered useful for the treatment of Kocuria keratitis. CONCLUSION: Clinicians should be aware of Kocuria keratitis as a corneal complication of AKC, and that rapid diagnosis of Kocuria keratitis may improve visual prognosis</style></abstract><notes><style face="normal" font="default">DA - 20170131IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1186/s13223-017-0178-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28138334">PM:28138334</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170131, Inada N</style></custom2><misc3><style face="normal" font="default">10.1186/s13223-017-0178-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40206</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tan,L.</style></author><author><style face="normal" font="default"> Ou,J.</style></author><author><style face="normal" font="default"> Tao,Z.</style></author><author><style face="normal" font="default"> Kong,Y.</style></author><author><style face="normal" font="default"> Xu,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, China</style></auth-address><titles><title><style face="normal" font="default">Neonatal Immune State Is Influenced by Maternal Allergic Rhinitis and Associated With Regulatory T cells</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="141" start="133">133-141</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Der p 1</style></keyword><keyword><style face="normal" font="default"> Dermatophagoides</style></keyword><keyword><style face="normal" font="default"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> Epigenetics</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Foxp3</style></keyword><keyword><style face="normal" font="default"> Histopathology</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL-17</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Methylation</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> regulatory T cell</style></keyword><keyword><style face="normal" font="default"> regulatory T cells</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Spleen</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> transmission</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">PURPOSE: Maternal influences contribute to the origin of allergic diseases, but the mechanisms are not clear. The current literature prompted the role of epigenetics in the development of allergic diseases. We sought to investigate the roles of regulatory T (Treg) cells and Forkhead box p3 (Foxp3) DNA methylation in the process of maternal transmission of allergic rhinitis (AR) susceptibility. METHODS: BALB/c female mice (AR mother) were sensitized by intraperitoneal injection of Dermatophagoides pteronyssinus (Der p) 1 on day 1 and 7. Then they mated with normal male mice on day 8. From day 21 to 28, the female mice were intranasal challenged with Der p 1 continuously. The normal controls were given with normal saline in the same way. On postnatal day 3, Female mice and their offspring were sacrificed to detect their histopathology in nasal mucosae, cytokines in sera of mother and spleen homogenates of offspring, Treg cells count, Foxp3 mRNA expressions, and Foxp3 DNA methylation levels in spleens. RESULTS: Compared with the normal controls, neonatal offspring of Der p 1-stimulated female mice (AR offspring) showed the elevation of interleukin (IL)-4 (P&lt;0.01) and IL-17 (P&lt;0.01), the submission of IL-10 (P&lt;0.01) in spleen homogenates. Further, Treg cells count in AR offspring decreased remarkably compared with the normal offspring (P&lt;0.01). Though the difference of Foxp3 DNA methylation level between AR offspring and normal control offspring was not obvious, correlation analysis demonstrated that there was significantly positive correlation between Foxp3 DNA methylation level of mother and that of offspring (r=0.803, P&lt;0.01). CONCLUSIONS: Under the influence of Maternal AR, their neonatal offspring develop into T-helper type 2 (Th2) dominant immune state, which is closely associated with the recession of Treg cells. Foxp3 DNA methylation may be a mechanism responsible for that maternal effect but still need more studies to ensure</style></abstract><notes><style face="normal" font="default">DA - 20170119IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.2.133</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28102058">PM:28102058</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-133-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-133-41.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170119, Tan L</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.2.133</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40207</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wardzynska,A.</style></author><author><style face="normal" font="default"> Makowska,J.S.</style></author><author><style face="normal" font="default"> Pawelczyk,M.</style></author><author><style face="normal" font="default"> Piechota-Polanczyk,A.</style></author><author><style face="normal" font="default"> Kurowski,M.</style></author><author><style face="normal" font="default"> Kowalski,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Immunology, Rheumatology and Allergy, Healthy Ageing Research Centre, Medical University of Lodz, Poland</style></auth-address><titles><title><style face="normal" font="default">Periostin in Exhaled Breath Condensate and in Serum of Asthmatic Patients: Relationship to Upper and Lower Airway Disease</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="132" start="126">126-132</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Exhaled Breath</style></keyword><keyword><style face="normal" font="default"> exhaled breath condensate</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> KIT</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> NSAID</style></keyword><keyword><style face="normal" font="default"> NSAIDs</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Periostin</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">PURPOSE: Periostin is considered a biomarker for eosinophilic airway inflammation and have been associated with NSAID-Exacerbated Respiratory Disease (NERD) and chronic rhinosinusitis (CRS). In this study, we aimed to evaluate periostin in exhaled breath condensate (EBC) and in serum of patients with various asthma phenotypes. METHODS: The study included 40 asthmatic patients (22 with NERD) and 17 healthy controls. All the procedures (questionnaire, spirometry, FeNO, nasal swabs, EBC collecting, and blood sampling) were performed on the same day. Periostin concentrations were measured using an ELISA kit. RESULTS: Periostin was detected in EBC from 37 of 40 asthmatics and in 16 from 17 of controls. The concentration of periostin in EBC did not differ between the study groups and was not associated with NERD or asthma severity. However, the EBC periostin was significantly higher in asthmatics with CRS as compared to those without (3.1 vs 2 ng/mL, P=0.046). Patients with positive bacterial culture from nasal swabs had higher EBC periostin concentrations than those without (3.2 vs 2.1 ng/mL; P=0.046). The mean serum periostin level was higher in asthmatics with a 1-year history of exacerbation than in those without (3.2 vs 2.3 ng/mL, P=0.045). Asthmatics with skin manifestation of NSAIDs hypersensitivity had higher serum periostin levels as compared to those without (3.5 vs 2.3 ng/mL; P=0.03). CONCLUSIONS: EBC periostin levels seem to reflect intensity of upper airway disease in asthmatics, while serum levels of periostin are associated with asthma activity (exacerbations or FeNO) or NERD subphenotypes</style></abstract><notes><style face="normal" font="default">DA - 20170119IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.2.126</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28102057">PM:28102057</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-126-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-126-32.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170119, Wardzynska A</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.2.126</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40208</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Park,C.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Respiratory Medicine, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.</style></auth-address><titles><title><style face="normal" font="default">Size of Inhaled Corticosteroid and Small Airway Inflammation in Asthma</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="100" start="99">99-100</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170119IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - EditorialCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.2.99</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28102053">PM:28102053</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-99-100.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-99-100.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170119, Park CS</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.2.99</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40209</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yang,L.Y.</style></author><author><style face="normal" font="default"> Li,X.</style></author><author><style face="normal" font="default"> Li,W.T.</style></author><author><style face="normal" font="default"> Huang,J.C.</style></author><author><style face="normal" font="default"> Wang,Z.Y.</style></author><author><style face="normal" font="default"> Huang,Z.Z.</style></author><author><style face="normal" font="default"> Chang,L.H.</style></author><author><style face="normal" font="default"> Zhang,G.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China</style></auth-address><titles><title><style face="normal" font="default">Vgamma1(+) gammadeltaT Cells Are Correlated With Increasing Expression of Eosinophil Cationic Protein and Metalloproteinase-7 in Chronic Rhinosinusitis With Nasal Polyps Inducing the Formation of Edema</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="151" start="142">142-151</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> cationic protein</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> ECP</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> Non-eosinophilic</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Staining</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">PURPOSE: We have found that expression of gammadeltaT cells is increased in pathological mucosa of chronic rhinosinusitis with nasal polyps (CRSwNP) compared with normal nasal mucosa. This increase is correlated with the infiltration of eosinophils in CRSwNP. Here, we investigated the expression of gammadeltaT cells, inflammation and tissue remodeling factors as well as their probable relationships in different types of chronic rhinosinusitis (CRS) in China. METHODS: A total of 76 surgical tissue samples that included 43 CRSwNP samples (15 eosinophilic and 28 non-eosinophilic), 17 CRS samples without nasal polyps (CRSsNP), and 16 controls were obtained. Quantitative reverse transcription-polymerase chain reaction (RT-PCR) was used to measure the mRNA expression levels of Vgamma1(+) gammadeltaT cells, Vgamma4(+) gammadeltaT cells, eosinophil cationic protein (ECP), interleukin (IL)-8, transforming growth factor (TGF)-beta2, metalloproteinase (MMP)-7, tissue inhibitor of metalloproteinase (TIMP)-4 and hypoxia-inducible factor (HIF)-1alpha. Enzyme linked immunosorbent assay (ELISA) was used to measure the protein level of ECP and MMP-7 in CRSwNP. The eosinophils were counted and the level of edema was analyzed with HE staining. RESULTS: The mRNA expression levels of the Vgamma1 subset, ECP and MMP-7 were significantly increased in CRSwNP with histological characteristics of eosinophilic infiltration and edema. The expression of the Vgamma1 gene in CRSwNP correlated positively with the expression of both ECP and MMP-7. No significant decreases in the mRNA expression levels of TGF-beta2, TIMP-4 or HIF-1alpha were observed in the CRSwNP samples. The expression levels of Vgamma1 gene, ECP and MMP-7 were significantly increased in eosinophilic CRSwNP compared to non-eosinophilic CRSwNP. CONCLUSIONS: Our results suggest the associations between Vgamma1(+) gammadeltaT cells, ECP and MMP-7 in CRSwNP, indicating that Vgamma1(+) gammadeltaT cells can induce the eosinophilic inflammation, which has a further effect on the formation of edema</style></abstract><notes><style face="normal" font="default">DA - 20170119IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.2.142</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28102059">PM:28102059</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-142-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-142-51.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170119, Yang LY</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.2.142</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40210</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Choi,Y.</style></author><author><style face="normal" font="default"> Park,H.</style></author><author><style face="normal" font="default"> Park,H.S.</style></author><author><style face="normal" font="default"> Kim,Y.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy and Clinical Immunology, Ajou University Medical Center, Suwon, Korea</style></auth-address><titles><title><style face="normal" font="default">Extracellular Vesicles, a Key Mediator to Link Environmental Microbiota to Airway Immunity</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="106" start="101">101-106</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> adaptive</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">Asthma is considered the hallmark of chronic airway inflammation, in which several inflammatory cells of the innate and adaptive immune system act together. The disease is thought to be caused by a combination of genetic and environmental factors; however, precise mechanisms for airway inflammation remain unclear. The human microbiota provides an increasingly favored explanation for inflammatory diseases; an altered microbiota composition has been shown to regulate immune responses. However, given the complexity of the microbiota, additional research is needed to elucidate its role in the development of disease. One of the candidate molecules that link microbiota to disease is the extracellular vesicles (EVs). EVs are secreted by diverse cell types and they possess the pathophysiological function of delivering signals between bacteria and host. We discuss the role of the microbiota in the development of asthma through releasing EVs</style></abstract><notes><style face="normal" font="default">DA - 20170119IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.2.101</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28102054">PM:28102054</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-101-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-101-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170119, Choi Y</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.2.101</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40211</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Postma,D.S.</style></author><author><style face="normal" font="default"> Dekhuijzen,R.</style></author><author><style face="normal" font="default"> van der Molen,T.</style></author><author><style face="normal" font="default"> Martin,R.J.</style></author><author><style face="normal" font="default"> van Aalderen,W.</style></author><author><style face="normal" font="default"> Roche,N.</style></author><author><style face="normal" font="default"> Guilbert,T.W.</style></author><author><style face="normal" font="default"> Israel,E.</style></author><author><style face="normal" font="default"> van Eickels,D.</style></author><author><style face="normal" font="default"> Khalid,J.M.</style></author><author><style face="normal" font="default"> Herings,R.M.</style></author><author><style face="normal" font="default"> Overbeek,J.A.</style></author><author><style face="normal" font="default"> Miglio,C.</style></author><author><style face="normal" font="default"> Thomas,V.</style></author><author><style face="normal" font="default"> Hutton,C.</style></author><author><style face="normal" font="default"> Hillyer,E.V.</style></author><author><style face="normal" font="default"> Price,D.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Groningen, Department of Pulmonology, University Medical Center Groningen, Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Asthma-Related Outcomes in Patients Initiating Extrafine Ciclesonide or Fine-Particle Inhaled Corticosteroids</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="125" start="116">116-125</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Beclomethasone</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> fluticasone propionate</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="default"> Gastroesophageal reflux disease</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">PURPOSE: Extrafine-particle inhaled corticosteroids (ICS) have greater small airway deposition than standard fine-particle ICS. We sought to compare asthma-related outcomes after patients initiated extrafine-particle ciclesonide or fine-particle ICS (fluticasone propionate or non-extrafine beclomethasone). METHODS: This historical, matched cohort study included patients aged 12-60 years prescribed their first ICS as ciclesonide or fine-particle ICS. The 2 cohorts were matched 1:1 for key demographic and clinical characteristics over the baseline year. Co-primary endpoints were 1-year severe exacerbation rates, risk-domain asthma control, and overall asthma control; secondary endpoints included therapy change. RESULTS: Each cohort included 1,244 patients (median age 45 years; 65% women). Patients in the ciclesonide cohort were comparable to those in the fine-particle ICS cohort apart from higher baseline prevalence of hospitalization, gastroesophageal reflux disease, and rhinitis. Median (interquartile range) prescribed doses of ciclesonide and fine-particle ICS were 160 (160-160) mug/day and 500 (250-500) mug/day, respectively (P&lt;0.001). During the outcome year, patients prescribed ciclesonide experienced lower severe exacerbation rates (adjusted rate ratio [95% CI], 0.69 [0.53-0.89]), and higher odds of risk-domain asthma control (adjusted odds ratio [95% CI], 1.62 [1.27-2.06]) and of overall asthma control (2.08 [1.68-2.57]) than those prescribed fine-particle ICS. The odds of therapy change were 0.70 (0.59-0.83) with ciclesonide. CONCLUSIONS: In this matched cohort analysis, we observed that initiation of ICS with ciclesonide was associated with better 1-year asthma outcomes and fewer changes to therapy, despite data suggesting more difficult-to-control asthma. The median prescribed dose of ciclesonide was one-third that of fine-particle ICS</style></abstract><notes><style face="normal" font="default">DA - 20170119IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - United States -CO - France -CO - Switzerland -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.2.116</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28102056">PM:28102056</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-116-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-116-25.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170119, Postma DS</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.2.116</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40212</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Karcioglu,O.</style></author><author><style face="normal" font="default"> Ulasli,S.S.</style></author><author><style face="normal" font="default"> Esquinas,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hacettepe University, School of Medicine, Department of Pulmonary Diseases, Ankara, Turkey.</style></auth-address><titles><title><style face="normal" font="default">Glucagon for refractory asthma exacerbation: Friend or foe?</style></title><secondary-title><style face="normal" font="default">Am J Emerg Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Emerg Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Glucagon</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="23" Month="12" Year="2016">2016/12/23</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170107IS - 1532-8171 (Electronic)IS - 0735-6757 (Linking)LA - engPT - LetterCO - Turkey -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.ajem.2016.12.053</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28062208">PM:28062208</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Emerg Med\20170107-KarciogluO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Emerg Med\20170107-KarciogluO.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170107, Karcioglu O</style></custom2><misc3><style face="normal" font="default">10.1016/j.ajem.2016.12.053</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40213</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cavallari,J.M.</style></author><author><style face="normal" font="default"> Jawaro,T.S.</style></author><author><style face="normal" font="default"> Awad,N.I.</style></author><author><style face="normal" font="default"> Bridgeman,P.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacy, Robert Wood Johnson University Hospital, New Brunswick, New Jersey</style></auth-address><titles><title><style face="normal" font="default">Response to Glucagon for refractory asthma exacerbation: Friend or foe?</style></title><secondary-title><style face="normal" font="default">Am J Emerg Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Emerg Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Glucagon</style></keyword><keyword><style face="normal" font="default"> New Jersey</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Wood</style></keyword></keywords><dates><year Day="23" Month="12" Year="2016">2016/12/23</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170102IS - 1532-8171 (Electronic)IS - 0735-6757 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.ajem.2016.12.051</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28041760">PM:28041760</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Emerg Med\20170102-CavallariJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Emerg Med\20170102-CavallariJM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170102, Cavallari JM</style></custom2><misc3><style face="normal" font="default">10.1016/j.ajem.2016.12.051</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40214</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pazzini,C.A.</style></author><author><style face="normal" font="default"> Pereira,L.J.</style></author><author><style face="normal" font="default"> Marques,L.S.</style></author><author><style face="normal" font="default"> Ramos-Jorge,J.</style></author><author><style face="normal" font="default"> Aparecida da Silva,T.</style></author><author><style face="normal" font="default"> Paiva,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Postgraduate student, Department of Pediatric Dentistry and Orthodontics, Faculty of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.</style></auth-address><titles><title><style face="normal" font="default">Nickel-free vs conventional braces for patients allergic to nickel: Gingival and blood parameters during and after treatment</style></title><secondary-title><style face="normal" font="default">Am J Orthod Dentofacial Orthop</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Orthod Dentofacial Orthop</style></full-title></periodical><pages end="1019" start="1014">1014-1019</pages><volume><style face="normal" font="default">150</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">abnormalities</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Braces</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Dentistry</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Orthodontics</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Quantification</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Allergic and inflammatory reactions have commonly been associated with the release of metal ions during orthodontic treatment. Our objective was to evaluate prospectively gingival and blood status in patients allergic to nickel. METHODS: Allergy to nickel was diagnosed using a patch test. Two groups were established: conventional braces (n = 21) and nickel-free braces (n = 21). The gingival index was used to determine gingival status before treatment, periodically for 12 months (evaluations every 3 months), and 1 month after the removal of the braces. Blood status was evaluated with a complete blood count, including the quantification of nickel and immunoglobin E before treatment, during treatment, and 1 month after removal of the braces. The data were analyzed using Mann-Whitney, Student t, Wilcoxon, repeated measures analysis of variance, Friedman, and chi-square tests. Either the Pearson or the Spearman correlation coefficients were calculated, when appropriate. RESULTS: The number of basophils increased significantly among the evaluations in both groups (conventional, P = 0.002; nickel-free, P = 0.001), whereas the number of eosinophils and the immunoglobin E levels decreased significantly in the conventional group (P = 0.004). Plasma nickel levels were increased before and during treatment, and decreased 1 month after removing the braces in both groups, but the differences were significant only in the nickel-free group (P = 0.002). No correlations were found between the concentrations of nickel and immunoglobin E, basophils, or eosinophils, or between the gingival index and either bands or segmented neutrophils (P >/= 0.05). CONCLUSIONS: Patients treated with nickel-free braces had better gingival health and smaller blood changes than did those treated with conventional braces. All abnormalities tended to be eliminated after the removal of the braces</style></abstract><notes><style face="normal" font="default">DA - 20161129IS - 1097-6752 (Electronic)IS - 0889-5406 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1016/j.ajodo.2016.05.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27894522">PM:27894522</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Orthod Dentofacial Orthop\2016-150-1014-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Orthod Dentofacial Orthop\2016-150-1014-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161129, Pazzini CA</style></custom2><misc3><style face="normal" font="default">10.1016/j.ajodo.2016.05.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40215</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Han,Y.Y.</style></author><author><style face="normal" font="default"> Celedon,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center University of Pittsburgh Pittsburgh, Pennsylvania</style></auth-address><titles><title><style face="normal" font="default">Maternal Folate Intake during Pregnancy and Childhood Asthma</style></title><secondary-title><style face="normal" font="default">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Crit Care Med</style></full-title></periodical><pages end="156" start="155">155-156</pages><volume><style face="normal" font="default">195</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> folate</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Pennsylvania</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="15" Month="1" Year="2017">2017/1/15</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170113IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1164/rccm.201608-1713ED</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28084816">PM:28084816</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Respir Crit Care Med\2017-195-155-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Respir Crit Care Med\2017-195-155-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170113, Han YY</style></custom2><misc3><style face="normal" font="default">10.1164/rccm.201608-1713ED</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40216</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gobbi,A.</style></author><author><style face="normal" font="default"> Dellaca,R.L.</style></author><author><style face="normal" font="default"> King,G.</style></author><author><style face="normal" font="default"> Thamrin,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Politecnico di Milano University Milan, Italy</style></auth-address><titles><title><style face="normal" font="default">Toward Predicting Individual Risk in Asthma Using Daily Home Monitoring of Resistance</style></title><secondary-title><style face="normal" font="default">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Crit Care Med</style></full-title></periodical><pages end="267" start="265">265-267</pages><volume><style face="normal" font="default">195</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="15" Month="1" Year="2017">2017/1/15</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170113IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1164/rccm.201603-0537LE</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28084825">PM:28084825</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Respir Crit Care Med\2017-195-265-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Respir Crit Care Med\2017-195-265-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170113, Gobbi A</style></custom2><misc3><style face="normal" font="default">10.1164/rccm.201603-0537LE</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40217</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,Z.</style></author><author><style face="normal" font="default"> Salam,M.T.</style></author><author><style face="normal" font="default"> Alderete,T.L.</style></author><author><style face="normal" font="default"> Habre,R.</style></author><author><style face="normal" font="default"> Bastain,T.M.</style></author><author><style face="normal" font="default"> Berhane,K.</style></author><author><style face="normal" font="default"> Gilliland,F.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Southern California, Department of Preventive Medicine, Los Angeles, California, United States</style></auth-address><titles><title><style face="normal" font="default">Effects of Childhood Asthma on the Development of Obesity among School-aged Children</style></title><secondary-title><style face="normal" font="default">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Crit Care Med</style></full-title></periodical><pages end="1188" start="1181">1181-1188</pages><volume><style face="normal" font="default">195</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescence</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> COX</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Los Angeles</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> overweight</style></keyword><keyword><style face="normal" font="default"> Preventive Medicine</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> rescue medication</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="19" Month="1" Year="2017">2017/1/19</year></dates><abstract><style face="normal" font="default">RATIONALE: Asthma and obesity often occur together in children. It is unknown whether asthma contributes to the childhood obesity epidemic. OBJECTIVES: We aimed to investigate the effects of asthma and asthma medication use on the development of childhood obesity. METHODS: The primary analysis was conducted among 2,171 non-obese children who were 5-8 years of age at study enrollment in the Southern California Children's Health Study (CHS) and were followed for up to 10 years. A replication analysis was performed in an independent sample of 2,684 CHS children followed from mean age of 9.7 to 17.8 years. MEASUREMENTS AND MAIN RESULTS: Height and weight were measured annually to classify children into normal, overweight and obese categories. Asthma status was ascertained by parent- or self-reported physician-diagnosed asthma. Cox proportional hazards models were fitted to assess associations of asthma history with obesity incidence during follow-up. RESULTS: We found that children with a diagnosis of asthma at cohort entry were at 51% increased risk of developing obesity during childhood and adolescence compared to children without asthma at baseline [HR (95% CI)=1.51 (1.08, 2.10)] after adjusting for confounders. Use of asthma rescue medications at cohort entry reduced the risk of developing obesity [HR (95% CI)=0.57 (0.33, 0.96)]. Additionally, the significant association between asthma history and increased risk of developing obesity was replicated in an independent CHS sample. CONCLUSIONS: Children with asthma may be at higher risk of obesity. Asthma rescue medication use appeared to reduce obesity risk independent of physical activity</style></abstract><notes><style face="normal" font="default">DA - 20170119IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1164/rccm.201608-1691OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28103443">PM:28103443</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Respir Crit Care Med\2017-195-1181-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Respir Crit Care Med\2017-195-1181-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170119, Chen Z</style></custom2><misc3><style face="normal" font="default">10.1164/rccm.201608-1691OC</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40218</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gomez,J.L.</style></author><author><style face="normal" font="default"> Kaminski,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine Yale University School of Medicine New Haven, Connecticut</style></auth-address><titles><title><style face="normal" font="default">Toward Precision Medicine of Symptom Control in Asthma</style></title><secondary-title><style face="normal" font="default">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Crit Care Med</style></full-title></periodical><pages end="148" start="147">147-148</pages><volume><style face="normal" font="default">195</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Connecticut</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="15" Month="1" Year="2017">2017/1/15</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170113IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1164/rccm.201608-1600ED</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28084831">PM:28084831</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Respir Crit Care Med\2017-195-147-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Respir Crit Care Med\2017-195-147-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170113, Gomez JL</style></custom2><misc3><style face="normal" font="default">10.1164/rccm.201608-1600ED</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40219</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Marques,R.Z.</style></author><author><style face="normal" font="default"> Criado,R.F.</style></author><author><style face="normal" font="default"> Machado,C.D.F.</style></author><author><style face="normal" font="default"> Tamanini,J.M.</style></author><author><style face="normal" font="default"> Mello,C.V.</style></author><author><style face="normal" font="default"> Speyer,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculdade de Medicina do ABC (FMABC) - Santo Andre (SP), Brazil</style></auth-address><titles><title><style face="normal" font="default">Correlation between the histopathology of chronic urticaria and its clinical picture</style></title><secondary-title><style face="normal" font="default">An Bras Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">An Bras Dermatol</style></full-title></periodical><pages end="763" start="760">760-763</pages><volume><style face="normal" font="default">91</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Histopathology</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pallor</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND:: Chronic urticaria is characterized by transient, pruritic lesions of varying sizes, with central pallor and well-defined edges, with disease duration longer than six weeks. Its cellular infiltrate consists of neutrophils, lymphocytes and eosinophils. There is a subgroup of patients with eosinophilic or neutrophilic urticaria, resistant to the treatment with antihistamines, but that respond to a combination of antihistamine with other drugs. OBJECTIVE:: To evaluate the present infiltration in chronic urticaria biopsies and correlate it with the clinical disease activity and response to treatment. METHODS:: Forty-one patients with chronic urticaria were classified according to the score of severity of the disease, response to treatment and type of perivascular infiltrate. Inflammatory infiltrates were divided in eosinophilic (46.30%), neutrophilic and mixed. RESULTS:: An association was found between the eosinophilic infiltrate and clinical scores of greater severity (p = 0.002). CONCLUSION:: This association shows that the eosinophilic inflammatory infiltrates denote high clinical activity, which means more severe and exuberant clinical pictures of the disease</style></abstract><notes><style face="normal" font="default">DA - 20170118IS - 1806-4841 (Electronic)IS - 0365-0596 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1590/abd1806-4841.20165066</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28099597">PM:28099597</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\An Bras Dermatol\2016-91-760-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\An Bras Dermatol\2016-91-760-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170118, Marques RZ</style></custom2><misc3><style face="normal" font="default">10.1590/abd1806-4841.20165066</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40220</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Plombom,G.Y.</style></author><author><style face="normal" font="default"> Oliveira,M.S.</style></author><author><style face="normal" font="default"> Tabushi,F.L.</style></author><author><style face="normal" font="default"> Kassem,A.J.</style></author><author><style face="normal" font="default"> Purim,K.S.</style></author><author><style face="normal" font="default"> Nisihara,R.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universidade Positivo - Curitiba (PR), Brazil</style></auth-address><titles><title><style face="normal" font="default">Epidemiological analysis of occupational dermatitis notified in Brazil in the period 2007 to 2012</style></title><secondary-title><style face="normal" font="default">An Bras Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">An Bras Dermatol</style></full-title></periodical><pages end="736" start="732">732-736</pages><volume><style face="normal" font="default">91</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Chromium</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational dermatitis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND:: Occupational dermatitis affects the quality of life and productivity of workers. Studies on the subject are scarce in Brazil. It is estimated that the disease is underreported and that many affected patients do not seek health care. OBJECTIVES:: To conduct an epidemiological analysis of occupational dermatitis notified via SINAN in Brazil from January 2007 to December 2012; evaluate the profile of patients assisted; and check the main etiological agents involved. METHODS:: We analyzed the compulsory notification forms of cases of occupational dermatitis filled nationwide during January 2007 to December 2012. RESULTS:: During the study period 3027 cases of occupational dermatitis were notified in Brazil. In 61.4% of cases patients were men aged between 35-49 years (39.6%). The most described etiological agent was chromium (13.9%). The location of the body most affected was the hands, with 28.4% of cases. The construction sector is implicated in 28.7% of cases and domestic services by 18%. Allergic contact dermatitis is the most prevalent occupational dermatitis (20.6%) and the region with the highest number of notifications was the Midwest, with 376.4 cases per million inhabitants. CONCLUSIONS:: The profile of patients most affected by occupational dermatitis in Brazil during the study period was: men with elementary school, aged between 20 and 49 years old and working in the construction industry. The most common occupational dermatitis were allergic contact dermatitis caused by chromium after years of exposure, being the hands and head the parts of the body most affected</style></abstract><notes><style face="normal" font="default">DA - 20170118IS - 1806-4841 (Electronic)IS - 0365-0596 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1590/abd1806-4841.20164762</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28099592">PM:28099592</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\An Bras Dermatol\2016-91-732-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\An Bras Dermatol\2016-91-732-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170118, Plombom GY</style></custom2><misc3><style face="normal" font="default">10.1590/abd1806-4841.20164762</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40221</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dias,G.A.</style></author><author><style face="normal" font="default"> Pires,G.V.</style></author><author><style face="normal" font="default"> Valle,S.O.</style></author><author><style face="normal" font="default"> Dortas,S.D.,Jr.</style></author><author><style face="normal" font="default"> Levy,S.</style></author><author><style face="normal" font="default"> Franca,A.T.</style></author><author><style face="normal" font="default"> Baiardini,I.</style></author><author><style face="normal" font="default"> Canonica,G.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universidade do Estado do Rio de Janeiro (UERJ) - Rio de Janeiro (RJ), Brazil</style></auth-address><titles><title><style face="normal" font="default">Impact of chronic urticaria on the quality of life of patients followed up at a university hospital</style></title><secondary-title><style face="normal" font="default">An Bras Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">An Bras Dermatol</style></full-title></periodical><pages end="759" start="754">754-759</pages><volume><style face="normal" font="default">91</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lip</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND:: Chronic urticaria is a debilitating disease that considerably affects health-related quality of life, and the Chronic Urticaria Quality of Life Questionnaire is the only questionnaire specifically designed for its evaluation. OBJECTIVE:: To evaluate the quality of life of patients with chronic urticaria, using the Brazilian Portuguese version of the Chronic Urticaria Quality of Life Questionnaire. METHODS:: The Chronic Urticaria Quality of Life Questionnaire was self-administered in 112 chronic urticaria patients and disease activity was assessed through the Urticaria Activity Score. Clinical and socio-demographic characteristics of patients were studied, such as: age, sex, etiologic diagnosis of chronic urticaria, duration of disease and Urticaria Activity Score. RESULTS:: The population studied was composed 85.72% of women with a mean age of 46 years (18-90), while the median disease duration period was 10 years (3 months-60 years). Regarding the etiologic diagnosis, 48.22% had chronic spontaneous urticaria; 22.32% associated with inducible urticaria, 28.57% with chronic autoimmune urticaria, and 23.21% had physical urticaria alone. Disease activity evaluated using the Urticaria Activity Score was 1.04 +/- 1.61 (0-6). The total score for the Chronic Urticaria Quality of Life Questionnaire was 36 (0-100) and dimension I (sleep/mental status/eating) had a greater impact on quality of life. The items with the highest mean scores were nervousness and shame over lesions, while the items with the lowest scores were lip swelling and limitations on sporting activities. CONCLUSIONS:: Chronic urticaria compromises patients' quality of life, mainly those with more severe disease or who are diagnosed with chronic autoimmune urticaria</style></abstract><notes><style face="normal" font="default">DA - 20170118IS - 1806-4841 (Electronic)IS - 0365-0596 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - Italy -</style></notes><work-type><style face="normal" font="default">10.1590/abd1806-4841.20165071</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28099596">PM:28099596</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\An Bras Dermatol\2016-91-754-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\An Bras Dermatol\2016-91-754-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170118, Dias GA</style></custom2><misc3><style face="normal" font="default">10.1590/abd1806-4841.20165071</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40222</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tang,K.T.</style></author><author><style face="normal" font="default"> Ku,K.C.</style></author><author><style face="normal" font="default"> Chen,D.Y.</style></author><author><style face="normal" font="default"> Lin,C.H.</style></author><author><style face="normal" font="default"> Tsuang,B.J.</style></author><author><style face="normal" font="default"> Chen,Y.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan</style></auth-address><titles><title><style face="normal" font="default">Adult atopic dermatitis and exposure to air pollutants-a nationwide population-based study</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollutants</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Income</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Particulate matter</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pollutants</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> standards</style></keyword><keyword><style face="normal" font="default"> Taiwan</style></keyword><keyword><style face="normal" font="default"> Transformation</style></keyword><keyword><style face="normal" font="default"> Urbanization</style></keyword><keyword><style face="normal" font="default"> Veterans</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="23" Month="1" Year="2017">2017/1/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: There is a trend toward an increased worldwide prevalence of allergic diseases. It is speculated that industrialization with resultant air pollution plays a role. However, there are sparse epidemiologic data on the relation between air pollution and atopic dermatitis (AD) in adults. OBJECTIVE: To investigate the relation between exposure to air pollutants and adult AD in a cross-sectional study based on data from the National Health Insurance Research Database in Taiwan. METHODS: We identified 1,023 adult patients with AD and 4,092 age- and sex-matched controls without allergic diseases in 2011. Using data from 71 Environmental Protection Agency monitoring stations across Taiwan, levels of exposure to air pollutants were determined by the location of a subject's place of residence. Multivariate logistic regression analysis, adjusted for age, sex, levels of urbanization, and family income, was performed. RESULTS: We found an association between particulate matter &lt;2.5 mum in diameter or the Pollutant Standards Index (the highest sub-index of the concentrations of 5 main air pollutants after transformation) and the development of adult AD. The adjusted odds ratios were 1.05 (95% confidence interval 1.02-1.08) and 1.02 (95% confidence interval 1.01-1.03), respectively. CONCLUSION: These results demonstrated that air pollution, represented by particulate matter &lt;2.5 mum in diameter or the Pollutant Standards Index, was modestly associated with the development of AD in adults</style></abstract><notes><style face="normal" font="default">DA - 20170127IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2016.12.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28126434">PM:28126434</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170127-TangKT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170127-TangKT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170127, Tang KT</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2016.12.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40223</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gharib,A.</style></author><author><style face="normal" font="default"> Khokhar,A.</style></author><author><style face="normal" font="default"> Caperton,C.V.</style></author><author><style face="normal" font="default"> Hamadani,S.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">C249 Medical Sciences I, University of California, Irvine, Irvine, California.</style></auth-address><titles><title><style face="normal" font="default">Desensitization to acetazolamide in a patient with previous antimicrobial sulfonamide allergy</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acetazolamide</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="12" Month="1" Year="2017">2017/1/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170116IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2016.11.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28089475">PM:28089475</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170116-GharibA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170116-GharibA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170116, Gharib A</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2016.11.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40224</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Heffler,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory Medicine and Allergology, Department of Clinical and Experimental Medicine, University of Catania, Via Santa Sofia 78 (Edificio 4, Piano 2), Catania, Italy.</style></auth-address><titles><title><style face="normal" font="default">Exhaled nitric oxide's ability to predict methacholine challenge: A matter of definition</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="236">236-</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergology</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> Methacholine challenge</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170203IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2016.11.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28153084">PM:28153084</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-236.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-236.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170203, Heffler E</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2016.11.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40225</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nickels,A.S.</style></author><author><style face="normal" font="default"> Lim,K.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Pulmonary, and Critical Care, Department of Medicine and Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee.</style></auth-address><titles><title><style face="normal" font="default">Exhaled nitric oxide or FEF25%-75% Balancing diagnostic value with efficacy despite evidentiary uncertainty</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="237" start="236">236-237</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Tennessee</style></keyword><keyword><style face="normal" font="default"> Uncertainty</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170203IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2016.12.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28153083">PM:28153083</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-236-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-236-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170203, Nickels AS</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2016.12.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40226</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ciprandi,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, IR</style></auth-address><titles><title><style face="normal" font="default">Fractional exhaled nitric oxide, methacholine, or forced expiratory flow between 25% and 75%: What's better in the daily clinical practice?</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="235">235-</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Clinical</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170203IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2016.11.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28153082">PM:28153082</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-235.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-235.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170203, Ciprandi G</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2016.11.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40227</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dass,K.</style></author><author><style face="normal" font="default"> Petrusan,A.J.</style></author><author><style face="normal" font="default"> Beaumont,J.</style></author><author><style face="normal" font="default"> Zee,P.</style></author><author><style face="normal" font="default"> Lai,J.S.</style></author><author><style face="normal" font="default"> Fishbein,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Department of Allergy and Immunology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois. Electronic address: kathleen.j.dass@gmail.com</style></auth-address><titles><title><style face="normal" font="default">Assessment of sleep disturbance in children with allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Illinois</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="28" Month="1" Year="2017">2017/1/28</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170201IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2016.12.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28143682">PM:28143682</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170201-DassK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170201-DassK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170201, Dass K</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2016.12.022</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40228</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kohn,G.</style></author><author><style face="normal" font="default"> Oppenheimer,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pulmonary and Allergy Associates, Summit, New Jersey</style></auth-address><titles><title><style face="normal" font="default">Control measures in asthma: one size likely does not fit all</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="124" start="123">123-124</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> New Jersey</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170203IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2016.12.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28153077">PM:28153077</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-123-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-123-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170203, Kohn G</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2016.12.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40229</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chipps,B.E.</style></author><author><style face="normal" font="default"> Corren,J.</style></author><author><style face="normal" font="default"> Israel,E.</style></author><author><style face="normal" font="default"> Katial,R.</style></author><author><style face="normal" font="default"> Lang,D.M.</style></author><author><style face="normal" font="default"> Panettieri,R.A.,Jr.</style></author><author><style face="normal" font="default"> Peters,S.P.</style></author><author><style face="normal" font="default"> Farrar,J.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Capital Allergy &amp; Respiratory Disease Center, Sacramento, California.</style></auth-address><titles><title><style face="normal" font="default">Asthma Yardstick: Practical recommendations for a sustained step-up in asthma therapy for poorly controlled asthma</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="142" start="133">133-142</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Asthma therapy</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">Current asthma guidelines recommend a control-based approach to management that involves assessment of impairment and risk followed by implementation of treatment strategies individualized according to the patient's needs and preferences. The fact that many patients still experience severe symptoms that negatively affect quality of life suggests that asthma control remains an objective to be achieved. Tools are available to help patients (and families) manage the day-to-day and short-term variability in asthma symptoms; however, when and how to implement a sustained step-up in therapy is less clear. The Asthma Yardstick is a comprehensive update on how to conduct a sustained step-up in asthma therapy for the patient with not well-controlled or poorly controlled asthma. Patient profiles and step-up strategies are based on current guidelines, newer data, and the authors' combined clinical experience and are intended to provide a practical and clinically meaningful guide toward the goal of well-controlled asthma for every patient. The development of this tool comes in response to the continued need to proactively address the sustained loss of asthma control at all levels of severity</style></abstract><notes><style face="normal" font="default">DA - 20170203IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - California -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2016.12.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28153079">PM:28153079</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-133-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-133-42.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170203, Chipps BE</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2016.12.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40230</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Eastman,J.J.</style></author><author><style face="normal" font="default"> Kim,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California, San Diego, California.</style></auth-address><titles><title><style face="normal" font="default">A patient with idiopathic angioedema presenting with superior vena cava syndrome and lymphedema</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Lymphedema</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="19" Month="1" Year="2017">2017/1/19</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170123IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2016.12.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28111111">PM:28111111</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170123-EastmanJJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170123-EastmanJJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170123, Eastman JJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2016.12.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40231</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Eginli,A.</style></author><author><style face="normal" font="default"> Shah,K.</style></author><author><style face="normal" font="default"> Watkins,C.</style></author><author><style face="normal" font="default"> Krishnaswamy,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Keck School of Medicine, University of Southern California, Los Angeles, California</style></auth-address><titles><title><style face="normal" font="default">Stevens-Johnson syndrome and toxic epidermal necrolysis</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="147" start="143">143-147</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Los Angeles</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default"> Stevens-Johnson Syndrome</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Toxic epidermal necrolysis</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170203IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2016.11.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28153080">PM:28153080</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-143-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-143-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170203, Eginli A</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2016.11.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40232</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wu,D.</style></author><author><style face="normal" font="default"> Li,L.</style></author><author><style face="normal" font="default"> Zhang,M.</style></author><author><style face="normal" font="default"> Wang,J.</style></author><author><style face="normal" font="default"> Wei,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China</style></auth-address><titles><title><style face="normal" font="default">Two inflammatory phenotypes of nasal polyps and comorbid asthma</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory phenotypes</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="23" Month="1" Year="2017">2017/1/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: Nasal polyps and comorbid asthma (NPCA) is a common united airway disease. However, the inflammatory phenotyes of NPCA are not clear. OBJECTIVE: To identify inflammatory phenotypes of NPCA. METHODS: A total of 106 patients diagnosed with NPCA were recruited from rhinologic clinics. A combined method of biopsies from nasal polyps and fractional exhaled nitric oxide (FeNO) was used to explore inflammatory phenotyes of NPCA. Patients were evaluated with respect to clinical, functional, and inflammatory parameters. Clinical outcomes after medical treatment were also assessed. RESULTS: Two distinct inflammatory phenotypes (eosinophilic [64.15%] and noneosinophilic phenotypes [35.85%]) were identified. Inflammatory patterns of upper and lower airways were consistent in NPCA. Patients with eosinophilic NPCA had a higher nasal polyps recurrence rate than did patients with noneosinophilic NPCA, a more severe asthma phenotype (P &lt; .001), higher exhaled nitric oxide levels (P &lt; .001), higher IgE levels (P &lt; .001), higher Lund-Mackay scores (P &lt; .05), and more blood eosinophilia (P &lt; .001). In addition, eosinophilic NPCA was associated with worse pulmonary function and responded well to an 8-week course of medical treatment based on computed tomographic findings and the ratio of forced expiratory volume in 1 second to forced vital capacity. The total IgE concentration was a marker for eosinophilic NPCA (optimal cutoff, >55.5 kU/L; sensitivity, 86.2%; specificity, 85.4%). CONCLUSION: Patients with NPCA had 2 inflammatory phenotypes with distinct clinical profiles. Total IgE is a marker of eosinophilic NPCA</style></abstract><notes><style face="normal" font="default">DA - 20170127IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2016.12.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28126433">PM:28126433</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170127-WuD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170127-WuD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170127, Wu D</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2016.12.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40233</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Carnes,M.U.</style></author><author><style face="normal" font="default"> Hoppin,J.A.</style></author><author><style face="normal" font="default"> Metwali,N.</style></author><author><style face="normal" font="default"> Wyss,A.B.</style></author><author><style face="normal" font="default"> Hankinson,J.L.</style></author><author><style face="normal" font="default"> O'Connell,E.L.</style></author><author><style face="normal" font="default"> Richards,M.</style></author><author><style face="normal" font="default"> Long,S.</style></author><author><style face="normal" font="default"> Beane Freeman,L.E.</style></author><author><style face="normal" font="default"> Sandler,D.P.</style></author><author><style face="normal" font="default"> Henneberger,P.K.</style></author><author><style face="normal" font="default"> Barker-Cummings,C.</style></author><author><style face="normal" font="default"> Umbach,D.M.</style></author><author><style face="normal" font="default"> Thorne,P.S.</style></author><author><style face="normal" font="default"> London,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Institute of Environmental Health Sciences, 6857, Epidemiology , 111 T.W. Alexander Drive , Durham, North Carolina, United States</style></auth-address><titles><title><style face="normal" font="default">House Dust Endotoxin Levels Are Associated with Adult Asthma in a U.S. Farming Population</style></title><secondary-title><style face="normal" font="default">Ann Am Thorac Soc</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Am Thorac Soc</style></abbr-1></periodical><pages end="331" start="324">324-331</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Adult asthma</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> CD14</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> endotoxin</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> House dust</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> innate immune system</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> nonatopic asthma</style></keyword><keyword><style face="normal" font="default"> North Carolina</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> TLR4</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">RATIONALE: Endotoxin initiates a pro-inflammatory response from the innate immune system. Studies in children suggest endotoxin exposure from house dust may be an important risk factor for asthma, but few studies have been conducted in adult populations. OBJECTIVES: To investigate the association of house dust endotoxin levels with asthma and related phenotypes (wheeze, atopy, and pulmonary function) in a large U.S. farming population. METHODS: Dust was collected from the bedrooms (n=2,485) of participants enrolled in a case-control study of current asthma (927 cases) nested within the Agricultural Health Study. Dust endotoxin was measured by Limulus amebocyte lysate assay. Outcomes were measured by questionnaire, spirometry, and blood draw. We evaluated associations using linear and logistic regression. MEASUREMENTS AND MAIN RESULTS: Endotoxin was significantly associated with current asthma (Odds Ratio (OR)=1.30, 95% confidence interval (CI)=1.14-1.47), and this relationship was modified by early life farm exposure (born on a farm: OR=1.18, 95% CI=1.02-1.37; not born on a farm: OR=1.67, 95% CI=1.26-2.20, Interaction p-value=0.05). Significant positive associations were seen with both atopic and nonatopic asthma. Endotoxin was not related to either atopy or wheeze. Higher endotoxin was related to lower FEV1/FVC in asthma cases only (Interaction p=0.01). For asthma, there was suggestive evidence of a gene by environment interaction for the CD14 variant, rs2569190 (Interaction p=0.16), but not for the TLR4 variants, rs4986790 or rs4986791. CONCLUSIONS: House dust endotoxin was associated with current atopic and nonatopic asthma in a U.S. farming population. The degree of the association with asthma depended on early life farm exposures. Furthermore, endotoxin was associated with lower pulmonary function in asthmatics</style></abstract><notes><style face="normal" font="default">DA - 20161215IS - 2325-6621 (Electronic)IS - 2325-6621 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1513/AnnalsATS.201611-861OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27977294">PM:27977294</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Am Thorac Soc\20161215-CarnesMU.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Am Thorac Soc\20161215-CarnesMU.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161215, Carnes MU</style></custom2><misc3><style face="normal" font="default">10.1513/AnnalsATS.201611-861OC</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40234</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martins,T.B.</style></author><author><style face="normal" font="default"> Bandhauer,M.E.</style></author><author><style face="normal" font="default"> Wilcock,D.M.</style></author><author><style face="normal" font="default"> Hill,H.R.</style></author><author><style face="normal" font="default"> Slev,P.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA</style></auth-address><titles><title><style face="normal" font="default">Specific Immunoglobulin (Ig) G Reference Intervals for Common Food, Insect, and Mold Allergens</style></title><secondary-title><style face="normal" font="default">Ann Clin Lab Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Clin Lab Sci</style></full-title></periodical><pages end="638" start="635">635-638</pages><volume><style face="normal" font="default">46</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> allergen-specific</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergens</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> Igg</style></keyword><keyword><style face="normal" font="default"> Immunoassay</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Interpretation</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> molds</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Specific desensitization</style></keyword><keyword><style face="normal" font="default"> Specific IgG</style></keyword><keyword><style face="normal" font="default"> Tuna</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> Venoms</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: The clinical utility of serum IgG measurement in the diagnosis of allergy and food-induced hypersensitivity has been largely discredited. Recent studies, however, have shown that specific IgG can inhibit IgE mediated allergies, and may play a role in allergen specific desensitization. Accurate reference intervals for IgG specific allergens have not been widely established and are needed for better interpretation of serum antibody concentrations. In this study we established 64 IgG reference intervals for 48 common food allergens, 5 venoms, and 11 molds. DESIGN: Specific IgG concentrations were determined employing an automated fluorescent enzyme immunoassay on serum samples from 130 normal adults (65 males and 65 females), age range 18-69 y, mean 37.3 y. RESULTS: The lower reference interval limit for all allergens tested (n=64) was &lt;2 mcg/mL. The median upper reference interval value for all 64 allergens was 12.9 mcg/mL, with Tuna (f40) having the lowest upper interval limit at 3.8 mcg/mL, and the mold Setomelanomma rostrate (m8) demonstrating the highest upper interval limit at 131 mcg/L. CONCLUSIONS: The considerable variation observed among the upper reference interval limits emphasizes the need for the establishment of allergen specific ranges for IgG. These newly established ranges should be a useful aid for clinicians in the interpretation of laboratory serum IgG results</style></abstract><notes><style face="normal" font="default">DA - 20161220IS - 1550-8080 (Electronic)IS - 0091-7370 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27993877">PM:27993877</url></web-urls><related-urls><url ppv-ref="no">presto - 2 anni</url></related-urls></urls><custom2><style face="normal" font="default">20161220, Martins TB</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40235</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Matok,I.</style></author><author><style face="normal" font="default"> Elizur,A.</style></author><author><style face="normal" font="default"> Perlman,A.</style></author><author><style face="normal" font="default"> Ganor,S.</style></author><author><style face="normal" font="default"> Levine,H.</style></author><author><style face="normal" font="default"> Kozer,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Hebrew University of Jerusalem, Jerusalem, Israel</style></auth-address><titles><title><style face="normal" font="default">Association of Acetaminophen and Ibuprofen Use With Wheezing in Children With Acute Febrile Illness</style></title><secondary-title><style face="normal" font="default">Ann Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Pharmacother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acetaminophen</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Ibuprofen</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="27" Month="10" Year="2016">2016/10/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Many infants and children receive acetaminophen and/or ibuprofen during febrile illness. Previously, some studies have linked acetaminophen and ibuprofen use to wheezing and exacerbation of asthma symptoms in infants and children. OBJECTIVE: To assess whether acetaminophen or ibuprofen use are associated with wheezing in children presenting to the emergency department (ED) with febrile illness. METHODS: This was a cross-sectional study of children who presented with fever to the pediatric ED between 2009 and 2013. The data were collected from questionnaires and from the children's medical files. Patients with wheezing in the ED were compared with nonwheezing patients. Associations between medication use and wheezing were assessed using univariate and multivariate analyses. The multivariate analysis adjusted for potential confounding variables (ie, age, atopic dermatitis, allergies, smoking, antibiotics use, etc) via propensity scores. RESULTS: During the study period, 534 children admitted to the ED met our inclusion criteria, of whom 347 (65%) were included in the study. The use of acetaminophen was similar in children diagnosed with wheezing compared with those without wheezing (n = 39, 81.3%, vs n = 229, 82.7%, respectively). Ibuprofen use was significantly lower in children diagnosed with wheezing (n = 22, 52.4%, vs n = 168, 69.4%, respectively). In multivariate analysis, acetaminophen was not associated with a higher rate of wheezing during acute febrile illness (adjusted odds ratio [OR] = 0.76, 95% CI = 0.24- 2.39), whereas ibuprofen was associated with a lower risk of wheezing (adjusted OR = 0.36, 95% CI = 0.13-0.96). CONCLUSIONS: Our study suggests that acetaminophen and ibuprofen are not associated with increased risk for wheezing during acute febrile illness</style></abstract><notes><style face="normal" font="default">DA - 20161029IS - 1542-6270 (Electronic)IS - 1060-0280 (Linking)LA - ENGPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">10.1177/1060028016678006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27794128">PM:27794128</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Pharmacother\20161029-MatokI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Pharmacother\20161029-MatokI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161029, Matok I</style></custom2><misc3><style face="normal" font="default">10.1177/1060028016678006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40236</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stathopoulos,I.P.</style></author><author><style face="normal" font="default"> Andrianopoulos,N.</style></author><author><style face="normal" font="default"> Paschaloglou,D.</style></author><author><style face="normal" font="default"> Tsarouchas,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Orthopaedic Department, Athens Medical Center, 56, Kifisias ave and Delfon, 15125, Amaroussio, Athens, Greece.</style></auth-address><titles><title><style face="normal" font="default">Revision total knee arthroplasty due to bone cement and metal hypersensitivity</style></title><secondary-title><style face="normal" font="default">Arch Orthop Trauma Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Arch Orthop Trauma Surg</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Arthroplasty</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Knee</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> metal hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Plastics</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Symptomatology</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Taste</style></keyword><keyword><style face="normal" font="default"> Temperature</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="1" Year="2017">2017/1/9</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Hypersensitivity to implants is a rare complication of total knee arthroplasty (TKA). Metal and, less frequently, bone cement can produce allergic symptomatology that if unresponsive to conservative treatment could lead to revision. MATERIALS AND METHODS: We present the case of a patient with generalized pruritus and metal taste starting during the first postoperative month after TKA. Dermal allergy exams revealed that the patient had hypersensitivity to nickel sulphate and cobalt chloride and bone cement. Conservative treatment with antihistamine medication and corticosteroids failed to control the symptoms. The patient underwent revision TKA with a hypoallergic prosthesis 8 months after the primary procedure. RESULTS: Full disappearance of the symptoms occurred 3 months after revision. The latest follow-up evaluation (3 years post-revision) was unremarkable. CONCLUSIONS: In our opinion, an exhaustive medical history should be obtained from every candidate for total joint replacement and in cases of prior severe allergic reactions to metals, plastics or glues, patch testing of the components of the future prosthesis should be done. When an already implanted prosthesis causes symptoms like pain, edema, pruritus, erythema, limited range of motion and increase in joint's temperature, the possibility of allergy to metals and/or bone cement (in case of cemented prosthesis) should be checked after the exclusion of other reasons like infection. If symptoms cannot be controlled by conservative measures, revision should be decided and carried out with hypoallergic prosthesis</style></abstract><notes><style face="normal" font="default">DA - 20170110IS - 1434-3916 (Electronic)IS - 0936-8051 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="default">10.1007/s00402-016-2614-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28070650">PM:28070650</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Arch Orthop Trauma Surg\20170110-StathopoulosIP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Arch Orthop Trauma Surg\20170110-StathopoulosIP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170110, Stathopoulos IP</style></custom2><misc3><style face="normal" font="default">10.1007/s00402-016-2614-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40237</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ezendam,J.</style></author><author><style face="normal" font="default"> Braakhuis,H.M.</style></author><author><style face="normal" font="default"> Vandebriel,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Innovative Testing Strategies, Center for Health Protection, National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720 BA, Bilthoven, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default">State of the art in non-animal approaches for skin sensitization testing: from individual test methods towards testing strategies</style></title><secondary-title><style face="normal" font="default">Arch Toxicol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Arch Toxicol</style></abbr-1></periodical><pages end="2883" start="2861">2861-2883</pages><volume><style face="normal" font="default">90</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Test method</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">The hazard assessment of skin sensitizers relies mainly on animal testing, but much progress is made in the development, validation and regulatory acceptance and implementation of non-animal predictive approaches. In this review, we provide an update on the available computational tools and animal-free test methods for the prediction of skin sensitization hazard. These individual test methods address mostly one mechanistic step of the process of skin sensitization induction. The adverse outcome pathway (AOP) for skin sensitization describes the key events (KEs) that lead to skin sensitization. In our review, we have clustered the available test methods according to the KE they inform: the molecular initiating event (MIE/KE1)-protein binding, KE2-keratinocyte activation, KE3-dendritic cell activation and KE4-T cell activation and proliferation. In recent years, most progress has been made in the development and validation of in vitro assays that address KE2 and KE3. No standardized in vitro assays for T cell activation are available; thus, KE4 cannot be measured in vitro. Three non-animal test methods, addressing either the MIE, KE2 or KE3, are accepted as OECD test guidelines, and this has accelerated the development of integrated or defined approaches for testing and assessment (e.g. testing strategies). The majority of these approaches are mechanism-based, since they combine results from multiple test methods and/or computational tools that address different KEs of the AOP to estimate skin sensitization potential and sometimes potency. Other approaches are based on statistical tools. Until now, eleven different testing strategies have been published, the majority using the same individual information sources. Our review shows that some of the defined approaches to testing and assessment are able to accurately predict skin sensitization hazard, sometimes even more accurate than the currently used animal test. A few defined approaches are developed to provide an estimate of the potency sub-category of a skin sensitizer as well, but these approaches need further independent evaluation with a new dataset of chemicals. To conclude, this update shows that the field of non-animal approaches for skin sensitization has evolved greatly in recent years and that it is possible to predict skin sensitization hazard without animal testing</style></abstract><notes><style face="normal" font="default">DA - 20160917IS - 1432-0738 (Electronic)IS - 0340-5761 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1007/s00204-016-1842-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27629427">PM:27629427</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Arch Toxicol\2016-90-2861-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Arch Toxicol\2016-90-2861-83.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160917, Ezendam J</style></custom2><misc3><style face="normal" font="default">10.1007/s00204-016-1842-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40238</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kocluk,Y.</style></author><author><style face="normal" font="default"> Yalniz-Akkaya,Z.</style></author><author><style face="normal" font="default"> Burcu,A.</style></author><author><style face="normal" font="default"> Ornek,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Ophthalmolgy Clinic, Ministry of Health Ankara Training and Research Hospital, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="default">Atopic keratoconjunctivitis: long-term results of medical treatment and penetrating keratoplasty</style></title><secondary-title><style face="normal" font="default">Arq Bras Oftalmol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arq Bras Oftalmol</style></full-title></periodical><pages end="379" start="376">376-379</pages><volume><style face="normal" font="default">79</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AKC</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Distance</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Keratoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Visual Acuity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">Purpose:: To evaluate the long-term outcomes of medically or surgically treated patients with atopic keratoconjunctivitis (AKC). Methods:: Charts of 16 patients with AKC (32 eyes) observed between 1996 and 2013 were reviewed retrospectively. Outcome measures included demographic features, follow-up duration, and biomicroscopic findings at the first and most recent visits. The corrected distance visual acuity (CDVA; in decimal units) was evaluated at the initial visit and the 1-, 6-, and 12-month follow-up visits. Results:: In the medically treated group (25 eyes of 15 patients), the median follow-up duration was 3 (range, 1-9) years, and the median CDVA values were 0.01 (0.001-1.0) at the first visit and 0.01 (0.001-0.8) at the most recent visit (p=0.916). In the penetrating keratoplasty (PK) group (7 eyes of 6 patients), the median follow-up duration was 7 years (range, 1-11), and the median CDVA increased from 0.01 (0.001-0.01) to 0.2 (0.001-0.7) postoperatively (p=0.043). Conclusion:: Whereas most AKC patients maintained a useful CDVA with medical treatment, PK may be required in some cases. Despite the frequent occurrence of complications, PK can significantly improve the CDVA</style></abstract><notes><style face="normal" font="default">DA - 20170111IS - 1678-2925 (Electronic)IS - 0004-2749 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.5935/0004-2749.20160107</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28076564">PM:28076564</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Arq Bras Oftalmol\2016-79-376-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Arq Bras Oftalmol\2016-79-376-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170111, Kocluk Y</style></custom2><misc3><style face="normal" font="default">10.5935/0004-2749.20160107</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40239</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Toti,G.</style></author><author><style face="normal" font="default"> Vilalta,R.</style></author><author><style face="normal" font="default"> Lindner,P.</style></author><author><style face="normal" font="default"> Lefer,B.</style></author><author><style face="normal" font="default"> Macias,C.</style></author><author><style face="normal" font="default"> Price,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Computer Science, University of Houston, Philip Guthrie Hoffman Hall, 3551 Cullen Blvd., Room 501, Houston, TX 77204-3010, USA.</style></auth-address><titles><title><style face="normal" font="default">Analysis of correlation between pediatric asthma exacerbation and exposure to pollutant mixtures with association rule mining</style></title><secondary-title><style face="normal" font="default">Artif Intell Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Artif Intell Med</style></abbr-1></periodical><pages end="52" start="44">44-52</pages><volume><style face="normal" font="default">74</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollutants</style></keyword><keyword><style face="normal" font="default"> Air quality</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Computer</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mining</style></keyword><keyword><style face="normal" font="default"> NO2</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Ozone</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> PM</style></keyword><keyword><style face="normal" font="default"> pollutants</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Traditional studies on effects of outdoor pollution on asthma have been criticized for questionable statistical validity and inefficacy in exploring the effects of multiple air pollutants, alone and in combination. Association rule mining (ARM), a method easily interpretable and suitable for the analysis of the effects of multiple exposures, could be of use, but the traditional interest metrics of support and confidence need to be substituted with metrics that focus on risk variations caused by different exposures. METHODS: We present an ARM-based methodology that produces rules associated with relevant odds ratios and limits the number of final rules even at very low support levels (0.5%), thanks to post-pruning criteria that limit rule redundancy and control for statistical significance. The methodology has been applied to a case-crossover study to explore the effects of multiple air pollutants on risk of asthma in pediatric subjects. RESULTS: We identified 27 rules with interesting odds ratio among more than 10,000 having the required support. The only rule including only one chemical is exposure to ozone on the previous day of the reported asthma attack (OR=1.14). 26 combinatory rules highlight the limitations of air quality policies based on single pollutant thresholds and suggest that exposure to mixtures of chemicals is more harmful, with odds ratio as high as 1.54 (associated with the combination day0 SO2, day0 NO, day0 NO2, day1 PM). CONCLUSIONS: The proposed method can be used to analyze risk variations caused by single and multiple exposures. The method is reliable and requires fewer assumptions on the data than parametric approaches. Rules including more than one pollutant highlight interactions that deserve further investigation, while helping to limit the search field</style></abstract><notes><style face="normal" font="default">DA - 20161214IS - 1873-2860 (Electronic)IS - 0933-3657 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.artmed.2016.11.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27964802">PM:27964802</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Artif Intell Med\2016-74-44-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Artif Intell Med\2016-74-44-52.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161214, Toti G</style></custom2><misc3><style face="normal" font="default">10.1016/j.artmed.2016.11.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40240</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shin,B.</style></author><author><style face="normal" font="default"> Kwon,H.S.</style></author><author><style face="normal" font="default"> Park,S.Y.</style></author><author><style face="normal" font="default"> Kim,T.B.</style></author><author><style face="normal" font="default"> Moon,H.B.</style></author><author><style face="normal" font="default"> Cho,Y.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Clinical Immunology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">The transition of sputum inflammatory cell profiles is variable in stable asthma patients</style></title><secondary-title><style face="normal" font="default">Asia Pac Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asia Pac Allergy</style></abbr-1></periodical><pages end="28" start="19">19-28</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> induced sputum</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> pulmonary function test</style></keyword><keyword><style face="normal" font="default"> Pulmonary function tests</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> sputum eosinophil</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: The sputum inflammatory cell profile is an important indicator for classifying asthma phenotypes. OBJECTIVE: To investigate if sputum inflammatory cell profile remains stable and there are different characteristics between groups that show different profile over time in stable asthmatic patients. METHODS: A total of 149 asthmatic patients, who were clinically stable at the time of sputum examination and had undergone sputum analysis twice, were subjected to a detailed review. Eosinophilic inflammation was diagnosed when the proportion of the sputum eosinophils was >3%. We divided the patients into 4 groups according to the transition patterns of their sputum profiles: group 1, persistent eosinophilia; group 2, eosinophilic to noneosinophilic; group 3, noneosinophilic to eosinophilic; and group 4, persistent noneosinophilia. The results of the pulmonary function tests and other clinical parameters were compared between these 4 groups. RESULTS: Thirty-four of the initially eosinophilic asthmatic patients (39.5%; 34 of 86 patients) demonstrated noneosinophilic airway inflammation at their second sputum examination, and 24 of the initially noneosinophilic patients (38.1%; 24 of 63 patients) demonstrated eosinophilic airway inflammation at follow-up. Various clinical parameters, except the blood eosinophil count, demonstrated no significant differences between the eosinophilic and noneosinophilic asthmatic patients or among the 4 groups. CONCLUSION: A substantial proportion of asthmatic patients who demonstrate a certain sputum inflammatory cell profile at the initial examination demonstrated profile transition in clinically stable settings over time. The clinical significance of using induced sputum analysis to phenotype stable asthmatic patients requires further evaluation</style></abstract><notes><style face="normal" font="default">DA - 20170203IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.5415/apallergy.2017.7.1.19</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28154802">PM:28154802</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-19-28.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-19-28.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170203, Shin B</style></custom2><misc3><style face="normal" font="default">10.5415/apallergy.2017.7.1.19</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40241</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Morita,Y.</style></author><author><style face="normal" font="default"> Campos,A.E.</style></author><author><style face="normal" font="default"> Suzuki,S.</style></author><author><style face="normal" font="default"> Sato,Y.</style></author><author><style face="normal" font="default"> Hoshioka,A.</style></author><author><style face="normal" font="default"> Abe,H.</style></author><author><style face="normal" font="default"> Saito,K.</style></author><author><style face="normal" font="default"> Tsubaki,T.</style></author><author><style face="normal" font="default"> Haraki,M.</style></author><author><style face="normal" font="default"> Sawa,A.</style></author><author><style face="normal" font="default"> Nakayama,Y.</style></author><author><style face="normal" font="default"> Kojima,H.</style></author><author><style face="normal" font="default"> Shigeta,M.</style></author><author><style face="normal" font="default"> Yamaide,F.</style></author><author><style face="normal" font="default"> Kohno,Y.</style></author><author><style face="normal" font="default"> Shimojo,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba 263-8522, Japan</style></auth-address><titles><title><style face="normal" font="default">Pranlukast reduces asthma exacerbations during autumn especially in 1- to 5-year-old boys</style></title><secondary-title><style face="normal" font="default">Asia Pac Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asia Pac Allergy</style></abbr-1></periodical><pages end="18" start="10">10-18</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Asthma therapy</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cold</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Leukotriene receptor antagonists have been used to prevent virus-induced asthma exacerbations in autumn. Its efficacy, however, might differ with age and sex. OBJECTIVE: This study aimed to investigate whether pranlukast added to usual asthma therapy in Japanese children during autumn, season associated with the peak of asthma, reduces asthma exacerbations. It was also evaluated the effect of age and sex on pranlukast's efficacy. METHODS: A total of 121 asthmatic children aged 1 to 14 years were randomly assigned to receive regular pranlukast or not according to sex, and were divided in 2 age groups, 1-5 years and 6-14 years. The primary outcome was total asthma score calculated during 8 weeks by using a sticker calendar related to the days in which a child experienced a worsening of asthma symptoms. This open study lasted 60 days from September 15 to November 14, 2007. RESULTS: Significant differences in pranlukast efficacy were observed between sex and age groups. Boys aged 1 to 5 years had the lower total asthma score at 8 weeks (p = 0.002), and experienced fewer cold episodes (p = 0.007). There were no significant differences between pranlukast and control group in total asthma score at 8 weeks (p = 0.35), and in the days in which a child experienced a worsening of asthma symptoms (p = 0.67). CONCLUSION: There was a substantial benefit of adding pranlukast to usual therapy in asthmatic children, especially in boys aged 1 to 5 years, during autumn season</style></abstract><notes><style face="normal" font="default">DA - 20170203IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.5415/apallergy.2017.7.1.10</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28154801">PM:28154801</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-10-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-10-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170203, Morita Y</style></custom2><misc3><style face="normal" font="default">10.5415/apallergy.2017.7.1.10</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40242</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Korematsu,S.</style></author><author><style face="normal" font="default"> Fujitaka,M.</style></author><author><style face="normal" font="default"> Ogata,M.</style></author><author><style face="normal" font="default"> Zaitsu,M.</style></author><author><style face="normal" font="default"> Motomura,C.</style></author><author><style face="normal" font="default"> Kuzume,K.</style></author><author><style face="normal" font="default"> Toku,Y.</style></author><author><style face="normal" font="default"> Ikeda,M.</style></author><author><style face="normal" font="default"> Odajima,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">West Japan Research Society Pediatric Clinical Allergy, Fukuoka 811-1394, Japan</style></auth-address><titles><title><style face="normal" font="default">Administration of the adrenaline auto-injector at the nursery/kindergarten/school in Western Japan</style></title><secondary-title><style face="normal" font="default">Asia Pac Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asia Pac Allergy</style></abbr-1></periodical><pages end="41" start="37">37-41</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adrenaline</style></keyword><keyword><style face="normal" font="default"> Adrenaline auto-injector</style></keyword><keyword><style face="normal" font="default"> Adrenaline autoinjector</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: In view of the increasing prevalence of food allergies, there has been an associated increase in frequency of situations requiring an emergency response for anaphylaxis at the home, childcare facilities and educational institutions. OBJECTIVE: To clarify the situation of adrenaline auto-injector administration in nursery/kindergarten/school, we carried out a questionnaire survey on pediatric physicians in Western Japan. METHODS: In 2015, self-reported questionnaires were mailed to 421 physicians who are members of the West Japan Research Society Pediatric Clinical Allergy and Shikoku Research Society Pediatric Clinical Allergy. RESULTS: The response rate was 44% (185 physicians) where 160 physicians had a prescription registration for the adrenaline auto-injector. In the past year, 1,330 patients were prescribed the adrenaline auto-injector where 83 patients (6% of the prescribed patients) actually administered the adrenaline auto-injector, of which 14 patients (17% of the administered patients) self-administered the adrenaline auto-injector. "Guardians" at the nursery/kindergarten and elementary school were found to have administered the adrenaline auto-injector the most. Among 117 adrenaline auto-injector prescription-registered physicians, 79% had experienced nonadministration of adrenaline auto-injector at nursery/kindergarten/school when anaphylaxis has occurred. The most frequent reason cited for not administering the adrenaline auto-injector was "hesitation about the timing of administration." CONCLUSION: If the adrenaline auto-injector was administered after the guardian arrived at the nursery/kindergarten/school, it may lead to delayed treatment of anaphylaxis in which symptoms develop in minutes. Education and cooperation among physicians and nursery/kindergarten/school staff will reduce the number of children suffering unfortunate outcomes due to anaphylaxis</style></abstract><notes><style face="normal" font="default">DA - 20170203IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.5415/apallergy.2017.7.1.37</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28154804">PM:28154804</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-37-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-37-41.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170203, Korematsu S</style></custom2><misc3><style face="normal" font="default">10.5415/apallergy.2017.7.1.37</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40243</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dai,J.</style></author><author><style face="normal" font="default"> Lyu,S.</style></author><author><style face="normal" font="default"> Ge,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Cardiology, Capital Medical University Affiliated to Beijing Anzhen Hospital, Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing 100029, China</style></auth-address><titles><title><style face="normal" font="default">Hypersensitivity to ticagrelor and low response to clopidogrel: a case report</style></title><secondary-title><style face="normal" font="default">Asia Pac Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asia Pac Allergy</style></abbr-1></periodical><pages end="53" start="51">51-53</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acute Coronary Syndrome</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> clopidogrel</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Thrombosis</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Warfarin</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">Ticagrelor is widely used to treat acute coronary syndrome. Hypersensitivity reaction of ticagrelor is rarely recognized. A low response to clopidogrel, which occurs in up to 23% of patients, is an independent risk factor for stent thrombosis. Management of patients with a low response to clopidogrel and ticagrelor hypersensitivity who are undergoing antithrombotic therapy remains to be a challenge. Herein, we report a patient with low response to clopidogrel and ticagrelor hypersensitivity, who was successfully managed using aspirin and warfarin</style></abstract><notes><style face="normal" font="default">DA - 20170203IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.5415/apallergy.2017.7.1.51</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28154807">PM:28154807</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-51-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-51-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170203, Dai J</style></custom2><misc3><style face="normal" font="default">10.5415/apallergy.2017.7.1.51</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40244</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Philpott,H.</style></author><author><style face="normal" font="default"> Kweh,B.</style></author><author><style face="normal" font="default"> Thien,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Gastroenterology, Eastern Health Clinical School, Monash University, Melbourne, Victoria 3128, Australia</style></auth-address><titles><title><style face="normal" font="default">Eosinophilic esophagitis: current understanding and evolving concepts</style></title><secondary-title><style face="normal" font="default">Asia Pac Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asia Pac Allergy</style></abbr-1></periodical><pages end="9" start="3">3-9</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy test</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Elimination</style></keyword><keyword><style face="normal" font="default"> Elimination diet</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Esophagitis</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> food challenge</style></keyword><keyword><style face="normal" font="default"> Gastroenterology</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pH</style></keyword><keyword><style face="normal" font="default"> proton pump inhibitor</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Victoria</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">Eosinophilic esophagitis (EoE) is now considered to represent a form of food allergy and this is demonstrated by a response to elimination diet in many patients. A critical additional factor may be an inherent impairment in epithelial barrier integrity, possibly worsened by reflux of gastric contents and improved with proton pump inhibitor (PPI) use. Key clinic challenges are posed by the absence of reliable allergy tests to guide elimination diet, and the subsequent need for invasive endoscopic assessment following empirical food challenge, meaning that corticosteroids will remain the mainstay of therapy for many. From a research standpoint, determining if impairments in barrier integrity are innate, and how PPIs address this deficit (which may be pH independent) are important questions that when answered may allow future therapeutic advancement</style></abstract><notes><style face="normal" font="default">DA - 20170203IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="default">10.5415/apallergy.2017.7.1.3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28154800">PM:28154800</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-3-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-3-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170203, Philpott H</style></custom2><misc3><style face="normal" font="default">10.5415/apallergy.2017.7.1.3</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40245</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Braido,F.</style></author><author><style face="normal" font="default"> Scichilone,N.</style></author><author><style face="normal" font="default"> Lavorini,F.</style></author><author><style face="normal" font="default"> Usmani,O.S.</style></author><author><style face="normal" font="default"> Dubuske,L.</style></author><author><style face="normal" font="default"> Boulet,L.P.</style></author><author><style face="normal" font="default"> Mosges,R.</style></author><author><style face="normal" font="default"> Nunes,C.</style></author><author><style face="normal" font="default"> Sanchez-Borges,M.</style></author><author><style face="normal" font="default"> Ansotegui,I.J.</style></author><author><style face="normal" font="default"> Ebisawa,M.</style></author><author><style face="normal" font="default"> Levi-Schaffer,F.</style></author><author><style face="normal" font="default"> Rosenwasser,L.J.</style></author><author><style face="normal" font="default"> Bousquet,J.</style></author><author><style face="normal" font="default"> Zuberbier,T.</style></author><author><style face="normal" font="default"> Canonica,G.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy and Respiratory Diseases Department DIMI, University of Genoa, IRCCS AOU San Martino-IST, Genoa, Italy</style></auth-address><titles><title><style face="normal" font="default">Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN)</style></title><secondary-title><style face="normal" font="default">Asthma Res Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asthma Res Pract</style></abbr-1></periodical><pages end="" start="12">12-</pages><volume><style face="normal" font="default">2</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">airflow</style></keyword><keyword><style face="normal" font="default"> airflow obstruction</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Airway dysfunction</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergic Rhinitis and its Impact on Asthma</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> ARIA</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Formulation</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Respiratory diseases</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> small airways</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Evidence that enables us to identify, assess, and access the small airways in asthma and chronic obstructive pulmonary disease (COPD) has led INTERASMA (Global Asthma Association) and WAO to take a position on the role of the small airways in these diseases. Starting from an extensive literature review, both organizations developed, discussed, and approved the manifesto, which was subsequently approved and endorsed by the chairs of ARIA and GA2LEN. The manifesto describes the evidence gathered to date and defines and proposes issues on small airway involvement and management in asthma and COPD with the aim of challenging assumptions, fostering commitment, and bringing about change. The small airways (defined as those with an internal diameter &lt;2 mm) are involved in the pathogenesis of asthma and COPD and are the major determinant of airflow obstruction in these diseases. Various tests are available for the assessment of the small airways, and their results must be integrated to confirm a diagnosis of small airway dysfunction. In asthma and COPD, the small airways play a key role in attempts to achieve disease control and better outcomes. Small-particle inhaled formulations (defined as those that, owing to their size [usually &lt;2 mum], ensure more extensive deposition in the lung periphery than large molecules) have proved beneficial in patients with asthma and COPD, especially those in whom small airway involvement is predominant. Functional and biological tools capable of accurately assessing the lung periphery and more intensive use of currently available tools are necessary. In patients with suspected COPD or asthma, small airway involvement must be assessed using currently available tools. In patients with subotpimal disease control and/or functional or biological signs of disease activity, the role of small airway involvement should be assessed and treatment tailored. Therefore, the choice between large- and small-particle inhaled formulations must reflect the physician's considerations of disease features, phenotype, and response to previous therapy. This article is being co-published in Asthma Research and Practice and the World Allergy Organization Journal</style></abstract><notes><style face="normal" font="default">DA - 20161214IS - 2054-7064 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - United KIngdom -CO - United States -CO - Spain -CO - Canada -CO - Germany -CO - Portugal -CO - Japan -CO - Israel -CO - France -</style></notes><work-type><style face="normal" font="default">10.1186/s40733-016-0027-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27965780">PM:27965780</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Res Pract\2016-2-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Res Pract\2016-2-12.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161214, Braido F</style></custom2><misc3><style face="normal" font="default">10.1186/s40733-016-0027-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40246</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nunes,C.</style></author><author><style face="normal" font="default"> Pereira,A.M.</style></author><author><style face="normal" font="default"> Morais-Almeida,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Algarve Immunoallergy Center, Portimao, Portugal</style></auth-address><titles><title><style face="normal" font="default">Asthma costs and social impact</style></title><secondary-title><style face="normal" font="default">Asthma Res Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asthma Res Pract</style></abbr-1></periodical><pages end="" start="1">1-</pages><volume><style face="normal" font="default">3</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Characterization</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Lifestyle</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">In recent decades, both asthma prevalence and incidence have been increasing worldwide, not only due to the genetic background, but mainly because of the effect of a wide number of environmental and lifestyle risk factors. In many countries noncommunicable diseases, like asthma, are not yet considered a healthcare priority. This review will analyze and discuss disparities in asthma management in several countries and regions, such as access to healthcare human resources and medications, due to limited financial capacity to develop strategies to control and prevent this chronic disease. This review tries to explore the social and economic burden of asthma impact on society. Although asthma is generally accepted as a costly illness, the total costs to society (direct, indirect and intangible asthma costs) are difficult to estimate, mainly due to different disease definitions and characterizations but also to the use of different methodologies to assess the asthma socio-economic impact in different societies. The asthma costs are very variables from country to country, however we can estimate that a mean cost per patient per year, including all asthmatics (intermittent, mild, moderate and severe asthma) in Europe is $USD 1,900, which seems lower than USA, estimated mean $USD 3,100</style></abstract><notes><style face="normal" font="default">DA - 20170112IS - 2054-7064 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.1186/s40733-016-0029-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28078100">PM:28078100</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Res Pract\2016-2-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Res Pract\2016-2-1.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170112, Nunes C</style></custom2><misc3><style face="normal" font="default">10.1186/s40733-016-0029-3</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40247</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Greenblatt,R.</style></author><author><style face="normal" font="default"> Mansour,O.</style></author><author><style face="normal" font="default"> Zhao,E.</style></author><author><style face="normal" font="default"> Ross,M.</style></author><author><style face="normal" font="default"> Himes,B.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">0000 0004 1936 8972grid.25879.31Department of Biostatistics and Epidemiology, University of Pennsylvania, 219 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104 USA</style></auth-address><titles><title><style face="normal" font="default">Gender-specific determinants of asthma among U.S. adults</style></title><secondary-title><style face="normal" font="default">Asthma Res Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asthma Res Pract</style></abbr-1></periodical><pages end="" start="2">2-</pages><volume><style face="normal" font="default">3</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma risk</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Income</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> National Health and Nutrition Examination Survey</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> overweight</style></keyword><keyword><style face="normal" font="default"> Pennsylvania</style></keyword><keyword><style face="normal" font="default"> Philadelphia</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> smokers</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> socioeconomic status</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma, a chronic respiratory disease affecting over 18.7 million American adults, has marked disparities by gender, race/ethnicity and socioeconomic status. Our goal was to identify gender-specific demographic and socioeconomic determinants of asthma prevalence among U.S. adults using data from the Behavioral Risk Factors Surveillance System (BRFSS) and the National Health and Nutrition Examination Survey (NHANES). METHODS: Gender-specific regression analyses were performed to model the relationship between asthma prevalence with age, race/ethnicity, income, education level, smoking status, and body mass index (BMI), while taking into account the study designs. RESULTS: Based on BRFSS data from 1,003,894 respondents, weighted asthma prevalence was 6.2% in males and 10.6% in females. Asthma prevalence among grade 2 obese and grade 3 obese vs. not overweight or obese women was 2.5 and 3.5 times higher, respectively, while that in men was 1.7 and 2.4 times higher; asthma prevalence among current vs. never smoker women was 1.4 times higher, while that in men was 1.1 times higher. Similar results were obtained with NHANES data from 13,364 respondents: asthma prevalence among grade 2 obese and grade 3 obese vs. not overweight or obese respondents was 2.0 and 3.3 times higher for women, though there was no significant difference for men; asthma prevalence among current vs. never smokers was 1.8 times higher for women and not significantly different in men. Asthma prevalence by race/ethnicity and income levels did not differ considerably between men and women. CONCLUSIONS: Our results underscore the importance of obesity and smoking as modifiable asthma risk factors that most strongly affect women</style></abstract><notes><style face="normal" font="default">DA - 20170131IS - 2054-7064 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1186/s40733-017-0030-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28138394">PM:28138394</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Res Pract\2016-2-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Res Pract\2016-2-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170131, Greenblatt R</style></custom2><misc3><style face="normal" font="default">10.1186/s40733-017-0030-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40248</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kawahara,T.</style></author><author><style face="normal" font="default"> Tsutsui,K.</style></author><author><style face="normal" font="default"> Nakanishi,E.</style></author><author><style face="normal" font="default"> Inoue,T.</style></author><author><style face="normal" font="default"> Hamauzu,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Sciences of Functional Foods, Graduate School of Agriculture, Shinshu University, 8304 Minamiminowa, Kamiina, Nagano, 399-4598, Japan.</style></auth-address><titles><title><style face="normal" font="default">Effect of the topical application of an ethanol extract of quince seeds on the development of atopic dermatitis-like symptoms in NC/Nga mice</style></title><secondary-title><style face="normal" font="default">BMC Complement Altern Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Complement Altern Med</style></abbr-1></periodical><pages end="" start="80">80-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Agriculture</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cell Line</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Ethanol</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> House dust</style></keyword><keyword><style face="normal" font="default"> house dust mite</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Keratinocytes</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Seeds</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> TARC</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="31" Month="1" Year="2017">2017/1/31</year></dates><abstract><style face="normal" font="default">BACKGROUND: Quince (Cydonia oblonga Miller) is a deciduous shrub belonging to the Rosaceae family. Quince seed extract has long been used as a cosmetic ingredient for its moisturizing effect. However, little is known about whether quince seed extract has therapeutic effects on keratinocyte-associated skin inflammation. METHODS: In the present study, we investigated the effect of the topical application of ethanol extract of quince seeds (QSEtE) on atopic dermatitis (AD) symptoms in NC/Nga mice. The direct effect of QSEtE on keratinocytes was evaluated using the human keratinocyte cell line HaCaT. RESULTS: The preliminary application of QSEtE markedly reduced house dust mite allergen-induced skin lesions. The expression of thymus- and activation-regulated chemokine (TARC) in dorsal skin was downregulated. QSEtE directly suppressed the expression and production of TARC in HaCaT cells. CONCLUSIONS: The results suggest that the topical application of QSEtE is effective in preventing the onset of and ameliorating the atopic symptoms of keratinocyte-associated skin inflammation by suppressing TARC production in keratinocytes</style></abstract><notes><style face="normal" font="default">DA - 20170131IS - 1472-6882 (Electronic)IS - 1472-6882 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1186/s12906-017-1606-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28137259">PM:28137259</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Complement Altern Med\2017-17-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Complement Altern Med\2017-17-80.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170131, Kawahara T</style></custom2><misc3><style face="normal" font="default">10.1186/s12906-017-1606-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40249</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Millares,L.</style></author><author><style face="normal" font="default"> Bermudo,G.</style></author><author><style face="normal" font="default"> Perez-Brocal,V.</style></author><author><style face="normal" font="default"> Domingo,C.</style></author><author><style face="normal" font="default"> Garcia-Nunez,M.</style></author><author><style face="normal" font="default"> Pomares,X.</style></author><author><style face="normal" font="default"> Moya,A.</style></author><author><style face="normal" font="default"> Monso,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Fundacio Parc Tauli, Parc Tauli 1, Edificio Santa Fe, planta baja, 08208, Sabadell, Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default">The respiratory microbiome in bronchial mucosa and secretions from severe IgE-mediated asthma patients</style></title><secondary-title><style face="normal" font="default">BMC Microbiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Microbiol</style></abbr-1></periodical><pages end="" start="20">20-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic asthma</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Amplification</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Lung Diseases</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Sequence</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Streptococcus</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="1" Year="2017">2017/1/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: The bronchial microbiome in chronic lung diseases presents an abnormal pattern, but its microbial composition and regional differences in severe asthma have not been sufficiently addressed. The aim of the study was to describe the bacterial community in bronchial mucosa and secretions of patients with severe chronic asthma chronically treated with corticosteroids in addition to usual care according to Global Initiative for Asthma. Bacterial community composition was obtained by 16S rRNA gene amplification and sequencing, and functional capabilities through PICRUSt. RESULTS: Thirteen patients with severe asthma were included and provided 11 bronchial biopsies (BB) and 12 bronchial aspirates (BA) suitable for sequence analyses. Bacteroidetes, Firmicutes, Proteobacteria and Actinobacteria showed relative abundances (RAs) over 5% in BB, a cutoff that was reached by Streptococcus and Prevotella at genus level. Legionella genus attained a median RA of 2.7 (interquartile range 1.1-4.7) in BB samples. In BA a higher RA of Fusobacteria was found, when compared with BB [8.7 (5.9-11.4) vs 4.2 (0.8-7.5), p = 0.037], while the RA of Proteobacteria was lower in BA [4.3 (3.7-6.5) vs 17.1 (11.2-33.4), p = 0.005]. RA of the Legionella genus was also significantly lower in BA [0.004 (0.001-0.02) vs. 2.7 (1.1-4.7), p = 0.005]. Beta-diversity analysis confirmed the differences between the microbial communities in BA and BB (R2 = 0.20, p = 0.001, Adonis test), and functional analysis revealed also statistically significant differences between both types of sample on Metabolism, Cellular processes, Human diseases, Organismal systems and Genetic information processing pathways. CONCLUSIONS: The microbiota in the bronchial mucosa of severe asthma has a specific pattern that is not accurately represented in bronchial secretions, which must be considered a different niche of bacteria growth</style></abstract><notes><style face="normal" font="default">DA - 20170120IS - 1471-2180 (Electronic)IS - 1471-2180 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1186/s12866-017-0933-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28103814">PM:28103814</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Microbiol\2017-17-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Microbiol\2017-17-20.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170120, Millares L</style></custom2><misc3><style face="normal" font="default">10.1186/s12866-017-0933-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40250</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wise,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">London</style></auth-address><titles><title><style face="normal" font="default">No asthma is found in third of adults with previous diagnosis</style></title><secondary-title><style face="normal" font="default">BMJ</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ</style></abbr-1></periodical><pages end="" start="j282">j282-</pages><volume><style face="normal" font="default">356</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170119IS - 1756-1833 (Electronic)IS - 0959-535X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1136/bmj.j282</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28100463">PM:28100463</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ\2017-356-j282.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ\2017-356-j282.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170119, Wise J</style></custom2><misc3><style face="normal" font="default">10.1136/bmj.j282</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40251</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Khwaja,Y.H.</style></author><author><style face="normal" font="default"> Tai,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, The Aga Khan University Hospital, Karachi, Pakistan</style></auth-address><titles><title><style face="normal" font="default">Takotsubo cardiomyopathy with use of salbutamol nebulisation and aminophylline infusion in a patient with acute asthma exacerbation</style></title><secondary-title><style face="normal" font="default">BMJ Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">acute asthma</style></keyword><keyword><style face="normal" font="default"> Aminophylline</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Arteries</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Beta-2 agonist</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Catecholamines</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Infarction</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pakistan</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Takotsubo Cardiomyopathy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="10" Year="2016">2016/10/28</year></dates><abstract><style face="normal" font="default">Takotsubo cardiomyopathy, apical ballooning syndrome or stress-induced cardiomyopathy is characterised by transient left ventricular dysfunction, mimicking myocardial infarction in the absence of obstructive coronary artery disease or acute plaque rupture on coronary angiography. The exact mechanism of myocardial dysfunction in Takotsubo cardiomyopathy is unknown; however, due to its association with physical and emotional stress, it is postulated that catecholamines play a central role in its pathogenesis. We present a case of a patient who was admitted with acute asthma exacerbation and was treated with beta-2 agonist nebulisation and intravenous aminophylline. During her hospital stay she developed Takotsubo cardiomyopathy</style></abstract><notes><style face="normal" font="default">DA - 20161029IS - 1757-790X (Electronic)IS - 1757-790X (Linking)LA - ENGPT - Journal ArticleCO - Pakistan -</style></notes><work-type><style face="normal" font="default">10.1136/bcr-2016-217364</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27793870">PM:27793870</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Case Rep\20161029-KhwajaYH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Case Rep\20161029-KhwajaYH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161029, Khwaja YH</style></custom2><misc3><style face="normal" font="default">10.1136/bcr-2016-217364</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40252</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chia Shi,Z.G.</style></author><author><style face="normal" font="default"> Green,A.</style></author><author><style face="normal" font="default"> Fong,Y.T.</style></author><author><style face="normal" font="default"> Lee,H.Y.</style></author><author><style face="normal" font="default"> Ho,S.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Singapore General Hospital, Singapore</style></auth-address><titles><title><style face="normal" font="default">Rare case of type I hypersensitivity reaction to sodium hypochlorite solution in a healthcare setting</style></title><secondary-title><style face="normal" font="default">BMJ Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Chlorine</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> Sodium Hypochlorite</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Type IV hypersensitivity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="21" Month="10" Year="2016">2016/10/21</year></dates><abstract><style face="normal" font="default">Sodium hypochlorite is a clear yellowish solution with a characteristic odour of chlorine and is commonly used as a disinfectant and a bleaching agent. It is used in various healthcare settings for its fast-acting and broad-spectrum antimicrobial activity. It is a known irritant and there are some reports that it can also cause allergic contact dermatitis of type IV hypersensitivity. We report a case of work-related type I hypersensitivity to sodium hypochlorite, presenting with recurrent urticarial rash and a positive prick test reaction to this chemical. He was subsequently excused from further exposure with no further recurrences of the urticarial rash. To the best of our knowledge, this is the first such reported case due to work in the healthcare setting</style></abstract><notes><style face="normal" font="default">DA - 20161022IS - 1757-790X (Electronic)IS - 1757-790X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1136/bcr-2016-217228</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27769978">PM:27769978</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Case Rep\20161022-ChiaShiZG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Case Rep\20161022-ChiaShiZG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161022, Chia Shi ZG</style></custom2><misc3><style face="normal" font="default">10.1136/bcr-2016-217228</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40253</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sadleir,P.H.</style></author><author><style face="normal" font="default"> Clarke,R.C.</style></author><author><style face="normal" font="default"> Platt,P.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Sir Charles Gairdner Hospital, Level 1, G Block, Hospital Avenue, Nedlands, WA 6009, Australia</style></auth-address><titles><title><style face="normal" font="default">Cefalotin as antimicrobial prophylaxis in patients with known intraoperative anaphylaxis to cefazolin</style></title><secondary-title><style face="normal" font="default">Br J Anaesth</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Anaesth</style></full-title></periodical><pages end="469" start="464">464-469</pages><volume><style face="normal" font="default">117</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse events</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Cefazolin</style></keyword><keyword><style face="normal" font="default"> cephalosporin</style></keyword><keyword><style face="normal" font="default"> Cephalosporins</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Intraoperative anaphylaxis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Structure activity relationship</style></keyword><keyword><style face="normal" font="default"> Structure-Activity Relationship</style></keyword><keyword><style face="normal" font="default"> structure-activity relationships</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Western Australia</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: The most common trigger for intraoperative anaphylaxis in Western Australia for the period 2014-5 was an antibiotic used for surgical prophylaxis, cefazolin. In these patients who subsequently present for surgery, alternative cephalosporins are forbidden by current guidelines because of concerns regarding an increased risk of anaphylaxis. However, consideration of the structure-activity relationships relevant to anaphylaxis suggests that cefalotin is a safe alternative because of structural dissimilarities, although there are no pubished clinical data relevant to the perioperative setting. METHODS: Patients diagnosed with intraoperative anaphylaxis to cefazolin at the Western Australian Anaesthetic Allergy Clinic were tested with intradermal cefalotin and, if negative, subsequently challenged i.v. If tolerated, cefalotin was recommended for subsequent surgery, and subjects were followed up to determine the safety of subsequent intraoperative doses. RESULTS: Twenty-one subjects diagnosed with immediate hypersensitivity to cephazolin, including 19 subjects with confirmed anaphylaxis, participated. None tested positive to intradermal cefalotin, and all received a graded i.v. challenge to cefalotin without developing signs or symptoms of anaphylaxis. Three subjects subsequently received intraoperative cefalotin 12-139 days later without adverse events. CONCLUSIONS: A negative intradermal cefalotin skin test has a good negative predictive value in patients who have previously suffered anaphylaxis to cefazolin, allowing the rational and desirable use of this alternative cephalosporin for future surgery and the avoidance of less desirable antimicrobial agents</style></abstract><notes><style face="normal" font="default">DA - 20170112IS - 1471-6771 (Electronic)IS - 0007-0912 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1093/bja/aew274</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28077533">PM:28077533</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Anaesth\2016-117-464-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Anaesth\2016-117-464-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170112, Sadleir PH</style></custom2><misc3><style face="normal" font="default">10.1093/bja/aew274</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40254</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Luyster,F.S.</style></author><author><style face="normal" font="default"> Strollo,P.J.,Jr.</style></author><author><style face="normal" font="default"> Holguin,F.</style></author><author><style face="normal" font="default"> Castro,M.</style></author><author><style face="normal" font="default"> Dunican,E.M.</style></author><author><style face="normal" font="default"> Fahy,J.</style></author><author><style face="normal" font="default"> Gaston,B.</style></author><author><style face="normal" font="default"> Israel,E.</style></author><author><style face="normal" font="default"> Jarjour,N.N.</style></author><author><style face="normal" font="default"> Mauger,D.T.</style></author><author><style face="normal" font="default"> Moore,W.C.</style></author><author><style face="normal" font="default"> Wenzel,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Nursing, University of Pittsburgh, Pittsburgh, PA.</style></auth-address><titles><title><style face="normal" font="default">Association between insomnia and asthma burden in the Severe Asthma Research Program (SARP) III</style></title><secondary-title><style face="normal" font="default">Chest</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chest</style></full-title></periodical><pages end="1250" start="1242">1242-1250</pages><volume><style face="normal" font="default">150</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nursing</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="6" Month="10" Year="2016">2016/10/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Sleep difficulties are commonly reported by patients with asthma. However, the prevalence of insomnia and its association with disease burden and well-being is unknown. OBJECTIVE: We aimed to determine the prevalance of insomnia, defined as combined sleep-specific complaints with associated daytime symptoms, among a large sample of adults with asthma, and to compare well-being, asthma control, and asthma-related healthcare utilization in individuals with asthma and insomnia and those without insomnia. METHODS: Baseline data from adults with physician-confirmed asthma enrolled in the Severe Asthma Research Program (SARP) III was used for the analyses (n = 714). Participants completed the Insomnia Severity Index (ISI), Asthma Control Test (ACT), Asthma Quality of Life Questionnaire (AQLQ), and Hospital Anxiety and Depression Scale (HADS). RESULTS: Insomnia (ISI >/= 10) was identified in 263 participants (37%). Presence of insomnia was associated with higher levels of depression and anxiety symptoms and poorer quality of life. Those with insomnia had a 2.4-fold increased risk for having not well-controlled asthma and a 1.5-fold increased risk for asthma-related healthcare utilization in the past year compared to those without insomnia. CONCLUSION: Insomnia is highly prevalent in asthma and is associated with adverse outcomes. Further studies are needed to gain a better understanding of the interaction between insomnia and asthma control</style></abstract><notes><style face="normal" font="default">DA - 20161010IS - 1931-3543 (Electronic)IS - 0012-3692 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.chest.2016.09.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27720882">PM:27720882</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Chest\2016-150-1242-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Chest\2016-150-1242-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161010, Luyster FS</style></custom2><misc3><style face="normal" font="default">10.1016/j.chest.2016.09.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40255</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kelly,R.S.</style></author><author><style face="normal" font="default"> Dahlin,A.</style></author><author><style face="normal" font="default"> McGeachie,M.J.</style></author><author><style face="normal" font="default"> Qiu,W.</style></author><author><style face="normal" font="default"> Sordillo,J.</style></author><author><style face="normal" font="default"> Wan,E.S.</style></author><author><style face="normal" font="default"> Wu,A.C.</style></author><author><style face="normal" font="default"> Lasky-Su,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Channing Division of Network Medicine, Brigham Women's Hospital and Harvard Medical School</style></auth-address><titles><title><style face="normal" font="default">Asthma metabolomics and the potential for integrative omics in research and the clinic</style></title><secondary-title><style face="normal" font="default">Chest</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chest</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenosine</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Alanine</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exhaled Breath</style></keyword><keyword><style face="normal" font="default"> exhaled breath condensate</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Lipid</style></keyword><keyword><style face="normal" font="default"> Lipid Metabolism</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> metabolomics</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Oxidative Stress</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> TCA</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> urine</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="21" Month="10" Year="2016">2016/10/21</year></dates><abstract><style face="normal" font="default">Asthma is a complex disease well suited to metabolomic profiling, both for the development of novel biomarkers and for the improved understanding of pathophysiology. In this review, we summarize the 21 existing metabolomic studies of asthma in humans, all of which reported significant findings and concluded that individual metabolites and metabolomic profiles measured in exhaled breath condensate, urine, plasma and serum could identify asthmatics and asthma phenotypes with high discriminatory ability. There was considerable consistency across the studies in terms of the reported biomarkers, regardless of biospecimen, profiling technology and population age. In particular, acetate, adenosine, alanine, hippurate, succinate, threonine and trans-aconitate, and pathways relating to hypoxia response, oxidative stress, immunity, inflammation, lipid metabolism and the TCA cycle were all identified as significant in at least two studies. There were also a number of non-replicated results; however, the literature is not yet sufficiently developed to determine whether these represent spurious findings or reflect the substantial heterogeneity and limited statistical power in the studies and their methods to date. This review highlights the need for additional asthma metabolomic studies to explore these issues, and further, the need for standardized methods in the way these studies are conducted. We conclude by discussing the potential of translation of these metabolomic findings into clinically useful biomarkers and the crucial role that integrated-omics is likely to play in this endeavor</style></abstract><notes><style face="normal" font="default">DA - 20161025IS - 1931-3543 (Electronic)IS - 0012-3692 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.chest.2016.10.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27776981">PM:27776981</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Chest\20161025-KellyRS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Chest\20161025-KellyRS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161025, Kelly RS</style></custom2><misc3><style face="normal" font="default">10.1016/j.chest.2016.10.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40256</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Russell,R.</style></author><author><style face="normal" font="default"> Brightling,C.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Infection, Immunity and Inflammation, Institute for Lung Health, Glenfield Hospital, University of Leicester, Leicester, England</style></auth-address><titles><title><style face="normal" font="default">Anti-IL-5 for Severe Asthma: Aiming High to Achieve Success</style></title><secondary-title><style face="normal" font="default">Chest</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chest</style></full-title></periodical><pages end="768" start="766">766-768</pages><volume><style face="normal" font="default">150</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> England</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161010IS - 1931-3543 (Electronic)IS - 0012-3692 (Linking)LA - ENGPT - EDITORIALCO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.chest.2016.06.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27719806">PM:27719806</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Chest\2016-150-766-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Chest\2016-150-766-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161010, Russell R</style></custom2><misc3><style face="normal" font="default">10.1016/j.chest.2016.06.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40257</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Moldaver,D.M.</style></author><author><style face="normal" font="default"> Larche,M.</style></author><author><style face="normal" font="default"> Rudulier,C.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Firestone Institute for Respiratory Health, St. Joseph's Healthcare, Divisions of Respirology and Clinical Immunology &amp; Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada</style></auth-address><titles><title><style face="normal" font="default">An update on lymphocyte subtypes in Asthma and Airway Disease</style></title><secondary-title><style face="normal" font="default">Chest</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chest</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> allergen-specific</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Endotypes</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Subsets</style></keyword><keyword><style face="normal" font="default"> lymphocyte subtypes</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> subtypes</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> Th2 response</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="3" Month="11" Year="2016">2016/11/3</year></dates><abstract><style face="normal" font="default">Inflammation is a hallmark of many airway diseases. Improved understanding of the cellular and molecular mechanisms of airway disease will facilitate the transition in our understanding from phenotypes to endotypes, thereby improving our ability to target treatments based on pathophysiology. For example, allergic asthma has long been considered to be driven by an allergen-specific Th2 response. However, clinical and mechanistic studies have begun to shed light on the role of other cell subsets in the pathogenesis and regulation of lung inflammation. In this review, we discuss the importance of different lymphocyte subsets to asthma and other airway diseases, while highlighting the growing evidence that asthma is a syndrome that incorporates many immune phenotypes</style></abstract><notes><style face="normal" font="default">DA - 20161107IS - 1931-3543 (Electronic)IS - 0012-3692 (Linking)LA - ENGPT - ReviewPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.chest.2016.10.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27818326">PM:27818326</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Chest\20161107-MoldaverDM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Chest\20161107-MoldaverDM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161107, Moldaver DM</style></custom2><misc3><style face="normal" font="default">10.1016/j.chest.2016.10.038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40258</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Barnes,P.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Heart and Lung Institute, Imperial College, London, UK.</style></auth-address><titles><title><style face="normal" font="default">COUNTERPOINT: Will new anti-eosinophilic drugs be useful in asthma management? No</style></title><secondary-title><style face="normal" font="default">Chest</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chest</style></full-title></periodical><pages end="20" start="17">17-20</pages><volume><style face="normal" font="default">151</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161017IS - 1931-3543 (Electronic)IS - 0012-3692 (Linking)LA - ENGPT - EDITORIALCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.chest.2016.09.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27746204">PM:27746204</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Chest\2017-151-17-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Chest\2017-151-17-20.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161017, Barnes PJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.chest.2016.09.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40259</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">O'Byrne,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Firestone Institute of Respiratory Health and the Department of Medicine, Michael G DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default">POINT: Will New Anti-eosinophilic Drugs Be Useful In Asthma Management: Yes</style></title><secondary-title><style face="normal" font="default">Chest</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chest</style></full-title></periodical><pages end="17" start="14">14-17</pages><volume><style face="normal" font="default">151</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Ontario</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161017IS - 1931-3543 (Electronic)IS - 0012-3692 (Linking)LA - ENGPT - EDITORIALCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.chest.2016.09.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27746203">PM:27746203</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Chest\2017-151-14-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Chest\2017-151-14-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161017, O'Byrne PM</style></custom2><misc3><style face="normal" font="default">10.1016/j.chest.2016.09.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40260</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Deng,Y.</style></author><author><style face="normal" font="default"> Qiu,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics West China Second University Hospital/Key Laboratory of Birth Defects and Related Disease of Women and Children Ministry of Education Sichuan University Chengdu 610041 China</style></auth-address><titles><title><style face="normal" font="default">Therapeutic plasma exchange: a second-line treatment for brodifacoum poisoning following an anaphylactoid reaction to vitamin K</style></title><secondary-title><style face="normal" font="default">Clin Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Case Rep</style></abbr-1></periodical><pages end="38" start="35">35-38</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> anaphylactoid reaction</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Plasma Exchange</style></keyword><keyword><style face="normal" font="default"> poisoning</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vitamin K</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">Vitamin K1 is the first-line therapy to brodifacoum poisoning. Anaphylactoid reactions may occur anytime during intravenous administration of vitamin K1 injection. Vitamin K1 must be ceased when anaphylactoid reactions emerge, and therapeutic plasma exchange could be a second-line option</style></abstract><notes><style face="normal" font="default">DA - 20170118IS - 2050-0904 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1002/ccr3.756</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28096987">PM:28096987</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Case Rep\2017-5-35-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Case Rep\2017-5-35-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170118, Deng Y</style></custom2><misc3><style face="normal" font="default">10.1002/ccr3.756</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40261</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Saito,N.</style></author><author><style face="normal" font="default"> Kamata,A.</style></author><author><style face="normal" font="default"> Itoga,M.</style></author><author><style face="normal" font="default"> Tamaki,M.</style></author><author><style face="normal" font="default"> Kayaba,H.</style></author><author><style face="normal" font="default"> Ritz,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Laboratory Medicine, Hirosaki University Graduate School of Medicine, Japan</style></auth-address><titles><title><style face="normal" font="default">Assessment of biological, psychological and adherence factors in the prediction of step-down treatment for patients with well-controlled asthma</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Somatoform Disorders</style></keyword><keyword><style face="normal" font="default"> Step down</style></keyword><keyword><style face="normal" font="default"> Step-down</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="21" Month="1" Year="2017">2017/1/21</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Inhaled corticosteroids (ICS) and inhaled corticosteroids combined with long-acting beta2-agonist (ICS/LABA) are standard treatments for asthma. However, factors that might help reduce medication in well-controlled asthma are unknown. We classified problems of asthma patients into biological, psychological and adherence factors, and investigated factors associated with the indication and failure of a medication step-down treatment. METHODS: Two hundred twenty two well-controlled asthma patients receiving ICS or ICS/LABA were assessed for physical and psychiatric problems and followed up for one year from adjustment of their treatment step. Factor B was defined as a presence of chronic upper airway complications. Factor P was defined as presence of psychiatric complications such as sleep disorder, depression, anxiety and somatoform disorders. Factor A was defined as poor adherence to ICS or ICS/LABA inhaler of 75% or less. Success in step-down treatment was defined as maintenance of well-controlled status for over one year after step-down. RESULTS: Factor B was the most important single negative predictive factor for indication for step-down treatment (Odds ratio; 0.19). Factor A increased the risk of failure to maintain step-down treatment most significantly by 23-fold, and factor B increased it by 11-fold. The combination of factors B and A increased failure by 24-fold, factors P and A by 21-fold, all three factors by 36-fold. Factor P only interacted with the other factors to reduce chances of stepping down, but did not constitute a problem factor when present alone. CONCLUSIONS: The evaluation of biological, psychological and adherence problems may lead to a more proactive and targeted approach to step-down treatment for patients with well-controlled asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170121IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12888</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28109164">PM:28109164</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170121-SaitoN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170121-SaitoN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170121, Saito N</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12888</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40262</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,Z.Q.</style></author><author><style face="normal" font="default"> Li,M.G.</style></author><author><style face="normal" font="default"> Geng,X.R.</style></author><author><style face="normal" font="default"> Liu,J.</style></author><author><style face="normal" font="default"> Yang,G.</style></author><author><style face="normal" font="default"> Qiu,S.Q.</style></author><author><style face="normal" font="default"> Liu,Z.G.</style></author><author><style face="normal" font="default"> Yang,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">ENT Institute of the Research Center of Allergy &amp; Immunology, Shenzhen University School of Medicine, Shenzhen, 518060, China</style></auth-address><titles><title><style face="normal" font="default">Vitamin D regulates immunoglobulin mucin domain molecule-4 expression in dendritic cells</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Calcitriol</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> DC</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Promoter</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="default">BACKGROUND AND AIMS: Dendritic cell (DC)-derived immunoglobulin domain molecule (TIM)4 plays a critical role in the initiation of T helper (Th)2 polarization. Vitamin D (VitD) involves the regulation of a number of immune responses. This study tests a hypothesis that VitD regulates TIM4 expression in DCs. METHODS: Peripheral blood samples were collected from patients with allergic rhinitis (AR) and healthy subjects. DCs were isolated from the samples and analyzed for the expression of TIM4. RESULTS: We observed that the levels of calcitriol, the active form of VitD3, in the sera of AR patients were lower than that in healthy subjects. The peripheral DC expressed higher levels of TIM4 and lower levels of VDR. A negative correlation was identified between the data of serum calcitriol and TIM4 in DCs. Exposure DCs to calcitriol in the culture increased the expression of VDR. We also found that VDR bound to the TIM4 promoter locus in DCs to repress the TIM4 gene transcription and expression. CONCLUSIONS: VitD deficiency may contribute to the pathogenesis of AR by increasing the TIM4 expression. The results suggest that to regulate the serum calcitriol levels and the expression of VDR in DCs may be necessary to be taken into account in the treatment of AR. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170204IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - China -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12894</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28160341">PM:28160341</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170204-LiuZQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170204-LiuZQ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, Liu ZQ</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12894</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40263</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Elbert,N.J.</style></author><author><style face="normal" font="default"> Duijts,L.</style></author><author><style face="normal" font="default"> den Dekker,H.T.</style></author><author><style face="normal" font="default"> de Jong,N.W.</style></author><author><style face="normal" font="default"> Nijsten,T.E.</style></author><author><style face="normal" font="default"> Jaddoe,V.W.</style></author><author><style face="normal" font="default"> de Jongste,J.C.</style></author><author><style face="normal" font="default"> Gerth van Wijk,R.</style></author><author><style face="normal" font="default"> Tiemeier,H.</style></author><author><style face="normal" font="default"> Pasmans,S.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Generation R Study Group Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Maternal psychiatric symptoms during pregnancy and risk of childhood atopic diseases</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic sensitization</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> Atopic diseases</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Inhalant</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="21" Month="1" Year="2017">2017/1/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: Maternal psychiatric symptoms during pregnancy might affect the developing immune system and subsequent risk of childhood atopic diseases. OBJECTIVE: Our aim was to examine the associations of maternal psychiatric symptoms during pregnancy with allergic sensitization, allergy and eczema in children until age 10 years. METHODS: This study among 5,205 children was performed in a population-based prospective cohort from fetal life onwards. We assessed maternal and paternal psychiatric symptoms (overall, depressive, anxiety) during pregnancy and at 36 months after delivery, and maternal psychiatric symptoms at 2 and 6 months after delivery using the Brief Symptom Inventory. Inhalant and food allergic sensitization were measured by skin prick tests, and physician-diagnosed inhalant and food allergy or eczema by questionnaires from birth until age 10 years. We used multivariate logistic regression, multinomial logistic regression or generalized estimating equation models where appropriate. RESULTS: We observed no association of maternal psychiatric symptoms during pregnancy with allergic sensitization. Maternal overall psychiatric, depressive and anxiety symptoms during pregnancy were associated with an increased risk of inhalant allergy only (adjusted odds ratio (95% confidence interval) 1.96 (1.44, 2.65), 1.58 (1.25, 1.98), and 1.61 (1.27, 2.03), respectively, per 1-unit increase). Maternal overall psychiatric and anxiety symptoms during pregnancy were associated with an increased risk of eczema (1.21 (1.05, 1.39) and 1.15 (1.02, 1.29), respectively, per 1-unit increase). Effect estimates did not materially change when maternal psychiatric symptoms after delivery, or paternal psychiatric symptoms during pregnancy and after delivery were taken into account. CONCLUSIONS &amp; CLINICAL RELEVANCE: Maternal psychiatric symptoms during pregnancy were associated with increased risks of childhood inhalant allergy and eczema, independent of maternal psychiatric symptoms after delivery and of paternal psychiatric symptoms. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170121IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12889</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28109169">PM:28109169</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170121-ElbertNJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170121-ElbertNJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170121, Elbert NJ</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12889</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40264</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pavord,I.D.</style></author><author><style face="normal" font="default"> Afzalnia,S.</style></author><author><style face="normal" font="default"> Menzies-Gow,A.</style></author><author><style face="normal" font="default"> Heaney,L.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK</style></auth-address><titles><title><style face="normal" font="default">The current and future role of biomarkers in type 2 cytokine-mediated asthma management</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="160" start="148">148-160</pages><volume><style face="normal" font="default">47</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Exhaled Breath</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Periostin</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Targeted therapy</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">Assessment and management of asthma is complicated by the heterogeneous pathophysiological mechanisms that underlie its clinical presentation, which are not necessarily reflected in standardized management paradigms and which necessitate an individualized approach to treatment. This is particularly important with the emerging availability of a variety of targeted forms of therapy that may only be appropriate for use in particular patient subgroups. The identification of biomarkers can potentially aid diagnosis and inform prognosis, help guide treatment decisions and allow clinicians to predict and monitor response to treatment. Biomarkers for asthma have been identified from a variety of sources, including airway, exhaled breath and blood. Biomarkers from exhaled breath include fractional exhaled nitric oxide, measurement of which can help identify patients most likely to benefit from inhaled corticosteroids and targeted anti-immunoglobulin E therapy. Biomarkers measured in blood are relatively non-invasive and technically more straightforward than those measured from exhaled breath or directly from the airway. The most well established of these are the blood eosinophil count and serum periostin, both of which have demonstrated utility in identifying patients most likely to benefit from targeted anti-interleukin and anti-immunoglobulin E therapies, and in monitoring subsequent treatment response. For example, serum periostin appears to be a biomarker for responsiveness to inhaled corticosteroid therapy and may help identify patients as suitable candidates for anti-IL-13 treatment. The use of biomarkers can therefore potentially help avoid unnecessary morbidity from high-dose corticosteroid therapy and allow the most appropriate and cost-effective use of targeted therapies. Ongoing clinical trials are helping to further elucidate the role of established biomarkers in routine clinical practice, and a range of other circulating novel potential biomarkers are currently being investigated in the research setting</style></abstract><notes><style face="normal" font="default">DA - 20170130IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12881</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28134501">PM:28134501</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\2017-47-148-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\2017-47-148-60.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170130, Pavord ID</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12881</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40265</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Leung,J.Y.</style></author><author><style face="normal" font="default"> Leung,G.M.</style></author><author><style face="normal" font="default"> Schooling,C.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China</style></auth-address><titles><title><style face="normal" font="default">Migrant status and childhood hospitalizations for asthma and other wheezing disorders</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> Bronchiolitis</style></keyword><keyword><style face="normal" font="default"> Bronchitis</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> COX</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hong Kong</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> SAR</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: In developed Western settings, asthma is more prevalent among second-generation compared to first-generation migrants. However, these studies are difficult to interpret as they include migrants of various ethnicities and countries of origin. OBJECTIVE: We assessed the association of parental migrant status with wheezing disorders among children born in Hong Kong, a developed non-Western setting, where many children have migrant parents from mainland China of the same ethnicity. METHODS: We used Cox regression to examine the adjusted associations of parental migrant status with time to first public hospital admission for asthma, bronchitis and bronchiolitis (International Classification of Diseases, Ninth Version Clinical Modification 466, 490 and 493) from 9 days to 12 years in a population-representative birth cohort of 8327 Chinese children in Hong Kong. RESULTS: Having both parents as migrants was associated with higher risk of hospitalization for asthma and other wheezing disorders, compared to both parents being Hong Kong born (hazard ratio 1.30, 95% confidence interval 1.05 to 1.60 from 9 days to 6 years), adjusted for type of hospital at birth, parental history of allergies, mother's age at birth, father's age at birth, and highest parental education. CONCLUSIONS AND CLINICAL RELEVANCE: In the unique, non-Western context of Hong Kong, second-generation migrants had higher risk of hospitalization for childhood wheezing disorders compared to the native population, particularly before 6 years of age. Further study is required to clarify the underlying mechanisms involved. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170204IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Hong Kong -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12896</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28160339">PM:28160339</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170204-LeungJY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170204-LeungJY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, Leung JY</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12896</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40266</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Horie,Y.</style></author><author><style face="normal" font="default"> Kitaichi,N.</style></author><author><style face="normal" font="default"> Hijioka,K.</style></author><author><style face="normal" font="default"> Sonoda,K.H.</style></author><author><style face="normal" font="default"> Saishin,Y.</style></author><author><style face="normal" font="default"> Kezuka,T.</style></author><author><style face="normal" font="default"> Goto,H.</style></author><author><style face="normal" font="default"> Takeuchi,M.</style></author><author><style face="normal" font="default"> Nakamura,S.</style></author><author><style face="normal" font="default"> Kimoto,T.</style></author><author><style face="normal" font="default"> Shimakawa,M.</style></author><author><style face="normal" font="default"> Kita,M.</style></author><author><style face="normal" font="default"> Sugita,S.</style></author><author><style face="normal" font="default"> Mochizuki,M.</style></author><author><style face="normal" font="default"> Hori,J.</style></author><author><style face="normal" font="default"> Iwata,M.</style></author><author><style face="normal" font="default"> Shoji,J.</style></author><author><style face="normal" font="default"> Fukuda,M.</style></author><author><style face="normal" font="default"> Kaburaki,T.</style></author><author><style face="normal" font="default"> Numaga,J.</style></author><author><style face="normal" font="default"> Kawashima,H.</style></author><author><style face="normal" font="default"> Fukushima,A.</style></author><author><style face="normal" font="default"> Joko,T.</style></author><author><style face="normal" font="default"> Takai,N.</style></author><author><style face="normal" font="default"> Ozawa,Y.</style></author><author><style face="normal" font="default"> Meguro,A.</style></author><author><style face="normal" font="default"> Mizuki,N.</style></author><author><style face="normal" font="default"> Namba,K.</style></author><author><style face="normal" font="default"> Ishida,S.</style></author><author><style face="normal" font="default"> Ohno,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, Health Sciences University of Hokkaido, Sapporo, Japan</style></auth-address><titles><title><style face="normal" font="default">Ocular Behcet's disease is less complicated with allergic disorders. A nationwide survey in Japan</style></title><secondary-title><style face="normal" font="default">Clin Exp Rheumatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Exp Rheumatol</style></abbr-1></periodical><pages end="114" start="111">111-114</pages><volume><style face="normal" font="default">34 Suppl 102</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Arthritis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Ocular</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Ophthalmology</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH17</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> Thrombosis</style></keyword><keyword><style face="normal" font="default"> Ulcer</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Behcet's disease (BD) is a systemic inflammatory disorder polarised to the Th1 and Th17 immune systems. Allergic diseases are polarised to the Th2 immune system. The aim of the present study is to investigate the prevalence of allergic diseases in patients who have BD. METHODS: The study involved a large-scale interview survey of Japanese patients with BD at 21 institutes of ophthalmology; 353 patients (255 males and 98 females) were recruited for this study. We analysed the history of allergic diseases such as atopic dermatitis (AD), allergic rhinitis (AR), bronchial asthma (BA) and drug/food allergies (FA). RESULTS: Oral aphthous ulcers, ocular lesions, skin lesions, genital ulcers, arthritis, neurological lesions, intestinal lesions, deep vein thrombosis and epididymitis were reported in 95.8%, 98.6%, 72.5%, 44.8%, 13.9%, 6.8%, 6.2%, 3.7% and 1.4% of the patients, respectively. It was also reported that 73 patients (20.7%) had histories of allergic diseases: AD (5 cases, 1.4%), AR (36 cases, 10.2%), BA (19 cases, 5.4%) and FA (30 cases, 8.5%). This percentage was significantly lower than in a survey that Japan's Ministry of Health, Labour and Welfare conducted for healthy population (47.6%) (odds ratio = 0.29, 95% confidence interval = 0.22-0.38, p=4.9x10-22). Frequencies of posterior/pan-uveitis, relatively severe ocular findings, and visual prognosis were not affected by a history of allergic diseases in BD. CONCLUSIONS: Patients with BD had fewer complications from allergic diseases than did the entire population of Japan</style></abstract><notes><style face="normal" font="default">DA - 20161028IS - 0392-856X (Print)IS - 0392-856X (Linking)LA - ENGPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27791954">PM:27791954</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Rheumatol\2016-34S102-111-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Rheumatol\2016-34S102-111-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161028, Horie Y</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40267</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kasternow,B.</style></author><author><style face="normal" font="default"> Karim,M.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Royal Surrey County Hospital, Surrey, UKFrimley Park Hospital, Surrey, UK</style></auth-address><titles><title><style face="normal" font="default">Introduction to drug allergy, and whom to refer for specialist assessment?</style></title><secondary-title><style face="normal" font="default">Clin Med (Lond)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Med (Lond)</style></abbr-1></periodical><pages end="592" start="588">588-592</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical guidelines</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Indications</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Patient Safety</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> standards</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">Drug allergy is defined as an adverse drug reaction with an established immunological mechanism. The National Institute for Health and Care Excellence published clinical guidelines on drug allergy in 2014 and quality standards in 2015. The intention of this article is to highlight indications for referral to specialists for management of drug allergy. Accurate diagnosis of drug allergy is critical of course for patient safety, but also for better use of the drugs that we have available and to reduce unnecessary avoidance of drugs. However, there are significant limitations in terms of resource availability and also in terms of testing. There is a careful balance here in that drug allergy is very common and clearly there is neither indication nor sufficient resource in the NHS for all patients with drug allergy to be reviewed by a specialist. It is, therefore, important to highlight to general physicians and physicians of other specialties, those patients who do require referral for specialist review</style></abstract><notes><style face="normal" font="default">DA - 20161208IS - 1473-4893 (Electronic)IS - 1470-2118 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.7861/clinmedicine.16-6-588</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27927827">PM:27927827</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Med (Lond)\2016-16-588-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Med (Lond)\2016-16-588-92.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161208, Kasternow B</style></custom2><misc3><style face="normal" font="default">10.7861/clinmedicine.16-6-588</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40268</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jung,M.C.</style></author><author><style face="normal" font="default"> Kim,J.K.</style></author><author><style face="normal" font="default"> Cho,J.Y.</style></author><author><style face="normal" font="default"> Song,J.W.</style></author><author><style face="normal" font="default"> Lee,B.</style></author><author><style face="normal" font="default"> Park,J.W.</style></author><author><style face="normal" font="default"> Seo,J.</style></author><author><style face="normal" font="default"> Kim,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea</style></auth-address><titles><title><style face="normal" font="default">A case of levocetirizine-induced liver injury</style></title><secondary-title><style face="normal" font="default">Clin Mol Hepatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Mol Hepatol</style></abbr-1></periodical><pages end="498" start="495">495-498</pages><volume><style face="normal" font="default">22</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Hepatitis</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Jaundice</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Prurigo</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">Levocetirizine is a second-generation nonsedative antihistaminic agent that has been demonstrated to be safe and effective for treating allergic disease. There was only one case report of levocetirizine-induced liver toxicity, but a liver biopsy was not performed. In this article, we present the first case of levocetirizine-induced liver injury with histologic findings. A 48-year-old man was hospitalized with jaundice and generalized pruritus that had developed after 2 months of therapy with levocetirizine for prurigo nodularis. Laboratory findings revealed acute hepatitis with cholestasis. A liver biopsy demonstrated portal inflammation and hepatitis with apoptotic hepatocytes. The patient fully recovered 3 weeks after withdrawing levocetirizine. Although levocetirizine is safe and effective, physicians should be aware of its potential hepatotoxicity</style></abstract><notes><style face="normal" font="default">DA - 20170113IS - 2287-285X (Electronic)IS - 2287-2728 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.3350/cmh.2016.0023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28081586">PM:28081586</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Mol Hepatol\2016-22-495-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Mol Hepatol\2016-22-495-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170113, Jung MC</style></custom2><misc3><style face="normal" font="default">10.3350/cmh.2016.0023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40269</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Larsen,K.R.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author><author><style face="normal" font="default"> Reibel,J.</style></author><author><style face="normal" font="default"> Zachariae,C.</style></author><author><style face="normal" font="default"> Pedersen,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Section for Oral Medicine, Clinical Oral Physiology, Oral Pathology and Anatomy, Department of Odontology, Faculty of Medical and Health Sciences, University of Copenhagen, 20 Noerre Alle, 2200, Copenhagen N, DK, Denmark.</style></auth-address><titles><title><style face="normal" font="default">Symptomatic oral lesions may be associated with contact allergy to substances in oral hygiene products</style></title><secondary-title><style face="normal" font="default">Clin Oral Investig</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Oral Investig</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anatomy</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dental Materials</style></keyword><keyword><style face="normal" font="default"> dentist</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hygiene</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Lichen Planus</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Stomatitis</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Toothpaste</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Dental materials and oral hygiene products may be responsible for oral contact allergic reactions. We aimed to determine the occurrence of allergies in patients with symptomatic oral lichen planus (OLP), oral lichenoid lesions (OLLs) and stomatitis and investigate if patch testing could identify contact allergies to dental materials and oral hygiene products in these patients. METHODS: Forty-nine patients (7 men, 42 women) aged 31 to 77 years (61 +/- 10.3 years) with symptomatic OLP, OLL or stomatitis and 29 healthy age- and gender-matched control subjects were included. They underwent an interview, clinical examination, oral mucosal biopsy and epicutan testing to the European baseline series, a toothpaste and dental material series. RESULTS: Nineteen patients had OLP, 19 OLL and 11stomatitis. Oral burning/itching was the most common symptom (83.7%), and 65.3% patients had more than one symptom. Patients visited their dentist more often than the healthy subjects and had statistically higher DMF-T and DMF-S scores. Nineteen patients (38.8%) and 10 healthy control subjects (34.5%) had allergic contact reactions primarily to fragrance ingredients. No differences could be found between OLP, OLL, stomatitis and healthy controls with regard to allergic contact reactions. However, contact allergy to aroma substances differed significantly between the patients and the healthy control subjects (p = 0.02). This type of contact allergy was most common in patients with OLP and OLL (p = 0.01). Avoidance cleared symptoms in all cases. CONCLUSION/CLINICAL RELEVANCE: Allergic reactions to aroma substances in oral hygiene products are common in patients with symptomatic OLP, OLL and stomatitis</style></abstract><notes><style face="normal" font="default">DA - 20170113IS - 1436-3771 (Electronic)IS - 1432-6981 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1007/s00784-017-2053-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28084550">PM:28084550</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Oral Investig\20170113-LarsenKR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Oral Investig\20170113-LarsenKR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170113, Larsen KR</style></custom2><misc3><style face="normal" font="default">10.1007/s00784-017-2053-y</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40270</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">duRivage,N.</style></author><author><style face="normal" font="default"> Ross,M.</style></author><author><style face="normal" font="default"> Mayne,S.L.</style></author><author><style face="normal" font="default"> Suh,A.</style></author><author><style face="normal" font="default"> Weng,D.</style></author><author><style face="normal" font="default"> Grundmeier,R.W.</style></author><author><style face="normal" font="default"> Fiks,A.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Children's Hospital of Philadelphia, Philadelphia, PA, USA</style></auth-address><titles><title><style face="normal" font="default">Asthma Control Test: Comparing Parent Proxy With Parent and Child Report for Children 6 to 12 Years</style></title><secondary-title><style face="normal" font="default">Clin Pediatr (Phila)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Pediatr (Phila)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> Barriers</style></keyword><keyword><style face="normal" font="default"> C-ACT</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Philadelphia</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="23" Month="10" Year="2016">2016/10/23</year></dates><abstract><style face="normal" font="default">We compared results of a modified version of the Asthma Control Test using parent proxy report (PP-ACT) with results reported by children and parents using the validated Childhood-Asthma Control Test (C-ACT). 104 parent-child dyads with a child aged 6 to 12 years with asthma were randomized to complete PP-ACT followed by C-ACT or C-ACT followed by PP-ACT. Scores &lt;/=19 indicated uncontrolled asthma. We calculated sensitivity, specificity, positive predictive value, and negative predictive value for the PP-ACT in comparison with the C-ACT, and calculated concordance between the 2 scales. The PP-ACT had sensitivity of 86% and negative predictive value of 88% for detecting uncontrolled asthma. More than 75% of surveys were concordant (kappa = 0.54, moderate agreement). Our results suggest that while the PP-ACT missed few children with uncontrolled asthma and may simplify reporting of asthma control in circumstances when child report is not feasible or creates barriers to survey receipt, limitations of proxy reporting should be considered</style></abstract><notes><style face="normal" font="default">DA - 20161031IS - 1938-2707 (Electronic)IS - 0009-9228 (Linking)LA - ENGPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/0009922816675013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27798397">PM:27798397</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Pediatr (Phila)\20161031-duRivageN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Pediatr (Phila)\20161031-duRivageN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161031, duRivage N</style></custom2><misc3><style face="normal" font="default">10.1177/0009922816675013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40271</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Britto,M.T.</style></author><author><style face="normal" font="default"> Rohan,J.M.</style></author><author><style face="normal" font="default"> Dodds,C.M.</style></author><author><style face="normal" font="default"> Byczkowski,T.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA</style></auth-address><titles><title><style face="normal" font="default">A Randomized Trial of User-Controlled Text Messaging to Improve Asthma Outcomes</style></title><secondary-title><style face="normal" font="default">Clin Pediatr (Phila)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Pediatr (Phila)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized trial</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="default">We enrolled 64 patients age 12 to 22 years with a diagnosis of poorly controlled persistent asthma in a 6-month longitudinal crossover study. During the 3 intervention months, participants created personalized text messages to be sent to their phones. Adherence was objectively monitored in 22 of the participants. The adolescent participants gave high ratings on the acceptability of the text messaging system. Asthma control improved from baseline to month 1 regardless of whether teens were in the texting or control group. While participants were in the texting group, their quality of life improved and worry about their asthma decreased. Receiving the text intervention resulted in an increase in adherence of 2.75% each month relative to no intervention, but the improvements were not sustained. There was modest improvement in asthma control and quality of life outcomes, as well as improved adherence during the texting intervention</style></abstract><notes><style face="normal" font="default">DA - 20170106IS - 1938-2707 (Electronic)IS - 0009-9228 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/0009922816684857</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28056541">PM:28056541</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Pediatr (Phila)\20170106-BrittoMT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Pediatr (Phila)\20170106-BrittoMT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170106, Britto MT</style></custom2><misc3><style face="normal" font="default">10.1177/0009922816684857</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40272</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Meltzer,L.J.</style></author><author><style face="normal" font="default"> Booster,G.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Behavioral Health, Department of Pediatrics, National Jewish HealthDivision of Behavioral Health, Department of Pediatrics, National Jewish Health</style></auth-address><titles><title><style face="normal" font="default">Evaluation of an Ecologically Valid Group Intervention to Address Sleep Health in Families of Children With Allergic Diseases</style></title><secondary-title><style face="normal" font="default">Clin Pract Pediatr Psychol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Pract Pediatr Psychol</style></abbr-1></periodical><pages end="213" start="206">206-213</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Habits</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hygiene</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="default">Sleep issues in children with allergic diseases may be a result of illness related factors (e.g., itching, wheezing) and/or poor sleep habits due to disrupted routines and parental permissiveness. However, the ability of parents to attend a multi-session sleep intervention may be limited. Thus we examined the validity of a one-time sleep health group intervention for parents of children with allergic diseases. Ninety-three parents of children who were admitted to a two-week intensive day hospital treatment program completed measures of child sleep habits (Children's Report of Sleep Patterns), parent sleep habits (Sleep Hygiene Inventory), parent sleep quality (Pittsburgh Sleep Quality Index), and parental insomnia symptoms (Insomnia Severity Index) before the group intervention and one-month after program discharge; 54 parents attended the sleep health group. Sleep habits and sleep quality improved for both parents and children at the one-month follow-up. However, improvements were seen regardless of group attendance. Potential reasons for the lack of difference between those who did and did not participate in group are presented, and implications of this study for pediatric psychologist in practice are discussed</style></abstract><notes><style face="normal" font="default">DA - 20170113IS - 2169-4826 (Print)IS - 2169-4826 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1037/cpp0000136</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28083466">PM:28083466</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Pract Pediatr Psychol\2016-4-206-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Pract Pediatr Psychol\2016-4-206-13.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170113, Meltzer LJ</style></custom2><misc3><style face="normal" font="default">10.1037/cpp0000136</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40273</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sonia,T.</style></author><author><style face="normal" font="default"> Meriem,M.</style></author><author><style face="normal" font="default"> Yacine,O.</style></author><author><style face="normal" font="default"> Nozha,B.S.</style></author><author><style face="normal" font="default"> Nadia,M.</style></author><author><style face="normal" font="default"> Bechir,L.</style></author><author><style face="normal" font="default"> Jalloul,D.</style></author><author><style face="normal" font="default"> Jouda,C.</style></author><author><style face="normal" font="default"> Majed,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory Department, Research Unit 12SP06, Faculty of Medicine of Tunis, Rabta Hospital, Tunis El Manar University, Tunis, 1007, Tunisia.</style></auth-address><titles><title><style face="normal" font="default">Prevalence of asthma and rhinitis in a Tunisian population</style></title><secondary-title><style face="normal" font="default">Clin Respir J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Respir J</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> ARIA</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Tunisia</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="12" Month="10" Year="2016">2016/10/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma and rhinitis are a major public health problem because of their frequency, their impact on quality of life and economic burden. In Tunisia, epidemiological data are scarce. The aim of the present study was to estimate the prevalence of asthma and rhinitis in a representative Tunisian population and to analyze the association between them. METHODS: It was a cross-sectional population-based study, involving individuals aged between 2 and 52 years, living in Tunis. A sample of the general population was generated using a random stratified sampling method. A detailed face-to-face questionnaire based on ISAAC and the ECRHS survey was used. Classification of rhinitis was evaluated according to ARIA. RESULTS: Data were obtained from 4470 responders (40.2% male and 59.8% female). The response rate was 96.5%. The prevalence of current asthma was 6.5% (CI 5.9%-7.8%). A slight female predominance was observed in children and adolescents but in adulthood gender-specific prevalence estimates were similar. The prevalence of rhinitis in the general population was 11.7% (CI 10.1%-13.5%) in children and 13.4% (CI 11.1%-14.6%) in 15 years and older. No statistically significant differences were found according to gender and age. Almost half of asthmatics' had current rhinitis or rhinoconjunctivitis versus 13.4% in the population sample (P &lt; 0.001). Current asthma was reported in 22.5% subjects with current rhinitis or with rhinoconjunctivitis. CONCLUSIONS: Asthma and rhinitis represent a considerable public health problem in children and adults up to age 52 in Tunisian population. Our results confirm also the strong association between them. These findings highlight the need for a clinical global assessment of asthma together with rhinitis</style></abstract><notes><style face="normal" font="default">DA - 20161012IS - 1752-699X (Electronic)IS - 1752-6981 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Tunisia -</style></notes><work-type><style face="normal" font="default">10.1111/crj.12570</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27731951">PM:27731951</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Respir J\20161012-SoniaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Respir J\20161012-SoniaT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161012, Sonia T</style></custom2><misc3><style face="normal" font="default">10.1111/crj.12570</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40274</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tang,W.</style></author><author><style face="normal" font="default"> Zhou,J.</style></author><author><style face="normal" font="default"> Miao,L.</style></author><author><style face="normal" font="default"> Shi,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respirology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China</style></auth-address><titles><title><style face="normal" font="default">Clinical features in patients of cough variant asthma with normal and high level of exhaled fractional nitric oxide</style></title><secondary-title><style face="normal" font="default">Clin Respir J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Respir J</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergen exposure</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic cough</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="12" Month="10" Year="2016">2016/10/12</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Cough variant asthma (CVA) is a subtype of asthma that is characterized by a chronic cough. The clinical characteristics and pulmonary function in patients with CVA who had normal and high exhaled fractional nitric oxide (FeNO) levels were compared. METHODS: The clinical history and pulmonary function data from 99 patients with newly diagnosed CVA were collected. RESULT: Newly diagnosed subjects with CVA were divided into a high FeNO group (FeNO value over or equal to 25 ppb, n = 52) and a normal FeNO group (FeNO lower than 25 ppb, n = 47). There were more patients with coexistent allergic rhinitis or with family histories of allergic diseases in the high FeNO group. More patients in the high FeNO group reported that their chronic cough was triggered by allergen exposure. In the high FeNO group, the patients were younger than in the normal FeNO group. It was shown that baseline lung function tests were normal in all subjects, apart from a reduced midexpiratory flow rate (FEF25-75). There was a significant decrease in FEF25-75 in the high FeNO group compared with the normal FeNO group. No difference was found in the PD20 or the maximal FEV1 drop between the two groups. The multi-factor logistic regression analysis showed that concomitant with allergic rhinitis was the high risk factor of a high FeNO in these subjects with CVA (OR = 5.03, 95% CI, 1.88-13.49). CONCLUSION: CVA patients showed heterogeneity according to FeNO level. Patients with high FeNO level are more likely to experience symptoms associated with allergies</style></abstract><notes><style face="normal" font="default">DA - 20161012IS - 1752-699X (Electronic)IS - 1752-6981 (Linking)LA - ENGPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1111/crj.12568</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27731932">PM:27731932</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Respir J\20161012-TangW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Respir J\20161012-TangW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161012, Tang W</style></custom2><misc3><style face="normal" font="default">10.1111/crj.12568</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40275</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Luskin,A.T.</style></author><author><style face="normal" font="default"> Antonova,E.N.</style></author><author><style face="normal" font="default"> Broder,M.S.</style></author><author><style face="normal" font="default"> Chang,E.Y.</style></author><author><style face="normal" font="default"> Omachi,T.A.</style></author><author><style face="normal" font="default"> Ledford,D.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">HealthyAirways, Madison, WI</style></auth-address><titles><title><style face="normal" font="default">Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis</style></title><secondary-title><style face="normal" font="default">Clinicoecon Outcomes Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clinicoecon Outcomes Res</style></abbr-1></periodical><pages end="648" start="641">641-648</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma therapy</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> Commercial</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Care Costs</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> office</style></keyword><keyword><style face="normal" font="default"> Office Visits</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">BACKGROUND: The objective of this study was to estimate the prevalence of possible oral corticosteroid (OCS)-related side effects and health care resource use and costs in patients with asthma. METHODS: This was a cross-sectional, matched-cohort, retrospective study using a commercial claims database. Adults with asthma diagnosis codes and evidence of asthma medication use were studied. Patients with high OCS use (>/=30 days of OCS annually) were divided into those who did versus those who did not experience OCS-related possible side effects. Their health care resource use and costs were compared using linear regression or negative binomial regression models, adjusting for age, sex, geographic region, Charlson Comorbidity Index score, and chronic obstructive pulmonary disease status. RESULTS: After adjustment, high OCS users with possible side effects were more likely to have office visits (23.0 vs 19.6; P&lt;0.001) and hospitalizations (0.44 vs 0.22; P&lt;0.001) than those without possible side effects. Emergency department visits were similar between the groups. High OCS users with possible side effects had higher adjusted total annual mean health care costs ($25,168) than those without such side effects ($21,882; P=0.009). CONCLUSION: Among high OCS users, patients with possible OCS-related side effects are more likely to use health care services than those without such side effects. Although OCS may help control asthma and manage exacerbations, OCS side effects may result in additional health care resource use and costs, highlighting the need for OCS-sparing asthma therapies</style></abstract><notes><style face="normal" font="default">DA - 20161108IS - 1178-6981 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2147/CEOR.S115025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27822075">PM:27822075</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clinicoecon Outcomes Res\2016-8-641-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clinicoecon Outcomes Res\2016-8-641-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161108, Luskin AT</style></custom2><misc3><style face="normal" font="default">10.2147/CEOR.S115025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40276</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Muti,A.D.</style></author><author><style face="normal" font="default"> Parvu,A.E.</style></author><author><style face="normal" font="default"> Muti,L.A.</style></author><author><style face="normal" font="default"> Moldovan,R.</style></author><author><style face="normal" font="default"> Muresan,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pulmonology and Allergy Department, CHU Gabriel Montpied Clermont-Ferrand, France</style></auth-address><titles><title><style face="normal" font="default">Vitamin E effect in a rat model of toluene diisocyanate-induced asthma</style></title><secondary-title><style face="normal" font="default">Clujul Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clujul Med</style></abbr-1></periodical><pages end="505" start="499">499-505</pages><volume><style face="normal" font="default">89</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> Antioxidants</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Glutathione</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> lung biopsy</style></keyword><keyword><style face="normal" font="default"> Malondialdehyde</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Oxidative Stress</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> rat</style></keyword><keyword><style face="normal" font="default"> Rats</style></keyword><keyword><style face="normal" font="default"> Romania</style></keyword><keyword><style face="normal" font="default"> ROS</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> TDI</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Toluene</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword><keyword><style face="normal" font="default"> Vitamin E</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">BACKGROUND AND AIM: The aim of the study was to evaluate vitamin E effect upon oxidative stress associated with toluene -2, 4-diisocyanate (TDI)-induced asthma in rats. METHODS: The five study groups were: control, vehicle, TDI, vehicle+E, TDI+E. TDI animals were sensitized by nasal administration of TDI 10% (5mul/nostril) between days 1-7 and 15-21. Between days 22-28 groups TDI+E and vehicle+E rats received vitamin E (50 mg/kg, i. v.), and control, vehicle and TDI groups received saline solution. On day 29 the rats were challenged by intranasal application of 5% TDI (5 mul/nostril). On day 30 blood, BALF and lung biopsy were harvested. Oxidative stress tests were malondialdehyde (MDA), protein carbonyls (PC), total thiols (tSH), 1,1-diphenyl-2-picryl hydrazyl (DPPH) and reduced glutathione (GSH). RESULTS: TDI sensitization increased oxidative stress systemically, but also locally in the respiratory airways and lung tissue. There was an increase of MDA and PC formation associated with a deficiency of the antioxidant defense reflected by DPPH decreases. There were no differences between systemic and local lung concentrations of oxidized molecules. After vitamin E treatment oxidative stress was reduced mostly due to serum, BALF and lung tissue GSH and DPPH increase. CONCLUSION: The study showed that in rat TDI-induced asthma there was oxidative stress caused by increased ROS production and antioxidants deficiency, and vitamin E reduced ROS production and improved antioxidant defense</style></abstract><notes><style face="normal" font="default">DA - 20161118IS - 1222-2119 (Print)IS - 1222-2119 (Linking)LA - engPT - Journal ArticleCO - France -CO - Romania -</style></notes><work-type><style face="normal" font="default">10.15386/cjmed-611</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27857519">PM:27857519</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clujul Med\2016-89-499-505.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clujul Med\2016-89-499-505.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161118, Muti AD</style></custom2><misc3><style face="normal" font="default">10.15386/cjmed-611</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40277</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schindler,T.</style></author><author><style face="normal" font="default"> Sinn,J.K.</style></author><author><style face="normal" font="default"> Osborn,D.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Newborn Care, Royal Hospital for Women, Barker Street, Randwick, NSW, Australia, 2031</style></auth-address><titles><title><style face="normal" font="default">Polyunsaturated fatty acid supplementation in infancy for the prevention of allergy</style></title><secondary-title><style face="normal" font="default">Cochrane Database Syst Rev</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cochrane Database Syst Rev</style></abbr-1></periodical><pages end="" start="CD010112">CD010112-</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acids</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Fatty acid</style></keyword><keyword><style face="normal" font="default"> Fatty Acids</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infancy</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Infant Formula</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> newborn</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Polyunsaturated fatty acids</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research Support</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Supplements</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="28" Month="10" Year="2016">2016/10/28</year></dates><abstract><style face="normal" font="default">Early dietary intakes may influence the development of allergic disease. It is important to determine if dietary polyunsaturated fatty acids (PUFAs) given as supplements or added to infant formula prevent the development of allergy. To determine the effect of higher PUFA intake during infancy to prevent allergic disease. We used the standard search strategy of the Cochrane Neonatal Review group to search the Cochrane Central Register of Controlled Trials (CENTRAL 2015, Issue 9), MEDLINE (1966 to 14 September 2015), EMBASE (1980 to 14 September 2015) and CINAHL (1982 to 14 September 2015). We also searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials and quasi-randomised trials. Randomised and quasi-randomised controlled trials that compared the use of a PUFA with no PUFA in infants for the prevention of allergy. Two review authors independently selected trials, assessed trial quality and extracted data from the included studies. We used fixed-effect analyses. The treatment effects were expressed as risk ratio (RR) with 95% confidence intervals (CI). We used the GRADE approach to assess the quality of evidence. The search found 17 studies that assessed the effect of higher versus lower intake of PUFAs on allergic outcomes in infants. Only nine studies enrolling 2704 infants reported allergy outcomes that could be used in meta-analyses. Of these, there were methodological concerns for eight.In infants up to two years of age, meta-analyses found no difference in incidence of all allergy (1 study, 323 infants; RR 0.96, 95% CI 0.73 to 1.26; risk difference (RD) -0.02, 95% CI -0.12 to 0.09; heterogeneity not applicable), asthma (3 studies, 1162 infants; RR 1.04, 95% CI 0.80 to 1.35, I2 = 0%; RD 0.01, 95% CI -0.04 to 0.05, I2 = 0%), dermatitis/eczema (7 studies, 1906 infants; RR 0.93, 95% CI 0.82 to 1.06, I2 = 0%; RD -0.02, 95% CI -0.06 to 0.02, I2 = 0%) or food allergy (3 studies, 915 infants; RR 0.81, 95% CI 0.56 to 1.19, I2 = 63%; RD -0.02, 95% CI -0.06 to 0.02, I2 = 74%). There was a reduction in allergic rhinitis (2 studies, 594 infants; RR 0.47, 95% CI 0.23 to 0.96, I2 = 6%; RD -0.04, 95% CI -0.08 to -0.00, I2 = 54%; number needed to treat for an additional beneficial outcome (NNTB) 25, 95% CI 13 to infinity).In children aged two to five years, meta-analysis found no difference in incidence of all allergic disease (2 studies, 154 infants; RR 0.69, 95% CI 0.47 to 1.02, I2 = 43%; RD -0.16, 95% CI -0.31 to -0.00, I2 = 63%; NNTB 6, 95% CI 3 to infinity), asthma (1 study, 89 infants; RR 0.45, 95% CI 0.20 to 1.02; RD -0.20, 95% CI -0.37 to -0.02; heterogeneity not applicable; NNTB 5, 95% CI 3 to 50), dermatitis/eczema (2 studies, 154 infants; RR 0.65, 95% CI 0.34 to 1.24, I2 = 0%; RD -0.09 95% CI -0.22 to 0.04, I2 = 24%) or food allergy (1 study, 65 infants; RR 2.27, 95% CI 0.25 to 20.68; RD 0.05, 95% CI -0.07 to 0.16; heterogeneity not applicable).In children aged two to five years, meta-analysis found no difference in prevalence of all allergic disease (2 studies, 633 infants; RR 0.98, 95% CI 0.81 to 1.19, I2 = 36%; RD -0.01, 95% CI -0.08 to 0.07, I2 = 0%), asthma (2 studies, 635 infants; RR 1.12, 95% CI 0.82 to 1.53, I2 = 0%; RD 0.02, 95% CI -0.04 to 0.09, I2 = 0%), dermatitis/eczema (2 studies, 635 infants; RR 0.81, 95% CI 0.59 to 1.09, I2 = 0%; RD -0.04 95% CI -0.11 to 0.02, I2 = 0%), allergic rhinitis (2 studies, 635 infants; RR 1.02, 95% CI 0.83 to 1.25, I2 = 0%; RD 0.01, 95% CI -0.06 to 0.08, I2 = 0%) or food allergy (1 study, 119 infants; RR 0.27, 95% CI 0.06 to 1.19; RD -0.10, 95% CI -0.20 to -0.00; heterogeneity not applicable; NNTB 10, 95% CI 5 to infinity). There is no evidence that PUFA supplementation in infancy has an effect on infant or childhood allergy, asthma, dermatitis/eczema or food allergy. However, the quality of evidence was very low. There was insufficient evidence to determine an effect on allergic rhinitis</style></abstract><notes><style face="normal" font="default">DA - 20161027IS - 1361-6137 (Linking)LA - ENGPT - ReviewPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tPT - Research Support, N.I.H., ExtramuralCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1002/14651858.CD010112.pub2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27788565">PM:27788565</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cochrane Database Syst Rev\2016-10-CD010112.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cochrane Database Syst Rev\2016-10-CD010112.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161027, Schindler T</style></custom2><misc3><style face="normal" font="default">10.1002/14651858.CD010112.pub2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40278</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ganaie,M.B.</style></author><author><style face="normal" font="default"> Munavvar,M.</style></author><author><style face="normal" font="default"> Gordon,M.</style></author><author><style face="normal" font="default"> Lim,H.F.</style></author><author><style face="normal" font="default"> Evans,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory Medicine, Royal Stoke University Hospital, Stoke-on-Trent, UK</style></auth-address><titles><title><style face="normal" font="default">Patient- and parent-initiated oral steroids for asthma exacerbations</style></title><secondary-title><style face="normal" font="default">Cochrane Database Syst Rev</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cochrane Database Syst Rev</style></abbr-1></periodical><pages end="" start="CD012195">CD012195-</pages><volume><style face="normal" font="default">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Cochrane Airways</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Data Collection</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Language</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral corticosteroids</style></keyword><keyword><style face="normal" font="default"> Oral steroids</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Self Administration</style></keyword><keyword><style face="normal" font="default"> Self-administration</style></keyword><keyword><style face="normal" font="default"> serious adverse events</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> World Health</style></keyword><keyword><style face="normal" font="default"> World Health Organization</style></keyword></keywords><dates><year Day="12" Month="12" Year="2016">2016/12/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is a chronic inflammatory disease of the airways affecting an estimated 334 million people worldwide. During severe exacerbations, patients may need to attend a medical centre or hospital emergency department for treatment with systemic corticosteroids, which can be administered intravenously or orally. Some people with asthma are prescribed oral corticosteroids (OCS) for self-administration (i.e. patient-initiated) or to administer to their child with asthma (i.e. parent-initiated), in the event of an exacerbation. This approach to treatment is becoming increasingly common. OBJECTIVES: To evaluate the effectiveness and safety of patient- or parent-initiated oral steroids for adults and children with asthma exacerbations. SEARCH METHODS: We identified trials from Cochrane Airways' Specialised Register (CASR) and also conducted a search of the US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization International Clinical Trials Registry Platform (apps.who.int/trialsearch). We searched CASR from its inception to 18 May 2016 and trial registries from their inception to 24 August 2016; we imposed no restriction on language of publication. SELECTION CRITERIA: We looked for randomised controlled trials (RCTs), reported as full-text, those published as abstract only, and unpublished data; we excluded cross-over trials.We looked for studies where adults (aged 18 years or older) or children of school age (aged 5 years or older) with asthma were randomised to receive: (a) any patient-/parent-initiated OCS or (b) placebo, normal care, alternative active treatment, or an identical personalised asthma action plan without the patient- or parent-initiated OCS component. DATA COLLECTION AND ANALYSIS: Two review authors independently screened the search results to identify any studies that met the prespecified inclusion criteria.The prespecified primary outcomes were hospital admissions for asthma, asthma symptoms at follow-up and serious adverse events. MAIN RESULTS: Despite comprehensive searches of electronic databases and clinical trial registries, we did not identify any studies meeting the inclusion criteria for this review. Five potentially relevant studies were excluded for two reasons: the intervention did not meet the inclusion criteria for this review (three studies) and studies had a cross-over design (two studies). Two of the excluded studies asked the relevant clinical question. However, these studies were excluded due to their cross-over design, as per the protocol. We contacted the authors of the cross-over trials who were unable to provide data for the first treatment period (i.e. prior to cross-over). AUTHORS' CONCLUSIONS: There is currently no evidence from randomised trials (non-cross-over design) to inform the use of patient- or parent-initiated oral corticosteroids in people with asthma</style></abstract><notes><style face="normal" font="default">DA - 20161212IS - 1469-493X (Electronic)IS - 1361-6137 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1002/14651858.CD012195.pub2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27943237">PM:27943237</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cochrane Database Syst Rev\2016-12-CD012195.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cochrane Database Syst Rev\2016-12-CD012195.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161212, Ganaie MB</style></custom2><misc3><style face="normal" font="default">10.1002/14651858.CD012195.pub2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40279</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kirkland,S.W.</style></author><author><style face="normal" font="default"> Vandenberghe,C.</style></author><author><style face="normal" font="default"> Voaklander,B.</style></author><author><style face="normal" font="default"> Nikel,T.</style></author><author><style face="normal" font="default"> Campbell,S.</style></author><author><style face="normal" font="default"> Rowe,B.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Emergency Medicine, University of Alberta, Edmonton, AB, Canada</style></auth-address><titles><title><style face="normal" font="default">Combined inhaled beta-agonist and anticholinergic agents for emergency management in adults with asthma</style></title><secondary-title><style face="normal" font="default">Cochrane Database Syst Rev</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cochrane Database Syst Rev</style></abbr-1></periodical><pages end="" start="CD001284">CD001284-</pages><volume><style face="normal" font="default">1</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">acute asthma</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Cochrane Airways</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Controlled Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Data Collection</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Emergency Medicine</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Language</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Peak expiratory flow</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> single dose</style></keyword><keyword><style face="normal" font="default"> Statistics</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Tremor</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="1" Year="2017">2017/1/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Inhaled short-acting anticholinergics (SAAC) and short-acting beta(2)-agonists (SABA) are effective therapies for adult patients with acute asthma who present to the emergency department (ED). It is unclear, however, whether the combination of SAAC and SABA treatment is more effective in reducing hospitalisations compared to treatment with SABA alone. OBJECTIVES: To conduct an up-to-date systematic search and meta-analysis on the effectiveness of combined inhaled therapy (SAAC + SABA agents) vs. SABA alone to reduce hospitalisations in adult patients presenting to the ED with an exacerbation of asthma. SEARCH METHODS: We searched MEDLINE, Embase, CINAHL, SCOPUS, LILACS, ProQuest Dissertations &amp; Theses Global and evidence-based medicine (EBM) databases using controlled vocabulary, natural language terms, and a variety of specific and general terms for inhaled SAAC and SABA drugs. The search spanned from 1946 to July 2015. The Cochrane Airways Group provided search results from the Cochrane Airways Group Register of Trials which was most recently conducted in July 2016. An extensive search of the grey literature was completed to identify any other potentially relevant studies. SELECTION CRITERIA: Included studies were randomised or controlled clinical trials comparing the effectiveness of combined inhaled therapy (SAAC and SABA) to SABA treatment alone to prevent hospitalisations in adults with acute asthma in the emergency department. Two independent review authors assessed studies for inclusion using pre-determined criteria. DATA COLLECTION AND ANALYSIS: For dichotomous outcomes, we calculated individual and pooled statistics as risk ratios (RR) or odds ratios (OR) with 95% confidence intervals (CI) using a random-effects model and reporting heterogeneity (I(2)). For continuous outcomes, we reported individual trial results using mean differences (MD) and pooled results as weighted mean differences (WMD) or standardised mean differences (SMD) with 95% CIs using a random-effects model. MAIN RESULTS: We included 23 studies that involved a total of 2724 enrolled participants. Most studies were rated at unclear or high risk of bias.Overall, participants receiving combination inhaled therapy were less likely to be hospitalised (RR 0.72, 95% CI 0.59 to 0.87; participants = 2120; studies = 16; I(2) = 12%; moderate quality of evidence). An estimated 65 fewer patients per 1000 would require hospitalisation after receiving combination therapy (95% 30 to 95), compared to 231 per 1000 patients receiving SABA alone. Although combination inhaled therapy was more effective than SABA treatment alone in reducing hospitalisation in participants with severe asthma exacerbations, this was not found for participants with mild or moderate exacerbations (test for difference between subgroups P = 0.02).Participants receiving combination therapy were more likely to experience improved forced expiratory volume in one second (FEV(1)) (MD 0.25 L, 95% CI 0.02 to 0.48; participants = 687; studies = 6; I(2) = 70%; low quality of evidence), peak expiratory flow (PEF) (MD 36.58 L/min, 95% CI 23.07 to 50.09; participants = 1056; studies = 12; I(2) = 25%; very low quality of evidence), increased percent change in PEF from baseline (MD 24.88, 95% CI 14.83 to 34.93; participants = 551; studies = 7; I(2) = 23%; moderate quality of evidence), and were less likely to return to the ED for additional care (RR 0.80, 95% CI 0.66 to 0.98; participants = 1180; studies = 5; I(2) = 0%; moderate quality of evidence) than participants receiving SABA alone.Participants receiving combination inhaled therapy were more likely to experience adverse events than those treated with SABA agents alone (OR 2.03, 95% CI 1.28 to 3.20; participants = 1392; studies = 11; I(2) = 14%; moderate quality of evidence). Among patients receiving combination therapy, 103 per 1000 were likely to report adverse events (95% 31 to 195 more) compared to 131 per 1000 patients receiving SABA alone. AUTHORS' CONCLUSIONS: Overall, combination inhaled therapy with SAAC and SABA reduced hospitalisation and improved pulmonary function in adults presenting to the ED with acute asthma. In particular, combination inhaled therapy was more effective in preventing hospitalisation in adults with severe asthma exacerbations who are at increased risk of hospitalisation, compared to those with mild-moderate exacerbations, who were at a lower risk to be hospitalised. A single dose of combination therapy and multiple doses both showed reductions in the risk of hospitalisation among adults with acute asthma. However, adults receiving combination therapy were more likely to experience adverse events, such as tremor, agitation, and palpitations, compared to patients receiving SABA alone</style></abstract><notes><style face="normal" font="default">DA - 20170111IS - 1469-493X (Electronic)IS - 1361-6137 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1002/14651858.CD001284.pub2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28076656">PM:28076656</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cochrane Database Syst Rev\2017-1-CD001284.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cochrane Database Syst Rev\2017-1-CD001284.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170111, Kirkland SW</style></custom2><misc3><style face="normal" font="default">10.1002/14651858.CD001284.pub2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40280</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chiriac,A.</style></author><author><style face="normal" font="default"> Birsan,C.</style></author><author><style face="normal" font="default"> Podoleanu,C.</style></author><author><style face="normal" font="default"> Chiriac,A.E.</style></author><author><style face="normal" font="default"> Stolnicu,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermato-Physiology, Apollonia University, Str. Muzicii 2, Iasi, 700399, Romania</style></auth-address><titles><title><style face="normal" font="default">Pragmatic management of (suspected allergic) diaper dermatitis</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="130" start="129">129-130</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Romania</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - LetterCO - Romania -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12663</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28095634">PM:28095634</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-129-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-129-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Chiriac A</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12663</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40281</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Karlberg,A.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Chemistry and Molecular Biology, Dermatochemistry, University of Gothenburg, SE-412 96, Gothenburg, Sweden</style></auth-address><titles><title><style face="normal" font="default">Oxidation products and the skin - the effect of hydroperoxides</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="66" start="63">63-66</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Biology</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Molecular Biology</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - EditorialCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12735</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28095630">PM:28095630</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-63-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-63-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Karlberg AT</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12735</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40282</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bruze,M.</style></author><author><style face="normal" font="default"> Mowitz,M.</style></author><author><style face="normal" font="default"> Zimerson,E.</style></author><author><style face="normal" font="default"> Bergendorff,O.</style></author><author><style face="normal" font="default"> Dahlin,J.</style></author><author><style face="normal" font="default"> Engfeldt,M.</style></author><author><style face="normal" font="default"> Isaksson,M.</style></author><author><style face="normal" font="default"> Ponten,A.</style></author><author><style face="normal" font="default"> Svedman,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Occupational and Environmental Dermatology, Skane University Hospital, Lund University, 205 02 Malmo, Sweden</style></auth-address><titles><title><style face="normal" font="default">No contact allergy to acrylic acid and methacrylic acid in routinely tested dermatitis patients</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="118" start="116">116-118</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12627</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28095636">PM:28095636</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-116-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-116-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Bruze M</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12627</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40283</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mohamoud,A.A.</style></author><author><style face="normal" font="default"> Andersen,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and the Allergy Centre, Odense University Hospital, 5000, Odense C, DenmarkDepartment of Dermatology and the Allergy Centre, Odense University Hospital, 5000, Odense C, DenmarkDermatological Investigations Scandinavia, 5000, Odense C, Denmark</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by textile dyes mimicking atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="120" start="119">119-120</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> Scandinavia</style></keyword><keyword><style face="normal" font="default"> textile dyes</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12630</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28095633">PM:28095633</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-119-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-119-20.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Mohamoud AA</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12630</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40284</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dekeyser,S.</style></author><author><style face="normal" font="default"> van Tomme,M.</style></author><author><style face="normal" font="default"> Boone,B.</style></author><author><style face="normal" font="default"> van Geel,N.</style></author><author><style face="normal" font="default"> Lapeere,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Ghent University Hospital, 9000, Ghent, Belgium</style></auth-address><titles><title><style face="normal" font="default">Occupational allergic contact dermatitis caused by thebaine and oripavine</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="122" start="120">120-122</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Thebaine</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12648</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28095631">PM:28095631</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-120-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-120-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Dekeyser S</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12648</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40285</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Elliott,J.F.</style></author><author><style face="normal" font="default"> Ramzy,A.</style></author><author><style face="normal" font="default"> Nilsson,U.</style></author><author><style face="normal" font="default"> Moffat,W.</style></author><author><style face="normal" font="default"> Suzuki,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Dermatology, Department of Medicine &amp; Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, T6G 2E1, Canada</style></auth-address><titles><title><style face="normal" font="default">Severe intractable eyelid dermatitis probably caused by exposure to hydroperoxides of linalool in a heavily fragranced shampoo</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="115" start="114">114-115</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Canada</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Eyelid</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12738</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28095632">PM:28095632</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-114-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-114-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Elliott JF</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12738</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40286</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bregnbak,D.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author><author><style face="normal" font="default"> Jellesen,M.S.</style></author><author><style face="normal" font="default"> Zachariae,C.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, National Allergy Research Centre, Herlev and Gentofte Hospital, University of Copenhagen, 2900, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Experimental patch testing with chromium-coated materials</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Alloys</style></keyword><keyword><style face="normal" font="default"> Chromium</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Corrosion</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Potassium</style></keyword><keyword><style face="normal" font="default"> Potassium Dichromate</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="25" Month="1" Year="2017">2017/1/25</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chromium coatings on metal alloys can be decorative, and prevent corrosion and metal ion release. We recently showed that handling of a chromium-containing disc resulted in chromium deposition on the skin. OBJECTIVES: To examine patch test reactivity to chromium-coated discs. METHODS: We included 15 patients: 10 chromium-allergic patients, and 5 patients without chromium allergy. All were patch tested with potassium dichromate, cobalt chloride, nickel sulfate, and nine different metallic discs. The chromium-allergic patients were also patch tested with serial dilutions of potassium dichromate. RESULTS: Positive/weaker reactions were observed to disc B (1 of 10), disc C (1 of 10), and disc D, disc E, and disc I (4 of 10 each). As no controls reacted to any of the discs, the weak reactions indicate allergic reactions. Positive patch test reactions to 1770 ppm chromium(VI) in the serial dilutions of potassium dichromate were observed in 7 of 10 patients. When the case group was narrowed down to include only the patients with a current positive patch test reaction to potassium dichromate, elicitation of dermatitis by both chromium(III) and chromium(VI) discs was observed in 4 of 7 of patients. CONCLUSIONS: Many of the patients reacted to both chromium(III) and chromium(VI) surfaces. Our results indicate that both chromium(VI) and chromium(III) pose a risk to chromium-allergic patients</style></abstract><notes><style face="normal" font="default">DA - 20170125IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">0.1111/cod.12747</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28120332">PM:28120332</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170125-BregnbakD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170125-BregnbakD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170125, Bregnbak D</style></custom2><misc3><style face="normal" font="default">0.1111/cod.12747</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40287</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nielsen,M.M.</style></author><author><style face="normal" font="default"> Schmidt,J.D.</style></author><author><style face="normal" font="default"> Christensen,J.P.</style></author><author><style face="normal" font="default"> Geisler,C.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author><author><style face="normal" font="default"> Bonefeld,C.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology and Microbiology, University of Copenhagen, 2200, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default">Detection of local inflammation induced by repeated exposure to contact allergens by use of IVIS SpectrumCT analyses</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact allergens</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Spleen</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="25" Month="1" Year="2017">2017/1/25</year></dates><abstract><style face="normal" font="default">BACKGROUND: Contact allergy is characterized by local skin inflammation that, in some cases, can result in systemic immune activation. OBJECTIVES: To investigate whether IVIS SpectrumCT analyses can be used to detect the immune response induced by contact allergens. METHODS: Mice were repeatedly exposed to vehicle or allergens on the ears. The local and systemic responses were analysed at different times with the ProSense 750 FAST probe in IVIS SpectrumCT measurements. In addition, changes in ear thickness, cytokine profile in the skin and immunological phenotype in the draining lymph nodes and spleen were determined. RESULTS: Local inflammation was detected by ProSense 750 FAST and correlated with changes in ear thickness, cytokine profile and immunological phenotype following exposure to the strong contact allergen 2,4-dinitrofluorobenzene. Analysis of the systemic response with ProSense 750 FAST did not show any difference between allergen-exposed and control mice, although fluorescence-activated cell sorting analysis of the spleen showed increased numbers of gammadelta T cells and CD11b+ CD11c+ MHCII+ cells in allergen-treated mice. CONCLUSIONS: IVIS SpectrumCT analyses with ProSense 750 FAST as the probe can be used to detect local immune responses induced by contact allergens</style></abstract><notes><style face="normal" font="default">DA - 20170125IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12746</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28120518">PM:28120518</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170125-NielsenMM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170125-NielsenMM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170125, Nielsen MM</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12746</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40288</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Foss-Skiftesvik,M.H.</style></author><author><style face="normal" font="default"> Winther,L.</style></author><author><style face="normal" font="default"> Johnsen,C.R.</style></author><author><style face="normal" font="default"> Zachariae,C.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, National Allergy Research Centre, Copenhagen University Hospital Gentofte, 2900, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Incidence of skin and respiratory diseases among Danish hairdressing apprentices</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact urticaria</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand eczema</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Profession</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Respiratory diseases</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="16" Month="1" Year="2017">2017/1/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hairdressing is one of the professions with the highest risk of occupational skin and respiratory diseases. The incidence of these diseases in hairdressing apprentices has been studied only sparsely. OBJECTIVE: To determine the incidence of skin and respiratory diseases in hairdressing apprentices, and to explore whether hairdressing apprentices leave the trade during training because of these diseases. METHODS: A 3-year follow-up questionnaire study was conducted among 248 hairdressing apprentices and a control group comprising 816 young adults from the general population. RESULTS: The incidence rate ratios (IRRs) for contact urticaria (IRR 4.7, 95%CI: 2.6-8.6), hand eczema (IRR 1.7, 95%CI: 1.1-2.6) and rhinitis symptoms (IRR 1.6, 95%CI: 1.2-2.2) were significantly increased in the hairdressing apprentices, whereas wheezing was similar between groups. During the follow-up period, 21.8% of the hairdressing apprentices had left the trade, and 70.3% of these had left because of health complaints. The most frequently reported reasons for leaving were musculoskeletal pain (47.4%) and skin diseases (47.4%), followed by respiratory symptoms (23.7%). CONCLUSIONS: Hairdressing apprentices are at increased risk for contact urticaria, hand eczema and rhinitis symptoms compared with the general population, and a substantial proportion leave the trade because of these diseases, causing a 'healthy worker survivor effect.'</style></abstract><notes><style face="normal" font="default">DA - 20170116IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12744</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28090651">PM:28090651</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170116-FossSkiftesvikMH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170116-FossSkiftesvikMH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170116, Foss-Skiftesvik MH</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12744</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40289</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Clerens,I.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Hospitals KU Leuven, 3000, Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by panthenol: a rare but relevant sensitizer</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="123" start="122">122-123</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12685</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28095635">PM:28095635</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-122-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-122-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Clerens I</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12685</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40290</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Smets,K.</style></author><author><style face="normal" font="default"> Werbrouck,J.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author><author><style face="normal" font="default"> Gilissen,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Hospitals KU Leuven, 3000, Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="default">Sensitization from ketotifen fumarate in eye drops presenting as chronic conjunctivitis</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="126" start="124">124-126</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Belgium</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Conjunctivitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Ketotifen</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12695</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28095628">PM:28095628</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-124-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-124-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Smets K</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12695</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40291</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rocha,V.B.</style></author><author><style face="normal" font="default"> Machado,C.J.</style></author><author><style face="normal" font="default"> Bittencourt,F.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Unit, Clinics Hospital, Federal University of Minas Gerais, Belo Horizonte, BrazilSocial Medicine of Medical School, Federal University of Minas Gerais, Belo Horizonte 30150-260, BrazilDermatology Unit, Clinics Hospital, Federal University of Minas Gerais, Belo Horizonte, Brazil</style></auth-address><titles><title><style face="normal" font="default">Presence of allergens in the vehicles of Brazilian dermatological products</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="128" start="126">126-128</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword><keyword><style face="normal" font="default"> Vehicles</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12648</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28095629">PM:28095629</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-126-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-126-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Rocha VB</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12648</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40292</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Woessner,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy, Asthma, and Immunology Division, Scripps Clinic Medical Group, 3811 Valley Centre Drive, San Diego, CA, 92130, USA.</style></auth-address><titles><title><style face="normal" font="default">Update on Aspirin-Exacerbated Respiratory Disease</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="2">2-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AERD</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Alcohol</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Arachidonic Acid</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin desensitization</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> dysregulation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate lymphoid cells</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyposis</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Platelet</style></keyword><keyword><style face="normal" font="default"> Platelets</style></keyword><keyword><style face="normal" font="default"> Polyposis</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">Aspirin-exacerbated respiratory disease (AERD) is an acquired disease characterized by chronic eosinophilic airway inflammation with underlying dysregulation of arachidonic acid metabolism. The purpose of this paper is to review the latest developments in our understanding of the underlying pathophysiology including the role of eosinophils, mast cells, innate lymphoid cells (ILC2), and platelets. Clinical features such as respiratory reactions induced by alcohol, aggressive nasal polyposis, and anosmia will allow for earlier recognition of these patients in clinical practice. The current state of the art management of AERD will be addressed including the ongoing central role for aspirin desensitization and high-dose aspirin therapy</style></abstract><notes><style face="normal" font="default">DA - 20170118IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0673-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28097500">PM:28097500</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170118, Woessner KM</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0673-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40293</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McLaughlin,L.P.</style></author><author><style face="normal" font="default"> Bollard,C.M.</style></author><author><style face="normal" font="default"> Keller,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Cancer and Immunology Research, Children's National Health System, Washington, DC, USA</style></auth-address><titles><title><style face="normal" font="default">Adoptive T Cell Immunotherapy for Patients with Primary Immunodeficiency Disorders</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="3">3-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cancer</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> DC</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hematopoietic Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Immunotherapy</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T lymphocyte</style></keyword><keyword><style face="normal" font="default"> T lymphocytes</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-lymphocyte</style></keyword><keyword><style face="normal" font="default"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral infection</style></keyword><keyword><style face="normal" font="default"> Viral infections</style></keyword><keyword><style face="normal" font="default"> Washington</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">Primary immunodeficiency disorders (PID) are a group of inborn errors of immunity with a broad range of clinical severity but often associated with recurrent and serious infections. While hematopoietic stem cell transplantation (HSCT) can be curative for some forms of PID, chronic and/or refractory viral infections remain a cause of morbidity and mortality both before and after HSCT. Although antiviral pharmacologic agents exist for many viral pathogens, these are associated with significant costs and toxicities and may not be effective for increasingly drug-resistant pathogens. Thus, the emergence of adoptive immunotherapy with virus-specific T lymphocytes (VSTs) is an attractive option for addressing the underlying impaired T cell immunity in many PID patients. VSTs have been utilized for PID patients following HSCT in many prior phase I trials, and may potentially be beneficial before HSCT in patients with chronic viral infections. We review the various methods of generating VSTs, clinical experience using VSTs for PID patients, and current limitations as well as potential ways to broaden the clinical applicability of adoptive immunotherapy for PID patients</style></abstract><notes><style face="normal" font="default">DA - 20170124IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0669-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28116637">PM:28116637</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170124, McLaughlin LP</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0669-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40294</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Papakonstantinou,E.</style></author><author><style face="normal" font="default"> Raap,U.</style></author></authors></contributors><titles><title><style face="normal" font="default">Oral Cavity and Allergy: Meeting the Diagnostic and Therapeutic Challenge</style></title><secondary-title><style face="normal" font="default">Curr Oral Health Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Oral Health Rep</style></full-title></periodical><pages end="355" start="347">347-355</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">additives</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Cheilitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Dental Materials</style></keyword><keyword><style face="normal" font="default"> dentist</style></keyword><keyword><style face="normal" font="default"> Dentists</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic tool</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hygiene</style></keyword><keyword><style face="normal" font="default"> Interpretation</style></keyword><keyword><style face="normal" font="default"> Lip</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> oral mucosa</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Stomatitis</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="default">2196-3002</style></isbn><abstract><style face="normal" font="default">Allergic reactions of the oral mucosa are associated with diverse symptoms and can severely affect patients</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖ quality of life. Oral mucosa changes such as stomatitis or lichenoid reactions can be the first evidence of a contact allergy, with oral lichenoid reactions after contact with dental restorations, especially amalgam fillings, being among the most common clinical reactions. Additives in foods and oral hygiene products may also cause allergic mucosal reactions. Subjective symptoms, such as pain, burning feeling, or dryness of the oral mucosa, as well as cheilitis or lip and facial swelling, may not only have an allergic component but may also be associated with other diseases that have to be excluded. A complete and thorough clinical examination of the oral mucosa is the first step in the diagnosis of a contact allergy. A detailed history of the patient</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖs oral care products, drugs, and dental materials is both essential and helpful for the clinician. As a result of the presence of mucosal changes, a patch test can be used for the diagnosis of contact allergy of delayed type. Although the patch test is the standard diagnostic tool for such types of contact allergy, proper interpretation of patch-test results and their clinical relevance can be challenging. As the number of patients with allergies resulting from different materials increases over the years, and a larger number of different dental materials are found to induce an allergy, it is essential for dentists to be aware of the possible allergic reactions to dental materials. Thus, we aimed to develop a systematic approach for contact allergy of the oral cavity, focusing not only on clinical manifestations and diagnosis but also on management and prediction of the risk of oral allergic reactions. A multidisciplinary approach for patients with an oral allergy is essential, with participation of physicians of different specialties, including dentists, allergists and dermatologists</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1007/s40496-016-0111-1</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40496-016-0111-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Oral Health Rep\2016-3-347-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Oral Health Rep\2016-3-347-55.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170125, Papakonstantinou E</style></custom2><misc3><style face="normal" font="default">10.1007/s40496-016-0111-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40295</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kishikawa,A.</style></author><author><style face="normal" font="default"> Amen,Y.</style></author><author><style face="normal" font="default"> Shimizu,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Systematic Forest and Forest Products Sciences, Department of Agro-Environmental Sciences, Graduate School of Bioresource and Bioenvironmental Science, Kyushu University, 6-10-1 Hakozaki, Higashi-ku, Fukuoka, 812-8581, Japan</style></auth-address><titles><title><style face="normal" font="default">Anti-allergic triterpenes isolated from olive milled waste</style></title><secondary-title><style face="normal" font="default">Cytotechnology</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cytotechnology</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> anti-allergic activity</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Egypt</style></keyword><keyword><style face="normal" font="default"> Ethanol</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Leukemia</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> rat</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Structure activity relationship</style></keyword><keyword><style face="normal" font="default"> Structure-Activity Relationship</style></keyword><keyword><style face="normal" font="default"> Triterpenes</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="default">The degranulation of basophils stimulated by antigen is one of the allergic mechanisms of immediate hypersensitivity reactions. In a previous study, the beta-hexosaminidase release of rat basophilic leukemia (RBL-2H3) cells stimulated by IgE cross-linking was specifically inhibited by ethanol extract of olive milled waste (OMW). OMW is a potential source of triterpenes, which show several biological activities. However, little is known about the effect of triterpenes in OMW on beta-hexosaminidase release. Here we investigated anti-allergic triterpenes from the ethanol extract of OMW, and we discuss the structure-activity relationship. We subjected ethanol extract of OMW to activity-guided fractionation; this led to the isolation of five known triterpenes, i.e., maslinic acid (1), oleanolic acid (2), punicanolic acid (3), 2-O-acetylmaslinic acid (4), and epimaslinic acid (5) as well as one new triterpene, 11-oxo-maslinic acid (6). An anti-allergic assay revealed that 2-O-acetylmaslinic acid (4) and 11-oxo-maslinic acid (6) showed anti-allergic activity. Considering the structure-activity relationship of these triterpenes, it appears that the existence of a ketone group at C-11 or an acetyl group at C-2 would influence the anti-allergic activity</style></abstract><notes><style face="normal" font="default">DA - 20170111IS - 0920-9069 (Print)IS - 0920-9069 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - Egypt -</style></notes><work-type><style face="normal" font="default">10.1007/s10616-016-0058-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28074390">PM:28074390</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cytotechnology\20170111-KishikawaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cytotechnology\20170111-KishikawaA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170111, Kishikawa A</style></custom2><misc3><style face="normal" font="default">10.1007/s10616-016-0058-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40296</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brix,N.</style></author><author><style face="normal" font="default"> Stokholm,L.</style></author><author><style face="normal" font="default"> Jonsdottir,F.</style></author><author><style face="normal" font="default"> Kristensen,K.</style></author><author><style face="normal" font="default"> Secher,N.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Comparable risk of childhood asthma after vaginal delivery and emergency caesarean section</style></title><secondary-title><style face="normal" font="default">Dan Med J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Dan Med J</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Birth Weight</style></keyword><keyword><style face="normal" font="default"> Caesarean section</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> pH</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Twins</style></keyword><keyword><style face="normal" font="default"> Umbilical Cord</style></keyword><keyword><style face="normal" font="default"> Vaginal delivery</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Caesarean section is thought to be a risk factor for childhood asthma, but this association may be caused by confounding from, for instance, familial factors. To address this problem, we used twin pairs to assess the risk of childhood asthma after emergency caesarean section. METHODS: The study was a register-based nation-wide matched cohort study using twin pairs to minimise residual confounding. Included were twin pairs in which the first twin was delivered vaginally and the second by emergency caesarean section during the study period from January 1997 through December 2012. RESULTS: In total, 464 twin pairs (928 twins) were included. In 30 pairs, the first twin (vaginal delivery) was diagnosed with asthma, but the second twin (emergency caesarean section) was not. In 20 pairs, the second twin (emergency caesarean section) was diagnosed with asthma, but the first twin (vaginal delivery) was not. In 11 pairs, both twins developed asthma. In the unadjusted analysis, emergency caesarean section did not affect the risk of asthma (odds ratio = 0.67 (95% confidence interval: 0.38-1.17); p = 0.16). After adjusting for birth weight, gender, umbilical cord pH, Apgar score at 5 min. and neonatal respiratory morbidity, the risk of childhood asthma following emergency caesarean section remained unchanged. CONCLUSION: Emergency caesarean section was not associated with childhood asthma. FUNDING: none. TRIAL REGISTRATION: not relevant</style></abstract><notes><style face="normal" font="default">DA - 20161223IS - 2245-1919 (Electronic)IS - 2245-1919 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28007049">PM:28007049</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dan Med J\20161223-BrixN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dan Med J\20161223-BrixN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161223, Brix N</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40297</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Baos,S.</style></author><author><style face="normal" font="default"> Calzada,D.</style></author><author><style face="normal" font="default"> Cremades,L.</style></author><author><style face="normal" font="default"> Sastre,J.</style></author><author><style face="normal" font="default"> Quiralte,J.</style></author><author><style face="normal" font="default"> Florido,F.</style></author><author><style face="normal" font="default"> Lahoz,C.</style></author><author><style face="normal" font="default"> Cardaba,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunology Department, IIS- Jimenez Diaz Foundation, UAM, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Data set on a study of gene expression in peripheral samples to identify biomarkers of severity of allergic and nonallergic asthma</style></title><secondary-title><style face="normal" font="default">Data Brief</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Data Brief</style></abbr-1></periodical><pages end="510" start="505">505-510</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical phenotypes</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> nonallergic asthma</style></keyword><keyword><style face="normal" font="default"> PBMCs</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">This article contains information related to the research article entitled "Biomarkers associated with disease severity in allergic and nonallergic asthma" (S. Baos, D. Calzada, L. Cremades, J. Sastre, J. Quiralte, F. Florido, C. Lahoz, B. Cardaba, In press). Specifically, the clinical criteria stablished for selecting the study population (n=104 subjects) are described. Moreover, this article describes the criteria for selecting the 94 genes to be analyzed in PBMCs (peripheral blood mononuclear cells), it is provided a description of these genes and a Table with the genes most differentially expressed by clinical phenotypes and, finally it is detailed the experimental methodology followed for studying the protein expression of MSR1 (macrophage scavenger receptor 1), one of the genes evaluated in the research</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 2352-3409 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.dib.2016.12.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28054016">PM:28054016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Data Brief\2017-10-505-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Data Brief\2017-10-505-10.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Baos S</style></custom2><misc3><style face="normal" font="default">10.1016/j.dib.2016.12.035</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40298</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arikkatt,J.</style></author><author><style face="normal" font="default"> Ullah,M.A.</style></author><author><style face="normal" font="default"> Short,K.R.</style></author><author><style face="normal" font="default"> Zhang,V.</style></author><author><style face="normal" font="default"> Gan,W.J.</style></author><author><style face="normal" font="default"> Loh,Z.</style></author><author><style face="normal" font="default"> Werder,R.B.</style></author><author><style face="normal" font="default"> Simpson,J.</style></author><author><style face="normal" font="default"> Sly,P.D.</style></author><author><style face="normal" font="default"> Mazzone,S.B.</style></author><author><style face="normal" font="default"> Spann,K.M.</style></author><author><style face="normal" font="default"> Ferreira,M.A.</style></author><author><style face="normal" font="default"> Upham,J.W.</style></author><author><style face="normal" font="default"> Sukkar,M.B.</style></author><author><style face="normal" font="default"> Phipps,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Biomedical Science, University of Queensland, Brisbane, Australia</style></auth-address><titles><title><style face="normal" font="default">RAGE deficiency predisposes mice to virus-induced paucigranulocytic asthma</style></title><secondary-title><style face="normal" font="default">Elife</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Elife</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway smooth muscle</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pneumonia</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Remodelling</style></keyword><keyword><style face="normal" font="default"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> RSV</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral Load</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="default">Asthma is a chronic inflammatory disease. Although many patients with asthma develop type-2 dominated eosinophilic inflammation, a number of individuals develop paucigranulocytic asthma, which occurs in the absence of eosinophilia or neutrophilia. The aetiology of paucigranulocytic asthma is unknown. However, both respiratory syncytial virus (RSV) infection and mutations in the receptor for advanced glycation endproducts (RAGE) are risk factors for asthma development. Here, we show that RAGE deficiency impairs anti-viral immunity during an early-life infection with pneumonia virus of mice (PVM; a murine analogue of RSV). The elevated viral load was associated with the release of high mobility group box-1 (HMGB1) which triggered airway smooth muscle remodelling in early-life. Re-infection with PVM in later-life induced many of the cardinal features of asthma in the absence of eosinophilic or neutrophilic inflammation. Anti-HMGB1 mitigated both early-life viral disease and asthma-like features, highlighting HMGB1 as a possible novel therapeutic target</style></abstract><notes><style face="normal" font="default">DA - 20170118IS - 2050-084X (Electronic)IS - 2050-084X (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.7554/eLife.21199</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28099113">PM:28099113</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\ERJ Open Res\20170118-ArikkattJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\ERJ Open Res\20170118-ArikkattJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170118, Arikkatt J</style></custom2><misc3><style face="normal" font="default">10.7554/eLife.21199</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40299</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Higham,A.</style></author><author><style face="normal" font="default"> Cadden,P.</style></author><author><style face="normal" font="default"> Southworth,T.</style></author><author><style face="normal" font="default"> Rossall,M.</style></author><author><style face="normal" font="default"> Kolsum,U.</style></author><author><style face="normal" font="default"> Lea,S.</style></author><author><style face="normal" font="default"> Knowles,R.</style></author><author><style face="normal" font="default"> Singh,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester and University Hospital of South Manchester, NHS Foundation Trust, Manchester, UK</style></auth-address><titles><title><style face="normal" font="default">Leukotriene B4 levels in sputum from asthma patients</style></title><secondary-title><style face="normal" font="default">ERJ Open Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">ERJ Open Res</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Dithiothreitol</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Leukotriene B4</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Repair</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Poor asthma control is associated with increased airway neutrophils. Leukotriene B4 (LTB4) is a potent neutrophil chemoattractant. We examined the levels of LTB4 levels in the sputum of asthma patients and the relationship with disease severity. 47 asthma patients (categorised according to Global Initiative for Asthma treatment stage) and 12 healthy controls provided sputum samples that were processed first with PBS to obtain supernatants and secondly with dithiothreitol (DTT) to obtain supernatants. LTB4 levels were determined by ELISA. LTB4 levels were significantly higher in step 1 (steroid naive) and step 3 (inhaled corticosteroid (ICS) plus long acting beta-agonist) patients than step 2 patients (ICS alone) (p=0.02 and p=0.01, respectively). There was very good correlation when comparing PBS processed to DTT processed supernatants. High LTB4 levels were found in the sputum of asthmatics at step 3 despite ICS use</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 2312-0541 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1183/23120541.00088-2015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28053970">PM:28053970</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\ERJ Open Res\20170105-HighamA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\ERJ Open Res\20170105-HighamA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Higham A</style></custom2><misc3><style face="normal" font="default">10.1183/23120541.00088-2015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40300</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Saito,M.</style></author><author><style face="normal" font="default"> Kikuchi,Y.</style></author><author><style face="normal" font="default"> Kawarai,Lefor A.</style></author><author><style face="normal" font="default"> Hoshina,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Haga Red Cross Hospital, 2461 Daimachi Mouka, Tochigi, 321-4306, Japan.</style></auth-address><titles><title><style face="normal" font="default">High-dose nebulized budesonide is effective for mild asthma exacerbations in children under 3 years of age</style></title><secondary-title><style face="normal" font="default">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="27" start="22">22-27</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Budesonide</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> cortisol</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nebulized</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Oxygen</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Prednisolone</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">Background. High-dose inhaled steroid therapy has been shown to be effective in children and adults with asthma exacerbations. However, few reports are available regarding its efficacy for asthma exacerbations in younger children. Objective. In this study, we administered high-dose nebulized budesonide therapy for mild asthma exacerbations in children &lt; 3 years of age and compared its efficacy and safety with systemic steroid therapy. Methods. This study included children &lt; 3 years old with mild asthma exacerbations. Patients were randomly assigned to two groups: the BIS group was given 1 mg of nebulized budesonide twice daily, and the PSL group received prednisolone 0.5 mg/kg iv three times daily. Days to disappearance of wheezing, days of steroid use, days of oxygen use, serum cortisol level, and incidence of adverse events during treatment were compared between the groups. Result. Wheezing disappeared after an average of five days, and steroids were administered for an average of five days in both groups, with no significant difference in days of oxygen use. Serum cortisol levels at initiation and during the course of treatment remained unchanged in the BIS group, and were decreased in the PSL group; however, the decrease in the latter group was not pathologic. Conclusion. For children &lt; 3 years old with mild asthma exacerbations, high-dose nebulized budesonide therapy is equally as effective as systemic steroid therapy</style></abstract><notes><style face="normal" font="default">DA - 20170125IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28120603">PM:28120603</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-22-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-22-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170125, Saito M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40301</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Christensen,S.H.</style></author><author><style face="normal" font="default"> Timm,S.</style></author><author><style face="normal" font="default"> Janson,C.</style></author><author><style face="normal" font="default"> Benediktsdottir,B.</style></author><author><style face="normal" font="default"> Forsberg,B.</style></author><author><style face="normal" font="default"> Holm,M.</style></author><author><style face="normal" font="default"> Jogi,R.</style></author><author><style face="normal" font="default"> Johannessen,A.</style></author><author><style face="normal" font="default"> Omenaas,E.</style></author><author><style face="normal" font="default"> Sigsgaard,T.</style></author><author><style face="normal" font="default"> Svanes,C.</style></author><author><style face="normal" font="default"> Schlunssen,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Public Health, Section for Environment, Occupation and Health, Danish Ramazzini Centre, Aarhus University, Aarhus, Denmark</style></auth-address><titles><title><style face="normal" font="default">A clear urban-rural gradient of allergic rhinitis in a population-based study in Northern Europe</style></title><secondary-title><style face="normal" font="default">Eur Clin Respir J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Eur Clin Respir J</style></abbr-1></periodical><pages end="" start="33463">33463-</pages><volume><style face="normal" font="default">3</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diversity</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Estonia</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Iceland</style></keyword><keyword><style face="normal" font="default"> inner city</style></keyword><keyword><style face="normal" font="default"> inner-city</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Norway</style></keyword><keyword><style face="normal" font="default"> Occupation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Pets</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Rural</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">BACKGROUND: The protective effect of farm upbringing on allergic rhinitis is well known, but how upbringing in other environments influences the development of allergic rhinitis is scarcely investigated. The aim of this study was to investigate the association between place of upbringing and pet keeping in childhood and allergic rhinitis and nasal symptoms in adulthood. METHODS: The population-based Respiratory Health in Northern Europe study includes subjects from Denmark, Norway, Sweden, Iceland, and Estonia born in 1945-1973. This paper analyses 13,376 participants of the third study wave. Six categories of place of upbringing were defined: farm with livestock, farm without livestock, village in rural area, small town, city suburb, and inner city. Pets in the home at birth and during childhood were recorded. Data were analysed using adjusted logistic regression models. RESULTS: Livestock farm upbringing predicted less adult allergic rhinitis [odds ratio (OR) 0.68, 0.54-0.85] and nasal symptoms (OR 0.82, 0.68-0.99) than city upbringing, and an urban-rural gradient with decreasing risk per level of urbanisation was observed (OR 0.92, 0.88-0.94). Pets in the home at birth (OR 0.78, 0.68-0.88) and during childhood (OR 0.83, 0.74-0.93) were associated with less subsequent allergic rhinitis. Pet keeping did not explain the protective effect of place of upbringing. CONCLUSION: Risk of allergic rhinitis and nasal symptoms in adulthood was inversely associated with the level of urbanisation during upbringing. Pets at birth decreased the risk further, but did not explain the urban-rural gradient. Persistent beneficial effects of microbial diversity in early life might be an explanation for the findings</style></abstract><notes><style face="normal" font="default">DA - 20161128IS - 2001-8525 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - Sweden -CO - Iceland -CO - Estonia -CO - Norway -</style></notes><work-type><style face="normal" font="default">10.3402/ecrj.v3.33463</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27890047">PM:27890047</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Clin Respir J\2016-3-33463.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Clin Respir J\2016-3-33463.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161128, Christensen SH</style></custom2><misc3><style face="normal" font="default">10.3402/ecrj.v3.33463</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40302</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Leung,E.</style></author><author><style face="normal" font="default"> Al Efraij,K.</style></author><author><style face="normal" font="default"> Fitzgerald,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a British Columbia Cancer Research Centre Ringgold standard institution - Integrative Oncology , 675 10th W Ave, Vancouver , British Columbia V5Z 1L3 , Canada</style></auth-address><titles><title><style face="normal" font="default">The safety of mepolizumab for the treatment of asthma</style></title><secondary-title><style face="normal" font="default">Expert Opin Drug Saf</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Expert Opin Drug Saf</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse events</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> British Columbia</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Columbia</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> Headache</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Interleukin-5</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> mepolizumab</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Nasopharyngitis</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral corticosteroids</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> pharmacokinetics</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="24" Month="1" Year="2017">2017/1/24</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Asthma is an airway disease characterized by airway inflammation. It is associated with significant morbidity, mortality, and costs to the healthcare system and society. Interleukin-5 (IL-5) was identified for its role in eosinophil development, maturation, and survival in tissues, which has been related to disease severity and airway eosinophilia. Areas covered: In this review, we will present the pharmacokinetics and dynamics of mepolizumab in addition to efficacy and safety data. Expert Opinion: Mepolizumab is novel, new, first-in-class therapy targeting IL-5. It has been found to be particularly effective in the management of patients with asthma whose peripheral blood eosinophil count is at a well-defined cut point within the normative range. This easily available biomarker, along with a history of asthma exacerbations, has translated into a clinically significant reduction in asthma exacerbations and the dose of oral corticosteroids in patients who previously have been prednisone-dependent. The pivotal studies indicate that mepolizumab was well tolerated, with the most frequently reported adverse events being headache, nasopharyngitis, worsening of asthma, and local injection reactions. These study investigators did not report any deaths or anaphylaxis related to mepolizumab</style></abstract><notes><style face="normal" font="default">DA - 20170124IS - 1744-764X (Electronic)IS - 1474-0338 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1080/14740338.2017.1286327</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28116937">PM:28116937</url></web-urls></urls><custom2><style face="normal" font="default">20170124, Leung E</style></custom2><misc3><style face="normal" font="default">10.1080/14740338.2017.1286327</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40303</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Thomson,N.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Institute of Infection, Immunity &amp; Inflammation , University of Glasgow , Glasgow , UK</style></auth-address><titles><title><style face="normal" font="default">New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma</style></title><secondary-title><style face="normal" font="default">Expert Opin Pharmacother</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Expert Opin Pharmacother</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> agonists</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic asthma</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> CRTH2</style></keyword><keyword><style face="normal" font="default"> CRTh2 receptor antagonist</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Endotypes</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> glucocorticoid receptor</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> macrolide</style></keyword><keyword><style face="normal" font="default"> Macrolides</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Muscarinic antagonist</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Protein Kinase Inhibitors</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Theophylline</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="default">Introduction Inhaled corticosteroids (ICS) alone or in combination with an inhaled long-acting beta2-agonist (LABA) are the preferred long-term treatment for adults and adolescents with symptomatic asthma. Additional drugs include leukotriene-receptor antagonists, slow-release theophylline and the long-acting muscarinic antagonist (LAMA) tiotropium (approved in 2015). There is a need for more effective therapies, as many patients continue to have poorly controlled asthma. Areas covered New and developing long-acting non-adrenoreceptor synthetic drugs for the treatment of symptomatic chronic asthma despite treatment with an ICS alone or combined with a LABA. Data was reviewed from studies published up until November 2016. Expert opinion Tiotropium improves lung function and has a modest effect in reducing exacerbations when added to ICS alone or ICS and LABA. The LAMAs umeclidinium and glycopyrronium are under development in fixed dose combination with ICS and LABA. Novel small molecule drugs, such as CRTH2 receptor antagonists, PDE4 inhibitors, protein kinase inhibitors and nonsteroidal glucocorticoid receptor agonists and 'off-label' use of licensed drugs, such as macrolides and statins are under investigation for asthma, although their effectiveness in clinical practice is not established. To better achieve the goal of developing effective novel small molecule drugs for asthma will require greater understanding of mechanisms of disease and the different phenotypes and endotypes of asthma</style></abstract><notes><style face="normal" font="default">DA - 20170118IS - 1744-7666 (Electronic)IS - 1465-6566 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1080/14656566.2017.1284794</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28099820">PM:28099820</url></web-urls></urls><custom2><style face="normal" font="default">20170118, Thomson NC</style></custom2><misc3><style face="normal" font="default">10.1080/14656566.2017.1284794</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40304</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cazzola,M.</style></author><author><style face="normal" font="default"> Ora,J.</style></author><author><style face="normal" font="default"> Rogliani,P.</style></author><author><style face="normal" font="default"> Matera,M.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Chair of Respiratory Medicine, Department of Systems Medicine , University of Rome Tor Vergata , Rome , Italy</style></auth-address><titles><title><style face="normal" font="default">Role of muscarinic antagonists in asthma therapy</style></title><secondary-title><style face="normal" font="default">Expert Rev Respir Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Expert Rev Respir Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> airway remodeling</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Asthma therapy</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> bronchodilation</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Documentation</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Muscarinic antagonist</style></keyword><keyword><style face="normal" font="default"> Muscarinic Antagonists</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Rome</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="31" Month="1" Year="2017">2017/1/31</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Higher parasympathetic tone has been reported in asthmatics. In general, cholinergic contractile tone is increased by airway inflammation associated with asthma. Nevertheless, the role of muscarinic antagonists for the treatment of asthma has not yet been clearly defined. Areas covered: The use of SAMAs and LAMAs in asthma has been examined and discussed according with the published evidence. Particular attention has been given to the large Phase III clinical trial programme designed to evaluate the efficacy and safety of tiotropium Respimat added to standard treatment in adults, adolescents and children with persistent asthma across the spectrum of asthma severity. Expert Opinion/Commentary: The current evidence is that in patients with poorly controlled severe asthma despite the use of ICS and LABA, the addition of tiotropium significantly increases the time to the first severe exacerbation and provides a modest but sustained bronchodilation. Identical results should be produced using other LAMAs. In any case, the documentation that, at least in animal or in vitro models, LAMAs show significant anti-inflammatory and anti-proliferative capacities and are able to inhibit airway remodeling induced by allergens makes a strong presumption that the use of LAMAs in asthma may go beyond the simple bronchodilator effect</style></abstract><notes><style face="normal" font="default">DA - 20170131IS - 1747-6356 (Electronic)IS - 1747-6348 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1080/17476348.2017.1289844</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28140686">PM:28140686</url></web-urls></urls><custom2><style face="normal" font="default">20170131, Cazzola M</style></custom2><misc3><style face="normal" font="default">10.1080/17476348.2017.1289844</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40305</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Xue,D.</style></author><author><style face="normal" font="default"> Desjardins,M.</style></author><author><style face="normal" font="default"> Kaufman,G.N.</style></author><author><style face="normal" font="default"> Beland,M.</style></author><author><style face="normal" font="default"> Al-Tememi,S.</style></author><author><style face="normal" font="default"> Ahmed,E.</style></author><author><style face="normal" font="default"> Tao,S.</style></author><author><style face="normal" font="default"> Friedel,R.H.</style></author><author><style face="normal" font="default"> Mourad,W.</style></author><author><style face="normal" font="default"> Mazer,B.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Translational Research in Respiratory Diseases, The Research Institute of the McGill University Health Center , Montreal, QC , Canada</style></auth-address><titles><title><style face="normal" font="default">Semaphorin 4C: A Novel Component of B-Cell Polarization in Th2-Driven Immune Responses</style></title><secondary-title><style face="normal" font="default">Front Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Immunol</style></abbr-1></periodical><pages end="" start="558">558-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Iga</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Igg</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> memory B cell</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Microscopy</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> Mutant</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Respiratory diseases</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Spleen</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> Validation studies</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">BACKGROUND: Semaphorins are important molecules in embryonic development and multiple semaphorins have been identified as having key roles in immune regulation. To date, there is little known about Semaphorin 4C (Sema4C) in immune biology. We report for the first time that Sema4C is inducible in human and murine B-cells and may be important for normal B-cell development. METHODS: Human tonsillar B-cells were studied following activation via anti-CD40 antibodies in the presence or absence of representative Th1, Th2, and regulatory cytokines. Murine B-cells from WT and Sema4C-/- mice were similarly stimulated. B-cell phenotyping in WT and Sema4C mutant mice was performed by flow cytometry and lymphoid architecture was studied by immunohistochemistry. Sema4C expression and synapse formation were analyzed by confocal microscopy. RESULTS: Gene array studies performed on human tonsillar B-cells stimulated to produce IgE revealed that Sema4C was among the top genes expressed at 24 h, and the only semaphorin to be increased under Th2 conditions. Validation studies demonstrated that human and murine B-cells expressed Sema4C under similar conditions. Sema4C-/- mice had impaired maturation of B-cell follicles in spleens and associated decreases in follicular and marginal zone B-cells as well as impaired IgG and IgA production. In keeping with a potential role in maturation of B-cells, Sema4C was expressed predominantly on CD27+ human B-cells. Within 72 h of B-cell activation, Sema4C was localized to one pole in a synapse-like structure, in association with F-actin, B-cell receptor, and Plexin-B2. Cell polarization was impaired in Sema4C-/- mice. CONCLUSION: We have identified a novel immune semaphorin induced in human and murine B-cells under Th2 conditions. Sema4C appears to be a marker for human memory B-cells. It may be important for B-cell polarization and for the formation of normal splenic follicles</style></abstract><notes><style face="normal" font="default">DA - 20161222IS - 1664-3224 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - Oman -CO - United States -</style></notes><work-type><style face="normal" font="default">10.3389/fimmu.2016.00558</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28003812">PM:28003812</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Immunol\2016-7-558.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Immunol\2016-7-558.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161222, Xue D</style></custom2><misc3><style face="normal" font="default">10.3389/fimmu.2016.00558</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40306</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Long,C.M.</style></author><author><style face="normal" font="default"> Lukomska,E.</style></author><author><style face="normal" font="default"> Marshall,N.B.</style></author><author><style face="normal" font="default"> Nayak,A.</style></author><author><style face="normal" font="default"> Anderson,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunology and Microbial Pathogenesis Graduate Program, West Virginia University, Morgantown, WV 26505, USA.</style></auth-address><titles><title><style face="normal" font="default">Potential Inhibitory Influence of miRNA 210 on Regulatory T Cells during Epicutaneous Chemical Sensitization</style></title><secondary-title><style face="normal" font="default">Genes (Basel)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Genes (Basel)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acetone</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> epicutaneous</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Foxp3</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> MicroRNAs</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Molecular Weight</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> occupational asthma</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> regulatory T cell</style></keyword><keyword><style face="normal" font="default"> regulatory T cells</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> suppression</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> TDI</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Toluene</style></keyword><keyword><style face="normal" font="default"> Toluene diisocyanate</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> Tregs</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Virginia</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword><keyword><style face="normal" font="default"> West Virginia</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="27" Month="12" Year="2016">2016/12/27</year></dates><abstract><style face="normal" font="default">Toluene diisocyanate (TDI) is a potent low molecular weight chemical sensitizer and a leading cause of chemical-induced occupational asthma. The regulatory potential of microRNAs (miRNAs) has been recognized in a variety of disease states, including allergic disease; however, the roles of miRNAs in chemical sensitization are largely unknown. In a previous work, increased expression of multiple miRNAs during TDI sensitization was observed and several putative mRNA targets identified for these miRNAs were directly related to regulatory T-cell (Treg) differentiation and function including Foxp3 and Runx3. In this work, we show that miR-210 expression is increased in the mouse draining lymph node (dLN) and Treg subsets following dermal TDI sensitization. Alterations in dLN mRNA and protein expression of Treg related genes/putative miR-210 targets (foxp3, runx3, ctla4, and cd25) were observed at multiple time points following TDI exposure and in ex vivo systems. A Treg suppression assay, including a miR-210 mimic, was utilized to investigate the suppressive ability of Tregs. Cells derived from TDI sensitized mice treated with miR-210 mimic had less expression of miR-210 compared to the acetone control suggesting other factors, such as additional miRNAs, might be involved in the regulation of the functional capabilities of these cells. These novel findings indicate that miR-210 may have an inhibitory role in Treg function during TDI sensitization. Because the functional roles of miRNAs have not been previously elucidated in a model of chemical sensitization, these data contribute to the understanding of the potential immunologic mechanisms of chemical induced allergic disease</style></abstract><notes><style face="normal" font="default">DA - 20161230IS - 2073-4425 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.3390/genes8010009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28035981">PM:28035981</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Genes (Basel)\20161230-LongCM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Genes (Basel)\20161230-LongCM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161230, Long CM</style></custom2><misc3><style face="normal" font="default">10.3390/genes8010009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40307</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bergamini,A.</style></author><author><style face="normal" font="default"> Pisano,C.</style></author><author><style face="normal" font="default"> Di Napoli,M.</style></author><author><style face="normal" font="default"> Arenare,L.</style></author><author><style face="normal" font="default"> Della Pepa,C.</style></author><author><style face="normal" font="default"> Tambaro,R.</style></author><author><style face="normal" font="default"> Facchini,G.</style></author><author><style face="normal" font="default"> Gargiulo,P.</style></author><author><style face="normal" font="default"> Rossetti,S.</style></author><author><style face="normal" font="default"> Mangili,G.</style></author><author><style face="normal" font="default"> Pignata,S.</style></author><author><style face="normal" font="default"> Cecere,S.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Urology and Gynaecology, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples, Italy</style></auth-address><titles><title><style face="normal" font="default">Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin</style></title><secondary-title><style face="normal" font="default">Gynecol Oncol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Gynecol Oncol</style></full-title></periodical><pages end="76" start="72">72-76</pages><volume><style face="normal" font="default">144</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Carboplatin</style></keyword><keyword><style face="normal" font="default"> Cisplatin</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Doxorubicin</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> ovarian cancer</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Platinum</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> ROC</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Hypersensitivity reactions (HSR) are frequently reported in patients rechallenged with carboplatin for recurrent ovarian cancer (ROC) and represent a critical issue, since discontinuation of the platinum-based therapy could affect prognosis. Several strategies to allow platinum rechallenge have been described, with controversial outcomes. The aim of this study is to illustrate a 10-year experience with cisplatin in patients with a previous HSR to carboplatin or at risk for allergy. METHODS: A retrospective review of all patients with platinum sensitive ROC retreated with carboplatin was performed between January 2007 and May 2016 at the Istituto Nazionale Tumori, Fondazione "G. Pascale", Naples. RESULTS: Among 183 patients, 49 (26.8%) presented HSR to carboplatin, mainly during second line therapy. Mean number of cycles before HSR was 8 (range 3-17). G2, G3 and G4 reaction were detected in 83%, 15% and 2% of patients, respectively. In a multivariate analysis including age, hystotype, BRCA status, previous known HSR, and combination drug administered, only the type of carboplatin-based doublet used as 2nd line therapy was found to significantly affect HSR development, with a protective effect of PLD (pegylated liposomal doxorubicin) (p = 0.014, OR = 0.027). Thirty seven patients (77%) with a previous HSR to carboplatin were rechallenged with cisplatin. Treatment was generally well tolerated. 5 patients (13.1%) experienced mild HSR to cisplatin, successfully managed in all cases. 14 patients were treated with cisplatin even without a carboplatin-related HSR due to other allergies. Among these, only one developed HSR (7.1%). CONCLUSIONS: Cisplatin rechallenge is a feasible approach in patients experiencing HSR to carboplatin to maintain the beneficial effect of platinum while reducing hypersensitivity-related risks</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1095-6859 (Electronic)IS - 0090-8258 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.ygyno.2016.10.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28094039">PM:28094039</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Gynecol Oncol\2017-44-72-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Gynecol Oncol\2017-44-72-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Bergamini A</style></custom2><misc3><style face="normal" font="default">10.1016/j.ygyno.2016.10.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40308</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Altwerger,G.</style></author><author><style face="normal" font="default"> Gressel,G.M.</style></author><author><style face="normal" font="default"> English,D.P.</style></author><author><style face="normal" font="default"> Nelson,W.K.</style></author><author><style face="normal" font="default"> Carusillo,N.</style></author><author><style face="normal" font="default"> Silasi,D.A.</style></author><author><style face="normal" font="default"> Azodi,M.</style></author><author><style face="normal" font="default"> Santin,A.</style></author><author><style face="normal" font="default"> Schwartz,P.E.</style></author><author><style face="normal" font="default"> Ratner,E.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Yale University, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, P.O. Box 208063, New Haven, CT 06511, USA.</style></auth-address><titles><title><style face="normal" font="default">Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study</style></title><secondary-title><style face="normal" font="default">Gynecol Oncol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Gynecol Oncol</style></full-title></periodical><pages end="82" start="77">77-82</pages><volume><style face="normal" font="default">144</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse events</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Carboplatin</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Platinum</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The carboplatin desensitization (CD) protocol presented here allows patients with either a positive skin test or a prior hypersensitivity reaction (HSR) to safely, rapidly and effectively continue with carboplatin infusions. Newly described factors can identify patients at risk for developing adverse events during CD. METHODS: A retrospective review was performed on patients with gynecologic cancer who underwent CD between 2005 and 2014. The CD protocol uses a four-step dilution process over 3.5h. RESULTS: 129 patients underwent CD and completed a total of 788cycles. The desensitization protocol prevented HSRs in 96% (753 out of 788) of these cycles. Patients achieved an average of 6.1cycles (SD+/-4.55, range 0-23) with CD. The CD protocol allowed 73% (94 of 129) of the patients to undergo carboplatin infusion without reaction. Patients with moderate to life-threatening HSRs (grade 2 through 4) were 10.5years younger at initial CD than patients with grades 0 or 1 HSRs (52.3 vs. 63, P = 0.0307). One patient death occurred during her thirteenth desensitization cycle. The HSR in this case was complicated by pre-exisiting pulmonary hypertension. CONCLUSIONS: This is the largest study of its kind showing a safe, effective and rapid (3.5h) CD protocol. The majority of patients with a history of either carboplatin hypersensitivity reaction or a positive skin test completed the CD protocol without HSRs. Age was identified as a risk factor for HSR severity during CD. Age can be employed along with pre-load dependent cardiac conditions as a way to help risk stratify patients undergoing CD</style></abstract><notes><style face="normal" font="default">DA - 20161028IS - 1095-6859 (Electronic)IS - 0090-8258 (Linking)LA - ENGPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.ygyno.2016.09.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27789084">PM:27789084</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Gynecol Oncol\2017-44-77-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Gynecol Oncol\2017-44-77-82.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161028, Altwerger G</style></custom2><misc3><style face="normal" font="default">10.1016/j.ygyno.2016.09.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40309</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fukui,H.</style></author><author><style face="normal" font="default"> Mizuguchi,H.</style></author><author><style face="normal" font="default"> Nemoto,H.</style></author><author><style face="normal" font="default"> Kitamura,Y.</style></author><author><style face="normal" font="default"> Kashiwada,Y.</style></author><author><style face="normal" font="default"> Takeda,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Molecular Studies for Incurable Diseases, Institute of Biomedical Sciences, Fujii Memorial Institute of Medical Science, Tokushima University Graduate School, 3-18-15 Kuramotocho, Tokushima, 770-8503, Japan.</style></auth-address><titles><title><style face="normal" font="default">Histamine H1 Receptor Gene Expression and Drug Action of Antihistamines</style></title><secondary-title><style face="normal" font="default">Handb Exp Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Handb Exp Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> H1 receptor</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> histamine H1 receptor</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Protein Kinase C-delta</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> rat</style></keyword><keyword><style face="normal" font="default"> Rats</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> receptor gene</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> suppression</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="25" Month="11" Year="2016">2016/11/25</year></dates><abstract><style face="normal" font="default">The upregulation mechanism of histamine H1 receptor through the activation of protein kinase C-delta (PKCdelta) and the receptor gene expression was discovered. Levels of histamine H1 receptor mRNA and IL-4 mRNA in nasal mucosa were elevated by the provocation of nasal hypersensitivity model rats. Pretreatment with antihistamines suppressed the elevation of mRNA levels. Scores of nasal symptoms were correlatively alleviated to the suppression level of mRNAs above. A correlation between scores of nasal symptoms and levels of histamine H1 receptor mRNA in the nasal mucosa was observed in patients with pollinosis. Both scores of nasal symptoms and the level of histamine H1 receptor mRNA were improved by prophylactic treatment of antihistamines. Similar to the antihistamines, pretreatment with antiallergic natural medicines showed alleviation of nasal symptoms with correlative suppression of gene expression in nasal hypersensitivity model rats through the suppression of PKCdelta. Similar effects of antihistamines and antiallergic natural medicines support that histamine H1 receptor-mediated activation of histamine H1 receptor gene expression is an important signaling pathway for the symptoms of allergic diseases. Antihistamines with inverse agonist activity showed the suppression of constitutive histamine H1 receptor gene expression, suggesting the advantage of therapeutic effect</style></abstract><notes><style face="normal" font="default">DA - 20161125IS - 0171-2004 (Print)IS - 0171-2004 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1007/164_2016_14</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27885525">PM:27885525</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Handb Exp Pharmacol\20161125-FukuiH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Handb Exp Pharmacol\20161125-FukuiH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161125, Fukui H</style></custom2><misc3><style face="normal" font="default">10.1007/164_2016_14</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40310</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Neumann,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hannover Medical School, Hannover, Germany.</style></auth-address><titles><title><style face="normal" font="default">Role of the Histamine H4-Receptor in Bronchial Asthma</style></title><secondary-title><style face="normal" font="default">Handb Exp Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Handb Exp Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="8" Month="10" Year="2016">2016/10/8</year></dates><abstract><style face="normal" font="default">Histamine is a pro-inflammatory mediator with a prominent role in allergic diseases. Antagonists at the histamine receptor subtype 1 are central in anti-allergic therapies, with the exception of allergic asthma, where they are clinically without effect. The latest identified histamine receptor subtype 4, which is expressed mainly in hematopoietic cells, now provides a reasonable target for new therapeutic strategies inhibiting histamine function. The pathophysiology of allergy, esp. allergic asthma, and in its context the effects of antagonists at the histamine receptor subtype 4 in preclinical and clinical settings are discussed in this chapter</style></abstract><notes><style face="normal" font="default">DA - 20161008IS - 0171-2004 (Print)IS - 0171-2004 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="default">10.1007/164_2016_11</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27718056">PM:27718056</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Handb Exp Pharmacol\20161008-NeumannD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Handb Exp Pharmacol\20161008-NeumannD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161008, Neumann D</style></custom2><misc3><style face="normal" font="default">10.1007/164_2016_11</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40311</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ohtsu,H.</style></author><author><style face="normal" font="default"> Seike,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Applied Quantum Medical Engineering, Graduate School of Engineering, Tohoku University, Sendai, Japan.</style></auth-address><titles><title><style face="normal" font="default">Histamine and Histamine Receptors in Allergic Dermatitis</style></title><secondary-title><style face="normal" font="default">Handb Exp Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Handb Exp Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Engineering</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Haptens</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> histamine receptors</style></keyword><keyword><style face="normal" font="default"> Histidine</style></keyword><keyword><style face="normal" font="default"> Histidine Decarboxylase</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="10" Year="2016">2016/10/28</year></dates><abstract><style face="normal" font="default">In this chapter we will first introduce the pathophysiological process of several skin diseases including allergic dermatitis, a common skin disease, including chronic allergic contact dermatitis (CACD), and atopic dermatitis (AD). In CACD and AD patients, repeated skin exposure to antigens contributes to the development of chronic eczematous lesions. Repeated application of haptens on mice allows emulation of the development of CACD in humans. Further, we will focus on H1, H2, and H4 histamine receptors and their effects on CACD and AD. Histamine-deficient mice, with a knockout histidine decarboxylase (HDC) gene, were used to investigate the role of histamine in CACD and AD. Histamine induces infiltration of inflammatory cells, including mast cells and eosinophils, and elevates Th2 cytokine levels in CACD. Histamine promotes the development of eczematous lesions, elevates IgE serum levels, and induces scratching behavior in CACD. The administration of H1 or H4 receptor antagonists was effective to ameliorate these symptoms in murine CACD models. The combination of H1 and H4 receptor antagonists is a potential therapeutic target for chronic inflammatory skin diseases such as CACD and AD, since combined therapy proved to be more effective than monotherapy</style></abstract><notes><style face="normal" font="default">DA - 20161027IS - 0171-2004 (Print)IS - 0171-2004 (Linking)LA - ENGPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1007/164_2016_9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27787718">PM:27787718</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Handb Exp Pharmacol\20161027-OhtsuH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Handb Exp Pharmacol\20161027-OhtsuH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161027, Ohtsu H</style></custom2><misc3><style face="normal" font="default">10.1007/164_2016_9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40312</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mobs,C.</style></author><author><style face="normal" font="default"> Pfutzner,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Klinisch-Experimentelle Allergologie, Allergiezentrum Hessen, Klinik fur Dermatologie und Allergologie, PhilippsUniversitat Marburg, Baldingerstr., 34043, Marburg, Deutschland</style></auth-address><titles><title><style face="normal" font="default">[Diagnostics of drug hypersensitivity reactions]</style></title><secondary-title><style face="normal" font="default">Hautarzt</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Hautarzt</style></full-title></periodical><pages end="28" start="19">19-28</pages><volume><style face="normal" font="default">68</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergologie</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophil activation test</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Challenge test</style></keyword><keyword><style face="normal" font="default"> Challenge tests</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> Counseling</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Dermatologie</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> In vitro tests</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Drug hypersensitivity reactions comprise approximately 25% of all adverse drug reactions and can be classified into allergic and pseudoallergic drug reactions. Immediate type anaphylactic and delayed type rash reactions of various clinical patterns can be distinguished, depending on the pathogenesis and clinical symptoms. The diagnostic work-up encompasses a thorough but also focused evaluation of the medical history, skin tests and when indicated challenge tests. Furthermore, in vitro tests, such as basophil activation tests and T cell assays not only add valuable additional information but can also yield decisive results for the diagnosis, especially in cases of severe drug reactions or reactions which cannot be further clarified by provocation tests. The aim of these measurements is not only the proof of drug intolerance and the detection of the causal drug but also the disclosure of the type of adverse reaction and the identification of potential, tolerated alternative drugs. This information is very important for the counseling of the patient and for prevention of new drug hypersensitivity reactions in the future</style></abstract><notes><style face="normal" font="default">DA - 20161222IS - 1432-1173 (Electronic)IS - 0017-8470 (Linking)LA - gerPT - ReviewPT - Journal ArticlePT - English AbstractCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1007/s00105-016-3908-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28005146">PM:28005146</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Hautarzt\2017-68-19-28.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Hautarzt\2017-68-19-28.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161222, Mobs C</style></custom2><misc3><style face="normal" font="default">10.1007/s00105-016-3908-x</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40313</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kumar,S.</style></author><author><style face="normal" font="default"> Singh,M.</style></author><author><style face="normal" font="default"> Das,R.R.</style></author><author><style face="normal" font="default"> Mathew,J.L.</style></author><author><style face="normal" font="default"> Saxena,A.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departments of Pediatrics and $Radiology, PGIMER, Chandigarh and Department of Pediatrics, All India Institute of Medical Sciences, Bhubaneswar; and $Radiology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Correspondence to: Dr Meenu Singh, Professor, Department of Pediatrics, PGIMER, Chandigarh 160 012, India. meenusingh4@gmail.com</style></auth-address><titles><title><style face="normal" font="default">Association of Allergic Rhinitis and Sinusitis with Childhood Asthma</style></title><secondary-title><style face="normal" font="default">Indian Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Indian Pediatr</style></abbr-1></periodical><pages end="24" start="21">21-24</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Sinusitis</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: To study the point prevalence of allergic rhinitis and sinusitis in childhood asthma and to examine the relationships among them. METHODS: In 250 children (age &lt;13 y) with mild-to-moderte asthma, allergic rhinitis was diagnosed by clinical plus nasal eosinophilia criteria, and sinusitis was diagnosed clinically plus confirmation by computerized tomography scan. RESULTS: The point prevalence of allergic rhinitis was 13.6%, and of sinusitis was 2%. On multivariate analysis, allergic rhinitis, sinusitis, and family history were significantly associated with asthma severity. CONCLUSION: Allergic rhinitis is common in childhood, but sinusitis is rare</style></abstract><notes><style face="normal" font="default">DA - 20161127IS - 0974-7559 (Electronic)IS - 0019-6061 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27889716">PM:27889716</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian Pediatr\2017-54-21-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian Pediatr\2017-54-21-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161127, Kumar S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40314</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hu,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Affiliated Anhui Provincial Hospital, Anhui Medical University, 17 Lujiang Road, Hefei, Anhui, 230001, China.</style></auth-address><titles><title><style face="normal" font="default">Role of Anti-inflammatory Cytokines IL-35 and IL-37 in Asthma</style></title><secondary-title><style face="normal" font="default">Inflammation</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Inflammation</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> airway remodeling</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mucus</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="23" Month="11" Year="2016">2016/11/23</year></dates><abstract><style face="normal" font="default">Asthma is a chronic airway inflammation that is characterized by intense eosinophil infiltrates, mucus hypersecretion, airway remodeling, and airway hyperresponsiveness. Interleukin (IL)-35 and IL-37 are two cytokines with anti-inflammatory effects found in immune response. Recent findings suggested that expressions of IL-35 and IL-37 are abnormal in asthma. Functional analysis further confirmed the important roles of them in the pathogenesis of asthma. The present study reviewed the updated evidence indicating the roles of IL-35 and IL-37 in asthma. Hopefully, the information obtained may lead to a better understanding of the pathogenesis of the disease</style></abstract><notes><style face="normal" font="default">DA - 20161123IS - 1573-2576 (Electronic)IS - 0360-3997 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1007/s10753-016-0480-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27878686">PM:27878686</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Inflammation\20161123-HuD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Inflammation\20161123-HuD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161123, Hu D</style></custom2><misc3><style face="normal" font="default">10.1007/s10753-016-0480-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40315</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Alasandagutti,M.L.</style></author><author><style face="normal" font="default"> Ansari,M.S.</style></author><author><style face="normal" font="default"> Sagurthi,S.R.</style></author><author><style face="normal" font="default"> Valluri,V.</style></author><author><style face="normal" font="default"> Gaddam,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Bhagwan Mahavir Medical Research Centre, Hyderabad, Telangana, 500004, India</style></auth-address><titles><title><style face="normal" font="default">Role of IL-13 Genetic Variants in Signalling of Asthma</style></title><secondary-title><style face="normal" font="default">Inflammation</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Inflammation</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">airflow</style></keyword><keyword><style face="normal" font="default"> airflow obstruction</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> nonatopic asthma</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> serum IgE levels</style></keyword><keyword><style face="normal" font="default"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="12" Month="1" Year="2017">2017/1/12</year></dates><abstract><style face="normal" font="default">Asthma is a chronic inflammatory disease of the lower airways characterised by intermittent airway narrowing and airflow obstruction. The aim of this study was to examine the association of IL-13 Arg 130 Gln (A/G) and -1112C/T cytokine gene polymorphisms and to know the secretion of IL-13 cytokine levels and the interactions between the IL-13 130A/G and IL-13Ralpha1/IL-4Ralpha complex cytokine genes. The study population comprised of atopic and non-atopic asthma patients and healthy controls (HC) (N = 120). Single nucleotide polymorphisms (SNPs) were determined by restriction fragment length polymorphism (RFLP). IL-13 cytokine serum levels were measured by enzyme-linked immunosorbent assay (ELISA), and homology modelling of IL-13 A/G cytokine gene was performed through in silico analysis. In IL-13 130A/G cytokine gene AG, GG genotypes (p &lt; 0.0042, OR = 2.87, CI 1.46-5.65; OR = 1.92, CI 1.06-3.48) were found to be significant in atopic asthma patients vs HC. The mean IL-13 serum cytokine levels were found to be significantly high in atopic (38.48 +/- 36.54) and non-atopic (36.05 +/- 34.54) asthma patients whereas total serum IgE levels were significantly high at p &lt; 0.0001 in atopic and low in non-atopic asthma patients at p &lt; 0.003 compared to HC. In silico analysis indicated that residue IL-13 130 with charge modifying variants was crucial in ligand-receptor interactions. IL-13 cytokine serum levels were significantly high in atopic and non-atopic asthma patients compared to HC. The GG genotype of IL-13 130A/G cytokine gene might be involved in the induced production of total IgE and IL-13 cytokine serum levels suggesting IL-13 may be important in the signalling of asthma</style></abstract><notes><style face="normal" font="default">DA - 20170113IS - 1573-2576 (Electronic)IS - 0360-3997 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default"> 10.1007/s10753-016-0503-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28083766">PM:28083766</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Inflammation\20170113-AlasandaguttiML.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Inflammation\20170113-AlasandaguttiML.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170113, Alasandagutti ML</style></custom2><misc3><style face="normal" font="default"> 10.1007/s10753-016-0503-3</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40316</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Merget,R.</style></author><author><style face="normal" font="default"> Pham,N.</style></author><author><style face="normal" font="default"> Schmidtke,M.</style></author><author><style face="normal" font="default"> Casjens,S.</style></author><author><style face="normal" font="default"> van Kampen,V.</style></author><author><style face="normal" font="default"> Sander,I.</style></author><author><style face="normal" font="default"> Hagemeyer,O.</style></author><author><style face="normal" font="default"> Sucker,K.</style></author><author><style face="normal" font="default"> Raulf,M.</style></author><author><style face="normal" font="default"> Bruning,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Burkle-de-la-Camp-Platz 1, 44789, Bochum, Germany.</style></auth-address><titles><title><style face="normal" font="default">Medical surveillance and long-term prognosis of occupational allergy due to platinum salts</style></title><secondary-title><style face="normal" font="default">Int Arch Occup Environ Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int Arch Occup Environ Health</style></full-title></periodical><pages end="81" start="73">73-81</pages><volume><style face="normal" font="default">90</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Airway Obstruction</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic asthma</style></keyword><keyword><style face="normal" font="default"> Conjunctivitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact urticaria</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational allergy</style></keyword><keyword><style face="normal" font="default"> occupational asthma</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> Occupational Medicine</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Plant</style></keyword><keyword><style face="normal" font="default"> Plants</style></keyword><keyword><style face="normal" font="default"> Platinum</style></keyword><keyword><style face="normal" font="default"> platinum salts</style></keyword><keyword><style face="normal" font="default"> Precious metals</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Salts</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">PURPOSE: Medical surveillance of workers in precious metals refineries and catalyst production plants is well established in many countries as a measure to prevent occupational asthma due to platinum (Pt) salts. It was the aim of this study to evaluate the impact of medical surveillance and to define prognostic factors with an emphasis on exposure determinants. METHODS: As part of an observational longitudinal study, 96 workers from German precious metals refineries and catalyst production plants with Pt salt allergy underwent a second examination several years (median 67 months) after the initial diagnosis was made. RESULTS: When the second examination was conducted, 92 subjects (96 %) had already been transferred to jobs with very low or no exposure to Pt salts. The number of subjects with sensitization to Pt salt as assessed by skin prick test (SPTPt) decreased from 86 to 52 %, and there was a clear improvement for rhinitis, conjunctivitis and contact urticaria between both examinations. Although the number of subjects with asthma symptoms decreased significantly, at the second examination 74 subjects (77 %) continued to suffer from asthma and 51 subjects (53 %) received asthma medication. Airway obstruction or bronchial hyperresponsiveness persisted in 83 subjects (86 %). CONCLUSIONS: Secondary prevention in subjects with occupational exposure to Pt salts, as practiced for over 25 years in Germany could not avoid persistent asthma in the majority of cases, although improvements occurred. This study reveals the limitations of the concept that removal from exposure after the occurrence of respiratory symptoms may prevent chronic asthma. It is recommended that removal from exposure should be done immediately after the occurrence of a positive SPTPt, irrespective of symptoms</style></abstract><notes><style face="normal" font="default">DA - 20161013IS - 1432-1246 (Electronic)IS - 0340-0131 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="default">10.1007/s00420-016-1172-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27734174">PM:27734174</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Occup Environ Health\2017-90-73-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Occup Environ Health\2017-90-73-81.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161013, Merget R</style></custom2><misc3><style face="normal" font="default">10.1007/s00420-016-1172-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40317</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cai,J.</style></author><author><style face="normal" font="default"> Liu,W.</style></author><author><style face="normal" font="default"> Hu,Y.</style></author><author><style face="normal" font="default"> Zou,Z.</style></author><author><style face="normal" font="default"> Shen,L.</style></author><author><style face="normal" font="default"> Huang,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Building Environment and Energy Engineering, School of Environment and Architecture, University of Shanghai for Science and Technology, 516 Jungong Road, Yangpu District, Shanghai, People's Republic of China</style></auth-address><titles><title><style face="normal" font="default">Household environment, lifestyle behaviors, and dietary habits in relation to childhood atopic eczema in Shanghai, China</style></title><secondary-title><style face="normal" font="default">Int Arch Occup Environ Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int Arch Occup Environ Health</style></full-title></periodical><pages end="159" start="141">141-159</pages><volume><style face="normal" font="default">90</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic eczema</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Engineering</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Habits</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Lifestyle</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword><keyword><style face="normal" font="default"> Wood</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">PURPOSES: We aim to investigate associations of the child's individual characteristics, building characteristics, home environmental exposures, family lifestyle behaviors, and dietary habits on childhood eczema during lifetime-ever and in the last year before the survey. METHODS: During April 2011-April 2012, we conducted a cross-sectional study and collected 13,335 parents-reported questionnaires of 4-6-year-old children from 72 kindergartens in Shanghai, China. Logistic regression model was used to investigate associations. RESULTS: After adjusted for sex, age, family history of atopy, and questionnaire reporter, the factors which were strongly associated (increased odds >30% and p value &lt;0.05) with lifetime-ever eczema included mother employed during pregnancy (adjusted OR 1.33), residence renovated during pregnancy (1.49) and in the child's first year of life (1.31), using laminate (1.58) and solid (1.42) wood as material of floor covering (compared to using cement), residence located in urban district (1.38), and dampness-related exposures in the early residence (mold spots/stains: 1.41; mold odor: 1.41) and in the current residence (water damage: 1.33; damp stains: 1.34; mold spots: 1.32; and windows pane condensation: 1.31). Parental smoking, pet-keeping, and incense-burning had no significant associations with childhood eczema. Similar associations were found for eczema in the last year before the survey. Families with sick children likely changed lifestyle behaviors and dietary habits. CONCLUSIONS: Childhood eczema could be influenced by many household environmental and non-environmental factors. Exposures during early lifetime likely have greater impact on childhood eczema than current exposures. Associations of lifestyle behaviors and dietary habits with childhood eczema could be modified by family avoidance behaviors</style></abstract><notes><style face="normal" font="default">DA - 20161104IS - 1432-1246 (Electronic)IS - 0340-0131 (Linking)LA - ENGPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1007/s00420-016-1177-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27812754">PM:27812754</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Occup Environ Health\2017-90-141-59.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Occup Environ Health\2017-90-141-59.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161104, Cai J</style></custom2><misc3><style face="normal" font="default">10.1007/s00420-016-1177-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40318</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">He,S.</style></author><author><style face="normal" font="default"> Mou,Z.</style></author><author><style face="normal" font="default"> Peng,L.</style></author><author><style face="normal" font="default"> Chen,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology, Shanghai Children's Medical Center, affiliated with Shanghai Jiaotong University School of Medicine, Shanghai, 200127, China</style></auth-address><titles><title><style face="normal" font="default">Impacts of meteorological and environmental factors on allergic rhinitis in children</style></title><secondary-title><style face="normal" font="default">Int J Biometeorol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Biometeorol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Humidity</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Particulate matter</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> PM</style></keyword><keyword><style face="normal" font="default"> PM10</style></keyword><keyword><style face="normal" font="default"> PM2.5</style></keyword><keyword><style face="normal" font="default"> Pollen</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Temperature</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="24" Month="10" Year="2016">2016/10/24</year></dates><abstract><style face="normal" font="default">Meteorological and environmental factors influence the pathogenesis of allergic rhinitis (AR). An understanding of the risk factors will facilitate the development of diagnostic and preventative tools for AR children and improve their quality of life. However, research on the impact of these factors on subjective symptoms in AR children remains scarce. This study explored the relationships between subjective symptoms in pollen and dust mite positive AR children, and meteorological and environmental factors. Using a linear mixed effect model, we analyzed the correlations between monthly data on the subjective symptoms of 351 AR children (from the Shanghai Children's Medical Center) and meteorological and environmental factors during 2013. The monthly meteorological and environmental data were provided by the Shanghai Meteorological Service and Shanghai Environmental Protection Bureau. Temperature and humidity were negatively correlated with the subjective symptom score, with a 0.04 point increase observed for every 1 degrees C decrease in temperature (P &lt; 0.0001) or 10 % decline in humidity (P = 0.0412). The particulate matter (PM) 10 and PM2.5 concentrations were positively correlated with the subjective symptom score, with a 10 mug/m3 increase in PM10 and PM2.5 yielding a 0.02 (P = 0.0235) and 0.03 (P = 0.0281) increase in the subjective symptom score, respectively. In conclusion, meteorological and environmental factors were correlated with subjective symptoms in AR children. Low temperatures, lower humidity, and high PM10 and PM2.5 concentrations aggravated subjective symptoms in AR children</style></abstract><notes><style face="normal" font="default">DA - 20161025IS - 1432-1254 (Electronic)IS - 0020-7128 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="default"> 10.1007/s00484-016-1257-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27778095">PM:27778095</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Biometeorol\20161025-HeS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Biometeorol\20161025-HeS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161025, He S</style></custom2><misc3><style face="normal" font="default"> 10.1007/s00484-016-1257-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40319</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhou,H.</style></author><author><style face="normal" font="default"> Li,J.</style></author><author><style face="normal" font="default"> Gao,P.</style></author><author><style face="normal" font="default"> Wang,Q.</style></author><author><style face="normal" font="default"> Zhang,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, The Second Affiliated Hospital of Jilin University, Changchun 130041, China.</style></auth-address><titles><title><style face="normal" font="default">miR-155: A Novel Target in Allergic Asthma</style></title><secondary-title><style face="normal" font="default">Int J Mol Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Mol Sci</style></abbr-1></periodical><pages end="" start=" E1773"> E1773-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Glucocorticoids</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> MicroRNAs</style></keyword><keyword><style face="normal" font="default"> Nucleotides</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rna</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> Th2 immunity</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="24" Month="10" Year="2016">2016/10/24</year></dates><abstract><style face="normal" font="default">MicroRNAs (miRNAs), a class of small non-coding RNAs of 18-24 nucleotides in length, function to posttranscriptionally regulate protein expression. miR-155 was one of the first identified and, to date, the most studied miRNA, and has been linked to various cellular processes such as modulation of immune responses and oncogenesis. Previous studies have identified miR-155 as a crucial positive regulator of Th1 immune response in autoimmune diseases, but as a suppressor of Th2 immunity in allergic disorders. However, recent studies have found new evidence that miR-155 plays an indispensible role in allergic asthma. This review summarizes the recent findings with respect to miR-155 in immune responses and the underlying mechanisms responsible for miR-155-related allergic diseases, as well as the similarities between miR-155 and glucocorticoids in immunity</style></abstract><notes><style face="normal" font="default">DA - 20161026IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - ENGPT - ReviewPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.3390/ijms17101773</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27783037">PM:27783037</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Mol Sci\2016-17-E1773.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Mol Sci\2016-17-E1773.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161026, Zhou H</style></custom2><misc3><style face="normal" font="default">10.3390/ijms17101773</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40320</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Strom,C.C.</style></author><author><style face="normal" font="default"> Andreasen,H.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pharmacosmos A/S, Roervangsvej 30, DK-4300 Holbaek, Denmark.</style></auth-address><titles><title><style face="normal" font="default">Comment on Neiser et al. Assessment of Dextran Antigenicity of Intravenous Iron Preparations with Enzyme-Linked Immunosorbent Assay (ELISA). Int. J. Mol. Sci. 2016, 17, 1185</style></title><secondary-title><style face="normal" font="default">Int J Mol Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Mol Sci</style></abbr-1></periodical><pages end="" start="E121">E121-</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Commercial</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> dextran</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Iron</style></keyword><keyword><style face="normal" font="default"> Nanoparticles</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Randomized clinical trial</style></keyword><keyword><style face="normal" font="default"> Randomized clinical trials</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="default">All IV iron complexes carry a risk of potentially fatal allergic type hypersensitivity reactions. The mechanism(s) behind these reactions is unknown but the limited data available suggests that classic IgE mediated allergy is exceedingly rare, if ever occurring. Iron-carbohydrate molecules are complex nano-particles and trying to reduce the risk of serious hypersensitivity to antibody binding of an artificial antibody seems meaningless. A recently published analysis of safety data from randomized clinical trials confirms the method reported by Neiser to be useless to predict reaction risk. In conclusion, the study by Neiser et al. is biased, contains no new information, and has no clinical relevance. We are concerned that the association of the authors with a commercial entity has caused a conflict of interest that biases not only the results, but the entire experimental setup against competitors. (Comment on Neiser et al. Int. J. Mol. Sci. 2016, 17, 1185, doi:10.3390/ijms17071185)</style></abstract><notes><style face="normal" font="default">DA - 20170111IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.3390/ijms18010121</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28075402">PM:28075402</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-E121.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-E121.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170111, Strom CC</style></custom2><misc3><style face="normal" font="default">10.3390/ijms18010121</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40321</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sur,B.</style></author><author><style face="normal" font="default"> Lee,B.</style></author><author><style face="normal" font="default"> Yoon,Y.S.</style></author><author><style face="normal" font="default"> Lim,P.</style></author><author><style face="normal" font="default"> Hong,R.</style></author><author><style face="normal" font="default"> Yeom,M.</style></author><author><style face="normal" font="default"> Lee,H.S.</style></author><author><style face="normal" font="default"> Park,H.</style></author><author><style face="normal" font="default"> Shim,I.</style></author><author><style face="normal" font="default"> Lee,H.</style></author><author><style face="normal" font="default"> Jang,Y.P.</style></author><author><style face="normal" font="default"> Hahm,D.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Acupuncture and Meridian Science Research Center, College of Korean Medicine, Kyung Hee University, Seoul 02447, Korea.</style></auth-address><titles><title><style face="normal" font="default">Extract of Polygala tenuifolia Alleviates Stress-Exacerbated Atopy-Like Skin Dermatitis through the Modulation of Protein Kinase A and p38 Mitogen-Activated Protein Kinase Signaling Pathway</style></title><secondary-title><style face="normal" font="default">Int J Mol Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Mol Sci</style></abbr-1></periodical><pages end="" start="E190">E190-</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cell Degranulation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Corticosterone</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> mitogen-activated protein kinase</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin dermatitis</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Substance P</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trimellitic anhydride</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) and stress create a vicious cycle: stress exacerbates atopic symptoms, and atopic disease elicits stress and anxiety. Targeting multiple pathways including stress and allergic inflammation is, therefore, important for treating AD. In this study, we investigated the remedial value of Polygala tenuifolia Willd. (PTW) for treating immobilization (IMO) stress-exacerbated atopy-like skin dermatitis and its underlying mechanism. Trimellitic anhydride (TMA) was applied to dorsal skin for sensitization and subsequently both ears for eliciting T-cell-dependent contact hypersensitivity in mice, which underwent 2 h-IMO stress and PTW administration for the latter 6 and 9 days in the ear exposure period of TMA, respectively. To elicit in vitro degranulation of human mast cell line-1 (HMC-1), 10 microM substance P (SP) and 200 nM corticotrophin-releasing factor (CRF) were sequentially added with 48 h-interval. PTW extract (500 microg/mL) was added 30 min before CRF treatment. IMO stress exacerbated TMA-induced scratching behavior by 252%, and increased their blood corticosterone levels by two-fold. Treatment with 250 mg/kg PTW significantly restored IMO stress-exacerbated scratching behavior and other indicators such as skin inflammation and water content, lymph node weights, and serum histamine and immunoglobulin E (lgE) levels. Furthermore, it also reversed TMA-stimulated expression of tumor necrosis factor (TNF)-alpha and interleukin (IL)-4 mRNAs in ear tissues. PTW significantly inhibited SP/CRF-stimulated degranulation of HMC-1 cells, subsequent tryptase secretion, and protein kinase A (PKA) activity. PTW also selectively inhibited p38 mitogen-activated protein kinase (MAPK) phosphorylation in SP/CRF-treated HMC-1 cells. PTW significantly inhibited HMC-1 cell degranulation and alleviated IMO stress-exacerbated atopic dermatitis symptoms by modulating the PKA/p38 MAPK signaling pathway</style></abstract><notes><style face="normal" font="default">DA - 20170120IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.3390/ijms18010190</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28106783">PM:28106783</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-E190.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-E190.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170120, Sur B</style></custom2><misc3><style face="normal" font="default">10.3390/ijms18010190</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40322</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kubota,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Kubota Thyroid Clinic, Japan</style></auth-address><titles><title><style face="normal" font="default">Successful Re-administration of Low-dose of Methimazole (MMI) in Graves' Disease Patients Who Experienced Allergic Cutaneous Reactions to MMI at Initial Treatment and Had Received Long-term Propylthiouracil (PTU)</style></title><secondary-title><style face="normal" font="default">Intern Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Intern Med</style></full-title></periodical><pages end="3237" start="3235">3235-3237</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">22</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous reaction</style></keyword><keyword><style face="normal" font="default"> Cutaneous reactions</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Methimazole</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Propylthiouracil</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Vasculitis</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Objective When patients with Graves' disease show severe allergic cutaneous reactions, physicians often suggest that they undergo radioiodine therapy instead of receiving propylthiouracil (PTU), another antithyroid drug, because anti-neutrophil cytoplasmic antibody (ANCA) -related vasculitis can occur with PTU, especially with long-term use. However, some patients refuse radioiodine therapy and chose PTU. Sometimes PTU treatment may be prolonged. Since the frequency of adverse effects of methimazole (MMI) is dose-related, there is a possibility that we can re-administer a low dose without adverse effects to patients well-controlled with PTU who once experienced an allergic reaction to MMI. Methods I prospectively re-administered a low dose of MMI to patients who previously experienced an allergic reaction to MMI at initial treatment. The dose of re-administered MMI ranged from 5 mg twice a week to 5 mg daily. Patients Nine patients with Graves' disease who developed urticaria at initial treatment with MMI and had been treated with PTU for 6 to 21 years were recruited. Results Eight of the 9 patients were successfully controlled with MMI without allergic cutaneous reactions. Only one patient felt itchiness 2 days after switching to MMI. However, skin change was not observed. Conclusion If the patients show allergic cutaneous reactions as a side effect of MMI at the initial treatment for Graves' disease, then there is a strong possibility that such patients can tolerate a low dose of MMI without adverse effects after the disease activity has subsided</style></abstract><notes><style face="normal" font="default">DA - 20161117IS - 1349-7235 (Electronic)IS - 0918-2918 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.2169/internalmedicine.55.7281</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27853063">PM:27853063</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Intern Med\2016-55-3235-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Intern Med\2016-55-3235-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161117, Kubota S</style></custom2><misc3><style face="normal" font="default">10.2169/internalmedicine.55.7281</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40323</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Watanabe,Y.</style></author><author><style face="normal" font="default"> Wada,H.</style></author><author><style face="normal" font="default"> Sakakura,K.</style></author><author><style face="normal" font="default"> Fujita,H.</style></author><author><style face="normal" font="default"> Momomura,S.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Japan</style></auth-address><titles><title><style face="normal" font="default">A Pitfall in the Diagnosis of Eosinophilic Myocarditis in a Patient who Received Steroid Therapy</style></title><secondary-title><style face="normal" font="default">Intern Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Intern Med</style></full-title></periodical><pages end="161" start="157">157-161</pages><volume><style face="normal" font="default">56</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acute Coronary Syndrome</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Myocarditis</style></keyword><keyword><style face="normal" font="default"> Myocardium</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Eosinophilic myocarditis is a rare form of myocardial inflammation that is characterized by the infiltration of eosinophilic cells into the myocardium. The clinical symptoms of eosinophilic myocarditis are similar to those of acute coronary syndrome, and eosinophilic myocarditis sometimes occurs in combination with bronchial asthma. We herein present a case of eosinophilic myocarditis in which additional time was required to make a definitive diagnosis because the patient received steroid therapy. The diagnosis of eosinophilic myocarditis is challenging, especially when a patient has other inflammatory diseases, such as bronchial asthma. We should pay attention to the possibility that steroid therapy may mask the presentation of eosinophilic myocarditis</style></abstract><notes><style face="normal" font="default">DA - 20170116IS - 1349-7235 (Electronic)IS - 0918-2918 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.2169/internalmedicine.56.7521</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28090045">PM:28090045</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Intern Med\2017-56-157-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Intern Med\2017-56-157-61.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170116, Watanabe Y</style></custom2><misc3><style face="normal" font="default">10.2169/internalmedicine.56.7521</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40324</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Trubiano,J.A.</style></author><author><style face="normal" font="default"> Worth,L.J.</style></author><author><style face="normal" font="default"> Urbancic,K.</style></author><author><style face="normal" font="default"> Brown,T.M.</style></author><author><style face="normal" font="default"> Paterson,D.L.</style></author><author><style face="normal" font="default"> Lucas,M.</style></author><author><style face="normal" font="default"> Phillips,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Infectious Diseases, Austin Health, Melbourne, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="default">Return to sender: the need to re-address patient antibiotic allergy labels in Australia and New Zealand</style></title><secondary-title><style face="normal" font="default">Intern Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Intern Med J</style></full-title></periodical><pages end="1317" start="1311">1311-1317</pages><volume><style face="normal" font="default">46</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotic allergy</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> Barriers</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> cross reactivity</style></keyword><keyword><style face="normal" font="default"> Cross-reactivity</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Delayed hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> New Zealand</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharmacist</style></keyword><keyword><style face="normal" font="default"> Pharmacists</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Stewardship</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Victoria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND/AIM: Antibiotic allergies are frequently reported and have significant impacts upon appropriate prescribing and clinical outcomes. We surveyed infectious diseases physicians, allergists, clinical immunologists and hospital pharmacists to evaluate antibiotic allergy knowledge and service delivery in Australia and New Zealand. METHODS: An online multi-choice questionnaire was developed and endorsed by representatives of the Australasian Society of Clinical Immunology and Allergy (ASCIA) and the Australasian Society of Infectious Diseases (ASID). The 37-item survey was distributed in April 2015 to members of ASCIA, ASID, the Society of Hospital Pharmacists of Australia and the Royal Australasian College of Physicians. RESULTS: Of 277 respondents, 94% currently use or would utilise antibiotic allergy testing (AAT) and reported seeing up to 10 patients/week labelled as antibiotic-allergic. Forty-two per cent were not aware of or did not have AAT available. Most felt that AAT would aid antibiotic selection, antibiotic appropriateness and antimicrobial stewardship (79, 69 and 61% respectively). Patients with the histories of immediate hypersensitivity were more likely to be referred than those with delayed hypersensitivities (76 vs 41%, P = 0.0001). Lack of specialist physicians (20%) and personal experience (17%) were barriers to service delivery. A multidisciplinary approach was a preferred AAT model (53%). Knowledge gaps were identified, with the majority overestimating rates of penicillin/cephalosporin (78%), penicillin/carbapenem (57%) and penicillin/monobactam (39%) cross-reactivity. CONCLUSIONS: A high burden of antibiotic allergy labelling and demand for AAT is complicated by a relative lack availability or awareness of AAT services in Australia and New Zealand. Antibiotic allergy education and deployment of AAT, accessible to community and hospital-based clinicians, may improve clinical decisions and reduce antibiotic allergy impacts. A collaborative approach involving infectious diseases physicians, pharmacists and allergists/immunologists is required</style></abstract><notes><style face="normal" font="default">DA - 20160816IS - 1445-5994 (Electronic)IS - 1444-0903 (Linking)LA - ENGPT - Journal ArticleCO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/imj.13221</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27527526">PM:27527526</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Intern Med J\2016-46-1311-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Intern Med J\2016-46-1311-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160816, Trubiano JA</style></custom2><misc3><style face="normal" font="default">10.1111/imj.13221</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40325</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aurich,S.</style></author><author><style face="normal" font="default"> Seitz,A.T.</style></author><author><style face="normal" font="default"> Tomm,J.</style></author><author><style face="normal" font="default"> Simon,J.C.</style></author><author><style face="normal" font="default"> Treudler,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Venereology and Allergology, University Hospital, Leipzig, Germany</style></auth-address><titles><title><style face="normal" font="default">A Case of Anaphylaxis to Patent Blue in a Patient with Sentinel Lymph Node Excision</style></title><secondary-title><style face="normal" font="default">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Iran J Allergy Asthma Immunol</style></abbr-1></periodical><pages end="550" start="547">547-550</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergology</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> Breast</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Cold</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Detergents</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostics</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paint</style></keyword><keyword><style face="normal" font="default"> Patent Blue</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> sentinel lymph node</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Staining</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Textiles</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">In medicine, patent blue violet (PBV) is utilized for staining lymphatic vessels in sentinel lymph node (SLN) surgery. Moreover, PBV (also called E131 ) is used as food additive. We report on a 51-year-old non-atopic female with early breast cancer, who was scheduled for SLN excision and experienced an intra-operative anaphylactic reaction. In diagnostics the skin prick test (SPT) was positive to PBV. Hypersensitivity reactions to PBV can arise after the first exposure in surgery as sensitization may arise from either PBV (E131) in foods (i.e. in sweets or blue curacao) or from other structurally closely related triarylmethane dyes in objects of everyday life like textiles, detergents, paints, cold remedies and cosmetics. This article supports the necessity of an increased awareness of the possibility of anaphylactic reactions to PBV during SLN surgery, even if the patient never had contact to PBV before</style></abstract><notes><style face="normal" font="default">DA - 20170128IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28129687">PM:28129687</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2016-15-547-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2016-15-547-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170128, Aurich S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40326</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,K.</style></author><author><style face="normal" font="default"> Kang,J.</style></author><author><style face="normal" font="default"> Won,Kim S.</style></author><author><style face="normal" font="default"> Sung,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Busan St. Mary's Hospital, Busan, Korea</style></auth-address><titles><title><style face="normal" font="default">Relationship Between the Presence of Eczema Herpeticum and the Significance of Clinical and Laboratory Tests in Korean Children With Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">Iran J Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Iran J Pediatr</style></abbr-1></periodical><pages end="" start="e4683">e4683-</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> cationic protein</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> herpes</style></keyword><keyword><style face="normal" font="default"> Herpes Simplex</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> MRSA</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Staphylococcus</style></keyword><keyword><style face="normal" font="default"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Eczema herpeticum (EH) is a herpes simplex virus (HSV) infection superimposed on atopic dermatitis (AD). OBJECTIVES: The aim of this study was to evaluate the relationship between clinical features and laboratory tests, including skin cultures, total IgE, eosinophil count, eosinophil cationic protein, and 25-hydroxyvitamin D3 (25-(OH)D3), in Korean children with AD according to the presence of EH. PATIENTS AND METHODS: We enrolled 380 patients aged 6 months to 18 years who were admitted to Busan St. Mary's hospital from January 2012 to December 2014. All 380 subjects were divided into two groups: the control and the AD group. The AD group was further divided into two subgroups: EH+ and EH-. RESULTS: The male gender was related to the presence of EH (odds ratio of 2.56; 95% confidence interval, 1.19 - 5.53, P = 0.01), but age and 25-(OH)D3 levels were not. After adjusting for age, gender, and 25-(OH)D3, no significant relationship was found between total IgE, eosinophil cationic protein or eosinophil count levels and the presence of EH. The relationship between positive skin cultures and the presence of EH was significant (P &lt; 0.001) and the presence of methicillin-resistant Staphylococcus aureus (MRSA) was also related to the development of EH (OR, 0.19; 95% CI, 0.04 - 0.92, P = 0.03). CONCLUSIONS: We conclude that while male gender, positive skin culture results, and the presence of MRSA are factors influencing EH, serum 25-(OH)D3 levels are not associated with EH in Korean AD children</style></abstract><notes><style face="normal" font="default">DA - 20161007IS - 2008-2142 (Print)IS - 2008-2142 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="default">10.5812/ijp.4683</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27713812">PM:27713812</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Iran J Pediatr\2016-26-e4683.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Iran J Pediatr\2016-26-e4683.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161007, Kim K</style></custom2><misc3><style face="normal" font="default">10.5812/ijp.4683</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40327</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Otten,J.J.</style></author><author><style face="normal" font="default"> Hirsch,T.</style></author><author><style face="normal" font="default"> Lim,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Factors Influencing the Food Purchases of Early Care and Education Providers</style></title><secondary-title><style face="normal" font="default">J Acad Nutr Diet</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Acad Nutr Diet</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Attitude</style></keyword><keyword><style face="normal" font="default"> Barriers</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Food Preferences</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Interviews</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Motivation</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Regulations</style></keyword><keyword><style face="normal" font="default"> Social Environment</style></keyword><keyword><style face="normal" font="default"> Software</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Washington</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="27" Month="1" Year="2017">2017/1/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: With the majority of US children enrolled in some form of early care and education, the settings for early care and education represent a valuable opportunity to positively impact young children's diets and their interactions with food. Little evidence exists on how early care and education providers make food purchasing and service decisions for this population of young children. OBJECTIVE: Our aim was to explore the factors that influence early care and education providers' food purchasing and service decisions. DESIGN: A qualitative design consisting of individual, in-person, and semi-structured interviews with providers and on-site observations was used. PARTICIPANTS/SETTING: Sixteen early care and education providers-selected across a variety of characteristics that might affect food selection (eg, size of site, participation in reimbursement programs, presence of staff assigned to foodservice) using maximum variation purposive sampling-based in the Puget Sound region, Washington, were interviewed from June to September 2014. MAIN OUTCOME MEASURE: Provider perspectives on food purchasing and service decisions. STATISTICAL ANALYSES PERFORMED: Inductive analysis of transcribed interviews using TAMS Analyzer software (GPL version 2, 2012) to identify themes. RESULTS: Ten main influencers emerged from the data. These were grouped into four categories based on an ecological framework: macro-level environments (ie, regulations; suppliers and vendors, including stores); physical environment and settings (ie, organizational mission, budget, and structure; the facility itself); social environments (ie, professional networks; peers; the site-specific parent and child community); and individual factors at both a provider and child-level (ie, providers' skills, behaviors, motivations, attitudes, knowledge, and values; child food preferences; and, child allergies). A model was then developed to identify potential pathways of intervention and underscore the need for a comprehensive approach to improve early care and education nutrition. CONCLUSIONS: This study suggests that a more system-based understanding and approach-one that accounts for an array of influencers and their interactions-is necessary to take advantage of opportunities and address barriers to improving early care and education-based nutrition</style></abstract><notes><style face="normal" font="default">DA - 20170131IS - 2212-2672 (Print)IS - 2212-2672 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jand.2016.10.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28139425">PM:28139425</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Acad Nutr Diet\20170131-OttenJJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Acad Nutr Diet\20170131-OttenJJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170131, Otten JJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jand.2016.10.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40328</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Trubiano,J.A.</style></author><author><style face="normal" font="default"> Redwood,A.</style></author><author><style face="normal" font="default"> Strautins,K.</style></author><author><style face="normal" font="default"> Pavlos,R.</style></author><author><style face="normal" font="default"> Woolnough,E.</style></author><author><style face="normal" font="default"> Chang,C.C.</style></author><author><style face="normal" font="default"> Phillips,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, Australia; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="default">Drug-specific upregulation of CD137 on CD8+ T cells aids in the diagnosis of multiple antibiotic toxic epidermal necrolysis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="826" start="823">823-826</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Antibiotic</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> CD8+ T cells</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Toxic epidermal necrolysis</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Victoria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161126IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.09.043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27888029">PM:27888029</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-823-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-823-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161126, Trubiano JA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.09.043</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40329</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jerschow,E.</style></author><author><style face="normal" font="default"> Edin,M.L.</style></author><author><style face="normal" font="default"> Pelletier,T.</style></author><author><style face="normal" font="default"> Abuzeid,W.M.</style></author><author><style face="normal" font="default"> Akbar,N.A.</style></author><author><style face="normal" font="default"> Gibber,M.</style></author><author><style face="normal" font="default"> Fried,M.</style></author><author><style face="normal" font="default"> Lih,F.B.</style></author><author><style face="normal" font="default"> Gruzdev,A.</style></author><author><style face="normal" font="default"> Bradbury,J.A.</style></author><author><style face="normal" font="default"> Han,W.</style></author><author><style face="normal" font="default"> Hudes,G.</style></author><author><style face="normal" font="default"> Keskin,T.</style></author><author><style face="normal" font="default"> Schuster,V.L.</style></author><author><style face="normal" font="default"> Spivack,S.</style></author><author><style face="normal" font="default"> Zeldin,D.C.</style></author><author><style face="normal" font="default"> Rosenstreich,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY.</style></auth-address><titles><title><style face="normal" font="default">Plasma 15-Hydroxyeicosatetraenoic Acid Predicts Treatment Outcomes in Aspirin-Exacerbated Respiratory Disease</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1007" start="998">998-1007</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AERD</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin desensitization</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eicosanoids</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Latino</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peak flow</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> Rhinoconjunctivitis Quality of Life Questionnaire</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Aspirin desensitization followed by daily aspirin provides therapeutic benefits to patients with aspirin-exacerbated respiratory disease (AERD). It is not well understood how eicosanoid levels change during aspirin treatment. OBJECTIVE: To investigate associations between clinical outcomes of aspirin treatment and plasma eicosanoid levels in patients with AERD. METHODS: Thirty-nine patients with AERD were offered aspirin treatment (650 mg twice daily) for 4 weeks. Respiratory parameters and plasma levels of multiple eicosanoids were recorded at baseline and after 4 weeks of aspirin therapy using the Asthma Control Test and Rhinoconjunctivitis Quality of Life Questionnaire. Respiratory function was evaluated using the FEV1 and nasal inspiratory peak flow. RESULTS: After aspirin treatment, respiratory symptoms improved in 16 patients, worsened in 12 patients, and did not change in 4 patients. Seven patients were unable to complete the desensitization protocol. Patients with symptom improvement had higher baseline plasma 15-hydroxyeicosatetraenoic acid (15-HETE) levels than did patients with symptom worsening: 7006 pg/mL (interquartile range, 6056-8688 pg/mL) versus 4800 pg/mL (interquartile range, 4238-5575 pg/mL), P = .0005. Baseline 15-HETE plasma levels positively correlated with the change in Asthma Control Test score (r = 0.61; P = .001) and in FEV1 after 4 weeks of aspirin treatment (r = 0.49; P = .01). It inversely correlated with Rhinoconjunctivitis Quality of Life Questionnaire score (r = -0.58; P = .002). Black and Latino patients were more likely to have symptom worsening on aspirin or fail to complete the initial desensitization than white, non-Latino patients (P = .02). CONCLUSIONS: In patients with AERD, low baseline 15-HETE plasma levels and black or Latino ethnicity are associated with worsening of respiratory symptoms during aspirin treatment</style></abstract><notes><style face="normal" font="default">DA - 20170204IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.11.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28159558">PM:28159558</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-998-1007.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-998-1007.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, Jerschow E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.11.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40330</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nair,P.</style></author><author><style face="normal" font="default"> Martin,J.G.</style></author><author><style face="normal" font="default"> Cockcroft,D.C.</style></author><author><style face="normal" font="default"> Dolovich,M.</style></author><author><style face="normal" font="default"> Lemiere,C.</style></author><author><style face="normal" font="default"> Boulet,L.P.</style></author><author><style face="normal" font="default"> O'Byrne,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Respirology, Department of Medicine, McMaster University and St Joseph's Healthcare, Hamilton, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default">Airway Hyperresponsiveness in Asthma: Measurement and Clinical Relevance</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="659" start="649">649-659</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">airflow</style></keyword><keyword><style face="normal" font="default"> airflow obstruction</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> bronchodilators</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Interpretation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> occupational asthma</style></keyword><keyword><style face="normal" font="default"> Ontario</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> relative potency</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword></keywords><dates><year Day="2" Month="2" Year="2017">2017/2/2</year></dates><abstract><style face="normal" font="default">Airway hyperresponsiveness is a characteristic feature of asthma, and its measurement is an important tool in its diagnosis. With a few caveats, methacholine bronchial provocation by a 2-minute tidal breathing method is highly sensitive; a negative test result (PC20 > 16 mg/mL, PD20 > 400 mug) rules out current asthma with reasonable certainty. A PC20 value of less than 1 mg/mL/PD20 value of less than 25 mug is highly specific (ie, diagnostic) but quite insensitive for asthma. For accurate interpretation of the test results, it is important to control and standardize technical factors that have an impact on nebulizer performance. In addition to its utility to relate symptoms such as cough, wheeze, and shortness of breath to variable airflow obstruction (ie, to diagnose current asthma), the test is useful to make a number of other clinical assessments. These include (1) evaluation of patients with occupational asthma, (2) evaluation of patients with exercise-induced respiratory symptoms, (3) evaluation of novel asthma medications, (4) evaluation of relative potency of inhaled bronchodilators, (5) as a biomarker to adjust anti-inflammatory therapy to improve clinical outcomes, and (6) in the evaluation of patients with severe asthma to rule out masqueraders such as laryngeal dysfunction. The actual mechanism of altered smooth muscle behavior in asthma that is assessed by direct (eg, methacholine) or indirect (eg, allergen) bronchial provocation remains one of the most fundamental questions related to asthma that needs to be determined. The test is underutilized in clinical practice</style></abstract><notes><style face="normal" font="default">DA - 20170206IS - 2213-2201 (Electronic)LA - engPT - Journal ArticlePT - ReviewCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.11.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28163029">PM:28163029</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-649-59.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-649-59.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170206, Nair P</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.11.030</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40331</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schatz,M.</style></author><author><style face="normal" font="default"> Sicherer,S.H.</style></author><author><style face="normal" font="default"> Zeiger,R.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy, Kaiser Permanente Southern California, San Diego, Calif.</style></auth-address><titles><title><style face="normal" font="default">The Journal of Allergy and Clinical Immunology: In Practice - 2016 Year in Review</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="236" start="218">218-236</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergen avoidance</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Communication</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic tool</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> In vitro tests</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="28" Month="1" Year="2017">2017/1/28</year></dates><abstract><style face="normal" font="default">As editors, we concluded that it would be helpful to our readers to write a Year in Review article that highlights the Review, Original, and Clinical Communication articles published in 2016 in The Journal of Allergy and Clinical Immunology: In Practice. We summarized articles on the topics of asthma, rhinitis/rhinosinusitis, food allergy, anaphylaxis, drug allergy, urticarial/angioedema, eosinophilic disorders, and immunodeficiency. Within each topic, epidemiologic findings are presented, relevant aspects of prevention are described, and diagnostic and therapeutic advances are enumerated. Diagnostic tools described include history, skin tests, and in vitro tests. Treatments discussed include behavioral therapy, allergen avoidance therapy, positive and negative effects of pharmacologic therapy, and various forms of immunologic and desensitization management. We hope this review will help you, our readers, consolidate and use this extensive and practical knowledge for the benefit of your patients</style></abstract><notes><style face="normal" font="default">DA - 20170201IS - 2213-2201 (Electronic)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.12.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28143692">PM:28143692</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-5-218-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-5-218-36.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170201, Schatz M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.12.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40332</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nagai,H.</style></author><author><style face="normal" font="default"> Nishigori,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan.</style></auth-address><titles><title><style face="normal" font="default">A delayed reaction to the magnetic resonance imaging contrast agent gadobutrol</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="851" start="850">850-851</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">delayed</style></keyword><keyword><style face="normal" font="default"> delayed reaction</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> imaging</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Imaging</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="30" Month="1" Year="2017">2017/1/30</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170203IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.01.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28153713">PM:28153713</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-850-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-850-1.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170203, Nagai H</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.01.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40333</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Alam,R.</style></author><author><style face="normal" font="default"> Good,J.</style></author><author><style face="normal" font="default"> Rollins,D.</style></author><author><style face="normal" font="default"> Verma,M.</style></author><author><style face="normal" font="default"> Chu,H.</style></author><author><style face="normal" font="default"> Pham,T.H.</style></author><author><style face="normal" font="default"> Martin,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Jewish Health, Department of Medicine, Denver, Colorado.</style></auth-address><titles><title><style face="normal" font="default">Airway and Serum Biochemical Correlates of Refractory Neutrophilic Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> BAL</style></keyword><keyword><style face="normal" font="default"> Basement Membrane</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default"> Bronchoscopy</style></keyword><keyword><style face="normal" font="default"> Characterization</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophilic asthma</style></keyword><keyword><style face="normal" font="default"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="2" Year="2017">2017/2/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Despite the progress in diagnosis and management of asthma, many patients have poorly controlled or refractory asthma. The mechanism of this refractory asthma is not well understood. OBJECTIVE: Explore the relationship between neutrophils and other biomarkers of refractory asthma. METHOD: Sixty subjects with refractory asthma (RA), 30 with non-refractory asthma (NRA) and 20 healthy subjects were enrolled. We performed a comprehensive characterization of these study subjects, which included laboratory and pulmonary function studies, chest CT, and bronchoscopy with bronchoalveolar lavage. We analyzed BAL and serum for a total of 244 biomolecules by multiplex assay and correlated them with the clinical and other laboratory parameters. RESULTS: RA was significantly different from NRA with regard to pulmonary function indices, bronchial basement membrane thickness, and BAL neutrophils and lymphocytes but not eosinophils. BAL neutrophils negatively and positively correlated with the forced vital capacity and age, respectively. Of the 244 biomolecules studied, 52 and 14 biomolecules from BAL and serum, respectively, were significantly different among the study groups. Thirteen of these 52 molecules correlated with BAL neutrophils. BAL from 40% of RA patients was positive for a pathogenic microbe. Infection-negative neutrophilic RA was associated with an increase in select biomarkers of inflammation in the serum suggesting the presence of systemic inflammation. CONCLUSIONS: RA was associated with increased number of neutrophils and proneutrophilic biomolecules in the airways. Subclinical infection was present in 40% of RA patients, which likely contributed to neutrophilic inflammation. A subgroup of non-infected neutrophilic RA was associated with systemic inflammation</style></abstract><notes><style face="normal" font="default">DA - 20170206IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.12.963</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28163052">PM:28163052</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170206-AlamR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170206-AlamR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170206, Alam R</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.12.963</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40334</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Katial,R.K.</style></author><author><style face="normal" font="default"> Bensch,G.W.</style></author><author><style face="normal" font="default"> Busse,W.W.</style></author><author><style face="normal" font="default"> Chipps,B.E.</style></author><author><style face="normal" font="default"> Denson,J.L.</style></author><author><style face="normal" font="default"> Gerber,A.N.</style></author><author><style face="normal" font="default"> Jacobs,J.S.</style></author><author><style face="normal" font="default"> Kraft,M.</style></author><author><style face="normal" font="default"> Martin,R.J.</style></author><author><style face="normal" font="default"> Nair,P.</style></author><author><style face="normal" font="default"> Wechsler,M.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Division of Allergy and Clinical Immunology, National Jewish Health, Denver, Colo.</style></auth-address><titles><title><style face="normal" font="default">Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="S14" start="S1">S1-S14</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">2S</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> Biologic therapy</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="default"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> subtypes</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="28" Month="1" Year="2017">2017/1/28</year></dates><abstract><style face="normal" font="default">Cytokine antagonists are monoclonal antibodies that offer new treatment options for refractory asthma but will also increase complexity because they are effective only for patients with certain asthma subtypes that remain to be more clearly defined. The clinical and inflammatory heterogeneity within refractory asthma makes it difficult to manage the disease and to determine which, if any, biologic therapy is suitable for a specific patient. The purpose of this article is to provide a data-driven discussion to clarify the use of biologic therapies in patients with refractory asthma. We first discuss the epidemiology and pathophysiology of refractory asthma. We then interpret current evidence for biomarkers of eosinophilic or type 2-high asthma so that clinicians can determine potential treatments for patients based on knowledge of their effectiveness in specific asthma phenotypes. We then assess clinical data on the efficacy, safety, and mechanisms of action of approved and pipeline biologic therapies. We conclude by discussing the potential of phenotyping or endotyping refractory asthma and how biologic therapies can play a role in treating patients with refractory asthma</style></abstract><notes><style face="normal" font="default">DA - 20170201IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.11.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28143691">PM:28143691</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5S-S1-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5S-S1-14.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170201, Katial RK</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.11.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40335</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Palomares,O.</style></author><author><style face="normal" font="default"> Subiza,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default">Reply (Refers to: Human basophils may not undergo modulation by DC-SIGN and mannose receptor-targeting immunotherapies due to absence of receptors)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> Biochemistry</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Immunotherapy</style></keyword><keyword><style face="normal" font="default"> Molecular Biology</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="11" Month="1" Year="2017">2017/1/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170115IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28088335">PM:28088335</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170115-PalomaresO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170115-PalomaresO.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170115, Palomares O</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.040</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40336</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Das,M.</style></author><author><style face="normal" font="default"> Galeotti,C.</style></author><author><style face="normal" font="default"> Stephen-Victor,E.</style></author><author><style face="normal" font="default"> Karnam,A.</style></author><author><style face="normal" font="default"> Kaveri,S.V.</style></author><author><style face="normal" font="default"> Bayry,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institut National de la Sante et de la Recherche Medicale Unite 1138, Paris, France; Sorbonne Universites, UPMC Univ Paris 06, UMR S 1138, Paris, France</style></auth-address><titles><title><style face="normal" font="default">Human basophils may not undergo modulation by DC-SIGN and mannose receptor-targeting immunotherapies due to absence of receptors</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immunotherapy</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword></keywords><dates><year Day="11" Month="1" Year="2017">2017/1/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170115IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.09.062</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28088336">PM:28088336</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170115-DasM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170115-DasM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170115, Das M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.09.062</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40337</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,E.</style></author><author><style face="normal" font="default"> Shalowitz,M.U.</style></author><author><style face="normal" font="default"> Story,R.E.</style></author><author><style face="normal" font="default"> Ehrlich,K.B.</style></author><author><style face="normal" font="default"> Manczak,E.M.</style></author><author><style face="normal" font="default"> Ham,P.J.</style></author><author><style face="normal" font="default"> Le,V.</style></author><author><style face="normal" font="default"> Miller,G.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Northwestern University, Institute for Policy Research &amp; Department of Psychology.</style></auth-address><titles><title><style face="normal" font="default">Parents' Childhood Socioeconomic Circumstances are Associated with their Children's Asthma Outcomes</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> psychology</style></keyword><keyword><style face="normal" font="default"> REACH</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Social Environment</style></keyword><keyword><style face="normal" font="default"> socioeconomic status</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: Previous literature documents associations between low socioeconomic status (SES) and poor health outcomes, including asthma. However, this literature has largely focused on the effects of current family circumstances. OBJECTIVE: To test an intergenerational hypothesis, that the childhood SES that parents experience will be associated with asthma outcomes in their children, independent of effects of current family SES. Secondly, to test whether this association is in part due to difficulties in current parent-child relationships. METHODS: Observational study, whereby 150 parents were interviewed about their childhood SES, and their children (physician-diagnosed with asthma, ages 9-17) were interviewed about current family stress. Asthma control was assessed by parent- and child-report (primary outcome), and blood was collected from children to measure cytokine production relevant to asthma (secondary outcomes). RESULTS: To the degree that parents had lower childhood SES, their offspring showed worse asthma outcomes across multiple indicators. This included lower asthma control scores (parent and child-report, p's&lt;.05), and greater stimulated production of Th-2 and Th-1 cytokines by peripheral blood mononuclear cells (PBMC) (p's&lt;.05). These associations were independent of current family SES. Mediation analyses were consistent with a scenario wherein parents with low childhood SES had current family relationships that were more stressful, and these difficulties in turn related to worse asthma control and greater cytokine production in children. CONCLUSIONS: These results suggest the potential 'long reach' of low socioeconomic status across generations, and the importance of expanding theories of how the social environment can affect childhood asthma to include characteristics of earlier generations</style></abstract><notes><style face="normal" font="default">DA - 20170116IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28089871">PM:28089871</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170116-ChenE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170116-ChenE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170116, Chen E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.040</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40338</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Song,W.J.</style></author><author><style face="normal" font="default"> Kim,H.J.</style></author><author><style face="normal" font="default"> Shim,J.S.</style></author><author><style face="normal" font="default"> Won,H.K.</style></author><author><style face="normal" font="default"> Kang,S.Y.</style></author><author><style face="normal" font="default"> Sohn,K.H.</style></author><author><style face="normal" font="default"> Kim,B.K.</style></author><author><style face="normal" font="default"> Jo,E.J.</style></author><author><style face="normal" font="default"> Kim,M.H.</style></author><author><style face="normal" font="default"> Kim,S.H.</style></author><author><style face="normal" font="default"> Park,H.W.</style></author><author><style face="normal" font="default"> Kim,S.S.</style></author><author><style face="normal" font="default"> Chang,Y.S.</style></author><author><style face="normal" font="default"> Morice,A.H.</style></author><author><style face="normal" font="default"> Lee,B.J.</style></author><author><style face="normal" font="default"> Cho,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Clinical Immunology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Diagnostic accuracy of fractional exhaled nitric oxide in predicting cough variant asthma and eosinophilic bronchitis in adult patients with chronic cough: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Area Under Curve</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bias</style></keyword><keyword><style face="normal" font="default"> Bronchitis</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic cough</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic test</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Language</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="1" Year="2017">2017/1/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Individual studies suggested the utility of fractional exhaled nitric oxide (FeNO) in detecting cough variant asthma (CVA) and eosinophilic bronchitis (EB) in chronic cough patients. OBJECTIVE: To obtain summary estimates of diagnostic test accuracy of FeNO in predicting CVA and/or EB in adult patients with chronic cough METHODS: Electronic databases were searched for studies published until January 2016, without language restriction. Cross-sectional studies which reported the diagnostic accuracy of FeNO for detecting CVA or EB were included. Risk of bias was assessed with QUADAS-2. Random effects meta-analyses were performed to obtain summary estimates of the diagnostic accuracy of FeNO. RESULTS: A total of 15 studies involving 2,187 adult patients with chronic cough were identified. FeNO had a moderate diagnostic accuracy in predicting CVA in patients with chronic cough, showing the summary area under curve (AUC) to be 0.87 (95% CI: 0.83-0.89). Specificity was higher and more consistent than sensitivity (0.85 [95% CI: 0.81-0.88] and 0.72 [95% CI: 0.61-0.81], respectively). However, in non-asthmatic chronic cough population, the diagnostic accuracy to predict EB was found to be relatively lower (the summary AUC 0.81 [95% CI: 0.77-0.84]) and specificity was inconsistent. CONCLUSIONS: The present meta-analyses indicated the diagnostic potential of FeNO as a 'rule in' test for detecting CVA in adult patients with chronic cough. However, FeNO may not be useful to predict EB in non-asthmatic chronic cough. These findings warrant further studies to validate the roles of FeNO in clinical practice of chronic cough patients</style></abstract><notes><style face="normal" font="default">DA - 20170115IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28088474">PM:28088474</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170115-SongWJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170115-SongWJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170115, Song WJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.037</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40339</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bakshi,S.S.</style></author><author><style face="normal" font="default"> Vaithy,K.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of ENT and Head &amp; Neck Surgery, Mahatma Gandhi Medical College and Research Institute, Pillaiyarkuppam, Pondicherry, India.</style></auth-address><titles><title><style face="normal" font="default">Antrochoanal Polyp</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="807" start="806">806-807</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Electronic</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161126IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.10.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27888030">PM:27888030</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-806-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-806-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161126, Bakshi SS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.10.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40340</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bielor,C.</style></author><author><style face="normal" font="default"> Sopel,N.</style></author><author><style face="normal" font="default"> Maier,A.</style></author><author><style face="normal" font="default"> Blau,A.</style></author><author><style face="normal" font="default"> Sharma,H.</style></author><author><style face="normal" font="default"> Vuorinen,T.</style></author><author><style face="normal" font="default"> Kross,B.</style></author><author><style face="normal" font="default"> Mittler,S.</style></author><author><style face="normal" font="default"> Graser,A.</style></author><author><style face="normal" font="default"> Mousset,S.</style></author><author><style face="normal" font="default"> Melichar,V.O.</style></author><author><style face="normal" font="default"> Kiefer,A.</style></author><author><style face="normal" font="default"> Zimmermann,T.</style></author><author><style face="normal" font="default"> Springel,R.</style></author><author><style face="normal" font="default"> Holzinger,C.</style></author><author><style face="normal" font="default"> Trump,S.</style></author><author><style face="normal" font="default"> Taka,S.</style></author><author><style face="normal" font="default"> Papadopoulos,N.G.</style></author><author><style face="normal" font="default"> Weiss,S.T.</style></author><author><style face="normal" font="default"> Finotto,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Molecular Pneumology, Friedrich-Alexander-Universitat (FAU) Erlangen-Nurnberg, Universitatsklinikum Erlangen, Erlangen, Germany</style></auth-address><titles><title><style face="normal" font="default">Role of TGF-beta in anti-rhinovirus immune responses in asthmatic patients</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="27" Month="1" Year="2017">2017/1/27</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170131IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Finland -CO - United States -CO - Greece -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28139316">PM:28139316</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170131-BielorC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170131-BielorC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170131, Bielor C</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.049</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40341</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Feeney,M.</style></author><author><style face="normal" font="default"> du Toit,G.</style></author><author><style face="normal" font="default"> Lack,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric Allergy, Division of Asthma, Allergy and Lung Biology, King's College London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Reply (Refers to: Early or delayed introduction of food? Misunderstanding is in the air)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="27" Month="1" Year="2017">2017/1/27</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170131IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28139315">PM:28139315</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170131-FeeneyM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170131-FeeneyM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170131, Feeney M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40342</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Litosh,V.A.</style></author><author><style face="normal" font="default"> Rochman,M.</style></author><author><style face="normal" font="default"> Rymer,J.K.</style></author><author><style face="normal" font="default"> Porollo,A.</style></author><author><style face="normal" font="default"> Kottyan,L.C.</style></author><author><style face="normal" font="default"> Rothenberg,M.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio</style></auth-address><titles><title><style face="normal" font="default">Calpain-14 and its association with eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Apoptosis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Cell Cycle</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Cysteine</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Desmoglein 1</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Enzymes</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> epithelia</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelium</style></keyword><keyword><style face="normal" font="default"> Esophagitis</style></keyword><keyword><style face="normal" font="default"> Esophagus</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Ohio</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> Protease</style></keyword><keyword><style face="normal" font="default"> proteases</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Sequence</style></keyword><keyword><style face="normal" font="default"> Signal Transduction</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword></keywords><dates><year Day="25" Month="1" Year="2017">2017/1/25</year></dates><abstract><style face="normal" font="default">Calpains are a family of intracellular, calcium-dependent cysteine proteases involved in a variety of regulatory processes, including cytoskeletal dynamics, cell-cycle progression, signal transduction, gene expression, and apoptosis. These enzymes have been implicated in a number of disease processes, notably for this review involving eosinophilic tissue inflammation, such as eosinophilic esophagitis (EoE), a chronic inflammatory disorder triggered by allergic hypersensitivity to food and associated with genetic variants in calpain 14 (CAPN14). Herein we review the genetic, structural, and biochemical properties of CAPN14 and its gene product CAPN14, and its emerging role in patients with EoE. The CAPN14 gene is localized at chromosome 2p23.1-p21 and is most homologous to CAPN13 (36% sequence identity), which is located 365 kb downstream of CAPN14. Structurally, CAPN14 has classical calpain motifs, including a cysteine protease core. In comparison with other human calpains, CAPN14 has a unique expression pattern, with the highest levels in the upper gastrointestinal tract, particularly in the squamous epithelium of the esophagus. The CAPN14 gene is positioned in an epigenetic hotspot regulated by IL-13, a TH2 cytokine with increased levels in patients with EoE that has been shown to be a mediator of the disease. CAPN14 induces disruptive effects on the esophageal epithelium by impairing epithelial barrier function in association with loss of desmoglein-1 expression and has a regulatory role in repairing epithelial changes induced by IL-13. Thus CAPN14 is a unique protease with distinct tissue-specific expression and function in patients with EoE and is a potential therapeutic target for EoE and related eosinophilic and allergic diseases</style></abstract><notes><style face="normal" font="default">DA - 20170129IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.09.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28131390">PM:28131390</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170129-LitoshVA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170129-LitoshVA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170129, Litosh VA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.09.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40343</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Keswani,A.</style></author><author><style face="normal" font="default"> Dunn,N.M.</style></author><author><style face="normal" font="default"> Manzur,A.</style></author><author><style face="normal" font="default"> Kashani,S.</style></author><author><style face="normal" font="default"> Bossuyt,X.</style></author><author><style face="normal" font="default"> Grammer,L.C.</style></author><author><style face="normal" font="default"> Conley,D.B.</style></author><author><style face="normal" font="default"> Tan,B.K.</style></author><author><style face="normal" font="default"> Kern,R.C.</style></author><author><style face="normal" font="default"> Schleimer,R.P.</style></author><author><style face="normal" font="default"> Peters,A.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy-Immunology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Ill.</style></auth-address><titles><title><style face="normal" font="default">The Clinical Significance of Specific Antibody Deficiency (SAD) Severity in Chronic Rhinosinusitis (CRS)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1111" start="1105">1105-1111</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> humoral</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulins</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pneumococcal vaccine</style></keyword><keyword><style face="normal" font="default"> Pneumonia</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> specific antibodies</style></keyword><keyword><style face="normal" font="default"> Specific antibody deficiency</style></keyword><keyword><style face="normal" font="default"> Streptococcus</style></keyword><keyword><style face="normal" font="default"> Streptococcus pneumoniae</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vaccination</style></keyword><keyword><style face="normal" font="default"> vaccine</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="26" Month="1" Year="2017">2017/1/26</year></dates><abstract><style face="normal" font="default">BACKGROUND: Despite the increased identification of specific antibody deficiency (SAD) in chronic rhinosinusitis (CRS), little is known about the relationship between SAD severity and the severity and comorbidities of CRS. The prevalence of an impaired antibody response in the general population is also unknown. OBJECTIVE: The objective of this study was to determine if the SAD severity stratification applies to real-life data of patients with CRS. METHODS: An electronic health record database was used to identify patients with CRS evaluated for humoral immunodeficiency with quantitative immunoglobulins and Streptococcus pneumoniae antibody titers before and after pneumococcal vaccine. SAD severity was defined, according to the guidelines, based on the numbers of titers >/=1.3 mug/dL after vaccination: severe (&lt;/=2 serotypes), moderate (3-6 serotypes), and mild (7-10 serotypes). Comorbidities and therapeutic response were assessed. The prevalence of an impaired antibody response in a normal population was assessed. RESULTS: Twenty-four percent of the patients with CRS evaluated for immunodeficiency had SAD, whereas 11% of a normal population had an impaired immune response to polysaccharide vaccination (P &lt; .05). When evaluated by the practice parameter definition, 239 of 595 (40%) met the definition of SAD. Twenty-four (10%) had severe SAD, 120 (50%) had moderate SAD, and 95 (40%) had mild SAD. Patients with moderate-to-severe SAD had worse asthma, a greater likelihood of pneumonia, and more antibiotic courses in the 2 years after vaccination than patients with mild SAD. CONCLUSIONS: This study provides real world data supporting stratification of SAD by severity, demonstrating a significant increase in the comorbid severity of asthma and infections in CRS patients with moderate-to-severe SAD compared with those with mild SAD and those without SAD</style></abstract><notes><style face="normal" font="default">DA - 20170130IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.11.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28132798">PM:28132798</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1105-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1105-11.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170130, Keswani A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.11.033</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40344</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gern,J.E.</style></author><author><style face="normal" font="default"> Calatroni,A.</style></author><author><style face="normal" font="default"> Jaffee,K.F.</style></author><author><style face="normal" font="default"> Lynn,H.</style></author><author><style face="normal" font="default"> Dresen,A.</style></author><author><style face="normal" font="default"> Cruikshank,W.W.</style></author><author><style face="normal" font="default"> Lederman,H.M.</style></author><author><style face="normal" font="default"> Sampson,H.A.</style></author><author><style face="normal" font="default"> Shreffler,W.</style></author><author><style face="normal" font="default"> Bacharier,L.B.</style></author><author><style face="normal" font="default"> Gergen,P.J.</style></author><author><style face="normal" font="default"> Gold,D.R.</style></author><author><style face="normal" font="default"> Kattan,M.</style></author><author><style face="normal" font="default"> O'Connor,G.T.</style></author><author><style face="normal" font="default"> Sandel,M.T.</style></author><author><style face="normal" font="default"> Wood,R.A.</style></author><author><style face="normal" font="default"> Bloomberg,G.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.</style></auth-address><titles><title><style face="normal" font="default">Patterns of Immune Development in Urban Preschoolers with Recurrent Wheeze and/or Atopy</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic sensitization</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Cockroach</style></keyword><keyword><style face="normal" font="default"> Cockroaches</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cord Blood</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> endotoxin</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Poverty</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> recurrent wheeze</style></keyword><keyword><style face="normal" font="default"> recurrent wheezing</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword><keyword><style face="normal" font="default"> Wisconsin</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: Disadvantaged urban children have high rates of allergic diseases and wheezing, which are diseases associated with Type 2-biased immunity. OBJECTIVE: To determine whether environmental exposures in early life influence cytokine responses which affect the development of recurrent wheezing illnesses and allergic sensitization. METHODS: A birth cohort of 560 urban families was recruited from neighborhoods with high rates of poverty, and 467 (83%) children were followed until 3 years of age. Cytokine responses were measured in blood cell samples obtained at birth (cord blood) and ages 1 and 3 years. Cytokine responses were examined in relation to personal characteristics and environmental exposures to allergens and endotoxin, and also to the development of allergic sensitization and recurrent wheeze assessed at age 3 years. RESULTS: Cytokine responses generally increased with age, but responses at birth were poorly predictive for those at ages 1 and 3 years. Exposure to certain allergens (cockroach, mouse, dust mite) was significantly associated with enhanced cytokine responses at age 3 years, including IFN-alpha and IL-10 responses to certain stimulants, and responses to phytohemagglutinin. Regarding the clinical outcomes, reduced LPS-induced IL-10 responses at birth was associated with recurrent wheeze. In contrast, reduced RSV-induced IL-8 responses, and increased CpG-induced IL-12p40 and allergen-induced IL-4 responses were associated with atopy. CONCLUSIONS: These findings suggest that diverse biologic exposures, including allergens and endotoxin, in urban homes stimulate the development of cytokine responses in early life, and that cytokine responses to specific microbial and viral stimuli are associated with the development of allergic sensitization and recurrent wheeze</style></abstract><notes><style face="normal" font="default">DA - 20170116IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.10.052</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28089873">PM:28089873</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170116-GernJE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170116-GernJE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170116, Gern JE</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.10.052</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40345</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Melo,F.R.</style></author><author><style face="normal" font="default"> Wallerman,O.</style></author><author><style face="normal" font="default"> Paivandy,A.</style></author><author><style face="normal" font="default"> Calounova,G.</style></author><author><style face="normal" font="default"> Gustafson,A.M.</style></author><author><style face="normal" font="default"> Sabari,B.R.</style></author><author><style face="normal" font="default"> Zabucchi,G.</style></author><author><style face="normal" font="default"> Allis,C.D.</style></author><author><style face="normal" font="default"> Pejler,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Uppsala University, Department of Medical Biochemistry and Microbiology, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default">Tryptase-catalyzed core histone truncation: a novel epigenetic regulatory mechanism in mast cells</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Biochemistry</style></keyword><keyword><style face="normal" font="default"> Cell Lineage</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Chromatin</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> Granules</style></keyword><keyword><style face="normal" font="default"> Histones</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lysine</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Protease</style></keyword><keyword><style face="normal" font="default"> proteases</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Secretory granules</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Mast cells are key effector cells in allergic reactions. When activated to degranulate, they release a plethora of bioactive compounds from their secretory granules, including mast cell-restricted proteases such as tryptase. In a previous study we showed that tryptase, in addition to its intragranular location, can be found within the nuclei of mast cells where it truncates core histones at their N-terminal ends. OBJECTIVE: Considering that the N-terminal portions of the core histones constitute sites for posttranslational modifications of major epigenetic impact, we here evaluated whether histone truncation by tryptase could have an impact on epigenetic events in mast cells. METHODS: Mast cells were cultured from wild type and tryptase null mice, followed by an assessment of their profile of epigenetic histone modifications and their phenotypic characteristics. RESULTS: We show that tryptase truncates nucleosomal histone 3 (H3) and H2B and that its absence results in accumulation of the epigenetic mark, lysine 5-acetylated H2B (H2BK5ac). Intriguingly, the accumulation of H2BK5ac was cell age-dependent and was associated with a profound upregulation of markers of non-mast cell lineages, loss of proliferative control, chromatin remodeling as well as extensive morphological alterations. CONCLUSION: These findings introduce tryptase-catalyzed histone clipping as a novel epigenetic regulatory mechanism, which in the mast cell context may be crucial for maintaining cellular identity</style></abstract><notes><style face="normal" font="default">DA - 20170121IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - United States -CO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28108335">PM:28108335</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170121-MeloFR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170121-MeloFR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170121, Melo FR</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.044</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40346</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bommart,S.</style></author><author><style face="normal" font="default"> Marin,G.</style></author><author><style face="normal" font="default"> Molinari,N.</style></author><author><style face="normal" font="default"> Knabe,L.</style></author><author><style face="normal" font="default"> Petit,A.</style></author><author><style face="normal" font="default"> Chanez,P.</style></author><author><style face="normal" font="default"> Gamez,A.S.</style></author><author><style face="normal" font="default"> Devautour,C.</style></author><author><style face="normal" font="default"> Vachier,I.</style></author><author><style face="normal" font="default"> Bourdin,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiology, Montpellier University Hospital, France; PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214, Montpellier University Hospital, France</style></auth-address><titles><title><style face="normal" font="default">CCSP Serum Level is A Surrogate Marker of Small Airway Involvment in Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> CCSP</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> Radiology</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> small airways</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="default">Serum CCSP level was independently related to small airway hyperresponsiveness, measured by the slope of air-trapping progression measured using CT. In asthmatic patients, this blood biomarker may identify small airways involvement</style></abstract><notes><style face="normal" font="default">DA - 20170121IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.09.063</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28108336">PM:28108336</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170121-BommartS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170121-BommartS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170121, Bommart S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.09.063</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40347</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guilbert,T.W.</style></author><author><style face="normal" font="default"> Colice,G.</style></author><author><style face="normal" font="default"> Grigg,J.</style></author><author><style face="normal" font="default"> van Aalderen,W.</style></author><author><style face="normal" font="default"> Martin,R.J.</style></author><author><style face="normal" font="default"> Israel,E.</style></author><author><style face="normal" font="default"> Postma,D.S.</style></author><author><style face="normal" font="default"> Roche,N.</style></author><author><style face="normal" font="default"> Phipatanakul,W.</style></author><author><style face="normal" font="default"> Hillyer,E.V.</style></author><author><style face="normal" font="default"> Evans,J.M.</style></author><author><style face="normal" font="default"> Dolovich,M.B.</style></author><author><style face="normal" font="default"> Price,D.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cincinnati Children's Hospital and Medical Center, Cincinnati, Ohio</style></auth-address><titles><title><style face="normal" font="default">Real-Life Outcomes for Patients with Asthma Prescribed Spacers for Use with Either Extrafine- or Fine-Particle Inhaled Corticosteroids</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1049" start="1040">1040-1049</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Beclomethasone</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Candidiasis</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Metered Dose Inhalers</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Ohio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pressurized metered-dose inhaler</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="default">BACKGROUND: Spacers are often used with pressurized metered-dose inhalers (pMDIs) to eliminate the need for coordinating inhalation with actuation. OBJECTIVE: To investigate the real-life effectiveness of spacers prescribed for use with either extrafine- or fine-particle inhaled corticosteroids (ICSs). METHODS: This historical matched cohort study examined anonymous medical record data over 2 years (1-year baseline, 1-year outcome) for patients with asthma aged 12 to 80 years initiating ICSs by pMDI with or without prescribed spacer. We compared outcomes for spacer versus no-spacer arms, matched for key baseline and asthma-related characteristics, within 2 ICS cohorts: (1) extrafine-particle ICS (beclomethasone) and (2) fine-particle ICS (fluticasone). Effectiveness end points were compared using conditional regression methods. RESULTS: Matched spacer and no-spacer arms of the extrafine-particle ICS cohort each included 2090 patients (69% females; median age, 46-47 years) and the 2 arms of the fine-particle ICS cohort each included 444 patients (67% females; median age, 45 years). With extrafine-particle ICS, we observed no significant difference between spacer and no-spacer arms in severe exacerbation rate (primary end point): adjusted rate ratio, 1.01 (95% CI, 0.83-1.23). With fine-particle ICS, the severe exacerbation rate ratio with spacers was 0.77 (0.47-1.25). Oropharyngeal candidiasis incidence was low and similar in spacer and no-spacer arms for both ICS cohorts. CONCLUSIONS: We found no evidence that prescribed spacer devices are associated with improved asthma outcomes for extrafine- or fine-particle ICS administered by pMDI. These findings challenge long-standing assumptions that spacers should improve pMDI effectiveness and indicate the need for pragmatic trials of spacers in clinical practice</style></abstract><notes><style face="normal" font="default">DA - 20170122IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - United KIngdom -CO - Netherlands -CO - Singapore -CO - Canada -CO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.11.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28110057">PM:28110057</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1040-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1040-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170122, Guilbert TW</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.11.026</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40348</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Blumenthal,K.G.</style></author><author><style face="normal" font="default"> Lai,K.H.</style></author><author><style face="normal" font="default"> Huang,M.</style></author><author><style face="normal" font="default"> Wallace,Z.S.</style></author><author><style face="normal" font="default"> Wickner,P.G.</style></author><author><style face="normal" font="default"> Zhou,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass</style></auth-address><titles><title><style face="normal" font="default">Adverse and Hypersensitivity Reactions to Prescription Nonsteroidal Anti-Inflammatory Agents in a Large Health Care System</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="743" start="737">737-743</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Anti-Inflammatory Agents</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Counseling</style></keyword><keyword><style face="normal" font="default"> Diclofenac</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Indomethacin</style></keyword><keyword><style face="normal" font="default"> Language</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> nabumetone</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> NSAID</style></keyword><keyword><style face="normal" font="default"> NSAIDs</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Outpatients</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Piroxicam</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective cohort study</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapeutic use</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="default">BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most frequently used medications in the United States. NSAID use can be limited by adverse drug reactions (ADRs), including hypersensitivity reactions (HSRs). OBJECTIVE: We aimed to use electronic health record data to determine the incidence and predictors of HSRs to prescription NSAIDs. METHODS: We performed a retrospective cohort study of all adult outpatients in a large health care system prescribed diclofenac, indomethacin, nabumetone, or piroxicam between January 1, 2004, and September 30, 2012. The primary outcome was an ADR or HSR attributed to the prescribed NSAID within 1 year of prescription, determined from a longitudinal allergy database. We used natural language processing to classify known ADRs as either HSRs or side effects. Multivariable logistic regression models were used to identify independent risk factors for NSAID HSRs. RESULTS: Of 62,719 patients prescribed NSAIDs, 1,035 (1.7%) had an ADR, of which 189 (18.3%) were HSRs. Multivariable regression analysis identified that patients with prior drug HSR history (odds ratio [OR] 1.8 [95% CI 1.3, 2.5]), female sex (OR 1.8 [95% CI 1.3, 2.4]), autoimmune disease (OR 1.7 [95% CI 1.1, 2.7]), and those prescribed the maximum standing NSAID dose (OR 1.5 [95% CI 1.1, 2.0]) had increased odds of NSAID HSR. CONCLUSIONS: NSAID therapeutic use can be limited by ADRs; about 1 in 5 NSAID ADRs is an HSR. Both patient and drug factors contribute to HSR risk and are important to guide patient counseling</style></abstract><notes><style face="normal" font="default">DA - 20170122IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.12.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28110055">PM:28110055</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-737-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-737-43.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170122, Blumenthal KG</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.12.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40349</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rochman,M.</style></author><author><style face="normal" font="default"> Travers,J.</style></author><author><style face="normal" font="default"> Miracle,C.E.</style></author><author><style face="normal" font="default"> Bedard,M.C.</style></author><author><style face="normal" font="default"> Wen,T.</style></author><author><style face="normal" font="default"> Azouz,N.P.</style></author><author><style face="normal" font="default"> Caldwell,J.M.</style></author><author><style face="normal" font="default"> Kc,K.</style></author><author><style face="normal" font="default"> Sherrill,J.D.</style></author><author><style face="normal" font="default"> Davis,B.P.</style></author><author><style face="normal" font="default"> Rymer,J.K.</style></author><author><style face="normal" font="default"> Kaufman,K.M.</style></author><author><style face="normal" font="default"> Rothenberg,M.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229-3039, USA</style></auth-address><titles><title><style face="normal" font="default">Profound Loss of Esophageal Tissue Differentiation in Eosinophilic Esophagitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> differentially expressed gene</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> disease pathogenesis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> Esophagitis</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-1</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Keratin</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Ohio</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Protease</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Serine</style></keyword><keyword><style face="normal" font="default"> Serpins</style></keyword><keyword><style face="normal" font="default"> Transcriptome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Western blot</style></keyword></keywords><dates><year Day="16" Month="1" Year="2017">2017/1/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: A key question in the allergy field is to understand how tissue specific disease is manifested. Eosinophilic esophagitis (EoE) is an emerging tissue specific allergic disease whose pathogenesis remains unclear. OBJECTIVE: Herein, we tested the hypothesis that a defect in tissue specific esophageal genes is an integral part of EoE pathogenesis. METHODS: We interrogated the pattern of expression of esophagus-specific signature genes derived from the Human Protein Atlas in the EoE transcriptome and in EPC2 esophageal epithelial cells. Western blot and immunofluorescence were used for evaluating expression of esophageal proteins in control and active EoE biopsies. Whole-exome sequencing (WES) was performed to identify mutations in esophagus-specific genes. RESULTS: We found that approximately 39% of the esophagus-specific transcripts were altered in EoE, with approximately 90% being downregulated. The majority of transcriptional changes observed in esophagus-specific genes were reproduced in vitro in esophageal epithelial cells differentiated in the presence of IL-13. Functional enrichment analysis revealed keratinization and differentiation as the most affected biological processes, and identified IL-1 cytokines and serine peptidase inhibitors (SERPINs) as the most dysregulated esophagus-specific protein families in EoE. Accordingly, EoE biopsies evidenced a profound loss of tissue differentiation, decreased expression of keratin 4 and cornulin and elevated expression of keratin 5 and 14. Whole-exome sequencing of 33 unrelated EoE cases revealed 39 rare mutations in 18 esophagus-specific differentially expressed genes. CONCLUSIONS: A tissue-centered analysis has revealed a profound loss of esophageal tissue differentiation as an integral and specific part of the pathophysiology of EoE, and implicated protease- and IL-1-related activities as putative central pathways in disease pathogenesis</style></abstract><notes><style face="normal" font="default">DA - 20170120IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28104354">PM:28104354</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170120-RochmanM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170120-RochmanM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170120, Rochman M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.042</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40350</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Semprini,R.</style></author><author><style face="normal" font="default"> Caswell-Smith,R.</style></author><author><style face="normal" font="default"> Fingleton,J.</style></author><author><style face="normal" font="default"> Holweg,C.</style></author><author><style face="normal" font="default"> Matthews,J.</style></author><author><style face="normal" font="default"> Weatherall,M.</style></author><author><style face="normal" font="default"> Beasley,R.</style></author><author><style face="normal" font="default"> Braithwaite,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical Research Institute of New Zealand, New Zealand; Victoria University of Wellington, New Zealand.</style></auth-address><titles><title><style face="normal" font="default">Longitudinal variation of serum periostin in adults with stable asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> New Zealand</style></keyword><keyword><style face="normal" font="default"> Periostin</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> Victoria</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="default">We have shown that serum periostin levels are stable within an individual with well-controlled asthma and have little seasonal variation. These are desirable characteristics if serum periostin is to be used as a biomarker in asthma</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - New Zealand -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28093216">PM:28093216</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170117-SempriniR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170117-SempriniR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Semprini R</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.041</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40351</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Silkoff,P.E.</style></author><author><style face="normal" font="default"> Laviolette,M.</style></author><author><style face="normal" font="default"> Singh,D.</style></author><author><style face="normal" font="default"> Fitzgerald,J.M.</style></author><author><style face="normal" font="default"> Kelsen,S.</style></author><author><style face="normal" font="default"> Backer,V.</style></author><author><style face="normal" font="default"> Porsbjerg,C.M.</style></author><author><style face="normal" font="default"> Girodet,P.O.</style></author><author><style face="normal" font="default"> Berger,P.</style></author><author><style face="normal" font="default"> Kline,J.N.</style></author><author><style face="normal" font="default"> Chupp,G.</style></author><author><style face="normal" font="default"> Susulic,V.S.</style></author><author><style face="normal" font="default"> Barnathan,E.S.</style></author><author><style face="normal" font="default"> Baribaud,F.</style></author><author><style face="normal" font="default"> Loza,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Janssen Research &amp; Development LLC, Spring House, USA.</style></auth-address><titles><title><style face="normal" font="default">Identification of Airway-Mucosal Type-2 inflammation by Clinical Biomarkers in Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Airways disease</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cell Line</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> differentially expressed gene</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient Selection</style></keyword><keyword><style face="normal" font="default"> Periostin</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutics</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="12" Month="1" Year="2017">2017/1/12</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVE: The Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study profiled mild, moderate and severe asthma, and non-atopic healthy controls. We explored this dataset to define Type-2 inflammation based on airway-mucosal IL-13-driven gene expression and how this related to clinically-accessible biomarkers. METHODS: IL-13-driven gene expression was evaluated in several human cell lines. We then defined Type-2 status in 25 healthy subjects, 28 mild, 29 moderate, and 26 severe asthmatics, based on airway-mucosal expression of 1) CC-motif chemokine ligand (CCL)-26, (the most differentially expressed gene), 2) periostin, or 3) a multi-gene IL-13 in-vitro signature (IVS). Clinically accessible biomarkers included fractional exhaled nitric oxide (FENO), blood eosinophils (bEOS), serum CCL26, and serum CCL17. RESULTS: Expression of airway-mucosal-CCL26, periostin, and IL-13-IVS all provided segregation into Type-2-high and -low asthmatics, but in the ADEPT population, CCL26 was optimal. All airway-mucosal-CCL26-high subjects with moderate-severe asthma were FENO-high (>/=35 ppb) and/or blood eosinophils-high (>/=300cells/mm3), compared to a minority (36%) of airway-mucosal- CCL26-low subjects. A combination of FENO, blood eosinophils, serum CCL17 and CCL26 had 100% positive-predictive-value and 87% negative-predictive-value for airway-mucosal-CCL26-high status. Clinical variables did not differ between Type-2 high and -low subjects. Eosinophilic inflammation was associated with, but not limited to, airway-mucosal Type-2 gene expression. CONCLUSION: A panel of clinical biomarkers accurately classified Type-2 status based on airway-mucosa CCL26, perisotin or IL-13-IVS gene expression. Use of FENO, blood eosinophils and serum markers e.g. CCL26, CCL17 in combination may allow patient selection for novel Type-2 therapeutics</style></abstract><notes><style face="normal" font="default">DA - 20170116IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -CO - France -CO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28089872">PM:28089872</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170116-SilkoffPE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170116-SilkoffPE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170116, Silkoff PE</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40352</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Li,P.H.</style></author><author><style face="normal" font="default"> Trigg,C.</style></author><author><style face="normal" font="default"> Rutkowski,R.</style></author><author><style face="normal" font="default"> Rutkowski,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Anaphylaxis to tranexamic acid-a rare reaction to a common drug</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="841" start="839">839-841</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="20" Month="1" Year="2017">2017/1/20</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170124IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United Kingdom -CO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.12.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28117269">PM:28117269</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-839-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-839-41.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170124, Li PH</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.12.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40353</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fukuyama,T.</style></author><author><style face="normal" font="default"> Ganchingco,J.R.</style></author><author><style face="normal" font="default"> Mishra,S.K.</style></author><author><style face="normal" font="default"> Olivry,T.</style></author><author><style face="normal" font="default"> Rzagalinski,I.</style></author><author><style face="normal" font="default"> Volmer,D.A.</style></author><author><style face="normal" font="default"> Baumer,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, NC, USA; Comparative Medicine Institute, North Carolina State University, NC, USA</style></auth-address><titles><title><style face="normal" font="default">Janus-kinase inhibitors display broad anti-itch properties - a possible link via the TRPV1 receptor</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> dog</style></keyword><keyword><style face="normal" font="default"> Dogs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Janus kinase</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> North Carolina</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> veterinary</style></keyword><keyword><style face="normal" font="default"> Veterinary Medicine</style></keyword></keywords><dates><year Day="25" Month="1" Year="2017">2017/1/25</year></dates><abstract><style face="normal" font="default">The antipruritic effect of JAK inhibitors is fast and sustained in dogs with atopic dermatitis and in human patients with psoriasis. The inhibitory profiles of these molecules might be more related to their direct inhibition of TRPV1 rather than that of JAKs</style></abstract><notes><style face="normal" font="default">DA - 20170129IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.12.960</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28131799">PM:28131799</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170129-FukuyamaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170129-FukuyamaT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170129, Fukuyama T</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.12.960</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40354</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Koplin,J.</style></author><author><style face="normal" font="default"> Allen,K.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Murdoch Childrens Research Institute, Royal Children's Hospital, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="default">Reply (Refers to: Early or delayed introduction of food? Misunderstanding is in the air)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Victoria</style></keyword></keywords><dates><year Day="27" Month="1" Year="2017">2017/1/27</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170131IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28139314">PM:28139314</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170131-KoplinJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170131-KoplinJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170131, Koplin J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40355</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Choi,S.</style></author><author><style face="normal" font="default"> Hoffman,E.A.</style></author><author><style face="normal" font="default"> Wenzel,S.E.</style></author><author><style face="normal" font="default"> Castro,M.</style></author><author><style face="normal" font="default"> Fain,S.</style></author><author><style face="normal" font="default"> Jarjour,N.</style></author><author><style face="normal" font="default"> Schiebler,M.L.</style></author><author><style face="normal" font="default"> Chen,K.</style></author><author><style face="normal" font="default"> Lin,C.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Mechanical and Industrial Engineering; IIHR-Hydroscience and Engineering; Department of Biomedical Engineering</style></auth-address><titles><title><style face="normal" font="default">Quantitative computed tomography imaging-based clustering differentiates asthmatic subgroups with distinctive clinical phenotypes</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">airflow</style></keyword><keyword><style face="normal" font="default"> airflow obstruction</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> Biomedical Engineering</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical phenotypes</style></keyword><keyword><style face="normal" font="default"> Cluster Analysis</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> Demography</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Engineering</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> imaging</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="1" Year="2017">2017/1/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: Imaging variables including airway diameter, wall thickness and air-trapping have been found to be important metrics when differentiating severe asthmatics from nonsevere asthmatics and healthy subjects. OBJECTIVE: The objective of this study was to identify imaging-based clusters and to explore the association of the clusters with existing clinical metrics. METHODS: We performed an imaging-based cluster analysis using quantitative computed tomography-based structural and functional variables extracted from the respective inspiration and expiration scans of 248 asthmatics. The imaging-based metrics included a broader-set of multiscale variables such as inspiratory airway dimension, expiratory air-trapping and registration-based lung deformation (inspiration vs. expiration). Asthma subgroups derived from a clustering method were associated with subject demography, questionnaire, medication history, and biomarker variables. RESULTS: Cluster 1 patients were early-onset younger nonsevere asthmatics with reversible airflow obstruction, who showed normal airway structure; Cluster 2 patients were a mix of nonsevere and severe asthmatics with marginal inflammation, who exhibited airway luminal narrowing without wall thickening. Cluster 3 and 4 patients were dominated by severe asthmatics. Cluster 3 patients were obese females with reversible airflow obstruction who exhibited airway wall thickening without airway narrowing. Cluster 4 patients were late-onset older males with persistent airflow obstruction, exhibiting significant air-trapping and reduced regional deformation. Clusters 3 and 4 patients also showed decreased lymphocyte and increased neutrophils, respectively. CONCLUSIONS: Four image-based clusters were identified and shown to be correlated with clinical characteristics. Such clustering serves to differentiate asthma subgroups which may be used as a basis for the development of new therapies</style></abstract><notes><style face="normal" font="default">DA - 20170201IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.053</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28143694">PM:28143694</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170201-ChoiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170201-ChoiS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170201, Choi S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.053</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40356</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Farahnik,B.</style></author><author><style face="normal" font="default"> Beroukhim,K.</style></author><author><style face="normal" font="default"> Danesh,M.</style></author><author><style face="normal" font="default"> Nakamura,M.</style></author><author><style face="normal" font="default"> Abrouk,M.</style></author><author><style face="normal" font="default"> Zhu,T.H.</style></author><author><style face="normal" font="default"> Singh,R.</style></author><author><style face="normal" font="default"> Lee,K.</style></author><author><style face="normal" font="default"> Bhutani,T.</style></author><author><style face="normal" font="default"> Koo,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Vermont College of Medicine, Burlington.</style></auth-address><titles><title><style face="normal" font="default">Successful use of a modified Goeckerman regimen in the treatment of chronic severe atopic dermatitis: A prospective pilot study</style></title><secondary-title><style face="normal" font="default">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am Acad Dermatol</style></full-title></periodical><pages end="1071" start="1068">1068-1071</pages><volume><style face="normal" font="default">75</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Pilot study</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161017IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaad.2016.06.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27745637">PM:27745637</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am Acad Dermatol\2016-75-1068-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Am Acad Dermatol\2016-75-1068-71.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161017, Farahnik B</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaad.2016.06.040</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40357</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Deshwal,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Consultant in Internal Medicine and HIV Medicine, Military Hospital, Agra Cantt</style></auth-address><titles><title><style face="normal" font="default">Clinical and Laboratory Profile of Hospitalized Malarial Patients: An Agra-Based Study</style></title><secondary-title><style face="normal" font="default">J Assoc Physicians India</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Assoc Physicians India</style></abbr-1></periodical><pages end="47" start="44">44-47</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic test</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Headache</style></keyword><keyword><style face="normal" font="default"> herpes</style></keyword><keyword><style face="normal" font="default"> Herpes Labialis</style></keyword><keyword><style face="normal" font="default"> Hiv</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Malaria</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Splenomegaly</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Thrombocytopenia</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The clinical presentations and laboratory profile of malaria has been changing over the years. Therefore this study was undertaken to study the clinical profile and laboratory parameters of malarial patients. METHODS: This prospective observational study was undertaken in military hospital with high prevalence of malaria. A total of 320 patients were studied. All patients tested positive by peripheral blood smear or rapid diagnostic test were included. Clinical presentations, hematological and biochemical parameters were noted. RESULTS: Of the total 320 patients, 249 had P vivax, 43 had P falciparum and 28 had mixed malaria.79% patients were male. Maximum (51.56%) patients were in 21-30 age group. The mean duration of symptoms was 2.54 days in vivax to 3.03 days in mixed malaria. Fever was observed in 97.8% of patients of vivax. Thrombocytopenia was observed in 99% of all patients. Splenomegaly was noticed in 24.84% patients of vivax and 34.5% of falciparum malaria. Herpes labialis was observed in 23.64% patients of vivax and 5.94% had urticaria. CONCLUSIONS: High index of suspicion should be maintained in picking up the diagnosis. Any patient with thrombocytopenia, leucopenia, headache, herpes labialis, pain epigastrium and urticaria deserves exclusion of malaria</style></abstract><notes><style face="normal" font="default">DA - 20161020IS - 0004-5772 (Print)IS - 0004-5772 (Linking)LA - ENGPT - JOURNAL ARTICLECO - India -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27762108">PM:27762108</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Assoc Physicians India\2016-64-44-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Assoc Physicians India\2016-64-44-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161020, Deshwal R</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40358</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tapp,H.</style></author><author><style face="normal" font="default"> Shade,L.</style></author><author><style face="normal" font="default"> Mahabaleshwarkar,R.</style></author><author><style face="normal" font="default"> Taylor,Y.J.</style></author><author><style face="normal" font="default"> Ludden,T.</style></author><author><style face="normal" font="default"> Dulin,M.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Family Medicine , Carolinas HealthCare System , Charlotte , NC , USA</style></auth-address><titles><title><style face="normal" font="default">Results from a pragmatic prospective cohort study: Shared decision making improves outcomes for children with asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Decision Making</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral steroids</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> prospective cohort study</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="11" Year="2016">2016/11/4</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Patient/provider shared decision making (SDM) improves asthma control in a pragmatic clinical trial setting. This study evaluated the impact of an evidence-based SDM toolkit on outcomes for patients with asthma implemented by providers in a real world setting. We hypothesized that these patients with asthma would demonstrate improved outcomes such as reduced emergency department (ED) visits, hospitalizations, and oral steroid use in the 12 months following a SDM visit compared to those who did not receive the intervention. METHODS: Patients with asthma were identified within six primary care practices that serve vulnerable populations in Charlotte, NC (746 children; 718 adult patients). Propensity scores were used to match 200 children and 206 adults for analysis. The primary outcome variable was asthma exacerbation defined as an ED visit or hospitalization for asthma or outpatient prescription of an oral steroid. Patients were monitored at 3, 6, and 12 months after the intervention date. The outcome variables of ED visits, hospitalizations, and oral steroids were compared between intervention and matched control patients. RESULTS: The proportion of pediatric patients with one or more exacerbations was significantly lower in the SDM intervention group compared to controls during 12 months after exposure to the intervention (33% vs. 47%, p = 0.023). For adults, there was not a strong association between use of the SDM intervention and outcomes improvement. CONCLUSIONS: The evidence-based SDM intervention implemented in this study was associated with improved asthma outcomes for pediatric patients but not adult patients in a real world clinical setting</style></abstract><notes><style face="normal" font="default">DA - 20161104IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1227333</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27813670">PM:27813670</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20161104-TappH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20161104-TappH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161104, Tapp H</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1227333</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40359</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Melo,J.</style></author><author><style face="normal" font="default"> Moreno,A.</style></author><author><style face="normal" font="default"> Ferriani,V.</style></author><author><style face="normal" font="default"> Araujo,A.C.</style></author><author><style face="normal" font="default"> Vianna,E.</style></author><author><style face="normal" font="default"> Borges,M.</style></author><author><style face="normal" font="default"> Roxo,P.,Jr.</style></author><author><style face="normal" font="default"> Goncalves,M.</style></author><author><style face="normal" font="default"> Mello,L.</style></author><author><style face="normal" font="default"> Parreira,R.</style></author><author><style face="normal" font="default"> Silva,J.</style></author><author><style face="normal" font="default"> Stefanelli,P.</style></author><author><style face="normal" font="default"> Panazolo,L.</style></author><author><style face="normal" font="default"> Cetlin,A.</style></author><author><style face="normal" font="default"> Queiroz,L.</style></author><author><style face="normal" font="default"> Araujo,R.</style></author><author><style face="normal" font="default"> Dias,M.</style></author><author><style face="normal" font="default"> Aragon,D.</style></author><author><style face="normal" font="default"> Domingos,N.</style></author><author><style face="normal" font="default"> Arruda,L.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Medicine , Ribeirao Preto Medical School, University of Sao Paulo , Ribeirao Preto , Brazil</style></auth-address><titles><title><style face="normal" font="default">University and public health system partnership: A real-life intervention to improve asthma management</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Albuterol</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma education</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Asthma specialist</style></keyword><keyword><style face="normal" font="default"> Beclomethasone</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> rescue medication</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="7" Month="10" Year="2016">2016/10/7</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Asthma is under-diagnosed in many parts of the world. We aimed to assess the outcome of a capacitating program on asthma for non-specialist physicians and other healthcare professionals working in the public system in Ribeirao Preto, Brazil. METHODS: A group of 16 asthma specialists developed a one-year capacitating program in 11 healthcare clinics in the Northern District of the city, which included lectures on asthma, training on inhalation device use and spirometry, and development of an asthma management protocol. Researchers visited one health unit 2-4 times monthly, working with doctors on patients' care, discussing cases, and delivering lectures. Asthma education was also directed to the general population, focusing on recognition of signs and symptoms and long-term treatment, including production of educational videos available on YouTube. Outcome measures were the records of doctors' prescriptions of individual asthma medications pre- and post-intervention. RESULTS: Prior to the program, 3205 units of inhaled albuterol and 2876 units of inhaled beclomethasone were delivered by the Northern District pharmacy. After the one-year program, there was increase to 4850 units (51.3%) for inhaled albuterol and 3526 units (22.6%) for inhaled beclomethasone. The albuterol increase followed the recommendation given to the non-specialist doctors by the asthma experts, that every patient with asthma should have inhaled albuterol as a rescue medication, by protocol. No increase was observed in other districts where no capacitating program was conducted. CONCLUSION: A systematic capacitating program was successful in changing asthma prescription profiles among non-specialist doctors, with increased delivery of inhaled albuterol and beclomethasone</style></abstract><notes><style face="normal" font="default">DA - 20161007IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1218012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27715349">PM:27715349</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20161007-MeloJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20161007-MeloJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161007, Melo J</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1218012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40360</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Radhakrishna,N.</style></author><author><style face="normal" font="default"> Tay,T.R.</style></author><author><style face="normal" font="default"> Hore-Lacy,F.</style></author><author><style face="normal" font="default"> Stirling,R.</style></author><author><style face="normal" font="default"> Hoy,R.</style></author><author><style face="normal" font="default"> Dabscheck,E.</style></author><author><style face="normal" font="default"> Hew,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Alfred Hospital; Allergy, Immunology &amp; Respiratory Medicine (AIRMED) , Melbourne , Victoria , Australia</style></auth-address><titles><title><style face="normal" font="default">Validated Questionnaires heighten detection of Difficult Asthma Comorbidities</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> Apnea</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma-comorbidity</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Difficult asthma</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Obstructive sleep apnea</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Sleep apnea</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> Victoria</style></keyword><keyword><style face="normal" font="default"> Vocal cord</style></keyword><keyword><style face="normal" font="default"> Vocal cord dysfunction</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="7" Month="10" Year="2016">2016/10/7</year></dates><abstract><style face="normal" font="default">Objective Multiple extra-pulmonary comorbidities contribute to difficult asthma, but their diagnosis can be challenging and time consuming. Previous data on comorbidity detection have focused on clinical assessment, which may miss certain conditions. We aimed to locate relevant validated screening questionnaires to identify extra-pulmonary comorbidities that contribute to difficult asthma, and evaluate their performance during a difficult asthma evaluation. Methods MEDLINE was searched to identify key extra-pulmonary comorbidities that contribute to difficult asthma. Screening questionnaires were chosen based on ease of use, presence of a cut off score, and adequate validation to help systematically identify comorbidities. In a consecutive series of 86 patients referred for systematic evaluation of difficult asthma, questionnaires were administered prior to clinical consultation. Results Six difficult asthma comorbidities and corresponding screening questionnaires were found: sinonasal disease (allergic rhinitis and chronic rhinosinusitis), vocal cord dysfunction, dysfunctional breathing, obstructive sleep apnea, anxiety and depression, and gastro-oesophageal reflux disease. When the questionnaires were added to the referring clinician's impression, the detection of all six comorbidities was significantly enhanced. The average time for questionnaire administration was approximately 40 minutes. Conclusions The use of validated screening questionnaires heightens detection of comorbidities in difficult asthma. The availability of data from a battery of questionnaires prior to consultation can save time and allow clinicians to systematically assess difficult asthma patients and to focus on areas of particular concern. Such an approach would ensure that all contributing comorbidities have been addressed before significant treatment escalation is considered</style></abstract><notes><style face="normal" font="default">DA - 20161007IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1212369</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27715354">PM:27715354</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20161007-RadhakrishnaN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20161007-RadhakrishnaN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161007, Radhakrishna N</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1212369</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40361</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Park,H.K.</style></author><author><style face="normal" font="default"> Cheng,K.C.</style></author><author><style face="normal" font="default"> Tetteh,A.O.</style></author><author><style face="normal" font="default"> Hildemann,L.M.</style></author><author><style face="normal" font="default"> Nadeau,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Division of Pulmonary and Critical Care, Department of Medicine, Stanford University School of Medicine , Stanford , CA , USA</style></auth-address><titles><title><style face="normal" font="default">Effectiveness of air purifier on health outcomes and indoor particles in homes of children with allergic diseases in Fresno, California: A pilot study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="default"> epidemiologic study</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> indoor</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Particulate matter</style></keyword><keyword><style face="normal" font="default"> peak flow</style></keyword><keyword><style face="normal" font="default"> Pilot study</style></keyword><keyword><style face="normal" font="default"> PM2.5</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> symptom scores</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="10" Month="10" Year="2016">2016/10/10</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Epidemiologic studies indicate that indoor air pollution is correlated with morbidity caused by allergic diseases. We evaluated the effectiveness of reducing the levels of indoor fine particulate matter &lt;2.5 micrometer diameter (PM2.5) in Fresno, California using air purifiers on health outcomes in children with asthma and/or allergic rhinitis. METHODS: The active group (with air purifiers) and the control group consisted of eight houses each. Air purifiers were installed in the living rooms and bedrooms of the subjects in the active group during the entire 12-week study duration. Childhood asthma control test, peak flow rate monitoring, and nasal symptom scores were evaluated at weeks 0, 6, and 12. RESULTS: At 12 weeks, the active group showed a trend toward an improvement of childhood asthma control test scores and mean evening peak flow rates, whereas the control group showed deterioration in the same measures. Total and daytime nasal symptoms scores significantly reduced in the active group (p = 0.001 and p = 0.011, respectively). The average indoor PM2.5 concentrations reduced by 43% (7.42 to 4.28 mug/m3) in the active group (p = 0.001). CONCLUSIONS: Intervention with air purifiers reduces indoor PM2.5 levels with significant improvements in nasal symptoms in children with allergic rhinitis in Fresno</style></abstract><notes><style face="normal" font="default">DA - 20161010IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -CO - South Korea -</style></notes><work-type><style face="normal" font="ArialUnicodeMS">10.1080/02770903.2016.1218011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27723364">PM:27723364</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20161010-ParkHK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20161010-ParkHK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161010, Park HK</style></custom2><misc3><style face="normal" font="ArialUnicodeMS">10.1080/02770903.2016.1218011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40362</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yorke,J.</style></author><author><style face="normal" font="default"> Adair,P.</style></author><author><style face="normal" font="default"> Doyle,A.M.</style></author><author><style face="normal" font="default"> Dubrow-Marshall,L.</style></author><author><style face="normal" font="default"> Fleming,S.</style></author><author><style face="normal" font="default"> Holmes,L.</style></author><author><style face="normal" font="default"> Menzies-Gow,A.</style></author><author><style face="normal" font="default"> Niven,R.</style></author><author><style face="normal" font="default"> Pilling,M.</style></author><author><style face="normal" font="default"> Shuldham,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">a School of Nursing, Midwifery and Social Work, University of Manchester , Manchester , UK</style></auth-address><titles><title><style face="normal" font="default">A randomised controlled feasibility trial of Group Cognitive Behavioural Therapy for people with severe asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anxiety</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Behavioural therapy</style></keyword><keyword><style face="normal" font="default"> Cognitive behavioural therapy</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Distance</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Feasibility Studies</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Nursing</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Social Work</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="23" Month="11" Year="2016">2016/11/23</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Evidence for the efficacy of Cognitive Behavioural Therapy (CBT) in asthma is developing but it is not known if this translates to benefits in severe asthma or if a group approach is acceptable to this patient group. This study aimed to assess the feasibility and acceptability of Group-CBT in severe asthma. METHOD: This was a two-centre, randomised controlled parallel group feasibility study. Eligible participants (patients with severe asthma and a clinically significant diagnosis of anxiety and/or depression - Hospital Anxiety and Depression Scale (HAD) score greater than 8 for the anxiety or depression sub-scale) received Group-CBT in weekly sessions for eight consecutive weeks and usual care or usual care only. Follow-up was for 16 weeks and end points were: Asthma Quality of Life Questionnaire, Asthma Control Questionnaire, HAD, Dyspnoea-12, EuroQual-5D and EuroQuol-VAS. RESULTS: 51 patients were randomised: 36% (51 out of 140) consent rate and attrition at week 16 was 12. Screening logs indicated that study take-up was influenced by patients living long distances from the treatment centre and inability to commit to the weekly demands of the programme. Drop-out was higher in Group-CBT compared due to inability to commit to the weekly programme because of poor health. Participants who contributed to focus group discussions reported that Group-CBT contributed to a better understanding of their illness and related approaches to anxiety management and acceptance of their asthma condition. Although weekly face-to-face sessions were challenging, this was the preferred method of delivery for these participants. CONCLUSIONS: This feasibility study shows that Group-CBT warrants further investigation as a potentially promising treatment option for patients with severe asthma. It has been possible but not easy to recruit and retain the sample. Options for a less demanding intervention schedule, such as less frequent face-to-face visits and the use of web-based interventions, require careful consideration</style></abstract><notes><style face="normal" font="default">DA - 20161123IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1229335</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27880064">PM:27880064</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20161123-YorkeJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20161123-YorkeJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161123, Yorke J</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1229335</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40363</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lourido-Cebreiro,T.</style></author><author><style face="normal" font="default"> Salgado,F.J.</style></author><author><style face="normal" font="default"> Valdes,L.</style></author><author><style face="normal" font="default"> Gonzalez-Barcala,F.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Respiratory Medicine - University Hospital of Santiago de Compostela , Spain</style></auth-address><titles><title><style face="normal" font="default">The association between paracetamol and asthma is still under debate</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="38" start="32">32-38</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> confounding factors</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Glutathione</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paracetamol</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> TH2 cytokines</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To analyse the relationship between paracetamol and asthma. DATA SOURCES: An English literature search using electronic search engines (PubMed and EMBASE) was conducted. STUDY SELECTIONS: Articles published in peer-review journals, from 1990 to December 2015 were included. To perform the search for the most suitable and representative articles, keywords were selected ("asthma," "paracetamol" and "acetaminophen"). The evidence level was rated according to the criteria of the Oxford Centre For Evidence-Based Medicine. RESULTS: The exposure to paracetamol during pregnancy was analysed in several cohort studies, showing an association between the prenatal exposure to paracetamol with suffering from asthma or presence of wheezing in childhood, especially for persistent wheezing. Nevertheless, a recent study concluded that the relationship between asthma and paracetamol is explained, at least in part, by confounding factors. Several works have also associated the exposure to paracetamol in the first years of life or in adults with the development of childhood asthma. Several pathophysiological mechanisms are known that could explain this relationship, such as the glutathione pathway, the decrease in the release of Th1 cytokines that are normally produced during febrile episodes, which would then lead to a predominance of Th2 cytokines, the cytotoxic effect of paracetamol for pneumocytes, a modulator effect on the activity of myeloperoxidase, as well as the possible antigenic effect of paracetamol, mediated by IgE. CONCLUSIONS: There are many arguments that suggest a relationship between the use of paracetamol with the appearance of asthmatic symptoms, however the evidence is inconclusive</style></abstract><notes><style face="normal" font="default">DA - 20160909IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1194431</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27575940">PM:27575940</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-32-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-32-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160909, Lourido-Cebreiro T</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1194431</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40364</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Walsted,E.S.</style></author><author><style face="normal" font="default"> Hull,J.H.</style></author><author><style face="normal" font="default"> Sverrild,A.</style></author><author><style face="normal" font="default"> Porsbjerg,C.</style></author><author><style face="normal" font="default"> Backer,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Respiratory Research Unit, Department of Respiratory Medicine , Bispebjerg University Hospital , Copenhagen , Denmark</style></auth-address><titles><title><style face="normal" font="default">Bronchial provocation testing does not detect exercise-induced laryngeal obstruction</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="83" start="77">77-83</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic test</style></keyword><keyword><style face="normal" font="default"> Differential diagnosis</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Gold</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Laryngoscopy</style></keyword><keyword><style face="normal" font="default"> Mannitol</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Exercise-induced laryngeal obstruction (EILO) is a key differential diagnosis for asthma in the presence of exertional respiratory symptoms. Continuous laryngoscopy during exercise (CLE), the current gold standard diagnostic test for EILO, has practical limitations. We aimed to establish if inspiratory flow data obtained during standard bronchoprovocation testing, to establish the presence of extra-thoracic hyper-responsiveness, may prove diagnostic for EILO and thus preclude requirement for CLE testing. METHODS: We consecutively evaluated 37 adult subjects with exertional dyspnea and possible asthma referred over 6 months. All subjects received comprehensive assessment including a detailed clinical evaluation; pulmonary function testing, indirect and direct bronchial provocation testing, and CLE testing. RESULTS: Out of 37 subjects, moderate or severe EILO was diagnosed in 8 subjects (22%, all female) while 5 (14%) had both asthma and EILO. There was no correlation between degree of EILO during CLE and mean decrease in forced inspiratory flow (%FIF50) obtained during neither the Methacholine (r = -0.15; p = 0.38) nor Mannitol (r = 0.04; p = 0.84) provocation tests. CONCLUSION: Inspiratory flow parameters obtained during bronchoprovocation tests did not reliably detect EILO. It remains that CLE is an important and key investigation modality in establishing a secure diagnosis of EILO</style></abstract><notes><style face="normal" font="default">DA - 20160926IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1195843</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27285291">PM:27285291</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-77-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-77-83.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160926, Walsted ES</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1195843</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40365</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Grzeskowiak,L.E.</style></author><author><style face="normal" font="default"> Smith,B.</style></author><author><style face="normal" font="default"> Roy,A.</style></author><author><style face="normal" font="default"> Schubert,K.O.</style></author><author><style face="normal" font="default"> Baune,B.T.</style></author><author><style face="normal" font="default"> Dekker,G.A.</style></author><author><style face="normal" font="default"> Clifton,V.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Robinson Research Institute, School of Medicine, University of Adelaide , Adelaide , Australia</style></auth-address><titles><title><style face="normal" font="default">Impact of a History of Maternal Depression and Anxiety on Asthma Control During Pregnancy</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anxiety</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="11" Month="1" Year="2017">2017/1/11</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To determine the impact of self-reported maternal depression/anxiety on asthma control during pregnancy. METHOD: Pregnant women with a doctor diagnosis of asthma (n = 189) were prospectively recruited at their antenatal booking visit and the presence of maternal depression and anxiety was identified using self-report and routine questionnaire assessments. Data on exacerbations and asthma control were collected during gestation. Asthma control was assessed using the Juniper asthma control questionnaire and women were classified as having recurrent uncontrolled asthma if their ACQ score was > 1.5 during two or more consecutive study visits. Exacerbations were defined as events that lead to increased treatment requirements, doctor or hospital visits. RESULTS: There were 85 women with self-reported depression/anxiety and 104 women without self-reported depression/anxiety. The presence of depression/anxiety was associated with an increased likelihood (adjusted HR 1.67: 95% CI 1.03-2.72), and incidence (adjusted IRR 1.71: 95% CI 1.13-2.58) of uncontrolled asthma during pregnancy, as well an increased risk of recurrent uncontrolled asthma during 2 or more study visits (adjusted RR 1.98: 95% CI 1.00-3.91). No impact of depression/anxiety was observed with respect to the likelihood (adjusted HR 0.70: 95% CI 0.35-1.41) or incidence of exacerbations during pregnancy (adjusted IRR 0.66: 95% CI 0.35-1.26). CONCLUSIONS: This study provides evidence that the presence of maternal depression/anxiety is associated with an increased likelihood and incidence of uncontrolled asthma during pregnancy. Given the high prevalence of comorbid depression/anxiety among asthmatics, further research investigating such associations is urgently required</style></abstract><notes><style face="normal" font="default">DA - 20170111IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1258080</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28075198">PM:28075198</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170111-GrzeskowiakLE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170111-GrzeskowiakLE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170111, Grzeskowiak LE</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1258080</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40366</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Carlson,S.M.</style></author><author><style face="normal" font="default"> Kim,J.</style></author><author><style face="normal" font="default"> Khan,D.A.</style></author><author><style face="normal" font="default"> King,K.</style></author><author><style face="normal" font="default"> Lucarelli,R.T.</style></author><author><style face="normal" font="default"> McColl,R.</style></author><author><style face="normal" font="default"> Peshock,R.</style></author><author><style face="normal" font="default"> Brown,E.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Psychiatry , The University of Texas Southwestern Medical Center , Dallas , TX , USA</style></auth-address><titles><title><style face="normal" font="default">Hippocampal volume in patients with asthma: Results from the Dallas Heart Study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="16" start="9">9-16</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Atrophy</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> gender difference</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Texas</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> treatment adherence</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Asthma is associated with an increased risk of mild cognitive impairment and dementia. Depression and oral corticosteroid use are associated with atrophy of the hippocampus and are common in asthma. However, minimal neuroimaging data are available in asthma patients. METHODS: We conducted a retrospective analysis of 1,287 adult participants from the Dallas Heart Study, an epidemiological sample of Dallas County residents. Study outcome variables were hippocampal volumes measured by FreeSurfer. ANOVA was used to examine a gender difference in hippocampal volumes. General Linear Models (GLM) were conducted to examine asthma diagnosis association with hippocampal volumes. RESULTS: The prevalence rate of asthma among our study sample was 10.8% with 9.6% in males and 11.7% in females. After controlling for demographic characteristics, participants with asthma had significantly smaller total, right, and left hippocampal volumes than those without asthma. The association of asthma with smaller hippocampal volume was significant among males but not among females. CONCLUSION: Hippocampal volume in a large and diverse sample of adults was significantly smaller in people with asthma as compared to those without asthma. These findings suggest that asthma may be associated with structural brain differences. Thus, medical illnesses without obvious direct neurodegenerative or even vascular involvement can be associated with brain changes. Because the hippocampus is a brain region involved in memory formation, these findings may have implications for treatment adherence that could have important implications for asthma treatment. Study limitations are the reliance on a self-reported asthma diagnosis and lack of additional asthma clinical information</style></abstract><notes><style face="normal" font="default">DA - 20160909IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1186174</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27187077">PM:27187077</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-9-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-9-16.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160909, Carlson SM</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1186174</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40367</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Good,J.</style></author><author><style face="normal" font="default"> Jagroop,D.</style></author><author><style face="normal" font="default"> Dogra,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Health Sciences, University of Ontario Institute of Technology , Oshawa , Ontario , Canada</style></auth-address><titles><title><style face="normal" font="default">Sociodemographic, health-related and lifestyle correlates of physical activity in adults with current asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="76" start="69">69-76</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Fruit</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Income</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Leisure Activities</style></keyword><keyword><style face="normal" font="default"> Lifestyle</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mood</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Ontario</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Regular physical activity is associated with better asthma control; however, little is known of the determinants of physical activity in a population of adults with asthma. Thus, the purpose of this study was to identify important sociodemographic, health and lifestyle correlates of physical activity among adults with asthma. METHODS: Data from adults with asthma aged 18-44 years (n = 2740) from the Canadian Community Health Survey (CCHS), 2011-2012 annual component were used for analysis. The main outcome was Daily Energy Expenditure (DEE). This variable was based on frequency and duration of leisure activities in the past 3 months. Self-reported sociodemographic (age, sex, total household income, highest education level, and ethnicity), health-related (body mass index (BMI), self-perceived health, mood disorder, anxiety disorder, and asthma symptoms/attacks, past year) and lifestyle (type of smoker, sedentary time, fruit and vegetable consumption) variables were assessed as correlates for DEE. Data were analysed using linear regressions. RESULTS: In the final model, sociodemographic correlates accounted for 4.2% of the variation in DEE. Adding health correlates increased the R2 to 12.1%. Finally, adding lifestyle correlates increased the R2 to 17.6%. CONCLUSIONS: In adults with current asthma, the main correlates of physical activity are age, total household income, BMI, self-perceived health, anxiety disorder, sedentary time, and fruit and vegetable consumption. These data are important for informing education and exercise interventions for adults with asthma. Future research is needed to determine asthma-specific correlates of physical activity</style></abstract><notes><style face="normal" font="default">DA - 20160909IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1194432</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27285062">PM:27285062</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-69-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-69-76.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160909, Good J</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1194432</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40368</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dilokthornsakul,P.</style></author><author><style face="normal" font="default"> Chaiyakunapruk,N.</style></author><author><style face="normal" font="default"> Campbell,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Center of Pharmaceutical Outcomes Research, Department of Pharmacy Practice , Faculty of Pharmaceutical Sciences, Naresuan University , Phitsanulok , Thailand</style></auth-address><titles><title><style face="normal" font="default">Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter?</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="23" start="17">17-23</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cost-effectiveness</style></keyword><keyword><style face="normal" font="default"> Cost-effectiveness analysis</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Policy</style></keyword><keyword><style face="normal" font="default"> Health Services</style></keyword><keyword><style face="normal" font="default"> Interpretation</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Malaysia</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> World Health</style></keyword><keyword><style face="normal" font="default"> World Health Organization</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To test the association of clinical evidence type, efficacy-based or effectiveness-based ("E"), versus whether or not asthma interventions' cost-effectiveness findings are favorable. DATA SOURCES: We conducted a systematic review of PubMed, EMBASE, Tufts CEA registry, Cochrane CENTRAL, and the UK National Health Services Economic Evaluation Database from 2009 to 2014. STUDY SELECTION: All cost-effectiveness studies evaluating asthma medication(s) were included. Clinical evidence type, "E," was classified as efficacy-based if the evidence was from an explanatory randomized controlled trial(s) or meta-analysis, while evidence from pragmatic trial(s) or observational study(s) was classified as effectiveness-based. We defined three times the World Health Organization cost-effectiveness willingness-to-pay (WTP) threshold or less as a favorable cost-effectiveness finding. Logistic regression tested the likelihood of favorable versus unfavorable cost-effectiveness findings against the type of "E." RESULTS AND CONCLUSIONS: 25 cost-effectiveness studies were included. Ten (40.0%) studies were effectiveness-based, yet 15 (60.0%) studies were efficacy-based. Of 17 studies using endpoints that could be compared to WTP threshold, 7 out of 8 (87.5%) effectiveness-based studies yielded favorable cost-effectiveness results, whereas 4 out of 9 (44.4%) efficacy-based studies yielded favorable cost-effectiveness results. The adjusted odds ratio was 15.12 (95% confidence interval; 0.59 to 388.75) for effectiveness-based versus efficacy-based achieving favorable cost-effectiveness findings. More asthma cost-effectiveness studies used efficacy-based evidence. Studies using effectiveness-based evidence trended toward being more likely to disseminate favorable cost-effective findings than those using efficacy. Health policy decision makers should pay attention to the type of clinical evidence used in cost-effectiveness studies for accurate interpretation and application</style></abstract><notes><style face="normal" font="default">DA - 20160909IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Thailand -CO - United States -CO - Malaysia -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1193601</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27284904">PM:27284904</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-17-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-17-23.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160909, Dilokthornsakul P</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1193601</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40369</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dmitrieva-Zdorova,E.V.</style></author><author><style face="normal" font="default"> Gabaeva,M.V.</style></author><author><style face="normal" font="default"> Seregin,Y.A.</style></author><author><style face="normal" font="default"> Bodoev,N.V.</style></author><author><style face="normal" font="default"> Voronko,O.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Biomedical Chemistry (IBMC) , Moscow , Russia</style></auth-address><titles><title><style face="normal" font="default">PDCD1 PD-1.3 polymorphism and allergic bronchial asthma in Russian and Buryat patients</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="52" start="46">46-52</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lupus</style></keyword><keyword><style face="normal" font="default"> Lupus erythematosus</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Moscow</style></keyword><keyword><style face="normal" font="default"> Multiple Sclerosis</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Russia</style></keyword><keyword><style face="normal" font="default"> Sclerosis</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The programmed death-1 receptor, PD-1, is a negative regulator of T-cell activation. The PD-1.3 polymorphism of the PD-1 gene (PDCD1) has been previously shown to be associated with several autoimmune and inflammatory disorders including systemic lupus erythematosus and multiple sclerosis. We examined for the first time PD-1.3 association with another inflammatory disease with strong immune component, IgE-mediated bronchial asthma, its severity and its biochemical markers (total serum IgE and IL-4). METHODS: PD-1.3 G/A was genotyped by PCR-RFLP analysis using two different populations: Caucasian (492 Russian individuals) and Asian (276 Buryat individuals). RESULTS: We found a significant association of the PD-1.3 polymorphism with IgE-mediated bronchial asthma and total serum IgE level in the Russian population. Combined genotype AA+AG was correlated with risk of developing allergic bronchial asthma (OR = 1.78, 95% CI 1.13-2.78, p = 0.011) and lower concentrations of total serum IgE (p = 0.001) compared with the wild-type genotype GG. However, PD-1.3 was not polymorphic in the Buryat population. CONCLUSIONS: PD-1.3 polymorphism of the PD-1 gene (PDCD1) may contribute to the development of allergic asthma in the Russians but not in the Buryats. Our results could be helpful for a better understanding of the effect of this polymorphism on the development of diseases with strong immune components</style></abstract><notes><style face="normal" font="default">DA - 20160914IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Russia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1196366</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27286421">PM:27286421</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-46-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-46-52.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160914, Dmitrieva-Zdorova EV</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1196366</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40370</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Al Aloola,N.A.</style></author><author><style face="normal" font="default"> Nissen,L.</style></author><author><style face="normal" font="default"> Alewairdhi,H.A.</style></author><author><style face="normal" font="default"> Al Faryan,N.</style></author><author><style face="normal" font="default"> Saini,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Faculty of Pharmacy, University of Sydney, King Saud University, College of Pharmacy , Department of Clinical Pharmacy</style></auth-address><titles><title><style face="normal" font="default">Parents' Asthma Information Needs and Preferences for School-based Asthma Support</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Communication</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> First Aid</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Interviews</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Saudi Arabia</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="default">Objectives This study sought to investigate parents' needs and preferences for school-based asthma support in Saudi Arabian primary schools. Methods Semi-structured qualitative interviews were conducted in the period between November 2015 and February 2016, with a convenience sample that comprised Saudi parents and carers of children with asthma. Recruitment of participants was primarily driven through Saudi primary schools; passive snowballing and social networks were used to boost participation rates further. Interviews were audio-recorded, transcribed verbatim, translated and data were thematically organised using a latent content analysis approach. Results Twenty interviews were conducted. Six themes emerged from the interviews and were grouped into three major categories: (1) general asthma management issues; (2) school-based asthma management issues; and (3) communication dissatisfaction. Participants expressed concern at schools' social and physical environments and a lack of confidence in the ability of schools to manage their child's asthma, especially when their child was ill. Most of the participants advocated for staff training and school community engagement to improve the management of asthma in Saudi primary schools. Conclusion This research clearly describes a need for school-based asthma support, including asthma-related policies, procedures and education on asthma and first aid in Saudi primary schools</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - Saudi Arabia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1281296</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28095117">PM:28095117</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170117-AlAloolaNA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170117-AlAloolaNA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Al Aloola NA</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1281296</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40371</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Delate,T.</style></author><author><style face="normal" font="default"> Rader,N.</style></author><author><style face="normal" font="default"> Jenkins,D.W.</style></author><author><style face="normal" font="default"> Lowe,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pharmacy Department , Kaiser Permanente Colorado , Aurora , CO , USA</style></auth-address><titles><title><style face="normal" font="default">Multidisciplinary intervention to improve albuterol inhaler utilization among patients with asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="110" start="105">105-110</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">acute asthma</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Albuterol</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacist</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> REACH</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The goal of this study was to examine the impact of a multidisciplinary intervention designed to improve appropriate albuterol inhaler utilization among patients with asthma. METHODS: This was a pre-post retrospective analysis. The study intervention included written information sent directly to patients, educated prescribers, and enhanced pharmacist training on appropriate albuterol inhaler utilization. Eligible study patients had a diagnosis of asthma and purchased at least two albuterol inhalers between 07/12/2012 and 06/30/2013 (pre-period) and 7/01/2013 to 06/30/2014 (post-period). The primary outcome was a comparison between study periods of the count of albuterol inhalers purchased per patient per month (PPPM). RESULTS: The median age of included patients was 41 years, 53% were females, and allergic rhinitis was the most common comorbidity. The median albuterol inhalers purchased PPPM decreased from 0.60 (interquartile range [IQR] = 0.39-0.87) to 0.37 (IQR = 0.26-0.53) from the pre- to post-period (p &lt; 0.001). The proportion of patients with at least one systemic corticosteroid purchase decreased (36% vs. 31%) and >1 albuterol inhaler purchased on the same day increased (3.1% vs. 5.7%) from the pre- to post-period (p &lt; 0.001). Numerically, the proportion of participants who experienced an acute asthma exacerbation decreased and asthma controller inhalers purchased PPPM increased but these did not reach statistical significance (both p > 0.05). CONCLUSIONS: A multidisciplinary approach to increasing appropriate albuterol inhaler use was associated with a decrease in albuterol inhalers purchased PPPM while not increasing acute asthma exacerbations. Future study is needed to evaluate patient perspectives on this intervention and assess its economic impact</style></abstract><notes><style face="normal" font="default">DA - 20160707IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.3109/02770903.2015.1127934</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27383130">PM:27383130</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-105-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-105-10.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160707, Delate T</style></custom2><misc3><style face="normal" font="default">10.3109/02770903.2015.1127934</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40372</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Baltrus,P.</style></author><author><style face="normal" font="default"> Xu,J.</style></author><author><style face="normal" font="default"> Immergluck,L.</style></author><author><style face="normal" font="default"> Gaglioti,A.</style></author><author><style face="normal" font="default"> Adesokan,A.</style></author><author><style face="normal" font="default"> Rust,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Center for Primary Care, Morehouse School of Medicine , Atlanta , GA , USA</style></auth-address><titles><title><style face="normal" font="default">Individual and county level predictors of asthma related emergency department visits among children on Medicaid: A multilevel approach</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="61" start="53">53-61</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air quality</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Controller medications</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Medicaid</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient Care</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> race</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective cohort study</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Disparities in asthma outcomes are well documented in the United States. Interventions to promote equity in asthma outcomes could target factors at the individual and community levels. The objective of this analysis was to understand the effect of individual (race, gender, age, and preventive inhaler use) and county-level factors (demographic, socioeconomic, health care, air-quality) on asthma emergency department (ED) visits among Medicaid-enrolled children. This was a retrospective cohort study of Medicaid-enrolled children with asthma in 29 states in 2009. Multilevel regression models of asthma ED visits were constructed utilizing individual-level variables (race, gender, age, and preventive inhaler use) from the Medicaid enrollment file and county-level variables reflecting population and health system characteristics from the Area Resource File (ARF). County-level measures of air quality were obtained from Environmental Protection Agency (EPA) data. RESULTS: The primary modifiable risk factor at the individual level was found to be the ratio of long-term controller medications to total asthma medications. County-level factors accounted for roughly 6% of the variance in the asthma ED visit risk. Increasing county-level racial segregation (OR=1.04, 95% CI=1.01-1.08) was associated with increasing risk of asthma ED visits. Greater supply of pulmonary physicians at the county level (OR=0.81, 95% CI=0.68-0.97) was associated with a reduction in risk of asthma ED visits. CONCLUSIONS: At the patient care level, proper use of controller medications is the factor most amenable to intervention. There is also a societal imperative to address negative social determinants, such as residential segregation</style></abstract><notes><style face="normal" font="default">DA - 20160926IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1196367</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27285734">PM:27285734</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-53-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-53-61.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160926, Baltrus P</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1196367</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40373</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Press,V.G.</style></author><author><style face="normal" font="default"> Hasegawa,K.</style></author><author><style face="normal" font="default"> Heidt,J.</style></author><author><style face="normal" font="default"> Bittner,J.C.</style></author><author><style face="normal" font="default"> Camargo,C.A.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Medicine , the University of Chicago Medicine , Chicago , IL</style></auth-address><titles><title><style face="normal" font="default">Missed opportunities to transition from nebulizers to inhalers during hospitalization for acute asthma: a multi-center observational study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">acute asthma</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Inpatients</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> MDI</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient Education</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Self-management</style></keyword><keyword><style face="normal" font="default"> Teaching</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Hospitalizations for acute asthma are thought to be highly preventable through the use of efficacious medications, though many patients have poor metered-dose inhaler (MDI) technique, lessening these medications' real-world effectiveness. Teaching MDI technique during hospitalization may therefore lead to improved outcomes. However, MDIs may be underutilized to deliver short-acting beta-agonists in the inpatient setting, despite equivalent efficacy to nebulizer delivery. We sought to characterize delivery methods of short-acting beta-agonist (SABA) therapy among hospitalized patients with acute asthma to understand if there are missed opportunities for self-management education. METHODS: In this secondary analysis of a cross-sectional 25-center chart review study of children and adults (ages 2-54 years) hospitalized for acute asthma across 18 states (2012-2013), we studied SABA therapy delivery methods during hospitalization and receipt of action plans and follow-up visits. Unadjusted associations were analyzed using chi-square, Fisher's exact, or Kruskal-Wallis tests. MEASUREMENTS AND MAIN RESULTS: Of 987 patients, 44% received only nebulizer-SABA (children 32% vs. adults 53%; p&lt;0.001) during hospitalization, and 55% (children 68% vs. adults 47%; p&lt;0.001) received any MDI-SABA during hospitalization. Children receiving only nebulizer- vs. MDI-SABA were significantly less-likely to receive individualized action plans (p&lt;0.001). Compared to children, adults were overall less-likely to receive written plans (47% vs. 78%, p&lt;0.001) or to have a follow-up appointment (38% vs. 59%, p&lt;0.001) at discharge. CONCLUSIONS: Opportunities exist to increase the delivery of MDI-SABA during hospitalization, particularly for adult inpatients with asthma. Future studies are needed to determine if increased use of MDI-delivered therapies improves patient education and outcomes</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1281295</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28095080">PM:28095080</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170117-PressVG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170117-PressVG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Press VG</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1281295</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40374</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liddell,B.S.</style></author><author><style face="normal" font="default"> Oberlin,J.M.</style></author><author><style face="normal" font="default"> Hsu,D.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics , San Antonio Military Medical Center , Fort Sam Houston , TX , USA</style></auth-address><titles><title><style face="normal" font="default">Inhaled corticosteroid related adrenal suppression detected by poor growth and reversed with ciclesonide</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="104" start="99">99-104</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Recovery</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> suppression</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="default">INTRODUCTION: This case series intends to highlight the association between decreased linear growth velocity and adrenal suppression in patients receiving inhaled corticosteroids for asthma. A potential treatment option is also discussed. Adrenal suppression secondary to inhaled corticosteroids has previously been reported and is often underrecognized. A decrease in linear height velocity has also been associated with inhaled corticosteroids. However, a decrease in height velocity has not been shown to predict adrenal suppression. CASE STUDY: This case series of 15 patients receiving inhaled corticosteroids for control of asthma were noted to have a decrease in linear growth velocity ultimately associated with adrenal suppression. A change in inhaled corticosteroid to ciclesonide led to recovery of adrenal function without impacting asthma control. RESULTS: Chart review from a pediatric pulmonology clinic was performed. Growth parameters and laboratory studies were recorded and analyzed. A mean decrease in height standard deviation score in the year prior to diagnosis of adrenal suppression was -0.59, -0.11, and -0.18, in pre-puberty, peri-puberty, and post-puberty patients, respectively. After ciclesonide therapy was initiated, a mean change in height standard deviation score of +0.40, +0.13, and -0.13, was noted for pre-puberty, peri-puberty, and post-puberty patients, respectively. A change in growth velocity of +5.3 cm/yr, +2.1 cm/yr, and -1.9 cm/yr, was noted for pre-puberty, peri-puberty, and post-puberty patients, respectively, after starting ciclesonide. CONCLUSIONS: Height velocity should be monitored closely during routine asthma visits to identify potential adrenal suppression associated with inhaled corticosteroids use. Ciclesonide is a good option for asthma treatment that allows for adrenal recovery</style></abstract><notes><style face="normal" font="default">DA - 20160610IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1196370</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27284755">PM:27284755</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-99-104.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-99-104.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160610, Liddell BS</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1196370</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40375</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sullivan,P.W.</style></author><author><style face="normal" font="default"> Ghushchyan,V.H.</style></author><author><style face="normal" font="default"> Campbell,J.D.</style></author><author><style face="normal" font="default"> Globe,G.</style></author><author><style face="normal" font="default"> Bender,B.</style></author><author><style face="normal" font="default"> Magid,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a School of Pharmacy, Regis University , Denver , CO , USA</style></auth-address><titles><title><style face="normal" font="default">Measuring the cost of poor asthma control and exacerbations</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="31" start="24">24-31</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Previous studies have shown an association between cost and poor asthma control. However, longitudinal studies of general populations are lacking. OBJECTIVE: To examine the cost of poor asthma control and exacerbations across a broad spectrum of asthma patients. METHODS: The Observational Study of Asthma Control and Outcomes (OSACO) was a prospective survey of persistent asthma patients in Kaiser Colorado in 2011-2012. Patients received a survey 3 times in one year, which included the Asthma Control Questionnaire (ACQ) and questions on exacerbations. Self-reported exacerbations were compared to actual oral corticosteroid (OCS) use. Regression analyses examined the association of control (ACQ-5 scores) and exacerbations with healthcare expenditures, controlling for sociodemographics and smoking. Analyses of expenditures used Generalized Linear Models (GLM) with log-link. RESULTS: 2681 individuals completed at least one survey; 1799 completed all three. ACQ-5 scores were associated with higher all-cause and asthma-specific expenditures across all categories of costs (medical, outpatient, ER, pharmacy) except for inpatient expenditures. Each 1-point increase in the ACQ-5 score (i.e., worse control) was associated with a corresponding increase in all-cause annual healthcare and asthma-specific expenditures of $1443 and $927 ($US 2013). Asthma exacerbations with documented OCS use were associated with an increase of $3014 and $1626 over 4 months, while self-reported exacerbations were $713 and $506. CONCLUSION: Results demonstrate that poor asthma control and exacerbations are strongly associated with higher healthcare expenditures. Results also confirm that collection of validated measures of control such as the ACQ-5 may provide valuable information toward improving clinical and economic outcomes</style></abstract><notes><style face="normal" font="default">DA - 20160909IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1194430</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27286240">PM:27286240</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-24-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-24-31.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160909, Sullivan PW</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1194430</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40376</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rodriguez,E.M.</style></author><author><style face="normal" font="default"> Kumar,H.</style></author><author><style face="normal" font="default"> Alba-Suarez,J.</style></author><author><style face="normal" font="default"> Sanchez-Johnsen,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Educational Psychology , University of Texas at Austin , Austin , Texas</style></auth-address><titles><title><style face="normal" font="default">Parental Coping, Depressive Symptoms, and Children's Asthma Control and School Attendance in Low-Income, Racially and Ethnically Diverse Urban Families</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Color</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Latino</style></keyword><keyword><style face="normal" font="default"> low income</style></keyword><keyword><style face="normal" font="default"> mental health</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> psychology</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Texas</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Low-income urban children of color are at elevated risk for poor asthma control. This cross-sectional study examined associations among parents' coping (primary control, secondary control, and disengagement), parental depressive symptoms, and children's asthma outcomes (asthma control and school attendance) in a predominantly low-income, racially/ethnically diverse sample of families. METHODS: Parents (N = 78; 90% female) of children (33% female; 46% Black; 38% Latino) ages 5 to 17 years old (M = 9.5 years) reported on their own coping and depressive symptoms, their child's asthma control, and full and partial days of school missed due to asthma. RESULTS: Parents' secondary control coping (i.e., coping efforts to accommodate/adapt to asthma-related stressors) was negatively correlated, and disengagement coping (i.e. coping efforts to avoid/detach from stressors) was positively correlated, with their depressive symptoms. Secondary control coping was also correlated with fewer partial days of school missed. Primary control coping (i.e., coping efforts to change stressors) was not associated with depressive symptoms or asthma outcomes. Parents' depressive symptoms were also positively correlated with poorer asthma control and partial days of school missed. Regression models showed direct and indirect effects of secondary control and disengagement coping on asthma outcomes via depressive symptoms, after controlling for demographic factors. CONCLUSIONS: Parents' secondary control and disengagement coping are related to children's asthma outcomes. Secondary control coping may support parents' mental health and children's asthma control in low-income urban families</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1274402</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28095072">PM:28095072</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170117-RodriguezEM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170117-RodriguezEM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Rodriguez EM</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1274402</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40377</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">O'Conor,R.</style></author><author><style face="normal" font="default"> Martynenko,M.</style></author><author><style face="normal" font="default"> Gagnon,M.</style></author><author><style face="normal" font="default"> Hauser,D.</style></author><author><style face="normal" font="default"> Young,E.</style></author><author><style face="normal" font="default"> Lurio,J.</style></author><author><style face="normal" font="default"> Wisnivesky,J.P.</style></author><author><style face="normal" font="default"> Wolf,M.S.</style></author><author><style face="normal" font="default"> Federman,A.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Division of General Internal Medicine , Northwestern University , Chicago , IL , USA</style></auth-address><titles><title><style face="normal" font="default">A qualitative investigation of the impact of asthma and self-management strategies among older adults</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="45" start="39">39-45</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Barriers</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic illness</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Controller medications</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> elderly</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fatigue</style></keyword><keyword><style face="normal" font="default"> Feedback</style></keyword><keyword><style face="normal" font="default"> Focus Groups</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Older adults</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Self Care</style></keyword><keyword><style face="normal" font="default"> Self-management</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> Uncertainty</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="default">OBJECTIVE: We sought feedback from elderly patients living with asthma to understand their experience with assuming self-management roles for their asthma in order to inform the design and implementation of a primary care-based strategy that could best support their asthma control. METHODS: We held six focus groups with a total of 31 English- and Spanish-speaking older adults with a current diagnosis of asthma. Focus groups addressed the effect of asthma on patients' lives and self-management strategies. Transcripts were analyzed using constant comparative techniques. RESULTS: Asthma exerted a consistent effect on patients' physical and psychological well-being. Common barriers to self-care included misuse of controller medications and uncertainty whether shortness of breath, fatigue, and cough were due to their asthma or some other chronic illness. Patients developed coping strategies to continue with daily activities even when experiencing symptoms, but did not recognize attainable asthma quality of life. CONCLUSIONS: Asthma had a distinct impact on elderly adults' quality of life; due to their longstanding history with this condition, many patients had accepted these symptoms as a "new normal." Developing strategies to reorient patients' perceptions of the possibilities for managing their illness will be critical to the success of asthma self-management support programs specific to older adults</style></abstract><notes><style face="normal" font="default">DA - 20160909IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1193602</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27315570">PM:27315570</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-39-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-39-45.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160909, O'Conor R</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1193602</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40378</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Krupp,N.L.</style></author><author><style face="normal" font="default"> Fiscus,C.</style></author><author><style face="normal" font="default"> Webb,R.</style></author><author><style face="normal" font="default"> Webber,E.C.</style></author><author><style face="normal" font="default"> Stanley,T.</style></author><author><style face="normal" font="default"> Pettit,R.</style></author><author><style face="normal" font="default"> Davis,A.</style></author><author><style face="normal" font="default"> Hollingsworth,J.</style></author><author><style face="normal" font="default"> Bagley,D.</style></author><author><style face="normal" font="default"> McCaskey,M.</style></author><author><style face="normal" font="default"> Stevens,J.C.</style></author><author><style face="normal" font="default"> Weist,A.</style></author><author><style face="normal" font="default"> Cristea,A.I.</style></author><author><style face="normal" font="default"> Warhurst,H.</style></author><author><style face="normal" font="default"> Bauer,B.</style></author><author><style face="normal" font="default"> Saysana,M.</style></author><author><style face="normal" font="default"> Montgomery,G.S.</style></author><author><style face="normal" font="default"> Howenstine,M.S.</style></author><author><style face="normal" font="default"> Davis,S.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Indiana University School of Medicine</style></auth-address><titles><title><style face="normal" font="default">Multi-faceted Quality Improvement Initiative to Decrease Pediatric Asthma Readmissions</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma education</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Running</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="24" Month="1" Year="2017">2017/1/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is the most common chronic disease of childhood, and a leading cause of hospitalization in children. A primary goal of asthma control is prevention of hospitalizations. A hospital admission is the single strongest predictor of future hospital admissions for asthma. The 30-day asthma readmission rate at our institution was significantly above that of other hospitals in the Children's Hospital Association. As a result, a multi-faceted quality improvement project was undertaken with the goal of reducing the 30-day inpatient asthma readmission rate by 50% within two years. METHODS: Analysis of our institution's readmission patterns, value stream mapping of asthma admission, discharge, and followup processes, literature review, and examination of comparable successful programs around the United States were all utilized to identify potential targets for intervention. Interventions were implemented in a step-wise manner, and included increasing inhaler availability after discharge, modifying asthma education strategies, and providing in home post-discharge followup. The primary outcome was a running 12-month average 30-day inpatient readmission rate. Secondary outcomes included process measures for individual interventions. RESULTS: From a peak of 7.98% in January 2013, a steady decline to 1.65% was observed by July 2014, which represented a 79.3% reduction in 30-day readmissions. CONCLUSION: A significant decrease in hospital readmissions for pediatric asthma is possible, through comprehensive, multidisciplinary quality improvement that spans the continuum of care</style></abstract><notes><style face="normal" font="default">DA - 20170124IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1281294</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28118056">PM:28118056</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170124-KruppNL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170124-KruppNL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170124, Krupp NL</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1281294</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40379</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brown,W.</style></author><author><style face="normal" font="default"> Scott,D.</style></author><author><style face="normal" font="default"> Friesner,D.</style></author><author><style face="normal" font="default"> Schmitz,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">a North Dakota State University</style></auth-address><titles><title><style face="normal" font="default">Impact of Telepharmacy Services as a Way to Increase Access to Asthma Care</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> asthma education</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Community pharmacy</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacist</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Rural</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To demonstrate that real-time, telepharmacy-based asthma educational services are feasible and support the efforts of local primary care prescribers to improve patient outcomes. METHODS: The lead investigator [a pharmacist, physician assistant and certified asthma educator] identified an independent community pharmacy with telehealth capabilities in a rural area with a high prevalence of asthma. Working with the pharmacy, an asthma education program was developed based on the National Asthma Education and Prevention Program guidelines. It consisted of three monthly education visits, with subsequent visits every three months for one year. The Asthma Control Test (ACT) was administered at baseline and at each visit to assess a patient's perception of asthma control. RESULTS: Eighteen of 20 patients (90%) with reversible airway disease completed all six visits in this year-long study. For the 18 patients, the mean ACT scores of 18 at baseline (initiation of intervention), did not meet the threshold for "well controlled" asthma. By the third educational visit (3 months), 16 patients met ACT criteria for well controlled asthma (mean score = 20), and they maintained control for the remaining 9 month follow-up period (ACT>/=21). Local prescribers authorized medication changes recommended by the asthma educator 20 times and also requested six direct consults with the asthma educator over the study period. CONCLUSION: Using the local community pharmacy as a vehicle to deliver asthma education services by telepharmacy was utilized by local prescribers. The findings show this is an effective means to engage patients to gain and maintain asthma control</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1281292</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28095068">PM:28095068</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170117-BrownW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170117-BrownW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Brown W</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1281292</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40380</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gerhardsson de Verdier,M.</style></author><author><style face="normal" font="default"> Gustafson,P.</style></author><author><style face="normal" font="default"> McCrae,C.</style></author><author><style face="normal" font="default"> Edsbacker,S.</style></author><author><style face="normal" font="default"> Johnston,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Medical Evidence and Observational Research Center, AstraZeneca R&amp;D Gothenburg , Sweden</style></auth-address><titles><title><style face="normal" font="default">Seasonal and geographic variation in the incidence of asthma exacerbations in the United States</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> elderly</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Hospital care</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="1" Year="2017">2017/1/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: Exacerbations drive the burden of asthma and lead to significant morbidity and consumption of healthcare resources. Many prior studies of the epidemiology of asthma exacerbations have relied upon data from hospital care. OBJECTIVE: To determine US patterns of geographic and seasonal variation of asthma exacerbations being defined as asthma episodes requiring hospital care and/or a prescription for oral steroid. METHODS: The study was a retrospective observational cohort study using administrative claims data for insured individuals from the HealthCore Integrated Research Database, including around 43 million members in US. Analyses examined 3 age groups, 6-17, 18-64, > = 65 years and four US regions, Northeast, Southeast, Central and Western. RESULTS: Monthly rates of asthma exacerbations showed the greatest variation over the year in children, less so in adults and in the elderly. Clinically important differences in rates of asthma exacerbation were observed between regions with the Western Region having the lowest in all three age groups followed by the Northeast, Central and Southeast regions. Peaks in children occurred in the early fall following troughs in the summer months, and peaks at year-end occurred in adults, particularly those over 65 years. CONCLUSIONS: There is striking seasonal variation in asthma exacerbations in the United States. Substantial differences between regions of the US in asthma exacerbation rates cannot readily be explained and invite further investigation</style></abstract><notes><style face="normal" font="default">DA - 20170119IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1277538</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28102717">PM:28102717</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170119-GerhardssondeVerdierM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170119-GerhardssondeVerdierM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170119, Gerhardsson de Verdier M</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1277538</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40381</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Faruque,M.U.</style></author><author><style face="normal" font="default"> Chen,G.</style></author><author><style face="normal" font="default"> Doumatey,A.P.</style></author><author><style face="normal" font="default"> Zhou,J.</style></author><author><style face="normal" font="default"> Huang,H.</style></author><author><style face="normal" font="default"> Shriner,D.</style></author><author><style face="normal" font="default"> Adeyemo,A.A.</style></author><author><style face="normal" font="default"> Rotimi,C.N.</style></author><author><style face="normal" font="default"> Dunston,G.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Human Genome Center, Howard University College of Medicine , Washington, DC , USA</style></auth-address><titles><title><style face="normal" font="default">Transferability of genome-wide associated loci for asthma in African Americans</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="8" start="1">1-8</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> African American</style></keyword><keyword><style face="normal" font="default"> African Americans</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> DC</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genome</style></keyword><keyword><style face="normal" font="default"> Genome-wide</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> GWAS</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Washington</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Transferability of significantly associated loci or GWAS "hits" adds credibility to genotype-disease associations and provides evidence for generalizability across different ancestral populations. We sought evidence of association of known asthma-associated single nucleotide polymorphisms (SNPs) in an African American population. METHODS: Subjects comprised 661 participants (261 asthma cases and 400 controls) from the Howard University Family Study. Forty-eight SNPs previously reported to be associated with asthma by GWAS were selected for testing. We adopted a combined strategy by first adopting an "exact" approach where we looked-up only the reported index SNP. For those index SNPs missing form our dataset, we used a "local" approach that examined all the regional SNPs in LD with the index SNP. RESULTS: Out of the 48 SNPs, our cohort had genotype data available for 27, which were examined for exact replication. Of these, two SNPs were found positively associated with asthma. These included: rs10508372 (OR = 1.567 [95%CI, 1.133-2.167], P = 0.0066) and rs2378383 (OR = 2.147 [95%CI, 1.149-4.013], P = 0.0166), located on chromosomal bands 10p14 and 9q21.31, respectively. Local replication of the remaining 21 loci showed association at two chromosomal loci (9p24.1-rs2381413 and 6p21.32-rs3132947; Bonferroni-corrected P values: 0.0033 and 0.0197, respectively). Of note, multiple SNPs in LD with rs2381413 located upstream of IL33 were significantly associated with asthma. CONCLUSIONS: This study has successfully transferred four reported asthma-associated loci in an independent African American population. Identification of several asthma-associated SNPs in the upstream of the IL33, a gene previously implicated in allergic inflammation of asthmatic airway, supports the generalizability of this finding</style></abstract><notes><style face="normal" font="default">DA - 20160909IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1188941</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27177148">PM:27177148</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-1-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-1-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160909, Faruque MU</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1188941</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40382</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kerwin,E.M.</style></author><author><style face="normal" font="default"> Gillespie,M.</style></author><author><style face="normal" font="default"> Song,S.</style></author><author><style face="normal" font="default"> Steinfeld,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Clinical Research Institute of Southern Oregon, PC, and Allergy &amp; Asthma Center of Southern Oregon, PC , Medford , OR , USA</style></auth-address><titles><title><style face="normal" font="default">Randomized, dose-ranging study of a fluticasone propionate multidose dry powder inhaler in adolescents and adults with uncontrolled asthma not previously treated with inhaled corticosteroids</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="98" start="89">89-98</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> fluticasone propionate</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Oregon</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> pharmacokinetics</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="default">OBJECTIVE: A novel, inhalation-driven, multidose dry powder inhaler (MDPI) eliminates the need to coordinate actuation with inhalation. To characterize dose response, efficacy, and safety of fluticasone propionate (Fp) MDPI, a dose-ranging study was conducted with placebo and active comparators. METHODS: This 12-week, double-blind, parallel-group study randomized patients aged >/=12 years with uncontrolled persistent asthma not previously treated with inhaled corticosteroid therapy (N = 622) to twice-daily treatment with Fp MDPI (12.5, 25, 50, or 100 microg), placebo MDPI, or open-label Fp dry powder inhaler (DPI) 100 microg. The primary efficacy endpoint was change from baseline over 12 weeks in trough (morning pre-dose and pre-rescue bronchodilator) forced expiratory volume in 1 second (FEV1). Blood samples were collected from a patient subset to evaluate pharmacokinetics. Adverse events were monitored. RESULTS: Fp MDPI 25, 50, and 100 microg significantly improved change from baseline in trough FEV1 over 12 weeks compared with placebo (p &lt; 0.01). There were no substantial differences in FEV1 change from baseline over 12 weeks between any Fp MDPI dose and Fp DPI 100 microg. Maximum observed concentration (Cmax) of Fp increased with increasing Fp MDPI doses; time of Cmax was similar across doses and treatments. Systemic exposures for Fp MDPI 25 and 50 microg were lower than that for Fp DPI 100 microg. The safety profile of Fp MDPI was consistent with that of Fp DPI. CONCLUSIONS: In this study, Fp MDPI 25 and 50 microg provided comparable efficacy and safety to Fp DPI 100 microg, with lower systemic exposure</style></abstract><notes><style face="normal" font="default">DA - 20160610IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1193870</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27285965">PM:27285965</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-89-98.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-89-98.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160610, Kerwin EM</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1193870</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40383</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,C.Z.</style></author><author><style face="normal" font="default"> Hsu,C.H.</style></author><author><style face="normal" font="default"> Li,C.Y.</style></author><author><style face="normal" font="default"> Hsiue,T.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Chest Medicine, Department of Internal Medicine , National Cheng Kung University Medical College and Hospital , Tainan Taiwan</style></auth-address><titles><title><style face="normal" font="default">Insulin use increases risk of asthma but metformin use reduces the risk in patients with diabetes in a Taiwanese population cohort</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway smooth muscle</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> COX</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Insulin</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Metformin</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Muscle Contraction</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Taiwan</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="31" Month="1" Year="2017">2017/1/31</year></dates><abstract><style face="normal" font="default">objective -Recent reports have suggested that insulin promotes airway smooth muscle contraction and enhances airway hyperresponsiveness, which are cardinal features of asthma. In contrast, metformin can reduce both airway inflammatory and remodeling properties. However, these results are all from in vitro and animal studies. This study investigated whether diabetes and various antidiabetic agents associate with the risk of asthma. methods -We used a retrospective population-based cohort study using Taiwan's National Health Insurance claim database from 2000 to 2010 and a Cox proportional hazards regression model to compare the incidence of asthma between patients with diabetes (n = 19,428) and a matched non-diabetic group (n = 38,856). We also used a case-control study nested within the above diabetes cohort including 1,982 incident cases of asthma and 1,982 age- and sex-matched controls. A time density sampling technique was used to assess the effects of various antidiabetic agents on the risk of asthma. Results -The incidence of asthma was significantly higher in the diabetic than non-diabetic cohort after adjustment for age, sex, and obesity, with a hazard ratio of 1.30 (95% confidence interval (CI):1.24-1.38). Insulin was found to increase the risk of asthma among diabetic patients (odds ratio [OR] 2.23; 95%CI: 1.52-3.58). In contrast, the use of metformin correlated with a decreased risk of asthma (OR 0.75; 95%CI: 0.60-0.95). Conclusions -Individuals with diabetes are at increased risk of asthma. Insulin may further increase the risk of asthma, but the risk could possibly be reduced by using metformin</style></abstract><notes><style face="normal" font="default">DA - 20170131IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1283698</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28135899">PM:28135899</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170131-ChenCZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170131-ChenCZ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170131, Chen CZ</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1283698</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40384</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Steinack,C.</style></author><author><style face="normal" font="default"> Lenherr,R.</style></author><author><style face="normal" font="default"> Hendra,H.</style></author><author><style face="normal" font="default"> Franzen,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Division of Pulmonology , University Hospital Zurich , Zurich , Switzerland</style></auth-address><titles><title><style face="normal" font="default">The use of life-saving extracorporeal membrane oxygenation (ECMO) for pregnant woman with status asthmaticus</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="88" start="84">84-88</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">acute respiratory distress syndrome</style></keyword><keyword><style face="normal" font="default"> agonists</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hematoma</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Magnesium</style></keyword><keyword><style face="normal" font="default"> Magnesium Sulfate</style></keyword><keyword><style face="normal" font="default"> Methylprednisolone</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Respiratory Insufficiency</style></keyword><keyword><style face="normal" font="default"> Rest</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Status Asthmaticus</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Ventilation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Status asthmaticus can develop into a life-threatening disorder that requires mechanical ventilation. Severe respiratory failure during pregnancy can worsen maternal and fetal outcomes. Previous case studies have demonstrated extracorporeal membrane oxygenation (ECMO) as a life-saving measure for pregnant women with acute respiratory distress syndrome (ARDS) as well as non-pregnant patients with status asthmaticus. CASE STUDY: A 25-year-old woman, who was 5 weeks pregnant, was admitted with status asthmaticus and severe hypercapnic respiratory failure. Despite rescue therapies such as pressure control ventilation with high inspiratory pressures, inhaled beta2 agonists and antimuscarinic drugs, intravenous salbutamol, methylprednisolone and magnesium sulfate, her condition gradually deteriorated. Veno-venous ECMO was initiated for respiratory support and the patient's clinical condition as well as the gas exchange improved within the next few days. ECMO was removed and the patient was extubated after 2 days. Sonography, however, revealed a retrochorial hematoma; the patient was diagnosed with abortus imminens and successfully treated with magnesium substitution and bed rest. Finally, she gave birth to a healthy boy at 38 weeks of gestation. CONCLUSIONS: This is the first case report on the successful use of ECMO in a pregnant woman with severe respiratory insufficiency due to status asthmaticus, who failed to respond to invasive mechanical ventilation and maximum pharmacological treatment. Despite this life-threatening condition, the use of ECMO in our patient has greatly improved the chance of survival for the mother and the baby, who was born without any complications</style></abstract><notes><style face="normal" font="default">DA - 20160909IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1193871</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27340744">PM:27340744</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-84-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-84-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160909, Steinack C</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1193871</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40385</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zandieh,S.O.</style></author><author><style face="normal" font="default"> Cespedes,A.</style></author><author><style face="normal" font="default"> Ciarleglio,A.</style></author><author><style face="normal" font="default"> Bourgeois,W.</style></author><author><style face="normal" font="default"> Rapoport,D.M.</style></author><author><style face="normal" font="default"> Bruzzese,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatrics , Weill Cornell Medical College , New York , NY , USA</style></auth-address><titles><title><style face="normal" font="default">Asthma and subjective sleep disordered breathing in a large cohort of urban adolescents</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="68" start="62">62-68</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> inner city</style></keyword><keyword><style face="normal" font="default"> inner-city</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Intervention Studies</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Students</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Sleep disordered breathing (SDB) has not been well studied in urban adolescents with asthma in community settings. Nor has the association of SDB symptoms and asthma severity been studied. We characterized self-reported symptoms suggesting SDB and investigated the association of SDB symptoms, probable asthma, and asthma severity. METHODS: 9,565 adolescents from 21 inner-city high schools were screened for an asthma intervention study. Students reported on symptoms suggesting SDB using questions from the 2007 NHANES, if they were ever diagnosed with asthma, and on asthma symptoms. Using generalized linear mixed models with logit link with school as a random intercept and adjusting for age, gender, and race/ethnicity, we examined associations of SDB symptoms, and demographic characteristics, probable asthma, and asthma severity. RESULTS: 12% reported SDB symptoms. Older and bi-racial participants (compared to Caucasian) had higher odds of symptoms suggesting SDB (p &lt;.001). Compared to those without probable asthma, adolescents with probable asthma had 2.63 greater odds of reporting SDB symptoms (p &lt;.001). Among those with probable asthma, the odds of reporting SDB symptoms increased with asthma severity. When exploring daytime severity and severity due to night wakening separately, results were similar. All results remained significant when controlling for age, gender, and ethnicity. CONCLUSIONS: In a large urban community cohort of predominately ethnic minority adolescents, self-reported SDB symptoms were associated with probable asthma and increased asthma severity. This study highlights the importance of SDB as a modifiable co-morbidity of asthma</style></abstract><notes><style face="normal" font="default">DA - 20161014IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1188942</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27740900">PM:27740900</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-62-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-62-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161014, Zandieh SO</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1188942</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40386</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Eid,N.S.</style></author><author><style face="normal" font="default"> O'Hagan,A.</style></author><author><style face="normal" font="default"> Bickel,S.</style></author><author><style face="normal" font="default"> Morton,R.</style></author><author><style face="normal" font="default"> Jacobson,S.</style></author><author><style face="normal" font="default"> Myers,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pediatric Pulmonology, University of Louisville</style></auth-address><titles><title><style face="normal" font="default">Anti-inflammatory dosing of theophylline in the treatment of status asthmaticus in children</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="189" start="183">183-189</pages><volume><style face="normal" font="default">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">acute asthma</style></keyword><keyword><style face="normal" font="default"> Albuterol</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> COX</style></keyword><keyword><style face="normal" font="default"> Discontinue</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Length of Stay</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Modeling</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Oxygen</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Status Asthmaticus</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroid Responsiveness</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Theophylline</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">BACKGROUND: Low-dose theophylline has been recognized for its ability to restore histone deacetylase-2 activity which leads to improved steroid responsiveness and thus improved clinical outcome. We retrospectively evaluated the effect of low-dose theophylline therapy in pediatric patients hospitalized for an acute asthma exacerbation as a proof of concept study. METHODS: We compared patients who received low-dose theophylline (5-7 mg/kg/day) in addition to current standard of care to patients who were treated with current standard of care alone. The primary outcome of the study was hospital length of stay (LOS). Generalized linear mixed-effects modeling (GLMM) was used to test whether receiving theophylline independently predicted outcomes. A Cox (proportional hazards) regression model was also developed to examine whether theophylline impacted LOS. RESULTS: After adjustment for illness severity measures, theophylline significantly reduces LOS (beta=-21.17, P&lt;0.001), time to discontinue oxygen (beta=-15.88, P=0.044), time to spirometric improvement (beta=-16.60, P=0.014), and time to space albuterol (beta=-23.2, P&lt;0.001) as well as reduced costs (beta=-US$2,746, P&lt;0.001). Furthermore, theophylline significantly increased the hazards of being discharged from the hospital (hazards ratio =1.75, 95% confidence interval 1.20-2.54, P=0.004). There was no difference in side effects between patients who receive low-dose theophylline and those who did not. CONCLUSION: The results of this retrospective study suggest low-dose theophylline may have a positive effect in acute status asthmaticus. This study suggests that further research with a prospective, randomized, double-blinded, placebo controlled trial may be warranted to confirm and extend our findings</style></abstract><notes><style face="normal" font="default">DA - 20161027IS - 1178-6965 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2147/JAA.S113747</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27785078">PM:27785078</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2016-9-183-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2016-9-183-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161027, Eid NS</style></custom2><misc3><style face="normal" font="default">10.2147/JAA.S113747</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40387</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cordero,C.</style></author><author><style face="normal" font="default"> Rubiolo,P.</style></author><author><style face="normal" font="default"> Reichenbach,S.E.</style></author><author><style face="normal" font="default"> Carretta,A.</style></author><author><style face="normal" font="default"> Cobelli,L.</style></author><author><style face="normal" font="default"> Giardina,M.</style></author><author><style face="normal" font="default"> Bicchi,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universita degli Studi di Torino, Turin, Italy.</style></auth-address><titles><title><style face="normal" font="default">Method translation and full metadata transfer from thermal to differential flow modulated comprehensive two dimensional gas chromatography: Profiling of suspected fragrance allergens</style></title><secondary-title><style face="normal" font="default">J Chromatogr A</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Chromatogr A</style></abbr-1></periodical><pages end="82" start="70">70-82</pages><volume><style face="normal" font="default">1480</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Chromatography</style></keyword><keyword><style face="normal" font="default"> DC</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Raw</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Transformation</style></keyword><keyword><style face="normal" font="default"> Translating</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="default">The possibility to transfer methods from thermal to differential-flow modulated comprehensive two-dimensional gas chromatographic (GCxGC) platforms is of high interest to improve GCxGC flexibility and increase the compatibility of results from different platforms. The principles of method translation are here applied to an original method, developed for a loop-type thermal modulated GCxGC-MS/FID system, suitable for quali-quantitative screening of suspected fragrance allergens. The analysis conditions were translated to a reverse-injection differential flow modulated platform (GCx2GC-MS/FID) with a dual-parallel secondary column and dual detection. The experimental results, for a model mixture of suspected volatile allergens and for raw fragrance mixtures of different composition, confirmed the feasibility of translating methods by preserving 1D elution order, as well as the relative alignment of resulting 2D peak patterns. A correct translation produced several benefits including an effective transfer of metadata (compound names, MS fragmentation pattern, response factors) by automatic template transformation and matching from the original/reference method to its translated counterpart. The correct translation provided: (a) 2D pattern repeatability, (b) MS fragmentation pattern reliability for identity confirmation, and (c) comparable response factors and quantitation accuracy within a concentration range of three orders of magnitude. The adoption of a narrow bore (i.e. 0.1mm dc) first-dimension column to operate under close-to-optimal conditions with the differential-flow modulation GCxGC platform was also advantageous in halving the total analysis under the translated conditions</style></abstract><notes><style face="normal" font="default">DA - 20161223IS - 1873-3778 (Electronic)IS - 0021-9673 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.chroma.2016.12.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28007300">PM:28007300</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Chromatogr A\2017-1480-70-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Chromatogr A\2017-1480-70-82.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161223, Cordero C</style></custom2><misc3><style face="normal" font="default">10.1016/j.chroma.2016.12.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40388</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Osman,B.M.</style></author><author><style face="normal" font="default"> Maga,J.M.</style></author><author><style face="normal" font="default"> Baquero,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesiology, Miller School of Medicine, University of Miami, 1400 NW 12th Avenue, Suite 3028, Miami, FL 33136, USA.</style></auth-address><titles><title><style face="normal" font="default">Case report: management of differential diagnosis and treatment of severe anaphylaxis in the setting of spinal anesthesia</style></title><secondary-title><style face="normal" font="default">J Clin Anesth</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Clin Anesth</style></full-title></periodical><pages end="149" start="145">145-149</pages><volume><style face="normal" font="default">35</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Anesthesia</style></keyword><keyword><style face="normal" font="default"> Anesthesiology</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> cephalosporin</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Differential diagnosis</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Knee</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Resuscitation</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> Sympathectomy</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">The purpose of this case report is to educate fellow anesthesiologists of a complicated differential diagnosis for sudden cardiovascular collapse after spinal anesthesia. We report a case where anaphylaxis occurred while under spinal anesthesia and resulted in difficult resuscitation. A 58-year-old woman undergoing bilateral knee replacements under spinal anesthesia experienced sudden seizure and cardiovascular collapse from acute anaphylactic shock while administering a cephalosporin. Local anesthetic toxicity, high spinal, and anaphylaxis were considered due to overlapping of symptoms. Successful resuscitation required prolonged advanced cardiac life support with substantially larger doses of epinephrine. Anaphylactic shock under spinal anesthesia is an acute and life-threatening complication, worsened by the spinal-induced sympathectomy, and aggressive resuscitation is warranted. Despite the presence of overlapping symptoms of differential diagnoses, rapid identification of the cause of cardiovascular collapse is crucial given that resuscitation treatment modalities may conflict. Timing of antibiotic administration should be adjusted for spinal anesthesia cases to allow time to detect possible anaphylaxis</style></abstract><notes><style face="normal" font="default">DA - 20161122IS - 1873-4529 (Electronic)IS - 0952-8180 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jclinane.2016.07.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27871512">PM:27871512</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Anesth\2016-35-145-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Anesth\2016-35-145-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161122, Osman BM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jclinane.2016.07.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40389</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Armoni,D.K.</style></author><author><style face="normal" font="default"> Gut,G.</style></author><author><style face="normal" font="default"> Yakir,B.E.</style></author><author><style face="normal" font="default"> Sivan,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric Pulmonology, Critical Care and Sleep Medicine, Dana Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv University Sackler Faculty of Medicine, Israel.</style></auth-address><titles><title><style face="normal" font="default">Variability in anesthesiologists' approach to the preoperative management of asthmatic children</style></title><secondary-title><style face="normal" font="default">J Clin Anesth</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Clin Anesth</style></full-title></periodical><pages end="69" start="62">62-69</pages><volume><style face="normal" font="default">35</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> Attitude</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> bronchodilators</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> preschool children</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">OBJECTIVE: No consensus guidelines exist for the preoperative treatment of asthmatic children referred for elective surgery. We investigated the attitude of pediatric anesthesiologists to this issue. DESIGN: A questionnaire survey was conducted. SETTING: National survey. SUBJECTS: Certified Israeli pediatric anesthesiologists from all 24 general hospitals in Israel. MEASUREMENT: Twenty-one questions regarding the approach to preoperative management of asthmatic children including 6 case scenarios with a variety of clinical situations and treatments of asthmatic children. The results were compared with the attitude of pediatric pulmonologists recently published using a similar methodology. MAIN RESULTS: Forty-four pediatric anesthesiologists from all 24 general hospitals in Israel responded. Twenty-five percent of pediatric anesthesiologists answered that, in addition to pediatric anesthesiologists, the primary pediatrician should be consulted, and 70% believed that a pediatric pulmonologists should also be consulted. Overall, results showed a wide variability between responders especially for preschool children and unstable school-aged asthmatic children for both disciplines. The variability referred to the use of any treatment, bronchodilators, inhaled corticosteroids and their combination, addition of systemic corticosteroids, and the length of preoperative treatment. Compared with pediatric pulmonologists, a better within-discipline agreement was observed by the pediatric anesthesiologists for stable school-aged asthmatic children with a lower inclination to augment preoperative treatment (P&lt; .001). No difference was observed for the preschool children with asthma and for the unstable school-aged asthmatic child. CONCLUSIONS: A wide variability exists in pediatric anesthesiologists' approach to the preoperative management of asthmatic children for most common case scenarios. This is probably explained by the heterogeneity of asthma, the type of surgery, the lack of guidelines, and the paucity of data. Similarities as well as differences exist between pediatric anesthesiologists and pulmonologists. Further studies and implementation of consensus guidelines are needed</style></abstract><notes><style face="normal" font="default">DA - 20161122IS - 1873-4529 (Electronic)IS - 0952-8180 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">10.1016/j.jclinane.2016.07.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27871597">PM:27871597</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Anesth\2016-35-62-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Anesth\2016-35-62-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161122, Armoni DK</style></custom2><misc3><style face="normal" font="default">10.1016/j.jclinane.2016.07.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40390</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Freundlich,R.E.</style></author><author><style face="normal" font="default"> Duggal,N.M.</style></author><author><style face="normal" font="default"> Housey,M.</style></author><author><style face="normal" font="default"> Tremper,T.T.</style></author><author><style face="normal" font="default"> Engoren,M.C.</style></author><author><style face="normal" font="default"> Kheterpal,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesiology, Vanderbilt University Medical Center, 1211 21st Ave S, Suite 526, Nashville, TN 37212.</style></auth-address><titles><title><style face="normal" font="default">Intraoperative medications associated with hemodynamically significant anaphylaxis</style></title><secondary-title><style face="normal" font="default">J Clin Anesth</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Clin Anesth</style></full-title></periodical><pages end="423" start="415">415-423</pages><volume><style face="normal" font="default">35</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Anesthesia</style></keyword><keyword><style face="normal" font="default"> Anesthesiology</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Michigan</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum tryptase</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">STUDY OBJECTIVE: To facilitate the identification of drugs and patient factors associated with hemodynamically significant anaphylaxis. DESIGN: Using an existing database containing complete perioperative records, instances of hemodynamically significant anaphylaxis were identified using a physiologic and treatment-based screening algorithm. All cases were manually reviewed by 2 clinicians, with a third adjudicating disagreements, and confirmed cases were matched 3:1 with control cases. Intraoperative medications given in instances of hemodynamically significant anaphylaxis and patient risk factors were compared with control cases. SETTING: University of Michigan Hospital, a large, tertiary care hospital. PATIENTS: All adult patients undergoing surgery between January 1, 2004, and January 5, 2015. INTERVENTIONS: None. MEASUREMENTS: Incidence of hemodynamically significant anaphylaxis during anesthesia. Patient risk factors and intraoperative medications associated with hemodynamically significant anaphylaxis. MAIN RESULTS: Hemodynamically significant anaphylaxis occurred in 55 of 461 986 cases (1 in 8400). Hemodynamically significant anaphylaxis occurred in 52 patients, with 1 patient experiencing 3 instances and another patient 2 instances. Only 1 drug was associated with an increased risk of hemodynamically significant anaphylaxis: protamine (odds ratio, 11.78; 95% confidence interval, 1.40-99.26; P=.0233). No category of drugs was associated with increased risk. Of patient risk factors, only personal history of anaphylaxis was associated with an increased risk (odds ratio, 77.1; 95% confidence interval, 10.46-567.69; P=&lt;.0001). Postoperative follow-up and evaluation of patients were low at our institution. A serum tryptase level was sent in only 49% of cases, and 41% of levels were positive, an overall positive rate of 20% of cases. Following instances of hemodynamically significant anaphylaxis, only 29% of patients were seen and evaluated by an allergist at our institution. CONCLUSIONS: Hemodynamically significant anaphylaxis is a rare complication of anesthesia, with an incidence consistent with the existing literature. Contrary to most existing literature, only protamine was associated with increased risk. A personal history of anaphylaxis appears to best predict risk of hemodynamically significant anaphylaxis</style></abstract><notes><style face="normal" font="default">DA - 20161122IS - 1873-4529 (Electronic)IS - 0952-8180 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jclinane.2016.09.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27871567">PM:27871567</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Anesth\2016-35-415-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Anesth\2016-35-415-23.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161122, Freundlich RE</style></custom2><misc3><style face="normal" font="default">10.1016/j.jclinane.2016.09.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40391</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vigneshkarthik,N.</style></author><author><style face="normal" font="default"> Ganguly,S.</style></author><author><style face="normal" font="default"> Kuruvila,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Junior Resident, Department of Dermatology, Venereology and Leprosy, Pondicherry Institute of Medical Sciences , Pondicherry, India</style></auth-address><titles><title><style face="normal" font="default">Patch Test as a Diagnostic Tool in Hand Eczema</style></title><secondary-title><style face="normal" font="default">J Clin Diagn Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Clin Diagn Res</style></abbr-1></periodical><pages end="WC07" start="WC04">WC04-WC07</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic tool</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Hair</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand eczema</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Leprosy</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> Para-phenylenediamine</style></keyword><keyword><style face="normal" font="default"> Paraphenylenediamine</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Pompholyx</style></keyword><keyword><style face="normal" font="default"> Potassium</style></keyword><keyword><style face="normal" font="default"> Potassium Dichromate</style></keyword><keyword><style face="normal" font="default"> Reading</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Standard series</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Allergic contact dermatitis is an important cause of hand eczema. Patch testing is the only investigation available to prove the diagnosis of allergic contact dermatitis. Exposures to allergens differ according to geographical, occupational, economic and social factors. Accordingly, patterns of allergic contact dermatitis differ in different parts of the world and different regions of the same country. AIM: To study the causes of allergic contact dermatitis in adult patients with hand eczema with the help of patch testing. MATERIALS AND METHODS: This was a cross-sectional study involving 54 hand eczema patients conducted between October 2013 and June 2015, at a tertiary care centre in Southern India. After a detailed history including history of occupational exposure and detailed examination, patch test was done on these patients with Indian standard series. The patches were removed after 48 hours. Another reading was taken after 72 hours. The readings were interpreted according to International Contact Dermatitis Research Group criteria and noted down. The data were summarized using mean and standard deviation for continuous variables and percentages for categorical and dichotomous variables. The test of association was done with Fisher's-exact test. RESULTS: Hyperkeratotic hand eczema was the commonest morphological type (29%), followed by discoid eczema. Pompholyx was significantly more common among patients with history of atopy. A total of 20 patients (37%) showed patch test positivity to a total of 25 allergens. Nickel was the most common allergen (11.11%) followed by para-phenylenediamine (PPD) (7.4%). Nickel (6 patients) and cobalt (3 patients) were the common allergens among women, while potassium dichromate (3 patients) and parthenium (2 patients) were the common allergens among men. Potassium dichromate allergy was significantly more common among masons and PPD allergy was significantly more common among hair dye users. Discoid pattern of hand eczema was common among patients with allergy to potassium dichromate. CONCLUSION: Majority of the cases of hand eczema are not due to allergic contact dermatitis. History of atopy is common among patients with pompholyx. Allergic contact dermatitis due to nickel remains a common cause of hand eczema</style></abstract><notes><style face="normal" font="default">DA - 20170104IS - 2249-782X (Print)IS - 0973-709X (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.7860/JCDR/2016/23994.8884</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28050486">PM:28050486</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Diagn Res\2016-10-WC04-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Diagn Res\2016-10-WC04-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170104, Vigneshkarthik N</style></custom2><misc3><style face="normal" font="default">10.7860/JCDR/2016/23994.8884</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40392</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sharma,P.K.</style></author><author><style face="normal" font="default"> Gupta,N.</style></author><author><style face="normal" font="default"> Hasan,N.</style></author><author><style face="normal" font="default"> Krishnamurthy,B.</style></author><author><style face="normal" font="default"> Singh,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Associate Professor, Department of Pharmacology, AIIMS , Jodhpur, Rajasthan, India</style></auth-address><titles><title><style face="normal" font="default">Hypersensitivity with Inhalational Budesonide: An Under Recognised Entity</style></title><secondary-title><style face="normal" font="default">J Clin Diagn Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Clin Diagn Res</style></abbr-1></periodical><pages end="FD02" start="FD01">FD01-FD02</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adverse effect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allopurinol</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Back</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> beta-Lactams</style></keyword><keyword><style face="normal" font="default"> Budesonide</style></keyword><keyword><style face="normal" font="default"> Buttocks</style></keyword><keyword><style face="normal" font="default"> Causality</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug-induced</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Fexofenadine</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Lactams</style></keyword><keyword><style face="normal" font="default"> Leg</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Sulphonamides</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">Hypersensitivity reactions are commonly encountered with drugs such as beta lactams, sulphonamides, allopurinol etc., Corticosteroids are frequently employed in the treatment of drug induced allergic reactions. Therefore, it is highly unlikely that a corticosteroid itself may cause such a reaction as an adverse effect. We had encountered a rare case of hypersensitivity reaction with inhalational budesonide in an eight-year-old boy. The patient developed maculopapular rashes over the back, buttocks and legs accompanied with pruritus within four hours of administration of the first dose. The reaction subsided within two days on withdrawal of the drug and treatment with oral fexofenadine. Re-introduction of budesonide by the same route after a month resulted in appearance of similar reaction. Both the parents of the patient were known cases of allergic rhinitis suggesting allergic pre-disposition in the family. Causality analysis using WHO-UMC scale suggested certain association of this allergic reaction with inhaled budesonide</style></abstract><notes><style face="normal" font="default">DA - 20161128IS - 2249-782X (Print)IS - 0973-709X (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.7860/JCDR/2016/22209.8737</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27891350">PM:27891350</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Diagn Res\2016-10-FD01-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Diagn Res\2016-10-FD01-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161128, Sharma PK</style></custom2><misc3><style face="normal" font="default">10.7860/JCDR/2016/22209.8737</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40393</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dupin,C.</style></author><author><style face="normal" font="default"> Marchand-Adam,S.</style></author><author><style face="normal" font="default"> Favelle,O.</style></author><author><style face="normal" font="default"> Costes,R.</style></author><author><style face="normal" font="default"> Gatault,P.</style></author><author><style face="normal" font="default"> Diot,P.</style></author><author><style face="normal" font="default"> Grammatico-Guillon,L.</style></author><author><style face="normal" font="default"> Guilleminault,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">CHRU Tours, Service de Pneumologie et explorations fonctionnelles respiratoires, Hopital Bretonneau, 2 boulevard Tonnelle, 37044, F-37044, Tours Cedex, France</style></auth-address><titles><title><style face="normal" font="default">Asthma and Hypogammaglobulinemia: an Asthma Phenotype with Low Type 2 Inflammation</style></title><secondary-title><style face="normal" font="default">J Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Clin Immunol</style></full-title></periodical><pages end="817" start="810">810-817</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Bronchiectasis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Exploration</style></keyword><keyword><style face="normal" font="default"> fraction of exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Igg</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> smokers</style></keyword><keyword><style face="normal" font="default"> Tobacco</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="6" Month="10" Year="2016">2016/10/6</year></dates><abstract><style face="normal" font="default">PURPOSE: Little is known about hypogammaglobulinemia (HGG) in asthma patients. No data are available on the characteristics of adult patients with asthma and HGG. METHODS: We conducted a retrospective monocentric study between January 2006 and December 2012. Asthma patients with a serum immunoglobulin (Ig) quantitative analysis were included and classified into two groups depending on their serum IgG concentration: presence or absence of HGG. Clinical, biological, functional, and radiologic characteristics were compared in univariate and multivariate analysis, using a logistic regression model. RESULTS: In univariate analysis, asthma patients with HGG (n = 25) were older (58 years old +/- 18 vs 49 +/- 18, p = 0.04) and more frequently active or former smokers as compared to patients with normoglobulinemia (n = 80) (56.0 vs 35.0 %, p = 0.01). Total IgE &lt; 30 kUI/L was more frequently observed in patients with HGG (53.0 vs 18.3 %, p = 0.01). HGG asthma patients had lower fraction of exhaled nitric oxide (p = 0.02), blood eosinophilia (p = 0.0009), and presented with more severe composite score for bronchiectasis (p = 0.01). In multivariate analysis, asthma patients with HGG had increased risk of being smokers [OR = 6.11 (IC 95 % = 1.16-32.04)], having total IgE concentration &lt; 30 kUI/L [OR = 12.87 (IC 95 % = 2.30-72.15)], and a more severe composite score of bronchiectasis [OR = 20.65 (IC 95 % = 2.13-199.74)]. CONCLUSION: Asthma patients with HGG are older and more often tobacco smoker than asthma patients without HGG. These patients have low type-2 inflammation markers</style></abstract><notes><style face="normal" font="default">DA - 20161007IS - 1573-2592 (Electronic)IS - 0271-9142 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="default"> 10.1007/s10875-016-0335-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27714565">PM:27714565</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Immunol\2016-36-810-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Immunol\2016-36-810-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161007, Dupin C</style></custom2><misc3><style face="normal" font="default"> 10.1007/s10875-016-0335-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40394</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Noguchi,A.</style></author><author><style face="normal" font="default"> Tominaga,M.</style></author><author><style face="normal" font="default"> Takahashi,N.</style></author><author><style face="normal" font="default"> Matsuda,H.</style></author><author><style face="normal" font="default"> Kamata,Y.</style></author><author><style face="normal" font="default"> Umehara,Y.</style></author><author><style face="normal" font="default"> Ko,K.C.</style></author><author><style face="normal" font="default"> Suga,Y.</style></author><author><style face="normal" font="default"> Ogawa,H.</style></author><author><style face="normal" font="default"> Takamori,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute for Environmental and Gender Specific Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Tomioka, Urayasu, Chiba 279-0021, Japan</style></auth-address><titles><title><style face="normal" font="default">Differences in therapeutic effects of topically applied corticosteroid and tacrolimus on atopic dermatitis-like symptoms in NC/Nga mice</style></title><secondary-title><style face="normal" font="default">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Betamethasone</style></keyword><keyword><style face="normal" font="default"> Calcineurin</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clobetasol</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatophagoides</style></keyword><keyword><style face="normal" font="default"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> innervation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Tacrolimus</style></keyword><keyword><style face="normal" font="default"> TEWL</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> transepidermal water loss</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> VAS</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword></keywords><dates><year Day="24" Month="12" Year="2016">2016/12/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: Topical corticosteroid and calcineurin inhibitor have similar therapeutic benefits in atopic dermatitis (AD), but the differences in therapeutic mechanisms of action of these agents against AD symptoms are not fully understood. OBJECTIVE: This study was performed to examine the different effects of topical betamethasone valerate (BMV), clobetasol propionate (CBP), and tacrolimus (TAC) on itch-related behavior and dermatitis in NC/Nga mice with AD-like symptoms. METHODS: AD-like dermatitis was induced in the dorsal skin of NC/Nga mice by repeated topical application of Dermatophagoides farinae body (Dfb) ointment twice weekly for three weeks. Mice with dermatitis scores over 5 were divided into five groups with equal dermatitis scores and treated with BMV, CBP, TAC, or Vaseline (Vas) once daily for two consecutive days, or were not treated (NT). Scratching behavior was analyzed using a SCLABA(R)-Real system. Transepidermal water loss (TEWL) before and after treatment was measured using a Tewameter(R) TM210. Skin collected from each group was analyzed histologically. RESULTS: After the second treatment, dermatitis showed significantly greater improvement in the CBP and TAC-treated groups than in the Vas-treated and NT groups. The numbers of scratching bouts were significantly lower in CBP and TAC-treated mice than in Vas-treated mice. TEWL was significantly lower in TAC-, but not in CBP-, treated mice than in Vas-treated mice. Immunohistochemical examination showed that BMV, CBP and TAC did not reduce the increased densities of epidermal protein gene product 9.5- and substance P-immunoreactive fibers. The numbers of dermal CD4-immunoreactive T cells were significantly lower in BMV and CBP-treated mice than in Vas-treated and NT mice. The numbers of dermal eosinophils were significantly lower in BMV, CBP and TAC-treated mice than in Vas-treated and NT mice, with CBP showing the strongest effect. CBP significantly reduced epidermal thickness compared with Vas and NT. There were no significant differences in the numbers of interleukin-31-immunoreactive cells and mast cells, or in expression of epidermal thymic stromal lymphopoietin among all five groups. CONCLUSION: The therapeutic potency of TAC against AD-like symptoms, including pruritus, is equal to that of the corticosteroid CBP. Epidermal innervation of sensory nerves itself might not be related to the therapeutic effects of topical tacrolimus and corticosteroids in its early phase</style></abstract><notes><style face="normal" font="default">DA - 20170110IS - 1873-569X (Electronic)IS - 0923-1811 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jdermsci.2016.12.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28069324">PM:28069324</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatol Sci\20170110-NoguchiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatol Sci\20170110-NoguchiA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170110, Noguchi A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jdermsci.2016.12.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40395</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nguyen,T.T.</style></author><author><style face="normal" font="default"> Baker,B.</style></author><author><style face="normal" font="default"> Ferguson,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacy, Virginia Commonwealth University Medical Center, Richmond, Virginia</style></auth-address><titles><title><style face="normal" font="default">Allergic Reaction to Ketamine as Monotherapy for Procedural Sedation</style></title><secondary-title><style face="normal" font="default">J Emerg Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Emerg Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Adverse effect</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Diphenhydramine</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Histamine Release</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Virginia</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="18" Month="10" Year="2016">2016/10/18</year></dates><abstract><style face="normal" font="default">BACKGROUND: Ketamine is a cyclohexamine derivative that acts as a noncompetitive N-methyl D-aspartate receptor antagonist. Its use for procedural sedation is recommended by national clinical policy. However, its immunogenic potential is not well documented. CASE REPORT: We report a case of allergic reaction associated with the administration of intravenous ketamine for procedural sedation in a 16-year-old male. Minutes after administration, the patient developed a morbilliform, erythematous rash that extended to the upper and lower torso and resolved with intravenous diphenhydramine. It is most likely that this allergic reaction was caused by a ketamine-induced histamine release that has been described in vitro. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: This is the first case report in which ketamine was used as monotherapy in the emergency department for the facilitation of procedural sedation that resulted in an allergic reaction. Supportive measures, including advanced airway procedures and hemodynamic support, may be necessary in more severe anaphylactic cases. Providers should be aware of this potential adverse effect when using ketamine for procedural sedation</style></abstract><notes><style face="normal" font="default">DA - 20161022IS - 0736-4679 (Print)IS - 0736-4679 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jemermed.2016.09.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27769614">PM:27769614</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Emerg Med\20161022-NguyenTT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Emerg Med\20161022-NguyenTT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161022, Nguyen TT</style></custom2><misc3><style face="normal" font="default">10.1016/j.jemermed.2016.09.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40396</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Eiffert,S.</style></author><author><style face="normal" font="default"> Noibi,Y.</style></author><author><style face="normal" font="default"> Vesper,S.</style></author><author><style face="normal" font="default"> Downs,J.</style></author><author><style face="normal" font="default"> Fulk,F.</style></author><author><style face="normal" font="default"> Wallace,J.</style></author><author><style face="normal" font="default"> Pearson,M.</style></author><author><style face="normal" font="default"> Winquist,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Environmental Health, Rollins School of Public Health, Emory University, 1518 Clifton Road NE, Atlanta, GA 30322, USA</style></auth-address><titles><title><style face="normal" font="default">A Citizen-Science Study Documents Environmental Exposures and Asthma Prevalence in Two Communities</style></title><secondary-title><style face="normal" font="default">J Environ Public Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Environ Public Health</style></abbr-1></periodical><pages end="" start="1962901">1962901-</pages><volume><style face="normal" font="default">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Documentation</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Georgia</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> indoor</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> low income</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> molds</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">A citizen-science study was conducted in two low-income, flood-prone communities in Atlanta, Georgia, in order to document environmental exposures and the prevalence of occupant asthma. Teams consisting of a public-health graduate student and a resident from one of the two communities administered a questionnaire, inspected residences for mold growth, and collected a dust sample for quantifying mold contamination. The dust samples were analyzed for the 36 molds that make up the Environmental Relative Moldiness Index (ERMI). Most residents (76%) were renters. The median duration of residence was 2.5 years. Although only 12% of occupants reported a history of flooding, 46% reported at least one water leak. Homes with visible mold (35%) had significantly (P &lt; 0.05) higher mean ERMI values compared to homes without (14.0 versus 9.6). The prevalence of self-reported, current asthma among participants was 14%. In logistic regression models controlling for indoor smoking, among participants residing at their current residence for two years or less, a positive association was observed between asthma and the homes' ERMI values (adjusted odds ratio per unit increase in ERMI = 1.12, 95% confidence intervals (CI): 1.01-1.25; two-tailed P = 0.04). Documentation of the exposures and asthma prevalence has been presented to the communities and public officials. Community-based organizations have taken responsibility for planning and implementing activities in response to the study findings</style></abstract><notes><style face="normal" font="default">DA - 20161222IS - 1687-9813 (Electronic)IS - 1687-9805 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1155/2016/1962901</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28003835">PM:28003835</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Environ Public Health\2016-2016-1962901.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Environ Public Health\2016-2016-1962901.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161222, Eiffert S</style></custom2><misc3><style face="normal" font="default">10.1155/2016/1962901</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40397</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mahemuti,L.</style></author><author><style face="normal" font="default"> Chen,Q.</style></author><author><style face="normal" font="default"> Coughlan,M.C.</style></author><author><style face="normal" font="default"> Zhang,M.</style></author><author><style face="normal" font="default"> Florian,M.</style></author><author><style face="normal" font="default"> Mailloux,R.J.</style></author><author><style face="normal" font="default"> Cao,X.L.</style></author><author><style face="normal" font="default"> Scoggan,K.A.</style></author><author><style face="normal" font="default"> Willmore,W.G.</style></author><author><style face="normal" font="default"> Jin,X.</style></author></authors></contributors><auth-address><style face="normal" font="default">Regulatory Toxicology Research Division, Bureau of Chemical Safety, Food Directorate, HPFB, Health Canada, Ottawa, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="default">Bisphenol A exposure alters release of immune and developmental modulators and expression of estrogen receptors in human fetal lung fibroblasts</style></title><secondary-title><style face="normal" font="default">J Environ Sci (China)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Environ Sci (China)</style></abbr-1></periodical><pages end="23" start="11">11-23</pages><volume><style face="normal" font="default">48</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bisphenol A</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Endothelin-1</style></keyword><keyword><style face="normal" font="default"> estrogen</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Fibroblasts</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Interferon</style></keyword><keyword><style face="normal" font="default"> Interleukin-6</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Ontario</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Serine</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Toxicology</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">Bisphenol A (BPA) has been shown to exert biological effects through estrogen receptor (ER)-dependent and ER-independent mechanisms. Recent studies suggest that prenatal exposure to BPA may increase the risk of childhood asthma. To investigate the underlying mechanisms in the actions of BPA, human fetal lung fibroblasts (hFLFs) were exposed to varying doses of BPA in culture for 24hr. Effects of BPA on localization and uptake of BPA, cell viability, release of immune and developmental modulators, cellular localization and expression of ERalpha, ERbeta and G-protein coupled estrogen receptor 30 (GPR30), and effects of ERs antagonists on BPA-induced changes in endothelin-1 (ET-1) release were examined. BPA at 0.01-100mumol/L caused no changes in cell viability after 24hr of exposure. hFLFs expresses all three ERs. BPA had no effects on either cellular distribution or protein expression of ERalpha, however, at 100mumol/L (or 23mumol/L intracellular BPA) increased ERbeta protein levels in the cytoplasmic fractions and GPR30 protein levels in the nuclear fractions. These paralleled with increased release of growth differentiation factor-15, decreased phosphorylation of nuclear factor kappa B p65 at serine 536, and decreased release of ET-1, interleukin-6, and interferon gamma-induced protein 10. ERs antagonists had no effects on BPA-induced decrease in ET-1 release. These data suggest that BPA at 100mumol/L altered the release of immune and developmental modulators in hFLFs, which may negatively influence fetal lung development, maturation, and susceptibility to environmental stressors, although the role of BPA in childhood asthma remains to be confirmed in in vivo studies</style></abstract><notes><style face="normal" font="default">DA - 20161017IS - 1001-0742 (Print)IS - 1001-0742 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jes.2016.02.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27745655">PM:27745655</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Environ Sci (China)\2016-48-11-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Environ Sci (China)\2016-48-11-23.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161017, Mahemuti L</style></custom2><misc3><style face="normal" font="default">10.1016/j.jes.2016.02.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40398</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tao,J.</style></author><author><style face="normal" font="default"> Sun,L.X.</style></author><author><style face="normal" font="default"> Le,X.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Analytical and Environmental Toxicology, Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, T6G 2G3, Canada</style></auth-address><titles><title><style face="normal" font="default">Study of the effects of bisphenol A using human fetal lung fibroblasts</style></title><secondary-title><style face="normal" font="default">J Environ Sci (China)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Environ Sci (China)</style></abbr-1></periodical><pages end="10" start="6">6-10</pages><volume><style face="normal" font="default">48</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Bisphenol A</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Fibroblasts</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Toxicology</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161017IS - 1001-0742 (Print)IS - 1001-0742 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jes.2016.09.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27745673">PM:27745673</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Environ Sci (China)\2016-48-6-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Environ Sci (China)\2016-48-6-10.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161017, Tao J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jes.2016.09.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40399</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,I.S.</style></author><author><style face="normal" font="default"> Uh,I.</style></author><author><style face="normal" font="default"> Kim,K.S.</style></author><author><style face="normal" font="default"> Kim,K.H.</style></author><author><style face="normal" font="default"> Park,J.</style></author><author><style face="normal" font="default"> Kim,Y.</style></author><author><style face="normal" font="default"> Jung,J.H.</style></author><author><style face="normal" font="default"> Jung,H.J.</style></author><author><style face="normal" font="default"> Jang,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">College of Korean Medicine, Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Anti-Inflammatory Effects of Ginsenoside Rg3 via NF-kappaB Pathway in A549 Cells and Human Asthmatic Lung Tissue</style></title><secondary-title><style face="normal" font="default">J Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Immunol Res</style></abbr-1></periodical><pages end="" start="7521601">7521601-</pages><volume><style face="normal" font="default">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway epithelial cell</style></keyword><keyword><style face="normal" font="default"> airway epithelial cells</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> COX-2</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eotaxin</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> IL-9</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Objective. There is limited information of the anti-inflammatory effects of Rg3 on inflamed lung cells and tissues. Therefore, we confirmed the anti-inflammatory mechanism of ginsenoside Rg3 in inflamed human airway epithelial cells (A549) and tissues whether Rg3 regulates nuclear factor kappa B (NF-kappaB) activity. Methods. To induce the inflammation, IL-1beta (10 ng/ml) was treated to A549 cells for 4 h. The effects of Rg3 on NF-kappaB activity and COX-2 expression were evaluated by western blotting analysis in both IL-1beta-induced inflamed A549 cell and human asthmatic airway epithelial tissues. Using multiplex cytokines assay, the secretion levels of NF-kappaB-mediated cytokines/chemokines were measured. Result. Rg3 showed the significant inhibition of NF-kappaB activity thereby reduced COX-2 expression was determined in both IL-1beta-induced inflamed A549 cell and human asthmatic airway epithelial tissues. In addition, among NF-kappaB-mediated cytokines, the secretion levels of IL-4, TNF-alpha, and eotaxin were significantly decreased by Rg3 in asthma tissues. Even though there was no significant difference, IL-6, IL-9, and IL-13 secretion showed a lower tendency compared to saline-treated human asthmatic airway epithelial tissues. Conclusion. The results from this study demonstrate the potential of Rg3 as an anti-inflammatory agent through regulating NF-kappaB activity and reducing the secretion of NF-kappaB-mediated cytokines/chemokines</style></abstract><notes><style face="normal" font="default">DA - 20170124IS - 2314-7156 (Electronic)IS - 2314-7156 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1155/2016/7521601</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28116321">PM:28116321</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Immunol Res\2016-2016-7521601.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Immunol Res\2016-2016-7521601.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170124, Lee IS</style></custom2><misc3><style face="normal" font="default">10.1155/2016/7521601</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40400</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Melamed,I.</style></author><author><style face="normal" font="default"> Heffron,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">IMMUNOe Research Centers, Centennial, CO 80112, USA</style></auth-address><titles><title><style face="normal" font="default">Attention Deficit Disorder and Allergic Rhinitis: Are They Related?</style></title><secondary-title><style face="normal" font="default">J Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Immunol Res</style></abbr-1></periodical><pages end="" start="1596828">1596828-</pages><volume><style face="normal" font="default">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Cetirizine</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Methylphenidate</style></keyword><keyword><style face="normal" font="default"> Nerve Growth Factor</style></keyword><keyword><style face="normal" font="default"> Nervous System</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">The association between ADHD and allergy remains controversial. Our previous findings suggest that nerve growth factor may link the nervous and immune systems. The primary objective of this study was to determine if a combination of cetirizine + methylphenidate is effective in children with comorbid ADHD and allergic rhinitis. We also examined the role of nerve growth factor in these comorbidities. Our randomized, double-blind, placebo-controlled, crossover study enrolled 38 children diagnosed with comorbid ADHD and allergy using cetirizine (n = 12), sustained-release methylphenidate (n = 12), or cetirizine + methylphenidate (n = 14). Endpoints compared baseline to posttreatment evaluations for allergic rhinitis and ADHD scores. Serum nerve growth factor levels were measured using ELISA. For allergy endpoints, combination therapy produced results superior to individual therapy. For ADHD, similar scores were achieved for individual therapy; however, combination therapy resulted in improved scores. Nerve growth factor levels were downregulated following this trend. We conclude that ADHD and allergic rhinitis may have common mechanism and represent a comorbid condition that links the nervous system to the immune system. Further studies are needed</style></abstract><notes><style face="normal" font="default">DA - 20161122IS - 2314-7156 (Electronic)IS - 2314-7156 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1155/2016/1596828</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27872863">PM:27872863</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Immunol Res\2016-2016-1596828.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Immunol Res\2016-2016-1596828.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161122, Melamed I</style></custom2><misc3><style face="normal" font="default">10.1155/2016/1596828</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40401</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hamano,S.</style></author><author><style face="normal" font="default"> Matsumoto,K.</style></author><author><style face="normal" font="default"> Tonai,K.</style></author><author><style face="normal" font="default"> Fukuyama,S.</style></author><author><style face="normal" font="default"> Kan,O.</style></author><author><style face="normal" font="default"> Seki,N.</style></author><author><style face="normal" font="default"> Inoue,H.</style></author><author><style face="normal" font="default"> Nakanishi,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka, 812-8582 Japan</style></auth-address><titles><title><style face="normal" font="default">Effects of corticosteroid plus long-acting beta2-agonist on the expression of PD-L1 in double-stranded RNA-induced lung inflammation in mice</style></title><secondary-title><style face="normal" font="default">J Inflamm (Lond)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Inflamm (Lond)</style></abbr-1></periodical><pages end="" start="2">2-</pages><volume><style face="normal" font="default">14</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway epithelial cell</style></keyword><keyword><style face="normal" font="default"> airway epithelial cells</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> persistence</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Rna</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral infection</style></keyword><keyword><style face="normal" font="default"> Viral infections</style></keyword><keyword><style face="normal" font="default"> Viruses</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Airway viral infections cause the exacerbations of asthma and chronic obstructive pulmonary disease. PD-L1, also known as B7-H1, is an immune-checkpoint molecule that plays a role in an escape mechanism of viruses from the host immune systems. This escape may be associated with the persistence of viral infection and the exacerbation of the underlying diseases. In a study in vitro, we have shown that corticosteroids plus long-acting beta2-agonists (LABAs) attenuate the upregulation of PD-L1 on airway epithelial cells stimulated with an analog of viral double-stranded RNA, polyinosinic-polycytidylic acid (poly I:C). To address its biological relevance in vivo, we investigated the effect of corticosteroid plus LABA on the expression of PD-L1 in double-stranded RNA-induced lung inflammation in mice. METHODS: Mice were intratracheally administered with poly I:C. The expression of PD-L1 on the lung cells was assessed by flow cytometry and inflammation was assessed for bronchoalveolar lavage fluid (BALF). Independent as well as combination effects of ciclesonide and indacaterol were examined. RESULTS: Administration of low dose poly I:C upregulated the expression of PD-L1, induced neutrophilia and increased keratinocyte-derived chemokine (KC), macrophage inflammatory protein-1beta (MIP-1beta), and IL-6 in BALF. The upregulation of PD-L1, neutrophilic inflammation and increase of KC were suppressed by ciclesonide plus indacaterol, but not by either when administered independently. Although the upregulation of PD-L1 by high dose poly I:C was suppressed by ciclesonide plus indacaterol, neutrophilia and increased KC, MIP-1beta, and IL-6 in BALF were not attenuated. CONCLUSIONS: Ciclesonide plus indacaterol attenuate double-stranded RNA-induced upregulation of PD-L1 in the lungs</style></abstract><notes><style face="normal" font="default">DA - 20170124IS - 1476-9255 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1186/s12950-017-0149-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28115915">PM:28115915</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Inflamm (Lond)\2017-14-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Inflamm (Lond)\2017-14-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170124, Hamano S</style></custom2><misc3><style face="normal" font="default">10.1186/s12950-017-0149-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40402</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Adam,C.</style></author><author><style face="normal" font="default"> Wohlfarth,J.</style></author><author><style face="normal" font="default"> Haussmann,M.</style></author><author><style face="normal" font="default"> Sennefelder,H.</style></author><author><style face="normal" font="default"> Rodin,A.</style></author><author><style face="normal" font="default"> Maler,M.</style></author><author><style face="normal" font="default"> Martin,S.F.</style></author><author><style face="normal" font="default"> Goebeler,M.</style></author><author><style face="normal" font="default"> Schmidt,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Hospital Wurzburg, Germany</style></auth-address><titles><title><style face="normal" font="default">Allergy-inducing chromium compounds trigger potent innate immune stimulation via ROS-dependent inflammasome activation</style></title><secondary-title><style face="normal" font="default">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Invest Dermatol</style></full-title></periodical><pages end="376" start="367">367-376</pages><volume><style face="normal" font="default">137</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> activation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Caspase 1</style></keyword><keyword><style face="normal" font="default"> caspase-1</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Chromium</style></keyword><keyword><style face="normal" font="default"> Chromium Compounds</style></keyword><keyword><style face="normal" font="default"> Cysteine</style></keyword><keyword><style face="normal" font="default"> cytotoxicity</style></keyword><keyword><style face="normal" font="default"> delayed-type hypersensitivity</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human monocytes</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Inflammasome</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Keratinocytes</style></keyword><keyword><style face="normal" font="default"> Monocyte</style></keyword><keyword><style face="normal" font="default"> Monocytes</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> NLRP3 inflammasome</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> priming</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> ROS</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Chromium allergy is a common occupational skin disease mediated by chromium (VI)-specific T cells that induce delayed-type hypersensitivity in sensitized individuals. Additionally, chromium (VI) can act as irritant. Both responses critically require innate immune activation, but if and how chromium (VI) elicits this signal is currently unclear.Using human monocytes, primary human keratinocytes and murine dendritic cells we show that chromium (VI) compounds fail to trigger direct proinflammatory activation but potently induce processing and secretion of IL-1beta. IL-1beta release required priming by phorbol-ester or Toll-like receptor stimulation and was prevented by inhibition of K+ efflux, NLRP3 depletion or Caspase-1 inhibition, identifying chromium (VI) as hapten activator of the NLRP3 inflammasome. Inflammasome activation was initiated by mitochondrial ROS production triggered by chromium (VI) as indicated by sensitivity to treatment with the ROS scavenger N-acetyl cysteine and a coinciding failure of K+ efflux, Caspase-1 or NLRP3 inhibition to prevent mitochondrial ROS accumulation. IL-1beta release further correlated with cytotoxicity that was secondary to ROS, K+ efflux and NLRP3 activation. Intriguingly, trivalent chromium was unable to induce mitochondrial ROS production, inflammasome activation and cytotoxicity, suggesting that oxidation state-specific differences in mitochondrial reactivity may determine inflammasome activation and allergic/irritant capacity of different chromium compounds</style></abstract><notes><style face="normal" font="default">DA - 20161018IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jid.2016.10.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27751866">PM:27751866</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Invest Dermatol\2017-137-367-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Invest Dermatol\2017-137-367-76.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161018, Adam C</style></custom2><misc3><style face="normal" font="default">10.1016/j.jid.2016.10.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40403</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Harrow,B.</style></author><author><style face="normal" font="default"> Sedaghat,A.R.</style></author><author><style face="normal" font="default"> Caldwell-Tarr,A.</style></author><author><style face="normal" font="default"> Dufour,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Meda Pharmaceuticals, Somerset, New Jersey</style></auth-address><titles><title><style face="normal" font="default">A Comparison of Health Care Resource Utilization and Costs for Patients with Allergic Rhinitis on Single-Product or Free-Combination Therapy of Intranasal Steroids and Intranasal Antihistamines</style></title><secondary-title><style face="normal" font="default">J Manag Care Spec Pharm</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Manag Care Spec Pharm</style></abbr-1></periodical><pages end="1436" start="1426">1426-1436</pages><volume><style face="normal" font="default">22</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Azelastine</style></keyword><keyword><style face="normal" font="default"> Azelastine hydrochloride</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Data Collection</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> fluticasone propionate</style></keyword><keyword><style face="normal" font="default"> Formulation</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Intranasal steroids</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> New Jersey</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic rhinitis (AR) is a common condition that can be treated with a number of different therapies. Treatments such as intranasal antihistamines (INAs) and intranasal steroids (INSs) are widely used by AR patients. For some allergy sufferers, a combination of therapies, specifically an INA and an INS, is required to address their symptoms. A new treatment, the formulation of azelastine hydrochloride and fluticasone pro-pionate used as a single spray (MP-AzeFlu), has become available for AR patients who need both types of treatment. In this regard, the comparison with the alternative concomitant use of INAs and INSs is of interest. The current study examines the health care resource utilization and costs for each cohort. OBJECTIVE: To examine the resource utilization and costs associated with AR for patients treated with MP-AzeFlu or concurrent therapy with single-ingredient INA and INS sprays (free-combination therapy). METHODS: A retrospective administrative claims study for commercially insured patients from a large U.S. health plan was performed. Patients with an AR diagnosis and a prescription claim for MP-AzeFlu or free-combination therapy between September 1, 2012, and September 30, 2013, were identified. Patients were aged at least 12 years at index date (first prescription fill for intranasal therapy) and were required to have 12 months pre-index and 6 months post-index of continuous enrollment. Health care resource utilization and costs were assessed for the post-index period. The cohorts were adjusted on baseline demographic and clinical characteristics using inverse propensity treatment weights. Other covariates, prescriber specialty, product switching during the post-index period, and pre-index total costs were included in the regression models measuring outcomes. One clinical characteristic of interest was the presence of asthma as comorbidity. A subset analysis of AR patients with asthma was also performed. RESULTS: All-cause-related pharmacy fills as well as pharmacy, medical, and total costs were significantly reduced by using MP-AzeFlu (N = 810) instead of the free combination of drugs (N = 726). For AR-related health care resource utilization, the MP-AzeFlu cohort had significantly fewer pharmacy fills than the free-combination cohort (1.01 and 1.17, respectively; P &lt; 0.001) with no significant difference in outpatient services and specialist visits (P = 0.139 and P = 0.117, respectively). Six-month AR-related pharmacy and total costs were significantly lower (P &lt; 0.001 and P = 0.001) for the MP-AzeFlu cohort ($128 and $334, respectively) than the free-combination cohort ($268 and $458, respectively). There was no statistically significant difference in AR-related medical costs between the 2 cohorts (P = 0.454). For the subcohort of AR patients with asthma, the MP-AzeFlu cohort had lower 6-month asthma resource utilization and costs than the free-combination cohort. CONCLUSIONS: These findings suggest that, for AR patients needing INAs and INSs, the single-spray formulation MP-AzeFlu had better economic outcomes than for patients who rely on the free combination of these agents. MP-AzeFlu also appears to keep asthma-related utilization and costs down for those AR patients who also suffer from asthma. Potential explanations for these findings are explored. DISCLOSURES: This study was funded by Meda Pharmaceuticals. Authors were either employed by Meda Pharmaceuticals or received consulting fees from Meda Pharmaceuticals. Comprehensive Health Insights and Sedaghat received funding from Meda Pharmaceuticals as a consultant to participate in this study. Dufour and Caldwell-Tarr are employees of Comprehensive Health Insights. Harrow is currently employed by TESARO. This study was conceived by Harrow, Dufour, and Caldwell-Tarr. All authors contributed to the design of the study. Dufour took the lead in data collection, along with Caldwell-Tarr, and data interpretion was performed by Harrow, along with the other authors. Analyses were performed by Dufour. The manuscript was written and revised by all authors</style></abstract><notes><style face="normal" font="default">DA - 20161124IS - 2376-1032 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.18553/jmcp.2016.22.12.1426</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27882840">PM:27882840</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Manag Care Spec Pharm\2016-22-1426-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Manag Care Spec Pharm\2016-22-1426-36.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161124, Harrow B</style></custom2><misc3><style face="normal" font="default">10.18553/jmcp.2016.22.12.1426</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40404</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Casciano,J.</style></author><author><style face="normal" font="default"> Krishnan,J.</style></author><author><style face="normal" font="default"> Dotiwala,Z.</style></author><author><style face="normal" font="default"> Li,C.</style></author><author><style face="normal" font="default"> Sun,S.X.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 eMAX Health, White Plains, New York</style></auth-address><titles><title><style face="normal" font="default">Clinical and Economic Burden of Elevated Blood Eosinophils in Patients With and Without Uncontrolled Asthma</style></title><secondary-title><style face="normal" font="default">J Manag Care Spec Pharm</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Manag Care Spec Pharm</style></abbr-1></periodical><pages end="91" start="85">85-91</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Aspergillosis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Control level</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Data Collection</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Records</style></keyword><keyword><style face="normal" font="default"> Interpretation</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> lung cancer</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Modeling</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective cohort study</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: The European Respiratory Society and American Thoracic Society (ERS/ATS) published guidelines in 2014 for the evaluation and treatment of asthma. These guidelines draw attention to management of patients with asthma that remains uncontrolled despite therapy. One phenotypic characteristic of therapy-resistant asthma is eosinophil elevation. It is important to better understand the burden of care gaps in this patient subgroup in order to support improved treatment strategies in the future. OBJECTIVE: To quantify the economic burden of asthma patients with and without peripheral blood eosinophil elevation. METHODS: A retrospective cohort study was conducted using data from patients aged 12 years or older with a diagnosis of asthma using electronic health records of over 2 million patients between 2004-2010. Patients with a diagnosis of chronic obstructive pulmonary disease, Churg Strauss syndrome/Wegener's granulomatosis, eosinophilia, cystic/pulmonary fibrosis, allergic bronchopulmonary aspergillosis, or lung cancer in the 12-month period before the date of asthma diagnosis were excluded. Patients with asthma were followed for 12 months after their initial asthma diagnosis to identify those with controlled versus uncontrolled asthma based on ERS/ATS criteria. Patients with at least 1 peripheral blood eosinophil test result of >/= 400 cells/microL were classified as those with elevated eosinophils. Total annual paid-claim cost was compared by eosinophil levels within the controlled and uncontrolled asthma subgroups. Costs were adjusted to 2015 U.S. dollars. Patients were stratified by control level, and generalized linear modeling regressions were used to assess the magnitude of increase in cost of the elevated eosinophil group. RESULTS: A total of 2,701 patients were included in the study, of which 17% had uncontrolled asthma and 21% had elevated eosinophils. The mean total annual cost of patients with uncontrolled asthma was more than 2 times the cost of those with controlled asthma ($18,341 vs. $8,670, P &lt; 0.001). Patients with uncontrolled asthma in the elevated eosinophil group had almost double the total cost ($28,644 vs. $14,188, P = 0.008) compared with those with blood eosinophil levels in a normal range. Similarly, patients classified as those with controlled asthma in the elevated eosinophil group had almost twice the average costs as those without elevated eosinophils ($14,754 vs. $7,203, P &lt; 0.001). Uncontrolled asthma with elevated eosinophils had 4 times greater hospital admissions and over 4 times higher total costs than controlled asthma without elevated eosinophils. Among patients with uncontrolled asthma, patients with elevated eosinophils had a 53% increase in mean cost ($17,723 vs. $11,581, P &lt; 0.001) compared with patients without elevated eosinophils. Among patients with controlled asthma, patients with elevated eosinophils had a 62% increase in mean cost ($8,897 vs. $5,486, P &lt; 0.001) compared with patients without elevated eosinophils. CONCLUSIONS: Elevated peripheral blood eosinophil level is associated with higher cost irrespective of disease control status. DISCLOSURES: This study was funded by Teva Pharmaceuticals. Dotiwala and Casciano report consulting and writing fees from Teva Pharmaceuticals for work on this study. Sun is an employee and stockholder of Teva Pharmaceuticals. Li reports consulting fees from eMAX Health. All authors contributed to study design. Dotiwala took the lead in data collection, along with the other authors, and data interpretation was performed primarily by Krishnan, Sun, and Li, along with Casciano and Dotiwala. The manuscript was written by Casciano, Dotiwala, and Li, along with Sun and Krishnan, and revised by Casciano, Dotiwala, Sun, and Li, with assistance from Krishnan</style></abstract><notes><style face="normal" font="default">DA - 20161227IS - 2376-1032 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.18553/jmcp.2017.23.1.85</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28025926">PM:28025926</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Manag Care Spec Pharm\2017-23-85-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Manag Care Spec Pharm\2017-23-85-91.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161227, Casciano J</style></custom2><misc3><style face="normal" font="default">10.18553/jmcp.2017.23.1.85</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40405</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Casciano,J.</style></author><author><style face="normal" font="default"> Krishnan,J.</style></author><author><style face="normal" font="default"> Small,M.B.</style></author><author><style face="normal" font="default"> Li,C.</style></author><author><style face="normal" font="default"> Dotiwala,Z.</style></author><author><style face="normal" font="default"> Martin,B.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">eMAX Health Systems, White Plains, New York</style></auth-address><titles><title><style face="normal" font="default">Progression to Uncontrolled Severe Asthma: A Novel Risk Equation</style></title><secondary-title><style face="normal" font="default">J Manag Care Spec Pharm</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Manag Care Spec Pharm</style></abbr-1></periodical><pages end="50" start="44">44-50</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Control level</style></keyword><keyword><style face="normal" font="default"> COX</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Interpretation</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> Quantification</style></keyword><keyword><style face="normal" font="default"> race</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Recently published asthma guidelines by the European Respiratory Society and the American Thoracic Society (ERS-ATS) define severe disease based on medication use and control level. These guidelines also emphasize that asthma severity involves certain biomarker phenotypes, one of them being eosinophilic phenotype. The quantification of the influence of eosinophil level toward predicting disease severity can help decision makers manage therapy better earlier. OBJECTIVE: To develop a risk-scoring algorithm to identify patients at greater risk of developing uncontrolled severe asthma as defined by ERS-ATS guidelines. METHODS: Data on asthma patients were extracted from the EMRClaims + database from January 2004 to July 2011. Patients with continuous enrollment 12 months before and after the date of the first encounter with a diagnosis of asthma (index date) with at least 1 blood eosinophil test result in the 12 months after the index date, but before the development of uncontrolled severe asthma or the study end date, were included. Uncontrolled severe asthma was defined as the first date on which all criteria of the ERS-ATS definition were first satisfied in the 12 months after the index date. Age (>/= 50 years vs. &lt; 50 years), race, and sex were measured at index, and the Charlson Comorbidity Index (CCI) score (> 0 vs. 0) was measured in the pre-index period. Elevated eosinophil level was defined as a test result with >/= 400 cells/microL. The study cohort was randomly split 50-50 into derivation and validation samples. Cox proportional hazards regression was used to develop the risk score for uncontrolled severe asthma using the derivation cohort with independent variables of eosinophil level, age, sex, race, and CCI. A bootstrapping procedure was used to generate 1,000 samples from the derivation cohort. Variables significant in >/= 50% of the samples were retained in the final regression model. A risk score was then calculated based on the coefficient estimates of the final model. C-statistic was used to test the model's discrimination power. RESULTS: The study included 2,405 patients, 147 (6%) of whom developed uncontrolled severe asthma. Higher eosinophil level and CCI score > 0 were significantly and independently associated with an increased risk of uncontrolled severe asthma in the derivation cohort (HR = 1.90, 95% CI = 1.17-3.08 and HR = 2.00, 95% CI = 1.28-3.13, respectively); findings were similar in the validation cohort. Total risk score was categorized as 0, 2, and 4. All models showed good C-statistics (0.79-0.80), indicating favorable model discrimination. There was a significantly greater number of patients with uncontrolled severe asthma in the risk score segments of 2 and 4 compared with 0 (each P &lt; 0.0001). CONCLUSIONS: A risk stratification tool using peripheral eosinophil counts and CCI can be used to predict the development of uncontrolled severe asthma. DISCLOSURES: This study was funded by Teva Pharmaceuticals. eMAX Health Systems was a consultant to Teva Pharmaceuticals for this study and received payment from Teva Pharmaceuticals for work on this study. Casciano and Dotiwala are employed by eMAX Health Systems. Krishnan, Li, and Martin received payment from eMAX Health Systems for work on this study. Small was employed by Teva Pharmaceuticals at the time of this study. Study concept and design were contributed primarily by Casciano, Krishnan, Small, and Martin, along with Li and Dotiwala. Dotiwala, Casciano, Small, and Li collected the data, along with Martin and Li and Krishnan. Data interpretation was provided by Martin, Casciano, and Li, with assistance from the other authors. The manuscript was written by Li, Casciano, Dotiwala, and Small, with assistance from the other authors, and revised by Dotiwala, Small, Li, and Martin, with assistance from Krishnan and Casciano</style></abstract><notes><style face="normal" font="default">DA - 20161227IS - 2376-1032 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.18553/jmcp.2017.23.1.44</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28025923">PM:28025923</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Manag Care Spec Pharm\2017-23-44-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Manag Care Spec Pharm\2017-23-44-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161228, Casciano J</style></custom2><misc3><style face="normal" font="default">10.18553/jmcp.2017.23.1.44</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40406</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kilinc,G.</style></author><author><style face="normal" font="default"> Uzuner,N.</style></author><author><style face="normal" font="default"> Karaman,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Children Dental Clinic, Dokuz Eylul University, School of Medicine, Turkey</style></auth-address><titles><title><style face="normal" font="default">Effect of dental care programme and fluoridation in the prevention of dental caries in asthmatic children</style></title><secondary-title><style face="normal" font="default">J Pak Med Assoc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Pak Med Assoc</style></full-title></periodical><pages end="1384" start="1378">1378-1384</pages><volume><style face="normal" font="default">66</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Dental Care</style></keyword><keyword><style face="normal" font="default"> Dental Caries</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Fluoridation</style></keyword><keyword><style face="normal" font="default"> Gingivitis</style></keyword><keyword><style face="normal" font="default"> Habits</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> pH</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Toothbrushing</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To investigate the effect of a regular dental care programme on the dental health of asthmatic children. METHODS: This prospective, controlled study was conducted at Dokuz Eylul University, Izmir, Turkey, between 2012 and 2014, and comprised asthmatic and non-asthmatic children between 4 and 16 years of age who used inhaler corticosteroid treatment for at least 1 year. Patients were examined for dental caries, gingival index, salivary flow rate, and salivary pH values at baseline, 6 months, and at the end of the first year. Demographic features and tooth-brushing habits of the asthmatic and non-asthmatic children were also analysed. SPSS 20 was used for data analysis. RESULTS: Of the 102 patients, there were 51(50%) each in asthmatic and non-asthmatic groups. Besides, 38(70.6%) participants were boys and 15(29.4%) were girls in the first group compared to 30(58.8%) boys and 21(41.2%) girls in the second group. The mean age was 11.16+/-3.10 years and 10.33+/-2.62 years, respectively, in the two groups. The number of asthmatic patients was 45(88.2%) in visit 2 and 37(72.5%) in visit 3, whereas the number of participants for the control group was 41(80.4%) in visit 2 and 36(70.4%) in visit 3. During the first visit, mean values for salivary pH and flow rate were 7.135 0.15 and 3.878 0.71 mL/min among asthma patients, and 7.158 0.14 and 4.684 0.50 among controls. In the first visit, the rate of gingivitis was 31(60.8%) in asthmatic children and 12(23.5%) in the control group. During the third visit, the rate was 4(11.1%) and 5(13.5%) among the two groups, respectively. CONCLUSIONS: Decreased salivary flow rates associated with the drugs used by asthmatic patients caused an increase in the rate of dental caries and gingival disorders</style></abstract><notes><style face="normal" font="default">DA - 20161104IS - 0030-9982 (Print)IS - 0030-9982 (Linking)LA - ENGPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27812052">PM:27812052</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Pak Med Assoc\2016-66-1378-84.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Pak Med Assoc\2016-66-1378-84.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161104, Kilinc G</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40407</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bellin,M.H.</style></author><author><style face="normal" font="default"> Newsome,A.</style></author><author><style face="normal" font="default"> Land,C.</style></author><author><style face="normal" font="default"> Kub,J.</style></author><author><style face="normal" font="default"> Mudd,S.S.</style></author><author><style face="normal" font="default"> Bollinger,M.E.</style></author><author><style face="normal" font="default"> Butz,A.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Asthma Home Management in the Inner-City: What can the Children Teach us?</style></title><secondary-title><style face="normal" font="default">J Pediatr Health Care</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Pediatr Health Care</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">African American</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Cessation</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Focus Groups</style></keyword><keyword><style face="normal" font="default"> Housing</style></keyword><keyword><style face="normal" font="default"> inner city</style></keyword><keyword><style face="normal" font="default"> inner-city</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> linkage</style></keyword><keyword><style face="normal" font="default"> low income</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicaid</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Self-management</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Smoking Cessation</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> youth</style></keyword></keywords><dates><year Day="9" Month="12" Year="2016">2016/12/9</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Knowledge of asthma home management from the perspective of poor, minority children with asthma is limited. METHOD: Convenience sampling methods were used to recruit families of low-income children who are frequently in the emergency department for uncontrolled asthma. Thirteen youths participated in focus groups designed to elicit reflections on asthma home management. Data were analyzed using grounded theory coding techniques. RESULTS: Participants (Mean age = 9.2 years) were African American (100%), enrolled in Medicaid (92.3%), averaged 1.4 (standard deviation = 0.7) emergency department visits over the prior 3 months, and resided in homes with at least 1 smoker (61.5%). Two themes reflecting multifaceted challenges to the development proper of self-management emerged in the analysis. DISCUSSION: Findings reinforce the need to provide a multipronged approach to improve asthma control in this high-risk population including ongoing child and family education and self-management support, environmental control and housing resources, linkages to smoking cessation programs, and psychosocial support</style></abstract><notes><style face="normal" font="default">DA - 20161213IS - 1532-656X (Electronic)IS - 0891-5245 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.pedhc.2016.11.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27955875">PM:27955875</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Pediatr Health Care\20161213-BellinMH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Pediatr Health Care\20161213-BellinMH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161213, Bellin MH</style></custom2><misc3><style face="normal" font="default">10.1016/j.pedhc.2016.11.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40408</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lampkin,S.J.</style></author><author><style face="normal" font="default"> Maslouski,C.A.</style></author><author><style face="normal" font="default"> Maish,W.A.</style></author><author><style face="normal" font="default"> John,B.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">D'Youville College School of Pharmacy, Buffalo, New York</style></auth-address><titles><title><style face="normal" font="default">Asthma Review for Pharmacists Providing Asthma Education</style></title><secondary-title><style face="normal" font="default">J Pediatr Pharmacol Ther</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Pediatr Pharmacol Ther</style></abbr-1></periodical><pages end="471" start="444">444-471</pages><volume><style face="normal" font="default">21</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Ambulatory Care</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma education</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Community pharmacy</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> office</style></keyword><keyword><style face="normal" font="default"> Office Visits</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacist</style></keyword><keyword><style face="normal" font="default"> Pharmacists</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="default">Asthma is the most common pediatric illness affecting more than 6 million children in the United States. Children with asthma have more frequent office visits and hospitalizations compared with adults. Despite advances in therapies, asthma still has a significant effect on the health care system. Regardless of the setting, pharmacists are uniquely equipped with an intimate knowledge of medications. With this knowledge, they can provide education to patients at various points throughout the health care system, from hospitalization to office visits to point of pick up at the pharmacy. The goal of this article is to equip the pharmacist with the necessary knowledge to provide education to these patients in a variety of practice settings, including community pharmacies, ambulatory care settings, and during transitions in care</style></abstract><notes><style face="normal" font="default">DA - 20161123IS - 1551-6776 (Print)IS - 1551-6776 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.5863/1551-6776-21.5.444</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27877099">PM:27877099</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Pediatr Pharmacol Ther\2016-21-444-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Pediatr Pharmacol Ther\2016-21-444-71.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161123, Lampkin SJ</style></custom2><misc3><style face="normal" font="default">10.5863/1551-6776-21.5.444</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40409</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Noh,J.</style></author><author><style face="normal" font="default"> Sohn,J.</style></author><author><style face="normal" font="default"> Cho,J.</style></author><author><style face="normal" font="default"> Cho,S.K.</style></author><author><style face="normal" font="default"> Choi,Y.J.</style></author><author><style face="normal" font="default"> Kim,C.</style></author><author><style face="normal" font="default"> Shin,D.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Short-term Effects of Ambient Air Pollution on Emergency Department Visits for Asthma: An Assessment of Effect Modification by Prior Allergic Disease History</style></title><secondary-title><style face="normal" font="default">J Prev Med Public Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Prev Med Public Health</style></abbr-1></periodical><pages end="341" start="329">329-341</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollutants</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Monoxide</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Nitrogen</style></keyword><keyword><style face="normal" font="default"> Nitrogen Dioxide</style></keyword><keyword><style face="normal" font="default"> NO2</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Ozone</style></keyword><keyword><style face="normal" font="default"> Particulate matter</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> PM10</style></keyword><keyword><style face="normal" font="default"> Poisson</style></keyword><keyword><style face="normal" font="default"> Poisson Distribution</style></keyword><keyword><style face="normal" font="default"> pollutants</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Preventive Medicine</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Sulfur</style></keyword><keyword><style face="normal" font="default"> Sulfur Dioxide</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The goal of this study was to investigate the short-term effect of ambient air pollution on emergency department (ED) visits in Seoul for asthma according to patients' prior history of allergic diseases. METHODS: Data on ED visits from 2005 to 2009 were obtained from the Health Insurance Review and Assessment Service. To evaluate the risk of ED visits for asthma related to ambient air pollutants (carbon monoxide [CO], nitrogen dioxide [NO2], ozone [O3], sulfur dioxide [SO2], and particulate matter with an aerodynamic diameter &lt;10 mum [PM10]), a generalized additive model with a Poisson distribution was used; a single-lag model and a cumulative-effect model (average concentration over the previous 1-7 days) were also explored. The percent increase and 95% confidence interval (CI) were calculated for each interquartile range (IQR) increment in the concentration of each air pollutant. Subgroup analyses were done by age, gender, the presence of allergic disease, and season. RESULTS: A total of 33 751 asthma attack cases were observed during the study period. The strongest association was a 9.6% increase (95% CI, 6.9% to 12.3%) in the risk of ED visits for asthma per IQR increase in O3 concentration. IQR changes in NO2 and PM10 concentrations were also significantly associated with ED visits in the cumulative lag 7 model. Among patients with a prior history of allergic rhinitis or atopic dermatitis, the risk of ED visits for asthma per IQR increase in PM10 concentration was higher (3.9%; 95% CI, 1.2% to 6.7%) than in patients with no such history. CONCLUSIONS: Ambient air pollutants were positively associated with ED visits for asthma, especially among subjects with a prior history of allergic rhinitis or atopic dermatitis</style></abstract><notes><style face="normal" font="default">DA - 20161017IS - 2233-4521 (Electronic)IS - 1975-8375 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="default">10.3961/jpmph.16.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27744674">PM:27744674</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Prev Med Public Health\2016-49-329-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Prev Med Public Health\2016-49-329-41.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161017, Noh J</style></custom2><misc3><style face="normal" font="default">10.3961/jpmph.16.038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40410</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rafael,C.F.</style></author><author><style face="normal" font="default"> Liebermann,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Clinical characteristics of an allergic reaction to a polyether dental impression material</style></title><secondary-title><style face="normal" font="default">J Prosthet Dent</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Prosthet Dent</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> allergic response</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Dental Impression Materials</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Mouth</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> rehabilitation</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Stomatitis</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="default">0022-3913</style></isbn><abstract><style face="normal" font="default">Abstract Allergic and hypersensitivity reactions to dental impression materials may occur throughout dental treatment, with diverse manifestations from slight redness to severe pain and a burning mouth with total stomatitis. Patients are often unaware of these allergic reactions, which makes early identification of the cause almost impossible. In addition, symptoms usually begin after 24 hours and mostly in patients with a preexisting history of allergic responses. This report describes a patient with a suspected allergic reaction to a polyether dental impression material during prosthetic rehabilitation associated with a mandibular telescopic denture. Although instances of such occurrence are rare, clinicians need to be aware of these symptoms and select materials carefully for patients with a history of allergy</style></abstract><notes><style face="normal" font="default">DA - 20161124IS - 1097-6841 (Electronic)IS - 0022-3913 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.prosdent.2016.08.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27881318">PM:27881318</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Prosthet Dent\20161124-RafaelCF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Prosthet Dent\20161124-RafaelCF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161124, Rafael CF</style></custom2><misc3><style face="normal" font="default">10.1016/j.prosdent.2016.08.031</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40411</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Youk,J.</style></author><author><style face="normal" font="default"> Park,H.</style></author><author><style face="normal" font="default"> Jin,K.N.</style></author><author><style face="normal" font="default"> Moon,H.J.</style></author><author><style face="normal" font="default"> Yang,M.S.</style></author><author><style face="normal" font="default"> Kim,K.H.</style></author><author><style face="normal" font="default"> Kim,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Successful desensitization of pemetrexed-induced anaphylaxis in a patient with malignant mesothelioma</style></title><secondary-title><style face="normal" font="default">Korean J Intern Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Korean J Intern Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="25" Month="11" Year="2016">2016/11/25</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161128IS - 2005-6648 (Electronic)IS - 1226-3303 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.3904/kjim.2015.250</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27889955">PM:27889955</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Korean J Intern Med\20161128-YoukJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Korean J Intern Med\20161128-YoukJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161128, Youk J</style></custom2><misc3><style face="normal" font="default">10.3904/kjim.2015.250</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40412</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">D'Amato,G.</style></author><author><style face="normal" font="default"> Vitale,C.</style></author><author><style face="normal" font="default"> Molino,A.</style></author><author><style face="normal" font="default"> Stanziola,A.</style></author><author><style face="normal" font="default"> Sanduzzi,A.</style></author><author><style face="normal" font="default"> Vatrella,A.</style></author><author><style face="normal" font="default"> Mormile,M.</style></author><author><style face="normal" font="default"> Lanza,M.</style></author><author><style face="normal" font="default"> Calabrese,G.</style></author><author><style face="normal" font="default"> Antonicelli,L.</style></author><author><style face="normal" font="default"> D'Amato,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Respiratory and Allergic Diseases, Department of Chest Diseases, High Speciality "A. Cardarelli" Hospital, Napoli, Italy</style></auth-address><titles><title><style face="normal" font="default">Asthma-related deaths</style></title><secondary-title><style face="normal" font="default">Multidiscip Respir Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Multidiscip Respir Med</style></abbr-1></periodical><pages end="" start="37">37-</pages><volume><style face="normal" font="default">11</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Emergency care</style></keyword><keyword><style face="normal" font="default"> Ethnic Groups</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Intubation</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral corticosteroids</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Self-management</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trends</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Ventilation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Despite major advances in the treatment of asthma and the development of several asthma guidelines, people still die of asthma currently. According to WHO estimates, approximately 250,000 people die prematurely each year from asthma. Trends of asthma mortality rates vary very widely across countries, age and ethnic groups. Several risk factors have been associated with asthma mortality, including a history of near-fatal asthma requiring intubation and mechanical ventilation, hospitalization or emergency care visit for asthma in the past year, currently using or having recently stopped using oral corticosteroids (a marker of event severity), not currently using inhaled corticosteroids, a history of psychiatric disease or psychosocial problems, poor adherence with asthma medications and/or poor adherence with (or lack of) a written asthma action plan, food allergy in a patient with asthma. Preventable factors have been identified in the majority of asthma deaths. Inadequate education of patients on recognising risk and the appropriate action needed when asthma control is poor, deficiencies in the accuracy and timing of asthma diagnosis, inadequate classification of severity and treatment, seem to play a part in the majority of asthma deaths. Improvements in management, epitomized by the use of guided self-management systems of care may be the key goals in reducing asthma mortality worldwide</style></abstract><notes><style face="normal" font="default">DA - 20161018IS - 1828-695X (Print)IS - 1828-695X (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="default">10.1186/s40248-016-0073-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27752310">PM:27752310</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Multidiscip Respir Med\2016-11-37.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Multidiscip Respir Med\2016-11-37.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161018, D'Amato G</style></custom2><misc3><style face="normal" font="default">10.1186/s40248-016-0073-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40413</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Price,D.B.</style></author><author><style face="normal" font="default"> van Boven,J.F.</style></author><author><style face="normal" font="default"> Law,L.M.</style></author><author><style face="normal" font="default"> Cifra,A.</style></author><author><style face="normal" font="default"> McQueen,R.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Academic Primary Care, Division of Applied Health Sciences, Polwarth building, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD UK</style></auth-address><titles><title><style face="normal" font="default">Cost comparison of asthma treatments in 12-week study: caution about matching and short observational follow-up</style></title><secondary-title><style face="normal" font="default">Multidiscip Respir Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Multidiscip Respir Med</style></abbr-1></periodical><pages end="" start="39">39-</pages><volume><style face="normal" font="default">11</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Interpretation</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">In the absence of randomisation, observational studies must take extra care to create treatment groups that are comparable in terms of key characteristics. Various matching methods exist which can create sound comparisons, minimising confounding where possible. A recent observational study by Dal Negro et al. carried out a cost analysis comparing two asthma medications. They report strong conclusions which favour one treatment over the other, however they include little discussion on the limitations of their study. The purpose of this letter is to comment on the weaknesses of the study design, including the level of matching used, and to urge readers to consider these issues alongside the interpretation of results</style></abstract><notes><style face="normal" font="default">DA - 20161108IS - 1828-695X (Print)IS - 1828-695X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1186/s40248-016-0076-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27822370">PM:27822370</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Multidiscip Respir Med\2016-11-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Multidiscip Respir Med\2016-11-39.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161108, Price DB</style></custom2><misc3><style face="normal" font="default">10.1186/s40248-016-0076-x</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40414</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dal Negro,R.W.</style></author><author><style face="normal" font="default"> Distante,C.</style></author><author><style face="normal" font="default"> Bonadiman,L.</style></author><author><style face="normal" font="default"> Turco,P.</style></author><author><style face="normal" font="default"> Iannazzo,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Centre for Respiratory Pharmacoeconomics and Pharmacoepidemiology, Verona, Italy</style></auth-address><titles><title><style face="normal" font="default">Cost of persistent asthma in Italy</style></title><secondary-title><style face="normal" font="default">Multidiscip Respir Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Multidiscip Respir Med</style></abbr-1></periodical><pages end="" start="44">44-</pages><volume><style face="normal" font="default">11</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> General practitioner</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> pharmacoeconomics</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> rescue medication</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is a common disease of the airways with a significant burden for the society and for patients' quality of life. The Social Impact of Respiratory Integrated Outcomes (SIRIO) study estimated a mean cost of 1,177.40 euro per patient/year in Italy, in 2007. The aim of the present study was to update the cost of persistent asthma patients in Italy. METHODS: An observational, retrospective, bottom-up analysis was carried out starting from the data base operating in the Lung Unit of the Specialist Medical Centre (CEMS), Verona (Italy), over the period June 2013-December 2015. Patients' data were recorded over the 12 +/- 2 months before the enrollment and during 12 +/- 2 months of follow-up. The prospective was the Italian National Health Service and the broad Italian society. Clinical data were measured in terms of forced expiratory volume in 1 s (FEV1%) and number of relapses. Healthcare resources (namely; number of hospitalizations and/or ER admissions; number of visits; drug use and duration, and indirect costs) were recorded. RESULTS: The cohort consisted of 817 patients with persistent asthma of different severity. They had a 42.96% male prevalence; a mean (+/-SE) age of 49.06 (+/-0.64) years; a mean 87.47% (+/-0.81) FEV1% pred. in baseline, and 69.16% of subjects had comorbidities. The mean (+/-SE) number of relapses was 0.91 (+/-0.09) per patient/year before the enrolment. After 12 months, FEV1% significantly improved by +6.31% (+/-0.45) from the corresponding baseline value (p &lt; 0.001). The number of relapses decreased of -0.46 (+/-0.09) (p &lt; 0.001). The estimated total annual cost per asthmatic patient was 1,183.14 euro (+/-65.79 euro) during the 12 months before the enrolment, and 1,290.89 euro (+/-68.74 euro) throughout the follow-up. The increase was mostly due to the significantly increased duration of therapeutic strategies. The costs of hospitalization, general practitioner and rescue medications were significantly decreased. CONCLUSIONS: The periodic update of cost analysis is a key to monitor the trend of main asthma outcomes and related expenditure over time. It allows to plan the most convenient actions in terms of prevention strategies and effective interventions, with the aim of optimizing the healthcare resources consumption and maximizing the impact on clinical outcomes and patients' quality of life. The role of an appropriate pharmacological strategy still proves crucial in minimizing asthma morbidity and the corresponding socio-economic impact</style></abstract><notes><style face="normal" font="default">DA - 20161226IS - 1828-695X (Print)IS - 1828-695X (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1186/s40248-016-0080-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28018593">PM:28018593</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Multidiscip Respir Med\2016-11-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Multidiscip Respir Med\2016-11-44.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161226, Dal Negro RW</style></custom2><misc3><style face="normal" font="default">10.1186/s40248-016-0080-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40415</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Belhassen,M.</style></author><author><style face="normal" font="default"> Nibber,A.</style></author><author><style face="normal" font="default"> Van Ganse,E.</style></author><author><style face="normal" font="default"> Ryan,D.</style></author><author><style face="normal" font="default"> LANGLOIS,C.</style></author><author><style face="normal" font="default"> Appiagyei,F.</style></author><author><style face="normal" font="default"> Skinner,D.</style></author><author><style face="normal" font="default"> Laforest,L.</style></author><author><style face="normal" font="default"> Soriano,J.B.</style></author><author><style face="normal" font="default"> Price,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">PELyon, HESPER 7425, Claude Bernard University, Lyon, France</style></auth-address><titles><title><style face="normal" font="default">Inappropriate asthma therapy-a tale of two countries: a parallel population-based cohort study</style></title><secondary-title><style face="normal" font="default">NPJ Prim Care Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">NPJ Prim Care Respir Med</style></full-title></periodical><pages end="" start="16076">16076-</pages><volume><style face="normal" font="default">26</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma therapy</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="13" Month="10" Year="2016">2016/10/13</year></dates><abstract><style face="normal" font="default">Against recurrent controversies around the safety of short- and long-acting beta2-agonists (SABA and LABA), and the National Review of Asthma Deaths inquiry in the United Kingdom, we investigated the prevalence of inappropriate therapy in asthma. Our study aimed to determine the prevalence of inappropriate use of asthma therapy in the United Kingdom and in France. Two interval, parallel, population-based cohorts (2007 and 2013) were developed in each country by using the UK OPCRD and the French EGB databases. Patients aged 6-40 years were studied over the 12-month period following inclusion, regarding overuse (12 units) of SABA, use of LABA without inhaled corticosteroids (ICS) and 2-fold higher use of LABA compared with that of ICS. Overall, 39,743 UK and 4,910 French patients were included in 2007, and 14,036 and 5,657 patients, respectively, were included in 2013. UK adults were more frequently exposed to SABA overuse compared with those in France in both periods, with an upward trend in the United Kingdom (P&lt;0.05). In 2013, LABA use without ICS occurred in 0.1% and 1.5% of United Kingdom and French adults, respectively. Unbalanced use of LABA relative to ICS became marginal in both countries in 2013. Inappropriate use of therapy was less marked, but present, in children. Inappropriate therapy remains a common issue in asthma. Based on our figures, it may be estimated that >210,000 British and >190,000 French asthmatics aged 6-40 years were inappropriately treated in 2013</style></abstract><notes><style face="normal" font="default">DA - 20161013IS - 2055-1010 (Electronic)IS - 2055-1010 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Francxe -CO - United Kingdom -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1038/npjpcrm.2016.76</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27735927">PM:27735927</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\NPJ Prim Care Respir Med\2016-26-16076.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\NPJ Prim Care Respir Med\2016-26-16076.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161013, Belhassen M</style></custom2><misc3><style face="normal" font="default">10.1038/npjpcrm.2016.76</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40416</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cave,A.J.</style></author><author><style face="normal" font="default"> Davey,C.</style></author><author><style face="normal" font="default"> Ahmadi,E.</style></author><author><style face="normal" font="default"> Drummond,N.</style></author><author><style face="normal" font="default"> Fuentes,S.</style></author><author><style face="normal" font="default"> Kazemi-Bajestani,S.M.</style></author><author><style face="normal" font="default"> Sharpe,H.</style></author><author><style face="normal" font="default"> Taylor,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Family Medicine, University of Alberta, Edmonton, AB, Canada</style></auth-address><titles><title><style face="normal" font="default">Development of a validated algorithm for the diagnosis of paediatric asthma in electronic medical records</style></title><secondary-title><style face="normal" font="default">NPJ Prim Care Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">NPJ Prim Care Respir Med</style></full-title></periodical><pages end="" start="16085">16085-</pages><volume><style face="normal" font="default">26</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Electronic medical records</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> paediatric asthma</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> Uncertainty</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="24" Month="11" Year="2016">2016/11/24</year></dates><abstract><style face="normal" font="default">An accurate estimation of the prevalence of paediatric asthma in Alberta and elsewhere is hampered by uncertainty regarding disease definition and diagnosis. Electronic medical records (EMRs) provide a rich source of clinical data from primary-care practices that can be used in better understanding the occurrence of the disease. The Canadian Primary Care Sentinel Surveillance Network (CPCSSN) database includes cleaned data extracted from the EMRs of primary-care practitioners. The purpose of the study was to develop and validate a case definition of asthma in children 1-17 who consult family physicians, in order to provide primary-care estimates of childhood asthma in Alberta as accurately as possible. The validation involved the comparison of the application of a theoretical algorithm (to identify patients with asthma) to a physician review of records included in the CPCSSN database (to confirm an accurate diagnosis). The comparison yielded 87.4% sensitivity, 98.6% specificity and a positive and negative predictive value of 91.2% and 97.9%, respectively, in the age group 1-17 years. The algorithm was also run for ages 3-17 and 6-17 years, and was found to have comparable statistical values. Overall, the case definition and algorithm yielded strong sensitivity and specificity metrics and was found valid for use in research in CPCSSN primary-care practices. The use of the validated asthma algorithm may improve insight into the prevalence, diagnosis, and management of paediatric asthma in Alberta and Canada</style></abstract><notes><style face="normal" font="default">DA - 20161124IS - 2055-1010 (Electronic)IS - 2055-1010 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1038/npjpcrm.2016.85</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27882997">PM:27882997</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\NPJ Prim Care Respir Med\2016-26-16085.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\NPJ Prim Care Respir Med\2016-26-16085.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161124, Cave AJ</style></custom2><misc3><style face="normal" font="default">10.1038/npjpcrm.2016.85</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40417</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bime,C.</style></author><author><style face="normal" font="default"> Gerald,J.K.</style></author><author><style face="normal" font="default"> Wei,C.Y.</style></author><author><style face="normal" font="default"> Holbrook,J.T.</style></author><author><style face="normal" font="default"> Teague,W.G.</style></author><author><style face="normal" font="default"> Wise,R.A.</style></author><author><style face="normal" font="default"> Gerald,L.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Department of Medicine, University of Arizona School of Medicine, Arizona Respiratory Center, Tucson, AZ, USA</style></auth-address><titles><title><style face="normal" font="default">Measurement characteristics of the childhood Asthma-Control Test and a shortened, child-only version</style></title><secondary-title><style face="normal" font="default">NPJ Prim Care Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">NPJ Prim Care Respir Med</style></full-title></periodical><pages end="" start="16075">16075-</pages><volume><style face="normal" font="default">26</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Arizona</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> C-ACT</style></keyword><keyword><style face="normal" font="default"> Caregivers</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> paediatric asthma</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="10" Year="2016">2016/10/20</year></dates><abstract><style face="normal" font="default">The childhood Asthma-Control Test (C-ACT) is validated for assessing asthma control in paediatric asthma. Among children aged 4-11 years, the C-ACT requires the simultaneous presence of both parent and child. There is an unmet need for a tool that can be used to assess asthma control in children when parents or caregivers are not present such as in the school setting. We assessed the psychometric properties and estimated the minimally important difference (MID) of the C-ACT and a modified version, comprising only the child responses (C-ACTc). Asthma patients aged 6-11 years (n=161) from a previously completed multicenter randomised trial were included. Demographic information, spirometry and questionnaire scores were obtained at baseline and during follow-up. Participants or their guardians kept a daily asthma diary. Internal consistency reliabilities of the C-ACT and C-ACTc were 0.76 and 0.67 (Cronbach's alpha), respectively. Test-retest reliabilities of the C-ACT and C-ACTc were 0.72 and 0.66 (intra-class correlation), respectively. Significant correlations were noted between C-ACT scores and ACQ scores (Spearman's correlation r=-0.56, 95% CI (-0.66, -0.44), P&lt;0.001). The strength of the correlation between C-ACTc scores and ACQ scores was weaker (Spearman's correlation r=-0.46, 95% CI (-0.58, -0.33), P&lt;0.001). We estimated the MID for the C-ACT and C-ACTc to be 2 points and 1 point, respectively. Among asthma patients aged 6-11 years, the C-ACT had good psychometric properties. The psychometric properties of a shortened child-only version (C-ACTc), although acceptable, are not as strong</style></abstract><notes><style face="normal" font="default">DA - 20161020IS - 2055-1010 (Electronic)IS - 2055-1010 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="default">10.1038/npjpcrm.2016.75</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27763622">PM:27763622</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\NPJ Prim Care Respir Med\2016-26-16075.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\NPJ Prim Care Respir Med\2016-26-16075.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161020, Birne C</style></custom2><misc3><style face="normal" font="default">10.1038/npjpcrm.2016.75</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40418</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chisholm,A.</style></author><author><style face="normal" font="default"> Price,D.B.</style></author><author><style face="normal" font="default"> Pinnock,H.</style></author><author><style face="normal" font="default"> Lee,T.T.</style></author><author><style face="normal" font="default"> Roa,C.</style></author><author><style face="normal" font="default"> Cho,S.H.</style></author><author><style face="normal" font="default"> David-Wang,A.</style></author><author><style face="normal" font="default"> Wong,G.</style></author><author><style face="normal" font="default"> van der Molen,T.</style></author><author><style face="normal" font="default"> Ryan,D.</style></author><author><style face="normal" font="default"> Castillo-Carandang,N.</style></author><author><style face="normal" font="default"> Yong,Y.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory Effectiveness Group, Cambridge, UK</style></auth-address><titles><title><style face="normal" font="default">Personalising care of adults with asthma from Asia: a modified e-Dephi consensus study to inform management tailored to attitude and control profiles</style></title><secondary-title><style face="normal" font="default">NPJ Prim Care Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">NPJ Prim Care Respir Med</style></full-title></periodical><pages end="" start="16089">16089-</pages><volume><style face="normal" font="default">27</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Asia</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Attitude</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hong Kong</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Malaysia</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pharmacist</style></keyword><keyword><style face="normal" font="default"> Philippines</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Self-management</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Social Support</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="5" Month="1" Year="2017">2017/1/5</year></dates><abstract><style face="normal" font="default">REALISE Asia-an online questionnaire-based study of Asian asthma patients-identified five patient clusters defined in terms of their control status and attitude towards their asthma (categorised as: 'Well-adjusted and at least partly controlled'; 'In denial about symptoms'; 'Tolerating with poor control'; 'Adrift and poorly controlled'; 'Worried with multiple symptoms'). We developed consensus recommendations for tailoring management of these attitudinal-control clusters. An expert panel undertook a three-round electronic Delphi (e-Delphi): Round 1: panellists received descriptions of the attitudinal-control clusters and provided free text recommendations for their assessment and management. Round 2: panellists prioritised Round 1 recommendations and met (or joined a teleconference) to consolidate the recommendations. Round 3: panellists voted and prioritised the remaining recommendations. Consensus was defined as Round 3 recommendations endorsed by >50% of panellists. Highest priority recommendations were those receiving the highest score. The multidisciplinary panellists (9 clinicians, 1 pharmacist and 1 health social scientist; 7 from Asia) identified consensus recommendations for all clusters. Recommended pharmacological (e.g., step-up/down; self-management; simplified regimen) and non-pharmacological approaches (e.g., trigger management, education, social support; inhaler technique) varied substantially according to each cluster's attitude to asthma and associated psychosocial drivers of behaviour. The attitudinal-control clusters defined by REALISE Asia resonated with the international panel. Consensus was reached on appropriate tailored management approaches for all clusters. Summarised and incorporated into a structured management pathway, these recommendations could facilitate personalised care. Generalisability of these patient clusters should be assessed in other socio-economic, cultural and literacy groups and nationalities in Asia</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 2055-1010 (Electronic)IS - 2055-1010 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Singapore -CO - Philippines -CO - South Korea -CO - Hong Kong -CO - Netherlands -CO - Malaysia -</style></notes><work-type><style face="normal" font="default">10.1038/npjpcrm.2016.89</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28055000">PM:28055000</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\NPJ Prim Care Respir Med\2016-26-16089.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\NPJ Prim Care Respir Med\2016-26-16089.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Chisholm A</style></custom2><misc3><style face="normal" font="default">10.1038/npjpcrm.2016.89</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40419</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tagiyeva,N.</style></author><author><style face="normal" font="default"> McLean,S.</style></author><author><style face="normal" font="default"> Sheikh,A.</style></author><author><style face="normal" font="default"> Julious,S.</style></author><author><style face="normal" font="default"> Thomas,M.</style></author><author><style face="normal" font="default"> Paton,J.</style></author><author><style face="normal" font="default"> Pinnock,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Asthma UK Centre for Applied Research, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK</style></auth-address><titles><title><style face="normal" font="default">Protocol for a systematic review to identify and weight the indicators of risk of asthma exacerbations in children aged 5-12 years</style></title><secondary-title><style face="normal" font="default">NPJ Prim Care Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">NPJ Prim Care Respir Med</style></full-title></periodical><pages end="" start="16088">16088-</pages><volume><style face="normal" font="default">27</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="5" Month="1" Year="2017">2017/1/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 2055-1010 (Electronic)IS - 2055-1010 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1038/npjpcrm.2016.88</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28055001">PM:28055001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\NPJ Prim Care Respir Med\2016-26-16088.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\NPJ Prim Care Respir Med\2016-26-16088.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, TagiYeva N</style></custom2><misc3><style face="normal" font="default">10.1038/npjpcrm.2016.88</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40420</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Halnes,I.</style></author><author><style face="normal" font="default"> Baines,K.J.</style></author><author><style face="normal" font="default"> Berthon,B.S.</style></author><author><style face="normal" font="default"> Donald-Wicks,L.K.</style></author><author><style face="normal" font="default"> Gibson,P.G.</style></author><author><style face="normal" font="default"> Wood,L.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Healthy Lungs, Hunter Medical Research Institute, University of Newcastle, Callaghan, NSW 2308, Australia.</style></auth-address><titles><title><style face="normal" font="default">Soluble Fibre Meal Challenge Reduces Airway Inflammation and Expression of GPR43 and GPR41 in Asthma</style></title><secondary-title><style face="normal" font="default">Nutrients</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nutrients</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acids</style></keyword><keyword><style face="normal" font="default"> activation</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal model</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Carbohydrates</style></keyword><keyword><style face="normal" font="default"> Cell Count</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Fatty acid</style></keyword><keyword><style face="normal" font="default"> Fatty Acids</style></keyword><keyword><style face="normal" font="default"> G protein-coupled receptor</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> induced sputum</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Interleukin-8</style></keyword><keyword><style face="normal" font="default"> Inulin</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pilot study</style></keyword><keyword><style face="normal" font="default"> Probiotics</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> single dose</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="default">Short chain fatty acids (SCFAs) are produced following the fermentation of soluble fibre by gut bacteria. In animal models, both dietary fibre and SCFAs have demonstrated anti-inflammatory effects via the activation of free fatty acid receptors, such as G protein-coupled receptor 41 and 43 (GPR41 and GPR43). This pilot study examined the acute effect of a single dose of soluble fibre on airway inflammation-including changes in gene expression of free fatty acid receptors-in asthma. Adults with stable asthma consumed a soluble fibre meal (n = 17) containing 3.5 g inulin and probiotics, or a control meal (n = 12) of simple carbohydrates. Exhaled nitric oxide (eNO) was measured and induced sputum was collected at 0 and 4 h for differential cell counts, measurement of interleukin-8 (IL-8) protein concentration, and GPR41 and GPR43 gene expression. At 4 h after meal consumption, airway inflammation biomarkers, including sputum total cell count, neutrophils, macrophages, lymphocytes, sputum IL-8, and eNO significantly decreased compared to baseline in the soluble fibre group only. This corresponded with upregulated GPR41 and GPR43 sputum gene expression and improved lung function in the soluble fibre group alone. Soluble fibre has acute anti-inflammatory effects in asthmatic airways. Long-term effects of soluble fibre as an anti-inflammatory therapy in asthma warrants further investigation</style></abstract><notes><style face="normal" font="default">DA - 20170111IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.3390/nu9010057</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28075383">PM:28075383</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nutrients\20170111-HalnesI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nutrients\20170111-HalnesI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170111, Halnes I</style></custom2><misc3><style face="normal" font="default">10.3390/nu9010057</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40421</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kang,J.</style></author><author><style face="normal" font="default"> Song,J.</style></author><author><style face="normal" font="default"> Shen,S.</style></author><author><style face="normal" font="default"> Li,B.</style></author><author><style face="normal" font="default"> Yang,X.</style></author><author><style face="normal" font="default"> Chen,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hubei Key Laboratory of Genetic Regulation and Integrative Biology, School of Life Sciences, Central China Normal University, Wuhan 430079, Hubei, China</style></auth-address><titles><title><style face="normal" font="default">Diisononyl phthalate aggravates allergic dermatitis by activation of NF-kB</style></title><secondary-title><style face="normal" font="default">Oncotarget</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Oncotarget</style></abbr-1></periodical><pages end="85482" start="85472">85472-85482</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">51</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidemiological studies</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Fluorescein</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> TH2 cytokines</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="11" Year="2016">2016/11/16</year></dates><abstract><style face="normal" font="default">Several epidemiological studies have suggested a possible link between exposure to Diisononyl phthalate (DINP) and the development of allergies. These findings remain controversial since there is insufficient scientific evidence to assess the ability of DINP to influence allergic immune responses. In addition, the mechanisms behind DINP-caused allergic diseases have not been fully elucidated. In this study, Balb/c mice were orally exposed to DINP for 3 weeks and were then sensitized with fluorescein isothiocyanate (FITC). We showed that oral exposure to DINP could aggravate allergic-dermatitis-like lesions, indicated by an increase in the number of mast cells, and in increased skin edema in FITC-induced contact hypersensitivity. This deterioration was concomitant with increased total serum immunoglobulin-E and Th2 cytokines. We determined the oxidative damage and the activation of nuclear factor-kb (NF-kB). The data demonstrated that DINP could promote oxidative damage and the activation of NF-kB in the skin. The expression of thymic stromal lymphopoietin and the activation of signal transducer and activator of transcriptions 3, 5 and 6 were enhanced concomitant with exacerbated allergic dermatitis effects and the activation of NF-kB induced by DINP. These effects were alleviated by pyrollidine dithiocarbamate, an inhibitor of NF-kB. The results suggest that oral exposure to DINP aggravated allergic contact dermatitis, which was positively regulated via NF-kB</style></abstract><notes><style face="normal" font="default">DA - 20161118IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.18632/oncotarget.13403</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27863430">PM:27863430</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Oncotarget\2016-7-85472-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Oncotarget\2016-7-85472-82.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161118, Kang J</style></custom2><misc3><style face="normal" font="default">10.18632/oncotarget.13403</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40422</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Movassagh,H.</style></author><author><style face="normal" font="default"> Tatari,N.</style></author><author><style face="normal" font="default"> Shan,L.</style></author><author><style face="normal" font="default"> Koussih,L.</style></author><author><style face="normal" font="default"> Alsubait,D.</style></author><author><style face="normal" font="default"> Khattabi,M.</style></author><author><style face="normal" font="default"> Redhu,N.S.</style></author><author><style face="normal" font="default"> Roth,M.</style></author><author><style face="normal" font="default"> Tamm,M.</style></author><author><style face="normal" font="default"> Chakir,J.</style></author><author><style face="normal" font="default"> Gounni,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada</style></auth-address><titles><title><style face="normal" font="default">Human airway smooth muscle cell proliferation from asthmatics is negatively regulated by semaphorin3A</style></title><secondary-title><style face="normal" font="default">Oncotarget</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Oncotarget</style></abbr-1></periodical><pages end="80251" start="80238">80238-80251</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">49</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway remodeling</style></keyword><keyword><style face="normal" font="default"> airway smooth muscle</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cell Proliferation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human airway smooth muscle</style></keyword><keyword><style face="normal" font="default"> Hyperplasia</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Lung Diseases</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Tyrosine</style></keyword><keyword><style face="normal" font="default"> tyrosine phosphorylation</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="25" Month="10" Year="2016">2016/10/25</year></dates><abstract><style face="normal" font="default">Airway smooth muscle (ASM) hyperplasia is a key feature of airway remodeling in development of lung diseases such as asthma. Anomalous proliferation of ASM cells directly contributes to ASM hyperplasia. However, the molecular mechanisms controlling ASM cell proliferation are not completely understood. Semaphorins are versatile regulators of various cellular processes including cell growth and proliferation. The role of semaphorins in ASM cell proliferation has remained to be addressed. Here, we report that semaphorin 3A (Sema3A) receptor, neuropilin 1 (Nrp1), is expressed on human ASM cells (HASMC) isolated from healthy and asthmatic donors and treatment of these cells with exogenous Sema3A inhibits growth factor-induced proliferation. Sema3A inhibitory effect on HASMC proliferation is associated with decreased tyrosine phosphorylation of PDGFR, downregulation of Rac1 activation, STAT3 and GSK-3beta phosphorylation. Bronchial sections from severe asthmatics displayed immunoreactivity of Nrp1, suggestive of functional contribution of Sema3A-Nrp1 axis in airway remodeling. Together, our data suggest Sema3A-Nrp1 signaling as a novel regulatory pathway of ASM hyperplasia</style></abstract><notes><style face="normal" font="default">DA - 20161028IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - ENGPT - Journal ArticleCO - Canada -CO - United States -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.18632/oncotarget.12884</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27791986">PM:27791986</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Oncotarget\2016-7-80238-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Oncotarget\2016-7-80238-51.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161028, Movassagh H</style></custom2><misc3><style face="normal" font="default">10.18632/oncotarget.12884</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40423</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,J.</style></author><author><style face="normal" font="default"> Zhou,X.</style></author><author><style face="normal" font="default"> Zhu,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, China</style></auth-address><titles><title><style face="normal" font="default">Beauveria attenuates asthma by inhibiting inflammatory response and inducing lymphocytic cell apoptosis</style></title><secondary-title><style face="normal" font="default">Oncotarget</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Oncotarget</style></abbr-1></periodical><pages end="74568" start="74557">74557-74568</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">46</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> Apoptosis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="default"> Cell Proliferation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> IL-12</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory mediators</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> Interferon-gamma</style></keyword><keyword><style face="normal" font="default"> Interleukin-12</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="27" Month="10" Year="2016">2016/10/27</year></dates><abstract><style face="normal" font="default">The present study aimed to investigate the role of beauveria (BEA) in asthma. We investigated the cytotoxic effect of BEA on the proliferation of inflammatory cells and secretion of inflammatory mediators both in-vitro and in-vivo. In in-vitro studies, BEA inhibited lymphocytic cell proliferation and the proliferation of lymphocytic cells induced by Phorbol-12-myristate-13-acetate (PMA). We used ELISA to test the effects of BEA on the secretion of inflammatory factors including tumor necrosis factor-alpha (TNF-alpha), interleukin-12 (IL-12) and interferon-gamma (IFN-gamma). Flow cytometry was used to evaluate the influence of BEA on cell apoptosis. The effect of BEA on the cell numbers of eosinophils, lymphocytes, macrophages, neutrophils and other cells in mouse bronchoalveolar lavage fluid (BALF) was also evaluated. The expression of apoptosis related molecules Bax, Caspase-3 and Bcl-2 was examined by Western blotting analysis. Our results indicated that BEA played a protective role in asthma. BEA inhibited lymphocytic cell proliferation and secretion of inflammatory mediators. BEA promoted cell apoptosis, stimulated the expression of Bax and Caspase-3 and inhibited Bcl-2 protein expression in a dose-dependent manner. In in-vivo experiments, BEA reduced the cell number of eosinophils, lymphocytes, macrophages, neutrophils and other cells in mouse BALF. BEA inhibited secretion of inflammatory mediators, stimulated expression of Bax and Caspase-3, and inhibited expression of Bcl-2 in mouse lung tissue dose-dependently. All together, our results indicated that BEA could attenuate asthma by inhibiting inflammatory response and induce apoptosis of inflammatory cells</style></abstract><notes><style face="normal" font="default">DA - 20161101IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - ENGPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.18632/oncotarget.12958</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27801673">PM:27801673</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Oncotarget\2016-7-74557-68.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Oncotarget\2016-7-74557-68.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161101, Zhang J</style></custom2><misc3><style face="normal" font="default">10.18632/oncotarget.12958</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40424</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zamanfar,D.</style></author><author><style face="normal" font="default"> Gaffari,J.</style></author><author><style face="normal" font="default"> Behzadnia,S.</style></author><author><style face="normal" font="default"> Yazdani-Charati,J.</style></author><author><style face="normal" font="default"> Tavakoli,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Infectious Disease Research Center with Focus on Nosocomial Infection, Department of Pediatrics, Mazandaran University of Medical Sciences, Sari, Iran</style></auth-address><titles><title><style face="normal" font="default">The Prevalence of Allergic Rhinitis, Eczema and Asthma in Students of Guidance Schools in Mazandaran Province, Iran</style></title><secondary-title><style face="normal" font="default">Open Access Maced J Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Open Access Maced J Med Sci</style></full-title></periodical><pages end="623" start="619">619-623</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pets</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Sneezing</style></keyword><keyword><style face="normal" font="default"> Software</style></keyword><keyword><style face="normal" font="default"> Sport</style></keyword><keyword><style face="normal" font="default"> Students</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="15" Month="12" Year="2016">2016/12/15</year></dates><abstract><style face="normal" font="default">BACKGROUND: Eczema, allergic rhinitis and asthma are common chronic allergic disorders in childhood. AIM: The aim of this study was to determine the prevalence of common allergic disorders among Iranian guidance schools students in Mazandaran Province, northern Iran. METHODS: This analytical cross-sectional study was performed on 3000 children aged 11-14 years old during 2012-13 according to ISAAC study. Of 3000 recruited children 1576 (52.54%) were female and 1424 (47.46%) were male. Data gathered by ISAAC first phase questionnaire analysed by SPSS software 20. RESULTS: The prevalence of wheezing, allergic rhinitis symptoms (sneezing and pruritus) and atopic dermatitis symptoms (pruritus skin lesion) were 30.5%, 30% and 15% respectively. History of pets contact and smoking was positive 6.6% and 36 % respectively. About 52% was born with caesarian section. There was wheezing in 32.5% during sport. The diagnosis of asthma, allergic rhinitis and eczema were 12.2%, 28.5% and 15% respectively. Eczema, asthma and allergic rhinitis were significantly more common in boys students (p &lt; 0.05). CONCLUSIONS: The results of this study showed that asthma, allergic rhinitis and eczema have a high prevalence and they are more common in boys</style></abstract><notes><style face="normal" font="default">DA - 20161228IS - 1857-9655 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">10.3889/oamjms.2016.112</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28028401">PM:28028401</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Open Access Maced J Med Sci\2016-4-619-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Open Access Maced J Med Sci\2016-4-619-23.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161228, Zamanfar D</style></custom2><misc3><style face="normal" font="default">10.3889/oamjms.2016.112</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40425</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Miyazaki,D.</style></author><author><style face="normal" font="default"> Fukushima,A.</style></author><author><style face="normal" font="default"> Ohashi,Y.</style></author><author><style face="normal" font="default"> Ebihara,N.</style></author><author><style face="normal" font="default"> Uchio,E.</style></author><author><style face="normal" font="default"> Okamoto,S.</style></author><author><style face="normal" font="default"> Shoji,J.</style></author><author><style face="normal" font="default"> Takamura,E.</style></author><author><style face="normal" font="default"> Nakagawa,Y.</style></author><author><style face="normal" font="default"> Namba,K.</style></author><author><style face="normal" font="default"> Fujishima,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Ophthalmology and Visual Science, Faculty of Medicine, Tottori University, Tottori, Japan.</style></auth-address><titles><title><style face="normal" font="default">Steroid-Sparing Effect of 0.1% Tacrolimus Eye Drop for Treatment of Shield Ulcer and Corneal Epitheliopathy in Refractory Allergic Ocular Diseases</style></title><secondary-title><style face="normal" font="default">Ophthalmology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ophthalmology</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adjuvant</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="default"> Betamethasone</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical signs</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Conjunctivitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Ocular</style></keyword><keyword><style face="normal" font="default"> Ophthalmology</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral steroids</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Staining</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Tacrolimus</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Ulcer</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="22" Month="12" Year="2016">2016/12/22</year></dates><abstract><style face="normal" font="default">PURPOSE: To evaluate the effects of 0.1% topical tacrolimus alone or in combination with steroids for the treatment of shield ulcers and corneal epitheliopathy in patients with refractory allergic ocular diseases. DESIGN: Open cohort study. PARTICIPANTS: Patients with refractory allergic conjunctivitis epitheliopathy, shield ulcers, or corneal plaques (N = 791). METHODS: The 791 patients were treated with topical tacrolimus alone or in combination with topical or oral steroids. The effectiveness of the treatments was determined by a corneal epitheliopathy score during the 3-month follow-up period. The clinical signs were rated on a 4-grade scale. Corneal epitheliopathy with no corneal staining was graded as 0, and shield ulcers or plaques were graded as 3, the highest grade. The effects of tacrolimus with and without topical steroids on the epitheliopathy scores were assessed after adjustments for the severity of the clinical signs and characteristics. MAIN OUTCOME MEASURES: Changes in the corneal epitheliopathy score. RESULTS: Adjusted mean epitheliopathy score at the baseline was 1.73 (95% confidence interval [CI], 1.65-1.81) for patients treated with tacrolimus alone, and this was significantly reduced by -0.93 at 1 month. The reduction of the score by topical and oral steroids was -0.02 for fluorometholone, 0.02 for betamethasone, and -0.02 for oral steroids, and these reductions were not significant compared with the reduction effect of topical tacrolimus alone at -0.93. The 238 patients with shield ulcer (score 3) were analyzed with adjustments, and the mean epitheliopathy score at 1 month was reduced to 1.38 with tacrolimus alone (95% CI, 1.24-1.51), 1.41 (95% CI, 1.26-1.56) with adjuvant fluorometholone, and 1.46 (95% CI, 1.32-1.61) with adjuvant betamethasone. No significant difference was observed in the adjunctive topical steroids. The presence of severe palpebral conjunctival symptoms, including giant papillae, was a significant resisting factor for topical tacrolimus. CONCLUSIONS: The significant effects of topical tacrolimus alone on shield ulcers and corneal epitheliopathy suggest that it may be used without the need for steroids</style></abstract><notes><style face="normal" font="default">DA - 20161226IS - 1549-4713 (Electronic)IS - 0161-6420 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.ophtha.2016.11.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28017421">PM:28017421</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ophthalmology\20161226-MiyazakiD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ophthalmology\20161226-MiyazakiD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161226, Miyazaki D</style></custom2><misc3><style face="normal" font="default">10.1016/j.ophtha.2016.11.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40426</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,I.S.</style></author><author><style face="normal" font="default"> Ahn,H.J.</style></author><author><style face="normal" font="default"> Kim,K.H.</style></author><author><style face="normal" font="default"> Park,J.</style></author><author><style face="normal" font="default"> Kim,Y.</style></author><author><style face="normal" font="default"> Han,J.W.</style></author><author><style face="normal" font="default"> Kim,D.H.</style></author><author><style face="normal" font="default"> Jung,J.H.</style></author><author><style face="normal" font="default"> Jung,H.J.</style></author><author><style face="normal" font="default"> Jang,H.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">The effects of Baekho-tang on 1-Fluoro-2, 4-dinitrofluorobenzene-induced allergic contact dermatitis in BALB/c mice</style></title><secondary-title><style face="normal" font="default">Oriental Pharm Exp Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Oriental Pharm Exp Med</style></full-title></periodical><pages end="354" start="349">349-354</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Encephalitis</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Hepatitis</style></keyword><keyword><style face="normal" font="default"> Hepatitis B</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Meningitis</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pneumonia</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> Splenomegaly</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="default">2211-1069</style></isbn><abstract><style face="normal" font="default">Allergic contact dermatitis (ACD) is a cutaneous inflammatory response that is characterized skin lesion, increased cytokines secretion and splenomegaly. Baekho-tang (BHT) has been clinically used for the treatment of heat-related illnesses in Korea. Recently, it was reported that has an effect on epidemics such as hepatitis B, pneumonia, epidemic cerebrospinal meningitis and Japanese encephalitis. However, the effects of BHT on ACD is not yet fully studied. Therefore, the aims of this study was to determine the anti-allergic effects of BHT on 2, 4-dinitrofluorobenzene (DNFB)-induced ACD mice by investigating histopathologic examination of DNFB-induced inflamed tissues. Also, cytokines secretion in serum was determined using multiplex assay. The topical repeated application of DNFB on the dorsal skin of BALB/c mice were manifested the typical ACD. Treatment of different dose of BHT (20 or 80-ámg/kg) attenuated DNFB-induced inflamed tissues such as erythema and crust. In addition, there is a trend for decreased serum cytokines levels in the treatment of high dose of BHT. Our results recommend that the high dose of BHT enhances the DNFB-induced ACD in mice</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1007/s13596-016-0250-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s13596-016-0250-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Oriental Pharm Exp Med\2016-16-349-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Oriental Pharm Exp Med\2016-16-349-54.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170210, Lee IS</style></custom2><misc3><style face="normal" font="default">10.1007/s13596-016-0250-x</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40427</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lohmann,C.H.</style></author><author><style face="normal" font="default"> Hameister,R.</style></author><author><style face="normal" font="default"> Singh,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Orthopaedic Surgery, Otto-von-Guericke University, 44, Leipziger Strasse, 39120 Magdeburg, Germany.</style></auth-address><titles><title><style face="normal" font="default">Allergies in orthopaedic and trauma surgery</style></title><secondary-title><style face="normal" font="default">Orthop Traumatol Surg Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Orthop Traumatol Surg Res</style></abbr-1></periodical><pages end="S81" start="S75">S75-S81</pages><volume><style face="normal" font="default">103</style></volume><number><style face="normal" font="default">1S</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Alloys</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Bone Resorption</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Haptens</style></keyword><keyword><style face="normal" font="default"> Histology</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> LTT</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Activation</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Transformation</style></keyword><keyword><style face="normal" font="default"> Lymphocyte transformation test</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> metal hypersensitivity</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> T lymphocyte</style></keyword><keyword><style face="normal" font="default"> T lymphocytes</style></keyword><keyword><style face="normal" font="default"> T-lymphocyte</style></keyword><keyword><style face="normal" font="default"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Titanium</style></keyword><keyword><style face="normal" font="default"> Transformation</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Hypersensitivity reactions to implants in orthopaedic and trauma surgery are a rare but devastating complication. They are considered as a delayed-type of hypersensitivity reaction (type IV), characterized by an antigen activation of sensitized T-lymphocytes releasing various cytokines and may result in osteoclast activation and bone resorption. Potential haptens are originated from metal alloys or bone-cement. A meta-analysis has confirmed a higher probability of developing a metal hypersensitivity postoperatively and noted a greater risk of failed replacements compared to stable implants. Hypersensitivity to implants may present with a variety of symptoms such as pain, joint effusion, delayed wound/bone healing, persistent secretion, allergic dermatitis (localized or systemic), clicking noises, loss of joint function, instability and failure of the implant. Various diagnostic options have been offered, including patch testing, metal alloy patch testing, histology, lymphocyte transformation test (LTT), memory lymphocyte immunostimulation assay (MELISA), leukocyte migration inhibition test (LIF) and lymphocyte activation test (LAT). No significant differences between in vivo and in vitro methods have been found. Due to unconvincing evidence for screening methods, predictive tests are not recommended for routine performance. Infectious aetiology always needs to be excluded. As there is a lack of evidence on large-scale studies with regards to the optimal treatment option, management currently relies on individual case-by-case decisions. Several options for patients with (suspected) metal-related hypersensitivity exist and may include materials based on ceramic, titanium or oxinium or modified surfaces. Promising results have been reported, but long-term experience is lacking. More large-scaled studies are needed in this context. In patients with bone-cement hypersensitivity, the component suspected for hypersensitivity should be avoided. The development of (predictive) biomarkers is considered as a major contribution for the future</style></abstract><notes><style face="normal" font="default">DA - 20170103IS - 1877-0568 (Electronic)IS - 1877-0568 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Germany -CO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1016/j.otsr.2016.06.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28043850">PM:28043850</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Orthop Traumatol Surg Res\2017-103-S75-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Orthop Traumatol Surg Res\2017-103-S75-81.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170103, Lohmann CH</style></custom2><misc3><style face="normal" font="default">10.1016/j.otsr.2016.06.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40428</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chastang,J.</style></author><author><style face="normal" font="default"> Baiz,N.</style></author><author><style face="normal" font="default"> Parnet,L.</style></author><author><style face="normal" font="default"> Cadwallader,J.S.</style></author><author><style face="normal" font="default"> de Blay,F.</style></author><author><style face="normal" font="default"> Caillaud,D.</style></author><author><style face="normal" font="default"> Charpin,D.A.</style></author><author><style face="normal" font="default"> Dwyer,J.</style></author><author><style face="normal" font="default"> Lavaud,F.</style></author><author><style face="normal" font="default"> Raherison,C.</style></author><author><style face="normal" font="default"> Ibanez,G.</style></author><author><style face="normal" font="default"> Annesi-Maesano,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universites Paris Sorbonne, UPMC Univ Paris 06, INSERM, Institut Pierre Louis d'Epidemiologie et de Sante Publique (IPLESP UMRS 1136 Equipe Epidemiologie des maladies allergiques et respiratoires (EPAR), Faculte de medecine de l'hopital Saint-Antoine, 75012, Paris, France</style></auth-address><titles><title><style face="normal" font="default">Changes in body mass index during childhood and risk of various asthma phenotypes: a retrospective analyse</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> allergique</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> Birth Weight</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Challenge test</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiologie</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Exercise-induced asthma</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> overweight</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Schoolchildren</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="31" Month="1" Year="2017">2017/1/31</year></dates><abstract><style face="normal" font="default">BACKGROUND: It is known that asthma is related to obesity but also to small birth weight. The objective of the present study was to clarify this issue by assessing the putative relationship between the change between birth and childhood in child's corpulence as assessed by body mass index (BMI) and asthma phenotypes. METHODS: The following status in corpulence were assessed in 7781 schoolchildren using quartile of BMI at birth and at around 10 (9-11years): underweight at birth and at around 10, underweight at birth and overweight at around 10, overweight at birth and underweight at around 10, overweight at birth and at around 10 and the reference group constituted by all the other children in whom corpulence changes were not extreme. Determination of asthma phenotypes (allergic, non-allergic and exercise-induced asthma) was based on a clinical examination including skin prick tests, an exercise challenge test and a questionnaire. RESULTS: The risk of allergic asthma was higher in children with persistent underweight, children with persistent overweight and children becoming markedly more corpulent. In boys, the risk of allergic asthma was significantly higher for the less corpulent children at birth, regardless of whether they remained so or become overweight. In girls, the risk of allergic asthma was significantly higher in those with persistent overweight. There were no significant associations between BMI changes and non-allergic and exercise-induced asthma. CONCLUSIONS: We observed that some extreme changes in BMI, persistent underweight and persistent overweight in childhood increased the risk of allergic asthma</style></abstract><notes><style face="normal" font="default">DA - 20170131IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12699</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28140475">PM:28140475</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170131-ChastangJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170131-ChastangJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170131, Chastang J</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12699</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40429</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Raywood,E.</style></author><author><style face="normal" font="default"> Lum,S.</style></author><author><style face="normal" font="default"> Aurora,P.</style></author><author><style face="normal" font="default"> Pike,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory, Critical Care and Anaesthesia Section, University College London Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">The bronchodilator response in preschool children: A systematic review</style></title><secondary-title><style face="normal" font="default">Pediatr Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Pulmonol</style></full-title></periodical><pages end="1250" start="1242">1242-1250</pages><volume><style face="normal" font="default">51</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Airways disease</style></keyword><keyword><style face="normal" font="default"> Anaesthesia</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Decision Making</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Interpretation</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Oscillometry</style></keyword><keyword><style face="normal" font="default"> Periodicals</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> Plethysmography</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> preschool children</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: The bronchodilator response (BDR) is frequently used to support diagnostic and therapeutic decision-making for children who wheeze. However, there is little evidence-based guidance describing the role of BDR testing in preschool children and it is unclear whether published cut-off values, which are derived from adult data, can be applied to this population. METHODS: We searched MEDLINE, EMBASE, Web of Science, and Cochrane databases (inception-September 2015) for studies reporting response to a bronchodilator in healthy preschool children, response following placebo inhalation, and the diagnostic efficacy of BDR compared with a clinical diagnosis of asthma/recurrent wheezing. FINDINGS: We included 14 studies. Thirteen studies provided BDR data from healthy preschool children. Two studies reported response to placebo in preschool children with asthma/recurrent wheezing. Twelve studies compared BDR measurements from preschool children with asthma/recurrent wheeze to those from healthy children and seven of these studies reported diagnostic efficacy. Significant differences between the BDR measured in healthy preschool children compared with that in children with asthma/recurrent wheeze were demonstrated in some, but not all studies. Techniques such as interrupter resistance, oscillometry, and plethysmography were more consistently successfully completed than spirometry. Between study heterogeneity precluded determination of an optimum technique. INTERPRETATION: There is little evidence to suggest spirometry-based BDR can be used in the clinical assessment of preschool children who wheeze. Further evaluation of simple alternative techniques is required. Future studies should recruit children in whom airways disease is suspected and should evaluate the ability of BDR testing to predict treatment response. Pediatr Pulmonol. 2016;51:1242-1250. (c) 2016 Wiley Periodicals, Inc</style></abstract><notes><style face="normal" font="default">DA - 20160608IS - 1099-0496 (Electronic)IS - 1099-0496 (Linking)LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1002/ppul.23459</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27273556">PM:27273556</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Pulmonol\2016-51-1242-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Pulmonol\2016-51-1242-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160608, Raywood</style></custom2><misc3><style face="normal" font="default">10.1002/ppul.23459</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40430</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Buchvald,F.</style></author><author><style face="normal" font="default"> Phillipsen,L.D.</style></author><author><style face="normal" font="default"> Hjuler,T.</style></author><author><style face="normal" font="default"> Nielsen,K.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Pulmonary Service, Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Denmark</style></auth-address><titles><title><style face="normal" font="default">Exercise-induced inspiratory symptoms in school children</style></title><secondary-title><style face="normal" font="default">Pediatr Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Pulmonol</style></full-title></periodical><pages end="1205" start="1200">1200-1205</pages><volume><style face="normal" font="default">51</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">abnormalities</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Exercise Test</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Laryngoscopy</style></keyword><keyword><style face="normal" font="default"> Larynx</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Periodicals</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND AND AIMS: Exercise-induced inspiratory symptoms (EIIS) have multiple causes, one of which is exercise-induced laryngeal obstruction (EILO). There is limited knowledge regarding EIIS in children, both in primary care practices and in pediatric asthma clinics. The aim of this study was to describe the feasibility of a diagnostic methodology and its results in a cohort of children with EIIS referred to our tertiary pediatric pulmonary center. METHODS: This study analyzed consecutively collected data in children from East Denmark and Greater Copenhagen referred during a 3(1/2) years period. The continuous laryngoscopy exercise (CLE) test directly visualizes the larynx using a flexible laryngoscope during a maximal exercise test. A post-test questionnaire evaluated the subjective impact of the examination. RESULTS: The study included 60 children (37 girls/23 boys) with a mean age of 14 years (range 9-18). The feasibility of the CLE test was 98%; 18 children (35%) had EILO, while 33 children (61%) showed no abnormalities. Other laryngeal abnormalities were observed in three children before the exercise test. Asthma medication was successfully discontinued in 13 (72%) children with EILO. A significantly greater proportion of children shown to have EILO in the CLE test reported coping better with their EIIS than children with negative test (85% vs. 45%; P = 0.03). CONCLUSIONS: Continuous laryngoscopy during exercise is feasible and useful for identifying children with EILO. A correct diagnosis of EILO can help relieve patient anxiety, improve their coping with symptoms, and prevent unnecessary long-term and potentially harmful asthma treatments involving high-dose inhaled steroids. Pediatr Pulmonol. 2016;51:1200-1205. (c) 2016 Wiley Periodicals, Inc</style></abstract><notes><style face="normal" font="default">- Denmark -DA - 20161007IS - 1099-0496 (Electronic)IS - 1099-0496 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1002/ppul.23530</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27717246">PM:27717246</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Pulmonol\2016-51-1200-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Pulmonol\2016-51-1200-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161007, Buchvald F</style></custom2><misc3><style face="normal" font="default">10.1002/ppul.23530</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40431</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ahmadizar,F.</style></author><author><style face="normal" font="default"> Souverein,P.C.</style></author><author><style face="normal" font="default"> Arets,H.G.</style></author><author><style face="normal" font="default"> de Boer,A.</style></author><author><style face="normal" font="default"> Maitland-van der Zee,A.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Asthma related medication use and exacerbations in children and adolescents with type 1 diabetes</style></title><secondary-title><style face="normal" font="default">Pediatr Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Pulmonol</style></full-title></periodical><pages end="1121" start="1113">1113-1121</pages><volume><style face="normal" font="default">51</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Insulin</style></keyword><keyword><style face="normal" font="default"> linkage</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Muscarinic antagonist</style></keyword><keyword><style face="normal" font="default"> Muscarinic Antagonists</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Periodicals</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To investigate the use of asthma medication and occurrence of asthma exacerbations up to 5 years before and after the onset of type 1 diabetes mellitus (T1DM) in children and adolescents. METHODS: Children and adolescents younger than 19 years with at least 2 insulin prescriptions between 1999 and 2009 classified as T1DM cohort (n = 915) and a 4 times larger reference cohort (n = 3,590) with the same age and gender were identified from the Dutch PHARMO Record Linkage System. The date of first insulin dispensing was selected as the index date. RESULTS: The 5-year prevalence rate of asthma medication use in the T1DM cohort (23.2%) was significantly higher than the reference cohort (18.3%) after the onset of diabetes. No statistically significant difference between the two cohorts was observed in the use of specific types of asthma medication except for short acting muscarinic antagonists that were significantly more used in the T1DM cohort (5.5%) compared with the reference cohort (0.62%) after the onset of diabetes. The incidence rate of asthma medication use declined over time with a peak in the T1DM cohort the 1st year after the onset of diabetes. Furthermore, 1 year after the index date there was a peak in incidence rate of asthma exacerbations in both T1DM (7.8 per 1,000 person year) and reference (6.8 per 1,000 person year) cohorts. CONCLUSIONS: T1DM is associated with statistically significantly higher asthma medication use after the onset of T1DM, especially in the 1st year after the onset of diabetes. Pediatr Pulmonol. 2016;51:1113-1121. (c) 2016 Wiley Periodicals, Inc</style></abstract><notes><style face="normal" font="default">DA - 20160502IS - 1099-0496 (Electronic)IS - 1099-0496 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1002/ppul.23428</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27132537">PM:27132537</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Pulmonol\2016-51-1113-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Pulmonol\2016-51-1113-21.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160502, Ahmadizar F</style></custom2><misc3><style face="normal" font="default">10.1002/ppul.23428</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40432</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ehsan,Z.</style></author><author><style face="normal" font="default"> Kercsmar,C.M.</style></author><author><style face="normal" font="default"> Collins,J.</style></author><author><style face="normal" font="default"> Simakajornboon,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric Pulmonology and Sleep Medicine, Children's Mercy Hospital, Kansas City, Missouri.</style></auth-address><titles><title><style face="normal" font="default">Validation of the pediatric sleep questionnaire in children with asthma</style></title><secondary-title><style face="normal" font="default">Pediatr Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Pulmonol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Apnea</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Kansas</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Missouri</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Obstructive sleep apnea</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Periodicals</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Sleep apnea</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The prevalence of obstructive sleep apnea (OSA) is higher in children with poorly controlled asthma. We aimed to determine the validity of the Pediatric Sleep Questionnaire (PSQ) to screen for OSA in children with asthma. METHODS: This retrospective review encompassed sleep studies and medical records of asthmatic children evaluated in the sleep center at CCHMC over 13 years. Measures of validity were calculated using various cut-off values for obstructive apnea-hypopnea index (OI; >1, >2, >5) and PSQ scores (>0.33, >0.5). Correlation between PSQ and OI, PSQ and spirometry, and OI and spirometry was assessed using Spearman's correlation coefficient. RESULTS: One-hundred and sixty children were included (mean age 11 +/- 4 years; 64% males). The mean OI was 4.2 +/- 14.3 and the mean PSQ score was 0.57 +/- 0.19. Thirty-eight percent of patients had a diagnosis of allergic rhinitis. A total of 70 children (43%) were obese (BMI >/=95th percentile). The correlation between OI and PSQ was statistically significant (r = 0.19, P = 0.015). Using a PSQ cutoff of 0.33, and OI cutoffs of 1, 2, and 5, the sensitivities were 81.6%, 81.6%, and 76.2%, and the specificities were 13.1%, 14.4%, and 14.4%, respectively. When the cutoff for PSQ was raised to 0.5 and using an OI of 1, the sensitivity decreased to 71.1%, but the specificity increased to 36.9%. CONCLUSIONS: The sensitivity of PSQ in asthmatic children is high and comparable to previous studies, but the specificity is low. The PSQ may be considered a reasonable first-line screening tool for OSA in asthmatic children. Pediatr Pulmonol. 2016; 9999:XX-XX. (c) 2016 Wiley Periodicals, Inc</style></abstract><notes><style face="normal" font="default">DA - 20161027IS - 1099-0496 (Electronic)IS - 1099-0496 (Linking)LA - ENGPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1002/ppul.23568</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27787950">PM:27787950</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Pulmonol\20161027-EhsanZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Pulmonol\20161027-EhsanZ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161027, Ehsan Z</style></custom2><misc3><style face="normal" font="default">10.1002/ppul.23568</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40433</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bar-Yoseph,R.</style></author><author><style face="normal" font="default"> Kugelman,N.</style></author><author><style face="normal" font="default"> Livnat,G.</style></author><author><style face="normal" font="default"> Gur,M.</style></author><author><style face="normal" font="default"> Hakim,F.</style></author><author><style face="normal" font="default"> Nir,V.</style></author><author><style face="normal" font="default"> Bentur,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Pulmonology Institute, Ruth Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel</style></auth-address><titles><title><style face="normal" font="default">Halotherapy as asthma treatment in children: A randomized, controlled, prospective pilot study</style></title><secondary-title><style face="normal" font="default">Pediatr Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Pulmonol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Complement</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Periodicals</style></keyword><keyword><style face="normal" font="default"> Pilot study</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVES: Asthma is a chronic inflammatory disorder requiring intermittent or continuous anti-inflammatory therapy. Patients often turn to alternative treatments as complements or replacements to conventional treatments. We aimed to evaluate the effect of salt room chambers (halotherapy) on bronchial hyper-responsiveness (BHR), fractional exhaled nitric oxide (FeNO), and quality of life in children with asthma. PATIENTS AND METHODS: Children aged 5-13 years with a clinical diagnosis of mild asthma not receiving anti-inflammatory therapy. Patients were randomized in this double-blind, controlled study to salt room with halogenerator (treatment group), or without halogenerator (control group). We evaluated the effect of salt room therapy on BHR, FeNO, spirometry, and pediatric asthma quality of life questionnaire (PAQLQ). The treatment period lasted 7 weeks, 14 sessions. RESULTS: Twenty-nine patients were randomized to the salt room with halogenerator (treatment group), and 26 patients to the salt room without salt halogenerator (control group). A statistically significant improvement in BHR was demonstrated in the treatment group, which remained unchanged in the control group. There was no improvement in spirometry or FeNO levels following treatment. The treatment group showed a statistical improvement in most parameters of quality of life questionnaires. CONCLUSIONS: Our pilot study suggests that salt room with halogenerator, may have some beneficial effects in mild asthmatic children. Randomized and larger controlled trials with long-term follow-up are necessary. Pediatr Pulmonol. 2016; 9999:XX-XX. (c) 2016 Wiley Periodicals, Inc</style></abstract><notes><style face="normal" font="default">DA - 20161010IS - 1099-0496 (Electronic)IS - 1099-0496 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Israel -</style></notes><work-type><style face="normal" font="default">10.1002/ppul.23621</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27723955">PM:27723955</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Pulmonol\20161010-BarYosephR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Pulmonol\20161010-BarYosephR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161010, Bar-Yoseph R</style></custom2><misc3><style face="normal" font="default">10.1002/ppul.23621</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40434</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ali-Dinar,T.</style></author><author><style face="normal" font="default"> Lang,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary and Sleep Medicine, Nemours Children's Hospital, Orlando, Florida</style></auth-address><titles><title><style face="normal" font="default">Is impaired glucose metabolism the missing piece in the obesity-asthma puzzle?</style></title><secondary-title><style face="normal" font="default">Pediatr Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Pulmonol</style></full-title></periodical><pages end="150" start="147">147-150</pages><volume><style face="normal" font="default">52</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> Airway dysfunction</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="default"> epidemiologic study</style></keyword><keyword><style face="normal" font="default"> Florida</style></keyword><keyword><style face="normal" font="default"> Glucose</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Insulin</style></keyword><keyword><style face="normal" font="default"> Insulin Resistance</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Periodicals</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Obesity is a major risk factor for several conditions including atherosclerotic disease, metabolic syndrome, and upper airway dysfunction. However, the purported link between obesity and asthma has remained more difficult to define, in part due to limitations in past epidemiologic studies and the inherent challenge in accurately defining asthma in children. It is possible that obesity leads to asthma only in the presence of a mediating variable such as an obesity-related conditions such as esophageal reflux or insulin resistance. The article by Karampatakis and colleagues in this week's edition of the journal is important because it addresses the hypothesis that altered glucose metabolism/insulin resistance associates with bronchial hyperresponsiveness (BHR), a central and objectively measured marker of asthma. They studied pre-pubertal children with and without asthma with a range of body mass indices and found for the first time in pre-pubertal asthmatic children that both insulin resistance and impaired glucose tolerance were more closely related to BHR than was obesity. Their work opens the way for directed mechanistic study of the effects of impaired glucose metabolism on airway development during childhood and airway responsiveness, and for the study of insulin sensitizing therapies in children to prevent lower airway disease. Pediatr Pulmonol. 2016; 9999:XX-XX. (c) 2016 Wiley Periodicals, Inc</style></abstract><notes><style face="normal" font="default">DA - 20161017IS - 1099-0496 (Electronic)IS - 1099-0496 (Linking)LA - ENGPT - EDITORIALCO - United States -</style></notes><work-type><style face="normal" font="default">10.1002/ppul.23625</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27749021">PM:27749021</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Pulmonol\2017-52-147-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Pulmonol\2017-52-147-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161017, Ali-Dinar T</style></custom2><misc3><style face="normal" font="default">10.1002/ppul.23625</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40435</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Razi,C.H.</style></author><author><style face="normal" font="default"> Corut,N.</style></author><author><style face="normal" font="default"> Andiran,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pediatric Allergy, Acibadem, Ankara Private Hospital, Ankara, TurkeyDivision of Pediatric Allergy, Department of Pediatrics, Sami Ulus Pediatrics and Gynecology Education and Research Hospital, Ankara, TurkeyDepartment of Pediatrics, Kecioren Education and Research Hospital, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="default">Budesonide reduces hospital admission rates in preschool children with acute wheezing</style></title><secondary-title><style face="normal" font="default">Pediatr Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Pulmonol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">acute asthma</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Budesonide</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Methylprednisolone</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Periodicals</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> preschool children</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: The object of this study was to determine whether high doses of inhaled budesonide provide additional benefits to a standardized treatment regimen that includes systemic steroids and salbutamol in preschool patients presented to the emergency department (ED) with acute wheezing attacks. Methods This randomized, double-blind, placebo-controlled, parallel group trial was conducted in children, 6 months-6 years with moderate or severe acute wheezing epizode, as determined based on a pulmonary index score (PIS) of 7-13 points. We compared the addition of budesonide 3 mg versus placebo to standard acute asthma treatment, which included salbutamol and a single 1 mg/kg dose of methylprednisolone given at the beginning of therapy. The primary outcome was differences in hospitalization rates within 4 hr. Secondary outcome was difference in median PIS between treatment groups at 2 hr. Results One hundred patients were enrolled. Cumulative hospitalization rate at 120, 180, and 240 min were 0.72, 0.62, and 0.58 in placebo group; and 0.44, 0.30, and 0.24 in budesonide group. Discharged rate in budesonide group was significantly higher than the placebo group (log-rank = 12.407 ve P &lt; 0.001). Expected mean discharged times were 200.4 (95%CI = 185.3-215.5) min in placebo group and 164.4 (95%CI = 149.4-179.4) min in budesonide group. Median (25-75%) PIS at the 120th min was significantly lower in budesonide group than the placebo group (5 [4-8] vs. 8 [5-9] respectively, P = 0.006). Conclusions The addition of budesonide nebulization may decrease the admission rate of preschool children who have moderate to severe acute wheezing epizodes. Pediatr Pulmonol. (c) 2017 Wiley Periodicals, Inc</style></abstract><notes><style face="normal" font="default">DA - 20170113IS - 1099-0496 (Electronic)IS - 1099-0496 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1002/ppul.23667</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28085236">PM:28085236</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Pulmonol\20170113-RaziCH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Pulmonol\20170113-RaziCH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170113, Razi CH</style></custom2><misc3><style face="normal" font="default">10.1002/ppul.23667</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40436</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,J.H.</style></author><author><style face="normal" font="default"> Qin,L.</style></author><author><style face="normal" font="default"> Shi,Y.Y.</style></author><author><style face="normal" font="default"> Feng,J.T.</style></author><author><style face="normal" font="default"> Zheng,Y.L.</style></author><author><style face="normal" font="default"> Wan,Y.F.</style></author><author><style face="normal" font="default"> Xu,C.Q.</style></author><author><style face="normal" font="default"> Yang,X.M.</style></author><author><style face="normal" font="default"> Hu,C.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Xiangya Hospital of Central South University (Key Site of National Clinical Research Center for Respiratory Disease), Changsha 410008, Hunan Province, China</style></auth-address><titles><title><style face="normal" font="default">IL-17 protein levels in both induced sputum and plasma are increased in stable but not acute asthma individuals with obesity</style></title><secondary-title><style face="normal" font="default">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respir Med</style></full-title></periodical><pages end="58" start="48">48-58</pages><volume><style face="normal" font="default">121</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">acute asthma</style></keyword><keyword><style face="normal" font="default"> adiposity</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Apnea</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="default"> Gastroesophageal reflux disease</style></keyword><keyword><style face="normal" font="default"> IL-17</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> induced sputum</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Mechanics</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Obstructive sleep apnea</style></keyword><keyword><style face="normal" font="default"> obstructive sleep apnea syndrome</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> overweight</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Sleep apnea</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> steroid resistance</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Obesity worsens asthma control partly through enhanced airway neutrophilia, altered lung mechanics and comorbidities, including obstructive sleep apnea syndrome, gastroesophageal reflux disease and depression. Although controversial, obesity may also cause poorer outcomes in acute asthma. IL-17 is associated with neutrophilic inflammation, steroid resistance and severe asthma, but its importance in the association between asthma and obesity is unknown. OBJECTIVE: To investigate the role of IL-17 in obese asthma in both acute and stable settings. METHODS: Both stable (n = 177) and acute (n = 78) asthmatics were recruited and categorized into lean (n = 77 and 39 respectively), overweight (n = 41 and 17 respectively) and obese (n = 59 and 22 respectively) groups and compared for clinical characteristics, including sputum and plasma IL-17 protein concentrations, sputum cellularity, spirometry and comorbidities. Correlations of IL-17 expression with other measures were explored. RESULTS: In stable subjects, airway neutrophilia and IL-17 concentrations were most prominent in the obese, and correlated positively with each other. Significant increase in plasma IL-17 levels was also noted and associated with elevated depressive symptoms in obesity. In acute asthma, IL-17 expression, like most other clinical measures, was similar among lean, overweight and obese groups, but was higher in acute versus stable asthma subjects, with sputum IL-17 correlating positively with sputum neutrophils and negatively with FEV1 and plasma IL-17 showing a positive connection to airway eosinophilia during exacerbation. CONCLUSIONS: IL-17 contributes to worse disease control in obese asthma through enhancing airway neutrophilia and depression, and may implicate in asthma exacerbations. Effects of adiposity on acute asthma remain uncertain</style></abstract><notes><style face="normal" font="default">DA - 20161127IS - 1532-3064 (Electronic)IS - 0954-6111 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.rmed.2016.10.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27888992">PM:27888992</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respir Med\2016-121-48-58.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respir Med\2016-121-48-58.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161127, Chen JH</style></custom2><misc3><style face="normal" font="default">10.1016/j.rmed.2016.10.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40437</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Comaru,T.</style></author><author><style face="normal" font="default"> Pitrez,P.M.</style></author><author><style face="normal" font="default"> Friedrich,F.O.</style></author><author><style face="normal" font="default"> Silveira,V.D.</style></author><author><style face="normal" font="default"> Pinto,L.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Infant Center, Institute of Biomedical Research, PUCRS, Porto Alegre, Brazil.</style></auth-address><titles><title><style face="normal" font="default">Free asthma medications reduces hospital admissions in Brazil (Free asthma drugs reduces hospitalizations in Brazil)</style></title><secondary-title><style face="normal" font="default">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respir Med</style></full-title></periodical><pages end="25" start="21">21-25</pages><volume><style face="normal" font="default">121</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Beclomethasone</style></keyword><keyword><style face="normal" font="default"> Biomedical Research</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Developing Countries</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Government</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Since June 2011, the Brazilian health system started providing asthma medications (beclomethasone and salbutamol), totally free of charge to patients with asthma. The aim of this study was to evaluate the impact of the provision of free asthma medications on hospital admissions for asthma in Brazil, using a national hospitalization database (DATASUS), comparing the incidence of hospital admissions before and after the free supply of these drugs. METHODS: Admissions of patients with 1-49 years of age by the Brazilian public health system with the diagnosis of asthma were compared pre (2008-2010) and post (2012-2014) provision of free medicines (beclomethasone and salbutamol). The number of hospital admissions due to asthma and non-respiratory diseases, as well as the amount spent with asthma hospitalization, were obtained from DATASUS, the Brazilian government open-access public health database system. RESULTS: Admission rates for asthma significantly decreased from 90.09/100.000 (2008-2010) to 59.85/100.000 (2012-2014), when the period pre and post provision of free medicines were compared [OR 0.67 (CI 0.48-0.92)]. Non-respiratory admission rates remained stable, when both periods were also compared. CONCLUSION: Asthma hospitalization rates significantly decreased in the three-year period after the provision of free medicines to treat asthma. Our findings suggest that the provision of free medications for asthma may have a particular public health impact by its own in developing countries</style></abstract><notes><style face="normal" font="default">DA - 20161127IS - 1532-3064 (Electronic)IS - 0954-6111 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1016/j.rmed.2016.10.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27888987">PM:27888987</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respir Med\2016-121-21-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respir Med\2016-121-21-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161127, Comaru T</style></custom2><misc3><style face="normal" font="default">10.1016/j.rmed.2016.10.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40438</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Checkley,W.</style></author><author><style face="normal" font="default"> Deza,M.P.</style></author><author><style face="normal" font="default"> Klawitter,J.</style></author><author><style face="normal" font="default"> Romero,K.M.</style></author><author><style face="normal" font="default"> Klawitter,J.</style></author><author><style face="normal" font="default"> Pollard,S.L.</style></author><author><style face="normal" font="default"> Wise,R.A.</style></author><author><style face="normal" font="default"> Christians,U.</style></author><author><style face="normal" font="default"> Hansel,N.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary and Critical Care, School of Medicine, Johns Hopkins University, Baltimore, USA.</style></auth-address><titles><title><style face="normal" font="default">Identifying biomarkers for asthma diagnosis using targeted metabolomics approaches</style></title><secondary-title><style face="normal" font="default">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respir Med</style></full-title></periodical><pages end="66" start="59">59-66</pages><volume><style face="normal" font="default">121</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Ascorbic Acid</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> Baltimore</style></keyword><keyword><style face="normal" font="default"> Betaine</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic tool</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fasting</style></keyword><keyword><style face="normal" font="default"> Glutathione</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metabolomics</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> Methacholine challenge</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> overweight</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Peru</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: The diagnosis of asthma in children is challenging and relies on a combination of clinical factors and biomarkers including methacholine challenge, lung function, bronchodilator responsiveness, and presence of airway inflammation. No single test is diagnostic. We sought to identify a pattern of inflammatory biomarkers that was unique to asthma using a targeted metabolomics approach combined with data science methods. METHODS: We conducted a nested case-control study of 100 children living in a peri-urban community in Lima, Peru. We defined cases as children with current asthma, and controls as children with no prior history of asthma and normal lung function. We further categorized enrollment following a factorial design to enroll equal numbers of children as either overweight or not. We obtained a fasting venous blood sample to characterize a comprehensive panel of targeted markers using a metabolomics approach based on high performance liquid chromatography-mass spectrometry. RESULTS: A statistical comparison of targeted metabolites between children with asthma (n = 50) and healthy controls (n = 49) revealed distinct patterns in relative concentrations of several metabolites: children with asthma had approximately 40-50% lower relative concentrations of ascorbic acid, 2-isopropylmalic acid, shikimate-3-phosphate, and 6-phospho-d-gluconate when compared to children without asthma, and 70% lower relative concentrations of reduced glutathione (all p &lt; 0.001 after Bonferroni correction). Moreover, a combination of 2-isopropylmalic acid and betaine strongly discriminated between children with asthma (2-isopropylmalic acid &lt;/= 13 077 normalized counts/second) and controls (2-isopropylmalic acid > 13 077 normalized counts/second and betaine &lt;/= 16 47 121 normalized counts/second). CONCLUSIONS: By using a metabolomics approach applied to serum, we were able to discriminate between children with and without asthma by revealing different metabolic patterns. These results suggest that serum metabolomics may represent a diagnostic tool for asthma and may be helpful for distinguishing asthma phenotypes</style></abstract><notes><style face="normal" font="default">DA - 20161127IS - 1532-3064 (Electronic)IS - 0954-6111 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.rmed.2016.10.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27888993">PM:27888993</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respir Med\2016-121-59-66.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respir Med\2016-121-59-66.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161127, Checkley W</style></custom2><misc3><style face="normal" font="default">10.1016/j.rmed.2016.10.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40439</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,J.U.</style></author><author><style face="normal" font="default"> Chang,H.S.</style></author><author><style face="normal" font="default"> Lee,H.J.</style></author><author><style face="normal" font="default"> Bae,D.J.</style></author><author><style face="normal" font="default"> Son,J.H.</style></author><author><style face="normal" font="default"> Park,J.S.</style></author><author><style face="normal" font="default"> Choi,J.S.</style></author><author><style face="normal" font="default"> Hwang,H.G.</style></author><author><style face="normal" font="default"> Park,C.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Interdisciplinary Program in Biomedical Science Major, Soonchunhyang Graduate School, Bucheon, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Association of interleukin-25 levels with development of aspirin induced respiratory diseases</style></title><secondary-title><style face="normal" font="default">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respir Med</style></full-title></periodical><pages end="78" start="71">71-78</pages><volume><style face="normal" font="default">123</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AERD</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin challenge</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cysteinyl leukotriene</style></keyword><keyword><style face="normal" font="default"> cysteinyl leukotrienes</style></keyword><keyword><style face="normal" font="default"> cysteinyl-leukotrienes</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Ingestion</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Leukotrienes</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drug</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Prostaglandin</style></keyword><keyword><style face="normal" font="default"> Prostaglandins</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Respiratory diseases</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> TH2 cytokines</style></keyword><keyword><style face="normal" font="default"> Th2 response</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Aspirin-exacerbated respiratory diseases (AERD) are caused by ingestion of non-steroidal anti-inflammatory drugs and are characterized by acute bronchospasms and marked infiltration of eosinophils, the latter being attributable to altered synthesis of cysteinyl leukotrienes (LT) and prostaglandins (PG). Recently, the innate Th2 response is revealed to induce eosinophil infiltration in allergic inflammation, however the role of the innate Th2 response has not been studies in AERD. Thus, we evaluated the relationship between the innate Th2 cytokines including IL-25, thymic stromal lymphopoietin (TSLP) and IL-33 and the development of AERD. METHODS AND MATERIALS: Plasma IL-25, IL-33, and TSLP levels were measured before and after aspirin challenge in subjects with AERD (n = 25) and aspirin-tolerant asthma (ATA, n = 25) by enzyme-linked immunosorbent assay (ELISA). Pre and post-aspirin challenge levels of LTC4 and PGD2 were measured using ELISA. RESULTS: Basal plasma IL-25 levels were significantly higher in AERD group than in normal controls and in ATA group (p = 0.025 and 0.031, respectively). IL-33 and TSLP levels were comparable in the AERD and ATA groups. After the aspirin challenge, the IL-25 levels were markedly decreased in the ATA group (p = 0.024), while not changed in the AERD group. The post-challenge IL-25 levels of all asthmatic subjects were significantly correlated with aspirin challenge - induced declines in FEV1 (r = 0.357, p = 0.011), but not with basal and post challenge LTC4 and PGD2 levels. CONCLUSIONS: IL-25 is associated with bronchospasm after aspirin challenge, possibly via mechanisms other than altered LTC4 and PGD2 production</style></abstract><notes><style face="normal" font="default">DA - 20170131IS - 1532-3064 (Electronic)IS - 0954-6111 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.rmed.2016.11.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28137499">PM:28137499</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respir Med\2017-123-71-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respir Med\2017-123-71-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170131, Lee JU</style></custom2><misc3><style face="normal" font="default">10.1016/j.rmed.2016.11.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40440</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Varsano,S.</style></author><author><style face="normal" font="default"> Segev,D.</style></author><author><style face="normal" font="default"> Shitrit,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonary Medicine, Meir Medical Center, Kfar Saba, Israel</style></auth-address><titles><title><style face="normal" font="default">Severe and non-severe asthma in the community: A large electronic database analysis</style></title><secondary-title><style face="normal" font="default">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respir Med</style></full-title></periodical><pages end="139" start="131">131-139</pages><volume><style face="normal" font="default">123</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> ethics</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Medicine</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: A large electronic database analysis was conducted in a community of 351,799 people, ages 20-70 years to determine the prevalence and clinical characteristics of severe asthma, according to 2014 international guidelines and healthcare utilization. METHODS: Severe asthmatics were grouped into controlled severe-asthma and uncontrolled severe-asthma and additional subgroups of uncontrolled severe asthma on the basis of medications dispensed. Non-asthmatic population at the same ages served as controls. RESULTS: A total of 19,991 (5.68%) were diagnosed as asthmatic, of which 4.65% had severe asthma. Of these, one-third was uncontrolled severe-asthma. Controlled severe-asthma group was similar to non-severe asthma and non-asthmatics in the rate of emergency room visits (21.5%, 22%, and 20%, respectively) and to all cause hospitalizations (7.4%, 7.4%, and 6.4%, respectively). Uncontrolled severe-asthmatics had significantly more hospitalizations (RR = 2.9) than controlled severe-asthmatics. Only 19.2% of uncontrolled-severe asthmatics had IgE testing and 3.6% were dispensed omalizumab. CONCLUSIONS: The prevalence of severe asthma is slightly less than 5% of all asthmatics. Controlling severe asthma is crucial to reducing healthcare utilization. A simple electronic database analysis, based on dispensed medications, can help healthcare providers identify subgroups of uncontrolled severe asthmatics that require focused efforts. CLINICAL TRIAL REGISTRATION: NCT01961258. Ethics Committee approval: 032/2013C</style></abstract><notes><style face="normal" font="default">DA - 20170131IS - 1532-3064 (Electronic)IS - 0954-6111 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">10.1016/j.rmed.2016.12.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28137489">PM:28137489</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respir Med\2017-123-131-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respir Med\2017-123-131-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170131, Varsano S</style></custom2><misc3><style face="normal" font="default">10.1016/j.rmed.2016.12.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40441</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guidos-Fogelbach,G.A.</style></author><author><style face="normal" font="default"> Paredes-Aguilar,J.A.</style></author><author><style face="normal" font="default"> Colin-Martinez,N.M.</style></author><author><style face="normal" font="default"> Rojo-Gutierrez,M.I.</style></author><author><style face="normal" font="default"> Lopez-Hidalgo,M.</style></author><author><style face="normal" font="default"> Reyes-Lopez,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Instituto Politecnico Nacional, Escuela Nacional de Medicina y Homeopatia, Laboratorio de Bioquimica Estructural. Ciudad de Mexico, Mexico.</style></auth-address><titles><title><style face="normal" font="default">[Determination and analysis of protein profile of different transfer factors]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="372" start="365">365-372</pages><volume><style face="normal" font="default">63</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> Chromatography</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electrophoresis</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> Gel</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Labeling</style></keyword><keyword><style face="normal" font="default"> Leukocytes</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mexico</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Spread</style></keyword><keyword><style face="normal" font="default"> standards</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Transfer Factor</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: The transfer factor (TF) is the dialyzable extract of leukocytes with cellular immunity transfer properties. Its use has spread in the treatment of a wide range of immunologic, infectious, and even oncological diseases. However, important aspects in their protein profile, component concentrations, and a well-defined action mechanism are not completely unknown. OBJECTIVES: To analyze the protein profiles of different transfer factors marketed in Mexico. METHODS: 6 TF marketed in Mexico were obtained and analyzed, quantifying protein with thaze Bradford method, by high-performance liquid chromatography (HPLC), and polyacrylamide gel electrophoresis (SDS-PAGE). All samples were analyzed in duplicate. RESULTS: The total protein concentrations of all TF analyzed are less than 0.2 mg/mL. The chromatographic profiles showed differences in some TF. The protein concentration was 6 to almost one thousand times lower compared to reports by some manufacturers. CONCLUSION: Almost all transfer factors marketed in Mexico lack a labeling and health record that meets the official standards</style></abstract><notes><style face="normal" font="default">DA - 20161031IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - Journal ArticlePT - English AbstractCO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27795217">PM:27795217</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2016-63-365-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2016-63-365-72.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161031, Guidos-Fogelbach GA</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40442</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Holguin-Gomez,L.</style></author><author><style face="normal" font="default"> Vasquez-Ochoa,L.A.</style></author><author><style face="normal" font="default"> Cardona,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universidad de Antioquia. Medellin, Antioquia, Colombia. l</style></auth-address><titles><title><style face="normal" font="default">[Angioedema]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="384" start="373">373-384</pages><volume><style face="normal" font="default">63</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adrenaline</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Bradykinin</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor deficiency</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> Capillaries</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Colombia</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> Histaminergic</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Permeability</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Venules</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">Angioedema is defined as edema of the skin or mucosa, including the respiratory and the gastrointestinal mucosa, which is self-limiting, and in most cases is completely resolved in less than 72 hours. It occurs due to increased permeability of the mucosal and submucosal capillaries and postcapillary venules, with resulting plasma extravasation. There are different types of angioedema: histaminergic (which may be mediated by immunoglobulin E), hereditary, from acquired C1 inhibitor deficiency, from angiotensin converting enzyme inhibitor, bradykinin-mediated, and non-histaminergic idiopathic angioedema. Treatment depends on the cause of angioedema, age, and the frequency and severity of manifestations. The main measures are avoiding external triggers or causes, giving antihistamines, steroids, or adrenaline for histaminergic angioedema; replacing the deficient protein or blocking the action of bradykinin in C1 inhibitor deficiency and angioedema from angiotensin converting enzyme inhibitor</style></abstract><notes><style face="normal" font="default">DA - 20161031IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - Journal ArticlePT - English AbstractCO - Colombia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27795218">PM:27795218</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2016-63-373-84.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2016-63-373-84.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161031, Holguin-Gomez L</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40443</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Irigoyen-Coria,M.L.</style></author><author><style face="normal" font="default"> Rojo-Gutierrez,M.I.</style></author><author><style face="normal" font="default"> Meyer-Gomez,R.H.</style></author><author><style face="normal" font="default"> Leyva-Carmona,I.</style></author><author><style face="normal" font="default"> Zendejas-Buitron,V.M.</style></author><author><style face="normal" font="default"> Garcia-Ruiz,A.D.</style></author><author><style face="normal" font="default"> Mellado-Abrego,J.</style></author><author><style face="normal" font="default"> Garcia-Ortega,I.</style></author><author><style face="normal" font="default"> Castillo-Narvaez,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratorios Clinicos Especializados Integrales Lindavista. Ciudad de Mexico, Mexico.</style></auth-address><titles><title><style face="normal" font="default">[Modified tests basophil degranulation and leukocyte migration inhibition factor in drug allergy. Study 2009-2014]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="350" start="342">342-350</pages><volume><style face="normal" font="default">63</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mexico</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Adverse reactions to drugs are increasing and there are few studies for the diagnosis. OBJECTIVE: To determine the utility of modified basophil degranulation (MBD) test and modified leukocyte migration inhibition factor (MLMIF) test to prove drug hypersensitivity. METHODS: 177 patients of both sexes were studied with the diagnosis of drug hypersensitivity, determining MBD, MLMIF, or both, between 2009 and 2014. They were matched with positive and negative controls and the non-allergic population. Applications are issued according to the type of hypersensitivity, considering type I MBD and type IV MLMIF. RESULTS: 170 patients (96.04%) were positive to at least one drug (RR = 4.71). 561 MBD (73.62%) and 201 MLMIF (26.37%) were performed. Female sex was more frequent (64.41%); the average age was 38.5. MBD was positive in 70.23% and MLMIF in 67.16%. The test sensitivity was increased complementarily and with two dilutions. The correlation of MBD and MLMIF was positive and highly significant. CONCLUSIONS: Women have more drug reactions. Modified MBD test is useful at any age. Since medications can activate one or other hypersensitivity mechanism, it is important to request the tests simultaneously</style></abstract><notes><style face="normal" font="default">DA - 20161031IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - Journal ArticlePT - English AbstractCO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27795214">PM:27795214</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2016-63-342-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2016-63-342-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161031, Irigoyen-Coria ML</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40444</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pozo-Beltran,C.F.</style></author><author><style face="normal" font="default"> Navarrete-Rodriguez,E.M.</style></author><author><style face="normal" font="default"> Fernandez-Soto,R.</style></author><author><style face="normal" font="default"> Navarro-Munguia,J.</style></author><author><style face="normal" font="default"> Hall-Mondragon,M.S.</style></author><author><style face="normal" font="default"> Sienra-Monge,J.J.</style></author><author><style face="normal" font="default"> Del Rio-Navarro,B.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Secretaria de Salud, Hospital Infantil de Mexico Federico Gomez, Departamento de Alergia e Inmunologia Clinica Pediatrica. Ciudad de Mexico, Mexico.</style></auth-address><titles><title><style face="normal" font="default">[Knowledge of asthma: educational intervention with the 2014 GINA guide in primary care physicians]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="364" start="358">358-364</pages><volume><style face="normal" font="default">63</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Alergia</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mexico</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patient Care</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatricians</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is a public health problem in the world, so updating the guidelines for the diagnosis and treatment of asthma is based primarily on the practice of primary care physicians. Educational interventions are useful for increasing knowledge. OBJECTIVE: To compare the level of knowledge of asthma before and after an educational intervention. METHODS: A quasi-experimental prospective study was conducted in general and family practitioners and pediatricians who attended a training workshop on general aspects of asthma and current guidelines for diagnosis and treatment (GINA 2014). A questionnaire consisting of 11 multiple choice questions relating to fundamental aspects of the disease and diagnosis, classification, treatment and management of attacks, was used in two assessments, baseline and post-intervention. RESULTS: A total of 178 patients participated in the study, with knowledge pre-intervention at 25.5 points and post-intervention at 97.5 points on a scale of 100, with p &lt; 0.05. CONCLUSION: Educational interventions are inexpensive and effective tools to increase the knowledge of health professionals, and they have an impact on improving patient care</style></abstract><notes><style face="normal" font="default">DA - 20161031IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - Journal ArticlePT - English AbstractCO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27795216">PM:27795216</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2016-63-358-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2016-63-358-64.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161031, Pozo-Beltran CF</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40445</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Beltran-Sierra,K.J.</style></author><author><style face="normal" font="default"> Sanchez,J.</style></author><author><style face="normal" font="default"> Cardona,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universidad de Antioquia, Grupo de Alergologia Clinica y Experimental. Medellin, Colombia</style></auth-address><titles><title><style face="normal" font="default">[Evaluation and characterization of 125 patients with a history of reaction to beta-lactams]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="236" start="227">227-236</pages><volume><style face="normal" font="default">63</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy test</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> beta-Lactams</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Betalactams</style></keyword><keyword><style face="normal" font="default"> Characterization</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> Colombia</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> delayed reaction</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Immune-mediated</style></keyword><keyword><style face="normal" font="default"> Immunological mechanisms</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Specific IgE</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Reactions to beta-lactams are frequent and it is difficult to establish the relationship between the drug and symptoms. OBJECTIVE: To describe the clinical characteristics and explore the immunological mechanisms of patients with suspected adverse reaction to beta-lactams. METHODS: Retrospective study of patients with a history of beta-lactam reaction and tests for reactions to drugs. RESULTS: Out of 125 patients, 71 were women (56.8%); 73 had a history of immediate reaction and 52 delayed reaction; 590 allergy tests were done: specific IgE measurement, skin prick, patch, and provocation tests. The drugs most often related were amoxycillin, in 62 patients (49.6%), crystalline penicillin in 17 (13.6%), benzathine penicillin in 15 (12%), and cefalexin in 13 (10.4%). The severity of the reaction was mild in the majority (82%). 7.7% had a history of anaphylaxis and 10.8% sought care for a positive penicillin skin test, without history of reaction. Only 6.7% resulted in a positive test. More than 62% began testing two years after the reaction for which they sought care. CONCLUSIONS: The clinical history is insufficient to determine allergy to beta-lactams. In our sample, few patients with a history of beta-lactam reaction had evidence of immune-mediated reactions</style></abstract><notes><style face="normal" font="default">DA - 20160826IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleSB - IMCO - Colombia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27560911">PM:27560911</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2016-63-227-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2016-63-227-36.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160826, Beltran-Sierra KJ</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40446</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Maza-De Franco,C.A.</style></author><author><style face="normal" font="default"> Morales-Sanchez,M.A.</style></author><author><style face="normal" font="default"> Morales-Barrera,M.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centro Dermatologico Dr. Ladislao de la Pascua. Ciudad de Mexico, Mexico.</style></auth-address><titles><title><style face="normal" font="default">[Transcultural translation-adaptation to Spanish of the Infants' Dermatitis Quality of Life questionnaire for children under four years with atopic dermatitis]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="277" start="270">270-277</pages><volume><style face="normal" font="default">63</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mexico</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis is observed in up to 20% of children, hence the importance of tools to support its evaluation. OBJECTIVE: To determine the validity and reliability of the Spanish adaptation of the IDQOL questionnaire in patients &lt;4 years of age with atopic dermatitis (AD). METHODS: Translation and back-translation of the questionnaire; a pilot test was done in 30 children with AD to arrive at a final version. Internal reliability (Cronbach's alpha) and correlation of IDQOL and SCORAD scores (Pearson correlation coefficient) were measured. RESULTS: 102 children aged between two and 48 months were included. The Pearson correlation coefficient (r) of IDQOL and SCORAD scores was 0.697 (p = 0.0001), indicating a high positive correlation. The correlation between the severity measured by the caregiver and the SCORAD score (r = 0.565, p = 0.0001) proved to be low positive. The internal consistency of IDQOL using Cronbach's alpha was 0.84, indicating good consistency of the instrument for assessing quality of life. CONCLUSION: The IDQOL questionnaire in Spanish is a valid measure of quality of life in patients &lt; 4 years with AD and is useful in monitoring and in clinical trials</style></abstract><notes><style face="normal" font="default">DA - 20160826IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleSB - IMCO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27560914">PM:27560914</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2016-63-270-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2016-63-270-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160826, Maza-De Franco CA</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40447</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bissinger,I.</style></author><author><style face="normal" font="default"> Matute-Turizo,G.</style></author><author><style face="normal" font="default"> Mejia-Barreneche,M.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinica El Rosario Sede Tesoro. Medellin, Antioquia, Colombia.</style></auth-address><titles><title><style face="normal" font="default">[Acute generalized exanthematous pustulosis induced by piroxicam]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="412" start="408">408-412</pages><volume><style face="normal" font="default">63</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Abdomen</style></keyword><keyword><style face="normal" font="default"> Acute Generalized Exanthematous Pustulosis</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> Back</style></keyword><keyword><style face="normal" font="default"> Back Pain</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Colombia</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Differential diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Forearm</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Kidney</style></keyword><keyword><style face="normal" font="default"> Leukocytes</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Low Back Pain</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Mupirocin</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> Piroxicam</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> Ranitidine</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Spread</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Thigh</style></keyword><keyword><style face="normal" font="default"> Thorax</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Between 62 and 90% of cases of acute generalized exanthematous pustulosis are caused by drugs. Its onset is rapid with generalized pustules, fever, and blood neutrophil count over 7000; pustules resolve spontaneously in less than 15 days. A case associated with piroxicam described. CASE REPORT: A 36-year-old with initial erythema of the thorax and abdomen, accompanied by burning, without fever, which later spread to his forearms, upper arms, and thighs, with face edema. A week earlier he had taken piroxicam for low back pain; at the time of hospitalization he received antihistamines, and topical and systemic steroids. Full blood count showed leukocytes at 8920, eosinophils at 600, neutrophils at 6600, total serum IgE at 188 UI, C-reactive protein at 2.9 mg/L, and no liver, kidney, or lung involvement. Treatment was initiated with intravenous antihistamines and ranitidine, saline, topical Vaseline plus topical mupirocin, and systemic steroids. On the second day of hospitalization neutrophils increased to 9000 and PCR to 3.3. The score to evaluate acute exanthematous pustulosis in the patient was 8, giving a definitive diagnosis. CONCLUSIONS: The differential diagnosis should be established primarily with pustular psoriasis. The prognosis is generally good, as reported</style></abstract><notes><style face="normal" font="default">DA - 20161031IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - Journal ArticlePT - English AbstractCO - Colombia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27795221">PM:27795221</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2016-63-408-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2016-63-408-12.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161031, Bissinger I</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40448</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Urrutia-Pereira,M.</style></author><author><style face="normal" font="default"> Sole,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universidade Federal do Pampa. Programa Infantil de Prevencao da Asma, Uruguaiana RS, Brasil.</style></auth-address><titles><title><style face="normal" font="default">[The allergic child at school. What do we need to know?]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="292" start="283">283-292</pages><volume><style face="normal" font="default">63</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Absenteeism</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> Asma</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Sleep Disorders</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="default">Allergy is a multisystem disease in children that often occurs with the coexistence of diverse clinical manifestations that cause great impact on quality of life and academic performance due to sleep disorders arising from the disease or treatment, and absenteeism that children may experience. Because of the time spent in school, there is a possibility that allergic reactions may occur first in these facilities, where a lack of staff knowledge has been found regarding how to proceed in allergy crisis situations. Cooperative action among health teams, community, parents, and school authorities is essential to ensure that the school can prevent, recognize, and ensure quick access to emergency services (if needed) and treatment protocols for allergic reactions, thus allowing allergic children to be better protected in the school environment, which should be considered an extension of the home environment and an important arm in proper management to control the disease</style></abstract><notes><style face="normal" font="default">DA - 20160826IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleSB - IMCO - Brazil -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27560916">PM:27560916</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2016-63-283-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2016-63-283-92.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160826, Urrutia-Pereira M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40449</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Almeida,J.</style></author><author><style face="normal" font="default"> Ferreira,S.</style></author><author><style face="normal" font="default"> Malheiro,J.</style></author><author><style face="normal" font="default"> Fonseca,P.</style></author><author><style face="normal" font="default"> Caeiro,D.</style></author><author><style face="normal" font="default"> Dias,A.</style></author><author><style face="normal" font="default"> Ribeiro,J.</style></author><author><style face="normal" font="default"> Gama,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Servico de Cardiologia, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.</style></auth-address><titles><title><style face="normal" font="default">A rare cause of acute coronary syndrome: Kounis syndrome</style></title><secondary-title><style face="normal" font="default">Rev Port Cardiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Rev Port Cardiol</style></abbr-1></periodical><pages end="699" start="699">699-699</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acute Coronary Syndrome</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Ciprofloxacin</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Disease</style></keyword><keyword><style face="normal" font="default"> Coronary Vasospasm</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Kounis syndrome</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Quinolones</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">Kounis syndrome is an acute coronary syndrome in the context of a hypersensitivity reaction. The main pathophysiological mechanism appears to be coronary vasospasm. We report the case of a patient with a history of allergy to quinolones, who was given ciprofloxacin before an elective surgical procedure and during drug administration developed symptoms and electrocardiographic changes suggestive of ST-segment elevation acute coronary syndrome. The drug was suspended and coronary angiography excluded epicardial coronary disease. Two hours after withdrawal of the drug the symptoms and ST elevation had resolved completely</style></abstract><notes><style face="normal" font="default">DA - 20161120IS - 2174-2030 (Electronic)IS - 0870-2551 (Linking)LA - engLA - porPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.1016/j.repc.2016.03.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27865673">PM:27865673</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Port Cardiol\2016-35-699.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Port Cardiol\2016-35-699.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161120, Almeida J</style></custom2><misc3><style face="normal" font="default">10.1016/j.repc.2016.03.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40450</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Baldacara,R.P.</style></author><author><style face="normal" font="default"> Silva,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">MD. Assistant Professor, Medicine, Universidade Federal do Tocantins (UFT), Palmas (TO), BrazilMD, PhD. Adjunct Professor, Gynecology, Universidade Federal do Sao Paulo (SP), Brazil</style></auth-address><titles><title><style face="normal" font="default">Association between asthma and female sex hormones</style></title><secondary-title><style face="normal" font="default">Sao Paulo Med J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sao Paulo Med J</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> estrogen</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hormone Replacement Therapy</style></keyword><keyword><style face="normal" font="default"> Hormones</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Interferon-gamma</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> Menopause</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Progesterone</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> TH2 cytokines</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> transcription factor</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="5" Month="1" Year="2017">2017/1/5</year></dates><abstract><style face="normal" font="default">CONTEXT AND OBJECTIVE:: The relationship between sex hormones and asthma has been evaluated in several studies. The aim of this review article was to investigate the association between asthma and female sex hormones, under different conditions (premenstrual asthma, use of oral contraceptives, menopause, hormone replacement therapy and pregnancy). DESIGN AND SETTING:: Narrative review of the medical literature, Universidade Federal do Tocantins (UFT) and Universidade Federal de Sao Paulo (Unifesp). METHODS:: We searched the CAPES journal portal, a Brazilian platform that provides access to articles in the MEDLINE, PubMed, SciELO, and LILACS databases. The following keywords were used based on Medical Subject Headings: asthma, sex hormones, women and use of oral contraceptives. RESULTS:: The associations between sex hormones and asthma remain obscure. In adults, asthma is more common in women than in men. In addition, mortality due to asthma is significantly higher among females. The immune system is influenced by sex hormones: either because progesterone stimulates progesterone-induced blocking factor and Th2 cytokines or because contraceptives derived from progesterone and estrogen stimulate the transcription factor GATA-3. CONCLUSIONS:: The associations between asthma and female sex hormones remain obscure. We speculate that estrogen fluctuations are responsible for asthma exacerbations that occur in women. Because of the anti-inflammatory action of estrogen, it decreases TNF-alpha production, interferon-gamma expression and NK cell activity. We suggest that further studies that highlight the underlying physiopathological mechanisms contributing towards these interactions should be conducted</style></abstract><notes><style face="normal" font="default">DA - 20170111IS - 1806-9460 (Electronic)IS - 1516-3180 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1590/1516-3180.2016.011827016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28076614">PM:28076614</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sao Paulo Med J\20170111-BaldacaraRP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sao Paulo Med J\20170111-BaldacaraRP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170111, Baldacara RP</style></custom2><misc3><style face="normal" font="default">10.1590/1516-3180.2016.011827016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40451</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shimi,A.</style></author><author><style face="normal" font="default"> Touzani,S.</style></author><author><style face="normal" font="default"> Derkaoui,A.</style></author><author><style face="normal" font="default"> Khatouf,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesiology and Intensive Care, Intensive Care Unit A1, Hassan II University Hospital, Sidi Mohamed Ben Abdellah University, Fes, Morocco</style></auth-address><titles><title><style face="normal" font="default">Kounis syndrome associated with amoxicillin/clavulanic acid</style></title><secondary-title><style face="normal" font="default">Saudi J Anaesth</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Saudi J Anaesth</style></abbr-1></periodical><pages end="445" start="444">444-445</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AC</style></keyword><keyword><style face="normal" font="default"> Acute Coronary Syndrome</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Anesthesiology</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Chest Pain</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic test</style></keyword><keyword><style face="normal" font="default"> Hypotension</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> intensive care unit</style></keyword><keyword><style face="normal" font="default"> Kounis syndrome</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Morocco</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">Kounis syndrome (KS) is a life-threatening medical condition that causes severes allergic reaction and acute coronary syndrome (ACS). We describe the case of 56-year-old woman who developed ACS following an anaphylactic reaction to amoxicillin/clavulanic acid. Immediately after the administration of amoxicillin/clavulanic acid, she presented a chest pain, cutaneous allergic, hypotension, and ST depression on the electrocardiogram. After the necessary diagnostic test, the final diagnosis was variant I of KS</style></abstract><notes><style face="normal" font="default">DA - 20161111IS - 1658-354X (Print)LA - engPT - Journal ArticleCO - Morocco -</style></notes><work-type><style face="normal" font="default">10.4103/1658-354X.177329</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27833491">PM:27833491</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Saudi J Anaesth\2016-10-444-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Saudi J Anaesth\2016-10-444-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161111, Shimi A</style></custom2><misc3><style face="normal" font="default">10.4103/1658-354X.177329</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40452</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Peng,W.</style></author><author><style face="normal" font="default"> Ge,S.</style></author><author><style face="normal" font="default"> Liu,Z.</style></author><author><style face="normal" font="default"> Furuta,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Materials Science and Engineering, Central South University of Forestry and Technology, Changsha 410004, China</style></auth-address><titles><title><style face="normal" font="default">Adsorption characteristics of sulfur powder by bamboo charcoal to restrain sulfur allergies</style></title><secondary-title><style face="normal" font="default">Saudi J Biol Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Saudi J Biol Sci</style></abbr-1></periodical><pages end="107" start="103">103-107</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adsorption</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Charcoal</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Engineering</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Forestry</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human health</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> NO2</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Particulate matter</style></keyword><keyword><style face="normal" font="default"> PM2.5</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Sulfur</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">Exposures to particulate matter with a diameter of 2.5 mum or less (PM2.5) may influence the risk of birth defects and make you allergic, which causes serious harm to human health. Bamboo charcoal can adsorb harmful substances,that was of benefitto people's health. In order to figure out the optimal adsorbtion condition and the intrinsic change of bamboo charcoal, five chemicals were adsorbed by bamboo charcoal and were analyzed by FT-IR. The optimal blast time was 80 min of Na2SO3, 100 min of Na2S2O8, 20 min of Na2SO4, 120 min of Fe2(SO4)3 and 60 min or 100 min of S. FT-IR spectra showed that bamboo charcoal had five characteristic peaks of S-S stretch, H2O stretch, O-H stretch, C 000000000000 000000000000 000000000000 111111111111 000000000000 111111111111 000000000000 000000000000 000000000000 O stretch or CC stretch, and NO2 stretch at 3850 cm-1, 3740 cm-1, 3430 cm-1, 1630 cm-1 and 1530 cm-1, respectively. For Na2SO3, the peaks at 3850 cm-1, 3740 cm-1, 3430 cm-1, 1630 cm-1 and 1530 cm-1 achieved the maximum at 20 min. For Na2S2O8, the peaks at 3850 cm-1, 3740 cm-1, 3430 cm-1 and 1530 cm-1 achieved the maximum at 40 min. For Na2SO4, the peaks at 3850 cm-1, 3740 cm-1 and 1530 cm-1 achieved the maximum at 40 min. For Fe2(SO4)3, the peaks at 3850 cm-1, 3740 cm-1, 1630 cm-1 and 1530 cm-1 achieved the maximum at 120 min. For S, the peaks at 3850 cm-1 and 3740 cm-1 achieved the maximum at 40 min, the peaks at 1630 cm-1 and 1530 cm-1 achieved the maximum at 40 min. It proved that bamboo charcoal could remove sulfur powder from air to restrain sulfur allergies</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1319-562X (Print)IS - 1319-562X (Linking)LA - engPT - Journal ArticleCO - China -CO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.sjbs.2016.08.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28053578">PM:28053578</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Saudi J Biol Sci\2017-24-103-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Saudi J Biol Sci\2017-24-103-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Peng W</style></custom2><misc3><style face="normal" font="default">10.1016/j.sjbs.2016.08.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40453</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Li,Y.Y.</style></author><author><style face="normal" font="default"> Jin,Y.M.</style></author><author><style face="normal" font="default"> He,L.P.</style></author><author><style face="normal" font="default"> Bai,J.S.</style></author><author><style face="normal" font="default"> Liu,J.</style></author><author><style face="normal" font="default"> Yu,M.</style></author><author><style face="normal" font="default"> Chen,J.H.</style></author><author><style face="normal" font="default"> Wen,J.</style></author><author><style face="normal" font="default"> Kuang,Y.Q.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Venerology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, P. R. China</style></auth-address><titles><title><style face="normal" font="default">Clinical analysis of HIV/AIDS patients with drug eruption in Yunnan, China</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="35938">35938-</pages><volume><style face="normal" font="default">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Alanine</style></keyword><keyword><style face="normal" font="default"> albumin</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Blood Cells</style></keyword><keyword><style face="normal" font="default"> Blood Urea Nitrogen</style></keyword><keyword><style face="normal" font="default"> CD4</style></keyword><keyword><style face="normal" font="default"> Cell Count</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Creatinine</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug eruption</style></keyword><keyword><style face="normal" font="default"> Drug Eruptions</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Nevirapine</style></keyword><keyword><style face="normal" font="default"> Nitrogen</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urea</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral Load</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="31" Month="10" Year="2016">2016/10/31</year></dates><abstract><style face="normal" font="default">Drug eruption is the most common clinical presentation in patients with HIV/AIDS. The systemic clinical and risk factors associated with drug eruption remain unknown. A retrospective analysis in HIV/AIDS patients with drug eruption was carried out with demographic data, epidemiological data, clinical characteristics, laboratory data and follow-up data. The risk factors correlated with prognosis were assessed by case control analysis. A total of 134 out of 1817 HIV/AIDS patients (7.4%) presented drug eruptions. The major class of sensitizing drug was HAART drugs (47.7%), followed by antibiotics (47.0%). Nevirapine (39.6%) was the most common sensitizing drug in the HAART regimens. The patients received HAART or had allergic history were prone to develop drug eruption. The alanine aminotransferase, albumin, globulin, creatinine, blood urea nitrogen (BUN), lymphocytes, red blood cells (RBC) and eosinophils of the drug eruption patients were significantly different the control patients. The allergic history, opportunistic infection, viral load, CD4 cell count, high globulin and low albumin were the risk factors correlated with death in HIV/AIDS patients with drug eruption. It is proposed that patients with higher viral loads, higher globulin levels and lower white blood cells (WBC) should be given special attention for the prevention of complications and death</style></abstract><notes><style face="normal" font="default">DA - 20161031IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - ENGPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1038/srep35938</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27796328">PM:27796328</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Rep\2016-6-35938.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Rep\2016-6-35938.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161031, Li YY</style></custom2><misc3><style face="normal" font="default">10.1038/srep35938</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40454</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bao,K.F.</style></author><author><style face="normal" font="default"> Yu,X.</style></author><author><style face="normal" font="default"> Wei,X.</style></author><author><style face="normal" font="default"> Gui,L.L.</style></author><author><style face="normal" font="default"> Liu,H.L.</style></author><author><style face="normal" font="default"> Wang,X.Y.</style></author><author><style face="normal" font="default"> Tao,Y.</style></author><author><style face="normal" font="default"> Jiang,G.R.</style></author><author><style face="normal" font="default"> Hong,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Jiangsu Key Laboratory of Pediatric Respiratory Disease, Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210046, China</style></auth-address><titles><title><style face="normal" font="default">Astragaloside IV ameliorates allergic inflammation by inhibiting key initiating factors in the initial stage of sensitization</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="38241">38241-</pages><volume><style face="normal" font="default">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate lymphoid cells</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="5" Month="12" Year="2016">2016/12/5</year></dates><abstract><style face="normal" font="default">To illuminate the anti-allergy mechanism of astragaloside IV (AS-IV), we assessed its effects in a murine model of allergic contact dermatitis (ACD). AS-IV administered in the sensitization phase, rather than in the elicitation phase, dramatically alleviated the symptoms of allergic inflammation. We hypothesized that AS-IV exerts its anti-allergy effects by regulating the production of key pro-allergic cytokines based on the fact that interleukin (IL)-33 and thymic stromal lymphopoietin (TSLP) levels increase significantly in the initial stage of the sensitization phase. AS-IV administered in the initial stage of ACD inhibited TSLP and IL-33 expression and reduced the proportion of type-2 innate lymphoid cells (ILC2s). An in vitro study showed that the production of pro-allergic cytokines was significantly inhibited in AS-IV presenting HaCaT cells. We also verified that AS-IV administered only in the initial stage markedly alleviated inflammation, including ear swelling, Th2 cytokine expression, and histological changes. Taken together, these results suggest that AS-IV effectively ameliorates the progression of allergic inflammation by inhibiting key initiating factors, including TSLP and IL-33, and can be used to prevent and/or treat patients with ACD. Our data also suggest that these key pro-allergic cytokines are potential therapeutic targets for allergic diseases</style></abstract><notes><style face="normal" font="default">DA - 20161205IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1038/srep38241</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27917896">PM:27917896</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Rep\2016-6-38241.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Rep\2016-6-38241.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161205, Bao KF</style></custom2><misc3><style face="normal" font="default">10.1038/srep38241</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40455</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ariza,A.</style></author><author><style face="normal" font="default"> Mayorga,C.</style></author><author><style face="normal" font="default"> Salas,M.</style></author><author><style face="normal" font="default"> Dona,I.</style></author><author><style face="normal" font="default"> Martin-Serrano,A.</style></author><author><style face="normal" font="default"> Perez-Inestrosa,E.</style></author><author><style face="normal" font="default"> Perez-Sala,D.</style></author><author><style face="normal" font="default"> Guzman,A.E.</style></author><author><style face="normal" font="default"> Montanez,M.I.</style></author><author><style face="normal" font="default"> Torres,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Laboratory, IBIMA-Regional University Hospital of Malaga-UMA, Malaga, Spain</style></auth-address><titles><title><style face="normal" font="default">The influence of the carrier molecule on amoxicillin recognition by specific IgE in patients with immediate hypersensitivity reactions to betalactams</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="35113">35113-</pages><volume><style face="normal" font="default">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">albumin</style></keyword><keyword><style face="normal" font="default"> Amoxicillin</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Betalactams</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human serum</style></keyword><keyword><style face="normal" font="default"> Human serum albumin</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE antibodies</style></keyword><keyword><style face="normal" font="default"> IgE antibody</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Immunoassay</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Molecular Weight</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillins</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> selective responders</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum Albumin</style></keyword><keyword><style face="normal" font="default"> Solid phase</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Specific IgE</style></keyword><keyword><style face="normal" font="default"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="12" Month="10" Year="2016">2016/10/12</year></dates><abstract><style face="normal" font="default">The optimal recognition of penicillin determinants, including amoxicillin (AX), by specific IgE antibodies is widely believed to require covalent binding to a carrier molecule. The nature of the carrier and its contribution to the antigenic determinant is not well known. Here we aimed to evaluate the specific-IgE recognition of different AX-derived structures. We studied patients with immediate hypersensitivity reactions to AX, classified as selective or cross-reactors to penicillins. Competitive immunoassays were performed using AX itself, amoxicilloic acid, AX bound to butylamine (AXO-BA) or to human serum albumin (AXO-HSA) in the fluid phase, as inhibitors, and amoxicilloyl-poli-L-lysine (AXO-PLL) in the solid-phase. Two distinct patterns of AX recognition by IgE were found: Group A showed a higher recognition of AX itself and AX-modified components of low molecular weights, whilst Group B showed similar recognition of both unconjugated and conjugated AX. Amoxicilloic acid was poorly recognized in both groups, which reinforces the need for AX conjugation to a carrier for optimal recognition. Remarkably, IgE recognition in Group A (selective responders to AX) is influenced by the mode of binding and/or the nature of the carrier; whereas IgE in Group B (cross-responders to penicillins) recognizes AX independently of the nature of the carrier</style></abstract><notes><style face="normal" font="default">DA - 20161012IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Spain -</style></notes><work-type><style face="normal" font="default">10.1038/srep35113</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27731424">PM:27731424</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Rep\2016-6-35113.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Rep\2016-6-35113.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161012, Ariza A</style></custom2><misc3><style face="normal" font="default">10.1038/srep35113</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40456</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,M.</style></author><author><style face="normal" font="default"> Lee,N.Y.</style></author><author><style face="normal" font="default"> Chung,K.S.</style></author><author><style face="normal" font="default"> Cheon,S.Y.</style></author><author><style face="normal" font="default"> Lee,K.T.</style></author><author><style face="normal" font="default"> An,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Catholic Precision Medicine Research Center, College of Medicine, The Catholic University of Korea</style></auth-address><titles><title><style face="normal" font="default">Roxatidine attenuates mast cell-mediated allergic inflammation via inhibition of NF-kappaB and p38 MAPK activation</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="41721">41721-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal model</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Caspase 1</style></keyword><keyword><style face="normal" font="default"> caspase-1</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> Ulcer</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="31" Month="1" Year="2017">2017/1/31</year></dates><abstract><style face="normal" font="default">Roxatidine is an active metabolite of roxatidine acetate hydrochloride which is a histamine H2-receptor antagonist that is used to treat gastric and duodenal ulcers. In this study, we investigated the anti-allergic inflammatory effects and the underlying molecular mechanism of roxatidine in phorbol 12-myristate 13-acetate and calcium ionophore (PMACI)-stimulated human mast cells-1 (HMC-1), compound 48/80-induced anaphylactic animal model and chemical allergen-induced contact hypersensitivity (CHS) models. Roxatidine suppressed the mRNA and protein expression of inflammatory cytokines such as TNF-alpha, IL-6, and IL-1beta in PMACI-stimulated HMC-1 and compound 48/80-induced anaphylactic mice. In addition, roxatidine attenuated PMACI-induced nuclear translocation of NF-kappaB and the phosphorylation of MKK3/6 and MK2, which are both involved in the p38 MAPK pathway. Furthermore, we observed that roxatidine suppressed the activation of caspase-1, an IL-1beta converting enzyme, in PMACI-stimulated HMC-1 and compound 48/80-induced anaphylactic mice. In CHS model, roxatidine significantly reduced ear swelling, increased number of mast cells, production levels of cytokines and migration of dendritic cells. Our findings provide evidence that the anti-allergic inflammatory properties of roxatidine are mediated by the inhibition of NF-kappaB and caspase-1 activation, p38 MAPK pathway and mast cell-derived cytokine production. Taken together, the in vitro and in vivo anti-allergic inflammatory effects suggest a possible therapeutic application of roxatidine in allergic inflammatory diseases</style></abstract><notes><style face="normal" font="default">DA - 20170131IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1038/srep41721</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28139747">PM:28139747</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Rep\2016-6-41721.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Rep\2016-6-41721.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170131, Lee M</style></custom2><misc3><style face="normal" font="default">10.1038/srep41721</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40457</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,W.</style></author><author><style face="normal" font="default"> Zhou,L.</style></author><author><style face="normal" font="default"> Zeng,Q.</style></author><author><style face="normal" font="default"> Luo,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China</style></auth-address><titles><title><style face="normal" font="default">Combination of mometasone furoate and oxymetazoline for the treatment of adenoid hypertrophy concomitant with allergic rhinitis: A randomized controlled trial</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="40425">40425-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hypertrophy</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Intranasal steroids</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Mometasone</style></keyword><keyword><style face="normal" font="default"> mometasone furoate</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Otolaryngology</style></keyword><keyword><style face="normal" font="default"> Oxymetazoline</style></keyword><keyword><style face="normal" font="default"> perennial</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> symptom scores</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="default">In the clinic, approximately 30% of children with adenoid hypertrophy (AH) concomitant with allergic rhinitis (AR) report poor responses to intranasal steroids. To determine whether the combination of mometasone furoate (MF) and oxymetazoline (OXY) is more effective than either agent alone, we performed a two-stage, parallel, randomized, double-blind, double-dummy, clinical trial with 240 AH children with concomitant perennial AR. During the first stage, all children were randomly assigned to the MF or control group for six weeks of treatment. During the second stage, the non-responders from stage one were randomly assigned to 4 groups for 8 weeks of treatment that involved receiving the following treatments: MF/OXY, MF/placebo, placebo/OXY, or placebo/placebo. During the first stage of treatment, 39% of the responders treated with MF achieved greater reductions in total and individual symptom scores than did those on placebo. During the second stage of treatment, the nasal congestion scores of the MF/OXY group significantly decreased. The adenoid/choana ratio of the MF/OXY-treated group decreased and the nasal volume increased significantly. Our results suggest that the combination of OXY and MF is effective and safe for the treatment of AH children with concomitant AR and has a rapid onset of action</style></abstract><notes><style face="normal" font="default">DA - 20170118IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1038/srep40425</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28098165">PM:28098165</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Rep\2016-6-40425.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Rep\2016-6-40425.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170118, Liu W</style></custom2><misc3><style face="normal" font="default">10.1038/srep40425</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40458</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,Y.M.</style></author><author><style face="normal" font="default"> Kim,J.</style></author><author><style face="normal" font="default"> Han,Y.</style></author><author><style face="normal" font="default"> Lee,B.J.</style></author><author><style face="normal" font="default"> Choi,D.C.</style></author><author><style face="normal" font="default"> Cheong,H.K.</style></author><author><style face="normal" font="default"> Jeon,B.H.</style></author><author><style face="normal" font="default"> Oh,I.</style></author><author><style face="normal" font="default"> Bae,G.N.</style></author><author><style face="normal" font="default"> Lee,J.Y.</style></author><author><style face="normal" font="default"> Kim,C.H.</style></author><author><style face="normal" font="default"> Seo,S.</style></author><author><style face="normal" font="default"> Noh,S.R.</style></author><author><style face="normal" font="default"> Ahn,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Environmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Comparison of diverse estimation methods for personal exposure to air pollutants and associations with allergic symptoms: The Allergy &amp; Gene-Environment Link (ANGEL) study</style></title><secondary-title><style face="normal" font="default">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Sci Total Environ</style></full-title></periodical><pages end="1136" start="1127">1127-1136</pages><volume><style face="normal" font="default">579</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Adult asthma</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollutants</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> Air quality</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> Atopic diseases</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Humidity</style></keyword><keyword><style face="normal" font="default"> indoor</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Nitrogen</style></keyword><keyword><style face="normal" font="default"> Nitrogen Dioxide</style></keyword><keyword><style face="normal" font="default"> NO2</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Particulate matter</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> PM10</style></keyword><keyword><style face="normal" font="default"> pollutants</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> symptom scores</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Temperature</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">We estimated the exposure to ambient air pollutants and analyzed the associations with allergic diseases. We enrolled 177 children with atopic dermatitis (AD) and 70 asthmatic adults living in Seoul Metropolitan Area, Korea, and followed for 17months between August 2013 and December 2014. Parents or patients recorded symptom scores on a daily basis. Exposure to particulate matter with a diameter &lt;10mum (PM10) and nitrogen dioxide (NO2) was estimated in four different ways in each individual, using the AQ1 (measurements from the nearest air quality monitoring station to residential houses), AQ2 (measurements modified from AQ1 with the indoor level of air pollutants and time activity of each individual), AQ1-DI, and AQ2-DI (measurements modified from AQ1 and AQ2, respectively, with daily inhalation intakes of air pollutants). A generalized linear mixed model (GLMM) was used to analyze the associations between exposure metrics and clinical symptoms after adjusting for ambient temperature and humidity, age, season, gender, and time trend. The exposure metrics for PM10 and NO2 showed different distributions. Symptoms of AD and asthma were positively associated with exposure to PM10, but not NO2, in all exposure metrics. The effect size of PM10 exposure on asthma symptoms was slightly greater in metrics with inhalation capacity (AQ-DIs) than in those without (AQs). This pattern was not observed in AD. Exposure to PM10 is associated with symptom aggravation in childhood AD and adult asthma. Different exposure estimates may be used to evaluate the impact of air pollution on different allergic diseases</style></abstract><notes><style face="normal" font="default">DA - 20161204IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.scitotenv.2016.11.090</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27914645">PM:27914645</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Total Environ\2017-579-1127-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Total Environ\2017-579-1127-36.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161204, Kim YM</style></custom2><misc3><style face="normal" font="default">10.1016/j.scitotenv.2016.11.090</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40459</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kuo,S.C.</style></author><author><style face="normal" font="default"> Tsai,Y.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicinal Chemistry, Chia Nan University of Pharmacy and Science, 60, Sec. 1, Erren Rd., Rende Dist., Tainan City 71710, Taiwan</style></auth-address><titles><title><style face="normal" font="default">Emission characteristics of allergenic terpenols in PM2.5 released from incense burning and the effect of light on the emissions</style></title><secondary-title><style face="normal" font="default">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Sci Total Environ</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Alcohol</style></keyword><keyword><style face="normal" font="default"> Allergenic</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> indoor</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> PM2.5</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Smoke</style></keyword><keyword><style face="normal" font="default"> Taiwan</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="25" Month="1" Year="2017">2017/1/25</year></dates><abstract><style face="normal" font="default">This study investigated allergenic terpenol compounds in incense powder and smoke. The powder of two Thai brands contained higher concentrations of terpenols up to 6.15 times higher than those of two Taiwanese brands. Consequently, Thai incense makers face a higher potential risk of contact dermatitis than Taiwanese incense makers do. d-Limonene was the primary terpenol compound in the powder of Thai B (64.0%) and Thai Y (31.5%), sold in Thailand. By contrast, anisyl alcohol was the primary terpenol compound in the powder of LST (40.3%) and SC (37.7%), sold in Taiwan. After the four brands of incense were ignited, their mean PM2.5 emission factor was 18.02+/-6.20mgg-1 incense. The PM2.5 mass emission factors of the Taiwanese brands were far higher than those of the Thai brands, and so were the PM2.5 terpenol emission factors, showing that the smokes of the Taiwanese incense were potentially more allergenic than those of the Thai incense. Geraniol, the most allergenic terpenol compound, was 2.8%-10.7% of total terpenol compounds in the powder of the four brands, yet was the main contributor to PM2.5, constituting 66.3%-83.5% of terpenol compounds in the smokes of the four brands. Furthermore, geraniol exhibited an IP ratio, defined as the incense/powder (IP) ratio of terpenol-related species, >1 in all four brands, and >5 in the Taiwanese brands, suggesting a greater health risk with the smoke from the Taiwanese incense. The IP ratios of other terpenol species were all &lt;1, indicating decomposition through combustion. Additionally, the light/darkroom ratios of the terpenol species were >1, meaning that the generation of PM2.5 terpenol compounds was potentially enhanced by indoor lighting</style></abstract><notes><style face="normal" font="default">DA - 20170129IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1016/j.scitotenv.2017.01.052</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28131447">PM:28131447</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Total Environ\20170129-KuoSC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Total Environ\20170129-KuoSC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170129, Kuo SC</style></custom2><misc3><style face="normal" font="default">10.1016/j.scitotenv.2017.01.052</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40460</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Carr,T.F.</style></author><author><style face="normal" font="default"> Bleecker,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Asthma and Airway Disease Research Center, University of Arizona, 1501 N Campbell Ave, Tucson, AZ 85724-5030 USA</style></auth-address><titles><title><style face="normal" font="default">Asthma heterogeneity and severity</style></title><secondary-title><style face="normal" font="default">World Allergy Organ J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">World Allergy Organ J</style></abbr-1></periodical><pages end="" start="41">41-</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">airflow</style></keyword><keyword><style face="normal" font="default"> airflow obstruction</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Airways disease</style></keyword><keyword><style face="normal" font="default"> Arizona</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutics</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Asthma is a common, chronic inflammatory airways disease characterized by a clinical syndrome of bronchial hyperresponsiveness, inflammation, and reversible airflow obstruction. Individuals with asthma can vary widely in clinical presentation, severity, and pathobiology. The incident factors, pathogenesis, prognosis, and treatment of asthma remain incompletely understood. Utilizing measurable characteristics of asthmatic patients, including demographic, physiologic, and biologic markers, can however identify meaningful phenotypic categories in asthma. Identification of these phenotypes may help improve precision therapeutics targeted toward an individual's' disease, and may identify strategies for preventing progression of disease severity</style></abstract><notes><style face="normal" font="default">DA - 20161216IS - 1939-4551 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1186/s40413-016-0131-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27980705">PM:27980705</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\World Allergy Organ J\2016-9-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\World Allergy Organ J\2016-9-41.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161216, Carr TF</style></custom2><misc3><style face="normal" font="default">10.1186/s40413-016-0131-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40461</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Canonica,G.W.</style></author><author><style face="normal" font="default"> Senna,G.</style></author><author><style face="normal" font="default"> Mitchell,P.D.</style></author><author><style face="normal" font="default"> O'Byrne,P.M.</style></author><author><style face="normal" font="default"> Passalacqua,G.</style></author><author><style face="normal" font="default"> Varricchi,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy &amp; Respiratory Disease Clinic, DIMI Department of Internal Medicine, IRCCS AOU San Martino-IST, University of Genoa, Genova, Italy</style></auth-address><titles><title><style face="normal" font="default">Therapeutic interventions in severe asthma</style></title><secondary-title><style face="normal" font="default">World Allergy Organ J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">World Allergy Organ J</style></abbr-1></periodical><pages end="" start="40">40-</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anti-IgE</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> benralizumab</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cell Degranulation</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Endotypes</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Glucocorticoids</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-17</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immunotherapy</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory mediators</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> linkage</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> mepolizumab</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="default"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Periostin</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> reslizumab</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> SLIT</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> sublingual</style></keyword><keyword><style face="normal" font="default"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> tablet</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">The present paper addresses severe asthma which is limited to 5-10% of the overall population of asthmatics. However, it accounts for 50% or more of socials costs of the disease, as it is responsible for hospitalizations and Emergency Department accesses as well as expensive treatments. The recent identification of different endotypes of asthma, based on the inflammatory pattern, has led to the development of tailored treatments that target different inflammatory mediators. These are major achievements in the perspective of Precision Medicine: a leading approach to the modern treatment strategy. Omalizumab, an anti-IgE antibody, has been the only biologic treatment available on the market for severe asthma during the last decade. It prevents the linkage of the IgE and the receptors, thereby inhibiting mast cell degranulation. In clinical practice omalizumab significantly reduced the asthma exacerbations as well as the concomitant use of oral glucocorticoids. In the "Th2-high asthma" phenotype, the hallmarks are increased levels of eosinophils and other markers (such as periostin). Because anti-IL-5 in this condition plays a crucial role in driving eosinophil inflammation, this cytokine or its receptors on the eosinophil surface has been studied as a potential target for therapy. Two different anti-IL-5 humanized monoclonal antibodies, mepolizumab and reslizumab, have been proven effective in this phenotype of asthma (recently they both came on the market in the United States), as well as an anti-IL-5 receptor alpha (IL5Ralpha), benralizumab. Other monoclonal antibodies, targeting different cytokines (IL-13, IL-4, IL-17 and TSLP) are still under evaluation, though the preliminary results are encouraging. Finally, AIT, Allergen Immunotherapy, a prototype of Precision Medicine, is considered, also in light of the recent evidences of Sublingual Immunotherapy (SLIT) tablet efficacy and safety in mite allergic asthma patients. Given the high costs of these therapies, however, there is an urgent need to identify biomarkers that can predict the clinical responders</style></abstract><notes><style face="normal" font="default">DA - 20161212IS - 1939-4551 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Italy -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1186/s40413-016-0130-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27942351">PM:27942351</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\World Allergy Organ J\2016-9-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\World Allergy Organ J\2016-9-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161212, Canonica GW</style></custom2><misc3><style face="normal" font="default">10.1186/s40413-016-0130-3</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40462</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yang,S.L.</style></author><author><style face="normal" font="default"> Zhu,G.X.</style></author><author><style face="normal" font="default"> Yin,S.C.</style></author><author><style face="normal" font="default"> Chen,H.Y.</style></author><author><style face="normal" font="default"> Zhang,Y.Q.</style></author><author><style face="normal" font="default"> Lai,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510630, China</style></auth-address><titles><title><style face="normal" font="default">[Analysis of the results of patch test in 192 patients with hand eczema]</style></title><secondary-title><style face="normal" font="default">Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi</style></full-title></periodical><pages end="772" start="770">770-772</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand eczema</style></keyword><keyword><style face="normal" font="default"> KIT</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Thimerosal</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="20" Month="10" Year="2016">2016/10/20</year></dates><abstract><style face="normal" font="default">Objective: To investigate the common allergens in the patients with hand eczema. Methods: From November 2014 to March 2016, the patients with hand eczema were tested by the patch test kit of daily life series. Results: The results of the patch test of 192 patients with hand eczema were collected. Allergens were detected in 178 (92.71%) cases. The top 5 allergens were nickel chloride (23.96%) , cobalt chloride (18.75%) , aromatic compounds (17.19%) , nickel sulfate (16.67%) and thimerosal (13.54%). The positive rates of kappa mixture, aromatic compounds, tertiary butyl phenolic resin in males were 16.88% , 14.29% , 11.69% , respectively, which were higher than those (5.22% , 4.35% , 3.48%) in females. Conclusion: Nickel chloride, cobalt chloride, aromatic compounds, nickel sulfate and thimerosal are common allergens in patients with hand eczema</style></abstract><notes><style face="normal" font="default">DA - 20170103IS - 1001-9391 (Print)IS - 1001-9391 (Linking)LA - chiPT - Journal ArticlePT - English AbstractCO - China -</style></notes><work-type><style face="normal" font="default">10.3760/cma.j.issn.1001-9391.2016.10.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28043252">PM:28043252</url></web-urls></urls><custom2><style face="normal" font="default">20170103, Yang SL</style></custom2><misc3><style face="normal" font="default">10.3760/cma.j.issn.1001-9391.2016.10.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40463</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Humblet-Baron,S.</style></author><author><style face="normal" font="default"> Schonefeldt,S.</style></author><author><style face="normal" font="default"> Garcia-Perez,J.</style></author><author><style face="normal" font="default"> Baron,F.</style></author><author><style face="normal" font="default"> Pasciuto,E.</style></author><author><style face="normal" font="default"> Liston,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Translational Immunology Laboratory, VIB, Leuven, Belgium; KU Leuven - University of Leuven, Department of Microbiology and Immunology, Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="default">CTLA4-Ig effectively controls immune activation and inflammatory disease in a novel murine model of leaky SCID</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cell Differentiation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Colitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Hematology</style></keyword><keyword><style face="normal" font="default"> Histology</style></keyword><keyword><style face="normal" font="default"> Hypereosinophilia</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> Mutant</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Severe Combined Immunodeficiency</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="6" Month="2" Year="2017">2017/2/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Severe combined immunodeficiency (SCID) can be caused by loss-of-function mutations in genes involved in the DNA recombination machinery, such as RAG1, RAG2 or DCLRE1C. Defective DNA recombination causes a developmental block in T cells and B cells, resulting in high susceptibility to infections. Hypomorphic mutations in the same genes can also give a partial loss of T cells, in a spectrum including leaky SCID (LS) and Omenn syndrome (OS). These patients not only develop life-threatening infections due to immunodeficiency, but also develop inflammatory/autoimmune conditions due to the presence of autoreactive T cells. OBJECTIVE: We sought to develop a preclinical model that fully recapitulates the symptoms of LS/OS patients including a model for testing therapeutic intervention. METHODS: We generated a novel mutant mouse (Dclre1cleaky) that develops a LS phenotype. Mice were monitored for diseases and immune phenotype and immune function were evaluated using flow cytometry, ELISA and histology. RESULTS: Dclre1cleaky mice present with a complete blockade of B cell differentiation, with a leaky block in T cell differentiation resulting in an oligoclonal TCR repertoire and enhanced cytokine secretion. Dclre1cleaky mice also developed inflammatory symptoms including wasting, dermatitis, colitis, hypereosinophilia and high IgE levels. Development of a preclinical murine model for LS allowed the testing of potential treatment, with administration of CTLA4-Ig reducing disease symptoms and immunological disturbance, resulting in increased survival. CONCLUSION: These data suggest that CTLA4-Ig should be evaluated as a potential treatment of inflammatory symptoms in LS and OS patients</style></abstract><notes><style face="normal" font="default">DA - 20170210IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleC</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.12.968</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28185879">PM:28185879</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170210-HumbletBaronS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170210-HumbletBaronS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170210, Humblet-Baron S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.12.968</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40464</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arshad,S.H.</style></author><author><style face="normal" font="default"> Karmaus,W.</style></author><author><style face="normal" font="default"> Zhang,H.</style></author><author><style face="normal" font="default"> Holloway,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">David Hide Asthma and Allergy Research Centre, Isle of Wight, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Multigenerational cohorts in patients with asthma and allergy</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="421" start="415">415-421</pages><volume><style face="normal" font="default">139</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bias</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> Epigenetics</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Recall</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Sequence</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> transmission</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">Recent observations that disease risk can be transmitted across generations without the need for direct exposure of the child to the index environmental insult has sparked interest in transgenerational inheritance. Epigenetics describes processes that modify gene expression without a change in the nucleotide sequence. Epigenetic processes can be induced in response to environmental exposures, can influence disease risk, and might explain these multigenerational effects. In experimental models a number of epigenetic mechanisms have been identified that could mediate vertical transmission of epigenetic inheritance. However, relevance of these findings to human disease is not yet clear. An alternative model is one in which transgenerational inheritance of disease risk requires the presence of exposure-related diseases in the mother during pregnancy (termed induced epigenetic transmission model). A number of cross-sectional studies have investigated multigenerational effects in allergy and asthma. However, given the early-life origins of asthma and allergy, birth cohort studies are ideal to investigate the effect of genetic predisposition, epigenetics, and environmental exposures, avoiding pitfalls, such as recall bias and confounding by ongoing exposures, disease, and treatment. The well-characterized 3 generations of the Isle of Wight cohort include 2 consecutive birth cohorts, providing longitudinal data that can be studied for epigenetic transfer of information, such as the effect of grand parental smoking or exposure to other toxic compounds. Further large multigenerational birth cohorts are needed to establish the clinical relevance of this phenomenon and differentiate between vertical and induced transmission models, which might influence future preventive strategies</style></abstract><notes><style face="normal" font="default">DA - 20170210IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.12.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28183434">PM:28183434</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-415-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-415-21.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170210, Arshad SH</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.12.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40465</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Honda,A.</style></author><author><style face="normal" font="default"> Sawahara,T.</style></author><author><style face="normal" font="default"> Hayashi,T.</style></author><author><style face="normal" font="default"> Tsuji,K.</style></author><author><style face="normal" font="default"> Fukushima,W.</style></author><author><style face="normal" font="default"> Oishi,M.</style></author><author><style face="normal" font="default"> Kitamura,G.</style></author><author><style face="normal" font="default"> Kudo,H.</style></author><author><style face="normal" font="default"> Ito,S.</style></author><author><style face="normal" font="default"> Yoshida,S.</style></author><author><style face="normal" font="default"> Ichinose,T.</style></author><author><style face="normal" font="default"> Ueda,K.</style></author><author><style face="normal" font="default"> Takano,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Environmental Health Division, Department of Environmental Engineering, Graduate School of Engineering, Kyoto University, Kyoto, Japan.</style></auth-address><titles><title><style face="normal" font="default">Biological factor related to Asian sand dust particles contributes to the exacerbation of asthma</style></title><secondary-title><style face="normal" font="default">J Appl Toxicol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Appl Toxicol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway epithelial cell</style></keyword><keyword><style face="normal" font="default"> airway epithelial cells</style></keyword><keyword><style face="normal" font="default"> antigen-presenting cell</style></keyword><keyword><style face="normal" font="default"> Antigen-Presenting Cells</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Atmosphere</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> cell surface molecules</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Engineering</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="default"> epidemiologic study</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Hydrocarbons</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Nursing</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Epidemiologic studies have revealed that Asian sand dust particles (ASDs) can affect respiratory and immune health represented by asthma. Factors responsible for the exacerbation of asthma remain unclear. The fungus Bjerkandera adusta (B.ad) and polycyclic aromatic hydrocarbons such as benzo[a]pyrene (BaP) have been identified in ASDs collected from the atmosphere when an ASD event occurred. We investigated the effects of B.ad and BaP related to ASDs on respiratory and immune systems. Bone marrow-derived antigen-presenting cells (APCs) and splenocytes from atopic prone NC/Nga mice and human airway epithelial cells were exposed to the B.ad or to BaP in the presence and absence of heated-ASDs (H-ASDs). B.ad and BaP in both the presence and absence of H-ASDs increased the expression of cell surface molecules on APCs. H-ASDs alone slightly activated APCs. The expressions induced by B.ad were higher than those induced by BaP in the presence and absence of H-ASDs. There were no remarkable effects on the activation of splenocytes or the proinflammatory responses in airway epithelial cells. These results suggest that B.ad rather than BaP contributes to the exacerbation of asthma regardless of the presence or absence of sand particles, particularly by the activation of the immune system via APCs. Copyright (c) 2016 John Wiley &amp; Sons, Ltd</style></abstract><notes><style face="normal" font="default">DA - 20161007IS - 1099-1263 (Electronic)IS - 0260-437X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="default">10.1002/jat.3395</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27714829">PM:27714829</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Appl Toxicol\20161007-HondaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Appl Toxicol\20161007-HondaA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161007, Honda A</style></custom2><misc3><style face="normal" font="default">10.1002/jat.3395</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40466</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ahmed,S.S.</style></author><author><style face="normal" font="default"> Wang,X.N.</style></author><author><style face="normal" font="default"> Fielding,M.</style></author><author><style face="normal" font="default"> Kerry,A.</style></author><author><style face="normal" font="default"> Dickinson,I.</style></author><author><style face="normal" font="default"> Munuswamy,R.</style></author><author><style face="normal" font="default"> Kimber,I.</style></author><author><style face="normal" font="default"> Dickinson,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Alcyomics Ltd, Bulman House, Regent Centre, Gosforth, Newcastle-upon-Tyne, NE3 3LS, UK</style></auth-address><titles><title><style face="normal" font="default">An in vitro human skin test for assessing sensitization potential</style></title><secondary-title><style face="normal" font="default">J Appl Toxicol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Appl Toxicol</style></abbr-1></periodical><pages end="684" start="669">669-684</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal Testing Alternatives</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Cell Proliferation</style></keyword><keyword><style face="normal" font="default"> Cell Survival</style></keyword><keyword><style face="normal" font="default"> Cells,Cultured</style></keyword><keyword><style face="normal" font="default"> Characterization</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> cytology</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Drug</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Haptens</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> In Vitro Techniques</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Interferon-gamma</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritants</style></keyword><keyword><style face="normal" font="default"> Leukocytes,Mononuclear</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research Support</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="5" Year="2016">2016/5</year></dates><abstract><style face="normal" font="default">Sensitization to chemicals resulting in an allergy is an important health issue. The current gold-standard method for identification and characterization of skin-sensitizing chemicals was the mouse local lymph node assay (LLNA). However, for a number of reasons there has been an increasing imperative to develop alternative approaches to hazard identification that do not require the use of animals. Here we describe a human in-vitro skin explant test for identification of sensitization hazards and the assessment of relative skin sensitizing potency. This method measures histological damage in human skin as a readout of the immune response induced by the test material. Using this approach we have measured responses to 44 chemicals including skin sensitizers, pre/pro-haptens, respiratory sensitizers, non-sensitizing chemicals (including skin-irritants) and previously misclassified compounds. Based on comparisons with the LLNA, the skin explant test gave 95% specificity, 95% sensitivity, 95% concordance with a correlation coefficient of 0.9. The same specificity and sensitivity were achieved for comparison of results with published human sensitization data with a correlation coefficient of 0.91. The test also successfully identified nickel sulphate as a human skin sensitizer, which was misclassified as negative in the LLNA. In addition, sensitizers and non-sensitizers identified as positive or negative by the skin explant test have induced high/low T cell proliferation and IFNgamma production, respectively. Collectively, the data suggests the human in-vitro skin explant test could provide the basis for a novel approach for characterization of the sensitizing activity as a first step in the risk assessment process</style></abstract><notes><style face="normal" font="default">DA - 20160322IS - 1099-1263 (Electronic)IS - 0260-437X (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Allergens)RN - 0 (Haptens)RN - 0 (Irritants)RN - 82115-62-6 (Interferon-gamma)SB - IMCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1002/jat.3197</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26251951">PM:26251951</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Appl Toxicol\2016-36-669-84.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Appl Toxicol\2016-36-669-84.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160322, Ahmed SS</style></custom2><misc3><style face="normal" font="default">10.1002/jat.3197</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40467</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zang,Q.</style></author><author><style face="normal" font="default"> Paris,M.</style></author><author><style face="normal" font="default"> Lehmann,D.M.</style></author><author><style face="normal" font="default"> Bell,S.</style></author><author><style face="normal" font="default"> Kleinstreuer,N.</style></author><author><style face="normal" font="default"> Allen,D.</style></author><author><style face="normal" font="default"> Matheson,J.</style></author><author><style face="normal" font="default"> Jacobs,A.</style></author><author><style face="normal" font="default"> Casey,W.</style></author><author><style face="normal" font="default"> Strickland,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">ILS, Research Triangle Park, NC, 27709, USA</style></auth-address><titles><title><style face="normal" font="default">Prediction of skin sensitization potency using machine learning approaches</style></title><secondary-title><style face="normal" font="default">J Appl Toxicol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Appl Toxicol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Cell Line</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Consumer Product Safety</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Learning</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> peptide</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Silver</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Test method</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="10" Month="1" Year="2017">2017/1/10</year></dates><abstract><style face="normal" font="default">The replacement of animal use in testing for regulatory classification of skin sensitizers is a priority for US federal agencies that use data from such testing. Machine learning models that classify substances as sensitizers or non-sensitizers without using animal data have been developed and evaluated. Because some regulatory agencies require that sensitizers be further classified into potency categories, we developed statistical models to predict skin sensitization potency for murine local lymph node assay (LLNA) and human outcomes. Input variables for our models included six physicochemical properties and data from three non-animal test methods: direct peptide reactivity assay; human cell line activation test; and KeratinoSens assay. Models were built to predict three potency categories using four machine learning approaches and were validated using external test sets and leave-one-out cross-validation. A one-tiered strategy modeled all three categories of response together while a two-tiered strategy modeled sensitizer/non-sensitizer responses and then classified the sensitizers as strong or weak sensitizers. The two-tiered model using the support vector machine with all assay and physicochemical data inputs provided the best performance, yielding accuracy of 88% for prediction of LLNA outcomes (120 substances) and 81% for prediction of human test outcomes (87 substances). The best one-tiered model predicted LLNA outcomes with 78% accuracy and human outcomes with 75% accuracy. By comparison, the LLNA predicts human potency categories with 69% accuracy (60 of 87 substances correctly categorized). These results suggest that computational models using non-animal methods may provide valuable information for assessing skin sensitization potency. Copyright (c) 2017 John Wiley &amp; Sons, Ltd</style></abstract><notes><style face="normal" font="default">DA - 20170111IS - 1099-1263 (Electronic)IS - 0260-437X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1002/jat.3424</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28074598">PM:28074598</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Appl Toxicol\20170111-ZangQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Appl Toxicol\20170111-ZangQ.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Appl Toxicol\20170111-ZangQ.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Appl Toxicol\20170111-ZangQ.xlsx</url></image-urls></urls><custom2><style face="normal" font="default">20170111, Zang Q</style></custom2><misc3><style face="normal" font="default">10.1002/jat.3424</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40468</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mukkanna,K.S.</style></author><author><style face="normal" font="default"> Stone,N.M.</style></author><author><style face="normal" font="default"> Ingram,J.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Department, Abertawe Bro Morgannwg University Health Board, Swansea</style></auth-address><titles><title><style face="normal" font="default">Para-phenylenediamine allergy: current perspectives on diagnosis and management</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="15" start="9">9-15</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact allergens</style></keyword><keyword><style face="normal" font="default"> Counseling</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Hair</style></keyword><keyword><style face="normal" font="default"> Hair Dyes</style></keyword><keyword><style face="normal" font="default"> Hairdresser</style></keyword><keyword><style face="normal" font="default"> Hairdressers</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Henna</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Para-phenylenediamine</style></keyword><keyword><style face="normal" font="default"> Paraphenylenediamine</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe reactions</style></keyword><keyword><style face="normal" font="default"> Tattooing</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> Temporary tattoo</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Para-phenylenediamine (PPD) is the commonest and most well-known component of hair dyes. Oxidative hair dyes and dark henna temporary tattoos contain PPD. Individuals may be sensitized to PPD by temporary henna tattooing in addition to dyeing their hair. PPD allergy can cause severe reactions and may result in complications. In recent years, frequency of positive patch test reactions to PPD has been increasing. Cross-sensitization to other contact allergens may occur, in particular to other hair dye components. Hairdressers are at a high risk for PPD allergy and require counseling regarding techniques to minimize exposure and protective measures while handling hair dye. We focus this review on the current perspectives of diagnosis and management of PPD allergy</style></abstract><notes><style face="normal" font="default">DA - 20170208IS - 1178-6965 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.2147/JAA.S90265</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28176912">PM:28176912</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-9-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-9-15.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170208, Mukkanna KS</style></custom2><misc3><style face="normal" font="default">10.2147/JAA.S90265</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40469</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yagami,A.</style></author><author><style face="normal" font="default"> Furue,M.</style></author><author><style face="normal" font="default"> Togawa,M.</style></author><author><style face="normal" font="default"> Saito,A.</style></author><author><style face="normal" font="default"> Hide,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, School of Medicine, Fujita Health University, Aichi, Japan</style></auth-address><titles><title><style face="normal" font="default">One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases</style></title><secondary-title><style face="normal" font="default">J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse events</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Headache</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Itch</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Nervous System</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Tolerability</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="14" Month="11" Year="2016">2016/11/14</year></dates><abstract><style face="normal" font="default">A number of second-generation non-sedating antihistamines are used in clinical practices over the world. However, long-term safety and efficacy have not been proved high level evidence based medicine. We have performed an open-label, multicenter, phase III study to evaluate the long-term safety and efficacy of bilastine, a novel non-sedating H1 -antihistamine for patients with chronic spontaneous urticaria (CSU) or pruritus associated with skin diseases (trial registration no. JapicCTI-142528). Patients aged 18-74 years were treated with bilastine 20 mg once daily for up to 52 weeks. Safety and tolerability were assessed on the basis of adverse events (AE), bilastine-related AE, laboratory tests and vital signs. Efficacy was assessed based on rash score, itch score, overall improvement and quality of life. One hundred and ninety-eight patients enrolled, 122 of whom (61.6%) completed the 52-week treatment period. AE were reported in 64.5% and bilastine-related AE in 2.5% of patients throughout the 52-week treatment period. All AE were mild to moderate in severity. AE associated with the nervous system occurred in 10 patients (5.1%) including seven patients (3.6%) with headache. Somnolence reported in two of these patients (1.0%) was related to bilastine. All efficacy variables improved during treatment with bilastine. In conclusion, long-term treatment with bilastine 20 mg once daily for 52 weeks is safe and well tolerated in Japanese patients with CSU or pruritus associated with skin diseases. Bilastine improved disease symptoms of both conditions early in treatment, and the efficacy was maintained throughout the treatment</style></abstract><notes><style face="normal" font="default">DA - 20161118IS - 1346-8138 (Electronic)IS - 0385-2407 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/1346-8138.13644</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27862227">PM:27862227</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatol\20161118-YagamiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatol\20161118-YagamiA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161118, Yagami A</style></custom2><misc3><style face="normal" font="default">10.1111/1346-8138.13644</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40470</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Honma,M.</style></author><author><style face="normal" font="default"> Nozaki,H.</style></author><author><style face="normal" font="default"> Nagahata,H.</style></author><author><style face="normal" font="default"> Fujii,M.</style></author><author><style face="normal" font="default"> Kanno,K.</style></author><author><style face="normal" font="default"> Minami-Hori,M.</style></author><author><style face="normal" font="default"> Ishida-Yamamoto,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan</style></auth-address><titles><title><style face="normal" font="default">Elevation of serum carcinoembryonic antigen in a case of cholinergic urticaria with failed detection of hypohidrosis by the conventional starch-iodine test</style></title><secondary-title><style face="normal" font="default">J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">antigen</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161119IS - 1346-8138 (Electronic)IS - 0385-2407 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/1346-8138.13689</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27864842">PM:27864842</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatol\20161119-HonmaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatol\20161119-HonmaM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161119, Honma M</style></custom2><misc3><style face="normal" font="default">10.1111/1346-8138.13689</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40471</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yokoi,A.</style></author><author><style face="normal" font="default"> Suzuki,K.</style></author><author><style face="normal" font="default"> Takahashi,M.</style></author><author><style face="normal" font="default"> Yagami,A.</style></author><author><style face="normal" font="default"> Matsunaga,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Plastic Surgery, Akita University School of Medicine, Akita, Japan</style></auth-address><titles><title><style face="normal" font="default">Case of allergic contact dermatitis caused by sorbitan derivatives included in an over-the-counter topical medicament</style></title><secondary-title><style face="normal" font="default">J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicament</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Over-the-counter</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="2" Month="2" Year="2017">2017/2/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170202IS - 1346-8138 (Electronic)IS - 0385-2407 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/1346-8138.13731</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28150337">PM:28150337</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatol\20170202-YokoiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatol\20170202-YokoiA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170202, Yokoi A</style></custom2><misc3><style face="normal" font="default">10.1111/1346-8138.13731</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40472</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Barton,A.K.</style></author><author><style face="normal" font="default"> Gehlen,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Equine Clinic, Freie Universitaet Berlin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="default">Pulmonary Remodeling in Equine Asthma: What Do We Know about Mediators of Inflammation in the Horse?</style></title><secondary-title><style face="normal" font="default">Mediators Inflamm</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Mediators Inflamm</style></full-title></periodical><pages end="" start="5693205">5693205-</pages><volume><style face="normal" font="default">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> Airway Obstruction</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="default"> Chemotaxis</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> cytology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Enzymes</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Fibrinolysis</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Horses</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Interleukins</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Matrix Metalloproteinases</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Equine inflammatory airway disease (IAD) and recurrent airway obstruction (RAO) represent a spectrum of chronic inflammatory disease of the airways in horses resembling human asthma in many aspects. Therefore, both are now described as severity grades of equine asthma. Increasing evidence in horses and humans suggests that local pulmonary inflammation is influenced by systemic inflammatory processes and the other way around. Inflammation, coagulation, and fibrinolysis as well as extracellular remodeling show close interactions. Cytology of bronchoalveolar lavage fluid and tracheal wash is commonly used to evaluate the severity of local inflammation in the lung. Other mediators of inflammation, like interleukins involved in the chemotaxis of neutrophils, have been studied. Chronic obstructive pneumopathies lead to remodeling of bronchial walls and lung parenchyma, ultimately causing fibrosis. Matrix metalloproteinases (MMPs) are discussed as the most important proteolytic enzymes during remodeling in human medicine and increasing evidence exists for the horse as well. A systemic involvement has been shown for severe equine asthma by increased acute phase proteins like serum amyloid A and haptoglobin in peripheral blood during exacerbation. Studies focusing on these and further possible inflammatory markers for chronic respiratory disease in the horse are discussed in this review of the literature</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1466-1861 (Electronic)IS - 0962-9351 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1155/2016/5693205</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28053371">PM:28053371</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mediators Inflamm\2016-2016-5693205.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mediators Inflamm\2016-2016-5693205.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Barton AK</style></custom2><misc3><style face="normal" font="default">10.1155/2016/5693205</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40473</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yoo,J.M.</style></author><author><style face="normal" font="default"> Yang,J.H.</style></author><author><style face="normal" font="default"> Kim,Y.S.</style></author><author><style face="normal" font="default"> Cho,W.K.</style></author><author><style face="normal" font="default"> Ma,J.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Korean Medicine (KM) Application Center, Korea Institute of Oriental Medicine (KIOM), Daegu 41062, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Inhibitory Effect of Loranthus parasiticus on IgE-Mediated Allergic Responses in RBL-2H3 Cells</style></title><secondary-title><style face="normal" font="default">Mediators Inflamm</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Mediators Inflamm</style></full-title></periodical><pages end="" start="8742562">8742562-</pages><volume><style face="normal" font="default">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">5-Lipoxygenase</style></keyword><keyword><style face="normal" font="default"> activation</style></keyword><keyword><style face="normal" font="default"> AKT</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic response</style></keyword><keyword><style face="normal" font="default"> Asia</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> COX-2</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flavonoids</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Interleukin-4</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> late phase</style></keyword><keyword><style face="normal" font="default"> late-phase</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Leukotriene C4</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> Prostaglandin</style></keyword><keyword><style face="normal" font="default"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="default"> prostaglandin E2</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Syk</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">The mistletoe Loranthus parasiticus has been used as a compound for traditional medicine in Northeast Asia for a long time and is known to possess neuroprotective action. Nonetheless, the effect of Loranthus parasiticus on allergic responses remains unknown. In the present study, we evaluated whether the water extract of Loranthus parasiticus (LPE) could inhibit IgE-mediated allergic responses in RBL-2H3 cells. LPE inhibited the release of beta-hexosaminidase (IC50, 184.5 mug/mL) and the formation of tumor necrosis factor-alpha (IC50, 84.27 mug/mL), interleukin-4 (IC50, 93.43 mug/mL), prostaglandin E2 (IC50, 84.10 mug/mL), prostaglandin D2, and leukotriene C4 (IC50, 43.27 mug/mL) in a concentration-dependent manner. Moreover, LPE inhibited phosphorylation of Syk, PLCgamma1/2, PKCdelta, ERK, JNK, p38, and Akt. In the late phase, LPE decreased 5-lipoxygenase phosphorylation and COX-2 expression but not cPLA2 phosphorylation. Additionally, LPE included total phenolic compounds (10.72 mg/g dry weight) and total flavonoids (56.20 mg/g dry weight). These results suggest that the phenolic compounds or flavonoids contained in LPE may be associated with antiallergic activity. The phenolic compounds and flavonoids in LPE are antiallergic phytochemicals capable of inhibiting the activation of the FcepsilonRI signaling cascade in mast cells. Such effects may provide further information for the development of a phytomedicine for allergic diseases</style></abstract><notes><style face="normal" font="default">DA - 20161020IS - 1466-1861 (Electronic)IS - 0962-9351 (Linking)LA - ENGPT - JOURNAL ARTICLECO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1155/2016/8742562</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27761061">PM:27761061</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mediators Inflamm\2016-2016-8742562.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mediators Inflamm\2016-2016-8742562.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161020, Yoo JM</style></custom2><misc3><style face="normal" font="default">10.1155/2016/8742562</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40474</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Qu,Y.L.</style></author><author><style face="normal" font="default"> Ji,Y.R.</style></author><author><style face="normal" font="default"> Zhang,L.X.</style></author><author><style face="normal" font="default"> Wu,C.M.</style></author><author><style face="normal" font="default"> Wen,B.L.</style></author><author><style face="normal" font="default"> Zhang,X.</style></author><author><style face="normal" font="default"> Ma,C.</style></author><author><style face="normal" font="default"> Wang,M.</style></author><author><style face="normal" font="default"> Zhang,Y.X.</style></author><author><style face="normal" font="default"> Zhou,X.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesiology, No 401 Hospital of PLA, Qingdao, China</style></auth-address><titles><title><style face="normal" font="default">17q21 locus rs7216389 polymorphism and childhood asthma risk: a meta-analysis</style></title><secondary-title><style face="normal" font="default">Minerva Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Minerva Pediatr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> Anesthesiology</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> association studies</style></keyword><keyword><style face="normal" font="default"> association study</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma risk</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic asthma</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Genome-wide</style></keyword><keyword><style face="normal" font="default"> genome-wide association</style></keyword><keyword><style face="normal" font="default"> genome-wide association studies</style></keyword><keyword><style face="normal" font="default"> genome-wide association study</style></keyword><keyword><style face="normal" font="default"> GWAS</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> paediatric asthma</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="22" Month="12" Year="2016">2016/12/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: Recently, a genome-wide association study (GWAS) indicated that rs7216389 polymorphism on chromosome 17q21 was associated with paediatric asthma risk. However, the results remained controversial. Therefore, a meta-analysis was performed. METHODS: A comprehensive literature retrieve was performed on PubMed, Embase and Science Direct databases up to Feb 20, 2016. The strength of association between 17q21 locus rs7216389 polymorphism and paediatric asthma risk was assessed by computing odds ratio (OR) with its corresponding 95% confidence interval (CI). RESULTS: A total of 10 studies with 7797 cases and 38757 controls were included. A statistically significant association of rs7216389 polymorphism and paediatric asthma risk was found (OR = 1.41, 95%CI = 1.34-1.49, p&lt;0.00001). Furthermore, both Caucasians (OR = 1.41, 95%CI = 1.33-1.49, p&lt;0.00001) and Asians (OR = 1.43, 95%CI = 1.25-1.63, p&lt;0.00001) with rs7216389 polymorphism showed significant association, respectively. A significantly increased susceptibility was identified in atopic asthma (OR = 1.45, 95%CI = 1.22-1.72, p&lt;0.00001). In the stratification analysis by study design, both case-control studies (OR = 1.40, 95%CI = 1.33-1.48, p&lt;0.00001) and cohort studies (OR = 2.05, 95%CI = 1.32-3.17, p=0.001) showed significant association, respectively. CONCLUSIONS: In conclusion, this meta-analysis suggests that 17q21 locus rs7216389 polymorphism was significantly associated with paediatric asthma risk</style></abstract><notes><style face="normal" font="default">DA - 20161223IS - 1827-1715 (Electronic)IS - 0026-4946 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28006895">PM:28006895</url></web-urls></urls><custom2><style face="normal" font="default">20161223, Qu YL</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40475</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ruggiero,G.</style></author><author><style face="normal" font="default"> Carnevale,C.</style></author><author><style face="normal" font="default"> Diociaiuti,A.</style></author><author><style face="normal" font="default"> Arcangeli,F.</style></author><author><style face="normal" font="default"> El Hachem,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Private practitioner, Salerno, Italy</style></auth-address><titles><title><style face="normal" font="default">Prospective multicenter survey on the clinical management of pediatric contact dermatitis</style></title><secondary-title><style face="normal" font="default">Minerva Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Minerva Pediatr</style></full-title></periodical><pages end="418" start="412">412-418</pages><volume><style face="normal" font="default">68</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse events</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Algorithms</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous manifestations</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritant contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatricians</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Protective Devices</style></keyword><keyword><style face="normal" font="default"> Remission</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin Care</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Contact dermatitis can be defined as an inflammatory process affecting the skin surface and induced by contact with chemical, physical and/or biotic agents in the environment. It causes lesions to skin, mucosae and semi-mucosae by means of allergic and irritant pathogenic mechanisms. Among the main triggers of contact dermatitis in the pediatric age are chemical or physical agents, which cause irritant contact dermatitis (ICD), and sensitizers, which cause a tissue damage through an allergic mechanism (allergic contact dermatitis [ACD]). METHODS: A prospective, multicenter, observational study was carried out in 204 children affected by contact dermatitis, aged up to 14 years, and enrolled by pediatricians from 7 different Italian provinces. The diagnosis of contact dermatitis was based on the pediatrician's clinical evaluation. The data were collected through a series of simple and multiple choice questions, anonymously filled out by pediatricians. RESULTS: In 90% of cases (184 of 204 patients), there was complete remission of contact dermatitis, with no cases of worsening. No adverse events were observed, either. The effectiveness of the therapy was rated as "very effective" by 84.4% of the parents and 86.8% of the pediatricians. In only 10 patients a new therapy had to be prescribed. CONCLUSIONS: Contact dermatitis is a heterogeneous inflammatory skin disease induced by contact with different kinds of environmental agents. Cutaneous manifestations are highly variable and depend on the modality of contact, on the causative agent and on the pathogenesis. This Italian experience of a clinical approach to contact dermatitis stresses the need of daily skin care through different therapeutic strategies, based on the diagnosis, the clinical severity and the parents and children compliance. The first therapeutic measure to be implemented is prevention, through the removal of the causative agent and the use of protective devices. Indeed, preserving the skin's barrier function is an important goal and a priority of treatment algorithms</style></abstract><notes><style face="normal" font="default">DA - 20161021IS - 1827-1715 (Electronic)IS - 0026-4946 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27768013">PM:27768013</url></web-urls></urls><custom2><style face="normal" font="default">20161021, Ruggiero G</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40476</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tahan,F.</style></author><author><style face="normal" font="default"> Eke,G.H.</style></author><author><style face="normal" font="default"> Akar,H.H.</style></author><author><style face="normal" font="default"> Saraymen,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric Allergy Erciyes University, School of Medicine</style></auth-address><titles><title><style face="normal" font="default">Increased Levels of Plasma Soluble Human Leukocyte Antigen G in Persistent Wheezy Infants</style></title><secondary-title><style face="normal" font="default">Pediatr Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pediatr Int</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Histocompatibility</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human leukocyte antigen</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Major Histocompatibility Complex</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> MHC</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Human leukocyte antigen (HLA)-G is a non-classical major histocompatibility complex (MHC) class I antigen characterized by limited polymorphism in its coding region, unique tissue expression pattern in physiologic conditions and immunomodulatory properties. Recently, many studies suggest that the levels of sHLA-G were higher in atopic asthma and allergic rhinitis (AR). However, this remains to be uncertain in wheezy infants. In the present study, it was aimed to determine sHLA-G levels in wheezy infants. METHODS: The study included infants with persistent wheezing and positive modified asthma predictive index (mAPI) (n=30) (persistent group) and those with transient wheezing and negative mAPI (n=17) (transient group). sHLA-G levels were determined in plasma by using enzyme-linked immunosorbent assay. Total immunoglobulin E (IgE) and eosinophil counts were obtained whereas skin testing was performed with a battery of 13 antigens with appropriate positive and negative controls. RESULTS: When infants with persistent wheezing and positive mAPI (persistent group) and those with transient wheezing and negative mAPI (transient group) were compared, sHLA-G levels were found to be significantly higher in persistent group (p = 0.008). There was not a significant difference in the peripheral blood eosinophil counts and total IgE levels among the groups. CONCLUSIONS: To best of our knowledge, this is the first study assessing sHLA-G levels in wheezy infants. The finding of increased sHLA-G levels in infants with persistent wheezing suggests that it may be a parameter which could be used to distinguish which wheezing would be persistent. Further comprehensive studies are needed in this topic. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161123IS - 1442-200X (Electronic)IS - 1328-8067 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1111/ped.13207</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27880031">PM:27880031</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Int\20161123-TahanF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Int\20161123-TahanF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161123, Tahan F</style></custom2><misc3><style face="normal" font="default">10.1111/ped.13207</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40477</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Valeriani,F.</style></author><author><style face="normal" font="default"> Protano,C.</style></author><author><style face="normal" font="default"> Vitali,M.</style></author><author><style face="normal" font="default"> Romano Spica,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Public Health Unit, University of Rome "Foro Italico", Rome, Italy</style></auth-address><titles><title><style face="normal" font="default">Swimming attendance during childhood and development of asthma: a meta-analysis</style></title><secondary-title><style face="normal" font="default">Pediatr Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pediatr Int</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disinfection</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidemiological studies</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> indoor</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Language</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rome</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Swimming</style></keyword><keyword><style face="normal" font="default"> Swimming Pools</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="29" Month="12" Year="2016">2016/12/29</year></dates><abstract><style face="normal" font="default">BACKGROUND: The association between asthma and swimming pool attendance has not been demonstrated and contrasting results emerged. In order to clarify the association between asthma diagnosis in children and swimming pool attendance, and to assess the consistency of findings of the available epidemiological studies, we completed a literature analysis focusing on literature about the relationship between the exposure to disinfection by-products in indoor swimming pool during childhood and asthma diagnosis. METHODS: Following the MOOSE and PRISMA criteria, a systematic review and meta-analysis was performed by searching MEDLINE via PubMed, TOXNET, and Scopus databases (inception - April 20, 2015) using the key word "Asthma" together with "swimming pool", "disinfection by-products", "indoor air pollution" and "children". Inclusion criteria were: English language, a complete analytic study design comprising a cohort of children (0-16 years), a well-defined definition of exposure, and the presence of data on effect and variance. Studies considering in vivo, in vitro or professional and accidental exposures were excluded. RESULTS: After a screening process, seven reports (n=5851 subjects) were included out of a total of 2928 references. The reported Odds Ratio (ORs) of the association between swimming pool attendance and asthma prevalence ranged from 0.58 to 2.30. The present meta-analysis failed to reveal a significant difference in asthma development between children attending swimming pools and controls (OR=1.084; 95%IC=0.89-1.31). CONCLUSION: Swimming in childhood does not increase the doctor diagnosed asthma. Based on this meta-analysis review, the association of the disease with attendance of indoor pools resulted inconsistent. Primary source of funding: This study was supported by IUSM grants 2014-2015. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161229IS - 1442-200X (Electronic)IS - 1328-8067 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/ped.13230</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28032933">PM:28032933</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Int\20161229-ValerianiF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Int\20161229-ValerianiF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161229, Valeriani F</style></custom2><misc3><style face="normal" font="default">10.1111/ped.13230</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40478</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Munoz,I.</style></author><author><style face="normal" font="default"> Danelli,L.</style></author><author><style face="normal" font="default"> Kurowska,M.</style></author><author><style face="normal" font="default"> Blank,U.</style></author><author><style face="normal" font="default"> Menasche,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Characterization of the transport machinery regulating mast cell degranulation</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> Bone Marrow</style></keyword><keyword><style face="normal" font="default"> Cell Degranulation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Characterization</style></keyword><keyword><style face="normal" font="default"> Cytoplasm</style></keyword><keyword><style face="normal" font="default"> Cytoskeleton</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Fc+øRI</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Granules</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Kinesin-1</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Molecular motor</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> PI3K</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Rab27b</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Secretory granule</style></keyword><keyword><style face="normal" font="default"> Secretory granules</style></keyword><keyword><style face="normal" font="default"> Slp3</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Vesicle trafficking</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Mast cells (MC) are granulated cells of hematopoietic origin localised to most tissues whose haematopoietic precursors are found in bone marrow. Their cytoplasm holds large numbers of granulations containing preformed mediators. MC express at their surface numerous receptors including the high-affinity IgE receptor (Fc?RI). Cross-linking of receptor-bound IgE by specific multivalent antigens triggers the release within minutes of preformed mediators contained in secretory granules (SGs), leading to immediate IgE-mediated type I hypersensitivity reaction. The secretory machinery that allows SG secretion by mast cells and its interaction with the cytoskeleton continue to be a poorly understood. We are particularly interested in analysing the role of kinesin-1 motor protein, a conventional member of the kinesin superfamily, in the transport of SG along the microtubule network to their site of secretion. The protein complex formed by the small GTPase Rab27b and its effector, synaptotagmin-like protein 3 (Slp3), is responsible for the stimulation-dependent recruitment of kinesin-1 to SG upon Fc?RI activation. Formation of the Rab27b/Slp3/kinesine-1 complex is dependent on phosphatidylinositol 3-kinase (PI3K) activity. Herein, we propose a brief overview of recent knowledge acquired regarding characterisation of the transport machinery regulating mast cell degranulation.</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2016.11.004</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2016.11.004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170215-MunozI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170215-MunozI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170215, Munoz I</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2016.11.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40479</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mughal,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Singleton Hospital, Sketty, Swansea, U.K</style></auth-address><titles><title><style face="normal" font="default">What substances are allergenic and in whom?</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="15" start="14">14-15</pages><volume><style face="normal" font="default">176</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergenic</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170118IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15101</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28098362">PM:28098362</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\2017-176-14-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\2017-176-14-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170118, Mughal AA</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15101</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40480</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Thomsen,S.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Bispebjerg Hospital, Bispebjerg Bakke 23, DK-2400, Copenhagen, NV, DenmarkCenter for Medical Research Methodology, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default">Effectiveness of phototherapy in chronic urticaria</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="8">8-</pages><volume><style face="normal" font="default">176</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170118IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28098370">PM:28098370</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\2017-176-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\2017-176-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170118, Thomsen SF</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40481</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Di Marco,F.</style></author><author><style face="normal" font="default"> Papa,G.F.</style></author><author><style face="normal" font="default"> Radovanovic,D.</style></author><author><style face="normal" font="default"> Santus,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory Unit, ASST Santi Paolo e Carlo, Milan, Italy ; 0000 0004 1757 2822grid.4708.bDipartimento Scienze della Salute, Universita degli Studi di Milano, Milan, Italy</style></auth-address><titles><title><style face="normal" font="default">Avoiding misdiagnosis in patients with dyspnea and wheezing: a case report illustrating the clinical implications of fixation error</style></title><secondary-title><style face="normal" font="default">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Mol Allergy</style></full-title></periodical><pages end="" start="3">3-</pages><volume><style face="normal" font="default">15</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> Bronchoscopy</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> formoterol</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Tracheal Stenosis</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Upper airways</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Bronchial asthma is a heterogeneous respiratory condition which can be mimicked by a wide range of pathologies including upper airways stenosis. The accurate diagnosis of asthma, as with other conditions, may be influenced by fixation errors, which are common in medicine and occur when a physician concentrates on only one element of a clinical case without considering other relevant aspects. Here we report a challenging case characterized by the contemporaneous presence of a common disease, asthma, together with a rare respiratory disease, idiopathic tracheal stenosis. CASE PRESENTATION: The 56-year-old female patient, a former smoker, was referred to our outpatient clinic for exertional dyspnea and persistent wheezing. There were no other respiratory or systemic symptoms over the past three months, and a psychological component was suspected. Spirometry with flow-volume evaluation and bronchoscopy were the key elements to establish the diagnoses and provide treatments. Once the diagnosis of asthma was confirmed, the combination of the anti-inflammatory corticosteroid fluticasone and the rapid-acting bronchodilator formoterol in a single inhaler effectively controlled the patient's symptoms, confirming the favorable efficacy and safety profile which are reflected in the recommendations of the international guidelines. CONCLUSIONS: In this paper we describe the clinical investigations and interventions that eventually confirmed a diagnosis of asthma complicated by an idiopathic tracheal stenosis and led to effective treatment of the patient. Awareness of fixation error may avoid misdiagnosis in patients with respiratory disease and a complicated history at presentation</style></abstract><notes><style face="normal" font="default">DA - 20170213IS - 1476-7961 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1186/s12948-017-0060-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28190974">PM:28190974</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170213, Di Marco F</style></custom2><misc3><style face="normal" font="default">10.1186/s12948-017-0060-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40482</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stander,S.</style></author><author><style face="normal" font="default"> Oppel,E.</style></author><author><style face="normal" font="default"> Thomas,P.</style></author><author><style face="normal" font="default"> Summer,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergology, Ludwig-Maximilians-University, 80337, Munich, Germany</style></auth-address><titles><title><style face="normal" font="default">Evaluation of lymphocyte transformation tests as compared with patch tests in nickel allergy diagnosis</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Gold</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> LTT</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Transformation</style></keyword><keyword><style face="normal" font="default"> Lymphocyte transformation test</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Nickel allergy</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Transformation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="7" Month="2" Year="2017">2017/2/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: The patch test is considered to be the gold standard for diagnosing nickel (Ni) allergy. The lymphocyte transformation test (LTT) can also be used to detect Ni sensitization. However, little is known about the correlation between patch test and LTT reactions to Ni. OBJECTIVE: To establish and validate an LTT for Ni sensitization by comparison with patch test reaction and history. METHODS: Fifty individuals without self-reported 'Ni allergy' (controls) and 50 patients with self-reported suspicion of Ni allergy were included. A questionnaire-aided history was taken, and patch tests with at least the baseline series and LTTs with various NiSO4 dilutions were performed. RESULTS: In the patch tests, 2 of 50 controls and 18 of 50 patients with self-reported suspicion of Ni allergy showed positive reactions to Ni. In the LTTs, 2 of 50 controls and 26 of 50 patients with self-reported suspicion of Ni allergy showed positive reactions to NiSO4 2.5 x 10-5 m, and 2 of 50 controls and 17 of 50 patients with self-reported suspicion of Ni allergy showed positive reactions to NiSO4 1 x 10-5 m. Sixteen of the 18 history-positive and patch test-positive patients (i.e. 88% sensitivity) were also LTT-positive, in contrast to only 2 of the 48 patch test-positive and history-negative patients (i.e. 96% specificity). CONCLUSION: Performing the LTT with optimized stimulating conditions might be a useful additional tool for the diagnosis of Ni allergy if non-sensitized controls are included</style></abstract><notes><style face="normal" font="default">DA - 20170208IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12751</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28176340">PM:28176340</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Dermatol\20170208-StanderSpdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Dermatol\20170208-StanderSpdf</url></text-urls></urls><custom2><style face="normal" font="default">20170208, Stander S</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12751</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40483</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gulseren,D.</style></author><author><style face="normal" font="default"> Hapa,A.</style></author><author><style face="normal" font="default"> Ersoy-Evans,S.</style></author><author><style face="normal" font="default"> Elcin,G.</style></author><author><style face="normal" font="default"> Karaduman,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hacettepe University, School of Medicine, Department of Dermatology, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="default">Is there a role of food additives in recurrent aphthous stomatitis? a prospective study with patch testing</style></title><secondary-title><style face="normal" font="default">Int J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Dermatol</style></full-title></periodical><pages end="306" start="302">302-306</pages><volume><style face="normal" font="default">56</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">additives</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Food Additives</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> oral mucosa</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Stomatitis</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Recurrent aphthous stomatitis (RAS) is a common disease of the oral mucosa with an unknown etiology. This study aimed to determine if food additives play a role in the etiology of RAS as well as to determine if patch testing can be used to detect which allergens cause RAS. METHODS: This prospective study included 24 patients with RAS and 22 healthy controls. All the participants underwent patch testing for 23 food additives. RESULTS: In total, 21 (87.5%) RAS patients and 3 (13.6%) controls had positive patch test reactions to >/=1 allergens; the difference in the patch test positivity rate between groups was significant (P &lt; 0.05). The most common allergen that elicited positive patch test results in the patient group was cochineal red (n = 15 [62.5%]), followed by azorubine (n = 11 [45.8%]) and amaranth (n = 6 [25%]). CONCLUSIONS: The present findings show that food additives might play a role in the etiology of RAS and that patch testing could be a method for determining the etiology of RAS</style></abstract><notes><style face="normal" font="default">DA - 20161230IS - 1365-4632 (Electronic)IS - 0011-9059 (Linking)LA - engPT - Journal ArticleCO - Turkey -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/ijd.13515</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28035659">PM:28035659</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Dermatol\2017-56-302-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Dermatol\2017-56-302-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161230, Gulseren D</style></custom2><misc3><style face="normal" font="default">10.1111/ijd.13515</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40484</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Botelho,L.F.</style></author><author><style face="normal" font="default"> Porro,A.M.</style></author><author><style face="normal" font="default"> Enokihara,M.M.</style></author><author><style face="normal" font="default"> Tomimori,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Federal University of Sao Paulo, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="default">Adverse cutaneous drug reactions in a single quaternary referral hospital</style></title><secondary-title><style face="normal" font="default">Int J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Dermatol</style></full-title></periodical><pages end="e203" start="e198">e198-e203</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acute Generalized Exanthematous Pustulosis</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Anti-Bacterial Agents</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Anticonvulsants</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> chemically induced</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous drug reaction</style></keyword><keyword><style face="normal" font="default"> Cutaneous drug reactions</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Exfoliative</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dermis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> DRESS</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Eruptions</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity Syndrome</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Erythema Multiforme</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Exanthema</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hand-Foot Syndrome</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Stevens-Johnson Syndrome</style></keyword><keyword><style face="normal" font="default"> Stevens-Johnson syndrome/toxic epidermal necrolysis</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Vasculitis</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Adverse cutaneous drug reactions are frequent in hospital settings and are responsible for increased morbidity, mortality, and socioeconomic costs. The objective of this study was to identify high risk factors in hospitalized patients with adverse cutaneous drug reactions. METHODS: This descriptive and retrospective study was performed with data from 117 patients admitted to a quaternary hospital over 44 months. We reviewed their epidemiological data, suspected drugs, clinical presentation, histopathological diagnosis, and outcome. Statistical analysis was performed using the chi-squared test with a significance level of 5%. RESULTS: Anticonvulsants were responsible for 23.9% of cases followed by antibiotics (22.2%). In 29% of cases, patients were taking multiple medications that could have triggered their reactions. The most common clinical forms were exanthema (37.6%), drug reaction with eosinophilia and systemic symptoms (DRESS) (14.5%), and Stevens-Johnson syndrome/toxic epidermal necrolysis (12.8%). Anticonvulsants were associated with severe forms of adverse drug reactions. Most patients (89.7%) presented clinical improvement after treatment. There was a relationship between the use of anticonvulsants and atypical lymphocytes in the dermal infiltrate, as well as the clinical form DRESS and atypical lymphocytes in the dermal infiltrate. CONCLUSIONS: The use of anticonvulsants was a high risk factor for severe clinical forms of drug reactions. The presence of atypical lymphocyte infiltrates in the dermis could indicate the use of anticonvulsants</style></abstract><notes><style face="normal" font="default">DA - 20160314IS - 1365-4632 (Electronic)IS - 0011-9059 (Linking)LA - engPT - Journal ArticleRN - 0 (Anti-Bacterial Agents)RN - 0 (Anticonvulsants)SB - IMCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1111/ijd.13126</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26710962">PM:26710962</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Dermatol\2016-55-e198-203.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Dermatol\2016-55-e198-203.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160314, Botelho LF</style></custom2><misc3><style face="normal" font="default">10.1111/ijd.13126</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40485</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dos Santos,V.</style></author><author><style face="normal" font="default"> Orfali,R.L.</style></author><author><style face="normal" font="default"> de Oliveira,T.T.</style></author><author><style face="normal" font="default"> Da Silva Duarte,A.J.</style></author><author><style face="normal" font="default"> Sato,M.N.</style></author><author><style face="normal" font="default"> Aoki,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Laboratory of Dermatology and Immunodeficiency (LIM-56), University of Sao Paulo School of Medicine, Sao Paulo-SP, Brazil</style></auth-address><titles><title><style face="normal" font="default">Evidence of regulatory myeloid dendritic cells and circulating inflammatory epidermal dendritic cells-like modulated by Toll-like receptors 2 and 7/8 in adults with atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Int J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> agonists</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> DC</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> LPS</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Rna</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Staphylococcal enterotoxin B</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TLR4</style></keyword><keyword><style face="normal" font="default"> TNF</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="12" Month="1" Year="2017">2017/1/12</year></dates><abstract><style face="normal" font="default">BACKGROUD: Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by intense pruritus and xerosis. Dendritic cells (DC) play an essential role in tissue inflammation in atopic dermatitis (AD) skin, especially the inflammatory epidermal dendritic cells (IDEC), a particular subset of myeloid dendritic cells (mDC). The aim of the present study was to assess the phenotype and function of mDC and circulating IDEC-like in peripheral blood mononuclear cells (PBMC) of adults with AD. METHODS: We selected 21 AD patients and 21 non-AD controls, age and gender matched. Expressions of FcepsilonRI, CD36, TNF, IFN- gamma, and IL-10 in mDC were analyzed by flow cytometry under various stimuli, such as staphylococcal enterotoxin B (SEB), TLR2 (Pam3CSK4), TLR4 (LPS), and TLR7/8 (CL097) agonists. RESULTS: The most prominent findings in AD patients were: (i) enhanced frequency of IL-10 under TLR4 (LPS), and decreased frequency of IFN-gamma and TNF under TLR2 (Pam3CSK4) and 7/8 (CL097) stimulation in classic mDC; (ii) elevation of circulating IDEC-like frequency with TLR2 (Pam3CSK4) stimuli, augmented frequency of IFN-gamma in nonstimulated condition, and of IL-10 under TLR7/8 (CL097) stimuli in IDEC-like population. CONCLUSIONS: In AD individuals, classic mDC showed an immunomodulatory profile, favoring tolerance in a combined action with IDEC-like, and inducing Th1 polarization. Our findings indicate a potential role of IDEC-like in the maintenance of inflammation in atopic dermatitis patients; moreover, IDEC-like may exert a regulatory impact on T cells of AD individuals through IL-10, often induced by agonist mimicking single stranded RNA virus</style></abstract><notes><style face="normal" font="default">DA - 20170113IS - 1365-4632 (Electronic)IS - 0011-9059 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1111/ijd.13537</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28083892">PM:28083892</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Dermatol\20170113-DosSantosV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Dermatol\20170113-DosSantosV.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170113, Dos Santos V</style></custom2><misc3><style face="normal" font="default">10.1111/ijd.13537</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40486</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Katoh,N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Atopic Dermatitis, Beyond the Skin Surface</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="159" start="159">159-159</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword></keywords><dates><year Day="30" Month="11" Year="2016">2016/11/30</year><pub-dates><date Day="15" Month="2" Year="2017">2017/2/15</date></pub-dates></dates><publisher><style face="normal" font="default">Mary Ann Liebert, Inc., publishers</style></publisher><isbn><style face="normal" font="default">2151-321X</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1089/ped.2016.29014.nk</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1089/ped.2016.29014.nk</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-159.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-159.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170215, Katoh N</style></custom2><misc3><style face="normal" font="default">10.1089/ped.2016.29014.nk</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40487</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Takaoka,R.</style></author><author><style face="normal" font="default"> Aoki,V.</style></author></authors></contributors><titles><title><style face="normal" font="default">Education of Patients with Atopic Dermatitis and Their Caregivers</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="163" start="160">160-163</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Caregivers</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Educational program</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> QOL</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> Solutions</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Thinking</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="1" Month="12" Year="2016">2016/12/1</year><pub-dates><date Day="15" Month="2" Year="2017">2017/2/15</date></pub-dates></dates><publisher><style face="normal" font="default">Mary Ann Liebert, Inc., publishers</style></publisher><isbn><style face="normal" font="default">2151-321X</style></isbn><abstract><style face="normal" font="default">Atopic dermatitis (AD) is the most prevalent dermatological disease in the pediatric population. It is a chronic, pruritic, and inflammatory skin disorder, with a complex etiology involving genetic predisposition, skin barrier defects, and immune dysfunction. AD can be a challenge for patients, physicians, and caregivers and has a clear impact in patients? quality of life (QoL). Educational programs for patients with AD and their caregivers are effective in improving adherence, QoL, and clinical outcomes. Different models of educational programs exist and their structures depend on cultural, social, and economic factors. To improve existing programs, the educational team should go beyond the disease and have a broader view of the many aspects involved in the pathological process. These include psychological, environmental, social, financial, and cultural aspects. Patients and their caregivers should have a more realistic expectation about the treatment. Innovative methods and approaches like design thinking can create new and effective solutions for patients with AD and their caregivers</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1089/ped.2016.0702</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1089/ped.2016.0702</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-160-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-160-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170215, Takaoka R</style></custom2><misc3><style face="normal" font="default">10.1089/ped.2016.0702</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40488</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nygaard,U.</style></author><author><style face="normal" font="default"> Riis,J.L.</style></author><author><style face="normal" font="default"> Deleuran,M.</style></author><author><style face="normal" font="default"> Vestergaard,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Attention-Deficit/Hyperactivity Disorder in Atopic Dermatitis: An Appraisal of the Current Literature</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="188" start="181">181-188</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Counseling</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="29" Month="11" Year="2016">2016/11/29</year><pub-dates><date Day="15" Month="2" Year="2017">2017/2/15</date></pub-dates></dates><publisher><style face="normal" font="default">Mary Ann Liebert, Inc., publishers</style></publisher><isbn><style face="normal" font="default">2151-321X</style></isbn><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a chronic inflammatory skin disease with hallmark characteristics in terms of pruritus, psychological stress, and sleep disturbance, all possibly associated with an increased risk of attention-deficit/hyperactivity disorder (ADHD). Epidemiological data indicate that AD and ADHD exhibit a parallel rise in global prevalence, and several cross-sectional studies have indicated co-occurrence of the 2 conditions. Furthermore, recent cohort studies have reported a temporal association between AD and later development of ADHD. However, underlying pathophysiological mechanisms of this association are insufficiently explored. The aim of the present review was to provide any clinician encountering AD an update on the most recent studies examining the possible AD-ADHD association. In turn, this could aid counseling of patients and parents. This review may encourage healthcare providers to refer AD patients and families to psychiatric specialists when ADHD is suspected</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1089/ped.2016.0705</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1089/ped.2016.0705</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-181-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-181-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170215, Nygaard U</style></custom2><misc3><style face="normal" font="default">10.1089/ped.2016.0705</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40489</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nicolescu,L.</style></author><author><style face="normal" font="default"> Rothenberger,C.</style></author><author><style face="normal" font="default"> Pinarci,M.</style></author><author><style face="normal" font="default"> Peric,J.</style></author><author><style face="normal" font="default"> Alharbi,R.</style></author><author><style face="normal" font="default"> Wollenberg,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">New Perspectives in the Treatment of Atopic Dermatitis in the Pediatric Population</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="195" start="189">189-195</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Calcineurin</style></keyword><keyword><style face="normal" font="default"> Caregivers</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Emollients</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Multidisciplinary team</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient Education</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Saudi Arabia</style></keyword><keyword><style face="normal" font="default"> Serbia</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin Physiology</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic therapy</style></keyword><keyword><style face="normal" font="default"> Tacrolimus</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutic patient education</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Topical calcineurin</style></keyword><keyword><style face="normal" font="default"> Topical corticosteroids</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="1" Month="12" Year="2016">2016/12/1</year><pub-dates><date Day="15" Month="2" Year="2017">2017/2/15</date></pub-dates></dates><publisher><style face="normal" font="default">Mary Ann Liebert, Inc., publishers</style></publisher><isbn><style face="normal" font="default">2151-321X</style></isbn><abstract><style face="normal" font="default">Treatment of children diagnosed with atopic dermatitis (AD) is an art. Age-dependent barrier function, skin physiology, body surface:weight ratio, the compliance of patient and caregivers, and legal considerations related to the license status of topical and systemic drugs must be considered. Mild to moderate AD can usually be treated sufficiently with a personalized regimen of emollients and topical anti-inflammatory therapy consisting of topical corticosteroids (TCSs) or topical calcineurin inhibitors. Emollients containing bacterial lysates, tailored wet wrap regimen, and proactive therapy with tacrolimus ointment or some TCSs are new developments in the field. Severe AD may need systemic therapy, but all currently available systemic agents for severe AD are either not licensed for children or not advisable on the long term, or both. Therapeutic patient education based on structured, interactive sessions with patients or caregivers and a multidisciplinary team is highly effective. This publication summarizes the current therapeutic options used in the pediatric AD population</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Germany -CO - Serbia -CO - Saudi Arabia -</style></notes><work-type><style face="normal" font="default">10.1089/ped.2016.0720</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1089/ped.2016.0720</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-189-95.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-189-95.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170215, Nicolescu L</style></custom2><misc3><style face="normal" font="default">10.1089/ped.2016.0720</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40490</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dissanayake,E.</style></author><author><style face="normal" font="default"> Shimojo,N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Probiotics and Prebiotics in the Prevention and Treatment of Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="180" start="174">174-180</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Prebiotics</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Probiotics</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword></keywords><dates><year Day="1" Month="12" Year="2016">2016/12/1</year><pub-dates><date Day="15" Month="2" Year="2017">2017/2/15</date></pub-dates></dates><publisher><style face="normal" font="default">Mary Ann Liebert, Inc., publishers</style></publisher><isbn><style face="normal" font="default">2151-321X</style></isbn><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a highly prevalent condition. Recent evidence suggests a link between the altered gut microbiome and the development of AD. Probiotics and/or prebiotics have been used in the treatment and prevention of AD with the intention of correcting the aberrant gut microbiome. As of now, data from meta-analyses show some promise in the use of probiotics for the prevention of AD with the effect being seen only when administered both prenatally and postnatally. Prebiotics and synbiotics have less compelling evidence to support their effectiveness in AD prevention or treatment, mainly due to the discrepancies of results. Explanations for the variations in the results may come from environmental factors, probiotic/prebiotic factors, and host factors that affect efficacy of the probiotic/prebiotic. More studies are needed to understand the mechanisms of action of probiotics/prebiotics and also to identify their true benefits in the prevention and treatment of AD</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1089/ped.2016.0708</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1089/ped.2016.0708</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-174-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-174-80.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170215, Dissanayake E</style></custom2><misc3><style face="normal" font="default">10.1089/ped.2016.0708</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40491</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tamagawa-Mineoka,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Biomarkers for Atopic Dermatitis in Children</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="169" start="164">164-169</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Chemokines</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword></keywords><dates><year Day="22" Month="11" Year="2016">2016/11/22</year><pub-dates><date Day="15" Month="2" Year="2017">2017/2/15</date></pub-dates></dates><publisher><style face="normal" font="default">Mary Ann Liebert, Inc., publishers</style></publisher><isbn><style face="normal" font="default">2151-321X</style></isbn><abstract><style face="normal" font="default">Numerous studies investigating the correlations between the severity of atopic dermatitis (AD) and various biomarkers have been reported over the past few decades. Recent studies have indicated that certain soluble mediators, including chemokines (such as thymus and activation-regulated chemokine/C-C motif chemokine ligand [CCL]17 and macrophage-derived chemokine/CCL22) and cytokines (such as thymic stromal lymphopoietin), could be good markers of inflammation in AD. This review focuses on circulating biomarkers of AD, including pediatric AD</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1089/ped.2016.0703</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1089/ped.2016.0703</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-164-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-164-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170215, Tamagawa-Mineoka R</style></custom2><misc3><style face="normal" font="default">10.1089/ped.2016.0703</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40492</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Murota,H.</style></author><author><style face="normal" font="default"> Katayama,I</style></author></authors></contributors><titles><title><style face="normal" font="default">Lifestyle Guidance for Pediatric Patients with Atopic Dermatitis Based on Age-Specific Physiological Function of Skin</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="201" start="196">196-201</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> Cornea</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Detergents</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> early childhood</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Humidity</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lifestyle</style></keyword><keyword><style face="normal" font="default"> Lipid</style></keyword><keyword><style face="normal" font="default"> Lipids</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> Miliaria</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pH</style></keyword><keyword><style face="normal" font="default"> Recovery</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin Care</style></keyword><keyword><style face="normal" font="default"> stratum corneum</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Sweat</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Temperature</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword></keywords><dates><year Day="1" Month="12" Year="2016">2016/12/1</year><pub-dates><date Day="15" Month="2" Year="2017">2017/2/15</date></pub-dates></dates><publisher><style face="normal" font="default">Mary Ann Liebert, Inc., publishers</style></publisher><isbn><style face="normal" font="default">2151-321X</style></isbn><abstract><style face="normal" font="default">Clinical features of atopic dermatitis change with age as skin homeostatic mechanisms develop. In some cases, symptoms persist from childhood to adult. In early childhood, the characteristic features of this disease are eczema or exudative papules accompanied by itching. After childhood, lichenified dermatitis preceded by severe itching is the major skin manifestation. Presumably, this difference in clinical symptoms between childhood and adulthood may derive from the age-specific physiological function of skin, such as maintenance of proper stratum corneum, secretion of lipids, and perspiration. The volume and composition of secreted lipids and sweat change with age; these changes affect water retention, skin surface pH, and the microbiome. These physiological activities do not follow a hierarchy, but instead are coordinated to harmonize the maintenance of skin homeostasis. Thus, daily skin care based on the characteristic age-specific physiological function of skin should be considered to manage atopic dermatitis. The usage of moisturizers contributes to reduce skin dryness and the incidence of atopic dermatitis, and is recommended immediately after bathing. A water temperature of 38 to 40 degrees during bathing can be beneficial for barrier recovery, and gentle detergents or soap should be chosen if necessary. After exercise, excess sweat on the skin surface should be rinsed off. Avoidance of perspiration-inducing activities is not necessary. High temperature and humidity on skin surface may cause the development of miliaria and subsequent anhidrosis. Wearing hygroscopic and breathable underwear is recommended</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1089/ped.2016.0723</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1089/ped.2016.0723</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-196-201.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol Pulmonol\2016-29-196-201.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170215, Murota H</style></custom2><misc3><style face="normal" font="default">10.1089/ped.2016.0723</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40493</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Garritsen,F.M.</style></author><author><style face="normal" font="default"> van der Schaft,J.</style></author><author><style face="normal" font="default"> van den Reek,J.M.</style></author><author><style face="normal" font="default"> Politiek,K.</style></author><author><style face="normal" font="default"> van Os-Medendorp,H.</style></author><author><style face="normal" font="default"> van Dijk,M.</style></author><author><style face="normal" font="default"> Hijnen,D.J.</style></author><author><style face="normal" font="default"> de Graaf,M.</style></author><author><style face="normal" font="default"> Bruijnzeel-Koomen,C.A.</style></author><author><style face="normal" font="default"> de Jong,E.M.</style></author><author><style face="normal" font="default"> Schuttelaar,M.A.</style></author><author><style face="normal" font="default"> Bruin-Weller,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default">Risk of Non-melanoma Skin Cancer in Patients with Atopic Dermatitis Treated with Oral Immunosuppressive Drugs</style></title><secondary-title><style face="normal" font="default">Acta Derm Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Acta Derm Venereol</style></full-title></periodical><pages end="730" start="724">724-730</pages><volume><style face="normal" font="default">97</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Uncertainty</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="2" Year="2017">2017/2/20</year></dates><abstract><style face="normal" font="default">There is uncertainty about the risk of developing non-melanoma skin cancer (NMSC), including basal cell carcinoma and squamous cell carcinoma (SCC), in patients with atopic dermatitis (AD) treated with oral immunosuppressive drugs. A total of 557 patients with AD treated with these drugs in the University Medical Center Utrecht and Groningen, the Netherlands, were analysed. NMSC after oral immunosuppressive treatment was reported in 18 patients (3.2%). The standardized incidence ratio for developing SCC was 13.1 (95% confidence interval (95% CI) 6.5-19.7). Patients developing NMSC were older at the start of therapy (p &lt; 0.001) and data lock (p &lt; 0.001) compared with patients without NMSC. Gender, cumulative days of oral immunosuppressive drugs and follow-up differed not significantly between these groups (p = 0.42, p=0.88, and p = 0.34, respectively). In interpreting these results it is important to include other factors, such as lack of association between treatment duration and tumour development and the long interval between treatment discontinuation and tumour development in some patients</style></abstract><notes><style face="normal" font="default">DA - 20170220IS - 1651-2057 (Electronic)IS - 0001-5555 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.2340/00015555-2637</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28218345">PM:28218345</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Acta Derm Venereol\2017-97-724-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Acta Derm Venereol\2017-97-724-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170220, Garritsen FM</style></custom2><misc3><style face="normal" font="default">10.2340/00015555-2637</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40494</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Marin-Cabanas,I.</style></author><author><style face="normal" font="default"> Berbegal-de Gracia,L.</style></author><author><style face="normal" font="default"> de Leon-Marrero,F.</style></author><author><style face="normal" font="default"> Hispan,P.</style></author><author><style face="normal" font="default"> Silvestre,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Servicio de Dermatologia, Hospital General Universitario de Elda, Elda, Alicante, Espana.</style></auth-address><titles><title><style face="normal" font="default">Management of Chronic Spontaneous Urticaria in Routine Clinical Practice Following the EAACI/GA(2)LEN/EDF/WAO Guidelines</style></title><secondary-title><style face="normal" font="default">Actas Dermosifiliogr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Actas Dermosifiliogr</style></full-title></periodical><pages end="353" start="346">346-353</pages><volume><style face="normal" font="default">108</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Anti-Inflammatory Agents</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> H1 antihistamines</style></keyword><keyword><style face="normal" font="default"> H1-antihistamine</style></keyword><keyword><style face="normal" font="default"> H1-antihistamines</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin allergy</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="2" Year="2017">2017/2/17</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Chronic spontaneous urticaria is a prevalent and difficult-to-treat condition that has a very negative impact on patient quality of life. OBJECTIVE: To describe the epidemiological and clinical characteristics of patients presenting with chronic spontaneous urticaria and the response to treatment administered according to the EAACI/GA(2)LEN/EDF/WAO consensus guideline. MATERIAL AND METHOD: Descriptive cross-sectional study of all the patients with chronic spontaneous urticaria who consulted a skin allergy unit in the dermatology department of a tertiary hospital in Spain between July 2011 and July 2015. RESULTS: The study included 100 patients with chronic spontaneous urticaria; inducible urticaria was present in 43% of cases, and angioedema in 40%. On diagnosis, 53% of patients were taking nonsteroidal anti-inflammatory drugs. All patients were treated with second generation H1-antihistamines, but the standard dose was sufficient in only 18% of cases. Higher doses (up to 4 times the standard dose) achieved control of the urticaria in 74% of the patients studied. Higher doses of second generation H1-antihistamines were required to control the condition in patients with angioedema, and the presence of angioedema was associated with a lack of response to treatment with these drugs (OR, 6.1%; P&lt;.001). One in 4 patients failed to respond to second generation H1-antihistamines and required treatment with omalizumab or ciclosporin to control their condition. CONCLUSIONS: Doses of H1-antihistamines higher than the standard dose are required in most cases to achieve control of chronic spontaneous urticaria. Angioedema is associated with failure to respond to treatment with antihistamines. In refractory cases, control of the condition can be achieved with omalizumab or ciclosporin. Patients with chronic spontaneous urticaria do not generally avoid the use of nonsteroidal anti-inflammatory agents</style></abstract><notes><style face="normal" font="default">DA - 20170221IS - 1578-2190 (Electronic)IS - 0001-7310 (Linking)LA - engLA - spaPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.ad.2016.12.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28219634">PM:28219634</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Actas Dermosifiliogr\2017-108-346-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Actas Dermosifiliogr\2017-108-346-53.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170221, Marin-Cabanas I</style></custom2><misc3><style face="normal" font="default">10.1016/j.ad.2016.12.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40495</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Okubo,K.</style></author><author><style face="normal" font="default"> Kurono,Y.</style></author><author><style face="normal" font="default"> Ichimura,K.</style></author><author><style face="normal" font="default"> Enomoto,T.</style></author><author><style face="normal" font="default"> Okamoto,Y.</style></author><author><style face="normal" font="default"> Kawauchi,H.</style></author><author><style face="normal" font="default"> Suzaki,H.</style></author><author><style face="normal" font="default"> Fujieda,S.</style></author><author><style face="normal" font="default"> Masuyama,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology, Nippon Medical School, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default">Japanese guidelines for allergic rhinitis 2017</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> ARIA</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> QOL</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Sinusitis</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="14" Month="2" Year="2017">2017/2/14</year></dates><abstract><style face="normal" font="default">Like asthma and atopic dermatitis, allergic rhinitis is an allergic disease, but of the three, it is the only type I allergic disease. Allergic rhinitis includes pollinosis, which is intractable and reduces quality of life (QOL) when it becomes severe. A guideline is needed to understand allergic rhinitis and to use this knowledge to develop a treatment plan. In Japan, the first guideline was prepared after a symposium held by the Japanese Society of Allergology in 1993. The current 8th edition was published in 2016, and is widely used today. To incorporate evidence based medicine (EBM) introduced from abroad, the most recent collection of evidence/literature was supplemented to the Practical Guideline for the Management of Allergic Rhinitis in Japan 2016. The revised guideline includes assessment of diagnosis/treatment and prescriptions for children and pregnant women, for broad clinical applications. An evidence-based step-by-step strategy for treatment is also described. In addition, the QOL concept and cost benefit analyses are also addressed. Along with Allergic Rhinitis and its Impact of Asthma (ARIA), this guideline is widely used for various clinical purposes, such as measures for patients with sinusitis, childhood allergic rhinitis, oral allergy syndrome, and anaphylaxis and for pregnant women. A Q&amp;A section regarding allergic rhinitis in Japan was added to the end of this guideline</style></abstract><notes><style face="normal" font="default">DA - 20170218IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2016.11.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28214137">PM:28214137</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170218-OkuboK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170218-OkuboK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170218, Okubo K</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2016.11.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40496</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Toyama,S.</style></author><author><style face="normal" font="default"> Okada,N.</style></author><author><style face="normal" font="default"> Matsuda,A.</style></author><author><style face="normal" font="default"> Morita,H.</style></author><author><style face="normal" font="default"> Saito,H.</style></author><author><style face="normal" font="default"> Fujisawa,T.</style></author><author><style face="normal" font="default"> Nakae,S.</style></author><author><style face="normal" font="default"> Karasuyama,H.</style></author><author><style face="normal" font="default"> Matsumoto,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">Human eosinophils constitutively express a unique serine protease, PRSS33</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway remodeling</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Chemokines</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Collagen</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="default"> Extracellular Matrix Proteins</style></keyword><keyword><style face="normal" font="default"> Fibroblasts</style></keyword><keyword><style face="normal" font="default"> fibronectin</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microarray</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protease</style></keyword><keyword><style face="normal" font="default"> proteases</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Recombinant</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serine</style></keyword><keyword><style face="normal" font="default"> Staining</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> Transcriptome</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="2" Year="2017">2017/2/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Eosinophils play important roles in asthma, especially airway remodeling, by producing various granule proteins, chemical mediators, cytokines, chemokines and proteases. However, protease production by eosinophils is not fully understood. In the present study, we investigated the production of eosinophil-specific proteases/proteinases by transcriptome analysis. METHODS: Human eosinophils and other cells were purified from peripheral blood by density gradient sedimentation and negative/positive selections using immunomagnetic beads. Protease/proteinase expression in eosinophils and release into the supernatant were evaluated by microarray analysis, qPCR, ELISA, flow cytometry and immunofluorescence staining before and after stimulation with eosinophil-activating cytokines and secretagogues. mRNAs for extracellular matrix proteins in human normal fibroblasts were measured by qPCR after exposure to recombinant protease serine 33 (PRSS33) protein (rPRSS33), created with a baculovirus system. RESULTS: Human eosinophils expressed relatively high levels of mRNA for metalloproteinase 25 (MMP25), a disintegrin and metalloprotease 8 (ADAM8), ADAM10, ADAM19 and PRSS33. Expression of PRSS33 was the highest and eosinophil-specific. PRSS33 mRNA expression was not affected by eosinophil-activating cytokines. Immunofluorescence staining showed that PRSS33 was co-localized with an eosinophil granule protein. PRSS33 was not detected in the culture supernatant of eosinophils even after stimulation with secretagogues, but its cell surface expression was increased. rPRSS33 stimulation of human fibroblasts increased expression of collagen and fibronectin mRNAs, at least in part via protease-activated receptor-2 activation. CONCLUSIONS: Activated eosinophils may induce fibroblast extracellular matrix protein synthesis via cell surface expression of PRSS33, which would at least partly explain eosinophils' role(s) in airway remodeling</style></abstract><notes><style face="normal" font="default">DA - 20170220IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.01.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28216055">PM:28216055</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170220-ToyamaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170220-ToyamaS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170220, Toyama S</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.01.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40497</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ichinose,M.</style></author><author><style face="normal" font="default"> Sugiura,H.</style></author><author><style face="normal" font="default"> Nagase,H.</style></author><author><style face="normal" font="default"> Yamaguchi,M.</style></author><author><style face="normal" font="default"> Inoue,H.</style></author><author><style face="normal" font="default"> Sagara,H.</style></author><author><style face="normal" font="default"> Tamaoki,J.</style></author><author><style face="normal" font="default"> Tohda,Y.</style></author><author><style face="normal" font="default"> Munakata,M.</style></author><author><style face="normal" font="default"> Yamauchi,K.</style></author><author><style face="normal" font="default"> Ohta,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.</style></auth-address><titles><title><style face="normal" font="default">Japanese guidelines for adult asthma 2017</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adrenaline</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Adult asthma</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> airway remodeling</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Aminophylline</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Aspirin-induced asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma therapy</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Bronchial thermoplasty</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Elimination</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Muscarinic antagonist</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral steroids</style></keyword><keyword><style face="normal" font="default"> Otitis</style></keyword><keyword><style face="normal" font="default"> Oxygen</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Theophylline</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="11" Month="2" Year="2017">2017/2/11</year></dates><abstract><style face="normal" font="default">Adult bronchial asthma is characterized by chronic airway inflammation, and presents clinically with variable airway narrowing (wheezes and dyspnea) and cough. Long-standing asthma induces airway remodeling, leading to intractable asthma. The number of patients with asthma has increased; however, the number of patients who die of asthma has decreased (1.2 per 100,000 patients in 2015). The goal of asthma treatment is to enable patients with asthma to attain normal pulmonary function and lead a normal life, without any symptoms. A good relationship between physicians and patients is indispensable for appropriate treatment. Long-term management by therapeutic agents and elimination of the causes and risk factors of asthma are fundamental to its treatment. Four steps in pharmacotherapy differentiate between mild and intensive treatments; each step includes an appropriate daily dose of an inhaled corticosteroid, varying from low to high levels. Long-acting beta2-agonists, leukotriene receptor antagonists, sustained-release theophylline, and long-acting muscarinic antagonist are recommended as add-on drugs, while anti-immunoglobulin E antibody and oral steroids are considered for the most severe and persistent asthma related to allergic reactions. Bronchial thermoplasty has recently been developed for severe, persistent asthma, but its long-term efficacy is not known. Inhaled beta2-agonists, aminophylline, corticosteroids, adrenaline, oxygen therapy, and other approaches are used as needed during acute exacerbations, by choosing treatment steps for asthma in accordance with the severity of exacerbations. Allergic rhinitis, eosinophilic chronic rhinosinusitis, eosinophilic otitis, chronic obstructive pulmonary disease, aspirin-induced asthma, and pregnancy are also important issues that need to be considered in asthma therapy</style></abstract><notes><style face="normal" font="default">DA - 20170215IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2016.12.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28196638">PM:28196638</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170215-IchinoseM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170215-IchinoseM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170215, Ichinose M</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2016.12.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40498</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Katayama,I.</style></author><author><style face="normal" font="default"> Aihara,M.</style></author><author><style face="normal" font="default"> Ohya,Y.</style></author><author><style face="normal" font="default"> Saeki,H.</style></author><author><style face="normal" font="default"> Shimojo,N.</style></author><author><style face="normal" font="default"> Shoji,S.</style></author><author><style face="normal" font="default"> Taniguchi,M.</style></author><author><style face="normal" font="default"> Yamada,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Course of Integrated Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.</style></auth-address><titles><title><style face="normal" font="default">Japanese guidelines for atopic dermatitis 2017</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> QOL</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin Care</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="10" Month="2" Year="2017">2017/2/10</year></dates><abstract><style face="normal" font="default">Given the importance of appropriate diagnosis and appropriate assessment of cutaneous symptoms in treatment of atopic dermatitis, the basics of treatment in this guideline are composed of (1) investigation and countermeasures of causes and exacerbating factors, (2) correction of skin dysfunctions (skin care), and (3) pharmacotherapy, as three mainstays. These are based on the disease concept that atopic dermatitis is an inflammatory cutaneous disease with eczema by atopic diathesis, multi-factorial in onset and aggravation, and accompanied by skin dysfunctions. These three points are equally important and should be appropriately combined in accordance with the symptoms of each patient. In treatment, it is important to transmit the etiological, pathological, physiological, or therapeutic information to the patient to build a favorable partnership with the patient or his/her family so that they may fully understand the treatment. This guideline discusses chiefly the basic therapy in relation to the treatment of this disease. The goal of treatment is to enable patients to lead an uninterrupted social life and to control their cutaneous symptoms so that their quality of life (QOL) may meet a satisfactory level. The basics of treatment discussed in this guideline are based on the "Guidelines for the Treatment of Atopic Dermatitis 2008" prepared by the Health and Labour Sciences Research and the "Guidelines for the Management of Atopic Dermatitis 2015 (ADGL2015)" prepared by the Atopic Dermatitis Guidelines Advisory Committee, Japanese Society of Allergology in principle. The guidelines for the treatment of atopic dermatitis are summarized in the "Japanese Guideline for the Diagnosis and Treatment of Allergic Disease 2016" together with those for other allergic diseases</style></abstract><notes><style face="normal" font="default">DA - 20170217IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2016.12.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28209325">PM:28209325</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170217-KatayamaI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170217-KatayamaI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170217, Katayama I</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2016.12.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40499</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dobashi,K.</style></author><author><style face="normal" font="default"> Akiyama,K.</style></author><author><style face="normal" font="default"> Usami,A.</style></author><author><style face="normal" font="default"> Yokozeki,H.</style></author><author><style face="normal" font="default"> Ikezawa,Z.</style></author><author><style face="normal" font="default"> Tsurikisawa,N.</style></author><author><style face="normal" font="default"> Nakamura,Y.</style></author><author><style face="normal" font="default"> Sato,K.</style></author><author><style face="normal" font="default"> Okumura,J.</style></author><author><style face="normal" font="default"> Takayama,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Graduate School of Health Sciences, Gunma University, Gunma, Japan.</style></auth-address><titles><title><style face="normal" font="default">Japanese guidelines for occupational allergic diseases 2017</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity Pneumonitis</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> occupational asthma</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="14" Month="2" Year="2017">2017/2/14</year></dates><abstract><style face="normal" font="default">In 2013, a guideline for occupational allergic diseases was published for the first time in Japan. Occupational allergic diseases are likely to worsen or become intractable as a result of continuous exposure to high concentrations of causative antigens, and are socioeconomically important diseases with which the patients might sometimes lose jobs due to work interruptions. Guidelines for occupational allergic diseases have been published in many countries. This guideline consists of six chapters about occupational asthma, occupational allergic rhinitis, occupational skin diseases, hypersensitivity pneumonitis and occupational anaphylaxis shock, and legal aspects of these diseases. The guideline is characterized with the following basic structure: Clinical Questions (CQs) are set with reference to Minds (Medical Information Network Distribution Service), statements by the committee are correspondingly listed, recommended grades and evidence levels are defined, and then descriptions and references are indicated</style></abstract><notes><style face="normal" font="default">DA - 20170218IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2016.12.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28214136">PM:28214136</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170218-DobashiK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170218-DobashiK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170218, Dobashi K</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2016.12.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40500</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Takamura,E.</style></author><author><style face="normal" font="default"> Uchio,E.</style></author><author><style face="normal" font="default"> Ebihara,N.</style></author><author><style face="normal" font="default"> Ohno,S.</style></author><author><style face="normal" font="default"> Ohashi,Y.</style></author><author><style face="normal" font="default"> Okamoto,S.</style></author><author><style face="normal" font="default"> Kumagai,N.</style></author><author><style face="normal" font="default"> Satake,Y.</style></author><author><style face="normal" font="default"> Shoji,J.</style></author><author><style face="normal" font="default"> Nakagawa,Y.</style></author><author><style face="normal" font="default"> Namba,K.</style></author><author><style face="normal" font="default"> Fukagawa,K.</style></author><author><style face="normal" font="default"> Fukushima,A.</style></author><author><style face="normal" font="default"> Fujishima,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, Tokyo Women's Medical University, School of Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default">Japanese guidelines for allergic conjunctival diseases 2017</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Conjunctiva</style></keyword><keyword><style face="normal" font="default"> Conjunctival Diseases</style></keyword><keyword><style face="normal" font="default"> Conjunctivitis</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Foreign Bodies</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Hyperemia</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Keratoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Ocular</style></keyword><keyword><style face="normal" font="default"> Ophthalmology</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Sensation</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Test method</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Type I allergy</style></keyword><keyword><style face="normal" font="default"> Ulcer</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vernal keratoconjunctivitis</style></keyword></keywords><dates><year Day="10" Month="2" Year="2017">2017/2/10</year></dates><abstract><style face="normal" font="default">The definition, classification, pathogenesis, test methods, clinical findings, criteria for diagnosis, and therapies of allergic conjunctival disease are summarized based on the Guidelines for Clinical Management of Allergic Conjunctival Disease (Second Edition) revised in 2010. Allergic conjunctival disease is defined as "a conjunctival inflammatory disease associated with a Type I allergy accompanied by some subjective or objective symptoms." Allergic conjunctival disease is classified into allergic conjunctivitis, atopic keratoconjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis. Representative subjective symptoms include ocular itching, hyperemia, and lacrimation, whereas objective symptoms include conjunctival hyperemia, swelling, folliculosis, and papillae. Patients with vernal keratoconjunctivitis, which is characterized by conjunctival proliferative changes called giant papilla accompanied by varying extents of corneal lesion, such as corneal erosion and shield ulcer, complain of foreign body sensation, ocular pain, and photophobia. In the diagnosis of allergic conjunctival diseases, it is required that type I allergic diathesis is present, along with subjective and objective symptoms accompanying allergic inflammation. The diagnosis is ensured by proving a type I allergic reaction in the conjunctiva. Given that the first-line drug for the treatment of allergic conjunctival disease is an antiallergic eye drop, a steroid eye drop will be selected in accordance with the severity. In the treatment of vernal keratoconjunctivitis, an immunosuppressive eye drop will be concomitantly used with the abovementioned drugs</style></abstract><notes><style face="normal" font="default">DA - 20170217IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2016.12.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28209324">PM:28209324</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170217-TakamuraE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170217-TakamuraE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170217, Takamura E</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2016.12.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40501</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Caswell-Smith,R.</style></author><author><style face="normal" font="default"> Cripps,T.</style></author><author><style face="normal" font="default"> Charles,T.</style></author><author><style face="normal" font="default"> Hosking,A.</style></author><author><style face="normal" font="default"> Handigol,M.</style></author><author><style face="normal" font="default"> Holweg,C.</style></author><author><style face="normal" font="default"> Matthews,J.</style></author><author><style face="normal" font="default"> Holliday,M.</style></author><author><style face="normal" font="default"> Maillot,C.</style></author><author><style face="normal" font="default"> Fingleton,J.</style></author><author><style face="normal" font="default"> Weatherall,M.</style></author><author><style face="normal" font="default"> Beasley,R.</style></author><author><style face="normal" font="default"> Braithwaite,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">0000 0004 0445 6830grid.415117.7Medical Research Institute of New Zealand, Private Bag 7902, Wellington, 6242 New Zealand</style></auth-address><titles><title><style face="normal" font="default">Day-time variation of serum periostin in asthmatic adults treated with ICS/LABA and adults without asthma</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Clin Immunol</style></full-title></periodical><pages end="" start="8">8-</pages><volume><style face="normal" font="default">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> New Zealand</style></keyword><keyword><style face="normal" font="default"> Periostin</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: We aimed to determine the effect of sampling time during the day on serum periostin levels in adult participants with and without asthma. METHODS: Serum periostin was measured at 2-h intervals from 0800 to 1800 h in 16 adult participants with stable asthma prescribed inhaled corticosteroid and long-acting beta-agonist therapy, and in 16 otherwise healthy participants without asthma. Mixed linear models were used to compare time zero (08:00 h) with subsequent measurement time for serum periostin for both groups. RESULTS: In both asthma and non-asthma, the mean (SD) serum periostin levels continuously reduced during the day from 53.5 (13.6) ng/mL at 0800 h to 50.9 (13.4) ng/mL at 1800 h (difference log periostin -0.05, P &lt;/= 0.001) and 50.5 (13.0) ng/mL at 0800 h to 46.2 (11.5) ng/mL at 1800 h (difference log periostin -0.08, P &lt;/= 0.001) respectively. CONCLUSIONS: Periostin values are higher in the morning compared with the afternoon in asthmatic and non-asthmatic adults. The small magnitude of the variation in serum periostin levels suggests that the time of day in which the serum periostin measurements are made is unlikely to influence treatment decisions if a specific serum periostin level is used to predict treatment responsiveness. Trial registration Australia New Zealand Trials Registry (ACTRN12614000072617)</style></abstract><notes><style face="normal" font="default">DA - 20170214IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - New Zealand -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1186/s13223-017-0182-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28194189">PM:28194189</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170214, Xaswell-Smith R</style></custom2><misc3><style face="normal" font="default">10.1186/s13223-017-0182-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40502</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wisniewski,J.A.</style></author><author><style face="normal" font="default"> McLaughlin,A.P.</style></author><author><style face="normal" font="default"> Stenger,P.J.</style></author><author><style face="normal" font="default"> Patrie,J.</style></author><author><style face="normal" font="default"> Brown,M.A.</style></author><author><style face="normal" font="default"> El-Dahr,J.M.</style></author><author><style face="normal" font="default"> Platts-Mills,T.A.</style></author><author><style face="normal" font="default"> Byrd,N.J.</style></author><author><style face="normal" font="default"> Heymann,P.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Asthma and Allergic Diseases Center, University of Virginia, Charlottesville, Virginia, USA</style></auth-address><titles><title><style face="normal" font="default">A comparison of seasonal trends in asthma exacerbations among children from geographic regions with different climates</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="481" start="475">475-481</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergen exposure</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Arizona</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Climate</style></keyword><keyword><style face="normal" font="default"> Commerce</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Louisiana</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> trends</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral infection</style></keyword><keyword><style face="normal" font="default"> Viral infections</style></keyword><keyword><style face="normal" font="default"> Virginia</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: The fall peak in childhood asthma exacerbations is thought to be related to an increase in viral infections and allergen exposure when children return to school. Whether the seasonality of asthma attacks among children from different geographic regions follows similar trends is unclear. OBJECTIVE: To compare seasonal trends in asthma exacerbations among school-age children who lived in different geographic locations, with different climates, within the United States. METHODS: Hospital billing data bases were examined to determine the monthly number of school-age children who were hospitalized or treated in the emergency department (ED) for asthma exacerbations. Data from four cities within three states were compared. Climate data were obtained from archives of the National Climate Data Center, U.S. Department of Commerce. RESULTS: An annual peak in asthma exacerbations was observed during the fall months (September through November) among children who lived in Charlottesville, Virginia, as well as throughout the state of Virginia. An increase in exacerbations, which peaked in November, was observed for exacerbations among children who lived in Tucson, Arizona, and Yuma, Arizona. In contrast, exacerbations among children from New Orleans, Louisiana, increased in September but remained elevated throughout the school year. Although there was annual variation in the frequency of exacerbations over time, the seasonal patterns observed remained similar within the locations from year to year. A nadir in the frequency of attacks was observed during the summer months in all the locations. CONCLUSION: Seasonal peaks for asthma exacerbations varied among the children who lived in geographic locations with different climates, and were not restricted to the beginning of the school year</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2016.37.3994)</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931303">PM:27931303</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2016-37-475-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2016-37-475-81.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161209, Wisniewski JA</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2016.37.3994)</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40503</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brightling,C.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute for Lung Health, National Institute for Health Research Respiratory Biomedical Research Unit, Department of Infection, Immunity and Inflammation, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UK</style></auth-address><titles><title><style face="normal" font="default">Chronic obstructive pulmonary disease phenotypes, biomarkers, and prognostic indicators</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="438" start="432">432-438</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Biomedical Research</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> diagnostic criteria</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Ecology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease associated with significant morbidity and mortality. Current diagnostic criteria are based on lung function impairment, symptoms, and exacerbation frequency but do not capture the heterogeneity of the disease in terms of the complex pathologic changes that occur within lung, the different airway inflammatory patterns, or the airway microbial ecology. Recognition of the importance of defining the heterogeneity of COPD has led to the identification of important phenotypes with specific biomarkers, treatment responses, and underlying pathophysiologic mechanisms. This review summarized the presentation at the Eastern Allergy Conference 2016, which considered how multidimensional phenotyping provides important clinical insights that enable the clinician to move toward a precision medicine approach for COPD</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2016.37.3996)</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931297">PM:27931297</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2016-37-432-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2016-37-432-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161209, Brightling CE</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2016.37.3996)</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40504</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Calais,C.J.</style></author><author><style face="normal" font="default"> Robertson,B.D.</style></author><author><style face="normal" font="default"> Beakes,D.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy-Immunology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA</style></auth-address><titles><title><style face="normal" font="default">Association of allergy/immunology and obstructive sleep apnea</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="449" start="443">443-449</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Alcohol</style></keyword><keyword><style face="normal" font="default"> Apnea</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Cardiovascular System</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Maryland</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Obstructive sleep apnea</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Sleep apnea</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Tobacco</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Vigilance</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">Obstructive sleep apnea (OSA) is characterized by repetitive upper airway collapse that results in nonrefreshing sleep, excessive daytime sleepiness, and, ultimately, adverse consequences on quality of life, the cardiovascular system, and neurocognitive performance. OSA has traditionally been linked to body habitus (obesity and increased neck circumference), racial demographics, alcohol, tobacco, and sedative use. Numerous other conditions are linked to OSA, which may have clinical relevance. Specifically, asthma and nasal obstructive syndromes, e.g., rhinitis, have been shown to be risk factors. This review used the anatomic homogeneity of the upper and lower airways as an explanation for the inflammatory conditions that underlie and interrelate rhinitis, asthma, and OSA. There is strong evidence that both immunoglobulin Emediated and irritant-induced inflammation in either airway location play a significant role in all three (OSA, rhinitis, and asthma). We highlighted pathophysiologic, chemical, and cellular factors that explain the distinct relationship among OSA, asthma, and rhinitis, with emphasis for increased provider vigilance of the other syndromes when a patient is diagnosed with either entity</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2016.37.4001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931299">PM:27931299</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2016-37-443-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2016-37-443-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161209, Calais CJ</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2016.37.4001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40505</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stelmach,I.</style></author><author><style face="normal" font="default"> Sztafiska,A.</style></author><author><style face="normal" font="default"> Jerzyska,J.</style></author><author><style face="normal" font="default"> Podlecka,D.</style></author><author><style face="normal" font="default"> Majak,P.</style></author><author><style face="normal" font="default"> Stelmach,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics and Allergy, Medical University of Lodz, Poland</style></auth-address><titles><title><style face="normal" font="default">New insights into treatment of children with exercise-induced asthma symptoms</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="474" start="466">466-474</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Exercise-induced asthma</style></keyword><keyword><style face="normal" font="default"> exercise-induced bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> Exhaled Breath</style></keyword><keyword><style face="normal" font="default"> exhaled breath condensate</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> formoterol</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory mediators</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="default"> LTRA</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> montelukast</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Exercise is one of the most common triggers of bronchoconstriction and affects up to 80% of children with asthma. OBJECTIVE: The purpose of this randomized, double-blind, placebo-controlled study was to assess the effectiveness of treatment with ciclesonide 160 microgram, either alone, with a higher dose, with a leukotriene receptor antagonist (LTRA), or with a long-acting beta-agonist (LABA) in children with asthma with postexercise-induced symptoms. METHODS: Eighty adolescents, ages 1218 years, with asthma and postexercise symptoms were enrolled. Children were treated in one of four treatment groups: ciclesonide 160 microgram daily dose (cic 160), ciclesonide 320 microgram daily dose (cic 320), ciclesonide 160 microgram daily dose combined with montelukast (cic + LTRA), or ciclesonide 160 microgram daily combined with formoterol (cic + LABA). The impact of treatment on clinical symptoms, maximum percentage decrease in forced expiratory volume in 1 second after intense exercise effort, fractional exhaled nitric oxide in exhaled breath, and the contribution of inflammatory mediators in exhaled breath condensate were assessed. RESULTS: In children with asthma and with postexercise symptoms, 8-week daily administration of ciclesonide 320 microgram, ciclesonide 160 microgram plus LABA, and ciclesonide 160 microgram alone decreased daytime symptoms; decrease in maximal fall in forced expiratory volume in 1 second reached the level of significance in the cic 320, cic + LABA, and cic + LTRA groups. A higher prevalence of positive responses to treatment after addition of an LTRA or LABA to ciclesonide 160 microgram for patients with exercise treadmill challengeinduced clinical symptoms only was revealed. CONCLUSION: Monotherapy with ciclesonide 320 microgram can be as effective as combined therapy in reducing exercise-induced bronchoconstriction. We revealed a higher prevalence of positive responses to treatment after the addition of LTRA or LABA to ciclesonide 160 microgram for patients with exercise treadmill challengeinduced clinical symptoms only. ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ClinicalTrials.gov"www.ClinicalTrials.gov/ext-link NCT01798823</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2016.37.3993</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931302">PM:27931302</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2016-37-466-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2016-37-466-74.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161219, Stelmach I</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2016.37.3993</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40506</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Riedl,M.A.</style></author><author><style face="normal" font="default"> Lumry,W.R.</style></author><author><style face="normal" font="default"> Li,H.H.</style></author><author><style face="normal" font="default"> Banerji,A.</style></author><author><style face="normal" font="default"> Bernstein,J.A.</style></author><author><style face="normal" font="default"> Ba,M.</style></author><author><style face="normal" font="default"> Bjrkander,J.</style></author><author><style face="normal" font="default"> Magerl,M.</style></author><author><style face="normal" font="default"> Maurer,M.</style></author><author><style face="normal" font="default"> Rockich,K.</style></author><author><style face="normal" font="default"> Chen,H.</style></author><author><style face="normal" font="default"> Schranz,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Allergy and Immunology, US HAEA Angioedema Center, University of CaliforniaSan Diego School of Medicine, La Jolla, California, USA</style></auth-address><titles><title><style face="normal" font="default">Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="500" start="489">489-500</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> C1 INH</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-INH</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Formulation</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Injections</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Recombinant</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> serious adverse events</style></keyword><keyword><style face="normal" font="default"> subcutaneous</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: The currently approved method of C1 inhibitor (C1 INH) administration for patients with hereditary angioedema with C1 INH deficiency (HAE) is by intravenous injection. A C1 INH subcutaneous formulation may provide an attractive mode of administration for some patients. OBJECTIVE: To evaluate efficacy and safety of two doses of subcutaneous, plasma-derived C1 INH with the dispersing agent, recombinant human hyaluronidase (rHuPH20) to prevent angioedema attacks in patients with HAE. METHODS: A randomized, double-blind, dose-ranging, crossover study, patients 12 years of age (n = 47) with a confirmed diagnosis of HAE were randomly assigned to receive subcutaneous injections of 1000 U C1 INH with 24,000 U rHuPH20 or 2000 U C1 INH with 48,000 U rHuPH20 every 3 or 4 days for 8 weeks and then crossed-over for another 8-week period. The primary efficacy end point was the number of angioedema attacks during each treatment period. RESULTS: The study was terminated early as a precaution related to non-neutralizing antibodies to rHuPH20 in 45% of patients. The mean standard deviation number of angioedema attacks during the 8-week treatment periods were 1.58 1.59 with 1000 U C1 INH and 0.97 1.26 with 2000 U. The mean (95% confidence interval [CI]) within-patient difference (2000 U-1000 U, respectively) was 0.61 (95% CI, 1.23 to 0.01) attacks per month (p = 0.0523), and 0.56 (95% CI, 1.06 to 0.05) attacks that required acute treatment, (p = 0.0315). No deaths or other serious adverse events were reported. Injection-site reaction was the most common adverse event. CONCLUSION: Despite early termination, this study demonstrated a clinically and statistically significant difference in burden of disease, which favored 2000 U C1 INH, without associated serious adverse events</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2016.37.4006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931305">PM:27931305</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2016-37-489-500.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2016-37-489-500.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161209, Riedl MA</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2016.37.4006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40507</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brooks,J.P.</style></author><author><style face="normal" font="default"> Ghaffari,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">1Department of Medical Education, Heart of Lancaster Regional Medical Center, Lititz, Pennsylvania, USA</style></auth-address><titles><title><style face="normal" font="default">Idiopathic CD4 lymphocytopenia</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="504" start="501">501-504</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acquired Immunodeficiency Syndrome</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> CD4</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> diagnostic criteria</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Hematopoietic Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> Hiv</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Indications</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Interferon</style></keyword><keyword><style face="normal" font="default"> Interferon-gamma</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Interleukin-2</style></keyword><keyword><style face="normal" font="default"> Interleukin-7</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphopenia</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Opportunistic Infections</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pennsylvania</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Idiopathic CD4 lymphocytopenia (ICL) is a rare disorder of unknown etiology. Diagnostic criteria include a persistent CD4 T-cell lymphopenia with no underlying primary or secondary immune deficiencies and a CD4 T-cell count of 300 cells/mL or 20% total lymphocyte on multiple occasions. OBJECTIVE: To increase awareness of ICL and to provide a review of the clinical characteristics, diagnosis, and management of this disease process. Presently, many of these patients receive prophylactic treatment similar to other T-cell deficient conditions, most notably patients with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome; however, the same indications may not necessarily apply to this patient population because the T cells are not affected by a virus as in HIV. METHODS: A literature search of salient articles that describe case reports and case series of ICL and their management were analyzed. RESULTS: A case of ICL with a literature review is presented with emphasis on clinical pearls and pitfalls. The patients with ICL are usually identified with a CD4 count of 200 cells/mL when complications develop. Opportunistic infections are the most common initial manifestations. Current therapies used to increase CD4 levels include interleukin 2, interferon gamma, interleukin 7, and allogeneic hematopoietic stem cell transplantation, with variable results. CONCLUSION: ICL is a diagnosis of exclusion when there is no identifiable underlying cause for a low CD4 count. Although the nature of the T-cell problem is not the same in ICL and HIV, in the absence of specific guidelines, patients receive the same prophylactic treatment as patients with HIV</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2016.37.3992</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931306">PM:27931306</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2016-37-501-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2016-37-501-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161209, Brooks JP</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2016.37.3992</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40508</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bellanti,J.A.</style></author><author><style face="normal" font="default"> Settipane,R.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">A Janus tale of the two faces of corticosteroid therapy: A potential for adverse effects versus a steroid-sparing benefit of certain therapies</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="425" start="423">423-425</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2016.37.4011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931295">PM:27931295</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2016-37-423-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2016-37-423-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161209, Bellanti JA</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2016.37.4011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40509</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Soyyiit,A.</style></author><author><style face="normal" font="default"> Gksel,Z.</style></author><author><style face="normal" font="default"> Aydn,M.</style></author><author><style face="normal" font="default"> Gentrk,Z.</style></author><author><style face="normal" font="default"> Bavbek,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunology and Allergy, Department of Chest Diseases, Ankara University School of Medicine, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="default">What is the clinical value of negative predictive values of skin tests to iodinated contrast media?</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="488" start="482">482-488</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> iodinated contrast media</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nonimmediate</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Predictive values</style></keyword><keyword><style face="normal" font="default"> Premedication</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Iodinated contrast media (ICM) can cause hypersensitivity reactions (HSR), yet data are scant about the negative predictive value (NPV) of ICM skin tests. OBJECTIVE: To determine the NPV of skin tests to ICM Methods: We enrolled 73 patients with a history of HSRs to ICM, 136 subjects with no previous exposure to ICM, and, as controls, 47 subjects who had previously tolerated ICM. All the subjects had skin tests with the culprit and/or alternative ICM and were later questioned as to whether they were reexposed and/or reacted to the skin-test-negative ICM. RESULTS: Sixty (82.2%) and 13 (17.8%) patients had a history of immediate HSR and those with a history of nonimmediate HSR, respectively. The sensitivity and specificity of the skin tests were 18% and 97%, respectively, in patients with immediate HSR and were 23% and 99%, respectively, in patients with nonimmediate HSR. Of a total of 237 subjects with negative skin test results, 207 (87.3%) were asked about further ICM administration; 158 (84.9%) confirmed subsequent use either with (n = 15 [9.4%]) or without premedication (n = 143 [90.6%]). Of the 143 individuals, 140 tolerated skin-test-negative ICMs but three (1.9%) reacted to ICMs (two with mild nonimmediate reactions, one with a grade 1 immediate reaction). Of 20 patients who had previous HSR to ICM, 17 tolerated further skin-test-negative ICM without premedication. The NPV of ICM skin tests, therefore, was 97% (95% confidence interval, 7599%). CONCLUSION: The NPV of skin tests with ICM was high. None of the reactions in patients who had negative skin test results were severe, which may reassure physicians who hesitate to perform further evaluations in patients with negative skin test results</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2016.37.4000</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931304">PM:27931304</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2016-37-482-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2016-37-482-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161209, Soyyiit A</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2016.37.4000</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40510</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kelly,R.S.</style></author><author><style face="normal" font="default"> Virkud,Y.</style></author><author><style face="normal" font="default"> Giorgio,R.</style></author><author><style face="normal" font="default"> Celedon,J.C.</style></author><author><style face="normal" font="default"> Weiss,S.T.</style></author><author><style face="normal" font="default"> Lasky-Su,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Channing Division of Network Medicine, Brigham and Women's Hospital Harvard Medical School, Boston, MA 02115, USA.</style></auth-address><titles><title><style face="normal" font="default">Metabolomic profiling of lung function in Costa-Rican children with asthma</style></title><secondary-title><style face="normal" font="default">Biochim Biophys Acta</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Biochim Biophys Acta</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Costa Rica</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Linoleic Acid</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> metabolomics</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutics</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="7" Month="2" Year="2017">2017/2/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: The development of novel therapeutics and treatment regimens for the management of asthma is hindered by an incomplete understanding of its heterogeneous nature and pathophysiology. Metabolomics can provide an integrated and global profile of a biological system in a dysregulated state, making it a valuable tool to identify biomarkers along the disease development pathway and to understand the biological mechanisms driving that pathway. METHODS: Liquid Chromatography-Mass spectrometry metabolomic profiling was conducted on plasma samples provided at recruitment for 380 children with asthma from the 'Genetic Epidemiology of Asthma in Costa Rica Cohort'. Metabolites associated with three clinical characteristics of asthma severity (i) airway hyper-responsiveness (AHR) (ii) percent-predicted forced expiratory volume in one second/forced vital capacity ratio (FEV1/FVC), and (iii) FEV1/FVC post-bronchodilator were identified and their discriminatory ability assessed. Metabolite set enrichment analyses was applied to explore the biology underlying these relationships. RESULTS: AHR was associated (p&lt;0.05) with 91 of 574 metabolites (15.9%), FEV1/FVC pre-bronchodilator with 102(17.8%), and FEV1/FVC post-bronchodilator with 155 (27.0%). The findings suggest these characteristics capture some common and some distinct phenotypic aspects of lung function; glycerophospholipid, linoleic acid and pyrimidine metabolism were common to all three characteristics. The corresponding metabolomic profiles showed moderate but robust discriminatory ability. CONCLUSIONS: The results confirm the existence of an asthma severity metabolome. However, differences in the metabolomic profiles of the three lung function characteristics studied, suggest that refinement of both phenotype classification and metabolite selection should be a priority as the field of asthma metabolomics progresses</style></abstract><notes><style face="normal" font="default">DA - 20170211IS - 0006-3002 (Print)IS - 0006-3002 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.bbadis.2017.02.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28188833">PM:28188833</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biochim Biophys Acta\20170211-KellyRS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biochim Biophys Acta\20170211-KellyRS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170211, Kelly RS</style></custom2><misc3><style face="normal" font="default">10.1016/j.bbadis.2017.02.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40511</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ku,J.M.</style></author><author><style face="normal" font="default"> Hong,S.H.</style></author><author><style face="normal" font="default"> Kim,H.I.</style></author><author><style face="normal" font="default"> Seo,H.S.</style></author><author><style face="normal" font="default"> Shin,Y.C.</style></author><author><style face="normal" font="default"> Ko,S.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, 02447, Korea</style></auth-address><titles><title><style face="normal" font="default">Effects of Angelicae dahuricae Radix on 2, 4-Dinitrochlorobenzene-Induced Atopic Dermatitis-Like Skin Lesions in mice model</style></title><secondary-title><style face="normal" font="default">BMC Complement Altern Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Complement Altern Med</style></abbr-1></periodical><pages end="" start="98">98-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration &amp; dosage</style></keyword><keyword><style face="normal" font="default"> Administration,Cutaneous</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Angelica</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal model</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> Anti-Allergic Agents</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Atopic</style></keyword><keyword><style face="normal" font="default"> Dinitrochlorobenzene</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease Models,Animal</style></keyword><keyword><style face="normal" font="default"> DNCB</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drug therapy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL-12</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Medicine,Traditional</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Mice,Inbred BALB C</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Phytotherapy</style></keyword><keyword><style face="normal" font="default"> Plant</style></keyword><keyword><style face="normal" font="default"> Plant Extracts</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> Spleen</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapeutic use</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="7" Month="2" Year="2017">2017/2/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis (AD) is an inflammatory, chronically relapsing, and intensively pruritic skin disease that affect 10-30% of the global population. Angelicae dahuricae Radix (ADR) has been reported to be anti-inflammatory in Korean Medicine. In the present study, we investigated whether ADR suppresses the progression of AD in animal model. METHODS: AD was induced by 2, 4-Dinitrochlorobenzene (DNCB). ADR was orally administered to mice to study the effect of ADR on AD. Histological Analysis, immunohistochemistry, blood analysis, RT-PCR, and ELISA assay were performed. RESULTS: ADR significantly suppressed AD-like symptoms in BALB/c mice: ADR decreased skin thickness and spleen weight of mice. ADR reduced infiltration of mast cells, inflammatory cells and CD4+ cells into mouse skin. ADR lowered the number of WBCs in the blood of mice. ADR reduced the levels of IgE, IL-6, IL-10 and IL-12 in mice serum. ADR down-regulated mRNA expression of IL-4, IL-6 and TNF-alpha in mouse skin tissue. CONCLUSION: Our present study clearly indicates that ADR suppresses the progression of AD induced by DNCB in BALB/c mice. This suggests that ADR might be a useful drug for the treatment of AD</style></abstract><notes><style face="normal" font="default">DA - 20170208IS - 1472-6882 (Electronic)IS - 1472-6882 (Linking)LA - engPT - Journal ArticleRN - 0 (Anti-Allergic Agents)RN - 0 (Plant Extracts)RN - 0 (Tumor Necrosis Factor-alpha)RN - GE3IBT7BMN (Dinitrochlorobenzene)SB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1186/s12906-017-1584-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28173791">PM:28173791</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Complement Altern Med\2017-17-98.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Complement Altern Med\2017-17-98.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170208, Ku JM</style></custom2><misc3><style face="normal" font="default">10.1186/s12906-017-1584-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40512</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Henmyr,V.</style></author><author><style face="normal" font="default"> Carlberg,D.</style></author><author><style face="normal" font="default"> Manderstedt,E.</style></author><author><style face="normal" font="default"> Lind-Hallden,C.</style></author><author><style face="normal" font="default"> Sall,T.</style></author><author><style face="normal" font="default"> Cardell,L.O.</style></author><author><style face="normal" font="default"> Hallden,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biology, Lund University, Lund, Sweden.</style></auth-address><titles><title><style face="normal" font="default">Genetic variation of the Toll-like receptors in a Swedish allergic rhinitis case population</style></title><secondary-title><style face="normal" font="default">BMC Med Genet</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Med Genet</style></abbr-1></periodical><pages end="" start="18">18-</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> association studies</style></keyword><keyword><style face="normal" font="default"> association study</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> candidate gene</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genome-wide</style></keyword><keyword><style face="normal" font="default"> genome-wide association</style></keyword><keyword><style face="normal" font="default"> genome-wide association studies</style></keyword><keyword><style face="normal" font="default"> genome-wide association study</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Promoter</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Sequence</style></keyword><keyword><style face="normal" font="default"> Sequences</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> TLR</style></keyword><keyword><style face="normal" font="default"> TLR genes</style></keyword><keyword><style face="normal" font="default"> TLR5</style></keyword><keyword><style face="normal" font="default"> TLR7</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="23" Month="2" Year="2017">2017/2/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: Variation in the 10 toll-like receptor (TLR) genes has been significantly associated with allergic rhinitis (AR) in several candidate gene studies and three large genome-wide association studies. These have all investigated common variants, but no investigations for rare variants (MAF &lt;/= 1%) have been made in AR. The present study aims to describe the genetic variation of the promoter and coding sequences of the 10 TLR genes in 288 AR patients. METHODS: Sanger sequencing and Ion Torrent next-generation sequencing was used to identify polymorphisms in a Swedish AR population and these were subsequently compared and evaluated using 1000Genomes and Exome Aggregation Consortium (ExAC) data. RESULTS: The overall level of genetic variation was clearly different among the 10 TLR genes. The TLR10-TLR1-TLR6 locus was the most variable, while the TLR7-TLR8 locus was consistently showing a much lower level of variation. The AR patients had a total of 37 promoter polymorphisms with 14 rare (MAF &lt;/= 1%) and 14 AR-specific polymorphisms. These numbers were highly similar when comparing the AR and the European part of the 1000Genomes populations, with the exception of TLR10 where a significant (P = 0.00009) accumulation of polymorphisms were identified. The coding sequences had a total of 119 polymorphisms, 68 were rare and 43 were not present in the European part of the 1000Genomes population. Comparing the numbers of rare and AR-specific SNPs in the patients with the European part of the 1000Genomes population it was seen that the numbers were quite similar both for individual genes and for the sum of all 10 genes. However, TLR1, TLR5, TLR7 and TLR9 showed a significant excess of rare variants in the AR population when compared to the non-Finnish European part of ExAC. In particular the TLR1 S324* nonsense mutation was clearly overrepresented in the AR population. CONCLUSIONS: Most TLR genes showed a similar level of variation between AR patients and public databases, but a significant excess of rare variants in AR patients were detected in TLR1, TLR5, TLR7, TLR9 and TLR10. This further emphasizes the frequently reproduced TLR10-TLR1-TLR6 locus as being involved in the pathogenesis of allergic rhinitis</style></abstract><notes><style face="normal" font="default">DA - 20170223IS - 1471-2350 (Electronic)IS - 1471-2350 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1186/s12881-017-0379-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28228119">PM:28228119</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Med Genet\2017-18-18.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Med Genet\2017-18-18.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170223, Henmyr V</style></custom2><misc3><style face="normal" font="default">10.1186/s12881-017-0379-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40513</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Williamson,G.R.</style></author><author><style face="normal" font="default"> O'Connor,A.</style></author><author><style face="normal" font="default"> Kayleigh,E.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Nursing and Midwifery, University of Plymouth, Drake Circus, Plymouth, Devon, PL48AA, UK.</style></auth-address><titles><title><style face="normal" font="default">Women's experiences of personalised support for asthma care during pregnancy: A systematic review of the literature</style></title><secondary-title><style face="normal" font="default">BMC Pregnancy Childbirth</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Pregnancy Childbirth</style></abbr-1></periodical><pages end="" start="69">69-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anxiety</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nursing</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="20" Month="2" Year="2017">2017/2/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma and pregnancy are both sources of anxiety for women. Although there has been a focus on physiological management of asthma and pregnancy, there has been little research on the impact that personalised support can have on asthma care during pregnancy. This systematic review and narrative synthesis of the literature set out to answer the question 'What are women's experiences of asthma care, its management and education, during pregnancy?' METHODS: This systematic review was carried out using accepted methodology from the York Centre for Reviews and Dissemination. Electronic database searches were conducted using PsycInfo, CINAHL, MedLine, Google Scholar and the Cochrane Library, using the combination search terms: 'Asthma' AND 'Pregnancy' AND 'Care' AND ('Education OR Information OR Experience'). Hand searching of journals and searches for grey literature were also undertaken. Independent quality appraisal by the three authors took place using the criteria detailed by Kmet et al. (Standard Quality Assessment Criteria for Evaluating Primary Research Papers from a Variety of Fields, 2004). RESULTS: All papers scoring in excess of 60% were deemed to be of adequate quality for inclusion, of which there were five: two qualitative designs and three quantitative designs. The designs were too methodologically heterogeneous to permit statistical meta-analysis so narrative review and synthesis was undertaken. Despite an embryonic evidence bases, it is reasonable to conclude that personalised care has beneficial outcomes for pregnant asthmatic women. CONCLUSIONS: Larger randomised controlled trials investigating personalised care are required to build an evidence base which can establish the efficacy of such interventions</style></abstract><notes><style face="normal" font="default">DA - 20170221IS - 1471-2393 (Electronic)IS - 1471-2393 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1186/s12884-017-1241-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28219350">PM:28219350</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Pregnancy Childbirth\2017-17-69.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Pregnancy Childbirth\2017-17-69.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170221, WIlliamson GR</style></custom2><misc3><style face="normal" font="default">10.1186/s12884-017-1241-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40514</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Esparaz,A.M.</style></author><author><style face="normal" font="default"> Ahmed,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Vascular and Interventional Radiology, Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, WCC-308F, Rosenberg Building, 1 Deaconess Road, Boston, MA, 02215, USA.</style></auth-address><titles><title><style face="normal" font="default">Resolution of Metallic Biliary Stent Allergic Reaction After Partial Stent Removal in a Patient with Nickel Sensitivity</style></title><secondary-title><style face="normal" font="default">Cardiovasc Intervent Radiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cardiovasc Intervent Radiol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Body Fluids</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> Eating</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Radiology</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic reaction</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="7" Month="2" Year="2017">2017/2/7</year></dates><abstract><style face="normal" font="default">Local and systemic reactions to implanted metallic devices, particularly to those containing nickel, are well documented. Metal ions are released due to exposure of the metal to blood, proteins, other body fluids, and sheer mechanical stress. Metal ions then complex with native proteins and become antigens, which can elicit hypersensitivity reactions. Another case report depicts a specific allergic complication (early stent occlusion) related to metallic biliary stent implantation. We present a case of allergic symptoms, associated with eating, in a patient who developed nickel sensitivity after biliary metal stent placement confirmed by allergic skin testing to the same metallic biliary stent placed one year earlier. Symptoms resolved following partial removal of the non-epithelialized portion of the biliary stent</style></abstract><notes><style face="normal" font="default">DA - 20170208IS - 1432-086X (Electronic)IS - 0174-1551 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s00270-017-1596-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28175974">PM:28175974</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cardiovasc Intervent Radiol\20170208-EsparazAM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cardiovasc Intervent Radiol\20170208-EsparazAM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170208, Esparaz AM</style></custom2><misc3><style face="normal" font="default">10.1007/s00270-017-1596-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40515</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,V.Y.</style></author><author><style face="normal" font="default"> Quintana-Quezada,R.A.</style></author><author><style face="normal" font="default"> Buja,L.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, 6431 Fannin, MSB 1.150, Houston, TXs 77030, United States..</style></auth-address><titles><title><style face="normal" font="default">Eosinophilic endomyocardial disease</style></title><secondary-title><style face="normal" font="default">Cardiovasc Pathol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cardiovasc Pathol</style></abbr-1></periodical><pages end="56" start="54">54-56</pages><volume><style face="normal" font="default">27</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Catheterization</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Texas</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vasculitides</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="23" Month="1" Year="2017">2017/1/23</year></dates><abstract><style face="normal" font="default">Eosinophilic granulomatosis with polyangiitis is the rarest of the antineutrophil cytoplasmic antibody-associated vasculitides. We describe the case of a 58-year-old woman with a history of asthma found to have a left ventricular apical thrombus. Cardiac catheterization with endomyocardial biopsy was consistent with eosinophilic endomyocardial disease. The disease affects several organ systems and shares many features with more common conditions, making it a difficult diagnosis</style></abstract><notes><style face="normal" font="default">DA - 20170203IS - 1879-1336 (Electronic)IS - 1054-8807 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.carpath.2017.01.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28157661">PM:28157661</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cardiovasc Pathol\2017-27-54-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cardiovasc Pathol\2017-27-54-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170203, Liu VY</style></custom2><misc3><style face="normal" font="default">10.1016/j.carpath.2017.01.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40516</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,Y.</style></author><author><style face="normal" font="default"> Xu,Y.</style></author><author><style face="normal" font="default"> Liu,S.</style></author><author><style face="normal" font="default"> Guo,X.</style></author><author><style face="normal" font="default"> Cen,D.</style></author><author><style face="normal" font="default"> Xu,J.</style></author><author><style face="normal" font="default"> Li,H.</style></author><author><style face="normal" font="default"> Li,K.</style></author><author><style face="normal" font="default"> Zeng,C.</style></author><author><style face="normal" font="default"> Lu,L.</style></author><author><style face="normal" font="default"> Zhou,Y.</style></author><author><style face="normal" font="default"> Shen,H.</style></author><author><style face="normal" font="default"> Cheng,H.</style></author><author><style face="normal" font="default"> Zhang,X.</style></author><author><style face="normal" font="default"> Ke,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pathology and Pathophysiology, Zhejiang University School of Medicine, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, China</style></auth-address><titles><title><style face="normal" font="default">Scaffolding protein Gab1 regulates myeloid dendritic cell migration in allergic asthma</style></title><secondary-title><style face="normal" font="default">Cell Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cell Res</style></abbr-1></periodical><pages end="1241" start="1226">1226-1241</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> adaptive</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Convalescence</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">Asthma is a common allergic disorder involving a complex interplay among multiple genetic and environmental factors. Recent studies identified genetic variants of human GAB1 as a novel asthma susceptibility factor. However, the functions of Gab1 in lung remain largely unexplored. In this study, we first observed an elevation of Gab1 level in peripheral blood mononuclear cells from asthmatic patients during acute exacerbation compared with convalescence. Mice with a selectively disrupted Gab1 in myeloid dendritic cells (mDCs) considerably attenuated allergic inflammation in experimental models of asthma. Further investigations revealed a prominent reduction in CCL19-mediated migration of Gab1-deficient mDCs to draining lymph nodes and subsequent impairment of Th2-driven adaptive activation. Mechanistically, Gab1 is an essential component of the CCL19/CCR7 chemokine axis that regulates mDC migration during asthmatic responses. Together, these findings provide the first evidence for the roles of Gab1 in lung, giving us deeper understanding of asthmatic pathogenesis</style></abstract><notes><style face="normal" font="default">DA - 20161104IS - 1748-7838 (Electronic)IS - 1001-0602 (Linking)LA - ENGPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1038/cr.2016.124</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27811945">PM:27811945</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cell Res\2016-26-1226-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cell Res\2016-26-1226-41.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161104, Zhang Y</style></custom2><misc3><style face="normal" font="default">10.1038/cr.2016.124</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40517</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Roberts,D.W.</style></author><author><style face="normal" font="default"> Aptula,A.</style></author><author><style face="normal" font="default"> Api,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University , Liverpool L3 3AF, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Structure-Potency Relationships for Epoxides in Allergic Contact Dermatitis</style></title><secondary-title><style face="normal" font="default">Chem Res Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chem Res Toxicol</style></full-title></periodical><pages end="531" start="524">524-531</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Alkylation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> peptide</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="25" Month="1" Year="2017">2017/1/25</year></dates><abstract><style face="normal" font="default">Epoxides are known or proposed to be involved in skin sensitization in various ways. Some are encountered directly, and others have been shown to be formed abiotically and metabolically from various unsaturated chemicals. They can react as SN2 electrophiles. To date no quantitative mechanistic models (QMMs) are known for skin sensitization potency of this subcategory of SN2 electrophiles. Here we have considered the reaction mechanistic chemistry of epoxides and combined published experimental kinetic data (rate constants k for reaction with a cysteine-based peptide) together with calculated hydrophobicity data (logP) to derive a QMM correlating potency in the local lymph node assay (LLNA), expressed as EC3, with a relative alkylation index (RAI, calculated as logk + 0.4 logP). The QMM equation, pEC3 = 2.42(+/-0.26) RAI + 4.04 (+/-0.25), n = 9, R2 = 0.928, R2(adj) = 0.917, F = 90, s = 0.18, fits the data well, with one positive outlier. The outlier can be rationalized by its exhibiting an alert for oxidation of an amine moiety to give, in this case, the highly reactive glycidaldehyde. The epoxide QMM predicts the potency of a nonepoxide SN2 electrophile (predicted EC3, 0.48%; observed EC3, 0.5%), which suggests that it could form the basis for a more general H-polar SN2 QMM that could be a valuable tool in skin sensitization risk assessment for this quite extensive and structurally diverse reaction mechanistic domain</style></abstract><notes><style face="normal" font="default">DA - 20170125IS - 1520-5010 (Electronic)IS - 0893-228X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1021/acs.chemrestox.6b00241</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28121139">PM:28121139</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Chem Res Toxicol\2017-30-524-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Chem Res Toxicol\2017-30-524-31.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170125, Roberts DW</style></custom2><misc3><style face="normal" font="default">10.1021/acs.chemrestox.6b00241</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40518</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Natsch,A.</style></author><author><style face="normal" font="default"> Emter,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Biosciences, Givaudan Schweiz AG , Ueberlandstrasse 138, CH-8600 Duebendorf, SwitzerlandBiosciences, Givaudan Schweiz AG , Ueberlandstrasse 138, CH-8600 Duebendorf, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Reaction Chemistry to Characterize the Molecular Initiating Event in Skin Sensitization: A Journey to Be Continued</style></title><secondary-title><style face="normal" font="default">Chem Res Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chem Res Toxicol</style></full-title></periodical><pages end="331" start="315">315-331</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Amino acid</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Kinetics</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> peptide</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Preservatives</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin allergy</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> Standardization</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="default">The publication by the OECD of the adverse outcome pathway (AOP) for skin sensitization has accelerated the development and validation of mechanistic tests and testing strategies to assess the potential of new molecules to trigger skin allergies. The molecular initiating event (MIE) in the AOP is reaction with skin peptides/proteins. It is followed by a number of cellular events. Currently, only one in chemico test to characterize the MIE was proposed to and underwent adoption by the OECD, while two cell-based assays have completed the process. A multitude of further cellular assays is currently in the validation pipeline, but no further reactivity test has gone through full standardization. Here, we review data on in chemico methods, identify gaps, and discuss how these methods can be improved to better characterize the MIE and to become even more informative. We focus on the importance of kinetics, the information gained from studying adduct formation, and the difficulties posed by side reactions such as peptide oxidation. We then highlight mechanistic insights from reaction chemistry: the relative contribution of different target nucleophiles, the migration of amino acid modifications, and the potential of peptide-cross-linking. We illustrate in a case study how kinetic in chemico methods might have been used to better predict the risk of three preservatives, which have led to serious epidemics of contact dermatitis. In a case study on Michael acceptors, we show the impact of additional substituents around the electrophilic olefin moiety on reactivity, and we highlight the shortcomings which current in silico methods to predict reaction chemistry still have, illustrating the need for experimental in chemico data to improve such models. Finally, based on the information reviewed and the presented case studies, a strong argument is made to continue the journey of developing nonredundant, informative in chemico methods, and not to solely focus on new cell-based methods to further populate the AOP for skin sensitization</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1520-5010 (Electronic)IS - 0893-228X (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1021/acs.chemrestox.6b00365</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28092944">PM:28092944</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Chem Res Toxicol\2017-30-315-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Chem Res Toxicol\2017-30-315-31.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Natsch A</style></custom2><misc3><style face="normal" font="default">10.1021/acs.chemrestox.6b00365</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40519</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rossini,R.</style></author><author><style face="normal" font="default"> Iorio,A.</style></author><author><style face="normal" font="default"> Pozzi,R.</style></author><author><style face="normal" font="default"> Bianco,M.</style></author><author><style face="normal" font="default"> Musumeci,G.</style></author><author><style face="normal" font="default"> Leonardi,S.</style></author><author><style face="normal" font="default"> Lettieri,C.</style></author><author><style face="normal" font="default"> Bossi,I.</style></author><author><style face="normal" font="default"> Colombo,P.</style></author><author><style face="normal" font="default"> Rigattieri,S.</style></author><author><style face="normal" font="default"> Dossena,C.</style></author><author><style face="normal" font="default"> Anzuini,A.</style></author><author><style face="normal" font="default"> Capodanno,D.</style></author><author><style face="normal" font="default"> Senni,M.</style></author><author><style face="normal" font="default"> Angiolillo,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Dipartimento Cardiovascolare, ASST Papa Giovanni XXIII, Bergamo, Italy</style></auth-address><titles><title><style face="normal" font="default">Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease)</style></title><secondary-title><style face="normal" font="default">Circ Cardiovasc Interv</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Circ Cardiovasc Interv</style></abbr-1></periodical><pages end="" start="e004368">e004368-</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acute Coronary Syndrome</style></keyword><keyword><style face="normal" font="default"> Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Arteries</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin desensitization</style></keyword><keyword><style face="normal" font="default"> Aspirin sensitivity</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Catheterization</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Indications</style></keyword><keyword><style face="normal" font="default"> Infarction</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Rapid desensitization</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: There are limited data on aspirin (ASA) desensitization for patients with coronary artery disease. The aim of the present study was to assess the safety and efficacy of a standard rapid desensitization protocol in patients with ASA sensitivity undergoing coronary angiography. METHODS AND RESULTS: This is a prospective, multicenter, observational study including 7 Italian centers including patients with a history of ASA sensitivity undergoing coronary angiography with intent to undergo percutaneous coronary intervention. A total of 330 patients with history of ASA sensitivity with known/suspected stable coronary artery disease or presenting with an acute coronary syndrome, including ST-segment-elevation myocardial infarction were enrolled. Adverse effects to aspirin included urticaria (n=177, 53.6%), angioedema (n=69, 20.9%), asthma (n=65, 19.7%), and anaphylactic reaction (n=19, 5.8%). Among patients with urticaria/angioedema, 13 patients (3.9%) had a history of idiopathic chronic urticaria. All patients underwent a rapid ASA (5.5 hours) desensitization procedure. The desensitization procedure was performed before cardiac catheterization in all patients, except for those (n=78, 23.6%) presenting with ST-segment-elevation myocardial infarction who underwent the desensitization after primary percutaneous coronary intervention. Percutaneous coronary intervention was performed in 235 patients (71%) of the overall study population. The desensitization procedure was successful in 315 patients (95.4%) and in all patients with a history of anaphylactic reaction. Among the 15 patients (4.6%) who did not successfully respond to the desensitization protocol, adverse reactions were minor and responded to treatment with corticosteroids and antihistamines. Among patients with successful in-hospital ASA desensitization, 253 patients (80.3%) continued ASA for at least 12 months. Discontinuation of ASA in the 62 patients (19.7%) who had responded to the desensitization protocol was because of medical decision and not because of hypersensitivity reactions. CONCLUSIONS: A standard rapid desensitization protocol is safe and effective across a broad spectrum of patients, irrespective of the type of aspirin sensitivity manifestation, with indications to undergo coronary angiography with intent to perform percutaneous coronary intervention. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT02848339</style></abstract><notes><style face="normal" font="default">DA - 20170214IS - 1941-7632 (Electronic)IS - 1941-7640 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1161/CIRCINTERVENTIONS.116.004368</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28193678">PM:28193678</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Circ Cardiovasc Interv\2017-10-e004368.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Circ Cardiovasc Interv\2017-10-e004368.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170214, Rossini R</style></custom2><misc3><style face="normal" font="default">10.1161/CIRCINTERVENTIONS.116.004368</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40520</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Frossard,C.P.</style></author><author><style face="normal" font="default"> Lazarevic,V.</style></author><author><style face="normal" font="default"> Gaia,N.</style></author><author><style face="normal" font="default"> Leo,S.</style></author><author><style face="normal" font="default"> Doras,C.</style></author><author><style face="normal" font="default"> Habre,W.</style></author><author><style face="normal" font="default"> Schrenzel,J.</style></author><author><style face="normal" font="default"> Burger,D.</style></author><author><style face="normal" font="default"> Eigenmann,P.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">University Hospitals of Geneva and University of Geneva, Inflammation and Allergy Research Group</style></auth-address><titles><title><style face="normal" font="default">The farming environment protects mice from allergen-induced skin contact hypersensitivity</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Blood Cells</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Foxp3</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL-17</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin allergy</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="15" Month="2" Year="2017">2017/2/15</year></dates><abstract><style face="normal" font="default">BACKGROUND: Being born and raised in a farm provides a long-lasting protection for allergies. The microbial environment provided by farm animals is crucial to induce this protective effect, although underlying immune mechanisms remain elusive. OBJECTIVE: To establish a mouse model of global exposure to the farming environment and to study immunologic changes linked to protection of allergy. METHODS: Mice colonies were bred in parallel in a farm cowshed and the University animal facility (AF). Mice from both locations were subjected to a skin contact allergy model. Peripheral blood cells and cell cytokine production were assessed in both populations. In addition, the gut microbiome at various ages was characterized. RESULTS: Mice born in the farm were less prone to develop allergy than mice bred in the AF. Mice transfers between the AF and the farm showed a better protection when mice were moved to the farm early in life. As compared to AF-bred mice, farm mice displayed early immune activation with higher CD4+ T cell population, in particular CD4+ CD25+ FoxP3- (activated cells). The cytokine profile of mice from the farm was skewed towards an IL-17, and IL-22 secreting cell profile accompanied by increased IL-10 secretion. These differences were mostly seen within a specific age window between birth and 8 weeks of age. Microbiome analysis showed differences between 4 and 20-weeks old mice and between farm and AF mice with an increased number of Murine mastadenovirus B in young farm mice exclusively. CONCLUSION: The farming environment provides a strong, allergy protective IL-22 stimulus and generates activated CD4+ T cells. Exposure to the farm environment early in their life may also provide a better protection for contact skin allergy. Whether a viral trigger might decisively influence protection for allergies remains to be determined. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170215IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12905</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28198584">PM:28198584</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170215-FrossardCP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170215-FrossardCP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170215, Frossard CP</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12905</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40521</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,Y.P.</style></author><author><style face="normal" font="default"> Rajamanikham,V.</style></author><author><style face="normal" font="default"> Baron,M.</style></author><author><style face="normal" font="default"> Patel,S.</style></author><author><style face="normal" font="default"> Mathur,S.K.</style></author><author><style face="normal" font="default"> Schwantes,E.A.</style></author><author><style face="normal" font="default"> Ober,C.</style></author><author><style face="normal" font="default"> Jackson,D.J.</style></author><author><style face="normal" font="default"> Gern,J.E.</style></author><author><style face="normal" font="default"> Lemanske,R.F.,Jr.</style></author><author><style face="normal" font="default"> Smith,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI</style></auth-address><titles><title><style face="normal" font="default">Association of ORMDL3 with rhinovirus-induced endoplasmic reticulum stress and type I Interferon responses in human leukocytes</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="382" start="371">371-382</pages><volume><style face="normal" font="default">47</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway remodeling</style></keyword><keyword><style face="normal" font="default"> Alleles</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> and primary</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Cell Line</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Chemokine CXCL10</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> CXCL10</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ER stress</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Interferon</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Leukocytes</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Monocyte</style></keyword><keyword><style face="normal" font="default"> Monocytes</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> plasmacytoid dendritic cell</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinovirus</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword><keyword><style face="normal" font="default"> Wisconsin</style></keyword></keywords><dates><year Day="13" Month="2" Year="2017">2017/2/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: Children with risk alleles at the 17q21 genetic locus who wheeze during rhinovirus illnesses have a greatly increased likelihood of developing childhood asthma. In mice, overexpression of the 17q21 gene ORMDL3 leads to airway remodeling and hyper-responsiveness. However, the mechanisms by which ORMDL3 predisposes to asthma are unclear. Previous studies have suggested that ORMDL3 induces endoplasmic reticulum (ER) stress and production of the type I interferon (IFN) regulated chemokine CXCL10. OBJECTIVE: The purpose of this study was to determine the relationship between ORMDL3 and rhinovirus-induced ER stress and type I IFN in human leukocytes. METHODS: ER stress was monitored by measuring HSPA5, CHOP and spliced XBP1 gene expression, and type I IFN by measuring IFNB1 (IFN-beta) and CXCL10 expression in human cell lines and primary leukocytes following treatment with rhinovirus. Requirements for cell contact and specific cell type in ORMDL3 induction were examined by transwell assay and depletion experiments, respectively. Finally, the effects of 17q21 genotype on the expression of ORMDL3, IFNB1, and ER stress genes were assessed. RESULTS: THP-1 monocytes overexpressing ORMDL3 responded to rhinovirus with increased IFNB1 and HSPA5. Rhinovirus-induced ORMDL3 expression in primary leukocytes required cell-cell contact, and induction was abrogated by plasmacytoid dendritic cell depletion. The degree of rhinovirus induced ORMDL3, HSPA5, and IFNB1 expression varied by leukocyte type and 17q21 genotype, with the highest expression of these genes in the asthma-associated genotype. CONCLUSIONS &amp; CLINICAL RELEVANCE: Multiple lines of evidence support an association between higher ORMDL3 and increased rhinovirus-induced HSPA5 and type I IFN gene expression. These associations with ORMDL3 are cell-type specific, with the most significant 17q21 genotype effects on ORMDL3 expression and HSPA5 induction evident in B cells. Together, these findings have implications for how the interaction of increased ORMDL3 and rhinovirus may predispose to asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170213IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12903</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28192616">PM:28192616</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\2017-47-371-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\2017-47-371-82.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170213, Liu YP</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12903</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40522</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">El-Heis,S.</style></author><author><style face="normal" font="default"> Crozier,S.R.</style></author><author><style face="normal" font="default"> Healy,E.</style></author><author><style face="normal" font="default"> Robinson,S.M.</style></author><author><style face="normal" font="default"> Harvey,N.C.</style></author><author><style face="normal" font="default"> Cooper,C.</style></author><author><style face="normal" font="default"> Inskip,H.M.</style></author><author><style face="normal" font="default"> Baird,J.</style></author><author><style face="normal" font="default"> Godfrey,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, UK</style></auth-address><titles><title><style face="normal" font="default">Maternal stress and psychological distress preconception: association with offspring atopic eczema at age 12 months</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> atopic eczema</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mood</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Perinatal</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="2" Year="2017">2017/2/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: Perinatal maternal stress and low mood have been linked to offspring atopic eczema. OBJECTIVES: To examine the relation of maternal stress/mood with atopic eczema in the offspring, focusing particularly on stress/psychological distress preconception. METHODS: At recruitment in the UK Southampton Women's Survey, preconception maternal reports of perceived stress in daily living and the effect of stress on health were recorded; in a sub-sample psychological distress was assessed (12-item General Health Questionnaire). Infants were followed up at ages 6 (n=2956) and 12 (n=2872) months and atopic eczema ascertained (based on UK Working Party Criteria for the Definition of Atopic Dermatitis). At 6 months postpartum, mothers were asked if they had experienced symptoms of low mood since childbirth and completed the Edinburgh Post-natal Depression Scale. RESULTS: Preconception perceived stress affecting health (OR 1.21 (95%CI 1.08-1.35), p=0.001) and stress in daily living (OR 1.16 (1.03-1.30), p=0.014) were associated with an increased risk of offspring atopic eczema at age 12 months but not at 6 months, robust to adjustment for potentially confounding variables. Findings were similar for maternal psychological distress preconception. Low maternal mood between delivery and 6 months postpartum was associated with an increased risk of infantile atopic eczema at age 12 months, but no significant association between postnatal mood and atopic eczema was seen after taking account of preconception stress. CONCLUSION &amp; CLINICAL RELEVANCE: Our data provide novel evidence linking maternal stress at preconception to atopic eczema risk, supporting a developmental contribution to the aetiology of atopic eczema and pointing to potentially modifiable influences. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170220IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12910</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28218994">PM:28218994</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170220-ElHeisS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170220-ElHeisS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170220, El-Heis S</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12910</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40523</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hmlinen,N.</style></author><author><style face="normal" font="default"> Nwaru,B.I.</style></author><author><style face="normal" font="default"> Erlund,I.</style></author><author><style face="normal" font="default"> Takkinen,H.M.</style></author><author><style face="normal" font="default"> Ahonen,S.</style></author><author><style face="normal" font="default"> Toppari,J.</style></author><author><style face="normal" font="default"> Ilonen,J.</style></author><author><style face="normal" font="default"> Veijola,R.</style></author><author><style face="normal" font="default"> Knip,M.</style></author><author><style face="normal" font="default"> Kaila,M.</style></author><author><style face="normal" font="default"> Virtanen,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Health Sciences, University of Tampere, Finland</style></auth-address><titles><title><style face="normal" font="default">Serum carotenoid and tocopherol concentrations and risk of asthma in childhood: a nested case-control study</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="409" start="401">401-409</pages><volume><style face="normal" font="default">47</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> Antioxidants</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma risk</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Carotenoids</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Increased prevalence</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nutrients</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Suggestion</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="15" Month="2" Year="2017">2017/2/15</year></dates><abstract><style face="normal" font="default">BACKGROUND: The antioxidant hypothesis regarding the risk of asthma in childhood has resulted in inconsistent findings. Some data indicate that the role of antioxidants in childhood asthma risk may have a critical time window of effect, but only a well-designed longitudinal cohort study can clarify this hypothesis. OBJECTIVE: To study the longitudinal associations between serum carotenoid and tocopherol concentrations during the first 4 years of life and asthma risk by the age of 5 years. METHODS: Based on a case-control design nested within a Finnish birth cohort, 146 asthma cases were matched to 270 controls on birth time, sex, genetic-risk, and birth place. Non-fasting blood samples were collected at the ages of 1, 1.5, 2, 3, and 4 years and serum carotenoids and tocopherols were analyzed. Parents reported the presence and age at start of persistent doctor-diagnosed asthma in the child at the age of 5 years. Data analyses were conducted using generalized estimating equations. RESULTS: We did not find strong associations between serum carotenoids and tocopherols and the risk of asthma based on age-specific and longitudinal analyses. Both lower and higher quarters of alpha-carotene and gamma-tocopherol increase the risk of asthma. CONCLUSIONS: The current findings do not support the suggestion that the increased prevalence of asthma may be a consequence of decreased intake of antioxidant nutrients. Moreover, we did not confirm any critical time window of impact of antioxidants on asthma risk. Replication of these findings in similar longitudinal settings will strengthen this evidence base. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170215IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Finland -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12904</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28198577">PM:28198577</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\2017-47-401-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\2017-47-401-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170215, Hemlinen N</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12904</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40524</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Egner,W.</style></author><author><style face="normal" font="default"> Helbert,M.</style></author><author><style face="normal" font="default"> Sargur,R.</style></author><author><style face="normal" font="default"> Swallow,K.</style></author><author><style face="normal" font="default"> Harper,N.</style></author><author><style face="normal" font="default"> Garcez,T.</style></author><author><style face="normal" font="default"> Savic,S.</style></author><author><style face="normal" font="default"> Savic,L.</style></author><author><style face="normal" font="default"> Effren,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical Immunology and Allergy Unit, Northern General Hospital, Sheffield, S5 7AU</style></auth-address><titles><title><style face="normal" font="default">Chlorhexidine Allergy in 4 Specialist Allergy Centres in the UK, 2009-2013: Clinical Features and Diagnostic Tests</style></title><secondary-title><style face="normal" font="default">Clin Exp Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Chlorhexidine</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic test</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> intradermal test</style></keyword><keyword><style face="normal" font="default"> Intradermal Tests</style></keyword><keyword><style face="normal" font="default"> Neuromuscular blocking agent</style></keyword><keyword><style face="normal" font="default"> Neuromuscular Blocking Agents</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Sensitisation</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> sIgE</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick testing</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="14" Month="2" Year="2017">2017/2/14</year></dates><abstract><style face="normal" font="default">We describe an observational survey of diagnostic pathways in 104 patients attending four specialist allergy clinics in the UK following perioperative hypersensitivity reactions to chlorhexidine reactions. The majority were life threatening. Men undergoing urological or cardiothoracic surgery predominated. Skin prick testing and sIgE testing were the most common tests used for diagnosis. Fifty-three % of diagnoses were made on the basis of a single positive test. Where multiple tests were performed the sensitivity of intradermal, basophil activation and skin prick testing was 68% (50-86%), 50% (10-90%) and 35% (17-55%) respectively. Seven percent were negative on screening tests initially, and 12 cases were only positive for a single test despite multiple testing. Intradermal tests appeared most sensitive in this context. Additional sensitisation to other substances used perioperatively, particularly neuromuscular blocking agents (NMBA), was found in 28 patients, emphasising the need to test for possible allergy to all drugs to which the patient was exposed even where chlorhexidine is positive. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170214IS - 1365-2249 (Electronic)IS - 0009-9104 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cei.12944</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28194756">PM:28194756</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Immunol\20170214-EgnerW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Immunol\20170214-EgnerW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170214, Egner W</style></custom2><misc3><style face="normal" font="default">10.1111/cei.12944</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40525</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kaur,S.</style></author><author><style face="normal" font="default"> Vasar,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinic of Dermatology, Tartu University, 50417 Tartu, Estonia</style></auth-address><titles><title><style face="normal" font="default">Contact allergy to the ingredients of moisturizers in a boy with atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="181" start="180">180-181</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Estonia</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170221IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Estonia -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12660</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28220565">PM:28220565</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-180-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-180-1.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170221, Kaur S</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12660</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40526</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Macan,J.</style></author><author><style face="normal" font="default"> Babic,Z.</style></author><author><style face="normal" font="default"> Samardzic,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute for Medical Research and Occupational Health, Unit for Occupational and Environmental Health, 10000 Zagreb, Croatia</style></auth-address><titles><title><style face="normal" font="default">Skin health and protection at work in Croatian beautician apprentices</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="179" start="178">178-179</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Croatia</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Health</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170221IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Croatia -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12684</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28220563">PM:28220563</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-178-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-178-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170221, Macan J</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12684</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40527</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Foti,C.</style></author><author><style face="normal" font="default"> Romita,P.</style></author><author><style face="normal" font="default"> Bufano,T.</style></author><author><style face="normal" font="default"> Antelmi,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biomedical Science and Human Oncology, Dermatological Clinic, University of Bari, 70124 Bari, ItalyDepartment of Biomedical Science and Human Oncology, Dermatological Clinic, University of Bari, 70124 Bari, ItalyDepartment of Biomedical Science and Human Oncology, Dermatological Clinic, University of Bari, 70124 Bari, ItalyDepartment of Occupational and Environmental Dermatology, Lund University, Skane University Hospital, 200 52 Malmo, Sweden</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by panthenyl ethyl ether in a patient with psoriasis</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="182" start="181">181-182</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170221IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12667</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28220570">PM:28220570</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-181-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-181-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170221, Foti C</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12667</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40528</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lefevre,S.</style></author><author><style face="normal" font="default"> Valois,A.</style></author><author><style face="normal" font="default"> Truchetet,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy, Unit of Allergy, Mercy Hospital, 57050 Metz, France</style></auth-address><titles><title><style face="normal" font="default">Utility of scratch tests for allergic contact dermatitis caused by Dermabond(R)</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="194" start="193">193-194</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Scratch tests</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170221IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - LetterCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12727</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28220567">PM:28220567</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-193-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-193-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170221, Lefevre S</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12727</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40529</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Al Malki,A.</style></author><author><style face="normal" font="default"> Marguery,M.C.</style></author><author><style face="normal" font="default"> Giordano-Labadie,F.</style></author><author><style face="normal" font="default"> Konstantinou,M.P.</style></author><author><style face="normal" font="default"> Mokeddem,L.</style></author><author><style face="normal" font="default"> Lamant,L.</style></author><author><style face="normal" font="default"> Paul,C.</style></author><author><style face="normal" font="default"> Maza,A.</style></author><author><style face="normal" font="default"> Mazereeuw-Hautier,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Paul Sabatier University and Toulouse University Hospital, 31400 Toulouse, France</style></auth-address><titles><title><style face="normal" font="default">Systemic allergic contact dermatitis caused by methyl aminolaevulinate in a patient with keratosis-ichthyosis-deafness syndrome</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="192" start="190">190-192</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170221IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12703</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28220562">PM:28220562</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-190-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-190-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170221, Al Malki A</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12703</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40530</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hirata,Y.</style></author><author><style face="normal" font="default"> Yanagi,T.</style></author><author><style face="normal" font="default"> Yamaguchi,Y.</style></author><author><style face="normal" font="default"> Sato,K.</style></author><author><style face="normal" font="default"> Shinkuma,S.</style></author><author><style face="normal" font="default"> Hata,H.</style></author><author><style face="normal" font="default"> Shimizu,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Hokkaido University Graduate School of Medicine, 060-8638 Sapporo, Japan</style></auth-address><titles><title><style face="normal" font="default">Ulcerative contact dermatitis caused by benzethonium chloride</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="190" start="188">188-190</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Benzethonium</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170221IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12682</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28220566">PM:28220566</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-188-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-188-90.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170221, Hirata Y</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12682</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40531</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chu,G.J.</style></author><author><style face="normal" font="default"> Murad,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology, Liverpool Hospital, Sydney, 2170, AustraliaDepartment of Immunology, Liverpool Hospital, Sydney, 2170, Australia</style></auth-address><titles><title><style face="normal" font="default">A case of ethanol-induced systemic allergic dermatitis</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="184" start="182">182-184</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170221IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12668</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28220569">PM:28220569</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-182-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-182-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170221, Chu GJ</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12668</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40532</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Muller,S.</style></author><author><style face="normal" font="default"> Kiritsi,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Medical Center-University of Freiburg, 79104 Freiburg, GermanyDepartment of Dermatology, Medical Center-University of Freiburg, 79104 Freiburg, Germany</style></auth-address><titles><title><style face="normal" font="default">Epidermolysis bullosa simplex complicated by allergic contact dermatitis caused by a hydrocolloid dressing</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="186" start="185">185-186</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170221IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12672</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28220564">PM:28220564</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-185-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-185-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170221, Muller S</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12672</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40533</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Grosch,E.</style></author><author><style face="normal" font="default"> Mahler,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Hospital Erlangen, 91054 Erlangen, GermanyDepartment of Dermatology, University Hospital Erlangen, 91054 Erlangen, Germany</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by a catheter system containing sodium metabisulfite</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="187" start="186">186-187</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> sodium metabisulfite</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170221IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12675</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28220568">PM:28220568</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-186-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-186-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170221, Grosch E</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12675</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40534</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Erfurt-Berge,C.</style></author><author><style face="normal" font="default"> Geier,J.</style></author><author><style face="normal" font="default"> Mahler,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Hospital Erlangen, 91054, Erlangen, Germany</style></auth-address><titles><title><style face="normal" font="default">The current spectrum of contact sensitization in patients with chronic leg ulcers or stasis dermatitis - new data from the Information Network of Departments of Dermatology (IVDK)</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Alcohol</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Balsam of Peru</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact allergens</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Fragrance mix</style></keyword><keyword><style face="normal" font="default"> Fragrances</style></keyword><keyword><style face="normal" font="default"> Framycetin</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Lanolin</style></keyword><keyword><style face="normal" font="default"> Leg</style></keyword><keyword><style face="normal" font="default"> Leg Ulcer</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Myroxylon</style></keyword><keyword><style face="normal" font="default"> Myroxylon pereirae</style></keyword><keyword><style face="normal" font="default"> Neomycin</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Peru</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Turpentine</style></keyword><keyword><style face="normal" font="default"> Ulcer</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Venous Insufficiency</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="14" Month="2" Year="2017">2017/2/14</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patients with lower leg dermatitis, chronic venous insufficiency or chronic leg ulcers have a high prevalence of contact sensitization. OBJECTIVES: To identify the current spectrum of contact allergens in these patients. PATIENTS AND METHODS: Data of the Information Network of Departments of Dermatology on 5264 patients with the above diagnoses from the years 2003 to 2014 (study group) were compared with data on 4881 corresponding patients from 1994 to 2003 (historical control group) and with a current control group without these diagnoses (n = 55 510). RESULTS: Allergic contact dermatitis was diagnosed less frequently in the study group than in the historical control group (25.9% versus 16.9%; p &lt; 0.001), and contact sensitization to most allergens had declined. The allergen spectrum, however, was largely unchanged. Important allergens are Myroxylon pereirae (balsam of Peru) (14.8% positive reactions), fragrance mix I (11.4%), lanolin alcohol (7.8%), colophonium (6.6%), neomycin sulfate (5.0%), cetearyl alcohol (4.4%), oil of turpentine (3.1%), and paraben mix (2.6%). Patch testing with additional series showed sensitization to Amerchol L-101 (9.7%), tert-butyl hydroquinone (8.7%), framycetin sulfate (5.0%), and gentamicin sulfate (3.1%). CONCLUSIONS: Topical preparations for treating the above-mentioned conditions should not contain fragrances, Myroxylon pereirae, and colophonium. The special allergen spectrum has to be considered in patch testing</style></abstract><notes><style face="normal" font="default">DA - 20170214IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12763</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28194803">PM:28194803</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170214-ErfurtBergeC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170214-ErfurtBergeC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170214, Erfurt-Berge C</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12763</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40535</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Paulsen,E.</style></author><author><style face="normal" font="default"> Hyldgaard,M.G.</style></author><author><style face="normal" font="default"> Andersen,K.E.</style></author><author><style face="normal" font="default"> Andersen,F.</style></author><author><style face="normal" font="default"> Christensen,L.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark, 5000 Odense C, Denmark</style></auth-address><titles><title><style face="normal" font="default">Allergenic sesquiterpene lactones from cushion bush (Leucophyta brownii Cass.): new and old sensitizers in a shrub-turned-a-pot plant</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergenic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Compositae</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lactones</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Plant</style></keyword><keyword><style face="normal" font="default"> Plants</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Sesquiterpene lactones</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="14" Month="2" Year="2017">2017/2/14</year></dates><abstract><style face="normal" font="default">BACKGROUND: The Australian cushion bush (Leucophyta brownii) of the Compositae family of plants has become a popular pot and container plant. The plant produces the sesquiterpene lactone allergen calocephalin. OBJECTIVES: To assess the sensitizing potential of sesquiterpene lactones from cushion bush. PATIENTS/MATERIALS/METHODS: Eleven Compositae-sensitive patients were patch tested with seven sesquiterpene lactones isolated from cushion bush. RESULTS: Six of seven sesquiterpene lactones elicited positive reactions in 4 of 11 patients. CONCLUSIONS: The well-known sesquiterpene lactone pseudoivalin and its derivative pseudoivalin acetate, as well as calocephalin and tomentosin, were confirmed to be sensitizers, whereas leucophytalin A and 4alpha-hydroxy-5alphaH,10alphaH-1,11(13)-guaidien-8beta,12-olide were shown to be allergenic for the first time. The patch test reaction patterns seem to follow the chemical patterns, which may eventually make it possible to trace primary sensitizers and advise patients more precisely</style></abstract><notes><style face="normal" font="default">DA - 20170214IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12757</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28194806">PM:28194806</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170214-PaulsenE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170214-PaulsenE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170214, Paulsen E</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12757</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40536</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Galvis,V.</style></author><author><style face="normal" font="default"> Tello,A.</style></author><author><style face="normal" font="default"> Carreno,N.I.</style></author><author><style face="normal" font="default"> Berrospi,R.D.</style></author><author><style face="normal" font="default"> Nino,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">*Centro Oftalmologico Virgilio Galvis, Floridablanca, Colombia daggerUniversidad Autonoma de Bucaramanga, Faculty of Health, Department of Ophthalmology, Bucaramanga, Colombia double daggerFundacion Oftalmologica de Santander (FOSCAL), Department of Ophthalmology, Floridablanca, Colombia</style></auth-address><titles><title><style face="normal" font="default">Risk Factors for Keratoconus: Atopy and Eye Rubbing</style></title><secondary-title><style face="normal" font="default">Cornea</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cornea</style></full-title></periodical><pages end="" start="e1">e1-</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Atopy</style></keyword><keyword><style face="normal" font="default"> Colombia</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Keratoconus</style></keyword><keyword><style face="normal" font="default"> Ophthalmology</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161018IS - 1536-4798 (Electronic)IS - 0277-3740 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Colombia -</style></notes><work-type><style face="normal" font="default">10.1097/ICO.0000000000001052</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27755195">PM:27755195</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cornea\2017-36-e1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cornea\2017-36-e1.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161018, Galvis V</style></custom2><misc3><style face="normal" font="default">10.1097/ICO.0000000000001052</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40537</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Montandon,S.V.</style></author><author><style face="normal" font="default"> Petrov,A.A.</style></author><author><style face="normal" font="default"> Fajt,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA</style></auth-address><titles><title><style face="normal" font="default">A Novel Pretreatment Regimen for Breakthrough Radiocontrast Media Anaphylaxis in Cardiac Patients</style></title><secondary-title><style face="normal" font="default">Crit Pathw Cardiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Crit Pathw Cardiol</style></full-title></periodical><pages end="164" start="161">161-164</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pretreatment</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Radiocontrast media</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Radiocontrast media allergy is a severe and potentially life-threatening condition. This creates a clinical dilemma for cardiac patients who require urgent interventions with radiocontrast media. Several pretreatment regimens have been suggested for patients with prior immediate hypersensitivity reactions to radiocontrast media. Despite using pretreatment regimens, breakthrough reactions have been reported in 2.1%-18% of patients with radiocontrast media allergy. Little is known about management of patients with a history of breakthrough radiocontrast media anaphylaxis who require urgent lifesaving procedures. METHODS: We report a retrospective analysis of 2 cardiac cases with a history of breakthrough radiocontrast media anaphylaxis despite standard pretreatment. These patients required urgent cardiac intervention with the use of radiocontrast media. RESULTS: We present a novel pretreatment regimen for high-risk cardiac patients with breakthrough radiocontrast media anaphylaxis despite prior pretreatment who need urgent coronary interventions. CONCLUSION: This protocol is both safe and effective in mitigating anaphylaxis in cardiac patients</style></abstract><notes><style face="normal" font="default">DA - 20161115IS - 1535-2811 (Electronic)IS - 1535-2811 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/HPC.0000000000000088</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27846008">PM:27846008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Crit Pathw Cardiol\2016-15-161-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Crit Pathw Cardiol\2016-15-161-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161115, Montandon SV</style></custom2><misc3><style face="normal" font="default">10.1097/HPC.0000000000000088</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40538</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rovina,K.</style></author><author><style face="normal" font="default"> Siddiquee,S.</style></author><author><style face="normal" font="default"> Shaarani,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Biotechnology Research Institute, Universiti Malaysia Sabah, Jalan UMS , 88400 Kota Kinabalu , Sabah , Malaysia</style></auth-address><titles><title><style face="normal" font="default">A review of extraction and analytical methods for the determination of Tartrazine (E 102) in foodstuffs</style></title><secondary-title><style face="normal" font="default">Crit Rev Anal Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Crit Rev Anal Chem</style></abbr-1></periodical><pages end="324" start="309">309-324</pages><volume><style face="normal" font="default">47</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Biotechnology</style></keyword><keyword><style face="normal" font="default"> Body Weight</style></keyword><keyword><style face="normal" font="default"> Capillaries</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Chromatography</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Electrophoresis</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> Filtration</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Food Industry</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> Government</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> Malaysia</style></keyword><keyword><style face="normal" font="default"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Solid phase</style></keyword><keyword><style face="normal" font="default"> Solid Phase Extraction</style></keyword><keyword><style face="normal" font="default"> Spectrophotometry</style></keyword><keyword><style face="normal" font="default"> Tartrazine</style></keyword><keyword><style face="normal" font="default"> Textiles</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="27" Month="1" Year="2017">2017/1/27</year></dates><abstract><style face="normal" font="default">Tartrazine is an azo food dye, orange-coloured and water soluble that usually used in foods, pharmaceuticals, cosmetics, and textiles. Tartrazine possess adverse health effect to human such as hyperactivity in children, allergy and asthma. Joint FAO/WHO Expert Committee on Food Additive (JECFA) and EU Scientific Committee for Food (SCF) standardized the acceptable daily intake (ADI) for Tartrazine is at 7.5 mg kg-1 body weight. Many researchers have been detected the presence of Tartrazine for monitoring the quality and safety of food products. In this review paper highlighted various detection and extraction methods of Tartrazine. Some of the analytical methods are available such as high performance liquid chromatography (HPLC), electrochemical sensor, thin-layer chromatography (TLC), spectrophotometry, capillary electrophoresis and liquid chromatography-tandem mass spectrometry (LC-MS). As extraction steps are discussed: liquid-liquid extraction (LLE), solid-phase extraction (SPE), membrane filtration, cloud point extraction and other extraction method. Also, brief overview explained the synthesis process and metabolism of Tartrazine and the maximum permitted level in different countries. This review paper will give insight scenario on different extraction and analytical methods for determination of Tartrazine on healthy food among public attract attention on food safety and quality which can provide incalculable interest to food industry and government bodies</style></abstract><notes><style face="normal" font="default">DA - 20170127IS - 1547-6510 (Electronic)IS - 1040-8347 (Linking)LA - engPT - Journal ArticleCO - Malaysia -</style></notes><work-type><style face="normal" font="default">10.1080/10408347.2017.1287558</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28128965">PM:28128965</url></web-urls><related-urls><url ppv-ref="no">presto - 18 mesi</url></related-urls></urls><custom2><style face="normal" font="default">20170127, Rovina K</style></custom2><misc3><style face="normal" font="default">10.1080/10408347.2017.1287558</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40539</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cleven,K.L.</style></author><author><style face="normal" font="default"> Webber,M.P.</style></author><author><style face="normal" font="default"> Zeig-Owens,R.</style></author><author><style face="normal" font="default"> Hena,K.M.</style></author><author><style face="normal" font="default"> Prezant,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Division of Pulmonary Medicine, Montefiore Medical Center and Albert Einstein College of Medicine, 111 E 210th St, Bronx, NY, 10467, USA</style></auth-address><titles><title><style face="normal" font="default">Airway Disease in Rescue/Recovery Workers: Recent Findings from the World Trade Center Collapse</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="5">5-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> persistence</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Medicine</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Our goal is to summarize the airway disease literature since September 11, 2001 (9/11), focusing on studies published since 2011 in World Trade Center-exposed rescue/recovery workers. RECENT FINDINGS: Since 2011, studies have confirmed relationships between initial World Trade Center exposure intensity, severity of symptoms, airway disease diagnoses, and biomarkers of disease progression. Studies continue to document ongoing morbidity in rescue/recovery workers over 10 years after 9/11. Future research should further identify correlates of symptom persistence and new airway disease diagnoses. The unique characteristics of the airway diseases in this population warrant ongoing monitoring and treatment</style></abstract><notes><style face="normal" font="default">DA - 20170209IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0670-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28181152">PM:28181152</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170209, Cleven KL</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0670-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40540</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yamashita,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Food for Health, Department of Bioscience in Daily Life, College of Bioresource Sciences, Nihon University, 1866 Kameino, Fujisawa, Kanagawa 252-0880, Japan</style></auth-address><titles><title><style face="normal" font="default">Aspirin Intolerance: Experimental Models for Bed-to-Bench</style></title><secondary-title><style face="normal" font="default">Curr Drug Targets</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Drug Targets</style></abbr-1></periodical><pages end="1970" start="1963">1963-1970</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">16</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> AERD</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway smooth muscle</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Arachidonic Acid</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin intolerance</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-induced urticaria</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cell Line</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Constriction</style></keyword><keyword><style face="normal" font="default"> CysLT</style></keyword><keyword><style face="normal" font="default"> cysteinyl leukotriene</style></keyword><keyword><style face="normal" font="default"> cysteinyl leukotrienes</style></keyword><keyword><style face="normal" font="default"> cysteinyl-leukotrienes</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Indomethacin</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Leukotrienes</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drug</style></keyword><keyword><style face="normal" font="default"> NSAID</style></keyword><keyword><style face="normal" font="default"> NSAIDs</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Prostaglandin</style></keyword><keyword><style face="normal" font="default"> rat</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Type I allergy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="5" Month="10" Year="2016">2016/10/5</year></dates><abstract><style face="normal" font="default">Aspirin is the oldest non-steroidal anti-inflammatory drug (NSAID), and it sometimes causes asthma-like symptoms known as aspirin-exacerbated respiratory disease (AERD), which can be serious. Unwanted effects of aspirin (aspirin intolerance) are also observed in patients with food-dependent exercise-induced anaphylaxis, a type I allergy disease, and aspirin-induced urticaria (AIU). However the target and the mechanism of the aspirin intolerance are still unknown. There is no animal or cellular model of AERD, because its pathophysiological mechanism is still unknown, but it is thought that inhibition of cyclooxygenase by causative agents lead to an increase of free arachidonic acid, which is metabolized into cysteinyl leukotrienes (cysLTs) that provoke airway smooth muscle constriction and asthma symptoms. As the bed-to-bench approach, to confirm the clinical discussion in experimental cellular models, we have tried to develop a cellular model of AERD using activated RBL-2H3 cells, a rat mast cell like cell line. Indomethacin (another NSAID and also causes AERD), enhances in vitro cysLTs production by RBL-2H3 cells, while there is no induction of cysLTs production in the absence of inflammatory activation. Since this suggests that all inflammatory cells with activation of prostaglandin and cysLT metabolism should respond to NSAIDs, and then I have concluded that aspirin intolerance should be separated from subsequent bronchoconstriction. Evidence about the cellular mechanisms of NSAIDs may be employed for development of in vitro AERD models as the approach from bench-to-bed</style></abstract><notes><style face="normal" font="default">DA - 20161010IS - 1873-5592 (Electronic)IS - 1389-4501 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27719658">PM:27719658</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Drug Targets\2016-17-1963-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Drug Targets\2016-17-1963-70.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161010, Yamashita M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40541</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,M.</style></author><author><style face="normal" font="default"> Asche,C.V.</style></author><author><style face="normal" font="default"> Tillis,W.</style></author><author><style face="normal" font="default"> Ren,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Center for Outcomes Research/Department of Internal Medicine , University of Illinois College of Medicine at Peoria , Peoria , IL , USA</style></auth-address><titles><title><style face="normal" font="default">Association between availability of care providers and healthcare utilizations among adults with asthma</style></title><secondary-title><style face="normal" font="default">Curr Med Res Opin</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Med Res Opin</style></abbr-1></periodical><pages end="487" start="479">479-487</pages><volume><style face="normal" font="default">33</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Barriers</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> cross-sectional analysis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Financial Support</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Illinois</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Rural</style></keyword><keyword><style face="normal" font="default"> Rural Health</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Limited accessibility to providers may delay appropriate control of asthma exacerbations. The objective of our study is to estimate the contributors to the hospital/emergency department (ED) visits among adults with asthma focusing on the availability of healthcare providers. METHODS: We conducted a pooled cross-sectional analysis using the 2011-2013 Asthma Call-Back Survey linked with 2012-2016 Area Health Resource Files. We employed multivariable logistic regression with dichotomous outcomes of hospitalization and ED visits. Key covariates were the availability of county-level healthcare provider variables per 100,000 persons such as the number of lung disease specialists (including pulmonary care specialists, and allergy and immunology specialists), the number of hospitals, the number of safety-net facilities including rural health centers (RHCs) and federally qualified health centers (FQHCs), and the number of primary care physicians (PCPs). RESULTS: Among 25,621 adults, proportions of hospital visits and ED visits were 3.3% and 13.2%, respectively. An additional RHC reduced by 3% the odds of having an ED visit (odds ratio [OR] = 0.97, p = .004). Patients with cost barriers to seeing a PCP were 60% (OR = 1.60, p = .028) more likely to have a hospital visit than those without. In addition, patients with cost barriers to seeing a specialist were 90% (OR = 1.90, p = .007) and 111% (OR = 2.11, p = .001) more likely to have a hospital visit and ED visit, respectively, than those without. CONCLUSIONS: Hospital and ED visits among adults with asthma are partially related to the availability of providers, and more related to financial barriers. Therefore, financial support for the vulnerable asthma population might be a target for policy makers interested in reducing hospitalizations and ED visits</style></abstract><notes><style face="normal" font="default">DA - 20161124IS - 1473-4877 (Electronic)IS - 0300-7995 (Linking)LA - engPT - Journal ArticleCO - United Strates -</style></notes><work-type><style face="normal" font="default">10.1080/03007995.2016.1264930</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27882775">PM:27882775</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Med Res Opin\2017-33-479-87.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Med Res Opin\2017-33-479-87.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161124, Kim M</style></custom2><misc3><style face="normal" font="default">10.1080/03007995.2016.1264930</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40542</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Worgall,T.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Columbia University Medical Center, New York City, New York, USA</style></auth-address><titles><title><style face="normal" font="default">Sphingolipids, ORMDL3 and asthma: what is the evidence?</style></title><secondary-title><style face="normal" font="default">Curr Opin Clin Nutr Metab Care</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Opin Clin Nutr Metab Care</style></abbr-1></periodical><pages end="103" start="99">99-103</pages><volume><style face="normal" font="default">20</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="default"> airway remodeling</style></keyword><keyword><style face="normal" font="default"> airway smooth muscle</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Alternaria</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> association studies</style></keyword><keyword><style face="normal" font="default"> association study</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma risk</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Ceramides</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Columbia</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genome-wide</style></keyword><keyword><style face="normal" font="default"> genome-wide association</style></keyword><keyword><style face="normal" font="default"> genome-wide association studies</style></keyword><keyword><style face="normal" font="default"> genome-wide association study</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> House dust</style></keyword><keyword><style face="normal" font="default"> house dust mite</style></keyword><keyword><style face="normal" font="default"> house dust mites</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Hypertrophy</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> Mites</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Mucus</style></keyword><keyword><style face="normal" font="default"> Muscle Contraction</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> New York City</style></keyword><keyword><style face="normal" font="default"> Ovalbumin</style></keyword><keyword><style face="normal" font="default"> persistence</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Genome-wide association studies identified ORMDL3, a protein of the endoplasmic reticulum, as a significant asthma risk factor. ORMDL3 is one of three ORMDL proteins that integrate multiple signals to maintain sphingolipid homeostasis. Studies that investigated potential mechanisms for how increased ORMDL3 might affect asthma are summarized. RECENT FINDINGS: Investigations focused on decreased sphingolipid synthesis and on the unfolded protein response because ORMDL3 had been implicated in both.Airway reactivity is increased in a genetic model with decreased de-novo sphingolipid synthesis and in wild-type mice treated with myriocin, a sphingolipid synthesis inhibitor. Inflammation, mucus production and airway smooth muscle hypertrophy are absent. ORMDL3 was not evaluated directly but results suggest that decreased sphingolipid synthesis is sufficient to induce airway hyperreactivity (AHR).Direct effects of ORMDL3 were investigated in allergic asthma models. Sensitization with ovalbumin, house dust mites and Alternaria alternata increase ORMDL3 mRNA. Universal overexpression of ORMDL3 decreases serum sphingolipids, increases inflammatory markers, airway remodeling and AHR in response to allergic stimuli. Addition of myriocin during sensitization drastically exacerbates house dust mites-induced AHR.ORMDL3 knockout mice are protected from developing A. alternata-induced AHR. The effect is specific to Alternaria and limited to smooth muscle contraction, as inflammation persists. ORMDL3 might have a critical role for smooth muscle contraction.Little is known about how the different ORMDL3 single nucleotide polymorphisms affect human blood and tissue sphingolipid profiles. One group measured total sphingoid levels and found no association with ORMDL3 single nucleotide polymorphisms in a general population. Others evaluated sphingolipid profiles in 7-8-year old children with mild asthma and found significantly higher C18 and C20 ceramides in those with persistence of asthma symptoms 3 years later, suggesting that sphingolipid profiles might predict asthma persistence. SUMMARY: Possible mechanisms how ORMDL3 affects asthma include inhibition of sphingolipid synthesis, synergistic effects with known allergens and a combination of both</style></abstract><notes><style face="normal" font="default">DA - 20161228IS - 1473-6519 (Electronic)IS - 1363-1950 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/MCO.0000000000000349</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28030368">PM:28030368</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Clin Nutr Metab Care\2017-20-99-103.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Clin Nutr Metab Care\2017-20-99-103.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161228, Worgall TS</style></custom2><misc3><style face="normal" font="default">10.1097/MCO.0000000000000349</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40543</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Terzakis,D.</style></author><author><style face="normal" font="default"> Georgalas,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">aDepartment of Otorhinolaryngology, Henry Dunant Hospital, Athens bEndoscopic Skull Base Center, Hygeia Hospital, Marousi, Greece cCenter for Skull Base Patients, Leiden University Medical Center, Leiden, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Polyps, asthma, and allergy: what's new</style></title><secondary-title><style face="normal" font="default">Curr Opin Otolaryngol Head Neck Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Opin Otolaryngol Head Neck Surg</style></abbr-1></periodical><pages end="18" start="12">12-18</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate lymphoid cells</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Multidisciplinary team</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Although chronic rhinosinusitis with nasal polyps, asthma, and allergy share common inflammatory mechanisms, there is no evidence of cause-and-effect relationship. In this review, we present new studies investigating the complex immunology that links these diseases. Advances in new therapies as well as evidence regarding indication and timing of surgery, especially of more complex cases, are highlighted. RECENT FINDINGS: New studies have endotyped patients in an effort to describe the exact inflammatory profile of each phenotype, whereas described cytokines seem to play a significant role in amplification of T2 inflammation, directly or via innate lymphoid cells. New mAbs that block specific cytokines of these pathways have been developed and seem to show reduced asthma severity as well as improved sinonasal outcomes. Moreover, it has been shown that operating early in the course of disease leads not only to bigger improvements in SNOT-22 outcomes but also to reduced asthma incidence postoperatively in refractory cases. SUMMARY: Applying data from current studies in clinical practice, we could better manage refractory cases with asthma and polyps, both medically and surgically. Treatment has to be patient-centered, and this demands a multidisciplinary-team approach of the airway diseases</style></abstract><notes><style face="normal" font="default">DA - 20161116IS - 1531-6998 (Electronic)IS - 1068-9508 (Linking)LA - engPT - Journal ArticleCO - Greece -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1097/MOO.0000000000000323</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27849652">PM:27849652</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Otolaryngol Head Neck Surg\2017-25-12-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Otolaryngol Head Neck Surg\2017-25-12-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161116, Terzakis D</style></custom2><misc3><style face="normal" font="default">10.1097/MOO.0000000000000323</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40544</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tajudeen,B.A.</style></author><author><style face="normal" font="default"> Schwartz,J.S.</style></author><author><style face="normal" font="default"> Bosso,J.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">aDepartment of Otorhinolaryngology - Head and Neck Surgery, Rush University Medical Center, Chicago, Illinois, USA bDepartment of Otolaryngology - Head and Neck Surgery, McGill University, Montreal, Quebec, Canada cDepartment of Otorhinolaryngology - Head and Neck Surgery, The University of Pennsylvania, Philadelphia, Pennsylvania, USA</style></auth-address><titles><title><style face="normal" font="default">The role of aspirin desensitization in the management of aspirin-exacerbated respiratory disease</style></title><secondary-title><style face="normal" font="default">Curr Opin Otolaryngol Head Neck Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Opin Otolaryngol Head Neck Surg</style></abbr-1></periodical><pages end="34" start="30">30-34</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AERD</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin desensitization</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease Management</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Illinois</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyposis</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Otolaryngology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pennsylvania</style></keyword><keyword><style face="normal" font="default"> Philadelphia</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> Polyposis</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Quebec</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sinus</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> symptom scores</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Aspirin-exacerbated respiratory disease (AERD) is a progressive inflammatory disease of the upper and lower airways characterized by marked eosinophilic nasal polyposis, asthma, and respiratory reactions to medications that inhibit the cyclooxygenase pathway. Aspirin desensitization has proven to be an effective tool in the management of this disease when used in a multidisciplinary setting. The purpose of this article is to review the current literature regarding AERD, aspirin desensitization, and share our opinion regarding the most optimal multidisciplinary approach to these complex patients. RECENT FINDINGS: Numerous studies, including randomized, double-blind, placebo-controlled trials, have demonstrated the therapeutic effectiveness of aspirin desensitization with significant improvement in number of sinus infections per year, olfactory scores, nasal symptom scores, asthma symptom scores, sinus operations, hospitalizations, emergency room visits, and oral steroid use. Furthermore, the role of surgery is becoming increasingly important for recalcitrant sinus disease with recent studies showing comprehensive surgery as more beneficial to disease management. SUMMARY: Aspirin desensitization is an effective therapeutic tool in the management of AERD. A multidisciplinary approach is critical between the otorhinolaryngologist and allergist to provide the most optimal care for this complex patient population</style></abstract><notes><style face="normal" font="default">DA - 20161116IS - 1531-6998 (Electronic)IS - 1068-9508 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/MOO.0000000000000331</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27849653">PM:27849653</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Otolaryngol Head Neck Surg\2017-25-30-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Otolaryngol Head Neck Surg\2017-25-30-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161116, Tajudeen BA</style></custom2><misc3><style face="normal" font="default">10.1097/MOO.0000000000000331</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40545</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Elcin,G.</style></author><author><style face="normal" font="default"> Gulseren,D.</style></author><author><style face="normal" font="default"> Bayraktar,M.</style></author><author><style face="normal" font="default"> Gunalp,S.</style></author><author><style face="normal" font="default"> Gurgan,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Dermatology and Venereology , Hacettepe University Faculty of Medicine , Ankara , Turkey</style></auth-address><titles><title><style face="normal" font="default">Autoimmune estrogen dermatitis in an infertile female</style></title><secondary-title><style face="normal" font="default">Cutan Ocul Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cutan Ocul Toxicol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">autoimmune</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> estrogen</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Intradermal skin tests</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Menstrual Cycle</style></keyword><keyword><style face="normal" font="default"> Menstruation</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="11" Year="2016">2016/11/2</year></dates><abstract><style face="normal" font="default">Autoimmune estrogen dermatitis is a cyclical cutaneous eruption that occurs premenstrually and goes to the rapid resolution within a few days of menstrual cycles. The disorder has variable clinical manifestations consisting of macules, papules, vesicles, urticarial lesions, bullae, eczematous plaques, and erythema multiforme-like lesions. Herein, we present a case of a 30-year-old woman with attacks of edema and erosions involving the oral and genital mucosal sites on every first day of her menstruation period. She had also multiple endocrinological problems such as hypotroidism and infertility. To determine the sex hormon sensitivity, intradermal skin tests were performed. Based on her personal history and skin test findings, a diagnosis of autoimmune estrogen dermatitis was made. After the oophorectomy, she was free from the skin and mucosal symptoms. We propose that it is important to suspect the diagnosis of autoimmune estrogen dermatitis in patients who present with recurrent cylic eruptions and it must be kept in mind that these patients might have a concomitant infertility</style></abstract><notes><style face="normal" font="default">DA - 20161011IS - 1556-9535 (Electronic)IS - 1556-9527 (Linking)LA - ENGPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1080/15569527.2016.1245197</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27723997">PM:27723997</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cutan Ocul Toxicol\20161011-ElcinG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cutan Ocul Toxicol\20161011-ElcinG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161011, Elcin G</style></custom2><misc3><style face="normal" font="default">10.1080/15569527.2016.1245197</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40546</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Colagiovanni,A.</style></author><author><style face="normal" font="default"> Feliciani,C.</style></author><author><style face="normal" font="default"> Fania,L.</style></author><author><style face="normal" font="default"> Pascolini,L.</style></author><author><style face="normal" font="default"> Buonomo,A.</style></author><author><style face="normal" font="default"> Nucera,E.</style></author><author><style face="normal" font="default"> Schiavino,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Department, Universita Cattolica del Sacro Cuore, Rome, Italy</style></auth-address><titles><title><style face="normal" font="default">Occupational contact dermatitis from carbapenems</style></title><secondary-title><style face="normal" font="default">Cutis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cutis</style></full-title></periodical><pages end="E3" start="E1">E1-E3</pages><volume><style face="normal" font="default">96</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anti-Bacterial Agents</style></keyword><keyword><style face="normal" font="default"> Carbapenems</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> chemically induced</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Occupational</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Nurses</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Rome</style></keyword></keywords><dates><year Day="0" Month="10" Year="2015">2015/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20151218IS - 2326-6929 (Electronic)IS - 0011-4162 (Linking)LA - ENGPT - Case ReportsPT - LetterRN - 0 (Anti-Bacterial Agents)RN - 0 (Carbapenems)SB - IMCO - Italy -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26682293">PM:26682293</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cutis\2015-96-E1-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cutis\2015-96-E1-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20151218, Colagiovanni A</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40547</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sekhon,S.</style></author><author><style face="normal" font="default"> Nedorost,S.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, Ohio, USACase Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, Ohio, USA</style></auth-address><titles><title><style face="normal" font="default">Patch testing for adverse drug reactions</style></title><secondary-title><style face="normal" font="default">Cutis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cutis</style></full-title></periodical><pages end="54" start="49">49-54</pages><volume><style face="normal" font="default">99</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Gold</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Transformation</style></keyword><keyword><style face="normal" font="default"> Lymphocyte transformation test</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Ohio</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Transformation</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">Adverse drug reactions result in a substantial number of hospital admissions and inpatient events. Diagnosis usually is made with clinical judgment and circumstantiality without diagnostic testing. Furthermore, even in situations where diagnostic testing is performed, no safe gold standard tests exist. Oral rechallenge is currently the gold standard but carries the risk of recrudescence of severe allergic symptoms. Other tests include skin prick tests, the lymphocyte transformation test, immunohistochemistry, and patch testing. This article provides a review of patch testing in cases of adverse drug reactions and presents new data on this topic</style></abstract><notes><style face="normal" font="default">DA - 20170216IS - 2326-6929 (Electronic)IS - 0011-4162 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28207004">PM:28207004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cutis\2017-99-49-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cutis\2017-99-49-54.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170216, Sekhon S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40548</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Trusler,A.R.</style></author><author><style face="normal" font="default"> Clark,A.K.</style></author><author><style face="normal" font="default"> Sivamani,R.K.</style></author><author><style face="normal" font="default"> Shi,V.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Drexel University College of Medicine, Philadelphia, PA; daggerSchool of Medicine, double daggerDepartment of Dermatology, University of California, Davis; and section signDermatology Division, Department of Medicine, University of Arizona, Tucson</style></auth-address><titles><title><style face="normal" font="default">The Endocannabinoid System and Its Role in Eczematous Dermatoses</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="32" start="22">22-32</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Arizona</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dermatoses</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endocrine System</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritant contact dermatitis</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lipid</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> mood</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Philadelphia</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">The skin serves as the foremost barrier between the internal body and the external world, providing crucial protection against pathogens and chemical, mechanical, and ultraviolet damages. The skin is a central player in the intricate network of immune, neurologic, and endocrine systems. The endocannabinoid system (ECS) includes an extensive network of bioactive lipid mediators and their receptors, functions to modulate appetite, pain, mood, and memory, and has recently been implicated in skin homeostasis. Disruption of ECS homeostasis is implicated in the pathogenesis of several prevalent skin conditions. In this review, we highlight the role of endocannabinoids in maintaining skin health and homeostasis and discuss evidence on the role of ECS in several eczematous dermatoses including atopic dermatitis, asteatotic eczema, irritant contact dermatitis, allergic contact dermatitis, and chronic pruritus. The compilation of evidence may spark directions for future investigations on how the ECS may be a therapeutic target for dermatologic conditions</style></abstract><notes><style face="normal" font="default">DA - 20170118IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000257</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28098721">PM:28098721</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-22-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-22-32.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170118, Trusler AR</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000257</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40549</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Holcomb,Z.E.</style></author><author><style face="normal" font="default"> Van Noord,M.G.</style></author><author><style face="normal" font="default"> Atwater,A.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Duke University School of Medicine, Duke University; daggerDuke University Medical Center Library; and double daggerDepartment of Dermatology, Duke University Medical Center, Durham, NC</style></auth-address><titles><title><style face="normal" font="default">Gallate Contact Dermatitis: Systematic Review and Product Update</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cosmetic products</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand dermatitis</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Preservatives</style></keyword><keyword><style face="normal" font="default"> Propyl Gallate</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="6" Month="2" Year="2017">2017/2/6</year></dates><abstract><style face="normal" font="default">Allergic contact dermatitis related to cosmetic use can result from allergens not routinely evaluated by standard patch test protocols. Propyl, octyl, and dodecyl gallates are commonly used as antioxidant preservatives with reports of associated allergic contact dermatitis in the literature. The objectives of this review were to investigate the role of gallates in allergic contact dermatitis and to explore products containing these preservatives. A systematic review of the literature through April 2016 was performed to explore cases of reported gallate allergy. Food and cosmetic product databases were searched for products containing gallates. Seventy-four cases of gallate contact allergy have been reported. In addition, a variety of commercially available cosmetic products and foods contain gallate chemicals. Propyl gallate is the most commonly reported gallate contact allergen and often causes facial and/or hand dermatitis</style></abstract><notes><style face="normal" font="default">DA - 20170207IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000263</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28169852">PM:28169852</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\20170207-HolcombZE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\20170207-HolcombZE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170207, Holcomb ZE</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000263</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40550</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schalock,P.C.</style></author><author><style face="normal" font="default"> Dunnick,C.A.</style></author><author><style face="normal" font="default"> Nedorost,S.</style></author><author><style face="normal" font="default"> Brod,B.</style></author><author><style face="normal" font="default"> Warshaw,E.</style></author><author><style face="normal" font="default"> Mowad,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Geisel School of Medicine at Dartmouth, Hanover, NH; daggerUniversity of Colorado Denver and the Denver VA Medical Center; double daggerUniversity Hospitals Cleveland Medical Center, OH; section signUniversity of Pennsylvania, Philadelphia; parallelUniversity of Minnesota, Minneapolis; and paragraph signGeisinger Health System, Danville, PA</style></auth-address><titles><title><style face="normal" font="default">American Contact Dermatitis Society Core Allergen Series: 2017 Update</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Benzoic Acid</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Glutaraldehyde</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Minnesota</style></keyword><keyword><style face="normal" font="default"> Pennsylvania</style></keyword><keyword><style face="normal" font="default"> Philadelphia</style></keyword><keyword><style face="normal" font="default"> Polymyxin B</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> Sodium Benzoate</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Triclosan</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="6" Month="2" Year="2017">2017/2/6</year></dates><abstract><style face="normal" font="default">The American Contact Dermatitis Society Core Allergen Series was introduced in 2012. After 4 years of use, changes in our recommended allergens are necessary. For the updated series, we have reordered the first 4 panels to approximately mirror the current TRUE Test and removed parthenolide, triclosan, glutaraldehyde, and jasmine. Polymyxin B, lavender, sodium benzoate, ethylhexylglycerin, and benzoic acid are new additions to the American Contact Dermatitis Society series</style></abstract><notes><style face="normal" font="default">DA - 20170207IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000261</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28169850">PM:28169850</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\20170207-SchalockPC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\20170207-SchalockPC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170207, Schalock PC</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000261</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40551</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Beene,K.M.</style></author><author><style face="normal" font="default"> Scheman,A.</style></author><author><style face="normal" font="default"> Severson,D.</style></author><author><style face="normal" font="default"> Reeder,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison</style></auth-address><titles><title><style face="normal" font="default">Prevalence of Preservatives Across All Product Types in the Contact Allergen Management Program</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="87" start="81">81-87</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergen exposure</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cosmetic products</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> European Union</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Hair</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Household Products</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> methylchloroisothiazolinone</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Parabens</style></keyword><keyword><style face="normal" font="default"> preservative</style></keyword><keyword><style face="normal" font="default"> Preservatives</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wisconsin</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Preservatives are known causes of allergic contact dermatitis. OBJECTIVE: The aim of this study was to determine the prevalence of preservatives in each product category in the Contact Allergen Management Program and compare prevalence with reported rates of allergic contact dermatitis. METHODS: Contact Allergen Management Program product information was queried based on the 53 approved preservatives for cosmetic products by the European Union and Association of Southeast Asian Nations plus 5 additional preservatives used in US products. RESULTS: Phenoxyethanol and parabens were the most common preservatives with 23.9% of products containing phenoxyethanol and 20.75% of products containing parabens. Methylisothiazolinone (MI) was found in 12.9% of products, most commonly in hair care and household products. Preservatives like MI and methylchloroisothiazolinone (MCI) that are both common in products and have a high incidence of allergic contact dermatitis are of greatest concern as contact allergy hazards. Phenoxyethanol and parabens are common and have weak sensitizing power, making them preferred preservatives. CONCLUSIONS: Evaluating the prevalence of preservatives provides important information on allergen exposures. Using current positive reaction rates, the risk of sensitization to a given preservative can be more accurately estimated and may affect the use of certain preservatives by industry in the future</style></abstract><notes><style face="normal" font="default">DA - 20170118IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000259</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28098722">PM:28098722</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-81-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-81-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170118, Beene KM</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000259</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40552</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aschenbeck,K.A.</style></author><author><style face="normal" font="default"> Warshaw,E.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *University of Minnesota School of Medicine; daggerDepartment of Dermatology, Minneapolis Veterans Affairs Medical Center; double daggerHCMC Parkside Occupational and Contact Dermatitis Clinic; and section signDepartment of Dermatology, University of Minnesota, Minneapolis</style></auth-address><titles><title><style face="normal" font="default">Periorbital Allergic Contact Dermatitis Due to Ketotifen</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Ketotifen</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Minnesota</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Veterans</style></keyword></keywords><dates><year Day="6" Month="2" Year="2017">2017/2/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170207IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000264</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28169851">PM:28169851</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\20170207-AschenbeckKA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\20170207-AschenbeckKA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170207, Aschenbeck KA</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000264</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40553</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Desai,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Central Florida College of Medicine, Indian Harbour Beach, Florida</style></auth-address><titles><title><style face="normal" font="default">Coconut oil: The future of atopic dermatitis treatment?</style></title><secondary-title><style face="normal" font="default">Dermatol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatol Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Florida</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="15" Month="2" Year="2017">2017/2/15</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170215IS - 1529-8019 (Electronic)IS - 1396-0296 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/dth.12472</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28198126">PM:28198126</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatol Ther\20170215-DesaiAS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatol Ther\20170215-DesaiAS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170215, Desai AS</style></custom2><misc3><style face="normal" font="default">10.1111/dth.12472</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40554</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Narala,S.</style></author><author><style face="normal" font="default"> Hata,T.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of California, San Diego, San Diego, CA, USA.</style></auth-address><titles><title><style face="normal" font="default">Adult Atopic Dermatitis with Comorbid Atopic Disease is Associated with Increased Risk of Infections: A Population-Based Cross-Sectional Study</style></title><secondary-title><style face="normal" font="default">Dermatol Ther (Heidelb)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Dermatol Ther (Heidelb)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> Atopic diseases</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Cold</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Sinusitis</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="30" Month="1" Year="2017">2017/1/30</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Atopic dermatitis (AD) is related to other atopic diseases asthma and allergic rhinitis. It is known that those with asthma or allergic rhinitis have impaired immune responses that may predispose them to infections. This study sought to determine whether adult AD is associated with systemic infections, and whether association is strengthened in those with AD plus another atopic disease. METHODS: This cross-sectional study obtained information from adults in the 2010 and the 2012 National Health Interview Survey (NHIS). The primary exposure was history of AD without or with an additional atopic disease, asthma or allergic rhinitis. Self-reported systemic infections were the primary outcomes. Survey logistic regression was performed and adjusted odds ratios (aOR) reported. RESULTS: AD in NHIS 2010 was associated with increased risk of sinusitis [aOR (95% CIs): 1.65 (1.42, 1.91), P &lt; 0.001], head or chest cold [1.31 (1.12, 1.52), P &lt; 0.001], and gastrointestinal illness [2.39 (1.97, 2.89), P &lt; 0.001], and in NHIS 2012, pneumonia/influenza [1.73 (1.54, 1.95), P &lt; 0.001], strep throat/tonsillitis [1.72 (1.54, 1.92), P &lt; 0.001], sinusitis [1.77 (1.54, 2.02), P &lt; 0.001], head or chest cold [1.49 (1.33, 1.67), P &lt; 0.001], and infectious disease [2.66 (2.20, 3.21), P &lt; 0.001]. An increase in atopic disease mirrored an increase in number of infectious outcomes and was statistically significant in the combined dataset (P &lt; 0.001). CONCLUSION: The associations between AD and AD plus another atopic disease with systemic infections suggest that an underlying immune defect may be contributing to microbial susceptibility. Further studies are warranted to understand the burden of infectious disease in this population</style></abstract><notes><style face="normal" font="default">DA - 20170131IS - 2193-8210 (Print)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s13555-017-0172-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28138890">PM:28138890</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatol Ther (Heidelb)\20170131-NaralaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatol Ther (Heidelb)\20170131-NaralaS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170131, Narala S</style></custom2><misc3><style face="normal" font="default">10.1007/s13555-017-0172-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40555</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Serup,J.</style></author><author><style face="normal" font="default"> Sepehri,M.</style></author><author><style face="normal" font="default"> Hutton,C.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">"Tattoo Clinic" at the Department of Dermatology, Bispebjerg University Hospital, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default">Classification of Tattoo Complications in a Hospital Material of 493 Adverse Events</style></title><secondary-title><style face="normal" font="default">Dermatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatology</style></full-title></periodical><pages end="678" start="668">668-678</pages><volume><style face="normal" font="default">232</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse events</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Bacterial Infections</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Histology</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Ink</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> malignancy</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photosensitivity</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Sarcoidosis</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Tattooing</style></keyword><keyword><style face="normal" font="default"> trends</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> World Health</style></keyword></keywords><dates><year Day="15" Month="12" Year="2016">2016/12/15</year></dates><abstract><style face="normal" font="default">BACKGROUND/AIMS: Tattooing is a global trend. Clinical knowledge of complications is based on case reports collected over a century. Larger cohorts reflecting complications associated with contemporary trends are lacking. METHODS: The study was a retrospective review of a consecutive cohort of patients with tattoo complications diagnosed in the "Tattoo Clinic" of Bispebjerg University Hospital in Copenhagen, Denmark, from 2008 to 2015, based on patient history and systematic clinical examination. RESULTS: A total of 493 tattoo complications in 405 patients were studied. Overall, 184 (37%) presented allergic reactions with plaque elevation in 32.2%, excessive hyperkeratosis in 3.7%, and ulceration in 1.4%, predominantly observed in red tattoos and nuances of red; 66 (13%) presented papulo-nodular reactions, mainly observed in black tattoos (considered non-allergic) and due to pigment agglomeration; 53 (11%) had bacterial infections; 46 (9%) were psycho-social complications; 144 (30%) belonged to several specific diagnostic entities, including photosensitivity, pain syndrome, and lymphopathy. We found no cases of cutaneous or other malignancies. Sarcoidosis was primarily seen in black tattoos and was a common associated disease, found in 23 reactions (5%), compared to the background population. CONCLUSION: The study introduces a new concept of classification of tattoo complications based on simple tools such as patient history and objective findings supplemented with histology. The study reflects complications originating from presently used tattoo inks, often with organic pigments. The introduced classification has been submitted to the World Health Organisation (WHO) as a proposal to the 11th revision of the International Classification of Diseases</style></abstract><notes><style face="normal" font="default">DA - 20161215IS - 1421-9832 (Electronic)IS - 1018-8665 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1159/000452148</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27974717">PM:27974717</url></web-urls></urls><custom2><style face="normal" font="default">20161215, Serup J</style></custom2><misc3><style face="normal" font="default">10.1159/000452148</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40556</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Akerman,L.</style></author><author><style face="normal" font="default"> Klein,T.</style></author><author><style face="normal" font="default"> Israeli,M.</style></author><author><style face="normal" font="default"> Fraser,A.</style></author><author><style face="normal" font="default"> Sagy,E.</style></author><author><style face="normal" font="default"> Snast,I.</style></author><author><style face="normal" font="default"> Mimouni,D.</style></author><author><style face="normal" font="default"> David,M.</style></author><author><style face="normal" font="default"> Trattner,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Rabin Medical Center, Beilinson Campus, Petah Tikva, Israel</style></auth-address><titles><title><style face="normal" font="default">Luminex LiquiChip System for the Evaluation of Cytokine Levels in Patients with Contact Dermatitis to Potassium Dichromate</style></title><secondary-title><style face="normal" font="default">Dermatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatology</style></full-title></periodical><pages end="751" start="748">748-751</pages><volume><style face="normal" font="default">232</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Chrome</style></keyword><keyword><style face="normal" font="default"> Chromium</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic tool</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Granulocyte-Macrophage Colony-Stimulating Factor</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL-2</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Interferon-gamma</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> PBMCs</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Potassium</style></keyword><keyword><style face="normal" font="default"> Potassium Dichromate</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic contact dermatitis (ACD) is associated with increased production of cytokines. The patch test is the "gold-standard" diagnostic method, but it poses a risk of false results. OBJECTIVE: To evaluate a novel laboratory technique, the Luminex LiquiChip, which simultaneously measures blood levels of multiple cytokines, as a diagnostic tool in patients with chrome-induced ACD. METHODS: The study group included 20 patients with ACD and relevant patch test results for potassium dichromate and 19 patients with ACD for nickel or fragrance as control. Peripheral blood mononuclear cells (PBMCs) were cultured in the presence and absence of potassium dichromate. The Luminex LiquiChip was used to measure levels of the following cytokines: granulocyte-macrophage colony-stimulating factor, interleukin (IL)-1beta, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, interferon-gamma, and tumor necrosis factor (TNF)-alpha. RESULTS: Potassium dichromate-stimulated PBMCs secreted significantly higher amounts of all cytokines except TNF-alpha than nonstimulated PBMCs. PBMCs from patients with ACD to chromium secreted significantly higher amounts of all cytokines tested, except IL-4, compared to PBMCs from patients with ACD to nickel or fragrance. CONCLUSIONS: Potassium dichromate stimulates the production of both Th1- and Th2-type cytokines in patients with chrome allergy. The Luminex LiquiChip is a promising in vitro method and may serve as a diagnostic tool for ACD</style></abstract><notes><style face="normal" font="default">DA - 20170223IS - 1421-9832 (Electronic)IS - 1018-8665 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">10.1159/000456031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28231571">PM:28231571</url></web-urls></urls><custom2><style face="normal" font="default">20170223, Akerman L</style></custom2><misc3><style face="normal" font="default">10.1159/000456031</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40557</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hon,K.L.</style></author><author><style face="normal" font="default"> Tsang,Y.C.K.</style></author><author><style face="normal" font="default"> Pong,N.H.H.</style></author><author><style face="normal" font="default"> Leung,T.F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Childhood eczema and household pets: a literature review</style></title><secondary-title><style face="normal" font="default">Drugs Ther Perspect</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Drugs Ther Perspect</style></abbr-1></periodical><pages end="487" start="484">484-487</pages><volume><style face="normal" font="default">32</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Asthma-comorbidity</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic eczema</style></keyword><keyword><style face="normal" font="default"> cat</style></keyword><keyword><style face="normal" font="default"> Cats</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> dog</style></keyword><keyword><style face="normal" font="default"> Dogs</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> Hong Kong</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pets</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="default">1179-1977</style></isbn><abstract><style face="normal" font="default">Many parents seek healthcare advice regarding whether keeping a household pet may be detrimental to the health of children with atopic eczema. Based on an extensive literature review, this article summarizes the evidence for recommendations regarding pets in households with children with eczema. The majority of studies did not provide definitive evidence on whether or not families with children with atopic eczema should get rid of their pets. The severity of atopic eczema and health-related quality of life do not directly correlate with skin sensitization to cats or dogs. Sensitized patients, especially those with concomitant asthma and severe symptoms, may consider non-furry pet alternatives if they plan to have a pet. Given the lack of good evidence, highly sensitized individuals, particularly those with asthma comorbidity, may need to remove their pet for a trial period to determine if symptoms improve in the absence of their pet</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Hong Kong -</style></notes><work-type><style face="normal" font="default">10.1007/s40267-016-0348-8</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40267-016-0348-8</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Drugs Ther Perspect\2016-32-484-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Drugs Ther Perspect\2016-32-484-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170225, Hon KL</style></custom2><misc3><style face="normal" font="default">10.1007/s40267-016-0348-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40558</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schultz,A.A.</style></author><author><style face="normal" font="default"> Schauer,J.J.</style></author><author><style face="normal" font="default"> Malecki,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Population Health Sciences, University of Wisconsin, Madison, Wisconsin, USA</style></auth-address><titles><title><style face="normal" font="default">Allergic disease associations with regional and localized estimates of air pollution</style></title><secondary-title><style face="normal" font="default">Environ Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Environ Res</style></abbr-1></periodical><pages end="85" start="77">77-85</pages><volume><style face="normal" font="default">155</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> Air quality</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Particulate matter</style></keyword><keyword><style face="normal" font="default"> PM2.5</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> United States Environmental Protection Agency</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword><keyword><style face="normal" font="default"> Wisconsin</style></keyword></keywords><dates><year Day="10" Month="2" Year="2017">2017/2/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Exposure to multiple types of air pollution may contribute to and exacerbate allergic diseases including asthma and wheezing. However, few studies have examined chronic air pollution exposure and allergic disease outcomes among an adult population. Associations between potential estimates of annual average fine particulate matter (PM2.5), traffic related air pollution, and industrial source air emissions and three allergic disease outcomes (asthma, allergies and wheezing) were examined in a state-wide general population of adults. METHODS: The study includes a representative sample of 3381 adult Wisconsin residents who participated in the 2008-2013 Survey of the Health of Wisconsin (SHOW) program. Participant data were geographically linked to The United States Environmental Protection Agency (USEPA) Baysian space-time downscaler air pollution model for PM2.5, the United States Census roadway, and USEPA's Toxic Release Inventory data. Self-report and lung function (FEV1) estimates were used to define prevalence of asthma, allergies and wheezing symptoms. RESULTS: Annual mean exposure to fine particulate matter (PM2.5) was between 6.59 and 15.14mug/m3. An increase of 5mug/m3 in the annual mean PM2.5 resulted in a 3.58 (2.36, 5.43) increase in the adjusted odds (95% CI) of having asthma. Exposure to vehicle traffic increased the odds of both current allergies [OR (95% CI)=1.35 (1.07, 1.35)] and current asthma [OR (95% CI)=1.51 (1.14, 2.00)]. Living within 300m of an Interstate roadway was associated with a 3-fold increase in the odds of asthma. Those living within 800m of an industrial site were 47% more likely to have asthma. No significant associations were seen with wheezing. CONCLUSIONS: Within this population exposed to overall annual average levels of estimated low level chronic exposure to fine particulate matter (PM2.5) at or near 12mug/m3, the USEPA standard for air quality, significant association between both modeled PM2.5 exposure and proximity to roadways with asthma and allergies but not wheezing were found. Industrial source emissions were not associated with any allergic disease outcomes</style></abstract><notes><style face="normal" font="default">DA - 20170214IS - 1096-0953 (Electronic)IS - 0013-9351 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.envres.2017.01.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28193558">PM:28193558</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Environ Res\2017-155-77-85.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Environ Res\2017-155-77-85.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170214, Schultz AA</style></custom2><misc3><style face="normal" font="default">10.1016/j.envres.2017.01.039</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40559</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bella,Z.</style></author><author><style face="normal" font="default"> Kiricsi,A.</style></author><author><style face="normal" font="default"> Viharosne,E.D.</style></author><author><style face="normal" font="default"> Dallos,A.</style></author><author><style face="normal" font="default"> Perenyi,A.</style></author><author><style face="normal" font="default"> Kiss,M.</style></author><author><style face="normal" font="default"> Koreck,A.</style></author><author><style face="normal" font="default"> Kemeny,L.</style></author><author><style face="normal" font="default"> Jori,J.</style></author><author><style face="normal" font="default"> Rovo,L.</style></author><author><style face="normal" font="default"> Kadocsa,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolarygology and Head and Neck Surgery, Faculty of Medicine, University of Szeged, Tisza Lajos krt 111, Szeged, 6725, Hungary.</style></auth-address><titles><title><style face="normal" font="default">Rhinophototherapy in persistent allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Eur Arch Otorhinolaryngol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Eur Arch Otorhinolaryngol</style></abbr-1></periodical><pages end="1550" start="1543">1543-1550</pages><volume><style face="normal" font="default">274</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Hungary</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peak flow</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Smell</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> symptom scores</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Previous published results have revealed that Rhinolight(R) intranasal phototherapy is safe and effective in intermittent allergic rhinitis. The present objective was to assess whether phototherapy is also safe and effective in persistent allergic rhinitis. Thirty-four patients with persistent allergic rhinitis were randomized into two groups; twenty-five subjects completed the study. The Rhinolight(R) group was treated with a combination of UV-B, UV-A, and high-intensity visible light, while the placebo group received low-intensity visible white light intranasal phototherapy on a total of 13 occasions in 6 weeks. The assessment was based on the diary of symptoms, nasal inspiratory peak flow, quantitative smell threshold, mucociliary transport function, and ICAM-1 expression of the epithelial cells. All nasal symptom scores and nasal inspiratory peak flow measurements improved significantly in the Rhinolight(R) group relative to the placebo group and this finding persisted after 4 weeks of follow-up. The smell and mucociliary functions did not change significantly in either group. The number of ICAM-1 positive cells decreased non-significantly in the Rhinolight(R) group. No severe side-effects were reported during the treatment period. These results suggest that Rhinolight(R) treatment is safe and effective in persistent allergic rhinitis</style></abstract><notes><style face="normal" font="default">DA - 20161119IS - 1434-4726 (Electronic)IS - 0937-4477 (Linking)LA - engPT - Journal ArticleCO - Hungary -</style></notes><work-type><style face="normal" font="default">10.1007/s00405-016-4358-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27864672">PM:27864672</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Arch Otorhinolaryngol\2017-274-1543-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Arch Otorhinolaryngol\2017-274-1543-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161119, Bella Z</style></custom2><misc3><style face="normal" font="default">10.1007/s00405-016-4358-x</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40560</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sato,A.</style></author><author><style face="normal" font="default"> Akiyama,D.</style></author><author><style face="normal" font="default"> Hoshi,T.</style></author><author><style face="normal" font="default"> Aonuma,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cardiovascular Division, Faculty of Medicine, University of Tsukuba, 1-1-1, Tennodai, Tsukuba, Ibaraki 305-8575, Japan</style></auth-address><titles><title><style face="normal" font="default">Life-threatening simultaneous acute stent thrombosis associated with anaphylactic shock due to contrast material</style></title><secondary-title><style face="normal" font="default">Eur Heart J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Eur Heart J</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylactic shock</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> Thrombosis</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="9" Month="1" Year="2017">2017/1/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170110IS - 1522-9645 (Electronic)IS - 0195-668X (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1093/eurheartj/ehw600</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28069734">PM:28069734</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Heart J\20170110-SatoA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Heart J\20170110-SatoA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170110, Sato A</style></custom2><misc3><style face="normal" font="default">10.1093/eurheartj/ehw600</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40561</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Le Dorze,M.</style></author><author><style face="normal" font="default"> Plaud,B.</style></author><author><style face="normal" font="default"> Mebazaa,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Department of Anaesthesiology, Critical Care, SMUR, and Burn Unit, GH Saint-Louis-Lariboisiere-Fernand Widal University Hospitals, Assistance Publique, Hopitaux de Paris, Paris, France (MLD, BP, AM)</style></auth-address><titles><title><style face="normal" font="default">A case series of life-threatening succinylcholine-induced anaphylaxis</style></title><secondary-title><style face="normal" font="default">Eur J Anaesthesiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Eur J Anaesthesiol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="16" Month="11" Year="2016">2016/11/16</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161118IS - 1365-2346 (Electronic)IS - 0265-0215 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1097/EJA.0000000000000561</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27861260">PM:27861260</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur J Anaesthesiol\20161118-LeDorzeM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur J Anaesthesiol\20161118-LeDorzeM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161118, Le Dorze M</style></custom2><misc3><style face="normal" font="default">10.1097/EJA.0000000000000561</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40562</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Varas-Meis,E.</style></author><author><style face="normal" font="default"> Fernandez-Canga,P.</style></author><author><style face="normal" font="default"> Ruiz-Gonzalez,I.</style></author><author><style face="normal" font="default"> Rodriguez-Prieto,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Complejo Asistencial Universitario de Leon, Department of Dermatology, Altos de Navas s/n, 24080 Leon, Spain</style></auth-address><titles><title><style face="normal" font="default">Residents' corner. sQuiz your knowledge: Perianal dermatitis: an allergic contact dermatitis?</style></title><secondary-title><style face="normal" font="default">Eur J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur J Dermatol</style></full-title></periodical><pages end="108" start="107">107-108</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword></keywords><dates><year Day="1" Month="2" Year="2017">2017/2/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170220IS - 1952-4013 (Electronic)IS - 1167-1122 (Linking)LA - engPT - Journal ArticleCO - spain -</style></notes><work-type><style face="normal" font="default">10.1684/ejd.2017.2967</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28218064">PM:28218064</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur J Dermatol\2017-27-107-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur J Dermatol\2017-27-107-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170220, Varas-Meis E</style></custom2><misc3><style face="normal" font="default">10.1684/ejd.2017.2967</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40563</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aerts,O.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author><author><style face="normal" font="default"> Lambert,J.</style></author><author><style face="normal" font="default"> Lepoittevin,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">University Hospital Antwerp (UZA) and University of Antwerp (UA), Antwerp, Belgium</style></auth-address><titles><title><style face="normal" font="default">Contact allergy caused by isothiazolinone derivatives: an overview of non-cosmetic and unusual cosmetic sources</style></title><secondary-title><style face="normal" font="default">Eur J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur J Dermatol</style></full-title></periodical><pages end="122" start="115">115-122</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Benzisothiazolinone</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cosmetic products</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Dental Care</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Detergents</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> Isothiazolinones</style></keyword><keyword><style face="normal" font="default"> Leather</style></keyword><keyword><style face="normal" font="default"> methylchloroisothiazolinone</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Paint</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Textile Industry</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="3" Month="2" Year="2017">2017/2/3</year></dates><abstract><style face="normal" font="default">The isothiazolinone derivatives, methylchloroisothiazolinone (MCI), methylisothiazolinone (MI), benzisothiazolinone (BIT), and octylisothiazolinone (OIT), owing to their strong bactericide, fungicide and algicide properties, are widely used in non-cosmetic products, such as chemical (industrial) products, household detergents, and water-based paints, and the former two derivatives are also used in cosmetic products. However, given their inherent sensitization potential (with MCI > MI > BIT > OIT), allergic contact dermatitis is frequently observed, both in consumers as well as workers in various industries. In this review, we provide an update on the use of MCI/MI and MI in cosmetics, highlighting certain aspects of MI; the use of excessive concentrations, the presence in some less familiar cosmetic products, and the association with unusual clinical manifestations. Furthermore, the use of isothiazolinones in dish-washing and washing-machine liquids, cleaning agents for dental care, and their general presence in multi-purpose household detergents, which may elicit (airborne) allergic contact dermatitis, is discussed. Finally, we provide a brief overview of the use of isothiazolinone derivatives in the paint and textile industry, and of OIT in the leather industry in particular</style></abstract><notes><style face="normal" font="default">DA - 20170208IS - 1952-4013 (Electronic)IS - 1167-1122 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - France -</style></notes><work-type><style face="normal" font="default">10.1684/ejd.2016.2951</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28174143">PM:28174143</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur J Dermatol\2017-27-115-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur J Dermatol\2017-27-115-22.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170208, Aerts O</style></custom2><misc3><style face="normal" font="default">10.1684/ejd.2016.2951</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40564</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Scalabrin,D.</style></author><author><style face="normal" font="default"> Harris,C.</style></author><author><style face="normal" font="default"> Johnston,W.H.</style></author><author><style face="normal" font="default"> Berseth,C.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical Research, Department of Medical Affairs, Mead Johnson Nutrition, Evansville, IN, 47712, USA</style></auth-address><titles><title><style face="normal" font="default">Long-term safety assessment in children who received hydrolyzed protein formulas with Lactobacillus rhamnosus GG: a 5-year follow-up</style></title><secondary-title><style face="normal" font="default">Eur J Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Eur J Pediatr</style></abbr-1></periodical><pages end="224" start="217">217-224</pages><volume><style face="normal" font="default">176</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse events</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Casein</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cow's milk</style></keyword><keyword><style face="normal" font="default"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Lactobacillus</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Milk</style></keyword><keyword><style face="normal" font="default"> Milk allergy</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> pH</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Extensively hydrolyzed (EH) formula with Lactobacillus rhamnosus GG (LGG) was demonstrated to alleviate cow's milk allergy (CMA) symptoms and promote faster acquisition of tolerance to cow's milk protein. We previously demonstrated that partially hydrolyzed (PH) and EH formulas with LGG supported normal growth in healthy-term infants through 120 days of age. The objective of the current study was to evaluate growth, development, and specific adverse events through 5 years of age in participants from that cohort who continued receiving study formula. Infants who completed a double-blind, randomized growth and tolerance study were eligible to continue receiving the assigned study formula through 1 year of age (control: EH casein formula, EHF, or one of two investigational formulas: EH casein formula with LGG (EHF-LGG) or a PH formula with LGG (PHF-LGG)) and participate in follow-up through 5 years of age. Anthropometric measures, behavior development, and specific adverse events were recorded. No significant differences in achieved weight and height or behavioral development outcomes at 3 or 5 years of age were observed among study groups. Few statistically significant differences in the incidence of specific infection-related events through years 3 or 5 were observed among study groups, none of which were considered clinically relevant. CONCLUSION: Extensively and partially hydrolyzed formulas with LGG were associated with normal growth and development and long-term safety through 5 years of age. What is Known: * Infants with cow's milk allergy often experience allergic manifestations that can lead to poor nutrition status and poor growth. * Providing partially hydrolyzed (PH) and EH formulas with or without LGG in infants can support normal growth in healthy-term infants. What is New: * This study provides long-term safety data for the first 5 years of life on the use of extensively and partially hydrolyzed formulas with LGG when fed through 1 year of age. * Extensively and partially hydrolyzed formulas with LGG are associated with normal growth, development, and long-term safety through 5 years of age</style></abstract><notes><style face="normal" font="default">DA - 20161215IS - 1432-1076 (Electronic)IS - 0340-6199 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s00431-016-2825-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27975116">PM:27975116</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur J Pediatr\2017-176-217-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur J Pediatr\2017-176-217-24.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161215, Scalabrin D</style></custom2><misc3><style face="normal" font="default">10.1007/s00431-016-2825-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40565</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Park,H.J.</style></author><author><style face="normal" font="default"> Park,J.W.</style></author><author><style face="normal" font="default"> Yang,M.S.</style></author><author><style face="normal" font="default"> Kim,M.Y.</style></author><author><style face="normal" font="default"> Kim,S.H.</style></author><author><style face="normal" font="default"> Jang,G.C.</style></author><author><style face="normal" font="default"> Nam,Y.H.</style></author><author><style face="normal" font="default"> Kim,G.W.</style></author><author><style face="normal" font="default"> Kim,S.</style></author><author><style face="normal" font="default"> Park,H.K.</style></author><author><style face="normal" font="default"> Jung,J.W.</style></author><author><style face="normal" font="default"> Park,J.S.</style></author><author><style face="normal" font="default"> Kang,H.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Re-exposure to low osmolar iodinated contrast media in patients with prior moderate-to-severe hypersensitivity reactions: A multicentre retrospective cohort study</style></title><secondary-title><style face="normal" font="default">Eur Radiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Eur Radiol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> iodinated contrast media</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Premedication</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective cohort study</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="14" Month="12" Year="2016">2016/12/14</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To evaluate the outcomes of re-exposure to low-osmolar iodinated contrast medium (LOCM) in patients with a history of moderate-to-severe hypersensitivity reaction (HSR). METHODS: We retrospectively evaluated a cohort comprising all subjects satisfying the following conditions at 11 centres: (1) experienced a moderate-to-severe HSR to LOCM by December 2014, and (2) underwent contrast-enhanced computed tomography after the initial HSR between January 2014 and December 2014. RESULTS: A total of 150 patients with 328 instances of re-exposure were included; the recurrence rate of HSR was 19.5%. Patients with severe initial HSR exhibited a higher recurrence rate of severe HSR compared to patients with moderate initial HSR, despite more intensive premedication. In the multivariate analysis, the independent risk factors for recurrence of HSR were diabetes, chronic urticaria, drug allergy other than to iodinated contrast media (ICM) and severe initial HSR. The risk of recurrent HSR was 67.1% lower in cases where the implicated ICM was changed to another one (odds ratio: 0.329; P = 0.001). However, steroid premedication did not show protective effects against recurrent HSR. CONCLUSION: In high-risk patients who have previously experienced a moderate-to-severe initial HSR to LOCM, we should consider changing the implicated ICM to reduce recurrence risk. KEY POINTS: * In patients with moderate-to-severe HSR, steroid premedication only shows limited effectiveness. * Changing the implicated ICM can reduce the recurrence of HSR to ICM. * Diabetes, chronic urticaria and drug allergies increase the risk of ICM HSR</style></abstract><notes><style face="normal" font="default">DA - 20161215IS - 1432-1084 (Electronic)IS - 0938-7994 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1007/s00330-016-4682-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27975150">PM:27975150</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Radiol\20161215-ParkHJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Radiol\20161215-ParkHJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161215, Park HJ</style></custom2><misc3><style face="normal" font="default">10.1007/s00330-016-4682-y</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40566</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Goutaki,M.</style></author><author><style face="normal" font="default"> Maurer,E.</style></author><author><style face="normal" font="default"> Halbeisen,F.S.</style></author><author><style face="normal" font="default"> Amirav,I.</style></author><author><style face="normal" font="default"> Barbato,A.</style></author><author><style face="normal" font="default"> Behan,L.</style></author><author><style face="normal" font="default"> Boon,M.</style></author><author><style face="normal" font="default"> Casaulta,C.</style></author><author><style face="normal" font="default"> Clement,A.</style></author><author><style face="normal" font="default"> Crowley,S.</style></author><author><style face="normal" font="default"> Haarman,E.</style></author><author><style face="normal" font="default"> Hogg,C.</style></author><author><style face="normal" font="default"> Karadag,B.</style></author><author><style face="normal" font="default"> Koerner-Rettberg,C.</style></author><author><style face="normal" font="default"> Leigh,M.W.</style></author><author><style face="normal" font="default"> Loebinger,M.R.</style></author><author><style face="normal" font="default"> Mazurek,H.</style></author><author><style face="normal" font="default"> Morgan,L.</style></author><author><style face="normal" font="default"> Nielsen,K.G.</style></author><author><style face="normal" font="default"> Omran,H.</style></author><author><style face="normal" font="default"> Schwerk,N.</style></author><author><style face="normal" font="default"> Scigliano,S.</style></author><author><style face="normal" font="default"> Werner,C.</style></author><author><style face="normal" font="default"> Yiallouros,P.</style></author><author><style face="normal" font="default"> Zivkovic,Z.</style></author><author><style face="normal" font="default"> Lucas,J.S.</style></author><author><style face="normal" font="default"> Kuehni,C.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland</style></auth-address><titles><title><style face="normal" font="default">The international primary ciliary dyskinesia cohort (iPCD Cohort): methods and first results</style></title><secondary-title><style face="normal" font="default">Eur Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Respir J</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Argentina</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> European Union</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Norway</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Preventive Medicine</style></keyword><keyword><style face="normal" font="default"> Primary ciliary dyskinesia</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Serbia</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">Data on primary ciliary dyskinesia (PCD) epidemiology is scarce and published studies are characterised by low numbers. In the framework of the European Union project BESTCILIA we aimed to combine all available datasets in a retrospective international PCD cohort (iPCD Cohort).We identified eligible datasets by performing a systematic review of published studies containing clinical information on PCD, and by contacting members of past and current European Respiratory Society Task Forces on PCD. We compared the contents of the datasets, clarified definitions and pooled them in a standardised format.As of April 2016 the iPCD Cohort includes data on 3013 patients from 18 countries. It includes data on diagnostic evaluations, symptoms, lung function, growth and treatments. Longitudinal data are currently available for 542 patients. The extent of clinical details per patient varies between centres. More than 50% of patients have a definite PCD diagnosis based on recent guidelines. Children aged 10-19 years are the largest age group, followed by younger children (&lt;/=9 years) and young adults (20-29 years).This is the largest observational PCD dataset available to date. It will allow us to answer pertinent questions on clinical phenotype, disease severity, prognosis and effect of treatments, and to investigate genotype-phenotype correlations</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1399-3003 (Electronic)IS - 0903-1936 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - Israel -CO - United Kingdom -CO - Belgium -CO - Norway -CO - Netherlands -CO - Poland -CO - Australia -CO - Denmark -CO - Argentina -CO - Cyprus -CO - Serbia -</style></notes><work-type><style face="normal" font="default">10.1183/13993003.01181-2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28052956">PM:28052956</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Respir J\20170105-GoutakiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Respir J\20170105-GoutakiM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Goutaki M</style></custom2><misc3><style face="normal" font="default">10.1183/13993003.01181-2016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40567</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bahmer,T.</style></author><author><style face="normal" font="default"> Waschki,B.</style></author><author><style face="normal" font="default"> Schatz,F.</style></author><author><style face="normal" font="default"> Herzmann,C.</style></author><author><style face="normal" font="default"> Zabel,P.</style></author><author><style face="normal" font="default"> Kirsten,A.M.</style></author><author><style face="normal" font="default"> Rabe,K.F.</style></author><author><style face="normal" font="default"> Watz,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">LungClinic Grosshansdorf, Grosshansdorf, Germany</style></auth-address><titles><title><style face="normal" font="default">Physical activity, airway resistance and small airway dysfunction in severe asthma</style></title><secondary-title><style face="normal" font="default">Eur Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Respir J</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Airway dysfunction</style></keyword><keyword><style face="normal" font="default"> Airway Resistance</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1399-3003 (Electronic)IS - 0903-1936 (Linking)LA - engPT - LetterCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1183/13993003.01827-2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28052957">PM:28052957</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Respir J\20170105-BahmerT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Respir J\20170105-BahmerT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Bahmer T</style></custom2><misc3><style face="normal" font="default">10.1183/13993003.01827-2016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40568</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yang,J.</style></author><author><style face="normal" font="default"> Min,S.</style></author><author><style face="normal" font="default"> Hong,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology &amp; Otolaryngology &amp; Dermatology, College of Korean Medicine, Dongguk University, Dongguk-ro 27, Ilsandong-gu, Goyang-si, Gyeonggi-do 10326, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Therapeutic Effects of Fermented Flax Seed Oil on NC/Nga Mice with Atopic Dermatitis-Like Skin Lesions</style></title><secondary-title><style face="normal" font="default">Evid Based Complement Alternat Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Evid Based Complement Alternat Med</style></full-title></periodical><pages end="" start="5469125">5469125-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> epithelia</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelium</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> iNOS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Ophthalmology</style></keyword><keyword><style face="normal" font="default"> Otolaryngology</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Raw</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background. Atopic Dermatitis (AD) is one of the most common chronic inflammatory skin diseases. Objective. This experiment aimed to study the effects of Fermented Flax Seed Oil (FFSO) on symptoms such as redness, eczema, and pruritus induced by AD. Materials and Methods. AD-induced NC/Nga mice were used to observe the immunological and therapeutic effects of FFSO on skin in vivo. Raw 264.7 cells were used to investigate the effects of FFSO in cells. Fc receptor expression and concentration of beta-hexosaminidase were measured. Nitric oxide assay, Western blotting, real-time PCR, image analysis, and statistical analysis were performed in vitro. Results. In the immunohistochemical results, p-ERK 1/2 expression decreased, fibrogenesis strongly increased, and distribution reduction is observed. Distribution of IL-4-positive cells in the corium near the basal portion of the epithelium in the AT group was reduced. FFSO treatment reduced the number of cells showing NF-kappaB p65 and iNOS expression. The level of LXR in the AT group was higher than that in the AE group, and elevation of PKC expression was significantly reduced by FFSO treatment. Conclusion. FFSO could alleviate symptoms of AD such as epithelial damage, redness, swelling, and pruritus</style></abstract><notes><style face="normal" font="default">DA - 20170215IS - 1741-427X (Print)IS - 1741-427X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1155/2017/5469125</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28197211">PM:28197211</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Evid Based Complement Alternat Med\2017-2017-5469125.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Evid Based Complement Alternat Med\2017-2017-5469125.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170215, Yang J</style></custom2><misc3><style face="normal" font="default">10.1155/2017/5469125</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40569</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Faschingbauer,M.</style></author><author><style face="normal" font="default"> Renner,L.</style></author><author><style face="normal" font="default"> Boettner,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">0000 0001 2285 8823grid.239915.5Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021 USA</style></auth-address><titles><title><style face="normal" font="default">Allergy in Total Knee Replacement. Does It Exist?: Review Article</style></title><secondary-title><style face="normal" font="default">HSS J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">HSS J</style></full-title></periodical><pages end="19" start="12">12-19</pages><volume><style face="normal" font="default">13</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Arthroplasty</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Gold</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Knee</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Titanium</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Zirconium</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: There is little data on whether preexisting allergies to implant materials and bone cement have an impact on the outcome of TKA. QUESTIONS/PURPOSES: This review article analyzes the current literature to evaluate the prevalence and importance of metal and cement allergies for patients undergoing total knee arthroplasty. METHODS: A review of the literature was performed using the following search criteria: "knee," "arthroplasty," and "allergy" as well as "knee," "arthroplasty," and "hypersensitivity." RESULTS: One hundred sixteen articles were identified on PubMed, Seventy articles could be excluded by reviewing the title and abstract leaving 46 articles to be included for this review. The majority of the studies cited patch testing as the gold standard for screening and diagnosis of hypersensitivity following TKA. There is consensus that patients with self-reported allergies against metals or bone cement and positive patch test should be treated with hypoallergenic materials or cementless TKA. Treatment options include the following: coated titanium or cobalt-chromium implants, ceramic, or zirconium oxide implants. CONCLUSION: Allergies against implant materials and bone cement are rare. Patch testing is recommended for patients with self-reported allergies. The use of special implants is recommended for patients with a confirmed allergy</style></abstract><notes><style face="normal" font="default">DA - 20170207IS - 1556-3316 (Print)IS - 1556-3316 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11420-016-9514-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28167868">PM:28167868</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\HSS J\2017-13-12-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\HSS J\2017-13-12-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170207, Faschingbauer M</style></custom2><misc3><style face="normal" font="default">10.1007/s11420-016-9514-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40570</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Trzeciak,M.</style></author><author><style face="normal" font="default"> Sakowicz-Burkiewicz,M.</style></author><author><style face="normal" font="default"> Wesserling,M.</style></author><author><style face="normal" font="default"> Glen,J.</style></author><author><style face="normal" font="default"> Dobaczewska,D.</style></author><author><style face="normal" font="default"> Bandurski,T.</style></author><author><style face="normal" font="default"> Nowicki,R.</style></author><author><style face="normal" font="default"> Pawelczyk,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departments of Dermatology, Venereology, and Allergology, Medical University of Gdansk, Gdansk, Poland</style></auth-address><titles><title><style face="normal" font="default">Altered Expression of Genes Encoding Cornulin and Repetin in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="19" start="11">11-19</pages><volume><style face="normal" font="default">172</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Filaggrin</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="21" Month="2" Year="2017">2017/2/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: It is assumed that beside alterations in the filaggrin gene (FLG), disturbances within genes encoding other cornified envelope proteins are also involved in atopic dermatitis (AD). To identify new potential markers of AD, we studied the polymorphisms of genes encoding repetin (RPTN), cornulin (CRNN), and their expression in the skin of AD patients. METHODS: Polymorphisms in CRNN (rs941934), RPTN (rs284544, rs28441202, rs3001978, and rs12117644), and FLG mutations (R2447X, S3247X) were analyzed by TaqMan genotyping assay and by PCR-RFLP in the blood samples of 159 AD patients and 108 healthy subjects. The expression levels of CRNN and RPTN were determined by qRT-PCR in 34 AD skin samples (17 lesional and 17 nonlesional) and in 27 skin biopsies from healthy volunteers. The AD patients were recruited from the clinic of the university hospital between 2012 and 2014. RESULTS: CRNN rs941934 (A allele) was associated with AD (OR 2.095, p = 0.008), a severe course of disease (p = 0.041), elevated IgE levels (p = 0.047), eosinophilia (p = 0.018), and concomitant asthma (p = 0.004). The mRNA level of CRNN was decreased in the AD skin (p = 0.041). In the AD patients without FLG mutations, the CC genotype of RPTN rs3001978 was associated with AD (OR 0.39, p = 0.037), early age at onset (p = 0.033), pruritus (p = 0.021), severity of AD (p = 0.045), and concomitant asthma (p = 0.041). The elevated mRNA levels of RPTN in lesional (p &lt; 0.001) and nonlesional (p = 0.017) AD skin were observed. CONCLUSIONS: The single-nucleotide polymorphisms of CRNN (rs941934) and RPTN (rs3001978, rs28441202) may contribute to AD development, but further studies on a larger group of AD patients are needed to verify this assumption</style></abstract><notes><style face="normal" font="default">DA - 20170220IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1159/000453452</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28219068">PM:28219068</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-172-11-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-172-11-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170220, Trzeciak M</style></custom2><misc3><style face="normal" font="default">10.1159/000453452</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40571</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Triggianese,P.</style></author><author><style face="normal" font="default"> Guarino,M.D.</style></author><author><style face="normal" font="default"> Pellicano,C.</style></author><author><style face="normal" font="default"> Borzi,M.</style></author><author><style face="normal" font="default"> Greco,E.</style></author><author><style face="normal" font="default"> Modica,S.</style></author><author><style face="normal" font="default"> De Carolis,C.</style></author><author><style face="normal" font="default"> Perricone,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Rheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy</style></auth-address><titles><title><style face="normal" font="default">Recurrent Angioedema: Occurrence, Features, and Concomitant Diseases in an Italian Single-Center Study</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="63" start="55">55-63</pages><volume><style face="normal" font="default">172</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="default"> C1 INH</style></keyword><keyword><style face="normal" font="default"> C1-INH</style></keyword><keyword><style face="normal" font="default"> C1Inh</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Early Diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Rome</style></keyword><keyword><style face="normal" font="default"> Statistics</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wheal</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: Angioedema (AE) is a potentially life-threatening condition with hereditary (HAE), acquired (AAE), or iatrogenic causes. A careful workup allows for the identification of the etiology of attacks and the appropriate management. In this cohort study, based on a clinical practice setting, we aimed at investigating clinical and laboratory findings concerning different features of patients with recurrent AE who were referred to a single, tertiary-level center for HAE. METHODS: Clinical and laboratory data of patients fulfilling the criteria for C1-inhibitor-deficient HAE (C1-INH-HAE), C1-INH-AAE, angiotensin-converting enzyme inhibitor-related AE (ACEI-RA), and idiopathic AAE (I-AAE) were evaluated. Descriptive statistics were analyzed by means of the Mann-Whitney U test. The Fisher exact test was used for group comparisons. RESULTS: Patients were diagnosed with type 1 HAE (n = 14), type 2 HAE (n = 1), C1-INH-AAE (n = 8), ACEI-RA (n = 16), or I-AAE (n = 26). We included only patients with concomitant autoimmune diseases from the I-AAE group (n = 8, aut-I-AAE). Age at disease onset and at diagnosis was younger in type 1 HAE than in all the other groups. The diagnostic delay was longer in type 1 HAE than in ACEI-RA. C4 and C1q levels were lower in C1-INH-AAE than in type 1 HAE, ACEI-RA, and aut-I-AAE. Both HAE and C1-INH-AAE showed lower C1-INH antigen and function compared to the other groups. Peripheral attacks were more frequent in type 1 HAE, while airway, abdominal, and oral attacks were prevalent in C1-INH-AAE. CONCLUSION: Investigating the clinical and laboratory features of recurrent AE without wheals represents a major topic for facilitating early diagnosis and improving treatment strategies for this heterogeneous and misdiagnosed condition</style></abstract><notes><style face="normal" font="default">DA - 20170221IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1159/000453663</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28222436">PM:28222436</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-172-55-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-172-55-63.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170221, Triggianese P</style></custom2><misc3><style face="normal" font="default">10.1159/000453663</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40572</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schwensen,J.F.</style></author><author><style face="normal" font="default"> Friis,U.F.</style></author><author><style face="normal" font="default"> Menne,T.</style></author><author><style face="normal" font="default"> Flyvholm,M.A.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermato-Allergology, National Allergy Research Centre, Copenhagen University Hospital Gentofte, Kildegardsvej 28, 2900, Hellerup, Denmark.</style></auth-address><titles><title><style face="normal" font="default">Contact allergy to preservatives in patients with occupational contact dermatitis and exposure analysis of preservatives in registered chemical products for occupational use</style></title><secondary-title><style face="normal" font="default">Int Arch Occup Environ Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int Arch Occup Environ Health</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Formaldehyde</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Isothiazolinones</style></keyword><keyword><style face="normal" font="default"> Legislation</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Paint</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> preservative</style></keyword><keyword><style face="normal" font="default"> Preservatives</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="6" Month="2" Year="2017">2017/2/6</year></dates><abstract><style face="normal" font="default">PURPOSE: The aim of the study is to investigate risk factors for sensitization to preservatives and to examine to which extent different preservatives are registered in chemical products for occupational use in Denmark. METHODS: A retrospective epidemiological observational analysis of data from a university hospital was conducted. All patients had occupational contact dermatitis and were consecutively patch tested with 11 preservatives from the European baseline series and extended patch test series during a 5-year period: 2009-2013. Information regarding the same preservatives in chemical products for occupational use ('substances and materials') registered in the Danish Product Register Database (PROBAS) was obtained. RESULTS: The frequency of preservative contact allergy was 14.2% (n = 141) in 995 patients with occupational contact dermatitis. Patients with preservative contact allergy had significantly more frequently facial dermatitis (19.9 versus 13.1%) and age > 40 years (71.6 versus 45.8%) than patients without preservative contact allergy, whereas atopic dermatitis was less frequently observed (12.1 versus 19.8%). Preservative contact allergy was more frequent in painters with occupational contact dermatitis as compared to non-painters with occupational contact dermatitis (p &lt; 0.001). This was mainly caused by contact allergy to methylisothiazolinone and contact allergy to formaldehyde. Analysis of the registered substances and materials in PROBAS revealed that preservatives occurred in several product categories, e.g., 'paints and varnishes', 'cleaning agents', 'cooling agents', and 'polishing agents'. Formaldehyde and isothiazolinones were extensively registered in PROBAS. CONCLUSIONS: The extensive use of formaldehyde and isothiazolinones in chemical products for occupational use may be problematic for the worker. Appropriate legislation, substitution, and employee education should be prioritized</style></abstract><notes><style face="normal" font="default">DA - 20170207IS - 1432-1246 (Electronic)IS - 0340-0131 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1007/s00420-017-1203-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28168422">PM:28168422</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Occup Environ Health\20170207-SchwensenJF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Occup Environ Health\20170207-SchwensenJF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170207, Schwensen JF</style></custom2><misc3><style face="normal" font="default">10.1007/s00420-017-1203-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40573</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Manji,J.</style></author><author><style face="normal" font="default"> Singh,G.</style></author><author><style face="normal" font="default"> Okpaleke,C.</style></author><author><style face="normal" font="default"> Dadgostar,A.</style></author><author><style face="normal" font="default"> Al-Asousi,F.</style></author><author><style face="normal" font="default"> Amanian,A.</style></author><author><style face="normal" font="default"> Dias-Valle,L.</style></author><author><style face="normal" font="default"> Finkelstein,A.</style></author><author><style face="normal" font="default"> Tacey,M.</style></author><author><style face="normal" font="default"> Thamboo,A.</style></author><author><style face="normal" font="default"> Javer,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">St. Paul's Sinus Centre, Vancouver, British Columbia, Canada</style></auth-address><titles><title><style face="normal" font="default">Safety of long-term intranasal budesonide delivered via the mucosal atomization device for chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Forum Allergy Rhinol</style></abbr-1></periodical><pages end="493" start="488">488-493</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> British Columbia</style></keyword><keyword><style face="normal" font="default"> Budesonide</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Chile</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Columbia</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> cortisol</style></keyword><keyword><style face="normal" font="default"> Cosyntropin</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Intraocular Pressure</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medication adherence</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mexico</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyposis</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polyposis</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sinus</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> suppression</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Symptomatology</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> treatment adherence</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="2" Year="2017">2017/2/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Although short-term use (&lt;/=2 months) of atomized topical nasal steroids has been shown to be safe and effective, the long-term safety has yet to be demonstrated. The aim of this study was to determine the impact of long-term topical budesonide treatment via the mucosal atomization device (MAD) on the hypothalamic-pituitary-adrenal axis (HPAA) and intraocular pressure (IOP). METHODS: A cross-sectional study of patients with chronic rhinosinusitis (CRS), with or without nasal polyposis, managed with daily nasal budesonide via MAD was conducted at a tertiary rhinology center. Patients using systemic steroids within 3 months of assessment were excluded. HPAA impact was assessed using the cosyntropin stimulation test for adrenal function and a survey of relevant symptomatology. Patients also underwent tonometry to assess for elevated IOP potentially related to corticosteroid use. Treatment adherence was subjectively assessed using a medication adherence scale (MMAS-8) to evaluate the validity of steroid exposure estimates. RESULTS: A total of 100 CRS patients were recruited with a mean budesonide treatment duration of 23.5 months (range, 6-37 months). Stimulated cortisol response was diminished in 3 patients (3%). No patients with adrenal suppression had relevant symptomatology. IOP was elevated in 6 patients (6%). A mean MMAS-8 score of 6.8 indicated moderate-to-high treatment adherence behavior among this population. CONCLUSION: These findings suggest that there is a risk of adrenal suppression and raised IOP associated with the long-term use of topical nasal budesonide via MAD. Otolaryngologists should consider periodic surveillance for these adverse events in this patient cohort</style></abstract><notes><style face="normal" font="default">DA - 20170202IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - Mexico -CO - Australia -CO - Chile -</style></notes><work-type><style face="normal" font="default">10.1002/alr.21910</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28151588">PM:28151588</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Forum Allergy Rhinol\2017-7-488-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Forum Allergy Rhinol\2017-7-488-93.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170202, Manji J</style></custom2><misc3><style face="normal" font="default">10.1002/alr.21910</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40574</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">El-Shazly,A.E.</style></author><author><style face="normal" font="default"> Roncarati,P.</style></author><author><style face="normal" font="default"> Lejeune,M.</style></author><author><style face="normal" font="default"> Lefebvre,P.P.</style></author><author><style face="normal" font="default"> Delvenne,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology and Head and Neck Surgery, Liege University Hospital-CHU, Liege, Belgium</style></auth-address><titles><title><style face="normal" font="default">Tyrosine kinase inhibition is an important factor for gene expression of CRTH2 in human eosinophils and lymphocytes: A novel mechanism for explaining eosinophils recruitment by the neuro-immune axis in allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int Immunopharmacol</style></full-title></periodical><pages end="186" start="180">180-186</pages><volume><style face="normal" font="default">45</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Chemotaxis</style></keyword><keyword><style face="normal" font="default"> CRTH2</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Genistein</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> late phase</style></keyword><keyword><style face="normal" font="default"> Late phase reaction</style></keyword><keyword><style face="normal" font="default"> late-phase</style></keyword><keyword><style face="normal" font="default"> Leukocytes</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal Provocation Tests</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Otolaryngology</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peptide</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Tyrosine</style></keyword><keyword><style face="normal" font="default"> tyrosine kinase</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vasoactive Intestinal Peptide</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Western blot</style></keyword></keywords><dates><year Day="18" Month="2" Year="2017">2017/2/18</year></dates><abstract><style face="normal" font="default">We recently shown a novel neuro-immune competition between vasoactive intestinal peptide (VIP) and PGD2 for CRTH2 receptor, and that genistein augmented VIP and PGD2-induced eosinophil chemotaxis. However, there are neither studies on the CRTH2 gene expression in allergic rhinitis (AR) nor in the effect of tyrosine kinase inhibitors in CRTH2 gene regulation. Our Objectives were to study the gene expression modulation of CRTH2 receptor in AR patients and the effect of tyrosine kinase inhibitors (TKIs) on CRTH2 gene modulation. Nasal provocation tests, ELISA, qRT-PCR, western blot, flow cytometry and chemotaxis assays in modified micro-Boyden chambers, were all used, to achieve our objectives. Herein we show that AR patients increased the amounts of VIP and PGD2 in their nasal secretions in the early phase reaction, however CRTH2 gene expression from leukocytes recovered in their nasal secretions was upregulated only during the late phase reaction. The TKIs; Genistein, Erbstatin and Herbimycin A, induced the gene expression of CRTH2 and increased the protein content of CRTH2 in both human lymphocytes and eosinophils. This was functional as PGD2/VIP-induced eosinophil chemotaxis was augmented by the TKIs and inhibited by pervanadate, the tyrosine phosphatase inhibitor. These results open channels for therapeutic modalities targeting CRTH2 molecules in AR</style></abstract><notes><style face="normal" font="default">DA - 20170221IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1016/j.intimp.2017.02.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28222358">PM:28222358</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Immunopharmacol\2017-45-180-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Immunopharmacol\2017-45-180-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170221, El-Shazly AE</style></custom2><misc3><style face="normal" font="default">10.1016/j.intimp.2017.02.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40575</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tammaro,A.</style></author><author><style face="normal" font="default"> De Marco,G.</style></author><author><style face="normal" font="default"> D'Arino,A.</style></author><author><style face="normal" font="default"> Pigliacelli,F.</style></author><author><style face="normal" font="default"> Daniele,A.</style></author><author><style face="normal" font="default"> Borgert,I.</style></author><author><style face="normal" font="default"> Parisella,F.R.</style></author><author><style face="normal" font="default"> Persechino,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">UOC Dermatology, NESMOS Department, S.Andrea Hospital, II Unit University of Rome, Rome, Italy</style></auth-address><titles><title><style face="normal" font="default">Aminoazobenzene in tattoo: another case of allergic contact dermatitis</style></title><secondary-title><style face="normal" font="default">Int J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Rome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="16" Month="2" Year="2017">2017/2/16</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170216IS - 1365-4632 (Electronic)IS - 0011-9059 (Linking)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/ijd.13531</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28205219">PM:28205219</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Dermatol\20170216-TammaroA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Dermatol\20170216-TammaroA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170216, Tammaro A</style></custom2><misc3><style face="normal" font="default">10.1111/ijd.13531</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40576</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Langton,D.</style></author><author><style face="normal" font="default"> Sha,J.</style></author><author><style face="normal" font="default"> Ing,A.</style></author><author><style face="normal" font="default"> Fielding,D.</style></author><author><style face="normal" font="default"> Wood,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Thoracic Medicine, Frankston Hospital, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="default">Bronchial thermoplasty in severe asthma in Australia</style></title><secondary-title><style face="normal" font="default">Intern Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Intern Med J</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">agonists</style></keyword><keyword><style face="normal" font="default"> airflow</style></keyword><keyword><style face="normal" font="default"> airflow obstruction</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchial thermoplasty</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Methotrexate</style></keyword><keyword><style face="normal" font="default"> montelukast</style></keyword><keyword><style face="normal" font="default"> Muscarinic antagonist</style></keyword><keyword><style face="normal" font="default"> Muscarinic Antagonists</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral corticosteroids</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient Selection</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prednisolone</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Teaching</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Victoria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="1" Year="2017">2017/1/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: Bronchial thermoplasty is an approved bronchoscopic intervention for the treatment of severe asthma. However, limited published experience exists outside of clinical trials regarding patient selection and outcomes achieved. Aims To evaluate the effectiveness and safety of bronchial thermoplasty in patients with severe asthma encountered in clinical practice. METHODS: This is a retrospective analysis of the first 'real world' data from Australia. The following outcomes were measured prior to, and 6 months following bronchial thermoplasty: Spirometry, Asthma Control Questionnaire-5 (ACQ-5) score, reliever and preventer medication use, and exacerbation history. RESULTS: Twenty patients were treated from June 2014 to December 2015 at three university teaching hospitals. All subjects met the ERS/ATS definition of severe asthma. Mean pre-bronchodilator FEV1 was 62.8 +/- 16.6% predicted (range: 33-95%). All patients were being treated with high dose inhaled corticosteroids, long-acting beta2 agonists, and long-acting muscarinic antagonists. Ten patients (50%) were taking maintenance oral prednisolone. Most subjects also required at least one of montelukast (65%), omalizumab (30%), and methotrexate (20%). ACQ-5 improved from 3.6 +/- 1.1 at baseline to 1.6 +/- 1.2 at 6 months, p &lt; 0.001. Short-acting reliever use decreased from a median of 8.0 to 0.25 puffs/day, p &lt; 0.001, and exacerbations requiring corticosteroids also significantly reduced. Five of 10 patients completely discontinued maintenance oral corticosteroids. Ten patients with a baseline FEV1 of &lt;60% predicted significantly improved from 49.2 +/- 9.6% to 61.8 +/- 17.6%, p &lt; 0.05. Only two procedures required hospitalisation beyond the planned overnight admission. CONCLUSION: Bronchial thermoplasty is a safe procedure which can achieve clinical improvement in those with uncontrolled symptoms and severe airflow obstruction</style></abstract><notes><style face="normal" font="default">DA - 20170119IS - 1445-5994 (Electronic)IS - 1444-0903 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/imj.1337</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28101900">PM:28101900</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Dermatol\20170119-LangtonD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Dermatol\20170119-LangtonD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170119, Langton D</style></custom2><misc3><style face="normal" font="default">10.1111/imj.1337</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40577</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Berlinski,A.</style></author><author><style face="normal" font="default"> von Hollen,D.</style></author><author><style face="normal" font="default"> Hatley,R.H.</style></author><author><style face="normal" font="default"> Hardaker,L.E.</style></author><author><style face="normal" font="default"> Nikander,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Pulmonology Section, Department of Pediatrics, UAMS/COM , Pediatric Aerosol Research Laboratory, Little Rock, Arkansas4 InDevCo AB , Nykoping, Sweden</style></auth-address><titles><title><style face="normal" font="default">Drug Delivery in Asthmatic Children Following Coordinated and Uncoordinated Inhalation Maneuvers: A Randomized Crossover Trial</style></title><secondary-title><style face="normal" font="default">J Aerosol Med Pulm Drug Deliv</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Aerosol Med Pulm Drug Deliv</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Chromatography</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exhalation</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Metered Dose Inhalers</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Tidal Volume</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="15" Month="12" Year="2016">2016/12/15</year></dates><abstract><style face="normal" font="default">BACKGROUND: Valved holding chambers (VHCs) are used in children to deliver pressurized metered dose inhalers (pMDI). In vitro data suggest that uncoordinated use decreases the amount of drug available for inhalation. We hypothesize that in an ex vivo study, the coordinated maneuver will deliver more drug than the uncoordinated one. PATIENTS AND METHODS: Thirty-two clinically stable asthmatic children, ages 5-8 years, completed the study. An aerosol filter was interposed between a small-volume nonelectrostatic VHC and a mouthpiece to capture the drug emitted by one puff of Flovent(R) 220 mcg during tidal breathing. Inhalation and actuation parameters were measured by an electronic monitor, and the number of breaths required to empty the VHC was calculated. Subjects completed three coordinated and three uncoordinated (actuation at the beginning of inhalation and exhalation, respectively) runs in random order. Drug content from the filter and VHC was measured by high-performance liquid chromatography and expressed as percentage of emitted dose. RESULTS: [mean (99% confidence interval)] Filter dose was higher during coordinated technique 46% (43%-50%) than during uncoordinated technique 41% (37%-44%) (p &lt; 0.001). Peak inspiratory flow and tidal volume were 23.2 L/min (21.3-25.1 L/min) and 281 mL (251-311 mL), respectively. Subjects required three breaths to empty the VHC in 96% of the tests. CONCLUSIONS: Actuating the pMDI into a small-volume nonelectrostatic VHC during exhalation reduced by 11% the amount of fluticasone captured at the exit of the VHC. Asthmatic children (5-8 years old) need three or less breaths to empty the small-volume VHC (NCT01714063)</style></abstract><notes><style face="normal" font="default">DA - 20161215IS - 1941-2703 (Electronic)IS - 1941-2711 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1089/jamp.2016.1337</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27977309">PM:27977309</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Aerosol Med Pulm Drug Deliv\20161215-BerlinskiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Aerosol Med Pulm Drug Deliv\20161215-BerlinskiA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161215, Berlinski A</style></custom2><misc3><style face="normal" font="default">10.1089/jamp.2016.1337</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40578</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zeiger,R.S.</style></author><author><style face="normal" font="default"> Schatz,M.</style></author><author><style face="normal" font="default"> Li,Q.</style></author><author><style face="normal" font="default"> Chen,W.</style></author><author><style face="normal" font="default"> Khatry,D.B.</style></author><author><style face="normal" font="default"> Tran,T.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departments of Allergy and Research and Evaluation, Kaiser Permanente Southern California, San Diego and Pasadena, Calif. Statistical Sciences, MedImmune LLC, Gaithersburg, MdObservational Research Center, AstraZeneca, Gaithersburg, Md</style></auth-address><titles><title><style face="normal" font="default">Burden of Chronic Oral Corticosteroid Use by Adults with Persistent Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1060" start="1050">1050-1060</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Asthma specialist</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Managed care organization</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyposis</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Poisson</style></keyword><keyword><style face="normal" font="default"> Polyposis</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Theophylline</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="10" Month="2" Year="2017">2017/2/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic oral corticosteroid (C-OCS) use in asthma is an indicator of disease severity, but its risk factors are largely unknown. OBJECTIVE: To describe patient characteristics and disease burden associated with C-OCS use by adults with persistent asthma. METHODS: We identified 9546 patients aged 18 to 64 years in a large managed care organization who met the Healthcare Effectiveness Data and Information Set 2-year criteria (2009-2010) for persistent asthma. A subgroup had blood eosinophil counts. We calculated cumulative OCS dispensed per patient in 2010 and examined the distribution of disease characteristics by average daily amounts of OCS dispensed. C-OCS use was defined as 2.5 mg/d or more. Baseline factors (2010) associated with C-OCS use during follow-up (2011) were investigated by multivariable Poisson regression. RESULTS: At baseline, 782 (8.2%) patients were C-OCS users. Compared with patients who received no or less than 2.5 mg/d OCS, C-OCS users were older and more often female and ethnic minorities; and had more comorbidities, asthma specialist care, greater step-care level, controllers, asthma exacerbations, and greater blood eosinophil counts (all P &lt; .01). Baseline factors significantly associated with C-OCS use in the follow-up year included (1) demographic characteristics: older age, females, blacks versus whites, and whites versus others/unknown ethnicities; (2) disease burden: more asthma emergency department or hospitalization visits, greater step-care level, excessive short-acting beta2-agonist dispensed, theophylline use, asthma specialist care, and nasal polyposis; (3) greater blood eosinophil counts; and (4) most strongly, C-OCS use. CONCLUSIONS: C-OCS use was associated with more asthma burden, comorbidities, and greater blood eosinophil counts. Prior C-OCS use was the strongest predictor of future C-OCS use</style></abstract><notes><style face="normal" font="default">DA - 20170220IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.12.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28215604">PM:28215604</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1050-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1050-60.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170220, Zeiger RS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.12.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40579</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Azimi,E.</style></author><author><style face="normal" font="default"> Reddy,V.B.</style></author><author><style face="normal" font="default"> Pereira,P.J.</style></author><author><style face="normal" font="default"> Talbot,S.</style></author><author><style face="normal" font="default"> Woolf,C.J.</style></author><author><style face="normal" font="default"> Lerner,E.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Charlestown</style></auth-address><titles><title><style face="normal" font="default">Substance P activates Mas-related G-protein coupled receptors to induce itch</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> G protein-coupled receptor</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Itch</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Neurokinin 1 receptor</style></keyword><keyword><style face="normal" font="default"> Neuron</style></keyword><keyword><style face="normal" font="default"> Neurons</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Substance P</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="2" Year="2017">2017/2/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Substance P (SP) is linked to itch and inflammation through activation of receptors on mast cells and sensory neurons. There is increasing evidence that SP functions through Mas-related G protein-coupled receptors (Mrgprs) in addition to its conventional receptor, neurokinin-1. OBJECTIVE: Because Mrgprs mediate some aspects of inflammation that had been considered mediated by neurokinin-1 receptor (NK-1R), we sought to determine whether itch induced by SP can also be mediated by Mrgprs. METHODS: Genetic and pharmacologic approaches were used to evaluate the contribution of Mrgprs to SP-induced scratching behavior and activation of cultured dorsal root ganglion neurons from mice. RESULTS: SP-induced scratching behavior and activation of cultured dorsal root ganglion neurons was dependent on Mrgprs rather than NK-1R. CONCLUSION: We deduce that SP activates MrgprA1 on sensory neurons rather than NK-1R to induce itch</style></abstract><notes><style face="normal" font="default">DA - 20170221IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.12.980</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28219706">PM:28219706</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170221-AzimiE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170221-AzimiE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170221, Azimi E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.12.980</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40580</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gevaert,E.</style></author><author><style face="normal" font="default"> Zhang,N.</style></author><author><style face="normal" font="default"> Krysko,O.</style></author><author><style face="normal" font="default"> Lan,F.</style></author><author><style face="normal" font="default"> Holtappels,G.</style></author><author><style face="normal" font="default"> De Ruyck,N.</style></author><author><style face="normal" font="default"> Nauwynck,H.</style></author><author><style face="normal" font="default"> Yousefi,S.</style></author><author><style face="normal" font="default"> Simon,H.U.</style></author><author><style face="normal" font="default"> Bachert,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Upper Airways Research Laboratory, Faculty of Medicine, Ghent University, Ghent, Belgium</style></auth-address><titles><title><style face="normal" font="default">Extracellular eosinophilic traps in association with Staphylococcus aureus at the site of epithelial barrier defects in severe airway inflammation</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> Periostin</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Staining</style></keyword><keyword><style face="normal" font="default"> Staphylococcus</style></keyword><keyword><style face="normal" font="default"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Upper airways</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="2" Year="2017">2017/2/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by a Th2-biased eosinophilic inflammation. Eosinophils have been shown to generate so-called extracellular eosinophilic traps (EETs) under similar pathological conditions. OBJECTIVE: Our aim was to investigate a possible link between EET formation and the presence of Staphylococcus aureus, an organism frequently colonizing the upper airways, at the human mucosal site of the disease. METHODS: Tissue slides were investigated for the presence of EETs and S. aureus, using immunofluorescent staining and PNA-fish assay respectively. An ex vivo human mucosal disease tissue model was used for artificial infection with S. aureus. Cell markers were analyzed using immunohistochemistry, luminex Multiplex assay, ELISA, PCR, immunobloting and linked to the presence of EETs. RESULTS: About 8.8 +/- 4.8 % of the infiltrating eosinophils exhibited EETs in patient's nasal polyp tissues. The formation of EETs was associated with increased IL-5 (p &lt; 0.05) and periostin (p &lt; 0.05) tissue levels, and colonization with S. aureus (p &lt; 0.05). Using an ex vivo human mucosal disease tissue model, EET formation was induced (4.2 +/- 0.9 fold) upon exposure to S. aureus, but not to S. epidermidis. Eosinophils were shown to migrate (p &lt; 0.01) towards S. aureus and entrap the bacteria both inside and outside the mucosal tissue. Blocking NAPDH oxidase activity, led to a complete inhibition (p &lt; 0.05) of EET formation by S. aureus. CONCLUSION: Eosinophils are likely to be specifically recruited to and form EETs at sites of airway epithelial damage to protect the host from infections with S. aureus and possibly other microorganisms in CRSwNP</style></abstract><notes><style face="normal" font="default">DA - 20170220IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28216437">PM:28216437</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170220-GevaertE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170220-GevaertE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170220, Gevaert E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40581</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,X.</style></author><author><style face="normal" font="default"> Pichulik,T.</style></author><author><style face="normal" font="default"> Wolz,O.O.</style></author><author><style face="normal" font="default"> Dang,T.M.</style></author><author><style face="normal" font="default"> Stutz,A.</style></author><author><style face="normal" font="default"> Dillen,C.</style></author><author><style face="normal" font="default"> Delmiro,G.M.</style></author><author><style face="normal" font="default"> Kraus,H.</style></author><author><style face="normal" font="default"> Dickhofer,S.</style></author><author><style face="normal" font="default"> Daiber,E.</style></author><author><style face="normal" font="default"> Munzenmayer,L.</style></author><author><style face="normal" font="default"> Wahl,S.</style></author><author><style face="normal" font="default"> Rieber,N.</style></author><author><style face="normal" font="default"> Kummerle-Deschner,J.</style></author><author><style face="normal" font="default"> Yazdi,A.</style></author><author><style face="normal" font="default"> Franz-Wachtel,M.</style></author><author><style face="normal" font="default"> Macek,B.</style></author><author><style face="normal" font="default"> Radsak,M.</style></author><author><style face="normal" font="default"> Vogel,S.</style></author><author><style face="normal" font="default"> Schulte,B.</style></author><author><style face="normal" font="default"> Walz,J.S.</style></author><author><style face="normal" font="default"> Hartl,D.</style></author><author><style face="normal" font="default"> Latz,E.</style></author><author><style face="normal" font="default"> Stilgenbauer,S.</style></author><author><style face="normal" font="default"> Grimbacher,B.</style></author><author><style face="normal" font="default"> Miller,L.</style></author><author><style face="normal" font="default"> Brunner,C.</style></author><author><style face="normal" font="default"> Wolz,C.</style></author><author><style face="normal" font="default"> Weber,A.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Interfaculty Institute for Cell Biology, Department of Immunology, University of Tubingen, Auf der Morgenstelle 15, 72076 Tubingen, Germany</style></auth-address><titles><title><style face="normal" font="default">Human NLRP3 inflammasome activity is regulated by and potentially targetable via BTK</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> adaptive</style></keyword><keyword><style face="normal" font="default"> Adaptive immunity</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Agammaglobulinemia</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Caspase 1</style></keyword><keyword><style face="normal" font="default"> caspase-1</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infection Control</style></keyword><keyword><style face="normal" font="default"> Inflammasome</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> NLRP3 inflammasome</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Staphylococcus</style></keyword><keyword><style face="normal" font="default"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tyrosine</style></keyword><keyword><style face="normal" font="default"> tyrosine kinase</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="2" Year="2017">2017/2/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: The Nod-like receptor, NACHT, LRR and PYD domains-containing protein 3 (NLRP3), and Bruton's tyrosine kinase (BTK) are protagonists in innate and adaptive immunity, respectively: NLRP3 senses exogenous and endogenous insults leading to inflammasome activation, which occurs spontaneously in Muckle-Wells Syndrome (MWS); BTK mutations cause the genetic immunodeficiency X-linked agammaglobulinemia (XLA). However, to date few proteins that regulate NLRP3 inflammasome activity in human primary immune cells have been identified and clinically promising pharmacological targeting strategies remain elusive. OBJECTIVE: We therefore sought to identify novel regulators of the NLRP3 inflammasome in human cells with a view to exploring interference with inflammasome activity at the level of such regulators. METHODS: Following proteome-wide phospho-proteomics, an identified novel regulator, BTK, was studied in human and murine cells using pharmacological and genetic BTK ablation. RESULTS: We here show that BTK is a critical regulator of NLRP3 inflammasome activation: Pharmacological (using the Food and Drug Administration (FDA)-approved inhibitor, ibrutinib) and genetic (in XLA patients and Btk-knockout mice) BTK ablation in primary immune cells led to reduced Interleukin (IL)-1beta processing and secretion in response to Nigericin and the Staphylococcus aureus toxin, Leukocidin (Luk) AB. BTK affected Apoptosis-associated speck-like protein containing a CARD (ASC) speck formation and caspase-1 cleavage and interacted with NLRP3 and ASC. S. aureus infection control in vivo and IL-1beta release from MWS patient cells were impaired by ibrutinib. Notably, IL-1beta processing and release from immune cells isolated from cancer patients on ibrutinib therapy was reduced. CONCLUSION: Our data suggest that XLA may partially result from genetic inflammasome deficiency and that NLRP3 inflammasome-linked inflammation could potentially be targeted pharmacologically via BTK</style></abstract><notes><style face="normal" font="default">DA - 20170220IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28216434">PM:28216434</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170220-LiuX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170220-LiuX.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170220, Liu X</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40582</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pepper,A.N.</style></author><author><style face="normal" font="default"> Westermann-Clark,E.</style></author><author><style face="normal" font="default"> Lockey,R.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida Morsani College of Medicine and James A. Haley Veterans' Affairs Hospital, Tampa, Fla.</style></auth-address><titles><title><style face="normal" font="default">The High Cost of Epinephrine Autoinjectors and Possible Alternatives</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="668" start="665">665-668</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="default"> EpiPen</style></keyword><keyword><style face="normal" font="default"> Eyeglasses</style></keyword><keyword><style face="normal" font="default"> Florida</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Self Administration</style></keyword><keyword><style face="normal" font="default"> Self-administration</style></keyword><keyword><style face="normal" font="default"> Syringes</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Veterans</style></keyword></keywords><dates><year Day="10" Month="2" Year="2017">2017/2/10</year></dates><abstract><style face="normal" font="default">Epinephrine autoinjectors provide potentially life-saving therapy for pediatric and adult subjects with systemic allergic reactions, including anaphylaxis. However, the cost of these devices, specifically the EpiPen (Mylan, Canonsburg, Pa), is increasing exponentially. Epinephrine autoinjectors are commonly prescribed in the United States but are not readily available worldwide. Alternatives for the self-administration of epinephrine exist and should be considered for patients who cannot afford or do not have access to these devices. The epinephrine prefilled syringe, stored in an eyeglass or pencil case, is a safe and viable option for the self-administration of epinephrine. Epinephrine prefilled syringes may not be as ideal as using autoinjectors but are superior to patients living without access to this medication</style></abstract><notes><style face="normal" font="default">DA - 20170220IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.12.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28215605">PM:28215605</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-665-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-665-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170220, Pepper AN</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.12.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40583</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gavino,C.</style></author><author><style face="normal" font="default"> Landekic,M.</style></author><author><style face="normal" font="default"> Zeng,J.</style></author><author><style face="normal" font="default"> Wu,N.</style></author><author><style face="normal" font="default"> Jung,S.</style></author><author><style face="normal" font="default"> Zhong,M.C.</style></author><author><style face="normal" font="default"> Cohen-Blanchet,A.</style></author><author><style face="normal" font="default"> Langelier,M.</style></author><author><style face="normal" font="default"> Neyret,O.</style></author><author><style face="normal" font="default"> Lejtenyi,D.</style></author><author><style face="normal" font="default"> Rochefort,C.</style></author><author><style face="normal" font="default"> Cotton-Montpetit,J.</style></author><author><style face="normal" font="default"> McCusker,C.</style></author><author><style face="normal" font="default"> Mazer,B.</style></author><author><style face="normal" font="default"> Veillette,A.</style></author><author><style face="normal" font="default"> Vinh,D.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Infectious Disease Susceptibility Program, McGill University Health Centre (MUHC) and Research Institute-MUHC (RI-MUHC), Montreal, Quebec, Canada</style></auth-address><titles><title><style face="normal" font="default">Morpholino-based correction of hypomorphic ZAP70 mutation in an adult with combined immunodeficiency</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Autoimmunity</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease Susceptibility</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Mutant</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Quebec</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Viruses</style></keyword></keywords><dates><year Day="16" Month="2" Year="2017">2017/2/16</year></dates><abstract><style face="normal" font="default">An adult with hypomorphic ZAP-70 deficiency due to de novo donor splice site mutation manifested autoimmunity, infections especially with DNA-based viruses and lymphoproliferation. Morpholino interference of mutant splice site increased expression of wild-type protein, significantly improving T cell responses</style></abstract><notes><style face="normal" font="default">DA - 20170220IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28216435">PM:28216435</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170220-GavinoC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170220-GavinoC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170220, Gavino C</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40584</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fischer,A.</style></author><author><style face="normal" font="default"> Provot,J.</style></author><author><style face="normal" font="default"> Jais,J.P.</style></author><author><style face="normal" font="default"> Alcais,A.</style></author><author><style face="normal" font="default"> Mahlaoui,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre de Reference Deficits Immunitaires Hereditaires (CEREDIH), Hopital Universitaire Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris, Paris, France</style></auth-address><titles><title><style face="normal" font="default">Autoimmune and inflammatory manifestations occur frequently in primary immunodeficiencies</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Autoimmunity</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Common Variable Immunodeficiency</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="2" Year="2017">2017/2/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Primary immunodeficiencies (PIDs) are inherited diseases associated with a considerably increase in susceptibility to infections. It is known that PIDs can also predispose to cancer and immune diseases including allergy, autoimmunity and inflammation. OBJECTIVE: We aimed at determining the incidence of autoimmunity and inflammation in PID patients. METHODS: We have retrospectively screen 2183 consecutive cases of PID in the French CEREDIH registry for the occurrence of autoimmunity and inflammation. RESULTS: One or more autoimmune and inflammatory complications were noted in 26.2% of patients, with a risk of onset throughout the patient's lifetime. The risk of autoimmune cytopenia was at least 120 times higher than in the general population, the risk of inflammatory bowel disease in children 80 times higher and the risk of other autoimmune manifestations was approximately 10 times higher. Remarkably, all types of PID were associated with a risk of autoimmune and inflammatory complications, although the greatest risk was associated with T cell PIDs and common variable immunodeficiency. The occurrence of autoimmune disease is a negative prognostic factor for survival. CONCLUSIONS: Our results provide the basis for a detailed, prospective evaluation of autoimmunity and inflammation in the context of PID, with a view to accurately assessing these risks and describing the possible impact of medical intervention</style></abstract><notes><style face="normal" font="default">DA - 20170213IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.12.978</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28192146">PM:28192146</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170213-FischerA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170213-FischerA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170213, Fischer A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.12.978</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40585</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Larsson,O.</style></author><author><style face="normal" font="default"> Tengroth,L.</style></author><author><style face="normal" font="default"> Xu,Y.</style></author><author><style face="normal" font="default"> Uddman,R.</style></author><author><style face="normal" font="default"> Georen,S.K.</style></author><author><style face="normal" font="default"> Cardell,L.O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Divison of ENT Diseases, CLINTEC, Karolinska Institutet, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default">Substance P represents a novel first-line defense mechanism in the nose</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">agonists</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> Aprepitant</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate immunity</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Microscopy</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> Movement</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal epithelial cell</style></keyword><keyword><style face="normal" font="default"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="default"> Neurogenic Inflammation</style></keyword><keyword><style face="normal" font="default"> Neurokinin 1 receptor</style></keyword><keyword><style face="normal" font="default"> Neuron</style></keyword><keyword><style face="normal" font="default"> Neurons</style></keyword><keyword><style face="normal" font="default"> Neuropeptides</style></keyword><keyword><style face="normal" font="default"> Nose</style></keyword><keyword><style face="normal" font="default"> priming</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Substance P</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> TLR</style></keyword><keyword><style face="normal" font="default"> TLR7</style></keyword><keyword><style face="normal" font="default"> Upper airways</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="2" Year="2017">2017/2/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Neuropeptides, such as substance P (SP), have long been seen as mediators of widespread, continuous airway inflammation, a process known as neurogenic inflammation. However, this has been difficult to demonstrate clinically, suggesting an alternative role for these signaling molecules. OBJECTIVES: To examine the role of SP in nasal infection, by assessing the release of SP in response to viral stimulation and characterizing the effects of SP on innate immunity, the latter reflected in changes in local Toll-like receptor (TLR) expression. METHODS: The distribution of SP and TLRs in the nasal mucosa and in local airway neurons was assessed with immunohistochemistry. The TLR7 agonists R-837 and R-848 were used to mimic a viral insult in upper airways, represented by primary human and mouse nasal epithelial cells (HNEC, MNEC) and isolated murine trigeminal ganglia (TGN). SP release from HNEC, MNEC and TGN was quantified with EIA. The effects of SP on TLR expression on HNEC were determined using flow cytometry and confocal microscopy. RESULTS: SP was released from the sensory neurons, MNEC and HNEC within 15 minutes of local TLR7 stimulation. Subsequently, stimulation with SP induced upregulation of TLR expression in HNEC within 30 minutes, via induction of TLR movement within HNEC. Upregulation of TLR expression was not evident when cells were treated with the neurokinin 1 receptor (NK1R) antagonist aprepitant prior to SP stimulation. CONCLUSIONS: This highlights a novel role for sensory neuropeptides as acute and local mediators of pathogen-driven inflammation, rapidly priming innate immune defenses in the airway</style></abstract><notes><style face="normal" font="default">DA - 20170221IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28219705">PM:28219705</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170221-LarssonO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170221-LarssonO.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170221, Larsson O</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40586</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tschudy,M.M.</style></author><author><style face="normal" font="default"> Sharfstein,J.</style></author><author><style face="normal" font="default"> Matsui,E.</style></author><author><style face="normal" font="default"> Barnes,C.S.</style></author><author><style face="normal" font="default"> Chacker,S.</style></author><author><style face="normal" font="default"> Codina,R.</style></author><author><style face="normal" font="default"> Cohn,J.R.</style></author><author><style face="normal" font="default"> Sandel,M.</style></author><author><style face="normal" font="default"> Wedner,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of General Pediatrics and Adolescent Medicine, Department of Pediatrics, Johns Hopkins School of Medicine.</style></auth-address><titles><title><style face="normal" font="default">Something New in the Air: Paying for Community-Based Environmental Approaches to Asthma Prevention and Control: Work Group Report of the Practice, Diagnostics and Therapeutics Committee of the American Academy of Allergy, Asthma &amp; Immunology</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostics</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> indoor</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutics</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="10" Month="2" Year="2017">2017/2/10</year></dates><abstract><style face="normal" font="default">Despite the recommendation in national asthma guidelines to target indoor environmental exposures, most insurers generally have not covered the outreach, education, environmental assessments, or durable goods integral to home environmental interventions. Emerging payment approaches, however, offer new potential for coverage of home-based environmental intervention costs. These opportunities are becoming available as public and private insurers shift reimbursement to reward better health outcomes and their key characteristic is a focus on the value rather than the volume of services. These new payment models for environmental interventions can be divided into two categories: enhanced fee-for-service reimbursement and set payments per patient that cover asthma-related costs. Several pilot programs across the United States are underway, and as they prove their value and as payment increasingly becomes aligned with better outcomes at lower cost, these efforts should have a bright future. Physicians should be aware that these new possibilities are emerging for payment of the goods and services needed for indoor environmental interventions for their patients with asthma</style></abstract><notes><style face="normal" font="default">DA - 20170213IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.12.975</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28192148">PM:28192148</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170213-TschudyMM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170213-TschudyMM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170213, Tschudy MM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.12.975</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40587</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Platt,C.D.</style></author><author><style face="normal" font="default"> Chou,J.</style></author><author><style face="normal" font="default"> Houlihan,P.</style></author><author><style face="normal" font="default"> Badran,Y.R.</style></author><author><style face="normal" font="default"> Kumar,L.</style></author><author><style face="normal" font="default"> Bainter,W.</style></author><author><style face="normal" font="default"> Poliani,P.L.</style></author><author><style face="normal" font="default"> Perez,C.J.</style></author><author><style face="normal" font="default"> Dent,S.Y.</style></author><author><style face="normal" font="default"> Clapham,D.E.</style></author><author><style face="normal" font="default"> Benavides,F.</style></author><author><style face="normal" font="default"> Geha,R.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA</style></auth-address><titles><title><style face="normal" font="default">LRRC8A-dependent volume regulated anion channel activity is dispensable for T cell development and function</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">abnormalities</style></keyword><keyword><style face="normal" font="default"> Agammaglobulinemia</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Cell Proliferation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Hair</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Kidney</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> Mutant</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="2" Year="2017">2017/2/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Leucine-rich repeat containing 8A (LRRC8A) is a ubiquitously expressed transmembrane protein with 17 LRRs at its C-terminal end, and is an essential component of the volume regulated anion channel (VRAC) which controls cellular volume. A heterozygous mutation in LRRC8A that truncates the two terminal LRRs was reported in a patient with agammaglobulinemia and absent B cells, and was demonstrated to exert a dominant negative effect on T and B cell development in mice. Lrrc8a-/- mice have severely defective T cell development and function. It is not known whether the T and B cell defects caused by LRRC8A deficiency are caused by loss of VRAC activity. OBJECTIVE: To determine whether VRAC activity is required for normal T cell development and function. METHODS: VRAC activity was examined by patch clamp analysis. Flow cytometry was used to examine T cell development. T cell proliferation, cytokine secretion and antibody titers were measured by standard techniques. RESULTS: We demonstrate that the spontaneous mouse mutant ebouriffe (ebo/ebo) harbors a homozygous 2 bp frameshift mutation in Lrrc8a that truncates the fifteen terminal LRRs of LRRC8A. The LRRC8Aebo mutation does not impact protein expression but drastically diminishes VRAC activity in T cells. ebo/ebo mice share features with Lrrc8a-/- mice that include curly hair, infertility, reduced longevity and kidney abnormalities. However, in contrast to Lrrc8a-/- mice, ebo/ebo mice have normal T cell development and function and intact antibody response to T-dependent antigen. CONCLUSION: LRRC8A-dependent VRAC activity is dispensable for T cell development and function</style></abstract><notes><style face="normal" font="default">DA - 20170213IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.12.974</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28192143">PM:28192143</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170213-PlattCD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170213-PlattCD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170213, Platt CD</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.12.974</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40588</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sullivan,A.</style></author><author><style face="normal" font="default"> Wang,E.</style></author><author><style face="normal" font="default"> Farrell,J.</style></author><author><style face="normal" font="default"> Whitaker,P.</style></author><author><style face="normal" font="default"> Faulkner,L.</style></author><author><style face="normal" font="default"> Peckham,D.</style></author><author><style face="normal" font="default"> Park,B.K.</style></author><author><style face="normal" font="default"> Naisbitt,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, The University of Liverpool, Liverpool, L69 3GE, England</style></auth-address><titles><title><style face="normal" font="default">beta-lactam hypersensitivity involves expansion of circulating and skin-resident Th22 cells</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Chemokine receptor</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> England</style></keyword><keyword><style face="normal" font="default"> expansion</style></keyword><keyword><style face="normal" font="default"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-17A</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Ligands</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Piperacillin</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cell clone</style></keyword><keyword><style face="normal" font="default"> T-cell clones</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="2" Year="2017">2017/2/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: beta-lactam hypersensitivity has been classified according to the phenotype and function of drug-specific T-cells; however, new T-cell subsets have not been considered. OBJECTIVE: The objective of this study was use piperacillin as a model of beta-lactam hypersensitivity to study the nature of the drug-specific T-cell response induced in the blood and skin of hypersensitive patients and healthy volunteers. METHODS: Drug-specific T-cells were cloned from blood and inflamed skin and cellular phenotype and function was explored. Naive T cells from healthy volunteers were primed to piperacillin, cloned and subjected to the similar analyses. RESULTS: PBMC and T-cell clones (n=570, 84% CD4+) from blood of piperacillin hypersensitive patients proliferated and secreted Th1/2 cytokines alongside IL-22 following drug stimulation. IL-17A secretion was not detected. Drug-specific clones from inflamed skin (n=96, 83% CD4+) secreted a similar profile of cytokines, but displayed greater cytolytic activity, secreting perforin, granzyme B and Fas L when activated. Blood- and skin-derived clones expressed high levels of skin-homing chemokine receptors and migrated in the presence of the ligands CCL17 and CCL27. Piperacillin-primed naive T-cells from healthy volunteers also secreted IFN-gamma, IL-13, IL-22 and cytolytic molecules. Aryl hydrocarbon (ArH) receptor blockade prevented differentiation of the naive T-cells into antigen-specific Il-22 secreting cells. CONCLUSION: Together our results reveal that circulating and skin resident antigen-specific IL-22 secreting T-cells are detectable in patients with beta-lactam hypersensitivity. Furthermore, differentiation of naive T-cells into antigen-specific Th22 cells is dependent on ArH receptor signalling</style></abstract><notes><style face="normal" font="default">DA - 20170221IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28219704">PM:28219704</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170221-SullivanA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170221-SullivanA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170221, Sullivan A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40589</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lin,S.K.</style></author><author><style face="normal" font="default"> Mulieri,K.M.</style></author><author><style face="normal" font="default"> Ishmael,F.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Penn State Hershey Medical Center, Hershey, Pa</style></auth-address><titles><title><style face="normal" font="default">Characterization of Vancomycin Reactions and Linezolid Utilization in the Pediatric Population</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="756" start="750">750-756</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Characterization</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Histamine Release</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> Vancomycin</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="8" Month="2" Year="2017">2017/2/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Red man syndrome (RMS) occurs because of non-IgE-mediated histamine release. Unlike vancomycin allergy, which necessitates the use of an alternative drug (often linezolid), RMS does not typically preclude further vancomycin use. Care should be taken to differentiate these reaction types from one another to prevent unnecessary vancomycin avoidance. OBJECTIVE: To characterize vancomycin reaction types in our population, and to determine whether having a reaction consistent with RMS is associated with otherwise unexplained vancomycin avoidance and linezolid use. METHODS: We retrospectively reviewed charts for children with documented vancomycin reactions. We classified the in-hospital reactions via an objective analysis and estimated the prevalence of different reaction types. We then identified children who received linezolid over 3 years, and investigated reasons for linezolid use instead of vancomycin. RESULTS: Of the 78 in-hospital reactions we characterized, 72 (92%) were objectively consistent with RMS, 5 we could not objectively classify (2 most likely RMS, 3 more suspicious for possible IgE-mediated allergy), and 1 was a non-RMS/non-IgE reaction. Of 60 children who received linezolid, 19 had previous reactions consistent with RMS, which should not preclude further vancomycin. Nevertheless, only 7 of 19 (37%) had a clear explanation for receiving linezolid instead of vancomycin compared with 32 of 39 (82%) children without previous vancomycin reactions (P &lt; .001). CONCLUSIONS: The vast majority of patients had vancomycin reactions consistent with RMS. These patients are at risk for unnecessary vancomycin avoidance and linezolid utilization. We propose that this may be related to how reactions appear in the electronic medical record</style></abstract><notes><style face="normal" font="default">DA - 20170212IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.12.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28189630">PM:28189630</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-750-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-750-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170212, Lin SK</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.12.022</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40590</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Long,X.</style></author><author><style face="normal" font="default"> Daya,M.</style></author><author><style face="normal" font="default"> Zhao,J.</style></author><author><style face="normal" font="default"> Rafaels,N.</style></author><author><style face="normal" font="default"> Liang,H.</style></author><author><style face="normal" font="default"> Potee,J.</style></author><author><style face="normal" font="default"> Campbell,M.</style></author><author><style face="normal" font="default"> Zhang,B.</style></author><author><style face="normal" font="default"> Araujo,M.I.</style></author><author><style face="normal" font="default"> Oliveira,R.R.</style></author><author><style face="normal" font="default"> Mathias,R.A.</style></author><author><style face="normal" font="default"> Gao,L.</style></author><author><style face="normal" font="default"> Ruczinski,I.</style></author><author><style face="normal" font="default"> Georas,S.N.</style></author><author><style face="normal" font="default"> Vercelli,D.</style></author><author><style face="normal" font="default"> Beaty,T.H.</style></author><author><style face="normal" font="default"> Barnes,K.C.</style></author><author><style face="normal" font="default"> Chen,X.</style></author><author><style face="normal" font="default"> Chen,Q.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical Study Center of Liver Surgery in Hubei Province; Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;</style></auth-address><titles><title><style face="normal" font="default">The role of ST2 and ST2 genetic variants in schistosomiasis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Cirrhosis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Liver Cirrhosis</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Schistosomiasis</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> ST2</style></keyword><keyword><style face="normal" font="default"> Staining</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> Th2 response</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="2" Year="2017">2017/2/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic schistosomiasis and its severe complication, periportal fibrosis, are characterized by a predominant Th2 response. To date, specific SNPs in ST2 have been some of the most consistently associated genetic variants for asthma. OBJECTIVES: We investigated the role of ST2 (a receptor for the Th2 cytokine IL-33) in chronic and late-stage schistosomiasis caused by S. japonicum, and the potential effect of ST2 genetic variants on stage of disease and ST2 expression. METHODS: 947 adult participants (339 with end-stage schistosomiasis and liver cirrhosis, 307 with chronic infections without liver fibrosis, and 301 health controls) were recruited from a S. japonicum-endemic area (Hubei, China). Six ST2 SNPs were genotyped. Serum sST2 was measured by ELISA, and ST2 expression in normal liver tissues, HBV-induced fibrotic liver tissues and S. japonicum-induced fibrotic liver tissues was measured by immunohistochemistry. RESULTS: sST2 levels were significantly higher in the end-stage group (36.04 [95 %CI 33.85;38.37]) compared to chronic cases and controls (22.7 [95% CI 22.0;23.4], p-value &lt; 1E-10). In addition, S. japonicum-induced fibrotic liver tissues showed increased ST2 staining compared to normal liver tissues (p-value=0.0001). Markers rs12712135, rs1420101 and rs6543119 were strongly associated with sST2 levels (p-values 2E-10, 5E-05 and 6E-05 respectively), and these results were replicated in an independent cohort from Brazil living in a S. mansoni endemic region. CONCLUSION: We demonstrate for the first time that end-stage schistosomiasis is associated with elevated sST2 levels, and show that ST2 genetic variants are associated with sST2 levels in patients with schistosomiasis</style></abstract><notes><style face="normal" font="default">DA - 20170212IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.12.969</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28189770">PM:28189770</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170212-LongX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170212-LongX.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170212, Long X</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.12.969</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40591</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Allen-Brady,K.</style></author><author><style face="normal" font="default"> Firszt,R.</style></author><author><style face="normal" font="default"> Fang,J.C.</style></author><author><style face="normal" font="default"> Wong,J.</style></author><author><style face="normal" font="default"> Smith,K.R.</style></author><author><style face="normal" font="default"> Peterson,K.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, University of Utah, Salt Lake City, Utah, 84108 USA.</style></auth-address><titles><title><style face="normal" font="default">Population-based Familial Aggregation of Eosinophilic Esophagitis Suggests a Genetic Contribution</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Electronic medical records</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default"> Esophagitis</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetic factors</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Spouses</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="10" Month="2" Year="2017">2017/2/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Prior familial clustering studies have observed an increased risk of eosinophilic esophagitis (EoE) mostly among first-degree relatives suggesting a genetic contribution to EoE, and twin studies have suggested a powerful contribution from environmental factors. OBJECTIVE: Clarify the contribution of genetic factors to EoE through estimation of familial aggregation and risk of EoE in extended relatives. METHODS: The Utah Population Database, a population-based genealogy resource linked to electronic medical records for healthcare systems across the state of Utah, was used to identify EoE cases and age, sex and birthplace-matched controls at a 5:1 ratio. Logistic regression was used to determine the odds of EoE among relatives of EoE probands compared to the odds of EoE among relatives of controls. RESULTS: There were 4,423 EoE cases and 24,322 controls. The population attributable risk of EoE was 31% (95% CI 28-34%), suggesting a relatively strong genetic contribution. Risks of EoE were significantly increased among first-degree relatives (OR=7.19; 95% CI 5.65-9.14), particularly first-degree relatives of EoE cases diagnosed &lt;18 years of age (OR=16.3; 95% CI 9.4-28.3); second-degree relatives (OR=1.99; 95% CI 1.49-2.65); and first cousins (OR=1.35; 95% CI 1.03-1.77), providing evidence of a genetic contribution. However, spouses of EoE probands were observed to be at increased risk of EoE (OR=2.86; 95% CI 1.31-6.25), suggesting either positive assortative mating or a shared environmental contribution to EoE. CONCLUSION: This study supports a significant genetic contribution to EoE as evidenced by increased risk of EoE in distant relatives</style></abstract><notes><style face="normal" font="default">DA - 20170213IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.12.979</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28192145">PM:28192145</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170213-AllenBradyK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170213-AllenBradyK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170213, Allen-Brady K</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.12.979</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40592</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Szefler,S.J.</style></author><author><style face="normal" font="default"> Murphy,K.</style></author><author><style face="normal" font="default"> Harper,T.,III</style></author><author><style face="normal" font="default"> Boner,A.</style></author><author><style face="normal" font="default"> Laki,I.</style></author><author><style face="normal" font="default"> Engel,M.</style></author><author><style face="normal" font="default"> El Azzi,G.</style></author><author><style face="normal" font="default"> Moroni-Zentgraf,P.</style></author><author><style face="normal" font="default"> Finnigan,H.</style></author><author><style face="normal" font="default"> Hamelmann,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Children's Hospital of Colorado and the University of Colorado School of Medicine, The Breathing Institute, 13123 E. 16th Avenue, Aurora, CO 80045, USA.</style></auth-address><titles><title><style face="normal" font="default">A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> Controller medications</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hungary</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tolerability</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="2" Year="2017">2017/2/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Studies in adults and adolescents have demonstrated that tiotropium is efficacious as an add-on therapy to inhaled corticosteroids (ICS) with or without other maintenance therapies in patients with moderate or severe symptomatic asthma. OBJECTIVE: To assess the efficacy and safety of once-daily tiotropium Respimat add-on therapy to high-dose ICS with 1 or more controller medications, or medium-dose ICS with 2 or more controller medications, in the first phase III trial of tiotropium in children with severe symptomatic asthma. METHODS: In this 12-week, double-blind, placebo-controlled, parallel-group trial, 401 participants aged 6-11 years were randomized to receive once-daily tiotropium 5 mug (2 puffs of 2.5 mug) or 2.5 mug (2 puffs of 1.25 mug), or placebo (2 puffs), administered through the Respimat device as add-on to background therapy. RESULTS: Compared with placebo, tiotropium 5 mug add-on therapy, but not 2.5 mug, improved the primary endpoint, peak forced expiratory volume in 1 second (FEV1) within 3 hours after dosing (5 mug, 139 mL [95% CI, 75-203; P &lt; 0.001]; 2.5 mug, 35 mL [95% CI, -28-99; P = 0.27]), and the key secondary endpoint, trough FEV1 (5 mug, 87 mL [95% CI, 19-154; P = 0.01]; 2.5 mug, 18 mL [95% CI, -48-85; P = 0.59]). The safety and tolerability of tiotropium were comparable with those of placebo. CONCLUSION: Once-daily tiotropium Respimat 5 mug improved lung function and was well tolerated as add-on therapy to ICS with other maintenance therapies in children with severe symptomatic asthma</style></abstract><notes><style face="normal" font="default">DA - 20170212IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Italy -CO - Hungary -CO - Germany -CO - Australia -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28189771">PM:28189771</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170212-SzeflerSJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170212-SzeflerSJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170212, Szefler SJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40593</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hagan,J.B.</style></author><author><style face="normal" font="default"> Laidlaw,T.M.</style></author><author><style face="normal" font="default"> Divekar,R.</style></author><author><style face="normal" font="default"> O'Brien,E.K.</style></author><author><style face="normal" font="default"> Kita,H.</style></author><author><style face="normal" font="default"> Volcheck,G.W.</style></author><author><style face="normal" font="default"> Hagan,C.R.</style></author><author><style face="normal" font="default"> Lal,D.</style></author><author><style face="normal" font="default"> Teaford,H.G.,III</style></author><author><style face="normal" font="default"> Erwin,P.J.</style></author><author><style face="normal" font="default"> Zhang,N.</style></author><author><style face="normal" font="default"> Rank,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergic Diseases, Mayo Clinic, Rochester, Minn.</style></auth-address><titles><title><style face="normal" font="default">Urinary Leukotriene E4 to Determine Aspirin Intolerance in Asthma: A Systematic Review and Meta-Analysis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="997" start="990">990-997</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin challenge</style></keyword><keyword><style face="normal" font="default"> aspirin intolerance</style></keyword><keyword><style face="normal" font="default"> aspirin intolerant asthma</style></keyword><keyword><style face="normal" font="default"> aspirin-intolerant asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immunoassay</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Leukotriene E4</style></keyword><keyword><style face="normal" font="default"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Predictive values</style></keyword><keyword><style face="normal" font="default"> Radioimmunoassay</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> subtypes</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="12" Month="2" Year="2017">2017/2/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Urinary leukotriene E4 (ULTE4) may be a biomarker that distinguishes aspirin-intolerant asthma from other asthma subtypes. OBJECTIVE: To estimate the diagnostic testing accuracy of ULTE4 as a marker of aspirin intolerance in patients with asthma using previously published studies. METHODS: We identified relevant clinical studies from a systematic review of English and non-English articles using MEDLINE, EMBASE, and CENTRAL (inception to February 10, 2015). Articles were screened at the abstract and full-text level by 2 independent reviewers. We included previously published studies that analyzed ULTE4 in human subjects with asthma characterized as having or not having aspirin intolerance on the basis of a specified definition: convincing history of aspirin intolerance, positive aspirin challenge, or both as the criterion standard. Individual-level data points from all included studies were obtained and analyzed. RESULTS: The search strategy identified 867 potential articles, of which 86 were reviewed at the full-text level and 10 met criteria for inclusion. The sensitivity, specificity, positive predictive value, and negative predictive values of ULTE4 to determine aspirin intolerance in subjects with asthma were 0.55, 0.82, 0.75, and 0.66 (Amersham-enzyme immunoassay); 0.76, 0.77, 0.70, and 0.78 (Cayman-enzyme immunoassay); 0.70, 0.81, 0.86, and 0.79 (mass spectrometry); and 0.81,0.79, 0.65, and 0.88 (radioimmunoassay) at optimal thresholds of 192, 510, 167 to 173, and 66 to 69 pg/mg Cr, respectively. The diagnostic odds ratio for each methodology was 6.0, 11.9, 10.5, and 19.1, respectively. CONCLUSIONS: ULTE4 is a marker for aspirin-intolerant asthma and could potentially be used as a clinical test to identify the risk of aspirin intolerance in subjects with asthma</style></abstract><notes><style face="normal" font="default">DA - 20170216IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.11.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28202405">PM:28202405</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-990-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-990-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170216, Hagan JB</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.11.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40594</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Baker,J.W.</style></author><author><style face="normal" font="default"> Reshef,A.</style></author><author><style face="normal" font="default"> Moldovan,D.</style></author><author><style face="normal" font="default"> Harper,J.R.</style></author><author><style face="normal" font="default"> Relan,A.</style></author><author><style face="normal" font="default"> Riedl,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Baker Allergy Asthma Dermatology Research Center, LLC, Portland, Ore.</style></auth-address><titles><title><style face="normal" font="default">Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> C1 esterase inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-esterase inhibitor</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> open-label extension</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pharmacokinetics</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Recombinant</style></keyword><keyword><style face="normal" font="default"> Recombinant human C1 esterase inhibitor</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Romania</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> single dose</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="12" Month="2" Year="2017">2017/2/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Recombinant human C1-esterase inhibitor (rhC1-INH) is efficacious and well tolerated for managing hereditary angioedema (HAE) attacks in adults. However, there are insufficient data on its efficacy and safety in adolescents. OBJECTIVE: To evaluate the efficacy and safety profiles of rhC1-INH for acute HAE attacks in adolescents. METHODS: Adolescents (aged 12-18 y) with HAE enrolled in 2 randomized controlled trials and 2 open-label extension trials were included and received intravenous rhC1-INH for acute attacks. Times to the beginning of sustained symptom relief (visual analog scale change from baseline >/=20 mm) and minimal symptoms (visual analog scale score of &lt;20 mm across locations) were assessed. Safety parameters included hypersensitivity reactions, anti-rhC1-INH antibodies, and host-related impurities. RESULTS: Sixteen adolescents (50 attacks, aged 14-18 y) received rhC1-INH. Attacks were managed with single-dose rhC1-INH 50 U/kg (46.0%) and single-dose rhC1-INH 2100 U (16%), and 32.0% were treated with additional doses after receiving an initial rhC1-INH 2100 U dose (total dose, 4200-6300 U). Most attacks (88.0%) occurred at a single location; 59.1% (26 of 44) were abdominal. Across the first 5 attacks, median times to the beginning of symptom relief ranged from 19.0 to 78.5 minutes; median times to minimal symptoms ranged from 120 to 190 minutes. Pharmacokinetics showed that rhC1-INH restored functional plasma C1-esterase inhibitor levels to the normal (>70%) range for almost all evaluable patients. No severe or drug-related adverse events or hypersensitivity reactions occurred. No treatment-emergent antibodies to rhC1-INH or host-related impurities were observed. CONCLUSIONS: rhC1-INH is efficacious and well tolerated among adolescents with HAE</style></abstract><notes><style face="normal" font="default">DA - 20170216IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - Israel -CO - Romania -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.11.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28202404">PM:28202404</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170216-BakerJW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170216-BakerJW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170216, Baker JW</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.11.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40595</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,C.C.</style></author><author><style face="normal" font="default"> Kobayashi,T.</style></author><author><style face="normal" font="default"> Iijima,K.</style></author><author><style face="normal" font="default"> Hsu,F.C.</style></author><author><style face="normal" font="default"> Kita,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology, Mayo Clinic Rochester, Rochester, MN, 55905</style></auth-address><titles><title><style face="normal" font="default">IL-33 dysregulates regulatory T (Treg) cells and impairs established immunological tolerance in the lungs</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adaptive</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> immunological tolerance</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> ST2</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> Th2 Cells</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> transcription factor</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="2" Year="2017">2017/2/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Airway exposure to environmental antigens generally leads to immunological tolerance. A fundamental question remains: why is airway tolerance compromised in patients with allergic airway diseases? Interleukin (IL)-33 promotes innate and adaptive type 2 immunity and may provide the answer to this question. OBJECTIVE: The goal of this study was to investigate the roles IL-33 plays in altering regulatory T (Treg) cells in the lungs and in affecting previously established airway immunological tolerance. METHODS: We analyzed CD4+ forkhead box p3 (Foxp3)+ Treg cells that were isolated from the lungs of naive BALB/c mice and those treated with IL-33. Airway tolerance and allergen-induced airway inflammation models in mice were used to investigate how IL-33 affects established immunological tolerance in vivo. RESULTS: CD4+Foxp3+ Treg cells in the lungs expressed IL-33 receptor ST2. When exposed to IL-33, Treg cells upregulated their expression of canonical Th2 transcription factor GATA3 as well as ST2, and produced type 2 cytokines. Treg cells lost their ability to suppress effector T cells in the presence of IL-33. Airway administration of IL-33 with an antigen impaired the immunological tolerance in the lungs that had been established by prior exposure to the antigen. Dysregulated Foxp3+ Treg cells with distinct characteristics of Th2 cells increased in the lungs of the mice undergoing IL-33-dependent allergen-driven airway inflammation. CONCLUSIONS: IL-33 dysregulated lung Treg cells and impaired immunological tolerance to inhaled antigens. Established airway tolerance may not be sustained in the presence of an innate immunological stimulation, such as IL-33</style></abstract><notes><style face="normal" font="default">DA - 20170215IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28196763">PM:28196763</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170215-ChenCC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170215-ChenCC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170215, Chen CC</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40596</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yamaoka,M.</style></author><author><style face="normal" font="default"> Deguchi,M.</style></author><author><style face="normal" font="default"> Ninomiya,K.</style></author><author><style face="normal" font="default"> Kurasako,T.</style></author><author><style face="normal" font="default"> Matsumoto,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesiology, Japanese Red Cross Society Himeji Hospital, 1-12-1, Shimoteno, Himeji, Japan.</style></auth-address><titles><title><style face="normal" font="default">A suspected case of rocuronium-sugammadex complex-induced anaphylactic shock after cesarean section</style></title><secondary-title><style face="normal" font="default">J Anesth</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Anesth</style></abbr-1></periodical><pages end="151" start="148">148-151</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Anesthesia</style></keyword><keyword><style face="normal" font="default"> Anesthesiology</style></keyword><keyword><style face="normal" font="default"> Cesarean Section</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> General anesthesia</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Intradermal skin tests</style></keyword><keyword><style face="normal" font="default"> intradermal test</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Perioperative anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Placenta</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Rocuronium</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum tryptase</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Sugammadex</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">An anaphylactic reaction during a cesarean section occurs rarely, and rocuronium is thought to be one of the common agents causing perioperative anaphylaxis. Here we report an anaphylactic shock after cesarean section that is suggested to be induced by the rocuronium-sugammadex complex. A 36-year-old primigravida underwent an elective cesarean section under general anesthesia due to placenta previa. While the operation was completed uneventfully, she developed anaphylactic shock following sugammadex administration. She was successfully managed with rapid treatments. Serum tryptase level was significantly elevated. Although sugammadex was first suspected to be the causative agent, the result of intradermal skin tests with sugammadex were negative. Surprisingly, a subsequent intradermal test with undiluted rocuronium caused the patient to fall into a state of shock. Furthermore, a later skin-prick test with pre-mixed rocuronium-sugammadex complex also revealed a strong positive reaction, and a test with only rocuronium showed negative. We finally concluded that the rocuronium-sugammadex complex is the causative agent in this case. To the best of our knowledge, this is the first report suggesting anaphylaxis caused by the rocuronium-sugammadex complex. This case highlights the importance of appropriate examinations to determinate the pathogenesis of anaphylaxis in order to establish risk reduction strategies</style></abstract><notes><style face="normal" font="default">DA - 20161117IS - 1438-8359 (Electronic)IS - 0913-8668 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1007/s00540-016-2280-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27853881">PM:27853881</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Anesth\2017-31-148-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Anesth\2017-31-148-51.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161117, Tamaoka M</style></custom2><misc3><style face="normal" font="default">10.1007/s00540-016-2280-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40597</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McDanel,D.</style></author><author><style face="normal" font="default"> Azar,A.</style></author><author><style face="normal" font="default"> Dowden,A.</style></author><author><style face="normal" font="default"> Murray-Bainer,S.</style></author><author><style face="normal" font="default"> Noiseux,N.</style></author><author><style face="normal" font="default"> Willenborg,M.</style></author><author><style face="normal" font="default"> Clark,C.</style></author><author><style face="normal" font="default"> Callaghan,J.</style></author><author><style face="normal" font="default"> Haleem,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Screening for Beta-Lactam Allergy in Joint Arthroplasty Patients to Improve Surgical Prophylaxis Practice</style></title><secondary-title><style face="normal" font="default">J Arthroplasty</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Arthroplasty</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Arthroplasty</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> betalactam allergy</style></keyword><keyword><style face="normal" font="default"> Cefazolin</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> Stewardship</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0883-5403</style></isbn><abstract><style face="normal" font="default">AbstractIntroduction The reliability of patient-reported penicillin allergies has been disputed. A Drug Allergy Clinic (DAC) was established at our institution in combination with an electronic best practice alert (BPA) in the Orthopedic Clinic. Joint arthroplasty patients with a reported history of beta-lactam allergy (HOBA) were preoperatively referred via the BPA to the DAC. The purpose of this study was to determine the effectiveness of beta-lactam allergy screening in enabling the surgical team to optimize antimicrobial prophylaxis. Methods Between February 2013 and May 2015, 161 patients with a HOBA were referred to the DAC where they underwent penicillin skin testing (PST), a drug challenge to a beta-lactam antibiotic, and/or had no intervention depending on the history obtained. Results PST was performed on 140 of 161 (87%) patients. A negative PST was noted in 139 (99%) patients, indicating no penicillin allergy. Cefazolin was safe to use in 145 (90%) patients evaluated. Significantly more patients evaluated in the DAC versus those not seen got cefazolin in any surgical prophylaxis regimen (90% vs 77%) without any adverse peri-operative reactions. Concurrently, the use of non-beta-lactam antibiotics was significantly less in the patients evaluated versus not evaluated (16% vs. 27%). The overall use of cefazolin in orthopedic surgeries in patients with HOBA was &amp;gt;84% over the course of the study period. Conclusions Beta-lactam allergy screening using a BPA and a DAC promotes the use of standard surgical prophylaxis with cefazolin. Joint arthroplasty surgeons should consider implementing allergy screening programs to promote antimicrobial stewardship</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.arth.2017.01.012</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.arth.2017.01.012</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Arthroplasty\20170226-McDanelD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Arthroplasty\20170226-McDanelD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170226, McDanel D</style></custom2><misc3><style face="normal" font="default">10.1016/j.arth.2017.01.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40598</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yang,H.J.</style></author><author><style face="normal" font="default"> Kim,M.J.</style></author><author><style face="normal" font="default"> Kang,S.</style></author><author><style face="normal" font="default"> Moon,N.R.</style></author><author><style face="normal" font="default"> Kim,D.S.</style></author><author><style face="normal" font="default"> Lee,N.R.</style></author><author><style face="normal" font="default"> Kim,K.S.</style></author><author><style face="normal" font="default"> Park,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Strategic Food Industry Research, Korea Food Research Institute; Department of Food Science and Nutrition, Yong In University.</style></auth-address><titles><title><style face="normal" font="default">Topical treatments of Saussurea costus root and Thuja orientalis L. synergistically alleviate atopic dermatitis-like skin lesions by inhibiting protease-activated receptor-2 and NF-kappaB signaling in HaCaT cells and Nc/Nga mice</style></title><secondary-title><style face="normal" font="default">J Ethnopharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Ethnopharmacol</style></abbr-1></periodical><pages end="105" start="97">97-105</pages><volume><style face="normal" font="default">199</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Anti-Inflammatory Agents</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Catechin</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Chlorogenic Acid</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> DNCB</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Food Industry</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Hemorrhage</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgG1</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> topical treatment</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="31" Month="1" Year="2017">2017/1/31</year></dates><abstract><style face="normal" font="default">ETHNOPHARMACOLOGICAL RELEVANCE: The root of Saussurea costus (Aucklandia lappa Decne, Aucklandiae Radix, SC) and Thuja orientalis L. (TOL) have been traditionally used as anti-inflammatory agents in Korea. However, they have not been studied for the efficacy of atopic dermatitis (AD) treatment, a chronic inflammatory skin disease. We investigated the efficacy of topical applications with 1,3-butyleneglycol extracts of SC and TOL to alleviate the symptoms of AD. MATERIALS AND METHODS: HaCaT cells and the dorsal skin of Nc/Nga mice had a local exposure of house mite extracts and 2,4-dinitrochlorobenzene (DNCB), respectively. After lesions developed, we topically applied 1,3-butylen glycol (vehicle; control), SC (30%), TOL (30%), or SC (15%)+TOL (15%) to the skin lesions for 5 weeks. The normal-control was not exposed to DNCB. The skin thickness, mast cell infiltration, serum immunoglobulin E (IgE) and IgG1 and gene expressions of interleukin (IL)-4, IL-13, and IFN-gamma in the dorsal skin and HaCaT cells were measured. RESULTS: Chlorogenic acid (129.6+/-10.2mug/g) for SC and catechin and apigenin (93.4+/-13.2 and 16.9+/-1.3mug/g, respectively) for TOL were used as indicator compounds for the strength of the extracts. SC+TOL decreased the expression of protease-activated receptor-2 and ICAM-1 and the release of TNF-alpha and IL-6 in HaCaT cells activated by 3ug/mL house mite extracts in comparison to either of SC or TOL alone. In Nc/Nga mice challenged with DNCB, SC+TOL synergistically attenuated clinical symptoms of AD such as erythema, hemorrhage, edema, excoriation and dryness in the dorsal skin better than either SC or TOL alone. Histological analysis of the dorsal skin also showed that SC+TOL treatment significantly and additively decreased the inflammatory cellular infiltrate, including mast cells and eosinophils in comparison to either of SC or TOL. SC+TOL also decreased serum IgE and IgG1 levels and the expression of IFN-gamma, IL-4, and IL-13 mRNA in dorsal skin in DNCB-treated Nc/Nga mice. CONCLUSION: SC+TOL relieved the symptoms of AD by reducing pro-inflammatory activity and over-activated immune responses. These data suggest that SC+TOL may be an effective alternative intervention for the management of AD</style></abstract><notes><style face="normal" font="default">DA - 20170204IS - 1872-7573 (Electronic)IS - 0378-8741 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.jep.2017.01.055</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28159725">PM:28159725</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Ethnopharmacol\2017-199-97-105.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Ethnopharmacol\2017-199-97-105.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, Yang HJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jep.2017.01.055</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40599</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kounis,N.G.</style></author><author><style face="normal" font="default"> Koniari,I.</style></author><author><style face="normal" font="default"> Soufras,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Cardiology, University of Patras Medical School, Rion, Patras, Achaia, Greece</style></auth-address><titles><title><style face="normal" font="default">Kounis Syndrome After Intake of Levofloxacin: Increasing Incidence of Hypersensitivity to Fluoroquinolones</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="77" start="76">76-77</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Fluoroquinolones</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Kounis syndrome</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170217IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28211353">PM:28211353</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-76-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-76-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170217, Kounis NG</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40600</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Perez-Alzate,D.</style></author><author><style face="normal" font="default"> Cornejo-Garcia,J.A.</style></author><author><style face="normal" font="default"> Perez-Sanchez,N.</style></author><author><style face="normal" font="default"> Andreu,I.</style></author><author><style face="normal" font="default"> Garcia-Moral,A.</style></author><author><style face="normal" font="default"> Agundez,J.A.</style></author><author><style face="normal" font="default"> Bartra,J.</style></author><author><style face="normal" font="default"> Dona,I.</style></author><author><style face="normal" font="default"> Torres,M.J.</style></author><author><style face="normal" font="default"> Blanca,M.</style></author><author><style face="normal" font="default"> Blanca-Lopez,N.</style></author><author><style face="normal" font="default"> Canto,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Service, Infanta Leonor University Hospital, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Immediate Reactions to More Than 1 NSAID Must Not Be Considered Cross-Hypersensitivity Unless Tolerance to ASA Is Verified</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="39" start="32">32-39</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> COX-1</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous reaction</style></keyword><keyword><style face="normal" font="default"> Cutaneous reactions</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Ibuprofen</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> immediate reactions</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> NSAID</style></keyword><keyword><style face="normal" font="default"> NSAIDs</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> Selectivity</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVES: Individuals who develop drug hypersensitivity reactions (DHRs) to chemically unrelated nonsteroidal anti-inflammatory drugs (NSAIDs) are considered cross-hypersensitive. The hallmark for this classification is that the patient presents a reaction after intake of or challenge with acetylsalicylic acid (ASA). Whether patients react to 2 or more NSAIDs while tolerating ASA remains to be studied (selective reactions, SRs). Objective: To identify patients with SRs to 2 or more NSAIDs including strong COX-1 inhibitors. METHODS: Patients who attended the Allergy Service of Hospital Infanta Leonor, Madrid, Spain with DHRs to NSAIDs between January 2011 and December 2014 were evaluated. Those with 2 or more immediate reactions occurring in less than 1 hour after intake were included. After confirming tolerance to ASA, the selectivity of the response to 2 or more NSAIDs was demonstrated by in vivo and/or in vitro testing or by controlled administration. RESULTS: From a total of 203 patients with immediate DHRs to NSAIDs, 16 (7.9%) met the inclusion criteria. The patients presented a total of 68 anaphylactic or cutaneous reactions (mean [SD], 4.2 [2.1]). Most reactions were to ibuprofen and other arylpropionic acid derivatives and to metamizole. Two different NSAIDs were involved in 11 patients and 3 in 5 patients. CONCLUSIONS: Patients with NSAID-induced anaphylaxis or urticaria/angioedema should not be considered cross-hypersensitive unless tolerance to ASA is verified</style></abstract><notes><style face="normal" font="default">DA - 20170217IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28211343">PM:28211343</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-32-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-32-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170217, Perez-Alzate D</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40601</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martins,C.</style></author><author><style face="normal" font="default"> Lima,J.</style></author><author><style face="normal" font="default"> Nunes,G.</style></author><author><style face="normal" font="default"> Borrego,L.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">CEDOC, Chronic Diseases Research Center, NOVA Medical School|FCM; Universidade Nova de Lisboa, Lisbon, Portugal</style></auth-address><titles><title><style face="normal" font="default">Regulatory T and B Cells in Asthmatic Women: Variations From Pregnancy to Postpartum</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="57" start="46">46-57</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Breg</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Foxp3</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> regulatory T cell</style></keyword><keyword><style face="normal" font="default"> regulatory T cells</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> Tregs</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVE: Allergic asthma and rhinitis are common in pregnancy. The immune mechanisms underlying the effects of asthma on pregnancy and vice versa are not completely understood. The aim of this study was to investigate changes in regulatory T and B cells in asthmatic women from late pregnancy to postpartum. METHODS: Four groups of women were enrolled for this study: asthmatic (n=23) and healthy (n=43) third trimester-pregnant women and asthmatic (n=33) and healthy (n=35) nonpregnant women. Pregnant women were also evaluated postpartum (>6 weeks after delivery). Blood samples were taken from each woman and flow cytometry was used to characterize circulating regulatory T cells (Tregs) and regulatory B cells (Bregs). Foxp3 expression was assessed in CD4DimCD25Hi Tregs. RESULTS: Tregs did not vary significantly from pregnancy to postpartum in asthmatic or healthy women, but CD24HiCD38Hi Bregs decreased in pregnancy and increased significantly postpartum. Foxp3 expression in Tregs was also impaired during pregnancy in both asthmatic and healthy women, but recovered postpartum. Asthmatic pregnant women had higher Foxp3 expression levels than healthy pregnant women (P=.007), probably due to the use of control medication. CONCLUSIONS: Women with controlled asthma showed variations in regulatory cell subsets during pregnancy and postpartum. A similar pattern was observed for Foxp3 expression and CD24HiCD38Hi Bregs during this period, corroborating the interaction between Tregs and Bregs in immune responses. Considering the immunomodulatory potential of these immune mediators, more studies are needed to evaluate their relationship with asthma and rhinitis complications in pregnancy</style></abstract><notes><style face="normal" font="default">DA - 20170217IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28211345">PM:28211345</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-46-57.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-46-57.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170217, Martins C</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40602</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Diaz Palacios,M.A.</style></author><author><style face="normal" font="default"> Lopez-Salgueiro,R.</style></author><author><style face="normal" font="default"> Mencia,S.G.</style></author><author><style face="normal" font="default"> Martinez,R.A.</style></author><author><style face="normal" font="default"> Morales-Rubio,A.</style></author><author><style face="normal" font="default"> Hernandez Fernandez de Rojas,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy, IIS Hospital La Fe, Valencia, Spain</style></auth-address><titles><title><style face="normal" font="default">Chronic Urticaria After Implantation of a Mitral Annuloplasty Ring in a Nickel-Allergic Patient</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="75" start="74">74-75</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170217IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28211352">PM:28211352</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-58-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-58-75.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170217, Diaz Palacios MA</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40603</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,X.</style></author><author><style face="normal" font="default"> Zhao,Y.</style></author><author><style face="normal" font="default"> Zheng,Y.</style></author><author><style face="normal" font="default"> Dong,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Nursing department, Peking Union Medical College Hospital, Beijing, P. R. China</style></auth-address><titles><title><style face="normal" font="default">The Effects of Prolonged Infusion on Reducing Oxaliplatin Hypersensitivity Reactions</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="66" start="65">65-66</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">China</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Nursing</style></keyword><keyword><style face="normal" font="default"> Oxaliplatin</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170217IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28211349">PM:28211349</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-58-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-58-75.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170217, Zhang X</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40604</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oda,T.</style></author><author><style face="normal" font="default"> Sawada,Y.</style></author><author><style face="normal" font="default"> Yamaguchi,T.</style></author><author><style face="normal" font="default"> Ohmori,S.</style></author><author><style face="normal" font="default"> Omoto,D.</style></author><author><style face="normal" font="default"> Haruyama,S.</style></author><author><style face="normal" font="default"> Yoshioka,M.</style></author><author><style face="normal" font="default"> Okada,E.</style></author><author><style face="normal" font="default"> Nakamura,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan</style></auth-address><titles><title><style face="normal" font="default">Psoriatic Erythroderma Caused by Terbinafine: A Possible Pathogenetic Role for IL-23</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="64" start="63">63-64</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Dermatology</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> IL-23</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170217IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28211348">PM:28211348</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-58-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-58-75.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170217, Oda T</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40605</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Quirce,S.</style></author><author><style face="normal" font="default"> Delgado,J.</style></author><author><style face="normal" font="default"> Entrenas,L.M.</style></author><author><style face="normal" font="default"> Grande,M.</style></author><author><style face="normal" font="default"> Llorente,C.</style></author><author><style face="normal" font="default"> Lopez,V.A.</style></author><author><style face="normal" font="default"> Martinez,M.E.</style></author><author><style face="normal" font="default"> Mascaros,E.</style></author><author><style face="normal" font="default"> Molina,J.</style></author><author><style face="normal" font="default"> Olaguibel,J.M.</style></author><author><style face="normal" font="default"> Perez de Llano,L.A.</style></author><author><style face="normal" font="default"> Perpina,T.M.</style></author><author><style face="normal" font="default"> Quintano,J.A.</style></author><author><style face="normal" font="default"> Rodriguez,M.</style></author><author><style face="normal" font="default"> Roman-Rodriguez,M.</style></author><author><style face="normal" font="default"> Sastre,J.</style></author><author><style face="normal" font="default"> Trigueros,J.A.</style></author><author><style face="normal" font="default"> Valero,A.L.</style></author><author><style face="normal" font="default"> Zoni,A.C.</style></author><author><style face="normal" font="default"> Plaza,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Servicio de Alergologia, Instituto de Investigacion Hospital Universitario La Paz (IdiPAZ), Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Quality Indicators of Asthma Care Derived From the Spanish Guidelines for Asthma Management (GEMA 4.0): A Multidisciplinary Team Report</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="73" start="69">69-73</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Multidisciplinary team</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170217IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28211351">PM:28211351</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-58-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-58-75.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170217, Quirce S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40606</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shiraki,Y.</style></author><author><style face="normal" font="default"> Shoji,J.</style></author><author><style face="normal" font="default"> Inada,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">Clinical Usefulness of Monitoring Expression Levels of CCL24 (Eotaxin-2) mRNA on the Ocular Surface in Patients with Vernal Keratoconjunctivitis and Atopic Keratoconjunctivitis</style></title><secondary-title><style face="normal" font="default">J Ophthalmol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Ophthalmol</style></abbr-1></periodical><pages end="" start="3573142">3573142-</pages><volume><style face="normal" font="default">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AKC</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Conjunctiva</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cytology</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Keratoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Ocular</style></keyword><keyword><style face="normal" font="default"> Ophthalmology</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vernal keratoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> VKC</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Purpose. This study aimed to evaluate the clinical efficacy of using expression levels of CCL24 (eotaxin-2) mRNA on the ocular surface as a biomarker in patients with vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC). Methods. Eighteen patients with VKC or AKC (VKC/AKC group) and 12 control subjects (control group) were enrolled in this study. The VKC/AKC clinical score was determined by objective findings in patients by using the 5-5-5 exacerbation grading scale. All subjects underwent modified impression cytology and specimens were obtained from the upper tarsal conjunctiva. Expression levels of CCL24 (eotaxin-2) mRNA on the ocular surface were determined using real-time reverse transcription polymerase chain reaction. Results. The VKC group was divided into two subgroups, depending on the clinical score: the active stage subgroup with 100 points or more of clinical scores and the stable stage subgroup with 100 points or less. CCL24 (eotaxin-2) mRNA expression levels in the active VKC/AKC stage subgroup were significantly higher than those in the stable VKC/AKC subgroup and the control group. Clinical scores correlated significantly with CCL24 (eotaxin-2) mRNA expression levels in the VKC group. Conclusions. CCL24 (eotaxin-2) mRNA expression levels on the ocular surface are a useful biomarker for clinical severity of VKC/AKC</style></abstract><notes><style face="normal" font="default">DA - 20161010IS - 2090-004X (Print)IS - 2090-004X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="default">10.1155/2016/3573142</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27721987">PM:27721987</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Ophthalmol\2016-2016-3573142.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Ophthalmol\2016-2016-3573142.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161010, Shiraki Y</style></custom2><misc3><style face="normal" font="default">10.1155/2016/3573142</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40607</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brittan,M.</style></author><author><style face="normal" font="default"> Richardson,T.</style></author><author><style face="normal" font="default"> Kenyon,C.</style></author><author><style face="normal" font="default"> Sills,M.</style></author><author><style face="normal" font="default"> Fieldston,E.</style></author><author><style face="normal" font="default"> Hall,M.</style></author><author><style face="normal" font="default"> Fox,D.</style></author><author><style face="normal" font="default"> Shah,S.</style></author><author><style face="normal" font="default"> Berry,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, CO.</style></auth-address><titles><title><style face="normal" font="default">Association between Postdischarge Oral Corticosteroid Prescription Fills and Readmission in Children with Asthma</style></title><secondary-title><style face="normal" font="default">J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Pediatr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Services</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medicaid</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="18" Month="10" Year="2016">2016/10/18</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To assess the relationships between postdischarge emergency department visits, oral corticosteroid (OCS) use, and 15- to 90-day asthma readmission in children. STUDY DESIGN: Retrospective study of 9288 children from 12 states in the Truven MarketScan Database, ages 2-18 years, hospitalized between January 1, 2009, and June 30, 2011, with asthma, and continuously enrolled in Medicaid for 6 months prior and 3 months after hospitalization. The primary outcome was 15- to 90-day readmission for asthma. Secondary outcomes were postdischarge emergency department visits (within 28 days) and outpatient OCS prescription fills (6-28 days postdischarge or earlier if coinciding with an outpatient asthma visit). Logistic regression was used to assess the relationship of hospital readmission with patient characteristics and asthma health services surrounding the index admission. RESULTS: Median age at index admission was 6 years (IQR, 3-9); 62% were male and 49% were black; 2.8% had a 15- to 90-day readmission (median, 50 days; IQR, 32-70). After index discharge, 4% had an emergency department visit (median, 17 days; IQR, 12-24) and 11% had an outpatient OCS fill (median, 14 days; IQR, 6-21). In multivariable analysis, children with a postdischarge outpatient OCS fill (OR, 3.2; 95% CI, 2.4-4.6) or hospitalization within 6 months preceding the index admission (OR, 2.9; 95% CI, 2.0-4.0) had the greatest likelihood for hospital readmission. CONCLUSIONS: OCS fill within 28 days of hospital discharge was most strongly associated with 15- to 90-day hospital readmission. This finding may inform evolving strategies to reduce asthma readmissions in children</style></abstract><notes><style face="normal" font="default">DA - 20161022IS - 1097-6833 (Electronic)IS - 0022-3476 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jpeds.2016.09.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27769549">PM:27769549</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Pediatr\20161022-BrittanM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Pediatr\20161022-BrittanM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161022, Brittan M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jpeds.2016.09.034</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40608</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chauhan,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Manitoba Winnipeg, Canada</style></auth-address><titles><title><style face="normal" font="default">Long-acting beta agonists do not increase serious asthma-related event risk</style></title><secondary-title><style face="normal" font="default">J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Pediatr</style></full-title></periodical><pages end="294" start="291">291-294</pages><volume><style face="normal" font="default">180</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">agonists</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> long acting beta agonists</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161224IS - 1097-6833 (Electronic)IS - 0022-3476 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jpeds.2016.10.057</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28010799">PM:28010799</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Pediatr\2017-180-291-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Pediatr\2017-180-291-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161224, Chauhan B</style></custom2><misc3><style face="normal" font="default">10.1016/j.jpeds.2016.10.057</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40609</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chae,W.J.</style></author><author><style face="normal" font="default"> Bothwell,A.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USADepartment of Immunobiology, Yale University School of Medicine, New Haven, CT, USA</style></auth-address><titles><title><style face="normal" font="default">Snapshots of CD4+ T cell plasticity in the pathogenesis of allergic asthma</style></title><secondary-title><style face="normal" font="default">J Thorac Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Thorac Dis</style></abbr-1></periodical><pages end="E1012" start="E1010">E1010-E1012</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161017IS - 2072-1439 (Print)IS - 2072-1439 (Linking)LA - ENGPT - JOURNAL ARTICLEPT - CommentCO - United States -</style></notes><work-type><style face="normal" font="default">10.21037/jtd.2016.08.19</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27747048">PM:27747048</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Thorac Dis\2016-8-E1010-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Thorac Dis\2016-8-E1010-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161017, Chae WJ</style></custom2><misc3><style face="normal" font="default">10.21037/jtd.2016.08.19</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40610</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Qu,J.</style></author><author><style face="normal" font="default"> Li,Y.</style></author><author><style face="normal" font="default"> Zhong,W.</style></author><author><style face="normal" font="default"> Gao,P.</style></author><author><style face="normal" font="default"> Hu,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China</style></auth-address><titles><title><style face="normal" font="default">Recent developments in the role of reactive oxygen species in allergic asthma</style></title><secondary-title><style face="normal" font="default">J Thorac Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Thorac Dis</style></abbr-1></periodical><pages end="E43" start="E32">E32-E43</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal model</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Oxygen</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pollutants</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> ROS</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">Allergic asthma has a global prevalence, morbidity, and mortality. Many environmental factors, such as pollutants and allergens, are highly relevant to allergic asthma. The most important pathological symptom of allergic asthma is airway inflammation. Accordingly, the unique role of reactive oxygen species (ROS) had been identified as a main reason for this respiratory inflammation. Many studies have shown that inhalation of different allergens can promote ROS generation. Recent studies have demonstrated that several pro-inflammatory mediators are responsible for the development of allergic asthma. Among these mediators, endogenous or exogenous ROS are responsible for the airway inflammation of allergic asthma. Furthermore, several inflammatory cells induce ROS and allergic asthma development. Airway inflammation, airway hyper-responsiveness, tissue injury, and remodeling can be induced by excessive ROS production in animal models. Based on investigations of allergic asthma and ROS formation mechanisms, we have identified several novel anti-inflammatory therapeutic treatments. This review describes the recent data linking ROS to the pathogenesis of allergic asthma</style></abstract><notes><style face="normal" font="default">DA - 20170216IS - 2072-1439 (Print)IS - 2072-1439 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - China -</style></notes><work-type><style face="normal" font="default">10.21037/jtd.2017.01.05</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28203435">PM:28203435</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Thorac Dis\2017-9-E32-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Thorac Dis\2017-9-E32-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170216, Qu J</style></custom2><misc3><style face="normal" font="default">10.21037/jtd.2017.01.05</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40611</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kallvik,E.</style></author><author><style face="normal" font="default"> Savolainen,J.</style></author><author><style face="normal" font="default"> Simberg,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Logopedics, Faculty of Arts, Psychology and Theology, Abo Akademi University, Abo, Finland.</style></auth-address><titles><title><style face="normal" font="default">Vocal Symptoms and Voice Quality in Children With Allergy and Asthma</style></title><secondary-title><style face="normal" font="default">J Voice</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Voice</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> Inhalant</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Norway</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> psychology</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Throat clearing</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Voice Quality</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The background for dysphonia is multifactorial, and health-related factors have been listed among the factors affecting voice. In previous studies with adult participants, allergy and asthma have been indicated to have a connection to vocal symptoms. With the majority of previous research being studies involving adult participants, it is unclear what the effect of allergy and asthma on children's voices is. The aim of this study was to investigate if allergies and asthma are risk factors for having vocal symptoms. METHODS: The material was collected through paper questionnaires distributed to the parents of new pediatric patients at an allergy clinic. The participants were 108 children aged 9 months to 17 years and 1 month. RESULTS: Of the children whose parents had filled in the questions on vocal symptoms, 18.2% (n = 18) had frequently occurring vocal symptoms, which was defined as having two or more vocal symptoms every week or more often. The most common vocal symptoms were throat clearing and coughing. There was a significant connection between inhalant allergy and having frequently occurring vocal symptoms. The connection between cough that lasted for more than 4 weeks and having frequently occurring vocal symptoms was also significant. In this study, we found no significant connection between having an asthma diagnosis and having frequently occurring vocal symptoms. CONCLUSIONS: Based on the results of this study, voice screening for children with inhalant allergy would be advisable. Prolonged cough should be taken seriously and be treated, as the mechanical trauma caused by cough seems to have a connection to vocal symptoms</style></abstract><notes><style face="normal" font="default">DA - 20170121IS - 1873-4588 (Electronic)IS - 0892-1997 (Linking)LA - engPT - Journal ArticleCO - Finland -CO - Norway -</style></notes><work-type><style face="normal" font="default">10.1016/j.jvoice.2016.12.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28108152">PM:28108152</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Voice\20170121-KallvikE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Voice\20170121-KallvikE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170121, Kallvik E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jvoice.2016.12.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40612</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rosen,A.</style></author><author><style face="normal" font="default"> Ngshanyi,S.</style></author><author><style face="normal" font="default"> Tosti,A.</style></author><author><style face="normal" font="default"> Schachner,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida</style></auth-address><titles><title><style face="normal" font="default">Allergic contact cheilitis in children and improvement with patch testing</style></title><secondary-title><style face="normal" font="default">JAAD Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JAAD Case Rep</style></abbr-1></periodical><pages end="28" start="25">25-28</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> Cheilitis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Florida</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170104IS - 2352-5126 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jdcr.2016.10.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28050593">PM:28050593</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JAAD Case Rep\2017-3-25-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JAAD Case Rep\2017-3-25-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170104, Rosen A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jdcr.2016.10.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40613</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhai,L.</style></author><author><style face="normal" font="default"> Guo,X.</style></author><author><style face="normal" font="default"> Zhang,H.</style></author><author><style face="normal" font="default"> Jin,Q.</style></author><author><style face="normal" font="default"> Zeng,Q.</style></author><author><style face="normal" font="default"> Tang,X.</style></author><author><style face="normal" font="default"> Gao,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pathology, School of Forensic Medicine, Shanxi Medical University, Taiyuan 030001, China</style></auth-address><titles><title><style face="normal" font="default">Non-ionic iodinated contrast media related immediate reactions: A mechanism study of 27 patients</style></title><secondary-title><style face="normal" font="default">Leg Med (Tokyo)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Leg Med (Tokyo)</style></full-title></periodical><pages end="62" start="56">56-62</pages><volume><style face="normal" font="default">24</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> activation</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chymase</style></keyword><keyword><style face="normal" font="default"> Complement</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Forensic Medicine</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE-dependent</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity</style></keyword><keyword><style face="normal" font="default"> immediate reactions</style></keyword><keyword><style face="normal" font="default"> iodinated contrast media</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Prostaglandin</style></keyword><keyword><style face="normal" font="default"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">The underlying mechanism of non-ionic iodinated contrast media-related immediate reactions was evaluated in this study. Patients presenting at least grade II immediate reactions after non-ionic iodinated contrast media injection were enrolled. Basophil activation was evaluated by flow cytometry. The plasma concentration of human terminal complement complex SC5b-9, as well as concentrations of serum chymase, tryptase, human mast cell carboxypeptidase A3, human prostaglandin D2, and total IgE were measured by enzyme-linked immunosorbent assay. The basophil activation percentage was significantly higher in the study group than in the control group (17.94+/-21.06% vs 3.45+/-1.49%). The plasma concentration of human terminal complement complex SC5b-9 and concentrations of serum chymase, human mast cell carboxypeptidase A3, prostaglandin D2, tryptase, and total IgE were also significantly increased (236.99+/-318.21 vs 49.70+/-30.41ng/mL, 0.41+/-0.49 vs 0.09+/-0.06ng/mL, 1.17+/-0.67 vs 0.30+/-0.17ng/mL, 203.52+/-137.27 vs 102.28+/-48.72pg/mL, 3.81+/-0.22 vs 2.70+/-0.16ng/mL, 102.00+/-51.84 vs 19.97+/-2.75ng/mL, respectively). Both mast cells and basophils were activated in non-ionic iodinated contrast media to mediate immediate hypersensitivity, and mast cells may be involved. Different mechanisms, including IgE-dependent, complement-dependent, and direct membrane effects, contributed to mast cell and basophil activation. Individual patients may use a single or combined mechanism involving single or combined mast cells and basophils. Immediate reactions following non-ionic iodinated contrast media injection may be a mechanically heterogenous disease</style></abstract><notes><style face="normal" font="default">DA - 20170113IS - 1873-4162 (Electronic)IS - 1344-6223 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.legalmed.2016.11.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28081790">PM:28081790</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Leg Med (Tokyo)\2017-24-56-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Leg Med (Tokyo)\2017-24-56-62.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170113, Zhai L</style></custom2><misc3><style face="normal" font="default">10.1016/j.legalmed.2016.11.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40614</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Andersen,H.H.</style></author><author><style face="normal" font="default"> Elberling,J.</style></author><author><style face="normal" font="default"> Arendt-Nielsen,L.</style></author></authors></contributors><titles><title><style face="normal" font="default">High-concentration topical capsaicin may abolish the clinical manifestations of allergic contact dermatitis by effects on induction and elicitation</style></title><secondary-title><style face="normal" font="default">Med Hypotheses</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Med Hypotheses</style></abbr-1></periodical><pages end="56" start="53">53-56</pages><volume><style face="normal" font="default">99</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergen exposure</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Capsaicin</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Indications</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Nerve Fibers</style></keyword><keyword><style face="normal" font="default"> Neuropeptides</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Substance P</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Type IV hypersensitivity</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><isbn><style face="normal" font="default">0306-9877</style></isbn><abstract><style face="normal" font="default">Abstract Allergic contact dermatitis (ACD) is a common skin condition caused by a type-IV hypersensitivity reaction. Even though ACD is considered as a T-cell mediated disease, indications exists that peptidergic nerve fibers at the site of allergen exposure and associated with the draining lymph node play a prominent role in both induction and elicitation of ACD. This neuro-immune cross talk seems rely on neuropeptides such as Substance P secreted by nerve fiber terminals. It is hypothesized that local complete or partial cutaneous denervation/defunctionalization of peptidergic fibers in humans could be a feasible approach towards treating allergic contact dermatitis. Recently, human experimental protocols for prominent, temporary defunctionalization of peptidergic fibers have been published relying on prolonged application of 8% topical capsaicin patches. Combined with human experimental ACD models the importance of peptidergic nerve fibers in the induction and elicitation phases of ACD could be accurately established. Understanding the role of cutaneous peptidergic fibers in the pathogenesis and potentially of ACD and how contact sensitization can be modulated by topical defunctionalization of these fibers could lead to new approaches to treatment for ACD. In patients with localized ACD occurring to an allergen that is difficult or unfeasible to evade this would have particular relevance</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1016/j.mehy.2016.12.012</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.mehy.2016.12.012</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Med Hypotheses\2017-99-53-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Med Hypotheses\2017-99-53-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170225, Andersen HH</style></custom2><misc3><style face="normal" font="default">10.1016/j.mehy.2016.12.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40615</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ben Ghezala,H.</style></author><author><style face="normal" font="default"> Kouraichi,N.</style></author><author><style face="normal" font="default"> Brahmi,N.</style></author><author><style face="normal" font="default"> Bouguerba,A.</style></author><author><style face="normal" font="default"> Thabet,H.</style></author><author><style face="normal" font="default"> Amamou,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Anaphylaxie en réanimation médicale : expérience d'un centre de référence tunisien</style></title><secondary-title><style face="normal" font="default">Med Intens Reanim</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Med Intens Reanim</style></full-title></periodical><pages end="234" start="228">228-234</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Accidents</style></keyword><keyword><style face="normal" font="default"> Anaphylaxie</style></keyword><keyword><style face="normal" font="default"> Tunisia</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><isbn><style face="normal" font="default">1951-6959</style></isbn><abstract><style face="normal" font="default">L'anaphylaxie est la manifestation la plus grave des réactions d'hypersensibilité immédiate. L'absence de données épidémiologiques en Tunisie nous a incités à mener ce travail. L'objectif principal était de dresser le profil épidémioclinique des accidents anaphylactiques admis dans un centre de référence tunisien.</style></abstract><notes><style face="normal" font="default">LA - FRECO - Tunisia -</style></notes><work-type><style face="normal" font="default">10.1007/s13546-016-1221-4</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s13546-016-1221-4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Med Intens Reanim\2016-25-228-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Med Intens Reanim\2016-25-228-34.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170224, Ben Ghezala H</style></custom2><misc3><style face="normal" font="default">10.1007/s13546-016-1221-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40616</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lyapina,M.G.</style></author><author><style face="normal" font="default"> Dencheva,M.</style></author><author><style face="normal" font="default"> Krasteva-Panova,A.</style></author><author><style face="normal" font="default"> Tzekova-Yaneva,M.</style></author><author><style face="normal" font="default"> Deliverska,M.</style></author><author><style face="normal" font="default"> Kisselova-Yaneva,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical University, Sofia, Bulgaria</style></auth-address><titles><title><style face="normal" font="default">Concomitant sensitization to glutaraldehyde and methacrylic monomers among dentists and their patients</style></title><secondary-title><style face="normal" font="default">Med Pr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Med Pr</style></full-title></periodical><pages end="320" start="311">311-320</pages><volume><style face="normal" font="default">67</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Aldehydes</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Bulgaria</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dental Materials</style></keyword><keyword><style face="normal" font="default"> dentist</style></keyword><keyword><style face="normal" font="default"> Dentistry</style></keyword><keyword><style face="normal" font="default"> Dentists</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Occupational</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Faculty,Dental</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Glutaral</style></keyword><keyword><style face="normal" font="default"> Glutaraldehyde</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Methacrylate</style></keyword><keyword><style face="normal" font="default"> Methacrylates</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Methyl methacrylate</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Students</style></keyword><keyword><style face="normal" font="default"> Students,Dental</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">BACKGROUND: A multitude of methacrylic monomers is used in dentistry. Glutaraldehyde (G) is used in dental practice and consumer products as a broad-spectrum antimicrobial agent. The purpose of our study is to evaluate the frequency and the risk of concomitant sensitization to some methacrylic monomers (methyl methacrylate (MMA), triethyleneglycol dimethacrylate (TEGDMA), ethyleneglycol dimethacrylate (EGDMA), 2,2-bis-[4-(2-hydroxy-3-methacrylo-xypropoxy)phenyl]-propane (Bis-GMA), 2-hydroxy-ethyl methacrylate (2-HEMA) and tetrahydrofurfuryl methacrylate (THFMA)) and glutaraldehyde in students of dentistry, students from the dental technician school, dental professionals and dental patients. MATERIAL AND METHODS: A total of 262 participants were included in the study: students of dentistry, students from the dental technician school, dental professionals, and dental patients as a control group. All were patch-tested with methacrylic monomers and glutaraldehyde. The results were subject to the statistical analysis (p &lt; 0.05). RESULTS: Among the group of dental students, the highest frequency of concomitant sensitization was to TEGDMA and G (15.5%). In the group of patients the highest frequency of concomitant sensitization was to EGDMA and G (16.4%). The frequency of concomitant sensitization among dental professionals was much lower, with the highest rate to TEGDMA and G (7.7%), too. We consider the students from the dental technician school, where the exposure to glutaraldehyde is less likely, to be the group at a lesser risk of concomitant sensitization. CONCLUSIONS: Dental students and dental patients could be outlined as groups at the risk of concomitant sensitization to glutaraldehyde and methacrylic monomers. For dental professionals, we assumed an increased risk for concomitant sensitization to TEGDMA and aldehydes that are commonly used in dentistry. We consider the students from the dental technician school to be the group at a lesser risk of concomitant sensitization to glutaraldehyde and methacrylic monomers. Med Pr 2016;67(3):311-320</style></abstract><notes><style face="normal" font="default">DA - 20160701IS - 0465-5893 (Print)IS - 0465-5893 (Linking)LA - engPT - Journal ArticleRN - 0 (Dental Materials)RN - 0 (Methacrylates)RN - T3C89M417N (Glutaral)SB - IMCO - Bulgaria -</style></notes><work-type><style face="normal" font="default">10.13075/mp.5893.00106</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27364105">PM:27364105</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Med Pr\2016-67-311-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Med Pr\2016-67-311-20.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160701, Lyapina MG</style></custom2><misc3><style face="normal" font="default">10.13075/mp.5893.00106</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40617</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,M.J.</style></author><author><style face="normal" font="default"> Lee,H.S.</style></author><author><style face="normal" font="default"> Sol,I.S.</style></author><author><style face="normal" font="default"> Kim,M.N.</style></author><author><style face="normal" font="default"> Hong,J.Y.</style></author><author><style face="normal" font="default"> Lee,K.E.</style></author><author><style face="normal" font="default"> Kim,Y.H.</style></author><author><style face="normal" font="default"> Kim,K.W.</style></author><author><style face="normal" font="default"> Sohn,M.H.</style></author><author><style face="normal" font="default"> Kim,K.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Severance Hospital, Institute of Allergy, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Sputum pentraxin 3 as a candidate to assess airway inflammation and remodeling in childhood asthma</style></title><secondary-title><style face="normal" font="default">Medicine (Baltimore)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Medicine (Baltimore)</style></abbr-1></periodical><pages end="" start="e5677">e5677-</pages><volume><style face="normal" font="default">95</style></volume><number><style face="normal" font="default">51</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">airflow</style></keyword><keyword><style face="normal" font="default"> Airflow limitation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Airway Obstruction</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> cationic protein</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Challenge test</style></keyword><keyword><style face="normal" font="default"> Challenge tests</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> ECP</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> Methacholine challenge</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Persistent airflow limitation</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">Pentraxin 3 (PTX3) is a soluble pattern recognition receptor and an acute-phase protein. It has gained attention as a new biomarker reflecting tissue inflammation and damage in a variety of diseases. Aim of this study is to investigate the role of PTX3 in childhood asthma.In total, 260 children (140 patients with asthma and 120 controls) were enrolled. PTX3 levels were measured in sputum supernatants using enzyme-linked immunosorbent assay test. We performed spirometry and methacholine challenge tests and measured the total eosinophil count and the serum levels of total IgE and eosinophil cationic protein (ECP) in all subjects.Sputum PTX3 concentration was significantly higher in children with asthma than in control subjects (P &lt; 0.001). Furthermore, sputum PTX3 levels correlated with atopic status and disease severity among patients with asthma. A positive significant correlation was found between sputum PTX3 and the bronchodilator response (r = 0.25, P = 0.013). Sputum PTX3 levels were negatively correlated with forced expiratory volume in 1 second (FEV1) (r = -0.30, P = 0.001), FEV1/forced vital capacity (FVC) (r = -0.27, P = 0.002), and FEF25-75 (r = -0.392, P &lt; 0.001), which are indicators of airway obstruction and inflammation. In addition, the PTX3 concentration in sputum showed negative correlations with post-bronchodilator (BD) FEV1 (r = -0.25, P &lt; 0.001) and post-BD FEV1/FVC (r = -0.25, P &lt; 0.001), which are parameters of persistent airflow limitation reflecting airway remodeling.Sputum PTX3 levels increased in children with asthma, suggesting that PTX3 in sputum could be a candidate molecule to evaluate airway inflammation and remodeling in childhood asthma</style></abstract><notes><style face="normal" font="default">DA - 20161221IS - 1536-5964 (Electronic)IS - 0025-7974 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1097/MD.0000000000005677</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28002338">PM:28002338</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Medicine (Baltimore)\2016-95-e5677.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Medicine (Baltimore)\2016-95-e5677.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161221, Kim MJ</style></custom2><misc3><style face="normal" font="default">10.1097/MD.0000000000005677</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40618</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shi,Z.</style></author><author><style face="normal" font="default"> Jiang,W.</style></author><author><style face="normal" font="default"> Wang,M.</style></author><author><style face="normal" font="default"> Wang,X.</style></author><author><style face="normal" font="default"> Li,X.</style></author><author><style face="normal" font="default"> Chen,X.</style></author><author><style face="normal" font="default"> Qiao,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology Head and Neck Surgery, Xijing Hospital, Fourth Military Medical University, No. 127, Changle West Road, Xi'an, 710032, Shaanxi, People's Republic of China</style></auth-address><titles><title><style face="normal" font="default">Inhibition of JAK/STAT pathway restrains TSLP-activated dendritic cells mediated inflammatory T helper type 2 cell response in allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Mol Cell Biochem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Mol Cell Biochem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Cell Proliferation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> DC</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Otolaryngology</style></keyword><keyword><style face="normal" font="default"> OX40 ligand</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> STAT1</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> Th2 Cells</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Western blot</style></keyword></keywords><dates><year Day="18" Month="2" Year="2017">2017/2/18</year></dates><abstract><style face="normal" font="default">Thymic stromal lymphopoietin (TSLP) has recently been implicated as a key molecule for initiating allergic rhinitis (AR) at the cell-dendritic cell (DC) interface. Previous studies demonstrated that TSLP activated DCs to express more OX40 ligand (OX40L), which is associated with the initiation of T helper type 2 (Th2) cell responses. STAT phosphorylation has been reported to be promoted by TSLP. Thus, we investigated if the JAK/STAT pathway inhibitor CYT387 could affect TSLP-DC-mediated Th2 cell response in naive T cell and AR mice model. Western blot showed that the levels of phosphorylated JAK1, JAK2, STAT1, STAT3, and STAT5 were increased in TSLP-DCs, which can be offset by CYT387. Flow cytometry indicated that CYT387 had obviously down-regulated the surface maturation co-stimulatory molecules (CD11c, CD80, CD86, and MHCII) in DCs, which were increased by TSLP. Moreover, CYT387 markedly reduced the ability of TSLP-DCs to promote the differentiation of naive CD4+ T cells into IL-4-expressing Th2 cells. The histological examination showed that the CYT387-treated group showed less epithelial disruption, epithelial cell proliferation, and reduced eosinophil infiltration compared with AR group. Western blot and RT-PCR demonstrated that the expression of OX40L was increased in AR mice, but that it was decreased by CYT387. Furthermore, CYT387 treatment resulted in the reduction of IL-4 and IL-5 expression and increased IFN-gamma level in AR mice, which was consistent with the levels of intracellular cytokine in Th2 cell. In conclusion, we suggest that blockading the JAK/STAT pathway restrains inflammatory Th2 cell response induced by TSLP-DCs in AR</style></abstract><notes><style face="normal" font="default">DA - 20170219IS - 1573-4919 (Electronic)IS - 0300-8177 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1007/s11010-017-2963-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28214951">PM:28214951</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mol Cell Biochem\20170219-ShiZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mol Cell Biochem\20170219-ShiZ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170219, Shi Z</style></custom2><misc3><style face="normal" font="default">10.1007/s11010-017-2963-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40619</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pinkerton,J.W.</style></author><author><style face="normal" font="default"> Kim,R.Y.</style></author><author><style face="normal" font="default"> Robertson,A.A.</style></author><author><style face="normal" font="default"> Hirota,J.A.</style></author><author><style face="normal" font="default"> Wood,L.G.</style></author><author><style face="normal" font="default"> Knight,D.A.</style></author><author><style face="normal" font="default"> Cooper,M.A.</style></author><author><style face="normal" font="default"> O'Neill,L.A.</style></author><author><style face="normal" font="default"> Horvat,J.C.</style></author><author><style face="normal" font="default"> Hansbro,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute and The University of Newcastle, Newcastle, New South Wales, Australia</style></auth-address><titles><title><style face="normal" font="default">Inflammasomes in the lung</style></title><secondary-title><style face="normal" font="default">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Mol Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammasome</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> innate immune system</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Ireland</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Lung Diseases</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> New South Wales</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> particulates</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Respiratory diseases</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Wales</style></keyword></keywords><dates><year Day="24" Month="1" Year="2017">2017/1/24</year></dates><abstract><style face="normal" font="default">Innate immune responses act as first line defences upon exposure to potentially noxious stimuli. The innate immune system has evolved numerous intracellular and extracellular receptors that undertake surveillance for potentially damaging particulates. Inflammasomes are intracellular innate immune multiprotein complexes that form and are activated following interaction with these stimuli. Inflammasome activation leads to the cleavage of pro-IL-1beta and release of the pro-inflammatory cytokine, IL-1beta, which initiates acute phase pro-inflammatory responses, and other responses are also involved (IL-18, pyroptosis). However, excessive activation of inflammasomes can result in chronic inflammation, which has been implicated in a range of chronic inflammatory diseases. The airways are constantly exposed to a wide variety of stimuli. Inflammasome activation and downstream responses clears these stimuli. However, excessive activation may drive the pathogenesis of chronic respiratory diseases such as severe asthma and chronic obstructive pulmonary disease. Thus, there is currently intense interest in the role of inflammasomes in chronic inflammatory lung diseases and in their potential for therapeutic targeting. Here we review the known associations between inflammasome-mediated responses and the development and exacerbation of chronic lung diseases</style></abstract><notes><style face="normal" font="default">DA - 20170128IS - 1872-9142 (Electronic)IS - 0161-5890 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - Ireland -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.molimm.2017.01.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28129896">PM:28129896</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mol Immunol\20170128-PinkertonJW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mol Immunol\20170128-PinkertonJW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170128, Pinkerton JW</style></custom2><misc3><style face="normal" font="default">10.1016/j.molimm.2017.01.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40620</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yoo,J.M.</style></author><author><style face="normal" font="default"> Yang,J.H.</style></author><author><style face="normal" font="default"> Kim,Y.S.</style></author><author><style face="normal" font="default"> Yang,H.J.</style></author><author><style face="normal" font="default"> Cho,W.K.</style></author><author><style face="normal" font="default"> Ma,J.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Korean Medicine (KM)-Application Center, Korea Institute of Oriental Medicine (KIOM), 70 Cheomdan-ro, Dong-gu, Daegu 41062, Korea.</style></auth-address><titles><title><style face="normal" font="default">Inhibitory Effects of Viscum coloratum Extract on IgE/Antigen-Activated Mast Cells and Mast Cell-Derived Inflammatory Mediator-Activated Chondrocytes</style></title><secondary-title><style face="normal" font="default">Molecules</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Molecules</style></abbr-1></periodical><pages end="" start="E37">E37-</pages><volume><style face="normal" font="default">22</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Ethanol</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Herbal</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory mediators</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Osteoarthritis</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rodent</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="12" Year="2016">2016/12/28</year></dates><abstract><style face="normal" font="default">The accumulation and infiltration of mast cells are found in osteoarthritic lesions in humans and rodents. Nonetheless, the roles of mast cells in osteoarthritis are almost unknown. Although Viscum coloratum has various beneficial actions, its effect on allergic and osteoarthritic responses is unknown. In this study, we established an in vitro model of mast cell-mediated osteoarthritis and investigated the effect of the ethanol extract of Viscum coloratum (VEE) on IgE/antigen (IgE/Ag)-activated mast cells and mast cell-derived inflammatory mediator (MDIM)-stimulated chondrocytes. The anti-allergic effect of VEE was evaluated by degranulation, inflammatory mediators, and the FcepsilonRI signaling cascade in IgE/Ag-activated RBL-2H3 cells. The anti-osteoarthritic action of VEE was evaluated by cell migration, and the expression, secretion, and activity of MMPs in MDIM-stimulated SW1353 cells. VEE significantly inhibited degranulation (IC50: 93.04 mug/mL), the production of IL-4 (IC50: 73.28 mug/mL), TNF-alpha (IC50: 50.59 mug/mL), PGD(2) and LTC(4), and activation of the FcepsilonRI signaling cascade in IgE/Ag-activated RBL-2H3 cells. Moreover, VEE not only reduced cell migration but also inhibited the expression, secretion, and/or activity of MMP-1, MMP-3, or MMP-13 in MDIM-stimulated SW1353 cells. In conclusion, VEE possesses both anti-allergic and anti-osteoarthritic properties. Therefore, VEE could possibly be considered a new herbal drug for anti-allergic and anti-osteoarthritic therapy. Moreover, the in vitro model may be useful for the development of anti-osteoarthritic drugs</style></abstract><notes><style face="normal" font="default">DA - 20161230IS - 1420-3049 (Electronic)IS - 1420-3049 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.3390/molecules22010037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28036032">PM:28036032</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Molecules\2016-22-E37.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Molecules\2016-22-E37.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161230, Yoo JM</style></custom2><misc3><style face="normal" font="default">10.3390/molecules22010037</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40621</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Radbruch,M.</style></author><author><style face="normal" font="default"> Pischon,H.</style></author><author><style face="normal" font="default"> Ostrowski,A.</style></author><author><style face="normal" font="default"> Volz,P.</style></author><author><style face="normal" font="default"> Brodwolf,R.</style></author><author><style face="normal" font="default"> Neumann,F.</style></author><author><style face="normal" font="default"> Unbehauen,M.</style></author><author><style face="normal" font="default"> Kleuser,B.</style></author><author><style face="normal" font="default"> Haag,R.</style></author><author><style face="normal" font="default"> Ma,N.</style></author><author><style face="normal" font="default"> Alexiev,U.</style></author><author><style face="normal" font="default"> Mundhenk,L.</style></author><author><style face="normal" font="default"> Gruber,A.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Veterinary Pathology, Freie Universitat Berlin, Robert-von-Ostertag-Str. 15, 14163, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="default">Dendritic Core-Multishell Nanocarriers in Murine Models of Healthy and Atopic Skin</style></title><secondary-title><style face="normal" font="default">Nanoscale Res Lett</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nanoscale Res Lett</style></abbr-1></periodical><pages end="" start="64">64-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cornea</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Kidney</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> Spleen</style></keyword><keyword><style face="normal" font="default"> stratum corneum</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> subcutaneous</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> Toxicity Tests</style></keyword><keyword><style face="normal" font="default"> veterinary</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">Dendritic hPG-amid-C18-mPEG core-multishell nanocarriers (CMS) represent a novel class of unimolecular micelles that hold great potential as drug transporters, e.g., to facilitate topical therapy in skin diseases. Atopic dermatitis is among the most common inflammatory skin disorders with complex barrier alterations which may affect the efficacy of topical treatment.Here, we tested the penetration behavior and identified target structures of unloaded CMS after topical administration in healthy mice and in mice with oxazolone-induced atopic dermatitis. We further examined whole body distribution and possible systemic side effects after simulating high dosage dermal penetration by subcutaneous injection.Following topical administration, CMS accumulated in the stratum corneum without penetration into deeper viable epidermal layers. The same was observed in atopic dermatitis mice, indicating that barrier alterations in atopic dermatitis had no influence on the penetration of CMS. Following subcutaneous injection, CMS were deposited in the regional lymph nodes as well as in liver, spleen, lung, and kidney. However, in vitro toxicity tests, clinical data, and morphometry-assisted histopathological analyses yielded no evidence of any toxic or otherwise adverse local or systemic effects of CMS, nor did they affect the severity or course of atopic dermatitis.Taken together, CMS accumulate in the stratum corneum in both healthy and inflammatory skin and appear to be highly biocompatible in the mouse even under conditions of atopic dermatitis and thus could potentially serve to create a depot for anti-inflammatory drugs in the skin</style></abstract><notes><style face="normal" font="default">DA - 20170124IS - 1931-7573 (Print)IS - 1556-276X (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1186/s11671-017-1835-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28116609">PM:28116609</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nanoscale Res Lett\2017-12-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nanoscale Res Lett\2017-12-64.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170124, Radbruch M</style></custom2><misc3><style face="normal" font="default">10.1186/s11671-017-1835-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40622</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pouessel,G.</style></author><author><style face="normal" font="default"> Galand,J.</style></author><author><style face="normal" font="default"> Beaudouin,E.</style></author><author><style face="normal" font="default"> Renaudin,J.M.</style></author><author><style face="normal" font="default"> Labreuche,J.</style></author><author><style face="normal" font="default"> Moneret-Vautrin,D.A.</style></author><author><style face="normal" font="default"> Deschildre,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Children's Hospital, 59100, Roubaix, France</style></auth-address><titles><title><style face="normal" font="default">The gaps in anaphylaxis diagnosis and management by French physicians</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adrenaline</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="8" Month="2" Year="2017">2017/2/8</year></dates><abstract><style face="normal" font="default">Several studies have assessed the knowledge of health professionals in recognition and treatment of anaphylaxis using case-based surveys with conflicting results [1-3]. The proportion of responders able to recognize anaphylaxis and treat with appropriate adrenaline ranged from 56% to 95% [1, 3]. The causes for this under optimal management are not clearly understood. In this context, EAACI anaphylaxis guidelines were recently updated. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170208IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12703</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28178763">PM:28178763</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170208-PousselG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170208-PousselG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170208, Pouessel G</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12703</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40623</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yoshida,K.</style></author><author><style face="normal" font="default"> Adachi,Y.</style></author><author><style face="normal" font="default"> Sasaki,M.</style></author><author><style face="normal" font="default"> Akashi,M.</style></author><author><style face="normal" font="default"> Itazawa,T.</style></author><author><style face="normal" font="default"> Ohya,Y.</style></author><author><style face="normal" font="default"> Odajima,H.</style></author><author><style face="normal" font="default"> Akasawa,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">Ultraviolet index is associated with childhood eczema prevalence: Sex and age differences</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Climate</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetic factors</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="16" Month="2" Year="2017">2017/2/16</year></dates><abstract><style face="normal" font="default">Eczema is a chronic inflammatory skin condition whose development is related to environmental and genetic factors. The report of a positive association of latitude with the prevalence of childhood eczema suggests an important role for climate in the pathogenesis of eczema (1). The effect of ultraviolet (UV) radiation exposure is one of the candidate explanations for this observation, and is corroborated by a study in the United States reporting an inverse relationship between UV index and the prevalence of childhood eczema (2). We aimed to verify this association by further evaluating sex and age differences. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170217IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12706</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28211092">PM:28211092</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170217-YoshidaK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170217-YoshidaK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170217, yOSHIDA k</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12706</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40624</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ferrante,G.</style></author><author><style face="normal" font="default"> Fasola,S.</style></author><author><style face="normal" font="default"> Cilluffo,G.</style></author><author><style face="normal" font="default"> Malizia,V.</style></author><author><style face="normal" font="default"> Montalbano,L.</style></author><author><style face="normal" font="default"> Landi,M.</style></author><author><style face="normal" font="default"> Passalacqua,G.</style></author><author><style face="normal" font="default"> La,Grutta S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Science for Health Promotion for Mother and Child Care, University of Palermo, Italy</style></auth-address><titles><title><style face="normal" font="default">Nasal budesonide efficacy for nasal nitric oxide and nasal obstruction in rhinitis</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Budesonide</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child Care</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Promotion</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Intranasal steroids</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> perennial</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Upper airways</style></keyword></keywords><dates><year Day="20" Month="2" Year="2017">2017/2/20</year></dates><abstract><style face="normal" font="default">Nasal nitric oxide (nNO) is a noninvasive tool that may be helpful in evaluating the inflammatory status in the upper airways [1]. Previous studies report that nNO is elevated in children with Allergic Rhinitis (AR) [2], especially in perennial sensitized subjects [3], and that it may be affected by topical administration of intranasal steroids (INSs) [4]. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170220IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12707</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28218956">PM:28218956</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170220-FerranteG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170220-FerranteG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170220, Ferrante G</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12707</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40625</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Admani,S.</style></author><author><style face="normal" font="default"> Goldenberg,A.</style></author><author><style face="normal" font="default"> Jacob,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of California, San Diego, La Jolla, California</style></auth-address><titles><title><style face="normal" font="default">Contact Alopecia: Improvement of Alopecia with Discontinuation of Fluocinolone Oil in Individuals Allergic to Balsam Fragrance</style></title><secondary-title><style face="normal" font="default">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Dermatol</style></full-title></periodical><pages end="e60" start="e57">e57-e60</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Alopecia</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Balsam of Peru</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dermatoses</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Fragrances</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Peru</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> Scalp</style></keyword><keyword><style face="normal" font="default"> Scalp Dermatoses</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Inflammatory scalp dermatoses can be associated with alopecia, which is nonscarring and reversible in its early stages. This association has been described in seborrheic dermatitis, psoriasis, and atopic dermatitis. We describe three girls with alopecia aggravated by contact allergy to balsam fragrances. All three had complete resolution with avoidance of balsam of Peru and other balsam derivatives (including discontinuation of fluocinolone oil, which contains balsam of pine)</style></abstract><notes><style face="normal" font="default">DA - 20161025IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - ENGPT - CASE REPORTSCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pde.13011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27778425">PM:27778425</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Dermatol\2017-34-e57-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Dermatol\2017-34-e57-60.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161025, Admani S</style></custom2><misc3><style face="normal" font="default">10.1111/pde.13011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40626</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mori,T.</style></author><author><style face="normal" font="default"> Abe,N.</style></author><author><style face="normal" font="default"> Saito,K.</style></author><author><style face="normal" font="default"> Toyama,H.</style></author><author><style face="normal" font="default"> Endo,Y.</style></author><author><style face="normal" font="default"> Ejima,Y.</style></author><author><style face="normal" font="default"> Yamauchi,M.</style></author><author><style face="normal" font="default"> Goto,M.</style></author><author><style face="normal" font="default"> Mushiake,H.</style></author><author><style face="normal" font="default"> Kazama,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Physiology, Tohoku University Graduate School of Medicine, Seiryo-cho, Aoba-ku, Sendai, Miyagi, Japan</style></auth-address><titles><title><style face="normal" font="default">Hydrocortisone and dexamethasone dose-dependently stabilize mast cells derived from rat peritoneum</style></title><secondary-title><style face="normal" font="default">Pharmacol Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pharmacol Rep</style></abbr-1></periodical><pages end="1365" start="1358">1358-1365</pages><volume><style face="normal" font="default">68</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Dexamethasone</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Exocytosis</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Hydrocortisone</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Peritoneum</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> rat</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="5" Month="9" Year="2016">2016/9/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Besides their anti-inflammatory properties, corticosteroid drugs exert anti-allergic effects. Exocytosis of mast cells is electrophysiologically detected as the increase in the whole-cell membrane capacitance (Cm). Therefore, the lack of such increase after exposure to the drugs suggests their mast cell-stabilizing effects. METHODS: We examined the effects of 1, 10, 100 and 200muM hydrocortisone or dexamethasone on the degranulation from rat peritoneal mast cells. Employing the whole-cell patch-clamp recording technique, we also tested their effects on the Cm during exocytosis. RESULTS: At relatively lower concentrations (1, 10muM), both hydrocortisone and dexamethasone did not significantly affect the degranulation from mast cells and the increase in the Cm induced by GTP-gamma-S. Nevertheless, at higher doses (100, 200muM), these drugs inhibited the degranulation from mast cells and markedly suppressed the GTP-gamma-S-induced increase in the Cm. CONCLUSIONS: Our results provided electrophysiological evidence for the first time that corticosteroid drugs, such as hydrocortisone and dexamethasone, inhibited the exocytotic process of mast cells in a dose-dependent manner. The mast cell-stabilizing effects of these drugs may be attributable to their "non-genomic" action, by which they exert rapid anti-allergic effects</style></abstract><notes><style face="normal" font="default">DA - 20161006IS - 1734-1140 (Print)IS - 1734-1140 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.pharep.2016.09.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27710865">PM:27710865</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pharmacol Rep\2016-68-1358-65.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pharmacol Rep\2016-68-1358-65.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161006, Mori T</style></custom2><misc3><style face="normal" font="default">10.1016/j.pharep.2016.09.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40627</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Landry,J.</style></author><author><style face="normal" font="default"> Martinov,T.</style></author><author><style face="normal" font="default"> Mengistu,H.</style></author><author><style face="normal" font="default"> Dhanwada,J.</style></author><author><style face="normal" font="default"> Benck,C.J.</style></author><author><style face="normal" font="default"> Kline,J.</style></author><author><style face="normal" font="default"> Boo,B.</style></author><author><style face="normal" font="default"> Swanson,L.</style></author><author><style face="normal" font="default"> Tonc,E.</style></author><author><style face="normal" font="default"> Daughters,R.</style></author><author><style face="normal" font="default"> Fife,B.T.</style></author><author><style face="normal" font="default"> Chatterjea,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Biology Department, Macalester College, St. Paul, Minnesota, United States of America</style></auth-address><titles><title><style face="normal" font="default">Repeated hapten exposure induces persistent tactile sensitivity in mice modeling localized provoked vulvodynia</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0169672">e0169672-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">48/80</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergen exposure</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Cell Adhesion</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="default"> epidemiologic study</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Minnesota</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Modeling</style></keyword><keyword><style face="normal" font="default"> Nerve Growth Factor</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Oxazolone</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Touch</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Vulvodynia is a remarkably prevalent chronic pain condition of unknown etiology. Epidemiologic studies associate the risk of vulvodynia with a history of atopic disease. We used an established model of hapten-driven contact hypersensitivity to investigate the underlying mechanisms of allergy-provoked prolonged sensitivity to pressure. METHODS: We sensitized female ND4 Swiss mice to the hapten oxazolone on their flanks, and subsequently challenged them four days later with oxazolone or vehicle for ten consecutive days on the labia. We evaluated labiar sensitivity to touch, local mast cell accumulation, and hyperinnervation after ten challenges. RESULTS: Oxazolone-challenged mice developed significant tactile sensitivity that persisted for over three weeks after labiar allergen exposures ceased. Allergic sites were characterized by mast cell accumulation, sensory hyper-innervation and infiltration of regulatory CD4+CD25+FoxP3+ T cells as well as localized early increases in transcripts encoding Nerve Growth Factor and nerve-mast cell synapse marker Cell Adhesion Molecule 1. Local depletion of mast cells by intra-labiar administration of secretagogue compound 48/80 led to a reduction in both nerve density and tactile sensitivity. CONCLUSIONS: Mast cells regulate allergy-provoked persistent sensitivity to touch. Mast cell-targeted therapeutic strategies may provide novel means to manage and limit chronic pain conditions associated with atopic disease</style></abstract><notes><style face="normal" font="default">DA - 20170203IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0169672</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28158195">PM:28158195</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0169672.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0169672.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170203, Landry J</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0169672</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40628</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,S.Y.</style></author><author><style face="normal" font="default"> Kim,M.S.</style></author><author><style face="normal" font="default"> Park,B.</style></author><author><style face="normal" font="default"> Kim,J.H.</style></author><author><style face="normal" font="default"> Choi,H.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology-Head &amp; Neck Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea</style></auth-address><titles><title><style face="normal" font="default">Allergic rhinitis, atopic dermatitis, and asthma are associated with differences in school performance among Korean adolescents</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0171394">e0171394-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Alcohol</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Students</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> youth</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Several studies have reported negative relations between allergic diseases and school performance but have not simultaneously considered various allergic diseases, including allergic rhinitis, asthma, and atopic dermatitis, and only examined a limited number of participants. The present study investigated the associations of allergic rhinitis, asthma, and atopic dermatitis with school performance in a large, representative Korean adolescent population. A total of 299,695 7th through 12th grade students participated in the Korea Youth Risk Behaviour Web-based Survey (KYRBWS) from 2009 to 2013. The subjects' history of allergic rhinitis, asthma, and atopic dermatitis and number of school absences due to these diseases in the previous 12 months were examined and compared. School performance was classified into 5 levels. The relations between allergic disorders and school performance were analyzed using multiple logistic regressions with complex sampling and adjusted for the subjects' durations of sleep, days of physical activity, body mass indexes (BMIs), regions of residence, economic levels, parents' education levels, stress levels, smoking status, and alcohol use. A subgroup analysis of the economic groups was performed. Allergic rhinitis was positively correlated with better school performance in a dose-dependent manner (adjusted odds ratios, AOR, [95% confidence interval, CI] = 1.50 [1.43-1.56 > 1.33 [1.28-1.38] > 1.17 [1.13-1.22] > 1.09 [1.05-1.14] for grades A > B > C > D; P &lt; 0.001). Asthma was negatively correlated with better school performance (AOR [95% CI] = 0.74 [0.66-0.83], 0.87 [0.79-0.96], 0.83 [0.75-0.91], 0.93 [0.85-1.02] for performance A, B, C, and D, respectively; P &lt; 0.001). Atopic dermatitis was not significantly correlated with school performance. The subgroup analysis of the students' economic levels revealed associations between allergic diseases and school performance. Compared to other allergic disorders, the asthma group had more school absences due to their symptoms (P &lt; 0.001). School performance was positively correlated with allergic rhinitis and negatively correlated with asthma in Korean adolescents, even after adjusting for other variables. The asthma group had an increased number of school absence days, which presumably contributes to these students' poor school performance</style></abstract><notes><style face="normal" font="default">DA - 20170216IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0171394</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28207843">PM:28207843</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0171394.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0171394.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170216, Kim SY</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0171394</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40629</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ender,F.</style></author><author><style face="normal" font="default"> Wiese,A.V.</style></author><author><style face="normal" font="default"> Schmudde,I.</style></author><author><style face="normal" font="default"> Sun,J.</style></author><author><style face="normal" font="default"> Vollbrandt,T.</style></author><author><style face="normal" font="default"> Konig,P.</style></author><author><style face="normal" font="default"> Laumonnier,Y.</style></author><author><style face="normal" font="default"> Kohl,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute for Systemic Inflammation Research, University of Lubeck, Lubeck, Germany</style></auth-address><titles><title><style face="normal" font="default">Differential regulation of C5a receptor 1 in innate immune cells during the allergic asthma effector phase</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0172446">e0172446-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Airway Resistance</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Constriction</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> DC</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate lymphoid cells</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> Mucus</style></keyword><keyword><style face="normal" font="default"> Myeloid Cells</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> OVA</style></keyword><keyword><style face="normal" font="default"> Ovum</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">C5a drives airway constriction and inflammation during the effector phase of allergic asthma, mainly through the activation of C5a receptor 1 (C5aR1). Yet, C5aR1 expression on myeloid and lymphoid cells during the allergic effector phase is ill-defined. Recently, we generated and characterized a floxed green fluorescent protein (GFP)-C5aR1 knock-in mouse. Here, we used this reporter strain to monitor C5aR1 expression in airway, pulmonary and lymph node cells during the effector phase of OVA-driven allergic asthma. C5aR1 reporter and wildtype mice developed a similar allergic phenotype with comparable airway resistance, mucus production, eosinophilic/neutrophilic airway inflammation and Th2/Th17 cytokine production. During the allergic effector phase, C5aR1 expression increased in lung tissue eosinophils but decreased in airway and pulmonary macrophages as well as in pulmonary CD11b+ conventional dendritic cells (cDCs) and monocyte-derived DCs (moDCs). Surprisingly, expression in neutrophils was not affected. Of note, moDCs but not CD11b+ cDCs from mediastinal lymph nodes (mLN) expressed less C5aR1 than DCs residing in the lung after OVA challenge. Finally, neither CD103+ cDCs nor cells of the lymphoid lineage such as Th2 or Th17-differentiated CD4+ T cells, B cells or type 2 innate lymphoid cells (ILC2) expressed C5aR1 under allergic conditions. Our findings demonstrate a complex regulation pattern of C5aR1 in the airways, lung tissue and mLN of mice, suggesting that the C5a/C5aR1 axis controls airway constriction and inflammation through activation of myeloid cells in all three compartments in an experimental model of allergic asthma</style></abstract><notes><style face="normal" font="default">DA - 20170223IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0172446</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28231307">PM:28231307</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0172446.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0172446.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170223, Ender F</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0172446</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40630</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Abramowicz,M.</style></author><author><style face="normal" font="default"> Kruszewski,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hypersensitivity to diazepam (Relanium)</style></title><secondary-title><style face="normal" font="default">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pol J Allergol</style></full-title></periodical><pages end="136" start="134">134-136</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Anesthesia</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Diazepam</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> intradermal test</style></keyword><keyword><style face="normal" font="default"> Intradermal Tests</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year><pub-dates><date Day="0" Month="12" Year="2016">2016/12</date></pub-dates></dates><isbn><style face="normal" font="default">2353-3854</style></isbn><abstract><style face="normal" font="default">Abstract Diazepam </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô a benzodiazepine derivative is a quite commonly administered drug. Despite a fairly long list of diazepam's common side effects, hypersensitivity to this drug including anaphylactic shock almost does not occur. The paper presents a case of 60-year-old patient after a documented anaphylactic shock. The suggested cause was an intravenous administration of diazepam during the induction of anesthesia for the planned surgery. During the hospitalization, hypersensitivity to diazepam was confirmed by positive reactions in intradermal tests with diazepam</style></abstract><notes><style face="normal" font="default">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.alergo.2016.11.007</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.alergo.2016.11.007</url></web-urls></urls><custom2><style face="normal" font="default">20170225, Abramowicz M</style></custom2><misc3><style face="normal" font="default">10.1016/j.alergo.2016.11.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40631</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Donka,K.</style></author><author><style face="normal" font="default"> Czarnocki,K.J.</style></author><author><style face="normal" font="default"> Emeryk,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Validation of the Polish version of Satisfaction with Asthma Treatment Questionnaire (SATQ)</style></title><secondary-title><style face="normal" font="default">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Postepy Dermatol Alergol</style></full-title></periodical><pages end="81" start="77">77-81</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Aerosols</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Efficiency</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Language</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patient Satisfaction</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Introduction: Among the chronically ill there is a tendency for non-compliance with medical recommendations, which is often due to low satisfaction with the offered treatment. Satisfaction with Asthma Treatment Questionnaire (SATQ) is a questionnaire for measuring satisfaction with the inhalation treatment of asthma in patients of more than 18 years of age. SATQ is a standardized tool that has not been previously used in Poland. SATQ consists of 4 domains: efficiency, ease of use, the burdening with asthma treatment and side effects and concerns. Aim: To validate the Polish language version of SATQ questionnaire and an overall verification of the usefulness of the tool relative to trials from clinical practice. Material and methods: The degree of difficulty and comprehension of the questions and the reliability and validity of the Polish version of the questionnaire was determined in 67 patients with asthma (mean age: 45.8 ±14.3 years (range maximum - at least 18-65 years). The vast majority of patients in the study group have used the inhalers for more than 1 year and were educated in the field of aerosols management. The resulting scores are calculated by adding up the scores for each question and dividing by the number of questions. The reliability of the questionnaire design was verified using the Spearman rank correlation coefficients between elements and ranges between band assessments and evaluations and overall assessment of quality and patient satisfaction with treatment. Internal consistency and reliability of the tool was assessed using Cronbach's ?. The values of Cronbach's a were evaluated with respect to the threshold value of 0.70. Results: SATQ questionnaire was understandable and easy to fill out for all subjects. The filling time of SATQ was designed as to be within 5-10 min. Cronbach's a was reached on all scales, demonstrating the reliability of the analyzed scale and lack of redundancy. Conclusions: The Polish version of SATQ questionnaire meets the basic psychometric criteria and can be used to assess satisfaction with the inhalation treatment of asthma.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="default">10.5114/ada.2017.65625</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.5114/ada.2017.65625</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-77-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-77-81.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170226, Donka K</style></custom2><misc3><style face="normal" font="default">10.5114/ada.2017.65625</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40632</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kawano,T.</style></author><author><style face="normal" font="default"> Scheuermeyer,F.X.</style></author><author><style face="normal" font="default"> Stenstrom,R.</style></author><author><style face="normal" font="default"> Rowe,B.H.</style></author><author><style face="normal" font="default"> Grafstein,E.</style></author><author><style face="normal" font="default"> Grunau,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Emergency Medicine, St. Paul's Hospital, Vancouver, BC, Canada; Department of Emergency Medicine, University of Fukui Hospital, Fukui Prefecture, Japan.</style></auth-address><titles><title><style face="normal" font="default">Epinephrine Use in Older Patients with Anaphylaxis: Clinical Outcomes and Cardiovascular Complications</style></title><secondary-title><style face="normal" font="default">Resuscitation</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Resuscitation</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Emergency Medicine</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective cohort study</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="6" Month="1" Year="2017">2017/1/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: There is little data describing the differences in epinephrine (epi) administration and cardiac complications among older and younger patients with anaphylaxis. METHODS: This retrospective cohort study was conducted at two urban emergency departments (ED) over a 5 year-period, and included adults who met a pre-specified criteria for anaphylaxis. Patients>/=50years of age were defined as "older". Univariate logistic regression was performed to compare the difference in frequency of epi administration between the "older" and "younger" groups. Among those who received epi, the proportion of patients who received doses exceeding the recommended maximum and who had pre-specified cardiovascular complications were compared between the two groups, stratified further by route of administration. RESULTS: Of 2995 allergy-related visits, 492 met criteria for anaphylaxis, including 122 (24.8%) older patients. Older patients were less likely to receive epi injection (36.1% vs. 60.5%). Of those who received epi, older patients were more likely to receive excessive dose of epi (7/44, 15.9% vs 2/225, 0.9%, unadjusted OR 20.7, 95% CI 3.8 to 211.7). Four (4/44, 9.1%) older patients experienced cardiovascular complications, compared to 1/225 (0.4%) in the younger group (unadjusted OR 22.4, 95% CI 2.1 to 1129.8). When examining only intra-muscular epinephrine, 1/31 older patients had cardiac complications, compared to 1/186 in the younger group. CONCLUSION: Older patients with anaphylaxis were less likely to receive epi injection. Intramuscular epi appears safe in this population; however, the use of intravenous epi should be avoided in older patients due to the potential of developing serious cardiac complications</style></abstract><notes><style face="normal" font="default">DA - 20170110IS - 1873-1570 (Electronic)IS - 0300-9572 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.resuscitation.2016.12.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28069483">PM:28069483</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Resuscitation\20170110-KawanoT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Resuscitation\20170110-KawanoT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170110, Kawano T</style></custom2><misc3><style face="normal" font="default">10.1016/j.resuscitation.2016.12.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40633</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pouessel,G.</style></author><author><style face="normal" font="default"> Deschildre,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Anaphylaxis in children</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescence</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Adrenaline</style></keyword><keyword><style face="normal" font="default"> Adrenaline auto-injector</style></keyword><keyword><style face="normal" font="default"> Adrenaline autoinjector</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Auto-injectors</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> contraindications</style></keyword><keyword><style face="normal" font="default"> Cow's milk</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Enfant</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Individualized care project</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Milk</style></keyword><keyword><style face="normal" font="default"> Nuts</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Peanut</style></keyword><keyword><style face="normal" font="default"> Peanuts</style></keyword><keyword><style face="normal" font="default"> Personalized care project</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe reactions</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> Vomiting</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Anaphylaxis is a severe and potentially life-threatening allergic emergency that has increased in frequency and over the two last decades, especially in young children. Death through anaphylactic shock remains rare, in particular in children, and its frequency has remained stable throughout this period. Food is the chief cause of anaphylactic shock in children, with cow's milk, peanuts and tree nuts being the mostly frequently incriminated foodstuffs. In infants, anaphylactic shock may be difficult to recognise. Vomiting, urticaria and laryngeal oedema are more frequent at this age. Cardiovascular involvement is rare and is most often encountered in adolescents. A history of asthma or atopy, allergy to particular foods such as peanuts and tree nuts, and adolescence, all constitute risk factors for anaphylaxis and more severe reactions. First-line treatment consists of intramuscular adrenaline for all patients in anaphylactic shock. There are no absolute contraindications. Guidelines for the prescription of adrenaline auto-injectors and for the conditions of establishment of personalized care projects for allergic children in schools have recently been updated. Improvements continue to be needed in the recognition and treatment of anaphylactic shock</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2016.12.003</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2016.12.003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170226-PouesselG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170226-PouesselG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170226, Pouessel G</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2016.12.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40634</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ane,S.</style></author><author><style face="normal" font="default"> Phillips,J.</style></author><author><style face="normal" font="default"> Bourgeois,O.</style></author><author><style face="normal" font="default"> Didier,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">List of educational tools to improve treatment compliance and control of asthma in children</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> Caregivers</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Documentation</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Educational tools</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Education</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Observance</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutic education</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Therapeutic education has been shown to be effective in the management of asthma in adults and children. In asthmatic children, such education should be presented in a playful and interactive way. This is facilitated by the use of various tools that must be adapted to the age of the children in question, to the aims sought, and to the educational context. The principal aim of this study was to identify the educational tools available to improve treatment compliance and control of asthma in children. A documentary search in English and French using search engines was carried out in PubMed, EM-áConsulte, the French Medical-Surgical Encyclopaedia, Elsevier-Masson journals, the French university documentation system, Google Scholar, the French Inter-Medical Faculties Library, the French Higher Health Authority, the French National Institute for Health Education and Prevention, asthme-allergie.org, and ginasthma.org. This search identified 28-átools, 16-áof which may be used during consultations. These tools may be classified as follows: follow-up and evaluation tools, knowledge acquisition tools, multifunction tools, and online educational tools. We discuss the value and uses of these different tools. This list should facilitate access to the educational tools suitable for use during consultations for children with asthma, as well as enhancing their utilisation by caregivers</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2016.12.004</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2016.12.004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170226-AneS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170226-AneS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170226, Ane S</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2016.12.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40635</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jabri,H.</style></author><author><style face="normal" font="default"> L'youssfi,H.</style></author><author><style face="normal" font="default"> Elkhattabi,W.</style></author><author><style face="normal" font="default"> Afif,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Value of the Asthma Control Test (ACT) in the treatment of asthmatic patients in Casablanca</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> ACT Score</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Casablanca</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Niveau socio+®conomique</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Socioeconomic level</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - FRECO - Moroco -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.01.001</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2017.01.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170226-JabriH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170226-JabriH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170226, Jabri H</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.01.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40636</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Degache,E.</style></author><author><style face="normal" font="default"> Pralong,P.</style></author><author><style face="normal" font="default"> Jacquier,J.P.</style></author><author><style face="normal" font="default"> Logerot,S.</style></author><author><style face="normal" font="default"> Pernollet,M.</style></author><author><style face="normal" font="default"> Chatain,C.</style></author><author><style face="normal" font="default"> Leccia,M.T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Immediate allergic hypersensitivity reaction to omeprazole and cross-reactivity</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophil activation test</style></keyword><keyword><style face="normal" font="default"> Basophil activation tests</style></keyword><keyword><style face="normal" font="default"> cross reactivity</style></keyword><keyword><style face="normal" font="default"> Cross-reaction</style></keyword><keyword><style face="normal" font="default"> Cross-reactivity</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity allergic reaction</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Lansoprazole</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Omeprazole</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> Proton pump inhibitors</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Introduction True anaphylactic reactions to PPIs are rare, and cross-sensitivity reactions are not widely known. Herein, we present two cases of anaphylactic reaction to omeprazole with cross-sensitivity to other PPIs. Patients and methods Patient 1: a 43-year-old male presented a grade II anaphylactic reaction 15 minutes after omeprazole intake. Prick tests were positive for omeprazole, pantoprazole and esomeprazole, and negative for rabeprazole and lansoprazole. The basophil activation tests were not interpretable for esomeprazole and were negative for the other drugs. Patient 2: a 39-year-old male presented isolated superficial urticaria within two hours of omeprazole intake. The omeprazole prick test was positive. IDR tests were positive for esomeprazole, pantoprazole and rabeprazole, and negative for lansoprazole. Basophil activation tests were positive for lansoprazole. Discussion We established a diagnosis of immediate hypersensitivity to omeprazole associated with cross-sensitivity to other PPIs. A literature review revealed the existence of three types of immediate hypersensitivity reactions to PPIs: 1) cross reaction to all PPIs; 2) partial cross reaction to either omeprazole/esomeprazole/pantoprazole or lansoprazole/rabeprazole; 3) isolated allergic reaction to a single PPI. Conclusion We present two rare cases of allergic immediate hypersensitivity reactions to omeprazole with cross-sensitivity to other PPIs that confirm the data in the literature</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2016.10.016</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2016.10.016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170226-DegacheF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170226-DegacheF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170226, Degache F</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2016.10.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40637</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Koch,S.</style></author><author><style face="normal" font="default"> Sopel,N.</style></author><author><style face="normal" font="default"> Finotto,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Molecular Pneumology, Friedrich-Alexander-Universitat (FAU) Erlangen-Nurnberg, Universitatsklinikum Erlangen, 91052, Erlangen, Germany</style></auth-address><titles><title><style face="normal" font="default">Th9 and other IL-9-producing cells in allergic asthma</style></title><secondary-title><style face="normal" font="default">Semin Immunopathol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Semin Immunopathol</style></abbr-1></periodical><pages end="68" start="55">55-68</pages><volume><style face="normal" font="default">39</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway epithelial cell</style></keyword><keyword><style face="normal" font="default"> airway epithelial cells</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Autoimmunity</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-9</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate immunity</style></keyword><keyword><style face="normal" font="default"> Innate lymphoid cells</style></keyword><keyword><style face="normal" font="default"> Interferon</style></keyword><keyword><style face="normal" font="default"> Interleukin-4</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Leucine</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mucus</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> STAT1</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH17</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> transcription factor</style></keyword><keyword><style face="normal" font="default"> Transcription Factors</style></keyword><keyword><style face="normal" font="default"> Transforming Growth Factor beta</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Allergic asthma is a worldwide increasing chronic disease of the airways which affects more than 300 million people. It is associated with increased IgE, mast cell activation, airway hyperresponsiveness (AHR), mucus overproduction and remodeling of the airways. Previously, this pathological trait has been associated with T helper type 2 (Th2) cells. Recently, different CD4+ T cell subsets (Th17, Th9) as well as cells of innate immunity, like mast cells and innate lymphoid cells type 2 (ILC2s), which are all capable of producing the rediscovered cytokine IL-9, are known to contribute to this disease. Regarding Th9 cells, it is known that naive T cells develop into IL-9-producing cells in the presence of interleukin-4 (IL-4) and transforming growth factor beta (TGFbeta). Downstream of IL-4, several transcription factors like signal transducer and activator of transcription 6 (STAT6), interferon regulatory factor 4 (IRF4), GATA binding protein 3 (GATA3), basic leucine zipper transcription factor, ATF-like (BATF) and nuclear factor of activated T cells (NFAT) are activated. Additionally, the transcription factor PU.1, which is downstream of TGFbeta signaling, also seems to be crucial in the development of Th9 cells. IL-9 is a pleiotropic cytokine that influences various distinct functions of different target cells such as T cells, B cells, mast cells and airway epithelial cells by activating STAT1, STAT3 and STAT5. Because of its pleiotropic functions, IL-9 has been demonstrated to be involved in several diseases, such as cancer, autoimmunity and other pathogen-mediated immune-regulated diseases. In this review, we focus on the role of Th9 and IL-9-producing cells in allergic asthma</style></abstract><notes><style face="normal" font="default">DA - 20161118IS - 1863-2300 (Electronic)IS - 1863-2297 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1007/s00281-016-0601-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27858144">PM:27858144</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Semin Immunopathol\2017-39-55-68.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Semin Immunopathol\2017-39-55-68.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161118, Koch S</style></custom2><misc3><style face="normal" font="default">10.1007/s00281-016-0601-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40638</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,Y.</style></author><author><style face="normal" font="default"> Liu,K.</style></author><author><style face="normal" font="default"> Hu,K.</style></author><author><style face="normal" font="default"> Yang,J.</style></author><author><style face="normal" font="default"> Li,Z.</style></author><author><style face="normal" font="default"> Nie,M.</style></author><author><style face="normal" font="default"> Dong,Y.</style></author><author><style face="normal" font="default"> Huang,H.</style></author><author><style face="normal" font="default"> Chen,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Diseases, Xiangyang Hospital, Hubei University of Medicine, 15 Jiefang Road, Fancheng, Xiangyang 441000, China</style></auth-address><titles><title><style face="normal" font="default">Impact of obstructive sleep apnea on severe asthma exacerbations</style></title><secondary-title><style face="normal" font="default">Sleep Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sleep Med</style></abbr-1></periodical><pages end="5" start="1">1-5</pages><volume><style face="normal" font="default">26</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Apnea</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> induced sputum</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Obstructive sleep apnea</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Respiratory diseases</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Sleep apnea</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patients with asthma have a higher incidence of obstructive sleep apnea (OSA). However, the association between OSA and the exacerbation of severe asthma remains unclear. In this study, we aimed to investigate the prevalence of OSA in a cross-sectional study of asthma patients and to prospectively examine the significance of the effect of OSA on severe asthma exacerbations. METHODS: One hundred and forty-six patients with asthma and 157 matched-controlled individuals were enrolled in this study. The patients with asthma were prospectively studied for one year, and exacerbation episodes were identified based on the patients' medical histories. Lung function and the percentages of eosinophils in induced sputum samples were determined, and the frequencies of severe asthma exacerbations during the previous year were evaluated in the group of patients with asthma. RESULTS: The rates of OSA were 19.2% (28/146) among the patients with asthma and 9.6% (15/157) among the control individuals (p = 0.016). The frequency of severe asthma exacerbations was significantly higher among the asthma patients with OSA compared with those who did not have OSA (p &lt; 0.001). The apnea-hypopnea index (AHI) correlated significantly with the number of severe asthma exacerbations (r = 0.507, 95% confidence interval [CI] 0.357-0.637, p &lt; 0.001). Logistic regression analyses determined that the AHI was significantly associated with the occurrence of severe asthma exacerbations (odds ratio 1.322, 95% CI 1.148-1.523, p &lt; 0.001). CONCLUSIONS: Patients with asthma had a high prevalence of OSA, which was an important factor associated with severe asthma exacerbations</style></abstract><notes><style face="normal" font="default">DA - 20161223IS - 1878-5506 (Electronic)IS - 1389-9457 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.sleep.2016.06.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28007353">PM:28007353</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sleep Med\2016-26-1-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sleep Med\2016-26-1-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161223, Wang Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.sleep.2016.06.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40639</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Olaniyan,L.W.</style></author><author><style face="normal" font="default"> Mkwetshana,N.</style></author><author><style face="normal" font="default"> Okoh,A.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">SAMRC Microbial Water Quality Monitoring Centre, University of Fort Hare, Private Bag X1314, Alice, Eastern Cape 5700 South Africa</style></auth-address><titles><title><style face="normal" font="default">Triclosan in water, implications for human and environmental health</style></title><secondary-title><style face="normal" font="default">Springerplus</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Springerplus</style></full-title></periodical><pages end="" start="1639">1639-</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Africa</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Apoptosis</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Breast</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Chlorine</style></keyword><keyword><style face="normal" font="default"> Chlorophenols</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> Epidemiological studies</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human health</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> Milk</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Nails</style></keyword><keyword><style face="normal" font="default"> Oxidative Phosphorylation</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Soaps</style></keyword><keyword><style face="normal" font="default"> Soil</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> Toothpaste</style></keyword><keyword><style face="normal" font="default"> Toothpastes</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> Triclosan</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> urine</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Triclosan (TCS) is a broad spectrum antibacterial agent present as an active ingredient in some personal care products such as soaps, toothpastes and sterilizers. It is an endocrine disrupting compound and its increasing presence in water resources as well as in biosolid-amended soils used in farming, its potential for bioaccumulation in fatty tissues and toxicity in aquatic organisms are a cause for concern to human and environmental health. TCS has also been detected in blood, breast milk, urine and nails of humans. The significance of this is not precisely understood. Data on its bioaccumulation in humans are also lacking. Cell based studies however showed that TCS is a pro-oxidant and may be cytotoxic via a number of mechanisms. Uncoupling of oxidative phosphorylation appears to be prevailing as a toxicity mechanism though the compound's role in apoptosis has been cited. TCS is not known to be carcinogenic per se in vitro but has been reported to promote tumourigenesis in the presence of a carcinogen, in mice. Recent laboratory reports appear to support the view that TCS oestrogenicity as well as its anti-oestrogenicity play significant role in cancer progression. Results from epidemiological studies on the effect of TCS on human health have implicated the compound as responsible for certain allergies and reproductive defects. Its presence in chlorinated water also raises toxicity concern for humans as carcinogenic metabolites such as chlorophenols may be generated in the presence of the residual chlorine. In this paper, we carried out a detailed overview of TCS pollution and the implications for human and environmental health</style></abstract><notes><style face="normal" font="default">DA - 20161010LA - ENGPT - REVIEWPT - JOURNAL ARTICLECO - South Africa -</style></notes><work-type><style face="normal" font="default">10.1186/s40064-016-3287-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27722057">PM:27722057</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Springerplus\2016-5-1639.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Springerplus\2016-5-1639.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161010, Olaniyan LW</style></custom2><misc3><style face="normal" font="default">10.1186/s40064-016-3287-x</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40640</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Li,Z.</style></author><author><style face="normal" font="default"> Rava,M.</style></author><author><style face="normal" font="default"> Bedard,A.</style></author><author><style face="normal" font="default"> Dumas,O.</style></author><author><style face="normal" font="default"> Garcia-Aymerich,J.</style></author><author><style face="normal" font="default"> Leynaert,B.</style></author><author><style face="normal" font="default"> Pison,C.</style></author><author><style face="normal" font="default"> Le Moual,N.</style></author><author><style face="normal" font="default"> Romieu,I.</style></author><author><style face="normal" font="default"> Siroux,V.</style></author><author><style face="normal" font="default"> Camargo,C.A.,Jr.</style></author><author><style face="normal" font="default"> Nadif,R.</style></author><author><style face="normal" font="default"> Varraso,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">INSERM, U1168, VIMA: Aging and Chronic Diseases. Epidemiological and Public Health Approaches, Villejuif, France</style></auth-address><titles><title><style face="normal" font="default">Cured meat intake is associated with worsening asthma symptoms</style></title><secondary-title><style face="normal" font="default">Thorax</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Thorax</style></full-title></periodical><pages end="212" start="206">206-212</pages><volume><style face="normal" font="default">72</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aging</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Meat</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Cured meat intake-a recent carcinogenic factor-may increase the risk of COPD, but its association with asthma remains unknown. Though body mass index (BMI) is a likely risk factor for asthma, its role in the diet-asthma association as a mediator has never been studied. We investigated the association between cured meat intake and worsening asthma symptoms in adults, and the role of BMI as a potential mediator. METHODS: Using data from the French prospective EGEA study (baseline: 2003-2007; follow-up: 2011-2013), we applied a mediation analysis in the counterfactual framework, a marginal structural model (MSM), to estimate the direct effect of baseline cured meat intake (&lt;1, 1-3.9, >/=4 servings/week) on change in asthma symptom score (worsening or not), and the indirect effect mediated by BMI. RESULTS: Among the 971 participants (mean age 43 years; 49% men; 42% with asthma), 20% reported worsening asthma symptoms during the mean follow-up time of 7 years. Using the MSM, we reported a positive direct effect of cured meat intake on worsening asthma symptoms (multivariable OR=1.76, 95% CI 1.01 to 3.06 for >/=4 vs &lt;1 serving/week). We also reported an indirect effect mediated by BMI (OR=1.07; 95% CI 1.01 to 1.14), accounting for 14% of the total effect. CONCLUSIONS: Higher cured meat intake was associated with worsening asthma symptoms over time, through a direct effect and to a lesser extent an effect mediated by BMI. This research extends the effect of diet on asthma in adults</style></abstract><notes><style face="normal" font="default">DA - 20161221IS - 1468-3296 (Electronic)IS - 0040-6376 (Linking)LA - engPT - Journal ArticleCO - France -CO - Spain -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1136/thoraxjnl-2016-208375</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27999171">PM:27999171</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Thorax\2017-72-206-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Thorax\2017-72-206-12.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161221, Li Z</style></custom2><misc3><style face="normal" font="default">10.1136/thoraxjnl-2016-208375</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40641</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Avonto,C.</style></author><author><style face="normal" font="default"> Rua,D.</style></author><author><style face="normal" font="default"> Lasonkar,P.B.</style></author><author><style face="normal" font="default"> Chittiboyina,A.G.</style></author><author><style face="normal" font="default"> Khan,I.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, The University of Mississippi, MS 38677, United States</style></auth-address><titles><title><style face="normal" font="default">Identification of a compound isolated from German chamomile (Matricaria chamomilla) with dermal sensitization potential</style></title><secondary-title><style face="normal" font="default">Toxicol Appl Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Toxicol Appl Pharmacol</style></abbr-1></periodical><pages end="22" start="16">16-22</pages><volume><style face="normal" font="default">318</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acids</style></keyword><keyword><style face="normal" font="default"> Adverse effect</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aging</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Chamomile</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> dermal sensitization</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Herbal</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Natural products</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin reaction</style></keyword><keyword><style face="normal" font="default"> skin reactions</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="19" Month="1" Year="2017">2017/1/19</year></dates><abstract><style face="normal" font="default">German chamomile is one of the most popular herbal ingredients used in cosmetics and personal care products. Allergic skin reactions following topical application of German chamomile have been occasionally reported, although it is not fully understood which of the chemical constituents is responsible for this adverse effect. In the present work, three candidate sensitizers were isolated from German chamomile based on activity-guided fractionation of chamomile extracts tested using the in vitro KeratinoSens assay. The compounds were identified as the polyacetylene tonghaosu (1), and both trans- and cis-glucomethoxycinnamic acids (2 and 3). These three compounds were classified as non- to weakly reactive using in chemico methods; however, aged tonghaosu was found to be more reactive when compared to freshly isolated tonghaosu. The polyacetylene (1) constituent was determined to be chemically unstable, generating a small electrophilic spirolactone, 1,6-dioxaspiro[4.4]non-3-en-2-one (4), upon aging. This small lactone (4) was strongly reactive in both in chemico HTS- and NMR-DCYA methods and further confirmed as a potential skin sensitizer by Local Lymph Node Assay (LLNA)</style></abstract><notes><style face="normal" font="default">DA - 20170122IS - 1096-0333 (Electronic)IS - 0041-008X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.taap.2017.01.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28109818">PM:28109818</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicol Appl Pharmacol\2017-318-16-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicol Appl Pharmacol\2017-318-16-22.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170122, Avonto C</style></custom2><misc3><style face="normal" font="default">10.1016/j.taap.2017.01.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40642</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">El Ali,Z.</style></author><author><style face="normal" font="default"> Delomenie,C.</style></author><author><style face="normal" font="default"> Botton,J.</style></author><author><style face="normal" font="default"> Pallardy,M.</style></author><author><style face="normal" font="default"> Kerdine-Romer,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">UMRIFR141 IPSIT, Univ Paris-Sud, Universite Paris-Saclay, Chatenay-Malabry, FranceINSERM, UMR1153 Epidemiology and Biostatistics Sorbonne Paris Cite Center (CRESS), TeamUMRUMR</style></auth-address><titles><title><style face="normal" font="default">Dendritic cells' death induced by contact sensitizers is controlled by Nrf2 and depends on glutathione levels</style></title><secondary-title><style face="normal" font="default">Toxicol Appl Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Toxicol Appl Pharmacol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Apoptosis</style></keyword><keyword><style face="normal" font="default"> Cell Death</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Characterization</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> DC</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Dinitrochlorobenzene</style></keyword><keyword><style face="normal" font="default"> DNCB</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Glutathione</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Oxidative Stress</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="17" Month="2" Year="2017">2017/2/17</year></dates><abstract><style face="normal" font="default">Dendritic cells (DC) are known to play a major role during contact allergy induced by contact sensitizers (CS). Our previous studies showed that Nrf2 was induced in DC and controlled allergic skin inflammation in mice in response to chemicals. In this work, we raised the question of the role of Nrf2 in response to a stress provoked by chemical sensitizers in DC. We used two well-described chemical sensitizers, dinitrochlorobenzene (DNCB) and cinnamaldehyde (CinA), known to have different chemical reactivity and mechanism of action. First, we performed a RT-qPCR array showing that CinA was a higher inducer of immune and detoxification genes compared to DNCB. Interestingly, in the absence of Nrf2, gene expression was dramatically affected in response to DNCB but was slightly affected in response to CinA. These observations prompted us to study DC's cell death in response to both chemicals. DNCB and CinA increased apoptotic cells and decreased living cells in the absence of Nrf2. The characterization of DC apoptosis induced by both CS involved the mitochondrial-dependent caspase pathway and was regulated via Nrf2 in response to both chemicals. Oxidative stress induced by DNCB, and leading to cell death, was regulated by Nrf2. Unlike CinA, DNCB treatment provoked a significant reduction of intracellular GSH levels and up-regulated bcl-2 gene expression, under the control of Nrf2. This work underlies that chemical reactivity may control Nrf2-dependent gene expression leading to different cytoprotective mechanisms in DC</style></abstract><notes><style face="normal" font="default">DA - 20170221IS - 1096-0333 (Electronic)IS - 0041-008X (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.taap.2017.02.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28219650">PM:28219650</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicol Appl Pharmacol\20170221-ElAziZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicol Appl Pharmacol\20170221-ElAziZ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170221, El Azi Z</style></custom2><misc3><style face="normal" font="default">10.1016/j.taap.2017.02.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40643</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tan,J.W.</style></author><author><style face="normal" font="default"> Israf,D.A.</style></author><author><style face="normal" font="default"> Harith,H.H.</style></author><author><style face="normal" font="default"> Md Hashim,N.F.</style></author><author><style face="normal" font="default"> Ng,C.H.</style></author><author><style face="normal" font="default"> Shaari,K.</style></author><author><style face="normal" font="default"> Tham,C.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43400, Malaysia</style></auth-address><titles><title><style face="normal" font="default">Anti-allergic activity of 2,4,6-trihydroxy-3-geranylacetophenone (tHGA) via attenuation of IgE-mediated mast cell activation and inhibition of passive systemic anaphylaxis</style></title><secondary-title><style face="normal" font="default">Toxicol Appl Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Toxicol Appl Pharmacol</style></abbr-1></periodical><pages end="58" start="47">47-58</pages><volume><style face="normal" font="default">319</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic response</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal model</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> anti-allergic activity</style></keyword><keyword><style face="normal" font="default"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Cell Degranulation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> cysteinyl leukotriene</style></keyword><keyword><style face="normal" font="default"> cysteinyl leukotrienes</style></keyword><keyword><style face="normal" font="default"> cysteinyl-leukotrienes</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Interleukin-4</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Leukotriene C4</style></keyword><keyword><style face="normal" font="default"> Leukotrienes</style></keyword><keyword><style face="normal" font="default"> Malaysia</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Pretreatment</style></keyword><keyword><style face="normal" font="default"> Prostaglandin</style></keyword><keyword><style face="normal" font="default"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="default"> rat</style></keyword><keyword><style face="normal" font="default"> Rats</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="default">tHGA, a geranyl acetophenone compound originally isolated from a local shrub called Melicope ptelefolia, has been previously reported to prevent ovalbumin-induced allergic airway inflammation in a murine model of allergic asthma by targeting cysteinyl leukotriene synthesis. Mast cells are immune effector cells involved in the pathogenesis of allergic diseases including asthma by releasing cysteinyl leukotrienes. The anti-asthmatic properties of tHGA could be attributed to its inhibitory effect on mast cell degranulation. As mast cell degranulation is an important event in allergic responses, this study aimed to investigate the anti-allergic effects of tHGA in cellular and animal models of IgE-mediated mast cell degranulation. For in vitro model of IgE-mediated mast cell degranulation, DNP-IgE-sensitized RBL-2H3 cells were pre-treated with tHGA before challenged with DNP-BSA to induce degranulation. For IgE-mediated passive systemic anaphylaxis, Sprague Dawley rats were sensitized by intraperitoneal injection of DNP-IgE before challenged with DNP-BSA. Both in vitro and in vivo models showed that tHGA significantly inhibited the release of preformed mediators (beta-hexosaminidase and histamine) as well as de novo mediators (interleukin-4, tumour necrosis factor-alpha, prostaglandin D2 and leukotriene C4). Pre-treatment of tHGA also prevented IgE-challenged RBL-2H3 cells and peritoneal mast cells from undergoing morphological changes associated with mast cell degranulation. These findings indicate that tHGA possesses potent anti-allergic activity via attenuation of IgE-mediated mast cell degranulation and inhibition of IgE-mediated passive systemic anaphylaxis. Thus, tHGA may have the potential to be developed as a mast cell stabilizer for the treatment of allergic diseases in the future</style></abstract><notes><style face="normal" font="default">DA - 20170207IS - 1096-0333 (Electronic)IS - 0041-008X (Linking)LA - engPT - Journal ArticleCO - Malaysia -</style></notes><work-type><style face="normal" font="default">10.1016/j.taap.2017.02.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28167223">PM:28167223</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicol Appl Pharmacol\20170207-TanJW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicol Appl Pharmacol\20170207-TanJW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170207, Tan JW</style></custom2><misc3><style face="normal" font="default">10.1016/j.taap.2017.02.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40644</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Onoue,S.</style></author><author><style face="normal" font="default"> Ohtake,H.</style></author><author><style face="normal" font="default"> Suzuki,G.</style></author><author><style face="normal" font="default"> Seto,Y.</style></author><author><style face="normal" font="default"> Nishida,H.</style></author><author><style face="normal" font="default"> Hirota,M.</style></author><author><style face="normal" font="default"> Ashikaga,T.</style></author><author><style face="normal" font="default"> Kouzuki,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacokinetics and Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.</style></auth-address><titles><title><style face="normal" font="default">Comparative study on prediction performance of photosafety testing tools on photoallergens</style></title><secondary-title><style face="normal" font="default">Toxicol In Vitro</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Toxicol In Vitro</style></full-title></periodical><pages end="152" start="147">147-152</pages><volume><style face="normal" font="default">33</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Absorption</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Balb 3T3 Cells</style></keyword><keyword><style face="normal" font="default"> Biological Assay</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Comparative Study</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Phototoxic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Neutral Red</style></keyword><keyword><style face="normal" font="default"> Oxygen</style></keyword><keyword><style face="normal" font="default"> pharmacokinetics</style></keyword><keyword><style face="normal" font="default"> Phototoxicity</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research Support</style></keyword><keyword><style face="normal" font="default"> ROS</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Sunlight</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="default">Several testing methods have been established to identify potential phototoxins. The present study was undertaken to clarify the predictive ability of in vitro photosafety assays for photoallergenicity. On the basis of animal and/or clinical photosafety information, 23 photoallergens and 7 non-phototoxic/non-photoallergenic chemicals were selected and subjected to UV/VIS spectral analysis, reactive oxygen species (ROS)/micellar ROS (mROS) assays, and 3T3 neutral red uptake phototoxicity testing (3T3 NRU PT). Of the photoallergens tested, ca. 96% of chemicals had intense UV/VIS absorption with a molar extinction coefficient of over 1000 M(-1) cm(-1), and false-positive predictions were made for 3 non-photoallergenic chemicals. In the ROS assay, all photoallergens were found to be potent ROS generators under exposure to simulated sunlight. In the photosafety prediction based on the ROS assay, the individual specificity was 85.7%, and the positive predictivity and negative predictivity were found to be 95.8% and 100%, respectively. Most of the photoirritant chemicals were correctly identified by the 3T3 NRU PT; however, it provided false predictions for ca. 48% of photoallergens. The orders of sensitivity and specificity for photoallergenicity prediction were estimated to be: [sensitivity] ROS assay>UV/VIS absorption >> 3T3 NRU PT, and [specificity] 3T3 NRU PT>ROS assay >> UV/VIS absorption. Thus, photochemical assays, in particular the ROS assay, can be used for assessment of photoallergenicity, although there were some false-positive predictions</style></abstract><notes><style face="normal" font="default">DA - 20160409IS - 1879-3177 (Electronic)IS - 0887-2333 (Linking)LA - engPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Allergens)RN - 0 (Reactive Oxygen Species)RN - 261QK3SSBH (Neutral Red)SB - IMCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.tiv.2016.03.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26973152">PM:26973152</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicol In Vitro\2016-33-147-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicol In Vitro\2016-33-147-52.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160409, Onoue S</style></custom2><misc3><style face="normal" font="default">10.1016/j.tiv.2016.03.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40645</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Galbiati,V.</style></author><author><style face="normal" font="default"> Papale,A.</style></author><author><style face="normal" font="default"> Marinovich,M.</style></author><author><style face="normal" font="default"> Gibbs,S.</style></author><author><style face="normal" font="default"> Roggen,E.</style></author><author><style face="normal" font="default"> Corsini,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Toxicology, DiSFeB, Universita degli Studi di Milano, Milan, Italy</style></auth-address><titles><title><style face="normal" font="default">Development of an in vitro method to estimate the sensitization induction level of contact allergens</style></title><secondary-title><style face="normal" font="default">Toxicol Lett</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Toxicol Lett</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">4-Aminobenzoic Acid</style></keyword><keyword><style face="normal" font="default"> Alcohol</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Benzyl Alcohol</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Chlorpromazine</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact allergens</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Epidermis</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Limonene</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> standards</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Toxicology</style></keyword><keyword><style face="normal" font="default"> Urea</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="8" Month="2" Year="2017">2017/2/8</year></dates><abstract><style face="normal" font="default">No standardized in vitro methods to assess potency of skin sensitizers are available. Recently, we standardized a procedure which combines the epidermal equivalent potency assay with assessment of IL-18 to provide a single test for identification and classification of skin sensitizers. This current study aimed to extend tested chemicals, and to provide a simple in vitro method for estimation of the expected sensitization induction level interpolating in vitro EC50 and IL-18 SI2 values to predict LLNA EC3 and/or human NOEL from standards curves generated using reference contact allergens. Reconstituted human epidermis was challenged with 14 chemicals not previously tested benzoquinone, chlorpromazine, chloramine T, benzyl salicylate, diethyl maleate, dihydroeugenol, 2,4-dichloronitrobenzene, benzyl cinnamate, imidazolidinyl urea, and limonene as contact sensitizers while benzyl alcohol, isopropanol, dimethyl isophthalate and 4-aminobenzoic acid as non-sensitizers in the LLNA. Where for benzyl salicylate and benzyl cinnamate no sensitization was observed in human predictive studies, positive responses to benzyl alcohol and dimethyl isophthalate were reported. The proposed method correlates better with human data, correctly predicting substances incorrectly classified by LLNA. With the exception of benzoquinone (interference with both MTT and IL-18 ELISA), and chloramine T (underestimated in the interpolation), a good estimation of LLNA EC3 and in vivo available human NOEL values was obtained</style></abstract><notes><style face="normal" font="default">DA - 20170212IS - 1879-3169 (Electronic)IS - 0378-4274 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Netherlands -CO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1016/j.toxlet.2017.01.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28189648">PM:28189648</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicol Lett\20170212-GalbiatiV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicol Lett\20170212-GalbiatiV.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170212, Galbiati V</style></custom2><misc3><style face="normal" font="default">10.1016/j.toxlet.2017.01.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40646</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Thomsen,M.</style></author><author><style face="normal" font="default"> Thomas,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Klinik fur Orthopadie und Unfallchirurgie, Klinikum Mittelbaden, Balger Strasse 50, 76532, Baden-Baden, Deutschland.</style></auth-address><titles><title><style face="normal" font="default">[Compatibility and allergies of osteosynthesis materials]</style></title><secondary-title><style face="normal" font="default">Unfallchirurg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Unfallchirurg</style></abbr-1></periodical><pages end="121" start="116">116-121</pages><volume><style face="normal" font="default">120</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Connective Tissue</style></keyword><keyword><style face="normal" font="default"> Corrosion</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> Friction</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Steel</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Titanium</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="20" Month="1" Year="2017">2017/1/20</year></dates><abstract><style face="normal" font="default">Metal implants for osteosynthesis are nowadays standard in orthopedic and trauma surgery. Steel implants, especially cerclages, bands and wires, can show more corrosion due to friction and lead to encapsulation in connective tissue with fluid borders even without loosening. Corrosion and fluid borders are potentially more susceptible to incompatibility and infections. Titanium implants have the advantage of better allergic compatibility. Problems may occur in material removal, especially with titanium implants because material fractures occur more frequently. Particularly with fixed angle constructions, the blocking of titanium-titanium bonding and/or screws in bone can occur by adhesion and ingrowth. Apart from single case reports there is no evidence that modern steel implants cause more allergic reactions than titanium; therefore, in the treatment by osteosynthesis the stability, risk of loosening, manifestation of allergies and the possibility of material removal must always be considered</style></abstract><notes><style face="normal" font="default">DA - 20170121IS - 1433-044X (Electronic)IS - 0177-5537 (Linking)LA - gerPT - English AbstractPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1007/s00113-016-0309-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28108751">PM:28108751</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Unfallchirurg\2017-120-116-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Unfallchirurg\2017-120-116-21.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170121, Thomsen M</style></custom2><misc3><style face="normal" font="default">10.1007/s00113-016-0309-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40647</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Joeris,A.</style></author><author><style face="normal" font="default"> Goldhahn,S.</style></author><author><style face="normal" font="default"> Rometsch,E.</style></author><author><style face="normal" font="default"> Hontzsch,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">AO Clinical Investigation and Documentation, AO Foundation, Stettbachstrasse 6, 8600, Dubendorf, Schweiz.</style></auth-address><titles><title><style face="normal" font="default">[Titanium or steel as osteosynthesis material : Systematic literature search for clinical evidence]</style></title><secondary-title><style face="normal" font="default">Unfallchirurg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Unfallchirurg</style></abbr-1></periodical><pages end="102" start="96">96-102</pages><volume><style face="normal" font="default">120</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Comparative Study</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Documentation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> Extremities</style></keyword><keyword><style face="normal" font="default"> Fracture Healing</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Internet</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Publications</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Stainless Steel</style></keyword><keyword><style face="normal" font="default"> Steel</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Titanium</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="1" Year="2017">2017/1/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: The selection of the appropriate implant material, stainless steel or titanium, is still the decision of the surgeon and/or the affiliated institution. Additionally, remarkable international differences can be found between the different markets, which cannot really be explained. OBJECTIVE: A systematic literature search was performed to verify whether there is clinical evidence for the preference of one material over the other. MATERIAL AND METHODS: The systematic literature search was performed utilizing the internet databases PubMed, Cochrane and Web of Science. Comparative studies were included that reported on adult patients with osteosynthesis of extremities after trauma using either stainless steel or titanium implants. Information was extracted about infection rates, incidence of clinically relevant allergies, problems with implant removal and other complications. RESULTS: A total of 18 publications were identified to be eligible and 2 referenced articles were added. In summary, there is insufficient clinical evidence that the use of titanium or steel implants has a positive or negative effect on fracture healing, shows different rates of allergies, different rates of infections or mechanical failure. No supporting evidence could be identified for the difficulties with removal of titanium implants reported by surgeons. CONCLUSION: This systematic literature search did not provide any clinical evidence for material-related differences between titanium or stainless steel implants for fracture fixation. Based on the current clinical evidence both titanium and steel implants can be considered to be of equal value. The reported difficulties with implant removal are not reflected in the published literature</style></abstract><notes><style face="normal" font="default">DA - 20170121IS - 1433-044X (Electronic)IS - 0177-5537 (Linking)LA - gerPT - English AbstractPT - Journal ArticleCO - Switzerland -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1007/s00113-016-0299-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28108750">PM:28108750</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Unfallchirurg\2017-120-96-102.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Unfallchirurg\2017-120-96-102.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170121, Joeris A</style></custom2><misc3><style face="normal" font="default">10.1007/s00113-016-0299-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40648</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lake,E.</style></author><author><style face="normal" font="default"> Twigg,M.</style></author><author><style face="normal" font="default"> Farquharson,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Acute hypersensitivity reaction to femoral drug-coated balloons</style></title><secondary-title><style face="normal" font="default">Vasa</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Vasa</style></abbr-1></periodical><pages end="3" start="1">1-3</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Hospitals</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="3" Month="1" Year="2017">2017/1/3</year></dates><abstract><style face="normal" font="default">We describe a case of an acute hypersensitivity reaction to a paclitaxel-coated balloon used in the peripheral arterial circulation. Clinicians using these products should be aware of this potential risk.</style></abstract><notes><style face="normal" font="default">DA - 20170103IS - 0301-1526 (Print)IS - 0301-1526 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1024/0301-1526/a000604</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28045341">PM:28045341</url></web-urls></urls><custom2><style face="normal" font="default">20170103, Lake E</style></custom2><misc3><style face="normal" font="default">10.1024/0301-1526/a000604</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40649</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chio,G.I.</style></author><author><style face="normal" font="default"> Guerrero,A.G.</style></author><author><style face="normal" font="default"> Huerta,L.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Tratamiento con terapia de vendaje húmedo en dermatitis atópic</style></title><secondary-title><style face="normal" font="default">Alergia Asma Inmunol Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Alergia Asma Inmunol Pediatr</style></full-title></periodical><pages end="55" start="52">52-55</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Mexico</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Remission</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> terapia</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tratamiento</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a chronic infl ammatory dermatosis, characterized by fl ares and remissions. ADaffects 10% of the pediatric population approximately. At present there are multiple treatment options forAD with different results. The wet-wrap therapy, gives us an alternative to the management of moderateto severe AD with excellent results.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://new.medigraphic.com/cgi-bin/resumen.cgi?IDARTICULO=66625</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Alergia Asma Inmunol Pediatr\2016-25-52-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Alergia Asma Inmunol Pediatr\2016-25-52-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170228, Chio GI</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40650</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kazankova,E.M.</style></author><author><style face="normal" font="default"> Tirskaya,O.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Irkutsk State Medical University, Irkutsk, RussiaIrkutsk State Medical University, Irkutsk, Russia</style></auth-address><titles><title><style face="normal" font="default">[Stevens-Johnson syndrome in the dentist practice]</style></title><secondary-title><style face="normal" font="default">Stomatologiia (Mosk)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Stomatologiia (Mosk)</style></abbr-1></periodical><pages end="52" start="51">51-52</pages><volume><style face="normal" font="default">95</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> Anti-Allergic Agents</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Anti-Inflammatory Agents</style></keyword><keyword><style face="normal" font="default"> Anti-Inflammatory Agents,Non-Steroidal</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Conjunctiva</style></keyword><keyword><style face="normal" font="default"> Conjunctivitis</style></keyword><keyword><style face="normal" font="default"> dentist</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug therapy</style></keyword><keyword><style face="normal" font="default"> Drug Therapy,Combination</style></keyword><keyword><style face="normal" font="default"> Exanthema</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Mouth</style></keyword><keyword><style face="normal" font="default"> Mouth Mucosa</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Russia</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default"> Stevens-Johnson Syndrome</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> therapeutic use</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">The article presents a clinical example of the manifestations of Stevens-Johnson syndrome in a young patient. The patient had extensive lesions of the mucosa of the mouth, inflammation of the conjunctiva, itchy skin rashes. Good clinical result was obtained due to the prescribe treatment. The treatment included desensitizing, detoxifying and anti-inflammatory systematic and topical therapy</style></abstract><notes><style face="normal" font="default">DA - 20161123IS - 0039-1735 (Print)IS - 0039-1735 (Linking)LA - rusPT - Case ReportsPT - Journal ArticleRN - 0 (Anti-Allergic Agents)RN - 0 (Anti-Inflammatory Agents, Non-Steroidal)SB - DSB - IMCO - Russia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27876724">PM:27876724</url></web-urls></urls><custom2><style face="normal" font="default">20161123, Kazankova EM</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40651</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,M.J.</style></author><author><style face="normal" font="default"> Lee,H.S.</style></author><author><style face="normal" font="default"> Sol,I.S.</style></author><author><style face="normal" font="default"> Kim,M.N.</style></author><author><style face="normal" font="default"> Hong,J.Y.</style></author><author><style face="normal" font="default"> Lee,K.E.</style></author><author><style face="normal" font="default"> Kim,Y.H.</style></author><author><style face="normal" font="default"> Kim,K.W.</style></author><author><style face="normal" font="default"> Sohn,M.H.</style></author><author><style face="normal" font="default"> Kim,K.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Severance Hospital, Institute of Allergy, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Increased sputum levels of thymus and activation-regulated chemokine in children with asthma not eosinophilic bronchitis</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Bronchitis</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> pulmonary function test</style></keyword><keyword><style face="normal" font="default"> Pulmonary function tests</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> Sputum eosinophilia</style></keyword><keyword><style face="normal" font="default"> TARC</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="18" Month="2" Year="2017">2017/2/18</year></dates><abstract><style face="normal" font="default">BACKGROUND: Thymus and activation-regulated chemokine (TARC), a member of the CC chemokine family, plays a crucial role in Th2-specific inflammation. We aimed to determine the concentration of sputum TARC in children with asthma and eosinophilic bronchitis (EB) and its relation with eosinophilic inflammation, pulmonary function, and bronchial hyper-responsiveness. METHODS: In total, 90 children with asthma, 38 with EB, and 45 control subjects were enrolled. TARC levels were measured in sputum supernatants using an ELISA. We performed pulmonary function tests and measured exhaled fractional nitric oxide, eosinophil counts in blood, and sputum and serum levels of total IgE in all children. RESULTS: Sputum TARC levels were significantly higher in children with asthma than in either children with EB (p=0.004) or the control subjects (p=0.014). Among patients with asthma, sputum TARC concentration was higher in children with sputum eosinophilia than in those without sputum eosinophilia (p=0.035). Sputum TARC levels positively correlated with eosinophil counts in sputum, serum total IgE levels, exhaled fractional nitric, and the bronchodilator response. Negative significant correlations were found between sputum TARC and FEV1/FVC (the ratio of forced expiratory volume in one second and forced expiratory vital capacity) or PC20 (the provocative concentration of methacholine causing a 20% decrease in the FEV1). CONCLUSION: Elevated TARC levels in sputum were detected in children with asthma but not in children with EB. Sputum TARC could be a supportive marker for discrimination of asthma from EB in children showing characteristics of eosinophilic airway inflammation</style></abstract><notes><style face="normal" font="default">DA - 20170227IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2016.12.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28238403">PM:28238403</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170227-KimMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170227-KimMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170227, Kim MJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2016.12.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40652</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Julia-Benito,J.C.</style></author><author><style face="normal" font="default"> Escarrer-Jaume,M.</style></author><author><style face="normal" font="default"> Guerra-Perez,M.T.</style></author><author><style face="normal" font="default"> Contreras-Porta,J.</style></author><author><style face="normal" font="default"> Tauler-Toro,E.</style></author><author><style face="normal" font="default"> Madronero-Tentor,A.</style></author><author><style face="normal" font="default"> Cerda-Mir,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centro Sanitario Integrado Alzira II, Valencia, Spain.</style></auth-address><titles><title><style face="normal" font="default">Knowledge of asthma and anaphylaxis among teachers in Spanish schools</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Asma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child Care</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Education</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> paediatric asthma</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Teaching</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="18" Month="2" Year="2017">2017/2/18</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Allergic diseases affect 15-20% of the paediatric population in the industrialised world. Most educational centres in Spain do not have health professionals among their staff, and the teachers are in charge of child care in school. The advisability of specific training of the teaching staff should be considered, with the introduction of concrete intervention plans in the event of life-threatening emergencies in schools. MATERIAL AND METHODS: Evaluation of the training needs constitutes the first step in planning an educational project. In this regard, the Health Education Group of the Spanish Society of Clinical Immunology, Allergology and Paediatric Asthma (Grupo de Educacion Sanitaria de la Sociedad Espanola de Inmunologia Clinica, Alergologia y Asma Pediatrica [SEICAAP]) assessed the knowledge of teachers in five Spanish Autonomous Communities, using a self-administered questionnaire specifically developed for this study. The data obtained were analysed using the SPSS statistical package. RESULTS: A total of 2479 teachers completed the questionnaire. Most of them claimed to know what asthma is, and almost one half considered that they would know how to act in the event of an asthma attack. This proportion was higher among physical education teachers. Most would not know how to act in the case of anaphylaxis or be able to administer the required medication. In general, the teachers expressed interest in receiving training and in having an interventional protocol applicable to situations of this kind. DISCUSSION: It is important to know what the training requirements are in order to develop plans for intervention in the event of an emergency in school. Teachers admit a lack of knowledge on how to deal with these disorders, but express a wish to receive training</style></abstract><notes><style face="normal" font="default">DA - 20170227IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2016.10.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28238404">PM:28238404</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170227-JuliaBenitoJC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170227-JuliaBenitoJC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170227, Julia-Benito JC</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2016.10.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40653</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wan,K.H.</style></author><author><style face="normal" font="default"> Radke,N.</style></author><author><style face="normal" font="default"> Lam,D.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hong Kong, China</style></auth-address><titles><title><style face="normal" font="default">Endophthalmitis After Intravitreal Injections in Patients With Self-reported Iodine Allergy</style></title><secondary-title><style face="normal" font="default">Am J Ophthalmol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Am J Ophthalmol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endophthalmitis</style></keyword><keyword><style face="normal" font="default"> Hong Kong</style></keyword><keyword><style face="normal" font="default"> Injections</style></keyword><keyword><style face="normal" font="default"> Iodine</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword></keywords><dates><year Day="9" Month="2" Year="2017">2017/2/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170213IS - 1879-1891 (Electronic)IS - 0002-9394 (Linking)LA - engPT - LetterCO - Hong Kong -CO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.ajo.2016.11.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28190511">PM:28190511</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Ophthalmol\20170213-WanKH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Ophthalmol\20170213-WanKH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170213, Wan KH</style></custom2><misc3><style face="normal" font="default">10.1016/j.ajo.2016.11.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40654</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Narayanan,P.P.</style></author><author><style face="normal" font="default"> Jeffres,M.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Mayo Clinic Hospital-Rochester, MN, USA2 University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA</style></auth-address><titles><title><style face="normal" font="default">Feasibility, Benefits, and Limitations of a Penicillin Allergy Skin Testing Service</style></title><secondary-title><style face="normal" font="default">Ann Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Pharmacother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> betalactam allergy</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic test</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Care Costs</style></keyword><keyword><style face="normal" font="default"> Increased prevalence</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacist</style></keyword><keyword><style face="normal" font="default"> Pharmacists</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> Stewardship</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="2" Year="2017">2017/2/1</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To critically examine the feasibility, benefits, and limitations of an inpatient penicillin skin testing service and how pharmacists can be utilized. DATA SOURCES: A PubMed search was performed from July 2016 through September 2016 using the following search terms: penicillin skin testing, penicillin allergy, beta-lactam allergy. Additional references were identified from a review of literature citations. STUDY SELECTION AND DATA EXTRACTION: All English-language studies assessing the use of penicillin skin testing as well as management and clinical outcomes of patients with a beta-lactam allergy were evaluated. DATA SYNTHESIS: The prevalence of people self-identifying as penicillin allergic ranges from 10% to 20% in the United States. Being improperly labeled as penicillin allergic is associated with higher health care costs, worse clinical outcomes, and an increased prevalence of multidrug-resistant infections. Penicillin skin testing can be a tool used to clarify penicillin allergies and has been demonstrated to be a successful addition to antimicrobial stewardship programs in multiple health care settings. Prior to implementing a penicillin skin testing service, institutions will need to perform a feasibility analysis of who will supply labor and accept the financial burden as well as identify if the positive benefits of a penicillin skin testing service overcome the limitations of this diagnostic test. CONCLUSION: We conclude that institutions with high percentages of patients receiving non-beta-lactams because of penicillin allergy labels would likely benefit the most from a penicillin skin testing service</style></abstract><notes><style face="normal" font="default">DA - 20170203IS - 1542-6270 (Electronic)IS - 1060-0280 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/1060028017690854</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28152605">PM:28152605</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Pharmacother\20170203-NarayananPP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Pharmacother\20170203-NarayananPP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170203, Narayanan PP</style></custom2><misc3><style face="normal" font="default">10.1177/1060028017690854</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40655</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Erdogan,T.</style></author><author><style face="normal" font="default"> Akdogan,A.</style></author><author><style face="normal" font="default"> Ugur Demir,A.</style></author><author><style face="normal" font="default"> Karakaya,G.</style></author><author><style face="normal" font="default"> Kalyoncu,A.F.</style></author></authors></contributors><titles><title><style face="normal" font="FrutigerRoman">Prevalance of Allergic Diseases in Patients with Raynaud Phenomenon</style></title><secondary-title><style face="normal" font="default">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asthma Allergy Immunol</style></full-title></periodical><pages end="163" start="157">157-163</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Arthritis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cold</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Ice</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Specific IgE</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> Vasomotor rhinitis</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Objective: Raynaud phenomenon (RP) is an exaggerated vascularresponse to cold or emotional stress. Cold is also a trigger for allergicdiseases like asthma, vasomotor rhinitis and urticaria (cold urticaria,idiopathic urticaria, dermographism). The aim of the present studywas to investigate the prevalence of allergic diseases in patients withprimary and secondary Raynaudfs phenomenon.Materials and Methods: A total of 53 consecutive patients with RPwho were followed at Hacettepe University Hospitalfs Division ofRheumatology and volunteered for allergic evaluation were enrolledbetween April 2013-September 2013. An additional 20 patientswith rheumatologic diseases and without Raynaud phenomenonwere included as the control group. A questionnaire evaluating thepresence of allergic diseases was administered to all patients. Eitherskin prick test or specific IgE (phadiatop) was requested dependingon oral corticosteroid usage. Pulmonary function and ice cube testswere performed for all patients.Results: Among the patients included in the study, 90.4%werewomen and 72.6% had RF. The most common rheumatologic diseaseswere scleroderma and rheumatoid arthritis. Patients with vasomotorrhinitis (12.3%), dermographism (8.2%) and cold urticaria (4.1%) allhad RF. Thirty seven percent of all patients had at least one allergicdisease. Having allergic diseases was not associated with RF. Conclusion: In conclusion, it has been shown that cold-relateddiseases such as asthma, vasomotor rhinitis, cold urticaria anddermographism were more frequent in patients with RF. In addition,the frequency of allergic diseases in patients with rheumatoidarthritis was not less than that of the normal population.</style></abstract><notes><style face="normal" font="default">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.aai.org.tr/index.php/aai/article/view/56</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-157-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-157-63.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170228, Erdogan T</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40656</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Altun,D.</style></author><author><style face="normal" font="default"> Akpinar,M.</style></author><author><style face="normal" font="default"> Haskologlu,Z.S.</style></author><author><style face="normal" font="default"> Koste Bal,S.</style></author><author><style face="normal" font="default"> Kavgaci,A.</style></author><author><style face="normal" font="default"> Figen Dogu,E.</style></author><author><style face="normal" font="default"> Ikinciogullari,K.A.</style></author></authors></contributors><titles><title><style face="normal" font="FrutigerRoman">Immunoglobulin Isotype Deficiency Together with Allergic Diseases</style></title><secondary-title><style face="normal" font="default">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asthma Allergy Immunol</style></full-title></periodical><pages end="169" start="164">164-169</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Iga</style></keyword><keyword><style face="normal" font="default"> IgA Deficiency</style></keyword><keyword><style face="normal" font="default"> Igm</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infancy</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Objective: Frequent infection is the most common reason forpresentation to outpatient clinics during infancy and in the pre-schoolperiod. The aim of this study was to evaluate the incidence of allergicdisorders in patients who apply to our allergy-immunology clinicfor frequent infections and receive a diagnosis of immunoglobulinisotype deficiency.Materials and Methods: The medical records of 2592 patients whopresented to the Department of Pediatric Immunology-Allergy ofthe Ankara University School of Medicine between January 2013 andFebruary 2016 complaining of frequent infections were investigatedretrospectively.Results: 258 (9.9%) patients had immunoglobulin isotype deficiency.The age range was 6-204 months. 151 (58.5%) were male and 107(41.5%) were female. 17% had parental consanguinity. The diagnosiswas selective IgA deficiency in 12 (4.6%), partial IgA deficiencyin 31 (12%), isolated IgM deficiency in 53 (20.5%), and transienthypogammaglobulinemia of infancy in 117 (45.3%). 33 (12.7%)were considered as prolonged hypogammaglobulinemia and 12(4.6%) as unclassified hypogammaglobulinemia. 173 (67%) patientshad an allergic disease besides immunoglobulin isotype deficiency.The allergic diagnoses of the patients were asthma in 90, atopic dermatitis in 66, allergic rhinoconjunctivitis in 47 and transientwheezing of infancy in 44. There was no statistical differencebetween the isotypes regarding co-incidence of allergic disease andimmunoglobulin deficiency (p=0.83).Conclusion: Rates of concurrence with an allergic disease regardlessof the type of immunoglobulin isotype deficiency was high inour patients. One must consider that immunodeficiency may becombined with recurrent infection and atopy in patients presentingwith allergy symptoms and it is important to investigate accordinglyfor the appropriate management of treatment.</style></abstract><notes><style face="normal" font="default">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.aai.org.tr/index.php/aai/article/view/55</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-164-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-164-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170228, Altun D</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40657</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Turkeli,A.</style></author><author><style face="normal" font="default"> Ayaz,O.</style></author><author><style face="normal" font="default"> Uncu,A.</style></author><author><style face="normal" font="default"> Ozhan,B.</style></author><author><style face="normal" font="default"> Kavaz Tufan,A.</style></author><author><style face="normal" font="default"> Nijat Bas,V.</style></author><author><style face="normal" font="default"> Yilmaz,O.</style></author><author><style face="normal" font="default"> Yuksel,H.</style></author></authors></contributors><titles><title><style face="normal" font="FrutigerRoman">Effects of Vitamin D Levels on Asthma Control and Severity in Children</style></title><secondary-title><style face="normal" font="default">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asthma Allergy Immunol</style></full-title></periodical><pages end="156" start="148">148-156</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> Vitamin D Deficiency</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Objective: The prevalence rates of asthma and vitamin D deficiency have been increasing in parallel, leading to significant morbidity.This study aimed to compare the vitamin D levels in the children with asthma and in healthy controls and to assess the relationshipbetween vitamin D levels and asthma clinical parameters and control.Materials and Methods: 115 children with asthma and 115 controlswho presented to the Pediatric Immunology and Allergy outpatientclinic between December 2014 and February 2015 were enrolled inthe study. Vitamin D levels were measured. Levels . 20 ng/ml wereconsidered adequate and those lower than 20 ng/ml as deficient.Asthma control was classified according to the Global Initiativefor Asthma guidelines (GINA) and Childhood asthma control test(C-ACT).Results: Serum vitamin D levels were 17.27 (5.77) ng/ml in theasthma group and 22.78 (10.64) ng/ml in the control group,indicating statistical significance (p= 0.001). When the asthmapatients were divided into groups according to vitamin D level,72.2% were deficient while 27.8% had adequate levels. The numberof asthma exacerbations, number of emergency service visits andthe number of hospitalizations within the last year were higher inthe deficient group, compared to the adequate group (p &lt;0.001, p&lt;0.001 and p &lt;0.002, respectively). Uncontrolled asthma rates werehigher in the deficient group, compared to the adequate group (p&lt;0.01). Serum vitamin D levels were correlated with the ACT score(r=0.204, p=0.03).Conclusion: The rate of vitamin D deficiency was higher in asthmaticchildren compared to the controls. We also showed that increasedasthma severity and reduced asthma control were associated withvitamin D deficiency. There was a positive correlation betweenserum vitamin D levels and asthma control.</style></abstract><notes><style face="normal" font="default">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.aai.org.tr/index.php/aai/article/view/68</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-148-56.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-148-56.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170228, Turkeli A</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40658</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ozdemir,O.</style></author><author><style face="normal" font="default"> Karavaizoglu,C.</style></author></authors></contributors><titles><title><style face="normal" font="FrutigerRoman">Utilization of Flow Cytometry in Immunologic and Allergic Diseases</style></title><secondary-title><style face="normal" font="default">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asthma Allergy Immunol</style></full-title></periodical><pages end="128" start="117">117-128</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophil activation test</style></keyword><keyword><style face="normal" font="default"> CD63</style></keyword><keyword><style face="normal" font="default"> Cell Size</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Common Variable Immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> Immunotherapy</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Severe Combined Immunodeficiency</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Flow cytometry is a device that analyzes the physical and/orchemical characteristics of cells or particles as they pass through afluid system one by one. Laser beam diffracted and florescent lightemitted by each cell or particle while passing through the fluidsystem are gathered by optic filters and mirrors, separated intovarying wavelengths, and transformed into analogue signals. Thesignals are digitalized and transferred to a screen as histograms.The histograms are based on the principle of demonstrating thefrequency distributions of the parameters measured visually. Whilethe data obtained can be demonstrated in different graphics, the cellsare separated according to cell size and granular structure. Analysisof cell groups through fluorescently labeled antibodies enablinganalysis of more than one surface antigen at the same time canalso be performed by flow cytometry. Today, immunologic diseasesare one of the most common fields where flow cytometry is used.Monoclonal antibodies used to detect lymphocyte subgroups inflow cytometry are crucial in the diagnosis of disease groups andtypes. Examples of some types of immunodeficiency diagnosed byflow cytometry are given in this study. Immunologic diseases suchas severe combined immunodeficiency, Brutonfs disease, chronicgranulomatous disease, common variable immunodeficiency andbare lymphocyte syndrome can be assessed with flow cytometry. Itsuse in allergic diseases is based on measuring basophil activationin flow cytometry. When the basophil contacts with antigen, thecell activates and expresses CD63 on the surface. Besides, there areclinical studies showing that the basophil activation test can be usedto monitor the effectiveness of allergen immunotherapy. In nearfuture, flow cytometry will be continued to be used more intenselyin the diagnosis and follow-up of allergic and immunologic diseaseswith new markers and more developed technology.</style></abstract><notes><style face="normal" font="default">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.aai.org.tr/index.php/aai/article/view/51</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-117-28.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-117-28.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170228, Ozdemir O</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40659</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gokturk,B.</style></author><author><style face="normal" font="default"> Reisli,I.</style></author></authors></contributors><titles><title><style face="normal" font="FrutigerRoman">DiGeorge Syndrome</style></title><secondary-title><style face="normal" font="default">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asthma Allergy Immunol</style></full-title></periodical><pages end="142" start="129">129-142</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Awareness</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Counseling</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> DiGeorge Syndrome</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic Counseling</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">DiGeorge syndrome, which is caused by abnormal development and migration of neural crest cells, is the most common micro deletion syndrome. The phenotype is variable due to the existence of more than 35 genes in the typical deletion region. However, the genotype phenotype correlation is very weak in this patient group. Every patient with facial dysmorphism, delay in developmental milestone sand macrothrombocytopenia should be questioned for the other specific findings of DGS, and tested if needed. All findings do not have to be together to make the diagnosis. It should be known that patients experience different problems at different stages of their lives, and genetic counseling should be provided to the patients and their families. Our aim in this review was to provide detailed information and raise awareness about DGS as it is common but rarely diagnosed, and presents many difficulties during follow-up.</style></abstract><notes><style face="normal" font="default">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.aai.org.tr/index.php/aai/article/view/37</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-129-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-129-42.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160228, Gokturk B</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40660</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ozceker,D.</style></author><author><style face="normal" font="default"> Kurkcu,D.</style></author><author><style face="normal" font="default"> Umur,O.</style></author><author><style face="normal" font="default"> Genco Gencay,A.</style></author><author><style face="normal" font="default"> Tamay,Z.</style></author><author><style face="normal" font="default"> Guler,N.</style></author></authors></contributors><titles><title><style face="normal" font="FrutigerRoman">The Importance of Diagnostic Tests in Delayed Type Beta-Lactam Allergy: A Case Report</style></title><secondary-title><style face="normal" font="default">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asthma Allergy Immunol</style></full-title></periodical><pages end="97" start="93">93-97</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> betalactam allergy</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic test</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Gold</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral infection</style></keyword><keyword><style face="normal" font="default"> Viral infections</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Adverse reactions to drugs have been defined by the WHO asunwanted effects that occur during the use of a drug. The diagnosisof drug allergies is not always straightforward due to confoundingfactors such as the use of multiple drugs and similarity of thepertinent symptoms to those that can be attributed to diseaseprocesses. In children, drug allergies are most commonly mistakenfor rashes induced by viral infections. The first step towards thediagnosis of drug allergies is a detailed history and the second stepis choosing a laboratory test according to this history. Skin pricktesting is preferred for immediate type reactions while skin patchtesting should be performed for delayed type reactions. When allergytests are negative, drug provocation testing is the gold standard. Inthis paper, a case with a negative skin patch test that was ultimatelydiagnosed through a provocation test is presented.</style></abstract><notes><style face="normal" font="default">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.aai.org.tr/index.php/aai/article/view/39</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-93-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-93-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170228, Ozceker D</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40661</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Koksal,B.T.</style></author><author><style face="normal" font="default"> Ozbek,O.Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effect of Obesity on Pulmonary Function in Children with Mild Persistent Asthma</style></title><secondary-title><style face="normal" font="default">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asthma Allergy Immunol</style></full-title></periodical><pages end="63" start="56">56-63</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">aeroallergens</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> cross-sectional analysis</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> pulmonary function test</style></keyword><keyword><style face="normal" font="default"> Pulmonary function tests</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Objective: The prevalence of asthma is increased in obese individuals.There is no concrete evidence that an increase in body mass index isassociated with a loss of pulmonary function in childhood asthma.Our aim was to investigate the effect of obesity, atopy, and sex onpulmonary function in asthmatic children.Materials and Methods: This study is a cross-sectional analysis inchildren with mild persistent asthma. A total of 76 obese and 55 leanchildren with asthma were recruited. All of the participants wereassessed by pulmonary function tests. Skin prick tests includingcommon aeroallergens were performed to all patients.Results: No differences were found in pulmonary function testparameters between obese and lean patients with asthma. In obesepatients with asthma, the ratio of forced expiratory volume in 1 sto forced vital capacity (FEV1/FVC) was significantly lower innonatopic (92.1±6.4) than in atopic patients (95.5±5.3, p=0.02).We also demonstrated that FEV1/FVC was significantly lower innonatopic obese patients (92.1±6.4) than in nonatopic lean patientswith asthma (95.6±4.7, p=0.05).Conclusion: Obesity does not seem to be affecting pulmonaryfunction in children with well-controlled mild persistent asthma.However, airways of nonatopic obese asthmatics are negativelyaffected.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.aai.org.tr/index.php/aai/article/view/65</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-56-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-56-63.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170228, Koksal BT</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40662</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kiykim,A.</style></author><author><style face="normal" font="default"> Aydiner,E.K.</style></author><author><style face="normal" font="default"> Ogulur,I.</style></author><author><style face="normal" font="default"> Baris,S.</style></author><author><style face="normal" font="default"> Ozen,A.</style></author><author><style face="normal" font="default"> Serifov,K.</style></author><author><style face="normal" font="default"> Bademci,G.</style></author><author><style face="normal" font="default"> Tekin,M.</style></author><author><style face="normal" font="default"> Elcioglu,N.H.</style></author><author><style face="normal" font="default"> Barlan,I.</style></author></authors></contributors><titles><title><style face="normal" font="FrutigerBold">Two Siblings Presenting with Different Phenotypes</style></title><secondary-title><style face="normal" font="default">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asthma Allergy Immunol</style></full-title></periodical><pages end="102" start="98">98-102</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Failure to Thrive</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Lymphopenia</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Otitis</style></keyword><keyword><style face="normal" font="default"> Otitis Media</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Siblings</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">The Nijmegen Breakage syndrome (NBS) is characterized bychromosomal instability, combined immunodeficiency, anddistinctive physical features. We present two siblings withNBS presenting with strikingly different manifestations. Theproband is a 6-year-old female with short stature, microcephaly,hepatosplenomegaly, rectovaginal fistula, anal atresia, an ectopickidney, recurrent fevers and otitis media. A 7-year-old brother hasdevelopmental delay, failure to thrive, and microcephaly withoutrecurring infections. Both patients have hypogammaglobulinemia,B cell lymphopenia and reduced phytohaemagglutinin-inducedlymphocyte proliferation. Both siblings are homozygous for thec.657_661delACAAA (p.Lys219Asnfs*16) mutation in the NBN(NBS1) gene.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.aai.org.tr/index.php/aai/article/view/64</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-98-102.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-98-102.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170228, Kiykim A</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40663</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Uzay Cetinkaya,P.</style></author><author><style face="normal" font="default"> Guvenir,H.</style></author><author><style face="normal" font="default"> Cetinkaya,E.</style></author><author><style face="normal" font="default"> Kocabas,C.N.</style></author></authors></contributors><titles><title><style face="normal" font="FrutigerRoman">How Reliable is the Information in the Internet on Atopic Dermatitis?</style></title><secondary-title><style face="normal" font="default">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asthma Allergy Immunol</style></full-title></periodical><pages end="70" start="64">64-70</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Internet</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Objective: The Internet is a very widely used information source andfrequently used to obtain information about health, in particular.The aim of this study was to investigate, with reference to theinternational guidelines, the contents of Turkish web pages, preparedto provide information about atopic dermatitis (AD).Materials and Methods: The web sites evaluated in this studywere obtained through the search engine http://www.google.com.tr/, using the keywords atopic dermatitis and eczema. Sites wereclassified according to their source and were examined in terms ofdefinition, diagnostic methods, and treatment recommendationswith reference to the international guidelines.Results: In the analysis according to source, most of the pages(29%) were blog/forum pages, prepared by unknown persons, andpersonal physician pages (22%). While the proportion of sites withvideo information was 6%, the proportion of social networkingsites was 2%. In the analysis according to their content, completeand accurate information in terms of diagnosis and treatment ofAD were found in child health and disease and child allergy andimmunology specialist personal pages, the page of associationsand the Internet encyclopedia Wikipedia. While the most accuratetreatment approaches were non-pharmacological treatment (17%)and prophylactic treatment (25%), topical medications were definedin an insufficient number of sites. The number of sites with proposalsof alternative medicine was found to be quite high (28%). Conclusion: Despite the large number of Internet sites providinginformation on atopic dermatitis, many sites were not based onmedical resources, and there was a lot of content that was incompleteor incorrect, mainly involving reviews by users. We believe thatInternet sites need to be reviewed for their content and the existinginformation needs to be improved in terms of reliability andtimeliness.</style></abstract><notes><style face="normal" font="default">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.aai.org.tr/index.php/aai/article/view/59</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-64-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-64-70.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170228, Uzay Cetinkaya P</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40664</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ozdemir,O.</style></author><author><style face="normal" font="default"> Bekis Bozkurt,H.</style></author></authors></contributors><titles><title><style face="normal" font="FrutigerRoman">A Case Developing Anaphylaxis After Intravenous Methylprednisolone and Review of the Literature</style></title><secondary-title><style face="normal" font="default">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asthma Allergy Immunol</style></full-title></periodical><pages end="174" start="170">170-174</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> Biochemistry</style></keyword><keyword><style face="normal" font="default"> Dexamethasone</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glucocorticoids</style></keyword><keyword><style face="normal" font="default"> Headache</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Methylprednisolone</style></keyword><keyword><style face="normal" font="default"> Nausea</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pulse</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> SIT</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Tachycardia</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Although glucocorticoids are also known as anti-allergic drugs,rare allergic side effects of glucocorticoids have been reported inthe literature. These reactions vary from simple rash to anaphylaxis.Here, a patient who developed anaphylaxis several minutes afterintravenous methylprednisolone administration is described. Withthis report, we want clinicians to be aware of rare side effectsincluding anaphylaxis due to methylprednisolone, known as ananti-allergic drug. An 11-year-old female presented to an outsideemergency clinic with ataxia, headache, blurred eyesight and beingunable to sit without help for the last week. There was an upperrespiratory tract infection within two weeks in her medical history.She seemed well and systemic examination revealed normal findings.Neurological exam showed ataxic gait with positive Romberg andBabinski signs. Eye examination revealed bilateral papillary edema.Laboratory investigations revealed normal CBC, ESR, CRP androutine biochemistry values. Cranial MR suggested pseudotumorcerebri and intravenous methylprednisolone pulse therapy wasinitiated at the pediatric ward. Several minutes later, a maculopapularrash appeared on her neck and trunk followed by nausea, tachypnea,dsypnea and tachycardia. Consequently, a type 1 hypersensitivityreaction was suspected so the infusion was stopped temporarily andan antihistaminic administered by the pediatrician. The symptomswere resolved but they reappeared when the infusion was restartedmistakenly. An anaphylactic reaction to methylprednisolone wasconsidered and dexamethasone pulse was advised by the allergy unitinstead of methylprednisolone. Previous tolerance to the oral form ofmethylprednisolone by the patient verified the presumption that thereaction was against an excipient. This case indicates that there mayeven be an allergic reaction to anti-allergic medications.</style></abstract><notes><style face="normal" font="default">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.aai.org.tr/index.php/aai/article/view/35</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-170-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-170-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170301, Ozdemir O</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40665</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guvenir,H.</style></author><author><style face="normal" font="default"> Dibek Misirlioglu,E.</style></author><author><style face="normal" font="default"> Ademhan Tural,D.</style></author><author><style face="normal" font="default"> Yaprak,S.</style></author><author><style face="normal" font="default"> Toyran,M.</style></author><author><style face="normal" font="default"> Naci Kocabas,C.</style></author></authors></contributors><titles><title><style face="normal" font="FrutigerRoman">The Knowledge Level and Attitude of the Pediatrics and Family Health Assistant Physicians Regarding Drug Allergy</style></title><secondary-title><style face="normal" font="default">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asthma Allergy Immunol</style></full-title></periodical><pages end="147" start="143">143-147</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Attitude</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> early intervention</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Family Health</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Syncope</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Objective: Drug hypersensitivity is an important problem becauseof its fatal consequences, prolonged hospitalization and increasedtreatment cost. In our study, we aimed to evaluate the knowledgelevel and attitude of the pediatrics and family health assistantphysicians regarding drug hypersensitivity.Materials and Methods: Pediatrics and family health assistantphysicians in Ankara and Muðla were enrolled into the study.Physicians who accepted to participate in the study completed asurvey form.Results: 73.2% (n: 60) of the participating physicians were pediatricsassistants and 26.8% (n: 22) were family health assistants; thus atotal of 82 assistants were included in the study. The average age was27.54±1.75 (minimum-maximum: 25 - 33) years and 80.5% (n: 66)were female. 48.8% (n: 40) of the participants stated that they wereencountering 1-2 drug allergy cases per month. Only 24.4% (n: 20)of them questioned drug allergy before prescribing. 80.5% (n: 66)of the participants stated that urticaria/angioedema emerging afterdrug administration is a type I hypersensitivity reaction and 81.7%(n: 67) claimed that anaphylaxis is a type I hypersensitivity reaction.We observed that patients diagnosed with vasovagal syncope after parenteral drug administration were diagnosed with anaphylaxis by54.9% (n: 45) of the participants.Conclusion: Increasing the awareness about drug allergies willenable early intervention, proper selection of alternative drugtreatment, and prevention of the mortality and morbidity. Physiciansshould be educated about drug allergies, in order to increase theirknowledge to a satisfactory level.</style></abstract><notes><style face="normal" font="default">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.aai.org.tr/index.php/aai/article/view/67</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-143-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Allergy Immunol\2016-14-143-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170228, Guvenir H</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40666</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Allen,G.</style></author><author><style face="normal" font="default"> Chan,D.</style></author><author><style face="normal" font="default"> Gue,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Paediatric Dentistry, Women's and Children's Hospital North, Adelaide, South Australia</style></auth-address><titles><title><style face="normal" font="default">Investigation and Diagnosis of an Immediate Allergy to Amide Local Anaesthetic in a Paediatric Dental Patient</style></title><secondary-title><style face="normal" font="default">Aust Dent J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Aust Dent J</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Dentistry</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Local anaesthetics</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="default">Local anaesthetics remain the most common prescription medication utilised in dental practice. Adverse reactions following administration of local anaesthetic are somewhat common and are frequently reported as 'allergies'. However, of these events, it is estimated that only 1% are confirmed allergies to the local anaesthetic. This case presents the process of referral for investigation and testing to confirm an amide local anaesthetic allergy in a paediatric patient. Testing for a safe alternative was also completed to identify local anaesthetic agents also of the amide variety that can be utilised safely on this individual. Following skin testing of alternative agents intraoral challenges were completed. Finally, restorative dental treatment was provided safely for the patient with the use of an alternative amide local anaesthetic on a number of occasions with no further adverse outcomes. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170204IS - 1834-7819 (Electronic)IS - 0045-0421 (Linking)LA - engPT - Case ReportsCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/adj.12501</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28160767">PM:28160767</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Aust Dent J\20170204-AllenG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Aust Dent J\20170204-AllenG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, Allen G</style></custom2><misc3><style face="normal" font="default">10.1111/adj.12501</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40667</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mattoo,H.</style></author><author><style face="normal" font="default"> Stone,J.H.</style></author><author><style face="normal" font="default"> Pillai,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Massachusetts General Hospital, Harvard Medical School , Boston , MA , USA</style></auth-address><titles><title><style face="normal" font="default">Clonally expanded cytotoxic CD4+ T cells and the pathogenesis of IgG4-related disease</style></title><secondary-title><style face="normal" font="default">Autoimmunity</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Autoimmunity</style></abbr-1></periodical><pages end="24" start="19">19-24</pages><volume><style face="normal" font="default">50</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expansion</style></keyword><keyword><style face="normal" font="default"> Granzymes</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> IgG4</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Plasma Cells</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Staining</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> Th2 Cells</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">IgG4-related disease (IgG4-RD) is a systemic condition of unknown cause characterized by highly fibrotic lesions, with dense lymphoplasmacytic infiltrates containing a preponderance of IgG4-expressing plasma cells. CD4+ T cells and B cells constitute the major inflammatory cell populations in IgG4-RD lesions. IgG4-RD patients with active, untreated disease show a marked expansion of plasmablasts in the circulation. Although the therapeutic depletion of B cells suggests a role for these cells in the disease, a direct role for B cells or IgG4 in the pathogenesis of IgG4-RD is yet to be demonstrated. Among the CD4+ T-cell subsets, Th2 cells were initially thought to contribute to IgG4-RD pathogenesis, but many previous studies were confounded by the concomitant history of allergic diseases in the patients studied and the failure to use multi-color staining to definitively identify T-cell subsets in tissue samples. More recently, using an unbiased approach to characterize CD4+ T-cell subsets in patients with IgG4-RD - based on their clonal expansion and ability to infiltrate affected tissue sites - CD4+ CTLs have been identified as the major CD4+ T-cell subset in disease lesions as well as in the circulation. CD4+ CTLs in affected tissues secrete pro-fibrotic cytokines including IL-1beta, TGF-beta1, and IFN-gamma as well as cytolytic molecules such as perforin and granzymes A and B. In this review, we examine possible mechanisms by which activated B cells and plasmablasts may collaborate with the expanded CD4+ CTLs in driving the fibrotic pathology of the disease and describe the lacunae in the field and in our understanding of IgG4-RD pathogenesis</style></abstract><notes><style face="normal" font="default">DA - 20170207IS - 1607-842X (Electronic)IS - 0891-6934 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/08916934.2017.1280029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28166682">PM:28166682</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Autoimmunity\2017-50-19-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Autoimmunity\2017-50-19-24.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170207, Mattoo H</style></custom2><misc3><style face="normal" font="default">10.1080/08916934.2017.1280029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40668</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Park,H.S.</style></author><author><style face="normal" font="default"> Nakagawa,I.</style></author><author><style face="normal" font="default"> Yokoyama,S.</style></author><author><style face="normal" font="default"> Wajima,D.</style></author><author><style face="normal" font="default"> Wada,T.</style></author><author><style face="normal" font="default"> Motoyama,Y.</style></author><author><style face="normal" font="default"> Kichikawa,K.</style></author><author><style face="normal" font="default"> Nakase,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan</style></auth-address><titles><title><style face="normal" font="default">Nickel-associated delayed multiple white matter lesions after stent-assisted coil embolization of intracranial unruptured aneurysm</style></title><secondary-title><style face="normal" font="default">BMJ Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Arteries</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pulse</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="20" Month="2" Year="2017">2017/2/20</year></dates><abstract><style face="normal" font="default">Metal-induced encephalopathy after stent-assisted coil embolization is extremely rare. The present report describes two patients who presented with symptomatic intracranial parenchymal edematous lesions after stent-assisted coil embolization. A 64-year-old woman underwent stent-assisted coil embolization for a left internal carotid artery aneurysm; 21 days after the procedure she presented with right hand weakness and MRI revealed multifocal white matter lesions. Another woman aged 52 years underwent stent-assisted coil embolization for right vertebral artery aneurysm; 18 days after the procedure she presented with left-sided sensory disturbance and MRI demonstrated multiple white matter lesions. Treatment in both cases resulted in improvement of these lesions after steroid pulse therapy, and the patients had no associated morbidity 4 months after the procedures. Clinicians should monitor for neurologic symptoms and postoperative delayed radiologic parenchymal edematous changes associated with the metal allergic reaction after nitinol stent-assisted coil embolization</style></abstract><notes><style face="normal" font="default">DA - 20170221IS - 1757-790X (Electronic)IS - 1757-790X (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1136/bcr-2017-013005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28219914">PM:28219914</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Case Rep\20170221-ParkHS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Case Rep\20170221-ParkHS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170221, Park HS</style></custom2><misc3><style face="normal" font="default">10.1136/bcr-2017-013005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40669</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Paul,S.P.</style></author><author><style face="normal" font="default"> Barber,C.D.</style></author><author><style face="normal" font="default"> Zaborowski,K.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Honorary Consultant Paediatrician in the Department of Paediatrics, Yeovil District Hospital NHS Foundation Trust, Higher Kingston, Yeovil, Somerset BA21 4AT</style></auth-address><titles><title><style face="normal" font="default">Spontaneous surgical emphysema: an unusual complication of paediatric asthma</style></title><secondary-title><style face="normal" font="default">Br J Hosp Med (Lond)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Br J Hosp Med (Lond)</style></abbr-1></periodical><pages end="" start="659">659-</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> Emphysema</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> paediatric asthma</style></keyword><keyword><style face="normal" font="default"> paediatrics</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="2" Month="11" Year="2016">2016/11/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161109IS - 1750-8460 (Print)IS - 1750-8460 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.12968/hmed.2016.77.11.659</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27828753">PM:27828753</url></web-urls></urls><custom2><style face="normal" font="default">20161109, Paul SP</style></custom2><misc3><style face="normal" font="default">10.12968/hmed.2016.77.11.659</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40670</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Li,X.</style></author><author><style face="normal" font="default"> Liu,H.</style></author><author><style face="normal" font="default"> Zhao,L.</style></author><author><style face="normal" font="default"> Liu,J.</style></author><author><style face="normal" font="default"> Cai,L.</style></author><author><style face="normal" font="default"> Liu,L.</style></author><author><style face="normal" font="default"> Zhang,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Department Of Radiology, Institute Of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, 400042, China</style></auth-address><titles><title><style face="normal" font="default">Clinical observation of adverse drug reactions to nonionic iodinated contrast media in population with underlying diseases and risk factors</style></title><secondary-title><style face="normal" font="default">Br J Radiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Br J Radiol</style></abbr-1></periodical><pages end="" start="20160729">20160729-</pages><volume><style face="normal" font="default">90</style></volume><number><style face="normal" font="default">170</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Data Collection</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> iodinated contrast media</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Metformin</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Radiology</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To determine the adverse drug reactions (ADRs) profile of nonionic iodinated contrast media (NICMs) in population with underlying diseases and risk factors, and to provide guidance for more safe and rational use of ICMs in clinic. METHODS: Data from 120,822 cases who underwent enhanced CT examination in our hospital from January 2014 to March 2016 were collected. A standardized case report form (CRF) was used for data collection and analysis. RESULTS: The incidence of ADRs was 0.4% and 0.44% in patients with and without underlying diseases, respectively (P=0.378). Risk factors analysis revealed that patients with asthma had the highest incidence of ADRs, followed by cardiac insufficiency, and aged patients the lowest. There was a low incidence of ADRs in patients with metformin (0.36%) and beta-adrenaline receptor antagonists (0.20%) medication. The incidence was the highest in patients with previous ADRs to ICMs (7.17%) and the lowest in those with a history of ICMs usage but no previous reactions (0.32%). ADRs were more common in high-risk patients at a higher injection dose (>/= 100 ml, P&lt;0.01) and speed (>/= 5 ml/s, P&lt;0.01). CONCLUSIONS: The incidence of ADRs was extremely low in patients regardless of underlying diseases. Some high-risk factors have certain correlations with the occurrence of ADRs. Particular attention should be given to the patients at high-risk when performing enhanced CT examination. Advances in knowledge: The correlation between various risk factors and underlying diseases and ADRs were comprehensively analyzed in a large scale population</style></abstract><notes><style face="normal" font="default">DA - 20161208IS - 1748-880X (Electronic)IS - 0007-1285 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1259/bjr.20160729</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27928926">PM:27928926</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Radiol\2017-90-20160729.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Radiol\2017-90-20160729.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161208, Li X</style></custom2><misc3><style face="normal" font="default">10.1259/bjr.20160729</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40671</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rocha Felix,M.M.</style></author><author><style face="normal" font="default"> Chiaverini Ensina,L.F.</style></author><author><style face="normal" font="default"> Reis e Silva de Queiroz,G.</style></author><author><style face="normal" font="default"> Perello,M.I.</style></author><author><style face="normal" font="default"> de Jesus Nunes dos Santos,C.</style></author><author><style face="normal" font="default"> Sanchez Aranda,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Highlights from the I Workshop on Drug Allergy in Children</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="240" start="233">233-240</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Alergia</style></keyword><keyword><style face="normal" font="default"> Algorithms</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> Beta-lactam antibiotics</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cofactors</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drug</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> nonimmediate</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral provocation test</style></keyword><keyword><style face="normal" font="default"> Oral provocation tests</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> vaccine</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="default">In November 2015, the I Workshop on Drug Allergy in Children (I Workshop de Alergia aMedicamentos em Crianças) was held in Brazil. This scientific meeting was organized by theAdvisory Group on Drug Allergy of the Brazilian Association of Allergy and Immunology (AssociaçãoBrasileira de Alergia e Imunologia, ASBAI) with the goal of discussing the most relevant and uniqueaspects of drug hypersensitivity reactions (DHR) in children. Knowledge of drug hypersensitivityin children is limited. Many algorithms used in adults are replicated in children without specificresearch in this age group. Children with suspected DHR should be evaluated for their clinicalhistory, which will reveal the need for complementary tests (in vivo and in vitro). Infections mayact as cofactors or as differential diagnoses. There are protocols developed specifically for thisage group. One example is the investigation of non-immediate benign skin rashes associated withthe use of beta-lactam antibiotics (BLs). In these cases, oral provocation tests (OPT) are importanttools or diagnosis. In cases of hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs),OPT can also assist in the diagnosis and search for a safe treatment option. The managementof patients with vaccine reactions is another important field in pediatric allergy. In these cases,knowledge of the risk-benefit ratio may avoid unnecessary exclusion recommnedations. Thisarticle was prepared based on discussions taking place at the workshop. The aim was to presentthe highlights of the sessions and provide recommendations on how to manage DHR in thepediatric population.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.bjai.org.br/detalhe_artigo.asp?id=743</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2015-3-233-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2015-3-233-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170227, Rocha Felix MM</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40672</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Melo Goncalves,M.</style></author><author><style face="normal" font="default"> Silva Segundo,G.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Asthma prevalence among medical and nursing students at Universidade Federal de Uberlândia</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="258" start="251">251-258</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> allergen sensitization</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Alternaria</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Cladosporium</style></keyword><keyword><style face="normal" font="default"> Dermatophagoides</style></keyword><keyword><style face="normal" font="default"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> epithelia</style></keyword><keyword><style face="normal" font="default"> Epithelium</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Grasses</style></keyword><keyword><style face="normal" font="default"> House dust</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nursing</style></keyword><keyword><style face="normal" font="default"> Penicillium</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick testing</style></keyword><keyword><style face="normal" font="default"> Students</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="default">Objectives: To determine the prevalence of asthma among students of the Schools of Medicineand Nursing at Universidade Federal de Uberlândia (UFU) and to investigate the allergens mostcommonly associated with the disease in the study group. Methods: The International Studyof Asthma and Allergies in Childhood (ISAAC) questionnaire, modified for adults, was applied tomedical and nursing students at UFU. Students with a positive profile for asthma were recruited toundergo skin prick testing (SPT) with the following extracts: Dermatophagoides pteronyssinus (Derp), D. farinae (Der f), Blomia tropicalis (Blo t), Blattella germanica (Bla g), Alternaria sp., Aspergillussp., Cladosporium sp., and Penicillium sp.; epithelia of Canis familiaris (Can f) and Felis domesticus(Fel d) and grasses were also tested. Results: A total of 457 valid questionnaires were obtained.Of those, 50 (10.9%) had a positive profile for asthma; 36 questionnaires (72%) were answeredby women and 14 (28%) by men (F:M ratio: 2.57). The age of participants with a positive profilefor asthma ranged from 17 to 39 years, at a median of 20 years. Of the 50 students with apositive profile, 21 underwent SPT, with 61.9% positivity for Der p, 66.7% for Der f, 28.6% to Blot, and 4.7% to Can f, Fel d, and Alternaria. Conclusion: The prevalence of asthma in the studiedpopulation was 10.9%, with a female predominance. Allergen sensitization to house dust miteswas the most common finding.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.bjai.org.br/detalhe_artigo.asp?id=745</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2015-3-251-8.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default">20170227, Melo Goncalves M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40673</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Costa,D.</style></author><author><style face="normal" font="default"> Lima Melo,J.M.</style></author><author><style face="normal" font="default"> Vivolo Aun,M.</style></author><author><style face="normal" font="default"> Giavina Bianchi,P.F.,Jr.</style></author><author><style face="normal" font="default"> Laerte Boechat,J.</style></author><author><style face="normal" font="default"> Falbo Wandalsen,G.</style></author><author><style face="normal" font="default"> Rizzo,J.A.</style></author><author><style face="normal" font="default"> Cruz,A.A.</style></author><author><style face="normal" font="default"> Souza-Machado,A.</style></author><author><style face="normal" font="default"> Sano,F.</style></author><author><style face="normal" font="default"> Sarquis Serpa,F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Guideline for the management of severe asthma</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="225" start="205">205-225</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Differential diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Targeted therapy</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><abstract><style face="normal" font="default">Over the past decades, the concept of and approach to severe asthma have changed. Currently,severe asthma patients are considered to be those who need Global Initiative for Asthma (GINA)treatment steps 4 or 5 to control the disease or those whose disease remains difficult to controldespite this therapy. The diagnosis of severe asthma should be established after the evaluationof conditions that contribute to poor control, namely: adherence and access to treatment,inhalation technique, differential diagnosis, and comorbidities that affect this population. Inaddition to high-dose inhaled corticosteroid therapy associated with long-acting beta-2 agonists,long-acting muscarinic receptor antagonists and biological agents targeted against bioactivemolecules involved in the pathophysiology of the disease have been shown to be effective inasthma control. The introduction of targeted therapies with biological agents in GINA step 5 allowsprecision treatment, based on the asthma phenotype and/or endotype, and represents a newwindow of opportunity for severe asthma control. In this context, this guide was developed withthe objective of contributing to a better approach to severe asthma by the specialist.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.bjai.org.br/detalhe_artigo.asp?id=741</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2015-3-205-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2015-3-205-25.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170227, Costa D</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40674</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Macy,E.</style></author><author><style face="normal" font="default"> Khan,D.A.</style></author><author><style face="normal" font="default"> Castells,M.C.</style></author><author><style face="normal" font="default"> Lang,D.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy Kaiser Permanente San Diego Medical Center San Diego, CA, USA</style></auth-address><titles><title><style face="normal" font="default">Penicillin Allergy Testing, A Key Component of Antibiotic Stewardship</style></title><secondary-title><style face="normal" font="default">Clin Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Infect Dis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> Stewardship</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161208IS - 1537-6591 (Electronic)IS - 1058-4838 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="default">10.1093/cid/ciw795</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27927854">PM:27927854</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Infect Dis\20161208-MacyE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Infect Dis\20161208-MacyE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161208, Macy E</style></custom2><misc3><style face="normal" font="default">10.1093/cid/ciw795</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40675</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Herbert,C.</style></author><author><style face="normal" font="default"> Do,K.</style></author><author><style face="normal" font="default"> Chiu,V.</style></author><author><style face="normal" font="default"> Garthwaite,L.</style></author><author><style face="normal" font="default"> Chen,Y.</style></author><author><style face="normal" font="default"> Young,P.M.</style></author><author><style face="normal" font="default"> Traini,D.</style></author><author><style face="normal" font="default"> Kumar,R.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pathology, UNSW Australia, School of Medical Sciences, Sydney, N/A, 2052, Australia</style></auth-address><titles><title><style face="normal" font="default">Allergic environment enhances airway epithelial pro-inflammatory responses to rhinovirus infection</style></title><secondary-title><style face="normal" font="default">Clin Sci (Lond)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Sci (Lond)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway epithelial cell</style></keyword><keyword><style face="normal" font="default"> airway epithelial cells</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Chemokines</style></keyword><keyword><style face="normal" font="default"> Complement</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immunoassay</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> Interferon</style></keyword><keyword><style face="normal" font="default"> Interferons</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinovirus</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> TH2 cytokines</style></keyword><keyword><style face="normal" font="default"> TLR</style></keyword><keyword><style face="normal" font="default"> TLR7</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="23" Month="1" Year="2017">2017/1/23</year></dates><abstract><style face="normal" font="default">Airway epithelial cells (AEC) exhibit a pro-inflammatory phenotype in patients with allergic asthma. We examined the effect of an allergic cytokine environment on the response of AEC to rhinovirus, the most common trigger of acute exacerbations of asthma. Calu-3 cells, a well-differentiated human AEC line, were cultured with or without the T-helper type 2 cytokines IL-4 and IL-13, then stimulated with a toll-like receptor (TLR) 3 agonist (poly I:C, dsRNA) or a TLR7 agonist (imiquimod), or infected with rhinovirus 16. Expression of pro-inflammatory and anti-viral mediators, and of viral pattern-recognition molecules, was assessed using nCounter assays, quantitative real-time PCR, and protein immunoassays. Both dsRNA and imiquimod stimulated expression of mRNA for IL6 and IL8 , while expression of several chemokines and anti-viral response genes was induced only by dsRNA. Conversely, expression of other cytokines and growth factors was induced only by imiquimod. Rhinovirus infection not only stimulated expression of the inflammation-related genes induced by dsRNA, but also the complement pathway gene CFB and the novel pro-inflammatory cytokine IL32 In the Th2 cytokine environment, several mediators exhibited significantly enhanced expression, while expression of interferons was either unchanged or enhanced. The allergic environment also increased expression of pattern recognition receptors and of ICAM1 , the cell surface receptor for rhinovirus. We conclude that Th2 cytokines promote increased production of pro-inflammatory mediators by AEC following infection with rhinovirus. Increased viral entry or enhanced signaling via pattern recognition receptors could also contribute to the exaggerated inflammatory response to rhinovirus observed in allergic asthmatics</style></abstract><notes><style face="normal" font="default">DA - 20170124IS - 1470-8736 (Electronic)IS - 0143-5221 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1042/CS20160939</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28115681">PM:28115681</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Sci (Lond)\20170124-HerbertC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Sci (Lond)\20170124-HerbertC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170124, Herbert C</style></custom2><misc3><style face="normal" font="default">10.1042/CS20160939</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40676</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fallahi,P.</style></author><author><style face="normal" font="default"> Ruffilli,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy</style></auth-address><titles><title><style face="normal" font="default">Contact dermatitis and interferon-gamma dependent chemokines</style></title><secondary-title><style face="normal" font="default">Clin Ter</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Ter</style></abbr-1></periodical><pages end="e116" start="e112">e112-e116</pages><volume><style face="normal" font="default">167</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Chemokines</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Interferon</style></keyword><keyword><style face="normal" font="default"> Interferon-gamma</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritation</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Keratinocytes</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="default">Inflammation of the skin is the pathological base of contact dermatitis (CD), and cytokines are very important in its pathogenesis. Recently it has been shown that interferon (IFN)-gamma, and the IFN-gamma dependent chemokines, monokine induced by IFN-gamma (MIG), IFN-gamma-induced protein 10 (IP-10), and IFN-inducible T cell alpha chemoattractant (I-TAC), play an important role in CD. Allergic CD (ACD) is a T-cell-mediated disease in which expression of a distinct repertoire of chemokines results in the recruitment of effector T cells into the skin. An increased expression of MIG, IP-10 and I-TAC in the skin has been observed by many studies in ACD, but not in irritant CD. The IFN-gamma dependent chemokines are produced by keratinocytes, mainly during the clinically inflammatory phase of ACD. Also chemokine (C-X-C motif) receptor (CXCR) 3, the common receptor of the three IFN-gamma dependent chemokines, is upregulated in chemical-induced allergic skin responses when compared with irritant skin responses. However, other studies have shown a low level increase of IP-10 in irritant sodium dodecyl sulphate dermatitis. The above mentioned results show that although skin inflammation contact sensitizer-induced is similar to irritant-induced, the regulation of allergic inflammation-related gene MIG and IP-10, could help to discriminate skin sensitization from chemically irritation</style></abstract><notes><style face="normal" font="default">DA - 20161115IS - 1972-6007 (Electronic)IS - 0009-9074 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.7417/CT.2016.1953</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27845488">PM:27845488</url></web-urls></urls><custom2><style face="normal" font="default">20161115, Fallahi P</style></custom2><misc3><style face="normal" font="default">10.7417/CT.2016.1953</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40677</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chamberlain,D.B.</style></author><author><style face="normal" font="default"> Kodgule,R.</style></author><author><style face="normal" font="default"> Fletcher,R.R.</style></author><author><style face="normal" font="default"> Chamberlain,D.B.</style></author><author><style face="normal" font="default"> Kodgule,R.</style></author><author><style face="normal" font="default"> Fletcher,R.R.</style></author><author><style face="normal" font="default"> Chamberlain,D.B.</style></author><author><style face="normal" font="default"> Fletcher,R.R.</style></author><author><style face="normal" font="default"> Kodgule,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">A mobile platform for automated screening of asthma and chronic obstructive pulmonary disease</style></title><secondary-title><style face="normal" font="default">Conf Proc IEEE Eng Med Biol Soc</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Conf Proc IEEE Eng Med Biol Soc</style></abbr-1></periodical><pages end="5195" start="5192">5192-5195</pages><volume><style face="normal" font="default">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Algorithms</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cause of Death</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> Computer</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Learning</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peak flow</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> ROC</style></keyword><keyword><style face="normal" font="default"> Roc Curve</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="default">Chronic Obstructive Pulmonary Disease (COPD) and asthma each represent a large proportion of the global disease burden; COPD is the third leading cause of death worldwide and asthma is one of the most prevalent chronic diseases, afflicting over 300 million people. Much of this burden is concentrated in the developing world, where patients lack access to physicians trained in the diagnosis of pulmonary disease. As a result, these patients experience high rates of underdiagnosis and misdiagnosis. To address this need, we present a mobile platform capable of screening for Asthma and COPD. Our solution is based on a mobile smart phone and consists of an electronic stethoscope, a peak flow meter application, and a patient questionnaire. This data is combined with a machine learning algorithm to identify patients with asthma and COPD. To test and validate the design, we collected data from 119 healthy and sick participants using our custom mobile application and ran the analysis on a PC computer. For comparison, all subjects were examined by an experienced pulmonologist using a full pulmonary testing laboratory. Employing a two-stage logistic regression model, our algorithms were first able to identify patients with either asthma or COPD from the general population, yielding an ROC curve with an AUC of 0.95. Then, after identifying these patients, our algorithm was able to distinguish between patients with asthma and patients with COPD, yielding an ROC curve with AUC of 0.97. This work represents an important milestone towards creating a self-contained mobile phone-based platform that can be used for screening and diagnosis of pulmonary disease in many parts of the world</style></abstract><notes><style face="normal" font="default">DA - 20170223IS - 1557-170X (Print)IS - 1557-170X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1109/EMBC.2016.7591897</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28227680">PM:28227680</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Conf Proc IEEE Eng Med Biol Soc\2016-2016-5192-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Conf Proc IEEE Eng Med Biol Soc\2016-2016-5192-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170223, Chamberlain DB</style></custom2><misc3><style face="normal" font="default">10.1109/EMBC.2016.7591897</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40678</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Satat,G.</style></author><author><style face="normal" font="default"> Ramchander,K.</style></author><author><style face="normal" font="default"> Raskar,R.</style></author><author><style face="normal" font="default"> Satat,G.</style></author><author><style face="normal" font="default"> Ramchander,K.</style></author><author><style face="normal" font="default"> Raskar,R.</style></author><author><style face="normal" font="default"> Satat,G.</style></author><author><style face="normal" font="default"> Raskar,R.</style></author><author><style face="normal" font="default"> Ramchander,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Identi-wheez - A device for in-home diagnosis of asthma</style></title><secondary-title><style face="normal" font="default">Conf Proc IEEE Eng Med Biol Soc</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Conf Proc IEEE Eng Med Biol Soc</style></abbr-1></periodical><pages end="4378" start="4375">4375-4378</pages><volume><style face="normal" font="default">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Algorithms</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic illness</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Stethoscopes</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="8" Year="2016">2016/8</year></dates><abstract><style face="normal" font="default">Asthma is the most common chronic illness among children. The skills required to diagnose it make it an even greater concern. In this work, we present a child-friendly wearable device, which allows in-home diagnosis of asthma. The device acquires simultaneous measurements from multiple stethoscopes. The recordings are then sent to a specialist who uses assistive diagnosis algorithms that enable auscultation (listening to lung sounds with a stethoscope) at any location in the lungs volume by sound refocusing. The specialist is also presented with a sound "heat map" which shows the location of sound sources in the lungs. We present design considerations of our device, as well as the algorithms for assistive diagnosis and their analysis which demonstrate reduction of ambient and measurement noise by over 10dB</style></abstract><notes><style face="normal" font="default">DA - 20170223IS - 1557-170X (Print)IS - 1557-170X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1109/EMBC.2016.7591696</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28227481">PM:28227481</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Conf Proc IEEE Eng Med Biol Soc\2016-2016-4375-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Conf Proc IEEE Eng Med Biol Soc\2016-2016-4375-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170223, Satat G</style></custom2><misc3><style face="normal" font="default">10.1109/EMBC.2016.7591696</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40679</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Scott,C.</style></author></authors></contributors><titles><title><style face="normal" font="ArialMT">Macrophage Activation Syndrome</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="201" start="198">198-201</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Africa</style></keyword><keyword><style face="normal" font="default"> Arthritis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> diagnostic criteria</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophage Activation</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic juvenile idiopathic arthritis</style></keyword><keyword><style face="normal" font="default"> T lymphocyte</style></keyword><keyword><style face="normal" font="default"> T lymphocytes</style></keyword><keyword><style face="normal" font="default"> T-lymphocyte</style></keyword><keyword><style face="normal" font="default"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Macrophage activation syndrome (MAS) is an uncommon condition in which hyperinflammation and excessivecytokine release lead to excessive stimulation of T-lymphocytes and macrophages and result in a characteristicclinical picture of haematological dysfunction and multiple organ failure. This condition occurs most commonlyin the context of inflammatory conditions such as systemic juvenile idiopathic arthritis (sJIA). MAS is currentlyclassified as one of the forms of secondary haemophagocytic lymphohistiocytosis (HLH).1 The diagnosis of MASis clinically important as specific therapy may be required and a missed diagnosis may lead to high mortality.Unfortunately, the diagnosis is often not easily made due to the broad range of presenting features and theiroverlap with other potential complications of sJIA, such as severe infection. Also, no single clinical or laboratorytest is able to diagnose MAS conclusively. In this review we highlight some of the most important clinical andlaboratory features, diagnostic criteria, outcomes and management of MAS.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/J2016September</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-198-201.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-198-201.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, Scott C</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40680</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Royal,C.</style></author><author><style face="normal" font="default"> Levin,M.E.</style></author></authors></contributors><titles><title><style face="normal" font="ArialMT">Reactions to food additives</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="230" start="226">226-230</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Africa</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/December2016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-226-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-226-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170301, Royal C</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40681</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kling,S.</style></author></authors></contributors><titles><title><style face="normal" font="ArialMT">Clinician integrity, patient autonomy and the patient's best interests</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="178" start="176">176-178</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Africa</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/J2016September</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-176-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-176-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, Kling S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40682</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chongo-Faruk,V.</style></author></authors></contributors><titles><title><style face="normal" font="ArialMT">Allergies and other occupational diseases in the hairdressing industry</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="188" start="180">180-188</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Africa</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Hairdresser</style></keyword><keyword><style face="normal" font="default"> Hairdressers</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hobbies</style></keyword><keyword><style face="normal" font="default"> Hygiene</style></keyword><keyword><style face="normal" font="default"> Income</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> low income</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational disease</style></keyword><keyword><style face="normal" font="default"> Occupational Diseases</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword><keyword><style face="normal" font="default"> Workplace</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">The demand for cosmetic and hairdressing services is high. The hairdressing industry has grown to becomean important source of wealth and income internationally, with informal salons and hairdressing being morecommon in low-income settings. The daily exposure to a wide variety of repetitive practices, substancesand chemicals puts hairdressers at an increased health risk for some conditions - particularly on the skinand respiratory and musculoskeletal systems - as the workers are exposed to a diverse range of chemicals(irritants and allergens) and ergonomic risk factors. By means of a case study we illustrate the challenges amedical practitioner faces in trying to identify the causal agent responsible for a health condition at work ina trade where products contain numerous changing chemicals, yet the same chemicals may be ingredientsin personal hygiene products, food and medicines to which the worker is non-occupationally exposed. Itindicates the necessity of identifying the potentially hazardous chemicals through good detective work,including a detailed workplace visit and report, an exposure and task-directed history of work, hobbies andactivities of daily living together with relevant special investigations in order to achieve the best managementof the clinical condition.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/J2016September</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-180-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-180-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, </style><style face="normal" font="Roboto-Regular">Chongo-Faruk V</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40683</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Odusote,O.</style></author><author><style face="normal" font="default"> Davidson,A.</style></author><author><style face="normal" font="default"> van Eyssen,A.</style></author><author><style face="normal" font="default"> Hendricks,M.</style></author><author><style face="normal" font="default"> Levin,M.E:</style></author></authors></contributors><titles><title><style face="normal" font="ArialMT">Reaction to chemotherapy: A focus on Asparaginase</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="234" start="232">232-234</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adrenaline</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Africa</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Asparaginase</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> desensitisation</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Formulation</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Premedication</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> REACH</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Severe allergic reactions occur to L-asparaginase, an important chemotherapeutic agent in treatment ofchildhood leukaemia. Newer formulations of asparaginase associated with less adverse reactions are notreadily affordable or accessible in many resource-poor countries.Two children with prior severe allergic reactions (anaphylaxis) to L-asparginase were pre-medicated with H1and H2 antihistamines, and received L-asparaginase administered using a four-dose, 13-step desensitisationprotocol. The protocols were commenced in individual patients with each step lasting 30 minutes for a totalduration of six-and-a-half hours, but with subsequent successful infusions on a single subject, subjects weretried on sequentially faster protocols by increasing the infusion rates of steps to reach a lower duration oftime and/or omitting the first three to six steps of this protocol. This was particularly successful in childrenon the lower dose (6 000 U/m2) infusions and for those with short delays between subsequent infusions.Where subjects received 3 ~ 6 000 U/m2 doses in one week, these were done preferably on subsequentdays to allow immunological memory to persist and allow more rapid infusion protocols. We performed37 desensitisation procedures on the two index patients over a seven-month period. One subject had noadverse reactions, the other had five adverse reactions comprising non-allergic side-effects (three), oneminor reaction (urticaria) and one major reaction (urticaria, stridor and behaviour change) requiring a singledose of IM adrenaline. The major reaction occurred when the higher dose of asparaginase (15 000/m2) wasgiven via a shorter duration of administration after a two-week intervening period since the last prior infusion.With premedication and desensitisation, L-asparaginase can be successfully administered to children withprior severe allergic reactions.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/December2016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-232-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-232-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170301, Odusote O</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40684</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Olaniyan,T.A.</style></author><author><style face="normal" font="default"> Dalvie,M.A.</style></author><author><style face="normal" font="default"> Roosli,M.</style></author><author><style face="normal" font="default"> Jeebhay,M.F.</style></author></authors></contributors><titles><title><style face="normal" font="ArialMT">Air pollution, pollens and childhood asthma - is there a link?</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="261" start="252">252-261</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Africa</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollutants</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Climate</style></keyword><keyword><style face="normal" font="default"> Climate change</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pollen</style></keyword><keyword><style face="normal" font="default"> Pollens</style></keyword><keyword><style face="normal" font="default"> pollutants</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">While the interplay between ambient air pollutants and their role in the development of asthma continues to remaina subject of detailed study, a link appears to be postulated between ambient air pollutants and airborne pollens inthe increasing prevalence of allergic airway disease. With an increasing focus on climate change and the effectsof global warming, pollen allergy has become the focus of recent studies looking at the interrelationship betweenambient air pollutants and pollen exposures in individuals with allergic respiratory disease. At the population level,little is known about the potential synergistic effects between pollen allergens and air pollutants since this typeof association poses challenges in uncontrolled real-life settings. The current knowledge of the pathogenesisof allergies and asthma due to the combined exposure to biological agents such as pollens and air pollutantshas been based primarily on animal or in vitro studies. This article highlights possible mechanisms involved inthe interrelationship between air pollutants and pollen allergens with asthma, and summarises the evidence onthe independent and/or co-effect of multiple environmental exposures (ambient air pollutants and pollens) onchildhood asthma.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/December2016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-252-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-252-61.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170301, OLaniyan TA</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40685</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kiragu,E.W.</style></author><author><style face="normal" font="default"> Levin,M.</style></author></authors></contributors><titles><title><style face="normal" font="ArialMT">Allergic reactions related to Benzalkonium chloride</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="266" start="264">264-266</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Africa</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/December2016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-264-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-264-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170301, Kiragu EW</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40686</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Levin,M.</style></author><author><style face="normal" font="default"> van Niekerk,A.</style></author><author><style face="normal" font="default"> Katz,H.</style></author><author><style face="normal" font="default"> Stuurman,C.</style></author></authors></contributors><titles><title><style face="normal" font="ArialMT">Allergies in schools</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="276" start="272">272-276</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Africa</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Barriers</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Learning</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">With the increase of allergic conditions in South Africa, it is becoming more common for schools to have childrenin their care who suffer from asthma, allergic rhinitis, food allergies, insect allergies, anaphylaxis and atopicdermatitis. Unfortunately, inadequate guidelines exist for addressing the needs of such children and existinglegislation does not cover many of the issues - being either vague or inadequate.Since children spend a large proportion of their time at school, it is inevitable that the schools will have toaccommodate children with chronic-care needs and also encounter events where children experience allergyemergencies. School authorities have a responsibility to ensure that learners are able to achieve their fullpotential, despite barriers to learning, and that they are taught and cared for in a safe environment.This article outlines a practical and implementable policy for use in schools which is aimed at reducing theimpact on learning of children suffering chronic health conditions and ensuring the safety of children with severeallergies. The fundamental aspects of the policy include:- establishing an eallergy action committeef (or echronic illness action committeef) at each school;- ensuring every child with a chronic health condition is identified and has both a chronic and an emergencytreatment plan signed by their doctor and that these include an ID photograph;- implementing measures to reduce potential exposure to identified allergens for those with severe allergies;- ensuring that emergency medication is available and accessible at all times;- training staff online in the identification and treatment of severe allergic reactions.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/December2016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-272-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-272-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170301, Levin M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40687</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Salie,S.</style></author></authors></contributors><titles><title><style face="normal" font="ArialMT">Life-threatening asthma: Ventilatory support in paediatric intensive care</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="239" start="236">236-239</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Africa</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Airway Obstruction</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Emergency Treatment</style></keyword><keyword><style face="normal" font="default"> Exhalation</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> Intubation</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Rocuronium</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Ventilation</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">The majority of children with acute severe asthma respond to emergency treatment with only a small proportionof children requiring paediatric intensive care (PICU) admission. Airway inflammation, oedema, excessivemucus secretion with airway plugging and bronchospasm results in severe inspiratory and expiratory airwayobstruction.Non-invasive ventilatory support has been shown to be a safe method of decreasing the work of breathing,improving oxygenation and relieving expiratory airway obstruction in children. Intubation is a high-risk procedure,with ketamine and rocuronium being the preferred drugs for intubation. There are no appreciable differencesbetween using either pressure or volume modes of ventilation. Lung-protective ventilator strategies should beused to avoid ventilator-induced lung injuries. Low respiratory rates allow for a longer period of exhalation andavoids breath stacking. External positive-end expiratory pressure (PEEP) can relieve the airway obstructionfrom high intrinsic PEEP.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/December2016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-236-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-236-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170301, Salie S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40688</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Laher,A.E.</style></author><author><style face="normal" font="default"> Motara,F.</style></author><author><style face="normal" font="default"> Moolla,M.</style></author><author><style face="normal" font="default"> White,D.A.</style></author></authors></contributors><titles><title><style face="normal" font="ArialMT">Asthma in the Emergency Department: Strategies beyond acute management protocols</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="246" start="240">240-246</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">acute asthma</style></keyword><keyword><style face="normal" font="default"> Africa</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Evidence-based guidelines and protocols describe the management of acute asthma in the EmergencyDepartment. However, secondary prevention measures and strategies aimed at reducing EmergencyDepartment re-presentation after discharge from an acute asthmatic exacerbation are generally poorlyadvocated by clinicians based in the acute-care environment. In this article, we discuss aspects beyond acutemanagement protocols that relate to the acute asthmatic patient presenting to the Emergency Department.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/December2016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-240-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-240-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170301, Laher AE</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40689</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kling,S.</style></author></authors></contributors><titles><title><style face="normal" font="ArialMT">Consent, confidentiality and allergy in the Emergency Department</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="251" start="248">248-251</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Africa</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Fear</style></keyword><keyword><style face="normal" font="default"> Heat</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> office</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> Television</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">'There's a good reason - many, in fact - that the television drama "ER" has been a runaway hit for 8 years. Theemergency room is a crucible for the medical encounter. Life-threatening illness and trauma are more likely toappear here than in the office or clinic, hence, decisions often must be made quickly. Patients' physical distressand fear push them to extremes of behaviour. Crisis, fear, strange behaviour, and the opportunity for heroicsuccess or failure - the elements on which drama and melodrama thrive - are commonplace in the emergencyroom or emergency "department", as the expanded service in most hospitals is now more properly known.It makes sense that these high-pressure conditions turn up the heat on the patient-physician interaction also. Thepersonalities of individual patient and physician and the range of personal, social, and professional expectationsthat each brings to the interaction always have the potential to turn the medical encounter into a difficult one; theyare almost certain to do so in the emergency department where patients are frequently hostile, angry, combative,or abusive if special care is not taken to avoid potential problems.'</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/December2016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-248-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-248-51.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170301, Kling S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40690</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ainslie,G.M.</style></author></authors></contributors><titles><title><style face="normal" font="ArialMT">The Asthma COPD Overlap Syndrome (ACOS): What is it and how should we treat it?</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="150" start="146">146-150</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Africa</style></keyword><keyword><style face="normal" font="default"> airflow</style></keyword><keyword><style face="normal" font="default"> airflow obstruction</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="default"> Gold</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Asthma and COPD are two distinct diseases but may overlap, especially in older patients. Typically,asthma patients have marked variability in their airflow obstruction with significant reversibility in responseto both bronchodilator and corticosteroid therapy. However, it has become increasingly clear that manypatients with asthma may develop fixed airflow obstruction, whereas many patients with COPD exhibitsome bronchodilator reversibility. The term 'Asthma-COPD Overlap Syndrome' (ACOS) has been coined todescribe patients who have features of both but, as yet, there is no validated definition for the combination offeatures. Patients with ACOS have worse outcomes than those with asthma or COPD alone: more frequentexacerbations, poorer quality of life, more rapid decline in lung function, higher mortality and greaterhealthcare use. The Global Initiative for Asthma (GINA) and the Global Initiative for Chronic ObstructiveLung Disease (GOLD) have recently published guidelines for the diagnosis and treatment of patients withasthma, COPD or ACOS.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/J2016September</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-146-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-146-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, </style><style face="normal" font="Roboto-Regular">Ainslie GM</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40691</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Green,R.J.</style></author><author><style face="normal" font="default"> Jeevarathnum,A.C.</style></author><author><style face="normal" font="default"> van Niekerk,A.</style></author></authors></contributors><titles><title><style face="normal" font="ArialMT">The wheezy infant and toddler asthmatic - a primary care approach</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="144" start="140">140-144</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Africa</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Differential diagnosis</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Leukotriene antagonist</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Wheeze is common in infants and young children. Asthma is but one cause and it is obviously important toexclude or include as it is amenable to specific therapy. It is also obvious that the pre-school or young child is notjust a smaller variety of the older child or adult and this is especially true of asthma, where special situations existwith regard to diagnosis and treatment. Although there is a differential diagnosis for the major symptoms thatconstitute asthma in this age group, no child should be left to wheeze or cough without the possibility of asthmabeing considered and excluded. New guidelines and reports suggest that differentiation of virally induced wheezefrom multi-trigger wheeze (or toddler asthma) is less important than making an attempt to manage the child. Ifan infant, or young child, has a chronic wheeze and is atopic or responds to a bronchodilator, asthma is morelikely and therapy should be tried. If, however, there is no response to the therapy, investigate for other causes.Remember that in South Africa wheeze may also be produced by chronic infections, gastro-oesophageal reflux,cardiac failure, cystic fibrosis and a host of other sinister conditions. Therapeutically, for mild and intermittentwheeze the choice of inhaled corticosteroid (ICS) or a leukotriene antagonist may be valuable options. Therapyis intermittent and should be started pre-emptively. However, for more severe and frequent symptoms regularuse of ICS (moderate dose) is clearly the best therapeutic option.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/J2016September</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-140-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-140-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, Grren RJ</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40692</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Peter,J.G.</style></author></authors></contributors><titles><title><style face="normal" font="ArialMT">Multiple Drug Intolerance Syndrome</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="156" start="152">152-156</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Africa</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> cephalosporin</style></keyword><keyword><style face="normal" font="default"> Cephalosporins</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous drug reaction</style></keyword><keyword><style face="normal" font="default"> Cutaneous drug reactions</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> MDI</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Multiple drug intolerance syndrome</style></keyword><keyword><style face="normal" font="default"> NSAID</style></keyword><keyword><style face="normal" font="default"> NSAIDs</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Quinolones</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Multiple-drug intolerance syndrome (MDIS) is a condition where patients experience adverse drug reactionsto three or more unrelated drugs. The immunological mechanism is unknown, hence the preferred labellingas 'intolerance' as opposed to 'allergy'. MDIS prevalence in South Africa is unknown, but may be as high as2.1% according to international electronic medical record data. The majority of specialist physicians haveencountered these complicated, sometimes frustrating, but always challenging patients.MDIS patients have high rates of healthcare and medication use, and are highly prone to developing newadverse drug reactions. Risk factors include female gender and multiple non-life-threatening co-morbidities,but not atopy. Antibiotics, particularly cephalosporins and quinolones, together with NSAIDs are the commonoffending drug classes. The severity of reactions is often overestimated, but life-threatening anaphylaxisor severe cutaneous drug reactions are reported. Optimal management involves the judicious use of drugprovocation testing in a safe environment to provide patients and treating physicians with safe drugs as andwhen medically indicated. Multiple costly in vitro and in vivo drug allergy testing should be limited.This brief review first presents an illustrative case from our newly established multi-disciplinary drughypersensitivity clinic and then provides a literature review on the risk factors, proposed mechanisms andoptimal management of MDIS.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/J2016September</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-152-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-152-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, Peter JG</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40693</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Raynham,O.</style></author></authors></contributors><titles><title><style face="normal" font="ArialMT">Paediatric nasal obstruction - a practical approach</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="169" start="164">164-169</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Africa</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> General practitioner</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="default"> Nose</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Nasal obstruction and subsequent partial upper-airway obstruction can result in troublesome morbidity forthe child. It is one of the most common reasons for the presentation of children to the doctor, whetherallergologist, paediatrician, general practitioner or ear, nose and throat (ENT) surgeon.1 This article offersa straightforward and practical approach to managing the most common causes of nasal obstruction in thepaediatric population.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/J2016September</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-164-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-164-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, Raynham O</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40694</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kritzinger,F.</style></author></authors></contributors><titles><title><style face="normal" font="ArialMT">A diagnostic approach to the chronic cough in children</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="163" start="158">158-163</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Africa</style></keyword><keyword><style face="normal" font="default"> Algorithms</style></keyword><keyword><style face="normal" font="default"> Bronchiectasis</style></keyword><keyword><style face="normal" font="default"> Bronchitis</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic cough</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Delayed Diagnosis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> preschool children</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Chronic cough, defined by the majority of studies and guidelines as a cough that lasts longer than fourweeks, is common in the paediatric population, but the true prevalence and burden of disease remainsdifficult to define. It is now understood that the aetiology of chronic cough in children differs from that inadults. Children with chronic cough should be managed with paediatric-specific algorithms because thosewho are treated in this manner have improved clinical outcomes. Recent studies have focused on protractedbacterial bronchitis as a major cause of chronic cough in pre-school children and its role as a possibleprecursor of bronchiectasis. Recognising those children with possibly serious underlying diseases is criticalto preventing delayed diagnosis and poor outcomes. However, it is equally important not to over-investigatethose children who have an isolated non-specific cough. Clinicians should be familiar with the vast list ofimportant causes of a chronic cough as well as the history-taking and clinical skill to define patients at risk ofhaving a potentially serious disease in order to manage them timeously and appropriately.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.allergysa.org/Journal/J2016September</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-158-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2016-29-158-63.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, Kritzinger F</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40695</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">El Sherbeny,M.M.</style></author><author><style face="normal" font="default"> Behairy,O.G.</style></author><author><style face="normal" font="default"> Mohammad,O.I.</style></author><author><style face="normal" font="default"> Elsayed,A.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Serum levels of lead and copper in a group of Egyptian children with bronchial asthma</style></title><secondary-title><style face="normal" font="default">Egypt J Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Egypt J Pediatr Allergy Immunol</style></full-title></periodical><pages end="52" start="47">47-52</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Copper</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Egypt</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Enzymes</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> oxidant</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> Trace Elements</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Background: Copper and lead are trace elements required for the activity of antioxidant enzymes and changes in their levels may lead to reduction in antioxidant activities in asthma. Objective: Our study aims to investigate the serum levels of copper and lead in asthmatic children in correlation to disease severity to anticipate their role as oxidant defenders in this disease. Methods: We enrolled 45 children who were divided into two groups: group 1 included 30 asthmatic children during disease quiescence and group 2 included 15 clinically healthy children matched for age and sex as a control group. Patients were subjected to: history taking, clinical examination, spirometry before and after bronchodilator therapy, complete blood counting, and measurement of serum levels of total IgE, copper and lead (in patients and controls). Results: Patients' group had significantly higher serum levels of lead (mean 8.2±3.1 µg/dl) and copper (122±31.5 µg/dl) in comparison to controls (mean 5.7±2.3 µg/dl and103.3±21.1 µg/dl respectively). Serum lead and copper levels were higher among patients with moderate persistent asthma than those with mild asthma. Serum total IgE levels correlated positively with serum lead levels among the asthmatic children. However, serum lead and copper levels did not correlate with any of the measured pulmonary function parameters tested. Conclusion: Increased serum level of lead and copper were high in a group of children with bronchial asthma in children and this was more evident in moderate than mild cases.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Egypt -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.jespai.org/ulogs/paperindex.php?paperID=228&amp;topicid=1&amp;issueid=28</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Egypt J Pediatr Allergy Immunol\2016-14-47-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Egypt J Pediatr Allergy Immunol\2016-14-47-52.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170227, El Sherbeny MM</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40696</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dolch,A.</style></author><author><style face="normal" font="default"> Kunz,S.</style></author><author><style face="normal" font="default"> Dorn,B.</style></author><author><style face="normal" font="default"> Roers,A.</style></author><author><style face="normal" font="default"> Martin,S.F.</style></author><author><style face="normal" font="default"> Jakob,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Research Group, Department of Dermatology, Medical Center - University of Freiburg, Freiburg, Germany</style></auth-address><titles><title><style face="normal" font="default">Contact allergens induce CD8+ T cell-derived interleukin 10 that appears dispensable for regulation of contact hypersensitivity</style></title><secondary-title><style face="normal" font="default">Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact allergens</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Interleukin-10</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="7" Month="10" Year="2016">2016/10/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161007IS - 1600-0625 (Electronic)IS - 0906-6705 (Linking)LA - ENGPT - LETTERCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/exd.13237</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27714845">PM:27714845</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Exp Dermatol\20161007-DolchA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Exp Dermatol\20161007-DolchA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161007, Dolch A</style></custom2><misc3><style face="normal" font="default">10.1111/exd.13237</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40697</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Minic,P.B.</style></author><author><style face="normal" font="default"> Sovtic,A.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Mother and Child Health Institute of Serbia, Department of Pulmonology, 6 Radoja Dakica St. 11070 Belgrade, Serbia</style></auth-address><titles><title><style face="normal" font="default">Exercise intolerance and exercise-induced bronchoconstriction in children</style></title><secondary-title><style face="normal" font="default">Front Biosci (Elite Ed)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Biosci (Elite Ed)</style></abbr-1></periodical><pages end="32" start="21">21-32</pages><volume><style face="normal" font="default">9</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Athlete</style></keyword><keyword><style face="normal" font="default"> Athletes</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> bronchodilators</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> exercise-induced bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hyperventilation</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> long acting beta agonists</style></keyword><keyword><style face="normal" font="default"> long-acting beta-agonists</style></keyword><keyword><style face="normal" font="default"> montelukast</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physical Fitness</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rest</style></keyword><keyword><style face="normal" font="default"> Serbia</style></keyword><keyword><style face="normal" font="default"> Sport</style></keyword><keyword><style face="normal" font="default"> Sports</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="default">Respiratory symptoms at rest or during exercise may restrain the physical capabilities required for normal motor and psychosocial development in children. The most frequent cause of exercise intolerance, apart from poor physical fitness, is exercise-induced bronchoconstriction (EIB), which may occur in some healthy children and in children with asthma. It is proposed that hyperventilation during exercise is associated with drying and cooling of airways, which can trigger a proinflammatory response. Several tests are used to confirm EIB, and the exercise-challenge test is the most common. Some nonpharmacologic therapies may induce airway refractoriness; warm-up exercise can result in the attenuation of EIB in more than half of the people with EIB. Prophylactic intermittent treatment with short-acting bronchodilators is the most commonly used treatment, but the conventional pharmacologic therapy for patients with uncontrolled asthma is the regular use of inhaled corticosteroids, with or without long-acting beta-agonists and montelukast. Therapy should result in optimal control of exercise-induced symptoms during habitual physical activity and also allow participation in sports activity in athletes</style></abstract><notes><style face="normal" font="default">DA - 20161104IS - 1945-0508 (Electronic)IS - 1945-0494 (Linking)LA - ENGPT - Journal ArticleCO - Serbia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27814586">PM:27814586</url></web-urls></urls><custom2><style face="normal" font="default">20161104, Minic PB</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40698</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Parsa,S.A.</style></author><author><style face="normal" font="default"> Khaheshi,I.</style></author><author><style face="normal" font="default"> Memaryan,M.</style></author><author><style face="normal" font="default"> Naderian,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cardiovascular Research Center, Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="default">Takotsubo cardiomyopathy following recurrent doses of albuterol due to asthma attack: a very rare case report</style></title><secondary-title><style face="normal" font="default">Future Cardiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Future Cardiol</style></full-title></periodical><pages end="612" start="609">609-612</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Albuterol</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Arteries</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Chest Pain</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Infarction</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Takotsubo Cardiomyopathy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">To present an unusual case in order to clarify one of the most important differential diagnoses of ST-elevation myocardial infarction in a postmenopausal woman. A 72-year-old woman with asthma attack and retrosternal chest pain was presented to our emergency unit. She had used albuterol spray ten-times before admission due to accentuated dyspnea. Initial ECG revealed ST-segment elevation in leads V1-V6, I and aVL. Emergent coronary angiography indicated normal coronary arteries, and left ventriculography showed significant akinesia of apical segments. This unusual case emphasizes the fact that emergency physicians and cardiologists should be familiar with Takotsubo cardiomyopathy following overuse of beta2-agonist due to asthma attack that can mimic ST-elevation myocardial infarction</style></abstract><notes><style face="normal" font="default">DA - 20161019IS - 1744-8298 (Electronic)IS - 1479-6678 (Linking)LA - ENGPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">10.2217/fca-2016-0040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27759421">PM:27759421</url></web-urls></urls><custom2><style face="normal" font="default">20161019, Parsa SA</style></custom2><misc3><style face="normal" font="default">10.2217/fca-2016-0040</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40699</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gupta,S.K.</style></author><author><style face="normal" font="default"> Garg,B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Fluoxetine Induced Erythematous Maculopapular Rash: A Case Report</style></title><secondary-title><style face="normal" font="default">Glob J Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Glob J Allergy</style></full-title></periodical><pages end="016" start="015">015-016</pages><volume><style face="normal" font="default">2</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Case Report</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="Roboto-Regular">10.17352/2455-8141.000014</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.17352/2455-8141.000014</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Glob J Allergy\2016-2-015-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Glob J Allergy\2016-2-015-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170226, Gupta SK</style></custom2><misc3><style face="normal" font="Roboto-Regular">10.17352/2455-8141.000014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40700</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aupiais,C.</style></author><author><style face="normal" font="default"> Wanin,S.</style></author><author><style face="normal" font="default"> Romanello,S.</style></author><author><style face="normal" font="default"> Spiri,D.</style></author><author><style face="normal" font="default"> Moretti,R.</style></author><author><style face="normal" font="default"> Boizeau,P.</style></author><author><style face="normal" font="default"> Massano,D.</style></author><author><style face="normal" font="default"> Zuccotti,G.V.</style></author><author><style face="normal" font="default"> Crichiutti,G.</style></author><author><style face="normal" font="default"> Kanagarajah,L.</style></author><author><style face="normal" font="default"> Houdouin,V.</style></author><author><style face="normal" font="default"> Alberti,C.</style></author><author><style face="normal" font="default"> Titomanlio,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Unit of Clinical Epidemiology, Assistance Publique-Hopitaux de Paris, CHU Robert Debre, Universite Paris Diderot, Sorbonne Paris-Cite, INSERM U1123 and CIC-EC 1426, Paris, France</style></auth-address><titles><title><style face="normal" font="default">Association Between Migraine and Atopic Diseases in Childhood: A Potential Protective Role of Anti-Allergic Drugs</style></title><secondary-title><style face="normal" font="default">Headache</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Headache</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> anti-allergic drug</style></keyword><keyword><style face="normal" font="default"> anti-allergic drugs</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> Atopic diseases</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Headache</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Migraine is a common cause of headache in childhood. Several studies have investigated the association between migraine and atopic diseases, mostly in the adult population. OBJECTIVE: This study aimed to investigate this association in children. METHODS: A case-control study was conducted across 3 European tertiary care hospitals between June 2014 and August 2014. Cases (n = 229) were children aged 6-18 years consulting for a migraine episode. Controls in the same age range (n = 406) were consulting for a minor injury and did not have a history of recurrent headache. Logistic regression analyses tested the effect of atopic diseases and anti-allergic therapies on occurrence of migraine. RESULTS: Children with migraine were more likely to have persistent asthma compared to absence of asthma (odds ratio [OR]: 4.57, 95% confidence interval [CI]: 2.04-10.24) and less likely to have been treated by inhaled or nasal corticosteroid (OR: 0.34, 95% CI: 0.15-0.76) or antihistamine therapy (OR: 0.33, 95% CI: 0.18-0.60). The median number of monthly migraine episodes was higher in children with persistent asthma (3; interquartile [IQR]: 1-4; range: 0.5-10) compared to children with intermittent asthma (2; IQR: 1-3; range: 0.1-4) or non-asthmatic children (2; IQR: 1-3; range: 0.1-12) (P &lt; .01). CONCLUSION: Persistent childhood asthma was associated with increased risk of migraine and higher frequency of migraine attacks. History of anti-asthmatic or anti-allergic therapies was associated with decreased risk of migraine in children and adolescents. The role of these therapies on the pathogenesis and occurrence of migraine needs to be further elucidated because of the huge potential impact in terms of public health</style></abstract><notes><style face="normal" font="default">DA - 20170204IS - 1526-4610 (Electronic)IS - 0017-8748 (Linking)LA - engPT - Journal ArticleCO - France -CO - Italy -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/head.13032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28160287">PM:28160287</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Headache\20170204-AupiaisC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Headache\20170204-AupiaisC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, Aupiais C</style></custom2><misc3><style face="normal" font="default">10.1111/head.13032</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40701</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ramsay,J.</style></author><author><style face="normal" font="default"> Schwindt,T.</style></author><author><style face="normal" font="default"> Nguyen,T.</style></author><author><style face="normal" font="default"> Margellos-Anast,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Sinai Health System, Chicago, IL, USA</style></auth-address><titles><title><style face="normal" font="default">Translating a Proven Pediatric Healthy Homes Asthma Intervention to Adults</style></title><secondary-title><style face="normal" font="default">Health Promot Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Health Promot Pract</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma education</style></keyword><keyword><style face="normal" font="default"> Cessation</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> community health worker</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Smoking Cessation</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> Translating</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="27" Month="10" Year="2016">2016/10/27</year></dates><abstract><style face="normal" font="default">Asthma is a serious public health concern, disproportionately affecting urban, minority populations. Chicago's West and Southwest sides are among the most burdened by asthma and environmental conditions that exacerbate asthma. Home-based, community health worker (CHW)-led interventions have repeatedly demonstrated effectiveness in addressing pediatric asthma. However, evidence of such interventions among adults is limited. Helping Chicago's Westside Adults Breathe and Thrive is a longitudinal cohort study that assesses the effectiveness of a CHW-led asthma and healthy homes intervention for adults. One of the first of its kind, the program aims to improve asthma control and quality of life among adults with poorly controlled asthma. This article provides a framework for implementing the intervention from start to finish. CHWs make five or six home visits over the course of 12 months, providing comprehensive and individualized asthma education to study participants. They work closely with participants to conduct home environmental assessments, collaboratively developing techniques to eliminate or avoid asthma triggers. They also assist with smoking cessation, comorbidities, and health system navigation. Between December 1, 2013, and August 31, 2015, 202 participants enrolled in the program. This article reports on successes, challenges, and recommendations from the program's first 21 months of operation</style></abstract><notes><style face="normal" font="default">DA - 20161029IS - 1524-8399 (Print)IS - 1524-8399 (Linking)LA - ENGPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/1524839916675118</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27794073">PM:27794073</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Health Promot Pract\20161029-RamsayJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Health Promot Pract\20161029-RamsayJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161029, Ramsay J</style></custom2><misc3><style face="normal" font="default">10.1177/1524839916675118</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40702</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ono,S.</style></author><author><style face="normal" font="default"> Kato,M.</style></author><author><style face="normal" font="default"> Nakagawa,S.</style></author><author><style face="normal" font="default"> Mabe,K.</style></author><author><style face="normal" font="default"> Sakamoto,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Endoscopy, Hokkaido University Hospital, Sapporo, Japan</style></auth-address><titles><title><style face="normal" font="default">Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin</style></title><secondary-title><style face="normal" font="default">Helicobacter</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Helicobacter</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clarithromycin</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endoscopy</style></keyword><keyword><style face="normal" font="default"> Helicobacter pylori</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Metronidazole</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> proton pump inhibitor</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="18" Month="1" Year="2017">2017/1/18</year></dates><abstract><style face="normal" font="default">BACKGROUND: Although all Helicobacter pylori (H. pylori)-positive patients should receive eradication therapy, the therapy is a challenge for patients allergic to penicillin. There have been a few reports on the efficacy of eradication therapy for such patients. OBJECTIVE: To analyze the efficacy of vonoprazan or proton pump inhibitor (PPI)-based 7-day triple therapy in patients allergic to penicillin. MATERIALS AND METHODS: A total of 88 consecutive patients allergic to penicillin who received H. pylori eradication therapy were retrospectively analyzed. Thirty-one patients had a history of failed eradication therapy. Four 7-day regimens were prescribed during the study period: clarithromycin-metronidazole-PPI (13 patients), clarithromycin-metronidazole-vonoprazan (14 patients), metronidazole-sitafloxacin-PPI (44 patients) and metronidazole-sitafloxacin-vonoprazan (17 patients). A 13 C-urea breath test was used for confirmation of eradication, and efficacy of eradication was evaluated by "intention-to-treat" analysis and "per-protocol" analysis. RESULTS: Intention-to-treat and per-protocol eradication rates were 46.2%/54.6% for patients who received clarithromycin-metronidazole-PPI, 92.9/92.9% for patients who received clarithromycin-metronidazole-vonoprazan, 100/100% for patients who received metronidazole-sitafloxacin-PPI and 88.2/93.8% for patients who received metronidazole-sitafloxacin-vonoprazan. For first eradication, vonoprazan significantly raised the intention-to-treat efficacy of the triple therapy including clarithromycin-metronidazole (vonoprazan: 92.9%, PPI: 46.2%, P=.0128). A 7-day regimen consisting of metronidazole and sitafloxacin was effective for patients allergic to penicillin with or without past failure of eradication. CONCLUSION: For first eradication in patients allergic to penicillin, a 7-day triple therapy consisting of clarithromycin, metronidazole and vonoprazan could be a candidate eradication regimen</style></abstract><notes><style face="normal" font="default">DA - 20170118IS - 1523-5378 (Electronic)IS - 1083-4389 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/hel.12374</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28098408">PM:28098408</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Helicobacter\20170118-OnoS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Helicobacter\20170118-OnoS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170118, Ono S</style></custom2><misc3><style face="normal" font="default">10.1111/hel.12374</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40703</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Borgmeyer,A.</style></author><author><style face="normal" font="default"> Ercole,P.M.</style></author><author><style face="normal" font="default"> Niesen,A.</style></author><author><style face="normal" font="default"> Strunk,R.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">St Louis Children's Hospital, St Louis, Missouri</style></auth-address><titles><title><style face="normal" font="default">Lack of Recognition, Diagnosis, and Treatment of Overweight/Obesity in Children Hospitalized for Asthma</style></title><secondary-title><style face="normal" font="default">Hosp Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Hosp Pediatr</style></abbr-1></periodical><pages end="676" start="667">667-676</pages><volume><style face="normal" font="default">6</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma education</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic asthma</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Missouri</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> overweight</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Information is lacking regarding recognition and treatment of overweight and obesity in children hospitalized for asthma. The study objectives were to determine the current practice of recognition, diagnosis, and treatment of overweight and obesity for children hospitalized for asthma and to describe demographic, asthma, and weight characteristics for these patients. METHODS: A retrospective record review was conducted for children admitted to the hospital with asthma in 2012. Charts were reviewed for evidence of recognition, diagnosis, and treatment of overweight and obesity. Subjects were classified into age-adjusted Centers for Disease Control and Prevention weight categories based on BMI percentile and chronic asthma severity categories according to National Asthma Education and Prevention Program guidelines. RESULTS: A total of 510 subjects aged 3 to 17 years were studied. Obesity was present in 19.6% and overweight in 13.3% of subjects. BMI percentile was recorded in only 3.3% of all charts, in only 11% of subjects with obesity, and in 0% of subjects with overweight. BMI percentile was documented more often in subjects with severe obesity (P = .013) and with moderate to severe persistent asthma (P = .035). Only 9 of 168 subjects who were overweight or obese (5.6%) were given a discharge diagnosis indicating overweight or obesity, and 14 (8.3%) received treatment. Chronic asthma severity differed by BMI weight category (P &lt; .001), with a significant relationship between obesity status and chronic asthma severity in older subjects (P = .033). There were no differences in severity of acute episodes based on weight group. CONCLUSIONS: Overweight and obesity were underrecognized, underdiagnosed, and undertreated in children hospitalized for asthma</style></abstract><notes><style face="normal" font="default">DA - 20161013IS - 2154-1663 (Print)IS - 2154-1671 (Linking)LA - ENGPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1542/hpeds.2015-0242</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27733428">PM:27733428</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Hosp Pediatr\2016-6-667-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Hosp Pediatr\2016-6-667-76.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161013, Borgmeyer A</style></custom2><misc3><style face="normal" font="default">10.1542/hpeds.2015-0242</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40704</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kuroda,E.</style></author><author><style face="normal" font="default"> Ozasa,K.</style></author><author><style face="normal" font="default"> Temizoz,B.</style></author><author><style face="normal" font="default"> Ohata,K.</style></author><author><style face="normal" font="default"> Koo,C.X.</style></author><author><style face="normal" font="default"> Kanuma,T.</style></author><author><style face="normal" font="default"> Kusakabe,T.</style></author><author><style face="normal" font="default"> Kobari,S.</style></author><author><style face="normal" font="default"> Horie,M.</style></author><author><style face="normal" font="default"> Morimoto,Y.</style></author><author><style face="normal" font="default"> Nakajima,S.</style></author><author><style face="normal" font="default"> Kabashima,K.</style></author><author><style face="normal" font="default"> Ziegler,S.F.</style></author><author><style face="normal" font="default"> Iwakura,Y.</style></author><author><style face="normal" font="default"> Ise,W.</style></author><author><style face="normal" font="default"> Kurosaki,T.</style></author><author><style face="normal" font="default"> Nagatake,T.</style></author><author><style face="normal" font="default"> Kunisawa,J.</style></author><author><style face="normal" font="default"> Takemura,N.</style></author><author><style face="normal" font="default"> Uematsu,S.</style></author><author><style face="normal" font="default"> Hayashi,M.</style></author><author><style face="normal" font="default"> Aoshi,T.</style></author><author><style face="normal" font="default"> Kobiyama,K.</style></author><author><style face="normal" font="default"> Coban,C.</style></author><author><style face="normal" font="default"> Ishii,K.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Vaccine Science, WPI Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan</style></auth-address><titles><title><style face="normal" font="default">Inhaled Fine Particles Induce Alveolar Macrophage Death and Interleukin-1alpha Release to Promote Inducible Bronchus-Associated Lymphoid Tissue Formation</style></title><secondary-title><style face="normal" font="default">Immunity</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immunity</style></abbr-1></periodical><pages end="1310" start="1299">1299-1310</pages><volume><style face="normal" font="default">45</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adjuvant</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> allergic response</style></keyword><keyword><style face="normal" font="default"> Aluminum</style></keyword><keyword><style face="normal" font="default"> alveolar macrophage</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Interleukin-1alpha</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lymphoid Tissue</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> particulates</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Recombinant</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Salts</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> vaccine</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="12" Year="2016">2016/12/20</year></dates><abstract><style face="normal" font="default">Particulate pollution is thought to function as an adjuvant that can induce allergic responses. However, the exact cell types and immunological factors that initiate the lung-specific immune responses are unclear. We found that upon intratracheal instillation, particulates such as aluminum salts and silica killed alveolar macrophages (AMs), which then released interleukin-1alpha (IL-1alpha) and caused inducible bronchus-associated lymphoid tissue (iBALT) formation in the lung. IL-1alpha release continued for up to 2 weeks after particulate exposure, and type-2 allergic immune responses were induced by the inhalation of antigen during IL-1alpha release and iBALT formation, even long after particulate instillation. Recombinant IL-1alpha was sufficient to induce iBALTs, which coincided with subsequent immunoglobulin E responses, and IL-1-receptor-deficient mice failed to induce iBALT formation. Therefore, the AM-IL-1alpha-iBALT axis might be a therapeutic target for particulate-induced allergic inflammation</style></abstract><notes><style face="normal" font="default">DA - 20161221IS - 1097-4180 (Electronic)IS - 1074-7613 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.immuni.2016.11.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28002730">PM:28002730</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunity\2016-45-1299-310.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunity\2016-45-1299-310.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161221, Kuroda E</style></custom2><misc3><style face="normal" font="default">10.1016/j.immuni.2016.11.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40705</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Byrne,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Acute Throat Swelling in Pregnancy: Review of the Literature and Management</style></title><secondary-title><style face="normal" font="default">Insights Allergy Asthma Bronchitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Insights Allergy Asthma Bronchitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://asthma-and-bronchitis.imedpub.com/acute-throat-swelling-in-pregnancy-review-of-the-literature-and-management.php?aid=13671</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Insights Allergy Asthma Bronchitis\20170226-ByrneT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Insights Allergy Asthma Bronchitis\20170226-ByrneT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170226, Byrne T</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40706</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Das,S.</style></author><author><style face="normal" font="default"> Broide,D.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Why is Chromosome 17q21 linked to Asthma?</style></title><secondary-title><style face="normal" font="default">Insights Allergy Asthma Bronchitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Insights Allergy Asthma Bronchitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> airway remodeling</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> association studies</style></keyword><keyword><style face="normal" font="default"> association study</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> functional study</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic Linkage</style></keyword><keyword><style face="normal" font="default"> Genome</style></keyword><keyword><style face="normal" font="default"> Genome-wide</style></keyword><keyword><style face="normal" font="default"> GWAS</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> linkage</style></keyword><keyword><style face="normal" font="default"> Linkage Disequilibrium</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Zinc</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Asthma is an inflammatory disorder of the airways associated with increased airway responsiveness and airway remodeling. Several genome wide association studies (GWAS) and non-GWAS studies have demonstrated a strong genetic linkage of chromosome 17q21 genes with asthma in populations of diverse ethnic backgrounds. In particular, SNPs in the 17q21 region are found within a large linkage disequilibrium (LD) block that contains not only the orosomucoid like-3 (ORMDL3) gene, but also includes other 17q21 genes i.e. gasdermin B (GSDMB), IKAROS family zinc finger 3 (IKZF3), and zona pellucida binding protein 2 (ZPBP2). Studies of mice expressing increased levels of the human ORMDL3 gene have demonstrated that these mice have spontaneous increased airway remodeling and airway responsiveness in the absence of airway inflammation. Further functional studies are needed to investigate whether some or all of these four genes could contribute to the pathogenesis of asthma.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://asthma-and-bronchitis.imedpub.com/why-is-chromosome-17q21-linked-to-asthma.php?aid=13668</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Insights Allergy Asthma Bronchitis\20170226-DasS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Insights Allergy Asthma Bronchitis\20170226-DasS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170226, Das S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40707</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Borowska,K.</style></author><author><style face="normal" font="default"> Wasylyszyn,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Medical applications for the contact allergen - diphenylcyclopropenone</style></title><secondary-title><style face="normal" font="default">Int Rev Allergol Clin Immunol Fam Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int Rev Allergol Clin Immunol Fam Med</style></full-title></periodical><pages end="178" start="173">173-178</pages><volume><style face="normal" font="default">22</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.medpress.com.pl/IR_01.htm</url></web-urls></urls><custom2><style face="normal" font="default">20170226, Borowska K</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40708</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pazheri,F.</style></author><author><style face="normal" font="default"> Schroer,B.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Agonizing over Beta 2 Agonists and Autism</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="534" start="533">533-534</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">agonists</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2213-2198</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.09.037</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jaip.2016.09.037</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-533-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-533-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170302, Pazheri F</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.09.037</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40709</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Benson,J.C.</style></author><author><style face="normal" font="default"> McKinney,A.M.</style></author><author><style face="normal" font="default"> Hines,P.</style></author><author><style face="normal" font="default"> McKinney,Z.</style></author></authors></contributors><titles><title><style face="normal" font="default">Use of Clinical Decision Support to Increase Premedication Regimen Homogeneity</style></title><secondary-title><style face="normal" font="default">J Am Coll Radiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Am Coll Radiol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical decision support</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> iodinated contrast</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Premedication</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1546-1440</style></isbn><abstract><style face="normal" font="default">AbstractPurpose Patients with prior allergic reactions to iodinated contrast require premedication. This study aimed to increase the homogeneity of premedication orders in such patients. Methods A point-of-care (POC) clinical decision support (CDS) alert accompanied by an order set was implemented in the electronic health record (EHR) to notify providers of a prior allergic reaction upon ordering an examination involving iodinated contrast. Premedication regimens were retrospectively compared 11 months pre</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô and 11 months post</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çôalert implementation, with the different regimens being classified as follows: (1) </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç£preferred</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇØ (per ACR recommendations), (2) </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç£nonpreferred</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇØ (corticosteroid administered &amp;lt;24 hours before examination, but not per ACR recommendations), or (3) </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç£no premedication.</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇØ Results Over 22 months, 22,023 iodinated contrast examinations were performed, 200 (186 intravascular, 12 gastrointestinal/genitourinary, 1 intraarticular, 1 intrathecal) being in patients with a documented iodinated contrast allergy (106 pre</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô, 94 post</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çôalert deployment). Prealert, 41 of 106 patients (38.7%) received a preferred regimen, 47 (44.3%) received nonpreferred regimens, and 18 (17.0%) received no premedication. Postalert, 58 of 94 patients (61.7%) received a preferred regimen, 21 (22.3%) nonpreferred regimens, and 15 (16.0%) no premedication. After alert initiation, the patients prescribed a preferred regimen significantly increased (Z-score-á= 3.25, P-á= .001), but there was no significant difference in the proportion of patients with no premedication (Z-score-á= -0.02, P-á= .85). In 2 of 200 patients (1.0%), an allergic reaction occurred, both after POC-CDS alert implementation with a preferred regimen administered. Conclusions The homogeneity of premedication regimens significantly increased after the alert</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖs launch. However, the proportion of patients with no premedication did not significantly change</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jacr.2016.10.023</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jacr.2016.10.023</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am Coll Radiol\20170303-BensonJC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Am Coll Radiol\20170303-BensonJC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170303, Benson JC</style></custom2><misc3><style face="normal" font="default">10.1016/j.jacr.2016.10.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40710</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sigona,N.S.</style></author><author><style face="normal" font="default"> Steele,J.M.</style></author><author><style face="normal" font="default"> Miller,C.D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Impact of a pharmacist-driven beta-lactam allergy interview on inpatient antimicrobial therapy: A pilot project</style></title><secondary-title><style face="normal" font="default">J Am Pharm Assoc (2003)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am Pharm Assoc (2003)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> betalactam allergy</style></keyword><keyword><style face="normal" font="default"> cephalosporin</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacist</style></keyword><keyword><style face="normal" font="default"> Pharmacists</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="8" Month="10" Year="2016">2016/10/8</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To determine the impact of a pharmacist-driven beta-lactam allergy interview on antimicrobial therapy. SETTING: Tertiary care academic medical center. PRACTICE SETTING: Clarification of beta-lactam allergy may expand treatment options for patients and potentially improve outcomes, reduce toxicity, and reduce costs. PRACTICE INNOVATION: At our institution, a pilot service using a pharmacy resident and infectious diseases clinical pharmacist was implemented to clarify beta-lactam allergy information and, where appropriate, recommend a change to the patient's antibiotic therapy. EVALUATION: Adult patients with a documented beta-lactam allergy who had received non-penicillin antibiotics and who had undergone a beta-lactam allergy interview were identified via pharmacy intervention data. A pharmacist interviewed these patients with the use of an internally developed allergy questionnaire. Recommendations for beta-lactam therapy were made to the patient's primary medical team based on the results of the allergy interview and factors including infection type and culture results. The primary objectives were to determine the percentage of patients successfully switched to beta-lactam therapy as a result of the drug allergy interview, to identify allergy discrepancies between the electronic medical record (EMR) and pharmacist's interview, and to quantify the acceptance rate of the pharmacist's antimicrobial recommendations after drug allergy clarification. RESULTS: Thirty-two patients were interviewed, and 24 were candidates for a beta-lactam recommendation. As a result of the interview, 21 patients (65.6%) were successfully switched from a non-penicillin antibiotic to a cephalosporin, carbapenem, or penicillin. A discrepancy between the EMR-reported allergy and history obtained on interview was identified in 11 patients (34.4%). Medical providers accepted 87.5% of pharmacists' antimicrobial recommendations. CONCLUSION: A pharmacist-driven beta-lactam allergy interview was effective in switching eligible patients to beta-lactam therapy and identifying discrepancies between EMR-documented allergies and confirmed allergies. Antimicrobial recommendations were well received by medical providers with a high acceptance rate</style></abstract><notes><style face="normal" font="default">DA - 20161017IS - 1544-3450 (Electronic)IS - 1086-5802 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.japh.2016.05.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27745795">PM:27745795</url></web-urls></urls><custom2><style face="normal" font="default">20161017, Sigona NS</style></custom2><misc3><style face="normal" font="default">10.1016/j.japh.2016.05.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40711</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kunikullaya,K.U.</style></author><author><style face="normal" font="default"> Vijayaraghava,A.</style></author><author><style face="normal" font="default"> Asha,P.</style></author><author><style face="normal" font="default"> Kunnavil,R.</style></author><author><style face="normal" font="default"> MuraliMohan,B.V.</style></author></authors></contributors><titles><title><style face="normal" font="default">Meteorological parameters and pollutants on asthma exacerbation in Bangalore, India - an ecological retrospective time-series study</style></title><secondary-title><style face="normal" font="default">J Basic Clin Physiol Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Basic Clin Physiol Pharmacol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nitrogen</style></keyword><keyword><style face="normal" font="default"> Nitrogen Dioxide</style></keyword><keyword><style face="normal" font="default"> NO2</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Particulate matter</style></keyword><keyword><style face="normal" font="default"> pollutants</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Temperature</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time series</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="1" Year="2017">2017/1/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Literature has shown a significant association between asthma exacerbations and pollutant levels during that time. There is very limited evidence in India, especially Bangalore, for impacts of meteorological changes and pollution on asthma hospital admissions in adults. The objective was to study the impact of air pollution and meteorological parameters on asthma exacerbation in Bangalore. METHODS: This study quantitatively analyzed the relation between acute exacerbations of asthma and related admissions to the hospital with the air pollution and the meteorological conditions during that time. Data regarding the daily hospital admissions in about 13 tertiary care centers in Bangalore, Karnataka and air pollutant levels and the meteorological conditions prevailing during each day over a year were collected from the Karnataka State pollution control board and meteorology departments, respectively. RESULTS: An average daily asthma admission of 4.84+/-2.91, with clear seasonal variation and autocorrelations between meteorological parameters and pollutants was observed. Multiple linear regression analysis revealed that average temperature (p=0.005) and nitrogen dioxide (NO2) (p=0.034) were the two factors that were affecting the number of admissions. Quasi-poisson regression analysis using multi-pollutants and meteorological variables showed that particulate matter and NO2 had significant lag effect for up to 5 days (p&lt;0.05) and rainfall for 1 day (p&lt;0.001). CONCLUSIONS: In Bangalore city, levels of NO2 and particulate matter, temperature, rainfall, and season increase asthma exacerbations</style></abstract><notes><style face="normal" font="default">DA - 20170111IS - 2191-0286 (Electronic)IS - 0792-6855 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.1515/jbcpp-2016-0074</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28076315">PM:28076315</url></web-urls><related-urls><url ppv-ref="no">presto - 6 mesi</url></related-urls></urls><custom2><style face="normal" font="default">20170111, Kunikullaya KU</style></custom2><misc3><style face="normal" font="default">10.1515/jbcpp-2016-0074</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40712</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ullman,M.A.</style></author><author><style face="normal" font="default"> Midgley,K.J.</style></author><author><style face="normal" font="default"> Kim,J.</style></author><author><style face="normal" font="default"> Ullman,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Department of Ophthalmology, MedStar Washington Hospital Center</style></auth-address><titles><title><style face="normal" font="default">Anaphylactic reaction secondary to topical preoperative moxifloxacin</style></title><secondary-title><style face="normal" font="default">J Cataract Refract Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Cataract Refract Surg</style></abbr-1></periodical><pages end="1837" start="1836">1836-1837</pages><volume><style face="normal" font="default">42</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="default"> Cataract</style></keyword><keyword><style face="normal" font="default"> cataract surgery</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endophthalmitis</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Ophthalmology</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> phacoemulsification</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Washington</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">We report a case of anaphylactic shock following topical administration of moxifloxacin for endophthalmitis prophylaxis prior to cataract surgery. Immunoglobulin E (IgE) serology and IgE skin testing confirmed the anaphylactic etiology. Phacoemulsification with posterior chamber intraocular lens implantation was later performed with identical preoperative preparation except for the exclusion of moxifloxacin; no anaphylactic response occurred. To our knowledge, this is the first report of an anaphylactic response to topical moxifloxacin. FINANCIAL DISCLOSURE: None of the authors has a financial or proprietary interest in any material or method mentioned</style></abstract><notes><style face="normal" font="default">DA - 20161223IS - 1873-4502 (Electronic)IS - 0886-3350 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jcrs.2016.11.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28007117">PM:28007117</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Cataract Refract Surg\2016-42-1836-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Cataract Refract Surg\2016-42-1836-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161223, Ullman MA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jcrs.2016.11.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40713</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cildag,S.</style></author><author><style face="normal" font="default"> Senturk,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Department of Immunology-Allergy, Adnan Menderes University, Aydin, Turkey</style></auth-address><titles><title><style face="normal" font="default">Sulfasalazine-Related Hypersensitivity Reactions in Patients With Rheumatic Diseases</style></title><secondary-title><style face="normal" font="default">J Clin Rheumatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Clin Rheumatol</style></full-title></periodical><pages end="79" start="77">77-79</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Arthritis</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> Drug provocation test</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Rheumatic Diseases</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Sulfasalazine</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="24" Month="1" Year="2017">2017/1/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: Sulfasalazine (SSZ), which has an arylamine sulfonamide structure, is an anti-inflammatory drug used in the treatment of many rheumatic diseases. Various adverse effects have been reported related to SSZ. In the present study, we aimed to define the frequency of SSZ-related hypersensitivity reaction in patients with rheumatoid arthritis and ankylosing spondylitis. METHODS: A total of 136 patients were included in this study. During follow-ups, reaction type, reaction duration, and drug doses were recorded in patients who developed hypersensitivity reactions. Drugs were discontinued in patients who developed reactions, and they were treated with antihistaminics and/or corticosteroids, according to requirements. Drug provocation tests with the drugs and aminosalicylic acid were performed in patients with negative skin prick test individually. RESULTS: A total of 136 patients, with ages ranging from 19 to 71 years (mean, 41.97 [SD, 12.04] years), were included in the study. Hypersensitivity reactions according to the drug provocation test were found against SSZ in 12 patients (8.8%). The SSZ-related hypersensitivity reaction types were urticaria in 7 patients, urticaria and angioedema in 4 patients, and pruritus in 1 patient. CONCLUSIONS: Sulfasalazine is widely used by rheumatologists in the treatment of rheumatic diseases. Whereas the frequency of sulfonamide-related hypersensitivity reactions was reported as 3.0% in the population, we detected hypersensitivity reactions to be 8.8% with SSZ usage in rheumatic diseases</style></abstract><notes><style face="normal" font="default">DA - 20170125IS - 1536-7355 (Electronic)IS - 1076-1608 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1097/RHU.0000000000000490</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28121807">PM:28121807</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Rheumatol\2017-23-77-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Rheumatol\2017-23-77-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170125, Cildag S</style></custom2><misc3><style face="normal" font="default">10.1097/RHU.0000000000000490</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40714</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nguyen,C.V.</style></author><author><style face="normal" font="default"> Miller,D.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Minnesota, Department of Dermatology, Minneapolis, MinnesotaUniversity of Minnesota, Department of Dermatology, Minneapolis, Minnesota</style></auth-address><titles><title><style face="normal" font="default">Serum sickness-like drug reaction: two cases with a neutrophilic urticarial pattern</style></title><secondary-title><style face="normal" font="default">J Cutan Pathol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Cutan Pathol</style></full-title></periodical><pages end="182" start="177">177-182</pages><volume><style face="normal" font="default">44</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Biopsy</style></keyword><keyword><style face="normal" font="default"> Bupropion</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Cefazolin</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Minnesota</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The diagnosis of serum sickness-like reaction (SSLR) is typically based on clinical findings. Histopathologic examination is often deferred, as these eruptions commonly present in young children, and often to primary care providers. A Pubmed literature search revealed only 5 existing cases of SSLR with described cutaneous histopathologic features. We report two cases of serum sickness-like reaction, one each to bupropion and cefazolin. Skin biopsy findings in both cases demonstrated a neutrophil-predominant urticarial pattern resembling neutrophilic urticaria or neutrophilic urticarial dermatosis. We also provide a summary of the histopathologic findings that can help support a diagnosis of serum sickness-like reaction</style></abstract><notes><style face="normal" font="default">DA - 20161118IS - 1600-0560 (Electronic)IS - 0303-6987 (Linking)LA - engPT - Case ReportsCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/cup.12863</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27862184">PM:27862184</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Cutan Pathol\2017-44-177-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Cutan Pathol\2017-44-177-82.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161118, Nguyen CV</style></custom2><misc3><style face="normal" font="default">10.1111/cup.12863</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40715</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Salz,M.</style></author><author><style face="normal" font="default"> Enk,A.</style></author><author><style face="normal" font="default"> Schakel,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Venereology, and Allergology, University Hospital Heidelberg, Ruprecht Karls University, Heidelberg, Germany.</style></auth-address><titles><title><style face="normal" font="default">Anaphylactic reaction to para-phenylenediamine</style></title><secondary-title><style face="normal" font="default">J Dtsch Dermatol Ges</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dtsch Dermatol Ges</style></full-title></periodical><pages end="1035" start="1034">1034-1035</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergology</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Para-phenylenediamine</style></keyword><keyword><style face="normal" font="default"> Paraphenylenediamine</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161021IS - 1610-0387 (Electronic)IS - 1610-0379 (Linking)LA - ENGPT - LETTERCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/ddg.13060</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27767265">PM:27767265</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dtsch Dermatol Ges\2016-14-1034-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dtsch Dermatol Ges\2016-14-1034-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161021, Salz M</style></custom2><misc3><style face="normal" font="default">10.1111/ddg.13060</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40716</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rivers,D.A.</style></author><author><style face="normal" font="default"> Stern,R.</style></author><author><style face="normal" font="default"> Maibach,H.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Touro College of Osteopathic Medicine, Department of Biomedical Sciences 230 West 125th Street New York, NY 10027Touro College of Osteopathic Medicine, Department of Biomedical Sciences 230 West 125th Street New York, NY 10027University of California San Francisco, Department of Dermatology 90 Medical Center Way, Surge 110 University of California San Francisco, CA 94143-0989</style></auth-address><titles><title><style face="normal" font="default">A Defective Inflammatory Response May Underlie Cases of Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AC</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Delayed hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research Support</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> San Francisco</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> Type IV hypersensitivity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="21" Month="12" Year="2016">2016/12/21</year></dates><abstract><style face="normal" font="default">An investigation of atopic dermatitis (AD) proposes an association between susceptibility to developing allergic contact sensitization (ACS) and a possible defect in the delayed hypersensitivity inflammatory response.1 Current research supports the predominant pathogenesis of AD to be T-helper cell 2 (Th2)-mediated Type I hypersensitivity response and allergic contact dermatitis (ACD) to be a T-helper cell 1 (Th1)-mediated Type IV hypersensitivity response.2 This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20161221IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.14099</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28000285">PM:28000285</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20161221-RiversDA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20161221-RiversDA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161221,, Rivers DA</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.14099</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40717</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Reinhard,R.</style></author><author><style face="normal" font="default"> Gebhardt,C.</style></author><author><style face="normal" font="default"> Schmieder,A.</style></author><author><style face="normal" font="default"> Umansky,V.</style></author><author><style face="normal" font="default"> Utikal,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany</style></auth-address><titles><title><style face="normal" font="default">Recurrent tattoo reactions in a patient treated with</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Ink</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="21" Month="2" Year="2017">2017/2/21</year></dates><abstract><style face="normal" font="default">Commonly tattoo reactions are acute occurrences in correspondence to tattoo ink. They usually present during the first 2 to 3 weeks, after the tattoo was done. Tattoo reactions can be classified as acute inflammatory reactions, allergic hypersensitivities, granulomatous and pseudolymphomatous types of reactions.1 This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170221IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.14181</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28222227">PM:28222227</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170221-ReinhardR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170221-ReinhardR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170221, Reinhard R</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.14181</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40718</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Horst,N.</style></author><author><style face="normal" font="default"> Leysen,J.</style></author><author><style face="normal" font="default"> Mellaerts,T.</style></author><author><style face="normal" font="default"> Lambert,J.</style></author><author><style face="normal" font="default"> Aerts,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Contact Allergy Unit, Department of Dermatology, University Hospital Antwerp, Wilrijkstraat 10, 2650, Antwerp, Belgium</style></auth-address><titles><title><style face="normal" font="default">Allergic contact cheilitis from anethole-containing toothpastes: a practical solution</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">abnormalities</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cheilitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Lip</style></keyword><keyword><style face="normal" font="default"> Mouth</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Sensation</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Taste</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Toothpaste</style></keyword><keyword><style face="normal" font="default"> Toothpastes</style></keyword><keyword><style face="normal" font="default"> Topical corticosteroids</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="18" Month="2" Year="2017">2017/2/18</year></dates><abstract><style face="normal" font="default">In patients presenting with therapy-resistant cheilitis, especially when extending to the perioral skin, patch tests should be performed, even in longstanding cases1-2 . A 55-year-old woman suffered from an oozing cheilitis for three months with erythema, edema and crusting of the lips and perioral skin (Fig. 1). An intra-oral burning sensation, loss of taste and a dry mouth were also present. Microbiological swabs and a blood analysis did not reveal any abnormalities, and the application of topical corticosteroids brought only temporary relief. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170218IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.14174</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28214382">PM:28214382</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170218-HorstN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170218-HorstN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170218, Horst N</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.14174</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40719</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gimenez-Rivera,V.A.</style></author><author><style face="normal" font="default"> Siebenhaar,F.</style></author><author><style face="normal" font="default"> Zimmermann,C.</style></author><author><style face="normal" font="default"> Siiskonen,H.</style></author><author><style face="normal" font="default"> Metz,M.</style></author><author><style face="normal" font="default"> Maurer,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, D-10405 Berlin, Germany</style></auth-address><titles><title><style face="normal" font="default">Mast Cells Limit the Exacerbation of Chronic Allergic Contact Dermatitis in Response to Repeated Allergen Exposure</style></title><secondary-title><style face="normal" font="default">J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Immunol</style></full-title></periodical><pages end="4246" start="4240">4240-4246</pages><volume><style face="normal" font="default">197</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> allergen challenge</style></keyword><keyword><style face="normal" font="default"> Allergen exposure</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact allergens</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> IL-23</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> Oxazolone</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="12" Year="2016">2016/12/1</year></dates><abstract><style face="normal" font="default">Allergic contact dermatitis is a chronic T cell-driven inflammatory skin disease that is caused by repeated exposure to contact allergens. Based on murine studies of acute contact hypersensitivity, mast cells (MCs) are believed to play a role in its pathogenesis. The role of MCs in chronic allergic contact dermatitis has not been investigated, in part because of the lack of murine models for chronic contact hypersensitivity. We developed and used a chronic contact hypersensitivity model in wild-type and MC-deficient mice and assessed skin inflammatory responses to identify and characterize the role of MCs in chronic allergic contact dermatitis. Ear swelling chronic contact hypersensitivity responses increased markedly, up to 4-fold, in MC-deficient KitW-sh/W-sh (Sash) and MCPT5-Cre+iDTR+ mice compared with wild-type mice. Local engraftment with MCs protected Sash mice from exacerbated ear swelling after repeated oxazolone challenge. Chronic contact hypersensitivity skin of Sash mice exhibited elevated levels of IFN-gamma, IL-17alpha, and IL-23, as well as increased accumulation of Ag-specific IFN-gamma-producing CD8+ tissue-resident memory T (TRM) cells. The CD8+ T cell mitogen IL-15, which was increased in oxazolone-challenged skin of Sash mice during the accumulation of cutaneous TRM cells, was efficiently degraded by MCs in vitro. MCs protect from the exacerbated allergic skin inflammation induced by repeated allergen challenge, at least in part, via effects on CD8+ TRM cells. MCs may notably influence the course of chronic allergic contact dermatitis. A better understanding of their role and the underlying mechanisms may lead to better approaches for the treatment of this common, disabling, and costly condition</style></abstract><notes><style face="normal" font="default">DA - 20161103IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - ENGPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.4049/jimmunol.1600236</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27807191">PM:27807191</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Immunol\2016-197-4240-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Immunol\2016-197-4240-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161103, Gimenez-Rivera VA</style></custom2><misc3><style face="normal" font="default">10.4049/jimmunol.1600236</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40720</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Baturcam,E.</style></author><author><style face="normal" font="default"> Snape,N.</style></author><author><style face="normal" font="default"> Yeo,T.H.</style></author><author><style face="normal" font="default"> Schagen,J.</style></author><author><style face="normal" font="default"> Thomas,E.</style></author><author><style face="normal" font="default"> Logan,J.</style></author><author><style face="normal" font="default"> Galbraith,S.</style></author><author><style face="normal" font="default"> Collinson,N.</style></author><author><style face="normal" font="default"> Phipps,S.</style></author><author><style face="normal" font="default"> Fantino,E.</style></author><author><style face="normal" font="default"> Sly,P.D.</style></author><author><style face="normal" font="default"> Spann,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Medicine, The University of Queensland, Brisbane, Qld., Australia</style></auth-address><titles><title><style face="normal" font="default">Human Metapneumovirus Impairs Apoptosis of Nasal Epithelial Cells in Asthma via HSP70</style></title><secondary-title><style face="normal" font="default">J Innate Immun</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Innate Immun</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway epithelial cell</style></keyword><keyword><style face="normal" font="default"> airway epithelial cells</style></keyword><keyword><style face="normal" font="default"> Apoptosis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma therapy</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Heat</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate immunity</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Metapneumovirus</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal epithelial cell</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> RSV</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral infection</style></keyword><keyword><style face="normal" font="default"> Viral infections</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> Viruses</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="10" Year="2016">2016/10/11</year></dates><abstract><style face="normal" font="default">Asthmatics are highly susceptible to respiratory viral infections, possibly due to impaired innate immunity. However, the exact mechanisms of susceptibility are likely to differ amongst viruses. Therefore, we infected primary nasal epithelial cells (NECs) from adults with mild-to-moderate asthma, with respiratory syncytial virus (RSV) or human metapneumovirus (hMPV) in vitro and investigated the antiviral response. NECs from these asthmatics supported elevated hMPV but not RSV infection, compared to non-asthmatic controls. This correlated with reduced apoptosis and reduced activation of caspase-9 and caspase-3/7 in response to hMPV, but not RSV. The expression of heat shock protein 70 (HSP70), a known inhibitor of caspase activation and subsequent apoptosis, was amplified in response to hMPV infection. Chemical inhibition of HSP70 function restored caspase activation and reduced hMPV infection in NECs from asthmatic subjects. There was no impairment in the production of IFN by NECs from asthmatics in response to either hMPV or RSV, demonstrating that increased infection of asthmatic airway cells by hMPV is IFN-independent. This study demonstrates, for the first time, a mechanism for elevated hMPV infection in airway epithelial cells from adult asthmatics and identifies HSP70 as a potential target for antiviral and asthma therapies</style></abstract><notes><style face="normal" font="default">DA - 20161010IS - 1662-8128 (Electronic)IS - 1662-811X (Linking)LA - ENGPT - JOURNAL ARTICLECO - Australia -</style></notes><work-type><style face="normal" font="default">10.1159/000449101</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27723652">PM:27723652</url></web-urls></urls><custom2><style face="normal" font="default">20161010, Baturcam E</style></custom2><misc3><style face="normal" font="default">10.1159/000449101</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40721</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Garcia-Marcos,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory and Allergy Units, Arrixaca Children's University Hospital, University of Murcia, Spain; IMIB Bio-health Research Institute, Spain</style></auth-address><titles><title><style face="normal" font="default">Should countries implement asthma strategies? Some fresh ideas from the Global Asthma Network; and a quote from Carl Sandburg</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="104" start="103">103-104</pages><volume><style face="normal" font="default">45</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170303IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - EditorialCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.02.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28253981">PM:28253981</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\2017-45-103-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\2017-45-103-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170305, Garcia-Marcos L</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.02.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40722</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yanez,A.</style></author><author><style face="normal" font="default"> Dimitroff,A.</style></author><author><style face="normal" font="default"> Bremner,P.</style></author><author><style face="normal" font="default"> Rhee,C.S.</style></author><author><style face="normal" font="default"> Luscombe,G.</style></author><author><style face="normal" font="default"> Prillaman,B.A.</style></author><author><style face="normal" font="default"> Johnson,N.</style></author></authors></contributors><titles><title><style face="normal" font="default">A patient preference study that evaluated fluticasone furoate and mometasone furoate nasal sprays for allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Rhinol (Providence)</style></abbr-1></periodical><pages end="e192" start="e183">e183-e192</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">acoustic rhinometry</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Argentina</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> crossover comparison</style></keyword><keyword><style face="normal" font="default"> Endoscopy</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> fluticasone furoate</style></keyword><keyword><style face="normal" font="default"> Hay Fever</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mometasone</style></keyword><keyword><style face="normal" font="default"> mometasone furoate</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal congestion</style></keyword><keyword><style face="normal" font="default"> nasal congestion index</style></keyword><keyword><style face="normal" font="default"> nasal polyposis</style></keyword><keyword><style face="normal" font="default"> Nasal Sprays</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient Preference</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polyposis</style></keyword><keyword><style face="normal" font="default"> Pretreatment</style></keyword><keyword><style face="normal" font="default"> product attribute ratings</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> saccharine clearance time</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sinonasal outcome test</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2016">2016/1/1</year></dates><abstract><style face="normal" font="default">Background:The management of chronic rhinosinusitis with nasal polyposis (CRSwNP) involves both surgical and medical approaches, and remains a controversial subject.Objective:The objective of this prospective, randomized, controlled trial was to compare the medical and surgical treatments of CRSwNP in terms of their effect on the nasal congestion index (NCI).Methods:Forty-eight patients with CRSwNP were randomized either to medical or surgical therapy. Pretreatment and 3- and 6-month posttreatment assessments of the visual analog scale score, the 20-Item Sino-Nasal Outcome Test, saccharine clearance time, nasal endoscopy, and NCI measurement with acoustic rhinometry were performed. Forty-one subjects were included in the analysis.Results:Both the medical and surgical interventions for CRSwNP resulted in significant improvement in the visual analog scale score, 20-Item Sino-Nasal Outcome Test, saccharine clearance time, and nasal endoscopic examination scores. There was no difference between the two groups in terms of the percentage change from baseline for any of the parameters at the 6-month posttreatment assessment. NCI showed no significant difference from baseline. Similarly, no significant difference was found between the medical and surgical groups in terms of their effect on the NCI (p > 0.05).Conclusion:Because NCI does not correlate with standard subjective measures in outcomes for this group of patients, it cannot be used as an outcome measurement of treatment of subjects with CRSwNP. Results of this prospective randomized study did not find any additional benefit of surgical therapy over medical therapy in subjects with CRSwNP.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Argentina -CO - Australia -CO - South Korea -CO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/ar.2016.7.0185</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.2500/ar.2016.7.0185</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Rhinol (Providence)\2016-7-e183-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Rhinol (Providence)\2016-7-e183-92.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170304, Yanez A</style></custom2><misc3><style face="normal" font="default">10.2500/ar.2016.7.0185</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40723</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sahin-Onder,S.</style></author><author><style face="normal" font="default"> Sahin-Yilmaz,A.</style></author><author><style face="normal" font="default"> Oysu,C.</style></author><author><style face="normal" font="default"> Deveci,I.</style></author><author><style face="normal" font="default"> Sahin,S.</style></author><author><style face="normal" font="default"> Aktas,B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Change in nasal congestion index after treatment in patients with chronic rhinosinusitis with nasal polyposis</style></title><secondary-title><style face="normal" font="default">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Rhinol (Providence)</style></abbr-1></periodical><pages end="e199" start="e193">e193-e199</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">acoustic rhinometry</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis with polyposis</style></keyword><keyword><style face="normal" font="default"> endoscopic sinus surgery</style></keyword><keyword><style face="normal" font="default"> Endoscopy</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal congestion</style></keyword><keyword><style face="normal" font="default"> nasal congestion index</style></keyword><keyword><style face="normal" font="default"> nasal polyposis</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polyposis</style></keyword><keyword><style face="normal" font="default"> Pretreatment</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> saccharine clearance time</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sinonasal outcome test</style></keyword><keyword><style face="normal" font="default"> Sinusitis</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2016">2016/1/1</year></dates><abstract><style face="normal" font="default">Background:The management of chronic rhinosinusitis with nasal polyposis (CRSwNP) involves both surgical and medical approaches, and remains a controversial subject.Objective:The objective of this prospective, randomized, controlled trial was to compare the medical and surgical treatments of CRSwNP in terms of their effect on the nasal congestion index (NCI).Methods:Forty-eight patients with CRSwNP were randomized either to medical or surgical therapy. Pretreatment and 3- and 6-month posttreatment assessments of the visual analog scale score, the 20-Item Sino-Nasal Outcome Test, saccharine clearance time, nasal endoscopy, and NCI measurement with acoustic rhinometry were performed. Forty-one subjects were included in the analysis.Results:Both the medical and surgical interventions for CRSwNP resulted in significant improvement in the visual analog scale score, 20-Item Sino-Nasal Outcome Test, saccharine clearance time, and nasal endoscopic examination scores. There was no difference between the two groups in terms of the percentage change from baseline for any of the parameters at the 6-month posttreatment assessment. NCI showed no significant difference from baseline. Similarly, no significant difference was found between the medical and surgical groups in terms of their effect on the NCI (p > 0.05).Conclusion:Because NCI does not correlate with standard subjective measures in outcomes for this group of patients, it cannot be used as an outcome measurement of treatment of subjects with CRSwNP. Results of this prospective randomized study did not find any additional benefit of surgical therapy over medical therapy in subjects with CRSwNP.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.2500/ar.2016.7.0177</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.2500/ar.2016.7.0177</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Rhinol (Providence)\2016-7-e193-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Rhinol (Providence)\2016-7-e193-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170304, Sahin-Onder S</style></custom2><misc3><style face="normal" font="default">10.2500/ar.2016.7.0177</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40724</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jones,B.M.</style></author><author><style face="normal" font="default"> Bland,C.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Infectious Diseases/Antimicrobial Management Program, St. Joseph's/Candler Health System, Inc., Savannah, GA</style></auth-address><titles><title><style face="normal" font="default">Penicillin skin testing as an antimicrobial stewardship initiative</style></title><secondary-title><style face="normal" font="default">Am J Health Syst Pharm</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Health Syst Pharm</style></full-title></periodical><pages end="237" start="232">232-237</pages><volume><style face="normal" font="default">74</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Aztreonam</style></keyword><keyword><style face="normal" font="default"> Carbapenems</style></keyword><keyword><style face="normal" font="default"> cephalosporin</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Costs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Length of Stay</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> Stewardship</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Vancomycin</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="15" Month="2" Year="2017">2017/2/15</year></dates><abstract><style face="normal" font="default">PURPOSE: An initiative to determine the effects of penicillin skin testing (PST) from an antimicrobial stewardship perspective is described. SUMMARY: Penicillin allergy is one of the most frequently reported allergies; however, only about 10% of self-reports of penicillin allergy are accurate. Incorrect penicillin allergies are therefore a significant barrier to antimicrobial stewardship, with important clinical and economic implications, including increased antimicrobial resistance, an increased overall cost of care, increased length of stay, and, ultimately, increased mortality. As part of its antimicrobial stewardship program, a community health system launched a PST initiative in order to optimize therapy, reduce adverse events acquisition costs, and minimize development of antibiotic resistance. The PST program involves the use of a standardized protocol for the assessment of hypersensitivity to penicillin in patients with suspected penicillin allergy. Among 36 patients who completed the PST protocol during an eight-month period, all had a negative result; in 27 of those patients, a conversion of antimicrobial therapy to a penicillin or cephalosporin was implemented as a direct result of PST. CONCLUSION: In patients with a self-reported penicillin allergy, PST led to a reduction in the use of carbapenems, aztreonam, vancomycin, and other broad-spectrum agents within a health system. A decrease in drug costs was documented in a sample of patients switched to a penicillin or a cephalosporin after PST</style></abstract><notes><style face="normal" font="default">DA - 20170209IS - 1535-2900 (Electronic)IS - 1079-2082 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2146/ajhp160233</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28179249">PM:28179249</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Health Syst Pharm\2017-74-232-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Health Syst Pharm\2017-74-232-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170209, Jones BM</style></custom2><misc3><style face="normal" font="default">10.2146/ajhp160233</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40725</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brooks,S.M.</style></author><author><style face="normal" font="default"> Truncale,T.</style></author><author><style face="normal" font="default"> Sams,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Laboratory Safety of Capsaicin Inhalation in Healthy Younger and Older Populations Potential Template for Inhalation Research</style></title><secondary-title><style face="normal" font="default">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Ther</style></full-title></periodical><pages end="" start="240">240-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Capsaicin</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Chromatography</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Exhaled Breath</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> impulse oscillometry</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Oscillometry</style></keyword><keyword><style face="normal" font="default"> Oxygen</style></keyword><keyword><style face="normal" font="default"> Pharmacist</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Pulse</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Reflex</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research Design</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Solutions</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Introduction: There are inconsistencies as to the effects of age on the human cough reflex. The investigation speaks to the Federal Drug Agency's (FDA) trepidations for conducting inhalation experiments with non-approved medications/chemicals. The investigation addresses the accuracy of the mixing methodology and analysis of capsaicin stability during seven months of storage. Methods: There is stringent safety monitoring while conducting 12 serial (0.49-1000 uMol) single breath capsaicin inhalation challenge testing (CICT) on 20 younger and 20 older healthy research volunteers using pharmaceutical-grade capsaicin (i.e., Investigational New Drug protocol-IND 69,642). The research design and subject safety measures are recommended by the Food &amp; Drug Agency (FDA) and approved by the Institutional Review Board (IRB). Mixing of inhaled capsaicin solutions are by a Registered Pharmacist and concentration verifications are by high performance liquid chromatography (HPLC). Potency of stored capsaicin (i.e., refrigerated and shielded from UV light) is examined over 7 months. Results: There are neither adverse reactions nor statistically significant difference in capsaicin cough parameters for older and younger volunteers at any dose of capsaicin. Physiologic monitoring by spirometry, impulse oscillometry, exhaled breath nitric oxide, electrocardiography, blood pressure, pulse and oxygen saturation measurements do not change at any dose. There are differences between the concentrations of capsaicin solutions mixed by a Registered Pharmacist and actual capsaicin determination by HPLC. The differences in capsaicin concentrations are 28.1% lower for 0.49 uMol compared to a 2.2% lesser concentration for 1000 uMol solution. During storage, capsaicin remains stable for 3-months but substantially falls by six (p&lt;0.03) and seven (p&lt;0.004) months, especially for the lower concentrations. Conclusion: The results of this investigation embrace the safety of serial Inhalations of dilute pharmacologic grade capsaicin aerosol among older and younger normal volunteers. Incorporating rigorous FDA recommendations, inclusion of IRB oversight and monitoring by spirometry, impulse oscillometry, exhaled breath nitric oxide, electrocardiography, blood pressure, pulse and oxygen saturation measurements document inhalation safety at any dilute capsaicin aerosol dose. However, there are lower capsaicin values determined by HPLC compared to expected capsaicin concentrations when mixed by a Registered Pharmacist or after six months of storage. The investigation champions the opinion that inhalation studies involving FDA non-approved drugs or chemicals/ medications can be safely conducted when following the appropriate safety procedures such as in this research protocol.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.4172/2155-6121.1000240</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000240</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Ther\2016-7-240.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Ther\2016-7-240.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170304, Brooks SM</style></custom2><misc3><style face="normal" font="default">10.4172/2155-6121.1000240</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40726</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jafari,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effects of Persistent Allergic Rhinitis on Spirometric Parameters</style></title><secondary-title><style face="normal" font="default">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Ther</style></full-title></periodical><pages end="" start="242">242-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> indoor</style></keyword><keyword><style face="normal" font="default"> indoor allergens</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> PAR</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> perennial</style></keyword><keyword><style face="normal" font="default"> perennial allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Background: Allergic rhinitis (AR) is an inflammatory process due to allergens. The relation between AR and inflammation of lower airways is documented. However, AR is considered as the strong risk factor for the onset of asthma in adults. Methods: This prospective cross sectional study carried out on 126 patients with perennial allergic rhinitis (PAR). Clinical examination, skin prick test and spirometry maneuver were performed in all patients. Results: Our results showed that there is a significant difference between forced expiratory flow at 25% and 75% of the pulmonary volume (FEF 25.75). &lt;80% of the predicted for PAR (P=0.003). There were no significant differences among patients with forced vital capacity (FVC)&lt;80% of predicted and forced expiratory volume in the first second( FEV1 )&lt;80% of the predicted, for PAR respectively (P>0.05, P=0.08). Furthermore, in patients who were sensitive to indoor allergens, FEF25-75&lt;80% of the predicted was more impaired (P=0.003). There was a negative correlation between FEF25-75 and the duration of disease (r=-0.13). Conclusion: This study highlights some risk factors such as the duration of PAR, age, indoor allergens and FEF25-75 as a marker of early bronchial involvement in patients with moderate-to severe and PAR alone.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Iran -</style></notes><work-type><style face="normal" font="default">10.4172/2155-6121.1000242</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000242</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Ther\2016-7-242.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Ther\2016-7-242.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, Jafari M</style></custom2><misc3><style face="normal" font="default">10.4172/2155-6121.1000242</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40727</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Calogiuri,G.F.</style></author><author><style face="normal" font="default"> Bonamonte,D.</style></author><author><style face="normal" font="default"> Foti,C.</style></author><author><style face="normal" font="default"> Al-Sowaidi,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Nickel Hypersensitivity: A General Review on Clinical Aspects and Potential Co-Morbidities</style></title><secondary-title><style face="normal" font="default">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Ther</style></full-title></periodical><pages end="" start="243">243-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical aspects</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Dental Prosthesis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Detergents</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Eyeglasses</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> Hip</style></keyword><keyword><style face="normal" font="default"> Hip Prosthesis</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Ink</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Jewelry</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metal allergies</style></keyword><keyword><style face="normal" font="default"> Metal allergy</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Nickel allergy</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> United Arab Emirates</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Allergic contact hypersensitivity to metals is a delayed-type allergy. Although various metals are able to induce an allergic reaction, nickel is the most frequent cause of metal allergy worldwide. The high prevalence of skin sensitization to that metal is the result of an ubiquitous exposure, being contained in different everyday things, such as detergents, cheap jewelry, cosmetics, coins, buttons, zippers, eyeglasses, buckles, clasps, inks, dental prosthesis and foods even. However, nickel is able to induce a wide range of morphological and clinical patterns, ranging from simple allergic contact dermatitis to systemic contact dermatitis and systemic nickel allergy syndrome. The latter seems to be promoted by nickel rich-foods or through endogenous route caused by metal implants which seem to elicit mainly in loco symptoms, sometimes with catastrophic consequences as aseptic bone necrosis following the implantation of hip prosthesis.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Italy -CO - United Arab Emirates -</style></notes><work-type><style face="normal" font="default">10.4172/2155-6121.1000243</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000243</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Ther\2016-7-243.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Ther\2016-7-243.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170304, Calogiuri GF</style></custom2><misc3><style face="normal" font="default">10.4172/2155-6121.1000243</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40728</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Takaoka,M.</style></author><author><style face="normal" font="default"> Suzuki,K.</style></author><author><style face="normal" font="default"> Norback,D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Current asthma, respiratory symptoms and airway infections among students in relation to the school and home environment in Japan</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Can f 1</style></keyword><keyword><style face="normal" font="default"> cat</style></keyword><keyword><style face="normal" font="default"> Cats</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> dampness</style></keyword><keyword><style face="normal" font="default"> dog</style></keyword><keyword><style face="normal" font="default"> Dogs</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Fel d 1</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Humidity</style></keyword><keyword><style face="normal" font="default"> indoor</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Paint</style></keyword><keyword><style face="normal" font="default"> Pets</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> Students</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Temperature</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="10" Month="2" Year="2017">2017/2/10</year></dates><publisher><style face="normal" font="default">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="default">0277-0903</style></isbn><abstract><style face="normal" font="default">AbstractObjective: To study associations between the school and home environment and current asthma, respiratory symptoms and airway infections among Japanese students. Methods: Japanese students (12?15 y) (N = 1048) in four schools responded to a questionnaire on respiratory health, allergy and the home environment. Temperature, relative air humidity (RH) and student density (students/m2 floor area) was measured in the classrooms: dust was collected from floors and in classroom air and analysed for cat (Fel d 1) and dog (Can f 1) allergens. Health associations were analysed by multi-level logistic regression. Results: Doctor's diagnosed asthma was common (13.4%), 8.8% reported cat allergy and 6.1% dog allergy. The median level in floor dust was 41-áng/g (IQR 23?92) for Fel d 1 and 101-áng/g (IQR 54?101) for Can f 1. The median level in air was 18.6-áng/ m2/ day (IQR5.9?25.1) for Fel d 1 and 18.6-áng/ m2/ day (IQR 6.0?13.3) for Can f 1. High RH, high student density and airborne cat allergen was associated with airway infections. In the home environment, recent indoor painting, new floor materials, odour, having cats as pets, window pane condensation in winter, and dampness in floor construction were associated with respiratory illness. Conclusion: High relative air humidity, high student density and airborne cat allergens at school may increase the risk of airway infections. Having cats as pets, chemical emissions from paint and new floor materials, odour and dampness can constitute domestic risk factors for respiratory symptoms while having dogs as pets could be protectiveAbstractObjective: To study associations between the school and home environment and current asthma, respiratory symptoms and airway infections among Japanese students. Methods: Japanese students (12?15 y) (N = 1048) in four schools responded to a questionnaire on respiratory health, allergy and the home environment. Temperature, relative air humidity (RH) and student density (students/m2 floor area) was measured in the classrooms: dust was collected from floors and in classroom air and analysed for cat (Fel d 1) and dog (Can f 1) allergens. Health associations were analysed by multi-level logistic regression. Results: Doctor's diagnosed asthma was common (13.4%), 8.8% reported cat allergy and 6.1% dog allergy. The median level in floor dust was 41-áng/g (IQR 23?92) for Fel d 1 and 101-áng/g (IQR 54?101) for Can f 1. The median level in air was 18.6-áng/ m2/ day (IQR5.9?25.1) for Fel d 1 and 18.6-áng/ m2/ day (IQR 6.0?13.3) for Can f 1. High RH, high student density and airborne cat allergen was associated with airway infections. In the home environment, recent indoor painting, new floor materials, odour, having cats as pets, window pane condensation in winter, and dampness in floor construction were associated with respiratory illness. Conclusion: High relative air humidity, high student density and airborne cat allergens at school may increase the risk of airway infections. Having cats as pets, chemical emissions from paint and new floor materials, odour and dampness can constitute domestic risk factors for respiratory symptoms while having dogs as pets could be protective</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1255957</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/02770903.2016.1255957</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170304-TakaokaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170304-TakaokaM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170304, Takaoka M</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1255957</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40729</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Russell,M.A.</style></author><author><style face="normal" font="default"> Janson,C.</style></author><author><style face="normal" font="default"> Gomez Real,F.</style></author><author><style face="normal" font="default"> Johannessen,A.</style></author><author><style face="normal" font="default"> Waatevik,M.</style></author><author><style face="normal" font="default"> Benediktsdottir,B.</style></author><author><style face="normal" font="default"> Holm,M.s</style></author><author><style face="normal" font="default"> Lindberg,E.</style></author><author><style face="normal" font="default"> Schlunssen,V.</style></author><author><style face="normal" font="default"> Raza,W.</style></author><author><style face="normal" font="default"> Dharmage,S.C.</style></author><author><style face="normal" font="default"> Svanes,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Physical activity and asthma: A longitudinal and multi-country study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> cross-sectional analysis</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Iceland</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Norway</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Poisson</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="16" Month="2" Year="2017">2017/2/16</year></dates><publisher><style face="normal" font="default">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="default">0277-0903</style></isbn><abstract><style face="normal" font="default">ABSTRACTObjective: To investigate the impact of physical activity on asthma in middle-aged adults, in one longitudinal analysis, and one multi-centre cross-sectional analysis. Methods: The Respiratory Health in Northern Europe (RHINE) is a population-based postal questionnaire cohort study. Physical activity, height and weight were self-reported in Bergen, Norway, at RHINE II (1999?2001) and all centres at RHINE III (2010?2012). A longitudinal analysis of Bergen data investigated the association of baseline physical activity with follow-up asthma, incident asthma and symptoms, using logistic and zero-inflated Poisson regression (n = 1782). A cross-sectional analysis of all RHINE III centres investigated the association of physical activity with concurrent asthma and symptoms (n = 13,542) using mixed-effects models. Body mass index (BMI) was categorised (&lt;20, 20?24.99, 25?29.99, 30+ kg/m2) and physical activity grouped by amount and frequency of lighter (no sweating/heavy breathing) and vigorous (sweating/heavy breathing) activity. Results: In the Bergen longitudinal analysis, undertaking light activity 3+ times/week at baseline was associated with less follow-up asthma (odds ratio [OR] 0.44, 95% confidence interval [CI] 0.22, 0.89), whilst an effect from undertaking vigorous activity 3+ times/week was not detected (OR 1.22, 95% CI 0.44, 2.76). The associations were attenuated with BMI adjustment. In the all-centre cross-sectional analysis an interaction was found, with the association between physical activity and asthma varying across BMI categories. Conclusion: These findings suggest potential longer-term benefit from lighter physical activity, whilst improvement in asthma outcomes from increasing activity intensity was not evident. Additionally, it appears the benefit from physical activity may differ according to BMIABSTRACTObjective: To investigate the impact of physical activity on asthma in middle-aged adults, in one longitudinal analysis, and one multi-centre cross-sectional analysis. Methods: The Respiratory Health in Northern Europe (RHINE) is a population-based postal questionnaire cohort study. Physical activity, height and weight were self-reported in Bergen, Norway, at RHINE II (1999?2001) and all centres at RHINE III (2010?2012). A longitudinal analysis of Bergen data investigated the association of baseline physical activity with follow-up asthma, incident asthma and symptoms, using logistic and zero-inflated Poisson regression (n = 1782). A cross-sectional analysis of all RHINE III centres investigated the association of physical activity with concurrent asthma and symptoms (n = 13,542) using mixed-effects models. Body mass index (BMI) was categorised (&lt;20, 20?24.99, 25?29.99, 30+ kg/m2) and physical activity grouped by amount and frequency of lighter (no sweating/heavy breathing) and vigorous (sweating/heavy breathing) activity. Results: In the Bergen longitudinal analysis, undertaking light activity 3+ times/week at baseline was associated with less follow-up asthma (odds ratio [OR] 0.44, 95% confidence interval [CI] 0.22, 0.89), whilst an effect from undertaking vigorous activity 3+ times/week was not detected (OR 1.22, 95% CI 0.44, 2.76). The associations were attenuated with BMI adjustment. In the all-centre cross-sectional analysis an interaction was found, with the association between physical activity and asthma varying across BMI categories. Conclusion: These findings suggest potential longer-term benefit from lighter physical activity, whilst improvement in asthma outcomes from increasing activity intensity was not evident. Additionally, it appears the benefit from physical activity may differ according to BMI</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Australia -CO - Sweden -CO - Norway -CO - Iceland -CO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1281293</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/02770903.2017.1281293</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170304-RussellMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170304-RussellMA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170304, Russell MA</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1281293</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40730</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rioseco,A.</style></author><author><style face="normal" font="default"> Serrano,C.</style></author><author><style face="normal" font="default"> Celedon,J.C.</style></author><author><style face="normal" font="default"> Padilla,O.</style></author><author><style face="normal" font="default"> Puschel,K.</style></author><author><style face="normal" font="default"> Castro-Rodriguez,J.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Caregiver's depressive symptoms and asthma control in children from an underserved community</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> C-ACT</style></keyword><keyword><style face="normal" font="default"> Caregivers</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Chile</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> cortisol</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Developing Countries</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Family Health</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="13" Month="2" Year="2017">2017/2/13</year></dates><publisher><style face="normal" font="default">Taylor &amp; Francis</style></publisher><isbn><style face="normal" font="default">0277-0903</style></isbn><abstract><style face="normal" font="default">Abstract:Caregiver?s or maternal depression has been associated with increased asthma morbidity in children from prosperous nations, but little is known about this link in developing countries. Objective: To examine if caregiver's depressive symptoms are associated with poor asthma control and abnormal immune responses in school-aged children. Methods: Case-control study of 87 asthmatic children (aged 4 to 11-áyears) attending a primary care clinic in an under-served area of Santiago (Chile). Cases were children with poor asthma control (a child's Asthma Control Test [c-ACT] &lt;20 points) and controls were children with adequate asthma control (c-ACT </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ëÑ20 points). The Beck Depression Inventory-II (BDI) and a locally validated family health vulnerability test (SALUFAM) were used to assess caregivers? depression and family health vulnerability. Serum from participating children was assayed for IFN-?, IL-4, IL-13, TGF-?, cortisol, and total IgE.Results: The mean (SD) age of study participants was 8.23 (2.15-áyears), and 55.2% were females. Use of inhaled corticosteroids (ICS), family health vulnerability and caregiver?s depressive symptoms were significantly more common in cases than in controls (65.4% vs. 34.6%, p =0.003; 41.3% vs. 24.8%, p=0.07; and 39.1% vs. 19.5%, p=0.04, respectively). There was no significant difference in the level of any serum biomarker between groups. In a multivariate analysis, only ICS use was significantly associated with better asthma control (OR= 3.56 [1.34 to 9.48], p=0.01). Conclusions: Presence of caregiver's depressive symptoms is associated with poor asthma control among children from an underserved community, but this association was no longer significant after accounting for ICS useAbstract:Caregiver?s or maternal depression has been associated with increased asthma morbidity in children from prosperous nations, but little is known about this link in developing countries. Objective: To examine if caregiver's depressive symptoms are associated with poor asthma control and abnormal immune responses in school-aged children. Methods: Case-control study of 87 asthmatic children (aged 4 to 11-áyears) attending a primary care clinic in an under-served area of Santiago (Chile). Cases were children with poor asthma control (a child's Asthma Control Test [c-ACT] &lt;20 points) and controls were children with adequate asthma control (c-ACT </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ëÑ20 points). The Beck Depression Inventory-II (BDI) and a locally validated family health vulnerability test (SALUFAM) were used to assess caregivers? depression and family health vulnerability. Serum from participating children was assayed for IFN-?, IL-4, IL-13, TGF-?, cortisol, and total IgE.Results: The mean (SD) age of study participants was 8.23 (2.15-áyears), and 55.2% were females. Use of inhaled corticosteroids (ICS), family health vulnerability and caregiver?s depressive symptoms were significantly more common in cases than in controls (65.4% vs. 34.6%, p =0.003; 41.3% vs. 24.8%, p=0.07; and 39.1% vs. 19.5%, p=0.04, respectively). There was no significant difference in the level of any serum biomarker between groups. In a multivariate analysis, only ICS use was significantly associated with better asthma control (OR= 3.56 [1.34 to 9.48], p=0.01). Conclusions: Presence of caregiver's depressive symptoms is associated with poor asthma control among children from an underserved community, but this association was no longer significant after accounting for ICS use</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Chile -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1292281</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1080/02770903.2017.1292281</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170304-RiosecoA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170304-RiosecoA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170304, Rioseco A</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1292281</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40731</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bando,K.</style></author><author><style face="normal" font="default"> Tanaka,Y.</style></author><author><style face="normal" font="default"> Kuroishi,T.</style></author><author><style face="normal" font="default"> Sasaki,K.</style></author><author><style face="normal" font="default"> Takano-Yamamoto,T.</style></author><author><style face="normal" font="default"> Sugawara,S.</style></author><author><style face="normal" font="default"> Endo,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Orthodontics and Dentofacial Orthopedics; Division of Molecular Regulation.</style></auth-address><titles><title><style face="normal" font="default">Mouse Model of Hydroquinone Hypersensitivity via Innate and Acquired Immunity, and its Promotion by Combined Reagents</style></title><secondary-title><style face="normal" font="default">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Invest Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adjuvant</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dexamethasone</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> IL-1</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> NK cells</style></keyword><keyword><style face="normal" font="default"> Orthodontics</style></keyword><keyword><style face="normal" font="default"> Orthopedics</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> TH2 cytokines</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> Tretinoin</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="default">We established a mouse model of contact hypersensitivity (CHS) to hydroquinone (HQ), a widespread chemical in our environment. HQ was painted onto flanks. Then, HQ was challenged by painting onto ear-pinnas on days 7 and 14. The CHS after the 2nd challenge was markedly greater than that after the 1st challenge. Both challenges increased thymic stromal lymphopoietin (TSLP) and Th2 cytokines in ear-pinnas, while IFN-gamma (typical Th1 cytokine) was decreased, despite an increase in IL-18 (typical IFN-gamma inducer). In nude mice (T-cell-reduced), although a 1st challenge induced CHS, a 2nd challenge did not augment it. In SCID, SCID-beige, and IL-1-deficient mice, CHS was not induced. However, CHS was inducible in SCID-beige mice following transfer of NK-cells from HQ-sensitized normal mice. Interestingly, tretinoin (used for enhancing the skin-whitening effect of HQ) and resin monomers (used to prevent polymerization of HQ) lowered the HQ concentration needed to establish sensitization to HQ. The augmented CHS after a 2nd challenge was reduced by JNJ7777120, dexamethasone, suplatast tosilate (Th2-cytokine inhibitor), and anti-TSLP antibody. These results suggest that (i) TSLP, IL-1, and T- and/or NK-cells are important in establishing and augmenting CHS to HQ, and (ii) inflammatory chemicals may promote CHS to HQ as adjuvants</style></abstract><notes><style face="normal" font="default">DA - 20170121IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jid.2016.12.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28108299">PM:28108299</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170121, Bando K</style></custom2><misc3><style face="normal" font="default">10.1016/j.jid.2016.12.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40732</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Langan,S.M.</style></author><author><style face="normal" font="default"> Abuabara,K.</style></author><author><style face="normal" font="default"> Henrickson,S.E.</style></author><author><style face="normal" font="default"> Hoffstad,O.</style></author><author><style face="normal" font="default"> Margolis,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Epidemiology &amp; Population Health, London School of Hygiene and Tropical Medicine.</style></auth-address><titles><title><style face="normal" font="default">Increased risk of cutaneous and systemic infections in atopic dermatitis - A cohort study</style></title><secondary-title><style face="normal" font="default">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Invest Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hygiene</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Tropical Medicine</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="12" Month="2" Year="2017">2017/2/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170216IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jid.2017.01.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28202403">PM:28202403</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170216, Langan SM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jid.2017.01.030</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40733</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Siegfried,E.C.</style></author><author><style face="normal" font="default"> Jaworski,J.C.</style></author><author><style face="normal" font="default"> Eichenfield,L.F.</style></author><author><style face="normal" font="default"> Hebert,A.A.</style></author><author><style face="normal" font="default"> Paller,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Division of Dermatology, Saint Louis University and Cardinal Glennon Children's Hospital.</style></auth-address><titles><title><style face="normal" font="default">Optimizing Clinical Trials for Atopic Dermatitis in Children</style></title><secondary-title><style face="normal" font="default">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Invest Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="9" Month="2" Year="2017">2017/2/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170212IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jid.2017.01.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28189536">PM:28189536</url></web-urls></urls><custom2><style face="normal" font="default">20170212, Siegfried EC</style></custom2><misc3><style face="normal" font="default">10.1016/j.jid.2017.01.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40734</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nesic,V.S.</style></author><author><style face="normal" font="default"> Djordjevic,V.Z.</style></author><author><style face="normal" font="default"> Tomic-Spiric,V.</style></author><author><style face="normal" font="default"> Dudvarski,Z.R.</style></author><author><style face="normal" font="default"> Soldatovic,I.A.</style></author><author><style face="normal" font="default"> Arsovic,N.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Medicine,University of Belgrade,Belgrade,Serbia</style></auth-address><titles><title><style face="normal" font="default">Measuring nasal nitric oxide in allergic rhinitis patients</style></title><secondary-title><style face="normal" font="default">J Laryngol Otol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Laryngol Otol</style></full-title></periodical><pages end="1071" start="1064">1064-1071</pages><volume><style face="normal" font="default">130</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Aspiration</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exhalation</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mouth</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Nose</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serbia</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">OBJECTIVE: This study aimed to compare two sampling methods for nasal nitric oxide in healthy individuals and allergic rhinitis patients, and to examine the within-subject reliability of nasal nitric oxide measurement. METHODS: The study included 23 allergic rhinitis patients without concomitant asthma and 10 healthy individuals. For all participants, nitric oxide levels were measured non-invasively from the lungs through the mouth (i.e. the oral fractional exhaled nitric oxide) and the nose. Nasal nitric oxide was measured by two different methods: (1) nasal aspiration via one nostril during breath holding and (2) single-breath quiet exhalation against resistance through a tight facemask (i.e. the nasal fractional exhaled nitric oxide). RESULTS: Compared with healthy participants, allergic rhinitis patients had significantly higher average oral and nasal nitric oxide levels. All methods of nitric oxide measurement had excellent reliability. CONCLUSION: Nasal nitric oxide measurement is a useful and reliable clinical tool for diagnosing allergic rhinitis in patients without asthma in an out-patient setting</style></abstract><notes><style face="normal" font="default">DA - 20161108IS - 1748-5460 (Electronic)IS - 0022-2151 (Linking)LA - engPT - Journal ArticleCO - Serbia -</style></notes><work-type><style face="normal" font="default">10.1017/S0022215116009087</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27823578">PM:27823578</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Laryngol Otol\2016-130-1064-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Laryngol Otol\2016-130-1064-71.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161108, Nesic VS</style></custom2><misc3><style face="normal" font="default">10.1017/S0022215116009087</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40735</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">de Bourayne,M.</style></author><author><style face="normal" font="default"> Gallais,Y.</style></author><author><style face="normal" font="default"> El Ali,Z.</style></author><author><style face="normal" font="default"> Rousseau,P.</style></author><author><style face="normal" font="default"> Damiens,M.H.</style></author><author><style face="normal" font="default"> Cochet,C.</style></author><author><style face="normal" font="default"> Filhol,O.</style></author><author><style face="normal" font="default"> Chollet-Martin,S.</style></author><author><style face="normal" font="default"> Pallardy,M.</style></author><author><style face="normal" font="default"> Kerdine-Romer,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">UMR996, Inflammation, Chemokines, and Immunopathology, INSERM, University Paris-Sud, Universite Paris-Saclay, Chatenay-Malabry, France</style></auth-address><titles><title><style face="normal" font="default">Protein kinase CK2 controls T-cell polarization through dendritic cell activation in response to contact sensitizers</style></title><secondary-title><style face="normal" font="default">J Leukoc Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Leukoc Biol</style></full-title></periodical><pages end="715" start="703">703-715</pages><volume><style face="normal" font="default">101</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> CD40</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Chemokines</style></keyword><keyword><style face="normal" font="default"> Coculture</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> DC</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> DNCB</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-23</style></keyword><keyword><style face="normal" font="default"> immunopathology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> peptide</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Up-Regulation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Allergic contact dermatitis (ACD) represents a severe health problem with increasing worldwide prevalence. It is a T-cell-mediated inflammatory skin disease caused by chemicals present in the daily or professional environment. NiSO4 and 2,4-dinitrochlorobenzene (DNCB) are 2 chemicals involved in ACD. These contact sensitizers are known to induce an up-regulation of phenotypic markers and cytokine secretion in dendritic cells (DCs; professional APCs), leading to the generation of CD8+ Tc1/Tc17 and CD4+ Th1/Th17 effector T cells. In the present study, using a peptide array approach, we identified protein kinase CK2 as a novel kinase involved in the activation of human monocyte-derived DCs (MoDCs) in response to NiSO4 and DNCB. Inhibition of CK2 activity in MoDCs led to an altered mature phenotype with lower expression of CD54, PDL-1, CD86, and CD40 in response to NiSO4 or DNCB. CK2 activity also regulated proinflammatory cytokine production, such as TNF-alpha, IL-1beta, and IL-23 in MoDCs. Moreover, in a DC/T cell coculture model in an allogeneic setup, CK2 activity in MoDCs played a major role in Th1 polarization in response to NiSO4 and DNCB. CK2 inhibition in MoDCs led to an enhanced Th2 polarization in the absence of contact sensitizer stimulation</style></abstract><notes><style face="normal" font="default">DA - 20161006IS - 1938-3673 (Electronic)IS - 0741-5400 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -</style></notes><work-type><style face="normal" font="default">10.1189/jlb.3A0715-320RR</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27707883">PM:27707883</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Leukoc Biol\2017-101-703-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Leukoc Biol\2017-101-703-15.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161006, de Bourayne M</style></custom2><misc3><style face="normal" font="default">10.1189/jlb.3A0715-320RR</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40736</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Soyer,P.</style></author><author><style face="normal" font="default"> Dohan,A.</style></author><author><style face="normal" font="default"> Patkar,D.</style></author><author><style face="normal" font="default"> Gottschalk,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Body and Interventional Imaging, Hopital Lariboisiere, AP-HP, Paris, France.</style></auth-address><titles><title><style face="normal" font="default">Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study</style></title><secondary-title><style face="normal" font="default">J Magn Reson Imaging</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Magn Reson Imaging</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Central Nervous System</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Creatinine</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Filtration</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Glomerular Filtration Rate</style></keyword><keyword><style face="normal" font="default"> imaging</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Indications</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Meglumine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nausea</style></keyword><keyword><style face="normal" font="default"> Nervous System</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Renal Insufficiency</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> Vomiting</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="10" Year="2016">2016/10/11</year></dates><abstract><style face="normal" font="default">PURPOSE: To investigate the safety of gadoterate meglumine and identify the incidence of nephrogenic systemic fibrosis (NSF). MATERIALS AND METHODS: An international prospective observational study was conducted from November 2008 to June 2013. A total of 35,499 adults and children who were scheduled to undergo contrast-enhanced MRI using gadoterate meglumine were analyzed (female, 53.1%; mean age: 49.5 years; range: 0-98 years). At least 3-month follow-up was planned for patients with an estimated creatinine clearance or glomerular filtration rate &lt;60 mL/min (/1.73 m2) to detect any suspicion or occurrence of NSF. Adverse events (AEs) were prospectively recorded. Demographic data, risk factors, indications for MRI examinations, characteristics of gadoterate meglumine administration, and efficacy were documented. RESULTS: MRI examinations were mainly for central nervous system (61%). The most frequent risk factor was renal insufficiency (14.7%). Seventy AEs were observed in 44 patients (0.12%). Among the 70 AEs, 38 in 32 patients (0.09% of all patients) were considered related to gadoterate meglumine and classified as adverse drug reaction (ADR).The most frequent ADRs were urticaria (9 patients, 0.03%), nausea (7 patients, 0.02%), and vomiting (4 patients, 0.01%). Within the pediatric population (1,629 patients), only one AE (vomiting) was observed. Nine adult patients (0.03%) experienced serious AEs. Moderate to severe renal insufficiency at inclusion was reported in 514 patients (1.5%). Among them, 476 (92.6%) were followed-up. No patients were suspected of having NSF and no cases of NSF were observed. CONCLUSION: Our study confirms the excellent safety profile of gadoterate meglumine in routine practice. Level of Evidence 1 J. Magn. Reson. Imaging 2016</style></abstract><notes><style face="normal" font="default">DA - 20161011IS - 1522-2586 (Electronic)IS - 1053-1807 (Linking)LA - ENGPT - JOURNAL ARTICLECO - France -CO - India -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1002/jmri.25486</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27726239">PM:27726239</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Magn Reson Imaging\20161011-SoyerP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Magn Reson Imaging\20161011-SoyerP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161011, Soyer P</style></custom2><misc3><style face="normal" font="default">10.1002/jmri.25486</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40737</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lind,N.</style></author><author><style face="normal" font="default"> Soderholm,A.</style></author><author><style face="normal" font="default"> Palmquist,E.</style></author><author><style face="normal" font="default"> Andersson,L.</style></author><author><style face="normal" font="default"> Millqvist,E.</style></author><author><style face="normal" font="default"> Nordin,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Psychology, Umea University, Umea</style></auth-address><titles><title><style face="normal" font="default">Comorbidity and Multimorbidity of Asthma and Allergy and Intolerance to Chemicals and Certain Buildings</style></title><secondary-title><style face="normal" font="default">J Occup Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Occup Environ Med</style></full-title></periodical><pages end="84" start="80">80-84</pages><volume><style face="normal" font="default">59</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nonallergic asthma</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> psychology</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">OBJECTIVES: We tested the hypothesis of high comorbidity between asthma/allergy and chemical intolerance (CI) and between asthma/allergy and building intolerance (BI), and high multimorbidity between asthma/allergy, CI, and BI. METHODS: Population-based questionnaire data were used from 530 participants with asthma/allergy (allergic asthma, nonallergic asthma, allergic rhinitis, and/or atopic dermatitis), 414 with self-reported and 112 with physician-diagnosed CI, and 165 with self-reported and 47 with physician-diagnosed BI. Separate reference groups were formed for each of the five case groups. RESULTS: Adjusted odds ratios varied from 4.6 to 13.1 for comorbidity, and from 6.6 to 46.4 for multimorbidity. CONCLUSION: The large comorbidity and multimorbidity between asthma/allergy, CI, and BI evokes the question as to whether there are similarities in underlying mechanisms between these conditions</style></abstract><notes><style face="normal" font="default">DA - 20170103IS - 1536-5948 (Electronic)IS - 1076-2752 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1097/JOM.0000000000000930</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28045802">PM:28045802</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Occup Environ Med\2017-59-80-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Occup Environ Med\2017-59-80-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170103, Lind N</style></custom2><misc3><style face="normal" font="default">10.1097/JOM.0000000000000930</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40738</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Baxley,A.</style></author><author><style face="normal" font="default"> Lee,Z.</style></author><author><style face="normal" font="default"> Medina,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Stephenson Cancer Center, OK, USA</style></auth-address><titles><title><style face="normal" font="default">Systemic hypersensitivity to fosaprepitant - A report of two cases</style></title><secondary-title><style face="normal" font="default">J Oncol Pharm Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Oncol Pharm Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cancer</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="21" Month="11" Year="2016">2016/11/21</year></dates><abstract><style face="normal" font="default">Fosaprepitant is a widely administered antiemetic used mainly for moderately to highly emetogenic chemotherapy. Local injection site reactions are the most common type of infusion reaction reported from fosaprepitant. At our institution, two separate patients have experienced systemic hypersensitivity reactions to their infusions of fosaprepitant. We report a review of the literature and the details of these reactions</style></abstract><notes><style face="normal" font="default">DA - 20161122IS - 1477-092X (Electronic)IS - 1078-1552 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/1078155216680118</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27872331">PM:27872331</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Oncol Pharm Pract\20161122-BaxleyA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Oncol Pharm Pract\20161122-BaxleyA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161122, Baxley A</style></custom2><misc3><style face="normal" font="default">10.1177/1078155216680118</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40739</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jerzak,K.J.</style></author><author><style face="normal" font="default"> Deghan,M.S.</style></author><author><style face="normal" font="default"> Ng,P.</style></author><author><style face="normal" font="default"> Maganti,M.</style></author><author><style face="normal" font="default"> McCuaig,J.M.</style></author><author><style face="normal" font="default"> Bulter,M.</style></author><author><style face="normal" font="default"> Oza,A.</style></author><author><style face="normal" font="default"> Mackay,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Medical Oncology and Hematology, Faculty of Medicine, University of Toronto, Sunnybrook Odette Cancer Center, Toronto, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="default">Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer</style></title><secondary-title><style face="normal" font="default">J Oncol Pharm Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Oncol Pharm Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Carboplatin</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Diphenhydramine</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Hematology</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Ontario</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> ovarian cancer</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="17" Month="11" Year="2016">2016/11/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Carboplatin-based chemotherapy offers high response rates and improved overall survival for women with epithelial ovarian cancer, but its use is limited by the occurrence of hypersensitivity reactions. To evaluate the efficacy of prophylactic diphenhydramine for hypersensitivity reaction prevention, we reviewed the incidence of hypersensitivity reactions and identified patients at high risk of hypersensitivity reactions. METHODS: Women receiving >/=6 cycles of carboplatin-based chemotherapy for epithelial ovarian cancer were identified from our institutional database at the Princess Margaret Cancer Centre. Institutional policy was changed in 2009 to introduce diphenhydramine prophylaxis for patients receiving >/=6 cycles of carboplatin. Additional clinical data were abstracted from the patient record. RESULTS: Between 2006 and 2012, 450 women received >/=6 cycles of carboplatin-based chemotherapy for epithelial ovarian cancer. Two hundred and ninety-one women received prophylaxis with diphenhydramine. Carboplatin-induced hypersensitivity reactions occurred in 41 of 449 patients (9%). Univariable predictors of carboplatin-induced hypersensitivity reactions included administration of 8 to 10 cycles of carboplatin, history of other drug allergies and a platinum-free interval >12 months. BRCA mutational status was not predictive. In a multivariable analysis, the number of cycles of carboplatin and a platinum-free interval >12 months were independent predictors of hypersensitivity reactions. There was a trend towards diphenhydramine prophylaxis reducing the incidence of hypersensitivity reactions in women with a platinum-free interval compared to continuous delivery; this was most marked when the platinum-free interval was >12 months (n = 64) (OR: 0.2 (95% CI: 0.046-0.83), p = 0.03). CONCLUSIONS: The administration of diphenhydramine to women who have a platinum-free interval may reduce the risk of hypersensitivity reaction, but prospective evaluation is required</style></abstract><notes><style face="normal" font="default">DA - 20161118IS - 1477-092X (Electronic)IS - 1078-1552 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1177/1078155216679028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27856924">PM:27856924</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Oncol Pharm Pract\20161118-JerzakKJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Oncol Pharm Pract\20161118-JerzakKJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161118, Jerzak KJ</style></custom2><misc3><style face="normal" font="default">10.1177/1078155216679028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40740</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cigic,L.</style></author><author><style face="normal" font="default"> Galic,T.</style></author><author><style face="normal" font="default"> Kero,D.</style></author><author><style face="normal" font="default"> Simunic,M.</style></author><author><style face="normal" font="default"> Medvedec,M.I.</style></author><author><style face="normal" font="default"> Kalibovic,G.D.</style></author><author><style face="normal" font="default"> Biocina,L.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Study of Dental Medicine, School of Medicine, University of Split, Split, Croatia.</style></auth-address><titles><title><style face="normal" font="default">The prevalence of celiac disease in patients with geographic tongue</style></title><secondary-title><style face="normal" font="default">J Oral Pathol Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Oral Pathol Med</style></abbr-1></periodical><pages end="796" start="791">791-796</pages><volume><style face="normal" font="default">45</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Celiac Disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Croatia</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic tool</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Early Diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Gliadin</style></keyword><keyword><style face="normal" font="default"> HLA</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human leukocyte antigen</style></keyword><keyword><style face="normal" font="default"> Iga</style></keyword><keyword><style face="normal" font="default"> Igg</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Increased prevalence</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Serologic Tests</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Tongue</style></keyword><keyword><style face="normal" font="default"> Transglutaminase</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Geographic tongue (GT) is a benign inflammatory condition usually involving the dorsal surface and lateral borders of the tongue. Numerous etiological factors of GT have been suggested, including immunological factors; genetic; atopic or allergic predisposition; emotional stress; and hormonal disturbances. GT may also coexist as one of the possible manifestations of celiac disease (CD). Therefore, the aim of this study was to investigate the prevalence of CD, positive serologic tests for CD screening, and HLA-DQ presence in patients with GT. METHODS: Tissue transglutaminase antibodies (anti-tTG), antibodies against gliadin (AGA), and human leukocyte antigen (HLA) typing were assessed for 60 GT patients and 60 healthy control subjects. The duodenal biopsy was performed in patients with positive serologic tests. RESULTS: We found that 9 (15%) GT patients were positive for IgA tTG, and in those patients histological changes consistent with CD were confirmed by duodenal biopsy. Only two of them reported the presence of gastrointestinal symptoms. There were statistically significant differences between the GT patients and control group for immunoglobulin (Ig) A tTG (P = 0.03), IgG tTG (P = 0.04), IgA AGA (P = 0.04), and IgG AGA (P = 0.02). CONCLUSION: The results of our study demonstrated the increased prevalence of CD in patients with GT. Therefore, the clinical oral examination should be considered a diagnostic tool, especially in atypical or silent forms of CD, since it may contribute to provide an early diagnosis</style></abstract><notes><style face="normal" font="default">DA - 20160501IS - 1600-0714 (Electronic)IS - 0904-2512 (Linking)LA - ENGPT - Journal ArticleCO - Croatia -</style></notes><work-type><style face="normal" font="default">10.1111/jop.12450</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27131886">PM:27131886</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Oral Pathol Med\2016-45-791-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Oral Pathol Med\2016-45-791-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160501, Cigic L</style></custom2><misc3><style face="normal" font="default">10.1111/jop.12450</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40741</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gomez,M.</style></author><author><style face="normal" font="default"> Reddy,A.L.</style></author><author><style face="normal" font="default"> Dixon,S.L.</style></author><author><style face="normal" font="default"> Wilson,J.</style></author><author><style face="normal" font="default"> Jacobs,D.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">New York State Health Department, Albany, New York (Ms Gomez); and National Center for Healthy Housing, Columbia, Maryland (Ms Reddy, Drs Dixon and Jacobs and Mr Wilson)</style></auth-address><titles><title><style face="normal" font="default">A Cost-Benefit Analysis of a State-Funded Healthy Homes Program for Residents With Asthma: Findings From the New York State Healthy Neighborhoods Program</style></title><secondary-title><style face="normal" font="default">J Public Health Manag Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Public Health Manag Pract</style></abbr-1></periodical><pages end="238" start="229">229-238</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Columbia</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Cost-Benefit Analysis</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health care utilization</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Housing</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Maryland</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Self-management</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">CONTEXT: Despite considerable evidence that the economic and other benefits of asthma home visits far exceed their cost, few health care payers reimburse or provide coverage for these services. OBJECTIVE: To evaluate the cost and savings of the asthma intervention of a state-funded healthy homes program. DESIGN: Pre- versus postintervention comparisons of asthma outcomes for visits conducted during 2008-2012. SETTING: The New York State Healthy Neighborhoods Program operates in select communities with a higher burden of housing-related illness and associated risk factors. PARTICIPANTS: One thousand households with 550 children and 731 adults with active asthma; 791 households with 448 children and 551 adults with asthma events in the previous year. INTERVENTION: The program provides home environmental assessments and low-cost interventions to address asthma trigger-promoting conditions and asthma self-management. Conditions are reassessed 3 to 6 months after the initial visit. MAIN OUTCOME MEASURES: Program costs and estimated benefits from changes in asthma medication use, visits to the doctor for asthma, emergency department visits, and hospitalizations over a 12-month follow-up period. RESULTS: For the asthma event group, the per person savings for all medical encounters and medications filled was $1083 per in-home asthma visit, and the average cost of the visit was $302, for a benefit to program cost ratio of 3.58 and net benefit of $781 per asthma visit. For the active asthma group, per person savings was $613 per asthma visit, with a benefit to program cost ratio of 2.03 and net benefit of $311. CONCLUSION: Low-intensity, home-based, environmental interventions for people with asthma decrease the cost of health care utilization. Greater reductions are realized when services are targeted toward people with more poorly controlled asthma. While low-intensity approaches may produce more modest benefits, they may also be more feasible to implement on a large scale. Health care payers, and public payers in particular, should consider expanding coverage, at least for patients with poorly controlled asthma or who may be at risk for poor asthma control, to include services that address triggers in the home environment</style></abstract><notes><style face="normal" font="default">DA - 20170125IS - 1550-5022 (Electronic)IS - 1078-4659 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/PHH.0000000000000528</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28121775">PM:28121775</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Public Health Manag Pract\2017-23-229-38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Public Health Manag Pract\2017-23-229-38.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170125, Gomez M</style></custom2><misc3><style face="normal" font="default">10.1097/PHH.0000000000000528</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40742</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Xie,D.</style></author><author><style face="normal" font="default"> Gheiler,V.</style></author><author><style face="normal" font="default"> Bianco,F.J.</style></author><author><style face="normal" font="default"> Perito,P.E.</style></author><author><style face="normal" font="default"> Gheiler,E.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">160 AMS CX 700 Coted with Minocycline and Rifampin Allergic Reaction, a Rare Event: A Novel Method of Treatment</style></title><secondary-title><style face="normal" font="default">J Sex Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Sex Med</style></full-title></periodical><pages end="" start="e66">e66-</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">2, Supplement</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Minocycline</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Rifampin</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><isbn><style face="normal" font="default">1743-6095</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jsxm.2016.12.148</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.jsxm.2016.12.148</url></web-urls></urls><custom2><style face="normal" font="default">20170304, Xie D</style></custom2><misc3><style face="normal" font="default">10.1016/j.jsxm.2016.12.148</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40743</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kespohl,S.</style></author><author><style face="normal" font="default"> Campo,P.</style></author><author><style face="normal" font="default"> Zahradnik,E.</style></author><author><style face="normal" font="default"> Maryska,S.</style></author><author><style face="normal" font="default"> Aranda-Guerrero,A.</style></author><author><style face="normal" font="default"> Rodriguez,J.</style></author><author><style face="normal" font="default"> Bruning,T.</style></author><author><style face="normal" font="default"> Raulf,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Institute for Prevention and Occupational Medicine of the German Social Accident Insurance , Institute of the Ruhr-Universitat Bochum (IPA) , Bochum , Germany</style></auth-address><titles><title><style face="normal" font="default">Quantification of obeche wood allergen: Development of a sensitive sandwich-ELISA for occupational exposure assessment</style></title><secondary-title><style face="normal" font="default">J Toxicol Environ Health A</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Toxicol Environ Health A</style></full-title></periodical><pages end="1077" start="1070">1070-1077</pages><volume><style face="normal" font="default">79</style></volume><number><style face="normal" font="default">22-23</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergen exposure</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Immunoassay</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> molds</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> occupational asthma</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> Occupational Medicine</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Quantification</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wood</style></keyword><keyword><style face="normal" font="default"> Workplace</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Obeche wood is a prominent cause of allergic occupational asthma. To reduce the risk of immunoglobulin E (IgE)-mediated sensitization it is important to assess airborne obeche wood allergen concentrations at exposed workplaces. Therefore, a highly sensitive obeche wood allergen immunoassay was developed and applicability was proven on airborne passive dust samples in Spanish wood workshops. Obeche wood sandwich enzyme-linked immunosorbent assay (ELISA) polyclonal antibodies (pAbs) were developed. Test specificity was verified by different wood and mold extracts. Obeche wood allergen monitoring was conducted in four Spanish wood workshops, including wood-dust-exposed and nonexposed areas inside and outside the workplaces, as well as controls. Dust was collected with electrostatic dust collectors (EDC). Measuring range of the obeche wood sandwich-ELISA was between 36 pg/ml and 1.6 microg/ml. The test system showed only marginal reactivity to other hardwoods and no reactivity to softwoods and molds. Obeche allergen was detected in all EDC from workplaces. The highest concentration was measured in the workshop with the longest obeche wood exposure (geometric mean [GM]: 7548 microg/m2); shorter obeche wood processing periods resulted in lower amounts of allergen (GM: 29 microg/m2). Obeche wood allergen transfer from exposed workplaces to nonexposed areas inside and outside the workshop was assessed. In control EDC from nonexposed facilities/homes no obeche wood allergen was found. The new obeche wood sandwich-ELISA is a valid tool to quantify obeche allergen exposure. Evidence indicates it will be possible to monitor obeche allergen exposure during different processes, as well as transfer effects in nonexposed areas</style></abstract><notes><style face="normal" font="default">DA - 20161207IS - 1528-7394 (Print)IS - 0098-4108 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1080/15287394.2016.1219577</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27924719">PM:27924719</url></web-urls></urls><custom2><style face="normal" font="default">20161207, Kespohl S</style></custom2><misc3><style face="normal" font="default">10.1080/15287394.2016.1219577</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40744</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zelga,P.J.</style></author><author><style face="normal" font="default"> Gornicz,M.M.</style></author><author><style face="normal" font="default"> Gluszkiewicz,J.M.</style></author><author><style face="normal" font="default"> Piasecka-Zelga,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical University of Lodz, Department of General and Colorectal Surgery, Pl. Hallera 1, 91-647 Lodz, Poland</style></auth-address><titles><title><style face="normal" font="default">Outcomes of acute dermal irritation and sensitisation tests on active dressings for chronic wounds: a comparative study</style></title><secondary-title><style face="normal" font="default">J Wound Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Wound Care</style></full-title></periodical><pages end="729" start="722">722-729</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Chitosan</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Comparative Study</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Guinea Pigs</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritation</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Nanoparticles</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> pig</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Rabbits</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Sensitisation</style></keyword><keyword><style face="normal" font="default"> Silver</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin reaction</style></keyword><keyword><style face="normal" font="default"> skin reactions</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> Ulcer</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="12" Year="2016">2016/12/2</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Chronic, non-healing ulcers are a significant problem in clinical practice. The numerous complications, associated with toxicological and allergic reactions, caused by certain compounds in active dressings have been reported. The aim of this study was to evaluate the local skin tolerance of active dressings and determine which of them carries a risk of causing local skin reactions. METHOD: We tested six active dressings from different categories (hydrogel dressing, chitosan sponge dressing, silver nanoparticles dressing, dry flax fibres dressing alone and coated with linfix or oilfix) for acute irritation in rabbits and for sensitisation in guinea pigs. RESULTS: Only the dry flax fibre dressing showed no irritant and sensitisation effects. The remaining dressings obtained Cumulative Irritation Index from 0.00-0.35 and evoked sensitisation reaction in up to 20 % animals, which according to skin reaction category puts them in the non-to mildly-irritating and sensitising products group. CONCLUSION: Based on the findings, it should be considered that although analysed dressings do not present a serious risk of allergic reactions in humans, only the dry flax fibre dressing can be perceived as having negligible risk. Declaration of interest The authors have no conflict of interests</style></abstract><notes><style face="normal" font="default">DA - 20161215IS - 0969-0700 (Print)IS - 0969-0700 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.12968/jowc.2016.25.12.722</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27974010">PM:27974010</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20161215, Zelga PJ</style></custom2><misc3><style face="normal" font="default">10.12968/jowc.2016.25.12.722</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40745</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Delstanche,S.</style></author><author><style face="normal" font="default"> Servais,L.</style></author><author><style face="normal" font="default"> Gidaro,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">CRMN Hopital de la Citadelle, Liege, Belgium</style></auth-address><titles><title><style face="normal" font="default">Improved Muscular Weakness During Asthma Exacerbation</style></title><secondary-title><style face="normal" font="default">JAMA Neurol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JAMA Neurol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> France</style></keyword></keywords><dates><year Day="3" Month="1" Year="2017">2017/1/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 2168-6157 (Electronic)IS - 2168-6149 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - France -</style></notes><work-type><style face="normal" font="default">10.1001/jamaneurol.2016.4069</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28055071">PM:28055071</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JAMA Neurol\20170105-DelstancheS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JAMA Neurol\20170105-DelstancheS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Delstanche S</style></custom2><misc3><style face="normal" font="default">10.1001/jamaneurol.2016.4069</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40746</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Matsui,E.C.</style></author><author><style face="normal" font="default"> McCormack,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pediatric Allergy and Immunology, Johns Hopkins School of Medicine, Baltimore, Maryland</style></auth-address><titles><title><style face="normal" font="default">Small Steps Toward Asthma-Friendly School Environments</style></title><secondary-title><style face="normal" font="default">JAMA Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JAMA Pediatr</style></abbr-1></periodical><pages end="14" start="13">13-14</pages><volume><style face="normal" font="default">171</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Baltimore</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Maryland</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161128IS - 2168-6211 (Electronic)IS - 2168-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1001/jamapediatrics.2016.3274</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27893071">PM:27893071</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JAMA Pediatr\2017-171-13-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JAMA Pediatr\2017-171-13-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161128, Matsui EC</style></custom2><misc3><style face="normal" font="default">10.1001/jamapediatrics.2016.3274</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40747</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kamal,Z.</style></author><author><style face="normal" font="default"> Saia,M.</style></author><author><style face="normal" font="default"> Morella,K.</style></author><author><style face="normal" font="default"> Bowman,M.C.</style></author><author><style face="normal" font="default"> Titus,O.</style></author></authors></contributors><titles><title><style face="normal" font="default">Evaluating the Use of the Aerobika Vibratory Positive expiratory Pressure Device in Children with Moderately Severe asthma Exacerbations</style></title><secondary-title><style face="normal" font="default">JSM Allergy Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">JSM Allergy Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">acute asthma</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Albuterol</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Flare</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Mucus</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Patient Compliance</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pneumothorax</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Acute asthma flares are associated with bronchospasm, inflammation and mucus plugging. We previously showed the benefits of a breath-actuated nebulizer (BAN) to deliver albuterol more effectively than other aerosol devices in the Pediatric Emergency Department (PED). Little has been published on interventions to improve mucus plugs which cause ventilation-perfusion defects, hypoxemia and limit aerosol deposition. A new oscillatory positive expiratory pressure (PEP) device, the AerobiKA was constructed to fit directly on the BAN device, so a patient can do airway clearance while receiving their aerosol treatments. This preliminary study was designed to explore the use of AerobiKA in patients presenting to the PED for asthma exacerbations, specifically its tolerance and safety. A convenience sample of patients, aged 5-16 yrs, presenting with acute asthma exacerbations from October 2014-June 2015 was selected and compared to similar patients treated with the BAN alone in our previous study from 2008. Patients with moderate asthma severity/clinical asthma score (CAS) 4-6/10 were compared. There were 21 patients in the AerobiKA (A) group and 39 patients in the BAN (B) group. The average initial CAS was identical between groups (3.7 + 0.2). The average improvement in CAS after the 1st treatment was similar (-2.0 + 0.4 [A] vs -2.2 + 0.2 [B]). 7 There were no adverse events such as pneumothorax or severe respiratory distress in the A patients. The AerobiKA is well-tolerated by children with acute asthma flares and did not lead to adverse events. Parents felt the device promoted more effective cough than their children experienced previously. We strongly feel that patient and parent satisfaction with use of the device will play a positive role in patient compliance for future studies.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.jscimedcentral.com/Allergy/earlyonline.php</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JSM Allergy Asthma\20170304-KamalZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JSM Allergy Asthma\20170304-KamalZ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170304, Kamal Z</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40748</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ho,B.</style></author><author><style face="normal" font="default"> Bahal,S.</style></author><author><style face="normal" font="default"> Bansal,A.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Urticaria and Angioedema - A Practical Perspective</style></title><secondary-title><style face="normal" font="default">JSM Allergy Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">JSM Allergy Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> anti-IgE</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Autoimmunity</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Dyspepsia</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="default"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="default"> montelukast</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> Specific IgE</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> Wheal</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Urticaria and Angioedema affect a significant proportion of the population. Symptoms lasting &lt;6 weeks are defined as acute and causes include infection, and allergy. Chronic Urticaria is defined by wheals and/or swelling lasting for >6 weeks. While reversible causes such as chronic infection or medications are sometimes implicated, often no trigger is found. This is known as Chronic Spontaneous Urticaria and in the majority of patients, symptoms resolve within 1 year. Investigations for all types of Urticaria and Angioedema are guided by the history and examination and particularly by the duration of the urticarial patches. A vasculiticurticaria is suggested when the latter last >36hours and bruising is evident as they fade. Relevant skin prick tests or specific IgE should be performed only if an allergic trigger is evident. Asymptomatic thyroid autoimmunity is frequent in CSU and suggests a possible pathogenic mechanism for the condition. Anti-helicobacter serology is indicated if there is significant dyspepsia. Management includes treating the underlying cause if one is identified. Symptoms control is managed stepwise starting with regular non-sedating antihistamines which can be titrated up to 4 times the usual recommended dose. Montelukast can be added as a second line treatment but sometimes additional agents are needed. The newest one is an anti IgE monoclonal antibody called Omalizumab which is now used in preference to older medications such as Ciclosporin. Vasculiticurticaria requires attention to the underlying antigenic source and in addition to anti-histamines may require steroids and disease modifying agents.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.jscimedcentral.com/Allergy/earlyonline.php</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JSM Allergy Asthma\20170304-HoB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JSM Allergy Asthma\20170304-HoB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170304, Ho B</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40749</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Alcan,A.O.</style></author><author><style face="normal" font="default"> van Giersbergen,M.Y.</style></author><author><style face="normal" font="default"> Yoltay,H.E.</style></author><author><style face="normal" font="default"> Geckil,O.S.</style></author><author><style face="normal" font="default"> Solak,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Turkish Nurses Awareness of Ventilator Bundle</style></title><secondary-title><style face="normal" font="default">JSM Allergy Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">JSM Allergy Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Awareness</style></keyword><keyword><style face="normal" font="default"> Data Collection</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nurses</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Recovery</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Care bundle is defined as implementation of a couple of interventions together that when each one of all executed individually, effect patients recovery process and outcomes positively; when executed all together providing better outcomes than implemented individually. This study is performed to show the nurses awareness about the ventilator bundle. Materials and methods: This descriptive study was conducted between September and November 2015. The sample consisted 286 nurses who agreed to take part in the study. An online questionnaire form was developed by the researchers for data collection in order to investigate the level of the nurse's awareness of the ventilator bundle. Results: It was found that 80.4% (n: 230) of the nurses included in the study had never heard of the term "ventilator bundle". Only 8.7% (n: 25) of the nurses in the study stated that their knowledge of the ventilator bundle was adequate. Conclusion: Our data indicated that Turkish nurses' awareness about ventilator bundle is inadequate. There is need of in service education about ventilator bundle and it's implication into current practice.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.jscimedcentral.com/Allergy/earlyonline.php</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JSM Allergy Asthma\20170304-AlcanAO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JSM Allergy Asthma\20170304-AlcanAO.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170304, Alcan AO</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40750</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Carra Forte,G.</style></author><author><style face="normal" font="default"> Cristofoli Barni,G.</style></author><author><style face="normal" font="default"> de Tarso Roth Dalcin,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Relationship between Self-Related Adherence to Asthma and Asthma Control in Adult Patients</style></title><secondary-title><style face="normal" font="default">JSM Allergy Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">JSM Allergy Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Outpatients</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> pulmonary function test</style></keyword><keyword><style face="normal" font="default"> Pulmonary function tests</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Objective: To assess the self-reported adherence to asthma treatment in outpatients with asthma, to investigate the relationship between adherence and asthma control. In addition, it aimed to describe the characteristics of patients with poor adherence. Methods: In a cross-sectional study we recruited patients aged 14 years and older with confirmed asthma diagnosis from the outpatient asthma clinic of Hospital de Clínicas de Porto Alegre, Brazil. They underwent an evaluation by a general questionnaire, an asthma control questionnaire (based on Global Initiative for Asthma - GINA 2011), an adherence questionnaire and pulmonary function tests. Poor adherence was defined as the reporting of non-use or use less than 5 times in the week of devices containing inhaled corticosteroids. Results: Out of 275 patients studied, 239 (86.9%) were considered with high level of adherence and 36 (13.1%) with poor adherence. There was a significant association between asthma control and self-reported adherence to treatment (p=0.005), so that most patients with high level of adherence kept their disease under control, whereas most patients with poor adherence had uncontrolled status. Logistic regression analysis identified that age was inversely associated with poor adherence (odds ratio=0.98, 95% confidence interval 0.95-0.99, p=0.016). Conclusions: Self-reported adherence to treatment of patients attending an asthma outpatient clinic was elevated (86.9%). The poor adherence was associated with uncontrolled asthma. Younger patients were more likely to be poorly adherent with treatment.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Brazil -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.jscimedcentral.com/Allergy/earlyonline.php</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JSM Allergy Asthma\20170304-CarraForteG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JSM Allergy Asthma\20170304-CarraForteG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170304, Carra Forte G</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40751</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rishton,L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Safety of long-acting beta2-agonists in asthma</style></title><secondary-title><style face="normal" font="default">Lancet Respir Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Lancet Respir Med</style></abbr-1></periodical><pages end="" start="860">860-</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20160925IS - 2213-2619 (Electronic)IS - 2213-2600 (Linking)LA - ENGPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/S2213-2600(16)30299-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27665514">PM:27665514</url></web-urls></urls><custom2><style face="normal" font="default">20160925, Rishton L</style></custom2><misc3><style face="normal" font="default">10.1016/S2213-2600(16)30299-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40752</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Smith,A.</style></author><author><style face="normal" font="default"> Ray,M.</style></author><author><style face="normal" font="default"> Jain,N.</style></author><author><style face="normal" font="default"> Zhang,H.</style></author><author><style face="normal" font="default"> Sebelik,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology-Head and Neck Surgery, University of Tennessee, Memphis, Tennessee, U.S.A</style></auth-address><titles><title><style face="normal" font="default">The burden of angioedema on United States emergency departments: 2006-2010</style></title><secondary-title><style face="normal" font="default">Laryngoscope</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Laryngoscope</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> African American</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Airway Obstruction</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Intubation</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Tennessee</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="15" Month="11" Year="2016">2016/11/15</year></dates><abstract><style face="normal" font="default">OBJECTIVES/HYPOTHESIS: Angioedema (AE) is a condition that may prompt a visit to an emergency department (ED), and can quickly progress to airway obstruction. To optimize treatment of AE, it is necessary to understand epidemiology and practice patterns. This study measured the magnitude of AE ED visits and characterized demographics, management, frequency of airway interventions, and mortality. STUDY DESIGN: Analysis of two national data sets. METHODS: From the Nationwide Emergency Department Sample and National Hospital Ambulatory Medical Care Survey, we identified all patients presenting from 2006 to 2010 with a primary diagnosis of AE, characterized by the International Classification of Diseases, Ninth Edition, Clinical Modification code 995.1. The discharges were weighted and stratified by comorbidities, age, treatments, and region. chi2 , t test, and linear regression were employed for comparisons. RESULTS: Total discharges increased from 87,481 (29.3 of 100,000 people) to 111,116 (35.8 of 100,000 people). More females were afflicted (57%), and 41.1% were African American. The majority (83%) of patients were discharged from the ED. Twelve percent of cases were attributed to antihypertensive adverse reaction, and these patients were older (P &lt; .0001, odds ratio [OR] = 1.02), and had more comorbidities (P &lt; .0001, OR = 5.66), hospital admissions (P &lt; .0001, OR = 4.83), and intubations (P &lt; .03, OR = 2.07). Overall, patients required intubation infrequently (&lt;1%) and mortality was low (0.08%). CONCLUSIONS: The AE burden on EDs has increased over time. Patients with adverse reactions to antihypertensives are older, have more comorbidities, and require admission and intubation more frequently. Further investigation is needed to better delineate causation and outcome predictors, and to understand regional practice variance. LEVEL OF EVIDENCE: 2c. Laryngoscope, 2016</style></abstract><notes><style face="normal" font="default">DA - 20161118IS - 1531-4995 (Electronic)IS - 0023-852X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1002/lary.26336</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27861934">PM:27861934</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Laryngoscope\20161118-SmithA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Laryngoscope\20161118-SmithA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161118, Smith A</style></custom2><misc3><style face="normal" font="default">10.1002/lary.26336</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40753</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lin,C.H.</style></author><author><style face="normal" font="default"> Chao,Y.H.</style></author><author><style face="normal" font="default"> Wu,K.H.</style></author><author><style face="normal" font="default"> Lin,W.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">aDivision of Pediatric Pulmonology, China Medical University Children's HospitalbDepartment of Biomedical Imaging and Radiological Science, College of Health Care, China Medical UniversitycDepartment of Pediatrics, Chung Shan Medical University HospitaldSchool of Medicine, Chung Shan Medical UniversityeSchool of Post-Baccalaureate Chinese Medicine, College of Chinese Medicine, China Medical UniversityfDivision of Pediatric Hematology-Oncology, China Medical University Children's HospitalgDepartment of Radiology, China Medical University HospitalhSchool of Medicine, China Medical University, Taichung, Taiwan</style></auth-address><titles><title><style face="normal" font="default">Primary mucoepidermoid carcinoma at the carina of trachea presenting with wheezing in an asthmatic child mimicking an attack of asthma: A case report</style></title><secondary-title><style face="normal" font="default">Medicine (Baltimore)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Medicine (Baltimore)</style></abbr-1></periodical><pages end="" start="e5292">e5292-</pages><volume><style face="normal" font="default">95</style></volume><number><style face="normal" font="default">44</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> imaging</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Radiology</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Taiwan</style></keyword><keyword><style face="normal" font="default"> Trachea</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is a very common disease, but primary tracheal tumors are extremely rare in children. Wheezing is not pathognomonic, but is the typical presentation of asthma and could also be found in patients with tracheal tumors. CLINICAL FINDINGS: This report describes a 12-year-old boy with a previous history of frequent asthma attacks and experienced responses to antiasthma treatment. He was admitted to the hospital due to persistent wheezing and progressive dyspnea. Hyperinflation in the bilateral lungs was detected on chest x-ray, but without other significant findings. Chest computed tomography revealed a mass at the carina. Tracheal mucoepidermoid carcinoma was diagnosed by histopathological assessment. CONCLUSION: Despite the rarity of tracheal tumors, chest computed tomography scans should be performed in the first place for children presenting persistent wheezing and having poor response to antiasthma treatment to rule out the other alternative diagnosis. Coexistence of other diseases such as tracheal tumor in asthmatic patients should be considered</style></abstract><notes><style face="normal" font="default">DA - 20161118IS - 1536-5964 (Electronic)IS - 0025-7974 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1097/MD.0000000000005292</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27858901">PM:27858901</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Medicine (Baltimore)\2016-95-e5292.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Medicine (Baltimore)\2016-95-e5292.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161118, Lin CH</style></custom2><misc3><style face="normal" font="default">10.1097/MD.0000000000005292</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40754</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Choi,Y.Y.</style></author><author><style face="normal" font="default"> Kim,M.H.</style></author><author><style face="normal" font="default"> Ahn,K.S.</style></author><author><style face="normal" font="default"> Um,J.Y.</style></author><author><style face="normal" font="default"> Lee,S.G.</style></author><author><style face="normal" font="default"> Yang,W.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Convergence Korean Medical Science, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Immunomodulatory effects of Pseudostellaria heterophylla (Miquel) Pax on regulation of Th1/Th2 levels in mice with atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Mol Med Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Mol Med Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermis</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> DNCB</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidermis</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> pH</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Protein Kinases</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="29" Month="12" Year="2016">2016/12/29</year></dates><abstract><style face="normal" font="default">Pseudostellaria heterophylla (PH) has various pharmacological effects that include immunologic enhancement and antioxidation. However, it remains unclear whether PH exerts beneficial effects in dermatological diseases. The present study examined the effects of PH on a 2,4-dinitrochlorobenzene (DNCB)induced atopic dermatitis (AD) mouse model and elucidated its underlying mechanism of action. PH extract (1 and 100 mg/ml) was applied topically to DNCB-treated dorsal skin of mice every day for 11 days. The immunomodulatory effects of PH were evaluated by measuring skin thickness, mast cell infiltration, serum levels of immunoglobulin E (IgE), and mRNA expression levels of T helper (h)1/Th2 and proinflammatory cytokines in dorsal skin. In addition, cluster of differentiation (CD)4+ T cells were detected in dorsal skin by immunohistochemistry. Topical application of PH significantly reduced the thickness of dermis, epidermis and serum IgE production compared with the DNCB group. PH treatment inhibited infiltration of inflammatory cells, including mast cells and CD4+ T cells, and suppressed the mRNA expression levels of cytokines (interferongamma, interleukin4, 6, 8 and 1beta, and tumor necrosis factoralpha) associated with the immune response. Furthermore, PH treatment significantly downregulated the protein expression levels of nuclear factorkappaB, phosphorylated inhibitor of kappaBalpha and mitogenactivated protein kinases. The results suggested that PH may be a potential therapeutic strategy for the treatment of AD via the modulation of Th1 and Th2 levels</style></abstract><notes><style face="normal" font="default">DA - 20161230IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.3892/mmr.2016.6093</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28035398">PM:28035398</url></web-urls><related-urls><url ppv-ref="no">presto - 1 anno</url></related-urls></urls><custom2><style face="normal" font="default">20161230, Choi YY</style></custom2><misc3><style face="normal" font="default">10.3892/mmr.2016.6093</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40755</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ramsden,C.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Lipid Mediators, Inflammation, and Pain Unit, Laboratory of Clinical Investigation, National Institute on Aging, in Baltimore, and the National Institute on Alcohol Abuse and Alcoholism, in Bethesda, MD</style></auth-address><titles><title><style face="normal" font="default">Breathing Easier with Fish Oil - A New Approach to Preventing Asthma?</style></title><secondary-title><style face="normal" font="default">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">N Engl J Med</style></full-title></periodical><pages end="2598" start="2596">2596-2598</pages><volume><style face="normal" font="default">375</style></volume><number><style face="normal" font="default">26</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aging</style></keyword><keyword><style face="normal" font="default"> Alcohol</style></keyword><keyword><style face="normal" font="default"> Alcoholism</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Baltimore</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> fish</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lipid</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="29" Month="12" Year="2016">2016/12/29</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161228IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - EditorialPT - CommentCO - United States -</style></notes><work-type><style face="normal" font="default">10.1056/NEJMe1611723</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28029914">PM:28029914</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\N Engl J Med\2016-375-2596-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\N Engl J Med\2016-375-2596-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161228, Ramsden CE</style></custom2><misc3><style face="normal" font="default">10.1056/NEJMe1611723</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40756</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yip,K.H.</style></author><author><style face="normal" font="default"> Kolesnikoff,N.</style></author><author><style face="normal" font="default"> Hauschild,N.</style></author><author><style face="normal" font="default"> Biggs,L.</style></author><author><style face="normal" font="default"> Lopez,A.F.</style></author><author><style face="normal" font="default"> Galli,S.J.</style></author><author><style face="normal" font="default"> Kumar,S.</style></author><author><style face="normal" font="default"> Grimbaldeston,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, South Australia 5000, Australia</style></auth-address><titles><title><style face="normal" font="default">The Nedd4-2/Ndfip1 axis is a negative regulator of IgE-mediated mast cell activation</style></title><secondary-title><style face="normal" font="default">Nat Commun</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nat Commun</style></abbr-1></periodical><pages end="" start="13198">13198-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-dependent</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Ligation</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Signal Transduction</style></keyword><keyword><style face="normal" font="default"> Syk</style></keyword><keyword><style face="normal" font="default"> Tyrosine</style></keyword><keyword><style face="normal" font="default"> tyrosine kinase</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="27" Month="10" Year="2016">2016/10/27</year></dates><abstract><style face="normal" font="default">Cross-linkage of the high-affinity immunoglobulin E (IgE) receptor (FcvarepsilonRI) on mast cells by antigen ligation has a critical role in the pathology of IgE-dependent allergic disorders, such as anaphylaxis and asthma. Restraint of intracellular signal transduction pathways that promote release of mast cell-derived pro-inflammatory mediators is necessary to dampen activation and restore homoeostasis. Here we show that the ligase Nedd4-2 and the adaptor Ndfip1 (Nedd4 family interacting protein 1) limit the intensity and duration of IgE-FcvarepsilonRI-induced positive signal transduction by ubiquitinating phosphorylated Syk, a tyrosine kinase that is indispensable for downstream FcvarepsilonRI signalosome activity. Importantly, loss of Nedd4-2 or Ndfip1 in mast cells results in exacerbated and prolonged IgE-mediated cutaneous anaphylaxis in vivo. Our findings reveal an important negative regulatory function for Nedd4-2 and Ndfip1 in IgE-dependent mast cell activity</style></abstract><notes><style face="normal" font="default">DA - 20161027IS - 2041-1723 (Electronic)IS - 2041-1723 (Linking)LA - ENGPT - Journal ArticleCO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1038/ncomms13198</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27786273">PM:27786273</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nat Commun\2016-7-13198.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nat Commun\2016-7-13198.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161027, Yip KH</style></custom2><misc3><style face="normal" font="default">10.1038/ncomms13198</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40757</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Le,D.D.</style></author><author><style face="normal" font="default"> Schmit,D.</style></author><author><style face="normal" font="default"> Heck,S.</style></author><author><style face="normal" font="default"> Omlor,A.J.</style></author><author><style face="normal" font="default"> Sester,M.</style></author><author><style face="normal" font="default"> Herr,C.</style></author><author><style face="normal" font="default"> Schick,B.</style></author><author><style face="normal" font="default"> Daubeuf,F.</style></author><author><style face="normal" font="default"> Fahndrich,S.</style></author><author><style face="normal" font="default"> Bals,R.</style></author><author><style face="normal" font="default"> Frossard,N.</style></author><author><style face="normal" font="default"> Al Kadah,B.</style></author><author><style face="normal" font="default"> Dinh,Q.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Experimental Pneumology and Allergology, Saarland University Hospital, Homburg, Germany</style></auth-address><titles><title><style face="normal" font="default">Increase of Mast Cell-Nerve Association and Neuropeptide Receptor Expression on Mast Cells in Perennial Allergic Rhinitis</style></title><secondary-title><style face="normal" font="default">Neuroimmunomodulation</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Neuroimmunomodulation</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Calcitonin</style></keyword><keyword><style face="normal" font="default"> Calcitonin Gene-Related Peptide</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="default"> Neurokinin 1 receptor</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> peptide</style></keyword><keyword><style face="normal" font="default"> perennial</style></keyword><keyword><style face="normal" font="default"> perennial allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tyrosine</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="29" Month="12" Year="2016">2016/12/29</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Mast cells (MCs) and nerves play an important role in allergic rhinitis (AR), but little is known about their crosstalk in AR. The aim of this study was to investigate MC-nerve interaction in the human nasal mucosa during AR. METHODS: The association between MCs and nerves, the expression of neuropeptide receptors (neurokinin 1 receptor [NK1R], neurokinin 2 receptor [NK2R], calcitonin gene-related peptide receptor [CGRPR], and MrgX2) on MCs, and protease-activated receptor 2 (PAR2) and tyrosine receptor kinase A (TrkA) on nerve fibres in the human nasal mucosa were investigated with immunofluorescence and real-time PCR. RESULTS: The association between MCs and nerves was found to be significantly increased, although the numbers of MCs and nerve fibres were unchanged during AR. MCs expressing tryptase-chymase (MCtc) were frequently associated with nerve fibres and these contacts increased significantly in AR. Neuropeptide receptors NK1R, NK2R, and CGRPR were firstly found to be largely localised on MCs. The number of MCs expressing NK1R and NK2R, but not CGRPR, was significantly increased in AR. Interestingly, MCtc mostly expressed these neuropeptide receptors. The newly discovered tachykinin receptor MrgX2 was not expressed on nasal MCs, but was expressed on gland cells and increased in AR. Additionally, tachykinergic nerve fibres were found to express PAR2 or TrkA as receptors for MCs. CONCLUSIONS: This study revealed for the first time an increase of MC-nerve association and neuropeptide receptor expression on MCs during AR as well as nerve fibres containing receptors for MCs. These results suggest that targeting or controlling airway sensory nerve function as a modulator of MCs may prevent allergic airway inflammation such as AR</style></abstract><notes><style face="normal" font="default">DA - 20161228IS - 1423-0216 (Electronic)IS - 1021-7401 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1159/000453068</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28030866">PM:28030866</url></web-urls></urls><custom2><style face="normal" font="default">20161228, Le DD</style></custom2><misc3><style face="normal" font="default">10.1159/000453068</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40758</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tanaka,K.</style></author><author><style face="normal" font="default"> Miyake,Y.</style></author><author><style face="normal" font="default"> Furukawa,S.</style></author><author><style face="normal" font="default"> Arakawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Epidemiology and Preventive Medicine, Ehime University Graduate School of Medicine, Ehime, Japan</style></auth-address><titles><title><style face="normal" font="default">Pre- and postnatal smoking exposure and risk of atopic eczema in young Japanese children: a prospective pre-birth cohort study</style></title><secondary-title><style face="normal" font="default">Nicotine Tob Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Nicotine Tob Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic eczema</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidemiological studies</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Perinatal</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Preventive Medicine</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> smokers</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Tobacco</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="28" Month="10" Year="2016">2016/10/28</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Epidemiological evidence regarding the effect of perinatal smoking exposure on atopic eczema in children continues to be inconclusive. The aim of this prospective prebirth cohort study was to investigate the association between prenatal smoking exposure and postnatal living with household smokers and the risk of atopic eczema in Japanese children aged 23 to 29 months. METHODS: Study subjects were 1354 Japanese mother-child pairs. Information on the variables under study was obtained through questionnaires which were completed by mothers, first prior to delivery, then shortly after birth and subsequently around 4, 12, and 24 months after delivery. Eczema in the last 12 months was defined according to the criteria of the International Study of Asthma and Allergies in Childhood (ISAAC). Physician-diagnosed atopic eczema was considered present if reported by mothers. RESULTS: Compared with no perinatal smoking exposure, prenatal smoking exposure only was associated with an increased risk of physician-diagnosed atopic eczema (adjusted odds ratio = 7.11, 95% confidence interval: 1.43 to 27.8). Postnatal living with at least one household smoker only was not associated with the risk of physician-diagnosed atopic eczema; neither was the combination of both prenatal smoking exposure and postnatal living with at least one household smoker. No association was observed between perinatal smoking exposure status and the risk of eczema as defined according to the ISAAC criteria. CONCLUSIONS: Our findings suggest that maternal smoking during pregnancy may increase the risk of atopic eczema in young children. IMPLICATION: In the present prebirth cohort study, we assessed the independent and additive effects of pre- and postnatal exposure to tobacco smoking on atopic eczema in children. Compared with no perinatal smoking exposure, prenatal smoking exposure only was significantly associated with an increased risk of atopic eczema. Postnatal smoking exposure only was not associated with the risk of atopic eczema; neither was the combination of both pre- and postnatal smoking exposure. This is the first epidemiological study to show a positive association between prenatal smoking exposure only and the risk of atopic eczema</style></abstract><notes><style face="normal" font="default">DA - 20161029IS - 1469-994X (Electronic)IS - 1462-2203 (Linking)LA - ENGPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1093/ntr/ntw299</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27794037">PM:27794037</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nicotine Tob Res\20161029-TanakaK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nicotine Tob Res\20161029-TanakaK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161029, Tanaka K</style></custom2><misc3><style face="normal" font="default">10.1093/ntr/ntw299</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40759</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Alcantara-Nicolas,F.A.</style></author><author><style face="normal" font="default"> Pastor-Nieto,M.A.</style></author><author><style face="normal" font="default"> Sanchez-Herreros,C.</style></author><author><style face="normal" font="default"> Perez-Mesonero,R.</style></author><author><style face="normal" font="default"> Melgar-Molero,V.</style></author><author><style face="normal" font="default"> Ballano,A.</style></author><author><style face="normal" font="default"> De-Eusebio,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Department, University Hospital of Guadalajara, Guadalajara 19002, Spain</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis from acrylic nails in a flamenco guitarist</style></title><secondary-title><style face="normal" font="default">Occup Med (Lond)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Occup Med (Lond)</style></full-title></periodical><pages end="753" start="751">751-753</pages><volume><style face="normal" font="default">66</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acrylate</style></keyword><keyword><style face="normal" font="default"> Acrylates</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Artificial nail</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fingers</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Methacrylate</style></keyword><keyword><style face="normal" font="default"> Nails</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Medicine</style></keyword><keyword><style face="normal" font="default"> Paronychia</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="7" Month="11" Year="2016">2016/11/7</year></dates><abstract><style face="normal" font="default">Acrylates are molecules that are well known for their strong sensitizing properties. Historically, many beauticians and individuals using store-bought artificial nail products have developed allergic contact dermatitis from acrylates. More recently, the use of acrylic nails among flamenco guitarists to strengthen their nails has become very popular. A 40-year-old non-atopic male patient working as a flamenco guitarist developed dystrophy, onycholysis and paronychia involving the first four nails of his right hand. The lesions were confined to the fingers where acrylic materials were used in order to strengthen his nails to play the guitar. He noticed improvement whenever he stopped using these materials and intense itching and worsening when he began reusing them. Patch tests were performed and positive results obtained with 2-hydroxyethyl methacrylate (2-HEMA), 2-hydroxyethyl acrylate (2-HEA), ethyleneglycol-dimethacrylate (EGDMA) and 2-hydroxypropyl methacrylate (2-HPMA). The patient was diagnosed with occupational allergic contact dermatitis likely caused by acrylic nails. Artificial nails can contain many kinds of acrylic monomers but most cases of contact dermatitis are induced by 2-HEMA, 2-HPMA and EGDMA. This is the first reported case of occupational allergic contact dermatitis from acrylates in artificial nails in a professional flamenco guitar player. Since the practice of self-applying acrylic nail products is becoming very popular within flamenco musicians, we believe that dermatology and occupational medicine specialists should be made aware of the potentially increasing risk of sensitization from acrylates in this setting</style></abstract><notes><style face="normal" font="default">DA - 20161111IS - 1471-8405 (Electronic)IS - 0962-7480 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1093/occmed/kqw158</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27834227">PM:27834227</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Occup Med (Lond)\2016-66-751-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Occup Med (Lond)\2016-66-751-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161111, Alcantara-Nicolas FA</style></custom2><misc3><style face="normal" font="default">10.1093/occmed/kqw158</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40760</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McDaniel,L.M.</style></author><author><style face="normal" font="default"> Couch,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">*Mason Eye Institute, Department of Ophthalmology, University of Missouri; and daggerDepartment of Ophthalmology and Visual Sciences, Washington University, School of Medicine, St. Louis, Missouri, U.S.A</style></auth-address><titles><title><style face="normal" font="default">Allergic Eyelid Dermatitis as the Sole Manifestation of Gold Hypersensitivity</style></title><secondary-title><style face="normal" font="default">Ophthal Plast Reconstr Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ophthal Plast Reconstr Surg</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Eyelid</style></keyword><keyword><style face="normal" font="default"> Eyelids</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Gold</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Jewelry</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Missouri</style></keyword><keyword><style face="normal" font="default"> Ophthalmology</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Washington</style></keyword></keywords><dates><year Day="11" Month="10" Year="2016">2016/10/11</year></dates><abstract><style face="normal" font="default">Gold hypersensitivity is a cause of periorbital dermatitis that often presents as a diagnostic challenge for many ophthalmologists. Six female patients are described as presenting with isolated bilateral periorbital dermatitis. Main symptoms included itching (3/6), eyelid redness (3/6), and drooping eyelids (3/6) for an average duration of 16.8 months prior to referral. All 6 patients failed conservative management. Recurrence of symptoms necessitated allergic patch testing, revealing a severe hypersensitivity reaction to gold in all cases. By discontinuing contact with gold, specifically gold jewelry, the allergic periorbital dermatitis completely resolved. No patients required surgical intervention for eyelid malposition. Increased awareness of this reversible cause of allergic periorbital dermatitis may improve patient outcomes</style></abstract><notes><style face="normal" font="default">DA - 20161028IS - 1537-2677 (Electronic)IS - 0740-9303 (Linking)LA - ENGPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.1097/IOP.0000000000000783</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27792680">PM:27792680</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ophthal Plast Reconstr Surg\20161028-McDanielLM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ophthal Plast Reconstr Surg\20161028-McDanielLM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161028, McDaniel LM</style></custom2><misc3><style face="normal" font="default">10.1097/IOP.0000000000000783</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40761</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Walgama,E.S.</style></author><author><style face="normal" font="default"> Hwang,P.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology/Head and Neck Surgery, Stanford School of Medicine, Stanford Sinus Center, 801 Welch Road, Palo Alto, CA 94304, USA</style></auth-address><titles><title><style face="normal" font="default">Aspirin-Exacerbated Respiratory Disease</style></title><secondary-title><style face="normal" font="default">Otolaryngol Clin North Am</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Otolaryngol Clin North Am</style></abbr-1></periodical><pages end="94" start="83">83-94</pages><volume><style face="normal" font="default">50</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">5-Lipoxygenase</style></keyword><keyword><style face="normal" font="default"> AERD</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin intolerance</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> cysteinyl leukotriene</style></keyword><keyword><style face="normal" font="default"> cysteinyl leukotrienes</style></keyword><keyword><style face="normal" font="default"> cysteinyl-leukotrienes</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Ingestion</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Leukotrienes</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polyposis</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sinus</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">Aspirin-exacerbated respiratory disease (AERD) is characterized by the triad of asthma, sinonasal polyposis, and aspirin intolerance. The hallmark of the disease is baseline overproduction of cysteinyl leukotrienes via the 5-lipoxygenase pathway, exacerbated by ingestion of aspirin. Patients with AERD have high rates of recidivistic polyposis following sinus surgery, although the improvement in quality of life following surgery is similar to aspirin-tolerant patients. The diagnosis is secured by a positive aspirin provocation test, usually administered by a medical allergist. Aspirin therapy is a unique treatment consideration for patients with AERD</style></abstract><notes><style face="normal" font="default">DA - 20161127IS - 1557-8259 (Electronic)IS - 0030-6665 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.otc.2016.08.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27888917">PM:27888917</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Otolaryngol Clin North Am\2017-50-83-94.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Otolaryngol Clin North Am\2017-50-83-94.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161127, Walgama ES</style></custom2><misc3><style face="normal" font="default">10.1016/j.otc.2016.08.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40762</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Johnston,E.B.</style></author><author><style face="normal" font="default"> King,C.</style></author><author><style face="normal" font="default"> Sloane,P.A.</style></author><author><style face="normal" font="default"> Cox,J.W.</style></author><author><style face="normal" font="default"> Youngblood,A.Q.</style></author><author><style face="normal" font="default"> Lynn,Z.J.</style></author><author><style face="normal" font="default"> Tofil,N.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesia, Baptist Health Paducah, Paducah, KY, USA</style></auth-address><titles><title><style face="normal" font="default">Pediatric anaphylaxis in the operating room for anesthesia residents: a simulation study</style></title><secondary-title><style face="normal" font="default">Paediatr Anaesth</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Paediatr Anaesth</style></abbr-1></periodical><pages end="210" start="205">205-210</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenoidectomy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Anesthesia</style></keyword><keyword><style face="normal" font="default"> Bradycardia</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Curriculum</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Intraoperative anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Learning</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pneumothorax</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tonsillectomy</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Pediatric intraoperative emergencies are rare but it is crucial for an anesthesia resident to be proficient in their management. Even the more common emergencies like anaphylaxis may not happen frequently for this proficiency to occur. Simulation increases exposure to these rare events in a safe learning environment to improve skills and build confidence while standardizing curriculum. OBJECTIVE: Anesthesia residents participated in a simulated case of intraoperative pediatric anaphylaxis to evaluate knowledge and performance gaps. The study also sought to determine whether a difference exists between second- (CA2) and third-year (CA3) anesthesia residents when managing pediatric anaphylaxis and cardiopulmonary arrest. METHODS: Anesthesia residents completed a standardized programmed simulation of intraoperative anaphylaxis in a 5-year old undergoing tonsillectomy and adenoidectomy. Anaphylaxis presented and progressed to bradycardia and pulseless electrical activity if anaphylaxis went unnoticed or untreated. Key time points were recorded. A scripted debriefing and written evaluation followed. RESULTS: Average time to diagnose anaphylaxis was 7.6 min, and time to give epinephrine was 6.5 min. Thirty-five percent of residents started epinephrine infusion following initial bolus. Average time calling for help between CA3 and CA2 residents was 2.5 min vs 5 min (P = 0.01). CA3 residents verbalized a broader differential, including malignant hyperthermia and pneumothorax. Progression to pulseless electrical activity occurred in 65% of sessions prior to epinephrine being administered. No resident initiated chest compressions for bradycardia. CONCLUSIONS: Important performance deficits were seen in senior anesthesia residents during a simulated case of pediatric intraoperative anaphylaxis. Although CA3 performed better, deficits still existed. Anesthesia residents and training programs should partner in developing additional training recognizing anaphylaxis, pulseless electrical activity, and indication for chest compressions in a child</style></abstract><notes><style face="normal" font="default">DA - 20161213IS - 1460-9592 (Electronic)IS - 1155-5645 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pan.13052</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27957774">PM:27957774</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Paediatr Anaesth\2017-27-205-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Paediatr Anaesth\2017-27-205-10.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161213, Johnston EB</style></custom2><misc3><style face="normal" font="default">10.1111/pan.13052</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40763</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Esposito,S.</style></author><author><style face="normal" font="default"> Fior,G.</style></author><author><style face="normal" font="default"> Mori,A.</style></author><author><style face="normal" font="default"> Osnaghi,S.</style></author><author><style face="normal" font="default"> Ghiglioni,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Universita degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Commenda 9, 20122, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="default">An Update on the Therapeutic Approach to Vernal Keratoconjunctivitis</style></title><secondary-title><style face="normal" font="default">Paediatr Drugs</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Paediatr Drugs</style></abbr-1></periodical><pages end="355" start="347">347-355</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration &amp; dosage</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Conjunctivitis,Allergic</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Cyclosporine</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> diagnostic criteria</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drug therapy</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> intensive care unit</style></keyword><keyword><style face="normal" font="default"> Irritation</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Keratoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Ocular</style></keyword><keyword><style face="normal" font="default"> Ophthalmic Solutions</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatricians</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Solutions</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Tacrolimus</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Vernal keratoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> VKC</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">Vernal keratoconjunctivitis (VKC) is an inflammatory disease of the ocular surface. It commonly occurs in the first decade of life, has a wide geographical distribution, and usually occurs in warm, dry areas. The pathogenesis of VKC seems to have an immune, nervous, and endocrine basis. The most common eye symptoms are itching, discharge, tearing, eye irritation, redness of the eyes, and photophobia. Although VKC generally has a good prognosis, the lack of clarity regarding the origin of the disease makes treatment a challenge for pediatricians and ophthalmologists. The purpose of this review is to discuss the pathogenesis, clinical features, and diagnostic criteria in VKC, with a focus on its therapeutic management. The selection of a therapeutic scheme from the many available options is based on clinical features and the personal preferences of both physicians and patients. Due to the lack of uniform grading of disease severity, there is no worldwide consensus on first-line and second-line therapeutic approaches. The choice of treatment for long-term moderate to severe VKC includes topical cyclosporine or tacrolimus. Further data are needed to define the minimal effective concentration and the safety of these drugs in eye drops and to clarify the diagnosis of VKC in patients who require these drugs. Finally, while promising newly discovered drugs are expected to enter into clinical practice, further studies on their efficacy and safety are required</style></abstract><notes><style face="normal" font="default">DA - 20160912IS - 1179-2019 (Electronic)IS - 1174-5878 (Linking)LA - engPT - Journal ArticlePT - ReviewRN - 0 (Ophthalmic Solutions)RN - 83HN0GTJ6D (Cyclosporine)SB - IMCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1007/s40272-016-0185-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27461427">PM:27461427</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Paediatr Drugs\2016-18-347-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Paediatr Drugs\2016-18-347-55.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160912, Esposito S</style></custom2><misc3><style face="normal" font="default">10.1007/s40272-016-0185-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40764</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lavin,T.</style></author><author><style face="normal" font="default"> Franklin,P.</style></author><author><style face="normal" font="default"> Preen,D.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Health Services Research, School of Population Health, The University of Western Australia, Perth, WA, AustraliaSchool of Population Health, The University of Western Australia, Perth, WA, AustraliaCentre for Health Services Research, School of Population Health, The University of Western Australia, Perth, WA, Australia</style></auth-address><titles><title><style face="normal" font="default">Association between Caesarean Delivery and Childhood Asthma in India and Vietnam</style></title><secondary-title><style face="normal" font="default">Paediatr Perinat Epidemiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Paediatr Perinat Epidemiol</style></abbr-1></periodical><pages end="54" start="47">47-54</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Cooking</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Services</style></keyword><keyword><style face="normal" font="default"> Housing</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parity</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> sociodemographic factors</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vietnam</style></keyword><keyword><style face="normal" font="default"> Western Australia</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: While there is evidence of an association between caesarean birth and increased asthma in children in high-income countries, it is unknown whether this association exists in low-to-middle-income countries (LMICs). We investigated whether children born through caesarean in India and Vietnam are at increased risk of caregiver-reported asthma by 8 years of age. METHODS: Data from an ongoing multi-national longitudinal cohort study (the Young Lives Study) in two LMICs (India n = 2026; Vietnam n = 2000) were used. Caregiver questionnaires captured information on caregiver-reported long-term respiratory problems such as asthma or wheeze at age 8 years, birth mode and a range of sociodemographic factors. Multivariable logistic regression models using propensity score adjustment were used to explore birth mode and asthma at age 8 years adjusted for a range of known confounders. RESULTS: Children delivered by caesarean in India (odds ratio (OR) 2.6, 95% confidence interval (CI) 1.3, 5.4) and Vietnam (OR 2.0, 95% CI 1.2, 3.3) had greater odds of asthma at age 8 years, after adjustment for other risk factors including wealth, liveborn parity, low birthweight, geographic location, cooking fuel used, livestock ownership, household size, housing quality and parental smoking. CONCLUSIONS: The study suggests that caesarean birth may be associated with an increased risk of childhood asthma in India and Vietnam. The underlying mechanisms of this finding need to be further elucidated</style></abstract><notes><style face="normal" font="default">DA - 20161228IS - 1365-3016 (Electronic)IS - 0269-5022 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/ppe.12324</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28029700">PM:28029700</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Paediatr Perinat Epidemiol\2017-31-47-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Paediatr Perinat Epidemiol\2017-31-47-54.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161228, Lavin T</style></custom2><misc3><style face="normal" font="default">10.1111/ppe.12324</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40765</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Castro-Rodriguez,J.A.</style></author><author><style face="normal" font="default"> Brockmann,P.E.</style></author><author><style face="normal" font="default"> Marcus,C.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric Cardiology and Respiratory, Division of Pediatrics, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile.</style></auth-address><titles><title><style face="normal" font="default">Relation between asthma and sleep disordered breathing in children: is the association causal?</style></title><secondary-title><style face="normal" font="default">Paediatr Respir Rev</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Paediatr Respir Rev</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Causality</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Chile</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="21" Month="8" Year="2016">2016/8/21</year></dates><abstract><style face="normal" font="default">Over the last few decades, asthma and sleep disordered breathing (SDB) in children have experienced similar increases in prevalence, and have both been shown to have airway inflammation, leading investigators to postulate an association between asthma and SDB. However, whether this relationship is causal or not needs to be proven. In this manuscript, we use the most widely accepted epidemiologic criteria for causality, the Bradford Hill criteria, to test step-by-step whether the relation between asthma and SBD in children is causal or not. We found studies supporting 8 of the 9 criteria (strength, consistency, specificity, biological gradient, coherence and biological plausibility, experiment, and analogy) for association between asthma and SDB. However, we did not find any study showing temporality or directionality between asthma and SDB. Therefore, establishing a causal association between asthma and SDB is not yet possible</style></abstract><notes><style face="normal" font="default">DA - 20161107IS - 1526-0550 (Electronic)IS - 1526-0542 (Linking)LA - ENGPT - ReviewPT - Journal ArticleCO - Chile -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.prrv.2016.08.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27818068">PM:27818068</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Paediatr Respir Rev\20161107-CastroRodriguezJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Paediatr Respir Rev\20161107-CastroRodriguezJA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161107, Castro-Rodriguez JA</style></custom2><misc3><style face="normal" font="default">10.1016/j.prrv.2016.08.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40766</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ten Hagen,A.</style></author><author><style face="normal" font="default"> Doldersum,P.</style></author><author><style face="normal" font="default"> van Raaij,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesiology, Martini Hospital Groningen, Van Swietenplein 1, 9728 NT Groningen, The NetherlandsDepartment of Anesthesiology, Martini Hospital Groningen, Van Swietenplein 1, 9728 NT Groningen, The NetherlandsDepartment of Orthopaedic Surgery, Martini Hospital Groningen, van Swietenplein 1, 9728 NT Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Anaphylactic shock during cement implantation of a total hip arthroplasty in a patient with underlying mastocytosis: case report of a rare intraoperative complication</style></title><secondary-title><style face="normal" font="default">Patient Saf Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Patient Saf Surg</style></abbr-1></periodical><pages end="" start="25">25-</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">abnormalities</style></keyword><keyword><style face="normal" font="default"> activation</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Anesthesiology</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Arthroplasty</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Decision Making</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Differential diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drug therapy</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electrocardiography</style></keyword><keyword><style face="normal" font="default"> Hip</style></keyword><keyword><style face="normal" font="default"> Hip Joint</style></keyword><keyword><style face="normal" font="default"> Hypotension</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> intensive care unit</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mastocytosis</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Muscle relaxants</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Oxygen</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Physical Examination</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Embolism</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Recovery</style></keyword><keyword><style face="normal" font="default"> rehabilitation</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Ultrasound</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">BACKGROUND: Cemented total hip arthroplasty (THA) is a safe and common procedure. In rare cases life threatening bone cement implantation syndrome (BCIS) may occur, which is commonly caused by pulmonary embolism (PE). CASE PRESENTATION: We describe the rare case of a 70-year old patient who underwent an elective total hip replacement. Before surgery he was diagnosed with underlying systemic indolent mastocytosis, a rare pathological disorder that may result in anaphylaxis after massive systemic mast cell activation. Triggers may be IgE-mediated, direct mast cell activation, or unclear. Some patients may be at risk for severe non IgE-mediated reactions, such as those experienced with nonsteroidal anti-inflammatory drugs, or with perioperative muscle relaxants. During cementing of the acetabular component, our patient developed acute hypotension (blood pressure dropped from 90/50 to 60/40 mmHg, and saturation dropped from 95 to 80 %). The differential diagnosis of acute PE was excluded (no signs of breathing abnormalities during physical examination, normal arterial blood sample, and no electrocardiography or cardiac ultrasound abnormalities). The patient was diagnosed with acute anaphylactic shock, which was successfully managed by 100 % oxygen administration, rapid fluid induction, and vasoconstrictive drug therapy. He recovered hemodynamically within 15 min, did not lose consciousness, and did not develop angioedema or an urticarial rash. Forty-five minutes after onset of the symptoms, the surgical procedure was completed after inserting a press fitted uncemented femoral stem component. The patient was transported to the Intensive Care Unit (ICU) for optimal monitoring. Our patient had an uneventful recovery. Within six hours after surgery he started to ambulate following our standard fast-track rehabilitation regime. Post-operative day one he was discharged to the specialized Orthopedic Department, and after five hospital days discharged to his home. Twelve months after THA surgery our patient was satisfied with an optimal functional status of his hip joint replacement. CONCLUSION: The differential diagnosis of anaphylactic shock must be taken into consideration in patients with acute hypotension during cementing of total hip arthroplasty components. Patients with underlying mastocytosis are at particular risk of this potential life-threatening intra-operative complication. This rare entity should be taken into consideration during the pre-operative risk stratification and shared decision-making process for elective cemented joint replacement</style></abstract><notes><style face="normal" font="default">DA - 20161108IS - 1754-9493 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1186/s13037-016-0113-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27822310">PM:27822310</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Patient Saf Surg\2016-10-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Patient Saf Surg\2016-10-25.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161108, Ten Hagen A</style></custom2><misc3><style face="normal" font="default">10.1186/s13037-016-0113-x</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40767</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Isik,S.</style></author><author><style face="normal" font="default"> Caglayan-Sozmen,S.</style></author><author><style face="normal" font="default"> Anal,O.</style></author><author><style face="normal" font="default"> Karaman,O.</style></author><author><style face="normal" font="default"> Uzuner,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Department of Pediatric Allergy and daggerDepartment of Pediatric Allergy and Immunology, Dokuz Eylul University Hospital, Izmir, Turkey</style></auth-address><titles><title><style face="normal" font="default">Severe Neck and Face Edema in an Adolescent-Delayed Hypersensitivity Reaction to Hair Dye</style></title><secondary-title><style face="normal" font="default">Pediatr Emerg Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Emerg Care</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> Hair</style></keyword><keyword><style face="normal" font="default"> Hair Dyes</style></keyword><keyword><style face="normal" font="default"> Henna</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Para-phenylenediamine</style></keyword><keyword><style face="normal" font="default"> Paraphenylenediamine</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Type IV hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="10" Year="2016">2016/10/4</year></dates><abstract><style face="normal" font="default">Allergic contact reactions to hair dyes arise mostly due to sensitization to para-phenylenediamine (PPD). Para-phenylenediamine, a derivative of p-nitroanaline, is widely used as an oxydizable hair dye and is also found in black henna tattoo. Subsequent exposure to PPD may lead to delayed type IV hypersensitivity reaction manifesting as acute contact dermatitis. Here, a 15-year-old girl is presented, who developed a hypersensitivity reaction after first exposure to hair dye. She was found to have been sensitized to PPD before, through application of black henna tatto</style></abstract><notes><style face="normal" font="default">DA - 20161017IS - 1535-1815 (Electronic)IS - 0749-5161 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1097/PEC.0000000000000898</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27749802">PM:27749802</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Emerg Care\20161017-IsikS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Emerg Care\20161017-IsikS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161017, Isik S</style></custom2><misc3><style face="normal" font="default">10.1097/PEC.0000000000000898</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40768</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Su,Z.</style></author><author><style face="normal" font="default"> Li,R.</style></author><author><style face="normal" font="default"> Gai,Z.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Pediatric Research Institute, Qilu Children's Hospital of Shandong University; daggerDepartment of Pediatric, Shandong Police Hospital; and double daggerDepartment of Radiation Oncology, Shandong Cancer Hospital, Ji'nan, China</style></auth-address><titles><title><style face="normal" font="default">Intravenous and Nebulized Magnesium Sulfate for Treating Acute Asthma in Children: A Systematic Review and Meta-Analysis</style></title><secondary-title><style face="normal" font="default">Pediatr Emerg Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Emerg Care</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">acute asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Magnesium</style></keyword><keyword><style face="normal" font="default"> Magnesium Sulfate</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> nebulized</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Police</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="10" Year="2016">2016/10/4</year></dates><abstract><style face="normal" font="default">OBJECTIVE: This study aimed to evaluate the efficacy of intravenous (IV) and nebulized magnesium sulfate in acute asthma in children. METHODS: The PubMed, Cochrane Library, and EMBASE databases were searched. Randomized controlled trials and quasi-randomized controlled trials of IV and nebulized magnesium sulfate in pediatric acute asthma were included. The outcomes subject to meta-analysis were pulmonary function, hospitalization, and further treatment. If statistical heterogeneity was significant, random-effects models were used for meta-analysis, otherwise, fixed-effects models were applied. RESULTS: Ten randomized and quasi-randomized trials (6 IV, 4 nebulized) were identified. Intravenous magnesium sulfate treatment is associated with significant effects on respiratory function (standardized mean difference, 1.94; 95% confidence interval [CI], 0.80-3.08; P = 0.0008) and hospital admission (risk ratio, 0.55; 95% CI, 0.31-0.95; P = 0.03). But nebulized magnesium sulfate treatment shows no significant effect on respiratory function (standardized mean difference, 0.19; 95% CI, -0.01-0.40; P = 0.07) or hospital admission (risk ratio, 1.11; 95% CI, 0.86-1.44; P = 0.42). CONCLUSIONS: The meta-analysis revealed that IV magnesium sulfate is an effective treatment in children, with the pulmonary function significantly improved and hospitalization and further treatment decreased. But nebulized magnesium sulfate treatment showed no significant effect on respiratory function or hospital admission and further treatment</style></abstract><notes><style face="normal" font="default">DA - 20161017IS - 1535-1815 (Electronic)IS - 0749-5161 (Linking)LA - ENGPT - JOURNAL ARTICLECO - China -</style></notes><work-type><style face="normal" font="default">10.1097/PEC.0000000000000909</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27749796">PM:27749796</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Emerg Care\20161017-SuZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Emerg Care\20161017-SuZ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161017, Su Z</style></custom2><misc3><style face="normal" font="default">10.1097/PEC.0000000000000909</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40769</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Halwani,R.</style></author><author><style face="normal" font="default"> Vazquez-Tello,A.</style></author><author><style face="normal" font="default"> Horanieh,N.</style></author><author><style face="normal" font="default"> Dulgom,S.</style></author><author><style face="normal" font="default"> Al-Aseri,Z.</style></author><author><style face="normal" font="default"> Al-Khamis,N.</style></author><author><style face="normal" font="default"> Al-Sum,Z.</style></author><author><style face="normal" font="default"> Al-Jahdali,H.</style></author><author><style face="normal" font="default"> Al-Muhsen,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunology Research laboratory and Asthma Research Chair, College of Medicine, King Saud University, Riyadh, Saudi Arabia</style></auth-address><titles><title><style face="normal" font="default">Risk factors hindering asthma symptoms control in Saudi children and adolescents</style></title><secondary-title><style face="normal" font="default">Pediatr Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pediatr Int</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> ACT Score</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Saudi Arabia</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="2" Year="2017">2017/2/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: Maintaining well control of asthma symptoms can help preventing exacerbations and its associated complications. The Asthma Control Test (ACT) can rapidly assess the effectiveness of asthma management plan and therapy. OBJECTIVE: To identify risk factors associated with uncontrolled asthma symptoms in young Saudi asthmatics (3-17 years-old). METHODS: In this cross-sectional hospital-based survey, the ACT was administered to 297 asthmatic children/adolescents, recruited at the emergency department (ED) of two major hospitals. RESULTS: Most recruited patients were intermittent (63.5%) and mild-persistent (27.6%) asthmatics; few were moderate-persistent (8.9%) and none were severe asthmatics. These patients visited the ED 4 times (3.9+/-3.2), on average. Almost half of patients declared not receiving education about asthma (47%) nor education about medication use (43%). Most patients (60.3%) had uncontrolled symptoms (ACT score &lt;/=19), of which intermittent asthmatics presented better scores than patients with more severe symptoms. Children &lt;/=6 years-old, with symptoms diagnosed &lt;5 years ago and who were not attending school, had significantly worse control than older patients. Poor medication compliance and inappropriate inhaler device use were ascribed to younger patients (&lt;12 years-old) and worse scores; particularly in relation to the practice to stop inhaled corticosteroid (ICS) therapy when their symptoms improve. Patients with poor control declared also not having received education about inhaler device use. CONCLUSIONS: Most Saudi asthmatic children/adolescents visiting the ED had poor control of symptoms; indeed, none achieved complete control, which is related to deficient medication compliance and improper medication inhaler device use; deficient knowledge about asthma was also another factor hindering control. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170220IS - 1442-200X (Electronic)IS - 1328-8067 (Linking)LA - engPT - Journal ArticleCO - Saudi Arabia -</style></notes><work-type><style face="normal" font="default">10.1111/ped.13268</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28218986">PM:28218986</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Int\20170220-HalwaniR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Int\20170220-HalwaniR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170220, Halwani R</style></custom2><misc3><style face="normal" font="default">10.1111/ped.13268</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40770</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhou,A.</style></author><author><style face="normal" font="default"> Chang,H.</style></author><author><style face="normal" font="default"> Huo,W.</style></author><author><style face="normal" font="default"> Zhang,B.</style></author><author><style face="normal" font="default"> Hu,J.</style></author><author><style face="normal" font="default"> Xia,W.</style></author><author><style face="normal" font="default"> Chen,Z.</style></author><author><style face="normal" font="default"> Xiong,C.</style></author><author><style face="normal" font="default"> Zhang,Y.</style></author><author><style face="normal" font="default"> Wang,Y.</style></author><author><style face="normal" font="default"> Xu,S.</style></author><author><style face="normal" font="default"> Li,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Key Laboratory of Environment and Health, Ministry of Education &amp; Ministry of Environmental Protection, and State Key Laboratory of Environmental Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China</style></auth-address><titles><title><style face="normal" font="default">Prenatal exposure to bisphenol A and risk of allergic diseases in early life</style></title><secondary-title><style face="normal" font="default">Pediatr Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pediatr Res</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bisphenol A</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Maternal Age</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> urine</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="31" Month="1" Year="2017">2017/1/31</year></dates><abstract><style face="normal" font="default">BACKGROUND: Prenatal exposure to bisphenol A (BPA) affects immune system and promotes allergy and asthma in mice, but findings in human studies are limited. We investigated whether prenatal exposure to BPA is associated with increased risk of allergic diseases in infants. METHODS: We measured BPA concentrations in maternal urine samples collected at delivery from 412 women in Wuhan, China. The occurrence of allergic diseases including eczema and wheeze were assessed at age 6 months through questionnaires. We used logistic regression to evaluate the association between urinary BPA levels and the risk of allergic diseases. RESULTS: Mothers of infants with allergic diseases had significantly higher urinary BPA levels than those of infants without allergic diseases (median: 2.35 vs. 4.55 microg/l, P = 0.03). Increased risk of infant allergic diseases was associated with creatinine-adjusted maternal urinary BPA concentrations. And this association was limited to females (OR = 1.36; 95% CI: 1.10-1.79) rather than males. After stratification by maternal age, the association was only significant in infants of mothers who were younger than 25 years old (OR = 1.90; 95% CI: 1.09-3.29). CONCLUSION: Prenatal exposure to BPA may potentially increase the risk of allergic diseases at very early life in female infants.Pediatric Research (2017); doi:10.1038/pr.2017.20</style></abstract><notes><style face="normal" font="default">DA - 20170131IS - 1530-0447 (Electronic)IS - 0031-3998 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1038/pr.2017.20</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28141789">PM:28141789</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Res\20170131-ZhouA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Res\20170131-ZhouA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170131, Zhou A</style></custom2><misc3><style face="normal" font="default">10.1038/pr.2017.20</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40771</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rutman,L.</style></author><author><style face="normal" font="default"> Atkins,R.C.</style></author><author><style face="normal" font="default"> Migita,R.</style></author><author><style face="normal" font="default"> Foti,J.</style></author><author><style face="normal" font="default"> Spencer,S.</style></author><author><style face="normal" font="default"> Lion,K.C.</style></author><author><style face="normal" font="default"> Wright,D.R.</style></author><author><style face="normal" font="default"> Leu,M.G.</style></author><author><style face="normal" font="default"> Zhou,C.</style></author><author><style face="normal" font="default"> Mangione-Smith,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Washington, Seattle, Washington</style></auth-address><titles><title><style face="normal" font="default">Modification of an Established Pediatric Asthma Pathway Improves Evidence-Based, Efficient Care</style></title><secondary-title><style face="normal" font="default">Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatrics</style></full-title></periodical><pages end="" start="e20161248">e20161248-</pages><volume><style face="normal" font="default">138</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Efficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Length of Stay</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patient Care</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time series</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Washington</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">OBJECTIVE: In September 2011, an established pediatric asthma pathway at a tertiary care children's hospital underwent significant revision. Modifications included simplification of the visual layout, addition of evidence-based recommendations regarding medication use, and implementation of standardized admission criteria. The objective of this study was to determine the impact of the modified asthma pathway on pathway adherence, percentage of patients receiving evidence-based care, length of stay, and cost. METHODS: Cases were identified by using International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes. Data were analyzed for 24 months before and after pathway modification. Statistical process control was used to examine changes in processes of care, and interrupted time series was used to examine outcome measures, including length of stay and cost in the premodification and postmodification periods. RESULTS: A total of 5584 patients were included (2928 premodification; 2656 postmodification). Pathway adherence was high (79%-88%) throughout the study period. The percentage of patients receiving evidence-based care improved after pathway modification, and the results were sustained for 2 years. There was also improved efficiency, with a 30-minute (10%) decrease in emergency department length of stay for patients admitted with asthma (P = .006). There was a nominal (&lt;10%) increase in costs of asthma care for patients in the emergency department (P = .04) and no change for those admitted to the hospital. CONCLUSIONS: Modification of an existing pediatric asthma pathway led to sustained improvement in provision of evidence-based care and patient flow without adversely affecting costs. Our results suggest that continuous re-evaluation of established clinical pathways can lead to changes in provider practices and improvements in patient care</style></abstract><notes><style face="normal" font="default">DA - 20161212IS - 1098-4275 (Electronic)IS - 0031-4005 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1542/peds.2016-1248</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27940683">PM:27940683</url></web-urls><related-urls><url ppv-ref="no">presto - 1 anno</url></related-urls></urls><custom2><style face="normal" font="default">20161212, Rutman L</style></custom2><misc3><style face="normal" font="default">10.1542/peds.2016-1248</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40772</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sicherer,S.H.</style></author><author><style face="normal" font="default"> Simons,F.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Professor of Pediatrics, Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, New York</style></auth-address><titles><title><style face="normal" font="default">Epinephrine for First-aid Management of Anaphylaxis</style></title><secondary-title><style face="normal" font="default">Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatrics</style></full-title></periodical><pages end="" start="e20164006">e20164006-</pages><volume><style face="normal" font="default">139</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adrenaline</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergen avoidance</style></keyword><keyword><style face="normal" font="default"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> cAMP</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> First Aid</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Immunotherapy</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> insect venom</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Sport</style></keyword><keyword><style face="normal" font="default"> Sports</style></keyword><keyword><style face="normal" font="default"> Thigh</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="13" Month="2" Year="2017">2017/2/13</year></dates><abstract><style face="normal" font="default">Anaphylaxis is a severe, generalized allergic or hypersensitivity reaction that is rapid in onset and may cause death. Epinephrine (adrenaline) can be life-saving when administered as rapidly as possible once anaphylaxis is recognized. This clinical report from the American Academy of Pediatrics is an update of the 2007 clinical report on this topic. It provides information to help clinicians identify patients at risk of anaphylaxis and new information about epinephrine and epinephrine autoinjectors (EAs). The report also highlights the importance of patient and family education about the recognition and management of anaphylaxis in the community. Key points emphasized include the following: (1) validated clinical criteria are available to facilitate prompt diagnosis of anaphylaxis; (2) prompt intramuscular epinephrine injection in the mid-outer thigh reduces hospitalizations, morbidity, and mortality; (3) prescribing EAs facilitates timely epinephrine injection in community settings for patients with a history of anaphylaxis and, if specific circumstances warrant, for some high-risk patients who have not previously experienced anaphylaxis; (4) prescribing epinephrine for infants and young children weighing &lt;15 kg, especially those who weigh 7.5 kg and under, currently presents a dilemma, because the lowest dose available in EAs, 0.15 mg, is a high dose for many infants and some young children; (5) effective management of anaphylaxis in the community requires a comprehensive approach involving children, families, preschools, schools, camps, and sports organizations; and (6) prevention of anaphylaxis recurrences involves confirmation of the trigger, discussion of specific allergen avoidance, allergen immunotherapy (eg, with stinging insect venom, if relevant), and a written, personalized anaphylaxis emergency action plan; and (7) the management of anaphylaxis also involves education of children and supervising adults about anaphylaxis recognition and first-aid treatment</style></abstract><notes><style face="normal" font="default">DA - 20170214IS - 1098-4275 (Electronic)IS - 0031-4005 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1542/peds.2016-4006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28193791">PM:28193791</url></web-urls><related-urls><url ppv-ref="no">presto - 1 anno</url></related-urls></urls><custom2><style face="normal" font="default">20170214, Sicherer SH</style></custom2><misc3><style face="normal" font="default">10.1542/peds.2016-4006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40773</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,J.</style></author><author><style face="normal" font="default"> Sicherer,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pediatric Allergy and Immunology</style></auth-address><titles><title><style face="normal" font="default">Guidance on Completing a Written Allergy and Anaphylaxis Emergency Plan</style></title><secondary-title><style face="normal" font="default">Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatrics</style></full-title></periodical><pages end="" start="e20164005">e20164005-</pages><volume><style face="normal" font="default">139</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health care provider</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="13" Month="2" Year="2017">2017/2/13</year></dates><abstract><style face="normal" font="default">Anaphylaxis is a potentially life-threatening, severe allergic reaction. The immediate assessment of patients having an allergic reaction and prompt administration of epinephrine, if criteria for anaphylaxis are met, promote optimal outcomes. National and international guidelines for the management of anaphylaxis, including those for management of allergic reactions at school, as well as several clinical reports from the American Academy of Pediatrics, recommend the provision of written emergency action plans to those at risk of anaphylaxis, in addition to the prescription of epinephrine autoinjectors. This clinical report provides information to help health care providers understand the role of a written, personalized allergy and anaphylaxis emergency plan to enhance the care of children at risk of allergic reactions, including anaphylaxis. This report offers a comprehensive written plan, with advice on individualizing instructions to suit specific patient circumstances</style></abstract><notes><style face="normal" font="default">DA - 20170214IS - 1098-4275 (Electronic)IS - 0031-4005 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1542/peds.2016-4005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28193793">PM:28193793</url></web-urls><related-urls><url ppv-ref="no">presto - 1 anno</url></related-urls></urls><custom2><style face="normal" font="default">20170214, Wang J</style></custom2><misc3><style face="normal" font="default">10.1542/peds.2016-4005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40774</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Johannes,C.B.</style></author><author><style face="normal" font="default"> McQuay,L.J.</style></author><author><style face="normal" font="default"> Midkiff,K.D.</style></author><author><style face="normal" font="default"> Calingaert,B.</style></author><author><style face="normal" font="default"> Andrews,E.B.</style></author><author><style face="normal" font="default"> Tennis,P.</style></author><author><style face="normal" font="default"> Brown,J.S.</style></author><author><style face="normal" font="default"> Camargo,C.A.,Jr.</style></author><author><style face="normal" font="default"> Disantostefano,R.L.</style></author><author><style face="normal" font="default"> Rothman,K.J.</style></author><author><style face="normal" font="default"> Sturmer,T.</style></author><author><style face="normal" font="default"> Lanes,S.</style></author><author><style face="normal" font="default"> Davis,K.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">RTI Health Solutions, Waltham, MA, USA</style></auth-address><titles><title><style face="normal" font="default">The feasibility of using multiple databases to study rare outcomes: the potential effect of long-acting beta agonists with inhaled corticosteroid therapy on asthma mortality</style></title><secondary-title><style face="normal" font="default">Pharmacoepidemiol Drug Saf</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pharmacoepidemiol Drug Saf</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">agonists</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> linkage</style></keyword><keyword><style face="normal" font="default"> long acting beta agonists</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective cohort study</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Solutions</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="21" Month="12" Year="2016">2016/12/21</year></dates><abstract><style face="normal" font="default">PURPOSE: Long-acting beta agonists (LABAs) when used without concomitant inhaled corticosteroids (ICS) increase the risk of asthma-related deaths, but the effect on asthma-related death of LABA used in combination with ICS therapy is unknown. To address this question, we explored the feasibility of conducting an observational study using multiple US health care data sources. METHODS: Retrospective cohort study to evaluate the likelihood of getting an upper 95% confidence limit &lt;/=1.4 for the asthma mortality rate ratio and &lt;/=0.40 per 10 000 person-years for the mortality rate difference, assuming no effect of new use of combined LABA + ICS (versus non-LABA maintenance therapy) on asthma mortality. Ten research institutions executed centrally distributed analytic code based on a standard protocol using an extracted (2000-2010) persistent asthma cohort (asthma diagnosis and >/=4 asthma medications in 12 months). Pooled results were analyzed by the coordinating center. Asthma deaths were ascertained by linkage with the National Death Index. RESULTS: In a cohort of 994 627 persistent asthma patients (2.4 million person-years; 278 asthma deaths), probabilities of the upper 95% confidence limit for effect estimates being less than targeted values, assuming a null relation, were about 0.05. Modifications in cohort and exposure definitions increased exposed person-time and outcome events, but study size remained insufficient to attain study goals. CONCLUSIONS: Even with 10 data sources and a 10-year study period, the rarity of asthma deaths among patients using certain medications made it infeasible to study the association between combined LABA + ICS and asthma mortality with our targeted level of study precision. Copyright (c) 2016 John Wiley &amp; Sons, Ltd</style></abstract><notes><style face="normal" font="default">DA - 20161221IS - 1099-1557 (Electronic)IS - 1053-8569 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1002/pds.4151</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28000298">PM:28000298</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pharmacoepidemiol Drug Saf\20161221-JohannesCB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pharmacoepidemiol Drug Saf\20161221-JohannesCB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161221, Johannes CB</style></custom2><misc3><style face="normal" font="default">10.1002/pds.4151</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40775</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McConeghy,K.W.</style></author><author><style face="normal" font="default"> Caffrey,A.R.</style></author><author><style face="normal" font="default"> Morrill,H.J.</style></author><author><style face="normal" font="default"> Trivedi,A.N.</style></author><author><style face="normal" font="default"> LaPlante,K.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center of Innovation in Long Term Services and Supports, Veterans Affairs Medical Center, Providence VA Medical Center, Providence, RI, USA</style></auth-address><titles><title><style face="normal" font="default">Are non-allergic drug reactions commonly documented as medication "allergies"? A national cohort of Veterans' admissions from 2000 to 2014</style></title><secondary-title><style face="normal" font="default">Pharmacoepidemiol Drug Saf</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pharmacoepidemiol Drug Saf</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy history</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Inpatients</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> NSAID</style></keyword><keyword><style face="normal" font="default"> NSAIDs</style></keyword><keyword><style face="normal" font="default"> opiates</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillins</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Sulfonamides</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Veterans</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="13" Month="11" Year="2016">2016/11/13</year></dates><abstract><style face="normal" font="default">PURPOSE: Adverse drug reactions (ADRs) including medication allergies are not well-described among large national cohorts. This study described the most common documented medication allergies and their reactions among a national cohort of Veterans Affairs (VA) inpatients. METHODS: We evaluated inpatient admissions in any VA Medical Center from 1 January 2000 to 31 December 2014. Each admission was linked with allergy history preceding or upon admission. Individual drugs were aggregated into drug class category including: penicillins, sulfonamides, angiotensin converting enzyme (ACE) inhibitors, opiates, HMG-CoA reductase inhibitors ("statins") and non-steroidal anti-inflammatory inhibitors (NSAID). Results were reported in aggregate and over time. RESULTS: Approximately ~10.8 million inpatient admissions occurred from 2000 to 2014. We found the most commonly reported allergy drug classes were penicillins (13%, n = 1 410 080), opiates (9.1%, n = 984 978), ACE inhibitors (5.7%, n = 618 075) sulfonamides (5.1%, n = 558 653), NSAIDs (5.1%, n = 551 216) and statins (3.6%, n = 391 983). Several allergy histories increased over time including opiates (6.2 to 11.2%), ACE inhibitors (1.3 to 10.2%), statins (0.3 to 7.3%) and NSAIDs (3.9 to 6.0%). Rash was the most commonly documented reaction on reports for penicillins (25.5%, n = 371 825), sulfonamides (25.6%, n = 165 954) and NSAIDs (10.3%, n = 65 741). The most common reaction for opiates was nausea/vomiting (17.9%, n = 211 864), cough/coughing for ACE inhibitors (41.0%, n = 270 537) and muscle pain/myalgia for statins (34.1%, n = 186 565). CONCLUSIONS: We report that penicillins and opiates are the most commonly documented drug allergies among VA inpatients, but other drug classes such as ACE inhibitors, statins and NSAIDs are becoming increasingly common. Clinicians also commonly document non-allergic ADRs in the allergy section such as cough or myalgia. Copyright (c) 2016 John Wiley &amp; Sons, Ltd</style></abstract><notes><style face="normal" font="default">DA - 20161118IS - 1099-1557 (Electronic)IS - 1053-8569 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1002/pds.4134</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27862587">PM:27862587</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pharmacoepidemiol Drug Saf\20161118-McConeghyKW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pharmacoepidemiol Drug Saf\20161118-McConeghyKW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161118, McConeghy KW</style></custom2><misc3><style face="normal" font="default">10.1002/pds.4134</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40776</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Roviezzo,F.</style></author><author><style face="normal" font="default"> Sorrentino,R.</style></author><author><style face="normal" font="default"> Iacono,V.M.</style></author><author><style face="normal" font="default"> Brancaleone,V.</style></author><author><style face="normal" font="default"> Terlizzi,M.</style></author><author><style face="normal" font="default"> Riemma,M.A.</style></author><author><style face="normal" font="default"> Bertolino,A.</style></author><author><style face="normal" font="default"> Rossi,A.</style></author><author><style face="normal" font="default"> Matteis,M.</style></author><author><style face="normal" font="default"> Spaziano,G.</style></author><author><style face="normal" font="default"> Pinto,A.</style></author><author><style face="normal" font="default"> D'Agostino,B.</style></author><author><style face="normal" font="default"> Cirino,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacy, University of Naples Federico II, Naples, Italy</style></auth-address><titles><title><style face="normal" font="default">Disodium cromoglycate inhibits asthma-like features induced by sphingosine-1-phosphate</style></title><secondary-title><style face="normal" font="default">Pharmacol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pharmacol Res</style></full-title></periodical><pages end="635" start="626">626-635</pages><volume><style face="normal" font="default">113</style></volume><number><style face="normal" font="default">Pt A</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Bronchi</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> CD23</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE-dependent</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> KIT</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> Mucus</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Prostaglandin</style></keyword><keyword><style face="normal" font="default"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> subcutaneous</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="3" Month="10" Year="2016">2016/10/3</year></dates><abstract><style face="normal" font="default">Compelling evidence suggests the involvement of sphingosine-1-phosphate (S1P) in the pathogenesis of asthma. The systemic administration of S1P causes asthma like features in the mouse involving mast cells. In this study we investigated whether disodium cromoglycate (DSCG), administered as a preventative treatment as in human therapy, could affect S1P effects on airways. BALB/c mice, treated with DSCG, received subcutaneous administration of S1P. Bronchi and pulmonary tissues were collected and functional, molecular and cellular studies were performed. DSCG inhibited S1P-induced airway hyper-reactivity as well as pulmonary inflammation. DSCG decreased the recruitment of solely mast cells and B cells in the lung. IgE serum levels, prostaglandin D2, mucus production and IL-13 were also reduced when mice were pretreated with DSCG. S1P induced pulmonary expression of CD23 on T and B cells, that was reversed by DSCG. Conversely, S1P failed to upregulate CD23 in mast cell-deficient Kit W-sh/W-sh mice. In conclusion we have shown that DSCG inhibits S1P-induced asthma like features in the mouse. This beneficial effect is due to a regulatory action on mast cell activity, and in turn to an inhibition of IgE-dependent T and B cells responses</style></abstract><notes><style face="normal" font="default">DA - 20161007IS - 1096-1186 (Electronic)IS - 1043-6618 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.phrs.2016.09.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27713021">PM:27713021</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pharmacol Res\2016-113-626-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pharmacol Res\2016-113-626-35.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161007, Roviezzo F</style></custom2><misc3><style face="normal" font="default">10.1016/j.phrs.2016.09.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40777</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Giovannini,M.</style></author><author><style face="normal" font="default"> Sarti,L.</style></author><author><style face="normal" font="default"> Barni,S.</style></author><author><style face="normal" font="default"> Pucci,N.</style></author><author><style face="normal" font="default"> Novembre,E.</style></author><author><style face="normal" font="default"> Mori,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Unit, Department of Pediatrics, Anna Meyer Children's University Hospital, Florence, Italy</style></auth-address><titles><title><style face="normal" font="default">Anaphylaxis to Over-the-Counter Flurbiprofen in a Child</style></title><secondary-title><style face="normal" font="default">Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pharmacology</style></full-title></periodical><pages end="123" start="121">121-123</pages><volume><style face="normal" font="default">99</style></volume><number><style face="normal" font="default">3-4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy workup</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Flurbiprofen</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drug</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> Over-the-counter</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe reactions</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="11" Month="11" Year="2016">2016/11/11</year></dates><abstract><style face="normal" font="default">Non-steroidal anti-inflammatory drugs are suspected to cause drug hypersensitivity very frequently in paediatric patients. In this article, we describe the first case of anaphylaxis to flurbiprofen in a child and provide insight into the possibility of severe reactions and even anaphylaxis to over-the-counter flurbiprofen. Finally, the importance of a rigorous allergy work-up in reaching a confident diagnosis and providing the patient with a safe alternative is shown</style></abstract><notes><style face="normal" font="default">DA - 20161110IS - 1423-0313 (Electronic)IS - 0031-7012 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1159/000452671</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27832658">PM:27832658</url></web-urls><related-urls><url ppv-ref="no">presto - 1 anno</url></related-urls></urls><custom2><style face="normal" font="default">20161110, Giovannini M</style></custom2><misc3><style face="normal" font="default">10.1159/000452671</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40778</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Haruna,T.</style></author><author><style face="normal" font="default"> Soga,M.</style></author><author><style face="normal" font="default"> Morioka,Y.</style></author><author><style face="normal" font="default"> Imura,K.</style></author><author><style face="normal" font="default"> Furue,Y.</style></author><author><style face="normal" font="default"> Yamamoto,M.</style></author><author><style face="normal" font="default"> Hayakawa,J.</style></author><author><style face="normal" font="default"> Deguchi,M.</style></author><author><style face="normal" font="default"> Arimura,A.</style></author><author><style face="normal" font="default"> Yasui,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Drug Discovery and Disease Research Laboratory,SHIONOGI &amp;amp; Co., Ltd., Osaka, Japan</style></auth-address><titles><title><style face="normal" font="default">The Inhibitory Effect of S-777469, a Cannabinoid Type 2 Receptor Agonist, on Skin Inflammation in Mice</style></title><secondary-title><style face="normal" font="default">Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pharmacology</style></full-title></periodical><pages end="267" start="259">259-267</pages><volume><style face="normal" font="default">99</style></volume><number><style face="normal" font="default">5-6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> oral administration</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword></keywords><dates><year Day="18" Month="2" Year="2017">2017/2/18</year></dates><abstract><style face="normal" font="default">We investigated the effects of S-777469 (1-[[6-Ethyl-1-[4-fluorobenzyl]-5-methyl-2-oxo-1, 2-dihydropyridine-3-carbonyl]amino]-cyclohexanecarboxylic acid), a novel cannabinoid type 2 receptor (CB2) agonist, on 1-fluoro-2,4-dinitrobenzene (DNFB)-induced ear inflammation and mite antigen-induced dermatitis in mice. The oral administration of S-777469 significantly suppressed DNFB-induced ear swelling in a dose-dependent manner. In addition, S-777469 significantly alleviated mite antigen-induced atopic dermatitis-like skin lesions in NC/Nga mice. A histological analysis revealed that S-777469 significantly reduced the epidermal thickness and the number of mast cells infiltrating skin lesions. We demonstrated that S-777469 inhibited mite antigen-induced eosinophil accumulation in skin lesions and an endogenous CB2 ligand, 2-arachidonoylglycerol (2-AG)-induced eosinophil migration in vitro. Moreover, we confirmed that 2-AG levels significantly increased in skin lesions of mite antigen-induced dermatitis model. Together, these results suggest that S-777469 inhibits skin inflammation in mice by blocking the activities of 2-AG</style></abstract><notes><style face="normal" font="default">DA - 20170219IS - 1423-0313 (Electronic)IS - 0031-7012 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1159/000455916</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28214870">PM:28214870</url></web-urls><related-urls><url ppv-ref="no">presto - 1 anno</url></related-urls></urls><custom2><style face="normal" font="default">20170219, Haruna T</style></custom2><misc3><style face="normal" font="default">10.1159/000455916</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40779</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kishimoto,I.</style></author><author><style face="normal" font="default"> Uetsu,N.</style></author><author><style face="normal" font="default"> Tanimura,H.</style></author><author><style face="normal" font="default"> Fujii,H.</style></author><author><style face="normal" font="default"> Okamoto,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Kansai Medical University, Osaka, Japan</style></auth-address><titles><title><style face="normal" font="default">Solar urticaria with a wide action spectrum from UVB to visible light complicated with UVA-induced polymorphous light eruption</style></title><secondary-title><style face="normal" font="default">Photodermatol Photoimmunol Photomed</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Photodermatol Photoimmunol Photomed</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Clinical</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Injections</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Photosensitivity</style></keyword><keyword><style face="normal" font="default"> Photosensitivity Disorders</style></keyword><keyword><style face="normal" font="default"> Phototesting</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Solar urticaria</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="2" Year="2017">2017/2/4</year></dates><abstract><style face="normal" font="default">Solar urticaria and polymorphous light eruption (PLE) are acquired idiopathic photosensitivity disorders, but each phenomenon is extremely different; one is an immediate reaction, and one is a delayed-type reaction. Phototesting is necessary not only for the diagnosis of these photosensitivity disorders but also for the determination of the action spectrum so that the patient can try to avoid the triggering wavelengths in ordinary life. Solar urticaria is unique in that the particular spectra that inhibit or enhance the reactions by action spectra are present in some cases. In contrast, with PLE, phototesting is difficult, because a single or even repeated exposure of ultraviolet light or visible light sometimes fails to provoke the reaction. Here, we report a case of solar urticaria complicated with PLE. Solar urticaria with an action spectrum ranging from UVB to visible light was diagnosed by clinical presentation, phototesting and intradermal injections of photo-irradiated autologous serum. PLE induced by UVA was diagnosed by clinical presentation and phototesting. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170204IS - 1600-0781 (Electronic)IS - 0905-4383 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/phpp.12300</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28160768">PM:28160768</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Photodermatol Photoimmunol Photomed\20170204-KishimotoI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Photodermatol Photoimmunol Photomed\20170204-KishimotoI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, Kishimoto I</style></custom2><misc3><style face="normal" font="default">10.1111/phpp.12300</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40780</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Willardson,H.B.</style></author><author><style face="normal" font="default"> Kobayashi,T.T.</style></author><author><style face="normal" font="default"> Arnold,J.G.</style></author><author><style face="normal" font="default"> Hivnor,C.M.</style></author><author><style face="normal" font="default"> Bowen,C.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Transitional Year Intern, Transitional Year Program, San Antonio Uniformed Services Health Education Consortium (SAUSHEC) , San Antonio, Texas</style></auth-address><titles><title><style face="normal" font="default">Diffuse Urticarial Reaction Associated with Titanium Dioxide Following Laser Tattoo Removal Treatments</style></title><secondary-title><style face="normal" font="default">Photomed Laser Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Photomed Laser Surg</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electron microscopy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Generalized urticaria</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Education</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Microscopy</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Texas</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Titanium</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="1" Year="2017">2017/1/2</year></dates><abstract><style face="normal" font="default">IMPORTANCE: Local and generalized allergic reactions following laser tattoo removal have been documented, but are rare. To our knowledge, this is the fourth documented case of widespread urticarial eruptions following laser tattoo removal treatment. Unlike previously documented cases, this patient's reaction was found to be associated with titanium dioxide within the tattoo and her symptoms were recalcitrant to medical therapy. OBSERVATIONS: A 46-year-old female experienced diffuse urticarial plaques, erythema, and pruritis following multiple laser tattoo removal treatments with an Nd:YAG laser. The systemic allergic reaction was recalcitrant to increasing doses of antihistamines and corticosteroids. The tattoo was finally surgically excised. The excised tissue was analyzed by scanning electron microscopy and energy-dispersive X-ray analysis and contained high levels of titanium dioxide. Two weeks following the excision, and without the use of medical therapy, the patient had complete resolution of her generalized urticaria. CONCLUSIONS: Ours is the first documented case of a diffuse urticarial reaction following laser tattoo removal treatments that shows a strong association to titanium dioxide within the tattoo pigment. Herein, we describe a novel surgical approach to treat recalcitrant generalized allergic reaction to tattoo pigment</style></abstract><notes><style face="normal" font="default">DA - 20170106IS - 1557-8550 (Electronic)IS - 1549-5418 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1089/pho.2016.4162</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28061317">PM:28061317</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Photomed Laser Surg\20170106-WillardsonHB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Photomed Laser Surg\20170106-WillardsonHB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170106, Willardson HB</style></custom2><misc3><style face="normal" font="default">10.1089/pho.2016.4162</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40781</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yagnatovsky,M.</style></author><author><style face="normal" font="default"> Pham,H.</style></author><author><style face="normal" font="default"> Rokito,A.</style></author><author><style face="normal" font="default"> Jazrawi,L.</style></author><author><style face="normal" font="default"> Strauss,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Orthopaedic Surgery , NYU Langone Hospital for Joint Diseases , New York , NY , USA</style></auth-address><titles><title><style face="normal" font="default">Type IV hypersensitivity reactions following Dermabond adhesive utilization in knee surgery: A Report of Three Cases</style></title><secondary-title><style face="normal" font="default">Phys Sportsmed</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Phys Sportsmed</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adhesives</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> Arthritis</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Delayed hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Delayed hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Dermabond</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Knee</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Sutures</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Type IV hypersensitivity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword><keyword><style face="normal" font="default"> Wound Infection</style></keyword></keywords><dates><year Day="25" Month="1" Year="2017">2017/1/25</year></dates><abstract><style face="normal" font="default">We retrospectively reviewed the records of 3 patients (3 knees) with a delayed type hypersensitivity reaction following Dermabond exposure after an orthopaedic knee procedure. Delayed hypersensitivity reactions are mediated by CD4+ helper T cells. The use of skin adhesives in place of traditional sutures is increasing in popularity given Dermabond's potential benefits of decreased wound infection rate and better wound approximation. However, hypersensitivity reactions to the cyanoacrylate material in Dermabond have been described. Differentiating hypersensitivity reactions from post-operative infections is important as septic arthritis is a potentially devastating complication. This case series presents the challenge of properly diagnosing and managing hypersensitivity reactions. Consultation with allergists and dermatologists may be appropriate for ascertaining the nature of the surgical site complication and proper management. The recommended management of hypersensitivity-type reactions is a course of topical steroids and infection work up if needed</style></abstract><notes><style face="normal" font="default">DA - 20170124IS - 2326-3660 (Electronic)IS - 0091-3847 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/00913847.2017.1283208</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28116947">PM:28116947</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Phys Sportsmed\20170124-YagnatovskyM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Phys Sportsmed\20170124-YagnatovskyM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170124, Yagnatovsky M</style></custom2><misc3><style face="normal" font="default">10.1080/00913847.2017.1283208</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40782</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Koshak,A.</style></author><author><style face="normal" font="default"> Wei,L.</style></author><author><style face="normal" font="default"> Koshak,E.</style></author><author><style face="normal" font="default"> Wali,S.</style></author><author><style face="normal" font="default"> Alamoudi,O.</style></author><author><style face="normal" font="default"> Demerdash,A.</style></author><author><style face="normal" font="default"> Qutub,M.</style></author><author><style face="normal" font="default"> Pushparaj,P.N.</style></author><author><style face="normal" font="default"> Heinrich,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Cluster Biodiversity and Medicines, UCL School of Pharmacy, University College London, London, UK</style></auth-address><titles><title><style face="normal" font="default">Nigella sativa Supplementation Improves Asthma Control and Biomarkers: A Randomized, Double-Blind, Placebo-Controlled Trial</style></title><secondary-title><style face="normal" font="default">Phytother Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Phytother Res</style></full-title></periodical><pages end="409" start="403">403-409</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Capsules</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> pulmonary function test</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Saudi Arabia</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="1" Year="2017">2017/1/17</year></dates><abstract><style face="normal" font="default">Poor compliance with conventional asthma medications remains a major problem in achieving asthma control. Nigella sativa oil (NSO) is used traditionally for many inflammatory conditions such as asthma. We aimed to investigate the benefits of NSO supplementation on clinical and inflammatory parameters of asthma. NSO capsules 500 mg twice daily for 4 weeks were used as a supplementary treatment in a randomized, double-blind, placebo-controlled trial in asthmatics (clinicaltrials.gov: NCT02407262). The primary outcome was Asthma Control Test score. The secondary outcomes were pulmonary function test, blood eosinophils and total serum Immunoglobulin E. Between 1 June and 30 December 2015, 80 asthmatics were enrolled, with 40 patients in each treatment and placebo groups. After 4 weeks, ten patients had withdrawn from each group. Compared with placebo, NSO group showed a significant improvement in mean Asthma Control Test score 21.1 (standard deviation = 2.6) versus 19.6 (standard deviation = 3.7) (p = 0.044) and a significant reduction in blood eosinophils by -50 (-155 to -1) versus 15 (-60 to 87) cells/muL (p = 0.013). NSO improved forced expiratory volume in 1 second as percentage of predicted value by 4 (-1.25 to 8.75) versus 1 (-2 to 5) but non-significant (p = 0.170). This randomized, double-blind, placebo-controlled trial demonstrated that NSO supplementation improves asthma control with a trend in pulmonary function improvement. This was associated with a remarkable normalization of blood eosinophlia. Future studies should follow asthmatics for longer periods in a multicentre trial. Copyright (c) 2017 John Wiley &amp; Sons, Ltd</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1099-1573 (Electronic)IS - 0951-418X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Saudi Arabia -</style></notes><work-type><style face="normal" font="default">10.1002/ptr.5761</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28093815">PM:28093815</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Phytother Res\2017-31-403-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Phytother Res\2017-31-403-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Koshak A</style></custom2><misc3><style face="normal" font="default">10.1002/ptr.5761</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40783</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tejera-Vaquerizo,A.</style></author><author><style face="normal" font="default"> Garcia-Gavin,J.</style></author><author><style face="normal" font="default"> Alhambra-Exposito,M.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Allergic contactc dermatitis to the adhesive of the FreeStyle® LibreTM sensor for the determination of glycemia</style></title><secondary-title><style face="normal" font="default">Piel</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Piel</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0213-9251</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - SPACO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.piel.2016.10.018</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.piel.2016.10.018</url></web-urls></urls><custom2><style face="normal" font="default">20170304, Tejera-Vaquerizo A</style></custom2><misc3><style face="normal" font="default">10.1016/j.piel.2016.10.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40784</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fujimura,M.</style></author><author><style face="normal" font="default"> Nakatsuji,Y.</style></author><author><style face="normal" font="default"> Ishimaru,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cyclosporin A Treatment in Intrinsic Canine Atopic Dermatitis (Atopic-like Dermatitis): Open Trial Study</style></title><secondary-title><style face="normal" font="default">Pol J Vet Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pol J Vet Sci</style></abbr-1></periodical><pages end="572" start="567">567-572</pages><volume><style face="normal" font="default">19</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Canine</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> dog</style></keyword><keyword><style face="normal" font="default"> Dogs</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyperplasia</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Remission</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="9" Year="2016">2016/9/1</year></dates><abstract><style face="normal" font="default">In this study, dogs were separated into two groups and treated with immunosuppressant (Cyclosporin A: CsA). The first group was the canine atopic dermatitis (CAD) group, which is similar to extrinsic atopic dermatitis (AD) in humans (treated with a CsA dose of 2.5-5.5 mg/kg, n=8), and the second group was the canine atopic-like dermatitis (ALD) group, which is similar to intrinsic AD in humans (treated with a CsA dose of 2.5-6.5 mg/kg, n=14). The canine atopic dermatitis extent and severity index (CADESI)-4 was evaluated before treatment (PRE) and after treatment (POST) to assess the effectiveness of CsA for the two groups. In the CAD group, CADESI-4 showed no change (PRE:79+/-29, POST:77+/-28) and out of the eight dogs, no dogs showed complete remission, three dogs showed partial remission, and five dogs showed no effect. Whereas in the ALD group, CADESI-4 showed a significant reduction (PRE: 61+/-42, POST: 32+/-25, p&lt;0.01) and out of the 14 dogs, 11 dogs showed complete remission, two dogs showed partial remission, and one dog showed no effect. The results indicate that the immunosuppressant showed effectiveness for the dogs diagnosed with ALD. One dog had to be treated for a year and eight months, which was the longest period in the study, this dog presented with hyperplasia of the lymphoidgland and mammary tumor</style></abstract><notes><style face="normal" font="default">DA - 20161019IS - 1505-1773 (Print)IS - 1505-1773 (Linking)LA - ENGPT - JOURNAL ARTICLECO - Japan -</style></notes><work-type><style face="normal" font="default">10.1515/pjvs-2016-0071</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27760033">PM:27760033</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pol J Vet Sci\2016-19-567-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pol J Vet Sci\2016-19-567-72.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161019, Fujimura M</style></custom2><misc3><style face="normal" font="default">10.1515/pjvs-2016-0071</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40785</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ibrahim,U.</style></author><author><style face="normal" font="default"> Asti,D.</style></author><author><style face="normal" font="default"> Saqib,A.</style></author><author><style face="normal" font="default"> Mudduluru,B.M.</style></author><author><style face="normal" font="default"> Ayaz,S.</style></author><author><style face="normal" font="default"> Odaimi,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Staten Island University Hospital , Staten Island , New York , United States</style></auth-address><titles><title><style face="normal" font="default">Eosinophilia as the presenting sign in pancreatic cancer: an extremely rare occurrence</style></title><secondary-title><style face="normal" font="default">Postgrad Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Postgrad Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Abdomen</style></keyword><keyword><style face="normal" font="default"> Adenocarcinoma</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Aspiration</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Collagen</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hematology</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> malignancy</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pancreas</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="8" Month="10" Year="2016">2016/10/8</year></dates><abstract><style face="normal" font="default">A case of pancreatic adenocarcinoma diagnosed following work up for eosinophilia is reported. A 68-year-old female was referred to our Hematology clinic for an absolute eosinophil count of 1869 per microliter. No allergic signs or symptoms were reported. Laboratory studies for parasitic infestations autoimmune disease and collagen vascular disease were negative. Computed tomography of the abdomen revealed a mass in the neck of the pancreas with fine needle aspiration biopsy consistent with adenocarcinoma. The patient received one cycle of modified FOLFIRINOX with complete resolution of the eosinophilia. There are rare case reports of tumor-associated blood eosinophilia in solid malignancies. The finding may be indicative of rapid disease progression and poor prognosis. Our case is the third in published English literature with eosinophilia being the initial finding in pancreatic cancer</style></abstract><notes><style face="normal" font="default">DA - 20161010IS - 1941-9260 (Electronic)IS - 0032-5481 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United states -</style></notes><work-type><style face="normal" font="default">10.1080/00325481.2017.1246345</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27718779">PM:27718779</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Postgrad Med\20161010-IbrahimU.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Postgrad Med\20161010-IbrahimU.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161010, Ibrahim U</style></custom2><misc3><style face="normal" font="default">10.1080/00325481.2017.1246345</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40786</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bohm,I.</style></author><author><style face="normal" font="default"> Morelli,J.</style></author><author><style face="normal" font="default"> Nairz,K.</style></author><author><style face="normal" font="default"> Silva Hasembank,K.P.</style></author><author><style face="normal" font="default"> Heverhagen,J.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital , University of Bern , Bern , Switzerland</style></auth-address><titles><title><style face="normal" font="default">Myths and misconceptions concerning contrast media-induced anaphylaxis: a narrative review</style></title><secondary-title><style face="normal" font="default">Postgrad Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Postgrad Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic tool</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Interleukin-2</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Premedication</style></keyword><keyword><style face="normal" font="default"> Radiology</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Suggestion</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="13" Month="1" Year="2017">2017/1/13</year></dates><abstract><style face="normal" font="default">Contrast-enhanced radiological examinations are an increasingly important diagnostic tool in modern medicine. All approved and available contrast media (iodinated and gadolinium-based) are safe compounds that are well-tolerated by most patients. However, a small percentage of patients exhibit contrast medium-induced adverse drug reactions that are dose-dependent and predictable (type A) or an even smaller cohort experience so-called type B (dose-independent, non-predictable). To increase patients' safety, recommendations/guidelines have been put forth in the literature and advice passed down informally by radiologists in practice to ensure contrast media safety. Through these, both reasonable suggestions as well as misinterpretations and myths (such as the misleading terms "allergy-like" reactions, and "iodine-allergy", the wrong assumption that the initial contact to a contrast medium could not induce an allergy, the estimation that an anti-allergy premedication could suppress all possible adverse reactions, and interleukin-2 as a risk/trigger for contrast medium adverse events) have arisen. Since the latter are not only unhelpful but also potentially reduce patients' safety, such myths and misconceptions are the focus of this review</style></abstract><notes><style face="normal" font="default">DA - 20170113IS - 1941-9260 (Electronic)IS - 0032-5481 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/00325481.2017.1282296</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28085538">PM:28085538</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Postgrad Med\20170113-BohmI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Postgrad Med\20170113-BohmI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170113, Bohm I</style></custom2><misc3><style face="normal" font="default">10.1080/00325481.2017.1282296</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40787</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,B.</style></author><author><style face="normal" font="default"> Tai,Y.</style></author><author><style face="normal" font="default"> Achanta,S.</style></author><author><style face="normal" font="default"> Kaelberer,M.M.</style></author><author><style face="normal" font="default"> Caceres,A.I.</style></author><author><style face="normal" font="default"> Shao,X.</style></author><author><style face="normal" font="default"> Fang,J.</style></author><author><style face="normal" font="default"> Jordt,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Neurobiology and Acupuncture Research, The Third Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, People's Republic of China</style></auth-address><titles><title><style face="normal" font="default">IL-33/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy</style></title><secondary-title><style face="normal" font="default">Proc Natl Acad Sci U S A</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Proc Natl Acad Sci U S A</style></abbr-1></periodical><pages end="E7579" start="E7572">E7572-E7579</pages><volume><style face="normal" font="default">113</style></volume><number><style face="normal" font="default">47</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Ca2+</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expansion</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> imaging</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Itch</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> microarray</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> Neuron</style></keyword><keyword><style face="normal" font="default"> Neurons</style></keyword><keyword><style face="normal" font="default"> neutralizing</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> ST2</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Transcriptome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="22" Month="11" Year="2016">2016/11/22</year></dates><abstract><style face="normal" font="default">Poison ivy-induced allergic contact dermatitis (ACD) is the most common environmental allergic condition in the United States. Case numbers of poison ivy ACD are increasing due to growing biomass and geographical expansion of poison ivy and increasing content of the allergen, urushiol, likely attributable to rising atmospheric CO2 Severe and treatment-resistant itch is the major complaint of affected patients. However, because of limited clinical data and poorly characterized models, the pruritic mechanisms in poison ivy ACD remain unknown. Here, we aim to identify the mechanisms of itch in a mouse model of poison ivy ACD by transcriptomics, neuronal imaging, and behavioral analysis. Using transcriptome microarray analysis, we identified IL-33 as a key cytokine up-regulated in the inflamed skin of urushiol-challenged mice. We further found that the IL-33 receptor, ST2, is expressed in small to medium-sized dorsal root ganglion (DRG) neurons, including neurons that innervate the skin. IL-33 induces Ca2+ influx into a subset of DRG neurons through neuronal ST2. Neutralizing antibodies against IL-33 or ST2 reduced scratching behavior and skin inflammation in urushiol-challenged mice. Injection of IL-33 into urushiol-challenged skin rapidly exacerbated itch-related scratching via ST2, in a histamine-independent manner. Targeted silencing of neuronal ST2 expression by intrathecal ST2 siRNA delivery significantly attenuated pruritic responses caused by urushiol-induced ACD. These results indicate that IL-33/ST2 signaling is functionally present in primary sensory neurons and contributes to pruritus in poison ivy ACD. Blocking IL-33/ST2 signaling may represent a therapeutic approach to ameliorate itch and skin inflammation related to poison ivy ACD</style></abstract><notes><style face="normal" font="default">DA - 20161108IS - 1091-6490 (Electronic)IS - 0027-8424 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1073/pnas.1606608113</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27821781">PM:27821781</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Proc Natl Acad Sci U S A\2016-113-E7572-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Proc Natl Acad Sci U S A\2016-113-E7572-9.pdf</url></text-urls><related-urls><url ppv-ref="no">xls in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20161108, Liu B</style></custom2><misc3><style face="normal" font="default">10.1073/pnas.1606608113</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40788</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Los-Rycharska,E.</style></author><author><style face="normal" font="default"> Kieraszewicz,Z.</style></author><author><style face="normal" font="default"> Czerwionka-Szaflarska,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department and Clinic of Paediatrics, Allergology, and Gastroenterology, Nicolaus Copernicus University in Torun, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Poland</style></auth-address><titles><title><style face="normal" font="default">Medium chain triglycerides (MCT) formulas in paediatric and allergological practice</style></title><secondary-title><style face="normal" font="default">Prz Gastroenterol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Prz Gastroenterol</style></full-title></periodical><pages end="231" start="226">226-231</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Absorption</style></keyword><keyword><style face="normal" font="default"> Acids</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Bile</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Digestion</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Fatty acid</style></keyword><keyword><style face="normal" font="default"> Fatty Acids</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Gastroenterology</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Indications</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> intestine</style></keyword><keyword><style face="normal" font="default"> Intestines</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Neonate</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> paediatrics</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Triglycerides</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Vitamins</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Fats constitute the most significant nutritional source of energy. Their proper use by the body conditions a number of complex mechanisms of digestion, absorption, distribution, and metabolism. These mechanisms are facilitated by fats made of medium chain fatty acids; therefore, they are an easy and quick source of energy. Thus, an increased supply of medium chain triglycerides (MCT) is particularly important in patients with disturbances of digestion and absorption such as disturbed bile secretion, classic coeliac disease, short bowel syndrome, inflammatory diseases of the intestines, disturbed outflow of lymph, some metabolic disease, and severe food allergies, as well as in prematurely born neonates. Use of preparations containing an additive of MCT is limited, especially if they are to be used for a longer period of time. With a large quantity of MCT in a diet, there is a risk of deficiency of necessary unsaturated fatty acids and some fat-soluble vitamins. The caloricity of MTC compared to long-chain triglycerides is lower, and formulas with MCT are characterised by higher osmolality. Medium chain triglycerides is not recommended as an additive to standard formulas for healthy children. The use of MCT should be limited to strictly specified medical indications</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1895-5770 (Print)IS - 1895-5770 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.5114/pg.2016.61374</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28053676">PM:28053676</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Prz Gastroenterol\2016-11-226-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Prz Gastroenterol\2016-11-226-31.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Los-Rycharska E</style></custom2><misc3><style face="normal" font="default">10.5114/pg.2016.61374</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40789</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Goodwin,R.D.</style></author><author><style face="normal" font="default"> Robinson,M.</style></author><author><style face="normal" font="default"> Sly,P.D.</style></author><author><style face="normal" font="default"> Holt,P.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Psychology,Queens College and The Graduate Center,City University of New York (CUNY),Queens,NY,USA</style></auth-address><titles><title><style face="normal" font="default">Childhood atopy and mental health: a prospective, longitudinal investigation</style></title><secondary-title><style face="normal" font="default">Psychol Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Psychol Med</style></abbr-1></periodical><pages end="325" start="317">317-325</pages><volume><style face="normal" font="default">47</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Barriers</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> mental health</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Western Australia</style></keyword><keyword><style face="normal" font="default"> youth</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Prior studies have suggested a relationship between atopy and mental health, although methodological barriers have limited the generalizability of these findings. The objective of this study was to investigate the relationship between early-life atopy and vulnerability to mental health problems among youth in the community. METHOD: Data were drawn from the Raine Study (N = 2868), a population-based birth cohort study in Western Australia. Logistic regression and generalized estimating equations were used to examine the relationship between atopy at ages 1-5 years [using parent report and objective biological confirmation (sera IgE)], and the range of internalizing and externalizing mental health problems at ages 5-17 years. RESULTS: Atopy appears to be associated with increased vulnerability to affective and anxiety problems, compared to youth without atopy. These associations remained significant after adjusting for a range of potential confounders. No relationship was evident between atopy and attention deficit hyperactivity disorder or externalizing problems. CONCLUSIONS: Findings are the first linking atopy (measured by both parent report and objective verification) with increased vulnerability to affective and anxiety problems. Therefore, replication is required. If replicated, future research aimed at understanding the possible biological and/or social and environmental pathways underlying these links is needed. Such information could shed light on shared pathways that could lead to more effective treatments for both atopy and internalizing mental health problems</style></abstract><notes><style face="normal" font="default">DA - 20161020IS - 1469-8978 (Electronic)IS - 0033-2917 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1017/S0033291716001896.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27762174">PM:27762174</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Psychol Med\2017-47-317-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Psychol Med\2017-47-317-25.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161020, Goodwin RD</style></custom2><misc3><style face="normal" font="default">10.1017/S0033291716001896.</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40790</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,E.</style></author><author><style face="normal" font="default"> Shalowitz,M.U.</style></author><author><style face="normal" font="default"> Story,R.E.</style></author><author><style face="normal" font="default"> Ehrlich,K.B.</style></author><author><style face="normal" font="default"> Levine,C.S.</style></author><author><style face="normal" font="default"> Hayen,R.</style></author><author><style face="normal" font="default"> Leigh,A.K.</style></author><author><style face="normal" font="default"> Miller,G.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Institute for Policy Research and Department of Psychology (Chen, Ehrlich, Levine, Hayen, Leigh, Miller), Northwestern University, Evanston, IL; Center for Clinical Research Informatics (Shalowitz), NorthShore University HealthSystem, and Department of Medicine (Story), NorthShore University HealthSystem, Evanston, IL</style></auth-address><titles><title><style face="normal" font="default">Dimensions of Socioeconomic Status and Childhood Asthma Outcomes: Evidence for Distinct Behavioral and Biological Associations</style></title><secondary-title><style face="normal" font="default">Psychosom Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Psychosom Med</style></abbr-1></periodical><pages end="1052" start="1043">1043-1052</pages><volume><style face="normal" font="default">78</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> allergen-specific</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Interviews</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> psychology</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Smoke</style></keyword><keyword><style face="normal" font="default"> socioeconomic status</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="30" Month="9" Year="2016">2016/9/30</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The objective of this study was to investigate 2 key dimensions of socioeconomic status (SES)-prestige and resources-and their associations with immune, behavioral, and clinical outcomes in childhood asthma. METHODS: Children ages 9 to 17 years with a physician's diagnosis of asthma (N = 150), and one of their parents participated in this study. Children and parents completed interviews and questionnaires about SES (prestige = parent education; resources = family assets), environmental exposures, and clinical asthma measures. Spirometry was conducted to assess children's pulmonary function, and blood was collected to measure cytokine production in response to nonspecific stimulation, allergen-specific stimulation, and microbial stimulation. RESULTS: Higher scores on both dimensions of childhood SES were associated with better clinical outcomes in children (beta's from |.18 to .27|, p values &lt; .05). Higher prestige, but not resources, was associated with better home environment control behaviors and less exposure to smoke (beta's from |.21 to .22|, p values &lt; .05). Higher resources, but not prestige, was associated with more favorable immune regulation, as manifest in smaller peripheral blood mononuclear cell (PBMC) TH1 and TH2 cytokine responses (beta's from -.18 to -.19; p values &lt; .05), and smaller proinflammatory cytokine responses (beta = -.19; p &lt; .05) after ex vivo stimulation. Higher resources also were associated with more sensitivity to glucocorticoid inhibition of TH1 and TH2 cytokine production (beta's from -.18 to -.22; p values &lt; .05). CONCLUSIONS: These results suggest that prestige and resources in childhood family environments have different implications for behavioral and immunological processes relevant to childhood asthma. They also suggest that childhood SES relates to multiple aspects of immunologic regulation of relevance to the pathophysiology of asthma</style></abstract><notes><style face="normal" font="default">DA - 20161017IS - 1534-7796 (Electronic)IS - 0033-3174 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/PSY.0000000000000392</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27749682">PM:27749682</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Psychosom Med\2016-78-1043-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Psychosom Med\2016-78-1043-52.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161017, Chen E</style></custom2><misc3><style face="normal" font="default">10.1097/PSY.0000000000000392</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40791</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tomfohr-Madsen,L.M.</style></author><author><style face="normal" font="default"> Bayrampour,H.</style></author><author><style face="normal" font="default"> Tough,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Department of Psychology (Tomfohr-Madsen), University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute for Child and Maternal Health (ACHRI) (Tomfohr-Madsen), Calgary, Alberta, Canada; Department of Pediatrics (Tomfohr-Madsen, Tough), Alberta Children's Hospital, Calgary, Alberta, Canada; Department of Family Practice (Bayrampour), University of British Columbia, Vancouver, British Columbia, Canada; Community Health Sciences (Tough), University of Calgary, Calgary, Alberta, Canada</style></auth-address><titles><title><style face="normal" font="default">Maternal History of Childhood Abuse and Risk of Asthma and Allergy in 2-Year-Old Children</style></title><secondary-title><style face="normal" font="default">Psychosom Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Psychosom Med</style></abbr-1></periodical><pages end="1042" start="1031">1031-1042</pages><volume><style face="normal" font="default">78</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> British Columbia</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child Abuse</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Columbia</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Family Practice</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Maternal Exposure</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> psychology</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Exposure to child abuse (CA) is associated with an increased risk of developing asthma and allergies; it is unknown if that risk is present across generations. This study investigated if 2-year-old children born to mothers with a history of CA were at an increased risk of receiving a diagnosis of asthma or allergies. METHODS: Data from 1,551 participants were collected as part of the All Our Babies (AOB) study, a prospective pregnancy cohort. During pregnancy, each woman provided information about her own history of CA, and at 24 months postpartum, she provided information about her child's medical diagnoses. Symptoms of maternal depression and anxiety were assessed during pregnancy and at 24 months postpartum. RESULTS: Unadjusted models showed that compared to children born to mothers without a history of CA, 2-year-old children born to mothers with a history of CA were more likely to have had a diagnosis of asthma (7.4% vs 4.2%, p = .016) or allergy (15.6% vs 9.2%, p &lt; .001). Maternal symptoms of depression assessed in late pregnancy and symptoms of depression and anxiety at 24 months postpartum were significant mediators of the relationship between maternal CA and 2-year-old asthma diagnosis. Maternal symptoms of depression and anxiety assessed in late pregnancy were also significant mediators of the relationship between maternal CA and 2-year-old allergy diagnosis. CONCLUSIONS: The results indicate that maternal exposure to CA is associated with increased risk of asthma and allergy in their 2-year-old children; symptoms of maternal depression and anxiety were identified as pathways linking the variables</style></abstract><notes><style face="normal" font="default">DA - 20161020IS - 1534-7796 (Electronic)IS - 0033-3174 (Linking)LA - ENGPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1097/PSY.0000000000000419</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27763990">PM:27763990</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Psychosom Med\2016-78-1031-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Psychosom Med\2016-78-1031-42.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161020,</style></custom2><misc3><style face="normal" font="default">10.1097/PSY.0000000000000419</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40792</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Boudreau,M.</style></author><author><style face="normal" font="default"> Bacon,S.L.</style></author><author><style face="normal" font="default"> Paine,N.J.</style></author><author><style face="normal" font="default"> Cartier,A.</style></author><author><style face="normal" font="default"> Trutschnigg,B.</style></author><author><style face="normal" font="default"> Morizio,A.</style></author><author><style face="normal" font="default"> Lavoie,K.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Montreal Behavioural Medicine Centre, Hopital du Sacre-Coeur de Montreal, 5400 Gouin West, Montreal, Quebec, H4J 1C5, Canada 2 Department of Psychology, University of Quebec at Montreal (UQAM), 100 Sherbrooke West, Montreal, Quebec, H3C 3P8, Canada 3 Department of Exercise Science, Concordia University, 7141 Sherbrooke St. West, Montreal, Quebec, H4B 1R6, Canada 4 Research Center, Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada</style></auth-address><titles><title><style face="normal" font="default">Impact of panic attacks on bronchoconstriction and subjective distress in asthma patients with and without panic disorder</style></title><secondary-title><style face="normal" font="default">Psychosom Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Psychosom Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Dioxide</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Hyperventilation</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Panic Disorder</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> psychology</style></keyword><keyword><style face="normal" font="default"> Quebec</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Tidal Volume</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Ventilation</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="12" Year="2016">2016/12/28</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Panic disorder (PD) is common among asthmatics and is associated with worse asthma outcomes. This may occur due to psychophysiological factors or to cognitive/affective factors. This study evaluated the impact of panic attacks (PAs) on bronchoconstriction and subjective distress in asthmatics with and without PD. METHODS: A total of 25 asthmatics (15 with PD who had a PA [PD/PA], 10 without PD who didn't have a PA [noPD/noPA]) were recruited from an outpatient clinic. They underwent a panic challenge (one vital capacity inhalation of 35% carbon dioxide [CO2]) and completed the Panic Symptom Scale (PSS), the Subjective Distress Visual Analogue Scale (SD-VAS) and the Borg Scale before and after CO2. Forced expiratory volume in one second (FEV1) was assessed pre and post CO2; respiratory (i.e., CO2 production [VCO2], minute ventilation [VE], tidal volume [VT]) were continuously recorded, and physiological measures (i.e., systolic and diastolic blood pressure [SBP/DBP]), every two minutes. RESULTS: Analyses adjusting for age, sex, and provocative concentration of methacholine revealed no significant differences between groups in FEV1 change after CO2 inhalation (F(1, 23)&lt;0.01, p=.961). However, PD/PA patients reported more panic (F(1, 22)=18.10, p&lt;.001), anxiety (F(1, 22)=21.93, p&lt;.001), worry (F(1, 22)=26.31, p&lt;.001) and dyspnea (F(1,22)=4.68, p=.042), and exhibited higher levels of VCO2 (F(1, 2843)=5.89, p=.015), VE (F(1, 2844) =4.48, p=.034), and VT (F (1, 2844) 4.62, p=.032) after the CO2 challenge, compared to noPD/noPA patients. CONCLUSIONS: Results, presented as hypothesis generating, suggest that asthmatics with PD/PA exhibit increased panic-like anxiety, breathlessness and a respiratory pattern consistent with hyperventilation that was not linked to statistically significant drops in bronchoconstriction</style></abstract><notes><style face="normal" font="default">DA - 20161229IS - 1534-7796 (Electronic)IS - 0033-3174 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1097/PSY.0000000000000443</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28033197">PM:28033197</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Psychosom Med\20161229-BoudreauM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Psychosom Med\20161229-BoudreauM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161229, Boudreau M</style></custom2><misc3><style face="normal" font="default">10.1097/PSY.0000000000000443</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40793</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brusselle,G.</style></author><author><style face="normal" font="default"> Germinaro,M.</style></author><author><style face="normal" font="default"> Weiss,S.</style></author><author><style face="normal" font="default"> Zangrilli,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.</style></auth-address><titles><title><style face="normal" font="default">Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils</style></title><secondary-title><style face="normal" font="default">Pulm Pharmacol Ther</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pulm Pharmacol Ther</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic asthma</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="default"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient-reported outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> reslizumab</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="31" Month="1" Year="2017">2017/1/31</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Asthma with adult onset and elevated blood eosinophils is a difficult-to-treat subgroup. This post hoc analysis evaluated reslizumab, an anti-interleukin-5 monoclonal antibody, in patients with late-onset eosinophilic asthma. METHODS: Data from two 52-week placebo-controlled trials of reslizumab IV 3 mg/kg every 4 weeks in patients aged 12-75 years with inadequately controlled asthma, >/=1 asthma exacerbation within 12 months, and screening blood eosinophils >/=400/muL (NCT01287039/NCT01285323) were stratified by age of asthma onset (&lt;40 or >/=40 years). Annual clinical asthma exacerbation rates, change in lung function, and patient-reported outcomes were analyzed. RESULTS: 273 patients with late-onset asthma (placebo, n = 130; reslizumab, n = 143) and 658 with early-onset asthma (placebo, n = 336; reslizumab, n = 322) were included. Baseline demographics were similar between groups. The interaction between age at onset of asthma and effect of reslizumab on asthma exacerbations was statistically significant (p = 0.0083). Compared with placebo, reslizumab produced a 75% relative reduction in asthma exacerbations in patients with late-onset asthma (rate ratio [RR] 0.25; 95% confidence interval [CI], 0.16, 0.40), substantially larger than the reduction in earlier onset patients (RR 0.58; 95% CI, 0.44, 0.76). Similar findings were observed for other measures of asthma, including forced expiratory volume in 1 s (FEV1). The adverse event profile of reslizumab was similar in patients with early- or late-onset asthma. CONCLUSIONS: Compared with placebo, reslizumab produced larger reductions in asthma exacerbations and larger improvements in lung function in patients with late versus early-onset asthma</style></abstract><notes><style face="normal" font="default">DA - 20170204IS - 1522-9629 (Electronic)IS - 1094-5539 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Israel -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.pupt.2017.01.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28159511">PM:28159511</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pulm Pharmacol Ther\20170204-BrusselleG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pulm Pharmacol Ther\20170204-BrusselleG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, Brusselle G</style></custom2><misc3><style face="normal" font="default">10.1016/j.pupt.2017.01.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40794</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gonzalez-Freire,B.</style></author><author><style face="normal" font="default"> Vazquez,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Private Psychological Practice Beatriz Gonzalez Freire. Psicologa, Ourense, Spain</style></auth-address><titles><title><style face="normal" font="default">Quality of life in adults with asthma treated in allergy and pneumology subspecialties: relationship with sociodemographic, clinical and psychological variables</style></title><secondary-title><style face="normal" font="default">Qual Life Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Qual Life Res</style></abbr-1></periodical><pages end="645" start="635">635-645</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Absenteeism</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Employment</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Outpatients</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">PURPOSE: Prior studies suggest that specialist care associates with improved health-related quality of life (HRQL) in asthmatic patients. However, there are limited studies focused on differences in HRQL among subspecialties. The aim of this study was to assess the differences in HRQL between adult asthmatic patients treated in pneumology or allergy practices, and to estimate to what extent the differences in HRQL can be explained by sociodemographic, clinical or psychological characteristics of patients from each specialty. METHODS: We recruited adult asthmatic outpatients from allergy and pneumology practices. Information on sociodemographic, clinical and psychological characteristics was collected, and HRQL was assessed with generic and disease-specific questionnaires. HRQL was compared between groups adjusting for sociodemographic, clinical and psychological characteristics. RESULTS: A total of 287 asthmatic patients participated in the study (105 from pneumology and 182 from allergy). Patients treated by pneumologists reported significantly poorer HRQL in physical dimensions of generic questionnaire and all dimensions of disease-specific questionnaire. Pneumology patients were older (p &lt; .001) and had a lower education level (p &lt; .001); a higher number of patients were in a non-active employment situation (p = .003) and had worse pulmonary function (p &lt; .001), longer duration of disease (p = .020), higher prevalence of obesity (p &lt; .001) and uncontrolled asthma (p &lt; .001), and a higher rate of previous absenteeism (p = .001). Depression and the use of cognitive avoidance coping were also higher among pneumology patients (p = .050 and p = .022, respectively). There were not significant differences in HRQL between pneumology and allergy patients after adjustment for these sociodemographic, clinical and psychological characteristics. CONCLUSIONS: Asthmatic patients treated by pneumologists reported poorer HRQL than patients treated by allergists, but this outcome is attributed to differences in several sociodemographic, clinical and psychological characteristics between the two groups of patients</style></abstract><notes><style face="normal" font="default">DA - 20161228IS - 1573-2649 (Electronic)IS - 0962-9343 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1007/s11136-016-1486-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28028697">PM:28028697</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Qual Life Res\2017-26-635-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Qual Life Res\2017-26-635-45.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161228, Gonzalez-Freire B</style></custom2><misc3><style face="normal" font="default">10.1007/s11136-016-1486-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40795</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Davenport,M.S.</style></author><author><style face="normal" font="default"> Cohan,R.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">The Evidence for and Against Corticosteroid Prophylaxis in At-Risk Patients</style></title><secondary-title><style face="normal" font="default">Radiol Clin North Am</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Radiol Clin North Am</style></abbr-1></periodical><pages end="421" start="413">413-421</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergiclike reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Contrast material</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroid prophylaxis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Premedication</style></keyword><keyword><style face="normal" font="default"> Pretreatment</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Steroid preparation</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><isbn><style face="normal" font="default">0033-8389</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">http://dx.doi.org/10.1016/j.rcl.2016.10.012</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.rcl.2016.10.012</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Radiol Clin North Am\2017-55-413-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Radiol Clin North Am\2017-55-413-21.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170304, Davenport MS</style></custom2><misc3><style face="normal" font="default">http://dx.doi.org/10.1016/j.rcl.2016.10.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40796</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Scheinfeld,M.H.</style></author><author><style face="normal" font="default"> Dym,R.J.</style></author><author><style face="normal" font="default"> Sprayregen,S.</style></author><author><style face="normal" font="default"> Jerschow,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiology, Division of Emergency Radiology</style></auth-address><titles><title><style face="normal" font="default">Allergic Status Is a Confounder for Inpatient Length of Stay and Outcome Analysis</style></title><secondary-title><style face="normal" font="default">Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Radiology</style></full-title></periodical><pages end="650" start="649">649-650</pages><volume><style face="normal" font="default">281</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Length of Stay</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Radiology</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161018IS - 1527-1315 (Electronic)IS - 0033-8419 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="default">10.1148/radiol.2016161116</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27755939">PM:27755939</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Radiology\2016-281-649-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Radiology\2016-281-649-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161018, Scheinfeld MH</style></custom2><misc3><style face="normal" font="default">10.1148/radiol.2016161116</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40797</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nazila,A.</style></author><author><style face="normal" font="default"> Reza,F.</style></author><author><style face="normal" font="default"> Fahimeh,S.</style></author><author><style face="normal" font="default"> Mohamad,S.</style></author><author><style face="normal" font="default"> Farahzad,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</style></auth-address><titles><title><style face="normal" font="default">Trace Elements Status in Sera of Patients with Allergic Asthma</style></title><secondary-title><style face="normal" font="default">Rep Biochem Mol Biol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Rep Biochem Mol Biol</style></abbr-1></periodical><pages end="25" start="20">20-25</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Copper</style></keyword><keyword><style face="normal" font="default"> Data Collection</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Selenium</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Trace Elements</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Zinc</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is a multifactorial disease and its severity varies with the inflammatory grade. There are conflicting reports about the roles of trace elements in asthma. This study examined the effects of zinc (Zn), copper (Cu), and selenium (Se) concentrations in sera of patients with allergic asthma attending Ghaem Hospital, Mashhad, Iran. METHODS: Forty-nine patients, aged 10 to 50 years, with asthma in moderate or severe stages, and 24 healthy controls, were enrolled in this study. After demographic data collection and clinical evaluations, the subjects' serum concentrations of Zn, Cu, and Se were measured via atomic absorbency. RESULTS: Mean serum levels of Zn and Se in patients with allergic asthma were lower than in the healthy control group, but the Cu concentration in sera of patients with allergic asthma was slightly higher than healthy controls. CONCLUSION: Low levels of trace elements, specifically Zn, may have a role in the pathogenesis of allergic asthma; replacement of these elements may be an effective treatment</style></abstract><notes><style face="normal" font="default">DA - 20170110IS - 2322-3480 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28070530">PM:28070530</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rep Biochem Mol Biol\2016-5-20-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rep Biochem Mol Biol\2016-5-20-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170110, Nazila A</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40798</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Movin,M.</style></author><author><style face="normal" font="default"> Garden,F.L.</style></author><author><style face="normal" font="default"> Protudjer,J.L.</style></author><author><style face="normal" font="default"> Ullemar,V.</style></author><author><style face="normal" font="default"> Svensdotter,F.</style></author><author><style face="normal" font="default"> Andersson,D.</style></author><author><style face="normal" font="default"> Kruse,A.</style></author><author><style face="normal" font="default"> Cowell,C.T.</style></author><author><style face="normal" font="default"> Toelle,B.G.</style></author><author><style face="normal" font="default"> Marks,G.B.</style></author><author><style face="normal" font="default"> Almqvist,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default">Impact of childhood asthma on growth trajectories in early adolescence: Findings from the Childhood Asthma Prevention Study (CAPS)</style></title><secondary-title><style face="normal" font="default">Respirology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respirology</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescence</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Puberty</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Trajectory</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="8" Month="11" Year="2016">2016/11/8</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVE: Understanding the associations between childhood asthma and growth in early adolescence by accounting for the heterogeneity of growth during puberty has been largely unexplored. The objective was to identify sex-specific classes of growth trajectories during early adolescence, using a method which takes the heterogeneity of growth into account and to evaluate the association between childhood asthma and different classes of growth trajectories in adolescence. METHODS: Our longitudinal study included participants with a family history of asthma born during 1997-1999 in Sydney, Australia. Hence, all participants were at high risk for asthma. Asthma status was ascertained at 8 years of age using data from questionnaires and lung function tests. Growth trajectories between 11 and 14 years of age were classified using a latent basis growth mixture model. Multinomial regression analyses were used to evaluate the association between asthma and the categorized classes of growth trajectories. RESULTS: In total, 316 participants (51.6% boys), representing 51.3% of the entire cohort, were included. Sex-specific classes of growth trajectories were defined. Among boys, asthma was not associated with the classes of growth trajectories. Girls with asthma were more likely than girls without asthma to belong to a class with later growth (OR: 3.79, 95% CI: 1.33, 10.84). Excluding participants using inhaled corticosteroids or adjusting for confounders did not significantly change the results for either sex. CONCLUSION: We identified sex-specific heterogeneous classes of growth using growth mixture modelling. Associations between childhood asthma and different classes of growth trajectories were found for girls only</style></abstract><notes><style face="normal" font="default">DA - 20161118IS - 1440-1843 (Electronic)IS - 1323-7799 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/resp.12928</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27859946">PM:27859946</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respirology\20161118-MovinM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respirology\20161118-MovinM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161118, Movin M</style></custom2><misc3><style face="normal" font="default">10.1111/resp.12928</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40799</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nguyen,H.V.</style></author><author><style face="normal" font="default"> Nadkarni,N.V.</style></author><author><style face="normal" font="default"> Sankari,U.</style></author><author><style face="normal" font="default"> Mital,S.</style></author><author><style face="normal" font="default"> Lye,W.K.</style></author><author><style face="normal" font="default"> Tan,N.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Pharmacy, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada</style></auth-address><titles><title><style face="normal" font="default">Association between asthma control and asthma cost: Results from a longitudinal study in a primary care setting</style></title><secondary-title><style face="normal" font="default">Respirology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respirology</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> ACT Score</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Newfoundland</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="10" Month="11" Year="2016">2016/11/10</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVE: Asthma control can be assessed with the Asthma Control Test (ACT) and a score of 20 or higher indicates good asthma control. Patients pay for their consultation and treatment in the fee-for-service primary healthcare system in Singapore. We hypothesized that achieving asthma control would result in lower asthma costs through reduced acute exacerbations, fewer physician consultations and lower lost productivity. The study compared the healthcare costs of patients who achieved asthma control and those with suboptimal asthma control based on ACT scores. Factors influencing asthma control and healthcare expenditure over time were also examined. METHODS: A total of 736 patients were enrolled into an asthma care programme in two polyclinics during 2008 and 2013. Direct costs of asthma management were derived from the frequency of polyclinic consultations, medication costs and hospitalization. Indirect costs were estimated from lost workdays due to exacerbations. The generalized estimating equation (GEE) approach was used to longitudinally model the factors associated with total healthcare expenditure. RESULTS: Patients with asthma control spent S$48 (US$36) more per doctor visit on asthma drugs (P &lt; 0.01) but incurred S$65 (US$48) less per doctor visit in total costs (P &lt; 0.01) than those with suboptimal asthma control. The savings from achieving asthma control for obese patients were greater than for normal-weight patients (S$42 or the equivalent of US$31; P &lt; 0.05). CONCLUSION: Optimal asthma control was associated with reduced healthcare costs. An effective treatment regimen should also consider other modifiable factors such as weight control to achieve asthma control and eventually reduce asthma costs</style></abstract><notes><style face="normal" font="default">DA - 20161118IS - 1440-1843 (Electronic)IS - 1323-7799 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1111/resp.12930</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27862645">PM:27862645</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respirology\20161118-NguyenHV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respirology\20161118-NguyenHV.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161118, Nguyen HV</style></custom2><misc3><style face="normal" font="default">10.1111/resp.12930</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40800</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Choi,H.</style></author><author><style face="normal" font="default"> Song,W.M.</style></author><author><style face="normal" font="default"> Zhang,B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Linking childhood allergic asthma phenotypes with endotype through integrated systems biology: current evidence and research needs</style></title><secondary-title><style face="normal" font="default">Rev Environ Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Rev Environ Health</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Apoptosis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Cell Cycle</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> subtypes</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword></keywords><dates><year Day="7" Month="2" Year="2017">2017/2/7</year></dates><abstract><style face="normal" font="default">Asthma and other complex diseases results from a complex web of interactions involving inflammation, immunity, cell cycle, apoptosis, and metabolic perturbations across multiple organ systems. The extent to which various degrees of the age at onset, symptom severity, and the natural progression of the disease reflect multiple disease subtypes, influenced by unique process of development remains unknown. One of the most critical challenges to our understanding stems from incomplete understanding of the mechanisms. Within this review, we focus on the phenotypes of childhood allergic asthma as the basis to better understand the endotype for quantitative define subtypes of asthma. We highlight some of the known mechanistic pathways associated with the key hallmark events before the asthma onset. In particular, we examine how the recent advent of multiaxial -omics technologies and systems biology could help to clarify our current understanding of the pathway. We review how a large volume of molecular, genomic data generated by multiaxial technologies could be digested to identify cogent pathophysiologic molecular networks. We highlight some recent successes in application of these technologies within the context of other disease conditions for therapeutic interventions. We conclude by summarizing the research needs for the predictive value of preclinical biomarkers</style></abstract><notes><style face="normal" font="default">DA - 20170207IS - 2191-0308 (Electronic)IS - 0048-7554 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1515/reveh-2016-0054</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28170342">PM:28170342</url></web-urls><related-urls><url ppv-ref="no">presto - 6 mesi</url></related-urls></urls><custom2><style face="normal" font="default">20170207, Choi H</style></custom2><misc3><style face="normal" font="default">10.1515/reveh-2016-0054</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40801</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">del Cuvillo,A.</style></author><author><style face="normal" font="default"> Santos,V.</style></author><author><style face="normal" font="default"> Montoro,J.</style></author><author><style face="normal" font="default"> Bartra,J.</style></author><author><style face="normal" font="default"> Davila,I.</style></author><author><style face="normal" font="default"> Ferrer,M.</style></author><author><style face="normal" font="default"> Jauregui,I.</style></author><author><style face="normal" font="default"> Sastre,J.</style></author><author><style face="normal" font="default"> Mullol,J.</style></author><author><style face="normal" font="default"> Valero,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Unidad de Rinologia y asma, UGC ORL Hospital de Jerez del Servicio Andaluz de Salud, Cadiz, Spain</style></auth-address><titles><title><style face="normal" font="default">Allergic rhinitis severity can be assessed using a visual analogue scale in mild, moderate and severe</style></title><secondary-title><style face="normal" font="default">Rhinology</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Rhinology</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> ARIA</style></keyword><keyword><style face="normal" font="default"> Asma</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Predictive values</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> VAS</style></keyword></keywords><dates><year Day="26" Month="12" Year="2016">2016/12/26</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic rhinitis is a global healthcare problem due to its high prevalence, impact on individuals and socioeconomic burden for the nations. Allergic rhinitis severity evaluation is the key to a correct treatment, prevention of comorbidities and improving the quality of life of patients. This evaluation should be made with a simple, easy, fast but accurate and reliable methodology, both in a primary care and specialist setting. The visual analogue scale (VAS) meets all requirements to be the ideal tool to assess allergic rhinitis severity and has already been validated by using a single cut-off point, but this classification in two degrees of severity suffer from not allocating the patients uniformly and from giving a blind interval to classify the patients when the score is between 5 to 6 cm. METHODOLOGY: The main objective of our study is to describe the optimal cut-off points by using a VAS to discriminate between three degrees of allergic rhinitis severity (mild, moderate, and severe) following the ARIA modified severity criteria that has been previously validated. Sensitivity, specificity, positive and negative predictive values just like receiver operating characteristic curves were used to select the best cut-off values. RESULTS: In a cross-sectional multicentre study with 3,572 patients included we have found that VAS has a significant correlation with nasal symptom score and quality of life and that the best cut-off points to differentiate between mild, moderate an severe allergic rhinitis are a VAS score of 4 and 7, respectively. CONCLUSIONS: Allergic rhinitis severity could be assessed in three degrees by using VAS in a simple, easy, and accurate method</style></abstract><notes><style face="normal" font="default">DA - 20161226IS - 0300-0729 (Print)IS - 0300-0729 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.4193/Rhin16.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28019644">PM:28019644</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20161226, Del Cuvillo A</style></custom2><misc3><style face="normal" font="default">10.4193/Rhin16.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40802</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Malmhall,C.</style></author><author><style face="normal" font="default"> Johansson,K.</style></author><author><style face="normal" font="default"> Winkler,C.</style></author><author><style face="normal" font="default"> Alawieh,S.</style></author><author><style face="normal" font="default"> Ekerljung,L.</style></author><author><style face="normal" font="default"> Radinger,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden</style></auth-address><titles><title><style face="normal" font="default">Altered miR-155 expression in Allergic Asthmatic airways</style></title><secondary-title><style face="normal" font="default">Scand J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Scand J Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal model</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Culture Media</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> induced sputum</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> MicroRNAs</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> PBMCs</style></keyword><keyword><style face="normal" font="default"> Pollen</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rna</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> subtypes</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="15" Month="2" Year="2017">2017/2/15</year></dates><abstract><style face="normal" font="default">MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression at posttranscriptional level. We and others have previously identified miRNAs with pathological roles in animal models of asthma. To date, few studies have investigated miRNA expression in human asthmatics and miRNA expression in specific cellular subtypes in asthmatics is largely unexplored. Therefore, the aim of this study was to assess miR-146a and miR-155 expression in airways- and blood-derived samples, two miRNA candidates which have previously been described to play important roles in inflammatory processes. Induced sputum and blood were obtained from allergic asthmatics and healthy controls. In the current study, significantly lower levels of miR-155 were detected in cell-free sputum from allergic asthmatics compared to healthy controls. Induced sputum isolated from allergic asthmatics in and out of pollen season revealed that miR-155 expression, but not miR-146a, is reduced in lymphocytes in season compared to post-season. In contrast, miR-155 was found to increase whereas miR-146a decreased in PBMCs and cell-free PBMC culture media upon T cell receptor stimulation via alphaCD3/CD28 both in allergic asthmatics and healthy controls. Our findings suggest that miR-155 is differentially expressed ex vivo in airways in allergic asthmatics compared to healthy controls, which may have implications in the local immune response in allergic asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170215IS - 1365-3083 (Electronic)IS - 0300-9475 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/sji.12535</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28199728">PM:28199728</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Scand J Immunol\20170215-MalmhallC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Scand J Immunol\20170215-MalmhallC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170215, Malmhall C</style></custom2><misc3><style face="normal" font="default">10.1111/sji.12535</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40803</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nakatsuji,T.</style></author><author><style face="normal" font="default"> Chen,T.H.</style></author><author><style face="normal" font="default"> Narala,S.</style></author><author><style face="normal" font="default"> Chun,K.A.</style></author><author><style face="normal" font="default"> Two,A.M.</style></author><author><style face="normal" font="default"> Yun,T.</style></author><author><style face="normal" font="default"> Shafiq,F.</style></author><author><style face="normal" font="default"> Kotol,P.F.</style></author><author><style face="normal" font="default"> Bouslimani,A.</style></author><author><style face="normal" font="default"> Melnik,A.V.</style></author><author><style face="normal" font="default"> Latif,H.</style></author><author><style face="normal" font="default"> Kim,J.N.</style></author><author><style face="normal" font="default"> Lockhart,A.</style></author><author><style face="normal" font="default"> Artis,K.</style></author><author><style face="normal" font="default"> David,G.</style></author><author><style face="normal" font="default"> Taylor,P.</style></author><author><style face="normal" font="default"> Streib,J.</style></author><author><style face="normal" font="default"> Dorrestein,P.C.</style></author><author><style face="normal" font="default"> Grier,A.</style></author><author><style face="normal" font="default"> Gill,S.R.</style></author><author><style face="normal" font="default"> Zengler,K.</style></author><author><style face="normal" font="default"> Hata,T.R.</style></author><author><style face="normal" font="default"> Leung,D.Y.</style></author><author><style face="normal" font="default"> Gallo,R.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of California, San Diego, La Jolla, CA 92092, USA</style></auth-address><titles><title><style face="normal" font="default">Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Sci Transl Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Transl Med</style></abbr-1></periodical><pages end="" start="eaah4680">eaah4680-</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">378</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adaptive</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antimicrobials</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> host defense</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human health</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> peptide</style></keyword><keyword><style face="normal" font="default"> Peptides</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Staphylococcus</style></keyword><keyword><style face="normal" font="default"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="default">The microbiome can promote or disrupt human health by influencing both adaptive and innate immune functions. We tested whether bacteria that normally reside on human skin participate in host defense by killing Staphylococcus aureus, a pathogen commonly found in patients with atopic dermatitis (AD) and an important factor that exacerbates this disease. High-throughput screening for antimicrobial activity against S. aureus was performed on isolates of coagulase-negative Staphylococcus (CoNS) collected from the skin of healthy and AD subjects. CoNS strains with antimicrobial activity were common on the normal population but rare on AD subjects. A low frequency of strains with antimicrobial activity correlated with colonization by S. aureus The antimicrobial activity was identified as previously unknown antimicrobial peptides (AMPs) produced by CoNS species including Staphylococcus epidermidis and Staphylococcus hominis These AMPs were strain-specific, highly potent, selectively killed S. aureus, and synergized with the human AMP LL-37. Application of these CoNS strains to mice confirmed their defense function in vivo relative to application of nonactive strains. Strikingly, reintroduction of antimicrobial CoNS strains to human subjects with AD decreased colonization by S. aureus These findings show how commensal skin bacteria protect against pathogens and demonstrate how dysbiosis of the skin microbiome can lead to disease</style></abstract><notes><style face="normal" font="default">DA - 20170223IS - 1946-6242 (Electronic)IS - 1946-6234 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1126/scitranslmed.aah4680</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28228596">PM:28228596</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Transl Med\2017-9-eaah4680.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Transl Med\2017-9-eaah4680.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170223, Nakatsuji T</style></custom2><misc3><style face="normal" font="default">10.1126/scitranslmed.aah4680</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40804</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stallings,A.</style></author><author><style face="normal" font="default"> Sood,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cleveland Clinic Dermatology and Plastic Surgery Institute, Cleveland, Ohio, USA</style></auth-address><titles><title><style face="normal" font="default">Hair-care practices in African American women: potential for allergic contact dermatitis</style></title><secondary-title><style face="normal" font="default">Semin Cutan Med Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Semin Cutan Med Surg</style></abbr-1></periodical><pages end="210" start="207">207-210</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">African American</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Beauty</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Delayed hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hair</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Ohio</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">Allergic contact dermatitis (ACD) is a delayed hypersensitivity reaction that occurs when the skin is re-exposed to a substance to which it was previously sensitized. One significant source of exposure to sensitizing chemicals is through personal grooming and beauty products. While the role of cosmetics and hair-care products in the development of ACD is well-documented, there has been very little literature that specifically addresses the role of hair-care practices of patients with tightly curled hair, such as in patients of African descent, in the development of ACD in this population. This review provides an integrated summary of the hair-care practices of female African American patients and the potential for exposure to sensitizing agents at each stage. This review will also discuss the challenges faced in recognizing and assessing ACD in these patients</style></abstract><notes><style face="normal" font="default">DA - 20161205IS - 1085-5629 (Print)IS - 1085-5629 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.12788/j.sder.2016.058</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27918002">PM:27918002</url></web-urls></urls><custom2><style face="normal" font="default">20161205, Stallings A</style></custom2><misc3><style face="normal" font="default">10.12788/j.sder.2016.058</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40805</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shoji,M.</style></author><author><style face="normal" font="default"> Shoji,J.</style></author><author><style face="normal" font="default"> Inada,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Division of Ophthalmology, Department of Visual Sciences , Nihon University School of Medicine , Tokyo , Japan</style></auth-address><titles><title><style face="normal" font="default">Clinical Severity and Tear Biomarkers, Eosinophil Cationic Protein and CCL23, in Chronic Allergic Conjunctival Diseases</style></title><secondary-title><style face="normal" font="default">Semin Ophthalmol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Semin Ophthalmol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> cationic protein</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Conjunctival Diseases</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> ECP</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Immunoassay</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Keratoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Ophthalmology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Tears</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vernal keratoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="8" Month="12" Year="2016">2016/12/8</year></dates><abstract><style face="normal" font="default">PURPOSE: To evaluate the relationship between clinical severity and tear levels of eosinophil cationic protein (ECP) and CC chemokine ligand 23 (CCL23) in patients with chronic allergic conjunctival disease (cACD). SUBJECTS AND METHODS: This clinical study included 21 patients with cACD, including atopic keratoconjunctivitis and vernal keratoconjunctivitis, and 14 subjects as controls. The clinical severity score was determined by objective findings. Tear ECP grade was evaluated using tear ECP levels determined by enzyme immunoassay. CCL23 expression in tears was also determined by enzyme immunoassay. RESULTS: In the cACD group, tear ECP grade was significantly correlated with the clinical severity score. Clinical severity scores and tear ECP grades in the CCL23-positive subgroup were significantly higher than those in the CCL23-negative subgroup. CONCLUSION: We have confirmed the value of tear ECP grade and CCL23 expression in tears as a severity grading system in patients with cACD</style></abstract><notes><style face="normal" font="default">DA - 20161208IS - 1744-5205 (Electronic)IS - 0882-0538 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1080/08820538.2016.1238097</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27929738">PM:27929738</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Semin Ophthalmol\20161208-ShojiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Semin Ophthalmol\20161208-ShojiM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161208, Shoji M</style></custom2><misc3><style face="normal" font="default">10.1080/08820538.2016.1238097</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40806</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Meena,S.</style></author><author><style face="normal" font="default"> Garg,T.</style></author><author><style face="normal" font="default"> Chander,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Lady Hardinge Medical College and Associated Hospitals, New Delhi, India</style></auth-address><titles><title><style face="normal" font="default">Patch Testing in Children and Adolescents With Suspected Allergic Contact Dermatitis</style></title><secondary-title><style face="normal" font="default">Skinmed</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Skinmed</style></full-title></periodical><pages end="258" start="253">253-258</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact allergens</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Standard series</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Allergic contact dermatitis (ACD) in children is not uncommon. The reported rates of positive patch test in various series in children with suspected ACD varies from 32.6% to 67%. At present, patch testing is the only reliable test to identify various contact allergens in a suspected case of ACD. The aim of this study was to find out the common allergens responsible for ACD in children and adolescents. Patch testing was carried out with Indian Standard Series. Additional allergens were added wherever implicated from history. Seventy-four patients were recruited during the study period, of which analysis was performed in 70 patients. Thirty-eight (54.3%) patients had one or more positive patch test results. The most common allergen found to be positive was nickel sulfate. The clinically relevant reactions were found in 78.94% of patients. The relevance of positive patch test reactions were higher in children (3-9 years) compared with adolescents (10-19 years) and it was found to be statistically significant (P=.030). ACD is a significant health problem in children, compromising their quality of life, therefore age should not be a bar for performing patch testing to diagnose this clinical condition</style></abstract><notes><style face="normal" font="default">DA - 20161027IS - 1540-9740 (Print)IS - 1540-9740 (Linking)LA - ENGPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27784513">PM:27784513</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20161027, Meena S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40807</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kumaran,M.S.</style></author><author><style face="normal" font="default"> Narang,T.</style></author><author><style face="normal" font="default"> Parsad,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Venereology and Leprology, Post-Graduate Institute of Medical Sciences and Research, Chandigarh, India</style></auth-address><titles><title><style face="normal" font="default">Contact Urticaria With Paraphenylene Diamine, Rare or Underreported?</style></title><secondary-title><style face="normal" font="default">Skinmed</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Skinmed</style></full-title></periodical><pages end="390" start="389">389-390</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cetirizine</style></keyword><keyword><style face="normal" font="default"> Color</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact urticaria</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> Hair</style></keyword><keyword><style face="normal" font="default"> Hair Color</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hives</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Scalp</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> tablet</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wheal</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">A 45-year old woman presented with a 2-day history of intensely itchy, erythematous wheals over her scalp and around her eyes, ears, and front of the chest. She had applied hair color and immediately developed hives on the scalp, face, and chest with rhinitis and redness in the eyes. The lesions recovered within a half hour of taking a cetirizine 10-mg tablet. She gave a similar history around three times in the past 6 months. She used a different brand of hair color every time but all were associated with the same symptoms. In the first and second episodes, the itchy wheals were localized to the scalp, but in the present episode it was most severe with eye and nasal mucosal involvement and lesions spreading to involve the face, ears, and chest. There was no oozing or eczematization present. All episodes responded well to oral cetrizine</style></abstract><notes><style face="normal" font="default">DA - 20161122IS - 1540-9740 (Print)IS - 1540-9740 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27871357">PM:27871357</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20161122, Kumaran MS</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40808</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Varricchi,G.</style></author><author><style face="normal" font="default"> Bagnasco,D.</style></author><author><style face="normal" font="default"> Ferrando,M.</style></author><author><style face="normal" font="default"> Puggioni,F.</style></author><author><style face="normal" font="default"> Passalacqua,G.</style></author><author><style face="normal" font="default"> Canonica,G.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Translational Medical Sciences, Division of Clinical Immunology and Allergy, University of Naples Federico II, Naples, Italy</style></auth-address><titles><title><style face="normal" font="default">Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience</style></title><secondary-title><style face="normal" font="default">Ther Adv Respir Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ther Adv Respir Dis</style></abbr-1></periodical><pages end="45" start="40">40-45</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Bone Marrow</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic asthma</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Granulocyte-Macrophage Colony-Stimulating Factor</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-3</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate lymphoid cells</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Leukocytes</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> mepolizumab</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> progenitor cells</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Subunit</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> T-helper-2</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Eosinophils represent approximately 1% of peripheral blood leukocytes in normal donors and their maturation and differentiation in the bone marrow are mainly regulated by interleukin (IL)-5 [Broughton et al. 2015]. IL-5, a cytokine that belongs to the beta common-chain family, together with IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF), stimulates also the activation and survival of eosinophils and, to some extent, of basophils. IL-5 binds to a heterodimer receptor composed of the specific subunit IL-5Ralpha and a common subunit betac shared with IL-3 and GM-CSF. Human eosinophils express approximately a three-fold higher level of IL-5Ralpha compared with basophils. Major sources of IL-5 are T-helper 2 (Th2) cells, mast cells, CD34+ progenitor cells, invariant natural killer (NK) T-cells, group 2 innate lymphoid cells (ILC2s), and eosinophils themselves. ILC2s control not only eosinophil number but also their circadian cycling through the production of IL-5</style></abstract><notes><style face="normal" font="default">DA - 20161118IS - 1753-4666 (Electronic)IS - 1753-4658 (Linking)LA - engPT - ReviewPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1177/1753465816673303</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27856823">PM:27856823</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ther Adv Respir Dis\2017-11-40-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ther Adv Respir Dis\2017-11-40-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161118, Varricchi G</style></custom2><misc3><style face="normal" font="default">10.1177/1753465816673303</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40809</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,D.K.</style></author><author><style face="normal" font="default"> Jin,H.R.</style></author><author><style face="normal" font="default"> Eun,K.M.</style></author><author><style face="normal" font="default"> Mo,J.H.</style></author><author><style face="normal" font="default"> Cho,S.H.</style></author><author><style face="normal" font="default"> Oh,S.</style></author><author><style face="normal" font="default"> Cho,D.</style></author><author><style face="normal" font="default"> Kim,D.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology-Head and Neck Surgery, Chuncheon Sacred Heart Hospital and Nano-Bio Regenerative Medical Institute, Hallym University College of Medicine, Chuncheon, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">The role of interleukin-33 in chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default">Thorax</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Thorax</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Collagen</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-1</style></keyword><keyword><style face="normal" font="default"> IL-17A</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Interferon</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Interleukin-33</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH17</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="24" Month="11" Year="2016">2016/11/24</year></dates><abstract><style face="normal" font="default">RATIONALE: Interleukin (IL)-33, a new member of the IL-1 family, is constitutively expressed in epithelial tissues and lymphoid organs and plays an important role in the pathogenesis of allergic disease. However, the role of IL-33 in chronic rhinosinusitis with nasal polyps (CRSwNP) remains unclear. OBJECTIVE: To investigate the role of IL-33 in the pathophysiology of CRSwNP. METHODS: We investigated IL-33 expression and its cellular origins in the nasal polyps (NPs) of human subjects by immunohistochemistry (IHC), quantitative reverse transcription PCR (qRT-PCR), and multiplex cytokine assays. Correlations between IL-33 expression and other inflammatory markers were also explored. To investigate the role of IL-33 in CRSwNP, anti-IL-33 antibody was used in a murine model of CRS. RESULTS: Uncinate process tissues from control (19), CRSsNP (61), CRSwNP (69) and NP tissues (71) were used in this study. Increased expression of IL-33 mRNA and protein in patients with CRSwNP compared with controls was observed. The concentration of IL-33 protein in CRSwNP was positively correlated with the number of neutrophils and the expression of several Th1 and Th17 inflammatory markers, including interferon (IFN)-gamma, IL-1beta, tumour necrosis factor (TNF)-alpha, IL-17A, IL-22, and various markers for neutrophil recruitment. However, protein levels of IL-5 and quantity of eosinophils were inversely correlated with levels of IL-33. The expression of tissue inhibitor of metalloproteinase (TIMP)-1 was negatively correlated with IL-33 protein levels, while the expression of matrix metalloproteinase (MMP)-2 and MMP-9 was positively correlated with IL-33 protein levels. In animal studies, IL-33 expression was upregulated in the CRSwNP group compared with controls. Anti-IL-33 treatment reduced the thickness of oedematous mucosa, subepithelial collagen deposition, and infiltration of neutrophils, but infiltration of eosinophils was not reduced. This treatment also inhibited the expression of neutrophilic inflammatory cytokines, but not IL-4. In addition, the expression of intracellular adhesion molecule 1, vascular adhesion molecule 1 and CXCL-2 in the nasal mucosa was suppressed in mice treated with anti-IL-33 antibody. CONCLUSIONS: Our data suggest a role for IL-33 in the pathogenesis of CRSwNP via neutrophil recruitment. Therefore, anti-IL-33 may provide a new treatment strategy to target infiltrating neutrophils in CRSwNP</style></abstract><notes><style face="normal" font="default">DA - 20161125IS - 1468-3296 (Electronic)IS - 0040-6376 (Linking)LA - engPT - Journal ArticleCO - South Korea -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1136/thoraxjnl-2016-208772</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27885166">PM:27885166</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Thorax\20161125-KimDK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Thorax\20161125-KimDK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161125, Kim DK</style></custom2><misc3><style face="normal" font="default">10.1136/thoraxjnl-2016-208772</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40810</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Moore,V.C.</style></author><author><style face="normal" font="default"> Burge,P.S.</style></author><author><style face="normal" font="default"> Robertson,A.S.</style></author><author><style face="normal" font="default"> Walters,G.I.</style></author></authors></contributors><titles><title><style face="normal" font="default">What causes occupational asthma in cleaners?</style></title><secondary-title><style face="normal" font="default">Thorax</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Thorax</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> occupational asthma</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="16" Month="1" Year="2017">2017/1/16</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1468-3296 (Electronic)IS - 0040-6376 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1136/thoraxjnl-2016-209228</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28093530">PM:28093530</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Thorax\20170117-MooreVC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Thorax\20170117-MooreVC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Moore VC</style></custom2><misc3><style face="normal" font="default">10.1136/thoraxjnl-2016-209228</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40811</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Heshmatzadeh,B.A.</style></author><author><style face="normal" font="default"> Prince,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">*Department of Radiology, Weill Cornell Medical Center daggerDepartment of Radiology, Columbia College of Physicians and Surgeons, New York, NY</style></auth-address><titles><title><style face="normal" font="default">Preventing Allergic Reactions to Gadolinium-Based Contrast Agents</style></title><secondary-title><style face="normal" font="default">Top Magn Reson Imaging</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Top Magn Reson Imaging</style></abbr-1></periodical><pages end="279" start="275">275-279</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse events</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Columbia</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient Selection</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Premedication</style></keyword><keyword><style face="normal" font="default"> Radiology</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="29" Month="6" Year="2016">2016/6/29</year></dates><abstract><style face="normal" font="default">Although the low incidence of immediate-type gadolinium-based contrast agent (GBCA) allergic reactions is widely known, preventing these reactions and properly managing them to reduce their adverse sequel can improve the already exceedingly favorable GBCA safety profile. This review article should help those who order, supervise, or administer GBCA contrast agents, including recognizing and handling allergic reaction risks intrinsic to their use. Areas of focus include factors indicating increased allergic reaction risk, patient selection strategies, skin testing, premedication, and treatment of adverse events</style></abstract><notes><style face="normal" font="default">DA - 20161017IS - 1536-1004 (Electronic)IS - 0899-3459 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/RMR.0000000000000106</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27748715">PM:27748715</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Top Magn Reson Imaging\2016-25-275-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Top Magn Reson Imaging\2016-25-275-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161017, Heshmatzadeh BA</style></custom2><misc3><style face="normal" font="default">10.1097/RMR.0000000000000106</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40812</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Costello,J.R.</style></author><author><style face="normal" font="default"> Kalb,B.</style></author><author><style face="normal" font="default"> Martin,D.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Imaging, University of Arizona, Tucson, AZ</style></auth-address><titles><title><style face="normal" font="default">Incidence and Risk Factors for Gadolinium-Based Contrast Agent Immediate Reactions</style></title><secondary-title><style face="normal" font="default">Top Magn Reson Imaging</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Top Magn Reson Imaging</style></abbr-1></periodical><pages end="263" start="257">257-263</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse events</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Arizona</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> imaging</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> immediate reactions</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Nursing</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="29" Month="6" Year="2016">2016/6/29</year></dates><abstract><style face="normal" font="default">Since their clinical introduction in 1988, gadolinium-based contrast agents (GBCAs) have demonstrated an excellent safety profile with a reported acute adverse reaction rate ranging from 0.01% to 2%. By comparison, the acute adverse reaction rate of low osmolar nonionic computed tomography contrast agents (CTCs) ranges from 0.7% to 3.1%. Many of the risk factors associated with CTC reactions (drug allergies, asthma, atopy, prior contrast reaction) also point toward an increased incidence of acute adverse events to GBCAs. With CTCs, an increased adverse event rate was associated with ionic preparations and high osmolality. In response to concerns for nephrogenic systemic fibrosis, GBCAs are now selected for their augmented chemical stability. These agents possess some combination of macrocyclic chelates or ionic preparations. With their improved chemical stability, these agents also possess higher osmolality and the increased potential to elicit an acute adverse reaction. In light of these concerns, researchers are now focusing greater efforts on reexamining acute adverse reactions to GBCAs and whether there is an increased association with certain agents. In addition to hypersensitivity reactions, this article will also discuss contrast extravasations, safety of GBCAs for pregnant and nursing patients, and the potential nephrotoxic effects of GBCAs</style></abstract><notes><style face="normal" font="default">DA - 20161017IS - 1536-1004 (Electronic)IS - 0899-3459 (Linking)LA - ENGPT - JOURNAL ARTICLECO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/RMR.0000000000000109</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27748714">PM:27748714</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Top Magn Reson Imaging\2016-25-257-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Top Magn Reson Imaging\2016-25-257-63.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161017, Costello JR</style></custom2><misc3><style face="normal" font="default">10.1097/RMR.0000000000000109</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40813</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Harkema,J.R.</style></author><author><style face="normal" font="default"> Hotchkiss,L.A.</style></author><author><style face="normal" font="default"> Vetter,N.A.</style></author><author><style face="normal" font="default"> Jackson-Humbles,D.N.</style></author><author><style face="normal" font="default"> Lewandowski,R.P.</style></author><author><style face="normal" font="default"> Wagner,J.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Department of Pathobiology and Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA</style></auth-address><titles><title><style face="normal" font="default">Strain Differences in a Murine Model of Air Pollutant-induced Nonatopic Asthma and Rhinitis</style></title><secondary-title><style face="normal" font="default">Toxicol Pathol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Toxicol Pathol</style></full-title></periodical><pages end="171" start="161">161-171</pages><volume><style face="normal" font="default">45</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="default"> epithelia</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelium</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetic factors</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Metaplasia</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Michigan</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Mucus</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nonatopic asthma</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Ozone</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> veterinary</style></keyword><keyword><style face="normal" font="default"> Veterinary Medicine</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">Ozone is an irritating gas found in photochemical smog. Epidemiological associations have been made between the onset of asthma and childhood exposures to increasing levels of ambient ozone (i.e., air pollutant-induced nonatopic asthma). Individuals, however, vary in their susceptibility to this outdoor air pollutant, which may be due, in part, to their genetic makeup. The present study was designed to test the hypothesis that there are murine strain-dependent differences in pulmonary and nasal pathologic responses to repeated ozone exposures. C57BL/6NTac and BALB/cNTac mice were exposed to 0 or 0.8 ppm ozone, 4 hr/day, for 9 consecutive weekdays. In both strains of mice, ozone induced eosinophilic inflammation and mucous cell metaplasia in the nasal and pulmonary airways. Lungs of ozone-exposed C57BL/6NTac mice, however, had greater eosinophilic inflammation, mucous cell metaplasia, and expression of genes related to type 2 immunity and airway mucus hypersecretion, as compared to similarly exposed BALB/cNTac mice. Ozone-exposed C57BL/6NTac mice also had greater eosinophilic rhinitis but a similar degree of mucous cell metaplasia in nasal epithelium, as ozone-exposed BALB/cNTac mice. These findings suggest that nonatopic individuals may differ in their inflammatory and epithelial responses to repeated ozone exposures that are due, in part, to genetic factors</style></abstract><notes><style face="normal" font="default">DA - 20170110IS - 1533-1601 (Electronic)IS - 0192-6233 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/0192623316674274</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28068894">PM:28068894</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicol Pathol\2017-45-161-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicol Pathol\2017-45-161-71.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170110, Harkema JR</style></custom2><misc3><style face="normal" font="default">10.1177/0192623316674274</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40814</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Parisi,C.A.</style></author><author><style face="normal" font="default"> Ritchie,C.</style></author><author><style face="normal" font="default"> Petriz,N.</style></author><author><style face="normal" font="default"> Morelo,T.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy division, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.</style></auth-address><titles><title><style face="normal" font="default">Direct Medical Costs of Chronic Urticaria in a Private Health Organization of Buenos Aires, Argentina</style></title><secondary-title><style face="normal" font="default">Value Health Reg Issues</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Value Health Reg Issues</style></abbr-1></periodical><pages end="59" start="57">57-59</pages><volume><style face="normal" font="default">11</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Argentina</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Care Costs</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral corticosteroids</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Scarce studies address the issue of resource consumption and direct health care costs of patients diagnosed with adult-onset chronic urticaria (CU). OBJECTIVES: To estimate medical resource consumption and direct health care costs of affected patients in a private health maintenance organization in Buenos Aires, Argentina. METHODS: Patients diagnosed with adult-onset CU (International Classification of Diseases, Ninth Revision, Clinical Modification code 708.1, 708.8, or 708.9) and who were members of the Italian Hospital Medical Care Program were included in the study. All data on hospitalizations, drug prescription, outpatient episodes, consultations, and investigations/tests in the 12 months before inclusion in the study were considered for the estimation of medical resource consumption and direct health care costs. Third-quarter 2014 costs were obtained from the Italian Hospital Medical Care Program and converted into US dollars (using the November 2014 exchange rate). RESULTS: A total of 232 patients were included in the study. The mean age at diagnosis was 54.2 +/- 20.0 years, and the mean disease duration was 5.4 +/- 2.6 years (range, 2-22 years). Of the total number of patients, 75% had allergists as their usual source of care, 23% had dermatologists, 18% had internists, and 3% had rheumatologists. Only 7.8% of the patients had an emergency room admission to manage CU symptoms. To manage the disease, 57.8% of patients used antihistamines and 11.6% used oral corticosteroids. The most relevant source of cost was the medical treatment received, followed by physician visits. The average yearly direct cost per patient was US $1015 +/- $752 (95% confidence interval 803-2003). CONCLUSIONS: This is the first Argentine study that evaluated the costs of CU considering the direct medical costs of the disease. The study provides information on resource utilization and the disease-related economic burden, which is valuable to better understand CU in the local setting. Future research that takes into consideration the direct and indirect costs of the disease will expand knowledge and improve management of the disease</style></abstract><notes><style face="normal" font="default">DA - 20161217IS - 2212-1102 (Electronic)IS - 2212-1099 (Linking)LA - engPT - Journal ArticleCO - Argentina -</style></notes><work-type><style face="normal" font="default">10.1016/j.vhri.2016.07.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27986199">PM:27986199</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Value Health Reg Issues\2016-11-57-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Value Health Reg Issues\2016-11-57-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161217, Parisi CA</style></custom2><misc3><style face="normal" font="default">10.1016/j.vhri.2016.07.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40815</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hopper,J.S.</style></author><author><style face="normal" font="default"> Holding,E.</style></author><author><style face="normal" font="default"> Scurrell,E.J.</style></author><author><style face="normal" font="default"> Featherstone,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Aspinall Foundation, Port Lympne Wild Animal Park, Aldington Road, Lympne, Kent, CT21 4PD, UKAspinall Foundation, Port Lympne Wild Animal Park, Aldington Road, Lympne, Kent, CT21 4PD, UKCytopath Ltd, PO Box 24, Ledbury, Hertfordshire, HR8 2YD, UKWillows Veterinary Centre and Referral service, Highlands Road, Shirley, Solihull, West Midlands, B90 4NH, UK</style></auth-address><titles><title><style face="normal" font="default">Vernal-like conjunctivitis in a western lowland gorilla (Gorilla gorilla gorilla)</style></title><secondary-title><style face="normal" font="default">Vet Ophthalmol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Vet Ophthalmol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Animal</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Conjunctivitis</style></keyword><keyword><style face="normal" font="default"> cytology</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Hematology</style></keyword><keyword><style face="normal" font="default"> Histopathology</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Hyperemia</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> Ocular</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> veterinary</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="5" Month="1" Year="2017">2017/1/5</year></dates><abstract><style face="normal" font="default">CASE DESCRIPTION: A 17-year-old female western lowland gorilla presented with bilateral ocular discharge, conjunctivitis, and rhinitis that was investigated and treated over a 34-month period. Clinical findings, diagnostic results, treatment, and follow-up are described. CLINICAL FINDING: A mild intermittent mucoid ocular discharge was initially noted. 10 months later, conjunctival hyperemia and thickening developed and progressed rapidly to a mass-like lesion covering the right eye. Hematology revealed eosinophilia. Conjunctival cytology revealed eosinophils and neutrophils, and histopathology revealed a chronic proliferative eosinophilic conjunctivitis. 21 months after, the ocular lesions were investigated the gorilla developed masses within both external nares. Histopathology of the nasal lesions revealed chronic-active eosinophilic rhinitis. TREATMENT AND OUTCOME: Treatment of the gorilla was based on protocols recommended for human patients. Protocols for mild, moderate, and finally severe disease were used, involving topical and oral combinations of treatments. The gorilla eventually responded to systemic immunosuppressant therapy recommended for severe refractory disease. CLINICAL SIGNIFICANCE: To the authors' knowledge, this is the first reported case of vernal-like conjunctivitis in a western lowland gorilla</style></abstract><notes><style face="normal" font="default">DA - 20170106IS - 1463-5224 (Electronic)IS - 1463-5216 (Linking)LA - engPT - Case ReportsCO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1111/vop.12457</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28058762">PM:28058762</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Vet Ophthalmol\20170106-HopperJS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Vet Ophthalmol\20170106-HopperJS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170106, Hopper JS</style></custom2><misc3><style face="normal" font="default">10.1111/vop.12457</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40816</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vyles,D.</style></author><author><style face="normal" font="default"> Chiu,A.</style></author><author><style face="normal" font="default"> Simpson,P.</style></author><author><style face="normal" font="default"> Nimmer,M.</style></author><author><style face="normal" font="default"> Adams,J.</style></author><author><style face="normal" font="default"> Brousseau,D.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Emergency Medicine, Medical College of Wisconsin, Milwaukee, Wis.</style></auth-address><titles><title><style face="normal" font="default">Parent-Reported Penicillin Allergy Symptoms in the Pediatric Emergency Department</style></title><secondary-title><style face="normal" font="default">Acad Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Acad Pediatr</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Emergency Medicine</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wisconsin</style></keyword></keywords><dates><year Day="5" Month="3" Year="2017">2017/3/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Children often present to the pediatric emergency department (ED) with a reported penicillin allergy. The true incidence of pediatric penicillin allergy is low, and patients may be inappropriately denied first-line antibiotics. We hypothesized that more than 70% of reported penicillin allergies in the pediatric ED are low risk for true allergy. METHODS: Parents of children presenting to the pediatric ED with parent-reported penicillin allergy completed an allergy questionnaire. The questionnaire included age at allergy diagnosis, symptoms of allergy, and time to allergic reaction from first dose. The allergy symptoms were dichotomized into high and low risk in consultation with a pediatric allergist before questionnaire implementation. RESULTS: A total of 605 parents were approached; 500 (82.6%) completed the survey. The median (interquartile range) age of the children at diagnosis was 1 year (7 months, 2 years); 75% were diagnosed before their third birthday. Overall, 380 (76%) (95% confidence interval 72.3, 79.7) children had exclusively low-risk symptoms. The most commonly reported symptoms were rash (466, 92.8%) and itching (203, 40.6%). Of the 120 children with one or more high-risk symptom, facial swelling (50, 10%) was the most common. Overall, 354 children (71%) were diagnosed after their first exposure to penicillin. Symptom onset within 24 hours of medication administration occurred in 274 children (54.8%). CONCLUSIONS: Seventy-six percent of patients with parent-reported penicillin allergy have symptoms unlikely to be consistent with true allergy. Determination of true penicillin allergy in patients with low-risk symptoms may permit the increased use of first-line penicillin antibiotics</style></abstract><notes><style face="normal" font="default">DA - 20170309IS - 1876-2867 (Electronic)IS - 1876-2859 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.acap.2016.11.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28274586">PM:28274586</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Acad Pediatr\20170309-VylesD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Acad Pediatr\20170309-VylesD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170309, Vyles D</style></custom2><misc3><style face="normal" font="default">10.1016/j.acap.2016.11.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40817</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Van den Poel,B.</style></author><author><style face="normal" font="default"> Kochuyt,A.M.</style></author><author><style face="normal" font="default"> Del Biondo,E.</style></author><author><style face="normal" font="default"> Dewaele,B.</style></author><author><style face="normal" font="default"> Lierman,E.</style></author><author><style face="normal" font="default"> Tousseyn,T.</style></author><author><style face="normal" font="default"> De Hertogh,G.</style></author><author><style face="normal" font="default"> Vandenberghe,P.</style></author><author><style face="normal" font="default"> Boeckx,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Laboratory Medicine , University Hospitals Leuven , Leuven , Belgium</style></auth-address><titles><title><style face="normal" font="default">Highly sensitive assays are mandatory for the differential diagnosis of patients presenting with symptoms of mast cell activation: diagnostic work-up of 38 patients</style></title><secondary-title><style face="normal" font="default">Acta Clin Belg</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Acta Clin Belg</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Bone Marrow</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Differential diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Immunophenotyping</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> KIT</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mastocytosis</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic mastocytosis</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> World Health</style></keyword><keyword><style face="normal" font="default"> World Health Organization</style></keyword></keywords><dates><year Day="6" Month="3" Year="2017">2017/3/6</year></dates><abstract><style face="normal" font="default">Mastocytosis is a heterogeneous disease caused by excessive mast cell (MC) proliferation. Diagnosis of systemic mastocytosis (SM) is based on the presence of major and minor criteria defined by the World Health Organization. Symptoms of MC activation can also occur in patients without SM or without allergic or inflammatory disease. These MC activation syndromes (MCAS) can be divided into primary (monoclonal) MCAS (MMAS) vs. secondary and idiopathic MCAS. In this single center study, the diagnostic work-up of 38 patients with a clinical suspicion of SM and/or with elevated basic tryptase levels is presented. Clinical symptoms, biochemical parameters, results of bone marrow investigation, flow cytometric immunophenotyping, and molecular analysis were retrospectively reviewed. Twenty-three patients were found to have a monoclonal MC disorder of which 19 were diagnosed with SM and 4 with MMAS. In 13/19 SM patients, multifocal MC infiltrates in the bone marrow were found (major criterion), while in 6 the diagnosis was based on the presence of >/=3 minor criteria. Flow cytometric analysis of bone marrow showed CD25 expression of MCs in all patients with SM and MMAS (range: 0.002-0.3% of cells). In bone marrow, the KIT D816V mutation was detected in all SM patients but in only 2 patients with MMAS (range: 0.007-9% mutated cells). Basic tryptase elevation was demonstrated in 16/19 patients with SM but also in 9/19 patients without SM. Our study reveals the heterogeneity of primary MC disorders and the importance of sensitive assays in patients suspected of having SM</style></abstract><notes><style face="normal" font="default">DA - 20170306IS - 2295-3337 (Electronic)IS - 1784-3286 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1080/17843286.2017.1293312</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28262030">PM:28262030</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Acta Clin Belg\20170306-VanderPoelB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Acta Clin Belg\20170306-VanderPoelB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170306, Van der Poel B</style></custom2><misc3><style face="normal" font="default">10.1080/17843286.2017.1293312</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40818</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ortiz Salvador,J.M.</style></author><author><style face="normal" font="default"> Esteve Martinez,A.</style></author><author><style face="normal" font="default"> Subiabre Ferrer,D.</style></author><author><style face="normal" font="default"> Victoria Martinez,A.M.</style></author><author><style face="normal" font="default"> de la Cuadra Oyanguren,J.</style></author><author><style face="normal" font="default"> Zaragoza Ninet,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Servicio de Dermatologia, Consorcio Hospital General Universitario de Valencia, Valencia, Espana.</style></auth-address><titles><title><style face="normal" font="default">Pediatric Allergic Contact Dermatitis: Clinical and Epidemiological Study in a Tertiary Hospital</style></title><secondary-title><style face="normal" font="default">Actas Dermosifiliogr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Actas Dermosifiliogr</style></full-title></periodical><pages end="578" start="571">571-578</pages><volume><style face="normal" font="default">108</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidemiological studies</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Mercury</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paraphenylenediamine</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Potassium</style></keyword><keyword><style face="normal" font="default"> Potassium Dichromate</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin allergy</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Few epidemiological studies have investigated the incidence of allergic contact dermatitis in children. Underdiagnosis has been observed in some studies, with many cases in which the condition is not suspected clinically and patch tests are not performed. However, the prevalence of pediatric sensitization to allergens has been reported to be as high as 20%, and the diagnosis should therefore be contemplated as a possibility in this age group. MATERIAL AND METHODS: We performed a retrospective analysis of the skin allergy database of the Dermatology Department of Consorcio Hospital General Universitario de Valencia. Children between 0 and 16 years of age diagnosed with allergic contact dermatitis in the previous 15 years (between 2000 and 2015) were included in the analysis. Epidemiological (age, sex, history of atopy) and clinical (site of the lesions, allergen series applied, positive reactions, and their relevance) variables were gathered. RESULTS: Patch tests had been performed on 4,593 patients during the study period. Of these, 265 (6%) were children aged between 0 and 16 years. A positive reaction to at least one of the allergens tested was observed in 144 (54.3%) patients in that group. The allergens most frequently identified were the following (in decreasing order of frequency): thiomersal, cobalt chloride, colophony, paraphenylenediamine, potassium dichromate, mercury, and nickel. The sensitization was considered relevant in 177 (61.3%) cases. CONCLUSIONS: More than half of the children studied showed sensitization to 1 or more allergens, with a high percentage of relevant sensitizations. All children with a clinical suspicion of allergic contact dermatitis should be referred for patch testing. As no standardized test series have been developed for this age group, a high level of clinical suspicion and knowledge of the allergens most commonly involved are required when selecting the allergens to be tested</style></abstract><notes><style face="normal" font="default">DA - 20170312IS - 1578-2190 (Electronic)IS - 0001-7310 (Linking)LA - engLA - spaPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.acap.2016.11.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284423">PM:28284423</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Actas Dermosifiliogr\2017-108-571-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Actas Dermosifiliogr\2017-108-571-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170312, Ortiz Salvador JM</style></custom2><misc3><style face="normal" font="default">10.1016/j.acap.2016.11.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40819</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ozturk,A.B.</style></author><author><style face="normal" font="default"> Bayraktar,R.</style></author><author><style face="normal" font="default"> Gogebakan,B.</style></author><author><style face="normal" font="default"> Mumbuc,S.</style></author><author><style face="normal" font="default"> Bayram,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Koc University Hospital, Department of Allergy and Immunology, Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="default">Comparison of inflammatory cytokine release from nasal epithelial cells of non-atopic non-rhinitic, allergic rhinitic and polyp subjects and effects of diesel exhaust particles in vitro</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollutants</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Diesel</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal epithelial cell</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> nasal polyposis</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pollutants</style></keyword><keyword><style face="normal" font="default"> Polyposis</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Rantes</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> transcription factor</style></keyword><keyword><style face="normal" font="default"> Transcription Factors</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="3" Year="2017">2017/3/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Although studies have reported an association between air pollutants and increased allergic airway diseases, such as allergic rhinitis and nasal polyposis, the underlying mechanisms are not fully understood. A limited number of studies have suggested that diesel exhaust particles (DEP) play a role in atopy and the pathogenesis of allergic upper airway diseases. The aim of this study was to investigate the effect of DEP on inflammatory cytokine release, and mRNA expression of transcription factors such as JNK and NF-beta in primary nasal epithelial cells (NECs), in vitro. METHODS: NECs from non-atopic, non-rhinitic subjects (controls) and patients with allergic rhinitis and nasal polyps were cultured and incubated with 0-100mug/ml DEP for 24h. ELISA and RT-PCR were used to assess the release of IL-8, GM-CSF, and RANTES, and mRNA expression for JNK and NF-kappaB, respectively. RESULTS: Compared to control cells, NECs from subjects with atopic polyps released significantly greater amounts of IL-8 (median=887 vs. 176.6pg/mug cellular protein; p&lt;0.0001) and RANTES (median=0.191 vs. 0.02pg/mug cellular protein; p&lt;0.001). While 50mug/ml DEP induced release of RANTES in NECs from patients with allergic rhinitis, 100mug/ml DEP decreased IL-8 levels in NECs from both control and allergic rhinitic subjects. DEP did not affect mRNA expression for JNK and NF-kappaB from NECs of subjects with polyps. CONCLUSIONS: NECs from subjects with various pathologies may respond differently to DEP</style></abstract><notes><style face="normal" font="default">DA - 20170305IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2016.10.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28259510">PM:28259510</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170305-OzturkAB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170305-OzturkAB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170305, Ozturk AB</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2016.10.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40820</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,J.B.</style></author><author><style face="normal" font="default"> Zhang,J.</style></author><author><style face="normal" font="default"> Hu,H.Z.</style></author><author><style face="normal" font="default"> Xue,M.</style></author><author><style face="normal" font="default"> Jin,Y.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Paediatrics, Jiangsu Taizhou People's Hospital, Taizhou, China</style></auth-address><titles><title><style face="normal" font="default">Polymorphisms of TGFB1, TLE4 and MUC22 are associated with childhood asthma in Chinese population</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> paediatrics</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="3" Year="2017">2017/3/2</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To investigate whether the genetic variants of TGFB1, TLE4, MUC22 and IKZF3 are associated with the development of asthma in Chinese children. METHODS: 572 adolescent asthma patients and 590 age-matched healthy controls were included in this study. A total of four SNPs were genotyped, including rs2241715 of TGFB1, rs2378383 of TLE4, rs2523924 of MUC22, and rs907092 of IKZF3. Allele frequencies of the patients and the control group were compared by the Chi-square test. The Student t test was used to analyse the relationship between genotypes and clinical feature of the patients. RESULTS: Patients were found to have significantly different frequencies of allele A of rs2241715, allele G of rs2378383 and allele A of rs2523924 as compared with the controls (40.4% vs. 45.9%, p=0.01 for rs2241715; 17.2% vs. 13.4%, p=0.01 for rs2378383; 15.3% vs. 11.9%, p=0.02 for rs2523924). For patients with severe asthma, those with genotype AA/AG of rs2241715 had remarkably higher FEV1% as compared with those with genotype GG (59.1+/-4.3% vs. 55.4+/-3.7%, p&lt;0.001). Moreover, those with genotype GG/GA of rs2378383 had remarkably lower FEV1% as compared with those with genotype AA (54.6+/-2.9% vs. 58.6+/-4.1%, p&lt;0.001). CONCLUSIONS: Genes TGFB1, TLE4 and MUC22 are associated with the risk of childhood asthma in Chinese population. Our results associating TGFB1 and TLE4 with clinical features of asthma suggest potential application of these parameters in the management of asthma children</style></abstract><notes><style face="normal" font="default">DA - 20170306IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2016.10.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28262390">PM:28262390</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170306-ChenJB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170306-ChenJB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170306, Chen JB</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2016.10.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40821</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fan,G.</style></author><author><style face="normal" font="default"> Wang,B.</style></author><author><style face="normal" font="default"> Liu,C.</style></author><author><style face="normal" font="default"> Li,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Norman Bethune Health Science Center, Jilin University, 828 Xinmin Avenue, Changchun 130021, Jilin, China</style></auth-address><titles><title><style face="normal" font="default">Prenatal paracetamol use and asthma in childhood: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma risk</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paracetamol</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Some studies have suggested that prenatal paracetamol exposure might associate with the risk of child asthma. However, other studies have not confirmed this result. Therefore, we conducted a meta-analysis to investigate their relationship. METHODS: Two authors searched Pubmed and Embase databases up to June 2016. The strength of the association was calculated with the OR and respective 95% CIs. The random-effects model was chosen to calculate the pooled OR. RESULTS: A total of 13 articles of more than 1,043,109 individuals were included in the meta-analysis. A statistically significant association between prenatal paracetamol exposure and child asthma risk was found. The data showed that prenatal paracetamol exposure could increase the risk of child asthma (OR=1.19; 95% CI, 1.12-1.27; P&lt;0.00001) in a random-effect model. Six studies reported paracetamol exposure during the first trimester of pregnancy. We found that paracetamol exposure during the first trimester of pregnancy was associated with increased risk of child asthma (OR=1.21; 95% CI, 1.14-1.28; P&lt;0.00001). Furthermore, we observed that paracetamol exposure during the 2-3 trimesters of pregnancy was also associated with child asthma risk (OR=1.13; 95% CI, 1.04-1.23; P=0.005). CONCLUSIONS: This study suggested that prenatal paracetamol exposure was significantly associated with the increased risk of child asthma</style></abstract><notes><style face="normal" font="default">DA - 20170226IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2016.10.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28237129">PM:28237129</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170226-FanG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170226-FanG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170226, Fan G</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2016.10.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40822</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Muraro,S.P.</style></author><author><style face="normal" font="default"> Pitrez,P.M.</style></author><author><style face="normal" font="default"> de Souza,A.P.</style></author><author><style face="normal" font="default"> Porto,B.N.</style></author><author><style face="normal" font="default"> Vargas,J.E.</style></author><author><style face="normal" font="default"> Ewald,I.P.</style></author><author><style face="normal" font="default"> Heinzmann-Filho,J.P.</style></author><author><style face="normal" font="default"> Dos Santos,G.</style></author><author><style face="normal" font="default"> Baptista,T.S.</style></author><author><style face="normal" font="default"> Gandolfi,T.D.</style></author><author><style face="normal" font="default"> Machado,F.D.</style></author><author><style face="normal" font="default"> Jones,M.H.</style></author><author><style face="normal" font="default"> Bonorino,C.</style></author><author><style face="normal" font="default"> Stein,R.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Clinical and Experimental Immunology, Brazil; Infant Center, Brazil; Institute of Biomedical Research, Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil</style></auth-address><titles><title><style face="normal" font="default">Immune response of toddlers with history of prematurity</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adaptive</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Biomedical Research</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Ligands</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> TLR</style></keyword><keyword><style face="normal" font="default"> Toddler</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="21" Month="2" Year="2017">2017/2/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: It is not quite well established how immune responses differ in term and preterm infants beyond the first year of life. This study aimed to evaluate aspects of the innate and adaptive immune responses in a group of preterm infants in comparison with their term peers. METHODS: In this cross-sectional study peripheral blood mononuclear cells (PBMC) were isolated from preterm and term children at age three years. Innate immune response was evaluated by the analysis of TLR receptors expression on CD11c+HLADRhigh cells and inflammatory cytokine production after PBMC stimulation with Toll like receptors (TLR) ligands. Adaptive immune response was evaluated by T cells' phenotyping and function after stimulation with polyclonal conventional T cell stimulus. CONCLUSION: We have found that the patterns of innate and adaptive immune responses at 3 years of age were not affected by the fact of the children having being born preterm or at term</style></abstract><notes><style face="normal" font="default">DA - 20170225IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2016.10.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28236541">PM:28236541</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170225-MuraroSP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170225-MuraroSP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170225, Muraro SP</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2016.10.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40823</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mohammadzadeh,I.</style></author><author><style face="normal" font="default"> Moazzami,B.</style></author><author><style face="normal" font="default"> Ghaffari,J.</style></author><author><style face="normal" font="default"> Aghamohammadi,A.</style></author><author><style face="normal" font="default"> Rezaei,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Noncommunicable Pediatric Diseases Research Center, Babol University of Medical Sciences, Babol, Iran; Primary Immunodeficiency Diseases Network (PIDNet), Universal Scientific Education and Research Network (USERN), Babol, Iran</style></auth-address><titles><title><style face="normal" font="default">Primary immunodeficiency diseases in Northern Iran</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Autoimmunity</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Complement</style></keyword><keyword><style face="normal" font="default"> Complement deficiencies</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> dysregulation</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> humoral</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune dysregulation</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate immunity</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of care</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Primary immunodeficiency diseases (PID) are a heterogeneous group of inherited disorders, characterised by recurrent severe infections, autoimmunity and lymphoproliferation. Despite impressive progress in identification of novel PID, there is an unfortunate lack of awareness among physicians in identification of patients with PID, especially in non-capital cities of countries worldwide. RESULT: This study was performed in a single-centre paediatric hospital in Northern Iran during a 21-year period (1994-2015). Ninety-four patients were included in this study. The majority of cases had antibody deficiencies (37.23%), followed by well-defined syndromes with immunodeficiency in 16 (17.02%), phagocytic disorders in 15 patients (15.95%), complement deficiencies in 15 patients (15.95%), immunodeficiencies affecting cellular and humoral immunity in nine patients (9.57%), disease of immune dysregulation in three (3.19%), and defects in intrinsic and innate immunity in one (1.06%). CONCLUSION: It seems that there are major variations in frequency of different types of PID in different regions of a country. Therefore, reporting local data could provide better ideas to improve the local health care system strategists and quality of care of PID patients</style></abstract><notes><style face="normal" font="default">DA - 20170226IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Iran - CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2016.11.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28237128">PM:28237128</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170226-MohammadzadehI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170226-MohammadzadehI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170226, Mohammadzadeh I</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2016.11.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40824</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yii,A.C.</style></author><author><style face="normal" font="default"> Tan,J.H.</style></author><author><style face="normal" font="default"> Lapperre,T.S.</style></author><author><style face="normal" font="default"> Chan,A.K.</style></author><author><style face="normal" font="default"> Low,S.Y.</style></author><author><style face="normal" font="default"> Ong,T.H.</style></author><author><style face="normal" font="default"> Tan,K.L.</style></author><author><style face="normal" font="default"> Chotirmall,S.H.</style></author><author><style face="normal" font="default"> Sterk,P.J.</style></author><author><style face="normal" font="default"> Koh,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory and Critical Care Medicine, Singapore General Hospital</style></auth-address><titles><title><style face="normal" font="default">Long-term future risk of severe exacerbations: distinct 5-year trajectories of problematic asthma</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> Apnea</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Modeling</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Obstructive sleep apnea</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Sleep apnea</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Trajectory</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="3" Year="2017">2017/3/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Assessing future risk of exacerbations is an important component of asthma management. Existing studies have investigated short-, but not long-term risk. Problematic asthma patients with unfavorable long-term disease trajectory and persistently frequent severe exacerbations need to be identified early to guide treatment. METHODS: Severe exacerbation rates over five years for 177 "problematic asthma" patients presenting to a specialist asthma clinic were tracked. Distinct trajectories of severe exacerbation rates were identified using group-based trajectory modeling. Baseline predictors of trajectory were identified and used to develop a clinical risk score for predicting the most unfavorable trajectory. RESULTS: Three distinct trajectories were found: 58.5% had rare intermittent severe exacerbations ("infrequent"), 32.0% had frequent severe exacerbations at baseline but improved subsequently ("non-persistently frequent"), and 9.5% exhibited persistently frequent severe exacerbations, with the highest incidence of near-fatal asthma ("persistently frequent"). A clinical risk score composed of >/=2 severe exacerbations in the past year (+2 points), history of near-fatal asthma (+1 point), body mass index>/=25kg/m2 (+1 point), obstructive sleep apnea (+1 point), gastroesophageal reflux (+1 point) and depression (+1 point) was predictive of the "persistently frequent" trajectory (area under the receiver operating characteristic curve: 0.84; sensitivity 72.2%, specificity 81.1% using cut-off >/=3 points). The trajectories and clinical risk score had excellent performance in an independent validation cohort. CONCLUSIONS: Patients with problematic asthma follow distinct illness trajectories over a period of five years. We have derived and validated a clinical risk score that accurately identifies patients who will have persistently frequent severe exacerbations in the future. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1111/all.13159</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28295424">PM:28295424</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170315-YiiAC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170315-YiiAC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Yii AC</style></custom2><misc3><style face="normal" font="default">10.1111/all.13159</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40825</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Overgaard,L.E.</style></author><author><style face="normal" font="default"> Main,K.M.</style></author><author><style face="normal" font="default"> Frederiksen,H.</style></author><author><style face="normal" font="default"> Stender,S.</style></author><author><style face="normal" font="default"> Szecsi,P.B.</style></author><author><style face="normal" font="default"> Williams,H.C.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Allergy Research Centre. Department of Dermatology and allergy, Herlev and Gentofte Hospital, Hellerup, Copenhagen University Hospital, Denmark</style></auth-address><titles><title><style face="normal" font="default">Children with atopic dermatitis and frequent emollient use have increased urinary levels of low molecular weight phthalate metabolites and parabens</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emollients</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Fixatives</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Molecular Weight</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parabens</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Plasticizers</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> Solvents</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="9" Month="3" Year="2017">2017/3/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Parabens may be added to cosmetic and personal care products for preservation purposes. Low-molecular weight (LMW) phthalate diesters function as plasticizers, fixatives or solvents in such products, but may also be found in small quantities as contaminants from plastic containers. OBJECTIVE: To evaluate the association between emollient use, atopic dermatitis and FLG mutations, respectively, with urinary concentrations of phthalate metabolites and parabens in Danish children. METHODS: 845 Danish children 4-9 years of age were studied. Urinary concentrations of phthalate metabolites and parabens were determined, and children were genotyped for common FLG loss-of-function mutations. Information about atopic dermatitis and use of emollients was obtained from questionnaires completed by parents. RESULTS: The prevalence of atopic dermatitis was 16.1%. Phthalate metabolite and paraben levels were generally higher in children with frequent use of emollients compared to uncommon users, reaching statistical significance for some LMW phthalates and parabens. While there was no association with common FLG mutations, children with atopic dermatitis had significantly higher urinary levels of one LMW phthalate and two parabens, respectively, when compared to children without atopic dermatitis. CONCLUSION: Emollient use and atopic dermatitis were associated with modestly increased internal LMW phthalate and paraben exposure in 4-9 year old children. It is unknown whether the difference is explained by increased use of the specific emollients that are used to treat pruritic and inflamed skin, and/or whether the impaired skin barrier allows chemicals to penetrate more easily. Moreover, the putative toxicological burden is unknown. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170310IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/all.13157</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28281298">PM:28281298</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170310-OvergaardLE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170310-OvergaardLE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170310, Overgaard LE</style></custom2><misc3><style face="normal" font="default">10.1111/all.13157</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40826</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,B.F.</style></author><author><style face="normal" font="default"> Cao,P.P.</style></author><author><style face="normal" font="default"> Wang,Z.C.</style></author><author><style face="normal" font="default"> Li,Z.Y.</style></author><author><style face="normal" font="default"> Wang,Z.Z.</style></author><author><style face="normal" font="default"> Ma,J.</style></author><author><style face="normal" font="default"> Liao,B.</style></author><author><style face="normal" font="default"> Deng,Y.K.</style></author><author><style face="normal" font="default"> Long,X.B.</style></author><author><style face="normal" font="default"> Xu,K.</style></author><author><style face="normal" font="default"> Wang,H.</style></author><author><style face="normal" font="default"> Wang,H.</style></author><author><style face="normal" font="default"> Zeng,M.</style></author><author><style face="normal" font="default"> Lu,X.</style></author><author><style face="normal" font="default"> Liu,Z.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China</style></auth-address><titles><title><style face="normal" font="default">Interferon-gamma induced insufficient autophagy contributes to p62-dependent apoptosis of epithelial cells in chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Apoptosis</style></keyword><keyword><style face="normal" font="default"> Cell Survival</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Degradation</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Electron microscopy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-17A</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Interferon-gamma</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Microscopy</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal epithelial cell</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Non-eosinophilic</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Rna</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> transmission</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Up-Regulation</style></keyword><keyword><style face="normal" font="default"> Vacuoles</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="3" Year="2017">2017/3/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Autophagy is a lysosomal degradation pathway that is essential for cell survival, differentiation, and homeostasis. This study aimed to investigate the contribution of autophagy to the pathogenesis of CRS with nasal polyps (CRSwNP). METHODS: The expression of autophagic proteins [microtubule-associated protein 1 light chain 3B (LC3B)-II, autophagy-related proteins (Atg), and Beclin 1], substrate proteins (p62 and ubiquitinated proteins), and apoptotic signaling molecules [cysteine-aspartic protease-3 and 8, and poly-ADP-ribose polymerase] in the sinonasal mucosa and nasal epithelial cells (NECs) was detected by immunohistochemistry and Western blotting. Autophagic vacuoles were observed with transmission electron microscopy. BEAS-2B cells and NECs were treated with rapamycin, bafilomycin A1, or various cytokines. In some experiments, cultured NECs were transfected with small interfering RNA targeting p62 (sip62) or Atg5 (siAtg5). Cultured cells were analyzed with Western blotting and flow cytometry. RESULTS: Although autophagic protein expression and autophagic vacuole formation were increased in both eosinophilic and non-eosinophilic CRSwNP, particularly in NECs, there was also an up-regulation of substrate proteins and apoptotic signaling molecules. IFN-gamma, but not IL-4, IL-13, or IL-17A, simultaneously enhanced LC3B-II and p62 levels as well as cell apoptosis in BEAS-2B cells and/or normal NECs. Bafilomycin A1 up-regulated the levels of LC3B-II and p62 in polyp NECs and IFN-gamma treated normal NECs. IFN-gamma-induced apoptosis of normal NECs was exaggerated by bafilomycin A1 and siAtg5. Sip62 suppressed apoptosis of polyp NECs and IFN-gamma treated NECs. IFN-gamma protein levels were increased in both eosinophilic and non-eosinophilic CRSwNP. CONCLUSIONS: IFN-gamma induces activated but insufficient autophagy and thus contributes to a degree to p62-dependent apoptosis of NECs in CRSwNP. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170304IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1111/all.13153</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28258963">PM:28258963</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170304-WangBF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170304-WangBF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170304, Wang BF</style></custom2><misc3><style face="normal" font="default">10.1111/all.13153</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40827</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Uchida,M.</style></author><author><style face="normal" font="default"> Anderson,E.L.</style></author><author><style face="normal" font="default"> Squillace,D.L.</style></author><author><style face="normal" font="default"> Patil,N.</style></author><author><style face="normal" font="default"> Maniak,P.J.</style></author><author><style face="normal" font="default"> Iijima,K.</style></author><author><style face="normal" font="default"> Kita,H.</style></author><author><style face="normal" font="default"> O'Grady,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergic Diseases and Department of Internal Medicine, Mayo Clinic, Rochester, MN, 55905</style></auth-address><titles><title><style face="normal" font="default">Oxidative stress serves as a key checkpoint for IL-33 release by airway epithelium</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> airway epithelial cell</style></keyword><keyword><style face="normal" font="default"> airway epithelial cells</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Alternaria</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cysteine</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelia</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> Epithelium</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Glutathione</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Oxidative Stress</style></keyword><keyword><style face="normal" font="default"> Oxygen</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> ROS</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> transcription factor</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Interleukin (IL)-33 is implicated in the pathophysiology of asthma and allergic diseases. However, our knowledge is limited regarding how IL-33 release is controlled. The transcription factor nuclear factor-erythroid-2-related factor 2 (Nrf2) plays a key role in antioxidant response regulation. OBJECTIVE: The goal of this project was to investigate the role of cellular oxidative stress in controlling IL-33 release in airway epithelium. METHODS: Complementary approaches were used that included human bronchial epithelial cells and mouse models of airway type-2 immunity that were exposed to fungus Alternaria extract. The clinically available Nrf2 activator 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid methyl ester (CDDO-Me) was used to evaluate the role of Nrf2-induced antioxidant molecules. RESULTS: Human bronchial epithelial cells produced reactive oxygen species (ROS) when they were exposed to Alternaria extract. ROS scavengers, such as glutathione (GSH) and N-acetyl cysteine, prevented extracellular secretion of ATP and increases in intracellular calcium concentrations that precede IL-33 release. Administration of CDDO-Me to mice enhanced expression of a number of antioxidant molecules in the lungs and elevated lung levels of endogenous GSH. Importantly, CDDO-Me treatment reduced allergen-induced ATP secretion and IL-33 release by airway epithelial cells in vitro and protected mice from IL-33 release and asthma-like pathological changes in the lungs. CONCLUSIONS: The balance between oxidative stress and antioxidant responses plays a key role in controlling IL-33 release in airway epithelium. The therapeutic potential of Nrf2 activators needs to be considered for asthma and allergic airway diseases. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170308IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.13158</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28273344">PM:28273344</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170308-UchidaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170308-UchidaM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170308, Uchida M</style></custom2><misc3><style face="normal" font="default">10.1111/all.13158</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40828</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Montrose,L.</style></author><author><style face="normal" font="default"> Ward,T.J.</style></author><author><style face="normal" font="default"> Semmens,E.O.</style></author><author><style face="normal" font="default"> Cho,Y.H.</style></author><author><style face="normal" font="default"> Brown,B.</style></author><author><style face="normal" font="default"> Noonan,C.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">0000000086837370grid.214458.eSchool of Public Health, University of Michigan, 1420 Washington Heights, Ann Arbor, MI 48109 USA</style></auth-address><titles><title><style face="normal" font="default">Dietary intake is associated with respiratory health outcomes and DNA methylation in children with asthma</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Clin Immunol</style></full-title></periodical><pages end="" start="12">12-</pages><volume><style face="normal" font="default">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> folate</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> indoor</style></keyword><keyword><style face="normal" font="default"> Interferon</style></keyword><keyword><style face="normal" font="default"> Interferon-gamma</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Methylation</style></keyword><keyword><style face="normal" font="default"> Michigan</style></keyword><keyword><style face="normal" font="default"> Nutrients</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> peak flow</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Promoter</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized trial</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Selenium</style></keyword><keyword><style face="normal" font="default"> Smoke</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Washington</style></keyword><keyword><style face="normal" font="default"> Wood</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is an increasingly common chronic disease among children, and data point toward a complex mechanism involving genetic, environmental and epigenetic factors. Epigenetic modifications such as DNA hypo- or hyper-methylation have been shown to occur in response to environmental exposures including dietary nutrients. METHODS: Within the context of the asthma randomized trial of indoor wood smoke (ARTIS) study, we investigated relationships between diet, asthma health measures, and DNA methylation. Asthma health measures included a quality of life instrument, diurnal peak flow variability (dPFV) and forced expiratory volume in the first second (FEV1). Dietary intake was assessed with a food frequency questionnaire. Methylation levels of LINE-1 repetitive element and two promoter CpG sites for interferon gamma (IFNgamma, -186 and -54) from buccal cell DNA were measured using pyrosequencing assays. RESULTS: Data were collected on 32 children with asthma living in western Montana who were recruited to the ARTIS study. Selenium and several methyl donor dietary nutrients were positively associated with the asthma quality of life measure. Intake of methyl donating nutrients including folate was positively associated LINE-1 methylation and negatively associated with IFNgamma CpG-186. Higher levels of LINE-1 methylation were associated with greater dPFV. CONCLUSION: We identified several nutrients that were associated with improved quality of life measures among children with asthma. The IFNgamma promoter CpG site -186 but not -54 was associated with the intake of selected dietary nutrients. However, in this small population of children with asthma, the IFNgamma promoter CpG sites were not associated with respiratory health measures so it remains unclear through which epigenetic mechanism these nutrients are impacting the quality of life measure. These findings add to the evidence that dietary nutrients, particularly foods containing methyl donors, may be important for epigenetic regulation as it pertains to the control of asthma. Trial registration ClincialTrials.gov NCT00807183. Registered 10 December 2008</style></abstract><notes><style face="normal" font="default">DA - 20170306IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1186/s13223-017-0187-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28261276">PM:28261276</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-12.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170306, Montrose L</style></custom2><misc3><style face="normal" font="default">10.1186/s13223-017-0187-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40829</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Orange,J.S.</style></author><author><style face="normal" font="default"> Akhter,J.</style></author><author><style face="normal" font="default"> Seeborg,F.O.</style></author><author><style face="normal" font="default"> Boyle,M.</style></author><author><style face="normal" font="default"> Scalchunes,C.</style></author><author><style face="normal" font="default"> Hernandez-Trujillo,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">department of Pediatrics, Section of Immunology, Allergy and Rheumatology, Texas Childrens Hospital and Baylor College of Medicine, Houston, Texas, USA</style></auth-address><titles><title><style face="normal" font="default">Pulmonologist perspectives regarding diagnosis and management of primary immunodeficiency diseases</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="168" start="162">162-168</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> American Medical Association</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Texas</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> vaccine</style></keyword><keyword><style face="normal" font="default"> Vaccines</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral Vaccines</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: The time from symptom onset to diagnosis for patients with primary immunodeficiency diseases (PIDD) is an average of 12 years, but prompt diagnosis and treatment can promote best outcomes. OBJECTIVE: Because the manifestations of PIDD are often sinopulmonary in nature, patients with undiagnosed PIDD are frequently referred to pulmonologists. This study sought to identify opportunities among these specialists to improve diagnosis and clinical management of patients with PIDD. METHODS: A survey was sent to American Medical Association and American Osteopathic Association members whose specialty was pulmonology. Responses were compared with those from a historical survey of 71 subspecialist immunologists (American Academy of Allergy, Asthma Immunology members who devoted 10% of their practice to patients with PIDD). RESULTS: The surveys were returned by 485 pulmonologists, 49% of whom had diagnosed at least one patient with PIDD. In comparison with subspecialist immunologists, fewer pulmonologists were aware of the professional PIDD diagnosis and management guidelines and fewer followed up patients with various PIDDs. Pulmonologists and subspecialist immunologists also differed in the practice of prescribing prophylactic antibiotics and immunoglobulin replacement and in avoiding live viral vaccines. CONCLUSION: Differences in the diagnosis and treatment of patients with PIDD between these two groups of specialists revealed areas in which PIDD-focused educational initiatives may be helpful for pulmonologists</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931293">PM:27931293</url></web-urls></urls><custom2><style face="normal" font="default">20161209, Orange JS</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40830</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gong,F.</style></author><author><style face="normal" font="default"> Qian,C.</style></author><author><style face="normal" font="default"> Zhu,H.</style></author><author><style face="normal" font="default"> Zhu,J.</style></author><author><style face="normal" font="default"> Pan,Y.</style></author><author><style face="normal" font="default"> Dong,Q.</style></author><author><style face="normal" font="default"> Jiang,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Laboratory Medicine, The Third Hospital Affiliated to Nantong University, Wuxi, Jiangsu, P.R. China</style></auth-address><titles><title><style face="normal" font="default">Circulating follicular T-helper cell subset distribution in patients with asthma</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="161" start="154">154-161</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">abnormalities</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cell Death</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Chemokine receptor</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> subtypes</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: The pathogenesis of allergic asthma is primarily characterized by abnormality in the immunoglobulin E (IgE) pathway, suggesting a possible role for follicular T-helper cells (Tfh) in the genesis of excessive IgE accumulation. The blood chemokine (C-X-C motif) receptor 5 (CXCR5)+CD4+ T cells, known as circulating Tfh, share common functional characteristics with Tfh cells from germinal centers. There are three subsets of circulating Tfh cells: Tfh1 (CXCR3+CC chemokine receptor [CCR] 6), Tfh2 (CXCR3CCR6) and Tfh17 (CXCR3CCR6+). However, data on circulating Tfh cell subsets distribution in patients with asthma are not available. OBJECTIVE: To investigate the circulating Tfh cell subsets distribution in patients with asthma and to assess the relationship between Tfh cell subsets distribution and the serum IgE level. METHODS: Thirty patients with severe allergic asthma and 30 age- and sex-matched healthy controls were enrolled in this study. The percentages and phenotypic assays of circulating Tfh cell subsets were assessed by flow cytometry. The total IgE levels were also measured. The correlation between the percentage of circulating Tfh cell subsets and the levels of serum total IgE was analyzed. RESULTS: Our results showed polarization of Tfh2 cells within circulating Tfh cell subsets in the patients with asthma. Phenotypic assays showed that activated Tfh2 subtypes displayed the features of Tfh cells, including invariably coexpressed programmed cell death 1 (PD-1), and inducible costimulator (ICOS). Furthermore, not only the frequency of Tfh2 cells but also the ratio (%Tfh2/%Tfh1) positively correlated with the total IgE level in the blood. CONCLUSION: Results of our data described an altered circulating Tfh subset distribution, which implied that this cell subset might play an important role in the pathogenesis of asthma</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931292">PM:27931292</url></web-urls></urls><custom2><style face="normal" font="default">20161209, Gong F</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40831</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hoshino,M.</style></author><author><style face="normal" font="default"> Ohtawa,J.</style></author><author><style face="normal" font="default"> Akitsu,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Clinical Allergy, Department of Internal Medicine, Atami Hospital, International University of Health and Welfare, Atami, Japan</style></auth-address><titles><title><style face="normal" font="default">Effects of the addition of tiotropium on airway dimensions in symptomatic asthma</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="153" start="147">147-153</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">airflow</style></keyword><keyword><style face="normal" font="default"> Airflow limitation</style></keyword><keyword><style face="normal" font="default"> airflow obstruction</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anticholinergic bronchodilator</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Body Surface Area</style></keyword><keyword><style face="normal" font="default"> bronchodilation</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Tiotropium, a once-daily, long-acting anticholinergic bronchodilator, has shown efficacy and safety as an add-on to maintenance therapy in patients with symptomatic asthma. OBJECTIVE: The aim of the present study was to assess the effect of tiotropium on airway geometry and airway inflammation in patients with asthma who were symptomatic despite treatment with inhaled corticosteroid (ICS) plus a long-acting beta 2agonist (LABA). METHODS: In total, 53 patients with symptomatic asthma who received ICS plus LABA and who had a prebronchodilator forced expiratory volume in 1 second of 6090% of the predicted value were randomized to the addition of tiotropium 5 g once daily (n = 25) or no add-on (n = 28) to maintenance therapy for 48 weeks. Quantitative computed tomography, fractional exhaled nitric oxide, and pulmonary function were measured. RESULTS: Compared with maintenance therapy, the addition of tiotropium significantly decreased airway wall area (WA) corrected for body surface area (BSA) (WA/BSA) (p 0.05) and wall thickness (T) (T/BSA, p 0.05), and improved airflow obstruction. No significant difference in the change of fractional exhaled nitric oxide was observed between the two treatment groups. Changes in WA/BSA and T/BSA were significantly correlated with the change in predicted forced expiratory volume in 1 second (r = 0.87, p 0.001, and r = 0.82, p 0.001, respectively). CONCLUSION: The addition of once-daily tiotropium to maintenance therapy improved airflow limitation and reduced airway T. A triple combination of tiotropium and ICS plus LABA may have additive protective effects of bronchodilation and remodeling</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931291">PM:27931291</url></web-urls></urls><custom2><style face="normal" font="default">20161209, Hoshino M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40832</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nguyen,V.Q.</style></author><author><style face="normal" font="default"> Ulrik,C.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Hvidovre Hospital, Hvidovre, Denmark</style></auth-address><titles><title><style face="normal" font="default">Measures to reduce maintenance therapy with oral corticosteroid in adults with severe asthma</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="139" start="125">125-139</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Biologic therapy</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> mepolizumab</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Methotrexate</style></keyword><keyword><style face="normal" font="default"> Mometasone</style></keyword><keyword><style face="normal" font="default"> mometasone furoate</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Maintenance therapy with oral corticosteroid (OCS) is used, although not based on evidence, for patients with severe asthma, but OCS is associated with serious adverse effects; therefore, management strategies aimed at steroid sparing are important. OBJECTIVE: To provide an update on the evidence for OCS-sparing strategies in adults with severe asthma. METHODS: A systematic literature review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. RESULTS: A total of 21 studies (which comprised 3060 subjects) were included. Of the nonbiologic oral steroidsparing strategies (n = 5), the following lowered the OCS dose: Internet-based tapering strategy (44% reduction in OCS dose), inhaled corticosteroids (mometasone furoate [mean daily OCS dose reduction of 39% and 31% in patients treated with 800 mcg/day and 1600 mcg/day, respectively] and ciclesonide [OCS dose reduction of 47% and 63% in patients treated with 640 mcg/day and 1.280 mcg/day, respectively]), and methotrexate (OCS dose reduction of 55%). Of the biologic oral steroidtapering strategies (16 studies) the following agents lowered the OCS dose: cyclosporin A (62% reduction in OCS dose), masitinib (78% reduction in OCS dose), mepolizumab (50%83% reduction in OCS dose), and omalizumab (30%64% of enrolled patients achieved a reduction in OCS dose, and one study reported a dose reduction of 45%). CONCLUSIONS: In adults with severe asthma, several corticosteroid-sparing interventions were shown to be effective in reducing systemic steroid exposure, not least in studies of add-on biologic therapy. However, based on the available studies, ciclesonide, based on the low potential for systemic effect, especially seems to be a good candidate for reducing steroid exposure in these patients before possible initiation of biologic therapy</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931289">PM:27931289</url></web-urls></urls><custom2><style face="normal" font="default">20161209, Nguyen VQ</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40833</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Abu-Kishk,I.</style></author><author><style face="normal" font="default"> Polakow-Farkash,S.</style></author><author><style face="normal" font="default"> Elizur,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Critical Care Unit, Assaf Harofeh Medical Center, Zerifin, Israel</style></auth-address><titles><title><style face="normal" font="default">Long-term outcome after pediatric intensive care unit asthma admissions</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="175" start="169">169-175</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> airflow</style></keyword><keyword><style face="normal" font="default"> airflow obstruction</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy skin tests</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> intensive care unit</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patients with asthma admitted to the pediatric intensive care unit (PICU) are often found to have had previous severe asthma exacerbations. OBJECTIVE: To prospectively evaluate the outcome of children after PICU admission. METHODS: Patients, ages 218 years, admitted to the PICU at Assaf Harofeh Medical Center over a 10-year period were assessed at a mean of 10 years after their admission and compared with matched patients admitted to the pediatric ward. Each patient filled out a questionnaire on subsequent hospitalizations and current asthma treatment and control. Pulmonary function studies and allergy skin tests were performed. RESULTS: Compared with patients admitted to the pediatric ward, those admitted to the PICU had more hospitalization and ICU admissions after their index admission (p = 0.022 and p = 0.021, respectively). Most patients in both groups (6070%) had uncontrolled asthma, and 47% of those (PICU) and 33% (ward) were not receiving controller therapy. Patients in the PICU group had more recent asthma exacerbations (p = 0.014), weekly wheezing (p = 0.017), and bronchodilator use (p = 0.007). Lung function tests were comparable between the two groups, but 3045% in each group had airflow obstruction. No significant differences were found between preschool and school-age children in any of the parameters. CONCLUSION: Compared with patients admitted to the pediatric ward, those admitted to the PICU with asthma exacerbations, experienced more asthma-related hospitalizations and their asthma was less controlled even years later. The lack of regular follow-up and controller therapy in most patients after asthma hospitalization indicated that this increased morbidity might be prevented</style></abstract><notes><style face="normal" font="default">DA - 20161209IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27931294">PM:27931294</url></web-urls></urls><custom2><style face="normal" font="default">20161209, Abu-Kishk I</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40834</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hamzavi,A.Y.</style></author><author><style face="normal" font="default"> Perkins,A.M.</style></author><author><style face="normal" font="default"> Morales,M.B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Childhood obesity in pediatric patients with difficult-to-control asthma in a tertiary pediatric subspecialty clinic</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="69" start="63">63-69</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">African American</style></keyword><keyword><style face="normal" font="default"> African Americans</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> overweight</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> race</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Identifying clinical features associated with difficult-to-control asthma will help address overall control and more-effective asthma management. OBJECTIVE: To evaluate our clinical observation that the proportion of patients who are overweight or obese is significantly higher in patients with difficult-to-control asthma than in patients with well-controlled asthma. METHODS: This was a retrospective chart review of 400 patients, ages 5 to 18 years. Cases (n = 200) were identified as 100 subjects with difficult-to-control asthma and an inhaled corticosteroid dose of >/=1000 mug/day and 100 subjects with well-controlled asthma and an inhaled corticosteroid dose of &lt;/=500 mug/day. The control group included 200 subjects without asthma. Multivariable logistic regression models were used to assess the relationships between asthma status and weight status, age, race, and sex. RESULTS: The mean body mass index percentile (+/- standard deviation at 95% confidence interval) was significantly higher in the difficult-to-control asthma group versus the well-controlled asthma group versus the control group (74.66 +/- 28.19 versus 54.25 +/- 29.92 versus 55.19 +/- 32.54; p &lt; 0.001). Thirty-six percent of the difficult-to-control patients with asthma were obese (versus 6% of the patients with well-controlled asthma [p &lt; 0.001] versus 13% of patients without asthma [p = 0.002]), and 47% normal weight (versus 79% of the patients with well-controlled asthma versus 75% of patients without asthma; p &lt; 0.001). The mean age and the proportion of African Americans in the difficult-to-control asthma group were significantly higher than in the well-controlled asthma group and in the control group (p &lt; 0.001). CONCLUSION: The results of this study demonstrated a significant association between severe persistent difficult-to-control asthma and obesity, age, and race. Patients who are obese and have difficult-to-control asthma need treatment approaches that address both asthma control and weight management</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28052803">PM:28052803</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-63-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-63-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Hamzavi AY</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40835</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Magen,E.</style></author><author><style face="normal" font="default"> Masalha,A.</style></author><author><style face="normal" font="default"> Waitman,D.A.</style></author><author><style face="normal" font="default"> Kahan,N.</style></author><author><style face="normal" font="default"> Viner,I.</style></author><author><style face="normal" font="default"> Klassov,L.</style></author><author><style face="normal" font="default"> Vardy,D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prevalence of dermatologic diseases among patients with selective immunoglobulin A deficiency</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="77" start="70">70-77</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="default"> epidemiologic study</style></keyword><keyword><style face="normal" font="default"> Iga</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin A</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: There are no published large-scale epidemiologic studies regarding the prevalence of skin diseases in patients with selective immunoglobulin A (IgA) deficiency (sIgAD). The purpose of this study was to investigate the prevalence of dermatological diseases in patients with sIgAD. METHODS: This retrospective matched case-control study was based on data from the Leumit Healthcare Services data base (approximately 725,000 residents of Israel), which was searched for all subjects aged >/=12 years who had undergone serum total IgA measurements during 2004-14 for any reason. The case group included subjects with sIgAD. The control A group was randomly sampled from those subjects in whom an IgA was drawn (n approximately 725,000), with a ratio of 10 controls for every case (1:10). The control A group was randomly sampled from those subjects in whom an IgA was drawn (n = 104,729) and the control B group was randomly sampled from the full study population (n approximately 725,000), with a ratio of 10 controls for every case (1:10). Comorbidity was compared between the study groups. RESULTS: The sIgAD group was characterized: 1) By a higher prevalence of atopic dermatitis (AD) (16 [4.6 %]) than the control A group (76 [2.1 %]; p = 0.004 and the control B group (64 [1.9 %]; p = 0.002). 2) By higher prevalence of acne (69 [19.9 %]) than the control A group (516 [13.8 %]; p = 0.013) and control B group (494 [14.2 %]; p &lt; 0.001). 3) By higher rate of chronic spontaneous urticaria (CSU) (17 [4.9 %)] than in the control A group (31 [0.9 %], with odds ratio 5.54 [3.04-10.13]; p &lt; 0.001) and the control B group (28 [0.8 %]; p &lt; 0.001). CONCLUSIONS: sIgAD is characterized by a higher prevalence of AD, CSU and acne</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4018)</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28052804">PM:28052804</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-70-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-70-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Magen E</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4018)</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40836</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mannucci,C.</style></author><author><style face="normal" font="default"> Casciaro,M.</style></author><author><style face="normal" font="default"> Minciullo,P.L.</style></author><author><style face="normal" font="default"> Calapai,G.</style></author><author><style face="normal" font="default"> Navarra,M.</style></author><author><style face="normal" font="default"> Gangemi,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Involvement of microRNAs in skin disorders: A literature review</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="15" start="9">9-15</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal model</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> delayed-type hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> MicroRNAs</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rna</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Toxic epidermal necrolysis</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: miRNAs are a class of noncoding RNA molecules that modulate gene expression after transcription. It is known that miRNAs are involved in various cellular processes of both normal and diseased skin. Recently, differential expressions of miRNAs have been reported and associated with several immunologic and inflammatory disorders, which indicate a common role in fundamental biologic processes. OBJECTIVE: To collect and review data from the literature on involvement of miRNA in inflammatory skin disorders. METHODS: A bibliographic search of scientific literature was carried out independently by two researchers in scientific data bases and search engines. The MeSH terms used were the following: "microRNAs" combined with "skin," "dermatitis," "urticaria," "eczema," "hypersensitivity." All research articles from inception until April 2016 were considered. RESULTS: A total of 11 research articles on the study of miRNAs in inflammatory skin disorders (atopic dermatitis, delayed-type hypersensitivity, eczema, toxic epidermal necrolysis) were identified. All the studies confirmed the main role of endogenous noncoding RNAs in diseases such as atopic dermatitis, allergic contact dermatitis, eczema, and toxic epidermal necrolysis. CONCLUSION: The miRNAs seem to influence regulatory mechanisms of inflammation in both inducing and contrasting acute and chronic skin inflammation. They also seem to be useful instruments in identifying and staging diseases such as dermatitis and other inflammatory skin diseases. Also, the potential application of miRNAs in genetic therapies demonstrated its efficacy on animal models</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28052797">PM:28052797</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-9-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-9-15.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Mannucci C</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40837</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,L.H.</style></author><author><style face="normal" font="default"> Chang,H.</style></author><author><style face="normal" font="default"> Namgoong,S.</style></author><author><style face="normal" font="default"> Kim,J.O.</style></author><author><style face="normal" font="default"> Cheong,H.S.</style></author><author><style face="normal" font="default"> Lee,S.G.</style></author><author><style face="normal" font="default"> Park,J.S.</style></author><author><style face="normal" font="default"> Baek,A.R.</style></author><author><style face="normal" font="default"> Koo,S.M.</style></author><author><style face="normal" font="default"> Choi,I.S.</style></author><author><style face="normal" font="default"> Kim,M.K.</style></author><author><style face="normal" font="default"> Park,H.S.</style></author><author><style face="normal" font="default"> Park,C.S.</style></author><author><style face="normal" font="default"> Shin,H.D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Genetic variants of the gasdermin B gene associated with the development of aspirin-exacerbated respiratory diseases</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="" start="83">83-</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Respiratory diseases</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28052809">PM:28052809</url></web-urls></urls><custom2><style face="normal" font="default">20170105, Kim LH</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40838</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Noh,H.R.</style></author><author><style face="normal" font="default"> Magpantay,G.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hypereosinophilic syndrome</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="81" start="78">78-81</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergist</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Hypereosinophilia</style></keyword><keyword><style face="normal" font="default"> Hypereosinophilic Syndrome</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hypereosinophilic syndrome (HES) is a myeloproliferative disorder characterized by persistent eosinophilia associated with multiple organ damage. OBJECTIVE: To increase awareness of the rare but potentially life-threatening disease and to provide a brief overview of the clinical presentation, diagnosis, and management of HES. METHODS: Pertinent data from the patient's clinical course was incorporated with salient articles on the topic. RESULTS: A case of HES is presented, followed by discussion of the clinical characteristics, diagnosis, and management. Clinical pearls and pitfalls are emphasized for the practicing allergist, clinical immunologist, and fellow-in-training. CONCLUSION: A diagnosis of HES should be considered in patients with an absolute eosinophil count of >1500 cells/muL documented on two occasions at least 1 month apart, and/or in those with pathologic confirmation of tissue hypereosinophilia. The decision to treat HES should be guided by both the clinical presentation and results of laboratory and mutational analysis</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.3995</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28052805">PM:28052805</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-78-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-78-81.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Noh HR</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.3995</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40839</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Drucker,A.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Atopic dermatitis: Burden of illness, quality of life, and associated complications</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="8" start="3">3-8</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Assessment</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> persistence</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis is a chronically relapsing inflammatory skin condition that is burdensome for individuals with the disease, their families, and for society as a whole. OBJECTIVES: The purpose of this review was to provide a broad overview of the burden of atopic dermatitis, including quality of life and its associated complications. METHODS AND RESULTS: This article was divided into four main sections: (1) atopic dermatitis prevalence, persistence, and population-level burden; (2) burden of atopic dermatitis for individuals and their families; (3) medical complications and comorbidities of atopic dermatitis; and (4) assessment of the burden of atopic dermatitis in clinical practice. CONCLUSION: Having an understanding of the burden of atopic dermatitis is important for clinicians as they assess and manage atopic dermatitis in the clinical setting</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28052794">PM:28052794</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-3-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-3-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, Drucker AM</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40840</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Weller,K.</style></author><author><style face="normal" font="default"> Maurer,M.</style></author><author><style face="normal" font="default"> Fridman,M.</style></author><author><style face="normal" font="default"> Supina,D.</style></author><author><style face="normal" font="default"> Schranz,J.</style></author><author><style face="normal" font="default"> Magerl,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="151" start="143">143-151</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Administration,Intravenous</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> C1 INH</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-INH</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> C1Inh</style></keyword><keyword><style face="normal" font="default"> Complement</style></keyword><keyword><style face="normal" font="default"> Complement C1</style></keyword><keyword><style face="normal" font="default"> Complement C1 Inhibitor Protein</style></keyword><keyword><style face="normal" font="default"> Complement Inactivating Agents</style></keyword><keyword><style face="normal" font="default"> Cross-Over Studies</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Double-Blind Method</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Health Status</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Hereditary Angioedema Types I and II</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hyaluronoglucosaminidase</style></keyword><keyword><style face="normal" font="default"> Infusions,Subcutaneous</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prevention &amp; control</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Recombinant</style></keyword><keyword><style face="normal" font="default"> recombinant protein</style></keyword><keyword><style face="normal" font="default"> Recombinant Proteins</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Secondary Prevention</style></keyword><keyword><style face="normal" font="default"> subcutaneous</style></keyword><keyword><style face="normal" font="default"> Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default"> therapeutic use</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: To estimate health-related quality-of-life changes in patients with hereditary angioedema due to C1-inhibitor (C1-INH) deficiency who received subcutaneous C1-INH with recombinant hyaluronidase (rHuPH20) for attack prophylaxis in a randomized, double-blind, dose-ranging, cross-over study. METHODS: Patients with type I/II hereditary angioedema received 1000 U of C1-INH with 24,000 U of rHuPH20 or 2000 U of C1-INH with 48,000 U of rHuPH20 every 3-4 days for 8 weeks and then crossed over for another 8-week period. The study was terminated early as a precaution related to non-neutralizing antibodies to rHuPH20. The Angioedema Quality of Life questionnaire (AE-QoL) was administered at weeks 1 and 5 of both periods, and at 1 week after the second treatment period. Changes in AE-QoL scores were calculated over both treatment periods and within each treatment period for patients with >/=4 weeks of treatment. RESULTS: Forty-one patients had evaluable AE-QoL data, and 22 patients completed treatment. At screening, 43% of the patients were receiving intravenous C1-INH. A significant average AE-QoL total score decline (improvement) of -8.1 (95% confidence interval, -13.7 to -2.5) was observed from baseline to the end of the study, and significant AE-QoL score declines were observed in the Functioning, Fear/Shame, and Nutrition domains. Patients on 2000 U reported higher mean AE-QoL score declines in Functioning and Nutrition domains relative to the 1000 U dose. Overall, 43.9% of all the patients, 45.5% of the study completers, and 46.7% of the nonprophylaxis users at baseline on high treatment doses achieved a reduction in the AE-QoL total score of six points. CONCLUSION: Despite early termination and prestudy prophylactic intravenous C1-INH use by 43% of the patients, improved AE-QoL scores were observed after &lt;/=16 weeks of subcutaneous C1-INH-rHuPH20 prophylaxis</style></abstract><notes><style face="normal" font="default">DA - 20170117IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticlePT - Randomized Controlled TrialRN - 0 (Complement C1 Inhibitor Protein)RN - 0 (Complement Inactivating Agents)RN - 0 (Recombinant Proteins)RN - EC 3.2.1.35 (Hyaluronoglucosaminidase)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28093999">PM:28093999</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-143-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-143-51.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170117, Weller K</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40841</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gupta,A.</style></author><author><style face="normal" font="default"> Gupta,L.K.</style></author><author><style face="normal" font="default"> Rehan,H.S.</style></author><author><style face="normal" font="default"> Prakash,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Response to inhaled corticosteroids on serum CD28, quality of life, and peak expiratory flow rate in bronchial asthma</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="18" start="13">13-18</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Administration,Inhalation</style></keyword><keyword><style face="normal" font="default"> Adrenal Cortex</style></keyword><keyword><style face="normal" font="default"> Adrenal Cortex Hormones</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> Antigens,CD28</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> drug therapy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glycoprotein</style></keyword><keyword><style face="normal" font="default"> Hormones</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Interleukin-2</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Peak expiratory flow</style></keyword><keyword><style face="normal" font="default"> Peak Expiratory Flow Rate</style></keyword><keyword><style face="normal" font="default"> physiopathology</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> QOL</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Severity of Illness Index</style></keyword><keyword><style face="normal" font="default"> Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> therapeutic use</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: CD28 is a 44 kDa glycoprotein that is important in initiating T-cell responses and that results in increased T-cell proliferation and interleukin-2 production. This study estimated the serum CD28 levels in patients with asthma and evaluated the effect of inhaled corticosteroids (ICS) on the levels of CD28, the peak expiratory flow rate (PEFR), and quality of life (QOL). METHODS: This prospective, open-label, observational study enrolled 40 adult patients with asthma of mild-to-moderate severity who were started on ICS and 40 healthy controls. Patients with bronchial asthma were evaluated for their serum CD28 level and QOL by using Mini Asthma Quality of Life Questionnaire scores, severity of symptoms, and PEFR at baseline and after 4 weeks. RESULTS: The mean (standard deviation [SD]) serum CD28 concentration in patients with asthma was 107 +/- 4.98 ng/mL, which was significantly elevated (p &lt; 0.01) compared with the healthy individuals (37.67 +/- 18.28 ng/mL). ICS treatment for 4 weeks reduced the mean (SD) serum CD28 levels to 40.9 +/- 2.82 ng/mL. PEFR increased significantly, from 190.75 +/- 10.55 to 263 +/- 10.69 L/min (p &lt; 0.01) after 4 weeks. Similarly, the mean (SD) Mini Asthma Quality of Life Questionnaire scores significantly increased, from 36.90 +/- 10.31 on day 0 to 70.63 +/- 11.56 on day 28 after ICS therapy (p &lt; 0.01). A negative correlation between the elevations of serum CD28 levels was seen with QOL. CONCLUSION: The serum CD28 concentration, a marker of inflammation, is increased in bronchial asthma and reduced by ICS therapy. ICS also improved QOL scores and objective clinical outcomes in patients with asthma</style></abstract><notes><style face="normal" font="default">DA - 20170224IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticlePT - Observational StudyRN - 0 (Adrenal Cortex Hormones)RN - 0 (Antigens, CD28)SB - IMCO - India -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28234041">PM:28234041</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-13-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-13-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170224, Gupta A</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4022</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40842</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kueppers,F.</style></author><author><style face="normal" font="default"> Sanders,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">State-of-the-art testing for alpha-1 antitrypsin deficiency</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="114" start="108">108-114</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">airflow</style></keyword><keyword><style face="normal" font="default"> airflow obstruction</style></keyword><keyword><style face="normal" font="default"> alpha 1-Antitrypsin</style></keyword><keyword><style face="normal" font="default"> alpha 1-Antitrypsin Deficiency</style></keyword><keyword><style face="normal" font="default"> Alpha-1 antitrypsin deficiency</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical guidelines</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnosis,Differential</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> economics</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic Testing</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Genotyping Techniques</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> High-Throughput Nucleotide Sequencing</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> Isoelectric Focusing</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Sequence Analysis,DNA</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="24" Month="3" Year="2017">2017/3/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) is a genetic condition characterized by low serum levels of the protein alpha-1 antitrypsin. Because there are no unique clinical symptoms that point to a definitive diagnosis of AATD, laboratory testing is crucial to differentiate this disease from others. OBJECTIVE: To summarize advances in laboratory techniques used to test for AATD. METHODS: Data were sourced from a nonsystematic literature review of MEDLINE and the author's personal literature collection, and by checking reference lists of sourced articles. RESULTS: Since the original description of AATD by Laurell and Eriksson in 1963, testing methods have undergone major changes. Currently, alpha-1 antitrypsin protein is quantified by immunologic measurement in serum, and the phenotype is characterized by isoelectric focusing and/or targeted genotyping of predefined mutations. In addition, whole-gene sequencing of the gene SERPINA1 can be undertaken. However, this is costly and generally used only if targeted genotyping cannot conclusively identify the variant. The introduction of next-generation sequencing (NGS), which enables rapid and accurate sequencing of large quantities of DNA fragments in a single reaction, may help reduce costs. With its increasing availability, NGS may begin to appear in testing protocols. Clinical guidelines recommend that patients are tested for AATD if they have chronic irreversible airflow obstruction, especially those with early onset disease or a positive family history of AATD. Despite this, AATD is still underrecognized, and significant delays exist between symptom onset and diagnosis. CONCLUSION: Traditional testing practices have limitations. Screening programs that incorporate NGS are the most comprehensive methods available for accurate diagnosis of AATD</style></abstract><notes><style face="normal" font="default">DA - 20170125IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticlePT - ReviewRN - 0 (SERPINA1 protein, human)RN - 0 (alpha 1-Antitrypsin)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28120746">PM:28120746</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-108-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-108-14.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170125, Kueppers F</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4031</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40843</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">LaForce,C.</style></author><author><style face="normal" font="default"> Taveras,H.</style></author><author><style face="normal" font="default"> Iverson,H.</style></author><author><style face="normal" font="default"> Shore,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Albuterol multidose dry powder inhaler efficacy and safety versus placebo in children with asthma</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="37" start="28">28-37</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Albuterol</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma therapy</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="1" Year="2017">2017/1/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: A novel, inhalation-driven, multidose dry powder inhaler (MDPI) that does not require coordination of actuation with inhalation has been developed. OBJECTIVE: To evaluate the efficacy and safety of albuterol MDPI versus placebo MDPI after chronic dosing in children with asthma. METHODS: This phase III, double-blind, parallel-group study included children with asthma (ages, 4-11 years) with forced expiratory volume in 1 second (FEV1) of 50-95% of predicted. After a 14-day run-in period wherein the patients continued their current asthma therapy and received single-blind placebo MDPI, they were randomized to albuterol MDPI 90 mug per inhalation, two inhalations four times daily (total daily dose, 720 mug), or placebo for 3 weeks. Pulmonary function was assessed on days 1 and 22. Efficacy and safety were evaluated by measuring the baseline-adjusted percent-predicted FEV1 (PPFEV1) area under the time curve over 6 hours (AUC0-6) after the dose and adverse events, respectively. RESULTS: The full analysis set included 184 patients. Patients treated with albuterol MDPI versus patients treated with placebo MDPI had significantly greater baseline-adjusted PPFEV1 AUC0-6 over 3 weeks (least squares mean difference, 25.0%*hour, which favored albuterol; p &lt; 0.001). The benefit of albuterol (mean change in PPFEV1) was evident 5 minutes after dosing and lasted several hours; the maximal effect was noted 1 to 2 hours after dosing. Albuterol MDPI was well tolerated. CONCLUSIONS: In children with persistent asthma, albuterol MDPI improved pulmonary function significantly better than placebo MDPI over 3 weeks of treatment. Clinical efficacy was evident within 5 minutes of dosing and maintained for >2 hours. Four times daily administration was well tolerated</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4015)</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28052799">PM:28052799</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-28-37.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-28-37.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170105, LaForce C</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4015)</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40844</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Miller,D.</style></author><author><style face="normal" font="default"> Wood,C.</style></author><author><style face="normal" font="default"> Bateman,E.</style></author><author><style face="normal" font="default"> LaForce,C.</style></author><author><style face="normal" font="default"> Blatchford,J.</style></author><author><style face="normal" font="default"> Hilbert,J.</style></author><author><style face="normal" font="default"> Gupta,A.</style></author><author><style face="normal" font="default"> Fowler,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="164" start="157">157-164</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Africa</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default"> Anti-Asthmatic Agents</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Anti-Inflammatory Agents</style></keyword><keyword><style face="normal" font="default"> Antiasthmatic agents</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Benzamides</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Cross-Over Studies</style></keyword><keyword><style face="normal" font="default"> CRTH2</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Double-Blind Method</style></keyword><keyword><style face="normal" font="default"> drug therapy</style></keyword><keyword><style face="normal" font="default"> Drug Therapy,Combination</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> fluticasone propionate</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory mediators</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pharmacokinetics</style></keyword><keyword><style face="normal" font="default"> physiopathology</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> Prostaglandin</style></keyword><keyword><style face="normal" font="default"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="default"> Pyrimidines</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Receptors,Immunologic</style></keyword><keyword><style face="normal" font="default"> Receptors,Prostaglandin</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> Th2 Cells</style></keyword><keyword><style face="normal" font="default"> therapeutic use</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is characterized by a complex interaction of inflammatory mediators. The prostaglandin D2 receptor, chemoattractant receptor-homologous molecule on Th2 cells (CRTH2), plays a pivotal role in the pathogenesis of allergic airway inflammation. OBJECTIVE: To ealuate the efficacy, safety, and pharmacokinetics of BI 671800, a CRTH2 antagonist, when added to inhaled corticosteroid therapy in adult patients with symptomatic asthma. METHODS: In this phase IIa, 12-week, randomized, double-blind, three-period, four-treatment, incomplete block crossover trial, BI 671800 was administered either as a single 400-mg dose in the morning (A.M.) or evening (P.M.), or 200 mg twice daily (A.M. and P.M.) versus placebo, together with fluticasone propionate (44 mug, two inhalations twice daily). The primary end point was the change from baseline in trough forced expiratory volume in 1 second percentage predicted after 4 weeks. The secondary end point was the change in Asthma Control Questionnaire score from baseline. RESULTS: A total of 108 patients were randomized and treated. After 4 weeks, the adjusted mean (+/- SE) treatment differences for the primary end point versus placebo were 0.08 +/- 0.62%, 0.28 +/- 0.61%, and 0.67 +/- 0.63% for BI 671800 at 200 mg twice daily, 400 mg A.M., and 400 mg P.M., respectively (not statistically significant). No statistically significant or clinically meaningful differences in the Asthma Control Questionnaire score were observed versus placebo. Each treatment was well tolerated. CONCLUSION: BI 671800 at a dose of 400 mg administered for 4 weeks with fluticasone propionate did not provide clinical improvement in patients with asthma; reasons for this are unclear, but it may be due to insufficient inhibition of the CRTH2 receptor at the doses used</style></abstract><notes><style face="normal" font="default">DA - 20170224IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Clinical Trial, Phase IIPT - Journal ArticlePT - Randomized Controlled TrialRN - 0 (Anti-Asthmatic Agents)RN - 0 (Anti-Inflammatory Agents)RN - 0 (BI 671800)RN - 0 (Benzamides)RN - 0 (Pyrimidines)RN - 0 (Receptors, Immunologic)RN - 0 (Receptors, Prostaglandin)RN - 0 (prostaglandin D2 receptor)RN - CUT2W21N7U (Fluticasone)SB - IMCO - South Africa -CO - United Kingdom -CO - Germany -</style></notes><work-type><style face="normal" font="Palatino-Roman">10.2500/aap.2017.38.4034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28234053">PM:28234053</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-157-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-157-64.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170224, Miller D</style></custom2><misc3><style face="normal" font="Palatino-Roman">10.2500/aap.2017.38.4034</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40845</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Voge,G.A.</style></author><author><style face="normal" font="default"> Carey,W.A.</style></author><author><style face="normal" font="default"> Ryu,E.</style></author><author><style face="normal" font="default"> King,K.S.</style></author><author><style face="normal" font="default"> Wi,C.I.</style></author><author><style face="normal" font="default"> Juhn,Y.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">What accounts for the association between late preterm births and risk of asthma?</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="156" start="152">152-156</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child,Preschool</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> COX</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> early childhood</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Infant,Newborn</style></keyword><keyword><style face="normal" font="default"> Infant,Premature</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Kaplan-Meier Estimate</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Minnesota</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Premature Birth</style></keyword><keyword><style face="normal" font="default"> Proportional Hazards Models</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Term Birth</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Although results of many studies have indicated an increased risk of asthma in former late preterm (LPT) infants, most of these studies did not fully address covariate imbalance. OBJECTIVE: To compare the cumulative frequency of asthma in a population-based cohort of former LPT infants to that of matched term infants in their early childhood, when accounting for covariate imbalance. METHODS: From a population-based birth cohort of children born 2002-2006 in Olmsted County, Minnesota, we assessed a random sample of LPT (34 to 36 6/7 weeks) and frequency-matched term (37 to 40 6/7 weeks) infants. The subjects were followed-up through 2010 or censored based on the last date of contact, with the asthma status based on predetermined criteria. The Kaplan-Meier method was used to estimate the cumulative incidence of asthma during the study period. Cox models were used to estimate the hazard ratio and 95% confidence interval for the risk of asthma, when adjusting for potential confounders. RESULTS: LPT infants (n = 282) had a higher cumulative frequency of asthma than did term infants (n = 297), 29.9 versus 19.5%, respectively; p = 0.01. After adjusting for covariates associated with the risk of asthma, an LPT birth was not associated with a risk of asthma, whereas maternal smoking during pregnancy was associated with a risk of asthma. CONCLUSION: LPT birth was not independently associated with a risk of asthma and other atopic conditions. Clinicians should make an effort to reduce exposure to smoking during pregnancy as a modifiable risk factor for asthma</style></abstract><notes><style face="normal" font="default">DA - 20170224IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28234052">PM:28234052</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-152-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-152-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170224, Voge GA</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40846</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Henao,M.P.</style></author><author><style face="normal" font="default"> Craig,T.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Understanding alpha-1 antitrypsin deficiency: A review with an allergist's outlook</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="107" start="98">98-107</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> alpha 1-Antitrypsin</style></keyword><keyword><style face="normal" font="default"> alpha 1-Antitrypsin Deficiency</style></keyword><keyword><style face="normal" font="default"> Alpha-1 antitrypsin deficiency</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnosis,Differential</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Early Diagnosis</style></keyword><keyword><style face="normal" font="default"> Early Medical Intervention</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Lung Diseases,Obstructive</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protease</style></keyword><keyword><style face="normal" font="default"> protease inhibitor</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Disease,Chronic Obstructive</style></keyword><keyword><style face="normal" font="default"> REACH</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Serine</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapeutic use</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trypsin</style></keyword><keyword><style face="normal" font="default"> Trypsin inhibitor</style></keyword><keyword><style face="normal" font="default"> Trypsin Inhibitors</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="default">Alpha-1 antitrypsin (AAT) is the prototypical protease inhibitor from the serine protease inhibitor (serpin) superfamily that protects lung tissue from proteolytic damage by inhibiting neutrophil elastase. Approximately 1 in 2750 to 1 in 4500 individuals have an autosomal codominant condition that leads to a deficiency of circulating AAT. In individuals with AAT deficiency (AATD), AAT is retained in liver cells, which predisposes them to liver disease, and does not reach lung tissues through circulation, where it normally acts as the primary natural regulator of proteolytic activity in the pulmonary tissues, which thus leads to lung disease. Despite being commonly labeled as a rare disease, AATD is one of the most common autosomal genetic disorders and is considered highly underrecognized, with &lt;/=10% of individuals suspected with AATD identified. Screening guidelines have been established, and the diagnosis is easy to confirm when the condition is suspected. Early recognition is key to prevent morbidity and mortality associated with the disease. For this reason, all patients with chronic obstructive pulmonary disease and patients with asthma and fixed obstruction should be tested to exclude the diagnosis of AATD. Augmentation therapy of the deficient protein is available for those with significant lung disease and protein deficiency, and analysis of recent data supported preservation of lung tissue with this treatment. In this review, oriented toward specialists in allergy and immunology, we focused our discussion on the presentation, diagnosis, and treatment of pulmonary symptoms of AATD</style></abstract><notes><style face="normal" font="default">DA - 20170224IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticlePT - ReviewRN - 0 (SERPINA1 protein, human)RN - 0 (Trypsin Inhibitors)RN - 0 (alpha 1-Antitrypsin)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28234047">PM:28234047</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-98-107.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-98-107.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170224, Henao MP</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40847</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Seneviratne,S.L.</style></author><author><style face="normal" font="default"> Maitland,A.</style></author><author><style face="normal" font="default"> Afrin,L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Mast cell disorders in Ehlers-Danlos syndrome</style></title><secondary-title><style face="normal" font="default">Am J Med Genet C Semin Med Genet</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Am J Med Genet C Semin Med Genet</style></abbr-1></periodical><pages end="236" start="226">226-236</pages><volume><style face="normal" font="default">175</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> angiogenesis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Blood Vessels</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Connective Tissue</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Delayed hypersensitivity</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> dysregulation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fibroblasts</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity syndrome</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Nerve Fibers</style></keyword><keyword><style face="normal" font="default"> Periodicals</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="6" Month="3" Year="2017">2017/3/6</year></dates><abstract><style face="normal" font="default">Well known for their role in allergic disorders, mast cells (MCs) play a key role in homeostatic mechanisms and surveillance, recognizing and responding to different pathogens, and tissue injury, with an array of chemical mediators. After being recruited to connective tissues, resident MCs progenitors undergo further differentiation, under the influence of signals from surrounding microenvironment. It is the differential tissue homing and local maturation factors which result in a diverse population of resident MC phenotypes. An abundance of MC reside in connective tissue that borders with the external world (the skin as well as gastrointestinal, respiratory, and urogenital tracts). Situated near nerve fibers, lymphatics, and blood vessels, as well as coupled with their ability to secrete potent mediators, MCs can modulate the function of local and distant structures (e.g., other immune cell populations, fibroblasts, angiogenesis), and MC dysregulation has been implicated in immediate and delayed hypersensitivity syndromes, neuropathies, and connective tissue disorders (CTDs). This report reviews basic biology of mast cells and mast cell activation as well as recent research efforts, which implicate a role of MC dysregulation beyond atopic disorders and in a cluster of Ehlers-Danlos Syndromes, non-IGE mediated hypersensitivity disorders, and dysautonomia. (c) 2017 Wiley Periodicals, Inc</style></abstract><notes><style face="normal" font="default">DA - 20170306IS - 1552-4876 (Electronic)IS - 1552-4868 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1002/ajmg.c.31555</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28261938">PM:28261938</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Med Genet C Semin Med Genet\2017-175-226-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Med Genet C Semin Med Genet\2017-175-226-36.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170306, Seneviratne SL</style></custom2><misc3><style face="normal" font="default">10.1002/ajmg.c.31555</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40848</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kennedy,J.L.</style></author><author><style face="normal" font="default"> Stoner,A.N.</style></author><author><style face="normal" font="default"> Borish,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA</style></auth-address><titles><title><style face="normal" font="default">Aspirin-exacerbated respiratory disease: Prevalence, diagnosis, treatment, and considerations for the future</style></title><secondary-title><style face="normal" font="default">Am J Rhinol Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Am J Rhinol Allergy</style></abbr-1></periodical><pages end="413" start="407">407-413</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AERD</style></keyword><keyword><style face="normal" font="default"> Alcoholic Beverages</style></keyword><keyword><style face="normal" font="default"> Arkansas</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin desensitization</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> Aspirin sensitivity</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Beverages</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Hypereosinophilia</style></keyword><keyword><style face="normal" font="default"> Ingestion</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Samter triad</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Wine</style></keyword></keywords><dates><year Day="1" Month="11" Year="2016">2016/11/1</year></dates><abstract><style face="normal" font="default">Aspirin-exacerbated respiratory disease (AERD) is a late onset condition characterized by the Samter triad (aspirin sensitivity [as well as sensitivity to any nonselective cyclooxygenase inhibitor], nasal polyps, asthma) and additional features, including eosinophilic chronic rhinosinusitis, hypereosinophilia, anosmia, frequent absence of atopy, and, intolerance to ingestion of red wine and other alcoholic beverages. The diagnosis is rare, and, because of this, it is also often missed by physicians. However, it is highly overexpressed in patients with severe asthma (and severe chronic rhinosinusitis with nasal polyps), which makes its recognition essential. For this review, we considered mechanisms involved in the pathogenesis of this disease and discussed the clinical symptoms of AERD. We also discussed the role of aspirin desensitization in the treatment of AERD. Also, we considered medications (e.g, leukotriene modifiers) and surgical interventions that have a role in the treatment of AERD</style></abstract><notes><style face="normal" font="default">DA - 20170126IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/ajra.2016.30.4370</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28124651">PM:28124651</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Rhinol Allergy\2016-30-407-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Rhinol Allergy\2016-30-407-13.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170126, Kennedy JL</style></custom2><misc3><style face="normal" font="default">10.2500/ajra.2016.30.4370</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40849</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Greiwe,J.C.</style></author><author><style face="normal" font="default"> Bernstein,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Bernstein Allergy Group, University of Cincinnati, College of Medicine, Cincinnati, Ohio, USA</style></auth-address><titles><title><style face="normal" font="default">Combination therapy in allergic rhinitis: What works and what does not work</style></title><secondary-title><style face="normal" font="default">Am J Rhinol Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Am J Rhinol Allergy</style></abbr-1></periodical><pages end="396" start="391">391-396</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Azelastine</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Care Costs</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Intranasal corticosteroid</style></keyword><keyword><style face="normal" font="default"> intranasal corticosteroids</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medication adherence</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal Decongestants</style></keyword><keyword><style face="normal" font="default"> Ohio</style></keyword><keyword><style face="normal" font="default"> Over-the-counter</style></keyword><keyword><style face="normal" font="default"> Pathomechanisms</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> subtypes</style></keyword><keyword><style face="normal" font="default"> Targeted therapy</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Vasomotor rhinitis</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="1" Month="11" Year="2016">2016/11/1</year></dates><abstract><style face="normal" font="default">Allergic rhinitis and other rhinitis subtypes are increasingly becoming some of the most prevalent and expensive medical conditions that affect the U.S. POPULATION: Both direct health care costs and indirect costs significantly impact the health care system due to delays in diagnosis, lack of treatment, ineffective treatment, poor medication adherence, and associated comorbidities. Many patients who have AR turn to over-the-counter medications for relief but often find themselves dissatisfied with the results. Determining the correct diagnosis, followed by initiation of the most-effective treatment(s), is essential to provide patients with better symptomatic management and quality of life. Although there are many options, currently available combination therapies, e.g., azelastine with fluticasone and intranasal corticosteroids with nasal decongestants, offer distinct advantages for the management of complex rhinitis phenotypes. Further research is required to investigate the pathomechanisms and biomarkers for mixed rhinitis and nonallergic vasomotor rhinitis subtypes that will lead to novel targeted therapies for these conditions</style></abstract><notes><style face="normal" font="default">DA - 20170126IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/ajra.2016.30.4391</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28124648">PM:28124648</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Rhinol Allergy\2016-30-391-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Rhinol Allergy\2016-30-391-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170126, Greiwe JC</style></custom2><misc3><style face="normal" font="default">10.2500/ajra.2016.30.4391</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40850</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Campbell,A.P.</style></author><author><style face="normal" font="default"> Phillips,K.M.</style></author><author><style face="normal" font="default"> Hoehle,L.P.</style></author><author><style face="normal" font="default"> Feng,A.L.</style></author><author><style face="normal" font="default"> Bergmark,R.W.</style></author><author><style face="normal" font="default"> Caradonna,D.S.</style></author><author><style face="normal" font="default"> Gray,S.T.</style></author><author><style face="normal" font="default"> Sedaghat,A.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology, Harvard Medical School, Boston, Massachusetts</style></auth-address><titles><title><style face="normal" font="default">Depression symptoms and lost productivity in chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="289" start="286">286-289</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Facial Pain</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="default"> Nose</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Otolaryngology</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Principal Component Analysis</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic rhinosinusitis (CRS) is associated with significant losses of patient productivity that cost billions of dollars every year. The causative factors for decreases in productivity in patients with CRS have yet to be determined. OBJECTIVE: To determine which patterns of CRS symptoms drive lost productivity. METHODS: Prospective, cross-sectional cohort study of 107 patients with CRS. Sinonasal symptom severity was measured using the 22-item Sinonasal Outcomes Test, from which sleep, nasal, otologic or facial pain, and emotional function subdomain scores were calculated using principal component analysis. Depression risk was assessed with the 2-item Patient Health Questionnaire (PHQ-2), whereas nasal obstruction was assessed with the Nasal Obstruction Symptom Evaluation (NOSE) instrument. Lost productivity was assessed by asking participants how many days of work and/or school they missed in the last 3 months because of CRS. Associations were sought between lost productivity and CRS symptoms. RESULTS: A total of 107 patients were recruited. Patients missed a mean (SD) of 3.1 (12.9) days of work or school because of CRS. Lost productivity was most strongly associated with the emotional function subdomain (beta = 7.48; 95% confidence interval [CI], 5.71-9.25; P &lt; .001). Reinforcing this finding, lost productivity was associated with PHQ-2 score (beta = 4.72; 95% CI, 2.62-6.83; P &lt; .001). Lost productivity was less strongly associated with the nasal symptom subdomain score (beta = 2.65; 95% CI, 0.77-4.52; P = .007), and there was no association between lost productivity and NOSE score (beta = 0.01; 95% CI, -0.12 to 0.13; P = .91). CONCLUSION: Symptoms associated with depression are most strongly associated with missed days of work or school because of CRS. Further treatment focusing on depression-associated symptoms in patients with CRS may reduce losses in productivity</style></abstract><notes><style face="normal" font="default">DA - 20170312IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2016.12.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284535">PM:28284535</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-286-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-286-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170312, Campbell AP</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2016.12.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40851</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bernstein,J.A.</style></author><author><style face="normal" font="default"> Relan,A.</style></author><author><style face="normal" font="default"> Harper,J.R.</style></author><author><style face="normal" font="default"> Riedl,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunology, Allergy and Rheumatology, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio</style></auth-address><titles><title><style face="normal" font="default">Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> C1 esterase inhibitor</style></keyword><keyword><style face="normal" font="default"> C1Inh</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> NCT00262301</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Ohio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistence</style></keyword><keyword><style face="normal" font="default"> Recombinant</style></keyword><keyword><style face="normal" font="default"> Recombinant human C1 esterase inhibitor</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Symptoms of hereditary angioedema (HAE) attacks can recur soon after initial treatment; the durability of response for recombinant human C1 esterase inhibitor (rhC1INH) treatment is unknown. OBJECTIVE: To examine the efficacy and durability of rhC1INH for acute HAE attacks. METHODS: In this pooled post hoc analysis of 2 trials, patients with type I or II HAE (functional C1INH levels &lt;50% of normal) and a baseline visual analog scale score of at least 50 mm were included if they had received at least 1 intravenous dose of 50 U/kg of rhC1INH. Response was defined as symptom relief within 4 hours after treatment with persistence (>/=20-mm decrease in visual analog scale scores [0 mm {"no symptoms at all"} to 100 mm {"extremely disabling"}] at 2 consecutive time points) during the 4 hours. Durability was the response without an increase of at least 20 mm in the minimum post-treatment visual analog scale score up to 24 hours. Recurrence and new attack symptoms were determined for patients with 72-hour post-treatment data. RESULTS: Data were analyzed for 127 patients treated with 50 U/kg of rhC1INH in 2 studies. Most attacks (90.7%) responded within 4 hours, with differences in response rates among attack locations (61.5%-94.4%). The median time to the beginning of symptom relief was 75.0 minutes (95% confidence interval 65.0-80.0). No relapse occurred during 24 hours for attacks that initially responded. Only 7.1% of attacks were associated with symptom recurrence within 72 hours of initial rhC1INH treatment. CONCLUSION: This integrated analysis supports the efficacy of rhC1INH for treatment of acute HAE across multiple attacks, with a sustained response for at least 3 days. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT00225147 and NCT00262301</style></abstract><notes><style face="normal" font="default">DA - 20170312IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United states -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.01.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284978">PM:28284978</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170312-BernsteinJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170312-BernsteinJA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170312, Bernstein JA</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.01.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40852</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Giraldi,E.A.</style></author><author><style face="normal" font="default"> Johnson,J.</style></author><author><style face="normal" font="default"> Tcheurekdjian,H.</style></author><author><style face="normal" font="default"> Hostoffer,R.W.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default">University Hospitals Cleveland Medical Center, Cleveland, Ohio.</style></auth-address><titles><title><style face="normal" font="default">Idiopathic avascular necrosis associated with humoral deficiency</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">deficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> humoral</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Ohio</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170305IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.01.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28259389">PM:28259389</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170305-GiraldiEA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170305-GiraldiEA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170305, Giraldi EA</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.01.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40853</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tse,K.Y.</style></author><author><style face="normal" font="default"> Zuraw,B.L.</style></author><author><style face="normal" font="default"> Chen,Q.</style></author><author><style face="normal" font="default"> Christiansen,S.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy, Kaiser Permanente Medical Center, San Diego, California.</style></auth-address><titles><title><style face="normal" font="default">Anabolic androgen use in the management of hereditary angioedema: Not so cheap after all</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Androgens</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor deficiency</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Hyperlipidemia</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Targeted therapy</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="7" Month="3" Year="2017">2017/3/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hereditary angioedema due to C1 inhibitor deficiency (HAE) is a rare, life-threatening disease that imposes a significant burden on affected patients. 17alpha-alkylated androgens (anabolic androgens) decrease attack frequency and severity but carry the risk of potentially serious dose-related adverse effects. Despite the emergence of targeted therapies for HAE, continued anabolic androgen use has been driven in part by their low cost. OBJECTIVE: To examine the hidden cost of anabolic androgen use related to the risk of developing non-HAE comorbidities. METHODS: Patients with HAE were identified in the Southern California Kaiser Permanente database using clinical and laboratory findings compatible with HAE. These patients were stratified into anabolic androgen exposed and nonexposed groups. Matched controls were selected from the Kaiser database who did not have HAE or anabolic androgen exposure. Using multivariate analysis, we determined the number of non-HAE comorbidities linked to anabolic androgen use. We next determined the association between dosing and increasing exposure to anabolic androgens and the likelihood of having various comorbidities. RESULTS: Patients with HAE exposed to anabolic androgens had a 28% increase (P = .04) in non-HAE comorbidities when compared with their matched (nonexposed) controls. With each gram per month increase in exposure, a 12% increase in non-HAE comorbidities is observed (P &lt; .01). The most commonly occurring non-HAE comorbidities were psychiatric, muscle cramps, obesity, and hyperlipidemia. CONCLUSION: Our data suggest that long-term anabolic androgen use enhances the risk of developing comorbid health conditions, thus amplifying the cost of care. Our report provides additional support for the preferred use of newer, targeted therapies for the management of HAE</style></abstract><notes><style face="normal" font="default">DA - 20170311IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.01.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283277">PM:28283277</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170311-TseKY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170311-TseKY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170311, Tse KY</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.01.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40854</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Desai,M.</style></author><author><style face="normal" font="default"> Oppenheimer,J.</style></author><author><style face="normal" font="default"> Tashkin,D.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Division of Allergy &amp; Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, New York.</style></auth-address><titles><title><style face="normal" font="default">Asthma-chronic obstructive pulmonary disease overlap syndrome: What we know and what we need to find out</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="245" start="241">241-245</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170312IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2016.12.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284529">PM:28284529</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-241-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-241-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170312, Desai M</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2016.12.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40855</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pearlman,D.S.</style></author><author><style face="normal" font="default"> Eckerwall,G.</style></author><author><style face="normal" font="default"> McLaren,J.</style></author><author><style face="normal" font="default"> Lamarca,R.</style></author><author><style face="normal" font="default"> Puu,M.</style></author><author><style face="normal" font="default"> Gilbert,I.</style></author><author><style face="normal" font="default"> Jorup,C.</style></author><author><style face="normal" font="default"> Sandin,K.</style></author><author><style face="normal" font="default"> Lanz,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Colorado Allergy &amp; Asthma Centers, P.C., Denver, Colorado.</style></auth-address><titles><title><style face="normal" font="default">Efficacy and safety of budesonide/formoterol pMDI vs budesonide pMDI in asthmatic children (6-&lt;12 years)</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> Budesonide</style></keyword><keyword><style face="normal" font="default"> budesonide/formoterol</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> formoterol</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Multicenter Studies</style></keyword><keyword><style face="normal" font="default"> Multicenter study</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Peak expiratory flow</style></keyword><keyword><style face="normal" font="default"> Pressurized metered-dose inhaler</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="27" Month="2" Year="2017">2017/2/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: The efficacy and safety of budesonide/formoterol pressurized metered-dose inhaler (pMDI) have been demonstrated in patients with asthma at least 12 years old. OBJECTIVE: To evaluate the efficacy of 2 formoterol doses added to budesonide as fixed combinations vs budesonide alone in children 6 to younger than 12 years with asthma. METHODS: This randomized, double-blinded, parallel-group, multicenter study (NCT02091986; CHASE 3) included children 6 to younger than 12 years with asthma previously receiving a medium-dose inhaled corticosteroid (ICS) or an ICS plus a long-acting beta2-agonist. Children symptomatic during a 7-28-day run-in on low-dose ICS, 1 inhalation of budesonide dry powder inhaler 90 mug twice daily (BID), were randomized to receive 2 inhalations of budesonide/formoterol pMDI 80/4.5 mug (160/9 mug) BID (n = 92), budesonide/formoterol pMDI 80/2.25 mug (160/4.5 mug) BID (n = 95), or budesonide pMDI 80 mug (160 mug) BID (n = 92) for 12 weeks. RESULTS: Change in forced expiratory volume in 1 second from baseline to 1 hour after dosing (primary end point), change in forced expiratory volume in 1 second 15 minutes after dosing, and peak expiratory flow 1 hour after dosing at week 12 were statistically significantly greater for budesonide/formoterol 160/9 mug vs budesonide (P &lt;/= .015 for all comparisons), but not for budesonide/formoterol 160/4.5 mug vs budesonide. Bronchodilator effects, evident 15 minutes after the dose on day 1, were maintained at week 12. Incidence of protocol-defined asthma exacerbations and improvements in asthma symptom-related and quality-of-life outcomes were similar across treatments. There were no notable safety differences among treatments. CONCLUSION: Budesonide/formoterol pMDI 160/9 mug showed statistically significant and clinically meaningful lung function improvements vs budesonide pMDI 160 mug, demonstrating appropriateness as a therapeutic option for children 6 to younger than 12 years with asthma symptomatic on ICS alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02091986</style></abstract><notes><style face="normal" font="default">DA - 20170303IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Sweden -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.01.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28256307">PM:28256307</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170303-PearlmanDS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170303-PearlmanDS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170303, Pearlman DS</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.01.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40856</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pasha,S.</style></author><author><style face="normal" font="default"> Kumar,S.</style></author><author><style face="normal" font="default"> Chatterjee,A.B.</style></author><author><style face="normal" font="default"> Krishnaswamy,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Neurology, Department of Medicine, Wake Forest School of Medicine, Winston Salem, North Carolina</style></auth-address><titles><title><style face="normal" font="default">An obstructive sleep apnea primer: What the practicing allergist needs to know</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="268" start="259">259-268</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergist</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Apnea</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> North Carolina</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Obstructive sleep apnea</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Sleep apnea</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170312IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2016.07.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284532">PM:28284532</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-259-68.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-259-68.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170312, Pasha S</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2016.07.033</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40857</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Costa,R.D.</style></author><author><style face="normal" font="default"> Figueiredo,C.A.</style></author><author><style face="normal" font="default"> Barreto,M.L.</style></author><author><style face="normal" font="default"> Alcantara-Neves,N.M.</style></author><author><style face="normal" font="default"> Rodrigues,L.C.</style></author><author><style face="normal" font="default"> Cruz,A.A.</style></author><author><style face="normal" font="default"> Vergara,C.</style></author><author><style face="normal" font="default"> Rafaels,N.</style></author><author><style face="normal" font="default"> Foster,C.</style></author><author><style face="normal" font="default"> Potee,J.</style></author><author><style face="normal" font="default"> Campbell,M.</style></author><author><style face="normal" font="default"> Mathias,R.A.</style></author><author><style face="normal" font="default"> Barnes,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Clinical Immunology, Johns Hopkins University, Baltimore, Maryland</style></auth-address><titles><title><style face="normal" font="default">Effect of polymorphisms on TGFB1 on allergic asthma and helminth infection in an African admixed population</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> Ascaris</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Baltimore</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic susceptibility</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> haplotype</style></keyword><keyword><style face="normal" font="default"> Helminths</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgG4</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune-mediated</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Interleukin-10</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Maryland</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> Specific IgE</style></keyword><keyword><style face="normal" font="default"> specific IgG4</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Transforming Growth Factor beta1</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic asthma is a complex disorder that results from a combination of genetic and environmental factors. Studies suggest that helminth infections can activate a regulatory network characterized by the production of regulatory cytokines, such as interleukin 10 and transforming growth factor beta1 (TGF-beta1) and subsequently protect against immune-mediated diseases, such as asthma. On the other hand, TGF-beta1 is increased in the lungs of individuals with asthma and may modulate airway inflammation. The role of TGF- beta 1 single-nucleotide polymorphisms (SNPs) in allergic disease remains inconclusive. OBJECTIVE: To evaluate the effects of genetic variations in the TGF-beta1 on allergy and helminths infections in children. METHODS: We tested for association among 4 TGF-beta1 SNPs and allergic asthma, specific IgE, skin prick test result, and IL-10 production in 1,335 Brazilians. In addition, we analyzed the association with markers of helminth infection (parasite burden, anti-Ascaris IgE, and worm specific IgG4). The polymorphisms were genotyped using Taq Man probes. RESULTS: We found an association between rs1800470 (C allele) and atopic wheezing (odds ratio [OR], 0.60; 95% confidence interval [CI], 0.37-0.95) and markers of allergy (OR, 0.41; 95% CI, 0.22-0.79). In contrast, a positive association was observed between the haplotype ACCA and Trichuris trichiura infection (OR, 1.85; P = .003) and Ascaris lumbricoides infection (OR, 2.01; P &lt; .001). This haplotype was also associated with increased IL-10 production (beta = 50.7; P &lt; .001). CONCLUSION: Individuals with TGF-beta1 polymorphisms have an increased susceptibility to helminth infections and a lower risk of developing allergy. These studies suggest that immune modulation of allergic disease results not only from environmental factors but also from genetic susceptibility and IL-10 production</style></abstract><notes><style face="normal" font="default">DA - 20170312IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Brazil -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.01.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284979">PM:28284979</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170312-CostaRD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170312-CostaRD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170312, Costa RD</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.01.028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40858</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">North,M.L.</style></author><author><style face="normal" font="default"> Brook,J.R.</style></author><author><style face="normal" font="default"> Lee,E.Y.</style></author><author><style face="normal" font="default"> Omana,V.</style></author><author><style face="normal" font="default"> Daniel,N.M.</style></author><author><style face="normal" font="default"> Steacy,L.M.</style></author><author><style face="normal" font="default"> Evans,G.J.</style></author><author><style face="normal" font="default"> Diamond,M.L.</style></author><author><style face="normal" font="default"> Ellis,A.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biomedical &amp; Molecular Sciences, Queen's University, Kingston, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="default">The Kingston Allergy Birth Cohort: Exploring parentally reported respiratory outcomes through the lens of the exposome</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cigarette</style></keyword><keyword><style face="normal" font="default"> cigarette smoke</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cold</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> COX</style></keyword><keyword><style face="normal" font="default"> dampness</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> diversity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Gestational Age</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Modeling</style></keyword><keyword><style face="normal" font="default"> Ontario</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Rural</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Siblings</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> Smoke</style></keyword><keyword><style face="normal" font="default"> socioeconomic status</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: The Kingston Allergy Birth Cohort (KABC) is a prenatally recruited cohort initiated to study the developmental origins of allergic disease. Kingston General Hospital was chosen for recruitment because it serves a population with notable diversity in environmental exposures relevant to the emerging concept of the exposome. OBJECTIVES: To establish a profile of the KABC using the exposome framework and examine parentally reported respiratory symptoms to 2 years of age. METHODS: Data on phase 1 of the cohort (n = 560 deliveries) were compiled, and multivariate Cox proportional hazards regression models were used to determine associations with respiratory symptoms. RESULTS: The KABC exhibits diversity within the 3 exposome domains of general external (socioeconomic status, rural or urban residence), specific external (cigarette smoke, breastfeeding, mold or dampness), and internal (respiratory health, gestational age), as well as significant associations between exposures from different domains. Significant associations emerged between parental reports of wheeze or cough without a cold and prenatal cigarette smoke exposure, mold or dampness in the home, and the use of air fresheners in the early-life home environment. Breastfeeding, older siblings, and increased gestational age were associated with decreased respiratory symptoms. CONCLUSION: The KABC is a unique cohort with diversity that can be leveraged for exposomics-based studies. This study found that all 3 domains of the exposome had effects on the respiratory health of KABC children. Ongoing studies using phase 1 of the KABC continue to explore the internal exposome through allergy skin testing and epigenetic analyses and the specific external domain through in-home environmental analyses, air pollution modeling, and ultimately potential convergences within and among domains</style></abstract><notes><style face="normal" font="default">DA - 20170312IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.01.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284980">PM:28284980</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170312-NorthML.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170312-NorthML.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170312, North ML</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.01.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40859</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Holderness,H.</style></author><author><style face="normal" font="default"> Chin,N.</style></author><author><style face="normal" font="default"> Ossip,D.J.</style></author><author><style face="normal" font="default"> Fagnano,M.</style></author><author><style face="normal" font="default"> Reznik,M.</style></author><author><style face="normal" font="default"> Halterman,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, University of Rochester School of Medicine, Rochester, New York</style></auth-address><titles><title><style face="normal" font="default">Physical activity, restrictions in activity, and body mass index among urban children with persistent asthma</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Caregivers</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicaid</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> overweight</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="4" Month="3" Year="2017">2017/3/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma and obesity are public health problems that disproportionately affect underserved children. Urban children with asthma may be limited in their participation in physical activity, further increasing their risk for overweight. OBJECTIVE: To determine the prevalence of overweight and obesity among high-risk children with persistent asthma, to assess physical activity and activity restrictions by level of asthma control, and to evaluate whether activity is associated with weight status. METHODS: We analyzed baseline data from 324 urban children with poorly controlled asthma (3-10 years old) enrolled in the School-Based Telemedicine Enhanced Asthma Management program in Rochester, New York. Caregivers reported their child's asthma symptoms, physical activity, and activity limitation, and height and weight were measured. RESULTS: Most children were black (59%), and 69% had Medicaid. Almost half (47%) of children had symptoms that indicated poorly controlled asthma, 15% were overweight, and 31% were obese. Few children (39%) participated in 1 or more hour of physical activity per day. In addition, most (85%) did not walk to and from school, 38% did not have any recess in school, and 35% reported no safe place to exercise. More children with very poorly controlled asthma symptoms, compared with children with more mild symptoms, reported limitation in gym class (58% vs 43%, P = .01) and even in mild activities (28% vs 14%, P = .004). Children with activity limitation were at significantly greater odds of being overweight or obese (odds ratio, 2.1; 95% confidence interval, 1.2-3.8). CONCLUSION: Many children with persistent asthma are overweight or obese, have limited opportunity for activity, and experience activity limitations. Efforts are needed to optimize asthma control and provide opportunity for increased physical activity in and outside school. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01650844</style></abstract><notes><style face="normal" font="default">DA - 20170307IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.01.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28268134">PM:28268134</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170307-HoldernessH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170307-HoldernessH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170307, Holderness H</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.01.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40860</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bork,K.</style></author><author><style face="normal" font="default"> Brehler,R.</style></author><author><style face="normal" font="default"> Witzke,G.</style></author><author><style face="normal" font="default"> Boor,S.</style></author><author><style face="normal" font="default"> Heineke,W.</style></author><author><style face="normal" font="default"> Hardt,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Johannes Gutenberg University, Mainz, Germany.</style></auth-address><titles><title><style face="normal" font="default">Blindness, tetraspasticity, and other signs of irreversible brain damage in hereditary angioedema</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">angioedema</style></keyword><keyword><style face="normal" font="default"> Blindness</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="6" Month="3" Year="2017">2017/3/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170310IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.01.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28279594">PM:28279594</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170310-BorkK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170310-BorkK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170310, Bork K</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.01.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40861</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Scherzer,D.J.</style></author><author><style face="normal" font="default"> Chime,N.O.</style></author><author><style face="normal" font="default"> Tofil,N.M.</style></author><author><style face="normal" font="default"> Hamilton,M.F.</style></author><author><style face="normal" font="default"> Singh,K.</style></author><author><style face="normal" font="default"> Stanley,R.M.</style></author><author><style face="normal" font="default"> Kline,J.</style></author><author><style face="normal" font="default"> McNamara,L.M.</style></author><author><style face="normal" font="default"> Rosen,M.A.</style></author><author><style face="normal" font="default"> Hunt,E.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Emergency Medicine, Nationwide Children's Hospital, Columbus, Ohio.</style></auth-address><titles><title><style face="normal" font="default">Survey of pediatric trainee knowledge: dose, concentration, and route of epinephrine</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Emergency Medicine</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Ohio</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="7" Month="3" Year="2017">2017/3/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170311IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.01.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283276">PM:28283276</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170311-ScherzerDJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170311-ScherzerDJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170311, Scherzer DJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.01.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40862</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Heath,J.L.</style></author><author><style face="normal" font="default"> Heath,R.D.</style></author><author><style face="normal" font="default"> Tamboli,C.</style></author><author><style face="normal" font="default"> Johnson,L.</style></author><author><style face="normal" font="default"> Wilson,A.S.</style></author><author><style face="normal" font="default"> Chervinskiy,S.</style></author><author><style face="normal" font="default"> Bell,M.C.</style></author><author><style face="normal" font="default"> Kennedy,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas</style></auth-address><titles><title><style face="normal" font="default">Mesalamine desensitization in a patient with treatment refractory ulcerative colitis and aspirin and nonsteroidal anti-inflammatory drug hypersensitivity</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Arkansas</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> Colitis</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mesalamine</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170312IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.01.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284977">PM:28284977</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170312-HeathJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170312-HeathJL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170312, Heath JL</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.01.026</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40863</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Coates,A.L.</style></author><author><style face="normal" font="default"> Dell,S.D.</style></author><author><style face="normal" font="default"> Cockcroft,D.W.</style></author><author><style face="normal" font="default"> Gauvreau,G.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Respiratory Medicine, Department of Pediatrics, Physiology and Experimental Medicine, Research Institute-Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default">The PD20 but not the PC20 in a methacholine challenge test is device independent</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Canada</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Challenge test</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> Methacholine challenge</style></keyword><keyword><style face="normal" font="default"> Ontario</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="5" Month="3" Year="2017">2017/3/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170309IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.01.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28274734">PM:28274734</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170309-CoatesAL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170309-CoatesAL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170309, Coates AL</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.01.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40864</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hart,K.M.</style></author><author><style face="normal" font="default"> Choy,D.F.</style></author><author><style face="normal" font="default"> Bradding,P.</style></author><author><style face="normal" font="default"> Wynn,T.A.</style></author><author><style face="normal" font="default"> Arron,J.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Program in Tissue Immunity and Repair, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA</style></auth-address><titles><title><style face="normal" font="default">Accurately measuring and modeling Th2 and Th17 endotypes in severe asthma</style></title><secondary-title><style face="normal" font="default">Ann Transl Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Transl Med</style></abbr-1></periodical><pages end="" start="91">91-</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Endotypes</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Modeling</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Parasitic Diseases</style></keyword><keyword><style face="normal" font="default"> Repair</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> TH17</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170309IS - 2305-5839 (Print)IS - 2305-5839 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.21037/atm.2017.02.07</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28275636">PM:28275636</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Transl Med\2017-5-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Transl Med\2017-5-91.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170309, Hart KM</style></custom2><misc3><style face="normal" font="default">10.21037/atm.2017.02.07</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40865</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lindberg,M.</style></author><author><style face="normal" font="default"> Soderquist,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Medical Sciences, Faculty of Medicine and Health, Orebro University, Orebro, SwedenSchool of Medical Sciences, Faculty of Medicine and Health, Orebro University, Orebro, Sweden</style></auth-address><titles><title><style face="normal" font="default">Atopic dermatitis and gut microbiota</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="298" start="297">297-298</pages><volume><style face="normal" font="default">176</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> Gut microbiota</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170228IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15276</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28244082">PM:28244082</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\2017-176-297-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\2017-176-297-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170228, Lindberg M</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15276</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40866</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chang,J.</style></author><author><style face="normal" font="default"> Bilker,W.B.</style></author><author><style face="normal" font="default"> Hoffstad,O.</style></author><author><style face="normal" font="default"> Margolis,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia</style></auth-address><titles><title><style face="normal" font="default">Cross-Sectional Comparisons of Patient-Reported Disease Control, Disease Severity, and Symptom Frequency in Children with Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Decision Making</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient-reported outcomes</style></keyword><keyword><style face="normal" font="default"> Pennsylvania</style></keyword><keyword><style face="normal" font="default"> Philadelphia</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Standardization</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="24" Month="2" Year="2017">2017/2/24</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a chronic inflammatory disease of the skin that commonly affects children. Research in AD has utilized an increasing variety of scoring measures to monitor disease, and this lack of standardization has been cited as an obstacle to evidence-based decision making. The Harmonizing Outcome Measures for Eczema (HOME) initiative aims to establish consensus on a core set of outcome measures for AD and currently recommends the Patient-Oriented Eczema Measure (POEM) for recording patient-reported outcomes. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170224IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15403</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28235240">PM:28235240</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20170224-ChangJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20170224-ChangJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170224, Chang J</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15403</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40867</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nag,D.S.</style></author><author><style face="normal" font="default"> Samaddar,D.P.</style></author><author><style face="normal" font="default"> Kant,S.</style></author><author><style face="normal" font="default"> Mahanty,P.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Tata Main Hospital, Department of Anesthesiology and Critical Care, Jamshedpur, India.</style></auth-address><titles><title><style face="normal" font="default">Perianesthetic refractory anaphylactic shock with cefuroxime in a patient with history of penicillin allergy on multiple antihypertensive medications</style></title><secondary-title><style face="normal" font="default">Braz J Anesthesiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Braz J Anesthesiol</style></abbr-1></periodical><pages end="220" start="217">217-220</pages><volume><style face="normal" font="default">67</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="default"> Anesthesiology</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Atenolol</style></keyword><keyword><style face="normal" font="default"> Cefuroxime</style></keyword><keyword><style face="normal" font="default"> Ciprofloxacin</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Dopamine</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Losartan</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Nicardipine</style></keyword><keyword><style face="normal" font="default"> Norepinephrine</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Prazosin</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Recovery</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Ventilation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">We report a case of perianesthetic refractory anaphylactic shock with cefuroxime in a patient with history of penicillin allergy on regular therapy with atenolol, losartan, prazosin and nicardipine. Severe anaphylactic shock was only transiently responsive to 10mL of (1:10,000) epinephrine and needed norepinephrine and dopamine infusion. Supportive therapy with vasopressors and inotropes along with mechanical ventilation for the next 24hours resulted in complete recovery. She was successfully operated upon 2 weeks later with the same anesthetic drugs but intravenous ciprofloxacin as the alternative antibiotic for perioperative prophylaxis</style></abstract><notes><style face="normal" font="default">DA - 20170226IS - 0104-0014 (Electronic)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.1016/j.bjane.2014.08.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28236873">PM:28236873</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Anesthesiol\2017-67-217-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Anesthesiol\2017-67-217-20.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170226, Nag DS</style></custom2><misc3><style face="normal" font="default">10.1016/j.bjane.2014.08.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40868</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Keber,T.</style></author><author><style face="normal" font="default"> Makuc,J.</style></author><author><style face="normal" font="default"> Sekavcnik,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, General Hospital Slovenj Gradec, Gosposvetska 1, SI-2380 Slovenj Gradec, Slovenia</style></auth-address><titles><title><style face="normal" font="default">Type 1 Kounis Syndrome in Patient with Idiopathic Anaphylaxis</style></title><secondary-title><style face="normal" font="default">Case Rep Cardiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Case Rep Cardiol</style></abbr-1></periodical><pages end="" start="1089023">1089023-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acute Coronary Syndrome</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Chest Pain</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Hypotension</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Kounis syndrome</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Slovenia</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Kounis syndrome represents the concurrence of acute coronary syndromes or anginal pain with allergic, hypersensitivity, and anaphylactic reactions. It can be associated with normal coronary angiogram or preexistent coronary pathology. Idiopathic anaphylaxis is defined as anaphylaxis without any identifiable precipitating agent or event. We present a case of male who experienced attacks of dyspnoea, hypoxemia, hypotension, purple-red skin, and chest pain over several years. He was diagnosed with idiopathic anaphylaxis. Based on the pattern of chest pain of ischemic origin during the attacks he was retrospectively diagnosed with Kounis syndrome</style></abstract><notes><style face="normal" font="default">DA - 20170303IS - 2090-6404 (Print)IS - 2090-6404 (Linking)LA - engPT - Journal ArticleCO - Slovenia -</style></notes><work-type><style face="normal" font="default">10.1155/2017/1089023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28255467">PM:28255467</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Case Rep Cardiol\2017-2017-1089023.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Case Rep Cardiol\2017-2017-1089023.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170303, Keber T</style></custom2><misc3><style face="normal" font="default">10.1155/2017/1089023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40869</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gulen,T.</style></author><author><style face="normal" font="default"> Moller Westerberg,C.</style></author><author><style face="normal" font="default"> Lyberg,K.</style></author><author><style face="normal" font="default"> Ekoff,M.</style></author><author><style face="normal" font="default"> Kolmert,J.</style></author><author><style face="normal" font="default"> Bood,J.</style></author><author><style face="normal" font="default"> Ohd,J.</style></author><author><style face="normal" font="default"> James,A.</style></author><author><style face="normal" font="default"> Dahlen,S.E.</style></author><author><style face="normal" font="default"> Nilsson,G.</style></author><author><style face="normal" font="default"> Dahlen,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Clinical Immunology and Allergy Research Unit, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default">Assessment of in vivo mast cell reactivity in patients with systemic mastocytosis</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Clinical signs</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Histamine Release</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Mannitol</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mastocytosis</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morphine</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Prostaglandin</style></keyword><keyword><style face="normal" font="default"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum tryptase</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic mastocytosis</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> urine</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="3" Year="2017">2017/3/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patients with systemic mastocytosis (SM) have clinical signs of mast cell (MC) activation and increased levels of MC mediators. It is unclear whether the increased mediator levels are caused by increased numbers of tissue MCs, or whether these cells in affected individuals have a hyperactive phenotype. OBJECTIVE: To determine reactivity of the skin and the airways to directly acting mediators and indirectly acting mast cell secretagogues in subjects with SM. METHODS: Skin reactivity to morphine and histamine, and airway responsiveness to mannitol and methacholine was assessed in 15 patients with SM, 11 patients with allergic asthma (A) and 13 healthy controls (HC). Serum tryptase and urinary metabolites of the MC mediators histamine and prostaglandin D2 were measured, as well as ex vivo basophil histamine release. RESULTS: Mast cell mediators in the blood and urine were significantly higher in patients with SM than in HC and A controls. Responsiveness to local activation of skin MCs (by morphine) and airway MCs (by mannitol) was similar in SM and HC groups. Likewise, end-organ responsiveness in the skin to histamine, and in the airways to methacholine, was similar in all three subject groups. There was no evidence of increased basophil reactivity in SM patients. CONCLUSIONS &amp; CLINICAL RELEVANCE: Mast cells in the skin and airways of subjects with SM do not exhibit hyper-reactivity towards the MC-activating stimuli morphine and mannitol, respectively. Therefore, the highly elevated baseline levels of MC mediators in SM are most likely due to increased MC numbers, rather than altered MC responsiveness. The underlying mechanisms could involve leakage of MC mediators, or dysfunctions in mediator synthesis, storage and release. One clinical implication of our study is that there is no contraindication to perform skin tests using morphine in subjects with mastocytosis This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170304IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12914</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28258965">PM:28258965</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170304-GulenT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170304-GulenT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170304, Gulen T</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12914</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40870</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tworek,D.</style></author><author><style face="normal" font="default"> Heroux,D.</style></author><author><style face="normal" font="default"> O'Byrne,S.N.</style></author><author><style face="normal" font="default"> Mitchell,P.</style></author><author><style face="normal" font="default"> O'Byrne,P.M.</style></author><author><style face="normal" font="default"> Denburg,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">McMaster University, Department of Medicine, Hamilton, ON, Canada</style></auth-address><titles><title><style face="normal" font="default">Toll-like receptor induced expression of epithelial cytokine receptors on hemopoietic progenitors is altered in allergic asthma</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> allergen challenge</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokine receptors</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dexamethasone</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Ligands</style></keyword><keyword><style face="normal" font="default"> Ligation</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> progenitor cells</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> ST2</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> TH2 cytokines</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> TLR</style></keyword><keyword><style face="normal" font="default"> TLR4</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hemopoietic progenitor cells (HPC) migrate to sites of allergic inflammation where, upon stimulation with epithelial cytokines, they produce Th2 cytokines and differentiate into mature eosinophils and basophils. They also express Toll-like receptors (TLR) involved in anti-microbial responses. OBJECTIVE: The objective of this study was to compare TLR expression on peripheral blood HPC and TLR-induced responses, in particular changes in epithelial cytokine receptors, in healthy and asthmatic subjects at baseline and following allergen challenge. METHODS: Ten healthy and 11 allergic asthmatic subjects were studied. HPC-enriched cell populations were stimulated with TLR-2, TLR-4 or TLR-9 ligands. TLR expression by circulating HPC and interleukin (IL)-25 (IL-17RB), IL-33 (ST2) and thymic stromal lymphopoietin (TSLPR) receptor expression after TLR ligation, were examined by flow cytometry at baseline and, in asthmatics, following allergen challenge. The effects of dexamethasone (Dex) on TLR-induced responses were also assessed. RESULTS: Asthmatics had significantly lower circulating HPC expressing TLR-2 and TLR-9 with a similar trend for TLR-4. TLR-4 stimulation of HPC yielded higher number of TSLPR+ cells in asthmatics compared with healthy subjects. A similar trend was seen for TLR-9 ligation, an effect further augmented by allergen inhalation. Allergen challenge also enhanced TLR-induced ST2 expression on HPC. Treatment with Dex in vitro increased TLR-4-induced TSLPR expression but had no effect on other epithelial cytokine receptors. CONCLUSIONS &amp; CLINICAL RELEVANCE: These data demonstrate an interaction between allergen and TLR ligand exposure in asthmatics. Allergen inhalation augments the TLR-induced inflammatory response by HPC, possibly leading to increased "in situ hemopoiesis" through upregulation of TSLPR. These findings show that HPC may be a part of the pro-inflammatory cascade in pathogen-induced asthma exacerbation through their increased responsiveness to TLR stimulation. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170302IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - Poland -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12913</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28252235">PM:28252235</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170302-TworekD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170302-TworekD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170302, Tworek D</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12913</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40871</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Timm,S.</style></author><author><style face="normal" font="default"> Schlunssen,V.</style></author><author><style face="normal" font="default"> Olsen,J.</style></author><author><style face="normal" font="default"> Ramlau-Hansen,C.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Public Health, Aarhus University, Denmark</style></auth-address><titles><title><style face="normal" font="default">Prenatal antibiotics and atopic dermatitis among 18-month old children in the Danish National Birth Cohort</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> diversity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Interviews</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Neonate</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rest</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Telephone</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="3" Year="2017">2017/3/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Despite extensive research, the aetiology of atopic dermatitis remains largely unknown, but reduced intestinal microbiota diversity in neonates has been linked to subsequent atopic dermatitis. Consequently, postnatal antibiotics have been proposed as a risk factor, but a potential association between prenatal antibiotics and atopic dermatitis is not well studied. Overall, the current evidence suggests a positive association between exposure to prenatal antibiotics and atopic dermatitis. OBJECTIVE: To investigate the association between prenatal antibiotics and atopic dermatitis among 18-month old children. METHODS: This study conducted within the Danish National Birth Cohort included 62,560 mother-child pairs. Data on maternal prenatal antibiotics were collected in the 30th gestation week and 6 months post partum, and offspring atopic dermatitis 18 months post partum through telephone interviews. Antibiotic use was categorised by the timing of exposure as 1st -2nd trimester (gestation week 0-29), 3rd trimester (gestation week 30-birth), all three trimesters or none. Data were analysed by logistic regression analyses adjusting for potential confounders. RESULTS: Exposure to antibiotics prenatally was associated with increased odds of atopic dermatitis among children born by atopic mothers but only when used in both 1st -2nd and 3rd trimester (ORadj 1.45, 95% CI 1.19-1.76). The findings were consistent using different definitions of atopic dermatitis. CONCLUSIONS AND CLINICAL RELEVANCE: Prenatal exposure to antibiotics throughout pregnancy was associated with an increased risk of atopic dermatitis but only within the first 18 months of life among children born by atopic mothers. The clinical usefulness of this finding must rest on corroboration in independent data sources.' This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170309IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12916</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28276107">PM:28276107</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170309-TimmS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170309-TimmS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170309, Timm S</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12916</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40872</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Heratizadeh,A.</style></author><author><style face="normal" font="default"> Geier,J.</style></author><author><style face="normal" font="default"> Molin,S.</style></author><author><style face="normal" font="default"> Werfel,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, 30625, Hannover, Germany</style></auth-address><titles><title><style face="normal" font="default">Contact sensitization in patients with suspected textile allergy. Data of the Information Network of Departments of Dermatology (IVDK) 2007-2014</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clothing</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Leg</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> orange</style></keyword><keyword><style face="normal" font="default"> p-Aminoazobenzene</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Rubber</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> textile dyes</style></keyword><keyword><style face="normal" font="default"> Textiles</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="24" Month="2" Year="2017">2017/2/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: Textile dyes, rubber, elements or textile resins carry the risk of inducing allergic contact sensitization. OBJECTIVES: To assess clinical data and patch test results for dermatitis patients with suspected textile allergy. METHODS: A retrospective analysis of Information Network of Departments of Dermatology data of the years 2007-2014 of patients patch tested because of suspected textile allergy was performed. RESULTS: Patients of the study group (n = 3207) suffered more frequently from leg, trunk and generalized dermatitis than patients of the control group (n = 95210). Among the allergens of the textile dye series, the highest frequency of positive reactions was observed for p-aminoazobenzene (5.1%) and p-phenylenediamine (PPD) (4.5%), followed by Disperse Orange 3 (3.1%), Disperse Blue 124 (2.3%), Disperse Blue 106 (2.0%), Disperse Red 17 (1.1%), and Disperse Yellow 3 (1.1%), partly with concomitant reactions. Patch testing with the patients' own textiles was performed in 315 patients, with positive reactions in 18 patients. These were mostly elicited by blue or black textiles with tight skin contact. Only 2 of these patients also reacted to textile dyes from the German Contact Dermatitis Research Group series. CONCLUSIONS: For the comprehensive diagnosis of contact sensitization in patients with suspected textile dermatitis, combined patch testing is indicated, with (i) PPD and a textile dye series and (ii) patients' own clothing</style></abstract><notes><style face="normal" font="default">DA - 20170224IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12760</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28233329">PM:28233329</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170224-HeratizadehA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170224-HeratizadehA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170224, Heratizadeh A</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12760</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40873</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Draijer,C.</style></author><author><style face="normal" font="default"> Peters-Golden,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, 6301 MSRB III, 1150 W. Medical Center Drive, Ann Arbor, MI, 48109-5642, USA</style></auth-address><titles><title><style face="normal" font="default">Alveolar Macrophages in Allergic Asthma: the Forgotten Cell Awakes</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="12">12-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergen exposure</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> alveolar macrophage</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Michigan</style></keyword><keyword><style face="normal" font="default"> Monocyte</style></keyword><keyword><style face="normal" font="default"> Monocytes</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: The role of alveolar macrophages in innate immune responses has long been appreciated. Here, we review recent studies evaluating the participation of these cells in allergic inflammation. RECENT FINDINGS: Immediately after allergen exposure, monocytes are rapidly recruited from the bloodstream and serve to promote acute inflammation. By contrast, resident alveolar macrophages play a predominantly suppressive role in an effort to restore homeostasis. As inflammation becomes established after repeated exposures, alveolar macrophages can polarize across a continuum of activation phenotypes, losing their suppressive functions and gaining pathogenic functions. Future research should focus on the diverse roles of monocytes/macrophages during various types and phases of allergic inflammation. These properties could lead us to new therapeutic opportunities</style></abstract><notes><style face="normal" font="default">DA - 20170224IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0681-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28233154">PM:28233154</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-12.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170224, Daijer C</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0681-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40874</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Opina,M.T.</style></author><author><style face="normal" font="default"> Moore,W.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonary, Critical Care, Allergy, and Immunologic Diseases, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC, 27157, USADepartment of Pulmonary, Critical Care, Allergy, and Immunologic Diseases, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC, 27157, USA. wmoore@wakehealth.edu</style></auth-address><titles><title><style face="normal" font="default">Phenotype-Driven Therapeutics in Severe Asthma</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="10">10-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Controller medications</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutics</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">Inhaled corticosteroids are the mainstay of asthma treatment using a step-up approach with incremental dosing and additional controller medications in order to achieve symptom control and prevent exacerbations. While most patients respond well to this treatment approach, some patients remain refractory despite high doses of inhaled corticosteroids and a long-acting beta-agonist. The problem lies in the heterogeneity of severe asthma, which is further supported by the emergence of severe asthma phenotypes. This heterogeneity contributes to the variability in treatment response. Randomized controlled trials involving add-on therapies in poorly controlled asthma have challenged the idea of a "one size fits all" approach targeting specific phenotypes in their subject selection. This review discusses severe asthma phenotypes from unbiased clustering approaches and the most recent scientific evidence on novel treatments to provide a guide in personalizing severe asthma treatment</style></abstract><notes><style face="normal" font="default">DA - 20170224IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0678-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28233153">PM:28233153</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-10.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170224, Opina MT</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0678-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40875</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rosas-Salazar,C.</style></author><author><style face="normal" font="default"> Hartert,T.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">aDivision of Allergy, Immunology, and Pulmonary Medicine, Department of Pediatrics bDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine cCenter for Asthma Research, Vanderbilt University School of Medicine, Nashville, Tennessee, USA</style></auth-address><titles><title><style face="normal" font="default">Prenatal exposures and the development of childhood wheezing illnesses</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="115" start="110">110-115</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acetaminophen</style></keyword><keyword><style face="normal" font="default"> Acids</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Fatty acid</style></keyword><keyword><style face="normal" font="default"> Fatty Acids</style></keyword><keyword><style face="normal" font="default"> Folic Acid</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In utero exposure</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Intervention Studies</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Nutrients</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Polyunsaturated fatty acids</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Primary Prevention</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Medicine</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Tennessee</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: To critically evaluate and summarize studies published between July 2015 and June 2016 linking prenatal exposures and the onset of childhood wheezing illnesses and to discuss future research directions in this field. RECENT FINDINGS: The aggregated evidence indicates a consistent detrimental effect of prenatal exposure to parental smoking, outdoor air pollution, and maternal stress on childhood wheezing illnesses. Less consistent evidence suggests an adverse impact of maternal obesity during pregnancy and prenatal exposure to antibiotics on these outcomes. There is insufficient evidence to support an association between in-utero exposure to acetaminophen or prenatal levels of specific nutrients (such as vitamin D, folic acid, or polyunsaturated fatty acids) and childhood wheezing illnesses. SUMMARY: Several common potentially modifiable prenatal exposures appear to be consistently associated with childhood wheezing illnesses (e.g. parental smoking, outdoor air pollution, and maternal stress). However, the effect of many other prenatal exposures on the onset of childhood wheezing illnesses remains unclear. The existing scientific evidence from the past year does not allow us to make any new recommendations on primary prevention measures. Intervention studies will best demonstrate whether changing the prenatal environment can prevent childhood wheezing illnesses and asthma</style></abstract><notes><style face="normal" font="default">DA - 20170112IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000342</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28079560">PM:28079560</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-110-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-110-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170112, Rosas-Salazar C</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000342</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40876</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Folletti,I.</style></author><author><style face="normal" font="default"> Siracusa,A.</style></author><author><style face="normal" font="default"> Paolocci,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">aDepartment of Medicine, Section of Occupational Medicine, Respiratory Diseases, Occupational and Environmental Toxicology bDepartment of Clinical and Experimental Medicine, University of Perugia, Perugia, Italy</style></auth-address><titles><title><style face="normal" font="default">Update on asthma and cleaning agents</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="95" start="90">90-95</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult-onset asthma</style></keyword><keyword><style face="normal" font="default"> Aldehydes</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disinfectants</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Fragrances</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Healthcare workers</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Occupation</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> Occupational Medicine</style></keyword><keyword><style face="normal" font="default"> Occupations</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Respiratory diseases</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Toxicology</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Asthma due to cleaning products has been known for 20 years, and the interest in this topic is still large because of the number of cleaning workers with respiratory problems. In this review, we sought to highlight the most recent findings on the relationship between exposure to cleaning products and asthma and to summarize the specific literature published between 2013 and 2016. RECENT FINDINGS: Women are confirmed as most of workers exposed to cleaning products and have a higher frequency than men of work-related respiratory symptoms and diseases. Many cases of asthma due to cleaning products occur in healthcare occupations. The increased risk of asthma has been shown to be related to the number of years in the job and to early life disadvantage. Recent evidence suggests that predisposition to adult-onset asthma may be related to interaction between genes and occupational exposure to low-molecular weight agents/irritants. There is some evidence that an irritant mechanism is more common, although several case reports showed animmunologic mechanism (e.g. disinfectants, amine compounds, aldehydes and fragrances). SUMMARY: The review updated recent findings on epidemiology, cleaning agents and their mechanism, and prevention of asthma due to cleaning agents. This article provides new information on the level of exposure, which is still high in professional cleaners and even more in domestic cleaners, and on the frequency of asthma in professional and domestic cleaners. An irritant mechanism is more common, although an immunological mechanism is possible, especially in healthcare workers exposed to disinfectants</style></abstract><notes><style face="normal" font="default">DA - 20170131IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000349</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28141626">PM:28141626</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-90-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-90-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170131, Folletti I</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000349</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40877</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bacharier,L.B.</style></author><author><style face="normal" font="default"> Szefler,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">aDivision of Pediatric Allergy, Immunology and Pulmonary Medicine, St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, Missouri</style></auth-address><titles><title><style face="normal" font="default">Pediatric asthma - moving ahead faster than ever</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="98" start="96">96-98</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Missouri</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Medicine</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Washington</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170222IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000353</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28225363">PM:28225363</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-96-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-96-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170222, Bacharier LB</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000353</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40878</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McGeachie,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA</style></auth-address><titles><title><style face="normal" font="default">Childhood asthma is a risk factor for the development of chronic obstructive pulmonary disease</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="109" start="104">104-109</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Infancy</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> persistence</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Trajectory</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: This review will catalog the many recent longitudinal studies that have investigated the relationship between asthma and lung function, or the persistence and trajectories of lung function deficits. RECENT FINDINGS: Recent work has reported on 50-year follow-ups of some prominent population cohorts. A history of asthma confers a 10-30-fold risk of chronic obstructive pulmonary disease. Individuals reaching a reduced maximum growth of forced expiratory volume in 1 s in early adulthood are at risk for early or more severe chronic obstructive pulmonary disease (COPD). SUMMARY: Taken together, there is a wealth of overlapping cohort studies of lung function, asthma and COPD. These show that asthma is associated with reduced lung function, which may start in infancy or prenatally, persists through childhood and adulthood and predisposes for early or more severe COPD</style></abstract><notes><style face="normal" font="default">DA - 20170124IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000348</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28118239">PM:28118239</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-104-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-104-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170124, McGeachie MJ</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000348</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40879</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Forno,E.</style></author><author><style face="normal" font="default"> Celedon,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary Medicine, Allergy, and Immunology, University of Pittsburgh School of Medicine and Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, USA</style></auth-address><titles><title><style face="normal" font="default">The effect of obesity, weight gain, and weight loss on asthma inception and control</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="130" start="123">123-130</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Pennsylvania</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Medicine</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword><keyword><style face="normal" font="default"> Weight Gain</style></keyword><keyword><style face="normal" font="default"> Weight Loss</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: There is ample and growing evidence that obesity increases the risk of asthma and morbidity from asthma. Here, we review recent clinical evidence supporting a causal link between obesity and asthma, and the mechanisms that may lead to 'obese asthma'. RECENT FINDINGS: Although in some children obesity and asthma simply co-occur, those with 'obese asthma' have increased asthma severity, lower quality of life, and reduced medication response. Underlying mechanistic pathways may include anatomical changes of the airways such as obstruction and dysanapsis, systemic inflammation, production of adipokines, impaired glucose-insulin metabolism, altered nutrient levels, genetic and epigenetic changes, and alterations in the airway and/or gut microbiome. A few small studies have shown that weight loss interventions may lead to improvements in asthma outcomes, but thus far research on therapeutic interventions for these children has been limited. SUMMARY: Obesity increases the risk of asthma - and worsens asthma severity or control - via multiple mechanisms. 'Obese asthma' is a complex, multifactorial phenotype in children. Obesity and its complications must be managed as part of the treatment of asthma in obese children</style></abstract><notes><style face="normal" font="default">DA - 20161228IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000339</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28030376">PM:28030376</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-123-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-123-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161228, Forno E</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000339</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40880</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Seed,M.J.</style></author><author><style face="normal" font="default"> Agius,R.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Occupational and Environmental Health, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK</style></auth-address><titles><title><style face="normal" font="default">Progress with Structure-Activity Relationship modelling of occupational chemical respiratory sensitizers</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="71" start="64">64-71</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity Pneumonitis</style></keyword><keyword><style face="normal" font="default"> Hypotheses</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Molecular Structure</style></keyword><keyword><style face="normal" font="default"> Molecular Weight</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> occupational asthma</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> QSAR</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Respiratory sensitization</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> SAR</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Structure activity relationship</style></keyword><keyword><style face="normal" font="default"> Structure-Activity Relationship</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> Toxicology</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: This appraises currently available computer-based ('in silico') models relating the molecular structure of low molecular weight compounds to their respiratory sensitization hazard. The present review places focus on the two main applications of such structure--activity relationship (SAR) models: hypotheses on disease mechanisms and toxicological prediction. RECENT FINDINGS: Analyses of the chemical structures of low molecular weight organic compounds known to have caused occupational asthma has led to the development of mechanistic alerts usually based on electrophilic reaction chemistry and protein cross-linking potential. Protein cross-linking potential has also been found to be a consistent feature of chemicals that have caused human cases of hypersensitivity pneumonitis. Stepwise iteration of quantitative SAR (QSAR) modelling has shown appreciable improvements in predictivity for occupational asthma hazard and useful prospects for practical application. A good case has also been made for the potential use of structural alert-based mechanistic SARs in predictive toxicology. SUMMARY: Further understanding of the molecular interactions between chemical respiratory sensitizers and components of human proteins have been obtained from in-vitro and in-silico techniques. There have been developments in both qualitative (mechanistic) SARs and QSARs, which offer potential for use in a predictive algorithm for the toxicological screening of industrial chemicals for respiratory sensitization potential</style></abstract><notes><style face="normal" font="default">DA - 20170208IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000355</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28177949">PM:28177949</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-64-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-64-71.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170208, Seed MJ</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000355</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40881</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Burbank,A.J.</style></author><author><style face="normal" font="default"> Szefler,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">aUniversity of North Carolina, Chapel Hill, North Carolina bChildren's Hospital Colorado, Aurora, Colorado, USA</style></auth-address><titles><title><style face="normal" font="default">Current and future management of the young child with early onset wheezing</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="152" start="146">146-152</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> allergen specific IgE</style></keyword><keyword><style face="normal" font="default"> allergen-specific</style></keyword><keyword><style face="normal" font="default"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma risk</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> macrolide</style></keyword><keyword><style face="normal" font="default"> Macrolides</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="default"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> North Carolina</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> recurrent wheezing</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> TH2 cytokines</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Thinking</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: In this review, we discuss current thinking in relation to available guidelines for the care of preschool-aged children with recurrent wheezing, while highlighting the gaps in our knowledge and discussing changes that could occur over the next 5 years. RECENT FINDINGS: The Asthma Predictive Index as well as allergen-specific IgE, peripheral eosinophil count and exhaled nitric oxide are perhaps underutilized sources of information that can assist in predicting progression to asthma and response to therapies. Inhaled corticosteroids and leukotriene receptor antagonists decrease impairment and exacerbation frequency in wheezing children but are not disease modifying. Macrolides may be useful during acute wheezing episodes for preventing progression to more severe symptoms. Monoclonal antibodies targeting IgE and TH2 cytokines have been successful in trials of adults and older children with asthma, but trials in younger children are needed. SUMMARY: Establishing the phenotype and endotype of young wheezing children can be useful for prognostication of future asthma risk as well as for selection of the most appropriate treatment. Primary asthma prevention strategies are needed during the critical developmental window in early life prior to the onset of irrecoverable loss of lung function</style></abstract><notes><style face="normal" font="default">DA - 20170116IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000341</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28092287">PM:28092287</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-146-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-146-52.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170116, Burbank</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000341</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40882</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kakumanu,S.</style></author><author><style face="normal" font="default"> Antos,N.</style></author><author><style face="normal" font="default"> Szefler,S.J.</style></author><author><style face="normal" font="default"> Lemanske,R.F.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default">aUniversity of Wisconsin School of Medicine and Public Health, Madison: Middleton Veterans Hospital</style></auth-address><titles><title><style face="normal" font="default">Building school health partnerships to improve pediatric asthma care: the School-based Asthma Management Program</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="166" start="160">160-166</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma education</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Communication</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Nurses</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Veterans</style></keyword><keyword><style face="normal" font="default"> Vision</style></keyword><keyword><style face="normal" font="default"> Wisconsin</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Children with asthma require care that is seamlessly coordinated so that asthma symptoms are recognized and managed at home and at school. The purpose of this review is to discuss recent consensus recommendations in school-based asthma care. RECENT FINDINGS: The School-based Asthma Management Program (SAMPRO) provides a widely endorsed framework to coordinate care with schools and consists of four components: establishing a circle of support around the child with asthma; facilitating bidirectional communication between clinicians and schools; comprehensive asthma education for schools; and assessment and remediation of environmental asthma triggers at school. SAMPRO standardizes recommendations for school-based asthma care coordination and provides a toolkit with websites and resources useful for the care of children with asthma in the school setting. SUMMARY: The review will discuss the need for coordinated school asthma partnerships, the inception and development of SAMPRO, and its vision to improve pediatric asthma care coordination within the circle of support, comprising clinicians, school nurses, families, and communities</style></abstract><notes><style face="normal" font="default">DA - 20170208IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000347</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28177950">PM:28177950</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-160-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-160-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170208, Kakumanu S</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000347</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40883</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Anderson,W.C.,III</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Section of Allergy and Immunology, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, USA</style></auth-address><titles><title><style face="normal" font="default">Incorporating technology to advance asthma controller adherence</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="159" start="153">153-159</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> electronic monitoring</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medication adherence</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Self Report</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Technological innovations, including text messaging, smart phone applications, and electronic monitoring devices, aimed at improving asthma controller adherence are being rapidly introduced both into clinical care and directly marketed to patients. This review analyzes recent clinical trials implementing these interventions, with a focus on their benefits and shortcomings. RECENT FINDINGS: Poor medication adherence continues to exert significant morbidity on patients with asthma. Objective, real-time measures to monitor adherence can overcome the limitations of prior methods, including self-report and prescription refills. Technological advances, especially those incorporating reminder systems, have demonstrated improved controller adherence. The increased adherence in these trials has not translated into consistent clinical improvement, including reducing hospitalizations, emergency department visits, and asthma exacerbations, possibly secondary to study design and poor inhalation technique. SUMMARY: Novel monitoring and reminder technology can augment patient medication adherence and provide clues to management before escalating therapy. Further studies are needed to investigate the overarching clinical impact of this technology, especially as it grows into routine clinical practice</style></abstract><notes><style face="normal" font="default">DA - 20170124IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000343</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28118240">PM:28118240</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-153-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-153-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170124, Anderson WC III</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000343</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40884</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Beigelman,A.</style></author><author><style face="normal" font="default"> Bacharier,L.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pediatric Allergy, Immunology and Pulmonary Medicine, Washington University School of Medicine, and St Louis Children's Hospital, St Louis, Missouri, USA</style></auth-address><titles><title><style face="normal" font="default">Management of preschool recurrent wheezing and asthma: a phenotype-based approach</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="138" start="131">131-138</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acetaminophen</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Azithromycin</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="default"> epidemiologic study</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Ibuprofen</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> Missouri</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral corticosteroids</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> preschool children</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Medicine</style></keyword><keyword><style face="normal" font="default"> recurrent wheezing</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Uncertainty</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Washington</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: The purpose of this review is to summarize the recent evidence on the management of preschool children with wheezing and asthma, and to propose a phenotype-based approach to the management of these children. RECENT FINDINGS: Recent studies have begun to identify populations of preschool children that are likely to benefit from inhaled corticosteroids (ICS) therapy and defined ICS regimens: daily ICS in preschool children with persistent asthma, and pre-emptive high-dose intermittent ICS among preschool children with intermittent disease reduce the risk of exacerbation. In addition, among preschool children with mild persistent asthma, the presence of aeroallergen sensitivity and/or blood eosinophil counts of 300/muL or greater are predictors of good response to daily ICS therapy. Other studies identified intermittent azithromycin as a therapy to prevent, and potentially to treat, acute exacerbations.The uncertainty of the role of oral corticosteroids (OCS) as a therapy for acute exacerbations continues, as a recent meta-analysis showed that OCS did not prevent hospitalizations or urgent visits, and did not reduce the need for additional courses of OCS. Whereas previous epidemiologic studies suggested acetaminophen may increase risk of exacerbations, a clinical trial clearly demonstrated acetaminophen use, compared to ibuprofen use,does not increase exacerbation risk among preschool children with mild-persistent asthma. SUMMARY: Recent studies have shown potential for phenotypic-driven therapies for the management of preschool children with asthma. Targeting airway bacteria has emerged as a promising therapeutic approach, but its effect on antibiotic resistance still needs to be investigated. Finally, more studies are required to evaluate if oral corticosteroids provide any benefits for acute episodic wheeze</style></abstract><notes><style face="normal" font="default">DA - 20170124IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000344</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28118241">PM:28118241</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-131-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-131-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170124, Beigelman A</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000344</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40885</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Carlsten,C.</style></author><author><style face="normal" font="default"> Rider,C.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada</style></auth-address><titles><title><style face="normal" font="default">Traffic-related air pollution and allergic disease: an update in the context of global urbanization</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="89" start="85">85-89</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergen exposure</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Asia</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> British Columbia</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Climate</style></keyword><keyword><style face="normal" font="default"> Climate change</style></keyword><keyword><style face="normal" font="default"> Columbia</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> Epigenetics</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> Gene-Environment Interaction</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urbanization</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: The review aims to give an update on the literature around traffic-related air pollution (TRAP) and allergic disease in the context of global urbanization, as the most populous countries in the world face severe TRAP exposure challenges. RECENT FINDINGS: As research continues to show that gene-environment interactions and epigenetics contribute to the TRAP-allergy link, evidence around the links to climate change grows. Greenspace may provide a buffer to adverse effects of traffic on health, overall, but pose risks in terms of allergic disease. SUMMARY: The link between traffic-related pollution and allergy continues to strengthen, in terms of supportive observational findings and mechanistic studies. Levels of TRAP across the world, particularly in Asia, continue to dramatically exceed acceptable levels, suggesting that the related adverse health consequences will accelerate. This could be counterbalanced by primary emission control and urban planning. Attention to combined effects of TRAP and allergen exposure is critical to avoiding misleading inferences drawn though examination only of isolated factors</style></abstract><notes><style face="normal" font="default">DA - 20170131IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000351</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28141628">PM:28141628</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-85-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-85-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170131, Carlsten C</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000351</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40886</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Becker,A.B.</style></author><author><style face="normal" font="default"> Abrams,E.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Section of Allergy and Clinical Immunology, University of Manitoba, Winnipeg, Manitoba, Canada</style></auth-address><titles><title><style face="normal" font="default">Asthma guidelines: the Global Initiative for Asthma in relation to national guidelines</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="103" start="99">99-103</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evolution</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: To compare and contrast national asthma guidelines with the Global Initiative for Asthma (GINA) strategy for asthma management and prevention. RECENT FINDINGS: The common goal of GINA and national asthma guidelines is to improve asthma care using the best evidence available from published data. This evidence-based approach has evolved from an initial perspective of expert opinion but with that evolution has not always considered the breadth of asthma phenotypes. GINA and national guidelines differ in a number of ways. GINA reviews available data and updates the core document and recommendations based on the latest data on a yearly basis to offer local, regional and national guidelines materials needed for knowledge mobilization. It remains the purview of those organizations to structure and implement those locally appropriate guidelines. SUMMARY: Both GINA and national guidelines have furthered asthma care to narrow the care gap from what is known to how asthma care is delivered, hopefully in a more directed, personalized manner. As well, both GINA and national guidelines have helped to shape the direction of research for the future benefit of children and their families</style></abstract><notes><style face="normal" font="default">DA - 20170124IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000346</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28118238">PM:28118238</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-99-103.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-99-103.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170124, Becker AB</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000346</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40887</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee-Sarwar,K.A.</style></author><author><style face="normal" font="default"> Bacharier,L.B.</style></author><author><style face="normal" font="default"> Litonjua,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">aDivision of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts</style></auth-address><titles><title><style face="normal" font="default">Strategies to alter the natural history of childhood asthma</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="145" start="139">139-145</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Cigarette</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> natural history</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> persistence</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> smokers</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Asthma exhibits significant heterogeneity in occurrence and severity over the lifespan. Our goal is to discuss recent evidence regarding determinants of the natural history of asthma during childhood, and review the rationale behind and status of major efforts to alter its course. RECENT FINDINGS: Variations in microbial exposures are associated with risk of allergic disease, and the use of bacterial lysates may be a promising preventive strategy. Exposure to air pollution appears to be particularly damaging in prenatal and early life, and interventions to reduce pollution are feasible and result in clinical benefit. E-cigarette use may have a role in harm reduction for conventional cigarette smokers with asthma, but has undefined short-term and long-term effects that must be clarified. Vitamin D insufficiency over the first several years of life is associated with risk of asthma, and vitamin D supplementation reduces the risk of severe exacerbations. SUMMARY: The identification of risk factors for asthma occurrence, persistence and severity will continue to guide efforts to alter the natural history of the disease. We have reviewed several promising strategies that are currently under investigation. Vitamin D supplementation and air pollution reduction have been shown to be effective strategies and warrant increased investigation and implementation</style></abstract><notes><style face="normal" font="default">DA - 20170112IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000340</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28079559">PM:28079559</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-139-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-139-45.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170112, Lee-Sarwar KA</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000340</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40888</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stachler,R.J.</style></author><author><style face="normal" font="default"> Dworkin-Valenti,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">aDownriver ENT PC bDepartment of Otolaryngology, Wayne State University, Detroit Medical Center, Detroit, MI</style></auth-address><titles><title><style face="normal" font="default">Allergic laryngitis: unraveling the myths</style></title><secondary-title><style face="normal" font="default">Curr Opin Otolaryngol Head Neck Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Opin Otolaryngol Head Neck Surg</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidemiological studies</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Laryngitis</style></keyword><keyword><style face="normal" font="default"> Laryngopharyngeal reflux</style></keyword><keyword><style face="normal" font="default"> Larynx</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Otolaryngology</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> proton pump inhibitor</style></keyword><keyword><style face="normal" font="default"> Proton pump inhibitors</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="4" Month="3" Year="2017">2017/3/4</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: This article provides a thorough review of the literature highlighting the articles that have advanced our knowledge about the sensitivity of the larynx to allergens in the air or ones consumed. This area of inquiry requires continued interest and investigation. As the field of clinical laryngology changes, and more information is discovered about the possible causal association between allergy and vocal pathologies, practicing otolaryngologists, allergists, and other medical professionals may discover more comprehensive methods to evaluate and treat their allergic patients, particularly those who present with complaints of dysphonia, dysphagia, laryngopharyngeal reflux (LPR), and/or dyspnea. RECENT FINDINGS: There continues to be epidemiological studies designed to describe the relationship of allergy to vocal symptoms and signs. Both population and smaller studies have recently attempted to link these two conditions. Unfortunately, the patient with chronic laryngeal complaints is often tagged by default with the diagnosis of LPR and treated with proton pump inhibitors, which are not always beneficial. The endoscopic assessment may not be as reliable to make the diagnosis of LPR as the examination is subjective and the inter-rater reliability is low. It has been demonstrated by direct laryngeal provocation studies that sticky-viscous endo-laryngeal mucous is the only reliable finding consistently associated with allergy potential allergic tissue reactivity. SUMMARY: The interrelationship of allergic sensitivity and chronic laryngitis in certain individuals is becoming clearer because our knowledge of inquiry has increased and the available routine technology to diagnose these conditions has remarkably improved. Notwithstanding these advancements, much more research is needed on this subject to reduce the frequency of mis-diagnoses and mis-management of allergic patients</style></abstract><notes><style face="normal" font="default">DA - 20170307IS - 1531-6998 (Electronic)IS - 1068-9508 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/MOO.0000000000000354</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28266945">PM:28266945</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Otolaryngol Head Neck Surg\20170307-StachlerRJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Otolaryngol Head Neck Surg\20170307-StachlerRJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170307, Stachler RJ</style></custom2><misc3><style face="normal" font="default">10.1097/MOO.0000000000000354</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40889</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">no authors</style></author></authors></contributors><titles><title><style face="normal" font="default">Penicillin allergy-getting the label right</style></title><secondary-title><style face="normal" font="default">Drug Ther Bull</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Drug Ther Bull</style></abbr-1></periodical><pages end="36" start="33">33-36</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> Penicillins</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">Penicillini allergy is a potentially serious adverse reaction that impacts on antibacterial treatment options. Although it is commonly reported and recorded in medical records, only a minority of patients with a label of penicillin allergy actually have the condition confirmed. The term 'allergy' may be incorrectly applied to adverse reactions that do not have an immunological basis and inappropriate labelling of penicillin allergy can lead to the unnecessary avoidance of penicillins and other beta-lactam antibacterials. Here, we discuss key features that help to distinguish patients at low or high risk of having a true penicillin allergy, summarise what is known about the risk of allergic reactions to other beta-lactam antibacterials in patients with penicillin allergy and discuss the steps to consider when assessing a label of penicillin allergy</style></abstract><notes><style face="normal" font="default">DA - 20170310IS - 1755-5248 (Electronic)IS - 0012-6543 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1136/dtb.2017.3.0463</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28279979">PM:28279979</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170310, no authors</style></custom2><misc3><style face="normal" font="default">10.1136/dtb.2017.3.0463</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40890</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Decuyper,I.I.</style></author><author><style face="normal" font="default"> Mangodt,E.A.</style></author><author><style face="normal" font="default"> Van Gasse,A.L.</style></author><author><style face="normal" font="default"> Claesen,K.</style></author><author><style face="normal" font="default"> Uyttebroek,A.</style></author><author><style face="normal" font="default"> Faber,M.</style></author><author><style face="normal" font="default"> Sabato,V.</style></author><author><style face="normal" font="default"> Bridts,C.H.</style></author><author><style face="normal" font="default"> Mertens,C.</style></author><author><style face="normal" font="default"> Hagendorens,M.M.</style></author><author><style face="normal" font="default"> De Clerck,L.S.</style></author><author><style face="normal" font="default"> Ebo,D.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Immunology, Department of Immunology, Allergology, Rheumatology, Faculty of Medicine and Health Science, Antwerp University Hospital, University of Antwerp, CDE T5.95, Universiteitsplein 1, 2610, Antwerp, Belgium</style></auth-address><titles><title><style face="normal" font="default">In Vitro Diagnosis of Immediate Drug Hypersensitivity Anno 2017: Potentials and Limitations</style></title><secondary-title><style face="normal" font="default">Drugs R D</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Drugs R D</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Ammonia</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophil activation test</style></keyword><keyword><style face="normal" font="default"> Basophil activation tests</style></keyword><keyword><style face="normal" font="default"> BAT</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> Beta-lactam antibiotics</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> CD203c</style></keyword><keyword><style face="normal" font="default"> CD63</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epitope</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE antibodies</style></keyword><keyword><style face="normal" font="default"> IgE antibody</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morphine</style></keyword><keyword><style face="normal" font="default"> Neuromuscular blocking agent</style></keyword><keyword><style face="normal" font="default"> Neuromuscular Blocking Agents</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drug</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> NSAID</style></keyword><keyword><style face="normal" font="default"> NSAIDs</style></keyword><keyword><style face="normal" font="default"> opiates</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> Quantification</style></keyword><keyword><style face="normal" font="default"> Quinolones</style></keyword><keyword><style face="normal" font="default"> Radiocontrast media</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rocuronium</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum tryptase</style></keyword><keyword><style face="normal" font="default"> sIgE</style></keyword><keyword><style face="normal" font="default"> Specific IgE</style></keyword><keyword><style face="normal" font="default"> Specific IgE antibodies</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="3" Year="2017">2017/3/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: For most physicians, quantification of drug-specific immunoglobulin E (drug-sIgE) antibodies constitutes the primary in vitro measure to document immediate drug hypersensitivity reactions (IDHR). Unfortunately, this is often insufficient to correctly identify patients with IgE-mediated IDHR and impossible for non-IgE-mediated IDHR that result from alternative routes of basophil and mast cell activation. In these difficult cases, diagnosis might benefit from cellular tests such as basophil activation tests (BAT). AIM: The aim was to review the potential and limitations of quantification of sIgE and BAT in diagnosing IDHR. The utility of quantification of serum tryptase is discussed. METHODS: A literature search was conducted using the key words allergy, basophil activation, CD63, CD203c, diagnosis, drugs, hypersensitivity, flow cytometry, specific IgE antibodies; this was complemented by the authors' own experience. RESULTS: The drugs that have been most studied with both techniques are beta-lactam antibiotics and curarizing neuromuscular blocking agents (NMBA). For sIgE morphine, data are available on the value of this test as a biomarker for sensitization to substituted ammonium structures that constitute the major epitope of NMBA, especially rocuronium and suxamethonium. For the BAT, there are also data on non-steroidal anti-inflammatory drugs (NSAIDs) and iodinated radiocontrast media. For beta-lactam antibiotics, sensitivity and specificity of sIgE varies between 0 and 85% and 52 and 100%, respectively. For NMBA, sensitivity and specificity varies between 38.5 and 92% and 85.7 and 100%, respectively. Specific IgE to morphine should not be used in isolation to diagnose IDHR to NMBA nor opiates. For the BAT, sensitivity generally varies between 50 and 60%, whereas specificity attains 80%, except for quinolones and NSAIDs. CONCLUSIONS: Although drug-sIgE assays and BAT can provide useful information in the diagnosis of IDHR, their predictive value is not absolute. Large-scale collaborative studies are mandatory to harmonize and optimize test protocols and to establish drug-specific decision thresholds</style></abstract><notes><style face="normal" font="default">DA - 20170304IS - 1179-6901 (Electronic)IS - 1174-5886 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1007/s40268-017-0176-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28258478">PM:28258478</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Drugs R D\20170304-DecuyperII.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Drugs R D\20170304-DecuyperII.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170304, Decuyper II</style></custom2><misc3><style face="normal" font="default">10.1007/s40268-017-0176-x</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40891</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,E.H.</style></author><author><style face="normal" font="default"> Jeon,B.H.</style></author><author><style face="normal" font="default"> Kim,J.</style></author><author><style face="normal" font="default"> Kim,Y.M.</style></author><author><style face="normal" font="default"> Han,Y.</style></author><author><style face="normal" font="default"> Ahn,K.</style></author><author><style face="normal" font="default"> Cheong,H.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Social and Preventive Medicine, Sungkyunkwan University School of Medicine, 2066 Seobu-ro, Jangan-gu, Suwon, Gyeonggi-do, 16419, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Exposure to phthalates and bisphenol A are associated with atopic dermatitis symptoms in children: a time-series analysis</style></title><secondary-title><style face="normal" font="default">Environ Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Environ Health</style></full-title></periodical><pages end="" start="24">24-</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Bisphenol A</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Day Care</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Preventive Medicine</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Time series</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> urine</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="3" Year="2017">2017/3/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Despite increasing evidence on the relationship between exposure to phthalates and bisphenol A with allergies and asthma, reports on atopic dermatitis (AD) with these chemicals are few. We assessed the association between AD symptoms and the exposure to phthalates and bisphenol A and in children. METHODS: We surveyed 18 boys with AD (age 3-7 years) in a day care center in Seoul between May 2009 and April 2010. AD symptoms were recorded by using a daily symptom diary. We collected 460 series of pooled urine twice a day, in the morning and afternoon, over 230 working days and measured the concentrations of mono-2-ethyl-5-oxohexyl phthalate (5-oxo-MEHP), mono-2-ethyl-5-hydroxyhexyl phthalate (5-OH-MEHP), mono-isobutyl phthalate (MnBP) and bisphenol A glucuronide (BPAG) in the pooled urine. Logistic regression was used for statistical analysis. RESULTS: Most phthalate metabolite levels were higher in the morning than in the afternoon (p &lt; 0.0001). There was seasonal variation in the levels of phthalates and bisphenol A metabolites. Levels of 5-OH-MEHP, MnBP, and BPAG were highest in summer (p &lt; 0.0001). Manifestation of AD symptoms was associated with an increase in urinary levels of MnBP (adjusted odds ratio, aOR = 2.85, 95% CI: 1.12-7.26 per 1 mug/L of MnBP) and BPAG (aOR = 1.79, 95% CI: 0.91-3.52 per 1 mug/L BPAG) on the same day. The levels of MnBP and BPAG in the previous day increased AD symptoms (aOR = 2.74, 95% CI: 1.21-6.20, for 1 mug/L of MnBP and aOR = 2.01, 95% CI: 1.08-3.74 for 1 mug/L BPAG). CONCLUSION: Our results suggest that exposure to phthalates and bisphenol A is associated with aggravation of AD symptoms in children</style></abstract><notes><style face="normal" font="default">DA - 20170309IS - 1476-069X (Electronic)IS - 1476-069X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1186/s12940-017-0225-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28274229">PM:28274229</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Environ Health\2017-16-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Environ Health\2017-16-24.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170309, Kim EH</style></custom2><misc3><style face="normal" font="default">10.1186/s12940-017-0225-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40892</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Almeida,J.P.</style></author><author><style face="normal" font="default"> Lopes,A.</style></author><author><style face="normal" font="default"> Campos Melo,A.</style></author><author><style face="normal" font="default"> Pereira Santos,M.C.</style></author><author><style face="normal" font="default"> Pereira Barbosa,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunoallergology, Santa Maria Hospital, Lisbon, Portugal Unit of Clinical Immunology, Institute of Molecular Medicine, Faculty of Medicine of Lisbon, Portugal.</style></auth-address><titles><title><style face="normal" font="default">Selective hypersensitivity to cefazolin and contribution of the basophil activation test</style></title><secondary-title><style face="normal" font="default">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="87" start="84">84-87</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Amoxicillin</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophil activation test</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> beta-Lactams</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Betalactams</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Cefazolin</style></keyword><keyword><style face="normal" font="default"> cephalosporin</style></keyword><keyword><style face="normal" font="default"> Cephalosporins</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Challenge test</style></keyword><keyword><style face="normal" font="default"> Challenge tests</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Ephedrine</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Hypotension</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Intradermal skin tests</style></keyword><keyword><style face="normal" font="default"> Lip</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> oral challenge</style></keyword><keyword><style face="normal" font="default"> oral challenge test</style></keyword><keyword><style face="normal" font="default"> Oxytocin</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Rocuronium</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">Summary: The authors present 2 case reports of selective cefazolin hypersensitivity: a 49 year-old woman with a history of two perioperative reactions (urticaria and severe anaphylaxis) after the use of rocuronium, propophol and cefazolin; a 36 year-old pregnant woman who developed facial erythema, lips angioedema and hypotension immediately after administration of ropivacain, sufentanil, cefazolin, oxytocin and ephedrine. In both cases, intradermal skin tests were positive for cefazolin. A basophil activation test was performed for cefazolin, which was positive in one patient. Oral challenge tests with penicillin, amoxicillin and other cephalosporins were negative. This selective hypersensitivity to cefazolin may be associated with a R1-side chain different from other beta-lactams</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28294589">PM:28294589</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-84-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-84-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Almeida JP</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40893</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lombardi,C.</style></author><author><style face="normal" font="default"> Passalacqua,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departmental Unit of Allergology, Clinical Immunology &amp; Pneumology, Fondazione Poliambulanza Hospital, Brescia, ItalyAllergy and Respiratory Diseases IRCCS San Martino IST University of Genoa, Pad. Maragliano, L.go R. Benzi 10 16133 Genoa, Italy.</style></auth-address><titles><title><style face="normal" font="default">Vitamin D levels and allergic diseases. An italian cross-sectional multicenter survey</style></title><secondary-title><style face="normal" font="default">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="79" start="75">75-79</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dander</style></keyword><keyword><style face="normal" font="default"> Data Collection</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> dog</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> House dust</style></keyword><keyword><style face="normal" font="default"> house dust mite</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Respiratory diseases</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">Summary: Background. During the two last decades, the interest in the role of Vitamin D (VD) in allergic disease has increased. Apart from the well-known actions of VD in bone metabolism, recent studies suggested its possible role as an immune-modulator in allergy. Objective. This study, conducted over the Italian territory, evaluated the possible correlations between VD serum level and diagnosed allergic diseases (rhinitis / asthma, food allergy, atopic dermatitis). Thus, VD was assessed in patients with physician-diagnosed allergic diseases. Methods. The study was carried out in hospital- and private practice-based setting between October 2012 and March 2013, and 18 Centers participated. Only adult patients, with at least one positive skin prick test were included. The diagnostic procedures and the data collection were standardized among the centers. VD levels were assayed by the same laboratory test. Results. Three hundred and nine patients were enrolled (132 male, mean age 37.5 +/- 17 years). Of them, 40% reported a positive family history for allergies (asthma / rhinitis). Rhinitis plus asthma was present in 47% of patients, atopic dermatitis in 15%, and a consistent clinical history of food allergy associated with positive skin tests was present in 25% of subjects. There was no significant association between VD level and age, sex, family history, rhinitis, or food allergy. VD levels were overall lower in patients with asthma and rhinitis, but without statistical significance. A significant difference in VD levels was detected between patient with or without atopic dermatitis. VD was not related to seasonal allergens, whereas a significant negative correlation was seen for house dust mite and dog dander. Conclusion. Our data, derived from a cross-sectional study involving only allergic patients, agree partially with the current literature. Nonetheless, the association between VD levels and allergies appeared weak. Studies involving larger samples would be required to better define the association between VD and allergies</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28294587">PM:28294587</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-75-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-75-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Lombardi C</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40894</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guttman-Yassky,E.</style></author><author><style face="normal" font="default"> Krueger,J.G.</style></author><author><style face="normal" font="default"> Lebwohl,M.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY</style></auth-address><titles><title><style face="normal" font="default">Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment</style></title><secondary-title><style face="normal" font="default">Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Arthritis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Body Surface Area</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> T-helper-2</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutics</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="7" Month="3" Year="2017">2017/3/7</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) and psoriasis are inflammatory skin diseases that negatively affect patients' quality of life. Although distinctions exist between these diseases, both are characterised by erythematous, thickened epidermal lesions that vary in intensity and affected body surface area. Early models of etiology attributed symptoms of both diseases to cutaneous inflammation at lesion sites, but recent studies have established that activated immune mediators in the circulation drive disease severity. Activation of T helper 2 (Th2) and Th22 cells in the circulation appears to be the principal initiator of acute AD pathology, with the emergence of Th1 and Th17/interleukin (IL)-23 pathway activation marking the transition to a chronic state. The Th17/IL-23 pathway also has an important role in psoriasis. The role of systemic inflammation in atopic dermatitis and psoriasis is supported by the occurrence of noncutaneous comorbidities that affect patients, most of which intensify morbidity and disability associated with lesional skin. Atopic dermatitis is associated with allergic disorders consisting of the "atopic march," whereas psoriasis is frequently accompanied by psoriatic arthritis. Patients with both disorders are at significantly higher risk of obesity, metabolic disorders, and cardiovascular diseases, all of which feature inflammatory components in their pathology models. These insights have led to novel therapeutics aimed at addressing psoriasis by targeting tumor necrosis factor- and Th17-related cytokine pathways. The success of these agents in psoriasis management is driving new therapeutic approaches for moderate-to-severe AD, including agents targeting the Th2 and Th17/Th22 cytokine pathways. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170307IS - 1600-0625 (Electronic)IS - 0906-6705 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/exd.13336</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28266782">PM:28266782</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Exp Dermatol\20170307-GuttmanYasskyE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Exp Dermatol\20170307-GuttmanYasskyE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170307, Guttman-Yassky E</style></custom2><misc3><style face="normal" font="default">10.1111/exd.13336</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40895</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,J.H.</style></author><author><style face="normal" font="default"> Jang,Y.S.</style></author><author><style face="normal" font="default"> Jang,S.H.</style></author><author><style face="normal" font="default"> Jung,K.S.</style></author><author><style face="normal" font="default"> Kim,S.H.</style></author><author><style face="normal" font="default"> Ye,Y.M.</style></author><author><style face="normal" font="default"> Park,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, South Korea</style></auth-address><titles><title><style face="normal" font="default">Toluene diisocyanate exposure induces airway inflammation of bronchial epithelial cells via the activation of transient receptor potential melastatin 8</style></title><secondary-title><style face="normal" font="default">Exp Mol Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Exp Mol Med</style></abbr-1></periodical><pages end="" start="e299">e299-</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway epithelial cell</style></keyword><keyword><style face="normal" font="default"> airway epithelial cells</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> association studies</style></keyword><keyword><style face="normal" font="default"> association study</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Genome-wide</style></keyword><keyword><style face="normal" font="default"> genome-wide association</style></keyword><keyword><style face="normal" font="default"> genome-wide association studies</style></keyword><keyword><style face="normal" font="default"> genome-wide association study</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Neurogenic Inflammation</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> occupational asthma</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> TDI</style></keyword><keyword><style face="normal" font="default"> Toluene</style></keyword><keyword><style face="normal" font="default"> Toluene diisocyanate</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="3" Month="3" Year="2017">2017/3/3</year></dates><abstract><style face="normal" font="default">Toluene diisocyanate (TDI) is the most important cause of occupational asthma (OA), and various pathogenic mechanisms have been suggested. Of these mechanisms, neurogenic inflammation is an important inducer of airway inflammation. Transient receptor potential melastatin 8 (TRPM8) is a well-established cold-sensing cation channel that is expressed in both neuronal cells and bronchial epithelial cells. A recent genome-wide association study of TDI-exposed workers found a significant association between the phenotype of TDI-induced OA and the single-nucleotide polymorphism rs10803666, which has been mapped to the TRPM8 gene. We hypothesized that TRPM8 located in airway epithelial cells may be involved in the pathogenic mechanisms of TDI-induced OA and investigated its role. Bronchial epithelial cells were treated with TDI in a dose- and time-dependent manner. The expression levels of TRPM8 mRNA and protein were determined by quantitative real-time polymerase chain reaction and western blotting. TDI-induced morphological changes in the cells were evaluated by immunocytochemistry. Alterations in the transcripts of inflammatory cytokines were examined in accordance with TRPM8 activation by TDI. TRPM8 expression at both the mRNA and protein levels was enhanced by TDI in airway epithelial cells. TRPM8 activation by TDI led to significant increases in the mRNA of interleukin (IL)-4, IL-13, IL-25 and IL-33. The increased expression of the cytokine genes by TDI was partly attenuated after treatment with a TRPM8 antagonist. TDI exposure induces increased expression of TRPM8 mRNA in airway epithelial cells coupled with enhanced expression of inflammatory cytokines, suggesting a novel role of TRPM8 in the pathogenesis of TDI-induced OA</style></abstract><notes><style face="normal" font="default">DA - 20170303IS - 2092-6413 (Electronic)IS - 1226-3613 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1038/emm.2016.161</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28255167">PM:28255167</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Exp Mol Med\2017-49-e299.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Exp Mol Med\2017-49-e299.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170303, KIm JH</style></custom2><misc3><style face="normal" font="default">10.1038/emm.2016.161</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40896</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oakes,T.</style></author><author><style face="normal" font="default"> Popple,A.L.</style></author><author><style face="normal" font="default"> Williams,J.</style></author><author><style face="normal" font="default"> Best,K.</style></author><author><style face="normal" font="default"> Heather,J.M.</style></author><author><style face="normal" font="default"> Ismail,M.</style></author><author><style face="normal" font="default"> Maxwell,G.</style></author><author><style face="normal" font="default"> Gellatly,N.</style></author><author><style face="normal" font="default"> Dearman,R.J.</style></author><author><style face="normal" font="default"> Kimber,I.</style></author><author><style face="normal" font="default"> Chain,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Infection and Immunity, UCL , London , UK</style></auth-address><titles><title><style face="normal" font="default">The T Cell Response to the Contact Sensitizer Paraphenylenediamine Is Characterized by a Polyclonal Diverse Repertoire of Antigen-Specific Receptors</style></title><secondary-title><style face="normal" font="default">Front Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Immunol</style></abbr-1></periodical><pages end="" start="162">162-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">albumin</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Amino acid</style></keyword><keyword><style face="normal" font="default"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Black henna</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> CD8+ T cells</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> diversity</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> expansion</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Hair</style></keyword><keyword><style face="normal" font="default"> Hair Dyes</style></keyword><keyword><style face="normal" font="default"> Henna</style></keyword><keyword><style face="normal" font="default"> HSA</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paraphenylenediamine</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Recall</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Sequence</style></keyword><keyword><style face="normal" font="default"> Sequences</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum Albumin</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Paraphenylenediamine (PPD) is a common component of hair dyes and black henna tattoos and can cause skin sensitization and allergic contact dermatitis (ACD). The cutaneous inflammatory reaction associated with ACD is driven by both CD4+ and CD8+ T cells. However, the characteristics of such responses with respect to clonal breadth and magnitude are poorly defined. In this study, we have characterized the in vitro recall response of peripheral blood T cells prepared from PPD-allergic individuals to a PPD-human serum albumin (HSA) conjugate (PPD-HSA). Quantitative high throughput sequencing was used to characterize the changes in the repertoire of T cell receptor (TCR) alpha and beta genes after exposure to antigen in vitro. The PPD conjugate induced expansion of T cells carrying selected TCRs, with around 800 sequences (around 1%) being 8 or more times as abundant after culture than before. The expanded sequences showed strong skewing of V and J usage, consistent with an antigen-driven clonal expansion. The complementarity-determining region 3 sequences of the expanded TCRs could be grouped into several families of related amino acid sequence, but the overall diversity of the expanded sample was not much less than that of a random sample of the same size. The results suggest a model in which PPD-HSA conjugate stimulates a broad diversity of TCRs, with a wide range of stimulation strengths, which manifest as different degrees of in vitro expansion</style></abstract><notes><style face="normal" font="default">DA - 20170306IS - 1664-3224 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.3389/fimmu.2017.00162</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28261218">PM:28261218</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Immunol\2017-8-162.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Immunol\2017-8-162.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170306, Oakes T</style></custom2><misc3><style face="normal" font="default">10.3389/fimmu.2017.00162</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40897</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lynch,J.P.</style></author><author><style face="normal" font="default"> Sikder,M.A.</style></author><author><style face="normal" font="default"> Curren,B.F.</style></author><author><style face="normal" font="default"> Werder,R.B.</style></author><author><style face="normal" font="default"> Simpson,J.</style></author><author><style face="normal" font="default"> Cuiv,P.O.</style></author><author><style face="normal" font="default"> Dennis,P.G.</style></author><author><style face="normal" font="default"> Everard,M.L.</style></author><author><style face="normal" font="default"> Phipps,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Respiratory Mucosal Immunity, School of Biomedical Sciences, The University of Queensland , St. Lucia, QLD , Australia</style></auth-address><titles><title><style face="normal" font="default">The Influence of the Microbiome on Early-Life Severe Viral Lower Respiratory Infections and Asthma-Food for Thought?</style></title><secondary-title><style face="normal" font="default">Front Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Immunol</style></abbr-1></periodical><pages end="" start="156">156-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Bronchiolitis</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Developing Countries</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> diversity</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> immunopathology</style></keyword><keyword><style face="normal" font="default"> Infancy</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> Mucosal immunity</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> respiratory infection</style></keyword><keyword><style face="normal" font="default"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> RSV</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Severe viral lower respiratory infections are a major cause of infant morbidity. In developing countries, respiratory syncytial virus (RSV)-bronchiolitis induces significant mortality, whereas in developed nations the disease represents a major risk factor for subsequent asthma. Susceptibility to severe RSV-bronchiolitis is governed by gene-environmental interactions that affect the host response to RSV infection. Emerging evidence suggests that the excessive inflammatory response and ensuing immunopathology, typically as a consequence of insufficient immunoregulation, leads to long-term changes in immune cells and structural cells that render the host susceptible to subsequent environmental incursions. Thus, the initial host response to RSV may represent a tipping point in the balance between long-term respiratory health or chronic disease (e.g., asthma). The composition and diversity of the microbiota, which in humans stabilizes in the first year of life, critically affects the development and function of the immune system. Hence, perturbations to the maternal and/or infant microbiota are likely to have a profound impact on the host response to RSV and susceptibility to childhood asthma. Here, we review recent insights describing the effects of the microbiota on immune system homeostasis and respiratory disease and discuss the environmental factors that promote microbial dysbiosis in infancy. Ultimately, this knowledge will be harnessed for the prevention and treatment of severe viral bronchiolitis as a strategy to prevent the onset and development of asthma</style></abstract><notes><style face="normal" font="default">DA - 20170306IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="default">10.3389/fimmu.2017.00156</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28261214">PM:28261214</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Immunol\2017-8-156.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Immunol\2017-8-156.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170306, Lynch JP</style></custom2><misc3><style face="normal" font="default">10.3389/fimmu.2017.00156</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40898</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yoshioka,Y.</style></author><author><style face="normal" font="default"> Kuroda,E.</style></author><author><style face="normal" font="default"> Hirai,T.</style></author><author><style face="normal" font="default"> Tsutsumi,Y.</style></author><author><style face="normal" font="default"> Ishii,K.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Vaccine Creation Project, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan</style></auth-address><titles><title><style face="normal" font="default">Allergic Responses Induced by the Immunomodulatory Effects of Nanomaterials upon Skin Exposure</style></title><secondary-title><style face="normal" font="default">Front Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Immunol</style></abbr-1></periodical><pages end="" start="169">169-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adjuvant</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic response</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Aluminum</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Inhalation Exposure</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> Skin barrier function</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> vaccine</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Over the past decade, a vast array of nanomaterials has been created through the development of nanotechnology. With the increasing application of these nanomaterials in various fields, such as foods, cosmetics, and medicines, there has been concern about their safety, that is, nanotoxicity. Therefore, there is an urgent need to collect information about the biological effects of nanomaterials so that we can exploit their potential benefits and design safer nanomaterials, while avoiding nanotoxicity as a result of inhalation or skin exposure. In particular, the immunomodulating effect of nanomaterials is one of most interesting aspects of nanotoxicity. However, the immunomodulating effects of nanomaterials through skin exposure have not been adequately discussed compared with the effects of inhalation exposure, because skin penetration by nanomaterials is thought to be extremely low under normal conditions. On the other hand, the immunomodulatory effects of nanomaterials via skin may cause severe problems for people with impaired skin barrier function, because some nanomaterials could penetrate the deep layers of their allergic or damaged skin. In addition, some studies, including ours, have shown that nanomaterials could exhibit significant immunomodulating effects even if they do not penetrate the skin. In this review, we summarize our current knowledge of the allergic responses induced by nanomaterials upon skin exposure. First, we discuss nanomaterial penetration of the intact or impaired skin barrier. Next, we describe the immunomodulating effects of nanomaterials, focusing on the sensitization potential of nanomaterials and the effects of co-exposure of nanomaterials with substances such as chemical sensitizers or allergens, on the onset of allergy, following skin exposure. Finally, we discuss the potential mechanisms underlying the immunomodulating effects of nanomaterials by describing the involvement of the protein corona in the interaction of nanomaterials with biological components and by presenting recent data about the adjuvant effects of well-characterized particle adjuvant, aluminum salt, as an example of immunomodulatory particulate</style></abstract><notes><style face="normal" font="default">DA - 20170306IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.3389/fimmu.2017.00169</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28261221">PM:28261221</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Immunol\2017-8-169.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Immunol\2017-8-169.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170306, Yoshioka Y</style></custom2><misc3><style face="normal" font="default">10.3389/fimmu.2017.00169</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40899</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gendron,D.R.</style></author><author><style face="normal" font="default"> Lecours,P.B.</style></author><author><style face="normal" font="default"> Lemay,A.M.</style></author><author><style face="normal" font="default"> Beaulieu,M.J.</style></author><author><style face="normal" font="default"> Huppe,C.A.</style></author><author><style face="normal" font="default"> Lee-Gosselin,A.</style></author><author><style face="normal" font="default"> Flamand,N.</style></author><author><style face="normal" font="default"> Don,A.S.</style></author><author><style face="normal" font="default"> Bissonnette,E.</style></author><author><style face="normal" font="default"> Blanchet,M.R.</style></author><author><style face="normal" font="default"> Laplante,M.</style></author><author><style face="normal" font="default"> Bourgoin,S.G.</style></author><author><style face="normal" font="default"> Bosse,Y.</style></author><author><style face="normal" font="default"> Marsolais,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec QC, Canada</style></auth-address><titles><title><style face="normal" font="default">A Phosphorylatable Sphingosine Analog Induces Airway Smooth Muscle Cytostasis and Reverses Airway Hyperresponsiveness in Experimental Asthma</style></title><secondary-title><style face="normal" font="default">Front Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Pharmacol</style></abbr-1></periodical><pages end="" start="78">78-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway smooth muscle</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Atrophy</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cell Proliferation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Challenge test</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Dexamethasone</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Immunomodulation</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> Methacholine challenge</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Quebec</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">In asthma, excessive bronchial narrowing associated with thickening of the airway smooth muscle (ASM) causes respiratory distress. Numerous pharmacological agents prevent experimental airway hyperresponsiveness (AHR) when delivered prophylactically. However, most fail to resolve this feature after disease is instated. Although sphingosine analogs are primarily perceived as immune modulators with the ability to prevent experimental asthma, they also influence processes associated with tissue atrophy, supporting the hypothesis that they could interfere with mechanisms sustaining pre-established AHR. We thus assessed the ability of a sphingosine analog (AAL-R) to reverse AHR in a chronic model of asthma. We dissected the pharmacological mechanism of this class of agents using the non-phosphorylatable chiral isomer AAL-S and the pre-phosphorylated form of AAL-R (AFD-R) in vivo and in human ASM cells. We found that a therapeutic course of AAL-R reversed experimental AHR in the methacholine challenge test, which was not replicated by dexamethasone or the non-phosphorylatable isomer AAL-S. AAL-R efficiently interfered with ASM cell proliferation in vitro, supporting the concept that immunomodulation is not necessary to interfere with cellular mechanisms sustaining AHR. Moreover, the sphingosine-1-phosphate lyase inhibitor SM4 and the sphingosine-1-phosphate receptor antagonist VPC23019 failed to inhibit proliferation, indicating that intracellular accumulation of sphingosine-1-phosphate or interference with cell surface S1P1/S1P3 activation, are not sufficient to induce cytostasis. Potent AAL-R-induced cytostasis specifically related to its ability to induce intracellular AFD-R accumulation. Thus, a sphingosine analog that possesses the ability to be phosphorylated in situ interferes with cellular mechanisms that beget AHR</style></abstract><notes><style face="normal" font="default">DA - 20170308IS - 1663-9812 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.3389/fphar.2017.00078</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28270767">PM:28270767</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Pharmacol\2017-8-78.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Pharmacol\2017-8-78.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170308, Gendron DR</style></custom2><misc3><style face="normal" font="default">10.3389/fphar.2017.00078</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40900</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Adjers,K.</style></author><author><style face="normal" font="default"> Luukkainen,A.</style></author><author><style face="normal" font="default"> Pekkanen,J.</style></author><author><style face="normal" font="default"> Hurme,M.</style></author><author><style face="normal" font="default"> Huhtala,H.</style></author><author><style face="normal" font="default"> Renkonen,R.</style></author><author><style face="normal" font="default"> Wang,Y.</style></author><author><style face="normal" font="default"> Makela,M.J.</style></author><author><style face="normal" font="default"> Karjalainen,J.</style></author><author><style face="normal" font="default"> Toppila-Salmi,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, Hatanpaa Hospital, Tampere, Finland</style></auth-address><titles><title><style face="normal" font="default">Self-Reported Allergic Rhinitis and/or Allergic Conjunctivitis Associate with IL13 rs20541 Polymorphism in Finnish Adult Asthma Patients</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="128" start="123">123-128</pages><volume><style face="normal" font="default">172</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AC</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Adult asthma</style></keyword><keyword><style face="normal" font="default"> aeroallergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Conjunctivitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Interleukin-13</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Ophthalmology</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="3" Year="2017">2017/3/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Our aim was to observe factors associated with IL13 rs20541 polymorphism and other factors with or without allergic comorbidities such as subject-reported allergic rhinitis (AR) and/or allergic conjunctivitis (AC) symptoms in adult asthmatics. METHODS: A population-based sample of Finnish adult asthma patients (n = 1,156) and matched controls (n = 1,792) filled in a questionnaire. Asthma was diagnosed based on a typical history of asthma symptoms and lung function tests. Skin prick tests with 17 aeroallergens and blood tests including analysis of interleukin 13 (IL13) rs20541 (G/A) genotypes were performed for a subsample (n = 193). RESULTS: The proportion of asthmatics reporting AR was 61.9% and reporting AC was 40.7%. After adjustments, the presence of the IL13 rs20</style></abstract><notes><style face="normal" font="default">DA - 20170308IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Finland -CO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1159/000456009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28273659">PM:28273659</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-172-123-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-172-123-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170308, Adjers K</style></custom2><misc3><style face="normal" font="default">10.1159/000456009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40901</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ciprandi,G.</style></author><author><style face="normal" font="default"> Gallo,F.</style></author><author><style face="normal" font="default"> Ricciardolo,F.L.</style></author><author><style face="normal" font="default"> Cirillo,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, IRCCS-Azienda Ospedaliera Universitaria San Martino-IST, Genoa, Italy</style></auth-address><titles><title><style face="normal" font="default">Fractional Exhaled Nitric Oxide: A Potential Biomarker in Allergic Rhinitis?</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="105" start="99">99-105</pages><volume><style face="normal" font="default">172</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> bronchial inflammation</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="3" Month="3" Year="2017">2017/3/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: The fractional concentration of exhaled nitric oxide (FeNO) is a surrogate biomarker for Th2-dependent bronchial inflammation. The present study investigated whether FeNO may characterize allergic rhinitis (AR) patients. METHODS: A total of 553 AR patients (497 males, mean age 28.8 years) were evaluated. Those patients with a high FeNO underwent a 2-year follow-up. RESULTS: Increased FeNO was associated with a significantly longer AR duration, impaired lung function, more severe symptoms, and more frequent bronchial hyperresponsiveness (BHR). At follow-up, 22 out of 82 patients (26.8%) with high FeNO levels (>50 ppb) developed asthma. CONCLUSIONS: AR patients may frequently have high FeNO values, exceeding 50 ppb. This might be associated with an initial impaired lung function, BHR, a perceived worsening of respiratory symptoms, and potential progression to asthma</style></abstract><notes><style face="normal" font="default">DA - 20170302IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1159/000456548</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28253520">PM:28253520</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-172-99-105.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-172-99-105.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170302, Ciprandi G</style></custom2><misc3><style face="normal" font="default">10.1159/000456548</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40902</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Babina,M.</style></author><author><style face="normal" font="default"> Artuc,M.</style></author><author><style face="normal" font="default"> Guhl,S.</style></author><author><style face="normal" font="default"> Zuberbier,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Charite Universitatsmedizin Berlin, 10117 Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default">Retinoic Acid Negatively Impacts Proliferation and MCTC Specific Attributes of Human Skin Derived Mast Cells, but Reinforces Allergic Stimulability</style></title><secondary-title><style face="normal" font="default">Int J Mol Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Mol Sci</style></abbr-1></periodical><pages end="" start="525">525-</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chymase</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Histamine Release</style></keyword><keyword><style face="normal" font="default"> Hormones</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Microscopy</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Protease</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="2" Year="2017">2017/2/28</year></dates><abstract><style face="normal" font="default">The Vitamin-A-metabolite retinoic acid (RA) acts as a master regulator of cellular programs. Mast cells (MCs) are primary effector cells of type-I-allergic reactions. We recently uncovered that human cutaneous MCs are enriched with RA network components over other skin cells. Yet, direct experimental evidence on the significance of the RA-MC axis is limited. Here, skin-derived cultured MCs were exposed to RA for seven days and investigated by flow-cytometry (BrdU incorporation, Annexin/PI, FcepsilonRI), microscopy, RT-qPCR, histamine quantitation, protease activity, and degranulation assays. We found that while MC size and granularity remained unchanged, RA potently interfered with MC proliferation. Conversely, a modest survival-promoting effect from RA was noted. The granule constituents, histamine and tryptase, remained unaffected, while RA had a striking impact on MC chymase, whose expression dropped by gene and by peptidase activity. The newly uncovered MRGPRX2 performed similarly to chymase. Intriguingly, RA fostered allergic MC degranulation, in a way completely uncoupled from FcepsilonRI expression, but it simultaneously restricted MRGPRX2-triggered histamine release in agreement with the reduced receptor expression. Vitamin-A-derived hormones thus re-shape skin-derived MCs numerically, phenotypically, and functionally. A general theme emerges, implying RA to skew MCs towards processes associated with (allergic) inflammation, while driving them away from the skin-imprinted MCTC ("MCs containing tryptase and chymase") signature (chymase, MRGPRX2). Collectively, MCs are substantial targets of the skin retinoid network</style></abstract><notes><style face="normal" font="default">DA - 20170307IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.3390/ijms18030525</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28264498">PM:28264498</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-525.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-525.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170307, Babina M</style></custom2><misc3><style face="normal" font="default">10.3390/ijms18030525</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40903</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">El Hachem,M.</style></author><author><style face="normal" font="default"> Gesualdo,F.</style></author><author><style face="normal" font="default"> Ricci,G.</style></author><author><style face="normal" font="default"> Diociaiuti,A.</style></author><author><style face="normal" font="default"> Giraldi,L.</style></author><author><style face="normal" font="default"> Ametrano,O.</style></author><author><style face="normal" font="default"> Occella,C.</style></author><author><style face="normal" font="default"> Fortina,A.B.</style></author><author><style face="normal" font="default"> Milioto,M.</style></author><author><style face="normal" font="default"> Arcangeli,F.</style></author><author><style face="normal" font="default"> Simonetti,O.</style></author><author><style face="normal" font="default"> Giancristoforo,S.</style></author><author><style face="normal" font="default"> Calamelli,E.</style></author><author><style face="normal" font="default"> Mazzatenta,C.</style></author><author><style face="normal" font="default"> Neri,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Dermatology Unit, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy</style></auth-address><titles><title><style face="normal" font="default">Topical corticosteroid phobia in parents of pediatric patients with atopic dermatitis: a multicentre survey</style></title><secondary-title><style face="normal" font="default">Ital J Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ital J Pediatr</style></abbr-1></periodical><pages end="" start="22">22-</pages><volume><style face="normal" font="default">43</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Fear</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Outpatients</style></keyword><keyword><style face="normal" font="default"> overweight</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Rome</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutic education</style></keyword><keyword><style face="normal" font="default"> Topical corticosteroids</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treatment Failure</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="2" Year="2017">2017/2/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: Families of children affected with atopic dermatitis (AD) often report fear and anxiety regarding treatment with topical corticosteroids (TCS), which may lead to reduced compliance. The objective of our study was to measure, through a standardized questionnaire, fear of TCS in families of pediatric patients with AD and to identify items associated with fear. METHODS: Families of pediatric patients with AD were enrolled in 9 Italian centers of pediatric dermatology. Enrolled parents were invited to fill in a questionnaire including questions on sociodemographic and clinical characteristics and 3 sets of questions on corticosteroid phobia (general fear, specific fears, behaviours regarding TCS). Determinants of the level of general fear were investigated through multivariable analysis. RESULTS: A total of 300 outpatients with AD were enrolled. Most parents (80%) had a high instruction level. Eighty-one percent reported to have a certain amount of fear of TCS. At the multivariable analysis, fear of TCS was associated with the following items: believing that TCS treatment advantages do not overweight disadvantages (P = 0.011); believing that TCS may be dangerous independently from the specific side effect (P &lt; 0.001). Moreover, TCS fear was associated with fear of applying too much cream (P = 0.001). CONCLUSION: TCS phobia is widespread among Italian families of children with AD. Fear of TCS is associated with fear of applying too much cream, thus increasing the risk of poor compliance and treatment failure. Therapeutic education of families on the use of TCS should be implemented</style></abstract><notes><style face="normal" font="default">DA - 20170301IS - 1824-7288 (Electronic)IS - 1720-8424 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1186/s13052-017-0330-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28245844">PM:28245844</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ital J Pediatr\2017-43-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ital J Pediatr\2017-43-22.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170301, El Hachem M</style></custom2><misc3><style face="normal" font="default">10.1186/s13052-017-0330-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40904</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cunningham,E.</style></author></authors></contributors><titles><title><style face="normal" font="default">What Role Does Diet Play in the Management of Nickel Allergy?</style></title><secondary-title><style face="normal" font="default">J Acad Nutr Diet</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Acad Nutr Diet</style></abbr-1></periodical><pages end="" start="500">500-</pages><volume><style face="normal" font="default">117</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Nickel allergy</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170226IS - 2212-2672 (Print)IS - 2212-2672 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jand.2017.01.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28236963">PM:28236963</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Acad Nutr Diet\2017-117-500.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Acad Nutr Diet\2017-117-500.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170226, Cunningham E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jand.2017.01.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40905</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liccardi,G.</style></author><author><style face="normal" font="default"> Calzetta,L.</style></author><author><style face="normal" font="default"> Salzillo,A.</style></author><author><style face="normal" font="default"> Apicella,G.</style></author><author><style face="normal" font="default"> Cavalli,F.</style></author><author><style face="normal" font="default"> Rogliani,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pneumology and Allergology, Department of Pulmonology, Haematology and Oncology, High Speciality "A.Cardarelli" Hospital, Naples, Italy</style></auth-address><titles><title><style face="normal" font="default">Is H1-antihistamine (desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria really safe and practicable in "real life"?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="535">535-</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergology</style></keyword><keyword><style face="normal" font="default"> desloratadine</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> H1-antihistamine</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Premedication</style></keyword><keyword><style face="normal" font="default"> tablet</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.12.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283171">PM:28283171</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-535.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-535.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170311, Liccardi G</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.12.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40906</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Goldstein,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy and Asthma Care of Long Island, Cough Medical Care of Long Island, Island Medical Research, New York, NY. Electronic address: drsgoldstein@gmail.com</style></auth-address><titles><title><style face="normal" font="default">Unlocking the Puzzle of Severe Asthma in Children</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="421" start="420">420-421</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.11.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283160">PM:28283160</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-420-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-420-1.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170311, Goldstein S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.11.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40907</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">no authors</style></author></authors></contributors><titles><title><style face="normal" font="default">Penicillin Allergy Testing Should Be Performed Routinely in Patients with Self-Reported Penicillin Allergy</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="334" start="333">333-334</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.12.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283158">PM:28283158</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-333-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-333-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170311, no authors</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.12.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40908</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wolsk,H.M.</style></author><author><style face="normal" font="default"> Harshfield,B.J.</style></author><author><style face="normal" font="default"> Laranjo,N.</style></author><author><style face="normal" font="default"> Carey,V.J.</style></author><author><style face="normal" font="default"> O'Connor,G.</style></author><author><style face="normal" font="default"> Sandel,M.</style></author><author><style face="normal" font="default"> Strunk,R.C.</style></author><author><style face="normal" font="default"> Bacharier,L.B.</style></author><author><style face="normal" font="default"> Zeiger,R.S.</style></author><author><style face="normal" font="default"> Schatz,M.</style></author><author><style face="normal" font="default"> Hollis,B.W.</style></author><author><style face="normal" font="default"> Weiss,S.T.</style></author><author><style face="normal" font="default"> Litonjua,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Mass</style></auth-address><titles><title><style face="normal" font="default">Vitamin D supplementation in pregnancy, prenatal 25(OH)D levels, race, and subsequent asthma or recurrent wheeze in offspring: Secondary analyses from the Vitamin D Antenatal Asthma Reduction Trial</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">African American</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> race</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized trial</style></keyword><keyword><style face="normal" font="default"> recurrent wheeze</style></keyword><keyword><style face="normal" font="default"> recurrent wheezing</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="9" Month="3" Year="2017">2017/3/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Nutrient trials differ from drug trials because participants have varying circulating levels at entry into the trial. OBJECTIVE: We sought to study the effect of a vitamin D intervention in pregnancy between subjects of different races and the association between 25-hydroxyvitamin D3 (25[OH]D) levels in pregnancy and the risk of asthma/recurrent wheeze in offspring. METHODS: The Vitamin D Antenatal Asthma Reduction Trial is a randomized trial of pregnant women at risk of having children with asthma randomized to 4400 international units/d vitamin D or placebo plus 400 international units/d vitamin D. Asthma and recurrent wheezing until age 3 years were recorded. RESULTS: African American (AA) women (n = 312) had lower initial levels of 25(OH)D (mean [SD], 17.6 ng/mL [8.3 ng/mL]) compared with non-AA women (n = 400; 27.1 ng/mL [9.7 ng/mL], P &lt; .001). No racial difference was found from vitamin D supplementation in pregnancy on asthma/recurrent wheezing in offspring (P for interaction = .77). Having an initial level of greater than 30 ng/mL and being randomized to the intervention group was associated with the lowest risk for asthma/recurrent wheeze by age 3 years compared with having an initial level of less than 20 ng/mL and receiving placebo (adjusted odds ratio, 0.42; 95% CI, 0.19-0.91). CONCLUSIONS: We did not find differences between AA and non-AA mothers in the effect of maternal vitamin D supplementation and asthma/recurrent wheeze in offspring at 3 years. Maternal supplementation of vitamin D, particularly in mothers with initial 25(OH)D levels of greater than 30 ng/mL, reduced asthma/recurrent wheeze in the offspring through age 3 years, suggesting that higher vitamin D status beginning in early pregnancy is necessary for asthma/recurrent wheeze prevention in early life</style></abstract><notes><style face="normal" font="default">DA - 20170313IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28285844">PM:28285844</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170313-WolskHM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170313-WolskHM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170313, Wolsk HM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40909</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zitt,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Division of Allergy/Immunology, State University of New York, Stony Brook, NY; Adult Allergy Clinic, Nassau University Medical Center, East Meadow, NY.</style></auth-address><titles><title><style face="normal" font="default">A Perspective on Fractional Exhaled Nitric Oxide Measurement for Adherence Monitoring</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="524" start="523">523-524</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.10.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283167">PM:28283167</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-523-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-523-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170311, Zitt M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.10.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40910</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bender,B.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pediatric Behavioral Health, Department of Pediatrics, National Jewish Health, Denver, Colo.</style></auth-address><titles><title><style face="normal" font="default">Revisiting What We Need to Do to Help Urban Minority Children with Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="520" start="519">519-520</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - United Statess -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.11.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283166">PM:28283166</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-519-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-519-20.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170311, Bender BG</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.11.031</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40911</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Trautmann,A.</style></author><author><style face="normal" font="default"> Stoevesandt,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, University Hospital Wurzburg, Wurzburg, Germany.</style></auth-address><titles><title><style face="normal" font="default">Reply (Refers To:  Is H1-antihistamine (desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria really safe and practicable in "real life"?)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="536" start="535">535-536</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> desloratadine</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> H1-antihistamine</style></keyword><keyword><style face="normal" font="default"> Premedication</style></keyword><keyword><style face="normal" font="default"> tablet</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170311IS - 2213-2201 (Electronic)LA - engPT - LetterCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.12.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283170">PM:28283170</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-535-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-535-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170311, Trautmann A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.12.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40912</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tay,T.R.</style></author><author><style face="normal" font="default"> Lee,J.</style></author><author><style face="normal" font="default"> Radhakrishna,N.</style></author><author><style face="normal" font="default"> Hore-Lacy,F.</style></author><author><style face="normal" font="default"> Stirling,R.</style></author><author><style face="normal" font="default"> Hoy,R.</style></author><author><style face="normal" font="default"> Dabscheck,E.</style></author><author><style face="normal" font="default"> O'Hehir,R.</style></author><author><style face="normal" font="default"> Hew,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy, Asthma and Clinical Immunology Service, The Alfred Hospital, Melbourne, Victoria, Australia.</style></auth-address><titles><title><style face="normal" font="default">A Structured Approach to Specialist-referred Difficult Asthma Patients Improves Control of Comorbidities and Enhances Asthma Outcomes</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Difficult asthma</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral corticosteroids</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sinonasal outcome test</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Victoria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Systematic evaluation is advocated for difficult asthma, but how best to deliver such care is unclear and outcome data are scarce. OBJECTIVE: We describe our institution's structured approach to difficult asthma management and report on the outcomes of such an approach. METHODS: Eighty-two consecutive patients with difficult asthma referred to our clinic from respiratory specialists were evaluated in 3 key areas: diagnostic confirmation, comorbidity detection, and inflammatory phenotyping. We then optimized treatment including relevant comorbidity interventions. The outpatient protocol was supported by comorbidity questionnaires, an electronic clinic template, and standardized panel discussion. Asthma outcomes were assessed at 6 months. RESULTS: Sixty-eight patients completed follow-up. Asthma diagnosis was refuted in 3 patients and the remaining 65 patients were included in the study analysis. There was no overall escalation of inhaled or oral corticosteroids. Patients had a median of 3 comorbidities, and a median of 3 comorbidity interventions. Control of chronic rhinosinusitis and dysfunctional breathing improved among patients with these diagnoses (22-item Sino-Nasal Outcome Test score from 47 +/- 20 to 37 +/- 22, P = .017; Nijmegen score from 32 +/- 6 to 25 +/- 9, P = .003). There were overall improvements in the Asthma Control Test score (from 14 +/- 5 to 16 +/- 6, P &lt; .001), the Asthma Quality of Life Questionnaire (from 4.29 +/- 1.4 to 4.65 +/- 1.5, P = .073), and the frequency of exacerbations over 6 months (from 2 [interquartile range, 0-4] to 0 [interquartile range, 0-2], P &lt; .001). CONCLUSIONS: In patients referred with difficult asthma from respiratory specialists, a structured approach coupled with targeted comorbidity interventions improved control of key comorbidities and enhanced asthma outcomes</style></abstract><notes><style face="normal" font="default">DA - 20170312IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.12.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284780">PM:28284780</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170312-TayTR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170312-TayTR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170312, Tay TR</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.12.030</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40913</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Perkins,T.</style></author><author><style face="normal" font="default"> Rosenberg,J.M.</style></author><author><style face="normal" font="default"> Le Coz,C.</style></author><author><style face="normal" font="default"> Alaimo,J.T.</style></author><author><style face="normal" font="default"> Trofa,M.</style></author><author><style face="normal" font="default"> Mullegama,S.V.</style></author><author><style face="normal" font="default"> Antaya,R.J.</style></author><author><style face="normal" font="default"> Jyonouchi,S.</style></author><author><style face="normal" font="default"> Elsea,S.H.</style></author><author><style face="normal" font="default"> Utz,P.J.</style></author><author><style face="normal" font="default"> Meffre,E.</style></author><author><style face="normal" font="default"> Romberg,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Yale University School of Medicine, New Haven, Conn</style></auth-address><titles><title><style face="normal" font="default">Smith-Magenis Syndrome Patients Often Display Antibody Deficiency but Not Other Immune Pathologies</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> Atopic diseases</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Autoimmunity</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Gastroenteritis</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> malignancy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> memory B cell</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microarray</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Otitis</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pneumonia</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Sinusitis</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> vaccine</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="3" Year="2017">2017/3/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Smith-Magenis syndrome (SMS) is a complex neurobehavioral disorder associated with recurrent otitis. Most SMS cases result from heterozygous interstitial chromosome 17p11.2 deletions that encompass not only the intellectual disability gene retinoic acid-induced 1 but also other genes associated with immunodeficiency, autoimmunity, and/or malignancy. OBJECTIVES: The goals of this study were to describe the immunological consequence of 17p11.2 deletions by determining the prevalence of immunological diseases in subjects with SMS and by assessing their immune systems via laboratory methods. METHODS: We assessed clinical histories of 76 subjects with SMS with heterozygous 17p11.2 deletions and performed in-depth immunological testing on 25 representative cohort members. Laboratory testing included determination of serum antibody concentrations, vaccine titers, and lymphocyte subset frequencies. Detailed reactivity profiles of SMS serum antibodies were performed using custom-made antigen microarrays. RESULTS: Of 76 subjects with SMS, 74 reported recurrent infections including otitis (88%), pneumonia (47%), sinusitis (42%), and gastroenteritis (34%). Infections were associated with worsening SMS-related neurobehavioral symptoms. The prevalence of autoimmune and atopic diseases was not increased. Malignancy was not reported. Laboratory evaluation revealed most subjects with SMS to be deficient of isotype-switched memory B cells and many to lack protective antipneumococcal antibodies. SMS antibodies were not more reactive than control antibodies to self-antigens. CONCLUSIONS: Patients with SMS with heterozygous 17p.11.2 deletions display an increased susceptibility to sinopulmonary infections, but not to autoimmune, allergic, or malignant diseases. SMS sera display an antibody reactivity profile favoring neither recognition of pathogen-associated antigens nor self-antigens. Prophylactic strategies to prevent infections may also provide neurobehavioral benefits to selected patients with SMS</style></abstract><notes><style face="normal" font="default">DA - 20170313IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.01.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28286158">PM:28286158</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170313-PerkinsT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170313-PerkinsT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170313, Perkins T</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.01.028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40914</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Eastman,J.J.</style></author><author><style face="normal" font="default"> Cavagnero,K.J.</style></author><author><style face="normal" font="default"> DeConde,A.S.</style></author><author><style face="normal" font="default"> Kim,A.S.</style></author><author><style face="normal" font="default"> Karta,M.R.</style></author><author><style face="normal" font="default"> Broide,D.H.</style></author><author><style face="normal" font="default"> Zuraw,B.L.</style></author><author><style face="normal" font="default"> White,A.A.</style></author><author><style face="normal" font="default"> Christiansen,S.C.</style></author><author><style face="normal" font="default"> Doherty,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, University of California, San Diego, Calif</style></auth-address><titles><title><style face="normal" font="default">Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> AERD</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Chemotaxis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> COX-1</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate lymphoid cells</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Leukotriene E4</style></keyword><keyword><style face="normal" font="default"> Leukotrienes</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Prostaglandin</style></keyword><keyword><style face="normal" font="default"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="default"> Prostaglandins</style></keyword><keyword><style face="normal" font="default"> Quantification</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Scraping</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> symptom scores</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> urine</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="27" Month="1" Year="2017">2017/1/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is characterized by tissue eosinophilia and mast cell activation, including abundant production of prostaglandin D2 (PGD2). Group 2 innate lymphoid cells (ILC2s), which promote tissue eosinophilia and mast cell responses, undergo chemotaxis and cytokine production in response to PGD2, but it is unknown whether ILC2s are active in patients with AERD. OBJECTIVE: We sought to determine whether ILC2 numbers change in peripheral blood and the nasal mucosa during COX-1 inhibitor-induced reactions in patients with AERD. METHODS: Blood and nasal scrapings were collected at baseline, during reactions, and after completion of ketorolac/aspirin challenge/desensitization in 12 patients with AERD. ILC2s and eosinophils were quantitated by means of flow cytometry. Urine was also collected, and quantification of PGD2 metabolite and leukotriene E4 levels was done by using ELISA. Baseline and nonsteroidal anti-inflammatory drug reaction clinical data were correlated with cell changes. RESULTS: ILC2 numbers significantly increased in nasal mucosal samples and decreased in blood at the time of COX-1 inhibitor reactions in 12 patients with AERD. These changes were not observed in 2 patients without AERD. Furthermore, eosinophil numbers decreased in blood concurrently with significant increases in urinary PGD2 metabolite and leukotriene E4 levels. The magnitude of increases in nasal mucosal ILC2 numbers positively correlated with maximum symptom scores during challenges. Furthermore, blood ILC2 numbers during the reaction correlated with time for the reaction to resolve, possibly reflecting reaction severity. CONCLUSIONS: ILC2s are recruited to the nasal mucosa during COX-1 inhibitor-induced reactions in patients with AERD, correlating with enhanced production of prostaglandins and leukotrienes</style></abstract><notes><style face="normal" font="default">DA - 20170310IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28279492">PM:28279492</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170310-EastmanJJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170310-EastmanJJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170310, Eastman JJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40915</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Price,D.B.</style></author><author><style face="normal" font="default"> Roman-Rodriguez,M.</style></author><author><style face="normal" font="default"> McQueen,R.B.</style></author><author><style face="normal" font="default"> Bosnic-Anticevich,S.</style></author><author><style face="normal" font="default"> Carter,V.</style></author><author><style face="normal" font="default"> Gruffydd-Jones,K.</style></author><author><style face="normal" font="default"> Haughney,J.</style></author><author><style face="normal" font="default"> Henrichsen,S.</style></author><author><style face="normal" font="default"> Hutton,C.</style></author><author><style face="normal" font="default"> Infantino,A.</style></author><author><style face="normal" font="default"> Lavorini,F.</style></author><author><style face="normal" font="default"> Law,L.M.</style></author><author><style face="normal" font="default"> Lisspers,K.</style></author><author><style face="normal" font="default"> Papi,A.</style></author><author><style face="normal" font="default"> Ryan,D.</style></author><author><style face="normal" font="default"> Stallberg,B.</style></author><author><style face="normal" font="default"> van der Molen,T.</style></author><author><style face="normal" font="default"> Chrystyn,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Academic Primary Care, University of Aberdeen, Aberdeen; Observational and Pragmatic Research Institute Pte Ltd, Singapore.</style></auth-address><titles><title><style face="normal" font="default">Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Metered Dose Inhalers</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Norway</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="3" Year="2017">2017/3/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Poor inhaler technique has been linked to poor asthma outcomes. Training can reduce the number of inhaler errors, but it is unknown which errors have the greatest impact on asthma outcomes. OBJECTIVE: The CRITical Inhaler mistaKes and Asthma controL study investigated the association between specific inhaler errors and asthma outcomes. METHODS: This analysis used data from the iHARP asthma review service-a multicenter cross-sectional study of adults with asthma. The review took place between 2011 and 2014 and captured data from more than 5000 patients on demographic characteristics, asthma symptoms, and inhaler errors observed by purposefully trained health care professionals. People with asthma receiving a fixed-dose combination treatment with inhaled corticosteroids and long-acting beta agonist were categorized by the controller inhaler device they used-dry-powder inhalers or metered-dose inhalers: inhaler errors were analyzed within device cohorts. Error frequency, asthma symptom control, and exacerbation rate were analyzed to identify critical errors. RESULTS: This report contains data from 3660 patients. Insufficient inspiratory effort was common (made by 32%-38% of dry-powder inhaler users) and was associated with uncontrolled asthma (adjusted odds ratios [95% CI], 1.30 [1.08-1.57] and 1.56 [1.17-2.07] in those using Turbohaler and Diskus devices, respectively) and increased exacerbation rate. In metered-dose inhaler users, actuation before inhalation (24.9% of patients) was associated with uncontrolled asthma (1.55 [1.11-2.16]). Several more generic and device-specific errors were also identified as critical. CONCLUSIONS: Specific inhaler errors have been identified as critical errors, evidenced by frequency and association with asthma outcomes. Asthma management should target inhaler training to reduce key critical errors</style></abstract><notes><style face="normal" font="default">DA - 20170313IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Singapore -CO - Spain -CO - United States -CO - United Kingdom -CO - Norway -CO - Italy -CO - Sweden -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.01.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28286157">PM:28286157</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170313-PriceDB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170313-PriceDB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170313, Price DB</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.01.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40916</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Keet,C.A.</style></author><author><style face="normal" font="default"> Matsui,E.</style></author><author><style face="normal" font="default"> McCormack,M.C.</style></author><author><style face="normal" font="default"> Peng,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Associate Professor, Johns Hopkins University School of Medicine, Division of Pediatric Allergy and Immunology.</style></auth-address><titles><title><style face="normal" font="default">Urban Residence, Neighborhood Poverty, race/ethnicity and Asthma Morbidity Among Children in Medicaid</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inner city</style></keyword><keyword><style face="normal" font="default"> inner-city</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> low income</style></keyword><keyword><style face="normal" font="default"> Medicaid</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Poverty</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urbanization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="7" Month="3" Year="2017">2017/3/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Although poor-urban (inner-city) areas are thought to have high asthma prevalence and morbidity, we recently found that inner-cities do not have higher prevalent pediatric asthma. Whether asthma morbidity is higher in inner-city areas across the U.S. not known. OBJECTIVE: To examine relationships between residence in poor and urban areas, race/ethnicity, and asthma morbidity among children with asthma enrolled in Medicaid. METHODS: Children aged 5-19 enrolled in Medicaid in 2009-2010 were included. Asthma was defined by at least one outpatient or emergency department (ED) visit with a primary diagnosis code of asthma over the 2 year period. Urbanization status was defined at the county level and neighborhood poverty at the zip-code level. Among children with asthma, logistic models were created to examine the effects of urbanization, neighborhood poverty and race/ethnicity on rates of asthma outpatient visits, ED visits and hospitalizations. RESULTS: 16,860,716 children were included (1,534,820 with asthma). Among children enrolled in Medicaid, residence in inner-city areas did not confer increased risk of prevalent asthma in either crude or adjusted analyses, but was associated with significantly more asthma-related emergency room visits and hospitalizations among those with asthma in crude analyses (RR 1.48, 95%CI:1.24-1.36 and 1.97, 95%CI:1.50-1.72, respectively) and when adjusted for race/ethnicity, age and gender (aRR 1.23, 95%CI:1.08-1.15 and 1.62, 95%CI:1.26-1.43). Residence in urban or poor areas, and non-Hispanic black race/ethnicity were all independently associated with increased risk of asthma related emergency room visits and hospitalizations. CONCLUSIONS: Residence in poor and urban areas is an important risk factor for asthma morbidity, but not prevalence, among low-income U.S. children</style></abstract><notes><style face="normal" font="default">DA - 20170311IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283418">PM:28283418</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170311-KeetCA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170311-KeetCA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170311, Keet CA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.036</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40917</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liccardi,G.</style></author><author><style face="normal" font="default"> Calzetta,L.</style></author><author><style face="normal" font="default"> Salzillo,A.</style></author><author><style face="normal" font="default"> Puxeddu,E.</style></author><author><style face="normal" font="default"> Rogliani,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pneumology and Allergology, Department of Pulmonology, Haematology and Oncology, High Speciality "A. Cardarelli" Hospital, Naples, Italy</style></auth-address><titles><title><style face="normal" font="default">Relationship between oxytocin/vasopressin and latex in obstetric surgery: how to recognize (and prevent) allergic reactions and differentiate them from side effects?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Latex</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword></keywords><dates><year Day="9" Month="3" Year="2017">2017/3/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170313IS - 2213-2201 (Electronic)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.10.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28286159">PM:28286159</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170313-LiccardiG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170313-LiccardiG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170313, Liccardi G</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.10.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40918</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kostjukovits,S.</style></author><author><style face="normal" font="default"> Klemetti,P.</style></author><author><style face="normal" font="default"> Valta,H.</style></author><author><style face="normal" font="default"> Martelius,T.</style></author><author><style face="normal" font="default"> Notarangelo,L.D.</style></author><author><style face="normal" font="default"> Seppanen,M.</style></author><author><style face="normal" font="default"> Taskinen,M.</style></author><author><style face="normal" font="default"> Makitie,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="default">Analysis of Clinical and Immunologic Phenotype in a Large Cohort of Children and Adults with Cartilage-hair Hypoplasia</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> specific antibodies</style></keyword><keyword><style face="normal" font="default"> Specific antibody deficiency</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="default">In our cohort of individuals with cartilage-hair hypoplasia 1) over 25% of patients manifest clinical combined immunodeficiency and they have lower CD3+, CD8+ and recent thymic emigrant counts; 2) specific antibody deficiency may exist; 3) low IgG2 levels associate with severe varicella</style></abstract><notes><style face="normal" font="default">DA - 20170312IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Finland -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284971">PM:28284971</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170312-KostjukovitsS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170312-KostjukovitsS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170312, Kostjukovits S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40919</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kelbel,T.</style></author><author><style face="normal" font="default"> Morris,D.</style></author><author><style face="normal" font="default"> Walker,D.</style></author><author><style face="normal" font="default"> Henao,M.P.</style></author><author><style face="normal" font="default"> Craig,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Section of Allergy &amp; Immunology, Division of Pulmonary, Allergy &amp; Critical Care Medicine, Department of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, Pa</style></auth-address><titles><title><style face="normal" font="default">The Allergist's Role in Detection of Severe Alpha-1 Antitrypsin Deficiency</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Alpha-1 antitrypsin deficiency</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Immunotherapy</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) frequently presents as difficult to manage asthma or asthma with fixed obstruction and is well documented as being underdiagnosed in the population. OBJECTIVE: This study aimed to better describe allergists'/immunologists' involvement in the care of patients with AATD and whether they currently contribute to the underdiagnosis by lack of screening for the condition. METHODS: Using the Research Electronic Data Capture tool, we submitted a questionnaire to 500 patients with severe AATD (ZZ, SZ, ZNull, and FZ) through the Alpha-1 Foundation Research Registry to collect information about patient diagnosis and treatment patterns. Approximately 45% completed the questionnaire, leading to a final enrollment of 226 participants. RESULTS: Seventy-eight participants (34%) had seen an allergist, but only 11 (5%) were diagnosed with AATD by their allergist. Likewise, allergists prescribed alpha-1 augmentation therapy to only 5 (8%) of the 59 patients on augmentation therapy. Nearly 46% (n = 104) of all participants were diagnosed with either asthma (28%) or allergic disease (18%) before receiving a diagnosis of AATD. Eighteen patients had been treated with immunotherapy before their diagnosis of AATD, with 94% of these participants receiving treatment for 3 years or longer. CONCLUSIONS: Our data suggest that specialists in Allergy and Immunology should consider and screen for AATD in patients with asthma in whom spirometry does not return to normal. Furthermore, we propose allergists/immunologists are well suited to screen and treat patients with AATD</style></abstract><notes><style face="normal" font="default">DA - 20170312IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.01.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284783">PM:28284783</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170312-KelbelT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170312-KelbelT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170312, Kelbel T</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.01.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40920</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Racine,G.</style></author><author><style face="normal" font="default"> Castano,R.</style></author><author><style face="normal" font="default"> Cartier,A.</style></author><author><style face="normal" font="default"> Lemiere,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre integre universitaire de sante et des services sociaux du Nord-de-l'Ile-de-Montreal, Hopital du Sacre-Coeur de Montreal, Universite de Montreal, Montreal, Quebec, Canada</style></auth-address><titles><title><style face="normal" font="default">Diagnostic Accuracy of Inflammatory Markers for Diagnosing Occupational Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cell Count</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> Methacholine challenge</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> occupational asthma</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Quebec</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> specific inhalation challenge</style></keyword><keyword><style face="normal" font="default"> Specific inhalation challenges</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> sputum eosinophil</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword></keywords><dates><year Day="9" Month="3" Year="2017">2017/3/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: The assessment of airway responsiveness and inflammation is key to the investigation of occupational asthma (OA). OBJECTIVE: We sought to assess and compare the diagnostic accuracies of the blood and sputum eosinophil counts and the methacholine challenge for the diagnosis of OA. METHODS: We conducted a retrospective study assessing 618 patients who underwent specific inhalation challenges (SICs) for symptoms suggestive of OA between 2000 and 2015. A sputum induction and a methacholine challenge were performed before and after SICs. Blood samples were collected in all subjects before the SICs and in 100 subjects before and after SICs. The diagnostic accuracies of blood and sputum eosinophil counts and methacholine challenge were calculated for diagnosing OA. RESULTS: The change in blood eosinophil count failed to differentiate workers with positive and negative SICs. The change in sputum eosinophil counts induced by the exposure to the offending agent had the highest diagnostic accuracy (receiver operating characteristic area under the curve: 86% [95% confidence interval: 0.8-0.9, P &lt; .001]) for diagnosing OA compared with changes in concentration of methacholine inducing a 20% fall in forced expiratory volume in 1 second (PC20) and blood eosinophils. Combining a 2-fold or greater decrease in PC20 or a 3% or greater increase in sputum eosinophil count achieved a sensitivity of 84% and a specificity of 74% with a negative predictive value of 91% for the diagnosis of OA. CONCLUSIONS: Blood eosinophil counts do not appear to be an effective aid for diagnosing OA. The performance of both sputum cell count analysis and a methacholine challenge before and after exposure to the offending agent may represent an effective alternative in diagnosing OA when SICs are unavailable</style></abstract><notes><style face="normal" font="default">DA - 20170313IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.02.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28286155">PM:28286155</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170313-RacineG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170313-RacineG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170313, Racine G</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.02.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40921</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Notarangelo,L.D.</style></author><author><style face="normal" font="default"> Fleisher,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Clinical Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md</style></auth-address><titles><title><style face="normal" font="default">Targeted strategies directed at the molecular defect: Toward precision medicine for select primary immunodeficiency disorders</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="723" start="715">715-723</pages><volume><style face="normal" font="default">139</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">abnormalities</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Autoimmunity</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> dysregulation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune dysregulation</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Targeted therapy</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">Primary immunodeficiency disorders (PIDs) represent a range of genetically determined diseases that typically have increased susceptibility to infections and in many cases also have evidence of immune dysregulation that often presents as autoimmunity. Most recently, the concept of gain-of-function mutations associated with PIDs has become well recognized and adds a new dimension to the understanding of this group of disorders, moving beyond the more commonly seen loss-of-function mutations. The rapidly expanding genetic defects that have been identified in patients with previously uncharacterized PIDs has opened up the potential for targeted therapy directed at the specific disease-causing abnormality. This has been driven by linking PID-specific genetic defects to the associated unique abnormalities in cellular signaling pathways amenable to directed therapies. These include agents that either block overactive or enhance underresponsive cellular pathways. Selected primary immunodeficiencies were chosen, the genetic defects of which have been recently characterized and are amenable to targeted therapy, as a reflection of the power of precision medicine</style></abstract><notes><style face="normal" font="default">DA - 20170308IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28270363">PM:28270363</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-715-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-715-23.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170308, Notarangelo LD</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40922</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Davis,B.P.</style></author><author><style face="normal" font="default"> Ballas,Z.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Iowa Hospitals and Clinics, Department of Internal Medicine, Division of Immunology, 200 Hawkins Drive, Iowa City IA 52246, Tel. 319-356-4899, Fax. 319-353-6290. Electronic address: ben-davis@uiowa.eduUniversity of Iowa and the Iowa City Veterans Administration, Department of Internal Medicine, Division of Immunology, 200 Hawkins Drive, Iowa City IA 52246, Tel. 319-356-3697, Fax. 319-353-6290. Electronic address: zuhair-ballas@uiowa.edu</style></auth-address><titles><title><style face="normal" font="default">Biologic Response Modifiers: Indications, Implications and Insights</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Indications</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Iowa</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Veterans</style></keyword></keywords><dates><year Day="2" Month="3" Year="2017">2017/3/2</year></dates><abstract><style face="normal" font="default">The field of biologic immune-modulators is currently mushrooming at a dizzying pace. While most of these biologics are tested and approved for one or a few indications, their un-anticipated side effects and their off-label use have contributed significantly to our understanding of basic immune mechanisms, of the involvement of cytokines in several apparently non-immunologic diseases, and of the importance of compartmentalized immune responses. In this review, we attempt to give a bird's-eye view of the major biologics and to highlight insights and implications derived from their secondary effects and adverse reactions</style></abstract><notes><style face="normal" font="default">DA - 20170306IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28263774">PM:28263774</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170306-DavisBP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170306-DavisBP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170306, Davis BP</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40923</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stevens,W.W.</style></author><author><style face="normal" font="default"> Peters,A.T.</style></author><author><style face="normal" font="default"> Hirsch,A.G.</style></author><author><style face="normal" font="default"> Nordberg,C.M.</style></author><author><style face="normal" font="default"> Schwartz,B.S.</style></author><author><style face="normal" font="default"> Mercer,D.G.</style></author><author><style face="normal" font="default"> Mahdavinia,M.</style></author><author><style face="normal" font="default"> Grammer,L.C.</style></author><author><style face="normal" font="default"> Hulse,K.E.</style></author><author><style face="normal" font="default"> Kern,R.C.</style></author><author><style face="normal" font="default"> Avila,P.</style></author><author><style face="normal" font="default"> Schleimer,R.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill.</style></auth-address><titles><title><style face="normal" font="default">Clinical Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps, Asthma, and Aspirin-Exacerbated Respiratory Disease</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AERD</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Computer</style></keyword><keyword><style face="normal" font="default"> COX-1</style></keyword><keyword><style face="normal" font="default"> Cyclooxygenase 1</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Electronic medical records</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Illinois</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> sinus</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="3" Year="2017">2017/3/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) comprises the triad of chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and intolerance to inhibitors of the cyclooxygenase-1 (COX-1) enzyme. The prevalence of AERD remains unclear, and few studies have compared the clinical characteristics of patients with AERD to those with CRSwNP alone, asthma alone, or both CRSwNP and asthma. OBJECTIVE: To determine the prevalence of AERD within a tertiary care setting, and to identify unique clinical features that could distinguish these patients from those with both CRSwNP and asthma or with CRSwNP alone. METHODS: Electronic medical records of patients at Northwestern in Chicago, Illinois, were searched by computer algorithm and then manual chart review to identify 459 patients with CRSwNP alone, 412 with both CRSwNP and asthma, 171 with AERD, and 300 with asthma only. Demographic and clinical features including sex, atopy, and sinus disease severity were characterized. RESULTS: The prevalence of AERD among patients with CRSwNP was 16%. Patients with AERD had undergone 2-fold more sinus surgeries (P &lt; .001) and were significantly younger at the time of their first surgery (40 +/- 13 years) than were patients with CRSwNP (43 +/- 14 years; P &lt; .05). Atopy was significantly more prevalent in patients with AERD (84%) or asthma (85%) than in patients with CRSwNP (66%, P &lt; .05). More patients with AERD (13%) had corticosteroid-dependent disease than patients with both CRSwNP and asthma (4%, P &lt; .01) or asthma (1%, P &lt; .001). CONCLUSIONS: AERD is common among patients with CRSwNP; even though patients with AERD have CRSwNP and asthma, the clinical course of their disease is not the same as of patients who have CRSwNP and asthma but are tolerant to COX-1 inhibitors</style></abstract><notes><style face="normal" font="default">DA - 20170313IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.12.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28286156">PM:28286156</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170313-StevensWW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170313-StevensWW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170313, Stevens WW</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.12.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40924</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kohn,D.B.</style></author><author><style face="normal" font="default"> Kuo,C.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Calif; Department of Microbiology, Immunology &amp; Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles, Calif; Eli &amp; Edythe Broad Center of Stem Cell Research &amp; Regenerative Medicine, David Geffen School of Medicine, University of California, Los Angeles, Calif; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Calif. Electronic address: dkohn1@mednet.ucla.eduDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Calif</style></auth-address><titles><title><style face="normal" font="default">New frontiers in the therapy of primary immunodeficiency: From gene addition to gene editing</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="732" start="726">726-732</pages><volume><style face="normal" font="default">139</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic granulomatous disease</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Deficiency Diseases</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Therapy</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Hematopoietic Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> Hematopoietic Stem Cells</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Los Angeles</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> Stem Cells</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">The most severe primary immune deficiency diseases (PIDs) have been successfully treated with allogeneic hematopoietic stem cell transplantation for more than 4 decades. However, such transplantations have the best outcomes when there is a well-matched donor available because immune complications, such as graft-versus-host disease, are greater without a matched sibling donor. Gene therapy has been developed as a method to perform autologous transplantations of a patient's own stem cells that are genetically corrected. Through an iterative bench-to-bedside-and-back process, methods to efficiently add new copies of the relevant gene to hematopoietic stem cells have led to safe and effective treatments for several PIDs, including forms of severe combined immune deficiency, Wiskott-Aldrich syndrome, and chronic granulomatous disease. New methods for gene editing might allow additional PIDs to be treated by gene therapy because they will allow the endogenous gene to be repaired and expressed under its native regulatory elements, which are essential for genes involved in cell processes of signaling, activation, and proliferation. Gene therapy is providing exciting new treatment options for patients with PIDs, and advances are sure to continue</style></abstract><notes><style face="normal" font="default">DA - 20170308IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28270364">PM:28270364</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-726-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-726-32.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170308, Kohn DB</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40925</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shum,M.</style></author><author><style face="normal" font="default"> Jerschow,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics and Medicine, Maria Fareri Children's Hospital at Westchester Medical Center and New York Medical College, Valhalla, NY.</style></auth-address><titles><title><style face="normal" font="default">Reply (Refers To:  Relationship between oxytocin/vasopressin and latex in obstetric surgery: how to recognize (and prevent) allergic reactions and differentiate them from side effects?)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Latex</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="9" Month="3" Year="2017">2017/3/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170313IS - 2213-2201 (Electronic)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.12.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28286154">PM:28286154</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170313-ShumM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170313-ShumM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170313, Shum M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.12.034</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40926</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Etzioni,A.</style></author><author><style face="normal" font="default"> Ciechanover,A.</style></author><author><style face="normal" font="default"> Pikarsky,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Ruth Children Hospital, Rambam Health Campus, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. Electronic address: etzioni@rambam.health.gov.ilTechnion Integrated Cancer Center (TICC), Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, IsraelLautenberg Center for Immunology and Cancer Research, Institute for Medical Research Israel Canada (IMRIC), Hebrew University-Hadassah Medical School, Jerusalem, Israel</style></auth-address><titles><title><style face="normal" font="default">Immune defects caused by mutations in the ubiquitin system</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="753" start="743">743-753</pages><volume><style face="normal" font="default">139</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> adaptive</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Autoimmunity</style></keyword><keyword><style face="normal" font="default"> Autoinflammation</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> dysregulation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune dysregulation</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">The importance of the ubiquitin system in health and disease has been widely recognized in recent decades, with better understanding of the various components of the system and their function. Ubiquitination, which is essential to almost all biological processes in eukaryotes, was also found to play an important role in innate and adaptive immune responses. Thus it is not surprising that mutations in genes coding for components of the ubiquitin system cause immune dysregulation. The first defect in the system was described 30 years ago and is due to mutations in the nuclear factor kappaB (NF-kappaB) essential modulator, a key regulator of the NF-kappaB pathway. With use of novel sequencing techniques, many additional mutations in different genes involved in ubiquitination and related to immune system function were identified. This can be clearly illustrated in mutations in the different activation pathways of NF-kappaB, which result in aberrations in production of various proinflammatory cytokines. The inherited diseases typically manifest with immunodeficiency, autoimmunity, or autoinflammation. In this perspective we provide a short description of the ubiquitin system, with specific emphasis given to its role in the immune system. The various immunodeficiency conditions identified thus far in association with defective ubiquitination are discussed in more detail</style></abstract><notes><style face="normal" font="default">DA - 20170308IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28270366">PM:28270366</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-743-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-743-53.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170308, Etzioni A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.031</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40927</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dorsey,M.J.</style></author><author><style face="normal" font="default"> Dvorak,C.C.</style></author><author><style face="normal" font="default"> Cowan,M.J.</style></author><author><style face="normal" font="default"> Puck,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Division of Allergy, Immunology, and Bone Marrow Transplantation, University of California, San Francisco, Calif.</style></auth-address><titles><title><style face="normal" font="default">Treatment of infants identified as having severe combined immunodeficiency by means of newborn screening</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="742" start="733">733-742</pages><volume><style face="normal" font="default">139</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Bone Marrow</style></keyword><keyword><style face="normal" font="default"> Bone Marrow Transplantation</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Lymphopenia</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> newborn</style></keyword><keyword><style face="normal" font="default"> Newborn screening</style></keyword><keyword><style face="normal" font="default"> Opportunistic Infections</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> San Francisco</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Severe Combined Immunodeficiency</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">Severe combined immunodeficiency (SCID) is characterized by severely impaired T-cell development and is fatal without treatment. Newborn screening (NBS) for SCID permits identification of affected infants before development of opportunistic infections and other complications. Substantial variation exists between treatment centers with regard to pretransplantation care, and transplantation protocols for NBS identified infants with SCID, as well as infants with other T-lymphopenic disorders detected by using NBS. We developed approaches to management based on the study of infants identified by means of NBS for SCID who received care at the University of California, San Francisco (UCSF). From August 2010 through October 2016, 32 patients with NBS-identified SCID and leaky SCID from California and other states were treated, and 42 patients with NBS-identified non-SCID T-cell lymphopenia were followed. Our center's approach supports successful outcomes; systematic review of our practice provides a framework for diagnosis and management, recognizing that more data will continue to shape best practices</style></abstract><notes><style face="normal" font="default">DA - 20170308IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28270365">PM:28270365</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-733-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-733-42.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170308, Dorsey MJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40928</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nicholas,B.</style></author><author><style face="normal" font="default"> Dudley,S.</style></author><author><style face="normal" font="default"> Tariq,K.</style></author><author><style face="normal" font="default"> Howarth,P.</style></author><author><style face="normal" font="default"> Lunn,K.</style></author><author><style face="normal" font="default"> Pink,S.</style></author><author><style face="normal" font="default"> Sterk,P.J.</style></author><author><style face="normal" font="default"> Adcock,I.M.</style></author><author><style face="normal" font="default"> Monk,P.</style></author><author><style face="normal" font="default"> Djukanovic,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, Sir Henry Wellcome Laboratories, Southampton General Hospital, Southampton, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Susceptibility to influenza virus infection of bronchial biopsies in asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Influenza</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> virus infection</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170305IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.12.964</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28259448">PM:28259448</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170305-NicholasB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170305-NicholasB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170305, Nicholas B</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.12.964</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40929</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McGeachie,M.J.</style></author><author><style face="normal" font="default"> Davis,J.S.</style></author><author><style face="normal" font="default"> Kho,A.T.</style></author><author><style face="normal" font="default"> Dahlin,A.</style></author><author><style face="normal" font="default"> Sordillo,J.E.</style></author><author><style face="normal" font="default"> Sun,M.</style></author><author><style face="normal" font="default"> Lu,Q.</style></author><author><style face="normal" font="default"> Weiss,S.T.</style></author><author><style face="normal" font="default"> Tantisira,K.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Channing Division of Network Medicine, Brigham and Women's Hospital, 181 Longwood Avenue, Boston, MA 02115, USA</style></auth-address><titles><title><style face="normal" font="default">Asthma Remission: Predicting Future Airways Responsiveness using a miRNA Network</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescence</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> MicroRNAs</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Remission</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="23" Month="2" Year="2017">2017/2/23</year></dates><abstract><style face="normal" font="default">A panel of circulating microRNAs can be used to predict airway hyperresponsiveness remission in growing children with asthma as they transition into adolescence and adulthood</style></abstract><notes><style face="normal" font="default">DA - 20170227IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28238746">PM:28238746</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170227-McGeachieMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170227-McGeachieMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170227, McGeachie MJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40930</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Takahashi,T.</style></author><author><style face="normal" font="default"> Kato,A.</style></author><author><style face="normal" font="default"> Berdnikovs,S.</style></author><author><style face="normal" font="default"> Stevens,W.W.</style></author><author><style face="normal" font="default"> Suh,L.A.</style></author><author><style face="normal" font="default"> Norton,J.</style></author><author><style face="normal" font="default"> Carter,R.G.</style></author><author><style face="normal" font="default"> Harris,K.E.</style></author><author><style face="normal" font="default"> Peters,A.T.</style></author><author><style face="normal" font="default"> Hulse,K.E.</style></author><author><style face="normal" font="default"> Grammer,L.C.</style></author><author><style face="normal" font="default"> Welch,K.</style></author><author><style face="normal" font="default"> Shintani-Smith,S.</style></author><author><style face="normal" font="default"> Tan,B.K.</style></author><author><style face="normal" font="default"> Conley,D.B.</style></author><author><style face="normal" font="default"> Kern,R.C.</style></author><author><style face="normal" font="default"> Bochner,B.S.</style></author><author><style face="normal" font="default"> Schleimer,R.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA</style></auth-address><titles><title><style face="normal" font="default">Microparticles in nasal lavage fluids in chronic rhinosinusitis; potential biomarkers for diagnosis of Aspirin Exacerbated Respiratory Disease</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> AERD</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> CD203c</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial injury</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal lavage</style></keyword><keyword><style face="normal" font="default"> Nasal Lavage Fluid</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Platelet</style></keyword><keyword><style face="normal" font="default"> Platelets</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="23" Month="2" Year="2017">2017/2/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: Microparticles (MPs) are submicron sized shed membrane vesicles released from activated or injured cells and are detectable by flow cytometry. MP levels have been utilized as biomarkers to evaluate cell injury or activation in patients with pathological conditions. OBJECTIVE: To compare MP types and levels in nasal lavage fluids (NLFs) from controls and patients with chronic rhinosinusitis without nasal polyps (CRSsNP), CRS with NP (CRSwNP) and aspirin exacerbated respiratory disease (AERD). METHODS: We collected NLFs from CRSsNP (n=33), CRSwNP (n=45), AERD (n=31), and control (n=24) subjects. Standardized flow cytometry methods were used to characterize the following MP types; endothelial MPs, epithelial MPs (EpCAM(+)MPs, E-cadherin(+)MPs), platelet MPs (CD31(+)CD41(+)MPs), eosinophil MPs (EMR1(+)MPs), mast cell MPs (FcepsilonRI(+)c-kit(+)MPs) and basophil MPs (CD203c(+)c-kit(-)MPs). Basophil activation was evaluated by the MFI of CD203c (CD203cMFI) on basophil MPs. RESULTS: Activated mast cell MPs (CD137(+)FcepsilonRI(+)c-kit(+)MPs) were significantly increased in NLFs compared to controls in CRSsNP (2.3-fold, p&lt;0.02), CRSwNP (2.3-fold, p&lt;0.03) and in AERD (7.4-fold, p&lt;0.0001). Platelet MPs (3.5-fold, p&lt;0.01) and basophil MPs (2.5-fold, p&lt;0.05) were increased only in AERD. CD203cMFI on MPs was increased in CRSwNP (p&lt;0.002) and AERD (p&lt;0.0001), but not CRSsNP. EpCAM(+)epithelial MPs in CRSwNP were no different from control (p= 0.91) and lower than those in CRSsNP (p&lt;0.02) and AERD (p&lt;0.002). CONCLUSION: Based on released MPs, mast cells, platelets, and basophils were more highly activated in AERD than in CRS. Epithelial injury was lower in CRSwNP than in CRSsNP and AERD. MP analysis may help identify phenotypes of CRS, and in distinguishing AERD from CRSwNP</style></abstract><notes><style face="normal" font="default">DA - 20170227IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28238741">PM:28238741</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170227-TakahashiT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170227-TakahashiT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170227, Takahashi T</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.022</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40931</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hoch,H.E.</style></author><author><style face="normal" font="default"> Calatroni,A.</style></author><author><style face="normal" font="default"> West,J.B.</style></author><author><style face="normal" font="default"> Liu,A.H.</style></author><author><style face="normal" font="default"> Gergen,P.J.</style></author><author><style face="normal" font="default"> Gruchalla,R.S.</style></author><author><style face="normal" font="default"> Hershey,K.G.</style></author><author><style face="normal" font="default"> Kercsmar,C.M.</style></author><author><style face="normal" font="default"> Kim,H.</style></author><author><style face="normal" font="default"> Lamm,C.I.</style></author><author><style face="normal" font="default"> Makhija,M.M.</style></author><author><style face="normal" font="default"> Mitchell,H.E.</style></author><author><style face="normal" font="default"> Teach,S.J.</style></author><author><style face="normal" font="default"> Wildfire,J.J.</style></author><author><style face="normal" font="default"> Busse,W.W.</style></author><author><style face="normal" font="default"> Szefler,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, CO.</style></auth-address><titles><title><style face="normal" font="default">Can We Predict Fall Asthma Exacerbations? Validation Of The Seasonal Asthma Exacerbation Index</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inner city</style></keyword><keyword><style face="normal" font="default"> inner-city</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Step-up therapy</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="23" Month="2" Year="2017">2017/2/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: A Seasonal Asthma Exacerbation Predictive Index (saEPI) was previously reported based on two prior NIAID Inner City Asthma Consortium trials. OBJECTIVE: We sought to validate the saEPI in a separate trial designed to prevent fall exacerbations with omalizumab therapy. METHODS: The saEPI and its components were analyzed to characterize those who had an asthma exacerbation during the PROSE (Preventative Omalizumab or Step-Up Therapy for Fall Exacerbations) study. We characterized those inner-city children with and without asthma exacerbations in the fall periods treated with guidelines based therapy (GBT) in the absence and presence of omalizumab. RESULTS: A higher saEPI was associated with an exacerbation in both the GBT alone (p&lt;0.001, AUC 0.76) and the GBT + omalizumab group (p&lt;0.01, AUC 0.65). In the GBT group, younger age at recruitment, higher total IgE, higher blood eosinophil percent and number, and higher treatment step were associated with those who had an exacerbation compared to those who did not. In the GBT + omalizumab group, younger age at recruitment, increased eosinophil number, recent exacerbation, and higher treatment step were also associated with those who had an exacerbation. The saEPI was associated with a high negative predictive value in both groups. CONCLUSIONS: An exacerbation in children treated with GBT with or without omalizumab was associated with a higher saEPI along with higher markers of allergic inflammation, treatment step, and a recent exacerbation. Those that exacerbated on omalizumab had similar features, indicating a need to develop better markers to predict poor response to omalizumab therapy and alternative treatment strategies for children with these risk factors. The saEPI was able to reliably predict those children unlikely to have an asthma exacerbation in both groups</style></abstract><notes><style face="normal" font="default">DA - 20170227IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28238748">PM:28238748</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170227-HochHE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170227-HochHE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170227, Hoch HE</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.026</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40932</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Johansson,E.</style></author><author><style face="normal" font="default"> Biagini Myers,J.M.</style></author><author><style face="normal" font="default"> Martin,L.J.</style></author><author><style face="normal" font="default"> He,H.</style></author><author><style face="normal" font="default"> Pilipenko,V.</style></author><author><style face="normal" font="default"> Mersha,T.</style></author><author><style face="normal" font="default"> Weirauch,M.</style></author><author><style face="normal" font="default"> Salomonis,N.</style></author><author><style face="normal" font="default"> Ryan,P.</style></author><author><style face="normal" font="default"> LeMasters,G.K.</style></author><author><style face="normal" font="default"> Bernstein,D.I.</style></author><author><style face="normal" font="default"> Lockey,J.</style></author><author><style face="normal" font="default"> Khurana Hershey,G.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Cincinnati, Cincinnati, OH, USA</style></auth-address><titles><title><style face="normal" font="default">KIF3A genetic variation is associated with pediatric asthma in the presence of eczema independent of allergic rhinitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> allergic sensitization</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword></keywords><dates><year Day="23" Month="2" Year="2017">2017/2/23</year></dates><abstract><style face="normal" font="default">KIF3A SNPs identify a subset of asthmatic children with prior or current eczema independent of AR, and may be useful biomarkers of an eczema phenotype that progresses to asthma, independent of allergic sensitization</style></abstract><notes><style face="normal" font="default">DA - 20170227IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28238750">PM:28238750</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170227-JohanssonE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170227-JohanssonE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170227, Johansson E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40933</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Blumenthal,K.G.</style></author><author><style face="normal" font="default"> Wickner,P.G.</style></author><author><style face="normal" font="default"> Hurwitz,S.</style></author><author><style face="normal" font="default"> Pricco,N.</style></author><author><style face="normal" font="default"> Nee,A.E.</style></author><author><style face="normal" font="default"> Laskowski,K.</style></author><author><style face="normal" font="default"> Shenoy,E.S.</style></author><author><style face="normal" font="default"> Walensky,R.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA</style></auth-address><titles><title><style face="normal" font="default">Tackling Inpatient Penicillin Allergies: Tools for Antimicrobial Stewardship</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse drug events</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> cephalosporin</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical decision support</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Inpatients</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Minnesota</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> Stewardship</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treatment Failure</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="27" Month="2" Year="2017">2017/2/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Reported penicillin allergy rarely reflects penicillin intolerance. Failure to address inpatient penicillin allergies results in more broad-spectrum antibiotic use, treatment failures, and adverse drug events. OBJECTIVE: We aimed to determine the optimal approach to penicillin allergies among medical inpatients. METHODS: We evaluated internal medicine inpatients reporting penicillin allergy in three periods: (1) standard of care (SOC), (2) penicillin skin testing (ST), and (3) computerized guideline application with decision support (APP). The primary outcome was use of a penicillin or cephalosporin, comparing interventions to SOC using multivariable logistic regression. RESULTS: There were 625 patients: SOC 148, ST 278, and APP 199. Of 278 ST patients, 179 (64%) were skin test eligible; 43 (24%) received testing and none were allergic. In the APP period, there were 292 unique website views; 112 users (38%) completed clinical decision support. While ST period patients did not have an increased odds of penicillin or cephalosporin use overall (aOR 1.3 [95% CI 0.8, 2.0]), we observed a significant increased odds of penicillin or cephalosporin use overall in the APP period (aOR 1.8 [95% CI 1.1, 2.9]), and in a per protocol analysis of the skin tested subset (aOR 5.7 [95% CI 2.6, 12.5]). CONCLUSIONS: Both the computerized guideline with decision support and penicillin skin testing - when completed - increased use of penicillin and cephalosporin antibiotics among inpatients reporting penicillin allergy. While the skin tested subset showed an almost 6-fold impact, the computerized guideline significantly increased penicillin or cephalosporin use overall nearly 2-fold and was readily implemented</style></abstract><notes><style face="normal" font="default">DA - 20170303IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28254470">PM:28254470</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170303-BlumenthalKG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170303-BlumenthalKG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170303, Blumenthal KG</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40934</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bal,E.</style></author><author><style face="normal" font="default"> Laplantine,E.</style></author><author><style face="normal" font="default"> Hamel,Y.</style></author><author><style face="normal" font="default"> Dubosclard,V.</style></author><author><style face="normal" font="default"> Boisson,B.</style></author><author><style face="normal" font="default"> Pesacatore,A.</style></author><author><style face="normal" font="default"> Picard,C.</style></author><author><style face="normal" font="default"> Hadj-Rabia,S.</style></author><author><style face="normal" font="default"> Royer,G.</style></author><author><style face="normal" font="default"> Steffann,J.</style></author><author><style face="normal" font="default"> Bonnefont,J.P.</style></author><author><style face="normal" font="default"> Ursini,V.M.</style></author><author><style face="normal" font="default"> Vabres,P.</style></author><author><style face="normal" font="default"> Munnich,A.</style></author><author><style face="normal" font="default"> Casanova,J.L.</style></author><author><style face="normal" font="default"> Bodemer,C.</style></author><author><style face="normal" font="default"> Weil,R.</style></author><author><style face="normal" font="default"> Agou,F.</style></author><author><style face="normal" font="default"> Smahi,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">INSERM U Laboratory of Signaling and Pathogenesis, CNRS UMR 3691, Institut Pasteur, F-75724 Paris, France</style></auth-address><titles><title><style face="normal" font="default">Lack of interaction between between NEMO and SHARPIN impairs linear ubiquitination and NF-kappaB activation, and leads to incontinentia pigmenti</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exons</style></keyword><keyword><style face="normal" font="default"> Fetus</style></keyword><keyword><style face="normal" font="default"> Fibroblasts</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Immunoblotting</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Ligation</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Microscopy</style></keyword><keyword><style face="normal" font="default"> Mutant</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> NEMO</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Subunit</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="26" Month="2" Year="2017">2017/2/26</year></dates><abstract><style face="normal" font="default">BACKGROUND: Incontinentia pigmenti (IP; MIM308300) is a severe, male-lethal, X-linked, dominant genodermatosis resulting from loss-of-function mutations in the IKBKG gene encoding NF-kappaB essential modulator (NEMO, the regulatory subunit of the IKK complex). In 80% of cases of IP, the deletion of exons 4 to 10 leads to the absence of NEMO and total inhibition of NF-kappaB signaling. Here, we described a new IKBKG mutation responsible for IP resulting in an inactive truncated form of NEMO. OBJECTIVES: To identify the mechanism(s) by which the truncated NEMO protein inhibits the NF-kB signalling pathway. METHODS: We sequenced the IKBKG gene in IP patients and performed complementation and transactivation assays in NEMO-deficient cells. We also used immunoprecipitation assays, immunoblotting and an in situ proximity ligation assay to characterize the truncated NEMO protein interactions with IKK-alpha, IKK-beta, TRAF6, TRAF2, RIP1 HOIL-1, HOIP and SHARPIN. Lastly, we assessed NEMO linear ubiquitination by immunoblotting and investigated the formation of NEMO-containing structures (using immunostaining and confocal microscopy) after cell stimulation with IL-1beta. RESULTS: We identified a novel splice mutation in IKBKG (c.518+2T>G, resulting in an in-frame deletion: p.DelQ134_R256). The mutant NEMO lacked part of the CC1 coiled-coil and the HLX2 helical domain. The p.DelQ134_R256 mutation caused inhibition of NF-kappaB signaling, although the truncated NEMO protein interacted with proteins involved in the activation of NF-kappaB signaling. The IL-1beta-induced formation of NEMO-containing structures was impaired in IP fibroblasts carrying the truncated NEMO form (as also observed in HOIL-1-/- cells). The truncated NEMO interaction with SHARPIN was impaired in a male fetus with IP, leading to defective linear ubiquitination. CONCLUSION: We identified a hitherto unreported disease mechanism (defective linear ubiquitination) in IP. CLINICAL IMPLICATIONS: A splice mutation in IKBKG gene responsible for IP result in an inactive truncated form of NEMO, unable to interact specifically with SHARPIN leading to defect in NEMO linear ubiquitination</style></abstract><notes><style face="normal" font="default">DA - 20170302IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - France -CO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.056</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28249776">PM:28249776</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170302-BalE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170302-BalE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170302, Bal E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.056</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40935</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,Y.</style></author><author><style face="normal" font="default"> Zhu,J.</style></author><author><style face="normal" font="default"> Zhang,L.</style></author><author><style face="normal" font="default"> Zhang,Z.</style></author><author><style face="normal" font="default"> He,L.</style></author><author><style face="normal" font="default"> Mou,Y.</style></author><author><style face="normal" font="default"> Deng,Y.</style></author><author><style face="normal" font="default"> Cao,Y.</style></author><author><style face="normal" font="default"> Yang,P.</style></author><author><style face="normal" font="default"> Su,Y.</style></author><author><style face="normal" font="default"> Zhao,J.</style></author><author><style face="normal" font="default"> Zhang,S.</style></author><author><style face="normal" font="default"> Yu,Q.</style></author><author><style face="normal" font="default"> Hu,J.</style></author><author><style face="normal" font="default"> Chen,Z.</style></author><author><style face="normal" font="default"> Ning,Q.</style></author><author><style face="normal" font="default"> Xiang,X.</style></author><author><style face="normal" font="default"> Xu,Y.</style></author><author><style face="normal" font="default"> Wang,C.Y.</style></author><author><style face="normal" font="default"> Xiong,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Center for Biomedical Research, Key Laboratory of Organ Transplantation, Ministry of Education, Key Laboratory of Organ Transplantation, Ministry of Health; Department of Respiratory and Critical Care Medicine, Key Laboratory of Pulmonary Diseases of Health Ministry, Key cite of National Clinical Research Center for Respiratory Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Sciences &amp; Technology, Wuhan, 430030 China</style></auth-address><titles><title><style face="normal" font="default">Role of C/EBP homologous protein (CHOP) and Endoplasmic Reticulum in Asthma Exacerbation by Regulating the IL-4/STAT6/Tfec/IL-4Ralpha Positive Feedback Loop in M2 Macrophages</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Biomedical Research</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ER stress</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Feedback</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> Organ Transplantation</style></keyword><keyword><style face="normal" font="default"> OVA</style></keyword><keyword><style face="normal" font="default"> Ovalbumin</style></keyword><keyword><style face="normal" font="default"> Ovum</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="23" Month="2" Year="2017">2017/2/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: C/EBP homologous protein (CHOP), a marker of endoplasmic reticulum (ER) stress, exhibits aberrant expression patterns during the development of asthma. However, its exact role in asthma pathogenesis is not fully understood. OBJECTIVES: We aimed to determine the function and mechanism of CHOP in the pathogenesis of allergic asthma in patients and animals. METHODS: Studies were conducted in asthmatic patients and CHOP-/- mice to dissect the role of CHOP and ER stress in asthma pathogenesis. An ovalbumin (OVA)-induced allergic airway inflammation model was employed to address the impact of CHOP deficiency on the development of asthma. Next, the effect of CHOP deficiency on macrophage polarization and related signaling pathways were investigated to demonstrate the underlying mechanisms. RESULTS: Asthmatic patients and mice after OVA induction exhibited aberrant CHOP expression along with ER stress. Specifically, CHOP was noted to be specifically overexpressed in macrophages, and mice deficient in CHOP were protected from OVA-induced allergic airway inflammation as manifested by attenuated airway inflammation, remodeling, and hyper-responsiveness. CHOP was found to exacerbate allergic airway inflammation by enhancing M2 programming in macrophages. Mechanistic studies characterized an interleukin-4/signal transducer and activator of transcription 6/transcription factor EC/IL-4Ralpha (IL-4/STAT6/Tfec/IL-4Ralpha) positive feedback regulatory loop, in which IL-4 induces CHOP expression, which then promotes STAT6 signaling to transcribe Tfec expression, and Tfec transcribes IL-4Ralpha expression to promote M2 programming in macrophages. CONCLUSIONS: CHOP and ER stress are implicated in asthma pathogenesis, which involves the regulation of M2 programming in macrophages</style></abstract><notes><style face="normal" font="default">DA - 20170227IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28238747">PM:28238747</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170227-WangY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170227-WangY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170227, Wang Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40936</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Heratizadeh,A.</style></author><author><style face="normal" font="default"> Werfel,T.</style></author><author><style face="normal" font="default"> Wollenberg,A.</style></author><author><style face="normal" font="default"> Abraham,S.</style></author><author><style face="normal" font="default"> Plank-Habibi,S.</style></author><author><style face="normal" font="default"> Schnopp,C.</style></author><author><style face="normal" font="default"> Sticherling,M.</style></author><author><style face="normal" font="default"> Apfelbacher,C.</style></author><author><style face="normal" font="default"> Biedermann,T.</style></author><author><style face="normal" font="default"> Breuer,K.</style></author><author><style face="normal" font="default"> Fell,I.</style></author><author><style face="normal" font="default"> Folster-Holst,R.</style></author><author><style face="normal" font="default"> Heine,G.</style></author><author><style face="normal" font="default"> Grimm,J.</style></author><author><style face="normal" font="default"> Hennighausen,L.</style></author><author><style face="normal" font="default"> Kugler,C.</style></author><author><style face="normal" font="default"> Reese,I.</style></author><author><style face="normal" font="default"> Ring,J.</style></author><author><style face="normal" font="default"> Schakel,K.</style></author><author><style face="normal" font="default"> Schmitt,J.</style></author><author><style face="normal" font="default"> Seikowski,K.</style></author><author><style face="normal" font="default"> von Stebut,E.</style></author><author><style face="normal" font="default"> Wagner,N.</style></author><author><style face="normal" font="default"> Wassmann-Otto,A.</style></author><author><style face="normal" font="default"> Wienke-Graul,U.</style></author><author><style face="normal" font="default"> Weisshaar,E.</style></author><author><style face="normal" font="default"> Worm,M.</style></author><author><style face="normal" font="default"> Gieler,U.</style></author><author><style face="normal" font="default"> Kupfer,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany.</style></auth-address><titles><title><style face="normal" font="default">Effects of structured patient education in adult atopic dermatitis - multi-center randomized controlled trial</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Multicenter Studies</style></keyword><keyword><style face="normal" font="default"> Multicenter study</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient Education</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> QOL</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="24" Month="2" Year="2017">2017/2/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis (AD) is a chronic relapsing skin disease prevalent in 1-3% of adults in Western industrialized countries. OBJECTIVE: To investigate the effectiveness of educational training in an outpatient setting on coping with the disease, quality of life (QoL), symptoms and severity in adults with AD. METHODS: In this German prospective, randomized controlled multi-center study, adult patients with moderate to severe AD were educated by referring to a comprehensive 12 hour training manual consented by a multi-professional study group from different centers ("ARNE=Arbeitsgemeinschaft Neurodermitisschulung fur Erwachsene"). Patients were randomly allocated to the intervention group or "waiting control group". Study visits were performed at baseline and after one year (1-year follow-up). Primary outcomes were defined as a decrease of (1) "catastrophizing cognitions" with respect to itching (JKF questionnaire), (2) "social anxiety" (MHF questionnaire), (3) subjective burden by symptoms of the disease (Skindex-29 questionnaire) and (4) improvement of disease signs and symptoms assessed by scoring atopic dermatitis (SCORAD) index at 1-year follow-up. Data was analyzed by intention-to-treat. RESULTS: At 1-year follow-up patients from the intervention group (n=168) showed a significantly better improvement compared to the waiting group (n=147) in the following defined primary study outcomes: coping behavior with respect to itching [P&lt;.001]; QoL assessed by Skindex-29 questionnaire [P&lt;.001] and SCORAD index [P&lt;.001]. CONCLUSIONS: This is the first randomized, controlled multi-center study on patient education in adulthood AD. The ARNE training program shows significant beneficial effects on a variety of psychosocial parameters as well as on AD severity</style></abstract><notes><style face="normal" font="default">DA - 20170228IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28242304">PM:28242304</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170228-HeratizadehA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170228-HeratizadehA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170228,  Heratizadeh A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40937</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,A.H.</style></author><author><style face="normal" font="default"> Zoratti,E.M.</style></author><author><style face="normal" font="default"> Pongracic,J.A.</style></author><author><style face="normal" font="default"> Babineau,D.C.</style></author><author><style face="normal" font="default"> Visness,C.M.</style></author><author><style face="normal" font="default"> Gergen,P.J.</style></author><author><style face="normal" font="default"> Togias,A.</style></author><author><style face="normal" font="default"> Busse,W.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, Colo.</style></auth-address><titles><title><style face="normal" font="default">Reply (Refers To: The multimorbid polysensitized phenotype is associated with the severity of allergic diseases)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170226IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.12.962</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28237730">PM:28237730</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170226-LiuAH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170226-LiuAH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170226, Liu AH</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.12.962</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40938</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zanichelli,A.</style></author><author><style face="normal" font="default"> Azin,G.M.</style></author><author><style face="normal" font="default"> Wu,M.A.</style></author><author><style face="normal" font="default"> Suffritti,C.</style></author><author><style face="normal" font="default"> Maggioni,L.</style></author><author><style face="normal" font="default"> Caccia,S.</style></author><author><style face="normal" font="default"> Perego,F.</style></author><author><style face="normal" font="default"> Vacchini,R.</style></author><author><style face="normal" font="default"> Cicardi,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biomedical and Clinical Sciences, Luigi Sacco Hospital, University of Milan, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="default">Diagnosis, Course, and Management of Angioedema in Patients With Acquired C1-Inhibitor Deficiency</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> Abdomen</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Androgens</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Autoantibodies</style></keyword><keyword><style face="normal" font="default"> Berinert</style></keyword><keyword><style face="normal" font="default"> C1 INH</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor deficiency</style></keyword><keyword><style face="normal" font="default"> C1-INH</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> C1Inh</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> diagnostic criteria</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Icatibant</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Laryngeal Edema</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Long-term prophylaxis</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> On demand</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> oral mucosa</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> subcutaneous</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tranexamic Acid</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wheal</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Acquired angioedema due to C1-inhibitor deficiency (C1-INH-AAE) is a rare disease with no prevalence data or approved therapies. OBJECTIVE: To report data on patients with C1-INH-AAE followed at Angioedema Center, Milan (from 1976 to 2015). METHODS: Diagnostic criteria included history of recurrent angioedema without wheals; decreased C1-INH antigen levels and/or functional activity of C1-INH and C4 antigen less than 50% of normal; late symptom onset (>40 years); no family history of angioedema and C1-INH deficiency. RESULTS: In total, 77 patients (58% females; median age, 70 years) were diagnosed with C1-INH-AAE and 675 patients with hereditary angioedema due to C1-INH deficiency (C1-INH-HAE) (1 patient with C1-INH-AAE/8.8 patients with C1-INH-HAE). Median age at diagnosis was 64 years. Median time between symptom onset and diagnosis was 2 years. Sixteen patients (21%) died since diagnosis, including 1 because of laryngeal edema. Angioedema of the face was most common (N = 63 [82%]), followed by abdomen (N = 51 [66%]), peripheries (N = 50 [65%]), and oral mucosa and/or glottis (N = 42 [55%]). Forty-eight of 71 patients (68%) had autoantibodies to C1-INH. In total, 56 patients (70%) used on-demand treatment for angioedema including intravenous pdC1-INH 2000 U (Berinert, CSL Behring, Marburg, Germany) (N = 49) and/or subcutaneous icatibant 30 mg (Firazyr, Shire; Milano, Italy) (N = 27). Eventually, 8 of 49 patients receiving pdC1-INH became nonresponsive; all had autoantibodies. Thirty-four patients received long-term prophylaxis with tranexamic acid (effective in 29) and 20 with androgens (effective in 8). CONCLUSIONS: The incidence of C1-INH-AAE was 1 for every 8.8 patients with C1-INH-HAE. Thirty percent of the deaths were related to the disease. Treatments approved for C1-INH-HAE are effective in C1-INH-AAE, although with minimal differences</style></abstract><notes><style face="normal" font="default">DA - 20170312IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.12.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28284781">PM:28284781</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170312-ZanichelliA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170312-ZanichelliA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170312, Zanichelli A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.12.032</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40939</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Busse,P.</style></author><author><style face="normal" font="default"> Baker,J.</style></author><author><style face="normal" font="default"> Martinez-Saguer,I.</style></author><author><style face="normal" font="default"> Bernstein,J.A.</style></author><author><style face="normal" font="default"> Craig,T.</style></author><author><style face="normal" font="default"> Magerl,M.</style></author><author><style face="normal" font="default"> Riedl,M.</style></author><author><style face="normal" font="default"> Shapiro,R.</style></author><author><style face="normal" font="default"> Frank,M.</style></author><author><style face="normal" font="default"> Lumry,W.</style></author><author><style face="normal" font="default"> Rosch,J.</style></author><author><style face="normal" font="default"> Edelman,J.</style></author><author><style face="normal" font="default"> Williams-Herman,D.</style></author><author><style face="normal" font="default"> Feuersenger,H.</style></author><author><style face="normal" font="default"> Rojavin,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Icahn School of Medicine at Mount Sinai, New York, NY.</style></auth-address><titles><title><style face="normal" font="default">Safety of C1-inhibitor concentrate use for hereditary angioedema in pediatric patients</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="9" Month="3" Year="2017">2017/3/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170313IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.12.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28286153">PM:28286153</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170313-BusseP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170313-BusseP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170313, Busse P</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.12.033</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40940</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Paroni,M.</style></author><author><style face="normal" font="default"> Maltese,V.</style></author><author><style face="normal" font="default"> De Simone,M.</style></author><author><style face="normal" font="default"> Ranzani,V.</style></author><author><style face="normal" font="default"> Larghi,P.</style></author><author><style face="normal" font="default"> Fenoglio,C.</style></author><author><style face="normal" font="default"> Pietroboni,A.M.</style></author><author><style face="normal" font="default"> De Riz,M.A.</style></author><author><style face="normal" font="default"> Crosti,M.C.</style></author><author><style face="normal" font="default"> Maglie,S.</style></author><author><style face="normal" font="default"> Moro,M.</style></author><author><style face="normal" font="default"> Caprioli,F.</style></author><author><style face="normal" font="default"> Rossi,R.</style></author><author><style face="normal" font="default"> Rossetti,G.</style></author><author><style face="normal" font="default"> Galimberti,D.</style></author><author><style face="normal" font="default"> Pagani,M.</style></author><author><style face="normal" font="default"> Scarpini,E.</style></author><author><style face="normal" font="default"> Abrignani,S.</style></author><author><style face="normal" font="default"> Geginat,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">INGM, Istituto Nazionale Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy</style></auth-address><titles><title><style face="normal" font="default">Recognition of viral and self-antigens by TH1 and TH1/TH17 central memory cells in patients with multiple sclerosis reveals distinct roles in immune surveillance and relapses</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Central Nervous System</style></keyword><keyword><style face="normal" font="default"> Cerebrospinal Fluid</style></keyword><keyword><style face="normal" font="default"> CXCL10</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Encephalomyelitis</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Multiple Sclerosis</style></keyword><keyword><style face="normal" font="default"> Nervous System</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Sclerosis</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> Th1 Cells</style></keyword><keyword><style face="normal" font="default"> TH17</style></keyword><keyword><style face="normal" font="default"> TH17 cells</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral infection</style></keyword><keyword><style face="normal" font="default"> Viral infections</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> Viruses</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="2" Year="2017">2017/2/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) that is caused by autoreactive T cells and associated with viral infections. However, the phenotype of pathogenic T cells in peripheral blood remains to be defined, and how viruses promote MS is debated. OBJECTIVE: We aimed to identify and characterize potentially pathogenic autoreactive T cells, as well as protective antiviral T cells, in patients with MS. METHODS: We analyzed CD4+ helper T-cell subsets from peripheral blood or cerebrospinal fluid for cytokine production, gene expression, plasticity, homing potentials, and their reactivity to self-antigens and viral antigens in healthy subjects and patients with MS. Moreover, we monitored their frequencies in untreated and fingolimod- or natalizumab-treated patients with MS. RESULTS: TH1/TH17 central memory (TH1/TH17CM) cells were selectively increased in peripheral blood of patients with relapsing-remitting MS with a high disease score. TH1/TH17CM cells were closely related to conventional TH17 cells but had more pathogenic features. In particular, they could shuttle between lymph nodes and the CNS and produced encephalitogenic cytokines. The cerebrospinal fluid of patients with active MS was enriched for CXCL10 and contained mainly CXCR3-expressing TH1 and TH1/TH17 subsets. However, while TH1 cells responded consistently to viruses, TH1/TH17CM cells reacted strongly with John Cunningham virus in healthy subjects but responded instead to myelin-derived self-antigens in patients with MS. Fingolimod and natalizumab therapies efficiently targeted autoreactive TH1/TH17CM cells but also blocked virus-specific TH1 cells. CONCLUSIONS: We propose that autoreactive TH1/TH17CM cells expand in patients with MS and promote relapses after bystander recruitment to the CNS, whereas TH1 cells perform immune surveillance. Thus the selective targeting of TH1/TH17 cells could inhibit relapses without causing John Cunningham virus-dependent progressive multifocal encephalomyelitis</style></abstract><notes><style face="normal" font="default">DA - 20170226IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28237728">PM:28237728</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170226-ParoniM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170226-ParoniM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170226, Paroni M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.045</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40941</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Di Candia,L.</style></author><author><style face="normal" font="default"> Gomez,E.</style></author><author><style face="normal" font="default"> Venereau,E.</style></author><author><style face="normal" font="default"> Chachi,L.</style></author><author><style face="normal" font="default"> Kaur,D.</style></author><author><style face="normal" font="default"> Bianchi,M.E.</style></author><author><style face="normal" font="default"> Challiss,R.A.</style></author><author><style face="normal" font="default"> Brightling,C.E.</style></author><author><style face="normal" font="default"> Saunders,R.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute for Lung Health, Department of Infection, Immunity &amp; Inflammation, Glenfield Hospital, University of Leicester, Leicester, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">HMGB1 is upregulated in the airways in asthma and potentiates airway smooth muscle contraction via TLR4</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway smooth muscle</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Muscle Contraction</style></keyword><keyword><style face="normal" font="default"> TLR4</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="23" Month="2" Year="2017">2017/2/23</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170305IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -CO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.11.049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28259445">PM:28259445</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170305-DiCandiaL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170305-DiCandiaL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170305, Di Candia L</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.11.049</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40942</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guttman-Yassky,E.</style></author><author><style face="normal" font="default"> Ungar,B.</style></author><author><style face="normal" font="default"> Malik,K.</style></author><author><style face="normal" font="default"> Dickstein,D.</style></author><author><style face="normal" font="default"> Suprun,M.</style></author><author><style face="normal" font="default"> Estrada,Y.D.</style></author><author><style face="normal" font="default"> Xu,H.</style></author><author><style face="normal" font="default"> Peng,X.</style></author><author><style face="normal" font="default"> Oliva,M.</style></author><author><style face="normal" font="default"> Todd,D.</style></author><author><style face="normal" font="default"> Labuda,T.</style></author><author><style face="normal" font="default"> Suarez-Farinas,M.</style></author><author><style face="normal" font="default"> Bissonnette,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Icahn School of Medicine at Mount Sinai, NY, USA;Innovaderm Research, Montreal, Canada</style></auth-address><titles><title><style face="normal" font="default">Molecular signatures order the potency of topically applied anti-inflammatory drugs in atopic dermatitis patients</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Betamethasone</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clobetasol</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Formulation</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Hyperplasia</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Sample Size</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> TEWL</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutics</style></keyword><keyword><style face="normal" font="default"> topical treatment</style></keyword><keyword><style face="normal" font="default"> transepidermal water loss</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword></keywords><dates><year Day="23" Month="2" Year="2017">2017/2/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic Dermatitis (AD) presents a large unmet need for treatments with better safety and efficacy. To facilitate development of topical therapeutics, we need an efficient model for assessing different formulations and concentrations. The "plaque model" has been successfully implemented in psoriasis, another common inflammatory disease, to assess efficacy of topical treatments. This model has not been validated for AD, which has higher placebo responses and less stable lesions than psoriasis. OBJECTIVE: We aimed to assess changes in molecular signatures of intra-patient target lesions treated with topical therapeutics. METHODS: We enrolled 30 mild-to-moderate AD patients in a randomized, double-blinded, intra-individual comparison of 3 approved agents applied blindly at the investigator site daily for 14d: pimecrolimus, betamethasone diproprionate, clobetasol proprionate, and a vehicle/emollient control. Changes in total sign scores (TSS), trans-epidermal water loss (TEWL), and tissue biomarkers (using RT-PCR and immunohistochemistry) were evaluated. RESULTS: TSS showed improvements of 30%, 40%, 68%, and 76% at 2wks with vehicle, pimecrolimus, betamethasone, and clobetasol, respectively, with parallel changes in TEWL (p&lt;0.05). Significant differences vs. vehicle were limited to steroids (p&lt;0.0001). Steroids (particularly clobetasol) restored epidermal hyperplasia and terminal differentiation vs. minimal changes with vehicle or pimecrolimus (p&lt;0.001). Cellular infiltrates and cytokines (IL-13, IL-22, S100As) were similarly reduced only by steroids (p&lt;0.001). TSS improvement correlated with changes in hyperplasia, infiltrates, and differentiation markers. CONCLUSION: We detected significant clinical and tissue differences between agents, providing a novel approach to study differential effects of topical formulations using a limited sample size</style></abstract><notes><style face="normal" font="default">DA - 20170227IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28238742">PM:28238742</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170227-GuttmanYasskyE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170227-GuttmanYasskyE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170227, Guttman-Yassky E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40943</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Huang,Y.J.</style></author><author><style face="normal" font="default"> Marsland,B.J.</style></author><author><style face="normal" font="default"> Bunyavanich,S.</style></author><author><style face="normal" font="default"> O'Mahony,L.</style></author><author><style face="normal" font="default"> Leung,D.Y.</style></author><author><style face="normal" font="default"> Muraro,A.</style></author><author><style face="normal" font="default"> Fleisher,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Michigan Health System</style></auth-address><titles><title><style face="normal" font="default">The Microbiome in Allergic Disease: Current Understanding and Future Opportunities - 2017 PRACTALL Document of the American Academy of Allergy, Asthma &amp; Immunology and the European Academy of Allergy and Clinical Immunology</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Michigan</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="28" Month="2" Year="2017">2017/2/28</year></dates><abstract><style face="normal" font="default">PRACTALL is a joint initiative of the American Academy of Allergy, Asthma and Immunology (AAAAI) with the European Academy of Allergy and Clinical Immunology (EAACI) to provide shared evidence-based recommendations on cutting-edge topics in the field of allergy and immunology PRACTALL 2017 is focused on what has been established regarding the role of the microbiome in asthma, atopic dermatitis (AD) and food allergy. This is complemented by outlining important knowledge gaps regarding its role in allergic disease and delineating strategies necessary to fill these gaps. In addition, a review of progress in approaches used to manipulate the microbiome will be addressed, identifying what has and has not worked to serve as a baseline for future directions to intervene in allergic disease development and/or progression</style></abstract><notes><style face="normal" font="default">DA - 20170304IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28257972">PM:28257972</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170304-HuangYJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170304-HuangYJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170304, Huang YJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40944</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Canipa,S.J.</style></author><author><style face="normal" font="default"> Chilton,M.L.</style></author><author><style face="normal" font="default"> Hemingway,R.</style></author><author><style face="normal" font="default"> Macmillan,D.S.</style></author><author><style face="normal" font="default"> Myden,A.</style></author><author><style face="normal" font="default"> Plante,J.P.</style></author><author><style face="normal" font="default"> Tennant,R.E.</style></author><author><style face="normal" font="default"> Vessey,J.D.</style></author><author><style face="normal" font="default"> Steger-Hartmann,T.</style></author><author><style face="normal" font="default"> Gould,J.</style></author><author><style face="normal" font="default"> Hillegass,J.</style></author><author><style face="normal" font="default"> Etter,S.</style></author><author><style face="normal" font="default"> Smith,B.P.</style></author><author><style face="normal" font="default"> White,A.</style></author><author><style face="normal" font="default"> Sterchele,P.</style></author><author><style face="normal" font="default"> De Smedt,A.</style></author><author><style face="normal" font="default"> O'Brien,D.</style></author><author><style face="normal" font="default"> Parakhia,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK</style></auth-address><titles><title><style face="normal" font="default">A quantitative in silico model for predicting skin sensitization using a nearest neighbours approach within expert-derived structure-activity alert spaces</style></title><secondary-title><style face="normal" font="default">J Appl Toxicol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Appl Toxicol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> European Union</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Toxicology</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="2" Year="2017">2017/2/28</year></dates><abstract><style face="normal" font="default">Dermal contact with chemicals may lead to an inflammatory reaction known as allergic contact dermatitis. Consequently, it is important to assess new and existing chemicals for their skin sensitizing potential and to mitigate exposure accordingly. There is an urgent need to develop quantitative non-animal methods to better predict the potency of potential sensitizers, driven largely by European Union (EU) Regulation 1223/2009, which forbids the use of animal tests for cosmetic ingredients sold in the EU. A Nearest Neighbours in silico model was developed using an in-house dataset of 1096 murine local lymph node (LLNA) studies. The EC3 value (the effective concentration of the test substance producing a threefold increase in the stimulation index compared to controls) of a given chemical was predicted using the weighted average of EC3 values of up to 10 most similar compounds within the same mechanistic space (as defined by activating the same Derek skin sensitization alert). The model was validated using previously unseen internal (n = 45) and external (n = 103) data and accuracy of predictions assessed using a threefold error, fivefold error, European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) and Globally Harmonized System of Classification and Labelling of Chemicals (GHS) classifications. In particular, the model predicts the GHS skin sensitization category of compounds well, predicting 64% of chemicals in an external test set within the correct category. Of the remaining chemicals in the previously unseen dataset, 25% were over-predicted (GHS 1A predicted: GHS 1B experimentally) and 11% were under-predicted (GHS 1B predicted: GHS 1A experimentally). Copyright (c) 2017 John Wiley &amp; Sons, Ltd</style></abstract><notes><style face="normal" font="default">DA - 20170228IS - 1099-1263 (Electronic)IS - 0260-437X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Germany -CO - United States -CO - Switzerland -CO - United Kingdom -CO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1002/jat.3448</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28244128">PM:28244128</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Appl Toxicol\20170228-CanipaSJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Appl Toxicol\20170228-CanipaSJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170228, Canipa SJ</style></custom2><misc3><style face="normal" font="default">10.1002/jat.3448</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40945</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kuric,V.</style></author><author><style face="normal" font="default"> Zaza,K.J.</style></author><author><style face="normal" font="default"> Algazlan,S.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesiology, King Faisal Specialist Hospital and Research Center (KFSH &amp; RC), P.O. Box 3354, Riyadh 11211, Saudi Arabia.</style></auth-address><titles><title><style face="normal" font="default">Atypical presentation to rocuronium allergy in a 19-year-old female patient</style></title><secondary-title><style face="normal" font="default">J Clin Anesth</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Clin Anesth</style></full-title></periodical><pages end="165" start="163">163-165</pages><volume><style face="normal" font="default">37</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Anesthesia</style></keyword><keyword><style face="normal" font="default"> Anesthesiology</style></keyword><keyword><style face="normal" font="default"> Anesthetics</style></keyword><keyword><style face="normal" font="default"> Cardiopulmonary Resuscitation</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Decision Making</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> General anesthesia</style></keyword><keyword><style face="normal" font="default"> instrumentation</style></keyword><keyword><style face="normal" font="default"> intradermal test</style></keyword><keyword><style face="normal" font="default"> Intradermal Tests</style></keyword><keyword><style face="normal" font="default"> Intubation</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Masks</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Resuscitation</style></keyword><keyword><style face="normal" font="default"> Rocuronium</style></keyword><keyword><style face="normal" font="default"> Saudi Arabia</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">The danger of anaphylaxis, a rare but life threatening complication of general anesthesia (GA) can be summarized in two: 1. General Anesthesia masks the typical early signs of allergy which can be seen in an awake patient. 2. Anaphylaxis during GA manifests mostly as circulatory/ventilatory failures which can be interpreted as adverse effects of anesthetics or surgery and this can lead to critical delay of effective therapy. A 19-year-old female admitted for posterior spinal fusion and instrumentation (the 5th surgery in patient's life) desaturated seconds after intubation. Cardiopulmonary resuscitation (CPR) was started and the absence of cutaneous signs along with a loud holosystolic murmur were questioned. The patient was promptly resuscitated and allergy to rocuronium was confirmed by intradermal tests 6weeks later. Factors influencing decision making and potential etiology of the newly heard holosystolic murmur during anaphylaxis are discussed</style></abstract><notes><style face="normal" font="default">DA - 20170225IS - 1873-4529 (Electronic)IS - 0952-8180 (Linking)LA - engPT - Journal ArticleCO - Saudi Arabia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jclinane.2016.11.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28235514">PM:28235514</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Anesth\2017-37-163-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Anesth\2017-37-163-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170225, Kuric V</style></custom2><misc3><style face="normal" font="default">10.1016/j.jclinane.2016.11.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40946</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Caltekin,I.</style></author><author><style face="normal" font="default"> Akyol,P.Y.</style></author><author><style face="normal" font="default"> Topal,F.E.</style></author><author><style face="normal" font="default"> Karagoz,A.</style></author><author><style face="normal" font="default"> Unluer,E.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Emergency Medicine, Malatya State Hospital, Malatya, Turkey</style></auth-address><titles><title><style face="normal" font="default">Contrast-induced nephropathy and allergic reaction in patients who were given intravenous contrast material in emergency department</style></title><secondary-title><style face="normal" font="default">J Emerg Trauma Shock</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Emerg Trauma Shock</style></abbr-1></periodical><pages end="49" start="48">48-49</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Contrast material</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Emergency Medicine</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170228IS - 0974-2700 (Print)IS - 0974-2700 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.4103/0974-2700.199523</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28243014">PM:28243014</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Emerg Trauma Shock\2017-10-48-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Emerg Trauma Shock\2017-10-48-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170228, Caltekin I</style></custom2><misc3><style face="normal" font="default">10.4103/0974-2700.199523</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40947</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Malakar,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Gastroenterology, Monash University and Alfred Hospital, Melbourne, Australia</style></auth-address><titles><title><style face="normal" font="default">Bioactive food chemicals and gastrointestinal symptoms: a focus of salicylates</style></title><secondary-title><style face="normal" font="default">J Gastroenterol Hepatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Gastroenterol Hepatol</style></abbr-1></periodical><pages end="77" start="73">73-77</pages><volume><style face="normal" font="default">32 Suppl 1</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Colon</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Formulation</style></keyword><keyword><style face="normal" font="default"> Gastroenterology</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Plant</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Salicylates</style></keyword><keyword><style face="normal" font="default"> Salicylic Acid</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">Bioactive food chemicals are substances present in food that are capable of interacting with living cells causing changes in physiological functions. Salicylic acid (SA), a plant hormone involved in plant immune response, is one such bioactive food chemical. Aspirin, a commercially available SA, might play beneficial roles in cardiovascular health and colon cancer. It may also cause urticaria, angioedema, asthma, and gastrointestinal symptoms in SA-sensitive individuals. Dietary SA might exert similar beneficial effects and/or may induce similar symptoms in hypersensitive individuals. Food-related SA sensitivity in relation to gastrointestinal symptoms is not well documented besides a few self-reported questionnaires and the knowledge that low doses of aspirin (equivalent of high dietary intake) can cause gastrointestinal injury. The only direct evidence that suggests benefits of reducing dietary SA was reported in asthmatic individuals. Although SA sensitivity in relation to gut symptoms in susceptible individuals is accepted by clinicians, the detection of this disease remains a challenge because of the complicated nature of dietary challenges and the risk of oral aspirin provocation tests in patients with severe hypersensitivity reactions. Given the non-IgE mediated nature of the disease, in vitro assays like basophil activation may have failed to produce reliable results. However, given the simplicity of this assay, further studies need to be formulated to firmly establish its reliability. Formulation of proper dietary strategies for symptom control is also impossible given the controversial and scant nature of the data on SA content of food. This issue needs to be resolved to formulate proper dietary strategies for effective symptom control</style></abstract><notes><style face="normal" font="default">DA - 20170228IS - 1440-1746 (Electronic)IS - 0815-9319 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/jgh.13702</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28244660">PM:28244660</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Gastroenterol Hepatol\2017-32S1-73-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Gastroenterol Hepatol\2017-32S1-73-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170228, Malakar S</style></custom2><misc3><style face="normal" font="default">10.1111/jgh.13702</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40948</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nunes,J.M.</style></author><author><style face="normal" font="default"> Santareno,S.</style></author><author><style face="normal" font="default"> Guerreiro,L.</style></author><author><style face="normal" font="default"> Margalho,A.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesiology, Funchal Central Hospital, Madeira, Portugal</style></auth-address><titles><title><style face="normal" font="default">Lyell's Syndrome and Antimalarials: A Case Report and Clinical Review</style></title><secondary-title><style face="normal" font="default">J Glob Infect Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Glob Infect Dis</style></abbr-1></periodical><pages end="30" start="23">23-30</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anesthesiology</style></keyword><keyword><style face="normal" font="default"> Antimalarials</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Body Surface Area</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Early Diagnosis</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Lyell syndrome</style></keyword><keyword><style face="normal" font="default"> Malaria</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Sulfonamides</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Toxic epidermal necrolysis</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">Toxic epidermal necrolysis (TEN) or Lyell's syndrome is a rare, however, life-threatening mucocutaneous disorder with an epidermal detachment of a total body surface area (TBSA) of >30%. It is triggered by an idiosyncratic immune-allergic reaction to a drug, with many possible drugs implicated. Treatment success relies on early diagnosis and withdrawal of suspected/causative drug(s) and supportive care. Clinical evidence for specific therapies is still sparse. It is described a case of Lyell syndrome by sulfonamides for chemoprophylaxis of malaria. The patient presented with an extensive, rapidly evolving skin detachment, which progressed, despite supportive therapy, involving about 80% of TBSA. This led us to initiate a course of immunoglobulin with good clinical response. The aim of this work is to provide a discussion of the case and simultaneously make a practical literature review of TEN</style></abstract><notes><style face="normal" font="default">DA - 20170302IS - 0974-777X (Print)IS - 0974-777X (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.4103/0974-777X.199994</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28250622">PM:28250622</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Glob Infect Dis\2017-9-23-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Glob Infect Dis\2017-9-23-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170302, Nunes JM</style></custom2><misc3><style face="normal" font="default">10.4103/0974-777X.199994</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40949</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Munoz,F.C.</style></author><author><style face="normal" font="default"> Cervantes,M.M.</style></author><author><style face="normal" font="default"> Cervantes-Garcia,D.</style></author><author><style face="normal" font="default"> Jimenez,M.</style></author><author><style face="normal" font="default"> Ventura-Juarez,J.</style></author><author><style face="normal" font="default"> Salinas,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Microbiology, Basic Science Center, Autonomous University of Aguascalientes, Av. Universidad No. 940, 20131 Aguascalientes, AGS, Mexico</style></auth-address><titles><title><style face="normal" font="default">Glycomacropeptide Attenuates Inflammation, Pruritus, and Th2 Response Associated with Atopic Dermatitis Induced by 2,4-Dinitrochlorobenzene in Rat</style></title><secondary-title><style face="normal" font="default">J Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Immunol Res</style></abbr-1></periodical><pages end="" start="6935402">6935402-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> alternative therapy</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> DNCB</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> epicutaneous</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Hydrolysis</style></keyword><keyword><style face="normal" font="default"> Hyperplasia</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mexico</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> peptide</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> rat</style></keyword><keyword><style face="normal" font="default"> Rats</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> Th2 response</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is one of the most common skin diseases, whose incidence is increasing in industrialized countries. The epicutaneous application of a hapten, such as 2,4-dinitrochlorobenzene (DNCB), evokes an experimental murine AD-like reaction. Glycomacropeptide (GMP) is a dairy bioactive peptide derived from hydrolysis of kappa-casein by chymosin action. It has anti-inflammatory, prebiotic, and immunomodulatory effects. The present study was aimed to investigate the effect of GMP administration on DNCB-induced AD in rats. The severity of inflammatory process, pruritus, production of cytokines, and total immunoglobulin E (IgE) content were measured, and the histopathological features were analyzed. GMP reduced the intensity of inflammatory process and edema of DNCB-induced dermatitis, with a significant decrease in eosinophils recruitment and mast cells hyperplasia. In addition GMP suppressed the serum levels of total IgE and IL-4, IL-5, and IL-13 expression in AD-lesions. Besides, the levels of IL-10 were significantly increased. Remarkably, GMP administration before AD-induction abolished pruritus in dermatitis-like reactions in the rats. Taken together, these results indicate that GMP has an inhibitory effect on AD by downregulating Th2 dominant immune response, suggesting GMP as a potential effective alternative therapy for the prevention and management of AD</style></abstract><notes><style face="normal" font="default">DA - 20170307IS - 2314-7156 (Electronic)IS - 2314-7156 (Linking)LA - engPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="default">10.1155/2017/6935402</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28265582">PM:28265582</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Immunol Res\2017-2017-6935402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Immunol Res\2017-2017-6935402.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170307, Munoz FC</style></custom2><misc3><style face="normal" font="default">10.1155/2017/6935402</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40950</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,H.J.</style></author><author><style face="normal" font="default"> Cho,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, The Catholic University of Korea College of Medicine, Incheon St. Mary's Hospital, Incheon, Korea</style></auth-address><titles><title><style face="normal" font="default">Therapeutic Effects of Korean Red Ginseng Extract in a Murine Model of Atopic Dermatitis: Anti-pruritic and Anti-inflammatory Mechanism</style></title><secondary-title><style face="normal" font="default">J Korean Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Korean Med Sci</style></full-title></periodical><pages end="687" start="679">679-687</pages><volume><style face="normal" font="default">32</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anti-allergic</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Back</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cyclosporine</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-31</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Interferon</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Movement</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Sensation</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> T-helper-2</style></keyword><keyword><style face="normal" font="default"> TEWL</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> transepidermal water loss</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">Korean red ginseng (KRG) and ginsenosides exhibit diverse biological effects, including anti-inflammatory and anti-allergic. We aimed to investigate the therapeutic effect of KRG in a murine model of atopic dermatitis (AD) is mediated whether by diminishing the pruritus or by suppressing the inflammation. Thirty NC/Nga mice were randomly divided to 5 groups. AD-like skin lesions were induced by percutaneous challenge with 2,4,6-trinitro-1-chrolobenzene (TNCB) on the ears and backs of NC/Nga mice. KRG extract, evening primrose oil, cyclosporine, and phosphate-buffered saline were administered orally by a gastric tube. Each study group was also divided into scratching-permitted and scratching-restricted subgroups to evaluate the impact of scratching behavior on AD. The effects of KRG and the other agents were assessed by measuring the clinical severity score, ear thickness, extent of transepidermal water loss (TEWL), number of scratching movements, total systemic immunoglobulin E (IgE) and interleukin (IL)-31 levels, histologic changes of cutaneous lesions, and mRNA expression levels of tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, thymic stromal lymphopoietin (TSLP), and IL-31. KRG exerts therapeutic effects against AD by inhibiting the T helper 2 (Th2) mediated inflammation as well as by diminishing the itching sensation. Moreover, restricting scratching behavior suppresses the vicious cycle of itching and scratching, thus reducing clinical and systemic inflammation in our murine model of AD</style></abstract><notes><style face="normal" font="default">DA - 20170228IS - 1598-6357 (Electronic)IS - 1011-8934 (Linking)LA - engPT - Journal ArticleCO - South KOrea -</style></notes><work-type><style face="normal" font="default">10.3346/jkms.2017.32.4.679</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28244297">PM:28244297</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Korean Med Sci\2017-32-679-87.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Korean Med Sci\2017-32-679-87.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170228, Lee HJ</style></custom2><misc3><style face="normal" font="default">10.3346/jkms.2017.32.4.679</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40951</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Park,H.S.</style></author><author><style face="normal" font="default"> Nakagawa,I.</style></author><author><style face="normal" font="default"> Yokoyama,S.</style></author><author><style face="normal" font="default"> Wajima,D.</style></author><author><style face="normal" font="default"> Wada,T.</style></author><author><style face="normal" font="default"> Motoyama,Y.</style></author><author><style face="normal" font="default"> Kichikawa,K.</style></author><author><style face="normal" font="default"> Nakase,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Neurosurgery, Nara Medical University, Kashihara, Nara, Japan</style></auth-address><titles><title><style face="normal" font="default">Nickel-associated delayed multiple white matter lesions after stent-assisted coil embolization of intracranial unruptured aneurysm</style></title><secondary-title><style face="normal" font="default">J Neurointerv Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Neurointerv Surg</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Arteries</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pulse</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="24" Month="2" Year="2017">2017/2/24</year></dates><abstract><style face="normal" font="default">Metal-induced encephalopathy after stent-assisted coil embolization is extremely rare. The present report describes two patients who presented with symptomatic intracranial parenchymal edematous lesions after stent-assisted coil embolization. A 64-year-old woman underwent stent-assisted coil embolization for a left internal carotid artery aneurysm; 21 days after the procedure she presented with right hand weakness and MRI revealed multifocal white matter lesions. Another woman aged 52 years underwent stent-assisted coil embolization for right vertebral artery aneurysm; 18 days after the procedure she presented with left-sided sensory disturbance and MRI demonstrated multiple white matter lesions. Treatment in both cases resulted in improvement of these lesions after steroid pulse therapy, and the patients had no associated morbidity 4 months after the procedures. Clinicians should monitor for neurologic symptoms and postoperative delayed radiologic parenchymal edematous changes associated with the metal allergic reaction after nitinol stent-assisted coil embolization</style></abstract><notes><style face="normal" font="default">DA - 20170225IS - 1759-8486 (Electronic)IS - 1759-8478 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1136/neurintsurg-2017-013005.rep</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28235953">PM:28235953</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Neurointerv Surg\20170225-ParkHS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Neurointerv Surg\20170225-ParkHS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170225, Park HS</style></custom2><misc3><style face="normal" font="default">10.1136/neurintsurg-2017-013005.rep</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40952</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lin,J.</style></author><author><style face="normal" font="default"> Chen,P.</style></author><author><style face="normal" font="default"> Liu,C.</style></author><author><style face="normal" font="default"> Kang,J.</style></author><author><style face="normal" font="default"> Xiao,W.</style></author><author><style face="normal" font="default"> Chen,Z.</style></author><author><style face="normal" font="default"> Tang,H.</style></author><author><style face="normal" font="default"> Du,X.</style></author><author><style face="normal" font="default"> Liu,C.</style></author><author><style face="normal" font="default"> Luo,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">China-Japan Friendship Hospital, Beijing 100029, China</style></auth-address><titles><title><style face="normal" font="default">Comparison of fluticasone propionate with budesonide administered via nebulizer: a randomized controlled trial in patients with severe persistent asthma</style></title><secondary-title><style face="normal" font="default">J Thorac Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Thorac Dis</style></abbr-1></periodical><pages end="385" start="372">372-385</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Budesonide</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> fluticasone propionate</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Peak expiratory flow</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: This study compared the efficacy and safety of fluticasone propionate (FP) inhalation n solution with budesonide (BUD) suspension for inhalation administered via nebulizer, in Chinese adult patients with severe, persistent asthma. METHODS: This was a multicenter, randomized, active-controlled, single-blind, parallel-group study, conducted at 26 clinical sites in China. Participants were randomized 1:1 to FP nebules 1 mg twice daily or BUD 2 mg twice daily via nebulizer for 12 weeks. RESULTS: A total of 317 adult patients were randomized. The primary endpoint was mean change in morning peak expiratory flow (PEF) over weeks 1-12 from baseline, and analyzed in the ITT (n=315) and PP populations (n=283). Week 12 PEF increase from baseline was 26.7 L/min (14.1%) and 28.0 L/min (15.3%) in the ITT population, and 29.1 L/min (15.7%) and 30.1 L/min (16.2%) in the PP population, in the FP and BUD groups, respectively; all improvements were of clinical significance. Lower limits of the two-sided 95% CIs for the least squares (LS) mean treatment difference (FP minus BUD) were -12.19 L/min (ITT) and -12.95 L/min (PP), both above the pre-specified non-inferiority criteria -12.00 L/min and not clinically meaningful. There was no significant difference in the week 12 mean FEV1 increase between the FP and BUD groups (0.237 L/16.79% vs. 0.236 L/17.73%). Lower limits of the 95% CIs for LS mean treatment difference in morning PEF change from baseline over weeks 1-4 in a post hoc analysis were -10.41 and -11.96 L/min in the ITT and PP populations respectively; both above -12.00 L/min. A review of safety data indicated that rates of AEs, SAEs, and drug-related AEs were similar between two groups. CONCLUSIONS: The 12-week treatment of FP inhalation solution administered via nebulizer is safe and effectively for treating severe, persistent asthma in Chinese patients over 12 week</style></abstract><notes><style face="normal" font="default">DA - 20170309IS - 2072-1439 (Print)IS - 2072-1439 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.21037/jtd.2017.02.51</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28275486">PM:28275486</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Thorac Dis\2017-9-372-85.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Thorac Dis\2017-9-372-85.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170309, Lin J</style></custom2><misc3><style face="normal" font="default">10.21037/jtd.2017.02.51</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40953</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guerra,A.</style></author><author><style face="normal" font="default"> Kirkwood,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Severe generalized dermatitis in a nickel-allergic patient with-áa-ápopliteal artery nitinol stent</style></title><secondary-title><style face="normal" font="default">J Vasc Surg Cases Innovat Techn</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Vasc Surg Cases Innovat Techn</style></abbr-1></periodical><pages end="25" start="23">23-25</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Arteries</style></keyword><keyword><style face="normal" font="default"> Cessation</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Ischemia</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Nickel allergy</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Prednisone</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Stents</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> topical treatment</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><isbn><style face="normal" font="default">2468-4287</style></isbn><abstract><style face="normal" font="default">We present the case of a patient who developed a full-body desquamating macular-papular, pruritic rash after endovascular placement of a popliteal artery nitinol stent for acute limb ischemia. The rash was resistant to high-dose steroid and immunosuppressive treatment and intensive topical treatment. Patch testing revealed nickel allergy. The stented arterial segment was removed, with significant improvement in his symptoms that allowed the cessation of prednisone and topical treatments. The epidemiology, pathophysiology, and clinical effect of nickel allergy are discussed in addition to the use of nickel-alloy stents</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jvscit.2016.08.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29349368">PM:29349368</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Vasc Surg Cases Innovat Techn\2017-3-23-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Vasc Surg Cases Innovat Techn\2017-3-23-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170324, Guerra A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jvscit.2016.08.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40954</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jacob,S.E.</style></author><author><style face="normal" font="default"> McGowan,M.</style></author><author><style face="normal" font="default"> Silverberg,N.B.</style></author><author><style face="normal" font="default"> Pelletier,J.L.</style></author><author><style face="normal" font="default"> Fonacier,L.</style></author><author><style face="normal" font="default"> Mousdicas,N.</style></author><author><style face="normal" font="default"> Powell,D.</style></author><author><style face="normal" font="default"> Scheman,A.</style></author><author><style face="normal" font="default"> Goldenberg,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Loma Linda University, Loma Linda, California</style></auth-address><titles><title><style face="normal" font="default">Pediatric Contact Dermatitis Registry Data on Contact Allergy in Children With Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">JAMA Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JAMA Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">African American</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Alcohol</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Betaine</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health care provider</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Lanolin</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Physician Assistants</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Potassium</style></keyword><keyword><style face="normal" font="default"> Potassium Dichromate</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin Care</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wool</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="default">Importance: Atopic dermatitis (AD) and allergic contact dermatitis (ACD) have a dynamic relationship not yet fully understood. Investigation has been limited thus far by a paucity of data on the overlap of these disorders in pediatric patients. Objective: To use data from the Pediatric Contact Dermatitis Registry to elucidate the associations and sensitizations among patients with concomitant AD and ACD. Design, Setting, and Participants: This retrospective case review examined 1142 patch test cases of children younger than 18 years, who were registered between January 1, 2015, and December 31, 2015, by 84 health care providers (physicians, nurse practitioners, physician assistants) from across the United States. Data were gathered electronically from multidisciplinary providers within outpatient clinics throughout the United States on pediatric patients (ages 0-18 years). Exposures: All participants were patch-tested to assess sensitizations to various allergens; history of AD was noted by the patch-testing providers. Main Outcomes and Measures: Primary outcomes were sensitization rates to various patch-tested allergens. Results: A total of 1142 patients were evaluated: 189 boys (34.2%) and 363 girls (65.8%) in the AD group and 198 boys (36.1%) and 350 girls (63.9%) in the non-AD group (data on gender identification were missing for 17 patients). Compared with those without AD, patch-tested patients with AD were 1.3 years younger (10.5 vs 11.8 years; P &lt; .001) and had longer history of dermatitis (3.5 vs 1.8 years; P &lt; .001). Patch-tested patients designated as Asian or African American were more likely to have concurrent AD (odds ratio [OR], 1.92; 95% CI, 1.20-3.10; P = .008; and OR, 4.09; 95% CI, 2.70-6.20; P &lt;.001, respectively). Patients with AD with generalized distribution were the most likely to be patch tested (OR, 4.68; 95% CI, 3.50-6.30; P &lt; .001). Patients with AD had different reaction profiles than those without AD, with increased frequency of reactions to cocamidopropyl betaine, wool alcohol, lanolin, tixocortol pivalate, and parthenolide. Patients with AD were also noted to have lower frequency of reaction to methylisothiazolinone, cobalt, and potassium dichromate. Conclusions and Relevance: Children with AD showed significant reaction patterns to allergens notable for their use in skin care preparations. This study adds to the current understanding of AD in ACD, and the continued need to investigate the interplay between these disease processes to optimize care for pediatric patients with these conditions</style></abstract><notes><style face="normal" font="default">DA - 20170227IS - 2168-6084 (Electronic)IS - 2168-6068 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1001/jamadermatol.2016.6136</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28241280">PM:28241280</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JAMA Dermatol\20170227-IacobSE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JAMA Dermatol\20170227-IacobSE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170227, Jacob SE</style></custom2><misc3><style face="normal" font="default">10.1001/jamadermatol.2016.6136</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40955</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Uzuriaga-Sanchez,R.J.</style></author><author><style face="normal" font="default"> Wong,A.</style></author><author><style face="normal" font="default"> Khan,S.</style></author><author><style face="normal" font="default"> Pividori,M.I.</style></author><author><style face="normal" font="default"> Picasso,G.</style></author><author><style face="normal" font="default"> Sotomayor,M.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Analytical Chemistry, Institute of Chemistry, State University of Sao Paulo (UNESP), 14801-970 Araraquara, SP, Brazil</style></auth-address><titles><title><style face="normal" font="default">Synthesis of a new magnetic-MIP for the selective detection of 1-chloro-2,4-dinitrobenzene, a highly allergenic compound</style></title><secondary-title><style face="normal" font="default">Mater Sci Eng C Mater Biol Appl</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Mater Sci Eng C Mater Biol Appl</style></abbr-1></periodical><pages end="373" start="365">365-373</pages><volume><style face="normal" font="default">74</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adsorption</style></keyword><keyword><style face="normal" font="default"> Allergenic</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Nanoparticles</style></keyword><keyword><style face="normal" font="default"> Oleic Acid</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Peru</style></keyword><keyword><style face="normal" font="default"> Polymers</style></keyword><keyword><style face="normal" font="default"> Precipitation</style></keyword><keyword><style face="normal" font="default"> Recovery</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> Selectivity</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="default">Molecularly imprinted polymers (MIPs) in combination with magnetic nanoparticles, in a core@shell format, were studied for selective detection of 1-chloro-2,4-dinitrobenzene (CDNB), a powerful allergenic substance. Magnetic nanoparticles were prepared by the co-precipitation method and mixed with oleic acid (OA). This material was then encapsulated in three types of hydrophobic polymeric matrix, poly-(MA-co-EDGMA), poly-(AA-co-EDGMA), and poly-(1-VN-co-EDGMA), by the mini-emulsion method. These matrices were used due to their ability to interact specifically with the functional groups of the analyte. Finally, the MIP-CDNB was obtained on the magnetic-hydrophobic surfaces using precipitation polymerization in the presence of the analyte. XRD diffraction patterns suggested the presence of magnetite in the composite and SEM analysis revealed a nanoparticle size between 10 and 18nm. Under the optimized adsorption conditions, the magnetic-MIP material showed a higher adsorption capacity (5.1mgg-1) than its non-magnetic counterpart (4.2mgg-1). In tests of the selectivity of the magnetic-MIP towards CDNB, alpha-values of 2.5 and 10.4, respectively, were obtained for dichlorophenol and o-nitrophenol, two structurally similar compounds, and no adsorption was observed for any other non-analogous analyte. The magnetic-MIP and magnetic-NIP were applied using water enriched with 0.5mgL-1 of CDNB, achieving recovery values of 83.8(+/-0.8)% and 66(+/-1)%, respectively, revealing the suitability of the material for detection of CDNB</style></abstract><notes><style face="normal" font="default">DA - 20170303IS - 1873-0191 (Electronic)IS - 0928-4931 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - Spain -CO - Peru -</style></notes><work-type><style face="normal" font="default">10.1016/j.msec.2016.12.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28254306">PM:28254306</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mater Sci Eng C Mater Biol Appl\2017-74-365-73.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mater Sci Eng C Mater Biol Appl\2017-74-365-73.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170303, Uzuriaga-Sanchez RJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.msec.2016.12.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40956</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Valitutti,S.</style></author><author><style face="normal" font="default"> Joulia,R.</style></author><author><style face="normal" font="default"> Espinosa,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">INSERM U1043, Centre de physiopathologie de Toulouse Purpan (CPTP), Toulouse, F-31300, France</style></auth-address><titles><title><style face="normal" font="default">The Mast Cell Antibody-Dependent Degranulatory Synapse</style></title><secondary-title><style face="normal" font="default">Methods Mol Biol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Methods Mol Biol</style></abbr-1></periodical><pages end="495" start="487">487-495</pages><volume><style face="normal" font="default">1584</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Igg</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Microscopy</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Mast cells are key effector cells in inflammation that can be activated by specific antigens via IgE or IgG binding on their FcR. Aggregation of mast cell Fc receptors by cell-bound antigens induces mast cell polarized degranulation toward the stimulatory cell, a process named antibody-dependent degranulatory synapse (ADDS). This polarized degranulation allows mast cells to expose bioactive material embedded in the granule matrix toward the antibody-targeted cell and is accompanied by the formation of a signaling area at the cell-cell contact site. In this chapter, we describe (1) how to stimulate mast cells with cell-bound antigens and (2) how to monitor ADDS formation and to investigate ADDS characteristics by confocal microscopy</style></abstract><notes><style face="normal" font="default">DA - 20170303IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1007/978-1-4939-6881-7_30</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28255721">PM:28255721</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Methods Mol Biol\2017-1584-487-95.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Methods Mol Biol\2017-1584-487-95.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170303, Valitutti S</style></custom2><misc3><style face="normal" font="default">10.1007/978-1-4939-6881-7_30</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40957</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Banerji,A.</style></author><author><style face="normal" font="default"> Busse,P.</style></author><author><style face="normal" font="default"> Shennak,M.</style></author><author><style face="normal" font="default"> Lumry,W.</style></author><author><style face="normal" font="default"> Davis-Lorton,M.</style></author><author><style face="normal" font="default"> Wedner,H.J.</style></author><author><style face="normal" font="default"> JACOBS,J.</style></author><author><style face="normal" font="default"> Baker,J.</style></author><author><style face="normal" font="default"> Bernstein,J.A.</style></author><author><style face="normal" font="default"> Lockey,R.</style></author><author><style face="normal" font="default"> Li,H.H.</style></author><author><style face="normal" font="default"> Craig,T.</style></author><author><style face="normal" font="default"> Cicardi,M.</style></author><author><style face="normal" font="default"> Riedl,M.</style></author><author><style face="normal" font="default"> Al-Ghazawi,A.</style></author><author><style face="normal" font="default"> Soo,C.</style></author><author><style face="normal" font="default"> Iarrobino,R.</style></author><author><style face="normal" font="default"> Sexton,D.J.</style></author><author><style face="normal" font="default"> TenHoor,C.</style></author><author><style face="normal" font="default"> Kenniston,J.A.</style></author><author><style face="normal" font="default"> Faucette,R.</style></author><author><style face="normal" font="default"> Still,J.G.</style></author><author><style face="normal" font="default"> Kushner,H.</style></author><author><style face="normal" font="default"> Mensah,R.</style></author><author><style face="normal" font="default"> Stevens,C.</style></author><author><style face="normal" font="default"> Biedenkapp,J.C.</style></author><author><style face="normal" font="default"> Chyung,Y.</style></author><author><style face="normal" font="default"> Adelman,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital</style></auth-address><titles><title><style face="normal" font="default">Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis</style></title><secondary-title><style face="normal" font="default">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">N Engl J Med</style></full-title></periodical><pages end="728" start="717">717-728</pages><volume><style face="normal" font="default">376</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> administration &amp; dosage</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Angioedemas,Hereditary</style></keyword><keyword><style face="normal" font="default"> antagonists &amp; inhibitors</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibodies,Monoclonal</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Bradykinin</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor deficiency</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Drug</style></keyword><keyword><style face="normal" font="default"> Double-Blind Method</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Elimination</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Headache</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Jordan</style></keyword><keyword><style face="normal" font="default"> Kallikrein</style></keyword><keyword><style face="normal" font="default"> Kininogen</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multicenter Studies</style></keyword><keyword><style face="normal" font="default"> Multicenter study</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Plasma Kallikrein</style></keyword><keyword><style face="normal" font="default"> prevention &amp; control</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research Support</style></keyword><keyword><style face="normal" font="default"> serious adverse events</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="23" Month="2" Year="2017">2017/2/23</year></dates><abstract><style face="normal" font="default">Background Hereditary angioedema with C1 inhibitor deficiency is characterized by recurrent, unpredictable swelling episodes caused by uncontrolled plasma kallikrein generation and excessive bradykinin release resulting from cleavage of high-molecular-weight kininogen. Lanadelumab (DX-2930) is a new kallikrein inhibitor with the potential for prophylactic treatment of hereditary angioedema with C1 inhibitor deficiency. Methods We conducted a phase 1b, multicenter, double-blind, placebo-controlled, multiple-ascending-dose trial. Patients with hereditary angioedema with C1 inhibitor deficiency were randomly assigned in a 2:1 ratio to receive either lanadelumab (24 patients) or placebo (13 patients), in two administrations 14 days apart. Patients assigned to lanadelumab were enrolled in sequential dose groups: total dose of 30 mg (4 patients), 100 mg (4 patients), 300 mg (5 patients), or 400 mg (11 patients). The pharmacodynamic profile of lanadelumab was assessed by measurement of plasma levels of cleaved high-molecular-weight kininogen, and efficacy was assessed by the rate of attacks of angioedema during a prespecified period (day 8 to day 50) in the 300-mg and 400-mg groups as compared with the placebo group. Results No discontinuations occurred because of adverse events, serious adverse events, or deaths in patients who received lanadelumab. The most common adverse events that emerged during treatment were attacks of angioedema, injection-site pain, and headache. Dose-proportional increases in serum concentrations of lanadelumab were observed; the mean elimination half-life was approximately 2 weeks. Lanadelumab at a dose of 300 mg or 400 mg reduced cleavage of high-molecular-weight kininogen in plasma from patients with hereditary angioedema with C1 inhibitor deficiency to levels approaching that from patients without the disorder. From day 8 to day 50, the 300-mg and 400-mg groups had 100% and 88% fewer attacks, respectively, than the placebo group. All patients in the 300-mg group and 82% (9 of 11) in the 400-mg group were attack-free, as compared with 27% (3 of 11) in the placebo group. Conclusions In this small trial, administration of lanadelumab to patients with hereditary angioedema with C1 inhibitor deficiency reduced cleavage of high-molecular-weight kininogen and attacks of angioedema. (Funded by Dyax; ClinicalTrials.gov number, NCT02093923 .)</style></abstract><notes><style face="normal" font="default">DA - 20170222IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - Clinical Trial, Phase IPT - Journal ArticlePT - Multicenter StudyPT - Randomized Controlled TrialPT - Research Support, Non-U.S. Gov'tRN - 0 (Antibodies, Monoclonal)RN - 0 (DX-2930)RN - EC 3.4.21.34 (Plasma Kallikrein)SB - AIMSB - IMCO - United States -CO - Jordan -CO - Italy -</style></notes><work-type><style face="normal" font="default">10.1056/NEJMoa1605767</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28225674">PM:28225674</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\N Engl J Med\2017-376-717-28.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\N Engl J Med\2017-376-717-28.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170222, Banerji A</style></custom2><misc3><style face="normal" font="default">10.1056/NEJMoa1605767</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40958</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Feller,L.</style></author><author><style face="normal" font="default"> Wood,N.H.</style></author><author><style face="normal" font="default"> Khammissa,R.A.G.</style></author><author><style face="normal" font="default"> Lemmer,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Allergic contact stomatitis</style></title><secondary-title><style face="normal" font="default">Oral Surg Oral Med Oral Pathol Oral Radiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Oral Surg Oral Med Oral Pathol Oral Radiol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AC</style></keyword><keyword><style face="normal" font="default"> Africa</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact stomatitis</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Delayed hypersensitivity</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> lichenoid tissue reaction</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> oral immunity</style></keyword><keyword><style face="normal" font="default"> oral mucosa</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Sensation</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> Stomatitis</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> T cell-mediated immunity</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2212-4403</style></isbn><abstract><style face="normal" font="default">Abstract Allergic contact stomatitis (ACS) is an oral mucosal immuno-inflammatory disorder variably characterized clinically by erythematous plaques, vesiculation, ulceration and/or hyperkeratosis, and by pain, burning sensation, or itchiness. ACS is brought about by a T cell-mediated, delayed hypersensitivity immune reaction generated by a second or subsequent contact exposure of an allergen with the oral mucosa, in a genetically susceptible, sensitized subject. Lichenoid contact reaction is a variant of ACS brought about by direct contact with the oral mucosa of certain metals in dental restorations. The features of ACS are neither clinically nor histopathologically specific, so the diagnosis is usually presumptive and can only be confirmed by resolution of the inflammation after withdrawal or removal of the suspected causative allergen. When ACS is suspected but an allergen cannot be identified, patch testing is necessary. In persistent cases, topical corticosteroid is the treatment of choice, but for severe and extensive lesions, systemic corticosteroid and systemic anti-histamine may be indicated. In this short review we highlight the clinical, immunological and histopathological features of ACS, and provide some guidelines for diagnosis and management</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">10.1016/j.oooo.2017.02.007</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.oooo.2017.02.007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Oral Surg Oral Med Oral Pathol Oral Radiol\20170320-FellerL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Oral Surg Oral Med Oral Pathol Oral Radiol\20170320-FellerL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Feller L</style></custom2><misc3><style face="normal" font="default">10.1016/j.oooo.2017.02.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40959</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Engel-Yeger,B.</style></author><author><style face="normal" font="default"> Farkas,H.</style></author><author><style face="normal" font="default"> Kivity,S.</style></author><author><style face="normal" font="default"> Veszeli,N.</style></author><author><style face="normal" font="default"> Kohalmi,K.V.</style></author><author><style face="normal" font="default"> Kesssel,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Haifa Occupational Therapy Department Faculty of Social Welfare and Health Sciences, Haifa, Israel</style></auth-address><titles><title><style face="normal" font="default">Health-Related Quality of Life among Children with Hereditary Angioedema</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor deficiency</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Hungary</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Therapy</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Self Report</style></keyword><keyword><style face="normal" font="default"> Social Welfare</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="3" Year="2017">2017/3/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: The clinical expressions of hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) and its related burden may negatively affect patient quality of life. This study aims to assess health-related quality of life (HRQoL) in children with C1-INH-HAE. METHODS: Children (N=98: 34 C1-INH-HAE patients, 64 healthy controls) aged 3-18 years were recruited in Israel and Hungary. All individuals completed a demographic questionnaire, a disease activity and site questionnaire, and the Pediatric Quality of Life Inventory (PedsQL ) 4.0 Generic Core Scales (child self-report and maternal proxy report) to assess HRQoL. RESULTS: Among C1-INH-HAE patients, 9 (26.5%) had 1-5 attacks/year; 6 (17.6%) had 6-18 attacks/year, 8 (23.5%) had 25-60 attacks/year, and 11 (32.4%) were asymptomatic over the previous year. Children with C1-INH-HAE attacks demonstrated lower HRQoL than healthy control children across the total score, school, and psychosocial dimensions of the PedsQL . The number of C1-INH-HAE attacks negatively correlated with the total HRQoL score (r=-.48, p=.008), school related HRQoL (r=-.39, p=.02), and psychosocial HRQoL (r=-.43, p=.01). Patients with multi-site laryngeal, abdominal, and peripheral C1-INH-HAE attacks had a lower HRQoL compared with those who experienced solely peripheral attacks across the total score (p=.04), physical (p=.04), and school (p=.02) domains. There was no significant difference between asymptomatic C1-INH-HAE patients and healthy controls. CONCLUSIONS: Children with symptomatic C1-INH-HAE demonstrate impaired HRQoL compared with healthy controls. HRQoL was affected by the frequency and site of C1-INH-HAE attacks and mostly in the school and physical domains. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170304IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Israel -CO - Hungary -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12712</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28258590">PM:28258590</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170304-EngelYegerB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170304-EngelYegerB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170304, Engel-Yeger B</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12712</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40960</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pignataro,F.S.</style></author><author><style face="normal" font="default"> Bonini,M.</style></author><author><style face="normal" font="default"> Forgione,A.</style></author><author><style face="normal" font="default"> Melandri,S.</style></author><author><style face="normal" font="default"> Usmani,O.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Human Movement and Health Sciences, University of Rome "Foro Italico", Rome, Italy</style></auth-address><titles><title><style face="normal" font="default">Asthma and gender: the female lung</style></title><secondary-title><style face="normal" font="default">Pharmacol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pharmacol Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> gender difference</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Movement</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> rescue medication</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Rome</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="23" Month="2" Year="2017">2017/2/23</year></dates><abstract><style face="normal" font="default">Asthma is a common chronic disease that affects over 300 million people worldwide, resulting in a considerable socio-economic burden. Literature data suggest that asthma has a higher incidence in females, particularly at certain stages of pubertal development. Moreover, women seem to experience more asthma symptom than man and to use more rescue medications, resulting in a reduced quality of life. Although several mechanisms have been proposed to explain these differences, there are not yet final data available in the literature on the role of gender in the pathogenesis of asthma and different behavior in females. Some study suggested a more prevalent hyper-responsiveness in women than in men. Nevertheless, in the literature definitive data on a possible different response to drugs used for asthma between male and female are not described. Understanding the mechanisms underlie these gender differences in clinical history of asthma patients could give inspiration to new areas of research to obtain a more specific diagnostic and therapeutic approach gender-oriented</style></abstract><notes><style face="normal" font="default">DA - 20170227IS - 1096-1186 (Electronic)IS - 1043-6618 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.phrs.2017.02.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28238829">PM:28238829</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pharmacol Res\20170227-PignataroFS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pharmacol Res\20170227-PignataroFS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170227, Pignataro FS</style></custom2><misc3><style face="normal" font="default">10.1016/j.phrs.2017.02.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40961</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Park,M.Y.</style></author><author><style face="normal" font="default"> Shim,W.H.</style></author><author><style face="normal" font="default"> Kim,J.M.</style></author><author><style face="normal" font="default"> Kim,G.W.</style></author><author><style face="normal" font="default"> Kim,H.S.</style></author><author><style face="normal" font="default"> Ko,H.C.</style></author><author><style face="normal" font="default"> Kim,M.B.</style></author><author><style face="normal" font="default"> Kim,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, School of Medicine, Pusan National University, Busan, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Pirfenidone-induced photoallergic reaction in a patient with idiopathic pulmonary fibrosis</style></title><secondary-title><style face="normal" font="default">Photodermatol Photoimmunol Photomed</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Photodermatol Photoimmunol Photomed</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Fibrosis</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="4" Month="3" Year="2017">2017/3/4</year></dates><abstract><style face="normal" font="default">Idiopathic pulmonary fibrosis (IPF) is a progressive, fibrotic, fatal lung disease associated with inevitable loss of lung function. The prognosis is poor, with a median survival of 2.5-3.5 years after diagnosis.1 Pirfenidone is a novel agent for the treatment of IPF that has anti-fibrotic, anti-inflammatory, and antioxidant effects. It may prevent the progression of lung fibrosis through inhibition of fibroblast. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170304IS - 1600-0781 (Electronic)IS - 0905-4383 (Linking)LA - engPT - LetterCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1111/phpp.12304</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28258587">PM:28258587</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Photodermatol Photoimmunol Photomed\20170304-ParkMY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Photodermatol Photoimmunol Photomed\20170304-ParkMY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170304, Park MY</style></custom2><misc3><style face="normal" font="default">10.1111/phpp.12304</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40962</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">MacDonald,K.D.</style></author><author><style face="normal" font="default"> Moran,A.R.</style></author><author><style face="normal" font="default"> Scherman,A.J.</style></author><author><style face="normal" font="default"> McEvoy,C.T.</style></author><author><style face="normal" font="default"> Platteau,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Oregon Health and Science University, Portland, Oregon</style></auth-address><titles><title><style face="normal" font="default">Maternal high-fat diet in mice leads to innate airway hyperresponsiveness in the adult offspring</style></title><secondary-title><style face="normal" font="default">Physiol Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Physiol Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Breeding</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Cell Count</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Lactation</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> Methacholine challenge</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Oregon</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">Maternal obesity prior to and during pregnancy has been associated with an increased incidence of childhood asthma. As diets rich in saturated fat are linked to obesity and inflammation, we created a murine model to investigate the effect of maternal high-fat diet (HFD) on adult offspring airway hyperreactivity (AHR), a cardinal feature of asthma. Balb/cByJ dams were fed a HFD (60% fat Calories) or normal-fat diet (NFD) (10% fat Calories) from 8 weeks prior to first breeding through their pregnancies. Pups were weaned to either a HFD or NFD (at 4 weeks of age). AHR was measured in the 10-week-old offspring following inhaled methacholine challenge by end-inflation technique. Bronchial alveolar lavage fluid (BALF) was analyzed for cell count, total protein, and IL-6. Offspring of HFD dams weaned to NFD had increased AHR compared to offspring of NFD dams weaned to NFD Offspring of HFD dams that remained on HFDs had increased AHR compared to offspring of NFD dams weaned to HFDs. Offspring of HFD dams had higher BALF cell counts, higher neutrophil percentage, greater total protein, and IL-6 in the BALF These results demonstrate that a maternal diet high in saturated fat through pregnancy and lactation plays a key role in programming adult offspring AHR</style></abstract><notes><style face="normal" font="default">DA - 20170309IS - 2051-817X (Electronic)IS - 2051-817X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.14814/phy2.13082</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28275108">PM:28275108</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Physiol Rep\20170309-MacDonaldKD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Physiol Rep\20170309-MacDonaldKD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170309, MacDonald KD</style></custom2><misc3><style face="normal" font="default">10.14814/phy2.13082</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40963</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vonk,J.M.</style></author><author><style face="normal" font="default"> Scholtens,S.</style></author><author><style face="normal" font="default"> Postma,D.S.</style></author><author><style face="normal" font="default"> Moffatt,M.F.</style></author><author><style face="normal" font="default"> Jarvis,D.</style></author><author><style face="normal" font="default"> Ramasamy,A.</style></author><author><style face="normal" font="default"> Wjst,M.</style></author><author><style face="normal" font="default"> Omenaas,E.R.</style></author><author><style face="normal" font="default"> Bouzigon,E.</style></author><author><style face="normal" font="default"> Demenais,F.</style></author><author><style face="normal" font="default"> Nadif,R.</style></author><author><style face="normal" font="default"> Siroux,V.</style></author><author><style face="normal" font="default"> Polonikov,A.V.</style></author><author><style face="normal" font="default"> Solodilova,M.</style></author><author><style face="normal" font="default"> Ivanov,V.P.</style></author><author><style face="normal" font="default"> Curjuric,I.</style></author><author><style face="normal" font="default"> Imboden,M.</style></author><author><style face="normal" font="default"> Kumar,A.</style></author><author><style face="normal" font="default"> Probst-Hensch,N.</style></author><author><style face="normal" font="default"> Ogorodova,L.M.</style></author><author><style face="normal" font="default"> Puzyrev,V.P.</style></author><author><style face="normal" font="default"> Bragina,E.Y.</style></author><author><style face="normal" font="default"> Freidin,M.B.</style></author><author><style face="normal" font="default"> Nolte,I.M.</style></author><author><style face="normal" font="default"> Farrall,A.M.</style></author><author><style face="normal" font="default"> Cookson,W.O.</style></author><author><style face="normal" font="default"> Strachan,D.P.</style></author><author><style face="normal" font="default"> Koppelman,G.H.</style></author><author><style face="normal" font="default"> Boezen,H.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, the Netherlands</style></auth-address><titles><title><style face="normal" font="default">Adult onset asthma and interaction between genes and active tobacco smoking: The GABRIEL consortium</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0172716">e0172716-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Adult asthma</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> association studies</style></keyword><keyword><style face="normal" font="default"> association study</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Chromosomes</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic Association</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Genome-wide</style></keyword><keyword><style face="normal" font="default"> genome-wide association</style></keyword><keyword><style face="normal" font="default"> genome-wide association studies</style></keyword><keyword><style face="normal" font="default"> genome-wide association study</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Norway</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Russia</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Tobacco</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Genome-wide association studies have identified novel genetic associations for asthma, but without taking into account the role of active tobacco smoking. This study aimed to identify novel genes that interact with ever active tobacco smoking in adult onset asthma. METHODS: We performed a genome-wide interaction analysis in six studies participating in the GABRIEL consortium following two meta-analyses approaches based on 1) the overall interaction effect and 2) the genetic effect in subjects with and without smoking exposure. We performed a discovery meta-analysis including 4,057 subjects of European descent and replicated our findings in an independent cohort (LifeLines Cohort Study), including 12,475 subjects. RESULTS: First approach: 50 SNPs were selected based on an overall interaction effect at p&lt;10-4. The most pronounced interaction effect was observed for rs9969775 on chromosome 9 (discovery meta-analysis: ORint = 0.50, p = 7.63*10-5, replication: ORint = 0.65, p = 0.02). Second approach: 35 SNPs were selected based on the overall genetic effect in exposed subjects (p &lt;10-4). The most pronounced genetic effect was observed for rs5011804 on chromosome 12 (discovery meta-analysis ORint = 1.50, p = 1.21*10-4; replication: ORint = 1.40, p = 0.03). CONCLUSIONS: Using two genome-wide interaction approaches, we identified novel polymorphisms in non-annotated intergenic regions on chromosomes 9 and 12, that showed suggestive evidence for interaction with active tobacco smoking in the onset of adult asthma</style></abstract><notes><style face="normal" font="default">DA - 20170302IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - United Kingdom -CO - Germany -CO - Norway -CO - France -CO - Russia -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0172716</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28253294">PM:28253294</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0172716.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0172716.pdf</url></text-urls><related-urls><url ppv-ref="no">.xls in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20170302, Vonk JM</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0172716</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40964</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rosner,S.R.</style></author><author><style face="normal" font="default"> Pascoe,C.D.</style></author><author><style face="normal" font="default"> Blankman,E.</style></author><author><style face="normal" font="default"> Jensen,C.C.</style></author><author><style face="normal" font="default"> Krishnan,R.</style></author><author><style face="normal" font="default"> James,A.L.</style></author><author><style face="normal" font="default"> Elliot,J.G.</style></author><author><style face="normal" font="default"> Green,F.H.</style></author><author><style face="normal" font="default"> Liu,J.C.</style></author><author><style face="normal" font="default"> Seow,C.Y.</style></author><author><style face="normal" font="default"> Park,J.A.</style></author><author><style face="normal" font="default"> Beckerle,M.C.</style></author><author><style face="normal" font="default"> Pare,P.D.</style></author><author><style face="normal" font="default"> Fredberg,J.J.</style></author><author><style face="normal" font="default"> Smith,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, United States of America</style></auth-address><titles><title><style face="normal" font="default">The actin regulator zyxin reinforces airway smooth muscle and accumulates in airways of fatal asthmatics</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0171728">e0171728-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway smooth muscle</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cytoskeleton</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Recovery</style></keyword><keyword><style face="normal" font="default"> Repair</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Bronchospasm induced in non-asthmatic human subjects can be easily reversed by a deep inspiration (DI) whereas bronchospasm that occurs spontaneously in asthmatic subjects cannot. This physiological effect of a DI has been attributed to the manner in which a DI causes airway smooth muscle (ASM) cells to stretch, but underlying molecular mechanisms-and their failure in asthma-remain obscure. Using cells and tissues from wild type and zyxin-/- mice we report responses to a transient stretch of physiologic magnitude and duration. At the level of the cytoskeleton, zyxin facilitated repair at sites of stress fiber fragmentation. At the level of the isolated ASM cell, zyxin facilitated recovery of contractile force. Finally, at the level of the small airway embedded with a precision cut lung slice, zyxin slowed airway dilation. Thus, at each level zyxin stabilized ASM structure and contractile properties at current muscle length. Furthermore, when we examined tissue samples from humans who died as the result of an asthma attack, we found increased accumulation of zyxin compared with non-asthmatics and asthmatics who died of other causes. Together, these data suggest a biophysical role for zyxin in fatal asthma</style></abstract><notes><style face="normal" font="default">DA - 20170309IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0171728</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28278518">PM:28278518</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0171728.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0171728.pdf</url></text-urls><related-urls><url ppv-ref="no">.mov in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20170309, Rosner SR</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0171728</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40965</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gorzelak-Pabis,P.</style></author><author><style face="normal" font="default"> Luczak,E.</style></author><author><style face="normal" font="default"> Wojdan,K.</style></author><author><style face="normal" font="default"> Antosik,K.</style></author><author><style face="normal" font="default"> Borowiec,M.</style></author><author><style face="normal" font="default"> Broncel,M.</style></author><author><style face="normal" font="default"> Chalubinski,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Diseases and Clinical Pharmacology, The Laboratory of Tissue Immunopharmacology, Medical University of Lodz, Poland</style></auth-address><titles><title><style face="normal" font="default">Endothelial integrity may be regulated by a specific antigen via an IgE-mediated mechanism</style></title><secondary-title><style face="normal" font="default">Postepy Hig Med Dosw (Online)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Postepy Hig Med Dosw (Online)</style></abbr-1></periodical><pages end="169" start="162">162-169</pages><volume><style face="normal" font="default">71</style></volume><number><style face="normal" font="default">0</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electric Impedance</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endothelial Cells</style></keyword><keyword><style face="normal" font="default"> Endothelium</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> Impedance</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="3" Year="2017">2017/3/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Human vascular endothelial function and integrity may be regulated by many non-specific factors. However, the potential influence of specific antigens via an IgE-mediated mechanism remains unknown. The aim of the study was to determine the expression of the IgE receptors FcepsilonRI and FcepsilonRII in the human vascular endothelium and to assess their relevance in the IgE-mediated regulation of endothelial integrity. MATERIAL/METHODS: FcepsilonRI and FcepsilonRII expression in human umbilical vein endothelial cells (HUVEC) was genetically assessed by PCR with respective primers and sequencing. HUVEC were cultured with IL-4, and changes in FcepsilonRI and FcepsilonRII mRNA expression were analyzed by real-time PCR. Changes in the integrity of endothelium pre-treated with anti-BSA-DNP IgE following exposure to the specific BSA-DNP antigen was assessed using the Real-time Cell Electric Impedance Sensing system (RTCA-DP). RESULTS: PCR and sequencing revealed the expression of FcepsilonRI and FcepsilonRII receptors in the human vascular endothelium. IL-4 caused respective 2- and 3-fold increases in FcepsilonRI and FcepsilonRII mRNA expression. Exposure of endothelium pre-treated with anti-BSA-DNP IgE to specific BSA-DNP antigen led to a 20% increase of endothelial integrity (p&lt;0.05) after 24 hours, but only in cells pre-incubated with IL-4. CONCLUSIONS: The presence of FcepsilonRI and FcepsilonRII may allow the human vascular endothelium to respond to a specific antigen by increasing its integrity via an IgE-mediated mechanism</style></abstract><notes><style face="normal" font="default">DA - 20170304IS - 1732-2693 (Electronic)IS - 0032-5449 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28258676">PM:28258676</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Postepy Hig Med Dosw (Online)\2017-71-162-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Postepy Hig Med Dosw (Online)\2017-71-162-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170304, Gorzelak-Pabis P</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40966</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kawashita,S.</style></author><author><style face="normal" font="default"> Kaneuchi,M.</style></author><author><style face="normal" font="default"> Nakayama,D.</style></author><author><style face="normal" font="default"> Fuchi,N.</style></author><author><style face="normal" font="default"> Murakami,Y.</style></author><author><style face="normal" font="default"> Miura,K.</style></author><author><style face="normal" font="default"> Masuzaki,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Carbon dioxide angiography and arterial embolization could successfully control postpartum uterine hemorrhage for the patient with hypersensitivity to iodine compound</style></title><secondary-title><style face="normal" font="default">Radiol Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Radiol Case Rep</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Arteries</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Dioxide</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Hemorrhage</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> iodinated contrast</style></keyword><keyword><style face="normal" font="default"> Iodinated contrast agents</style></keyword><keyword><style face="normal" font="default"> iodinated contrast media</style></keyword><keyword><style face="normal" font="default"> Iodine</style></keyword><keyword><style face="normal" font="default"> Iodine allergy</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Placenta</style></keyword><keyword><style face="normal" font="default"> Postpartum hemorrhage</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Recovery</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1930-0433</style></isbn><abstract><style face="normal" font="default">Abstract Transcatheter arterial embolization has become a common management option for intractable postpartum uterine hemorrhage. Iodinated contrast agents are commonly used for embolotherapy but cannot be used in patients with renal dysfunction or iodine allergy. A 37-year-old woman spontaneously delivered a healthy girl but developed severe postpartum uterine hemorrhage, probably due to placenta accrete. Contrast-enhanced computed tomography revealed extravasation of the iodinated contrast agent into the uterine cavity. The patient subsequently developed allergic reaction to this agent. After recovery from the allergic reaction with appropriate treatment, we performed carbon dioxide angiography and found that the extravasation originated from the right uterine artery. Embolization of the right internal iliac artery was performed, and hemostasis was verified. Based on this experience, we suggest carbon dioxide angiography and arterial embolization can be used for treating intractable postpartum hemorrhage in patients with iodinated contrast media allergy or renal dysfunction</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.radcr.2017.01.017</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.radcr.2017.01.017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Radiol Case Rep\20170323-KawashitaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Radiol Case Rep\20170323-KawashitaS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170323, Kawashita S</style></custom2><misc3><style face="normal" font="default">10.1016/j.radcr.2017.01.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40967</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Roberts,D.W.</style></author><author><style face="normal" font="default"> Api,A.M.</style></author><author><style face="normal" font="default"> Aptula,A.O.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, L3 3AF, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default">Chemical applicability domain of the Local Lymph Node Assay (LLNA) for skin sensitisation potency. Part 2. The biological variability of the murine Local Lymph Node Assay (LLNA) for skin sensitisation</style></title><secondary-title><style face="normal" font="default">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="259" start="255">255-259</pages><volume><style face="normal" font="default">80</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Administration,Cutaneous</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Data Mining</style></keyword><keyword><style face="normal" font="default"> Databases,Factual</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Drug</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritants</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Models,Molecular</style></keyword><keyword><style face="normal" font="default"> Molecular Structure</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Sensitisation</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin Absorption</style></keyword><keyword><style face="normal" font="default"> skin allergy</style></keyword><keyword><style face="normal" font="default"> Solubility</style></keyword><keyword><style face="normal" font="default"> Species Specificity</style></keyword><keyword><style face="normal" font="default"> Structure-Activity Relationship</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Thymidine</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> Toxicology</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">The Local Lymph Node Assay (LLNA) is the most common in vivo regulatory toxicology test for skin sensitisation, quantifying potency as the EC3, the concentration of chemical giving a threefold increase in thymidine uptake in the local lymph node. Existing LLNA data can, along with clinical data, provide useful comparator information on the potency of sensitisers. Understanding of the biological variability of data from LLNA studies is important for those developing non-animal based risk assessment approaches for skin allergy. Here an existing set of 94 EC3 values for 12 chemicals, all tested at least three times in the same vehicle have been analysed by calculating standard deviations (SD) for logEC3 values. The SDs range from 0.08 to 0.22. The overall SD for the 94 logEC3 values is 0.147. Thus the 95% confidence limits (2xSD) for LLNA EC3 values are within a factor of 2, comparable to those for physico-chemical measurements such as partition coefficients and solubility. The residual SDs of Quantitative Mechanistic Models (QMMs) based on physical organic chemistry parameters are similar to the overall SD of the LLNA, indicating that QMMs of this type are unlikely to be bettered for predictive accuracy</style></abstract><notes><style face="normal" font="default">DA - 20160903IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Journal ArticlePT - ReviewRN - 0 (Irritants)SB - IMCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.yrtph.2016.07.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27470439">PM:27470439</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2016-80-255-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2016-80-255-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160905, Roberts DW</style></custom2><misc3><style face="normal" font="default">10.1016/j.yrtph.2016.07.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40968</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Roberts,D.W.</style></author><author><style face="normal" font="default"> Schultz,T.W.</style></author><author><style face="normal" font="default"> Api,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, L3 3AF, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default">Chemical applicability domain of the Local Lymph Node Assay (LLNA) for skin sensitisation potency. Part 3. Apparent discrepancies between LLNA and GPMT sensitisation potential: False positives or differences in sensitivity?</style></title><secondary-title><style face="normal" font="default">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="267" start="260">260-267</pages><volume><style face="normal" font="default">80</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acids</style></keyword><keyword><style face="normal" font="default"> Administration,Cutaneous</style></keyword><keyword><style face="normal" font="default"> Alcohol</style></keyword><keyword><style face="normal" font="default"> Alcohols</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Data Mining</style></keyword><keyword><style face="normal" font="default"> Databases,Factual</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Drug</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> False Positive Reactions</style></keyword><keyword><style face="normal" font="default"> Fatty acid</style></keyword><keyword><style face="normal" font="default"> Fatty Acids</style></keyword><keyword><style face="normal" font="default"> Gold</style></keyword><keyword><style face="normal" font="default"> Guinea Pigs</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritants</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Models,Molecular</style></keyword><keyword><style face="normal" font="default"> Molecular Structure</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> pig</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Sensitisation</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin Absorption</style></keyword><keyword><style face="normal" font="default"> Species Specificity</style></keyword><keyword><style face="normal" font="default"> Structural Alerts</style></keyword><keyword><style face="normal" font="default"> Structure-Activity Relationship</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> Toxicology</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">The Local Lymph Node Assay (LLNA) is the gold standard regulatory toxicology test for skin sensitisation along with the guinea pig maximisation test (GPMT). Compared with the GPMT, LLNA uses fewer animals, it is quantitative, and it gives a numerical prediction of potency. However several concerns have been raised with this assay, mainly related to false positives and false negatives. Over the years, many authors, including the developers of the assay, have presented cases where there have been discrepancies between the GMPT and LLNA results. Several theories have been put forward for these discrepancies, the main one being the "over-sensitivity" of the GPMT. This paper analyses the data from a systematic study, published in three papers from 2008 to 2011, covering several classes of chemicals, in particular unsaturated fatty acids, sugar surfactants and ethoxylated alcohols, with many cases of chemicals testing positive in the LLNA being negative in the GPMT. Based on consideration of reaction chemistry and structural alerts, it is concluded that these discrepancies are not LLNA false positives, but can be rationalised in terms of the different protocols of the assays</style></abstract><notes><style face="normal" font="default">DA - 20160903IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Journal ArticlePT - ReviewRN - 0 (Irritants)SB - IMCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.yrtph.2016.07.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27477089">PM:27477089</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2016-80-260-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2016-80-260-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160904, Roberts DW</style></custom2><misc3><style face="normal" font="default">10.1016/j.yrtph.2016.07.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40969</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Roberts,D.W.</style></author><author><style face="normal" font="default"> Api,A.M.</style></author><author><style face="normal" font="default"> Patlewicz,G.</style></author><author><style face="normal" font="default"> Schultz,T.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool L3 3AF, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default">Chemical applicability domain of the Local Lymph Node Assay (LLNA) for skin sensitization potency. Part 1. Underlying physical organic chemistry principles and the extent to which they are represented in the LLNA validation dataset</style></title><secondary-title><style face="normal" font="default">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="254" start="247">247-254</pages><volume><style face="normal" font="default">80</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Administration,Cutaneous</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Data Mining</style></keyword><keyword><style face="normal" font="default"> Databases,Factual</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Drug</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Guinea Pigs</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hydrophobic and Hydrophilic Interactions</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritants</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Models,Molecular</style></keyword><keyword><style face="normal" font="default"> Molecular Structure</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin Absorption</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> Species Specificity</style></keyword><keyword><style face="normal" font="default"> Structure-Activity Relationship</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20160903IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Journal ArticlePT - ReviewRN - 0 (Irritants)SB - IMCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.yrtph.2016.07.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27424000">PM:27424000</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2016-80-247-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2016-80-247-54.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160903, Roberts DW</style></custom2><misc3><style face="normal" font="default">10.1016/j.yrtph.2016.07.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40970</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Basketter,D.</style></author><author><style face="normal" font="default"> Poole,A.</style></author><author><style face="normal" font="default"> Kimber,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">DABMEB Consultancy Ltd, Sharnbrook, Bedfordshire, UK.</style></auth-address><titles><title><style face="normal" font="default">Behaviour of chemical respiratory allergens in novel predictive methods for skin sensitisation</style></title><secondary-title><style face="normal" font="default">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Health</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Respiratory allergens</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Sensitisation</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Test method</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="5" Month="3" Year="2017">2017/3/5</year></dates><abstract><style face="normal" font="default">Asthma resulting from sensitisation of the respiratory tract to chemicals is an important occupational health issue, presenting many toxicological challenges. Most importantly there are no recognised predictive methods for respiratory allergens. Nevertheless, it has been found that all known chemical respiratory allergens elicit positive responses in assays for skin sensitising chemicals. Thus, chemicals failing to induce a positive response in skin sensitisation assays such as the local lymph node assay (LLNA) lack not only skin sensitising activity, but also the potential to cause respiratory sensitisation. However, it is unclear whether it will be possible to regard chemicals that are negative in in vitro skin sensitisation tests also as lacking respiratory sensitising activity. To address this, the behaviour of chemical respiratory allergens in the LLNA and in recently validated non-animal tests for skin sensitisation have been examined. Most chemical respiratory allergens are positive in one or more newly validated non-animal test methods, although the situation varies between individual assays. The use of an integrated testing strategy could provide a basis for recognition of most respiratory sensitising chemicals. However, a more complete picture of the performance characteristics of such tests is required before specific recommendations can be made</style></abstract><notes><style face="normal" font="default">DA - 20170309IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1016/j.yrtph.2017.03.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28274809">PM:28274809</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\20170309-BasketterD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\20170309-BasketterD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170309, Basketter D</style></custom2><misc3><style face="normal" font="default">10.1016/j.yrtph.2017.03.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40971</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Francois,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">On the basis of which clinical symptoms and examinations may GOR be evoked in children?</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acute laryngitis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="default"> pH-metry</style></keyword><keyword><style face="normal" font="default"> Proton-pump inhibitor</style></keyword><keyword><style face="normal" font="default"> Rhinosinusite chronique</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2016.12.005</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2016.12.005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170320-FrancoisM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170320-FrancoisM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Francois M</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2016.12.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40972</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Waton,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Avoiding false negatives with patch tests and overview of alternative test methods</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">diagnosis</style></keyword><keyword><style face="normal" font="default"> False negative</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Photopatch tests</style></keyword><keyword><style face="normal" font="default"> Repeated open application test</style></keyword><keyword><style face="normal" font="default"> Semi-open test</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Test method</style></keyword><keyword><style face="normal" font="default"> Test semi-ouvert</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">And if we miss a diagnosis because of a false negative test? If it is usual to question the relevance of the tests and suspect a </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç£false positive</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇØ, we sometimes forget to mention the possibility of a false negative test. At each stage of the tests, certain errors can be avoided</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.01.005</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.reval.2017.01.005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170320-WatonJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170320-WatonJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Waton J</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.01.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40973</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bohm,I.</style></author><author><style face="normal" font="default"> Nairz,K.</style></author><author><style face="normal" font="default"> Morelli,J.N.</style></author><author><style face="normal" font="default"> Keller,P.S.</style></author><author><style face="normal" font="default"> Heverhagen,J.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Iodinated Contrast Media and the Alleged "Iodine Allergy": An Inexact Diagnosis Leading to Inferior Radiologic Management and Adverse Drug Reactions</style></title><secondary-title><style face="normal" font="default">Rofo</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Rofo</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disinfectants</style></keyword><keyword><style face="normal" font="default"> Documentation</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> imaging</style></keyword><keyword><style face="normal" font="default"> iodinated contrast</style></keyword><keyword><style face="normal" font="default"> iodinated contrast media</style></keyword><keyword><style face="normal" font="default"> Iodine</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Radiology</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Uncertainty</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="default">Purpose To test the hypothesis that the incomplete diagnosis "iodine allergy" is a possibly dangerous concept for patients under routine radiologic conditions. Materials and Methods 300 patients with a history of an "iodine allergy" were retrospectively screened and compared with two age-, sex-, and procedure-matched groups of patients either diagnosed with a nonspecific "iodine contrast medium (ICM) allergy" or an allergy to a specific ICM agent. For all groups, the clinical symptoms of the most recent past adverse drug reaction (ADR), prophylactic actions taken for subsequent imaging, and ultimate outcome were recorded and analyzed. Results The diagnosis "iodine allergy" was not otherwise specified in 84.3 % patients. For this group, in most cases, the symptoms of the previous ADRs were not documented. In contrast, the type of ADR was undocumented in only a minority of patients in the comparison groups. In the group of patients with an "iodine allergy" the percentage of unenhanced CT scans was greater than within the other two groups (36.7 % vs. 28.7 %/18.6 %). ADRs following prophylactic measures were only observed in the "iodine allergy" group (OR of 9.24 95 % CI 1.16 - 73.45; p &lt; 0.04). Conclusion This data confirms the hypothesis that the diagnosis "iodine allergy" is potentially dangerous and results in uncertainty in clinical management and sometimes even ineffective prophylactic measures. Key points . The term "iodine allergy" is imprecise, because it designates allergies against different substance classes, such as disinfectants with complexed iodine and contrast media containing covalently bound iodine.. . There is a clear correlation between the exactness of the diagnosis - from the alleged "iodine allergy" to "contrast media allergy" to naming the exact culprit CM - and the quality of documentation of the symptoms.. . Management of patients diagnosed with "iodine allergy" was associated with uncertainty leading to unenhanced scans and sometimes unnecessary prophylactic actions.. . The term "iodine allergy" should be omitted, because it is potentially dangerous and can decrease the quality of radiology exams.. Citation Format . Bohm Ingrid, Nairz Knud, Morelli John N et al. Iodinated Contrast Media and the Alleged "Iodine Allergy": An Inexact Diagnosis Leading to Inferior Radiologic Management and Adverse Drug Reactions. Fortschr Rontgenstr ; DOI:</style></abstract><notes><style face="normal" font="default">DA - 20170301IS - 1438-9010 (Electronic)IS - 1438-9010 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1055/s-0042-122148</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28249309">PM:28249309</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rofo\20170301-BohmI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rofo\20170301-BohmI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170301, Bohm I</style></custom2><misc3><style face="normal" font="default">10.1055/s-0042-122148</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40974</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kang,J.</style></author><author><style face="normal" font="default"> Ding,Y.</style></author><author><style face="normal" font="default"> Li,B.</style></author><author><style face="normal" font="default"> Liu,H.</style></author><author><style face="normal" font="default"> Yang,X.</style></author><author><style face="normal" font="default"> Chen,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hubei Key Laboratory of Genetic Regulation and Integrative Biology, School of Life Sciences, Central China Normal University, Wuhan 430079, Hubei, China</style></auth-address><titles><title><style face="normal" font="default">TRPA1 mediated aggravation of allergic contact dermatitis induced by DINP and regulated by NF-kappaB activation</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="43586">43586-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> adjuvant</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Cell Degranulation</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Down-Regulation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> IgG1</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="27" Month="2" Year="2017">2017/2/27</year></dates><abstract><style face="normal" font="default">The possible pathogenic role and mechanism of Di-iso-nonyl phthalate (DINP) in allergic dermatitis is still controversial. This work has shown that oral exposure to DINP exacerbated allergic dermatitis tissue lesions in FITC-sensitized mice. The lesions was accompanied by an enhancement of TRPA1 expression and an increase in IgG1, IL-6 and IL-13 levels. This work also found that blocking TRPA1 by HC030031 effectively prevented the development of allergic dermatitis resulting from oral exposure to DINP and/or FITC-sensitized mice. This result is marked by the down regulation of IgG1 levels, a reduction in mast cell degranulation and a decrease in IL-6 and IL-13 levels. We also showed that blocking NF-kappaB inhibited TRPA1 expression, and that blocking TRPA1 had no significant effect on the activation of NF-kappaB or TSLP expression. This study helps in understanding the role DINP exposure plays in the development of allergic dermatitis and provides new insight into the mechanisms behind the DINP-induced adjuvant effect</style></abstract><notes><style face="normal" font="default">DA - 20170227IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1038/srep43586</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28240277">PM:28240277</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Rep\2017-7-43586.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Rep\2017-7-43586.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170227, Kang J</style></custom2><misc3><style face="normal" font="default">10.1038/srep43586</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40975</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,X.</style></author><author><style face="normal" font="default"> Gao,X.</style></author><author><style face="normal" font="default"> Yang,Q.</style></author><author><style face="normal" font="default"> Wang,X.</style></author><author><style face="normal" font="default"> Li,S.</style></author><author><style face="normal" font="default"> Jiang,F.</style></author><author><style face="normal" font="default"> Zhang,J.</style></author><author><style face="normal" font="default"> Ouyang,F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Sleep disorders and allergic diseases in chinese toddlers</style></title><secondary-title><style face="normal" font="default">Sleep Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sleep Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hong Kong</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Income</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> passive smoking</style></keyword><keyword><style face="normal" font="default"> Pediatricians</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Sleep Disorders</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Snoring</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Toddler</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1389-9457</style></isbn><abstract><style face="normal" font="default">AbstractObjective Optimal sleep is important for child growth, development, and immune function. We aimed to explore whether sleep disorders were associated with the risk of allergic diseases in Chinese toddlers. Methods This study included 566 children (aged 23.9 -¦ 0.7 months; 51.1% boys) in Shanghai, China. Sleep parameters (total sleep time, sleep onset latency, nocturnal awaking and snoring) were assessed by an expanded version of the Brief Infant Sleep Questionnaire (BISQ-expanded). Information on four allergic diseases (wheeze, eczema, food allergy, and allergic rhinitis) in the past year was collected via standard questionnaire and judged by pediatricians. We used logistic regression to calculate odds ratios (ORs) and their 95% confidence intervals (CIs) for having any/and each of the four allergic diseases, based on sleep parameters, adjusting for children</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖs age and gender, mode of delivery, any breastfeeding duration, children</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖs body mass index (BMI), children</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖs exposure to passive smoking, maternal education, family income, family allergic history, and children</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖs antibiotic use. Results There were 23.3% of children with at least one of the four allergic diseases. Snoring was significantly associated with increased odds of having any allergy (adjusted OR=1.95; 95% CI: 1.17, 3.26), eczema (OR=1.83, 95% CI: 1.03, 3.23) and food allergy (OR=4.31, 95% CI: 1.23, 15.14), after adjustment for potential confounders. Nocturnal awaking </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ëÑ 2 times per night was associated with higher risk of food allergy (OR=3.92, 95% CI: 1.00, 15.35) and wheeze (OR=6.16, 95% CI: 1.28, 29.74). Conclusion In this study, presence of certain sleep disorders was associated with higher risk of having allergic diseases in Chinese toddlers</style></abstract><notes><style face="normal" font="default">LA - ENGCO - China -CO - United States -CO - Hong Kong -</style></notes><work-type><style face="normal" font="default">10.1016/j.sleep.2017.02.011</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1016/j.sleep.2017.02.011</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sleep Med\20170323-WangX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sleep Med\20170323-WangX.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170323, Wang X</style></custom2><misc3><style face="normal" font="default">10.1016/j.sleep.2017.02.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40976</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Satia,I.</style></author><author><style face="normal" font="default"> Badri,H.</style></author><author><style face="normal" font="default"> Woodhead,M.</style></author><author><style face="normal" font="default"> O'Byrne,P.M.</style></author><author><style face="normal" font="default"> Fowler,S.J.</style></author><author><style face="normal" font="default"> Smith,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Infection, Immunity and Respiratory Medicine, University of Manchester and Manchester Academic Health Science Centre, Manchester, UK</style></auth-address><titles><title><style face="normal" font="default">The interaction between bronchoconstriction and cough in asthma</style></title><secondary-title><style face="normal" font="default">Thorax</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Thorax</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> airflow</style></keyword><keyword><style face="normal" font="default"> airflow obstruction</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Capsaicin</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> Reflex</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="24" Month="2" Year="2017">2017/2/24</year></dates><abstract><style face="normal" font="default">Variable airflow obstruction is a pathophysiological hallmark of asthma; however, the interactions between acute bronchoconstriction and the cough reflex are poorly understood. We performed a randomised, single-blind, placebo-controlled, crossover study to investigate the interaction between bronchoconstriction and cough in asthma. Capsaicin was administered to evoke coughs and methacholine to induce bronchoconstriction. We demonstrated that acute bronchoconstriction increased capsaicin-evoked coughs, which improved as airway calibre spontaneously resolved. However, capsaicin-evoked coughing had no impact on methacholine-induced bronchoconstriction. This study provides evidence that bronchoconstriction increases the activation of capsaicin-responsive airway nerves, but the precise mechanisms and mediators involved require further evaluation. TRIAL REGISTRATION NUMBER: ISRCTN14900082</style></abstract><notes><style face="normal" font="default">DA - 20170225IS - 1468-3296 (Electronic)IS - 0040-6376 (Linking)LA - engPT - LetterCO - United Kingdom -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1136/thoraxjnl-2016-209625</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28235887">PM:28235887</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Thorax\20170325-SatiaI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Thorax\20170325-SatiaI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170225, Satia I</style></custom2><misc3><style face="normal" font="default">10.1136/thoraxjnl-2016-209625</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40977</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Horita,K.</style></author><author><style face="normal" font="default"> Horita,D.</style></author><author><style face="normal" font="default"> Tomita,H.</style></author><author><style face="normal" font="default"> Yasoshima,M.</style></author><author><style face="normal" font="default"> Yagami,A.</style></author><author><style face="normal" font="default"> Matsunaga,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Laboratory, Ikedamohando Co., Ltd., Jinden, Kamiichi-machi, Nakaniikawa, Toyama 930-0394, Japan.</style></auth-address><titles><title><style face="normal" font="default">Effects of different base agents on prediction of skin irritation by sodium lauryl sulfate using patch testing and repeated application test</style></title><secondary-title><style face="normal" font="default">Toxicology</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Toxicology</style></abbr-1></periodical><pages end="15" start="10">10-15</pages><volume><style face="normal" font="default">382</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic disease</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> Back</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Ethanol</style></keyword><keyword><style face="normal" font="default"> European Union</style></keyword><keyword><style face="normal" font="default"> Gel</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritation</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Petrolatum</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> rat</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="5" Month="3" Year="2017">2017/3/5</year></dates><abstract><style face="normal" font="default">Animal testing for cosmetics was banned in the European Union (EU) in 2013; therefore, human tests to predict and ensure skin safety such as the patch test or usage test are now in demand in Japan as well as in the EU. In order to investigate the effects of different bases on the findings of tests to predict skin irritation, we performed patch testing (PT) and the repeated application test (RAT) using sodium lauryl sulfate (SLS), a well-known irritant, dissolved in 6 different base agents to examine the effects of these bases on skin irritation by SLS. The bases for PT were distilled water, 50% ethanol, 100% ethanol, a gel containing 50% ethanol, white petrolatum, and hydrophilic cream. The concentrations of SLS were 0.2% and 0.5%. Twelve different base combinations were applied to the normal back skin of 19 individuals for 24h. RAT was performed with distilled water, 50% ethanol, 100% ethanol, a gel containing 50% ethanol, white petrolatum, and hydrophilic cream containing SLS at concentrations of 0.2%, 2%, and 5%, being applied to the arms of the same PT subjects. The test preparation of each base was applied at the same site, with 0.2% SLS being used in the first week, 2% SLS in the following week, and 5% SLS in the final week. The results of PT revealed that skin irritation scores varied when SLS at the same concentration was dissolved in a different base. The results of RAT showed that although skin irritation appeared with every base at a concentration of 5%, the positive rate was approximately the same. In conclusion, our results suggest that skin irritation elicited in PT depends on the base, while in RAT, it does not depend on the type of base employed</style></abstract><notes><style face="normal" font="default">DA - 20170309IS - 1879-3185 (Electronic)IS - 0300-483X (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.tox.2017.03.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28274658">PM:28274658</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicology\2017-382-10-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicology\2017-382-10-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170309, Horita K</style></custom2><misc3><style face="normal" font="default">10.1016/j.tox.2017.03.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40978</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yesin,M.</style></author><author><style face="normal" font="default"> Kalcik,M.</style></author><author><style face="normal" font="default"> Gursoy,M.O.</style></author><author><style face="normal" font="default"> Karakoyun,S.</style></author><author><style face="normal" font="default"> Cagdas,M.</style></author><author><style face="normal" font="default"> Ozkan,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Cardiology, Kars Harakani State Hospital, Kars, Turkey.</style></auth-address><titles><title><style face="normal" font="default">Acute myocardial infarction in a patient suffering from penicillin-induced laryngeal edema : Kounis syndrome aggravated by adrenaline</style></title><secondary-title><style face="normal" font="default">Wien Klin Wochenschr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Wien Klin Wochenschr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adrenaline</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Angina Pectoris</style></keyword><keyword><style face="normal" font="default"> Arrhythmia</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Chest Pain</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Coronary Vasospasm</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Infarction</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory mediators</style></keyword><keyword><style face="normal" font="default"> Ischemia</style></keyword><keyword><style face="normal" font="default"> Kounis syndrome</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Laryngeal Edema</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="default"> Myocardial Ischemia</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin G</style></keyword><keyword><style face="normal" font="default"> Procaine</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="3" Year="2017">2017/3/2</year></dates><abstract><style face="normal" font="default">Kounis syndrome or allergic angina is defined as the coincidental occurrence of chest pain and allergic reactions accompanied by clinical and laboratory findings of classical angina pectoris. It is triggered by the action of potent vasoactive and inflammatory mediators, which are released from the mast cells during the allergic reaction. Epinephrine is a life-saving medication in anaphylaxis; however, it can aggravate ischemia and induce coronary vasospasm and arrhythmias. Here, we present a patient with Kounis syndrome that was caused by intramuscular injection of procaine penicillin G, and in whom epinephrine administration for treatment of laryngeal edema had provoked severe myocardial ischemia</style></abstract><notes><style face="normal" font="default">DA - 20170303IS - 1613-7671 (Electronic)IS - 0043-5325 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1007/s00508-017-1183-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28255796">PM:28255796</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Wien Klin Wochenschr\20170303-YesinM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Wien Klin Wochenschr\20170303-YesinM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170303, Yesin M</style></custom2><misc3><style face="normal" font="default">10.1007/s00508-017-1183-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40979</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yan,S.</style></author><author><style face="normal" font="default"> Chen,W.</style></author><author><style face="normal" font="default"> Su,J.</style></author><author><style face="normal" font="default"> Chen,M.</style></author><author><style face="normal" font="default"> Zhu,W.</style></author><author><style face="normal" font="default"> Zhang,J.</style></author><author><style face="normal" font="default"> Yi,M.</style></author><author><style face="normal" font="default"> Chen,X.</style></author><author><style face="normal" font="default"> Li,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China</style></auth-address><titles><title><style face="normal" font="default">[Association between C reactive protein and clinical characteristics in patients with chronic spontaneous urticaria]</style></title><secondary-title><style face="normal" font="default">Zhong Nan Da Xue Xue Bao Yi Xue Ban</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Zhong Nan Da Xue Xue Bao Yi Xue Ban</style></abbr-1></periodical><pages end="172" start="168">168-172</pages><volume><style face="normal" font="default">42</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="28" Month="2" Year="2017">2017/2/28</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To explore the association among C reactive protein (CRP) level, disease severity and non-sedating antihistamine drug efficacy in patients with chronic spontaneous urticaria. Methods: A total of 605 patients with chronic spontaneous urticaria from August 2013 to March 2015, diagnosed by dermatologist of Xiangya Hospital according to the guideline, were enrolled in present study. The patients were divided into two groups according to the weekly urticaria activity score (UAS): a response group (more than 50% reduction) and a nonresponse group (less than 50% reduction). T test and Pearson correlation analysis were used to analyze the correlation between the clinical characteristics (such as disease severity, drug efficacy) and CRP in patients with chronic spontaneous urticaria. Results: The CRP levels were significantly higher in patients with severe chronic spontaneous urticaria as compared to those with moderate chronic spontaneous urticaria (t=-2.715, P&lt;0.01). Meanwhile, after treatment with secondary antihistamine drug, the patients with lower CRP levels showed better responses than those with higher CRP levels [(2.5764+/-2.5059) and (3.6715+/-4.7732) mg/dL respectively; t=-2.187, P&lt;0.05]. Conclusion: Serum CRP level before the treatment may be correlated with the severity of chronic spontaneous urticaria and efficacy of treatment</style></abstract><notes><style face="normal" font="default">DA - 20170303IS - 1672-7347 (Print)IS - 1672-7347 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.11817/j.issn.1672-7347.2017.02.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28255118">PM:28255118</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Zhong Nan Da Xue Xue Bao Yi Xue Ban\2017-42-168-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Zhong Nan Da Xue Xue Bao Yi Xue Ban\2017-42-168-72.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170303, Yan S</style></custom2><misc3><style face="normal" font="default">10.11817/j.issn.1672-7347.2017.02.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40980</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Reese,I.</style></author><author><style face="normal" font="default"> Ballmer-Weber,B.</style></author><author><style face="normal" font="default"> Beyer,K.</style></author><author><style face="normal" font="default"> Fuchs,T.</style></author><author><style face="normal" font="default"> Kleine-Tebbe,J.</style></author><author><style face="normal" font="default"> Klimek,L.</style></author><author><style face="normal" font="default"> Lepp,U.</style></author><author><style face="normal" font="default"> Niggemann,B.</style></author><author><style face="normal" font="default"> Saloga,J.</style></author><author><style face="normal" font="default"> Schafer,C.</style></author><author><style face="normal" font="default"> Werfel,T.</style></author><author><style face="normal" font="default"> Zuberbier,T.</style></author><author><style face="normal" font="default"> Worm,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical Nutrition Therapy, Munich, Germany</style></auth-address><titles><title><style face="normal" font="default">German guideline for the management of adverse reactions to ingested histamine: Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Association of Allergologists (AeDA), and the Swiss Society for Allergology and Immunology (SGAI)</style></title><secondary-title><style face="normal" font="default">Allergo J Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergo J Int</style></abbr-1></periodical><pages end="79" start="72">72-79</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Ingestion</style></keyword><keyword><style face="normal" font="default"> Internet</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Adverse food reactions are far more often perceived than objectively verified. In our scientific knowledge on non-allergic adverse reactions including the so called histamine intolerance, there are large deficits. Due to the fact that this disorder is increasingly discussed in the media and the internet, more and more people suspect it to be the trigger of their symptoms. The scientific evidence to support the postulated link between ingestion of histamine and adverse reactions is limited, and a reliable laboratory test for objective diagnosis is lacking. This position paper by the "Food Allergy" Working Group of the German Society for Allergology and Clinical Immunology (DGAKI) in collaboration with the German Association of Allergologists (AeDA), the Society for Pediatric Allergology and Environmental Medicine (GPA), and the Swiss Society for Allergology and Immunology (SGAI) reviews the data on the clinical picture of adverse reactions to ingested histamine, summarizes important aspects and their consequences, and proposes a practical diagnostic and therapeutic approach</style></abstract><notes><style face="normal" font="default">DA - 20170327IS - 2197-0378 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1007/s40629-017-0011-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28344921">PM:28344921</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergo J Int\2017-26-72-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergo J Int\2017-26-72-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170327, Reese I</style></custom2><misc3><style face="normal" font="default">10.1007/s40629-017-0011-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40981</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Girbovan,A.</style></author><author><style face="normal" font="default"> Sur,G.</style></author><author><style face="normal" font="default"> Samasca,G.</style></author><author><style face="normal" font="default"> Lupan,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania</style></auth-address><titles><title><style face="normal" font="default">Is the evidence of breast feeding protection against coeliac disease real?</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Breast</style></keyword><keyword><style face="normal" font="default"> Breast Feeding</style></keyword><keyword><style face="normal" font="default"> Breast-feeding</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Romania</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="default">Many recent studies discredit breastfeeding protection against coeliac disease. We will try to answer the question: "Is the evidence of breast feeding protection against coeliac disease real?"</style></abstract><notes><style face="normal" font="default">DA - 20170415IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Romania -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.01.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28410871">PM:28410871</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170415-GirbovanA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170415-GirbovanA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170415, Girbovan A</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.01.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40982</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,Y.</style></author><author><style face="normal" font="default"> Wang,L.</style></author><author><style face="normal" font="default"> Hua,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Pediatrics, The First Hospital of Jilin University, Changchun, China</style></auth-address><titles><title><style face="normal" font="default">Interleukin-33 in children with asthma: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Early Diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Interleukin-33</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Software</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Previous studies have shown that serum interleukin 33 serving as an "alarmin" is increased in children with asthma. The objective of this study was to assess the validity of serum IL33 test for early diagnosis of childhood asthma. METHODS: A literature search was performed in June 2016 using PubMed, Embase, the Cochrane Library and other Chinese Medical Databases to identify studies. The search terms used were "cytokine", "interleukin-33", "asthma" and "children". The meta-analysis was performed using Review Manager 5.3 software. Random-effects model was used to estimate the standardized mean differences (SMDs) with 95% confidence intervals (CIs). RESULTS: A total of eight studies were included into this meta-analysis, involving 330 asthmatic children and 248 healthy children. The meta-analysis results revealed that the serum IL33 level was higher in asthmatic children compared to that in healthy children (SMD=1.29, 95%CI=0.53-2.05, P=0.0009), with significant heterogeneity across studies (I2=94% and P&lt;0.00001). CONCLUSIONS: The meta-analysis showed that serum IL33 is a helpful biomarker for early diagnosis of childhood asthma. However, owing to lack of enough data, the increased serum concentration of IL33 cannot be an indicator for the asthma severity</style></abstract><notes><style face="normal" font="default">DA - 20170415IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2016.12.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28410870">PM:28410870</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170415-WangY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170415-WangY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170415, Wang Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2016.12.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40983</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Verduci,E.</style></author><author><style face="normal" font="default"> Martelli,A.</style></author><author><style face="normal" font="default"> Miniello,V.L.</style></author><author><style face="normal" font="default"> Landi,M.</style></author><author><style face="normal" font="default"> Mariani,B.</style></author><author><style face="normal" font="default"> Brambilla,M.</style></author><author><style face="normal" font="default"> Diaferio,L.</style></author><author><style face="normal" font="default"> Peroni,D.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Paediatrics, San Paolo Hospital, Department of Health Sciences, University of Milan, Italy.</style></auth-address><titles><title><style face="normal" font="default">Nutrition in the first 1000 days and respiratory health: A descriptive review of the last five years' literature</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergenic</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergic sensitisation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> Epigenetics</style></keyword><keyword><style face="normal" font="default"> Exposition</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lactation</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Micronutrients</style></keyword><keyword><style face="normal" font="default"> Milk</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> Nutrients</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> paediatrics</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> respiratory infection</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Sensitisation</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="12" Month="4" Year="2017">2017/4/12</year></dates><abstract><style face="normal" font="default">The aim of this paper is to discuss the current evidence regarding short and long-term health respiratory effects of nutrients and dietary patterns during the first 1000 days from conception. Population of interest included children from birth to two years and their mothers (during pregnancy and lactation). Studies were searched on MEDLINE(R) and Cochrane database, inserting individually and using the Boolean ANDs and ORs, 'nutrients', 'micronutrients', 'LC-PUFA', 'Mediterranean Diet', 'human milk', 'complementary food', 'pregnancy', 'respiratory disease', 'pulmonary disease', 'asthma', 'epigenetics', 'first 1000 days', 'maternal diet' and 'respiratory health'. All sources were retrieved between 01-09-2015 and 07-12-2016. While unhealthy maternal dietary patterns (high fat intake) during pregnancy can result in alteration of foetal lung development, with increased risk of respiratory disorders, Mediterranean diet has been associated with a lower risk of allergic sensitisation and allergic rhinitis. Breastfeeding has beneficial effects on respiratory infections while evidences about its protective effect on allergic disorders are unclear. During complementary feeding there is no evidence to avoid or encourage exposition to 'highly allergenic' foods to have modification of tolerance development. In children from birth to two years of age, Mediterranean diet has been associated with a lower risk of atopy, wheezing and asthma. Micronutrients, antioxidant and LCPUFA supplementation is not recommended and a whole food approach should be preferred, except for Vitamin D</style></abstract><notes><style face="normal" font="default">DA - 20170416IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.01.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28411961">PM:28411961</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170416-VerduciE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170416-VerduciE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170416, Verduci E</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.01.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40984</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Park,H.K.</style></author><author><style face="normal" font="default"> Kang,M.G.</style></author><author><style face="normal" font="default"> Yang,M.S.</style></author><author><style face="normal" font="default"> Jung,J.W.</style></author><author><style face="normal" font="default"> Cho,S.H.</style></author><author><style face="normal" font="default"> Kang,H.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea</style></auth-address><titles><title><style face="normal" font="default">Epidemiology of drug-induced anaphylaxis in a tertiary hospital in Korea</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug-induced</style></keyword><keyword><style face="normal" font="default"> Drug-induced anaphylaxis</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> iodinated contrast</style></keyword><keyword><style face="normal" font="default"> iodinated contrast media</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Neuromuscular blocking agent</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacovigilance</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Platinum</style></keyword><keyword><style face="normal" font="default"> Platinum Compounds</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="10" Month="3" Year="2017">2017/3/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Epidemiology and risk factors of drug-induced anaphylaxis are difficult to estimate due to lack of confirmative diagnosis and under reporting. Here we report the current state of drug-induced anaphylaxis in Korea based on an in-hospital pharmacovigilance database in a tertiary hospital. METHODS: This study is a retrospective analysis of drug-induced anaphylaxis, reported to an in-hospital pharmacovigilance center in Seoul National University Hospital from June 2009 to May 2013. Anaphylaxis occurred in patients under 18 years of age or developed by medications administered from outside pharmacies or hospitals were excluded. We assessed causative drug, incidence per use of each drug and risk factors of fatal anaphylactic shock. RESULTS: A total of 152 in-hospital drug-induced anaphylaxis cases were reported during the study period. The single most frequently reported drug was platinum compound and the incidence of anaphylaxis and anaphylactic shock in platinum compounds users was 2.84 and 1.39 per 1000 patients use. Risk factors of anaphylactic shock among total anaphylaxis cases were identified as older age >/=70 years [Odd's ratio (OR), 5.86; 95% confidence interval (CI), 1.70-20.14]. The use of iodinated contrast media (OR, 6.19; 95% CI, 1.87-20.53) and aminosteroid neuromuscular blocking agent (NMBA) (OR, 12.82; 95% CI, 1.50-109.92) were also a risk factor for the development of anaphylactic shock. CONCLUSIONS: Platinum compounds are the most commonly reported causative agents of in-hospital drug-induced anaphylaxis. Older age >/=70 years and drugs such as iodinated contrast media and aminosteroid NMBA are related with high risk of anaphylactic shock</style></abstract><notes><style face="normal" font="default">DA - 20170314IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.02.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28291680">PM:28291680</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170314-ParkHK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170314-ParkHK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170314, Park HK</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.02.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40985</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kanazawa,J.</style></author><author><style face="normal" font="default"> Masuko,H.</style></author><author><style face="normal" font="default"> Yatagai,Y.</style></author><author><style face="normal" font="default"> Sakamoto,T.</style></author><author><style face="normal" font="default"> Yamada,H.</style></author><author><style face="normal" font="default"> Kaneko,Y.</style></author><author><style face="normal" font="default"> Kitazawa,H.</style></author><author><style face="normal" font="default"> Iijima,H.</style></author><author><style face="normal" font="default"> Naito,T.</style></author><author><style face="normal" font="default"> Saito,T.</style></author><author><style face="normal" font="default"> Noguchi,E.</style></author><author><style face="normal" font="default"> Konno,S.</style></author><author><style face="normal" font="default"> Nishimura,M.</style></author><author><style face="normal" font="default"> Hirota,T.</style></author><author><style face="normal" font="default"> Tamari,M.</style></author><author><style face="normal" font="default"> Hizawa,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonary Medicine, University of Tsukuba, Tsukuba, Japan</style></auth-address><titles><title><style face="normal" font="default">Genetic association of the functional CDHR3 genotype with early-onset adult asthma in Japanese populations</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Adult asthma</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> association studies</style></keyword><keyword><style face="normal" font="default"> association study</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> candidate gene</style></keyword><keyword><style face="normal" font="default"> case-control association study</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic Association</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human rhinovirus</style></keyword><keyword><style face="normal" font="default"> Infancy</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Medicine</style></keyword><keyword><style face="normal" font="default"> Rhinovirus</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral infection</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Recent studies have demonstrated that a coding SNP (rs6967330, Cys529-->Tyr) in cadherin-related family member 3 (CDHR3), which was previously associated with wheezing illness and hospitalizations in infancy, could support efficient human rhinovirus C (RV-C) entry and replication. Here, we sought to examine the genetic contribution of this variant to the development of adult asthma. METHODS: We performed a candidate gene case-control association study of 2 independent Japanese populations (a total of 3366 adults). The odds ratios (ORs) for association of the A allele at rs6967330 with adult asthma were calculated according to age at onset of asthma. In addition, the effect of the CDHR3 genotype on the development of specific asthma phenotypes was examined. RESULTS: The A allele was associated with asthma (OR = 1.56; Mantel-Haenszel p = 0.0040) when the analysis was limited to patients with early-onset adult asthma. In addition, when the analysis was limited to atopic individuals, a stronger association of the CDHR3 variant with early-onset asthma was found, and interaction of the CDHR3 genotype with atopy was demonstrated. Finally, a significant association of this variant was specifically found with a phenotype of asthma characterized by atopy, early-onset, and lower lung function. CONCLUSIONS: Our study supports the concept that the CDHR3 variant is an important susceptibility factor for severe adult asthma in individuals who develop the disease in early life. The interaction between the CDHR3 variant and atopy indicates that genetic predisposition to early respiratory viral infection is combined with atopy in promoting asthma</style></abstract><notes><style face="normal" font="default">DA - 20170320IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.02.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28318885">PM:28318885</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170320-KanazawaJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170320-KanazawaJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Kanazawa J</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.02.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40986</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ito,S.</style></author><author><style face="normal" font="default"> Wakahara,K.</style></author><author><style face="normal" font="default"> Kojima,T.</style></author><author><style face="normal" font="default"> Takahashi,N.</style></author><author><style face="normal" font="default"> Nishiwaki,K.</style></author><author><style face="normal" font="default"> Yamaguchi,E.</style></author><author><style face="normal" font="default"> Hasegawa,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.</style></auth-address><titles><title><style face="normal" font="default">Two cases of autoimmune pulmonary alveolar proteinosis with rheumatoid arthritis</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Arthritis</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Alveolar Proteinosis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="24" Month="2" Year="2017">2017/2/24</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170228IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.02.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28242199">PM:28242199</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170228-ItoS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170228-ItoS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170228, Ito S</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.02.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40987</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Suzuki,K.</style></author><author><style face="normal" font="default"> Meguro,K.</style></author><author><style face="normal" font="default"> Nakagomi,D.</style></author><author><style face="normal" font="default"> Nakajima,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan.</style></auth-address><titles><title><style face="normal" font="default">Roles of alternatively activated M2 macrophages in allergic contact dermatitis</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal model</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Repair</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> suppression</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="17" Month="3" Year="2017">2017/3/17</year></dates><abstract><style face="normal" font="default">Alternatively activated macrophages (M2 macrophages) play key roles in the suppression of Th1 cell responses and the orchestration of tissue repair. However, recent studies have shown that M2 macrophages have potentials to produce high levels of proinflammatory cytokines such as IL-1beta, IL-6, and TNF-alpha, suggesting that M2 macrophages may exacerbate inflammation in some settings. In this regard, we have recently shown that large numbers of M2 macrophages accumulate in the sites of hapten-induced contact hypersensitivity (CHS), an animal model of allergic contact dermatitis, and that M2 macrophages exacerbate hapten-induced CHS by producing matrix metalloproteinase 12 (MMP12). We have also shown that suppressor of cytokine signaling-3 (SOCS3), a member of SOCS family proteins that are cytokine-inducible negative regulators of the JAK/STAT signaling pathways, is highly and preferentially expressed in M2 macrophages in hapten-induced CHS and that SOCS3 expressed in M2 macrophages is involved in the attenuation of CHS by suppressing MMP12 production. These findings underscore the importance of M2 macrophage-derived MMP12 in the development of CHS, and suggest that inhibition of M2 macrophages or MMP12 could be a potential therapeutic strategy for the treatment of allergic contact dermatitis</style></abstract><notes><style face="normal" font="default">DA - 20170321IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.02.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28320580">PM:28320580</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170321-SuzukiK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170321-SuzukiK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170321, Suzuki K</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.02.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40988</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tanaka,A.</style></author><author><style face="normal" font="default"> Uno,T.</style></author><author><style face="normal" font="default"> Sato,H.</style></author><author><style face="normal" font="default"> Jinno,M.</style></author><author><style face="normal" font="default"> Hirai,K.</style></author><author><style face="normal" font="default"> Miyata,Y.</style></author><author><style face="normal" font="default"> Yamaguchi,M.</style></author><author><style face="normal" font="default"> Ohta,S.</style></author><author><style face="normal" font="default"> Homma,T.</style></author><author><style face="normal" font="default"> Yamamoto,M.</style></author><author><style face="normal" font="default"> Suzuki,S.</style></author><author><style face="normal" font="default"> Yokoe,T.</style></author><author><style face="normal" font="default"> Sagara,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Division of Respiratory Medicine and Allergology, Showa University, School of Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default">Predicting future risk of exacerbations in Japanese patients with adult asthma: A prospective 1-year follow up study</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> ACT Score</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Adult asthma</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Comparative Study</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: To avoid future risk is a definitive goal of long-term asthma management. Exacerbations are considered to be the most relevant future risk in real life asthma management. Few comparative studies have evaluated the risk factors associated with exacerbations in Japanese patients with asthma. METHODS: We performed the prospective 1-year follow up study in Japanese patients with adult asthma. A total of 189 patients with asthma were enrolled and followed up for 1 year. Finally, 181 patients completed the study protocol. RESULTS: Of 181 patients, 43 patients (23.8%) had exacerbations during the follow-up period. Among the 45 patients who had exacerbations during the preceding year, 32 patients (71.1%) had exacerbations. Prevalence of patients with previous exacerbations and those with previous admissions were significantly higher in patients with exacerbations than those with no exacerbation. Logistic regression analysis also identified a significant association between exacerbations during the follow-up period and exacerbations during the preceding year, admissions during the preceding 3 years, ACT score below 20, low %FVC (&lt;80%), or low FEV1 (&lt;70%), respectively. Of the 55 patients with severe asthma, 29 patients (52.7%) had exacerbations. Among the 36 patients with severe asthma with previous exacerbations, 26 patients (72.2%) had exacerbations. The history of exacerbations during the preceding year was associated with a significantly increased risk of exacerbations both among the patients with severe asthma and those with non-severe asthma. CONCLUSIONS: This study implicated that exacerbations during the preceding year reliably predict future risk of exacerbations in Japanese patients with asthma</style></abstract><notes><style face="normal" font="default">DA - 20170320IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.02.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28318883">PM:28318883</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170320-TanakaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170320-TanakaA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Tanaka A</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.02.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40989</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shimoda,T.</style></author><author><style face="normal" font="default"> Obase,Y.</style></author><author><style face="normal" font="default"> Nagasaka,Y.</style></author><author><style face="normal" font="default"> Nakano,H.</style></author><author><style face="normal" font="default"> Kishikawa,R.</style></author><author><style face="normal" font="default"> Iwanaga,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical Research Center, Fukuoka National Hospital, Fukuoka, Japan.</style></auth-address><titles><title><style face="normal" font="default">Airway inflammation phenotype prediction in asthma patients using lung sound analysis with fractional exhaled nitric oxide</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Airway Obstruction</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> induced sputum</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung sound analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> sputum eosinophil</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: We previously reported the results of lung sound analysis in patients with bronchial asthma and demonstrated that the exhalation-to-inhalation sound pressure ratio in the low frequency range between 100 and 200 Hz (E/I LF) was correlated with the presence of airway inflammation and airway obstruction. We classified asthma patients by airway inflammation phenotype using the induced sputum eosinophil and neutrophil ratio and determined whether this phenotype could be predicted using E/I LF and fractional exhaled nitric oxide values. METHODS: Steroid-naive bronchial asthma patients were classified into four phenotypes, including "Low inflammation" (35 patients), "Eosinophilic type" (58 patients), "Neutrophilic type" (15 patients), and "Mixed type" (15 patients) based on the results of induced sputum examinations. The E/I LF data and FeNO levels were then evaluated for the four phenotype groups; the prediction powers of these two indices were then analyzed for each phenotype. RESULTS: The median E/I LF value was highest in the "Mixed type" and lowest in the "Low inflammation" group. FeNO differentiated between the "Low inflammation" and "Eosinophilic type" groups, "Low inflammation" and "Neutrophilic type" groups, and "Neutrophilic type" and "Mixed type" (p &lt; 0.0001, p = 0.007, and p = 0.04, respectively). E/I LF differentiated between the "Low inflammation" and "Eosinophilic type" groups (p = 0.006). E/I LF could distinguish the "Mixed type" group from the "Low inflammation" and "Eosinophilic type" groups (p = 0.002). CONCLUSIONS: A combination of the E/I LF value and FeNO may be useful for the classification of the airway inflammation phenotype in patients with bronchial asthma</style></abstract><notes><style face="normal" font="default">DA - 20170320IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.02.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28318886">PM:28318886</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170320-ShimodaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170320-ShimodaT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Shimoda T</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.02.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40990</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tsukioka,K.</style></author><author><style face="normal" font="default"> Koya,T.</style></author><author><style face="normal" font="default"> Ueno,H.</style></author><author><style face="normal" font="default"> Hayashi,M.</style></author><author><style face="normal" font="default"> Sakagami,T.</style></author><author><style face="normal" font="default"> Hasegawa,T.</style></author><author><style face="normal" font="default"> Arakawa,M.</style></author><author><style face="normal" font="default"> Suzuki,E.</style></author><author><style face="normal" font="default"> Kikuchi,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan</style></auth-address><titles><title><style face="normal" font="default">Phenotypic analysis of asthma in Japanese athletes</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Athlete</style></keyword><keyword><style face="normal" font="default"> Athletes</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cluster Analysis</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> fraction of exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Pretreatment</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> pulmonary function test</style></keyword><keyword><style face="normal" font="default"> Pulmonary function tests</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Sport</style></keyword><keyword><style face="normal" font="default"> Sports</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="12" Month="3" Year="2017">2017/3/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma in athlete populations such as Olympic athletes has various pathogeneses. However, few reports are available on the features of asthma in the athlete population in clinical practice. In this study, we focused on classifying asthma in Japanese athlete population. METHODS: We performed a cluster analysis of data from pulmonary function tests and clinical biomarkers before administering inhaled corticosteroids (ICS) therapy in athlete population of individuals diagnosed with asthma (n = 104; male, 76.9%; median age, 16.0 years), based on respiratory symptoms and positive data on methacholine provocation tests. We also compared backgrounds, sports types, and treatments between clusters. RESULTS: Three clusters were identified. Cluster 1 (32%) comprised athletes with a less atopic phenotype and normal pulmonary function. Cluster 2 (44%) comprised athletes with a less atopic phenotype and lower percent predicted forced expiratory volume in 1 s (%FEV1) values, despite less symptomatic state. Cluster 3 (24%) comprised athletes with a strong atopic phenotype such as high eosinophil count in the blood and total serum immunoglobulin E level. After treatment with ICS or ICS plus long-acting beta-adrenergic receptor agonist for 6-12 months, %FEV1 values were significantly improved in Cluster 2 athletes, whereas Cluster 3 athletes had a significant decrease in the fraction of exhaled nitric oxide compared to pretreatment values. CONCLUSIONS: These data suggest three clusters exist in Japanese athlete population with asthma. Between the clusters, the characteristics differed with regard to symptoms, atopic features, and lower %FEV1 values. The pathogeneses between clusters may vary depending on the inflammation type and airway hyperresponsiveness</style></abstract><notes><style face="normal" font="default">DA - 20170316IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.02.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28298259">PM:28298259</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170316-TsukiokaK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170316-TsukiokaK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170316, Tsukioka K</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.02.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40991</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gon,Y.</style></author><author><style face="normal" font="default"> Maruoka,S.</style></author><author><style face="normal" font="default"> Ito,R.</style></author><author><style face="normal" font="default"> Mizumura,K.</style></author><author><style face="normal" font="default"> Kozu,Y.</style></author><author><style face="normal" font="default"> Hiranuma,H.</style></author><author><style face="normal" font="default"> Hattori,T.</style></author><author><style face="normal" font="default"> Takahashi,M.</style></author><author><style face="normal" font="default"> Hikichi,M.</style></author><author><style face="normal" font="default"> Hashimoto,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Respiratory Medicine, Nihon University School of Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default">Utility of serum YKL-40 levels for identification of patients with asthma and COPD</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="9" Month="3" Year="2017">2017/3/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170313IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.02.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28285848">PM:28285848</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170313-GonY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170313-GonY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170313, Gon Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.02.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40992</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tamagawa-Mineoka,R.</style></author><author><style face="normal" font="default"> Nakamura,N.</style></author><author><style face="normal" font="default"> Ueda,S.</style></author><author><style face="normal" font="default"> Masuda,K.</style></author><author><style face="normal" font="default"> Katoh,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.</style></auth-address><titles><title><style face="normal" font="default">Patch testing in patients with recurrent vesicular hand eczema</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Dermatology</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand eczema</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="2" Month="4" Year="2017">2017/4/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170406IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.03.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28381367">PM:28381367</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170406-TamagawaMineokaR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170406-TamagawaMineokaR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170406, Tamagawa-Mineoka R</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.03.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40993</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hotta,E.</style></author><author><style face="normal" font="default"> Tamagawa-Mineoka,R.</style></author><author><style face="normal" font="default"> Masuda,K.</style></author><author><style face="normal" font="default"> Katoh,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan</style></auth-address><titles><title><style face="normal" font="default">Pustular allergic contact dermatitis caused by Disperse Yellow 3 in a dark blue dress</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> DRESS</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="30" Month="3" Year="2017">2017/3/30</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170403IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.03.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28366676">PM:28366676</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170403-HottaE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170403-HottaE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170403, Hotta E</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.03.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40994</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nagasaki,T.</style></author><author><style face="normal" font="default"> Matsumoto,H.</style></author><author><style face="normal" font="default"> Izuhara,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan</style></auth-address><titles><title><style face="normal" font="default">Utility of serum periostin in combination with exhaled nitric oxide in the management of asthma</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> fraction of exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Periostin</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="27" Month="2" Year="2017">2017/2/27</year></dates><abstract><style face="normal" font="default">Type-2/eosinophilic inflammation plays a pivotal role in asthma. The identification of severe type-2/eosinophilic asthma is important for improving the management of patients with asthma. Therefore, efforts to develop non-invasive biomarkers for type-2/eosinophilic airway inflammation have been made during this decade. Currently, fraction of exhaled nitric oxide (FeNO) and serum periostin levels are considered markers of type-2/eosinophilic inflammation in asthma. However, a single-marker approach has limited the ability to diagnose severe type-2/eosinophilic asthma accurately and predict disease outcomes precisely. The present article reviews the utility of FeNO and serum periostin levels in a single-marker approach and in a multiple-marker approach in identifying patients with severe type-2/eosinophilic asthma. Furthermore, based on a sub-analysis of the Kinki Hokuriku Airway disease Conference (KiHAC), geno-endo-phenotypes of patients were stratified into four groups according to the FeNO and serum periostin levels</style></abstract><notes><style face="normal" font="default">DA - 20170303IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.02.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28256388">PM:28256388</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170303-NagasakiT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170303-NagasakiT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170303, Nagasaki T</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.02.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40995</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Takita,K.</style></author><author><style face="normal" font="default"> Kondo,R.</style></author><author><style face="normal" font="default"> Horiguchi,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine II, Fujita Health University School of Medicine, Nagoya, Japan.</style></auth-address><titles><title><style face="normal" font="default">Effectiveness of training patients using DVD in the accurate use of inhalers for the treatment of bronchial asthma</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> impulse oscillometry</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> induced sputum</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhalant</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oscillometry</style></keyword><keyword><style face="normal" font="default"> Outpatients</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pilot study</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> sputum eosinophil</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword></keywords><dates><year Day="20" Month="3" Year="2017">2017/3/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: Inhalants are the standard treatment for patients with bronchial asthma. Inaccurate inhaler use leads to inadequate therapeutic effects and unnecessary dosage increases. However, it is a challenge for practitioners to master the various devices available and train patients on the accurate use of inhalers. Thus, establishing a system to instruct patients on how to accurately use inhalers is essential. We prepared a DVD and accompanying user manual explaining the operation of each inhaler device used in Japan. This pilot study aimed to examine the efficacy of these materials. METHODS: The subjects were 33 outpatients with bronchial asthma who received treatment in our facility for asthma and had already received conventional inhalant training. The oral medication and inhalants used by the patients were not changed. The patients were randomly assigned to a DVD viewing group or non-viewing group; various parameters were comparatively examined after 4 weeks. RESULTS: Significant improvements in Asthma Control Test scores, inhalation technique, forced vital capacity, forced expiratory volume in 1 s, impulse oscillometry resonant frequency, and induced sputum eosinophil count were observed in the DVD viewing group at 4 weeks post training. CONCLUSIONS: Pulmonary function and inflammatory parameters improved significantly in the DVD viewing group. These findings suggest that unnecessary step-up of asthma treatment can be avoided, leading to treatment cost reduction. Training patients with asthma in accurate inhaler use improves quality of life and therefore has great clinical significance. Hence, this method should be used more extensively in Japan and worldwide</style></abstract><notes><style face="normal" font="default">DA - 20170324IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.02.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28336254">PM:28336254</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170324-TakitaK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170324-TakitaK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170324, Takita K</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.02.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40996</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kampitak,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Unit, Department of Medicine, Samitivej Sukhumvit Hospital, Bangkok, Thailand.</style></auth-address><titles><title><style face="normal" font="default">Nonepisodic angioedema with eosinophilia: A case series from Thailand</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword></keywords><dates><year Day="25" Month="2" Year="2017">2017/2/25</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170301IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Thailand -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.02.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28245971">PM:28245971</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170301-KampitakT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170301-KampitakT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170301, Kampitak T</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.02.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40997</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kawauchi,T.</style></author><author><style face="normal" font="default"> Ishimaru,K.</style></author><author><style face="normal" font="default"> Nakamura,Y.</style></author><author><style face="normal" font="default"> Nakano,N.</style></author><author><style face="normal" font="default"> Hara,M.</style></author><author><style face="normal" font="default"> Ogawa,H.</style></author><author><style face="normal" font="default"> Okumura,K.</style></author><author><style face="normal" font="default"> Shibata,S.</style></author><author><style face="normal" font="default"> Nakao,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology, University of Yamanashi Faculty of Medicine, Yamanashi, Japan</style></auth-address><titles><title><style face="normal" font="default">Clock-dependent temporal regulation of IL-33/ST2-mediated mast cell response</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">association</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Down-Regulation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Interleukin 1</style></keyword><keyword><style face="normal" font="default"> Interleukin-1</style></keyword><keyword><style face="normal" font="default"> Interleukin-33</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Kinetics</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Mammals</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophil Infiltration</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Peritoneal Cavity</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Promoter</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> ST2</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="3" Year="2017">2017/3/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Interleukin-33 (IL-33) is an alarmin cytokine that binds to the interleukin 1 receptor-like 1 protein ST2. Clock is a key circadian gene that is essential for endogenous clockworks in mammals. This study investigated whether Clock temporally regulated IL-33-mediated responses in mast cells. METHODS: The kinetics of IL-33-mediated IL-6, IL-13, and TNF-alpha productions were compared between bone marrow-derived mast cells (BMMCs) from wild-type and Clock-mutated mice (ClockDelta19/Delta19 mice). The kinetics of the neutrophil influx into the peritoneal cavity or expression of IL-13 and Gob-5 in the lung in response to IL-33 were compared between wild-type and ClockDelta19/Delta19 mice. We also examined the kinetics of ST2 expression in mast cells and its association with Clock expression. RESULTS: There was a time-of-day-dependent variation in IL-33-mediated IL-6, IL-13, and TNF-alpha production in wild-type BMMCs, which was absent in Clock-mutated BMMCs. IL-33-induced neutrophil infiltration into the peritoneal cavity also showed a time-of-day-dependent variation in wild-type mice, which was absent in ClockDelta19/Delta19 mice. Furthermore, IL-33-induced IL-13 and Gob-5 expression in the lung exhibited a time-of-day-dependent variation in wild-type mice. These temporal variations in IL-33-mediated mast cell responses were associated with temporal variations of ST2 expression in mast cells. In addition, CLOCK bound to the promoter region of ST2 and Clock deletion resulted in down-regulation of ST2 expression in mast cells. CONCLUSIONS: CLOCK temporally gates mast cell responses to IL-33 via regulation of ST2 expression. Our findings provide novel insights into IL-33/mast cell-associated physiology and pathologies</style></abstract><notes><style face="normal" font="default">DA - 20170305IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.02.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28259547">PM:28259547</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170305-KawauchiT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170305-KawauchiT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170305, Kawauchi T</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.02.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40998</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ntontsi,P.</style></author><author><style face="normal" font="default"> Loukides,S.</style></author><author><style face="normal" font="default"> Bakakos,P.</style></author><author><style face="normal" font="default"> Kostikas,K.</style></author><author><style face="normal" font="default"> Papatheodorou,G.</style></author><author><style face="normal" font="default"> Papathanassiou,E.</style></author><author><style face="normal" font="default"> Hillas,G.</style></author><author><style face="normal" font="default"> Koulouris,N.</style></author><author><style face="normal" font="default"> Papiris,S.</style></author><author><style face="normal" font="default"> Papaioannou,A.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">2nd Respiratory Medicine Department, University of Athens, Attikon Hospital</style></auth-address><titles><title><style face="normal" font="default">Clinical, functional and inflammatory characteristics in patients with pauci-granulocytic stable asthma: comparison with different sputum phenotypes</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Cell Count</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> ECP</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> induced sputum</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> pulmonary function test</style></keyword><keyword><style face="normal" font="default"> Pulmonary function tests</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="13" Month="4" Year="2017">2017/4/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: According to induced sputum cell count, four different asthma phenotypes have been recognised(eosinophilic, neutrophilic, mixed and pauci-granulocytic). The aim of the present study was to detect functional and inflammatory characteristics of patients with pauci-granulocytic asthma. METHODS: 240 asthmatic patients were categorised in the four phenotypes according to cell counts in induced sputum. All patients underwent pulmonary function tests, and measurement of FeNO. The levels of IL-8, IL-13, and ECP were also measured in sputum supernatant. Treatment, asthma control and the presence of Severe Refractory Asthma(SRA) were also recorded. RESULTS: Patients were categorized in the four phenotypes as follows: eosinophilic (40%), mixed (6.7%), neutrophilic (5.4%) and pauci-granulocytic (47.9%). Although ACT did not differ between groups (p=0.288) patients with pauci-granulocytic asthma had better lung function (FEV1 %pred) (median (IQR):71.5(59.0-88.75) vs 69.0(59.0-77.6) vs 68.0(60.0-85.5) vs 80.5(69.7-95.0), p=0.009] for eosinophilic, mixed, neutrophilic and pauci-granulocytic asthma respectively, p=0.009). SRA occurred more frequently in the eosinophilic and mixed phenotype (41.6% and 43.7% respectively) and less frequently in the neutrophilic and pauci-granulocytic phenotype (25% and 21.7% respectively, p=0.01). FeNO, ECP and IL-8 were all low in the pauci-granulocytic, whereas as expected FeNO and ECP were higher in eosinophilic and mixed asthma, while IL-8 was higher in patients with neutrophilic and mixed asthma(p&lt;0.001 for all comparisons). Interestingly, 14.8% of patients with pauci-granulocytic asthma had poor asthma control. CONCLUSION: Pauci-granulocytic asthma most likely represents a "benign" asthma phenotype, related to a good response to treatment, rather than a "true" phenotype of asthma. However, pauci-granulocytic patients that remain not-well-controlled despite optimal treatment represent an asthmatic population that requires further study for potential novel targeted interventions. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170413IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="default">10.1111/all.13184</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28407269">PM:28407269</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170413-NtonsiP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170413-NtonsiP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170413, Ntontsi P</style></custom2><misc3><style face="normal" font="default">10.1111/all.13184</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>40999</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">James,A.</style></author><author><style face="normal" font="default"> Janson,C.</style></author><author><style face="normal" font="default"> Malinovschi,A.</style></author><author><style face="normal" font="default"> Holweg,C.</style></author><author><style face="normal" font="default"> Alving,K.</style></author><author><style face="normal" font="default"> Ono,J.</style></author><author><style face="normal" font="default"> Ohta,S.</style></author><author><style face="normal" font="default"> Ek,A.</style></author><author><style face="normal" font="default"> Middelveld,R.</style></author><author><style face="normal" font="default"> Dahlen,B.</style></author><author><style face="normal" font="default"> Forsberg,B.</style></author><author><style face="normal" font="default"> Izuhara,K.</style></author><author><style face="normal" font="default"> Dahlen,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Experimental Asthma and Allergy Research, National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default">Serum periostin relates to type-2 inflammation and lung function in asthma; data from the large population-based cohort Swedish GA(2)LEN</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> cationic protein</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Periostin</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Periostin has been suggested as a novel, phenotype-specific biomarker for asthma driven by type-2 inflammation. However, large studies examining relationships between circulating periostin and patient characteristics are lacking and the suitability of periostin as a biomarker in asthma remains unclear. AIM: To examine circulating periostin in healthy controls and subjects with asthma from the general population with different severity and treatment profiles, both with and without chronic rhinosinusitis (CRS), in relation to other biomarkers and clinical characteristics. METHODS: Serum periostin was examined by ELISA in 1091 subjects aged 17-76 from the Swedish GA(2)LEN study, which included 460 asthmatics with/without chronic rhinosinusitis (CRS), 97 individuals with CRS only, and 203 healthy controls. Clinical tests included measurement of lung function, FeNO, IgE, urinary eosinophil derived neurotoxin (U-EDN) and serum eosinophil cationic protein (S-ECP), as well as completion of questionnaires regarding respiratory symptoms, medication and quality of life. RESULTS: Although median periostin values showed no differences when comparing disease groups with healthy controls, multiple regression analyses revealed that periostin was positively associated with higher FeNO, U-EDN and total IgE. In patients with asthma, an inverse relationship with lung function was also observed. Current smoking was associated with decreased periostin levels, whereas increased age and lower BMI related to higher periostin levels in subjects both with and without asthma. CONCLUSION: We confirm associations between periostin and markers of type-2 inflammation, as well as lung function, and identify novel constitutional factors of importance to the use of periostin as a phenotype-specific biomarker in asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - United States -CO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/all.13181</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28398635">PM:28398635</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170411-JamesA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170411-JamesA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, James A</style></custom2><misc3><style face="normal" font="default">10.1111/all.13181</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41000</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hellings,P.W.</style></author><author><style face="normal" font="default"> Fokkens,W.J.</style></author><author><style face="normal" font="default"> Bachert,C.</style></author><author><style face="normal" font="default"> Akdis,C.A.</style></author><author><style face="normal" font="default"> Bieber,T.</style></author><author><style face="normal" font="default"> Agache,I.</style></author><author><style face="normal" font="default"> Bernal-Sprekelsen,M.</style></author><author><style face="normal" font="default"> Canonica,G.W.</style></author><author><style face="normal" font="default"> Gevaert,P.</style></author><author><style face="normal" font="default"> Joos,G.</style></author><author><style face="normal" font="default"> Lund,V.</style></author><author><style face="normal" font="default"> Muraro,A.</style></author><author><style face="normal" font="default"> Onerci,M.</style></author><author><style face="normal" font="default"> Zuberbier,T.</style></author><author><style face="normal" font="default"> Pugin,B.</style></author><author><style face="normal" font="default"> Seys,S.F.</style></author><author><style face="normal" font="default"> Bousquet,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology-Head and Neck Surgery, UZ, Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="default">Positioning the Principles of Precision Medicine in Care Pathways for Allergic Rhinitis and Chronic Rhinosinusitis - an EUFOREA-ARIA-EPOS-AIRWAYS ICP statement</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> Algorithms</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Biological treatment</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Consensus</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient Care</style></keyword><keyword><style face="normal" font="default"> Patient Participation</style></keyword><keyword><style face="normal" font="default"> Patient Satisfaction</style></keyword><keyword><style face="normal" font="default"> PM</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Romania</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="17" Month="3" Year="2017">2017/3/17</year></dates><abstract><style face="normal" font="default">Precision medicine (PM) is increasingly recognized as the way forward for optimizing patient care. Introduced in the field of oncology, it is now considered of major interest in other medical domains like allergy and chronic airway diseases, which face an urgent need to improve the level of disease control, enhance patient satisfaction and increase effectiveness of preventive interventions. The combination of personalized care, prediction of treatment success, prevention of disease and patient participation in the elaboration of the treatment plan is expected to substantially improve the therapeutic approach for individuals suffering from chronic disabling conditions. Given the emerging data on the impact of patient stratification on treatment outcomes, European and American regulatory bodies support the principles of PM and its potential advantage over current treatment strategies. The aim of the current document is to propose a consensus on the position and gradual implementation of the principles of PM within existing adult treatment algorithms for allergic rhinitis (AR) and chronic rhinosinusitis (CRS). At the time of diagnosis, prediction of success of the initiated treatment and patient participation in the decision of the treatment plan can be implemented. The second level approach ideally involves strategies to prevent progression of disease, in addition to prediction of success of therapy, and patient participation in the long-term therapeutic strategy. Endotype-driven treatment is part of a personalized approach and should be positioned at the tertiary level of care, given the efforts needed for its' implementation and the high cost of molecular diagnosis and biological treatment. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170317IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Netherlands -CO - Sweden -CO - Switzerland -CO - Germany -CO - Romania -CO - Spain -CO - Italy -CO - United Kingdom -CO - Turkey -CO - France -</style></notes><work-type><style face="normal" font="default">10.1111/all.1316</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28306159">PM:28306159</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170317-HellingsPW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170317-HellingsPW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170317, Hellings PW</style></custom2><misc3><style face="normal" font="default">10.1111/all.1316</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41001</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hasegawa,K.</style></author><author><style face="normal" font="default"> Mansbach,J.M.</style></author><author><style face="normal" font="default"> Ajami,N.J.</style></author><author><style face="normal" font="default"> Petrosino,J.F.</style></author><author><style face="normal" font="default"> Freishtat,R.J.</style></author><author><style face="normal" font="default"> Teach,S.J.</style></author><author><style face="normal" font="default"> Piedra,P.A.</style></author><author><style face="normal" font="default"> Camargo,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA</style></auth-address><titles><title><style face="normal" font="default">The relationship between nasopharyngeal CCL5 and microbiota on disease severity among infants with bronchiolitis</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Bronchiolitis</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Emergency Medicine</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Length of Stay</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> prospective cohort study</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="3" Year="2017">2017/3/17</year></dates><abstract><style face="normal" font="default">Emerging evidence suggests that the airway microbiota plays an important role in viral bronchiolitis pathobiology. However, little is known about the combined role of airway microbiota and CCL5 in infants with bronchiolitis. In this multicenter prospective cohort study of 1,005 infants (age &lt;1 year) hospitalized for bronchiolitis during 2011-2014, we observed statistically-significant interactions between nasopharyngeal airway CCL5 levels and microbiota profiles with regard to the risk of both intensive care use (Pinteraction =0.02) and hospital length-of-stay >/=3 days (Pinteraction =0.03). Among infants with lower CCL5 levels, the Haemophilus-dominant microbiota profile was associated with a higher risk of intensive care use (OR, 3.20; 95%CI, 1.18-8.68; P=0.02) and hospital length-of-stay >/=3 days (OR, 4.14; 95%CI, 2.08-8.24; P&lt;0.001) compared to the Moraxella-dominant profile. Conversely, among those with higher CCL5 levels, there were no significant associations between the microbiota profiles and these severity outcomes (all P>/=0.10). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170317IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.13160</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28306146">PM:28306146</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170317-HasegawaK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170317-HasegawaK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170317, Hasegawa K</style></custom2><misc3><style face="normal" font="default">10.1111/all.13160</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41002</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rodriguez-Perez,N.</style></author><author><style face="normal" font="default"> Schiavi,E.</style></author><author><style face="normal" font="default"> Frei,R.</style></author><author><style face="normal" font="default"> Ferstl,R.</style></author><author><style face="normal" font="default"> Wawrzyniak,P.</style></author><author><style face="normal" font="default"> Smolinska,S.</style></author><author><style face="normal" font="default"> Sokolowska,M.</style></author><author><style face="normal" font="default"> Sievi,N.A.</style></author><author><style face="normal" font="default"> Kohler,M.</style></author><author><style face="normal" font="default"> Schmid-Grendelmeier,P.</style></author><author><style face="normal" font="default"> Michalovich,D.</style></author><author><style face="normal" font="default"> Simpson,K.D.</style></author><author><style face="normal" font="default"> Hessel,E.M.</style></author><author><style face="normal" font="default"> Jutel,M.</style></author><author><style face="normal" font="default"> Martin-Fontecha,M.</style></author><author><style face="normal" font="default"> Palomares,O.</style></author><author><style face="normal" font="default"> Akdis,C.A.</style></author><author><style face="normal" font="default"> O'Mahony,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Altered Fatty Acid Metabolism and Reduced Stearoyl-Coenzyme A Desaturase Activity in Asthma</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acids</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Fatty acid</style></keyword><keyword><style face="normal" font="default"> Fatty Acids</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> House dust</style></keyword><keyword><style face="normal" font="default"> house dust mite</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Lipid</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> OVA</style></keyword><keyword><style face="normal" font="default"> Ovalbumin</style></keyword><keyword><style face="normal" font="default"> Ovum</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Protein C</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Fatty acids and lipid mediator signaling play an important role in the pathogenesis of asthma, yet this area remains largely under-explored. The aims of this study were (i) to examine fatty acid levels and their metabolism in obese and non-obese asthma patients and (ii) to determine the functional effects of altered fatty acid metabolism in experimental models. METHODS: Medium- and long-chain fatty acid levels were quantified in serum from 161 human volunteers by LC/MS. Changes in stearoyl-coenzyme A desaturase (SCD) expression and activity was evaluated in the ovalbumin (OVA) and house dust mite (HDM) murine models. Primary human bronchial epithelial cells from asthma patients and controls were evaluated for SCD expression and activity. RESULTS: The serum desaturation index (an indirect measure of SCD) was significantly reduced in non-obese asthma patients and in the OVA murine model. SCD1 gene expression was significantly reduced within the lungs following OVA or HDM challenge. Inhibition of SCD in mice promoted airway hyperresponsiveness. SCD1 expression was suppressed in bronchial epithelial cells from asthma patients. IL-4 and IL-13 reduced epithelial cell SCD1 expression. Inhibition of SCD reduced surfactant protein C expression and suppressed rhinovirus-induced IP-10 secretion, which was associated with increased viral titers. CONCLUSIONS: This is the first study to demonstrate decreased fatty acid desaturase activity in humans with asthma. Experimental models in mice and human epithelial cells suggest that inhibition of desaturase activity leads to airway hyperresponsiveness and reduced anti-viral defense. SCD may represent a new target for therapeutic intervention in asthma patients. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - Poland -CO - United Kingdom -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/all.13180</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28397284">PM:28397284</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170411-RodriguezPerezN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170411-RodriguezPerezN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, Rodriguez-Perez N</style></custom2><misc3><style face="normal" font="default">10.1111/all.13180</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41003</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kopfnagel,V.</style></author><author><style face="normal" font="default"> Wagenknecht,S.</style></author><author><style face="normal" font="default"> Brand,L.</style></author><author><style face="normal" font="default"> Zeitvogel,J.</style></author><author><style face="normal" font="default"> Harder,J.</style></author><author><style face="normal" font="default"> Hofmann,K.</style></author><author><style face="normal" font="default"> Kleine,M.</style></author><author><style face="normal" font="default"> Werfel,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Germany</style></auth-address><titles><title><style face="normal" font="default">RNase 7 downregulates TH2 cytokine production by activated human T-cells</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Electrophoretic Mobility Shift Assay</style></keyword><keyword><style face="normal" font="default"> Epidermis</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microarray</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Mutant</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peptide</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> Recombinant</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Ribonuclease</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> Th2 Cells</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> TH2 cytokines</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="4" Year="2017">2017/4/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: The antimicrobial peptide (AMP) RNase 7 is constitutively expressed in the epidermis of healthy human skin and has been found to be upregulated in chronic inflammatory skin diseases such as atopic dermatitis and psoriasis. Activated T-cells in lesional skin of patients with atopic dermatitis (AD) and psoriasis (PSO) might be directly exposed to RNase 7. In addition to their antimicrobial activity immunoregulatory functions have been published for several AMPs. In this study we investigated immunoregulatory effects of the antimicrobial peptide RNase 7 on activated T-cells. METHODS: Isolated human CD3+ T-cells were stimulated with RNase 7 and screened for possible effects by mRNA microarray analysis. The results of the mRNA microarray were confirmed in isolated CD4+T-cells and in polarised TH2 cells using skin derived native RNase 7 and a recombinant ribonuclease-inactive RNase 7 mutant. Activation of GATA3 was analysed by electrophoretic mobility shift assay. RESULTS: Treatment of activated human CD4+ T-cells and TH2 cells with RNase 7 selectively reduced the expression of TH2 cytokines (IL-13, IL-4 and IL-5). Experiments with a ribonuclease-inactive recombinant RNase 7 mutant showed that RNase 7 ribonuclease activity is dispensable for the observed regulatory effect. We further demonstrate that CD4+T-cells from AD patients revealed a significantly less pronounced downregulation of IL-13 in response to RNase 7 compared to healthy control. Finally, we show that GATA3 activation was diminished upon cultivation of T-cells with RNase7. CONCLUSION: Our data indicate that RNase 7 has immunomodulatory functions on TH2-cells and decreases the production of TH2 cytokines in the skin This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170405IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/all.13173</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28378334">PM:28378334</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170405-KopfnagelV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170405-KopfnagelV.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170405, Kopfnagel V</style></custom2><misc3><style face="normal" font="default">10.1111/all.13173</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41004</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Koch,S.</style></author><author><style face="normal" font="default"> Stroisch,T.J.</style></author><author><style face="normal" font="default"> Vorac,J.</style></author><author><style face="normal" font="default"> Herrmann,N.</style></author><author><style face="normal" font="default"> Leib,N.</style></author><author><style face="normal" font="default"> Schnautz,S.</style></author><author><style face="normal" font="default"> Kirins,H.</style></author><author><style face="normal" font="default"> Forster,I.</style></author><author><style face="normal" font="default"> Weighardt,H.</style></author><author><style face="normal" font="default"> Bieber,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy and Christine Kuhne - Center for Allergy Research and Education (CK-CARE),University of Bonn, Sigmund-Freud-Strasse 25, 53105, Bonn, Germany</style></auth-address><titles><title><style face="normal" font="default">AhR mediates an anti-inflammatory feed-back mechanism in human Langerhans cells involving FcepsilonRI and IDO</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Affinity</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Down-Regulation</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Epidermis</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Feedback</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hematopoietic Stem Cells</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> Keratinocytes</style></keyword><keyword><style face="normal" font="default"> Langerhans Cells</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Stem Cells</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> transcription factor</style></keyword><keyword><style face="normal" font="default"> Transcription Factors</style></keyword><keyword><style face="normal" font="default"> Up-Regulation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="4" Year="2017">2017/4/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Aryl hydrocarbon receptor (AhR), an important regulator of immune responses, is activated by UVB irradiation in the skin. Langerhans cells (LC) in the epidermis of atopic dermatitis (AD) patients carry the high affinity receptor for IgE, FcepsilonRI, and are crucially involved in the pathogenesis of AD by inducing inflammatory responses and regulating tolerogenic processes. OBJECTIVES: We investigated AhR and AhR repressor (AhRR) expression and functional consequences of AhR activation in human ex vivo skin cells and in in vitro generated LC. METHODS: Epidermal cells from healthy skin were analyzed for their expression of AhR and AhRR. LC generated from CD34+ hematopoietic stem cells (CD34LC) were treated with the UV photoproduct and AhR ligand 6-formylindolo[3,2-b]carbazole (FICZ). Cell surface receptors, transcription factors and the tolerogenic tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO) were analyzed using flow cytometry and quantitative PCR. RESULTS: Epidermal LC and CD34LC express AhR and AhRR. AhR was also found in keratinocytes, which lack AhRR. AhR activation of LC by FICZ caused down-regulation of FcepsilonRI in CD34LC without affecting their maturation. AhR-mediated regulation of FcepsilonRI did not involve any known transcription factors related to this receptor. Furthermore, we could show up-regulation of IDO mediated by AhR engagement. CONCLUSIONS: Our study shows that AhR activation by FICZ reduces FcepsilonRI and up-regulates IDO expression in LC. This AhR-mediated anti-inflammatory feedback mechanism may dampen the allergen-induced inflammation in AD. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170404IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/all.13170</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28376268">PM:28376268</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170404-KochS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170404-KochS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170404, Koch S</style></custom2><misc3><style face="normal" font="default">10.1111/all.13170</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41005</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Logan,C.A.</style></author><author><style face="normal" font="default"> Brandt,S.</style></author><author><style face="normal" font="default"> Wabitsch,M.</style></author><author><style face="normal" font="default"> Brenner,H.</style></author><author><style face="normal" font="default"> Wiens,F.</style></author><author><style face="normal" font="default"> Stahl,B.</style></author><author><style face="normal" font="default"> Marosvolgyi,T.</style></author><author><style face="normal" font="default"> Decsi,T.</style></author><author><style face="normal" font="default"> Rothenbacher,D.</style></author><author><style face="normal" font="default"> Genuneit,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany</style></auth-address><titles><title><style face="normal" font="default">New approach shows no association between maternal milk fatty acid composition and childhood wheeze or asthma</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acids</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic eczema</style></keyword><keyword><style face="normal" font="default"> Biometry</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> Breast</style></keyword><keyword><style face="normal" font="default"> Capillaries</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Chromatography</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Fatty acid</style></keyword><keyword><style face="normal" font="default"> Fatty Acids</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hungary</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Milk</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Poisson</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Toddler</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="17" Month="3" Year="2017">2017/3/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Previous observational studies have implied breast milk fatty acid composition may play a role in development of atopic eczema or atopic sensitization in breastfed infants and toddlers. However, studies investigating associations with wheeze and asthma in later childhood are scarce and did not account for inherent correlation of compositional data. Our aim was to explore the association of maternal milk fatty acid composition with childhood wheezing phenotypes and asthma up to age 13 years using a new statistical approach. METHODS: Breast milk was collected 6 weeks and 6 months post-delivery in the Ulm Birth Cohort Study (n=720 and n=454, respectively). Concentrations of 28 fatty acids were measured by high-resolution capillary gas-liquid chromatography. To control for constant sum constraint, concentration data were transformed using the centered log ratio method. Compositional biplots and correlation matrices were used to group centered log ratio transformed fatty acids. Adjusted risk ratios with parent-reported wheezing phenotypes and doctor-diagnosed asthma were computed using a modified Poisson regression. RESULTS: We observed no straightforward evidence of associations between overall breast milk fatty acid composition and specific wheeze phenotypes or doctor-diagnosed asthma. CONCLUSION: Using appropriate statistical methodology, we report null associations. These findings may partly be attributable to several cohort-specific factors associated with breastfeeding and breast milk collection. Further studies could improve on ours by analyzing samples of breast milk and formula and by including all children for whom these are exclusively or together the major source of fatty acids in the first months of life. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170317IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Netherlands -CO - Hungary -</style></notes><work-type><style face="normal" font="default">10.1111/all.13161</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28306160">PM:28306160</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170317-LoganCA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170317-LoganCA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170317, Logan CA</style></custom2><misc3><style face="normal" font="default">10.1111/all.13161</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41006</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Okubo,K.</style></author><author><style face="normal" font="default"> Hashiguchi,K.</style></author><author><style face="normal" font="default"> Takeda,T.</style></author><author><style face="normal" font="default"> Baba,K.</style></author><author><style face="normal" font="default"> Kitagoh,H.</style></author><author><style face="normal" font="default"> Miho,H.</style></author><author><style face="normal" font="default"> Tomomatsu,H.</style></author><author><style face="normal" font="default"> Yamaguchi,S.</style></author><author><style face="normal" font="default"> Odani,M.</style></author><author><style face="normal" font="default"> Yamamotoya,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology, Nippon Medical School, Tokyo</style></auth-address><titles><title><style face="normal" font="default">A randomized controlled phase II clinical trial comparing ONO-4053, a novel DP1 antagonist, with a leukotriene receptor antagonist pranlukast in patients with seasonal allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Prostaglandin</style></keyword><keyword><style face="normal" font="default"> Prostaglandin D2</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> SAR</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Sneezing</style></keyword><keyword><style face="normal" font="default"> symptom scores</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="4" Year="2017">2017/4/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Prostaglandin D2 (PGD2 ) is primarily produced by mast cells and is contributing to the nasal symptoms including nasal obstruction and rhinorrhea. OBJECTIVE: This study aimed to evaluate the efficacy and safety of a novel PGD2 receptor 1 (DP1) antagonist, ONO-4053, in patients with seasonal allergic rhinitis (SAR). METHODS: This study was a multicenter, randomized, double-blind, parallel-group study of patients with SAR. Following a one-week period of placebo run-in, patients who met the study criteria were randomized to either the ONO-4053, leukotriene receptor antagonist pranlukast, or placebo group for a two-week treatment period. 200 patients were planned to be randomly assigned to receive ONO-4053, pranlukast, or placebo in a 2:2:1 ratio. Nasal and eye symptoms were evaluated. RESULTS: Both ONO-4053 and pranlukast had higher efficacy than placebo on all nasal and eye symptoms. ONO-4053 outperformed pranlukast in a total of three nasal symptom scores (T3NSS) as well as in individual scores for sneezing, rhinorrhea, and nasal itching. For T3NSS, the Bayesian posterior probabilities that pranlukast was better than placebo and ONO-4053 was better than pranlukast were 70.0% and 81.6%, respectively, suggesting that ONO-4053 has a higher efficacy compared with pranlukast. There was no safety-related issue in this study. CONCLUSIONS: We demonstrated that the efficacy of ONO-4053 was greater than that of pranlukast with a similar safety profile. This study indicates the potential of ONO-4053 for use as a treatment for SAR (JapicCTI-142706). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170405IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/all.13174</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28378369">PM:28378369</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170405-OkuboK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170405-OkuboK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170405, Okubo K</style></custom2><misc3><style face="normal" font="default">10.1111/all.13174</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41007</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aziz-Ur-Rehman,A.</style></author><author><style face="normal" font="default"> Dasgupta,A.</style></author><author><style face="normal" font="default"> Kjarsgaard,M.</style></author><author><style face="normal" font="default"> Hargreave,F.E.</style></author><author><style face="normal" font="default"> Nair,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">grid.416721.7Department of Medicine, McMaster University and St Joseph's Healthcare Hamilton, Hamilton, ON Canada</style></auth-address><titles><title><style face="normal" font="default">Sputum cell counts to manage prednisone-dependent asthma: effects on FEV1 and eosinophilic exacerbations</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Clin Immunol</style></full-title></periodical><pages end="" start="17">17-</pages><volume><style face="normal" font="default">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cell Count</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prednisone</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> sputum eosinophil</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Prednisone dependence in asthma is usually described based on clinical and spirometric characteristics. It is generally believed that these patients have frequent exacerbations and lose lung function rapidly because of uncontrolled airway eosinophilia. OBJECTIVES: The objectives of this study are to report the effect on asthma exacerbations and the change in lung function over time in prednisone-dependent asthma when severe asthma is managed using a protocol that aims to maintain normal sputum cell counts. METHODS: A retrospective survey of patients prospectively assessed in a university tertiary care asthma clinic. RESULTS: 52 patients (30 males, mean age 51 years, 64% non-atopic) were followed for a median period of 5.4 years (min-max: 0.2-35.2). Monitoring with the aim of keeping sputum eosinophils below 3% resulted in higher doses of corticosteroids (median daily dose of prednisone was 10 mg and for inhaled corticosteroids was 1500 mug of fluticasone equivalent) than at baseline and this was associated with predictable adverse effects. Despite the disease severity, 10 patients (19%) did not require LABA for symptom control. Most importantly, over the period of follow-up, there were only 0.3 eosinophilic exacerbations/patient/year. Overall, there was an increase in FEV1 over the period of follow-up (mean +84.6 ml/year) rather than an expected decline. CONCLUSIONS: Monitoring of eosinophils in sputum enables to maintain symptom control and preserve FEV1 in patients with severe prednisone-dependent asthma</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1186/s13223-017-0190-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28396690">PM:28396690</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-17.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-17.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, Aziz-Ur-Rehman A</style></custom2><misc3><style face="normal" font="default">10.1186/s13223-017-0190-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41008</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shin,M.</style></author><author><style face="normal" font="default"> Lee,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Soonchunhyang University School of Medicine, Bucheon, Korea</style></auth-address><titles><title><style face="normal" font="default">Prevalence and Causes of Childhood Urticaria</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="190" start="189">189-190</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cause</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - EditorialCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.3.189</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293924">PM:28293924</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-189-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-189-90.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Shin M</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.3.189</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41009</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Song,J.W.</style></author><author><style face="normal" font="default"> Jang,Y.S.</style></author><author><style face="normal" font="default"> Jung,M.C.</style></author><author><style face="normal" font="default"> Kim,J.H.</style></author><author><style face="normal" font="default"> Choi,J.H.</style></author><author><style face="normal" font="default"> Park,S.</style></author><author><style face="normal" font="default"> Hwang,Y.I.</style></author><author><style face="normal" font="default"> Jang,S.H.</style></author><author><style face="normal" font="default"> Jung,K.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea</style></auth-address><titles><title><style face="normal" font="default">Levodropropizine-Induced Anaphylaxis: Case Series and Literature Review</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="280" start="278">278-280</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophil activation test</style></keyword><keyword><style face="normal" font="default"> Basophil activation tests</style></keyword><keyword><style face="normal" font="default"> BAT</style></keyword><keyword><style face="normal" font="default"> Bats</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic cough</style></keyword><keyword><style face="normal" font="default"> Cold</style></keyword><keyword><style face="normal" font="default"> Common Cold</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> Generalized urticaria</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral provocation test</style></keyword><keyword><style face="normal" font="default"> Oral provocation tests</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharmacovigilance</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Levodropropizine is commonly used as an antitussive drug for acute and chronic cough. It is a non-opioid agent with peripheral antitussive action via the modulation of sensory neuropeptide levels in the airways. Thus, levodropropizine has a more tolerable profile than opioid antitussives. However, we experienced 3 cases of levodropropizine-induced anaphylaxis. Three patients commonly presented with generalized urticaria, dyspnea, and collapse after taking cold medication including levodropropizine. To find out the culprit drug, we performed skin tests, oral provocation tests (OPTs), and basophil activation tests (BATs). Two patients were confirmed as having levodropropizine-induced anaphylaxis by OPTs, and one of them showed positive to skin prick tests (SPTs). The other patient was confirmed by skin tests and BATs. When we analyzed pharmacovigilance data related to levodropropizine collected for 5 years, most cases (78.9%) had allergic reactions, such as rash, urticaria, angioedema, and anaphylaxis. Therefore, physicians should consider that levodropropizine can be a culprit drug, when anaphylaxis occurs after taking anti-cough or common cold medication</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Case ReportsPT - LetterCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.3.278</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293935">PM:28293935</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-278-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-278-80.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Song JW</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.3.278</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41010</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,S.J.</style></author><author><style face="normal" font="default"> Ha,E.K.</style></author><author><style face="normal" font="default"> Jee,H.M.</style></author><author><style face="normal" font="default"> Lee,K.S.</style></author><author><style face="normal" font="default"> Lee,S.W.</style></author><author><style face="normal" font="default"> Kim,M.A.</style></author><author><style face="normal" font="default"> Kim,D.H.</style></author><author><style face="normal" font="default"> Jung,Y.H.</style></author><author><style face="normal" font="default"> Sheen,Y.H.</style></author><author><style face="normal" font="default"> Sung,M.S.</style></author><author><style face="normal" font="default"> Han,M.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Bundang CHA Medical Center, CHA University School of Medicine, Seongnam, Korea</style></auth-address><titles><title><style face="normal" font="default">Prevalence and Risk Factors of Urticaria With a Focus on Chronic Urticaria in Children</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="219" start="212">212-219</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Income</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">PURPOSE: Limited data is available on the prevalence and risk factors of acute and chronic urticaria in children. Our purpose was to determine the prevalence and identify the risk factors of acute and chronic urticaria in Korean children. METHODS: This population-based study examined 4,076 children (age 4 to 13 years) who were enrolled in the 2015 prospective Seongnam Atopy Project (SAP 2015) in Korea. The parents completed an urticaria questionnaire that included questions regarding the duration, severity, and triggering factors of urticaria. Blood sampling (n=464) was performed to measure vitamin D, total eosinophil count (TEC), and total IgE levels, and skin prick tests (n=503) were done. RESULTS: The prevalences of the life-time, acute, and chronic urticaria were 22.5%, 13.9%, and 1.8% (chronic continuous urticaria, 0.7%; and chronic recurrent urticaria, 1.1%), respectively. Acute urticaria was significantly associated with allergic diseases and parental history of allergy (P&lt;0.001), but chronic urticaria was not associated with these clinical factors. There was no significant difference in the 25-hydroxyvitamin D level between subjects with chronic urticaria and controls (P=0.124). Chronic continuous urticaria was associated with living in a new residence (aOR=2.38, 95% CI=1.02-5.54, P=0.044) and belonging to a family with a high income (aOR=4.24, 95% CI=1.24-14.56, P=0.022). CONCLUSIONS: A total of 1.8% of children were found to have chronic urticaria. Living in a new residence and belonging to a family with a high income increased the risk of chronic continuous urticaria</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.3.212</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293927">PM:28293927</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-212-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-212-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Lee SJ</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.3.212</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41011</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Suh,D.I.</style></author><author><style face="normal" font="default"> Chang,H.Y.</style></author><author><style face="normal" font="default"> Lee,E.</style></author><author><style face="normal" font="default"> Yang,S.I.</style></author><author><style face="normal" font="default"> Hong,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Prenatal Maternal Distress and Allergic Diseases in Offspring: Review of Evidence and Possible Pathways</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="211" start="200">200-211</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> early childhood</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> Fetus</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> indoor</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Oxidative Stress</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> pollutants</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Recent studies have suggested a close association between prenatal maternal distress and allergic diseases in the offspring. We selected relevant birth-cohort or national registry studies using a keyword search of the PubMed database and summarized current evidence on the impact of prenatal maternal distress on the development of offspring's allergic diseases. Moreover, we postulated possible pathways linking prenatal distress and allergic diseases based on relevant human and animal studies. Both dysregulated hypothalamic-pituitary-adrenal axis and increased oxidative stress may cause structural (altered brain/lung development) and functional (skewed immune development) changes, which may predispose the fetus to developing allergic diseases during childhood. Although many facts are yet to be discovered, changes in the placental response and epigenetic modification are presumed to mediate the whole process from maternal distress to allergic diseases. Maternal prenatal distress can also interact with other physical or environmental factors, including familial or physical factors, indoor and outdoor pollutants, and early childhood psychological distress. The gut-microbiome-brain axis and the role of the microbiome as an immune modulator should be considered when investigating the stress-allergy relationship and exploring potential intervention modalities. Further research is needed, and particular attention should be given to defining the most vulnerable subjects and critical time periods. To this end, studies exploring relevant biomarkers are warranted, which can enable us to explore adequate intervention strategies</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.3.200</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293926">PM:28293926</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-200-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-200-11.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Suh DI</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.3.200</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41012</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Park,H.W.</style></author><author><style face="normal" font="default"> Tantisira,K.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Genetic Signatures of Asthma Exacerbation</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="199" start="191">191-199</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Exacerbation-prone asthma</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Gene-Environment Interaction</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetic factors</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> pharmacogenetic</style></keyword><keyword><style face="normal" font="default"> Pharmacogenetics</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> race</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral infection</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Asthma exacerbation (AE) usually denotes worsening of asthma symptoms that requires intense management to prevent further deterioration. AE has been reported to correlate with clinical and demographic factors, such as race, gender, and treatment compliance as well as environmental factors, such as viral infection, smoking, and air pollution. In addition, recent observations suggest that there are likely to be genetic factors specific to AE. Understanding genetic factors specific to AE is essential to develop therapy tailored for exacerbation-prone asthma. Here, we summarize the results of studies involving genetic risk factors for AE. To simplify and enhance understanding, we reviewed the studies according to the following categories: hypothesis-driven approaches, hypothesis-free approaches, gene-environment interactions, and pharmacogenetics</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - South Korea -CO - United States -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.3.191</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293925">PM:28293925</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-191-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-191-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Park HW</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.3.191</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41013</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,J.</style></author><author><style face="normal" font="default"> Park,S.</style></author><author><style face="normal" font="default"> Jung,C.M.</style></author><author><style face="normal" font="default"> Oh,C.W.</style></author><author><style face="normal" font="default"> Kwon,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Kangwon National University School of Medicine, Chuncheon, Korea</style></auth-address><titles><title><style face="normal" font="default">A Case of Cycloserine-Induced Lichenoid Drug Eruption Supported by the Lymphocyte Transformation Test</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="284" start="281">281-284</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug eruption</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> LTT</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Transformation</style></keyword><keyword><style face="normal" font="default"> Lymphocyte transformation test</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Transformation</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Lichenoid drug eruption (LDE) is a rare form of delayed-type drug eruption. Among anti-tuberculosis (Tb) agents, cycloserine (CS) has been reported as a rare cause of LDE. Positive results on the lymphocyte transformation test (LTT) have not been reported in patients with LDE. In the present case, we performed LTT and a patch test, and successfully proved CS as the offending drug in this patient, who had been treated with multiple anti-Tb drugs. These observations suggest that CS should be considered a possible cause of LDE and that LTT can be an option for the diagnosis of LDE</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Case ReportsPT - LetterCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.3.281</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293936">PM:28293936</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-281-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-281-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Kim J</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.3.281</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41014</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yang,H.J.</style></author><author><style face="normal" font="default"> Kim,Y.H.</style></author><author><style face="normal" font="default"> Lee,B.</style></author><author><style face="normal" font="default"> Kong,D.Y.</style></author><author><style face="normal" font="default"> Kim,D.K.</style></author><author><style face="normal" font="default"> Kim,M.A.</style></author><author><style face="normal" font="default"> Kim,B.S.</style></author><author><style face="normal" font="default"> Kim,W.Y.</style></author><author><style face="normal" font="default"> Kim,J.H.</style></author><author><style face="normal" font="default"> Park,Y.</style></author><author><style face="normal" font="default"> Park,S.Y.</style></author><author><style face="normal" font="default"> Bae,W.Y.</style></author><author><style face="normal" font="default"> Song,K.</style></author><author><style face="normal" font="default"> Yang,M.S.</style></author><author><style face="normal" font="default"> Lee,S.M.</style></author><author><style face="normal" font="default"> Lee,Y.M.</style></author><author><style face="normal" font="default"> Lee,H.J.</style></author><author><style face="normal" font="default"> Cho,J.H.</style></author><author><style face="normal" font="default"> Jee,H.M.</style></author><author><style face="normal" font="default"> Choi,J.H.</style></author><author><style face="normal" font="default"> Yoo,Y.</style></author><author><style face="normal" font="default"> Koh,Y.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Pediatric Allergy and Respiratory Center, Soonchunhyang University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Unmet Primary Physicians' Needs for Allergic Rhinitis Care in Korea</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="271" start="265">265-271</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> Pediatricians</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Respiratory diseases</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Unmet needs</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Allergic rhinitis (AR) is one of the most common chronic allergic respiratory diseases worldwide. Various practical guidelines for AR have been developed and updated to improve the care of AR patients; however, up to 40% patients remain symptomatic. The unmet need for AR care is one of the greatest public health problems in the world. The gaps between guideline and real-world practice, and differences according to the region, culture, and medical environments may be the causes of unmet needs for AR care. Because there is no evidence-based AR practical guideline reflecting the Korean particularity, various needs are increasing. The purpose of the study was to evaluate whether existing guidelines are sufficient for AR patient management in real practice and whether development of regional guidelines to reflect regional differences is needed in Korea. A total of 99 primary physicians comprising internists, pediatricians, and otolaryngologists (n=33 for each) were surveyed by a questionnaire relating to unmet needs for AR care between June 2 and June 16 of 2014. Among 39 question items, participants strongly agreed on 15 items that existing guidelines were highly insufficient and needed new guidelines. However, there was some disagreement according to specialties for another 24 items. In conclusion, the survey results demonstrated that many physicians did not agree with the current AR guideline, and a new guideline reflecting Korean particularity was needed</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South KOrea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.3.265</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293933">PM:28293933</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-265-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-265-71.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Yang HJ</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.3.265</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41015</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fodor,L.E.</style></author><author><style face="normal" font="default"> Gezsi,A.</style></author><author><style face="normal" font="default"> Ungvari,L.</style></author><author><style face="normal" font="default"> Semsei,A.F.</style></author><author><style face="normal" font="default"> Gal,Z.</style></author><author><style face="normal" font="default"> Nagy,A.</style></author><author><style face="normal" font="default"> Galffy,G.</style></author><author><style face="normal" font="default"> Tamasi,L.</style></author><author><style face="normal" font="default"> Kiss,A.</style></author><author><style face="normal" font="default"> Antal,P.</style></author><author><style face="normal" font="default"> Szalai,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary</style></auth-address><titles><title><style face="normal" font="default">Investigation of the Possible Role of the Hippo/YAP1 Pathway in Asthma and Allergy</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="256" start="247">247-256</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> economics</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> Exercise-induced asthma</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> haplotype</style></keyword><keyword><style face="normal" font="default"> Haplotypes</style></keyword><keyword><style face="normal" font="default"> Hungary</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> induced sputum</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Western blot</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">PURPOSE: Several lines of evidence indicate that the Hippo/Yes-associated protein 1 (YAP1) pathways might play a role in the pathogenesis of asthma. To investigate the possible role of the Hippo/YAP1 pathway in the pathogenesis of asthma or its phenotypes. METHODS: The levels of gene expressions of the members of the Hippo/YAP1 were compared. The presence of the proteins of the YAP1 and FRMD6 were analyzed with Western blot in induced sputum of 18 asthmatic subjects and 10 control subjects. Fourteen single nucleotide polymorphisms (SNPs) in the YAP1 gene were genotyped in 522 asthmatic subjects and 711 healthy controls. The results were evaluated with traditional frequentist methods and with Bayesian network-based Bayesian multilevel analysis of relevance (BN-BMLA). RESULTS: The mRNA of all the members of the Hippo/YAP1 pathway could be detected in the induced sputum of both controls and cases. A correlation was found between YAP1 mRNA levels and sputum bronchial epithelial cells (r=0.575, P=0.003). The signal for the FRMD6 protein could be detected in all sputum samples while the YAP1 protein could not be detected in the sputum samples, of the healthy controls and severe asthmatics, but it was detectable in mild asthmatics. The rs2846836 SNP of the YAP1 gene was significantly associated with exercise-induced asthma (odds ratio [OR]=2.1 [1.3-3.4]; P=0.004). The distribution of genotypes of rs11225138 and certain haplotypes of the YAP1 gene showed significant differences between different asthma severity statuses. With BN-BMLA, 2 SNPs, genetic variations in the FRMD6 gene proved to be the most relevant to exercise-induced asthma and allergic rhinitis. These 2 SNPs through allergic rhinitis and exercise-induced asthma were in epistatic interaction with each other. CONCLUSIONS: Our results provided additional evidence that the FRMD6/Hippo/YAP1 pathway plays a role in the pathogenesis of asthma. If additional studies can confirm these findings, this pathway can be a potential novel therapeutic target in asthma and other inflammatory airway diseases</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - Hungary -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.3.247</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293931">PM:28293931</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-247-56.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-247-56.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Fodor LE</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.3.247</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41016</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Craig,T.</style></author><author><style face="normal" font="default"> Shapiro,R.</style></author><author><style face="normal" font="default"> Vegh,A.</style></author><author><style face="normal" font="default"> Baker,J.W.</style></author><author><style face="normal" font="default"> Bernstein,J.A.</style></author><author><style face="normal" font="default"> Busse,P.</style></author><author><style face="normal" font="default"> Magerl,M.</style></author><author><style face="normal" font="default"> Martinez-Saguer,I.</style></author><author><style face="normal" font="default"> Riedl,M.A.</style></author><author><style face="normal" font="default"> Lumry,W.</style></author><author><style face="normal" font="default"> Williams-Herman,D.</style></author><author><style face="normal" font="default"> Edelman,J.</style></author><author><style face="normal" font="default"> Feuersenger,H.</style></author><author><style face="normal" font="default"> Machnig,T.</style></author><author><style face="normal" font="default"> Rojavin,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Efficacy and safety of an intravenous C1-inhibitor concentrate for long-term prophylaxis in hereditary angioedema</style></title><secondary-title><style face="normal" font="default">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Rhinol (Providence)</style></abbr-1></periodical><pages end="19" start="13">13-19</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Berinert</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> Chest Pain</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> Headache</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Long-term prophylaxis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> On demand</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Thrombosis</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: The plasma-derived, pasteurized, nanofiltered C1-inhibitor concentrate (pnfC1-INH) is approved in the United States as an intravenous (IV) on-demand treatment for hereditary angioedema (HAE) attacks, and, in Europe, as on demand and short-term prophylaxis. OBJECTIVE: This analysis evaluated Berinert Patient Registry data regarding IV pnfC1-INH used as long-term prophylaxis (LTP). METHODS: The international registry (2010-2014) collected prospective and retrospective usage, dosing, and safety data on individuals who used pnfC1-INH for any reason. RESULTS: The registry included data on 47 subjects (80.9% female subjects; mean age, 44.8 years), which reflected 4082 infusions categorized as LTP and a total of 430.2 months of LTP administration. The median absolute dose of pnfC1-INH given for LTP was 1000 IU (range, 500-3000 IU), with a median time interval between infusion and a subsequent pnfC1-INH-treated attack of 72.0 hours (range, 0.0-166.4 hours). Fifteen subjects (31.9%) had no pnfC1-INH-treated HAE attacks within 7 days after pnfC1-INH infusion for LTP; 32 subjects (68.1%) experienced 246 attacks, with rates of 0.06 attacks per infusion and 0.57 attacks per month. A total of 81 adverse events were reported in 16 subjects (34.0%) (0.02 events per infusion; 0.19 events per month); only 3 adverse events were considered related to pnfC1-INH (noncardiac chest pain, postinfusion headache, deep vein thrombosis in a subject with an IV port). CONCLUSION: In this international registry, IV pnf-C1-INH given as LTP for HAE was safe and efficacious, with a low rate of attacks that required pnfC1-INH treatment, particularly within the first several days after LTP administration</style></abstract><notes><style face="normal" font="default">DA - 20170406IS - 2152-6575 (Print)IS - 2152-6567 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.2500/ar.2017.8.0192)</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28381322">PM:28381322</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Rhinol (Providence)\2017-8-13-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Rhinol (Providence)\2017-8-13-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170406, Craig T</style></custom2><misc3><style face="normal" font="default">10.2500/ar.2017.8.0192)</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41017</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lemos-Rodriguez,A.M.</style></author><author><style face="normal" font="default"> Farzal,Z.</style></author><author><style face="normal" font="default"> Sreenath,S.B.</style></author><author><style face="normal" font="default"> Thorp,B.D.</style></author><author><style face="normal" font="default"> Senior,B.A.</style></author><author><style face="normal" font="default"> Zanation,A.M.</style></author><author><style face="normal" font="default"> Ebert,C.S.,Jr.</style></author></authors></contributors><titles><title><style face="normal" font="default">The impact of total immunoglobulin E levels on outcomes of maximal medical therapy for chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Rhinol (Providence)</style></abbr-1></periodical><pages end="12" start="5">5-12</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Chronic sinusitis</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> prospective cohort study</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Sinusitis</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="default">INTRODUCTION: The goal of this project was to evaluate the impact of immunoglobulin E (IgE) levels on outcomes in patients with chronic rhinosinusitis (CRS) who received maximal medical therapy (MMT). STUDY DESIGN: Prospective cohort study. METHODS: Thirty-eight patients who underwent MMT for CRS were assigned to three different cohorts based on their IgE levels: low IgE (&lt;25 IU), moderate (>25 to &lt;149 IU), and high (>/=150 IU). The primary outcome evaluated was MMT failure with a surgical recommendation within each IgE cohort. Secondary outcomes included changes in pre- and post-MMT scores for the Rhinosinusitis Disability Index, Chronic Sinusitis Survey, and computed tomography-based Lund-Mackay evaluation. The cohorts were substratified based on the presence of nasal polyps and nasal allergies. RESULTS: No significant difference was found when MMT failure was compared between the cohorts in terms of quality of life. When substratified based on the presence of nasal polyps and nasal allergies, there was no significant difference between the cohorts. In the high-IgE cohort, all patients regardless of presence of nasal polyps and nasal allergic disease, frequently failed MMT and were recommended for surgery. CONCLUSIONS: Overall, IgE levels did not seem to have a significant effect on the quality of life or outcomes of MMT in the patients with CRS. However, the presence of nasal allergies regardless of IgE levels seemed to result in more frequent recommendations for surgery after MMT. In the patients with higher-IgE levels (>/=150 IU), MMT seemed to fail at high rates with or without the presence of polyps or allergic disease</style></abstract><notes><style face="normal" font="default">DA - 20170406IS - 2152-6575 (Print)IS - 2152-6567 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/ar.2017.8.0188</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28381321">PM:28381321</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Rhinol (Providence)\2017-8-5-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Rhinol (Providence)\2017-8-5-12.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170406, Lemos-Rodriguez AM</style></custom2><misc3><style face="normal" font="default">10.2500/ar.2017.8.0188</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41018</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lam,K.</style></author><author><style face="normal" font="default"> Bigcas,J.L.</style></author><author><style face="normal" font="default"> Luong,A.</style></author><author><style face="normal" font="default"> Yao,W.</style></author><author><style face="normal" font="default"> Citardi,M.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Flexible microsensor technology for real-time navigation tracking in balloon sinus ostial dilation</style></title><secondary-title><style face="normal" font="default">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Rhinol (Providence)</style></abbr-1></periodical><pages end="24" start="20">20-24</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Anatomy</style></keyword><keyword><style face="normal" font="default"> Anesthesia</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> endoscopic sinus surgery</style></keyword><keyword><style face="normal" font="default"> Feasibility Studies</style></keyword><keyword><style face="normal" font="default"> Feedback</style></keyword><keyword><style face="normal" font="default"> Frontal Sinus</style></keyword><keyword><style face="normal" font="default"> General anesthesia</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Optimization</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> sinus</style></keyword><keyword><style face="normal" font="default"> Software</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Microsensor navigation has the potential to aid balloon sinus ostial dilation by providing real-time tracking of balloon devices within the complex anatomy of the sinonasal cavities. OBJECTIVE: This feasibility study evaluated the incorporation of a new microsensor technology into a flexible guidewire for use with current instruments in balloon sinus ostial dilation. METHODS: A retrospective study was conducted to include seven men and one woman (age range, 33-68 years), who underwent balloon sinus ostial dilation with flexible microsensor navigation in the operating room setting. All the procedures were performed at target sinuses with the patient under general anesthesia, in conjunction with subsequent endoscopic sinus surgery. RESULTS: Balloon dilation was attempted at the maxillary (n = 3), frontal (n = 14), and sphenoid (n = 1) sinuses. In all the cases, the surgical navigation system displayed the flexible wire tip as it was advanced to the target sinus ostia; this visual feedback for wire position guided the balloon placement. Successful balloon dilation with assistance of flexible microsensor navigation was performed on most sinuses, except a single frontal sinus with adjacent type 2 frontal cells. CONCLUSION: Flexible navigation technology may be combined with balloon sinus technology to facilitate localization of instruments in the sinus anatomy. Additional optimization of both the device and software technology is warranted</style></abstract><notes><style face="normal" font="default">DA - 20170406IS - 2152-6575 (Print)IS - 2152-6567 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/ar.2017.8.0193</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28381323">PM:28381323</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Rhinol (Providence)\2017-8-20-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Rhinol (Providence)\2017-8-20-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170406, Lam K</style></custom2><misc3><style face="normal" font="default">10.2500/ar.2017.8.0193</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41019</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zeller,K.S.</style></author><author><style face="normal" font="default"> Forreryd,A.</style></author><author><style face="normal" font="default"> Lindberg,T.</style></author><author><style face="normal" font="default"> Gradin,R.</style></author><author><style face="normal" font="default"> Chawade,A.</style></author><author><style face="normal" font="default"> Lindstedt,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunotechnology, Medicon Village, Lund, Sweden</style></auth-address><titles><title><style face="normal" font="default">The GARD platform for potency assessment of skin sensitizing chemicals</style></title><secondary-title><style face="normal" font="default">ALTEX</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">ALTEX</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> cat</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Learning</style></keyword><keyword><style face="normal" font="default"> Legislation</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Rapid detection</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="12" Month="4" Year="2017">2017/4/12</year></dates><abstract><style face="normal" font="default">Contact allergy induced by certain chemicals is a common health concern, and several alternative methods have been developed to fulfill the requirements of European legislation with regard to hazard assessment of potential skin sensitizers. However, validated methods, which provide information about the potency of skin sensitizers, are still lacking. The cell-based assay Genomic Allergen Rapid Detection (GARD), targeting key event 3, dendritic cell activation, of the skin sensitizer AOP, uses gene expression profiling and a machine learning approach for the prediction of chemicals as sensitizers or non-sensitizers. Based on the GARD platform, we here expanded the assay to predict three sensitizer potency classes according to the European Classification, Labelling and Packaging (CLP) Regulation, targeting categories 1A (strong), 1B (weak) and no cat (non-sensitizer). Using arandom forest approach and 70 training samples, a potential biomarker signature of 52 transcripts was identified. The resulting model could predict an independent test set consisting of 18 chemicals, six from each CLP category and all previously unseen to the model, with an overall accuracy of 78%. Importantly, the model was shown to be conservative and only underestimated the class label of one chemical. Furthermore, an association of defined chemical protein reactivity with distinct biological pathways illustrates that transcriptional approach can reveal information contributing to the understanding of underlying mechanisms in sensitization</style></abstract><notes><style face="normal" font="default">DA - 20170413IS - 1868-596X (Print)IS - 1868-596X (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.14573/altex.1701101</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28403479">PM:28403479</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\ALTEX\20170413-ZellerKS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\ALTEX\20170413-ZellerKS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170413, Zeller KS</style></custom2><misc3><style face="normal" font="default">10.14573/altex.1701101</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41020</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Belot,N.</style></author><author><style face="normal" font="default"> Sim,B.</style></author><author><style face="normal" font="default"> Longmore,C.L.</style></author><author><style face="normal" font="default"> Roscoe,L.</style></author><author><style face="normal" font="default"> Treasure,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">XCellR8 Ltd, the Innovation Centre, Sci-Tech Daresbury, Keckwick Lane, Daresbury, Cheshire, UK</style></auth-address><titles><title><style face="normal" font="default">Adaptation of the KeratinoSens skin sensitisation test to animal-product-free cell culture</style></title><secondary-title><style face="normal" font="default">ALTEX</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">ALTEX</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Cell Culture</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> Keratinocytes</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Legislation</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Protein Binding</style></keyword><keyword><style face="normal" font="default"> REACH</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Regulations</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Sensitisation</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> standards</style></keyword><keyword><style face="normal" font="default"> T lymphocyte</style></keyword><keyword><style face="normal" font="default"> T-lymphocyte</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="default">Skin sensitisation is the process by which a substance leads to an allergic reaction following skin contact. The process has been described as an adverse outcome pathway (AOP), including several key events, from skin penetration and covalent protein binding, to keratinocyte activation, dendritic cell activation and T-lymphocyte proliferation. The in vitro assay KeratinoSens measures the activation of keratinocytes. It is fully accepted at a regulatory level (OECD TG 442d) and appropriate for compliance with a range of legislation including the EU Cosmetics Regulation, REACH, and the CLP Regulation. Currently, many in vitro methods use animal-derived components in the cell culture systems. Many stakeholders in the cosmetics industry have both scientific and ethical concerns relating to this issue and have stated a strong preference for fully human in vitro test systems. We have adapted the KeratinoSensTM method to animal product-free conditions, and carried out an in-house validation with 21 reference substances, including those listed in the Performance Standards associated with OECD TG442d. The modified method was shown to be totally equivalent to the Validated Reference Method (VRM), with comparable values for accuracy (85.7%), sensitivity (84.6%) and specificity (87.5%), and all acceptance criteria being met. In Europe, data generated by the adapted method may be used in REACH submissions, and we are now seeking approval to list the adaptation in OECD TG 442d, enabling formal compliance with a range of global regulations</style></abstract><notes><style face="normal" font="default">DA - 20170316IS - 1868-596X (Print)IS - 1868-596X (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.14573/altex.170131</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28301666">PM:28301666</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\ALTEX\20170416-BelotN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\ALTEX\20170416-BelotN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170316, Belot N</style></custom2><misc3><style face="normal" font="default">10.14573/altex.170131</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41021</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yang,I.V.</style></author><author><style face="normal" font="default"> Richards,A.</style></author><author><style face="normal" font="default"> Davidson,E.J.</style></author><author><style face="normal" font="default"> Stevens,A.D.</style></author><author><style face="normal" font="default"> Kolakowski,C.A.</style></author><author><style face="normal" font="default"> Martin,R.J.</style></author><author><style face="normal" font="default"> Schwartz,D.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Colorado School of Medicine Aurora, Colorado</style></auth-address><titles><title><style face="normal" font="default">The Nasal Methylome: A Key to Understanding Allergic Asthma</style></title><secondary-title><style face="normal" font="default">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Crit Care Med</style></full-title></periodical><pages end="831" start="829">829-831</pages><volume><style face="normal" font="default">195</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="15" Month="3" Year="2017">2017/3/15</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.1164/rccm.201608-1558LE</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28294656">PM:28294656</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Respir Crit Care Med\2017-195-829-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Respir Crit Care Med\2017-195-829-31.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Yang IV</style></custom2><misc3><style face="normal" font="default">10.1164/rccm.201608-1558LE</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41022</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pfeffer,P.E.</style></author><author><style face="normal" font="default"> Corrigan,C.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 William Harvey Research Institute Queen Mary University of London</style></auth-address><titles><title><style face="normal" font="default">An Imbalance between Proteases and Endogenous Protease Inhibitors in Eosinophilic Airway Disease</style></title><secondary-title><style face="normal" font="default">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Crit Care Med</style></full-title></periodical><pages end="708" start="707">707-708</pages><volume><style face="normal" font="default">195</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Protease</style></keyword><keyword><style face="normal" font="default"> protease inhibitor</style></keyword><keyword><style face="normal" font="default"> Protease Inhibitors</style></keyword><keyword><style face="normal" font="default"> proteases</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="15" Month="3" Year="2017">2017/3/15</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1164/rccm.201610-2020ED</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28294660">PM:28294660</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Respir Crit Care Med\2017-195-707-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Respir Crit Care Med\2017-195-707-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Pfeffer PE</style></custom2><misc3><style face="normal" font="default">10.1164/rccm.201610-2020ED</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41023</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cui,C.</style></author><author><style face="normal" font="default"> Basen,T.</style></author><author><style face="normal" font="default"> Philipp,A.T.</style></author><author><style face="normal" font="default"> Yusin,J.</style></author><author><style face="normal" font="default"> Krishnaswamy,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy and Immunology, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California</style></auth-address><titles><title><style face="normal" font="default">Celiac disease and nonceliac gluten sensitivity</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="393" start="389">389-393</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Celiac Disease</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Gluten</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Los Angeles</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Veterans</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170409IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.01.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28390579">PM:28390579</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-389-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-389-93.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170409, Cui C</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.01.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41024</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kumar,B.</style></author><author><style face="normal" font="default"> Dolovcak,S.</style></author><author><style face="normal" font="default"> Vogelgesang,S.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunology, Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa.</style></auth-address><titles><title><style face="normal" font="default">Dual training in allergy/immunology and rheumatology: A viable and satisfying career path</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cities</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Iowa</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="4" Year="2017">2017/4/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170405IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.02.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28377174">PM:28377174</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170405-KumarB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170405-KumarB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170405, Kumar B</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.02.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41025</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Izadi,N.</style></author><author><style face="normal" font="default"> Tam,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Children's Hospital Los Angeles, Los Angeles, California</style></auth-address><titles><title><style face="normal" font="default">Benefits of subspecialty adherence after asthma hospitalization and patient perceived barriers to care</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Allergy specialist</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma education</style></keyword><keyword><style face="normal" font="default"> Barriers</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Comparative Study</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> intensive care unit</style></keyword><keyword><style face="normal" font="default"> Interviews</style></keyword><keyword><style face="normal" font="default"> Los Angeles</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Teaching</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="4" Year="2017">2017/4/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Comparative studies have demonstrated that asthma education to pediatric patients decreases average hospital usage and that allergy specialists provide stronger asthma education and more improved outcomes. OBJECTIVE: To evaluate the real-world benefits of allergy subspecialty involvement outside inpatient consultation and the impediments for patients in establishing allergy subspecialty care. METHODS: The study population was composed mostly of minority children 0 to 18 years old seen at a large university-affiliated stand-alone children's hospital who had a hospital discharge diagnosis of asthma from 2009 to 2013. The retrospective portion of the study compared all variables pertaining to asthma, teaching, and discharge reconciliation for the following subgroups: patients recommended to allergy and immunology (AI) follow-up who adhered to the appointment (adherent), patients recommended to AI follow-up who did not adhere (nonadherent), and patients not recommended to AI follow-up (non-referred). In the phone interview portion of the study, the nonadherent patients were contacted to identify barriers to AI follow-up. RESULTS: Of the referred sample, the adherent group had significantly fewer visits to the pediatric intensive care unit, days in the pediatric intensive care unit, and days in the hospital. Providing more specific hospital discharge instructions increased AI follow-up and hospital teaching given on the baseline admission decreased hospital visits. Phone interviews showed that nonadherent patients most commonly missed follow-up because the parents believed it unnecessary because their child showed acute improvement or from advice from their primary care physician. CONCLUSION: These results showed improvement in outcomes for patients who attended AI follow-up and specifically identified key barriers that could be addressed in a standardized form to prevent nonadherence in the future</style></abstract><notes><style face="normal" font="default">DA - 20170405IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.02.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28377171">PM:28377171</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170405-IzadiN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170405-IzadiN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170405, Izadi N</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.02.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41026</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Amaral,R.</style></author><author><style face="normal" font="default"> Carneiro,A.C.</style></author><author><style face="normal" font="default"> Wandalsen,G.</style></author><author><style face="normal" font="default"> Fonseca,J.A.</style></author><author><style face="normal" font="default"> Sole,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Research in Health Technologies and Information Systems, Faculty of Medicine, University of Porto, Porto, Portugal; Allergy Unit, CUF Porto Institute and Hospital, Porto, Portugal</style></auth-address><titles><title><style face="normal" font="default">Control of Allergic Rhinitis and Asthma Test for Children (CARATKids): Validation in Brazil and cutoff values</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Information Systems</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> standards</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> VAS</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="30" Month="3" Year="2017">2017/3/30</year></dates><abstract><style face="normal" font="default">BACKGROUND: The Control of Allergic Rhinitis and Asthma Test for Children (CARATKids) assesses asthma and allergic rhinitis control in children younger than 12 years. OBJECTIVE: To validate the Brazilian Portuguese version of the CARATKids and to define the cutoff values for identifying uncontrolled disease. METHODS: Children aged 6 to 12 years with asthma and allergic rhinitis were studied (n = 102). CARATKids, childhood Asthma Control Test (cACT), total nasal symptom score (TNSS), and visual analog scale (VAS) scores were obtained at baseline and after 4 to 6 weeks. Internal consistency, test-retest reliability, responsiveness, and validity of the Brazilian CARATKids were assessed according to the Consensus-based Standards for the Selection of Health Measurements Instruments checklist. The minimal clinically important difference (MCID) was evaluated using distribution and anchor methods. Spearman correlations were used to compare CARATKids scores with external measures of control. Receiver operating characteristic curve analysis was performed to establish cutoff values. RESULTS: Fifty children completed both visits. The Cronbach alpha and intraclass correlation coefficient of CARATKids were 0.81 and 0.85, respectively. The Guyatt responsiveness index was -1.34, and within-patient change in clinically unstable patients (n = 31) was significant (P = .02). As for cross-sectional and longitudinal validity, correlation coefficients ranged from 0.58 to 0.77 (P &lt; .001) and 0.30 to 0.57 (P &lt; .05), respectively. The estimated MCID for CARATKids was 3. The optimal cutoffs (sensitivity and specificity) to exclude uncontrolled and controlled disease were 3 or less (97% and 67%) and 6 or greater (56% and 96%), respectively. CONCLUSION: CARATKids is a reliable and valid tool to assess asthma and allergic rhinitis control in Brazilian children. A score of 6 or higher on CARATKids identifies uncontrolled disease, and a score of 3 or lower excludes poor disease control</style></abstract><notes><style face="normal" font="default">DA - 20170403IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Portugal -CO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.02.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28366584">PM:28366584</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170403-AmaralR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170403-AmaralR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170403, Amaral R</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.02.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41027</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bishopp,A.</style></author><author><style face="normal" font="default"> Sathyamurthy,R.</style></author><author><style face="normal" font="default"> Manney,S.</style></author><author><style face="normal" font="default"> Webbster,C.</style></author><author><style face="normal" font="default"> Krishna,M.T.</style></author><author><style face="normal" font="default"> Mansur,A.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Birmingham Regional Severe Asthma Service, Heartlands Hospital and University of Birmingham, Birmingham, England</style></auth-address><titles><title><style face="normal" font="default">Biomarkers of oxidative stress and antioxidants in severe asthma: A Prospective Case-Control Study</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="451" start="445">445-451</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> Antioxidants</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Copper</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> England</style></keyword><keyword><style face="normal" font="default"> Exhaled Breath</style></keyword><keyword><style face="normal" font="default"> exhaled breath condensate</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral corticosteroids</style></keyword><keyword><style face="normal" font="default"> Oxidative Stress</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Selenium</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Trace Elements</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vitamin A</style></keyword><keyword><style face="normal" font="default"> Vitamin E</style></keyword><keyword><style face="normal" font="default"> Vitamins</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword><keyword><style face="normal" font="default"> Zinc</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Bronchial airway inflammation is the hallmark of asthma, which may be driven by an imbalance between oxidative stress and antioxidant defenses. Antioxidants deficiency may play a role, but this has remained unconfirmed. OBJECTIVE: To evaluate the oxidative stress burden and antioxidants defenses in patients with increasing asthma severity. METHODS: This prospective case-control study compared fractional exhaled nitric oxide (FeNO), exhaled breath condensate nitrite/nitrate (EBC-NOx), spirometry, and serum vitamins and trace elements among patients with and without asthma. RESULTS: Sixty participants were recruited (30 with severe asthma number; 23 women [76.7%]; mean age, 41.4 years; mean forced expiratory volume in 1 second [FEV1], 2.2 L [72.2% predicted]; mean inhaled corticosteroid dosage, 2,540 mug/d; 18/30 [60%] receiving maintenance oral corticosteroids; 15 with mild asthma; all corticosteroids naive; 9 women [60%]; mean age, 34.6 years; mean FEV1, 3.48 L [100.5% predicted]; 15 healthy controls; 12 women [80%]; mean age, 37.6 years; and mean FEV1, 3.53 L [111.7% predicted]). The mean FeNO levels increased significantly with increasing asthma severity (P = .01), but the EBC-NOx levels did not change significantly (P = .90). Paradoxically, vitamin A and vitamin E increased with increased disease severity, with vitamin E levels increasing significantly (P = .07 and P &lt; .001, respectively). There was no significant difference between groups in the levels of copper (P = .37), zinc (P = .97), or selenium (P = .90). CONCLUSION: FeNO but not EBC-NOx is increased significantly with asthma severity with no evidence of vitamins or trace elements deficiency in severe asthma. Impaired oxidative stress defenses in severe asthma may be driven by factors other than vitamins or trace elements deficiency</style></abstract><notes><style face="normal" font="default">DA - 20170409IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.02.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28390585">PM:28390585</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-445-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-445-51.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170409, Bishopp A</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.02.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41028</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ali,A.M.</style></author><author><style face="normal" font="default"> Selim,S.</style></author><author><style face="normal" font="default"> Abbassi,M.M.</style></author><author><style face="normal" font="default"> Sabry,N.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.</style></auth-address><titles><title><style face="normal" font="default">Effect of alfacalcidol on the pulmonary function of adult asthmatic patients: A randomized trial</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Egypt</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Osteoporosis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized trial</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> Vitamin D Deficiency</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="4" Year="2017">2017/4/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Despite the use of alfacalcidol in the management of corticosteroid-induced osteoporosis, it has never been considered an adjunct treatment for asthma management. It can target vitamin D deficiency, a possible risk factor for asthma, and, hence, improve pulmonary function of patients with asthma. OBJECTIVE: To explore the effect of alfacalcidol administration on pulmonary function and study the pattern of vitamin D deficiency in adults with asthma in Egypt. METHODS: Serum 25-hydroxyvitamin D was measured in 115 adults: 33 healthy subjects and 82 patients with asthma. Then, patients with asthma were randomized to receive standard asthma treatment only (n = 39) or receive it in addition to 1 mug of alfacalcidol daily for 4 months (n = 43). Randomization was stratified by the stage of asthma severity. Spirometry and measurement of 25-hydroxyvitamin were performed at baseline and end of follow-up. RESULTS: Vitamin D deficiency was more common in patients with asthma (57.3%) than in healthy subjects (21.2%; P &lt; .001). In patients with asthma, alfacalcidol significantly improved forced expiratory volume in the first second and forced vital capacity (P &lt; .001 for the 2 tests). Moreover, more patients in the intervention arm showed improvement in asthma severity stage (P = .04). A nonsignificant difference was observed in improvement of forced expiratory volume in the first second between patients with vitamin D deficiency and those without deficiency in the intervention group (P > .05). CONCLUSION: Alfacalcidol supplementation improved the pulmonary function and severity stage of adult patients with asthma regardless of deficiency. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02747381</style></abstract><notes><style face="normal" font="default">DA - 20170405IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Egypt -</style></notes><work-type><style face="normal" font="default">0.1016/j.anai.2017.02.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28377173">PM:28377173</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170405-AliAM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170405-AliAM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170405, Ali AM</style></custom2><misc3><style face="normal" font="default">0.1016/j.anai.2017.02.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41029</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,B.K.</style></author><author><style face="normal" font="default"> Jung,J.W.</style></author><author><style face="normal" font="default"> Kim,T.B.</style></author><author><style face="normal" font="default"> Chang,Y.S.</style></author><author><style face="normal" font="default"> Park,H.S.</style></author><author><style face="normal" font="default"> Moon,J.</style></author><author><style face="normal" font="default"> Lee,S.T.</style></author><author><style face="normal" font="default"> Jung,K.H.</style></author><author><style face="normal" font="default"> Jung,K.Y.</style></author><author><style face="normal" font="default"> Chu,K.</style></author><author><style face="normal" font="default"> Lee,S.K.</style></author><author><style face="normal" font="default"> Kang,H.R.</style></author><author><style face="normal" font="default"> Park,H.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea; Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">HLA-A*31:01 and lamotrigine-induced severe cutaneous adverse drug reactions in a Korean population</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Cutaneous adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="25" Month="3" Year="2017">2017/3/25</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170329IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.02.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28351624">PM:28351624</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170329-Kim BK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170329-Kim BK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170329, Kim BK</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.02.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41030</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zazzali,J.L.</style></author><author><style face="normal" font="default"> Kaplan,A.</style></author><author><style face="normal" font="default"> Maurer,M.</style></author><author><style face="normal" font="default"> Raimundo,K.</style></author><author><style face="normal" font="default"> Trzaskoma,B.</style></author><author><style face="normal" font="default"> Antonova,E.N.</style></author><author><style face="normal" font="default"> Rosen,K.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Genentech Inc, South San Francisco, California</style></auth-address><titles><title><style face="normal" font="default">Importance of angioedema-free days in patients with chronic idiopathic or spontaneous urticaria</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="524">524-</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> San Francisco</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170409IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - LetterCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2016.12.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28390589">PM:28390589</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-524.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-524.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170409, Zazzali JL</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2016.12.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41031</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tsai,Y.G.</style></author><author><style face="normal" font="default"> Sun,H.L.</style></author><author><style face="normal" font="default"> Chien,J.W.</style></author><author><style face="normal" font="default"> Chen,C.Y.</style></author><author><style face="normal" font="default"> Lin,C.H.</style></author><author><style face="normal" font="default"> Lin,C.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Changhua Christian Children Hospital, Changhua, Taiwan, School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan</style></auth-address><titles><title><style face="normal" font="default">High exhaled nitric oxide levels correlate with nonadherence in acute asthmatic children</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="523" start="521">521-523</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Taiwan</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170409IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.01.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28390588">PM:28390588</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-521-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-521-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170409, Tsai YG</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.01.031</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41032</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hamad,A.</style></author><author><style face="normal" font="default"> Jithpratuck,W.</style></author><author><style face="normal" font="default"> Krishnaswamy,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Clinical Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina</style></auth-address><titles><title><style face="normal" font="default">Urticarial vasculitis and associated disorders</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="398" start="394">394-398</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> North Carolina</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vasculitis</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170409IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.01.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28390580">PM:28390580</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-394-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-394-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170409, Hamad A</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.01.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41033</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zawawi,F.</style></author><author><style face="normal" font="default"> Campisi,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology-Head and Neck Surgery, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default">Re: "Addendum guidelines for the prevention of peanut allergy in the United States: report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel"</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="526" start="525">525-526</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Ontario</style></keyword><keyword><style face="normal" font="default"> Peanut</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170409IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - LetterCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.01.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28390590">PM:28390590</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-525-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-525-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170409, Zawawi F</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.01.022</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41034</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Johnson,W.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana.</style></auth-address><titles><title><style face="normal" font="default">Author's response (Refers To: Importance of angioedema-free days in patients with chronic idiopathic or spontaneous urticaria)</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="525">525-</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Biomedical Research</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Louisiana</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170409IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.02.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28390591">PM:28390591</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-525.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-525.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170409, Johnson WD</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.02.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41035</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wan,X.C.</style></author><author><style face="normal" font="default"> Lai,A.</style></author><author><style face="normal" font="default"> Kompala,T.</style></author><author><style face="normal" font="default"> Ten,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of California-San Francisco, San Francisco, California.</style></auth-address><titles><title><style face="normal" font="default">Mimicker of hereditary angioedema: Idiopathic systemic capillary leak syndrome successfully treated with intravenous immunoglobulin</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">angioedema</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Capillaries</style></keyword><keyword><style face="normal" font="default"> Capillary Leak Syndrome</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> San Francisco</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="4" Year="2017">2017/4/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170405IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.02.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28377172">PM:28377172</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170405-WanXC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170405-WanXC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170405, Wan XC</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.02.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41036</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,Y.X.</style></author><author><style face="normal" font="default"> Gao,B.A.</style></author><author><style face="normal" font="default"> Cheng,H.Y.</style></author><author><style face="normal" font="default"> Li,L.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China</style></auth-address><titles><title><style face="normal" font="default">Survey of Occupational Allergic Contact Dermatitis and Patch Test among Clothing Employees in Beijing</style></title><secondary-title><style face="normal" font="default">Biomed Res Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Biomed Res Int</style></abbr-1></periodical><pages end="" start="3102358">3102358-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Beijing</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Clothing</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> Formaldehyde</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand dermatitis</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> major allergen</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wrist</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Occupational population-based epidemiological data relating to occupational contact allergies in the Chinese clothing industry are limited. To investigate the prevalence of occupational allergic contact dermatitis (OACD) and to identify the causative allergens among clothing employees in China, a cross-sectional study was conducted in 529 clothing employees at 12 clothing factories in Beijing. All employees were subjected to an interview using self-administered questionnaire and skin examination, and those who were diagnosed with occupational contact dermatitis (OCD) were patch tested. In the present survey, we found that the overall 1-year prevalence of OACD among the clothing employees was 8.5%. The 1-year prevalence of OACD among workers (10.8%) was significantly higher than that among managers (3.2%). The lesions were primarily on the hands and wrists in workers, but the face and neck in managers. The major allergens were nickel sulfate and cobalt dichloride in workers and colophony and p-tert-butylphenol formaldehyde resin in managers. In conclusion, workers are at a higher risk of OACD compared with managers in the Chinese clothing industry. In addition to hand dermatitis in workers, airborne contact dermatitis on the face and neck should be also addressed in managers</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 2314-6141 (Electronic)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1155/2017/3102358</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28396866">PM:28396866</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biomed Res Int\2017-2017-3102358.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biomed Res Int\2017-2017-3102358.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, Chen YX</style></custom2><misc3><style face="normal" font="default">10.1155/2017/3102358</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41037</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Linauskiene,K.</style></author><author><style face="normal" font="default"> Malinauskiene,L.</style></author><author><style face="normal" font="default"> Blaziene,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinic of Infectious and Chest Diseases, Dermatovenereology and Allergology, Centre of Pulmonology and Allergology, Vilnius University, Vilnius, Lithuania</style></auth-address><titles><title><style face="normal" font="default">Metals Are Important Contact Sensitizers: An Experience from Lithuania</style></title><secondary-title><style face="normal" font="default">Biomed Res Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Biomed Res Int</style></abbr-1></periodical><pages end="" start="3964045">3964045-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Chromium</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> cross reactivity</style></keyword><keyword><style face="normal" font="default"> Cross-reactivity</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> Gold</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Palladium</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Titanium</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background. Metals are very frequent sensitizers causing contact allergy and allergic contact dermatitis worldwide; up-to-date data based on patch test results has proved useful for the identification of a problem. Objectives. In this retrospective study prevalence of contact allergy to metals (nickel, chromium, palladium, gold, cobalt, and titanium) in Lithuania is analysed. Patients/Methods. Clinical and patch test data of 546 patients patch tested in 2014-2016, in Vilnius University Hospital Santariskiu Klinikos, was analysed and compared with previously published data. Results. Almost third of tested patients (29.56%) were sensitized to nickel. Younger women were more often sensitized to nickel than older ones (36% versus 22.8%, p = 0.0011). Women were significantly more often sensitized to nickel than men (33% versus 6.1%, p &lt; 0.0001). Younger patients were more often sensitized to cobalt (11.6% versus 5.7%, p = 0.0183). Sensitization to cobalt was related to sensitization to nickel (p &lt; 0.0001). Face dermatitis and oral discomfort were related to gold allergy (28% versus 6.9% dermatitis of other parts, p &lt; 0.0001). Older patients were patch test positive to gold(I) sodium thiosulfate statistically significantly more often than younger ones (44.44% versus 21.21%, p = 0.0281). Conclusions. Nickel, gold, cobalt, and chromium are leading metal sensitizers in Lithuania. Cobalt sensitization is often accompanied by sensitization to nickel. Sensitivity rate to palladium and nickel indicates possible cross-reactivity. No sensitization to titanium was found</style></abstract><notes><style face="normal" font="default">DA - 20170412IS - 2314-6141 (Electronic)LA - engPT - Journal ArticleCO - Lithuania -</style></notes><work-type><style face="normal" font="default">10.1155/2017/3964045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28401153">PM:28401153</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biomed Res Int\2017-2017-3964045.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biomed Res Int\2017-2017-3964045.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170412, Linauskiene K</style></custom2><misc3><style face="normal" font="default">10.1155/2017/3964045</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41038</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Miyazaki,C.</style></author><author><style face="normal" font="default"> Koyama,M.</style></author><author><style face="normal" font="default"> Ota,E.</style></author><author><style face="normal" font="default"> Swa,T.</style></author><author><style face="normal" font="default"> Mlunde,L.B.</style></author><author><style face="normal" font="default"> Amiya,R.M.</style></author><author><style face="normal" font="default"> Tachibana,Y.</style></author><author><style face="normal" font="default"> Yamamoto-Hanada,K.</style></author><author><style face="normal" font="default"> Mori,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Health Policy, National Center for Child Health and Development, 10-1-2 Okura, Setagaya-ku, Tokyo, 157-8535, Japan</style></auth-address><titles><title><style face="normal" font="default">Allergic diseases in children with attention deficit hyperactivity disorder: a systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default">BMC Psychiatry</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Psychiatry</style></abbr-1></periodical><pages end="" start="120">120-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> bias</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Comparative Study</style></keyword><keyword><style face="normal" font="default"> Conjunctivitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Control Groups</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Policy</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="31" Month="3" Year="2017">2017/3/31</year></dates><abstract><style face="normal" font="default">BACKGROUND: Reports of frequent manifestation of allergic diseases in children with attention deficit hyperactivity disorder (ADHD) have been the subject of mounting clinical interest. However, evidence supporting the association between ADHD and allergies is inconsistent and has yet to be systematically reviewed. The objective of this study was to compile and assess available studies on the association between ADHD and allergic diseases in children. METHODS: A comprehensive search using MEDLINE, EMBASE, the Cochrane library, and CINAHL databases was completed in 23 November 2015. The inclusion criteria for studies were that the research assessed allergic diseases in children, 18 years of age and younger, with a diagnosis of ADHD and that a distinct comparison group was incorporated. Any comparative studies, encompassing both randomized controlled trials and observational studies, were considered for inclusion. Two review authors independently assessed the quality of the selected studies by the use of validated assessment tools, performed data extraction and conducted meta-analysis according to Cochrane Collaboration guidelines. RESULTS: Five eligible studies were included in this systematic review. Of these studies, three were case-control and two were cross sectional studies. A majority of information from the five studies was classified as having low or unclear risk of bias. The meta-analysis showed an association between children with ADHD and asthma compared with the control groups (OR: 1.80, 95% CI: 1.57 - 2.07; five studies, low quality of evidence), but did not indicate an association between food allergy and ADHD (OR: 1.13, 95% CI: 0.88 - 1.47; three studies very low quality of evidence). The odds of experiencing allergic rhinitis, atopic dermatitis, and allergic conjunctivitis were slightly higher in children with ADHD compared with control groups, though a substantial statistical heterogeneity was notable in the overall effect estimates. CONCLUSIONS: The findings from this review and meta-analysis show that children with ADHD are more likely to have asthma, allergic rhinitis, atopic dermatitis, and allergic conjunctivitis than their counterparts. Interventions including strategies for managing allergies in children with ADHD would be beneficial</style></abstract><notes><style face="normal" font="default">DA - 20170331IS - 1471-244X (Electronic)IS - 1471-244X (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1186/s12888-017-1281-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28359274">PM:28359274</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Psychiatry\2017-17-120.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Psychiatry\2017-17-120.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170331, Miyazaki C</style></custom2><misc3><style face="normal" font="default">10.1186/s12888-017-1281-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41039</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Roberts,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK</style></auth-address><titles><title><style face="normal" font="default">Quality of life, when to step down asthma therapy and remembering allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="441" start="440">440-441</pages><volume><style face="normal" font="default">47</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma therapy</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Step down</style></keyword><keyword><style face="normal" font="default"> Step-down</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170403IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12917</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28370598">PM:28370598</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\2017-47-440-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\2017-47-440-1.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170403, Roberts G</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12917</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41040</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jee,Y.K.</style></author><author><style face="normal" font="default"> Kim,S.</style></author><author><style face="normal" font="default"> Lee,J.M.</style></author><author><style face="normal" font="default"> Park,H.S.</style></author><author><style face="normal" font="default"> Kim,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea</style></auth-address><titles><title><style face="normal" font="default">CD8+ T-cell activation by methazolamide causes methazolamide-induced Stevens-Johnson syndrome and toxic epidermal necrolysis</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acetazolamide</style></keyword><keyword><style face="normal" font="default"> activation</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> CD8+ T cells</style></keyword><keyword><style face="normal" font="default"> Cell Proliferation</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human leukocyte antigen</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Transformation</style></keyword><keyword><style face="normal" font="default"> Lymphocyte transformation test</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default"> Stevens-Johnson Syndrome</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cell clone</style></keyword><keyword><style face="normal" font="default"> T-cell clones</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Toxic epidermal necrolysis</style></keyword><keyword><style face="normal" font="default"> Transformation</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="13" Month="3" Year="2017">2017/3/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: Methazolamide (MZ), a carbonic anhydrase inhibitor, occasionally causes Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Susceptibility to MZ-induced SJS/TEN is strongly associated with HLA-B*59:01. OBJECTIVE: To characterize the T-cell response against MZ in patients with MZ-induced SJS/TEN. METHODS: We enrolled four patients with MZ-induced SJS/TEN, performed lymphocyte transformation tests, generated MZ-specific T-cell clones, and evaluated the cytotoxic activities of these clones. Subsequently, we analyzed the human leukocyte antigen (HLA)-restricted T-cell response. RESULTS: Strong proliferative response to MZ was evident, whereas mild proliferative response to acetazolamide was also apparent. MZ-specific T-cell clones (CD8+ T-cells) were generated from the patient. These clones proliferated and secreted granzyme B upon MZ stimulation; MZ also increased the expression level of CD107a and granzyme B. Cell proliferation and granzyme B secretion stimulated by MZ were blocked by anti-HLA class I antibodies. CONCLUSIONS: This is the first demonstration of the immunologic mechanism by which MZ -induces SJS/TEN. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12919</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28295713">PM:28295713</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170315-JeeYK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170315-JeeYK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Jee YK</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12919</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41041</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Villasenor,A.</style></author><author><style face="normal" font="default"> Rosace,D.</style></author><author><style face="normal" font="default"> Obeso,D.</style></author><author><style face="normal" font="default"> Perez-Gordo,M.</style></author><author><style face="normal" font="default"> Chivato,T.</style></author><author><style face="normal" font="default"> Barbas,C.</style></author><author><style face="normal" font="default"> Barber,D.</style></author><author><style face="normal" font="default"> Escribese,M.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Medicine, Institute of Applied Molecular Medicine (IMMA), CEU San Pablo University, Boadilla del Monte, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Allergic asthma: an overview of metabolomic strategies leading to the identification of biomarkers in the field</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="456" start="442">442-456</pages><volume><style face="normal" font="default">47</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> House dust</style></keyword><keyword><style face="normal" font="default"> house dust mite</style></keyword><keyword><style face="normal" font="default"> house dust mites</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> indoor</style></keyword><keyword><style face="normal" font="default"> indoor allergens</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Interpretation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metabolomics</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> Mites</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> Remodelling</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">Allergic asthma is a prominent disease especially during childhood. Indoor allergens, in general, and particularly house dust mites (HDM) are the most prevalent sensitizers associated with allergic asthma. Available data show that 65-130 million people are mite-sensitized world-wide and as many as 50% of these are asthmatic. In fact, sensitization to HDM in the first years of life can produce devastating effects on pulmonary function leading to asthmatic syndromes that can be fatal. To date, there has been considerable research into the pathological pathways and structural changes associated with allergic asthma. However, limitations related to the disease heterogeneity and a lack of knowledge into its pathophysiology have impeded the generation of valuable data needed to appropriately phenotype patients and, subsequently, treat this disease. Here, we report a systematic and integral analysis of the disease, from airway remodelling to the immune response taking place throughout the disease stages. We present an overview of metabolomics, the management of complex multifactorial diseases through the analysis of all possible metabolites in a biological sample, obtaining a global interpretation of biological systems. Special interest is placed on the challenges to obtain biological samples and the methodological aspects to acquire relevant information, focusing on the identification of novel biomarkers associated with specific phenotypes of allergic asthma. We also present an overview of the metabolites cited in the literature, which have been related to inflammation and immune response in asthma and other allergy-related diseases</style></abstract><notes><style face="normal" font="default">DA - 20170204IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12902</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28160515">PM:28160515</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\2017-47-442-56.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\2017-47-442-56.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, Villasenor A</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12902</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41042</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sunadome,H.</style></author><author><style face="normal" font="default"> Matsumoto,H.</style></author><author><style face="normal" font="default"> Petrova,G.</style></author><author><style face="normal" font="default"> Kanemitsu,Y.</style></author><author><style face="normal" font="default"> Tohda,Y.</style></author><author><style face="normal" font="default"> Horiguchi,T.</style></author><author><style face="normal" font="default"> Kita,H.</style></author><author><style face="normal" font="default"> Kuwabara,K.</style></author><author><style face="normal" font="default"> Tomii,K.</style></author><author><style face="normal" font="default"> Otsuka,K.</style></author><author><style face="normal" font="default"> Fujimura,M.</style></author><author><style face="normal" font="default"> Ohkura,N.</style></author><author><style face="normal" font="default"> Tomita,K.</style></author><author><style face="normal" font="default"> Yokoyama,A.</style></author><author><style face="normal" font="default"> Ohnishi,H.</style></author><author><style face="normal" font="default"> Nakano,Y.</style></author><author><style face="normal" font="default"> Oguma,T.</style></author><author><style face="normal" font="default"> Hozawa,S.</style></author><author><style face="normal" font="default"> Nagasaki,T.</style></author><author><style face="normal" font="default"> Ito,I.</style></author><author><style face="normal" font="default"> Oguma,T.</style></author><author><style face="normal" font="default"> Inoue,H.</style></author><author><style face="normal" font="default"> Tajiri,T.</style></author><author><style face="normal" font="default"> Iwata,T.</style></author><author><style face="normal" font="default"> Izuhara,Y.</style></author><author><style face="normal" font="default"> Ono,J.</style></author><author><style face="normal" font="default"> Ohta,S.</style></author><author><style face="normal" font="default"> Hirota,T.</style></author><author><style face="normal" font="default"> Tamari,M.</style></author><author><style face="normal" font="default"> Yokoyama,T.</style></author><author><style face="normal" font="default"> Niimi,A.</style></author><author><style face="normal" font="default"> Izuhara,K.</style></author><author><style face="normal" font="default"> Mishima,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan</style></auth-address><titles><title><style face="normal" font="default">IL4Ralpha and ADAM33 as genetic markers in asthma exacerbations and type-2 inflammatory endotype</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> airflow</style></keyword><keyword><style face="normal" font="default"> Airflow limitation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic Markers</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Interleukin-4</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Multicenter Studies</style></keyword><keyword><style face="normal" font="default"> Multicenter study</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Periostin</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: Genetic markers of susceptibility to asthma exacerbations in adults remain unclear. OBJECTIVE: To identify genetic markers of asthma exacerbations, particularly in patients with type-2 inflammatory endotype. METHODS: In this observational study of patients enrolled in the Kinki Hokuriku Airway disease Conference multicenter study, frequency of exacerbations requiring systemic corticosteroids during 2 years after enrolment and associated risk factors were determined. For genetic marker analysis, interleukin-4 receptor alpha (IL4RA) rs8832 and a disintegrin and metalloprotease 33 (ADAM33) S_2 (rs528557), T_1 (rs2280091), T_2 (rs2280090), and V_4 (rs2787094) variants were included. Elevated serum periostin levels at enrolment (>/=95 ng/mL, defined as type-2 inflammatory endotype) were considered in the analysis. RESULTS: Among 217 patients who were successfully followed up for 2 years after enrolment, 60 patients showed at least one asthma exacerbation during the 2 years. Airflow limitation (%FEV1 &lt;80%) and recent exacerbations but not genetic variants were identified as risk markers of exacerbations. A total of 27 patients showed type-2 inflammatory endotype (serum periostin >/=95 ng/mL at enrolment) and subsequent exacerbations; risk factors in these patients were airflow limitation (odds ratio, 6.51; 95% confidence interval, 2.37 to 18.6; P = 0.0003), GG genotype of IL4RA rs8832 (odds ratio, 4.01; 95% confidence interval, 1.47 to 11.0; P = 0.007), and A allele of ADAM33 T_2 (odds ratio, 2.81; 95% confidence interval, 1.05 to 7.67; P = 0.04) by multivariate analysis. In addition, GG genotype of IL4RA rs8832 was associated with type-2 endotype, whereas A allele of ADAM33 T_2 was associated with mixed type of eosinophilic/type-2 and neutrophilic inflammations. CONCLUSIONS AND CLINICAL RELEVANCE: IL4RA and ADAM33 variants may be risk markers of asthma exacerbations in type-2 inflammatory endotype. Precise endotyping may facilitate the identification of genetic risk markers of asthma exacerbations. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170322IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12927</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28326636">PM:28326636</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170322-SunadomeH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170322-SunadomeH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170322, Sunadome H</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12927</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41043</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Johansson,M.W.</style></author><author><style face="normal" font="default"> Khanna,M.</style></author><author><style face="normal" font="default"> Bortnov,V.</style></author><author><style face="normal" font="default"> Annis,D.S.</style></author><author><style face="normal" font="default"> Nguyen,C.L.</style></author><author><style face="normal" font="default"> Mosher,D.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departments of Biomolecular Chemistry, University of Wisconsin, Madison, Wisconsin, USA</style></auth-address><titles><title><style face="normal" font="default">IL-5-stimulated eosinophils adherent to periostin undergo stereotypic morphological changes and ADAM8-dependent migration</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> epitope</style></keyword><keyword><style face="normal" font="default"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="default"> Glycoprotein</style></keyword><keyword><style face="normal" font="default"> Granules</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Immunoblotting</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Microscopy</style></keyword><keyword><style face="normal" font="default"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="default"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> P-Selectin</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Periostin</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Tail</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wisconsin</style></keyword></keywords><dates><year Day="4" Month="4" Year="2017">2017/4/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: IL-5 causes suspended eosinophils to polarize with filamentous (F)-actin and granules at one pole and the nucleus in a specialized uropod, the "nucleopod", which is capped with P-selectin glycoprotein ligand-1 (PSGL-1). IL-5 enhances eosinophil adhesion and migration on periostin, an extracellular matrix protein upregulated in asthma by type 2 immunity mediators. OBJECTIVE: Determine how the polarized morphology evolves to foster migration of IL-5-stimulated eosinophils on a surface coated with periostin. METHODS: Blood eosinophils adhering to adsorbed periostin were imaged at different time points by fluorescent microscopy, and migration of eosinophils on periostin was assayed. RESULTS: After 10 min in the presence of IL-5, adherent eosinophils were polarized with PSGL-1 at the nucleopod tip and F-actin distributed diffusely at the opposite end. After 30-60 min, the nucleopod had dissipated such that PSGL-1 was localized in a crescent or ring away from the cell periphery, and F-actin was found in podosome-like structures. The periostin layer, detected with monoclonal antibody Stiny-1, shown here to recognize the FAS1 4 module, was cleared in wide areas around adherent eosinophils. Clearance was attenuated by metalloproteinase inhibitors or antibodies to disintegrin metalloproteinase 8 (ADAM8), a major eosinophil metalloproteinase, previously implicated in asthma pathogenesis. ADAM8 was not found in podosome-like structures, which are associated with proteolytic activity in other cell types. Instead, immunoblotting demonstrated proteoforms of ADAM8 that lack the cytoplasmic tail in the supernatant. Anti-ADAM8 inhibited migration of IL-5-stimulated eosinophils on periostin. CONCLUSIONS AND CLINICAL RELEVANCE: Migrating IL-5-activated eosinophils on periostin exhibit loss of nucleopodal features and appearance of prominent podosomes along with clearance of the Stiny-1 periostin epitope. Migration and epitope clearance are both attenuated by inhibitors of ADAM8. We propose, therefore, that eosinophils remodel and migrate on periostin-rich extracellular matrix in the asthmatic airway in an ADAM8-dependent manner, making ADAM8 a possible therapeutic target. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170405IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12934</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28378503">PM:28378503</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170405-JohanssonMW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170405-JohanssonMW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170405, Johansson MW</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12934</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41044</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bjerregaard,A.</style></author><author><style face="normal" font="default"> Laing,I.A.</style></author><author><style face="normal" font="default"> Backer,V.</style></author><author><style face="normal" font="default"> Sverrild,A.</style></author><author><style face="normal" font="default"> Khoo,S.K.</style></author><author><style face="normal" font="default"> Chidlow,G.</style></author><author><style face="normal" font="default"> Sikazwe,C.</style></author><author><style face="normal" font="default"> Smith,D.W.</style></author><author><style face="normal" font="default"> Le Souef,P.</style></author><author><style face="normal" font="default"> Porsbjerg,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory Research Unit, Bispebjerg University Hospital, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default">High fractional exhaled nitric oxide and sputum eosinophils are associated with an increased risk of future virus-induced exacerbations -N</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Cell Count</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rhinovirus</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> sputum eosinophil</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword></keywords><dates><year Day="8" Month="4" Year="2017">2017/4/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: The major trigger of asthma exacerbations is infection with a respiratory virus, most commonly rhinovirus. Type 2 inflammation is known to be associated with an increased risk of exacerbations in general. Whether type 2 inflammation at baseline increases the risk of future virus-induced exacerbations is unknown. OBJECTIVE: To assess whether type 2 inflammation is associated with an increased risk of virus-induced exacerbations of asthma. METHODS: Stable asthmatics had spirometry, skin prick test, measurement of FeNO and sputum induced for differential cell counts. Patients were followed-up for 18-months, during which they were assessed at the research unit when they had symptoms of an exacerbation. Nasal swabs collected at these assessments underwent viral detection by PCR. RESULTS: A total of 81 asthma patients were recruited, of which 22 (27%) experienced an exacerbation during the follow-up period. Of these, 15 (68%) had a respiratory virus detected at exacerbation. Sputum eosinophils > 1% at baseline increased the risk of having a subsequent virus-induced exacerbation (HR 7.6 95% CI 1.6-35.2, p=0.010), as did having FeNO > 25 ppb (HR 3.4 95% CI 1.1-10.4, p=0.033). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170408IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12935</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28390083">PM:28390083</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170408-BjerregaardA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170408-BjerregaardA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170408, Bjerregaard A</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12935</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41045</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zurzolo,G.A.</style></author><author><style face="normal" font="default"> Peters,R.L.</style></author><author><style face="normal" font="default"> Koplin,J.J.</style></author><author><style face="normal" font="default"> de Courten,M.</style></author><author><style face="normal" font="default"> Mathai,M.L.</style></author><author><style face="normal" font="default"> Tye-Din,J.A.</style></author><author><style face="normal" font="default"> Tang,M.L.</style></author><author><style face="normal" font="default"> Campbell,D.E.</style></author><author><style face="normal" font="default"> Ponsonby,A.L.</style></author><author><style face="normal" font="default"> Prescott,S.L.</style></author><author><style face="normal" font="default"> Gurrin,L.</style></author><author><style face="normal" font="default"> Dharmage,S.</style></author><author><style face="normal" font="default"> Allen,K.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Chronic Disease, College of Health and Biomedicine, Victoria University, Melbourne, Australia</style></auth-address><titles><title><style face="normal" font="default">The Practice and Perception of Precautionary Allergen Labelling by the Australasian Food Manufacturing Industry</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Biomedicine</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> Government</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> Manufacturing Industry</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Victoria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="14" Month="3" Year="2017">2017/3/14</year></dates><abstract><style face="normal" font="default">BACKGROUND: The precautionary allergen labelling (PAL) and Voluntary Incidental Trace Allergen Labelling (VITAL(R) ) tools were designed by industry to assist consumers with selecting safe foods for consumption. However, a sizeable proportion of food products bear no label and it is unclear whether these products are free from allergens and therefore safe to consume or have simply not undergone a risk assessment and therefore remain unlabelled for that reason. OBJECTIVE: To assess the prevalence of unlabelled products that have undergone a risk assessment process and to examine the factors influencing industry's uptake of the VITAL(R) process. METHODS: A web-based questionnaire was distributed to Australasian food and grocery manufacturers. RESULTS: One hundred and thirty seven Australasian manufacturers were contacted and 59 questionnaires were returned (response rate: 43%). The respondents represented 454 different manufacturing sites. Manufacturers reported that 23% (95% CI 19-28) of products (n = 102/434) that had been through the VITAL(R) risk assessment process had no PAL statement on the label. 34% (95% CI 30-38), (n = 204/600) of products that had undergone another (non-VITAL(R) ) risk assessment process had no PAL statement. In examining the factors that influenced industry's uptake of the VITAL(R) process, 25 manufacturers reported on factors that influenced the uptake of the VITAL(R) process, 76% (CI 95% 55-91) reported that VITAL(R) was an effective tool because it was based on science; 52% (CI 95% 31-72) reported that it was too time-consuming and 36% (CI 95% 18-57) identified a concern with it not being endorsed by the government. CONCLUSION AND CLINICAL RELEVANCE: Currently we estimate that at least 30% of products may have been through a risk assessment process and yet bear no PAL statement on the label. Permissive labelling could be incorporated onto these products if they have been assessed to be safe for consumption. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12923</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28295718">PM:28295718</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170315-SZurzoloGA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170315-SZurzoloGA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Zurzolo GA</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12923</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41046</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Peldan,P.</style></author><author><style face="normal" font="default"> Kukkonen,A.K.</style></author><author><style face="normal" font="default"> Savilahti,E.</style></author><author><style face="normal" font="default"> Kuitunen,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Children's Hospital, University of Helsinki and Helsinki University Hospital</style></auth-address><titles><title><style face="normal" font="default">Perinatal probiotics decreased eczema up to 10 years of age but at 5-10 years allergic rhino-conjunctivitis was increased</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic eczema</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Lactobacillus</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Perinatal</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Probiotics</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="3" Year="2017">2017/3/17</year></dates><abstract><style face="normal" font="default">Perinatal use of Lactobacillus GG (LGG) has been associated with fewer allergic diseases, mainly eczema in high-risk children at the age of two years [1,2], a phenomenon still seen at 6-9 years [2-5]. We reported earlier that in high-risk children pre- and postnatal use of a mixture of probiotics reduced the incidence of atopic eczema at two years of age, and during the first five years atopic eczema reduction was seen in Caesarean-delivered children but not in the whole cohort [1,6]. Mothers were recruited during pregnancy and randomized at 35 weeks of gestation to the probiotic or placebo group. Prematurity (less than 37 weeks of gestation), infants having major malformations or infants born as B-twins were excluded. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170319IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - Finland -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12924</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28316095">PM:28316095</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170319-PeldanP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170319-PeldanP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170319, Peldan P</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12924</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41047</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Polley,D.J.</style></author><author><style face="normal" font="default"> Mihara,K.</style></author><author><style face="normal" font="default"> Ramachandran,R.</style></author><author><style face="normal" font="default"> Vliagoftis,H.</style></author><author><style face="normal" font="default"> Renaux,B.</style></author><author><style face="normal" font="default"> Saifeddine,M.</style></author><author><style face="normal" font="default"> Daines,M.O.</style></author><author><style face="normal" font="default"> Boitano,S.</style></author><author><style face="normal" font="default"> Hollenberg,M.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Inflammation Research Network-Snyder Institute for Chronic Disease, Department of Physiology &amp; Pharmacology</style></auth-address><titles><title><style face="normal" font="default">Cockroach allergen serine proteinases: Isolation, sequencing and signalling via proteinase-activated receptor-2 (PAR2)</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> allergen sensitization</style></keyword><keyword><style face="normal" font="default"> Allergenicity</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Amino acid</style></keyword><keyword><style face="normal" font="default"> Amino Acid Sequence</style></keyword><keyword><style face="normal" font="default"> and primary</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma risk</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium Signaling</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Chromatography</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cockroach</style></keyword><keyword><style face="normal" font="default"> Cockroaches</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Enzymes</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inner city</style></keyword><keyword><style face="normal" font="default"> inner-city</style></keyword><keyword><style face="normal" font="default"> Ion Exchange</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Kinetics</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> PAR</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Proteinase</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Sequence</style></keyword><keyword><style face="normal" font="default"> Sequences</style></keyword><keyword><style face="normal" font="default"> Serine</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="3" Year="2017">2017/3/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergy to the German cockroach (Blattella germanica) is a significant asthma risk factor for inner-city communities. Cockroach, like other allergens, contains trypsin-like enzyme activity that contributes to allergenicity and airway inflammation by activating proteinase-activated receptors (PARs). To date, the enzymes responsible for the proteolytic activity of German cockroach allergen have not been characterized. OBJECTIVES: We aimed to identify, isolate and characterize the trypsin-like proteinases in German cockroach allergen extracts used for clinical skin tests. For each enzyme, we sought to determine (1) its substrate and inhibitor enzyme kinetics (Km and IC50); (2) its amino acid sequence and (3) its ability to activate calcium signaling and/or ERK1/2 phosphorylation via PAR2. METHODS: Using a trypsin-specific activity-based probe, we detected three distinct enzymes that were isolated using ion-exchange chromatography. Each enzyme was sequenced by mass spectometery (deconvoluted with an expressed sequence tag library), evaluated kinetically for its substrate/inhibitor profile and assessed for its ability to activate PAR2 signaling. FINDINGS: Each of the three serine proteinase-activity-based probe-labelled enzymes isolated were biochemically distinct, with different enzyme kinetic profiles and primary amino acid sequences. The three enzymes showed a 57 to 71% sequence identity with a proteinase previously cloned from the American cockroach (Per a 10). Each enzyme was found to activate both Ca++ and MAPK signaling via PAR2. CONCLUSIONS AND RELEVANCE: We have identified three different serine proteinases from the German cockroach that may, via PAR2 activation, play different roles for allergen-sensitization in vivo and may represent attractive therapeutic targets for asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170320IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12921</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28317204">PM:28317204</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170320-PolleyDJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170320-PolleyDJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Polley DJ</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12921</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41048</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kang,S.Y.</style></author><author><style face="normal" font="default"> Park,D.E.</style></author><author><style face="normal" font="default"> Song,W.J.</style></author><author><style face="normal" font="default"> Bae,B.R.</style></author><author><style face="normal" font="default"> Lee,J.W.</style></author><author><style face="normal" font="default"> Sohn,K.H.</style></author><author><style face="normal" font="default"> Lee,H.S.</style></author><author><style face="normal" font="default"> Kang,H.R.</style></author><author><style face="normal" font="default"> Park,H.W.</style></author><author><style face="normal" font="default"> Chang,Y.S.</style></author><author><style face="normal" font="default"> Choi,S.J.</style></author><author><style face="normal" font="default"> Oh,W.I.</style></author><author><style face="normal" font="default"> Min,K.U.</style></author><author><style face="normal" font="default"> Cho,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Clinical Immunology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Immunologic regulatory effects of human umbilical cord blood-derived mesenchymal stem cells in a murine ovalbumin asthma model</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adjuvant</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> allergen-specific</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> Aluminum</style></keyword><keyword><style face="normal" font="default"> Aluminum Hydroxide</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> BAL</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> expansion</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgG1</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> OVA</style></keyword><keyword><style face="normal" font="default"> Ovalbumin</style></keyword><keyword><style face="normal" font="default"> Ovum</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> regulatory T cell</style></keyword><keyword><style face="normal" font="default"> regulatory T cells</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Spleen</style></keyword><keyword><style face="normal" font="default"> Stem Cells</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Umbilical Cord</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="14" Month="3" Year="2017">2017/3/14</year></dates><abstract><style face="normal" font="default">BACKGROUND: Mesenchymal stem cells (MSCs) have multiple immunomodulatory properties and hold therapeutic potential for inflammatory diseases. However, the therapeutic and immunologic effects of human umbilical cord blood-derived MSCs (huMSCs) remain largely unexamined for asthma. OBJECTIVE: This study was to investigate the immunomodulatory properties of huMSCs in an ovalbumin (OVA)-induced murine asthma model. METHODS: Mice were injected intraperitoneally with OVA and an aluminum hydroxide adjuvant. huMSCs were administered via the tail-vein (5x105 cells/100uL) to female BALB/c mice prior to the initial OVA challenge. The effects of huMSCs were assessed by investigating airway hyperresponsiveness, histological changes, inflammatory cell numbers, serum allergen-specific antibodies, cytokine production in spleen, lung tissue, and BAL fluid as well as expansion of regulatory T cells. RESULTS: Administration of huMSCs significantly reduced methacholine bronchial hyperresponsiveness and eosinophil counts in BAL cells. Similarly, there was a significant decrease in serum OVA-specific IgE and IgG1 levels along with Th2 cytokine production (IL-4, IL-5, and IL-13) in the lung and spleen tissues, whereas increased percentage of regulatory T cells was observed after treatment with huMSCs. CONCLUSIONS: Our results suggest that huMSC treatment reduces OVA-induced allergic inflammation, which could be mediated by regulatory T cells. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12920</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28294434">PM:28294434</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170315-KangSY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170315-KangSY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Kang SY</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12920</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41049</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Strombeck,A.</style></author><author><style face="normal" font="default"> Nordstrom,I.</style></author><author><style face="normal" font="default"> Andersson,K.</style></author><author><style face="normal" font="default"> Andersson,H.</style></author><author><style face="normal" font="default"> Johansen,S.</style></author><author><style face="normal" font="default"> Maglio,C.</style></author><author><style face="normal" font="default"> Rabe,H.</style></author><author><style face="normal" font="default"> Adlerberth,I.</style></author><author><style face="normal" font="default"> Wold,A.E.</style></author><author><style face="normal" font="default"> Hesselmar,B.</style></author><author><style face="normal" font="default"> Rudin,A.</style></author><author><style face="normal" font="default"> Lundell,A.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg</style></auth-address><titles><title><style face="normal" font="default">Allergic disease in 8-year old children is preceded by delayed B-cell maturation</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> memory B cell</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> regulatory T cell</style></keyword><keyword><style face="normal" font="default"> regulatory T cells</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> Tregs</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="14" Month="3" Year="2017">2017/3/14</year></dates><abstract><style face="normal" font="default">BACKGROUND: We previously reported that exposure to a farming environment is allergy-protective, while high proportions of neonatal immature/naive CD5+ B cells and putative regulatory T cells (Tregs) are risk factors for development of allergic disease and sensitization up to 3 years of age. OBJECTIVE: To examine if B- and T-cell maturation are associated with allergic disease and farming environment over the first 8 years in life. METHODS: In the prospective FARMFLORA study, including both farming and non-farming families, 48 out of 65 children took part in the 8-year follow-up study. Various B- and T-cell maturation variables were examined in blood samples obtained at several occasions from birth to 8 years of age and related to doctors' diagnosed allergic disease and sensitization, and to farming environment. RESULTS: We found that the incidence of allergic disease was lower among farmers' compared to non-farmers' children during the 8-years follow-up period, and that farmers' children had higher proportions of memory B cells at 8 years of age. Moreover, a high proportion of neonatal CD5+ B cells was a risk factor for and may predict development of allergic disease at 8 years of age. A high proportion of Tregs was not protective against development of these conditions. CONCLUSION &amp; CLINICAL RELEVANCE: High proportions of neonatal naive B cells remained as a risk factor for allergic disease in school-aged children. Thus, the accelerated B-cell maturation observed among farmers' children may be crucial for the allergy-protective effect of a farming environment. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12922</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28295779">PM:28295779</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170315-StrombeckA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170315-StrombeckA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Strombeck A</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12922</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41050</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kuroishi,T.</style></author><author><style face="normal" font="default"> Bando,K.</style></author><author><style face="normal" font="default"> Tanaka,Y.</style></author><author><style face="normal" font="default"> Shishido,K.</style></author><author><style face="normal" font="default"> Kinbara,M.</style></author><author><style face="normal" font="default"> Ogawa,T.</style></author><author><style face="normal" font="default"> Muramoto,K.</style></author><author><style face="normal" font="default"> Endo,Y.</style></author><author><style face="normal" font="default"> Sugawara,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Oral Immunology, Department of Oral Biology</style></auth-address><titles><title><style face="normal" font="default">CXCL4 is a novel nickel-binding protein and augments nickel allergy</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adjuvant</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Chromatography</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Filtration</style></keyword><keyword><style face="normal" font="default"> Gel</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory mediators</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="default"> LPS</style></keyword><keyword><style face="normal" font="default"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Nickel allergy</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Recombinant</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="3" Year="2017">2017/3/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: Nickel (Ni) is the most frequent metal allergen and induces a TH1 -dependent type-IV allergy. Although Ni2+ is considered to bind to endogenous proteins, it currently remains unclear whether these Ni-binding proteins are involved in Ni allergy in vivo. We previously reported the adjuvant effects of lipopolysaccharide (LPS) in a Ni allergy mouse model. Since LPS induces a number of inflammatory mediators, we hypothesized that Ni-binding protein(s) are also induced by LPS. OBJECTIVE: The objective of this study was to purify and identify Ni-binding protein(s) from serum taken from LPS-injected mice (referred as LPS serum) and examined the augmenting effects of these Ni-binding protein(s) on Ni allergy in an in vivo model. METHODS: BALB/cA mice were sensitized with an i.p. injection of NiCl2 and LPS. Ten days after sensitization, mice were challenged with NiCl2 by an i.d. injection into ear pinnae. Ni-binding protein(s) were purified by Ni-affinity column chromatography and gel filtration. RESULTS: LPS serum, but not serum taken from saline-injected mice augmented ear swelling induced by Ni-allergic inflammation. Ni-binding, but not non-binding fraction purified from LPS serum augmented Ni-allergic inflammation. Mass spectrometry and Western blotting detected CXCL4 in the active fraction. A batch analysis with Ni-sepharose and a surface plasmon resonance analysis revealed direct binding between CXCL4 and Ni2+ . Recombinant CXCL4 augmented Ni-allergic inflammation and exerted adjuvant effects at the sensitization phase. CONCLUSIONS: These results indicate that CXCL4 is a novel Ni-binding protein that augments Ni allergy at the elicitation and sensitization phases. This is the first study to demonstrate that the Ni-binding protein augments Ni allergy in vivo. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170320IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12926</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28319310">PM:28319310</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170320-KuroishiT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170320-KuroishiT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Kuroishi T</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12926</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41051</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Senna,G.</style></author><author><style face="normal" font="default"> Guerriero,M.</style></author><author><style face="normal" font="default"> Paggiaro,P.L.</style></author><author><style face="normal" font="default"> Blasi,F.</style></author><author><style face="normal" font="default"> Caminati,M.</style></author><author><style face="normal" font="default"> Heffler,E.</style></author><author><style face="normal" font="default"> Latorre,M.</style></author><author><style face="normal" font="default"> Canonica,G.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">grid.5611.3Asthma Center and Allergy Unit, Verona University and General Hospital, Piazzale Stefani 1, 37126 Verona, Italy</style></auth-address><titles><title><style face="normal" font="default">SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma</style></title><secondary-title><style face="normal" font="default">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Mol Allergy</style></full-title></periodical><pages end="" start="9">9-</pages><volume><style face="normal" font="default">15</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Biologic therapy</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> natural history</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Even if severe asthma (SA) accounts for 5-10% of all cases of the disease, it is currently a crucial unmet need, owing its difficult clinical management and its high social costs. For this reason several networks, focused on SA have been organized in some countries, in order to select these patients, to recognize their clinical features, to evaluate their adherence, to classify their biological/clinical phenotypes, to identify their eligibility to the new biologic therapies and to quantify the costs of the disease. Aim of the present paper is to describe the ongoing Italian Severe Asthma Network (SANI). Up today 49 centres have been selected, widespread on the national territory. Sharing the same diagnostic protocol, data regarding patients with SA will be collected and processed in a web platform. After their recruitment, SA patients will be followed in the long term in order to investigate the natural history of the disease. Besides clinical data, the cost/benefit evaluation of the new biologics will be verified as well as the search of peculiar biomarker(s) of the disease</style></abstract><notes><style face="normal" font="default">DA - 20170412IS - 1476-7961 (Linking)LA - engPT - EditorialCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1186/s12948-017-0065-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28400707">PM:28400707</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170412, Senna G</style></custom2><misc3><style face="normal" font="default">10.1186/s12948-017-0065-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41052</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Calogiuri,G.</style></author><author><style face="normal" font="default"> Di Leo,E.</style></author><author><style face="normal" font="default"> Butani,L.</style></author><author><style face="normal" font="default"> Pizzimenti,S.</style></author><author><style face="normal" font="default"> Incorvaia,C.</style></author><author><style face="normal" font="default"> Macchia,L.</style></author><author><style face="normal" font="default"> Nettis,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pneumology and Allergy Department, Hospital Sacro Cuore, Gallipoli, Lecce, Italy</style></auth-address><titles><title><style face="normal" font="default">Hypersensitivity reactions due to black henna tattoos and their components: are the clinical pictures related to the immune pathomechanism?</style></title><secondary-title><style face="normal" font="default">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Mol Allergy</style></full-title></periodical><pages end="" start="8">8-</pages><volume><style face="normal" font="default">15</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Africa</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Asia</style></keyword><keyword><style face="normal" font="default"> Black henna</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical aspects</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Henna</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Para-phenylenediamine</style></keyword><keyword><style face="normal" font="default"> Paraphenylenediamine</style></keyword><keyword><style face="normal" font="default"> Pathomechanisms</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Plant</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Hypersensitivity to para-phenylenediamine (PPD) and related compounds induced by temporary black henna tattoos has become a serious health problem worldwide. Different patterns of sensitization with various clinical aspects are described in literature due to PPD associated to henna tattoo and these manifestations are likely correlated with the immunological and dermatological pathomechanisms involved. Henna is the Persian name of the plant Lawsonia inermis, Fam. Lythraceae. It is a woody shrub that grow in regions of North Africa, South Asia, India and Sri Lanka. Nowadays it is rather frequent to see temporary "tattoos" performed with henna. To make tattoos darker and long-lasting PPD has been associated to henna in tattoo drawings mixtures, so obtaining "black henna". In these years there has been a rise of contact sensitization to PPD and in medical literature an increased number of cases have been reported on temporary henna tattoo application. Here we review the various clinical patterns related to PPD and henna tattoo, to investigate the possible link between clinic-morphological pictures and the immunological response to PPD and henna. The literature underlines that different clinical manifestations are related to black henna containing PPD, and its derivative products may cause delayed-type as well as immediate-type reactions. Further studies are needed to investigate the relationship between clinical and morphological aspects of PPD contact dermatitis and the T cell subsets predominance</style></abstract><notes><style face="normal" font="default">DA - 20170412IS - 1476-7961 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1186/s12948-017-0063-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28400706">PM:28400706</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170412, Calogiuri G</style></custom2><misc3><style face="normal" font="default">10.1186/s12948-017-0063-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41053</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Riario Sforza,G.G.</style></author><author><style face="normal" font="default"> Marinou,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">grid.432778.dDivision of Sub Acute Care, Sesto San Giovanni Hospital, ASST Nord Milano, Sesto San Giovanni, Italygrid.432778.dDivision of Sub Acute Care, Sesto San Giovanni Hospital, ASST Nord Milano, Sesto San Giovanni, Italy</style></auth-address><titles><title><style face="normal" font="default">Hypersensitivity pneumonitis: a complex lung disease</style></title><secondary-title><style face="normal" font="default">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Mol Allergy</style></full-title></periodical><pages end="" start="6">6-</pages><volume><style face="normal" font="default">15</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> diagnostic criteria</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity Pneumonitis</style></keyword><keyword><style face="normal" font="default"> Igg</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Inorganic Chemicals</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Life Style</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microbes</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> organic dust</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Plant</style></keyword><keyword><style face="normal" font="default"> Plant Proteins</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Uncertainty</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Hypersensitivity pneumonitis (HP), also called extrinsic allergic alveolitis, is a respiratory syndrome involving the lung parenchyma and specifically the alveoli, terminal bronchioli, and alveolar interstitium, due to a delayed allergic reaction. Such reaction is secondary to a repeated and prolonged inhalation of different types of organic dusts or other substances to which the patient is sensitized and hyper responsive, primarily consisting of organic dusts of animal or vegetable origin, more rarely from chemicals. The prevalence of HP is difficult to evaluate because of uncertainties in detection and misdiagnosis and lacking of widely accepted diagnostic criteria, and varies considerably depending on disease definition, diagnostic methods, exposure modalities, geographical conditions, agricultural and industrial practices, and host risk factors. HP can be caused by multiple agents that are present in work places and in the home, such as microbes, animal and plant proteins, organic and inorganic chemicals. The number of environment, settings and causative agents is increasing over time. From the clinical point of view HP can be divided in acute/subacute and chronic, depending on the intensity and frequency of exposure to causative antigens. The mainstay in managing HP is the avoidance of the causative antigen, though the complete removal is not always possible due to the difficulties to identify the agent or because its avoidance may lead to major changes in life style or occupational settings. HP is a complex syndrome that needs urgently for more stringent and selective diagnostic criteria and validation, including wider panels of IgG, and a closer collaboration with occupational physicians, as part of a multidisciplinary expertise</style></abstract><notes><style face="normal" font="default">DA - 20170313IS - 1476-7961 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1186/s12948-017-0062-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28286422">PM:28286422</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170313, Riario Sforza GG</style></custom2><misc3><style face="normal" font="default">10.1186/s12948-017-0062-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41054</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Genuneit,J.</style></author><author><style face="normal" font="default"> Seibold,A.M.</style></author><author><style face="normal" font="default"> Apfelbacher,C.J.</style></author><author><style face="normal" font="default"> Konstantinou,G.N.</style></author><author><style face="normal" font="default"> Koplin,J.J.</style></author><author><style face="normal" font="default"> La Grutta,S.</style></author><author><style face="normal" font="default"> Logan,K.</style></author><author><style face="normal" font="default"> Flohr,C.</style></author><author><style face="normal" font="default"> Perkin,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">grid.6582.9Institute of Epidemiology and Medical Biometry, Ulm University, Helmholtzstr. 22, 89081 Ulm, Germany</style></auth-address><titles><title><style face="normal" font="default">The state of asthma epidemiology: an overview of systematic reviews and their quality</style></title><secondary-title><style face="normal" font="default">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Transl Allergy</style></full-title></periodical><pages end="" start="12">12-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Biometry</style></keyword><keyword><style face="normal" font="default"> Birth Weight</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetic factors</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> occupational asthma</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pets</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Recently, we have published an overview of systematic reviews in allergy epidemiology and identified asthma as the most commonly reviewed allergic disease. Building on this work, we aimed to investigate the quality of systematic reviews in asthma using the AMSTAR checklist and to provide a reference for future, more in-depth assessment of the extent of previous knowledge. METHODS: We included all 307 systematic reviews indexed with asthma, including occupational asthma, and/or wheeze from our previous search in PubMed and EMBASE up to December 2014 for systematic reviews on epidemiological research on allergic diseases. Topics of the included systematic reviews were indexed and we applied the AMSTAR checklist for methodological quality to all. Statistical analyses include description of lower and upper bounds of AMSTAR scores and variation across publication time and topics. RESULTS: Of 43 topics catalogued, family history, birth weight, and feeding of formula were only covered once in systematic reviews published from 2011 onwards. Overall, at least one meta-analysis was conducted for all topics except for "social determinants", "perinatal", "birth weight", and "climate". AMSTAR quality scores were significantly higher in more recently published systematic reviews, in those with meta-analysis, and in Cochrane reviews. There was evidence of variation of quality across topics even, after accounting for these characteristics. Genetic factors in asthma development were often covered by systematic reviews with some evidence of unsubstantiated updates or repetition. CONCLUSIONS: We present a comprehensive overview with an indexed database of published systematic reviews in asthma epidemiology including quality scores. We highlight some topics including active smoking and pets, which should be considered for future systematic reviews. We propose that our search strategy and database could be a basis for topic-specific overviews of systematic reviews in asthma epidemiology</style></abstract><notes><style face="normal" font="default">DA - 20170412IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Greece -CO - Australia -CO - Italy -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1186/s13601-017-0146-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28400946">PM:28400946</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-12.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170412, Genuneit J</style></custom2><misc3><style face="normal" font="default">10.1186/s13601-017-0146-y</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41055</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Torres,M.J.</style></author><author><style face="normal" font="default"> Romano,A.</style></author><author><style face="normal" font="default"> Celik,G.</style></author><author><style face="normal" font="default"> Demoly,P.</style></author><author><style face="normal" font="default"> Khan,D.A.</style></author><author><style face="normal" font="default"> Macy,E.</style></author><author><style face="normal" font="default"> Park,M.</style></author><author><style face="normal" font="default"> Blumenthal,K.</style></author><author><style face="normal" font="default"> Aberer,W.</style></author><author><style face="normal" font="default"> Castells,M.</style></author><author><style face="normal" font="default"> Barbaud,A.</style></author><author><style face="normal" font="default"> Mayorga,C.</style></author><author><style face="normal" font="default"> Bonadonna,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">grid.452525.1Allergy Unit, National Network ARADyAL, IBIMA-Regional University Hospital of Malaga-UMA (Pavilion C), Plaza del Hospital Civil, 29009 Malaga, Spain</style></auth-address><titles><title><style face="normal" font="default">Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America</style></title><secondary-title><style face="normal" font="default">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Transl Allergy</style></full-title></periodical><pages end="" start="7">7-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Austria</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> Consensus</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> Drug provocation test</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> immediate reactions</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> In vitro tests</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> North America</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Drug hypersensitivity reactions (DHRs) affect an unknown proportion of the general population, and are an important public health problem due to their potential to cause life-threatening anaphylaxis and rare severe cutaneous allergic reactions. DHR evaluations are frequently needed in both ambulatory and hospital settings and have a complex diagnosis that requires a detailed clinical history and other tests that may include in vitro tests and in vivo procedures such as skin tests and drug provocation tests. Although over the years both European and U.S. experts have published statements on general procedures for evaluating DHRs, a substantial discordance in their daily management exists. In this review, we highlight both the differences and the similarities between the European and U.S. PERSPECTIVES: While a general consensus exists on the importance of skin tests for evaluating DHRs, concordance between Americans and Europeans exists solely regarding their use in immediate reactions and the fact that a confirmation of a presumptive diagnosis by drug provocation tests is often the only reliable way to establish a diagnosis. Finally, great heterogeneity exists in the application of in vitro tests, which require further study to be well validated</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 2045-7022 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -CO - Italy -CO - Turkey -CO - France -CO - United States -CO - Austria -</style></notes><work-type><style face="normal" font="default">10.1186/s13601-017-0144-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293415">PM:28293415</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Torres MJ</style></custom2><misc3><style face="normal" font="default">10.1186/s13601-017-0144-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41056</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oosterhaven,J.A.</style></author><author><style face="normal" font="default"> Politiek,K.</style></author><author><style face="normal" font="default"> Schuttelaar,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Groningen, University Medical Centre Groningen, 9700 RB Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Azathioprine treatment and drug survival in patients with chronic hand eczema - results from daily practice</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="307" start="304">304-307</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Azathioprine</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic hand eczema</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand eczema</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170407IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12691</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28386975">PM:28386975</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-304-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-304-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170407, Oosterhaven JA</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12691</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41057</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ljubojevic,H.S.</style></author><author><style face="normal" font="default"> Murtezani,I.</style></author><author><style face="normal" font="default"> Bradamante,M.</style></author><author><style face="normal" font="default"> Ilic,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Venereology, School of Medicine University, University Hospital Centre Zagreb, 10000, Zagreb, Croatia</style></auth-address><titles><title><style face="normal" font="default">Pacemaker allergy</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="309" start="307">307-309</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Croatia</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170407IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Croatia -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12696</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28386971">PM:28386971</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-307-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-307-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170407, Ljubojevic HS</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12696</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41058</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fernandez-Canga,P.</style></author><author><style face="normal" font="default"> Ruiz-Gonzalez,I.</style></author><author><style face="normal" font="default"> Varas-Meis,E.</style></author><author><style face="normal" font="default"> Valladares-Narganes,L.M.</style></author><author><style face="normal" font="default"> Rodriguez-Prieto,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Complejo Asistencial Universitario de Leon, 24008 Leon, Spain</style></auth-address><titles><title><style face="normal" font="default">Contact allergy to benzyl salicylate</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="316" start="315">315-316</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170407IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12707</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28386976">PM:28386976</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-315-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-315-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170407, Fernandez-Canga P</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12707</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41059</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Drewe,W.C.</style></author><author><style face="normal" font="default"> Payne,M.P.</style></author><author><style face="normal" font="default"> Williams,R.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Lhasa Limited, Leeds LS11 5PS, UK</style></auth-address><titles><title><style face="normal" font="default">Phosphite esters: a novel class of contact allergen</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="314" start="312">312-314</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Esters</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170407IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12704</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28386969">PM:28386969</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-312-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-312-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170407, Drewe WC</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12704</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41060</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Moner,V.</style></author><author><style face="normal" font="default"> Fernandez,E.</style></author><author><style face="normal" font="default"> Del Pozo,A.</style></author><author><style face="normal" font="default"> Rodriguez,G.</style></author><author><style face="normal" font="default"> Cocera,M.</style></author><author><style face="normal" font="default"> De La Maza,A.</style></author><author><style face="normal" font="default"> Lopez,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Chemical and Surfactant Technology, Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), 08034, Barcelona, SpainBicosome S.L., 08034, Barcelona, SpainFaculty of Pharmacy, Department of Pharmacy and Pharmaceutical Technology, University of Barcelona, 08028, Barcelona, SpainBicosome S.L., 08034, Barcelona, SpainBicosome S.L., 08034, Barcelona, SpainDepartment of Chemical and Surfactant Technology, Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), 08034, Barcelona, SpainDepartment of Chemical and Surfactant Technology, Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), 08034, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default">Sorption-desorption test for functional assessment of skin treated with a lipid system that mimics epidermal lamellar bodies</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Assessment</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Kinetics</style></keyword><keyword><style face="normal" font="default"> Lipid</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Many skin diseases are associated with either increases or decreases in lamellar body secretion, or dysfunctional lamellar bodies. Consequently, diseased skin is characterized by reduced barrier function and altered lipid composition and organization. Human skin is commonly evaluated in vivo with non-invasive biophysical techniques. The dynamic functions of the skin are evaluated with repeat measurements such as the sorption-desorption test (SDT). OBJECTIVES: The aim of this study was to evaluate in vivo skin hydration-dehydration kinetics after treatment with a lipid system that mimics the morphology, structure and composition of lamellar bodies in both healthy and irritated human skin. METHODS: A patch with an aqueous solution of 2% sodium lauryl sulfate (SLS) was used to irritate the skin of the volunteers. The SDT was performed with the CM 820 corneometer. RESULTS: After treatment with this system, both healthy and SLS-irritated skin increased their ability to retain water and to release water slowly during the desorption phase. CONCLUSIONS: Treatment with this system seems to reinforce the barrier function in both healthy and SLS-irritated human skin. Therefore, the present study provides evidence that this system could be of interest for developing future treatments for protecting and repairing the skin</style></abstract><notes><style face="normal" font="default">DA - 20170316IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default"> 10.1111/cod.12771</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28300294">PM:28300294</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170316-MonerV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170316-MonerV.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170316, Moner V</style></custom2><misc3><style face="normal" font="default"> 10.1111/cod.12771</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41061</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Flores Echaiz,C.</style></author><author><style face="normal" font="default"> Al Ali,A.</style></author><author><style face="normal" font="default"> Cao,A.Q.</style></author><author><style face="normal" font="default"> Sasseville,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Dermatology, McGill University Health Centre, Montreal H3G 1A4, Canada</style></auth-address><titles><title><style face="normal" font="default">Simultaneous contact dermatitis caused by Asteraceae and Verbascum thapsus</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="318" start="316">316-318</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Asteraceae</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170407IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12710</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28386973">PM:28386973</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-316-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-316-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170407, Flores Echaiz C</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12710</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41062</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dittmar,D.</style></author><author><style face="normal" font="default"> Politiek,K.</style></author><author><style face="normal" font="default"> Coenraads,P.J.</style></author><author><style face="normal" font="default"> Flach,P.A.</style></author><author><style face="normal" font="default"> Schuttelaar,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Medical Centre, University of Groningen, 9713 GZ Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis in two employees of an ethylene amine-producing factory</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="312" start="310">310-312</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170407IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12701</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28386980">PM:28386980</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-310-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-310-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170407, Dittmar D</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12701</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41063</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schindewolf,M.</style></author><author><style face="normal" font="default"> Recke,A.</style></author><author><style face="normal" font="default"> Zillikens,D.</style></author><author><style face="normal" font="default"> Lindhoff-Last,E.</style></author><author><style face="normal" font="default"> Ludwig,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Haemostaseology, Department of Internal Medicine, Goethe University Hospital, 60590, Frankfurt am Main, Germany</style></auth-address><titles><title><style face="normal" font="default">Nadroparin carries a potentially high risk of inducing cutaneous delayed-type hypersensitivity responses</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergenicity</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dalteparin</style></keyword><keyword><style face="normal" font="default"> delayed-type hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enoxaparin</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Fondaparinux</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Heparin</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immune-mediated</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nadroparin</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Thrombocytopenia</style></keyword><keyword><style face="normal" font="default"> Thromboembolic events</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="14" Month="3" Year="2017">2017/3/14</year></dates><abstract><style face="normal" font="default">BACKGROUND: Heparins are widely used for the prophylaxis/treatment of thromboembolic events. As adverse effects, heparin-induced skin lesions occur frequently (in 7.5-39% of patients). Skin lesions may be the only clinical manifestation of life-threatening immune-mediated heparin-induced thrombocytopenia, but are commonly caused by a delayed-type hypersensitivity response [heparin-induced delayed-type hypersensitivity (HIHS)]. Risk factors have not been prospectively identified. OBJECTIVES: To identify possible risk factors for heparin-induced skin lesions from three independent clinical trials in a combined analysis. METHODS: A pooled analysis from prospective studies was performed, and possible risk factors were included in a multiple logistic regression analysis. RESULTS: Obesity (body mass index of > 25), prolonged anticoagulant therapy, prior heparin exposure and younger age (&lt; 55 years) were confirmed as independent risk factors for HIHS. The choice of anticoagulant preparation had the greatest influence. On comparison of dalteparin, enoxaparin, fondaparinux, unfractionated heparin, and nadroparin, the latter was associated with the highest risk of eliciting HIHS (odds ratio of 30.2, 95%CI: 11.7-77.9). CONCLUSIONS: The high risk associated with nadroparin has been validated in controlled trials, and this emphasizes the singularity of each heparin preparation in terms of allergenicity and that individualized anticoagulation is required</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12764</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28294347">PM:28294347</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170315-SchindewolfM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170315-SchindewolfM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Schindewolf M</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12764</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41064</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shin,E.J.</style></author><author><style face="normal" font="default"> Gwak,M.J.</style></author><author><style face="normal" font="default"> Jeong,K.H.</style></author><author><style face="normal" font="default"> Shin,M.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, College of Medicine, Kyung Hee University, Seoul, 02447, Korea</style></auth-address><titles><title><style face="normal" font="default">Lack of differentiation of allergic and irritant reactions by skin autofluorescence</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="321" start="318">318-321</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170407IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12708</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28386970">PM:28386970</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-318-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-318-21.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170407, Shin EJ</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12708</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41065</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bregnhoj,A.</style></author><author><style face="normal" font="default"> Sommerlund,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermato-Venereology, Aarhus University Hospital, 8000 Aarhus C, DenmarkDepartment of Dermato-Venereology, Aarhus University Hospital, 8000 Aarhus C, Denmark</style></auth-address><titles><title><style face="normal" font="default">Severe bullous allergic contact dermatitis caused by diethylthiourea 20 years after sensitization to neoprene</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="237" start="236">236-237</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Neoprene</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170320IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12766</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28317196">PM:28317196</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-236-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-236-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Bregnhoj A</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12766</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41066</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Milanesi,N.</style></author><author><style face="normal" font="default"> Gola,M.</style></author><author><style face="normal" font="default"> Francalanci,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergological and Occupational Dermatology Unit, Department of Surgery and Translational Medicine, University of Florence, 50125 Florence, Italy</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by motorcycle heated grips</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="236" start="235">235-236</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170320IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12694</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28317191">PM:28317191</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-235-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-235-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Milanesi N</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12694</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41067</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ahlstrom,M.G.</style></author><author><style face="normal" font="default"> Menne,T.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, National Allergy Research Centre, Herlev and Gentofte Hospital, University of Copenhagen, 2900, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Nickel allergy in a Danish population 25 years after the first nickel regulation</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clothing</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Nickel allergy</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> REACH</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword><keyword><style face="normal" font="default"> Wrist</style></keyword></keywords><dates><year Day="7" Month="4" Year="2017">2017/4/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Nickel in metallic items has been regulated in Denmark since 1990; however, 10% of young Danish women are still sensitized to nickel. There is a need for continuous surveillance of the effect of regulation. OBJECTIVES: To identify current self-reported metallic exposures leading to dermatitis in nickel-allergic patients, and the minimum contact time needed for dermatitis to occur. METHODS: A questionnaire was sent to all patients who reacted positively to nickel sulfate 5% pet. within the last 5 years at the Department of Dermatology and Allergy, Gentofte Hospital. RESULTS: The response rate was 63.2%. Earrings were the foremost cause of dermatitis after the EU Nickel Directive had been implemented, followed by other jewellery, buttons on clothing, belt buckles, and wrist watches. Dermatitis reactions within 10 min of contact were reported by 21.4% of patients, and dermatitis reactions within 30 min of contact were reported by 30.7% of patients. CONCLUSIONS: Nickel exposures that led to implementation of a nickel regulation seem to persist. The durations of contact with metallic items to fall under the current REACH regulation of nickel correspond well with the results of this study</style></abstract><notes><style face="normal" font="default">DA - 20170407IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12782</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28386993">PM:28386993</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170407-AhlstromMG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170407-AhlstromMG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170407, Ahlstrom MG</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12782</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41068</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Friedmann,P.S.</style></author><author><style face="normal" font="default"> Haddadeen,C.</style></author><author><style face="normal" font="default"> Lai,C.</style></author><author><style face="normal" font="default"> Healy,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Medicine, Dermatopharmacology Unit, Sir Henry Wellcome Laboratories, Southampton General Hospital, University of Southampton, Southampton, SO16 6YD, UK</style></auth-address><titles><title><style face="normal" font="default">In vitro human T cell responses to diphencyprone</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="253" start="251">251-253</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170320IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12697</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28317194">PM:28317194</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-251-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-251-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Friedmann PS</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12697</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41069</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pinho,A.</style></author><author><style face="normal" font="default"> Santiago,L.</style></author><author><style face="normal" font="default"> Goncalo,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Department, Hospitais da Universidade de Coimbra, Centro Hospitalar e Universitario de Coimbra, 3000-045 Coimbra, Portugal</style></auth-address><titles><title><style face="normal" font="default">Patch testing in the investigation of non-immediate cutaneous adverse drug reactions to metamizole</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="239" start="238">238-239</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Cutaneous adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> nonimmediate</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170320IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12641</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28317195">PM:28317195</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-238-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-238-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Pinho A</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12641</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41070</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hernandez,N.</style></author><author><style face="normal" font="default"> Hernandez,Z.</style></author><author><style face="normal" font="default"> Liuti,F.</style></author><author><style face="normal" font="default"> Borrego,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Hospital Universitario Nuestra Senora de la Candelaria, Santa Cruz de Tenerife, Spain</style></auth-address><titles><title><style face="normal" font="default">Intolerance to cosmetics as key to the diagnosis in a patient with allergic contact dermatitis caused by propylene glycol contained in a topical medication</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="247" start="246">246-247</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Propylene Glycol</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170320IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12689</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28317186">PM:28317186</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-246-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-246-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Hernandez N</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12689</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41071</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bianchi,L.</style></author><author><style face="normal" font="default"> Hansel,K.</style></author><author><style face="normal" font="default"> Antonelli,E.</style></author><author><style face="normal" font="default"> Bellini,V.</style></author><author><style face="normal" font="default"> Stingeni,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Section of Clinical, Allergological and Venereological Dermatology, University of Perugia, 06156 Perugia, Italy</style></auth-address><titles><title><style face="normal" font="default">Contact allergy to isoconazole nitrate with unusual spreading over extensive regions</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="245" start="243">243-245</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170320IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12688</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28317189">PM:28317189</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-243-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-243-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Bianchi L</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12688</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41072</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bosker,H.M.</style></author><author><style face="normal" font="default"> Politiek,K.</style></author><author><style face="normal" font="default"> Urgert,M.C.</style></author><author><style face="normal" font="default"> Flach,P.A.</style></author><author><style face="normal" font="default"> Coenraads,P.J.</style></author><author><style face="normal" font="default"> Schuttelaar,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Medical Centre Groningen, University of Groningen, 9700 RB, Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Occupational allergic contact dermatitis caused by 1-propanol in a hand disinfectant</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="243" start="241">241-243</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">1-Propanol</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170320IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12673</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28317187">PM:28317187</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-241-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-241-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Bosker HM</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12673</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41073</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Colomb,S.</style></author><author><style face="normal" font="default"> Bourrain,J.L.</style></author><author><style face="normal" font="default"> Bonardel,N.</style></author><author><style face="normal" font="default"> Chiriac,A.</style></author><author><style face="normal" font="default"> Demoly,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departement de Pneumologie et d'Addictologie, Service d'Allergologie, Pole Coeur-Poumon, Centre Hospitalier Universitaire de Montpellier, 34295 Montpellier, France</style></auth-address><titles><title><style face="normal" font="default">Occupational opiate contact dermatitis</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="241" start="240">240-241</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170320IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12666</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28317188">PM:28317188</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-240-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-240-1.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Colomb S</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12666</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41074</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Adler,W.</style></author><author><style face="normal" font="default"> Gefeller,O.</style></author><author><style face="normal" font="default"> Uter,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander University of Erlangen/Nurnberg, 91054, Erlangen, Germany</style></auth-address><titles><title><style face="normal" font="default">Positive reactions to pairs of allergens associated with polysensitization: analysis of IVDK data with machine-learning techniques</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="251" start="247">247-251</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Biometry</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Informatics</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170320IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12706</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28317190">PM:28317190</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-247-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-247-51.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Adler W</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12706</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41075</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Du-Thanh,A.</style></author><author><style face="normal" font="default"> Lalande,M.</style></author><author><style face="normal" font="default"> Raison-Peyron,N.</style></author><author><style face="normal" font="default"> Dereure,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Montpellier University Hospital, 34295 Montpellier, France</style></auth-address><titles><title><style face="normal" font="default">Atypical and severe airborne isothiazolinone contact dermatitis mimicking Kaposi-Juliusberg syndrome</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="298" start="297">297-298</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170407IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12690</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28386979">PM:28386979</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-297-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-297-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170407, Du-Thanh A</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12690</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41076</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Trokoudes,D.</style></author><author><style face="normal" font="default"> Banerjee,P.</style></author><author><style face="normal" font="default"> Fityan,A.</style></author><author><style face="normal" font="default"> Sarkany,R.</style></author><author><style face="normal" font="default"> White,I.R.</style></author><author><style face="normal" font="default"> White,J.M.</style></author><author><style face="normal" font="default"> McFadden,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London SE1 7EH, UK</style></auth-address><titles><title><style face="normal" font="default">Photoaggravated contact dermatitis caused by methylisothiazolinone</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="304" start="303">303-304</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170407IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12718</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28386977">PM:28386977</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-303-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-303-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170407, Trokoudes D</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12718</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41077</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Craig,S.</style></author><author><style face="normal" font="default"> Urwin,R.</style></author><author><style face="normal" font="default"> Latheef,F.</style></author><author><style face="normal" font="default"> Wilkinson,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Leeds Teaching Hospitals NHS Foundation Trust, Leeds LS7 4SA, UK</style></auth-address><titles><title><style face="normal" font="default">Patch test clinic experience of potential cross-reactivity of isothiazolinones</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="300" start="299">299-300</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">cross reactivity</style></keyword><keyword><style face="normal" font="default"> Cross-reactivity</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Isothiazolinones</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Teaching</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170407IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12741</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28386981">PM:28386981</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-299-300.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-299-300.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170407, Craig S</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12741</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41078</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Urwin,R.</style></author><author><style face="normal" font="default"> Craig,S.</style></author><author><style face="normal" font="default"> Latheef,F.</style></author><author><style face="normal" font="default"> Wilkinson,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Leeds Teaching Hospitals NHS Foundation Trust, Leeds LS7 4SA, UK</style></auth-address><titles><title><style face="normal" font="default">Methylisothiazolinone: the epidemic is declining - but not gone</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="302" start="301">301-302</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidemic</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Teaching</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170407IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12750</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28386974">PM:28386974</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-301-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-301-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170407, Urwin R</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12750</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41079</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dickel,H.</style></author><author><style face="normal" font="default"> Geier,J.</style></author><author><style face="normal" font="default"> Kreft,B.</style></author><author><style face="normal" font="default"> Pfutzner,W.</style></author><author><style face="normal" font="default"> Kuss,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Venereology and Allergology, Ruhr University Bochum, 44791, Bochum, Germany</style></auth-address><titles><title><style face="normal" font="default">Comparing reliabilities of strip and conventional patch testing</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Alcohol</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> False negative</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lanolin</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Potassium</style></keyword><keyword><style face="normal" font="default"> Potassium Dichromate</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Test method</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="7" Month="3" Year="2017">2017/3/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: The standardized protocol for performing the strip patch test has proven to be valid, but evidence on its reliability is still missing. OBJECTIVE: To estimate the parallel-test reliability of the strip patch test as compared with the conventional patch test. METHODS: In this multicentre, prospective, randomized, investigator-blinded reliability study, 132 subjects were enrolled. Simultaneous duplicate strip and conventional patch tests were performed with the Finn Chambers(R) on Scanpor(R) tape test system and the patch test preparations nickel sulfate 5% pet., potassium dichromate 0.5% pet., and lanolin alcohol 30% pet. Reliability was estimated by the use of Cohen's kappa coefficient. RESULTS: Parallel-test reliability values of the three standard patch test preparations turned out to be acceptable, with slight advantages for the strip patch test. The differences in reliability were 9% (95%CI: -8% to 26%) for nickel sulfate and 23% (95%CI: -16% to 63%) for potassium dichromate, both favouring the strip patch test. CONCLUSIONS: The standardized strip patch test method for the detection of allergic contact sensitization in patients with suspected allergic contact dermatitis is reliable. Its application in routine clinical practice can be recommended, especially if the conventional patch test result is presumably false negative</style></abstract><notes><style face="normal" font="default">DA - 20170308IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12758</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28271532">PM:28271532</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170308-DickelH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170308-DickelH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170308, Dickel H</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12758</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41080</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dittmar,D.</style></author><author><style face="normal" font="default"> Schuttelaar,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Medical Centre Groningen, University of Groningen, 9700 RB, Groningen, The NetherlandsDepartment of Dermatology, University Medical Centre Groningen, University of Groningen, 9700 RB, Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Immunology and genetics of tumour necrosis factor in allergic contact dermatitis</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="271" start="257">257-271</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Functionality</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Histocompatibility</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> Major Histocompatibility Complex</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Promoter</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Suggestion</style></keyword><keyword><style face="normal" font="default"> TNF</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="default">During the sensitization phase of allergic contact dermatitis, the proinflammatory cytokine tumour necrosis factor (TNF) plays an important role by promoting epidermal Langerhans cell migration to draining lymph nodes. It also plays a role during the elicitation phase. The TNF gene (TNF) is located within the major histocompatibility complex region. Many single-nucleotide variants exist in the promoter region of TNF, and these may either increase or decrease mRNA transcription and therefore lead to higher or lower levels of TNF. The most extensively studied single-nucleotide variant of TNF is a base pair substitution in the promoter region at location -308 relative to the transcription start site (rs1800629, TNF -308G>A), which is believed to increase transcription and lead to higher TNF levels. The role of TNF in allergic contact dermatitis and the functionality of TNF -308G>A are reviewed in this article. The association between genetic variants and disease can be studied in a case-control design. Only a few case-control studies investigating the association between TNF -308G>A and allergic contact dermatitis have been published, with contradictory results. These are reviewed critically, and suggestions for future case-control studies on this topic are given</style></abstract><notes><style face="normal" font="default">DA - 20170316IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12769</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28300283">PM:28300283</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-257-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-257-71.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170316, Dittmar D</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12769</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41081</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dumycz,K.</style></author><author><style face="normal" font="default"> Osinka,K.</style></author><author><style face="normal" font="default"> Feleszko,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Paediatric Respiratory Diseases and Allergy, The Medical University of Warsaw, 02-091, Warsaw, Poland</style></auth-address><titles><title><style face="normal" font="default">Contact allergens in topical corticosteroid vehicles: analysis of product composition</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="255" start="254">254-255</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact allergens</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Respiratory diseases</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword><keyword><style face="normal" font="default"> Vehicles</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170320IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12693</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28317192">PM:28317192</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-254-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-254-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Dumycz K</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12693</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41082</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Koppes,S.A.</style></author><author><style face="normal" font="default"> Ljubojevic,H.S.</style></author><author><style face="normal" font="default"> Jakasa,I.</style></author><author><style face="normal" font="default"> Franceschi,N.</style></author><author><style face="normal" font="default"> Riethmuller,C.</style></author><author><style face="normal" font="default"> Jurakic,T.R.</style></author><author><style face="normal" font="default"> Marinovic,B.</style></author><author><style face="normal" font="default"> Raj,N.</style></author><author><style face="normal" font="default"> Rawlings,A.V.</style></author><author><style face="normal" font="default"> Voegeli,R.</style></author><author><style face="normal" font="default"> Lane,M.E.</style></author><author><style face="normal" font="default"> Haftek,M.</style></author><author><style face="normal" font="default"> Frings-Dresen,M.H.</style></author><author><style face="normal" font="default"> Rustemeyer,T.</style></author><author><style face="normal" font="default"> Kezic,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Academic Medical Center, Department: Coronel institute of Occupational Health, Amsterdam Public Health Research Institute, 1105AZ, Amsterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Effect of allergens and irritants on levels of natural moisturizing factor and corneocyte morphology</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="295" start="287">287-295</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergen exposure</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cornea</style></keyword><keyword><style face="normal" font="default"> Croatia</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritants</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> methylchloroisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Health</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Potassium</style></keyword><keyword><style face="normal" font="default"> Potassium Dichromate</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> stratum corneum</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="14" Month="3" Year="2017">2017/3/14</year></dates><abstract><style face="normal" font="default">BACKGROUND: The irritant sodium lauryl sulfate (SLS) is known to cause a decrease in the stratum corneum level of natural moisturizing factor (NMF), which in itself is associated with changes in corneocyte surface topography. OBJECTIVE: To explore this phenomenon in allergic contact dermatitis. METHODS: Patch testing was performed on patients with previously positive patch test reactions to potassium dichromate (Cr), nickel sulfate (Ni), methylchloroisothiazolinone (MCI)/methylisothiazolinone (MI), or p-phenylenediamine. Moreover, a control (pet.) patch and an irritant (SLS) patch were applied. After 3 days, the stratum corneum from tested sites was collected, and NMF levels and corneocyte morphology, expressed as the amount of circular nanosize objects, quantified according to the Dermal Texture Index (DTI), were determined. RESULTS: Among allergens, only MCI/MI reduced NMF levels significantly, as did SLS. Furthermore, only MCI/MI caused remarkable changes at the microscopic level; the corneocytes were hexagonal-shaped with pronounced cell borders and a smoother surface. The DTI was increased after SLS exposure but not after allergen exposure. CONCLUSIONS: MCI/MI significantly decreased NMF levels, similarly to SLS. The altered corneocyte morphology suggests that skin barrier damage plays a role in the pathogenesis of MCI/MI contact allergy. The DTI seems to differentiate reactions to SLS from those to the allergens tested, as SLS was the only agent that caused a DTI increase</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Croatia -CO - Germany -CO - United Kingdom -CO - Switzerland -CO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12770</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28295421">PM:28295421</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-287-95.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-287-95.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Koppes SA</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12770</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41083</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Waton,J.</style></author><author><style face="normal" font="default"> Brault,F.</style></author><author><style face="normal" font="default"> Laveine,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology and Allergy Department, University Hospital of Nancy, 54500 Vandoeuvre les Nancy, France</style></auth-address><titles><title><style face="normal" font="default">A putative case of allergic contact dermatitis caused by a jagua tattoo</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="297" start="296">296-297</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170407IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12767</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28386982">PM:28386982</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-296-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-76-296-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170407, Waton J</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12767</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41084</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chipps,B.E.</style></author><author><style face="normal" font="default"> Parikh,N.G.</style></author><author><style face="normal" font="default"> Maharaj,S.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Capital Allergy and Respiratory Disease Center, 5609 J Street, Suite C, Sacramento, CA, 95819, USA.</style></auth-address><titles><title><style face="normal" font="default">Severe Asthma in Children</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="21">21-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral infection</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: The aim of this study is to characterize, diagnose, evaluate, and treat severe childhood asthma. RECENT FINDINGS: Understanding the occurrence of the physiologic and clinical presentations of childhood severe asthma, the treatment and response may be predicted by biomarkers, but the patient's response is highly variable. The onset of severe asthma occurs early and is primarily predicted by severity of viral infection and coexistence of the atopic state</style></abstract><notes><style face="normal" font="default">DA - 20170329IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0688-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28353215">PM:28353215</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-21.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170329, Chipps BE</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0688-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41085</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tan,K.S.</style></author><author><style face="normal" font="default"> Yan,Y.</style></author><author><style face="normal" font="default"> Ong,H.H.</style></author><author><style face="normal" font="default"> Chow,V.T.</style></author><author><style face="normal" font="default"> Shi,L.</style></author><author><style face="normal" font="default"> Wang,D.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, Singapore, 119228, Singapore</style></auth-address><titles><title><style face="normal" font="default">Impact of Respiratory Virus Infections in Exacerbation of Acute and Chronic Rhinosinusitis</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="24">24-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic tool</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease Management</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Otolaryngology</style></keyword><keyword><style face="normal" font="default"> Respiratory viruses</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral infection</style></keyword><keyword><style face="normal" font="default"> Viral infections</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> virus infection</style></keyword><keyword><style face="normal" font="default"> Viruses</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">Rhinosinusitis (RS) is a symptomatic disease classification of many causes and is a major economic burden worldwide. It is widely accepted that RS is further classified into acute (ARS) and chronic (CRS) rhinosinusitis based on the duration of the symptoms, and that viral infection plays a large role in initiating or potentiating the disease. In this review, we examine the role of respiratory virus infection in the exacerbation of ARS and CRS. We explore the epidemiology of viral exacerbation of ARS and CRS and highlight key viruses that may cause exacerbation. We also review the current understanding of viral infections in the upper airway to further explain the putative underlying mechanisms of inflammatory events in ARS and CRS exacerbation. Advances in accurate diagnosis of the etiologic respiratory viruses of ARS and CRS symptoms which can lead to better disease management are also surveyed. In addition to the current treatments which provide symptomatic relief, we also explore the potential of harnessing existing antiviral strategies to prevent ARS and CRS exacerbation, especially with improved viral diagnostic tools to guide accurate prescription of antivirals against causative respiratory viruses</style></abstract><notes><style face="normal" font="default">DA - 20170408IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Singapore -CO - China -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0693-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28389843">PM:28389843</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-24.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170408, Tan KS</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0693-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41086</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Romano,A.</style></author><author><style face="normal" font="default"> Valluzzi,R.L.</style></author><author><style face="normal" font="default"> Caruso,C.</style></author><author><style face="normal" font="default"> Maggioletti,M.</style></author><author><style face="normal" font="default"> Gaeta,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Unit, Presidio Columbus, Via G. Moscati, 31, 00168, Rome, Italy.</style></auth-address><titles><title><style face="normal" font="default">Non-immediate Cutaneous Reactions to Beta-Lactams: Approach to Diagnosis</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="23">23-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Acute Generalized Exanthematous Pustulosis</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy test</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> beta-Lactams</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Betalactams</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous reaction</style></keyword><keyword><style face="normal" font="default"> Cutaneous reactions</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic tool</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug eruption</style></keyword><keyword><style face="normal" font="default"> Drug-induced</style></keyword><keyword><style face="normal" font="default"> drug-induced hypersensitivity syndrome</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exanthema</style></keyword><keyword><style face="normal" font="default"> Fixed drug eruption</style></keyword><keyword><style face="normal" font="default"> Graded challenge</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity syndrome</style></keyword><keyword><style face="normal" font="default"> intradermal test</style></keyword><keyword><style face="normal" font="default"> Intradermal Tests</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Transformation</style></keyword><keyword><style face="normal" font="default"> nonimmediate</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rome</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe reactions</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Transformation</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">Non-immediate cutaneous reactions (i.e., occurring at least 1 h after the initial drug administration), particularly maculopapular exanthemas and urticarial eruptions, are common during beta-lactam treatments. A T cell-mediated pathogenic mechanism has been demonstrated in some cutaneous reactions, such as maculopapular exanthema, fixed drug eruption, acute generalized exanthematous pustulosis, and drug-induced hypersensitivity syndrome. In the diagnostic work-up, patch testing is useful, together with delayed-reading intradermal testing. Patch tests are a simple and safe diagnostic tool, which in the case of severe reactions should be used as the first line of investigation. However, patch tests are less sensitive than intradermal tests, which are preferable in subjects with mild reactions. Lymphocyte transformation or activation tests and enzyme-linked immunosorbent spot assays can be used as complementary tests. In selected cases of mild or moderate reactions, displaying negative results in the aforesaid allergy tests, a graded challenge with the implicated beta-lactam can be performed</style></abstract><notes><style face="normal" font="default">DA - 20170406IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0691-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28382604">PM:28382604</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-23.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170406, Romano A</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0691-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41087</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rudmik,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Richmond Road Diagnostic and Treatment Centre, University of Calgary, 1820 Richmond Road SW, Calgary, AB, T2T 5C7, Canada.</style></auth-address><titles><title><style face="normal" font="default">Economics of Chronic Rhinosinusitis</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="20">20-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Burden</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> economics</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> endoscopic sinus surgery</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> QOL</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> sinus</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: The objective of this article is to provide an updated review of the economic burden of chronic rhinosinusitis (CRS) and discuss how both medical and surgical interventions impact direct and indirect costs related to CRS. By understanding the economics of CRS, clinicians may improve the patient-centeredness of their care and help distinguish between low and high value interventions. RECENT FINDINGS: Direct costs related to CRS are primarily driven by outpatient physician visits, prescription medical therapy, and endoscopic sinus surgery (ESS). CRS produces large indirect costs and these costs often vary based on the severity of the patients CRS-specific QoL impairment. The overall direct cost related to CRS is estimated to range between $10 and $13 billion per year in the USA. The overall indirect cost related to CRS-related losses in work productivity is estimated to be in excess of $20 billion per year. In the appropriate patients with refractory CRS, ESS provides significant reductions in both direct and indirect costs; however, continued medical therapy alone may be a high value intervention in select patients who have lower severity in their baseline QoL and work productivity</style></abstract><notes><style face="normal" font="default">DA - 20170324IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0690-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28337570">PM:28337570</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-20.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170324, Rudmik L</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0690-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41088</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pawelczyk,M.</style></author><author><style face="normal" font="default"> Kowalski,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunology, Rheumatology and Allergy Clinic, Healthy Ageing Research Centre Medical University of Lodz, 251 Pomorska Street, 92-213, Lodz, Poland</style></auth-address><titles><title><style face="normal" font="default">The Role of Human Parainfluenza Virus Infections in the Immunopathology of the Respiratory Tract</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="16">16-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> Coronavirus</style></keyword><keyword><style face="normal" font="default"> Croup</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human rhinovirus</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> immunopathology</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Influenza</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pneumonia</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> respiratory infection</style></keyword><keyword><style face="normal" font="default"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Rhinovirus</style></keyword><keyword><style face="normal" font="default"> Rna</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral infection</style></keyword><keyword><style face="normal" font="default"> Viral infections</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> virus infection</style></keyword><keyword><style face="normal" font="default"> Viruses</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">Viral infections are leading causes of both upper and lower airway acute illness in all age groups of healthy persons, and have also been implicated in the acute exacerbations of chronic respiratory disorders like asthma and COPD. Human rhinovirus, respiratory syncytial virus, influenza virus and coronavirus have been considered as the most important respiratory pathogens and relatively little attention has been paid to the role of parainfluenza viruses (hPIVs). Human parainfluenza viruses are single-stranded RNA viruses belonging to the paramyxovirus family that may evoke lower respiratory infections in infants, children and immunocompromised individuals. Among non-immune compromised adults, hPIV infection typically causes mild disease manifested as upper respiratory tract symptoms and is infrequently associated with severe croup or pneumonia. Moreover, hPIV infection may be associated with viral exacerbations of chronic airway diseases, asthma or COPD or chronic rhinosinusitis. In this review, we summarized the basic epidemiology and immunology of hPIVs and addressed the more recent data implicating the role of parainfluenza viruses in the exacerbation of chronic airway disorders</style></abstract><notes><style face="normal" font="default">DA - 20170311IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0685-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283855">PM:28283855</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-16.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170311, Pawelczyk M</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0685-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41089</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hines,K.L.</style></author><author><style face="normal" font="default"> Peebles,R.S.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Vanderbilt University Medical Center, T-1218 MCN, 1161 21st Avenue South, Nashville, TN, 37232-2650, USA</style></auth-address><titles><title><style face="normal" font="default">Management of the Asthma-COPD Overlap Syndrome (ACOS): a Review of the Evidence</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="15">15-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma therapy</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> bronchodilators</style></keyword><keyword><style face="normal" font="default"> Cessation</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="default"> Gold</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Smoking Cessation</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Vaccination</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Examine the definition of the asthma-COPD overlap syndrome (ACOS) and current treatment strategies. RECENT FINDINGS: Patients with the ACOS have a lower quality of life and suffer from more complications than those affected by either disease alone. Diagnosis of ACOS is difficult because of the clinical similarities between the two diseases and the various phenotypes that comprise the syndrome. Defining treatment strategies for ACOS has been challenging because many clinical trials for asthma therapy have purposefully excluded patients with features of COPD, and COPD clinical trials have not included patients who might have an asthmatic component to their disease. Therefore, there are few randomized treatment trials which have included patients who have ACOS. Smoking cessation and appropriate vaccinations are cornerstone therapies, and pharmacologic therapy has focused on bronchodilators and inhaled corticosteroids. The role of biologics, such as omalizumab and IL-5 antagonists, in ACOS treatment is still being defined. As of now, with the paucity of randomized control trials guiding treatment strategies, the Global Initiative for Asthma (GINA) and Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend treating ACOS according to the dominant phenotype</style></abstract><notes><style face="normal" font="default">DA - 20170311IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0683-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28283854">PM:28283854</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-15.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170311, Hines KL</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0683-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41090</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fuseini,H.</style></author><author><style face="normal" font="default"> Newcomb,D.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, TN, 37232, USA</style></auth-address><titles><title><style face="normal" font="default">Mechanisms Driving Gender Differences in Asthma</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="19">19-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal model</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> DC</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> estrogen</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> gender difference</style></keyword><keyword><style face="normal" font="default"> Hormones</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mechanics</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Menopause</style></keyword><keyword><style face="normal" font="default"> Menstruation</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Mucus</style></keyword><keyword><style face="normal" font="default"> Muscle Contraction</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Puberty</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Testosterone</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Many phenotypes of asthma exist, ranging from mild asthma with onset during childhood to severe asthma with later onset, making asthma a broad disease with different pathologies. A gender disparity exists in asthma prevalence. As adults, women have an increased asthma prevalence compared to men. Further, women are more likely to have severe asthma and a later onset of asthma compared to men. Here, we review clinical and animal studies that have defined the role of sex hormones in airway inflammation, smooth muscle contraction, mucus production, and airway mechanics associated with asthma pathogenesis. RECENT FINDINGS: Clinical evidence shows that increased asthma symptoms occur in females starting at puberty compared to those in boys. However, after puberty, the role for sex hormones in regulating asthma symptoms during menstruation, pregnancy, and menopause is not as clear. Animal studies have shown that estrogen increases and testosterone decreases Th2-mediated airway inflammation, and that females have increased IL-17A-mediated airway inflammation compared to males. Further, females had increased DC and Mvarphi function compared to males. However, the mechanisms driving the types of allergic inflammation are not fully elucidated. Overall, ovarian hormones increased and testosterone decreased airway inflammation in asthma, but the mechanisms remain unclear. Delineating these pathways using animal models as well as women and men with various phenotypes of asthma will help determine if women with asthma should take (or avoid) hormonal contraceptives as well as predict changes in asthma symptoms during life phases, including pregnancy and menopause, when sex hormones are dramatically changing</style></abstract><notes><style face="normal" font="default">DA - 20170323IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0686-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28332107">PM:28332107</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-19.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-19.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170323, Fuseini H</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0686-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41091</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Carpenter,D.M.</style></author><author><style face="normal" font="default"> Roberts,C.A.</style></author><author><style face="normal" font="default"> Sage,A.J.</style></author><author><style face="normal" font="default"> George,J.</style></author><author><style face="normal" font="default"> Horne,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Eshelman School of Pharmacy, University of North Carolina, CPO 2125, Asheville, NC, 28804, USA.</style></auth-address><titles><title><style face="normal" font="default">A Review of Electronic Devices to Assess Inhaler Technique</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="17">17-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Australia</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Feedback</style></keyword><keyword><style face="normal" font="default"> MDI</style></keyword><keyword><style face="normal" font="default"> North Carolina</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Multiple electronic devices exist that provide feedback on the accuracy of patient inhaler technique. Our purpose is to describe the inhaler technique feedback provided by these devices, including specific technique steps measured, how feedback is displayed, target of feedback (patient, provider, researcher), and compatibility with inhaler type (metered-dose inhaler [MDI], diskus, etc.). RECENT FINDINGS: We identified eight devices that provide feedback on inhaler technique. Only one device assessed all evidence-based MDI technique steps. Most devices provide limited real-time feedback to patients, if any feedback at all. Technologies to assess inhaler technique are advancing and hold great potential for improving patient inhaler technique. Many devices are limited in their ability to detect all evidence-based technique steps and provide real-time user-friendly feedback to patients and providers. Usability tests with patients and providers could identify ways to improve these devices to improve their utility in clinical settings</style></abstract><notes><style face="normal" font="default">DA - 20170314IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -CO - United Kingdom -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0684-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28290015">PM:28290015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-17.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-17.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170314, Carpenter DM</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0684-3</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41092</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Scheman,A.</style></author><author><style face="normal" font="default"> Hipolito,R.</style></author><author><style face="normal" font="default"> Severson,D.</style></author><author><style face="normal" font="default"> Youkhanis,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Northwestern University Medical Center, Chicago, IL</style></auth-address><titles><title><style face="normal" font="default">Contact Allergy Cross-reactions: Retrospective Clinical Data and Review of the Literature</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="140" start="128">128-140</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cross Reactions</style></keyword><keyword><style face="normal" font="default"> Cross-reaction</style></keyword><keyword><style face="normal" font="default"> cross-reactions</style></keyword><keyword><style face="normal" font="default"> Crossreactions</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Philippines</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">We discuss cross-reactions that can occur when a patient allergic to a specific allergen also reacts to a similar allergen. Currently, The American Contact Dermatitis Society Contact Allergy Management Program, which allows physicians to identify safe products for their patients, uses a 10% threshold to distinguish significant cross-reactors. New clinical data from a patch testing center along with previous data in the literature are analyzed to help determine whether current cross-reactor definitions are reasonable or should be altered</style></abstract><notes><style face="normal" font="default">DA - 20170314IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - Philippines -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000254</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28291074">PM:28291074</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-128-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-128-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170314, Scheman A</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000254</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41093</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liang,J.</style></author><author><style face="normal" font="default"> Liu,Y.</style></author><author><style face="normal" font="default"> Xue,R.</style></author><author><style face="normal" font="default"> Chen,L.</style></author><author><style face="normal" font="default"> Chen,H.</style></author><author><style face="normal" font="default"> Shao,L.</style></author><author><style face="normal" font="default"> Wang,J.</style></author><author><style face="normal" font="default"> Zhang,X.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Dermatology, Guangzhou Medical University</style></auth-address><titles><title><style face="normal" font="default">Interleukin 4 -590C/T (rs2243250) Polymorphism Is Associated With Increased Risk of Atopic Dermatitis: Meta-Analysis of Case-Control Studies</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="151" start="144">144-151</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Interleukin-4</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Interleukin 4 (IL-4) -590C/T polymorphism has been reported to influence atopic dermatitis (AD) susceptibility, but the results are controversial. OBJECTIVE: This meta-analysis was performed to study the association between IL-4 -590C/T polymorphism and AD susceptibility. METHODS: The PubMed, Embase, and China National Knowledge Infrastructure databases were searched. Odds ratios (ORs) with 95% confidence intervals (CIs) were performed to estimate the strength of the association. RESULTS: Ten studies comprising 923 cases and 1215 controls were included. The overall population revealed significant associations between IL-4 -590C/T polymorphism and AD susceptibility under the allele (OR, 1.19; 95% CI, 1.03-1.38; I = 0.0%), recessive (OR, 1.27; 95% CI, 1.002-1.61; I = 0.0%), and dominant (OR, 1.33; 95% CI, 1.003-1.76; I = 0.0%) models; similar results were found under the allele (OR, 1.19; 95% CI, 1.01-1.39; I = 0.0%) and recessive (OR, 1.27; 95% CI, 1.001-1.62; I = 0.0%) models after excluding not-in-Hardy-Weinberg equilibrium studies. However, subgroup analyses by ethnicity showed no significant association in Asians or whites. Subgroup analyses by age indicated a significant association in children under the allele (OR, 1.30; 95% CI, 1.06-1.60; I = 0.0%) and dominant (OR, 1.42; 95% CI, 1.02-1.97; I = 0.0%) models, children in articles with Hardy-Weinberg equilibrium under the allele model (OR, 1.33; 95% CI, 1.05-1.69; I = 0.0%), and Asian children under the allele model (OR, 1.41; 95% CI, 1.02-1.95; I = 0.0%) but not in white children. CONCLUSIONS: The IL-4 -590C/T polymorphism may contribute to AD susceptibility in the overall population and children, especially for Asian children, but large well-designed studies are warranted to confirm this conclusion</style></abstract><notes><style face="normal" font="default">DA - 20170207IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000265</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28169853">PM:28169853</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-144-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-144-51.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170207, Liang J</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000265</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41094</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Berton,F.</style></author><author><style face="normal" font="default"> Stacchi,C.</style></author><author><style face="normal" font="default"> Bussani,R.</style></author><author><style face="normal" font="default"> Berton,T.</style></author><author><style face="normal" font="default"> Lombardi,T.</style></author><author><style face="normal" font="default"> Di Lenarda,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical, Surgical and Health Sciences, University of Trieste; daggerPrivate practice in Treviso; and double daggerPrivate practice in Cassano allo Ionio, Italy</style></auth-address><titles><title><style face="normal" font="default">Toothpaste-Induced Oral Mucosal Desquamation</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="163" start="162">162-163</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161024IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000227</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27775968">PM:27775968</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-162-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-162-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161024, Berton F</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000227</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41095</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Grey,K.R.</style></author><author><style face="normal" font="default"> Hagen,S.L.</style></author><author><style face="normal" font="default"> Hylwa,S.A.</style></author><author><style face="normal" font="default"> Warshaw,E.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Minnesota Medical School</style></auth-address><titles><title><style face="normal" font="default">Utility of Store and Forward Teledermatology for Skin Patch Test Readings</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="161" start="152">152-161</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Assessment</style></keyword><keyword><style face="normal" font="default"> Barriers</style></keyword><keyword><style face="normal" font="default"> bias</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Distance</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> imaging</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Minnesota</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Reading</style></keyword><keyword><style face="normal" font="default"> Recall</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Teledermatology (TD) is the use of imaging technology to provide dermatology services at a distance. To date, studies assessing its application for grading skin patch test reactions have been lacking. OBJECTIVES: The aim was to compare conventional, in-person (IP) grading of skin patch test reactions with store-forward TD. METHODS: Patients undergoing patch testing to the North American Contact Dermatitis Group (NACDG) screening series were invited to participate in this repeated-measures study. Photographs of the NACDG screening series patch sites were obtained at 2 time points (48-hour and final readings). Teledermatology assessments were completed by the same staff dermatologist who performed the IP readings; 48-hour and final TD photographs were viewed at weeks 4 and 8 after the IP encounter, respectively, to prevent recall bias. Staff dermatologists were blinded to IP grading results. The main outcome was percent agreement. Eight categories of agreement were created according to possible pairings of TD and IP reading results. Three final outcome groups of "success," "indeterminate," and "failure" were defined based on clinical significance. RESULTS: One hundred one participants completed the study. There were 7070 comparison points between IP and TD final readings. Excluding negative/negative agreement, there was "success" of TD in 54% of final readings. "Indeterminate" agreement with possible clinical significance was present in 40% of final readings. There was "failure" (definite clinical significance) in 6% of final readings. CONCLUSIONS: Teledermatology may be a viable option for grading skin patch test reactions, particularly for clinicians who perform limited patch testing. However, a clinically significant "failure" rate of 6% and practical barriers to TD implementation may preclude its widespread use for skin patch testing in tertiary referral centers where large numbers of patches are tested per patient</style></abstract><notes><style face="normal" font="default">DA - 20170207IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000258</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28169849">PM:28169849</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-152-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-152-61.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170207, Grey KR</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000258</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41096</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aschenbeck,K.A.</style></author><author><style face="normal" font="default"> Warshaw,E.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Minnesota School of Medicine, Minneapolis</style></auth-address><titles><title><style face="normal" font="default">Allergenic Ingredients in Facial Wet Wipes</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Alcohol</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergenic</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Aloe</style></keyword><keyword><style face="normal" font="default"> Chamomile</style></keyword><keyword><style face="normal" font="default"> Citric Acid</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cucumis sativus</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Fragrances</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Glucosides</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> methylchloroisothiazolinone</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Minnesota</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Polyethylene</style></keyword><keyword><style face="normal" font="default"> Polyethylene glycol</style></keyword><keyword><style face="normal" font="default"> Preservatives</style></keyword><keyword><style face="normal" font="default"> Propylene Glycol</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> Sodium Benzoate</style></keyword><keyword><style face="normal" font="default"> Sorbic Acid</style></keyword><keyword><style face="normal" font="default"> Tea</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="23" Month="3" Year="2017">2017/3/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic contact dermatitis commonly occurs on the face. Facial cleansing wipes may be an underrecognized source of allergens. OBJECTIVE: The aim of this study was to determine the frequency of potentially allergenic ingredients in facial wet wipes. METHODS: Ingredient lists from name brand and generic facial wipes from 4 large retailers were analyzed. RESULTS: In the 178 facial wipes examined, a total of 485 ingredients were identified (average, 16.7 ingredients per wipe). Excluding botanicals, the top 15 potentially allergenic ingredients were glycerin (64.0%), fragrance (63.5%), phenoxyethanol (53.9%), citric acid (51.1%), disodium EDTA (44.4%), sorbic acid derivatives (39.3%), tocopherol derivatives (38.8%), polyethylene glycol derivatives (32.6%), glyceryl stearate (31.5%), sodium citrate (29.8%), glucosides (27.5%), cetearyl alcohol (25.8%), propylene glycol (25.3%), sodium benzoate (24.2%), and ceteareth-20 (23.6%)/parabens (23.6%). Of note, methylisothiazolinone (2.2%) and methylchloroisothiazolinone (1.1%) were uncommon. The top potential allergens of botanical origin included Aloe barbadensis (41.0%), chamomile extracts (27.0%), tea extracts (21.3%), Cucumis sativus (20.2%), and Hamamelis virginiana (10.7%). CONCLUSIONS: Many potential allergens are present in facial wet wipes, including fragrances, preservatives, botanicals, glucosides, and propylene glycol</style></abstract><notes><style face="normal" font="default">DA - 20170324IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000275</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28338538">PM:28338538</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\20170324-AschenbeckKA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\20170324-AschenbeckKA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170324, Aschenbeck KA</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000275</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41097</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Agullo-Perez,A.D.</style></author><author><style face="normal" font="default"> Hervella-Garces,M.</style></author><author><style face="normal" font="default"> Oscoz-Jaime,S.</style></author><author><style face="normal" font="default"> Azcona-Rodriguez,M.</style></author><author><style face="normal" font="default"> Larrea-Garcia,M.</style></author><author><style face="normal" font="default"> Yanguas-Bayona,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Department of Dermatology, Complejo Hospitalario de Navarra, Pamplona, Spain</style></auth-address><titles><title><style face="normal" font="default">Clinical Study of 124 Patients Having Perianal Dermatitis</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Exploration</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritant contact dermatitis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neurodermatitis</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Own products</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="23" Month="3" Year="2017">2017/3/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: Perianal complaints are often consulted in dermatology clinics, and in many cases, a conclusive diagnosis is not easily made. OBJECTIVE: The aim of this study was to study and identify the epidemiological, clinical, and contact allergy features of patients with perianal dermatitis who attended at a contact dermatitis unit in a tertiary hospital in Spain. METHODS: Adult patients with long-lasting (>4 weeks) perianal dermatitis were recruited during the past 10 years for investigation and follow-up. Every patient underwent a diagnostic workup consisting of dermatological exploration and patch tests with the standard and specific series, as well as the patients' own products. General surgical exploration was also performed in some patients. RESULTS: One hundred twenty-four patients were included. The MOAHLFA index was as follows: 43.5, 0, 4.8, 11.3, 1.6, 8.1, and 75. The main final diagnoses were allergic contact dermatitis (32.3%), psoriasis (24.2%), irritant contact dermatitis (17.7%), and lichen simplex (neurodermatitis) (10%). Eighty-one patients (66.1%) showed 1 or more positive reactions, and in 52 patients (43%), positive reactions relevant to the present disease were found. CONCLUSIONS: Contact allergy in patients with long-lasting perianal complaints is frequent. It is mandatory for these patients to be referred to a dermatologist for an adequate evaluation and patch testing. Methylchloroisothiazolinone/methylisothiazolinone seems as the most common allergen implicated in perianal contact dermatitis</style></abstract><notes><style face="normal" font="default">DA - 20170324IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000274</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28338543">PM:28338543</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\20170324-AgulloPerezAD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\20170324-AgulloPerezAD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170324, Agullo-Perez AD</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000274</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41098</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,X.</style></author><author><style face="normal" font="default"> Wang,G.</style></author><author><style face="normal" font="default"> Zeng,Q.</style></author><author><style face="normal" font="default"> Zhang,H.</style></author><author><style face="normal" font="default"> Hu,Y.</style></author><author><style face="normal" font="default"> Yu,A.</style></author><author><style face="normal" font="default"> Li,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Shanghai Jiading Nanxiang Hospital, Shanghai, China</style></auth-address><titles><title><style face="normal" font="default">Intralesional Treatment With 5-Fluorouracil and Steroid Improves Allergic Contact Dermatitis Without Causing Skin Atrophy and Rebound Lesions</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Atrophy</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="23" Month="3" Year="2017">2017/3/23</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170324IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000270</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28338541">PM:28338541</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\20170324-ChenX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\20170324-ChenX.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170324, Chen X</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000270</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41099</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Warshaw,E.M.</style></author><author><style face="normal" font="default"> Hagen,S.L.</style></author><author><style face="normal" font="default"> Belsito,D.V.</style></author><author><style face="normal" font="default"> DeKoven,J.G.</style></author><author><style face="normal" font="default"> Maibach,H.I.</style></author><author><style face="normal" font="default"> Mathias,C.G.</style></author><author><style face="normal" font="default"> Zug,K.A.</style></author><author><style face="normal" font="default"> Sasseville,D.</style></author><author><style face="normal" font="default"> Zirwas,M.J.</style></author><author><style face="normal" font="default"> Fowler,J.F.,Jr.</style></author><author><style face="normal" font="default"> Fransway,A.F.</style></author><author><style face="normal" font="default"> Deleo,V.A.</style></author><author><style face="normal" font="default"> Marks,J.G.,Jr.</style></author><author><style face="normal" font="default"> Pratt,M.D.</style></author><author><style face="normal" font="default"> Taylor,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">HCMC Parkside Occupational and Contact Dermatitis Clinic and Department of Dermatology, Minneapolis Veterans Affairs Medical Center</style></auth-address><titles><title><style face="normal" font="default">Occupational Contact Dermatitis in North American Print Machine Operators Referred for Patch Testing: Retrospective Analysis of Cross-Sectional Data From the North American Contact Dermatitis Group 1998 to 2014</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> cross-sectional analysis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Formaldehyde</style></keyword><keyword><style face="normal" font="default"> Gloves</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Ink</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Minnesota</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Preservatives</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Printing</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Rubber</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Thiuram mix</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Veterans</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="23" Month="3" Year="2017">2017/3/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: Little is known about the epidemiology of contact dermatitis (CD) in print machine operators (PMOs). OBJECTIVE: The aims of this study were to estimate the prevalence of CD and characterize clinically relevant and occupationally related allergens among PMOs undergoing patch testing. METHODS: This was a retrospective cross-sectional analysis of the North American Contact Dermatitis Group data from 1998 to 2014. RESULTS: Of 39,332 patch-tested patients, 132 (0.3%) were PMOs. Among PMOs, most were male (75.0%) and white (92.4%). The majority were printing press operators (85.6%). The most frequent sites of dermatitis were hands (63.6%), arms (29.5%), and face/scalp (24.2%). More than half had an occupationally related skin condition (56.1%). Final diagnoses were most commonly allergic CD (58.3%) and irritant CD (33.3%). Cobalt (20.8%), carba mix (12.5%), thiuram mix (8.3%), and formaldehyde (8.3%) were the most frequent occupationally related allergens. The top allergen sources included inks (22.9%), gloves (20.8%), and coatings/dye/copy/photographic chemicals (14.6%). CONCLUSIONS: Allergic CD, irritant CD, and involvement of exposed body areas were common among PMOs. Common allergens included rubber accelerators, metals, and preservatives</style></abstract><notes><style face="normal" font="default">DA - 20170324IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000269</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28338540">PM:28338540</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\20170324-WarshawEM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\20170324-WarshawEM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170324, Warshaw EM</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000269</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41100</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Isaksson,M.</style></author><author><style face="normal" font="default"> Ale,I.</style></author><author><style face="normal" font="default"> Andersen,K.E.</style></author><author><style face="normal" font="default"> Elsner,P.</style></author><author><style face="normal" font="default"> Goh,C.L.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author><author><style face="normal" font="default"> Jerajani,H.</style></author><author><style face="normal" font="default"> Matsunaga,K.</style></author><author><style face="normal" font="default"> McFadden,J.</style></author><author><style face="normal" font="default"> Bruze,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Occupational and Environmental Dermatology, Skane University Hospital, Lund University, Malmo, Sweden</style></auth-address><titles><title><style face="normal" font="default">Multicenter Patch Testing With Methylisothiazolinone and Methylchloroisothiazolinone/Methylisothiazolinone Within the International Contact Dermatitis Research Group</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Baseline series</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> Preservatives</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="23" Month="3" Year="2017">2017/3/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: The preservatives methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) and MI are well-known contact sensitizers. Recently, an increase in the contact allergy frequency for MI 0.2% aqueous (aq) has been seen in many European countries paralleled with an increase in MCI/MI allergy. Many of the MI-allergic patients do not react to MCI/MI 0.01% or 0.02% because the concentration of MI in these preparations is too low (25 and 50 ppm, respectively) to elicit a positive patch test reaction. OBJECTIVES: The aims of this study were to investigate the prevalence of contact allergy to MI in the participating clinics representing various countries all over the world, to assess how many additional individuals with contact allergy are found by testing MI 0.2% aq in parallel with MCI/MI 0.02%, and to assess the clinical relevance of MI and MCI/MI allergies. PATIENTS AND METHODS: In 9 dermatology clinics representing 9 countries, 3865 consecutive patients with dermatitis were patch tested with MI 0.2% aq and in parallel with MCI/MI 0.02% aq, provisionally included into the baseline series. An assessment of clinical relevance in those allergic to MI was also made. RESULTS: Contact allergy to MI was found in 284 patients (7.3%). The frequency of contact allergy varied from 0.8% to 10.9% in different centers. Simultaneous reactivity to 200 ppm of MCI/MI was found in 67.3% of the MI-positive patients. Contact allergy to MI alone without any simultaneous contact allergy to 200 ppm of MCI/MI was diagnosed in 93 patients (32.7%; 2.4% of all tested patients). The contact allergy to MI and/or MCI/MI could explain or contribute to dermatitis in more than 60% of the MI-allergic patients. CONCLUSIONS: Methylisothiazolinone of 2000 ppm needs to be patch tested on its own to not miss contact allergy</style></abstract><notes><style face="normal" font="default">DA - 20170324IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Uruguay -CO - Denmark -CO - Germany -CO - Singapore -CO - Belgium -CO - India -CO - Japan -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000272</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28338542">PM:28338542</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\20170324-IsakssonM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\20170324-IsakssonM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170324, Isaksson M</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000272</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41101</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aschenbeck,K.A.</style></author><author><style face="normal" font="default"> Warshaw,E.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Minnesota School of Medicine</style></auth-address><titles><title><style face="normal" font="default">Allergenic Ingredients in Personal Hygiene Wet Wipes</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergenic</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Aloe</style></keyword><keyword><style face="normal" font="default"> Chamomile</style></keyword><keyword><style face="normal" font="default"> Citric Acid</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Hygiene</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Lanolin</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> methylchloroisothiazolinone</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Minnesota</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Parabens</style></keyword><keyword><style face="normal" font="default"> Polyethylene</style></keyword><keyword><style face="normal" font="default"> Polyethylene glycol</style></keyword><keyword><style face="normal" font="default"> Preservatives</style></keyword><keyword><style face="normal" font="default"> Propylene Glycol</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> Sodium Benzoate</style></keyword><keyword><style face="normal" font="default"> Sorbic Acid</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="23" Month="3" Year="2017">2017/3/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: Wet wipes are a significant allergen source for anogenital allergic contact dermatitis. OBJECTIVE: The aim of the study was to calculate the frequency of potentially allergenic ingredients in personal hygiene wet wipes. METHODS: Ingredient lists from brand name and generic personal hygiene wet wipes from 4 large retailers were compiled. RESULTS: In the 54 personal hygiene wet wipes evaluated, a total of 132 ingredients were identified (average of 11.9 ingredients per wipe). The most common ingredients were Aloe barbadensis (77.8%), citric acid (77.8%), fragrance (72.2%), sorbic acid derivatives (63.0%), tocopherol derivatives (63.0%), glycerin (59.3%), phenoxyethanol (55.6%), disodium cocoamphodiacetate (53.7%), disodium ethylenediaminetetraacetic acid (EDTA) (42.6%), propylene glycol (42.6%), iodopropynyl butylcarbamate (40.7%), chamomile extracts (38.9%), sodium benzoate (35.2%), bronopol (22.2%), sodium citrate (22.2%), lanolin derivatives (20.4%), parabens (20.4%), polyethylene glycol derivatives (18.5%), disodium phosphate (16.7%), dimethylol dimethyl (DMDM) hydantoin (14.8%), and cocamidopropyl propylene glycol (PG)-dimonium chloride phosphate (11.1%). Of note, methylisothiazolinone (5.6%) was uncommon; methylchloroisothiazolinone was not identified in the personal hygiene wet wipes examined. CONCLUSIONS: There are many potential allergens in personal hygiene wet wipes, especially fragrance and preservatives</style></abstract><notes><style face="normal" font="default">DA - 20170324IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000275</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28338537">PM:28338537</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\20170325-AschenbeckKA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\20170325-AschenbeckKA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170325, Aschenbeck KA</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000275</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41102</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">de Groot,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">From acdegroot publishing, Wapserveen, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Contact Allergy to (Ingredients of) Toothpastes</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="114" start="95">95-114</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Burning Mouth Syndrome</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Cheilitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Gingivitis</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Mouth</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Publishing</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Stomatitis</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Toothpaste</style></keyword><keyword><style face="normal" font="default"> Toothpastes</style></keyword><keyword><style face="normal" font="default"> Ulcer</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">The literature on contact allergy to (ingredients of) toothpastes is critically reviewed. We have found 47 case reports, small case series (n = 2-5) and citations published between 1900 and 2016 describing more than 60 patients allergic to toothpastes, and in addition 3 larger case series and many descriptions of toothpaste allergy among selected groups of patients. Allergic reactions usually manifest as cheilitis with or without dermatitis around the mouth, less frequently by oral symptoms. Formerly, many reactions were caused by cinnamon derivatives; more recently, reported allergens are diverse. A semiopen test or closed patch test with the toothpaste "as is" may be performed as an initial test, but a positive reaction should always be followed by confirmatory tests. The role of contact allergy to toothpastes in patients with oral symptoms (stomatitis, glossitis, gingivitis, buccal mucositis, burning, soreness, and possibly burning mouth syndrome and recurrent aphthous ulcers) is unclear and should be further investigated</style></abstract><notes><style face="normal" font="default">DA - 20170314IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000255</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28291073">PM:28291073</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-95-114.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-95-114.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170314, de Groot A</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000255</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41103</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Warshaw,E.M.</style></author><author><style face="normal" font="default"> Hagen,S.L.</style></author><author><style face="normal" font="default"> DeKoven,J.G.</style></author><author><style face="normal" font="default"> Zug,K.A.</style></author><author><style face="normal" font="default"> Sasseville,D.</style></author><author><style face="normal" font="default"> Belsito,D.V.</style></author><author><style face="normal" font="default"> Zirwas,M.J.</style></author><author><style face="normal" font="default"> Fowler,J.F.,Jr.</style></author><author><style face="normal" font="default"> Taylor,J.S.</style></author><author><style face="normal" font="default"> Fransway,A.F.</style></author><author><style face="normal" font="default"> Deleo,V.A.</style></author><author><style face="normal" font="default"> Marks,J.G.,Jr.</style></author><author><style face="normal" font="default"> Pratt,M.D.</style></author><author><style face="normal" font="default"> Maibach,H.I.</style></author><author><style face="normal" font="default"> Mathias,C.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *HCMC Parkside Occupational and Contact Dermatitis Clinic</style></auth-address><titles><title><style face="normal" font="default">Occupational Contact Dermatitis in North American Production Workers Referred for Patch Testing: Retrospective Analysis of Cross-sectional Data From the North American Contact Dermatitis Group 1998 to 2014</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> cross-sectional analysis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Formaldehyde</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritant contact dermatitis</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Minnesota</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Occupation</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Occupations</style></keyword><keyword><style face="normal" font="default"> Oils</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Preservatives</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Rubber</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Thiuram mix</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="7" Month="4" Year="2017">2017/4/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Little is known about the epidemiology of contact dermatitis in production workers (PWs). OBJECTIVE: The aims of this study were to estimate the prevalence of contact dermatitis and characterize clinically relevant and occupationally related allergens among North American PWs undergoing patch testing. METHODS: This was a retrospective cross-sectional analysis of North American Contact Dermatitis Group data from 1998 to 2014. RESULTS: Of 39,332 patch-tested patients, 2732 (7.0%) were PWs. Among PWs, most were men (62.4%) and white (83.9%). A history of childhood eczema was uncommon (11.3%). Prevalent occupations included machine operators (27.3%); fabricators, assemblers, and hand-working occupations (16.8%); and precision metalworking occupations (16.1%). The most frequent sites of dermatitis were the hands (53.8%) and arms (29.4%), which were significantly more commonly affected compared with non-PWs (P &lt; 0.0001). Occupationally related skin disease, allergic contact dermatitis, and irritant contact dermatitis were also significantly more common in PWs (49.9% vs 10.6%, 58.9% vs 53.7%, and 32.7% vs 25.7%, respectively; all Ps &lt; 0.0001). Epoxy (15.3%), thiuram mix (8.3%), carba mix (8.1%), formaldehyde (6.3%), and cobalt (5.9%) were the most frequent occupationally related allergens. The top allergen sources included adhesives/glues (16.0%), metalworking fluids/cutting oils (6.8%), and coatings (6.3%). CONCLUSIONS: Production workers had a high rate of occupationally related skin disease, as well as irritant and allergic contact dermatitis. Involvement of exposed body areas was common. Frequently identified allergens included adhesives/glues, rubber accelerators, metals, and preservatives</style></abstract><notes><style face="normal" font="default">DA - 20170410IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000277</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28394773">PM:28394773</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\20170410-WarshawEM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\20170410-WarshawEM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170410, Warshaw EM</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000277</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41104</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cheape,A.C.</style></author><author><style face="normal" font="default"> Murrell,D.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Dermatology , St George Hospital , Sydney , Australia</style></auth-address><titles><title><style face="normal" font="default">2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Expert Rev Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> cAMP</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cyclic AMP</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Itch</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Sensation</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword></keywords><dates><year Day="5" Month="4" Year="2017">2017/4/5</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Crisaborole 2% topical ointment is an anti-inflammatory, non-steroidal phosphodiesterase 4 inhibitor which is currently under investigation for its potential role in the treatment of atopic dermatitis and psoriasis. Areas covered: So far, 7 trials have been completed in atopic dermatitis. The 2% strength appeared to be the superior dosing regimen. Pruritus improved significantly within one week. The improvements in objective efficacy assessments in crisaborole-treated patients were also statistically significant compared to the vehicle. Expert commentary: Crisaborole has several key features in its mode of action which distinguish it from existing treatments for atopic dermatitis (AD), notably its activity against the phosphodiesterase E4 (PDE4) pathway, regulating cyclic AMP (cAMP) levels. This is less immunosuppressive than other pathways and has no effect on skin thinning. The pathway interrupts the itch sensation (pruritus) which means that the itch-scratch cycle, the bane in the life of patients with AD, is interrupted, usually as early as a few days into treatment. Hence, with the promising safety profile demonstrated, early treatment of mild to moderate AD patients might help to control AD better and improve quality of life for patients</style></abstract><notes><style face="normal" font="default">DA - 20170314IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - Australia -CO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1080/1744666X.2017.1304820.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28290219">PM:28290219</url></web-urls></urls><custom2><style face="normal" font="default">20170314, Cheape AC</style></custom2><misc3><style face="normal" font="default">10.1080/1744666X.2017.1304820.</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41105</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chung,K.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Airways Disease , National Heart &amp; Lung Institute, Imperial College London , United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Clinical management of severe therapy-resistant asthma</style></title><secondary-title><style face="normal" font="default">Expert Rev Clin Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Expert Rev Clin Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Airways disease</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> difficult-to-treat asthma</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Targeted therapy</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="7" Month="4" Year="2017">2017/4/7</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Severe therapy-resistant asthma is an area where there has been recent advances in understanding that is percolating into improvements in management. Areas covered: This review covers the recent definition and approach to the diagnosis of severe asthma and its differentiation from difficult-to-treat asthma. The recent advances in phenotyping severe asthma and in ensuing changes in management approaches together with the introduction of new therapies are covered from a review of the recent literature. Expert commentary After ascertaining the diagnosis of severe asthma, patients need to be treated adequately with existing therapies. The management approach to severe asthma now comprises of a phenotyping step for the definition of either an allergic or eosinophilic severe asthma for which targeted therapies are currently available. This will lead to a precision medicine approach to the management of severe asthma</style></abstract><notes><style face="normal" font="default">DA - 20170407IS - 1747-6356 (Electronic)IS - 1747-6348 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1080/17476348.2017.1317597</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28388228">PM:28388228</url></web-urls></urls><custom2><style face="normal" font="default">20170407, Chung KF</style></custom2><misc3><style face="normal" font="default">10.1080/17476348.2017.1317597</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41106</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Johnson,V.J.</style></author><author><style face="normal" font="default"> Auerbach,S.S.</style></author><author><style face="normal" font="default"> Luster,M.I.</style></author><author><style face="normal" font="default"> Waidyanatha,S.</style></author><author><style face="normal" font="default"> Masten,S.A.</style></author><author><style face="normal" font="default"> Wolfe,M.S.</style></author><author><style face="normal" font="default"> Burleson,F.G.</style></author><author><style face="normal" font="default"> Burleson,G.R.</style></author><author><style face="normal" font="default"> Germolec,D.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Burleson Research Technologies, Inc., Morrisville, NC, USA.</style></auth-address><titles><title><style face="normal" font="default">Evaluation of 4-methylcyclohexanemethanol (MCHM) in a combined irritancy and Local Lymph Node Assay (LLNA) in mice</style></title><secondary-title><style face="normal" font="default">Food Chem Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Food Chem Toxicol</style></full-title></periodical><pages end="105" start="99">99-105</pages><volume><style face="normal" font="default">105</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">area</style></keyword><keyword><style face="normal" font="default"> Coal</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epicutaneous</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human health</style></keyword><keyword><style face="normal" font="default"> Irritation</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="default">4-Methylcyclohexanemethanol (MCHM) is a flotation reagent used in fine coal beneficiation. On January 9, 2014, crude MCHM, a mixture containing predominantly MCHM, was inadvertently released into the Elk River, a municipal water source that serves about 300,000 people in the Charleston, WV area, resulting in temporary contamination of 15 percent of the state's tap water and causing significant dermal exposure. The current studies were undertaken to determine whether crude MCHM or MCHM has the potential to produce dermal irritancy and/or sensitization. BALB/c female mice were treated daily for 3 consecutive days by direct epicutaneous application of 25 muL of various concentrations of crude MCHM or MCHM to the dorsum of each ear. A mouse ear-swelling test was used to determine irritancy potential and was undertaken in combination with the standardized Local Lymph Node Assay (LLNA) to determine skin sensitizing potential. MCHM was found to produce skin irritation at concentrations above 20% and did not produce sensitization. Crude MCHM also produced irritation, although weaker, and in addition was found to be a weak to moderate skin sensitizer. The results are discussed in terms of potential human health hazard</style></abstract><notes><style face="normal" font="default">DA - 20170326IS - 1873-6351 (Electronic)IS - 0278-6915 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.fct.2017.03.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28343035">PM:28343035</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Food Chem Toxicol\2017-105-99-105.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Food Chem Toxicol\2017-105-99-105.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170326, Johnson VJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.fct.2017.03.034</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41107</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Varricchi,G.</style></author><author><style face="normal" font="default"> Senna,G.</style></author><author><style face="normal" font="default"> Loffredo,S.</style></author><author><style face="normal" font="default"> Bagnasco,D.</style></author><author><style face="normal" font="default"> Ferrando,M.</style></author><author><style face="normal" font="default"> Canonica,G.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Clinical Immunology and Allergy, Department of Translational Medical Sciences, School of Medicine, University of Naples Federico II, Naples, Italy</style></auth-address><titles><title><style face="normal" font="default">Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?</style></title><secondary-title><style face="normal" font="default">Front Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Immunol</style></abbr-1></periodical><pages end="" start="242">242-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acids</style></keyword><keyword><style face="normal" font="default"> activation</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Affinity</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Amino acid</style></keyword><keyword><style face="normal" font="default"> Amino Acids</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Apoptosis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic asthma</style></keyword><keyword><style face="normal" font="default"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Interleukin-5</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Leukocytes</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="default"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> reslizumab</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Targeted therapy</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Human eosinophils represent approximately 1% of peripheral blood leukocytes. However, these cells have the propensity to leave the blood stream and migrate into inflamed tissues. Eosinophilic inflammation is present in a significant proportion of patients with severe asthma. Asthma is a chronic inflammatory disorder that affects more than 315 million people worldwide, with 10% having severe uncontrolled disease. Although the majority of patients can be efficiently treated, severe asthmatics continue to be uncontrolled and are at risk of exacerbations and even death. Interleukin-5 (IL-5) plays a fundamental role in eosinophil differentiation, maturation, activation and inhibition of apoptosis. Therefore, targeting IL-5 is an appealing approach to the treatment of patients with severe eosinophilic asthma. Reslizumab, a humanized anti-IL-5 monoclonal antibody, binds with high affinity to amino acids 89-92 of IL-5 that are critical for binding to IL-5 receptor alpha. Two phase III studies have demonstrated that reslizumab administration in adult patients with severe asthma and eosinophilia (>/=400 cells/muL) improved lung function, asthma control, and symptoms. Thus, the use of blood eosinophils as a baseline biomarker could help to select patients with severe uncontrolled asthma who are likely to achieve benefits in asthma control with reslizumab. In conclusion, targeted therapy with reslizumab represents one step closer to precision medicine in patients with severe eosinophilic asthma</style></abstract><notes><style face="normal" font="default">DA - 20170327IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="default">10.3389/fimmu.2017.00242</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28344579">PM:28344579</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Immunol\2017-8-242.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Immunol\2017-8-242.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170327, Varricchi G</style></custom2><misc3><style face="normal" font="default">10.3389/fimmu.2017.00242</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41108</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Poon,A.H.</style></author><author><style face="normal" font="default"> Choy,D.F.</style></author><author><style face="normal" font="default"> Chouiali,F.</style></author><author><style face="normal" font="default"> Ramakrishnan,R.K.</style></author><author><style face="normal" font="default"> Mahboub,B.</style></author><author><style face="normal" font="default"> Audusseau,S.</style></author><author><style face="normal" font="default"> Mogas,A.</style></author><author><style face="normal" font="default"> Harris,J.M.</style></author><author><style face="normal" font="default"> Arron,J.R.</style></author><author><style face="normal" font="default"> Laprise,C.</style></author><author><style face="normal" font="default"> Hamid,Q.</style></author></authors></contributors><auth-address><style face="normal" font="default">Meakins-Christie Laboratories, Faculty of Medicine, McGill University, Montreal, QC, Canada</style></auth-address><titles><title><style face="normal" font="default">Increased Autophagy-Related 5 Gene Expression Is Associated with Collagen Expression in the Airways of Refractory Asthmatics</style></title><secondary-title><style face="normal" font="default">Front Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Immunol</style></abbr-1></periodical><pages end="" start="355">355-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway remodeling</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> association studies</style></keyword><keyword><style face="normal" font="default"> association study</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Collagen</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Degradation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> dysregulation</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic Association</style></keyword><keyword><style face="normal" font="default"> Genetic Association Studies</style></keyword><keyword><style face="normal" font="default"> genetic association study</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Transforming Growth Factor beta</style></keyword><keyword><style face="normal" font="default"> type III</style></keyword><keyword><style face="normal" font="default"> United Arab Emirates</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Fibrosis, particularly excessive collagen deposition, presents a challenge for treating asthmatic individuals. At present, no drugs can remove or reduce excessive collagen in asthmatic airways. Hence, the identification of pathways involved in collagen deposition would help to generate therapeutic targets to interfere with the airway remodeling process. Autophagy, a cellular degradation process, has been shown to be dysregulated in various fibrotic diseases, and genetic association studies in independent human populations have identified autophagy-related 5 (ATG5) to be associated with asthma pathogenesis. Hence, the dysregulation of autophagy may contribute to fibrosis in asthmatic airways. OBJECTIVE: This study aimed to determine if (1) collagen deposition in asthmatic airways is associated with ATG5 expression and (2) ATG5 protein expression is associated with asthma per se and severity. METHODS: Gene expression of transforming growth factor beta 1, various asthma-related collagen types [collagen, type I, alpha 1; collagen, type II, alpha 1; collagen, type III, alpha 1; collagen, type V, alpha 1 (COL5A1) and collagen, type V, alpha 2], and ATG5 were measured using mRNA isolated from bronchial biopsies of refractory asthmatic subjects and assessed for pairwise associations. Protein expression of ATG5 in the airways was measured and associations were assessed for asthma per se, severity, and lung function. MAIN RESULTS: In refractory asthmatic individuals, gene expression of ATG5 was positively associated with COL5A1 in the airways. No association was detected between ATG5 protein expression and asthma per se, severity, and lung function. CONCLUSION AND CLINICAL RELEVANCE: Positive correlation between the gene expression patterns of ATG5 and COL5A1 suggests that dysregulated autophagy may contribute to subepithelial fibrosis in the airways of refractory asthmatic individuals. This finding highlights the therapeutic potential of ATG5 in ameliorating airway remodeling in the difficult-to-treat refractory asthmatic individuals</style></abstract><notes><style face="normal" font="default">DA - 20170420IS - 1664-3224 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United Arab Emirates -CO - United States -</style></notes><work-type><style face="normal" font="default">10.3389/fimmu.2017.00355</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28424691">PM:28424691</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Immunol\2017-8-355.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Immunol\2017-8-355.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170420, Poon AH</style></custom2><misc3><style face="normal" font="default">10.3389/fimmu.2017.00355</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41109</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Negherbon,J.P.</style></author><author><style face="normal" font="default"> Romero,K.</style></author><author><style face="normal" font="default"> Williams,D.L.</style></author><author><style face="normal" font="default"> Guerrero-Preston,R.E.</style></author><author><style face="normal" font="default"> Hartung,T.</style></author><author><style face="normal" font="default"> Scott,A.L.</style></author><author><style face="normal" font="default"> Breysse,P.N.</style></author><author><style face="normal" font="default"> Checkley,W.</style></author><author><style face="normal" font="default"> Hansel,N.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Environmental Health Sciences, Bloomberg School of Public Health, The Johns Hopkins University, BaltimoreMD, USA</style></auth-address><titles><title><style face="normal" font="default">Whole Blood Cytokine Response to Local Traffic-Related Particulate Matter in Peruvian Children With and Without Asthma</style></title><secondary-title><style face="normal" font="default">Front Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Pharmacol</style></abbr-1></periodical><pages end="" start="157">157-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> adaptive</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="default"> Chemotaxis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Diesel</style></keyword><keyword><style face="normal" font="default"> endotoxin</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Particulate matter</style></keyword><keyword><style face="normal" font="default"> Peru</style></keyword><keyword><style face="normal" font="default"> PM</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Sample Size</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">This study sought to investigate if acute phase immune responses of whole blood from Peruvian children with controlled and uncontrolled asthma differed from children without asthma, following exposure to traffic-related particulate matter (TRPM). TRPM, including particulate matter from diesel combustion, has been shown to stimulate acute airway inflammation in individuals with and without asthma. For this study, a whole blood assay (WBA) was used to test peripheral whole blood samples from 27 children with asthma, and 12 without asthma. Participant blood samples were stimulated, ex vivo, for 24-h with an aqueous extract of TRPM that was collected near study area highways in Lima, Peru. All participant blood samples were tested against the same TRPM extract, in addition to purified bacterial endotoxin and pyrogen-free water, which served as positive and negative WBA controls, respectively. The innate and adaptive cytokine responses were evaluated in cell-free supernatants of the whole blood incubations. Comparatively similar levels were recorded for nine out of the 10 cytokines measured [e.g., - Interleukin (IL)-1beta, IL-6, IL-10], regardless of study participant asthma status. However, IL-8 levels in TRPM-stimulated blood from children with uncontrolled asthma were diminished, compared to subjects without asthma (633 pg/ml vs. 1,023 pg/ml, respectively; p &lt; 0.01); IL-8 responses for subjects with controlled asthma were also reduced, but to a lesser degree (799 pg/ml vs. 1,023 pg/ml, respectively; p = 0.10). These relationships were present before, and after, adjusting for age, sex, obesity/overweight status, C-reactive protein levels, and residential proximity to the study area's major roadway. For tests conducted with endotoxin, there were no discernible differences in cytokine response between groups, for all cytokines measured. The WBA testing conducted for this study highlighted the capacity of the TRPM extract to potently elicit the release of IL-8 from the human whole blood system. Although the small sample size of the study limits the capacity to draw definitive conclusions, the IL-8 responses suggest that that asthma control may be associated with the regulation of a key mediator in neutrophil chemotaxis, at a systemic level, following exposure to PM derived from traffic-related sources</style></abstract><notes><style face="normal" font="default">DA - 20170420IS - 1663-9812 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Peru -</style></notes><work-type><style face="normal" font="default">10.3389/fphar.2017.00157</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28424616">PM:28424616</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Pharmacol\2017-8-157.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Pharmacol\2017-8-157.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170420, Negherbon JP</style></custom2><misc3><style face="normal" font="default">10.3389/fphar.2017.00157</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41110</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Souliotis,K.</style></author><author><style face="normal" font="default"> Kousoulakou,H.</style></author><author><style face="normal" font="default"> Hillas,G.</style></author><author><style face="normal" font="default"> Bakakos,P.</style></author><author><style face="normal" font="default"> Toumbis,M.</style></author><author><style face="normal" font="default"> Loukides,S.</style></author><author><style face="normal" font="default"> Vassilakopoulos,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Social and Educational Policy, University of Peloponnese, Corinth, Greece</style></auth-address><titles><title><style face="normal" font="default">Direct and Indirect Costs of Asthma Management in Greece: An Expert Panel Approach</style></title><secondary-title><style face="normal" font="default">Front Public Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Public Health</style></abbr-1></periodical><pages end="" start="67">67-</pages><volume><style face="normal" font="default">5</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease Management</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> General practitioner</style></keyword><keyword><style face="normal" font="default"> General practitioners</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Policy</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of care</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Self-management</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Travel</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Asthma is a major cause of morbidity and mortality and is associated with significant economic burden worldwide. The objectives of this study were to map current resource use associated with the disease management and to estimate the annual direct and indirect costs per adult patient with asthma. METHODS: A Delphi panel with seven leading pulmonologists was conducted. A semistructured questionnaire was developed to elicit data on resource use and treatment patterns. Unit costs from official, published sources were subsequently assigned to resource use to estimate direct medical costs. Indirect costs were estimated as number of work loss days. Cost base year was 2015, and the perspective adopted was that of the National Organization of Health Care Services Provision, as well as the societal. RESULTS: Patients with asthma are mainly managed by pulmonologists (71.4%) and secondarily by general practitioners and internists (28.6%). The annual cost of managing exacerbations was estimated at euro273.1, while maintenance costs were estimated at euro1,100.2 per year. Total costs of managing asthma per patient per year were estimated at euro2,281.8, 64.4% of which represented direct medical costs. Of the direct costs, pharmaceutical treatment was the key driver, accounting for 63.9 and 41.2% of direct and total costs, respectively. Direct non-medical costs (patient travel and waiting time) were estimated at euro152.3. Indirect costs accounted for 28.9% of total costs. CONCLUSION: Asthma is a chronic condition, the management of which constrains the already limited Greek health care resources. The increasing prevalence of the disease raises concerns as it could translate per patient costs into a significant burden for the Greek health care system. Thus, the prevention, self-management, and improved quality of care for asthma should find a place in the health policy agenda in Greece</style></abstract><notes><style face="normal" font="default">DA - 20170420IS - 2296-2565 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="default">10.3389/fpubh.2017.00067</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28424767">PM:28424767</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Public Health\2017-5-67.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Public Health\2017-5-67.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170420, Souliotis K</style></custom2><misc3><style face="normal" font="default">10.3389/fpubh.2017.00067</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41111</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lembo,S.</style></author><author><style face="normal" font="default"> Lembo,C.</style></author><author><style face="normal" font="default"> Patruno,C.</style></author><author><style face="normal" font="default"> Cuomo,P.</style></author><author><style face="normal" font="default"> Ayala,F.</style></author><author><style face="normal" font="default"> Balato,N.</style></author><author><style face="normal" font="default"> Balato,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Surgery and Odontology, &amp;quot;Scuola Medica Salernitana&amp;quot;, University of Salerno, Salerno, Italy</style></auth-address><titles><title><style face="normal" font="default">Contact sensitization of children referred to the Dermatology Department of the University Federico II of Naples, Italy: a two-decade years history</style></title><secondary-title><style face="normal" font="default">G Ital Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">G Ital Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Attitude</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dermatoses</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational dermatoses</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> premature</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="14" Month="3" Year="2017">2017/3/14</year></dates><abstract><style face="normal" font="default">BACKGROUND: Contact sensitization (CS) and allergic contact dermatitis (ACD) were once thought to be rare in children. The aim of our study was to assess CS and ACD in children affected by eczematous conditions referring to our contact and occupational dermatoses service, and to compare the obtained data to the results of a similar study performed in our Department in late eighties. METHODS: A retrospective analysis of patch test data from the Database of Contact Allergy of the Dermatology Department - University Federico II of Naples was performed. Moreover results were compared to previous data recorded and analyzed in our centre. RESULTS: Of the 416 examined patients, tested during 2005-2010 with the paediatric series, 37.5% developed at least one positive reaction, 15.4% was diagnosed with ACD. The most common allergen was nickel sulphate (16.8%) and the most frequently involved body sites were head and neck (16.3%). Compared to the 1989 study data, our current results highlighted an increase of CS (p&lt;0.001) and ACD diagnosis (p&lt;0.01). CONCLUSIONS: ACD and CS are significantly increased during the last 20 years in our young patients population. The widespread chemical use and premature adult-like attitude may be responsible for earlier and extended exposure to sensitizers</style></abstract><notes><style face="normal" font="default">DA - 20170314IS - 1827-1820 (Electronic)IS - 0392-0488 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.23736/S0392-0488.17.05466-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28290621">PM:28290621</url></web-urls></urls><custom2><style face="normal" font="default">20170314, Lembo S</style></custom2><misc3><style face="normal" font="default">10.23736/S0392-0488.17.05466-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41112</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Koch,L.</style></author><author><style face="normal" font="default"> Aberer,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Univ. Klinik fur Dermatologie und Venerologie, Medizinische Universitat Graz, Auenbruggerplatz 8, 8036, Graz, Osterreich.</style></auth-address><titles><title><style face="normal" font="default">[Allergic contact dermatitis of the scalp]</style></title><secondary-title><style face="normal" font="default">Hautarzt</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Hautarzt</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergen avoidance</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Austria</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatologie</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Differential diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> epicutaneous</style></keyword><keyword><style face="normal" font="default"> Eyelid</style></keyword><keyword><style face="normal" font="default"> Eyelids</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> preservative</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Scalp</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe reactions</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Topical drugs</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword><keyword><style face="normal" font="default"> Vehicles</style></keyword></keywords><dates><year Day="10" Month="4" Year="2017">2017/4/10</year></dates><abstract><style face="normal" font="default">Contact allergy represents an important differential diagnosis to other skin diseases of the scalp. The typical efflorescences, spreading in the periphery, pruritus, and the clinical history support the differential diagnosis. Since the scalp is particularly resistant to contact dermatitis, allergens applied to this area often produce dermatitis of the eyelids, ears and neck. Nevertheless, potent allergens such as para-phenylendiamine can also cause severe reactions of the scalp. The most important allergens eliciting contact allergy of the scalp are found in bleaches and dyes, shampoos and conditioners, products for perm waves and straighteners as well as topical drugs. Besides active ingredients or drugs, vehicles and preservative agents represent additional allergens. The use of topical steroids and oral antihistamines usually results in rapid resolution of the dermatitis, systemic steroids are only necessary in severe cases. Epicutaneous patch testing on the basis of available series combined with the ingredients of the suspected elicitors confirms the diagnosis and facilitates allergen avoidance as well as the selection of alternative products</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 1432-1173 (Electronic)IS - 0017-8470 (Linking)LA - gerPT - English AbstractPT - Journal ArticlePT - ReviewCO - Austria -</style></notes><work-type><style face="normal" font="default">10.1007/s00105-017-3975-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28396898">PM:28396898</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Hautarzt\20170411-KochL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Hautarzt\20170411-KochL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, Koch L</style></custom2><misc3><style face="normal" font="default">10.1007/s00105-017-3975-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41113</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kumaran,M.S.</style></author><author><style face="normal" font="default"> Mangal,S.</style></author><author><style face="normal" font="default"> Narang,T.</style></author><author><style face="normal" font="default"> Parsad,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India</style></auth-address><titles><title><style face="normal" font="default">Autologous Serum and Plasma Skin Tests in Chronic Spontaneous Urticaria: A Reappraisal</style></title><secondary-title><style face="normal" font="default">Indian Dermatol Online J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Indian Dermatol Online J</style></abbr-1></periodical><pages end="99" start="94">94-99</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> serum IgE levels</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">AIM: The objective of this study was to assess autologous serum skin test (ASST) vs autologous plasma skin test (APST) response in chronic spontaneous urticaria (CSU) patients and study the significance of intensity of positive responses in relation to clinicoepidemiological parameters. MATERIALS AND METHODS: One hundred CSU patients and 100 age and sex-matched controls were recruited. The demographic and clinical features were recorded in all patients and routine investigations were performed. ASST and APST tests were performed as per the standard guidelines. RESULTS: The mean duration of illness was 4.85 +/- 5.07 years, 90% patients were APST (+), 68% ASST (+), and 22 patients were only APST (+). Positive predictive value (PPV) of ASST and APST was 90.7% and 95.7%, respectively. A significant inverse association was seen between thyroid status and serum IgE levels with APST and ASST positivity. CONCLUSION: APST appears to have better PPV and high intensity of positive response on autologous tests, and correlates with ANA positivity and angioedema</style></abstract><notes><style face="normal" font="default">DA - 20170413IS - 2229-5178 (Print)IS - 2229-5178 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/2229-5178.202266</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28405547">PM:28405547</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian Dermatol Online J\2017-8-94-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian Dermatol Online J\2017-8-94-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170413, Kumaran MS</style></custom2><misc3><style face="normal" font="default">10.4103/2229-5178.202266</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41114</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hisham,M.</style></author><author><style face="normal" font="default"> Sivakumar,M.N.</style></author><author><style face="normal" font="default"> Senthil Kumar,R.S.</style></author><author><style face="normal" font="default"> Nandakumar,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Critical Care Medicine, Kovai Medical Center and Hospital, Coimbatore, Tamil Nadu, India</style></auth-address><titles><title><style face="normal" font="default">Ludwig's Angina: A Nightmare Worsened by Adverse Drug Reaction to Antibiotics</style></title><secondary-title><style face="normal" font="default">Indian J Crit Care Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Indian J Crit Care Med</style></abbr-1></periodical><pages end="181" start="179">179-181</pages><volume><style face="normal" font="default">21</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Airway Obstruction</style></keyword><keyword><style face="normal" font="default"> Angioneurotic Edema</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Clindamycin</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> intensive care unit</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Metronidazole</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> Tracheostomy</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">A 52-year-old obese gentleman presented to the hospital with complaints of fever and shortness of breath for 10 days. He was admitted in the ward and treated for acute exacerbation of asthma. He was shifted to the Intensive Care Unit (ICU) for persistent fever, neck swelling, airway obstruction and desaturation. Ludwig's angina was suspected and computed tomography of neck confirmed it. A difficult airway was anticipated and preceded with surgical tracheostomy. The patient had hypersensitivity reactions to piperacillin/tazobactam; hence, he was treated with clindamycin and metronidazole. The patient improved and was discharged after five days of ICU stay and 12 days of hospitalization. This case summarizes the rare incidence of Ludwig's angina with antibiotic adverse reactions. If angioneurotic edema is coincidental with features of Ludwig's angina, it becomes more challenging. Early identification, securing the airway, and antibiotic administration are the keystone to better survival</style></abstract><notes><style face="normal" font="default">DA - 20170412IS - 0972-5229 (Print)IS - 0972-5229 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/ijccm.IJCCM_189_15</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28400693">PM:28400693</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Crit Care Med\2017-21-179-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Crit Care Med\2017-21-179-81.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170412, Hisham M</style></custom2><misc3><style face="normal" font="default">10.4103/ijccm.IJCCM_189_15</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41115</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gupta,J.</style></author><author><style face="normal" font="default"> Raval,R.C.</style></author><author><style face="normal" font="default"> Shah,A.N.</style></author><author><style face="normal" font="default"> Solanki,R.B.</style></author><author><style face="normal" font="default"> Patel,D.D.</style></author><author><style face="normal" font="default"> Shah,K.B.</style></author><author><style face="normal" font="default"> Badheka,A.D.</style></author><author><style face="normal" font="default"> Shah,K.B.</style></author><author><style face="normal" font="default"> Aggarwal,N.K.</style></author><author><style face="normal" font="default"> Ravishankar,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, NHL Medical College, VS Hospital, Ahmedabad, Gujarat, India</style></auth-address><titles><title><style face="normal" font="default">Low-dose rituximab as an adjuvant therapy in pemphigus</style></title><secondary-title><style face="normal" font="default">Indian J Dermatol Venereol Leprol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Indian J Dermatol Venereol Leprol</style></full-title></periodical><pages end="325" start="317">317-325</pages><volume><style face="normal" font="default">83</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adjuvant</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Complete Blood Count</style></keyword><keyword><style face="normal" font="default"> contraindications</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> herpes</style></keyword><keyword><style face="normal" font="default"> Herpes Zoster</style></keyword><keyword><style face="normal" font="default"> Immunosuppressants</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Liver Function Tests</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pemphigus</style></keyword><keyword><style face="normal" font="default"> Pulse</style></keyword><keyword><style face="normal" font="default"> Remission</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic therapy</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="29" Month="3" Year="2017">2017/3/29</year></dates><abstract><style face="normal" font="default">BACKGROUND: Pemphigus is a chronic autoimmune blistering disease where systemic steroids and immunosuppressants are the mainstay of therapy, but long-term treatment with these agents is associated with many side effects. Rituximab, a chimeric monoclonal anti-CD20 antibody, in low doses has shown efficacy as an adjuvant to reduce the dose of steroids. AIM: To study the clinical efficacy and safety of low-dose rituximab as an adjuvant therapy in pemphigus. METHODS: Fifty patients with extensive pemphigus were selected, who either had recalcitrant pemphigus, were steroid dependent, had relapsed after pulse therapy, had anti-desmoglein levels >20, had contraindications to conventional treatment or wanted to avoid conventional treatment and its side effects. Two doses of rituximab (500 mg) were given 2 weeks apart and patients were regularly followed up every 2 weeks for 3 months and then monthly upto 2 years. Complete blood counts, liver function tests, renal function tests, skin biopsy, direct immunofluorescence and desmoglein levels were checked before and after rituximab administration. Pre-rituximab chest X-ray and electrocardiograph were also obtained. RESULTS: At 3 months, 41 (82%) patients showed complete remission. Nine (18%) patients had partial remission. After 6-12 months, 20 (40% of enrolled patients) continued to be in remission and were off all systemic therapy and the remaining 19 (38%) were continuing to take low doses of steroids with or without other adjuvant immunosuppressants and 2 (4%) had to be given another 2 doses of rituximab and subsequently could be managed with low-dose steroids. Of the 9 patients in partial remission at 3 months, after 6-12 months 5 (10% of the total) were completely off treatment and went into complete remission and 4 (8%) were on additional treatment out of which 2 (4%) had to be given 2 additional doses of rituximab and were in partial remission with low-dose therapy at the end of 12 months. One patient developed urticaria as a side effect. Another developed herpes zoster. CONCLUSION: Our results show that low-dose rituximab is a well-tolerated and beneficial adjuvant therapy in recalcitrant pemphigus which helps reduce both the severity of disease as well as the dose of steroids and immunosuppressants</style></abstract><notes><style face="normal" font="default">DA - 20170403IS - 0973-3922 (Electronic)IS - 0378-6323 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/ijdvl.IJDVL_1078_14</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28366912">PM:28366912</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Dermatol Venereol Leprol\2017-83-317-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Dermatol Venereol Leprol\2017-83-317-25.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170403, Gupta J</style></custom2><misc3><style face="normal" font="default">10.4103/ijdvl.IJDVL_1078_14</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41116</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sakai,H.</style></author><author><style face="normal" font="default"> Sato,K.</style></author><author><style face="normal" font="default"> Sato,F.</style></author><author><style face="normal" font="default"> Kai,Y.</style></author><author><style face="normal" font="default"> Mandokoro,K.</style></author><author><style face="normal" font="default"> Matsumoto,K.</style></author><author><style face="normal" font="default"> Kato,S.</style></author><author><style face="normal" font="default"> Yumoto,T.</style></author><author><style face="normal" font="default"> Narita,M.</style></author><author><style face="normal" font="default"> Chiba,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pharmacy Professional Development and Research, Department of Analytical Pathophysiology, School of Pharmacy, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan.</style></auth-address><titles><title><style face="normal" font="default">Curcumin inhibits epigen and amphiregulin upregulated by 2,4,6-trinitrochlorobenzene associated with attenuation of skin swelling</style></title><secondary-title><style face="normal" font="default">Inflamm Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Inflamm Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Cell Proliferation</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Curcumin</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="12" Month="4" Year="2017">2017/4/12</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Contact dermatitis model involving repeated application of hapten is used as a tool to assess dermatitis, as characterized by thickening. Involvement of cell proliferation, elicited by repeated hapten-stimulation, in this swelling has been unclear. Curcumin is reported to reduce inflammation. We examined involvement of cell proliferation and the role of extracellular regulated kinase (ERK) in 2,4,6-trinitrochlorobenzene (TNCB) challenge-induced ear swelling. We also examined the effects of curcumin in this model. METHODS: Mice were sensitized with TNCB to the abdominal skin. Then, they were challenged with TNCB to the ear three times. The ERK activation inhibitor U0126 or curcumin was applied 30 min before each TNCB challenge. RESULTS: TNCB challenge-induced increased epidermal cell number and dermal thickening. Gene expressions of epithelial mitogen (EPGN), amphiregulin (AREG) and heparin-binding-epidermal growth factor (HB-EGF) were increased in the ears after the last TNCB challenge. Ki-67 immunoreactivity was increased in the dermis in TNCB-challenged ears. TNCB-induced swelling was inhibited by U0126 and curcumin. Curcumin also attenuated TNCB-induced ERK phosphorylation and expression of EPGN and AREG genes. CONCLUSION: Ear swelling induced by TNCB challenge might be mediated, in part, by the</style></abstract><notes><style face="normal" font="default">DA - 20170413IS - 1420-908X (Electronic)IS - 1023-3830 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1007/s00011-017-1048-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28405735">PM:28405735</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Inflamm Res\20170413-SakaiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Inflamm Res\20170413-SakaiM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170413, Sakai H</style></custom2><misc3><style face="normal" font="default">10.1007/s00011-017-1048-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41117</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pichler,W.J.</style></author><author><style face="normal" font="default"> Srinoulprasert,Y.</style></author><author><style face="normal" font="default"> Yun,J.</style></author><author><style face="normal" font="default"> Hausmann,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">ADR-AC, Bern, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Multiple Drug Hypersensitivity</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="138" start="129">129-138</pages><volume><style face="normal" font="default">172</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Agranulocytosis</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> DRESS</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Drug rash</style></keyword><keyword><style face="normal" font="default"> Drug-induced</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Exanthema</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Hepatitis</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> In vitro tests</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Stevens-Johnson syndrome/toxic epidermal necrolysis</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="18" Month="3" Year="2017">2017/3/18</year></dates><abstract><style face="normal" font="default">Multiple drug hypersensitivity (MDH) is a syndrome that develops as a consequence of massive T-cell stimulations and is characterized by long-lasting drug hypersensitivity reactions (DHR) to different drugs. The initial symptoms are mostly severe exanthems or drug rash with eosinophilia and systemic symptoms (DRESS). Subsequent symptoms due to another drug often appear in the following weeks, overlapping with the first DHR, or months to years later after resolution of the initial presentation. The second DHR includes exanthema, erythroderma, DRESS, Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), hepatitis, and agranulocytosis. The eliciting drugs can be identified by positive skin or in vitro tests. The drugs involved in starting the MDH are the same as for DRESS, and they are usually given in rather high doses. Fixed drug combination therapies like sulfamethoxazole/trimethoprim or piperacillin/tazobactam are frequently involved in MDH, and 30-40% of patients with severe DHR to combination therapy show T-cell reactions to both components. The drug-induced T-cell stimulation appears to be due to the p-i mechanism. Importantly, a permanent T-cell activation characterized by PD-1+/CD38+ expression on CD4+/CD25low T cells can be found in the circulation of patients with MDH for many years. In conclusion, MDH is a drug-elicited syndrome characterized by a long-lasting hyperresponsiveness to multiple, structurally unrelated drugs with clinically diverse symptoms</style></abstract><notes><style face="normal" font="default">DA - 20170319IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1159/000458725</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28315874">PM:28315874</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-172-129-38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-172-129-38.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170319, Pichler WJ</style></custom2><misc3><style face="normal" font="default">10.1159/000458725</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41118</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Azimi,E.</style></author><author><style face="normal" font="default"> Reddy,V.B.</style></author><author><style face="normal" font="default"> Lerner,E.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cutaneous Biology Research Center, Massachusetts General Hospital, 149, 13th Street, Charlestown, MA 02129 USA</style></auth-address><titles><title><style face="normal" font="default">Brief communication: MRGPRX2, atopic dermatitis and red man syndrome</style></title><secondary-title><style face="normal" font="default">Itch (Phila)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Itch (Phila)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cell Degranulation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Communication</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Itch</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Staphylococcus</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">Vancoymycin causes red man syndrome, an itchy erythematous eruption involving the face, neck and upper torso. Atopic dermatitis also manifests itch and erythema, and staphylococcus delta-toxin contributes to this process. The antibiotic and toxin each provoke mast cell degranulation but the mechanism had not been understood. We have determined that these compounds evoke degranulation via interaction with the same receptor, MRGPRX2, on mast cells. A receptor antagonist inhibits this process. Antagonists of this receptor may have therapeutic potential</style></abstract><notes><style face="normal" font="default">DA - 20170403LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/itx.0000000000000005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28367504">PM:28367504</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Itch (Phila)\20170403-AzimiE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Itch (Phila)\20170403-AzimiE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170403, Azimi E</style></custom2><misc3><style face="normal" font="default">10.1097/itx.0000000000000005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41119</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Banerji,A.</style></author><author><style face="normal" font="default"> Blumenthal,K.G.</style></author><author><style face="normal" font="default"> Lai,K.H.</style></author><author><style face="normal" font="default"> Zhou,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass</style></auth-address><titles><title><style face="normal" font="default">Epidemiology of ACE Inhibitor Angioedema Utilizing a Large Electronic Health Record</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Angiotensin converting enzyme inhibitors</style></keyword><keyword><style face="normal" font="default"> Angiotensin-Converting Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Drug-induced</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Lip</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mouth</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective cohort study</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Tongue</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="4" Year="2017">2017/4/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs) are a common cause of drug-induced angioedema in the United States. Most epidemiologic ACEI angioedema data are from large multicenter clinical trials. OBJECTIVE: The objective of this study was to identify the incidence of and risk factors for ACEI angioedema using a large integrated electronic health record (EHR). METHODS: We conducted a retrospective cohort study of all ACEI prescriptions in the outpatient setting of a large academic center between January 1, 2000, and September 30, 2008. We determined frequency, timing, and risk factors for ACEI angioedema within 5 years of prescription. All data were derived from EHR sources, with angioedema defined by EHR reactions of angioedema, swelling, edema, or lip, eye, face, tongue, throat or mouth swelling. RESULTS: Among 134,945 patients prescribed an ACEI, 0.7% (n = 888) developed angioedema during the subsequent 5 years. Sex was similar but patients who developed ACEI angioedema were younger (61.5 vs 62.7 years, P = .007). Patients with ACEI angioedema were more likely to have a history of nonsteroidal anti-inflammatory drug allergy compared with patients who did not develop angioedema (7.1% vs 4.2%, P &lt; .001). We identified a 0.07% incidence of ACEI angioedema within 1 month of prescription and a 0.23% incidence during the first year. Incidence of angioedema was relatively constant annually over the subsequent 4 years (0.10% to 0.12%). CONCLUSIONS: The incidence of ACEI angioedema within a large EHR is consistent with large clinical trial data. We observed a persistent and relatively constant annual risk; however, angioedema risk factors and underlying genetic and pathophysiological mechanisms require further study</style></abstract><notes><style face="normal" font="default">DA - 20170405IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.02.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28377081">PM:28377081</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170405-BanerjiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170405-BanerjiA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170405, Banerji A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.02.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41120</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dixon,A.E.</style></author><author><style face="normal" font="default"> Castro,M.</style></author><author><style face="normal" font="default"> Gerald,L.B.</style></author><author><style face="normal" font="default"> Holbrook,J.T.</style></author><author><style face="normal" font="default"> Henderson,R.J.</style></author><author><style face="normal" font="default"> Casale,T.B.</style></author><author><style face="normal" font="default"> Irvin,C.G.</style></author><author><style face="normal" font="default"> Black,K.</style></author><author><style face="normal" font="default"> Wise,R.A.</style></author><author><style face="normal" font="default"> Sugar,E.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Vermont, Burlington, Vt.</style></auth-address><titles><title><style face="normal" font="default">Effect of intranasal corticosteroids on allergic airway disease in asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Intranasal corticosteroid</style></keyword><keyword><style face="normal" font="default"> intranasal corticosteroids</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="7" Month="4" Year="2017">2017/4/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.02.022.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28396113">PM:28396113</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170411-DixonAE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170411-DixonAE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, Dixon AE</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.02.022.</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41121</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cook,K.A.</style></author><author><style face="normal" font="default"> Kelso,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Asthma and Immunology, Scripps Clinic, San Diego, Calif.</style></auth-address><titles><title><style face="normal" font="default">Surgery-Related Contact Dermatitis: A Review of Potential Irritants and Allergens</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adhesives</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anesthetics</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Antiseptics</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bandages</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Gloves</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritants</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tissue Adhesives</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="7" Month="4" Year="2017">2017/4/7</year></dates><abstract><style face="normal" font="default">Surgical procedures utilize an increasing number of medical products including antiseptics, anesthetics, gloves, suture materials, tissue adhesives, topical antibiotics, and bandages. Many of these products have irritant potential. Allergic contact dermatitis has also been reported. This review covers preoperative, operative, and postoperative exposures that may result in contact dermatitis. Testing with standard patch panels such as T.R.U.E. Test and the North American Contact Dermatitis Group 65 allergen series does not evaluate for all relevant contactants. A thorough understanding of potential exposures is vital to effectively evaluate a patient with surgery-related contact dermatitis. A systematic approach is needed to ensure that standard patch panels and supplementary patches adequately address each encountered contactant</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28396114">PM:28396114</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170411-CookKA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170411-CookKA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, Cook KA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41122</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bending,D.</style></author><author><style face="normal" font="default"> Ono,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Life Sciences, Faculty of Natural Sciences, Imperial College London, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Interplay Between the Skin Barrier and Immune Cells in Patients with Atopic Dermatitis Unraveled by Means of Mathematical Modeling</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Modeling</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170410IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28392329">PM:28392329</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170410-BendingD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170410-BendingD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170410, Bending D</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41123</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sugita,K.</style></author><author><style face="normal" font="default"> Steer,C.A.</style></author><author><style face="normal" font="default"> Martinez-Gonzalez,I.</style></author><author><style face="normal" font="default"> Altunbulakli,C.</style></author><author><style face="normal" font="default"> Morita,H.</style></author><author><style face="normal" font="default"> Castro-Giner,F.</style></author><author><style face="normal" font="default"> Kubo,T.</style></author><author><style face="normal" font="default"> Wawrzyniak,P.</style></author><author><style face="normal" font="default"> Ruckert,B.</style></author><author><style face="normal" font="default"> Sudo,K.</style></author><author><style face="normal" font="default"> Nakae,S.</style></author><author><style face="normal" font="default"> Matsumoto,K.</style></author><author><style face="normal" font="default"> O'Mahony,L.</style></author><author><style face="normal" font="default"> Akdis,M.</style></author><author><style face="normal" font="default"> Takei,F.</style></author><author><style face="normal" font="default"> Akdis,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Type 2 innate Lymphoid Cells Disrupt Bronchial Epithelial Barrier Integrity by Targeting Tight Junctions Via IL-13 in Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="default"> bronchial epithelium</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Coculture</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelia</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> Epithelium</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate lymphoid cells</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Permeability</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Recombinant</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> tight junctions</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Bronchial epithelial barrier leakiness and type 2 innate lymphoid cells (ILC2s) have been separately linked to asthma pathogenesis, however the influence of ILC2s on bronchial epithelial barrier has not been previously investigated. OBJECTIVE: We investigated the role of ILC2s in the regulation of bronchial epithelial tight junctions (TJs) and barrier function both in bronchial epithelial cells of asthmatic and healthy individuals and general ILC- and ILC2-deficient mice. METHODS: Co-cultures of human ILC2s and bronchial epithelial cells were used to determine transepithelial resistance (TER), paracellular flux, TJ mRNA and protein expressions. To analyze the in vivo relevance of barrier disruption by ILC2s, the effect of ILC2s on TJs was examined using a murine model of IL-33-induced airway inflammation in wild-type (WT), Rag2-/-, Rag2-/-Il2rg-/-, and Rorasg/sg bone marrow-transplanted (BMT) mice. RESULTS: ILC2s significantly impaired epithelial barrier as demonstrated by reduced TER and increased FITC-dextran permeability in air-liquid interface cultures of human bronchial epithelial cells. This was in parallel to decreased mRNAs and disrupted protein expression of TJ proteins, and was restored by neutralization of IL-13. The intranasal administration of recombinant IL-33 to WT and Rag2-/- mice lacking T and B cells triggered TJ disruption, whereas Rag2-/-Il2rg-/- and Rorasg/sg BMT mice that lack ILC2s did not show any barrier leakiness. Direct nasal administration of IL-13 was sufficient to induce deficiency in TJ barrier in bronchial epithelium of mice in vivo. CONCLUSION: These data highlight an essential mechanism in asthma pathogenesis by demonstrating that ILC2s are responsible for bronchial epithelial TJ barrier leakiness via IL-13</style></abstract><notes><style face="normal" font="default">DA - 20170410IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - Japan -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28392332">PM:28392332</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170410-SugitaK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170410-SugitaK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170410, Sugita K</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41124</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Van Gerven,L.</style></author><author><style face="normal" font="default"> Alpizar,Y.A.</style></author><author><style face="normal" font="default"> Steelant,B.</style></author><author><style face="normal" font="default"> Callebaut,I.</style></author><author><style face="normal" font="default"> Kortekaas,K.I.</style></author><author><style face="normal" font="default"> Wouters,M.</style></author><author><style face="normal" font="default"> Vermeulen,F.</style></author><author><style face="normal" font="default"> Boeckxstaens,G.</style></author><author><style face="normal" font="default"> Talavera,K.</style></author><author><style face="normal" font="default"> Hellings,P.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical division of Otorhinolaryngology, Head &amp; Neck Surgery, University Hospitals Leuven, Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="default">Enhanced Chemosensory Sensitivity in Idiopathic Rhinitis Patients and its Reversal by Nasal Capsaicin Treatment</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">abnormalities</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Capsaicin</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="4" Month="4" Year="2017">2017/4/4</year></dates><abstract><style face="normal" font="default">We show electrophysiological evidence for an increased chemical sensitivity in idiopathic rhinitis patients compared to healthy controls. This abnormality is decreased after capsaicin treatment, along with a reduction of symptoms</style></abstract><notes><style face="normal" font="default">DA - 20170408IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28389389">PM:28389389</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170408-VanGervenL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170408-VanGervenL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170408, Van Gerven L</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41125</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Grabiec,A.M.</style></author><author><style face="normal" font="default"> Denny,N.</style></author><author><style face="normal" font="default"> Doherty,J.A.</style></author><author><style face="normal" font="default"> Happonen,K.E.</style></author><author><style face="normal" font="default"> Hankinson,J.</style></author><author><style face="normal" font="default"> Connolly,E.</style></author><author><style face="normal" font="default"> Fife,M.E.</style></author><author><style face="normal" font="default"> Fujimori,T.</style></author><author><style face="normal" font="default"> Fujino,N.</style></author><author><style face="normal" font="default"> Goenka,A.</style></author><author><style face="normal" font="default"> Holden,S.</style></author><author><style face="normal" font="default"> Tavernier,G.</style></author><author><style face="normal" font="default"> Shah,R.</style></author><author><style face="normal" font="default"> Cook,P.C.</style></author><author><style face="normal" font="default"> MacDonald,A.S.</style></author><author><style face="normal" font="default"> Niven,R.M.</style></author><author><style face="normal" font="default"> Dahlback,B.</style></author><author><style face="normal" font="default"> Fowler,S.J.</style></author><author><style face="normal" font="default"> Simpson,A.</style></author><author><style face="normal" font="default"> Hussell,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Manchester Collaborative Centre for Inflammation Research, The University of Manchester, Manchester, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Diminished airway macrophage expression of the Axl receptor tyrosine kinase is associated with defective efferocytosis in asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Tyrosine</style></keyword><keyword><style face="normal" font="default"> tyrosine kinase</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="12" Month="4" Year="2017">2017/4/12</year></dates><abstract><style face="normal" font="default">The apoptotic cell recognition receptor Axl is highly expressed on human airway/alveolar macrophages, its expression is driven by the lung microenvironment and is significantly reduced in asthma, which may explain defects in apoptotic cell clearance</style></abstract><notes><style face="normal" font="default">DA - 20170416IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Poland -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28412392">PM:28412392</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170416-GrabiecAM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170416-GrabiecAM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170416, Grabiec AM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41126</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Choi,J.</style></author><author><style face="normal" font="default"> Fernandez,R.</style></author><author><style face="normal" font="default"> Maecker,H.T.</style></author><author><style face="normal" font="default"> Butte,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Medicine, Stanford University, Stanford, California 94305, USA</style></auth-address><titles><title><style face="normal" font="default">Systems Approach to Uncover Signaling Networks in Primary Immunodeficiency Diseases</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="12" Month="4" Year="2017">2017/4/12</year></dates><abstract><style face="normal" font="default">CAPSULE SUMMARY: This broad, unbiased approach of studying signaling across all circulating immune cells in healthy subjects allowed identification of disrupted signaling networks in patients with primary immunodeficiencies</style></abstract><notes><style face="normal" font="default">DA - 20170416IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28412396">PM:28412396</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170416-ChoiJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170416-ChoiJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170416, Choi J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41127</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Radonjic-Hoesli,S.</style></author><author><style face="normal" font="default"> Wang,X.</style></author><author><style face="normal" font="default"> de Graauw,E.</style></author><author><style face="normal" font="default"> Stoeckle,C.</style></author><author><style face="normal" font="default"> Styp-Rekowska,B.</style></author><author><style face="normal" font="default"> Hlushchuk,R.</style></author><author><style face="normal" font="default"> Simon,D.</style></author><author><style face="normal" font="default"> Spaeth,P.J.</style></author><author><style face="normal" font="default"> Yousefi,S.</style></author><author><style face="normal" font="default"> Simon,H.U.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Pharmacology, University of Bern, Bern, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Adhesion-induced eosinophil cytolysis requires the RIPK3-MLKL signaling pathway which is counter-regulated by autophagy</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cell Death</style></keyword><keyword><style face="normal" font="default"> Characterization</style></keyword><keyword><style face="normal" font="default"> Complement</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electron microscopy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Esophagitis</style></keyword><keyword><style face="normal" font="default"> Fluorescence</style></keyword><keyword><style face="normal" font="default"> Glass</style></keyword><keyword><style face="normal" font="default"> Granules</style></keyword><keyword><style face="normal" font="default"> Granulocytes</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> immunopathology</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> IVIG</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Microscopy</style></keyword><keyword><style face="normal" font="default"> mitogen-activated protein kinase</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Oxygen</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> PI3K</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="default"> ROS</style></keyword><keyword><style face="normal" font="default"> Sequence</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="12" Month="4" Year="2017">2017/4/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Eosinophils are a subset of granulocytes which can be involved in the pathogenesis of different diseases, including allergy. Their effector functions are closely linked to their cytotoxic granule proteins. The release takes place by several different mechanisms, one of which is cytolysis, which is associated with the release of intact granules, so-called clusters of free eosinophil granules. The mechanism underlying this activation-induced form of cell death in eosinophils has remained unclear. OBJECTIVE: We aimed to elucidate the molecular mechanism of eosinophil cytolysis. METHODS: Isolated blood eosinophils were incubated on glass cover slips coated with intravenous immunoglobulin (IVIG) and inactive complement component 3b (iC3b). A morphological characterization of the distinct stages of the proposed cascade was addressed by means of time-lapse automated fluorescence microscopy, electron microscopy, and immunohistochemistry. Experiments with pharmacological inhibitors were performed to elucidate the sequence of events within the cascade. Tissue samples of patients suffering from eosinophilic skin diseases or eosinophilic esophagitis were used for in vivo analyses. RESULTS: Following eosinophil adhesion, we observed reactive oxygen species (ROS) production, early degranulation, and granule fusion processes leading to a distinct morphology exhibiting cytoplasmic vacuolization and, finally, to cytolysis. Using a pharmacological approach, we demonstrate the presence of a receptor-interacting protein kinase 3 (RIPK3) - mixed lineage kinase-like (MLKL) signaling pathway in eosinophils, which, following its activation, leads to the production of high levels of reactive oxygen species (ROS) in a p38 mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3'-kinase (PI3K) - dependent manner. All these steps are required for cytoplasmic vacuolization and subsequent cytolysis to occur. Interestingly, triggering cytolysis is associated with an induction of autophagy in eosinophils and additional stimulation of autophagy by pharmacological inhibition of the mechanistic target of rapamycin (mTOR) counter-regulates cell death. Moreover, MLKL phosphorylation, cytoplasmic vacuolization, and cytolysis were observed in eosinophils under in vivo inflammatory conditions. CONCLUSION: We report that adhesion-induced eosinophil cytolysis takes place by a RIPK3-MLKL-dependent necroptosis which can be counter-regulated by autophagy. The receptor-interacting protein kinase 3 (RIPK3) - mixed lineage kinase-like (MLKL) signaling pathway mediates eosinophil cytolysis, a phenomenon often observed in eosinophilic tissues of patients suffering from diseases with eosinophil-mediated immunopathology</style></abstract><notes><style face="normal" font="default">DA - 20170416IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28412393">PM:28412393</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170416-RadonjicHoesliS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170416-RadonjicHoesliS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170416, Radonjic-Hoesli S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.044</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41128</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Takeda,A.J.</style></author><author><style face="normal" font="default"> Zhang,Y.</style></author><author><style face="normal" font="default"> Dornan,G.L.</style></author><author><style face="normal" font="default"> Siempelkamp,B.D.</style></author><author><style face="normal" font="default"> Jenkins,M.L.</style></author><author><style face="normal" font="default"> Matthews,H.F.</style></author><author><style face="normal" font="default"> McElwee,J.J.</style></author><author><style face="normal" font="default"> Bi,W.</style></author><author><style face="normal" font="default"> Seeborg,F.O.</style></author><author><style face="normal" font="default"> Su,H.C.</style></author><author><style face="normal" font="default"> Burke,J.E.</style></author><author><style face="normal" font="default"> Lucas,C.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunobiology, Yale University School of Medicine, New Haven, CT, 06511</style></auth-address><titles><title><style face="normal" font="default">Novel PIK3CD mutations affecting N-terminal residues of p110delta cause APDS1 in humans</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="13" Month="4" Year="2017">2017/4/13</year></dates><abstract><style face="normal" font="default">APDS is a newly described and prevalent primary immunodeficiency disease, and we now expand the list of mutation sites to include E81K and G124D of p110delta and uncover an intramolecular mechanism of activation that is inhibited by clinically relevant targeting of p110delta</style></abstract><notes><style face="normal" font="default">DA - 20170417IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United states -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28414062">PM:28414062</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170417-TakedaAJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170417-TakedaAJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170417, Takeda AJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.026</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41129</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Thomas,B.</style></author><author><style face="normal" font="default"> Anthony Hirst,R.</style></author><author><style face="normal" font="default"> Brett-Pitt,H.</style></author><author><style face="normal" font="default"> Williams,G.</style></author><author><style face="normal" font="default"> Andrew,P.W.</style></author><author><style face="normal" font="default"> Sousa,A.R.</style></author><author><style face="normal" font="default"> Marshall,R.P.</style></author><author><style face="normal" font="default"> Brightling,C.</style></author><author><style face="normal" font="default"> O'Callaghan,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for PCD diagnosis and Research, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Severe Asthma: differential chemokine response of airway epithelial cells</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway epithelial cell</style></keyword><keyword><style face="normal" font="default"> airway epithelial cells</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic asthma</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Dermatophagoides</style></keyword><keyword><style face="normal" font="default"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Streptococcus</style></keyword><keyword><style face="normal" font="default"> Streptococcus pneumoniae</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="12" Month="4" Year="2017">2017/4/12</year></dates><abstract><style face="normal" font="default">The differential chemokine response of airway basal cells of severe asthma patients to Streptococcus pneumoniae and Dermatophagoides pteronyssinus allergen may be of significance in the context of developing novel immunomodulatory therapeutic strategies for atopic asthma</style></abstract><notes><style face="normal" font="default">DA - 20170416IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28412395">PM:28412395</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170416-ThomasB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170416-ThomasB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170416, Thomas B</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.040</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41130</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Renz,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Autophagy - Nobel Prize 2016 and Allergy and Asthma Research</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Nobel Prize</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword></keywords><dates><year Day="8" Month="4" Year="2017">2017/4/8</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170412IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28400114">PM:28400114</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170412-RenzH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170412-RenzH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170412, Renz H</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41131</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Konstantellou,E.</style></author><author><style face="normal" font="default"> Loukides,S.</style></author><author><style face="normal" font="default"> Ntontsi,P.</style></author><author><style face="normal" font="default"> Papathanasiou,E.</style></author><author><style face="normal" font="default"> Kostikas,K.</style></author><author><style face="normal" font="default"> Paptheodorou,G.</style></author><author><style face="normal" font="default"> Hillas,G.</style></author><author><style face="normal" font="default"> Papiris,S.</style></author><author><style face="normal" font="default"> Koulouris,N.G.</style></author><author><style face="normal" font="default"> Bakakos,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">1st Respiratory Medicine Department, National and Kapodistrian University of Athens Medical School, Sotiria Chest Hospital, Athens, Greece</style></auth-address><titles><title><style face="normal" font="default">The association between serum periostin and a type 2 helper airway composite index in optimally treated asthmatics</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Periostin</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="7" Month="4" Year="2017">2017/4/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28396112">PM:28396112</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170411-KonstantellouE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170411-KonstantellouE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, Konstantellou E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41132</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Iammatteo,M.</style></author><author><style face="normal" font="default"> Akenroye,A.</style></author><author><style face="normal" font="default"> Jariwala,S.</style></author><author><style face="normal" font="default"> Lee,B.</style></author><author><style face="normal" font="default"> Schairer,D.</style></author><author><style face="normal" font="default"> Rosenstreich,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.</style></auth-address><titles><title><style face="normal" font="default">Severe contact dermatitis due to ethylenediamine dihydrochloride in nystatin cream</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Nystatin</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="7" Month="4" Year="2017">2017/4/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28396110">PM:28396110</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170411-IammatteoM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170411-IammatteoM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, Iammatteo ;</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41133</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Peebles,R.S.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University School of Medicine, T-1218 MCN, Vanderbilt University Medical Center, Nashville, Tennessee 37232-2650, USA. Electronic address: stokes.peebles@vanderbilt.edu</style></auth-address><titles><title><style face="normal" font="default">Is IL-1beta inhibition the next therapeutic target in asthma?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Tennessee</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="7" Month="4" Year="2017">2017/4/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28396074">PM:28396074</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170411-PeeblesRSJr.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170411-PeeblesRSJr.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, Peebles RS Jr</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41134</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Davies,E.G.</style></author><author><style face="normal" font="default"> Cheung,M.</style></author><author><style face="normal" font="default"> Gilmour,K.</style></author><author><style face="normal" font="default"> Maimaris,J.</style></author><author><style face="normal" font="default"> Curry,J.</style></author><author><style face="normal" font="default"> Furmanski,A.</style></author><author><style face="normal" font="default"> Sebire,N.</style></author><author><style face="normal" font="default"> Halliday,N.</style></author><author><style face="normal" font="default"> Mengrelis,K.</style></author><author><style face="normal" font="default"> Adams,S.</style></author><author><style face="normal" font="default"> Bernatoniene,J.</style></author><author><style face="normal" font="default"> Bremner,R.</style></author><author><style face="normal" font="default"> Browning,M.</style></author><author><style face="normal" font="default"> Devlin,B.</style></author><author><style face="normal" font="default"> Erichsen,H.C.</style></author><author><style face="normal" font="default"> Gaspar,H.B.</style></author><author><style face="normal" font="default"> Hutchison,L.</style></author><author><style face="normal" font="default"> Ip,W.</style></author><author><style face="normal" font="default"> Ifversen,M.</style></author><author><style face="normal" font="default"> Leahy,T.R.</style></author><author><style face="normal" font="default"> McCarthy,E.</style></author><author><style face="normal" font="default"> Moshous,D.</style></author><author><style face="normal" font="default"> Neuling,K.</style></author><author><style face="normal" font="default"> Pac,M.</style></author><author><style face="normal" font="default"> Papadopol,A.</style></author><author><style face="normal" font="default"> Parsley,K.L.</style></author><author><style face="normal" font="default"> Poliani,L.</style></author><author><style face="normal" font="default"> Ricciardelli,I.</style></author><author><style face="normal" font="default"> Sansom,D.M.</style></author><author><style face="normal" font="default"> Voor,T.</style></author><author><style face="normal" font="default"> Worth,A.</style></author><author><style face="normal" font="default"> Crompton,T.</style></author><author><style face="normal" font="default"> Markert,M.L.</style></author><author><style face="normal" font="default"> Thrasher,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Child Health, University College London</style></auth-address><titles><title><style face="normal" font="default">Thymus Transplantation for Complete Digeorge Syndrome: European Experience</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Antimicrobials</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> CD4</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> DiGeorge Syndrome</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Estonia</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Ireland</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neutropenia</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> REACH</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Romania</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Survivors</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cell receptor</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Thrombocytopaenia</style></keyword><keyword><style face="normal" font="default"> Thyroiditis</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral infection</style></keyword><keyword><style face="normal" font="default"> Viral infections</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="8" Month="4" Year="2017">2017/4/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Thymus transplantation is a promising strategy for the treatment of athymic complete DiGeorge syndrome (cDGS). METHODS: Twelve patients with cDGS were transplanted with allogeneic cultured thymus. OBJECTIVE: To confirm and extend the results previously obtained in a single centre. RESULTS: Two patients died of pre-existing viral infections without developing thymopoeisis and one late death occurred from autoimmune thrombocytopaenia. One infant suffered septic shock shortly after transplant resulting in graft loss and the need for a second transplant. Evidence of thymopoeisis developed from 5-6 months after transplantation in ten patients. The median (range) of circulating naive CD4 counts (x106/L) were 44(11-440) and 200(5-310) at twelve and twenty-four months post-transplant and T-cell receptor excision circles were 2238 (320-8807) and 4184 (1582 -24596) per106 T-cells. Counts did not usually reach normal levels for age but patients were able to clear pre-existing and later-acquired infections. At a median of 49 months (22-80), eight have ceased prophylactic antimicrobials and five immunoglobulin replacement. Histological confirmation of thymopoeisis was seen in seven of eleven patients undergoing biopsy of transplanted tissue including five showing full maturation through to the terminal stage of Hassall body formation. Autoimmune regulator (AIRE) expression was also demonstrated. Autoimmune complications were seen in 7/12 patients. In two, early transient autoimmune haemolysis settled after treatment and did not recur. The other five suffered ongoing autoimmune problems including: thyroiditis (3); haemolysis (1), thrombocytopaenia (4) and neutropenia (1). CONCLUSIONS: This study confirms the previous reports that thymus transplantation can reconstitute T cells in cDGS but with frequent autoimmune complications in survivors</style></abstract><notes><style face="normal" font="default">DA - 20170412IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - United States -CO - Denmark -CO - Ireland -CO - France -CO - POland -CO - Romania -CO - Italy -CO - Estonia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28400115">PM:28400115</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170412-DaviesEG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170412-DaviesEG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170412, Davies EG</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41135</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">To,T.</style></author><author><style face="normal" font="default"> Ryckman,K.</style></author><author><style face="normal" font="default"> Zhu,J.</style></author><author><style face="normal" font="default"> Williams,D.</style></author><author><style face="normal" font="default"> Feldman,L.Y.</style></author><author><style face="normal" font="default"> Larsen,K.</style></author><author><style face="normal" font="default"> Gershon,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="default">Mental Health Services Claims and Adult Onset Asthma in Ontario, Canada</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Activities of Daily Living</style></keyword><keyword><style face="normal" font="default"> Administrative data</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Adult asthma</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Services</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Mental Disorders</style></keyword><keyword><style face="normal" font="default"> mental health</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Ontario</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Poisson</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Substance-Related Disorders</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="7" Month="4" Year="2017">2017/4/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Living with asthma is associated with a decrease in quality of life due to reductions in activities of daily living and increased psychological stress, both of which are associated with poor mental health outcomes. OBJECTIVE: The objective of this study was to quantify the burden of mental disorders on the adult asthma population and compare the risk of mental health services claims (MHSCs) in the 1 year before and 1 year after asthma diagnosis. METHODS: Ontario residents aged 25 to 65 years with incident physician-diagnosed asthma between April 1, 2005, and March 31, 2012, were included. MHSCs, which consisted of hospitalizations, emergency department (ED), and outpatient physician visits, were identified from universal health administrative data. Poisson regression models with repeated measures were used to estimate the relative risk (RR) of MHSCs for 2 time periods: 1 year after asthma diagnosis compared with the 1 year before and 2 years after compared with 2 years before. RESULTS: A total of 145,881 adults had incident asthma. In the 1 year after asthma diagnosis, 27% had an MHSC. The risk of ED visits for any mental disorders increased by 13% in the 1 year after asthma diagnosis compared with the 1 year before (adjusted RR [aRR], 1.13; 95% confidence interval [CI], 1.06-1.21). This increased risk of ED visits was not found when comparing 2 years after asthma diagnosis with 2 years before. The risk for outpatient physician visits for substance-related disorders increased by 21% at 1 year (aRR, 1.21; 95% CI, 1.14-1.28) and 37% at 2 years (aRR, 1.37; 95% CI, 1.28-1.46). CONCLUSIONS: The significant comorbid burden of mental disorders in adults with newly diagnosed asthma highlights the need for primary care physicians to assess mental health needs and provide appropriate care</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default"> 10.1016/j.jaip.2017.02.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28396111">PM:28396111</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170411-ToT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170411-ToT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, To T</style></custom2><misc3><style face="normal" font="default"> 10.1016/j.jaip.2017.02.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41136</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dorn,J.M.</style></author><author><style face="normal" font="default"> Patnaik,M.S.</style></author><author><style face="normal" font="default"> Van Hee,M.</style></author><author><style face="normal" font="default"> Smith,M.J.</style></author><author><style face="normal" font="default"> Lagerstedt,S.A.</style></author><author><style face="normal" font="default"> Newman,C.C.</style></author><author><style face="normal" font="default"> Boyce,T.G.</style></author><author><style face="normal" font="default"> Abraham,R.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergic Diseases, Department of Medicine, Mayo Clinic, Rochester, Minn</style></auth-address><titles><title><style face="normal" font="default">WILD syndrome is GATA2 deficiency: A novel deletion in the GATA2 gene</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="31" Month="3" Year="2017">2017/3/31</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170404IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.02.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28373026">PM:28373026</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170404-DornJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170404-DornJM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170404, Dorn JM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.02.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41137</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Marciano,B.E.</style></author><author><style face="normal" font="default"> Allen,E.S.</style></author><author><style face="normal" font="default"> Cantilena,C.C.</style></author><author><style face="normal" font="default"> Kristosturyan,E.</style></author><author><style face="normal" font="default"> Klein,H.G.</style></author><author><style face="normal" font="default"> Fleisher,T.A.</style></author><author><style face="normal" font="default"> Holland,S.M.</style></author><author><style face="normal" font="default"> Malech,H.L.</style></author><author><style face="normal" font="default"> Rosenzweig,S.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases (NIAID)</style></auth-address><titles><title><style face="normal" font="default">Granulocyte transfusions in patients with chronic granulomatous disease and refractory infections: the NIH experience</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic granulomatous disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Fungal infection</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="default">Granulocyte transfusions are a relatively safe adjunctive therapeutic option for patients with chronic granulomatous disease and severe/refractory bacterial or fungal infections. Early initiation, high frequency and sustained therapy is associated with significantly better outcomes</style></abstract><notes><style face="normal" font="default">DA - 20170326IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28342916">PM:28342916</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170326-MarcianoBE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170326-MarcianoBE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170326, Marciano BE</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.026</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41138</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Krug,N.</style></author><author><style face="normal" font="default"> Hohlfeld,J.M.</style></author><author><style face="normal" font="default"> Buhl,R.</style></author><author><style face="normal" font="default"> Renz,J.</style></author><author><style face="normal" font="default"> Garn,H.</style></author><author><style face="normal" font="default"> Renz,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany</style></auth-address><titles><title><style face="normal" font="default">Blood eosinophils predict therapeutic effects of a GATA3-specific DNAzyme in asthma patients</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Toxicology</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="default">The effect of the GATA3-mRNA-specific DNAzyme SB010 treatment on EAR and LAR responses continuously increased with higher relative levels of blood eosinophils making them a suitable biomarker to stratify asthma patients for inhaled SB010 treatment</style></abstract><notes><style face="normal" font="default">DA - 20170326IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28342914">PM:28342914</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170326-KrugN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170326-KrugN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170326, Krug N</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41139</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hacini-Rachinel,F.</style></author><author><style face="normal" font="default"> Gomez de Aguero,M.</style></author><author><style face="normal" font="default"> Kanjarawi,R.</style></author><author><style face="normal" font="default"> Moro-Sibilot,L.</style></author><author><style face="normal" font="default"> Le Luduec,J.B.</style></author><author><style face="normal" font="default"> Macari,C.</style></author><author><style face="normal" font="default"> Boschetti,G.</style></author><author><style face="normal" font="default"> Bardel,E.</style></author><author><style face="normal" font="default"> Langella,P.</style></author><author><style face="normal" font="default"> Dubois,B.</style></author><author><style face="normal" font="default"> Kaiserlian,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">"Mucosal immunity, Vaccination &amp; Biotherapies" Laboratory, INSERM U1111-CNRS UMR5</style></auth-address><titles><title><style face="normal" font="default">Intestinal dendritic cell licensing through TLR4 is required for oral tolerance in allergic contact dermatitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adoptive Transfer</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Biotherapies</style></keyword><keyword><style face="normal" font="default"> Biotherapy</style></keyword><keyword><style face="normal" font="default"> Bone Marrow</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Chimera</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> DC</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Foxp3</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Haptens</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Ligands</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> regulatory T cell</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> suppression</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TLR4</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> Tolerance induction</style></keyword><keyword><style face="normal" font="default"> Vaccination</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: Induction of oral tolerance to haptens is an efficient way to prevent allergic contact dermatitis (ACD) in mice. Toll-like receptor (TLRs)-mediated sensing of the microbiota contributes to gut homeostasis, yet whether it contributes to induction of oral tolerance has not been documented. OBJECTIVE: We examined whether oral tolerance to the contact sensitizer DNFB depends on microbiota/TLRs and evaluated the role of TLR4 on the tolerogenic function of intestinal dendritic cells (DCs). METHODS: Oral tolerance was induced by DNFB gavage in germ-free (GF) and several TLR-deficient mice. Tolerance was assessed by suppression of contact hypersensitivity and of hapten-specific IFNgamma-producing effector T cells. The tolerogenic function of intestinal DCs was tested by adoptive transfer experiments, ex vivo hapten-presentation and Foxp3 regulatory T cell conversion. RESULTS: Oral tolerance induced by DNFB gavage was impaired in GF mice and in TLR4-deficient mice. Bone marrow chimeras revealed that TLR4 expression on hematopoietic cells was necessary for oral tolerance induction. TLR4 appeared to be essential for the ability of intestinal dendritic cells from DNFB-fed mice to inhibit ACD upon adoptive transfer. Indeed, TLR4 conditioned the in vivo mobilization to mesenteric lymph nodes of intestinal migratory CD103+ DCs carrying oral DNFB, especially the CD103+CD11b+ DC subset expressing the vitamin A-converting enzyme RALDH+ and specialized in Foxp3+Treg conversion. CONCLUSIONS: Our data demonstrate that TLR4 conditions induction of oral tolerance to DNFB via licensing tolerogenic gut DCs. Oral biotherapy with TLR4 ligands might be usefull to potentiate oral tolerance to haptens and alleviate ACD in humans</style></abstract><notes><style face="normal" font="default">DA - 20170326IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28342908">PM:28342908</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170326-HaciniRachinel.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170326-HaciniRachinel.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170326, Hacini-Rachinel F</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.022</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41140</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Salas,M.</style></author><author><style face="normal" font="default"> Laguna,J.J.</style></author><author><style face="normal" font="default"> Dona,I.</style></author><author><style face="normal" font="default"> Barrionuevo,E.</style></author><author><style face="normal" font="default"> Fernandez-Santamaria,R.</style></author><author><style face="normal" font="default"> Ariza,A.</style></author><author><style face="normal" font="default"> Perez-Inestrosa,E.</style></author><author><style face="normal" font="default"> Mayorga,C.</style></author><author><style face="normal" font="default"> Fernandez,T.D.</style></author><author><style face="normal" font="default"> Torres,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Unit, IBIMA-Regional University Hospital of Malaga-UMA, Malaga, Spain</style></auth-address><titles><title><style face="normal" font="default">Patients Taking Amoxicillin-Clavulanic Can Become Simultaneously Sensitized to Both Drugs</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Amoxicillin</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophil activation test</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Clavulanic Acid</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostics</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> Drug provocation test</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> immediate reactions</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nonimmediate</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin V</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum specific IgE</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Specific IgE</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> T lymphocyte</style></keyword><keyword><style face="normal" font="default"> T-lymphocyte</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patients can react to amoxicillin (AX) and clavulanic acid (CLV) taken in combination because of selective reactions to either drug. However, scant information exists concerning patients who react simultaneously to both compounds. OBJECTIVE: To analyze the mechanisms involved in 4 patients who developed allergic reactions to AX-CLV administration (3 with immediate IgE-mediated reaction and 1 with nonimmediate T-cell-mediated reaction) and who responded specifically to both AX and CLV. METHODS: Skin tests with benzylpenicillin (BP), AX, and CLV were done and, if necessary, drug provocation tests with BP/penicillin V, AX, and AX-CLV were carried out. In immediate reactors, serum specific IgE to benzylpenicilloyl and amoxicilloyl was determined by using the CAP-FEIA system (Pharmacia Diagnostics, Uppsala, Sweden), and basophil activation test to BP, AX, CLV, and AX-CLV was done. In nonimmediate reactors, immunohistochemistry of skin biopsy and analysis of dendritic cell maturation and T-cell-specific response to BP, AX, CLV, and AX-CLV at both acute and resolution phases of the reaction were conducted. RESULTS: All patients with immediate reactions (N = 3) had good tolerance to BP and penicillin V. Two cases also had specific IgE to AX and all had a basophil activation test positive to AX, CLV, and AX-CLV. The patient with a nonimmediate reaction exhibited dendritic cell and T-lymphocyte responses specific to both AX and CLV. Finally, the analysis of the cells infiltrating the skin and peripheral blood during the acute phase indicated a TH1 pattern response. CONCLUSIONS: Our study provides evidence that reactions to both AX and CLV can appear in the same patient</style></abstract><notes><style face="normal" font="default">DA - 20170326IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.02.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28342830">PM:28342830</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170326-SalasM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170326-SalasM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170326, Salas M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.02.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41141</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chung,K.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Heart &amp; Lung Institute, Imperial College, London &amp; Respiratory Biomedical Research Unit, Royal Brompton &amp; Harefield NHS Trust and Imperial College London, London, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default">Airway microbial dysbiosis in asthmatic patients: A target for prevention and treatment?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="1081" start="1071">1071-1081</pages><volume><style face="normal" font="default">139</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> allergic sensitization</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> Biomedical Research</style></keyword><keyword><style face="normal" font="default"> Causality</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> diversity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> Gut microbiota</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory phenotypes</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Prebiotics</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Probiotics</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">There has been long-standing interest in the role of bacterial communities in the complex and heterogeneous disease of asthma. With the advent of 16s rRNA sequencing replacing traditional culture methods, a strong association between the presence of bacterial communities with asthma has emerged. These microbiota can be modulated by various environmental factors, including diet, antibiotics, and early-life microbial exposures. Microbiota in the gut and lungs can influence both the inception and progress of asthma. In babies and infants the presence of pathogenic bacteria in the lungs and gut has been associated with subsequent development of allergic sensitization and asthma. Lung microbiota are present in the airways of healthy subjects but are dysregulated in adults with asthma, with a reduced diversity and community composition that has been linked to severity and inflammatory phenotypes. Causality between certain gut microbiota and the development of allergic asthma has been shown in experiments conducted in neonatal mice. Manipulation of the airway microbiome, particularly in early life, might be a strategy to prevent or treat asthma, although the results of studies of probiotics used together with prebiotics have been overall negative. A better understanding of the regulation of both the lung and gut microbiota to derive appropriate targets for prevention or treatment of asthma is needed</style></abstract><notes><style face="normal" font="default">DA - 20170409IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28390574">PM:28390574</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-1071-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-1071-81.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170409, Chung KF</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41142</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Battersby,A.C.</style></author><author><style face="normal" font="default"> Braggins,H.</style></author><author><style face="normal" font="default"> Pearce,M.S.</style></author><author><style face="normal" font="default"> Cale,C.M.</style></author><author><style face="normal" font="default"> Burns,S.O.</style></author><author><style face="normal" font="default"> Hackett,S.</style></author><author><style face="normal" font="default"> Hughes,S.</style></author><author><style face="normal" font="default"> Barge,D.</style></author><author><style face="normal" font="default"> Goldblatt,D.</style></author><author><style face="normal" font="default"> Gennery,A.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK</style></auth-address><titles><title><style face="normal" font="default">Inflammatory and Autoimmune Manifestations in X-linked carriers of Chronic Granulomatous Disease in the United Kingdom</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">autoimmune</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic granulomatous disease</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="23" Month="3" Year="2017">2017/3/23</year></dates><abstract><style face="normal" font="default">CAPSULE SUMMARY: It has been recognized that X-linked carriers may have skin</style></abstract><notes><style face="normal" font="default">DA - 20170327IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28343844">PM:28343844</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170327-BattersbyAC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170327-BattersbyAC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170327, Battersby AC</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41143</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">van Lier,R.A.</style></author><author><style face="normal" font="default"> Kuijpers,T.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departments of Hematopoiesis.</style></auth-address><titles><title><style face="normal" font="default">The Cellular Immune System Comes of Age</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hematopoiesis</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170326IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28342909">PM:28342909</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170326-vanLierRA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170326-vanLierRA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170326, van Lier RA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41144</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Levy,E.D.</style></author><author><style face="normal" font="default"> Meyers,K.E.</style></author><author><style face="normal" font="default"> Sullivan,K.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Nephrology, The Children's Hospital of Philadelphia, Philadelphia, PA; University of Pennsylvania, Perelman School of Medicine.</style></auth-address><titles><title><style face="normal" font="default">C3 nephritic factors: a changing landscape</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Pennsylvania</style></keyword><keyword><style face="normal" font="default"> Philadelphia</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170321IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28322851">PM:28322851</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170321-LevyED.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170321-LevyED.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170321, Levy ED</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41145</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Marlu,R.</style></author><author><style face="normal" font="default"> Deroux,A.</style></author><author><style face="normal" font="default"> Du-Thanh,A.</style></author><author><style face="normal" font="default"> Boccon-gibod,I.</style></author><author><style face="normal" font="default"> Launay,D.</style></author><author><style face="normal" font="default"> Bouillet,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hemostasis Unit, University Hospital, Grenoble, France; French National Reference Center for Angioedema (CREAK), France</style></auth-address><titles><title><style face="normal" font="default">Normal PAI-2 level in French FXII-HAE patients</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">angioedema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170320IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.12.982</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28318558">PM:28318558</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170320-MarluR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170320-MarluR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Marlu R</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.12.982</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41146</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Joseph,K.</style></author><author><style face="normal" font="default"> Constantino-Silva,R.N.</style></author><author><style face="normal" font="default"> Grumach,A.S.</style></author><author><style face="normal" font="default"> Feldweg,A.</style></author><author><style face="normal" font="default"> Wright,L.</style></author><author><style face="normal" font="default"> Frank,N.</style></author><author><style face="normal" font="default"> Vuzman,D.</style></author><author><style face="normal" font="default"> Sharma,R.</style></author><author><style face="normal" font="default"> Suffritti,C.</style></author><author><style face="normal" font="default"> Cicardi,M.</style></author><author><style face="normal" font="default"> Varga,L.</style></author><author><style face="normal" font="default"> Farkas,H.</style></author><author><style face="normal" font="default"> Bork,K.</style></author><author><style face="normal" font="default"> Kaplan,A.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC.</style></auth-address><titles><title><style face="normal" font="default">Reply (Refers To: Normal PAI-2 level in French FXII-HAE patients)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Biochemistry</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hungary</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Molecular Biology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> South Carolina</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170320IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - United States -CO - Brazil -CO - Italy -CO - Hungary -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2016.12.983</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28318557">PM:28318557</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170320-JosephK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170320-JosephK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Joseph K</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2016.12.983</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41147</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kloepfer,K.M.</style></author><author><style face="normal" font="default"> Sarsani,V.K.</style></author><author><style face="normal" font="default"> Poroyko,V.</style></author><author><style face="normal" font="default"> Lee,W.M.</style></author><author><style face="normal" font="default"> Pappas,T.E.</style></author><author><style face="normal" font="default"> Kang,T.</style></author><author><style face="normal" font="default"> Grindle,K.A.</style></author><author><style face="normal" font="default"> Bochkov,Y.A.</style></author><author><style face="normal" font="default"> Janga,S.C.</style></author><author><style face="normal" font="default"> Lemanske,R.F.,Jr.</style></author><author><style face="normal" font="default"> Gern,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Indiana University School of Medicine.</style></auth-address><titles><title><style face="normal" font="default">Community Acquired Rhinovirus Infection Is Associated With Changes in the Airway Microbiome</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Rhinovirus</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral Load</style></keyword></keywords><dates><year Day="18" Month="3" Year="2017">2017/3/18</year></dates><abstract><style face="normal" font="default">In school-age children with asthma, RV infection changes the upper airway microbiome and these changes are associated with symptom severity and viral load</style></abstract><notes><style face="normal" font="default">DA - 20170322IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28327377">PM:28327377</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170322-KloepferKM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170322-KloepferKM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170322, Kloepfer KM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41148</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tucker,M.H.</style></author><author><style face="normal" font="default"> Lomas,C.M.</style></author><author><style face="normal" font="default"> Ramchandar,N.</style></author><author><style face="normal" font="default"> Waldram,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy and Immunology, Naval Branch Health Clinic, San Diego, Calif.</style></auth-address><titles><title><style face="normal" font="default">Amoxicillin challenge without penicillin skin testing in evaluation of penicillin allergy in a cohort of Marine recruits</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Amoxicillin</style></keyword><keyword><style face="normal" font="default"> cAMP</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="21" Month="3" Year="2017">2017/3/21</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170325IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.01.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28341170">PM:28341170</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170325-TuckerMH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170325-TuckerMH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170325, Ticker MH</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.01.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41149</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kolenda,C.</style></author><author><style face="normal" font="default"> Dubost,R.</style></author><author><style face="normal" font="default"> Hacard,F.</style></author><author><style face="normal" font="default"> Mullet,C.</style></author><author><style face="normal" font="default"> Le Quang,D.</style></author><author><style face="normal" font="default"> Garnier,L.</style></author><author><style face="normal" font="default"> Bienvenu,J.</style></author><author><style face="normal" font="default"> Piriou,V.</style></author><author><style face="normal" font="default"> Berard,F.</style></author><author><style face="normal" font="default"> Bienvenu,F.</style></author><author><style face="normal" font="default"> Viel,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratoire d'Immunologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Benite, France</style></auth-address><titles><title><style face="normal" font="default">Evaluation of basophil activation test in the management of immediate hypersensitivity reactions to gadolinium-based contrast agents: a five-year experience</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophil activation test</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword></keywords><dates><year Day="21" Month="3" Year="2017">2017/3/21</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170325IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.01.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28341169">PM:28341169</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170325-KolendaC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170325-KolendaC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170325, Kolenda C</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.01.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41150</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bravo Garcia-Morato,M.</style></author><author><style face="normal" font="default"> Nevado,J.</style></author><author><style face="normal" font="default"> Gonzalez-Granado,L.I.</style></author><author><style face="normal" font="default"> Sastre Urgelles,A.</style></author><author><style face="normal" font="default"> Rodriguez,Pena R.</style></author><author><style face="normal" font="default"> Ferreira Cerdan,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology, La Paz University Hospital, Madrid, Spain; Lymphocyte Pathophysiology Group, La Paz Institute of Biomedical Research, IdiPAZ, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default">Chronic granulomatous disease caused by maternal uniparental isodisomy of chromosome 16</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Biomedical Research</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic granulomatous disease</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="21" Month="3" Year="2017">2017/3/21</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170325IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.01.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28341171">PM:28341171</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170325-BravoGarciaMoratoM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170325-BravoGarciaMoratoM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170325, Bravo Garcia-Morato M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.01.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41151</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Butto,L.F.</style></author><author><style face="normal" font="default"> Haller,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Technische Universitat Munchen, Chair of Nutrition and Immunology, Freising, Germany</style></auth-address><titles><title><style face="normal" font="default">Functional relevance of microbiome signatures: The correlation era requires tools for consolidation</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="1098" start="1092">1092-1098</pages><volume><style face="normal" font="default">139</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease Susceptibility</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> expansion</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human health</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infancy</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> Reproducibility</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">Compelling research over the past decade identified a fundamental role of the intestinal microbiome on human health. Compositional and functional changes of this microbial ecosystem are correlated with a variety of human pathologies. Metagenomic resolution and bioinformatic tools considerably improved, allowing even strain-level analysis. However, the search for microbial risk patterns in human cohorts is often confounded by environmental factors (eg, medication) and host status (eg, disease relapse), questioning the prognostic and therapeutic value of the currently available information. In addition to a better stratification of human phenotypes, the implementation of standardized protocols for sampling and analysis is needed to improve the reproducibility and comparability of microbiome signatures at a meaningful taxonomic resolution. At the level of mechanistic understanding, the molecular integration of pleiotropic signals coming from this complex and dynamically changing ecosystem is one of the biggest challenges in this field. The first successful attempts to apply reverse genetics based on the available metagenomic information yielded identification of small molecules and metabolites with functional relevance for microbe-host interactions. Further expansion on the isolation of bacteria from the "unculturable biomass" will help characterize microbiome signatures in model systems, finally aiming at the development of clinically relevant synthetic consortia with safe and functionally well-defined strains. In conclusion and beyond reasonable enthusiasm, the mechanistic implementation and clinical relevance of microbiome alterations on disease susceptibility is still in its infancy, but the integration of all the above-mentioned strategies will help overcome the correlation era in microbiome research and lead to a rational evaluation of clinical strategies relevant for targeted microbial intervention</style></abstract><notes><style face="normal" font="default">DA - 20170409IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28390576">PM:28390576</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-1092-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-1092-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170409, Butto LF</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41152</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mauracher,A.A.</style></author><author><style face="normal" font="default"> Pagliarulo,F.</style></author><author><style face="normal" font="default"> Faes,L.</style></author><author><style face="normal" font="default"> Vavassori,S.</style></author><author><style face="normal" font="default"> Gungor,T.</style></author><author><style face="normal" font="default"> Bachmann,L.M.</style></author><author><style face="normal" font="default"> Pachlopnik,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunology, University Children's Hospital Zurich, Children's Research Center (CRC), Zurich, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Causes of low neonatal T-cell receptor excision circles: A systematic review</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cause</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cell receptor</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="27" Month="3" Year="2017">2017/3/27</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170331IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.02.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28359806">PM:28359806</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170331-MauracherAA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170331-MauracherAA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170331, Mauracher AA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.02.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41153</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Usmani,O.S.</style></author><author><style face="normal" font="default"> Kemppinen,A.</style></author><author><style face="normal" font="default"> Gardener,E.</style></author><author><style face="normal" font="default"> Thomas,V.</style></author><author><style face="normal" font="default"> Konduru,P.R.</style></author><author><style face="normal" font="default"> Callan,C.</style></author><author><style face="normal" font="default"> McLoughlin,A.</style></author><author><style face="normal" font="default"> Woodhead,V.</style></author><author><style face="normal" font="default"> Brady,A.</style></author><author><style face="normal" font="default"> Juniper,E.F.</style></author><author><style face="normal" font="default"> Barnes,P.J.</style></author><author><style face="normal" font="default"> Price,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Heart and Lung Institute, Imperial College London, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">A Randomized Pragmatic Trial of Changing to and Stepping Down Fluticasone/Formoterol in Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Step down</style></keyword><keyword><style face="normal" font="default"> Step-down</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="25" Month="3" Year="2017">2017/3/25</year></dates><abstract><style face="normal" font="default">BACKGROUND: Guidelines recommend reducing treatment in patients with well-controlled asthma after 3 months of stability. However, there is inadequate real-life data to guide physicians on therapy change in daily practice. OBJECTIVE: To assess asthma control after change to and step-down of fluticasone propionate/formoterol fumarate dihydrate (FP/FOR) in real-life patients. METHODS: In a randomized controlled, pragmatic, open-label trial, 225 well-controlled patients with asthma were randomized (1:2) to maintain high-dose fluticasone propionate/salmeterol xinafoate (FP/SAL, 1000/100 mug) or switch to FP/FOR (1000/40 mug) daily for 12 weeks (phase 1). One hundred sixteen patients stable on FP/FOR at week 12 were subsequently randomized (1:1) to maintain this therapy, or stepped down to FP/FOR (500/20 mug) daily for 12 weeks (phase 2). The primary end point was the 7-question Asthma Control Questionnaire (ACQ7) score. RESULTS: In phase 1, FP/FOR (1000/40 mug) (n = 126) was noninferior to FP/SAL (1000/100 mug) (n = 73) for ACQ7 (difference in means, -0.12; 95% CI, -0.32 to 0.09). In phase 2, FP/FOR (500/20 mug) (n = 52) was noninferior to FP/FOR (1000/40 mug) (n = 52) for ACQ7 (difference in means, 0.01; 95% CI, -0.20 to 0.22). There was no significant difference in exacerbation rate between the groups in either phase. However, 1 to 2 exacerbations in 12 months before phase 1 were associated with the occurrence of an exacerbation after step-down (P = .007). CONCLUSIONS: In patients with well-controlled asthma, a change from FP/SAL to FP/FOR did not compromise asthma control. Step-down of FP/FOR was well tolerated; however, in contrast to current guidelines, our data suggest caution in stepping down patients uncontrolled in the last 12 months. Larger step-down studies are required to confirm these findings</style></abstract><notes><style face="normal" font="default">DA - 20170329IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.02.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28351782">PM:28351782</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170329-UsmaniOS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170329-UsmaniOS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170329, Usmani OS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.02.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41154</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Macy,E.</style></author><author><style face="normal" font="default"> Shu,Y.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Southern California Permanente Medical Group, Department of Allergy, San Diego Medical Center, San Diego, Calif.</style></auth-address><titles><title><style face="normal" font="default">The Effect of Penicillin Allergy Testing on Future Health Care Utilization: A Matched Cohort Study</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> cephalosporin</style></keyword><keyword><style face="normal" font="default"> Cephalosporins</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Clindamycin</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health care utilization</style></keyword><keyword><style face="normal" font="default"> macrolide</style></keyword><keyword><style face="normal" font="default"> Macrolides</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> Penicillins</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Stewardship</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="30" Month="3" Year="2017">2017/3/30</year></dates><abstract><style face="normal" font="default">BACKGROUND: The effect that penicillin allergy testing has on future health care utilization is uncertain. OBJECTIVE: Determine whether penicillin allergy testing affects future overall health care utilization as measured by outpatient department (OPD) visits, emergency department (ED) visits, and hospital days. METHODS: Potential cases and control subjects were penicillin allergic Kaiser Permanente Southern California members who had at least 2 visits between 2010 and 2012 and at least 1 year of continuous health plan coverage before their index visit. RESULTS: It was possible to match 308 (73.2%) of the potential cases to 1251 unique controls, on the basis of age, sex, weighted Charlson comorbidity index, drug class allergies, OPD visits, ED visits, and hospital days during the years before their index visit. Cases and controls were then followed for an average of 3.6 and 4.0 years, respectively. Based on results analyzed using a generalized linear mixed model, cases were estimated to have 0.09 fewer OPD visits (P &lt; .001), 0.13 fewer ED visits (P = .29), and 0.55 fewer hospital days (P &lt; .001) per health plan coverage year during follow-up compared with controls. Cases were exposed to more penicillins and first- and second-generation cephalosporins and less clindamycin and macrolides. CONCLUSIONS: Penicillin allergy testing, primarily done in the setting of an outpatient Allergy consultation, was associated with significantly less health care utilization during 3.6+ years of follow-up and greater use of narrow-spectrum antibiotics. Penicillin allergy testing has a favorable cost-benefit ratio for the incremental cost of testing versus future health care utilization and improves antibiotic stewardship</style></abstract><notes><style face="normal" font="default">DA - 20170403IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.02.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28366717">PM:28366717</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170403-MacyE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170403-MacyE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170403, Macy E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.02.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41155</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Macy,E.</style></author><author><style face="normal" font="default"> Romano,A.</style></author><author><style face="normal" font="default"> Khan,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy, Kaiser Permanente San Diego Medical Center, San Diego, Calif.</style></auth-address><titles><title><style face="normal" font="default">Practical Management of Antibiotic Hypersensitivity in 2017</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotic allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> delayed-type hypersensitivity</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> Stewardship</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="29" Month="3" Year="2017">2017/3/29</year></dates><abstract><style face="normal" font="default">Antibiotics are the most common class of medications that individuals report allergy or intolerance to. Adverse reactions are reported at a predictable rate with all antibiotic use that vary by antibiotic. Antibiotic allergy incidence rates are sex dependent, higher in females than in males. Most of these events are not reproducible or immunologically mediated. Antibiotic allergy prevalence increases with increasing age and is more common in hospitalized populations and in populations that use more antibiotics. Determining potential mechanisms for the observed symptoms of the adverse reactions is the starting point for effective management of antibiotic hypersensitivity. Skin testing and direct challenges are the primary tools used to determine acute tolerance in 2017. Commercially available in vitro testing is not currently clinically useful in determining antibiotic hypersensitivity, with rare exceptions. Desensitization can be used when acute-onset immunologically mediated hypersensitivity is confirmed to safely administer a needed antibiotic. Desensitization is not possible when clinically significant T-cell-mediated delayed-type hypersensitivity is present. Effective management of antibiotic allergy is an important part of a comprehensive antibiotic stewardship program</style></abstract><notes><style face="normal" font="default">DA - 20170402IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.02.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28365277">PM:28365277</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170402-MacyE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170402-MacyE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170402, Macy E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.02.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41156</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">White,S.R.</style></author><author><style face="normal" font="default"> Nicodemus-Johnson,J.</style></author><author><style face="normal" font="default"> Laxman,B.</style></author><author><style face="normal" font="default"> Denner,D.R.</style></author><author><style face="normal" font="default"> Naureckas,E.T.</style></author><author><style face="normal" font="default"> Hogarth,D.K.</style></author><author><style face="normal" font="default"> Stern,R.</style></author><author><style face="normal" font="default"> Minc,A.</style></author><author><style face="normal" font="default"> Solway,J.</style></author><author><style face="normal" font="default"> Sperling,A.</style></author><author><style face="normal" font="default"> Ober,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departments of Medicine, University of Chicago, Chicago, IL, 60637.</style></auth-address><titles><title><style face="normal" font="default">Elevated levels of Soluble Human Leukocyte Antigen-G (sHLA-G) in the Airways are a Marker for a Low-inflammatory Endotype of Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="28" Month="3" Year="2017">2017/3/28</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170401IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28363527">PM:28363527</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170401-WhiteSR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170401-WhiteSR.pdf</url></text-urls><image-urls><url ppv-ref="no">.xlsx in cartella</url></image-urls></urls><custom2><style face="normal" font="default">20170401, White SR</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.031</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41157</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guiddir,T.</style></author><author><style face="normal" font="default"> Saint-Pierre,P.</style></author><author><style face="normal" font="default"> Purenne-Denis,E.</style></author><author><style face="normal" font="default"> Lambert,N.</style></author><author><style face="normal" font="default"> Laoudi,Y.</style></author><author><style face="normal" font="default"> Couderc,R.</style></author><author><style face="normal" font="default"> Gouvis-Echraghi,R.</style></author><author><style face="normal" font="default"> Amat,F.</style></author><author><style face="normal" font="default"> Just,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergology Department, Armand Trousseau Children Hospital, Assistance Publique-Hopitaux de Paris (AP-HP), Paris, France</style></auth-address><titles><title><style face="normal" font="default">Neutrophilic Steroid-Refractory Recurrent Wheeze and Eosinophilic Steroid-Refractory Asthma in Children</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> BAL</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cluster Analysis</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="default"> Gastroesophageal reflux disease</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Pneumonia</style></keyword><keyword><style face="normal" font="default"> preschool children</style></keyword><keyword><style face="normal" font="default"> recurrent wheeze</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword></keywords><dates><year Day="28" Month="3" Year="2017">2017/3/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: Little is known about inflammatory pathways of severe recurrent wheeze in preschool children and severe asthma in children. OBJECTIVES: The aim of the Severe Asthma Molecular Phenotype cohort was to characterize phenotypes of severe recurrent wheeze and severe asthma during childhood in terms of triggers (allergic or not), involved cells (eosinophil or neutrophil), and corticoid responsiveness. METHODS: Children with moderate-to-severe asthma and preschool children with moderate-to-severe recurrent wheeze were enrolled prospectively. They underwent standardized clinical and blood workup, and bronchoalveolar lavage (BAL) evaluation. Cluster analysis was applied to 350 children with 34 variables. RESULTS: Three clusters were identified: cluster 1, Neutrophilic steroid-refractory recurrent wheeze phenotype, with 138 children uncontrolled despite high-dose inhaled corticosteroids (ICS) (92%, P &lt; .001), with more history of pneumonia (31%, P &lt; .001), more gastroesophageal reflux disease (37%, P &lt; .001), and the highest blood neutrophil count (mean 4.524 cells/mm3, P = .05); cluster 2, Severe recurrent wheeze with sensitization to a single aeroallergen (12%, P = .002), with 104 children controlled with high-dose ICS (63%, P &lt; .001); cluster 3, Eosinophilic steroid-refractory asthma phenotype, with 108 children uncontrolled despite high-dose ICS (76%, P &lt; .001) with more allergic rhinitis, atopic dermatitis, and food allergies (82%, 40%, 31%, P &lt; .001, respectively). They also had a higher blood eosinophil count and a higher percentage of BAL eosinophil (506/mm3, 2.6%, P &lt; .001 respectively). CONCLUSIONS: Inflammation pathway of asthma and recurrent wheeze are related to eosinophil cells in older children and neutrophil cells in younger children. These results could improve personalized treatments</style></abstract><notes><style face="normal" font="default">DA - 20170401IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.02.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28363401">PM:28363401</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170401-GuiddirT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170401-GuiddirT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170401, Guiddir T</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.02.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41158</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Murray,C.S.</style></author><author><style face="normal" font="default"> Thomas,M.</style></author><author><style face="normal" font="default"> Richardson,K.</style></author><author><style face="normal" font="default"> Price,D.B.</style></author><author><style face="normal" font="default"> Turner,S.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Infection, Immunity and Respiratory Medicine, Manchester Academic Health Science Centre, The University of Manchester</style></auth-address><titles><title><style face="normal" font="default">Comparative Effectiveness of Step-up Therapies in Children with Asthma Prescribed Inhaled Corticosteroids: A Historical Cohort Study</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Comparative effectiveness</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="default"> LTRA</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Step-up therapy</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="25" Month="3" Year="2017">2017/3/25</year></dates><abstract><style face="normal" font="default">BACKGROUND: In children with uncontrolled asthma prescribed low-dose inhaled corticosteroids (ICSs), various step-up options are available: fixed-dose combination ICS/long-acting beta2-agonist (FDC), increasing ICS dose, or adding leukotriene receptor antagonist (LTRA). However, evidence of their relative effectiveness is limited. OBJECTIVE: To compare the effectiveness of step-up treatment to FDC in children with asthma versus increased ICS dose, or LTRA. METHODS: This matched cohort study used UK primary-care databases to study children prescribed their first step-up treatment to FDC, increased ICS dose, or LTRA. A year of baseline data was used for matching and identifying confounders. Outcomes over the following year were examined. The primary outcome was severe exacerbation rate; secondary outcomes included overall asthma control, derived from databases (no asthma-related admissions/hospital attendances/oral corticosteroids or antibiotics prescribed with a respiratory review, and average prescribed salbutamol &lt;/=200 mug/day). RESULTS: There were 971 matched pairs in the FDC and increased ICS dose cohorts (59% males; mean age, 9.4 years) and 785 in the FDC and LTRA cohorts (60% males; mean age, 9.0 years). Exacerbation rates in the outcome year were similar between FDC and increased ICS (adjusted incidence rate ratio [95% CI], 1.09 [0.75-1.59]) and FDC and LTRA (incidence rate ratio, 1.36 [0.93-2.01]). Increased ICS and LTRA significantly reduced the odds of achieving overall asthma control, compared with FDC (odds ratios [95% CI], 0.52 [0.42-0.64] and 0.53 [0.42-0.66], respectively)-this was driven by reduced short-acting beta-agonist use. CONCLUSIONS: FDC is as effective as increased ICS or LTRA in reducing severe exacerbation rate, but more effective in achieving asthma control</style></abstract><notes><style face="normal" font="default">DA - 20170329IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United Kingdom -CO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.12.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28351789">PM:28351789</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170329-MurrayCS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170329-MurrayCS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170329, Murray CS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.12.028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41159</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hurst,J.R.</style></author><author><style face="normal" font="default"> Verma,N.</style></author><author><style face="normal" font="default"> Lowe,D.</style></author><author><style face="normal" font="default"> Baxendale,H.E.</style></author><author><style face="normal" font="default"> Jolles,S.</style></author><author><style face="normal" font="default"> Kelleher,P.</style></author><author><style face="normal" font="default"> Longhurst,H.J.</style></author><author><style face="normal" font="default"> Patel,S.Y.</style></author><author><style face="normal" font="default"> Renzoni,E.A.</style></author><author><style face="normal" font="default"> Sander,C.R.</style></author><author><style face="normal" font="default"> Avery,G.R.</style></author><author><style face="normal" font="default"> Babar,J.L.</style></author><author><style face="normal" font="default"> Buckland,M.S.</style></author><author><style face="normal" font="default"> Burns,S.</style></author><author><style face="normal" font="default"> Egner,W.</style></author><author><style face="normal" font="default"> Gompels,M.M.</style></author><author><style face="normal" font="default"> Gordins,P.</style></author><author><style face="normal" font="default"> Haddock,J.A.</style></author><author><style face="normal" font="default"> Hart,S.P.</style></author><author><style face="normal" font="default"> Hayman,G.R.</style></author><author><style face="normal" font="default"> Herriot,R.</style></author><author><style face="normal" font="default"> Hoyles,R.K.</style></author><author><style face="normal" font="default"> Huissoon,A.P.</style></author><author><style face="normal" font="default"> Jacob,J.</style></author><author><style face="normal" font="default"> Nicholson,A.G.</style></author><author><style face="normal" font="default"> Rassl,D.M.</style></author><author><style face="normal" font="default"> Sargur,R.B.</style></author><author><style face="normal" font="default"> Savic,S.</style></author><author><style face="normal" font="default"> Seneviratne,S.L.</style></author><author><style face="normal" font="default"> Sheaff,M.</style></author><author><style face="normal" font="default"> Vaitla,P.M.</style></author><author><style face="normal" font="default"> Walters,G.I.</style></author><author><style face="normal" font="default"> Whitehouse,J.L.</style></author><author><style face="normal" font="default"> Wright,P.A.</style></author><author><style face="normal" font="default"> Condliffe,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">UCL Respiratory, University College London, London, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default">British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Bronchoscopy</style></keyword><keyword><style face="normal" font="default"> Common Variable Immunodeficiency</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> Consensus</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Granuloma</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> interstitial lung disease</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> lung biopsy</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Optimization</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="25" Month="3" Year="2017">2017/3/25</year></dates><abstract><style face="normal" font="default">A proportion of people living with common variable immunodeficiency disorders develop granulomatous-lymphocytic interstitial lung disease (GLILD). We aimed to develop a consensus statement on the definition, diagnosis, and management of GLILD. All UK specialist centers were contacted and relevant physicians were invited to take part in a 3-round online Delphi process. Responses were graded as Strongly Agree, Tend to Agree, Neither Agree nor Disagree, Tend to Disagree, and Strongly Disagree, scored +1, +0.5, 0, -0.5, and -1, respectively. Agreement was defined as greater than or equal to 80% consensus. Scores are reported as mean +/- SD. There was 100% agreement (score, 0.92 +/- 0.19) for the following definition: "GLILD is a distinct clinico-radio-pathological ILD occurring in patients with [common variable immunodeficiency disorders], associated with a lymphocytic infiltrate and/or granuloma in the lung, and in whom other conditions have been considered and where possible excluded." There was consensus that the workup of suspected GLILD requires chest computed tomography (CT) (0.98 +/- 0.01), lung function tests (eg, gas transfer, 0.94 +/- 0.17), bronchoscopy to exclude infection (0.63 +/- 0.50), and lung biopsy (0.58 +/- 0.40). There was no consensus on whether expectant management following optimization of immunoglobulin therapy was acceptable: 67% agreed, 25% disagreed, score 0.38 +/- 0.59; 90% agreed that when treatment was required, first-line treatment should be with corticosteroids alone (score, 0.55 +/- 0.51)</style></abstract><notes><style face="normal" font="default">DA - 20170329IS - 2213-2201 (Electronic)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.01.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28351785">PM:28351785</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170329-HurstJR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170329-HurstJR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170329, Hurst JR</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.01.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41160</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dibek,M.E.</style></author><author><style face="normal" font="default"> Guvenir,H.</style></author><author><style face="normal" font="default"> Bahceci,S.</style></author><author><style face="normal" font="default"> Haktanir,A.M.</style></author><author><style face="normal" font="default"> Can,D.</style></author><author><style face="normal" font="default"> Usta Guc,B.E.</style></author><author><style face="normal" font="default"> Erkocoglu,M.</style></author><author><style face="normal" font="default"> Toyran,M.</style></author><author><style face="normal" font="default"> Nacaroglu,H.T.</style></author><author><style face="normal" font="default"> Civelek,E.</style></author><author><style face="normal" font="default"> Buyuktiryaki,B.</style></author><author><style face="normal" font="default"> Ginis,T.</style></author><author><style face="normal" font="default"> Orhan,F.</style></author><author><style face="normal" font="default"> Kocabas,C.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric Allergy and Immunology, Ankara Children's Hematology Oncology Training and Research Hospital, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="default">Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acute Generalized Exanthematous Pustulosis</style></keyword><keyword><style face="normal" font="default"> adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Antiepileptic</style></keyword><keyword><style face="normal" font="default"> Antiepileptic drugs</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Cutaneous adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> DRESS</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Early Diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Hematology</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Multicenter Studies</style></keyword><keyword><style face="normal" font="default"> Multicenter study</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Recovery</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default"> Stevens-Johnson Syndrome</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Toxic epidermal necrolysis</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="25" Month="3" Year="2017">2017/3/25</year></dates><abstract><style face="normal" font="default">BACKGROUND: The severe cutaneous adverse drug reactions (SCARs) are rare but could be life-threatening. These include drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN), and acute generalized exanthematous pustulosis. OBJECTIVE: The purpose of this study was the evaluation of the clinical characteristics of patients with the diagnosis of SCARs. METHODS: Patients who were diagnosed with SCARs between January 2011 and May 2016 by pediatric allergy clinics in the provinces of Ankara, Trabzon, Izmir, Adana, and Bolu were included in this multicenter study. Clinical and laboratory findings, the time between suspected drug intake and development of clinical findings, treatments they have received, and length of recovery time were recorded. RESULTS: Fifty-eight patients with SCARs were included in this study. The median age of the patients was 8.2 years (interquartile range, 5.25-13 years) and 50% (n = 29) were males. Diagnosis was Stevens-Johnson syndrome/TEN in 60.4% (n = 35), DRESS in 27.6% (n = 16), and acute generalized exanthematous pustulosis in 12% (n = 7) of the patients. In 93.1% of the patients, drugs were the cause of the reactions. Antibiotics ranked first among the drugs (51.7%) and antiepileptic drugs were the second (31%) most common. A patient who was diagnosed with TEN developed lagophthalmos and a patient who was diagnosed with DRESS developed secondary diabetes mellitus. Only 1 patient with the diagnosis of TEN died. CONCLUSIONS: SCARs in children are not common but potentially serious. Early diagnosis and appropriate treatment of SCARs will reduce the incidence of morbidity and mortality</style></abstract><notes><style face="normal" font="default">DA - 20170329IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.02.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28351788">PM:28351788</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170329-DibekME.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170329-DibekME.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170329, DIbek ME</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.02.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41161</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lieberman,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, The University of Tennessee Health Science Center, Memphis, Tenn.</style></auth-address><titles><title><style face="normal" font="default">Wells Syndrome with Bullous Lesions</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Tennessee</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="25" Month="3" Year="2017">2017/3/25</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170329IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.02.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28351790">PM:28351790</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170329-LiebermanCA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170329-LiebermanCA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170329, Lieberman JA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.02.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41162</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Land,M.H.</style></author><author><style face="normal" font="default"> Wang,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Department, Southern California Permanente Medical Group, San Diego, Calif.</style></auth-address><titles><title><style face="normal" font="default">Complementary and Alternative Medicine Use among Allergy Practices: Results of a Nationwide Survey of Allergists</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> office</style></keyword><keyword><style face="normal" font="default"> Office Visits</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="25" Month="3" Year="2017">2017/3/25</year></dates><abstract><style face="normal" font="default">The use of complementary and alternative practices in the field of Allergy/Immunology is growing. A recent survey of American Academy of Allergy, Asthma, and Immunology members examining patterns of complementary and alternative medicine (CAM) use and adverse effects from CAM revealed that a majority of practitioners (81% of respondents) had patients who are using CAM therapies over conventional treatments and many practitioners (60% of survey respondents) have encountered patients experiencing adverse reactions. During routine office visits, a majority of practitioners do not ask patients about CAM use, and when they do, most do not have a standard intake form to take a CAM history. There is a strong need to increase knowledge and improve measures to prevent adverse reactions to CAMs</style></abstract><notes><style face="normal" font="default">DA - 20170329IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.01.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28351787">PM:28351787</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170329-LandMH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170329-LandMH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170329, Land MH</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.01.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41163</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ramirez,F.</style></author><author><style face="normal" font="default"> Chren,M.M.</style></author><author><style face="normal" font="default"> Botto,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of California, San Francisco, San Francisco, California.</style></auth-address><titles><title><style face="normal" font="default">A review of the impact of patch testing on quality of life in allergic contact dermatitis</style></title><secondary-title><style face="normal" font="default">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am Acad Dermatol</style></full-title></periodical><pages end="1004" start="1000">1000-1004</pages><volume><style face="normal" font="default">76</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> San Francisco</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170416IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaad.2016.12.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28411766">PM:28411766</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am Acad Dermatol\2017-76-1000-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Am Acad Dermatol\2017-76-1000-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170416, Ramirez F</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaad.2016.12.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41164</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hamann,C.R.</style></author><author><style face="normal" font="default"> Hamann,D.</style></author><author><style face="normal" font="default"> Egeberg,A.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author><author><style face="normal" font="default"> Silverberg,J.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.</style></auth-address><titles><title><style face="normal" font="default">Association between atopic dermatitis and contact sensitization: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> Skin barrier function</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: It is unclear whether patients with atopic dermatitis (AD) have an altered prevalence or risk for contact sensitization. Increased exposure to chemicals in topical products together with impaired skin barrier function suggest a higher risk, whereas the immune profile suggests a lower risk. OBJECTIVE: To perform a systematic review and meta-analysis of the association between AD and contact sensitization. METHODS: The PubMed/Medline, Embase, and Cochrane databases were searched for articles that reported on contact sensitization in individuals with and without AD. RESULTS: The literature search yielded 10,083 citations; 417 were selected based on title and abstract screening and 74 met inclusion criteria. In a pooled analysis, no significant difference in contact sensitization between AD and controls was evident (random effects model odds ratio [OR] = 0.891; 95% confidence interval [CI] = 0.771-1.03). There was a positive correlation in studies that compared AD patients with individuals from the general population (OR 1.50, 95% CI 1.23-1.93) but an inverse association when comparing with referred populations (OR 0.753, 95% CI 0.63-0.90). LIMITATIONS: Included studies used different tools to diagnose AD and did not always provide information on current or past disease. Patch test allergens varied between studies. CONCLUSION: No overall relationship between AD and contact sensitization was found. We recommend that clinicians consider patch testing AD patients when allergic contact dermatitis is suspected</style></abstract><notes><style face="normal" font="default">DA - 20170410IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaad.2017.02.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28392290">PM:28392290</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am Acad Dermatol\20170410-HamannCR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Am Acad Dermatol\20170410-HamannCR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170410, Hamann CR</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaad.2017.02.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41165</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Konishi,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">A case of stent thrombosis caused by metal allergy complicated with protein's deficiency and heparin-induced thrombocytopenia</style></title><secondary-title><style face="normal" font="default">J Am College Cardiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am College Cardiol</style></full-title></periodical><pages end="" start="2431">2431-</pages><volume><style face="normal" font="default">69</style></volume><number><style face="normal" font="default">11, Supplement</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metal allergies</style></keyword><keyword><style face="normal" font="default"> Metal allergy</style></keyword><keyword><style face="normal" font="default"> Thrombocytopenia</style></keyword><keyword><style face="normal" font="default"> Thrombosis</style></keyword></keywords><dates><year Day="21" Month="3" Year="2017">2017/3/21</year></dates><isbn><style face="normal" font="default">0735-1097</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/S0735-1097(17)35820-5</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/S0735-1097(17)35820-5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am College Cardiol\2017-69S11-2431.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Am College Cardiol\2017-69S11-2431.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170429, Konishi T</style></custom2><misc3><style face="normal" font="default">10.1016/S0735-1097(17)35820-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41166</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Savage,A.</style></author><author><style face="normal" font="default"> Nadler,M.K.</style></author><author><style face="normal" font="default"> Ortega,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesiology, Boston Medical Center, Boston University School of Medicine, Boston, USA</style></auth-address><titles><title><style face="normal" font="default">External ear findings during anaphylaxis</style></title><secondary-title><style face="normal" font="default">J Anesth</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Anesth</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Anesthesiology</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="28" Month="3" Year="2017">2017/3/28</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170329IS - 1438-8359 (Electronic)IS - 0913-8668 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s00540-017-2342-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28352963">PM:28352963</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Anesth\20170329-SavageA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Anesth\20170329-SavageA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170329, Savage A</style></custom2><misc3><style face="normal" font="default">10.1007/s00540-017-2342-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41167</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Foudi,N.</style></author><author><style face="normal" font="default"> Badi,A.</style></author><author><style face="normal" font="default"> Amrane,M.</style></author><author><style face="normal" font="default"> Hodroj,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Laboratory of Cardiovascular Genetic and Nutritional Diseases , University Setif 1 , Algeria</style></auth-address><titles><title><style face="normal" font="default">Asthma causes inflammation of human pulmonary arteries and decreases vasodilatation induced by prostaglandin I2 analogs</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acetylcholine</style></keyword><keyword><style face="normal" font="default"> acute asthma</style></keyword><keyword><style face="normal" font="default"> Adenosine</style></keyword><keyword><style face="normal" font="default"> Adenosine Monophosphate</style></keyword><keyword><style face="normal" font="default"> Algeria</style></keyword><keyword><style face="normal" font="default"> Angiotensin II</style></keyword><keyword><style face="normal" font="default"> Arteries</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> cAMP</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cell Adhesion</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Cyclooxygenase 2</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Forskolin</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Intercellular Adhesion Molecule-1</style></keyword><keyword><style face="normal" font="default"> KIT</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Nitroprusside</style></keyword><keyword><style face="normal" font="default"> Norepinephrine</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prostaglandin</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Artery</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Vascular Cell Adhesion Molecule-1</style></keyword><keyword><style face="normal" font="default"> Vasodilation</style></keyword><keyword><style face="normal" font="default"> Vasodilator Agents</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Western blot</style></keyword></keywords><dates><year Day="21" Month="2" Year="2017">2017/2/21</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Asthma is a chronic inflammatory disease associated with increased cardiovascular events. This study assesses the presence of inflammation and the vascular reactivity of pulmonary arteries in patients with acute asthma. METHODS: Rings of human pulmonary arteries obtained from non-asthmatic and asthmatic patients were set up in organ bath for vascular tone monitoring. Reactivity was induced by vasoconstrictor and vasodilator agents. Protein expression of inflammatory markers was detected by western blot. Prostanoid releases and cyclic adenosine monophosphate (cAMP) levels were quantified using specific enzymatic kits. RESULTS: Protein expression of cluster of differentiation 68, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and cyclooxygenase-2 was significantly increased in arteries obtained from asthmatic patients. These effects were accompanied by an alteration of vasodilatation induced by iloprost and treprostinil, a decrease in cAMP levels and an increase in prostaglandin (PG) E2 and PGI2 synthesis. The use of forskolin (50 micromol/L) has restored the vasodilatation and cAMP release. No difference was observed between the two groups in reactivity induced by norepinephrine, angiotensin II, PGE2, KCl, sodium nitroprusside, and acetylcholine. CONCLUSION: Acute asthma causes inflammation of pulmonary arteries and decreases vasodilation induced by PGI2 analogs through the impairment of cAMP pathway</style></abstract><notes><style face="normal" font="default">DA - 20170317IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Algeria -CO - France -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1292282</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28306357">PM:28306357</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170317-FoudiN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170317-FoudiN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170317, Foudi N</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1292282</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41168</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hallit,S.</style></author><author><style face="normal" font="default"> Bou,Assy T.</style></author><author><style face="normal" font="default"> Hallit,R.</style></author><author><style face="normal" font="default"> Salameh,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Lebanese University, School of Pharmacy , Hadath , Lebanon</style></auth-address><titles><title><style face="normal" font="default">Allergic Diseases, Smoking and Environmental Exposure Among University Students in Lebanon</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Cigarette</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electricity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Habits</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> smokers</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Students</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Transportation</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="15" Month="3" Year="2017">2017/3/15</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Smoking habits among university students in Lebanon are not clearly identified, and studies correlating these habits to asthma and allergic diseases are lacking. The primary objective of this study is to assess the asthma and allergic diseases' predictors, particularly cigarette and/or waterpipe smoking and other environmental exposures, among university students. A second objective is to evaluate the potential role of these predictors as correlates of health-related self-assessment. METHODS: A cross-sectional study, using a proportionate cluster sample of 3000 Lebanese students in both public and private universities, was conducted between January 2015 and December 2015. RESULTS: The number of smokers at home, living close to an electricity generator and exposure to sand and dust significantly increased the odds of having asthma or allergic diseases by two and three times respectively (p = 0.015; OR = 1.183; CI 1.033-1.356; p = 0.01; OR = 2.062; CI 1.193-3.566; p = 0.001; OR = 3.558; CI 1.684-7.517 respectively). Having tried cigarette smoking and having an air conditioner inside the means of transportation would decrease the odds of having asthma or allergic diseases by around 68% and 56.1% respectively (p = 0.009; ORa = 0.320; CI 0.136-0.753; p = 0.01; ORa = 0.439; CI 0.234-0.822 respectively). CONCLUSION: Although students with asthma or allergic diseases tended to avoid all identifiable atopic risk factors, lesser known environmental factors such as living close to an electricity generator, exposure to sand and dust, and exposure to car exhaust fumes were associated with a higher risk of asthma and a decrease in health related self-assessment. This study also showed that students with asthma and allergic diseases smoked cigarettes and waterpipe at similar percentages, but cigarette smokers had a lower health related self-assessment</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Lebanon -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1306075</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28296532">PM:28296532</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170315-HallitS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170315-HallitS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Hallit S</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1306075</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41169</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bosnic-Anticevich,S.</style></author><author><style face="normal" font="default"> Callan,C.</style></author><author><style face="normal" font="default"> Chrystyn,H.</style></author><author><style face="normal" font="default"> Lavorini,F.</style></author><author><style face="normal" font="default"> Nikolaou,V.</style></author><author><style face="normal" font="default"> Kritikos,V.</style></author><author><style face="normal" font="default"> Dekhuijzen,P.N.</style></author><author><style face="normal" font="default"> Roche,N.</style></author><author><style face="normal" font="default"> Bjermer,L.</style></author><author><style face="normal" font="default"> Rand,C.</style></author><author><style face="normal" font="default"> Zwar,N.</style></author><author><style face="normal" font="default"> Price,D.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Woolcock Institute of Medical Research, University of Sydney , NSW , Australia</style></auth-address><titles><title><style face="normal" font="default">Inhaler technique mastery and maintenance in healthcare professionals trained on different devices</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Australia</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cross-Over Studies</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Dry Powder Inhalers</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="23" Month="3" Year="2017">2017/3/23</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Healthcare professionals (HCPs) are required to assess and train patients in the correct use of inhalers but are often unable to demonstrate correct technique themselves. We sought to assess the level of training required for HCPs to master and maintain device mastery when using two different dry powder inhalers (DPIs). METHODS: We conducted a randomised, un-blinded, cross-over study in undergraduate HCPs who undertook a six-step training procedure (intuitive use, patient information leaflet, instructional video, individual tuition from expert, then two repeats of individual tuition) for the use of Turbuhaler(R) (an established device) and Spiromax(R) (a newer device, reportedly easier to use). Device mastery (absence of errors) was evaluated by expert assessors at each training step. Maintenance of mastery was assessed 4 +/- 1 week (visit 2) and 8 +/- 2 weeks (visit 3) after initial training (visit 1). RESULTS: Of 516 eligible participants, 113 (22%) demonstrated device mastery prior to training on Spiromax(R) compared with 20 (4%) on Turbuhaler(R) (p&lt;0.001). The median number of training steps required to achieve mastery was 2 (interquartile range [IQR] 2-4) for Spiromax(R) and 3 (IQR 2-4) for Turbuhaler(R) (p&lt;0.001). A higher number of participants maintained mastery with Spiromax(R) compared with Turbuhaler(R), at visits 2 and 3 (64% vs 41% and 79% vs 65%, respectively; p&lt;0.001). CONCLUSIONS: There are significant differences in the nature and extent of training required to achieve and maintain mastery for Spiromax(R) and Turbuhaler(R) devices. The implications on clinical practice, device education delivery and patient outcomes require further evaluation</style></abstract><notes><style face="normal" font="default">DA - 20170323IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Australia -Co - Singapore -CO - United Kingdom -CO - Italy -CO - Netherlands -CO - France -CO - Sweden -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1310227</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28332886">PM:28332886</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170323-BosnicAnticevichS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170323-BosnicAnticevichS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170323, Bosnic-Anticevich S</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1310227</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41170</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,N.</style></author><author><style face="normal" font="default"> Huang,X.</style></author><author><style face="normal" font="default"> Chen,W.</style></author><author><style face="normal" font="default"> Zhang,X.</style></author><author><style face="normal" font="default"> Zhang,Y.</style></author><author><style face="normal" font="default"> Chen,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Traditional Chinese Medicine , Xuanwu Hospital of Capital Medical University , Beijing , China</style></auth-address><titles><title><style face="normal" font="default">Psychometric properties of a Chinese asthma quality of life questionnaire</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Beijing</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Factor analysis</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="21" Month="2" Year="2017">2017/2/21</year></dates><abstract><style face="normal" font="default">PURPOSE: To assess the acceptability, reliability, validity, and responsiveness of the Chinese Asthma Quality of Life Questionnaire (C-AQLQ) in a sample of Chinese asthma patients. METHODS: The C-AQLQ and Short Form 36 Health Survey (SF-36) scales were administered to patients at baseline and 3 months later. Asthma severity condition and lung function were evaluated. Necessary data were gathered to assess the psychometric properties such as the feasibility, internal consistency, test-retest reliability, structural validity, discriminant validity, convergent validity, and responsiveness of the C-AQLQ. RESULTS: One hundred and thirty-seven patients completed the investigation. The Cronbach's alpha coefficient for the total scale was 0.96. Factor analysis yielded five factors that generally corresponded to the five proposed subscales. Patients with mild asthma reported higher scores than patients with moderate/severe asthma on all subscales other than environmental stimuli. Lung function measurement and the asthma severity score correlated significantly with domains of the C-AQOL but with fewer domains of the SF-36. The questionnaire detected within-subject changes in patients' asthma status during follow-up. CONCLUSIONS: Results indicated preliminary support that the C-AQLQ is a reliable, valid, discriminating, and responsive measure of quality of life in Chinese asthma patients. It is more sensitive than the generic SF-36 in detecting differences in asthma severity</style></abstract><notes><style face="normal" font="default">DA - 20170321IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1291674</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28323488">PM:28323488</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170321-WangN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170321-WangN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170321, Wang N</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1291674</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41171</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zahran,H.S.</style></author><author><style face="normal" font="default"> Bailey,C.M.</style></author><author><style face="normal" font="default"> Qin,X.</style></author><author><style face="normal" font="default"> Johnson,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Division of Environmental Hazards and Health Effects, National Center for Environmental Health , Centers for Disease Control and Prevention , Atlanta , GA , USA</style></auth-address><titles><title><style face="normal" font="default">Long-term control medication use and asthma control status among children and adults with asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Adult asthma</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Contributing factors</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> health care use</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="10" Month="3" Year="2017">2017/3/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Uncontrolled asthma decreases quality of life and increases health care use. Most people with asthma need daily use of long-term control (LTC) medications for asthma symptoms and to prevent asthma attacks. Ongoing assessment of a person's level of asthma control and medication use is important in determining the effectiveness of current treatment to decrease the frequency and intensity of symptoms and functional limitations. OBJECTIVE: To assess the use of LTC medication among children and adults with current asthma and identify contributing factors for LTC medication use. METHODS: We used the 2006-2010 Behavioral Risk Factor Surveillance System (BRFSS) child and adult Asthma Call-back Survey (ACBS) data to assess the level of asthma control and LTC medication use. Asthma control was classified as well controlled and uncontrolled using guideline-based measures. We used multivariable logistic regression models to identify contributing factors for LTC medication use and having uncontrolled asthma. RESULTS: Among persons with current asthma, 46.0% of children and 41.5% of adults were taking LTC medications and 38.4% of children and 50.0% of adults had uncontrolled asthma. Among children who had uncontrolled asthma (38.4%), 24.1% were taking LTC medications and 14.3% were not taking LTC medications. Among adults who had uncontrolled asthma (50.0%), 26.7% were taking LTC medications and 23.3% were not taking LTC medications. CONCLUSIONS: Using BRFSS ACBS data to assess the level of asthma control and LTC medication use can identify subpopulations of persons with asthma who receive suboptimal treatment, for which better asthma-related medical treatment and management are needed</style></abstract><notes><style face="normal" font="default">DA - 20170310IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1290105</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28282217">PM:28282217</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170310-ZahranHS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170310-ZahranHS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170310, Zahran HS</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1290105</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41172</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wojsyk-Banaszak,I.</style></author><author><style face="normal" font="default"> Mikos,M.</style></author><author><style face="normal" font="default"> Szczepankiewicz,A.</style></author><author><style face="normal" font="default"> Wielebska,A.</style></author><author><style face="normal" font="default"> Sobkowiak,P.</style></author><author><style face="normal" font="default"> Kaminska,A.</style></author><author><style face="normal" font="default"> Breborowicz,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pneumonology, Pediatric Allergy and Clinical Immunology , Poznan University of Medical Sciences , Poznan , Poland</style></auth-address><titles><title><style face="normal" font="default">Evaluation of exhaled breath temperature (EBT) as a marker and predictor of asthma exacerbation in children and adolescents</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Exhaled Breath</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> glucocorticosteroids</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> ROC</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Temperature</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="10" Month="3" Year="2017">2017/3/10</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Noninvasive and easy-to-use tools to monitor airway inflammation in asthma are needed to maintain disease control, particularly in pediatric population. The aim of the study was to evaluate exhaled breath temperature (EBT) in pediatric respiratory clinic setting. METHODS: We evaluated 37 children and adolescents with asthma (5-17 years; median: 11 years). The patients were followed up in stable condition and during exacerbations (paired observations in n = 19 subjects). We evaluated medication use, EBT, fractional exhaled nitric oxide (FeNO), spirometry and atopic status of patients. RESULTS: EBT was significantly higher in children with asthma exacerbation {entire group: median [interquartile range (IQR)]: 32.3 [1.1] degrees C vs. 33.8 [1.7] degrees C; p &lt; 0.001 and mean +/- SD: 33.1 +/- 1.0 degrees C vs. 33.6 +/- 1.1 degrees C; p = 0.038 for paired observations}. Significant correlation was observed between EBT and FeNO in the entire group (r = 0.22; p = 0.03). No difference was observed in EBT median values in atopic and non-atopic subjects in the entire group (median [IQR]: 32.6 [1.6] vs. 32.7 [2.0]; p = 0.88) and in subgroups. There was no difference in EBT values in patients receiving systemic or inhaled glucocorticosteroids (p = 0.45 and 0.83). There was no significant correlation between EBT and body or room temperature. The only significant predictor of exacerbation in logistic regression model was EBT {aOR = 2.4; 95% [confidence interval (CI)]: 1.4-4.1}. ROC analysis demonstrated applicability of EBT as a marker of asthma exacerbation in children (AUC = 0.748; p &lt; 0.001; cut-off = 33.3 degrees C; sensitivity: 64.3%; specificity: 82.1%). CONCLUSIONS: We suggest that EBT may serve as marker and predictor of asthma exacerbation in children. EBT follow-up may be useful in asthma monitoring in children and adolescents</style></abstract><notes><style face="normal" font="default">DA - 20170310IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1290104</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28282228">PM:28282228</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170310-WojsykBanaszakI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170310-WojsykBanaszakI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170310, Wojsyk-Banaszak I</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1290104</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41173</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Meteran,H.</style></author><author><style face="normal" font="default"> Meteran,H.</style></author><author><style face="normal" font="default"> Porsbjerg,C.</style></author><author><style face="normal" font="default"> Backer,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Respiratory Research Unit , Bispebjerg University Hospital , Copenhagen , Denmark</style></auth-address><titles><title><style face="normal" font="default">Novel monoclonal treatments in severe asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">anti-IgE</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> Biological treatment</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-2</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL-9</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="13" Month="3" Year="2017">2017/3/13</year></dates><abstract><style face="normal" font="default">AIM: To provide a general overview of the current biological treatments and discuss their potential anti-asthmatic effects. DATA SOURCES: We reviewed articles in PubMed found using the search words "Asthma/therapy AND antibodies, monoclonal/therapeutic use AND cytokines." STUDY SELECTIONS: Only articles published in English since 2000 were considered. The search identified 29 studies; 8 additional studies were found by hand search, generating 37 studies. RESULTS: Of the 37 studies investigating biological treatments of asthma, 5 were on the effects of anti-IgE (omalizumab); 12 on anti-IL-5; 8 on anti-IL-13; 5 on anti-IL-4R-alpha; 3 on anti-IL-9; one on TNF-alpha; one on anti-IL-2R-alpha; one on TSLP (Thymic Stromal Lymphopoietin); and one on OX40L. Sample sizes ranged from 3 to 943 participants. Studies of therapies targeting IgE, IL-2, IL4R-alpha, IL-5, and IL-13 showed some efficacy, whereas those targeting TSLP, IL-9, and TNF-alpha lacked convincing effectiveness. CONCLUSION: Research on the biological treatment of asthma shows promising results. While anti-IgE (omalizumab) has been used in the treatment of asthma for some years, anti-IL-5 has recently been approved for use. The efficacy of results of other large studies with a longer duration is needed to draw a firm conclusion. Such studies should not only focus on clinical outcomes, but also consider asthma-related quality of life. Knowledge on the asthma phenotypes and identification of biomarkers associated with these will be useful for physicians considering the right treatment for the asthma patient</style></abstract><notes><style face="normal" font="default">DA - 20170313IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">0.1080/02770903.2017.1296157</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28287273">PM:28287273</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170313-MeteranH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170313-MeteranH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170313, Meteran H</style></custom2><misc3><style face="normal" font="default">0.1080/02770903.2017.1296157</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41174</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Li,F.</style></author><author><style face="normal" font="default"> Zhu,Y.</style></author><author><style face="normal" font="default"> Xie,X.</style></author><author><style face="normal" font="default"> Ke,R.</style></author><author><style face="normal" font="default"> Li,S.</style></author><author><style face="normal" font="default"> Liu,L.</style></author><author><style face="normal" font="default"> Lu,J.</style></author><author><style face="normal" font="default"> Li,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Respiratory Medicine , the First Affiliated Hospital of Xi'an Jiaotong University , Xi'an , China</style></auth-address><titles><title><style face="normal" font="default">Interleukin-12B gene polymorphisms and bronchial asthma risk: A meta-analysis</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AC</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma risk</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic polymorphisms</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> IL-12B</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Promoter</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="13" Month="3" Year="2017">2017/3/13</year></dates><abstract><style face="normal" font="default">OBJECTIVE: This meta-analysis aims to investigate whether interleukin-12B (IL-12B) -1188A/C or the promoter polymorphisms may be a risk factor for asthma. DATA SOURCES: Web of Science, PubMed, China National Knowledge Infrastructure (CNKI) and Wanfang databases were searched (updated August 20, 2015). STUDY SELECTIONS: Articles evaluating the association between IL-12B genetic polymorphisms and asthma risk were selected. RESULTS: 13 eligible studies with a total of 5092 subjects were finally included in this meta-analysis. For IL-12B -1188A/C, analysis by ethnicity indicated that there was a markedly reduced risk for asthma in East Asian (CC + AC vs. AA: OR = 0.64, 95% CI = 0.50-0.81, P &lt; 0.001). For IL-12B promoter, analysis by ethnicity indicated there was a markedly increased risk in East Asian (MM vs. WM + WW: OR = 1.57, 95% CI = 1.18-2.10, P = 0.002). Analysis by allergic state revealed the similar results in atopic subgroup. CONCLUSIONS: IL-12B -1188 C allele may be a protective factor against asthma in East Asian. In addition, promoter MM genotype may be a risk factor for asthma in East Asian and allergic people</style></abstract><notes><style face="normal" font="default">DA - 20170313IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1277536</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28287286">PM:28287286</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170313-LiF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170313-LiF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170313, Li F</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1277536</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41175</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Harris,K.</style></author><author><style face="normal" font="default"> Mosler,G.</style></author><author><style face="normal" font="default"> Williams,S.A.</style></author><author><style face="normal" font="default"> Whitehouse,A.</style></author><author><style face="normal" font="default"> Raine,R.</style></author><author><style face="normal" font="default"> Grigg,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Centre for Genomics and Child Health , Blizard Institute, Barts and The London School of Medicine and Dentistry , London , UK</style></auth-address><titles><title><style face="normal" font="default">Asthma control in London secondary school children</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> ACT Score</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Dentistry</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Genomics</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schoolchildren</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Students</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="23" Month="3" Year="2017">2017/3/23</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The asthma control test (ACT) is a validated tool for assessing control in asthmatic children aged 12 years and older. Using the ACT, we sought to assess asthma control and knowledge in London secondary school children. METHODS: Secondary schools in London, UK, participated in this study. Children with doctor-diagnosed asthma were invited to complete an online questionnaire that included the ACT and questions about asthma. Suboptimal asthma control was defined as an ACT score of &lt;/= 19 out of a maximum score of 25. Data are summarised as median and interquartile range (IQR), and were analysed by either Mann-Whitney test, or chi-square test. A p value of &lt; 0.05 was considered significant. RESULTS: A total of 799 children completed the questionnaire; 689 (86.2%) were included for analysis. Suboptimal asthma control was reported by 49.6% of students. Over a third (42.4%) of students prescribed a short-acting beta2-agonist inhaler felt uncomfortable using it at school, and 29.2% (n = 173) reported not using this inhaler when wheezy. 56.4% (n = 220) of those with regular inhaled corticosteroids did not take them as prescribed, and 41.7% did not know what this inhaler was for. Suboptimal control was associated with a greater proportion of students reporting that they were 'somewhat', 'hardly' or 'not at all' comfortable using inhalers at school (52.7% vs 29.1%, p &lt; 0.01) and outside school (22.8% vs. 14.8%, p &lt; 0.01). CONCLUSIONS: Suboptimal asthma control and poor asthma knowledge are common in London schoolchildren</style></abstract><notes><style face="normal" font="default">DA - 20170323IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1299757</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28332884">PM:28332884</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170323-HarrisK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170323-HarrisK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170323, Harris K</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1299757</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41176</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ping,L.</style></author><author><style face="normal" font="default"> Yang,Z.</style></author><author><style face="normal" font="default"> Zhang,Q.</style></author><author><style face="normal" font="default"> Wang,W.</style></author><author><style face="normal" font="default"> Yang,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pulmonology , Affiliated Xiangyang Hospital of Hubei University of Medicine , Xiangyang 441000 , China</style></auth-address><titles><title><style face="normal" font="default">Increased IL-4- and IL-17-producing CD8+ cells are related to decreased CD39+CD4+Foxp3+ cells in allergic asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Airway Resistance</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="default"> CD8+ T cells</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Histology</style></keyword><keyword><style face="normal" font="default"> Hyperplasia</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> IL-17</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> OVA</style></keyword><keyword><style face="normal" font="default"> Ovalbumin</style></keyword><keyword><style face="normal" font="default"> Ovum</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> regulatory T cell</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> Tregs</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="27" Month="3" Year="2017">2017/3/27</year></dates><abstract><style face="normal" font="default">OBJECTIVE: In allergic asthma, regulatory T cell (Treg) number and function are decreased. Antigen primed CD8+ T cells play an indispensable role in the full development of airway inflammation and airway hyper-responsiveness (AHR) occurring in asthma. In this study, we investigated the relationship between subpopulations of CD8+ T cells and CD39+ Tregs. METHODS: Female C57BL/6 mice were used to develop the model of allergic asthma. Experimental mice were immunized with ovalbumin (OVA) by intra-peritoneal (i.p) injection and then challenged with OVA by intra-tracheal administration. Control mice were immunized with vehicle by i.p injection and challenged with OVA. Airway inflammation was determined by histology and AHR was measured by an invasive method. Levels of IFN-lambda, IL-4 and IL-17 in bronchoalveolar lavage fluid (BALF) were determined by enzyme-linked immunosorbent assay. The frequencies of CD8+IFN-gamma+ cells (Tc1), CD8+IL-4+ cells (Tc2), CD8+IL-17+cells (Tc17) and CD39+Tregs were measured by flow cytometry. The correlation between CD39+Tregs and Tc subsets was analyzed by Pearson's test. RESULTS: Experimental mice displayed phenotypes of allergic asthma, including inflammatory cell infiltration into the lungs, goblet-cell hyperplasia, increased airway resistance, and increased IL-4 and IL-17 in BALF. Compared to control mice, experimental mice displayed lower CD39+Tregs and Tc1 but higher Tc2 and Tc17. There was a negative correlation between CD39+Tregs and Tc2 or Tc17. CONCLUSION: In allergic asthma, increased Tc2 and Tc17 are possibly related to insufficient CD39+Tregs</style></abstract><notes><style face="normal" font="default">DA - 20170327IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1310225.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28346024">PM:28346024</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170327-PingL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170327-PingL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170327, Ping L</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1310225.</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41177</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Li,W.</style></author><author><style face="normal" font="default"> Liang,R.</style></author><author><style face="normal" font="default"> Huang,H.</style></author><author><style face="normal" font="default"> Wu,B.</style></author><author><style face="normal" font="default"> Zhong,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatrics , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , Guangdong 510120 , P.R. China</style></auth-address><titles><title><style face="normal" font="default">Effects of IFN-gammaon the cell growth and the expression of ADAM33 gene in human embryonic lung Mrc-5 fibroblasts in vitro</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway remodeling</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Dermatophagoides</style></keyword><keyword><style face="normal" font="default"> Dermatophagoides farinae</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Fibroblasts</style></keyword><keyword><style face="normal" font="default"> Fluorescence</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Interferon-gamma</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="27" Month="3" Year="2017">2017/3/27</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To investigate the effects of interferon-gamma (IFN-gamma) on the proliferation and viability of human embryonic lung Mrc-5 fibroblasts in vitro and the expression of the A Disintegrin and Metalloprotease 33 (ADAM33) gene and to explore the mechanism of airway remodeling. METHODS: Mrc-5 fibroblasts were sensitized with Dermatophagoides farinae 1 (Derf1) in vitro to mimic in vivo conditions observed in bronchial asthma. An inverted fluorescence microscope was used to observe changes in cell morphology before and after treatment. The viability of Mrc-5 cells was tested using the Cell Counting kit-8 (CCK8). Expression of the ADAM33 gene and protein in Mrc-5 cells was assessed using qPCR and Western blotting, respectively. RESULTS: Different concentrations of Derf1 increased cell growth and the expression of the ADAM33 gene in Mrc-5 cells, and these changes were most obvious in the 10 mug/ml group. In contrast, IFN-gamma decreased cell growth and the expression of the ADAM33 gene in both Mrc-5 cells and Derf1-induced Mrc-5 cells, and these changes were most obvious in the 10 ng/ml group. The negative effects of 10 ng/ml IFN-gamma were the most significant at 32 h. CONCLUSIONS: Derf1-induced Mrc-5 cells successfully imitated the in vivo conditions observed in patients with asthma. IFN-gamma inhibited the proliferation and viability of Mrc-5 cells, and Derf1-induced Mrc-5 cells were more sensitive to IFN-gamma treatment. IFN-gamma treatment significantly downregulated the expression of the ADAM33 gene in a concentration- and time-dependent manner. IFN-gamma may participate in airway remodeling in asthma by regulating the expression of the ADAM33 gene</style></abstract><notes><style face="normal" font="default">DA - 20170327IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1310226</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28346792">PM:28346792</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170327-LiW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170327-LiW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170327, Li W</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1310226</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41178</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Alas,R.</style></author><author><style face="normal" font="default"> Williams,M.T.</style></author><author><style face="normal" font="default"> Yamin,G.</style></author><author><style face="normal" font="default"> Rofoogaran,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Internal Medicine , Saint Mary/Harbor-UCLA Medical Centers , Long Beach , CA</style></auth-address><titles><title><style face="normal" font="default">Chronic cough and an atypical peripheral pattern on chest imaging: A case report secondary to suspected drug onset</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult-onset asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> BAL</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Chest Pain</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic cough</style></keyword><keyword><style face="normal" font="default"> Chronic eosinophilic pneumonia</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic asthma</style></keyword><keyword><style face="normal" font="default"> eosinophilic pneumonia</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> imaging</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> interstitial lung disease</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Pneumonia</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="12" Month="4" Year="2017">2017/4/12</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Chronic eosinophilic pneumonia (CEP) is an uncommon interstitial lung disease with nonspecific symptoms that is a diagnostic and treatment challenge. The exact pathology is unknown and putatively involves a complex inflammatory cascade associated with the abnormal accumulation of eosinophils. Our patient had a history of adult-onset asthma after initiating TNF-inhibitor therapy. CEP coexisting with asthma has been reported, but never linked to the use of a TNF-inhibitor-as we report here. CASE STUDY: A 36-year-old prisoner with a history of psoriasis presented with progressive worsening dyspnea, pleuritic chest pain, and cough. His symptoms started 2-months prior while taking adalimumab, a TNF-inhibitor, for the treatment of psoriasis. RESULTS: His initial workup revealed 26.9% eosinophils on CBC, elevated IgE levels on BAL, and bilateral lung opacities on imaging. The patient's symptoms and eosinophilia improved markedly after starting corticosteroids. Based on these findings, the patient was ultimately diagnosed with CEP. CONCLUSION: To our knowledge, this is the first case of asthma and CEP in a patient taking adalimumab (a TNF-inhibitor). Our patient likely had eosinophilic asthma phenotype, which works through the Th2 cell pathway. His psoriasis, which is primarily a Th1 cell pathway disease, likely masked his asthma most of his life. Once on adalimumab, the Th1 response was suppressed and the Th2 pathway was unmasked-revealing itself clinically as asthma. The events that led to the diagnosis of asthma were unknown. However, his symptoms began after starting adalimumab and may explain the chronic pulmonary changes and the possibility that this drug indirectly caused CEP</style></abstract><notes><style face="normal" font="default">DA - 20170413IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1313271</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28402696">PM:28402696</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170413-AlasR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170413-AlasR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170413, Alas R</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1313271</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41179</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jiang,X.G.</style></author><author><style face="normal" font="default"> Yang,X.D.</style></author><author><style face="normal" font="default"> Lv,Z.</style></author><author><style face="normal" font="default"> Zhuang,P.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Biochemistry and Molecular Biology , Xi'an Jiaotong University College of Medicine , Xi'an 710061 , P. R. China</style></auth-address><titles><title><style face="normal" font="default">Elevated serum levels of TNF-alpha, IL-8, and ECP can be involved in the development and progression of bronchial asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Biochemistry</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> cationic protein</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> ECP</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> Interleukin-8</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Molecular Biology</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Remission</style></keyword><keyword><style face="normal" font="default"> ROC</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="default">OBJECTIVE: This study aimed to explore the value of elevated serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-8 (IL-8) and eosinophil cationic protein (ECP) in the diagnosis of bronchial asthma (BA). METHODS: Totally 170 patients with BA (case group, 85 patients in acute attack and 85 patients in clinical remission) and 150 healthy individuals (control group). Enzyme-linked immunosorbent assay (ELISA) and receiver operating characteristic (ROC) curves were calculated for the contents and diagnostic values of serum TNF-alpha, IL-8, and ECP in BA. RESULTS: Compared with the control group, the TNF-alpha, IL-8, and ECP levels were higher in patients in acute attack and clinical remission (P &lt; 0.05). The serum level of TNF-alpha was positively correlated with IL-8 and ECP (P &lt; 0.05). ROC curves showed that the diagnostic threshold value of IL-8 was 13.53 ng/ml, its area under the curve (AUC) was 0.87, its specificity was 99.3%, and its sensitivity was 57.6%. The diagnostic threshold value of TNF-alphawas 1.29 ng/ml with AUC was 0.94, specificity was 89.3% and sensitivity was 83.5%. ECP showed 7.22 ng/ml diagnostic threshold value (AUC = 0.88, specificity = 74.0%, sensitivity = 86.5%). The FEV1/pre(%) and FEV1/FVC were negatively correlated and the Z5/pre(%) and resonance frequency (Fres) were positively correlated with the serum levels of TNF-alpha, IL-8, and ECP in patients in acute attack and in clinical remission (all P &lt; 0.05). CONCLUSION: Our findings reveal that elevated serum levels of TNF-alpha, IL-8 and ECP can be involved in the development and progression of BA</style></abstract><notes><style face="normal" font="default">DA - 20170412IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1318141</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28399677">PM:28399677</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170412-JiangXG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170412-JiangXG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170412, Jiang XG</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1318141</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41180</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Utidjian,L.H.</style></author><author><style face="normal" font="default"> Fiks,A.G.</style></author><author><style face="normal" font="default"> Localio,A.R.</style></author><author><style face="normal" font="default"> Song,L.</style></author><author><style face="normal" font="default"> Ramos,M.J.</style></author><author><style face="normal" font="default"> Keren,R.</style></author><author><style face="normal" font="default"> Bell,L.M.</style></author><author><style face="normal" font="default"> Grundmeier,R.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Biomedical and Health Informatics , Children's Hospital of Philadelphia , Philadelphia , PA , USA</style></auth-address><titles><title><style face="normal" font="default">Pediatric asthma hospitalizations among urban minority children and the continuity of primary care</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">African American</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Controller medications</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Records</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Influenza</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Philadelphia</style></keyword><keyword><style face="normal" font="default"> Poisson</style></keyword><keyword><style face="normal" font="default"> Primary Health Care</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective cohort study</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Vaccination</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="25" Month="2" Year="2017">2017/2/25</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To examine the effect of ambulatory health care processes on asthma hospitalizations. METHODS: A retrospective cohort study using electronic health records was completed. Patients aged 2-18 years receiving health care from 1 of 5 urban practices between Jan 1, 2004 and Dec 31, 2008 with asthma documented on their problem list were included. Independent variables were modifiable health care processes in the primary care setting: (1) use of asthma controller medications; (2) regular assessment of asthma symptoms; (3) use of spirometry; (4) provision of individualized asthma care plans; (5) timely influenza vaccination; (6) access to primary healthcare; and (7) use of pay for performance physician incentives. Occurrence of one or more asthma hospitalizations was the primary outcome of interest. We used a log linear model (Poisson regression) to model the association between the factors of interest and number of asthma hospitalizations. RESULTS: 5,712 children with asthma were available for analysis. 96% of the children were African American. The overall hospitalization rate was 64 per 1,000 children per year. None of the commonly used asthma-specific indicators of high quality care were associated with fewer asthma hospitalizations. Children with documented asthma who experienced a lack of primary health care (no more than one outpatient visit at their primary care location in the 2 years preceding hospitalization) were at higher risk of hospitalization compared to those children with a greater number of visits (incidence rate ratio 1.39; 95% CI 1.09-1.78). CONCLUSIONS: In children with asthma, more frequent primary care visits are associated with reduced asthma hospitalizations</style></abstract><notes><style face="normal" font="default">DA - 20170323IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1294695</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28332939">PM:28332939</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170323-UtidjianLH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170323-UtidjianLH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170323, Utidjian LH</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1294695</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41181</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tay,T.</style></author><author><style face="normal" font="default"> Choo,X.</style></author><author><style face="normal" font="default"> Ihsan,R.</style></author><author><style face="normal" font="default"> Toh,H.P.</style></author><author><style face="normal" font="default"> Wong,H.S.</style></author><author><style face="normal" font="default"> Tee,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Respiratory and Critical Care Medicine , Changi General Hospital , Singapore , Singapore</style></auth-address><titles><title><style face="normal" font="default">Characteristics of non-smoking adult asthma patients with chronic airflow limitation</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Adult asthma</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> airflow</style></keyword><keyword><style face="normal" font="default"> Airflow limitation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="23" Month="3" Year="2017">2017/3/23</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Chronic airflow limitation (CAL) can develop in a subgroup of patients with asthma. Characterising these patients is important because reduced lung function is a risk factor for adverse asthma outcomes. We hypothesised that heterogeneity in patients with CAL may be influenced by age at asthma onset. We first compared never-smoking asthma patients with and without CAL, and subsequently examined the differences between patients with late and early-onset asthma within the CAL cohort. METHODS: Patients seen in our hospital's respiratory clinic between 1 Jan 2015 and 31 December 2015 were recruited to the study. CAL was defined as post-bronchodilator forced expiratory volume in 1 second (FEV1)&lt;80% predicted, in the presence of post-bronchodilator ratio &lt;70%. Variables independently associated with CAL were determined using a multivariate logistic regression model. Comparisons between patients with late-onset asthma (age >/=18 years) and early-onset asthma were made within the CAL cohort. RESULTS: 247 patients were included in the study. Age was the only variable independently associated with CAL after regression analysis, with an increase in odds of 3.8% (95% CI 0.4-7.3%) for every 1 year increase in age, p = 0.027. 63.2% of patients with CAL had late-onset asthma. Compared to patients with early-onset asthma, those with late-onset asthma had higher fractional exhaled nitric oxide levels (43 +/- 32 ppb vs 20 +/- 8 pb, p = 0.008). CONCLUSIONS: An increase in age is associated with CAL in never-smoking asthma patients. In addition, age at asthma onset appears to influence airway inflammation in patients with CAL</style></abstract><notes><style face="normal" font="default">DA - 20170323IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1299756</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28332897">PM:28332897</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170323-TayT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170323-TayT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170323, Tay T</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1299756</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41182</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chu,L.M.</style></author><author><style face="normal" font="default"> Pahwa,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">a College of Medicine and Canadian Center for Health and Safety in Agriculture , University of Saskatchewan , Canada</style></auth-address><titles><title><style face="normal" font="default">Prevalence and associated factors for self-reported asthma in a Canadian population: The Canadian Community Health Survey, 2014</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Adult asthma</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Agriculture</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Income</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Life Style</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Saskatchewan</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> socioeconomic status</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="27" Month="3" Year="2017">2017/3/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma prevalence is increasing among adults, yet limited information regarding the association between adult asthma and environmental and personal exposures is available using large nationally representative population-based survey. OBJECTIVE: To determine the prevalence of asthma and associated factors for self-reported asthma in a Canadian population aged 12 years and older by using the Canadian Community Health Survey (CCHS) 2014 cross-sectional cohort. METHODS: We used data from the 2014 CCHS. Asthma as determined through self-reported health professional diagnosis. Information regarding covariates of importance, such as socio-economic status, life styles variables, was obtained. A weighted logistic regression analysis was performed with appropriate technique for clustering effects. RESULTS: Estimated self-reported asthma prevalence of 8.1% in the greater than 12 year old Canadian population was observed. We found that a substantial proportion of Canadians (aged 12 and older) reported having asthma and geographical differences and differences between specific provinces in asthma prevalence. Women had higher prevalence of asthma than men, but the relationship depended on age and body mass index. Interactions between household income and smoking status were observed to predict the probability of asthma. CONCLUSIONS: Additional studies are needed to determine which factors influence the asthma prevalence between sex, body mass index as well as smoking status and household income and its interactions with each other</style></abstract><notes><style face="normal" font="default">DA - 20170327IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1310228</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28346028">PM:28346028</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170327-ChuLM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170327-ChuLM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170327, Chu LM</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1310228</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41183</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Weinberg,J.L.</style></author><author><style face="normal" font="default"> Flattery,J.</style></author><author><style face="normal" font="default"> Harrison,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Public Health Institute , Contractors to the California Department of Public Health , Richmond , CA , USA</style></auth-address><titles><title><style face="normal" font="default">Fragrances and work-related asthma-California surveillance data, 1993-2012</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Fragrances</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> office</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Perfume</style></keyword><keyword><style face="normal" font="default"> Perfumes</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Ventilation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work-aggravated asthma</style></keyword><keyword><style face="normal" font="default"> Work-related asthma</style></keyword><keyword><style face="normal" font="default"> Workplace</style></keyword></keywords><dates><year Day="23" Month="3" Year="2017">2017/3/23</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Fragrance chemicals are used in a large array of products. Workers may be exposed to these chemicals in the workplace directly when used as air fresheners, or indirectly in personal care products used by coworkers or others. This study characterizes work-related asthma (WRA) cases associated with fragrance exposures in California workplaces from 1993 through 2012. METHODS: We used the California Work-Related Asthma Prevention Program's surveillance database to identify individuals with physician-diagnosed WRA associated with the use of air fresheners and scented personal care products (perfumes, colognes, etc.). Cases were classified using previously published, standardized surveillance methods. RESULTS: Perfume was the ninth most common exposure identified from 1993 through 2012. A total of 270 WRA cases associated with fragrance exposure were reported during this period, representing 3.8% of all confirmed cases. These 270 cases included 242 associated with perfume or cologne, 32 associated with air freshener, and 4 associated with both. Similar to non-fragrance cases, nearly a quarter of fragrance-associated cases were classified as new-onset asthma. Fragrance-associated cases were significantly more likely to be in office, health, and education jobs than non-fragrance-associated cases. When compared to non-fragrance cases, fragrance cases were significantly more likely to be female (94% vs 62%) and be classified as having work-aggravated asthma (38% vs 20%), yet had similar outcomes compared with cases associated with other exposures. CONCLUSIONS: Our surveillance data show that fragrance use in the workplace is associated with WRA. Prevention methods include employee education, enforced fragrance-free policies, well-designed ventilation systems, and good building maintenance</style></abstract><notes><style face="normal" font="default">DA - 20170323IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - UnitedSstates -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1299755</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28332885">PM:28332885</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170323-WeinbergJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170323-WeinbergJL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170323, Weinberg JL</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1299755</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41184</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ciprandi,G.</style></author><author><style face="normal" font="default"> Gallo,F.</style></author><author><style face="normal" font="default"> Ricciardolo,F.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Medicine , IR</style></auth-address><titles><title><style face="normal" font="default">Asthma control test in real life</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="115" start="114">114-115</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20160615IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1196372</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27304861">PM:27304861</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-114-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-114-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160616, Ciprandi G</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1196372</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41185</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bellin,M.H.</style></author><author><style face="normal" font="default"> Land,C.</style></author><author><style face="normal" font="default"> Newsome,A.</style></author><author><style face="normal" font="default"> Kub,J.</style></author><author><style face="normal" font="default"> Mudd,S.S.</style></author><author><style face="normal" font="default"> Bollinger,M.E.</style></author><author><style face="normal" font="default"> Butz,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a School of Social Work, University of Maryland , Baltimore , MD , US</style></auth-address><titles><title><style face="normal" font="default">Caregiver perception of asthma management of children in the context of poverty</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="172" start="162">162-172</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> African American</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma education</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Baltimore</style></keyword><keyword><style face="normal" font="default"> Barriers</style></keyword><keyword><style face="normal" font="default"> Caregivers</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Communication</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Focus Groups</style></keyword><keyword><style face="normal" font="default"> Income</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> low income</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Maryland</style></keyword><keyword><style face="normal" font="default"> Medicaid</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> Poverty</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Social Work</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Low-income caregivers of young children with high-risk asthma experience social stressors and illness-related demands that may impede effective home asthma management. Knowledge of the caregiving experience in the context of poverty is limited. METHODS: Convenience sampling methods were used to recruit low-income caregivers of children aged 7-12 years, who are frequently in the Emergency Room (ED) for uncontrolled asthma. Thirteen caregivers participated in focus groups that were designed to elicit reflections on asthma home and community management from the caregiver perspective. A grounded theory approach was used in the open coding of transcript data from three focus groups, as well as to revise and reorganize emerging themes and sub-themes. RESULTS: Participants (Mean age = 33.9 years) were predominantly the biological mother (92.3%), single (84.6%), and impoverished (69.2% reported annual household income &lt;/= $30,000). Their children (Mean age = 7.8 years) were African-American (100%), enrolled in Medicaid (92.3%), averaged 1.38 (SD = 0.7) ED visits over the prior 3 months, resided in homes with at least one smoker (61.5%), and nearly all (84.6%) experienced activity limitations due to asthma. Five themes emerged in the analysis: intensive caregiving role, complex and shared asthma management responsibility, parental beliefs and structural barriers to guideline-based care, lack of control over environmental triggers, and parent advocacy to improve child asthma care and outcomes. CONCLUSIONS: Caregivers managing a child with high-risk asthma in the context of poverty indicate the need for ongoing asthma education, increased sensitivity to the complexity of home asthma management, and family-centered interventions that enhance communication and collaboration between caregivers and providers</style></abstract><notes><style face="normal" font="default">DA - 20160615IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1198375</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27304455">PM:27304455</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-162-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-162-72.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160615, Bellin MH</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1198375</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41186</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Huang,F.</style></author><author><style face="normal" font="default"> Del-Rio-Navarro,B.E.</style></author><author><style face="normal" font="default"> Torres-Alcantara,S.</style></author><author><style face="normal" font="default"> Perez-Ontiveros,J.A.</style></author><author><style face="normal" font="default"> Ruiz-Bedolla,E.</style></author><author><style face="normal" font="default"> Saucedo-Ramirez,O.J.</style></author><author><style face="normal" font="default"> Villafana,S.</style></author><author><style face="normal" font="default"> Sanchez,Munoz F.</style></author><author><style face="normal" font="default"> Bravo,G.</style></author><author><style face="normal" font="default"> Hong,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Laboratory of Pharmacology and Toxicology, Hospital Infantil de Mexico Federico Gomez (HIMFG) , Mexico City , Mexico</style></auth-address><titles><title><style face="normal" font="default">Adipokines, asymmetrical dimethylarginine, and pulmonary function in adolescents with asthma and obesity</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="161" start="153">153-161</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">abnormalities</style></keyword><keyword><style face="normal" font="default"> Adiponectin</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Leptin</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mexico</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Toxicology</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">OBJECTIVE: This study was to investigate whether the metabolic abnormalities of adipokines and asymmetrical dimethylarginine (ADMA) associate with pulmonary function deficits in adolescents with obesity and asthma. METHODS: This study enrolled 28 obese adolescents with asthma, 46 obese adolescents without asthma, 58 normal-weight adolescents with asthma, and 63 healthy control subjects. Serum levels of leptin, high-molecule-weight (HMW) adiponectin, retinol binding protein 4 (RBP4), asymmetrical dimethylarginine (ADMA), and pulmonary function were qualified. RESULTS: The obese subjects had higher levels of leptin and ADMA but lower levels of HMW adiponectin than the normal-weight subjects with or without asthma. The subjects with asthma had higher levels of RBP4 than those without asthma. The obese adolescents with asthma had lowest forced expiratory lung volume in the first second (FEV1)/forced vital capacity (FVC) ratio among the four study groups. In all the study subjects and in the subjects with asthma alone, the FEV1/FVC ratio associated negatively with leptin, however, such association was rendered non-significant when adjusted for BMI. The pulmonary function deficits associated inversely with BMI percentile in the subjects with asthma. However, the decreased FEV1/FVC ratio was not correlated with HMW adiponectin, RBP4 or ADMA. CONCLUSIONS: Our present study confirmed obstructive pattern of pulmonary function characterized by the reduced FEV1/FVC ratio in the obese adolescents with asthma. These pulmonary deficits were associated inversely with the increased BMI percentile</style></abstract><notes><style face="normal" font="default">DA - 20160623IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1200611</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27337146">PM:27337146</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-153-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-153-61.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160623, Huang F</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1200611</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41187</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mammen,J.R.</style></author><author><style face="normal" font="default"> Rhee,H.</style></author><author><style face="normal" font="default"> Norton,S.A.</style></author><author><style face="normal" font="default"> Butz,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a University of Rochester School of Nursing , Rochester , NY , USA</style></auth-address><titles><title><style face="normal" font="default">Perceptions and experiences underlying self-management and reporting of symptoms in teens with asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="152" start="143">143-152</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Data Collection</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nursing</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> rescue medication</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Self-management</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Teens often have inadequate asthma self-management and control. However, little is known of their perceptions of or rationales for self-management behaviors. OBJECTIVES: To explore how teens self-manage asthma, including experiences, perceptions, responses to and reporting of symptoms. METHODS: A case-based, qualitative-descriptive design was used. Data were collected from minority and non-minority teens with controlled and uncontrolled asthma and their respective parents (N = 28). There were four data-collection points, including: (1) a primary teen interview; (2) parent interview; (3) 2-week self-management voice-diary; and (4) follow-up teen interview, incorporating symptom-response card-sorting to map symptoms and associated self-management responses. Seventy data sources were included in the analysis. RESULTS: Teens thought of their asthma symptoms as normal or unusual relative to their personal baseline symptom pattern; Those with uncontrolled asthma normalized higher levels of asthma symptoms than their counterparts with controlled asthma. Second, teens' decisions to treat symptoms of asthma with rescue medication were based on perceived benefits, burdens and accessibility of treatment balanced against perceived normalcy of symptoms. Teens with uncontrolled asthma had substantially higher treatment thresholds and delayed responses to symptoms compared to controlled peers. Third, teens never reported perceived normal symptoms of asthma to parents or providers, who were thus only aware of unusual or visible/audible symptoms. CONCLUSIONS: Teen's perceptions of symptoms and understanding of what is normal is the basis for self-management decisions. Improving self-management will likely entail modifying perceptions of symptoms and benefits/burdens of treatment to achieve healthier self-management patterns</style></abstract><notes><style face="normal" font="default">DA - 20160929IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1201835</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27337035">PM:27337035</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-143-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-143-52.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160929, Mammen JR</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1201835</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41188</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Torchyan,A.A.</style></author><author><style face="normal" font="default"> Binsaeed,A.A.</style></author><author><style face="normal" font="default"> Khashogji,S.A.</style></author><author><style face="normal" font="default"> Alawad,S.H.</style></author><author><style face="normal" font="default"> Al-Ka'abor,A.S.</style></author><author><style face="normal" font="default"> Alshehri,M.A.</style></author><author><style face="normal" font="default"> Alrajhi,A.A.</style></author><author><style face="normal" font="default"> Alshammari,M.M.</style></author><author><style face="normal" font="default"> Papikyan,S.L.</style></author><author><style face="normal" font="default"> Gosadi,I.M.</style></author><author><style face="normal" font="default"> Al-Hazmi,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Prince Sattam Chair for Epidemiology and Public Health Research, Department of Family and Community Medicine , College of Medicine, King Saud University , Riyadh , Saudi Arabia</style></auth-address><titles><title><style face="normal" font="default">Asthma quality of life in Saudi Arabia: Gender differences</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="209" start="202">202-209</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> gender difference</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Income</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Saudi Arabia</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Socioeconomic Factors</style></keyword><keyword><style face="normal" font="default"> Tobacco</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To explore potential gender differences in the factors associated with asthma-specific quality of life (AQL). METHODS: A cross-sectional study of consecutive series of adult patients attending primary care centers at three major hospitals in Riyadh, Saudi Arabia, was performed. AQL was measured using a standardized version of the AQL questionnaire (min = 1, max = 7), with higher scores indicating a better AQL. Multiple linear regression analysis was performed. RESULTS: The mean AQL was 4.3 (standard deviation [SD] = 1.5) for males and 4.0 (SD = 1.3) for females (p = 0.113). With each unit increase in asthma control, the AQL improved by 0.19 points (95% confidence interval [CI] = 0.14-0.23) in men and by 0.21 points (95% CI = 0.16-0.25) in women. Daily tobacco smoking was associated with a 0.72 point (95% CI = 0.14-1.30) decrease in the AQL among males. Women who had a household member who smoked inside the house had a significantly lower AQL (B = -0.59, 95% CI = -1.0 - -0.19). A monthly household income of 25,000 Saudi Riyals or more was associated with a better AQL among men (B = 0.51, 95% CI = 0.01-1.01), whereas being employed exhibited a protective effect in women (B = 0.48, 95% CI = 0.11-0.84). Higher levels of perceived asthma severity were associated with better AQL in women (B = 0.82, 95% CI = 0.36-1.28). CONCLUSIONS: Our findings revealed gender-specific differences in the correlates of AQL in Saudi Arabia, particularly in tobacco exposure, socio-economic factors and perceived asthma severity</style></abstract><notes><style face="normal" font="default">DA - 20160926IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Saudi Arabia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1196369</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27284849">PM:27284849</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-202-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-202-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160926, Torchyan AA</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1196369</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41189</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Belice,P.J.</style></author><author><style face="normal" font="default"> Becker,E.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a College of Health Sciences, Rush University Medical Center , Chicago , IL , USA</style></auth-address><titles><title><style face="normal" font="default">Effective education parameters for trigger remediation in underserved children with asthma: A systematic review</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="201" start="186">186-201</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Cockroach</style></keyword><keyword><style face="normal" font="default"> Cockroaches</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Education</style></keyword><keyword><style face="normal" font="default"> health literacy</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Learning</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> Mites</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Poverty</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> rat</style></keyword><keyword><style face="normal" font="default"> Rats</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Self-management</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urban Population</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The prevalence of asthma is highest in minority children living in urban areas. Pediatric asthma research has focused on self-management education and trigger remediation using a multi-trigger, multi-component educational intervention approach. The purpose of this systematic review was to identify common educational parameters of these proposed interventions. The review also sought to identify which clinical outcomes improved with multi-trigger, multi-component educational interventions. DATA SOURCES: PubMed, SCOPUS and ProQuest Dissertations were searched between 2000 to 2014 using the following terms: asthma; urban population or poverty area; environmental remediation; health education; allergens or dust mites or cockroaches or mold or mice or rats. STUDY SELECTIONS: Studies were included if they met the following criteria: 1) participants were minority children identified as underserved; 2) there was a multi-trigger and multi-component intervention; 3) asthma severity was classified as persistent; and 4) asthma control was classified as not well controlled. RESULTS: A total of 531 articles were retrieved of which 17 met the inclusion criteria. The interventions lacked consistency in their explanation. Most studies were vague in reporting pedagogical methods and educational content. Few studies reported a theoretical framework to guide their approach. Over half the studies did not report a learning assessment nor health literacy of the caregiver or the child with asthma. Yet all of the findings demonstrated statistically significant results in some or all of their primary outcomes. CONCLUSION: Overall, the research lacked clarity in the approach to impact asthma outcomes and reduces the opportunity to substantiate the findings through replication</style></abstract><notes><style face="normal" font="default">DA - 20160929IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1198374</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27304997">PM:27304997</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-186-201.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-186-201.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160629, Belice PJ</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1198374</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41190</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rodriguez-Martinez,C.E.</style></author><author><style face="normal" font="default"> Sossa-Briceno,M.P.</style></author><author><style face="normal" font="default"> Nino,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatrics , School of Medicine, Universidad Nacional de Colombia , Bogota , Colombia</style></auth-address><titles><title><style face="normal" font="default">A systematic review of instruments aimed at evaluating metered-dose inhaler administration technique in children</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="185" start="173">173-185</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Colombia</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pressurized metered-dose inhaler</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The objective of the present study was to perform a systematic review of instruments aimed at evaluating pressurized metered-dose inhaler (pMDI) administration technique in children and evaluating the measurement properties of these instruments. METHODS: A systematic search of the literature was performed in order to identify studies in which an instrument (scale, checklist, or questionnaire) for evaluating pMDI administration technique in children was described. Instruments were evaluated based on their reliability, validity, utility, endorsement frequency, restrictions in range, comprehension, lack of ambiguity, and lack of value-laden or offensive content. RESULTS: A total of 24 instruments were identified. The age of the children ranged from 1 month to 18 years, the number of steps or items included in the instruments ranged from 3 to 21, and nearly half of the instruments distinguished between essential and non-essential steps or items. In only 7 of the 24 instruments was there a report of their measurement properties, mainly reliability and utility. Taking into consideration the information contained in the instruments, as well as their measurement properties, we determined four instruments to be the best of the available ones. CONCLUSIONS: Among the 24 instruments for the assessment of pMDI administration technique in children that were identified and systematically examined, four were considered to be the best ones available. However, additional evaluation of their measurement properties should be done before using them in clinical practice and for research purposes</style></abstract><notes><style face="normal" font="default">DA - 20160615IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Colombia -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1198373</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27304666">PM:27304666</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-173-85.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-173-85.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160615, Rodriguez-Martinez CE</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1198373</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41191</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Karam,M.</style></author><author><style face="normal" font="default"> Kaur,B.P.</style></author><author><style face="normal" font="default"> Baptist,A.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Division of Allergy and Clinical Immunology, Department of Internal Medicine, University of Michigan , Ann Arbor , MI , USA</style></auth-address><titles><title><style face="normal" font="default">A modified breathing exercise program for asthma is easy to perform and effective</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="222" start="217">217-222</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> ACT Score</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Breathing Exercises</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Complementary Therapies</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Lip</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Michigan</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Yoga</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Breathing exercises are used by some asthmatic patients, yet are often difficult to perform and time-consuming. This study evaluated a simple, modified breathing exercise program regarding ease to perform and effectiveness as an adjunctive therapy. METHODS: Subjects age 18 to 65 with a current diagnosis of persistent asthma were enrolled. A program that incorporated three different breathing exercises (yoga pranayama techniques, diaphragmatic breathing and pursed lip breathing) was taught to subjects. The program was designed to be completed in less than 10 minutes per day. Subjects completed the Asthma Control Test (ACT) and mini-Asthma Quality of Life Questionnaire (AQLQ) at baseline and at 1-month follow-up. They also completed a survey that asked them to rate the effectiveness and difficulty of the exercises, and whether they would recommend them in the future. RESULTS: A total of 74 subjects were enrolled in this study. The intervention improved breathing for 52.9% of the subjects, while 67.6% felt that their daily activity was improved and 66.1% noted that the exercises allowed decreased use of a rescue inhaler. Most subjects (80.9%) recommended breathing exercises as a complementary therapy for asthma and 79.4% of the subjects stated the exercises took less than 10 minutes per day total. Overall, ACT scores improved significantly (p = 0.002) with a statistically non-significant improvement in AQLQ scores. CONCLUSION: A simple program of breathing exercises was found to be effective and could be completed in less than 10 minutes per day. Furthermore, there was a statistically significant improvement in ACT scores post-exercise</style></abstract><notes><style face="normal" font="default">DA - 20160926IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1196368</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27285510">PM:27285510</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-217-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-217-22.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160926, Karam M</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1196368</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41192</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Roscioli,E.</style></author><author><style face="normal" font="default"> Hamon,R.</style></author><author><style face="normal" font="default"> Ruffin,R.E.</style></author><author><style face="normal" font="default"> Grant,J.</style></author><author><style face="normal" font="default"> Hodge,S.</style></author><author><style face="normal" font="default"> Zalewski,P.</style></author><author><style face="normal" font="default"> Lester,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Discipline of Medicine, University of Adelaide , North Tce, Adelaide , South Australia , Australia</style></auth-address><titles><title><style face="normal" font="default">BIRC3 single nucleotide polymorphism associate with asthma susceptibility and the abundance of eosinophils and neutrophils</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="124" start="116">116-124</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Alleles</style></keyword><keyword><style face="normal" font="default"> Apoptosis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease Susceptibility</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> epithelia</style></keyword><keyword><style face="normal" font="default"> Epithelium</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> haplotype</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhibitor of Apoptosis Proteins</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVE: Aberrant apoptosis is a disease susceptibility mechanism relevant for asthma, whereby fragility of the airway epithelium and enhanced survival of inflammatory cells, contributes to its pathogenesis and prolongation. Cellular Inhibitor of Apoptosis Proteins (cIAP) suppress apoptosis, and participate in the immune response. In this study, single nucleotide polymorphisms (SNP) in the BIRC2 (codes cIAP1) and BIRC3 (cIAP2) genes were evaluated for an association with asthma. METHODS: Caucasian asthmatic (n = 203) and control (n = 198) subjects were selected from participants in the North West Adelaide Health Study. SNPs (n = 9) spanning the consecutively positioned BIRC2 and BIRC3 genes, were selected using a haplotype tagging approach. Alleles and haplotype associations were analysed by logistic regression, assuming an additive genetic model, and adjusted for gender and atopy. RESULTS: The frequency of the minor allele for the BIRC3 SNP rs3460 was significantly lower in asthmatics compared to the control cases (P = 0.046). BIRC3 SNPs rs7928663 and rs7127583 associated with a reduction in eosinophil and neutrophil abundance when assessed across the study population (multivariate P values = 0.002, and 0.005, respectively). Further, the frequency of a haplotype tagged by rs3460, rs7928663 and rs7127583 was reduced in the asthma sub group (P = 0.05), while the presence of the major allele for rs7928663 associated with an increased load of circulating eosinophils and neutrophils (multivariate P value = 0.001). CONCLUSIONS: Polymorphisms in the BIRC3 gene, but not BIRC2, are associated with a protective effect with regards to asthma susceptibility, and a reduced load of inflammatory cells</style></abstract><notes><style face="normal" font="default">DA - 20160929IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1196371</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27304223">PM:27304223</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-116-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-116-24.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160929, Roscioli E</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1196371</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41193</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hartmann,B.</style></author><author><style face="normal" font="default"> Leucht,V.</style></author><author><style face="normal" font="default"> Loerbroks,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Institute of Occupational, Social and Environmental Medicine, Centre for Health and Society, Faculty of Medicine, University of Dusseldorf , Dusseldorf , Germany</style></auth-address><titles><title><style face="normal" font="default">Work stress, asthma control and asthma-specific quality of life: Initial evidence from a cross-sectional study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="216" start="210">210-216</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> Causality</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Employment</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Occupation</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Research has suggested that psychological stress is positively associated with asthma morbidity. One major source of stress in adulthood is one's occupation. However, to date, potential links of work stress with asthma control or asthma-specific quality of life have not been examined. We aimed to address this knowledge gap. METHODS: In 2014/2015, we conducted a cross-sectional study among adults with asthma in Germany (n = 362). For the current analyses that sample was restricted to participants in employment and reporting to have never been diagnosed with chronic obstructive pulmonary disease (n = 94). Work stress was operationalized by the 16-item effort-reward-imbalance (ERI) questionnaire, which measures the subcomponents "effort", "reward" and "overcommitment." Participants further completed the Asthma Control Test and the Asthma Quality of Life Questionnaire-Sydney. Multivariable associations were quantified by linear regression and logistic regression. RESULTS: Effort, reward and their ratio (i.e. ERI ratio) did not show meaningful associations with asthma morbidity. By contrast, increasing levels of overcommitment were associated with poorer asthma control and worse quality of life in both linear regression (ss = -0.26, p = 0.01 and ss = 0.44, p &lt; 0.01, respectively) and logistic regression (odds ratio [OR] = 1.87, 95% confidence interval [CI] = 1.14-3.07 and OR = 2.34, 95% CI = 1.32-4.15, respectively). CONCLUSIONS: The present study provides initial evidence of a positive relationship of work-related overcommitment with asthma control and asthma-specific quality of life. Longitudinal studies with larger samples are needed to confirm our findings and to disentangle the potential causality of associations</style></abstract><notes><style face="normal" font="default">DA - 20160621IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1201836</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27328314">PM:27328314</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-210-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-54-210-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160621, Hartmann B</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1201836</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41194</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Munoz-Miguelsanz,M.A.</style></author><author><style face="normal" font="default"> Alvarez Morales,T.</style></author><author><style face="normal" font="default"> Martin Garcia,J.A.</style></author><author><style face="normal" font="default"> Martinez,G.M.</style></author><author><style face="normal" font="default"> Santos Perez,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Surgery Department, Virgen de las Nieves Children's Hospital, Granada, Spain</style></auth-address><titles><title><style face="normal" font="default">Pseudomonas aeruginosa Liver Abscess as the First Manifestation of X-Linked Agammaglobulinemia With a Novel Mutation</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="131" start="129">129-131</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Abscess</style></keyword><keyword><style face="normal" font="default"> Agammaglobulinemia</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Liver Abscess</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pseudomonas</style></keyword><keyword><style face="normal" font="default"> Pseudomonas aeruginosa</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0129</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28398200">PM:28398200</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, Munoz-Miguelsanz MA</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0129</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41195</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gonzalez-Cavero,L.</style></author><author><style face="normal" font="default"> Dominguez-Ortega,J.</style></author><author><style face="normal" font="default"> Gonzalez-Munoz,M.</style></author><author><style face="normal" font="default"> Mayor-Ibarguren,A.</style></author><author><style face="normal" font="default"> Tomas,M.</style></author><author><style face="normal" font="default"> Fiandor,A.</style></author><author><style face="normal" font="default"> Quirce,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Delayed Allergic Reaction to Terbinafine With a Positive Lymphocyte Transformation Test</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="137" start="136">136-137</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Transformation</style></keyword><keyword><style face="normal" font="default"> Lymphocyte transformation test</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Transformation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0133</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28398203">PM:28398203</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, Gonzalez-Cavero L</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0133</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41196</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sabatelli,L.</style></author><author><style face="normal" font="default"> Seppala,U.</style></author><author><style face="normal" font="default"> Sastre,J.</style></author><author><style face="normal" font="default"> Crater,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">GLOBMOD Health, Barcelona, SpainMedical Affairs, Aerocrine AB, Solna, SwedenHospital Universitario Fundacion Jimenez Diaz, Madrid, SpainGlobal Clinical Development &amp; Medical Affairs, Morrisville, North Carolina, USA</style></auth-address><titles><title><style face="normal" font="default">Cost-effectiveness and Budget Impact of Routine Use of Fractional Exhaled Nitric Oxide Monitoring for the Management of Adult Asthma Patients in Spain</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="97" start="89">89-97</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Adult asthma</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Cost-effectiveness</style></keyword><keyword><style face="normal" font="default"> Cost-effectiveness analysis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> North Carolina</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> quality-adjusted life year</style></keyword><keyword><style face="normal" font="default"> Quality-Adjusted Life Years</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> treatment guidelines</style></keyword><keyword><style face="normal" font="default"> Uncertainty</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Fractional exhaled nitric oxide (FeNO) is a marker for type 2 airway inflammation. The objective of this study was to evaluate the cost-effectiveness and budget impact of FeNO monitoring for management of adult asthma in Spain. METHODS: A cost-effectiveness analysis model was used to evaluate the effect on costs of adding FeNO monitoring to asthma management. Over a 1-year period, the model estimated the incremental cost per quality-adjusted life year and incremental number of exacerbations avoided when FeNO monitoring was added to standard guideline-driven asthma care compared with standard care alone. Univariate and multivariate sensitivity analyses were applied to explore uncertainty in the model. A budget impact model was used to examine the impact of FeNO monitoring on primary care costs across the Spanish health system. RESULTS: The results showed that adding FeNO to standard asthma care saved euro62.53 per patient-year in the adult population and improved quality-adjusted life years by 0.026 per patient-year. The budget impact analysis revealed a potential net yearly saving of euro129 million if FeNO monitoring had been used in primary care settings in Spain. CONCLUSIONS: The present economic model shows that adding FeNO to the treatment algorithm can considerably reduce costs and improve quality of life when used to manage asthma in combination with current treatment guidelines</style></abstract><notes><style face="normal" font="default">DA - 20160826IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Sweden -CO - United States -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0103</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27564130">PM:27564130</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-89-97.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-89-97.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160826, Sabatelli L</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0103</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41197</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mattoussi,N.</style></author><author><style face="normal" font="default"> Ben Mansour,A.</style></author><author><style face="normal" font="default"> Essadam,L.</style></author><author><style face="normal" font="default"> Guedri,R.</style></author><author><style face="normal" font="default"> Fitouri,Z.</style></author><author><style face="normal" font="default"> Ben Becher,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universite de Tunis El Manar, Faculty of Medicine and Pediatrics Department, Bechir Hamza Children s Hospital, Tunis, Tunisia</style></auth-address><titles><title><style face="normal" font="default">Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome in Children: A Case Report</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="146" start="144">144-146</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Case Report</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> DRESS</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Tunisia</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Tunisia -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0140</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28398207">PM:28398207</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, Mattoussi N</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0140</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41198</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Holguin-Gomez,L.</style></author><author><style face="normal" font="default"> Sastre Dominguez,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Alergologia Clinica, Universidad de Antioquia, Colombia and Allergy Division, Fundacion Jimenez DiazAllergy Division, Fundacion Jimenez Diaz, Universidad Autonoma de Madrid, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Occupational Contact Dermatitis in Spain</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="136" start="134">134-136</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Colombia</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Colombia -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0131</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28398202">PM:28398202</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-127-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, Holguin-Gomez L</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0131</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41199</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oda,T.</style></author><author><style face="normal" font="default"> Sawada,Y.</style></author><author><style face="normal" font="default"> Yamaguchi,T.</style></author><author><style face="normal" font="default"> Ohmori,S.</style></author><author><style face="normal" font="default"> Haruyama,S.</style></author><author><style face="normal" font="default"> Yoshioka,M.</style></author><author><style face="normal" font="default"> Okada,E.</style></author><author><style face="normal" font="default"> Nakamura,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan</style></auth-address><titles><title><style face="normal" font="default">Drug Eruption Caused by Rosuvastatin</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="141" start="140">140-141</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Dermatology</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug eruption</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0136</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28398205">PM:28398205</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-140-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-140-1.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, Oda T</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0136</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41200</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,H.Y.</style></author><author><style face="normal" font="default"> Choi,J.</style></author><author><style face="normal" font="default"> Ahn,K.</style></author><author><style face="normal" font="default"> Hahm,M.I.</style></author><author><style face="normal" font="default"> Lee,S.Y.</style></author><author><style face="normal" font="default"> Kim,W.K.</style></author><author><style face="normal" font="default"> Chae,Y.</style></author><author><style face="normal" font="default"> Park,Y.M.</style></author><author><style face="normal" font="default"> Han,M.Y.</style></author><author><style face="normal" font="default"> Lee,K.J.</style></author><author><style face="normal" font="default"> Kwon,H.J.</style></author><author><style face="normal" font="default"> Kim,S.</style></author><author><style face="normal" font="default"> Yoo,H.</style></author><author><style face="normal" font="default"> Kim,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Medical Research Institute of Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea</style></auth-address><titles><title><style face="normal" font="default">Reference Values and Utility of Serum Total Immunoglobulin E for Predicting Atopy and Allergic Diseases in Korean Schoolchildren</style></title><secondary-title><style face="normal" font="default">J Korean Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Korean Med Sci</style></full-title></periodical><pages end="809" start="803">803-809</pages><volume><style face="normal" font="default">32</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Inhalant</style></keyword><keyword><style face="normal" font="default"> Inhalant allergens</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Predictive values</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Reference Values</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schoolchildren</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Students</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">The present study aimed to investigate the distribution of total serum immunoglobulin E (IgE) levels in Korean schoolchildren and to evaluate its utility in the prediction of atopy and allergic diseases. A nationwide, cross-sectional survey was conducted in first grade students from randomly selected elementary and middle schools. Total IgE levels were measured by ImmunoCAP. Skin prick tests were performed for 18 common inhalant allergens to determine the presence of atopy. Children aged 12-13 years and parents of children aged 6-7 years were asked to complete questionnaire assessing allergic diseases. The cut-off levels of total IgE were determined by analyzing receiver operating characteristic curves. The median total IgE level was 86.7 kU/L (range: 1.5-4,523.1) in 3,753 children aged 6-7 years and 94.7 kU/L (range: 1.5-3,000.0) in 3,930 children aged 12-13 years. Total IgE concentrations were higher in children with atopy or allergic diseases than in those without (all P &lt; 0.001). At the cut-off value of 127.7 kU/L, sensitivity, specificity, and positive and negative predictive values (PPV and NPV) were 67.1%, 75.4%, 65.4%, and 76.7%, respectively, in elementary schoolchildren. At the cut-off value of 63.0 kU/L, sensitivity, specificity, PPV, and NPV were 81.9%, 66.6%, 75.0%, and 75.1%, respectively, in middle schoolchildren. PPV and NPV were >/= 70% when cut-offs of 258.8 kU/L and 38.4 kU/L were used for the diagnosis of atopy in 6-7 year-olds and 12-13 year-olds, respectively. This nationwide population-based study provided the first normal reference ranges of total IgE in Korean schoolchildren</style></abstract><notes><style face="normal" font="default">DA - 20170405IS - 1598-6357 (Electronic)IS - 1011-8934 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.3346/jkms.2017.32.5.803</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28378554">PM:28378554</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Korean Med Sci\2017-32-803-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Korean Med Sci\2017-32-803-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170405, Kim HY</style></custom2><misc3><style face="normal" font="default">10.3346/jkms.2017.32.5.803</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41201</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kraemer,L.S.</style></author><author><style face="normal" font="default"> Brenner,T.A.</style></author><author><style face="normal" font="default"> Krumholz,J.O.</style></author><author><style face="normal" font="default"> Rosenberg,H.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Inflammation Immunobiology Section, Laboratory of Allergic Diseases, NIAID, National Institutes of Health, Bethesda, MD 20892, United States</style></auth-address><titles><title><style face="normal" font="default">A flow-cytometric method to evaluate eosinophil-mediated uptake of probiotic Lactobacillus reuteri</style></title><secondary-title><style face="normal" font="default">J Microbiol Methods</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Microbiol Methods</style></abbr-1></periodical><pages end="24" start="19">19-24</pages><volume><style face="normal" font="default">137</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lactobacillus</style></keyword><keyword><style face="normal" font="default"> Lactobacillus reuteri</style></keyword><keyword><style face="normal" font="default"> Leukocytes</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="27" Month="3" Year="2017">2017/3/27</year></dates><abstract><style face="normal" font="default">Eosinophils are resident leukocytes of gut mucosa. Here we present a combined flow cytometric-antibiotic protection assay to identify mouse eosinophils capable of bacterial uptake, specifically, Gram-positive Lactobacillus reuteri, in studies performed ex vivo. The assay may be adapted for use in vivo</style></abstract><notes><style face="normal" font="default">DA - 20170331IS - 1872-8359 (Electronic)IS - 0167-7012 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.mimet.2017.03.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28359737">PM:28359737</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Microbiol Methods\2017-137-19-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Microbiol Methods\2017-137-19-24.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170331, Kraemer LS</style></custom2><misc3><style face="normal" font="default">10.1016/j.mimet.2017.03.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41202</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bernardini,R.</style></author><author><style face="normal" font="default"> Bonadonna,P.</style></author><author><style face="normal" font="default"> Catania,P.</style></author><author><style face="normal" font="default"> Passalacqua,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Unit, San Giuseppe Hospital, Empoli (Florence), Italy</style></auth-address><titles><title><style face="normal" font="default">Perioperative midazolam hypersensitivity in a seven-year old boy</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Benzodiazepines</style></keyword><keyword><style face="normal" font="default"> Butyric Acid</style></keyword><keyword><style face="normal" font="default"> Central Nervous System</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical aspects</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Nervous System</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="24" Month="3" Year="2017">2017/3/24</year></dates><abstract><style face="normal" font="default">Midazolam is a short-acting benzodiazepine with a central nervous system depressing action. The pharmacologic properties of midazolam and its metabolites (similar to those of other benzodiazepines), include sedative, anxiolytic, amnesic and hypnotic activities. The favorable clinical aspects of the use of benzodiazepines are the result of a reversible allosteric interaction with the (gamma)-amino butyric acid (GABA) receptor A, that accounts for the major inhibitory neurotransmitter pathway within the central nervous system (1). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170324IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12717</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28339137">PM:28339137</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170324-BernardiniR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170324-BernardiniR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170324, Bernardini R</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12717</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41203</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rossi,G.A.</style></author><author><style face="normal" font="default"> Colin,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pulmonary and Allergy Disease Pediatric Unit and Cystic Fibrosis Center, Istituto Giannina Gaslini, Genoa, Italy</style></auth-address><titles><title><style face="normal" font="default">Respiratory syncytial virus - host interaction in the pathogenesis of bronchiolitis and its impact on respiratory morbidity in later life</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic sensitization</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bronchiolitis</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Efficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="default"> epidemiologic study</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic susceptibility</style></keyword><keyword><style face="normal" font="default"> Infancy</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> recurrent wheezing</style></keyword><keyword><style face="normal" font="default"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> RSV</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="24" Month="3" Year="2017">2017/3/24</year></dates><abstract><style face="normal" font="default">Rossi GA, Colin AA. Respiratory syncytial virus - host interaction in the pathogenesis of bronchiolitis and its impact on respiratory morbidity in later life. Pediatr Allergy Immunol. Respiratory syncytial virus (RSV) is the most common agent of severe airway disease in infants and young children. Large epidemiologic studies have demonstrated a clear relationship between RSV infection and subsequent recurrent wheezing and asthma into childhood, thought to be predominantly related to long-term changes in neuroimmune control of airway tone rather than to allergic sensitization. These changes appear to be governed by the severity of the first RSV infection in infancy which in term depends on viral characteristics and load, but perhaps as importantly, on the genetic susceptibility and on the constitutional characteristic of the host. A variety of viral and host factors and their interplay modify the efficiency of the response to infection, including viral replication and the magnitude of structural and functional damage to the respiratory structures, and ultimately the extent, severity and duration of subsequent wheezing. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170324IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12716</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28339145">PM:28339145</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170324-RossiGA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170324-RossiGA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170324, Rossi GA</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12716</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41204</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,Y.M.</style></author><author><style face="normal" font="default"> Kim,J.</style></author><author><style face="normal" font="default"> Han,Y.</style></author><author><style face="normal" font="default"> Jeon,B.H.</style></author><author><style face="normal" font="default"> Cheong,H.K.</style></author><author><style face="normal" font="default"> Ahn,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Environmental Health Center for Atopic Diseases, Samsung Medical Center, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Short-term effects of weather and air pollution on atopic dermatitis symptoms in children: A panel study in Korea</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0175229">e0175229-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Air Pollutants</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> Atopic diseases</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> confounding factors</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Humidity</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Nitrogen</style></keyword><keyword><style face="normal" font="default"> Nitrogen Dioxide</style></keyword><keyword><style face="normal" font="default"> NO2</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Ozone</style></keyword><keyword><style face="normal" font="default"> Particulate matter</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> persistence</style></keyword><keyword><style face="normal" font="default"> PM10</style></keyword><keyword><style face="normal" font="default"> pollutants</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Temperature</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Weather</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">INTRODUCTION: The effects of weather and air pollution on the severity and persistence of atopic dermatitis (AD) are important issues that have not been investigated in detail. The objective of our study was to determine the short-term effects of meteorological variables and air pollution on AD symptoms in children. METHODS: We enrolled 177 AD patients with 5 years or younger from the Seoul Metropolitan Area, Korea, and followed for 17 months between August 2013 and December 2014. Symptoms records of 35,158 person-days, including itching, sleep disturbance, erythema, dry skin, oozing, and edema, were obtained. We estimated the effect of meteorological variables including daily mean temperature, relative humidity (RH), diurnal temperature range (DTR), rainfall and air pollutants including particulate matter with an aerodynamic diameter &lt;/=10 mum (PM10), nitrogen dioxide (NO2), and tropospheric ozone (O3) on AD symptoms using a generalized linear mixed model with adjustment for related confounding factors. RESULTS: A 5 degrees C increase in outdoor temperature and a 5% increase in outdoor RH was associated with 12.8% (95% confidence intervals (CI): 10.5, 15.2) and 3.3% (95% CI: 1.7, 4.7) decrease in AD symptoms, respectively, on the same day. An increase of rainfall by 5 mm increased AD symptoms by 7.3% (95% CI: 3.6, 11.1) for the days with &lt;40 mm rainfall. The risk of AD symptoms increased by 284.9% (95% CI: 67.6, 784.2) according to a 5 degrees C increase in DTR when it was >14 degrees C. An increase in PM10, NO2, and O3 by 10 units increased the risk of AD symptoms on the same day by 3.2% (95% CI: 1.5, 4.9), 5.0% (95% CI: 1.4, 8.8), and 6.1% (95% CI: 3.2, 9.0), respectively. CONCLUSION: Exposure to meteorological variables and air pollutants are associated with AD symptoms in young children</style></abstract><notes><style face="normal" font="default">DA - 20170406IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">    10.1371/journal.pone.0175229</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28384276">PM:28384276</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0175229.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0175229.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170506, Kim YM</style></custom2><misc3><style face="normal" font="default">    10.1371/journal.pone.0175229</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41205</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Santamaria,E.</style></author><author><style face="normal" font="default"> Estevez,J.A.</style></author><author><style face="normal" font="default"> Riba,J.</style></author><author><style face="normal" font="default"> Izquierdo,I.</style></author><author><style face="normal" font="default"> Valle,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical Development, R&amp;D, J. Uriach y Compania, S.A., Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default">Population pharmacokinetic modelling of rupatadine solution in 6-11 year olds and optimisation of the experimental design in younger children</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0176091">e0176091-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Absorption</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Elimination</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">AIMS: To optimise a pharmacokinetic (PK) study design of rupatadine for 2-5 year olds by using a population PK model developed with data from a study in 6-11 year olds. The design optimisation was driven by the need to avoid children's discomfort in the study. METHODS: PK data from 6-11 year olds with allergic rhinitis available from a previous study were used to construct a population PK model which we used in simulations to assess the dose to administer in a study in 2-5 year olds. In addition, an optimal design approach was used to determine the most appropriate number of sampling groups, sampling days, total samples and sampling times. RESULTS: A two-compartmental model with first-order absorption and elimination, with clearance dependent on weight adequately described the PK of rupatadine for 6-11 year olds. The dose selected for a trial in 2-5 year olds was 2.5 mg, as it provided a Cmax below the 3 ng/ml threshold. The optimal study design consisted of four groups of children (10 children each), a maximum sampling window of 2 hours in two clinic visits for drawing three samples on day 14 and one on day 28 coinciding with the final examination of the study. CONCLUSIONS: A PK study design was optimised in order to prioritise avoidance of discomfort for enrolled 2-5 year olds by taking only four blood samples from each child and minimising the length of hospital stays</style></abstract><notes><style face="normal" font="default">DA - 20170418IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0176091</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28419164">PM:28419164</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0176091.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0176091.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170418, Santamaria E</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0176091</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41206</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aberle,D.</style></author><author><style face="normal" font="default"> Wu,S.E.</style></author><author><style face="normal" font="default"> Oklu,R.</style></author><author><style face="normal" font="default"> Erinjeri,J.</style></author><author><style face="normal" font="default"> Deipolyi,A.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association Between Allergies and Psychiatric Disorders in Patients Undergoing Invasive Procedures</style></title><secondary-title><style face="normal" font="default">Psychosomatics</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Psychosomatics</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Invasive procedure</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> Psychiatric disorder</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Sedation</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0033-3182</style></isbn><abstract><style face="normal" font="default">Background Associations between allergies and psychiatric disorders have been reported in the context of depression and suicide; psychiatric disorders may impact pain perception. Objective To investigate the relationship of allergies with psychiatric disorders and pain perception in the context of invasive procedures, specifically during tunneled hemodialysis catheter placement (THDCP). Methods We identified 89 patients (51 men, 38 women), mean age 66 years (range 23</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô96), who underwent THDCP (1/2014</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô2/2015), recording Numeric Rating Scale pain scores, medications, psychiatric history, allergies, and smoking status. Results Of 89 patients, 47 patients had no allergies, and 42 had </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ëÑ1 allergy. Patients with allergies were more likely to have a preexisting psychiatric disorder compared to those without allergies, odds ratio 2.6 (95% CI 1.0</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô6.8). Having allergies did not impact procedural sedation or post-procedural pain scores. Multiple logistic regression with age, gender, smoking, presence of allergies, psychiatric history, inpatient/outpatient status, procedure time, and procedural sedation administration as inputs and post-procedural pain as the outcome showed that the only independent predictor was receiving procedural sedation (p=0.005). Conclusions Findings corroborate anecdotal reports of allergies as a marker for psychiatric history. However, having allergies was not associated with increased pain or need for more sedation. Further studies could prospectively assess whether allergies and psychiatric disorders impact patient/doctor perceptions beyond pain during invasive procedures</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.psym.2017.03.015</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.psym.2017.03.015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Psychosomatics\20170429-AberleD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Psychosomatics\20170429-AberleD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170429, Aberle D</style></custom2><misc3><style face="normal" font="default">10.1016/j.psym.2017.03.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41207</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Trebuchon,F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Therapeutic assessment tools in asthma</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutic alliance</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.02.022</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.022</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-TrebuchonF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-TrebuchonF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170429, Trebuchon F</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.02.022</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41208</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Meininger,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Traitement des allergies graves-á: l</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖadr+®naline dans l</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖurgence</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adrenaline</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Auto-injectors</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Emergency medical service</style></keyword><keyword><style face="normal" font="default"> Emergency Medical Services</style></keyword><keyword><style face="normal" font="default"> Emergency Medicine</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> traitement</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Anaphylaxis is a severe and potentially life-threatening allergic emergency. Food is the main trigger of anaphylaxis in children and young adults. Early epinephrine by intramuscular injection is the recommended first-line therapy. There is a need to improve the recognition and treatment of anaphylaxis. Its management, in emergency medicine, has been the subject of recent guidelines. The on-call physician at emergency medical services dispatch centers should promote rapid access to adrenaline and the early use of epinephrine auto-injectors</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.02.024</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.024</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-MeiningerC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-MeiningerC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170429, Meininger C</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.02.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41209</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jniene,A.</style></author><author><style face="normal" font="default"> El Fassy Fihry,M.T.</style></author><author><style face="normal" font="default"> Mahraoui,C.</style></author><author><style face="normal" font="default"> Benyounes,A.</style></author><author><style face="normal" font="default"> Douagui,H.</style></author><author><style face="normal" font="default"> Tritar,F.</style></author><author><style face="normal" font="default"> Beji,M.</style></author><author><style face="normal" font="default"> El Gueddari,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Diagnostic et prise en charge de l</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖasthme s+®v+¿re dans 3-ápays du Maghreb</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Algeria</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> bronchodilators</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Long-acting bronchodilator</style></keyword><keyword><style face="normal" font="default"> Maghreb</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morocco</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prise en charge</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutics</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Tunisia</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Objective of the Study Severe asthma concerns 5</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô10% of asthma patients who are poorly controlled despite a rigorous and systematic approach and maximum treatment. This population requires phenotypic diagnostic techniques and therapeutics that are difficult to obtain in our countries. The main objective of our work is to describe the diagnosis and management of severe asthma in three Maghreb countries (Morocco, Algeria and Tunisia). Patients and methods Prospective study carried out from 15 September to 15 December 2016 by doctors, who collected the data via a pre-established electronic list, in all asthmatic patients aged over 6 years, regardless of their level of control. Results Twenty-seven doctors participated in the study, which included 333 (42%) patients from Morocco, 291 (36.7%) from Algeria and 169 (21.3%) from Tunisia. A diagnosis of severe asthma was made in 260 (32.8%) patients. In the latter, a preliminary 8-step diagnostic approach was incomplete. Investigation of respiratory function, chest X-ray, total IgE and blood count were performed respectively in 80%, 73.5%, 23.1% and 18.5% of patients. The main therapeutic approach consisted of increasing the therapeutic level in 84.6% of patients given that 45% of these patients were not initially on long-acting bronchodilators (GINA treatment stage 2 maximum). Conclusion This Maghreb study shows that severe asthma appears to be overestimated, with several gaps apparent as regards the diagnosis and management of the disease</style></abstract><notes><style face="normal" font="default">LA - FRECO - Moroco -CO - Algeria -CO - Tunisia -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.01.007</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.01.007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-JnieneA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-JnieneA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170429, Jniene A</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.01.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41210</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Juchet,A.</style></author><author><style face="normal" font="default"> Chabbert-Broue,A.</style></author><author><style face="normal" font="default"> Martin-Blondel,A.</style></author><author><style face="normal" font="default"> Pontcharraud,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">The practical value of cooked food in immunotherapy</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aliments cuits</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cooked food</style></keyword><keyword><style face="normal" font="default"> Cow's milk</style></keyword><keyword><style face="normal" font="default"> Cow's milk allergy</style></keyword><keyword><style face="normal" font="default"> egg</style></keyword><keyword><style face="normal" font="default"> Egg allergy</style></keyword><keyword><style face="normal" font="default"> Eggs</style></keyword><keyword><style face="normal" font="default"> Enfant</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Flour</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Immunotherapy</style></keyword><keyword><style face="normal" font="default"> Ingestion</style></keyword><keyword><style face="normal" font="default"> Lait de vache</style></keyword><keyword><style face="normal" font="default"> Milk</style></keyword><keyword><style face="normal" font="default"> Milk allergy</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral immunotherapy</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Cow's milk and egg food allergies are very common and incapacitating in children and the outcome is not always spontaneously favourable. In the most severe cases, it may be useful to first reintroduce the cooked food mixed with flour. The introduction of cooked food is generally well tolerated: 70-á% of children allergic to milk or eggs can tolerate cooked milk or egg. Regular ingestion of cooked food will accelerate the healing of food allergy and improve the quality of life of the child and his/her family. Cooked food is most often introduced after initial oral immunotherapy in a hospital environment, although this may sometimes be initiated at home in certain forms of non-IgE mediated cow's milk allergy or moderate egg allergy</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.02.002</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-JuchetA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-JuchetA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170429, Juchet A</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.02.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41211</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vigan,M.</style></author><author><style face="normal" font="default"> Castelain,F.</style></author></authors></contributors><titles><title><style face="normal" font="default">What can be done to stem an epidemic of contact allergy?</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Counseling</style></keyword><keyword><style face="normal" font="default"> Epidemic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Media coverage</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Peer counseling network</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> Vigilance</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Epidemics of contact allergy are of environmental origin. They may be overcome by reducing or removing exposure. Public vigilance, industrial surveillance and peer counseling networks must be used since these measures may end epidemics. If they fail, media coverage and consumer or patient associations have proved effective. Economic, political and pragmatic factors are involved</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">http://doi.org/10.1016/j.reval.2017.02.018</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.018</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-ViganM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-ViganM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170429, Vigan M</style></custom2><misc3><style face="normal" font="default">http://doi.org/10.1016/j.reval.2017.02.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41212</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rolland-Debord,C.</style></author><author><style face="normal" font="default"> Morelot-Panzini,C.</style></author><author><style face="normal" font="default"> Similowski,T.</style></author><author><style face="normal" font="default"> Chenivesse,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Interactions neuro-immunologiques-á</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô-áBases cellulaires et mol+®culaires</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Action potential</style></keyword><keyword><style face="normal" font="default"> Central Nervous System</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> inflammatory mediators</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Peripheral nervous system</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.02.149</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.149</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-RollandDebordC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-RollandDebordC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170429, Rolland-Debord C</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.02.149</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41213</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pin,D.</style></author></authors></contributors><titles><title><style face="normal" font="default">IL-31 and pruritus in veterinary dermatology</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Canine</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical signs</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cyclosporine</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> dog</style></keyword><keyword><style face="normal" font="default"> Dogs</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-2</style></keyword><keyword><style face="normal" font="default"> IL-31</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> Prednisolone</style></keyword><keyword><style face="normal" font="default"> Prurit</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Urinalysis</style></keyword><keyword><style face="normal" font="default"> veterinary</style></keyword><keyword><style face="normal" font="default"> Veterinary dermatology</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Canine and human atopic dermatitis share the same signature cytokines including IL-2, -4, -6, -13, and -31, which utilize the JAK-STAT pathway. IL-31, administered intradermally, subcutaneously or intravenously, to dogs, mice or monkeys induces transient pruritus. Oclacitinib (Apoquel; Zoetis) is a novel JAK inhibitor approved for the control or treatment of pruritus associated with allergic dermatitis, particularly atopic dermatitis, in dogs aged at least 12-ámonths. The efficacy and safety of those have been evaluated in several studies versus placebo, and prednisolone or cyclosporine. Oclacitinib provided rapid, effective and safe control of allergic dermatitis, particularly atopic dermatitis, superior to that of a placebo and similar to that provided by prednisolone or cyclosporine. The incidence of abnormal clinical signs was similar for all groups. Haematology, serum chemistry and urinalysis results remained within the normal reference ranges</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.02.023</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.023</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-PinD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-PinD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170429, Pin D</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.02.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41214</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Seneschal,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Atopic dermatitis in infants: A therapeutic emergency? Emollients: From prevention to treatment</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Emollient</style></keyword><keyword><style face="normal" font="default"> Emollients</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.02.003</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-SeneschalJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-SeneschalJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170429, Seneschal J</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.02.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41215</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bourrain,J.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Allergy news - Drug hypersensitivity</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.02.233</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.233</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-BourrainJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-BourrainJL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170429, Bourrain JL</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.02.233</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41216</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aerts,O.</style></author><author><style face="normal" font="default"> Lambert,J.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Isothiazolinone derivatives: Chemical structure and cross-reactivity patterns</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal model</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Benzisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cross Reactions</style></keyword><keyword><style face="normal" font="default"> cross reactivity</style></keyword><keyword><style face="normal" font="default"> Cross-reaction</style></keyword><keyword><style face="normal" font="default"> cross-reactions</style></keyword><keyword><style face="normal" font="default"> Cross-reactivity</style></keyword><keyword><style face="normal" font="default"> Crossreactions</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> methylchloroisothiazolinone</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Octylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">The four most used isothiazolinone derivatives include methylisothiazolinone (MI), methylchloroisothiazolinone (MCI), benzisothiazolinone (BIT) and octylisothiazolinone (OIT). These substances, despite their different sidechains, appear to have a very similar chemical structure. Potential cross-reactivity has been only rarely studied, and the majority of studies are case reports, small case series, or retrospective, observational studies, often with different (sometimes inadequate) patch-test concentrations. This review of potential cross-reactions of isothiazolinone derivatives is based upon expert opinions, epidemiological data, animal models, in vitro studies, clinical observations, and, finally, market surveys of products containing isothiazolinone derivatives</style></abstract><notes><style face="normal" font="default">LA - FRECO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.02.013</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-AertsO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-AertsO.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170429, Aerts O</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.02.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41217</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Crepy,M.N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Recent data on occupational skin allergy</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Epidemic</style></keyword><keyword><style face="normal" font="default"> Epoxy resin</style></keyword><keyword><style face="normal" font="default"> Epoxy Resins</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Gloves</style></keyword><keyword><style face="normal" font="default"> Increased prevalence</style></keyword><keyword><style face="normal" font="default"> Isothiazolinones</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Profession</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin allergy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Our review of the recent literature will focus on the main allergens either emerging or incriminated in occupational contact dermatitis, and on the development of new legislative and preventive measures: new sensitizing epoxy resins, increased prevalence of allergy to (meth)acrylates among beauticians, accelerator-free medical gloves, epidemics of allergy to isothiazolinones, and assessment of occupational metal exposure</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.02.028</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.028</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-CrepyMN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-CrepyMN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170429, Crepy MN</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.02.028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41218</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guez,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Current developments in allergy and internal medicine: Allergy and autoimmunity</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Autoimmunity</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.02.021</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.021</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-GuezS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-GuezS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170429, Guez S</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.02.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41219</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ferrier Le Bouedec,M.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">What do you know about the practice and interpretation of the baseline series?</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Baseline series</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Interpretation</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.02.025</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.reval.2017.02.025</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-FerrierleBouedecMC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170429-FerrierleBouedecMC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170429, Ferrier le Bouedec MC</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.02.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41220</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ferreira,R.D.</style></author><author><style face="normal" font="default"> Viana,F.</style></author><author><style face="normal" font="default"> Duarte,F.C.</style></author><author><style face="normal" font="default"> Barbosa,M.P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Fluorescein hypersensitivity - A case report and review</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="235" start="231">231-235</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Angiography</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Fluorescein</style></keyword><keyword><style face="normal" font="default"> Fluorescein Angiography</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> Intradermal skin tests</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Ophthalmology</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><publisher><style face="normal" font="default">scielopt</style></publisher><isbn><style face="normal" font="default">0871-9721</style></isbn><abstract><style face="normal" font="default">Retinal angiography with sodium fluorescein is a safe diagnostic method with an extremely low mortality rate. However, it is also the most common cause of outpatient emergencies in ophthalmology clinics due to the risk of unpredictable adverse reactions. The prevalence of fluorescein allergy is not known. We present the case of a man with a history of several retinal angiographies. During his last procedure, he developped acute urticaria. Intradermal skin tests were positive on the 1/10 dilution. Most adverse reactions to fluorescein are due to non IgE-mediated mechanisms. Fluorescein allergy can be confirmed by skin testing. Fluorescein angiography presents potentially fatal risks, such as anaphylaxis, which should be rapidly identified and effectively treated</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212015000400004&amp;lng=pt&amp;nrm=iso&amp;tlng=en</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Port Imunoalergol\2015-23-231-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Port Imunoalergol\2015-23-231-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20151010, Ferreira D</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41221</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martins,M.</style></author><author><style face="normal" font="default"> Pereira,N.</style></author><author><style face="normal" font="default"> Reis,R.</style></author><author><style face="normal" font="default"> Tomaz,E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Risk factors for recurrent wheezing after the first hospitalization for bronchiolitis</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="230" start="223">223-230</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Bronchiolitis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> indoor</style></keyword><keyword><style face="normal" font="default"> Interviews</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Oxygen</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Pets</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> race</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> recurrent wheezing</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Siblings</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutics</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><publisher><style face="normal" font="default">scielopt</style></publisher><isbn><style face="normal" font="default">0871-9721</style></isbn><abstract><style face="normal" font="default">Background: Acute bronchiolitis is a frequent pathology in the first months of life. Most of the children with bronchiolitis are treated in outpatient care, but some develop severe respiratory symptoms requiring hospitalization. Risk factors for severity as well as for wheezing recurrence remain poorly understood. The objective of this study was to analyze the relevance of some intrinsic variables of the patient, environmental variables and the severity of the first episode of bronchiolitis requiring hospitalization with the recurrence of wheezing in the following 12 months. Methods: We made a review of clinical files belonging to 79 children under six months of age hospitalized by their first episode of bronchiolitis. The intrinsic variables analyzed were gender, age, race, weight at birth, prematurity and parental atopy. The environmental variables evaluated were breastfeeding, parental smoking, number of siblings and indoor pets. Evaluated as indicators of severity of bronchiolitis were the following hospital data: days of hospitalization, lowest peripheral oxygen saturation, therapeutics, viral etiology, complications and prophylactic treatment initiated and referral to specialist appointments. Data about the twelve months follow-up were collected from clinical files and complemented by interviews with the parents. The role of studied variables on wheezing recurrence was evaluated using the Multiple Regression Analysis. Results: Forty three per cent of children (n=34) repeated 1 to 3 episodes of wheezing and 9% of children (n=7) had recurrent wheezing (> 3 episodes of acute bronchiolitis). Children with atopic parents had higher number of recurrences (63%) than children with non-atopic parents (33%). Conclusions: From variables studied only parental atopy showed significant association with wheezing recurrence (p&lt;0,01).</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212015000400003&amp;lng=pt&amp;nrm=iso&amp;tlng=en</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Port Imunoalergol\2015-23-223-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Port Imunoalergol\2015-23-223-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20151010, Martins M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41222</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pestana,L.</style></author><author><style face="normal" font="default"> Pedro,E.</style></author><author><style face="normal" font="default"> Camara,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Is ice an option? - A clinical case report.</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="185" start="181">181-185</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> bee venom</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Eviction</style></keyword><keyword><style face="normal" font="default"> Hymenoptera</style></keyword><keyword><style face="normal" font="default"> Ice</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> Immunotherapy</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Indications</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic reaction</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> vaccine</style></keyword><keyword><style face="normal" font="default"> venom allergy</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wheal</style></keyword></keywords><dates><year Day="0" Month="0" Year="2015">2015</year></dates><publisher><style face="normal" font="default">scielopt</style></publisher><isbn><style face="normal" font="default">0871-9721</style></isbn><abstract><style face="normal" font="default">Allergen immunotherapy consists in the administration of allergen extracts with the aim of inducing tolerance to allergens responsible for the allergic reactions, as observed in hymenoptera venom allergy. Venom immunotherapy is indicated in patients with insect sting allergy with severe or moderate systemic reactions and IgE-mediated mechanism. The authors present the case of a 40 year-old patient submitted to bee venom immunotherapy with an ultra-rush protocol that developed large local reactions at the vaccine injection site. During the maintenance phase of the vaccine there was gradual worsening of the large local reactions with erythema, edema and wheal. Following clinical and etiologic investigation, cold-induced urticaria was diagnosed and controlled after appropriate treatment and eviction of ice application after vaccine administration. The authors report the case drawing the attention to the indications of venom immunotherapy and that, besides the local and systemic reactions to immunotherapy already known in the literature, there may be less common side effects which may be related to other pathologies not previously diagnosed</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212015000300004&amp;lng=pt&amp;nrm=iso&amp;tlng=en</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Port Imunoalergol\2015-23-181-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Port Imunoalergol\2015-23-181-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20151010, Pestana L</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41223</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pereira dos Santos,M.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Drug hypersensitivity - In vitro diagnosis: An update.</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="97" start="93">93-97</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> Drug provocation test</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Immune-mediated</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> In vitro tests</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><publisher><style face="normal" font="default">scielopt</style></publisher><isbn><style face="normal" font="default">0871-9721</style></isbn><abstract><style face="normal" font="default">Adverse drug reactions (ADR) represent a frequent problem in medical routine. Drug hypersensitivity relies on different pathomecanisms: immune-mediated (drug allergy) and nonimmune-mediated. In both types of reaction in vitro tests are of great interest, due to possible reduction of drug provocation tests that are timing consuming and potentially hazardous. Here we focus in the cellular in vitro tests that can play an important role in the identification of the causative drug</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212016000200005&amp;lng=pt&amp;nrm=iso&amp;tlng=en</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-93-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-93-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161010, Pereira dos Santos MC</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41224</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martins,P.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Drug hypersensitivity - Epidemiological aspects and risk factors</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="109" start="107">107-109</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><publisher><style face="normal" font="default">scielopt</style></publisher><isbn><style face="normal" font="default">0871-9721</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_arttext&amp;pid=S0871-97212016000200007&amp;lng=pt&amp;nrm=iso&amp;tlng=pt</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-107-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-107-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161010, Martins PC</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41225</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Regateiro,F.</style></author><author><style face="normal" font="default"> Faria,E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Immunopathological mechanisms of drug hypersensitivity reactions</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="78" start="62">62-78</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> adaptive</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostics</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Activation</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><publisher><style face="normal" font="default">scielopt</style></publisher><isbn><style face="normal" font="default">0871-9721</style></isbn><abstract><style face="normal" font="default">Immune-mediateddrug hypersensitivity (HS) reactions involve lymphocyte activation and present the hallmark characteristics of adaptive responses: specificity and immunological memory. Lymphocyte activation requires specific recognition of the drug by lymphocyte receptors (signal 1) and co-stimulation (signal 2) by the antigen presenting cell (APC). The type of inflammatory reaction is determined by the cytokine microenvironment during activation (signal 3). The origin of these stimulatory signals in drug HS is controversial. Small drug recognition by lymphocytes occurs by haptenization, pro-haptenization and "p-I concept" mechanisms. Co-stimulatory signals might be induced on the APC by the drug itself or originate from the microenvironment surrounding the APC. Cytokines polarize the effector response of lymphocytes and give rise to different types of HS with distinct clinical manifestations. The recognition of the immunopathological mechanisms involved in the HS reactions is crucial for the diagnostics, treatment and management of patients with drug HS</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212016000200002&amp;lng=pt&amp;nrm=iso&amp;tlng=en</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-62-78.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-62-78.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161010, Regateiro F</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41226</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cadinha,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Drug Hypersensitivity - In vivo diagnosis</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="92" start="87">87-92</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> Drug provocation test</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><publisher><style face="normal" font="default">scielopt</style></publisher><isbn><style face="normal" font="default">0871-9721</style></isbn><abstract><style face="normal" font="default">Hypersensitivity reactions represent about one third of all adverse drug reactions and affect more than 7 % of the general population and therefore represent an important public health problem. Drug allergies are drug hypersensitivity reactions for which a definite immunological mechanism is demonstrated. Misclassification based on the drug hypersensitivity reaction history alone may limit therapeutic options and can lead to the use of more-expensive and potentially less-effective drugs. This review summarizes the available in vivo diagnostic procedures, such as skin biopsy, skin tests and drug provocation test, and evaluates its importance in order to establish a solid drug hypersensitivity diagnosis</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212016000200004&amp;lng=pt&amp;nrm=iso&amp;tlng=en</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-87-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-87-92.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161010, Cadinha S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41227</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Geraldes,L.</style></author><author><style face="normal" font="default"> Alendouro,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Drug Hypersensitivity - Usual and unusual suspects</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="85" start="78">78-85</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acids</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Antiepileptic</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> Beta-lactam antibiotics</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Epidemiological studies</style></keyword><keyword><style face="normal" font="default"> Gadolinium</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Immunological reactions</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> iodinated contrast</style></keyword><keyword><style face="normal" font="default"> iodinated contrast media</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drug</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pharmacovigilance</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Propionic Acids</style></keyword><keyword><style face="normal" font="default"> proton pump inhibitor</style></keyword><keyword><style face="normal" font="default"> Proton pump inhibitors</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Self Report</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Supplements</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> vaccine</style></keyword><keyword><style face="normal" font="default"> Vaccines</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><publisher><style face="normal" font="default">scielopt</style></publisher><isbn><style face="normal" font="default">0871-9721</style></isbn><abstract><style face="normal" font="default">In order to understand hypersensitivity reactions to drugs over years, in different pharmacological classes or populations, an analysis of epidemiological studies on adverse and hypersensitivity reactions to drugs since 1964 until today was made. The information in these studies was collected, mostly, by medical, pharmacovigilance system and self-report questionnaires records. In Portugal there are some studies with data analysis from anaphylaxis notification of the Portuguese Society of Allergology and Clinical Immunology or Portuguese Report of Allergy and Adverse Reactions. We concluded that hypersensitivity to beta-lactam antibiotics and non-steroidal anti-inflammatory drugs like acetylsalicylic acid and propionic acids derivates, have a high prevalence over time and patient age. Less frequent hypersensitivity reactions to anaesthetic drugs, iodinated contrast media, antiepileptic, hormonal substitutes, vitamin supplements and vaccines were reported in the same analysis. Immunological reactions with the use of anti-monoclonal antibodies and chemotherapy drugs are increasingly described. Unusual hypersensitivity reports of reactions to non-beta-lactam antibiotics, corticosteroids, proton pump inhibitors and gadolinium contrast medium were also founded</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212016000200003&amp;lng=pt&amp;nrm=iso&amp;tlng=en</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-78-85.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-78-85.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161010, Geraldes L</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41228</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aun,M.V.</style></author><author><style face="normal" font="default"> Garro,L.S.</style></author><author><style face="normal" font="default"> Ribeiro,M.R.</style></author><author><style face="normal" font="default"> Motta,A.A.</style></author><author><style face="normal" font="default"> Kalil,J.</style></author><author><style face="normal" font="default"> Giavina-Bianchi,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Perioperative anaphylaxis: The brazilian experience</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="106" start="99">99-106</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Latex</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Neuromuscular blocking agent</style></keyword><keyword><style face="normal" font="default"> Neuromuscular Blocking Agents</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Perioperative anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><publisher><style face="normal" font="default">scielopt</style></publisher><isbn><style face="normal" font="default">0871-9721</style></isbn><abstract><style face="normal" font="default">Perioperative anaphylaxis is a rare hypersensitivity reaction, but it has a rapid onset and is potentially fatal. The true incidence is not well known and varies in accordance with the country from 1:1 250 to 1:13 000 surgeries. It may occur through an allergic (IgE-mediated or not) or non-allergic mechanism, but it is believed that the IgE-mediated reactions are the most common and severe. Any product or drug used in the procedure has the potential to be the cause of a reaction, but neuromuscular blocking agents are the most frequently reported, followed by latex and antibiotics. In this mini-review we discuss some key points of the management of these patients and w present Brazilian data, which suggest that an active search for cases by working together with anesthesiologists could lead to an increase in diagnosis and, therefore, better prevention of future reactions</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212016000200006&amp;lng=pt&amp;nrm=iso&amp;tlng=en</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-99-106.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-99-106.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161010, Aun MV</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41229</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,I.H.</style></author><author><style face="normal" font="default"> Kang,G.W.</style></author><author><style face="normal" font="default"> Kim,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Nephrology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, 17-Gil 33, Duryugongwon-ro, Nam-gu, Daegu, 42472, Korea.</style></auth-address><titles><title><style face="normal" font="default">Hypersensitivity pneumonitis associated with azathioprine therapy in a patient with granulomatosis with polyangiitis</style></title><secondary-title><style face="normal" font="default">Rheumatol Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Rheumatol Int</style></abbr-1></periodical><pages end="1032" start="1027">1027-1032</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> administration &amp; dosage</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Alveolitis,Extrinsic Allergic</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Azathioprine</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default"> Bronchoscopy</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> chemically induced</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> Cyclophosphamide</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Differential diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug therapy</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Glomerulonephritis</style></keyword><keyword><style face="normal" font="default"> Granuloma</style></keyword><keyword><style face="normal" font="default"> granulomas</style></keyword><keyword><style face="normal" font="default"> Granulomatosis with Polyangiitis</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity Pneumonitis</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Immunosuppressive Agents</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Kidney</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> lung biopsy</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Remission</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vasculitis</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="default">Granulomatosis with polyangiitis (GPA), an autoimmune disease characterized by inflammatory granulomas and necrotizing small-vessel vasculitis, primarily affects the respiratory tract and kidneys. Azathioprine (AZA) is a purine analog that is commonly used for maintaining GPA remission after induction therapy with cyclophosphamide. While the dose-dependent side effects of AZA are common and well known, hypersensitivity reactions such as pulmonary toxicity are rare. Here, we describe a case involving a 38-year-old man with GPA-associated pauci-immune crescentic glomerulonephritis who developed subacute hypersensitivity pneumonitis (HP) during AZA maintenance therapy. Five months after the initiation of AZA administration (100 mg/day), the patient was admitted with a 7-day history of cough, dyspnea, and fever. High-resolution computed tomography of the chest showed ill-defined centrilobular nodules and diffuse ground-glass opacities in both lung fields. Bronchoscopy with bronchoalveolar lavage was negative for infectious etiologies. A transbronchial lung biopsy specimen revealed poorly formed non-necrotizing granulomas. A chest radiograph obtained at 2 weeks after discontinuation of AZA showed normal findings. The findings from this case suggest that AZA-induced HP should be considered as a differential diagnosis when a patient with GPA exhibits fresh pulmonary lesions accompanied by respiratory symptoms during AZA therapy</style></abstract><notes><style face="normal" font="default">DA - 20160623IS - 1437-160X (Electronic)IS - 0172-8172 (Linking)LA - engPT - Case ReportsPT - Journal ArticleRN - 0 (Immunosuppressive Agents)RN - MRK240IY2L (Azathioprine)SB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1007/s00296-016-3489-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27155976">PM:27155976</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rheumatol Int\2016-24-78-85.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rheumatol Int\2016-24-78-85.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160623, Lee IH</style></custom2><misc3><style face="normal" font="default">10.1007/s00296-016-3489-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41230</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hatsuse,M.</style></author><author><style face="normal" font="default"> Odaira,E.</style></author><author><style face="normal" font="default"> Fuchida,S.I.</style></author><author><style face="normal" font="default"> Okano,A.</style></author><author><style face="normal" font="default"> Murakami,S.</style></author><author><style face="normal" font="default"> Shimazaki,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Hematology, Japan Community Health Care Organization, Kyoto Kuramaguchi Medical Center</style></auth-address><titles><title><style face="normal" font="default">Quincke's edema and hypersensitivity pneumonitis induced by lenalidomide for multiple myeloma</style></title><secondary-title><style face="normal" font="default">Rinsho Ketsueki</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Rinsho Ketsueki</style></abbr-1></periodical><pages end="2506" start="2502">2502-2506</pages><volume><style face="normal" font="default">57</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Alveolitis,Extrinsic Allergic</style></keyword><keyword><style face="normal" font="default"> analogs &amp; derivatives</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> angiogenesis</style></keyword><keyword><style face="normal" font="default"> Angiogenesis Inhibitors</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> chemically induced</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Dexamethasone</style></keyword><keyword><style face="normal" font="default"> Diagnostic Imaging</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Dose escalation</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drug therapy</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Eyelid</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hematology</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity Pneumonitis</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lenalidomide</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multiple Myeloma</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Prednisolone</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Thalidomide</style></keyword><keyword><style face="normal" font="default"> therapeutic use</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">A 64-year-old man with recurrent multiple myeloma (BJP-kappa type) was treated with 15 mg of lenalidomide (LEN) and dexamethasone. He developed Quincke's edema on his eyelid on day 4. Since the edema improved after withdrawal of LEN, the drug was subsequently re-administered at a decreased dose. However, the edema developed again on day 4. After withdrawal of LEN, the drug was administered again with gradually dose escalation, while confirming the absence of eyelid edema. Although edema did not develop, eosinophils and basophils were increased, and the CRP level was elevated. During the third course of LEN administration, his chest CT showed bilateral ground-glass opacity, and LEN-induced hypersensitivity pneumonitis was diagnosed. The pneumonitis resolved after LEN withdrawal and prednisolone administration. These observations suggested that Quincke's edema, eosinophilia and basophilia, CRP elevation, and hypersensitivity pneumonitis might occur due to the immunological effects of LEN, which is classified as an immunomodulatory drug</style></abstract><notes><style face="normal" font="default">DA - 20170116IS - 0485-1439 (Print)IS - 0485-1439 (Linking)LA - engPT - Case ReportsPT - Journal ArticlePT - ReviewRN - 0 (Angiogenesis Inhibitors)RN - 4Z8R6ORS6L (Thalidomide)RN - 9PHQ9Y1OLM (Prednisolone)RN - F0P408N6V4 (lenalidomide)SB - IMCO - Japan -</style></notes><work-type><style face="normal" font="default">10.11406/rinketsu.57.2502</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28090017">PM:28090017</url></web-urls></urls><custom2><style face="normal" font="default">20170116, Hatsuse M</style></custom2><misc3><style face="normal" font="default">10.11406/rinketsu.57.2502</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41231</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zachariassen,L.F.</style></author><author><style face="normal" font="default"> Krych,L.</style></author><author><style face="normal" font="default"> Engkilde,K.</style></author><author><style face="normal" font="default"> Nielsen,D.S.</style></author><author><style face="normal" font="default"> Kot,W.</style></author><author><style face="normal" font="default"> Hansen,C.H.</style></author><author><style face="normal" font="default"> Hansen,A.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default">Sensitivity to oxazolone induced dermatitis is transferable with gut microbiota in mice</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="44385">44385-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Animal</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> Gut microbiota</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> Oxazolone</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> veterinary</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="14" Month="3" Year="2017">2017/3/14</year></dates><abstract><style face="normal" font="default">Atopic Dermatitis (AD) has been associated with gut microbiota (GM) dysbiosis in humans, indicating a causative role of GM in AD etiology. Furthermore, the GM strongly correlates to essential disease parameters in the well-known oxazolone-induced mouse model of AD. Here, we demonstrate that it is possible to transfer both a high-responding and a low-responding AD phenotype with GM from conventional mice to germ-free mice. The mice inoculated with the high-responding GM had significantly higher clinical score, increased ear thickness, and increased levels of IL-1beta, TNFalpha, IL-4, IL-5, and IL-6 compared to the mice inoculated with the low-responding GM. The inter-individual variation was in general not affected by this increase in effect size. Germ-free mice induced with AD revealed a high disease response as well as high inter-individual variation indicating protective properties of certain microbial taxa in this model. This study underlines that the GM has a strong impact on AD in mouse models, and that the power of studies may be increased by the application of mice inoculated with a specific GM from high responders to increase the effect size</style></abstract><notes><style face="normal" font="default">DA - 20170314IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1038/srep44385</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28290517">PM:28290517</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Rep\2017-7-44385.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Rep\2017-7-44385.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170314, Zachariassen LF</style></custom2><misc3><style face="normal" font="default">10.1038/srep44385</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41232</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Huo,Z.</style></author><author><style face="normal" font="default"> Shi,J.</style></author><author><style face="normal" font="default"> Shu,Y.</style></author><author><style face="normal" font="default"> Xiang,M.</style></author><author><style face="normal" font="default"> Lu,J.</style></author><author><style face="normal" font="default"> Wu,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology-Head &amp;Neck Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China</style></auth-address><titles><title><style face="normal" font="default">The relationship between allergic status and adenotonsillar regrowth: a retrospective research on children after adenotonsillectomy</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="46615">46615-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Apnea</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Foxp3</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Obstructive sleep apnea</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Sleep apnea</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> Th2 Cells</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> Tregs</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="18" Month="4" Year="2017">2017/4/18</year></dates><abstract><style face="normal" font="default">Adenotonsillar regrowth in children after adenotonsillectomy (T&amp;A) for obstructive sleep apnea (OSA) is often seen in clinical treatment, however, the relationship between allergic disease and adenotonsillar regrowth remains unclear. In this retrospective study, children were assigned to either the recurrence or control group, and subdivided by age at operation. Among children over 36 months, those in the recurrence group had more allergic disease and higher IgE, IL-4, and IL-5 levels than the same-aged children in control group. The Paediatric Allergic Disease Quality of Life Questionnaire (PADQLQ) scores for nasal symptoms and activity were higher in children older than 36 months in recurrence group. The results of immunohistochemistry and immunofluorescence showed that FoxP3+ cells (Tregs) were less, while GATA3+ cells (Th2 cells) were more in recurrence group for all ages. Allergic status and low levels of FoxP3 were proved as independent risk factors for adenotonsillar regrowth by multivariate logistic regression. These results indicate that allergic disease is a risk factor for adenotonsillar regrowth in children following T&amp;A for OSA, and this risk increases with age. The decreased level of Tregs and subsequent changes in immune function play an important role in the pathogenesis of adenotonsillar regrowth</style></abstract><notes><style face="normal" font="default">DA - 20170418IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1038/srep46615</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28418014">PM:28418014</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Rep\2017-7-46615.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Rep\2017-7-46615.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170418, Huo Z</style></custom2><misc3><style face="normal" font="default">10.1038/srep46615</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41233</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Al Said,A.</style></author><author><style face="normal" font="default"> Cushen,B.</style></author><author><style face="normal" font="default"> Costello,R.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin 9, Ireland</style></auth-address><titles><title><style face="normal" font="default">Targeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money</style></title><secondary-title><style face="normal" font="default">Ther Adv Chronic Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ther Adv Chronic Dis</style></abbr-1></periodical><pages end="45" start="31">31-45</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">2-3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> Asthma therapy</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Cost-effectiveness</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Endotypes</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> Ireland</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="default"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Targeted treatment</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">The asthma syndrome has many manifestations, termed phenotypes, that arise by specific cellular and molecular mechanisms, termed endotypes. Understanding an individual's asthma phenotype helps clinicians make rational therapeutic decisions while the understanding of endotypes has led to the development of specific precision medications. Allergic asthma is an example of an asthma phenotype and omalizumab, a monoclonal antibody that neutralizes serum immunoglobulin (Ig)E, is a specific targeted treatment which was developed as a result of an understanding of the endotype of allergic asthma. Omalizumab has been widely used in clinical practice in Europe for over a decade as an add-on therapy to treat patients who have severe refractory allergic asthma. Over this period, many centres have reported their experience with omalizumab as an add-on therapy in patients with severe asthma. These 'real world' clinical effectiveness studies have confirmed the benefits, cost-effectiveness and clinical utility of this medication. Combining the outcomes of both sources of research has yielded important insights that may benefit patients with severe asthma, clinicians who treat them, as well as the funding agencies that reimburse the cost of this medication. The purpose of this review is to describe how to identify and evaluate a patient with asthma for whom treatment with omalizumab may be of clinical and cost-effective benefit. The assessment and investigations used to confirm allergic asthma, the objective assessment of adherence to asthma therapy and the expected benefits of add-on omalizumab treatment are described</style></abstract><notes><style face="normal" font="default">DA - 20170328IS - 2040-6223 (Print)IS - 2040-6223 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Ireland -</style></notes><work-type><style face="normal" font="default">10.1177/2040622317690494</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28348726">PM:28348726</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ther Adv Chronic Dis\2017-8-31-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ther Adv Chronic Dis\2017-8-31-45.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170328, Al Said A</style></custom2><misc3><style face="normal" font="default">10.1177/2040622317690494</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41234</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Asturiol,D.</style></author><author><style face="normal" font="default"> Casati,S.</style></author><author><style face="normal" font="default"> Worth,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Joint Research Centre, Via Enrico Fermi 2749, Ispra 21027, VA, Italy.</style></auth-address><titles><title><style face="normal" font="default">Consensus of classification trees for skin sensitisation hazard prediction</style></title><secondary-title><style face="normal" font="default">Toxicol In Vitro</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Toxicol In Vitro</style></full-title></periodical><pages end="209" start="197">197-209</pages><volume><style face="normal" font="default">36</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Animal</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Computer Simulation</style></keyword><keyword><style face="normal" font="default"> Consensus</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> European Union</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Haptens</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Models,Biological</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Sensitisation</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Software</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> Trees</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">Since March 2013, it is no longer possible to market in the European Union (EU) cosmetics containing new ingredients tested on animals. Although several in silico alternatives are available and achievements have been made in the development and regulatory adoption of skin sensitisation non-animal tests, there is not yet a generally accepted approach for skin sensitisation assessment that would fully substitute the need for animal testing. The aim of this work was to build a defined approach (i.e. a predictive model based on readouts from various information sources that uses a fixed procedure for generating a prediction) for skin sensitisation hazard prediction (sensitiser/non-sensitiser) using Local Lymph Node Assay (LLNA) results as reference classifications. To derive the model, we built a dataset with high quality data from in chemico (DPRA) and in vitro (KeratinoSens and h-CLAT) methods, and it was complemented with predictions from several software packages. The modelling exercise showed that skin sensitisation hazard was better predicted by classification trees based on in silico predictions. The defined approach consists of a consensus of two classification trees that are based on descriptors that account for protein reactivity and structural features. The model showed an accuracy of 0.93, sensitivity of 0.98, and specificity of 0.85 for 269 chemicals. In addition, the defined approach provides a measure of confidence associated to the prediction</style></abstract><notes><style face="normal" font="default">DA - 20160904IS - 1879-3177 (Electronic)IS - 0887-2333 (Linking)LA - engPT - Journal ArticleRN - 0 (Haptens)SB - IMCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.tiv.2016.07.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27458072">PM:27458072</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicol In Vitro\2016-36-197-209.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicol In Vitro\2016-36-197-209.xls</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicol In Vitro\2016-36-197-209.pdf</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicol In Vitro\2016-36-197-209.xls</url></image-urls></urls><custom2><style face="normal" font="default">20160904, Asturiol D</style></custom2><misc3><style face="normal" font="default">10.1016/j.tiv.2016.07.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41235</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Toropova,A.P.</style></author><author><style face="normal" font="default"> Toropov,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">IRCCS, Istituto di Ricerche Farmacologiche Mario Negri, 20156, Via La Masa 19, Milano, Italy.</style></auth-address><titles><title><style face="normal" font="default">Hybrid optimal descriptors as a tool to predict skin sensitization in accordance to OECD principles</style></title><secondary-title><style face="normal" font="default">Toxicol Lett</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Toxicol Lett</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Calibration</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Interpretation</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Molecular Structure</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Predictive models</style></keyword><keyword><style face="normal" font="default"> QSAR</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Quantitative Structure-Activity Relationship</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> Software</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Structure activity relationship</style></keyword><keyword><style face="normal" font="default"> Structure-Activity Relationship</style></keyword><keyword><style face="normal" font="default"> structure-activity relationships</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword></keywords><dates><year Day="27" Month="3" Year="2017">2017/3/27</year></dates><abstract><style face="normal" font="default">Skin sensitization (allergic contact dermatitis) is a widespread problem arising from the contact of chemicals with the skin. The detection of molecular features with undesired effect for skin is complex task owing to unclear biochemical mechanisms and unclearness of conditions of action of chemicals to skin. The development of computational methods for estimation of this endpoint in order to reduce animal testing is recommended (Cosmetics Directive EC regulation 1907/2006; EU Regulation, Regulation, 1223/2009). The CORAL software (http://www.insilico.eu/coral) gives good predictive models for the skin sensitization. Simplified molecular input-line entry system (SMILES) together with molecular graph are used to represent the molecular structure for these models. So-called hybrid optimal descriptors are used to establish quantitative structure-activity relationships (QSARs). The aim of this study is the estimation of the predictive potential of the hybrid descriptors. Three different distributions into the training ( approximately 70%), calibration ( approximately 15%), and validation ( approximately 15%) sets are studied. QSAR for these three distributions are built up with using the Monte Carlo technique. The statistical characteristics of these models for external validation set are used as a measure of predictive potential of these models. The best model, according to the above criterion, is characterized by nvalidation=29, r2validation=0.8596, RMSEvalidation=0.489. Mechanistic interpretation and domain of applicability for these models are defined</style></abstract><notes><style face="normal" font="default">DA - 20170331IS - 1879-3169 (Electronic)IS - 0378-4274 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.toxlet.2017.03.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28359801">PM:28359801</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicol Lett\20170331-ToropovaAP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicol Lett\20170331-ToropovaAP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170331, Toropova AP</style></custom2><misc3><style face="normal" font="default">10.1016/j.toxlet.2017.03.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41236</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Magnoni,M.S.</style></author><author><style face="normal" font="default"> Latorre,M.</style></author><author><style face="normal" font="default"> Bettoncelli,G.</style></author><author><style face="normal" font="default"> Sanchez-Herrero,M.G.</style></author><author><style face="normal" font="default"> Lopez,A.</style></author><author><style face="normal" font="default"> Calvo,E.</style></author><author><style face="normal" font="default"> Rizzi,A.</style></author><author><style face="normal" font="default"> Caminati,M.</style></author><author><style face="normal" font="default"> Senna,G.</style></author><author><style face="normal" font="default"> Paggiaro,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical and Scientific Department, GlaxoSmithKline, Via A. Fleming 2, 37135 Verona, Italy</style></auth-address><titles><title><style face="normal" font="default">Asthma control in primary care: the results of an observational cross-sectional study in Italy and Spain</style></title><secondary-title><style face="normal" font="default">World Allergy Organ J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">World Allergy Organ J</style></abbr-1></periodical><pages end="" start="13">13-</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> ACT Score</style></keyword><keyword><style face="normal" font="default"> adherence</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drug therapy</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> General practitioner</style></keyword><keyword><style face="normal" font="default"> General practitioners</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> office</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> smokers</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Poor asthma control observed in several surveys may be related to a lack of systematic assessment by physicians and/or to patient underestimation of symptoms. Along this line, the purpose of this study was to investigate the level of asthma control in patients attending the GP office for different reasons, either for renewal of drug prescription or for worsening of asthma symptoms. METHODS: Each of the 145 General Practitioners (GP) in Italy and Spain selected at least eight asthmatic patients attending their office for a renewal of drug prescription (Group A) or for worsening of asthma symptoms (Group B), between May and December 2009. Asthma Control Test (ACT) and other clinical information (including SF-12 questionnaire) were collected. RESULTS: Data from 1375 patients with moderate-severe asthma were analysed (mean age: 47.2 years; female: 59%; smokers or ex-smokers: 35.4%); 57% were on treatment with ICS-LABA combination. ACT score &lt; 20 (uncontrolled asthma) was observed in 77.8% Group B patients, as expected, but also in 28.6% Group A patients. Uncontrolled patients reported their asthma being well or fairly well controlled in 68.4% of cases. Risk factors for uncontrolled asthma were older age, asthma severity, and smoking habit. In uncontrolled patients, GPs changed or increased the level of therapy in 75.8% and initiated asthma treatment in 61.3% of cases, in association with educational intervention, closer monitoring or pulmonologist consultations. DISCUSSION: The systematic use of ACT in asthmatics attending GP's clinic may detect high rates of uncontrolled patients who underestimate their clinical conditions, particularly those asking solely for asthma medication renewal. Poor adherence to daily drug therapy was reported in more than 40% of patients and could be an important contributor of uncontrolled asthma. CONCLUSIONS: The results highlight the importance of routine longitudinal assessment of asthma patients in primary care and point to the need for an increased attention to asthma management by GPs</style></abstract><notes><style face="normal" font="default">DA - 20170417IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1186/s40413-017-0144-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28413571">PM:28413571</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\World Allergy Organ J\2017-10-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\World Allergy Organ J\2017-10-13.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170417, Magnoni MS</style></custom2><misc3><style face="normal" font="default">10.1186/s40413-017-0144-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41237</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">D'Amato,G.</style></author><author><style face="normal" font="default"> Vitale,C.</style></author><author><style face="normal" font="default"> Rosario,N.</style></author><author><style face="normal" font="default"> Neto,H.J.</style></author><author><style face="normal" font="default"> Chong-Silva,D.C.</style></author><author><style face="normal" font="default"> Mendonca,F.</style></author><author><style face="normal" font="default"> Perini,J.</style></author><author><style face="normal" font="default"> Landgraf,L.</style></author><author><style face="normal" font="default"> Sole,D.</style></author><author><style face="normal" font="default"> Sanchez-Borges,M.</style></author><author><style face="normal" font="default"> Ansotegui,I.</style></author><author><style face="normal" font="default"> D'Amato,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">grid.413172.2Division of Respiratory and Allergic Diseases, Department of Respiratory Diseases, High Specialty Hospital A. Cardarelli, Napoli, Italy</style></auth-address><titles><title><style face="normal" font="default">Climate change, allergy and asthma, and the role of tropical forests</style></title><secondary-title><style face="normal" font="default">World Allergy Organ J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">World Allergy Organ J</style></abbr-1></periodical><pages end="" start="11">11-</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> Agriculture</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Atmosphere</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Dioxide</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Climate</style></keyword><keyword><style face="normal" font="default"> Climate change</style></keyword><keyword><style face="normal" font="default"> Colombia</style></keyword><keyword><style face="normal" font="default"> Degradation</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Ecuador</style></keyword><keyword><style face="normal" font="default"> Fires</style></keyword><keyword><style face="normal" font="default"> Gases</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Heat</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Peru</style></keyword><keyword><style face="normal" font="default"> Plant</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Precipitation</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Respiration</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Respiratory diseases</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rest</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> South America</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Temperature</style></keyword><keyword><style face="normal" font="default"> trends</style></keyword><keyword><style face="normal" font="default"> Venezuela</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Tropical forests cover less than 10 per cent of all land area (1.8 x 107 km2) and over half of the tropical-forest area (1.1 x 107 Km2) is represented by humid tropical forests (also called tropical rainforests). The Amazon basin contains the largest rainforest on Earth, almost 5.8 million km2, and occupies about 40% of South America; more than 60% of the basin is located in Brazil and the rest in Bolivia, Colombia, Ecuador, French Guiana, Guyana, Peru, Suriname and Venezuela. Over the past decade the positive role of tropical rainforests in capturing large amounts of atmospheric carbon dioxide (CO2) has been demonstrated. In response to the increase in atmospheric CO2 concentration, tropical forests act as a global carbon sink. MAIN BODY: Accumulation of carbon in the tropical terrestrial biosphere strongly contributes to slowing the rate of increase of CO2 into the atmosphere, thus resulting in the reduction of greenhouse gas effect. Tropical rainforests have been estimated to account for 32-36% of terrestrial Net Primary Productivity (NPP) that is the difference between total forest photosynthesis and plant respiration. Tropical rainforests have been acting as a strong carbon sink in this way for decades. However, over the past years, increased concentrations of greenhouse gases, and especially CO2, in the atmosphere have significantly affected the net carbon balance of tropical rainforests, and have warmed the planet substantially driving climate changes through more severe and prolonged heat waves, variability in temperature, increased air pollution, forest fires, droughts, and floods. The role of tropical forests in mitigating climate change is therefore critical. Over the past 30 years almost 600,000 km2 have been deforested in Brazil alone due to the rapid development of Amazonia, this is the reason why currently the region is one of the 'hotspots' of global environmental change on the planet. CONCLUSION: Deforestation represents the second largest anthropogenic source of CO2 to the atmosphere, after fossil fuel combustion. There are many causes of deforestation, including socioeconomic and natural factors, such as clear-cutting for agriculture, ranching and development, unsustainable logging for timber, as well as droughts, fires and degradation due to climate change. About natural causes of forest degradation, in the context of the Amazon, the major agent of change in the forest ecosystem would most likely be decreased dry-season precipitation. Of the 23 global climate models employed by the Intergovernmental Panel on Climate Change (IPCC) in their 2007 report, 50-70% predict a substantial (above 20%) reduction of dry-season rainfall in eastern Amazonia under mid-range greenhouse gas emissions scenarios, 40% in central Amazonia and 20% in the west. While annual carbon emissions from fossil-fuel combustion have been continually increasing since 1960s, historical trends of deforestation and associated carbon emissions have remained poorly understood</style></abstract><notes><style face="normal" font="default">DA - 20170313IS - 1939-4551 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -CO - Brazil -CO - Venezuela -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1186/s40413-017-0142-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28286602">PM:28286602</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\World Allergy Organ J\2017-10-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\World Allergy Organ J\2017-10-11.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170313, D'Amato G</style></custom2><misc3><style face="normal" font="default">10.1186/s40413-017-0142-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41238</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sato,H.</style></author><author><style face="normal" font="default"> Nakajima,N.</style></author><author><style face="normal" font="default"> Takahashi,K.</style></author><author><style face="normal" font="default"> Hasegawa,G.</style></author><author><style face="normal" font="default"> Mizuno,K.I.</style></author><author><style face="normal" font="default"> Hashimoto,S.</style></author><author><style face="normal" font="default"> Ikarashi,S.</style></author><author><style face="normal" font="default"> Hayashi,K.</style></author><author><style face="normal" font="default"> Honda,Y.</style></author><author><style face="normal" font="default"> Yokoyama,J.</style></author><author><style face="normal" font="default"> Sato,Y.</style></author><author><style face="normal" font="default"> Terai,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">University Medical and Dental Hospital, Niigata 951-8520, Japan</style></auth-address><titles><title><style face="normal" font="default">Proposed criteria to differentiate heterogeneous eosinophilic gastrointestinal disorders of the esophagus, including eosinophilic esophageal myositis</style></title><secondary-title><style face="normal" font="default">World J Gastroenterol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">World J Gastroenterol</style></full-title></periodical><pages end="2423" start="2414">2414-2423</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">13</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Biopsy</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endoscopy</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> epithelia</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelium</style></keyword><keyword><style face="normal" font="default"> Esophagitis</style></keyword><keyword><style face="normal" font="default"> Esophagus</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> Histology</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Manometry</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> Myositis</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> sIgE</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="7" Month="4" Year="2017">2017/4/7</year></dates><abstract><style face="normal" font="default">AIM: To define clinical criteria to differentiate eosinophilic gastrointestinal disorder (EoGD) in the esophagus. METHODS: Our criteria were defined based on the analyses of the clinical presentation of eosinophilic esophagitis (EoE), subepithelial eosinophilic esophagitis (sEoE) and eosinophilic esophageal myositis (EoEM), identified by endoscopy, manometry and serum immunoglobulin E levels (s-IgE), in combination with histological and polymerase chain reaction analyses on esophageal tissue samples. RESULTS: In five patients with EoE, endoscopy revealed longitudinal furrows and white plaques in all, and fixed rings in two. In one patient with sEoE and four with EoEM, endoscopy showed luminal compression only. Using manometry, failed peristalsis was observed in patients with EoE and sEoE with some variation, while EoEM was associated with hypercontractile or hypertensive peristalsis, with elevated s-IgE. Histology revealed the following eosinophils per high-power field values. EoE = 41.4 +/- 7.9 in the epithelium and 2.3 +/- 1.5 in the subepithelium; sEoE = 3 in the epithelium and 35 in the subepithelium (conventional biopsy); EoEM = none in the epithelium, 10.7 +/- 11.7 in the subepithelium (conventional biopsy or endoscopic mucosal resection) and 46.8 +/- 16.5 in the muscularis propria (peroral esophageal muscle biopsy). Presence of dilated epithelial intercellular space and downward papillae elongation were specific to EoE. Eotaxin-3, IL-5 and IL-13 were overexpressed in EoE. CONCLUSION: Based on clinical and histological data, we identified criteria, which differentiated between EoE, sEoE and EoEM, and reflected a different pathogenesis between these esophageal EoGDs</style></abstract><notes><style face="normal" font="default">DA - 20170421IS - 2219-2840 (Electronic)IS - 1007-9327 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.3748/wjg.v23.i13.2414</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28428721">PM:28428721</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\World J Gastroenterol\2017-23-2414-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\World J Gastroenterol\2017-23-2414-23.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170421, Sato H</style></custom2><misc3><style face="normal" font="default">10.3748/wjg.v23.i13.2414</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41239</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Maxey-Jones,C.L.</style></author><author><style face="normal" font="default"> Palmerton,A.</style></author><author><style face="normal" font="default"> Farmer,J.R.</style></author><author><style face="normal" font="default"> Bateman,B.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Department of Anesthesiology, University of Cincinnati, Cincinnati, Ohio; Departments of daggerAnesthesia, Critical Care, and Pain Medicine, and double daggerAllergy and Immunology, Massachusetts General Hospital, Boston, Massachusetts</style></auth-address><titles><title><style face="normal" font="default">Difficult Airway Management Resulting From Local Anesthetic Allergy During Emergent Cesarean Delivery: A Case Report</style></title><secondary-title><style face="normal" font="default">A A Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">A A Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Airway Management</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anesthesiology</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Ohio</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="26" Month="4" Year="2017">2017/4/26</year></dates><abstract><style face="normal" font="default">Difficult airway management in the gravid patient is a well-described phenomenon. We present a case of emergent cesarean delivery complicated by a "cannot intubate, cannot ventilate" scenario that was later determined to be secondary to an allergic, IgE-mediated reaction to epidurally administered local anesthetic</style></abstract><notes><style face="normal" font="default">DA - 20170427IS - 2325-7237 (Electronic)IS - 2325-7237 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1213/XAA.0000000000000533</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28448320">PM:28448320</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\A A Case Rep\20170427-MaxeyJonesCL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\A A Case Rep\20170427-MaxeyJonesCL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170427, Maxey-Jones CL</style></custom2><misc3><style face="normal" font="default">10.1213/XAA.0000000000000533</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41240</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Boras,V.V.</style></author><author><style face="normal" font="default"> Zidovec-Lepej,S.</style></author><author><style face="normal" font="default"> Marinovic,B.</style></author><author><style face="normal" font="default"> Seiwerth,S.</style></author><author><style face="normal" font="default"> Skrinjar,I.</style></author><author><style face="normal" font="default"> Pulanic,D.</style></author><author><style face="normal" font="default"> Juras,D.V.</style></author></authors></contributors><titles><title><style face="normal" font="default">DRUG-INDUCED ORAL ULCERATIONS: CASE REPORT</style></title><secondary-title><style face="normal" font="default">Acta Clin Croat</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Acta Clin Croat</style></abbr-1></periodical><pages end="337" start="334">334-337</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Allopurinol</style></keyword><keyword><style face="normal" font="default"> Aspergillosis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Candidiasis</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Chlorambucil</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Croatia</style></keyword><keyword><style face="normal" font="default"> Cryptococcosis</style></keyword><keyword><style face="normal" font="default"> Cytomegalovirus</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Differential diagnosis</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug-induced</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Gastritis</style></keyword><keyword><style face="normal" font="default"> Gingiva</style></keyword><keyword><style face="normal" font="default"> herpes</style></keyword><keyword><style face="normal" font="default"> Herpes Simplex</style></keyword><keyword><style face="normal" font="default"> Histoplasmosis</style></keyword><keyword><style face="normal" font="default"> Hyperplasia</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Kidney</style></keyword><keyword><style face="normal" font="default"> Leukemia</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Pemphigus</style></keyword><keyword><style face="normal" font="default"> Pneumonia</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Renal Insufficiency</style></keyword><keyword><style face="normal" font="default"> Respiratory Insufficiency</style></keyword><keyword><style face="normal" font="default"> Sepsis</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Ulcer</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viruses</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="default">A 70-year-old patient was admitted to the Department of Oral Medicine for multiple oral ulcerations on the left buccal mucosa, around 0.5 cm in diameter, as well as on the gingiva. Otherwise, the patient suffered from chronic lymphocytic leukemia, hypogammaglobulinemia, chronic renal insufficiency, with complete afunction of the right kidney, asthma, hypertension, gastritis and prostate hyperplasia. Differential diagnosis of oral ulcerations included drug induced oral ulcerations, paraneoplastic pemphigus, viral ulcerations (cytomegalovirus, herpes simplex viruses), fungal ulcerations (candidiasis, aspergillosis, histoplasmosis, cryptococcosis) and bacterial ulcerations, as well as neutropenic ulcers. One of the possible explanations was that the lesions were due to the use of drugs, the more so as oral lesions evolved when the doses of allopurinol and chlorambucil were increased, and subsided when the doses of both drugs were decreased. However, we could not establish for sure whether the lesions were due to allopurinol or chlorambucil. According to literature data, allopurinol is one of the most frequent drugs known to induce skin adverse reactions, therefore we assumed that it was the culprit drug. Unfortunately, several weeks later the patient died from sepsis, pneumonia with respiratory insufficiency and multiorgan failure</style></abstract><notes><style face="normal" font="default">DA - 20170410IS - 0353-9466 (Print)IS - 0353-9466 (Linking)LA - engPT - Journal ArticleCO - Croatia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28394553">PM:28394553</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Acta Clin Croat\2016-55-334-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Acta Clin Croat\2016-55-334-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170410, Boras VV</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41241</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hedman,L.</style></author><author><style face="normal" font="default"> Stridsman,C.</style></author><author><style face="normal" font="default"> Andersson,M.</style></author><author><style face="normal" font="default"> Backman,H.</style></author><author><style face="normal" font="default"> Jansson,S.A.</style></author><author><style face="normal" font="default"> Ronmark,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Public Health and Clinical Medicine, Occupational and Environmental Medicine, The OLIN Unit, Umea University, Umea, Sweden</style></auth-address><titles><title><style face="normal" font="default">Population-based study shows that teenage girls with asthma had impaired health-related quality of life</style></title><secondary-title><style face="normal" font="default">Acta Paediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Acta Paediatr</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical Medicine</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Schoolchildren</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="27" Month="3" Year="2017">2017/3/27</year></dates><abstract><style face="normal" font="default">AIM: This study examined the health-related quality of life (HRQoL) of teenagers with and without asthma, including the impact of their sex, allergic conditions, smoking, living conditions and physical activity. METHODS: The Obstructive Lung Disease in Northern Sweden (OLIN) studies recruited a cohort of schoolchildren in 2006. The parents of all children aged 7-8 years in three municipalities were invited to complete a questionnaire and 2,585 (96%) participated. The cohort was followed up at the ages of 11-12 years and 14-15 years with high participation rates. At 14-15 years, the HRQoL questionnaire KIDSCREEN-10 and Asthma Control Test were added. RESULTS: Girls with current asthma at 14-15 years had a lower mean HRQoL score than girls without asthma (46.4 versus 49.3, p&lt;0.001), but this was not seen among boys (53.8 versus 52.8, p=0.373). Poor HRQoL was related to current asthma, uncontrolled asthma and teenage onset of asthma. It was also related to eczema, living in a single parent household, maternal smoking, daily smoking and inversely related to physical activity. CONCLUSION: Teenage girls with asthma had lower HRQoL than girls without asthma. Possible interventions to improve HRQoL among teenagers with asthma were identified: increasing asthma control, preventing smoking and promoting physical activity. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170327IS - 1651-2227 (Electronic)IS - 0803-5253 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/apa.13847</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28345180">PM:28345180</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Acta Paediatr\20170327-HedmanL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Acta Paediatr\20170327-HedmanL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170327, Hedman L</style></custom2><misc3><style face="normal" font="default">10.1111/apa.13847</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41242</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hernandez-Ostiz,S.</style></author><author><style face="normal" font="default"> Prieto-Torres,L.</style></author><author><style face="normal" font="default"> Xirotagaros,G.</style></author><author><style face="normal" font="default"> Noguera-Morel,L.</style></author><author><style face="normal" font="default"> Hernandez-Martin,A.</style></author><author><style face="normal" font="default"> Torrelo,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Servicio de Dermatologia, Hospital Nino Jesus. Madrid, Espana</style></auth-address><titles><title><style face="normal" font="default">Autoinflammatory Diseases in Pediatric Dermatology-Part 1: Urticaria-like Syndromes, Pustular Syndromes, and Mucocutaneous Ulceration Syndromes</style></title><secondary-title><style face="normal" font="default">Actas Dermosifiliogr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Actas Dermosifiliogr</style></full-title></periodical><pages end="619" start="609">609-619</pages><volume><style face="normal" font="default">108</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Autoinflammatory disease</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic mutations</style></keyword><keyword><style face="normal" font="default"> Hereditary periodic fever</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="23" Month="4" Year="2017">2017/4/23</year></dates><abstract><style face="normal" font="default">Monogenic autoinflammatory diseases are a heterogeneous emergent group of conditions that are currently under intensive study. We review the etiopathogenesis of these syndromes and their principal manifestations. Our aim is to propose a classification system based on the clinicopathologic features of typical skin lesions for routine clinical use in dermatology. Our focus is on diagnosis in pediatric practice given that this is the period when the signs and symptoms of these syndromes first appear. In Part 1 we discuss the course of urticaria-like syndromes, which include cryopyrin-associated periodic conditions and hereditary periodic fever syndromes. Pustular syndromes are also covered in this part. Finally, we review the range of therapies available as well as the genetic mutations associated with these autoinflammatory diseases</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 1578-2190 (Electronic)IS - 0001-7310 (Linking)LA - engLA - spaPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.ad.2016.12.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28442130">PM:28442130</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Actas Dermosifiliogr\2017-108-609-19.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Actas Dermosifiliogr\2017-108-609-19.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Hernandez-Ostiz S</style></custom2><misc3><style face="normal" font="default">10.1016/j.ad.2016.12.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41243</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kocwin,M.</style></author><author><style face="normal" font="default"> Jonakowski,M.</style></author><author><style face="normal" font="default"> Przemecka,M.</style></author><author><style face="normal" font="default"> Panek,M.</style></author><author><style face="normal" font="default"> Kuna,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz.</style></auth-address><titles><title><style face="normal" font="default">Selected bone morphogenetic proteins - the possibility of their use in the diagnostics and therapy of severe asthma</style></title><secondary-title><style face="normal" font="default">Adv Respir Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Adv Respir Med</style></abbr-1></periodical><pages end="115" start="109">109-115</pages><volume><style face="normal" font="default">85</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bronchi</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Degradation</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostics</style></keyword><keyword><style face="normal" font="default"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Remodelling</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Transforming Growth Factor beta</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Asthma is a chronic heterogeneous illness of the lower airway with an inflammatory basis, developing from hyperresponsiveness and bronchial obstruction. One of the more unfavourable processes occurring in the airway are the long-term changes of the respiratory tract known as remodelling, resulting in complete irreversible obstruction. Bone morphogenetic protein (BMP) is a member of the Transforming Growth Factor beta (TGF-b) superfamily, which regulates processes in embryonic and post-embryonic development. The role played by BMP is regulation of degradation and remodelling of the extracellular matrix, which is one of the elements involved in the reconstruction of the structure of the bronchi in severe asthma. This paper presents the antagonistic properties of BMP against TGF-b, anti-inflammatory and counteracting fibrosis in the respiratory tract. The current state of knowledge indicates that this group of cytokines are potential new markers of remodelling in severe asthma, and further studies on their therapeutic value are necessary</style></abstract><notes><style face="normal" font="default">DA - 20170425IS - 2451-4934 (Print)LA - engCO - Poland -PT - Journal Article</style></notes><work-type><style face="normal" font="default">10.5603/ARM.2017.0017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28440536">PM:28440536</url></web-urls></urls><custom2><style face="normal" font="default">20170425, Kocwin M</style></custom2><misc3><style face="normal" font="default">10.5603/ARM.2017.0017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41244</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Klak,A.</style></author><author><style face="normal" font="default"> Raciborski,F.</style></author><author><style face="normal" font="default"> Samolinski,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Poland.</style></auth-address><titles><title><style face="normal" font="default">Searching online for health-related information by people suffering from respiratory allergy and asthma: the results of a survey study</style></title><secondary-title><style face="normal" font="default">Adv Respir Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Adv Respir Med</style></abbr-1></periodical><pages end="96" start="87">87-96</pages><volume><style face="normal" font="default">85</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Internet</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Respiratory allergies</style></keyword><keyword><style face="normal" font="default"> Respiratory allergy</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">INTRODUCTION: The objective of the study was to compare online behaviour in groups of persons suffering from respiratory allergy and/or asthma and in the reference group. MATERIAL AND METHODS: Comparative analysis of two independent questionnaire studies. Study A was carried out in the Masovian Voivodeship, Poland in 2013. As many as 1,728 questionnaires were collected and 51 respondents were selected for analysis (study A, reference group). Study B was carried out in 2014 in a group of 59 patients of the outpatient allergy clinic. RESULTS: More than 92% of the general population (study A) declared that they used the Internet to search for health-related information, health protection, while in the group of patients (study B) the same was declared by 97%. Both studies showed that more than 74% of respondents looked for online information on a specific disease (p &amp;gt; 0.05). Information on how other persons cope with similar health issues was searched by 20% (study A) and 33% (study B) of respondents. Advice on different methods of treatment of a given disease was sought by 40% and 51% of respondents, respectively. Nearly 51% of respondents in study A and 56% of subjects in study B searched online for health information when they did not feel well or were sick. CONCLUSIONS: Both in the group of chronically ill persons and in the reference group, it is common to search online for health- -related information. Persons suffering from respiratory allergy and/or asthma verified the physician's diagnosis on the Internet much more often than did the reference group</style></abstract><notes><style face="normal" font="default">DA - 20170425IS - 2451-4934 (Print)LA - engPT - Journal ArticleCO - POland -</style></notes><work-type><style face="normal" font="default">10.5603/ARM.2017.0015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28440534">PM:28440534</url></web-urls></urls><custom2><style face="normal" font="default">20170425, Klak A</style></custom2><misc3><style face="normal" font="default">10.5603/ARM.2017.0015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41245</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ding,B.</style></author><author><style face="normal" font="default"> Small,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">AstraZeneca Gothenburg, Molndal, Sweden. Adelphi Real World, Bollington, UK</style></auth-address><titles><title><style face="normal" font="default">Disease Burden of Mild Asthma: Findings from a Cross-Sectional Real-World Survey</style></title><secondary-title><style face="normal" font="default">Adv Ther</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Adv Ther</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medication adherence</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Theophylline</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> treatment adherence</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="8" Month="4" Year="2017">2017/4/8</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Most asthma patients have mild disease, although the burden of mild asthma is not well understood nor studied. Some evidence suggests that many patients with mild asthma experience suboptimal symptom control and exacerbations. This study characterizes the burden of illness and treatment patterns among patients with a confirmed diagnosis of mild asthma, defined as GINA Step 1 or Step 2, and residing in China, France, Germany, Italy, Japan, Spain, the United Kingdom, or the United States. METHODS: The Respiratory Disease-Specific Programme prospective cross-sectional survey was conducted with primary care and specialty physicians in each of the eight countries. Physician and patient surveys assessed demographic and clinical characteristics, frequency and timing of asthma symptoms, exacerbations, and rescue inhaler usage, the most recent FEV1% predicted, and healthcare utilization. GINA Step was determined by prescribed treatment regimen. GINA Step 1 patients were prescribed as-needed reliever medication and Step 2 required treatment with a low-dose inhaled corticosteroid, leukotriene receptor antagonist, or theophylline. Treatment adherence was assessed with the Morisky Medication Adherence scale, disease control with the Asthma Control Test, and work and activity impairments with the Work Productivity and Activity Impairment scale. RESULTS: The sample included 1115 GINA Step 1 and 2 patients, with 53% classified as Step 2. Overall asthma control was suboptimal, with reports of nocturnal symptoms (40.6%), symptom worsening (10.5%), and rescue inhaler usage in the last 4 weeks (33.6%). 25% of patients were uncontrolled. The overall mean number of exacerbations in the last 12 months was 0.4, with a higher frequency of exacerbations in Step 2 patients who also experienced more exacerbations requiring treatment intensification, an emergency department visit, or hospitalization. CONCLUSION: Mild asthma imposes a substantial burden on patients, establishing the need for comprehensive management plans and ongoing support for treatment adherence. FUNDING: AstraZeneca</style></abstract><notes><style face="normal" font="default">DA - 20170409IS - 1865-8652 (Electronic)IS - 0741-238X (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1007/s12325-017-0520-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28391549">PM:28391549</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Adv Ther\20170409-DingB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Adv Ther\20170409-DingB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170409, Ding B</style></custom2><misc3><style face="normal" font="default">10.1007/s12325-017-0520-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41246</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Castro-Rodriguez,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric Pulmonology, Division of Pediatrics, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile.</style></auth-address><titles><title><style face="normal" font="default">What are the real effects of the Mediterranean diet on recurrent colds and their complications?</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Chile</style></keyword><keyword><style face="normal" font="default"> Cold</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> school</style></keyword></keywords><dates><year Day="22" Month="4" Year="2017">2017/4/22</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - EditorialCO - Chile -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.02.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28442171">PM:28442171</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170426-CastroRodriguezJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170426-CastroRodriguezJA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Castro-Rodriguez JA</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.02.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41247</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sharapova,S.O.</style></author><author><style face="normal" font="default"> Pashchenko,O.E.</style></author><author><style face="normal" font="default"> Guryanova,I.E.</style></author><author><style face="normal" font="default"> Migas,A.A.</style></author><author><style face="normal" font="default"> Kondratenko,I.V.</style></author><author><style face="normal" font="default"> Aleinikova,O.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Department, Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Minsk Region, Belarus.</style></auth-address><titles><title><style face="normal" font="default">Recent thymic emigrants, T regulatory cells, and BAFF level in children with X-linked agammaglobulinaemia in association with chronic respiratory disease</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">association</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Bacterial Infections</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Hematology</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> regulatory T cell</style></keyword><keyword><style face="normal" font="default"> regulatory T cells</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Russia</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> T regulatory cell</style></keyword><keyword><style face="normal" font="default"> T regulatory cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> Tregs</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="3" Month="5" Year="2017">2017/5/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: X-linked agammaglobulinaemia (XLA) is a genetic disorder affecting B cell maturation, which is characterised by a low number of B cells, agammaglobulinaemia and increased susceptibility to a variety of bacterial infections. This study was performed to assess T cell subpopulations in a group of children with XLA in association with chronic respiratory disease (CRD). METHODS: Numbers of T cell subpopulations (CD3+, CD4+, CD8+, CD3+DR+, naive, memory, recent thymic emigrants (RTE), regulatory T cells, follicular T helpers) were measured by eight-colour flow cytometry in 22 XLA patients and 50 controls. BAFF level was measured by ELISA. RESULTS: XLA patients with CRD had a significantly lower percentage of RTE numbers and Tregs, while significantly higher absolute counts of lymphocytes, CD3+, CD8+, CD3+DR+ and CD4+CD45RO+ T cells were detected as compared with healthy controls. In patients with XLA without CRD, the number of follicular T helper cells was altered significantly (percentage and absolute), as compared with healthy controls. Additionally, they had significantly higher counts (percentage and absolute) of CD4+CD45RA+ cells and lower percentage of CD4+CD45RO+ cells in comparison with healthy controls. CONCLUSIONS: Our study affords new information concerning CRD and T cell subsets that differentiate or are maintained in the absence of B cells in children with XLA. T cell's homeostasis depends on the presence of chronic respiratory disease that may be caused by the delay in diagnosis</style></abstract><notes><style face="normal" font="default">DA - 20170507IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Belarus -CO - Russia -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.01.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477853">PM:28477853</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170507-SharapovaSO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170507-SharapovaSO.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170507, Sharapova SO</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.01.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41248</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tokunaga,T.</style></author><author><style face="normal" font="default"> Ninomiya,T.</style></author><author><style face="normal" font="default"> Kato,Y.</style></author><author><style face="normal" font="default"> Imoto,Y.</style></author><author><style face="normal" font="default"> Sakashita,M.</style></author><author><style face="normal" font="default"> Takabayashi,T.</style></author><author><style face="normal" font="default"> Noguchi,E.</style></author><author><style face="normal" font="default"> Fujieda,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Otorhinolaryngology - Head &amp; Neck Surgery, Department of Sensory and Locomotor Medicine, Faculty of Medical Science, University of Fukui, Fukui, Japan</style></auth-address><titles><title><style face="normal" font="default">The significant expression of TRPV3 in nasal polyps of eosinophilic chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> endoscopic sinus surgery</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> epithelia</style></keyword><keyword><style face="normal" font="default"> Epithelium</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microarray</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> sinus</style></keyword><keyword><style face="normal" font="default"> Staining</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="24" Month="4" Year="2017">2017/4/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: The number of patients with eosinophilic chronic rhinosinusitis (ECRS) has been increasing in recent years in Japan. In ECRS, nasal polyps recur immediately after endoscopic sinus surgery. The molecular biological mechanism underlying the refractoriness of ECRS is unclear. METHODS: Whole-transcriptome analysis with next-generation sequencing (RNA-seq) was conducted to investigate the molecular biological mechanism of ECRS. Real-time PCR, immunohistochemical staining, and immunofluorescence staining were performed to validate the results of RNA-seq. RESULTS: RNA-seq analysis revealed that in the nasal polyps of ECRS, the levels of 3 transcripts were elevated significantly and those of 7 transcripts were diminished significantly. Among the genes encoding these transcripts, TRPV3 (transient receptor potential cation channel, subfamily V, member 3) was identified as the only gene that is highly expressed in ECRS nasal polyps but this gene's expression was not previously detected using DNA microarray analysis in peripheral blood eosinophils. TRPV3 is newly identified here as a gene transcribed in ECRS. Our analysis also revealed that TRPV3 was highly expressed in the infiltrating eosinophils and mucosal epithelium of the nasal polyps of ECRS, and further that the more severe the refractoriness was after surgery, the higher the TRPV3 expression was in nasal polyps. CONCLUSIONS: TRPV3 might play a role in the refractoriness of ECRS. Additional studies are required to evaluate the function of TRPV3 in ECRS</style></abstract><notes><style face="normal" font="default">DA - 20170502IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.04.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28462829">PM:28462829</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170502-TokunagaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170502-TokunagaT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170502, Tokunaga T</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.04.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41249</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Honda,D.</style></author><author><style face="normal" font="default"> Ohsawa,I.</style></author><author><style face="normal" font="default"> Sato,N.</style></author><author><style face="normal" font="default"> Inoshita,H.</style></author><author><style face="normal" font="default"> Mano,S.</style></author><author><style face="normal" font="default"> Tomino,Y.</style></author><author><style face="normal" font="default"> Suzuki,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">Diminished capacity of opsonization and immune complex solubilization, and detection of anti-C1q antibodies in sera from patients with hereditary angioedema</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">abnormalities</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> C1 esterase inhibitor</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Complement</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Elimination</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immune complexes</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Jurkat Cells</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Peroxidase</style></keyword><keyword><style face="normal" font="default"> Phagocytosis</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hereditary angioedema (HAE) is an autosomal dominant disease caused by deficiency of C1 esterase inhibitor. Symptoms of HAE include edema, which can potentially cause suffocation. Some patients with HAE exhibit immunological abnormalities, which could prevent an accurate diagnosis. Low levels of complement components are characteristic of HAE and in other settings are thought to reduce elimination of apoptotic cells and immune complex (IC). Thus, we aimed to experimentally clarify the mechanism of immunological abnormalities using sera from HAE patients. METHODS: Serum samples from 18 patients with HAE were collected when free from angioedema attack and compared with normal human pooled sera (NHPS) from 20 healthy volunteers. Opsonization was measured as the rate of phagocytosis of apoptotic Jurkat cells by macrophages differentiated from THP-1 cells incubated with serum. IC solubilization in serum was analyzed by quantifying peroxidase released from a synthetic IC composed of peroxidase and anti-peroxidase antibodies. Anti-C1q antibody levels were detected using an enzyme-linked immunosorbent assay. RESULTS: Serological immunological abnormalities were detected in 12 patients. Opsonization in serum samples from each patient with HAE was lower than that in NHPS ( approximately 20% versus 70%, respectively). The rate of IC solubilization was lower in serum from HAE patients than NHPS. Some patients had high serum anti-C1q antibody levels with increased serum IC levels. CONCLUSIONS: Sera from patients with HAE exhibit anti-C1q antibodies, with a lower capacity for opsonization and IC solubilization. This may be associated with immunological abnormalities and should be investigated further to facilitate accurate diagnosis of HAE</style></abstract><notes><style face="normal" font="default">DA - 20170423IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.03.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28433622">PM:28433622</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170423-HondaD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170423-HondaD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170423, Honda D</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.03.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41250</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Xue,J.M.</style></author><author><style face="normal" font="default"> Yang,L.T.</style></author><author><style face="normal" font="default"> Yang,G.</style></author><author><style face="normal" font="default"> Geng,X.R.</style></author><author><style face="normal" font="default"> Liu,Z.Q.</style></author><author><style face="normal" font="default"> Wang,S.</style></author><author><style face="normal" font="default"> Zhao,H.L.</style></author><author><style face="normal" font="default"> Liu,Z.G.</style></author><author><style face="normal" font="default"> Zhao,C.Q.</style></author><author><style face="normal" font="default"> Yang,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology, Head &amp; Neck Surgery, the Second Hospital, Shanxi Medical University, Taiyuan, China</style></auth-address><titles><title><style face="normal" font="default">Protease-activated receptor-2 suppresses interleukin (IL)-10 expression in B cells via up regulating Bcl2L12 in patients with allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Liposomes</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Otolaryngology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> suppression</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="4" Year="2017">2017/4/20</year></dates><abstract><style face="normal" font="default">BACKGROUND AND AIMS: The function of interleukin (IL)-10 producing B cells (B10 cell) is compromised in patients with allergic diseases. Protease-activated receptor (PAR)-2 has immune regulatory functions. This study aims to elucidate the role of PAR2 in the suppression of IL-10 expression in peripheral B cells. METHODS: Peripheral blood B cells were collected from patients with allergic rhinitis (AR). A correlation between the expression of Bcl2 like protein 12 (Bcl2L12) and IL-10 in the B cells was analyzed. An AR mouse model was developed. RESULTS: We observed that the expression of IL-10 was lower in the peripheral B cells from patients with airway allergy. A negative correlation was identified between the expression of IL-10 and PAR2 in B cells. Activation of PAR2 of B cells increased the expression of Bcl2L12 and suppression of LPS-induced IL-10 expression, which was abolished by knocking down the Bcl2L12 gene. Treating B cells from AR patients with Bcl2L12-shRNA carrying liposomes reversed the capability of IL-10 expression and the immune suppressor function. Administration of Bcl2L12 shRNA-carrying liposomes attenuated experimental AR in mice. CONCLUSIONS: Activation of PAR2 inhibits the expression of IL-10 in B cells, which can be reversed by treating B cells with Bcl2L12 shRNA-carrying liposomes. The data suggest that regulation of Bcl2L12 may be a novel approach in the treatment of AR. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170420IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1111/all.13186</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28426164">PM:28426164</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170420-XueJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170420-XueJM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170420, Xue JM</style></custom2><misc3><style face="normal" font="default">10.1111/all.13186</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41251</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Boligan,K.F.</style></author><author><style face="normal" font="default"> von Gunten,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Pharmacology, University of Bern, Bern, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Innate lymphoid cells in asthma: cannabinoids on the balance</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="841" start="839">839-841</pages><volume><style face="normal" font="default">72</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate lymphoid cells</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170222IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - EditorialCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1111/all.13145</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28226397">PM:28226397</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\2017-72-839-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\2017-72-839-41.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170222, Boligan KF</style></custom2><misc3><style face="normal" font="default">10.1111/all.13145</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41252</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kristensen,T.</style></author><author><style face="normal" font="default"> Vestergaard,H.</style></author><author><style face="normal" font="default"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="default"> Mortz,C.G.</style></author><author><style face="normal" font="default"> Kjaer,H.F.</style></author><author><style face="normal" font="default"> Ollert,M.</style></author><author><style face="normal" font="default"> Moller,M.B.</style></author><author><style face="normal" font="default"> Broesby-Olsen,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pathology, Odense University Hospital, Odense, Denmark</style></auth-address><titles><title><style face="normal" font="default">Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Bone Marrow</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> False negative</style></keyword><keyword><style face="normal" font="default"> Hymenoptera</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> KIT</style></keyword><keyword><style face="normal" font="default"> Mastocytosis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Serum tryptase</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic mastocytosis</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="22" Month="4" Year="2017">2017/4/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: Sensitive KIT D816V mutation analysis of blood has been proposed to guide bone marrow (BM) investigation in suspected systemic mastocytosis (SM). The aim of this prospective study was for the first time to compare the D816V-status of the "screening blood sample" used to guide BM biopsy in suspected SM to the outcome of the subsequent BM investigation. METHODS: 58 adult patients with suspected SM were included. The outcome of sensitive KIT D816V-analysis of blood was compared to the result of the BM investigation. RESULTS: Screening blood samples from 44 of 58 patients tested D816V-positive. In 43 of these, SM was subsequently diagnosed in the BM investigation. One patient with a D816V-positive screening sample was diagnosed with monoclonal MC activation syndrome. Screening blood samples from 14 patients tested D816V-negative. SM was subsequently diagnosed in five of these, whereas nine patients did not fulfil any diagnostic SM criteria (excluding tryptase-criterion). Of the 48 SM patients, 90% tested D816V-positive. Thirteen SM patients presented with hymenoptera venom-induced anaphylaxis, no skin lesions and baseline serum-tryptase &lt;/=20 ng/mL. Of these, 92% tested D816V-positive in the screening blood sample. CONCLUSION: This prospective study demonstrates that a D816V-positive result in a screening blood sample identifies SM among patients with hymenoptera venom-induced anaphylaxis in whom the diagnosis would most probably have been missed, with potential severe implications. The observed false negative screening results also underline that BM investigation is mandatory in all adult patients with clear signs of, or highly suspected SM, regardless of the KIT mutation status. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170422IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/all.13187</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28432683">PM:28432683</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170422-KristensenT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170422-KristensenT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170422, Kristensen T</style></custom2><misc3><style face="normal" font="default">10.1111/all.13187</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41253</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ketelaar,M.E.</style></author><author><style face="normal" font="default"> van de Kant,K.D.G.</style></author><author><style face="normal" font="default"> Dijk,F.N.</style></author><author><style face="normal" font="default"> Klaassen,E.M.M.</style></author><author><style face="normal" font="default"> Grotenboer,N.</style></author><author><style face="normal" font="default"> Nawijn,M.C.</style></author><author><style face="normal" font="default"> Dompeling,E.</style></author><author><style face="normal" font="default"> Koppelman,G.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">University Medical Center Groningen, University of Groningen, Pediatric Pulmonology and Pediatric Allergology, Beatrix Children's Hospital, Groningen Research Institute for Asthma and COPD (GRIAC), Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Predictive value of serum sST2 in preschool wheezers for development of asthma with high FeNO</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Modeling</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> paediatric asthma</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="default">Wheezing is common in childhood. However, current prediction models of paediatric asthma have only modest accuracy. Novel biomarkers and definition of subphenotypes may improve asthma prediction. Interleukin-1-receptor-Like-1 is a well-replicated asthma-gene and associates with eosinophilia. We investigated whether serum sST2 predicts asthma and asthma with elevated exhaled NO (FeNO), compared to the commonly used Asthma Prediction Index (API). Using logistic regression modeling, we found that serum sST2 levels in 2-3y old wheezers do not predict doctors' diagnosed asthma at age 6y. Instead sST2 predicts a subphenotype of asthma characterized by increased levels of FeNO, a marker for eosinophilic airway inflammation. Herein, sST2 improved the predictive value of the API (AUC=0.70, 95CI 0.56-0.84), but had also significant predictive value on its own (AUC=0.65, 95CI 0.52-0.79). Our study indicates that sST2 in preschool wheezers has predictive value for the development of eosinophilic airway inflammation in asthmatic children at school age. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170425IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/all.13193</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28440062">PM:28440062</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170425-KetelaarME.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170425-KetelaarME.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170425, Ketelaar ME</style></custom2><misc3><style face="normal" font="default">10.1111/all.13193</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41254</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stalder,J.F.</style></author><author><style face="normal" font="default"> Aubert,H.</style></author><author><style face="normal" font="default"> Anthoine,E.</style></author><author><style face="normal" font="default"> Moret,L.</style></author><author><style face="normal" font="default"> Barbarot,S.</style></author><author><style face="normal" font="default"> Futamura,M.</style></author><author><style face="normal" font="default"> Marcoux,D.</style></author><author><style face="normal" font="default"> Morren,M.A.</style></author><author><style face="normal" font="default"> Trzeciak,M.</style></author><author><style face="normal" font="default"> Szalai,Z.</style></author><author><style face="normal" font="default"> Veres,K.</style></author><author><style face="normal" font="default"> Deleuran,M.</style></author><author><style face="normal" font="default"> Vestergaard,C.</style></author><author><style face="normal" font="default"> Boralevi,F.</style></author><author><style face="normal" font="default"> Chu,C.Y.</style></author><author><style face="normal" font="default"> De Raeve,L.</style></author><author><style face="normal" font="default"> Svensson,A.</style></author><author><style face="normal" font="default"> Folster-Holst,R.</style></author><author><style face="normal" font="default"> Buchner,M.</style></author><author><style face="normal" font="default"> Takaoka,R.</style></author><author><style face="normal" font="default"> Aoki,V.</style></author><author><style face="normal" font="default"> Chernyshov,P.</style></author><author><style face="normal" font="default"> Chernyshova,L.</style></author><author><style face="normal" font="default"> Murrell,D.F.</style></author><author><style face="normal" font="default"> Zhao,C.</style></author><author><style face="normal" font="default"> Mckinster,C.D.</style></author><author><style face="normal" font="default"> Von Kobyletzky,L.</style></author><author><style face="normal" font="default"> Eichenfield,L.</style></author><author><style face="normal" font="default"> Totri,C.</style></author><author><style face="normal" font="default"> Lio,P.</style></author><author><style face="normal" font="default"> Seneschal,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Nantes University Hospital, Nantes, France</style></auth-address><titles><title><style face="normal" font="default">Topical corticosteroid phobia in atopic dermatitis: international feasibility study of the TOPICOP score</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fear</style></keyword><keyword><style face="normal" font="default"> Feasibility Studies</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Hungary</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Language</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mexico</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Patient Education</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Taiwan</style></keyword><keyword><style face="normal" font="default"> Topical corticosteroids</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="default">BACKGROUND: Adherence to topical corticosteroids (TCS) is essential for the effective treatment of atopic dermatitis but can be limited by concerns about their use. This study examined the feasibility of applying the validated TOPICOP score for assessing TCS phobia across different countries. METHODS: This was a prospective multicenter feasibility study conducted in 21 hospitals in 17 countries. Patients >3 months of age with atopic dermatitis or their parents or legal representatives completed a validated translation of the TOPICOP questionnaire in the country's native language. Respondents also completed questionnaires collecting opinions about the feasibility and acceptability of the TOPICOP questionnaire. RESULTS: 1564 participants in 15 countries were included in the analysis. 81% of respondents considered the questions clear or very clear and 79% reported that it took less than 5 min to complete. Each of the individual items in the TOPICOP questionnaire was considered to be not at all difficult to answer by 49% to 74% of participants. The mean global TOPICOP score was 44.7% +/- 20.5. Mean TOPICOP subscores were 37.0 +/- 22.8% for knowledge and beliefs, 54.7 +/- 27.8% for fears, and 50.1 +/- 29.1% for behaviours. Global scores and subscores differed between countries, although the subscores did not always vary in parallel, suggesting different levels of TCS phobia and different drivers for each country. CONCLUSIONS: The TOPICOP score can be feasibly applied across countries and may therefore be useful for obtaining qualitative and quantitative data from international studies and for adapting patient education and treatment. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170425IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - France -CO - Poland -CO - Hungary -CO - Japan -CO - Canada -CO - Belgium -CO - Denmark -CO - Taiwan -CO - Sweden -CO - Germany -CO - Brazil -CO - Ukraine -CO - United States -CO - Australia -CO - Mexico -</style></notes><work-type><style face="normal" font="default">10.1111/all.13189</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28439896">PM:28439896</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170425-StalderJF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170425-StalderJF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170425, Stalder JF</style></custom2><misc3><style face="normal" font="default">10.1111/all.13189</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41255</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brooks,C.R.</style></author><author><style face="normal" font="default"> van Dalen,C.J.</style></author><author><style face="normal" font="default"> Hermans,I.F.</style></author><author><style face="normal" font="default"> Gibson,P.G.</style></author><author><style face="normal" font="default"> Simpson,J.L.</style></author><author><style face="normal" font="default"> Douwes,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Public Health Research, Massey University, Wellington Campus, Wellington, New Zealand</style></auth-address><titles><title><style face="normal" font="default">Sputum basophils are increased in eosinophilic asthma compared with non-eosinophilic asthma phenotypes</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic asthma</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> New Zealand</style></keyword><keyword><style face="normal" font="default"> Non-eosinophilic</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> sputum eosinophil</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="4" Year="2017">2017/4/20</year></dates><abstract><style face="normal" font="default">Sputum basophil numbers are increased in allergic asthmatics, but it is unclear what role airway basophils play in "TH2-low" asthma phenotypes. Using flow cytometry we found that basophils were significantly increased in all asthmatics (n=26) compared with healthy controls (n=8) (p=0.007) with highest levels observed in eosinophilic asthma (EA; median 0.22%, IQR 0.11-0.47%; n=14) compared with non-EA (0.06%, 0.00-0.20%; n=12; p&lt;0.05). In asthmatics, basophils were positively correlated with sputum eosinophils (r=0.54; p&lt;0.005), and inversely with sputum neutrophils (r=-0.46: p&lt;0.05), but not with FEV1 (% predicted), FEV1 /FVC, or bronchodilator reversibility. In a subgroup initially identified as inadequately controlled asthma (n=7), there was a trend (p=0.08) towards a reduction in sputum basophils following increased ICS treatment. Our findings suggest that basophils may be particularly important in eosinophilic asthma, and that sputum basophil assessment could be a useful additional indicator of 'TH2-high' asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170420IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - New Zealand -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/all.13185</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28426171">PM:28426171</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170420-BrooksCR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170420-BrooksCR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170420, Brooks CR</style></custom2><misc3><style face="normal" font="default">10.1111/all.13185</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41256</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Conde-Fernandes,I.</style></author><author><style face="normal" font="default"> Sampaio,R.</style></author><author><style face="normal" font="default"> Moreno,F.</style></author><author><style face="normal" font="default"> Palla-Garcia,J.</style></author><author><style face="normal" font="default"> Teixeira,M.D.A.</style></author><author><style face="normal" font="default"> Freitas,I.</style></author><author><style face="normal" font="default"> Neves,E.</style></author><author><style face="normal" font="default"> Jara-Acevedo,M.</style></author><author><style face="normal" font="default"> Escribano,L.</style></author><author><style face="normal" font="default"> Lima,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Consulta Multidisciplinar de Linfomas Cutaneos e Mastocitoses (CMLC), Hospital de Santo Antonio (HSA), Centro Hospitalar do Porto (CHP), Porto, Portugal</style></auth-address><titles><title><style face="normal" font="default">Systemic mastocytosis with KIT V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcome</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Clin Immunol</style></full-title></periodical><pages end="" start="21">21-</pages><volume><style face="normal" font="default">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Bone Marrow</style></keyword><keyword><style face="normal" font="default"> Bone Marrow Cells</style></keyword><keyword><style face="normal" font="default"> CD63</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> Codon</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Flushing</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Histopathology</style></keyword><keyword><style face="normal" font="default"> HSA</style></keyword><keyword><style face="normal" font="default"> Hypotension</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> KIT</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mastocytosis</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Rare Diseases</style></keyword><keyword><style face="normal" font="default"> Remission</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum tryptase</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syncope</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic mastocytosis</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Mastocytosis are rare diseases characterized by an accumulation of clonal mast cells (MCs) in one or multiple organs or tissues. Patients with systemic mastocytosis (SM), whose MCs frequently arbor the activating D816V KIT mutation, may have indolent to aggressive diseases, and they may experience MC mediator related symptoms. Indolent SM with recurrent anaphylaxis or vascular collapse in the absence of skin lesions, ISMs(-), is a specific subtype indolent SM (ISM), and this clonal MC activation disorder represents a significant fraction of all MC activation syndromes. The V560G KIT mutation is extremely rare in patients with SM and its biological and prognostic impact remains unknown. CASE PRESENTATION: A 15-year old boy was referred to our hospital because of repeated episodes of flushing, hypotension and syncope since the age of 3-years, preceded by skin lesions compatible with mastocytosis on histopathology that had disappeared in the late-early childhood. Diagnosis of ISM, more precisely the ISMs(-) variant, was confirmed based on the clinical manifestations together with increased baseline serum tryptase levels and the presence of morphologically atypical, mature appearing (CD117+high, FcepsilonRI+) phenotypically aberrant (CD2+, CD25+) MCs, expressing activation-associated markers (CD63, CD69), in the bone marrow. Molecular genetic studies revealed the presence of the KIT V560G mutation in bone marrow MCs, but not in other bone marrow cells, whereas the screening for mutations in codon 816 of KIT was negative. The patient was treated with oral disodium cromoglycate and the disease had a favorable outcome after an eleven-year follow-up period, during which progressively lower serum tryptase levels together with the fully disappearance of all clinical manifestations was observed. CONCLUSIONS: To the best of our knowledge this first report of a patient with ISM, whose bone marrow MCs carry the KIT V560G activating mutation, manifesting as recurrent spontaneous episodes of flushing and vascular collapse in the absence of skin lesions at the time of diagnosis, in whom disodium cromoglycate had led to long term clinical remission</style></abstract><notes><style face="normal" font="default">DA - 20170425IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Portugal -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1186/s13223-017-0193-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28439288">PM:28439288</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-21.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170425, Conde-Fernandes I</style></custom2><misc3><style face="normal" font="default">10.1186/s13223-017-0193-x</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41257</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rhee,H.</style></author><author><style face="normal" font="default"> Belyea,M.</style></author><author><style face="normal" font="default"> Mammen,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Rochester, School of Nursing, 601 Elmwood Avenue, Box SON, Rochester, NY 14642 USA</style></auth-address><titles><title><style face="normal" font="default">Visual analogue scale (VAS) as a monitoring tool for daily changes in asthma symptoms in adolescents: a prospective study</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Clin Immunol</style></full-title></periodical><pages end="" start="24">24-</pages><volume><style face="normal" font="default">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Modeling</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Nursing</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> Symptom Assessment</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> VAS</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Success in asthma management hinges on patients' competency to detect and respond to ever-changing symptom severity. Thus, it is crucial to have reliable, simple, and sustainable methods of symptom monitoring that can be readily incorporated into daily life. Although visual analogue scale (VAS) has been considered as a simple symptom assessment method, its utility as a daily symptom monitoring tool in adolescents is unknown. This study was to determine the concurrent validity of VAS in capturing diurnal changes in symptoms and to examine the relationships between VAS and asthma control and pulmonary function. METHODS: Forty-two adolescents (12-17 years old) with asthma completed daily assessment of symptoms twice per day, morning and bedtime, for a week using VAS and 6-item symptom diary concurrently. Asthma control was measured at enrollment and 6 month later, and spirometry was conducted at enrollment. Pearson correlations, multilevel modeling and regression were conducted to assess the relationships between VAS and symptom diary, asthma control and FEV1. RESULTS: Morning and evening VAS was positively associated with symptom diary items of each corresponding time frame of the day (r = 0.41-0.58, p &lt; 0.0001). Morning VAS was significantly predicted by morning diary data reflecting nocturnal wakening (beta = 2.13, p = 0.033) and morning symptoms (beta = 4.09, p = 0.002), accounting for 57% of the total variance of morning VAS. Similarly, changes in four evening diary items, particularly shortness of breath (beta = 2.60, p = 0.028), significantly predicted changes in evening VAS, accounting for 55% of the total variance. Average VAS scores correlated with asthma control (r = 0.65, p &lt; 0.001) and FEV1 (r = -0.38, p = 0.029), and were predictive of asthma control 6 months later (beta = 0.085, p = 0.006). CONCLUSIONS: VAS is a valid tool capturing diurnal changes in symptoms reflected in a multi-item symptom diary. Moreover, VAS is a valid measure predicting concurrent and future asthma control. The findings suggest VAS can be a simple alternative to daily dairies for daily symptom monitoring, which can provide invaluable information about current and future asthma control without substantially increasing self-monitoring burdens for adolescent patients. Clinical Trial Registration NCT01696357. Registered 18 September 2012</style></abstract><notes><style face="normal" font="default">DA - 20170503IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1186/s13223-017-0196-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28465694">PM:28465694</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-24.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170503, Rhee H</style></custom2><misc3><style face="normal" font="default">10.1186/s13223-017-0196-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41258</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Saito,S.</style></author><author><style face="normal" font="default"> Aoki,A.</style></author><author><style face="normal" font="default"> Arai,I.</style></author><author><style face="normal" font="default"> Takaishi,S.</style></author><author><style face="normal" font="default"> Ito,H.</style></author><author><style face="normal" font="default"> Akiyama,N.</style></author><author><style face="normal" font="default"> Kiyonari,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Molecular Immunology, Research Center for Medical Science, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461 Japan</style></auth-address><titles><title><style face="normal" font="default">Regulation of Th2 responses by different cell types expressing the interleukin-31 receptor</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Clin Immunol</style></full-title></periodical><pages end="" start="23">23-</pages><volume><style face="normal" font="default">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Cell Proliferation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgG1</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-31</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> major allergen</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Monocyte</style></keyword><keyword><style face="normal" font="default"> Monocytes</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pollen</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> Th2 Cells</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> Th2 response</style></keyword><keyword><style face="normal" font="default"> Th2 responses</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Interleukin-31 (IL-31) is a recently identified cytokine produced by Th2 cells that is involved in the development of atopic dermatitis-induced skin inflammation and pruritus. Its receptor, IL-31RA, is expressed by a number of cell types, including epithelial cells, eosinophils, and activated monocytes and macrophages. To date, however, the regulation of Th2 responses by distinct cell types and tissues expressing IL-31RA has not been well studied. METHODS: In this study, Cry j 2, one of the major allergens of Japanese cedar pollen, was administered to IL-31RA-deficient or wild-type (WT) mice via nasal or intraperitoneal injection for induction of specific Th2 responses. RESULTS: After nasal administration of Cry j 2, IL-31RA-deficient mice showed lower Cry j 2-specific CD4+ T cell proliferation, Th2 cytokine (IL-5 and IL-13) production, and Th2-mediated (IgE, IgG1, and IgG2b) antibody responses than WT mice. In contrast, IL-31RA-deficient mice administered Cry j 2 intraperitoneally showed stronger Th2 immune responses than WT mice. CONCLUSIONS: These results indicate that IL-31R signaling positively regulates Th2 responses induced by nasal administration of Cry j 2, but negatively regulates these responses when Cry j 2 is administered intraperitoneally. Collectively, these data indicate that the induction of antigen-specific Th2 immune responses might depend on tissue-specific cell types expressing IL-31RA</style></abstract><notes><style face="normal" font="default">DA - 20170421IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1186/s13223-017-0194-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28428802">PM:28428802</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-23.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170421, Saito S</style></custom2><misc3><style face="normal" font="default">10.1186/s13223-017-0194-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41259</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,L.H.</style></author><author><style face="normal" font="default"> Chang,H.</style></author><author><style face="normal" font="default"> Namgoong,S.</style></author><author><style face="normal" font="default"> Kim,J.O.</style></author><author><style face="normal" font="default"> Cheong,H.S.</style></author><author><style face="normal" font="default"> Lee,S.G.</style></author><author><style face="normal" font="default"> Park,J.S.</style></author><author><style face="normal" font="default"> Baek,A.R.</style></author><author><style face="normal" font="default"> Koo,S.M.</style></author><author><style face="normal" font="default"> Choi,I.S.</style></author><author><style face="normal" font="default"> Kim,M.K.</style></author><author><style face="normal" font="default"> Park,H.S.</style></author><author><style face="normal" font="default"> Park,C.S.</style></author><author><style face="normal" font="default"> Shin,H.D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Genetic variants of the gasdermin B gene associated with the development of aspirin-exacerbated respiratory diseases</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="12" start="4">4-12</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AERD</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> haplotype</style></keyword><keyword><style face="normal" font="default"> Ingestion</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Respiratory diseases</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is characterized by a severe and sudden asthma attack after aspirin ingestion in patients with asthma. We studied associations with six common single nucleotide polymorphisms (SNP) of the gasdermin B gene (GSDMB). OBJECTIVE: DNA obtained from 572 patients with asthma (with AERD, n = 165; and with aspirin-tolerant asthma, n = 407) and 391 normal controls was subjected to genotyping of six SNPs of GSDMB. METHODS: An association analysis between GSDMB variants and AERD, with a fall rate of the forced expiratory volume in the first second of expiration (FEV1), was performed by using logistic and regression models. RESULTS: Two SNPs in the intron (rs870830, rs7216389) showed significant associations with AERD (minimum p = 7.00 x 10-4 in the dominant model), even after Bonferroni correction (pcorr = 0.01 for the rs870830). Regression analysis of the genetic variants with FEV1 revealed significant associations with rs870830 and the haplotype 2 (pcorr = 4.71 x 10-4 for rs870830 and pcorr = 1.14 x 10-3 for haplotype 2, respectively). CONCLUSION: We found strong associations among GSDMB polymorphisms and the presence of AERD and FEV1 in Korean patients with asthma. Our findings indicated that genetic variations of GSDMB may be associated with the development of AERD and aspirin-induced bronchospasm</style></abstract><notes><style face="normal" font="default">DA - 20170105IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28052796">PM:28052796</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170105, Kim LH</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41260</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Frings,V.G.</style></author><author><style face="normal" font="default"> Boer-Auer,A.</style></author><author><style face="normal" font="default"> Breuer,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">*Department of Dermatology, Venereology and Allergology, University Hospital Wurzburg, Wurzburg, Germany</style></auth-address><titles><title><style face="normal" font="default">Histomorphology and Immunophenotype of Eczematous Skin Lesions Revisited-Skin Biopsies Are Not Reliable in Differentiating Allergic Contact Dermatitis, Irritant Contact Dermatitis, and Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">Am J Dermatopathol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Am J Dermatopathol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy test</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> CD34</style></keyword><keyword><style face="normal" font="default"> CD4</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Histopathology</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-17</style></keyword><keyword><style face="normal" font="default"> Immunophenotyping</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritant contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Keratinocytes</style></keyword><keyword><style face="normal" font="default"> Lymphoma</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Modeling</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> serum IgE levels</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Tinea</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="10" Month="3" Year="2017">2017/3/10</year></dates><abstract><style face="normal" font="default">Lesions of allergic contact dermatitis (ACD), irritant contact dermatitis (ICD), and atopic dermatitis (AD) share similar clinical features and thus, their diagnosis can be challenging. The aim of this study was to reassess histopathology and immunophenotyping properties to distinguish between ACD, ICD, and AD. Charts of patients with eczema, who had undergone complete routine diagnostic workup (skin biopsies, patch tests, skin prick tests, and respectively or serum IgE levels), were reviewed. Thirty-five skin biopsy specimens of 28 patients (mean age 64 +/- 15 years; female symbol = 13 male symbol = 15) with clear diagnosis of ACD (n = 15), ICD (n = 6), or AD (n = 14) were analyzed. Histomorphological and immunohistochemical (CD3, CD4, CD8, CD11c, CD34, CD123, S100, and IL-17) parameters were evaluated using Kruskal-Wallis test, Wilcoxon test, Fisher exact test, and decision tree analysis. Eosinophils were statistically significant (P = 0.0184), more often observed in AD than in ACD or ICD. No other statistically significant differences were found with regard to epidermal patterns, patterns of dermal infiltrates, or immunophenotyping. Using predictive modeling approaches, dermal eosinophils were found to be associated with AD, necrotic epidermal keratinocytes with ICD, and a focal type of parakeratosis with ACD. As an additional finding, pseudo-Pautrier microabscesses, which were present in the skin of 2 AD and 2 ACD patients, contained myeloid dendritic cells (CD11c-+). Differentiation of ACD, ICD, and AD should be based on clinical features and results of allergy tests. Histopathology does not reliably differentiate between ACD, ICD, and AD, but helps to exclude psoriasis, tinea, or T-cell lymphoma</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 1533-0311 (Electronic)IS - 0193-1091 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1097/DAD.0000000000000842</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28296664">PM:28296664</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Dermatopathol\20170315-FringsVG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Dermatopathol\20170315-FringsVG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Frings VG</style></custom2><misc3><style face="normal" font="default">10.1097/DAD.0000000000000842</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41261</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rusconi,F.</style></author><author><style face="normal" font="default"> Zugna,D.</style></author><author><style face="normal" font="default"> Annesi-Maesano,I.</style></author><author><style face="normal" font="default"> Baiz,N.</style></author><author><style face="normal" font="default"> Barros,H.</style></author><author><style face="normal" font="default"> Correia,S.</style></author><author><style face="normal" font="default"> Duijts,L.</style></author><author><style face="normal" font="default"> Forastiere,F.</style></author><author><style face="normal" font="default"> Inskip,H.</style></author><author><style face="normal" font="default"> Kelleher,C.C.</style></author><author><style face="normal" font="default"> Larsen,P.S.</style></author><author><style face="normal" font="default"> Mommers,M.</style></author><author><style face="normal" font="default"> Andersen,A.N.</style></author><author><style face="normal" font="default"> Penders,J.</style></author><author><style face="normal" font="default"> Pike,K.</style></author><author><style face="normal" font="default"> Porta,D.</style></author><author><style face="normal" font="default"> Sonnenschein-van der Voort,A.</style></author><author><style face="normal" font="default"> Sunyer,J.</style></author><author><style face="normal" font="default"> Torrent,M.</style></author><author><style face="normal" font="default"> Viljoen,K.</style></author><author><style face="normal" font="default"> Vrijheid,M.</style></author><author><style face="normal" font="default"> Richiardi,L.</style></author><author><style face="normal" font="default"> Galassi,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Mode of Delivery and Asthma at School Age in 9 European Birth Cohorts</style></title><secondary-title><style face="normal" font="default">Am J Epidemiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Am J Epidemiol</style></abbr-1></periodical><pages end="473" start="465">465-473</pages><volume><style face="normal" font="default">185</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Ireland</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Perinatal</style></keyword><keyword><style face="normal" font="default"> Poisson</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Sample Size</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Vaginal delivery</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="15" Month="3" Year="2017">2017/3/15</year></dates><abstract><style face="normal" font="default">Evidence on the association between mode of delivery and asthma at school age is inconclusive. We assessed the associations between specific modes of delivery and asthma in children from 9 European birth cohorts that enrolled participants between 1996 and 2006. Cohort-specific crude and adjusted risk ratios for asthma at ages 5-9 years were calculated using Poisson regression models and pooled. A sensitivity analysis was carried out in children born at term to reduce confounding due to perinatal factors. The study included 67,613 participants. Cohort-specific rates of cesarean delivery varied from 9.4% to 37.5%. Cesarean delivery, as opposed to vaginal delivery, was associated with an increased risk of asthma (adjusted risk ratio (aRR) = 1.22, 95% confidence interval (CI): 1.02, 1.46). Compared with spontaneous vaginal delivery, the adjusted risk ratio was 1.33 (95% CI: 1.02, 1.75) for elective cesarean delivery, 1.07 (95% CI: 0.94, 1.22) for emergency cesarean delivery, and 0.97 (95% CI: 0.84, 1.12) for operative vaginal delivery. In children born at term, the associations were strengthened only for elective cesarean delivery (aRR = 1.49, 95% CI: 1.13, 1.97). The large sample size allowed analysis of the associations between specific modes of delivery and asthma at school age. The increased risk of asthma associated with elective cesarean delivery, especially among children born at term, is relevant in counteracting the increasing use of this procedure, which is often performed without a clear medical indication</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 1476-6256 (Electronic)IS - 0002-9262 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - France -CO - Portugal -CO - Netherlands -CO - United Kingdom -CO - Ireland -CO - Denmark -CO - Netherlands -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1093/aje/kwx021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28399567">PM:28399567</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Epidemiol\2017-185-465-73.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Epidemiol\2017-185-465-73.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, Rusconi F</style></custom2><misc3><style face="normal" font="default">10.1093/aje/kwx021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41262</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Akgedik,R.</style></author><author><style face="normal" font="default"> Yagiz,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Is Decreased MPV in Allergic Airway Diseases Associated with Extent of The Inflammation Area?</style></title><secondary-title><style face="normal" font="default">Am J Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Med Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Complete Blood Count</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Mean Platelet Volume</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Platelet</style></keyword><keyword><style face="normal" font="default"> Platelet Count</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0002-9629</style></isbn><abstract><style face="normal" font="default">AbstractObjective The aim of this study was to determine the relationship between MPV level and the extent of airway inflammation in allergic airway diseases and in sub-groups by comparison of inflammatory markers. Methods A retrospective examination was made of 250 patients with allergic airway disease in the symptomatic phase, who had been newly-diagnosed or who had abandoned treatment for at least 6 months. These patients were separated into 3 groups of asthma without allergic rhinitis (A-AR, n=107), asthma with allergic rhinitis (A+AR, n=83) and allergic rhinitis without asthma (AR-A, n=60). Results MPV values of the study groups were found to be statistically significantly lower than those of the control group (p&amp;lt;0.001). MPV was determined to be negatively correlated with WBC, neutrophil count, platelet count and IgE level in the study groups. The lowest MPV value was determined in the A+AR group (8.035-¦1.05 fL), which had the most extensive airway involvement, and the highest MPV value was determined in the AR-A group (8.109-¦1.11 fL) with the least airway involvement. MPV level sensitivity and the specificity of the best cut-off level were 74,5 % and 40,8 %, respectively. The cut-off level of 8,18 fL for MPV level was found to have moderate sensitivity and low specificity for predicting PE. Conclusion The results of this study showed that MPV is lower in allergic airway diseases and a negative correlation was determined between MPV and inflammation markers but no statistically significant difference was determined between MPV and extent of the inflammation area</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1016/j.amjms.2017.04.001</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.amjms.2017.04.001</url></web-urls></urls><custom2><style face="normal" font="default">20170501, Akgedik R</style></custom2><misc3><style face="normal" font="default">10.1016/j.amjms.2017.04.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41263</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aschenbrenner,D.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch: daschenbrenner@ndm.edu</style></auth-address><titles><title><style face="normal" font="default">Rare Allergic Reaction to Topical Chlorhexidine Gluconate</style></title><secondary-title><style face="normal" font="default">Am J Nurs</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Am J Nurs</style></abbr-1></periodical><pages end="" start="20">20-</pages><volume><style face="normal" font="default">117</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Baltimore</style></keyword><keyword><style face="normal" font="default"> Chlorhexidine</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Maryland</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170427IS - 1538-7488 (Electronic)IS - 0002-936X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/01.NAJ.0000516268.32086.24</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28448359">PM:28448359</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Epidemiol\2017-117-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Epidemiol\2017-117-20.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170427, Aschenbrenner DS</style></custom2><misc3><style face="normal" font="default">10.1097/01.NAJ.0000516268.32086.24</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41264</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Uter,W.</style></author><author><style face="normal" font="default"> Bruze,M.</style></author><author><style face="normal" font="default"> Rustemeyer,T.</style></author><author><style face="normal" font="default"> Orton,D.</style></author><author><style face="normal" font="default"> Mahler,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Informatics, Biometry and Epidemiology, University of Erlangen/Nurnberg, Waldstr. 6, 91054 Erlangen, GermanyDepartment of Occupational and Environmental Dermatology, Skane University Hospital, Lund University, 205 02 Malmo, SwedenDepartment of Dermatology, VU University Medical Centre, 1081 HV Amsterdam, The NetherlandsHillingdon Hospital, Uxbridge, UB8 3NN UKAllergy Unit, Department of Dermatology, University Hospital Erlangen, 91054 Erlangen, Germany</style></auth-address><titles><title><style face="normal" font="default">Re "International survey on skin patch test procedures, attitudes and interpretation" L.K. Tanno et al., WAOJ (2016) 9:8</style></title><secondary-title><style face="normal" font="default">World Allergy Organ J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">World Allergy Organ J</style></abbr-1></periodical><pages end="" start="18">18-</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Attitude</style></keyword><keyword><style face="normal" font="default"> Biometry</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Informatics</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">A previous survey on the practice of diagnostic patch testing among representatives of member societies of the World Allergy Organization (WAO) has, in some countries, not addressed those stakeholders actually involved in patch testing, mainly dermatologists. The need for further standardisation is acknowledged and has been addressed e.g. by publication of a patch test guideline by the European Society of Contact Dermatitis in October 2015</style></abstract><notes><style face="normal" font="default">DA - 20170504IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1186/s40413-017-0149-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28469764">PM:28469764</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\World Allergy Organ J\2017-10-18.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\World Allergy Organ J\2017-10-18.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170504, Uter W</style></custom2><misc3><style face="normal" font="default">10.1186/s40413-017-0149-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41265</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Juel-Berg,N.</style></author><author><style face="normal" font="default"> Darling,P.</style></author><author><style face="normal" font="default"> Bolvig,J.</style></author><author><style face="normal" font="default"> Foss-Skiftesvik,M.H.</style></author><author><style face="normal" font="default"> Halken,S.</style></author><author><style face="normal" font="default"> Winther,L.</style></author><author><style face="normal" font="default"> Hansen,K.S.</style></author><author><style face="normal" font="default"> Askjaer,N.</style></author><author><style face="normal" font="default"> Heegaard,S.</style></author><author><style face="normal" font="default"> Madsen,A.R.</style></author><author><style face="normal" font="default"> Opstrup,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergology, Copenhagen University Hospital, Gentofte, Denmark</style></auth-address><titles><title><style face="normal" font="default">Intranasal corticosteroids compared with oral antihistamines in allergic rhinitis: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default">Am J Rhinol Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Am J Rhinol Allergy</style></abbr-1></periodical><pages end="28" start="19">19-28</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Intranasal corticosteroid</style></keyword><keyword><style face="normal" font="default"> intranasal corticosteroids</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal Obstruction</style></keyword><keyword><style face="normal" font="default"> Nasal Sprays</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Ocular</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Sneezing</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="1" Year="2017">2017/1/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Intranasal corticosteroids (INS) (corticosteroid nasal sprays) and oral antihistamines (OA) are two of the most common treatments for patients with allergic rhinitis (AR). To our knowledge, there are no systematic reviews on this topic including trials published after 2007. OBJECTIVE: To compare INS with nonsedating OAs as treatments for AR. METHODS: The systematic review and meta-analysis were based on the Grades of Recommendation, Assessment, Development, and Evaluation principles and the Patient, Intervention, Comparison, and Outcome approach. Primary literature was searched up to January 22, 2015. Criteria for eligibility were randomized controlled trials that compared the efficacy and/or adverse effects of INS and OA in patients with AR. Continuous outcome data were analyzed by using standardized mean differences (SMD) for multiple outcome measures, and mean differences in the case of a single study or outcome. Pooled estimates of effects, 95% confidence interval (CI), were calculated by using random-effects models. RESULTS: The meta-analysis included five randomized controlled trials with a total of 990 patients. INS were superior to OAs in improving total nasal symptoms score (SMD -0.70 [95% CI, -0.93 to -0.47]) and in relieving the following: nasal obstruction (SMD -0.56 [95% CI, -0.82 to -0.29]), rhinorrhea (SMD -0.47 [95% CI, -1.00 to 0.05]), nasal itching (SMD -0.42 [95% CI, -0.65 to -0.18]), sneezing (SMD -0.52 [95% CI, -0.73 to -0.32]), and quality of life mean difference -0.90 [95% CI, -1.18 to -0.62]). There was no difference in relief of ocular symptoms (SMD -0.08 [95% CI, -0.23 to 0.08]). In addition, four randomized controlled trials were included in a narrative analysis. The results in the narrative analysis were comparable with those found in the meta-analysis. CONCLUSION: INS were superior to OAs in improving nasal symptoms and quality of life in patients with AR</style></abstract><notes><style face="normal" font="default">DA - 20170224IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.2500/ajra.2016.30.4397</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28234147">PM:28234147</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Rhinol Allergy\2015-29-19-28.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Rhinol Allergy\2015-29-19-28.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170324, Juel-Berg N</style></custom2><misc3><style face="normal" font="default">10.2500/ajra.2016.30.4397</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41266</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McAleer,P.T.</style></author><author><style face="normal" font="default"> McNicol,L.</style></author><author><style face="normal" font="default"> Rose,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Chair, Australian and New Zealand Anaesthetic Allergy Group Chair, Anaesthetic Allergy Subcommittee of the ANZCA Safety &amp; Quality Committee</style></auth-address><titles><title><style face="normal" font="default">Perioperative anaphylaxis: progress, prevention and pholcodine policy</style></title><secondary-title><style face="normal" font="default">Anaesth Intensive Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Anaesth Intensive Care</style></full-title></periodical><pages end="150" start="147">147-150</pages><volume><style face="normal" font="default">45</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> New Zealand</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Perioperative anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Pholcodine</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170307IS - 0310-057X (Print)IS - 0310-057X (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28267935">PM:28267935</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Anaesth Intensive Care\2017-45-147-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Anaesth Intensive Care\2017-45-147-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170307, McAleer PT</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41267</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kolawole,H.</style></author><author><style face="normal" font="default"> Marshall,S.D.</style></author><author><style face="normal" font="default"> Crilly,H.</style></author><author><style face="normal" font="default"> Kerridge,R.</style></author><author><style face="normal" font="default"> Roessler,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Specialist Anaesthetist, Anaesthesia, Peninsula Health, Adjunct Senior Lecturer, Anaesthesia and Perioperative Medicine, Monash University, Melbourne, Victoria</style></auth-address><titles><title><style face="normal" font="default">Australian and New Zealand Anaesthetic Allergy Group/Australian and New Zealand College of Anaesthetists Perioperative Anaphylaxis Management Guidelines</style></title><secondary-title><style face="normal" font="default">Anaesth Intensive Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Anaesth Intensive Care</style></full-title></periodical><pages end="158" start="151">151-158</pages><volume><style face="normal" font="default">45</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaesthesia</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> New Zealand</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Perioperative anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Victoria</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">Anaphylaxis is an uncommon but important cause of serious morbidity and even mortality in the perioperative period. The Australian and New Zealand College of Anaesthetists (ANZCA) with the Australian and New Zealand Anaesthetic Allergy Group (ANZAAG) have developed clinical management guidelines that include six crisis management cards. The content of the guidelines and cards is based on published literature and other international guidelines for the management of anaesthesia-related and non-anaesthesia-related anaphylaxis. The evidence is summarised in the associated background paper (Perioperative Anaphylaxis Management Guidelines [2016] www.anzca.edu.au/resources/endorsed-guidelines and www.anzaag.com/Mgmt%20Resources.aspx). These guidelines are intended to apply to anaphylaxis occurring only during the perioperative period. They are not intended to apply to anaphylaxis outside the setting of dedicated monitoring and management by an anaesthetist. In this paper guidelines will be presented along with a brief background to their development</style></abstract><notes><style face="normal" font="default">DA - 20170307IS - 0310-057X (Print)IS - 0310-057X (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28267936">PM:28267936</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Anaesth Intensive Care\2017-45-151-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Anaesth Intensive Care\2017-45-151-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170307, Kolawole H</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41268</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kounis,N.G.</style></author><author><style face="normal" font="default"> Tsigkas,G.</style></author><author><style face="normal" font="default"> Tzanis,G.</style></author><author><style face="normal" font="default"> Koniari,I.</style></author><author><style face="normal" font="default"> Soufras,G.</style></author><author><style face="normal" font="default"> Hahalis,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Cardiology, University of Patras Medical School, Rion, Patras, Achaia, Greece.</style></auth-address><titles><title><style face="normal" font="default">Anaphylaxis during cardiac surgery for hypertrophic cardiomyopathy: patholophysiologic and therapeutic considerations</style></title><secondary-title><style face="normal" font="default">Anaesthesiol Intensive Ther</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Anaesthesiol Intensive Ther</style></abbr-1></periodical><pages end="80" start="79">79-80</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170331IS - 1731-2515 (Electronic)IS - 1642-5758 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="default">10.5603/AIT.2017.0015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28362038">PM:28362038</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Anaesthesiol Intensive Ther\2017-49-79-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Anaesthesiol Intensive Ther\2017-49-79-80.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170331, Kounis NG</style></custom2><misc3><style face="normal" font="default">10.5603/AIT.2017.0015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41269</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wasowicz,M.</style></author><author><style face="normal" font="default"> Yee,K.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">University Health Network, Toronto General Hospital, Canada.</style></auth-address><titles><title><style face="normal" font="default">In response to: Anaphylaxis during cardiac surgery for hypetrophic cardiomyopathy: pathophysiologic and therapeutic considerations</style></title><secondary-title><style face="normal" font="default">Anaesthesiol Intensive Ther</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Anaesthesiol Intensive Ther</style></abbr-1></periodical><pages end="82" start="81">81-82</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170331IS - 1731-2515 (Electronic)IS - 1642-5758 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.5603/AIT.2017.0016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28362039">PM:28362039</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Anaesthesiol Intensive Ther\2017-49-81-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Anaesthesiol Intensive Ther\2017-49-81-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170331, Wasowicz M</style></custom2><misc3><style face="normal" font="default">10.5603/AIT.2017.0016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41270</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Laroche,D.</style></author><author><style face="normal" font="default"> Leturgie,P.</style></author><author><style face="normal" font="default"> Mariotte,D.</style></author><author><style face="normal" font="default"> Ollivier,Y.</style></author><author><style face="normal" font="default"> Hanouz,J.L.</style></author><author><style face="normal" font="default"> Le Mauff,B.</style></author><author><style face="normal" font="default"> Parienti,J.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Laboratory of Hormonology (D.L.) and Laboratory of Immunology and Immunopathology (D.M., B.L.M.), Pole Biologie, Caen University Hospital, Caen, France</style></auth-address><titles><title><style face="normal" font="default">In Vivo Cysteinyl Leukotriene Release in Allergic and Nonallergic Immediate Hypersensitivity Reactions during Anesthesia</style></title><secondary-title><style face="normal" font="default">Anesthesiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Anesthesiology</style></full-title></periodical><pages end="841" start="834">834-841</pages><volume><style face="normal" font="default">126</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Anesthesia</style></keyword><keyword><style face="normal" font="default"> Biologie</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Constriction</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> CysLT</style></keyword><keyword><style face="normal" font="default"> cysteinyl leukotriene</style></keyword><keyword><style face="normal" font="default"> cysteinyl leukotrienes</style></keyword><keyword><style face="normal" font="default"> cysteinyl-leukotrienes</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions during anesthesia</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Immunoassay</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> immunopathology</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Leukotrienes</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Immediate hypersensitivity reactions occurring during anesthesia are classified as allergic when skin tests and mast cell tryptase are positive and as nonallergic when negative results are obtained. Cysteinyl leukotrienes (cysLTs) are potent mediators synthesized by mast cell and eosinophil that induce bronchial constriction. They could play a role in hypersensitivity reactions. METHODS: cysLT C4, D4, and E4 concentrations were measured by a competition immunoassay in serial plasma samples obtained prospectively from 21 anesthetized controls and retrospectively from 34 patients who reacted at induction of anesthesia (24 with allergic and 10 with nonallergic reactions). RESULTS: In controls, the median (interquartile range) cysLT concentration was 0.83 (0.69 to 1.02) mug/l before anesthesia and was unchanged 30 min, 6 h, and 24 h afterward. In the patients with allergic reactions, the values were highly increased 30 to 60 min after the reaction (17.9 [7.8 to 36.0] mug/l), while the patients with nonallergic reactions had less increased values (7.3 [3.0 to 11.5] mug/l). The difference between the three groups was significant (P &lt; 0.0001). Increased values persisted during the 24 h of observation. Concentrations were significantly higher in patients with bronchospasm (P = 0.016). CONCLUSIONS: cysLTs appear to be an important mediator of allergic and nonallergic immediate hypersensitivity reactions. These findings might open a new field for management of patients with hypersensitivity reactions, especially nonallergic ones</style></abstract><notes><style face="normal" font="default">DA - 20170316IS - 1528-1175 (Electronic)IS - 0003-3022 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1097/ALN.0000000000001600</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28301407">PM:28301407</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Anesthesiology\2017-126-834-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Anesthesiology\2017-126-834-41.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170316, Laroche D</style></custom2><misc3><style face="normal" font="default">10.1097/ALN.0000000000001600</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41271</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Manuyakorn,W.</style></author><author><style face="normal" font="default"> Bamrungchaowkasem,B.</style></author><author><style face="normal" font="default"> Ruangwattanapaisarn,N.</style></author><author><style face="normal" font="default"> Kamchaisatian,W.</style></author><author><style face="normal" font="default"> Benjaponpitak,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.</style></auth-address><titles><title><style face="normal" font="default">Optimal needle length for epinephrine prefilled syringe in children</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Children</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="29" Month="4" Year="2017">2017/4/29</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170503IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.04.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28465054">PM:28465054</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170503-ManuyakornW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170503-ManuyakornW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170503, Manuyakorn W</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.04.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41272</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martinez Saguer,I.</style></author><author><style face="normal" font="default"> Escuriola Ettingshausen,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Haemophilia Centre Rhine Main GmbH, Frankfurt-Morfelden, Germany.</style></auth-address><titles><title><style face="normal" font="default">Successful management of hereditary angioedema during pregnancy in a patient with heterozygous MTHFR mutation</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">angioedema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword></keywords><dates><year Day="29" Month="4" Year="2017">2017/4/29</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170503IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.04.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28465053">PM:28465053</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170503-MartinezSaguerI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170503-MartinezSaguerI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170503, Martinez Saguer I</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.04.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41273</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stone,C.A.,Jr.</style></author><author><style face="normal" font="default"> Markert,M.L.</style></author><author><style face="normal" font="default"> Abraham,R.S.</style></author><author><style face="normal" font="default"> Norton,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.</style></auth-address><titles><title><style face="normal" font="default">A case of atypical, complete DiGeorge syndrome without 22q11 mutation</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="642" start="640">640-642</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> DiGeorge Syndrome</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Minnesota</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Tennessee</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170507IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.02.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477796">PM:28477796</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-640-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-640-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170507, Stone CA Jr</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.02.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41274</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hui,J.W.</style></author><author><style face="normal" font="default"> Ong,J.</style></author><author><style face="normal" font="default"> Herdegen,J.J.</style></author><author><style face="normal" font="default"> Kim,H.</style></author><author><style face="normal" font="default"> Codispoti,C.D.</style></author><author><style face="normal" font="default"> Kalantari,V.</style></author><author><style face="normal" font="default"> Tobin,M.C.</style></author><author><style face="normal" font="default"> Schleimer,R.P.</style></author><author><style face="normal" font="default"> Batra,P.S.</style></author><author><style face="normal" font="default"> Losavio,P.S.</style></author><author><style face="normal" font="default"> Mahdavinia,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine and Pediatrics, Rush University Medical Center, Chicago, Illinois</style></auth-address><titles><title><style face="normal" font="default">Risk of obstructive sleep apnea in African American patients with chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">African American</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Apnea</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> diagnostic criteria</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Illinois</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Obstructive sleep apnea</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Polysomnography</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> race</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> sinus</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Sleep apnea</style></keyword><keyword><style face="normal" font="default"> Sleep Disorders</style></keyword><keyword><style face="normal" font="default"> Smell</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="27" Month="4" Year="2017">2017/4/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: It is widely known that patients with chronic rhinosinusitis (CRS) commonly experience sleep disruption. Many of these patients have the associated diagnosis of obstructive sleep apnea (OSA). However, little is known about the risk factors for developing OSA in the CRS population. OBJECTIVE: To identify the risk factors for OSA in CRS to determine who should be screened for OSA among patients with CRS. METHODS: We evaluated a large cohort of patients with confirmed diagnostic criteria for CRS. Patient medical records were reviewed to identify those with OSA confirmed by overnight polysomnography. Records were further reviewed for demographic information (age, sex, race, and ethnicity), body mass index, and medical history, including the presence of nasal polyps, asthma, aspirin-exacerbated respiratory disease, allergic rhinitis, and eczema. The number of endoscopic sinus operations, duration of CRS, presence of subjective smell loss, and computed tomography Lund-Mackay score were also ascertained. RESULTS: A total of 916 patients with CRS were included in the study. Implementation of a multivariable regression model for identifying adjusted risk factors revealed that African American patients had a significantly higher risk for OSA than white patients, with an adjusted odds ratio of 1.98 (95% confidence interval, 1.19-3.29). Furthermore, patients with CRS without nasal polyps were at higher risk for OSA, with an odds ratio of 1.63 (95% confidence interval, 1.02-2.61) compared with patients with CRS with nasal polyps. CONCLUSION: African American patients with CRS were at higher risk for OSA compared with white patients, and this patient group needs to be screened for OSA</style></abstract><notes><style face="normal" font="default">DA - 20170501IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.03.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28457643">PM:28457643</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170501-HuiJW.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default">20170501, Hui JW</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.03.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41275</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Butani,L.</style></author><author><style face="normal" font="default"> Calogiuri,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of California Davis Medical Center, Sacramento, California.</style></auth-address><titles><title><style face="normal" font="default">Hypersensitivity reactions in patients receiving hemodialysis</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Anesthetics</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Bradykinin</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Complement</style></keyword><keyword><style face="normal" font="default"> Complement Activation</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> delayed-type hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Erythropoietin</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Heparin</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Iron</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Membranes</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Publications</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of care</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="26" Month="4" Year="2017">2017/4/26</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To describe hypersensitivity reactions in patients receiving maintenance hemodialysis. DATA SOURCES: PubMed search of articles published during the past 30 years with an emphasis on publications in the past decade. STUDY SELECTIONS: Case reports and review articles describing hypersensitivity reactions in the context of hemodialysis. RESULTS: Pharmacologic agents are the most common identifiable cause of hypersensitivity reactions in patients receiving hemodialysis. These include iron, erythropoietin, and heparin, which can cause anaphylactic or pseudoallergic reactions, and topical antibiotics and anesthetics, which lead to delayed-type hypersensitivity reactions. Many hypersensitivity reactions are triggered by complement activation and increased bradykinin resulting from contact system activation, especially in the context of angiotensin-converting enzyme inhibitor use. Several alternative pharmacologic preparations and dialyzer membranes are available, such that once an etiology for the reaction is established, recurrences can be prevented without affecting the quality of care provided to patients. CONCLUSION: Although hypersensitivity reactions are uncommon in patients receiving hemodialysis, they can be life-threatening. Moreover, considering the large prevalence of the end-stage renal disease population, the implications of such reactions are enormous. Most reactions are pseudoallergic and not mediated by immunoglobulin E. The multiplicity of potential exposures and the complexity of the environment to which patients on dialysis are exposed make it challenging to identify the precise cause of these reactions. Great diligence is needed to investigate hypersensitivity reactions to avoid recurrence in this high-risk population</style></abstract><notes><style face="normal" font="default">DA - 20170430IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -CO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.04.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28456484">PM:28456484</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170430-ButaniL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170430-ButaniL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170430, Butani L</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.04.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41276</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Watts,T.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Adult Allergy, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default">Severe delayed-type hypersensitivity to chloramphenicol with systemic reactivation during intradermal testing</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="645" start="644">644-645</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Chloramphenicol</style></keyword><keyword><style face="normal" font="default"> delayed-type hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170507IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.03.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477797">PM:28477797</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-644-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-644-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170507, Watts TJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.03.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41277</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Franklin,J.M.</style></author><author><style face="normal" font="default"> Grunwell,J.R.</style></author><author><style face="normal" font="default"> Bruce,A.C.</style></author><author><style face="normal" font="default"> Smith,R.C.</style></author><author><style face="normal" font="default"> Fitzpatrick,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Emory University, Atlanta, Georgia</style></auth-address><titles><title><style face="normal" font="default">Predictors of emergency department use in children with persistent asthma in metropolitan Atlanta, Georgia</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergen exposure</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Controller medications</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Georgia</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Lung function testing</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Pets</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> race</style></keyword><keyword><style face="normal" font="default"> racial disparities</style></keyword><keyword><style face="normal" font="default"> Racial disparity</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> socioeconomic status</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Racial disparities are evident among children with asthma in the United States, with non-Hispanic black children at particularly high risk for poor asthma outcomes, including frequent emergency department (ED) use for asthma exacerbations. OBJECTIVE: To compare asthma features in non-Hispanic black vs white children in Atlanta, Georgia, and determine what clinical features predict future ED use for asthma. METHODS: Self-reported black and white children 6 to 17 years of age with persistent asthma treated with controller medications completed medical history questionnaires, lung function testing, aeroallergen sensitization testing, and venipuncture. Medical records were reviewed for asthma-related ED visits for 12 months after the initial study visit. RESULTS: A total of 276 children were enrolled. Black children, compared with white children, resided in more disadvantaged zip code areas and were more likely to have public insurance. Black children also had more features of asthma severity and more ED visits during the study period. Predictors of ED use, aside from a previous ED visit, differed by race. After adjustment for socioeconomic status, predictors of ED use in white children included an ED visit in the previous year and sensitization to pets and dust; in black children, predictors included ED use in the previous year, the number of asthma controller medications, forced expiratory volume in 1 second less than 80% predicted, blood eosinophil count greater than 4%, and mold sensitization. CONCLUSION: Asthma features and ED use differ between black and white children in metropolitan Atlanta. Strategies to eliminate allergen exposure in the home and improve asthma control in these children may require tailoring for different racial groups</style></abstract><notes><style face="normal" font="default">DA - 20170508IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Georgia -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.04.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28479192">PM:28479192</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170508-FranklinJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170508-FranklinJM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170508, Franklin JM</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.04.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41278</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cook,K.A.</style></author><author><style face="normal" font="default"> Modena,B.D.</style></author><author><style face="normal" font="default"> Wineinger,N.E.</style></author><author><style face="normal" font="default"> Woessner,K.M.</style></author><author><style face="normal" font="default"> Simon,R.A.</style></author><author><style face="normal" font="default"> White,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Asthma and Immunology, Scripps Clinic, San Diego, California.</style></auth-address><titles><title><style face="normal" font="default">Use of a composite symptom score during challenge in patients with suspected aspirin-exacerbated respiratory disease</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="602" start="597">597-602</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin challenge</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Ketorolac</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyposis</style></keyword><keyword><style face="normal" font="default"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> office</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polyposis</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Aspirin-exacerbated respiratory disease is characterized by asthma, chronic rhinosinusitis, nasal polyposis, and sensitivity to aspirin and other nonsteroidal anti-inflammatory drugs. Confirmation of the diagnosis requires provocation challenge with resulting upper and/or lower airways reactivity. Currently, determination of a positive challenge result is based solely on clinical judgment that synthesizes subjective symptoms and objective measures, as a concomitant increase in nasal or bronchial airways resistance is measured in only half of patients. OBJECTIVE: To describe a quantitative scoring system, based on symptoms typically reported during provocation challenge, used to identify a positive challenge result. METHODS: A total of 115 patients were asked to record 10 symptoms, rated on a scale from 1 (mild) to 10 (most severe), at regular intervals during intranasal ketorolac with modified oral aspirin challenge performed in our office. Composite scores, a simple sum of all individual scores, were calculated at each time point and compared with baseline, prechallenge values. RESULTS: One hundred of the 115 patients were determined to have a positive challenge result. A statistically significant difference in composite scores was observed in reactors vs nonreactors. All nonreactors recorded an increase in composite score of less than 5, whereas 69% of reactors recorded an increase of 5 or more. CONCLUSION: Our 10-symptom composite score provides a quantitative and comparable measure of symptoms that typically present during a challenge with a positive result. Although an external validation is needed to confirm its diagnostic performance characteristics, a change in composite score of 5 or more appears to be specific to reactors</style></abstract><notes><style face="normal" font="default">DA - 20170507IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.02.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477789">PM:28477789</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-597-602.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-597-602.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170507, Cook KA</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.02.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41279</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Broder,M.S.</style></author><author><style face="normal" font="default"> Raimundo,K.</style></author><author><style face="normal" font="default"> Ngai,K.M.</style></author><author><style face="normal" font="default"> Chang,E.</style></author><author><style face="normal" font="default"> Griffin,N.M.</style></author><author><style face="normal" font="default"> Heaney,L.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Partnership for Health Analytic Research, LLC, Beverly Hills, California.</style></auth-address><titles><title><style face="normal" font="default">Cost and health care utilization in patients with asthma and high oral corticosteroid use</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="639" start="638">638-639</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health care utilization</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170507IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.02.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477795">PM:28477795</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-638-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-638-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170507, Broder MS</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.02.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41280</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Prieto-Garcia,A.</style></author><author><style face="normal" font="default"> Roa Medellin,D.</style></author><author><style face="normal" font="default"> Baeza,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Angioedema attacks related to endometrial hyperplasia in a case of estrogen-dependent factor XII hereditary angioedema</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Factor XII</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Hyperplasia</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword></keywords><dates><year Day="2" Month="5" Year="2017">2017/5/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170506IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.04.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28476524">PM:28476524</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170506-PrietoGarciaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170506-PrietoGarciaA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170506, Prieto-Garcia A</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.04.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41281</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Harville,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departments of Pathology and Laboratory Services and Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas.</style></auth-address><titles><title><style face="normal" font="default">Can we effectively use radiographic imaging and clinical parameters for making an earlier diagnosis of granulomatous interstitial lung disease in patients with common variable immunodeficiency?</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="530" start="529">529-530</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Arkansas</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Common Variable Immunodeficiency</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> imaging</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> interstitial lung disease</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170507IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.03.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477784">PM:28477784</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-529-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-529-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170507, Harville T</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.03.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41282</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pham,M.N.</style></author><author><style face="normal" font="default"> Ho,H.E.</style></author><author><style face="normal" font="default"> Desai,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Icahn School of Medicine at Mount Sinai, New York, New York</style></auth-address><titles><title><style face="normal" font="default">Penicillin desensitization: Treatment of syphilis in pregnancy in penicillin-allergic patients</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="541" start="537">537-541</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">desensitization</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Syphilis</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170507IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.03.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477786">PM:28477786</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-537-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-537-41.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170507, Pham MN</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.03.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41283</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liang,J.B.</style></author><author><style face="normal" font="default"> Liu,L.J.</style></author><author><style face="normal" font="default"> Fang,Q.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory and Critical Care Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China</style></auth-address><titles><title><style face="normal" font="default">Clinical characteristics of patients with chronic obstructive pulmonary disease overlapped with bronchial asthma</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="569" start="564">564-569</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">airflow</style></keyword><keyword><style face="normal" font="default"> Airflow limitation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Beijing</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Persistent airflow limitation</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum specific IgE</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Specific IgE</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> Suggestion</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: The clinical characteristics of patients with chronic obstructive pulmonary disease overlapped with bronchial asthma (COPD-BA) have not been discussed thoroughly. OBJECTIVE: To reveal the clinical features of patients with COPD-BA, to evaluate the risk factors of COPD-BA, and to provide suggestions for COPD individualized therapy. METHODS: A retrospective observational study was performed. A total of 182 patients with COPD (90 with COPD-BA and 92 with pure COPD) were recruited in the study. Information on the following items was collected: demographics, clinical manifestations, complications, laboratory findings, other histories, and inpatient treatments during exacerbation. RESULTS: A total of 182 patients were diagnosed with COPD, with 90 (49.45%) being classified as having COPD-BA. Patients with COPD-BA were more likely to be female (P = .004) and experienced more severe respiratory exacerbations (P = .04) despite being younger (P = .008). Those patients at onset of recurrent cough and sputum production were younger (P = .001). Significantly, a positive asthmatic family history (P = .03) was observed. Patients with COPD-BA usually had higher level of total serum IgE (although no differences were observed), had higher positive rates of the serum specific IgE (P = .004), and were more like to have an allergic history (P = .003). Allergic factor was the risk factor of COPD-BA (odds ratio, 4.477). During hospitalization, patients with COPD-BA tended to be treated with systemic corticosteroids (P = .008). CONCLUSION: Patients with COPD-BA were characterized by persistent airflow limitation with unique clinical features. Allergic factor was associated with the presence of asthmatic characteristics in patients with COPD. When hospitalized for exacerbation, the individualized therapy for COPD-BA might include the use of corticosteroids systemically</style></abstract><notes><style face="normal" font="default">DA - 20170507IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.02.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477787">PM:28477787</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-564-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-564-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170507, Liang JB</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.02.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41284</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jonsdottir,U.</style></author><author><style face="normal" font="default"> Lang,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Medicine, University of Iceland, Reykjavik, IcelandDivision of Pulmonary and Sleep Medicine, Nemours Children's Hospital, Orlando, Florida; Division of Allergy/Immunology and Pulmonary Medicine, Duke University School of Medicine, Durham, North Carolina.</style></auth-address><titles><title><style face="normal" font="default">How does autism spectrum disorder affect the risk and severity of childhood asthma?</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="576" start="570">570-576</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> airflow</style></keyword><keyword><style face="normal" font="default"> airflow obstruction</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Asthma risk</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Autism spectrum disorder</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Florida</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Records</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Iceland</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> North Carolina</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> Pulmonary Medicine</style></keyword><keyword><style face="normal" font="default"> race</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Autism spectrum disorder (ASD) and asthma are among the most common chronic disorders in childhood. Both are associated with altered immune regulation and share several risk factors. The effects of ASD on risk for later asthma and asthma severity remain unclear. OBJECTIVE: To determine whether ASD in children increases the risk of incident asthma and worsens asthma severity. METHODS: We performed 2 distinct analytic designs (case-control and retrospective longitudinal cohort) using a multistate electronic health records database to assess the odds of new asthma and asthma severity among children with ASD. In both designs, children with ASD were matched with children without ASD according to sex, age, race, ethnicity, location, and insurance status. Pulmonary function, controller medication prescriptions, asthma exacerbations, and asthma-related hospitalizations were collected. The effects of ASD on asthma risk and severity were assessed using multivariable linear and logistic regression. RESULTS: Among children with asthma, ASD was associated with reduced exacerbations (odds ratio [OR], 0.71; 95% confidence interval [CI], 0.54-0.92), better forced expiratory volume in 1 second/forced vital capacity ratio (0.876 vs 0.841, P &lt; .001), and lower odds of airflow obstruction (OR, 0.53; 95% CI, 0.31-0.90) but had higher odds of asthma controller prescription (OR, 2.18; 95% CI, 1.62-2.93). In a longitudinal analysis of children without asthma, ASD was found to be protective for new asthma (OR, 0.44; 95% CI, 0.26-0.74). CONCLUSION: Among children with asthma, concomitant ASD is associated with better asthma-related outcomes but a higher controller treatment burden. In addition, our data did not support ASD as a risk factor for incident asthma</style></abstract><notes><style face="normal" font="default">DA - 20170507IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.02.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477788">PM:28477788</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-570-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-570-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170507, Jonsdottir U</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.02.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41285</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Volerman,A.</style></author><author><style face="normal" font="default"> Ignoffo,S.</style></author><author><style face="normal" font="default"> Hull,A.</style></author><author><style face="normal" font="default"> McArthur Hanshaw,S.</style></author><author><style face="normal" font="default"> Taylor,S.</style></author><author><style face="normal" font="default"> Vela,M.</style></author><author><style face="normal" font="default"> Press,V.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Chicago Medicine, Chicago, Illinois.</style></auth-address><titles><title><style face="normal" font="default">Identification of students with asthma in Chicago schools: Missing the mark</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Illinois</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> Students</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170508IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.04.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28479193">PM:28479193</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170508-VolermanA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170508-VolermanA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170508, Volerman A</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.04.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41286</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wan,J.</style></author><author><style face="normal" font="default"> Mitra,N.</style></author><author><style face="normal" font="default"> Hoffstad,O.J.</style></author><author><style face="normal" font="default"> Margolis,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Pennsylvania</style></auth-address><titles><title><style face="normal" font="default">Influence of FLG mutations and TSLP polymorphisms on atopic dermatitis onset age</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Pennsylvania</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170508IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.04.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28479194">PM:28479194</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170508-WanJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170508-WanJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170508, Wan J</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.04.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41287</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Veronez,C.L.</style></author><author><style face="normal" font="default"> Serpa,F.S.</style></author><author><style face="normal" font="default"> Pesquero,J.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biophysics, Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil</style></auth-address><titles><title><style face="normal" font="default">A rare mutation in the F12 gene in a patient with ACE inhibitor-induced angioedema</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">angioedema</style></keyword><keyword><style face="normal" font="default"> Biophysics</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword></keywords><dates><year Day="5" Month="5" Year="2017">2017/5/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.04.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483295">PM:28483295</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170509-VeronezCL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170509-VeronezCL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Veronez CL</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.04.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41288</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,H.</style></author><author><style face="normal" font="default"> Dinakar,C.</style></author><author><style face="normal" font="default"> McInnis,P.</style></author><author><style face="normal" font="default"> Rudin,D.</style></author><author><style face="normal" font="default"> Benain,X.</style></author><author><style face="normal" font="default"> Daley,W.</style></author><author><style face="normal" font="default"> Platz,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Western University, London, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="default">Inadequacy of current pediatric epinephrine autoinjector needle length for use in infants and toddlers</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Distance</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergency Medicine</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Injections</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Ontario</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Thigh</style></keyword><keyword><style face="normal" font="default"> Toddler</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> ultrasonography</style></keyword><keyword><style face="normal" font="default"> Ultrasound</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="5" Month="5" Year="2017">2017/5/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Epinephrine injection represents the standard of care for anaphylaxis treatment. It is most effective if delivered intramuscularly, whereas inadvertent intraosseous injection may be harmful. The needle length in current pediatric epinephrine autoinjectors (EAIs) is 12.7 mm; however, the ideal needle length for infants and toddlers weighing less than 15 kg is unknown. OBJECTIVE: To determine the skin-to-bone distance (STBD) and skin-to-muscle distance (STMD) at baseline and after simulated EAI application in infants and toddlers (weighing 7.5-15 kg). METHODS: Study participants recruited from 2 North American allergy clinics underwent baseline and compression (10-lb pressure) ultrasonography of the anterolateral thigh with a modified ultrasound transducer mimicking the footprint and maximum pressure application of an EAI device. Ultrasound images, with clinical data masked, were analyzed offline for STBD and STMD in short-axis approach. RESULTS: Of 53 infants (mean age, 18.9 months; 54.7% male; 81.1% white; mean weight, 11.0 kg), 51 had adequate images for short-axis STBD measurements. In these infants, the mean (SD) baseline STBD was 22.4 (3.8 mm), and the mean (SD) STMD was 7.9 (1.7) mm. With 10-lb compression, the mean (SD) STBD was 13.3 (2.1) mm, and the mean (SD) STMD was 6.3 (1.2) mm. An EAI with a needle length of 12.7 mm applying 10-lb pressure could strike the bone in 43.1% of infants and toddlers in this cohort. CONCLUSION: Our data suggest that the optimal EAI needle length for infants and toddlers weighing 7.5 to 15 kg should be shorter than the needle length in currently available pediatric EAIs to avoid accidental intraosseous injections</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - France -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.03.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483294">PM:28483294</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170509-KimH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170509-KimH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Kim H</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.03.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41289</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,J.M.</style></author><author><style face="normal" font="default"> Lim,K.M.</style></author><author><style face="normal" font="default"> Kim,H.S.</style></author><author><style face="normal" font="default"> Ko,H.C.</style></author><author><style face="normal" font="default"> Kim,M.B.</style></author><author><style face="normal" font="default"> Kim,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Pusan National University School of Medicine, Busan, Korea</style></auth-address><titles><title><style face="normal" font="default">Urticarial Dermatitis: Clinical Characteristics of Itch and Therapeutic Response to Cyclosporine</style></title><secondary-title><style face="normal" font="default">Ann Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Dermatol</style></abbr-1></periodical><pages end="148" start="143">143-148</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Cyclosporine</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Extremities</style></keyword><keyword><style face="normal" font="default"> Itch</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wheal</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Urticarial dermatitis, which is characterised by persistent wheals with eczematous papules and plaques, is frequently misdiagnosed and difficult to treat. Patients commonly experience intolerable pruritus which may greatly affect their quality of life. OBJECTIVE: The objective of this study is to characterize the clinical patterns of pruritus in patients with urticarial dermatitis and to determine the effectiveness of cyclosporine treatment. METHODS: This prospective study included 50 histopathologically confirmed patients with urticarial dermatitis. A face-to-face structured questionnaire was given to all patients, and they were treated with low-dose cyclosporine (1~3 mg/kg/d) for at least 2 weeks. RESULTS: The majority of patients (80.0%) had moderate to severe pruritus. Most patients experienced exacerbation of the itch in the evening (74.0%), with the extremities (upper, 86.0%; lower, 94.0%) being the most commonly involved sites. Due to severe pruritus, patients complained about reduced social contact, quality of life and difficulties in falling asleep et al. Cyclosporine significantly reduced the mean itch score and extent of erythema, and improved interference with daily activities and sleep. CONCLUSION: Our study highlights the detailed description and characteristics of pruritus in patients with urticarial dermatitis. And we recommend alternative and effective therapeutic option of low-dose cyclosporine</style></abstract><notes><style face="normal" font="default">DA - 20170410IS - 1013-9087 (Print)IS - 1013-9087 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.5021/ad.2017.29.2.143</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28392640">PM:28392640</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Dermatol\2017-29-143-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Dermatol\2017-29-143-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170410, Kim JM</style></custom2><misc3><style face="normal" font="default">10.5021/ad.2017.29.2.143</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41290</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kluger,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Helsinki and Helsinki University Central Hospital, Departments of Dermatology, Allergology and Venereology, Meilahdentie 2, PO Box 160, 00029 Hus, Finlande.</style></auth-address><titles><title><style face="normal" font="default">[Skin and mucosal diseases in musicians]</style></title><secondary-title><style face="normal" font="default">Ann Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Dermatol Venereol</style></full-title></periodical><pages end="422" start="415">415-422</pages><volume><style face="normal" font="default">144</style></volume><number><style face="normal" font="default">6-7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergology</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="default">Whether they are professional or amateur, musicians are exposed to a various number of complications in relation to their practice, including cutaneous ones. The latter are often a simple musical stigma and a reason for pride for the musician. If they are symptomatic and disturb the musician, they have to be treated and prevented. We reviewed here those occupational and peculiar lesions that are often not that well known to the dermatologist</style></abstract><notes><style face="normal" font="default">DA - 20170410IS - 0151-9638 (Print)IS - 0151-9638 (Linking)LA - frePT - English AbstractPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="default">10.1016/j.annder.2017.03.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28391981">PM:28391981</url></web-urls></urls><custom2><style face="normal" font="default">20170410, Kluger N</style></custom2><misc3><style face="normal" font="default">10.1016/j.annder.2017.03.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41291</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Barniol,C.</style></author><author><style face="normal" font="default"> Dehours,E.</style></author><author><style face="normal" font="default"> Mallet,J.</style></author><author><style face="normal" font="default"> Houze-Cerfon,C.H.</style></author><author><style face="normal" font="default"> Lauque,D.</style></author><author><style face="normal" font="default"> Charpentier,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pole de Medecine d'Urgences, Centre Hospitalier Universitaire, Toulouse, France</style></auth-address><titles><title><style face="normal" font="default">Levocetirizine and Prednisone Are Not Superior to Levocetirizine Alone for the Treatment of Acute Urticaria: A Randomized Double-Blind Clinical Trial</style></title><secondary-title><style face="normal" font="default">Ann Emerg Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Emerg Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse events</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Glucocorticoids</style></keyword><keyword><style face="normal" font="default"> H1-antihistamine</style></keyword><keyword><style face="normal" font="default"> Itch</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> Prednisone</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Randomized clinical trial</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="5" Year="2017">2017/5/2</year></dates><abstract><style face="normal" font="default">STUDY OBJECTIVE: We evaluate the efficacy of a 4-day course of prednisone added to antihistamine for the management of acute urticaria in an emergency department (ED). METHODS: In this double-blind randomized clinical trial, patients were eligible for inclusion if aged 18 years or older and with acute urticaria of no more than 24 hours' duration. Patients with anaphylaxis or who had received antihistamines or glucocorticoids during the previous 5 days were not included. In addition to levocetirizine (5 mg orally for 5 days), patients were assigned to receive prednisone (40 mg orally for 4 days) or placebo. The primary endpoint of the study was itching relief 2 days after the ED visit, rated on a numeric scale of 0 to 10. Secondary endpoints were rash resolution, relapses, and adverse events. RESULTS: A total of 100 patients were included, 50 in each group. Seven patients in the prednisone group and 8 in the placebo group discontinued treatment. At 2-day follow-up, 62% of patients in the prednisone group had an itch score of 0 versus 76% of those in the placebo group (Delta 14%; 95% confidence interval -31% to 4%). Thirty percent of patients in the prednisone group and 24% in the placebo group reported relapses (Delta 6%; 95% confidence interval -23% to 11%). Mild adverse events were reported by 12% of patients in the prednisone group and 14% in the placebo group. CONCLUSION: The addition of a prednisone burst did not improve the symptomatic and clinical response of acute urticaria to levocetirizine. This study does not support the addition of corticosteroid to H1 antihistamine as first-line treatment of acute urticaria without angioedema</style></abstract><notes><style face="normal" font="default">DA - 20170506IS - 1097-6760 (Electronic)IS - 0196-0644 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.annemergmed.2017.03.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28476259">PM:28476259</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Emerg Med\20170506-BarniolC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Emerg Med\20170506-BarniolC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170506, Barniol C</style></custom2><misc3><style face="normal" font="default">10.1016/j.annemergmed.2017.03.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41292</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Xu,M.</style></author><author><style face="normal" font="default"> Xu,J.</style></author><author><style face="normal" font="default"> Yang,X.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dr. Xiangjun Yang,, NO. 188, Shizi Street, Suzhou, 215006, China</style></auth-address><titles><title><style face="normal" font="default">Asthma and risk of cardiovascular disease or all-cause mortality: a meta-analysis</style></title><secondary-title><style face="normal" font="default">Ann Saudi Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Saudi Med</style></abbr-1></periodical><pages end="105" start="99">99-105</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bias</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Publication Bias</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective cohort study</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Previous studies have demonstrated that asthma might be associated with an increase in cardiovascular disease (CVD) and death. However, this relationship differs by gender. OBJECTIVES: To systematically evaluate the association of asthma on the incidence of CVD and death in cohort studies. DESIGN: Fixed and random effects models were used to calculate risk estimates in a meta-analysis. Potential publication bias was calculated using a funnel plot, Begg's rank correlation test, and Egger's linear regression test. SEARCH STRATEGY: We searched the PubMed and Embase databases for studies that examined the relationship between asthma and CVD or all-cause mortality. SELECTION CRITERIA: Prospective and retrospective cohort studies. RESULTS: Ten studies containing 406 426 participants were included. The summary relative risk (95% confi-dence interval, CI) for patients with asthma was 1.33 (95% CI: 1.15-1.53), for CVD in women, it was 1.55 (95% CI: 1.20-2.00), for CVD in men it was 1.20 (95% CI: 0.92-1.56), and for all-cause mortality in both genders it was 1.36 (95% CI: 1.01-1.83). These findings remained consistent after sensitivity analysis. CONCLUSION: The results indicate that asthma was associated with an increased risk of CVD and all-cause mortality. SYSTEMATIC REVIEW REGISTRATION NUMBER: Systematic review was not registered</style></abstract><notes><style face="normal" font="default">DA - 20170405IS - 0975-4466 (Electronic)IS - 0256-4947 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - China -</style></notes><work-type><style face="normal" font="default">10.5144/0256-4947.2017.99</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28377538">PM:28377538</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Saudi Med\2017-37-99-105.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Saudi Med\2017-37-99-105.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170405, Xu M</style></custom2><misc3><style face="normal" font="default">10.5144/0256-4947.2017.99</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41293</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ozturk,S.</style></author><author><style face="normal" font="default"> Turhan,H.</style></author><author><style face="normal" font="default"> Yetkin,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Cardiology, Izzet Baysal Hospital, Bolu, Turkey</style></auth-address><titles><title><style face="normal" font="default">Asthma-like attacks terminated by slow pathway ablation</style></title><secondary-title><style face="normal" font="default">Ann Thorac Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Thorac Med</style></abbr-1></periodical><pages end="128" start="127">127-128</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> Airway Obstruction</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Arrhythmia</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Chest Pain</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Constriction</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Heart Rate</style></keyword><keyword><style face="normal" font="default"> Hyperventilation</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Tachycardia</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">Asthma is a chronic airway disease in which the pathological mechanisms are reversible airway obstruction, bronchial hyper reactivity, and constriction of the lower airways. Supraventricular tachycardia (SVT) is a common arrhythmia which originates above the bundle of His and causing heart rates exceeding 150 beats/min. SVT patients present with palpitation, chest pain, chest discomfort, dyspnea, hyperventilation, and lightheadedness, occasionally. Besides, extraordinary presentations of SVT are available in literature. In this report, we describe a case of a patient presenting with treatment-resistant asthma-like attacks lasting for 20 years whom was suspected SVT as an underlying etiology and treated by slow pathway radiofrequency ablation</style></abstract><notes><style face="normal" font="default">DA - 20170504IS - 1817-1737 (Print)IS - 1998-3557 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.4103/1817-1737.203739</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28469725">PM:28469725</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Thorac Med\2017-12-127-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Thorac Med\2017-12-127-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170504, Ozturk S</style></custom2><misc3><style face="normal" font="default">10.4103/1817-1737.203739</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41294</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ari,A.</style></author><author><style face="normal" font="default"> Morgenstern,S.</style></author><author><style face="normal" font="default"> Chodick,G.</style></author><author><style face="normal" font="default"> Matar,M.</style></author><author><style face="normal" font="default"> Silbermintz,A.</style></author><author><style face="normal" font="default"> Assa,A.</style></author><author><style face="normal" font="default"> Mozer-Glassberg,Y.</style></author><author><style face="normal" font="default"> Rinawi,F.</style></author><author><style face="normal" font="default"> Nachmias-Friedler,V.</style></author><author><style face="normal" font="default"> Shamir,R.</style></author><author><style face="normal" font="default"> Zevit,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Petach Tikvah, Israel</style></auth-address><titles><title><style face="normal" font="default">Oesophageal eosinophilia in children with coeliac disease</style></title><secondary-title><style face="normal" font="default">Arch Dis Child</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arch Dis Child</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endoscopy</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Gastroenterology</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Liver Diseases</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> proton pump inhibitor</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Telephone</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="12" Month="4" Year="2017">2017/4/12</year></dates><abstract><style face="normal" font="default">OBJECTIVES: An association between coeliac disease (CD) and eosinophilic oesophagitis (EoE)/oesophageal eosinophilia (EE) has been suggested. We sought to characterise children with CD+EE in-depth and assess the contribution of each condition to the clinical presentation and treatment response. STUDY DESIGN: Medical records of children with both CD+EE, or isolated EoE diagnosed between 2000 and 2014, were retrospectively reviewed and compared with patients with isolated CD or epigastric pain. Frequency of EE was calculated from endoscopy results of patients with suspected CD or epigastric pain between 2011 and 2014. Missing data were obtained via a telephone questionnaire. SETTING: Single large, tertiary paediatric centre. PATIENTS: 17 CD+EE, 46 EoE, 302 isolated CD and 247 epigastric pain. RESULTS: The patients with CD+EE shared characteristics of both individual conditions. While age at diagnosis, family history of autoimmunity/CD and anaemia were similar to patients with CD, other characteristics such as male gender, personal/family history of atopy, peripheral eosinophilia and oesophageal white papules were more similar to patients with EoE. Combined patients (CD+EE) tended to present with CD-associated symptoms; the majority (63%) later developed typical EoE symptoms. Only a minority (21%) of combined patients had EE that resolved after a gluten-free diet; another 21% had normalisation of EE upon proton pump inhibitor treatment. The remainder required EoE-specific treatment. CONCLUSION: Patients with CD found to have EE share characteristics with both isolated CD and EoE. It appears that these are two coexisting entities presenting in the same patient rather than eosinophilia associated with CD, and therefore, interventions separately addressing each condition may be considered</style></abstract><notes><style face="normal" font="default">DA - 20170413IS - 1468-2044 (Electronic)IS - 0003-9888 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">10.1136/archdischild-2016-311944</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28404554">PM:28404554</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Arch Dis Child\20170413-AriA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Arch Dis Child\20170413-AriA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170413, Ari A</style></custom2><misc3><style face="normal" font="default">10.1136/archdischild-2016-311944</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41295</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Berthet,A.</style></author><author><style face="normal" font="default"> Spring,P.</style></author><author><style face="normal" font="default"> Vernez,D.</style></author><author><style face="normal" font="default"> Plateel,G.</style></author><author><style face="normal" font="default"> Hopf,N.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute for Work and Health (IST), University of Lausanne and Geneva, Lausanne, Switzerland.</style></auth-address><titles><title><style face="normal" font="default">Ex vivo human skin permeation of methylchloroisothiazolinone (MCI) and methylisothiazolinone (MI)</style></title><secondary-title><style face="normal" font="default">Arch Toxicol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Arch Toxicol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Biocides</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Commercial</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Diffusion</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Formulation</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Histology</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritation</style></keyword><keyword><style face="normal" font="default"> methylchloroisothiazolinone</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paint</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Solutions</style></keyword><keyword><style face="normal" font="default"> standards</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="3" Month="5" Year="2017">2017/5/3</year></dates><abstract><style face="normal" font="default">Methylchloroisothiazolinone (MCI) and methylisothiazolinone (MI) are biocides used in many types of products such as cosmetics, paints, and cleaning agents. Skin contact is often encountered when using these products. Although MCI and MI are strong allergens and cause skin irritation, no scientific skin permeation study has been reported except for some unpublished data. Therefore, this study assessed the permeation of MCI and MI both separately and as a mixture through freshly dermatomed human skin (800 microm) in a flow-through diffusion cell system. Different concentrations of aqueous standards (1.5/1, 70/50, 150/35, and 750/175 microg/mL of MCI/MI) and various commercial products were assessed after 15-20 h of exposure. In parallel, the dose-dependent irritant effects of MCI/MI and MI were estimated by histology following 6- or 24-h exposure. Overall results show that MI in formulations or in aqueous standard solutions quickly permeated the skin with time lags less than 15 min while MCI was much slower (>3.5 h). MCI in formulations had permeation rates up to five times greater than that for MI in the same product, and in two tested creams were not found to permeate skin. Some signs of irritation were observed by histology; especially at the highest MCI/MI concentrations (750/250 microg/mL) in aqueous solutions. This confirms that MCI reacts readily with skin and may induce local irritation. The MCI and MI permeations are also greatly influenced by the topical vehicle. It is, therefore, more relevant to test exposures to formulations than aqueous standard solutions</style></abstract><notes><style face="normal" font="default">DA - 20170504IS - 1432-0738 (Electronic)IS - 0340-5761 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1007/s00204-017-1978-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28470404">PM:28470404</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Arch Toxicol\20170504-BerthetA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Arch Toxicol\20170504-BerthetA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170504, Berthet A</style></custom2><misc3><style face="normal" font="default">10.1007/s00204-017-1978-x</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41296</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bovornkitti,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Adademy of Science, The Royal Society of Thailand, Bangkok 10300</style></auth-address><titles><title><style face="normal" font="default">Asthma-COPD overlap syndrome and precision medicine</style></title><secondary-title><style face="normal" font="default">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="2" start="1">1-2</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Medicine</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170422IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28431471">PM:28431471</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2017-35-1-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2017-35-1-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170422, Bovornkitti S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41297</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Seo,W.H.</style></author><author><style face="normal" font="default"> Choi,B.M.</style></author><author><style face="normal" font="default"> Lee,H.</style></author><author><style face="normal" font="default"> Yoo,Y.</style></author><author><style face="normal" font="default"> Choung,J.T.</style></author><author><style face="normal" font="default"> Han,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Korea University College of Medicine, 73, Inchon-ro, Seongbuk-gu, Seoul 12841, Korea</style></auth-address><titles><title><style face="normal" font="default">Effect of the prenatal maternal environments and diets on cord blood interleukin-4 and interferon -gamma: A pilot study</style></title><secondary-title><style face="normal" font="default">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="53" start="46">46-53</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy history</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> carpet</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Cord Blood</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> folate</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> indoor</style></keyword><keyword><style face="normal" font="default"> Indoor environment</style></keyword><keyword><style face="normal" font="default"> Interferon</style></keyword><keyword><style face="normal" font="default"> Interleukin-4</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> Neonate</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pilot study</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVE: TThe environment of a pregnant woman can affect not only fetal growth and development, but also diseases in childhood. Neonatal cord blood cytokines are commonly used to evaluate the immune development of neonates. The purpose of this study was to evaluate the effects of the environment and diet during pregnancy on IL-4 and IFN-gamma in neonatal cord blood. METHOD: A total of 111 pregnant women participated in this study from April to November 2010. Allergy history, sensitization assessed by the skin prick test, dietary intake and indoor environment were evaluated. IL-4 and IFN-gamma levels were measured in the complete cord blood of neonates using real-time PCR. RESULTS: There were 54 pregnant women with allergic disease. Both IL-4 and IFN-gamma levels in neonatal cord blood were higher in samples from allergic mothers than in non-allergic mothers (p&lt;0.05). The indoor environment and nutrient intake were not different between allergic and non-allergic mothers, except regarding carpet use. When the cytokine levels were divided into quartiles, lower folate and vitamin B6 intake was associated with the highest levels of IL-4 in neonatal cord blood (p&lt;0.05), and higher folate and vitamin B6 intake was associated with highest levels of IFN-gamma in neonatal cord blood. CONCLUSIONS: In this study, a strong association between IL-4 and IFN-gamma levels in cord blood and the intake of folate and vitamin B6 was found, which indicates that food intake during pregnancy might have a strong influence on IL-4 and IFN-gamma levels in cord blood, to a greater extent than environmental factors</style></abstract><notes><style face="normal" font="default">DA - 20160630IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.12932/AP0765</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27362407">PM:27362407</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2017-35-46-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2017-35-46-53.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160630, Seo WH</style></custom2><misc3><style face="normal" font="default">10.12932/AP0765</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41298</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Li,Y.</style></author><author><style face="normal" font="default"> Wu,R.</style></author><author><style face="normal" font="default"> Tian,Y.</style></author><author><style face="normal" font="default"> Bao,T.</style></author><author><style face="normal" font="default"> Tian,Z.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Huai'an First People's Hospital, Nanjing Medical University, 6 Beijing Road West, Huai'an, Jiangsu 223300, PR China</style></auth-address><titles><title><style face="normal" font="default">Fraction of exhaled nitric oxide and soluble receptors for advanced glycation end products are negatively correlated in children with recurrent wheezing</style></title><secondary-title><style face="normal" font="default">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="37" start="33">33-37</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> Beijing</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> fraction of exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> recurrent wheezing</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: The fraction of exhaled nitric oxide (FeNO) and serum levels of the soluble receptor for advanced glycation end products (sRAGE) have been suggested as biomarkers for asthma. OBJECTIVE: This study aimed to assess the correlation between FeNO and sRAGE serum levels in children &lt;5 years old with recurrent wheezing. METHOD: In total, 88 children with recurrent wheezing were divided into the high-risk group or low-risk group according to their clinical features. The high-risk group included 60 children, 42 male and 18 female, average age 36.7 months (range 32-48.7 months); the low-risk group included 28 children, 20 male and 8 female, average age 38.1 months (range 33-46.2 months).Asthma in high-risk children was treated with aerosol inhalation of Pulmicort respules 1 mg/d for four continuous weeks, while asthma in low-risk children was treated with symptomatic treatment. FeNO, serum sRAGE and eosinophils (EOS) were examined by ELISA and a regular blood cell analyzer. RESULTS: The serum sRAGE level was 738+/-191 and 992.4+/-210 pg/ml and the mean FeNO level was 27.3 and 17.6 ppm, respectively, in the asthma high-risk and low-risk group, showing significant differences between the two groups. In addition, FeNO and sRAGE serum levels were negatively correlated.After the inhalation of Pulmicort respules, FeNO decreased and sRAGE increased, while EOS showed no significant change. CONCLUSIONS: FeNO and sRAGE serum levels are negatively correlated in children with recurrent wheezing. Further larger scale studies are needed to test the use of FeNO and sRAGE as biomarkers for the prediction of asthma in children</style></abstract><notes><style face="normal" font="default">DA - 20160630IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.12932/AP0746</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27362403">PM:27362403</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2017-35-33-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2017-35-33-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160630, Li Y</style></custom2><misc3><style face="normal" font="default">10.12932/AP0746</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41299</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Thongsri,T.</style></author><author><style face="normal" font="default"> Chularojanamontri,L.</style></author><author><style face="normal" font="default"> Pichler,W.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Buddhachinaraj Hospital, Phitsanulok, ThailandDepartment of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandADR-AC GmbH, Holligenstr 91, 3008 Bern Switzerland</style></auth-address><titles><title><style face="normal" font="default">Cardiac involvement in DRESS syndrome</style></title><secondary-title><style face="normal" font="default">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="10" start="3">3-10</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> cytotoxicity</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> DRESS</style></keyword><keyword><style face="normal" font="default"> DRESS syndrome</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug rash</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Hepatitis</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> imaging</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Myocarditis</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Review Literature</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> suppression</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic treatment</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Thrombosis</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Cardiac involvement in drug rash with eosinophilia and systemic symptoms (DRESS) syndrome varies considerably between 4% and 21%. Here we present our case and review literatures for its diagnosis and management. An algorithm for diagnosis of cardiac involvement in DRESS syndrome is proposed in this article. DATA SOURCES: Data regarding DRESS-associated myocarditis and eosinophilic myocarditis were gather primarily from MEDLINE database. RESULTS: DRESS syndrome is a hypersensitivity reaction which is due to massive T cell stimulation resulting in cytotoxicity and eosinophil activation and recruitment. It is characterized by fever, morbilliform rash, and various systemic symptoms, in particular hepatitis. Hypersensitivity myocarditis (acute eosinophilic myocarditis) which is typically related to a drug reaction can lead to acute necrotizing eosinophilic myocarditis, cardiac thrombosis and fibrotic stage. Cardiac symptoms range from no symptoms to cardiogenic shock. Diagnosis is based on history, clinical findings, cardiac biomarkers and cardiac imaging techniques. Endomyocardial biopsy is done in a minority of patients for definite diagnosis. If suspected, drug discontinuation and suppression of immune reactions are the first therapies. Corticosteroids are the cornerstone of systemic treatments and should be initiated at the time of diagnosis of DRESS syndrome. Additional therapy and ventricular assist devices could be considered in refractory cases. CONCLUSIONS: According to its high morbidity and mortality, patients with DRESS syndrome should be carefully monitored or screened for cardiac involvement. Multidisciplinary care is important for a successful treatment outcome</style></abstract><notes><style face="normal" font="default">DA - 20161220IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="default">10.12932/AP0847</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996289">PM:27996289</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2017-35-3-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2017-35-3-10.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161220, Thongsri T</style></custom2><misc3><style face="normal" font="default">10.12932/AP0847</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41300</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dararattanaroj,W.</style></author><author><style face="normal" font="default"> Pootongkam,S.</style></author><author><style face="normal" font="default"> Rojanawatsirivej,N.</style></author><author><style face="normal" font="default"> Liwsrisakun,C.</style></author><author><style face="normal" font="default"> Wongpiyabovorn,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand</style></auth-address><titles><title><style face="normal" font="default">Patterns and risk factors of causative contact allergens in Thai adult patients with contact dermatitis at King Chulalongkorn Memorial Hospital</style></title><secondary-title><style face="normal" font="default">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="32" start="27">27-32</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact allergens</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> contact sensitization</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Fragrance mix</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Myroxylon</style></keyword><keyword><style face="normal" font="default"> Myroxylon pereirae</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Potassium</style></keyword><keyword><style face="normal" font="default"> Potassium Dichromate</style></keyword><keyword><style face="normal" font="default"> preservative</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Seafood</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Standard series</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Surveillance on common allergens identified by patch testing plays an important role in emerging allergen detection, which leads to both individual and societal level prevention. OBJECTIVE: To study the changes in the pattern of contact sensitization and to identify risk factors associated with allergens. METHOD: The data of 206 patients who underwent patch testing at King Chulalongkorn Memorial Hospital during 2012 to 2015 were assessed. The associations between patient risk factors and positive reactions to each allergen were evaluated. The results were compared with data from 2003-2004. RESULTS: The top five most common allergens during 2012-2015 were nickel sulfate (19.4%), methylchloroisothiazolinone/ methylisothiazolinone (MCI/MI) (13.6%), fragrance mix I (FM I) (10.7%), carba mix (9.2%) and cobalt chloride (6.3%) whereas, during 2003-2004, these were nickel sulfate, cobalt chloride, FM I, potassium dichromate and Myroxylon pereirae. A positive patch test to nickel was strongly associated with a history of metal and seafood allergy (p&lt;0.001; OR, 4.94; 95% CI = 2.33-10.47 and p=0.028; OR, 2.55; 95% CI, 1.11-5.85, respectively). MCI/MI was correlated with a history of personal care products allergy, and fragrance was correlated with a history of urticaria (p=0.005; OR, 4.05; 95% CI = 1.54-10.66 and p=0.031; OR, 2.71; 95% CI, 1.10-6.68, respectively). CONCLUSIONS: There was an alteration in the pattern of contact sensitization detected by our standard series. MCI/MI has become the most common preservative causing contact allergy</style></abstract><notes><style face="normal" font="default">DA - 20160630IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="default">10.12932/AP0757</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27362404">PM:27362404</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2017-35-27-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2017-35-27-32.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160630, Dararattanaroj W</style></custom2><misc3><style face="normal" font="default">10.12932/AP0757</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41301</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Columbo,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Bryn Mawr Hospital, Bryn Mawr, PA USA</style></auth-address><titles><title><style face="normal" font="default">Asthma in the elderly: a double-blind, placebo-controlled study of the effect of montelukast</style></title><secondary-title><style face="normal" font="default">Asthma Res Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asthma Res Pract</style></abbr-1></periodical><pages end="" start="3">3-</pages><volume><style face="normal" font="default">3</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Albuterol</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> elderly</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Leukotriene antagonist</style></keyword><keyword><style face="normal" font="default"> Leukotriene Antagonists</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> montelukast</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> symptom scores</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Little is known about asthma in the elderly as most studies of this condition have not included this patient group. It is unclear whether leukotriene antagonists benefit older asthmatics. We studied the effect of adding montelukast to the asthma treatment of elderly subjects. METHODS: Twenty-five subjects 65 years old and older with asthma were evaluated at week 0, 1, 5, 9, 13, and 17. Each subject received montelukast 10 mg and placebo each for 8 weeks in a cross-over design. RESULTS: Montelukast for 4 or 8 weeks did not significantly affect ACT, daily symptom scores, number of puffs of albuterol, spirometric values, peripheral blood eosinophils, or serum IgE vs. baseline or placebo. Similar results were obtained when analyzing subgroups of patients with lower ACT, lower FEV1, and higher eosinophils. CONCLUSIONS: In this study of elderly asthmatics, montelukast had no effect on asthma symptoms, number of puffs of albuterol, spirometric values, peripheral blood eosinophils or serum IgE. These results will require confirmation in larger patient cohorts and in patients with uncontrolled asthmatic symptoms</style></abstract><notes><style face="normal" font="default">DA - 20170421IS - 2054-7064 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1186/s40733-017-0031-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28428890">PM:28428890</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Res Pract\2017-3-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Res Pract\2017-3-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170421, Columbo M</style></custom2><misc3><style face="normal" font="default">10.1186/s40733-017-0031-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41302</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sifakakis,I.</style></author><author><style face="normal" font="default"> Eliades,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Orthodontics, School of Dentistry, National and Kapodistrian University of Athens, Athens, Greece</style></auth-address><titles><title><style face="normal" font="default">Adverse reactions to orthodontic materials</style></title><secondary-title><style face="normal" font="default">Aust Dent J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Aust Dent J</style></abbr-1></periodical><pages end="28" start="20">20-28</pages><volume><style face="normal" font="default">62 Suppl 1</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">additives</style></keyword><keyword><style face="normal" font="default"> Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Aging</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic response</style></keyword><keyword><style face="normal" font="default"> Alloys</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Bisphenol A</style></keyword><keyword><style face="normal" font="default"> Chromium</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Corrosion</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Degradation</style></keyword><keyword><style face="normal" font="default"> Dentistry</style></keyword><keyword><style face="normal" font="default"> Efficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Iron</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Mouth</style></keyword><keyword><style face="normal" font="default"> Movement</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Orthodontic Appliances</style></keyword><keyword><style face="normal" font="default"> Orthodontics</style></keyword><keyword><style face="normal" font="default"> Polymers</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Stainless Steel</style></keyword><keyword><style face="normal" font="default"> Steel</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Titanium</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">Adverse effects can arise from the clinical use of orthodontic materials, due to the release of constituent substances (ions from alloys and monomers, degradation by-products, and additives from polymers). Moreover, intraoral aging affects the biologic properties of materials. The aim of this review is to present the currently identified major adverse effects of the metallic and polymeric components found in orthodontic appliances and materials. Corrosion in metallic orthodontic attachments releases metal ions, mainly iron, chromium, and nickel. The latter has received the greatest attention because of its reported potential for an allergic response. The formation of an oxide layer may inhibit the outward movement of ions, thereby acting as an obstacle for release. Titanium alloys have superior corrosion resistance than stainless steel. The efficiency of polymerisation is considered an essential property for all polymers. A poor polymer network is susceptible to the release of biologically reactive substances, such as bisphenol-A (BPA), which is capable of inducing hormone-related effects. The close proximity of a light-curing tip to the adhesive, pumice prophylaxis after bonding, indirect irradiation and mouth rinsing during the first hour after bonding may decrease BPA release. The adverse effects of some orthodontic materials should be considered during material selection and throughout orthodontic treatment, in order to minimise possible undesirable implications</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 1834-7819 (Electronic)IS - 0045-0421 (Linking)LA - engPT - Journal ArticleCO - Greece -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1111/adj.12473</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28297095">PM:28297095</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Aust Dent J\2017-62S1-20-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Aust Dent J\2017-62S1-20-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Sifakakis I</style></custom2><misc3><style face="normal" font="default">10.1111/adj.12473</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41303</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Turhal,G.</style></author><author><style face="normal" font="default"> Gode,S.</style></author><author><style face="normal" font="default"> Tunakan Dalgic,C.</style></author><author><style face="normal" font="default"> Sin,A.Z.</style></author><author><style face="normal" font="default"> Kismali,E.</style></author><author><style face="normal" font="default"> Kaya,I.</style></author><author><style face="normal" font="default"> Ozturk,A.</style></author><author><style face="normal" font="default"> Goksel,O.</style></author><author><style face="normal" font="default"> Midilli,R.</style></author><author><style face="normal" font="default"> Ozturk,K.</style></author><author><style face="normal" font="default"> Karci,B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Evaluation of Inferior Turbinate Stroma with Ultrasound Elastography in Allergic Rhinitis Patients</style></title><secondary-title><style face="normal" font="default">Balkan Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Balkan Med J</style></full-title></periodical><pages end="322" start="318">318-322</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic tool</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> perennial</style></keyword><keyword><style face="normal" font="default"> perennial allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Physical Examination</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> RQLQ</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Turbinates</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Ultrasound</style></keyword><keyword><style face="normal" font="default"> VAS</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Diagnosis of allergic rhinitis is primarily based on history, physical examination and allergy testing. A technique that noninvasively evaluates the soft tissue changes in the nasal mucosa of allergic rhinitis patients has not been defined. AIMS: To assess nasal mucosal changes and measure the submucosal fibrosis in allergic rhinitis patients with sonoelastography. STUDY DESIGN: Case control study Methods: Eighty-eight turbinates of 44 patients were included in the study. There were twenty-three prick test positive allergic rhinitis patients. The control group was constituted of 21 patients. Rhinitis quality of life questionnaire (RQLQ) and visual analog scale (VAS) was applied to the allergic rhinitis patients. A higher VAS score indicated more severe allergic rhinitis symptoms. Sonoelastographic measurements were made from the lateral nasal wall. Propagation speed of sound waves were recorded in meters/seconds (m/s). The presence of asthma and the type of allergic rhinitis (seasonal or perennial) was noted. RESULTS: Ten patients had seasonal allergic rhinitis and thirteen patients had perennial allergic rhinitis. Six patients (26.1%) had accompanying asthma along with allergic rhinitis. Median VAS scores were 7 (3-9) in allergic rhinitis patients. Median symptom duration was 7 (1-24) months. Median RQLQ scores were 3.39 (1.68-5.43) points. Median sonoelastography scores of allergic rhinitis patients and healthy subjects were 2.38 m/s (0.93-4.47) and 2.42 m/s (1.62-3.50), respectively. Sonoelastographic measurements of seasonal and perennial allergic rhinitis patients didn't differ significantly (p>0.05). Presence of asthma didn't cause a significant impact on elastography measurements (p>0.05). However regression analysis revealed a significant inverse correlation (coefficients: B=0.005, Std. Error=0.097, Beta 0=0.008) between VAS and sonoelastography scores (p&lt;0.05). CONCLUSION: Sonoelastography was failed to be a diagnostic tool in allergic rhinitis. Reduced sonoelastography scores were measured in more symptomatic patients. Higher VAS scores could be a indicator for disease severity</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 2146-3131 (Electronic)IS - 2146-3123 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.4274/balkanmedj.2016.1339</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28443598">PM:28443598</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Balkan Med J\2017-34-318-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Balkan Med J\2017-34-318-22.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Turhal G</style></custom2><misc3><style face="normal" font="default">10.4274/balkanmedj.2016.1339</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41304</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Choi,Y.Y.</style></author><author><style face="normal" font="default"> Kim,M.H.</style></author><author><style face="normal" font="default"> Lee,H.</style></author><author><style face="normal" font="default"> Ahn,K.S.</style></author><author><style face="normal" font="default"> Um,J.Y.</style></author><author><style face="normal" font="default"> Lee,S.G.</style></author><author><style face="normal" font="default"> Kim,J.</style></author><author><style face="normal" font="default"> Yang,W.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">College of Korean Medicine, Basic Research Laboratory for Comorbidity Regulation, Graduate School, Kyung Hee University, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Cynanchum atratum inhibits the development of atopic dermatitis in 2,4-dinitrochlorobenzene-induced mice</style></title><secondary-title><style face="normal" font="default">Biomed Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Biomed Pharmacother</style></full-title></periodical><pages end="327" start="321">321-327</pages><volume><style face="normal" font="default">90</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidermis</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human mast cells</style></keyword><keyword><style face="normal" font="default"> Hyperplasia</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="30" Month="3" Year="2017">2017/3/30</year></dates><abstract><style face="normal" font="default">Cynanchum atratum Bunge (Apocynaceae) is a folk medicine to treat skin inflammatory diseases. However, the effects of C. atratum on atopic dermatitis have not been elucidated. In this study, we evaluate the effects of aqueous extract of C. atratum (CA) and its molecular mechanism on atopic dermatitis (AD). 1 and 100mg/mL CA were topically applied to 2,4-dinitrochlorobenzene (DNCB)-induced AD-like skin lesions for 11 days. The number of scratching behavior was evaluated for 20min. AD-like symptoms including elevated serum IgE, skin hyperplasia and mast cell infiltration were investigated. The expressions of pro-inflammatory cytokines and mediators were analyzed in AD-like skin legions. In addition, pro-inflammatory cytokine production was confirmed in human mast cells (HMC)-1 stimulated with PMA plus A23187 (PMACI). Topical application of CA attenuated total serum IgE level and scratching behavior. Skin hyperplasia including epidermis and dermis was ameliorated in CA-treated skin legions. The number of infiltrated mast cells was significantly decreased by CA treatment. In addition, CA reduced pro-inflammatory cytokines, such as IL-6, IL-1beta and TNF-alpha and Th2 cytokine, IL-4, in both of AD-like skin lesions and PMACI-sensitized HMC-1 cells. Furthermore, CA decreased the expressions of NF-kappaB, phospho-IkappaBalpha and MAP kinase. These results suggest the inhibitory effects of CA on the development of AD by regulating pro-inflammatory cytokines and mediators. CA could be an effective substance for the treatment of AD</style></abstract><notes><style face="normal" font="default">DA - 20170402IS - 1950-6007 (Electronic)IS - 0753-3322 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.biopha.2017.03.065</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28365521">PM:28365521</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biomed Pharmacother\2017-90-321-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biomed Pharmacother\2017-90-321-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170402, Choi YY</style></custom2><misc3><style face="normal" font="default">10.1016/j.biopha.2017.03.065</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41305</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aroke,D.</style></author><author><style face="normal" font="default"> Tchouakam,D.N.</style></author><author><style face="normal" font="default"> Awungia,A.T.</style></author><author><style face="normal" font="default"> Mapoh,S.Y.</style></author><author><style face="normal" font="default"> Ngassa,S.N.</style></author><author><style face="normal" font="default"> Kadia,B.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Nkwen Baptist Health Center, Bamenda, Cameroon.</style></auth-address><titles><title><style face="normal" font="default">Ivermectin induced Steven-Johnsons syndrome: case report</style></title><secondary-title><style face="normal" font="default">BMC Res Notes</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Res Notes</style></abbr-1></periodical><pages end="" start="179">179-</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Adverse effect</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antimicrobials</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic illness</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evolution</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Facilities</style></keyword><keyword><style face="normal" font="default"> Hiv</style></keyword><keyword><style face="normal" font="default"> HIV infection</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Ingestion</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lip</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> oral mucosa</style></keyword><keyword><style face="normal" font="default"> Physical Examination</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default"> Stevens-Johnson Syndrome</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="8" Month="5" Year="2017">2017/5/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Stevens-Johnson syndrome is one of the manifestations of mucocutaneous adverse drug reactions. Although antimicrobials are responsible for greater than 50% of these adverse drug reactions, there is no documented case implicating ivermectin as the culprit. A 38 year old adult Cameroonian male presented to our health facility with facial rash, painful oral sores, black eschars on lips and red tearing eyes 3 days following ingestion of ivermectin received during a nationwide anti-filarial campaign. He had no known chronic illness, no known allergies and was not on any medications prior to the campaign. Physical examination revealed discharging erythematous eyes, crusted and blister-like lesions with cracks on his lips and oral mucosa. His laboratory tests were unremarkable but for a positive Human Immunodeficiency Virus (HIV) test. A diagnosis of Ivermectin induced Stevens-Johnson syndrome in a newly diagnosed HIV patient was made. The patient was managed with supportive therapy and the evolution thereafter was favourable. CONCLUSION: Stevens-Johnson syndrome is a potential side effect of ivermectin and susceptibility to this adverse effect may be increased in HIV infection</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 1756-0500 (Electronic)IS - 1756-0500 (Linking)LA - engPT - Journal ArticleCO - Cameroon -CO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1186/s13104-017-2500-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28482929">PM:28482929</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Res Notes\2017-10-179.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Res Notes\2017-10-179.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Aroke D</style></custom2><misc3><style face="normal" font="default">10.1186/s13104-017-2500-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41306</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kemp,H.I.</style></author><author><style face="normal" font="default"> Cook,T.M.</style></author><author><style face="normal" font="default"> Thomas,M.</style></author><author><style face="normal" font="default"> Harper,N.J.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pain Research Group, Department of Surgery &amp; Cancer, Imperial College London, Chelsea &amp; Westminster Hospital NHS Foundation Trust, 369 Fulham Road, London SW10?9NH, UK</style></auth-address><titles><title><style face="normal" font="default">UK anaesthetists' perspectives and experiences of severe perioperative anaphylaxis: NAP6 baseline surveydagger</style></title><secondary-title><style face="normal" font="default">Br J Anaesth</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Anaesth</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Atracurium</style></keyword><keyword><style face="normal" font="default"> Attitude</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Neuromuscular blocking agent</style></keyword><keyword><style face="normal" font="default"> Neuromuscular Blocking Agents</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillins</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Perioperative anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rocuronium</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Teicoplanin</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="default">Background: There is limited information on UK anaesthetists' perspectives and experiences of perioperative anaphylaxis. This baseline survey of the Sixth National Audit Project (NAP6) aimed to identify relevant departmental preparedness and practices, and individual experiences, perceptions and drug-avoidance patterns. Methods: All anaesthetists in 356 UK NHS hospitals were invited to complete an electronic survey. Results: 11 104 anaesthetists (77% crude response rate) from 341 (96%) hospitals responded. Most had immediate access to guidelines for anaphylaxis treatment (87%) and established referral pathways for investigation (82%), but a minority reported access to designated treatment packs (37%) or an anaphylaxis lead (35%). Anaesthetists reported 1734 cases of suspected perioperative anaphylaxis in 2014-5 of which 81% were referred for specialist investigation and 14% reported to the Medicines and Healthcare Products Regulatory Agency (MHRA). In their career, 76% of respondents had seen a case of perioperative anaphylaxis (1:7.25 years of practice) and 4% reported a death (1:311 years of practice), equivalent to 2.3% of events being fatal. Agents most frequently perceived to cause anaphylaxis were antibiotics, particularly penicillins, and neuromuscular blocking agents, notably rocuronium. Suxamethonium and penicillins were avoided by a higher proportion of respondents than events attributed to these drugs whereas the converse was true for atracurium and teicoplanin. Conclusions: This is the largest ever survey of anaesthetists' practices and experiences relating to perioperative anaphylaxis. It identifies gaps in preparedness and referral for further investigation and to the UK MHRA. It provides important data about drugs implicated in such events and anaesthetists' attitudes to anaphylaxis</style></abstract><notes><style face="normal" font="default">DA - 20170512IS - 1471-6771 (Electronic)IS - 0007-0912 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1093/bja/aex124</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28498889">PM:28498889</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Anaesth\20170512-KempHI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Anaesth\20170512-KempHI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170512, Kemp HI</style></custom2><misc3><style face="normal" font="default">10.1093/bja/aex124</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41307</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Qian,C.J.</style></author><author><style face="normal" font="default"> Coulombe,J.</style></author><author><style face="normal" font="default"> Suissa,S.</style></author><author><style face="normal" font="default"> Ernst,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec</style></auth-address><titles><title><style face="normal" font="default">Pneumonia Risk in Asthma Patients using Inhaled Corticosteroids: A Quasi-Cohort Study</style></title><secondary-title><style face="normal" font="default">Br J Clin Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Clin Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> bias</style></keyword><keyword><style face="normal" font="default"> Budesonide</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Health</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pneumonia</style></keyword><keyword><style face="normal" font="default"> Quebec</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="3" Year="2017">2017/3/28</year></dates><abstract><style face="normal" font="default">AIM: Studies have linked the use of inhaled corticosteroids (ICS) to excess pneumonia risk in COPD patients. The risk in asthma patients remains unclear. The objective was to examine the risk of pneumonia with ICS in patients 12 to 35 years old with asthma. METHODS: We formed a cohort of asthma patients treated from 1990-2007 using Quebec health insurance databases. Subjects were considered currently exposed if they had an ICS dispensed within the 60 days prior to their pneumonia index event or matched person-moment. Secondary analyses investigated the risk of pneumonia according to ICS dose and type. Rate ratios and rate differences were both estimated through a quasi-cohort approach. RESULTS: The cohort included 152,412 subjects, of whom 1928 had a pneumonia event during follow-up. There was an increased risk of pneumonia associated with current-use of ICS (RR 1.83; 95% CI 1.57-2.14) or an excess risk of 2.03 cases per 1000 person-years (RD 1.44; 95% CI 1.03 to 1.85). There was an excess pneumonia risk with low doses (RR 1.60; 95% CI 1.06-2.45), moderate doses (RR 1.53; 95% CI 1.12-2.08), high doses (RR 1.96; 95% CI 1.64-2.34), and with budesonide (RR 2.67; 95% CI 2.05-3.49) and fluticasone (RR 1.93; 95% CI 1.58-2.36), relative to no-use. When accounting for potential protopathic bias, the risk with current use of ICS was attenuated (RR 1.48; 95% CI 1.22 to 1.78). CONCLUSION: ICS use in asthma patients appears associated with an increased risk of pneumonia and is present for both budesonide and fluticasone</style></abstract><notes><style face="normal" font="default">DA - 20170420IS - 1365-2125 (Electronic)IS - 0306-5251 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1111/bcp.13295</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28425216">PM:28425216</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Clin Pharmacol\20170420-QianCJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Clin Pharmacol\20170420-QianCJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170420, Qian CJ</style></custom2><misc3><style face="normal" font="default">10.1111/bcp.13295</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41308</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Teo,Y.</style></author><author><style face="normal" font="default"> Walsh,S.</style></author><author><style face="normal" font="default"> Creamer,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, King's College Hospital, Denmark Hill, London, SE5 9RS, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Cutaneous Adverse Drug Reactions Referrals to a Liaison Dermatology Service</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Cutaneous adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Cutaneous drug reaction</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> standards</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="3" Year="2017">2017/3/16</year></dates><abstract><style face="normal" font="default">Adverse drug reactions (ADRs) are a common consequence of medications, with an estimated 10-20% of all hospitalised patients experiencing a drug side effect1-2 ; those affecting the skin being the most frequently recorded. The need to optimise management of cutaneous ADRs has been underlined by the recent publication of NICE Guidelines on Drug Allergy3 , setting out a range of standards to enhance the diagnosis and management of patients developing allergic reactions to drugs. This study was undertaken to assess the number of drug allergy referrals, and the types of cutaneous drug reaction encountered in the in-patient population. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170316IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - LetterCO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15461</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28301679">PM:28301679</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20170316-TeoY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20170316-TeoY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170316, Teo Y</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15461</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41309</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Simonsen,A.B.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author><author><style face="normal" font="default"> Deleuran,M.</style></author><author><style face="normal" font="default"> Mortz,C.G.</style></author><author><style face="normal" font="default"> Sommerlund,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Venereology, Aarhus University Hospital</style></auth-address><titles><title><style face="normal" font="default">Contact allergy in children with atopic dermatitis: a systematic review</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Manuscripts</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="3" Month="5" Year="2017">2017/5/3</year></dates><abstract><style face="normal" font="default">The importance of contact allergy in children with atopic dermatitis is frequently debated. Previously, patients with atopic dermatitis were believed to have a reduced ability to produce a type IV immunologic response. However, this belief has been challenged and authors have highlighted the risk of underestimating and overlooking allergic contact dermatitis in children with atopic dermatitis. Several studies have been published aiming to shed light on this important question but results are contradictory. To provide an overview of the existing knowledge, we systematically reviewed studies that report frequencies of positive patch test reactions in children with atopic dermatitis. We identified 436 manuscripts of which 31 met the inclusion criteria. Although the literature is conflicting, it is evident that contact allergy is a common problem in children with atopic dermatitis. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170504IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15628</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28470762">PM:28470762</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20170504-SimonsenAB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20170504-SimonsenAB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170504, Simonsen AB</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15628</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41310</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Koppes,S.A.</style></author><author><style face="normal" font="default"> Ljubojevic,H.S.</style></author><author><style face="normal" font="default"> Jakasa,I.</style></author><author><style face="normal" font="default"> Franceschi,N.</style></author><author><style face="normal" font="default"> Jurakic,T.R.</style></author><author><style face="normal" font="default"> Marinovic,B.</style></author><author><style face="normal" font="default"> Brans,R.</style></author><author><style face="normal" font="default"> Gibbs,S.</style></author><author><style face="normal" font="default"> Frings-Dresen,M.H.</style></author><author><style face="normal" font="default"> Rustemeyer,T.</style></author><author><style face="normal" font="default"> Kezic,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Coronel Institute of Occupational Health, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105AZ, Amsterdam, the Netherlands</style></auth-address><titles><title><style face="normal" font="default">Stratum corneum profiles of inflammatory mediators in patch test reactions to common contact allergens and sodium lauryl sulfate</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> allergen-specific</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Chromium</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact allergens</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cornea</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Croatia</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory mediators</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritant contact dermatitis</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Health</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Para-phenylenediamine</style></keyword><keyword><style face="normal" font="default"> Paraphenylenediamine</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Petrolatum</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> stratum corneum</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Recent studies have demonstrated allergen-specific differences in the gene expression of inflammatory mediators in patch tested skin. OBJECTIVES: To determine levels of various inflammatory mediators in the stratum corneum (SC) after patch testing with common contact allergens and the skin irritant sodium lauryl sulfate (SLS). METHODS: In total, 27 individuals who had previously patch tested positive to nickel, chromium, methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) or para-phenylenediamine were retested and then patch tested with SLS and petrolatum, with petrolatum serving as the patch test control. At 72 h, the test sites were clinically graded and the SC samples collected on adhesive tape. RESULTS: The levels of 18 of the 32 quantified mediators differed significantly from that of the control patches for at least one of the tested substances. SLS and MCI/MI induced the largest number of immunomediators. Interleukin (IL)-16 levels were significantly higher in patch test reactions in all allergens than they were in the controls, while no significant difference was detected for SLS. Furthermore, a strong negative correlation was found between strength of patch test reaction and IL-1alpha levels. CONCLUSIONS: Cytokine profiles in the SC of patch tested skin did not show a distinct allergen-specific pattern. However, MCI/MI induced a larger and wider immune response than the other allergens, perhaps due to its potency as an irritant. The levels of IL-16 were significantly increased in patch test reactions to allergens but not to SLS; thus, they may help clinicians to differentiate between allergic contact dermatitis and irritant contact dermatitis</style></abstract><notes><style face="normal" font="default">DA - 20170406IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Croatia -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15163</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28382616">PM:28382616</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Clin Pharmacol\20170406-KopperSA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Clin Pharmacol\20170406-KopperSA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170406, Koppes SA</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15163</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41311</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cheok,S.</style></author><author><style face="normal" font="default"> Yee,F.</style></author><author><style face="normal" font="default"> Ma,J.Y.S.</style></author><author><style face="normal" font="default"> Leow,R.</style></author><author><style face="normal" font="default"> Ho,M.S.L.</style></author><author><style face="normal" font="default"> Yew,Y.W.</style></author><author><style face="normal" font="default"> Tay,Y.K.</style></author><author><style face="normal" font="default"> Rebello,S.A.</style></author><author><style face="normal" font="default"> Luo,N.</style></author><author><style face="normal" font="default"> Koh,M.J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Yong Loo Lin School of Medicine, National University of Singapore, Singapore</style></auth-address><titles><title><style face="normal" font="default">Prevalence and Descriptive Epidemiology of Atopic Dermatitis and Its Impact on Quality of Life in Singapore</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> QOL</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schoolchildren</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="17" Month="4" Year="2017">2017/4/17</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a common, chronic, pruritic skin condition that is known to negatively impact the quality of life (QOL) of patients1,2 . Due to its increasing prevalence, AD can impose a substantial economic burden on a country's healthcare system.3 A study in 2002 found a prevalence of 20.8% of AD in Singapore schoolchildren aged between 7 and 12 years4 . This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170417IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - LetterCO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15587</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28415136">PM:28415136</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20170417-CheokS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20170417-CheokS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170417, Cjeok S</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15587</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41312</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stull,D.</style></author><author><style face="normal" font="default"> McBride,D.</style></author><author><style face="normal" font="default"> Tian,H.</style></author><author><style face="normal" font="default"> Gimenez Arnau,A.</style></author><author><style face="normal" font="default"> Maurer,M.</style></author><author><style face="normal" font="default"> Marsland,A.</style></author><author><style face="normal" font="default"> Balp,M.M.</style></author><author><style face="normal" font="default"> Khalil,S.</style></author><author><style face="normal" font="default"> Grattan,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">RTI Health Solutions, 200 Park Offices Drive, PO Box 12194, Research Triangle Park, NC, 27709-2194, USA</style></auth-address><titles><title><style face="normal" font="default">Analysis of Disease Activity Categories in Chronic Spontaneous/Idiopathic Urticaria</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Diphenhydramine</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hives</style></keyword><keyword><style face="normal" font="default"> Itch</style></keyword><keyword><style face="normal" font="default"> Life quality</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> office</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient-reported outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Solutions</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="13" Month="3" Year="2017">2017/3/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: Measurement of disease activity guides treatment of chronic spontaneous urticaria (CSU). A weekly Urticaria Activity Score-here, the average of twice-daily patient assessment of itch and hives scores summed over 1 week (UAS7TD )-measures severity from 0 to 42. Insufficient evidence exists whether disease activity states, defined by categorical UAS7TD scores, correlate with other patient-reported outcomes and treatment response. OBJECTIVE: To evaluate and compare categorical UAS7TD scores with selected measures of disease-related quality of life and impact. METHODS: Data from three randomised clinical trials of omalizumab in CSU were pooled. Continuous UAS7TD scores were categorised into five disease activity states: urticaria-free, well-controlled, mild, moderate, and severe urticaria. Total scores from the Dermatology Life Quality Index (DLQI); the Chronic Urticaria Quality of Life questionnaire (CU-Q2 oL); and questions on sleep and daily activity interference, presence of angioedema, and diphenhydramine use were compared within categorised UAS7TD disease-state scores, using one-way analyses of variance for analysis at different time points and mixed-effects regressions for analysis of all data pooled. RESULTS: Pooled analyses showed that categorical UAS7TD disease states accurately predicted differences among treated CSU patients with different levels of disease activity. A consistent pattern existed between categories, with higher-activity disease states associated with significantly higher impact and an increase in angioedema frequency. Results at different treatment time points were consistent. CONCLUSION: Categorical UAS7TD disease states can discriminate between measures when considering the impact of urticaria activity. Using five categorical disease states could simplify clinical assessment and monitoring of treatment efficacy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -CO - Spain -CO - Germany -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15454</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28295198">PM:28295198</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20170315-StullD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20170315-StullD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Stull D</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15454</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41313</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Scaffidi,M.A.</style></author><author><style face="normal" font="default"> Garg,A.</style></author><author><style face="normal" font="default"> Ro,B.</style></author><author><style face="normal" font="default"> Wang,C.</style></author><author><style face="normal" font="default"> Yang,T.T.</style></author><author><style face="normal" font="default"> Plener,I.S.</style></author><author><style face="normal" font="default"> Grin,A.</style></author><author><style face="normal" font="default"> Colak,E.</style></author><author><style face="normal" font="default"> Grover,S.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Gastroenterology, St. Michael's Hospital, Toronto, ON, Canada</style></auth-address><titles><title><style face="normal" font="default">Esophageal Intramural Pseudodiverticulosis and Concomitant Eosinophilic Esophagitis: A Case Series</style></title><secondary-title><style face="normal" font="default">Can J Gastroenterol Hepatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Can J Gastroenterol Hepatol</style></abbr-1></periodical><pages end="" start="1761874">1761874-</pages><volume><style face="normal" font="default">2016</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Deglutition Disorders</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Atopic</style></keyword><keyword><style face="normal" font="default"> Diagnostic Imaging</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Diverticulum,Esophageal</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default"> Esophagitis</style></keyword><keyword><style face="normal" font="default"> Esophagoscopy</style></keyword><keyword><style face="normal" font="default"> Esophagus</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Gastroenterology</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> radiography</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Background. Esophageal intramural pseudodiverticulosis (EIPD) is an idiopathic benign chronic disease characterized by flask-like outpouchings of the esophageal wall. It is unknown whether there is a genuine association between EIPD and eosinophilic esophagitis (EoE). Aims. To investigate a possible relationship between EIPD and EoE. Methods. Patients with radiographic or endoscopic evidence of pseudodiverticulosis were identified from the database at a single academic center. Cases were analyzed in three areas: clinical information, endoscopic findings, and course. Results. Sixteen cases of esophageal pseudodiverticulosis were identified. Five patients had histologic evidence of eosinophilic esophagitis. Patients with EoE had pseudodiverticula in the mid-to-distal esophagus while those with EIPD had pseudodiverticula predominantly in the proximal esophagus (p &lt; 0.001). EoE with pseudodiverticulosis occurred in younger patients (p &lt; 0.019). Food bolus obstructions were more common in patients with EoE and pseudodiverticulosis than in EIPD (p &lt; 0.034). Conclusions. This is the first case series supporting a potential association between EoE and pseudodiverticulosis. We also identify characteristic features of pseudodiverticulosis that may raise clinical suspicion of underlying eosinophilic esophagitis</style></abstract><notes><style face="normal" font="default">DA - 20160920IS - 2291-2797 (Electronic)IS - 2291-2789 (Linking)LA - engPT - Journal ArticleSB - IMCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1155/2016/1761874</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27648438">PM:27648438</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Can J Gastroenterol Hepatol\2016-2016-1761874.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Can J Gastroenterol Hepatol\2016-2016-1761874.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160920, Scaffidi MA</style></custom2><misc3><style face="normal" font="default">10.1155/2016/1761874</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41314</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hannoodi,F.</style></author><author><style face="normal" font="default"> Sabbagh,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Wayne State University, Detroit, MI, USA</style></auth-address><titles><title><style face="normal" font="default">ACE Inhibitor-Induced Angioedema following Cervical Spine Surgery</style></title><secondary-title><style face="normal" font="default">Case Rep Cardiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Case Rep Cardiol</style></abbr-1></periodical><pages end="" start="4268962">4268962-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Angiotensin converting enzyme inhibitors</style></keyword><keyword><style face="normal" font="default"> Bradykinin</style></keyword><keyword><style face="normal" font="default"> Dexamethasone</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Lisinopril</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Weaning</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Angioedema is a well-known side effect of angiotensin converting enzyme inhibitors (ACEi). However, ACE inhibitors induced angioedema after cervical surgery is a rare condition. They result in increased levels of circulating bradykinins. Rare cases of angioedema following local trauma in patients using ACE inhibitors have been published. We present such a case. A 54-year-old Caucasian female with a history significant for hypertension, controlled with lisinopril, was admitted for routine cervical spine surgery. She has severe degenerative cervical disc disease and was admitted to the hospital for an elective cervical diskectomy. The patient failed weaning off the ventilator on multiple attempts postoperatively. There were no observed symptoms of an allergic reaction. A CT scan of the neck showed extensive soft tissue edema at the level of the arytenoids. Dexamethasone was given to reduce the edema without successful resolution. On review of her medications, it was found that the patient was resumed on lisinopril following the procedure. It was subsequently discontinued. By the following day the patient had a positive leak around the ET tube cuff and patient was successfully extubated</style></abstract><notes><style face="normal" font="default">DA - 20170328IS - 2090-6404 (Print)IS - 2090-6404 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1155/2017/4268962</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28348897">PM:28348897</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Case Rep Cardiol\2017-2017-4268962.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Case Rep Cardiol\2017-2017-4268962.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170328, Hannoodi F</style></custom2><misc3><style face="normal" font="default">10.1155/2017/4268962</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41315</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,L.</style></author><author><style face="normal" font="default"> Mei,X.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Allergy and Clinical Immunology Centre, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China</style></auth-address><titles><title><style face="normal" font="default">Drug Reaction with Eosinophilia and Systemic Symptoms: Retrospective Analysis of 104 Cases over One Decade</style></title><secondary-title><style face="normal" font="default">Chin Med J (Engl)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chin Med J (Engl)</style></full-title></periodical><pages end="949" start="943">943-949</pages><volume><style face="normal" font="default">130</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Antiepileptic</style></keyword><keyword><style face="normal" font="default"> Antiepileptic drugs</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Beijing</style></keyword><keyword><style face="normal" font="default"> Body Surface Area</style></keyword><keyword><style face="normal" font="default"> Body Temperature</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> DRESS</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Drug-induced</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> IVIG</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe cutaneous adverse reaction</style></keyword><keyword><style face="normal" font="default"> Severe cutaneous adverse reactions</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Temperature</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="4" Year="2017">2017/4/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe, life-threatening disorder caused by drugs. In the present study, we tried to explore the types of DRESS-inducing drugs, incubation period, features of skin rashes, accompanying visceral damage, and effectiveness of glucocorticoid therapy so as to inform clinical practice. METHODS: Patients diagnosed with a drug-induced rash, dermatitis, and DRESS admitted to our hospital from January 2006 to December 2015 were included in the study. The diagnosis followed the criteria and scoring system set by the European Registry of Severe Cutaneous Adverse Reactions. Statistical analyses were carried out using SPSS version 17.0 (IBM, Armonk, NY, USA), and a value of P &lt; 0.05 was considered statistically significant. RESULTS: Among 104 patients, 38 were male and 66 female (aged 18-83 years). The latent period was 13 (interquartile range [IQR]: 10-17) days. The most common allergy-inducing drugs were antibiotics (n = 37, 35.6%), followed by antiepileptic drugs and traditional Chinese medicines (TCMs). Eighty-two cases (78.8%) had rash with area >50% body surface area (BSA). Liver damage occurred in 90% of cases. Patients were divided into oral antihistamine group and glucocorticoid/immunosuppressive agent/intravenous immunoglobulin (IVIG) group. Sex, age, incubation period, duration of hospital stay, and the number of patients with body temperature >/=38.5 degrees C were not significantly different between the two groups. However, the number of patients meeting the criteria of "definite" and "probable" (chi2 = 5.852, P = 0.016), with an eosinophilic granulocyte count of >/=1.5 x 109/L (chi2 = 7.129, P = 0.008), and with rash area of >50% BSA (chi2 = 4.750, P = 0.029), was significantly different. CONCLUSIONS: Antibiotics were associated with allergic reactions, but TCMs also had an important role. Allergy resulting from repeat use of the same drug was more severe with a shorter incubation period. The most typical rash was widespread erythematous papules. Liver damage accounted for >90% of cases</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 0366-6999 (Print)IS - 0366-6999 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.4103/0366-6999.204104</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28397724">PM:28397724</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Chin Med J (Engl)\2017-130-943-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Chin Med J (Engl)\2017-130-943-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, Wang L</style></custom2><misc3><style face="normal" font="default">10.4103/0366-6999.204104</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41316</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pinto,P.</style></author><author><style face="normal" font="default"> Rothnie,K.J.</style></author><author><style face="normal" font="default"> Lui,K.</style></author><author><style face="normal" font="default"> Timmis,A.</style></author><author><style face="normal" font="default"> Smeeth,L.</style></author><author><style face="normal" font="default"> Quint,J.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK</style></auth-address><titles><title><style face="normal" font="default">Presentation, management and mortality after a first MI in people with and without asthma: A study using UK MINAP data</style></title><secondary-title><style face="normal" font="default">Chron Respir Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chron Respir Dis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Cardiovascular Diseases</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hygiene</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infarction</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Secondary Prevention</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tropical Medicine</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="default">Asthma has been associated with a higher incidence of myocardial infarction (MI), higher prevalence of MI risk factors and higher burden of cardiovascular diseases. However, detailed associations between the presentation and initial management at the time of MI and post-MI outcomes in people with asthma compared to the general population have not been studied. A total of 300,161 people were identified with a first MI over the period 2003-2013 in the Myocardial Ischaemia National Audit Project database, of whom 8922 (3%) had asthma. Logistic regression was used to compare presentation, in-hospital care, in-hospital and 180-day post-discharge all-cause mortality in people with and without asthma adjusting for demographics and comorbidities, diagnosis on arrival and secondary prevention. People with asthma were more likely to have a delay in their MI diagnosis following an STEMI (ST-elevation myocardial infarction; odds ratio (OR) 1.38, confidence interval CI 1.06-1.79) but not an nSTEMI (non-ST-elevation myocardial infarction; OR 1.04, CI 0.92-1.17) compared to people without asthma and a delay in reperfusion (OR 1.19, CI 1.09-1.30) following an STEMI. They were much less likely to be discharged on a beta blocker following an STEMI or nSTEMI (OR 0.24, CI 0.21-0.28 and OR 0.27, CI 0.24-0.30, respectively). There was no difference in in-hospital or 180-day mortality (OR 0.98, CI 0.59-1.62 and OR 0.99, CI 0.72-1.36) following an STEMI or nSTEMI (OR 0.89, CI 0.47-1.68 and OR 1.05, CI 0.85-1.28). Although people with asthma were more likely to have a delay in diagnosis following an STEMI but not an nSTEMI compared to the general population, were more likely to have a delay in reperfusion therapy and were much less likely to receive beta blockers following an STEMI or nSTEMI, there was no difference in the prescriptions of other secondary prevention medications. None of the differences in presentation or management were associated with an increase in all-cause in-hospital or 180-day mortality in people with asthma compared to the general population</style></abstract><notes><style face="normal" font="default">DA - 20170410IS - 1479-9731 (Electronic)IS - 1479-9723 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1177/1479972317702140</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28393591">PM:28393591</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Chron Respir Dis\20170410-PintoP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Chron Respir Dis\20170410-PintoP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170410, Pinto P</style></custom2><misc3><style face="normal" font="default">10.1177/1479972317702140</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41317</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kher,S.</style></author><author><style face="normal" font="default"> Mota,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Assistant Professor of Medicine, Tufts University School of Medicine, Boston, MA, USA</style></auth-address><titles><title><style face="normal" font="default">Maternal asthma: Management strategies</style></title><secondary-title><style face="normal" font="default">Cleve Clin J Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cleve Clin J Med</style></abbr-1></periodical><pages end="302" start="296">296-302</pages><volume><style face="normal" font="default">84</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">Asthma in pregnancy is common, and its prevalence is rising. Internists need to be aware of the effects of maternal asthma control on the health of the expectant mother and the baby. With the ever-present worry about medication use and teratogenicity in pregnant women, these patients are often undertreated for their asthma. This review focuses on effects of uncontrolled maternal asthma as well as appropriate management of maternal asthma in the outpatient setting and during exacerbations</style></abstract><notes><style face="normal" font="default">DA - 20170407IS - 1939-2869 (Electronic)IS - 0891-1150 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.3949/ccjm.84a.15046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28388385">PM:28388385</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cleve Clin J Med\2017-84-296-302.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cleve Clin J Med\2017-84-296-302.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170407, Kher S</style></custom2><misc3><style face="normal" font="default">10.3949/ccjm.84a.15046</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41318</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fukunaga,A.</style></author><author><style face="normal" font="default"> Washio,K.</style></author><author><style face="normal" font="default"> Hatakeyama,M.</style></author><author><style face="normal" font="default"> Oda,Y.</style></author><author><style face="normal" font="default"> Ogura,K.</style></author><author><style face="normal" font="default"> Horikawa,T.</style></author><author><style face="normal" font="default"> Nishigori,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.</style></auth-address><titles><title><style face="normal" font="default">Cholinergic urticaria: epidemiology, physiopathology, new categorization, and management</style></title><secondary-title><style face="normal" font="default">Clin Auton Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Auton Res</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Attention</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> physiopathology</style></keyword><keyword><style face="normal" font="default"> Publications</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> subtypes</style></keyword><keyword><style face="normal" font="default"> Sweating</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="5" Month="4" Year="2017">2017/4/5</year></dates><abstract><style face="normal" font="default">PURPOSE: The aim of this study was to review the evidence on the epidemiology, physiopathology, categorization, and management of cholinergic urticaria. We specifically focused on several subtypes of cholinergic urticaria and investigated the relationship between cholinergic urticaria and idiopathic anhidrosis. METHODS: Using an integrative approach, we reviewed publications addressing the epidemiology, clinical features, diagnostic approach, physiopathology, subtype classification, and therapeutic approach to cholinergic urticaria. RESULTS: Multiple mechanisms were found to contribute to the development of cholinergic urticaria. This disorder should be classified based on the pathogenesis and clinical characteristics of each subtype. Such a classification system would lead to better management of this resistant condition. In particular, sweating function should be given more attention when examining patients with cholinergic urticaria. CONCLUSIONS: Because cholinergic urticaria is not a homogeneous disease, its subtype classification is essential for selection of the most suitable therapeutic method</style></abstract><notes><style face="normal" font="default">DA - 20170406IS - 1619-1560 (Electronic)IS - 0959-9851 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1007/s10286-017-0418-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28382552">PM:28382552</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Auton Res\20170406-FukunagaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Auton Res\20170406-FukunagaA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170406, Fukunaga A</style></custom2><misc3><style face="normal" font="default">10.1007/s10286-017-0418-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41319</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shikino,K.</style></author><author><style face="normal" font="default"> Masuyama,T.</style></author><author><style face="normal" font="default"> Yamashita,T.</style></author><author><style face="normal" font="default"> Ikusaka,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of General MedicineChiba University HospitalChiba-cityJapan</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis following drug rash due to chlorpheniramine maleate</style></title><secondary-title><style face="normal" font="default">Clin Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Case Rep</style></abbr-1></periodical><pages end="719" start="718">718-719</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Chin</style></keyword><keyword><style face="normal" font="default"> Chlorpheniramine</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug rash</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Allergic contact dermatitis (ACD) is one of the common causes of facial swelling. Clinical clues for diagnosing ACD include a rash that spares the area behind the ears, nasolabial folds, and under the chin. Once clinicians suspect ACD, the substances that cause contact dermatitis should be avoided</style></abstract><notes><style face="normal" font="default">DA - 20170504IS - 2050-0904 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1002/ccr3.897</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28469883">PM:28469883</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Case Rep\2017-5-718-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Case Rep\2017-5-718-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170504, Shikino K</style></custom2><misc3><style face="normal" font="default">10.1002/ccr3.897</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41320</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rundle,C.W.</style></author><author><style face="normal" font="default"> Bergman,D.</style></author><author><style face="normal" font="default"> Goldenberg,A.</style></author><author><style face="normal" font="default"> Jacob,S.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Contact Dermatitis Considerations in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">Clin Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> biofilm</style></keyword><keyword><style face="normal" font="default"> Biofilms</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> contact sensitization</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Filaggrin</style></keyword><keyword><style face="normal" font="default"> Filaggrin mutations</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> Lanolin</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pH</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> Staphylococcus</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0738-081X</style></isbn><abstract><style face="normal" font="default">Abstract Complex immunologic pathways, influenced by both genetic and environment triggers, contribute to the development of atopic dermatitis and allergic contact dermatitis. Suppressing mechanisms between the Th1-driven allergic contact dermatitis and the Th2-driven atopic dermatitis conditions were thought to reduce the simultaneous expression of both; however, recent evidence demonstrates pediatric patients with atopic dermatitis area as likely to develop clinically relevant positive patch tests and more likely to react to specific allergens, such as lanolin. We review the potential role of skin barrier defects, such as filaggrin mutations and impaired barrier function, including aberrancies in epidermal pH buffering capabilities, which may promote bacterial biofilms and create an environment favoring sensitization</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.clindermatol.2017.03.009</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.clindermatol.2017.03.009</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Dermatol\20170510-RundleCW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Dermatol\20170510-RundleCW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170510, Rundle CW</style></custom2><misc3><style face="normal" font="default">10.1016/j.clindermatol.2017.03.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41321</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Just,J.</style></author><author><style face="normal" font="default"> Bourgoin-Heck,M.</style></author><author><style face="normal" font="default"> Amat,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Service d'Allergologie, Centre de l'Asthme et des Allergies, AP-HP, Groupe hospitalier Trousseau-La Roche Guyon, Paris, France</style></auth-address><titles><title><style face="normal" font="default">Clinical phenotypes in asthma during childhood</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical phenotypes</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Endotypes</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Targeted treatment</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="default">In the 21st century, the heterogeneity of asthma and allergic diseases in childhood will be characterized by multiple phenotypes related to different pathophysiologic pathways or endotypes. From a medical point of view, improved understanding of disease etiology and mechanisms will lead to optimal management including personalized targeted treatment. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170419IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12939</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28422351">PM:28422351</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170419-JustJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170419-JustJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170419, Just J</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12939</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41322</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Al-Khami,A.A.</style></author><author><style face="normal" font="default"> Ghonim,M.A.</style></author><author><style face="normal" font="default"> Del Valle,L.</style></author><author><style face="normal" font="default"> Ibba,S.V.</style></author><author><style face="normal" font="default"> Zheng,L.</style></author><author><style face="normal" font="default"> Pyakurel,K.</style></author><author><style face="normal" font="default"> Okpechi,S.C.</style></author><author><style face="normal" font="default"> Garay,J.</style></author><author><style face="normal" font="default"> Wyczechowska,D.</style></author><author><style face="normal" font="default"> Sanchez-Pino,M.D.</style></author><author><style face="normal" font="default"> Rodriguez,P.C.</style></author><author><style face="normal" font="default"> Boulares,H.A.</style></author><author><style face="normal" font="default"> Ochoa,A.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center, New Orleans, LA</style></auth-address><titles><title><style face="normal" font="default">Fueling the Mechanisms of Asthma: Increased Fatty Acid Oxidation in Inflammatory Immune Cells May Represent a Novel Therapeutic Target</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial epithelium</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Chemokines</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Egypt</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Energy Metabolism</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Enzymes</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> epithelia</style></keyword><keyword><style face="normal" font="default"> Epithelium</style></keyword><keyword><style face="normal" font="default"> Fatty acid</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Glucose</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> House dust</style></keyword><keyword><style face="normal" font="default"> house dust mite</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Louisiana</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> Myeloid Cells</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> OVA</style></keyword><keyword><style face="normal" font="default"> Ovum</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Up-Regulation</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="29" Month="4" Year="2017">2017/4/29</year></dates><abstract><style face="normal" font="default">BACKGROUND: Increasing evidence has shown the close link between energy metabolism and the differentiation, function, and longevity of immune cells. Chronic inflammatory conditions such as parasitic infections and cancer trigger a metabolic reprogramming from the preferential use of glucose to the up-regulation of fatty acid oxidation (FAO) in myeloid cells, including macrophages and granulocytic and monocytic myeloid-derived suppressor cells. Asthma is another chronic inflammatory condition where macrophages, eosinophils, and polymorphonuclear cells play an important role in its pathophysiology. OBJECTIVE: We tested whether FAO might play a role in the development of asthma-like traits and whether the inhibition of this metabolic pathway could represent a novel therapeutic approach. METHODS: OVA and house dust mite (HDM)-induced murine asthma models were used in this study. RESULTS: Key FAO enzymes were significantly increased in the bronchial epithelium and inflammatory immune cells infiltrating the respiratory epithelium of mice exposed to OVA or HDM. Pharmacologic inhibition of FAO significantly decreased allergen-induced airway hyperresponsiveness, decreased the number of inflammatory cells, and reduced the production of cytokines and chemokines associated with asthma. CONCLUSIONS AND CLINICAL RELEVANCE: These novel observations suggest that allergic airway inflammation increases FAO in inflammatory cells to support the production of cytokines, chemokines, and other factors important in the development of asthma. Inhibition of FAO may therefore provide a novel therapeutic approach for the treatment of asthma by re-purposing existing drugs that block FAO and are approved for the treatment of heart disease. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170430IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Egypt -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12947</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28456994">PM:28456994</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170430-AlKhamiAA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170430-AlKhamiAA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170430, Al-Khami AA</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12947</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41323</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,W.</style></author><author><style face="normal" font="default"> Qu,X.</style></author><author><style face="normal" font="default"> Dang,X.</style></author><author><style face="normal" font="default"> Shang,D.</style></author><author><style face="normal" font="default"> Yang,L.</style></author><author><style face="normal" font="default"> Li,Y.</style></author><author><style face="normal" font="default"> Xu,D.</style></author><author><style face="normal" font="default"> Martin,J.G.</style></author><author><style face="normal" font="default"> Hamid,Q.</style></author><author><style face="normal" font="default"> Liu,J.</style></author><author><style face="normal" font="default"> Chang,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Translational Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology and Frontier Institute of Science and Technology, Xi'an Jiaotong University, Xi'an, China</style></auth-address><titles><title><style face="normal" font="default">Human beta-defensin-3 Induces IL-8 Release and Apoptosis in Airway Smooth Muscle Cells</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> airway smooth muscle</style></keyword><keyword><style face="normal" font="default"> airway smooth muscle cells</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Apoptosis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> beta-Defensins</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Engineering</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human airway smooth muscle</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory mediators</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> Muscle Cells</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> ROS</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Western blot</style></keyword></keywords><dates><year Day="24" Month="4" Year="2017">2017/4/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: Human airway smooth muscle cells (ASMCs) may have a pro-inflammatory role through the release of inflammatory mediators. Increasing evidence indicates that human beta-defensins (HBDs) are related to pathogenesis of asthma. OBJECTIVES: To examine the plasma level of HBD-1, -2 and -3 in asthmatic patients and the expression of their mouse orthologs in the lung tissue of a mouse model of chronic severe asthma. Further to investigate the effect of HBD-3 on the release of the pro-inflammatory cytokine IL-8 and to explore the mechanisms. METHODS: The plasma levels of HBD-1, -2 and -3 from 34 healthy controls and 25 asthmatic patients were determined by ELISA. The expression of mouse beta-defensins MBD-1, -3 and -14 in the lung tissue of asthmatic mice was detected by Western blot. The ASMCs were cultured with HBD-3 for 24h, and then the supernatant level of IL-8 was evaluated by ELISA and the cell viability was examined by WST-1 assay. The signaling pathway was investigated with blocking antibodies or pharmacological inhibitors. RESULTS: The plasma levels of HBD-1 and -3 were elevated in asthmatic patients, and the expression of MBD-14, the mouse ortholog for HBD-3, was increased in asthmatic mice. HBD-3 induced IL-8 production in a CCR6 receptor-specific manner and was dependent on multiple signaling pathways. Moreover, HBD-3 induced cell apoptosis concurrently, which was dependent on the ERK1/2 MAPK pathway. Mitochondrial ROS regulated both HBD-3-induced IL-8 production and cell apoptosis. CONCLUSIONS &amp; CLINICAL RELEVANCE: These observations provide clear evidence of an important new mechanism for the promotion of airway inflammation and tissue remodeling with potential relevance for the treatment of asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170424IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12943</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28437599">PM:28437599</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170424-WangW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170424-WangW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170424, Wang W</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12943</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41324</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chapman,D.G.</style></author><author><style face="normal" font="default"> Mougey,E.B.</style></author><author><style face="normal" font="default"> Van der Velden,J.L.</style></author><author><style face="normal" font="default"> Lahue,K.G.</style></author><author><style face="normal" font="default"> Aliyeva,M.</style></author><author><style face="normal" font="default"> Daphtary,N.</style></author><author><style face="normal" font="default"> George,K.L.</style></author><author><style face="normal" font="default"> Hoffman,S.M.</style></author><author><style face="normal" font="default"> Schneider,R.W.</style></author><author><style face="normal" font="default"> Tracy,R.P.</style></author><author><style face="normal" font="default"> Worthen,G.S.</style></author><author><style face="normal" font="default"> Poynter,M.E.</style></author><author><style face="normal" font="default"> Peters,S.P.</style></author><author><style face="normal" font="default"> Lima,J.J.</style></author><author><style face="normal" font="default"> Janssen-Heininger,Y.M.</style></author><author><style face="normal" font="default"> Irvin,C.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departments of Medicine, University of Vermont College of Medicine, Burlington, Vermont, United States</style></auth-address><titles><title><style face="normal" font="default">The Duffy Antigen Receptor for Chemokines (DARC) Regulates Asthma Pathophysiology</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Airways disease</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal model</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Chemokines</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> House dust</style></keyword><keyword><style face="normal" font="default"> house dust mite</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: The Duffy Antigen Receptor for Chemokines (DARC) is an atypical receptor that regulates pro-inflammatory cytokines. However, the role of DARC in asthma pathophysiology is unknown. OBJECTIVE: To determine the role of DARC in allergic airways disease in mice, and the association between DARC single nucleotide polymorphisms (SNPs) and clinical outcomes in patients with asthma. METHODS: Mice with targeted disruption of the Darc gene (DarcE2 ) or WT mice were challenged over three weeks with house dust mite (HDM) antigen. Allergic airways disease was assessed 24 hours and 7 days following the final challenge. Additionally, associations between DARC SNPs and clinical outcomes were analyzed in a cohort of poorly-controlled asthmatics. RESULTS: Total airway inflammation following HDM did not differ between DarcE2 and WT mice. At 24 hours, DarcE2 mice had increased airway hyperresponsiveness; however, at 7 days airway hyperresponsiveness had completely resolved in DarcE2 but persisted in WT mice. In poorly-controlled asthmatics, DARC SNPs were associated with worse asthma control at randomization and subsequent increased risk of healthcare utilization (odds ratio 3.13(1.37-7.27), p=0.0062). CONCLUSIONS AND CLINICAL RELEVANCE: Our animal model and human patient data suggest a novel role for DARC in the temporal regulation in asthma pathophysiology and symptoms. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170504IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12949</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28471517">PM:28471517</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170504-ChapmanDG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170504-ChapmanDG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170504, Chapman DG</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12949</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41325</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Magnoni,M.S.</style></author><author><style face="normal" font="default"> Caminati,M.</style></author><author><style face="normal" font="default"> Canonica,G.W.</style></author><author><style face="normal" font="default"> Arpinelli,F.</style></author><author><style face="normal" font="default"> Rizzi,A.</style></author><author><style face="normal" font="default"> Senna,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical and Scientific Department, GlaxoSmithKline, Verona, Italy</style></auth-address><titles><title><style face="normal" font="default">Asthma management among allergists in Italy: results from a survey</style></title><secondary-title><style face="normal" font="default">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Mol Allergy</style></full-title></periodical><pages end="" start="11">11-</pages><volume><style face="normal" font="default">15</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Asma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Challenge test</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Exercise Tolerance</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Gastro-esophageal reflux</style></keyword><keyword><style face="normal" font="default"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> Methacholine challenge</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Unmet needs</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: In Europe more than 50% of asthmatic treated patients have not well-controlled asthma. Asthma affects about 2.5 million of patients in Italy. AIMS AND OBJECTIVES: The present survey aims at investigating how Italian allergists approach asthmatic patients, in order to highlight pitfalls and unmet needs concerning real-life asthma management. METHODS: An anonymous 16 item web questionnaire was available (April-October 2015) to all allergists who visited the web site of SIAAIC (Societa Italiana di Allergologia, Asma Immunologia Clinica). Those who wished to give their contribution had the opportunity to answer about epidemiology, risk factors, treatment approaches, and adherence to therapy. RESULTS: One hundred and seventy four allergists answered the survey. 54% of them reported up to 10 patient visits per week and 35.3% between 10 and 30. The most frequent reasons of follow up visits are routine check-up (56.5% of allergists), and worsening of symptoms (41% of allergists). Nocturnal apnoeas, gastro-esophageal reflux and obesity are the most important comorbidities/risk factors of poorly controlled asthma. Bronchial hyper-responsiveness, increased NO levels and reduced exercise tolerance are the most important indicators of asthma severity. Concerning therapy, ICS combined with LABA is the treatment of choice suitable for the majority of patients. A rapid onset of action and a flexible ICS dosage are indicated as the optimal characteristics for achieving the therapeutic goals. Poor adherence to therapy is an important reason for symptom worsening for the majority of allergists. Complex dosage regimens and economic aspects are considered the most important factors impacting on adherence. CONCLUSIONS: Allergists are involved in the management of asthma, regularly seeing their patients. Co-morbidities are frequent in asthmatic patients and may impact negatively on disease control, thus identifying patients who need a more careful and strict monitoring. Airway hyper-responsiveness to methacholine challenge test and nitric oxide are considered important indicators of asthma severity. The combination of LABA and inhaled steroids is considered the treatment of choice for most asthmatic patients, in keeping with broad evidence indicating that the combination therapy is more effective and rapid in gaining asthma control than inhaled corticosteroids alone. Adherence to medication regimens is considered of essence to achieve the therapeutic goals</style></abstract><notes><style face="normal" font="default">DA - 20170515IS - 1476-7961 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1186/s12948-017-0067-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28503097">PM:28503097</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-11.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170515, Magnoni MS</style></custom2><misc3><style face="normal" font="default">10.1186/s12948-017-0067-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41326</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cohen,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Johns Hopkins Children's Center, Baltimore, MD, USA</style></auth-address><titles><title><style face="normal" font="default">Differential Diagnosis of Diaper Dermatitis</style></title><secondary-title><style face="normal" font="default">Clin Pediatr (Phila)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Pediatr (Phila)</style></abbr-1></periodical><pages end="22S" start="16S">16S-22S</pages><volume><style face="normal" font="default">56</style></volume><number><style face="normal" font="default">5_suppl</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Baltimore</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Differential diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health care provider</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritant contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Irritant dermatitis</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Mild diaper dermatitis often occurs in children before toilet training is complete, particularly from 9 to 12 months of age, and the most common presentation is an irritant contact dermatitis. Diaper dermatitis may account for up to 25% of dermatology visits to health care providers during the first year of life. Fortunately, since the introduction of hypoallergenic, superabsorbent modern disposable diapers, the incidence and severity of irritant and allergic contact dermatitis has decreased dramatically. Diaper dermatitis broadly refers to skin disorders that occur in the diaper area, such as skin eruptions triggered by diapers, rashes exacerbated by the diaper, and other events that occur in the diaper area. A number of skin conditions that can occur anywhere on the skin may present with distinctive findings in the diaper area. The following discussion will review the most common triggers of diaper dermatitis and contact irritant dermatitis, while focusing on the skin conditions that may be associated or overlap clinically with contact dermatitis</style></abstract><notes><style face="normal" font="default">DA - 20170419IS - 1938-2707 (Electronic)IS - 0009-9228 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/0009922817706982</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28420251">PM:28420251</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Pediatr (Phila)\2017-56S5-16-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Pediatr (Phila)\2017-56S5-16-22.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170419, Cohen B</style></custom2><misc3><style face="normal" font="default">10.1177/0009922817706982</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41327</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Erfani,B.</style></author><author><style face="normal" font="default"> Midander,K.</style></author><author><style face="normal" font="default"> Liden,C.</style></author><author><style face="normal" font="default"> Julander,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Environmental Medicine, Karolinska Institutet, 171 77, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default">Development, validation and testing of a skin sampling method for assessment of metal exposure</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">area</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Chromium</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Efficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Fingers</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Leisure Activities</style></keyword><keyword><style face="normal" font="default"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Quantification</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="27" Month="4" Year="2017">2017/4/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Nickel, cobalt and chromium are frequent skin sensitizers. Skin exposure results in eczema in sensitized individuals, the risk being related to the skin dose. OBJECTIVES: To develop a self-sampling method for quantification of skin exposure to metals, to validate the method, and to assess its feasibility. METHODS: Defined metal doses (0.01-5 microg) were applied to the fingers of 5 participants. Skin areas (2 cm2 ) were sampled with 1% HNO3 , either as 0.1 ml on a swab, or as 0.5 ml on a wipe. Furthermore, 17 participants performed self-sampling by swab after 2 h of leisure activity. Samples were extracted in 1% HNO3 and analysed by inductively coupled plasma mass spectrometry. RESULTS: The sampling efficiency by swab was 46%, as compared with 93% for acid wipe sampling, for all tested doses. Most metal from the skin dose was detected in the first swab (33-43%). Despite lower sampling efficiency by swab, skin doses of metals following 2 h of leisure activity without hand washing were quantified in all participants, and ranged from 0.0016 to 0.15 microg/cm2 , from 0.00014 to -0.0020 microg/cm2 and from 0.00048 to -0.027 microg/cm2 for nickel, cobalt, and chromium, respectively. CONCLUSIONS: The results indicate a future potential of skin sampling by swab to detect and monitor metals on skin by self-sampling. This will contribute to better knowledge of metal skin exposure among dermatitis patients, workers, and the general population</style></abstract><notes><style face="normal" font="default">DA - 20170427IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12781</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28449188">PM:28449188</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170427-ErfaniB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170427-ErfaniB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170427, Erfani B</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12781</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41328</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oosterhaven,J.A.F.</style></author><author><style face="normal" font="default"> Schuttelaar,M.L.A.</style></author><author><style face="normal" font="default"> Apfelbacher,C.</style></author><author><style face="normal" font="default"> Diepgen,T.L.</style></author><author><style face="normal" font="default"> Ofenloch,R.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Medical Centre Groningen, University of Groningen, 9700 RB, Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Guideline for translation and national validation of the Quality of Life in Hand Eczema Questionnaire (QOLHEQ)</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Dermatology</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand eczema</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> Language</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Reproducibility</style></keyword><keyword><style face="normal" font="default"> Sample Size</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> standards</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> Validation studies</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword></keywords><dates><year Day="8" Month="5" Year="2017">2017/5/8</year></dates><abstract><style face="normal" font="default">There is a need for well-developed and validated questionnaires to measure patient reported outcomes. The Quality of Life in Hand Eczema Questionnaire (QOLHEQ) is such a validated instrument measuring disease-specific health-related quality of life in hand eczema patients. A re-validation of measurement properties is required before an instrument is used in a new population. With the objective of arriving at a guideline for translation and national validation of the QOLHEQ, we have developed the design of a reference study on how to adequately assess measurement properties of the QOLHEQ based on interdisciplinary discussions and current standards. We present a step-by-step guideline to assess translation (including cross-cultural adaptation), scale structure, validity, reproducibility, responsiveness, and interpretability. We describe which outcomes should be reported for each measurement property, and give advice on how to calculate these. It is also specified which sample size is needed, how to deal with missing data, and which cutoff values should be applied for the measurement properties assessed during the validation process. In conclusion, this guideline, presenting a reference validation study for the QOLHEQ, creates the possibility to harmonize the national validation of the various language versions of the QOLHEQ</style></abstract><notes><style face="normal" font="default">DA - 20170508IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12788</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28481015">PM:28481015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170508-OosterhavenJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170508-OosterhavenJA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170508, Oosterhaven JA</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12788</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41329</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aalto-Korte,K.</style></author><author><style face="normal" font="default"> Suuronen,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Occupational Medicine, Finnish Institute of Occupational Health (FIOH), 00250, Helsinki, FinlandOccupational Medicine, Finnish Institute of Occupational Health (FIOH), 00250, Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="default">Screening allergic reactions to resol resin based on phenol and formaldehyde in a clinic of occupational dermatology</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Baseline series</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> Formaldehyde</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Occupation</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Health</style></keyword><keyword><style face="normal" font="default"> Occupational Medicine</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenol</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic reactions to resol-type phenol formaldehyde resin [phenol formaldehyde resin 2 (PFR2)] are relatively common. It has been suggested that PFR2 should be included in baseline series. However, a recent international study found clinical relevance in only 25% of patients. OBJECTIVES: To report the results of screening with PFR2 over a 5-year period (2012-2016), and to study the clinical relevance of allergic reactions to PFR2 over a 15-year period (2002-2016). METHODS: At the Finnish Institute of Occupational Health, PFR2 was added to the baseline series in 2012. We had previously tested PFR2 in the plastic and glue series. We searched the patch test files for patients with allergic reactions to PFR2, and analysed their patch test results, occupation, exposure, and diagnosis. RESULTS: During the screening period of 5 years, a total of 10 (1.6%) patients reacted positively to PFR2. Seven of these had occupational allergic contact dermatitis caused by phenol formaldehyde resin (PFR). In 3 patients, we found no exposure to PFR. Over the preceding 10 years, the clinical relevance of 10 additional allergic reactions to PFR2 was similarly high. CONCLUSIONS: In an occupational dermatology clinic, 70% of PFR2 reactions were clinically relevant. Further studies in general dermatology clinics are needed</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12792</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28444762">PM:28444762</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170426-AaltoKorteK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170426-AaltoKorteK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Aalto-Korte K</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12792</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41330</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vindenes,H.K.</style></author><author><style face="normal" font="default"> Svanes,C.</style></author><author><style face="normal" font="default"> Lygre,S.H.L.</style></author><author><style face="normal" font="default"> Hollund,B.E.</style></author><author><style face="normal" font="default"> Langhammer,A.</style></author><author><style face="normal" font="default"> Bertelsen,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Occupational Medicine, Haukeland University Hospital, 5021, Bergen, Norway</style></auth-address><titles><title><style face="normal" font="default">Prevalence of and work-related risk factors for hand eczema in a Norwegian general population (The HUNT Study)</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Detergents</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand eczema</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Norway</style></keyword><keyword><style face="normal" font="default"> Occupation</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Medicine</style></keyword><keyword><style face="normal" font="default"> Occupations</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="27" Month="4" Year="2017">2017/4/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chemical exposures at work and at home may cause hand eczema. However, this has been scarcely described for Norway. OBJECTIVES: To investigate the prevalence of, and occupational risk factors for, hand eczema in Norway. METHODS: Among 50 805 respondents (aged >/=20 years) to the third Nord-Trondelag Health Study (HUNT3), 5757 persons reported ever having hand eczema, and 4206 answered a hand eczema questionnaire. RESULTS: The lifetime prevalences of hand eczema were 8.4% in men and 13.8% in women (p &lt; 0.001), with onset at age &lt;/=10 years in 24% (men) and 20% (women), and onset at age >/=30 years in 37% (men) and 25% (women) (p &lt; 0.001). Work-related hand eczema affected 4.8% of the population, and was most frequently associated with health/social work (29%) and occupational cleaning (20%) in women, and with farming (26%) and industrial occupations (27%) in men. Cleaning detergents (75%) and other chemicals (36%) were the most common exacerbating factors. CONCLUSIONS: The prevalence of hand eczema was 11.3%, and that of work-related hand eczema was 4.8%. Hand eczema was more common in women than in men, but with a later onset in men. Cleaning detergents were the most common aggravating factors. A large proportion of the Nord-Trondelag population is employed in farming, providing the possibility to identify farming as an important risk factor for hand eczema</style></abstract><notes><style face="normal" font="default">DA - 20170427IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Norway -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12800</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28449354">PM:28449354</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170427-VindenesHK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170427-VindenesHK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170427, Vindenes HK</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12800</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41331</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Heede,N.G.</style></author><author><style face="normal" font="default"> Thuesen,B.H.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author><author><style face="normal" font="default"> Linneberg,A.</style></author><author><style face="normal" font="default"> Szecsi,P.B.</style></author><author><style face="normal" font="default"> Stender,S.</style></author><author><style face="normal" font="default"> Menne,T.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, The National Allergy Research Centre, Copenhagen University Hospital Herlev-Gentofte, 2900, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Hand eczema, atopic dermatitis and filaggrin mutations in adult Danes: a registry-based study assessing risk of disability pension</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Filaggrin</style></keyword><keyword><style face="normal" font="default"> Filaggrin mutations</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand eczema</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Occupation</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupations</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="20" Month="4" Year="2017">2017/4/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis and hand eczema often impair the ability of people to work. Only a few studies have investigated whether individuals with loss-of-function filaggrin gene (FLG) mutations, who often have severe and early onset of dermatitis, experience occupational consequences. OBJECTIVE: To investigate the personal consequences of having atopic dermatitis and/or hand eczema and FLG mutations. METHOD: Adult Danes from the general population (n = 3247) and patients with atopic dermatitis and/or hand eczema (n = 496) were genotyped for common FLG mutations, and completed a questionnaire about skin symptoms and hand eczema. Socioeconomic variables, including disability pension, and information on work in risk occupations were retrieved from national registries. The reasons for granting disability pension were unknown. RESULTS: Disability pension was associated with hand eczema in the general population, especially among individuals with a history of atopic dermatitis. Moreover, self-reported hand eczema and atopic dermatitis were associated with particularly high risk of disability pension among FLG mutation carriers [odds ratio (OR) 4.02 and 95% confidence interval (CI): 1.15-14.11; and OR 6.01 and 95%CI: 2.37-15.34, respectively]. Furthermore, 60% of the FLG mutation carriers with atopic dermatitis who developed hand eczema had experienced symptoms before adulthood. CONCLUSION: In the general population, self-reported hand eczema and atopic dermatitis, particularly in individuals with a genetically impaired skin barrier, were associated with disability pension, suggesting that FLG mutations carriers with a history of atopic dermatitis and hand eczema could benefit from early attention with respect to choice of occupation</style></abstract><notes><style face="normal" font="default">DA - 20170420IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12786</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28425595">PM:28425595</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170420-HeedeNG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170420-HeedeNG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170420, Heede NG</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12786</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41332</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ito,A.</style></author><author><style face="normal" font="default"> Nishioka,K.</style></author><author><style face="normal" font="default"> Kanto,H.</style></author><author><style face="normal" font="default"> Yagami,A.</style></author><author><style face="normal" font="default"> Yamada,S.</style></author><author><style face="normal" font="default"> Sugiura,M.</style></author><author><style face="normal" font="default"> Yasunaga,C.</style></author><author><style face="normal" font="default"> Yoshii,K.</style></author><author><style face="normal" font="default"> Kobayashi,H.</style></author><author><style face="normal" font="default"> Adachi,A.</style></author><author><style face="normal" font="default"> Ikezawa,Y.</style></author><author><style face="normal" font="default"> Washizaki,K.</style></author><author><style face="normal" font="default"> Inui,S.</style></author><author><style face="normal" font="default"> Miyazawa,H.</style></author><author><style face="normal" font="default"> Oiso,N.</style></author><author><style face="normal" font="default"> Nakata,T.</style></author><author><style face="normal" font="default"> Matsunaga,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, 951-8520, Japan</style></auth-address><titles><title><style face="normal" font="default">A multi-institutional joint study of contact dermatitis related to hair colouring and perming agents in Japan</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Ammonia</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cysteamine</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hair</style></keyword><keyword><style face="normal" font="default"> Hair Dyes</style></keyword><keyword><style face="normal" font="default"> Hairdresser</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Solutions</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="4" Year="2017">2017/4/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: In Japan, allergic contact dermatitis caused by hair colouring agents is a considerable problem for those occupationally exposed and also for consumers. Over the last 20 years, p-phenylenediamine (PPD) has been a common allergen, with approximately 7% positive patch test reactions. OBJECTIVES: To investigate which ingredients caused allergic contact dermatitis related to hair dye and perming solutions in Japan, to assess whether PPD is suitable for screening for hair dye allergy, and to propose allergens for a Japanese hairdresser series. METHODS: We selected 19 hair cosmetic allergens, including PPD, Bandrowski's base, cysteamine HCl, and ammonium thioglycolate. Altogether 203 patients (26 males and 177 females) with suspected contact allergy to hair colouring or perming solutions at 14 hospitals in Japan were included. RESULTS: The highest prevalence of positive reactions (35.1%) was for PPD. p-Methylaminophenol and o-aminophenol were often positive, both in the PPD-positive and in the PPD-negative patients. Moreover, cysteamine HCl often yielded positive test reactions. CONCLUSIONS: PPD is insufficient to diagnose contact allergy caused by to hair dyes. We recommend 13 allergens to be included in a Japanese hairdresser series</style></abstract><notes><style face="normal" font="default">DA - 20170420IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12783</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28425114">PM:28425114</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170420-ItoA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170420-ItoA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170420, Ito A</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12783</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41333</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ackermann,L.</style></author><author><style face="normal" font="default"> Virtanen,H.</style></author><author><style face="normal" font="default"> Korhonen,L.</style></author><author><style face="normal" font="default"> Laukkanen,A.</style></author><author><style face="normal" font="default"> Huilaja,L.</style></author><author><style face="normal" font="default"> Riekki,R.</style></author><author><style face="normal" font="default"> Hasan,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Helsinki University Hospital, Skin and Allergy Hospital, Department of Dermatology, Helsinki, 00250, Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="default">An epidemic of allergic contact dermatitis caused by a new allergen, caprylhydroxamic acid, in moisturizers</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidemic</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> Formulation</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Potassium</style></keyword><keyword><style face="normal" font="default"> preservative</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: In 2016, dermatologists in Finland suspected contact allergy in several patients using moisturizers under the trade name Apobase(R). Following a formulation change, Phenostat, which is a mixture of phenoxyethanol, caprylhydroxamic acid, and methylpropanediol, was used as a preservative in Apobase(R) moisturizers in Finland. OBJECTIVES: To confirm the suspected contact allergy to Apobase(R) cream, oily cream, and/or lotion, and to identify the specific contact allergen and define its optimal patch test concentration. METHODS: Thirty-nine patients with suspected contact allergy to Apobase(R) creams or lotion were patch tested in four Finnish dermatological clinics. The patch tests included old and new Apobase(R) formulas and their preservative agents: phenoxyethanol, methylpropanediol, and dilution series of Phenostat and caprylhydroxamic acid or its potassium salt. RESULTS: The patch tests showed positive reactions to the new Apobase(R) formulas, Phenostat, and caprylhydroxamic acid or its potassium salt, but not to the old Apobase(R) formulas, methylpropanediol, or phenoxyethanol. CONCLUSIONS: We found a new contact allergen, caprylhydroxyamic acid, which caused an epidemic of allergic contact dermatitis in patients using moisturizers containing this preservative. Whether the sensitizing capacity of caprylhydroxamic acid depends on the other chemicals used in Apobase(R) moisturizers needs further investigation</style></abstract><notes><style face="normal" font="default">DA - 20170419IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12787</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28421670">PM:28421670</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170419-AckermannL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170419-AckermannL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170419, Ackermann L</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12787</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41334</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Amsler,E.</style></author><author><style face="normal" font="default"> Aerts,O.</style></author><author><style face="normal" font="default"> Raison-Peyron,N.</style></author><author><style face="normal" font="default"> Debons,M.</style></author><author><style face="normal" font="default"> Milpied,B.</style></author><author><style face="normal" font="default"> Giordano-Labadie,F.</style></author><author><style face="normal" font="default"> Waton,J.</style></author><author><style face="normal" font="default"> Ferrier-Le Bouedec,M.C.</style></author><author><style face="normal" font="default"> Lartigau,I.</style></author><author><style face="normal" font="default"> Pecquet,C.</style></author><author><style face="normal" font="default"> Assier,H.</style></author><author><style face="normal" font="default"> Avenel-Audran,M.</style></author><author><style face="normal" font="default"> Bernier,C.</style></author><author><style face="normal" font="default"> Castelain,F.</style></author><author><style face="normal" font="default"> Collet,E.</style></author><author><style face="normal" font="default"> Crepy,M.N.</style></author><author><style face="normal" font="default"> Genillier,N.</style></author><author><style face="normal" font="default"> Girardin,P.</style></author><author><style face="normal" font="default"> Pralong,P.</style></author><author><style face="normal" font="default"> Tetart,F.</style></author><author><style face="normal" font="default"> Vital-Durand,D.</style></author><author><style face="normal" font="default"> Soria,A.</style></author><author><style face="normal" font="default"> Barbaud,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology and Allergology Department, Tenon Hospital (AP-HP), Sorbonne Universities, UPMC University Paris 06, 75020, Paris, France</style></auth-address><titles><title><style face="normal" font="default">Airborne allergic contact dermatitis caused by isothiazolinones in water-based paints: a retrospective study of 44 cases</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Isothiazolinones</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> methylchloroisothiazolinone</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Paint</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Sick Leave</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="27" Month="4" Year="2017">2017/4/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Airborne allergic contact dermatitis caused by paints containing isothiazolinones has been recognized as a health hazard. OBJECTIVES: To collect epidemiological, clinical and patch test data on airborne allergic contact dermatitis caused by isothiazolinone-containing paints in France and Belgium. METHODS: A descriptive, retrospective study was initiated by the Dermatology and Allergy Group of the French Society of Dermatology, including methylchloroisothiazolinone (MCI)/methylisothiazolinone (MI)- and/or MI-sensitized patients who developed airborne allergic contact dermatitis following exposure to isothiazolinone-containing paint. RESULTS: Forty-four cases were identified, with mostly non-occupational exposure (79.5%). Of the patients, 22.5% of also had mucosal symptoms. In several cases, the dermatitis required systemic corticosteroids (27.3%), hospitalization (9.1%), and/or sick leave (20.5%). A median delay of 5.5 weeks was necessary to enable patients to enter a freshly painted room without a flare-up of their dermatitis. Approximately one-fifth of the patients knew that they were allergic to MI and/or MCI/MI before the exposure to paints occurred. CONCLUSION: Our series confirms that airborne allergic contact dermatitis caused by paints containing isothiazolinones is not rare, and may be severe and long-lasting. Better regulation of isothiazolinone concentrations in paints, and their adequate labelling, is urgently needed</style></abstract><notes><style face="normal" font="default">DA - 20170427IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12795</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28449346">PM:28449346</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170427-AmslerE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170427-AmslerE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170427, Amsler E</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12795</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41335</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Forte,G.C.</style></author><author><style face="normal" font="default"> da Silva,D.R.</style></author><author><style face="normal" font="default"> Hennemann,M.L.</style></author><author><style face="normal" font="default"> Sarmento,R.</style></author><author><style face="normal" font="default"> Almeida,J.C.</style></author><author><style face="normal" font="default"> de Tarso Roth,D.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Universidade Federal do Rio Grande do Sul, Programa de Pos Graduacao em Ciencias Pneumologicas , Porto Alegre , 90040-060 Brazil</style></auth-address><titles><title><style face="normal" font="default">Diet effects in the asthma treatment: A systematic review</style></title><secondary-title><style face="normal" font="default">Crit Rev Food Sci Nutr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Crit Rev Food Sci Nutr</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Caffeine</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fatty acid</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Magnesium</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Propolis</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Randomized clinical trial</style></keyword><keyword><style face="normal" font="default"> Randomized clinical trials</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword><keyword><style face="normal" font="default"> Weight Loss</style></keyword></keywords><dates><year Day="31" Month="3" Year="2017">2017/3/31</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Obesity in asthmatic patients has important relationships with asthma control, pulmonary function, and quality of life. The objective of this study was to conduct a systematic review of the literature on the effect of diet on asthma management in adults. METHODS: We searched PubMed, Embase, and Scopus (January 1948-October 2014) for randomized clinical trials that evaluated the effects of diet in adults with asthma. RESULTS: Of 12,215 studies identified, 21 were included. A reduction in weight of at least 7.5% from baseline as a result of caloric restriction can be beneficial for improving disease control, quality of life, and pulmonary function in obese patients with asthma. A dietary pattern rich in foods with potential antioxidant effect had an impact in improving asthma control, but with little clinical significance. Studies involving antioxidant supplementation showed improvements in asthma control with magnesium supplementation and less decline in lung function with vitamin C supplementation. Studies of fatty acid supplementation demonstrated effects on weight loss and improvement of asthma control and lung function. Studies of supplementation with propolis and caffeine reported significant increases in FEV1. Conversely, studies of high dietary salt intake reported greater declines in lung function. CONCLUSIONS: The evidence shows that, for obese adults with asthma, the best dietary intervention seems to be caloric restriction, regardless of specific dietary components</style></abstract><notes><style face="normal" font="default">DA - 20170331IS - 1549-7852 (Electronic)IS - 1040-8398 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1080/10408398.2017.1289893</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28362110">PM:28362110</url></web-urls></urls><custom2><style face="normal" font="default">20170331, Forte GC</style></custom2><misc3><style face="normal" font="default">10.1080/10408398.2017.1289893</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41336</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vukmanovic,S.</style></author><author><style face="normal" font="default"> Sadrieh,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Cosmetics Division, Office of Cosmetics and Colors (OCAC) , Center for Food Safety and Applied Nutrition (CFSAN), Food and Drug Administration (FDA) , MD , USAa Cosmetics Division, Office of Cosmetics and Colors (OCAC) , Center for Food Safety and Applied Nutrition (CFSAN), Food and Drug Administration (FDA) , MD , USA</style></auth-address><titles><title><style face="normal" font="default">Skin sensitizers in cosmetics and beyond: potential multiple mechanisms of action and importance of T-cell assays for in vitro screening</style></title><secondary-title><style face="normal" font="default">Crit Rev Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Crit Rev Toxicol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Autoantigens</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Color</style></keyword><keyword><style face="normal" font="default"> Computer</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cosmetic products</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> delayed-type hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Modeling</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> office</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Vaccination</style></keyword></keywords><dates><year Day="22" Month="3" Year="2017">2017/3/22</year></dates><abstract><style face="normal" font="default">Allergic contact dermatitis (ACD) is a delayed-type hypersensitivity (DTH) reaction induced by repeated contact with sensitizers. The ability of a chemical to act as a sensitizer has most frequently been tested in animals. As the use of animals for these purposes is gradually and globally being phased out, there is a need for reliable in vitro surrogate assays. Currently proposed in vitro assays are designed to test four key events of the adverse outcome pathway (AOP) involving covalent modification of self-proteins by sensitizers (haptenation) and presentation of new antigens (hapten/carrier complexes) to the immune system. There appears to be imperfect alignment of in vitro assays with clinical and/or animal data, suggesting possibly additional mechanisms of ACD development. Indeed, studies on allergies to small drugs, small chemical-induced HLA-peptide exchange for vaccination purposes and cosmetic ingredient-induced exposure of autoantigens suggest a possibility of DTH response promotion by hapten/carrier-independent mechanisms. Therefore, there is a need for additional appropriate in vitro assays, in order to achieve maximal concordance between clinical and/or animal data and in vitro assays. In this paper, we will review evidence supporting the idea of diverse mechanisms of ACD development. We will also discuss the impact of these multiple mechanisms, on the AOP and on the in vitro assays that should be used for allergen detection. We will propose alloreactivity-like reactions, aided by computer modeling and biochemical tests of compound-HLA binding, as additional tools for better prediction of DTH reactions, resulting from exposure to ingredients in cosmetic products. The combination of the proposed tests, along with the existing assays, should further enhance animal-free assessment of sensitizing potential of individual chemicals</style></abstract><notes><style face="normal" font="default">DA - 20170322IS - 1547-6898 (Electronic)IS - 1040-8444 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/10408444.2017.1288025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28326907">PM:28326907</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Crit Rev Toxicol\20170322-VukmanovicS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">CF:\A&amp;H LMW Papers\Crit Rev Toxicol\20170322-VukmanovicS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170322, Vukmanovic S</style></custom2><misc3><style face="normal" font="default">10.1080/10408444.2017.1288025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41337</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Iyer,D.</style></author><author><style face="normal" font="default"> Mishra,N.</style></author><author><style face="normal" font="default"> Agrawal,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">CSIR Institute of Genomics and Integrative Biology, Delhi University campus, Mall Road, Delhi, 110007, India</style></auth-address><titles><title><style face="normal" font="default">Mitochondrial Function in Allergic Disease</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="29">29-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Pollutants</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Genomics</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Mitochondria</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Oxidative Stress</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> pollutants</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> ROS</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">PURPOSE OF THE REVIEW: The connections between allergy, asthma and metabolic syndrome are becoming increasingly clear. Recent research suggests a unifying mitochondrial link between the diverse phenotypes of these interlinked morbidities. The scope of this review is to highlight cellular mechanisms, epidemiology and environmental allergens influencing mitochondrial function and its importance in allergy and asthma. We briefly also consider the potential of mitochondria-targeted therapies in prevention and cure. RECENT FINDINGS: Recent research has shown allergy, asthma and metabolic syndrome to be linked to mitochondrial dysfunction. Environmental pollutants and allergens are observed to cause mitochondrial dysfunction, primarily by inducing oxidative stress and ROS production. Malfunctioning mitochondria change the bioenergetics of the cell and its metabolic profile to favour systemic inflammation, which drives all three types of morbidities. Given the existing experimental evidence, approaches targeting mitochondria (e.g. antioxidant therapy and mitochondrial replacement) are being conducted in relevant disease models-with some progressing towards clinical trials, making mitochondrial function the focus of translational therapy research in asthma, allergy and linked metabolic syndrome</style></abstract><notes><style face="normal" font="default">DA - 20170421IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - India -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0695-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28429306">PM:28429306</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-29.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-29.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170421, Iyer D</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0695-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41338</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oakley,G.M.</style></author><author><style face="normal" font="default"> Harvey,R.J.</style></author><author><style face="normal" font="default"> Lund,V.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Otolaryngology-Head and Neck Surgery, University of Utah, 50 N. Medical Dr., 3C120, Salt Lake City, UT, 84132, USA.</style></auth-address><titles><title><style face="normal" font="default">The Role of Macrolides in Chronic Rhinosinusitis (CRSsNP and CRSwNP)</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="30">30-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Indications</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> macrolide</style></keyword><keyword><style face="normal" font="default"> Macrolides</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Non-eosinophilic</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient Selection</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pharmacokinetics</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: We assess the literature on the pharmacokinetics, indications, important considerations, and effectiveness of long-term, low-dose macrolide antibiotics in chronic rhinosinusitis (CRS). RECENT FINDINGS: The key to effective implementation of macrolide therapy in CRS is appropriate patient selection. Macrolides have demonstrated the most benefit in Th1-mediated non-eosinophilic CRS when used for durations of at least 3 months. Macrolide antibiotics have demonstrated great benefit when used for their anti-inflammatory or immunomodulatory properties, which include the blockage of pro-inflammatory cytokines, such as interleukin (IL)-8 and tumor necrosis factor-alpha (TNF-alpha). They have been used in CRS patients not responding to traditional corticosteroid-based treatment regimens, but appear to be most effective specifically in Th1-mediated non-eosinophilic CRS in long durations and low doses. Further research is needed to better identify characteristics known to correlate with macrolide response so early directed therapy can be implemented</style></abstract><notes><style face="normal" font="default">DA - 20170421IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -CO - Australia -CO - United KIngdom -</style></notes><work-type><style face="normal" font="default"> 10.1007/s11882-017-0696-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28429305">PM:28429305</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170421, Oakley GM</style></custom2><misc3><style face="normal" font="default"> 10.1007/s11882-017-0696-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41339</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ueki,S.</style></author><author><style face="normal" font="default"> Ohta,N.</style></author><author><style face="normal" font="default"> Takeda,M.</style></author><author><style face="normal" font="default"> Konno,Y.</style></author><author><style face="normal" font="default"> Hirokawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan.</style></auth-address><titles><title><style face="normal" font="default">Eosinophilic Otitis Media: the Aftermath of Eosinophil Extracellular Trap Cell Death</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="33">33-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Cell Death</style></keyword><keyword><style face="normal" font="default"> Cell Degranulation</style></keyword><keyword><style face="normal" font="default"> Chromatin</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> eotaxin</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Interleukin-5</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> Otitis</style></keyword><keyword><style face="normal" font="default"> Otitis Media</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Polymers</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Viscosity</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Eosinophilic otitis media (EOM) is a refractory disease characterized by the accumulation of eosinophils in middle ear effusion and mucosa. We summarize current knowledge regarding the clinical characteristics and management of EOM. Although eosinophil activation in inflamed foci is involved in the pathogenesis of EOM, little is known about the fate of the eosinophils and aftermath of their cell death. We discuss the possibility that eosinophils undergo non-apoptotic cell death that worsens tissue damage and increases effusion viscosity. RECENT FINDINGS: Unlike chronic otitis media, EOM is strongly associated with an allergic background. Corticosteroids are currently the only effective pharmacological treatment, and surgical intervention is often required. Mucosal eosinophils infiltrate extensively into the middle ear cavity where they are stimulated by locally produced activators including interleukin-5 and eotaxin. The eosinophils undergo cytolysis in the effusion, which represents a major fate of activated eosinophils in vivo. Recent data revealed cytolysis could be renamed as extracellular trap cell death (ETosis). ETosis represents suicidal cell death involving total cell degranulation and development of sticky chromatin structures (extracellular traps (ETs)). The characteristics of eosinophil- and neutrophil-derived ET polymers might contribute to the difference in viscosity of secretions between EOM and common chronic otitis media. The extracellular products remaining after eosinophil ETosis are an important aspect of EOM pathology. The concept of ETosis also has novel implications for potential therapeutic modalities in various eosinophilic disorders</style></abstract><notes><style face="normal" font="default">DA - 20170429IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0702-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28455742">PM:28455742</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-33.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170429, Ueki S</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0702-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41340</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Coffin,S.L.</style></author><author><style face="normal" font="default"> Turrentine,J.E.</style></author><author><style face="normal" font="default"> Cruz,P.D.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Dermatology, Augusta University, 1004 Chafee Ave, FH-100, Augusta, GA, 30904, USA</style></auth-address><titles><title><style face="normal" font="default">Photodermatitis for the Allergist</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="36">36-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> Immunomodulation</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: The photodermatoses represent a group of disorders of sensitivity to light that continue to pose difficulties in diagnosis and management. Photodermatoses are of interest to allergists because many photosensitive skin disorders have immunologic underpinnings, and patients often present to clinic complaining of "allergy" to the sun. We provide a concise reference for allergists on the clinical recognition and management of photodermatitis. RECENT FINDINGS: New developments in the understanding of immunomodulatory effects of light have demonstrated normally immunosuppressive responses in the skin to light exposure, and a blunted immunosuppressive response in the pathogenesis of many photodermatoses. Vitamin D plays an important role in immunomodulation and itself may be affected by photodermatoses due to the impact of photoprotective treatment strategies on circulating vitamin D levels. The elucidation of the immunological basis of many photodermatoses may provide guidance for developing new treatment modalities. Further research is necessary to determine the optimal management of vitamin D metabolism in patients with photodermatoses</style></abstract><notes><style face="normal" font="default">DA - 20170506IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0705-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477263">PM:28477263</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-36.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170506, Coffin SL</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0705-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41341</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kwong,C.G.</style></author><author><style face="normal" font="default"> Bacharier,L.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Immunology and Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine in St. Louis, St. Louis Children's Hospital, One Children's Place, St. Louis, MO, 63110, USA</style></auth-address><titles><title><style face="normal" font="default">Microbes and the Role of Antibiotic Treatment for Wheezy Lower Respiratory Tract Illnesses in Preschool Children</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="34">34-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Azithromycin</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> early childhood</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infancy</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> macrolide</style></keyword><keyword><style face="normal" font="default"> Macrolides</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbes</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> preschool children</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Medicine</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Respiratory tract infection</style></keyword><keyword><style face="normal" font="default"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viruses</style></keyword><keyword><style face="normal" font="default"> Washington</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Antibiotics are commonly used to treat wheezy lower respiratory tract illnesses in preschoolers, although these infections have been traditionally thought to be predominantly of viral origin. Our purpose is to review recent research pertaining to the role of antibiotics in lower respiratory tract illnesses and on subsequent asthma development, as well as the possible mechanisms of their effects. RECENT FINDINGS: Increasing evidence suggests that asthma pathogenesis is associated with events during infancy and early childhood, particularly respiratory tract infections. While viruses are frequently detected in children with lower respiratory tract infections, the presence of potentially pathogenic bacteria is also often detected and may play a role in asthma pathogenesis. Recent evidence suggests that use of macrolides, particularly azithromycin, may decrease the risk of and duration of lower respiratory tract illnesses and prevent future episodes in specific high-risk populations. Infants and preschoolers who have wheezy lower respiratory tract illnesses have a higher risk of asthma development. Alterations in the microbiome are thought to be influential. While several recent studies identify azithromycin as a therapeutic option in these illnesses, additional research is needed</style></abstract><notes><style face="normal" font="default">DA - 20170430IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0701-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28456910">PM:28456910</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-34.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170430, Kwong CG</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0701-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41342</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Estrada,R.D.</style></author><author><style face="normal" font="default"> Ownby,D.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">College of Nursing, University of South Carolina, Columbia, SC, USA.</style></auth-address><titles><title><style face="normal" font="default">Rural Asthma: Current Understanding of Prevalence, Patterns, and Interventions for Children and Adolescents</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="37">37-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Barriers</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic illness</style></keyword><keyword><style face="normal" font="default"> Cigarette</style></keyword><keyword><style face="normal" font="default"> cigarette smoke</style></keyword><keyword><style face="normal" font="default"> Columbia</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Housing</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Nursing</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Population Density</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rural</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Smoke</style></keyword><keyword><style face="normal" font="default"> South Carolina</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Asthma is the most common chronic illness of children and adolescents in the USA. While asthma has been understood to disproportionately affect urban dwellers, recent investigations have revealed rural pediatric asthma prevalence to be very similar to urban and to be more closely correlated with socioeconomic and environmental factors than geographic location or population density. RECENT FINDINGS: Rural children experience factors unique to location that impact asthma development and outcomes, including housing quality, cigarette smoke exposure, and small/large-scale farming. Additionally, there are challenging barriers to appropriate asthma care that frequently are more severe for those living in rural areas, including insurance status, lack of primary care providers and pulmonary specialists, knowledge deficits (both patient and provider), and a lack of culturally tailored asthma interventions. Interventions designed to address rural pediatric asthma disparities are more likely to be successful when targeted to specific challenges, such as the use of school-based services or telemedicine to mitigate asthma care access issues. Continued research on understanding the complex interaction of specific rural environmental factors with host factors can inform future interventions designed to mitigate asthma disparities</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default"> 10.1007/s11882-017-0704-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28484946">PM:28484946</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-37.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-37.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Estrada RD</style></custom2><misc3><style face="normal" font="default"> 10.1007/s11882-017-0704-3</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41343</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mosnaim,G.S.</style></author><author><style face="normal" font="default"> Akkoyun,E.</style></author><author><style face="normal" font="default"> Eng,J.</style></author><author><style face="normal" font="default"> Shalowitz,M.U.</style></author></authors></contributors><auth-address><style face="normal" font="default">NorthShore University HealthSystem, Evanston, Illinois, USA</style></auth-address><titles><title><style face="normal" font="default">Behavioral interventions to improve asthma outcomes: a systematic review of recent publications</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="200" start="194">194-200</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">acute asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma education</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Illinois</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> low income</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Publications</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Self-management</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Asthma outcomes are influenced by factors at multiple ecological levels: the individual and his/her family, home, medical care, and community. This systematic review describes recently published single-level and multilevel behavioral interventions to improve asthma outcomes. RECENT FINDINGS: Of the 23 total title/abstracts reviewed in the original systematic search of PubMed, Ovid, Scopus, PsychINFO, and CIHAHL reference review databases, six met inclusion criteria. Five of the studies focused on low-income and/or minority populations. Promising interventions include culturally tailored online asthma self-management programs and family-centered asthma education delivered at the bedside during hospitalization for an acute asthma exacerbation. SUMMARY: Culturally, tailored online self-management programs offer difficult-to-reach populations asthma support that can be completed at the time and pace most convenient for the individual user. Family-focused asthma education, delivered at the bedside during an acute asthma hospitalization by highly motivated lay volunteers, is an efficacious and low-cost approach to improving pediatric asthma self-management</style></abstract><notes><style face="normal" font="default">DA - 20170331IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000359</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28362676">PM:28362676</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-194-200.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-194-200.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170331, Mosnaim GS</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000359</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41344</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cruz,A.A.</style></author><author><style face="normal" font="default"> Stelmach,R.</style></author><author><style face="normal" font="default"> Ponte,E.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">aProAR-Nucleo de Excelencia em Asma da Universidade Federal da Bahia, Salvador, Bahia bPulmonary Division, Heart Institute (InCor), Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo cFaculdade de Medicina de Jundiai, Jundiai, Brazil</style></auth-address><titles><title><style face="normal" font="default">Asthma prevalence and severity in low-resource communities</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="193" start="188">188-193</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Asma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Controller medications</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Developed Countries</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Income</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> low income</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Publications</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Urbanization</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword><keyword><style face="normal" font="default"> World Health</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: The prevalence of asthma was thought to be low in most low-income countries, but several reports have indicated this is not always true. This is a narrative review of recent publications on the burden of asthma in low and middle-income countries (LMIC) and underprivileged communities from developed countries. RECENT FINDINGS: Several studies have reported a low prevalence of asthma is LMIC, but indicate it is increasing. In the last few years, however, many surveys demonstrated this may not always be true. An analysis of the International Study for Asthma and Allergy in Childhood phase III database indicated although the prevalence of asthma among children and adolescents is higher in the developed countries, symptoms of asthma are often more severe in less affluent nations. The rate of uncontrolled asthma is also higher among underprivileged communities of developed countries. Secondary analysis of data generated by the WHO's world health survey performed among adults of 70 countries indicate symptoms of asthma are less frequent in middle-income countries and more frequent in the extremes, low income and high income. This sort of U shaped distribution suggests the disease (or syndrome) comprise more than one major phenotype related to diverse underlying mechanisms. In fact, recent reports show symptoms of asthma among the poor are associated with unhygienic living conditions, which may reduce the risk of atopy but increase the risk of nonatopic wheezing. Urbanization and exposure to air pollution also seem to contribute to an increasing prevalence severity of asthma in LMIC. Access to proper diagnosis and treatment with controller medications for asthma, specially with inhaled corticosteroids is feasible and cost-effective, reduce symptoms, health resource utilization, improves quality of life, and reduce mortality in low-resource settings. SUMMARY: Prevalence of asthma was thought to be low in low-income countries, but several reports have indicated this is not always true. Under diagnosis, under treatment, exposure to air pollution, and unhygienic living conditions may contribute to a higher frequency and severity of symptoms of asthma among the poor. Proper diagnosis and treatment with controller medications for asthma is feasible and cost-effective in low-resource settings</style></abstract><notes><style face="normal" font="default">DA - 20170323IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000360</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28333691">PM:28333691</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-188-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Allergy Clin Immunol\2017-17-188-93.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170323, Cruz AA</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000360</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41345</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wada,K.J.</style></author><author><style face="normal" font="default"> Calhoun,K.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Department of Otolaryngology Head &amp; Neck Surgery, The Ohio State University Wexner School of Medicine, Columbus, Ohio, USA</style></auth-address><titles><title><style face="normal" font="default">US antibiotic stewardship and penicillin allergy</style></title><secondary-title><style face="normal" font="default">Curr Opin Otolaryngol Head Neck Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Opin Otolaryngol Head Neck Surg</style></abbr-1></periodical><pages end="254" start="252">252-254</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy history</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Ohio</style></keyword><keyword><style face="normal" font="default"> Otolaryngology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> Stewardship</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: The purpose of this review is to improve otolaryngologists' antibiotic stewardship by detailing current approaches to penicillin allergy. RECENT FINDINGS: Although up to 15% of hospitalized patients in the United States have a penicillin allergy recorded on their charts, fewer than 10% of these have a true penicillin allergy. SUMMARY: Using a combination of a detailed allergy history, skin testing and graded-dose administration, many patients whose charts say 'penicillin-allergic' can safely be treated with penicillin and cross-reacting antibiotics. This permits use of narrower-spectrum antibiotics and saves money</style></abstract><notes><style face="normal" font="default">DA - 20170420IS - 1531-6998 (Electronic)IS - 1068-9508 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/MOO.0000000000000364</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28426527">PM:28426527</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Otolaryngol Head Neck Surg\2017-25-252-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Otolaryngol Head Neck Surg\2017-25-252-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170420, Wada KJ</style></custom2><misc3><style face="normal" font="default">10.1097/MOO.0000000000000364</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41346</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Maspero,J.F.</style></author><author><style face="normal" font="default"> Serrano,F.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Allergic Rhinitis and Sexual Dysfunction</style></title><secondary-title><style face="normal" font="default">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Treat Options Allergy</style></full-title></periodical><pages end="70" start="62">62-70</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Argentina</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2196-3053</style></isbn><abstract><style face="normal" font="default">Sexual dysfunction is perhaps an important co-morbidity of allergic rhinitis and other upper airway diseases in adults; however, its prevalence and importance are underestimated mainly due to lack of assessment by the physician and lack of reporting by the patients. The clue for a successful treatment relies in adequate diagnosis and understanding of the mechanisms involved in the generation of the symptoms</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Argentina -</style></notes><work-type><style face="normal" font="default">10.1007/s40521-017-0112-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-017-0112-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-62-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-62-70.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170514, Maspero JF</style></custom2><misc3><style face="normal" font="default">10.1007/s40521-017-0112-x</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41347</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Maouia,A.</style></author><author><style face="normal" font="default"> Youssef,M.</style></author><author><style face="normal" font="default"> Leban,N.</style></author><author><style face="normal" font="default"> Helal,A.N.</style></author><author><style face="normal" font="default"> Kassab,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Laboratory of Bioressources , Integrative Biology and Valorization, Higher Institute of Biotechnology of Monastir , Tunisia</style></auth-address><titles><title><style face="normal" font="default">CRP relevance in clinical assessment of chronic spontaneous urticaria Tunisian patients</style></title><secondary-title><style face="normal" font="default">Cutan Ocul Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cutan Ocul Toxicol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">albumin</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Biotechnology</style></keyword><keyword><style face="normal" font="default"> cat</style></keyword><keyword><style face="normal" font="default"> Catalase</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> desloratadine</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gamma-Globulins</style></keyword><keyword><style face="normal" font="default"> Globulins</style></keyword><keyword><style face="normal" font="default"> Glutathione</style></keyword><keyword><style face="normal" font="default"> Glutathione Peroxidase</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Leukocytes</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Oxidative Stress</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Peroxidase</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Remission</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Superoxide Dismutase</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Tunisia</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wheal</style></keyword></keywords><dates><year Day="28" Month="3" Year="2017">2017/3/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic spontaneous urticaria (CSU) is a common dermatological condition defined by the sudden occurrence of daily wheals and pruritus for at least 6 weeks. Multifactorial origin is suggested such as Oxidative stress. This latter may play a double role as a trigger and remnant agent. OBJECTIVES: The first aim of this study is to investigate antioxidant status, inflammatory proteins, hematologic counts and clinical assessment in CSU patients. The second aim is to evaluate the effect of a first-line treatment: Desloratadine 5mg/day on these different parameters. PATIENTS AND METHODS: This study enrolled 30 CSU patients and same number of controls. We assessed the Urticaria Activity Score (UAS), Total antioxidant status (TAS), glutathione S-Transferase (GST), Superoxide dismutase (SOD), glutathione peroxidase (GPx), Catalase (CAT), Albumin, Alpha 1, alpha2, beta1 beta2, gamma globulins, CRP and hematologic numeration. RESULTS: At baseline Alpha1, alpha2, beta1, beta2, gamma globulins, CRP, SOD activity, leukocytes and basophils were significantly higher in patients versus controls (p &lt; 0.05). TAS, GST, CAT, GPx and albumin were significantly low in patients versus controls (p &lt; 0.05). After treatment, TAS, GST and GPx were significantly increased in patients versus patients before treatment (p &lt; 0.001). SOD, alpha1, alpha2, beta1, beta2, gamma globulins, CRP, albumin, leukocytes and basophils were significantly decreased after treatment versus before treatment (p &lt; 0.05). A significant correlation between CRP and UAS (r = 0.3; p = 0.011) was noted. UAS assessment revealed the efficacy of 30 days-antihistaminic treatment. CONCLUSION: Desloratadine exerted anti-inflammatory and antioxidant effects on CSU patients revealed by CRP. Patients' remission was synergistic to CRP attenuation emphasizing CRP relevance for CSU clinical assessment</style></abstract><notes><style face="normal" font="default">DA - 20170329IS - 1556-9535 (Electronic)IS - 1556-9527 (Linking)LA - engPT - Journal ArticleCO - Tunisia -</style></notes><work-type><style face="normal" font="default">10.1080/15569527.2017.1311338</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28351163">PM:28351163</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cutan Ocul Toxicol\20170329-Maouia.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cutan Ocul Toxicol\20170329-Maouia.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170329, Maouia A</style></custom2><misc3><style face="normal" font="default">10.1080/15569527.2017.1311338</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41348</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Balakirski,G.</style></author><author><style face="normal" font="default"> Merk,H.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Dermatology and Allergology , RWTH Aachen University , Aachen , Germanya Department of Dermatology and Allergology , RWTH Aachen University , Aachen , Germany</style></auth-address><titles><title><style face="normal" font="default">Cutaneous Allergic Drug Reactions: Update on Pathophysiology, Diagnostic Procedures and Differential Diagnostic</style></title><secondary-title><style face="normal" font="default">Cutan Ocul Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cutan Ocul Toxicol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acute Generalized Exanthematous Pustulosis</style></keyword><keyword><style face="normal" font="default"> adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic drug reactions</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allopurinol</style></keyword><keyword><style face="normal" font="default"> Amoxicillin</style></keyword><keyword><style face="normal" font="default"> Ampicillin</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Anticonvulsants</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clavulanic Acid</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Differential diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> DRESS</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Drug-induced</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Fluoroquinolones</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> NSAID</style></keyword><keyword><style face="normal" font="default"> NSAIDs</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photosensitivity</style></keyword><keyword><style face="normal" font="default"> Photosensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default"> Stevens-Johnson Syndrome</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Targeted therapy</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Toxic epidermal necrolysis</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="17" Month="4" Year="2017">2017/4/17</year></dates><abstract><style face="normal" font="default">Important changes in the understanding and management of drug hypersensitivity reactions during the last years result from the increasing importance of biologics in medical practice, which differ in their spectrum of adverse drug reactions (ADRs) from the classical covalent drugs. With regard to covalent drugs, ampicillin and amoxicillin as well as clavulanic acid play an increasing role among ADRs to betalactam antibiotics. Fluoroquinolones are mainly the cause of anaphylactic and photosensitivity reactions. Especially in allergic reactions to NSAIDs, pseudoallergic reactions should be considered in the differential diagnosis. In opposite to the main cutaneous allergic drug reactions such as urticaria or maculopapular skin rash, in which antibiotics are the main culprits, in severe drug allergic reactions such as SJS (Stevens-Johnson Syndrome), TEN (Toxic Epidermal Necrolysis), or DRESS (Drug Reaction with Eosinophilia and Systemic Symptom Syndrome) compounds like allopurinol and anticonvulsants are the main causes. Similar mutations in the IL36R gene, which were found in both patients with an AGEP (Acute Generalized Exanthematous Pustulosis) and pustular psoriasis, makes the differential diagnosis more difficult and raises the question whether there is a difference between these diseases or whether AGEP is not just a drug induced pustular psoriasis. Finally, some special aspects of side effects of biologics and targeted therapies respectively are discussed</style></abstract><notes><style face="normal" font="default">DA - 20170417IS - 1556-9535 (Electronic)IS - 1556-9527 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1080/15569527.2017.1319379</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28412864">PM:28412864</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cutan Ocul Toxicol\20170417-BalakirskiG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cutan Ocul Toxicol\20170417-BalakirskiG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170417, Balakirski G</style></custom2><misc3><style face="normal" font="default">10.1080/15569527.2017.1319379</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41349</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Engelhart,S.</style></author><author><style face="normal" font="default"> Segal,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Harvard Medical School, Boston, Massachusetts, USADivision of Dermatology, University of Arizona, Tucson, USA</style></auth-address><titles><title><style face="normal" font="default">Allergic reaction to vanadium causes a diffuse eczematous eruption and titanium alloy orthopedic implant failure</style></title><secondary-title><style face="normal" font="default">Cutis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cutis</style></full-title></periodical><pages end="249" start="245">245-249</pages><volume><style face="normal" font="default">99</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Aluminum</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Arizona</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Corrosion</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Foot</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Titanium</style></keyword><keyword><style face="normal" font="default"> Trace Elements</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Vanadium</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">Allergy as a cause of adverse outcomes in patients with implanted orthopedic hardware is controversial. Allergy to titanium-based implants has not been well researched, as titanium is traditionally thought to be inert. We highlight the case of a patient who developed systemic dermatitis and implant failure after surgical placement of a titanium alloy (Ti6Al4V) plate in the left foot. The hardware was removed and the eruption cleared in the following weeks. The plate and screws were submitted for metal analysis. The elemental composition of both the plate and screws included 3 major elements-titanium, aluminum, and vanadium-as well as trace elements. Metal analysis revealed that the plate and screws had different microstructures, and electrochemical studies demonstrated that galvanic corrosion could have occurred between the plate and screws due to their different microstructures, contributing to the release of vanadium in vivo. The patient was patch tested with several metals including components of the implant and had a positive patch test reaction only to vanadium trichloride. These findings support a diagnosis of vanadium allergy and suggests that clinicians should consider including vanadium when patch testing patients with a suspected allergic reaction to vanadium-containing implants</style></abstract><notes><style face="normal" font="default">DA - 20170511IS - 2326-6929 (Electronic)IS - 0011-4162 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28492599">PM:28492599</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cutis\2017-99-245-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cutis\2017-99-245-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170511, Engelhart S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41350</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Penn,E.H.</style></author><author><style face="normal" font="default"> Chung,H.J.</style></author><author><style face="normal" font="default"> Keller,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Jefferson Medical College, Philadelphia, Pennsylvania, USA</style></auth-address><titles><title><style face="normal" font="default">Imatinib mesylate-induced lichenoid drug eruption</style></title><secondary-title><style face="normal" font="default">Cutis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cutis</style></full-title></periodical><pages end="192" start="189">189-192</pages><volume><style face="normal" font="default">99</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Alopecia</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous manifestations</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug eruption</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Erythema Multiforme</style></keyword><keyword><style face="normal" font="default"> Folliculitis</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> imatinib</style></keyword><keyword><style face="normal" font="default"> Leukemia</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Pennsylvania</style></keyword><keyword><style face="normal" font="default"> Philadelphia</style></keyword><keyword><style face="normal" font="default"> Photosensitivity</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default"> Stevens-Johnson Syndrome</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Tyrosine</style></keyword><keyword><style face="normal" font="default"> tyrosine kinase</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Vasculitis</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). Since then, the number of indicated uses for imatinib has substantially increased. It is increasingly important that dermatologists recognize adverse cutaneous manifestations of imatinib and are aware of their management and outcomes to avoid unnecessarily discontinuing a potentially lifesaving medication. Adverse cutaneous manifestations in response to imat-inib are not infrequent and can include dry skin, alopecia, facial edema, and photosensitivity rash. Other less common manifestations include exfoliative dermatitis, nail disorders, psoriasis, folliculitis, hypotrichosis, urticaria, petechiae, Stevens-Johnson syndrome, erythema multiforme, Sweet syndrome, and leukocytoclastic vasculitis. We report a case of imatinib-induced lichenoid drug eruption (LDE), a rare cutaneous manifestation, along with a review of the literature</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 2326-6929 (Electronic)IS - 0011-4162 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28398413">PM:28398413</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cutis\2017-99-189-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cutis\2017-99-189-92.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, Penn EH</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41351</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Signore,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology, Private Practice, Tinley Park, Illinois.</style></auth-address><titles><title><style face="normal" font="default">Prevention of poison ivy dermatitis with oral homeopathic Rhus toxicodendron</style></title><secondary-title><style face="normal" font="default">Dermatol Online J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatol Online J</style></full-title></periodical><pages end="" start="17">17-</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dermatosis</style></keyword><keyword><style face="normal" font="default"> Discontinue</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Illinois</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Mouth</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Private Practice</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Rhus</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Soaps</style></keyword><keyword><style face="normal" font="default"> Solvents</style></keyword><keyword><style face="normal" font="default"> Toxicodendron</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="15" Month="1" Year="2017">2017/1/15</year></dates><abstract><style face="normal" font="default">Acute allergic contact dermatitis to poison ivy is acommon and miserable dermatosis which affectsmillions of Americans each year. Preventativemeasures, such as avoidance, protective clothing,barrier creams, soaps, and solvents often fail despiteour patients' best attempts. Severe allergic reactionsto poison ivy are a significant source of decreasedemployee productivity owing to inability to work anda major health care expenditure. Patients may haveto leave their jobs and discontinue favorite outdoorrecreational activities as a result of severe urushiolsensitivity. Thus, a simple and effective method ofpreventing poison ivy dermatitis would be of greatbenefit to clinical dermatologists and their patients.Complementary and alternative medical practitionerscommonly prescribe homeopathic poison ivyproducts by mouth for the prevention of poisonivy dermatitis. Yet, conventional dermatologists aremostly unaware of this little known clinical pearl. Theauthor discusses two open studies and anecdotalexperience with administration of homeopathicpoison ivy in the prevention of acute allergic contactdermatitis related to poison ivy exposure. Potentialadvantages could include patient acceptability,ease of administration, affordability, and availability.Randomized clinical trials are needed to furtherevaluate the safety and efficacy of this interesting andpromising clinical tip</style></abstract><notes><style face="normal" font="default">DA - 20170322IS - 1087-2108 (Electronic)IS - 1087-2108 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28329482">PM:28329482</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatol Online J\2017-23-17.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatol Online J\2017-23-17.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170322, Signore RJ</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41352</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Han,S.B.</style></author><author><style face="normal" font="default"> Kim,H.</style></author><author><style face="normal" font="default"> Cho,S.H.</style></author><author><style face="normal" font="default"> Chung,J.H.</style></author><author><style face="normal" font="default"> Kim,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">*Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea; daggerLaboratory of Cutaneous Aging Research, Clinical Research Institute, Seoul National University Hospital, Seoul, Korea; double daggerInstitute of Dermatological Science, Seoul National University, Seoul, Korea; section signDepartment of Dermatology, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Protective Effect of Botulinum Toxin Type A Against Atopic Dermatitis-Like Skin Lesions in NC/Nga Mice</style></title><secondary-title><style face="normal" font="default">Dermatol Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatol Surg</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aging</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Back</style></keyword><keyword><style face="normal" font="default"> Cell Count</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> Injections</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Itch</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Rosacea</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> Tacrolimus</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> TEWL</style></keyword><keyword><style face="normal" font="default"> transepidermal water loss</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword></keywords><dates><year Day="24" Month="4" Year="2017">2017/4/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: Botulinum neurotoxin (BTX) A possesses various biological activities, including anti-inflammatory and antipruritic actions. Human and animal studies have shown that BTX is effective in treating histamine-induced itch, lichen simplex chronicus, psoriasis, rosacea, allergic rhinitis, and scar prevention. However, its effect on atopic dermatitis (AD) has not been studied yet. OBJECTIVE: To examine the effect of BTX on AD using a mouse model. The primary outcome was skin thickness and transepidermal water loss (TEWL), and the secondary outcome was the alteration in skin severity scores, histological, and laboratory test results. METHODS: Forty-two NC/Nga mice (a mouse model for AD) were allocated into 6 groups (the untreated, 2-Chloro-1,3,5-trinitrobenzene [TNCB] alone, TNCB + BTX 30 U/kg, TNCB + BTX 60 U/kg, TNCB + vehicle [0.9% saline], TNCB + 0.03% tacrolimus). Those of the BTX group received intradermal injections of BTX on the rostral back once on the day of TNCB sensitization. The effect of BTX in TNCB-treated NC/Nga mice was assessed by measuring skin thickness, TEWL (primary outcome), the skin severity scores, histological changes of test skin including mast cell count, interleukin (IL)-4 mRNA and protein expression, and total serum IgE (secondary outcome). RESULTS: A single intradermal injection of BTX significantly suppressed skin thickness and TEWL in the TNCB-applied skin. The clinical severity scores, acanthosis and mast cell infiltration, were less in the BTX groups. BTX injection also inhibited TNCB-induced increase in IL-4 mRNA and protein expression in mice, but its effect on serum IgE level was not significant. CONCLUSION: The preliminary results suggest that BTX may be a novel approach to the prevention and supplemental treatment of acute AD lesions</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 1524-4725 (Electronic)IS - 1076-0512 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1097/DSS.0000000000001170</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28445195">PM:28445195</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatol Surg\20170426-HanSB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatol Surg\20170426-HanSB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Han SB</style></custom2><misc3><style face="normal" font="default">10.1097/DSS.0000000000001170</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41353</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jenkinson,H.A.</style></author><author><style face="normal" font="default"> Wilmas,K.M.</style></author><author><style face="normal" font="default"> Silapunt,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">*University of Texas McGovern Medical School at Houston, Houston, Texas; daggerDepartment of Dermatology, University of Texas McGovern Medical School at Houston, Houston, Texas</style></auth-address><titles><title><style face="normal" font="default">Sodium Tetradecyl Sulfate: A Review of Clinical Uses</style></title><secondary-title><style face="normal" font="default">Dermatol Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatol Surg</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Granuloma</style></keyword><keyword><style face="normal" font="default"> Hyperpigmentation</style></keyword><keyword><style face="normal" font="default"> Infarction</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Embolism</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Sarcoma</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> Stroke</style></keyword><keyword><style face="normal" font="default"> Texas</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Varicose Veins</style></keyword><keyword><style face="normal" font="default"> Veins</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: Sodium tetradecyl sulfate (STS) is Food and Drug Administration approved for treatment of varicose veins, but numerous other off-label applications have been reported. OBJECTIVE: To describe the clinical uses of STS, as well as efficacy and adverse effects. METHODS: Review of studies searchable on PubMed from 1938 to 2016 describing clinical uses of STS to determine efficacy and adverse effects associated with various applications. RESULTS: Sodium tetradecyl sulfate has shown efficacy in the treatment of varicose veins, telangiectasias, hemangioma, pyogenic granuloma, cherry angioma, Kaposi sarcoma, lymphangioma circumscriptum, digital mucous cyst, ganglion cyst, glomangioma, angiokeratoma of Fordyce, pseudocyst of the auricle, and verruca. Commonly reported side effects include pain, erythema, swelling, hyperpigmentation, telangiectatic matting, and ulceration. Serious side effects such as anaphylaxis, pulmonary embolism, stroke, and myocardial infarction have also been reported. Most sources were case reports and small prospective studies, as such the strength of data supporting many uses is limited by small sample sizes and lack of controls. CONCLUSION: Although not always the most effective method of treatment in off-label usage, use of STS has been frequently selected for a variety of applications for reasons of simplicity, low cost, lack of availability of technologically advanced equipment, and intricacies related to anatomic location</style></abstract><notes><style face="normal" font="default">DA - 20170421IS - 1524-4725 (Electronic)IS - 1076-0512 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DSS.0000000000001143</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28430735">PM:28430735</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatol Surg\20170421.JenkinsonHA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatol Surg\20170421.JenkinsonHA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170421, Jenkinson HA</style></custom2><misc3><style face="normal" font="default">10.1097/DSS.0000000000001143</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41354</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fioranelli,M.</style></author><author><style face="normal" font="default"> Roccia,M.G.</style></author><author><style face="normal" font="default"> Lotti,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">G.Marconi University, Rome, Italy</style></auth-address><titles><title><style face="normal" font="default">Therapy with anti-interleukin-31 receptor A antibody for atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Dermatol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatol Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Rome</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="10" Month="4" Year="2017">2017/4/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170410IS - 1529-8019 (Electronic)IS - 1396-0296 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/dth.12490</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28394466">PM:28394466</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatol Ther\20170410-FioranelliM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatol Ther\20170410-FioranelliM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170410, Fioranelli M</style></custom2><misc3><style face="normal" font="default">10.1111/dth.12490</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41355</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kluger,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="default">Cutaneous Complications Related to Tattoos: 31 Cases from Finland</style></title><secondary-title><style face="normal" font="default">Dermatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatology</style></full-title></periodical><pages end="109" start="100">100-109</pages><volume><style face="normal" font="default">233</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> Internet</style></keyword><keyword><style face="normal" font="default"> Lichen Planus</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Melanoma</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Ointments</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Private Practice</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Sarcoidosis</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Uveitis</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="26" Month="4" Year="2017">2017/4/26</year></dates><abstract><style face="normal" font="default">BACKGROUND: Cutaneous complications related to permanent tattoos affect 2-30% of those patients who have tattooed their skin. Little is known about the cases of tattoo complications in Finland. OBJECTIVE: The aim of this study was to conduct a retrospective review of a series of Finnish patients with cutaneous tattoo reactions. METHODS: We collected cases of tattoo reactions from the Department of Dermatology at Helsinki University Central Hospital, from members of the Finnish dermatological society and from various other sources (author's private practice, tattooists, professional internet forum). We analysed the demographics, clinical presentation, diagnosis, and microscopic findings on the skin biopsies, and evaluated the therapeutic outcome. RESULTS: Thirty-one patients (16 men and 15 women, mean age 37.8) were included from 9 cities, mainly from Helsinki. Fifty-two percent (16/31) presented with an allergic tattoo reaction mainly against the red colour (75%, 12/16). Reactions were clinically polymorph ranging from scattered papules or nodules to complete infiltration of a colour. Lesions were itchy and sometimes painful. The reactions were lichenoid, granulomatous, pseudolymphomatous or less specific with a dermal lympho-histiocytic or plasmocytic infiltrate. Other diagnoses included tattoo blow-out (13%), melanoma within a tattoo, naevi within a tattoo (10% each), lichen planus (6%), granulomatous reaction with uveitis, sarcoidosis and dermatofibroma (3% each). Allergic tattoo reactions were mainly treated with local corticosteroid (CS) ointments, CS infiltration or surgical removal. CONCLUSION: This review is the largest series of tattoo complications in the Baltic area. It illustrates the wide spectrum of complications. Prospective, controlled therapeutic studies are necessary to assess the best treatment protocols for tattoo allergies and tattoo reaction management in general</style></abstract><notes><style face="normal" font="default">DA - 20170425IS - 1421-9832 (Electronic)IS - 1018-8665 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="default">10.1159/000468536</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28441655">PM:28441655</url></web-urls><related-urls><url ppv-ref="no">presto - 1 anno</url></related-urls></urls><custom2><style face="normal" font="default">20170425, Kluger N</style></custom2><misc3><style face="normal" font="default">10.1159/000468536</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41356</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,D.J.</style></author><author><style face="normal" font="default"> Collaku,A.</style></author><author><style face="normal" font="default"> Dosik,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical Development, GSK, Collegeville, PA, USA</style></auth-address><titles><title><style face="normal" font="default">Skin Irritation and Sensitization Potential of Fixed-Dose Combination of Diclofenac 1% and Menthol 3% Topical Gel: Results of Two Phase I Patch Studies</style></title><secondary-title><style face="normal" font="default">Drug Res (Stuttg)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Drug Res (Stuttg)</style></full-title></periodical><pages end="126" start="119">119-126</pages><volume><style face="normal" font="default">67</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration &amp; dosage</style></keyword><keyword><style face="normal" font="default"> Administration,Cutaneous</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Anti-Inflammatory Agents</style></keyword><keyword><style face="normal" font="default"> Anti-Inflammatory Agents,Non-Steroidal</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Antipruritics</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Irritant</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diclofenac</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Combinations</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Formulation</style></keyword><keyword><style face="normal" font="default"> Gel</style></keyword><keyword><style face="normal" font="default"> Gels</style></keyword><keyword><style face="normal" font="default"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Irritation</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Menthol</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Transdermal Patch</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">Phase I, randomized, controlled patch studies were conducted to evaluate skin sensitization and irritation potential of a new gel formulation containing 1% diclofenac and 3% menthol as a fixed-combination product.In study A, healthy volunteers were exposed to 4 test patches containing 1% diclofenac+3% menthol, diclofenac, menthol, or placebo gels during an induction (nine 48 to 72-h applications) and challenge phase (one 48-h application). Some subjects were re-challenged to evaluate suspected sensitization. Study B participants underwent 21 consecutive 24-h patch applications of the 4 treatments from study A, 0.2% sodium lauryl sulfate (positive control), 0.9% saline, and a marketed gel (1% diclofenac, Voltaren). Application sites were visually scored by blinded observers for skin sensitization/irritation.In study A, 77% of participants showed minimal erythema and signs of glazing and peeling with 1% diclofenac+3% menthol by the end of the induction phase, which diminished during the challenge phase. Similar patterns were seen with menthol gel. Only 1 subject exhibited possible sensitization to 1% diclofenac+3% menthol. In study B, mean cumulative irritation score with 1% diclofenac+3% menthol was significantly higher (P&lt;0.0001) vs. reference treatments; however, the positive control failed to produce the expected level of irritation. No treatment-related adverse events were reported.The sensitization and irritation potential of 1% diclofenac+3% menthol was greater than with the reference treatments. Comparison with positive control was not possible because it did not produce irritation under semiocclusive patch conditions</style></abstract><notes><style face="normal" font="default">DA - 20161125IS - 2194-9387 (Electronic)IS - 2194-9379 (Linking)LA - engPT - Clinical Trial, Phase IPT - Journal ArticlePT - Randomized Controlled TrialRN - 0 (Anti-Inflammatory Agents, Non-Steroidal)RN - 0 (Antipruritics)RN - 0 (Drug Combinations)RN - 0 (Gels)RN - 144O8QL0L1 (Diclofenac)RN - 1490-04-6 (Menthol)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.1055/s-0042-118861</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27887033">PM:27887033</url></web-urls></urls><custom2><style face="normal" font="default">20161125, Liu DJ</style></custom2><misc3><style face="normal" font="default">10.1055/s-0042-118861</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41357</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Snidvongs,K.</style></author><author><style face="normal" font="default"> Seresirikachorn,K.</style></author><author><style face="normal" font="default"> Khattiyawittayakun,L.</style></author><author><style face="normal" font="default"> Chitsuthipakorn,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology, Faculty of Medicine, Chulalongkorn University, 1873 Rama 4 Road, Pathumwan, Bangkok, 10330, Thailand.</style></auth-address><titles><title><style face="normal" font="default">Sedative Effects of Levocetirizine: A Systematic Review and Meta-Analysis of Randomized Controlled Studies</style></title><secondary-title><style face="normal" font="default">Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Drugs</style></full-title></periodical><pages end="186" start="175">175-186</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Azelastine</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cetirizine</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> desloratadine</style></keyword><keyword><style face="normal" font="default"> drug therapy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Fexofenadine</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypnotics and Sedatives</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Loratadine</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Otolaryngology</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> P-Glycoprotein</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="default"> Randomized Controlled Trials as Topic</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Reaction Time</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword><keyword><style face="normal" font="default"> therapeutic use</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">INTRODUCTION: As a substrate of P-glycoprotein, levocetirizine should not cause sedative effects. However, while cetirizine, a mixture of levocetirizine and dextrocetirizine, can slightly penetrate the blood brain barrier, the sedative effects of levocetirizine are still under study. OBJECTIVES: The aim of this study was to investigate the sedative effects of levocetirizine. METHODS: An electronic literature search was performed using Medline and EMBASE from January 01, 2001 through August 6, 2015. Randomized controlled trials (RCTs) comparing levocetirizine with other antihistamines or placebo for patients with allergy and healthy subjects were selected. Primary outcome was risk ratio between levocetirizine and comparators. Secondary outcome was change in psychomotor speed. Data were pooled for meta-analysis using a fixed-effect model. RESULTS: Forty-eight studies of 18,014 patients met the inclusion criteria. When compared to placebo, levocetirizine produced modest sedative effects (RR: 1.67; 95% CI 1.17, 2.38). However, when compared to other second-generation antihistamines, sedative effects of levocetirizine did not differ (RR: 1.23; 95% CI 0.96, 1.58). In subgroup analysis, there was no difference between the sedative effects of levocetirizine and fexofenadine (RR: 1.7; 95% CI 0.59, 4.88), desloratadine (RR: 1.58; 95% CI 0.9, 2.77), loratadine (RR: 1.56; 95% CI 0.28, 8.56), bilastine (RR: 1.17; 95% CI 0.48, 2.84), olopatadine (RR: 1.09; 95% CI 0.81, 1.47), azelastine (RR: 0.19; 95% CI 0.01, 3.68) and rupatadine (RR: 1.47; 95% CI 0.14, 15.72). When compared to first-generation antihistamines, levocetirizine had less sedative effects and less change of reaction time (mean difference: -250.76 s; 95% CI -338.53, -162.98). CONCLUSION: Levocetirizine has modest sedative effects with a risk ratio of 1.67 when compared with placebo. The sedative effects observed for levocetirizine are not different from other second-generation antihistamines</style></abstract><notes><style face="normal" font="default">DA - 20170110IS - 1179-1950 (Electronic)IS - 0012-6667 (Linking)LA - engPT - Journal ArticlePT - Meta-AnalysisPT - ReviewRN - 0 (Hypnotics and Sedatives)RN - 6U5EA9RT2O (levocetirizine)RN - YO7261ME24 (Cetirizine)SB - IMCO - Thailand -</style></notes><work-type><style face="normal" font="default">10.1007/s40265-016-0682-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28070872">PM:28070872</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Drugs\2017-77-175-86.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Drugs\2017-77-175-86.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170110, Snidvongs K</style></custom2><misc3><style face="normal" font="default">10.1007/s40265-016-0682-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41358</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Marwood,J.</style></author><author><style face="normal" font="default"> Aguirrebarrena,G.</style></author><author><style face="normal" font="default"> Kerr,S.</style></author><author><style face="normal" font="default"> Welch,S.A.</style></author><author><style face="normal" font="default"> Rimmer,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Emergency Medicine, St Vincent's Hospital, Sydney, New South Wales, Australia</style></auth-address><titles><title><style face="normal" font="default">De-labelling self-reported penicillin allergy within the emergency department through the use of skin tests and oral drug provocation testing</style></title><secondary-title><style face="normal" font="default">Emerg Med Australas</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Emerg Med Australas</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse events</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Amoxicillin</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Emergency Medicine</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> New South Wales</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> oral challenge</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Self Report</style></keyword><keyword><style face="normal" font="default"> serious adverse events</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Wales</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="5" Month="4" Year="2017">2017/4/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Self-reported penicillin allergy is common among patients attending the ED, but is a poor predictor of true immunoglobulin E-mediated hypersensitivity to penicillin. We hypothesise that with a combination of skin testing and drug provocation testing, selected patients can be safely de-labelled of their allergy. METHODS: This prospective study enrolled a sample of patients presenting to an urban academic ED between 2011 and 2016 with a self-reported allergy to penicillin. Standardised skin prick and intradermal testing with amoxicillin and both major and minor determinants of penicillin was performed in the department. If negative, testing was followed by a graded oral challenge of amoxicillin over 9 days. The primary end point was the allergy status of participants at the end of the study. RESULTS: A total of 100 patients (mean age 42; standard deviation 14 years; 54% women) completed the testing. Of these, 81% (95% confidence interval 71.9-88.2) showed no hypersensitivity to penicillin and were labelled non-allergic. The majority (16/19) of allergies were confirmed by skin testing, with three suspected allergies detected by the oral challenge. Women were more likely than men to have a true penicillin allergy, with odds ratio of 4.0 (95% confidence interval 1.23-13.2). There were no serious adverse events. CONCLUSION: Selected patients in the ED who self-report an allergy to penicillin can be safely tested there for penicillin allergy, using skin tests and oral drug provocation testing. This testing allows a significant de-labelling of penicillin allergy, with the majority of these patients able to tolerate penicillin without incident</style></abstract><notes><style face="normal" font="default">DA - 20170405IS - 1742-6723 (Electronic)IS - 1742-6723 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/1742-6723.12774</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28378949">PM:28378949</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Emerg Med Australas\20170405-MarwoodJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Emerg Med Australas\20170405-MarwoodJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170405, Marwood J</style></custom2><misc3><style face="normal" font="default">10.1111/1742-6723.12774</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41359</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Singer,A.B.</style></author><author><style face="normal" font="default"> Burstyn,I.</style></author><author><style face="normal" font="default"> Thygesen,M.</style></author><author><style face="normal" font="default"> Mortensen,P.B.</style></author><author><style face="normal" font="default"> Fallin,M.D.</style></author><author><style face="normal" font="default"> Schendel,D.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Epidemiology and Wendy Klag Center for Autism and Developmental Disabilities, Johns Hopkins University Bloomberg School of Public Health, 615 N. Wolfe St, Baltimore, MD, 21205, USA</style></auth-address><titles><title><style face="normal" font="default">Parental exposures to occupational asthmagens and risk of autism spectrum disorder in a Danish population-based case-control study</style></title><secondary-title><style face="normal" font="default">Environ Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Environ Health</style></full-title></periodical><pages end="" start="31">31-</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Autism spectrum disorder</style></keyword><keyword><style face="normal" font="default"> Baltimore</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Developmental Disabilities</style></keyword><keyword><style face="normal" font="default"> economics</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Fathers</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> linkage</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> Occupation</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> Occupations</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Workplace</style></keyword></keywords><dates><year Day="31" Month="3" Year="2017">2017/3/31</year></dates><abstract><style face="normal" font="default">BACKGROUND: Environmental exposures and immune conditions during pregnancy could influence development of autism spectrum disorder (ASD) in offspring. However, few studies have examined immune-triggering exposures in relation to ASD. We evaluated the association between parental workplace exposures to risk factors for asthma ("asthmagens") and ASD. METHODS: We conducted a population-based case-control study in the Danish population using register linkage. Our study population consisted of 11,869 ASD cases and 48,046 controls born from 1993 through 2007. Cases were identified by ICD-10 codes in the Danish Psychiatric Central Register. ASD cases and controls were linked to parental Danish International Standard Classification of Occupations (DISCO-88) job codes. Parental occupational asthmagen exposure was estimated by linking DISCO-88 codes to an asthma-specific job-exposure matrix. RESULTS: Our maternal analyses included 6706 case mothers and 29,359 control mothers employed during the pregnancy period. We found a weak inverse association between ASD and any maternal occupational asthmagen exposure, adjusting for sociodemographic covariates (adjusted OR: 0.92, 95% CI: 0.86-0.99). In adjusted analyses, including 7647 cases and 31,947 controls with employed fathers, paternal occupational asthmagen exposure was not associated with ASD (adjusted OR: 0.98, 95% CI: 0.92-1.05). CONCLUSIONS: We found a weak inverse association between maternal occupational asthmagen exposure and ASD, and a null association between paternal occupational exposure and ASD. We suggest that unmeasured confounding negatively biased the estimate, but that this unmeasured confounding is likely not strong enough to bring the effect above the null. Overall, our results were consistent with no positive association between parental asthmagen exposure and ASD in the children</style></abstract><notes><style face="normal" font="default">DA - 20170331IS - 1476-069X (Electronic)IS - 1476-069X (Linking)LA - engPT - Journal ArticleCO - United States -CO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1186/s12940-017-0230-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28359263">PM:28359263</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Environ Health\20170331-SingerAB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Environ Health\20170331-SingerAB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170331, Singer AB</style></custom2><misc3><style face="normal" font="default">10.1186/s12940-017-0230-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41360</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guo,J.</style></author><author><style face="normal" font="default"> Yu,D.</style></author><author><style face="normal" font="default"> Lv,N.</style></author><author><style face="normal" font="default"> Bai,R.</style></author><author><style face="normal" font="default"> Xu,C.</style></author><author><style face="normal" font="default"> Chen,G.</style></author><author><style face="normal" font="default"> Cao,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Environmental Health, Department of Public Health, Zhejiang University School of Medicine, Hangzhou, China</style></auth-address><titles><title><style face="normal" font="default">Relationships between acrylamide and glycidamide hemoglobin adduct levels and allergy-related outcomes in general US population, NHANES 2005-2006</style></title><secondary-title><style face="normal" font="default">Envoron Pollut</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Envoron Pollut</style></abbr-1></periodical><pages end="513" start="506">506-513</pages><volume><style face="normal" font="default">225</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acrylamide</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="default"> allergic sensitization</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Cotinine</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Hay Fever</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> National Health and Nutrition Examination Survey</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Smoke</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword></keywords><dates><year Day="18" Month="3" Year="2017">2017/3/18</year></dates><abstract><style face="normal" font="default">BACKGROUND: Acrylamide-induced immunotoxicity and allergic dermatitis have been reported in animal experiments and clinical reports, respectively. However, epidemiological evidence from the general population is limited. OBJECTIVES: The purpose of the present study was to estimate the associations between acrylamide exposure and allergy-related outcomes in the general US population. METHODS: A total of 6982 subjects were selected from the National Health and Nutrition Examination Survey 2005-2006 (NHANES). Internal exposure was measured by the hemoglobin adducts of acrylamide (HbAA) and its metabolite glycidamide (HbGA). Allergy-related outcomes including asthma, hay fever, allergy, itchy rash, sneeze, wheeze and eczema were obtained by self-administered questionnaires. Allergic sensitization was assessed by the total immunoglobulin E (IgE) levels. The associations of HbAA and HbGA quartiles with allergy-related outcomes were calculated using logistic regression models with multivariable adjustments. Analyses were additionally stratified according to age, gender and serum cotinine levels. RESULTS: When setting quartile 1 of HbAA as reference, the odds ratios (ORs) [95% confidence intervals (CIs)] of quartile 2 to 4 for eczema were 1.18 (0.79-1.76), 1.14 (0.73-1.78) and 1.58 (1.14-2.18), respectively (ptrend = 0.002). Individuals at the highest quartile of HbGA had significantly elevated likelihoods of itchy rash (OR = 1.37, 95% CI = 1.02-1.83, ptrend = 0.032) and eczema (OR = 1.45, 95% CI = 1.06-1.97, ptrend = 0.044). The stratification analyses indicated various results in different subgroups. CONCLUSIONS: This study indicated significant associations between HbAA and HbGA levels and the likelihoods of allergy-related outcomes in the general US population, depending on age, gender and smoke exposure status. These findings suggested potential public health concerns for the widespread exposure to acrylamide</style></abstract><notes><style face="normal" font="default">DA - 20170322IS - 1873-6424 (Electronic)IS - 0269-7491 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.envpol.2017.03.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28325597">PM:28325597</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Envoron Pollut\2017-225-506-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">:\A&amp;H LMW Papers\Envoron Pollut\2017-225-506-13.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170322, Guo J</style></custom2><misc3><style face="normal" font="default">10.1016/j.envpol.2017.03.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41361</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Potaczek,D.P.</style></author><author><style face="normal" font="default"> Harb,H.</style></author><author><style face="normal" font="default"> Michel,S.</style></author><author><style face="normal" font="default"> Alhamwe,B.A.</style></author><author><style face="normal" font="default"> Renz,H.</style></author><author><style face="normal" font="default"> Tost,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps-Universitat Marburg, Marburg, Germany</style></auth-address><titles><title><style face="normal" font="default">Epigenetics and allergy: from basic mechanisms to clinical applications</style></title><secondary-title><style face="normal" font="default">Epigenomics</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Epigenomics</style></abbr-1></periodical><pages end="571" start="539">539-571</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> association studies</style></keyword><keyword><style face="normal" font="default"> association study</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic tool</style></keyword><keyword><style face="normal" font="default"> Diagnostics</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> Epigenetics</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Immunotherapy</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">Allergic diseases are on the rise in the Western world and well-known allergy-protecting and -driving factors such as microbial and dietary exposure, pollution and smoking mediate their influence through alterations of the epigenetic landscape. Here, we review key facts on the involvement of epigenetic modifications in allergic diseases and summarize and critically evaluate the lessons learned from epigenome-wide association studies. We show the potential of epigenetic changes for various clinical applications: as diagnostic tools, to assess tolerance following immunotherapy or possibly predict the success of therapy at an early time point. Furthermore, new technological advances such as epigenome editing and DNAzymes will allow targeted alterations of the epigenome in the future and provide novel therapeutic tools</style></abstract><notes><style face="normal" font="default">DA - 20170321IS - 1750-192X (Electronic)IS - 1750-192X (Linking)LA - engPT - Journal ArticleCO - Germany -CO - France -</style></notes><work-type><style face="normal" font="default">10.2217/epi-2016-0162</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28322581">PM:28322581</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Epigenomics\2017-9-539-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Epigenomics\2017-9-539-71.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170321, Potaczek DP</style></custom2><misc3><style face="normal" font="default">10.2217/epi-2016-0162</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41362</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ryan,D.</style></author><author><style face="normal" font="default"> Blakey,J.</style></author><author><style face="normal" font="default"> Chisholm,A.</style></author><author><style face="normal" font="default"> Price,D.</style></author><author><style face="normal" font="default"> Thomas,M.</style></author><author><style face="normal" font="default"> Stallberg,B.</style></author><author><style face="normal" font="default"> Lisspers,K.</style></author><author><style face="normal" font="default"> Kocks,J.W.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK</style></auth-address><titles><title><style face="normal" font="default">Use of electronic medical records and biomarkers to manage risk and resource efficiencies</style></title><secondary-title><style face="normal" font="default">Eur Clin Respir J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Eur Clin Respir J</style></abbr-1></periodical><pages end="" start="1293386">1293386-</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Algorithms</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Decision Making</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Efficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Electronic medical records</style></keyword><keyword><style face="normal" font="default"> Evolution</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Solutions</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The migration from paper to electronic medical records (EMRs) was motivated by the administrative need to record, retrieve and process increasing amounts of clinical data in the 1980s. In the intervening period, there has been growing recognition of the potential of such records for achieving care efficiencies, informing clinical decision making and real-life research. EMRs can be used to characterise patient groups, management approaches and differential outcomes. Characterisation can also help with identification of potential biomarkers for future risk determination and likely treatment response. The future heralds even greater opportunities through integration of clinical records and a range of technology-based solutions within a more complete electronic health record (EHR). Through application of algorithms based on identified risk predictors and disease determinants, clinical records could also be used to enable risk stratification of patients to optimise targeted interventions, conserving resources to achieve individual patient and system-wide benefit. In this review, we reflect on the evolution of the EMR and EHR and discuss current and emerging opportunities, particularly with respect to biomarkers and targeting of innovative biologic interventions. We also consider some of the critical issues associated with realising the potential of the EHR as a clinical aid and research tool in an age of emerging technologies.</style></abstract><notes><style face="normal" font="default">DA - 20170504IS - 2001-8525 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -CO - Singapore -CO - Sweden -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1080/20018525.2017.1293386</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28469833">PM:28469833</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Clin Respir J\2017-4-1293386.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Clin Respir J\2017-4-1293386.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170504, Ryan D</style></custom2><misc3><style face="normal" font="default">10.1080/20018525.2017.1293386</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41363</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mitsis,A.</style></author><author><style face="normal" font="default"> Christodoulou,E.</style></author><author><style face="normal" font="default"> Georgiou,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Cardiology and Aortic Centre, Royal Brompton Hospital, UK2 AICU, Royal Brompton Hospital, UK3 Intensive Care Unit, Nicosia General Hospital, Cyprus</style></auth-address><titles><title><style face="normal" font="default">Coronary spasm secondary to cefuroxime injection, complicated with cardiogenic shock - a manifestation of Kounis syndrome: case report and literature review</style></title><secondary-title><style face="normal" font="default">Eur Heart J Acute Cardiovasc Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Heart J Acute Cardiovasc Care</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acute Coronary Syndrome</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Arteries</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cefuroxime</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Infarction</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory mediators</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> intensive care unit</style></keyword><keyword><style face="normal" font="default"> Kounis syndrome</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> Spasm</style></keyword><keyword><style face="normal" font="default"> suppression</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Thrombosis</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> Vasodilation</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="default">Kounis syndrome is defined as the coincidental occurrence of an acute coronary syndrome with hypersensitivity reactions following an allergic event. The three reported variants of Kounis syndrome are vasospastic allergic angina, allergic myocardial infarction and stent thrombosis with occluding thrombus. The syndrome is caused by various inflammatory mediators. The pathophysiological characteristics of Kounis syndrome involve coronary artery spasm and/or atheromatous plaque erosion or rupture during an allergic reaction. Several causes have been described to induce Kounis syndrome, and their number is increasing rapidly. The haemodynamic effect of the syndrome complicated by cardiogenic shock seems to combine allergic shock with extensive peripheral vasodilation and myocardial suppression with the characteristics of cardiogenic shock. Treatment of Kounis syndrome is challenging because it needs management of both cardiac and allergic manifestation simultaneously. We present a case report of type I Kounis syndrome, with coronary spasm secondary to cefuroxime injection complicated with cardiogenic shock. A brief review of the literature on the various facets of this condition is also provided</style></abstract><notes><style face="normal" font="default">DA - 20170327IS - 2048-8734 (Electronic)IS - 2048-8726 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Cyprus -</style></notes><work-type><style face="normal" font="default">10.1177/2048872617701885</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28345355">PM:28345355</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Heart J Acute Cardiovasc Care\20170327-MitsisA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Heart J Acute Cardiovasc Care\20170327-MitsisA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170327, Mitsis A</style></custom2><misc3><style face="normal" font="default">10.1177/2048872617701885</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41364</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bouillet,L.</style></author><author><style face="normal" font="default"> Boccon-gibod,I.</style></author><author><style face="normal" font="default"> Gompel,A.</style></author><author><style face="normal" font="default"> Floccard,B.</style></author><author><style face="normal" font="default"> Martin,L.</style></author><author><style face="normal" font="default"> Blanchard-Delaunay,C.</style></author><author><style face="normal" font="default"> Launay,D.</style></author><author><style face="normal" font="default"> Fain,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Univ. Grenoble Alpes, Joint unit 1036 INSERM-CEA-CNRS, CREAK, Department of Internal Medicine, PPMGC, CHU Grenoble, Grenoble, France, National Reference Centre for Angioedema, CREAK, France</style></auth-address><titles><title><style face="normal" font="default">Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert(R)) in a French cohort</style></title><secondary-title><style face="normal" font="default">Eur J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur J Dermatol</style></full-title></periodical><pages end="159" start="155">155-159</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Berinert</style></keyword><keyword><style face="normal" font="default"> C1 INH</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-INH</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> C1Inh</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> diagnostic criteria</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Hereditary angioedema with normal C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> normal C1-INH</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="3" Year="2017">2017/3/1</year></dates><abstract><style face="normal" font="default">Hereditary angioedema (HAE) is a rare genetic disorder characterised by episodes of swelling without urticaria. Berinert(R) (CSL Behring) is a plasma-derived human C1 inhibitor (C1-INH) concentrate, approved for the treatment of HAE with C1-INH deficiency (C1-INH-HAE), however, it is often used off-label in Europe to treat HAE with normal C1-INH. OBJECTIVES: To report the clinical characteristics of patients with HAE with normal C1-INH (with F12 gene mutation; FXII-HAE) or of unknown origin (U-HAE), and their response to Berinert(R). Data from 2007 to 2016 (obtained retrospectively from the French Cohort BeRinert Angioedeme [COBRA] registry of HAE patients with everyday use of Berinert(R)) were analysed; no control group was included. Diagnostic criteria for FXII-HAE and U-HAE included a normal C1-INH antigenic level and function and refractoriness to high-dose antihistamines. For FXII-HAE, diagnosis also included F12 gene mutation, and U-HAE a positive family history for the disease. To date, 28 patients with FXII-HAE or U-HAE were identified (mean age: 27 years; first angioedema attack at 19.8 years; 85.7% female) with 78 documented Berinert(R)-treated attacks, the majority occurring in the laryngeal and abdominal regions. Efficacy assessment of Berinert(R) was available for 38 of 78 documented Berinert(R)-treated attacks; 22 improved within 60 minutes of treatment initiation, nine within 60-180 minutes, four after 180 minutes, and three showed no improvement. No severe or serious adverse effects were reported. Data to date suggest that Berinert(R) may be a safe and efficacious treatment option for the majority of HAE patients</style></abstract><notes><style face="normal" font="default">DA - 20170302IS - 1952-4013 (Electronic)IS - 1167-1122 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1684/ejd.2016.2948</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28251901">PM:28251901</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur J Dermatol\2017-27-155-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur J Dermatol\2017-27-155-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170302, Bouillet L</style></custom2><misc3><style face="normal" font="default">10.1684/ejd.2016.2948</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41365</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Betts,R.J.</style></author><author><style face="normal" font="default"> Perkovic,A.</style></author><author><style face="normal" font="default"> Mahapatra,S.</style></author><author><style face="normal" font="default"> Bufalo,A.D.</style></author><author><style face="normal" font="default"> Camara,K.</style></author><author><style face="normal" font="default"> Howell,A.R.</style></author><author><style face="normal" font="default"> Teissier,S.M.</style></author><author><style face="normal" font="default"> De Libero,G.</style></author><author><style face="normal" font="default"> Mori,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Singapore Immunology Network, Agency for Science, Technology and Research, Singapore</style></auth-address><titles><title><style face="normal" font="default">Contact sensitizers trigger human CD1-autoreactive T-cell responses</style></title><secondary-title><style face="normal" font="default">Eur J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur J Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigen Presentation</style></keyword><keyword><style face="normal" font="default"> antigen-presenting cell</style></keyword><keyword><style face="normal" font="default"> Antigen-Presenting Cells</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dinitrochlorobenzene</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Haptens</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Lipid</style></keyword><keyword><style face="normal" font="default"> Lipids</style></keyword><keyword><style face="normal" font="default"> Molecular Weight</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="default">Allergic contact dermatitis is a primarily T-cell-mediated inflammatory skin disease induced by exposure to small molecular-weight haptens, which covalently bind to proteins. The abundance of cutaneous T cells that recognize CD1a antigen-presenting molecules raises the possibility that MHC-independent antigen presentation may be relevant in some hapten-driven immune responses. Here we examine the ability of contact sensitizers to influence CD1-restricted immunity. Exposure of human antigen-presenting cells such as monocyte-derived dendritic cells and THP-1 cells to the prototypical contact sensitizer dinitrochlorobenzene potentiated the response of CD1a- and CD1d-autoreactive T cells, which released a vast array of cytokines in a CD1- and TCR-dependent manner. The potentiating effects of dinitrochlorobenzene depended upon newly synthesized CD1 molecules and the presence of endogenous stimulatory lipids. Further examination of a broad panel of contact sensitizers revealed 1,4-benzoquinone, resorcinol, isoeugenol and cinnamaldehyde to activate the same type of CD1-restricted responses. These findings provide a basis for the antigen-specific activation of skin-associated CD1-restricted T cells by small molecules and may have implications for contact sensitizer-induced inflammatory skin diseases. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170425IS - 1521-4141 (Electronic)IS - 0014-2980 (Linking)LA - engPT - Journal ArticleCO - Singapore -CO - Switzerland -CO - France -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1002/eji.201746939</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28440548">PM:28440548</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur J Immunol\20170425-BettsRJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur J Immunol\20170425-BettsRJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170425, Betts RJ</style></custom2><misc3><style face="normal" font="default">10.1002/eji.201746939</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41366</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Papoutsakis,C.</style></author><author><style face="normal" font="default"> Papadakou,E.</style></author><author><style face="normal" font="default"> Chondronikola,M.</style></author><author><style face="normal" font="default"> Antonogeorgos,G.</style></author><author><style face="normal" font="default"> Matziou,V.</style></author><author><style face="normal" font="default"> Drakouli,M.</style></author><author><style face="normal" font="default"> Konstantaki,E.</style></author><author><style face="normal" font="default"> Priftis,K.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Academy of Nutrition and Dietetics, 120 South Riverside Plaza, Suite 2000, Chicago, IL, 60606-6995, USA.</style></auth-address><titles><title><style face="normal" font="default">An obesity-preventive lifestyle score is negatively associated with pediatric asthma</style></title><secondary-title><style face="normal" font="default">Eur J Nutr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Eur J Nutr</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anthropometry</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> Asthma risk</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Body Weight</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Eating</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> Hip</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Intervention Studies</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Lifestyle</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> waist circumference</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="9" Month="4" Year="2017">2017/4/9</year></dates><abstract><style face="normal" font="default">PURPOSE: Lifestyle (diet and physical activity) may increase asthma risk, but evidence in this area is lacking. The aims of the present study were to calculate an obesity-preventive lifestyle score comprising of eating and physical activity behaviors and investigate the overall effect of lifestyle on asthma in children. METHODS: A cross-sectional case-control study was carried out in 514 children (217 asthma cases and 297 healthy controls). Data were collected on medical history, anthropometry, dietary intake, and physical activity. We constructed an overweight/obesity-preventive score (OPLS) using study-specific quartile rankings for nine target lifestyle behaviors that were either favorable or unfavorable in preventing obesity (i.e., screen time was an unfavorable lifestyle behavior). The score was developed using the recommendations of the Expert Committee of American Academy of Pediatrics. Score values ranged from 0-18 points; the higher the score, the more protective against high body weight. RESULTS: The OPLS was negatively associated with obesity indices (BMI, waist circumference, and hip circumference), (p &lt; 0.05). Control children had a higher score when compared to asthma cases (9.3 +/- 2.7 vs. 8.6 +/- 2.9, p = 0.007). A high OPLS was protective against physician-diagnosed asthma (OR 0.92; 95% CI 0.86-0.98, p = 0.014), adjusted for several confounders. The OPLS was no longer protective after adjustment for BMI. CONCLUSION: Higher adherence to an obesity-preventive lifestyle score-consistent with several behaviors for the prevention of childhood overweight/obesity-is negatively associated with obesity indices and lowers the odds for asthma in children. Lifestyle behaviors that contribute to a higher body weight may contribute to the obesity-asthma link. These findings are hypothesis-generating and warrant further investigation in prospective intervention studies</style></abstract><notes><style face="normal" font="default">DA - 20170410IS - 1436-6215 (Electronic)IS - 1436-6207 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Greece -</style></notes><work-type><style face="normal" font="default">10.1007/s00394-017-1446-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28393284">PM:28393284</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur J Nutr\20170410-PapoutsakisC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur J Nutr\20170410-PapoutsakisC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170410, Papoutsakis C</style></custom2><misc3><style face="normal" font="default">10.1007/s00394-017-1446-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41367</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lin,H.C.</style></author><author><style face="normal" font="default"> Lin,H.P.</style></author><author><style face="normal" font="default"> Yu,H.H.</style></author><author><style face="normal" font="default"> Wang,L.C.</style></author><author><style face="normal" font="default"> Lee,J.H.</style></author><author><style face="normal" font="default"> Lin,Y.T.</style></author><author><style face="normal" font="default"> Yang,Y.H.</style></author><author><style face="normal" font="default"> Li,P.Y.</style></author><author><style face="normal" font="default"> Sun,W.Z.</style></author><author><style face="normal" font="default"> Chiang,B.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan</style></auth-address><titles><title><style face="normal" font="default">Tai-Chi-Chuan Exercise Improves Pulmonary Function and Decreases Exhaled Nitric Oxide Level in Both Asthmatic and Nonasthmatic Children and Improves Quality of Life in Children with Asthma</style></title><secondary-title><style face="normal" font="default">Evid Based Complement Alternat Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Evid Based Complement Alternat Med</style></full-title></periodical><pages end="" start="6287642">6287642-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Peak expiratory flow</style></keyword><keyword><style face="normal" font="default"> Peak Expiratory Flow Rate</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Students</style></keyword><keyword><style face="normal" font="default"> Taiwan</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Tai-Chi-Chuan (TCC) is an exercise of low-to-moderate intensity which is suitable for asthmatic patients. The aim of our study is to investigate improvements of the lung function, airway inflammation, and quality of life of asthmatic children after TCC. Participants included sixty-one elementary school students and they were divided into asthmatic (n = 29) and nonasthmatic (n = 32) groups by the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire. Among them, 20 asthmatic and 18 nonasthmatic children volunteered to participate in a 60-minute TCC exercise weekly for 12 weeks. Baseline and postintervention assessments included forced expiratory volume in one second (FEV1), forced vital capacity (FVC), peak expiratory flow rate (PEFR), fractional exhaled nitric oxide (FeNO) level, and Standardised Pediatric Asthma Quality of Life Questionnaire (PAQLQ(S)). After intervention, the level of FeNO decreased significantly; PEFR and the FEV1/FVC also improved significantly in both asthmatic group and nonasthmatic group after TCC. The asthmatic children also had improved quality of life after TCC. The results indicated that TCC could improve the pulmonary function and decrease airway inflammation in both children with mild asthma and those without asthma. It also improves quality of life in mild asthmatic children. Nevertheless, further studies are required to determine the effect of TCC on children with moderate-to-severe asthma</style></abstract><notes><style face="normal" font="default">DA - 20170511IS - 1741-427X (Print)IS - 1741-427X (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1155/2017/6287642</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28491110">PM:28491110</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Evid Based Complement Alternat Med\2017-2017-6287642.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Evid Based Complement Alternat Med\2017-2017-6287642.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170511, Lin HC</style></custom2><misc3><style face="normal" font="default">10.1155/2017/6287642</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41368</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Best,K.</style></author><author><style face="normal" font="default"> Makrides,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Healthy Mothers, Babies and Children, SAHMRI, Adelaide, SA, 5000Healthy Mothers, Babies and Children, SAHMRI, Adelaide, SA, 5000</style></auth-address><titles><title><style face="normal" font="default">Possible protective effect of prenatal omega-3 long-chain polyunsaturated fatty acids supplementation on persistent wheeze and asthma in early childhood</style></title><secondary-title><style face="normal" font="default">Evid Based Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Evid Based Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acids</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> early childhood</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fatty acid</style></keyword><keyword><style face="normal" font="default"> Fatty Acids</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> Polyunsaturated fatty acids</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170513IS - 1473-6810 (Electronic)IS - 1356-5524 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1136/ebmed-2017-110696</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28500062">PM:28500062</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Evid Based Med\20170513-BestK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Evid Based Med\20170513-BestK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170513, Best K</style></custom2><misc3><style face="normal" font="default">10.1136/ebmed-2017-110696</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41369</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mose,K.F.</style></author><author><style face="normal" font="default"> Burton,M.</style></author><author><style face="normal" font="default"> Thomassen,M.</style></author><author><style face="normal" font="default"> Andersen,F.</style></author><author><style face="normal" font="default"> Kruse,T.A.</style></author><author><style face="normal" font="default"> Tan,Q.</style></author><author><style face="normal" font="default"> Skov,L.</style></author><author><style face="normal" font="default"> Ropke,M.A.</style></author><author><style face="normal" font="default"> Litman,T.</style></author><author><style face="normal" font="default"> Clemmensen,O.</style></author><author><style face="normal" font="default"> Kristensen,B.W.</style></author><author><style face="normal" font="default"> Friedmann,P.S.</style></author><author><style face="normal" font="default"> Andersen,K.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark, 5000, Odense C, Denmark</style></auth-address><titles><title><style face="normal" font="default">The gene expression and immunohistochemical time-course of diphenylcyclopropenone induced contact allergy in healthy humans following repeated epicutaneous challenges</style></title><secondary-title><style face="normal" font="default">Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epicutaneous</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Histopathology</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> IL-1</style></keyword><keyword><style face="normal" font="default"> IL-17</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> microarray</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Staining</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Trajectory</style></keyword><keyword><style face="normal" font="default"> Transcriptome</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="31" Month="3" Year="2017">2017/3/31</year></dates><abstract><style face="normal" font="default">The gene expression time-course of repeated challenge of contact allergy (CA) remains largely unknown. Therefore, using diphenylcyclopropenone (DPCP) as model allergen in healthy humans we set out to examine: i) the monotonous and complex gene expression time-course trajectories following repeated challenges with DPCP to find the predominant gene expression pattern, ii) the time-course of cell infiltration following repeated DPCP challenges, and iii) the transcriptome of a repeated CA exposure model. We obtained punch biopsies from control and DPCP exposed skin from ten DPCP sensitized individuals at 5-6 monthly elicitation challenges. Biopsies were used for microarray gene expression profiling, histopathology and immunohistochemical staining. Validation of microarray data by qRT-PCR was performed on 15 selected genes. Early gene expression time points were also validated in an independent dataset. An increasing and decreasing trend in gene expression followed by a plateau was predominantly observed during repeated DPCP challenges. Immune responses reached a plateau after two challenges histopathologically, immunohistochemically and in the time-course gene expression analysis. Transcriptional responses over time revealed a Th1/Th17 polarization as three upstream regulators (IFN-gamma, IL-1 and IL-17) activated most of the top upregulated genes. Of the latter genes, 9 out of 10 were the same throughout the time-course. Excellent correlations between array and PCR data were observed. The transcriptional responses to DPCP over time followed a monotonous pattern. This response pattern confirms and supports the newly reported clinical time-course observations in de novo sensitized individuals showing a plateau response, and thus, there is concordance between clinical response, histopathology, immunohistochemistry, and microarray gene expression in volunteers de novo sensitized to DPCP. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170403IS - 1600-0625 (Electronic)IS - 0906-6705 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1111/exd.13345</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28370374">PM:28370374</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Exp Dermatol\20170403-MoseKF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Exp Dermatol\20170403-MoseKF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170403, Mose KF</style></custom2><misc3><style face="normal" font="default">10.1111/exd.13345</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41370</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ciprandi,G.</style></author><author><style face="normal" font="default"> Tosca,M.A.</style></author><author><style face="normal" font="default"> Silvestri,M.</style></author><author><style face="normal" font="default"> Ricciardolo,F.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory Allergy, Department of Medicine , IR</style></auth-address><titles><title><style face="normal" font="default">Inflammatory biomarkers for asthma endotyping and consequent personalized therapy</style></title><secondary-title><style face="normal" font="default">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Expert Rev Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">airflow</style></keyword><keyword><style face="normal" font="default"> Airflow limitation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> allergen specific IgE</style></keyword><keyword><style face="normal" font="default"> allergen-specific</style></keyword><keyword><style face="normal" font="default"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cytology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Endotypes</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal cytology</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Personalized medicine</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Respiratory allergies</style></keyword><keyword><style face="normal" font="default"> Respiratory allergy</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="default">INTRODUCTION: We argue that asthma be considered a syndrome caused by multiple inflammatory pathogenic processes. Bronchial hyperresponsiveness, reversible airflow limitation, and chronic airway inflammation characterize asthma pathophysiology. Personalized Medicine, i.e. a tailored management approach, is appropriate for asthma management and is based on the identification of discrete phenotypes and endotypes. Biomarkers can help define phenotypes and endotypes. Several biomarkers have been described in asthma, but most of them are not commonly available or still need external validation. Areas covered: This review presents useful pragmatic biomarkers available in daily clinical practice for assessing airway inflammation in asthmatic patients. Expert commentary: Eosinophil counts and serum allergen-specific IgE assessments are the most reliable biomarkers. Lung function, mainly concerning FEF25-75, and nasal cytology may be envisaged as ancillary biomarkers in asthma management. In conclusion, biomarkers have a clinical relevance in asthma in identifying asthma endotypes to direct personalized therapy</style></abstract><notes><style face="normal" font="default">DA - 20170328IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1080/1744666X.2017.1313117</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28347164">PM:28347164</url></web-urls></urls><custom2><style face="normal" font="default">20170328, Ciprandi G</style></custom2><misc3><style face="normal" font="default">10.1080/1744666X.2017.1313117</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41371</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yin,H.Y.</style></author><author><style face="normal" font="default"> Wen,H.W.</style></author></authors></contributors><titles><title><style face="normal" font="default">Dual-Labeled PCR-Based Immunofluorescent Assay for the Rapid and Sensitive Detection of Enterotoxic Staphylococcus aureus Using Cocktail-Sized Liposomal Nanovesicles as Signal Enhancer</style></title><secondary-title><style face="normal" font="default">Food Anal Methods</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Food Anal Methods</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Bacteria</style></keyword><keyword><style face="normal" font="default"> Biotin</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Enterotoxins</style></keyword><keyword><style face="normal" font="default"> Escherichia</style></keyword><keyword><style face="normal" font="default"> Escherichia coli</style></keyword><keyword><style face="normal" font="default"> Fluorescent Dyes</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Food Poisoning</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Limit of Detection</style></keyword><keyword><style face="normal" font="default"> Milk</style></keyword><keyword><style face="normal" font="default"> Optimization</style></keyword><keyword><style face="normal" font="default"> poisoning</style></keyword><keyword><style face="normal" font="default"> Salmonella</style></keyword><keyword><style face="normal" font="default"> Staphylococcus</style></keyword><keyword><style face="normal" font="default"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default"> Taiwan</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1936-976X</style></isbn><abstract><style face="normal" font="default">Staphylococcus aureus is a major foodborne pathogen worldwide, and as little as 1-á++g of staphylococcal enterotoxins (SEs) can cause food poisoning. Among SEs, enterotoxin A is the most common toxin that causes staphylococcal food poisoning. Hence, this work has developed a dual-labeled PCR-based immunofluorescent assay using anti-digoxigenin (DIG) antibody-tagged immunomagnetic beads (IMBs) as the capture reagent and cocktail-sized NeutrAvidin-tagged liposomal nanovesicles (NA-LNs) that encapsulate fluorescent dyes as the detection reagent. In this approach, the amplicon of sea gene was doubly labeled with DIG and biotin using modified primers and biotin-11-dUTP. The system depends on the immunocapture of IMB to pre-concentrate the labeled amplicons, which were further quantified using cocktail-sized NA-LNs, based on the release and subsequent measurement of encapsulated fluorescent dyes following the lysis of NA-LNs. After optimization, the developed assay could detect S. aureus and differentiate it from other common foodborne bacteria, such as Salmonella enterica and Escherichia coli, with a limit of detection (LOD) of 101-áCFU-ámL</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">êÆ1 without pre-enrichment. With a 2-h pre-enrichment, this developed assay could detect as little as 1-áCFU in 25-ámL of milk within a workday. Hence, this work established a rapid and sensitive PCR-based immunofluorescent assay using liposomal nanovesicles as an instant signal enhancer to detect the contamination of enterotoxic S. aureus in milk</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1007/s12161-017-0893-3</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s12161-017-0893-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Food Anal Methods\20170512-YinHY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Food Anal Methods\20170512-YinHY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170512, Yin HY</style></custom2><misc3><style face="normal" font="default">10.1007/s12161-017-0893-3</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41372</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Varricchi,G.</style></author><author><style face="normal" font="default"> Galdiero,M.R.</style></author><author><style face="normal" font="default"> Loffredo,S.</style></author><author><style face="normal" font="default"> Marone,G.</style></author><author><style face="normal" font="default"> Iannone,R.</style></author><author><style face="normal" font="default"> Marone,G.</style></author><author><style face="normal" font="default"> Granata,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Translational Medical Sciences (DiSMeT), Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy</style></auth-address><titles><title><style face="normal" font="default">Are Mast Cells MASTers in Cancer?</style></title><secondary-title><style face="normal" font="default">Front Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Immunol</style></abbr-1></periodical><pages end="" start="424">424-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Breast</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-9</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lymphoma</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> ultrastructure</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Prolonged low-grade inflammation or smoldering inflammation is a hallmark of cancer. Mast cells form a heterogeneous population of immune cells with differences in their ultra-structure, morphology, mediator content, and surface receptors. Mast cells are widely distributed throughout all tissues and are stromal components of the inflammatory microenvironment that modulates tumor initiation and development. Although canonically associated with allergic disorders, mast cells are a major source of pro-tumorigenic (e.g., angiogenic and lymphangiogenic factors) and antitumorigenic molecules (e.g., TNF-alpha and IL-9), depending on the milieu. In certain neoplasias (e.g., gastric, thyroid and Hodgkin's lymphoma) mast cells play a pro-tumorigenic role, in others (e.g., breast cancer) a protective role, whereas in yet others they are apparently innocent bystanders. These seemingly conflicting results suggest that the role of mast cells and their mediators could be cancer specific. The microlocalization (e.g., peritumoral vs intratumoral) of mast cells is another important aspect in the initiation/progression of solid and hematologic tumors. Increasing evidence in certain experimental models indicates that targeting mast cells and/or their mediators represent a potential therapeutic target in cancer. Thus, mast cells deserve focused consideration also as therapeutic targets in different types of tumors. There are many unanswered questions that should be addressed before we understand whether mast cells are an ally, adversary, or innocent bystanders in human cancers</style></abstract><notes><style face="normal" font="default">DA - 20170427IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="default">10.3389/fimmu.2017.00424</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28446910">PM:28446910</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Immunol\2017-8-424.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Immunol\2017-8-424.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170427, Varricchi G</style></custom2><misc3><style face="normal" font="default">10.3389/fimmu.2017.00424</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41373</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mi,Y.N.</style></author><author><style face="normal" font="default"> Ping,N.N.</style></author><author><style face="normal" font="default"> Li,B.</style></author><author><style face="normal" font="default"> Xiao,X.</style></author><author><style face="normal" font="default"> Zhu,Y.B.</style></author><author><style face="normal" font="default"> Cao,L.</style></author><author><style face="normal" font="default"> Ren,J.K.</style></author><author><style face="normal" font="default"> Cao,Y.X.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, China</style></auth-address><titles><title><style face="normal" font="default">Finding the optimal dose of vitamin K1 to treat vitamin K deficiency and to avoid anaphylactoid reactions</style></title><secondary-title><style face="normal" font="default">Fundam Clin Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Fundam Clin Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">anaphylactoid reaction</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> dog</style></keyword><keyword><style face="normal" font="default"> Dogs</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Overdose</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Prothrombin</style></keyword><keyword><style face="normal" font="default"> Prothrombin Time</style></keyword><keyword><style face="normal" font="default"> rat</style></keyword><keyword><style face="normal" font="default"> Rats</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Thromboplastin</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vitamin K</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="13" Month="4" Year="2017">2017/4/13</year></dates><abstract><style face="normal" font="default">Vitamin K1 injection induces severe dose-related anaphylactoid reactions and overdose for the treatment of vitamin K deficiency. We aimed to find an optimal and small dose of vitamin K1 injection to treat vitamin K deficiency and avoid anaphylactoid reactions in animal. Rats were administered a vitamin K-deficient diet and gentamicin to establish vitamin K deficiency model. Behaviour tests were performed in beagle dogs to observe anaphylactoid reactions. The results showed an increased protein induced by vitamin K absence or antagonist II (PIVKA-II) levels, a prolonging of prothrombin time (PT) and activated partial thromboplastin time (APTT), and a decrease in vitamin K-dependent coagulation factor (F) II, VII, IX and X activities in the model group. In vitamin K1 0.01 mg/kg group, the liver vitamin K1 levels increased 5-fold and the liver vitamin K2 levels increased to the normal amount. Coagulation markers PT, APTT, FVII and FIX activities returned to normal. Both in the 0.1 and 1.0 mg/kg vitamin K1 group, coagulation functions completely returned to normal. Moreover, the amount of liver vitamin K1 was 40 (0.1 mg/kg) or 100 (1.0 mg/kg) times as in normal. Vitamin K2 was about 4 (0.1 mg/kg) or 5 (1.0 mg/kg) times as the normal amount. There was no obvious anaphylactoid symptom in dogs with the dose of 0.03 mg/kg, which is equivalent to the dose of 0.01 mg/kg in rats. These results demonstrated that a small dose of vitamin K1 is effective to improve vitamin K deficiency and to prevent anaphylactoid reactions, simultaneously. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170413IS - 1472-8206 (Electronic)IS - 0767-3981 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1111/fcp.12290</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28407450">PM:28407450</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Fundam Clin Pharmacol\20170413-MiYN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Fundam Clin Pharmacol\20170413-MiYN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170413, Mi YN</style></custom2><misc3><style face="normal" font="default">10.1111/fcp.12290</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41374</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Alangari,A.A.</style></author><author><style face="normal" font="default"> Morris,K.</style></author><author><style face="normal" font="default"> Lwaleed,B.A.</style></author><author><style face="normal" font="default"> Lau,L.</style></author><author><style face="normal" font="default"> Jones,K.</style></author><author><style face="normal" font="default"> Cooper,R.</style></author><author><style face="normal" font="default"> Jenkins,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia</style></auth-address><titles><title><style face="normal" font="default">Honey is potentially effective in the treatment of atopic dermatitis: Clinical and mechanistic studies</style></title><secondary-title><style face="normal" font="default">Immun Inflamm Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immun Inflamm Dis</style></abbr-1></periodical><pages end="199" start="190">190-199</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cell Degranulation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Controlled Clinical Trials</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Honey</style></keyword><keyword><style face="normal" font="default"> Immunoassay</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pretreatment</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Saudi Arabia</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">INTRODUCTION: As manuka honey (MH) exhibits immunoregulatory and anti-staphylococcal activities, we aimed to investigate if it could be effective in the treatment of atopic dermatitis (AD). METHODS: Adult volunteers with bilateral AD lesions were asked to apply MH on one site overnight for seven consecutive days and leave the contralateral site untreated as possible. Three Item Severity score was used to evaluate the response. Skin swabs were obtained from both sites before and after treatment to investigate the presence of staphylococci and enterotoxin production. In addition, the ability of MH and its methanolic and hexane extracts to down regulate IL4-induced CCL26 protein release from HaCaT cells was evaluated by enzyme linked immunosorbent assay. Also, the ability of MH to modulate calcium ionophore-induced mast cell degranulation was assessed by enzyme immunoassay. RESULTS: In 14 patients, AD lesions significantly improved post MH treatment versus pre-treatment as compared to control lesions. No significant changes in the skin staphylococci were observed after day 7, irrespective of honey treatment. Consistent with the clinical observation, MH significantly down regulated IL4-induced CCL26 release from HaCaT cells in a dose-dependent manner. This effect was partially lost, though remained significant, when methanolic and hexane extracts of MH were utilized. In addition, mast cell degranulation was significantly inhibited following treatment with MH. CONCLUSIONS: MH is potentially effective in the treatment of AD lesions based on both clinical and cellular studies through different mechanisms. This needs to be confirmed by randomized and controlled clinical trials</style></abstract><notes><style face="normal" font="default">DA - 20170505IS - 2050-4527 (Electronic)IS - 2050-4527 (Linking)LA - engPT - Journal ArticleCO - Saudi Arabia -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1002/iid3.153</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28474502">PM:28474502</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immun Inflamm Dis\2017-5-190-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immun Inflamm Dis\2017-5-190-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170505, Alangari AA</style></custom2><misc3><style face="normal" font="default">10.1002/iid3.153</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41375</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oishi,K.</style></author><author><style face="normal" font="default"> Hirano,T.</style></author><author><style face="normal" font="default"> Suetake,R.</style></author><author><style face="normal" font="default"> Ohata,S.</style></author><author><style face="normal" font="default"> Yamaji,Y.</style></author><author><style face="normal" font="default"> Ito,K.</style></author><author><style face="normal" font="default"> Edakuni,N.</style></author><author><style face="normal" font="default"> Matsunaga,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University, Ube, Japan</style></auth-address><titles><title><style face="normal" font="default">A trial of oral corticosteroids for persistent systemic and airway inflammation in severe asthma</style></title><secondary-title><style face="normal" font="default">Immun Inflamm Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immun Inflamm Dis</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> fraction of exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral corticosteroids</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="default">INTRODUCTION: The fraction of exhaled nitric oxide (FeNO) and blood eosinophils, markers of local and systemic eosinophilic inflammation, respectively, are increased in asthmatic patients. Little is known concerning the relationship between the FeNO levels and blood eosinophils in asthmatics. METHODS: Twenty severe asthmatics with persistent FeNO elevation (>/=40 ppb) and blood eosinophilia (>/=3%) despite maintenance therapy including high-daily-dose inhaled corticosteroids were analyzed. We investigated the response of FeNO and blood eosinophils to systemic corticosteroids treatment and the change in Asthma Control Questionnaire (ACQ) according to differences in the response of FeNO and blood eosinophils to steroid. RESULTS: The changes in blood eosinophils were not correlated with the changes in FeNO levels by systemic steroid treatment (r = 0.37, P = 0.11). 50% of the subjects showed both >/=20% reductions in FeNO levels and blood eosinophils. There were significant differences in the ACQ score between the steroid response group and poor response group (P &lt; 0.005). The group in which both FeNO and blood eosinophils were suppressed fulfilled the change in score of >/=0.5 on the ACQ. CONCLUSIONS: In the patients with severe asthma, responses to systemic corticosteroids were variable in terms of FeNO and blood eosinophils. It was necessary to suppress both persistent eosinophilia and high FeNO for the improvement of asthma control</style></abstract><notes><style face="normal" font="default">DA - 20170505IS - 2050-4527 (Electronic)IS - 2050-4527 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1002/iid3.166</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28474411">PM:28474411</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immun Inflamm Dis\20170505-OishiK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immun Inflamm Dis\20170505-OishiK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170505, Oishi K</style></custom2><misc3><style face="normal" font="default">10.1002/iid3.166</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41376</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jiang,X.</style></author><author><style face="normal" font="default"> Lan,Y.</style></author><author><style face="normal" font="default"> Wei,B.</style></author><author><style face="normal" font="default"> Dai,C.</style></author><author><style face="normal" font="default"> Gu,Y.</style></author><author><style face="normal" font="default"> Ma,J.</style></author><author><style face="normal" font="default"> Liu,X.</style></author><author><style face="normal" font="default"> Umezawa,K.</style></author><author><style face="normal" font="default"> Zhang,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pharmacology, School of Life Science and Biopharmaceutics , Shenyang Pharmaceutical University , Shenyang , China</style></auth-address><titles><title><style face="normal" font="default">External application of NF-kappaB inhibitor DHMEQ suppresses development of atopic dermatitis-like lesions induced with DNCB/OX in BALB/c mice</style></title><secondary-title><style face="normal" font="default">Immunopharmacol Immunotoxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunopharmacol Immunotoxicol</style></full-title></periodical><pages end="164" start="157">157-164</pages><volume><style face="normal" font="default">39</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Biopharmaceutics</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> DNCB</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Histopathology</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Interferon</style></keyword><keyword><style face="normal" font="default"> Interferon-gamma</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Interleukin-4</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Oxazolone</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">CONTEXT: Dehydroxymethylepoxyquinomicin (DHMEQ) which is originally developed as an analog of antibiotic epoxyquinomicin C is a specific and potent inhibitor of NF-kappaB and has been shown to possess promising potential as an anti-inflammatory and anti-tumor agent. OBJECTIVE: This study examines DHMEQ's effect on therapeutic potential for atopic dermatitis (AD)-like lesions. MATERIALS AND METHODS: AD lesions were chronically induced by the repetitive and alternative application of 2,4-dinitrochlorobenzene (DNCB) and oxazolone (OX) on ears in BALB/c mice. The mice were then externally treated with DHMEQ ointment. Macroscopic and microscopic changes of the skin lesions were observed and recorded. RESULTS: DHMEQ inhibited ear swelling and relieved clinical symptoms of the AD-like lesions induced by DNCB/OX in BALB/c mice. Histopathology examination illustrated that it significantly decreased DNCB/OX-induced epidermal thickness, the infiltration of inflammatory cells, and the count of mast cell. The elevated level of immunoglobulin E (IgE) in serum and the mRNA levels of interferon gamma (IFN-gamma), interleukin 4 (IL-4) and IL-13 in the ear tissues, were also suppressed by DHMEQ. DISCUSSION AND CONCLUSION: This study indicated that DHMEQ would be useful for the treatment of AD</style></abstract><notes><style face="normal" font="default">DA - 20170418IS - 1532-2513 (Electronic)IS - 0892-3973 (Linking)LA - engPT - Journal ArticleCO - China -CO - Japan -</style></notes><work-type><style face="normal" font="default">10.1080/08923973.2017.1312436</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28418286">PM:28418286</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunopharmacol Immunotoxicol\2017-39-157-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunopharmacol Immunotoxicol\2017-39-157-64.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170418, Jiang X</style></custom2><misc3><style face="normal" font="default">10.1080/08923973.2017.1312436</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41377</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Panella,P.</style></author><author><style face="normal" font="default"> Casas,M.</style></author><author><style face="normal" font="default"> Donaire-Gonzalez,D.</style></author><author><style face="normal" font="default"> Garcia-Esteban,R.</style></author><author><style face="normal" font="default"> Robinson,O.</style></author><author><style face="normal" font="default"> Valentin,A.</style></author><author><style face="normal" font="default"> Gulliver,J.</style></author><author><style face="normal" font="default"> Momas,I.</style></author><author><style face="normal" font="default"> Nieuwenhuijsen,M.</style></author><author><style face="normal" font="default"> Vrijheid,M.</style></author><author><style face="normal" font="default"> Sunyer,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">ISGlobal, Centre for Research in Environmental Epidemiology (CREAL). Doctor Aiguader, 88 . E-08003, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default">Ultrafine particles and black carbon personal exposures in asthmatic and non-asthmatic children at school-age</style></title><secondary-title><style face="normal" font="default">Indoor Air</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Indoor Air</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pollutants</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Transportation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="3" Year="2017">2017/3/20</year></dates><abstract><style face="normal" font="default">Traffic-related air pollution (TRAP) exposure during childhood is associated with asthma; however, the contribution of the different TRAP pollutants in each microenvironment (home, school, transportation, others) in asthmatic and non-asthmatic children is unknown. Daily (24 h) personal black carbon (BC), ultrafine particles (UFP), and alveolar lung deposited surface area (LDSA) individual exposure measurements were obtained from 100 children (29 past and 21 current asthmatics, 50 non-asthmatics) aged 9+/-0.7 years from the INMA-Sabadell cohort (Catalonia, Spain). Time spent in each microenvironment was derived by the geolocation provided by the smartphone and a new spatiotemporal map-matching algorithm. Asthmatics and non-asthmatics spent the same amount of time at home (60% and 61%, respectively), at school (20%, 23%), on transportation (8%, 7%), and in other microenvironments (7%, 5%). The highest concentrations of all TRAPs were attributed to transportation. No differences in TRAP concentrations were found overall or by type of microenvironment between asthmatics and non-asthmatics, nor when considering past and current asthmatics, separately. In conclusion, asthmatic and non-asthmatic children had a similar time activity pattern and similar average exposures to BC, UFP and LDSA concentrations. This suggests that interventions should be tailored to general population, rather than to subgroups defined by disease. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170321IS - 1600-0668 (Electronic)IS - 0905-6947 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/ina.12382</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28321937">PM:28321937</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indoor Air\20170321-PanellaP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indoor Air\20170321-PanellaP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170321, Panella P</style></custom2><misc3><style face="normal" font="default">10.1111/ina.12382</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41378</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,Z.</style></author><author><style face="normal" font="default"> Yi,T.</style></author><author><style face="normal" font="default"> Long,M.</style></author><author><style face="normal" font="default"> Gao,Y.</style></author><author><style face="normal" font="default"> Cao,C.</style></author><author><style face="normal" font="default"> Huang,C.</style></author><author><style face="normal" font="default"> Wang,Q.</style></author><author><style face="normal" font="default"> Yin,N.</style></author><author><style face="normal" font="default"> Chen,Z.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pathogen Biology, College of Basic Medicine, Hubei University of Chinese Medicine, Wuhan, 430065, China</style></auth-address><titles><title><style face="normal" font="default">Electro-Acupuncture at Zusanli Acupoint (ST36) Suppresses Inflammation in Allergic Contact Dermatitis Via Triggering Local IL-10 Production and Inhibiting p38 MAPK Activation</style></title><secondary-title><style face="normal" font="default">Inflammation</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Inflammation</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Coculture</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> cytology</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Histology</style></keyword><keyword><style face="normal" font="default"> Hyperhidrosis</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> rat</style></keyword><keyword><style face="normal" font="default"> Rats</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> serum IgE levels</style></keyword><keyword><style face="normal" font="default"> Spleen</style></keyword><keyword><style face="normal" font="default"> subcutaneous</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="default">Acupuncture has shown beneficial effect in the treatment of multiple dermatologic conditions including dermatitis, pruritus, urticaria, and hyperhidrosis; however, the detailed mechanisms are still kept unclear. This study aimed to investigate if electro-acupuncture (EA) treatment prevents 2,4-dinitrofluorobenzene (DNFB)-induced allergic contact dermatitis (ACD) in rats and explore its underlying mechanisms. ACD was induced by sensitizing and challenging with DNFB topically. Rats were treated daily following bilateral subcutaneous stimulation of EA at Zusanli acupoint (ST36) for 1 week. Ear swelling and serum IgE levels were measured. The ear biopsies were obtained for histology. Inflammatory cytokines on the dermatological ear and local acupoint tissue were assayed. Spleen lymphocytes and the homogenized supernatant of local acupuncture area were used to co-culture for flow cytology and immune analysis, respectively. EA treatment at ST36 notably inhibited ear swelling and inflammatory cell infiltration on DNFB-induced ACD. EA also decreased serum IgE concentrations and alleviated the production of inflammatory cytokines in dermatological ear. Additionally, EA treatment attenuated the percentage of CD4+IFN-gamma+ and CD4+IL-4+ T cells associated with ACD. Interestingly, secretion of interleukin (IL)-10 in the local acupoint tissue following EA stimulation was increased and showed suppressive function when co-cultured with the spleen lymphocytes from DNFB group. Lastly, EA treatment demonstrably suppressed p38 MAPK activation in DNFB-treated rats. Our findings suggest that EA treatment at ST36 may ameliorate inflammation associated with DNFB-induced ACD via triggering local IL-10 production and inhibiting p38 MAPK activation, which provide an alternative and promising therapy for ACD</style></abstract><notes><style face="normal" font="default">DA - 20170511IS - 1573-2576 (Electronic)IS - 0360-3997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1007/s10753-017-0578-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28493082">PM:28493082</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Inflammation\20170511-WangZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Inflammation\20170511-WangZ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170511, Wang Z</style></custom2><misc3><style face="normal" font="default">10.1007/s10753-017-0578-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41379</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Adachi,S.</style></author><author><style face="normal" font="default"> Hoshi,N.</style></author><author><style face="normal" font="default"> Inoue,J.</style></author><author><style face="normal" font="default"> Yasutomi,E.</style></author><author><style face="normal" font="default"> Otsuka,T.</style></author><author><style face="normal" font="default"> Dhakhwa,R.</style></author><author><style face="normal" font="default"> Wang,Z.</style></author><author><style face="normal" font="default"> Koo,Y.</style></author><author><style face="normal" font="default"> Takamatsu,T.</style></author><author><style face="normal" font="default"> Matsumura,Y.</style></author><author><style face="normal" font="default"> Yamairi,H.</style></author><author><style face="normal" font="default"> Watanabe,D.</style></author><author><style face="normal" font="default"> Ooi,M.</style></author><author><style face="normal" font="default"> Tanahashi,T.</style></author><author><style face="normal" font="default"> Nishiumi,S.</style></author><author><style face="normal" font="default"> Yoshida,M.</style></author><author><style face="normal" font="default"> Azuma,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Hyogo, Japan</style></auth-address><titles><title><style face="normal" font="default">Indigo Naturalis Ameliorates Oxazolone-Induced Dermatitis but Aggravates Colitis by Changing the Composition of Gut Microflora</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="33" start="23">23-33</pages><volume><style face="normal" font="default">173</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Body Weight</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Colitis</style></keyword><keyword><style face="normal" font="default"> Colon</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Feces</style></keyword><keyword><style face="normal" font="default"> Gastroenterology</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> Herbal</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Oxazolone</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="9" Month="5" Year="2017">2017/5/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Indigo naturalis (IND) is an herbal medicine that has been used as an anti-inflammatory agent to treat diseases including dermatitis and inflammatory bowel disease in China. However, the mechanism by which IND exerts its immunomodulatory effect is not well understood. METHODS: A murine model of dermatitis and inflammatory bowel disease, both induced by oxazolone (OXA), was treated with IND. The severity of dermatitis was evaluated based on ear thickness measurements and histological scoring. The severity of colitis was evaluated by measuring body weight, histological scoring, and endoscopic scoring. The expression of inflammatory cytokines in ear and colon tissue was evaluated using real-time PCR. 16S rRNA DNA sequencing of feces from OXA-induced colitis mice was performed before and after IND treatment. The effects of IND on OXA-induced colitis were also evaluated after depleting the gut flora with antibiotics to test whether alteration of the gut flora by IND influenced the course of intestinal inflammation in this model. RESULTS: IND treatment ameliorated OXA dermatitis with a reduction in IL-4 and eosinophil recruitment. However, OXA colitis was significantly aggravated in spite of a reduction in intestinal IL-13, a pivotal cytokine in the induction of the colitis. It was found that IND dramatically altered the gut flora and IND no longer exacerbated colitis when colitis was induced after gut flora depletion. CONCLUSIONS: Our data suggest that IND could modify the inflammatory immune response in multiple ways, either directly (i.e., modification of the allergic immune cell activity) or indirectly (i.e., alteration of commensal compositions)</style></abstract><notes><style face="normal" font="default">DA - 20170508IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1159/000471923</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28482341">PM:28482341</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-23-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-23-33.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170508, Adachi S</style></custom2><misc3><style face="normal" font="default">10.1159/000471923</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41380</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mazurek,J.M.</style></author><author><style face="normal" font="default"> Henneberger,P.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory Health Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Mailstop HG 900.2, 1095 Willowdale Road, Morgantown, WV, 26505, USA.</style></auth-address><titles><title><style face="normal" font="default">Lifetime allergic rhinitis prevalence among US primary farm operators: findings from the 2011 Farm and Ranch Safety survey</style></title><secondary-title><style face="normal" font="default">Int Arch Occup Environ Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int Arch Occup Environ Health</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Hay Fever</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pesticides</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Workplace</style></keyword></keywords><dates><year Day="24" Month="3" Year="2017">2017/3/24</year></dates><abstract><style face="normal" font="default">PURPOSE: Allergic rhinitis is associated with decreased quality of life, and reduced workplace performance and productivity. This study investigated the prevalence of lifetime allergic rhinitis and factors associated with allergic rhinitis among US primary farm operators. METHODS: The 2011 Farm and Ranch Safety Survey data collected from 11,210 active farm operators were analyzed. Survey respondents were determined to have lifetime allergic rhinitis based on a "yes" response to the question: "Have you ever been told by a doctor, nurse, or other health professional that you had hay fever, seasonal allergies, or allergic rhinitis?" Data were weighted to produce nationally representative estimates. RESULTS: An estimated 30.8% of the 2.1 million active farm operators had lifetime allergic rhinitis in 2011. The allergic rhinitis prevalence varied by demographic and farm characteristics. Farm operators with allergic rhinitis were 1.38 (95% CI 1.22-1.56) times more likely to be exposed to pesticides compared with operators with no allergic rhinitis. The association with pesticide exposure for allergic rhinitis and current asthma, and allergic rhinitis alone was statistically significant and greater than that for current asthma alone. CONCLUSION: Certain groups of farm operators may be at increased risk of allergic rhinitis. Studies should further investigate the association of allergic rhinitis with specific pesticide exposure</style></abstract><notes><style face="normal" font="default">DA - 20170325IS - 1432-1246 (Electronic)IS - 0340-0131 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s00420-017-1217-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28341882">PM:28341882</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Occup Environ Health\20170325-MazurekJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Occup Environ Health\20170325-MazurekJM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170325, Mazurek JM</style></custom2><misc3><style face="normal" font="default">10.1007/s00420-017-1217-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41381</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bernstein,J.A.</style></author><author><style face="normal" font="default"> Cremonesi,P.</style></author><author><style face="normal" font="default"> Hoffmann,T.K.</style></author><author><style face="normal" font="default"> Hollingsworth,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunology/Allergy, University of Cincinnati, 231 Albert Sabin Way, Cincinnati, OH, 45267, USA.</style></auth-address><titles><title><style face="normal" font="default">Angioedema in the emergency department: a practical guide to differential diagnosis and management</style></title><secondary-title><style face="normal" font="default">Int J Emerg Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Emerg Med</style></abbr-1></periodical><pages end="" start="15">15-</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Angiotensin converting enzyme inhibitors</style></keyword><keyword><style face="normal" font="default"> Angiotensin-Converting Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="default"> C1 esterase inhibitor</style></keyword><keyword><style face="normal" font="default"> C1 INH</style></keyword><keyword><style face="normal" font="default"> C1-INH</style></keyword><keyword><style face="normal" font="default"> C1Inh</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Differential diagnosis</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Emergency Medicine</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Angioedema is a common presentation in the emergency department (ED). Airway angioedema can be fatal; therefore, prompt diagnosis and correct treatment are vital. OBJECTIVE OF THE REVIEW: Based on the findings of two expert panels attended by international experts in angioedema and emergency medicine, this review aims to provide practical guidance on the diagnosis, differentiation, and management of histamine- and bradykinin-mediated angioedema in the ED. REVIEW: The most common pathophysiology underlying angioedema is mediated by histamine; however, ED staff must be alert for the less common bradykinin-mediated forms of angioedema. Crucially, bradykinin-mediated angioedema does not respond to the same treatment as histamine-mediated angioedema. Bradykinin-mediated angioedema can result from many causes, including hereditary defects in C1 esterase inhibitor (C1-INH), side effects of angiotensin-converting enzyme inhibitors (ACEis), or acquired deficiency in C1-INH. The increased use of ACEis in recent decades has resulted in more frequent encounters with ACEi-induced angioedema in the ED; however, surveys have shown that many ED staff may not know how to recognize or manage bradykinin-mediated angioedema, and hospitals may not have specific medications or protocols in place. CONCLUSION: ED physicians must be aware of the different pathophysiologic pathways that lead to angioedema in order to efficiently and effectively manage these potentially fatal conditions</style></abstract><notes><style face="normal" font="default">DA - 20170413IS - 1865-1372 (Print)IS - 1865-1372 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -CO - Italy -CO - Germany -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1186/s12245-017-0141-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28405953">PM:28405953</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Emerg Med\2017-10-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Emerg Med\2017-10-15.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170413, Bernstein JA</style></custom2><misc3><style face="normal" font="default">10.1186/s12245-017-0141-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41382</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Panfili,E.</style></author><author><style face="normal" font="default"> Esposito,S.</style></author><author><style face="normal" font="default"> Di Cara,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Clinic, Universita degli Studi di Perugia, 06129 Perugia, Italy.</style></auth-address><titles><title><style face="normal" font="default">Temporary Black Henna Tattoos and Sensitization to para-Phenylenediamine (PPD): Two Paediatric Case Reports and a Review of the Literature</style></title><secondary-title><style face="normal" font="default">Int J Environ Res Public Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Environ Res Public Health</style></abbr-1></periodical><pages end="" start="E421">E421-</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Black henna</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cross Reactions</style></keyword><keyword><style face="normal" font="default"> Cross-reaction</style></keyword><keyword><style face="normal" font="default"> cross-reactions</style></keyword><keyword><style face="normal" font="default"> Crossreactions</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Henna</style></keyword><keyword><style face="normal" font="default"> Hypopigmentation</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> Para-phenylenediamine</style></keyword><keyword><style face="normal" font="default"> Paraphenylenediamine</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Temporary henna tattoos</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="14" Month="4" Year="2017">2017/4/14</year></dates><abstract><style face="normal" font="default">Background: The use of temporary henna tattoos has increased dramatically in recent years, especially in children and adolescents. To obtain a darker colour and prolong the life of the tattoo, red henna, a plant-derived substance, is typically added to para-phenylenediamine (PPD). The mixture is called temporary black henna tattoo (TBHT). Because of its molecular characteristics, PPD can induce skin sensitization that may cause various clinical manifestations with successive exposures, among which the most common is allergic contact dermatitis (ACD). This report describes two paediatric cases of PPD sensitization and ACD after the exposure to TBHT and summarizes the literature on this emerging clinical problem. Case Presentation: We describe two cases of childhood-onset ACD that occurred 2 and 10 days, respectively, after the application of a TBHT during the summer holidays. Patch tests showed an evident positive response to 1% PPD in both cases. Sensitization to PPD occurred in the first case because a previous henna tattoo did not result in overt symptoms; in the second case, the reaction occurred after the same tattoo was retouched. In both cases, hypopigmentation persisted and both the patients and their families were advised to avoid further contact with PPD-containing materials and substances that could lead to cross-reactions. Conclusions: Sensitization to PPD is a growing phenomenon in children. The most common cause appears to be exposure to TBHT in which PPD might be present at unknown or high concentrations. Once sensitization occurs, patients may experience severe clinical symptoms which can present with a persistent hypopigmentation when they are re-exposed to substances that contain or cross-react with PPD. Given the widespread use of PPD, TBHT could adversely affect the daily life of paediatric patients; thus, for this reason, this practice as a fashion accessory must be discouraged. In addition, it is extremely important to provide scientific information on the risks of TBHT to consumers, especially to adolescents and to the parents of younger children to prevent PPD sensitization</style></abstract><notes><style face="normal" font="default">DA - 20170419IS - 1660-4601 (Electronic)IS - 1660-4601 (Linking)LA - engPT - Case ReportsCO - Italy -</style></notes><work-type><style face="normal" font="default">10.3390/ijerph14040421</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28420106">PM:28420106</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Environ Res Public Health\2017-14-E421.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Environ Res Public Health\2017-14-E421.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170419, Panfili E</style></custom2><misc3><style face="normal" font="default">10.3390/ijerph14040421</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41383</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Son,H.U.</style></author><author><style face="normal" font="default"> Lee,S.</style></author><author><style face="normal" font="default"> Heo,J.C.</style></author><author><style face="normal" font="default"> Lee,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Food Science and Biotechnology, Kyungpook National University, Daegu 41566, P.R. China</style></auth-address><titles><title><style face="normal" font="default">The solid-state fermentation of Artemisia capillaris leaves with Ganoderma lucidum enhances the anti-inflammatory effects in a model of atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Int J Mol Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Mol Med</style></abbr-1></periodical><pages end="1241" start="1233">1233-1241</pages><volume><style face="normal" font="default">39</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AC</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Artemisia</style></keyword><keyword><style face="normal" font="default"> Asteraceae</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Biotechnology</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Staining</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Artemisia capillaris, which belongs to the Asteraceae family and the genus Artemisia, has been reported to exert inhibitory effects on diabetes, cancer and inflammation. In this study, in order to enhance the bioactivity potential of the leaves of Artemisia by Ganoderma lucidum mycelium, we prepared aqueous samples of Artemisia capillaris (Ac) leaves, Ganoderma lucidum (Gl) and aqueous fractions produced by the solid fermentation of Ganoderma lucidum on Artemisia capillaris leaves (afAc/Gl). Thereafter, we evaluated whether these samples have potential to attenuate inflammation-related symptoms in an amimal model of 2,4-dinitrofluorobenzene (DNFB)-induced atopic dermatitis. We found that afAc/Gl exhibited enhanced anti-inflamamatory activity following the solid fermentation process when compared with Ac or Gl on ear thickness, ear epidermal thickness and eosinophil infiltration in the skin tissues. The expression of nitric oxide (NO) synthases (NOSs) was measured by immunohistochemical staining. The results revealed that afAc/Gl decreased endothelial NOS and inducible NOS expression compared with the DNFB group, while neuronal NOS expression was not altered. By comparing NO production, we found that as opposed to Ac, afAc/Gl has potential to inhibit atopic dermatitis-related symptoms during the inflammatory event. As regards matrix metalloproteinase (MMP) expression patterns, afAc/Gl exerted potent inhibitory activity on the mRNA expression of MMP-2, -7, -9, -12, -14 and -19. Taken together, these results suggest that the solid state fermentation of Ac by Gl is an effective strategy to obtaining useful ingredients which are converted into valuable compounds during an atopic inflammatory insult</style></abstract><notes><style face="normal" font="default">DA - 20170410IS - 1791-244X (Electronic)IS - 1107-3756 (Linking)LA - engPT - Journal ArticleCO - China -CO - South Korea -</style></notes><work-type><style face="normal" font="default">10.3892/ijmm.2017.2945</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28393198">PM:28393198</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Mol Med\2017-39-1233-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Mol Med\2017-39-1233-41.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170410, Son HU</style></custom2><misc3><style face="normal" font="default">10.3892/ijmm.2017.2945</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41384</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Park,J.H.</style></author><author><style face="normal" font="default"> Choi,J.Y.</style></author><author><style face="normal" font="default"> Son,D.J.</style></author><author><style face="normal" font="default"> Park,E.K.</style></author><author><style face="normal" font="default"> Song,M.J.</style></author><author><style face="normal" font="default"> Hellstrom,M.</style></author><author><style face="normal" font="default"> Hong,J.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">College of Pharmacy and Medical Research Center, Chungbuk National University, 194-31 Osongsaengmyeong 1-ro, Osong-eup, Heungduk-gu, Cheongju 361-951, Korea.</style></auth-address><titles><title><style face="normal" font="default">Anti-Inflammatory Effect of Titrated Extract of Centella asiatica in Phthalic Anhydride-Induced Allergic Dermatitis Animal Model</style></title><secondary-title><style face="normal" font="default">Int J Mol Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Mol Sci</style></abbr-1></periodical><pages end="" start="E378">E378-</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal model</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Back</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> COX-2</style></keyword><keyword><style face="normal" font="default"> Cyclooxygenase 2</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> iNOS</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="default"> LPS</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide Synthase</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Spread</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="30" Month="3" Year="2017">2017/3/30</year></dates><abstract><style face="normal" font="default">Centella asiatica has potent antioxidant and anti-inflammatory properties. However, its anti-dermatitic effect has not yet been reported. In this study, we investigated the anti-dermatitic effects of titrated extract of Centella asiatica (TECA) in a phthalic anhydride (PA)-induced atopic dermatitis (AD) animal model as well as in vitro model. An AD-like lesion was induced by the topical application of five percent PA to the dorsal skin or ear of Hos:HR-1 mouse. After AD induction, 100 muL of 0.2% and 0.4% of TECA (40 mug or 80 mug/cm(2)) was spread on the dorsum of the ear or back skin three times a week for four weeks. We evaluated dermatitis severity, histopathological changes and changes in protein expression by Western blotting for inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and NF-kappaB activity, which were determined by electromobility shift assay (EMSA). We also measured TNF-alpha, IL-1beta, IL-6, and IgE concentration in the blood of AD mice by enzyme-linked immunosorbent assay (ELISA). TECA treatment attenuated the development of PA-induced atopic dermatitis. Histological analysis showed that TECA inhibited hyperkeratosis, mast cells and infiltration of inflammatory cells. TECA treatment inhibited expression of iNOS and COX-2, and NF-kappaB activity as well as the release of TNF-alpha, IL-1beta, IL-6, and IgE. In addition, TECA (1, 2, 5 mug/mL) potently inhibited Lipopolysaccharide (LPS) (1 mug/mL)-induced NO production, expression of iNOS and COX-2, and NF-kappaB DNA binding activities in RAW264.7 macrophage cells. Our data demonstrated that TECA could be a promising agent for AD by inhibition of NF-kappaB signaling</style></abstract><notes><style face="normal" font="default">DA - 20170330IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.3390/ijms18040738</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28358324">PM:28358324</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-E378.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-E378.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170330, Park JH</style></custom2><misc3><style face="normal" font="default">10.3390/ijms18040738</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41385</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lyapina,M.G.</style></author><author><style face="normal" font="default"> Krasteva,A.</style></author><author><style face="normal" font="default"> Dencheva,M.</style></author><author><style face="normal" font="default"> Tzekova,M.</style></author><author><style face="normal" font="default"> Nikolov,G.</style></author><author><style face="normal" font="default"> Yaneva-Deliverska,M.</style></author><author><style face="normal" font="default"> Kisselova-Yaneva,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical University - Sofia, Sofia, Bulgaria</style></auth-address><titles><title><style face="normal" font="default">Pilot study of contact sensitization to rubber allergens and bisphenol A amongst dental students</style></title><secondary-title><style face="normal" font="default">Int J Occup Med Environ Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Occup Med Environ Health</style></abbr-1></periodical><pages end="405" start="397">397-405</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Benzoyl Peroxide</style></keyword><keyword><style face="normal" font="default"> Bisphenol A</style></keyword><keyword><style face="normal" font="default"> Bulgaria</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact sensitization</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dental Materials</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Formaldehyde</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pilot study</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Rubber</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Students</style></keyword><keyword><style face="normal" font="default"> Thiuram mix</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="8" Month="5" Year="2017">2017/5/8</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The aim of this study has been to evaluate the rate of contact sensitization to some rubber allergens and to bisphenol A (BPA) amongst students of dental medicine and dental patients. MATERIAL AND METHODS: A total of 50 participants were included in the study: 40 students of dental medicine exposed to the studied rubber allergens and BPA-based dental materials during the course of their education; 10 dental patients without occupational exposure to the latter substances served as a control group. All of them were patch-tested with the studied rubber allergens and bisphenol A. RESULTS: Highest was the sensitizing action of carba mix, followed by benzoyl peroxide and mercapto mix. The sensitization rate for carba mix was significantly higher for dental students as well as for the whole studied population, if compared to the one for thiuram mix (Chi&lt;sup>2&lt;/sup> = 12.9, p &lt; 0.001; Chi&lt;sup>2&lt;/sup> = 13.9, p &lt; 0.001), bisphenol A (Chi&lt;sup>2&lt;/sup> = 8.9, p &lt; 0.001; Chi&lt;sup>2&lt;/sup> = 11.9, p &lt; 0.001), toluenesulfonamide formaldehyde resin (Chi&lt;sup>2&lt;/sup> = 10.7, p &lt; 0.001; Chi&lt;sup>2&lt;/sup> = 13.9, p &lt; 0.001) and benzoyl peroxide (Chi&lt;sup>2&lt;/sup> = 4.7, p = 0.03; Chi&lt;sup>2&lt;/sup> = 5.8, p = 0.016), and for dental patients, if compared to the one for mercapto mix (Chi&lt;sup>2&lt;/sup> = 7.07, p = 0.008). Concomitant positive skin patch-test reactions to carba mix and to benzoyl peroxide, and to all the studied allergens were established. CONCLUSIONS: Carba mix could be outlined as a sensitizer of paramount importance for dental students as well as for dental patients. Benzoyl peroxide was the second ranked sensitizer for dental students. Positive skin patch-test reactions to bisphenol A and toluenesulfonamide formaldehyde resin were established only among the group of dental students. Int J Occup Med Environ Health 2017;30(3):397-405</style></abstract><notes><style face="normal" font="default">DA - 20170508IS - 1896-494X (Electronic)IS - 1232-1087 (Linking)LA - engPT - Journal ArticleCO - Bulgaria -</style></notes><work-type><style face="normal" font="default">10.13075/ijomeh.1896.00949</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28481373">PM:28481373</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Occup Med Environ Health\2017-30-397-405.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Occup Med Environ Health\2017-30-397-405.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170508, Lyapina MG</style></custom2><misc3><style face="normal" font="default">10.13075/ijomeh.1896.00949</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41386</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jarolimek,J.</style></author><author><style face="normal" font="default"> Urban,P.</style></author><author><style face="normal" font="default"> Pavlinek,P.</style></author><author><style face="normal" font="default"> Dzurova,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Charles University, Prague, Czechia</style></auth-address><titles><title><style face="normal" font="default">Occupational diseases in the automotive industry in Czechia - Geographic and medical context</style></title><secondary-title><style face="normal" font="default">Int J Occup Med Environ Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Occup Med Environ Health</style></abbr-1></periodical><pages end="468" start="455">455-468</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Czech Republic</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Services</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> Isocyanate</style></keyword><keyword><style face="normal" font="default"> Isocyanates</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational disease</style></keyword><keyword><style face="normal" font="default"> Occupational Diseases</style></keyword><keyword><style face="normal" font="default"> Occupational Health</style></keyword><keyword><style face="normal" font="default"> Occupational Health Services</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Textiles</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="8" Month="5" Year="2017">2017/5/8</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The automotive industry represents the most important industrial sector in Czechia. The objective of this study has been to analyze the occurrence of occupational diseases (OD) in the automotive industry during the period from 2001 till 2014. MATERIAL AND METHODS: Data on OD cases was retrieved from the National Registry of OD. Further, we conducted a survey in automotive companies with focus on occupational health services and positions of the companies in global production networks (GPNs). An analysis of OD distribution in the automotive industry was performed (age, gender, company size and its role in GPNs, regional distribution of studied companies, and regional unemployment rate), and was accompanied by assessment of the quality and range of occupational health services. RESULTS: Employees older than 40 years old have nearly 2.5 times higher probability of OD occurrence as compared with employees younger than 40 years old (odds ratio (OR) = 2.41, 95% confidence interval (CI): 2.05-2.85). Occupational diseases occurrence probability was 3 times higher for women than for men (OR = 3.01, 95% CI: 2.55-3.55). Occupational diseases incidence rates increased with the size of the company (0 OD/10 000 employees in micro enterprises to 57 OD/10 000 employees in large enterprises). A particularly steep rise in OD incidents in the automotive industry was observed in the Plzen Region between 2001 and 2011. An association between OD incidents and the unemployment rate was not statistically confirmed. CONCLUSIONS: A statistically significant increase in OD incidents dependent on company size may be arguably attributed to a higher quality of occupational medical services in bigger companies, which ensures better detection and diagnosis of OD. In the Plzen Region, the rapid increase in OD incidents was mainly caused by a change in the production process of automobile textiles in one factory due to the introduction of a glue containing isocyanates, which are potent allergising agents. This led to an increase in occupational allergic diseases - bronchial asthma in particular. Int J Occup Med Environ Health 2017;30(3):455-468</style></abstract><notes><style face="normal" font="default">DA - 20170508IS - 1896-494X (Electronic)IS - 1232-1087 (Linking)LA - engPT - Journal ArticleCO - Czechia -</style></notes><work-type><style face="normal" font="default">10.13075/ijomeh.1896.00919</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28481378">PM:28481378</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Occup Med Environ Health\2017-30-455-68.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Occup Med Environ Health\2017-30-455-68.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170508, Jarolimek J</style></custom2><misc3><style face="normal" font="default">10.13075/ijomeh.1896.00919</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41387</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Esmaeilzedeh,H.</style></author><author><style face="normal" font="default"> Esmaeilzadeh,E.</style></author><author><style face="normal" font="default"> Faramarzi,M.</style></author><author><style face="normal" font="default"> Nabavi,M.</style></author><author><style face="normal" font="default"> Farhadi,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran</style></auth-address><titles><title><style face="normal" font="default">Salicylate Food Intolerance and Aspirin Hypersensitivity in Nasal Polyposis</style></title><secondary-title><style face="normal" font="default">Iran J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Iran J Immunol</style></abbr-1></periodical><pages end="88" start="81">81-88</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> AERD</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin challenge</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> Aspirin hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Aspirin sensitivity</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> food challenge</style></keyword><keyword><style face="normal" font="default"> Food intolerance</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Multicenter Studies</style></keyword><keyword><style face="normal" font="default"> Multicenter study</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyposis</style></keyword><keyword><style face="normal" font="default"> NSAID</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> oral food challenge</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polyposis</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: A clear association between allergy and nasal polyposis (NP) is not determined and the role of food intolerance in patients with NP is not investigated by oral food challenge (OFC). OBJECTIVE: To investigate the relation of salicylate food intolerance and atopy in patients with NP according to recurrence and aspirin sensitivity. METHODS: A cross sectional multicenter study was done in two tertiary centers for allergy in Iran. Adult patients with NP were selected for the study that had been referred to allergy clinics. The oral aspirin challenge (OAC) test was performed to identify aspirin exacerbated respiratory disease (AERD) and the OFC test was used to investigate food intolerance. Atopic evaluation was performed by skin-prick tests, nasal smear and blood eosinophil count as well as serum total IgE. RESULTS: One hundred and nineteen Iranian patients (female to male ratio 1.05) with NP were enrolled (mean age, 38 +/- 11 years). Recurrence of nasal polyposis was 64.7%. OAC was performed in all cases; 43.79% cases had aspirin hypersensitivity. In addition, OFC tests determined that 69.9% of patients had salicylate food allergy. Salicylate food intolerance was significantly higher in NP cases with AERD than in aspirin tolerant patients (p&lt;0.05). Yet, positive skin prick test was not associated with NP recurrence and AERD. CONCLUSION: Atopy and NSAID exacerbated respiratory disease; therefore, they can both be considered as predictors of NP recurrence. Our study also showed that salicylate food intolerance was associated with AERD in nasal polyposis</style></abstract><notes><style face="normal" font="default">DA - 20170325IS - 1735-367X (Electronic)IS - 1735-1383 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28341821">PM:28341821</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Iran J Immunol\2017-14-81-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Iran J Immunol\2017-14-81-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170325, Esmaeilzedeh H</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41388</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Soltani,S.</style></author><author><style face="normal" font="default"> Zakeri-Milani,P.</style></author><author><style face="normal" font="default"> Barzegar-Jalali,M.</style></author><author><style face="normal" font="default"> Jelvehgari,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran</style></auth-address><titles><title><style face="normal" font="default">Fabrication and in-vitro Evaluation of Ketotifen Fumarate-loaded PLGA Nanoparticles as a Sustained Delivery System</style></title><secondary-title><style face="normal" font="default">Iran J Pharm Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Iran J Pharm Res</style></abbr-1></periodical><pages end="34" start="22">22-34</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Calorimetry</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Efficiency</style></keyword><keyword><style face="normal" font="default"> Electron microscopy</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Formulation</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory mediators</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> Ketotifen</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Microscopy</style></keyword><keyword><style face="normal" font="default"> Nanoparticles</style></keyword><keyword><style face="normal" font="default"> Particle Size</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Ketotifen fumarate is a non-bronchodilator anti-asthmatic drug which inhibits the effects of certain endogenous substances known to be inflammatory mediators, and thereby exerts antiallergic activity. The present study describes the formulation of a sustained release nanoparticle (NP) drug delivery system containing ketoftifen, using poly (D,L lactide-co-glycolide) acid (PLGA). Biodegradable NPs were prepared using 50 : 50 PLGA by a water in-oil-in-water (w/o/w) double emulsion-solvent evaporation procedure and characterized for drug content, DSC (differential scanning calorimetry, XRD (X-ray diffractionl), FTIR (Fourier transform spectroscopy), particle size , surface morphology using scanning electron microscopy, and drug release rate. The effects of different drug-to-polymer ratios on the characteristics of the NPs were investigated. NPs prepared were spherical with a smooth surface. Size of NPs was dependent on the concentration of polymer (10 mg/mL, 754.6 nm). Increasing the external organic phase volume (primary emulsion) resulted in larger particles with higher encapsulation efficiency (55%). The best drug to polymer ratio in the NP was F3 (1:10 ratio) which showed loading efficiency of 55%, and mean particle size of 754.6 nm, respectively. The FTIR, XRPD, and DSC results ruled out any chemical interaction between the drug and PLGA. The NPs prepared with low ratio of drug to polymer (1:5) F1 formulation showed faster dissolution rate than those with high drug to polymer ratio (1:10) F3 formulation. In conclusion, by selecting an appropriate level of the investigated parameters, spherical NPs with encapsulation efficiencies higher than 55% and a prolonged drug release over 24h (73.67-90.05%) were obtained</style></abstract><notes><style face="normal" font="default">DA - 20170512IS - 1735-0328 (Print)IS - 1726-6882 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28496459">PM:28496459</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Iran J Pharm Res\2017-16-22-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Iran J Pharm Res\2017-16-22-34.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170512, Soltani S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41389</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Barni,S.</style></author><author><style face="normal" font="default"> Mori,F.</style></author><author><style face="normal" font="default"> Valleriani,C.</style></author><author><style face="normal" font="default"> Mangone,G.</style></author><author><style face="normal" font="default"> Testi,S.</style></author><author><style face="normal" font="default"> Saretta,F.</style></author><author><style face="normal" font="default"> Sarti,L.</style></author><author><style face="normal" font="default"> Pucci,N.</style></author><author><style face="normal" font="default"> de Martino,M.</style></author><author><style face="normal" font="default"> Azzari,C.</style></author><author><style face="normal" font="default"> Novembre,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Unit, A. Meyer Children's Hospital, University of Florence, Viale Pieraccini, 24, 50134, Florence, Italy.</style></auth-address><titles><title><style face="normal" font="default">The utility of the basophil activation test in the diagnosis of immediate amoxicillin or amoxicillin-clavulanate hypersensitivity in children and adults</style></title><secondary-title><style face="normal" font="default">Ital J Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ital J Pediatr</style></abbr-1></periodical><pages end="" start="42">42-</pages><volume><style face="normal" font="default">43</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy workup</style></keyword><keyword><style face="normal" font="default"> Amoxicillin</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophil activation test</style></keyword><keyword><style face="normal" font="default"> BAT</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> beta-Lactams</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Betalactams</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity</style></keyword><keyword><style face="normal" font="default"> immediate reactions</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> intradermal test</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe reactions</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="21" Month="4" Year="2017">2017/4/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: The basophil activation test (BAT), has been proposed as a possible assay for the diagnosis of immediate-type allergy to beta-lactams (BLs). The aim of this study was to assess the utility of BAT in the diagnosis of amoxicillin (AMX) or AMX-clavulanate (AMX-C) IgE-mediated hypersensitivity in children and adults. MATERIAL AND METHODS: Eighteen children and 21 adults, with clinical history of immediate reactions to AMX or AMX-C, were referred to Anna Meyer Children's Hospital and San Giovanni di Dio Hospital, respectively. They underwent in vivo tests (skin prick test and intradermal test). Moreover, BAT with AMX or AMX-C was performed within 6 months from the reaction. RESULTS: In the pediatric group, the concordance between the skin tests (ST) and BAT results was 83.3%. Upon comparing the symptom grades and ST results to the BAT results, we found that the reaction severity and ST positivity did not correlate with BAT results in children. In the adult group, the concordance between the ST and BAT results was 61.9%. Upon comparing patients with severe reactions and patients with mild reactions in terms of BAT results, we found a BAT sensitivity of 38.5% and a specificity of 100%. When comparing the symptom grades to the BAT results, we found that no patients with mild symptoms had a positive BAT result, whereas 38.5% of patients with severe symptoms had a positive BAT result. CONCLUSIONS: BAT does not seem to be a useful tool to increase the sensitivity of an allergy work-up to diagnose immediate hypersensitivity to AMX or AMX-C</style></abstract><notes><style face="normal" font="default">DA - 20170422IS - 1824-7288 (Electronic)IS - 1720-8424 (Linking)LA - engPT - LetterCO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1186/s13052-017-0360-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28431585">PM:28431585</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ital J Pediatr\2017-43-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ital J Pediatr\2017-43-42.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170422, Barni S</style></custom2><misc3><style face="normal" font="default">10.1186/s13052-017-0360-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41390</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Johnson,S.F.</style></author><author><style face="normal" font="default"> Woodgate,R.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of ManitobaChild and Youth Health Services and Policy Research, University of Manitoba</style></auth-address><titles><title><style face="normal" font="default">Qualitative Research in Teen Experiences Living with Food-Induced Anaphylaxis: A Meta-Aggregation</style></title><secondary-title><style face="normal" font="default">J Adv Nurs</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Adv Nurs</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Consensus</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Services</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Qualitative Research</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> youth</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="default">AIM: To describe the central experiences of teens living with Food-Induced Anaphylaxis as a first step in responding to health care needs in this population. BACKGROUND: As prevalence of allergy increases and commonly-outgrown allergies persist longer, chronic management for teens becomes increasingly important. This review seeks to understand how teens experience living with Food-Induced Anaphylaxis. DESIGN: Meta-aggregation for qualitative systematic review, to create synthesis for clinical improvement; guided by Joanna Briggs Institute methods and their Qualitative Assessment and Review Instrument. DATA SOURCES: Seven relevant databases were searched for original qualitative research July 2015; 10 studies (published 2007-2015) met inclusion criteria. REVIEW METHODS: Both authors undertook critical appraisal, with consensus by discussion. Findings from line-by-line extraction were grouped into categories and syntheses. In studies with mixed populations, we included only teens (age 12-19) with Food-Induced Anaphylaxis. RESULTS: We developed three syntheses from nine categories and 64 subcategories to reflect central experiences of teens with Food-Induced Anaphylaxis, including: (1) Defining the allergic self,;(2) Finding a balance; and (3) Controlling the uncontrollable. The syntheses encompass importance of allergic identity/understanding, difficulties in coping with burdens of food allergy and reflect the complex risk interactions teens must negotiate in social contexts. CONCLUSION: There is a need to respect teens as active participants in managing Food-Induced Anaphylaxis, while recognizing that social expectations and a lack of public awareness/safety can dangerously affect one's needs and decisions. This helps broaden how we conceptualize the needs of teens living with Food-Induced Anaphylaxis, informing ongoing care and management. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170425IS - 1365-2648 (Electronic)IS - 0309-2402 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1111/jan.13325</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28440959">PM:28440959</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Adv Nurs\20170425-JohnsonSF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Adv Nurs\20170425-JohnsonSF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170425, Johnson SF</style></custom2><misc3><style face="normal" font="default">10.1111/jan.13325</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41391</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Amaral,L.</style></author><author><style face="normal" font="default"> Carolino,F.</style></author><author><style face="normal" font="default"> Carneiro-Leao,L.</style></author><author><style face="normal" font="default"> Dias de Castro,E.</style></author><author><style face="normal" font="default"> Cernadas,J.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Servico de Imunoalergologia, Centro Hospitalar Sao Joao E.P.E., Porto, Portugal.</style></auth-address><titles><title><style face="normal" font="default">Thiocolchicoside: An unusual suspect of drug hypersensitivity</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170423IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28433341">PM:28433341</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170423-AmaralL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170423-AmaralL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170423, Amaral L</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41392</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Giavina-Bianchi,P.</style></author><author><style face="normal" font="default"> Patil,S.U.</style></author><author><style face="normal" font="default"> Banerji,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical Immunology and Allergy Division, University of Sao Paulo, Sao Paulo, Brazil.</style></auth-address><titles><title><style face="normal" font="default">Immediate Hypersensitivity Reaction to Chemotherapeutic Agents</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="599" start="593">593-599</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drug desensitization</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Rapid drug desensitization</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treatment Failure</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">An increase by 70% in new cases of cancer is expected over the next 2 decades, with more than 8 million people dying each year from the disease, an estimated 13% of all deaths worldwide. Several new chemotherapeutic agents have been rapidly developed and many of them approved through a fast-track process. In parallel, adverse reactions to chemotherapy have increased dramatically worldwide, frequently preventing the use of first-line therapy for cancer and jeopardizing patients' treatment outcomes. The present review focuses on immediate hypersensitivity reactions (IHRs) induced by chemotherapeutic agents. We address general features of these reactions and specific characteristics of the most prevalent agents involved. On the basis of scientific evidence, we suggest classifying acute reactions to chemotherapy as toxic, systemic inflammatory response syndrome, and IHRs (anaphylactic-type reactions). IHRs to chemotherapeutic agents are unpredictable adverse reactions with potentially lethal consequences. Correct diagnosis and proper management of oncologic patients with IHRs are fundamental in order not to deprive them of the first-line treatment for their disease. In this scenario, rapid drug desensitization is a groundbreaking procedure that enables selected patients to receive the drug that induced an IHR in a safe way, minimizing the risks of anaphylaxis and treatment failure</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Brazil -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483313">PM:28483313</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-593-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-593-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Giavina-Bianchi P</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41393</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fransson,S.</style></author><author><style face="normal" font="default"> Mosbech,H.</style></author><author><style face="normal" font="default"> Kappel,M.</style></author><author><style face="normal" font="default"> Hjortlund,J.</style></author><author><style face="normal" font="default"> Poulsen,L.K.</style></author><author><style face="normal" font="default"> Kvisselgaard,A.D.</style></author><author><style face="normal" font="default"> Garvey,L.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Clinic, Department of Dermato-Allergology, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.</style></auth-address><titles><title><style face="normal" font="default">The Importance of Prolonged Provocation in Drug Allergy - Results From a Danish Allergy Clinic</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Analgesics</style></keyword><keyword><style face="normal" font="default"> Anesthetics</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> local anesthetics</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillins</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="default">BACKGROUND: Drug provocation is the "Gold Standard" in drug allergy investigation. Recent studies suggest that a negative drug provocation on first dose should be followed by a prolonged provocation over several days. OBJECTIVE: To evaluate drug allergy investigations on the basis of drug provocation, including prolonged provocation. METHODS: Data from adult patients investigated for drug allergy in a Danish Allergy Clinic during the period 2010 to 2014 were entered into a database. Data included clinical details and results of provocations with suspected culprit drug (for penicillins performed only in specific IgE-negative patients). If provocation was negative on first dose, treatment was continued for 3 to 10 days. RESULTS: A total of 1,913 provocations were done in 1,659 patients, median age 46 years, of whom 1,237 (74.6%) were females. Drugs investigated were antibiotics, 1,776 (92.8%), of which 1,590 (89.5%) were penicillins; analgesics, 59 (3.1%); local anesthetics, 33 (1.7%); and other drugs, 45 (2.4%). In total, 211 of 1,913 (11.0%) provocations were positive. Causes were antibiotics, 198 (93.8%), of which 167 (84.3%) were penicillins; analgesics, 7 (3.3%); local anesthetics, 0; and other drugs, 6 (2.8%). Only 43 (20.4%) provocations were positive on first dose, whereas 95 (45.0%) turned positive more than 3 days later. CONCLUSIONS: Only 11.0% of the provocations were positive. Importantly, only 1 of 5 patients tested positive on the first dose, indicating that prolonged exposure should always be considered when drug provocation is included in allergy investigations. Most provocations were with penicillins, reflecting the pattern of antibiotic use in Denmark, which differs from that in other countries, especially outside Northern Europe</style></abstract><notes><style face="normal" font="default">DA - 20170429IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.02.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28454683">PM:28454683</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170429-FranssonS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170429-FranssonS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170429, Fransson S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.02.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41394</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mitsui,C.</style></author><author><style face="normal" font="default"> Kajiwara,K.</style></author><author><style face="normal" font="default"> Ono,E.</style></author><author><style face="normal" font="default"> Watai,K.</style></author><author><style face="normal" font="default"> Hayashi,H.</style></author><author><style face="normal" font="default"> Kamide,Y.</style></author><author><style face="normal" font="default"> Fukutomi,Y.</style></author><author><style face="normal" font="default"> Sekiya,K.</style></author><author><style face="normal" font="default"> Tsuburai,T.</style></author><author><style face="normal" font="default"> Yamamoto,K.</style></author><author><style face="normal" font="default"> Taniguchi,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Kanagawa, Japan</style></auth-address><titles><title><style face="normal" font="default">Analysis of basophil activation in patients with aspirin-exacerbated respiratory disease</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> AERD</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> CD203c</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cysteinyl leukotriene</style></keyword><keyword><style face="normal" font="default"> cysteinyl leukotrienes</style></keyword><keyword><style face="normal" font="default"> cysteinyl-leukotrienes</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Leukotrienes</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="default">Basophils are a major source of cysteinyl leukotrienes, but little is known about their association with the pathogenesis of aspirin-exacerbated respiratory disease (AERD). We assessed CD203c expression on peripheral basophils of patients with AERD</style></abstract><notes><style face="normal" font="default">DA - 20170429IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28454740">PM:28454740</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170429-MitsuiC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170429-MitsuiC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170429, Mitsui C</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.036</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41395</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Banoth,B.</style></author><author><style face="normal" font="default"> Cassel,S.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Women's Guild Lung Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA</style></auth-address><titles><title><style face="normal" font="default">BTK inhibition: Clinical Relevance Beyond B Cells</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Los Angeles</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="26" Month="4" Year="2017">2017/4/26</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170430IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28456622">PM:28456622</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170430-BanothB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170430-BanothB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170430, Banoth B</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.041</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41396</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Laidlaw,T.M.</style></author><author><style face="normal" font="default"> Cahill,K.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass.</style></auth-address><titles><title><style face="normal" font="default">Current Knowledge and Management of Hypersensitivity to Aspirin and NSAIDs</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="545" start="537">537-545</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug-induced</style></keyword><keyword><style face="normal" font="default"> Drug-induced hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> In vitro tests</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> NSAID</style></keyword><keyword><style face="normal" font="default"> NSAIDs</style></keyword><keyword><style face="normal" font="default"> Patient Safety</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) are some of the most common culprits of drug-induced hypersensitivity reactions, and can lead to a wide array of adverse effects. The accurate and timely diagnosis of aspirin and NSAID-induced hypersensitivity reactions is important for both patient safety and for the initiation of appropriate disease-specific management and treatment. Because there are no reliably validated in vitro tests available, aspirin and NSAID challenges are considered to be the criterion standard for the diagnosis of these hypersensitivity reactions, though in some patients the diagnosis can be made on the basis of a clear clinical history</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.10.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483309">PM:28483309</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-537-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-537-45.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Laidlaw TM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.10.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41397</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Confino-Cohen,R.</style></author><author><style face="normal" font="default"> Rosman,Y.</style></author><author><style face="normal" font="default"> Meir-Shafrir,K.</style></author><author><style face="normal" font="default"> Stauber,T.</style></author><author><style face="normal" font="default"> Lachover-Roth,I.</style></author><author><style face="normal" font="default"> Hershko,A.</style></author><author><style face="normal" font="default"> Goldberg,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy and Clinical Immunology Unit, Meir General Hospital, Kfar-Saba, Israel</style></auth-address><titles><title><style face="normal" font="default">Oral Challenge without Skin Testing Safely Excludes Clinically Significant Delayed-Onset Penicillin Hypersensitivity</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="675" start="669">669-675</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> cephalosporin</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nonimmediate</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> oral challenge</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> Penicillins</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Penicillins are the drug family most commonly associated with hypersensitivity reactions. Current guidelines recommend negative skin tests (ST) before re-administering penicillins to patients with previous nonimmediate reactions (NIR). OBJECTIVE: The objective of this study was to examine whether ST are necessary before re-administering penicillin to patients with NIR. METHODS: Patients with NIR to penicillins starting longer than 1 hour after last dose administration or starting any time after the first treatment day or patients with vague recollection of their reaction underwent penicillin ST. Disregarding ST results, patients were challenged with the relevant penicillins. One-tenth of the therapeutic dose followed by the full dose was administered at 1-hour interval and patients continued taking the full dose for 5 days. RESULTS: A total of 710 patients with alleged BL allergy were evaluated. Patients with a history of immediate reaction (52, 7.3%) or cephalosporin allergy (16, 2.2%) were excluded. Of the remaining 642 patients, 62.3% had negative ST, 5.3% positive ST, and 32.4% equivocal ST. A total of 617 (96.1%) patients were challenged. Immediate reaction was observed in 9 patients (1.5%): 1-positive ST, 7-negative ST, and 1-equivocal ST (P = .7). Late reaction to the first-day challenge occurred in 24 patients (4%). An at-home challenge was continued by 491 patients. Complete 5-day and partial challenges were well tolerated by 417 (85%) and 44 patients (8.9%), respectively, disregarding ST results. Thirty patients (6.1%) developed mild reactions to the home challenge regardless of their ST results. CONCLUSION: A 5-day oral challenge without preceding ST is safe and sufficient to exclude penicillin allergy after NIR developing during penicillin treatment</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.02.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483317">PM:28483317</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-669-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-669-75.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Confino-Cohen R</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.02.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41398</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Roujeau,J.C.</style></author><author><style face="normal" font="default"> Dupin,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Universite Paris-Est Creteil, Creteil, France.</style></auth-address><titles><title><style face="normal" font="default">Virus Reactivation in Drug Reaction with Eosinophilia and Systemic Symptoms (Dress) Results from a Strong Drug-Specific Immune Response</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="812" start="811">811-812</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Dermatology</style></keyword><keyword><style face="normal" font="default"> DRESS</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drug reaction with eosinophilia and systemic symptoms</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.11.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483323">PM:28483323</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-811-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-811-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Roujeau JC</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.11.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41399</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Buchheit,K.M.</style></author><author><style face="normal" font="default"> Bernstein,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Mass; Department of Medicine, Harvard Medical School, Boston, Mass</style></auth-address><titles><title><style face="normal" font="default">Progestogen Hypersensitivity: Heterogeneous Manifestations with a Common Trigger</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="574" start="566">566-574</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Fertility</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Luteal Phase</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Menstrual Cycle</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathomechanisms</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pH</style></keyword><keyword><style face="normal" font="default"> Progesterone</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Hypersensitivity to progestogen, previously known as autoimmune progesterone dermatitis, is an increasingly recognized clinical entity that presents specific diagnostic and treatment challenges. Clinical presentations are heterogeneous, but can consist of hypersensitivity symptoms associated with the progesterone surge during the luteal phase of the menstrual cycle or after exposure to exogenous progestins. With the increasing use of exogenous progesterone for contraception and fertility, more cases of hypersensitivity to exogenous progestins have been described. Here we will review proposed pathomechanisms for progestogen hypersensitivity (PH) as well as the clinical presentation of PH, testing strategies to aid in diagnosis, and treatment options for patients with hypersensitivity to progestogens</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.01.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483311">PM:28483311</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-566-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-566-74.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Buchheit KM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.01.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41400</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Peter,J.G.</style></author><author><style face="normal" font="default"> Lehloenya,R.</style></author><author><style face="normal" font="default"> Dlamini,S.</style></author><author><style face="normal" font="default"> Risma,K.</style></author><author><style face="normal" font="default"> White,K.D.</style></author><author><style face="normal" font="default"> Konvinse,K.C.</style></author><author><style face="normal" font="default"> Phillips,E.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergology and Clinical Immunology, Department of Medicine, University of Cape Town, Cape Town, South Africa</style></auth-address><titles><title><style face="normal" font="default">Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="563" start="547">547-563</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Africa</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Clinical phenotypes</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Cutaneous adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> delayed reaction</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> HLA</style></keyword><keyword><style face="normal" font="default"> Immune-mediated</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> immunopathology</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Stevens-Johnson syndrome/toxic epidermal necrolysis</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic reaction</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Most immune-mediated adverse drug reactions (IM-ADRs) involve the skin, and many have additional systemic features. Severe cutaneous adverse drug reactions (SCARs) are an uncommon, potentially life-threatening, and challenging subgroup of IM-ADRs with diverse clinical phenotypes, mechanisms, and offending drugs. T-cell-mediated immunopathology is central to these severe delayed reactions, but effector cells and cytokines differ by clinical phenotype. Strong HLA-gene associations have been elucidated for specific drug-SCAR IM-ADRs such as Stevens-Johnson syndrome/toxic epidermal necrolysis, although the mechanisms by which carriage of a specific HLA allele is necessary but not sufficient for the development of many IM-ADRs is still being defined. SCAR management is complicated by substantial short- and long-term morbidity/mortality and the potential need to treat ongoing comorbid disease with related medications. Multidisciplinary specialist teams at experienced units should care for patients. In the setting of SCAR, patient outcomes as well as preventive, diagnostic, treatment, and management approaches are often not generalizable, but rather context specific, driven by population HLA-genetics, the pharmacology and genetic risk factors of the implicated drug, severity of underlying comorbid disease necessitating ongoing treatments, and cost considerations. In this review, we update the basic and clinical science of SCAR diagnosis and management</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - South Africa -CO - United States -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.01.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483310">PM:28483310</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-547-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-547-63.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Peter JG</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.01.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41401</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Litonjua,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.</style></auth-address><titles><title><style face="normal" font="default">Vitamin D Levels, Asthma, and Lung Function: Time to Act on Deficiency?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="798" start="797">797-798</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2016.12.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483321">PM:28483321</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-797-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-797-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Litonjua AA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2016.12.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41402</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Castells,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.</style></auth-address><titles><title><style face="normal" font="default">Drug Allergy: Phenotypes, Endotypes, and Biomarkers</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="627" start="626">626-627</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Endotypes</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483316">PM:28483316</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-626-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-626-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Castells MC</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.026</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41403</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kampitak,T.</style></author><author><style face="normal" font="default"> Betschel,S.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Clinical Immunology and Allergy, Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default">Subcutaneous abdominal abscesses in a patient with common variable immunodeficiency receiving subcutaneous immunoglobulin therapy</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Abscess</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Common Variable Immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Ontario</style></keyword><keyword><style face="normal" font="default"> subcutaneous</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170502IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28460848">PM:28460848</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170502-KampitakT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170502-KampitakT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170502, Kampitak T</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.037</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41404</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hsu Blatman,K.S.</style></author><author><style face="normal" font="default"> Hepner,D.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, Mass.</style></auth-address><titles><title><style face="normal" font="default">Current Knowledge and Management of Hypersensitivity to Perioperative Drugs and Radiocontrast Media</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="592" start="587">587-592</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Chlorhexidine</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Consensus</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Fluid Therapy</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Latex</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Neuromuscular blocking agent</style></keyword><keyword><style face="normal" font="default"> Neuromuscular Blocking Agents</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Perioperative anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Premedication</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Radiocontrast media</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Rocuronium</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Secondary Prevention</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum tryptase</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Sugammadex</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Perioperative anaphylaxis is an iatrogenic clinical condition, most often after anesthetic induction. Several mechanisms are implicated, including IgE- and non-IgE-mediated mechanisms. Perioperative anaphylaxis tends to be severe and has a higher mortality rate than anaphylaxis in other settings. This is partly due to factors that impair early recognition of anaphylaxis. Neuromuscular blocking agents, latex containing products, and antibiotics are the most common etiology. Chlorhexidine and dyes are increasingly culprits. The newest emerging cause is sugammadex, which is used for reversal of the effects of steroidal neuromusclar agents, such as rocuronium. Latex-induced allergy is becoming less common than in the 1980s due to primary and secondary prevention measures. Serum tryptase levels during the time of anaphylaxis and skin testing to suspected agents as an outpatient are necessary to confirm the diagnosis. Management includes epinephrine and aggressive fluid therapy. With radiocontrast media allergy, patients with a history of immediate hypersensitivity reactions to radiocontrast media should receive steroid and antihistamine premedication before re-exposure. Because IgE-mediated anaphylaxis to radiocontrast media is rare, there is a universal consensus that routinely skin testing all patients with a past reaction is not effective</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483312">PM:28483312</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-587-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-587-92.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Htsu Blatman KS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41405</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hamada,S.</style></author><author><style face="normal" font="default"> Tatsumi,S.</style></author><author><style face="normal" font="default"> Kobayashi,Y.</style></author><author><style face="normal" font="default"> Matsumoto,H.</style></author><author><style face="normal" font="default"> Yasuba,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Hikone Municipal Hospital, Hikone, Japan</style></auth-address><titles><title><style face="normal" font="default">Radiographic Evidence of Sinonasal Inflammation in Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome: An Underrecognized Association</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> imaging</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Maxillary Sinus</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> sinus</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: Sinonasal inflammation on both clinical examinations and imaging significantly impacts both asthma and chronic obstructive pulmonary disease (COPD). OBJECTIVE: The objective of this study was to examine the association between sinonasal inflammation and asthma-COPD overlap syndrome (ACOS). METHODS: A total of 112 patients with a ratio of forced expiratory volume in 1 s to forced vital capacity of less than 70% were enrolled. COPD, asthma, and ACOS were clinically diagnosed according to the 2014 Global Initiative for Asthma and Global Initiative for Chronic Obstructive Lung Disease guidelines. Sinonasal inflammatory condition was evaluated using sinus computed tomography, and its severity was assessed according to the Lund-Mackay staging (LMS) system. Ethmoid sinus-dominant shadow was defined as the presence of greater LMS scores for the anterior and posterior ethmoid sinuses than for the maxillary sinus. RESULTS: COPD, asthma, and ACOS were diagnosed in 55 (49.1%), 39 (34.8%), and 18 patients (16.1%), respectively. The frequency of radiographic evidence of sinonasal inflammation in patients with COPD, asthma, ACOS was 60.0%, 94.9%, and 72.2%, respectively. Patients with ACOS and COPD had only mild radiographic evidence of sinonasal inflammation (LMS score, 1-7), whereas moderate (LMS score, 8-11) and severe (LMS score, >/=12) radiographic evidence of sinonasal inflammation were detected only in patients with asthma. Furthermore, the frequency of ethmoid sinus-dominant shadow was significantly higher in patients with asthma than in those with COPD and ACOS. CONCLUSIONS: Radiographic evidence of sinonasal inflammation was a common comorbidity in ACOS. Future studies are required to examine the role of sinonasal inflammation in ACOS</style></abstract><notes><style face="normal" font="default">DA - 20170502IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28460847">PM:28460847</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170502-HamadaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170502-HamadaS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170502, Hamada S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.031</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41406</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Canna,S.W.</style></author><author><style face="normal" font="default"> Girard,C.</style></author><author><style face="normal" font="default"> Malle,L.</style></author><author><style face="normal" font="default"> de Jesus,A.</style></author><author><style face="normal" font="default"> Romberg,N.</style></author><author><style face="normal" font="default"> Kelsen,J.</style></author><author><style face="normal" font="default"> Surrey,L.F.</style></author><author><style face="normal" font="default"> Russo,P.</style></author><author><style face="normal" font="default"> Sleight,A.</style></author><author><style face="normal" font="default"> Schiffrin,E.</style></author><author><style face="normal" font="default"> Gabay,C.</style></author><author><style face="normal" font="default"> Goldbach-Mansky,R.</style></author><author><style face="normal" font="default"> Behrens,E.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pa.</style></auth-address><titles><title><style face="normal" font="default">Reply (Refers To:  IL-18 binding protein reverses the life-threatening hyperinflammation of a baby with the NLRC4 mutation)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Electronic</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170502IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - United States -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28460789">PM:28460789</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170502-CannaSW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170502-CannaSW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170502, Canna SW</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41407</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Novick,D.</style></author><author><style face="normal" font="default"> Dinarello,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Weizmann Institute of Science, Molecular Genetics, Rehovot, Israel.</style></auth-address><titles><title><style face="normal" font="default">IL-18 binding protein reverses the life-threatening hyperinflammation of a baby with the NLRC4 mutation</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Electronic</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170501IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - United States -CO - Israel -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28457594">PM:28457594</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170501-NovickD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170501-NovickD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170501, Novick D</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.037</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41408</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hudey,S.N.</style></author><author><style face="normal" font="default"> Westermann-Clark,E.</style></author><author><style face="normal" font="default"> Lockey,R.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida, Morsani College of Medicine, Tampa, Fla</style></auth-address><titles><title><style face="normal" font="default">Cardiovascular and Diabetic Medications That Cause Bradykinin-Mediated Angioedema</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="615" start="610">610-615</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Bradykinin</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Degradation</style></keyword><keyword><style face="normal" font="default"> Drug-induced</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Florida</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Neprilysin</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Substance P</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Medication-induced angioedema is a bradykinin-mediated process that results from increased production or decreased degradation of bradykinin. These reactions are documented for several cardiac medications including blockers of the renin-angiotensin-aldosterone system (RAAS). Other cardiovascular and diabetes medications further increase the risk of medication-induced angioedema, particularly with concomitant use of RAAS inhibitors. Dipeptidyl peptidase IV inhibitors are a class of oral diabetic agents that affect bradykinin and substance P degradation and therefore can lead to angioedema. Neprilysin inhibitors are a separate class of cardiac medications, which includes sacubitril, and can lead to drug-induced angioedema especially when used in combination with RAAS inhibitors. This article discusses the proposed mechanisms by which these medications cause angioedema and how medication-induced angioedema differs from mast cell-mediated angioedema. It also details how to recognize medication-induced angioedema and the treatment options available</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483314">PM:28483314</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-610-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-610-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Hudey SN</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41409</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Langan,S.M.</style></author><author><style face="normal" font="default"> Stuart,B.</style></author><author><style face="normal" font="default"> Bradshaw,L.</style></author><author><style face="normal" font="default"> Schmitt,J.</style></author><author><style face="normal" font="default"> Williams,H.C.</style></author><author><style face="normal" font="default"> Thomas,K.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine.</style></auth-address><titles><title><style face="normal" font="default">Measuring Long-term Disease Control in Atopic Dermatitis: a Validation Study of Well Controlled Weeks</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Data Collection</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hygiene</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Tropical Medicine</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> Validation studies</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="26" Month="4" Year="2017">2017/4/26</year></dates><abstract><style face="normal" font="default">BACKGROUND: Because atopic dermatitis (AD) is a relapsing, remitting disease, assessing long-term control is important. Well controlled weeks (WCWs) have been used to assess asthma long-term control, but never validated for AD. OBJECTIVES: To assess feasibility, validity and interpretability of WCWs in AD patients. METHODS: Three studies of patients with moderate-to-severe AD including 4-6 months of daily/weekly symptom and treatment use data were evaluated (Study A: n=336; Study B: n=60; Study C: n=224). WCWs were defined by worsening symptoms and increased medication use. Feasibility, construct validity and interpretability of WCWs were determined by assessing missing data, association with validated AD outcomes, and floor/ceiling effects. Analysis used linear and logistic regression. RESULTS: WCWs were feasible to collect - 95.2% (study A) and 94.7% (study B) contributed data for at least half of the weekly data-points, and 93.2% and 88.7% contributed to all data-points up to 4 months. WCWs were significantly associated with validated AD severity instruments including patient-reported (POEM) and objective signs (EASI, TIS and SASSAD). The odds of experiencing a WCW if AD severity was clear/mild was 5.8 (95% confidence interval (CI) 3.5 to 9.7), 1.9 (95%CI 0.8 to 4.4) and 8.1 (95%CI 4.5 to 14.6) in Studies A, B and C, respectively. WCWs were associated with ceiling effects- 31.6% (study A) and 37.5% (study B) of participants had no WCWs for >90% of the time. CONCLUSIONS: WCWs are valid and feasible for measuring long-term control in AD trials. However, ceiling effects and burden of data collection may limit use</style></abstract><notes><style face="normal" font="default">DA - 20170430IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28456619">PM:28456619</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170430-LanganSM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170430-LanganSM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170430, Langan SM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.043</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41410</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,W.J.</style></author><author><style face="normal" font="default"> Koo,J.H.</style></author><author><style face="normal" font="default"> Cho,H.J.</style></author><author><style face="normal" font="default"> Lee,J.U.</style></author><author><style face="normal" font="default"> Kim,J.Y.</style></author><author><style face="normal" font="default"> Lee,H.G.</style></author><author><style face="normal" font="default"> Lee,S.</style></author><author><style face="normal" font="default"> Kim,J.H.</style></author><author><style face="normal" font="default"> Oh,M.S.</style></author><author><style face="normal" font="default"> Suh,M.</style></author><author><style face="normal" font="default"> Shin,E.C.</style></author><author><style face="normal" font="default"> Ko,J.Y.</style></author><author><style face="normal" font="default"> Sohn,M.H.</style></author><author><style face="normal" font="default"> Choi,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Life Science, College of Natural Sciences, Hanyang University, Seoul 04763, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Protein Tyrosine Phosphatase Conjugated with a Novel Transdermal Delivery Peptide, AP-rPTP Alleviates both Atopic Dermatitis-like and Psoriasis-like Dermatitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Efficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidermis</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Fibroblasts</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Keratinocytes</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Microscopy</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> peptide</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Protein-Tyrosine-Phosphatase</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> Recombinant</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Tyrosine</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="26" Month="4" Year="2017">2017/4/26</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis and psoriasis are the two most common chronic inflammatory skin diseases. There is an unmet medical need to overcome limitations for transcutaneous drug development posed by the skin barrier. OBJECTIVE: We aimed to identify a novel transdermal delivery peptide and to develop a transcutaneously applicable immunomodulatory protein for treating atopic dermatitis and psoriasis. METHODS: We identified and generated reporter proteins conjugated to AP, a novel transdermal delivery peptide of human origin, and analyzed the intracellular delivery efficiency of these proteins in mouse and human skin cells and tissues using multi-photon confocal microscopy. We also generated a recombinant therapeutic protein, AP-rPTP, consisting of the phosphatase domain of T cell protein tyrosine phosphatase (TC-PTP) conjugated to AP. The immunomodulatory function of AP-rPTP was confirmed in splenocytes upon cytokine stimulation and TcR stimulation. Finally, we confirmed the in vivo efficacy of AP-rPTP transdermal delivery in OXA-induced contact hypersensitivity, OVA-induced atopic dermatitis-like, and imiquimod-induced psoriasis-like skin inflammation models. RESULTS: AP-conjugated reporter proteins exhibited significant intracellular transduction efficacy in keratinocytes, fibroblasts, and immune cells. In addition, transcutaneous administration of AP-dTomato resulted in showed significant localization into the dermis and epidermis in both mouse and human skin. AP-rPTP inhibited pSTAT1, pSTAT3, and pSTAT6 in splenocytes and also regulated T cell activation and proliferation. Transcutaneous administration of AP-rPTP via the paper-patch technique significantly ameliorated skin tissue thickening, inflammation, and cytokine expression in both atopic dermatitis-like and psoriasis-like dermatitis models. CONCLUSION: We identified a 9-amino acid-long novel transdermal delivery peptide, AP, and demonstrated its feasibility for transcutaneous biologic drug development. Moreover, AP-rPTP is a novel immunomodulatory drug candidate for human dermatitis</style></abstract><notes><style face="normal" font="default">DA - 20170430IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28456618">PM:28456618</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170430-KimWJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170430-KimWJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170430, Kim WJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41411</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ortqvist,A.K.</style></author><author><style face="normal" font="default"> Lundholm,C.</style></author><author><style face="normal" font="default"> Fang,F.</style></author><author><style face="normal" font="default"> Fall,T.</style></author><author><style face="normal" font="default"> Almqvist,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default">Parental antibiotics and childhood asthma-a population-based study</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword></keywords><dates><year Day="29" Month="4" Year="2017">2017/4/29</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170503IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28465011">PM:28465011</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170503-OrtqvistAK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170503-OrtqvistAK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170503, Ortqvist AK</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41412</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sullivan,P.W.</style></author><author><style face="normal" font="default"> Ghushchyan,V.H.</style></author><author><style face="normal" font="default"> Globe,G.</style></author><author><style face="normal" font="default"> Schatz,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Regis University School of Pharmacy, Denver, CO</style></auth-address><titles><title><style face="normal" font="default">Oral Corticosteroid Exposure and Adverse Effects in Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Cataract</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral corticosteroids</style></keyword><keyword><style face="normal" font="default"> Osteoporosis</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective cohort study</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="26" Month="4" Year="2017">2017/4/26</year></dates><abstract><style face="normal" font="default">BACKGROUND: Significant adverse effects (AEs) have been associated with continuous exposure to oral corticosteroids (OCS). The potential association with intermittent exposure is unknown. OBJECTIVE: Assess the association between OCS and AEs based on the number of OCS prescriptions. METHODS: This was a retrospective cohort study of asthma patients >/= 18 years in the 2000-2014 MarketScan(R) dataset. Propensity Score Matching was used at baseline (12 months prior to index date: first OCS use). Logistic regression was used to examine the association between OCS and new-incident AEs (either combined or individual) controlling for covariates. Follow-up continued for 24 months minimum and 10 years maximum after index. RESULTS: There were 72,063 and 156,373 individuals in the OCS and no OCS cohorts, respectively. Individuals taking >/= 4 OCS (1-3) prescriptions within the year had 1.29 (1.04) times the odds of experiencing a new AE within the year. Each year of exposure to >/= 4 OCS prescriptions (current and past) resulted in 1.20 times the odds of developing an AE in the current year. Exposure to >/= four prescriptions was associated with significantly greater odds of AEs for: osteoporosis, hypertension, obesity, type 2 diabetes, gastrointestinal ulcers/bleeds, fractures and cataracts (odds 1.21 - 1.44 depending on the AE). CONCLUSION: While previous research has documented the deleterious effect of continuous OCS exposure in severe asthma, our results suggest that each OCS prescription may result in a cumulative burden on current and future health, regardless of dose and duration. OCS sparing strategies are extremely important to improving patient outcomes</style></abstract><notes><style face="normal" font="default">DA - 20170430IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28456623">PM:28456623</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170430-SullivanPW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170430-SullivanPW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170430, Sullivan PW</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41413</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Leitao Filho,F.S.</style></author><author><style face="normal" font="default"> Won,R.S.</style></author><author><style face="normal" font="default"> Mattman,A.</style></author><author><style face="normal" font="default"> Schellenberg,R.S.</style></author><author><style face="normal" font="default"> Fishbane,N.</style></author><author><style face="normal" font="default"> Criner,G.J.</style></author><author><style face="normal" font="default"> Woodruff,P.G.</style></author><author><style face="normal" font="default"> Lazarus,S.C.</style></author><author><style face="normal" font="default"> Albert,R.</style></author><author><style face="normal" font="default"> Connett,J.E.</style></author><author><style face="normal" font="default"> Han,M.K.</style></author><author><style face="normal" font="default"> Martinez,F.J.</style></author><author><style face="normal" font="default"> Leung,J.M.</style></author><author><style face="normal" font="default"> Paul Man,S.F.</style></author><author><style face="normal" font="default"> Aaron,S.D.</style></author><author><style face="normal" font="default"> Reed,R.M.</style></author><author><style face="normal" font="default"> Sin,D.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Heart Lung Innovation, St. Paul's Hospital, &amp; Department of Medicine (Division of Respiratory Medicine), University of British Columbia, Vancouver, BC, Canada</style></auth-address><titles><title><style face="normal" font="default">Serum Immunoglobulin G and Risk of Exacerbations and Hospitalizations in Chronic Obstructive Pulmonary Disease</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">British Columbia</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> Columbia</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Igg</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Minnesota</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="26" Month="4" Year="2017">2017/4/26</year></dates><abstract><style face="normal" font="default">Hypogammaglobulinemia (total IgG levels &lt; 7.0 g/L) is present in 1 in 4 patients with moderate to severe COPD and is associated with 50% to 100% increase in the risk of exacerbations and hospitalizations</style></abstract><notes><style face="normal" font="default">DA - 20170430IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28456620">PM:28456620</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170430-LeitaoFilhoFS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170430-LeitaoFilhoFS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170430, Leitao Filho FS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.046</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41414</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kopel,L.S.</style></author><author><style face="normal" font="default"> Petty,C.R.</style></author><author><style face="normal" font="default"> Gaffin,J.M.</style></author><author><style face="normal" font="default"> Sheehan,W.J.</style></author><author><style face="normal" font="default"> Baxi,S.N.</style></author><author><style face="normal" font="default"> Kanchongkittiphon,W.</style></author><author><style face="normal" font="default"> Fu,C.</style></author><author><style face="normal" font="default"> Gold,D.R.</style></author><author><style face="normal" font="default"> Phipatanakul,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Respiratory Medicine, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada</style></auth-address><titles><title><style face="normal" font="default">Caregiver stress among inner-city school children with asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inner city</style></keyword><keyword><style face="normal" font="default"> inner-city</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Quebec</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170423IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.02.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28433340">PM:28433340</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170423-KopelLS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170423-KopelLS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170423, Kopel LS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.02.026</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41415</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Elias,M.S.</style></author><author><style face="normal" font="default"> Long,H.A.</style></author><author><style face="normal" font="default"> Newman,C.F.</style></author><author><style face="normal" font="default"> Wilson,P.A.</style></author><author><style face="normal" font="default"> West,A.</style></author><author><style face="normal" font="default"> McGill,P.J.</style></author><author><style face="normal" font="default"> Wu,K.C.</style></author><author><style face="normal" font="default"> Donaldson,M.J.</style></author><author><style face="normal" font="default"> Reynolds,N.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatological Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Proteomic analysis of filaggrin deficiency identifies molecular signatures characteristic of atopic eczema</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic eczema</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Filaggrin</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protease</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> proteome</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Rna</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Transcriptome</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic eczema (AE) is characterized by skin barrier and immune dysfunction. Null mutations in filaggrin (FLG), a key epidermal barrier protein, strongly predispose to AE; however, the precise role of FLG deficiency in AE pathogenesis remains incompletely understood. OBJECTIVES: We sought to identify global proteomic changes downstream of FLG deficiency in human epidermal living skin-equivalent (LSE) models and validate findings in skin of patients with AE. METHODS: Differentially expressed proteins from paired control (nontargeting control short hairpin RNA [shNT]) and FLG knockdown (FLG knockdown short hairpin RNA [shFLG]) LSEs were identified by means of proteomic analysis (liquid chromatography-mass spectrometry) and Ingenuity Pathway Analysis. Expression of key targets was validated in independent LSE samples (quantitative RT-PCR and Western blotting) and in normal and AE skin biopsy specimens (immunofluorescence). RESULTS: Proteomic analysis identified 17 (P &lt;/= .05) differentially expressed proteins after FLG knockdown, including kallikrein-7 (KLK7; 2.2-fold), cyclophilin A (PPIA; 0.9-fold), and cofilin-1 (CFL1, 1.3-fold). Differential protein expression was confirmed in shNT/shFLG LSEs; however, only KLK7 was transcriptionally dysregulated. Molecular pathways overrepresented after FLG knockdown included inflammation, protease activity, cell structure, and stress. Furthermore, KLK7 (1.8-fold) and PPIA (0.65-fold) proteins were differentially expressed in lesional biopsy specimens from patients with AE relative to normal skin. CONCLUSIONS: For the first time, we show that loss of FLG in the absence of inflammation is sufficient to alter the expression level of proteins relevant to the pathogenesis of AE. These include proteins regulating inflammatory, proteolytic, and cytoskeletal functions. We identify PPIA as a novel protein with levels that are decreased in clinically active AE skin and show that the characteristic upregulation of KLK7 expression in patients with AE occurs downstream of FLG loss. Importantly, we highlight disconnect between the epidermal proteome and transcriptome, emphasizing the utility of global proteomic studies</style></abstract><notes><style face="normal" font="default">DA - 20170508IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28479159">PM:28479159</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170508-EliasMS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170508-EliasMS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170508, Elias MS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.039</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41416</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Morita,H.</style></author><author><style face="normal" font="default"> Nakae,S.</style></author><author><style face="normal" font="default"> Saito,H.</style></author><author><style face="normal" font="default"> Matsumoto,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">IL-33 in clinical practice: size matters?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword></keywords><dates><year Day="3" Month="5" Year="2017">2017/5/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170507IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - Japan -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28478050">PM:28478050</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170507-MoritaH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170507-MoritaH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170507, Morita H</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.042</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41417</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hua,X.</style></author><author><style face="normal" font="default"> Yuan,X.</style></author><author><style face="normal" font="default"> Li,Y.</style></author><author><style face="normal" font="default"> Chen,H.</style></author><author><style face="normal" font="default"> Yuan,J.</style></author><author><style face="normal" font="default"> Tanumiharjo,S.</style></author><author><style face="normal" font="default"> Bian,F.</style></author><author><style face="normal" font="default"> Su,L.</style></author><author><style face="normal" font="default"> Hong,Y.</style></author><author><style face="normal" font="default"> Liu,Y.</style></author><author><style face="normal" font="default"> Chi,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, Second Hospital of Tianjin Medical University, Tianjin Medical University, Tianjin 300211, P.R. China</style></auth-address><titles><title><style face="normal" font="default">Desiccating stress worsens alkali burn injury by magnifying caspase-8-induced imbalance of NLRP3 and NLRP6</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Ophthalmology</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="default">We reveal novel discoveries of an innate immune pathway mediated by the imbalanced activation of NLRP3 and NLRP6 promoted by caspase-8 activation in AB and secondary dry eye and create new intervention strategies to treat inflammatory diseases</style></abstract><notes><style face="normal" font="default">DA - 20170508IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28479336">PM:28479336</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170508-HuaX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170508-HuaX.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170508, Hua X</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41418</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Muehling,L.M.</style></author><author><style face="normal" font="default"> Lawrence,M.G.</style></author><author><style face="normal" font="default"> Woodfolk,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Division, Department of Medicine, University of Virginia School of Medicine, Charlottesville, Va</style></auth-address><titles><title><style face="normal" font="default">Pathogenic CD4+ T cells in patients with asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Barriers</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical phenotypes</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> epitope</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate lymphoid cells</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> pathogenicity</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> Th1 Cells</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> Th2 Cells</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Virginia</style></keyword></keywords><dates><year Day="22" Month="4" Year="2017">2017/4/22</year></dates><abstract><style face="normal" font="default">Asthma encompasses a variety of clinical phenotypes that involve distinct T cell-driven inflammatory processes. Improved understanding of human T-cell biology and the influence of innate cytokines on T-cell responses at the epithelial barrier has led to new asthma paradigms. This review captures recent knowledge on pathogenic CD4+ T cells in asthmatic patients by drawing on observations in mouse models and human disease. In patients with allergic asthma, TH2 cells promote IgE-mediated sensitization, airway hyperreactivity, and eosinophilia. Here we discuss recent discoveries in the myriad molecular pathways that govern the induction of TH2 differentiation and the critical role of GATA-3 in this process. We elaborate on how cross-talk between epithelial cells, dendritic cells, and innate lymphoid cells translates to T-cell outcomes, with an emphasis on the actions of thymic stromal lymphopoietin, IL-25, and IL-33 at the epithelial barrier. New concepts on how T-cell skewing and epitope specificity are shaped by multiple environmental cues integrated by dendritic cell "hubs" are discussed. We also describe advances in understanding the origins of atypical TH2 cells in asthmatic patients, the role of TH1 cells and other non-TH2 types in asthmatic patients, and the features of T-cell pathogenicity at the single-cell level. Progress in technologies that enable highly multiplexed profiling of markers within a single cell promise to overcome barriers to T-cell discovery in human asthmatic patients that could transform our understanding of disease. These developments, along with novel T cell-based therapies, position us to expand the assortment of molecular targets that could facilitate personalized treatments</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28442213">PM:28442213</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170426-MuehlingLM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170426-MuehlingLM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Muehling LM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41419</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Westerhof,G.A.</style></author><author><style face="normal" font="default"> Coumou,H.</style></author><author><style face="normal" font="default"> de Nijs,S.B.</style></author><author><style face="normal" font="default"> Weersink,E.</style></author><author><style face="normal" font="default"> Bel,E.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default">Clinical predictors of remission and persistence of adult-onset asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Adult-onset asthma</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> nasal polyposis</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> natural course</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistence</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Polyposis</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Remission</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Statistics</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="21" Month="4" Year="2017">2017/4/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: Adult-onset asthma is an important but relatively understudied asthma phenotype and little is known about its natural course and prognosis. The remission rate is believed to be low, and it is still obscure which factors predict remission or persistence of the disease. OBJECTIVE: To determine the remission rate, and identify predictors of persistence and remission of adult-onset asthma. METHODS: Two hundred adult patients with recently diagnosed (&lt;1 year) asthma were recruited from secondary and tertiary pulmonary clinics and prospectively followed for 5 years. Clinical, functional and inflammatory parameters were assessed at baseline and at yearly visits. Asthma remission was defined as absence of asthma symptoms for >/=1 year and no asthma medication use for >/=1 year. Descriptive statistics and logistic regression analysis were performed. RESULTS: Five-year follow-up data of 170 patients (85%) was available. Of these, 27 patients (15.9%) experienced asthma remission. Patients with asthma persistence were older, had worse asthma control, required higher doses of inhaled corticosteroids, had more severe airway hyperresponsiveness, more often nasal polyps and higher levels of blood neutrophils as compared to patients who experienced clinical remission. In a multivariable logistic regression analysis, only moderate-severe bronchial hyperresponsiveness and nasal polyps were independent predictors of asthma persistence. Patients with these two characteristics had less than 1% chance of asthma remission. CONCLUSION: One in six patients with adult-onset asthma experiences remission within the first 5 years of the disease. In patients with moderate to severe bronchial hyperresponsiveness and nasal polyposis the chance of remission is close to zero</style></abstract><notes><style face="normal" font="default">DA - 20170425IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28438546">PM:28438546</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170425-WesterhofGA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170425-WesterhofGA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170425, Westerhof GA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.034</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41420</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Frans,G.</style></author><author><style face="normal" font="default"> Van der Werff Ten Bosch,J.</style></author><author><style face="normal" font="default"> Moens,L.</style></author><author><style face="normal" font="default"> Wuyts,G.</style></author><author><style face="normal" font="default"> Schaballie,H.</style></author><author><style face="normal" font="default"> Tuerlinckx,D.</style></author><author><style face="normal" font="default"> De Bie,M.</style></author><author><style face="normal" font="default"> Vermeulen,F.</style></author><author><style face="normal" font="default"> Schrijvers,R.</style></author><author><style face="normal" font="default"> Meert,W.</style></author><author><style face="normal" font="default"> Hestand,M.S.</style></author><author><style face="normal" font="default"> Delanghe,J.</style></author><author><style face="normal" font="default"> Vermeesch,J.R.,I</style></author><author><style face="normal" font="default"> Meyts,I.</style></author><author><style face="normal" font="default"> Bossuyt,X.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Microbiology and Immunology, Experimental Laboratory Immunology, KU Leuven, Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="default">Clinical characteristics of patients with low functional IL-6 production upon TLR/IL-1R stimulation</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Ligands</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="default">Low IL-6 production upon stimulation by TLR/IL-1R ligands is associated with increased susceptibility to bacterial skin infections and to invasive infections with P. aeruginosa and/or with a IRAK-4/MyD88/NEMO defect</style></abstract><notes><style face="normal" font="default">DA - 20170508IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28479328">PM:28479328</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170508-FransG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170508-FransG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170508, Frans G</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41421</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shemesh,E.</style></author><author><style face="normal" font="default"> Kleinman,L.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Associate Professor of Pediatrics and Psychiatry and Chief, Division of Developmental and Behavioral Health, The Department of Pediatrics, Icahn School of Medicine, New York.</style></auth-address><titles><title><style face="normal" font="default">Asthma: the past, the future, the environment, and the costs</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170423IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28433690">PM:28433690</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170423-ShemeshE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170423-ShemeshE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170423, Shemesh E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.031</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41422</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,S.</style></author><author><style face="normal" font="default"> Verma,M.</style></author><author><style face="normal" font="default"> Michalec,L.</style></author><author><style face="normal" font="default"> Liu,W.</style></author><author><style face="normal" font="default"> Sripada,A.</style></author><author><style face="normal" font="default"> Rollins,D.</style></author><author><style face="normal" font="default"> Good,J.</style></author><author><style face="normal" font="default"> Ito,Y.</style></author><author><style face="normal" font="default"> Chu,H.</style></author><author><style face="normal" font="default"> Gorska,M.M.</style></author><author><style face="normal" font="default"> Martin,R.J.</style></author><author><style face="normal" font="default"> Alam,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Jewish Health, Department of Medicine, Division of Allergy &amp; Immunology, and Division of Pulmonary and Critical Care Medicine, Denver, Colorado</style></auth-address><titles><title><style face="normal" font="default">Steroid Resistance of Airway Type 2 Innate Lymphoid Cells (ILC2s) from Severe Asthma: The Role of Thymic Stromal cell Lymphopoietin (TSLP)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> BAL</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> CRTH2</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Dexamethasone</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human rhinovirus</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate lymphoid cells</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Ligands</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> Rhinovirus</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> steroid resistance</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: ILC2s represent an important type 2 immune cell. Glucocorticoid regulation of human ILC2s is largely unknown. OBJECTIVE: To assess steroid resistance of human blood and airway ILC2s from asthmatic patients and examine its mechanism of induction. METHODS: We studied human blood and lung ILC2s from asthmatic and control subjects by flow cytometry and ELISA. RESULTS: Dexamethasone (Dex) inhibited (P=0.04) CRTH2 and type 2 cytokine expression by blood ILC2s stimulated with IL25 and IL33. However, it failed to do so when ILC2s were stimulated with IL7 and TSLP, two ligands of IL7Ralpha. Unlike blood ILC2s, BAL ILC2s from asthmatic patients were resistant to Dex. BAL from the asthmatic patients had elevated TSLP but not IL7. The BAL TSLP level correlated (r=0.74) with steroid resistance of ILC2s. TSLP was synergistically induced in epithelial cells by IL13 and human rhinovirus. Mechanistically, Dex upregulated ILC2 expression of IL7Ralpha , which augmented and sustained STAT5 signaling by TSLP. TSLP induced MEK, c-Fos, ID3, pSTAT3 and pSTAT5-molecules linked to steroid resistance. Dex inhibited c-Fos, ID3 and pSTAT3, but not pSTAT5 and MEK. The MEK inhibitor Trametinib, the JAK-STAT inhibitor Tofacitinib and the STAT5 inhibitor Pimozide reversed steroid resistance of BAL ILC2s. CONCLUSIONS: Dex inhibited type 2 cytokine production by blood ILC2s. IL7 and TSLP abrogated this inhibition and induced steroid resistance of ILC2s in a MEK and STAT5-dependent manner. BAL ILC2s from asthmatic patients with elevated TSLP were steroid resistant, which was reversed by clinically available inhibitors of MEK and STAT5</style></abstract><notes><style face="normal" font="default">DA - 20170423IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United states -CO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28433687">PM:28433687</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170423-LiuS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170423-LiuS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170423, Liu S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.032</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41423</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Veskitkul,J.</style></author><author><style face="normal" font="default"> Wongkaewpothong,P.</style></author><author><style face="normal" font="default"> Thaweethamchareon,T.</style></author><author><style face="normal" font="default"> Ungkanont,K.</style></author><author><style face="normal" font="default"> Visitsunthorn,N.</style></author><author><style face="normal" font="default"> Pacharn,P.</style></author><author><style face="normal" font="default"> Vichyanond,P.</style></author><author><style face="normal" font="default"> Jirapongsananuruk,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Medicine, Department of Pediatrics, Siriraj Hospital, Mahidol University, Bangkok, Thailand</style></auth-address><titles><title><style face="normal" font="default">Recurrent Acute Rhinosinusitis Prevention by Azithromycin in Children with Nonallergic Rhinitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotic Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Azithromycin</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Igg</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nonallergic rhinitis</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> specific antibodies</style></keyword><keyword><style face="normal" font="default"> Specific antibody deficiency</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="21" Month="4" Year="2017">2017/4/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: Recurrent acute rhinosinusitis (RARS) is characterized by multiple episodes of acute rhinosinusitis between which symptoms and signs resolve completely. The role of antibiotic prophylaxis to prevent RARS in children with nonallergic rhinitis (NAR) has not been investigated. OBJECTIVE: To evaluate the effect of azithromycin to prevent RARS in children with NAR. METHODS: A randomized, double-blind, placebo-controlled study was conducted in NAR children (5-15 years) with RARS. Azithromycin (5 mg/kg/d) 3 d/wk for 12 months or placebo was assigned to the study group and the control group, respectively. Patients with allergic rhinitis were excluded. Number of rhinosinusitis episodes in 12 months, visual analog scale score of nasal symptoms, and adjunctive medication score were recorded. RESULTS: Forty patients were enrolled and 20 patients were assigned randomly to the azithromycin and placebo groups. IgG subclass and specific antibody deficiencies were found in 83% and 2.5% of patients, respectively. After 12 months, the number of rhinosinusitis episodes/y in the azithromycin group reduced significantly from 5 to 0.5 (P &lt; .001) in contrast to the placebo group. Number needed to treat using azithromycin prophylaxis to prevent 1 patient from having RARS was 2. The average visual analog scale score and the average adjunctive medication score in the azithromycin (but not in the placebo) group reduced significantly compared with baseline (2.2 +/- 1.4 vs 5.4 +/- 1.8) and (3.9 +/- 1.7 vs 5.4 +/- 1.1), respectively (P &lt; .001). CONCLUSIONS: Azithromycin prophylaxis can reduce the number of rhinosinusitis episodes and medication score, and improve nasal symptoms in NAR children with RARS</style></abstract><notes><style face="normal" font="default">DA - 20170425IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28438539">PM:28438539</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170425-VeskitkulJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170425-VeskitkulJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170425, Veskitkul J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41424</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Patel,D.R.</style></author><author><style face="normal" font="default"> Yu,H.</style></author><author><style face="normal" font="default"> Wong,L.C.</style></author><author><style face="normal" font="default"> Lupski,J.R.</style></author><author><style face="normal" font="default"> Seeborg,F.O.</style></author><author><style face="normal" font="default"> Rider,N.L.</style></author><author><style face="normal" font="default"> Martinez,C.A.</style></author><author><style face="normal" font="default"> Orange,J.S.</style></author><author><style face="normal" font="default"> Hanson,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunology, Allergy and Rheumatology Section, Baylor College of Medicine, Houston, Texas</style></auth-address><titles><title><style face="normal" font="default">Linking newborn severe combined immunodeficiency screening with targeted exome sequencing: A case report</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> newborn</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Severe Combined Immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Texas</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="21" Month="4" Year="2017">2017/4/21</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170425IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28438538">PM:28438538</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170425-PatelDR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170425-PatelDR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170425, Patel DR</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41425</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Turi,K.N.</style></author><author><style face="normal" font="default"> Romick-Rosendale,L.</style></author><author><style face="normal" font="default"> Ryckman,K.K.</style></author><author><style face="normal" font="default"> Hartert,T.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN</style></auth-address><titles><title><style face="normal" font="default">A review of metabolomics approaches and their application in identifying causal pathways of childhood asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> disease pathogenesis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Endotypes</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metabolomics</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="default">As asthma is a disease that results from host x environment interactions, an approach which allows assessment of the impact of the environment on the host is needed to understand disease. Metabolomics has appealing potential as an application to study pathways to childhood asthma development. The objective of this review is to provide an overview of metabolomics methods, and their application to understanding host x environment pathways in asthma development. We reviewed recent literature on advances in metabolomics and their application to study pathways to childhood asthma development. We highlighted 1) the potential of metabolomics in understanding the pathogenesis of disease and the discovery of biomarkers, 2) choice of metabolomics techniques, biospecimen handling, and data analysis, 3) the application to studying the role of environment on asthma development, 4) review of metabolomics applied to the outcome of asthma, 5) recommendations for application of metabolomics based -omics data integration in understanding disease pathogenesis, and 6) limitations. In conclusion metabolomics allows use of biospecimens to identify useful biomarkers and pathways involved in disease development, and subsequently to inform a greater understanding of the disease pathogenesis and endotypes, and predicting the clinical course of childhood asthma phenotypes</style></abstract><notes><style face="normal" font="default">DA - 20170508IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28479327">PM:28479327</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170508-TuriKN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170508-TuriKN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170508, Turi KN</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41426</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Taylor,S.L.</style></author><author><style face="normal" font="default"> Leong,L.E.X.</style></author><author><style face="normal" font="default"> Choo,J.M.</style></author><author><style face="normal" font="default"> Wesselingh,S.</style></author><author><style face="normal" font="default"> Yang,I.A.</style></author><author><style face="normal" font="default"> Upham,J.W.</style></author><author><style face="normal" font="default"> Reynolds,P.N.</style></author><author><style face="normal" font="default"> Hodge,S.</style></author><author><style face="normal" font="default"> James,A.L.</style></author><author><style face="normal" font="default"> Jenkins,C.</style></author><author><style face="normal" font="default"> Peters,M.J.</style></author><author><style face="normal" font="default"> Baraket,M.</style></author><author><style face="normal" font="default"> Marks,G.B.</style></author><author><style face="normal" font="default"> Gibson,P.G.</style></author><author><style face="normal" font="default"> Simpson,J.L.</style></author><author><style face="normal" font="default"> Rogers,G.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia; SAHMRI Microbiome Research Laboratory, School of Medicine, Flinders University, Adelaide, South Australia, Australia</style></auth-address><titles><title><style face="normal" font="default">Inflammatory phenotypes in severe asthma are associated with distinct airway microbiology</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> diversity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic asthma</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> induced sputum</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory phenotypes</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophilic asthma</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Streptococcus</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma pathophysiology and treatment responsiveness are predicted by inflammatory phenotype. However, the relationship between airway microbiology and asthma phenotype is poorly understood. We aimed to characterise airway microbiota in patients with symptomatic stable asthma, and relate composition to airway inflammatory phenotype and other phenotypic characteristics. METHODS: The microbial composition of induced sputum specimens collected from adult patients screened for a multicenter randomized controlled trial was determined by 16S rRNA gene sequencing. Inflammatory phenotypes were defined by sputum neutrophil and eosinophil cell proportions. Microbiota were defined using alpha and beta diversity measures, and inter-phenotype differences identified using SIMPER, network analysis, and taxon fold change. Phenotypic predictors of airway microbiology were identified using multivariate linear regression. RESULTS: Microbiota composition was determined in 167 participants, classified as eosinophilic (n=84), neutrophilic (n=14), paucigranulocytic (n=60), or mixed neutrophilic-eosinophilic (n=9) phenotypes of asthma. Airway microbiology was significantly less diverse (p=0.022) and more dissimilar (p=0.005) in neutrophilic compared to eosinophilic participants. Sputum neutrophil proportion, but not eosinophil proportion, correlated significantly with these diversity measures (alpha-diversity: Spearman's r=-0.374, p&lt;0.001; beta-diversity: r=0.238, p=0.002). Inter-phenotype differences were characterised by a greater frequency of pathogenic taxa at high relative abundance, and reduced Streptococcus, Gemella and Porphyromonas relative abundance in neutrophilic asthma. Multivariate regression confirmed sputum neutrophil proportion was the strongest predictor of microbiota composition. CONCLUSIONS: Neutrophilic asthma is associated with airway microbiology that is significantly different to that in other inflammatory phenotypes, particularly eosinophilic asthma. Differences in microbiota composition may influence response to antimicrobial and steroid therapies, and risk of lung infection</style></abstract><notes><style face="normal" font="default">DA - 20170508IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28479329">PM:28479329</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170508-TaylorSL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170508-TaylorSL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170508, Taylor SL</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.044</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41427</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Saffari,H.</style></author><author><style face="normal" font="default"> Baer,K.</style></author><author><style face="normal" font="default"> Boynton,K.K.</style></author><author><style face="normal" font="default"> Gleich,G.J.</style></author><author><style face="normal" font="default"> Peterson,K.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Utah, Salt Lake City, Utah.</style></auth-address><titles><title><style face="normal" font="default">Pharyngeal mucosa brushing does not correlate with disease activity in patients with eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1456" start="1455">1455-1456</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cities</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default"> Esophagitis</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="3" Month="5" Year="2017">2017/5/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170508IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28478919">PM:28478919</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1455-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1455-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170508, Saffari H</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41428</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tannert,L.K.</style></author><author><style face="normal" font="default"> Mortz,C.G.</style></author><author><style face="normal" font="default"> Skov,P.S.</style></author><author><style face="normal" font="default"> Bindslev-Jensen,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Odense Research Center for Anaphylaxis, Odense, Denmark; Department of Dermatology and Allergy Center, Odense University Hospital, Odense, Denmark.</style></auth-address><titles><title><style face="normal" font="default">Positive Skin Test or Specific IgE to Penicillin Does Not Reliably Predict Penicillin Allergy</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="683" start="676">676-683</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> delayed reaction</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Reproducibility</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> sIgE</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> Specific IgE</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">INTRODUCTION: According to guidelines, patients are diagnosed with penicillin allergy if skin test (ST) result or specific IgE (s-IgE) to penicillin is positive. However, the true sensitivity and specificity of these tests are presently not known. OBJECTIVE: To investigate the clinical relevance of a positive ST result and positive s-IgE and to study the reproducibility of ST and s-IgE. METHODS: A sample of convenience of 25 patients with positive penicillin ST results, antipenicillin s-IgE results, or both was challenged with their culprit penicillin. Further 19 patients were not challenged, but deemed allergic on the basis of a recent anaphylactic reaction or delayed reactions to skin testing. Another sample of convenience of 18 patients, 17 overlapping with the 25 challenged, with initial skin testing and s-IgE (median, 25; range, 3-121), months earlier (T-1), was repeat skin tested and had s-IgE measured (T0), and then skin tested and had s-IgE measured 4 weeks later (T1). RESULTS: Only 9 (36%) of 25 were challenge positive. There was an increased probability of being penicillin allergic if both ST result and s-IgE were positive at T0. Positive ST result or positive s-IgE alone did not predict penicillin allergy. Among the 18 patients repeatedly tested, 46.2% (12 of 25) of positive ST results at T-1 were reproducibly positive at T0. For s-IgE, 54.2% (14 of 24) positive measurements were still positive at T0 and 7 converted to positive at T1. CONCLUSIONS: The best predictor for a clinically significant (IgE-mediated) penicillin allergy is a combination of a positive case history with simultaneous positive ST result and s-IgE or a positive challenge result</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.014.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483318">PM:28483318</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-676-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-676-83.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Tannert LK</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.014.</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41429</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Blumenthal,K.G.</style></author><author><style face="normal" font="default"> Shenoy,E.S.</style></author><author><style face="normal" font="default"> Wolfson,A.R.</style></author><author><style face="normal" font="default"> Berkowitz,D.N.</style></author><author><style face="normal" font="default"> Carballo,V.A.</style></author><author><style face="normal" font="default"> Balekian,D.S.</style></author><author><style face="normal" font="default"> Marquis,K.A.</style></author><author><style face="normal" font="default"> Elshaboury,R.</style></author><author><style face="normal" font="default"> Gandhi,R.G.</style></author><author><style face="normal" font="default"> Meka,P.</style></author><author><style face="normal" font="default"> Kubiak,D.W.</style></author><author><style face="normal" font="default"> Catella,J.</style></author><author><style face="normal" font="default"> Lambl,B.B.</style></author><author><style face="normal" font="default"> Hsu,J.T.</style></author><author><style face="normal" font="default"> Freeley,M.M.</style></author><author><style face="normal" font="default"> Gruszecki,A.</style></author><author><style face="normal" font="default"> Wickner,P.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass</style></auth-address><titles><title><style face="normal" font="default">Addressing Inpatient Beta-Lactam Allergies: A Multihospital Implementation</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="625" start="616">616-625</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> betalactam allergy</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Inpatients</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Stewardship</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Addressing inaccurate penicillin allergies is encouraged as part of antibiotic stewardship in the inpatient setting. However, implementing interventions targeted at the 10% to 15% of inpatients reporting a previous penicillin allergy can pose substantial logistic challenges. We implemented a computerized guideline for patients with reported beta-lactam allergy at 5 hospitals within a single health care system in the Boston area. In this article, we describe our implementation roadmap, including both successes achieved and challenges faced. We explain key implementation steps, including assembling a team, stakeholder engagement, developing or selecting an approach, spreading the change, establishing measures, and measuring impact. The objective was to detail the lessons learned while empowering others to be part of this important, multidisciplinary work to improve the care of patients with reported beta-lactam allergies</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 2213-2201 (Electronic)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.02.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483315">PM:28483315</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-616-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-616-25.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Blumenthal KG</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.02.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41430</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aberer,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Medical University of Graz, Graz, Austria.</style></auth-address><titles><title><style face="normal" font="default">Penicillin Allergy: Mono-, Double-, and Multiple-Drug Hypersensitivity, or Even No Sensitivity?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="704" start="703">703-704</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Austria</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - Austria -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483320">PM:28483320</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-703-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-703-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Aberer W</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41431</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Konya,V.</style></author><author><style face="normal" font="default"> Czarnewski,P.</style></author><author><style face="normal" font="default"> Forkel,M.</style></author><author><style face="normal" font="default"> Rao,A.</style></author><author><style face="normal" font="default"> Kokkinou,E.</style></author><author><style face="normal" font="default"> Villablanca,E.J.</style></author><author><style face="normal" font="default"> Almer,S.</style></author><author><style face="normal" font="default"> Lindforss,U.</style></author><author><style face="normal" font="default"> Friberg,D.</style></author><author><style face="normal" font="default"> Hoog,C.</style></author><author><style face="normal" font="default"> Bergman,P.</style></author><author><style face="normal" font="default"> Mjosberg,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Infectious Medicine, Department of Medicine, Huddinge, Karolinska Institutet and University Hospital, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default">Vitamin D downregulates the IL-23 receptor pathway in human mucosal ILC3</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> Austria</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-23</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Immunoassay</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microarray</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Suspensions</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tonsil</style></keyword><keyword><style face="normal" font="default"> Transcriptome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> Vitamin D Deficiency</style></keyword><keyword><style face="normal" font="default"> Vitamin D3</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: Vitamin D deficiency is a risk factor for inflammatory bowel disease (IBD). The IL-23-driven tissue-resident ILC3 play essential roles in intestinal immunity, and targeting IL-23/12 is a promising approach in IBD therapy. OBJECTIVE: We set out to define the role of 1alpha,25-dihydroxy vitamin D3 (1,25D) in regulating functional responses of human mucosal ILC3 to IL-23 plus IL-1beta stimulation. METHODS: Transcriptomes of sorted tonsil ILC3 were assessed by microarray analysis. ILC3 cytokine production, proliferation and differentiation were determined by flow cytometry, ELISA and multiplex immunoassay. Intestinal cell suspensions and ILC3 sorted from gut biopsies of IBD patients were also analyzed along with plasma 25-hydroxy vitamin D3 (25D) detection. RESULTS: ILC3 stimulated with IL-23 plus IL-1beta upregulated the vitamin D receptor (VDR) and responded to 1,25D with downregulation of the IL-23 receptor (IL-23R) pathway. Consequently, 1,25D suppressed the IL-22, IL-17F and GM-CSF production from tonsil and gut ILC3. In parallel, 1,25D upregulated genes linked to the IL-1beta signaling pathway as well as the IL-1beta-inducible cytokines IL-6, IL-8 and MIP-1alpha/beta. The 1,25D-triggered skewing in ILC3 function was not accompanied or caused by changes in viability, proliferation or phenotype. Finally, we confirmed low 25D plasma levels in IBD patients with active inflammation. CONCLUSION: In the light of the beneficial targeting of IL-23/12 in IBD, 1,25D appears as an interesting therapeutic agent that inhibits the IL-23R pathway, providing a novel mechanism for how ILC3 could be manipulated to regulate intestinal inflammation</style></abstract><notes><style face="normal" font="default">DA - 20170423IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Austria -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.01.045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28433688">PM:28433688</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170423-KonyaV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170423-KonyaV.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170423, Konya V</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.01.045</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41432</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rastogi,D.</style></author><author><style face="normal" font="default"> Nico,J.</style></author><author><style face="normal" font="default"> Johnston,A.D.</style></author><author><style face="normal" font="default"> Tobias,T.A.M.</style></author><author><style face="normal" font="default"> Jorge,Y.</style></author><author><style face="normal" font="default"> Macian,F.</style></author><author><style face="normal" font="default"> Greally,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departments of Pediatrics.</style></auth-address><titles><title><style face="normal" font="default">CDC42-related genes are upregulated in helper T cells from obese asthmatic children</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> differentially expressed gene</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mitogen-activated protein kinase</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Rna</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> Transcriptome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Pediatric obesity-related asthma is more severe and less responsive to medications than asthma in normal-weight children. Obese asthmatic children have nonatopic TH1-polarized systemic inflammation that correlates with pulmonary function deficits, but the pathways underlying TH1-polarized inflammation are not well understood. OBJECTIVE: We compared the CD4+ T-cell transcriptome in obese children with asthma with that in normal-weight children with asthma to identify key differentially expressed genes associated with TH1-polarized inflammation. METHODS: CD4+ T-cell transcriptome-wide differential gene expression was compared between 21 obese and 21 normal-weight children by using directional RNA sequencing. High-confidence differentially expressed genes were verified in the first cohort and validated in a second cohort of 20 children (10 obese and 10 normal-weight children) by using quantitative RT-PCR. RESULTS: Transcriptome-wide differential gene expression among obese asthmatic children was enriched for genes, including VAV2, DOCK5, PAK3, PLD1, CDC42EP4, and CDC42PBB, which are associated with CDC42, a small guanosine triphosphate protein linked to T-cell activation. Upregulation of MLK3 and PLD1, genes downstream of CDC42 in the mitogen-activated protein kinase and mammalian target of rapamycin pathways and the inverse correlation of CDC42EP4 and DOCK5 transcript counts with FEV1/forced vital capacity ratio together support a role of CDC42 in the TH1 polarization and pulmonary function deficits found in patients with obesity-related asthma. CONCLUSIONS: Our study identifies the CDC42 pathway as a novel target that is upregulated in TH cells of obese asthmatic children, suggesting its role in nonatopic TH1-polarized systemic inflammation and pulmonary function deficits found in patients with pediatric obesity-related asthma</style></abstract><notes><style face="normal" font="default">DA - 20170508IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28479334">PM:28479334</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170508-RastogiD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170508-RastogiD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170508, Rastogi D</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41433</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Goleva,E.</style></author><author><style face="normal" font="default"> Harris,J.K.</style></author><author><style face="normal" font="default"> Robertson,C.E.</style></author><author><style face="normal" font="default"> Jackson,L.P.</style></author><author><style face="normal" font="default"> Martin,R.J.</style></author><author><style face="normal" font="default"> Leung,D.Y.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, National Jewish Health, Denver, Colo.</style></auth-address><titles><title><style face="normal" font="default">Airway microbiome and responses to corticosteroids in corticosteroid-resistant asthma patients treated with acid suppression medications</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> suppression</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="3" Month="5" Year="2017">2017/5/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170507IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28477847">PM:28477847</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170507-GolevaE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170507-GolevaE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170507, Goleva E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41434</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brinkhaus,B.</style></author><author><style face="normal" font="default"> Roll,S.</style></author><author><style face="normal" font="default"> Jena,S.</style></author><author><style face="normal" font="default"> Icke,K.</style></author><author><style face="normal" font="default"> Adam,D.</style></author><author><style face="normal" font="default"> Binting,S.</style></author><author><style face="normal" font="default"> Lotz,F.</style></author><author><style face="normal" font="default"> Willich,S.N.</style></author><author><style face="normal" font="default"> Witt,C.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Institute for Social Medicine , Epidemiology and Health Economics, Charite Universitatsmedizin Berlin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="default">Acupuncture in Patients with Allergic Asthma: A Randomized Pragmatic Trial</style></title><secondary-title><style face="normal" font="default">J Altern Complement Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Altern Complement Med</style></abbr-1></periodical><pages end="277" start="268">268-277</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic asthma</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> economics</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Although the available evidence is insufficient, acupuncture is used in patients suffering from chronic asthma. The aim of this pragmatic study was to investigate the effectiveness of acupuncture in addition to routine care in patients with allergic asthma compared to treatment with routine care alone. METHODS: Patients with allergic asthma were included in a randomized controlled trial and randomized to receive up to 15 acupuncture sessions over 3 months or to a control group receiving routine care alone. Patients who did not consent to randomization received acupuncture treatment for the first 3 months and were followed as a cohort. All trial patients were allowed to receive routine care in addition to study treatment. The primary endpoint was the asthma quality of life questionnaire (AQLQ, range: 1-7) at 3 months. Secondary endpoints included general health related to quality of life (Short-Form-36, SF-36, range 0-100). Outcome parameters were assessed at baseline and at 3 and 6 months. RESULTS: A total of 1,445 patients (mean age 43.8 [SD 13.5] years, 58.7% female) were randomized and included in the analysis (184 patients randomized to acupuncture and 173 to control, and 1,088 in the nonrandomized acupuncture group). In the randomized part, acupuncture was associated with an improvement in the AQLQ score compared to the control group (difference acupuncture vs. control group 0.7 [95% confidence interval (CI) 0.5-1.0]) as well as in the physical component scale and the mental component scale of the SF-36 (physical: 2.5 [1.0-4.0]; mental 4.0 [2.1-6.0]) after 3 months. Treatment success was maintained throughout 6 months. Patients not consenting to randomization showed similar improvements as the randomized acupuncture group. CONCLUSIONS: In patients with allergic asthma, additional acupuncture treatment to routine care was associated with increased disease-specific and health-related quality of life compared to treatment with routine care alone</style></abstract><notes><style face="normal" font="default">DA - 20170313IS - 1557-7708 (Electronic)IS - 1075-5535 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1089/acm.2016.0357</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28287818">PM:28287818</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Altern Complement Med\2017-23-268-77.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Altern Complement Med\2017-23-268-77.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170313, Brinkhaus B</style></custom2><misc3><style face="normal" font="default">10.1089/acm.2016.0357</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41435</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jung,D.</style></author><author><style face="normal" font="default"> Che,J.H.</style></author><author><style face="normal" font="default"> Lim,K.M.</style></author><author><style face="normal" font="default"> Chun,Y.J.</style></author><author><style face="normal" font="default"> Heo,Y.</style></author><author><style face="normal" font="default"> Seok,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Microbiology and Immunology, and Institute of Endemic Disease, College of Medicine, Seoul National University, Seoul, 110-799, South Korea</style></auth-address><titles><title><style face="normal" font="default">Discrimination of skin sensitizers from non-sensitizers by interleukin-1alpha and interleukin-6 production on cultured human keratinocytes</style></title><secondary-title><style face="normal" font="default">J Appl Toxicol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Appl Toxicol</style></abbr-1></periodical><pages end="1136" start="1129">1129-1136</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Animal</style></keyword><keyword><style face="normal" font="default"> Animal model</style></keyword><keyword><style face="normal" font="default"> Animal Testing Alternatives</style></keyword><keyword><style face="normal" font="default"> Cell Line</style></keyword><keyword><style face="normal" font="default"> Cell Survival</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> cytology</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> guinea pig maximization test</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Interleukin-1alpha</style></keyword><keyword><style face="normal" font="default"> Interleukin-6</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritants</style></keyword><keyword><style face="normal" font="default"> Keratinocytes</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> pig</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research Support</style></keyword><keyword><style face="normal" font="default"> Salts</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tetrazolium Salts</style></keyword><keyword><style face="normal" font="default"> Thiazoles</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Xenobiotic</style></keyword><keyword><style face="normal" font="default"> Xenobiotics</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="default">In vitro testing methods for classifying sensitizers could be valuable alternatives to in vivo sensitization testing using animal models, such as the murine local lymph node assay (LLNA) and the guinea pig maximization test (GMT), but there remains a need for in vitro methods that are more accurate and simpler to distinguish skin sensitizers from non-sensitizers. Thus, the aim of our study was to establish an in vitro assay as a screening tool for detecting skin sensitizers using the human keratinocyte cell line, HaCaT. HaCaT cells were exposed to 16 relevant skin sensitizers and 6 skin non-sensitizers. The highest dose used was the dose causing 75% cell viability (CV75) that we determined by an MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. The levels of extracellular production of interleukin-1alpha (IL-1alpha) and IL-6 were measured. The sensitivity of IL-1alpha was 63%, specificity was 83% and accuracy was 68%. In the case of IL-6, sensitivity: 69%, specificity: 83% and accuracy: 73%. Thus, this study suggests that measuring extracellular production of pro-inflammatory cytokines IL-1alpha and IL-6 by human HaCaT cells may potentially classify skin sensitizers from non-sensitizers. Copyright (c) 2015 John Wiley &amp; Sons, Ltd</style></abstract><notes><style face="normal" font="default">DA - 20160714IS - 1099-1263 (Electronic)IS - 0260-437X (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (IL1A protein, human)RN - 0 (IL6 protein, human)RN - 0 (Interleukin-1alpha)RN - 0 (Interleukin-6)RN - 0 (Irritants)RN - 0 (Tetrazolium Salts)RN - 0 (Thiazoles)RN - 0 (Xenobiotics)RN - EUY85H477I (thiazolyl blue)SB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1002/jat.3274</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26691653">PM:26691653</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Appl Toxicol\2016-36-1129-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Appl Toxicol\2016-36-1129-36.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160714, Jung D</style></custom2><misc3><style face="normal" font="default">10.1002/jat.3274</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41436</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tsujita-Inoue,K.</style></author><author><style face="normal" font="default"> Hirota,M.</style></author><author><style face="normal" font="default"> Atobe,T.</style></author><author><style face="normal" font="default"> Ashikaga,T.</style></author><author><style face="normal" font="default"> Tokura,Y.</style></author><author><style face="normal" font="default"> Kouzuki,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Shiseido Research Center, Shiseido Co. Ltd, 2-2-1 Hayabuchi, Tsuzuki-ku, Yokohama, Kanagawa, 224-8558, Japan</style></auth-address><titles><title><style face="normal" font="default">Development of novel in vitro photosafety assays focused on the Keap1-Nrf2-ARE pathway</style></title><secondary-title><style face="normal" font="default">J Appl Toxicol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Appl Toxicol</style></abbr-1></periodical><pages end="968" start="956">956-968</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> Antioxidant Response Elements</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> Cell Line</style></keyword><keyword><style face="normal" font="default"> Cell Line,Tumor</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Coumarins</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Phototoxic</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Radiation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Gene Expression Regulation</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic Markers</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> In vitro tests</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Kelch-Like ECH-Associated Protein 1</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> NF-E2-Related Factor 2</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Photoallergy</style></keyword><keyword><style face="normal" font="default"> Phototoxicity</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Signal Transduction</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> Ultraviolet Rays</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="default">Although photoallergens require UV energy for antigen formation, the subsequent immune response is considered to be the same as in ordinary skin sensitization. Therefore, in vitro tests for skin sensitization should also be applicable for photoallergy testing. In this study, we examined whether activation of the Keap1 (Kelch-like ECH-associated protein 1)-Nrf2 (nuclear factor-erythroid 2-related factor 2)-ARE (antioxidant response element) pathway could be used to assess the photoallergenic potential of chemicals, using the reporter cell line AREc32 or KeratinoSens(TM) . First, we identified an appropriate UVA irradiation dose [5 J cm(-2) irradiation in phosphate-buffered saline (PBS)] by investigating the effect of UV irradiation on ARE-dependent gene induction using untreated or 6-methylcoumarin (6-MC)-treated cells. Irradiation of well-known photoallergens under this condition increased ARE-dependent gene expression by more than 50% compared with both vehicle and non-irradiated controls. When the cut-off value for detecting photoallergens was set at 50% induction, the accuracy of predicting photoallergenic/phototoxic chemicals was 70% in AREc32 cells and 67% in KeratinoSens(TM) cells, and the specificity was 100% in each case. We designate these assays as a photo-ARE assay and photo-KeratinoSens(TM) , respectively. Our results suggest that activation of the Keap1-Nrf2-ARE pathway is an effective biomarker for evaluating both photoallergenic and phototoxic potentials. Either of the above tests might be a useful component of a battery of in vitro tests/in silico methods for predicting the photoallergenicity and phototoxicity of chemicals. Copyright (c) 2015 John Wiley &amp; Sons, Ltd</style></abstract><notes><style face="normal" font="default">DA - 20160514IS - 1099-1263 (Electronic)IS - 0260-437X (Linking)LA - engPT - Journal ArticleRN - 0 (Allergens)RN - 0 (Coumarins)RN - 0 (Genetic Markers)RN - 0 (KEAP1 protein, human)RN - 0 (Kelch-Like ECH-Associated Protein 1)RN - 0 (NF-E2-Related Factor 2)RN - 0 (NFE2L2 protein, human)RN - EHP8W0L01A (6-methylcoumarin)SB - IMCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1002/jat.3234</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26511905">PM:26511905</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Appl Toxicol\2016-36-956-68.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Appl Toxicol\2016-36-956-68.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160514, Tsujita-Inoue K</style></custom2><misc3><style face="normal" font="default">10.1002/jat.3234</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41437</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shi,L.</style></author><author><style face="normal" font="default"> Liang,D.</style></author><author><style face="normal" font="default"> Gao,Y.</style></author><author><style face="normal" font="default"> Huang,J.</style></author><author><style face="normal" font="default"> Nolan,C.</style></author><author><style face="normal" font="default"> Mulvaney,A.</style></author><author><style face="normal" font="default"> Poole,T.</style></author><author><style face="normal" font="default"> Zhang,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Public Health Sciences , Clemson University , Clemson , SC , USA</style></auth-address><titles><title><style face="normal" font="default">Mindfulness and asthma symptoms: A study among college students</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> economics</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Self Report</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Students</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Given the known link between asthma and stress as well as the link between mindfulness and stress, we explore the possible association between trait mindfulness and asthma-related diagnosis and symptoms with a cross-sectional study. METHOD: In 2014, we surveyed a sample of college students in their freshman year, from a public university in Shanghai, China. We used three multilevel logistic regressions to estimate the association between trait mindfulness (measured by Mindful Awareness Attention Scale, MAAS) and self-report of ever having an asthma diagnosis, ever having had persistent dry cough, and ever having had wheezing symptoms. Age, gender, household registration status, and the frequency of smog in the respondent's hometown were used as control variables in the study. The home province of the student was used as the cluster variable in the multilevel models. RESULTS: Among the 1392 students in the analysis sample (mean age = 18.3), 47 (3.4%) self-reported an asthma diagnosis, 251 (18.1%) reported having had persistent dry cough, and 100 (7.2%) reported having had wheezing symptoms. A one-unit increase in MAAS is negatively associated with having a self-reported asthma diagnosis (Odds Ratio (OR): 0.662, 95% Confidence Interval (CI): 0.452, 0.969, p = 0.034), having had persistent dry cough (OR: 0.658, 95% CI: 0.545, 0.795, p &lt; 0.001), and wheezing (OR = 0.747, 95% CI: 0.569, 0.981, p = 0.036). DISCUSSION: This is the first study to suggest a link between trait mindfulness and asthma. Our finding provides evidence that people with higher level of mindfulness are less likely to have had an asthma diagnosis and less likely to have the symptoms of persistent dry cough and wheezing</style></abstract><notes><style face="normal" font="default">DA - 20170501IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -CO - China -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1306545</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28459349">PM:28459349</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170501-ShiL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170501-ShiL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170501, Shi L</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1306545</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41438</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Molinengo,G.</style></author><author><style face="normal" font="default"> Baiardini,I.</style></author><author><style face="normal" font="default"> Braido,F.</style></author><author><style face="normal" font="default"> Loera,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Psychology , University of Turin , Turin , Italy</style></auth-address><titles><title><style face="normal" font="default">RhinAsthma patient perspective: A Rasch validation study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Multicenter Studies</style></keyword><keyword><style face="normal" font="default"> Multicenter study</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> psychology</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Statistics</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> Validation studies</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="default">OBJECTIVE: In daily practice, Health-Related Quality of Life (HRQoL) tools are useful for supplementing clinical data with the patient's perspective. To encourage their use by clinicians, the availability of tools that can quickly provide valid results is crucial. A new HRQoL tool has been proposed for patients with asthma and rhinitis: the RhinAsthma Patient Perspective-RAPP. The aim of this study was to evaluate the psychometric robustness of the RAPP using the Item Response Theory (IRT) approach, to evaluate the scalability of items and test whether or not patients use the items response scale correctly. METHODS: 155 patients (53.5% women, mean age 39.1, range 16-76) were recruited during a multicenter study. RAPP metric properties were investigated using IRT models. Differential item functioning (DIF) was used for gender, age, and asthma control test (ACT). RESULTS: The RAPP adequately fitted the Rating Scale model, demonstrating the equality of the rating scale structure for all items. All statistics on items were satisfactory. The RAPP had adequate internal reliability and showed good ability to discriminate among different groups of participants. DIF analysis indicated that there were no differential item functioning issues for gender. One item showed a DIF by age and four items by ACT. CONCLUSIONS: The psychometric evaluation performed using IRT models demonstrated that the RAPP met all the criteria to be considered a reliable and valid method of measurement. From a clinical perspective, this will allow physicians to confidently interpret scores as good indicators of Quality of Life of patients with asthma</style></abstract><notes><style face="normal" font="default">DA - 20170504IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1316391</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28471703">PM:28471703</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170504-MolinengoG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170504-MolinengoG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170504, Molinengo G</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1316391</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41439</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nabors,L.</style></author><author><style face="normal" font="default"> Odar-Stough,C.</style></author><author><style face="normal" font="default"> Peugh,J.</style></author><author><style face="normal" font="default"> Merianos,A.L.</style></author><author><style face="normal" font="default"> Cunningham,J.</style></author><author><style face="normal" font="default"> Yockey,R.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Health Promotion and Education Program, School of Human Services, College of Education Criminal Justice and Human Services , University of Cincinnati , Cincinnati , Ohio , USA</style></auth-address><titles><title><style face="normal" font="default">Adolescent flourishing in relation to having asthma: Results from a population-based cross-sectional study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Promotion</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mood</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Ohio</style></keyword><keyword><style face="normal" font="default"> race</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> youth</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="default">OBJECTIVE: This study investigated parent report of adolescent behaviors and flourishing of adolescents with asthma from a nationwide sample. METHODS: A secondary analysis of the 2011-2012 National Survey of Children's Health was conducted. There were 2,880 youth with asthma in our sample and 25,841 without asthma between 13 and 17 years of age. Analyses examined flourishing among adolescents with and without asthma and the impact of adolescent arguing, bullying, and mood difficulties on adolescent flourishing for adolescents with asthma, while controlling for sex, age, and race. RESULTS: Findings indicated lower flourishing for youth with asthma compared to youth without asthma. Moreover, adolescents with asthma who experienced negative behaviors, such as arguing and bullying, and adolescents who were experiencing sad feelings had lower flourishing. CONCLUSIONS: The results were consistent with literature, indicating that relatively poorer behavioral and emotional functioning is related to lower flourishing in adolescents with asthma. The results highlight the importance of screening for emotional functioning in adolescents and the need for further research to understand characteristics of adolescents related to their positive functioning</style></abstract><notes><style face="normal" font="default">DA - 20170504IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1316390</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28471696">PM:28471696</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170504-NaborsL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170504-NaborsL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170504, Nabors L</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1316390</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41440</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lawani,M.A.</style></author><author><style face="normal" font="default"> Zongo,F.</style></author><author><style face="normal" font="default"> Breton,M.C.</style></author><author><style face="normal" font="default"> Moisan,J.</style></author><author><style face="normal" font="default"> Gregoire,J.P.</style></author><author><style face="normal" font="default"> Dorval,E.</style></author><author><style face="normal" font="default"> Boulet,L.P.</style></author><author><style face="normal" font="default"> Jobin,F.M.</style></author><author><style face="normal" font="default"> Guenette,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Chair on adherence to treatments , Laval University , Quebec City , Quebec , Canada</style></auth-address><titles><title><style face="normal" font="default">Factors associated with adherence to asthma treatment with inhaled corticosteroids: a cross-sectional exploratory study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Income</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Intervention Studies</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> Quebec</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Self Report</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Understanding factors at the patient, provider or organizational level associated with inhaled corticosteroids (ICS) adherence is important when planning adherence-enhancing interventions. OBJECTIVE: To explore factors associated with adherence to ICS among patients with asthma aged 12 to 45 years. METHODS: A cross-sectional study was conducted among patients with asthma reporting ICS prescription during the baseline interview of an intervention study. Three methods were used to measure ICS adherence: a 4-item self-report questionnaire, a single question (SQ) measuring past 7-day exposure to ICS and a medication possession ratio (MPR, i.e., the sum of ICS days of supply/365). We assessed 46 potential factors of ICS adherence derived from the Predisposing, Reinforcing and Enabling Constructs in Educational Diagnosis and Evaluation (PRECEDE) model. Their association with ICS adherence was measured using multivariate logistic regressions. RESULTS: Among the 319 participants included, 16.0%, 43.0% and 9.1% were adherent according to the 4-item questionnaire, SQ and MPR, respectively. Ten factors were associated with good ICS adherence. Among them, a low family income level, a high number of asthma drugs used, a good knowledge of asthma pathophysiology and the perception that following the ICS prescription was easy were associated with adherence through one of the measures. Two factors emerged through more than one measure: perceiving asthma severity as moderate to very severe and perceiving a high risk of death if ICS are not taken as prescribed. CONCLUSION: ICS adherence was poor in those individuals with asthma. Future adherence-enhancing interventions could target the identified modifiable risk factors. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT02093013</style></abstract><notes><style face="normal" font="default">DA - 20170504IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1326131</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28471286">PM:28471286</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170504-LawaniMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170504-LawaniMA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170504, Lawani MA</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1326131</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41441</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Li,C.</style></author><author><style face="normal" font="default"> Sheng,A.</style></author><author><style face="normal" font="default"> Jia,X.</style></author><author><style face="normal" font="default"> Zeng,Z.</style></author><author><style face="normal" font="default"> Zhang,X.</style></author><author><style face="normal" font="default"> Zhao,W.</style></author><author><style face="normal" font="default"> Zhang,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatric Pulmonology , The Second Affiliated Hospital &amp;Yuying Children's Hospital of Wenzhou Medical University , Wenzhou, Zhejiang Province , China</style></auth-address><titles><title><style face="normal" font="default">Th17/Treg Dysregulation in Allergic Asthmatic Children is Associated with Elevated Notch Expression</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> dysregulation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Notch</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> TH17</style></keyword><keyword><style face="normal" font="default"> TH17 cells</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="5" Year="2017">2017/5/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Notch signaling pathway is critically involved in the differentiation of T helper (Th) cells, key players in the pathogenesis of allergic diseases. OBJECTIVE: To explore whether Th17/Treg dysregulation in children with allergic asthma is associated with alteration of Notch expression. METHODS: Thirty-five patients with allergic asthma and thirty-five healthy control children were selected. Flow cytometry was used to detect Th17 and Treg cells. Quantitative real-time polymerase chain reaction (QRT-PCR) was used to measure the expression of Notch1 mRNA. The correlations among Notch1 mRNA expression, the percentage of Th17 cells, and Th17/Treg ratio were calculated. RESULTS: Th17 and Treg cells were significantly increased and decreased, respectively, in children with allergic asthma than in healthy control (p&lt;0.001). mRNA level of Notch1 was elevated in children with allergic asthma comparing to healthy controls (p&lt;0.001). The mRNA expression of Notch1 was positively correlated with the percentage of Th17 cells (r = 0.775, p&lt;0.001) and Th17/Treg ratio (r = 0.698, p&lt;0.001). CONCLUSION: Children with allergic asthma showed dysregulation of Th17/Treg cells in peripheral blood. Such change is accompanied with overexpression of Notch1, indicating Th17/Treg dysregulation in children with allergic asthma is associated with elevated Notch expression</style></abstract><notes><style face="normal" font="default">DA - 20170502IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1266494</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28463581">PM:28463581</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170502-LiC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170502-LiC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170502, Li C</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1266494</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41442</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bokov,P.</style></author><author><style face="normal" font="default"> Delclaux,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Service de Physiologie - Explorations Fonctionnelles , Hopital Robert Debre , Paris , France</style></auth-address><titles><title><style face="normal" font="default">Evidence of pneumoconstriction in asthmatics</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchial smooth muscle</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> bronchodilators</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cytoskeleton</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exploration</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Muscle Cells</style></keyword><keyword><style face="normal" font="default"> Muscle Contraction</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="default">INTRODUCTION: In asthma, bronchial smooth muscle contraction is responsible for the obstructive ventilatory defect that may be relieved by the administration of bronchodilators. It has been observed that deep inspiration causes dilation of the airways in both asthmatic and nonasthmatic subjects. Pneumoconstriction is a rare manifestation of the contractile cells present in the perialveolar space leading to a restrictive defect in asthmatics. CASE STUDY: We present the lung function tests of two asthmatic patients (a boy and a woman) depicting a restrictive defect (pneumoconstriction) that disappeared after salbutamol administration while no improvement was noted in the spirometric data. RESULTS: We observed a particular static lung volume distribution that could be explained by a concept of cellular mechanoresponsiveness called "glassy dynamics" applied to smooth muscle cells. CONCLUSION: We concluded that the presence of contractile interstitial cells in the perialveolar space could be responsible for the observed anomalies reflecting pneumoconstriction. We explained the observed distribution of static lung volumes by the glassy dynamics of cytoskeleton, a concept that had no clinical validation</style></abstract><notes><style face="normal" font="default">DA - 20170504IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1316393</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28471693">PM:28471693</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170504-BokovP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170504-BokovP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170504, Bokov P</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1316393</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41443</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Coelho,C.M.</style></author><author><style face="normal" font="default"> Campos,L.A.</style></author><author><style face="normal" font="default"> Pereira,F.O.</style></author><author><style face="normal" font="default"> Cardoso,R.M.</style></author><author><style face="normal" font="default"> Nascimento,L.M.</style></author><author><style face="normal" font="default"> Oliveira,J.B.L.</style></author><author><style face="normal" font="default"> Andrade,L.R.</style></author><author><style face="normal" font="default"> Carvalho,E.V.</style></author><author><style face="normal" font="default"> Reboredo,M.M.</style></author><author><style face="normal" font="default"> Pinheiro,B.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Physical Therapy , Universidade Federal de Juiz de Fora , Minas Gerais , Brazil</style></auth-address><titles><title><style face="normal" font="default">Objectively measured daily-life physical activity of moderate-to-severe Brazilian asthmatic women in comparison to healthy controls: A cross-sectional study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="default">Considering the complex relationship between asthma symptoms and exercise, asthmatics are usually believed to be less active in daily life than healthy subjects. However, few studies have objectively assessed daily-life physical activity (DLPA) of asthmatic adults. OBJECTIVE: To objectively assess DLPA of a sample of Brazilian asthmatic women in comparison to healthy controls, and to investigate the associations between DLPA and asthma control, health-related quality of life, anxiety and depression levels, and the Six-minute walk test (6MWT) in this population. METHODS: Sixty-six women were included, 36 in the asthma group (AG) and 30 in the control group (CG). The AG was composed by clinically stable moderate-to-severe asthmatics. The CG was composed by apparently healthy volunteers. All subjects underwent DLPA assessment (considered as the average of steps taken during six consecutive days measured by a pedometer) and performed the 6MWT. Additionally, participants in the AG were assessed using the Asthma Control Questionnaire, the Asthma Quality of Life Questionnaire (AQLQ), and the Hospital Anxiety and Depression Scale. RESULTS: There was no difference between the AG and the CG regarding DLPA (7490.3 +/- 3330.2 vs 6876.4 +/- 3242.1 steps respectively, p = 0.45), even after adjustment for covariates. DLPA was significantly correlated to the activity limitation domain of the AQLQ among asthmatics (r = 0.43, p &lt; 0.01). CONCLUSION: Despite the association between self-perceived activity limitation and DLPA among asthmatics, there were no differences regarding DLPA between a sample of moderate-to-severe Brazilian asthmatic women and apparently healthy controls</style></abstract><notes><style face="normal" font="default">DA - 20170501IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1306547</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28459605">PM:28459605</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170501-CoelhoCM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170501-CoelhoCM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170501, Coelho CM</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1306547</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41444</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Borschuk,A.P.</style></author><author><style face="normal" font="default"> Rodweller,C.</style></author><author><style face="normal" font="default"> Salorio,C.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Departments of Behavioral Psychology, Neuropsychology, and Pediatric Rehabilitation , Kennedy Krieger Institute , Baltimore , MD , USA</style></auth-address><titles><title><style face="normal" font="default">The influence of comorbid asthma on the severity of symptoms in children with attention-deficit hyperactivity disorder</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Baltimore</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> gender difference</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neuropsychology</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> psychology</style></keyword><keyword><style face="normal" font="default"> rehabilitation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The current study examined the association between asthma and attention-deficit hyperactivity disorder (ADHD) symptoms in a clinical pediatric sample. METHODS: Demographic and neuropsychological data for children with a billing diagnosis of ADHD were extracted from a clinical database. Families completed standard rating scales. Seventy-one patients with a co-morbid asthma diagnosis were identified and matched by age to a group of 71 patients with only ADHD. RESULTS: Children with asthma and ADHD were more likely to display clinically elevated levels of hyperactivity, externalizing behaviors, anxiety, and hyperactive/impulsive behaviors compared to children with ADHD alone. Boys with asthma and ADHD had more symptoms than boys with only ADHD of somatization and emotional internalizing, while girls with asthma and ADHD had more symptoms of hyperactivity/impulsivity, conduct problems, anxiety, and emotional internalizing compared to girls with only ADHD. CONCLUSIONS: Findings suggest that in children with ADHD, co-morbid asthma is associated with increased behavioral and internalizing symptoms, with distinct gender differences present. Increased behavioral and internalizing symptoms seen in children with both asthma and ADHD may be due to the burden of their medical condition. No difference was found on cognitive variables, suggesting chronic hypoxia may be less influential in explaining these differences. Future research should determine the specific mechanisms of these differences</style></abstract><notes><style face="normal" font="default">DA - 20170501IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1306549</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28459608">PM:28459608</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170501-BorschukAP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170501-BorschukAP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170501, Borschuk AP</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1306549</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41445</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sullivan,P.</style></author><author><style face="normal" font="default"> Ghushchyan,V.G.</style></author><author><style face="normal" font="default"> Navaratnam,P.</style></author><author><style face="normal" font="default"> Friedman,H.S.</style></author><author><style face="normal" font="default"> Kavati,A.</style></author><author><style face="normal" font="default"> Ortiz,B.</style></author><author><style face="normal" font="default"> Lanier,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">a School of Pharmacy , Regis University , Denver , CO , USA</style></auth-address><titles><title><style face="normal" font="default">School absence and productivity outcomes associated with childhood asthma in the USA</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Caregivers</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> premature</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> SAC</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: Previous studies have examined the association between childhood asthma and lost productivity; however, more data are needed to understand its impact. METHODS: This was a retrospective analysis of cross-sectional data in the nationally representative 2007-2013 Medical Expenditure Panel Survey (MEPS). School-aged children (SAC), children (age 6-11), and adolescents (age 12-17) with asthma were compared to those without asthma to examine annual missed school days. Adult parents/caregivers of SAC with asthma were compared to those of SAC without asthma to examine missed work days. The cost of premature asthma mortality for SAC was also estimated. Negative binomial regression was used for missed school days, and a two-part model structure was used for missed work days. All analyses controlled for sociodemographics and other covariates. RESULTS: There were 44,320 SAC of whom 5,890 had asthma. There were 43,496 employed adults with at least one child. SAC (6-17) with asthma missed 1.54 times the number of school days compared to SAC without asthma. Caregivers of SAC (6-17) with asthma missed 1.16 times the number of work days to care for others compared to caregivers of SAC without asthma. SAC in the USA missed an additional 7 million school days associated with asthma (3.7 million children and 3.3 million adolescent). There were 130 asthma deaths resulting in an annual cost of $211 million ($US 2015). CONCLUSIONS: Childhood asthma is associated with a significant school absence and productivity loss in the USA. Better treatment and asthma management programs are needed to alleviate this burden</style></abstract><notes><style face="normal" font="default">DA - 20170428IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Armenia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1313273</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28453370">PM:28453370</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170428-SullivanP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170428-SullivanP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170428, Sullivan P</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1313273</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41446</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Villa-Roel,C.</style></author><author><style face="normal" font="default"> Voaklander,B.</style></author><author><style face="normal" font="default"> Ospina,M.B.</style></author><author><style face="normal" font="default"> Nikel,T.</style></author><author><style face="normal" font="default"> Campbell,S.</style></author><author><style face="normal" font="default"> Rowe,B.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Emergency Medicine , University of Alberta , Edmonton , Alberta , Canada</style></auth-address><titles><title><style face="normal" font="default">Effectiveness of written action plans for acute asthma: A systematic review</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">acute asthma</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> bias</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Emergency Medicine</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Self-management</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Self-management is an essential part of achieving asthma control and improving long-term outcomes. While guidelines recommend the provision of written asthma action plans (AAPs), few patients presenting to emergency departments (ED) have one. This systematic review examined if individualized written AAPs reduce relapses in adults following an ED visit for acute asthma. DATA SOURCES: Comprehensive searches of seven electronic databases and grey literature were conducted. STUDY SELECTIONS: Randomized controlled trials (RCTs) examining the effectiveness of individualized written AAPs to reduce relapses after ED visits for acute asthma were included. Study quality was determined using the Cochrane Risk of Bias (RoB) tool; intervention fidelity was assessed. RESULTS: From 695 potentially relevant studies, three RCTs were included. The RoB was low in two studies and high in one study; description of intervention fidelity varied across studies. The provision of individualized written AAPs in adults following an ED visit for acute asthma did not reduce the risk of relapse after ED discharge (risk ratio [RR] = 0.66; 95% confidence intervals [CI]: 0.36, 1.23; I2 = 40%). There was a 49% reduction in the risk of relapse after ED discharge when only studies with low RoB were pooled (RR = 0.51; 95% CI: 0.31, 0.83; I2 = 0%). CONCLUSION: This review didn't provide conclusive evidence to support the consideration of individualized written AAPs for the reduction of relapses after an ED visit; however, the low frequency of events, small number of studies and samples and their methodological quality might play an important role in this overall finding</style></abstract><notes><style face="normal" font="default">DA - 20170428IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1318142</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28453378">PM:28453378</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170428-VillaRoelC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170428-VillaRoelC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170428, Villa-Roel C</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1318142</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41447</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yilmaz,M.</style></author><author><style face="normal" font="default"> Bozkurt Yilmaz,H.E.</style></author><author><style face="normal" font="default"> Sen,N.</style></author><author><style face="normal" font="default"> Altin,C.</style></author><author><style face="normal" font="default"> Tekin,A.</style></author><author><style face="normal" font="default"> Muderrisoglu,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Cardiology , Baskent University Faculty of Medicine , Adana , Turkey</style></auth-address><titles><title><style face="normal" font="default">Investigation of the relationship between asthma and subclinical atherosclerosis by carotid/femoral intima media and epicardial fat thickness measurement</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="4" Year="2017">2017/4/28</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Since asthma and atherosclerosis may share similar pathophysiological mechanism, this study is planned to investigate whether epicardial fat thickness (EFT), carotid and femoral intima media thicknesses, which are markers of subclinical atherosclerosis, are increased in patients with asthma. METHODS: The study was designed as a cross-sectional study. A total of 154 participants (83 patients with asthma and 71 healthy volunteers) were enrolled into the study. Epicardial fat, carotid, and femoral intima media thicknesses were measured and recorded in both groups. The statistical difference between the two groups was examined. RESULTS: Both carotid and femoral intima media thicknesses were significantly higher in patients with asthma compared to control group (5.52 +/- 0.4 mm vs. 5.36 +/- 0.4 mm; p = 0.038 and 5.64 +/- 0.4 mm vs. 5.46 +/- 0.5 mm; p = 0.036, respectively). However, there was not a significant difference in EFT between the groups [5.9 mm (5.3-6.6; IQR = 1.3) vs. 5.6 mm (4.7-6.5; IQR = 1.8); p = 0.1]. On comparison of control group and asthma subgroups (mild, moderate, and severe), there was a statistically significant difference among these four groups in terms of carotid and femoral intima media thicknesses (p = 0.002 and p &lt; 0.001, respectively). Subgroup analyses showed that this difference was mainly due to patients with severe asthma. CONCLUSIONS: Carotid and femoral intima media thicknesses in asthmatic patients were found to be increased compared to the normal population. As a result, the risk of subclinical atherosclerosis in asthmatic patients may be high</style></abstract><notes><style face="normal" font="default">DA - 20170428IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1313272</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28453377">PM:28453377</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170428-YilmazM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170428-YilmazM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170428, Yilmaz M</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1313272</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41448</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Duong-Quy,S.</style></author><author><style face="normal" font="default"> Vu-Minh,T.</style></author><author><style face="normal" font="default"> Hua-Huy,T.</style></author><author><style face="normal" font="default"> Tang-Thi-Thao,T.</style></author><author><style face="normal" font="default"> Le-Quang,K.</style></author><author><style face="normal" font="default"> Tran-Thanh,D.</style></author><author><style face="normal" font="default"> Doan-Thi-Quynh,N.</style></author><author><style face="normal" font="default"> Le-Dong,N.N.</style></author><author><style face="normal" font="default"> Craig,T.J.</style></author><author><style face="normal" font="default"> nh-Xuan,A.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Physiology, Cochin Hospital, Paris Descartes University, Sorbonne Paris Cite, Paris, France</style></auth-address><titles><title><style face="normal" font="default">Study of nasal exhaled nitric oxide levels in diagnosis of allergic rhinitis in subjects with and without asthma</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="82" start="75">75-82</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Peak expiratory flow</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Respiratory Physiology</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vietnam</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: The measure of fractional exhaled nitric oxide (FENO) in the airways is a useful tool to guide the diagnosis and titration of inhaled corticosteroids in patients with asthma. However, its role in diagnosis of allergic rhinitis (AR), especially in subjects with asthma, is not well established. OBJECTIVE: To study the cutoff of nasal FENO in the diagnosis of subjects with AR and AR-asthma compared to age-matched subjects without AR or asthma and its correlations with the clinical and functional characteristics. METHODS: The study was cross sectional and descriptive. Subjects were grouped into control subjects, AR, and AR-asthma, based on the inclusion criteria. Exhaled NO (nasal FENO, bronchial FENO, and alveolar concentration of NO) was measured by multiple flow electro-luminescence device. RESULTS: Six hundred twenty-eight subjects were included: 217 control subjects (children: n=98, 10+/-4 years; adults: n=119, 50+/-16 years), 168 subjects with AR (children: n=54, 10+/-3 years; adults: n=114, 49+/-15 years), and 243 subjects with AR-asthma (children: n=115, 10+/-3 years; adults: n=128, 51+/-14 years). Nasal peak inspiratory flow and peak expiratory flow were lower in subjects with AR and AR-asthma than in control subjects (P&lt;0.01 and P&lt;0.01; and P&lt;0.05 and P&lt;0.01, respectively). Nasal FENO levels were significantly higher in subjects with AR and AR-asthma than in control subjects (1614+/-629 and 1686+/-614 ppb vs 582+/-161 ppb; P&lt;0.001 and P&lt;0.001, respectively). In subjects with AR non-asthma, the cutoffs of nasal FENO for those diagnosed with AR were 775 ppb in children, 799 ppb in adults, and 799 in the general population (sensitivity: 92.68%, 92.63%, and 92.65%, respectively; specificity: 91.67%, 95.00%, and 96.87%, respectively). In subjects with AR-asthma, the cutoffs of nasal FENO were higher, especially in asthma children (1458 ppb; sensitivity: 72.97% and specificity: 95.83%). CONCLUSION: Nasal FENO measurement is a useful technique for the diagnosis of AR in subjects with and without asthma</style></abstract><notes><style face="normal" font="default">DA - 20170330IS - 1178-6965 (Linking)LA - engPT - Journal ArticleCO - Vietnam -CO - Belgium -CO - United States -CO - France -</style></notes><work-type><style face="normal" font="default">10.2147/JAA.S129047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28356764">PM:28356764</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-75-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-75-82.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170330, Duong-Quy S</style></custom2><misc3><style face="normal" font="default">10.2147/JAA.S129047</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41449</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rangachari,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">College of Allied Health Sciences, Augusta University, Augusta, GA, USA</style></auth-address><titles><title><style face="normal" font="default">A framework for measuring self-management effectiveness and health care use among pediatric asthma patients and families</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="122" start="111">111-122</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> health care use</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medication adherence</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Self-management</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Asthma is associated with substantial health care expenditures, including an estimated US$56 billion per year in direct costs. A recurring theme in the asthma management literature is that costly asthma symptoms, including hospitalizations and multiple emergency department (ED)/outpatient visits, can often be prevented through patient/family adherence to the national (National Institutes of Health Expert Panel Report-3) guidelines for effective self-management of asthma, specifically 1) medication adherence and 2) environmental trigger avoidance, as outlined in the patient's personalized Asthma-Action Plan. It is important to note however that while effective self-management of asthma is known to reduce ED visits and hospitalizations, the relationship between asthma self-management effectiveness and outpatient visit frequency remains ambiguous, reflecting a gap in the literature. For instance, do patients/families who self-manage effectively visit outpatient clinics more frequently for asthma care (compared to those who do not self-manage effectively), after accounting for differences in asthma severity, demographic characteristics, and risk factors? Do patients/families who visit outpatient clinics more frequently for asthma care, in turn have fewer ED and inpatient encounters for asthma? On the other hand, do patients/families who do not revisit outpatient clinics regularly have higher ED visits and hospitalizations? It is important to address these gaps, in order to reduce the costs and public health burden of asthma. This paper provides a foundation for addressing these gaps, by conducting an integrative review of the asthma management literature, to develop a conceptual framework for measuring self-management effectiveness and health care use among pediatric asthma patients/families. In doing so, the paper lays the groundwork for future research seeking to explicate the relationship between asthma self-management effectiveness and health care use, which in turn has potential to engage asthma providers in promoting ideal self-management and optimal health care use for pediatric asthma, in accordance with national evidence-based guidelines for asthma management</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 1178-6965 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.2147/JAA.S133481</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28442924">PM:28442924</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-111-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-111-22.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Rangachari P</style></custom2><misc3><style face="normal" font="default">10.2147/JAA.S133481</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41450</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cook,J.</style></author><author><style face="normal" font="default"> Beresford,F.</style></author><author><style face="normal" font="default"> Fainardi,V.</style></author><author><style face="normal" font="default"> Hall,P.</style></author><author><style face="normal" font="default"> Housley,G.</style></author><author><style face="normal" font="default"> Jamalzadeh,A.</style></author><author><style face="normal" font="default"> Nightingale,M.</style></author><author><style face="normal" font="default"> Winch,D.</style></author><author><style face="normal" font="default"> Bush,A.</style></author><author><style face="normal" font="default"> Fleming,L.</style></author><author><style face="normal" font="default"> Saglani,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London</style></auth-address><titles><title><style face="normal" font="default">Managing the pediatric patient with refractory asthma: a multidisciplinary approach</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="130" start="123">123-130</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Characterization</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Difficult asthma</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Multidisciplinary team</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Repair</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Children with asthma that is refractory to high levels of prescribed treatment are described as having problematic severe asthma. Those in whom persistent symptoms result from a failure of basic asthma management are described as having "difficult asthma", while those who remain symptomatic despite these factors having been addressed are described as having "severe therapy-resistant asthma" (STRA). The majority of children have difficult asthma; asthma that is poorly controlled because of a failure to get the basics of asthma management right. Modifiable factors including nonadherence to medication, persistent adverse environmental exposures, and psychosocial factors often contribute to poor control in these patients. As our skill in identifying and addressing modifiable factors has improved, we have found that a progressively smaller proportion of our clinic patients is categorized as having true STRA, resulting in an infrequent resort to escalation of treatment. Many of the modifiable factors associated with the diagnosis of difficult asthma can be identified in a general pediatric clinic. Characterization of more complex factors, however, requires the time, skill, and expertise of multiple health care professionals within the asthma multidisciplinary team. In this review, we will describe the structured approach adopted by The Royal Brompton Hospital in the management of the child with problematic severe asthma. We highlight the roles of members of the multidisciplinary team at various stages of assessment and focus on prominent themes in the identification and treatment of modifiable factors</style></abstract><notes><style face="normal" font="default">DA - 20170502IS - 1178-6965 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="default"> 10.2147/JAA.S129159</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28461761">PM:28461761</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-123-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-123-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170502, Cook J</style></custom2><misc3><style face="normal" font="default"> 10.2147/JAA.S129159</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41451</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shimoda,T.</style></author><author><style face="normal" font="default"> Obase,Y.</style></author><author><style face="normal" font="default"> Nagasaka,Y.</style></author><author><style face="normal" font="default"> Nakano,H.</style></author><author><style face="normal" font="default"> Ishimatsu,A.</style></author><author><style face="normal" font="default"> Kishikawa,R.</style></author><author><style face="normal" font="default"> Iwanaga,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical Research Center, Fukuoka National Hospital, Fukuoka</style></auth-address><titles><title><style face="normal" font="default">Lung sound analysis helps localize airway inflammation in patients with bronchial asthma</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="108" start="99">99-108</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung sound analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Trachea</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">PURPOSE: Airway inflammation can be detected by lung sound analysis (LSA) at a single point in the posterior lower lung field. We performed LSA at 7 points to examine whether the technique could identify the location of airway inflammation in patients with asthma. PATIENTS AND METHODS: Breath sounds were recorded at 7 points on the body surface of 22 asthmatic subjects. Inspiration sound pressure level (ISPL), expiration sound pressure level (ESPL), and the expiration-to-inspiration sound pressure ratio (E/I) were calculated in 6 frequency bands. The data were analyzed for potential correlation with spirometry, airway hyperresponsiveness (PC20), and fractional exhaled nitric oxide (FeNO). RESULTS: The E/I data in the frequency range of 100-400 Hz (E/I low frequency [LF], E/I mid frequency [MF]) were better correlated with the spirometry, PC20, and FeNO values than were the ISPL or ESPL data. The left anterior chest and left posterior lower recording positions were associated with the best correlations (forced expiratory volume in 1 second/forced vital capacity: r=-0.55 and r=-0.58; logPC20: r=-0.46 and r=-0.45; and FeNO: r=0.42 and r=0.46, respectively). The majority of asthmatic subjects with FeNO >/=70 ppb exhibited high E/I MF levels in all lung fields (excluding the trachea) and V50%pred &lt;80%, suggesting inflammation throughout the airway. Asthmatic subjects with FeNO &lt;70 ppb showed high or low E/I MF levels depending on the recording position, indicating uneven airway inflammation. CONCLUSION: E/I LF and E/I MF are more useful LSA parameters for evaluating airway inflammation in bronchial asthma; 7-point lung sound recordings could be used to identify sites of local airway inflammation</style></abstract><notes><style face="normal" font="default">DA - 20170410IS - 1178-6965 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.2147/JAA.S125938</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28392708">PM:28392708</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-99-108.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-99-108.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170410, Shimoda T</style></custom2><misc3><style face="normal" font="default">10.2147/JAA.S125938</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41452</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rodriguez-Martinez,C.E.</style></author><author><style face="normal" font="default"> Sossa-Briceno,M.P.</style></author><author><style face="normal" font="default"> Castro-Rodriguez,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, School of Medicine, Universidad Nacional de Colombia, Bogota, Colombia</style></auth-address><titles><title><style face="normal" font="default">Factors predicting persistence of early wheezing through childhood and adolescence: a systematic review of the literature</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="98" start="83">83-98</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescence</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Algorithms</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> allergic sensitization</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> Atopic diseases</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> cationic protein</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Chile</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cold</style></keyword><keyword><style face="normal" font="default"> Colombia</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> fraction of exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> parental asthma</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> persistence</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> recurrent wheezing</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: For the early identification of persistent asthma symptoms among young children with recurrent wheezing, it would be helpful to identify all available studies that have identified at least one factor for predicting the persistence of early wheezing. The objective of the present study was to perform a systematic review of all studies that have identified factors that predict the persistence of symptoms among young patients with recurring wheezing. METHODS: A systematic review of relevant studies was conducted through searching in MEDLINE, EMBASE, CINHAL, and SCOPUS databases up to June 2016. Studies that identified predictors of persistence of wheezing illness among young children with recurrent wheezing were retrieved. Two independent reviewers screened the literature and extracted relevant data. RESULTS: The literature search returned 649 references, 619 of which were excluded due to their irrelevance. Five additional studies were identified from reference lists, and 35 studies were finally included in the review. Among all the identified predictors, the most frequently identified ones were the following: family asthma or atopy; personal history of atopic diseases; allergic sensitization early in life; and frequency, clinical pattern, or severity of wheezing/symptoms. CONCLUSION: Parental asthma (especially maternal), parental allergy, eczema, allergic rhinitis, persistent wheezing, wheeze without colds, exercise-induced wheeze, severe wheezing episodes, allergic sensitization (especially polysensitization), eosinophils (blood or eosinophil cationic protein in nasal sample), and fraction of exhaled nitric oxide were risk factors predicting persistence of early wheezing through school age. All of them are included in conventional algorithms, for example, Asthma Predictive Index and its modifications, for predicting future asthma</style></abstract><notes><style face="normal" font="default">DA - 20170410IS - 1178-6965 (Linking)LA - engPT - Journal ArticleCO - Colombia -CO - Chile -</style></notes><work-type><style face="normal" font="default">10.2147/JAA.S128319</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28392707">PM:28392707</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-83-98.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-83-98.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170410, Rodriguez-Martinez CE</style></custom2><misc3><style face="normal" font="default">10.2147/JAA.S128319</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41453</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gelardi,M.</style></author><author><style face="normal" font="default"> de Luca,C.</style></author><author><style face="normal" font="default"> Taliente,S.</style></author><author><style face="normal" font="default"> Fiorella,M.L.</style></author><author><style face="normal" font="default"> Quaranta,N.</style></author><author><style face="normal" font="default"> Russo,C.</style></author><author><style face="normal" font="default"> Ciofalo,A.</style></author><author><style face="normal" font="default"> Macchi,A.</style></author><author><style face="normal" font="default"> Mancini,M.</style></author><author><style face="normal" font="default"> Rosso,P.</style></author><author><style face="normal" font="default"> Seccia,V.</style></author><author><style face="normal" font="default"> Guagnini,F.</style></author><author><style face="normal" font="default"> Ciprandi,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Otolaryngology, Department of Basic Medical Science, Neuroscience and Sensory Organs, University of Bari Aldo Moro, Bari, Italy</style></auth-address><titles><title><style face="normal" font="default">Adjuvant treatment with a symbiotic in patients with inflammatory non-allergic rhinitis</style></title><secondary-title><style face="normal" font="default">J Biol Regul Homeost Agents</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Biol Regul Homeost Agents</style></abbr-1></periodical><pages end="206" start="201">201-206</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adjuvant</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Bifidobacterium</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> cytology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lactobacillus</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal cytology</style></keyword><keyword><style face="normal" font="default"> Nonallergic rhinitis</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> Otolaryngology</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutics</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">Inflammatory non-allergic rhinitis (INAR) is characterized by the presence of an inflammatory infiltrate and a non-IgE-mediated pathogenesis. This retrospective, controlled, multicentre study investigated whether a symbiotic, containing Lactobacillus acidophilus NCFM, Bifidobacterium lactis, and fructo-oligosaccharides (Pollagen(R), Allergy Therapeutics, Italy), prescribed as adjunctive therapy to a standard pharmacological treatment, was able to reduce symptom severity, endoscopic features, and nasal cytology in 93 patients (49 males and 44 females, mean age 36.3+/-7.1 years) with INAR. The patients were treated with nasal corticosteroid, oral antihistamine, and isotonic saline. At randomization, 52 patients were treated also with symbiotic as adjunctive therapy, whereas the remaining 41 patients served as controls. Treatment lasted for 4 weeks. Patients were visited at baseline, after treatment, and after 4-week follow-up. Adjunctive symbiotic treatment significantly reduced the percentages of patients with symptoms and endoscopic signs, and diminished inflammatory cells. In conclusion, the present study demonstrates that a symbiotic was able, as adjuvant treatment, to significantly improve symptoms, endoscopic feature, and cytology in patients with INAR, and its effect may be long lasting</style></abstract><notes><style face="normal" font="default">DA - 20170324IS - 0393-974X (Print)IS - 0393-974X (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28337893">PM:28337893</url></web-urls></urls><custom2><style face="normal" font="default">20170324, Gelardi M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41454</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jahani,N.</style></author><author><style face="normal" font="default"> Choi,S.</style></author><author><style face="normal" font="default"> Choi,J.</style></author><author><style face="normal" font="default"> Haghighi,B.</style></author><author><style face="normal" font="default"> Hoffman,E.A.</style></author><author><style face="normal" font="default"> Comellas,A.P.</style></author><author><style face="normal" font="default"> Kline,J.N.</style></author><author><style face="normal" font="default"> Lin,C.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Mechanical and Industrial Engineering, The University of Iowa, Iowa City, IA, USA</style></auth-address><titles><title><style face="normal" font="default">A four-dimensional computed tomography comparison of healthy and asthmatic human lungs</style></title><secondary-title><style face="normal" font="default">J Biomech</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Biomech</style></abbr-1></periodical><pages end="110" start="102">102-110</pages><volume><style face="normal" font="default">56</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">airflow</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Airway Resistance</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Engineering</style></keyword><keyword><style face="normal" font="default"> Exhalation</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Iowa</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Total Lung Capacity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Ventilation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="18" Month="3" Year="2017">2017/3/18</year></dates><abstract><style face="normal" font="default">The purpose of this study was to explore new insights in non-linearity, hysteresis and ventilation heterogeneity of asthmatic human lungs using four-dimensional computed tomography (4D-CT) image data acquired during tidal breathing. Volumetric image data were acquired for 5 non-severe and one severe asthmatic volunteers. Besides 4D-CT image data, function residual capacity and total lung capacity image data during breath-hold were acquired for comparison with dynamic scans. Quantitative results were compared with the previously reported analysis of five healthy human lungs. Using an image registration technique, local variables such as regional ventilation and anisotropic deformation index (ADI) were estimated. Regional ventilation characteristics of non-severe asthmatic subjects were similar to those of healthy subjects, but different from the severe asthmatic subject. Lobar airflow fractions were also well correlated between static and dynamic scans (R2>0.84). However, local ventilation heterogeneity significantly increased during tidal breathing in both healthy and asthmatic subjects relative to that of breath-hold perhaps because of airway resistance present only in dynamic breathing. ADI was used to quantify non-linearity and hysteresis of lung motion during tidal breathing. Non-linearity was greater on inhalation than exhalation among all subjects. However, exhalation non-linearity among asthmatic subjects was greater than healthy subjects and the difference diminished during inhalation. An increase of non-linearity during exhalation in asthmatic subjects accounted for lower hysteresis relative to that of healthy ones. Thus, assessment of non-linearity differences between healthy and asthmatic lungs during exhalation may provide quantitative metrics for subject identification and outcome assessment of new interventions</style></abstract><notes><style face="normal" font="default">DA - 20170404IS - 1873-2380 (Electronic)IS - 0021-9290 (Linking)LA - engPT - Journal ArticleCO - United States -CO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.jbiomech.2017.03.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28372795">PM:28372795</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Biomech\2017-56-102-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Biomech\2017-56-102-10.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170404, Jahani N</style></custom2><misc3><style face="normal" font="default">10.1016/j.jbiomech.2017.03.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41455</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Graudenz,G.S.</style></author><author><style face="normal" font="default"> Carneiro,D.P.</style></author><author><style face="normal" font="default"> Vieira,R.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">. Departamento de Ciencias Medicas, Universidade Nove de Julho, Sao Paulo (SP) Brasil</style></auth-address><titles><title><style face="normal" font="default">Trends in asthma mortality in the 0- to 4-year and 5- to 34-year age groups in Brazil</style></title><secondary-title><style face="normal" font="default">J Bras Pneumol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Bras Pneumol</style></abbr-1></periodical><pages end="31" start="24">24-31</pages><volume><style face="normal" font="default">43</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Asma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> corticosteroide</style></keyword><keyword><style face="normal" font="default"> corticosteroides</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Public Policy</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Time series</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trends</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">Objective:: To provide an update on trends in asthma mortality in Brazil for two age groups: 0-4 years and 5-34 years. Methods:: Data on mortality from asthma, as defined in the International Classification of Diseases, were obtained for the 1980-2014 period from the Mortality Database maintained by the Information Technology Department of the Brazilian Unified Health Care System. To analyze time trends in standardized asthma mortality rates, we conducted an ecological time-series study, using regression models for the 0- to 4-year and 5- to 34-year age groups. Results:: There was a linear trend toward a decrease in asthma mortality in both age groups, whereas there was a third-order polynomial fit in the general population. Conclusions:: Although asthma mortality showed a consistent, linear decrease in individuals &lt;/= 34 years of age, the rate of decline was greater in the 0- to 4-year age group. The 5- to 34-year group also showed a linear decline in mortality, and the rate of that decline increased after the year 2004, when treatment with inhaled corticosteroids became more widely available. The linear decrease in asthma mortality found in both age groups contrasts with the nonlinear trend observed in the general population of Brazil. The introduction of inhaled corticosteroid use through public policies to control asthma coincided with a significant decrease in asthma mortality rates in both subsets of individuals over 5 years of age. The causes of this decline in asthma-related mortality in younger age groups continue to constitute a matter of debate. Objetivo:: Apresentar uma atualizacao das tendencias da mortalidade da asma no Brasil em duas faixas etarias: 0-4 anos e 5-34 anos. Metodos:: Dados relativos ao periodo de 1980 a 2014 referentes a mortalidade da asma, conforme se definiu na Classificacao Internacional de Doencas, foram extraidos Sistema de Informacao sobre Mortalidade do Departamento de Tecnologia da Informacao do Sistema Unico de Saude. Para analisar as tendencias temporais das taxas padronizadas de mortalidade da asma, realizou-se um estudo ecologico de series temporais com modelos de regressao para as faixas etarias de 0 a 4 anos e 5 a 34 anos. Resultados:: Houve uma tendencia linear de reducao da mortalidade da asma em ambas as faixas etarias e uma tendencia polinomial de terceira ordem na populacao geral. Conclusoes:: Embora a mortalidade da asma tenha apresentado reducao linear consistente em individuos com idade &lt;/= 34 anos, a taxa de declinio foi maior na faixa etaria de 0 a 4 anos. A faixa etaria de 5 a 34 anos tambem apresentou reducao linear da mortalidade, e essa reducao tornou-se mais pronunciada apos o ano de 2004, quando o tratamento com corticosteroides inalatorios tornou-se mais amplamente disponivel. A reducao linear da mortalidade da asma em ambas as faixas etarias contrasta com a tendencia nao linear observada na populacao geral do Brasil. A introducao do uso de corticosteroides inalatorios por meio de politicas publicas de controle da asma coincidiu com uma diminuicao significativa das taxas de mortalidade da asma em ambos os subgrupos de individuos com mais de 5 anos de idade. As causas dessa reducao da mortalidade da asma em faixas etarias mais jovens ainda sao objeto de debate</style></abstract><notes><style face="normal" font="default">DA - 20170405IS - 1806-3756 (Electronic)IS - 1806-3713 (Linking)LA - engLA - porPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1590/s1806-37562015000000253</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28380185">PM:28380185</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Bras Pneumol\2017-43-24-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Bras Pneumol\2017-43-24-31.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170405, Graudenz GS</style></custom2><misc3><style face="normal" font="default">10.1590/s1806-37562015000000253</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41456</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kounis,N.G.</style></author><author><style face="normal" font="default"> Koniari,I.</style></author><author><style face="normal" font="default"> Soufras,G.</style></author><author><style face="normal" font="default"> Tsigkas,G.</style></author><author><style face="normal" font="default"> Hahalis,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Cardiology, University of Patras Medical School, Rion, Patras, Greece.</style></auth-address><titles><title><style face="normal" font="default">Anaphylaxis During Intracardiac and Endovascular Implantations: A Multifactorial Problem Involving Kounis Syndrome</style></title><secondary-title><style face="normal" font="default">J Cardiothorac Vasc Anesth</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Cardiothorac Vasc Anesth</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> Kounis syndrome</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170326IS - 1532-8422 (Electronic)IS - 1053-0770 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Greece -</style></notes><work-type><style face="normal" font="default">10.1053/j.jvca.2016.12.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28342591">PM:28342591</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Cardiothorac Vasc Anesth\20170326-KounisNG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Cardiothorac Vasc Anesth\20170326-KounisNG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170326, Kounis NG</style></custom2><misc3><style face="normal" font="default">10.1053/j.jvca.2016.12.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41457</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">MacBeth,L.S.</style></author><author><style face="normal" font="default"> Volcheck,G.W.</style></author><author><style face="normal" font="default"> Sprung,J.</style></author><author><style face="normal" font="default"> Weingarten,T.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesiology, Mayo Clinic, Rochester, MN</style></auth-address><titles><title><style face="normal" font="default">Perioperative course in patients with hereditary or acquired angioedema</style></title><secondary-title><style face="normal" font="default">J Clin Anesth</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Clin Anesth</style></full-title></periodical><pages end="391" start="385">385-391</pages><volume><style face="normal" font="default">34</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse effects</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Airway Management</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Androgens</style></keyword><keyword><style face="normal" font="default"> Anesthesia</style></keyword><keyword><style face="normal" font="default"> Anesthesia,General</style></keyword><keyword><style face="normal" font="default"> Anesthesiology</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Angioedemas,Hereditary</style></keyword><keyword><style face="normal" font="default"> Bradykinin</style></keyword><keyword><style face="normal" font="default"> C1 esterase inhibitor</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> Complement</style></keyword><keyword><style face="normal" font="default"> Complement C1</style></keyword><keyword><style face="normal" font="default"> Complement C1 Inhibitor Protein</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Consensus</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme Replacement Therapy</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fresh frozen plasma</style></keyword><keyword><style face="normal" font="default"> General anesthesia</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Perioperative Period</style></keyword><keyword><style face="normal" font="default"> Permeability</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications</style></keyword><keyword><style face="normal" font="default"> Pretreatment</style></keyword><keyword><style face="normal" font="default"> prevention &amp; control</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Stanozolol</style></keyword><keyword><style face="normal" font="default"> Surgical Procedures,Operative</style></keyword><keyword><style face="normal" font="default"> therapeutic use</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">PURPOSE: Two types of bradykinin-mediated angioedema, hereditary angioedema (HAE) and acquired angioedema (AAE), result from deficiency or dysfunction of C1 esterase inhibitor, leading to an overproduction of bradykinin, which can lead to vascular permeability and life-threatening angioedema of the airway. The objective of this study was to review perioperative outcomes in a series of patients with HAE and AAE and to review current knowledge about anesthetic complications in patients with HAE or AAE. METHODS: Medical records were retrospectively reviewed for perioperative complications in patients with HAE or AAE who underwent general anesthesia from January 1, 2000, to December 31, 2014, at our institution. RESULTS: Twenty-four patients (13 with HAE, 10 with AAE, and 1 with unspecified angioedema) underwent 38 instances of general anesthesia with airway manipulation. All except 4 received prophylactic therapy. One patient, a 67-year-old woman who was pretreated with stanozolol and fresh frozen plasma required reintubation after postoperative airway edema developed. CONCLUSION: Life-threatening episodes of angioedema of the airway occur infrequently, but they can occur in patients who received pretreatment and in patients who have previously undergone anesthesia uneventfully. Anesthesiologists must be ready to emergently manage a difficult airway and must be familiar with recommendations provided in consensus guidelines for the treatment of HAE and AAE patients</style></abstract><notes><style face="normal" font="default">DA - 20160930IS - 1873-4529 (Electronic)IS - 0952-8180 (Linking)LA - engPT - Journal ArticleRN - 0 (Androgens)RN - 0 (Complement C1 Inhibitor Protein)RN - S8TIM42R2W (Bradykinin)RN - Acquired angioedemaSB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jclinane.2016.05.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27687418">PM:27687418</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Anesth\2016-34-385-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Anesth\2016-34-385-91.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160930, MacBeth LS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jclinane.2016.05.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41458</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kounis,N.G.</style></author><author><style face="normal" font="default"> Koniari,I.</style></author><author><style face="normal" font="default"> Koutsogiannis,N.</style></author><author><style face="normal" font="default"> Soufras,G.D.</style></author><author><style face="normal" font="default"> Hahalis,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Cardiology, University of Patras Medical School, Rion, Patras 26504, Achaia, Greece.</style></auth-address><titles><title><style face="normal" font="default">Intraoperative anaphylaxis, cardiac arrest and hypertrophic cardiomyopathy: Implications for Kounis syndrome</style></title><secondary-title><style face="normal" font="default">J Clin Anesth</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Clin Anesth</style></full-title></periodical><pages end="10" start="9">9-10</pages><volume><style face="normal" font="default">38</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> Intraoperative anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Kounis syndrome</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170404IS - 1873-4529 (Electronic)IS - 0952-8180 (Linking)LA - engPT - LetterCO - Greece -</style></notes><work-type><style face="normal" font="default">10.1016/j.jclinane.2017.01.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28372694">PM:28372694</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Anesth\2017-38-9-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Anesth\2017-38-9-10.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170404, Kounis NG</style></custom2><misc3><style face="normal" font="default">10.1016/j.jclinane.2017.01.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41459</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Komasawa,N.</style></author><author><style face="normal" font="default"> Nishihara,I.</style></author><author><style face="normal" font="default"> Nishimura,W.</style></author><author><style face="normal" font="default"> Minami,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesiology, Osaka Medical College, Japan.</style></auth-address><titles><title><style face="normal" font="default">Treatment of ventilation failure after tracheal intubation due to asthma attack with high concentration sevoflurane</style></title><secondary-title><style face="normal" font="default">J Clin Anesth</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Clin Anesth</style></full-title></periodical><pages end="" start="6">6-</pages><volume><style face="normal" font="default">38</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anesthesiology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Intubation</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Ventilation</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170404IS - 1873-4529 (Electronic)IS - 0952-8180 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jclinane.2017.01.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28372681">PM:28372681</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Anesth\2017-38-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Anesth\2017-38-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170404, Komasawa N</style></custom2><misc3><style face="normal" font="default">10.1016/j.jclinane.2017.01.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41460</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Inci,D.</style></author><author><style face="normal" font="default"> Guggenheim,R.</style></author><author><style face="normal" font="default"> Altintas,D.U.</style></author><author><style face="normal" font="default"> Wildhaber,J.H.</style></author><author><style face="normal" font="default"> Moeller,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Respiratory Medicine, University Children's Hospital Zurich, Steinwiesstrasse 75, 8032 Zurich, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Reported Exercise-Related Respiratory Symptoms and Exercise-Induced Bronchoconstriction in Asthmatic Children</style></title><secondary-title><style face="normal" font="default">J Clin Med Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Clin Med Res</style></abbr-1></periodical><pages end="415" start="410">410-415</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Challenge test</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> exercise-induced bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Unlimited physical activity is one of the key issues of asthma control and management. We investigated how reliable reported exercise-related respiratory symptoms (ERRS) are in predicting exercise-induced bronchoconstriction (EIB) in asthmatic children. METHODS: In this prospective study, 179 asthmatic children aged 7 - 15 years were asked for specific questions on respiratory symptoms related to exercise and allocated into two groups according to whether they complained about symptoms. Group I (n = 134) consisted of children answering "yes" to one or more of the questions and group II (n = 45) consisted of children answering "no" to all of the questions. RESULTS: Sixty-four of 179 children showed a positive exercise challenge test (ECT). There was no difference in the frequency of a positive test between children in group I (n = 48) and group II (n = 12) (P = 0.47). The sensitivity of a positive report for ERRS to predict a positive ECT was only 37%, with a specificity of 0.72. CONCLUSION: According to current guidelines, the report or lack of ERRS has direct consequences on treatment decisions. However, the history of ERRS did not predict EIB and one-third of asthmatic children without complaints of ERRS developed EIB during the ECT. This raises the question of the need for objective measures of bronchial hyperresponsiveness (BHR) in pediatric asthma management</style></abstract><notes><style face="normal" font="default">DA - 20170410IS - 1918-3003 (Print)IS - 1918-3003 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - Turkey -</style></notes><work-type><style face="normal" font="default">10.14740/jocmr2935w</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28392861">PM:28392861</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Med Res\2017-9-410-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Med Res\2017-9-410-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170410, Inci D</style></custom2><misc3><style face="normal" font="default">10.14740/jocmr2935w</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41461</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sohaib,M.</style></author><author><style face="normal" font="default"> Shafiq,F.</style></author><author><style face="normal" font="default"> Haq,M.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Deparment of Anaesthesia, The Aga Khan University Hospital, Karachi</style></auth-address><titles><title><style face="normal" font="default">Severe Anaphylactic Reaction to Preoperative Aspiration Prophylaxis</style></title><secondary-title><style face="normal" font="default">J Coll Physicians Surg Pak</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Coll Physicians Surg Pak</style></full-title></periodical><pages end="S3" start="S2">S2-S3</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaesthesia</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Aspiration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> Norepinephrine</style></keyword><keyword><style face="normal" font="default"> Pakistan</style></keyword><keyword><style face="normal" font="default"> Phenylephrine</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">It is a case of severe anaphylactic reaction in a young female who had received aspiration prophylaxis preoperatively. Patient required intensive care and developed severe lactic acidosis. She responded very well to fluid and phenylephrine boluses and later on norepinephrine infusion</style></abstract><notes><style face="normal" font="default">DA - 20170317IS - 1681-7168 (Electronic)IS - 1022-386X (Linking)LA - engPT - Journal ArticleCO - Pakistan -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28302226">PM:28302226</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Coll Physicians Surg Pak\2017-27S3-2-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Coll Physicians Surg Pak\2017-27S3-2-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170317, Sohaib M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41462</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wilford,J.E.</style></author><author><style face="normal" font="default"> de Gannes,G.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada</style></auth-address><titles><title><style face="normal" font="default">Methylisothiazolinone Contact Allergy Prevalence in Western Canada</style></title><secondary-title><style face="normal" font="default">J Cutan Med Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Cutan Med Surg</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> British Columbia</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Columbia</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> methylchloroisothiazolinone</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Preservatives</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Contact allergy to methylisothiazolinone (MI) or to the combination of methylchloroisothiazolinone and MI (MCI/MI) is an important and increasing cause of allergic contact dermatitis, with prevalence rates higher than 10% in some centers. OBJECTIVES: The objective of this retrospective chart review is to provide a western Canadian perspective on whether the positive patch testing rate to MCI/MI or MI increased during the testing period of 2008 to 2015 and whether the addition of MI at 2000 ppm resulted in increased detection. METHODS: We conducted a retrospective chart review of patients who tested positive (n = 104) of 2177 total patients who were patch tested for MCI/MI or MI at a community dermatology clinic in Vancouver, British Columbia, Canada, from January 2008 through April 2015. RESULTS: One hundred and four patients had positive patch testing results for MCI/MI, MI, or both. Positive results increased over the study period, with the highest prevalence in 2015 at 9.41% for MCI/MI, 12.94% for MI, and 15.29% for either. When testing for MI at 2000 ppm was introduced in 2013, the initial positive patch testing prevalence was 6.6%, followed by 10.1% in 2014, and 12.9% in 2015. CONCLUSIONS: We demonstrate an increasing prevalence of MCI/MI and MI allergy between 2008 and 2015, with the highest prevalence of 15.29% in 2015 for MCI/MI and/or MI allergy. The addition of MI 2000 ppm greatly increased the positive patch testing yield for MI. Our results support the importance of continued efforts to monitor and regulate these preservatives</style></abstract><notes><style face="normal" font="default">DA - 20170316IS - 1615-7109 (Electronic)IS - 1203-4754 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1177/1203475417690307</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28300444">PM:28300444</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Cutan Med Surg\20170316-WilfordJE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Cutan Med Surg\20170316-WilfordJE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170316, Wilford JE</style></custom2><misc3><style face="normal" font="default">10.1177/1203475417690307</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41463</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Okawa,T.</style></author><author><style face="normal" font="default"> Hotta,A.</style></author><author><style face="normal" font="default"> Sato,M.</style></author><author><style face="normal" font="default"> Takahashi,S.</style></author><author><style face="normal" font="default"> Komori,J.</style></author><author><style face="normal" font="default"> Aihara,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by diethyl thiourea in a neoprene-containing wet suit</style></title><secondary-title><style face="normal" font="default">J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Thiourea</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="22" Month="4" Year="2017">2017/4/22</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170422IS - 1346-8138 (Electronic)IS - 0385-2407 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/1346-8138.13873</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28432694">PM:28432694</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatol\20170422-OkawaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatol\20170422-OkawaT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170422, Okawa T</style></custom2><misc3><style face="normal" font="default">10.1111/1346-8138.13873</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41464</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fukumoto,T.</style></author><author><style face="normal" font="default"> Tsuchiyama,S.</style></author><author><style face="normal" font="default"> Fukunaga,A.</style></author><author><style face="normal" font="default"> Nishigori,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan</style></auth-address><titles><title><style face="normal" font="default">Hypohidrosis and metal allergy: Trigger factors for unilateral lichen planus</style></title><secondary-title><style face="normal" font="default">J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dermis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Heat</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Keratin</style></keyword><keyword><style face="normal" font="default"> Lichen Planus</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metal allergies</style></keyword><keyword><style face="normal" font="default"> Metal allergy</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> Staining</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> Sweat</style></keyword><keyword><style face="normal" font="default"> Sweating</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wrist</style></keyword></keywords><dates><year Day="24" Month="3" Year="2017">2017/3/24</year></dates><abstract><style face="normal" font="default">Unilateral lichen planus (LP) is a rare clinical variant of LP. The etiology of unilateral LP has not been clarified, although various causes have been reported because of the characteristic distribution. We focused on the contribution of metal allergy and sweating in the development of unilateral LP in this case. To confirm the presence of metal allergy, patch tests with metal allergens were performed. To investigate the cause of the unilateral distribution in unilateral LP, the function of sweating and sweat leaking in the dermis was assessed by a thermoregulatory sweat test and immunohistochemical staining of dermcidin. The patch tests with SnCl2 , H2 PtCl6 , ZnCl2 and MnCl2 were positive. The thermoregulatory sweat test using the starch-iodine method (Minor test) with sweating provoked by heat stimulation revealed hypohidrosis of the affected area, whereas no skin lesions were observed on the dorsal hand and wrist where sweating was normal. Histopathological examination showed keratin plugging of the acrosyringium and lymphocytic infiltrations in the papillary and subpapillary dermis around the intraepidermal and intradermal eccrine duct in the affected area. The immunohistochemical staining of dermcidin confirmed sweat leakage in the subpapillary dermis in the affected area. The symptoms refractory to the topical steroids were markedly improved after removal of the dental metals. The coexistence of metal allergy and sweat leakage in the hypohidrotic area may be involved in the development of unilateral LP</style></abstract><notes><style face="normal" font="default">DA - 20170325IS - 1346-8138 (Electronic)IS - 0385-2407 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/1346-8138.13836</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28342246">PM:28342246</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatol\20170325-FukumotoT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatol\20170325-FukumotoT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170325, Fukumoto T</style></custom2><misc3><style face="normal" font="default">10.1111/1346-8138.13836</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41465</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Onoue,S.</style></author><author><style face="normal" font="default"> Seto,Y.</style></author><author><style face="normal" font="default"> Sato,H.</style></author><author><style face="normal" font="default"> Nishida,H.</style></author><author><style face="normal" font="default"> Hirota,M.</style></author><author><style face="normal" font="default"> Ashikaga,T.</style></author><author><style face="normal" font="default"> Api,A.M.</style></author><author><style face="normal" font="default"> Basketter,D.</style></author><author><style face="normal" font="default"> Tokura,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacokinetics and Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.</style></auth-address><titles><title><style face="normal" font="default">Chemical photoallergy: photobiochemical mechanisms, classification, and risk assessments</style></title><secondary-title><style face="normal" font="default">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatol Sci</style></full-title></periodical><pages end="11" start="4">4-11</pages><volume><style face="normal" font="default">85</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse effects</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Chemically-Induced Disorders</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Photoallergic</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Phototoxic</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Drug-Related Side Effects and Adverse Reactions</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> pharmacokinetics</style></keyword><keyword><style face="normal" font="default"> Photoallergy</style></keyword><keyword><style face="normal" font="default"> Photosensitivity</style></keyword><keyword><style face="normal" font="default"> Phototoxicity</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Sunlight</style></keyword><keyword><style face="normal" font="default"> Ultraviolet Rays</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">Chemical photosensitivity can be elicited by exposure of the skin to various pharmaceutical substances, foods, cosmetics and other environmental chemicals, followed by exposure to sunlight. There are at least three types of chemical photosensitivity, i.e., photoirritancy (narrowly defined as phototoxicity), photogenotoxicity and photoallergenicity, and their clinical characteristics and mechanisms are quite different. Concerns about chemical photoallergy is increasing, and various studies have been made to clarify the photobiochemical characteristics of photoallergens and the mechanisms involved. Various methodologies, including in silico prediction models, photochemical assay systems, and in vitro phototoxicity prediction tools, have been developed to predict the photoallergenic potential of chemicals over the past few years. The aim of this manuscript is to review the clinical characteristics, pathogenetic mechanisms and photobiochemical features of photoallergens, with special emphasis on the current status about development of screening systems for predicting photoallergenic potential of chemicals</style></abstract><notes><style face="normal" font="default">DA - 20160816IS - 1873-569X (Electronic)IS - 0923-1811 (Linking)LA - engPT - Journal ArticlePT - ReviewRN - 0 (Allergens)RN - 0 (Cosmetics)SB - IMCO - Japan -CO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jdermsci.2016.08.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27528585">PM:27528585</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatol Sci\2017-85-4-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatol Sci\2017-85-4-11.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160816, Onoue S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jdermsci.2016.08.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41466</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rzany,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">RZANY &amp; HUND, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="default">Too many instruments for measuring Quality of Life in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="" start="574">574-</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170420IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.14185</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28425597">PM:28425597</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\2017-31-574.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\2017-31-574.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170420, Rzany B</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.14185</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41467</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gisondi,P.</style></author><author><style face="normal" font="default"> Deangelis,G.</style></author><author><style face="normal" font="default"> Venturelli,G.</style></author><author><style face="normal" font="default"> Girolomoni,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Section of Dermatology and Venereology, University of Verona, Italy</style></auth-address><titles><title><style face="normal" font="default">Public perception of dermatology and dermatologists in Italy: Results from a population-based national survey</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> General practitioner</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health care provider</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Promoter</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin Care</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Telephone</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="27" Month="4" Year="2017">2017/4/27</year></dates><abstract><style face="normal" font="default">INTRODUCTION: The public perception of Dermatology and dermatologists may be very relevant in guiding strategies for improving dermatologic care but it has been poorly investigated in Europe. OBJECTIVE: To investigate the public's perception of Dermatology and dermatologists in Italy. METHODS: A representative sampling of Italian adults (n=1500, aged 18-70 years), residing throughout the national territory was interviewed through a population-based telephone survey using a structured questionnaire. RESULTS: The majority of interviewed aged between 35 and 54 years (45%) and had an intermediate educational level (57%), were employed (56%), and had at least one child in the family (68%). 70% of the interviewed knew at least one skin disease, particularly psoriasis, dermatitis, urticaria, skin tumors and nevi. The general practitioner resulted to be the first health care provider to consult in the case of skin problems for 73% of surveyed, with only 27% referring directly the private dermatologist. The dermatologist was the main referral specialist for psoriasis, pruritus and skin tumors by 66%, 54% and 53% of the sample, respectively. The most common reason for dermatological consultation was the control of nevi. In the case of childhood dermatitis, 52% indicated the paediatrician and 38% the dermatologist as the reference specialist. Almost half of the surveyed turned out to have a trusted dermatologist to consult in the case of skin problems. Finally, among those visited at least one time by a dermatologist, 46% were promoters, i.e. they would recommend their dermatologist to a friend (net promoter score, 27). CONCLUSIONS: The general population has a wide-ranging understanding of skin diseases and the central role of dermatologists in skin care. Patients are looking for technical competence and loyalty, because this lead to more trusted and satisfactory physician-patient relationship. Public campaigns may be relevant in increasing awareness on curability of common skin diseases. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170427IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.14296</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28449275">PM:28449275</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170427-GisondiP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170427-GisondiP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170427, Gisondi P</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.14296</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41468</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Thomsen,S.F.</style></author><author><style face="normal" font="default"> Pritzier,E.C.</style></author><author><style face="normal" font="default"> Anderson,C.D.</style></author><author><style face="normal" font="default"> Vaugelade-Baust,N.</style></author><author><style face="normal" font="default"> Dodge,R.</style></author><author><style face="normal" font="default"> Dahlborn,A.K.</style></author><author><style face="normal" font="default"> Vestergaard,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Bispebjerg Hospital &amp; Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default">Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> H1 antihistamines</style></keyword><keyword><style face="normal" font="default"> H1-antihistamine</style></keyword><keyword><style face="normal" font="default"> H1-antihistamines</style></keyword><keyword><style face="normal" font="default"> Hives</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> Life quality</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> montelukast</style></keyword><keyword><style face="normal" font="default"> Norway</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> QOL</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="10" Month="3" Year="2017">2017/3/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic urticaria (CU) is characterized by the recurrence of itchy hives and/or angioedema for more than 6 weeks. AWARE (A World-wide Antihistamine-Refractory Chronic Urticaria Patient Evaluation) is a multinational study designed to document the real-life treatment situation, burden of disease and clinical resource usage of H1-antihistamine-refractory CU patients. OBJECTIVE: To examine baseline data from Scandinavian AWARE patients. METHODS: AWARE is a prospective, non-interventional, multinational, umbrella design study, which includes adults (>/=18 years) with a confirmed CU diagnosis (>2 months) that is refractory to H1-antihistamines. Baseline patient characteristics, disease activity (urticaria control test [UCT]), pharmacological treatment, comorbidities and healthcare usage were documented by the treating physician. Quality of life (QoL; dermatology life quality index [DLQI]; chronic urticaria quality of life questionnaire [CU-Q2 oL; Danish patients only]) and work productivity and activity impairment (WPAI) scores were also assessed. RESULTS: Overall, 158 CU patients from seven centres in Denmark (n = 80), Norway (n = 50) and Sweden (n = 28) were included in this baseline analysis. Mean age and BMI were 40.3 years and 26.5 kg/m2 , respectively. The majority of patients were female (69.6%), had uncontrolled CU (75.6%; UCT score &lt;12) and had a 'spontaneous' component to their CU (61.4% CSU; 20.3% both CSU and chronic inducible urticaria). Common comorbidities included asthma (19.6%), allergic rhinitis (16.5%) and food allergies (8.2%). Overall, 60.1% of patients reported using treatments for CU including non-sedative H1-antihistamines (40.5%), corticosteroids (19%), montelukast (14.6%) and omalizumab (8.2%). Pharmacological treatment rates increased to 96.2% during the baseline visit. On average, patient QoL was moderately affected (mean DLQI score 7.7) and healthcare resource usage was high. CONCLUSION: Adult Scandinavian H1-antihistamine-refractory CU patients reported high rates of healthcare usage and QoL impairment. Rates of pharmacological treatment use were low before study enrolment but increased to almost 100% during the baseline visit</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Norway -CO - Denmark -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.14210</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28294420">PM:28294420</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170315-ThomsenSF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170315-ThomsenSF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Thomsen SF</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.14210</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41469</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oosterhaven,J.A.</style></author><author><style face="normal" font="default"> Febriana,S.A.</style></author><author><style face="normal" font="default"> Soebono,H.</style></author><author><style face="normal" font="default"> Coenraads,P.J.</style></author><author><style face="normal" font="default"> Schuttelaar,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Results of patch testing in Indonesian shoe factory workers</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="e17" start="e15">e15-e17</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Indonesia</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Shoe</style></keyword><keyword><style face="normal" font="default"> Shoes</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20160128IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)CO - Netherlands -CO - Indonesia -LA - engPT - LetterSB - IMCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.13586</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26818891">PM:26818891</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\2017-31-e15-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\2017-31-e15-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160128, Oosterhaven JA</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.13586</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41470</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kitayama,N.</style></author><author><style face="normal" font="default"> Otsuka,A.</style></author><author><style face="normal" font="default"> Nonomura,Y.</style></author><author><style face="normal" font="default"> Nakashima,C.</style></author><author><style face="normal" font="default"> Honda,T.</style></author><author><style face="normal" font="default"> Kabashima,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan</style></auth-address><titles><title><style face="normal" font="default">Decrease of serum IL-32 level in patients with atopic dermatitis after cyclosporine treatment</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Arthritis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> Crohn Disease</style></keyword><keyword><style face="normal" font="default"> Cyclosporine</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="12" Month="4" Year="2017">2017/4/12</year></dates><abstract><style face="normal" font="default">Interleukin (IL)-32 is a proinflammatory cytokine that is involved in the inflammatory processes of rheumatoid arthritis, chronic obstructive pulmonary disease, and Crohn disease. [1] Recent studies have reported that IL-32 also contributes to the pathophysiology of atopic dermatitis (AD) in the early stages. [2] IL-32 is expressed in the lesional skin of patients with AD and that serum levels of IL-32 in patients with AD are elevated. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170413IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.14274</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28403511">PM:28403511</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170424-KitayamaN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170424-KitayamaN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170413, Kitayama N</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.14274</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41471</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jarisch,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">FA fur Dermatologie, FAZ Floridsdorfer Allergie Zentrum Wien, Vienna, AustriaFH Campus Wien und, Vienna, AustriaFH St. Polten und FH. Wr. Neustadt, Wachau, AustriaWinzer in der Wachau, Wachau, Austria</style></auth-address><titles><title><style face="normal" font="default">Histamine intolerance in chronic urticaria</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="" start="575">575-</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergie</style></keyword><keyword><style face="normal" font="default"> Austria</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Dermatologie</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170420IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.14219</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28425596">PM:28425596</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\2017-31-575.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\2017-31-575.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170420, Jarisch R</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.14219</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41472</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hegazy,S.</style></author><author><style face="normal" font="default"> Tauber,M.</style></author><author><style face="normal" font="default"> Bulai-Livideanu,C.</style></author><author><style face="normal" font="default"> Uthuriague,C.</style></author><author><style face="normal" font="default"> Giordano-Labadie,F.</style></author><author><style face="normal" font="default"> Marguery,M.C.</style></author><author><style face="normal" font="default"> Regnault,M.M.</style></author><author><style face="normal" font="default"> Konstantinou,M.P.</style></author><author><style face="normal" font="default"> Paul,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Hopital Larrey, Toulouse University, 31059, Toulouse, France</style></auth-address><titles><title><style face="normal" font="default">Systemic treatment of severe adult Atopic dermatitis in clinical practice: analysis of prescribing pattern in a cohort of 241 patients</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic treatment</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="21" Month="3" Year="2017">2017/3/21</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170321IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - LetterCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.14238</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28322469">PM:28322469</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170321-HegazyS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170321-HegazyS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170321, Hegazy S</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.14238</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41473</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Grieco,T.</style></author><author><style face="normal" font="default"> Faina,V.</style></author><author><style face="normal" font="default"> Porzia,A.</style></author><author><style face="normal" font="default"> Paolino,G.</style></author><author><style face="normal" font="default"> Morrone,S.</style></author><author><style face="normal" font="default"> Bottoni,U.</style></author><author><style face="normal" font="default"> Calvieri,S.</style></author><author><style face="normal" font="default"> Mainiero,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatologic Clinic, Sapienza University of Rome, Viale del Policlinico 15, 00161, Rome, Italy</style></auth-address><titles><title><style face="normal" font="default">Atopic dermatitisIL17A and IFN-gamma-producing lymphocytes: investigation in blood, chronic lesions and APT</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> IgG1</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Rome</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Software</style></keyword><keyword><style face="normal" font="default"> Staining</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="5" Month="4" Year="2017">2017/4/5</year></dates><abstract><style face="normal" font="default">After stimulation, skin and blood-derived mononuclear cells were washed with phosphate buffered saline and stained with anti-CD4 FITC, anti-CD3 PerCP and anti-CD45 APC antibodies, then fixed with 2% paraformaldehyde and permeabilized with 0.5% saponin/1% fetal calf serum, before an additional staining with intracytoplasmic anti-IL17A PE or anti-IFN-gamma PE or control isotype IgG1 PE. Cells were acquired with FACSCANTO II and analyzed with FlowJo software. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170405IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.14258</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28380262">PM:28380262</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170405-GriecoT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170405-GriecoT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170405, Grieco T</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.14258</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41474</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,I.J.</style></author><author><style face="normal" font="default"> Karmaus,W.J.</style></author><author><style face="normal" font="default"> Yang,C.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Taipei Hospital, Ministry of Health and Welfare, Taipei, Taiwan</style></auth-address><titles><title><style face="normal" font="default">Lead exposure, IgE, and the risk of asthma in children</style></title><secondary-title><style face="normal" font="default">J Expo Sci Environ Epidemiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Expo Sci Environ Epidemiol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Nervous System</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Taiwan</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="12" Month="4" Year="2017">2017/4/12</year></dates><abstract><style face="normal" font="default">Lead (Pb) has adverse effects on our nervous system and renal systems. Young children are more vulnerable to Pb exposure. However, the role of low-level Pb exposure in the immune system and allergic diseases in children is not well established. The aims of this study are to investigate the associations between Pb exposure and allergic diseases; between Pb and immunoglobulin E (IgE) as an intervening variable; and gender-based differences. We used multistage stratified random sampling to recruit kindergarten children nationwide in Taiwan. Information about allergic diseases and environmental exposures was collected by questionnaire. We compared children with and without allergic diseases for blood Pb levels measured by inductively coupled plasma mass spectrometry. The association between blood Pb and allergic diseases was assessed by logistic regression and those between Pb and IgE by generalized linear models. We also conducted mediation analysis to evaluate how much risk of allergic diseases related to Pb exposure is explained by IgE. A total of 930 children completed specimen collections. There was a positive association between Pb and asthma. Blood Pb were also positively linked with serum IgE (beta=0.26 kU/l per ln-unit increase Pb concentration; 95% CI 0.009-0.50 kU/l), after adjusting for potential confounders. Analyses stratified by gender revealed that blood Pb correlated with IgE only in boys (beta=0.40 kU/l; 95% CI 0.03-0.76 kU/l). We estimated that 38% of the total effect of Pb exposure on asthma is mediated by IgE levels. In conclusion, Pb exposure is associated with both blood IgE and asthma in boys. Moreover, the effect of Pb exposure on asthma may be mediated by IgE levels.Journal of Exposure Science and Environmental Epidemiology advance online publication, 12 April 2017; doi:10.1038/jes.2017.5</style></abstract><notes><style face="normal" font="default">DA - 20170412IS - 1559-064X (Electronic)IS - 1559-0631 (Linking)LA - engPT - Journal ArticleCO - Taiwan -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1038/jes.2017.5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28401896">PM:28401896</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Expo Sci Environ Epidemiol\20170412-WangIJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Expo Sci Environ Epidemiol\20170412-WangIJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170412, Wang iJ</style></custom2><misc3><style face="normal" font="default">10.1038/jes.2017.5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41475</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kee,J.Y.</style></author><author><style face="normal" font="default"> Jeon,Y.D.</style></author><author><style face="normal" font="default"> Kim,D.S.</style></author><author><style face="normal" font="default"> Han,Y.H.</style></author><author><style face="normal" font="default"> Park,J.</style></author><author><style face="normal" font="default"> Youn,D.H.</style></author><author><style face="normal" font="default"> Kim,S.J.</style></author><author><style face="normal" font="default"> Ahn,K.S.</style></author><author><style face="normal" font="default"> Um,J.Y.</style></author><author><style face="normal" font="default"> Hong,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Oriental Pharmacy, College of Pharmacy, Wonkwang-Oriental Medicines Research Institute, Wonkwang University, Iksan, Korea</style></auth-address><titles><title><style face="normal" font="default">Korean Red Ginseng improves atopic dermatitis-like skin lesions by suppressing expression of proinflammatory cytokines and chemokines in vivo and in vitro</style></title><secondary-title><style face="normal" font="default">J Ginseng Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Ginseng Res</style></abbr-1></periodical><pages end="143" start="134">134-143</pages><volume><style face="normal" font="default">41</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="default"> Asia</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Chemokines</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human mast cells</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Keratinocytes</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> mitogen-activated protein kinase</style></keyword><keyword><style face="normal" font="default"> Mitogen-Activated Protein Kinases</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Monocyte</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Protein Kinases</style></keyword><keyword><style face="normal" font="default"> Rantes</style></keyword><keyword><style face="normal" font="default"> Recovery</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> TARC</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: The prevalence of allergic inflammatory diseases such as atopic dermatitis (AD), asthma, and allergic rhinitis worldwide has increased and complete recovery is difficult. Korean Red Ginseng, which is the heat-processed root of Panax ginseng Meyer, is widely and frequently used as a traditional medicine in East Asia. In this study, we investigated whether Korean Red Ginseng water extract (RGE) regulates the expression of proinflammatory cytokines and chemokines via the mitogen-activated protein kinases (MAPKs)/nuclear factor kappa B (NF-kappaB) pathway in allergic inflammation. METHODS: Compound 48/80-induced anaphylactic shock and 1-fluoro-2,4-dinitrobenzene (DNFB)-induced AD-like skin lesion mice models were used to investigate the antiallergic effects of RGE. Human keratinocytes (HaCaT cells) and human mast cells (HMC-1) were also used to clarify the effects of RGE on the expression of proinflammatory cytokines and chemokines. RESULTS: Anaphylactic shock and DNFB-induced AD-like skin lesions were attenuated by RGE administration through reduction of serum immunoglobulin E (IgE) and interleukin (IL)-6 levels in mouse models. RGE also reduced the production of proinflammatory cytokines including IL-1beta, IL-6, and IL-8, and expression of chemokines such as IL-8, thymus and activation-regulated chemokine (TARC), and macrophage-derived chemokine (MDC) in HaCaT cells. Additionally, RGE decreased the release of tumor necrosis factor-alpha (TNF-alpha), IL-1beta, IL-6, and IL-8 as well as expressions of chemokines including macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, regulated on activation, normal T cell expressed and secreted (RANTES), monocyte chemoattractant protein (MCP)-1, and IL-8 in HMC-1 cells. Furthermore, our data demonstrated that these inhibitory effects occurred through blockage of the MAPK and NF-kappaB pathway. CONCLUSION: RGE may be a useful therapeutic agent for the treatment of allergic inflammatory diseases such as AD-like dermatitis</style></abstract><notes><style face="normal" font="default">DA - 20170417IS - 1226-8453 (Print)IS - 1226-8453 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.jgr.2016.02.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28413317">PM:28413317</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Ginseng Res\2017-41-134-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Ginseng Res\2017-41-134-43.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170417, Kee JY</style></custom2><misc3><style face="normal" font="default">10.1016/j.jgr.2016.02.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41476</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Abuabara,K.</style></author><author><style face="normal" font="default"> Magyari,A.M.</style></author><author><style face="normal" font="default"> Hoffstad,O.</style></author><author><style face="normal" font="default"> Jabbar-Lopez,Z.K.</style></author><author><style face="normal" font="default"> Smeeth,L.</style></author><author><style face="normal" font="default"> Williams,H.C.</style></author><author><style face="normal" font="default"> Gelfand,J.M.</style></author><author><style face="normal" font="default"> Margolis,D.J.</style></author><author><style face="normal" font="default"> Langan,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Program in Clinical Research, Department of Dermatology, University of California San Francisco.</style></auth-address><titles><title><style face="normal" font="default">Development and validation of an algorithm to accurately identify atopic eczema patients in primary care electronic health records from the UK</style></title><secondary-title><style face="normal" font="default">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Invest Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic eczema</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Records</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> San Francisco</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="18" Month="4" Year="2017">2017/4/18</year></dates><abstract><style face="normal" font="default">Electronic health records hold great promise for clinical and epidemiologic research. Undertaking atopic eczema (AE) research using such data is challenging due to its episodic and heterogeneous nature. We sought to develop and validate a diagnostic algorithm that identifies AE cases based on codes used for electronic records used in the UK Health Improvement Network (THIN). We found that at least one of 5 diagnosis codes plus two treatment codes for any skin-directed therapy were likely to accurately identify patients with AE. To validate this algorithm, a questionnaire was sent to the physicians of 200 randomly selected children and adults. The primary outcome, the positive predictive value (PPV) for a physician-confirmed diagnosis of AE, was 86% (95%CI 80-91%). Additional criteria increased the PPV up to 95% but would miss up to 89% of individuals with physician-confirmed AE. The first and last entered diagnosis codes for individuals showed good agreement with the physician-confirmed age at onset and last disease activity; the mean difference was 0.8 years (95% CI -0.3,1.9) and -1.3 years respectively (95%CI -2.5, -0.1). A combination of diagnostic and prescription codes can be used to reliably estimate the diagnosis and duration of AE from the THIN primary care electronic health records in the UK</style></abstract><notes><style face="normal" font="default">DA - 20170421IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jid.2017.03.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28428130">PM:28428130</url></web-urls><related-urls><url ppv-ref="no">presto - 1 anno</url></related-urls></urls><custom2><style face="normal" font="default">20170421, Abuabara K</style></custom2><misc3><style face="normal" font="default">10.1016/j.jid.2017.03.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41477</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liew,P.Y.L.</style></author><author><style face="normal" font="default"> Craven,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Emergency Medicine, Flinders Medical Centre, Flinders Drive, Bedford Park, 5042, Adelaide, Australia.</style></auth-address><titles><title><style face="normal" font="default">Adrenaline overdose in pediatric anaphylaxis: a case report</style></title><secondary-title><style face="normal" font="default">J Med Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Med Case Rep</style></abbr-1></periodical><pages end="" start="129">129-</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adrenaline</style></keyword><keyword><style face="normal" font="default"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Emergency Medicine</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Overdose</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="8" Month="5" Year="2017">2017/5/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Adrenaline is the standard treatment for anaphylaxis but appropriate administration remains challenging, and iatrogenic overdose is easily overlooked. Despite the established importance of pediatric blood pressure measurement, its use remains inconsistent in clinical practice. CASE PRESENTATION: We report a case of adrenaline overdose in a 9-year-old white boy with anaphylaxis, where signs of adrenaline overdose were indistinguishable from progressive shock until blood pressure measurement was taken. CONCLUSIONS: The consequences of under-dosing adrenaline in anaphylaxis are well-recognized, but the converse is less so. Blood pressure measurement should be a routine part of pediatric assessment as it is key to differentiating adrenaline overdose from anaphylactic shock</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 1752-1947 (Electronic)IS - 1752-1947 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1186/s13256-017-1290-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28482886">PM:28482886</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Med Case Rep\2017-41-129.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Med Case Rep\2017-41-129.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Liew PY</style></custom2><misc3><style face="normal" font="default">10.1186/s13256-017-1290-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41478</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Qu,L.</style></author><author><style face="normal" font="default"> Fu,K.</style></author><author><style face="normal" font="default"> Shimada,S.G.</style></author><author><style face="normal" font="default"> Lamotte,R.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Yale University School of Medicine</style></auth-address><titles><title><style face="normal" font="default">Cl- channel is required for CXCL10-induced neuronal activation and itch response in a murine model of allergic contact dermatitis</style></title><secondary-title><style face="normal" font="default">J Neurophysiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Neurophysiol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Ca2+</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> CXCL10</style></keyword><keyword><style face="normal" font="default"> CXCR3</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Itch</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> Neuron</style></keyword><keyword><style face="normal" font="default"> Neurons</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="26" Month="4" Year="2017">2017/4/26</year></dates><abstract><style face="normal" font="default">Persistent itch often accompanies allergic contact dermatitis (ACD), but the underlying mechanisms remain largely unexplored. We previously demonstrated that CXCL10/ CXCR3 signaling activated a subpopulation of cutaneous primary sensory neurons and mediated itch response after contact hypersensitivity (CHS), a murine model of ACD, induced by squaric acid dibutylester. The purpose of this study was to determine the ionic mechanisms underlying CXCL10-induced neuronal activation and allergic itch. In whole-cell recordings, CXCL10 triggered a current in dorsal root ganglion (DRG) neurons innervating the area of CHS. This current was modulated by intracellular Cl- and blocked by the general Cl- channel inhibitors. Moreover, increasing Ca2+ buffering capacity reduced this current. In addition, blockade of Cl- channels significantly suppressed CXCL10-induced Ca2+ response. In behavioral tests, injection of CXCL10 into CHS site exacerbated itch-related scratching behaviors. Moreover, the potentiating behavioral effects of CXCL10 were attenuated by either of two Cl- channel blockers. Thus, we suggest that the Cl- channel acts as a downstream target mediating the excitatory and pruritic behavioral effects of CXCL10. Cl- channels may provide a promising therapeutic target for the treatment of allergic itch in which CXCL10/CXCR3 signaling may participate</style></abstract><notes><style face="normal" font="default">DA - 20170427IS - 1522-1598 (Electronic)IS - 0022-3077 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1152/jn.00187.2017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28446581">PM:28446581</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Neurophysiol\20170427-QuL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Neurophysiol\20170427-QuL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170427, Qu L</style></custom2><misc3><style face="normal" font="default">10.1152/jn.00187.2017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41479</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Suzuki,R.A.</style></author><author><style face="normal" font="default"> Irokawa,T.</style></author><author><style face="normal" font="default"> Ogawa,H.</style></author><author><style face="normal" font="default"> Ohkouchi,S.</style></author><author><style face="normal" font="default"> Tabata,M.</style></author><author><style face="normal" font="default"> Togashi,S.</style></author><author><style face="normal" font="default"> Nakamura,T.</style></author><author><style face="normal" font="default"> Ohisa,N.</style></author><author><style face="normal" font="default"> Nikkuni,E.</style></author><author><style face="normal" font="default"> Miura,E.</style></author><author><style face="normal" font="default"> Yoshida,K.</style></author><author><style face="normal" font="default"> Inomata,H.</style></author><author><style face="normal" font="default"> Kurosawa,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Occupational Health, Tohoku University Graduate School of Medicine, Sendai, Japan</style></auth-address><titles><title><style face="normal" font="default">Fractional Exhaled Nitric Oxide (FeNO) and Spirometry as Indicators of Inhalation Exposure to Chemical Agents in Pathology Workers</style></title><secondary-title><style face="normal" font="default">J Occup Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Occup Environ Med</style></full-title></periodical><pages end="473" start="467">467-473</pages><volume><style face="normal" font="default">59</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Formaldehyde</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Inhalation Exposure</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Health</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The objective of this study was to examine whether fractional exhaled nitric oxide (FeNO) and spirometry can be used as indices to evaluate adverse health effects of low-concentrated chemical inhalation exposure, mainly to formaldehyde. METHODS: Thirty-three subjects (pathology technicians) and 30 controls (workers without handling any chemicals in the same hospitals) participated in this study. All participants underwent FeNO measurement and spirometry before and after 5 days of work. RESULTS: FeNO significantly increased in the subjects with a history of asthma (P &lt; 0.05), whereas forced vital capacity (FVC) and forced expiratory volume in the first second (FEV1) decreased in the subjects (P &lt; 0.05). Furthermore, work duration and pre-work levels of FEV1 in the subjects had a significant association. CONCLUSION: The results suggest that FeNO, FVC, and FEV1 represent effective health-effect indices of low-concentrated chemical inhalation exposure</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 1536-5948 (Electronic)IS - 1076-2752 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1097/JOM.0000000000000976</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28486343">PM:28486343</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Occup Environ Med\2017-59-467-73.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Occup Environ Med\2017-59-467-73.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Suzuki RA</style></custom2><misc3><style face="normal" font="default">10.1097/JOM.0000000000000976</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41480</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wahler,R.G.,Jr.</style></author><author><style face="normal" font="default"> Smith,D.B.</style></author><author><style face="normal" font="default"> Mulcahy,K.B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Nebulized Fentanyl for Dyspnea in a Hospice Patient with True Allergy to Morphine and Hydromorphone</style></title><secondary-title><style face="normal" font="default">J Pain Palliat Care Pharmacother</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Pain Palliat Care Pharmacother</style></abbr-1></periodical><pages end="42" start="38">38-42</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic response</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fentanyl</style></keyword><keyword><style face="normal" font="default"> Hydromorphone</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> lung cancer</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Morphine</style></keyword><keyword><style face="normal" font="default"> nebulized</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">An 86-year-old white female was admitted to hospice care with lung cancer. Even with optimal medical management, she suffered from dyspnea and required opioid therapy. However, the patient had a true morphine and hydromorphone allergy. She was administered nebulized fentanyl for symptomatic relief of dyspnea with good effect and she did not experience any allergic response</style></abstract><notes><style face="normal" font="default">DA - 20170313IS - 1536-0539 (Electronic)IS - 1536-0288 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/15360288.2017.1279499</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28287363">PM:28287363</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Pain Palliat Care Pharmacother\2017-31-38-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Pain Palliat Care Pharmacother\2017-31-38-42.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170313, Wahler RG Jr</style></custom2><misc3><style face="normal" font="default">10.1080/15360288.2017.1279499</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41481</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dascalu,J.</style></author><author><style face="normal" font="default"> Donath,S.</style></author><author><style face="normal" font="default"> Tiller,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of General Medicine Royal Children's Hospital Melbourne, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="default">Fluticasone furoate for inadequately controlled asthma</style></title><secondary-title><style face="normal" font="default">J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Pediatr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> fluticasone furoate</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Victoria</style></keyword></keywords><dates><year Day="13" Month="3" Year="2017">2017/3/13</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170317IS - 1097-6833 (Electronic)IS - 0022-3476 (Linking)LA - engPT - LetterCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jpeds.2017.02.056</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28302326">PM:28302326</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Pediatr\20170317-DascaluJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Pediatr\20170317-DascaluJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170317, Dascalu J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jpeds.2017.02.056</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41482</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fable,J.M.</style></author><author><style face="normal" font="default"> Fernandez,M.</style></author><author><style face="normal" font="default"> Goodine,S.</style></author><author><style face="normal" font="default"> Lerer,T.</style></author><author><style face="normal" font="default"> Sayej,W.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">*Division of Digestive Diseases, Hepatology &amp; Nutrition, Connecticut Children's Medical Center, Hartford, CT</style></auth-address><titles><title><style face="normal" font="default">Retrospective Comparison of Fluticasone Propionate and Oral Viscous Budesonide in Children with Eosinophilic Esophagitis</style></title><secondary-title><style face="normal" font="default">J Pediatr Gastroenterol Nutr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Pediatr Gastroenterol Nutr</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Budesonide</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Comparative Study</style></keyword><keyword><style face="normal" font="default"> Connecticut</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default"> Esophagitis</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> fluticasone propionate</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pretreatment</style></keyword><keyword><style face="normal" font="default"> Remission</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="5" Year="2017">2017/5/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Eosinophilic esophagitis (EoE) is treated with dietary modification and/or pharmacologic management with swallowed topical steroids (TS). Swallowed fluticasone propionate (FP) and oral viscous budesonide (OVB) have proven to be effective in resolving symptoms and reversing histologic changes in children and adults with EoE. There are minimal comparative studies between the two agents. AIM: To retrospectively compare endoscopic and histologic outcomes following FP versus OVB therapy in children with EoE in our center. METHODS: We performed a retrospective chart review of subjects diagnosed with EoE at a tertiary care center between 2010 and 2015. Inclusion criteria were FP or OVB therapy for >/=8 weeks along with pre- and post-treatment endoscopic evaluation. Demographic and clinical features as well as endoscopic and histologic assessment was recorded for comparative analysis. Histologic response was defined as &lt;15 eos/hpf and remission as &lt;5 eos/hpf. RESULTS: The study included 68 EoE patients (20 FP and 48 OVB) with a mean age of 10.6 +/- 5.2 years (range 1-20 years); 81% were male and 68% were Caucasian. No significant demographic or clinical differences were noted between the two study groups. Overall histologic response to TS's was seen in 44/68 (65%) patients. A significantly greater number of patients achieved histologic response with OVB (36/48, 75%) than with FP (8/20, 40%) (P = 0.0059). Mean pre-treatment peak eos/hpf was 46 +/- 19 in the FP group vs. 45 +/- 23 in the OVB group. Mean post-treatment peak eos/hpf was 20 +/- 29 in the FP group vs. 12 +/- 16 in the OVB group (P = 0.002). There was also a significantly greater difference in the change of absolute eos/hpf from pre- to post-treatment in the OVB group (-33) vs. FP (-18) (P = 0.047). A greater number of OVB-treated patients without asthma had a histologic response compared to those with asthma (P = 0.031). The response to OVB was not affected by the delivery vehicle, namely sucralose (Splenda(R)) vs. Neocate(R) Duocal. CONCLUSION: Our data suggest that treatment with OVB leads to better endoscopic and histologic outcomes than FP. Adherence to treatment and history of asthma are major determining factors in the response to treatments. Using Neocate(R) Duocal as the OVB delivery vehicle is just as effective as sucralose</style></abstract><notes><style face="normal" font="default">DA - 20170510IS - 1536-4801 (Electronic)IS - 0277-2116 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/MPG.0000000000001626</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28489670">PM:28489670</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Pediatr Gastroenterol Nutr\20170510-FableJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Pediatr Gastroenterol Nutr\20170510-FableJM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170510, Fable JM</style></custom2><misc3><style face="normal" font="default">10.1097/MPG.0000000000001626</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41483</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wicinski,M.</style></author><author><style face="normal" font="default"> Weclewicz,M.M.</style></author><author><style face="normal" font="default"> Mietkiewicz,M.</style></author><author><style face="normal" font="default"> Malinowski,B.</style></author><author><style face="normal" font="default"> Grzesk,E.</style></author><author><style face="normal" font="default"> Klonowska,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">WICINSKI, WECLEWICZ, MIETKIEWICZ, MALINOWSKI, and GRZESK: Department of Pharmacology and Therapeutics, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Bydgoszcz, Poland KLONOWSKA: College of Engineering and Health, Warsaw, Poland</style></auth-address><titles><title><style face="normal" font="default">Potential Mechanisms of Hematological Adverse Drug Reactions in Patients Receiving Clozapine in Combination With Proton Pump Inhibitors</style></title><secondary-title><style face="normal" font="default">J Psychiatr Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Psychiatr Pract</style></abbr-1></periodical><pages end="120" start="114">114-120</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Agranulocytosis</style></keyword><keyword><style face="normal" font="default"> Apoptosis</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Engineering</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Enzymes</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="default"> Gastroesophageal reflux disease</style></keyword><keyword><style face="normal" font="default"> Granulocytes</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Lansoprazole</style></keyword><keyword><style face="normal" font="default"> Leukocytes</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Neutropenia</style></keyword><keyword><style face="normal" font="default"> Omeprazole</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> proton pump inhibitor</style></keyword><keyword><style face="normal" font="default"> Proton pump inhibitors</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Schizophrenia</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutics</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">Clozapine is a second-generation antipsychotic which has proven efficacy in treating the symptoms of schizophrenia. Although clozapine therapy is associated with a number of adverse drug reactions, it is frequently used. One of the most common adverse drug reactions is gastroesophageal reflux disease which is an indication for treatment with proton pump inhibitors (PPIs). Coadministration of clozapine and PPIs increases the risk of hematological adverse drug reactions, including neutropenia and agranulocytosis. The mechanism in idiosyncratic agranulocytosis is not dose related and involves either a direct toxic or an immune-allergic effect. It is suspected that the clozapine metabolites nitrenium ion and N-desmethylclozapine may cause apoptosis or impair growth of granulocytes. Formation of N-desmethylclozapine is correlated with activity of the cytochrome P450 enzymes 1A2 and 3A4 (CYP1A2 and CYP3A4). Nitrenium ion is produced by the flavin-containing monooxygenase system of leukocytes. A drug interaction between clozapine and a PPI is a consequence of the induction of common metabolic pathways either by the PPI or clozapine. Findings to date suggest that indirect induction of flavin-containing monooxygenase by omeprazole through the aryl hydrocarbon receptor increases the expression of the enzyme mRNA and in the long term may cause the increase in activity. Moreover, induction of CYP1A2, especially by omeprazole and lansoprazole, may increase the serum concentration of N-desmethylclozapine, which can accumulate in lymphocytes and may achieve toxic levels. Another hypothesis that may explain hematological adverse drug reactions is competitive inhibition of CYP2C19, which may contribute to increased serum concentrations of toxic metabolites</style></abstract><notes><style face="normal" font="default">DA - 20170314IS - 1538-1145 (Electronic)IS - 1527-4160 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1097/PRA.0000000000000223</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28291036">PM:28291036</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Psychiatr Pract\2017-23-114-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Psychiatr Pract\2017-23-114-20.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170314, Wicinski M</style></custom2><misc3><style face="normal" font="default">10.1097/PRA.0000000000000223</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41484</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Haber,R.</style></author><author><style face="normal" font="default"> Ram-Wolff,C.</style></author><author><style face="normal" font="default"> Laly,P.</style></author><author><style face="normal" font="default"> Bagot,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Venereology, Universite Paris 13, Bobigny, Saint Louis Hospital, Paris, France</style></auth-address><titles><title><style face="normal" font="default">Focal Pegylated Liposomal Doxorubicin-Induced Urticarialike Reaction at Cutaneous Transformed Sezary Lesions</style></title><secondary-title><style face="normal" font="default">JAMA Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JAMA Dermatol</style></abbr-1></periodical><pages end="476" start="475">475-476</pages><volume><style face="normal" font="default">153</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword></keywords><dates><year Day="29" Month="3" Year="2017">2017/3/29</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170329IS - 2168-6084 (Electronic)IS - 2168-6068 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1001/jamadermatol.2017.0038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28355426">PM:28355426</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JAMA Dermatol\2017-153-475-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JAMA Dermatol\2017-153-475-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170329, Haber R</style></custom2><misc3><style face="normal" font="default">10.1001/jamadermatol.2017.0038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41485</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mahesh,P.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonary Medicine, JSS Medical College, JSS University, Mysore, Karnataka, India</style></auth-address><titles><title><style face="normal" font="default">Evaluation of asthma severity: Relevance of total serum IgE, sputum and peripheral eosinophilia</style></title><secondary-title><style face="normal" font="default">Lung India</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Lung India</style></abbr-1></periodical><pages end="291" start="290">290-291</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Medicine</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170505IS - 0970-2113 (Print)IS - 0970-2113 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/lungindia.lungindia_109_17</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28474660">PM:28474660</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170505, Mahesh PA</style></custom2><misc3><style face="normal" font="default">10.4103/lungindia.lungindia_109_17</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41486</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dangi,B.M.</style></author><author><style face="normal" font="default"> Bhise,A.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Physiotherapy, Government Spine Institute and Physiotherapy College, Civil Hospital Campus, Ahmedabad, Gujarat, India</style></auth-address><titles><title><style face="normal" font="default">Cotton dust exposure: Analysis of pulmonary function and respiratory symptoms</style></title><secondary-title><style face="normal" font="default">Lung India</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Lung India</style></abbr-1></periodical><pages end="149" start="144">144-149</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">abnormalities</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bronchitis</style></keyword><keyword><style face="normal" font="default"> Byssinosis</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Government</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Peak expiratory flow</style></keyword><keyword><style face="normal" font="default"> Peak Expiratory Flow Rate</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Cotton industry workers are exposed to various hazards in the different departments of textile factories. The major health problems associated with cotton dust are respiratory problems, byssinosis, bronchitis and asthma. OBJECTIVE: To study the effect of cotton dust exposure on pulmonary function and respiratory symptoms. SETTINGS AND DESIGN: This cross-sectional observational study was conducted at cotton mill in the Ahmedabad city. MATERIALS AND METHODS: One hundred cotton mill workers of the weaving and spinning area participated in this study while 100 age- and gender-matched male subjects living in the residential area served as the control group. A questionnaire was used to inquire about respiratory symptoms and spirometry was done in both the groups. STATISTICAL ANALYSIS USED: Student's t-test was used to find the difference between spirometric parameters, and Chi-square test was used to find the difference between respiratory symptoms. RESULTS: Respiratory symptoms were statistically significantly more common in the cotton mill workers compared to control group. Cotton mill workers group also showed significant (P &lt; 0.0001) decrease in forced expiratory volume in 1 s (FEV1), ratio of FEV1 and forced vital capacity (FVC) and peak expiratory flow rate, and no significant difference of FVC between groups. There was an association of duration of exposure and symptoms with spirometric abnormality. CONCLUSION: Cotton mill workers showed a significant decrease in spirometric parameters and increase in respiratory symptoms. As the duration of exposure and symptoms increased, spirometric abnormality increased</style></abstract><notes><style face="normal" font="default">DA - 20170331IS - 0970-2113 (Print)IS - 0970-2113 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/0970-2113.201319</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28360462">PM:28360462</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Lung India\2017-34-144-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Lung India\2017-34-144-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170331, Dangi BM</style></custom2><misc3><style face="normal" font="default">10.4103/0970-2113.201319</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41487</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kumar,R.M.</style></author><author><style face="normal" font="default"> Pajanivel,R.</style></author><author><style face="normal" font="default"> Koteeswaran,G.</style></author><author><style face="normal" font="default"> Menon,S.K.</style></author><author><style face="normal" font="default"> Charles,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonary Medicine, Mahatma Gandhi Medical College and Research Institute, Puducherry, India</style></auth-address><titles><title><style face="normal" font="default">Correlation of total serum immunoglobulin E level, sputum, and peripheral eosinophil count in assessing the clinical severity in bronchial asthma</style></title><secondary-title><style face="normal" font="default">Lung India</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Lung India</style></abbr-1></periodical><pages end="261" start="256">256-261</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory mediators</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> pulmonary function test</style></keyword><keyword><style face="normal" font="default"> Pulmonary Medicine</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> serum IgE levels</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> sputum eosinophil</style></keyword><keyword><style face="normal" font="default"> Sputum eosinophilia</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">CONTEXT: Asthma is a chronic inflammatory disorder of the airway with involvement of various cellular populations and release of many inflammatory mediators. Eosinophils and serum immunoglobulin E (IgE) are considered a good marker of airway inflammation in asthma. The correlation of clinical assessment with various markers of airway inflammation in asthma is not well established in the Indian population. AIMS: This study aims to study the correlation of serum IgE, sputum eosinophil count, and peripheral eosinophil count with clinical severity of Asthma. METHODS: This is a cross-sectional study involving 76 stable asthmatic patients of 18-60 years of age attending the pulmonary medicine OPD. Spirometry measured at baseline. Participants were categorized according to the GINA criteria based on clinical symptoms and pulmonary function test. Blood samples were collected for peripheral eosinophil count, serum IgE levels, and sputum samples for eosinophil count. All three parameters were compared with severity of asthma. The correlation of sputum eosinophil count, peripheral eosinophil count, and serum IgE with severity of asthma was analyzed by Pearson's Chi-square test, Fisher's exact test, and the correlation coefficient was reported together with standard error of the estimate. RESULTS: The mean age of patients in our study was 37.42 years and 56.6% were male. There was a significant inverse correlation between serum IgE levels and predicted forced expiratory volume 1 s (FEV1). Sputum eosinophilia was significantly seen in severe persistent asthma patients (19.7%). There was a significant inverse correlation between sputum eosinophil count and predicted FEV1and forced vital capacity. We also found there was a significant association between peripheral eosinophil count, sputum eosinophil count, and elevated serum IgE (g100 IU/mL) with severe persistent asthma. CONCLUSIONS: The assessment of sputum eosinophil count is simple, inexpensive, noninvasive, and direct measurement of airway inflammation. It could be the preferred method in monitoring airway inflammation and guided management in day-to-day practice</style></abstract><notes><style face="normal" font="default">DA - 20170505IS - 0970-2113 (Print)IS - 0970-2113 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/lungindia.lungindia_73_16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28474652">PM:28474652</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170505, Kumar RM</style></custom2><misc3><style face="normal" font="default">10.4103/lungindia.lungindia_73_16</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41488</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nassiri-Kashani,M.</style></author><author><style face="normal" font="default"> Nassiri-Kashani,M.H.</style></author><author><style face="normal" font="default"> Ghafari,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Associate Professor, Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran.</style></auth-address><titles><title><style face="normal" font="default">Evaluation of occupational allergic contact dermatitis and its related factors in Iran</style></title><secondary-title><style face="normal" font="default">Med J Islam Repub Iran</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Med J Islam Repub Iran</style></abbr-1></periodical><pages end="" start="468">468-</pages><volume><style face="normal" font="default">30</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Employment</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Foot</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Healthcare workers</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Leprosy</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Occupation</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Background: Occupational contact dermatitis, especially in hand, is one of the most common occupational disorders. The present study aimed at evaluating patients with occupational allergic contact dermatitis (ACD) caused by common allergens based on occupation type and disease history. Methods: This cross-sectional study aimed at evaluating the data of the patients with probable diagnosis of ACD in Center for Research and Training in Skin Diseases and Leprosy (CRTSDL) in Iran. In the present study, 946 patients were assessed from different regions of Iran. One hundred fifty-one cases with positive patch test and relevant exposure were entered into the study; data related to their occupation and disease activity history were evaluated and recorded. Then, factors related to disease activity history were assessed considering the occupational groups and common exposures. Results: Nickel sulphate was the most common allergen in the 151 patients. Disease activity was constant in 29.8% of the patients; it increased in 27.8%, and decreased just before doing the patch test in 42.4%. Of the patients, 52.3% were getting worse during the working days. Occupational groups were significantly different in age and gender. Disease duration was also different in the occupational groups (p=0.001). The least disease duration was observed in healthcare workers, and the most in service workers. Lesions in the foot were related to period of employment. In administrative work group, (teachers, technicians and housewives) disease activity was decreased in the most cases, while it was increased in most patients of service workers (p=0.086). Conclusion: The present study, similar to previous reports, revealed that nickel sulphate is the most common allergen in ACD cases. Moreover, it was found that the symptoms of disease activity remained constant or increased in a significant proportion of the cases during the working days. Therefore, these workers should seriously follow up on this matter and change their occupation, or limit the exposure to allergens</style></abstract><notes><style face="normal" font="default">DA - 20170511IS - 1016-1430 (Print)IS - 1016-1430 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28491843">PM:28491843</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Med J Islam Repub Iran\2016-30-468.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Med J Islam Repub Iran\2016-30-468.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170511, Nassiri-Kashani M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41489</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">How,K.N.</style></author><author><style face="normal" font="default"> Tang,M.M.</style></author><author><style face="normal" font="default"> Kaur,R.</style></author><author><style face="normal" font="default"> Johar,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hospital Kuala Lumpur, Department of Dermatology, Kuala Lumpur, Malaysia.</style></auth-address><titles><title><style face="normal" font="default">Contact sensitisation in adults: a 5-year retrospective review in hospital Kuala Lumpur</style></title><secondary-title><style face="normal" font="default">Med J Malaysia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Med J Malaysia</style></full-title></periodical><pages end="118" start="113">113-118</pages><volume><style face="normal" font="default">72</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Foot</style></keyword><keyword><style face="normal" font="default"> Foot eczema</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Fragrance mix</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand eczema</style></keyword><keyword><style face="normal" font="default"> Healthcare workers</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Malaysia</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> methylchloroisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Miconazole</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Palladium</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Potassium</style></keyword><keyword><style face="normal" font="default"> Potassium Dichromate</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Sensitisation</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Thimerosal</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: The pattern of contact sensitisation should be monitored in order to detect the changing trend of sensitising allergens. We aim to evaluate contact sensitisation in adults suspected to have allergic contact dermatitis. METHODS: This is a five-year retrospective review on contact sensitisation in adults patch-tested with the European Standard and extended series between 2011 and 2015 in the Department of Dermatology, Hospital Kuala Lumpur. RESULTS: There were 689 adults (M:F= 1:2.04; mean age 40.5 years) who were patch-tested. The majority (175, 25.4%) were white collar workers and 118 (17.1%) were healthcare workers. The provisional diagnoses of patients included contact dermatitis (80.8%); endogenous eczema (7.9%); hand eczema (3.2%); hand and foot eczema (3.5%); foot eczema (1.4%) and photodermatitis (1.2%). The allergens selected for testing were based on past and present history of exposure. Almost all (688, 99.8%) were patch-tested with the European standard allergens and 466 (67.6%) were tested with the extended series. About three quarter (528, 76.6%) developed at least one positive reaction. The top five most frequent reactions were to nickel sulphate (35.3%); potassium dichromate (16.5%); methylchloroisothiazolinone (12.9%), fragrance mix I (12.6%), and cobalt chloride (10.2%). The commonest sensitisations identified in the extended series were palladium chloride (23/105, 21.9%), stannous chloride (18/85, 21.2%), miconazole (7/44, 15.9%), gold(I)sodium thiosulfate (16/105, 15.2%) and thimerosal (29/202, 14.4%). CONCLUSION: Contact sensitisation was detected in 76.6% of adults patch-tested. Nickel sulphate was found to be the most frequently sensitising allergen. The rising prevalence of methylchloroisothiazolinone/methylisothiazolinone sensitization poses significant concern</style></abstract><notes><style face="normal" font="default">DA - 20170505IS - 0300-5283 (Print)IS - 0300-5283 (Linking)LA - engPT - Journal ArticleCO - Malaysia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28473674">PM:28473674</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Med J Malaysia\2017-72-113-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Med J Malaysia\2017-72-113-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170505, How KN</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41490</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,S.K.</style></author><author><style face="normal" font="default"> Seok,H.</style></author><author><style face="normal" font="default"> Park,H.J.</style></author><author><style face="normal" font="default"> Han,K.</style></author><author><style face="normal" font="default"> Kang,S.W.</style></author><author><style face="normal" font="default"> Ban,J.Y.</style></author><author><style face="normal" font="default"> Jung,H.J.</style></author><author><style face="normal" font="default"> Kim,K.I.</style></author><author><style face="normal" font="default"> Lee,B.J.</style></author><author><style face="normal" font="default"> Kim,J.</style></author><author><style face="normal" font="default"> Chung,J.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Kohwang Medical Research Institute, School of Medicine, Kyung Hee University, Seoul, South Korea</style></auth-address><titles><title><style face="normal" font="default">Association Between Secretoglobin Family 3A Member 2 (SCGB3A2) Gene Polymorphisms and Asthma in a Korean Population</style></title><secondary-title><style face="normal" font="default">Med Sci Monit</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Med Sci Monit</style></abbr-1></periodical><pages end="1885" start="1880">1880-1885</pages><volume><style face="normal" font="default">23</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Codon</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Promoter</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> transcription factor</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="default">BACKGROUND Secretoglobin family 3A member 2 (SCGB3A2) plays an important role in secreting lung surfactant protein, which is a downstream target of thyroid transcription factor. MATERIAL AND METHODS We investigated whether single-nucleotide polymorphisms (SNPs) of SCGB3A2 gene contribute to susceptibility to asthma. To explore this possible association, 2 promoter SNPs (rs6882292, 659 G/A and rs1368408, -112 G/A) and missense SNP (rs151333009, stop codon) were tested in SCGB3A2 gene in 101 asthma patients and 377 healthy control subjects. SNPStats was used to obtain odds ratio (OR), 95% confidence intervals (CI), and P value adjusted for age and sex as covariables. Logistic regression method in each model (dominant, recessive, and log-additive) was applied to analyze genetic data. RESULTS rs151333009 SNP showed a monomorphic genotype. Two promoter SNPs (rs6882292, -659 G/A and rs1368408, -112 G/A) showed significant association with asthma (rs6882292, OR=2.66, 95% CI=1.42-5.01, p=0.0033 in dominant model, OR=2.45, 95% CI=1.33-4.54, p=0.0055 in log-additive model; rs1368408, OR=1.59, 95% CI=1.02-2.49, p=0.041 in dominant model, OR=3.02, 95% CI=1.15-7.90, p=0.03 in recessive model, OR=1.63, 95% CI=1.63, 95% CI=1.12-2.37, p=0.012 in log-additive model). CONCLUSIONS These results suggest that the promoter SNPs (rs6882292 and rs1368408) of SCGB3A2 gene may contribute to susceptibility to asthma in a Korean population</style></abstract><notes><style face="normal" font="default">DA - 20170419IS - 1643-3750 (Electronic)IS - 1234-1010 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.12659/MSM.903983</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28422086">PM:28422086</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Med Sci Monit\2017-23-1880-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Med Sci Monit\2017-23-1880-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170419, Kim SK</style></custom2><misc3><style face="normal" font="default">10.12659/MSM.903983</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41491</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,Y.X.</style></author><author><style face="normal" font="default"> Cheng,H.Y.</style></author><author><style face="normal" font="default"> Li,L.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">aDepartment of Dermatology, Beijing Friendship Hospital, Capital Medical University bDepartment of Dermatology, Beijing Aerospace General Hospital, Beijing, China</style></auth-address><titles><title><style face="normal" font="default">Prevalence and risk factors of contact dermatitis among clothing manufacturing employees in Beijing: A cross-sectional study</style></title><secondary-title><style face="normal" font="default">Medicine (Baltimore)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Medicine (Baltimore)</style></abbr-1></periodical><pages end="" start="e6356">e6356-</pages><volume><style face="normal" font="default">96</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Beijing</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Clothing</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Contact</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> Leather</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Manufacturing Industry</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Occupation</style></keyword><keyword><style face="normal" font="default"> Occupational Diseases</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Surveys and Questionnaires</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">Little is known about the epidemiology of contact dermatitis (CD) in the Chinese clothing industry. This study aimed to investigate the prevalence and some risk factors of contact dermatitis among clothing manufacturing employees in Beijing.This cross-sectional study was conducted by interview using self-administered questionnaires and skin examination between May and August in 2016. Five-hundred twenty-nine employees who had worked at sewing, ironing, and as managers at 12 clothing manufacturing factories were studied.The overall 1-year prevalence of CD among the clothing employees was 28.5% (151/529 employees), with significantly higher prevalence among ironing workers (50%) and sewers (31.7%) compared with managers (12.7%; P &lt; 0.001, n = 529). A significant association was noticed between the 1-year prevalence of CD and types of occupation (sewers and ironing workers versus managers, respectively), exposure to garment materials (leather and feather), dry skin, allergic rhinitis, age, and smoking.Among employees in Chinese clothing industry, sewers and ironing workers had a higher 1-year prevalence of CD than managers. It is noteworthy that exposure to leather and feather materials and the types of manual work are associated with CD, as well as dry skin and allergic rhinitis</style></abstract><notes><style face="normal" font="default">DA - 20170322IS - 1536-5964 (Electronic)IS - 0025-7974 (Linking)LA - engPT - Journal ArticlePT - Observational StudySB - AIMSB - IMCO - China -</style></notes><work-type><style face="normal" font="default">10.1097/MD.0000000000006356</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28328819">PM:28328819</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Medicine (Baltimore)\2017-96-e6356.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Medicine (Baltimore)\2017-96-e6356.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170322, Chen YX</style></custom2><misc3><style face="normal" font="default">10.1097/MD.0000000000006356</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41492</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Escudero,J.B.</style></author><author><style face="normal" font="default"> Gonzalez,M.J.</style></author><author><style face="normal" font="default"> Antolin Amerigo,D.</style></author><author><style face="normal" font="default"> Rodriguez Rodriguez,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Therapeutic management protocol for severe allergic reactions in the Emergency Department</style></title><secondary-title><style face="normal" font="default">Medicine (Madrid)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Medicine (Madrid)</style></full-title></periodical><pages end="1808" start="1804">1804-1808</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">30</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Alergia</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anafilaxia</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Differential diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Edema de glotis</style></keyword><keyword><style face="normal" font="default"> Edema of the glottis</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Status asmaticus</style></keyword><keyword><style face="normal" font="default"> Status Asthmaticus</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Tratamiento</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><isbn><style face="normal" font="default">0304-5412</style></isbn><abstract><style face="normal" font="default">ResumenIntroducci+¦n Las urgencias m+ís relevantes en alergolog+¡a son el estado asm+ítico, la anafilaxia grave y el edema de glotis. Cada una de estas tres entidades requiere un reconocimiento r+ípido al tratarse de emergencias m+®dicas. Estado asm+ítico Un broncoespasmo puede llegar a ser tan intenso que puede provocar un estado de compromiso vital, denominado status asmaticus. Anafilaxia Puede estar provocada por m+¦ltiples agentes, siendo los alimentos y los f+írmacos las causas m+ís frecuentes. Edema de glotis Puede ser provocado de forma aislada o estar asociado a edema en otras localizaciones. Diagn+¦stico diferencial En cada uno de estos cuadros es fundamental el diagn+¦stico diferencial para asegurar un correcto tratamiento. AbstractIntroduction Most relevant emergencies in allergology are the status asthmaticus, severe anaphylaxis and edema of the glottis. Each of these three entities requires a rapid examination as they are medical emergencies. Status asthmaticus A bronchospasm can be so intense it can cause a respiratory compromise called status asthmaticus. Anaphylaxis It can be caused by multiple agents, being food and drugs the most frequent triggers. Edema of the glottis It can be caused on its own or associated to edema in other locations. Differential diagnosis In each of these cases it is key to perform a differential diagnosis to ensure a correct treatment</style></abstract><notes><style face="normal" font="default">LA - SPA CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.med.2017.03.017</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.med.2017.03.017</url></web-urls></urls><custom2><style face="normal" font="default">20170512, Escudero JB</style></custom2><misc3><style face="normal" font="default">10.1016/j.med.2017.03.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41493</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Escudero,J.B.</style></author><author><style face="normal" font="default"> Gonzalez,M.J.</style></author><author><style face="normal" font="default"> Antolin Amerigo,D.</style></author><author><style face="normal" font="default"> Soto,M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Alergias profesionales. Asma relacionada con el medio laboral. Dermatitis de origen ocupacional</style></title><secondary-title><style face="normal" font="default">Medicine (Madrid)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Medicine (Madrid)</style></full-title></periodical><pages end="1785" start="1777">1777-1785</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">30</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Alergia</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Asma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bronquitis eosinof+¡lica</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatosis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Eosinophilic bronchitis</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity Pneumonitis</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> Neumonitis por hipersensibilidad</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> occupational asthma</style></keyword><keyword><style face="normal" font="default"> Ocupacional</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tratamiento</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><isbn><style face="normal" font="default">0304-5412</style></isbn><abstract><style face="normal" font="default">ResumenDefinici+¦n El asma ocupacional es el asma producida por exposici+¦n a causas existentes en el medio laboral y que no se produce fuera de este +ímbito profesional. Clasificaci+¦n Existen dos tipos distintos de asma ocupacional, inmunol+¦gica y no inmunol+¦gica, dependiendo del mecanismo patog+®nico e histopatol+¦gico implicado. Etiopatogenia En su patogenia influyen mecanismos gen+®ticos y mecanismos propios de la sustancia sensibilizante. Diagn+¦stico Para su diagn+¦stico es necesario demostrar que el paciente presenta asma causada en su medio laboral por medio de estudios alergol+¦gicos o inmunol+¦gicos. Dermatosis profesional Es una afectaci+¦n de la piel, mucosas o anexos, de origen f+¡sico o qu+¡mico, que es directa o indirectamente causada, condicionada, mantenida o agravada por todo aquello que sea utilizado en la actividad profesional o exista en el ambiente de trabajo, y que obliguen a una interrupci+¦n del trabajo de una forma permanente, temporal o recidivante. Tratamiento El +¦nico tratamiento eficaz de todas estas patolog+¡as es apartar al paciente de la fuente que le provoque la enfermedad, conllevando en ocasiones importantes dificultades m+®dico-legales. AbstractDefinition Occupational asthma is produced by an exposure to causes existing in the work environment and it is not produced outside this professional area. Classification There are two types of occupational asthma: immunological and non-immunological, depending on the pathogenic and histological mechanisms involved. Etiopathogenesis Its pathogenesis is influenced by genetic mechanisms and mechanisms inherent to the sensitising substance. Diagnosis In order to establish a diagnosis, it is necessary to prove that the patient presents asthma caused in the work place by means of allergy or inmmunological studies. Occupational dermatosis It is an alteration of the skin, mucosa or annexes, of physical or chemical origin, that is directly or indirectly caused, conditioned, maintained or aggravated by anything used in the professional activity or that exists in the work environment, forcing to interrupt work in a permanent, temporary or relapsing form. Treatment The only efficient treatment for all these conditions is to separate the patient from the source of the disease, which could at times cause medico-legal difficulties</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.med.2017.03.013</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.med.2017.03.013</url></web-urls></urls><custom2><style face="normal" font="default">20170512, Escudero JB</style></custom2><misc3><style face="normal" font="default">10.1016/j.med.2017.03.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41494</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bravo-Soto,G.A.</style></author><author><style face="normal" font="default"> Harismendy,C.</style></author><author><style face="normal" font="default"> Rojas,P.</style></author><author><style face="normal" font="default"> Silva,R.</style></author><author><style face="normal" font="default"> von Borries,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Facultad de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile</style></auth-address><titles><title><style face="normal" font="default">Is dexamethasone as effective as other corticosteroids for acute asthma exacerbation in children?</style></title><secondary-title><style face="normal" font="default">Medwave</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Medwave</style></full-title></periodical><pages end="" start="e6931">e6931-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">Suppl2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">acute asthma</style></keyword><keyword><style face="normal" font="default"> Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Chile</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Dexamethasone</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized trial</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword></keywords><dates><year Day="18" Month="4" Year="2017">2017/4/18</year></dates><abstract><style face="normal" font="default">Dexamethasone has been proposed as an alternative in the treatment of acute asthma exacerbation in children. It allows shortening the duration of treatment, reducing costs and adverse effects. However, it is not clear whether its efficacy is similar to the traditional steroid regimen. To answer this question, we searched in Epistemonikos database, which is maintained by screening multiple information sources. We identified six systematic reviews including 10 randomized trials. We extracted data, conducted a meta-analysis and generated a summary of findings table using the GRADE approach. We concluded dexamethasone has probably fewer adverse effects than others corticosteroids, and might be equally effective in reducing hospitalizations and revisits</style></abstract><notes><style face="normal" font="default">DA - 20170421IS - 0717-6384 (Electronic)IS - 0717-6384 (Linking)LA - spaLA - engPT - Journal ArticleCO - Chile -</style></notes><work-type><style face="normal" font="default">10.5867/medwave.2017.6931</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28430773">PM:28430773</url></web-urls></urls><custom2><style face="normal" font="default">20170421, Bravo-Soto GA</style></custom2><misc3><style face="normal" font="default">10.5867/medwave.2017.6931</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41495</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Contestable,J.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">U.S. Navy Aviation Medicine, Carrier Air Wing TWO, Naval Base Coronado Building 601, McCain Boulevard, San Diego, CA 92135-7046</style></auth-address><titles><title><style face="normal" font="default">Jet Fuel-Associated Occupational Contact Dermatitis</style></title><secondary-title><style face="normal" font="default">Mil Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Mil Med</style></abbr-1></periodical><pages end="e1873" start="e1870">e1870-e1873</pages><volume><style face="normal" font="default">182</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Aviation</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emollient</style></keyword><keyword><style face="normal" font="default"> Emollients</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> immunomodulators</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Occupational Health</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient Education</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Solvents</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword><keyword><style face="normal" font="default"> Workplace</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Occupational contact dermatitis is a ubiquitous problem. Sailors onboard U.S. Navy vessels are at high risk given the multitude of potential workplace exposures. Solvents, petrochemicals, and fuels are abundant and can cause irritant or allergic contact dermatitis. Symptoms of contact dermatitis can cause inability to work and, if chronic, may require a change in rating or job. Prevention of this issue requires patient education about the risks and correct personnel protective equipment. Even with preventative strategies in place, exposures and cases of contact dermatitis will occur. Treatment consists of topical steroids and immunomodulators, as well as barrier creams and emollients. The goal of treatment is to fully restore the skin's natural barrier and prevent further exposure. MATERIALS AND METHODS: A classic case of jet fuel-associated contact dermatitis is reviewed. A literature review utilizing PubMed, Google Scholar, and Google Search was conducted to elucidate our understanding of this issue, current occupational health guidelines, preventative approaches, and treatments. RESULTS: This case report provides guidance and recommendations for providers who encounter contact dermatitis related to petrochemicals, such as jet fuel. The literature review revealed limited knowledge surrounding in vivo human skin effects of jet fuel, specifically JP-5. Even larger gaps were found in our understanding of, and guidelines for, protective modalities against jet fuel exposure and dermatitis. CONCLUSION: A case is presented to facilitate recognition of jet fuel contact dermatitis and guidance for treatment and prevention. Given our current limited knowledge and guidelines concerning protective equipment and skin protectants, multiple proposals for future studies are suggested</style></abstract><notes><style face="normal" font="default">DA - 20170314IS - 1930-613X (Electronic)IS - 0026-4075 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.7205/MILMED-D-16-00217</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28290976">PM:28290976</url></web-urls></urls><custom2><style face="normal" font="default">20170314, Contestable JJ</style></custom2><misc3><style face="normal" font="default">10.7205/MILMED-D-16-00217</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41496</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Peterson,M.R.</style></author><author><style face="normal" font="default"> Wong,P.H.</style></author><author><style face="normal" font="default"> Dickson,S.D.</style></author><author><style face="normal" font="default"> Coop,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy and Immunology, Wilford Hall Ambulatory Surgical Center, 2200 Bergquist Drive, Lackland Air Force Base, TX 78236</style></auth-address><titles><title><style face="normal" font="default">Allergic Stomatitis From Orthodontic Adhesives</style></title><secondary-title><style face="normal" font="default">Mil Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Mil Med</style></abbr-1></periodical><pages end="e1885" start="e1883">e1883-e1885</pages><volume><style face="normal" font="default">182</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acrylate</style></keyword><keyword><style face="normal" font="default"> Adhesives</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Stomatitis</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Type IV hypersensitivity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">We report a case of a type IV hypersensitivity reaction causing oral stomatitis, presumed to be the result of common dental adhesives. The case was diagnosed using patch testing to the dental adhesives that were used in the patient. Both of the adhesives tested contained a form of acrylate that is being seen more frequently in the literature as a cause of type IV hypersensitivity reactions. Metals can cause allergic reactions; however, other contact items need to be considered as a cause of oral allergic reactions. Cases of allergic stomatitis are rising and there is question if all-in-one adhesives may be contributing to this rise</style></abstract><notes><style face="normal" font="default">DA - 20170314IS - 1930-613X (Electronic)IS - 0026-4075 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.7205/MILMED-D-16-00232</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28290980">PM:28290980</url></web-urls></urls><custom2><style face="normal" font="default">20170314, Peterson MR</style></custom2><misc3><style face="normal" font="default">10.7205/MILMED-D-16-00232</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41497</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Solidoro,P.</style></author><author><style face="normal" font="default"> Patrucco,F.</style></author><author><style face="normal" font="default"> Fagoonee,S.</style></author><author><style face="normal" font="default"> Pellicano,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonology U, Cardiothoracic and Vascular Department, AOU Citta della Salute e della Scienza di Torino, Turin, ItalyUnit of Gastroenterology, Molinette Hospital, Turin, Italy</style></auth-address><titles><title><style face="normal" font="default">Asthma and gastro-oesophageal reflux disease: a multidisciplinary point of view</style></title><secondary-title><style face="normal" font="default">Minerva Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Minerva Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Abdomen</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Exhaled Breath</style></keyword><keyword><style face="normal" font="default"> exhaled breath condensate</style></keyword><keyword><style face="normal" font="default"> Gastric Juice</style></keyword><keyword><style face="normal" font="default"> Gastroenterology</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pH</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> proton pump inhibitor</style></keyword><keyword><style face="normal" font="default"> Proton pump inhibitors</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> REACH</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Reflex</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Thorax</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword></keywords><dates><year Day="4" Month="4" Year="2017">2017/4/4</year></dates><abstract><style face="normal" font="default">Asthma and gastro-oesophageal reflux (GORD) are widespread and potentially coexisting diseases. Incidence and prevalence of concomitant asthma and GORD are highly variable among studies. This is mainly due to the heterogeneity of study designs. To explain a potential link, it has been proposed some pathophysiological anomaly such as the altered pressure gradient between thorax and abdomen, the parasympathethic reflex, the hightened bronchial reactivity and chemical effects of microaspired gastric juice. An accurate diagnosis of asthma and GORD are pivotal in order to lead effective treatment and to reach a significant positive outcome, in terms of quality of life and respiratory function amelioration. Gastroenterological evaluation of GORD includes the empiric proton pump-inhibitors (PPIs) trial, the esophageal pH monitoring and endoscopic evaluation. Besides spirometric investigations, pulmonologist have more specific examens such as bronchoalveolar lavage and exhaled breath condensate. Actually, international recommendations regarding the management of asthma, suggest the assessment of potential comorbidities, including the presence of GORD, mostly in children, only in patients with normal pulmonary functional tests with frequent respiratory symptoms, and in case of uncontrolled asthma. Symptomatic gastro-oesophageal reflux patients should be treated, but those with uncontrolled asthma should not be treated with anti-reflux drugs unless they are symptomatic for reflux. This review explores the state of the art about the pathogenesis and the management of relationship between asthma and GORD</style></abstract><notes><style face="normal" font="default">DA - 20170405IS - 1827-1669 (Electronic)IS - 0026-4806 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.23736/S0026-4806.17.05181-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28378957">PM:28378957</url></web-urls></urls><custom2><style face="normal" font="default">20170405, Solidoro P</style></custom2><misc3><style face="normal" font="default">10.23736/S0026-4806.17.05181-3</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41498</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Naik,R.</style></author><author><style face="normal" font="default"> Khan,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Oncology, HCG Hospital, Bangalore, Karnataka 560027, IndiaDepartment of Medical Affairs, Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat 382210, India</style></auth-address><titles><title><style face="normal" font="default">Doceaqualip in a patient with prostate cancer who had an allergic reaction to conventional docetaxel: A case report</style></title><secondary-title><style face="normal" font="default">Mol Clin Oncol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Mol Clin Oncol</style></full-title></periodical><pages end="343" start="341">341-343</pages><volume><style face="normal" font="default">6</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Ethanol</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Lipid</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Pharmaceuticals</style></keyword><keyword><style face="normal" font="default"> Premedication</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">Docetaxel has been widely used in the treatment of several cancers, including adenocarcinoma of the prostate gland. As docetaxel is insoluble in water, it must be administered with polysorbate 80 and ethanol, which are known to cause hypersensitivity reactions. Premedication with corticosteroids and antihistamines is advocated prior to docetaxel administration; however, toxicities, occasionally fatal, have been reported, even with corticosteroid premedication. We herein report the case of a patient with adenocarcinoma of the prostate, with bone metastasis and an Eastern Cooperative Oncology Group performance status of &lt;2, who developed an allergic reaction to conventional docetaxel (Taxotere), despite being premedicated with corticosteroids and antihistamines. The patient was managed with corticosteroids and antihistamines, and was later started on Doceaqualip, a nanosomal docetaxel lipid suspension. Doceaqualip was well-tolerated by the patient and 5 cycles were subsequently administered, without any adverse reactions. Adenocarcinoma also regressed, as evidenced by positron emission tomography/computed tomography</style></abstract><notes><style face="normal" font="default">DA - 20170428IS - 2049-9450 (Print)IS - 2049-9450 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.3892/mco.2017.1147</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28451410">PM:28451410</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mol Clin Oncol\2017-6-341-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mol Clin Oncol\2017-6-341-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170428, Naik R</style></custom2><misc3><style face="normal" font="default">10.3892/mco.2017.1147</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41499</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ehlers,A.</style></author><author><style face="normal" font="default"> Xie,W.</style></author><author><style face="normal" font="default"> Agapov,E.</style></author><author><style face="normal" font="default"> Brown,S.</style></author><author><style face="normal" font="default"> Steinberg,D.</style></author><author><style face="normal" font="default"> Tidwell,R.</style></author><author><style face="normal" font="default"> Sajol,G.</style></author><author><style face="normal" font="default"> Schutz,R.</style></author><author><style face="normal" font="default"> Weaver,R.</style></author><author><style face="normal" font="default"> Yu,H.</style></author><author><style face="normal" font="default"> Castro,M.</style></author><author><style face="normal" font="default"> Bacharier,L.B.</style></author><author><style face="normal" font="default"> Wang,X.</style></author><author><style face="normal" font="default"> Holtzman,M.J.</style></author><author><style face="normal" font="default"> Haspel,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St Louis, MO, USA</style></auth-address><titles><title><style face="normal" font="default">BMAL1 links the circadian clock to viral airway pathology and asthma phenotypes</style></title><secondary-title><style face="normal" font="default">Mucosal Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Mucosal Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> Airway Resistance</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Bronchiolitis</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Circadian Rhythm</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Influenza</style></keyword><keyword><style face="normal" font="default"> Influenza A virus</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Mammals</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Mucus</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Sendai virus</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Washington</style></keyword></keywords><dates><year Day="12" Month="4" Year="2017">2017/4/12</year></dates><abstract><style face="normal" font="default">Patients with asthma experience circadian variations in their symptoms. However it remains unclear how specific aspects of this common airway disease relate to clock genes, which are critical to the generation of circadian rhythms in mammals. Here, we used a viral model of acute and chronic airway disease to examine how circadian clock disruption affects asthmatic lung phenotypes. Deletion of the core clock gene bmal1 or environmental disruption of circadian function by jet lag exacerbated acute viral bronchiolitis caused by Sendai virus (SeV) and influenza A virus in mice. Post-natal deletion of bmal1 was sufficient to trigger increased SeV susceptibility and correlated with impaired control of viral replication. Importantly, bmal1-/- mice developed much more extensive asthma-like airway changes post infection, including mucus production and increased airway resistance. In human airway samples from two asthma cohorts, we observed altered expression patterns of multiple clock genes. Our results suggest a role for bmal1 in the development of asthmatic airway disease via the regulation of lung antiviral responses to common viral triggers of asthma.Mucosal Immunology advance online publication, 12 April 2017; doi:10.1038/mi.2017.24</style></abstract><notes><style face="normal" font="default">DA - 20170412IS - 1935-3456 (Electronic)IS - 1933-0219 (Linking)LA - engPT - Journal ArticleCO - United States -CO - China -</style></notes><work-type><style face="normal" font="default">10.1038/mi.2017.24</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28401936">PM:28401936</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mucosal Immunol\20170412-EhlersA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mucosal Immunol\20170412-EhlersA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170412, Ehlers A</style></custom2><misc3><style face="normal" font="default">10.1038/mi.2017.24</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41500</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Baraldi,E.</style></author><author><style face="normal" font="default"> Galderisi,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Padua, Padua, Italy</style></auth-address><titles><title><style face="normal" font="default">Fish Oil in Pregnancy and Asthma in Offspring</style></title><secondary-title><style face="normal" font="default">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">N Engl J Med</style></full-title></periodical><pages end="" start="1191">1191-</pages><volume><style face="normal" font="default">376</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acids</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Dietary Supplements</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Fatty acid</style></keyword><keyword><style face="normal" font="default"> Fatty Acids</style></keyword><keyword><style face="normal" font="default"> Fatty Acids,Omega-3</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> fish</style></keyword><keyword><style face="normal" font="default"> Fish Oils</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Oils</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="23" Month="3" Year="2017">2017/3/23</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170322IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - LetterPT - CommentRN - 0 (Fatty Acids, Omega-3)RN - 0 (Fish Oils)SB - AIMSB - IMCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1056/NEJMc1701020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28328329">PM:28328329</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\N Engl J Med\2017-376-1191-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\N Engl J Med\2017-376-1191-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170322, Baraldi E</style></custom2><misc3><style face="normal" font="default">10.1056/NEJMc1701020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41501</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bisgaard,H.</style></author><author><style face="normal" font="default"> Bonnelykke,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Copenhagen Prospective Studies on Asthma in Childhood, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default">Fish Oil in Pregnancy and Asthma in Offspring</style></title><secondary-title><style face="normal" font="default">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">N Engl J Med</style></full-title></periodical><pages end="1192" start="1191">1191-1192</pages><volume><style face="normal" font="default">376</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acids</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dietary Supplements</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Fatty acid</style></keyword><keyword><style face="normal" font="default"> Fatty Acids</style></keyword><keyword><style face="normal" font="default"> Fatty Acids,Omega-3</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> fish</style></keyword><keyword><style face="normal" font="default"> Fish Oils</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Oils</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword></keywords><dates><year Day="23" Month="3" Year="2017">2017/3/23</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170322IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - LetterPT - CommentRN - 0 (Fatty Acids, Omega-3)RN - 0 (Fish Oils)SB - AIMSB - IMCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1056/NEJMc1701020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28328328">PM:28328328</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\N Engl J Med\2017-376-1191-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\N Engl J Med\2017-376-1191-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170322, Bisgaard H</style></custom2><misc3><style face="normal" font="default">10.1056/NEJMc1701020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41502</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Longhurst,H.</style></author><author><style face="normal" font="default"> Cicardi,M.</style></author><author><style face="normal" font="default"> Craig,T.</style></author><author><style face="normal" font="default"> Bork,K.</style></author><author><style face="normal" font="default"> Grattan,C.</style></author><author><style face="normal" font="default"> Baker,J.</style></author><author><style face="normal" font="default"> Li,H.H.</style></author><author><style face="normal" font="default"> Reshef,A.</style></author><author><style face="normal" font="default"> Bonner,J.</style></author><author><style face="normal" font="default"> Bernstein,J.A.</style></author><author><style face="normal" font="default"> Anderson,J.</style></author><author><style face="normal" font="default"> Lumry,W.R.</style></author><author><style face="normal" font="default"> Farkas,H.</style></author><author><style face="normal" font="default"> Katelaris,C.H.</style></author><author><style face="normal" font="default"> Sussman,G.L.</style></author><author><style face="normal" font="default"> JACOBS,J.</style></author><author><style face="normal" font="default"> Riedl,M.</style></author><author><style face="normal" font="default"> Manning,M.E.</style></author><author><style face="normal" font="default"> Hebert,J.</style></author><author><style face="normal" font="default"> Keith,P.K.</style></author><author><style face="normal" font="default"> Kivity,S.</style></author><author><style face="normal" font="default"> Neri,S.</style></author><author><style face="normal" font="default"> Levy,D.S.</style></author><author><style face="normal" font="default"> Baeza,M.L.</style></author><author><style face="normal" font="default"> Nathan,R.</style></author><author><style face="normal" font="default"> Schwartz,L.B.</style></author><author><style face="normal" font="default"> Caballero,T.</style></author><author><style face="normal" font="default"> Yang,W.</style></author><author><style face="normal" font="default"> Crisan,I.</style></author><author><style face="normal" font="default"> Hernandez,M.D.</style></author><author><style face="normal" font="default"> Hussain,I.</style></author><author><style face="normal" font="default"> Tarzi,M.</style></author><author><style face="normal" font="default"> Ritchie,B.</style></author><author><style face="normal" font="default"> Kralickova,P.</style></author><author><style face="normal" font="default"> Guilarte,M.</style></author><author><style face="normal" font="default"> Rehman,S.M.</style></author><author><style face="normal" font="default"> Banerji,A.</style></author><author><style face="normal" font="default"> Gower,R.G.</style></author><author><style face="normal" font="default"> sen-Kennedy,D.</style></author><author><style face="normal" font="default"> Edelman,J.</style></author><author><style face="normal" font="default"> Feuersenger,H.</style></author><author><style face="normal" font="default"> Lawo,J.P.</style></author><author><style face="normal" font="default"> Machnig,T.</style></author><author><style face="normal" font="default"> Pawaskar,D.</style></author><author><style face="normal" font="default"> Pragst,I.</style></author><author><style face="normal" font="default"> Zuraw,B.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Barts Health NHS Trust (H.L.) and St. John's Institute of Dermatology, Guy's Hospital (C.G.), London, and the Clinical Investigation and Research Unit, Royal Sussex County Hospital, Brighton</style></auth-address><titles><title><style face="normal" font="default">Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor</style></title><secondary-title><style face="normal" font="default">N Engl J Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">N Engl J Med</style></full-title></periodical><pages end="1140" start="1131">1131-1140</pages><volume><style face="normal" font="default">376</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse events</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Body Weight</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Czech Republic</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Hungary</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> rescue medication</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research Support</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Romania</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Sequence</style></keyword><keyword><style face="normal" font="default"> Sequences</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> subcutaneous</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="23" Month="3" Year="2017">2017/3/23</year></dates><abstract><style face="normal" font="default">Background Hereditary angioedema is a disabling, potentially fatal condition caused by deficiency (type I) or dysfunction (type II) of the C1 inhibitor protein. In a phase 2 trial, the use of CSL830, a nanofiltered C1 inhibitor preparation that is suitable for subcutaneous injection, resulted in functional levels of C1 inhibitor activity that would be expected to provide effective prophylaxis of attacks. Methods We conducted an international, prospective, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase 3 trial to evaluate the efficacy and safety of self-administered subcutaneous CSL830 in patients with type I or type II hereditary angioedema who had had four or more attacks in a consecutive 2-month period within 3 months before screening. We randomly assigned the patients to one of four treatment sequences in a crossover design, each involving two 16-week treatment periods: either 40 IU or 60 IU of CSL830 per kilogram of body weight twice weekly followed by placebo, or vice versa. The primary efficacy end point was the number of attacks of angioedema. Secondary efficacy end points were the proportion of patients who had a response (>/=50% reduction in the number of attacks with CSL830 as compared with placebo) and the number of times that rescue medication was used. Results Of the 90 patients who underwent randomization, 79 completed the trial. Both doses of CSL830, as compared with placebo, reduced the rate of attacks of hereditary angioedema (mean difference with 40 IU, -2.42 attacks per month; 95% confidence interval [CI], -3.38 to -1.46; and mean difference with 60 IU, -3.51 attacks per month; 95% CI, -4.21 to -2.81; P&lt;0.001 for both comparisons). Response rates were 76% (95% CI, 62 to 87) in the 40-IU group and 90% (95% CI, 77 to 96) in the 60-IU group. The need for rescue medication was reduced from 5.55 uses per month in the placebo group to 1.13 uses per month in the 40-IU group and from 3.89 uses in the placebo group to 0.32 uses per month in the 60-IU group. Adverse events (most commonly mild and transient local site reactions) occurred in similar proportions of patients who received CSL830 and those who received placebo. Conclusions In patients with hereditary angioedema, the prophylactic use of a subcutaneous C1 inhibitor twice weekly significantly reduced the frequency of acute attacks. (Funded by CSL Behring; COMPACT EudraCT number, 2013-000916-10 , and ClinicalTrials.gov number, NCT01912456 .)</style></abstract><notes><style face="normal" font="default">DA - 20170322IS - 1533-4406 (Electronic)IS - 0028-4793 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tCO - United Kingdom -CO - Italy -CO - Germany -CO - United states -CO - Australia -CO - Canada -CO - Czechia -CO - Spain -CO - Romania -CO - Hungary -CO - Israel -</style></notes><work-type><style face="normal" font="default">10.1056/NEJMoa1613627</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28328347">PM:28328347</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\N Engl J Med\2017-376-1131-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\N Engl J Med\2017-376-1131-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170322, Longhurst H</style></custom2><misc3><style face="normal" font="default">10.1056/NEJMoa1613627</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41503</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Verstraete,K.</style></author><author><style face="normal" font="default"> Peelman,F.</style></author><author><style face="normal" font="default"> Braun,H.</style></author><author><style face="normal" font="default"> Lopez,J.</style></author><author><style face="normal" font="default"> Van Rompaey,D.</style></author><author><style face="normal" font="default"> Dansercoer,A.</style></author><author><style face="normal" font="default"> Vandenberghe,I.</style></author><author><style face="normal" font="default"> Pauwels,K.</style></author><author><style face="normal" font="default"> Tavernier,J.</style></author><author><style face="normal" font="default"> Lambrecht,B.N.</style></author><author><style face="normal" font="default"> Hammad,H.</style></author><author><style face="normal" font="default"> De Winter,H.</style></author><author><style face="normal" font="default"> Beyaert,R.</style></author><author><style face="normal" font="default"> Lippens,G.</style></author><author><style face="normal" font="default"> Savvides,S.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">VIB-UGent Center for Inflammation Research, Zwijnaarde, Ghent 9052, Belgium</style></auth-address><titles><title><style face="normal" font="default">Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma</style></title><secondary-title><style face="normal" font="default">Nat Commun</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nat Commun</style></abbr-1></periodical><pages end="" start="14937">14937-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Electrostatics</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Interleukin-7</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="default"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Peru</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword></keywords><dates><year Day="3" Month="4" Year="2017">2017/4/3</year></dates><abstract><style face="normal" font="default">The pro-inflammatory cytokine thymic stromal lymphopoietin (TSLP) is pivotal to the pathophysiology of widespread allergic diseases mediated by type 2 helper T cell (Th2) responses, including asthma and atopic dermatitis. The emergence of human TSLP as a clinical target against asthma calls for maximally harnessing its therapeutic potential via structural and mechanistic considerations. Here we employ an integrative experimental approach focusing on productive and antagonized TSLP complexes and free cytokine. We reveal how cognate receptor TSLPR allosterically activates TSLP to potentiate the recruitment of the shared interleukin 7 receptor alpha-chain (IL-7Ralpha) by leveraging the flexibility, conformational heterogeneity and electrostatics of the cytokine. We further show that the monoclonal antibody Tezepelumab partly exploits these principles to neutralize TSLP activity. Finally, we introduce a fusion protein comprising a tandem of the TSLPR and IL-7Ralpha extracellular domains, which harnesses the mechanistic intricacies of the TSLP-driven receptor complex to manifest high antagonistic potency</style></abstract><notes><style face="normal" font="default">DA - 20170403IS - 2041-1723 (Electronic)IS - 2041-1723 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - France -CO - Peru -</style></notes><work-type><style face="normal" font="default">10.1038/ncomms14937</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28368013">PM:28368013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nat Commun\2017-8-14937.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nat Commun\2017-8-14937.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170403, Verstraete K</style></custom2><misc3><style face="normal" font="default">10.1038/ncomms14937</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41504</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jing,P.B.</style></author><author><style face="normal" font="default"> Cao,D.L.</style></author><author><style face="normal" font="default"> Li,S.S.</style></author><author><style face="normal" font="default"> Zhu,M.</style></author><author><style face="normal" font="default"> Bai,X.Q.</style></author><author><style face="normal" font="default"> Wu,X.B.</style></author><author><style face="normal" font="default"> Gao,Y.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pain Research Laboratory, Institute of Nautical Medicine, Jiangsu Key Laboratory of Neuroregeneration, Nantong University, Nantong, 226019, China</style></auth-address><titles><title><style face="normal" font="default">Chemokine Receptor CXCR3 in the Spinal Cord Contributes to Chronic Itch in Mice</style></title><secondary-title><style face="normal" font="default">Neurosci Bull</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Neurosci Bull</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">48/80</style></keyword><keyword><style face="normal" font="default"> Acetone</style></keyword><keyword><style face="normal" font="default"> activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Chemokine receptor</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> CXCL10</style></keyword><keyword><style face="normal" font="default"> CXCR3</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Itch</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Spinal Cord</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="default">Recent studies have shown that the chemokine receptor CXCR3 and its ligand CXCL10 in the dorsal root ganglion mediate itch in experimental allergic contact dermatitis (ACD). CXCR3 in the spinal cord also contributes to the maintenance of neuropathic pain. However, whether spinal CXCR3 is involved in acute or chronic itch remains unclear. Here, we report that Cxcr3 -/- mice showed normal scratching in acute itch models but reduced scratching in chronic itch models of dry skin and ACD. In contrast, both formalin-induced acute pain and complete Freund's adjuvant-induced chronic inflammatory pain were reduced in Cxcr3 -/- mice. In addition, the expression of CXCR3 and CXCL10 was increased in the spinal cord in the dry skin model induced by acetone and diethyl ether followed by water (AEW). Intrathecal injection of a CXCR3 antagonist alleviated AEW-induced itch. Furthermore, touch-elicited itch (alloknesis) after compound 48/80 or AEW treatment was suppressed in Cxcr3 -/- mice. Finally, AEW-induced astrocyte activation was inhibited in Cxcr3 -/- mice. Taken together, these data suggest that spinal CXCR3 mediates chronic itch and alloknesis, and targeting CXCR3 may provide effective treatment for chronic pruritus</style></abstract><notes><style face="normal" font="default">DA - 20170412IS - 1995-8218 (Electronic)IS - 1995-8218 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1007/s12264-017-0128-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28401489">PM:28401489</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Neurosci Bull\20170412-JingPB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Neurosci Bull\20170412-JingPB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170412, Jing PB</style></custom2><misc3><style face="normal" font="default">10.1007/s12264-017-0128-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41505</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gungen,A.C.</style></author><author><style face="normal" font="default"> Gungen,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Adil Can Gungen, MD. Department of Pulmonology, Sakarya University, Education and Research Hospital, Sakarya, TurkeyBelma Gungen, MD. Department of Neurology, Sakarya University, Education and Research Hospital, Sakarya, Turkey</style></auth-address><titles><title><style face="normal" font="default">Assessment of Headache in Asthma Patients</style></title><secondary-title><style face="normal" font="default">Pak J Med Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pak J Med Sci</style></abbr-1></periodical><pages end="161" start="156">156-161</pages><volume><style face="normal" font="default">33</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> Adverse effect</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Headache</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVE: Headache is a common health problem, which may present with neurological diseases and other chronic diseases, and has an adverse effect on the emotional status. We think that headache is a common disease in asthmatic patients. This study aims to evaluate the presence of headache and risk factors in patients with asthma. METHODS: Ninety-three patients with asthma and 58 healthy control subjects were included in the study. The presence of headache was evaluated according to the revised criteria of the International Classification of Headache Disorders, 2nd edition (ICDH-II). Asthma control test (ACT) was performed to determine asthma control status. The Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI) were performed in all participants. Demographic features, used medications, and presence of headaches were recorded. RESULTS: Fifty-eight patients with asthma (62.4%) had headaches, whereas only 19 control subjects (32.8%) had headaches. Thirty-two patients (34.4%) had tension-type headache, 19 patients (20.3%) had migraine-type headache, and 7 patients (7.5%) had other types of headaches. The frequency of headaches was significantly higher in patients with asthma, compared to healthy control subjects (p=0.001). There was a significant correlation between migraine-type headache and inhaled steroid use, and presence of allergies. CONCLUSION: Migraine-type and tension-type headaches are more common in patients with asthma, compared to the overall population. The frequency of migraine-type headache is higher in patients with asthma who have allergies and low respiratory function test scores</style></abstract><notes><style face="normal" font="default">DA - 20170403IS - 1682-024X (Print)IS - 1681-715X (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.12669/pjms.331.11720</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28367191">PM:28367191</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pak J Med Sci\2017-33-156-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pak J Med Sci\2017-33-156-61.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170403, Gungen AC</style></custom2><misc3><style face="normal" font="default">10.12669/pjms.331.11720</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41506</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Valls-Mateus,M.</style></author><author><style face="normal" font="default"> Marino-Sanchez,F.</style></author><author><style face="normal" font="default"> Ruiz-Echevarria,K.</style></author><author><style face="normal" font="default"> Cardenas-Escalante,P.</style></author><author><style face="normal" font="default"> Jimenez-Feijoo,R.</style></author><author><style face="normal" font="default"> Blasco-Lozano,J.</style></author><author><style face="normal" font="default"> Giner-Munoz,M.T.</style></author><author><style face="normal" font="default"> Haag,O.</style></author><author><style face="normal" font="default"> Alobid,I.</style></author><author><style face="normal" font="default"> Martin,A.M.P.</style></author><author><style face="normal" font="default"> Mullol,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Unitat de Rinologia Pediatrica, Otorhinolaringology Department, Hospital Sant Joan de Deu, Barcelona, Catalonia, Spain</style></auth-address><titles><title><style face="normal" font="default">Nasal obstructive disorders impair health-related quality of life in adolescents with persistent allergic rhinitis: a real-life study</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endoscopy</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> Hyperplasia</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Intranasal steroids</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> QOL</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Septal deviation</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treatment Failure</style></keyword><keyword><style face="normal" font="default"> VAS</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: We previously reported a higher prevalence of nasal obstructive disorders (NOD) in pediatric patients with persistent allergic rhinitis (PER) not responding to medical treatment. The aim of this study was to determine the impact of NOD on quality of life (QoL) in this population. METHODS: Real-life prospective study including 142 patients (41 children, 6-11 yo and 101 adolescents, 12-17 yo) with moderate and severe PER. After two months of medical treatment (intranasal steroids and antihistamines) patients were asked if their symptoms had improved (yes/no) and classified accordingly in R, responders and NR, non-responders. Nasal symptoms (Visual Analogue Scale, VAS), NOD (nasal endoscopy) and QoL (PRQLQ, AdolQRLQ) were also assessed. RESULTS: Sixty-nine adolescents and 24 children were included in the NR group. NR presented worse QoL overall scores in adolescents (3.16+/-1.1 vs. 1.63+/-0.99; p=0.00001) and children (2.19+/-0.82 vs. 1.51+/-0.77, p=0.02). Medical treatment failure was associated with worse outcomes in QoL (adolescents OR: 1.6, p&lt;0.0001; children OR: 1.04, p=0.036). Female adolescents presented worse QoL scores than males (3.19 vs. 2.36, p=0.001). The presence of obstructive septal deviation (OR: 1.02, p=0.005), obstructive turbinate hyperplasia (OR: 1.03, p=0.0006) and coexistence of both (OR=2.06, p=0.001) was associated with worse QoL in adolescents. A strong and highly significant correlation was found between nasal symptoms VAS and QoL. CONCLUSION: The presence of NOD, particularly in adolescents, is associated with poor QoL outcomes. Assessment of NOD in pediatric PER should be considered an essential approach to determine the response to treatment and its impact on patient's QoL. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170419IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12724</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28423474">PM:28423474</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170419-VallsMateusM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170419-VallsMateusM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170419, Valls-Mateus M</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12724</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41507</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aranda,C.S.</style></author><author><style face="normal" font="default"> Pereira,K.</style></author><author><style face="normal" font="default"> Velasco,H.</style></author><author><style face="normal" font="default"> Mallozi,M.</style></author><author><style face="normal" font="default"> Andrade,R.</style></author><author><style face="normal" font="default"> Rodrigues,W.</style></author><author><style face="normal" font="default"> Pesquero,J.B.</style></author><author><style face="normal" font="default"> Martins,A.M.</style></author><author><style face="normal" font="default"> Sole,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy, Clinical Immunology and Rheumatology, Federal University of Sao Paulo, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="default">Isoleucine and Atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adaptive</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic sensitization</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Barrier dysfunction</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Clinical phenotypes</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Isoleucine</style></keyword><keyword><style face="normal" font="default"> Latin America</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="5" Month="5" Year="2017">2017/5/5</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is one of the most common inflammatory skin diseases, especially during childhood, with an estimated prevalence of 11% in Latin America (1). The complexity of AD clinical phenotypes occurs due to the existence of different physiopathological pathways for the illness, including changes in innate and adaptive immune responses, skin barrier dysfunction and allergic sensitization (2). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170505IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12731</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28474841">PM:28474841</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170505-ArandaCS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170505-ArandaCS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170505, Aranda CS</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12731</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41508</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Couto,M.</style></author><author><style face="normal" font="default"> Barbosa,C.</style></author><author><style face="normal" font="default"> Silva,D.</style></author><author><style face="normal" font="default"> Rudnitskaya,A.</style></author><author><style face="normal" font="default"> Delgado,L.</style></author><author><style face="normal" font="default"> Moreira,A.</style></author><author><style face="normal" font="default"> Rocha,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Basic and Clinical Immunology Unit, Department of Pathology, Faculty of Medicine, University of Porto, Portugal</style></auth-address><titles><title><style face="normal" font="default">Oxidative stress in asthmatic and non-asthmatic adolescent swimmers - a breathomics approach</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Aldehydes</style></keyword><keyword><style face="normal" font="default"> Alkanes</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Athlete</style></keyword><keyword><style face="normal" font="default"> Athletes</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Chromatography</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> elite swimmers</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Exhaled Breath</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Lipid</style></keyword><keyword><style face="normal" font="default"> Lipid Peroxidation</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metabolomics</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Oxidative Stress</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Swimming</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="27" Month="4" Year="2017">2017/4/27</year></dates><abstract><style face="normal" font="default">We hypothesize that oxidative stress induced by trichloramine exposure during swimming could be related to etiopathogenesis of asthma among elite swimmers. AIM: To investigate the effect of a swimming training session on oxidative stress markers of asthmatic compared to non-asthmatic elite swimmers using exhaled breath (EB) metabolomics. METHODS: Elite swimmers annually screened in our department (n=27) were invited and those who agreed to participate (n=20, of which 9 with asthma) had EB collected (Tedlar(R) bags) before and after a swimming training session. SPME fibre (DVB/CAR/PDMS) was used to extract EB metabolites followed by a multidimensional gas chromatography analysis (GCxGC-ToFMS). Dataset comprises 8 metabolites end-products of lipid peroxidation: 5 aliphatic alkanes (nonane, 2,2,4,6,6-pentamethylheptane, decane, dodecane, and tetradecane) and 3 aldehydes (nonanal, decanal, and dodecanal). To assess exercise impact on lipid peroxidation markers, data were analyzed using Principle Component Analysis (PCA), which was run on the original data set and on the data set constructed using differences in the metabolite total areas before and after exercise session. RESULTS: Heatmap representation revealed that metabolites content decreased after exercise, both for control and asthma groups; however the greater decrease was observed for controls. Asthmatics and controls did not form separated clusters, however control swimmers demonstrated a more varied response to the exercise being dispersed along all score plot. CONCLUSION: In well-trained athletes, swimming is associated with a decrease in oxidative stress markers independently of the presence of asthma, although a more pronounced decrease was seen in controls. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170428IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12729</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28452071">PM:28452071</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170428-CoutoM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170428-CoutoM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170428, Couto M</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12729</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41509</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ahmadizar,F.</style></author><author><style face="normal" font="default"> Vijverberg,S.J.H.</style></author><author><style face="normal" font="default"> Arets,H.G.M.</style></author><author><style face="normal" font="default"> de Boer,A.</style></author><author><style face="normal" font="default"> Turner,S.</style></author><author><style face="normal" font="default"> Devereux,G.</style></author><author><style face="normal" font="default"> Arabkhazaeli,A.</style></author><author><style face="normal" font="default"> Soares,P.</style></author><author><style face="normal" font="default"> Mukhopadhyay,S.</style></author><author><style face="normal" font="default"> Garssen,J.</style></author><author><style face="normal" font="default"> Palmer,C.N.A.</style></author><author><style face="normal" font="default"> de Jongste,J.C.</style></author><author><style face="normal" font="default"> Jaddoe,V.W.</style></author><author><style face="normal" font="default"> Duijts,L.</style></author><author><style face="normal" font="default"> van Meel,E.R.</style></author><author><style face="normal" font="default"> Kraneveld,A.D.</style></author><author><style face="normal" font="default"> Maitland-van der Zee,A.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of science, Utrecht University, Utrecht, the Netherlands</style></auth-address><titles><title><style face="normal" font="default">Early life antibiotic use and the risk of asthma and asthma exacerbations in children</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Scotland</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="4" Year="2017">2017/4/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: The use of antibiotic therapy early in life might influence the risk of developing asthma. Studies assessing the influence of early life antibiotic use on the risk of asthma exacerbations are limited, and the results are inconsistent. Therefore, the aim of this study was to assess the association between use of antibiotic during the first three years of life and the risk of developing childhood asthma and the occurrence of asthma exacerbations. METHODS: Data from four large childhood cohorts were used; two population-based cohorts to study the risk of developing asthma: Generation R (n=7,393, the Netherlands) and SEATON (n=891, Scotland, UK), and two asthma cohorts to assess the risk of asthma exacerbations: PACMAN (n=668, the Netherlands) and BREATHE (n=806, Scotland, UK). Odds ratios (ORs) were derived from logistic regression analysis within each database followed by pooling the results using a fixed- or random-effect model. RESULTS: Antibiotic use in early life was associated with an increased risk of asthma in a meta-analysis of the Generation R and SEATON data (OR: 2.18, 95% CI: 1.04-4.60; I2 : 76.3%). There was no association between antibiotic use in early life and risk of asthma exacerbations later in life in a meta-analysis of the PACMAN and BREATHE data (OR: 0.93, 95% CI: 0.65-1.32; I2 : 0.0%). CONCLUSION: Children treated with antibiotic in the first three years of life are more likely to develop asthma, but there is no evidence that the exposure to antibiotic is associated with increased risk of asthma exacerbations. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170419IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12725</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28423467">PM:28423467</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170419-AhmadizarF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170419-AhmadizarF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170419, Ahmadizar F</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12725</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41510</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Khanna,S.</style></author><author><style face="normal" font="default"> Reeder,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.</style></auth-address><titles><title><style face="normal" font="default">Vesicular Hand Dermatitis in a Child: Allergy to Methylisothiazolinone</style></title><secondary-title><style face="normal" font="default">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Dermatol</style></full-title></periodical><pages end="e273" start="e272">e272-e273</pages><volume><style face="normal" font="default">33</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse effects</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disinfectants</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand dermatitis</style></keyword><keyword><style face="normal" font="default"> Hand Dermatoses</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Thiazoles</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Wisconsin</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="default">A 7-year-old girl presented with a history of vesicular hand dermatitis that only partially improved with the use of steroids. Patch testing revealed a 1+ reaction to 0.2% aqueous methylisothiazolinone (MI) and 0.01% aqueous methylchloroisothazolinone/methylisothiazolinone (MCI/MI). Dyshidrosiform hand dermatitis is rare in children younger than 10 years of age, and this pattern has not been reported with MCI/MI allergy</style></abstract><notes><style face="normal" font="default">DA - 20160906IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Case ReportsPT - Journal ArticleRN - 0 (Disinfectants)RN - 0 (Thiazoles)RN - 229D0E1QFA (2-methyl-4-isothiazolin-3-one)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pde.12884</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27339084">PM:27339084</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Dermatol\2016-33-e272-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Dermatol\2016-33-e272-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160906, Khanna S</style></custom2><misc3><style face="normal" font="default">10.1111/pde.12884</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41511</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shreberk-Hassidim,R.</style></author><author><style face="normal" font="default"> Hassidim,A.</style></author><author><style face="normal" font="default"> Gronovich,Y.</style></author><author><style face="normal" font="default"> Dalal,A.</style></author><author><style face="normal" font="default"> Molho-Pessach,V.</style></author><author><style face="normal" font="default"> Zlotogorski,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel</style></auth-address><titles><title><style face="normal" font="default">Atopic Dermatitis in Israeli Adolescents from 1998 to 2013: Trends in Time and Association with Migraine</style></title><secondary-title><style face="normal" font="default">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Conjunctivitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> socioeconomic status</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> trends</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> youth</style></keyword></keywords><dates><year Day="20" Month="3" Year="2017">2017/3/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: Recent data have shown an increasing occurrence of atopic dermatitis (AD) in children and adolescents, as well as in adults. Most of the epidemiologic research on AD is limited to pediatric and youth populations and is based on self-reported questionnaires. METHODS: A nationwide, population-based, cross-sectional retrospective study of adolescents with AD was performed to estimate its prevalence, trends, and association with demographic factors and comorbidities. The study included all Israeli teens going through medical evaluation as part of the assessment before being conscripted into the military from 1998 to 2013. RESULTS: A total of 1,187,757 adolescents were included in the study population, with an overall prevalence of AD of 0.64% in boys and 0.9% in girls. Over the study period, the prevalence of AD steadily increased, especially in the mild disease group. A greater risk of AD was found in subjects with high predicted socioeconomic status (male: odds ratio [OR] 1.14 [95% confidence interval {CI} 1.11, 1.16]; female: OR 1.08, [95% CI 1.05, 1.10]) and Israeli-born subjects (male: OR 1.34 [95% CI 1.21, 1.48]; female: OR 1.12 [95% CI 1.01, 1.23]). Allergic conditions such as asthma, conjunctivitis, and contact dermatitis were more prevalent in subjects with AD. There was a significantly higher prevalence of migraine in patients with AD (male: OR 1.35 [95% CI 1.18, 1.54]; female: OR 1.51 [95% CI 1.30, 1.74]). CONCLUSION: This large cross-sectional study demonstrates the increasing prevalence of AD in adolescents and its relation to other allergic diseases and migraine. It is hoped that greater awareness of the distinctive epidemiologic characteristics of this population will lead to better recognition and management of the disease and its comorbidities</style></abstract><notes><style face="normal" font="default">DA - 20170320IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">10.1111/pde.13084</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28318051">PM:28318051</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Dermatol\20170320-ShreberkHassidimR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Dermatol\20170320-ShreberkHassidimR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Shreberk-Hassidim R</style></custom2><misc3><style face="normal" font="default">10.1111/pde.13084</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41512</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,C.A.</style></author><author><style face="normal" font="default"> Carlberg,V.</style></author><author><style face="normal" font="default"> Kroshinsky,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Harvard Medical School, Boston, Massachusetts</style></auth-address><titles><title><style face="normal" font="default">Angioedema After Squaric Acid Treatment in a 6-Year-Old Girl</style></title><secondary-title><style face="normal" font="default">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Dermatol</style></full-title></periodical><pages end="e46" start="e44">e44-e46</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adjuvant</style></keyword><keyword><style face="normal" font="default"> Adjuvants,Immunologic</style></keyword><keyword><style face="normal" font="default"> administration &amp; dosage</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Alopecia</style></keyword><keyword><style face="normal" font="default"> Alopecia Areata</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chemically induced</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> cross reactivity</style></keyword><keyword><style face="normal" font="default"> Cross-reactivity</style></keyword><keyword><style face="normal" font="default"> Cyclobutanes</style></keyword><keyword><style face="normal" font="default"> drug therapy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hair</style></keyword><keyword><style face="normal" font="default"> Hair Follicle</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Scalp</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">Alopecia areata (AA) involves the immune-related destruction of hair follicles, resulting in patches of complete hair loss, most often on the scalp. The topical sensitizer squaric acid dibutylester (SADBE) is a popular treatment option given its low side-effect profile, hair regrowth potential, and lack of cross-reactivity with other chemicals. We describe a unique case of a 6-year-old girl who developed angioedema after SADBE treatment for AA</style></abstract><notes><style face="normal" font="default">DA - 20161004IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Case ReportsRN - 0 (Adjuvants, Immunologic)RN - 0 (Allergens)RN - 0 (Cyclobutanes)RN - 4RTO57VG65 (squaric acid dibutyl ester)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pde.12993</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27699860">PM:27699860</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Dermatol\2017-34-e44-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Dermatol\2017-34-e44-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161004, Chen CA</style></custom2><misc3><style face="normal" font="default">10.1111/pde.12993</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41513</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gnarra,M.</style></author><author><style face="normal" font="default"> De Simone,C.</style></author><author><style face="normal" font="default"> Garcovich,M.</style></author><author><style face="normal" font="default"> Garcovich,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Columbia University Medical Center, New YorkInstitute of Dermatology, Policlinico A. Gemelli, Catholic University, Rome, ItalyDivision of Gastroenterology, Department of Internal Medicine, Policlinico A. Gemelli, Catholic University, Rome, ItalyInstitute of Dermatology, Policlinico A. Gemelli, Catholic University, Rome, Italy</style></auth-address><titles><title><style face="normal" font="default">Low-Dose Cyclosporine A in the Treatment of Severe Atopic Dermatitis Complicated by Chronic Hepatitis C Virus Infection</style></title><secondary-title><style face="normal" font="default">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Columbia</style></keyword><keyword><style face="normal" font="default"> Cyclosporine</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Gastroenterology</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Hepatitis</style></keyword><keyword><style face="normal" font="default"> Hepatitis C</style></keyword><keyword><style face="normal" font="default"> Immunosuppressive therapy</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Rome</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> topical treatment</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> virus infection</style></keyword></keywords><dates><year Day="6" Month="4" Year="2017">2017/4/6</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is the most frequent chronic inflammatory skin disorder in children and is usually accompanied by genetic and environmental factors. Effective management and treatment of AD is challenging and often requires systemic immunosuppressive therapy when refractory to topical treatments. We report a rare association between chronic hepatitis C virus (HCV) and severe AD, management of which required systemic cyclosporine because of its favorable effects on inflammatory and viral-related clinical outcomes</style></abstract><notes><style face="normal" font="default">DA - 20170406IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/pde.13115</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28382768">PM:28382768</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Dermatol\20170406-GnarraM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Dermatol\20170406-GnarraM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170406, Gnarra M</style></custom2><misc3><style face="normal" font="default">10.1111/pde.13115</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41514</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gutierrez-Castaneda,L.D.</style></author><author><style face="normal" font="default"> Jaimes,A.O.</style></author><author><style face="normal" font="default"> Sanchez Bottomley,W.</style></author></authors></contributors><titles><title><style face="normal" font="default">Epidemiology of contact dermatitis: standard epicutaneous patch tests used in the National Institute of Dermatology of Colombia</style></title><secondary-title><style face="normal" font="default">Piel</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Piel</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Al+®rgenos</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Budesonide</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Colombia</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis por contacto</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> epicutaneous</style></keyword><keyword><style face="normal" font="default"> Epicutaneous tests</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Fragrances</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Immunisation</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Inmunizaci+¦n</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Occupation</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Preservatives</style></keyword><keyword><style face="normal" font="default"> Pruebas cut+íneas</style></keyword><keyword><style face="normal" font="default"> Pruebas epicut+íneas</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0213-9251</style></isbn><abstract><style face="normal" font="default">tIntroduction Contact dermatitis is a frequent cause of consultation in Colombia, where there is a lack of information about its epidemiology and its origin. Objective To describe the clinical and epidemiological characteristics and the results of epicutaneous tests performed at the Federico Lleras Acosta Dermatology Center, Bogot+í, Colombia. Materials and methods A descriptive study and analysis was performed on the demographic and epidemiological characteristics of the patients who underwent epicutaneous tests with the standard European battery of allergens. Results More than two-thirds (68%) of the patients showeded positive results in the epicutaneous tests. The most common allergen was nickel, followed by Peruvian balm, and fragrances. The age groups between 20 to 29 and 50 to 59 years were the most affected. The most common occupation and outside work activity were household tasks. The most affected areas of the body were hands (27.4%). Erythematous desquamative plaques were observed in 52% of those affected, and current relevance was found in 80% of the patients studied. Conclusions Women were more affected than men. Nickel, fragrances, and preservatives were the predominant allergens, which is consistent with that reported in the international literature. There were no positive results to allergens such as budesonide, which shows the need to develop multicentre studies in Colombia that would help include new allergens and discard others</style></abstract><notes><style face="normal" font="default">LA - SPA CO - Colombia -</style></notes><work-type><style face="normal" font="default">10.1016/j.piel.2017.01.011</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.piel.2017.01.011</url></web-urls></urls><custom2><style face="normal" font="default">20170512, Gutierrez-Castaneda LD</style></custom2><misc3><style face="normal" font="default">10.1016/j.piel.2017.01.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41515</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fan,X.</style></author><author><style face="normal" font="default"> Dong,M.</style></author><author><style face="normal" font="default"> Li,T.</style></author><author><style face="normal" font="default"> Ma,Q.</style></author><author><style face="normal" font="default"> Yin,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Maxillofacial Surgery of the Third Hospital Affiliated to Fourth Military Medical University, Xi'an, China; Department of Industrial Engineering, Xidian University, Xi'an, China</style></auth-address><titles><title><style face="normal" font="default">Two Cases of Adverse Reactions of Hyaluronic Acid-based Filler Injections</style></title><secondary-title><style face="normal" font="default">Plast Reconstr Surg Glob Open</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Plast Reconstr Surg Glob Open</style></abbr-1></periodical><pages end="" start="e1112">e1112-</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Engineering</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Hyaluronic Acid</style></keyword><keyword><style face="normal" font="default"> Injections</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Learning</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Thrombosis</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">Hyaluronic acid (HA) is one of the natural components of the human body with high biocompatibility, biodegradability, and nonimmunogenicity, which makes it the ideal biomedical filling agent currently available. However, for many medical practitioners, HA filler injections remain a relatively new item to carry out. Learning while practicing, it is inevitable to encounter some difficulties and adverse reactions in its application. Here we report two cases of adverse reactions to HA-based filler injections, including anaphylactic reaction on the face and vascular thrombosis after augmentation rhinoplasty with HA filler. In this report, we highlight the management and prevention of the adverse reactions, especially in case 2, because vascular thrombosis is one of the severe complications and injectors should know how to avoid it and how to deal with it, thereby increasing the safety of HA-based procedures</style></abstract><notes><style face="normal" font="default">DA - 20170315IS - 2169-7574 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1097/GOX.0000000000001112</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28293495">PM:28293495</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Plast Reconstr Surg Glob Open\2016-4-e1112.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Plast Reconstr Surg Glob Open\2016-4-e1112.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170315, Fan X</style></custom2><misc3><style face="normal" font="default">10.1097/GOX.0000000000001112</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41516</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arathimos,R.</style></author><author><style face="normal" font="default"> Granell,R.</style></author><author><style face="normal" font="default"> Henderson,J.</style></author><author><style face="normal" font="default"> Relton,C.L.</style></author><author><style face="normal" font="default"> Tilling,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Sex discordance in asthma and wheeze prevalence in two longitudinal cohorts</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0176293">e0176293-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> persistence</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Puberty</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> sex differences</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Sex discordance in asthma prevalence has been previously reported, with higher prevalence in males before puberty, and in females after puberty; the adolescent "switch". However, cross-sectional studies have suggested a narrowing of this discordance in recent decades. We used a combination of cross-sectional and longitudinal modelling to examine sex differences in asthma, wheeze and longitudinal wheezing phenotypes in two UK birth cohorts, the Avon Longitudinal Study of Parents and Children (ALSPAC; born 1991-92 with data from age 0-18 years) and the Millennium Cohort Study (MCS; born 2000-02 with data from age 3-10 years). We derived measures of asthma and wheeze from questionnaires completed by mothers and cohort children. Previously-derived ALSPAC wheezing phenotype models were applied to MCS. Males had a higher prevalence of asthma at 10.7 years in ALSPAC (OR 1.45 95%CI: 1.26, 1.66 n = 7778 for current asthma) and MCS (OR 1.42 95%CI: 1.29, 1.56 n = 6726 for asthma ever) compared to females, decreasing in ALSPAC after puberty (OR 0.94 95%CI: 0.79, 1.11 n = 5023 for current asthma at 16.5 years). In longitudinal models using restricted cubic splines, males had a clear excess for asthma in the last 12 months and wheeze in the last 12 months up until 16.5 years of age in ALSPAC. Males had an increased risk of all derived longitudinal wheezing phenotypes in MCS when compared to never wheeze and no evidence of being at lower risk of late wheeze when compared to early wheeze. By comparing data in two large, contemporary cohorts we have shown the persistence of sex discordance in childhood asthma, with no evidence that the sex discordance is narrowing in recent cohorts</style></abstract><notes><style face="normal" font="default">DA - 20170425IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0176293</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28441402">PM:28441402</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0176293.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0176293.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170425, Arathimos R</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0176293</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41517</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Braido,F.</style></author><author><style face="normal" font="default"> Baiardini,I.</style></author><author><style face="normal" font="default"> Alleri,P.</style></author><author><style face="normal" font="default"> Bacci,E.</style></author><author><style face="normal" font="default"> Barbetta,C.</style></author><author><style face="normal" font="default"> Bellocchia,M.</style></author><author><style face="normal" font="default"> Benfante,A.</style></author><author><style face="normal" font="default"> Blasi,F.</style></author><author><style face="normal" font="default"> Bucca,C.</style></author><author><style face="normal" font="default"> Busceti,M.T.</style></author><author><style face="normal" font="default"> Centanni,S.</style></author><author><style face="normal" font="default"> Colanardi,M.C.</style></author><author><style face="normal" font="default"> Contoli,M.</style></author><author><style face="normal" font="default"> Corsico,A.</style></author><author><style face="normal" font="default"> D'Amato,M.</style></author><author><style face="normal" font="default"> Di Marco,F.</style></author><author><style face="normal" font="default"> Dottorini,M.</style></author><author><style face="normal" font="default"> Ferrari,M.</style></author><author><style face="normal" font="default"> Florio,G.</style></author><author><style face="normal" font="default"> Fois,A.G.</style></author><author><style face="normal" font="default"> Foschino Barbaro,M.P.</style></author><author><style face="normal" font="default"> Garuti,S.</style></author><author><style face="normal" font="default"> Girbino,G.</style></author><author><style face="normal" font="default"> Grosso,A.</style></author><author><style face="normal" font="default"> Latorre,M.</style></author><author><style face="normal" font="default"> Maniscalco,S.</style></author><author><style face="normal" font="default"> Mazza,F.</style></author><author><style face="normal" font="default"> Mereu,C.</style></author><author><style face="normal" font="default"> Molinengo,G.</style></author><author><style face="normal" font="default"> Ora,J.</style></author><author><style face="normal" font="default"> Paggiaro,P.</style></author><author><style face="normal" font="default"> Patella,V.</style></author><author><style face="normal" font="default"> Pelaia,G.</style></author><author><style face="normal" font="default"> Pirina,P.</style></author><author><style face="normal" font="default"> Proietto,A.</style></author><author><style face="normal" font="default"> Rogliani,P.</style></author><author><style face="normal" font="default"> Santus,P.</style></author><author><style face="normal" font="default"> Scichilone,N.</style></author><author><style face="normal" font="default"> Simioli,F.</style></author><author><style face="normal" font="default"> Solidoro,P.</style></author><author><style face="normal" font="default"> Terraneo,S.</style></author><author><style face="normal" font="default"> Zuccon,U.</style></author><author><style face="normal" font="default"> Canonica,G.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy &amp; Respiratory Diseases, Department of Internal Medicine- University of Genoa, Italy.</style></auth-address><titles><title><style face="normal" font="default">Asthma management in a specialist setting: Results of an Italian Respiratory Society survey</style></title><secondary-title><style face="normal" font="default">Pulm Pharmacol Ther</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pulm Pharmacol Ther</style></abbr-1></periodical><pages end="87" start="83">83-87</pages><volume><style face="normal" font="default">44</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Biological Therapy</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Respiratory diseases</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="21" Month="3" Year="2017">2017/3/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma considerably impairs patients' quality of life and increases healthcare costs. Severity, morbidity, and degree of disease control are the major drivers of its clinical and economic impact. National scientific societies are required to monitor the application of international guidelines and to adopt strategies to improve disease control and better allocate resources. AIM: to provide a detailed picture of the characteristics of asthma patients and modalities of asthma management by specialists in Italy and to develop recommendations for the daily management of asthma in a specialist setting. METHOD: A quantitative research program was implemented. Data were collected using an ad hoc questionnaire developed by a group of specialists selected by the Italian Pneumology Society/Italian Respiratory Society. RESULTS: The records of 557 patients were analyzed. In the next few years, specialists are expected to focus their activity patients with more severe disease and will be responsible for selection of patients for personalized biological therapy; however, only 20% of patients attending Italian specialist surgery can be considered severe. In 84.4% of cases, the visit was a follow-up visit requested in 82.2% of cases by the specialist him/herself. The Asthma Control Test is used only in 65% of patients. When available, a significant association has been observed between the test score and asthma control as judged by the physician, although concordance was only moderate (kappa = 0.68). Asthma was considered uncontrolled by the specialist managing the case in 29.1% of patients; nevertheless, treatment was not stepped up in uncontrolled or partly controlled patients (modified in only 37.2% of patients). CONCLUSIONS: The results of this survey support re-evaluation of asthma management by Italian specialists. More resources should be made available for the initial visit and for more severely ill patients. In addition, more extensive use should be made of validated tools, and available drugs should be used more appropriately</style></abstract><notes><style face="normal" font="default">DA - 20170325IS - 1522-9629 (Electronic)IS - 1094-5539 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.pupt.2017.03.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28341462">PM:28341462</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pulm Pharmacol Ther\2017-84-83-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pulm Pharmacol Ther\2017-84-83-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170325, Braido F</style></custom2><misc3><style face="normal" font="default">10.1016/j.pupt.2017.03.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41518</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lewandowski,T.A.</style></author><author><style face="normal" font="default"> Cohen,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Gradient, 600 Stewart Street, Suite No. 1900, Seattle, WA 98101, USA.</style></auth-address><titles><title><style face="normal" font="default">Skin sensitization risk assessment: Considering available data for weight of evidence assessments</style></title><secondary-title><style face="normal" font="default">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="187" start="186">186-187</pages><volume><style face="normal" font="default">82</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20160929IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - LetterPT - CommentRN - 0 (Allergens)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.yrtph.2016.09.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27681532">PM:27681532</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2016-82-186-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2016-82-186-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160929, Lewandowski TA</style></custom2><misc3><style face="normal" font="default">10.1016/j.yrtph.2016.09.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41519</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Macmillan,D.S.</style></author><author><style face="normal" font="default"> Canipa,S.J.</style></author><author><style face="normal" font="default"> Chilton,M.L.</style></author><author><style face="normal" font="default"> Williams,R.V.</style></author><author><style face="normal" font="default"> Barber,C.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds, LS11 5PS, UK.</style></auth-address><titles><title><style face="normal" font="default">Predicting skin sensitisation using a decision tree integrated testing strategy with an in silico model and in chemico/in vitro assays</style></title><secondary-title><style face="normal" font="default">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="38" start="30">30-38</pages><volume><style face="normal" font="default">76</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal Testing Alternatives</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Computer Simulation</style></keyword><keyword><style face="normal" font="default"> Databases,Factual</style></keyword><keyword><style face="normal" font="default"> Decision Trees</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Irritant</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritants</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Knowledge Bases</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Sensitisation</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin Irritancy Tests</style></keyword><keyword><style face="normal" font="default"> Software</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Structure-Activity Relationship</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Workflow</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><abstract><style face="normal" font="default">There is a pressing need for non-animal methods to predict skin sensitisation potential and a number of in chemico and in vitro assays have been designed with this in mind. However, some compounds can fall outside the applicability domain of these in chemico/in vitro assays and may not be predicted accurately. Rule-based in silico models such as Derek Nexus are expert-derived from animal and/or human data and the mechanism-based alert domain can take a number of factors into account (e.g. abiotic/biotic activation). Therefore, Derek Nexus may be able to predict for compounds outside the applicability domain of in chemico/in vitro assays. To this end, an integrated testing strategy (ITS) decision tree using Derek Nexus and a maximum of two assays (from DPRA, KeratinoSens, LuSens, h-CLAT and U-SENS) was developed. Generally, the decision tree improved upon other ITS evaluated in this study with positive and negative predictivity calculated as 86% and 81%, respectively. Our results demonstrate that an ITS using an in silico model such as Derek Nexus with a maximum of two in chemico/in vitro assays can predict the sensitising potential of a number of chemicals, including those outside the applicability domain of existing non-animal assays</style></abstract><notes><style face="normal" font="default">DA - 20160501IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Journal ArticleRN - 0 (Irritants)SB - IMCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.yrtph.2016.01.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26796566">PM:26796566</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2016-76-30-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2016-76-30-8.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2016-76-30-8.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2016-76-30-8.xlsx</url></image-urls></urls><custom2><style face="normal" font="default">20160501, Macmillan DS</style></custom2><misc3><style face="normal" font="default">10.1016/j.yrtph.2016.01.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41520</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Patlewicz,G.</style></author><author><style face="normal" font="default"> Casati,S.</style></author><author><style face="normal" font="default"> Basketter,D.A.</style></author><author><style face="normal" font="default"> Asturiol,D.</style></author><author><style face="normal" font="default"> Roberts,D.W.</style></author><author><style face="normal" font="default"> Lepoittevin,J.P.</style></author><author><style face="normal" font="default"> Worth,A.P.</style></author><author><style face="normal" font="default"> Aschberger,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">US Environmental Protection Agency, National Center for Computational Toxicology, Research Triangle Park, NC, USA.</style></auth-address><titles><title><style face="normal" font="default">Can currently available non-animal methods detect pre and pro-haptens relevant for skin sensitization?</style></title><secondary-title><style face="normal" font="default">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="155" start="147">147-155</pages><volume><style face="normal" font="default">82</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal Testing Alternatives</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Cell Line</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Congresses</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Databases,Factual</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Haptens</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritants</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> peptide</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Prehapten</style></keyword><keyword><style face="normal" font="default"> Prohapten</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Regulations</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin Irritancy Tests</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Test method</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> Toxicology</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Workflow</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">Predictive testing to characterize substances for their skin sensitization potential has historically been based on animal tests such as the Local Lymph Node Assay (LLNA). In recent years, regulations in the cosmetics and chemicals sectors have provided strong impetus to develop non-animal alternatives. Three test methods have undergone OECD validation: the direct peptide reactivity assay (DPRA), the KeratinoSens and the human Cell Line Activation Test (h-CLAT). Whilst these methods perform relatively well in predicting LLNA results, a concern raised is their ability to predict chemicals that need activation to be sensitizing (pre- or pro-haptens). This current study reviewed an EURL ECVAM dataset of 127 substances for which information was available in the LLNA and three non-animal test methods. Twenty eight of the sensitizers needed to be activated, with the majority being pre-haptens. These were correctly identified by 1 or more of the test methods. Six substances were categorized exclusively as pro-haptens, but were correctly identified by at least one of the cell-based assays. The analysis here showed that skin metabolism was not likely to be a major consideration for assessing sensitization potential and that sensitizers requiring activation could be identified correctly using one or more of the current non-animal methods</style></abstract><notes><style face="normal" font="default">DA - 20160905IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - CongressesRN - 0 (Haptens)RN - 0 (Irritants)SB - IMCO - United States -CO - United Kingdom -CO - France -CO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.yrtph.2016.08.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27569201">PM:27569201</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2016-82-147-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2016-82-147-55.pdf</url></text-urls><related-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2016-82-147-55.xlsx</url></related-urls><image-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2016-82-147-55.xlsx</url></image-urls></urls><custom2><style face="normal" font="default">20160905, Patlewicz G</style></custom2><misc3><style face="normal" font="default">10.1016/j.yrtph.2016.08.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41521</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Scientific Committee Of Consumer Safety-Sccs</style></author><author><style face="normal" font="default"> Gimenez-Arnau,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">SCCS Secretariat at the European Commission, Directorate General for Health and Food Safety, 11, rue E. Ruppert, L-2920 Luxembourg, Luxembourg</style></auth-address><titles><title><style face="normal" font="default">Opinion of the Scientific Committee on Consumer safety (SCCS) - Opinion on the safety of the use of Methylisothiazolinone (MI) (P94), in cosmetic products (sensitisation only)</style></title><secondary-title><style face="normal" font="default">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="212" start="211">211-212</pages><volume><style face="normal" font="default">76</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Consumer Product Safety</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Cosmetic products</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Hair</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> preservative</style></keyword><keyword><style face="normal" font="default"> Preservatives</style></keyword><keyword><style face="normal" font="default"> Preservatives,Pharmaceutical</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Sensitisation</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Thiazoles</style></keyword><keyword><style face="normal" font="default"> Toxicity Tests</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="4" Year="2016">2016/4</year></dates><abstract><style face="normal" font="default">CONCLUSION OF THE OPINION: The information provided does not support the safe use of MI as a preservative in rinse-off cosmetic products up to a concentration limit of 100 ppm from the view of induction of contact allergy. For rinse-off cosmetic products, a concentration of 15 ppm (0.0015%) MI is considered safe for the consumer from the point of view of induction of contact allergy. The information provided does not support the safe use of MI as a preservative in leave-on hair cosmetic products up to a concentration limit of 100 ppm from the point of view of induction of contact allergy. The concerns and opinions raised in SCCS Opinion SCCS/1521/13 (12 December 2013 with revision 27 March 2014) remain. The results of the recent Scandinavian study do not support safety of MI in rinse-off products at either 100 ppm or at 50 ppm for elicitation or induction</style></abstract><notes><style face="normal" font="default">DA - 20160501IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Journal ArticleRN - 0 (Cosmetics)RN - 0 (Preservatives, Pharmaceutical)RN - 0 (Thiazoles)RN - 229D0E1QFA (2-methyl-4-isothiazolin-3-one)SB - IMCO - Luxembourg -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.yrtph.2016.01.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26790577">PM:26790577</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2016-76-211-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2016-76-211-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160501, Scientific Committee Of Consumer Safety-Sccs</style></custom2><misc3><style face="normal" font="default">10.1016/j.yrtph.2016.01.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41522</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Costigan,S.</style></author><author><style face="normal" font="default"> Lopez-Belmonte,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Nicoventures R&amp;D, Regents Park, Southampton SO15 8TL, UK.</style></auth-address><titles><title><style face="normal" font="default">An approach to allergy risk assessments for e-liquid ingredients</style></title><secondary-title><style face="normal" font="default">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="8" start="1">1-8</pages><volume><style face="normal" font="default">87</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy risk</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Flavour</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergens</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Fragrances</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Respiratory allergies</style></keyword><keyword><style face="normal" font="default"> Respiratory allergy</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Management</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Sensitisation</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="4" Month="4" Year="2017">2017/4/4</year></dates><abstract><style face="normal" font="default">Many flavours and fragrances are known allergens. Their selection and inclusion levels in e-liquids must therefore be guided by toxicological principles, taking into account the exposure pattern and inhalation route of exposure. For contact sensitisation, a general, agreed quantitative risk assessment approach to prevent dermal sensitisation exists. Here we propose exposure parameters and safety factors to apply this approach to e-liquid ingredients. Additionally, as a risk management approach for pre-sensitised individuals, we derive a threshold of 0.1% for indicating the presence of a contact sensitiser in e-liquid. Risk assessment for respiratory sensitisation is not well established. Occupational exposure limits that protect against respiratory allergy are generally very low. Cocoa shell extract is used as a case study to discuss the issues. A tolerable exposure level is derived and estimates of consumer exposure are presented, leading to the practical risk management approach of excluding respiratory sensitisers as e-liquid ingredients. Related to this, if natural extracts are used as flavourings in e-liquids, we recommend only protein-free versions are used. Additionally, we recommend the presence of any potential food allergens should be noted on the product information</style></abstract><notes><style face="normal" font="default">DA - 20170408IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.yrtph.2017.04.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28389323">PM:28389323</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2017-87-1-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2017-87-1-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170408, Costigan S</style></custom2><misc3><style face="normal" font="default">10.1016/j.yrtph.2017.04.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41523</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kimber,I.</style></author><author><style face="normal" font="default"> Gerberick,G.F.</style></author><author><style face="normal" font="default"> Basketter,D.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Manchester, Faculty of Life Sciences, Michael Smith Building, Oxford Road, Manchester, M13 9PT, UK</style></auth-address><titles><title><style face="normal" font="default">Quantitative risk assessment for skin sensitization: Success or failure?</style></title><secondary-title><style face="normal" font="default">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="108" start="104">104-108</pages><volume><style face="normal" font="default">83</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration &amp; dosage</style></keyword><keyword><style face="normal" font="default"> Administration,Cutaneous</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Consumer Product Safety</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Drug</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidemic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Feedback</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritants</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patient Safety</style></keyword><keyword><style face="normal" font="default"> Preservatives</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin Irritancy Tests</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Test method</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> Toxicology</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">Skin sensitization is unique in the world of toxicology. There is a combination of reliable, validated predictive test methods for identification of skin sensitizing chemicals, a clearly documented and transparent approach to risk assessment, and effective feedback from dermatology clinics around the world delivering evidence of the success or failure of the hazard identification/risk assessment/management process. Recent epidemics of contact allergy, particularly to preservatives, have raised questions of whether the safety/risk assessment process is working in an optimal manner (or indeed is working at all!). This review has as its focus skin sensitization quantitative risk assessment (QRA). The core toxicological principles of QRA are reviewed, and evidence of use and misuse examined. What becomes clear is that skin sensitization QRA will only function adequately if two essential criteria are met. The first is that QRA is applied rigourously, and the second is that potential exposure to the sensitizing substance is assessed adequately. This conclusion will come as no surprise to any toxicologist who appreciates the basic premise that "risk = hazard x exposure". Accordingly, use of skin sensitization QRA is encouraged, not least because the essential feedback from dermatology clinics can be used as a tool to refine QRA in situations where this risk assessment tool has not been properly used</style></abstract><notes><style face="normal" font="default">DA - 20161122IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Journal ArticlePT - ReviewRN - 0 (Irritants)SB - IMCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.yrtph.2016.11.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27871868">PM:27871868</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2017-83-104-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2017-83-104-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161122, Kimber I</style></custom2><misc3><style face="normal" font="default">10.1016/j.yrtph.2016.11.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41524</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Watzek,N.</style></author><author><style face="normal" font="default"> Berger,F.</style></author><author><style face="normal" font="default"> Kolle,S.N.</style></author><author><style face="normal" font="default"> Kaufmann,T.</style></author><author><style face="normal" font="default"> Becker,M.</style></author><author><style face="normal" font="default"> van Ravenzwaay,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Product Safety Department, BASF SE, 67056 Ludwigshafen am Rhein, Germany.</style></auth-address><titles><title><style face="normal" font="default">Assessment of skin sensitization under REACH: A case report on vehicle choice in the LLNA and its crucial role preventing false positive results</style></title><secondary-title><style face="normal" font="default">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="32" start="25">25-32</pages><volume><style face="normal" font="default">85</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acetone</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cyclohexylamines</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Excipients</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Haptens</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Mice,Inbred CBA</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> Olive Oil</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Propylene Glycol</style></keyword><keyword><style face="normal" font="default"> REACH</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">In the EU, chemicals with a production or import volume in quantities of one metric ton per year or more have to be tested for skin sensitizing properties under the REACH regulation. The murine Local Lymph Node Assay (LLNA) and its modifications are widely used to fulfil the data requirement, as it is currently considered the first-choice method for in vivo testing to cover this endpoint. This manuscript describes a case study highlighting the importance of understanding the chemistry of the test material during testing for 'skin sensitization' of MCDA (mixture of 2,4- and 2,6-diamino-methylcyclohexane) with particular focus on the vehicle used. While the BrdU-ELISA modification of the LLNA using acetone/olive oil (AOO) as vehicle revealed expectable positive results. However, the concentration control analysis unexpectedly revealed an instability of MCDA in the vehicle AOO. Further studies on the reactivity showed MCDA to rapidly react with AOO under formation of various imine structures, which might have caused the positive LLNA result. The repetition of the LLNA using propylene glycol (PG) as vehicle did not confirm the positive results of the LLNA using AOO. Finally, a classification of MCDA as skin sensitizer according to the Globally Harmonized System (GHS) was not justified</style></abstract><notes><style face="normal" font="default">DA - 20170204IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Journal ArticleRN - 0 (Allergens)RN - 0 (Cyclohexylamines)RN - 0 (Excipients)RN - 0 (Haptens)RN - 0 (Olive Oil)RN - 1364PS73AF (Acetone)RN - 6DC9Q167V3 (Propylene Glycol)SB - IMCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.yrtph.2017.01.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28159477">PM:28159477</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2017-85-25-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2017-85-25-32.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170204, Watzek N</style></custom2><misc3><style face="normal" font="default">10.1016/j.yrtph.2017.01.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41525</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Petry,T.</style></author><author><style face="normal" font="default"> Bosch,A.</style></author><author><style face="normal" font="default"> Coste,X.</style></author><author><style face="normal" font="default"> Eigler,D.</style></author><author><style face="normal" font="default"> Germain,P.</style></author><author><style face="normal" font="default"> Seidel,S.</style></author><author><style face="normal" font="default"> Jean,P.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">ToxMinds BVBA, Product Safety &amp; Regulatory Affairs, B-1200 Brussels, Belgium.</style></auth-address><titles><title><style face="normal" font="default">Evaluation of in vitro assays for the assessment of the skin sensitization hazard of functional polysiloxanes and silanes</style></title><secondary-title><style face="normal" font="default">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="76" start="64">64-76</pages><volume><style face="normal" font="default">84</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Animal Testing Alternatives</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Biological Assay</style></keyword><keyword><style face="normal" font="default"> Cell Line</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Comparative Study</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Evaluation Studies</style></keyword><keyword><style face="normal" font="default"> Feasibility Studies</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Gene Expression Regulation</style></keyword><keyword><style face="normal" font="default"> Genes,Reporter</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Guinea Pigs</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritants</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Keratinocytes</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice,Inbred CBA</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> peptide</style></keyword><keyword><style face="normal" font="default"> pig</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Silanes</style></keyword><keyword><style face="normal" font="default"> Siloxanes</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin Irritancy Tests</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Test method</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> U937 Cells</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">The skin sensitization potential of chemicals has traditionally been evaluated in vivo according to OECD testing guidelines in guinea pigs or the mouse local lymph node assay. There has lately been a great emphasis on establishing in vitro test methods reflecting the key biological events in the adverse outcome pathway (AOP) for skin sensitization as published by the OECD. Against this background, a group of 8 polysiloxanes and silanes, seven of them aminofunctionalised, for which in vivo data were already available, has been tested in vitro in the direct peptide reactivity assay (DPRA), the KeratinoSens and the human cell line activation test (h-CLAT) and in the modified myeloid U937 skin sensitization test (mMUSST) as far as technically feasible. The main objective of the programme was to determine the utility of these systems for this heterogeneous group of silicone-based substances, recognizing that some substances are outside the assays applicability domains. The presented data provided some interesting mechanistical insights into the performance of these assays for functionalised siloxanes and silanes. The data also allow for a preliminary evaluation of proposed integrated testing strategies (ITS) to determine the skin sensitization potential of chemicals which were not considered in the training sets of the respective ITS</style></abstract><notes><style face="normal" font="default">DA - 20161226IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Comparative StudyPT - Evaluation StudiesPT - Journal ArticleRN - 0 (Irritants)RN - 0 (Silanes)RN - 0 (Siloxanes)SB - IMCO - Belgium -CO - Germany -CO - France -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.yrtph.2016.10.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28017767">PM:28017767</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2017-84-64-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2017-84-64-76.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161\226, Petry T</style></custom2><misc3><style face="normal" font="default">10.1016/j.yrtph.2016.10.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41526</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,Y.S.</style></author><author><style face="normal" font="default"> Yi,J.S.</style></author><author><style face="normal" font="default"> Seo,S.J.</style></author><author><style face="normal" font="default"> Kim,J.H.</style></author><author><style face="normal" font="default"> Jung,M.S.</style></author><author><style face="normal" font="default"> Seo,I.K.</style></author><author><style face="normal" font="default"> Ahn,I.</style></author><author><style face="normal" font="default"> Ko,K.</style></author><author><style face="normal" font="default"> Kim,T.S.</style></author><author><style face="normal" font="default"> Lim,K.M.</style></author><author><style face="normal" font="default"> Sohn,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Toxicological Screening &amp; Testing Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju-si, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Comparison of BALB/c and CBA/J mice for the local lymph node assay using bromodeoxyuridine with flow cytometry (LLNA: BrdU-FCM)</style></title><secondary-title><style face="normal" font="default">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="22" start="13">13-22</pages><volume><style face="normal" font="default">83</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration &amp; dosage</style></keyword><keyword><style face="normal" font="default"> Administration,Cutaneous</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Bromodeoxyuridine</style></keyword><keyword><style face="normal" font="default"> Cell Proliferation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Comparative Study</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Drug</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Evaluation Studies</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritants</style></keyword><keyword><style face="normal" font="default"> Irritation</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Mice,Inbred BALB C</style></keyword><keyword><style face="normal" font="default"> Mice,Inbred CBA</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Species Specificity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="2" Year="2017">2017/2</year></dates><abstract><style face="normal" font="default">The local lymph node assay using 5-bromo-2-deoxyuridine (BrdU) with flow cytometry (LLNA: BrdU-FCM) is a modified LLNA that is used to identify skin sensitizers by counting BrdU-incorporated lymph node cells (LNCs) with flow cytometry. Unlike other LLNA methods (OECD TG 429, 442A and 442B) in which the CBA/J mouse strain is used, LLNA: BrdU-FCM was originally designed to be compatible with BALB/c, a mouse strain that is more widely used in many countries. To justify the substitution of CBA/J for BALB/c, the equivalence of the test results between two strains shall be established prior to the official implementation of LLNA: BrdU-FCM. This study aims to compare the test results of LLNA: BrdU-FCM produced in BALB/c mice with those in CBA/J mice for 18 reference substances, including 13 sensitizers and 5 non-sensitizers, listed in OECD Test Guideline 429. Based on the LLNA: BrdU-FCM test procedure, we selected an appropriate solvent and then performed preliminary tests to determine the non-irritating dose ranges for the main study, which revealed the difference in the irritation responses to 8 of the 18 chemicals between the two strains. In the main study, we measured the changes in the number of total LNCs, which indicated differences in the responses to test chemicals between the two strains. However, the stimulation index obtained with the counts of BrdU-incorporated LNCs with 7-AAD using flow cytometry yielded comparable results and 100% concordance between the BALB/c and CBA/J mouse strains was achieved, suggesting that the performance of LLNA: BrdU-FCM using BALB/c mice was equivalent to that with CBA/J mice</style></abstract><notes><style face="normal" font="default">DA - 20161106IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Comparative StudyPT - Evaluation StudiesPT - Journal ArticleRN - 0 (Irritants)RN - G34N38R2N1 (Bromodeoxyuridine)SB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.yrtph.2016.10.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27816673">PM:27816673</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2017-83-13-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2017-83-13-22.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161106, Lee YS</style></custom2><misc3><style face="normal" font="default">10.1016/j.yrtph.2016.10.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41527</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ha,S.</style></author><author><style face="normal" font="default"> Ahn,I.Y.</style></author><author><style face="normal" font="default"> Kim,D.E.</style></author><author><style face="normal" font="default"> Lee,J.K.</style></author><author><style face="normal" font="default"> Sohn,S.</style></author><author><style face="normal" font="default"> Jung,M.S.</style></author><author><style face="normal" font="default"> Heo,Y.</style></author><author><style face="normal" font="default"> Omori,T.</style></author><author><style face="normal" font="default"> Bae,S.</style></author><author><style face="normal" font="default"> Lim,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">College of Pharmacy, Ewha Womans University, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Evaluation of radioisotopic and non-radioisotopic versions of local lymph node assays for subcategorization of skin sensitizers compliant to UN GHS rev 4</style></title><secondary-title><style face="normal" font="default">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="131" start="124">124-131</pages><volume><style face="normal" font="default">85</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Haptens</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Radioisotopes</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> United Nations</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">Recently UN GHS has introduced the sub-categorization of skin sensitizers for which ECt (concentration estimated to induce stimulation index above threshold) of the murine local lymph node assay (LLNA) is used as criteria. Non-radioisotopic variants of LLNA, LLNA: DA, LLNA: BrdU-ELISA, LNCC and LLNA: BrdU-FCM were developed yet their utilities for potency sub-categorization are not established. Here we assessed the agreement of LLNA variants with LLNA or human data in potency sub-categorization for 22 reference substances of OECD TG429. Concordance of sub-categorization with LLNA was highest for LLNA: BrdU-FCM(91%, kappa = 0.833, weighted kappa) followed by LLNA: BrdU-ELISA (82%, kappa = 0.744) and LLNA: DA (73%, kappa = 0.656) whereas LNCC only showed a modest association (64%, kappa = 0.441). With human data, LLNA agreed best (77%) followed by LLNA: DA and LLNA: BrdU-FCM(73%), LLNA: BrdU-ELISA (68%) and LNCC(55%). Bland-Altman plot revealed that ECt's of LLNA variants largely agreed with LLNA where most values fell within 95% limit of agreement. Correlation between ECt's of LLNA and LLNA variants were high except for LNCC(pair-wise with LLNA, LLNA: DA, r = 0.848, LLNA: BrdU-ELISA, r = 0.744, LLNA: BrdU-FCM, r=0.786, and LNCC, r = 0.561 by Pearson). Collectively, these results demonstrated that LLNA variants exhibit performance comparable to LLNA in the potency sub-categorization although additional substances shall be analyzed in the future</style></abstract><notes><style face="normal" font="default">DA - 20170214IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Journal ArticleRN - 0 (Allergens)RN - 0 (Haptens)RN - 0 (Radioisotopes)SB - IMCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.yrtph.2017.02.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28193562">PM:28193562</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2017-85-124-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2017-85-124-31.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170214, Ha S</style></custom2><misc3><style face="normal" font="default">10.1016/j.yrtph.2017.02.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41528</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Santos,Y.A.</style></author><author><style face="normal" font="default"> Silva,B.R.</style></author><author><style face="normal" font="default"> Lira,P.N.</style></author><author><style face="normal" font="default"> Vaz,L.C.</style></author><author><style face="normal" font="default"> Mafort,T.T.</style></author><author><style face="normal" font="default"> Bruno,L.P.</style></author><author><style face="normal" font="default"> Lopes,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Medicine, University Hospital Pedro Ernesto, State University of Rio de Janeiro, Boulevard 28 de Setembro, 77, 3 masculine andar, Vila Isabel, 20551-030, Rio de Janeiro, Brazil</style></auth-address><titles><title><style face="normal" font="default">Eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss syndrome) as a differential diagnosis of hypereosinophilic syndromes</style></title><secondary-title><style face="normal" font="default">Respir Med Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Respir Med Case Rep</style></abbr-1></periodical><pages end="6" start="1">1-6</pages><volume><style face="normal" font="default">21</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Churg-Strauss Syndrome</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical Medicine</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Differential diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Granulomatosis with Polyangiitis</style></keyword><keyword><style face="normal" font="default"> Hypereosinophilic Syndrome</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> systemic disease</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vasculitides</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare systemic disease situated between primary small vessel vasculitides associated with antineutrophil cytoplasmic antibodies (ANCAs) and hypereosinophilic syndromes (HES). Here, we present a case of EGPA in a 38-year-old male, with a previous diagnosis of asthma, who presented with fever, migratory lung infiltrates and systemic eosinophilia that was refractory to previous courses of antibiotics. This case highlights the importance of the primary care physician understanding the differential diagnosis of pulmonary eosinophilic syndromes</style></abstract><notes><style face="normal" font="default">DA - 20170324IS - 2213-0071 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1016/j.rmcr.2017.03.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28337408">PM:28337408</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respir Med Case Rep\2017-21-1-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respir Med Case Rep\2017-21-1-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170324, Santos YA</style></custom2><misc3><style face="normal" font="default">10.1016/j.rmcr.2017.03.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41529</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">George,M.</style></author><author><style face="normal" font="default"> Joshi,S.V.</style></author><author><style face="normal" font="default"> Concepcion,E.</style></author><author><style face="normal" font="default"> Lee,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, SUNY Downstate Medical Center and Kings County Hospital Center, Brooklyn, NY 11203, USA</style></auth-address><titles><title><style face="normal" font="default">Paradoxical bronchospasm from benzalkonium chloride (BAC) preservative in albuterol nebulizer solution in a patient with acute severe asthma. A case report and literature review of airway effects of BAC</style></title><secondary-title><style face="normal" font="default">Respir Med Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Respir Med Case Rep</style></abbr-1></periodical><pages end="41" start="39">39-41</pages><volume><style face="normal" font="default">21</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Albuterol</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Benzalkonium chloride</style></keyword><keyword><style face="normal" font="default"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Chlorobutanol</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> levalbuterol</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> nebulized</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Peak expiratory flow</style></keyword><keyword><style face="normal" font="default"> Peak Expiratory Flow Rate</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> preservative</style></keyword><keyword><style face="normal" font="default"> Respiratory System</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Solutions</style></keyword><keyword><style face="normal" font="default"> Sulfites</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Nebulized bronchodilator solutions are available in the United States as both nonsterile and sterile-filled products. Sulfites, benzalkonium chloride (BAC), or chlorobutanol are added to nonsterile products to prevent bacterial growth. Bronchoconstriction from inhaled BAC is cumulative, prolonged, and correlates directly with basal airway responsiveness. The multi-dose dropper bottle of albuterol sulfate solution contains 50 mug BAC per/2.5 mg of albuterol, which may be below or at the lower limit of the threshold dose for bronchoconstriction. However, with repeated albuterol nebulization, the effect can be additive and cumulative, often exceeding the bronchoconstriction threshold. We report a case of a 17 years old patient, who received 32 mg of BAC via nebulization over a period of 3.5 days that probably caused persistent bronchospasm evidenced by failure to improve clinically and to increase peak expiratory flow rate (PEFR) from 125 L/min (27% of predicted value) to 300 L/min (68% of predicted value) within 2 hours of withdrawing BAC. The patient's respiratory status and PEFR improved dramatically once the nebulization solution was switched to BAC free lev-albuterol solution. The pediatric providers, particularly the emergency department physicians, intensivists and pulmonologists need to be aware of this rare albeit possible toxicity to the respiratory system caused by BAC used as a preservative in albuterol nebulizer solution</style></abstract><notes><style face="normal" font="default">DA - 20170405IS - 2213-0071 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.rmcr.2017.03.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28377880">PM:28377880</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respir Med Case Rep\2017-21-39-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respir Med Case Rep\2017-21-39-41.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170405, George M</style></custom2><misc3><style face="normal" font="default">10.1016/j.rmcr.2017.03.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41530</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Molkhou,P.</style></author><author><style face="normal" font="default"> Metayer,C.</style></author><author><style face="normal" font="default"> Baranes,T.</style></author><author><style face="normal" font="default"> Waguet,J.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Manifestations atypiques du reflux gastro-+ôsophagien (RGO) et maladies allergiques, les liaisons dangereuses</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Age of Onset</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergique</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Atypical forms</style></keyword><keyword><style face="normal" font="default"> Barett's esophagus</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Formes atypiques</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Gastr+ôsophageal reflux</style></keyword><keyword><style face="normal" font="default"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="default"> GERD</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Multidisciplinary team</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Prise en charge</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">There is frequently failure in the diagnosis and management of gastroesophageal reflux (GERD) regardless of the age of onset. The discussion based upon the clinical observations presented below should prompt doctors in every medical specialty to be more aware of multiform variants, which can be misleading. Diagnosis is particularly difficult in atypical cases that mimic or complicate allergic symptoms. Therapeutic management of GERD is necessary to improve respiratory, cutaneous and digestive symptoms. The six clinical cases presented herein by a multidisciplinary team of allergists clearly illustrate such situations</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.02.237</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.02.237</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170509-MolkhouP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170509-MolkhouP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Molkhou P</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.02.237</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41531</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Soares de Almeida,L.</style></author></authors></contributors><titles><title><style face="normal" font="default">SCARs - A face negra da hipersensibilidade a f+írmacos</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="116" start="115">115-116</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Face</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><publisher><style face="normal" font="default">scielopt</style></publisher><isbn><style face="normal" font="default">0871-9721</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_arttext&amp;pid=S0871-97212016000200009&amp;lng=pt&amp;nrm=iso&amp;tlng=pt</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-115-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-115-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170506, Soares de Almeida L</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41532</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guimaraes,C.</style></author><author><style face="normal" font="default"> Seidi,M.</style></author><author><style face="normal" font="default"> Alves,S.C.</style></author><author><style face="normal" font="default"> Fonseca,V.</style></author><author><style face="normal" font="default"> Irimia,M.</style></author><author><style face="normal" font="default"> Ramos,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Critical asthma syndrome in a portuguese intensive care unit</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="162" start="155">155-162</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Asma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Characterization</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Emergency care</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> intensive care unit</style></keyword><keyword><style face="normal" font="default"> Intubation</style></keyword><keyword><style face="normal" font="default"> Length of Stay</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pH</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Propofol</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Ventilation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><publisher><style face="normal" font="default">scielopt</style></publisher><isbn><style face="normal" font="default">0871-9721</style></isbn><abstract><style face="normal" font="default">Introduction: critical asthma syndrome (CAS) needs emergency care, usually in intensive/intermediate care unit (ICU/ITCU). Objectives: characterization of patients admitted to the ICU/ITCU with the diagnosis of CAS. Methods: retrospective review of medical records of patients admitted with CAS, over a period of four years. Results: 18 patients were admitted with the diagnosis of CAS; 9 patients (50%) had severe asthma, and only once (5.6 %) was steroid dependent. Of the 11 patients admitted to the ICU the New Simplified Acute Physiology score was 35.5 ± 20.9, Acute Physiologic and Chronic Health Evaluation was 17.5 ± 9.2 and predicted mortality was 30.2% ± 34.8. Blood gas values at admission in emergency department: pH 7.19 ± 0.17, PaCO2 78.6 ± 33.7, PaO2 91.7 ± 60.8. At hospital discharge, there was a statistically significant increase in pH (7.42 ± 0.06, p = 0.001) and a statistically significant decreased in PaCO2 (41.3 ± 6.2, p=0,001). Cardiopulmonary arrest occurred in 4 patients (22.2 %), and was necessary endotracheal intubation in 12 patients (83.3% intubated in the first 24 hours). Propofol was the most commonly used sedative (11 patients); 2 patients were sedated with sevoflurane and one patient with ketamine. Three patients were curarized [longer length of stay (p=0.027) and more days under mechanical ventilation (p=0.009)]. Noninvasive ventilation was used in 4 patients (22.2 %). We only registered one death (5.6%). Conclusion: half patients had severe asthma criteria, which supports the need for hospitalization in ICU/ITCU. Although most patients required mechanical ventilation, the outcome was favorable, with significant blood gas improvement and low mortality rate.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212016000300003&amp;lng=pt&amp;nrm=iso&amp;tlng=enhttp://www.scielo.mec.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212016000300003&amp;lng=pt&amp;nrm=iso&amp;tlng=en</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-155-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-155-62.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170506, Guimaraes C</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41533</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chambel,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hipersensibilidade a farmacos - Manifestacoes menos frequentes</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="119" start="117">117-119</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Portugal</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><publisher><style face="normal" font="default">scielopt</style></publisher><isbn><style face="normal" font="default">0871-9721</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_arttext&amp;pid=S0871-97212016000200009&amp;lng=pt&amp;nrm=iso&amp;tlng=pt</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-117-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-117-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170506, Chambel M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41534</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kong Cardoso,B.</style></author><author><style face="normal" font="default"> Tomaz,E.</style></author><author><style face="normal" font="default"> Correia,S.</style></author><author><style face="normal" font="default"> Inacio,F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hypersensitivity to nonsteroidal anti-inflammatory drugs revisited - Clinical and laboratory data considering the new EAACI Classification.</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="175" start="163">163-175</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophil activation test</style></keyword><keyword><style face="normal" font="default"> BAT</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Challenge test</style></keyword><keyword><style face="normal" font="default"> Challenge tests</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Efficiency</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> NSAID</style></keyword><keyword><style face="normal" font="default"> NSAID hypersensitivity</style></keyword><keyword><style face="normal" font="default"> NSAIDs</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><publisher><style face="normal" font="default">scielopt</style></publisher><isbn><style face="normal" font="default">0871-9721</style></isbn><abstract><style face="normal" font="default">Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) represent the second most common cause of drug hypersensivity (0.6-5.7% of general population). The wide spectrum of symptoms, the various mechanisms involved and the lack of efficient diagnosing methods turn it into a challenge to the allergist. Objective: The aim of this study was to classify a group of patients with a history of NSAID hypersensitivity according to the system proposed by the EAACI Task Force on NSAIDs Hypersensitivity, to characterize the resulting groups and to evaluate clinical and laboratory data accordingly. Material and methods: Medical records of 64 patients referred to our Centre between 2010 and 2015 and investigated for NSAID hypersensitivity with a basophil activation test (BAT) performed were investigated and classified: group 1- NSAIDs-exacerbated respiratory disease; group 2 - NSAIDs-exacerbated cutaneous disease NSAIDs; group 3 - induced urticaria/angioedema; group 4 - Single-NSAID-induced urticaria/angioedema or anaphylaxis. Demographic and clinical data as well as skin tests, challenge tests and BAT results were analysed. Results: We were able to classify 59 out of 64 patients. Atopy prevalence was significantly higher in group 3 (50%) than in group 4 (5%), p=0,027. The records showed 3 positive provocation tests to nimesulide and 1 to celecoxib. Metamizol was the culprit drug of 54% group 4 reactions and 56% of overall anaphylactic reactions. Skin tests and BAT positivity taken together could identify 11 (79%) of patients reacting to metamizol in group 4. Conclusions: Most of our study patients fitted into the proposed classification. We underline the role of provocation tests to find a safe alternative NSAID and also the efficiency of skin tests and BAT in the diagnosis of metamizol hypersensitivity as single NSAID offender</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212016000300004&amp;lng=pt&amp;nrm=iso&amp;tlng=enhttp://www.scielo.mec.pt/scielo.php?script=sci_abstract&amp;pid=S0871-97212016000300004&amp;lng=pt&amp;nrm=iso&amp;tlng=en</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-163-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-163-75.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170506, Kong Cardoso B</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41535</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Caiado,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hipersensibilidade a f+amacos - Tratar, documentar e dessensibilizar</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="114" start="111">111-114</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Portugal</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><publisher><style face="normal" font="default">scielopt</style></publisher><isbn><style face="normal" font="default">0871-9721</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.scielo.mec.pt/scielo.php?script=sci_arttext&amp;pid=S0871-97212016000200008&amp;lng=pt&amp;nrm=iso&amp;tlng=pthttp://www.scielo.mec.pt/scielo.php?script=sci_arttext&amp;pid=S0871-97212016000200008&amp;lng=pt&amp;nrm=iso&amp;tlng=pt</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-111-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-111-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170506, Caiado J</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41536</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhou,Y.</style></author><author><style face="normal" font="default"> Hu,L.W.</style></author><author><style face="normal" font="default"> Qian,Z.M.</style></author><author><style face="normal" font="default"> Geiger,S.D.</style></author><author><style face="normal" font="default"> Parrish,K.L.</style></author><author><style face="normal" font="default"> Dharmage,S.C.</style></author><author><style face="normal" font="default"> Campbell,B.</style></author><author><style face="normal" font="default"> Roponen,M.</style></author><author><style face="normal" font="default"> Jalava,P.</style></author><author><style face="normal" font="default"> Hirvonen,M.R.</style></author><author><style face="normal" font="default"> Heinrich,J.</style></author><author><style face="normal" font="default"> Zeng,X.W.</style></author><author><style face="normal" font="default"> Yang,B.Y.</style></author><author><style face="normal" font="default"> Qin,X.D.</style></author><author><style face="normal" font="default"> Lee,Y.L.</style></author><author><style face="normal" font="default"> Dong,G.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Guangzhou Key Laboratory of Environmental Pollution and Health Risk Assessment, Department of Preventive Medicine, School of Public Health, Sun Yat-sen University, Guangzhou, 510080, China</style></auth-address><titles><title><style face="normal" font="default">Interaction effects of polyfluoroalkyl substances and sex steroid hormones on asthma among children</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="899">899-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Pollution</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Estradiol</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hormones</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Preventive Medicine</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Taiwan</style></keyword><keyword><style face="normal" font="default"> Testosterone</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="18" Month="4" Year="2017">2017/4/18</year></dates><abstract><style face="normal" font="default">To evaluate the interactions between polyfluoroalkyl substances (PFASs) and reproductive hormones and associated asthma, a total of 231 asthmatic and 225 non-asthmatic adolescents were selected from northern Taiwan in the Genetic and Biomarkers study for Childhood Asthma from 2009-2010. The interaction between PFASs and reproductive hormones on asthma was analyzed with a two-level binary logistic regression model. The results showed that, among asthmatics, PFASs were positively associated with estradiol levels and negatively associated with testosterone levels. However, only significant association was identified for PFNA and estradiol in control group. After controlling for hormone levels, associations between PFAS exposure and asthma were consistently stronger among children with higher than lower estradiol, with odds ratios (OR) for asthma ranging from 1.25 for PFOS (95% Confidence Interval [CI]: 0.90, 1.72) to 4.01 for PFDA (95% CI: 1.46, 11.06) among boys and 1.25 for PFOS (95% CI: 0.84, 1.86) to 4.16 for PFNA (95% CI: 1.36, 12.73) among girls. Notably, the interactions between estradiol and PFASs were significant for PFOS (p = 0.026) and PFNA (p = 0.043) among girls. However, testosterone significantly attenuated the association between PFOS and asthma across sex. In conclusions, our findings suggested that reproductive hormones amplify the association between PFASs and asthma among adolescents</style></abstract><notes><style face="normal" font="default">DA - 20170419IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -CO - Australia -CO - Finland -CO - Germany -CO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1038/s41598-017-01140-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28420867">PM:28420867</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Rep\2017-7-899.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Rep\2017-7-899.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170419, Zhou Y</style></custom2><misc3><style face="normal" font="default">10.1038/s41598-017-01140-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41537</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">LaHood,B.R.</style></author><author><style face="normal" font="default"> Andrew,N.</style></author><author><style face="normal" font="default"> Goggin,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Queen Elizabeth Hospital, Adelaide, Australia, The South Australian Institute of Ophthalmology, The University of Adelaide, South Australia.</style></auth-address><titles><title><style face="normal" font="default">Antibiotic Prophylaxis in Cataract Surgery in The Setting of Penicillin Allergy: A Decision Making Algorithm</style></title><secondary-title><style face="normal" font="default">Surv Ophthalmol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Surv Ophthalmol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotic Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Cataract</style></keyword><keyword><style face="normal" font="default"> cataract surgery</style></keyword><keyword><style face="normal" font="default"> Cefuroxime</style></keyword><keyword><style face="normal" font="default"> cephalosporin</style></keyword><keyword><style face="normal" font="default"> Cephalosporins</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> Consensus</style></keyword><keyword><style face="normal" font="default"> cross reactivity</style></keyword><keyword><style face="normal" font="default"> Cross-reactivity</style></keyword><keyword><style face="normal" font="default"> Decision Making</style></keyword><keyword><style face="normal" font="default"> Developed Countries</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endophthalmitis</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Ophthalmology</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> Penicillins</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Statistics</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="21" Month="4" Year="2017">2017/4/21</year></dates><abstract><style face="normal" font="default">Cataract surgery is the most commonly performed surgical procedure in many developed countries. Post-operative endophthalmitis is a rare complication with potentially devastating visual outcomes. Currently, there is no global consensus regarding antibiotic prophylaxis in cataract surgery despite growing evidence of the benefits of prophylactic intracameral cefuroxime at the conclusion of surgery. The decision about which antibiotic regimen to use is further complicated in patients reporting penicillin allergy. Historic statistics suggesting cross-reactivity of penicillins and cephalosporins have persisted into modern surgery. It is important for ophthalmologists to consider all available antibiotic options and have an up-to-date knowledge of antibiotic cross-reactivity when faced with the dilemma of choosing appropriate antibiotic prophylaxis for patients undergoing cataract surgery with a history of penicillin allergy. Each option carries risks and the choice may have medico-legal implications in the event of an adverse outcome. We assess the options for antibiotic prophylaxis in cataract surgery in the setting of penicillin allergy and provide an algorithm to assist decision making for individual patients</style></abstract><notes><style face="normal" font="default">DA - 20170425IS - 1879-3304 (Electronic)IS - 0039-6257 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.survophthal.2017.04.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28438590">PM:28438590</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Surv Ophthalmol\20170425-LaHoodBR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Surv Ophthalmol\20170425-LaHoodBR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170425, LaHood BR</style></custom2><misc3><style face="normal" font="default">10.1016/j.survophthal.2017.04.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41538</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ben Mahmoud,L.</style></author><author><style face="normal" font="default"> Bahloul,N.</style></author><author><style face="normal" font="default"> Ghozzi,H.</style></author><author><style face="normal" font="default"> Kammoun,B.</style></author><author><style face="normal" font="default"> Hakim,A.</style></author><author><style face="normal" font="default"> Sahnoun,Z.</style></author><author><style face="normal" font="default"> Kammoun,S.</style></author><author><style face="normal" font="default"> Zeghal,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre regional de pharmacovigilance de Sfax, faculte de medecine de Sfax, avenue Majida-Boulila, 3029 Sfax, Tunisie.</style></auth-address><titles><title><style face="normal" font="default">[Epicutaneous patch testing in delayed drug hypersensitivity reactions induced by antiepileptic drugs]</style></title><secondary-title><style face="normal" font="default">Therapie</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Therapie</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> Antiepileptic</style></keyword><keyword><style face="normal" font="default"> Antiepileptic drugs</style></keyword><keyword><style face="normal" font="default"> Carbamazepine</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> cross reactivity</style></keyword><keyword><style face="normal" font="default"> Cross-reactivity</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Delayed hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Delayed hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> DRESS</style></keyword><keyword><style face="normal" font="default"> DRESS syndrome</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug eruption</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> epicutaneous</style></keyword><keyword><style face="normal" font="default"> Epicutaneous tests</style></keyword><keyword><style face="normal" font="default"> Exanthema</style></keyword><keyword><style face="normal" font="default"> Fixed drug eruption</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharmacovigilance</style></keyword><keyword><style face="normal" font="default"> Phenobarbital</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin reaction</style></keyword><keyword><style face="normal" font="default"> skin reactions</style></keyword><keyword><style face="normal" font="default"> Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default"> Stevens-Johnson Syndrome</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Tunisia</style></keyword><keyword><style face="normal" font="default"> Valproic Acid</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="25" Month="3" Year="2017">2017/3/25</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Antiepileptic drugs are widely used and are associated with numerous side effects including skin eruptions. Epicutaneous tests have been used with variable success in skin drug reactions. The purpose of this study was to evaluate the profitability of epicutaneous tests in delayed hypersensitivity reactions induced by antiepileptic drugs. METHODS: We analyzed all cases of allergic skin reactions to antiepileptic drugs notified in regional pharmacovigilance center of Sfax (Tunisia) between June 1, 2014 and April 30, 2016. The imputation score, determined using the French imputation method, should be at least doubtful. Patch-tests were performed in accordance with the general Europen network on Drug Allergy/European Academy of Allergy and Clinical Immunology (ENDA/EAACI) guidelines. Patch-tests were read according to the generally accepted criteria of the International contact dermatitis research group (ICDRG). RESULTS: In our study, 20 patients were included, among which 23 events were observed. The drug involved in delayed hypersensitivity reactions was carbamazepine in 11 cases, phenobarbital in 10 cases and valproic acid in 4 cases. The clinical reactions caused by the drug were classified as maculopapular exanthema (11 cases), DRESS syndrome (6 cases), Stevens-Johnson syndrome (2 cases), fixed drug eruption (2 cases) and erythroderma (2 cases). Patch-tests were positive in 19 patients (95 %). Cross-reactivity between antiepileptic drugs was observed in 4 cases: between valproic acid and carbamazepine in 2 cases between valproic acid and phenobarbital in 1 case and between phenobarbital and carbamazepine in 1 case. CONCLUSION: In this study, patch testing was a safe and useful method in confirming the culprit drug in delayed hypersensitivity reactions induced by antiepileptic drugs</style></abstract><notes><style face="normal" font="default">DA - 20170418IS - 0040-5957 (Print)IS - 0040-5957 (Linking)LA - frePT - English AbstractPT - Journal ArticleCO - Tunisia -</style></notes><work-type><style face="normal" font="default">10.1016/j.therap.2017.01.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28416298">PM:28416298</url></web-urls></urls><custom2><style face="normal" font="default">20170418, Ben Mahmoud L</style></custom2><misc3><style face="normal" font="default">10.1016/j.therap.2017.01.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41539</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rolfes,M.C.</style></author><author><style face="normal" font="default"> Juhn,Y.J.</style></author><author><style face="normal" font="default"> Wi,C.I.</style></author><author><style face="normal" font="default"> Sheen,Y.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Mayo Medical School, Rochester, MN, USADepartment of Pediatric and Adolescent Medicine/Internal Medicine, Mayo Clinic, Rochester, MN, USADepartment of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USADepartment of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USADepartment of Pediatrics, CHA Gangnam Medical Center, CHA University, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Asthma and the Risk of Rheumatoid Arthritis: An Insight into the Heterogeneity and Phenotypes of Asthma</style></title><secondary-title><style face="normal" font="default">Tuberc Respir Dis (Seoul)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Tuberc Respir Dis (Seoul)</style></abbr-1></periodical><pages end="135" start="113">113-135</pages><volume><style face="normal" font="default">80</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> Arthritis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">Asthma is traditionally regarded as a chronic airway disease, and recent literature proves its heterogeneity, based on distinctive clusters or phenotypes of asthma. In defining such asthma clusters, the nature of comorbidity among patients with asthma is poorly understood, by assuming no causal relationship between asthma and other comorbid conditions, including both communicable and noncommunicable diseases. However, emerging evidence suggests that the status of asthma significantly affects the increased susceptibility of the patient to both communicable and noncommunicable diseases. Specifically, the impact of asthma on susceptibility to noncommunicable diseases such as chronic systemic inflammatory diseases (e.g., rheumatoid arthritis), may provide an important insight into asthma as a disease with systemic inflammatory features, a conceptual understanding between asthma and asthma-related comorbidity, and the potential implications on the therapeutic and preventive interventions for patients with asthma. This review discusses the currently under-recognized clinical and immunological phenotypes of asthma; specifically, a higher risk of developing a systemic inflammatory disease such as rheumatoid arthritis and their implications, on the conceptual understanding and management of asthma. Our discussion is divided into three parts: literature summary on the relationship between asthma and the risk of rheumatoid arthritis; potential mechanisms underlying the association; and implications on asthma management and research</style></abstract><notes><style face="normal" font="default">DA - 20170418IS - 1738-3536 (Print)IS - 1738-3536 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -CO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4046/trd.2017.80.2.113</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28416952">PM:28416952</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Tuberc Respir Dis (Seoul)\2017-80-113-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Tuberc Respir Dis (Seoul)\2017-80-113-35.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170418, Rolfes MC</style></custom2><misc3><style face="normal" font="default">10.4046/trd.2017.80.2.113</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41540</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Unal,S.</style></author><author><style face="normal" font="default"> Kaya,A.</style></author><author><style face="normal" font="default"> Bilgin,L.</style></author><author><style face="normal" font="default"> Misirlioglu,E.</style></author><author><style face="normal" font="default"> Kocabas,C.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Neonatology, Ankara Children's Hematology Oncology Research and Training Hospital, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="default">Wheezing, asthma, and atopy in premature infants at 2 years of age</style></title><secondary-title><style face="normal" font="default">Turk J Med Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Turk J Med Sci</style></abbr-1></periodical><pages end="613" start="607">607-613</pages><volume><style face="normal" font="default">47</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Birth Weight</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Bronchopulmonary Dysplasia</style></keyword><keyword><style face="normal" font="default"> Cereals</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> egg</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Gestational Age</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hematology</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Peanut</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> premature</style></keyword><keyword><style face="normal" font="default"> Premature Birth</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Sepsis</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Ventilation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="18" Month="4" Year="2017">2017/4/18</year></dates><abstract><style face="normal" font="default">BACKGROUND/AIM: We aimed to evaluate wheezing, bronchial asthma (BA), and atopy in premature infants at 2 years of age via a cross-sectional study. MATERIALS AND METHODS: Premature infants at &lt;37 weeks of gestational age (GA) were assessed for atopy by skin-prick test and serum immunoglobulin E level at 2 years of age. The family's and infant's histories of allergy, BA, atopy, and wheezing were obtained by questionnaire and from hospital records. RESULTS: There were 98 infants, with mean birth weight (BW) 1517.4 +/- 486.5 g and GA 30.8 +/- 2.9 weeks. The frequencies of wheezing, asthma, and bronchopulmonary dysplasia (BPD) were 32.7%, 16.3%, and 14.3%, respectively. Skin-prick tests were positive for 11 subjects, with allergy to cereals for 7 infants, egg for 3, and peanut for 1. Wheezing was related to GA, BW, respiratory distress syndrome, mechanical ventilation, sepsis, asphyxia, smoking, antenatal steroid, BA, palivizumab prophylaxis, number of people in the household, and duration of hospitalization (P &lt; 0.05). Wheezing was negatively correlated to GA. Family history of BA, smoking, and number of people in the household were linked to BA (P &lt; 0.05). CONCLUSION: Wheezing was related to degree of premature birth, but BA was linked to BA in the family and smoking. Increased gestation should improve the infant's respiratory health up to 2 years of age</style></abstract><notes><style face="normal" font="default">DA - 20170420IS - 1300-0144 (Print)IS - 1300-0144 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.3906/sag-1511-37</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28425254">PM:28425254</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Turk J Med Sci\2017-47-607-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Turk J Med Sci\2017-47-607-13.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170420, Unal S</style></custom2><misc3><style face="normal" font="default">10.3906/sag-1511-37</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41541</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Erkocoglu,M.</style></author><author><style face="normal" font="default"> Metin,A.</style></author><author><style face="normal" font="default"> Kaya,A.</style></author><author><style face="normal" font="default"> Ozcan,C.</style></author><author><style face="normal" font="default"> Akan,A.</style></author><author><style face="normal" font="default"> Civelek,E.</style></author><author><style face="normal" font="default"> Capanoglu,M.</style></author><author><style face="normal" font="default"> Ginis,T.</style></author><author><style face="normal" font="default"> Kocabas,C.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric Allergy and Immunology, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey</style></auth-address><titles><title><style face="normal" font="default">Allergic and autoimmune disorders in families with selective IgA deficiency</style></title><secondary-title><style face="normal" font="default">Turk J Med Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Turk J Med Sci</style></abbr-1></periodical><pages end="598" start="592">592-598</pages><volume><style face="normal" font="default">47</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Autoimmunity</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Iga</style></keyword><keyword><style face="normal" font="default"> IgA Deficiency</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> Peroxidase</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="18" Month="4" Year="2017">2017/4/18</year></dates><abstract><style face="normal" font="default">BACKGROUND/AIM: IgA deficiency is the most common human primary immunodeficiency. The prevalence of allergic disorders and autoimmunity is thought to be increased in selective IgA deficiency (sIgAD). However, it is currently unclear if these disorders coincide within these families. We aimed to evaluate the frequency of allergic and autoimmune disorders in children with sIgAD and their first-degree relatives (FDRs). MATERIALS AND METHODS: The study included 81 children diagnosed with sIgAD and 274 of their FDRs. The presence of allergic and autoimmune disorders was evaluated and serum antithyroglobulin and antithyroid peroxidase levels were measured in both patients and their first-degree relatives. RESULTS: The mean age of the patients was 9.9 +/- 3.9 years. Among the patients with sIgAD, 45.7% of them had at least one allergic disorder and 17.3% of them had at least one autoimmune disorder. The frequencies of asthma, allergic rhinitis, and eczema in the FDRs of sIgAD patients were 10.9%, 9.1%, and 7.7%, respectively. Among their FDRs, 14.6% had autoimmunity, compared to an estimate of 5% in the general population. CONCLUSION: Increased frequency of allergic and autoimmune disorders in patients with sIgAD and their FDRs suggests a possible common predisposing genetic component for sIgAD and autoimmunity in these families</style></abstract><notes><style face="normal" font="default">DA - 20170420IS - 1300-0144 (Print)IS - 1300-0144 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.3906/sag-1605-50</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28425252">PM:28425252</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Turk J Med Sci\2017-47-592-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Turk J Med Sci\2017-47-592-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170420, Erkocoglu M</style></custom2><misc3><style face="normal" font="default">10.3906/sag-1605-50</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41542</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yesil,S.</style></author><author><style face="normal" font="default"> Kan,A.</style></author><author><style face="normal" font="default"> Abdulmajed,O.</style></author><author><style face="normal" font="default"> Bakirtas,A.</style></author><author><style face="normal" font="default"> Sultan,N.</style></author><author><style face="normal" font="default"> Demirsoy,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric Oncology, Dr. Sami Ulus Maternity, Children's Health, and Disease Training and Research Hospital,Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="default">Role of hygienic factors in the etiology of allergic disorders in children</style></title><secondary-title><style face="normal" font="default">Turk J Med Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Turk J Med Sci</style></abbr-1></periodical><pages end="632" start="627">627-632</pages><volume><style face="normal" font="default">47</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hepatitis</style></keyword><keyword><style face="normal" font="default"> Hygiene</style></keyword><keyword><style face="normal" font="default"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="default"> Igg</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Microscopy</style></keyword><keyword><style face="normal" font="default"> Neisseria</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> Streptococcus</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword></keywords><dates><year Day="18" Month="4" Year="2017">2017/4/18</year></dates><abstract><style face="normal" font="default">BACKGROUND/AIM: We investigated the role of body flora and chronic inflammatory infections in the etiology of allergic disorders in Turkish children. MATERIALS AND METHODS: Forty pediatric asthma patients with positive skin prick tests and 40 age-matched healthy subjects with negative skin prick tests were enrolled in this cross-sectional study. Serum H. pylori IgG, viral hepatitis serology, IL-10, and TGF-beta levels were measured. Stool and throat cultures were taken and tested for occurrence of microorganisms. RESULTS: A significantly higher percentage of nonatopic subjects tested positive for anti-H. pylori antibodies compared to atopic subjects (60% vs. 20%). Serum IL-10 levels were also significantly higher in nonatopic subjects. No significant differences in direct microscopy and culture specimens of stools were observed. Examination of throat flora showed significantly higher occurrences of Neisseria and beta-hemolytic Streptococcus in nonatopic subjects, but higher occurrences of gram-positive bacilli in atopic subjects. CONCLUSION: Higher prevalence of anti-H. pylori antibody and higher serum levels of IL-10 in nonatopic subjects suggest that chronic infection and inflammation may protect against atopic disease. Higher occurrences of Neisseria and beta-hemolytic Streptococcus in throat cultures from nonatopic subjects are novel findings that lend further support to the hygiene hypothesis</style></abstract><notes><style face="normal" font="default">DA - 20170420IS - 1300-0144 (Print)IS - 1300-0144 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.3906/sag-1603-22</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28425257">PM:28425257</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Turk J Med Sci\2017-47-627-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Turk J Med Sci\2017-47-627-32.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170420, Yesil S</style></custom2><misc3><style face="normal" font="default">10.3906/sag-1603-22</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41543</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Straarup,T.S.</style></author><author><style face="normal" font="default"> Bang,U.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Treatment of anaphylactic schock in pregnant women]</style></title><secondary-title><style face="normal" font="default">Ugeskr Laeger</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ugeskr Laeger</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="default">179</style></volume><number><style face="normal" font="default">15</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adrenaline</style></keyword><keyword><style face="normal" font="default"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> Ephedrine</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="10" Month="4" Year="2017">2017/4/10</year></dates><abstract><style face="normal" font="default">This is an update on the treatment of anaphylactic shock in pregnant women. Most guidelines recommend adrenaline as first-line treatment in all patients, but in pregnant patients some recommend ephedrine due to a potential risk of utero-placental hypoperfusion with adrenaline. However, ephedrine is a less potent vasopressor than adrenaline and does not possess the same anti-inflammatory or broncho-dilating effects. As immediate and correct treatment is essential for both the maternal and the fetal outcome, adrenaline should be first-line treatment also in pregnant women</style></abstract><notes><style face="normal" font="default">DA - 20170418IS - 1603-6824 (Electronic)IS - 0041-5782 (Linking)LA - danPT - English AbstractPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28416053">PM:28416053</url></web-urls></urls><custom2><style face="normal" font="default">20170418, Straarup TS</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41544</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chu,W.</style></author><author><style face="normal" font="default"> Chennamsetty,A.</style></author><author><style face="normal" font="default"> Toroussian,R.</style></author><author><style face="normal" font="default"> Lau,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">City of Hope National Medical Center, Department of Urology and Urologic Oncology, Duarte, CA, USA</style></auth-address><titles><title><style face="normal" font="default">Anaphylactic Shock After Intravenous Administration of Indocyanine Green During Robotic Partial Nephrectomy</style></title><secondary-title><style face="normal" font="default">Urol Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Urol Case Rep</style></abbr-1></periodical><pages end="38" start="37">37-38</pages><volume><style face="normal" font="default">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="default"> Anesthesia</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Indocyanine Green</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Indocyanine Green (ICG) is frequently used during urologic robotic procedures and is generally considered to be safe. However, there are reported cases of severe complications from ICG when used for non-urologic purposes. We present the first case to our knowledge of anaphylactic shock in response to intravenous ICG during a robotic partial nephrectomy</style></abstract><notes><style face="normal" font="default">DA - 20170320IS - 2214-4420 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.eucr.2017.02.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28316935">PM:28316935</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Urol Case Rep\2017-12-37-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Urol Case Rep\2017-12-37-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170320, Chu W</style></custom2><misc3><style face="normal" font="default">10.1016/j.eucr.2017.02.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41545</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Labor,M.</style></author><author><style face="normal" font="default"> Labor,S.</style></author><author><style face="normal" font="default"> Juric,I.</style></author><author><style face="normal" font="default"> Fijacko,V.</style></author><author><style face="normal" font="default"> Popovic,G.S.</style></author><author><style face="normal" font="default"> Plavec,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonology, University Hospital Center Osijek, Osijek, Croatia</style></auth-address><titles><title><style face="normal" font="default">Long-term predictors of anxiety and depression in adult patients with asthma</style></title><secondary-title><style face="normal" font="default">Wien Klin Wochenschr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Wien Klin Wochenschr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Adult asthma</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Croatia</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mood</style></keyword><keyword><style face="normal" font="default"> Mood Disorders</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistence</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="18" Month="4" Year="2017">2017/4/18</year></dates><abstract><style face="normal" font="default">BACKGROUND: It is well established that anxiety and depression are associated with asthma, but there is limited evidence about the persistence of anxiety/depression in asthma. The aim of our study was to assess the long-term predictors of anxiety and depression in adult asthmatic patients. METHODS: A total of 90 adult asthma patients (63 women, age 18-50 years) with different levels of disease control (28 uncontrolled and 34 partially controlled) were assessed at baseline and at follow-up after 7 years for anxiety, depression and asthma control. The same work-up on both occasions included: demographics, living conditions, medical history (e.g. comorbidities, adherence and exacerbations), Hospital Anxiety and Depression Scale (HADS), Asthma Quality of Life Questionnaire (AQLQ), disease control and lung function. Persistence was defined as the HADS scores for anxiety and depression present at baseline and follow-up. RESULTS: The HADS results at follow-up visit showed 36 (40%) asthma patients with anxiety and 13 (14%) with depression, with the persistence of anxiety in 17 (19%) and of depression in 7 (8%) patients. Significant predictors of anxiety at follow-up were HADS and AQLQ results at baseline and several parameters of asthma control at follow-up (area under the curve AUC 0.917, 95% confidence interval CI 0.829-0.969, p &lt; 0.001) and for depression AQLQ mood disorder domain, asthma control and lung function (AUC 0.947, 95% CI 0.870-0.986, p &lt; 0.001). CONCLUSION: Anxiety and depression persist over years in some patients with asthma. The association between mood disorders and asthma suggests potential mutual treatability</style></abstract><notes><style face="normal" font="default">DA - 20170419IS - 1613-7671 (Electronic)IS - 0043-5325 (Linking)LA - engPT - Journal ArticleCO - Croatia -</style></notes><work-type><style face="normal" font="default">10.1007/s00508-017-1203-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28421345">PM:28421345</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Wien Klin Wochenschr\20170419-LaborM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Wien Klin Wochenschr\20170419-LaborM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170419, Labor M</style></custom2><misc3><style face="normal" font="default">10.1007/s00508-017-1203-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41546</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Petrisor,C.</style></author><author><style face="normal" font="default"> Gherman,N.</style></author><author><style face="normal" font="default"> Sfichi,M.</style></author><author><style face="normal" font="default"> Muresan,M.</style></author><author><style face="normal" font="default"> Hagau,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Departments of *Anesthesia and Intensive Care</style></auth-address><titles><title><style face="normal" font="default">Multiple Anesthetic Drug Sensitization in a Hairdresser With Previous Immediate-Type Hypersensitivity to Penicillin: A Case Report</style></title><secondary-title><style face="normal" font="default">A A Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">A A Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy test</style></keyword><keyword><style face="normal" font="default"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="default"> Anesthesia</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> General anesthesia</style></keyword><keyword><style face="normal" font="default"> Hairdresser</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Immediate-type hypersensitivity</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> Neuromuscular blocking agent</style></keyword><keyword><style face="normal" font="default"> Neuromuscular Blocking Agents</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Romania</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="default">Risk factors for intraoperative immediate-type hypersensitivity reactions may require allergological evaluation. We report the case of a hairdresser with a positive history of penicillin hypersensitivity and anaphylactic shock during previous general anesthesia, whose in vivo and in vitro allergy tests were positive for neuromuscular blocking agents, opioids, and midazolam. Immediate-type hypersensitivity reactions to antibiotics and professional exposure to hairdressing products might induce simultaneous cross-sensitization to multiple drugs that are commonly used during general anesthesia</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 2325-7237 (Electronic)IS - 2325-7237 (Linking)LA - engPT - Journal ArticleCO - Romania -</style></notes><work-type><style face="normal" font="default">10.1213/XAA.0000000000000552</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28509778">PM:28509778</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\A A Case Rep\20170516-PetrisorC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\A A Case Rep\20170516-PetrisorC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Petrisor C</style></custom2><misc3><style face="normal" font="default">10.1213/XAA.0000000000000552</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41547</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gunduz,S.</style></author><author><style face="normal" font="default"> Usak,E.</style></author><author><style face="normal" font="default"> Ozen,S.</style></author><author><style face="normal" font="default"> Gorpelioglu,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Turgut Ozal University, Department of Pediatrics, Turkey.</style></auth-address><titles><title><style face="normal" font="default">Obsessive Compulsive Symptoms and Quality of Life in mothers of Children With Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">Actas Dermosifiliogr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Actas Dermosifiliogr</style></full-title></periodical><pages end="437" start="432">432-437</pages><volume><style face="normal" font="default">108</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVES: Atopic dermatitis is one of the most common skin disorders in children and it can negatively affect both children and their families. The purpose of this study was to investigate the effect of atopic dermatitis on quality of life related to maternal health and maternal obsessive compulsive symptoms. METHODS: A cross-sectional study was conducted in the pediatric and dermatology polyclinics. The SCORAD index was used for determining the severity of disease, and the Maudsley Obsessive Compulsive Inventory (MOCI) and SF-36 form were applied to the participants' mothers. RESULTS: A total of 120 children and their mothers participated the study. Comparing the atopic dermatitis group and the healthy control group, no statistically significant differences were seen in terms of MOCI and SF-36 scores, except for the physical functioning subscore. CONCLUSION: The results showed that having a child with atopic dermatitis and the severity of the disease do not influence their mothers in terms of obsessive-compulsive symptoms and health-related quality of life, except for physical functioning scores</style></abstract><notes><style face="normal" font="default">DA - 20170514IS - 1578-2190 (Electronic)IS - 0001-7310 (Linking)LA - engLA - spaPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1016/j.ad.2017.01.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28501261">PM:28501261</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Actas Dermosifiliogr\2017-108-432-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Actas Dermosifiliogr\2017-108-432-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170514, Gunduz S</style></custom2><misc3><style face="normal" font="default">10.1016/j.ad.2017.01.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41548</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lipinska-Opalka,A.</style></author><author><style face="normal" font="default"> Wawrzyniak,A.</style></author><author><style face="normal" font="default"> Lewicki,S.</style></author><author><style face="normal" font="default"> Zdanowski,R.</style></author><author><style face="normal" font="default"> Kalicki,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric, Nephrology and Allergology Clinic, Military Institute of Medicine, Warsaw, Poland.</style></auth-address><titles><title><style face="normal" font="default">Evaluation of Immune Indices and Serum Vitamin D Content in Children with Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">Adv Exp Med Biol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Adv Exp Med Biol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> CD4</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human leukocyte antigen</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> natural killer T cells</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> regulatory T cell</style></keyword><keyword><style face="normal" font="default"> regulatory T cells</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="default">The influence of vitamin D on allergic diseases, including atopic dermatitis, is linked to the presence of vitamin D nuclear receptors in immune cells. The present study seeks to determine the possible relationship between serum vitamin D content and immune indices in children with atopic dermatitis. The study was conducted in 19 children with atopic dermatitis. The control consisted of 17 age-matched healthy children. A single significant finding was a distinctly lower number of serum regulatory T cells in atopic dermatitis compared with controls (p &lt; 0.00001). There were no appreciable differences between the two groups concerning the immunological indices such as the phenotypes: CD3, CD4, CD8, CD4/CD8, CD19, CD16/56, natural killer T cells, and anti-CD3 human leukocyte antigen - antigen D related cell surface receptor (HLA-DR3), or the percentage of lymphocytes, eosinophils, and the IgE level. We also revealed an inverse association between the serum vitamin D and the percentage of CD8+ cells (p &lt; 0.05; r = 0.62) in atopic dermatitis. In conclusion, the results point to a regulatory role of T cells in the pathogenesis of atopic dermatitis, but fail to substantiate the influence of vitamin D on the course of the disease</style></abstract><notes><style face="normal" font="default">DA - 20170517IS - 0065-2598 (Print)IS - 0065-2598 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1007/5584_2017_20</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28512681">PM:28512681</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Adv Exp Med Biol\20170517-LipinskaOpalkaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Adv Exp Med Biol\20170517-LipinskaOpalkaA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170517, Lipinska-Opalka A</style></custom2><misc3><style face="normal" font="default">10.1007/5584_2017_20</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41549</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Venegas-Montoya,E.</style></author><author><style face="normal" font="default"> Lopez-Perez,G.T.</style></author><author><style face="normal" font="default"> Mendoza-Hernandez,D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Trascendencia de la prueba de activación de basófilos en alergia a anestésicos ¿Son suficientes las pruebas cutáneas? Reporte de caso y revisión de la literatura</style></title><secondary-title><style face="normal" font="default">Alergia Asma Inmunol Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Alergia Asma Inmunol Pediatr</style></full-title></periodical><pages end="110" start="106">106-110</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Alergia</style></keyword><keyword><style face="normal" font="default"> Anafilaxia</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Anestesia</style></keyword><keyword><style face="normal" font="default"> Anesthesia</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophil activation test</style></keyword><keyword><style face="normal" font="default"> BAT</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Fatal Outcome</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Mexico</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Perioperative anaphylaxis</style></keyword><keyword><style face="normal" font="default"> REACH</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Hypersensitivity reactions to anesthesia are rare, but are associated with significant morbidity andmortality. Confirming the diagnosis is complex due to the large number of drugs administered to thepatient at the same time, making it difficult to identify the causative agent. The incidence is 1 in 1,250to 1 in 10,000, with a fatal outcome that varies by country, from 4% in the US to 1.4% in Australia. Skintest and basophil activation test are included within the diagnostic approach, which has specificity of90%, making BAT a useful alternative to confirm the diagnosis if skin test result is negative or difficult tointerpret. The following case, a three year old female with history of perioperative anaphylaxis, is shownto illustrate that, despite the initial approach with negative skin tests, the test activation of basophil ispositive, highlighting the importance to reach the final diagnostic option given the magnitude of theresponse of the patient and the high risk of a new anaphylactic reaction with fatal outcome.</style></abstract><notes><style face="normal" font="default">LA - SPACO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://new.medigraphic.com/cgi-bin/resumen.cgi?IDARTICULO=69609</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Alergia Asma Inmunol Pediatr\2016-25-106-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Alergia Asma Inmunol Pediatr\2016-25-106-10.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170520, Venegas-Montoya E</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41550</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Haberle,M.</style></author><author><style face="normal" font="default"> Geier,J.</style></author><author><style face="normal" font="default"> Mahler,V.</style></author></authors></contributors><titles><title><style face="normal" font="default">Contact allergy and intolerance to sulphite compounds: clinical and occupational relevance</style></title><secondary-title><style face="normal" font="default">Allergo J Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergo J Int</style></abbr-1></periodical><pages end="66" start="53">53-66</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> Antioxidants</style></keyword><keyword><style face="normal" font="default"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Preservatives</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin reaction</style></keyword><keyword><style face="normal" font="default"> skin reactions</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2197-0378</style></isbn><abstract><style face="normal" font="default">Sulphites are widely used as preservatives and antioxidants, e.</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çëg., in the food, cosmetic, and pharmaceutical industries. They are known to trigger epidermal sensitizations and associated eczematous contact allergic skin reactions; to identify these, patch testing is performed using sodium disulphite (=-ásodium metabisulphite; CAS-á7681-57-4). In addition to this, inhalation or oral exposure to sulphite can cause the clinical picture of sulphite intolerance, including bronchoconstriction, urticaria, cardiovascular, intestinal, and/or life-threatening anaphylactic reactions, the identification of which requires challenge testing</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1007/s40629-016-0003-x</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40629-016-0003-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergo J Int\2017-26-53-66.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergo J Int\2017-26-53-66.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170520, Haberle M</style></custom2><misc3><style face="normal" font="default">10.1007/s40629-016-0003-x</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41551</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nagao,M.</style></author><author><style face="normal" font="default"> Ikeda,M.</style></author><author><style face="normal" font="default"> Fukuda,N.</style></author><author><style face="normal" font="default"> Habukawa,C.</style></author><author><style face="normal" font="default"> Kitamura,T.</style></author><author><style face="normal" font="default"> Katsunuma,T.</style></author><author><style face="normal" font="default"> Fujisawa,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Center, Mie National Hospital, Tsu, Japan</style></auth-address><titles><title><style face="normal" font="default">Early control treatment with montelukast in preschool children with asthma: A randomized controlled trial</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">acute asthma</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> montelukast</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> preschool children</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: While Japanese guideline recommends initial control treatment for preschool children with asthma symptoms more than once a month, Western guidelines do not. To determine whether control treatment with montelukast was more effective than as-needed beta2-agonists in this population, we conducted a randomized controlled trial. METHODS: Eligible patients were children aged 1-5 years who had asthma symptoms more than once a month but less than once a week. Patients were randomly assigned in a 1:1 ratio to receive montelukast 4 mg daily for 48 weeks or as-needed beta2-agonists. The primary endpoint was the number of acute asthma exacerbations before starting step-up treatment with inhaled corticosteroids. This study is registered with the University Hospital Medical Information Network clinical trials registry, number UMIN000002219. RESULTS: From September 2009 to November 2012, 93 patients (47 in the montelukast group and 46 in the no-controller group) were enrolled into the study. All patients were included in the analysis. During the study, 13 patients (28%) in the montelukast group and 23 patients (50%) in the no-controller group had acute exacerbations with the mean numbers of 0.9 and 1.9/year, respectively (P = 0.027). In addition, 10 (21%) and 19 (41%) patients received step-up treatment, respectively. Cumulative incidence of step-up treatment was significantly lower in the montelukast group (hazard ratio 0.45, 95% confidence interval 0.21 to 0.92; P = 0.033). CONCLUSIONS: Montelukast is an effective control treatment for preschool children who had asthma symptoms more than once a month but less than once a week</style></abstract><notes><style face="normal" font="default">DA - 20170520IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.04.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28526210">PM:28526210</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170520-NagaoM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170520-NagaoM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170520, Nagao M</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.04.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41552</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Miyasaka,T.</style></author><author><style face="normal" font="default"> Dobashi-Okuyama,K.</style></author><author><style face="normal" font="default"> Takahashi,T.</style></author><author><style face="normal" font="default"> Takayanagi,M.</style></author><author><style face="normal" font="default"> Ohno,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pathophysiology, Department of Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, Sendai, Japan</style></auth-address><titles><title><style face="normal" font="default">The interplay between neuroendocrine activity and psychological stress-induced exacerbation of allergic asthma</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Autonomic Nervous System</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endocrine System</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> glucocorticoid receptor</style></keyword><keyword><style face="normal" font="default"> Glucocorticoids</style></keyword><keyword><style face="normal" font="default"> Hormones</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunomodulators</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Nervous System</style></keyword><keyword><style face="normal" font="default"> Norepinephrine</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rodent</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> TH17</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="20" Month="5" Year="2017">2017/5/20</year></dates><abstract><style face="normal" font="default">Psychological stress is recognized as a key factor in the exacerbation of allergic asthma, whereby brain responses to stress act as immunomodulators for asthma. In particular, stress-induced enhanced type 2 T-helper (Th2)-type lung inflammation is strongly associated with asthma pathogenesis. Psychological stress leads to eosinophilic airway inflammation through activation of the hypothalamic-pituitary-adrenal pathway and autonomic nervous system. This is followed by the secretion of stress hormones into the blood, including glucocorticoids, epinephrine, and norepinephrine, which enhance Th2 and type 17 T-helper (Th17)-type asthma profiles in humans and rodents. Recent evidence has shown that a defect of the mu-opioid receptor in the brain along with a defect of the peripheral glucocorticoid receptor signaling completely disrupted stress-induced airway inflammation in mice. This suggests that the stress response facilitates events in the central nervous and endocrine systems, thus exacerbating asthma. In this review, we outline the recent findings on the interplay between stress and neuroendocrine activities followed by stress-induced enhanced Th2 and Th17 immune responses and attenuated regulatory T (Treg) cell responses that are closely linked with asthma exacerbation. We will place a special focus on our own data that has emphasized the continuity from central sensing of psychological stress to enhanced eosinophilic airway inflammation. The mechanism that modulates psychological stress-induced exacerbation of allergic asthma through neuroendocrine activities is thought to involve a series of consecutive pathological events from the brain to the lung, which implies there to be a "neuropsychiatry phenotype" in asthma</style></abstract><notes><style face="normal" font="default">DA - 20170525IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.04.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28539203">PM:28539203</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170525-MiyasakaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170525-MiyasakaT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170525, Miyasaka T</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.04.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41553</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Miyake,K.</style></author><author><style face="normal" font="default"> Karasuyama,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immune Regulation, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default">Emerging roles of basophils in allergic inflammation</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adaptive</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Chemokines</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endothelial Cells</style></keyword><keyword><style face="normal" font="default"> Fibroblasts</style></keyword><keyword><style face="normal" font="default"> humoral</style></keyword><keyword><style face="normal" font="default"> IgE-dependent</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate lymphoid cells</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> Protease</style></keyword><keyword><style face="normal" font="default"> proteases</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Serine</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="11" Month="5" Year="2017">2017/5/11</year></dates><abstract><style face="normal" font="default">Basophils have long been neglected in immunological studies because they were regarded as only minor relatives of mast cells. However, recent advances in analytical tools for basophils have clarified the non-redundant roles of basophils in allergic inflammation. Basophils play crucial roles in both IgE-dependent and -independent allergic inflammation, through their migration to the site of inflammation and secretion of various mediators, including cytokines, chemokines, and proteases. Basophils are known to produce large amounts of IL-4 in response to various stimuli. Basophil-derived IL-4 has recently been shown to play versatile roles in allergic inflammation by acting on various cell types, including macrophages, innate lymphoid cells, fibroblasts, and endothelial cells. Basophil-derived serine proteases are also crucial for the aggravation of allergic inflammation. Moreover, recent reports suggest the roles of basophils in modulating adaptive immune responses, particularly in the induction of Th2 differentiation and enhancement of humoral memory responses. In this review, we will discuss recent advances in understanding the roles of basophils in allergic inflammation</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.04.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28506528">PM:28506528</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170516-MiyakeK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170516-MiyakeK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Miyake K</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.04.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41554</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kubo,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Molecular Pathology, Research Institute for Biomedical Science, Tokyo University of Science, Noda, Japan</style></auth-address><titles><title><style face="normal" font="default">T follicular helper and TH2 cells in allergic responses</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic response</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgG1</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Notch</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> Th2 Cells</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="9" Month="5" Year="2017">2017/5/9</year></dates><abstract><style face="normal" font="default">IL-4 is a cytokine commonly secreted by TH2 and follicular helper T (TFH) cells after antigenic sensitization. TH2 cells have been thought to be the major contributor of B cell help as a source of IL-4 responsible for class switch recombination to Immunoglobulin G1 (IgG1) and Immunoglobulin E (IgE). Importantly, there are some differences in transcriptional regulation between these two T cell subsets. The IL-4 production by TH2 and TFH cells is distinctively regulated by two pathways, GATA-3-mediated Il4-HS2 enhancer and Notch mediated Il4-CNS-2 enhancer. IgE and IgG1 antibody responses are mainly controlled by IL-4-secreting TFH cells, but not by TH2 cells. In this review, we discuss the role of TH2 and TFH cells in IgE production and allergic responses</style></abstract><notes><style face="normal" font="default">DA - 20170513IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.04.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28499720">PM:28499720</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170513-KuboM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170513-KuboM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170513, Kubo M</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.04.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41555</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Milger,K.</style></author><author><style face="normal" font="default"> Gotschke,J.</style></author><author><style face="normal" font="default"> Krause,L.</style></author><author><style face="normal" font="default"> Nathan,P.</style></author><author><style face="normal" font="default"> Alessandrini,F.</style></author><author><style face="normal" font="default"> Tufman,A.</style></author><author><style face="normal" font="default"> Fischer,R.</style></author><author><style face="normal" font="default"> Bartel,S.</style></author><author><style face="normal" font="default"> Theis,F.J.</style></author><author><style face="normal" font="default"> Behr,J.</style></author><author><style face="normal" font="default"> Dehmel,S.</style></author><author><style face="normal" font="default"> Mueller,N.S.</style></author><author><style face="normal" font="default"> Kneidinger,N.</style></author><author><style face="normal" font="default"> Krauss-Etschmann,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine V, University of Munich, Comprehensive Pneumology Center, Munich, Germany</style></auth-address><titles><title><style face="normal" font="default">Identification of a plasma miRNA biomarker-signature for allergic asthma: a translational approach</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> House dust</style></keyword><keyword><style face="normal" font="default"> house dust mite</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> MicroRNAs</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Ovalbumin</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is a heterogeneous chronic disease with different phenotypes and treatment responses. Thus, there is a high clinical need for molecular disease biomarkers to aid in differentiating these distinct phenotypes. As MicroRNAs (miRNAs), that regulate gene expression at the post-transcriptional level, are altered in experimental and human asthma, circulating miRNAs are attractive candidates for the identification of novel biomarkers. This study aimed to identify plasmatic miRNA-based biomarkers of asthma, through a translational approach. METHODS: We pre-screened miRNAs in plasma samples from two different murine models of experimental asthma (ovalbumin and house dust mite); miRNAs deregulated in both models were further tested in a human training cohort of 20 asthma patients and 9 healthy controls. Candidate miRNAs were then validated in a second, independent group of 26 asthma patients and 12 healthy controls. RESULTS: 10 miRNA ratios consisting of 13 miRNAs were differentially regulated in both murine models. Measuring these miRNAs in the training cohort identified a biomarker signature consisting of 5 miRNA ratios (7 miRNAs). This signature showed a good sensitivity and specificity in the test cohort with an area under the receiver operating characteristic curve (AUC) of 0.92. Correlation of miRNA ratios with clinical characteristics further revealed associations with FVC % predicted, and oral corticosteroid or antileukotriene use. CONCLUSION: Distinct plasma miRNAs are differentially regulated both in murine and human allergic asthma and were associated with clinical characteristics of patients. Thus, we suggest that miRNA levels in plasma might have future potential to subphenotype patients with asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170517IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/all.13205</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28513859">PM:28513859</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170517-MilgerK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170517-MilgerK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170517, Milger K</style></custom2><misc3><style face="normal" font="default">10.1111/all.13205</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41556</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Letourneau,N.L.</style></author><author><style face="normal" font="default"> Kozyrskyj,A.L.</style></author><author><style face="normal" font="default"> Cosic,N.</style></author><author><style face="normal" font="default"> Ntanda,H.N.</style></author><author><style face="normal" font="default"> Anis,L.</style></author><author><style face="normal" font="default"> Hart,M.J.</style></author><author><style face="normal" font="default"> Campbell,T.S.</style></author><author><style face="normal" font="default"> Giesbrecht,G.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Nursing, University of Calgary, Calgary, AB T2N 1N4 Canada</style></auth-address><titles><title><style face="normal" font="default">Maternal sensitivity and social support protect against childhood atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Clin Immunol</style></full-title></periodical><pages end="" start="26">26-</pages><volume><style face="normal" font="default">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Gestational Age</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> Nursing</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Perinatal</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Pregnancy Outcome</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Social Support</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Many studies have identified associations between qualities of maternal-child relationships and childhood asthma, but few have examined associations with childhood atopic dermatitis (AD), a common precursor to asthma. Moreover, maternal psychological distress, including prenatal and postnatal depression, anxiety and stress, may increase risk, while social support from partners may reduce risk for childhood AD. We sought to uncover the association between maternal-infant relationship qualities (maternal sensitivity towards infant behavioral signals, controlling behavior, and unresponsiveness) and child AD after accounting for risk (i.e., prenatal and postnatal maternal depression, anxiety and stress) and protective (i.e., social support) factors. METHODS: We conducted a secondary analysis of data collected on a subsample of 242 women and their infants enrolled during pregnancy in the ongoing Alberta Pregnancy Outcomes and Nutrition cohort study. Inclusion criteria required mothers to be >16 years of age, English speaking and &lt;22 weeks gestational age at enrollment. Data on depression, anxiety and stress in the prenatal and postnatal periods and physician diagnosis of childhood AD at 18 months were gathered via maternal report. Maternal sensitivity, unresponsiveness and controlling behaviours were assessed via videotaped observations using the Child-Adult Relationship Experimental (CARE)-Index at 6 months of infant age. RESULTS: Higher maternal sensitivity, or the inability of the mother to appropriately understand and respond to infant needs based on behavioral signals, predicted reduced odds of AD independent of and in combination with low prenatal and postnatal anxiety and high paternal support. After adjustment, higher maternal controlling behaviours and unresponsiveness also predicted greater odds of AD. CONCLUSIONS: Low maternal sensitivity is a risk factor for childhood AD, independently and in combination with perinatal anxiety and low social support. Thus, interventions that improve maternal-infant relationship quality, especially sensitivity, reduce anxiety and improve social support from partners could reduce odds of childhood AD</style></abstract><notes><style face="normal" font="default">DA - 20170531IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1186/s13223-017-0199-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28559916">PM:28559916</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-26.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-26.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170531, Letourneau NL</style></custom2><misc3><style face="normal" font="default">10.1186/s13223-017-0199-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41557</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Demir,S.</style></author><author><style face="normal" font="default"> Gelincik,A.</style></author><author><style face="normal" font="default"> Akdeniz,N.</style></author><author><style face="normal" font="default"> ktas-Cetin,E.</style></author><author><style face="normal" font="default"> Olgac,M.</style></author><author><style face="normal" font="default"> Unal,D.</style></author><author><style face="normal" font="default"> Ertek,B.</style></author><author><style face="normal" font="default"> Coskun,R.</style></author><author><style face="normal" font="default"> Colakoglu,B.</style></author><author><style face="normal" font="default"> Deniz,G.</style></author><author><style face="normal" font="default"> Buyukozturk,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="default">Usefulness of In Vivo and In Vitro Diagnostic Tests in the Diagnosis of Hypersensitivity Reactions to Quinolones and in the Evaluation of Cross-Reactivity: A Comprehensive Study Including the Latest Quinolone Gemifloxacin</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="359" start="347">347-359</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophil activation test</style></keyword><keyword><style face="normal" font="default"> BAT</style></keyword><keyword><style face="normal" font="default"> Ciprofloxacin</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross reactivity</style></keyword><keyword><style face="normal" font="default"> Cross-reactivity</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic test</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> Drug provocation test</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> LTT</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Transformation</style></keyword><keyword><style face="normal" font="default"> Lymphocyte transformation test</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Ofloxacin</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> Quinolones</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Transformation</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">PURPOSE: Reports evaluating diagnosis and cross reactivity of quinolone hypersensitivity have revealed contradictory results. Furthermore, there are no reports investigating the cross-reactivity between gemifloxacin (GFX) and the others. We aimed to detect the usefulness of diagnostic tests of hypersensitivity reactions to quinolones and to evaluate the cross reactivity between different quinolones including the latest quinolone GFX. METHODS: We studied 54 patients (mean age 42.31+/-10.39 years; 47 female) with 57 hypersensitivity reactions due to different quinolones and 10 nonatopic quinolone tolerable control subjects. A detailed clinical history, skin test (ST), and single-blind placebo-controlled drug provocation test (SBPCDPT), as well as basophil activation test (BAT) and lymphocyte transformation test (LTT) were performed with the culprit and alternative quinolones including ciprofloxacin (CFX), moxifloxacin (MFX), levofloxacin (LFX), ofloxacin (OFX), and GFX. RESULTS: The majority (75.9%) of the patients reported immediate type reactions to various quinolones. The most common culprit drug was CFX (52.6%) and the most common reaction type was urticaria (26.3%). A quarter of the patients (24.1%) reacted to SBPCDPTs, although their STs were negative; while false ST positivity was 3.5% and ST/SBPCDPTs concordance was only 1.8%. Both BAT and LTT were not found useful in quinolone hypersensitivity. Cross-reactivity was primarily observed between LFX and OFX (50.0%), whereas it was the least between MFX and the others, and in GFX hypersensitive patients the degree of cross-reactivity to the other quinolones was 16.7%. CONCLUSIONS: These results suggest that STs, BAT, and LTT are not supportive in the diagnosis of a hypersensitivity reaction to quinolone as well as in the prediction of cross-reactivity. Drug provocation tests (DPTs) are necessary to identify both culprit and alternative quinolones</style></abstract><notes><style face="normal" font="default">DA - 20170512IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.4.347</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497922">PM:28497922</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-347-59.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-347-59.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170512, Demir S</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.4.347</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41558</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ban,G.Y.</style></author><author><style face="normal" font="default"> Ye,Y.M.</style></author><author><style face="normal" font="default"> Kim,S.H.</style></author><author><style face="normal" font="default"> Hur,G.Y.</style></author><author><style face="normal" font="default"> Kim,J.H.</style></author><author><style face="normal" font="default"> Shim,J.J.</style></author><author><style face="normal" font="default"> Cho,K.</style></author><author><style face="normal" font="default"> Cho,J.Y.</style></author><author><style face="normal" font="default"> Park,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea</style></auth-address><titles><title><style face="normal" font="default">Plasma LTE4/PGF2alpha Ratio and Blood Eosinophil Count Are Increased in Elderly Asthmatics With Previous Asthma Exacerbation</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="382" start="378">378-382</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Budesonide</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> elderly</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Leukotriene E4</style></keyword><keyword><style face="normal" font="default"> LTE4</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> montelukast</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Prostaglandin</style></keyword><keyword><style face="normal" font="default"> ROC</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> sputum eosinophil</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">The tools for asthma control assessment recommended by the current guideline are cognitive function- and effort-dependent, which is substantially impaired in the elderly. The aim of this study is to investigate objective assessment tools of asthma control status and previous asthma exacerbation (AE) in elderly subjects. Asthmatics aged >60 years who were treated with step 2 or 3 by the Global Initiative for Asthma (GINA) guideline were enrolled. During the 12-week study period, the subjects used either 400 mug of budesonide plus 10 mg of montelukast or 800 mug of inhaled budesonide. The occurrence of AE during the 4-week run-in and 12-week treatment period was monitored. After 12-week of treatment, sputum eosinophil count, peripheral eosinophil count, the plasma leukotriene E4 (LTE4), and prostaglandin F2alpha (PGF2alpha) metabolite levels were measured using the UHPLC/Q-ToF MS system. The study subjects were divided into group 1 (asthmatics who experienced AE during the study period) and group 2 (those who did not). A total of 101 patients aged 60-85 years were enrolled. Twenty-three patients (22.8%) had experienced AE. The plasma LTE4 level, LTE4/PGF2alpha ratio, and peripheral eosinophil count were significantly higher in group 1 than in group 2 (P=0.023, P=0.010, P=0.033, respectively). The plasma LTE4/PGF2alpha ratio and peripheral eosinophil count at week 12 were significantly associated with previous AE (odds ratio [OR]=1.748, P=0.013; OR=1.256, P=0.027). Receiver operating characteristic (ROC) curves to discriminate the subjects with previous AE, including these 2 parameters, showed that the area under the curve was 0.700 (P=0.004), with 73.9% sensitivity and 47.9% specificity. In conclusion, a combination of plasma LTE4/PGF2alpha ratio and peripheral eosinophil count can be an objective assessment tool which is significantly associated with asthma control status in elderly asthmatics</style></abstract><notes><style face="normal" font="default">DA - 20170512IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.4.378</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497926">PM:28497926</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-378-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-378-82.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170512, Ban GY</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.4.378</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41559</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,D.W.</style></author><author><style face="normal" font="default"> Cho,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Boramae Medical Center, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Emerging Endotypes of Chronic Rhinosinusitis and Its Application to Precision Medicine</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="306" start="299">299-306</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Biologicals</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical phenotypes</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Endotypes</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory mediators</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate lymphoid cells</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Publications</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> subtypes</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> T lymphocyte</style></keyword><keyword><style face="normal" font="default"> T lymphocytes</style></keyword><keyword><style face="normal" font="default"> T-helper-2</style></keyword><keyword><style face="normal" font="default"> T-lymphocyte</style></keyword><keyword><style face="normal" font="default"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory disease with various underlying pathophysiologic mechanisms which translate to endotypes, in contrast to clinical phenotypes or histological subtypes. Defining endotypes can help clinicians predict disease prognosis, select subjects suitable for a specific therapy, and assess risks for comorbid conditions, including asthma. Therefore, with recent advancement of biologicals in CRS clinical trials, endotyping can be a breakthrough in treating recalcitrant CRS. CRS is caused by dysregulated immunologic responses to external stimuli, which induce various inflammatory mediators from inflammatory cells, including innate lymphoid cells (ILCs) and T lymphocytes as well as epithelial cells. Thymic stromal lymphopoietin (TSLP), interleukin (IL)-25, and IL-33, which are mainly secreted by epithelial cells in response to external stimuli, act on type 2 ILCs and T helper 2 (Th2) cells, inducing IL-4, IL-5, and IL-13. Local immunoglobulin E (IgE) production is also a signature event in nasal polyps (NP). These inflammatory mediators are novel potential therapeutic targets for recalcitrant CRS. This article reviews recent publications regarding endotypes and endotype-based therapeutic strategies in CRS and NP</style></abstract><notes><style face="normal" font="default">DA - 20170512IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - South Korea -CO - United States -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.4.299</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497916">PM:28497916</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-299-306.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-299-306.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170512, Kim DW</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.4.299</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41560</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dona,I.</style></author><author><style face="normal" font="default"> Torres,M.J.</style></author><author><style face="normal" font="default"> Montanez,M.I.</style></author><author><style face="normal" font="default"> Fernandez,T.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Unit, IBIMA-Regional University Hospital of Malaga-UMA, Malaga, Spain</style></auth-address><titles><title><style face="normal" font="default">In Vitro Diagnostic Testing for Antibiotic Allergy</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="298" start="288">288-298</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotic allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophil activation test</style></keyword><keyword><style face="normal" font="default"> Basophil activation tests</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Betalactams</style></keyword><keyword><style face="normal" font="default"> Clindamycin</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> Drug provocation test</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> immediate reactions</style></keyword><keyword><style face="normal" font="default"> Immunoassay</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> In Vitro Techniques</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Transformation</style></keyword><keyword><style face="normal" font="default"> Lymphocyte transformation test</style></keyword><keyword><style face="normal" font="default"> macrolide</style></keyword><keyword><style face="normal" font="default"> Macrolides</style></keyword><keyword><style face="normal" font="default"> Metronidazole</style></keyword><keyword><style face="normal" font="default"> non-immediate reactions</style></keyword><keyword><style face="normal" font="default"> nonimmediate</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> Quinolones</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Sulfonamides</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Transformation</style></keyword><keyword><style face="normal" font="default"> trends</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Allergy to antibiotics is an important worldwide problem, with an estimated prevalence of up to 10% of the population. Reaction patterns for different antibiotics have changed in accordance with consumption trends. Most of the allergic reactions to antibiotics have been reported for betalactams, followed by quinolones and macrolides and, to a lesser extent, to others, such as metronidazole clindamycin and sulfonamides. The diagnostic procedure includes a detailed clinical history, which is not always possible and can be unreliable. This is usually followed by in vivo, skin, and drug provocation tests. These are not recommended for severe, potentially lifethreaten reactions or for drugs that are known to produce a high rate of false positive results. Given the limitations of in vivo tests, in vitro test can be helpful for diagnosis, despite having suboptimal sensitivity. The most highly employed techniques for diagnosing immediate reactions to antibiotics are immunoassays and basophil activation tests, while lymphocyte transformation tests are more commonly used to diagnose non-immediate reactions. In this review, we describe different in vitro techniques employed to diagnose antibiotic allergy</style></abstract><notes><style face="normal" font="default">DA - 20170512IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.4.288</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497915">PM:28497915</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-288-98.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-288-98.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170512, Dona I</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.4.288</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41561</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,K.S.</style></author><author><style face="normal" font="default"> Rha,Y.H.</style></author><author><style face="normal" font="default"> Oh,I.H.</style></author><author><style face="normal" font="default"> Choi,Y.S.</style></author><author><style face="normal" font="default"> Kim,Y.E.</style></author><author><style face="normal" font="default"> Choi,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea</style></auth-address><titles><title><style face="normal" font="default">Does Breast-feeding Relate to Development of Atopic Dermatitis in Young Korean Children?: Based on the Fourth and Fifth Korea National Health and Nutrition Examination Survey 2007-2012</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="313" start="307">307-313</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Breast Feeding</style></keyword><keyword><style face="normal" font="default"> Breast-feeding</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> early childhood</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> National Health and Nutrition Examination Survey</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">PURPOSE: There have been conflicting reports concerning the relationship between breast-feeding and the development of atopic dermatitis (AD) in early childhood. The objective of this study was to investigate the associations between breast-feeding and the risk of AD in early childhood in Korea. METHODS: We combined the fourth and fifth Korea National Health and Nutrition Examination Survey data collected from 2007 to 2012 and analyzed 2,015 children at 1 to 3 years old. Regression analysis was used to determine the association of the following variables: AD, feeding types, duration of breast-feeding, and others. RESULTS: The annual prevalence of exclusive breast-feeding and AD decreased. Parents with allergic diseases preferred breast-feeding and extended duration of feeding compared with those without. In multiple logistic regression analyses, exclusive breast-feeding in feeding type I (P=0.070; adjusted odds ratio [OR]=1.990), exclusive breast-feeding in feeding type II (P=0.095; adjusted OR=1.495) and breast-feeding duration (P=0.430; adjusted OR=1.013) were not significantly related to AD. CONCLUSIONS: Breast-feeding was not found to be associated with an occurrence of AD in young children. Rather, parents with histories of allergic diseases tended to prefer breast-feeding and extend its duration. To clarify the role of breast-feeding in the development of AD, a nation-wide prospective study is needed</style></abstract><notes><style face="normal" font="default">DA - 20170512IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.4.307</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497917">PM:28497917</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-307-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-307-13.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170512, Lee KS</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.4.307</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41562</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yoon,J.</style></author><author><style face="normal" font="default"> Choi,Y.J.</style></author><author><style face="normal" font="default"> Lee,E.</style></author><author><style face="normal" font="default"> Cho,H.J.</style></author><author><style face="normal" font="default"> Yang,S.I.</style></author><author><style face="normal" font="default"> Kim,Y.H.</style></author><author><style face="normal" font="default"> Jung,Y.H.</style></author><author><style face="normal" font="default"> Seo,J.H.</style></author><author><style face="normal" font="default"> Kwon,J.W.</style></author><author><style face="normal" font="default"> Kim,H.B.</style></author><author><style face="normal" font="default"> Lee,S.Y.</style></author><author><style face="normal" font="default"> Kim,B.S.</style></author><author><style face="normal" font="default"> Shim,J.Y.</style></author><author><style face="normal" font="default"> Kim,E.J.</style></author><author><style face="normal" font="default"> Lee,J.S.</style></author><author><style face="normal" font="default"> Hong,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Childhood Asthma Atopy Center, Research Center for the Standardization of Allergic Diseases, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Allergic Rhinitis in Preschool Children and the Clinical Utility of FeNO</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="321" start="314">314-321</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Infancy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> preschool children</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Standardization</style></keyword><keyword><style face="normal" font="default"> subtypes</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">PURPOSE: The nature of allergic rhinitis (AR) in preschool aged children remains incompletely characterized. This study aimed to investigate the prevalence of AR and its associated risk factors in preschool-aged children and to assess the clinical utility of fractional exhaled nitric oxide (FeNO). METHODS: This general population-based, cross-sectional survey included 933 preschool-aged (3- to 7-year-old) children from Korea. Current AR was defined as having nasal symptoms within the last 12 months and physician-diagnosed AR. RESULTS: The prevalence of current AR in preschool children was 17.0% (156/919). Mold exposure (adjusted odds ratio [aOR], 1.67; 95% confidence interval [CI], 1.15-2.43) and the use of antibiotics (aOR, 1.97; 95% CI, 1.33-2.90) during infancy were associated with an increased risk of current AR, whereas having an older sibling (aOR, 0.52; 95% CI, 0.35-0.75) reduced the risk. Children with current atopic AR had significantly higher geometric mean levels of FeNO compared to those with non-atopic rhinitis (12.43; range of 1standard deviation [SD], 7.31-21.14 vs 8.25; range of 1SD, 5.62-12.10, P=0.001) or non-atopic healthy children (8.58; range of 1SD, 5.51-13.38, P&lt;0.001). The FeNO levels were higher in children with current atopic AR compared with atopic healthy children (9.78; range of 1SD, 5.97-16.02, P=0.083). CONCLUSIONS: Mold exposure and use of antibiotics during infancy increases the risk of current AR, whereas having an older sibling reduces it. Children with current atopic AR exhibit higher levels of FeNO compared with non-atopic rhinitis cases, suggesting that FeNO levels may be a useful discriminatory marker for subtypes of AR in preschool children</style></abstract><notes><style face="normal" font="default">DA - 20170512IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.4.314</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497918">PM:28497918</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-314-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-314-21.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170512, Yoon J</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.4.314</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41563</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,J.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, School of Medicine, Inha University Hospital, Incheon, Korea</style></auth-address><titles><title><style face="normal" font="default">Role of Breast-feeding in the Development of Atopic Dermatitis in Early Childhood</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="287" start="285">285-287</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Breast Feeding</style></keyword><keyword><style face="normal" font="default"> Breast-feeding</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> early childhood</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170512IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - EditorialCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.4.285</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497914">PM:28497914</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-285-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-285-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170512, Kim JH</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.4.285</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41564</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rosner,G.A.</style></author><author><style face="normal" font="default"> Fonacier,L.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hypersensitivity to biomedical implants: Prevention and diagnosis</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="183" start="177">177-183</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse cutaneous reactions</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Causality</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Consensus</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous reaction</style></keyword><keyword><style face="normal" font="default"> Cutaneous reactions</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Delayed hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Delayed hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health care provider</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> metal hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: There has been growing interest in the potential for adverse immunologic reactions to metals in biomedical devices and increasing referrals for the evaluation and management of metal hypersensitivity reactions reported in orthopedic, cardiac, gynecologic, and dental implant devices. However, there are few studies that give evidence-based recommendations on how to evaluate this issue in our practices. METHODS: We reviewed reasonable evidence and expert opinion on biomedical device hypersensitivity and published guidelines on pre- and postimplantation evaluation of delayed hypersensitivity reactions in patients suspected of possible metal hypersensitivity to biomedical devices. RESULTS: There is consensus that routine preimplantation evaluation in individuals with no history of adverse cutaneous reactions to metals or a history of implant-related adverse events is not necessary. However, patients with a history of metal hypersensitivity of a magnitude sufficient to cause concern for the patient or health care provider may benefit from evaluation by patch testing (PT) before device implantation. Patients after implantation and with chronic unexplained implant failure or with dermatitis may benefit from patch test evaluation after other causes, such as infection and biomechanical issues, are ruled out. However, a positive metal patch test result does not prove symptom causality, and the decision regarding implant revision can only be made after a thorough discussion among the patient, the allergist or dermatologist, and the orthopedic surgeon. CONCLUSION: Consensus guidelines for the evaluation of hypersensitivity to biomedical devices can be used by the practicing physician while awaiting for the results of further investigations</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4052</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28441987">PM:28441987</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-177-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-177-83.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Rosner GA</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4052</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41565</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sypniewska,G.</style></author><author><style face="normal" font="default"> Krintus,M.</style></author><author><style face="normal" font="default"> Fulgheri,G.</style></author><author><style face="normal" font="default"> Siodmiak,J.</style></author><author><style face="normal" font="default"> Kuligowska-Prusinska,M.</style></author><author><style face="normal" font="default"> Stepien-Jaszowska,B.</style></author><author><style face="normal" font="default"> Staszak-Kowalska,R.</style></author><author><style face="normal" font="default"> Zawadzka-Krajewska,A.</style></author><author><style face="normal" font="default"> Kierat,S.</style></author><author><style face="normal" font="default"> Bergmann,K.</style></author><author><style face="normal" font="default"> Demkow,U.</style></author></authors></contributors><titles><title><style face="normal" font="default">25-Hydroxyvitamin D, biomarkers of eosinophilic inflammation, and airway remodeling in children with newly diagnosed untreated asthma</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="" start="238">238-</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway remodeling</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28441998">PM:28441998</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-238.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-238.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Sypniewska G</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4026</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41566</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chehade,M.</style></author><author><style face="normal" font="default"> Sher,E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Medical therapy versus dietary avoidance in eosinophilic esophagitis: Which approach is better?</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="176" start="170">170-176</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Comparative Study</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endoscopy</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default"> Esophagitis</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Immune-mediated</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Ingestion</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> QOL</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Remission</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Topical corticosteroids</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Eosinophilic esophagitis (EoE) is a chronic immune-mediated esophageal disease characterized by esophageal symptoms and esophageal eosinophilia. It is induced by food triggers and by environmental allergens in some patients. No U.S. Food and Drug Administration approved therapies exist for patients with EoE. Common therapies include topical corticosteroids (TCS) and dietary restriction. METHODS: This article reviewed the pros and cons of a medical versus dietary approach in treating EoE in children and adults. Available data on short- and long-term efficacy, ease of implementation, cost, adverse effects, and quality of life (QoL) were summarized. RESULTS: Although no comparative studies of TCS versus dietary restrictions exist, they seemed to be equivalent from an efficacy standpoint. However, each therapy offers different advantages and disadvantages. TCS allow ingestion of multiple food triggers and improve QoL of patients with EoE. However, TCS have the potential for topical and/or systemic adverse effects and can be costly in the long run. Dietary restriction therapies allow identification of food triggers and are less costly in the long run. However, they are more challenging to implement because they require a team approach with a dietitian and an allergist. In addition, they decrease the QoL of some children with EoE, often require extensive allergy testing and multiple endoscopies, and are not effective when environmental allergens trigger EoE. Therefore, the choice of medical versus dietary therapy needs to be individualized based on a thorough medical evaluation and discussion with patients with EoE and their families. CONCLUSION: Research is needed to establish the lowest most effective and safe dose of TCS and the extent of adherence needed when eliminating foods for EoE, and to find less-invasive ways to monitor histologic disease activity. Potential results from this research may allow more tailored therapies or specific combination therapies that would take advantage of each treatment modality to maximize benefits to the patient while maintaining disease remission</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28441986">PM:28441986</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-170-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-170-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Chehade M</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4036</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41567</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bellanti,J.A.</style></author><author><style face="normal" font="default"> Settipane,R.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Atopy, asthma, and the elderly: A paradigm for personalized therapy</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="169" start="167">167-169</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> elderly</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4056</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28441985">PM:28441985</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-167-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-167-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Bellanti JA</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4056</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41568</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cook,K.A.</style></author><author><style face="normal" font="default"> Lynch,M.T.</style></author><author><style face="normal" font="default"> Weis,P.J.</style></author><author><style face="normal" font="default"> White,A.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">A 30-year-old woman with chronic hives, intermittent fevers, and joint pain</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="235" start="231">231-235</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Arthralgia</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Hives</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Targeted therapy</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="default">Chronic urticaria with concomitant systemic symptoms may be seen in several rheumatologic and autoinflammatory conditions. Although most of these conditions tend to improve with corticosteroids, symptoms often recur with dose tapering. The appearance of the rash in addition to the symptom pattern and laboratory data must be considered to differentiate potential causes. We presented a unique case of chronic urticaria with fevers and arthralgias. A diagnosis was made, and the patient had rapid improvement with targeted therapy</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28441994">PM:28441994</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-231-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-231-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Cook KA</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4039</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41569</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fox,J.</style></author><author><style face="normal" font="default"> Vegh,A.B.</style></author><author><style face="normal" font="default"> Martinez-Saguer,I.</style></author><author><style face="normal" font="default"> Wuillemin,W.A.</style></author><author><style face="normal" font="default"> Edelman,J.</style></author><author><style face="normal" font="default"> Williams-Herman,D.</style></author><author><style face="normal" font="default"> Rojavin,M.</style></author><author><style face="normal" font="default"> Rosenberg,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="221" start="216">216-221</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Berinert</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> estrogen</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Increased estrogen levels during pregnancy can exacerbate hereditary angioedema (HAE), yet disease and treatment ramifications remain poorly studied in pregnant women. OBJECTIVE: Data from the international Berinert Patient Registry were used to evaluate outcomes of pregnancies exposed to plasma-derived, pasteurized, nanofiltered C1-inhibitor concentrate (pnfC1-INH) during routine HAE management. METHODS: This observational registry, conducted between 2010 and 2014 at 30 U.S. and 7 European sites, gathered data on 318 subjects and 15,000 pnfC1-INH infusions. Whenever possible, the subjects who used pnfC1-INH during pregnancy were followed up to term to assess neonatal outcomes and to collect maternal adverse events (AE) that occurred up to 1 month after pnfC1-INH administration. RESULTS: The registry data base included 11 pregnancies in 10 subjects who used pnfC1-INH for HAE attack treatment and/or prophylaxis (>261 doses during pregnancy). Eight pregnancies concluded in the birth of a healthy baby. Of the remaining three pregnancies: one was voluntarily terminated at 9 weeks of gestation; a second ended as a first-trimester spontaneous abortion 1 week after the subject's most recent pnfC1-INH infusion and was considered unrelated to pnf-C1INH treatment; and the third occurred in a subject who exited the registry approximately 2 months before her due date, with no further follow up. As assessed for 30 days after each pnfC1-INH infusion, there were no AEs that were considered related to pnfC1-INH therapy. CONCLUSION: Administration of pnfC1-INH during pregnancy was generally safe and not associated with any treatment-related AEs. In all registry pregnancies followed up to term, the birth of a healthy baby was reported</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28441992">PM:28441992</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-216-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-216-21.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Fox J</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41570</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pasha,M.A.</style></author><author><style face="normal" font="default"> Sundquist,B.</style></author><author><style face="normal" font="default"> Townley,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Asthma pathogenesis, diagnosis, and management in the elderly</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="191" start="184">184-191</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Aging</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> elderly</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Due to the aging population, there is an increase in the number of elderly patients with asthma. Although signs and symptoms are similar to those in younger patients, diagnosis can be challenging due to presence of coexisting conditions in this population. OBJECTIVES: The purpose of this review was to highlight the challenges with regards to diagnosis, management, the high rates of medical costs and mortality in elderly asthmatics. METHODS AND RESULTS: Scientific literature regarding asthma in the elderly population was reviewed. When compared to younger patients, elderly asthmatics have different drug responses, higher rates of bronchial hyper reactivity, more severe phenotype, and lower prevalence of atopy. In addition, there are issues with the adverse effects of asthma medications, use of proper inhaler technique and compliance. CONCLUSION: There is an unmet need for research in elderly patients with asthma, specifically to facilitate diagnosis, and to investigate therapeutic strategies to improve quality of life in this population</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4048</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28441988">PM:28441988</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-184-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-184-91.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Pasha MA</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4048</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41571</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Manti,S.</style></author><author><style face="normal" font="default"> Leonardi,S.</style></author><author><style face="normal" font="default"> Parisi,G.F.</style></author><author><style face="normal" font="default"> De Vivo,D.</style></author><author><style face="normal" font="default"> Salpietro,A.</style></author><author><style face="normal" font="default"> Spinuzza,A.</style></author><author><style face="normal" font="default"> Arrigo,T.</style></author><author><style face="normal" font="default"> Salpietro,C.</style></author><author><style face="normal" font="default"> Cuppari,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">High mobility group box 1: Biomarker of inhaled corticosteroid treatment response in children with moderate-severe asthma</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="203" start="197">197-203</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: High mobility group box 1 (HMGB1) is abnormally expressed in serum and sputum of patients with allergic asthma. OBJECTIVE: The aim of this study was to investigate the role of HMGB1 as guidance for treatment management of children with asthma. METHODS: Thirty children with asthma and 44 healthy children were enrolled. The patients were classified according to Global Initiative for Asthma Guideline disease severity criteria. Sputum HMGB1 levels and lung function index (percentage forced expiratory volume in 1 second [FEV1%]) were recorded in the cohort study at baseline (T0) and after 3 (T3) and 6 (T6) months of inhaled corticosteroids (ICS) treatment. RESULTS: Sputum HMGB1 levels were significantly higher in all the patients with asthma (p &lt; 0.001). An inverse correlation between sputum HMGB1 levels and pulmonary function parameters was observed only in the children with moderate asthma (T0: FEV1%, r = -0.9891, p &lt; 0.001; T3: FEV1%, r = -0.6763, p &lt; 0.001; T6: FEV1%, r = -0.5419, p &lt; 0.05) and in the children with severe asthma (T0: FEV1%, r = -0.8696, p &lt; 0.001; T3: FEV1%, r = -0.6477, p &lt; 0.05; T6: FEV1%, r = -0.8627, p &lt; 0.001). After ICS treatment, a significant decrease of sputum HMGB1 levels was noted in moderate (T0 [93.44 +/- 20.65 ng/mL] versus T3 [77.96 +/- 1.81 ng/mL] versus T6 [67.75 +/- 3.01 ng/mL]; p &lt; 0.0001) and in the children with severe asthma (T0 [130.3 +/- 7.48 ng/mL] versus T3 [156.9 +/- 1.09 ng/mL] versus T6 [116.08 +/- 4.77 ng/mL]; p &lt; 0.0001) data are mean +/- standard deviation, respectively. The area under the receiver operating characteristic curve, performed to define the diagnostic profile of sputum HMGB1 levels in identifying the children with asthma, was 0.713. CONCLUSION: In addition to the findings that HMGB1 is a sensitive biomarker of allergic asthma in children, our data demonstrated a significant correlation between the decrease of HMGB1 levels and a successful treatment response</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28441990">PM:28441990</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-197-203.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-197-203.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Manti S</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4047</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41572</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nayak,A.S.</style></author><author><style face="normal" font="default"> Berger,W.E.</style></author><author><style face="normal" font="default"> LaForce,C.F.</style></author><author><style face="normal" font="default"> Urdaneta,E.R.</style></author><author><style face="normal" font="default"> Patel,M.K.</style></author><author><style face="normal" font="default"> Franklin,K.B.</style></author><author><style face="normal" font="default"> Wu,M.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="230" start="222">222-230</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse events</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Caregivers</style></keyword><keyword><style face="normal" font="default"> Cetirizine</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> grass pollen</style></keyword><keyword><style face="normal" font="default"> Grasses</style></keyword><keyword><style face="normal" font="default"> Headache</style></keyword><keyword><style face="normal" font="default"> Loratadine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Over-the-counter</style></keyword><keyword><style face="normal" font="default"> Pharyngitis</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> Pollen</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> SAR</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Pharmacologic treatment is a mainstay of allergy therapy and many caregivers use over-the-counter antihistamines for the treatment of seasonal allergic rhinitis (SAR) symptoms in children. OBJECTIVE: To assess the efficacy and safety of cetirizine 10 mg syrup versus loratadine 10 mg syrup versus placebo syrup in a randomized double-blind study of children, ages 6-11 years, with SAR. METHODS: This randomized, double-blind, parallel-group, placebo-controlled study was conducted at 71 U.S. centers during the spring tree and grass pollen season. After a 1-week placebo run-in period, qualified subjects were randomized to once-daily cetirizine 10 mg (n = 231), loratadine 10 mg (n = 221), and placebo (n = 231) for 2 weeks. The primary efficacy end point was change from baseline in the subject's mean reflective total symptom severity complex (TSSC) score over 14 days. RESULTS: Children treated with cetirizine experienced significantly greater TSSC score reductions versus children treated with placebo over 14 days (least square mean change, -2.1 versus -1.6; p = 0.006). The differences in TSSC score improvement over 14 days between the cetirizine versus loratadine groups (-2.1 versus -1.8; p = 0.124) and between the loratadine versus placebo groups (-1.8 versus -1.6; p = 0.230) were not statistically significant. Predominant adverse events in the cetirizine, loratadine, and placebo groups were headache (3.5, 3.6, and 3.1%, respectively) and pharyngitis (3.5, 2.7, and 3.5%, respectively). Somnolence was reported in three subjects (1.3%) treated with cetirizine and in none of the other subjects. CONCLUSION: Cetirizine 10 mg was statistically significantly more efficacious than placebo in the treatment of SAR symptoms in children ages 6-11 years. Symptom improvement was not significantly different between the loratadine 10 mg and placebo groups</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4050</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28441993">PM:28441993</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-222-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-222-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Nayak AS</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4050</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41573</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liccardi,G.</style></author><author><style face="normal" font="default"> Calzetta,L.</style></author><author><style face="normal" font="default"> Salzillo,A.</style></author><author><style face="normal" font="default"> Apicella,G.</style></author><author><style face="normal" font="default"> Croce,G.</style></author><author><style face="normal" font="default"> Rogliani,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Can a better patients' phenotyping predict the efficacy of tiotropium in symptomatic asthma?</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="20" start="19">19-20</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28441979">PM:28441979</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-19-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-19-20.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Liccardi G</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4045</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41574</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Choi,S.</style></author><author><style face="normal" font="default"> Kim,S.H.</style></author><author><style face="normal" font="default"> Lee,J.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association between depression and asthma in Korean adults</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="239" start="238">238-239</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4051</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28442000">PM:28442000</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-238-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-238-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Choi S</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4051</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41575</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Torchyan,A.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Asthma control in Saudi Arabia: Gender implications</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="" start="239">239-</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Saudi Arabia</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - Saudi Arabia -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28442001">PM:28442001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-239.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-239.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Torchyan AA</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4035</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41576</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pongpairoj,K.</style></author><author><style face="normal" font="default"> Puangpet,P.</style></author><author><style face="normal" font="default"> Thaiwat,S.</style></author><author><style face="normal" font="default"> McFadden,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, 1873 Rama 4 Road, Pathumwan, Bangkok, 10330, Thailand.</style></auth-address><titles><title><style face="normal" font="default">Diagnosing Allergic Contact Dermatitis Through Elimination, Perception, Detection and Deduction</style></title><secondary-title><style face="normal" font="default">Am J Clin Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Clin Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergen exposure</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Elimination</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Publications</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="15" Month="5" Year="2017">2017/5/15</year></dates><abstract><style face="normal" font="default">Several authors have commented upon the skills of detection required in making a diagnosis of allergic contact dermatitis. Here, we emphasise the search for clues in a systematic manner. We describe four stages as part of a systematic method for diagnosing allergic contact dermatitis. Firstly, elimination (or inclusion) of non-allergic diagnoses. Secondly, perception: the pre-patch test diagnosis and the 'three scenarios' principle. Thirdly, detection: optimising the sensitivity of the patch test process. Fourthly, deduction: diagnosing allergic contact dermatitis by associating the dermatitis with the allergen exposure. We further compare and contrast the pre-patch test history and examination with the markedly different one ('microhistory' and 'microexamination') used after patch testing. The importance of knowledge of contact dermatitis literature is emphasised with a review of recent publications. Finally, we also highlight the use of contact allergy profiling as an investigative tool in the diagnosis of allergic contact dermatitis</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 1179-1888 (Electronic)IS - 1175-0561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Thailand -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1007/s40257-017-0287-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28508257">PM:28508257</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Clin Dermatol\20170516-PongpairojK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Clin Dermatol\20170516-PongpairojK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Pongpairoj K</style></custom2><misc3><style face="normal" font="default">10.1007/s40257-017-0287-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41577</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Morphew,T.</style></author><author><style face="normal" font="default"> Altamirano,W.</style></author><author><style face="normal" font="default"> Bassin,S.L.</style></author><author><style face="normal" font="default"> Galant,S.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Morphew Consulting, LLC, 2208 242nd St SW, Bothell, WA 98021.</style></auth-address><titles><title><style face="normal" font="default">The Breathmobile improves the asthma medication ratio and decreases emergency department utilization</style></title><secondary-title><style face="normal" font="default">Am J Manag Care</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Am J Manag Care</style></abbr-1></periodical><pages end="e126" start="e120">e120-e126</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Poisson</style></keyword><keyword><style face="normal" font="default"> Program Evaluation</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of care</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="4" Year="2017">2017/4/1</year></dates><abstract><style face="normal" font="default">OBJECTIVES: An Asthma Medication Ratio (AMR) of >/=0.50 has gained recognition as a metric related to improved asthma outcomes. The goals of this study were to evaluate asthma outcomes in relation to this threshold in Hispanic children with high-risk asthma and to compare the effectiveness of the Breathmobile (BM) program with usual care (UC), utilizing the AMR-related emergency department utilization (ED) rate. STUDY DESIGN: Healthcare utilization and prescription claims recorded January 1, 2011, to June 23, 2014, were evaluated pre- versus post year in 164 Medicaid-enrolled children, aged 2 to 18 years, with high-risk persistent asthma (BM group: n = 72; UC group: n = 92). METHODS: High risk was defined by >/=2 oral corticosteroid fills, or >/=2 ED visits (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes 493.0-493.9) or >/=1 IP stay (ICD-9-CM codes 493.0-493.9) in the pre-year. Poisson regression was utilized to compare asthma outcomes pre- versus post year in BM and UC groups and to describe the average number of ED days per 100 patients treated in relation to AMR. RESULTS: An AMR of >/=0.50 versus &lt;0.50 was related to 49% fewer ED visits (P &lt;.05). BM proved to be more effective than UC in increasing the percent who achieved an AMR >/=0.50 from a baseline of 47.2% to 80.6% versus 50.0% to 65.2% post year, respectively. This difference was reflected in the significant 52% reduction in average number of ED visits post year for the BM cohort versus 13% for the UC cohort. CONCLUSIONS: View achievement of the AMR >/=0.50 as an informative metric in program evaluation and for healthcare organizations to measure the quality of care provided to high-risk patients with asthma</style></abstract><notes><style face="normal" font="default">DA - 20170530IS - 1936-2692 (Electronic)IS - 1088-0224 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28554211">PM:28554211</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Manag Care\2017-23-e120-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Manag Care\2017-23-e120-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170530, Morphew T</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41578</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zein,J.G.</style></author><author><style face="normal" font="default"> Love,T.E.</style></author><author><style face="normal" font="default"> Erzurum,S.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cleveland Clinic, Cleveland, Ohio, United States</style></auth-address><titles><title><style face="normal" font="default">Asthma is Associated with a Lower Risk of Sepsis and Sepsis Related Mortality</style></title><secondary-title><style face="normal" font="default">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Crit Care Med</style></full-title></periodical><pages end="790" start="787">787-790</pages><volume><style face="normal" font="default">196</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Ohio</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Sepsis</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="22" Month="5" Year="2017">2017/5/22</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170522IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1164/rccm.201608-1583LE</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28530491">PM:28530491</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Respir Crit Care Med\2017-196-787-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Respir Crit Care Med\2017-196-787-90.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170522, Zein JG</style></custom2><misc3><style face="normal" font="default">10.1164/rccm.201608-1583LE</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41579</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Feng,B.</style></author><author><style face="normal" font="default"> Jin,H.</style></author><author><style face="normal" font="default"> Xiang,H.</style></author><author><style face="normal" font="default"> Li,B.</style></author><author><style face="normal" font="default"> Zheng,X.</style></author><author><style face="normal" font="default"> Chen,R.</style></author><author><style face="normal" font="default"> Shi,Y.</style></author><author><style face="normal" font="default"> Chen,S.</style></author><author><style face="normal" font="default"> Chen,B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association of pediatric allergic rhinitis with the ratings of attention-deficit/hyperactivity disorder</style></title><secondary-title><style face="normal" font="default">Am J Rhinol Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Am J Rhinol Allergy</style></abbr-1></periodical><pages end="167" start="161">161-167</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Asia</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Child Behavior</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Increased prevalence</style></keyword><keyword><style face="normal" font="default"> major allergen</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> Rhinoconjunctivitis Quality of Life Questionnaire</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Smoke</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tobacco</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic rhinitis (AR) is currently the most prevalent allergic disease in children and adolescents. OBJECTIVE: Surveys conducted by population-based studies of East Asia revealed an increased prevalence of behavioral disorders in patients with AR. Thus, in this study, we explored the prevalence of attention-deficit/hyperactivity disorder (ADHD) in pediatric patients with AR. METHODS: A total of 333 children (6-12 years of age) with AR and a total of 322 age-matched controls were included in this study. An otorhinolaryngologist diagnosed all AR cases and evaluated the severity of the disease. Skin-prick test results for 18 major allergens, Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ), Child Behavior Checklist (CBCL), and Swanson, Nolan, and Pelham version IV (SNAP-IV) scores were recorded. RESULTS: In total, 320 age-matched controls and 323 children with AR completed the study. With respect to the Total Nasal Symptom Score and the PRQLQ, the condition of the experimental group was more serious than that of the controls. The scores on the hyperactivity/impulsivity and inattention subscales, which evaluate ADHD symptoms, and those on the CBCL subscales were significantly higher in patients with AR than in the controls (all p values were &lt;0.01). From the results of the Pearson correlation, we deduced that there were significant positive correlations between the AR-related data and each subscale of the CBCL and SNAP-IV in the AR group. Moreover, two basic characteristics (males and environmental exposure to tobacco smoke) present significant positive and age showed a significant negative correlations affect ADHD symptom in both the AR group and the control group. Also, in the "pure AR" group, hierarchical regression analyses were performed to determine the subtests of the PRQLQ, which are significant predictors of SNAP-IV and CBCL. CONCLUSIONS: Apart from AR per se, the possible comorbidities of impulsivity and inattention are important when managing children with AR. It is essential to evaluate the symptoms of ADHD in children and adolescents with AR</style></abstract><notes><style face="normal" font="default">DA - 20170511IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.2500/ajra.2017.31.4439</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28490400">PM:28490400</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Rhinol Allergy\2017-31-161-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Rhinol Allergy\2017-31-161-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170511, Feng B</style></custom2><misc3><style face="normal" font="default">10.2500/ajra.2017.31.4439</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41580</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">van Meel,E.R.</style></author><author><style face="normal" font="default"> de Jong,M.</style></author><author><style face="normal" font="default"> Elbert,N.J.</style></author><author><style face="normal" font="default"> den Dekker,H.T.</style></author><author><style face="normal" font="default"> Reiss,I.K.</style></author><author><style face="normal" font="default"> de Jongste,J.C.</style></author><author><style face="normal" font="default"> Jaddoe,V.W.V.</style></author><author><style face="normal" font="default"> Duijts,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Generation R Study Group, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands</style></auth-address><titles><title><style face="normal" font="default">Duration and exclusiveness of breastfeeding and school-age lung function and asthma</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic sensitization</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> early childhood</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Inhalant</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> prospective cohort study</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Respiratory tract infection</style></keyword><keyword><style face="normal" font="default"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="26" Month="5" Year="2017">2017/5/26</year></dates><abstract><style face="normal" font="default">BACKGROUND: Breastfeeding reduces the risk of asthma in early childhood, but it is not clear whether its effect on respiratory morbidity is still present in later childhood. OBJECTIVES: To examine the associations of any breastfeeding, breastfeeding duration, and breastfeeding exclusiveness with lung function and asthma in school-aged children and whether associations were influenced by respiratory tract infections and maternal or child's atopic status. METHODS: This study of 4,464 children was embedded in a population-based prospective cohort study. Information on breastfeeding was obtained by multiple questionnaires from birth until 1 year of age. At 10 years of age, lung function was measured by spirometry, and information on asthma was obtained by questionnaire. Adjusted linear and logistic regression models were used to examine the associations. RESULTS: Shorter duration of breastfeeding was associated with a lower forced expiratory volume in 1 second (FEV1) only (z score change, -0.01; 95% confidence interval [CI], -0.02 to -0.00) per month shorter breastfeeding, but not asthma. When categorized, breastfeeding for 2 to 4 months was associated with a lower forced vital capacity (FVC) (z score change, -0.11; 95% CI, -0.20 to -0.03) compared with breastfeeding for 6 months or longer. Nonexclusive breastfeeding for 4 months was associated with a lower FVC (z score change, -0.08; 95% CI, -0.16 to -0.01) compared with exclusive breastfeeding for 4 months. Results did not materially change after additional adjustment for lower respiratory tract infections and were not modified by maternal history of asthma or atopy, child's eczema, or inhalant allergic sensitization. CONCLUSION: Shorter duration and nonexclusivity of breastfeeding were associated with a lower FEV1 and FVC but not asthma at school-age</style></abstract><notes><style face="normal" font="default">DA - 20170530IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.05.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28554704">PM:28554704</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170530-vanMeelER.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170530-vanMeelER.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170530, van Meel ER</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.05.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41581</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Laisuan,W.</style></author><author><style face="normal" font="default"> Wongsa,C.</style></author><author><style face="normal" font="default"> Dchapaphapeaktak,N.</style></author><author><style face="normal" font="default"> Tongdee,M.</style></author><author><style face="normal" font="default"> Chatmapanrangsee,J.</style></author><author><style face="normal" font="default"> Rerkpattanapipat,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Anaphylaxis following intralesional triamcinolone acetonide (Kenacort) injection</style></title><secondary-title><style face="normal" font="default">Asia Pac Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asia Pac Allergy</style></abbr-1></periodical><pages end="118" start="115">115-118</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Alcohol</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Alopecia</style></keyword><keyword><style face="normal" font="default"> Alopecia Areata</style></keyword><keyword><style face="normal" font="default"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Benzyl Alcohol</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Carboxymethylcellulose</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Dexamethasone</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Excipients</style></keyword><keyword><style face="normal" font="default"> Extremities</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> Hydrocortisone</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity,Immediate</style></keyword><keyword><style face="normal" font="default"> Hypotension</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Injections</style></keyword><keyword><style face="normal" font="default"> Keloid</style></keyword><keyword><style face="normal" font="default"> Lichen Planus</style></keyword><keyword><style face="normal" font="default"> Lidocaine</style></keyword><keyword><style face="normal" font="default"> Methylprednisolone</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> oral challenge</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> subcutaneous</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Triamcinolone</style></keyword><keyword><style face="normal" font="default"> Triamcinolone Acetonide</style></keyword><keyword><style face="normal" font="default"> Upper Extremity</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><publisher><style face="normal" font="default">Asia Pacific Association of Allergy, Asthma and Clinical Immunology</style></publisher><isbn><style face="normal" font="default">2233-8276</style></isbn><abstract><style face="normal" font="default">Intralesional triamcinolone acetonide injection is indicated for multiple skin conditions such as keloid scars, alopecia areata, and hypertrophic lichen planus. Immediate hypersensitivity reaction remains uncommon. We report on a 24-year-old woman who had received multiple intralesional injections with triamcinolone acetonide (Kenacort) plus lidocaine for keloid scar treatment without any reaction for the previous 10 years. The immediate reaction occurred 15 minutes after injection, with numbness on her face and 5 minutes later with urticaria on her chest wall and upper extremities, together with hypotension (blood pressure of 90/60 mmHg). Allergology workup revealed positive skin prick test for triamcinolone acetonide (Kenacort). Skin tests for other corticosteroids (hydrocortisone, methylprednisolone, and dexamethasone), excipients (carboxymethylcellulose, benzyl alcohol, and polysorbate 80) and lidocaine were negative, including subcutaneous challenge for lidocaine and oral challenge for carboxymethylcellulose. IgE-mediated hypersensitivity reaction must be considered in cases of multiple applications of triamcinolone acetonide injection</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Thailand -</style></notes><work-type><style face="normal" font="default">10.5415/apallergy.2017.7.2.115</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.5415/apallergy.2017.7.2.115</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-115-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-115-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170520, Laisuan W</style></custom2><misc3><style face="normal" font="default">10.5415/apallergy.2017.7.2.115</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41582</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Thien,F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Thunderstorm asthma: potential danger but a unique opportunity</style></title><secondary-title><style face="normal" font="default">Asia Pac Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asia Pac Allergy</style></abbr-1></periodical><pages end="56" start="55">55-56</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><publisher><style face="normal" font="default">Asia Pacific Association of Allergy, Asthma and Clinical Immunology</style></publisher><isbn><style face="normal" font="default">2233-8276</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Australia -</style></notes><work-type><style face="normal" font="default">10.5415/apallergy.2017.7.2.55</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.5415/apallergy.2017.7.2.55</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-55-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-55-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160520, Thien F</style></custom2><misc3><style face="normal" font="default">10.5415/apallergy.2017.7.2.55</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41583</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Recto,M.S.</style></author><author><style face="normal" font="default"> Genuino,M.L.</style></author><author><style face="normal" font="default"> Castor,M.A.</style></author><author><style face="normal" font="default"> Casis-Hao,R.J.</style></author><author><style face="normal" font="default"> Tamondong-Lachica,D.R.</style></author><author><style face="normal" font="default"> Sales,M.I.</style></author><author><style face="normal" font="default"> Tan,M.G.</style></author><author><style face="normal" font="default"> Mondonedo,K.S.</style></author><author><style face="normal" font="default"> Dionisio-Capulong,R.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Dietary primary prevention of allergic diseases in children: the Philippine guidelines</style></title><secondary-title><style face="normal" font="default">Asia Pac Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asia Pac Allergy</style></abbr-1></periodical><pages end="114" start="102">102-114</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> dietary intervention</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Gastroenterology</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infancy</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Philippines</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Primary Prevention</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><publisher><style face="normal" font="default">Asia Pacific Association of Allergy, Asthma and Clinical Immunology</style></publisher><isbn><style face="normal" font="default">2233-8276</style></isbn><abstract><style face="normal" font="default">Allergic diseases, such as asthma, allergic rhinitis, eczema, and food allergy, are preventable diseases. Primary prevention strategies of allergic diseases have been in scrutiny. Effective prevention strategies maybe started prenatally, postnatally, during infancy, and even during childhood. These guidelines have been prepared by the Philippine Society of Allergy, Asthma and Immunology and the Philippine Society for Pediatric Gastroenterology, Hepatology and Nutrition. They aim to provide evidence-based recommendations for the dietary primary prevention of allergic diseases in children. The primary audience of these guidelines is all healthcare practitioners who manage patients with potential allergic conditions. These guidelines are based on an exhaustive review of evidences, mostly systematic reviews, randomized controlled trials, and cohort studies. However, there are still many gaps in the evidence of dietary primary prevention of allergic diseases</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Philippines -</style></notes><work-type><style face="normal" font="default">10.5415/apallergy.2017.7.2.102</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.5415/apallergy.2017.7.2.102</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-102-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-102-14.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170520, Recto MS</style></custom2><misc3><style face="normal" font="default">10.5415/apallergy.2017.7.2.102</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41584</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shim,J.S.</style></author><author><style face="normal" font="default"> Chung,S.J.</style></author><author><style face="normal" font="default"> Kim,B.K.</style></author><author><style face="normal" font="default"> Kim,S.H.</style></author><author><style face="normal" font="default"> Lee,K.S.</style></author><author><style face="normal" font="default"> Yoon,Y.E.</style></author><author><style face="normal" font="default"> Chang,Y.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Bullous hemorrhagic dermatosis due to enoxaparin use in a bullous pemphigoid patient</style></title><secondary-title><style face="normal" font="default">Asia Pac Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asia Pac Allergy</style></abbr-1></periodical><pages end="101" start="97">97-101</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Bullous dermatoses</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous reaction</style></keyword><keyword><style face="normal" font="default"> Cutaneous reactions</style></keyword><keyword><style face="normal" font="default"> Dermatosis</style></keyword><keyword><style face="normal" font="default"> Drug-induced</style></keyword><keyword><style face="normal" font="default"> Drug-Induced Liver Injury</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Enoxaparin</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Heparin</style></keyword><keyword><style face="normal" font="default"> Heparin,Low-Molecular-Weight</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Low molecular weight heparin</style></keyword><keyword><style face="normal" font="default"> Molecular Weight</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Osteoporosis</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> subcutaneous</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Thrombocytopenia</style></keyword><keyword><style face="normal" font="default"> Thrombosis</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><publisher><style face="normal" font="default">Asia Pacific Association of Allergy, Asthma and Clinical Immunology</style></publisher><isbn><style face="normal" font="default">2233-8276</style></isbn><abstract><style face="normal" font="default">Adverse reactions of subcutaneous low molecular weight heparin or unfractionated heparin could be complications by bleeding, heparin-induced thrombocytopenia, drug-induced liver injury, osteoporosis, and cutaneous reactions. Heparin-induced skin lesions vary from allergic reactions like erythema, urticaria, eczema to intradermal microvascular thrombosis associated with heparin-induced thrombocytopenia. There is a rare cutaneous complication, called bullous hemorrhagic dermatosis. We experienced this rare case of the cutaneous complication caused by enoxaparin. Several tense bullous hemorrhagic lesions occurred after 3 days of enoxaparin in a known bullous pemphigoid patient who had aortic valve replacement surgery with a mechanical prosthesis. The bullous hemorrhagic lesions were regressed after the discontinuation of enoxaparin but recurred after re-administration. The lesions were controlled by the administration of systemic corticosteroid and alternative anticoagulant. To date, less than 20 cases have been reported worldwide. This is the first case of bullous hemorrhagic dermatosis induced by enoxaparin, a low-molecular-weight heparin in Korea. This is also the first case of bullous hemorrhagic dermatosis in a known bullous pemphigoid patient</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.5415/apallergy.2017.7.2.97</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.5415/apallergy.2017.7.2.97</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-97-101.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-97-101.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170520, Shim JS</style></custom2><misc3><style face="normal" font="default">10.5415/apallergy.2017.7.2.97</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41585</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tian,H.Q.</style></author><author><style face="normal" font="default"> Cheng,L.</style></author></authors></contributors><titles><title><style face="normal" font="default">The role of vitamin D in allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Asia Pac Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asia Pac Allergy</style></abbr-1></periodical><pages end="73" start="65">65-73</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Rhinitis,Allergic</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><publisher><style face="normal" font="default">Asia Pacific Association of Allergy, Asthma and Clinical Immunology</style></publisher><isbn><style face="normal" font="default">2233-8276</style></isbn><abstract><style face="normal" font="default">Recent studies suggest that vitamin D is related to allergic rhinitis (AR). In this review, we first discuss the physiology and metabolism of vitamin D, then we review the function of vitamin D in the immune system, and above all, we highlight the current research regarding the role of vitamin D in AR. Finally, we find that there are both experimental and clinical studies showing that vitamin D is associated with AR, although the results are not consistent and even conflicting. Evidences from those clinical studies show a slightly tendency that serum vitamin D level might be inversely associated with the risk of AR. Meanwhile, it seems that gender and age may influence the relationship between vitamin D and AR. However, because of the heterogeneity in defining AR, differences in study design and so on, all these findings need to be confirmed by further studies. Additional clinical studies as well as experimental research are needed to better understand how vitamin D influences AR</style></abstract><notes><style face="normal" font="default">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="default">10.5415/apallergy.2017.7.2.65</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.5415/apallergy.2017.7.2.65</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-65-73.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-65-73.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160520, Tian HQ</style></custom2><misc3><style face="normal" font="default">10.5415/apallergy.2017.7.2.65</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41586</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kutkug,S.</style></author><author><style face="normal" font="default"> Celiksoy,M.H.</style></author><author><style face="normal" font="default"> Eroglu,B.</style></author><author><style face="normal" font="default"> Yildiz,L.</style></author><author><style face="normal" font="default"> Yildiran,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">A Case of Acute Generalised Exanthematous Pustulosis Induced by Paracetamol</style></title><secondary-title><style face="normal" font="default">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asthma Allergy Immunol</style></full-title></periodical><pages end="54" start="49">49-54</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Acute Generalized Exanthematous Pustulosis</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Paracetamol</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe cutaneous adverse reaction</style></keyword><keyword><style face="normal" font="default"> Severe cutaneous adverse reactions</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral infection</style></keyword><keyword><style face="normal" font="default"> Viral infections</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Acute generalized exanthematous pustulosis is an exanthematousdisease characterized by a great number of pustules on an acutelyerythematous and edematous surface on the skin. These pustulesare smaller than 5 mm, have non-follicular localization, and aresterile and superficial. Drugs are held responsible for 90% of thecases and antibiotics are the main culprits. Viral infections, mercuryexposure, spider bite and radiation have also been rarely reportedas the causative agent. The mortality of AGEP, which is consideredto be one of the Severe Cutaneous Adverse Reactions (SCAR), is5%. Many of the cases reported are adults. Since AGEP is rare inchildren, we present a ten-month-old boy who developed AGEPafter paracetamol use.</style></abstract><notes><style face="normal" font="default">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.21911/aai.5007</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.21911/aai.5007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Allergy Immunol\2017-15-49-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Allergy Immunol\2017-15-49-54.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170519, Kutkug S</style></custom2><misc3><style face="normal" font="default">10.21911/aai.5007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41587</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sekerel,B.E.</style></author><author><style face="normal" font="default"> Misirligil,Z.</style></author><author><style face="normal" font="default"> Orhan,F.</style></author><author><style face="normal" font="default"> Mungan,D.</style></author><author><style face="normal" font="default"> Buyuktiryaki,B.</style></author></authors></contributors><titles><title><style face="normal" font="default">New Developments in the Diagnosis and Therapy of Allergic Rhinitis</style></title><secondary-title><style face="normal" font="default">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asthma Allergy Immunol</style></full-title></periodical><pages end="6" start="1">1-6</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Azelastine</style></keyword><keyword><style face="normal" font="default"> Azelastine hydrochloride</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostics</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> fluticasone propionate</style></keyword><keyword><style face="normal" font="default"> Formulation</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Health</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> Immunotherapy</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Intranasal steroids</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Primary ciliary dyskinesia</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Recombinant</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Sneezing</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> tablet</style></keyword><keyword><style face="normal" font="default"> Tablets</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Allergic rhinitis (AR) is one of the most common chronic diseases in all age groups. It is an IgE-mediated allergic inflammation of the nasal airways and is characterized by sneezing, swelling and inflammation of the nasal mucosa as well as itchy and watery eyes. It is a global health problem and a burdensome disorder affecting many people from childhood to adulthood. The prevalence of childhood AR shows wide variation throughout the world, ranging from 0.8 to 45%. The prevalence rates for different regions of Turkey ranges from 2.9 to 44%. The aim of the present review is to provide an update on AR treatment and diagnosis. Because of its burden on patient's lives and its impact on asthma, AR should be taken care of properly with effective and safe treatments. Second-generation antihistamines and intranasal steroids represent the milestone of AR therapy. New formulations of available drugs (rupatadine oral solution, ebastine fast-dissolving tablets, combination of intranasal fluticasone propionate and azelastine hydrochloride), recently discovered molecules (ciclesonide, bilastine, roflumilast, etc.), immunologic targets (omalizumab) and unconventional treatments (homeopathic treatments) are representing new frontiers in AR management. An accurate diagnosis of AR is also crucial to increase treatment success. Further promising improvements in diagnostics are expected from recombinant allergen diagnostics identifying particular molecules of risk. Purified native or recombinant allergens, identifying the individual molecules to which patients are sensitized, can be determined by molecular or component resolved diagnostics. These may decrease the need for provocation testing and improve the specificity of allergen immunotherapy. Different methods to measure nasal nitric oxide (nNO) levels are currently being revealed. Decreased nNO concentration is also typical of cystic fibrosis, even though nNO is not as low as in primary ciliary dyskinesia. The clinical utility of nNO remains to be established in upper airway disorders such as AR.</style></abstract><notes><style face="normal" font="default">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.21911/aai.5033</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.21911/aai.5033</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Allergy Immunol\2017-15-1-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Allergy Immunol\2017-15-1-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170519, Sekerel BE</style></custom2><misc3><style face="normal" font="default">10.21911/aai.5033</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41588</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Akelma,Z.</style></author><author><style face="normal" font="default"> Bulus,A.D.</style></author><author><style face="normal" font="default"> Kocak,M.</style></author><author><style face="normal" font="default"> Gunbey,S.</style></author><author><style face="normal" font="default"> Andiran,N.</style></author><author><style face="normal" font="default"> Simsek,G.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">An Unusual Trigger for Cutaneous Mastocytosis: The Insulin Pump</style></title><secondary-title><style face="normal" font="default">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asthma Allergy Immunol</style></full-title></periodical><pages end="59" start="55">55-59</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Biopsy</style></keyword><keyword><style face="normal" font="default"> Bone Marrow</style></keyword><keyword><style face="normal" font="default"> Cell Proliferation</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> cutaneous mastocytosis</style></keyword><keyword><style face="normal" font="default"> Dermis</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> Insulin</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mastocytosis</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Spleen</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Mastocytosis is a relatively infrequent disorder characterized by mast cell proliferation within primarily the skin, but also various organs such as the bone marrow, liver, spleen, lymph nodes and the gastrointestinal system. Several factors are known to induce symptoms in patients with mastocytosis. A 13-year-old boy with cutaneous mastocytosis and type 1 diabetes mellitus developed multiple itchy papules 2 to 3 days after he started receiving insulin (lispro) pump therapy. Punch biopsy revealed widespread mast cell infiltration on the papillary dermis. We hypothesized that the insulin pump catheter caused a physical stimulus due to local microtrauma and resulted in the formation of the lesions. We, therefore, discontinued insulin pump treatment and switched to SC insulin therapy. While previous lesions healed successfully, no new lesions occurred. To confirm our hypothesis, we repeated the procedure and observed the occurrence of similar lesions around the insulin pump catheter. Herein, we present for the first time, a patient with type 1 diabetes mellitus and cutaneous mastocytosis who developed exacerbation of lesions during insulin pump therapy.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="FrutigerRoman">10.21911/aai.5027</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.21911/aai.5027</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Allergy Immunol\2017-15-55-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Allergy Immunol\2017-15-55-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170519, Akelma Z</style></custom2><misc3><style face="normal" font="FrutigerRoman">10.21911/aai.5027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41589</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Caliskan,S.S.</style></author><author><style face="normal" font="default"> Erdenen,F.</style></author><author><style face="normal" font="default"> Celik,N.</style></author><author><style face="normal" font="default"> Sak,D.</style></author><author><style face="normal" font="default"> Kantarci,E.N.</style></author></authors></contributors><titles><title><style face="normal" font="default">The Compliance of Asthma Patients with Their Medication According to the Gina Guideline</style></title><secondary-title><style face="normal" font="default">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asthma Allergy Immunol</style></full-title></periodical><pages end="31" start="23">23-31</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> ACT Score</style></keyword><keyword><style face="normal" font="default"> adherence</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> asthma education</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Caregivers</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Control level</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Life quality</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medication adherence</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> pulmonary function test</style></keyword><keyword><style face="normal" font="default"> Pulmonary function tests</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Objective: Even though asthma patients receive their treatment under a physician's follow-up, there are many problems with asthma control and medicine usage due to the patients' incorrect expression of their symptoms and lack of asthma education. Patients are treated with a higher level of treatment to prevent possible exacerbations. The purpose of our study was to detect if the patient treatment was well-adjusted to the GINA guideline.Materials and Methods: 101 asthmatic patients older than 18 years were enrolled. Demographic data, BMI (Body Mass Index), symptoms, comorbidities, medications, exacerbation risk factors and pulmonary function tests were recorded. The Asthma Control Test, SF-36 for life quality assessment and the Morisky Medication Adherence Scale were used.Results: Of the 101 patients, 43 were male and 58 female. Based on the ACT results, 59.4% of the cases was under control. As per Morisky-8, 31.86% of the cases were in high alignment. Controlled asthma level was higher in males (p=0.037). When ACT scores were compared with asthma control levels, a significant difference was detected in ACT scores between under controlled group and the other cases (p=&lt;0.001). Asthma control levels and FEV1 were correlated (p=&lt;0.001). SF-36 levels were higher in controlled and partially controlled asthma patients (p=0.037). A substantial relationship of poor asthma control with comorbid 'rhinitis' and 'ischemic hypertensive heart disease' was found (p=0.048, p=0.035). ACT scores were significantly lower in patients with rhinosinusitis (p=0.025). Only 20 of the 101 cases (19.8%) received appropriate treatment. There was a significant difference between the treatment they should receive and their asthma control levels (p&lt;0.001). While comparing asthma control levels and the received treatment, we observed a statistical significance (p=0.004).Conclusion: Asthma education and awareness are essential for both the patients and the caregivers. The compliance of the patient with the prescribed medicine and the proper use of the medication should be sought out and comorbidities must be scrutinized.</style></abstract><notes><style face="normal" font="default">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.21911/aai.14</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.21911/aai.14</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Allergy Immunol\2017-15-23-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Allergy Immunol\2017-15-23-31.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170519, Caliskan SS</style></custom2><misc3><style face="normal" font="default">10.21911/aai.14</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41590</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Akkoca,Y.</style></author><author><style face="normal" font="default"> Kenar,F.</style></author><author><style face="normal" font="default"> Inci Kenar,A.N.</style></author><author><style face="normal" font="default"> Karabulut,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Psychiatry, Ankara Training a Research Hospital, Turkey</style></auth-address><titles><title><style face="normal" font="default">Is there a Relationship between Social Support a High Histamine in Allergic-Non Allergic Rhinitis?</style></title><secondary-title><style face="normal" font="default">Austin J Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Austin J Allergy</style></full-title></periodical><pages end="" start="1023">1023-</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Arousal</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Histaminergic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Social Support</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Background: The histaminergic system has been shown to be important for emotional state, anxiety, allergy, a the brain arousal system. In this study, we aimed to investigate the relationship between social support a high histamine in patients with Allergic-Non allergic Rhinitis (AR-NAR).Methods: Diagnosis of AR was made using the fiings of physical a nasal eoscopic examination a the results of the skin prick test. Of 131 patients, 90 were diagnosed as having AR, a 41 as having NAR. Competence of social support of all patients was assessed using the Multidimensional Scale of Perceived Social Support.Results: Allergic patients aged less than 40 years a women who were allergic had higher scores in the "Perceived Family Support Subscale" (PFSS) than patients with NAR. We also fou increased scores of PFSS, special a social support total scores in male patients with NAR than in female patients with NAR.Conclusion: Although patients with AR a NAR have similar symptoms, our results show that patients who are allergic have increased social ability. These results can explain which allergic patients have high histamine. In accordance with our results, we fou that patients who were depressive a/ or anxious had social introversion, a increased histamine in the brain reduced social introversion, as well as depressive a anxiety symptoms.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://austinpublishinggroup.com/allergy/fulltext/aja-v3-id1023.php</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Austin J Allergy\2016-3-1023.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Austin J Allergy\2016-3-1023.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170519, Akkoca Y</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41591</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Roldan,E.</style></author><author><style face="normal" font="default"> Munoz,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Sports Medicine, Consultant Politécnico Colombiano Jaime Isaza Cadavid and Head of the Physical Activity and Health Research Group-SIAFYS, Medellin, Colombia</style></auth-address><titles><title><style face="normal" font="default">Asthma and Physical Activity</style></title><secondary-title><style face="normal" font="default">Austin J Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Austin J Allergy</style></full-title></periodical><pages end="" start="1021">1021-</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Athlete</style></keyword><keyword><style face="normal" font="default"> Athletes</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Colombia</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Exercise-induced asthma</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Lifestyle</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Sport</style></keyword><keyword><style face="normal" font="default"> Sports</style></keyword><keyword><style face="normal" font="default"> Sports Medicine</style></keyword><keyword><style face="normal" font="default"> Swimming</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Asthma is a high prevalence disease all around the world that compromise mainly children. It is cause of increased health cost and diminishes quality of life both in patients and in their families. Sedentary lifestyle is a risk factor in asthma; therefore, exercise gives some benefits to the asthmatic patient. However, 80% of asthmatics suffer Exercise-Induced Asthma (EIA), and that difficult exercise performance at the level required to get significant physiologic changes. The aim of this review is to discuss the benefits and risks of physical activity in asthmatics with respect to the Exercise-Induced Asthma (EIA), Exercise- Induced Bronchospasm (EIB), and swimming, training high-level athletes and end up with some recommendations for physical training in asthmatics</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Colombia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://austinpublishinggroup.com/allergy/fulltext/aja-v3-id1021.php</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Austin J Allergy\2016-3-1021.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Austin J Allergy\2016-3-1021.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170519, Roldan E</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41592</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yusuf Eken,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Konings, Stijn chief internal medicine, Demeyere Thomas MD Pathologist Catharina Hospital, Eindhoven, the Netherlands</style></auth-address><titles><title><style face="normal" font="default">The Challenges in the Diagnosis and Treatment of Still's Disease</style></title><secondary-title><style face="normal" font="default">BAOJ Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">BAOJ Allergy Immunol</style></full-title></periodical><pages end="" start="006">006-</pages><volume><style face="normal" font="default">2</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Arthritis</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> malignancy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic juvenile idiopathic arthritis</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Adult onset Still's disease (AOSD) is a rare disease in adults, in children also known as systemic juvenile idiopathic arthritis. We describe two patients with intermittent fevers without unknown origin. 27 years man and 75 years old woman, who presented with lymphadenopathy and recurrent fevers, There has been used intensive serologic, radiologic, laboratory investigation to exclude infectious diseases and malignancy. All the investigation showed no diagnosis. The clinical disease described for the first time at 1897 by Dr Still is finally diagnosed. Both patients received Anakinra with rapid response in hematologic, biochemical, and cytokine markers with reduction of systemic and local inflammation.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Netherlands -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://bioaccent.org/immunology/immunology06.php</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BAOJ Allergy Immunol\2016-2-006.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BAOJ Allergy Immunol\2016-2-006.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170518, Yusuf Eken Y</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41593</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Miles,J.</style></author><author><style face="normal" font="default"> Mudgal,K.</style></author><author><style face="normal" font="default"> Patel,S.</style></author><author><style face="normal" font="default"> Punjabi,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Imperial College London, London, UK</style></auth-address><titles><title><style face="normal" font="default">Contact allergy to commonly prescribed emollients</style></title><secondary-title><style face="normal" font="default">BMJ</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ</style></abbr-1></periodical><pages end="" start="j2008">j2008-</pages><volume><style face="normal" font="default">357</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emollient</style></keyword><keyword><style face="normal" font="default"> Emollients</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170602IS - 1756-1833 (Electronic)IS - 0959-535X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1136/bcr-2017-220197</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28572252">PM:28572252</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ\2017-357-j2008.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ\2017-357-j2008.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170602, Miles J</style></custom2><misc3><style face="normal" font="default">10.1136/bcr-2017-220197</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41594</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">O'Donnell,R.</style></author><author><style face="normal" font="default"> Hammond,J.</style></author><author><style face="normal" font="default"> Soltanifar,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anaesthetics, Ashford and St. Peter's Hospitals NHS Trust, Chertsey, UK</style></auth-address><titles><title><style face="normal" font="default">A confirmed case of sugammadex-induced anaphylaxis in a UK hospital</style></title><secondary-title><style face="normal" font="default">BMJ Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaesthesia</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Hypotension</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum tryptase</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Sugammadex</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="13" Month="5" Year="2017">2017/5/13</year></dates><abstract><style face="normal" font="default">We report the first published case of confirmed anaphylaxis to sugammadex in a UK hospital. The patient was given a bolus of sugammadex at the end of surgery. Four minutes later, he developed hypotension and a widespread erythematous rash. Multiple epinephrine boluses were administered and a continuous intravenous infusion of epinephrine commenced. The patient later reported auditory awareness, which occurred while the diagnosis of anaphylaxis was being made and initial treatment initiated. Serial serum tryptase levels were consistent with a type I hypersensitivity reaction. Skin prick and intradermal testing were performed 6 months later confirming allergy to sugammadex. This case restates the potential for hypersensitivity reactions to develop following the administration of sugammadex and makes clinicians aware that such reactions may require prolonged treatment with intravenous infusions of epinephrine. Finally, this case highlights the importance of maintaining or re-establishing anaesthesia while managing the emergent situation in order to avoid unintentional awareness</style></abstract><notes><style face="normal" font="default">DA - 20170514IS - 1757-790X (Electronic)IS - 1757-790X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1136/bcr-2017-220197</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28501827">PM:28501827</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Case Rep\20170514-ODonnellR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Case Rep\20170514-ODonnellR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170514, O'Donnell R</style></custom2><misc3><style face="normal" font="default">10.1136/bcr-2017-220197</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41595</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ortega Lopez,M.C.</style></author><author><style face="normal" font="default"> Leon Quintero,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Ataxia-telangiectasia syndrome without ataxia: a case report</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="57" start="54">54-57</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> Asparagine</style></keyword><keyword><style face="normal" font="default"> Ataxia Telangiectasia</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cell Cycle</style></keyword><keyword><style face="normal" font="default"> Colombia</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Failure to Thrive</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Iga</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Igm</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulins</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Movement</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Ocular</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Sequence</style></keyword><keyword><style face="normal" font="default"> Serine</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> T lymphocyte</style></keyword><keyword><style face="normal" font="default"> T lymphocytes</style></keyword><keyword><style face="normal" font="default"> T-lymphocyte</style></keyword><keyword><style face="normal" font="default"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Walking</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Ataxia-telangiectasia syndrome (AT) is a complex syndrome with an autosomal recessive inheritancepattern and a low prevalence, which involves multiple organs. It is characterized by neurologicaldisorders, progressive cerebellar ataxia, variable immunodeficiency with increased susceptibilityto recurrent sinopulmonary infections, X-ray hypersensitivity, oculocutaneous telangiectasia,predisposition to neoplasia, chromosomal instability, and high alpha-fetoprotein levels. Mostmutations detected in the AT mutated gene (ATM gene) cause truncation of the ATM proteinkinase, which is responsible for repairing DNA and regulating cell cycle. We describe the caseof an 8-year old girl, daughter of non-consanguineous parents, who had a history of recurrentinfections, ocular telangiectasia, ocular apraxia, failure to thrive, and no associated neurologicalsymptoms, normal walking movements, and no ataxia. Serum levels of immunoglobulins IgA, IgG,and IgE were low, with increased IgM levels, normal T lymphocytes, and very high alpha-fetoproteinlevels. Relatively mild AT was suspected. Genetic analysis revealed the presence of two variantswithin the ATM gene coding sequence. The first one was the deletion of a nucleotide in position3802 (c.3802delG), resulting in the synthesis of a truncated protein (p.Val1268Xfs). The secondvariant was a homozygous missense mutation (c.5948 A>G); at the protein level, this mutationleads to replacement of asparagine (Asn) with serine (Ser) at position 1983 (p.Asn1938Ser). Thediagnosis of AT syndrome was confirmed, even in the absence of ataxia, as a rare presentationof the disease.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Colombia -</style></notes><work-type><style face="normal" font="default">10.5935/2318-5015.20160006</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2318-5015.20160006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2016-4-54-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2016-4-54-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170519, Ortega Lopez MC</style></custom2><misc3><style face="normal" font="default">10.5935/2318-5015.20160006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41596</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Duarte Dortas,S.,Jr.</style></author><author><style face="normal" font="default"> Lupi,O.</style></author><author><style face="normal" font="default"> Andrade Coelho Dias,G.</style></author><author><style face="normal" font="default"> Boleira Sieiro Guimaraes,M.</style></author><author><style face="normal" font="default"> Oliveira Rodrigues Valle,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cross-cultural adaptation and validation of health questionnaires</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="30" start="26">26-30</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">bias</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Language</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Selection Bias</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Translating</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">A good questionnaire for assessing the progression of a disease should generate valid answers,be well accepted by responders and encourage their participation and the provision of the desiredinformation. Because of the increasing number of multicenter clinical trials being conducted,there is a need to develop specific measures to be used in countries where languages other thanEnglish are spoken. Considering that important cultural differences may be present, there are twoways to develop such specific measures: developing a new tool, or translating and cross-culturallyadapting an existing tool previously validated in another language. Cross-cultural adaptation of aninstrument is less costly and requires less time to obtain a common measure for the evaluationof disease status. In addition, it allows comparisons among different cultural groups. Adapting aquestionnaire for use in a new, culturally distinct population is time-consuming and expensive.However, we believe that this is the best and most appropriate way to ensure equivalence. Itwill allow the collection of data in different countries or among individuals of different cultureswithin the same country, and avoid a selection bias.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2318-5015.20160003</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2318-5015.20160003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2016-4-26-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2016-4-26-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160519, Duarte Dortas S Jr</style></custom2><misc3><style face="normal" font="default">10.5935/2318-5015.20160003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41597</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Barreto Silva,A.C.</style></author><author><style face="normal" font="default"> Seiler,M.T.</style></author><author><style face="normal" font="default"> Tostes,C.</style></author><author><style face="normal" font="default"> Arce,J.</style></author><author><style face="normal" font="default"> Maurici da Silva,R.</style></author><author><style face="normal" font="default"> Menezes Pizzichini,M.M.</style></author><author><style face="normal" font="default"> Ferreira da Silva,A.,Jr.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prevalence of asthma and rhinoconjunctivitis using the International Study of Asthma and Allergies in Childhood (ISAAC) and the 22-Item Sinonasal Outcome Test (SNOT-22) questionnaires in 13- to 14-year-old adolescents</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="50" start="31">31-50</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mood</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> sinonasal outcome test</style></keyword><keyword><style face="normal" font="default"> sinus</style></keyword><keyword><style face="normal" font="default"> Students</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Asthma and rhinoconjunctivitis, alone or in combination, are conditions that have direct impacton productivity and consequently on the quality of life of individuals, particularly when notdiagnosed or properly treated. The use of validated questionnaires enables comparisons amongstudies that used the same tool in different cultures and countries, leading to early diagnosisand treatment, and therefore to a significant reduction in the burden of disease. Objectives: Toestimate the prevalence of asthma and rhinoconjunctivitis in adolescents aged 13 to 14 years, theirassociation with the domains of the 22-Item Sinonasal Outcome Test (SNOT-22) questionnaire, and the impact of these conditions on the adolescents' lives. Methods: In this cross-sectionalstudy, two self-administered instruments, namely the International Study of Asthma and Allergiesin Childhood (ISAAC) and the SNOT-22 questionnaires, were applied to adolescents aged 13 to 14years, currently enrolled in private and public schools of the city of Florianopolis, state of SantaCatarina, between May and July 2012. Results: Of a total of 2,558 students who participatedin the survey, 67.1% were enrolled in public schools, and 50.9% were girls. The age of 13 wasmore prevalent. The prevalence rates for asthma and rhinoconjunctivitis were 11.1 and 31%,respectively, according to the ISAAC questionnaire. The two conditions were associated in 4.5%of the adolescents. The association between rhinoconjunctivitis and nasal and sinus symptoms,according to SNOT-22 domains, showed significant correlations with all the analyzed variables,with increased severity when the condition was present. Analysis of the impact of combinedrhinoconjunctivitis and asthma on the adolescentsf lives revealed significant associations withmood swings and decreased academic and personal productivity. Conclusion: The prevalence ofasthma was 11.1%, and of rhinoconjunctivitis, 31%. There was a significant association of theseconditions with mood swings and decreased academic and personal productivity.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2318-5015.20160004</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2318-5015.20160004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2016-4-31-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2016-4-31-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170519, Barreto SIlva AC</style></custom2><misc3><style face="normal" font="default">10.5935/2318-5015.20160004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41598</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Parrott,J.</style></author><author><style face="normal" font="default"> Tener,M.</style></author><author><style face="normal" font="default"> Dennis,K.</style></author><author><style face="normal" font="default"> Sharpe,M.</style></author><author><style face="normal" font="default"> Clark-Ganheart,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Kansas School of Medicine, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA</style></auth-address><titles><title><style face="normal" font="default">A Case of Sevoflurane Use during Pregnancy in the Management of Persistent Status Asthmaticus</style></title><secondary-title><style face="normal" font="default">Case Rep Obstet Gynecol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Case Rep Obstet Gynecol</style></full-title></periodical><pages end="" start="3547242">3547242-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Biopsy</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug-induced</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> Kansas</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Neonate</style></keyword><keyword><style face="normal" font="default"> pH</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Sevoflurane</style></keyword><keyword><style face="normal" font="default"> Status Asthmaticus</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Sevoflurane is rarely used for the treatment of status asthmaticus. We report a case of sevoflurane hepatotoxicity in pregnancy with presentation similar to HELLP syndrome. CASE: A G2P1001 at 23 weeks in status asthmaticus presented with pCO2 > 130 and pH &lt; 7. She was nonresponsive to traditional therapy. Sevoflurane was added for a 24 hr period. Respiratory status improved. Extubation occurred on day 12. Workup for preeclampsia spectrum disorders occurred due to maternal hypertension. Given the atypical presentation and hepatotoxicity, a liver biopsy was performed. Histologic features suggested drug induced hepatic injury. Liver function subsequently normalized. She delivered a term neonate without short-term complications. CONCLUSION: The use of sevoflurane is a treatment option of status asthmaticus during pregnancy. Providers should be aware of the potential for hepatotoxicity</style></abstract><notes><style face="normal" font="default">DA - 20170530IS - 2090-6684 (Print)IS - 2090-6692 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1155/2017/3547242</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28555168">PM:28555168</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Case Rep Obstet Gynecol\2017-2017-3547242.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Case Rep Obstet Gynecol\2017-2017-3547242.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170530, Parrott J</style></custom2><misc3><style face="normal" font="default">10.1155/2017/3547242</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41599</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kato,A.</style></author><author><style face="normal" font="default"> Takita,T.</style></author><author><style face="normal" font="default"> Furuhashi,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Blood Purification Unit, Hamamatsu University Hospital, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, 431-3192, Japan.</style></auth-address><titles><title><style face="normal" font="default">Hypersensitivity reactions to acetate in the bicarbonate dialysate in a patient undergoing pre-dilution online hemodiafiltration</style></title><secondary-title><style face="normal" font="default">CEN Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">CEN Case Rep</style></full-title></periodical><pages end="33" start="31">31-33</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">blood</style></keyword><keyword><style face="normal" font="default"> Dialysis</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2016">2016/5</year></dates><abstract><style face="normal" font="default">A 63-year-old male patient first experienced recurrent hypotensive episode during the dialysis session just after switching the mode from hemodialysis to online hemodiafiltration (OL-HDF) with infusion in pre-dilution of the bicarbonate dialysate containing 9.2 mEq/L of acetate. Peripheral eosinophil count and serum IgE were both elevated to 16,440/muL and 2000 IU/L. The reactions promptly dissolved with substitution of acetate-free solution. This case illustrated that pre-dilution OL-HDF can induce an occult hypersensitivity to acetate in the standard bicarbonate dialysate</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 2192-4449 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1007/s13730-015-0185-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28509160">PM:28509160</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\CEN Case Rep\2016-5-31-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\CEN Case Rep\2016-5-31-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Kato A</style></custom2><misc3><style face="normal" font="default">10.1007/s13730-015-0185-y</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41600</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sherenian,M.G.</style></author><author><style face="normal" font="default"> Cho,S.H.</style></author><author><style face="normal" font="default"> Levin,A.</style></author><author><style face="normal" font="default"> Min,J.Y.</style></author><author><style face="normal" font="default"> Oh,S.S.</style></author><author><style face="normal" font="default"> Hu,D.</style></author><author><style face="normal" font="default"> Galanter,J.</style></author><author><style face="normal" font="default"> Sen,S.</style></author><author><style face="normal" font="default"> Huntsman,S.</style></author><author><style face="normal" font="default"> Eng,C.</style></author><author><style face="normal" font="default"> Rodriguez-Santana,J.R.</style></author><author><style face="normal" font="default"> Serebrisky,D.</style></author><author><style face="normal" font="default"> Avila,P.C.</style></author><author><style face="normal" font="default"> Kalhan,R.</style></author><author><style face="normal" font="default"> Smith,L.J.</style></author><author><style face="normal" font="default"> Borrell,L.N.</style></author><author><style face="normal" font="default"> Seibold,M.A.</style></author><author><style face="normal" font="default"> Keoki,W.L.</style></author><author><style face="normal" font="default"> Burchard,E.G.</style></author><author><style face="normal" font="default"> Kumar,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy-Immunology, Department of Pediatrics, Northwestern University, Chicago, Illinois, USA</style></auth-address><titles><title><style face="normal" font="default">PAI-1 gain-of-function genotype, factors increasing PAI-1 levels, and airway obstruction: the GALA II Cohort</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">African American</style></keyword><keyword><style face="normal" font="default"> African Americans</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Airway Obstruction</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Illinois</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Latino</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Plasminogen</style></keyword><keyword><style face="normal" font="default"> Plasminogen Activator Inhibitor 1</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Tobacco</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="24" Month="5" Year="2017">2017/5/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: PAI-1 gain of function variants promote airway fibrosis, and are associated with asthma and with worse lung function in subjects with asthma. OBJECTIVE: We sought to determine if the association of a gain-of-function polymorphism in Plasminogen Activator Inhibitor -1 (PAI-1) with airway obstruction is modified by asthma status, and whether any genotype effect persists after accounting for common exposures that increase PAI-1 level. METHODS: We studied 2070 Latino children (8-21y) with genotypic and pulmonary function data from the GALA II cohort. We estimated the relationship of the PAI-1 risk allele with FEV1/FVC by multivariate linear regression, stratified by asthma status. We examined the association of the polymorphism with asthma and airway obstruction within asthmatics via multivariate logistic regression. We replicated associations in the SAPPHIRE cohort of African Americans (n=1056). Secondary analysis included the effect of the at-risk polymorphism on post bronchodilator lung function. RESULTS: There was an interaction between asthma status and the PAI-1 polymorphism on FEV1 /FVC (p=0.03). The gain-of-function variants, genotypes (AA/AG), were associated with lower FEV1 /FVC in subjects with asthma (beta=-1.25, CI:-2.14,-0.35, p=0.006), but not in controls. Subjects with asthma and the AA/AG genotypes had a 5% decrease in FEV1 /FVC (p&lt;0.001). In asthmatics, the risk genotype (AA/AG) was associated with a 39% increase in risk of clinically relevant airway obstruction (OR=1.39, CI:1.01, 1.92, p=0.04). These associations persisted after exclusion of factors that increase PAI-1 including tobacco exposure and obesity. CONCLUSIONS AND CLINICAL RELEVANCE: The decrease in the FEV1 /FVC ratio associated with the risk genotype was modified by asthma status. The genotype increased the odds of airway obstruction by 75% within asthmatics only. Since exposures known to increase PAI-1 levels did not mitigate this association, PAI-1 may contribute to airway obstruction in the context of chronic asthmatic airway inflammation. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170525IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12958</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28543872">PM:28543872</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170525-SherenianMG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170525-SherenianMG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170525, Sherenian MG</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12958</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41601</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Takahagi,S.</style></author><author><style face="normal" font="default"> Tanaka,A.</style></author><author><style face="normal" font="default"> Iwamoto,K.</style></author><author><style face="normal" font="default"> Ishii,K.</style></author><author><style face="normal" font="default"> Hide,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan</style></auth-address><titles><title><style face="normal" font="default">Contact urticaria syndrome with IgE antibody against a cefotiam-unique structure, evoked by nonapparent exposure to cefotiam</style></title><secondary-title><style face="normal" font="default">Clin Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">albumin</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cefotiam</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact urticaria</style></keyword><keyword><style face="normal" font="default"> contact urticaria syndrome</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Histamine Release</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human serum</style></keyword><keyword><style face="normal" font="default"> Human serum albumin</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE antibodies</style></keyword><keyword><style face="normal" font="default"> IgE antibody</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Pretreatment</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum Albumin</style></keyword><keyword><style face="normal" font="default"> Side chain</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin reaction</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Workplace</style></keyword></keywords><dates><year Day="22" Month="5" Year="2017">2017/5/22</year></dates><abstract><style face="normal" font="default">A 26-year-old woman presented with recurrent attacks of widespread urticaria and systemic symptoms. The patient was a nurse, and the attacks occurred only in her workplace, without an apparent trigger. A patch test to cefotiam (CTM) induced an immediate skin reaction. ELISA detected the patient's serum IgE antibody binding to CTM conjugated with human serum albumin (CTM-HSA), and her basophils released histamine in response to CTM-HSA in a histamine release assay (HRA). Both reactions in ELISA and HRA were inhibited by pretreatment of the patient's serum or basophils with cefotiam. No crossreactivity in skin tests or in vitro assays was observed against other antibiotics, even those containing a beta-lactam ring and/or side chains similar to CTM. Certain antibiotics including CTM may cause extremely sensitive and specific contact urticaria syndrome, which is mediated by IgE and evoked even without apparent skin contact with the culprit drug and in the absence of any history of an allergic reaction against other antibiotics with similar structures</style></abstract><notes><style face="normal" font="default">DA - 20170525IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/ced.13126</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28543395">PM:28543395</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Dermatol\20170525-TakahagiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Dermatol\20170525-TakahagiS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170525, Takahagi S</style></custom2><misc3><style face="normal" font="default">10.1111/ced.13126</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41602</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sathishkumar,D.</style></author><author><style face="normal" font="default"> Al-Abadi,E.</style></author><author><style face="normal" font="default"> Nicklaus-Wollenteit,I.</style></author><author><style face="normal" font="default"> Moss,C.</style></author><author><style face="normal" font="default"> Hawkins,P.N.</style></author><author><style face="normal" font="default"> Gach,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Birmingham Children's Hospital NHS Foundation Trust, Birmingham, UK</style></auth-address><titles><title><style face="normal" font="default">Early-onset urticaria: a marker of cryopyrin-associated periodic syndrome</style></title><secondary-title><style face="normal" font="default">Clin Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170517IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/ced.13106</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28512856">PM:28512856</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Dermatol\20170517-SathishkumarD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Dermatol\20170517-SathishkumarD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170517, Sathishkumar D</style></custom2><misc3><style face="normal" font="default">10.1111/ced.13106</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41603</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cozacov,R.</style></author><author><style face="normal" font="default"> Halasz,K.</style></author><author><style face="normal" font="default"> Haj,T.</style></author><author><style face="normal" font="default"> Vadasz,Z.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Clinical immunology, Bnai-Zion Medical Center, The Rappaport Faculty of Medicine, Technion, Haifa, Israel</style></auth-address><titles><title><style face="normal" font="default">Semaphorin 3A: Is a key player in the pathogenesis of asthma</style></title><secondary-title><style face="normal" font="default">Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Coculture</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Foxp3</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune-mediated</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Recombinant</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T regulatory cell</style></keyword><keyword><style face="normal" font="default"> T regulatory cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> Tregs</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="5" Year="2017">2017/5/11</year></dates><abstract><style face="normal" font="default">Immune semaphorins are key players in regulating immune mediated inflammation. Semaphorin3A (sema3A) a secreted and membrane bound member of this family, is well reported for its properties in maintaining self-tolerance. Semaphorin3A was recognized to be a marker for T-regulatory cells (Tregs), and as such is a useful tool for assessing the status of these cells in preventing immune mediated diseases. This study was designed aiming to evaluate how sema3A is possibly involved in bronchial asthma. Here, we found sema3A serum levels and the expression of sema3A on Tregs significantly lower in patients with moderate to severe asthma when compared to healthy individuals. Co-culture of condition medium with 2mcg/ml of recombinant human sema3A with CD4+ T cells, increased the expression of FoxP3 in Tregs, suggesting sema3A a potent immune-regulator of inflammation including that of asthma. Further in-vivo studies will better establish the beneficial effect of sema3A in regulating inflammation in asthma</style></abstract><notes><style face="normal" font="default">DA - 20170515IS - 1521-7035 (Electronic)IS - 1521-6616 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">10.1016/j.clim.2017.05.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28502680">PM:28502680</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Immunol\20170515-CozacovR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Immunol\20170515-CozacovR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170515, Cozacov R</style></custom2><misc3><style face="normal" font="default">10.1016/j.clim.2017.05.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41604</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Alavinezhad,A.</style></author><author><style face="normal" font="default"> Boskabady,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Neurogeneeic Inflammation Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran</style></auth-address><titles><title><style face="normal" font="default">The prevalence of asthma and related symptoms in Middle East countries</style></title><secondary-title><style face="normal" font="default">Clin Respir J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Respir J</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Cigarette</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Constriction</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Kuwait</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> Middle East</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="24" Month="5" Year="2017">2017/5/24</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Asthma is a chronic inflammatory airway disease characterized by reversible airway constriction and airway hyperresponsiveness. Asthma is a worldwide problem and its prevalence varies among different parts of the world. There are insufficient data about the prevalence and risk factors of this disease in Middle East countries. DATA SOURCE: The objective of this review article was to determine the prevalence of asthma in Middle East countries by searching EMBASE, Medline, Web of Science and Google Scholar for articles about asthma prevalence in children and adults in this region. STUDY SELECTION: The prevalence of asthma in different countries and different cities of each country in the Middle East was reviewed in children and adults of both sexes. The possible risk factors for asthma in different areas were also reviewed from 1985 to 2012. RESULTS: The highest asthma prevalence in children and adults was 35.4% in Tehran, Iran by ISAAC phase I and 15% in Kuwait by Self-designed questionnaire and the lowest prevalence was 1% in Kermanshah, Iran by ISAAC and 2% in Tehran, Iran by ECRHS questionnaire, respectively. Most studies showed that the prevalence of this common disease declines with increasing age. CONCLUSION: The data showed that the prevalence of asthma varies among different countries and even among different cities of the same country. The common risk factors for this disease were genetic predisposition, cigarette smoking, family history of asthma and allergic diseases. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170525IS - 1752-699X (Electronic)IS - 1752-6981 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Iran -</style></notes><work-type><style face="normal" font="default">10.1111/crj.12655</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28544458">PM:28544458</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Respir J\20170525-AlavinezhadA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Respir J\20170525-AlavinezhadA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170525, Alavinezhad A</style></custom2><misc3><style face="normal" font="default">10.1111/crj.12655</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41605</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kroona,L.</style></author><author><style face="normal" font="default"> Warfvinge,G.</style></author><author><style face="normal" font="default"> Isaksson,M.</style></author><author><style face="normal" font="default"> Ahlgren,C.</style></author><author><style face="normal" font="default"> Dahlin,J.</style></author><author><style face="normal" font="default"> Sorensen,O.</style></author><author><style face="normal" font="default"> Bruze,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Oral Pathology, Faculty of Odontology, Malmo University, 205 06, Malmo, Sweden</style></auth-address><titles><title><style face="normal" font="default">Quantification of l-carvone in toothpastes available on the Swedish market</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Chromatography</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Flavour</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Limonene</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> oral mucosa</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Quantification</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Stomatitis</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Toothpaste</style></keyword><keyword><style face="normal" font="default"> Toothpastes</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="5" Year="2017">2017/5/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: Toothpastes have widespread use in the population, and contain flavours used to give a pleasant and often minty aroma. Flavours are prevalent allergens in toothpastes, and adverse reactions often present as perioral dermatitis or stomatitis. l-Carvone, a mint flavour found in spearmint oil, is one of these allergens. There are few studies on contact allergy to l-carvone, and some of them have indicated a positive relationship with oral lichenoid lesions. OBJECTIVES: To qualitatively and quantitatively investigate the presence of l-carvone in commercially available toothpastes on the Swedish market. METHODS: l-Carvone in 66 toothpastes was analysed with straight-phase high-performance liquid chromatography. The product labels were studied with regard to limonene. RESULTS: l-Carvone was found in 64 of 66 toothpastes (concentration: 0.00005-0.35%). In 10 of these, the concentration exceeded 0.1%. Higher concentrations of l-carvone were found if limonene was listed on the label. CONCLUSION: The majority of toothpastes on the Swedish market contain l-carvone, but the concentration hardly relates to the advertised flavour or labelled ingredients. It is hitherto unknown whether the found concentrations are sufficient for induction of contact allergy in individuals with healthy oral mucosa or in those with oral lichenoid lesions or other mucosal disease</style></abstract><notes><style face="normal" font="default">DA - 20170519IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12803</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28524256">PM:28524256</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170517-KroonaL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170517-KroonaL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170519, Kroona L</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12803</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41606</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Battais,F.</style></author><author><style face="normal" font="default"> Huppert,C.</style></author><author><style face="normal" font="default"> Langonne,I.</style></author><author><style face="normal" font="default"> Muller,S.</style></author><author><style face="normal" font="default"> Sponne,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Toxicology and Biometrology, National Institute for Research and Safety (INRS), 54019, Vandoeuvre cedex, France</style></auth-address><titles><title><style face="normal" font="default">In vitro detection of chemical allergens: an optimized assay using mouse bone marrow-derived dendritic cells</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergenic</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Chemical allergens</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact allergens</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Respiratory allergens</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Toxicology</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="29" Month="5" Year="2017">2017/5/29</year></dates><abstract><style face="normal" font="default">BACKGROUND: Identification of the allergenic potency of chemicals is a key step in the safety assessment process. Predictive assays that require no or few animals are needed. OBJECTIVES: To develop an alternative in vitro mouse bone marrow-derived dendritic cell (BMDC) assay to determine the allergenic potential of chemicals. METHODS: BMDCs were exposed to well-known allergens and to non-allergenic chemicals. Surface marker expression and cytokine release of BMDCs were analysed after treatment. RESULTS: Eleven tested chemicals showed a significant stimulation index (SI) of >1.5 (accuracy, 75%; sensitivity, 69%). The four non-allergens all showed a SI of &lt;1.5. Eight contact allergens tested showed a significant SI of >1.5 (accuracy, 92%; sensitivity, 89%), whereas only two respiratory allergens showed a significant SI of >1.5 (accuracy, 60%; sensitivity, 33%). CONCLUSIONS: The results indicate that the BMDC assay could become a reliable test for assessment of the allergenic potential of chemicals. The next step should include the testing of further chemicals, with the aim of integrating this assay into the toolbox of in vitro methods for the evaluation of the allergenic potential of chemicals</style></abstract><notes><style face="normal" font="default">DA - 20170530IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12829</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28555887">PM:28555887</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170530-BattaisF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170530-BattaisF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170530, Battais F</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12829</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41607</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hamada,H.</style></author><author><style face="normal" font="default"> Bruze,M.</style></author><author><style face="normal" font="default"> Zimerson,E.</style></author><author><style face="normal" font="default"> Isaksson,M.</style></author><author><style face="normal" font="default"> Engfeldt,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Lund University, Department of Occupational and Environmental Dermatology, Skane University Hospital, 205 02, Malmo, Sweden</style></auth-address><titles><title><style face="normal" font="default">Sensitization and cross-reactivity patterns of contact allergy to diisocyanates and corresponding amines: investigation of diphenylmethane-4,4'-diisocyanate, diphenylmethane-4,4'-diamine, dicyclohexylmethane-4,4'-diisocyanate, and dicylohexylmethane-4,4'-diamine</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Amines</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> cross reactivity</style></keyword><keyword><style face="normal" font="default"> Cross-reactivity</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> guinea pig maximization test</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Isocyanate</style></keyword><keyword><style face="normal" font="default"> Isocyanates</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Strong sensitizers</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="29" Month="5" Year="2017">2017/5/29</year></dates><abstract><style face="normal" font="default">BACKGROUND: Isocyanates are used in polyurethane production. Dermal exposure to isocyanates can induce contact allergy. The most common isocyanate is diphenylmethane diisocyanate used for industrial purposes. The isomer diphenylmethane-4,4'-diisocyanate (4,4'-MDI) is used in patch testing. Diphenylmethane-4,4'-diamine (4,4'-MDA) is its corresponding amine. Concurrent reactions to 4,4'-MDI and 4,4'-MDA have been reported, as have concurrent reactions to 4,4'-MDI and dicyclohexylmethane-4,4'-diisocyanate (4,4'-DMDI). OBJECTIVES: To investigate the sensitization capacities and the cross-reactivity of 4,4'-MDI, 4,4'-MDA, 4,4'-DMDI, and dicyclohexylmethane-4,4'-diamine (4,4'-DMDA). METHODS: The guinea-pig maximization test (GPMT) was used. RESULTS: The GPMT showed sensitizing capacities for all investigated substances: 4,4'-MDI, 4,4'-MDA, 4,4'-DMDI, and 4,4'-DMDA (all p &lt; 0.001). 4,4'-MDI-sensitized animals showed cross-reactivity to 4,4'-MDA (p &lt; 0.001) and 4,4'-DMDI (all p &lt; 0.05). 4,4'-MDA-sensitized animals showed cross-reactivity to 4,4'-DMDA (p = 0.008). CONCLUSION: All of the investigated substances were shown to be strong sensitizers. Animals sensitized to 4,4'-MDI showed cross-reactivity to 4,4'-MDA and 4,4'-DMDI, supporting previous findings in the literature. The aromatic amine 4,4'-MDA showed cross-reactivity to the aliphatic amine 4,4'-DMDA</style></abstract><notes><style face="normal" font="default">DA - 20170530IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12809</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28555927">PM:28555927</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170530-HamadaH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170530-HamadaH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170530, Hamada H</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12809</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41608</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Minciullo,P.L.</style></author><author><style face="normal" font="default"> Calapai,G.</style></author><author><style face="normal" font="default"> Miroddi,M.</style></author><author><style face="normal" font="default"> Mannucci,C.</style></author><author><style face="normal" font="default"> Chinou,I.</style></author><author><style face="normal" font="default"> Gangemi,S.</style></author><author><style face="normal" font="default"> Schmidt,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria, 98125, Messina, ItalyBoDD - Botanical Dermatology Database, Penarth, UK</style></auth-address><titles><title><style face="normal" font="default">Contact dermatitis as an adverse reaction to some topically used European herbal medicinal products - part 4: Solidago virgaurea-Vitis vinifera</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> European Union</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> Herbal</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="23" Month="5" Year="2017">2017/5/23</year></dates><abstract><style face="normal" font="default">This review focuses on contact dermatitis as an adverse effect of a selection of topically used herbal medicinal products for which the European Medicines Agency has completed an evaluation up to the end of November 2013 and for which a Community herbal monograph - now (since 2014) called a 'European Union herbal monograph' - has been produced. The present part 4 addresses species from Solidago virgaurea L. to Vitis vinifera L</style></abstract><notes><style face="normal" font="default">DA - 20170525IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -CO - Greece -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12807</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28543097">PM:28543097</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170525-MinciulloPL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170525-MinciulloPL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170525, Minciullo PL</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12807</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41609</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bennike,N.H.</style></author><author><style face="normal" font="default"> Zachariae,C.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, National Allergy Research Centre, Herlev-Gentofte Hospital, University of Copenhagen, 2900, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Non-mix fragrances are top sensitizers in consecutive dermatitis patients - a cross-sectional study of the 26 EU-labelled fragrance allergens</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Baseline series</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Fragrance mix</style></keyword><keyword><style face="normal" font="default"> Fragrances</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: For cosmetics, it is mandatory to label 26 fragrance substances, including all constituents of fragrance mix I (FM I) and fragrance mix II (FM II). Earlier reports have not included oxidized R-limonene [hydroperoxides of R-limonene (Lim-OOH)] and oxidized linalool [hydroperoxides of linalool (Lin-OOH)], and breakdown testing of FM I and FM II has mainly been performed in selected, mix-positive patients. OBJECTIVES: To report the prevalence of sensitization to the 26 fragrances, and to assess concomitant reactivity to FM I and/or FM II. METHODS: A cross-sectional study on consecutive dermatitis patients patch tested with the 26 fragrances and the European baseline series from 2010 to 2015 at a single university clinic was performed. RESULTS: Of 6004 patients, 940 (15.7%, 95%CI: 14.7-16.6%) were fragrance-sensitized. Regarding the single fragrances, most patients were sensitized to Lin-OOH (3.9%), Evernia furfuracea (3.0%), Lim-OOH (2.5%), and hydroxyisohexyl 3-cyclohexene carboxaldehyde (2.1%). Significantly fewer patients were 'FM I-positive and constituent-positive' than 'FM II-positive and constituent-positive' (32.7% versus 57.0%, p &lt; 0.0001). Additionally, significantly more patients were 'FM II-negative but constituent-positive' than 'FM I-negative but constituent-positive' (12.4% versus 3.2%, p = 0.0008). CONCLUSIONS: Non-mix fragrances are the most important single fragrance allergens among consecutive patients. The test concentration of the single FM I constituents should be increased when possible</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12822</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28511284">PM:28511284</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170516-BennikeNH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170516-BennikeNH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Bennike NH</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12822</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41610</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Raposo,I.</style></author><author><style face="normal" font="default"> Lobo,I.</style></author><author><style face="normal" font="default"> Amaro,C.</style></author><author><style face="normal" font="default"> Lobo,M.L.</style></author><author><style face="normal" font="default"> Melo,H.</style></author><author><style face="normal" font="default"> Parente,J.</style></author><author><style face="normal" font="default"> Pereira,T.</style></author><author><style face="normal" font="default"> Rocha,J.</style></author><author><style face="normal" font="default"> Cunha,A.P.</style></author><author><style face="normal" font="default"> Baptista,A.</style></author><author><style face="normal" font="default"> Serrano,P.</style></author><author><style face="normal" font="default"> Correia,T.</style></author><author><style face="normal" font="default"> Travassos,A.R.</style></author><author><style face="normal" font="default"> Dias,M.</style></author><author><style face="normal" font="default"> Pereira,F.</style></author><author><style face="normal" font="default"> Goncalo,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Centro Hospitalar do Porto, 4099-001, Porto, Portugal</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by (meth)acrylates in nail cosmetic products in users and nail technicians - a 5-year study</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic hand eczema</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cosmetic products</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand eczema</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Methacrylate</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="15" Month="5" Year="2017">2017/5/15</year></dates><abstract><style face="normal" font="default">BACKGROUND: The increasing use of long-lasting nail aesthetic products has led to a growing number of cases of allergic contact dermatitis (ACD) caused by (meth)acrylates in recent years. OBJECTIVES: To provide information on ACD caused by (meth)acrylates related to nail cosmetic products. METHODS: We retrospectively reviewed files of patients with ACD caused by (meth)acrylates related to nail cosmetic products, who were patch tested between January 2011 and December 2015 in 13 departments of dermatology in Portugal. RESULTS: Two-hundred and thirty cases of ACD caused by (meth)acrylates (55 technicians, 56 consumers, and 119 with mixed exposure) had been documented, mostly as chronic hand eczema (93%). The most common sensitizers were: 2-hydroxyethyl methacrylate (HEMA), which was positive in 90% of the tested patients, 2-hydroxypropyl methacrylate (HPMA), which was positive in 64.1%, and ethyleneglycol dimethacrylate, which was positive in 54.5%. CONCLUSION: HEMA and HPMA were the most frequent positive allergens. HEMA, which identified 90% of cases, can be considered to be a good screening allergen. The high number of cases of ACD caused by (meth)acrylates in nail cosmetic products certainly warrants better preventive measures at the occupational level, and specific regulation in the field of consumer safety</style></abstract><notes><style face="normal" font="default">DA - 20170515IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12817</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28504363">PM:28504363</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170515-RaposoI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170515-RaposoI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170515, Raposo I</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12817</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41611</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Koppes,S.A.</style></author><author><style face="normal" font="default"> Engebretsen,K.A.</style></author><author><style face="normal" font="default"> Agner,T.</style></author><author><style face="normal" font="default"> Angelova-Fischer,I.</style></author><author><style face="normal" font="default"> Berents,T.</style></author><author><style face="normal" font="default"> Brandner,J.</style></author><author><style face="normal" font="default"> Brans,R.</style></author><author><style face="normal" font="default"> Clausen,M.L.</style></author><author><style face="normal" font="default"> Hummler,E.</style></author><author><style face="normal" font="default"> Jakasa,I.</style></author><author><style face="normal" font="default"> Jurakic-Toncic,R.</style></author><author><style face="normal" font="default"> John,S.M.</style></author><author><style face="normal" font="default"> Khnykin,D.</style></author><author><style face="normal" font="default"> Molin,S.</style></author><author><style face="normal" font="default"> Holm,J.O.</style></author><author><style face="normal" font="default"> Suomela,S.</style></author><author><style face="normal" font="default"> Thierse,H.J.</style></author><author><style face="normal" font="default"> Kezic,S.</style></author><author><style face="normal" font="default"> Martin,S.F.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Coronel Institute of Occupational Health, Academic Medical Center, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Current knowledge on biomarkers for contact sensitization and allergic contact dermatitis</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> contact sensitization</style></keyword><keyword><style face="normal" font="default"> Croatia</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory mediators</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Lipid</style></keyword><keyword><style face="normal" font="default"> Lipids</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Norway</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Health</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> peptide</style></keyword><keyword><style face="normal" font="default"> Peptides</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Protease</style></keyword><keyword><style face="normal" font="default"> proteases</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> tight junctions</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="default">Contact sensitization is common and affects up to 20% of the general population. The clinical manifestation of contact sensitization is allergic contact dermatitis. This is a clinical expression that is sometimes difficult to distinguish from other types of dermatitis, for example irritant and atopic dermatitis. Several studies have examined the pathogenesis and severity of allergic contact dermatitis by measuring the absence or presence of various biomarkers. In this review, we provide a non-systematic overview of biomarkers that have been studied in allergic contact dermatitis. These include genetic variations and mutations, inflammatory mediators, alarmins, proteases, immunoproteomics, lipids, natural moisturizing factors, tight junctions, and antimicrobial peptides. We conclude that, despite the enormous amount of data, convincing specific biomarkers for allergic contact dermatitis are yet to be described</style></abstract><notes><style face="normal" font="default">DA - 20170512IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Netherlands -CO - Denmark -CO - Germany -CO - Norway -CO - Switzerland -CO - Croatia -CO - Finland -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12789</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497472">PM:28497472</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170512-KoppesSA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170512-KoppesSA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170512, Koppes SA</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12789</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41612</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Leomicronn,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Microbiology, University of Alabama at Birmingham, 1825 University Blvd, SHEL 406, Birmingham, AL, 35294, USA.</style></auth-address><titles><title><style face="normal" font="default">T Cells in Allergic Asthma: Key Players Beyond the Th2 Pathway</style></title><secondary-title><style face="normal" font="default">Cur Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cur Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="43">43-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Alabama</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic asthma</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Constriction</style></keyword><keyword><style face="normal" font="default"> DC</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> Mucus</style></keyword><keyword><style face="normal" font="default"> Muscles</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Asthma is a common chronic lung disease that affects 300 million people worldwide. It causes the airways of the lungs to swell and narrow due to inflammation (swelling and excess mucus build-up in the airways) and airway constriction (tightening of the muscles surrounding the airways). Atopic asthma is the most common form of asthma, and is triggered by inhaled allergens that ultimately promote the activation of the Th2-like T cells and the development of Th2-mediated chronic inflammation. Different subsets of T cells, including T follicular helper cells, tissue-resident T, cells and Th2 effector cells, play different functions during allergic immune response. Dendritic cells (DCs) are known to play a central role in initiating allergic Th2-type immune responses and in the development of the T cell phenotype. However, this function depends on the complex interaction with other cells of the immune system and determines whether the response to environmental allergens will be one of tolerance or allergic inflammation. This review discusses cell interactions leading to the initiation and maintenance of allergic Th2-type immune responses, particularly those associated with allergic asthma</style></abstract><notes><style face="normal" font="default">DA - 20170530IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0714-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28555329">PM:28555329</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cur Allergy Asthma Rep\2017-17-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cur Allergy Asthma Rep\2017-17-43.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170530, Leomicronn B</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0714-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41613</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sidbury,R.</style></author><author><style face="normal" font="default"> Khorsand,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Division of Dermatology, Seattle Childrens Hospital, University of Washington School of Medicine, OC 9.835, Seattle Childrens Hospital, 4800 Sand Point Way NE, Seattle, WA, 98105, USA.</style></auth-address><titles><title><style face="normal" font="default">Evolving Concepts in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">Cur Allergy Asthma Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cur Allergy Asthma Rep</style></abbr-1></periodical><pages end="" start="42">42-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anemia</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emollient</style></keyword><keyword><style face="normal" font="default"> Epidemiologic Studies</style></keyword><keyword><style face="normal" font="default"> epidemiologic study</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Hay Fever</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Primary Prevention</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Washington</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Tremendous advances have been made in the field of atopic dermatitis in the past 5 years. We will explore developments in burden of disease, co-morbidities, pathogenesis, prevention, and management. RECENT FINDINGS: The tremendous burden moderate to severe atopic dermatitis (AD) places on families from a medical, psychosocial, and financial perspective has been characterized. Epidemiologic studies have identified intriguing new associations beyond the well-characterized "atopic march" of food allergies, asthma, and hay fever. Studies of primary prevention have gained traction including the remarkable impacts of early emollient therapy. Basic advances have simultaneously elucidated the nature of atopic inflammation, setting the stage for an explosion of new potential therapeutic targets. After a fallow period of nearly 15 years without a substantial therapeutic advance, this year has already seen two new FDA-approved treatments for AD. AD has a tremendous impact on quality of life with an underappreciated burden of disease; there are important newly described co-morbidities including ADHD and anemia; new insights into etio-pathogenesis have paved the way for novel topical therapies like crisaborole, and new systemic interventions like dupilumab</style></abstract><notes><style face="normal" font="default">DA - 20170530IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0710-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28555328">PM:28555328</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cur Allergy Asthma Rep\2017-17-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cur Allergy Asthma Rep\2017-17-42.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170530, Sidbury R</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0710-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41614</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Malik,K.</style></author><author><style face="normal" font="default"> Guttman-Yassky,E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Systemic Therapy of Atopic Dermatitis: When, How, for How Long?</style></title><secondary-title><style face="normal" font="default">Curr Dermatol Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Dermatol Rep</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Indications</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> systemic disease</style></keyword><keyword><style face="normal" font="default"> Systemic therapy</style></keyword><keyword><style face="normal" font="default"> Systemic treatment</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2162-4933</style></isbn><abstract><style face="normal" font="default">The increasingly recognized nature of atopic dermatitis/AD as a cytokine-driven, systemic disease has led to rapid development of target-specific therapies. We review advances in systemic treatments for AD, including indications for use, as well as available data on safety and efficacy</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s13671-017-0176-7</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s13671-017-0176-7</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Dermatol Rep\20170520-MalikK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Dermatol Rep\20170520-MalikK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170520, Malik K</style></custom2><misc3><style face="normal" font="default">10.1007/s13671-017-0176-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41615</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jacob,S.E.</style></author><author><style face="normal" font="default"> Brankov,N.</style></author><author><style face="normal" font="default"> Kerr,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">aDepartment of Dermatology bDepartment of Medicine, Loma Linda University, Loma Linda, California, USA cDepartment of Dermatology, Crosshouse Hospital, Kilmarnock, Scotland, UK</style></auth-address><titles><title><style face="normal" font="default">Diagnosis and management of allergic contact dermatitis in children: common allergens that can be easily missed</style></title><secondary-title><style face="normal" font="default">Curr Opin Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Opin Pediatr</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Arizona</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact allergens</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Scotland</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="18" Month="5" Year="2017">2017/5/18</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Contact dermatitis is an economically burdensome pediatric disease, and it is important to know the top allergens that have remained as top offenders for over the last decade. RECENT FINDINGS: A comparative analysis of the 20-allergen screen was done against the current top 40 pediatric allergens, and it revealed that the 20-allergen screening series would have theoretically only captured 47.5% of the relevant contact allergens (52.5% failure to detect rate). In addition, the T.R.U.E. Test (SmartPractice, Phoenix, Arizona, USA) would have revealed 60% of the top 40 allergens (40% failure to detect rate). SUMMARY: Patch testing in children has become a more common practice, and management requires the identification and avoidance of the offending allergen from the sensitized person's environment</style></abstract><notes><style face="normal" font="default">DA - 20170519IS - 1531-698X (Electronic)IS - 1040-8703 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1097/MOP.0000000000000513</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28525402">PM:28525402</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Pediatr\20170519-JacobSE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Pediatr\20170519-JacobSE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170519, Jacob SE</style></custom2><misc3><style face="normal" font="default">10.1097/MOP.0000000000000513</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41616</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Amritwar,A.U.</style></author><author><style face="normal" font="default"> Lowry,C.A.</style></author><author><style face="normal" font="default"> Brenner,L.A.</style></author><author><style face="normal" font="default"> Hoisington,A.J.</style></author><author><style face="normal" font="default"> Stiller,J.W.</style></author><author><style face="normal" font="default"> Hamilton,R.</style></author><author><style face="normal" font="default"> Postolache,T.T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Mental Health in Allergic Rhinitis: Depression and Suicidal Behavior</style></title><secondary-title><style face="normal" font="default">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Treat Options Allergy</style></full-title></periodical><pages end="97" start="71">71-97</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergen exposure</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> mental health</style></keyword><keyword><style face="normal" font="default"> mood</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Remission</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2196-3053</style></isbn><abstract><style face="normal" font="default">A high proportion of suicides visit their medical provider in the month prior to death, but depression, suicidal thoughts, and substance use are seldom addressed. For the clinicians routinely treating a substantial patient population with allergic diseases, there are additional concerns, as allergy has been linked with both depression and suicidal behavior. While psychotropic medications may affect diagnosis of allergies, medications used to treat allergies impact mood and behavior. Thus, we present an overview of the overlap of allergic rhinitis with depression and suicidal behavior in adults, based on clinical and epidemiological data, and our research and clinical experience. In summary, we suggest: (1) inquiring among patients with allergies about personal and family history of depression, substance use disorders, suicidal ideation, and attempts; (2) increased mindfulness regarding the potential effects of allergy medications on mood and behavior; and (3) for people identified with certain types of depression or increased suicide risk, a systematic multilevel collaborative approach. While, for practical reasons the majority of patients with depression will continue to be treated by general or family practitioners, the allergy-treating provider should always consider integrated care for bipolar, psychotic, or suicidal depression and incomplete remission, or relapsing and highly recurrent course. While awaiting results of a much needed basic and clinical research to guide the clinical approach to patients with comorbid allergic rhinitis and depression, the simple steps recommended here are expected to lead to improved clinical outcomes in depression, and, perhaps, contributing to lowering the highly resilient suicide mortality.Learning objectives: a) Present overlaps between allergy, allergen exposure, depression, and suicidal behavior in adults and b) Familiarize allergists with the principles of diagnosis and treatment of depression in adults and importance to monitor suicide risk</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s40521-017-0110-z</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40521-017-0110-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-71-97.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-71-97.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170518, Amritwar AU</style></custom2><misc3><style face="normal" font="default">10.1007/s40521-017-0110-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41617</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aschenbeck,K.A.</style></author><author><style face="normal" font="default"> Hylwa,S.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Minnesota School of Medicine</style></auth-address><titles><title><style face="normal" font="default">Brushing Your Way to Allergic Contact Dermatitis: Anethole Allergy</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="220" start="219">219-220</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Minnesota</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000276</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28511194">PM:28511194</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-219-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-219-20.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Aschenbeck KA</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000276</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41618</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hagen,S.L.</style></author><author><style face="normal" font="default"> Warshaw,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Minnesota Medical School</style></auth-address><titles><title><style face="normal" font="default">The Latest Occult "Hypoallergenic" Allergen: Ethylhexylglycerin</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="222" start="220">220-222</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Minnesota</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161221IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000249</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28002237">PM:28002237</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-220-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-220-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161221, Hagen SL</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000249</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41619</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zack,B.</style></author><author><style face="normal" font="default"> Arrandale,V.H.</style></author><author><style face="normal" font="default"> Holness,D.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dalla Lana School of Public Health, University of Toronto</style></auth-address><titles><title><style face="normal" font="default">Preventing Occupational Skin Disease: A Review of Training Programs</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="182" start="169">169-182</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> Learning</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Occupational disease</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Primary Prevention</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin Care</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Workplace</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Occupational contact dermatitis (OCD) is a common occupational disease that impacts a variety of worker groups. Skin protection and disease prevention training programs have shown promise for improving prevention practices and reducing the incidence of OCD. This review details the features of training programs for primary prevention of OCD and identifies gaps in the literature. Twelve studies were identified for in-depth review: many studies included wet workers employed in health care, hairdressing, cleaning, and food preparation; 1 program featured manufacturing workers. Few programs provided content on allergic contact dermatitis, and only 1 was evaluated for long-term effectiveness. Effective programs were similar in content, delivery method, and timing and were characterized by industry specificity, multimodal learning, participatory elements, skin care resource provision, repeated sessions, and management engagement. Long-term effectiveness, generalizability beyond OCD, workplace health and safety culture impact, and translation of programs in the North American context represent areas for future research</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000278</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28509714">PM:28509714</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-169-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-169-82.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Zack B</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000278</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41620</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zirwas,M.J.</style></author><author><style face="normal" font="default"> Hamann,D.</style></author><author><style face="normal" font="default"> Warshaw,E.M.</style></author><author><style face="normal" font="default"> Maibach,H.I.</style></author><author><style face="normal" font="default"> Taylor,J.S.</style></author><author><style face="normal" font="default"> Sasseville,D.</style></author><author><style face="normal" font="default"> DeKoven,J.G.</style></author><author><style face="normal" font="default"> Fransway,A.F.</style></author><author><style face="normal" font="default"> Mathias,C.G.T.</style></author><author><style face="normal" font="default"> Zug,K.A.</style></author><author><style face="normal" font="default"> Deleo,V.A.</style></author><author><style face="normal" font="default"> Fowler,J.F.</style></author><author><style face="normal" font="default"> Marks,J.G.</style></author><author><style face="normal" font="default"> Pratt,M.D.</style></author><author><style face="normal" font="default"> Belsito,D.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Dermatology, The Ohio State University, Columbus</style></auth-address><titles><title><style face="normal" font="default">Epidemic of Isothiazolinone Allergy in North America: Prevalence Data From the North American Contact Dermatitis Group, 2013-2014</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="209" start="204">204-209</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidemic</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand dermatitis</style></keyword><keyword><style face="normal" font="default"> Isothiazolinones</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> methylchloroisothiazolinone</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> North America</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Ohio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> preservative</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Preservative sensitivity patterns evolve with changing use patterns in products. During the last decade, the use of methylisothiazolinone (MI) at higher concentrations in both leave-on and rinse-off products has significantly increased. This is the first North American Contact Dermatitis Group reporting cycle that includes both methylchloroisothiazolinone (MCI)/MI and MI data. OBJECTIVE: The aim of this study was to report the prevalence of isothiazolinone allergy (MCI/MI and MI) in the North American Contact Dermatitis Group patch-test population from January 1, 2013, to December 31, 2014. METHODS: At 13 centers in North America, 4860 patients were patch tested in a standardized manner with a series of 70 allergens, including MCI/MI 0.01% aqueous (aq) and MI 0.2% aq. RESULTS: Three hundred five patients (6.3%) had a positive reaction to MCI/MI; this is a significant increase from the previous cycle (5.0%, 2011-2012; P = 0.011). Five hundred twenty-one patients (10.7%) had a positive reaction to MI. These 2 isothiazolinones were among the most common preservative allergens in the 2013 to 2014 cycle; 11.9% of patch-tested individuals were allergic to 1 or both isothiazolinones. Individuals with MCI/MI and MI allergy were significantly more likely to have occupationally related skin disease (P &lt; 0.0001) and hand dermatitis (P &lt; 0.0001, P = 0.0474). CONCLUSIONS: The epidemic of isothiazolinone sensitivity documented in Europe is now in North America. Patch testing with only MCI/MI 0.01% aq will miss approximately half of isothiazolinone allergy cases, whereas testing with only MI 0.2% aq will miss approximately 10% of isothiazolinone allergy cases</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000288</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28509715">PM:28509715</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-204-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-204-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Zirwas MJ</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000288</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41621</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Engfeldt,M.</style></author><author><style face="normal" font="default"> Ale,I.</style></author><author><style face="normal" font="default"> Andersen,K.E.</style></author><author><style face="normal" font="default"> Elsner,P.</style></author><author><style face="normal" font="default"> Goh,C.L.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author><author><style face="normal" font="default"> Jerajani,H.</style></author><author><style face="normal" font="default"> Matsunaga,K.</style></author><author><style face="normal" font="default"> Bruze,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Occupational and Environmental Dermatology, Skane University Hospital, Lund University, Malmo, Sweden</style></auth-address><titles><title><style face="normal" font="default">Multicenter Patch Testing With Methylchloroisothizoline/Methylisothiazolinone in 100 and 200 ppm Within the International Contact Dermatitis Research Group</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="218" start="215">215-218</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Baseline series</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> preservative</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: The preservative methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) is a well-known contact sensitizer. Historically, there have been different opinions on the optimal patch test concentration of MCI/MI, and both 0.01% and 0.02% aqueous (aq.) have been proposed. In 2011, based on literature reviews, it was recommended that the concentration of 0.02% aq. should be used in the international baseline series. OBJECTIVES: The aim of this study was to verify the recommendation from 2011 by comparing the patch test results from consecutive patch testing with MCI/MI 0.01% and 0.02% in clinics representing countries around the world. PATIENTS AND METHODS: Two thousand seven hundred three consecutive patients with dermatitis in 8 dermatology clinics representing 8 countries were patch tested with MCI/MI 0.01% aq. and, in parallel with MCI/MI 0.02% aq., provisionally included in the baseline series. RESULTS: Contact allergy to MCI/MI at 0.01% and 0.02% was found in 3.7% and 5.6% of the patients, respectively (P &lt; 0.001). CONCLUSIONS: Methylchloroisothiazolinone/MI 0.02% aq. (dose, 6 mug/cm) diagnoses significantly more contact allergy than 0.01% (dose, 3 mug/cm), without resulting in more adverse reactions. Methylchloroisothiazolinone/MI at 0.02% aq. should therefore be continuously used in the international baseline series</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Uruguay -CO - Singapore -CO - Denmark -CO - Germany -CO - Belgium -CO - India -CO - Japan -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000287</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28509716">PM:28509716</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-215-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-215-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Engfeldt M</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000287</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41622</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Parker,J.K.</style></author><author><style face="normal" font="default"> Eng,D.J.</style></author><author><style face="normal" font="default"> Rasmussen,A.</style></author><author><style face="normal" font="default"> Rundle,C.W.</style></author><author><style face="normal" font="default"> Bergman,D.</style></author><author><style face="normal" font="default"> Jacob,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Medicine, Loma Linda University, CA; Department of Dermatology, Loma Linda University, CA</style></auth-address><titles><title><style face="normal" font="default">Unreported Sources of Nickel Exposure in Community-Based Facilities Frequented by Children</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="226" start="224">224-226</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Children</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000271</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28509717">PM:28509717</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-224-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-224-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Parker JK</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000271</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41623</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sasseville,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Dermatology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada</style></auth-address><titles><title><style face="normal" font="default">Alkyl Glucosides: American Contact Dermatitis Society 2017 "Allergen of the Year"</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Canada</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Glucosides</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Quebec</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="23" Month="5" Year="2017">2017/5/23</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170524IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000290</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28538011">PM:28538011</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\20170524-SassevilleD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\20170524-SassevilleD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170524, Sasseville D</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000290</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41624</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Spiker,A.</style></author><author><style face="normal" font="default"> Mowad,C.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Geisinger Medical Center, Danville, PA</style></auth-address><titles><title><style face="normal" font="default">Evaluation and Management of Patch Test-Negative Patients With Generalized Dermatitis</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Blood Cell Count</style></keyword><keyword><style face="normal" font="default"> Cell Count</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Methotrexate</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prednisone</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic treatment</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="23" Month="5" Year="2017">2017/5/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patients with generalized dermatitis are common in dermatology practices. Allergic contact dermatitis is often suspected, and patients frequently undergo patch testing. When patch testing result is negative, further evaluation and management of these patients are challenging. OBJECTIVE: The purpose of this study was to survey members of the American Contact Dermatitis Society regarding the evaluation and management of patch test-negative patients with generalized dermatitis. RESULTS: Generalized dermatitis was the most common term identified for patch test-negative patients with diffuse dermatitis. After having negative expanded patch testing results, most physicians proceeded with additional testing including skin biopsy, complete blood cell count with differential, and liver and renal function tests. The most commonly used systemic treatment is prednisone, followed by methotrexate. Narrow-band ultraviolet B (UVB) is the most commonly used light source. Antihistamines are frequently prescribed. Food allergy is not felt to be causative. This cohort of patients experiences significant impairment in quality of life, stress on personal relationships, and time off work. CONCLUSIONS: The management of patch test-negative patients with generalized dermatitis is challenging. This study provides insight into management of these complex patients. It also demonstrated practice gaps in the management of these patients, indicating a need for further studies to direct the evaluation and management of this patient population</style></abstract><notes><style face="normal" font="default">DA - 20170524IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000282</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28538006">PM:28538006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\20170524-SpikerA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\20170524-SpikerA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170524, Spiker A</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000282</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41625</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Latif,I.</style></author><author><style face="normal" font="default"> Hassan,I.</style></author><author><style face="normal" font="default"> Akhtar,S.</style></author><author><style face="normal" font="default"> Rasool,F.</style></author><author><style face="normal" font="default"> Zeerak,S.</style></author><author><style face="normal" font="default"> Sheikh,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Sexually Transmitted Diseases &amp; Leprosy, Government Medical College, University of Kashmir, Srinagar, Jammu and Kashmir, India</style></auth-address><titles><title><style face="normal" font="default">Contact Allergens in Food Handlers of Kashmir Valley in North India</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="227" start="226">226-227</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact allergens</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Food handlers</style></keyword><keyword><style face="normal" font="default"> Government</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Leprosy</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000267</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28509718">PM:28509718</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-226-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-226-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Latif I</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000267</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41626</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Siegel,J.A.</style></author><author><style face="normal" font="default"> Mounessa,J.S.</style></author><author><style face="normal" font="default"> Dellavalle,R.P.</style></author><author><style face="normal" font="default"> Dunnick,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Massachusetts Medical School Worcester University of Colorado School of Medicine</style></auth-address><titles><title><style face="normal" font="default">Comparison of Contact Allergens in Bar Soaps and Liquid Body Washes</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact allergens</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Soaps</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="23" Month="5" Year="2017">2017/5/23</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170524IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000289</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28538004">PM:28538004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\20170524-SiegelJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\20170524-SiegelJA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170524, Siegel JA</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000289</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41627</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bosak,M.</style></author><author><style face="normal" font="default"> Porebski,G.</style></author><author><style face="normal" font="default"> Slowik,A.</style></author><author><style face="normal" font="default"> Turaj,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dept. of Neurology, Jagiellonian University Medical College, Krakow, Poland.</style></auth-address><titles><title><style face="normal" font="default">Common allergies do not influence the prevalence of cutaneous hypersensitivity reactions to antiepileptic drugs</style></title><secondary-title><style face="normal" font="default">Epilepsy Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Epilepsy Res</style></abbr-1></periodical><pages end="13" start="9">9-13</pages><volume><style face="normal" font="default">135</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antiepileptic</style></keyword><keyword><style face="normal" font="default"> Antiepileptic drugs</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Carbamazepine</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epilepsy</style></keyword><keyword><style face="normal" font="default"> Exanthema</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> lamotrigine</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default"> Stevens-Johnson Syndrome</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The aim of the study was to establish whether the presence of common allergies increases the risk of drug-related hypersensitivity reactions among patients with epilepsy treated with antiepileptic drugs (AEDs). METHODS: We studied 753 patients with epilepsy seen in tertiary outpatient epilepsy clinic. We obtained data related to epilepsy type, past and ongoing treatment with AEDs, occurrence of maculopapular exanthema or more serious cutaneous adverse reactions (Stevens-Johnson syndrome - SJS) and their characteristics. We noted an occurrence of allergic reactions unrelated to treatment with AED, including rash unrelated to AED, bronchial asthma, persistent or seasonal allergic rhinitis, atopic dermatitis, rash after specific food and other allergic reactions. RESULTS: There were 61 cases of AED-related cutaneous hypersensitivity reaction (including 3 cases of SJS) noted in association with 2319 exposures to AEDs (2.63%) among 55 out of 753 patients (7.3%). Cutaneous hypersensitivity reaction to AED was most commonly noted after lamotrigine (12.1%), carbamazepine (5.4%) and oxcarbazepine (4.1%). Prevalence of allergic reactions unrelated to AED was similar between patients with and without AED-related cutaneous hypersensitivity reaction (rash unrelated to AED: 16.4% vs. 10.2%; bronchial asthma: 1.8% vs. 0.1%; persistent allergic rhinitis: 7.3% vs. 10.2%; seasonal allergic rhinitis: 7.3% vs. 11.7%; atopic dermatitis: 0 vs. 0.7%; rash after specific food: 5.4% vs. 6.4%; other allergic reactions: 5.4% vs. 5.2%, respectively; P>0.1 for each difference). CONCLUSIONS: Presence of common allergies is not a significant risk factor for AED-related cutaneous hypersensitivity reaction among patients with epilepsy</style></abstract><notes><style face="normal" font="default">DA - 20170529IS - 1872-6844 (Electronic)IS - 0920-1211 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.eplepsyres.2017.05.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28552676">PM:28552676</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Epilepsy Res\2017-135-9-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Epilepsy Res\2017-135-9-13.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170529, Bosak M</style></custom2><misc3><style face="normal" font="default">10.1016/j.eplepsyres.2017.05.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41628</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Moayeri,M.</style></author><author><style face="normal" font="default"> van Os-Medendorp,H.</style></author><author><style face="normal" font="default"> Baiardini,I.</style></author><author><style face="normal" font="default"> Rockmann,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Assessment of validity and reliability of Drug Hypersensitivity Quality of Life Questionnaire: The Dutch experience</style></title><secondary-title><style face="normal" font="default">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="134" start="129">129-134</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Factor analysis</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> prospective cohort study</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Summary: Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q) is the first questionnaire that captures health related quality of life impact in patients with drug hypersensitivity. The aim of this study was to translate and validate the original Italian 15-item DrHy-Q for use among Dutch-speaking residents. We also compared the DrHy-Q scores obtained across countries. In a prospective cohort study, the Dutch DrHy-Q was completed by 124 patients (65.3% female, age 56.8 +/- 14.0) with a confirmed drug hypersensitivity. Median DrHy-Q score was 12 [0-88]. Validity and reliability of the DrHy-Q was confirmed through, 1, confirmatory factor analysis; 2, concurrent validity with a generic health related quality of life questionnaire (RAND-36); 3, internal consistency; and 4, test-retest reliability. A country specific difference in scores was observed</style></abstract><notes><style face="normal" font="default">DA - 20170512IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Italy -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497676">PM:28497676</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-129-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-129-34.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170512, Moayeri M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41629</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gelardi,M.</style></author><author><style face="normal" font="default"> Guarino,R.</style></author><author><style face="normal" font="default"> Taliente,S.</style></author><author><style face="normal" font="default"> Quaranta,N.</style></author><author><style face="normal" font="default"> Carpentieri,A.</style></author><author><style face="normal" font="default"> Passalacqua,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Section of Otolaryngology, Department of Basic Medical Science, Neuroscience and Sensory Organs, University of Bari, Bari, Italy</style></auth-address><titles><title><style face="normal" font="default">Allergic and nonallergic rhinitis and skin sensitization to metals: is there a link?</style></title><secondary-title><style face="normal" font="default">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="109" start="106">106-109</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> ACT</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Chromium</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cytology</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Endoscopy</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritants</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal cytology</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Nonallergic rhinitis</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> Otolaryngology</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Summary: Background. Chromium, Cobalt and Nickel are responsible for contact dermatitis, that is largely prevalent in the general population. They can act also as irritants in the upper and lower respiratory airways. Also rhinitis (allergic and nonallergic) is a high prevalence disorder. Both diseases could share some common inflammatory mechanisms, but the clinical association between skin sensitization to metals and rhinitis was never studied. Objective. We assessed the presence of skin sensitization to metals in subjects with rhinitis. Methods. Patients suffering from rhinitis underwent a standard diagnostic procedure, including skin testing, nasal endoscopy and nasal cytology. Control healthy subjects were also included. None of the patients had skin diseases. All subjects underwent patch test with Chromium, Cobalt and Nickel. Results. None of the 26 controls had positive skin prick test or nasal cytology. The 82 rhinitis patients were subdivided into allergic (group A = 27), nonallergic (group B = 31) and overlapping (group C = 24). The prevalence of positive patch test to metals was 26% in group A, 45% in group B, 42% in group C and 31% in controls. The percentage of patch-positive subjects was significantly different between Group A and B (p = 0.0045; OR: 0.43), Group A and C (p = 0.0186; OR: 0.49), and Group B and controls (p = 0.0360; OR: 1.85). There was a significant difference between groups A + controls and B + C. Conclusion. Even in the absence of skin diseases, the prevalence of sensitization to metals (patch test) is greater in nonallergic and overlapping rhinitis, as compared to allergic rhinitis and controls</style></abstract><notes><style face="normal" font="default">DA - 20170512IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28497672">PM:28497672</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-106-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-106-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170512, Gelardi M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41630</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ribaldone,D.G.</style></author><author><style face="normal" font="default"> Saracco,G.</style></author><author><style face="normal" font="default"> Pellicano,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Gastroenterology - U, General and Specialist Medicine Department, Citta della Salute e della Scienza of Turin, C.so Bramante 88, 10126, Turin, Italy.</style></auth-address><titles><title><style face="normal" font="default">Does Helicobacter pylori infection increase the risk of adult-onset asthma?</style></title><secondary-title><style face="normal" font="default">Eur J Clin Microbiol Infect Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur J Clin Microbiol Infect Dis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult-onset asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Gastroenterology</style></keyword><keyword><style face="normal" font="default"> Helicobacter pylori</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword></keywords><dates><year Day="15" Month="5" Year="2017">2017/5/15</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 1435-4373 (Electronic)IS - 0934-9723 (Linking)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1007/s10096-017-3004-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28508347">PM:28508347</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur J Clin Microbiol Infect Dis\20170516-RibaldoneDG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur J Clin Microbiol Infect Dis\20170516-RibaldoneDG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Ribaldone DG</style></custom2><misc3><style face="normal" font="default">10.1007/s10096-017-3004-x</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41631</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Holm,J.G.</style></author><author><style face="normal" font="default"> Agner,T.</style></author><author><style face="normal" font="default"> Thomsen,S.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermato-Venereology, Bispebjerg Hospital, University of Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default">Diagnostic properties of provocation tests for cold, heat, and delayed-pressure urticaria</style></title><secondary-title><style face="normal" font="default">Eur J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur J Dermatol</style></full-title></periodical><pages end="408" start="406">406-408</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cold</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Heat</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 1952-4013 (Electronic)IS - 1167-1122 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1684/ejd.2017.3014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28508749">PM:28508749</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur J Dermatol\2017-27-406-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur J Dermatol\2017-27-406-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Holm JG</style></custom2><misc3><style face="normal" font="default">10.1684/ejd.2017.3014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41632</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hull,J.H.</style></author><author><style face="normal" font="default"> Walsted,E.S.</style></author><author><style face="normal" font="default"> Backer,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Respiratory Medicine , Royal Brompton Hospital , London , UK</style></auth-address><titles><title><style face="normal" font="default">The Asthma-plus syndrome</style></title><secondary-title><style face="normal" font="default">Expert Rev Respir Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Expert Rev Respir Med</style></abbr-1></periodical><pages end="515" start="513">513-515</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Denmark</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="25" Month="5" Year="2017">2017/5/25</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170525IS - 1747-6356 (Electronic)IS - 1747-6348 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1080/17476348.2017.1335602</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28544852">PM:28544852</url></web-urls></urls><custom2><style face="normal" font="default">20170525, Hull JH</style></custom2><misc3><style face="normal" font="default">10.1080/17476348.2017.1335602</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41633</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Napolitano,M.</style></author><author><style face="normal" font="default"> Megna,M.</style></author><author><style face="normal" font="default"> Cappello,M.</style></author><author><style face="normal" font="default"> Mazzella,C.</style></author><author><style face="normal" font="default"> Patruno,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Naples Federico II, Naples, Italy</style></auth-address><titles><title><style face="normal" font="default">Skin diseases and tattoos: a five-year experience</style></title><secondary-title><style face="normal" font="default">G Ital Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">G Ital Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dermatoses</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lichen Planus</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Regulations</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> Skin reaction</style></keyword><keyword><style face="normal" font="default"> skin reactions</style></keyword><keyword><style face="normal" font="default"> Tattooing</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Vitiligo</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Decorative tattooing as a body art form underwent an exponential increase during the last two decades, particularly among teenagers and young adults. Consequently, the number of reported adverse reactions after tattooing has increased. The most frequent reported skin reactions to tattoo include infectious (bacterial, viral, fungal) or inflammatory (allergic contact dermatitis and granulomatous reaction) diseases. Moreover, tattoos can also induce the development of typical skin lesions of pre-existing dermatoses, a phenomenon known as isomorphism reactive or Koebner phenomenon, which commonly occurs in patients with psoriasis, vitiligo, or lichen planus. METHODS: A retrospective study analyzing records data of patients attending the Department of Dermatology, University of Naples "Federico II" during 2011-2015 was performed. All cases of tattoorelated or closely located dermatitis were selected. RESULTS: We observed 19 patients (mean age: 26.4 year-old) showing cutaneous conditions related to the practice of tattooing. Allergic contact dermatitis was reported as the most common cutaneous disease linked to tattooing (31.6%), followed by granulomatous reactions (26.3%). These data are consistent with those already reported in literature. CONCLUSIONS: Our results highlight the need to develop detailed regulations regarding tattoos practice, used materials, as well as execution procedures in order to limit the outbreak of tattooing related skin diseases</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 1827-1820 (Electronic)IS - 0392-0488 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.23736/S0392-0488.17.05496-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28509523">PM:28509523</url></web-urls></urls><custom2><style face="normal" font="default">20170516, Napolitano M</style></custom2><misc3><style face="normal" font="default">10.23736/S0392-0488.17.05496-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41634</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Minov,J.</style></author><author><style face="normal" font="default"> Karadzinska-Bislimovska,J.</style></author><author><style face="normal" font="default"> Vasilevska,K.</style></author><author><style face="normal" font="default"> Stoleski,S.</style></author><author><style face="normal" font="default"> Mijakoski,D.</style></author><author><style face="normal" font="default"> Atanasovska,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Asthma-COPD Overlap Syndrome Developed in Herbal Tea Processor with Sensitizer-Induced Occupational Asthma - A Case Report</style></title><secondary-title><style face="normal" font="default">Glob J Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Glob J Allergy</style></full-title></periodical><pages end="3" start="1">1-3</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Cessation</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Herbal</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> occupational asthma</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Smoking Cessation</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Tea</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Workplace</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Asthma-COPD overlap syndrome (ACOS), a clinical syndrome common in routine practice, is stillnot fully defi ned entity characterized by features of both asthma and chronic obstructive pulmonarydisease (COPD). In the present article a case with clinical syndrome of chronic airways diseasesharing characteristics of asthma and COPD is described. In a 57-year old man working in herbal teamanufacture the diagnosis of sensitizer-induced occupational asthma (OA) was established at the age of45 by recommended diagnostic work-up. After the diagnosis was established he was removed from theoffending workplace exposure, the pharmacological treatment with inhaled corticosteroid was startedand he was advised to quit smoking. He stopped use of the recommended medications after about twoyears and did not quit smoking. We saw the patient about 10 years after his last visit and he reportedcough with sputum production and exertional dyspnea in the past one to two years. The spirometricfi ndings indicated persistent airfl ow obstruction with positive response to bronchodilator. The features ofCOPD in the previously diagnosed asthmatic suggested overlap between two chronic airways diseases,i.e. the diagnosis of ACOS. Pharmacological treatment with combined therapy (inhaled corticosteroid andlong-acting ƒÒ2-agonist) was started and he was advised to attend the programme for smoking cessation.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Macedonia -</style></notes><work-type><style face="normal" font="Roboto-Regular">10.17352/2455-8141.000015</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.17352/2455-8141.000015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Glob J Allergy\2017-3-1-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Glob J Allergy\2017-3-1-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170520, Minov J</style></custom2><misc3><style face="normal" font="Roboto-Regular">10.17352/2455-8141.000015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41635</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Patella,V.</style></author><author><style face="normal" font="default"> Florio,G.</style></author><author><style face="normal" font="default"> Cafeo,V.</style></author><author><style face="normal" font="default"> Calapai,G.</style></author><author><style face="normal" font="default"> Calapai,F.</style></author><author><style face="normal" font="default"> Gangemi,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Periocular Erythema and Eczema after Local Application of Calendula Officinalis in Pediatric Age</style></title><secondary-title><style face="normal" font="default">Glob J Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Glob J Allergy</style></full-title></periodical><pages end="12" start="11">11-12</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Asteraceae</style></keyword><keyword><style face="normal" font="default"> Calendula</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Herbal</style></keyword><keyword><style face="normal" font="default"> Irritation</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Plant</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Supplements</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> Ulcer</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Calendula officinalis is a plant belonging to the Asteraceae family. Herbal preparations from Calendulahave been used topically as a natural anti-inflammatory medicine and for the healing of wounds andleg ulcers. Although data on dermal irritation and sensitization are available, the risk of subchronicsystemic toxicity following dermal application of Calendula officinalis preparations has not been evaluated.The threshold of toxicological concern is only based on a pragmatic risk assessment approach thatgained regulatory acceptance for food. Here we describe a case of a 12 year old girl forced to the hospitalfor an acute periocular erythema and eczema after use for two days of Calendula Officinalis compresseson the eyes.The use of Calendula extracts is very common in traditional medicine, as these products are highlyavailable because sold in many countries as food supplements or medical devices. Even though it is notconsidered toxic, adequate safety data of use in children are not existing. On the light of the case herereported, we think that pediatric use of these extracts should be very careful, especially in subjects allergicto Asteraceae.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="default">10.17352/2455-8141.000017</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.17352/2455-8141.000017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Glob J Allergy\2017-3-11-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Glob J Allergy\2017-3-11-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170520, Patella V</style></custom2><misc3><style face="normal" font="default">10.17352/2455-8141.000017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41636</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zheleva,D.</style></author><author><style face="normal" font="default"> Darlenski,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Atopic Eczema - From Epidemiology to Therapeutic Approach</style></title><secondary-title><style face="normal" font="default">Glob J Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Glob J Allergy</style></full-title></periodical><pages end="10" start="4">4-10</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> atopic eczema</style></keyword><keyword><style face="normal" font="default"> Bulgaria</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Atopic dermatitis is one of the epidemically expanding non-infectious diseases in the 21 century. Itposes immense challenges to both patients and physicians. With a steady growth in its incidence andprevalence, the disease carries a heavy social and economical burden. Herein we discuss the therapeuticalgorithm for atopic dermatitis in accordance with the disease severity. We emphasize on the personalizedapproach in selecting the proper treatment method and regimen for each patient.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Bulgaria -</style></notes><work-type><style face="normal" font="Roboto-Regular">10.17352/2455-8141.000016</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.17352/2455-8141.000016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Glob J Allergy\2017-3-4-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Glob J Allergy\2017-3-4-10.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170520, Zheleva D</style></custom2><misc3><style face="normal" font="Roboto-Regular">10.17352/2455-8141.000016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41637</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Szema,A.M.</style></author><author><style face="normal" font="default"> Jo,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Director, Northwell Health International Center for Excellence in Deployment Health and Medical Geosciences, United States</style></auth-address><titles><title><style face="normal" font="default">A plane screw fixation is a nidus for Paecilomyces sinusitis in a patient with aspirin exacerbated respiratory disease</style></title><secondary-title><style face="normal" font="default">IDCases</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">IDCases</style></full-title></periodical><pages end="100" start="96">96-100</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anti-IgE</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin desensitization</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Esophagitis</style></keyword><keyword><style face="normal" font="default"> Frontal Sinus</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Immunotherapy</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> sinus</style></keyword><keyword><style face="normal" font="default"> Sinusitis</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Titanium</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Titanium plane screw fixation of the frontal sinus is an approach used by otolaryngologists to obliterate this space in an attempt to reduce sinus infections. In this case, however, the titanium used became a nidus of infection which cultured the fungus Paecilomyces. The patient also had a hypersensitivity reaction to mold with positive skin tests and IgE, as well as eosinophilic esophagitis. Treatment entailed anti-fungals, anti-IgE, and fungal immunotherapy to multiple fungal antigens prevalent to the geographic region. The patient also had aspirin exacerbated respiratory disease which responded to aspirin desensitization. Her symptoms resolved after 3 months</style></abstract><notes><style face="normal" font="default">DA - 20170518IS - 2214-2509 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.idcr.2017.04.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28516039">PM:28516039</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\IDCases\2017-8-96-100.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\IDCases\2017-8-96-100.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170518, Szema AM</style></custom2><misc3><style face="normal" font="default">10.1016/j.idcr.2017.04.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41638</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nadri,G.</style></author><author><style face="normal" font="default"> Taneja,S.</style></author><author><style face="normal" font="default"> Singh,V.</style></author><author><style face="normal" font="default"> Mittal,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Madhuraj Hospital (P) Ltd., Kanpur, India</style></auth-address><titles><title><style face="normal" font="default">Anaphylaxis to rifampicin and pyrazinamide in a child with tuberculous meningitis: A case report</style></title><secondary-title><style face="normal" font="default">Indian J Tuberc</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Indian J Tuberc</style></abbr-1></periodical><pages end="146" start="144">144-146</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Meningitis</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Pyrazinamide</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Rifampicin</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">Rifampicin (RFP) and pyrazinamide (PZA) are the primary anti-tubercular drugs with a considerably safe profile. However, none of the drugs are without adverse reactions. They both can lead to a variety of adverse effects including life-threatening anaphylaxis. We report an interesting and possibly the first case of concurrent hypersensitivity to two primary anti-tubercular treatment (ATT) drugs. Hypersensitivity to RFP and PZA was confirmed in this patient by drug provocation and intradermal skin testing. He improved on alternative ATT regime withdrawing RFP and PZA</style></abstract><notes><style face="normal" font="default">DA - 20170415IS - 0019-5707 (Print)IS - 0019-5707 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.1016/j.ijtb.2016.06.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28410699">PM:28410699</url></web-urls></urls><custom2><style face="normal" font="default">20170415, Nadri G</style></custom2><misc3><style face="normal" font="default">10.1016/j.ijtb.2016.06.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41639</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,T.</style></author><author><style face="normal" font="default"> Ma,X.</style></author><author><style face="normal" font="default"> Xing,Y.</style></author><author><style face="normal" font="default"> Sun,S.</style></author><author><style face="normal" font="default"> Zhang,H.</style></author><author><style face="normal" font="default"> Sturmer,T.</style></author><author><style face="normal" font="default"> Wang,B.</style></author><author><style face="normal" font="default"> Li,X.</style></author><author><style face="normal" font="default"> Tang,H.</style></author><author><style face="normal" font="default"> Jiao,L.</style></author><author><style face="normal" font="default"> Zhai,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacy, Peking University Third Hospital, Beijing, China</style></auth-address><titles><title><style face="normal" font="default">Use of Epinephrine in Patients with Drug-Induced Anaphylaxis: An Analysis of the Beijing Pharmacovigilance Database</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="60" start="51">51-60</pages><volume><style face="normal" font="default">173</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Beijing</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical signs</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug-induced</style></keyword><keyword><style face="normal" font="default"> Drug-induced anaphylaxis</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Injections</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Overdose</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacovigilance</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> subcutaneous</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Few studies assessing the use of epinephrine in drug-induced anaphylaxis (DIA) in the hospital setting are available. We utilized the Beijing Pharmacovigilance Database (BPD) to evaluate the appropriateness of epinephrine for DIA management. METHODS: DIA cases collected in the BPD from January 2004 to December 2014 were adjudicated and analyzed for demographics, causative drugs, clinical signs, outcomes, initial treatment, route, dosing, and cardiovascular adverse events (CAE) of epinephrine. RESULTS: DIA was primarily caused by antibiotics (38.4%), radiocontrast agents (11.9%), traditional Chinese medicine injections (10.9%), and chemotherapeutic drugs (10.3%). Only 708 (59.5%) patients received epinephrine treatment. Patients who received epinephrine were more likely to experience wheezing (p &lt; 0.001) and respiratory arrest (p &lt; 0.001). Among 518 patients with a complete record of the epinephrine administration route, the percentage of patients receiving it by intramuscular (IM) injection, subcutaneous (SC) injection, intravenous (IV) bolus injection, or IV continuous infusion was 16.9, 31.5, 43.5, and 8.1%, respectively. Among the 427 patients with a record of both the administration route and the dosing, an overdose was more likely with IV bolus (94.1%) in contrast to IM injection (56.6%; p &lt; 0.001) or SC injection (43.7%; p &lt; 0.001). Among the patients analyzed for CAE (n = 349), 17 patients accounted for 19 CAE, and 13 (76.5%) of these patients were overdosed with epinephrine. CONCLUSION: Underuse, inappropriate IV bolus use, and overdosing were the 3 major problems with epinephrine use in DIA in China. Educational training for health care professionals on the appropriate use of epinephrine in managing anaphylactic reactions is suggested</style></abstract><notes><style face="normal" font="default">DA - 20170515IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1159/000475498</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28505618">PM:28505618</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-51-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-51-60.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170515, Wang T</style></custom2><misc3><style face="normal" font="default">10.1159/000475498</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41640</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yoo,G.</style></author><author><style face="normal" font="default"> Lee,K.</style></author><author><style face="normal" font="default"> Lee,D.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biomedical Technology, Kangwon National University, Kangwondaehakgil 1, Chuncheon, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Inhibitory effects of 2-oxo-2H-chromen-4-yl 4-methylbenzenesulfonate on allergic inflammatory responses in rat basophilic leukemia cells</style></title><secondary-title><style face="normal" font="default">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int Immunopharmacol</style></full-title></periodical><pages end="202" start="196">196-202</pages><volume><style face="normal" font="default">48</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> anti-allergic drug</style></keyword><keyword><style face="normal" font="default"> anti-allergic drugs</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Cell Degranulation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Leukemia</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Leukotrienes</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> mitogen-activated protein kinase</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> rat</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="default">Mast cells play crucial roles in the initiation of allergic inflammatory responses by releasing various mediators such as histamines, cytokines, and leukotrienes. In addition, signaling cascade pathways, such as the mitogen-activated protein kinase (MAPK) pathway, contribute to the regulation of mast cell degranulation. Accordingly, different research strategies have been pursued to develop anti-inflammatory and anti-allergic drugs by regulating these signaling pathways. The development of new drugs that inhibit mast cell degranulation may help in the treatment of allergies. In this study, we investigated the effects of coumarin derivatives on mast cell degranulation. The effect of coumarin derivatives on degranulation in rat basophilic leukemia (RBL)-2H3 cells was determined by a beta-hexosaminidase assay and histamine assay. A coumarin derivative 1 (C1), 2-oxo-2H-chromen-4-yl 4-methylbenzenesulfonate, inhibited degranulation in a dose-dependent manner and demonstrated maximum therapeutic effect when used at 25muM. Additionally, these compounds inhibited the phosphorylation of the extracellular signal-regulated kinase (ERK) pathway. Taken together, these results indicate that 2-oxo-2H-chromen-4-yl 4-methylbenzenesulfonate inhibits mast cell degranulation by suppressing the activation of the ERK pathway and this inhibitory effect suggests potential therapeutic strategies towards the prevention of allergic disorders</style></abstract><notes><style face="normal" font="default">DA - 20170520IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.intimp.2017.05.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28527346">PM:28527346</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Immunopharmacol\2017-48-196-202.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Immunopharmacol\2017-48-196-202.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170520, Yoo G</style></custom2><misc3><style face="normal" font="default">10.1016/j.intimp.2017.05.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41641</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sugiura,M.</style></author><author><style face="normal" font="default"> Sugiura,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Mariko Sugiura* and Keiji Sugiura</style></auth-address><titles><title><style face="normal" font="default">Contact Dermatitis Caused by Tanacetum Parthenium</style></title><secondary-title><style face="normal" font="default">Int J Allergy Medic</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Allergy Medic</style></full-title></periodical><pages end="" start="021">021-</pages><volume><style face="normal" font="default">2</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Chrysanthemum</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lactones</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Sesquiterpene lactones</style></keyword><keyword><style face="normal" font="default"> Tanacetum parthenium</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">We report the case of a 63-year-old female homemaker with contact dermatitis on her hands caused by extract of Tanacetum parthenium (feverfew). Forty-eight-hour closed patch testing showed positive reactions to sesquiterpene lactone mix (0.1% pet) and extract of Tanacetum parthenium (0.2%). The extract, sesquiterpene lactones of Tanacetum parthenium, is identified as a contact allergen. A member of the chrysanthemum family, feverfew is common worldwide, and there are many products that include extract of sesquiterpene lactones. It is therefore easy to be exposed to sesquiterpene lactones in daily life.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="default">10.23937/2572-3308.1510021</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.23937/2572-3308.1510021</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Allergy Medic\2016-2-021.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Allergy Medic\2016-2-021.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170520, Sugiura M</style></custom2><misc3><style face="normal" font="default">10.23937/2572-3308.1510021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41642</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mukesi,M.</style></author><author><style face="normal" font="default"> Phillipus,I.I.</style></author><author><style face="normal" font="default"> Moyo,S.R.</style></author><author><style face="normal" font="default"> Mtambo,O.P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prevalence of Skin Allergies in Adolescents in Namibia</style></title><secondary-title><style face="normal" font="default">Int J Allergy Medic</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Allergy Medic</style></full-title></periodical><pages end="" start="022">022-</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Hay Fever</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Namibia</style></keyword><keyword><style face="normal" font="default"> Occupation</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Sample Size</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin allergy</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> sociodemographic factors</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Weather</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Skin allergy is a type of allergy that results in skin lesions due to reactions that occur in the immune system when the body is exposed to allergens. There are several types of skin allergies which include atopic dermatitis, contact dermatitis, urticaria, angioedema and hay fever. However, there is little known about skin allergy in Namibia as no studies have ever been done on this condition among adolescents in the country. The aim of this study was to determine the most prevalent skin allergy, find out the most common causes of skin allergies as understood by participants and confirmation by clinicians, and assess the impact of socio-demographic factors on prevalence in skin allergies in adolescents in Namibia. The study was cross sectional with sample size of 150 participants aged 15-30 years who were selected using simple random sampling technique. The questionnaires were administered to the randomly selected young patients that attended the dermatology clinic at Windhoek Central Hospital between July and September 2014. All descriptive and inferential analyses were performed using Microsoft Excel, SPSS 22, and Stata 12. The most prevalent skin allergy was the atopic dermatitis (43.4%) seconded by contact dermatitis (31.3%). It was observed that the type of occupation and exposure to possible causes significantly affected the prevalence of skin allergies in adolescents in Namibia. It was also observed, though not significant at 5% level, that the age-specific prevalence in skin allergies tended to increase with age. Furthermore, ethnicity and gender did not reveal any significant effects on skin allergies. Skin allergy is becoming a significant public health burden in adolescents in Namibia. It was found that atopic dermatitis and contact dermatitis were the most prevalent skin allergies in adolescents in Namibia. Furthermore, it was observed that occupation and weather change significantly affected the prevalence of skin allergies in adolescents in Namibia.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Namibia -</style></notes><work-type><style face="normal" font="default">10.23937/2572-3308.1510022</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.23937/2572-3308.1510022</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Allergy Medic\2017-3-022.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Allergy Medic\2017-3-022.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170520, Mukesi M</style></custom2><misc3><style face="normal" font="default">10.23937/2572-3308.1510022</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41643</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ngatu,N.R.</style></author><author><style face="normal" font="default"> Motoyama,K.</style></author><author><style face="normal" font="default"> Nishimura,Y.</style></author><author><style face="normal" font="default"> Okajima,M.K.</style></author><author><style face="normal" font="default"> Hirota,R.</style></author><author><style face="normal" font="default"> Higashi,T.</style></author><author><style face="normal" font="default"> Lee,S.</style></author><author><style face="normal" font="default"> Arima,H.</style></author><author><style face="normal" font="default"> Ikeda,M.</style></author><author><style face="normal" font="default"> Nojima,S.</style></author><author><style face="normal" font="default"> Kaneko,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Graduate School of Health Sciences &amp; Nursing, University of Kochi, Kochi, Japan.</style></auth-address><titles><title><style face="normal" font="default">Anti-allergic and Profilaggrin (ProFLG)-mRNA Expression Modulatory Effects of Sacran</style></title><secondary-title><style face="normal" font="default">Int J Biol Macromol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Biol Macromol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Filaggrin</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL-17A</style></keyword><keyword><style face="normal" font="default"> IL-2</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Nursing</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> Prednisolone</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> Solutions</style></keyword><keyword><style face="normal" font="default"> Tacrolimus</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH17</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="15" Month="5" Year="2017">2017/5/15</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a skin disorder characterized by filaggrin (FLG) defect. We evaluated sacran's effects on dust-mite extracts (DME)-induced AD-like disease and also its effect on profilaggrin (proFLG) in a murine model of 2,4-dinitroflurobenze (DNFB)-induced contact hypersensitivity. In the murine AD-like disease model, allergic NC/Nga mice (N=60) were randomly divided into five treatment groups of 12 animals each: 0.2% and 1%sacran; 0.1% Tacrolimus; Vaseline and buffer-treated controls. Blood samples were drawn and serum levels of representative Th-1, Th-2 and also Th-17 (IL-17A) cytokines were assayed by Cytometric Bead Array (CBA). In the contact hypersensitivity model, diseased NC/Nga mice (N=20) were divided into four groups of five mice each [0.05%sacran, 0.05% chondroitin sulfate (CS), 0.5% prednisolone (PD), non-treated control group] and were treated for 14 days. Skin biopsies were performed for the measurement of proFLG-mRNA by real-time PCR. Sacran solutions and 0.1%Tacrolimus reduced disease severity, suppressed histological changes and decreased the serum Th-1 (IFN-gamma, TNF-alpha, IL-2) and Th-2 (IL-4, IL-6, IL-10) cytokines in allergic mice (vs. controls). Additionally, a marked increase of proFLG-mRNA expression was observed in 0.05%sacran group (vs. control 0.05% CS and 0.5% PD groups). Thus, Sacran might be useful as a natural skin barrier enhancer and anti-allergic agent</style></abstract><notes><style face="normal" font="default">DA - 20170519IS - 1879-0003 (Electronic)IS - 0141-8130 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.ijbiomac.2017.05.049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28522399">PM:28522399</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Biol Macromol\20170519-NgatuNR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Biol Macromol\20170519-NgatuNR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170519, Ngatu NR</style></custom2><misc3><style face="normal" font="default">10.1016/j.ijbiomac.2017.05.049</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41644</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Moestrup,K.</style></author><author><style face="normal" font="default"> Ghazanfar,M.N.</style></author><author><style face="normal" font="default"> Thomsen,S.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default">Patient-reported outcomes (PROs) in chronic urticaria</style></title><secondary-title><style face="normal" font="default">Int J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient-reported outcomes</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="default">Chronic urticaria is an itching skin disease which persists for more than 6 weeks. Chronic urticaria has great impact on the daily life of the patient, and the fluctuating nature of the symptoms complicates the monitoring and treatment of the disease. Currently, there are no reliable biomarkers to identify and measure disease activity in chronic spontaneous urticaria. Consequently, use of patient-reported outcomes (PROs) is crucial when evaluating and monitoring different aspects of chronic urticaria such as disease activity/severity, disease control, and quality of life. We present an overview of seven different PROs used in chronic urticaria and highlight their strengths, limitations, and use in clinical practice and research</style></abstract><notes><style face="normal" font="default">DA - 20170601IS - 1365-4632 (Electronic)IS - 0011-9059 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/ijd.13668</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28567776">PM:28567776</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Dermatol\20170601-MoestrupK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Dermatol\20170601-MoestrupK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170601, Moestrup K</style></custom2><misc3><style face="normal" font="default">10.1111/ijd.13668</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41645</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cossu,D.</style></author><author><style face="normal" font="default"> Otsubo,S.</style></author><author><style face="normal" font="default"> Otsubo,Y.</style></author><author><style face="normal" font="default"> Eda,S.</style></author><author><style face="normal" font="default"> Suzuki,T.</style></author><author><style face="normal" font="default"> Iwao,Y.</style></author><author><style face="normal" font="default"> Kuribayashi,T.</style></author><author><style face="normal" font="default"> Yamamoto,S.</style></author><author><style face="normal" font="default"> Sechi,L.A.</style></author><author><style face="normal" font="default"> Momotani,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Human Care, Tohto College of Health Sciences, Fukaya, Saitama, Japan</style></auth-address><titles><title><style face="normal" font="default">Mycobacterium avium Subsp. paratuberculosis Induces Specific IgE Production in Japanese People with Allergies</style></title><secondary-title><style face="normal" font="default">Int J Inflam</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Inflam</style></full-title></periodical><pages end="" start="7959154">7959154-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Mycobacterium</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Specific IgE</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> Th2 response</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background. The prevalence of allergies is steadily increasing worldwide; however, the pathogenesis is still unclear. We hypothesized that Mycobacterium avium subsp. paratuberculosis (MAP) may contribute to allergy development. This organism can be present in dairy foods, it can elicit an immunomodulatory switch from a Th1 to a Th2 response, and it has been speculated that it is linked to several human autoimmune diseases. To determine the contribution, sera from 99 individuals with various atopic disorders and 45 healthy nonallergic controls were assessed for total IgE levels and successively for MAP-specific IgE by ELISA. Results. The mean total serum IgE level in allergic patients was 256 +/- 235 IU/mL, and in the healthy controls it was 62 +/- 44 IU/mL (AUC = 0.88; p &lt; 0.0001). Among the patient groups, 50 of the 99 subjects had increased IgE total level >/= 150 IU/mL, while 49 subjects had IgE &lt;/= 150 IU/mL (mean level: 407 +/- 256 IU/mL versus 106 +/- 16 IU/mL; p &lt; 0.0001). Additionally, 6 out of 50 subjects (12%) with IgE >/= 150 IU/mL and none (0%) with IgE &lt;/= 150 IU/mL were positive for specific MAP IgE (AUC = 0.63; p = 0.03). Conclusion. The present study revealed that MAP has the ability to induce specific IgE and might contribute to the induction of allergic inflammation in genetically predisposed individuals</style></abstract><notes><style face="normal" font="default">DA - 20170519IS - 2090-8040 (Print)IS - 2042-0099 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - Italy -</style></notes><work-type><style face="normal" font="default">10.1155/2017/7959154</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28523203">PM:28523203</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Inflam\2017-2017-7959154.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Inflam\2017-2017-7959154.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170519, Cossu D</style></custom2><misc3><style face="normal" font="default">10.1155/2017/7959154</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41646</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Takeda,Y.</style></author><author><style face="normal" font="default"> Suto,Y.</style></author><author><style face="normal" font="default"> Ito,K.</style></author><author><style face="normal" font="default"> Hashimoto,W.</style></author><author><style face="normal" font="default"> Nishiya,T.</style></author><author><style face="normal" font="default"> Ueda,K.</style></author><author><style face="normal" font="default"> Narushima,T.</style></author><author><style face="normal" font="default"> Takahashi,T.</style></author><author><style face="normal" font="default"> Ogasawara,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunobiology, Institute of Development, Aging and Cancer, Tohoku University 4-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.</style></auth-address><titles><title><style face="normal" font="default">TRAV7-2*02 Expressing CD8(+) T Cells Are Responsible for Palladium Allergy</style></title><secondary-title><style face="normal" font="default">Int J Mol Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Mol Sci</style></abbr-1></periodical><pages end="" start="1162">1162-</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adoptive Transfer</style></keyword><keyword><style face="normal" font="default"> Aging</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Consensus</style></keyword><keyword><style face="normal" font="default"> delayed-type hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostics</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Histocompatibility</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Major Histocompatibility Complex</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metal allergies</style></keyword><keyword><style face="normal" font="default"> Metal allergy</style></keyword><keyword><style face="normal" font="default"> MHC</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Palladium</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="31" Month="5" Year="2017">2017/5/31</year></dates><abstract><style face="normal" font="default">While metallic biomaterials have led to an improvement in the quality of life, metal allergies, especially to palladium (Pd), has caused a recent increase in allergic patients. Metal allergy is known to be a T cell-mediated delayed-type hypersensitivity (DTH); however, the pathogenic T cell subsets and the specific T cell receptor (TCR) have not been identified. Therefore, we attempted to identify the pathogenic T cells responsible for Pd allergy. We found that activating CD8(+) T cells significantly increased and that the TRAV (TCRalpha variable) 7-2*02 chain skewed in Pd allergic mice. Furthermore, adoptive transfer experiments revealed that in vitro-cultured Pd-stimulated antigen presenting cells (APCs) function as memory APCs with recipient mice developing Pd allergy and that the frequency of TRAV7-2*02 increases the same as conventional Pd allergic mice. In contrast, neither proliferation of CD8(+) T cells nor increasing of TRAV7-2*02 was observed in major histocompatibility complex I (MHC I)-deficient Pd-APCs transferred to mice. Taken together, we revealed that TRAV7-2*02-expressing CD8(+) T cells are the pathogenic T cells for the development of Pd allergy. We also identified the CDR3 consensus motif of pathogenic TCRs as CAAXSGSWQLIF in TRAV7-2*02/TRAJ (TCRalpha junction)22*01 positive cells. These results suggest that the specific TCRs represent novel targets for the development of diagnostics and treatments for metal allergy</style></abstract><notes><style face="normal" font="default">DA - 20170531IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.3390/ijms18061162</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28561797">PM:28561797</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-1162.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-1162.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170531, Takeda Y</style></custom2><misc3><style face="normal" font="default">10.3390/ijms18061162</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41647</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vaezi,A.</style></author><author><style face="normal" font="default"> Haghighi,L.</style></author><author><style face="normal" font="default"> Beigmohammadi,F.</style></author><author><style face="normal" font="default"> Nojomi,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Community Medicine, School of Medicine, Medical University of Isfahan, Isfahan, Iran</style></auth-address><titles><title><style face="normal" font="default">Maternal Asthma, Pregnancy, Delivery and Birth Outcomes: A Retrospective Cohort Study</style></title><secondary-title><style face="normal" font="default">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Iran J Allergy Asthma Immunol</style></abbr-1></periodical><pages end="98" start="92">92-98</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Birth Weight</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Fetal Death</style></keyword><keyword><style face="normal" font="default"> Gestational Age</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Placenta</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> premature</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective cohort study</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Teaching</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">The aim of current study was to determine women s maternal asthma in pregnancy, delivery and birth outcomes. Using a retrospective cohort design, data of 580 pregnant women were gathered form a large teaching hospital in Tehran, Iran. The medical records of pregnant women who had attended this hospital between 2009 and 2011 were assessed. Data of delivery and birth outcomes were gathered by observation and medical records of women. Multiple logistic regression and adjusted odds ratio (OR) were used to assess the independent association of asthma and outcomes. 274 patients (47.2%) were in "asthmatic group" and 306 patients (52.8%) were in the "non-asthmatic group". Basic and demographic variables showed the same distribution across two groups. Maternal asthma showed an adjusted relationship with gestational diabetes (OR=2.64), gestational hypertension (OR=3.79), cesarean delivery (OR=2.68), small for gestational age (OR=2.86), premature rupture of membrane (OR=2.18), preterm delivery (OR=1.74), abnormal vaginal bleeding (OR=3.75), and low birth weight (OR=1.78) significantly (p&lt;0.05 for all associations). The majority of pregnancy, delivery and birth outcomes except fetal death, abortion, placenta previa and placenta abruption) were significantly associated with maternal asthma. The largest association of maternal asthma was with gestational hypertension and abnormal vaginal bleeding respectively</style></abstract><notes><style face="normal" font="default">DA - 20170611IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28601048">PM:28601048</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2017-16-92-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2017-16-92-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170611, Vaezi A</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41648</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Alizadeh,Z.</style></author><author><style face="normal" font="default"> Mortaz,E.</style></author><author><style face="normal" font="default"> Adcock,I.</style></author><author><style face="normal" font="default"> Moin,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="default">Role of Epigenetics in the Pathogenesis of Asthma</style></title><secondary-title><style face="normal" font="default">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Iran J Allergy Asthma Immunol</style></abbr-1></periodical><pages end="91" start="82">82-91</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical phenotypes</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> Epigenetics</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Methylation</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Rna</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> Th2 response</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">Asthma is a complex, heterogeneous and chronic airway inflammatory disease with different clinical phenotypes caused by diverse triggers and pathophysiological mechanisms. Asthma heritability has been established in many genetic studies but it is evident that only genetic elements are not responsible for the development of asthma. Increasing rate of asthma incidence during past decades has implicated the role of epigenetics in development of asthma. Environmental factors perform as initiator signals through epigenetic mechanisms. Three epigenetic mechanisms have been identified, including DNA methylation, histone modifications, and small noncoding RNAs. These mechanisms regulate the immune responses and inflammatory genes expression in asthma and allergy. This review explains the role of epigenetic modifications in controlling Th2 response and IgE production in asthma and also briefly overviews the role of environmental factors such as pollutions, allergens, prenatal exposures and diet in developing asthma. Recognizing environmental risk factors and their effects on epigenetic mechanisms would be of great interest for prognostic and preventive aspect in treatment of asthma</style></abstract><notes><style face="normal" font="default">DA - 20170611IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Iran -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28601047">PM:28601047</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2017-16-82-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2017-16-82-91.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170611, Alizadeh Z</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41649</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Antonelli,D.</style></author><author><style face="normal" font="default"> Rozner,E.</style></author><author><style face="normal" font="default"> Turgeman,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Cardiology, HaEmek Medical Center, Afula, Israel</style></auth-address><titles><title><style face="normal" font="default">Kounis Syndrome: Acute ST segment Elevation Myocardial Infarction following Allergic Reaction to Amoxicillin</style></title><secondary-title><style face="normal" font="default">Isr Med Assoc J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Isr Med Assoc J</style></abbr-1></periodical><pages end="60" start="59">59-60</pages><volume><style face="normal" font="default">19</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Amoxicillin</style></keyword><keyword><style face="normal" font="default"> Infarction</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> Kounis syndrome</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Myocardial Infarction</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170430IS - 1565-1088 (Print)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28457118">PM:28457118</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Isr Med Assoc J\2017-19-59-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Isr Med Assoc J\2017-19-59-60.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170430, Antonelli D</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41650</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Marciano,B.E.</style></author><author><style face="normal" font="default"> Zerbe,C.S.</style></author><author><style face="normal" font="default"> Falcone,E.L.</style></author><author><style face="normal" font="default"> Ding,L.</style></author><author><style face="normal" font="default"> Deravin,S.S.</style></author><author><style face="normal" font="default"> Daub,J.</style></author><author><style face="normal" font="default"> Kreuzburg,S.</style></author><author><style face="normal" font="default"> Yockey,L.</style></author><author><style face="normal" font="default"> Hunsberger,S.</style></author><author><style face="normal" font="default"> Foruraghi,L.</style></author><author><style face="normal" font="default"> Barnhart,L.A.</style></author><author><style face="normal" font="default"> Matharu,K.</style></author><author><style face="normal" font="default"> Anderson,V.</style></author><author><style face="normal" font="default"> Darnell,D.N.</style></author><author><style face="normal" font="default"> Frein,C.</style></author><author><style face="normal" font="default"> Fink,D.L.</style></author><author><style face="normal" font="default"> Lau,K.P.</style></author><author><style face="normal" font="default"> Long Priel,D.A.</style></author><author><style face="normal" font="default"> Gallin,J.I.</style></author><author><style face="normal" font="default"> Malech,H.L.</style></author><author><style face="normal" font="default"> Uzel,G.</style></author><author><style face="normal" font="default"> Freeman,A.F.</style></author><author><style face="normal" font="default"> Kuhns,D.B.</style></author><author><style face="normal" font="default"> Rosenzweig,S.D.</style></author><author><style face="normal" font="default"> Holland,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH</style></auth-address><titles><title><style face="normal" font="default">X-linked Carriers of Chronic Granulomatous Disease: Illness, Lyonization and Stability</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Autoimmunity</style></keyword><keyword><style face="normal" font="default"> Carrier State</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic granulomatous disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fungal infection</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Twins</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> X Chromosome</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic granulomatous disease (CGD) is characterized by recurrent life-threatening bacterial and fungal infections and aberrant inflammation. Mutations in CYBB cause X-linked CGD and account for 65%-70% of cases in western countries. OBJECTIVE: To understand the clinical manifestations associated with the X-linked CGD carrier state. METHODS: We undertook a comprehensive retrospective study of 162 affected females. We examined dihydrorhodamine oxidation (DHR) data for percent (%) X chromosome inactivation. We correlated lyonization (%DHR+) with clinical features. Where possible, we followed %DHR+ levels over time. RESULTS: Clinical data were available for 93 females: The %DHR+ was 46% (mean) and 47% (median)(SD=24). Using %DHR+ as the criterion for X inactivation, 78% of patients had levels of inactivation 20-80%, suggesting random inactivation that was independent of age. In contrast, carriers with CGD-type infections had median %DHR+ of 8% (n=14, range 0.06-48 %); those with only autoimmune or inflammatory manifestations (AIM) had median %DHR+ of 39% (n=31, range 7.4-74%). Those with both infections and autoimmunity had low %DHR+ (n=6, range=3-14%). A %DHR+ &lt;10 % was strongly associated with infections (OR:99). Strong association persisted when the %DHR+ was &lt;20% (OR=12) Autoimmunity was not associated with %DHR+. In two sets of identical twins the %DHR+ populations tracked closely over time. While the %DHR+ populations were very similar between sisters, those between mothers and daughters were unrelated. CONCLUSIONS: A low %DHR+ strongly predicts infection risk in X-linked CGD carriers, while the carrier state itself is associated with autoimmunity</style></abstract><notes><style face="normal" font="default">DA - 20170521IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28528201">PM:28528201</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170521-MarcianoBE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170521-MarcianoBE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170521, Marciano BE</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.035</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41651</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Robinson,R.K.</style></author><author><style face="normal" font="default"> Birrell,M.A.</style></author><author><style face="normal" font="default"> Adcock,J.J.</style></author><author><style face="normal" font="default"> Wortley,M.A.</style></author><author><style face="normal" font="default"> Dubuis,E.D.</style></author><author><style face="normal" font="default"> Chen,S.</style></author><author><style face="normal" font="default"> McGilvery,C.M.</style></author><author><style face="normal" font="default"> Hu,S.</style></author><author><style face="normal" font="default"> Shaffer,M.S.</style></author><author><style face="normal" font="default"> Bonvini,S.J.</style></author><author><style face="normal" font="default"> Maher,S.A.</style></author><author><style face="normal" font="default"> Mudway,I.S.</style></author><author><style face="normal" font="default"> Porter,A.E.</style></author><author><style face="normal" font="default"> Carlsten,C.</style></author><author><style face="normal" font="default"> Tetley,T.D.</style></author><author><style face="normal" font="default"> Belvisi,M.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory Pharmacology Group, Airway Disease, National Heart &amp; Lung Institute, Imperial College London, exhibition Road, London SW7 2AZ, UK</style></auth-address><titles><title><style face="normal" font="default">Mechanistic Link between Diesel Exhaust Particles and Respiratory Reflexes</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> Cysteine</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diesel</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Guinea Pigs</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Hydrocarbons</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Particulate matter</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> pig</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Reflex</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> ROS</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="5" Year="2017">2017/5/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: Diesel exhaust particles (DEP) are a major component of particulate matter in Europe's largest cities and epidemiological evidence links exposure with respiratory symptoms and asthma exacerbations. Respiratory reflexes are responsible for symptoms and are regulated by vagal afferent nerves which innervate the airway. It is not known how DEP exposure activates airway afferents to elicit symptoms such as cough and bronchospasm. OBJECTIVE: To identify the mechanisms involved in the activation of airway sensory afferents by DEPs. METHODS: In this study we utilize in vitro and in vivo electrophysiological techniques including a unique model which assess depolarization (a marker of sensory nerve activation) of human vagus. RESULTS: We demonstrate a direct interaction between DEP and airway C-fiber afferents. In anaesthetized guinea pigs, intratracheal administration of DEP activated airway C-fibers. The organic extract (DEP-OE), and not the cleaned particles, evoked depolarization of guinea-pig and human vagus and this was inhibited by a TRPA1 antagonist and the antioxidant N-acetyl cysteine (NAC). Polycyclic aromatic hydrocarbons (PAHs), major constituents of DEP, were implicated in this process via activation of the aryl hydrocarbon receptor (AhR) and subsequent mitochondrial ROS production, which is known to activate TRPA1 on nociceptive C-fibers. CONCLUSIONS: This study provides the first mechanistic insights into how exposure to urban air pollution leads to activation of guinea-pig and human sensory nerves which are responsible for respiratory symptoms. Mechanistic information will enable the development of appropriate therapeutic interventions and mitigation strategies for those susceptible individuals who are most at risk</style></abstract><notes><style face="normal" font="default">DA - 20170523IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28532657">PM:28532657</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170523-RobinsonRK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170523-RobinsonRK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170523, Robinson RK</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41652</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Murphy,V.E.</style></author><author><style face="normal" font="default"> Jensen,M.E.</style></author><author><style face="normal" font="default"> Powell,H.</style></author><author><style face="normal" font="default"> Gibson,P.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Priority Research Centre Grow Up Well, University of Newcastle, Newcastle, New South Wales, Australia.</style></auth-address><titles><title><style face="normal" font="default">Influence of Maternal Body Mass Index and Macrophage Activation on Asthma Exacerbations in Pregnancy</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="987" start="981">981-987</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophage Activation</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> New South Wales</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral corticosteroids</style></keyword><keyword><style face="normal" font="default"> overweight</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Wales</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword><keyword><style face="normal" font="default"> Weight Gain</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="25" Month="5" Year="2017">2017/5/25</year></dates><abstract><style face="normal" font="default">BACKGROUND: Obesity is a risk factor for exacerbations of asthma, but the mechanisms of this effect in pregnancy are unknown. OBJECTIVE: This study determined the influence of maternal body mass index, gestational weight gain, eosinophilic inflammation, and systemic macrophage activation on the risk of exacerbations during pregnancy. METHODS: Women with asthma (n = 164) participated in the study. Body mass index recorded at baseline (17 weeks gestation) was categorized as healthy weight (18.5-24.9 kg/m2), overweight (25-29.9 kg/m2), or obese (>30 kg/m2). Exacerbations requiring medical intervention were recorded prospectively. Asthma control, medication use, and fractional exhaled nitric oxide were assessed monthly; additional visits occurred during exacerbations. Peripheral blood was collected at baseline for the measurement of eosinophils, soluble CD-163, C-reactive protein, and IL-6. RESULTS: Exacerbations occurred in a higher proportion of overweight (51.1%) and obese (48.4%) women compared with healthy weight women (25%; P = .026). Excess weight gain during pregnancy was not associated with exacerbation risk. Macrophage activation (elevated serum soluble CD-163) was associated with exacerbations requiring oral corticosteroids (P = .043), whereas high peripheral blood eosinophils or fractional exhaled nitric oxide were not associated with exacerbation or oral corticosteroid use. CONCLUSIONS: Being overweight or obese confers a greater risk of asthma exacerbation during pregnancy, and may be due to systemic macrophage activation</style></abstract><notes><style face="normal" font="default">DA - 20170529IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28552381">PM:28552381</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-981-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-981-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170529, Murphy VE</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.040</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41653</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hervier,B.</style></author><author><style face="normal" font="default"> Cremer,I.</style></author><author><style face="normal" font="default"> Vieillard,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Sorbonne Universites, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France</style></auth-address><titles><title><style face="normal" font="default">Polyfunctionality of bona fide resident lung CD69+ natural killer cells</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cells</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Killer Cells</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Natural Killer cells</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword></keywords><dates><year Day="18" Month="5" Year="2017">2017/5/18</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170522IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28528926">PM:28528926</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170522-HervierB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170522-HervierB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170522, Hervier B</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.042</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41654</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rosenzweig,D.</style></author><author><style face="normal" font="default"> Nickels,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Notre Dame, Notre Dame, Ind</style></auth-address><titles><title><style face="normal" font="default">#Asthma #Inhaler: Evaluation of visual social media depictions of inhalers and spacers</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1788" start="1787">1787-1788</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="19" Month="5" Year="2017">2017/5/19</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170523IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.04.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28533122">PM:28533122</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170523, Rosenzweig D</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.04.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41655</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Waldram,J.</style></author><author><style face="normal" font="default"> Walters,K.</style></author><author><style face="normal" font="default"> Simon,R.</style></author><author><style face="normal" font="default"> Woessner,K.</style></author><author><style face="normal" font="default"> Waalen,J.</style></author><author><style face="normal" font="default"> White,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">the Department of Allergy and Immunology at Scripps Clinic, San Diego, CA.</style></auth-address><titles><title><style face="normal" font="default">Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: a single center study</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AERD</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin desensitization</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Efficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe reactions</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="24" Month="5" Year="2017">2017/5/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: Aspirin desensitization is an effective treatment option for aspirin-exacerbated respiratory disease (AERD). Aspirin desensitization protocol modifications have improved the safety and efficiency of this procedure, yet some providers remain reluctant to perform it. OBJECTIVE: The primary objective of this study was to evaluate the safety and outcomes of outpatient aspirin desensitization procedures. A secondary objective was to assess for clinical characteristics that might predict reaction severity during aspirin desensitization. METHODS: Two hundred seventy-five patients underwent aspirin desensitization at Scripps Clinic between January 2009 and August 2015. Baseline patient characteristics and reaction results were analyzed in the 167 patients who reacted during desensitization. RESULTS: All of the 167 reactors, including 23 who were classified as severe reactors, were successfully desensitized in the outpatient setting. The average desensitization duration among reactors was 1.67 days, and the average duration for GI reactors was 2.29 days. Mean baseline SNOT-22 score was higher in severe reactors compared to non-severe reactors (p=.05). Overall, patients on omalizumab had a similar reaction profile to those not on omalizumab. CONCLUSIONS: Most patients undergoing aspirin desensitization will develop symptoms. It remains difficult to predict the severity of these symptoms. However, desensitization can be done safely and efficiently in an appropriately equipped outpatient setting. This treatment option should be made available to all patients with AERD. The SNOT-22 score may be able to predict more severe reactions and merits further study. Eight of the 9 patients on omalizumab reacted during desensitization, suggesting that it does not block reactions during aspirin desensitization. CLINICAL IMPLICATIONS: Aspirin desensitization is a relatively safe procedure that may be performed in a properly equipped outpatient setting and it is a treatment option that should be made available to all patients with AERD</style></abstract><notes><style face="normal" font="default">DA - 20170528IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28550988">PM:28550988</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170528-WaldramJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170528-WaldramJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170528, Waldram J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41656</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hornsby,E.</style></author><author><style face="normal" font="default"> Pfeffer,P.E.</style></author><author><style face="normal" font="default"> Laranjo,N.</style></author><author><style face="normal" font="default"> Cruikshank,W.</style></author><author><style face="normal" font="default"> Tuzova,M.</style></author><author><style face="normal" font="default"> Litonjua,A.A.</style></author><author><style face="normal" font="default"> Weiss,S.T.</style></author><author><style face="normal" font="default"> Carey,V.J.</style></author><author><style face="normal" font="default"> O'Connor,G.</style></author><author><style face="normal" font="default"> Hawrylowicz,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">MRC and Asthma UK Centre for Allergic Mechanisms in Asthma, King's College London School of Medicine, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Vitamin D supplementation during pregnancy: Effect on the neonatal immune system in a randomized controlled trial</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Cord Blood</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Dexamethasone</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL-17A</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> Neonate</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> TLR</style></keyword><keyword><style face="normal" font="default"> TLR9</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> Vitamin D3</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Programming of the immune system during fetal development can influence asthma-related risk factors and outcomes in later life. Vitamin D is a well-recognized immune modulator, and deficiency of this nutrient during pregnancy is hypothesized to influence disease development in offspring. OBJECTIVE: We sought to investigate the effect on neonatal immunity of maternal supplementation with 4400 IU/d vitamin D3 during the second and third trimesters of pregnancy by using a subset of cord blood samples from a randomized, double-blind, placebo-controlled clinical trial (the Vitamin D Antenatal Asthma Reduction Trial). METHODS: Cord blood samples from neonates born to mothers supplemented with 4400 IU/d (n = 26) or 400 IU/d (n = 25) of vitamin D3 were analyzed for immune cell composition by flow cytometry, Toll-like receptor (TLR) expression by quantitative PCR, and cytokine secretion after stimulation with mitogenic, TLR, and T-cell stimuli by cytometric bead array. Responsiveness to the glucocorticoid dexamethasone was determined. RESULTS: Supplementation of mothers with 4400 IU of vitamin D3 resulted in an enhanced broad-spectrum proinflammatory cytokine response of cord blood mononuclear cells to innate and mitogenic stimuli (P = .0009), with an average 1.7- to 2.1-fold increase in levels of several proinflammatory cytokines (GM-CSF, IFN-gamma, IL-1beta, IL-6, and IL-8) across stimuli, a higher gene expression level of TLR2 (P = .02) and TLR9 (P = .02), a greater than 4-fold increase in IL-17A (P = .03) production after polyclonal T-cell stimulation, and an enhanced IL-10 response of cord blood mononuclear cells to dexamethasone treatment in culture (P = .018). CONCLUSION: Vitamin D exposure during fetal development influences the immune system of the neonate, which can contribute to protection from asthma-related, including infectious, outcomes in early life</style></abstract><notes><style face="normal" font="default">DA - 20170529IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28552588">PM:28552588</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170529-HornsbyE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170529-HornsbyE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170529, Hornsby E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.039</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41657</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ali,Z.</style></author><author><style face="normal" font="default"> Nilas,L.</style></author><author><style face="normal" font="default"> Ulrik,C.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonary Medicine, Hvidovre Hospital, Hvidovre, Denmark.</style></auth-address><titles><title><style face="normal" font="default">Excessive gestational weight gain in first trimester is a risk factor for exacerbation of asthma during pregnancy: A prospective study of 1283 pregnancies</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Elimination</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Medicine</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword><keyword><style face="normal" font="default"> Weight Gain</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="24" Month="5" Year="2017">2017/5/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: Acute exacerbation during pregnancy is the most important risk factor for an unfavorable outcome of pregnancy in women with asthma. OBJECTIVE: We sought to identify pregnancy-related risk factors for acute exacerbations of asthma during pregnancy. METHODS: Since 2007, all pregnant women referred to give birth at Hvidovre Hospital, Denmark, have been offered participation in the prospective Management of Asthma during Pregnancy (MAP) program. Women were included in the present analysis if they fulfilled the following criteria: (1) diagnosed with asthma, (2) prescribed at least rescue bronchodilator, and (3) had the first visit to the respiratory outpatient clinic within the first 18 weeks of pregnancy. Data were analyzed using multiple logistic regression models with backward stepwise elimination (Proc Logistic procedure in SAS). RESULTS: Over an 8-year study period, a total of 1283 pregnancies in 1208 women fulfilled the criteria for inclusion in the MAP cohort. Women with asthma exacerbation(s) had larger gestational weight gain (GWG) in the first trimester of pregnancy (P &lt; .001) and increased total GWG (P &lt; .001) compared with women without exacerbation. More than 5 kg first-trimester weight gain was associated with an increased risk of asthma exacerbation (odds ratio, 9.35; 95% CI, 6.39-13.68; P &lt; .001), and the risk increased in a dose-dependent manner with additional weight gain in excess of 5 kg. CONCLUSIONS: Excessive GWG in the first trimester is a risk factor for asthma exacerbation during pregnancy and the risk increases in a dose-dependent manner with increasing GWG</style></abstract><notes><style face="normal" font="default">DA - 20170528IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28551030">PM:28551030</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170528-AliZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170528-AliZ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170528, Ali Z</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.040</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41658</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cardet,J.C.</style></author><author><style face="normal" font="default"> Louisias,M.</style></author><author><style face="normal" font="default"> King,T.S.</style></author><author><style face="normal" font="default"> Castro,M.</style></author><author><style face="normal" font="default"> Codispoti,C.D.</style></author><author><style face="normal" font="default"> Dunn,R.</style></author><author><style face="normal" font="default"> Engle,L.</style></author><author><style face="normal" font="default"> Giles,B.L.</style></author><author><style face="normal" font="default"> Holguin,F.</style></author><author><style face="normal" font="default"> Lima,J.J.</style></author><author><style face="normal" font="default"> Long,D.</style></author><author><style face="normal" font="default"> Lugogo,N.</style></author><author><style face="normal" font="default"> Nyenhuis,S.</style></author><author><style face="normal" font="default"> Ortega,V.E.</style></author><author><style face="normal" font="default"> Ramratnam,S.</style></author><author><style face="normal" font="default"> Wechsler,M.E.</style></author><author><style face="normal" font="default"> Israel,E.</style></author><author><style face="normal" font="default"> Phipatanakul,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Brigham and Women's Hospital, Boston, MA</style></auth-address><titles><title><style face="normal" font="default">Income is an independent risk factor for worse asthma outcomes</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> airflow</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Income</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> low income</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medication adherence</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Poisson</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> race</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> socioeconomic status</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treatment Failure</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="5" Year="2017">2017/5/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: Socioeconomic status (SES) is associated with asthma morbidity in observational studies but the factors underlying this association are uncertain. OBJECTIVE: We investigated whether three SES correlates-low income, low education, and high perceived stress- were independent risk factors for treatment failure and asthma exacerbations in the context of a randomized controlled trial (RCT). METHODS: The effect of low SES [household income (defined as &lt;$50,000/year), household educational level (defined as less than a bachelor's degree) and high perceived stress (defined as a score of >20 on a perceived stress scale)] on asthma morbidity was analyzed in 381 participants utilizing Poisson regression models. The primary outcome was treatment failure (defined in the trial protocol as a significant clinical or airflow deterioration) and the secondary outcome was asthma exacerbations requiring systemic corticosteroids. RESULTS: 54% of participants had a low income, 40% had a low educational level, and 17% had high perceived stress levels. Even after adjusting for race and other important confounders, participants with lower income had higher rates of both treatment failures [RR=1.6, 95%CI 1.1-2.3, p=0.03] and exacerbations [RR=1.9, 95%CI 1.1-3.3, p=0.02]. Adherence with inhaled corticosteroids was similarly high for both income categories. Education and perceived stress were not significantly associated with either outcome. CONCLUSIONS: In the context of a RCT, participants with lower income were more likely to experience adverse asthma outcomes independent of education, perceived stress, race, and medication adherence</style></abstract><notes><style face="normal" font="default">DA - 20170524IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28535964">PM:28535964</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170524-CardetJC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170524-CardetJC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170524, Cardet JC</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.036</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41659</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rossios,C.</style></author><author><style face="normal" font="default"> Pavlidis,S.</style></author><author><style face="normal" font="default"> Hoda,U.</style></author><author><style face="normal" font="default"> Kuo,C.H.</style></author><author><style face="normal" font="default"> Wiegman,C.</style></author><author><style face="normal" font="default"> Russell,K.</style></author><author><style face="normal" font="default"> Sun,K.</style></author><author><style face="normal" font="default"> Loza,M.J.</style></author><author><style face="normal" font="default"> Baribaud,F.</style></author><author><style face="normal" font="default"> Durham,A.L.</style></author><author><style face="normal" font="default"> Ojo,O.</style></author><author><style face="normal" font="default"> Lutter,R.</style></author><author><style face="normal" font="default"> Rowe,A.</style></author><author><style face="normal" font="default"> Bansal,A.</style></author><author><style face="normal" font="default"> Auffray,C.</style></author><author><style face="normal" font="default"> Sousa,A.</style></author><author><style face="normal" font="default"> Corfield,J.</style></author><author><style face="normal" font="default"> Djukanovic,R.</style></author><author><style face="normal" font="default"> Guo,Y.</style></author><author><style face="normal" font="default"> Sterk,P.J.</style></author><author><style face="normal" font="default"> Chung,K.F.</style></author><author><style face="normal" font="default"> Adcock,I.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Airways Disease, National Heart &amp; Lung Institute, Imperial College London, UK &amp; Biomedical Research Unit, Royal Brompton &amp; Harefield NHS Trust, London, UK</style></auth-address><titles><title><style face="normal" font="default">Sputum transcriptomics reveal up-regulation of IL-1 receptor family members in severe asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Airways disease</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Biomedical Research</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Cell Count</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic asthma</style></keyword><keyword><style face="normal" font="default"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> IL-1</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> induced sputum</style></keyword><keyword><style face="normal" font="default"> Inflammasome</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microarray</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Neutrophilic asthma</style></keyword><keyword><style face="normal" font="default"> NLRP3 inflammasome</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutics</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Up-Regulation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Sputum analysis in asthma is used to define airway inflammatory processes and may guide therapy. OBJECTIVE: To determine differential gene and protein expression in sputum samples from patients with severe asthma (SA) compared to mild-moderate non-smoking asthmatics (MMA). METHODS: Induced sputum was obtained from non-smoking SA (SAn), smokers/ex-smokers with SA (SAsm), MMA and healthy non-smoking controls. Differential cell counts, microarray analysis of cell pellets and SOMAscan analysis of sputum analytes was performed. CRID3 was used to inhibit the inflammasome in a mouse model of severe asthma. RESULTS: Eosinophilic and mixed neutrophilic/eosinophilic inflammation were more prevalent in SA compared to MMA. 42 genes probes were up-regulated (>2-fold) in SAn compared to MMA including IL-1R family and NRLP3 inflammasome members (FDR&lt;0.05). The inflammasome proteins NLRP1, NLRP3 and NLRC4 were associated with neutrophilic asthma and with sputum IL-1beta protein whilst eosinophilic asthma was associated with an IL-13-induced Th2 signature and IL1RL1 mRNA expression. These differences were sputum-specific since no activation of NLRP3 or enrichment of IL-1R family genes in bronchial brushings or biopsies in SA was observed. Expression of NLRP3 and of the IL-1R family genes was validated in the Airway Disease Endotyping for Personalized Therapeutics (ADEPT) cohort. Inflammasome inhibition using CRID3 prevented airway hyperresponsiveness and airway inflammation (both neutrophilia and eosinophilia) in a mouse model of severe allergic asthma. CONCLUSION: IL1RL1 gene expression is associated with eosinophilic SA whilst NLRP3 inflammasome expression is highest in neutrophilic SA. Th2-driven eosinophilic inflammation and neutrophil-associated inflammasome activation may represent interacting pathways in SA</style></abstract><notes><style face="normal" font="default">DA - 20170521IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Netherlands -CO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28528200">PM:28528200</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170521-RossiosC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170521-RossiosC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170521, Rossios C</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.045</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41660</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Steinke,J.W.</style></author><author><style face="normal" font="default"> Smith,A.R.</style></author><author><style face="normal" font="default"> Carpenter,D.J.</style></author><author><style face="normal" font="default"> Patrie,J.T.</style></author><author><style face="normal" font="default"> Payne,S.C.</style></author><author><style face="normal" font="default"> Borish,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, University of Virginia Health Systems, Charlottesville, Va</style></auth-address><titles><title><style face="normal" font="default">Lack of Efficacy of Symptoms and Medical History in Distinguishing the Degree of Eosinophilia in Nasal Polyps</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1588" start="1582">1582-1588</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hyperplasia</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Lack of efficacy</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> sinonasal outcome test</style></keyword><keyword><style face="normal" font="default"> sinus</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Virginia</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Distinguishing eosinophilic nasal polyps (NP) from noneosinophilic NP will impact prognosis and therapeutic responsiveness. OBJECTIVE: To investigate the ability of clinical history and biomarkers to distinguish these conditions. METHODS: A total of 74 consecutive patients undergoing surgery for NP were enrolled. Clinical presentations were evaluated using the 22-item sinonasal outcome test (SNOT-22). Biomarkers included absolute eosinophil count, IgE, and extent of tissue hyperplasia on sinus computed tomography scan. Tissue eosinophilia was quantified in 10 random hpf and data analyzed addressing both peak and average results. RESULTS: No component of the SNOT-22 was predictive of tissue eosinophilia. Similarly, a medical history of allergic rhinitis, asthma, or aspirin-exacerbated respiratory disease was not predictive. An absolute eosinophil count of more than 300 was associated with NP tissue eosinophilia. In contrast, neither IgE nor extent of sinus computed tomography hyperplasia was predictive. CONCLUSIONS: The ability to individualize therapies for NP is dependent on identifying clinical features or biomarkers of eosinophilia. However, with the exception of circulating eosinophilia, we could not identify a clinical feature or biomarker that robustly predicted the presence of tissue eosinophilia. Even more problematic, even the seeming "criterion standard" determination of tissue pathology was of limited value, as our cohort displayed a continuous spectrum of tissue eosinophil expression, making arbitrary any definitive cutoff distinguishing these conditions</style></abstract><notes><style face="normal" font="default">DA - 20170513IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.04.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28499777">PM:28499777</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170513, Steinke JW</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.04.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41661</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vos,B.J.P.R.</style></author><author><style face="normal" font="default"> van Anrooij,B.</style></author><author><style face="normal" font="default"> Van Doormaal,J.J.</style></author><author><style face="normal" font="default"> Dubois,A.E.J.</style></author><author><style face="normal" font="default"> Oude Elberink,J.N.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Fatal Anaphylaxis to Yellow Jacket Stings in Mastocytosis: Options for Identification and Treatment of At-Risk Patients</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1271" start="1264">1264-1271</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Immunotherapy</style></keyword><keyword><style face="normal" font="default"> Mastocytosis</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> natural course</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe reactions</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> sIgE</style></keyword><keyword><style face="normal" font="default"> Specific IgE</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic mastocytosis</style></keyword><keyword><style face="normal" font="default"> Systemic reaction</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> venom allergy</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patients with indolent systemic mastocytosis (ISM) are at risk for severe anaphylactic reactions to yellow jacket (YJ) stings while demonstration of sensitization can be challenging because specific IgE (sIgE) levels are regularly below 0.35 kUA/L. The implication of missing YJ allergy is illustrated by a case of fatal anaphylaxis. OBJECTIVE: To explore the natural course of YJ venom allergy and the diagnostic accuracy and therapeutic consequence of YJ venom sIgE in patients with ISM. METHODS: All patients with ISM seen from 1981 to 2015 (n = 243) were evaluated on the number of YJ stings, reaction severity, and sensitivity and specificity of YJ venom sIgE. YJ venom allergic patients without mastocytosis served as control (n = 313). RESULTS: A total of 153 patients with ISM were stung during adult life. The first systemic reaction was more often severe in patients with ISM than in patients without mastocytosis (69.9% vs 22.0%) and reactions recurred in 40 of 41 re-stung patients with ISM. ISM reactors showed lower YJ venom sIgE levels than nonmastocytosis reactors (0.61 vs 4.83 kUA/L; P &lt; .001) and asymptomatic sensitization was exceedingly rare. In ISM the current clinical threshold of 0.35 kUA/L yields a sensitivity and specificity of 77.6% and 87.5%, respectively. The optimal diagnostic accuracy is achieved at 0.17 kUA/L (sensitivity, 83.6%; specificity, 85.0%). CONCLUSIONS: The high rate of severe reactions and the fatal case underscore the importance of adequate diagnostic sensitivity of sIgE in patients with ISM. The sensitivity of sIgE can be ameliorated by lowering the threshold to 0.17 kUA/L, retaining good specificity. We recommend sIgE screening in all patients with ISM and discussing immunotherapy when YJ venom sIgE exceeds 0.17 kUA/L</style></abstract><notes><style face="normal" font="default">DA - 20170513IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28499778">PM:28499778</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1264-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1264-71.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170513, Vos JP</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41662</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wright,A.K.A.</style></author><author><style face="normal" font="default"> Weston,C.</style></author><author><style face="normal" font="default"> Rana,B.M.J.</style></author><author><style face="normal" font="default"> Brightling,C.E.</style></author><author><style face="normal" font="default"> Cousins,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Infection, Immunity and Inflammation, University of Leicester, Leicestershire, UK.</style></auth-address><titles><title><style face="normal" font="default">Human Group 2 innate lymphoid cells do not express the IL-5 receptor</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> benralizumab</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate lymphoid cells</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="default">CAPSULE SUMMARY: Group 2 innate lymphoid cells (ILC2s) are upstream regulators of IL-5-dependent eosinophil function in asthma. We've shown that ILC2s do not express the IL-5R and thus IL-5R-dependent therapeutic interventions (e.g. Benralizumab) are unlikely to be mediated directly on ILC2s</style></abstract><notes><style face="normal" font="default">DA - 20170515IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28502824">PM:28502824</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170515-WrightAK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170515-WrightAK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170515, Wright AK</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41663</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Garcia Rodriguez,R.</style></author><author><style face="normal" font="default"> Alfaya Arias,T.</style></author><author><style face="normal" font="default"> Borja,S.J.</style></author><author><style face="normal" font="default"> Mendez,D.Y.</style></author><author><style face="normal" font="default"> Moreno,L.L.</style></author><author><style face="normal" font="default"> Extremera,O.A.</style></author><author><style face="normal" font="default"> Gomez,T.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hospital General Universitario de Ciudad Real, Calle Obispo Rafael Torija, Ciudad Real, Spain.</style></auth-address><titles><title><style face="normal" font="default">Drug-induced enterocolitis in an adult patient</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1753" start="1752">1752-1753</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Drug-induced</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword></keywords><dates><year Day="9" Month="5" Year="2017">2017/5/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170513IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28499780">PM:28499780</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170513, Garcia Rodriguez R</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41664</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Johnson,K.M.</style></author><author><style face="normal" font="default"> Fitzgerald,J.M.</style></author><author><style face="normal" font="default"> Tavakoli,H.</style></author><author><style face="normal" font="default"> Chen,W.</style></author><author><style face="normal" font="default"> Sadatsafavi,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada</style></auth-address><titles><title><style face="normal" font="default">Stability of Asthma Symptom Control in a Longitudinal Study of Mild-Moderate Asthmatics</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1670" start="1663">1663-1670</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> British Columbia</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Columbia</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Control level</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="5" Year="2017">2017/5/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Achieving and maintaining symptom control is a primary goal of asthma management. Although factors associated with the likelihood of achieving symptom control have been studied, there are unanswered questions on the stability of symptom control, that is, the tendency of individuals to remain at a given symptom control level over time. OBJECTIVE: The objective of this study was to evaluate the stability of symptom control using a longitudinal cohort of mild-moderate asthmatics. METHODS: Participants reported symptom control using the Global Initiative for Asthma criteria at 5 assessments during the 1-year follow-up period. We described variability in the stability of symptom control between individuals, and used a random-effects logistic regression model to evaluate the impact of a suite of factors on the stability of symptom control. RESULTS: A total of 429 individuals (67% female, mean age 51.6) contributed 2141 study visits. Individuals varied from completely stable in symptom control (18% remained at the same control level in all 5 visits) to completely unstable (12% changed the control level between all subsequent visits). Only 4% of between-individual variation in the stability of symptom control was explained by the included exposures, and a secondary analysis indicated that the history of symptom control stability was the best predictor of current stability. CONCLUSIONS: The tendency to remain at a given control level varies significantly among patients with asthma. Only a small fraction of this variability is explained by observable characteristics. In the absence of predictors, a previous history of symptom control stability is the best indicator of future stability and should be considered when monitoring symptom control</style></abstract><notes><style face="normal" font="default">DA - 20170513IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.04.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28499773">PM:28499773</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170513, Johnson KM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.04.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41665</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Trautmann,A.</style></author><author><style face="normal" font="default"> Benoit,S.</style></author><author><style face="normal" font="default"> Goebeler,M.</style></author><author><style face="normal" font="default"> Stoevesandt,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Venereology, and Allergy, University Hospital Wurzburg, Wurzburg, Germany</style></auth-address><titles><title><style face="normal" font="default">"Treating Through" Decision and Follow-up in Antibiotic Therapy-Associated Exanthemas</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1656" start="1650">1650-1656</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Bacterial Infections</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> beta-Lactams</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Betalactams</style></keyword><keyword><style face="normal" font="default"> Cefuroxime</style></keyword><keyword><style face="normal" font="default"> Cellulitis</style></keyword><keyword><style face="normal" font="default"> Ciprofloxacin</style></keyword><keyword><style face="normal" font="default"> Clindamycin</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Enzymes</style></keyword><keyword><style face="normal" font="default"> Exanthema</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin reaction</style></keyword><keyword><style face="normal" font="default"> skin reactions</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="5" Year="2017">2017/5/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Immediate discontinuation or replacement of suspected drugs is considered standard medical care in acute exanthematous skin reactions. In the treatment of bacterial infections, structurally different alternative antibiotics, however, are commonly second choice options due to a suboptimal antimicrobial activity or an unfavorable side effect profile. Nonetheless, "treating through," the continuation of antibiotic treatment despite an objective exanthema, is practiced only rarely. OBJECTIVE: We aimed to assess whether "treating through" is an option for patients with severe bacterial soft tissue infections (severe cellulitis) who experience maculopapular exanthema (MPE) during antibiotic therapy. METHODS: We retrospectively reviewed clinical data from 18 patients who developed MPE within a few days after initiation of intravenous antibiotic treatment. A decision to "treat through" was made when the suspected antibiotics (beta-lactams, clindamycin, ciprofloxacin) were clinically effective and the benefits of continued treatment outweighed potential risks. Clinical and laboratory findings were closely monitored in an inpatient setting. RESULTS: In 2 patients, a modification of antibiotic therapy was deemed necessary due to a significant increase of liver enzymes within 4 days after the initial decision to "treat through." Because of a progression of MPE under ongoing treatment with cefuroxime and clindamycin, clindamycin was discontinued in 1 patient. In another 3 patients, antibiotic treatment was modified because of insufficient improvement of the soft tissue infection. In the remaining 12 "treated through" cases, the skin symptoms improved despite unchanged continued antibiotic treatment, and relevant laboratory parameters remained within the normal range. CONCLUSIONS: Careful risk-benefit assessment may enable the continuation of antibiotic therapy despite MPE, provided that patients are under close medical observation</style></abstract><notes><style face="normal" font="default">DA - 20170513IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28499779">PM:28499779</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170513, Trautmann A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.032</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41666</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rosain,J.</style></author><author><style face="normal" font="default"> Miot,C.</style></author><author><style face="normal" font="default"> Lambert,N.</style></author><author><style face="normal" font="default"> Rousselet,M.C.</style></author><author><style face="normal" font="default"> Pellier,I.</style></author><author><style face="normal" font="default"> Picard,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Study Center for Primary Immunodeficiencies, Necker-Enfants Malades Hospital, Assistance Publique Hopitaux de Paris (APHP), Necker Medical School, Paris, France</style></auth-address><titles><title><style face="normal" font="default">CD21 deficiency in 2 siblings with recurrent respiratory infections and hypogammaglobulinemia</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1767" start="1765">1765-1767</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">deficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> respiratory infection</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Siblings</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170513IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.04.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28499783">PM:28499783</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170513, Rosain J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.04.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41667</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Korwin,A.</style></author><author><style face="normal" font="default"> Black,H.</style></author><author><style face="normal" font="default"> Perez,L.</style></author><author><style face="normal" font="default"> Morales,K.H.</style></author><author><style face="normal" font="default"> Klusaritz,H.</style></author><author><style face="normal" font="default"> Han,X.</style></author><author><style face="normal" font="default"> Huang,J.</style></author><author><style face="normal" font="default"> Rogers,M.</style></author><author><style face="normal" font="default"> Ndicu,G.</style></author><author><style face="normal" font="default"> Apter,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pa</style></auth-address><titles><title><style face="normal" font="default">Exploring Patient Engagement: A Qualitative Analysis of Low-Income Urban Participants in Asthma Research</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1631" start="1625">1625-1631</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Barriers</style></keyword><keyword><style face="normal" font="default"> Communication</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Focus Groups</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> low income</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pennsylvania</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> Philadelphia</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Uncontrolled asthma is a common highly morbid condition with worse outcomes in low-income and minority patients in part due to barriers accessing and engaging with health care. We developed a patient advocate to educate about and assist with navigating access to care and provider-patient communication. Participants completed an End of Study Questionnaire (ESQ) that was analyzed to assess experience and engagement with the protocol. OBJECTIVE: This study uses qualitative analysis to evaluate participant experience with the patient advocate and control group interventions. METHODS: The ESQ aimed to prompt an open-ended discussion of study experience. Questions were developed from patient focus groups about the patient advocate intervention (PAI), and were revised based on early responses. The questionnaire was administered after 12 months of study participation: 6 months of control or PAI, followed by 6 months of follow-up. Answers were evaluated using qualitative coding and a grounded theory analytical approach. RESULTS: A total of 102 low-income and minority adults with moderate or severe asthma who had completed the study protocol at the time of publication (approximately one-third of total participants) found PAI and control group activities acceptable. Four themes emerged from both groups: (1) appreciation of interpersonal and educational interaction, (2) perception of improved health care adherence, (3) preparedness for physician appointments, (4) improved patient-provider communication. Attention from study personnel and review of asthma-related information was unanimously well received and empowered patients' active health care participation. CONCLUSIONS: Patient engagement and empowerment were elicited by perceived education and personal attention. This study suggests a low-resource, feasible method to improve patient engagement</style></abstract><notes><style face="normal" font="default">DA - 20170513IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28499772">PM:28499772</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170513, Korwin A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.022</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41668</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Seidel,M.G.</style></author><author><style face="normal" font="default"> Bohm,K.</style></author><author><style face="normal" font="default"> Dogu,F.</style></author><author><style face="normal" font="default"> Worth,A.</style></author><author><style face="normal" font="default"> Thrasher,A.</style></author><author><style face="normal" font="default"> Florkin,B.</style></author><author><style face="normal" font="default"> Ikinciogullari,A.</style></author><author><style face="normal" font="default"> Peters,A.</style></author><author><style face="normal" font="default"> Bakhtiar,S.</style></author><author><style face="normal" font="default"> Meeths,M.</style></author><author><style face="normal" font="default"> Stepensky,P.</style></author><author><style face="normal" font="default"> Meyts,I.</style></author><author><style face="normal" font="default"> Sharapova,S.O.</style></author><author><style face="normal" font="default"> Gamez-Diaz,L.</style></author><author><style face="normal" font="default"> Hammarstrom,L.</style></author><author><style face="normal" font="default"> Ehl,S.</style></author><author><style face="normal" font="default"> Grimbacher,B.</style></author><author><style face="normal" font="default"> Gennery,A.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Unit Pediatric Hematology and Immunology, Div. of Pediatric Hematology-Oncology, Dept. of Pediatrics an Adolescent Medicine, Medical University Graz, Graz, Austria</style></auth-address><titles><title><style face="normal" font="default">Treatment of Severe Forms of LPS-Responsive Beige-like Anchor Protein (LRBA) Deficiency by Allogeneic Hematopoietic Stem Cell Transplantation</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Austria</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hematology</style></keyword><keyword><style face="normal" font="default"> Hematopoietic Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Immunosuppression</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Remission</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="default">CAPSULE SUMMARY: LRBA deficiency, a life-threatening immunodeficiency/autoimmunity disorder, was treated by HSCT in 12 patients, four of whom died from transplant-related causes. Six patients were cured without further need of immunosuppression, and two are in partial remission</style></abstract><notes><style face="normal" font="default">DA - 20170515IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Turkey -CO - United Kingdom -CO - Belgium -CO - Germany -CO - Sweden -CO - Israel -CO - Belarus -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28502825">PM:28502825</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170515-SeidelMG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170515-SeidelMG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170515, Seidel MG</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41669</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Movassagh,H.</style></author><author><style face="normal" font="default"> Shan,L.</style></author><author><style face="normal" font="default"> Chakir,J.</style></author><author><style face="normal" font="default"> McConville,J.F.</style></author><author><style face="normal" font="default"> Halayko,A.J.</style></author><author><style face="normal" font="default"> Koussih,L.</style></author><author><style face="normal" font="default"> Gounni,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology, Rady Faculty of Health Sciences, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada</style></auth-address><titles><title><style face="normal" font="default">Expression of Semaphorin 3E Is Suppressed in Severe Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="default">The level of a previously unknown mediator, Semaphorin 3E, is diminished in the airways of severe allergic asthmatic patients. This study suggests a potential role of Semaphorin3E in the pathogenesis of asthma severity</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28506853">PM:28506853</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170516-MovassaghH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170516-MovassaghH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Movassagh H</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.031</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41670</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Marquardt,N.</style></author><author><style face="normal" font="default"> Ljunggren,H.G.</style></author><author><style face="normal" font="default"> Michaelsson,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default">Reply (Refers to: Polyfunctionality of bona fide resident lung CD69+ natural killer cells)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Electronic</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="18" Month="5" Year="2017">2017/5/18</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170522IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28528925">PM:28528925</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170522-MarquardtN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170522-MarquardtN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170522, Marquardt N</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.041</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41671</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Burbank,A.J.</style></author><author><style face="normal" font="default"> Duran,C.G.</style></author><author><style face="normal" font="default"> Almond,M.</style></author><author><style face="normal" font="default"> Wells,H.</style></author><author><style face="normal" font="default"> Jenkins,S.</style></author><author><style face="normal" font="default"> Jiang,Q.</style></author><author><style face="normal" font="default"> Yang,C.</style></author><author><style face="normal" font="default"> Wang,T.</style></author><author><style face="normal" font="default"> Zhou,H.</style></author><author><style face="normal" font="default"> Hernandez,M.L.</style></author><author><style face="normal" font="default"> Peden,D.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Environmental Medicine, Asthma and Lung Biology, University of North Carolina, Chapel Hill, NC</style></auth-address><titles><title><style face="normal" font="default">A short course of gamma-tocopherol mitigates LPS-induced inflammatory responses in humans ex vivo</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> LPS</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> North Carolina</style></keyword><keyword><style face="normal" font="default"> PBMCs</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vitamin E</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="default">Vitamin E, gamma-tocopherol (gammaT), possesses unique anti-inflammatory activities. A short course of gammaT supplementation in healthy adults reduced inflammatory cytokine production and gene expression following ex vivo LPS challenge of PBMCs</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28506847">PM:28506847</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170516-BurbankAJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170516-BurbankAJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Burbank AJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.030</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41672</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kolsum,U.</style></author><author><style face="normal" font="default"> Damera,G.</style></author><author><style face="normal" font="default"> Pham,T.H.</style></author><author><style face="normal" font="default"> Southworth,T.</style></author><author><style face="normal" font="default"> Mason,S.</style></author><author><style face="normal" font="default"> Karur,P.</style></author><author><style face="normal" font="default"> Newbold,P.</style></author><author><style face="normal" font="default"> Singh,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Infection, Immunity &amp; Respiratory Medicine, Medicines Evaluation Unit, University Hospital of South Manchester Foundation Trust, University of Manchester, Southmoor Road, Manchester, M23 9QZ United Kingdom.</style></auth-address><titles><title><style face="normal" font="default">Pulmonary Inflammation in COPD Patients with Higher Blood Eosinophil Counts</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="12" Month="5" Year="2017">2017/5/12</year></dates><abstract><style face="normal" font="default">The different nature of airway inflammation in COPD patients with higher blood eosinophil counts supports the concept of eosinophilic COPD being a subgroup of patients with distinct characteristics</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28506852">PM:28506852</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170516-KolsumU.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170516-KolsumU.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Kolsum U</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41673</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Khorsandi,D.</style></author><author><style face="normal" font="default"> Moghanian,A.</style></author><author><style face="normal" font="default"> Nazari,R.</style></author><author><style face="normal" font="default"> Arabzadeh,G.</style></author><author><style face="normal" font="default"> Borhani,S.</style></author><author><style face="normal" font="default"> Rahimmalek,M.</style></author><author><style face="normal" font="default"> Sabzi,H.</style></author><author><style face="normal" font="default"> Ziamahmoudi,N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Personalized Medicine: Regulation of Genes in Human Skin Ageing</style></title><secondary-title><style face="normal" font="default">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Ther</style></full-title></periodical><pages end="" start="245">245-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Aging</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> Antioxidants</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cosmetic products</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Elasticity</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Formulation</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Genome</style></keyword><keyword><style face="normal" font="default"> Genomics</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Personalized medicine</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin Aging</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">As people grow older, the common conditions and developments that happen by aging are skin changes. For example, over period of time, the skin becomes drier and thin, and other changes will start to occur such as appearing spots, decreasing elasticity, increasing stiffening and appearance of wrinkles on skin. There are many medical procedures which can be helpful to mitigate skin changing process. Most of the commercialized cosmetic products have been created for the majority of customer's population. For instance, the use of many anti-aging creams may or may not prevent or even treat the changes of skin. Therefore, the effect of these products, and the reaction of the body is not the same for different people. The causes of this difference can be related to many parameters such as environment, nutrition, etc. Therefore, the human genome book can be the best source of finding the most accurate solution. The appropriate type of cream for an individual's skin type can be verified and used accordingly. Global gene expression profiling (commonly called genomics) is an approach that can be used for the identification of compounds for inclusion in cosmetic formulations that improve the appearance of aged skin. In this study, the evaluations of all genes and their related antioxidants, which lead to skin aging have been studied. The main goal is to match the appropriate medical procedure with the correct type of cream.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -CO - Spain -CO - Iran-</style></notes><work-type><style face="normal" font="default">10.4172/2155-6121.1000245</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.4172/2155-6121.1000245</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Ther\2016-7-245.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Ther\2016-7-245.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170520, Khorsandi D</style></custom2><misc3><style face="normal" font="default">10.4172/2155-6121.1000245</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41674</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stewart,A.</style></author><author><style face="normal" font="default"> Sulkowski,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Pharmacist use of the electronic medical record to identify adults at risk for anaphylaxis without epinephrine for self-administration</style></title><secondary-title><style face="normal" font="default">J Am Pharm Assoc (2003)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am Pharm Assoc (2003)</style></full-title></periodical><pages end="374" start="369">369-374</pages><volume><style face="normal" font="default">57</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy history</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Interviews</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharmacist</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Program Evaluation</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Self Administration</style></keyword><keyword><style face="normal" font="default"> Self-administration</style></keyword><keyword><style face="normal" font="default"> Statistics</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic reaction</style></keyword><keyword><style face="normal" font="default"> Telephone</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="8" Month="3" Year="2017">2017/3/8</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To describe an innovative pharmacist-led approach, with the use of electronic medical record (EMR) data, to identify patients at risk of anaphylaxis in need of epinephrine auto-injector (EAI) for self-administration. SETTING: An urban free health care center for an uninsured indigent adult population in Pittsburgh, PA. PRACTICE INNOVATION: In this pilot service, patients with allergy history fields containing the words "anaphylaxis," "nut," "bee," or "shellfish" were screened for inclusion. PRACTICE DESCRIPTION: Patients were identified with the use of a report generated by the EMR vendor and were contacted via telephone by a clinical pharmacist. Using the patient-reported clinical history related to anaphylaxis and allergies, the pharmacist assessed the need for EAI, counseled the patient, and provided physician referral when appropriate. EVALUATION: The service was evaluated with the use of a cross-sectional study of patients with electronic records at the health center during the time period studied. Data obtained from patient interviews were used to classify patients who were candidates for EAI and to assess prescribing and access to EAI. Demographic data and outcomes related to the availability of non-expired EAI were collected and analyzed using descriptive statistics. RESULTS: Ninety-five patients were identified as potential candidates for the service, and 20 patients were able to be contacted via telephone. Fourteen participants provided consent for their data to be used in the program evaluation. A treatment gap likely existed for 11 of the 14 participants (79%) owing to history of anaphylaxis (57%) or history of systemic reaction (29%). The most common indication for EAI was anaphylaxis in response to bee stings. CONCLUSION: The findings from this project demonstrate that pharmacist use of EMR data, coupled with patient interview, may be an effective means for identifying treatment gaps in the long-term management of anaphylaxis and has the potential to ultimately improve management of anaphylaxis in patients within the community</style></abstract><notes><style face="normal" font="default">DA - 20170312IS - 1544-3450 (Electronic)IS - 1086-5802 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.japh.2017.01.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28285065">PM:28285065</url></web-urls></urls><custom2><style face="normal" font="default">20170312, Stewart A</style></custom2><misc3><style face="normal" font="default">10.1016/j.japh.2017.01.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41675</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wilkinson,M.</style></author><author><style face="normal" font="default"> King,B.</style></author><author><style face="normal" font="default"> Iyer,S.</style></author><author><style face="normal" font="default"> Higginbotham,E.</style></author><author><style face="normal" font="default"> Wallace,A.</style></author><author><style face="normal" font="default"> Hovinga,C.</style></author><author><style face="normal" font="default"> Allen,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatrics , University of Texas at Austin Dell Medical School , Austin , TX , USA</style></auth-address><titles><title><style face="normal" font="default">Comparison of a rapid albuterol pathway with a standard pathway for the treatment of children with a moderate to severe asthma exacerbation in the emergency department</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Albuterol</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Emergency Medicine</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Length of Stay</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Texas</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="26" Month="5" Year="2017">2017/5/26</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The objective of this study was to determine if a rapid albuterol delivery pathway with a breath-enhanced nebulizer can reduce emergency department (ED) length of stay (LOS), while maintaining admission rates and side effects, when compared to a traditional asthma pathway with a standard jet nebulizer. METHODS: Children aged 3-18 presenting to a large urban pediatric ED for asthma were enrolled if they were determined by pediatric asthma score to have a moderate to severe exacerbation. Subjects were randomized to either a standard treatment arm where they received up to 2 continuous albuterol nebulizations, or a rapid albuterol arm where they received up to 4 rapid albuterol treatments with a breath-enhanced nebulizer, depending on severity scoring. The primary endpoint was ED LOS from enrollment until disposition decision. Asthma scores, albuterol dose, side effects, and return visits were also recorded. RESULTS: A total of 50 subjects were enrolled (25 in each arm). The study LOS was shorter in the rapid albuterol group (118 vs. 163 minutes, p = 0.0002). When total ED LOS was analyzed, the difference was no longer statistically significant (192 vs. 203 minutes, p = 0.65). There were no statistically significant differences with respect to admission rates, asthma score changes, side effects, or return visits. CONCLUSION: A rapid albuterol treatment pathway that utilizes a breath-enhanced nebulizer is an effective alternative to traditional pathways that utilize continuous nebulizations for children with moderate to severe asthma exacerbations in the ED</style></abstract><notes><style face="normal" font="default">DA - 20170526IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1323920</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28548898">PM:28548898</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170526-WilkinsonM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170526-WilkinsonM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170526, Wilkinson M</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1323920</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41676</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Labor,M.</style></author><author><style face="normal" font="default"> Labor,S.</style></author><author><style face="normal" font="default"> Juric,I.</style></author><author><style face="normal" font="default"> Fijacko,V.</style></author><author><style face="normal" font="default"> Grle,S.P.</style></author><author><style face="normal" font="default"> Plavec,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonology , University Hospital Center Osijek , Osijek , Croatia</style></auth-address><titles><title><style face="normal" font="default">Mood disorders in adult asthma phenotypes</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Adult asthma</style></keyword><keyword><style face="normal" font="default"> AERD</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> Cluster Analysis</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Croatia</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> fraction of exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mood</style></keyword><keyword><style face="normal" font="default"> Mood Disorders</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Outpatients</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Physical Examination</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> respiratory infection</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Studies show high comorbidity of mood disorders in asthma. As asthma is a highly heterogeneous disease with different phenotypes it can be expected that there is a difference in this association with different asthma phenotypes. The aim of our cross-sectional study was to assess the association of specific asthma phenotypes with anxiety and/or depression and their impact on asthma control. METHODS: A cross-sectional study in 201 consecutive adult outpatients with asthma (>/=18 years of age) was conducted. Each patient underwent physical examination, detailed medical history, Hospital Anxiety and Depression Scale, Asthma Control Questionnaire, Asthma Control Test, together with measurements of lung function and fraction of exhaled nitric oxide. Phenotypes were assessed using cluster analysis, and a multivariate analysis was used to identify associations of mood disorders with different phenotypes. RESULTS: Five asthma phenotypes were identified: allergic (AA, 43.8%), aspirin-exacerbated respiratory disease (AERD, 21.9%), late-onset (LOA, 18.9%), obesity-associated (OAA, 10.0%), and respiratory infections associated asthma (RIAA, 5.5%). A multivariate analysis showed a significant association of anxiety with LOA and comorbid hypertension (LOA, odds ratio (OR) = 2.12; hypertension, OR = 2.37, p = 0.012), and depression with AA, RIAA, hypertension, and ACQ score (AA, OR = 6.07; RIAA, OR = 4.73; hypertension, OR = 5.67; ACQ, OR = 1.87; p &lt; 0.001). Comorbid anxiety/depression was associated with AA, LOA, RIAA, hypertension, and ACQ score (AA, OR = 10.15; LOA, OR = 2.98; RIAA, OR = 6.29; hypertension, OR = 5.15; ACQ, OR = 1.90; p &lt; 0.001. CONCLUSION: Mood disorders were significantly associated with AA, LOA, and infection-associated asthma, together with comorbid hypertension and the level of asthma control</style></abstract><notes><style face="normal" font="default">DA - 20170510IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Croatia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1306546</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28489959">PM:28489959</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170510-LaborM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170510-LaborM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170510, Labor M</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1306546</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41677</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kaiser,S.V.</style></author><author><style face="normal" font="default"> Rodean,J.</style></author><author><style face="normal" font="default"> Bekmezian,A.</style></author><author><style face="normal" font="default"> Hall,M.</style></author><author><style face="normal" font="default"> Shah,S.S.</style></author><author><style face="normal" font="default"> Mahant,S.</style></author><author><style face="normal" font="default"> Parikh,K.</style></author><author><style face="normal" font="default"> Morse,R.</style></author><author><style face="normal" font="default"> Puls,H.</style></author><author><style face="normal" font="default"> Cabana,M.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatrics , University of California , San Francisco , CA , USA</style></auth-address><titles><title><style face="normal" font="default">Rising utilization of inpatient pediatric asthma pathways</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Efficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> San Francisco</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="5" Year="2017">2017/5/19</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Clinical pathways are detailed care plans that operationalize evidence-based guidelines into an accessible format for health providers. Their goal is to link evidence to practice to optimize patient outcomes and delivery efficiency. It is unknown to what extent inpatient pediatric asthma pathways are being utilized nationally. OBJECTIVES: (1) Describe inpatient pediatric asthma pathway design and implementation across a large hospital network. (2) Compare characteristics of hospitals with and without pathways. METHODS: We conducted a descriptive, cross-sectional, survey study of hospitals in the Pediatric Research in Inpatient Settings Network (75% children's hospitals, 25% community hospitals). Our survey determined if each hospital used a pathway and pathway characteristics (e.g. pathway elements, implementation methods). Hospitals with and without pathways were compared using Chi-square tests (categorical variables) and Student's t-tests (continuous variables). RESULTS: Surveys were distributed to 3-5 potential participants from each hospital and 302 (74%) participants responded, representing 86% (106/123) of surveyed hospitals. From 2005-2015, the proportion of hospitals utilizing inpatient asthma pathways increased from 27% to 86%. We found variation in pathway elements, implementation strategies, electronic medical record integration, and compliance monitoring across hospitals. Hospitals with pathways had larger inpatient pediatric programs [mean 12.1 versus 6.1 full-time equivalents, p = 0.04] and were more commonly free-standing children's hospitals (52% versus 23%, p = 0.05). CONCLUSIONS: From 2005-2015, there was a dramatic rise in implementation of inpatient pediatric asthma pathways. We found variation in many aspects of pathway design and implementation. Future studies should determine optimal implementation strategies to better support hospital-level efforts in improving pediatric asthma care and outcomes</style></abstract><notes><style face="normal" font="default">DA - 20170519IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1316392</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28521558">PM:28521558</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170519-KaiserSV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170519-KaiserSV.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170519, Kaiser SV</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1316392</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41678</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gagne,M.E.</style></author><author><style face="normal" font="default"> Boulet,L.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Knowledge Translation, Education and Prevention Chair in Respiratory and Cardiovascular Health , Laval University , Quebec City , Quebec , Canada</style></auth-address><titles><title><style face="normal" font="default">Implementation of asthma clinical practice guidelines in primary care: A cross-sectional study based on the Knowledge-to-Action Cycle</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma education</style></keyword><keyword><style face="normal" font="default"> Barriers</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Motivation</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Practice Guidelines</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Quebec</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="26" Month="5" Year="2017">2017/5/26</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Based on the Knowledge-to-Action Cycle, we assessed the self-reported implementation and perception of asthma clinical practice guideline (CPG) recommendations in primary care physicians (PCPs), along with the barriers and facilitators to CPG use in primary care. METHODS: We conducted a cross-sectional study. Using the extended Asthma Physicians' Practice Assessment Questionnaire(c), PCPs self-reported the following: their knowledge of 15 key asthma CPG recommendations, the perceived usefulness of each of these recommendations, their motivation to apply these recommendations, and their agreement with the content of these recommendations. Participants also reported the barriers and facilitators to CPG use in primary care. RESULTS: Out of the 46 potential participants, 43 physicians completed the questionnaire (response rate: 93%). Results underlined care gaps regarding the provision of asthma education and written action plans, inhaler technique demonstrations, and assessment of patients' concerns. Results showed that the majority of physicians knew the key asthma CPG recommendations, but their motivation to implement them and the perceived usefulness of these recommendations varied from one proposal to another. Main barriers to the implementation of these recommendations were related to time and resources. PCPs stressed the importance of teamwork for enhancing the use of asthma CPGs in primary care. CONCLUSIONS: Our results suggest that the implementation of asthma CPGs remains suboptimal in primary care. Interventions addressing the identified barriers and providing facilitators to asthma CPG implementation, such as continuing education, could be implemented and evaluated to sustain asthma CPG use in primary care settings</style></abstract><notes><style face="normal" font="default">DA - 20170526IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1323919</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28548896">PM:28548896</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170526-GagneME.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170526-GagneME.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170526, Gagne ME</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1323919</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41679</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Adams,S.N.</style></author><author><style face="normal" font="default"> Abel,M.</style></author><author><style face="normal" font="default"> Fowler,D.</style></author><author><style face="normal" font="default"> Braden,J.</style></author><author><style face="normal" font="default"> Ebeling,M.D.</style></author><author><style face="normal" font="default"> Simpson,A.N.</style></author><author><style face="normal" font="default"> Titus,M.O.</style></author><author><style face="normal" font="default"> Andrews,A.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine , Vanderbilt University , Nashville , TN , USA</style></auth-address><titles><title><style face="normal" font="default">Inhaled corticosteroid prescribing in a pediatric emergency department: Sustained success and prescription filling rates</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Back</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Feedback</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="26" Month="5" Year="2017">2017/5/26</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To determine if improvement in Inhaled Corticosteroid (ICS) prescribing in the pediatric emergency department (PED) can be sustained after transition from intense intervention to low-intervention phase, and to determine ICS fill rates. METHODS: A Quality Improvement (QI) project began in Aug 2012. Results through Feb 2014 were previously published. In Feb 2014 interventions were scaled back to determine the sustainability of QI success. Eligible patients included children aged 2-17 seen in the PED for asthma between Feb 2014 and Sept 2016. The primary change when moving to the low-intervention phase was stopping monthly attending feedback. The primary outcome was the proportion of patients who were prescribed an ICS at the time of PED discharge. The secondary objective of this study was to determine the proportion of patients who filled their ICS prescription in the 6 months following Emergency Department (ED) visit. RESULTS: The goal rate of ICS prescribing was 75%. After transition to the low-intervention phase, the ICS prescribing rate was maintained at a median of 79% through Sept 2016. ICS fill rate in the first 30 days following ED visit was 89%, although this quickly fell to below 40% for months 2-6. CONCLUSIONS: The ICS prescribing rate remained the goal of 75% over a 2.5-year period after transition to a low-intervention phase. High ICS fill rates immediately after ED visit have been demonstrated. However, rapid decline in these rates over subsequent months suggests a need for future efforts to focus on long-term ICS adherence among children with ED visits for asthma</style></abstract><notes><style face="normal" font="default">DA - 20170526IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1323917</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28548868">PM:28548868</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170526-AdamsSN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170526-AdamsSN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170526, Adams SN</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1323917</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41680</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Goyal,V.</style></author><author><style face="normal" font="default"> Gupta,A.</style></author><author><style face="normal" font="default"> Gupta,O.</style></author><author><style face="normal" font="default"> Lal,D.</style></author><author><style face="normal" font="default"> Gill,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Associate Professor and Head, Department of Dermatology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India</style></auth-address><titles><title><style face="normal" font="default">Comparative Efficacy and Safety of Ebastine 20 mg, Ebastine 10 mg and Levocetirizine 5 mg in Acute Urticaria</style></title><secondary-title><style face="normal" font="default">J Clin Diagn Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Clin Diagn Res</style></abbr-1></periodical><pages end="WC09" start="WC06">WC06-WC09</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> Cetirizine</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> desloratadine</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Fexofenadine</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> H1 antihistamines</style></keyword><keyword><style face="normal" font="default"> H1-antihistamine</style></keyword><keyword><style face="normal" font="default"> H1-antihistamines</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mouth</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Sedation</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Tolerability</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Acute and chronic urticaria can result in severely impaired quality of life from pruritus and associated sleep lessness, as well as anxiety and depression. Various treatment modalities are available out of which second generation non sedating H1 antihistamines e.g., fexofenadine, loratidine, desloratadine, cetirizine, levocetirizine, ebastine etc., are used as the first line treatment. AIM: To compare the safety and efficacy of ebastine 20 mg, ebastine 10 mg and levocetirizine 5 mg in the patients of urticaria. MATERIALS AND METHODS: A longitudinal study was conducted in dermatology Outpatient Department (OPD) of Adesh Institute of Medical Sciences and Research, Bathinda, India. A total of 150 patients between the age group 10-70 years, both men and women having urticaria were enrolled and divided into three groups of 50 each. Group A was given ebastine 20 mg OD, Group B was given ebastine 10 mg OD and Group C was given levocetirizine 5 mg OD. The patients were asked to scale their severity of disease over a period of follow up based on Urticarial Activity Score 7 (UAS7). RESULTS: The mean age of patients was 32.82 years. The mean UAS 7 score at the end of 4th week was 1.08 with ebastine 20 mg, 1.98 with levocetirizine 5 mg and 3.98 with ebastine 10 mg. In group A, 40 out of 50 patients (i.e., 80%), in Group B 25 out of 50 (i.e., 50%) get UAS7=0 and in Group C, 35 (i.e., 70%) patients who got relieved of symptoms at the end of treatment. When the scores were redefined and categorized under relieved and not relieved, and comparison done between all three groups, then there was a significant difference in the number of patients getting relieved, with p&lt;0.001 (highly significant). Levocetirizine 5 mg had shown more side effects like dryness of mouth and sedation as compare to ebastine irrespective of dosage. The comparison made between the number of patients developing side effects among the groups was highly significant (p&lt;0.001) for all the side effects. CONCLUSION: Ebastine 20 mg is found to have superior efficacy for treatment of Urticaria as compared to ebastine 10 mg but with levocetirizine 5 mg the results were almost similar. Tolerability of ebastine 20 mg is similar to ebastine 10 mg but with levocetirizine 5 mg there were more side effects and less tolerability</style></abstract><notes><style face="normal" font="default">DA - 20170517IS - 2249-782X (Print)IS - 0973-709X (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.7860/JCDR/2017/23961.9550</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28511488">PM:28511488</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Diagn Res\2017-11-WC06-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Diagn Res\2017-11-WC06-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170517, Goyal V</style></custom2><misc3><style face="normal" font="default">10.7860/JCDR/2017/23961.9550</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41681</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gugkaeva,Z.</style></author><author><style face="normal" font="default"> Crago,J.S.</style></author><author><style face="normal" font="default"> Yasnogorodsky,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacy, Maury Regional Medical Center, Columbia, TN, USA</style></auth-address><titles><title><style face="normal" font="default">Next step in antibiotic stewardship: Pharmacist-provided penicillin allergy testing</style></title><secondary-title><style face="normal" font="default">J Clin Pharm Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Clin Pharm Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy specialist</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> beta-Lactams</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Betalactams</style></keyword><keyword><style face="normal" font="default"> Columbia</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacist</style></keyword><keyword><style face="normal" font="default"> Pharmacists</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Stewardship</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="14" Month="5" Year="2017">2017/5/14</year></dates><abstract><style face="normal" font="default">WHAT IS KNOWN: Penicillin allergy limits therapeutic options for patients but often disappears over time, leaving patients erroneously labelled allergic and leading to the utilization of broad-spectrum and more expensive antibiotics. Penicillin allergy can be effectively assessed via skin testing. OBJECTIVE: To improve patient access to penicillin allergy testing by implementing a pharmacist-provided service in a hospital setting. COMMENT: Beta-lactams remain a mainstream therapy for many infections due to their effectiveness, low side effects and affordability. Typically, patient access to penicillin allergy testing is limited by the availability of allergy specialists, who traditionally perform such testing. A pharmacist-provided penicillin allergy testing service was implemented at our hospital in 2015 and became a powerful antibiotic stewardship tool. Removing penicillin allergy from patient profiles significantly expanded therapeutic options, expedited discharges and reduced costs of care. WHAT IS NEW: Pharmacists can expand patient access to penicillin allergy testing. CONCLUSION: Pharmacist-provided penicillin allergy testing permitted optimized antibiotic treatment and expedited discharges</style></abstract><notes><style face="normal" font="default">DA - 20170515IS - 1365-2710 (Electronic)IS - 0269-4727 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/jcpt.12530</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28504314">PM:28504314</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Pharm Ther\20170515-GugkaevaZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Pharm Ther\20170515-GugkaevaZ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170515, Gugkaeva Z</style></custom2><misc3><style face="normal" font="default">10.1111/jcpt.12530</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41682</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Garg,T.</style></author><author><style face="normal" font="default"> Agarwal,S.</style></author><author><style face="normal" font="default"> Chander,R.</style></author><author><style face="normal" font="default"> Singh,A.</style></author><author><style face="normal" font="default"> Yadav,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and STD, Lady Hardinge Medical College, New Delhi, India</style></auth-address><titles><title><style face="normal" font="default">Patch testing in patients with suspected cosmetic dermatitis: A retrospective study</style></title><secondary-title><style face="normal" font="default">J Cosmet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Cosmet Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cosmetic products</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Fragrance mix</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Hair</style></keyword><keyword><style face="normal" font="default"> Hair Dyes</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Paraphenylenediamine</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Soaps</style></keyword><keyword><style face="normal" font="default"> Standard series</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Thimerosal</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Growing use of cosmetics has led to an increase in the incidence of allergic contact dermatitis (ACD) to cosmetics. Patch testing helps to confirm allergy to cosmetics and pinpoint the exact offending allergens. AIMS AND OBJECTIVES: The study aimed to find the frequency of positive patch test reactions in cases with suspected ACD to cosmetics, and the common allergens responsible for it. METHODS: This is a retrospective record-based study of 58 patients, with suspected ACD to cosmetics, who had undergone patch testing with Indian standard series and Indian cosmetic and fragrance series from January 2013 to December 2015. RESULTS: The majority of patients (60.34%) belonged to the age group of 20-40 years. The most common site of involvement was face (94.8%) followed by neck (22.4%). The most commonly implicated cosmetics in history were soaps (53.4%), and face creams (24.1%). The most common allergens detected on patch testing were cetrimide (20.7%) and thimerosal (15.5%) followed by paraphenylenediamine (6.9%), and fragrance mix (5.2). Positive allergic reactions were obtained in 2.12% of the patches. CONCLUSION: Most common cosmetic products implicated for causing ACD were face creams, soaps, and hair dyes. The principal culprit allergens were cetrimide and thimerosal</style></abstract><notes><style face="normal" font="default">DA - 20170601IS - 1473-2165 (Electronic)IS - 1473-2130 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.1111/jocd.12359</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28568892">PM:28568892</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Cosmet Dermatol\20170601-GargT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Cosmet Dermatol\20170601-GargT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170601, Garg T</style></custom2><misc3><style face="normal" font="default">10.1111/jocd.12359</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41683</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kogame,T.</style></author><author><style face="normal" font="default"> Uetsu,N.</style></author><author><style face="normal" font="default"> Nguyen,C.T.H.</style></author><author><style face="normal" font="default"> Kawada,A.</style></author><author><style face="normal" font="default"> Okamoto,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Kansai Medical University, Hirakata, Osaka, Japan</style></auth-address><titles><title><style face="normal" font="default">Solar urticaria with an augmentation spectrum in a child</style></title><secondary-title><style face="normal" font="default">J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Child</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Solar urticaria</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="23" Month="5" Year="2017">2017/5/23</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170525IS - 1346-8138 (Electronic)IS - 0385-2407 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/1346-8138.13914</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28543282">PM:28543282</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatol\20170525-KogameT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatol\20170525-KogameT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170525, Kogame T</style></custom2><misc3><style face="normal" font="default">10.1111/1346-8138.13914</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41684</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Holm,J.G.</style></author><author><style face="normal" font="default"> Ivyanskiy,I.</style></author><author><style face="normal" font="default"> Thomsen,S.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Dermatology , Bispebjerg Hospital , Copenhagen , Denmark</style></auth-address><titles><title><style face="normal" font="default">Use of non-biologic treatments in antihistamine-refractory chronic urticaria: a review of published evidence</style></title><secondary-title><style face="normal" font="default">J Dermatolog Treat</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatolog Treat</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Azathioprine</style></keyword><keyword><style face="normal" font="default"> Chloroquine</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Colchicine</style></keyword><keyword><style face="normal" font="default"> Cyclosporine</style></keyword><keyword><style face="normal" font="default"> Dapsone</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> IVIG</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Methotrexate</style></keyword><keyword><style face="normal" font="default"> montelukast</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Plasmapheresis</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Russia</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Sulfasalazine</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Tranexamic Acid</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Knowledge of effectiveness and safety of the non-biologic, non-antihistamine treatments used for chronic urticaria is important as in some cases the principal guideline-recommended drug; omalizumab, has limited effect, side effects, or is too expensive or unavailable. Herein we systematically review the evidence for the use of the non-biologic treatments in antihistamine-refractory chronic urticaria. METHODS: We performed a systematic review of the literature using PubMed and Webofscience and identified studies that reported use of one or more of the non-biological, non-antihistamine treatment options for chronic urticaria. The studies were evaluated based on study design, number of patients, effect of treatment and safety. RESULTS: We identified 118 studies or case-series with 13 different treatments (azathioprine, chloroquine, colchicine, cyclosporine, dapsone, intravenous immunoglobulin (IVIG), methotrexate, montelukast, mycophenolate mofetil, plasmapheresis, sulfasalazine, tranexamic acid and ultraviolet light (UV) A, UVB) totaling 1682 patients. There was a paucity of controlled trials for most of the treatments reviewed albeit the strongest evidence in favour of a beneficial effect in chronic urticaria was, apart from montelukast and cyclosporine, seen for UV-therapy and dapsone followed by IVIG. CONCLUSION: The treatment options reviewed should be seen as potential alternatives in treatment-resistant chronic urticaria where guideline-based selections have failed. However, larger controlled trials are warranted to advance the level of evidence, possibly supporting some treatments' future recommendation in selected patients</style></abstract><notes><style face="normal" font="default">DA - 20170517IS - 1471-1753 (Electronic)IS - 0954-6634 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - Russia -</style></notes><work-type><style face="normal" font="default">10.1080/09546634.2017.1329505</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28513247">PM:28513247</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatolog Treat\20170517-HolmJG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatolog Treat\20170517-HolmJG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170517, Holm JG</style></custom2><misc3><style face="normal" font="default">10.1080/09546634.2017.1329505</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41685</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aurich,S.</style></author><author><style face="normal" font="default"> Schuurmann,M.</style></author><author><style face="normal" font="default"> Simon,J.C.</style></author><author><style face="normal" font="default"> Treudler,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Venereology, and Allergology, University Medical Center Leipzig, Leipzig, Germany</style></auth-address><titles><title><style face="normal" font="default">Anaphylactic shock caused by intradermal testing with cefuroxime</style></title><secondary-title><style face="normal" font="default">J Dtsch Dermatol Ges</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dtsch Dermatol Ges</style></full-title></periodical><pages end="670" start="668">668-670</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergology</style></keyword><keyword><style face="normal" font="default"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="default"> Cefuroxime</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170517IS - 1610-0387 (Electronic)IS - 1610-0379 (Linking)LA - engPT - LetterCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/ddg.13246</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28514118">PM:28514118</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dtsch Dermatol Ges\2017-15-668-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dtsch Dermatol Ges\2017-15-668-70.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20150517, Aurich S</style></custom2><misc3><style face="normal" font="default">10.1111/ddg.13246</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41686</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Meng,X.</style></author><author><style face="normal" font="default"> Al-Attar,Z.</style></author><author><style face="normal" font="default"> Yaseen,F.S.</style></author><author><style face="normal" font="default"> Jenkins,R.</style></author><author><style face="normal" font="default"> Earnshaw,C.</style></author><author><style face="normal" font="default"> Whitaker,P.</style></author><author><style face="normal" font="default"> Peckham,D.</style></author><author><style face="normal" font="default"> French,N.S.</style></author><author><style face="normal" font="default"> Naisbitt,D.J.</style></author><author><style face="normal" font="default"> Park,B.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical Research Council Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, The University of Liverpool, Liverpool L69 3GE, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Definition of the Nature and Hapten Threshold of the beta-Lactam Antigen Required for T Cell Activation In Vitro and in Patients</style></title><secondary-title><style face="normal" font="default">J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Immunol</style></full-title></periodical><pages end="4227" start="4217">4217-4227</pages><volume><style face="normal" font="default">198</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> albumin</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epitope</style></keyword><keyword><style face="normal" font="default"> Epitopes</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> HSA</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human serum</style></keyword><keyword><style face="normal" font="default"> Human serum albumin</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Activation</style></keyword><keyword><style face="normal" font="default"> Lysine</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Piperacillin</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum Albumin</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="default">Covalent modification of protein by drugs may disrupt self-tolerance, leading to lymphocyte activation. Until now, determination of the threshold required for this process has not been possible. Therefore, we performed quantitative mass spectrometric analyses to define the epitopes formed in tolerant and hypersensitive patients taking the beta-lactam antibiotic piperacillin and the threshold required for T cell activation. A hydrolyzed piperacillin hapten was detected on four lysine residues of human serum albumin (HSA) isolated from tolerant patients. The level of modified Lys541 ranged from 2.6 to 4.8%. Analysis of plasma from hypersensitive patients revealed the same pattern and levels of modification 1-10 d after the commencement of therapy. Piperacillin-responsive skin-homing CD4+ clones expressing an array of Vbeta receptors were activated in a dose-, time-, and processing-dependent manner; analysis of incubation medium revealed that 2.6% of Lys541 in HSA was modified when T cells were activated. Piperacillin-HSA conjugates that had levels and epitopes identical to those detected in patients were shown to selectively stimulate additional CD4+ clones, which expressed a more restricted Vbeta repertoire. To conclude, the levels of piperacillin-HSA modification that activated T cells are equivalent to the ones formed in hypersensitive and tolerant patients, which indicates that threshold levels of drug Ag are formed in all patients. Thus, the propensity to develop hypersensitivity is dependent on other factors, such as the presence of T cells within an individual's repertoire that can be activated with the beta-lactam hapten and/or an imbalance in immune regulation</style></abstract><notes><style face="normal" font="default">DA - 20170425IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.4049/jimmunol.1700209</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28438900">PM:28438900</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Immunol\2017-198-4217-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Immunol\2017-198-4217-27.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170425, Meng X</style></custom2><misc3><style face="normal" font="default">10.4049/jimmunol.1700209</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41687</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sader,S.</style></author><author><style face="normal" font="default"> Cai,J.</style></author><author><style face="normal" font="default"> Muller,A.C.G.</style></author><author><style face="normal" font="default"> Wu,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department Chemistry &amp; Biochemistry and Department of Translational Biomedical Sciences, College of Science and Mathematics, Rowan University, Glassboro, NJ, 08028, USA</style></auth-address><titles><title><style face="normal" font="default">Can human allergy drug fexofenadine, an antagonist of histamine (H1) receptor, be used to treat dog and cat? Homology modeling, docking and molecular dynamic Simulation of three H1 receptors in complex with fexofenadine</style></title><secondary-title><style face="normal" font="default">J Mol Graph Model</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Mol Graph Model</style></full-title></periodical><pages end="116" start="106">106-116</pages><volume><style face="normal" font="default">75</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Biochemistry</style></keyword><keyword><style face="normal" font="default"> Canine</style></keyword><keyword><style face="normal" font="default"> cat</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Conjunctivitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> dog</style></keyword><keyword><style face="normal" font="default"> Doxepin</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fexofenadine</style></keyword><keyword><style face="normal" font="default"> H1 receptor</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Mathematics</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Modeling</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pets</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="default">Fexofenadine, a potent antagonist to human histamine 1 (H1) receptor, is a non-sedative third generation antihistamine that is widely used to treat various human allergic conditions such as allergic rhinitis, conjunctivitis and atopic dermatitis. Encouragingly, it's been successfully used to treat canine atopic dermatitis, this supports the notion that it might have a great potential for treating other canine allergic conditions and other mammal pets such as dog. Regrettably, while there is a myriad of studies conducted on the interactions of antihistamines with human H1 receptor, the similar studies on non-human pet H1 are considerably scarce. The published studies using the first and second generation antihistamines drugs have shown that the antihistamine response is varied and unpredictable. Thus, to probe its efficacy on pet, the homology models of dog and cat H1 receptors were built based on the crystal structure of human H1 receptor bound to antagonist doxepin (PDB 3RZE) and fexofenadine was subsequently docked to human, dog and cat H1 receptors. The docked complexes are then subjected to 1000ns molecular dynamics (MD) simulations with explicit membrane. Our calculated MM/GBSA binding energies indicated that fexofenadine binds comparably to the three receptors; and our MD data also showed the binding poses, structural and dynamic features among three receptors are very similar. Therefore, our data supported the application of fexofenadine to the H1 related allergic conditions of dog and cat. Nonetheless, subtle systemic differences among human, dog and cat H1 receptors were also identified. Clearly, there is still a space to develop a more selective, potent and safe antihistamine alternatives such as Fexofenadine for dog or cat based on these differences. Our computation approach might provide a fast and economic way to predict if human antihistamine drugs can also be safely and efficaciously administered to animals</style></abstract><notes><style face="normal" font="default">DA - 20170525IS - 1873-4243 (Electronic)IS - 1093-3263 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jmgm.2017.05.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28544909">PM:28544909</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Mol Graph Model\2017-75-106-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Mol Graph Model\2017-75-106-16.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170525, Sader S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jmgm.2017.05.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41688</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rath,J.</style></author><author><style face="normal" font="default"> Mauritz,M.</style></author><author><style face="normal" font="default"> Zulehner,G.</style></author><author><style face="normal" font="default"> Hilger,E.</style></author><author><style face="normal" font="default"> Cetin,H.</style></author><author><style face="normal" font="default"> Kasprian,G.</style></author><author><style face="normal" font="default"> Auff,E.</style></author><author><style face="normal" font="default"> Zimprich,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Neurology, Medical University of Vienna, Wahringer Gurtel 18-20, 1090, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="default">Iodinated contrast agents in patients with myasthenia gravis: a retrospective cohort study</style></title><secondary-title><style face="normal" font="default">J Neurol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Neurol</style></abbr-1></periodical><pages end="1217" start="1209">1209-1217</pages><volume><style face="normal" font="default">264</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acute Disease</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> Austria</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> iodinated contrast</style></keyword><keyword><style face="normal" font="default"> Iodinated contrast agents</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Myasthenia Gravis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective cohort study</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="26" Month="5" Year="2017">2017/5/26</year></dates><abstract><style face="normal" font="default">Currently, it has not been satisfactorily established, whether modern low-osmolality iodinated contrast agents (ICAs) used in computed tomography (CT) studies are a risk factor for exacerbation of myasthenic symptoms. The rate of acute adverse events as well as delayed clinical worsening up to 30 days were analyzed in 73 patients with confirmed myasthenia gravis (MG) who underwent contrast-enhanced CT studies and compared to 52 patients who underwent unenhanced CT studies. One acute adverse event was documented. 12.3% of MG patients experienced a delayed exacerbation of symptoms after ICA administration. The rate of delayed severe exacerbation was higher in the contrast-enhanced group. Alternative causes for the exacerbation of MG-related symptoms were more likely than ICA administration in all cases. ICA administration for CT studies in MG patients should not be withheld if indicated, but patients particularly those with concomitant acute diseases should be carefully monitored for exacerbation of symptoms</style></abstract><notes><style face="normal" font="default">DA - 20170527IS - 1432-1459 (Electronic)IS - 0340-5354 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="default">10.1007/s00415-017-8518-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28550477">PM:28550477</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Neurol\2017-264-1209-17.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Neurol\2017-264-1209-17.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170527, Rath J</style></custom2><misc3><style face="normal" font="default">10.1007/s00415-017-8518-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41689</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,W.</style></author><author><style face="normal" font="default"> Xing,C.</style></author><author><style face="normal" font="default"> Hou,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Toxicology, National Institute of Occupational Health and Poison Control, Chinese Center for Disease Control and Prevention, Beijing, China</style></auth-address><titles><title><style face="normal" font="default">Intra-laboratory study to determine the reproducibility of LLNA:BrdU-ELISA for the prediction of the skin sensitizing potential of chemicals</style></title><secondary-title><style face="normal" font="default">J Pharmacol Toxicol Methods</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Pharmacol Toxicol Methods</style></abbr-1></periodical><pages end="30" start="26">26-30</pages><volume><style face="normal" font="default">82</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acetone</style></keyword><keyword><style face="normal" font="default"> Acrolein</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> analogs &amp; derivatives</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Beijing</style></keyword><keyword><style face="normal" font="default"> Bromodeoxyuridine</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cytology</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> DNCB</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> Eugenol</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Laboratory Proficiency Testing</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Mice,Inbred CBA</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Health</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> Reproducibility</style></keyword><keyword><style face="normal" font="default"> Reproducibility of Results</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> Toxicology</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> Validation studies</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">INTRODUCTION: The Local Lymph Node Assay (LLNA) has been designated as the first-choice in vivo assay for identification the skin sensitization potential of new chemicals. The LLNA:BrdU-ELISA is a validated non-radioactive modification to the LLNA. An intra-laboratory reproducibility study for the LLNA:BrdU-ELISA was conducted to demonstrate its adequate performance in our laboratory. METHODS: Ten independent LLNA:BrdU-ELISAs with the preferred positive controls (PCs), i.e., 25% hexyl cinnamic aldehyde (HCA) and 25% eugenol, were conducted within a period of less than one year. In addition, different concentrations of 2,4-dinitrochlorobenzene (DNCB, an extreme sensitizer) (0.01, 0.1 and 0.3%), HCA (10, 25 and 50%) and eugenol (10, 25 and 50%), were tested to determine the EC1.6 values. Special Pathogen Free female CBA/J mice of 8-10weeks old were randomly allocated to the groups, each group having 4 mice. 25mul of AOO (vehicle, acetone: olive oil=4:1, v/v) or HCA, eugenol, DNCB at the needed concentration was applied to the dorsum of each ear of the mice, daily for 3 consecutive days. A single intraperitoneal injection of 0.5ml of BrdU solution (10mg/ml) was given on day 5. On day 6, a pair of auricular lymph nodes from each mouse was excised, and BrdU ELISA analysis was conducted. RESULTS: The result for each group is expressed as the mean Stimulation Index (SI). The mean of the 10 mean SIs for 25% HCA (2.58+/-0.95) and 25% eugenol (3.51+/-1.25) was not significantly different to that from the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) (i.e., the data on the formal validation study for the LLNA:BrdU-ELISA by the ICCVAM) (3.03+/-2.00 for 25% HCA, 6.13+/-6.06 for 25% eugenol) (P>0.05), with even smaller Coefficient of Variations (CV) (36.8% for 25% HCA, 35.6% for 25% eugenol) than that from the ICCVAM (66.0% for 25% HCA, 98.8% for 25% eugenol). In addition, the EC1.6 values for HCA, eugenol and DNCB (15.2, 12.5 and 0.25%, respectively) were consistent with that from the ICCVAM (12.92, 8.85 and 0.34%, respectively). DISCUSSION: The results indicate that the reliability for our laboratory to conduct the LLNA:BrdU-ELISA is successfully determined</style></abstract><notes><style face="normal" font="default">DA - 20160904IS - 1873-488X (Electronic)IS - 1056-8719 (Linking)LA - engPT - Journal ArticleRN - 0 (Allergens)RN - 101-86-0 (hexyl cinnamic aldehyde)RN - 3T8H1794QW (Eugenol)RN - 7864XYD3JJ (Acrolein)RN - G34N38R2N1 (Bromodeoxyuridine)SB - IMCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.vascn.2016.07.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27456929">PM:27456929</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Pharmacol Toxicol Methods\2016-82-26-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Pharmacol Toxicol Methods\2016-82-26-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160904, Chen W</style></custom2><misc3><style face="normal" font="default">10.1016/j.vascn.2016.07.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41690</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kounis,N.G.</style></author><author><style face="normal" font="default"> Koniari,I.</style></author><author><style face="normal" font="default"> Roumeliotis,A.</style></author><author><style face="normal" font="default"> Tsigas,G.</style></author><author><style face="normal" font="default"> Soufras,G.</style></author><author><style face="normal" font="default"> Grapsas,N.</style></author><author><style face="normal" font="default"> Davlouros,P.</style></author><author><style face="normal" font="default"> Hahalis,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Cardiology, University of Patras Medical School, Patras, Rion, Achaia, Greece</style></auth-address><titles><title><style face="normal" font="default">Thrombotic responses to coronary stents, bioresorbable scaffolds and the Kounis hypersensitivity-associated acute thrombotic syndrome</style></title><secondary-title><style face="normal" font="default">J Thorac Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Thorac Dis</style></abbr-1></periodical><pages end="1164" start="1155">1155-1164</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> activation</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Adsorption</style></keyword><keyword><style face="normal" font="default"> albumin</style></keyword><keyword><style face="normal" font="default"> Angioplasty</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Arteries</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Complement</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> coronary angioplasty</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug-Eluting Stents</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Fibrinogen</style></keyword><keyword><style face="normal" font="default"> fibronectin</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foreign Bodies</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory mediators</style></keyword><keyword><style face="normal" font="default"> Irritation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Transformation</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Platelet</style></keyword><keyword><style face="normal" font="default"> Platelets</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Stents</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Thrombosis</style></keyword><keyword><style face="normal" font="default"> Transformation</style></keyword><keyword><style face="normal" font="default"> type III</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">Percutaneous transluminal coronary angioplasty with coronary stent implantation is a life-saving medical procedure that has become, nowadays, the most frequent performed therapeutic procedure in medicine. Plain balloon angioplasty, bare metal stents, first and second generation drug-eluting stents, bioresorbable and bioabsorbable scaffolds have offered diachronically a great advance against coronary artery disease and have enriched our medical armamentarium. Stented areas constitute vulnerable sites for endothelial damage, endothelial dysfunction, flow turbulence, hemorheologic changes, platelet dysfunction, coagulation changes and fibrinolytic disturbances. Implant surface attracts several proteins such as albumin, fibronectin, fibrinogen, and complement that lead to complement system activation. Macrophages recognize the implant as foreign substance due to protein adsorption and its continuous presence results in macrophage differentiation and fusion into foreign body giant cells. Polymer coating, stent metallic platforms and the released drugs can act as strong antigenic complex that apply continuous, repetitive, persistent and chronic hypersensitivity irritation to the coronary intima. The concomitant administration of oral antiplatelet drugs and environmental exposures can induce hypersensitivity inflammation. A class of platelets, activated via high-affinity and low-affinity IgE hypersensitivity receptors FCgammaRI, FCgammaRII, FCepsilonRI and FCepsilonRII, can induce Kounis hypersensitivity-associated thrombotic syndrome inside the stented coronaries. Type III variant of this syndrome is diagnosed when coronary artery stent thrombosis is associated with thrombus infiltrated by eosinophils or mast cells and/or when coronary intima, media and adventitia adjacent to stent, is infiltrated by eosinophils or mast cells. Careful history of hypersensitivity reactions to all implanted materials and concomitant drugs with monitoring of inflammatory mediators as well as lymphocyte transformation studies to detect hypersensitivity must be undertaken in order to avoid disastrous consequences. Food and Drug Administration recommendations for coronary stent implantation should be applied also to bioresorbable scaffolds. Further studies with inert and non-allergenic implants are necessary</style></abstract><notes><style face="normal" font="default">DA - 20170519IS - 2072-1439 (Print)IS - 2072-1439 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Greece -</style></notes><work-type><style face="normal" font="default">10.21037/jtd.2017.03.134</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28523173">PM:28523173</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Thorac Dis\2017-9-1155-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Thorac Dis\2017-9-1155-64.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170519, Kounis NG</style></custom2><misc3><style face="normal" font="default">10.21037/jtd.2017.03.134</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41691</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,Q.</style></author><author><style face="normal" font="default"> Ren,Y.</style></author><author><style face="normal" font="default"> Babar,S.M.</style></author><author><style face="normal" font="default"> Zhang,W.</style></author><author><style face="normal" font="default"> Pan,X.</style></author><author><style face="normal" font="default"> Zhang,S.</style></author><author><style face="normal" font="default"> Zhang,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Stomatology, China Medical University, Shenyang 110002, China</style></auth-address><titles><title><style face="normal" font="default">Design and characterization of a novel nickel-free cobalt-base alloy for intravascular stents</style></title><secondary-title><style face="normal" font="default">Mater Sci Eng C Mater Biol Appl</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Mater Sci Eng C Mater Biol Appl</style></abbr-1></periodical><pages end="571" start="565">565-571</pages><volume><style face="normal" font="default">77</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Apoptosis</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Characterization</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Corrosion</style></keyword><keyword><style face="normal" font="default"> cytotoxicity</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Embolism</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> Restenosis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Stainless Steel</style></keyword><keyword><style face="normal" font="default"> Steel</style></keyword><keyword><style face="normal" font="default"> Stents</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="default">Co-Cr-W-Ni alloy (L605) with high tensile strength is used in coronary stents. The thickness of individual strut of the stent is reduced which can decrease the stent restenosis rate. However, about 10% Ni element content in L605 is found to cause allergic reactions and pulmonary embolism, similar to the traditional 316L stainless steel. In this study, a novel nickel-free cobalt-base alloy Co-20Cr-12Fe-18Mn-2Mo-4W-N (wt%) was designed and fabricated in order to efficiently avoid the potential hazards of Ni element. Fe and Mn, essential elements of human body, were added in the alloy to substitute part of Co element. In comparison to L605 alloy, the tensile strength of the new alloy was higher than 1000MPa while elongation was above 55%. The pitting potential of the new alloy was measured close to 1000mV, also higher than that of L605 alloy. CCK-8 test indicated that the cytotoxicity of the new alloy is grade 1, reflecting that Co-20Cr-12Fe-18Mn-2Mo-4W-N alloy has no cytotoxic effects. There was no significant difference in the apoptosis rates between Co-20Cr-12Fe-18Mn-2Mo-4W-N and L605 alloy. The newly developed cobalt-base alloy showed excellent mechanical, corrosion resistance and biological properties, which could make it a desirable material for future clinical investigations</style></abstract><notes><style face="normal" font="default">DA - 20170523IS - 1873-0191 (Electronic)IS - 0928-4931 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.msec.2017.03.304</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28532066">PM:28532066</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mater Sci Eng C Mater Biol Appl\2017-77-565-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mater Sci Eng C Mater Biol Appl\2017-77-565-71.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170523, Wang Q</style></custom2><misc3><style face="normal" font="default">10.1016/j.msec.2017.03.304</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41692</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hansen,S.</style></author><author><style face="normal" font="default"> Probst-Hensch,N.</style></author><author><style face="normal" font="default"> Bettschart,R.</style></author><author><style face="normal" font="default"> Pons,M.</style></author><author><style face="normal" font="default"> Leynaert,B.</style></author><author><style face="normal" font="default"> Gomez,R.F.</style></author><author><style face="normal" font="default"> Rochat,T.</style></author><author><style face="normal" font="default"> Dratva,J.</style></author><author><style face="normal" font="default"> Schneider,C.</style></author><author><style face="normal" font="default"> Keidel,D.</style></author><author><style face="normal" font="default"> Schindler,C.</style></author><author><style face="normal" font="default"> Zemp,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Swiss Tropical and Public Health Institute, Socinstrasse 57, 4051 Basel, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Early menarche and new onset of asthma: Results from the SAPALDIA cohort study</style></title><secondary-title><style face="normal" font="default">Maturitas</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Maturitas</style></abbr-1></periodical><pages end="63" start="57">57-63</pages><volume><style face="normal" font="default">101</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Heart Diseases</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Norway</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> parental asthma</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> REACH</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">RATIONALE: The association between early menarche and new onset of asthma warrants further investigation in those aged >30 years. OBJECTIVES: Using data from the Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults (SAPALDIA), we investigated whether early menarche was associated with new onset of asthma in women aged 18-60 years at baseline. METHODS: Our analysis included 2492 women with information on age at menarche and doctor-diagnosed asthma, who had been asthma free at the time of menarche and had complete covariate information. New onset of asthma was defined as newly reported doctor-diagnosed asthma which occurred at least one year after menarche. Asthma incidence and its association with early menarche was analysed using logistic regression, adjusting for age, atopy, smoking, BMI, parental asthma, urbanity, education and study area, and additionally stratifying by atopy and BMI. RESULTS: After adjustment of relevant confounders, women with early menarche did not have a significantly higher risk of onset of asthma than women without early menarche (OR 1.23, 95% CI 0.85-1.80). Young atopic women with early menarche appeared to have an increased risk of asthma compared with non-atopic women (OR 2.21, 95% CI 0.90-5.43); however, our results did not reach statistical significance. CONCLUSION: We could not substantiate an association of early menarche with new onset of asthma in this Swiss population-based cohort aged 18-60 years at baseline. Future studies may need to prospectively assess age of menarche to investigate the association with new onset of asthma in those aged >30 years</style></abstract><notes><style face="normal" font="default">DA - 20170525IS - 1873-4111 (Electronic)IS - 0378-5122 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - France -CO - Norway -</style></notes><work-type><style face="normal" font="default">10.1016/j.maturitas.2017.04.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28539170">PM:28539170</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Maturitas\2017-101-57-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Maturitas\2017-101-57-63.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170525, Hansen S</style></custom2><misc3><style face="normal" font="default">10.1016/j.maturitas.2017.04.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41693</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Herrera-Mozo,I.</style></author><author><style face="normal" font="default"> Sanz-Gallen,P.</style></author><author><style face="normal" font="default"> Marti-Amengual,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinica Creu Blanca, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default">Occupational contact allergy to omeprazole and ranitidine</style></title><secondary-title><style face="normal" font="default">Med Pr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Med Pr</style></full-title></periodical><pages end="435" start="433">433-435</pages><volume><style face="normal" font="default">68</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lifestyle</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> Omeprazole</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Peptic Ulcer</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> Ranitidine</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Reflex</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Type IV hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Ulcer</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="default">Omeprazole is a proton pump inhibition and ranitidine is an H2 histamine receptor antagonist widely used in the treatment of gastroesophageal reflex disease, peptic ulcer disease, Zollinger-Ellison syndrome and as a protector of the gastric mucosae. We report a case of occupational contact allergy to omeprazole and ranitidine. A 48-year-old man, with no pre-existing history of atopy or lifestyle factors. He neither had any medical history of consumption of drugs such as ranitidine and omeprazole. He worked for 19 months in the pharmaceutical company that manufactured ranitidine base. He presented rash in the face and eczema on the dorsum of the hands with itching. The study by prick tests with ranitidine gave negative response. Patch testing with ranitidine base and ranitidine hydrochloride gave positive response. A month later, when the patient was asymptomatic he returned to the pharmaceutical company, being switched from this previous job to the reactor manufacturing omeprazole. A few days after that, he presented erythematous eruptions involving face and neck with itching. Prick tests, path tests and in vitro laboratories studies with omeprazole gave positives. In this case the patient presented hypersensitivity type I at omeprazole and hypersensitivity type IV at omeprazole and ranitidine. Our aportation indicates the importance of careful analysis of the occupational exposure histories of patients with the suspected type I or type IV hypersensitivity to allergens, to determine whether work exposure is the cause. Med Pr 2017;68(3):433-435</style></abstract><notes><style face="normal" font="default">DA - 20170517IS - 0465-5893 (Print)IS - 0465-5893 (Linking)LA - engPT - Case ReportsCO - Spain -</style></notes><work-type><style face="normal" font="default">10.13075/mp.5893.00612</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28512370">PM:28512370</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Med Pr\2017-68-433-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Med Pr\2017-68-433-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170517, Herrera-Mozo I</style></custom2><misc3><style face="normal" font="default">10.13075/mp.5893.00612</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41694</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Al-Abduljabbar,K.A.</style></author><author><style face="normal" font="default"> Stone,D.U.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Department, King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saud Arabia</style></auth-address><titles><title><style face="normal" font="default">Risks of Cefuroxime Prophylaxis for Postcataract Endophthalmitis</style></title><secondary-title><style face="normal" font="default">Middle East Afr J Ophthalmol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Middle East Afr J Ophthalmol</style></full-title></periodical><pages end="29" start="24">24-29</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Cataract</style></keyword><keyword><style face="normal" font="default"> cataract surgery</style></keyword><keyword><style face="normal" font="default"> Cefuroxime</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endophthalmitis</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Ocular</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Saudi Arabia</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Endophthalmitis after cataract surgery is a rare but vision-threatening complication. Intracameral cefuroxime (ICC) has been reported to be effective at reducing the risk, but concerns regarding the risks associated with this intervention remain. METHODS: Systematic review and synthesis of the literature on ICC, with a focus on the risks of therapy. RESULTS: Level 2a evidence was found to support the use of cefuroxime in penicillin-allergic patients. Compounding or dilutional errors are associated with ocular toxicity, but the incidence and risk of this occurrence are unknown. Level 4 evidence supports interventions that reduce the risk of dilutional errors. The association of cefuroxime injection with toxic anterior segment syndrome (TASS) is not established; Level 5 evidence supports standard measures to reduce the incidence of TASS related to cefuroxime administration. CONCLUSION: Cefuroxime can be administered safely to penicillin-allergic patients, and steps should be taken to reduce the risk of compounding or dilutional errors to avoid negating the benefits of this intervention. Recommended practice patterns for endophthalmitis prophylaxis should consider the risks and benefits of ICC</style></abstract><notes><style face="normal" font="default">DA - 20170526IS - 0975-1599 (Electronic)IS - 0974-9233 (Linking)LA - engPT - Journal ArticleCO - Saudi Arabia -CO - United States -</style></notes><work-type><style face="normal" font="default">10.4103/meajo.MEAJO_255_16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28546689">PM:28546689</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Middle East Afr J Ophthalmol\2017-24-24-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Middle East Afr J Ophthalmol\2017-24-24-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170526, Al-Abduljabbar KA</style></custom2><misc3><style face="normal" font="default">10.4103/meajo.MEAJO_255_16</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41695</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,K.</style></author><author><style face="normal" font="default"> Tao,L.</style></author><author><style face="normal" font="default"> Su,J.</style></author><author><style face="normal" font="default"> Zhang,Y.</style></author><author><style face="normal" font="default"> Zou,B.</style></author><author><style face="normal" font="default"> Wang,Y.</style></author><author><style face="normal" font="default"> Zou,M.</style></author><author><style face="normal" font="default"> Chen,N.</style></author><author><style face="normal" font="default"> Lei,L.</style></author><author><style face="normal" font="default"> Li,X.</style></author></authors></contributors><titles><title><style face="normal" font="default">TLR4 supports the expansion of FasL+CD5+CD1dhi regulatory B cells, which decreases in contact hypersensitivity</style></title><secondary-title><style face="normal" font="default">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Mol Immunol</style></full-title></periodical><pages end="199" start="188">188-199</pages><volume><style face="normal" font="default">87</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anti-CD40</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Breg</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Efficiency</style></keyword><keyword><style face="normal" font="default"> expansion</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> FasL</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Ligation</style></keyword><keyword><style face="normal" font="default"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="default"> LPS</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> NF-+¦B</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Regulatory B cell</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> suppression</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TLR4</style></keyword><keyword><style face="normal" font="default"> TLR9</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><isbn><style face="normal" font="default">0161-5890</style></isbn><abstract><style face="normal" font="default">Abstract Certain B cells termed as </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç£regulatory B cells</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇØ (Bregs) can suppress the ongoing immune responses and a splenic CD5+CD1dhi Breg subset identified earlier was shown to exert its regulatory functions through secretion of IL-10. Though FasL expression is an alternative mechanism of immune suppression used by B cells, little is known about the FasL expressing CD5+CD1dhi Bregs. In this study, we isolated splenocytes or splenic CD19+ B cells and compared the efficiency of toll-like receptor(TLR)4 ligand (lipopolysaccharide) with TLR9 ligand (CpG), anti-CD40 and TLR9 ligand (CpG) plus anti-CD40 on the FasL expression of splenic CD5+CD1dhi Bregs by flow cytometry. FasL expression in CD5+CD1dhi B cells was rapidly increased after TLR4 ligation. Intriguingly, anti-CD40 and CpG plus anti-CD40 combinations failed to stimulate FasL expression in CD5+CD1dhi B cells although the IL-10 production was up-regulated in this subset. In addition, LPS and other B10-cell inducers increased the expression of surface molecules like CD86 and CD25, which are correlated to the regulatory functions of B cells. Furthermore, NF-+¦B and NF-AT inhibitors decreased the TLR4-activated FasL expression in CD5+CD1dhi B cells. Then we sorted splenic CD5+CD1dhi Bregs using flow cytometry and found that TLR4-activated CD5+CD1dhi Bregs suppressed the proliferation of CFSE-labeled CD4+ T cells in vitro, which was partly blocked by anti-FasL antibody. In oxazolone-sensitized mice having contact hypersensitivity, FasL expression in splenic CD5+CD1dhi B cells was decreased compared to the control group after TLR4 ligation. Our findings suggest that the regulatory function of CD5+CD1dhi B cells could be partly mediated by Fas-FasL pathway and this FasL expressing CD5+CD1dhi Bregs might participate in the regulation of inflammatory diseases</style></abstract><notes><style face="normal" font="default">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.molimm.2017.04.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28505514">PM:28505514</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mol Immunol\2017-87-188-99.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mol Immunol\2017-87-188-99.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170601, Wang K</style></custom2><misc3><style face="normal" font="default">10.1016/j.molimm.2017.04.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41696</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fei,X.</style></author><author><style face="normal" font="default"> Je,I.G.</style></author><author><style face="normal" font="default"> Shin,T.Y.</style></author><author><style face="normal" font="default"> Kim,S.H.</style></author><author><style face="normal" font="default"> Seo,S.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">College of Pharmacy and Gachon Institute of Pharmaceutical Sciences, Gachon University, Incheon 21936, Korea.</style></auth-address><titles><title><style face="normal" font="default">Synthesis of Gallic Acid Analogs as Histamine and Pro-Inflammatory Cytokine Inhibitors for Treatment of Mast Cell-Mediated Allergic Inflammation</style></title><secondary-title><style face="normal" font="default">Molecules</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Molecules</style></abbr-1></periodical><pages end="" start="898">898-</pages><volume><style face="normal" font="default">22</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Amines</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> Antioxidants</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> Gallic Acid</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Histamine Release</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Optimization</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="29" Month="5" Year="2017">2017/5/29</year></dates><abstract><style face="normal" font="default">Gallic acid (3,4,5-trihydroxybenzoic acid), is a natural product found in various foods and herbs that are well known as powerful antioxidants. Our previous report demonstrated that it inhibits mast cell-derived inflammatory allergic reactions by blocking histamine release and pro-inflammatory cytokine expression. In this report, various amide analogs of gallic acid have been synthesized by introducing different amines through carbodiimide-mediated amide coupling and Pd/C-catalyzed hydrogenation. These compounds showed a modest to high inhibitory effect on histamine release and pro-inflammatory cytokine expression. Among them, the amide bearing (S)-phenylglycine methyl ester 3d was found to be more active than natural gallic acid. Further optimization yielded several (S)- and (R)-phenylglycine analogs that inhibited histamine release in vitro. Our findings suggest that some gallamides could be used as a treatment for allergic inflammatory diseases</style></abstract><notes><style face="normal" font="default">DA - 20170530IS - 1420-3049 (Electronic)IS - 1420-3049 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.3390/molecules22060898</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28555061">PM:28555061</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Molecules\2017-22-898.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Molecules\2017-22-898.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170530, Fei X</style></custom2><misc3><style face="normal" font="default">10.3390/molecules22060898</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41697</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pavord,I.D.</style></author><author><style face="normal" font="default"> Mathieson,N.</style></author><author><style face="normal" font="default"> Scowcroft,A.</style></author><author><style face="normal" font="default"> Pedersini,R.</style></author><author><style face="normal" font="default"> Isherwood,G.</style></author><author><style face="normal" font="default"> Price,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory Medicine Unit, Nuffield Department of Medicine, NDM Research Building, Old Road Campus, University of Oxford, Oxford, OX3 7FZ, UK.</style></auth-address><titles><title><style face="normal" font="default">The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting beta2-agonists in the United Kingdom: a cross-sectional analysis</style></title><secondary-title><style face="normal" font="default">NPJ Prim Care Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">NPJ Prim Care Respir Med</style></full-title></periodical><pages end="" start="17">17-</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> cross-sectional analysis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">There are several new treatment options for patients whose asthma remains uncontrolled on free-dose and fixed-dose combinations of inhaled corticosteroids plus long-acting beta2-agonists (ICS+LABA). In order to evaluate the likely impact of these treatments, we assessed the effect of uncontrolled asthma on healthcare and patient burden within the UK among adult patients treated with ICS+LABA. Data obtained from 2010-2011 UK National Health and Wellness Surveys identified 701 patients treated with ICS+LABA. Patients with not well-controlled asthma (Asthma Control Test score &lt;20) were compared with well-controlled asthma (score >/= 20) patients on multiple measures. Cost burden was calculated using healthcare resource utilisation models and work productivity and impairment questionnaire. Overall, 452 and 249 patients reported not well-controlled and well-controlled asthma, respectively. A greater proportion of not well-controlled patients visited the accident &amp; emergency department (21 vs. 14%, P = 0.016), were hospitalised (13 vs. 8%, P = 0.022) and had lower mental and physical health-related quality of life (P &lt; 0.001) and impaired work productivity and activity scores: presenteeism (23 vs. 11%, P &lt; 0.001), work impairment (29 vs. 17%, P &lt; 0.001) and activity impairment (46 vs. 24%, P &lt; 0.001). Calculated direct and indirect yearly costs/person doubled among not well-controlled compared to well-controlled asthma patients ( pound6592 vs. pound3220). Total cost to society was estimated at pound6172 million/year (direct costs, pound1307 million; indirect costs, pound4865 million). In conclusion, not well-controlled asthma is common among UK adults treated with ICS+LABA, resulting in impairments across a number of important health outcomes and represents a significant unmet need and resource burden. ASTHMA: DRUG COMBO LEAVES MANY WITH UNCONTROLLED DISEASE: Many people who take inhaled steroids combined with long-acting beta2-agonist drugs still have poorly controlled asthma. A team led by Ian Pavord from the University of Oxford, UK, identified 701 people from the 2010-2011 UK National Health and Wellness Surveys who were taking this drug combination for their asthma. The researchers found that nearly two-thirds of these individuals had poorly controlled asthma associated with more visits to the emergency room, worse quality of life (both mentally and physically), impaired productivity and other health problems. The calculated direct and indirect costs per person with poorly controlled asthma were about double that for someone whose asthma was under control. The authors conclude that better treatment and management is needed to reduce costs and address the unmet medical need for people with persistent uncontrolled asthma</style></abstract><notes><style face="normal" font="default">DA - 20170308IS - 2055-1010 (Electronic)IS - 2055-1010 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1038/s41533-017-0014-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28270657">PM:28270657</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\NPJ Prim Care Respir Med\2017-27-17.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\NPJ Prim Care Respir Med\2017-27-17.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170308, Pavord ID</style></custom2><misc3><style face="normal" font="default">10.1038/s41533-017-0014-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41698</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Limone,B.A.</style></author><author><style face="normal" font="default"> Rasmussen,A.</style></author><author><style face="normal" font="default"> Kwon,S.M.</style></author><author><style face="normal" font="default"> Jacob,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Loma Linda University, 11370 Anderson Street, Suite 2600, Loma Linda, CA 92354, USA.</style></auth-address><titles><title><style face="normal" font="default">Complementary Intradermal and Patch Testing for Increased Diagnostic Accuracy of Nickel Allergy in Non-Celiac Wheat Insensitivity</style></title><secondary-title><style face="normal" font="default">Nutrients</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nutrients</style></abbr-1></periodical><pages end="" start="536">536-</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Algorithms</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epicutaneous</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Nickel allergy</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Wheat</style></keyword></keywords><dates><year Day="24" Month="5" Year="2017">2017/5/24</year></dates><abstract><style face="normal" font="default">D'Alcamo et al. astutely highlighted a potential immunologic association between nickel allergy, determined by positive epicutaneous patch testing, and the rise of non-celiac wheat sensitivity (NCWS) in the world of gluten-related diseases. Consecutive algorithms including both patch and intradermal testing could provide vital information to more accurately define the patient populations with NCWS, systemic nickel allergy syndrome, and nickel-associated allergic contact dermatitis</style></abstract><notes><style face="normal" font="default">DA - 20170524IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="default">10.3390/nu9060536</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28538677">PM:28538677</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nutrients\2017-9-536.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nutrients\2017-9-536.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170524, Limone BA</style></custom2><misc3><style face="normal" font="default">10.3390/nu9060536</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41699</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Weinmann,T.</style></author><author><style face="normal" font="default"> Gerlich,J.</style></author><author><style face="normal" font="default"> Heinrich,S.</style></author><author><style face="normal" font="default"> Nowak,D.</style></author><author><style face="normal" font="default"> Mutius,E.V.</style></author><author><style face="normal" font="default"> Vogelberg,C.</style></author><author><style face="normal" font="default"> Genuneit,J.</style></author><author><style face="normal" font="default"> Lanzinger,S.</style></author><author><style face="normal" font="default"> Al-Khadra,S.</style></author><author><style face="normal" font="default"> Lohse,T.</style></author><author><style face="normal" font="default"> Motoc,I.</style></author><author><style face="normal" font="default"> Walter,V.</style></author><author><style face="normal" font="default"> Radon,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Occupational and Environmental Epidemiology &amp; NetTeaching Unit, Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital of Munich (LMU), Munich, Germany</style></auth-address><titles><title><style face="normal" font="default">Association of household cleaning agents and disinfectants with asthma in young German adults</style></title><secondary-title><style face="normal" font="default">Occup Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Occup Environ Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy risk</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Disinfectants</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational allergy</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="8" Month="5" Year="2017">2017/5/8</year></dates><abstract><style face="normal" font="default">OBJECTIVES: We scrutinised the association of private use of household sprays and disinfectants with asthma incidence in young adults in the transition from school to working life. METHODS: Between 2007 and 2009,2051 young adults aged 19-24 years living in two major German cities took part in the Study on Occupational Allergy Risks II. Self-reported exposure to household sprays and disinfectants was characterised according to a composite score for frequency of use as no use (score=0), low use (score between 1 and the median), medium use (score between the median and the 90th percentile) and high use (score above the 90th percentile). Two outcome variables (current asthma and current wheezing) with four mutually exclusive categories (never, incident, persistent and remittent) were used for the risk analyses. Multinomial logistic regression models examined the association between the frequency of using household sprays and disinfectants with asthma and wheezing adjusting for potential confounders. RESULTS: Compared with no use, high use of disinfectants was associated with a more than twofold increased odds of incident asthma (OR 2.79, 95% CI 1.14 to 6.83). In addition, low/medium use of disinfectants was associated with remittent asthma (OR 2.39, 95% CI 1.29 to 4.47). The evidence for an association between high usage of household sprays and asthma incidence was weak (OR 2.79, 95% CI 0.84 to 9.20). CONCLUSION: Our results support the hypothesis of an association between the use of cleaning products and elevated risks for asthma and wheezing in young adults at the start of working life</style></abstract><notes><style face="normal" font="default">DA - 20170509IS - 1470-7926 (Electronic)IS - 1351-0711 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Switzerland -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1136/oemed-2016-104086</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28483971">PM:28483971</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Occup Environ Med\20170509-WeinmannT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Occup Environ Med\20170509-WeinmannT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170509, Weinmann T</style></custom2><misc3><style face="normal" font="default">10.1136/oemed-2016-104086</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41700</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Walters,G.I.</style></author><author><style face="normal" font="default"> Robertson,A.S.</style></author><author><style face="normal" font="default"> Moore,V.C.</style></author><author><style face="normal" font="default"> Burge,P.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Occupational Lung Disease Service, Birmingham Chest Clinic, 151 Great Charles Street, Birmingham B3 3HX, UK</style></auth-address><titles><title><style face="normal" font="default">Occupational asthma caused by acrylic compounds from SHIELD surveillance (1989-2014)</style></title><secondary-title><style face="normal" font="default">Occup Med (Lond)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Occup Med (Lond)</style></full-title></periodical><pages end="289" start="282">282-289</pages><volume><style face="normal" font="default">67</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acrylate</style></keyword><keyword><style face="normal" font="default"> Acrylates</style></keyword><keyword><style face="normal" font="default"> Adhesives</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Beauty</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Challenge test</style></keyword><keyword><style face="normal" font="default"> Challenge tests</style></keyword><keyword><style face="normal" font="default"> Cyanoacrylates</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Employment</style></keyword><keyword><style face="normal" font="default"> Epoxy resin</style></keyword><keyword><style face="normal" font="default"> Epoxy Resins</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Inhalation Exposure</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> Isocyanate</style></keyword><keyword><style face="normal" font="default"> Isocyanates</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Methacrylate</style></keyword><keyword><style face="normal" font="default"> Methacrylates</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> occupational asthma</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peak flow</style></keyword><keyword><style face="normal" font="default"> Printing</style></keyword><keyword><style face="normal" font="default"> Respiratory sensitization</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> smokers</style></keyword><keyword><style face="normal" font="default"> specific inhalation challenge</style></keyword><keyword><style face="normal" font="default"> Statistics</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> trends</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="20" Month="4" Year="2017">2017/4/20</year></dates><abstract><style face="normal" font="default">Background: Acrylic monomers (acrylates), methacrylates and cyanoacrylates all cause asthma by respiratory sensitization. Occupational inhalation exposures occur across a variety of industries including health care and dental work, beauty, laboratory science, assembly and plastic moulding. Aims: To examine notifications of occupational asthma caused by acrylic compounds from a UK-based regional surveillance scheme, in order to highlight prevalent exposures and trends in presentation. Methods: Retrospective review of all cases reported to the SHIELD surveillance scheme for occupational asthma, West Midlands, UK between 1989 and 2014. Patient data were gathered on demographics, employment, asthma symptoms and diagnostic investigations including serum immunological testing, serial peak flow analysis and specific inhalation challenge tests. Descriptive statistics were used to illustrate worker characteristics and evidence for sensitization to acrylic compounds. Results: There were 20 affected patients out of 1790 total cases of occupational asthma (1%); all cases were confirmed by OASYS (Occupational Asthma SYStem) analysis of serial peak flow measurements, with three additional positive specific inhalation challenge tests. Three out of 20 (15%) patients were current smokers and 11/20 (55%) were atopic. A variety of exposures and industries were implicated including: manufacturing, health care, beauty and printing and a novel presentation seen in teachers exposed to floor adhesives. Conclusions: This is the largest reported series of occupational asthma caused by acrylic compounds, which remain an important aetiological factor in this disease. Exposure occurs in a variety of industries, particularly in manufacturing and is seen with other, perhaps better recognized sensitizing agents such as isocyanates and epoxy resins</style></abstract><notes><style face="normal" font="default">DA - 20170421IS - 1471-8405 (Electronic)IS - 0962-7480 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1093/occmed/kqx036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28431005">PM:28431005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Occup Med (Lond)\2017-67-282-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Occup Med (Lond)\2017-67-282-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170421, Walters GI</style></custom2><misc3><style face="normal" font="default">10.1093/occmed/kqx036</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41701</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kilduff,C.L.S.</style></author><author><style face="normal" font="default"> Casswell,E.J.</style></author><author><style face="normal" font="default"> Imonikhe,R.</style></author><author><style face="normal" font="default"> Marjanovic,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">a St Mary's Hospital, Imperial Healthcare Trust , London , UK</style></auth-address><titles><title><style face="normal" font="default">Type IV Hypersensitivity to Gold Weight Upper-Eyelid Implant: Case Report and Review of the Literature</style></title><secondary-title><style face="normal" font="default">Ocul Immunol Inflamm</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ocul Immunol Inflamm</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Eyelid</style></keyword><keyword><style face="normal" font="default"> Gold</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Type IV hypersensitivity</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="default">PURPOSE: Complications associated with gold-weight insertion for lagophthalmos are uncommon, recent reports have provided evidence to suggest that type IV hypersensitivity to gold can cause a persistent inflammatory reaction. METHODS: We present a case of a 46-year-old man who experienced persistent post-operative inflammation, and summarize previously documented cases. This patient underwent uncomplicated insertion of an upper eyelid gold weight for right-sided facial nerve palsy. He had no allergies or implanted metalwork. Post-operatively erythema was noted at seven-weeks and did not resolve. The weight was removed after six-months. RESULTS: The histopathological findings were in keeping with type IV hypersensitivity and similar to previous cases. CONCLUSIONS: Although infrequent, this complication has poor outcomes. The definitive management is removal of the weight. Information regarding implanted gold, and previous reactions should be elicited pre-operatively. Type IV hypersensitivity should be considered in patients with persistent inflammation that do not respond to antibiotic or steroid therapy</style></abstract><notes><style face="normal" font="default">DA - 20170504IS - 1744-5078 (Electronic)IS - 0927-3948 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1080/09273948.2017.1311922</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28471252">PM:28471252</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ocul Immunol Inflamm\20170504-KilduffCL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ocul Immunol Inflamm\20170504-KilduffCL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170504, Kilduff CL</style></custom2><misc3><style face="normal" font="default">10.1080/09273948.2017.1311922</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41702</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chiem,J.</style></author><author><style face="normal" font="default"> Ivanova,I.</style></author><author><style face="normal" font="default"> Parker,A.</style></author><author><style face="normal" font="default"> Krengel,W.,III</style></author><author><style face="normal" font="default"> Jimenez,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesiology and Pain Medicine, Seattle Children's Hospital, University of Washington, Seattle, WA, USA</style></auth-address><titles><title><style face="normal" font="default">Anaphylactic reaction to tranexamic acid in an adolescent undergoing posterior spinal fusion</style></title><secondary-title><style face="normal" font="default">Paediatr Anaesth</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Paediatr Anaesth</style></abbr-1></periodical><pages end="775" start="774">774-775</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Anesthesiology</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Flushing</style></keyword><keyword><style face="normal" font="default"> Headache</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Nausea</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Tranexamic Acid</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Washington</style></keyword></keywords><dates><year Day="21" Month="3" Year="2017">2017/3/21</year></dates><abstract><style face="normal" font="default">Tranexamic acid is an anti-fibrinolytic agent frequently used in pediatric surgery. Common side effects include nausea, flushing, and headache, but in rare instances, it may produce anaphylaxis; with only one previously reported case in a 72-year-old man. We report a case of a delayed anaphylactic reaction in a pediatric patient undergoing posterior spine fusion; and discuss the intraoperative management of the acute event, immunologic confirmation, and subsequent anesthetic approach</style></abstract><notes><style face="normal" font="default">DA - 20170321IS - 1460-9592 (Electronic)IS - 1155-5645 (Linking)LA - engPT - Case ReportsCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pan.13141</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28321954">PM:28321954</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Paediatr Anaesth\2017-27-774-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Paediatr Anaesth\2017-27-774-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170321, Chiem J</style></custom2><misc3><style face="normal" font="default">10.1111/pan.13141</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41703</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Azizi,G.</style></author><author><style face="normal" font="default"> Abolhassani,H.</style></author><author><style face="normal" font="default"> Mahdaviani,S.A.</style></author><author><style face="normal" font="default"> Chavoshzadeh,Z.</style></author><author><style face="normal" font="default"> Eshghi,P.</style></author><author><style face="normal" font="default"> Yazdani,R.</style></author><author><style face="normal" font="default"> Kiaee,F.</style></author><author><style face="normal" font="default"> Shaghaghi,M.</style></author><author><style face="normal" font="default"> Mohammadi,J.</style></author><author><style face="normal" font="default"> Rezaei,N.</style></author><author><style face="normal" font="default"> Hammarstrom,L.</style></author><author><style face="normal" font="default"> Aghamohammadi,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Laboratory Medicine, Imam Hassan Mojtaba Hospital, Alborz University of Medical Sciences, Karaj, Iran</style></auth-address><titles><title><style face="normal" font="default">Clinical, Immunological, Molecular Analyses and Outcomes of Iranian Patients with LRBA Deficiency: A Longitudinal Study</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Autoimmunity</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Lymphoproliferative Disorders</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Pneumonia</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Respiratory tract infection</style></keyword><keyword><style face="normal" font="default"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Sirolimus</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> Survival Rate</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: LPS-responsive beige-like anchor protein (LRBA) deficiency is a combined immunodeficiency caused by mutation in LRBA gene. The patients have a variety of clinical symptoms including hypogammaglobulinemia, recurrent infections, autoimmunity and enteropathy. METHODS: A total of 17 LRBA-deficient patients were enrolled in this longitudinal study. For all patients, demographic information, clinical records, laboratory and molecular data were collected. RESULTS: Hypogammaglobulinemia were reported in 14 (82.4%), CD4+ T cell deficiency in five (29.4%), NK cell deficiency in three (21.4%) and CD19+ B cell deficiency in 11 (64.7%) patients. All patients had history of infectious complications; pneumonia was the most common (76.5%) occurring infection. A history of lymphoproliferative disorders was observed in 14 (82.3%), enteropathy in 13 (76.5%), allergic symptoms in six (35.5%), neurological problems in four (23.5) and autoimmunity (mostly autoimmune cytopenia) in 13 (76.5%) patients. Sirolimus treatment improved enteropathy of patients with remarkable success. The 20-year overall survival rate declined to 70.6%. CONCLUSION: LRBA deficiency has a very broad and variable phenotype and should be considered, especially in children with early onset hypogammaglobulinemia, severe autoimmune manifestations, enteropathy, lymphoproliferation, and recurrent respiratory tract infections. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170517IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12735</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28512785">PM:28512785</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170517-AziziG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170517-AziziG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170517, Azizi G</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12735</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41704</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tegtmeyer,D.</style></author><author><style face="normal" font="default"> Seidl,M.</style></author><author><style face="normal" font="default"> Gerner,P.</style></author><author><style face="normal" font="default"> Baumann,U.</style></author><author><style face="normal" font="default"> Klemann,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Paediatrics, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany</style></auth-address><titles><title><style face="normal" font="default">IBD due to PID: Inflammatory bowel disease caused by primary immunodeficiencies - Clinical presentations, review of literature, and proposal of a rational diagnostic algorithm</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">blood</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic granulomatous disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Colitis</style></keyword><keyword><style face="normal" font="default"> Common Variable Immunodeficiency</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Early Diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Immunosuppressive therapy</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="default"> Inflammatory Bowel Diseases</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> NEMO</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> paediatrics</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Rare Diseases</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="default">Inflammatory bowel diseases (IBD) including Crohn's disease (CD) and ulcerative colitis (UC) have a multifactorial pathogenesis with complex interactions between polygenetic predispositions and environmental factors. However, IBD can also be caused by monogenic diseases, such as primary immunodeficiencies (PID). Recently, an increasing number of these altogether rare diseases has been described to present often primarily, or solely as IBD. Early recognition of these conditions enables adaption of therapies and thus directly benefits the course of IBDs. Here, we discuss the different clinical presentations in IBD and characteristic features of patient's history, clinical findings, and diagnostic results indicative for a causative PID. Possible predictors are early onset of disease, necessity of parenteral nutrition, failure to respond to standard immunosuppressive therapy, parental consanguinity, increased susceptibility for infections, certain histopathologic findings, and blood tests that are atypical for classic IBD. We illustrate this with exemplary case studies of IBD due to NEMO deficiency, chronic granulomatous disease (CGD), common variable immunodeficiency (CVID), CTLA-4 and LRBA deficiency. Taking these factors into account, we propose a diagnostic pathway to enable early diagnosis of IBD due to PID. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170517IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12734</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28513998">PM:28513998</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170517-TegtmeyerD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170517-TegtmeyerD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170517, Tegtmeyer D</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12734</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41705</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chime,N.O.</style></author><author><style face="normal" font="default"> Riese,V.G.</style></author><author><style face="normal" font="default"> Scherzer,D.J.</style></author><author><style face="normal" font="default"> Perretta,J.S.</style></author><author><style face="normal" font="default"> McNamara,L.</style></author><author><style face="normal" font="default"> Rosen,M.A.</style></author><author><style face="normal" font="default"> Hunt,E.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">1Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. 2National Institutes of Health of Library, Bethesda, MD. 3Division of Emergency Medicine, Department of Emergency Medicine, Nationwide Children's Hospital, Columbus, OH. 4Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD. 5Armstrong Institute for Patient Safety and Quality, Johns Hopkins Medicine, Baltimore, MD. 6Departments of Pediatrics and Health Informatics, Johns Hopkins University School of Medicine, Baltimore, MD</style></auth-address><titles><title><style face="normal" font="default">Epinephrine Auto-Injector Versus Drawn Up Epinephrine for Anaphylaxis Management: A Scoping Review</style></title><secondary-title><style face="normal" font="default">Pediatr Crit Care Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pediatr Crit Care Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Anesthesiology</style></keyword><keyword><style face="normal" font="default"> Auto-injectors</style></keyword><keyword><style face="normal" font="default"> Baltimore</style></keyword><keyword><style face="normal" font="default"> Caregivers</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Emergency Medicine</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="default"> Feedback</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patient Safety</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of care</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Anaphylaxis is a life-threatening event. Most clinical symptoms of anaphylaxis can be reversed by prompt intramuscular administration of epinephrine using an auto-injector or epinephrine drawn up in a syringe and delays and errors may be fatal. The aim of this scoping review is to identify and compare errors associated with use of epinephrine drawn up in a syringe versus epinephrine auto-injectors in order to assist hospitals as they choose which approach minimizes risk of adverse events for their patients. DATA SOURCES: PubMed, Embase, CINAHL, Web of Science, and the Cochrane Library were searched using terms agreed to a priori. STUDY SELECTION: We reviewed human and simulation studies reporting errors associated with the use of epinephrine in anaphylaxis. There were multiple screening stages with evolving feedback. DATA EXTRACTION: Each study was independently assessed by two reviewers for eligibility. Data were extracted using an instrument modeled from the Zaza et al instrument and grouped into themes. DATA SYNTHESIS: Three main themes were noted: 1) ergonomics, 2) dosing errors, and 3) errors due to route of administration. Significant knowledge gaps in the operation of epinephrine auto-injectors among healthcare providers, patients, and caregivers were identified. For epinephrine in a syringe, there were more frequent reports of incorrect dosing and erroneous IV administration with associated adverse cardiac events. For the epinephrine auto-injector, unintentional administration to the digit was an error reported on multiple occasions. CONCLUSIONS: This scoping review highlights knowledge gaps and a diverse set of errors regardless of the approach to epinephrine preparation during management of anaphylaxis. There are more potentially life-threatening errors reported for epinephrine drawn up in a syringe than with the auto-injectors. The impact of these knowledge gaps and potentially fatal errors on patient outcomes, cost, and quality of care is worthy of further investigation</style></abstract><notes><style face="normal" font="default">DA - 20170511IS - 1529-7535 (Print)IS - 1529-7535 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/PCC.0000000000001197</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28492400">PM:28492400</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Crit Care Med\20170511-ChimeNO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Crit Care Med\20170511-ChimeNO.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170511, Chime NO</style></custom2><misc3><style face="normal" font="default">10.1097/PCC.0000000000001197</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41706</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Leitenberger,S.</style></author><author><style face="normal" font="default"> Hajar,T.</style></author><author><style face="normal" font="default"> Simpson,E.L.</style></author><author><style face="normal" font="default"> von Kobyletzki,L.</style></author><author><style face="normal" font="default"> Hanifin,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Oregon Health and Science University, Portland, Oregon</style></auth-address><titles><title><style face="normal" font="default">Validation of a Parent-Reported Diagnostic Instrument in a U.S. Referral Population: The Childhood Eczema Questionnaire</style></title><secondary-title><style face="normal" font="default">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic tool</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Oregon</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="19" Month="5" Year="2017">2017/5/19</year></dates><abstract><style face="normal" font="default">BACKGROUND/OBJECTIVES: There is a paucity of validated tools for diagnosing atopic dermatitis (AD) in very young children that do not rely on clinical evaluation. The Childhood Eczema Questionnaire (CEQ)-a diagnostic tool for AD in children younger than 2 years that a caretaker can complete-was recently validated in Sweden. The objective of this study was to validate the tool in a U.S. POPULATION: As a substudy, we added an additional question that was independently assessed. METHODS: Children younger than 2 years old were recruited from a dermatology clinic. Their caretakers completed a questionnaire containing the original tool's three questions as well as a fourth question that increased the time frame measured from 1 week to 6 months. Questionnaires with all "yes" answers were considered positive and were compared with a dermatologist diagnosis of AD. RESULTS: A total of 283 subjects were recruited. The first three questions (the original CEQ) predicted a positive diagnosis of AD with a sensitivity of 0.72 (95% confidence interval [CI] 0.58, 0.82) and a specificity of 0.93 (95% CI 0.87, 0.95). In a separate analysis we included the first two questions and the fourth question and found that the sensitivity increased to 0.82 (95% CI 0.69, 0.90) with a specificity of 0.89 (95% CI 0.83, 0.93). CONCLUSION: This study validates a novel parental questionnaire for the diagnosis of AD in children younger than 2 years in a U.S. clinic population</style></abstract><notes><style face="normal" font="default">DA - 20170519IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pde.13139</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28523849">PM:28523849</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Dermatol\20170519-LeitenbergerS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Dermatol\20170519-LeitenbergerS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170519, Leitenberger S</style></custom2><misc3><style face="normal" font="default">10.1111/pde.13139</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41707</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cotton,C.H.</style></author><author><style face="normal" font="default"> Duah,C.G.</style></author><author><style face="normal" font="default"> Matiz,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Dermatology, Department of Medicine, College of Medicine, University of Arizona, Tucson, Arizona</style></auth-address><titles><title><style face="normal" font="default">Allergic Contact Dermatitis Due to Methylisothiazolinone in a Young Girl's Laundry Detergent</style></title><secondary-title><style face="normal" font="default">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Arizona</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="19" Month="5" Year="2017">2017/5/19</year></dates><abstract><style face="normal" font="default">Methylisothiazolinone (MI) is an emerging and increasing cause of allergic contact dermatitis (ACD) in children. We present the case of a 7-year-old girl with an unusual dermatitis suspicious for contact allergy. Patch testing confirmed allergy to MI, found only in the patient's laundry detergent. This case highlights the importance of checking household product ingredients and the role of MI as an increasing cause of ACD in children</style></abstract><notes><style face="normal" font="default">DA - 20170519IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/pde.13122</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28523864">PM:28523864</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Dermatol\20170519-CottonCH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Dermatol\20170519-CottonCH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170519, Cotton CH</style></custom2><misc3><style face="normal" font="default">10.1111/pde.13122</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41708</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jacob,S.E.</style></author><author><style face="normal" font="default"> Lipp,M.B.</style></author><author><style face="normal" font="default"> Suh,E.</style></author><author><style face="normal" font="default"> Goldenberg,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Loma Linda University, Loma Linda, California</style></auth-address><titles><title><style face="normal" font="default">Practice Patterns of Dermatologists in the Pediatric Contact Dermatitis Registry</style></title><secondary-title><style face="normal" font="default">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> bias</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Columbia</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> District of Columbia</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> Sample Size</style></keyword><keyword><style face="normal" font="default"> Selection Bias</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="23" Month="5" Year="2017">2017/5/23</year></dates><abstract><style face="normal" font="default">BACKGROUND/OBJECTIVES: U.S. adults and children are equally likely to have allergic contact dermatitis. Historically the narrow geographic location of data-reporting providers has quantitatively and qualitatively limited the pediatric contact dermatitis data. The Pediatric Contact Dermatitis Registry was used to evaluate self-identified pediatric patch test providers within the United States with regard to demographic characteristics, geographic location, and practice patterns. METHODS: A wide range of U.S. providers were invited to join the registry by completing a secure online 11-question registration survey. RESULTS: There were 252 respondents from 50 states and the District of Columbia; 28.6% were pediatric dermatologists and members of the Society for Pediatric Dermatology (SPD), and 38% were members of the American Contact Dermatitis Society. The cumulative range of pediatric patch-test evaluations performed each year was 1,726 to 4,613 children. SPD members had a significantly greater likelihood of performing a commercially available patch test (odds ratio 7.14 [95% confidence interval 5.11, 9.97], p &lt; .001) than those who were not SPD members. SPD members also had significantly lower odds of performing North American Contact Dermatitis Group standard tests than nonmembers. CONCLUSIONS: The frequency of patch test evaluations in children is significantly underreported. This study provides insight into the practice patterns of various providers who are patch testing children and makes recommendations for evidence-based modifications regarding these practices. Limitations of the study include survey responder selection bias and small sample size</style></abstract><notes><style face="normal" font="default">DA - 20170525IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pde.13154</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28543809">PM:28543809</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Dermatol\20170525-JacobSE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Dermatol\20170525-JacobSE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170525, Jacob SE</style></custom2><misc3><style face="normal" font="default">10.1111/pde.13154</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41709</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vaughn,A.R.</style></author><author><style face="normal" font="default"> Tannhauser,P.</style></author><author><style face="normal" font="default"> Sivamani,R.K.</style></author><author><style face="normal" font="default"> Shi,V.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">College of Medicine, Drexel University, Philadelphia, Pennsylvania</style></auth-address><titles><title><style face="normal" font="default">Mother Nature in Eczema: Maternal Factors Influencing Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Dermatol</style></full-title></periodical><pages end="246" start="240">240-246</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Barrier dysfunction</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> Immunologic Factors</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Pennsylvania</style></keyword><keyword><style face="normal" font="default"> Philadelphia</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> Skin barrier function</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a highly prevalent chronic inflammatory skin disease. Current knowledge about the etiology of AD suggests that it is multifactorial and involves the interaction of several factors, including environmental triggers, genetics, immunologic factors, and skin barrier dysfunction. The prenatal environment has a significant influence on fetal development, including the maturation of skin barrier function. This review summarizes maternal factors that have been reported to influence the development of AD in offspring, including maternal genetics, nutrition, breastfeeding, environment, and behaviors</style></abstract><notes><style face="normal" font="default">DA - 20170519IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pde.13149</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28523877">PM:28523877</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Dermatol\2017-34-240-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Dermatol\2017-34-240-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170519, Vaughn AR</style></custom2><misc3><style face="normal" font="default">10.1111/pde.13149</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41710</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Goetz,V.L.</style></author><author><style face="normal" font="default"> Kim,K.</style></author><author><style face="normal" font="default"> Stang,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Alberta Children's Hospital; and daggerDepartments of Pediatrics and Community Health Sciences, University of Calgary, Alberta Children's Hospital Research Institute, Calgary, Alberta, Canada</style></auth-address><titles><title><style face="normal" font="default">Pediatric Anaphylaxis in the Emergency Department: Clinical Presentation, Quality of Care, and Reliability of Consensus Criteria</style></title><secondary-title><style face="normal" font="default">Pediatr Emerg Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Emerg Care</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Consensus</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Documentation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of care</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Statistics</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="4" Year="2017">2017/4/11</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The objective of this study was to describe the quality of emergency department (ED) care for pediatric patients with anaphylaxis. The secondary objectives were to describe (1) the clinical presentation of pediatric patients with anaphylaxis including the proportion of patients meeting each of the National Institute of Allergy and Infectious Diseases (NIAID) consensus criteria and subcriteria and (2) the Interrater reliability (IRR) for applying the NIAID criteria. METHODS: We conducted a retrospective cross-sectional chart review of patients seen in a pediatric ED during a 2-year period. All charts were reviewed by a trained chart reviewer with 10% abstracted by a second reviewer. Data were analyzed using descriptive statistics including proportions, medians, and interquartile range. Interrater reliability was calculated using Cohen unweighted kappa or percent agreement. RESULTS: Of the 250 charts reviewed, 84% (211) met the NIAID criteria for anaphylaxis (IRR, 1.0). Only 68% of patients received epinephrine in the ED or within 3 hours of the ED visit. Adherence was poor and IRR was variable, for measures reflecting documentation of discharge instructions and follow-up with a specialist. The IRR of reviewers for determining which patients met the NIAID criteria overall and for each subcriterion was high. CONCLUSIONS: Our findings highlight a gap between best practice and ED care. In addition, our results suggest that the NIAID criteria can reliably be used to retrospectively identify pediatric patients with anaphylaxis. Accurately identifying cases is a prerequisite for measuring gaps in management and developing interventions to improve care</style></abstract><notes><style face="normal" font="default">DA - 20170411IS - 1535-1815 (Electronic)IS - 0749-5161 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1097/PEC.0000000000001136</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28398938">PM:28398938</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Emerg Care\20170411-GoetzVL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Emerg Care\20170411-GoetzVL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170411, Goetz VL</style></custom2><misc3><style face="normal" font="default">10.1097/PEC.0000000000001136</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41711</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stridsman,C.</style></author><author><style face="normal" font="default"> Backman,H.</style></author><author><style face="normal" font="default"> Eklund,B.M.</style></author><author><style face="normal" font="default"> Ronmark,E.</style></author><author><style face="normal" font="default"> Hedman,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Health Sciences, Lulea University of Technology, Lulea, Sweden</style></auth-address><titles><title><style face="normal" font="default">Adolescent girls with asthma have worse asthma control and health-related quality of life than boys-A population based study</style></title><secondary-title><style face="normal" font="default">Pediatr Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Pulmonol</style></full-title></periodical><pages end="872" start="866">866-872</pages><volume><style face="normal" font="default">52</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> ACT Score</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="26" Month="4" Year="2017">2017/4/26</year></dates><abstract><style face="normal" font="default">BACKGROUND: Population-based studies investigating health-related quality of life (HRQoL) among asthmatic adolescents are rare. Further, among subjects with asthma, HRQoL may be affected by asthma control and severity. AIM: To investigate HRQoL in relation to asthma control and asthma severity among adolescents. METHOD: As a part of the population-based OLIN pediatric study, 266 adolescents with current asthma (14-15 yr) were identified. N = 247 completed the DISABKIDS HRQoL asthma module, including the domains impact and worry. The Asthma Control Test (ACT) was used and a disease severity score was calculated based on symptoms and medicine use. RESULTS: The prevalence of current asthma was 11%. Well-controlled asthma was reported by 15% of the adolescents, and 53% had partly controlled asthma. The prevalence of uncontrolled asthma was significantly higher among girls than boys (38% vs 25%), and girls also reported lower HRQoL scores. There was a fairly strong correlation between the ACT and DISABKIDS scores. Independent risk factors for low HRQoL impact (a score &lt;67) were female sex (OR 4.66, 95%CI 1.82-9.54) and decreased ACT scores (1.38, 1.18-1.62). Risk factors for low HRQoL worry (a score &lt;70) were female sex (3.33, 1.41-7.86), decreased ACT scores (1.35, 1.16-1.57), severe asthma (6.23, 1.46-16.50), and having current eczema (2.68, 1.00-7.24). CONCLUSION: Only a minority of the asthmatic adolescents reported well-controlled asthma, and poor asthma control and female sex were risk factors for low HRQoL. Our results demonstrate that evaluation of asthma control is of great importance for asthma management</style></abstract><notes><style face="normal" font="default">DA - 20170426IS - 1099-0496 (Electronic)IS - 1099-0496 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1002/ppul.23723</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28444980">PM:28444980</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Pulmonol\2017-52-866-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Pulmonol\2017-52-866-72.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170426, Stridsman C</style></custom2><misc3><style face="normal" font="default">10.1002/ppul.23723</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41712</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Das,L.T.</style></author><author><style face="normal" font="default"> Abramson,E.L.</style></author><author><style face="normal" font="default"> Stone,A.E.</style></author><author><style face="normal" font="default"> Kondrich,J.E.</style></author><author><style face="normal" font="default"> Kern,L.M.</style></author><author><style face="normal" font="default"> Grinspan,Z.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Healthcare Policy &amp; Research, Weill Cornell Medicine, New York, New York</style></auth-address><titles><title><style face="normal" font="default">Predicting frequent emergency department visits among children with asthma using EHR data</style></title><secondary-title><style face="normal" font="default">Pediatr Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Pulmonol</style></full-title></periodical><pages end="890" start="880">880-890</pages><volume><style face="normal" font="default">52</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Algorithms</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Learning</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective cohort study</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Statistics</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="30" Month="5" Year="2017">2017/5/30</year></dates><abstract><style face="normal" font="default">OBJECTIVE: For children with asthma, emergency department (ED) visits are common, expensive, and often avoidable. Though several factors are associated with ED use (demographics, comorbidities, insurance, medications), its predictability using electronic health record (EHR) data is understudied. METHODS: We used a retrospective cohort study design and EHR data from one center to examine the relationship of patient factors in 1 year (2013) and the likelihood of frequent ED use (>/=2 visits) in the following year (2014), using bivariate and multivariable statistics. We applied and compared several machine-learning algorithms to predict frequent ED use, then selected a model based on accuracy, parsimony, and interpretability. RESULTS: We identified 2691 children. In bivariate analyses, future frequent ED use was associated with demographics, co-morbidities, insurance status, medication history, and use of healthcare resources. Machine learning algorithms had very good AUC (area under the curve) values [0.66-0.87], though fair PPV (positive predictive value) [48-70%] and poor sensitivity [16-27%]. Our final multivariable logistic regression model contained two variables: insurance status and prior ED use. For publicly insured patients, the odds of frequent ED use were 3.1 [2.2-4.5] times that of privately insured patients. Publicly insured patients with 4+ ED visits and privately insured patients with 6+ ED visits in a year had >/=50% probability of frequent ED use the following year. The model had an AUC of 0.86, PPV of 56%, and sensitivity of 23%. CONCLUSION: Among children with asthma, prior frequent ED use and insurance status strongly predict future ED use</style></abstract><notes><style face="normal" font="default">DA - 20170530IS - 1099-0496 (Electronic)IS - 1099-0496 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1002/ppul.23735</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28557381">PM:28557381</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Pulmonol\2017-52-880-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Pulmonol\2017-52-880-90.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170530, Das LT</style></custom2><misc3><style face="normal" font="default">10.1002/ppul.23735</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41713</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Farber,H.J.</style></author><author><style face="normal" font="default"> Silveira,E.A.</style></author><author><style face="normal" font="default"> Vicere,D.R.</style></author><author><style face="normal" font="default"> Kothari,V.D.</style></author><author><style face="normal" font="default"> Giardino,A.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Section of Pulmonology and Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas</style></auth-address><titles><title><style face="normal" font="default">Oral Corticosteroid Prescribing for Children With Asthma in a Medicaid Managed Care Program</style></title><secondary-title><style face="normal" font="default">Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatrics</style></full-title></periodical><pages end="" start="e20164146">e20164146-</pages><volume><style face="normal" font="default">139</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Medicaid</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatricians</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Texas</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVE: Short courses of oral corticosteroid (OCS) medication are recommended for treatment of moderate to severe asthma exacerbations. Concern has been raised about OCS overuse. Our objective is to describe rates of OCS dispensing among children with asthma and factors associated with variation in OCS dispensing. METHODS: Claims data for children 1 to &lt;18 years of age with an asthma diagnosis between January 2011 and January 2016 were extracted from the computerized databases of Texas Children's Health Plan. RESULTS: In the years 2011 to 2015, 17.1% to 21.8% of children had an asthma diagnosis. In each of these years 42.1% to 44.2% of these children had >/=1 OCS dispensing. OCS dispensing rates were higher for the children 1 to 4 years of age compared with older children. Repeated OCS dispensing was common, and was most common for children 1 to 4 years of age. Most children with an OCS dispensing (81%-83%) did not have other utilization suggesting poor asthma control (excessive beta-agonist refills, emergency department visit, or hospitalization for asthma). OCSs were less commonly prescribed to patients whose primary care provider was a board-certified pediatrician compared with other types of primary care providers. There was large variation in OCS prescribing rates among pediatricians (15%-86%). There were minimal differences in asthma emergency department visits and no differences in hospitalization rates by the pediatrician's OCS dispensing rate quartile. CONCLUSIONS: The patterns of dispensing observed suggest substantial overprescribing of OCS for children with an asthma diagnosis</style></abstract><notes><style face="normal" font="default">DA - 20170530IS - 1098-4275 (Electronic)IS - 0031-4005 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1542/peds.2016-4146</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28557753">PM:28557753</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatrics\2017-139-e20164146.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatrics\2017-139-e20164146.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170530, Farber HJ</style></custom2><misc3><style face="normal" font="default">10.1542/peds.2016-4146</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41714</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pawliczak,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">The sublingual tablet - a new quality in allergen immunotherapy</style></title><secondary-title><style face="normal" font="default">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pol J Allergol</style></full-title></periodical><pages end="31" start="25">25-31</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Conjunctivitis</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> GRAZAX</style></keyword><keyword><style face="normal" font="default"> Immunotherapy</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> ORALAIR</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> subcutaneous</style></keyword><keyword><style face="normal" font="default"> sublingual</style></keyword><keyword><style face="normal" font="default"> Sublingual immunotherapy</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> tablet</style></keyword><keyword><style face="normal" font="default"> Tablets</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year><pub-dates><date Day="0" Month="3" Year="2017">2017/3</date></pub-dates></dates><isbn><style face="normal" font="default">2353-3854</style></isbn><abstract><style face="normal" font="default">Abstract Allergen immunotherapy has a well-established role in the treatment of allergic rhinitis and conjunctivitis. Sublingual allergen immunotherapy seems to have a similar impact on symptoms and medication score as compared to classic, subcutaneous immunotherapy. Due to the fact that sublingual immunotherapy utilizes several approaches, in this review we are comparing clinical trials data for two of the most common allergen tablets, Grazax and Oralair. Based on these data we suggest that pre and co-seasonal treatment is efficient only when Oralair is prescribed, whereas Grazax should be used in only in an all-year-around manner in order to obtain clinical efficacy. Further, more well-designed clinical trials are needed to establish the pre and co-seasonal treatment efficacy with Grazax</style></abstract><notes><style face="normal" font="default">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.alergo.2017.02.005</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.alergo.2017.02.005</url></web-urls></urls><custom2><style face="normal" font="default">20170611, Pawliczak R</style></custom2><misc3><style face="normal" font="default">10.1016/j.alergo.2017.02.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41715</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kokot,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Asthma treatment today and tomorrow - personal perspective</style></title><secondary-title><style face="normal" font="default">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pol J Allergol</style></full-title></periodical><pages end="24" start="20">20-24</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anti-Asthmatic Agents</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Attitude</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Evidence-Based Medicine</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Personalized medicine</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Precision med.</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year><pub-dates><date Day="0" Month="3" Year="2017">2017/3</date></pub-dates></dates><isbn><style face="normal" font="default">2353-3854</style></isbn><abstract><style face="normal" font="default">Abstract Contemporary asthma treatment has been started with inhaled corticosteroids</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖ introduction to the common medical practice. Universal abundance of this kind of treatment completely changed the clinical picture of asthma and therefore these drugs permanently entered the treatment canon. Current attitude to asthma pharmacotherapy was shaped by the evidence based medicine paradigm. That time inhaled long acting beta 2 mimetics were launched as well. Today, still inhaled corticosteroids and long acting beta 2 mimetics are the mainstay asthma treatment. Beginning of the XXI century was the stormy entrance of the new personalized medicine paradigm and the crisis of the evidence-based medicine could be noticed as a result. These new concepts influence more and more the current asthma treatment. Especially the new biologics and pharmacotherapy tailored to individual patients needs will form the future of the medical behavior in this area</style></abstract><notes><style face="normal" font="default">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.alergo.2017.02.006</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.alergo.2017.02.006</url></web-urls></urls><custom2><style face="normal" font="default">20170611, Kokot M</style></custom2><misc3><style face="normal" font="default">10.1016/j.alergo.2017.02.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41716</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kuna,P.</style></author><author><style face="normal" font="default"> Jurkiewicz,D.</style></author><author><style face="normal" font="default"> Czarnecka-Operacz,M.M.</style></author><author><style face="normal" font="default"> Pawliczak,R.</style></author><author><style face="normal" font="default"> Woron,J.</style></author><author><style face="normal" font="default"> Moniuszko,M.</style></author><author><style face="normal" font="default"> Emeryk,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">The role and choice criteria of antihistamines in allergy management </style><style face="normal" font="Symbol">-</style><style face="normal" font="default"> Expert opinion</style></title><secondary-title><style face="normal" font="default">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pol J Allergol</style></full-title></periodical><pages end="19" start="7">7-19</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Absenteeism</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Bilastin</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Choice criteria</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> standards</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year><pub-dates><date Day="0" Month="3" Year="2017">2017/3</date></pub-dates></dates><isbn><style face="normal" font="default">2353-3854</style></isbn><abstract><style face="normal" font="default">Abstract Allergic diseases are the most common chronic conditions lasting throughout the patient's life. They not only cause significant deterioration in the quality of life of patients but also lead to significant absenteeism and reduced productivity, resulting in very high costs for society. Effective and safe treatment of allergic diseases is therefore one of the main challenges for public health and should be carried out by all the specialists in family medicine, internists and paediatricians in collaboration with allergists, otorhinolaryngologists and dermatologists. Antihistamines are most commonly used in the treatment of allergies. Several dozen drugs are available on the pharmaceutical market, and their generic forms are advertised widely as very effective drugs for the treatment of allergic diseases. What is the truth? What are the data from clinical trials and observational studies? Are all drugs equally effective and safe for the patient? According to a panel of experts representing various fields of medicine, inappropriate treatment of allergies can be very risky for patients, and seemingly equally acting medications may differ greatly. Therefore, a panel of experts gathered the latest data from the entire scientific literature and analyzed the latest standards and recommendations prepared by scientific societies. This paper provides a summary of these studies and highlights the importance for the patient of the proper choice of drug to treat his allergies</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="default">https://doi.org/10.1016/j.alergo.2017.02.001</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.alergo.2017.02.001</url></web-urls></urls><custom2><style face="normal" font="default">20170611, Kuna P</style></custom2><misc3><style face="normal" font="default">https://doi.org/10.1016/j.alergo.2017.02.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41717</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ograczyk,A.</style></author><author><style face="normal" font="default"> Miniszewska,J.</style></author><author><style face="normal" font="default"> Pietrzak,A.</style></author><author><style face="normal" font="default"> Zalewska-Janowska,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Psychodermatology Department, Medical University of Lodz, Lodz, Poland</style></auth-address><titles><title><style face="normal" font="default">Sense of coherence as a protective factor in chronic urticaria</style></title><secondary-title><style face="normal" font="default">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Postepy Dermatol Alergol</style></full-title></periodical><pages end="173" start="168">168-173</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anxiety</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Life quality</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Psychological intervention</style></keyword><keyword><style face="normal" font="default"> QOL</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Chronic urticaria (CU) seems to be perceived as a psychodermatological disorder. Different psychological factors play an important role in CU triggering and course. One of them is a sense of coherence (SOC), which is believed to be a protective factor against anxiety and depression. AIM: To investigate quality of life (QoL) in CU patients and to compare selected psychological parameters (anxiety, depression and sense of coherence) between CU individuals and the control group. MATERIAL AND METHODS: The study comprised 46 female patients with chronic urticaria and 33 healthy females as a control group. The following methods were employed: Urticaria Activity Score (UAS), Hospital Anxiety and Depression Scale (HADS), Sense of Coherence Questionnaire (SOC-29) and Dermatology Life Quality Index (DLQI). RESULTS: The CU patients presented a significantly higher anxiety level in comparison to the control group (z = 4.488; p &lt; 0.001). There were no statistically significant differences regarding depression intensity and SOC. In both groups anxiety and depression negatively correlated with global SOC and all its components. Disease severity positively correlated with QoL (rho = 0.46, p &lt; 0.01) and negatively with global SOC (rho = -0.33, p &lt; 0.05). CONCLUSIONS: Bearing in mind higher prevalence of anxiety and depressive symptoms in our CU group, it would be useful to perform screening of these aspects in all CU patients and subsequently develop respective psychological interventions, based on enhancement of personal resources</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.5114/ada.2017.67084</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28507497">PM:28507497</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-168-73.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-168-73.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Ograczyk A</style></custom2><misc3><style face="normal" font="default">10.5114/ada.2017.67084</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41718</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hadasik,K.</style></author><author><style face="normal" font="default"> Bergler-Czop,B.</style></author><author><style face="normal" font="default"> Miziolek,B.</style></author><author><style face="normal" font="default"> Salwowska,N.</style></author><author><style face="normal" font="default"> Skrzypek-Salamon,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, School of Medicine, Medical University of Silesia, Katowice, Poland</style></auth-address><titles><title><style face="normal" font="default">Pruritus ani and perianal eczema as a manifestation of systemic contact dermatitis</style></title><secondary-title><style face="normal" font="default">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Postepy Dermatol Alergol</style></full-title></periodical><pages end="176" start="174">174-176</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Pruritus Ani</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.5114/ada.2017.67085</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28507498">PM:28507498</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-174-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-174-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Hadasik K</style></custom2><misc3><style face="normal" font="default">10.5114/ada.2017.67085</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41719</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Butterfield,J.H.</style></author><author><style face="normal" font="default"> Kane,G.C.</style></author><author><style face="normal" font="default"> Weiler,C.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Division of Allergic Diseases, and Mayo Clinic Program for Mast Cell and Eosinophilic Disorders , Mayo Clinic , Rochester , MN , USA</style></auth-address><titles><title><style face="normal" font="default">Hypereosinophilic syndrome: endomyocardial biopsy versus echocardiography to diagnose cardiac involvement</style></title><secondary-title><style face="normal" font="default">Postgrad Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Postgrad Med</style></full-title></periodical><pages end="523" start="517">517-523</pages><volume><style face="normal" font="default">129</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">abnormalities</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Echocardiography</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Enzymes</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic Fasciitis</style></keyword><keyword><style face="normal" font="default"> Fasciitis</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Gastroenteritis</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Hypereosinophilia</style></keyword><keyword><style face="normal" font="default"> Hypereosinophilic Syndrome</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prednisone</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum tryptase</style></keyword><keyword><style face="normal" font="default"> Staining</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="25" Month="4" Year="2017">2017/4/25</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To compare echocardiograms and endomyocardial biopsies to diagnose cardiac involvement in hypereosinophilic syndrome. METHODS: We examined the agreement between echocardiography and endomyocardial biopsies to detect cardiac involvement in hypereosinophilic syndrome by reviewing cases identified as hypereosinophilia or hypereosinophilic syndrome in Mayo Clinic databases from January 1978 through June 2009. Single-organ cases of eosinophilia such as eosinophilic fasciitis and eosinophilic gastroenteritis were excluded. We recorded echocardiogram and endomyocardial biopsy results including biopsy staining for eosinophil granule major basic protein (if performed). Clinical and laboratory features documented included presenting symptom(s), maximum total eosinophil count, dose of prednisone (if any) and eosinophil count at the time of endomyocardial biopsy, cardiac enzymes, serum tryptase level, electrocardiogram result, the result of testing for the FIP1L1-PDGFRA fusion gene, complications associated with the biopsy procedures and available follow-up information. RESULTS: From a total of 387 patients' records screened 288 met the criteria for hypereosinophilic syndrome and of these 240 had echocardiograms. Among these patients there were 138 normal echocardiograms, 67 had echocardiograms without findings of hypereosinophilic syndrome but with one or more other abnormalities, and 35 had echocardiograms with findings consistent with hypereosinophilic syndrome. Twenty-five patients from this group of 35 patients had both echocardiogram and endomyocardial biopsy. In 15 patients there was agreement between both endomyocardial biopsy and echocardiography as to the presence (n = seven) or absence (n = eight) for findings of cardiac involvement. In 10 of 25 patients test results diverged: 3 patients with positive echocardiographic changes did not have confirmatory findings by endomyocardial biopsy and seven patients with positive biopsy findings had echocardiograms without findings of hypereosinophilic syndrome. CONCLUSIONS: Echocardiograms and endomyocardial biopsies agree for presence or absence of cardiac involvement 60% of the time. Endomyocardial biopsy detected cardiac involvement in 7 patients in whom the echocardiogram was negative for findings of hypereosinophilic syndrome</style></abstract><notes><style face="normal" font="default">DA - 20170425IS - 1941-9260 (Electronic)IS - 0032-5481 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/00325481.2017.1317215</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28440714">PM:28440714</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Postgrad Med\2017-129-517-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">f:\A&amp;H LMW Papers\Postgrad Med\2017-129-517-23.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170425, bUTTERFIELD jh</style></custom2><misc3><style face="normal" font="default">10.1080/00325481.2017.1317215</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41720</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bil,W.</style></author><author><style face="normal" font="default"> Schuur,A.G.</style></author><author><style face="normal" font="default"> Ezendam,J.</style></author><author><style face="normal" font="default"> Bokkers,B.G.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default">Probabilistic derivation of the interspecies assessment factor for skin sensitization</style></title><secondary-title><style face="normal" font="default">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="44" start="34">34-44</pages><volume><style face="normal" font="default">88</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Assessment</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="22" Month="5" Year="2017">2017/5/22</year></dates><abstract><style face="normal" font="default">An interspecies sensitization assessment factor (SAF) is used in the quantitative risk assessment (QRA) for skin sensitization when a murine-based NESIL (No Expected Sensitization Induction Level) is taken as point of departure. Several studies showed that, on average, the murine sensitization threshold is in good correspondence with that determined in humans. However, on an individual level, the murine and human sensitization thresholds may differ considerably. In this study, the interspecies SAF was quantified by using a probabilistic approach, to be able to take these cases into account. As expected, the geometric means of the probability distributions of murine and human sensitization threshold ratios were close to one, but taking the 95 th percentile of these distributions resulted in an interspecies SAF of 15. By using this value, one is sure that with 95% probability, the sensitization threshold determined in mice does not underestimate the human threshold. It can be concluded that a murine-based NESIL requires the use of an interspecies SAF (of 15) in the QRA for skin sensitization, to correct for the differences between mice and humans. This empirically derived interspecies SAF contributes to refinement of the risk assessment methodology</style></abstract><notes><style face="normal" font="default">DA - 20170526IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.yrtph.2017.05.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28545776">PM:28545776</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2017-88-34-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\2017-88-34-44.pdf</url></text-urls><related-urls><url ppv-ref="no">xlsx in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20170526, Bil W</style></custom2><misc3><style face="normal" font="default">10.1016/j.yrtph.2017.05.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41721</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Plourde,A.</style></author><author><style face="normal" font="default"> Lavoie,K.L.</style></author><author><style face="normal" font="default"> Raddatz,C.</style></author><author><style face="normal" font="default"> Bacon,S.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Montreal Behavioural Medicine Centre, CIUSSS-NIM, Hopital du Sacre-Coeur de Montreal, Canada; Research Centre, CIUSSS-NIM, Hopital du Sacre-Coeur de Montreal, Canada</style></auth-address><titles><title><style face="normal" font="default">Effects of acute psychological stress induced in laboratory on physiological responses in asthma populations: A systematic review</style></title><secondary-title><style face="normal" font="default">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respir Med</style></full-title></periodical><pages end="32" start="21">21-32</pages><volume><style face="normal" font="default">127</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Bronchi</style></keyword><keyword><style face="normal" font="default"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> cortisol</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nervous System</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Sympathetic Nervous System</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Psychological stress has long been suspected to have a deleterious effect on asthma, with acute psychological stress being associated with physiological responses in asthma patients. OBJECTIVES: The purpose of this systematic review was to provide a narrative synthesis of the impact of acute laboratory psychological stress on physiological responses among asthma patients. METHODS: An extensive search was conducted by two independent authors using Pubmed, PsycINFO, PsyArticles and the Cochrane Library electronic databases (up to September 2016). English and French articles which assessed physiological responses during or post-stress and compare them to baseline or pre-stress values were included. RESULTS: Thirty-two studies met the inclusion criteria. Studies indicated that exposure to active stressors (e.g., arithmetic tasks) was associated with an increase in sympathetic nervous system (SNS) responses, cortisol, and inflammatory responses, but had little effect on the caliber of the bronchi. Exposure to passive stressors (e.g., watching stressful movies or pictures) was also associated with an increase in SNS responses and with mild bronchoconstriction. However, a paucity of data for passive stressors limited conclusions on other measures. CONCLUSIONS: In patients with asthma, both active and passive stressors seem to be associated with an increased activation of the SNS. Passive stressors seem to have a more immediate, deleterious impact on the airways than active stressors, but the latter may be associated with delayed inflammatory driven an asthma exacerbation. Further studies are needed to understand the impact of acute stressors on the physiological mechanisms associated with asthma, particularly HPA and immune markers. Systematic review registration number: CRD42015026431</style></abstract><notes><style face="normal" font="default">DA - 20170515IS - 1532-3064 (Electronic)IS - 0954-6111 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.rmed.2017.03.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28502415">PM:28502415</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respir Med\2017-127-21-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respir Med\2017-127-21-32.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170515, Plourde A</style></custom2><misc3><style face="normal" font="default">10.1016/j.rmed.2017.03.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41722</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sole,D.</style></author><author><style face="normal" font="default"> Urrutia-Pereira,M.</style></author><author><style face="normal" font="default"> Sisul-Alvariza,J.C.</style></author><author><style face="normal" font="default"> Jares,E.J.</style></author><author><style face="normal" font="default"> Sanchez-Borges,M.</style></author><author><style face="normal" font="default"> Ansotegui,I.J.</style></author><author><style face="normal" font="default"> Cruz,A.A.</style></author><author><style face="normal" font="default"> Chong-Neto,H.J.</style></author><author><style face="normal" font="default"> Rosario,N.</style></author><author><style face="normal" font="default"> Gonzalez-Diaz,S.N.</style></author><author><style face="normal" font="default"> Badellino,H.</style></author><author><style face="normal" font="default"> Valentin-Rostan,M.</style></author><author><style face="normal" font="default"> Gomez,R.M.</style></author><author><style face="normal" font="default"> Teijeiro,A.</style></author><author><style face="normal" font="default"> Ensina,L.F.</style></author><author><style face="normal" font="default"> Cocco,R.</style></author><author><style face="normal" font="default"> Saccardo-Sarni,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universidad Federal de Sao Paulo. Sao Paulo, Brasil.</style></auth-address><titles><title><style face="normal" font="default">[The Jerusalem Chapter: A new paradigm in the care of allergic children and adolescents in Latin-American schools]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="6" start="3">3-6</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170211IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28188707">PM:28188707</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-3-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-3-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170211, Sole D</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41723</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Calderon,J.C.</style></author><author><style face="normal" font="default"> Davila,F.</style></author><author><style face="normal" font="default"> Mantilla,R.</style></author><author><style face="normal" font="default"> Cherrez,A.</style></author><author><style face="normal" font="default"> Calero,E.</style></author><author><style face="normal" font="default"> Cabrera,D.</style></author><author><style face="normal" font="default"> Cherrez-Ojeda,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universidad de Especialidades Espiritu Santo, Escuela de Medicina. Samborondon, Ecuador</style></auth-address><titles><title><style face="normal" font="default">[Knowledge and attitudes about aspirin exacerbated respiratory disease among Ecuadorian physicians]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="23" start="13">13-23</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AERD</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> Attitude</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Ecuador</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> General practitioner</style></keyword><keyword><style face="normal" font="default"> General practitioners</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is an asthma phenotype that involves high costs and significant burden for health systems. OBJECTIVE: To determine the level of knowledge and attitudes towards AERD among Ecuadorian physicians. METHODS: Descriptive, observational study. A questionnaire about knowledge on the disease and attitude towards it (confidence in the treatment and importance of AERD, measured with a Likert scale) was developed. The answers about knowledge were dichotomized into right and wrong; attitude was rated as high or low. Means and percentages were obtained; the answers of doctors with or without specialty were compared using the chi-square test. RESULTS: One-hundred eighteen physicians participated. The age was 41.3 +/- 11.7 years; 48.3 % were specialists. Less than 50% answered correctly the questions about knowledge. Specialist physicians obtained more correct answers regarding first symptoms, prevalence and leukotriene overproduction (67.9 %, 46.3% and 90.7 %), when compared with general practitioners (45.0 %, 25% and 74.6 %) (p &lt; 0.05). More than 70 % of physicians indicated high confidence in the identification of patients with AERD. There were no significant differences in attitudes (p > 0.05). CONCLUSION: Medical education programs should be developed in order to improve the level of knowledge about AERD</style></abstract><notes><style face="normal" font="default">DA - 20170211IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - eCUADOR -</style></notes><work-type><style face="normal" font="default">no-doi</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28188709">PM:28188709</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-13-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">f:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-13-23.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170211, Calderon JC</style></custom2><misc3><style face="normal" font="default">no-doi</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41724</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bevilacqua-Alen,E.</style></author><author><style face="normal" font="default"> Illodo-Miramontes,G.</style></author><author><style face="normal" font="default"> Lopez-Gonzalez,J.M.</style></author><author><style face="normal" font="default"> Jimenez-Gomez,B.M.</style></author><author><style face="normal" font="default"> Lopez-Freire,S.</style></author><author><style face="normal" font="default"> Carballada-Gonzalez,F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Anesthetic management of muscle relaxant allergy</style></title><secondary-title><style face="normal" font="default">Rev Arg Anestesiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Arg Anestesiol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Alergia</style></keyword><keyword><style face="normal" font="default"> Alergia perioperatoria</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anafilaxia</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Anestesia</style></keyword><keyword><style face="normal" font="default"> Anesthesia</style></keyword><keyword><style face="normal" font="default"> Bloqueantes neuromusculares</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Efectos secundarios</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Neuromuscular Blocking Agents</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Perioperative allegy</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Tratamiento</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0370-7792</style></isbn><abstract><style face="normal" font="default">Resumen La alergia perioperatoria puede ser un cuadro cl+¡nico que amenaza la vida del paciente. El primer causa es la alergia a relajantes musculares. El objetivo de este art+¡culo es hacer una revisi+¦n del diagn+¦stico y el tratamiento de estas reacciones. Se realiz+¦ una b+¦squeda bibliogr+ífica en PubMed en enero del 2015 con las palabras clave indicadas. Abstract perioperative allergy may be a life threatening clinical condition. The most commonly involved agent are muscle relaxant. The aim of this article was to review diagnosis and treatment of these reactions. We performed a search in PubMed in January 2015 using keywords above</style></abstract><notes><style face="normal" font="default">LA - SPACO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.raa.2017.01.005</style></work-type><urls><web-urls><url ppv-ref="no">http://doi.org/10.1016/j.raa.2017.01.005</url></web-urls></urls><custom2><style face="normal" font="default">20170610, Bevilacqua-Alen E</style></custom2><misc3><style face="normal" font="default">10.1016/j.raa.2017.01.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41725</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fernandez Martin,M.T.</style></author><author><style face="normal" font="default"> Alvarez Lopez,J.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Sevoflurane anaesthesia for nasal surgery in a patient with multiple chemical sensitivity</style></title><secondary-title><style face="normal" font="default">Rev Esp Anestesiol Reanim</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Rev Esp Anestesiol Reanim</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Anaesthesia</style></keyword><keyword><style face="normal" font="default"> Anestesia</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Environmental allergy</style></keyword><keyword><style face="normal" font="default"> Fatigue</style></keyword><keyword><style face="normal" font="default"> Fentanyl</style></keyword><keyword><style face="normal" font="default"> Multiple Chemical Sensitivity</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal surgery</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Psychiatric disorder</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Sevoflurane</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Symptomatology</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Toxins</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0034-9356</style></isbn><abstract><style face="normal" font="default">Multiple chemical sensitivity syndrome is a group of complex disorders that include psychiatric disorders, chronic fatigue and/or respiratory problems. This syndrome could be triggered by specific allergens and toxins that cause neurophysiological sensitization and the appearance of the clinical symptomatology. Anaesthesia for these patients always poses a challenge for the anaesthetist, because they need to find and use drugs that do not trigger or aggravate the symptoms of the disease. Therefore, sevoflurane in these circumstances might be </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç£the ideal anaesthetic</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇØ. Performing general anaesthesia with sevoflurane as the sole anaesthetic agent, together with a series of environmental measures formed the basis for successful anaesthesia and surgery in our patient with a multiple chemical sensitivity syndrome</style></abstract><notes><style face="normal" font="default">LA - SPACO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.redar.2017.03.018</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.redar.2017.03.018</url></web-urls></urls><custom2><style face="normal" font="default">20170610, Fernandez Martin MT</style></custom2><misc3><style face="normal" font="default">10.1016/j.redar.2017.03.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41726</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Benhamou,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Scrambling des phospholipides et Phospholipid Scramblase-á1 (PLSCR1) dans les mastocytes activ+®s</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Activation signals</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Chemokines</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Cytoplasmic Granules</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Granules</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Lipid</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mastocyte</style></keyword><keyword><style face="normal" font="default"> Mastocytes</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Phospholipid scramblase-á1</style></keyword><keyword><style face="normal" font="default"> Phospholipid scrambling</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptor Aggregation</style></keyword><keyword><style face="normal" font="default"> Repair</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Scrambling</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Following activation, mast cells can release an array of mediators stored in their cytoplasmic granules or synthesized de novo (lipid mediators, cytokines, chemokines, growth factors). While these cells are critically involved in type-áI hypersensitivity reactions (mainly through the release of their granule content), they also play a number of positive roles in organizing the immune response and in tissue repair constitutive of the inflammatory reaction. New therapeutic approaches in allergology selectively targeting mast-cell degranulation could enable the essential physiologic functions of these cells to be maintained while expanding available antiallergy therapeutic options. We have identified phospholipid scramblase-á1 (PLSCR1) as an amplifier of mast-cell degranulation induced by immunoglobulin-áE receptor aggregation. Herein, we review current knowledge on the role of membrane phospholipid scrambling and of phospholipid scramblase-á1 in activated mast cells</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.02.235</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.02.235</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170610-BenhamouM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170610-BenhamouM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170610, Benhamou M</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.02.235</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41727</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cisamolo,I.</style></author><author><style face="normal" font="default"> Duquesne,O.</style></author><author><style face="normal" font="default"> Escourrou,B.</style></author><author><style face="normal" font="default"> Didier,A.</style></author><author><style face="normal" font="default"> Oustric,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Reiterating to adolescents that they have asthma. A qualitative study using semi-structured interviews</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescence</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> chronic illness</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Interviews</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Qualitative Research</style></keyword><keyword><style face="normal" font="default"> Qualitative study</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutic education</style></keyword><keyword><style face="normal" font="default"> Therapeutic non-compliance</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Non-compliance is a problem in the treatment of adolescents with asthma. Objectives To study experience of healthcare management for adolescents with asthma and to explore reasons for non-compliance. Patients and methods Qualitative research using semi-structured interviews and thematic analysis involving 16 adolescents with asthma between August 2013 and March 2014 in the Midi-Pyr+®n+®es region of southern France. Results Four main themes emerged: Experience of medication, experience of healthcare, experience of and reflexion on educational methods, the role of parents. Treatment compliance runs counter to the will of adolescents, who wish to assume a more active role in the design of their therapeutic project. Parents have an important and complex part to play in their child's healthcare management. Conclusion To anticipate hurdles to therapeutic compliance, it appears to be of value to renew the announcement to adolescents of their asthmatic disease taking into account their improved knowledge and awareness of their disease</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.03.005</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.03.005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170610-CisamoloI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170610-CisamoloI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170610, Cisamolo I</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.03.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41728</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mjid,M.</style></author><author><style face="normal" font="default"> Belloumi,N.</style></author><author><style face="normal" font="default"> Hedhli,A.</style></author><author><style face="normal" font="default"> Toujani,S.</style></author><author><style face="normal" font="default"> Ouahchi,Y.</style></author><author><style face="normal" font="default"> Cherif,J.</style></author><author><style face="normal" font="default"> Beji,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Factors associated with asthma control in Tunisian adults</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Age of Onset</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Observance</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Recommandations</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Sex Ratio</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Teaching</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Tunisia</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Introduction The key objective of asthma management is to achieve optimal control of the disease. Despite current recommendations, asthmatics remain largely insufficiently controlled. Aims To evaluate asthma control and to determine factors associated with asthma control in patients followed in a teaching hospital in Tunis. Patients and methods A cross-sectional study was carried out at the allergy department of Rabta Hospital in Tunis. Asthmatic patients were included. Sociodemographic data, comorbidities, smoking status and history of asthma were recorded. Asthma control was assessed using the Asthma Control Test (ACT) score. Compliance to treatment was specified according to the Morisky questionnaire (4-áitems). Associations between asthma control and patient characteristics were investigated. Results During the study period, 140 patients (mean age: 47 -¦ 16-áyears, sex ratio: 0.53) were included. Seventy-eight patients had severe asthma. According to the Morisky questionnaire, 52.9% were compliant with their treatment. Asthma control was achieved in 76-ápatients (54%). The main causes of poor control were low socioeconomic conditions, presence of comorbidities, age of onset and disease duration. Conclusion Improved knowledge of the predictive factors for poor control of asthma enables the introduction of targeted action to improve the control of the disease</style></abstract><notes><style face="normal" font="default">LA - FRECO - Tunisia -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.03.003</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.03.003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170610-MjidM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170610-MjidM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170610, Mjid M</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.03.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41729</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Baghad,B.</style></author><author><style face="normal" font="default"> Elfiboumi,A.</style></author><author><style face="normal" font="default"> Elfatoiki,F.Z.</style></author><author><style face="normal" font="default"> Chiheb,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Two cases of hemorrhagic cystitis induced by penicillin G used to treat actinomycosis</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Actinomycosis</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Cessation</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> Cystitis</style></keyword><keyword><style face="normal" font="default"> Hemorrhagic cystitis</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Morocco</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin G</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">The reference treatment for actinomycosis is high-dose intravenous penicillin G over an extended period. Herein, we report two cases of hemorrhagic cystitis probably induced by penicillin G, with disappearance of symptoms after cessation of treatment. In the literature, only a few similar cases have been reported, and penicillin G-induced hemorrhagic cystitis remains a rare and unexplained complication</style></abstract><notes><style face="normal" font="default">LA - FRECO - Morocco -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.02.243</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.02.243</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170610-BaghadB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170610-BaghadB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170610, Baghad B</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.02.243</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41730</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wawrzynski,J.</style></author><author><style face="normal" font="default"> Gil,J.A.</style></author><author><style face="normal" font="default"> Goodman,A.D.</style></author><author><style face="normal" font="default"> Waryasz,G.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Warren Alpert Medical School, Brown University, Providence, RI, USADepartment of Orthopaedic Surgery, Warren Alpert Medical School, Brown University, Providence, RI, USA.</style></auth-address><titles><title><style face="normal" font="default">Hypersensitivity to Orthopedic Implants: A Review of the Literature</style></title><secondary-title><style face="normal" font="default">Rheumatol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rheumatol Ther</style></full-title></periodical><pages end="56" start="45">45-56</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Arthroplasty</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Communication</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Differential diagnosis</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metal allergies</style></keyword><keyword><style face="normal" font="default"> Metal allergy</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">Awareness of rare etiologies for implant failure is becoming increasingly important. In addition to the overall increase in joint arthroplasties, revision surgeries are projected to increase dramatically in the coming years, with volume increasing up to seven-fold between 2005 and 2030. The literature regarding the relationship between metal allergy and implant failure is controversial. It has proven difficult to determine whether sensitization is a cause or a consequence of implant failure. Testing patients with functional implants is not a clinically useful approach, as the rate of hypersensitivity is higher in implant recipients than in the general population, regardless of the status of the implant. As a result of the ineffectiveness of preoperative patch testing for predicting adverse outcomes, as well as the high cost of implementing such patch testing as standard procedure, most orthopedists and dermatologists agree that an alternative prosthesis should only be considered for patients with a history of allergy to a metal in the standard implant. In patients with a failed implant requiring revision surgery, hypersensitivity to an implant component should be considered in the differential diagnosis. Because a metal allergy to implant components is currently not commonly considered in the differential for joint failure in the orthopedic literature, there should be improved communication and collaboration between orthopedists and dermatologists when evaluating joint replacement patients with a presentation suggestive of allergy</style></abstract><notes><style face="normal" font="default">DA - 20170401IS - 2198-6576 (Print)IS - 2198-6576 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s40744-017-0062-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28364382">PM:28364382</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rheumatol Ther\2017-4-45-56.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rheumatol Ther\2017-4-45-56.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170401, Wawrzynski J</style></custom2><misc3><style face="normal" font="default">10.1007/s40744-017-0062-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41731</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Verheyen,G.R.</style></author><author><style face="normal" font="default"> Braeken,E.</style></author><author><style face="normal" font="default"> Van Deun,K.</style></author><author><style face="normal" font="default"> Van Miert,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">a RADIUS group , Thomas More University College , Geel , Belgium</style></auth-address><titles><title><style face="normal" font="default">Evaluation of in silico tools to predict the skin sensitization potential of chemicals</style></title><secondary-title><style face="normal" font="default">SAR QSAR Environ Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">SAR QSAR Environ Res</style></full-title></periodical><pages end="73" start="59">59-73</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Commercial</style></keyword><keyword><style face="normal" font="default"> Computer Simulation</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Contact</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Hazardous Substances</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Models,Statistical</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Predictive Value of Tests</style></keyword><keyword><style face="normal" font="default"> Predictive values</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> Structure-Activity Relationship</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">Public domain and commercial in silico tools were compared for their performance in predicting the skin sensitization potential of chemicals. The packages were either statistical based (Vega, CASE Ultra) or rule based (OECD Toolbox, Toxtree, Derek Nexus). In practice, several of these in silico tools are used in gap filling and read-across, but here their use was limited to make predictions based on presence/absence of structural features associated to sensitization. The top 400 ranking substances of the ATSDR 2011 Priority List of Hazardous Substances were selected as a starting point. Experimental information was identified for 160 chemically diverse substances (82 positive and 78 negative). The prediction for skin sensitization potential was compared with the experimental data. Rule-based tools perform slightly better, with accuracies ranging from 0.6 (OECD Toolbox) to 0.78 (Derek Nexus), compared with statistical tools that had accuracies ranging from 0.48 (Vega) to 0.73 (CASE Ultra - LLNA weak model). Combining models increased the performance, with positive and negative predictive values up to 80% and 84%, respectively. However, the number of substances that were predicted positive or negative for skin sensitization in both models was low. Adding more substances to the dataset will increase the confidence in the conclusions reached. The insights obtained in this evaluation are incorporated in a web database www.asopus.weebly.com that provides a potential end user context for the scope and performance of different in silico tools with respect to a common dataset of curated skin sensitization data</style></abstract><notes><style face="normal" font="default">DA - 20170120IS - 1029-046X (Electronic)IS - 1026-776X (Linking)LA - engPT - Journal ArticleRN - 0 (Allergens)SB - IMCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1080/1062936X.2017.1278617</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28105856">PM:28105856</url></web-urls></urls><custom2><style face="normal" font="default">20170120, Verheyen GR</style></custom2><misc3><style face="normal" font="default">10.1080/1062936X.2017.1278617</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41732</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mansour,A.I.</style></author><author><style face="normal" font="default"> Abd Almonaem,E.R.</style></author><author><style face="normal" font="default"> Behairy,O.G.</style></author><author><style face="normal" font="default"> Gouda,T.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Departments of Clinical and Chemical Pathology , Benha University , Benha , Egypt</style></auth-address><titles><title><style face="normal" font="default">Predictive value of IL-35 and IL-17 in diagnosis of childhood asthma</style></title><secondary-title><style face="normal" font="default">Scand J Clin Lab Invest</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Scand J Clin Lab Invest</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Complete Blood Count</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Egypt</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-17</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> pulmonary function test</style></keyword><keyword><style face="normal" font="default"> Pulmonary function tests</style></keyword><keyword><style face="normal" font="default"> ROC</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="30" Month="5" Year="2017">2017/5/30</year></dates><abstract><style face="normal" font="default">This study aimed to evaluate the correlation between serum levels of IL-17 and IL-35 and the presence and severity of childhood asthma. The study was performed on 60 diagnosed asthmatic children, who were further classified into four groups according to the Global Initiative for Asthma Guidelines for Asthma Severity and Control (GINA) 2016, plus 30 age- and sex-matched apparently healthy children. All participants were subjected to full medical history, clinical examination, pulmonary function tests and laboratory evaluation in the form of complete blood count (CBC), serum total IgE, IL-17 and IL-35 by ELISA. Our results revealed that eosinophils count, IgE and IL-17 were significantly higher in the asthmatic group than the control group (p &lt; .001), while IL-35 levels were significantly lower in asthmatics than control (p &lt; .001). A strong negative correlation was found between serum IL-17 and serum IL-35; a positive correlation was found between serum IL-17 and both of serum total IgE and eosinophils counts in atopic asthmatic patients, and serum IL-35 showed significant negative correlations with both. ROC analysis of the data showed that the cut-off value of IL-35 level was &lt;189.5 pg/mL and for IL-17 level, it was >13.1 pg/mL; this value could predict childhood asthma with sensitivity of 81.7% and 83.3%, and specificity of 76.7% and 70%, respectively. A combination of both cytokines yielded an increase in sensitivity to 95%. In conclusion, in the current study, IL-17 is upregulated while IL-35 is downregulated in childhood asthma with a significant negative correlation between both. These results suggest that both may play an important role in the pathogenesis of childhood asthma</style></abstract><notes><style face="normal" font="default">DA - 20170530IS - 1502-7686 (Electronic)IS - 0036-5513 (Linking)LA - engPT - Journal ArticleCO - Egypt -</style></notes><work-type><style face="normal" font="default">10.1080/00365513.2017.1328739</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28554228">PM:28554228</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Scand J Clin Lab Invest\20170530-MansourAI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Scand J Clin Lab Invest\20170530-MansourAI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170530, Mansour AI</style></custom2><misc3><style face="normal" font="default">10.1080/00365513.2017.1328739</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41733</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Eriksson,L.M.</style></author><author><style face="normal" font="default"> Irewall,T.</style></author><author><style face="normal" font="default"> Lindberg,A.</style></author><author><style face="normal" font="default"> Stenfors,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Unit of Medicine - Ostersund, Department of Public Health and Clinical Medicine, Umea University, Umea, Sweden</style></auth-address><titles><title><style face="normal" font="default">Prevalence, age at onset, and risk factors of self-reported asthma among Swedish adolescent elite cross-country skiers</style></title><secondary-title><style face="normal" font="default">Scand J Med Sci Sports</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Scand J Med Sci Sports</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical Medicine</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Pupil</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Skiing</style></keyword><keyword><style face="normal" font="default"> Sport</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="3" Year="2017">2017/3/17</year></dates><abstract><style face="normal" font="default">The objective of the study was to compare the prevalence of self-reported physician-diagnosed asthma and age at asthma onset between Swedish adolescent elite skiers and a reference group and to assess risk factors associated with asthma. Postal questionnaires were sent to 253 pupils at the Swedish National Elite Sport Schools for cross-country skiing, biathlon, and ski-orienteering ("skiers") and a random sample of 500 adolescents aged 16-20, matched for sport school municipalities ("reference"). The response rate was 96% among the skiers and 48% in the reference group. The proportion of participants with self-reported physician-diagnosed asthma was higher among skiers than in the reference group (27 vs 19%, P=.046). Female skiers reported a higher prevalence of physician-diagnosed asthma compared to male skiers (34 vs 20%, P=.021). The median age at asthma onset was higher among skiers (12.0 vs 8.0 years; P&lt;.001). Female sex, family history of asthma, nasal allergy, and being a skier were risk factors associated with self-reported physician-diagnosed asthma. Swedish adolescent elite cross-country skiers have a higher asthma prevalence and later age at asthma onset compared to a reference population. Being an adolescent, elite skier is an independent risk factor associated with asthma</style></abstract><notes><style face="normal" font="default">DA - 20170317IS - 1600-0838 (Electronic)IS - 0905-7188 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/sms.12879</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28314090">PM:28314090</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Scand J Med Sci Sports\20170317-ErikssonLM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Scand J Med Sci Sports\20170317-ErikssonLM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170317, Eriksson LM</style></custom2><misc3><style face="normal" font="default">10.1111/sms.12879</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41734</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Murphy,V.E.</style></author><author><style face="normal" font="default"> Jensen,M.E.</style></author><author><style face="normal" font="default"> Gibson,P.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Priority Research Centre Grow Up Well, University of Newcastle, Newcastle, New South Wales, Australia</style></auth-address><titles><title><style face="normal" font="default">Asthma during Pregnancy: Exacerbations, Management, and Health Outcomes for Mother and Infant</style></title><secondary-title><style face="normal" font="default">Semin Respir Crit Care Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Semin Respir Crit Care Med</style></abbr-1></periodical><pages end="173" start="160">160-173</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> Budesonide</style></keyword><keyword><style face="normal" font="default"> Cigarette</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> congenital</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> mental health</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> Multidisciplinary team</style></keyword><keyword><style face="normal" font="default"> New South Wales</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral corticosteroids</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Perinatal</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Publications</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Wales</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">One in 10 pregnant women worldwide has asthma and of these, 10% will have a severe exacerbation requiring oral corticosteroids (OCSs) in pregnancy. This review of recent publications in the field will describe the effects of exacerbation on maternal and neonatal health, the use of asthma medications during pregnancy, and will suggest novel management approaches for asthma in pregnancy. Pregnancy results in unpredictable changes in the disease; therefore, regular monitoring of symptoms is recommended. Uncontrolled asthma is frequently described in cohorts of pregnant women with asthma, and some recent studies show associations with adverse perinatal outcomes, as previously demonstrated with exacerbations. Guidelines for the management of asthma recommend the continued use of inhaled corticosteroids (ICSs) in pregnancy, with budesonide having a particularly good safety profile. Recent data suggest small effects of asthma and/or asthma medication use on congenital malformations; however, there is less data available on the safety of ICS/long-acting beta agonist combinations, which are increasingly used for maintenance treatment. Novel management strategies are needed to address the complex needs of pregnant women with asthma. These include medication nonadherence and the presence of numerous comorbidities which can affect asthma, such as rhinitis, cigarette smoking, obesity, and mental health issues. Inflammation-based management has been shown to be effective in reducing exacerbations in pregnancy and may also improve perinatal outcomes. The involvement of a multidisciplinary team and the assessment of comorbidities have potential to improve the health of mothers and their offspring</style></abstract><notes><style face="normal" font="default">DA - 20170531IS - 1098-9048 (Electronic)IS - 1069-3424 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1055/s-0037-1600906</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28561247">PM:28561247</url></web-urls></urls><custom2><style face="normal" font="default">20170531, Murphy VE</style></custom2><misc3><style face="normal" font="default">10.1055/s-0037-1600906</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41735</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wiggans,R.E.</style></author><author><style face="normal" font="default"> Barber,C.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Infection, Immunity and Cardiovascular Science, University of Sheffield, Sheffield, UKNorthern General Hospital, Sheffield, UK</style></auth-address><titles><title><style face="normal" font="default">Metalworking fluids: a new cause of occupational non-asthmatic eosinophilic bronchitis</style></title><secondary-title><style face="normal" font="default">Thorax</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Thorax</style></full-title></periodical><pages end="580" start="579">579-580</pages><volume><style face="normal" font="default">72</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Bronchitis</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic bronchitis</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> nonasthmatic eosinophilic bronchitis</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 1468-3296 (Electronic)IS - 0040-6376 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1136/thoraxjnl-2016-208827</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28507075">PM:28507075</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Thorax\2017-72-579-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Thorax\2017-72-579-80.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Wiggans RE</style></custom2><misc3><style face="normal" font="default">10.1136/thoraxjnl-2016-208827</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41736</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Clouet,E.</style></author><author><style face="normal" font="default"> Kerdine-Romer,S.</style></author><author><style face="normal" font="default"> Ferret,P.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pierre Fabre Dermo-Cosmetics Research &amp; Development, Toxicology Division, Safety Department, Toulouse, France</style></auth-address><titles><title><style face="normal" font="default">Comparison and validation of an in vitro skin sensitization strategy using a data set of 33 chemical references</style></title><secondary-title><style face="normal" font="default">Toxicol In Vitro</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Toxicol In Vitro</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Sequence</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Test method</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Toxicology</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="21" Month="5" Year="2017">2017/5/21</year></dates><abstract><style face="normal" font="default">Allergic contact dermatitis (ACD) is an adverse health effect that develops following repeated exposure to skin sensitizing chemicals. An animal testing ban has been applied in EU, leading to development of reliably predictive non-animal methods. Several in vitro methods have been developed as alternatives but one single non-animal test method is not been sufficient to fully address since the LLNA test ban. Here, we have selected an ITS (Integrated Testing Strategy) for skin sensitization which focuses on three in vitro methods that covered the first three steps of the AOP (DPRA, SENS-IS or h-CLAT). The aim of this study was to compare these three methods due to the WoE approach based on a 2-out-of-3-assessment. The results of 33 references were compared to in vivo data (especially human). We have shown that tested firstly DPRA and SENS-IS have permitted to conclude on 29 of 33 chemicals, whereas DPRA and h-CLAT on 25, and SENS-IS and h-CLAT on 23. With this sequence, DPRA and SENS-IS and then h-CLAT in case of equivocal results, we conclude more quickly by performing fewer tests. Thereby, we have shown that it is better to follow a preferential sequence than testing chemicals simultaneously with these three methods</style></abstract><notes><style face="normal" font="default">DA - 20170525IS - 1879-3177 (Electronic)IS - 0887-2333 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.tiv.2017.05.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28539215">PM:28539215</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicol In Vitro\20170525-ClouetE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicol In Vitro\20170525-ClouetE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170525, Clouet E</style></custom2><misc3><style face="normal" font="default">10.1016/j.tiv.2017.05.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41737</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,Y.</style></author><author><style face="normal" font="default"> Le,Y.</style></author><author><style face="normal" font="default"> Zhao,W.</style></author><author><style face="normal" font="default"> Lin,Y.</style></author><author><style face="normal" font="default"> Wu,Y.</style></author><author><style face="normal" font="default"> Yu,C.</style></author><author><style face="normal" font="default"> Xiong,J.</style></author><author><style face="normal" font="default"> Zou,F.</style></author><author><style face="normal" font="default"> Dong,H.</style></author><author><style face="normal" font="default"> Cai,S.</style></author><author><style face="normal" font="default"> Zhao,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China</style></auth-address><titles><title><style face="normal" font="default">Short TSLP attenuates toluene diisocyanate (TDI)-induced airway inflammation and inhibits HMGB1-RAGE and long TSLP expression</style></title><secondary-title><style face="normal" font="default">Toxicol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Toxicol Sci</style></full-title></periodical><pages end="290" start="276">276-290</pages><volume><style face="normal" font="default">157</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Airways disease</style></keyword><keyword><style face="normal" font="default"> albumin</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Colitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> endotoxin</style></keyword><keyword><style face="normal" font="default"> epithelia</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> Epithelium</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> House dust</style></keyword><keyword><style face="normal" font="default"> house dust mite</style></keyword><keyword><style face="normal" font="default"> HSA</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human serum</style></keyword><keyword><style face="normal" font="default"> Human serum albumin</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> peptide</style></keyword><keyword><style face="normal" font="default"> Peptides</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Recombinant</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum Albumin</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> TDI</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> Toluene</style></keyword><keyword><style face="normal" font="default"> Toluene diisocyanate</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="27" Month="2" Year="2017">2017/2/27</year></dates><abstract><style face="normal" font="default">Short thymic stromal lymphopoietin (short TSLP), one of TSLP variants, exerts anti-inflammatory activities in endotoxin shock and colitis mouse models. Our latest work reported that short TSLP prevented house dust mite (HDM)-induced epithelial barrier disruption. Yet the role of short TSLP in toluene diisocyanate (TDI)-induced asthma is unknown. Male BALB/c mice were sensitized and challenged with TDI to generate a chemical-induced asthma model. Synthetic short TSLP peptides were given intranasally (i.n.) or intraperitoneally (i.p.) before each challenge. TDI significantly increased inflammation and hyperresponsiveness of airway, which were suppressed by short TSLP treatment. Levels of mouse TSLP, high mobility group box 1 (HMGB1) and receptor for advanced glycation end products (RAGE) in airway epithelium and whole lung tissues were markedly increased in TDI group compared to control mice, which were decreased after administration of short TSLP. Meanwhile, short TSLP also inhibited STAT5(Y694) phosphorylation, which was highly expressed in airways of TDI-exposure mice. In vitro, both TDI- human serum albumin (HSA) and recombinant human (rh) HMGB1 promoted long TSLP but not short TSLP gene production in human bronchial epithelial cells (16HBE). Cells pretreated with short TSLP exhibited less expression of RAGE and long TSLP and lower phosphorylation of Akt(S473), p38 MAPK(T180/Y182) and STAT5(Y694) than stimulated with TDI-HSA or rhHMGB1 alone. Results suggest that short TSLP prevents airway inflammation in a chemical-induced asthma model, which might be associated with the inhibitions of HMGB1-RAGE and long TSLP expression and STAT5(Y694) phosphorylation</style></abstract><notes><style face="normal" font="default">DA - 20170322IS - 1096-0929 (Electronic)IS - 1096-0929 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1093/toxsci/kfx043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28329851">PM:28329851</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicol Sci\2017-157-276-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicol Sci\2017-157-276-90.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170322, Wang Y</style></custom2><misc3><style face="normal" font="default">10.1093/toxsci/kfx043</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41738</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pallardy,M.</style></author><author><style face="normal" font="default"> Bechara,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Inflammation, Chimiokines et Immunopathologie, INSERM, Fac. de pharmacie - Univ.Paris-Sud, Universite Paris-Saclay, 92290, Chatenay-Malabry, France</style></auth-address><titles><title><style face="normal" font="default">Chemical or drug hypersensitivity: is the immune system clearing the danger?</style></title><secondary-title><style face="normal" font="default">Toxicol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Toxicol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adaptive</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Chimiokines</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> delayed-type hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Elimination</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> Evolution</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Glutathione</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Immune Tolerance</style></keyword><keyword><style face="normal" font="default"> immunopathology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Viruses</style></keyword></keywords><dates><year Day="4" Month="5" Year="2017">2017/5/4</year></dates><abstract><style face="normal" font="default">Hypersensitivity reaction or allergy, initially perceived as a secondary disorder, is now believed to be a major public health. For instance, contact dermatitis is a type IV delayed-type hypersensitivity reaction to skin allergens. An estimated 15-20% of the general population has acquired contact allergy. To maintain immune tolerance our immune system need to differentiate between harmful non-self and innocuous non-self. Living organisms have developed during their evolution a set of biological mechanisms to protect them from the "outside": physical barrier, inflammation, cell-based mechanisms, metabolism and elimination and biochemical pathways such as glutathione. The innate and adaptive immune systems are also involved in the protection from the "outside" by mounting specific or non-specific responses leading to the clearance of dangerous triggers such as viruses, bacteria or parasites.In the case of chemical or drug allergy, is our immune system clearing the danger resulting from environmental exposure to these harmful chemicals with a true immune response? The immune system is then triggered specifically for its role: clearing a specific problem? Alternatively, should we perceive chemical or drug hypersensitivity as an accident with uncontrolled consequences leading to immunopathology?</style></abstract><notes><style face="normal" font="default">DA - 20170504IS - 1096-0929 (Electronic)IS - 1096-0929 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1093/toxsci/kfx084</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28472426">PM:28472426</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicol Sci\20170504-PallardyM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicol Sci\20170504-PallardyM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170504, Pallardy M</style></custom2><misc3><style face="normal" font="default">10.1093/toxsci/kfx084</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41739</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fanton,N.</style></author><author><style face="normal" font="default"> Santoro,D.</style></author><author><style face="normal" font="default"> Cornegliani,L.</style></author><author><style face="normal" font="default"> Marsella,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinica Veterinaria San Siro, via Lampugnano 99, Milano, 20151, Italy</style></auth-address><titles><title><style face="normal" font="default">Increased filaggrin-metabolizing enzyme activity in atopic skin: a pilot study using a canine model of atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Vet Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergen exposure</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Canine</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cornea</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> dog</style></keyword><keyword><style face="normal" font="default"> Dogs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Enzymes</style></keyword><keyword><style face="normal" font="default"> Epidermis</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Filaggrin</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pilot study</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> Skin barrier function</style></keyword><keyword><style face="normal" font="default"> stratum corneum</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="4" Year="2017">2017/4/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Filaggrin (FLG) and its metabolites are essential for skin barrier function and hydration of the stratum corneum. Alteration of the FLG metabolism could be the basis for an abnormal skin barrier in allergic dogs. OBJECTIVES: To investigate the expression and distribution of calpain-1, caspase-14, furin and matriptase, four enzymes involved in FLG metabolism, in the skin of atopic and healthy beagles. METHODS: Skin biopsies were collected from four healthy and four atopic beagles before and after allergen exposure. The dogs were challenged for three consecutive days to mimic an acute exposure, or once weekly to mimic a chronic exposure to allergens. Skin biopsies were taken on days 0 (nonlesional), 3 and 10 in the "acute" model and on days 0 (nonlesional), 14 and 28 in the "chronic" model. Four healthy dogs were used as controls. Indirect immunofluorescence was used to analyse the distribution and the expression of FLG enzymes in a semi-quantitative manner. Five consecutive pictures/section were taken and the intensity analysed tracing the epidermis and using ImageJ on the traced areas. The enzymes' expression was compared between healthy and atopic nonlesional skin (Day 0) and over time in each group. RESULTS: All enzymes were expressed in all layers of the epidermis. A significantly higher expression of calpain-1 (P = 0.028), caspase 14 (P = 0.028) and matriptase (P = 0.028) was evident in atopic compared to control dogs on Day 0. No differences over time were seen for any enzyme analysed. CONCLUSIONS AND CLINICAL IMPORTANCE: This preliminary study suggests an abnormal catabolism of FLG in canine atopic skin</style></abstract><notes><style face="normal" font="default">DA - 20170410IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/vde.12443</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28393458">PM:28393458</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Vet Dermatol\20170410-FantonN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Vet Dermatol\20170410-FantonN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170410, Fanton N</style></custom2><misc3><style face="normal" font="default">10.1111/vde.12443</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41740</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Simpson,A.C.</style></author><author><style face="normal" font="default"> Schissler,J.R.</style></author><author><style face="normal" font="default"> Rosychuk,R.A.W.</style></author><author><style face="normal" font="default"> Moore,A.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 300 West Drake Road, Fort Collins, CO, 80525, USA</style></auth-address><titles><title><style face="normal" font="default">The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study</style></title><secondary-title><style face="normal" font="default">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Vet Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic dermatitis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Canine</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical signs</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> dog</style></keyword><keyword><style face="normal" font="default"> Dogs</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Glucocorticoids</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Janus kinase</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urinalysis</style></keyword><keyword><style face="normal" font="default"> Urinary Tract</style></keyword><keyword><style face="normal" font="default"> urine</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> veterinary</style></keyword><keyword><style face="normal" font="default"> Veterinary Medicine</style></keyword></keywords><dates><year Day="17" Month="5" Year="2017">2017/5/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Oclacitinib is a selective Janus kinase inhibitor for the treatment of canine allergic pruritus and atopic dermatitis in dogs. Glucocorticoids and ciclosporin increase urinary tract infection (UTI) frequency in dogs with inflammatory skin disease. OBJECTIVE: Prospective study to evaluate the frequency of UTI and subclinical bacteriuria in dogs with allergic dermatitis receiving oclacitinib. METHODS: Client-owned dogs >/=2 years of age with a history of allergic dermatitis without apparent history of urinary tract disease or predisposition to UTI were included. Prior to enrolment, urinalysis and quantitative urine culture were performed after a washout period of at least 14 days from systemic antimicrobial drugs and 28 days for ciclosporin and systemic glucocorticoids. Dogs received oclacitinib at labelled dosing for an intended period of 180-230 days with a follow-up urinalysis and urine culture performed regardless of urinary tract signs. Systemic antimicrobial and immune-modulating drugs were not administered during the study. RESULTS: None of the 55 dogs in this study developed UTI while receiving oclacitinib based on follow-up urinalysis and urine culture performed during a range of 58-280 days (mean 195 days). Two dogs developed self-limiting abnormal urinary tract signs without urine culture or urinalysis findings consistent with UTI. CONCLUSIONS AND CLINICAL IMPORTANCE: These findings indicate that bacteriuria is not an expected adverse effect in dogs treated with oclacitinib without a prior history of UTI or predisposing condition during this treatment period. Therefore, routine urine culture is not indicated for such dogs in the absence of abnormal urinalysis or clinical signs of urinary tract disease</style></abstract><notes><style face="normal" font="default">DA - 20170517IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/vde.12450</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28513001">PM:28513001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Vet Dermatol\20170517-Simpson AC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Vet Dermatol\20170517-Simpson AC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170517, Simpson AC</style></custom2><misc3><style face="normal" font="default">10.1111/vde.12450</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41741</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Samuels,L.E.</style></author><author><style face="normal" font="default"> Patel,V.</style></author></authors></contributors><titles><title><style face="normal" font="default">Foot dermatitis mistaken for cellulitis</style></title><secondary-title><style face="normal" font="default">Visual J Emerg Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Visual J Emerg Med</style></full-title></periodical><pages end="62" start="61">61-62</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> Cellulitis</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Foot</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><isbn><style face="normal" font="default">2405-4690</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.visj.2017.04.012</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.visj.2017.04.012</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Visual J Emerg Med\2017-8-61-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Visual J Emerg Med\2017-8-61-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170611, Samuels IE</style></custom2><misc3><style face="normal" font="default">10.1016/j.visj.2017.04.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41742</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kub,J.</style></author><author><style face="normal" font="default"> Bellin,M.H.</style></author><author><style face="normal" font="default"> Butz,A.</style></author><author><style face="normal" font="default"> Bollinger,E.M.</style></author><author><style face="normal" font="default"> Lewis-Land,C.</style></author><author><style face="normal" font="default"> Osteen,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 University of Southern California, Los Angeles, CA, USA</style></auth-address><titles><title><style face="normal" font="default">The Chronicity of Depressive Symptoms in Mothers of Children With Asthma</style></title><secondary-title><style face="normal" font="default">West J Nurs Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">West J Nurs Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma health status</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Status</style></keyword><keyword><style face="normal" font="default"> inner city</style></keyword><keyword><style face="normal" font="default"> inner-city</style></keyword><keyword><style face="normal" font="default"> Los Angeles</style></keyword><keyword><style face="normal" font="default"> low income</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Social Support</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Symptomatology</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="1" Month="5" Year="2017">2017/5/1</year></dates><abstract><style face="normal" font="default">Depression can disproportionately affect low-income women. The purpose of this study was to explore the chronicity of depressive symptoms in a sample of 276 low-income inner-city mothers of children with high-risk asthma. The aims were to identify factors (asthma health status, stress, social support) associated with change in depressive symptomatology over 12 months as well as to ascertain what factors are most consistently associated with depressive symptoms. Using latent growth curve analysis, demographic variables, asthma severity, stress, and social support failed to explain changes in depressive symptomatology. The growth curve models, however, were predictive of Center for Epidemiologic Studies-Depression Scale (CES-D) scores at distinct time points indicating that higher daily stress and lower social support were associated with increased depressive symptoms. Our data highlight the chronic nature of depressive symptoms in low-income mothers of children with poorly controlled asthma. Integrating questions about caregiver psychological state across all clinical encounters with the family may be indicated</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 1552-8456 (Electronic)IS - 0193-9459 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/0193945917705858</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28508700">PM:28508700</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\West J Nurs Res\20170516-KubJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\West J Nurs Res\20170516-KubJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Kub J</style></custom2><misc3><style face="normal" font="default">10.1177/0193945917705858</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41743</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wisnewski,A.V.</style></author><author><style face="normal" font="default"> Kanyo,J.</style></author><author><style face="normal" font="default"> Asher,J.</style></author><author><style face="normal" font="default"> Goodrich,J.A.</style></author><author><style face="normal" font="default"> Barnett,G.</style></author><author><style face="normal" font="default"> Patrylak,L.</style></author><author><style face="normal" font="default"> Liu,J.</style></author><author><style face="normal" font="default"> Redlich,C.A.</style></author><author><style face="normal" font="default"> Nassar,A.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Internal Medicine , Yale University School of Medicine , New Haven , CT 06520 , USA</style></auth-address><titles><title><style face="normal" font="default">Reaction Products of Hexamethylene Diisocyanate Vapors with "Self" Molecules in the Airways of Rabbits Exposed Via Tracheostomy</style></title><secondary-title><style face="normal" font="default">Xenobiotica</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Xenobiotica</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> albumin</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> BAL</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Glutathione</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Lysine</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Molecular Weight</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> occupational asthma</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Rabbits</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> Tracheostomy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Uteroglobin</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="10" Month="5" Year="2017">2017/5/10</year></dates><abstract><style face="normal" font="default">Hexamethylene diisocyanate (HDI) is a widely used aliphatic diisocyanate and a well-recognized cause of occupational asthma. "Self" molecules (peptides/proteins) in the lower airways, susceptible to chemical reactivity with HDI, have been hypothesized to play a role in asthma pathogenesis and/or chemical metabolism, but remain poorly characterized. This study employed unique approaches to identify and characterize "self" targets of HDI reactivity in the lower airways. Anesthetized rabbits free breathed through a tracheostomy tube connected to chambers containing either, O2, or O2 plus approximately 200 ppb HDI vapors. Following 60 minutes of exposure, the airways were lavaged and the fluid was analyzed by LC-MS and LC-MS/MS. The low-molecular weight (&lt;3 kDa) fraction of HDI exposed, but not control rabbit bronchoalveolar lavage (BAL) fluid identified 783.26 and 476.18 m/z [M+H]+ ions with high energy collision-induced dissociation (HCD) fragmentation patterns consistent with bis glutathione (GSH)-HDI and mono(GSH)-HDI. Proteomic analyses of the high molecular weight (>3kDa) fraction of exposed rabbit BAL fluid identified HDI modification of specific lysines in uteroglobin (aka clara cell protein) and albumin. In summary, this study utilized a unique approach to chemical vapor exposure in rabbits, to identify HDI reaction products with "self" molecules in the lower airways</style></abstract><notes><style face="normal" font="default">DA - 20170510IS - 1366-5928 (Electronic)IS - 0049-8254 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/00498254.2017.1329569</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28489470">PM:28489470</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Xenobiotica\20170510-WisnewskiAV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Xenobiotica\20170510-WisnewskiAV.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170510, Wisnewski AV</style></custom2><misc3><style face="normal" font="default">10.1080/00498254.2017.1329569</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41744</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Evans,T.</style></author><author><style face="normal" font="default"> Patel,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Moffitt Cancer Center, Department of Anesthesiology, University of South Florida School of Medicine, Tampa, Florida</style></auth-address><titles><title><style face="normal" font="default">Two Consecutive Preoperative Cardiac Arrests Involving Vancomycin in a Patient Presenting for Hip Disarticulation: A Case Report</style></title><secondary-title><style face="normal" font="default">A A Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">A A Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acute Kidney Injury</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Anesthesiology</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Cardiopulmonary Resuscitation</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Florida</style></keyword><keyword><style face="normal" font="default"> Hip</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> Kidney</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Nausea</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Resuscitation</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vancomycin</style></keyword><keyword><style face="normal" font="default"> Vomiting</style></keyword></keywords><dates><year Day="15" Month="6" Year="2017">2017/6/15</year></dates><abstract><style face="normal" font="default">While an abundance of literature exists describing adverse reactions to vancomycin (eg, nausea, vomiting, red man syndrome, acute kidney injury), there is scarce evidence demonstrating vancomycin anaphylactic reactions requiring cardiopulmonary resuscitation. We report a case of a patient who had 2 separate preoperative episodes of cardiac arrest following vancomycin that occurred 4 weeks apart. Both episodes of anaphylaxis required cardiopulmonary resuscitation, which led to a successful patient outcome. We discuss identification and treatment of vancomycin-induced anaphylaxis</style></abstract><notes><style face="normal" font="default">DA - 20170616IS - 2325-7237 (Electronic)IS - 2325-7237 (Linking)LA - engPT - Journal ArticleCO - Florida -</style></notes><work-type><style face="normal" font="default">10.1213/XAA.0000000000000586</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28622151">PM:28622151</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\A A Case Rep\20170616-EvansT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\A A Case Rep\20170616-EvansT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170616, Evans T</style></custom2><misc3><style face="normal" font="default">10.1213/XAA.0000000000000586</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41745</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Innocenti,M.</style></author><author><style face="normal" font="default"> Vieri,B.</style></author><author><style face="normal" font="default"> Melani,T.</style></author><author><style face="normal" font="default"> Paoli,T.</style></author><author><style face="normal" font="default"> Carulli,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Metal hypersensitivity after knee arthroplasty: fact or fiction?</style></title><secondary-title><style face="normal" font="default">Acta Biomed</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Acta Biomed</style></abbr-1></periodical><pages end="83" start="78">78-83</pages><volume><style face="normal" font="default">88</style></volume><number><style face="normal" font="default">2 -S</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Arthroplasty</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Knee</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> metal hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> Publications</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="default">BACKGROUND AND AIM OF THE WORK: Hypersensitivity to metals in the general population has an incidence of about 15%, and in rising also for the higher number of joint replacements in the last decades. Total Knee Arthroplasty (TKA) represents the most performed orthopaedic procedure during last years, and it seems to be particularly associated with sensitization after surgery. On the other hand, there is a rising amount of patients with painful but well implanted and functioning TKAs: in certain cases, after the exclusion of the most frequent causes of failure, a condition of hypersensitivity may be found, and a revision with anallergic implants is mandatory. The present study is a review of the potential problems related to hypersensitivity in TKA, its possible diagnostic procedures, and the surgical options to date available. METHODS: Medical history, patch testing, and other specific laboratory assays are useful to assess a status of metals hypersensitivity before surgery in subjects undergoing a knee replacement, or even after TKA in patients complaining pain in otherwise well implanted and aligned prostheses. However, few groups worlwide deal with such condition, and all proposed diagnostic protocols may be considered still today conjectural. On the other hand, these represent the most updated knowledge of this condition, and may be useful for both the patient and the orthopaedic surgeon. Once assessed a possible or ascertained allergy to metals, several options are available for primary andr revision knee surgery, in order to avoid the risk of hypersensitivity. RESULTS: A review of the recent publications on this topic and an overview of the related aspects has been made to understand a condition to date considered negligible. CONCLUSIONS: Hypersensitivity to metals has not to be nowadays considered a "fiction", but rather a possible preoperative risk or a postoperative cause of failure of TKA. Crucial is the information of patients and the medical history, associated in suspect cases to laboratory testings. Today in the market several knee implants are available and safe for allergic patients undergoing TKA</style></abstract><notes><style face="normal" font="default">DA - 20170628IS - 0392-4203 (Print)IS - 0392-4203 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.23750/abm.v88i2 -S.6517</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28657568">PM:28657568</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Acta Biomed\2017-88-78-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Acta Biomed\2017-88-78-83.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170628, Innocenti M</style></custom2><misc3><style face="normal" font="default">10.23750/abm.v88i2 -S.6517</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41746</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lugovic-Mihic,L.</style></author><author><style face="normal" font="default"> Fercek,I.</style></author><author><style face="normal" font="default"> Duvancic,T.</style></author><author><style face="normal" font="default"> Bulat,V.</style></author><author><style face="normal" font="default"> Jezovita,J.</style></author><author><style face="normal" font="default"> Novak-Bilic,G.</style></author><author><style face="normal" font="default"> Situm,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">OCCUPATIONAL CONTACT DERMATITIS AMONGST DENTISTS AND DENTAL TECHNICIANS</style></title><secondary-title><style face="normal" font="default">Acta Clin Croat</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Acta Clin Croat</style></abbr-1></periodical><pages end="300" start="293">293-300</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acrylate</style></keyword><keyword><style face="normal" font="default"> Acrylates</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Croatia</style></keyword><keyword><style face="normal" font="default"> Dental Materials</style></keyword><keyword><style face="normal" font="default"> Dental Technicians</style></keyword><keyword><style face="normal" font="default"> dentist</style></keyword><keyword><style face="normal" font="default"> Dentistry</style></keyword><keyword><style face="normal" font="default"> Dentists</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Occupational</style></keyword><keyword><style face="normal" font="default"> Detergents</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Gloves</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Latex</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Occupational disease</style></keyword><keyword><style face="normal" font="default"> Occupational Medicine</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> prevention &amp; control</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Solvents</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Workplace</style></keyword></keywords><dates><year Day="0" Month="6" Year="2016">2016/6</year></dates><abstract><style face="normal" font="default">Since the working medical personnel including dentists and dental technicians mainly use their hands, it is understandable that the most common occupational disease amongst medical personnel is contact dermatitis (CD) (80%-90% of cases). Development of occupational CD is caused by contact of the skin with various substances in occupational environment. Occupational etiologic factors for dental personnel are foremost reactions to gloves containing latex, followed by various dental materials (e.g., metals, acrylates), detergents, lubricants, solvents, chemicals, etc. Since occupational CD is relatively common in dental personnel, its timely recognition, treatment and taking preventive measures is needed. Achieving skin protection at exposed workplaces is of special importance, as well as implementing necessary measures consequently and sufficiently, which is sometimes difficult to achieve. Various studies have shown the benefit of applying preventive measures, such as numerous protocols for reducing and managing latex sensitivity and other forms of CD in dentistry. Active involvement of physicians within the health care system, primarily dermatologists, occupational medicine specialists and general medicine doctors is needed for establishing an accurate medical diagnosis and confirmation of occupational skin disease</style></abstract><notes><style face="normal" font="default">DA - 20170410IS - 0353-9466 (Print)IS - 0353-9466 (Linking)LA - engPT - Journal ArticlePT - ReviewRN - 0 (Acrylates)RN - 0 (Dental Materials)SB - IMCO - Croatia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28394546">PM:28394546</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Acta Clin Croat\2016-55-293-300.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Acta Clin Croat\2016-55-293-300.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170410, Lugovic-Mihic L</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41747</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ahlstrom,M.G.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author><author><style face="normal" font="default"> Menne,T.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Allergy Research Centre Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, DK-2900 Hellerup, Denmark. malin.glindvad.ahlstroem.01@regionh.dk</style></auth-address><titles><title><style face="normal" font="default">Consumer Behaviour Among Nickel-allergic Patients</style></title><secondary-title><style face="normal" font="default">Acta Derm Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Acta Derm Venereol</style></full-title></periodical><pages end="1248" start="1247">1247-1248</pages><volume><style face="normal" font="default">97</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="6" Month="7" Year="2017">2017/7/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170706IS - 1651-2057 (Electronic)IS - 0001-5555 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.2340/00015555-2751</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28681065">PM:28681065</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Acta Derm Venereol\2017-97-1247-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Acta Derm Venereol\2017-97-1247-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170706, Ahlstrom MG</style></custom2><misc3><style face="normal" font="default">10.2340/00015555-2751</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41748</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dieris-Hirche,J.</style></author><author><style face="normal" font="default"> Gieler,U.</style></author><author><style face="normal" font="default"> Petrak,F.</style></author><author><style face="normal" font="default"> Milch,W.</style></author><author><style face="normal" font="default"> Te Wildt,B.</style></author><author><style face="normal" font="default"> Dieris,B.</style></author><author><style face="normal" font="default"> Herpertz,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Psychosomatic Medicine and Psychotherapy, LWL-University Clinic Bochum, Ruhr-University Bochum, Alexandrinenstr. 1-3, DE-44791 Bochum, Germany.</style></auth-address><titles><title><style face="normal" font="default">Suicidal Ideation in Adult Patients with Atopic Dermatitis: A German Cross-sectional Study</style></title><secondary-title><style face="normal" font="default">Acta Derm Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Acta Derm Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Life quality</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Psychosomatic Medicine</style></keyword><keyword><style face="normal" font="default"> Psychotherapy</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="5" Month="7" Year="2017">2017/7/5</year></dates><abstract><style face="normal" font="default">A cross-sectional study was performed to assess symptoms of suicidality, depression and anxiety in adult patients with atopic dermatitis. The study describes the relationships between these psychiatric symptoms and skin-specific factors, such as atopic dermatitis severity and skin satisfaction. A sample of 181 German patients with atopic dermatitis was compared with a control group of 64 persons with healthy skin with a similar age and gender distribution. Standardized questionnaires were used to assess suicidality (Poldinger's Scale), depression and anxiety (Hospital Anxiety and Depression Scale; HADS), quality of life (Dermatology Life Quality Index; DLQI), atopic dermatitis severity (Patient-Oriented Scoring Atopic Dermatitis; PO-SCORAD) and skin satisfaction (Skin Satisfaction Questionnaire; SSQ). The prevalence of suicidal ideation among patients with atopic dermatitis was high (21.3%); 3.9% scored above the cut-off that might be an indicator for acute suicidality. Depression symptoms, high severity of atopic dermatitis, lower age, and little touching within the family were identified as significant factors to predict suicidality in atopic dermatitis. Psychiatric screening in dermatological treatment of atopic dermatitis is discussed</style></abstract><notes><style face="normal" font="default">DA - 20170705IS - 1651-2057 (Electronic)IS - 0001-5555 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.2340/00015555-2741</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28676884">PM:28676884</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Acta Derm Venereol\20170705-DierisHircheJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Acta Derm Venereol\20170705-DierisHircheJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170705, Dieris-Hirche J</style></custom2><misc3><style face="normal" font="default">10.2340/00015555-2741</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41749</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Erdem,S.B.</style></author><author><style face="normal" font="default"> Can,D.</style></author><author><style face="normal" font="default"> Girit,S.</style></author><author><style face="normal" font="default"> Catal,F.</style></author><author><style face="normal" font="default"> Sen,V.</style></author><author><style face="normal" font="default"> Pekcan,S.</style></author><author><style face="normal" font="default"> Yuksel,H.</style></author><author><style face="normal" font="default"> Bingol,A.</style></author><author><style face="normal" font="default"> Bostanci,I.</style></author><author><style face="normal" font="default"> Erge,D.</style></author><author><style face="normal" font="default"> Ersu,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dr Behcet Uz Children's Hospital, Department of Pediatric Allergy, Izmir, Turkey</style></auth-address><titles><title><style face="normal" font="default">Does atopy affect the course of viral pneumonia?</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Coronavirus</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> environmental tobacco smoke</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Influenza</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Metapneumovirus</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> parental asthma</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> Pneumonia</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="default"> Rhinovirus</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Sensitisation</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> Smoke</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Tobacco</style></keyword><keyword><style face="normal" font="default"> tobacco smoke exposure</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="17" Month="6" Year="2017">2017/6/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: The presence of atopy is considered as a risk factor for severe respiratory symptoms in children. The objective of this study was to examine the effect of atopy on the course of disease in children hospitalised with viral pneumonia. METHODS: Children between the ages of 1 and 6 years hospitalised due to viral pneumonia between the years of 2013 and 2016 were included to this multicentre study. Patients were classified into two groups as mild-moderate and severe according to the course of pneumonia. Presence of atopy was evaluated with skin prick tests. Groups were compared to evaluate the risk factors associated with severe viral pneumonia. RESULTS: A total of 280 patients from nine centres were included in the study. Of these patients, 163 (58.2%) were male. Respiratory syncytial virus (29.7%), Influenza A (20.5%), rhinovirus (18.9%), adenovirus (10%), human metapneumovirus (8%), parainfluenza (5.2%), coronavirus (6%), and bocavirus (1.6%) were isolated from respiratory samples. Eighty-five (30.4%) children had severe pneumonia. Atopic sensitisation was found in 21.4% of the patients. Ever wheezing (RR: 1.6, 95% CI: 1.1-2.4), parental asthma (RR: 1.5, 95% CI: 1.1-2.2), other allergic diseases in the family (RR: 1.8, 95% CI: 1.2-2.9) and environmental tobacco smoke (RR: 1.6, 95% CI: 1.1-3.5) were more common in the severe pneumonia group. CONCLUSIONS: When patients with mild-moderate pneumonia were compared to patients with severe pneumonia, frequency of atopy was not different between the two groups. However, parental asthma, ever wheezing and environmental tobacco smoke exposure are risk factors for severe viral pneumonia in children</style></abstract><notes><style face="normal" font="default">DA - 20170621IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.04.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28634031">PM:28634031</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170621-ErdemSB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170621-ErdemSB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170621, Erdem SB</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.04.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41750</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sultesz,M.</style></author><author><style face="normal" font="default"> Balogh,I.</style></author><author><style face="normal" font="default"> Katona,G.</style></author><author><style face="normal" font="default"> Mezei,G.</style></author><author><style face="normal" font="default"> Hirschberg,A.</style></author><author><style face="normal" font="default"> Galffy,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Oto-Rhino-Laryngology, Heim Pal Children's Hospital, 86 Ulloi ut, Budapest H-1089, Hungary.</style></auth-address><titles><title><style face="normal" font="default">Trends in prevalence and risk factors of allergic rhinitis symptoms in primary schoolchildren six years apart in Budapest</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hungary</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Respiratory tract infection</style></keyword><keyword><style face="normal" font="default"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Schoolchildren</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> trends</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="6" Year="2017">2017/6/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Few data are available concerning the time trends and risk factors associated with allergic rhinitis (AR) in schoolchildren in Hungary. METHODS: At an interval of six years, parents of 6-12-year-old children completed identical ISAAC-based and additional questionnaires related to possible risk factors. RESULTS: Response rate was 62.8% with 6335 questionnaires distributed in 2007, and 52.9% with 6441 questionnaires in 2013. The prevalence of current AR symptoms (subjects presenting clinical symptoms of AR in the past 12 months, but had yet to be diagnosed by physician) increased significantly from 14.9% to 23.5% (p&lt;0.001). There was no significant change in the prevalence of physician-diagnosed AR (11.6-11.2%). In multivariate analysis, gender (OR 0.733; CI 0.642-0.931), a family history of atopy (OR 2.017; CI 1.669-2.436), frequent upper respiratory tract infections (OR 2.033; CI 1.659-2.492), long-lasting disease before the appearance of the allergy (OR 2.119; CI 1.311-3.428), feather bedding (OR 0.773; CI 0.599-0.996) and living in a green area (OR 1.367; CI 1.133-1.650) were found to be significant risk factors of cumulative AR in 2013. In both of the groups with (p&lt;0.000) or without (p&lt;0.003) AR the families with a history of atopy used feather bedding less frequently than families without atopy. CONCLUSION: Although the prevalence of physician-diagnosed AR has not shown significant changes during the studied interval, the significant increase of the current AR symptoms suggests growing prevalence of AR among children in Budapest. Our results revealed new aspects of bedding customs in atopic families</style></abstract><notes><style face="normal" font="default">DA - 20170620IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Hungary -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.02.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28629670">PM:28629670</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170620-SulteszM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170620-SulteszM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170620, Sultesz M</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.02.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41751</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Segura-Navas,L.</style></author><author><style face="normal" font="default"> Arnedo-Pena,A.</style></author><author><style face="normal" font="default"> Tosca-Segura,R.</style></author><author><style face="normal" font="default"> Romeu-Garcia,M.A.</style></author><author><style face="normal" font="default"> Meseguer-Ferrer,N.</style></author><author><style face="normal" font="default"> Silvestre-Silvestre,E.</style></author><author><style face="normal" font="default"> Conde,F.</style></author><author><style face="normal" font="default"> Fernandez-Gonzalez,S.</style></author><author><style face="normal" font="default"> Dubon,M.</style></author><author><style face="normal" font="default"> Ortuno-Forcada,M.</style></author><author><style face="normal" font="default"> Fabregat-Puerto,J.</style></author><author><style face="normal" font="default"> Fenollosa-Amposta,C.</style></author><author><style face="normal" font="default"> Pac-Sa,M.R.</style></author><author><style face="normal" font="default"> Museros-Recatala,L.</style></author><author><style face="normal" font="default"> Vizcaino-Batlles,A.</style></author><author><style face="normal" font="default"> Bellido-Blasco,J.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Health Centre, Burriana, Castellon, Spain</style></auth-address><titles><title><style face="normal" font="default">Incidence of asthma in young adults from Castellon, Spain: A prospective cohort study</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bronchitis</style></keyword><keyword><style face="normal" font="default"> cat</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> dog</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> prospective cohort study</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Self Report</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Telephone</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: The objective was to estimate the incidence of asthma in young adults from 13-15 years old to 23-25 years old, and associated factors. METHODS: In 2012, a population-based prospective cohort study was carried out in Castellon from the cohort who had participated in the International Study of Asthma and Allergy in Childhood in 1994 and 2002. A telephone survey was undertaken using the same questionnaires. A new case of asthma was defined as a participant free of the disease in 2002 who suffered asthma, was diagnosed with asthma, or took medications against asthma based on self-report from 2002 to 2012. RESULTS: The mean age of participants was 24.9+/-0.6 with a follow-up of 79.1%. Asthma cumulative incidence was 3.4%: 44 new cases occurred among 1280 participants. The incidence was higher in females than males with relative risk (RR)=2.02 (95% confidence interval [CI] 1.1-3.8). A significant decrease of asthma incidence density was observed (8.2 cases to 3.5 cases per 1000 person/year). Factors associated with the incidence of asthma were allergic rhinitis (RR=4.05; 95% CI 1.7-9.6), bronchitis (RR=2.13; 95% CI 1.0-4.5), mother's age at time of birth (RR=0.87; 95% CI 0.8-0.9) and a pet other than a dog or cat (RR=0.42; 95% CI 0.2-0.9). For gender, some variations in the risk factors were observed. CONCLUSIONS: A significant decrease in the incidence of asthma was observed. Several risk and protective factors were found</style></abstract><notes><style face="normal" font="default">DA - 20170705IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.03.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28676230">PM:28676230</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170705-SeguraNavasL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170705-SeguraNavasL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170705, Segura-Navas L</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.03.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41752</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fouda,E.M.</style></author><author><style face="normal" font="default"> Kamel,T.B.</style></author><author><style face="normal" font="default"> Nabih,E.S.</style></author><author><style face="normal" font="default"> Abdelazem,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Ain Shams University, Egypt.</style></auth-address><titles><title><style face="normal" font="default">Helicobacter pylori seropositivity protects against childhood asthma and inversely correlates to its clinical and functional severity</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Developed Countries</style></keyword><keyword><style face="normal" font="default"> Egypt</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Helicobacter pylori</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Igg</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="6" Year="2017">2017/6/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: In recent years, the prevalence of asthma has risen in developed countries, and its extent related to a change in our indigenous microbiota. Helicobacter pylori disappearance across the population represents a fundamental change in our human microbiota and has preceded the rise in asthma prevalence. OBJECTIVE: To assess the relationship between childhood asthma and Helicobacter pylori infection. METHODS: Quantitative determination of Helicobacter pylori IgG among 90 asthmatic children and 90 - age and gender - matched non-atopic, non-asthmatic healthy children was performed using ELISA in serum of all participants. RESULTS: Helicobacter pylori IgG seropositivity was found in 25.6% of asthmatics compared to 44.4% of controls. Asthmatics showed lower median Helicobacter pylori IgG titre compared to healthy controls. We also detected a significant inverse relationship between Helicobacter pylori IgG titre and asthma severity. CONCLUSION: Helicobacter pylori seropositivity protects against childhood asthma and inversely correlates to its clinical and functional severity</style></abstract><notes><style face="normal" font="default">DA - 20170624IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Egypt -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.03.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28645881">PM:28645881</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170624-FoudaEM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170624-FoudaEM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170624, Fouda EM</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.03.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41753</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Perez Tarazona,S.</style></author><author><style face="normal" font="default"> Solano Galan,P.</style></author><author><style face="normal" font="default"> Bartoll Alguacil,E.</style></author><author><style face="normal" font="default"> Alfonso Diego,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Neonatology, University &amp; Polytechnic Hospital La Fe, Valencia, Spain.</style></auth-address><titles><title><style face="normal" font="default">Bronchopulmonary dysplasia as a risk factor for asthma in school children and adolescents: A systematic review</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bias</style></keyword><keyword><style face="normal" font="default"> Bronchopulmonary Dysplasia</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> confounding factors</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> diagnostic criteria</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> REACH</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schoolchildren</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="6" Year="2017">2017/6/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: Bronchopulmonary dysplasia (BPD) is a chronic lung disease that mainly affects extremely pre-term infants, and remains the most common complication of prematurity. Several studies have shown that prematurity predisposes to the development of asthma in school children and adolescents. Nevertheless, it is not clear to what extent a history of BPD involves an additional risk. METHODS: A systematic review of studies assessing the association between BPD and asthma in school-children and adolescents was made. A literature search was carried out in the MEDLINE and EMBASE databases to retrieve articles published between 1 January 2000 and 31 August 2016. RESULTS: A total of 17 studies comprising 7433 patients were included in the review. There was considerable heterogeneity in the definitions of BPD and asthma among studies. Overall, the prevalence of asthma was higher in children and adolescents with a history of prematurity and BPD compared with those who did not develop BPD. However, in only one of the studies did this difference reach statistical significance. The main limitation of this review was potential bias due to the lack of adjustment for confounding factors between exposure (BPD) and outcome (asthma) in most of the studies. CONCLUSION: Based on the studies reviewed, it cannot be argued that BPD, as an independent factor of prematurity, increases the risk of asthma defined by clinical parameters in school-children and adolescents. Further studies of greater methodological quality and homogeneous diagnostic criteria of BPD and asthma are needed for improved assessment of this association</style></abstract><notes><style face="normal" font="default">DA - 20170702IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.02.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668285">PM:28668285</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170702-PerezTarazonaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170702-PerezTarazonaS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170702, Perez Tarazona S</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.02.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41754</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nacaroglu,H.T.</style></author><author><style face="normal" font="default"> Gayret,O.B.</style></author><author><style face="normal" font="default"> Erol,M.</style></author><author><style face="normal" font="default"> Buke,O.</style></author><author><style face="normal" font="default"> Zengi,O.</style></author><author><style face="normal" font="default"> Tasdemir,M.</style></author><author><style face="normal" font="default"> Tasdemir,Z.</style></author><author><style face="normal" font="default"> Yigit,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Bagcilar Training and Research Hospital, Pediatric Allergy and Immunology, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="default">Biomarkers of airway and systemic inflammation in obese asthmatic paediatric patients</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> BAL</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Complete Blood Count</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Matrix Metalloproteinase 9</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="6" Year="2017">2017/6/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: It is thought that airway inflammation is more common in obese asthmatic patients because inflammation is harder to control and does not respond well to glucocorticoid treatment. OBJECTIVE: This study's aim was to investigate the effect of obesity on airway and systemic inflammation in children with asthma and to identify the biomarkers that play a role in this inflammation. METHODS: The study included patients aged 6-16 years who were diagnosed with asthma in the paediatric allergy outpatient clinic of Bagcilar Training and Research Hospital in Turkey. Complete blood count parameters were compared between three groups: obese asthmatic (n=43), obese non-asthmatic (n=45), and non-obese non-asthmatic (control group, n=30). Levels of high-sensitive CRP (hs-CRP), neutrophil gelatinase-associated lipocalin (NGAL), osteopontin (OPN), and matrix metalloproteinase-9 (MMP-9), and 25(OH)-vitamin D were compared between the groups. RESULTS: No statistically significant differences were observed in 25(OH)-vitamin D, NGAL, OPN, hs-CRP, and MMP-9 levels between groups. There was a statistically significant negative correlation between FEV1/FVC and NGAL and MMP-9. CONCLUSION: This is the first study to investigate levels of hs-CRP, NGAL, OPN, MMP-9, and 25(OH)-vitamin D in obese asthmatic children. Larger studies with sputum and BAL examinations are required to determine the potential of biomarkers for identifying inflammation in obese asthmatic children</style></abstract><notes><style face="normal" font="default">DA - 20170624IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.01.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28645880">PM:28645880</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170624-NacarogluHT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170624-NacarogluHT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170624, Nacaroglu HT</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.01.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41755</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rivas-Juesas,C.</style></author><author><style face="normal" font="default"> Rius Peris,J.M.</style></author><author><style face="normal" font="default"> Garcia,A.L.</style></author><author><style face="normal" font="default"> Madramany,A.A.</style></author><author><style face="normal" font="default"> Peris,M.G.</style></author><author><style face="normal" font="default"> Alvarez,L.V.</style></author><author><style face="normal" font="default"> Primo,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hospital de Sagunto, Avda Ramon y Cajal s.n, Sagunto, 46520 Valencia, Spain.</style></auth-address><titles><title><style face="normal" font="default">A comparison of two clinical scores for bronchiolitis. A multicentre and prospective study conducted in hospitalised infants</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Bronchiolitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic test</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> ROC</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> Validation studies</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wood</style></keyword></keywords><dates><year Day="16" Month="6" Year="2017">2017/6/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: There are a number of clinical scores for bronchiolitis but none of them are firmly recommended in the guidelines. METHOD: We designed a study to compare two scales of bronchiolitis (ESBA and Wood Downes Ferres) and determine which of them better predicts the severity. A multicentre prospective study with patients &lt;12 months with acute bronchiolitis was conducted. Each patient was assessed with the two scales when admission was decided. We created a new variable "severe condition" to determine whether one scale afforded better discrimination of severity. A diagnostic test analysis of sensitivity and specificity was made, with a comparison of the AUC. Based on the optimum cut-off points of the ROC curves for classifying bronchiolitis as severe we calculated new Se, Sp, LR+ and LR- for each scale in our sample. RESULTS: 201 patients were included, 66.7% males and median age 2.3 months (IQR=1.3-4.4). Thirteen patients suffered bronchiolitis considered to be severe, according to the variable severe condition. ESBA showed a Se=3.6%, Sp=98.1%, and WDF showed Se=46.2% and Sp=91.5%. The difference between the two AUC for each scale was 0.02 (95%CI: 0.01-0.15), p=0.72. With new cut-off points we could increase Se and Sp for ESBA: Se=84.6%, Sp=78.7%, and WDF showed Se=92.3% and Sp=54.8%; with higher LR. CONCLUSIONS: None of the scales studied was considered optimum for assessing our patients. With new cut-off points, the scales increased the ability to classify severe infants. New validation studies are needed to prove these new cut-off points</style></abstract><notes><style face="normal" font="default">DA - 20170620IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.01.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28629673">PM:28629673</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170620-RivasJuesasC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170620-RivasJuesasC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170620, Rivas-Juesas C</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.01.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41756</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Karakullukcu,A.</style></author><author><style face="normal" font="default"> Tokman,H.B.</style></author><author><style face="normal" font="default"> Nepesov,S.</style></author><author><style face="normal" font="default"> Demirci,M.</style></author><author><style face="normal" font="default"> Saribas,S.</style></author><author><style face="normal" font="default"> Vehid,S.</style></author><author><style face="normal" font="default"> Caliskan,R.</style></author><author><style face="normal" font="default"> Taner,Z.</style></author><author><style face="normal" font="default"> Cokugras,H.</style></author><author><style face="normal" font="default"> Ziver,T.</style></author><author><style face="normal" font="default"> Demiryas,S.</style></author><author><style face="normal" font="default"> Kocazeybek,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Istanbul University, Department of Medical Microbiology Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="default">The protective role of Helicobacter pylori neutrophil-activating protein in childhood asthma</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AC</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> gender difference</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Helicobacter pylori</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Rna</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="31" Month="5" Year="2017">2017/5/31</year></dates><abstract><style face="normal" font="default">BACKGROUND: Helicobacter pylori quantity and HP-NAP gene expression were evaluated in the faeces of healthy and asthmatic children. METHODS: H. pylori DNAs and RNAs were isolated from the stool samples of 92 asthmatic children (AC; 3-8 years) and 88 healthy controls (HC). Quantitative PCR was used to determine the quantity of H. pylori and HP-NAP expression relative to the 16S rRNA (reference gene). Gene expression was analysed using the delta delta-Ct method. RESULTS: H. pylori DNA was detected in the stool samples of 18 (20.4%) of the 88 HC (p&lt;0.0001, OR=0.79) and none of AC. No meaningful statistical differences were found between individuals with positive and negative family histories for asthma in AC and HC (p>0.05). H. pylori quantity was higher in seven of 18 H. pylori-positive samples, but HP-NAP expression levels were low in four of these seven samples. Based on a multivariate logistic regression analysis of these three variables together, only males displayed a significant difference based on gender differences (p&lt;0.02) and it was determined that, based on the OR value of 0.46 and the 95% CI range of 0.241-0.888, male gender was an independent protective factor in asthma. CONCLUSIONS: HP-NAP levels vary to the relative concentrations of bacteria in the stationary or late logarithmic phases. Different napA expression levels may be caused by different endogenous napA gene expression or different environmental conditions</style></abstract><notes><style face="normal" font="default">DA - 20170605IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Turkey -CO - Cyprus -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.01.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28579087">PM:28579087</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170605-KarakullukcuA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170605-KarakullukcuA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170605, Karakullukcu A</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.01.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41757</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Alvarez Zallo,N.</style></author><author><style face="normal" font="default"> Aguinaga-Ontoso,I.</style></author><author><style face="normal" font="default"> Alvarez-Alvarez,I.</style></author><author><style face="normal" font="default"> Marin-Fernandez,B.</style></author><author><style face="normal" font="default"> Guillen-Grima,F.</style></author><author><style face="normal" font="default"> Azcona-San Julian,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Extrahospitalary Paediatric Emergency Service, Osasunbidea, Pamplona, Navarra, Spain.</style></auth-address><titles><title><style face="normal" font="default">Influence of the Mediterranean diet during pregnancy in the development of wheezing and eczema in infants in Pamplona, Spain</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> fish</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Fruit</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> recurrent wheezing</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="16" Month="6" Year="2017">2017/6/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: This study examined the relationship between different food groups and the adherence to a Mediterranean diet during pregnancy and the risk of wheezing and eczema in children aged 12-15 months. METHODS: The study involves 1087 Spanish infants from the International Study of Wheezing in Infants (Estudio Internacional de Sibilancias en Lactantes, EISL). The study of the association of the different food consumption and Mediterranean diet with wheezing, recurrent wheezing and eczema was performed using different models of unconditional logistic regression to obtain adjusted prevalence odds ratios (OR) and 95% confidence intervals (95% CI). RESULTS: No association was found between a good adherence to the Mediterranean diet during pregnancy and the development of wheezing (p=0.372), recurrent wheezing (p=0.118) and eczema (p=0.315). The consumption once or twice a week of white fish (OR: 1.95[1.01-3.75]), cooked potatoes (OR: 1.75[1.22-2.51]) and industrial pastry (OR: 1.59[1.13-2.24]), and the consumption more than three times a week of industrial pastry (OR: 1.47 [1.01-2.13]) during pregnancy increases the risk of "wheezing" at 12 months. Instead, high fruit consumption during the pregnancy has a protective effect against "wheezing" in 12-month-old infants (OR: 0.44 [0.20-0.99]). No statistically significant differences were observed between food intake during pregnancy and "recurrent wheezing". No statistically significant differences were observed between the consumption of any food during pregnancy and the presence of eczema at 12 months. CONCLUSIONS: The present study showed that the consumption of Mediterranean diet during pregnancy did not have a protective effect for wheezing, recurrent wheezing or eczema</style></abstract><notes><style face="normal" font="default">DA - 20170620IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.02.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28629669">PM:28629669</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170620-AlvarezZalloN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170620-AlvarezZalloN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170620, Alvarez Zallo N</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.02.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41758</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">To,M.</style></author><author><style face="normal" font="default"> Kono,Y.</style></author><author><style face="normal" font="default"> Ogura,N.</style></author><author><style face="normal" font="default"> Mikami,S.</style></author><author><style face="normal" font="default"> Honda,N.</style></author><author><style face="normal" font="default"> Hitani,A.</style></author><author><style face="normal" font="default"> Kano,I.</style></author><author><style face="normal" font="default"> Haruki,K.</style></author><author><style face="normal" font="default"> To,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Laboratory Medicine, Dokkyo Medical University, Koshigaya Hospital, Saitama, Japan</style></auth-address><titles><title><style face="normal" font="default">Obesity-related systemic oxidative stress: An important factor of poor asthma control</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Oxidative Stress</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="23" Month="6" Year="2017">2017/6/23</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170626IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.06.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28648979">PM:28648979</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170626-ToM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170626-ToM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170626, To M</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.06.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41759</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Komatsu-Fujii,T.</style></author><author><style face="normal" font="default"> Chinuki,Y.</style></author><author><style face="normal" font="default"> Niihara,H.</style></author><author><style face="normal" font="default"> Hayashida,K.</style></author><author><style face="normal" font="default"> Ohta,M.</style></author><author><style face="normal" font="default"> Okazaki,R.</style></author><author><style face="normal" font="default"> Kaneko,S.</style></author><author><style face="normal" font="default"> Morita,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Shimane University Faculty of Medicine, Izumo, Japan</style></auth-address><titles><title><style face="normal" font="default">The thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption is a prognostic biomarker of severity of systemic inflammation</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">albumin</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Blood Cell Count</style></keyword><keyword><style face="normal" font="default"> Blood Pressure</style></keyword><keyword><style face="normal" font="default"> Body Temperature</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="default"> Cell Count</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug eruption</style></keyword><keyword><style face="normal" font="default"> Drug Eruptions</style></keyword><keyword><style face="normal" font="default"> Drug rash</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Erythema Multiforme</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Exanthema</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity syndrome</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Pulse</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default"> Stevens-Johnson Syndrome</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> TARC</style></keyword><keyword><style face="normal" font="default"> Temperature</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="22" Month="6" Year="2017">2017/6/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: In severe drug eruptions, precise evaluation of disease severity at an early stage is needed to start appropriate treatment. It is not always easy to diagnose these conditions at their early stage. In addition, there are no reported prognostic biomarkers of disease severity in drug eruptions. The aim of this study was to test whether the thymus and activation-regulated chemokine (TARC) level in serum at an early stage of a drug eruption can serve as a prognostic biomarker of systemic inflammation. METHODS: Study participants included 76 patients who received a diagnosis of a drug eruption, one of the following: drug rash with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome, maculopapular exanthema, and erythema multiforme. Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) was eliminated in this study because scoring system for evaluating the severity was established. Correlation coefficients between serum TARC levels and indicators of systemic inflammation, including the neutrophil-to-lymphocyte ratio, Glasgow prognostic score, modified systemic inflammatory response syndrome (mSIRS) score, and C-reactive protein in serum were evaluated. RESULTS: Serum TARC levels positively correlated with the neutrophil-to-lymphocyte ratio, Glasgow prognostic score, mSIRS score, C-reactive protein, albumin, white blood cell count, body temperature, and pulse rate. TARC levels negatively correlated with systolic blood pressure. Among these parameters, the mSIRS score showed strong correlation (correlation coefficient: 0.68). CONCLUSIONS: Serum TARC levels correlate well with indicators of systemic inflammation and of disease severity among patients with a drug eruption except SJS/TEN. Serum TARC may be a prognostic biomarker of severity of inflammation in drug eruptions</style></abstract><notes><style face="normal" font="default">DA - 20170626IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.06.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28648978">PM:28648978</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170626-KomatsuFujiiT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170626-KomatsuFujiiT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170626, Komatsu-Fujii T</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.06.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41760</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ujino,M.</style></author><author><style face="normal" font="default"> Sugimoto,N.</style></author><author><style face="normal" font="default"> Koizumi,Y.</style></author><author><style face="normal" font="default"> Ro,S.</style></author><author><style face="normal" font="default"> Kojima,Y.</style></author><author><style face="normal" font="default"> Asae,K.H.</style></author><author><style face="normal" font="default"> Yamashita,N.</style></author><author><style face="normal" font="default"> Ohta,K.</style></author><author><style face="normal" font="default"> Nagase,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">Leukotriene receptor antagonist attenuated airway inflammation and hyperresponsiveness in a double-stranded RNA-induced asthma exacerbation model</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acetylcholine</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> BAL</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> CysLT</style></keyword><keyword><style face="normal" font="default"> cysteinyl leukotriene</style></keyword><keyword><style face="normal" font="default"> cysteinyl leukotrienes</style></keyword><keyword><style face="normal" font="default"> cysteinyl-leukotrienes</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-9</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="default"> Leukotrienes</style></keyword><keyword><style face="normal" font="default"> LTRA</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> montelukast</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> OVA</style></keyword><keyword><style face="normal" font="default"> Ovalbumin</style></keyword><keyword><style face="normal" font="default"> Ovum</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Rna</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral infection</style></keyword><keyword><style face="normal" font="default"> Viral infections</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="21" Month="6" Year="2017">2017/6/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: Viral infections are the most common triggers of asthma exacerbation, but the key molecules involved in this process have not been fully identified. Although cysteinyl leukotrienes (cysLTs) have been postulated as the key mediators, their precise roles remain largely unclear. To investigate the roles of cysLTs in virus-induced asthma exacerbation, we developed a murine model using a viral double-stranded RNA analog, polyinosinic-polycytidylic acid (poly I:C), and analyzed the effect of leukotriene receptor antagonist (LTRA) administration. METHODS: A/J mice were immunized with ovalbumin (OVA) + alum (days 0, 28, 42, and 49), followed by intranasal challenge with OVA (phase 1: days 50-52) and poly I:C (phase 2: days 53-55). Montelukast was administered during poly I:C challenge (phase 2) in the reliever model or throughout the OVA and poly I:C challenges (phases 1 and 2) in the controller model. Airway responsiveness to acetylcholine chloride was assessed, and bronchoalveolar lavage (BAL) was performed on day 56. RESULTS: Administration of poly I:C to OVA-sensitized and -challenged mice increased the number of eosinophils and levels of IL-13, IL-9, CCL3, and CXCL1 in BAL fluid (BALF) and tended to increase airway responsiveness. Montelukast significantly attenuated the poly I:C-induced increase in the number of eosinophils and levels of IL-13, IL-9, and CCL3 in BALF and airway hyperresponsiveness in both the reliever and controller models. CONCLUSIONS: This is the first report showing that LTRA functionally suppressed the pathophysiology of a virus-induced asthma exacerbation model, suggesting the importance of cysLTs as a potential treatment target</style></abstract><notes><style face="normal" font="default">DA - 20170625IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.05.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28647381">PM:28647381</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170625-UjinoM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170625-UjinoM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170625, Ujino M</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.05.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41761</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Holster,A.</style></author><author><style face="normal" font="default"> Terasjarvi,J.</style></author><author><style face="normal" font="default"> Lauhkonen,E.</style></author><author><style face="normal" font="default"> Tormanen,S.</style></author><author><style face="normal" font="default"> Helminen,M.</style></author><author><style face="normal" font="default"> Koponen,P.</style></author><author><style face="normal" font="default"> Korppi,M.</style></author><author><style face="normal" font="default"> Peltola,V.</style></author><author><style face="normal" font="default"> He,Q.</style></author><author><style face="normal" font="default"> Nuolivirta,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Seinajoki Central Hospital, Seinajoki, FinlandDepartment of Medical Microbiology and Immunology, Turku University, Turku, Finland</style></auth-address><titles><title><style face="normal" font="default">IL-17A gene polymorphism rs2275913 is associated with the development of asthma after bronchiolitis in infancy</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Bronchiolitis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> IL-17</style></keyword><keyword><style face="normal" font="default"> IL-17A</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infancy</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Interleukin-17</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> Promoter</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="21" Month="6" Year="2017">2017/6/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: Interleukin-17 (IL-17A) is a mainly pro-inflammatory cytokine, and IL-17 signaling implicates in the development of allergic asthma. The polymorphism rs2275913 in the promoter region of the IL-17A gene has in previous studies been associated with asthma susceptibility. The objective was to evaluate the association between IL-17A rs2275913 (-197G>A) polymorphism and post-bronchiolitis asthma and/or allergic rhinitis in a prospective 11-13 years post-bronchiolitis follow-up. METHODS: 166 previously healthy full-term infants, hospitalized for bronchiolitis at age less than 6 months, were invited to follow-up visits at the ages of 5-7 years and 11-13 years. Asthma diagnoses and presumptive symptoms, allergic rhinitis and use of inhaled corticosteroids (ICS) were registered. Blood samples for IL-17A rs2275913 (-197G>A) polymorphism were obtained during hospitalization or at the 5-7 years control visit. RESULTS: There were no significant differences between children with the wild GG and variant GA or AA genotype in the severity of bronchiolitis during hospitalization or in the outcomes until the age 5-7 years. At 11-13 years of age, children with the variant GA or AA genotype had significantly less often current asthma, use of ICSs during last 12 months or allergic rhinitis than those with the wild GG genotype. The ICS use during last 12 months retained the statistical significance in adjusted analyses (adjusted OR 0.25), whereas current asthma and allergic rhinitis marginally lost it. CONCLUSIONS: The IL-17A rs2275913 (-197G>A) polymorphism decreased the risk of post-bronchiolitis asthma at 11-13 years of age, but not earlier in life, in the present prospective, long-term follow-up study</style></abstract><notes><style face="normal" font="default">DA - 20170625IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Finland -CO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.05.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28647382">PM:28647382</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170625-HolsterA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170625-HolsterA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170625, Holster A</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.05.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41762</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ohno,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Medical Education, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan.</style></auth-address><titles><title><style face="normal" font="default">Neuropsychiatry phenotype in asthma: Psychological stress-induced alterations of the neuroendocrine-immune system in allergic airway inflammation</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Brain</style></keyword><keyword><style face="normal" font="default"> Central Nervous System</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Glucocorticoids</style></keyword><keyword><style face="normal" font="default"> Hormones</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Nervous System</style></keyword><keyword><style face="normal" font="default"> Norepinephrine</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Signal Transduction</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="29" Month="6" Year="2017">2017/6/29</year></dates><abstract><style face="normal" font="default">Since the recognition of asthma as a syndrome with complex pathophysiological signs and symptoms, recent research has sought to classify asthma phenotypes based on its clinical and molecular pathological features. Psychological stress was first recognized as a potential immune system modulator of asthma at the end of the 19th century. The activation of the central nervous system (CNS) upon exposure to psychological stress is integral for the initiation of signal transduction processes. The stress hormones, including glucocorticoids, epinephrine, and norepinephrine, which are secreted following CNS activation, are involved in the immunological alterations involved in psychological stress-induced asthma exacerbation. The mechanisms underlying this process may involve a pathological series of events from the brain to the lungs, which is attracting attention as a conceptually advanced phenotype in asthma pathogenesis. This review presents insights into the critical role of psychological stress in the development and exacerbation of allergic asthma, with a special focus on our own data that emphasizes on the continuity from the central sensing of psychological stress to enhanced eosinophilic airway inflammation</style></abstract><notes><style face="normal" font="default">DA - 20170703IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.06.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28669635">PM:28669635</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170703-OhnoI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170703-OhnoI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170703, Ohno I</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.06.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41763</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kanegane,H.</style></author><author><style face="normal" font="default"> Hoshino,A.</style></author><author><style face="normal" font="default"> Okano,T.</style></author><author><style face="normal" font="default"> Yasumi,T.</style></author><author><style face="normal" font="default"> Wada,T.</style></author><author><style face="normal" font="default"> Takada,H.</style></author><author><style face="normal" font="default"> Okada,S.</style></author><author><style face="normal" font="default"> Yamashita,M.</style></author><author><style face="normal" font="default"> Yeh,T.W.</style></author><author><style face="normal" font="default"> Nishikomori,R.</style></author><author><style face="normal" font="default"> Takagi,M.</style></author><author><style face="normal" font="default"> Imai,K.</style></author><author><style face="normal" font="default"> Ochs,H.D.</style></author><author><style face="normal" font="default"> Morio,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default">Flow cytometry-based diagnosis of primary immunodeficiency diseases</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Agammaglobulinemia</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Candidiasis</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic granulomatous disease</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Haploinsufficiency</style></keyword><keyword><style face="normal" font="default"> Igm</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Severe Combined Immunodeficiency</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="3" Month="7" Year="2017">2017/7/3</year></dates><abstract><style face="normal" font="default">Primary immunodeficiencies (PIDs) are a heterogeneous group of inherited diseases of the immune system. The definite diagnosis of PID is ascertained by genetic analysis; however, this takes time and is costly. Flow cytometry provides a rapid and highly sensitive tool for diagnosis of PIDs. Flow cytometry can evaluate specific cell populations and subpopulations, cell surface, intracellular and intranuclear proteins, biologic effects associated with specific immune defects, and certain functional immune characteristics, each being useful for the diagnosis and evaluation of PIDs. Flow cytometry effectively identifies major forms of PIDs, including severe combined immunodeficiency, X-linked agammaglobulinemia, hyper IgM syndromes, Wiskott-Aldrich syndrome, X-linked lymphoproliferative syndrome, familial hemophagocytic lymphohistiocytosis, autoimmune lymphoproliferative syndrome, IPEX syndrome, CTLA 4 haploinsufficiency and LRBA deficiency, IRAK4 and MyD88 deficiencies, Mendelian susceptibility to mycobacterial disease, chronic mucocuneous candidiasis, and chronic granulomatous disease. While genetic analysis is the definitive approach to establish specific diagnoses of PIDs, flow cytometry provides a tool to effectively evaluate patients with PIDs at relatively low cost</style></abstract><notes><style face="normal" font="default">DA - 20170707IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan - CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.06.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28684198">PM:28684198</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170707-KaneganeH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170707-KaneganeH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170707, Kanegane H</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.06.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41764</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hirata,S.I.</style></author><author><style face="normal" font="default"> Kunisawa,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Vaccine Materials and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan</style></auth-address><titles><title><style face="normal" font="default">Gut microbiome, metabolome, and allergic diseases</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Dentistry</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> vaccine</style></keyword></keywords><dates><year Day="8" Month="7" Year="2017">2017/7/8</year></dates><abstract><style face="normal" font="default">The number of patients with allergic and inflammatory disorders has been increasing during the past several decades. Accumulating evidence has refined our understanding of the relationship between allergic diseases and the gut microbiome. In addition, the gut microbiome is now known to produce both useful and harmful metabolites from dietary materials. These metabolites and bacterial components help to regulate host immune responses and potentially affect the development of allergic diseases. Here, we describe recent findings regarding the immunologic crosstalk between commensal bacteria and dietary components in the regulation of host immunity and the influence of this relationship on the development of allergic diseases</style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.06.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28693971">PM:28693971</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170711-HirataSI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170711-HirataSI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170711, Hirata SI</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.06.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41765</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Calaforra-Mendez,S.</style></author><author><style face="normal" font="default"> Ibanez Echevarria,E.</style></author><author><style face="normal" font="default"> Perales Chorda,C.</style></author><author><style face="normal" font="default"> Pacheco-Coronel,M.V.</style></author><author><style face="normal" font="default"> Fernandez Llopez,A.</style></author><author><style face="normal" font="default"> Hernandez Fernandez de Rojas,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hospital Universitari i Politecnic La Fe, Valencia, Spain</style></auth-address><titles><title><style face="normal" font="default">Successful long-term prophylaxis with human plasma-derived C1 inhibitor in planning and carrying out pregnancy</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Long-term prophylaxis</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword></keywords><dates><year Day="14" Month="6" Year="2017">2017/6/14</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170618IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.05.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28624252">PM:28624252</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170618-CalaforraMendezS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170618-CalaforraMendezS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170618, Calaforra-Mendez S</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.05.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41766</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Imai,E.</style></author><author><style face="normal" font="default"> Enseki,M.</style></author><author><style face="normal" font="default"> Nukaga,M.</style></author><author><style face="normal" font="default"> Tabata,H.</style></author><author><style face="normal" font="default"> Hirai,K.</style></author><author><style face="normal" font="default"> Kato,M.</style></author><author><style face="normal" font="default"> Mochizuki,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Tokai University School of Medicine, Kanagawa, Japan</style></auth-address><titles><title><style face="normal" font="default">A lung sound analysis in a child thought to have cough variant asthma: A case report</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung sound analysis</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="30" Month="6" Year="2017">2017/6/30</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170704IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">0.1016/j.alit.2017.06.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28673440">PM:28673440</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170704-ImaiE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170704-ImaiE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170704, Imai E</style></custom2><misc3><style face="normal" font="default">0.1016/j.alit.2017.06.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41767</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ferstl,R.</style></author><author><style face="normal" font="default"> Frei,R.</style></author><author><style face="normal" font="default"> Barcik,W.</style></author><author><style face="normal" font="default"> Schiavi,E.</style></author><author><style face="normal" font="default"> Wanke,K.</style></author><author><style face="normal" font="default"> Ziegler,M.</style></author><author><style face="normal" font="default"> Rodriguez-Perez,N.</style></author><author><style face="normal" font="default"> Groeger,D.</style></author><author><style face="normal" font="default"> Konieczna,P.</style></author><author><style face="normal" font="default"> Zeiter,S.</style></author><author><style face="normal" font="default"> Nehrbass,D.</style></author><author><style face="normal" font="default"> Lauener,R.</style></author><author><style face="normal" font="default"> Akdis,C.A.</style></author><author><style face="normal" font="default"> O'Mahony,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Histamine Receptor 2 Modifies iNKT Cell Activity within the Inflamed Lung</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Dimaprit</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Famotidine</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> House dust</style></keyword><keyword><style face="normal" font="default"> house dust mite</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lipid</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Mucus</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> OVA</style></keyword><keyword><style face="normal" font="default"> Ovalbumin</style></keyword><keyword><style face="normal" font="default"> Ovum</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="15" Month="6" Year="2017">2017/6/15</year></dates><abstract><style face="normal" font="default">BACKGROUND: Histamine is a key immunoregulatory mediator and can dampen proinflammatory responses via activation of histamine receptor 2 (H2 R). The aim of this study was to determine the role of H2 R in modulating lung inflammatory responses. METHODS: H2 R was blocked using famotidine or activated using dimaprit in both the ovalbumin (OVA) and house dust mite extract (HDM) murine models of respiratory inflammation. H2 R-deficient animals and CD1d/ H2 R-deficient animals were utilized to examine the CD1d presentation of lipid antigens (alphaGal-Cer or OCH) to invariant Natural Killer T (iNKT) cells. RESULTS: Famotidine treatment resulted in more severe airway disease in the OVA model, while dimaprit treatment significantly reduced disease severity. Both OVA and HDM-induced airway disease were more severe in H2 R-deficient animals. Flow cytometric analysis of lung tissue from H2 R-deficient animals revealed increased numbers of CD1d+ dendritic cells and increased numbers of iNKT cells. In vitro, alphaGal-Cer-stimulated iNKT cells from H2 R-deficient mice secreted higher levels of IL-4, IL-5 and GM-CSF. In vivo, alphaGal-Cer or OCH administration to the lung resulted in enhanced mucus secretion, inflammatory cell recruitment and cytokine production in H2 R-deficient or famotidine-treated animals, while dimaprit dampened the lung iNKT cell response to alphaGalCer. Removal of iNKT cells in H2 R-deficient (CD1d-/- H2 R-/- ) animals normalized the lung response to HDM. CONCLUSION: The deliberate activation of H2 R, or its downstream signaling molecules, may represent a novel therapeutic target for chronic lung inflammatory diseases, especially when CD1d-mediated presentation of lipid antigens to iNKT cells are contributing to the pathology. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170615IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1111/all.13227</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28618071">PM:28618071</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170615-FerstlR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170615-FerstlR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170615, Ferstl R</style></custom2><misc3><style face="normal" font="default">10.1111/all.13227</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41768</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Furue,M.</style></author><author><style face="normal" font="default"> Yamamura,K.</style></author><author><style face="normal" font="default"> Kido-Nakahara,M.</style></author><author><style face="normal" font="default"> Nakahara,T.</style></author><author><style face="normal" font="default"> Fukui,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Division of Skin Surface Sensing, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan</style></auth-address><titles><title><style face="normal" font="default">Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Barrier dysfunction</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> dog</style></keyword><keyword><style face="normal" font="default"> Dogs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> IL-31</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Itch</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rodent</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> T-helper-2</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="3" Month="7" Year="2017">2017/7/3</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, severely pruritic skin disorder associated with skin barrier dysfunction. The lesional skin of AD exhibits T helper 2 (TH 2)-deviated immune reactions. Interleukin-31 (IL-31), preferentially produced from TH 2 cells, is a potent pruritogenic cytokine, and its systemic and local administration induces scratching behavior in rodents, dogs and monkeys. Recent clinical trials have revealed that administration of an anti-IL-31 receptor antibody significantly alleviates pruritus in patients with AD. In this review, we summarize recent topics related to IL-31 and its receptor with special references to atopic itch. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170703IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/all.13239</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28670717">PM:28670717</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170703-FurueM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170703-FurueM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170703, Furue M</style></custom2><misc3><style face="normal" font="default">10.1111/all.13239</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41769</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Couto,M.</style></author><author><style face="normal" font="default"> Kurowski,M.</style></author><author><style face="normal" font="default"> Moreira,A.</style></author><author><style face="normal" font="default"> Bullens,D.M.A.</style></author><author><style face="normal" font="default"> Carlsen,K.H.</style></author><author><style face="normal" font="default"> Delgado,L.</style></author><author><style face="normal" font="default"> Kowalski,M.L.</style></author><author><style face="normal" font="default"> Seys,S.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Unit, Hospital &amp; Instituto CUF Porto, PortugalDepartment of Immunology, Rheumatology and Allergy; Healthy Ageing Research Centre; Medical University of Lodz, Lodz, PolandBasic and Clinical Immunology, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal AND Servico de Imunoalergologia, Centro Hospitalar Sao Joao E.P.E, Porto, PortugalLaboratory of Pediatric Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium; AND Division of Pediatrics, UZ Leuven, Leuven, BelgiumUniversity of Oslo, Institute for Clinical Medicine, Oslo, NorwayBasic and Clinical Immunology, Department of Pathology, Faculty of Medicine, University of Porto, Porto, Portugal AND Servico de Imunoalergologia, Centro Hospitalar Sao Joao E.P.E, Porto, PortugalDepartment of Immunology, Rheumatology and Allergy; Healthy Ageing Research Centre; Medical University of Lodz, Lodz, PolandLaboratory of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="default">Mechanisms of exercise-induced bronchoconstriction in athletes: current perspectives and future challenges</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Athlete</style></keyword><keyword><style face="normal" font="default"> Athletes</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Clinical Medicine</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Endotypes</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial injury</style></keyword><keyword><style face="normal" font="default"> exercise-induced bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hypotheses</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> Norway</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="default">The evidence of exercise-induced bronchoconstriction (EIB) without asthma (EIBwA ) occurring in athletes led to speculate about different endotypes inducing respiratory symptoms within athletes. Classical postulated mechanisms for bronchial obstruction in this population include the osmotic and the thermal hypotheses. More recently, the presence of epithelial injury and inflammation in the airways of athletes was demonstrated. In addition, neuronal activation has been suggested as a potential modulator of bronchoconstriction. Investigation of these emerging mechanisms are of major importance since EIB is a significant problem for both recreational and competitive athletes and is the most common chronic condition among Olympic athletes, with obvious implications for their competing performance, health and quality of life. Hereby we summarize the latest achievements in this area and identify the current gaps of knowledge so that future research heads towards better defining the etiologic factors and mechanisms involved in development of EIB in elite athletes as well as essential aspects to ultimately propose preventive and therapeutic measures. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170609IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Portugal -CO - POland -CO - Belgium -CO - Norway -</style></notes><work-type><style face="normal" font="default">10.1111/all.13224</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28599081">PM:28599081</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170609-CoutoM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170609-CoutoM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170609, Couto M</style></custom2><misc3><style face="normal" font="default">10.1111/all.13224</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41770</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brunner,P.M.</style></author><author><style face="normal" font="default"> Emerson,R.O.</style></author><author><style face="normal" font="default"> Tipton,C.</style></author><author><style face="normal" font="default"> Garcet,S.</style></author><author><style face="normal" font="default"> Khattri,S.</style></author><author><style face="normal" font="default"> Coats,I.</style></author><author><style face="normal" font="default"> Krueger,J.G.</style></author><author><style face="normal" font="default"> Guttman-Yassky,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA</style></auth-address><titles><title><style face="normal" font="default">Non-lesional atopic dermatitis skin shares similar T-cell clones with lesional tissues</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> CXCL10</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diversity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expansion</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory mediators</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Lymphoma</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> persistence</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cell clone</style></keyword><keyword><style face="normal" font="default"> T-cell clones</style></keyword><keyword><style face="normal" font="default"> T-cell receptor</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Triamcinolone</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis (AD) is characterized by robust immune activation. Various T-cell subsets, including Th2/Th22 cells, are increased in lesional and non-lesional skin. However, there is conflicting literature on the diversity of the T-cell receptor (TCR) repertoire in lesional AD, and its relation to non-lesional skin remains unclear. METHODS: We performed high-throughput deep sequencing of the beta-TCR repertoire in 29 lesional and 19 non-lesional AD biopsies, compared to 6 healthy control and 6 cutaneous T-cell lymphoma (CTCL) samples from previously published cohorts. RESULTS: While greater T-cell infiltrates were observed in lesional vs. non-lesional AD, TCR repertoire diversity was similar in lesional and non-lesional tissues, and absolute numbers of unique T-cell clones correlated with respective T-cell counts. Most (87%) top expanded lesional T-cell clones were shared with non-lesional tissues, and they were largely maintained after 16 weeks of successful treatment with topical triamcinolone. Nevertheless, both lesional and non-lesional AD showed a highly polyclonal TCR pattern, without evidence of oligoclonal expansion, or a preferred usage of certain V-beta genes in AD skin. Size of the overall T-cell infiltrate, but not the level of clonality, correlated with mRNA levels of key inflammatory mediators (e.g. IL-13, CCL17, IL23p19, CXCL10). CONCLUSION: While AD harbors a highly polyclonal T-cell receptor repertoire, and despite the lack of information on TCR antigen specificity, the sharing of top abundant clones between lesional and non-lesional skin, and their persistence after months of therapy, points to the continuous presence of potentially pathogenic skin resident memory T-cells well beyond clinically inflamed lesions. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170609IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.13223</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28599078">PM:28599078</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170609-BrunnerPM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170609-BrunnerPM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170609, Brunner PM</style></custom2><misc3><style face="normal" font="default">10.1111/all.13223</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41771</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Baretto,R.L.</style></author><author><style face="normal" font="default"> Beck,S.</style></author><author><style face="normal" font="default"> Heslegrave,J.</style></author><author><style face="normal" font="default"> Melchior,C.</style></author><author><style face="normal" font="default"> Mohamed,O.</style></author><author><style face="normal" font="default"> Ekbote,A.</style></author><author><style face="normal" font="default"> Huissoon,A.P.</style></author><author><style face="normal" font="default"> Krishna,M.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy &amp; Immunology, Heart of England NHS Foundation Trust, Birmingham, UK</style></auth-address><titles><title><style face="normal" font="default">Validation of International consensus equation for acute serum total tryptase in mast cell activation: A perioperative perspective</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaesthesia</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Chlorhexidine</style></keyword><keyword><style face="normal" font="default"> Consensus</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> England</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patent Blue</style></keyword><keyword><style face="normal" font="default"> Patent blue dye</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Perioperative anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> ROC</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="13" Month="6" Year="2017">2017/6/13</year></dates><abstract><style face="normal" font="default">INTRODUCTION: There is no standardised method for assessing serum total mast cell tryptase (MCT) in anaphylaxis. The consensus equation (peak MCT should be>1.2x baseline tryptase+2mg/L) has been proposed to interpret acute MCT in mast cell activation syndrome (MCAS). AIM: To validate consensus equation in a setting of perioperative anaphylaxis. METHODS: Analyses of suspected perioperative anaphylaxis during general anaesthesia (GA). Anaphylaxis was defined as per World Allergy Organisation (WAO) criteria. Timed serial MCT measurements were mapped against the consensus equation and receiver operating characteristic (ROC) curves produced. RESULTS: 82 patients (60 females, mean age 56.5 years +/- SD17.2) underwent investigation. 60 (73%) patients fulfilled WAO criteria for anaphylaxis and 22 patients did not (controls). Aetiology: 59% IgE-mediated anaphylaxis, 2% non-IgE mediated anaphylaxis, 12% anaphylaxis of unknown cause, and 27% deemed non-anaphylaxis. IgE-mediated anaphylaxis included - NMBA (35%), antibiotics (46%), chlorhexidine (8%), patent blue dye (8%) and others (8%). An acute MCT with a comparable baseline was available in 71/82 (87%) patients (60-anaphylaxis and 11-controls).The median (IQR) time from reaction to peak MCT was 1.34 (0.82-2.51) hours. Analyses confirmed that a rise in acute MCT greater than that defined by the equation had a sensitivity, specificity, positive predictive value (PPV) and negative (N) PV of 78%, 91%, 98%, and 44% respectively. The magnitude of increase in acute MCT above the threshold predicted by consensus equation was higher in the anaphylaxis group compared to controls (P=0.0001). CONCLUSION: This equation has a high specificity, PPV with a moderate NPV and sensitivity in perioperative anaphylaxis. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170613IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/all.13226</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28609557">PM:28609557</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170613-BarettoRL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170613-BarettoRL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170613, Baretto RL</style></custom2><misc3><style face="normal" font="default">10.1111/all.13226</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41772</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jatzlauk,G.</style></author><author><style face="normal" font="default"> Bartel,S.</style></author><author><style face="normal" font="default"> Heine,H.</style></author><author><style face="normal" font="default"> Schloter,M.</style></author><author><style face="normal" font="default"> Krauss-Etschmann,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Early Life Origins of Chronic Lung Diseases, Priority Area Asthma and Allergy, Research Center Borstel, Leibniz-Center for Medicine and Biosciences, Member of the Airway Research Center North (ARCN), German Center for Lung Research (DZL), Borstel, Germany</style></auth-address><titles><title><style face="normal" font="default">Influences of environmental bacteria and their metabolites on allergies, asthma and host microbiota</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Epidemiological studies</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Lung Diseases</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbes</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword></keywords><dates><year Day="10" Month="6" Year="2017">2017/6/10</year></dates><abstract><style face="normal" font="default">The prevalence of allergic diseases and asthma has dramatically increased over the last decades, resulting in a high burden for patients and health care systems. Thus, there is an unmet need to develop preventative strategies for these diseases. Epidemiological studies show that reduced exposure to environmental bacteria in early life (e.g birth by cesarian section, being formula-fed, growing up in an urban environment or with less contact to various persons) is associated with an increased risk to develop allergies and asthma later in life. Conversely, a reduced risk for asthma is consistently found in children growing up on traditional farms, thereby being exposed to a wide spectrum of microbes. However, clinical studies are still rare and to some extent contradicting. A detailed mechanistic understanding how environmental microbes influence the development of the human microbiome and the immune system is important to enable the development of novel preventative approaches that are based on the early modulation of the host microbiota and immunity. In this mini-review we summarize current knowledge and experimental evidence for the potential of bacteria and their metabolites to be used for the prevention of asthma and allergic diseases. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170610IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/all. 13220</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28600901">PM:28600901</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170610-Jatzlauk.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170610-Jatzlauk.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170610, Jatzlauk</style></custom2><misc3><style face="normal" font="default">10.1111/all. 13220</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41773</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bousquet,J.</style></author><author><style face="normal" font="default"> Agache,I.</style></author><author><style face="normal" font="default"> Aliberti,M.R.</style></author><author><style face="normal" font="default"> Angles,R.</style></author><author><style face="normal" font="default"> Annesi-Maesano,I.</style></author><author><style face="normal" font="default"> Anto,J.M.</style></author><author><style face="normal" font="default"> Arnavielhe,S.</style></author><author><style face="normal" font="default"> Asayag,E.</style></author><author><style face="normal" font="default"> Bacci,E.</style></author><author><style face="normal" font="default"> Bedbrook,A.</style></author><author><style face="normal" font="default"> Bachert,C.</style></author><author><style face="normal" font="default"> Baroni,I.</style></author><author><style face="normal" font="default"> Barreto,B.A.</style></author><author><style face="normal" font="default"> Bedolla-Barajas,M.</style></author><author><style face="normal" font="default"> Bergmann,K.C.</style></author><author><style face="normal" font="default"> Bertorello,L.</style></author><author><style face="normal" font="default"> Bewick,M.</style></author><author><style face="normal" font="default"> Bieber,T.</style></author><author><style face="normal" font="default"> Birov,S.</style></author><author><style face="normal" font="default"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="default"> Blua,A.</style></author><author><style face="normal" font="default"> Bochenska Marciniak,M.</style></author><author><style face="normal" font="default"> Bogus-Buczynska,I.</style></author><author><style face="normal" font="default"> Bosnic-Anticevich,S.</style></author><author><style face="normal" font="default"> Bosse,I.</style></author><author><style face="normal" font="default"> Bourret,R.</style></author><author><style face="normal" font="default"> Bucca,C.</style></author><author><style face="normal" font="default"> Buonaiuto,R.</style></author><author><style face="normal" font="default"> Caiazza,D.</style></author><author><style face="normal" font="default"> Caillot,D.</style></author><author><style face="normal" font="default"> Caimmi,D.P.</style></author><author><style face="normal" font="default"> Camargos,P.</style></author><author><style face="normal" font="default"> Canfora,G.</style></author><author><style face="normal" font="default"> Cardona,V.</style></author><author><style face="normal" font="default"> Carriazo,A.M.</style></author><author><style face="normal" font="default"> Cartier,C.</style></author><author><style face="normal" font="default"> Castellano,G.</style></author><author><style face="normal" font="default"> Chavannes,N.H.</style></author><author><style face="normal" font="default"> Ciaravolo,M.M.</style></author><author><style face="normal" font="default"> Cingi,C.</style></author><author><style face="normal" font="default"> Ciceran,A.</style></author><author><style face="normal" font="default"> Colas,L.</style></author><author><style face="normal" font="default"> Colgan,E.</style></author><author><style face="normal" font="default"> Coll,J.</style></author><author><style face="normal" font="default"> Conforti,D.</style></author><author><style face="normal" font="default"> de Sousa,J.C.</style></author><author><style face="normal" font="default"> Cortes-Grimaldo,R.M.</style></author><author><style face="normal" font="default"> Corti,F.</style></author><author><style face="normal" font="default"> Costa,E.</style></author><author><style face="normal" font="default"> Courbis,A.L.</style></author><author><style face="normal" font="default"> Cousein,E.</style></author><author><style face="normal" font="default"> Cruz,A.A.</style></author><author><style face="normal" font="default"> Custovic,A.</style></author><author><style face="normal" font="default"> Cvetkovski,B.</style></author><author><style face="normal" font="default"> Dario,C.</style></author><author><style face="normal" font="default"> da Silva,M.</style></author><author><style face="normal" font="default"> Dauvilliers,Y.</style></author><author><style face="normal" font="default"> de Blay,F.</style></author><author><style face="normal" font="default"> Dedeu,T.</style></author><author><style face="normal" font="default"> De Feo,G.</style></author><author><style face="normal" font="default"> De Martino,B.</style></author><author><style face="normal" font="default"> Demoly,P.</style></author><author><style face="normal" font="default"> De Vries,G.</style></author><author><style face="normal" font="default"> Di Capua,E.S.</style></author><author><style face="normal" font="default"> Di Carluccio,N.</style></author><author><style face="normal" font="default"> Doulapsi,M.</style></author><author><style face="normal" font="default"> Dray,G.</style></author><author><style face="normal" font="default"> Dubakiene,R.</style></author><author><style face="normal" font="default"> Eller,E.</style></author><author><style face="normal" font="default"> Emuzyte,R.</style></author><author><style face="normal" font="default"> Espinoza-Contreras,J.M.</style></author><author><style face="normal" font="default"> Estrada-Cardona,A.</style></author><author><style face="normal" font="default"> Farrell,J.</style></author><author><style face="normal" font="default"> Ferrero,J.</style></author><author><style face="normal" font="default"> Fokkens,W.J.</style></author><author><style face="normal" font="default"> Fonseca,J.</style></author><author><style face="normal" font="default"> Fontaine,J.F.</style></author><author><style face="normal" font="default"> Forti,S.</style></author><author><style face="normal" font="default"> Galvez-Romero,J.L.</style></author><author><style face="normal" font="default"> Garcia-Cobas,C.I.</style></author><author><style face="normal" font="default"> Cruz,M.H.G.</style></author><author><style face="normal" font="default"> Gemicioglu,B.</style></author><author><style face="normal" font="default"> van Wijk,R.G.</style></author><author><style face="normal" font="default"> Guidacci,M.</style></author><author><style face="normal" font="default"> Gomez-Vera,J.</style></author><author><style face="normal" font="default"> Guldemond,N.A.</style></author><author><style face="normal" font="default"> Gutter,Z.</style></author><author><style face="normal" font="default"> Haahtela,T.</style></author><author><style face="normal" font="default"> Hajjam,J.</style></author><author><style face="normal" font="default"> Hellings,P.W.</style></author><author><style face="normal" font="default"> Hernandez-Velazquez,L.</style></author><author><style face="normal" font="default"> Illario,M.</style></author><author><style face="normal" font="default"> Ivancevich,J.C.</style></author><author><style face="normal" font="default"> Jares,E.</style></author><author><style face="normal" font="default"> Joos,G.</style></author><author><style face="normal" font="default"> Just,J.</style></author><author><style face="normal" font="default"> Kalayci,O.</style></author><author><style face="normal" font="default"> Kalyoncu,A.F.</style></author><author><style face="normal" font="default"> Karjalainen,J.</style></author><author><style face="normal" font="default"> Keil,T.</style></author><author><style face="normal" font="default"> Khaltaev,N.</style></author><author><style face="normal" font="default"> Klimek,L.</style></author><author><style face="normal" font="default"> Kritikos,V.</style></author><author><style face="normal" font="default"> Kull,I.</style></author><author><style face="normal" font="default"> Kuna,P.</style></author><author><style face="normal" font="default"> Kvedariene,V.</style></author><author><style face="normal" font="default"> Kolek,V.</style></author><author><style face="normal" font="default"> Krzych-Falta,E.</style></author><author><style face="normal" font="default"> Kupczyk,M.</style></author><author><style face="normal" font="default"> Lacwik,P.</style></author><author><style face="normal" font="default"> Larenas-Linnemann,D.</style></author><author><style face="normal" font="default"> Laune,D.</style></author><author><style face="normal" font="default"> Lauri,D.</style></author><author><style face="normal" font="default"> Lavrut,J.</style></author><author><style face="normal" font="default"> Lessa,M.</style></author><author><style face="normal" font="default"> Levato,G.</style></author><author><style face="normal" font="default"> Lewis,L.</style></author><author><style face="normal" font="default"> Lieten,I.</style></author><author><style face="normal" font="default"> Lipiec,A.</style></author><author><style face="normal" font="default"> Louis,R.</style></author><author><style face="normal" font="default"> Luna-Pech,J.A.</style></author><author><style face="normal" font="default"> Magnan,A.</style></author><author><style face="normal" font="default"> Malva,J.</style></author><author><style face="normal" font="default"> Maspero,J.F.</style></author><author><style face="normal" font="default"> Matta-Campos,J.J.</style></author><author><style face="normal" font="default"> Mayora,O.</style></author><author><style face="normal" font="default"> Medina-Avalos,M.A.</style></author><author><style face="normal" font="default"> Melen,E.</style></author><author><style face="normal" font="default"> Menditto,E.</style></author><author><style face="normal" font="default"> Millot-Keurinck,J.</style></author><author><style face="normal" font="default"> Moda,G.</style></author><author><style face="normal" font="default"> Morais-Almeida,M.</style></author><author><style face="normal" font="default"> Mosges,R.</style></author><author><style face="normal" font="default"> Mota-Pinto,A.</style></author><author><style face="normal" font="default"> Mullol,J.</style></author><author><style face="normal" font="default"> Muraro,A.</style></author><author><style face="normal" font="default"> Murray,R.</style></author><author><style face="normal" font="default"> Nogues,M.</style></author><author><style face="normal" font="default"> Nalin,M.</style></author><author><style face="normal" font="default"> Napoli,L.</style></author><author><style face="normal" font="default"> Neffen,H.</style></author><author><style face="normal" font="default"> O'Hehir,R.E.</style></author><author><style face="normal" font="default"> Onorato,G.</style></author><author><style face="normal" font="default"> Palkonen,S.</style></author><author><style face="normal" font="default"> Papadopoulos,N.G.</style></author><author><style face="normal" font="default"> Passalacqua,G.</style></author><author><style face="normal" font="default"> Pepin,J.L.</style></author><author><style face="normal" font="default"> Pereira,A.M.</style></author><author><style face="normal" font="default"> Persico,M.</style></author><author><style face="normal" font="default"> Pfaar,O.</style></author><author><style face="normal" font="default"> Pozzi,A.C.</style></author><author><style face="normal" font="default"> Prokopakis,E.</style></author><author><style face="normal" font="default"> Raciborski,F.</style></author><author><style face="normal" font="default"> Rimmer,J.</style></author><author><style face="normal" font="default"> Rizzo,J.A.</style></author><author><style face="normal" font="default"> Robalo-Cordeiro,C.</style></author><author><style face="normal" font="default"> Rodriguez-Gonzalez,M.</style></author><author><style face="normal" font="default"> Rolla,G.</style></author><author><style face="normal" font="default"> Roller-Wirnsberger,R.E.</style></author><author><style face="normal" font="default"> Romano,A.</style></author><author><style face="normal" font="default"> Romano,M.</style></author><author><style face="normal" font="default"> Salimaki,J.</style></author><author><style face="normal" font="default"> Samolinski,B.</style></author><author><style face="normal" font="default"> Serpa,F.S.</style></author><author><style face="normal" font="default"> Shamai,S.</style></author><author><style face="normal" font="default"> Sierra,M.</style></author><author><style face="normal" font="default"> Sova,M.</style></author><author><style face="normal" font="default"> Sorlini,M.</style></author><author><style face="normal" font="default"> Stellato,C.</style></author><author><style face="normal" font="default"> Stelmach,R.</style></author><author><style face="normal" font="default"> Strandberg,T.</style></author><author><style face="normal" font="default"> Stroetmann,V.</style></author><author><style face="normal" font="default"> Stukas,R.</style></author><author><style face="normal" font="default"> Szylling,A.</style></author><author><style face="normal" font="default"> Tan,R.</style></author><author><style face="normal" font="default"> Tibaldi,V.</style></author><author><style face="normal" font="default"> Todo-Bom,A.</style></author><author><style face="normal" font="default"> Toppila-Salmi,S.</style></author><author><style face="normal" font="default"> Tomazic,P.</style></author><author><style face="normal" font="default"> Trama,U.</style></author><author><style face="normal" font="default"> Triggiani,M.</style></author><author><style face="normal" font="default"> Valero,A.</style></author><author><style face="normal" font="default"> Valovirta,E.</style></author><author><style face="normal" font="default"> Valiulis,A.</style></author><author><style face="normal" font="default"> van Eerd,M.</style></author><author><style face="normal" font="default"> Vasankari,T.</style></author><author><style face="normal" font="default"> Vatrella,A.</style></author><author><style face="normal" font="default"> Ventura,M.T.</style></author><author><style face="normal" font="default"> Verissimo,M.T.</style></author><author><style face="normal" font="default"> Viart,F.</style></author><author><style face="normal" font="default"> Williams,S.</style></author><author><style face="normal" font="default"> Wagenmann,M.</style></author><author><style face="normal" font="default"> Wanscher,C.</style></author><author><style face="normal" font="default"> Westman,M.</style></author><author><style face="normal" font="default"> Wickman,M.</style></author><author><style face="normal" font="default"> Young,I.</style></author><author><style face="normal" font="default"> Yorgancioglu,A.</style></author><author><style face="normal" font="default"> Zernotti,E.</style></author><author><style face="normal" font="default"> Zurbierber,T.</style></author><author><style face="normal" font="default"> Zurkuhlen,A.</style></author><author><style face="normal" font="default"> De Oliviera,B.</style></author><author><style face="normal" font="default"> Senn,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">MACVIA-France, Contre les MAladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France</style></auth-address><titles><title><style face="normal" font="default">Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - Reference Site Twinning (EIP on AHA)</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Argentina</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Austria</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Communication</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Czech Republic</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dentistry</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> elderly</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Ireland</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Mexico</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Romania</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> VAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="10" Month="6" Year="2017">2017/6/10</year></dates><abstract><style face="normal" font="default">The overarching goals of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) are to enable European citizens to lead healthy, active and independent lives while ageing. The EIP on AHA includes 74 Reference Sites. The aim of this study is to transfer innovation from an App developed by the MACVIA-France EIP on AHA reference site (Allergy Diary) to other reference sites. The phenotypic characteristics of rhinitis and asthma multimorbidity in adults and the elderly will be compared using validated information and communication technology (ICT) tools (i.e. the Allergy Diary and CARAT: Control of Allergic Rhinitis and Asthma Test) in 22 Reference Sites or regions across Europe. This will improve understanding, assessment of burden, diagnosis and management of rhinitis in the elderly by comparison with an adult population. Specific objectives will: (i) assess the percentage of adults and elderly who are able to use the Allergy Diary, (ii) study phenotypic characteristics and treatment over a period of one year of rhinitis and asthma multimorbidity at baseline (cross-sectional study) and (iii) follow-up using visual analogue scale (VAS). This part of the study may provide some insight into the differences between the elderly and adults in terms of response to treatment and practice. Finally (iv) work productivity will be examined in adults. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170610IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - France -CO - Romania -CO - Spain -CO - Italy -CO - Argentina -CO - Belgium -CO - Brazil -CO - Mexico -CO - Germany -CO - United Kingdom -CO - Turkey -CO - Sweden -CO - Denmark -CO - Portugal -CO - Netherlands -CO - Austria -CO - Australia -CO - Finland -CO - Poland -CO - Lithuania -CO - Czechia -CO - Switzerland -CO - Ireland -CO - Greece -</style></notes><work-type><style face="normal" font="default">10.1111/all.13218</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28600902">PM:28600902</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170610-BousquetJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170610-BousquetJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170610, Bousquet J</style></custom2><misc3><style face="normal" font="default">10.1111/all.13218</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41774</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Khan,S.J.</style></author><author><style face="normal" font="default"> Dharmage,S.C.</style></author><author><style face="normal" font="default"> Matheson,M.C.</style></author><author><style face="normal" font="default"> Gurrin,L.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="default">Is the atopic march related to confounding by genetics and early life environment? A systematic review of sibship and twin data</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Developed Countries</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> early childhood</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Health</style></keyword><keyword><style face="normal" font="default"> Hay Fever</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Victoria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="15" Month="6" Year="2017">2017/6/15</year></dates><abstract><style face="normal" font="default">A popular hypothesis known as the atopic march proposes a set of sequential allergy and respiratory disorders in early childhood contributes enormously to the burden of disease in developed countries. Although the concept of the atopic march has been refined and strengthened by many cross-sectional and longitudinal studies linking eczema as the initial manifestation with progression to hay fever and then asthma, there is yet no definitive proof that the atopic march is the primary causal factor in childhood allergic disease. This debate is mainly related to the controversy around potential confounding of these associations by genetic and environmental factors. Family studies are ideally suited to unravelling the role of these factors. While multiple reviews have synthesised evidence from studies investigating this question, no review to date has explored specific evidence generated by twin and sibling studies to understand the aetiology of atopic march diseases. Our aim was to conduct a systematic review of twin and sibling studies that examine the allergic phenotypes that form the atopic march, to determine whether such analyses of data from these studies attempt to control for the effect confounding by shared factors, and to report estimates the magnitude of associations between multiple phenotypes. Our review suggests that (1) genetics play a bigger role predisposing eczema to hay fever and eczema to asthma than environmental factors; and (2) the link between eczema, and asthma and hay fever is independent of shared early life environmental factors and genetics. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170615IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/all.13228</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28618023">PM:28618023</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170615-KhanSJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170615-KhanSJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170615, Khan SJ</style></custom2><misc3><style face="normal" font="default">10.1111/all.13228</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41775</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lin,X.</style></author><author><style face="normal" font="default"> Lv,J.</style></author><author><style face="normal" font="default"> Lv,J.</style></author><author><style face="normal" font="default"> Di,C.</style></author><author><style face="normal" font="default"> Zhang,Y.</style></author><author><style face="normal" font="default"> Zhou,T.</style></author><author><style face="normal" font="default"> Liu,J.</style></author><author><style face="normal" font="default"> Xia,Z.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, 197 Ruijin 2nd Road, Shanghai, 200025, China</style></auth-address><titles><title><style face="normal" font="default">Heme oxygenase-1 directly binds STAT3 to control the generation of pathogenic Th17 cells during neutrophilic airway inflammation</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Cell Differentiation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Feedback</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Heme Oxygenase-1</style></keyword><keyword><style face="normal" font="default"> Hemin</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> Mutant</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Rna</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH17</style></keyword><keyword><style face="normal" font="default"> TH17 cells</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Western blot</style></keyword></keywords><dates><year Day="5" Month="6" Year="2017">2017/6/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Specific JAK/STAT pathways play a critical role in the functional differentiation of distinct Th subsets. Previously, we showed that HO-1, a stress-inducible protein, inhibits Th17 cell differentiation and alleviates neutrophilic airway inflammation, but the responsible molecular basis remains unclear. METHODS: We employed Th17-skewing differentiation and NEA mouse models to study the role of HO-1 regulating IL-6-STAT3-RORgammat/SOCS3 signaling pathway to control Th17 cell-mediated neutrophilic airway inflammation. The levels of cytokines and expressions of relative signaling molecular were measured by ELISA, western blot and qPCR, respectively. Frequency of CD4+ IL-17A+ , CD4+ IL-6R+ and CD4+ IL-23R+ cells was analyzed by FCM. The interaction between HO-1 and signaling pathway-related proteins was determined by Co-Immunoprecipitation and western blot. RESULTS: Here, we show that hemin-induced HO-1 over-expression is required to mediate this process. Specifically, HO-1 decreased STAT3 phosphorylation but not IL-6R/IL-23R expression or JAK1/JAK2 activation in CD4+ T cells. The effect was accompanied by co-inhibition of SOCS3, a negative feedback factor of STAT3 activation. HO-1 bound to three domains on STAT3, (DNA-binding, linker and transactivation domains) to directly regulate STAT3 activation. Conversely, either forced expression of a constitutively active STAT3 mutant or application of small interfering RNA (siRNA) for HO-1 reversed these effects. CONCLUSIONS: Our data suggest that HO-1 exerts its inhibitory effect on Th17 cell differentiation by directly associating and blocking STAT3 phosphorylation. We speculate that hemin may be a potential therapeutic candidate for the treatment of other types of immune and pulmonary inflammatory-related diseases. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170605IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1111/all.13216</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28580587">PM:28580587</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170605-LinX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170605-LinX.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170605, Lin X</style></custom2><misc3><style face="normal" font="default">10.1111/all.13216</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41776</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Loffredo,L.F.</style></author><author><style face="normal" font="default"> Abdala-Valencia,H.</style></author><author><style face="normal" font="default"> Anekalla,K.R.</style></author><author><style face="normal" font="default"> Cuervo-Pardo,L.</style></author><author><style face="normal" font="default"> Gottardi,C.J.</style></author><author><style face="normal" font="default"> Berdnikovs,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</style></auth-address><titles><title><style face="normal" font="default">Beyond epithelial-to-mesenchymal transition: common suppression of differentiation programs underlies epithelial barrier dysfunction in mild, moderate and severe asthma</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> and primary</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Barrier dysfunction</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> dysregulation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> Epigenetics</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Illinois</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> Insulin</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mining</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Notch</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Repair</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> suppression</style></keyword><keyword><style face="normal" font="default"> Transcriptome</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Epithelial barrier dysfunction is a central feature in the pathogenesis of allergic disease. Epithelial-to-mesenchymal transition (EMT) has been proposed as one mechanism afflicting barrier in asthma. However, genes and pathways involved in aberrant epithelial-mesenchymal signaling, and their relationship to asthma severity, are poorly understood. METHODS: We used unbiased gene network analysis to evaluate functional convergence in epithelial gene expression signatures across multiple public access transcriptomics datasets of human asthma, followed by text mining to evaluate functional marker relevance of discovered genes. We objectively confirmed these findings in epithelial brushings and primary asthmatic epithelial cells cultured in different biological contexts. RESULTS: We found a striking suppression of epithelial differentiation in asthma, overrepresented by insufficiency in insulin and Notch signaling, but with the absence of conventional EMT markers. We identified EFNB2, FGFR1, FGFR2, INSR, IRS2, NOTCH2, TLE1, and NTRK2 as novel markers central to dysregulation of epithelial-mesenchymal signaling, but surprisingly overlooked in asthma research. We found that this "core" signature of asthma is shared by mild, moderate, and severe forms of disease, progressing with severity. Loss of epithelial differentiation induced by insulin deprivation in normal human bronchial epithelial cells cultured in organotypic conditions closely approximated gene expression in asthmatic epithelial brushings. CONCLUSIONS: The comparative analysis of publically available transcriptomes demonstrated that epithelial barrier dysfunction in asthma is characterized by persistent underlying de-differentiation program with complex etiology. The lasting alteration of the asthmatic epithelial cell transcriptome implicates regulation involving metabolism and epigenetics, beyond EMT driven by injury and repair in chronic inflammation. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170609IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.13222</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28599074">PM:28599074</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170609-LoffredoLF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170609-LoffredoLF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170609, Loffredo LF</style></custom2><misc3><style face="normal" font="default">10.1111/all.13222</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41777</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Klimek,L.</style></author><author><style face="normal" font="default"> Koennecke,M.</style></author><author><style face="normal" font="default"> Mullol,J.</style></author><author><style face="normal" font="default"> Hellings,P.W.</style></author><author><style face="normal" font="default"> Wang,D.Y.</style></author><author><style face="normal" font="default"> Fokkens,W.</style></author><author><style face="normal" font="default"> Gevaert,P.H.</style></author><author><style face="normal" font="default"> Wollenberg,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Rhinology and Allergology, An den Quellen 10, D-65183, Wiesbaden, Germany</style></auth-address><titles><title><style face="normal" font="default">A possible role of stem cells in nasal polyposis</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergology</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Characterization</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyposis</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Polyposis</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Stem Cells</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="default">Since its discovery, the understanding of stem/progenitor cells raised dramatically in the last decade. Their regenerative potential is important to develop new therapeutic applications, but the identification advanced much faster than our understanding of stem/progenitor cells. In nasal polyposis, little is known about stem cells/progenitor cells and their ability. However, the further characterization of stem cells/progenitor cells may provide new treatment options for combating nasal polyposis. This review highlights the knowledge of the current literature about stem cells/progenitor cells in nasal polyposis and how this may be exploited in the development of novel treatment strategies. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170609IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -CO - Belgium -CO - Netherlands -CO - Spain -CO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1111/all.13221</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28599061">PM:28599061</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170609-KlimekL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170609-KlimekL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170609, Klimek L</style></custom2><misc3><style face="normal" font="default">10.1111/all.13221</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41778</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Laratta,C.R.</style></author><author><style face="normal" font="default"> Williams,K.</style></author><author><style face="normal" font="default"> Vethanayagam,D.</style></author><author><style face="normal" font="default"> Ulanova,M.</style></author><author><style face="normal" font="default"> Vliagoftis,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pulmonary Research Group, Department of Medicine, University of Alberta, Edmonton, AB Canada</style></auth-address><titles><title><style face="normal" font="default">A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Clin Immunol</style></full-title></periodical><pages end="" start="27">27-</pages><volume><style face="normal" font="default">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Adult asthma</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pneumococcal disease</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vaccination</style></keyword><keyword><style face="normal" font="default"> vaccine</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is an independent risk factor for invasive pneumococcal disease; however, the immune response of adult asthma patients to pneumococcal vaccination is unknown. We explore the serologic response of patients with moderate to severe asthma to the 23-valent pneumococcal polysaccharide vaccine (PPSV23). METHODS: Seventeen moderate to severe adult asthma patients that had not been vaccinated against pneumococcus over the 5 previous years were prospectively recruited from a tertiary care asthma clinic. Serum was analyzed for the presence of antibodies to five capsular polysaccharide (CP) antigens (6B, 9V, 19A, 19F, 23F) before and 4 weeks after PPSV23 vaccination. RESULTS: There was a wide variability in baseline anti-CP antibody concentrations. Other than for serotype 19A, our patients frequently have baseline anti-CP antibody concentrations below 1 microg/mL (35% for serotype 19F, 41% for serotypes 9V and 23F, and 59% for serotype 6B). All post-vaccination geometric mean antibody concentrations were significantly higher than baseline. In the 31 tests where the baseline antibody concentration was &lt;1 microg/mL, 77.4% had at least a twofold increase post-vaccination. Despite this, a large proportion of post-vaccination anti-CP antibody concentrations remained &lt;1 microg/mL (51.6% of tests). Nine patients had at least one anti-CP antibody concentration &lt;1 microg/mL post-vaccination. There was no difference between these patients and the remaining eight patients in demographic or clinical variables. CONCLUSIONS: Patients with moderate to severe asthma have variable baseline and low post-vaccination antibody concentrations to common CP antigens included in the PPSV23 vaccine. The clinical relevance of these observations remains to be determined since the threshold concentration in adults required for clinical protection from invasive pneumococcal disease is uncertain</style></abstract><notes><style face="normal" font="default">DA - 20170609IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1186/s13223-017-0200-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28596792">PM:28596792</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-27.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170609, Laratta CR</style></custom2><misc3><style face="normal" font="default">10.1186/s13223-017-0200-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41779</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aberer,W.</style></author><author><style face="normal" font="default"> Maurer,M.</style></author><author><style face="normal" font="default"> Bouillet,L.</style></author><author><style face="normal" font="default"> Zanichelli,A.</style></author><author><style face="normal" font="default"> Caballero,T.</style></author><author><style face="normal" font="default"> Longhurst,H.J.</style></author><author><style face="normal" font="default"> Perrin,A.</style></author><author><style face="normal" font="default"> Andresen,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Venerology, Medical University of Graz, Auenbruggerplatz 8, A-8036 Graz, Austria</style></auth-address><titles><title><style face="normal" font="default">Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Clin Immunol</style></full-title></periodical><pages end="" start="31">31-</pages><volume><style face="normal" font="default">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Austria</style></keyword><keyword><style face="normal" font="default"> C1 INH</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor deficiency</style></keyword><keyword><style face="normal" font="default"> C1-INH</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> C1Inh</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Emergency Treatment</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Icatibant</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Long-term prophylaxis</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> rescue medication</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patients with hereditary angioedema (HAE) due to C1-inhibitor deficiency (C1-INH-HAE) experience recurrent attacks of cutaneous or submucosal edema that may be frequent and severe; prophylactic treatments can be prescribed to prevent attacks. However, despite the use of long-term prophylaxis (LTP), breakthrough attacks are known to occur. We used data from the Icatibant Outcome Survey (IOS) to evaluate the characteristics of breakthrough attacks and the effectiveness of icatibant as a treatment option. METHODS: Data on LTP use, attacks, and treatments were recorded. Attack characteristics, treatment characteristics, and outcomes (time to treatment, time to resolution, and duration of attack) were compared for attacks that occurred with versus without LTP. RESULTS: Data on 3228 icatibant-treated attacks from 448 patients with C1-INH-HAE were analyzed; 30.1% of attacks occurred while patients were using LTP. Attack rate, attack severity, and the distribution of attack sites were similar across all types of LTP used, and were comparable to the results found in patients who did not receive LTP. Attacks were successfully treated with icatibant; 82.5% of all breakthrough attacks were treated with a single icatibant injection without C1-INH rescue medication. Treatment outcomes were comparable for breakthrough attacks across all LTP types, and for attacks without LTP. CONCLUSIONS: Patients who use LTP should be aware that breakthrough attacks can occur, and such attacks can be severe. Thus, patients with C1-INH-HAE using LTP should have emergency treatment readily available. Data from IOS show that icatibant is effective for the treatment of breakthrough attacks. Trial Registration NCT01034969</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Germany -CO - France -CO - Italy -CO - Spain -CO - United Kingdom -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1186/s13223-017-0203-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28690642">PM:28690642</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-31.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170710, Aberer W</style></custom2><misc3><style face="normal" font="default">10.1186/s13223-017-0203-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41780</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sellers,W.F.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Broadgate House, 22 Broadgate, Great Easton, Leicestershire, LE16 8SH UK</style></auth-address><titles><title><style face="normal" font="default">Asthma pressurised metered dose inhaler performance: propellant effect studies in delivery systems</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Clin Immunol</style></full-title></periodical><pages end="" start="30">30-</pages><volume><style face="normal" font="default">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> chlorofluorocarbon</style></keyword><keyword><style face="normal" font="default"> Chlorofluorocarbons</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> delivery devices</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Oxygen</style></keyword><keyword><style face="normal" font="default"> Partial Pressure</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Current pressurised metered dose asthma inhaler (pMDI) propellants are not inert pharmacologically as were previous chlorofluorocarbons, have smooth muscle relaxant' partial pressure effects in the lungs and inhaled hydrofluoroalkane 134a (norflurane) has anaesthetic effects. Volumes of propellant gas per actuation have never been measured. METHODS: In-vitro studies measured gas volumes produced by pMDIs on air oxygen (O2) levels in valved holding chambers (VHC) and the falls in O2% following actuation into lung ventilator delivery devices. RESULTS: Volumes of propellant gas hydrofluoroalkane (HFA) 134a and 227ea and redundant chlorofluorocarbons (CFC) varied from 7 ml per actuation from a small salbutamol HFA inhaler to 16 ml from the larger. Similar-sized CFC pMDI volumes were 15.6 and 20.4 ml. Each HFA salbutamol inhaler has 220 full volume discharges; total volume of gas from a small 134a pMDI was 1640 ml, and large 3885 ml. Sensing the presence of liquid propellant by shaking was felt at the 220th discharge in both large and small inhalers. Because of a partial pressure effect, VHC O2% in air was reduced to 11% in the smallest 127 ml volume VHC following 10 actuations of a large 134a salbutamol inhaler. The four ventilator delivery devices studied lowered 100% oxygen levels to a range of 93 to 81% after five actuations, depending on the device and type of pMDI used. CONCLUSION: Pressurised inhaler propellants require further study to assess smooth muscle relaxing properties</style></abstract><notes><style face="normal" font="default">DA - 20170703IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1186/s13223-017-0202-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28670327">PM:28670327</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170703, Sellers WF</style></custom2><misc3><style face="normal" font="default">10.1186/s13223-017-0202-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41781</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Manuyakorn,W.</style></author><author><style face="normal" font="default"> Klangkalya,N.</style></author><author><style face="normal" font="default"> Kamchaisatian,W.</style></author><author><style face="normal" font="default"> Benjaponpita,S.</style></author><author><style face="normal" font="default"> Sasisakulporn,C.</style></author><author><style face="normal" font="default"> Jotikasthira,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.</style></auth-address><titles><title><style face="normal" font="default">Efficacy of Nasal Cellulose Powder in the Symptomatic Treatment of Allergic Rhinitis: A Randomized, Double-Blind, Placebo-Controlled Trial</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="452" start="446">446-452</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> airflow</style></keyword><keyword><style face="normal" font="default"> Airflow limitation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Airway Resistance</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cellulose</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dermatophagoides</style></keyword><keyword><style face="normal" font="default"> Dermatophagoides pteronyssinus</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Maximum Tolerated Dose</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> Placebos</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Scraping</style></keyword><keyword><style face="normal" font="default"> symptom scores</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">PURPOSE: Nasal Cellulose Powder (NCP), which can prevent from binding an allergen to nasal mucosa, may reduce allergic rhinitis (AR) symptoms in dust mite-sensitized children. This study was conducted to assess the efficacy of NCP in improving clinical symptoms of a nasal airflow limitation and the response of nasal inflammatory cells. METHODS: Children with dust mite-sensitized AR aged 6-18 years were recruited. After a 4-week run-in period, NCP or a placebo was administered, 1 puff per nostril 3 times daily for 4 weeks. The nasal provocation test (NPT) with Dermatophagoides pteronyssinus (Der p) was performed before and after treatment. The daily symptom scores (DSS), daily medication scores (DMS), the peak nasal inspiratory flows (PNIF), nasal airway resistance (NAR), as well as the maximum tolerated dose of NPT and eosinophil counts in nasal scraping, were evaluated. RESULTS: Sixty children (30 NCP and 30 placebos) were enrolled. Before treatment, there were no significant differences in age, dust mite control measures, DSS, DMS, PNIF, NAR, the maximum tolerated dose of NPT, or nasal eosinophil scores between children receiving NCP and placebos. After treatment, there were no significant differences between the NCP and placebo groups in the median (range) of the outcomes-DSS: 2.06 (0.18-3.77) vs 1.79 (0.08-7.79), P=0.756; DMS: 1.60 (0-5.13) vs 0.56 (0-4.84), P=0.239; PNIF (L/min): 110 (60-160) vs 100 (50-180), P=0.870; NAR (Pa/cm(3)/s): 0.40 (0.20-0.97) vs 0.39 (0.24-1.32), P=0.690; the maximum tolerated dose of NPT and the nasal eosinophil scores: 1 (0-4) vs 1 (0-4), P=0.861. CONCLUSIONS: NCP treatment may not be more effective than placebo treatment in dust mite-sensitized AR children</style></abstract><notes><style face="normal" font="default">DA - 20170705IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.5.446</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28677359">PM:28677359</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-446-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-446-52.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170705, Manuyakorn W</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.5.446</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41782</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,M.H.</style></author><author><style face="normal" font="default"> Rho,M.</style></author><author><style face="normal" font="default"> Choi,J.P.</style></author><author><style face="normal" font="default"> Choi,H.I.</style></author><author><style face="normal" font="default"> Park,H.K.</style></author><author><style face="normal" font="default"> Song,W.J.</style></author><author><style face="normal" font="default"> Min,T.K.</style></author><author><style face="normal" font="default"> Cho,S.H.</style></author><author><style face="normal" font="default"> Cho,Y.J.</style></author><author><style face="normal" font="default"> Kim,Y.K.</style></author><author><style face="normal" font="default"> Yang,S.</style></author><author><style face="normal" font="default"> Pyun,B.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">A Metagenomic Analysis Provides a Culture-Independent Pathogen Detection for Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="461" start="453">453-461</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> diversity</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Igg</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin G</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microbes</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> Pseudomonas</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> Staphylococcus</style></keyword><keyword><style face="normal" font="default"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default"> Streptococcus</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">PURPOSE: Atopic dermatitis (AD) is an inflammatory skin disease, significantly affecting the quality of life. Using AD as a model system, we tested a successive identification of AD-associated microbes, followed by a culture-independent serum detection of the identified microbe. METHODS: A total of 43 genomic DNA preparations from washing fluid of the cubital fossa of 6 healthy controls, skin lesions of 27 AD patients, 10 of which later received treatment (post-treatment), were subjected to high-throughput pyrosequencing on a Roche 454 GS-FLX platform. RESULTS: Microbial diversity was decreased in AD, and was restored following treatment. AD was characterized by the domination of Staphylococcus, Pseudomonas, and Streptococcus, whereas Alcaligenaceae (f), Sediminibacterium, and Lactococcus were characteristic of healthy skin. An enzyme-linked immunosorbent assay (ELISA) showed that serum could be used as a source for the detection of Staphylococcus aureus extracellular vesicles (EVs). S. aureus EV-specific immunoglobulin G (IgG) and immunoglobulin E (IgE) were quantified in the serum. CONCLUSIONS: A metagenomic analysis together with a serum detection of pathogen-specific EVs provides a model for successive identification and diagnosis of pathogens of AD</style></abstract><notes><style face="normal" font="default">DA - 20170705IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.5.453</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28677360">PM:28677360</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-453-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-453-61.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170705, Kim MH</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.5.453</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41783</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,N.</style></author><author><style face="normal" font="default"> Lee,J.D.</style></author><author><style face="normal" font="default"> Lee,H.Y.</style></author><author><style face="normal" font="default"> Kang,D.R.</style></author><author><style face="normal" font="default"> Ye,Y.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy and Clinical Immunology, Ajou University School of Medicine and Graduate School of Medicine, Suwon, Korea</style></auth-address><titles><title><style face="normal" font="default">Epidemiology of Chronic Urticaria in Korea Using the Korean Health Insurance Database, 2010-2014</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="445" start="438">438-445</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Algorithms</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Cold</style></keyword><keyword><style face="normal" font="default"> Common Cold</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Cyclosporine</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Epidemiological studies</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Older adults</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">PURPOSE: There are very few epidemiological studies on chronic urticaria (CU). We aimed to investigate the prevalence of CU and to depict demographics and medication patterns for the disease in a nationwide population-based study. METHODS: Data on urticaria (L50 of the International Classification of Diseases, 10th revision) from 2010 to 2014 were obtained from the Korean Health Insurance Review and Assessment Service. Algorithms designed to evaluate prescription drug claims for antihistamines were applied to identify CU. RESULTS: The crude prevalence of CU was 2,256.5 per 100,000 person-years and tended to increase every year. The age-standardized prevalence of CU was significantly higher in females than in males (2,466.8 vs 1,819.2 per 100,000 person-years, P&lt;0.001). Age-specific prevalence was highest for older adults over the age of 65 years and lowest for ages 10-29 years. The median duration of CU was 591 days, and symptoms lasted for at least 1 year in 61.9% of patients. Gastrointestinal disease was the most common comorbidity in adults, whereas allergic rhinitis and common cold were more prevalent in children with CU. Around a third of CU patients were taking antihistamine treatment alone, and 70% were treated with both antihistamines and systemic corticosteroids. Cyclosporine was prescribed for 0.02% of CU patients. CONCLUSIONS: The present study outlines recent longitudinal epidemiological data on the prevalence of CU in Korea. In light of limitations on the use of claims data, including no specific disease code for CU and a possible discordance between drug claims and the presence of urticaria symptoms, further investigations are necessary to describe the exact epidemiologic profile of CU patients</style></abstract><notes><style face="normal" font="default">DA - 20170705IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.5.438</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28677358">PM:28677358</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-438-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-438-45.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170705, Lee N</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.5.438</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41784</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Song,W.J.</style></author><author><style face="normal" font="default"> Morice,A.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Clinical Immunology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Cough Hypersensitivity Syndrome: A Few More Steps Forward</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="402" start="394">394-402</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> Aspiration</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic cough</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity syndrome</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Neurophysiology</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Randomized clinical trial</style></keyword><keyword><style face="normal" font="default"> Randomized clinical trials</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Reflex</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutics</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Cough reflex is a vital protective mechanism against aspiration, but when dysregulated, it can become hypersensitive. In fact, chronic cough is a significant medical problem with a high degree of morbidity. Recently, a unifying paradigm of cough hypersensitivity syndrome has been proposed. It represents a clinical entity in which chronic cough is a major presenting problem, regardless of the underlying condition. Although it remains a theoretical construct, emerging evidence suggests that aberrant neurophysiology is the common etiology of this syndrome. Recent success in randomized clinical trials using a P2X3 receptor antagonist is the first major advance in the therapeutics of cough in the past 30 years; it at last provides a strategy for treating intractable cough as well as an invaluable tool for dissecting the mechanism underpinning cough hypersensitivity. Additionally, several cough measurement tools have been validated for use and will help assess the clinical relevance of cough in various underlying conditions. Along with this paradigm shift, our understanding of cough mechanisms has improved during the past decades, allowing us to continue to take more steps forward in the future</style></abstract><notes><style face="normal" font="default">DA - 20170705IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - South Korea -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.5.394</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28677352">PM:28677352</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-394-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-394-402.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170705, Song WJ</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.5.394</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41785</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aalbers,R.</style></author><author><style face="normal" font="default"> Park,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonology, Martini Hospital, Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="393" start="386">386-393</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> bronchodilators</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Muscarinic antagonist</style></keyword><keyword><style face="normal" font="default"> Muscarinic Antagonists</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Despite a range of efficacious therapies for asthma, including inhaled corticosteroids (ICS) and long-acting beta(2)-agonists (LABA), a significant proportion of patients have poor asthma control and retain a risk of future worsening of their symptoms. Long-acting muscarinic antagonist (LAMA) bronchodilators offer a well-tolerated, efficacious, and cost-effective add-on to a patient's treatment. Of the LAMAs currently under investigation or available for the treatment of asthma, evidence from a comprehensive clinical trial program in adults and children shows that once-daily treatment with tiotropium provides benefits for patients with uncontrolled asthma despite the use of ICS and LABAs. Tiotropium is included in the Global Initiative for Asthma (GINA) strategy document as an add-on therapy option for patients at Step 4 or 5 with a history of asthma exacerbations. Tiotropium Respimat(R) has demonstrated safety and efficacy in patients with a range of disease severities, ages, and phenotypes. This review describes the evidence for the use of LAMA as add-on therapy for patients with asthma who remain uncontrolled despite the use of ICS and LABA treatments</style></abstract><notes><style face="normal" font="default">DA - 20170705IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Netherlands -CO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.5.386</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28677351">PM:28677351</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-386-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-386-93.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170705, Aalbers R</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.5.386</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41786</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,J.</style></author><author><style face="normal" font="default"> Zhou,Y.</style></author><author><style face="normal" font="default"> Zhang,L.</style></author><author><style face="normal" font="default"> Wang,Y.</style></author><author><style face="normal" font="default"> Pepper,A.N.</style></author><author><style face="normal" font="default"> Cho,S.H.</style></author><author><style face="normal" font="default"> Kong,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</style></auth-address><titles><title><style face="normal" font="default">Individualized Treatment of Allergic Rhinitis According to Nasal Cytology</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="409" start="403">403-409</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Clarithromycin</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cytology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Loratadine</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mometasone</style></keyword><keyword><style face="normal" font="default"> mometasone furoate</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal cytology</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Sneezing</style></keyword><keyword><style face="normal" font="default"> symptom scores</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> VAS</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">PURPOSE: Nasal cytology is important in the diagnosis and treatment of nasal inflammatory diseases. Treatment of allergic rhinitis (AR) according to nasal cytology has not been fully studied. We plan to explore the individualized treatment of AR according to nasal cytology. METHODS: Nasal cytology from 468 AR patients was examined for inflammatory cell quantity (grade 0-5) and the percentage of neutrophils and eosinophils. Results were subdivided into the following categories: AR(Eos), eosinophil >/=50% of the whole inflammatory cells; AR(Neu), neutrophils >/=90%; AR(Eos/Neu), 10%&lt;/= eosinophil &lt;50%; AR(Low), grade 0/1 inflammatory cell quantity. Nasal cytology-guided treatment was implemented: all AR(Eos) patients (n=22) and half of the AR(Neu) patients (AR[Neu1], n=22) were treated with mometasone furoate spray and oral loratadine. Another half of the AR(Neu) patients (AR[Neu2], n=22) were treated with oral clarithromycin. Visual analog scale (VAS), symptom scores, and nasal cytology were evaluated 2 weeks before and after treatment. RESULTS: There were 224/468 (47.86%) AR(Eos), 67/468 (14.32%) AR(Neu), 112/468 (23.93%) AR(Eos/Neu), and 65/468 (13.89%) AR(Low) of the AR patients studied. There were no significant differences in clinical characteristics among these subgroups, except that the nasal blockage score was higher in AR(Eos) patients than in AR(Neu) patients (1.99 vs 1.50, P=0.02). Comparing AR(Eos) patients with AR(Neu1) patients 2 weeks after treatment, nasal symptoms and VAS were significantly lower in AR(Eos) patients, except for nasal blockage symptoms (P&lt;0.05 of nasal itching and sneezing; P&lt;0.01 for nasal secretion, total scores, and VAS). Comparing AR(Neu1) with AR(Neu2) patients, nasal symptoms, and VAS were significantly lower in AR(Neu2), except for nasal blockage and nasal itching symptoms (P&lt;0.05 for nasal secretions, sneezing, total score, and VAS). CONCLUSIONS: Nasal cytology may have important value in subtyping AR and optimizing AR treatment. Treating neutrophils is very important in AR patients with locally predominant neutrophils</style></abstract><notes><style face="normal" font="default">DA - 20170705IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.5.403</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28677353">PM:28677353</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-403-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-403-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170705, Chen J</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.5.403</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41787</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cho,S.W.</style></author><author><style face="normal" font="default"> Kim,D.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Individualized Treatment for Allergic Rhinitis</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="385" start="383">383-385</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170705IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - EditorialCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.5.383</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28677350">PM:28677350</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-383-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-383-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170705, Cho W</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.5.383</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41788</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Park,H.J.</style></author><author><style face="normal" font="default"> Byun,M.K.</style></author><author><style face="normal" font="default"> Kim,H.J.</style></author><author><style face="normal" font="default"> Ahn,C.M.</style></author><author><style face="normal" font="default"> Lee,J.H.</style></author><author><style face="normal" font="default"> Shin,K.C.</style></author><author><style face="normal" font="default"> Uh,S.T.</style></author><author><style face="normal" font="default"> Ra,S.W.</style></author><author><style face="normal" font="default"> Yoo,K.H.</style></author><author><style face="normal" font="default"> Jung,K.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Asthma-COPD Overlap Shows Favorable Clinical Outcomes Compared to Pure COPD in a Korean COPD Cohort</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="437" start="431">431-437</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Consensus</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Recovery</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> smokers</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">PURPOSE: Comparisons of the characteristics of chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap syndrome (ACOS) have been the focus of several studies since the diseases were defined by the Global Initiative for Asthma and Global Initiative for Chronic Obstructive Lung Disease guidelines. However, no consensus is available yet. In this study, we aimed to compare the characteristics of asthma-COPD overlap (ACO) and COPD. METHODS: We retrospectively reviewed 1,504 patients with COPD in a Korean COPD Subtype Study cohort. The occurrence of ACO was defined as a positive response to a bronchodilator (an increase in forced expiratory volume in 1 second [FEV1] of 12% and 200 mL). RESULTS: Among 1,504 patients with COPD, 223 (14.8%) were diagnosed with ACO. Men (95.5%) and current smokers (32.9%) were more prevalent in the ACO group compared with the pure COPD group (90.5% and 25.3%, respectively; P=0.015 and P=0.026, respectively). Patients with ACO had a better quality of life (St. George's Respiratory Questionnaire for COPD score=31.0+/-18.0 [mean+/-standard deviation]) than those with pure COPD (35.3+/-19.1) (P=0.002). Although the prevalence of acute exacerbation was not different between the 2 groups, patients with severe exacerbation required hospital admission significantly more frequently in the pure COPD group than in the ACO group. Patients with ACO showed a higher likelihood of FEV1 recovery than those with pure COPD (P&lt;0.001). CONCLUSIONS: We suggest that ACO is characterized by less severe symptoms, and therefore it might lead to rare severe exacerbation and the possibility of lung function recovery</style></abstract><notes><style face="normal" font="default">DA - 20170705IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.5.431</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28677357">PM:28677357</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-431-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-431-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170705, Park HJ</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.5.431</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41789</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mansfield,L.</style></author><author><style face="normal" font="default"> Yiu,G.</style></author><author><style face="normal" font="default"> Sakov,A.</style></author><author><style face="normal" font="default"> Liu,S.</style></author><author><style face="normal" font="default"> Caracta,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">A 6-month safety and efficacy study of fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers in persistent asthma</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="276" start="264">264-276</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse events</style></keyword><keyword><style face="normal" font="default"> Albuterol</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> Candidiasis</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Dry Powder Inhalers</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> fluticasone propionate</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nasopharyngitis</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Peak expiratory flow</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Respiratory tract infection</style></keyword><keyword><style face="normal" font="default"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Sinusitis</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="24" Month="7" Year="2017">2017/7/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: A novel multidose dry powder inhaler (MDPI) that is breath actuated, easy, and intuitive to use has been developed for administering fluticasone propionate (Fp) and Fp/salmeterol (FS). OBJECTIVE: To assess the safety and efficacy of Fp MDPI versus Fp hydrofluoroalkane (HFA) and FS MDPI versus FS dry-powder inhaler (DPI). METHODS: This phase III, 26-week, open-label, active drug-controlled study enrolled subjects >/=12 years old with persistent asthma. Based on entry controller medication (inhaled corticosteroid [ICS] or ICS/long-acting beta-agonist), the subjects were randomized to twice-daily mid-strength Fp MDPI 100 mug or Fp HFA 220 mug, high-strength Fp MDPI 200 mug or Fp HFA 440 mug, mid-strength FS MDPI 100/12.5 mug or FS DPI 250/50 mug, or high-strength FS MDPI 200/12.5 mug or FS DPI 500/50 mug in a 3:1 MDPI to Fp HFA or FS DPI ratio. Safety and efficacy were assessed by adverse events (AE) and pulmonary function and asthma symptoms, respectively. RESULTS: A total of 674 subjects were randomized. The AE incidence was similar across treatment groups (upper respiratory tract infections, sinusitis, and nasopharyngitis were most frequent). A higher percentage of subjects in the Fp HFA 440 mug and FS DPI 500/50 mug groups had oral candidiasis versus those who received Fp MDPI 200 mug or FS MDPI 200/12.5 mug, respectively. Serious AEs were similar between the treatments, with no unexpected findings. The incidence of asthma exacerbations was low and generally similar between the groups. Noninferiority was established for all Fp MDPI and FS MDPI doses compared with Fp HFA and FS DPI, respectively, for forced expiratory volume in 1 second. Changes in peak expiratory flow, rescue albuterol use, and symptoms were similar between treatments. CONCLUSION: The safety and efficacy profiles of Fp MDPI and FS MDPI administered at lower doses were generally comparable with those of Fp HFA and FS DPI, respectively, after 26 weeks of treatment.The ClinicalTrials.gov identifier is NCT02175771</style></abstract><notes><style face="normal" font="default">DA - 20170525IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - Israel -CO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4061</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28540844">PM:28540844</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-38-264-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-38-264-76.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170525, Mansfie4ld L</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4061</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41790</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Corren,J.</style></author><author><style face="normal" font="default"> Kavati,A.</style></author><author><style face="normal" font="default"> Ortiz,B.</style></author><author><style face="normal" font="default"> Colby,J.A.</style></author><author><style face="normal" font="default"> Ruiz,K.</style></author><author><style face="normal" font="default"> Maiese,B.A.</style></author><author><style face="normal" font="default"> Cadarette,S.M.</style></author><author><style face="normal" font="default"> Panettieri,R.A.,Jr.</style></author></authors></contributors><titles><title><style face="normal" font="default">Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="263" start="250">250-263</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patient-reported outcomes</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Randomized clinical trial</style></keyword><keyword><style face="normal" font="default"> Randomized clinical trials</style></keyword><keyword><style face="normal" font="default"> rescue medication</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: There are limited pediatric data about the use of omalizumab, especially the effectiveness and safety of omalizumab in the real-world management of allergic asthma. OBJECTIVE: The objective of this study was to summarize the safety and efficacy of omalizumab in both randomized clinical trials (RCT) used for U.S. Food and Drug Administration registration and real-world studies (RWS) based on clinical care of children with moderate-to-severe asthma. METHODS: Studies that evaluated omalizumab use in patients &lt;18 years old and with asthma, published between January 2003 and October 2016, were retrieved from medical literature data bases. Assessed outcomes included the following: exacerbation rates, spirometric indices, changes in asthma medication use, asthma control, patient-reported outcomes, and health care resource utilization. RESULTS: A total of five RWS were identified; outcomes reported were compared with three omalizumab RCTs. Overall, the mean rate of annual exacerbations was significantly lower after 6 months to 2 years of treatment with omalizumab in both RCTs and RWS. In two RCTs and three RWS, inhaled corticosteroid use was significantly reduced in patients who used omalizumab. Similar reductions in the use of rescue medication were also observed in the RCTs and RWS on omalizumab. Real-world evidence demonstrated improvement in forced expiratory volume in the first second of expiration (% predicted) in patients treated with omalizumab as well as significant improvement in the level of asthma control observed over 1 year. There also was evidence that omalizumab treatment reduced health care resource utilization, including fewer hospitalizations, emergency department visits, and unscheduled medical visits. Safety outcomes in all five RWS showed no new safety signals and demonstrated that omalizumab was well tolerated. CONCLUSION: Overall, RCT evidence strongly supported omalizumab efficacy and safety as add-on treatment in children 6 to 11 years old with moderate-to-severe persistent allergic asthma. RWS data confirmed these findings in an extended patient population of children and adolescents that is more generalizable to the actual day-to-day management of these patients</style></abstract><notes><style face="normal" font="default">DA - 20170620IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4067</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28631599">PM:28631599</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-38-250-63.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-38-250-63.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170620, Corren J</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4067</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41791</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Silverberg,J.I.</style></author></authors></contributors><titles><title><style face="normal" font="default">Atopic dermatitis treatment: Current state of the art and emerging therapies</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="249" start="243">243-249</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Interleukin-4</style></keyword><keyword><style face="normal" font="default"> Interleukins</style></keyword><keyword><style face="normal" font="default"> Janus kinase</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="default"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic therapy</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis (AD) can be debilitating and often requires the use of combination topical and systemic therapy to achieve adequate disease control. METHODS: A non-systematic review was performed of current state of the art and emerging therapies for AD. RESULTS: There are a number of topical agents approved by the U.S. Food and Drug Administration (FDA) for the treatment of AD and multiple nonapproved systemic agents that are used off label for the treatment of AD. All of these have limitations of efficacy and/or safety, which leads to a number of unmet disease-treatment needs. Recent insight has identified a number of novel pathways as treatment targets for AD, including the T-helper type 2 cytokines, interleukins (IL) 4, IL-13, IL-33, phosphodiesterase E 4, and Janus kinase signaling. Dupilumab is a monoclonal antibody that inhibits interleukin 4 and 13 signaling and was recently approved by the FDA for the treatment of moderate-severe AD in adults. DISCUSSION: There are a number of current treatment approaches and emerging therapies for AD</style></abstract><notes><style face="normal" font="default">DA - 20170702IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4054</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668106">PM:28668106</url></web-urls></urls><custom2><style face="normal" font="default">20170702, Silverberg JI</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4054</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41792</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Morales-Suarez-Varela,M.</style></author><author><style face="normal" font="default"> Llopis-Gonzalez,A.</style></author><author><style face="normal" font="default"> Vergara-Hernandez,C.</style></author><author><style face="normal" font="default"> Fernandez-Fabrellas,E.</style></author><author><style face="normal" font="default"> Sanz,F.</style></author><author><style face="normal" font="default"> Perez-Lozano,M.J.</style></author><author><style face="normal" font="default"> Martin,V.</style></author><author><style face="normal" font="default"> Astray,J.</style></author><author><style face="normal" font="default"> Castilla,J.</style></author><author><style face="normal" font="default"> Egurrola,M.</style></author><author><style face="normal" font="default"> Force,L.</style></author><author><style face="normal" font="default"> Toledo,D.</style></author><author><style face="normal" font="default"> Dominguez,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Asthma in older people hospitalized with influenza in Spain: A case-control study</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="285" start="277">277-285</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Activities of Daily Living</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evolution</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Influenza</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pneumonia</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Seasons</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Vaccination</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Influenza infection is an exacerbating factor for asthma, and its prevention is critical in older patients with asthma. OBJECTIVE: This study investigated the association between asthma and influenza-related hospitalization, in Spain, of patients ages >/= 65 years and their clinical evolution. METHODS: A multicenter case-control study was carried out in 20 Spanish hospitals during the 2013-2014 and 2014-2015 influenza seasons. Patients ages >/= 65 years hospitalized with laboratory-confirmed influenza with and without asthma were matched with controls according to the presence of asthma, sex, age, hospital, and date of hospitalization. RESULTS: A total of 561 patients with influenza (15.9% with asthma) and 1258 patients without influenza (8.0% with asthma) were included as cases and controls, respectively. The adjusted risk of influenza for patients with asthma was calculated by multivariate conditional logistic regression. The adjustment variables were the following: smoker/nonsmoker, pneumonia in the 2 years before hospital admission, previous oral treatment with corticosteroids, influenza vaccination during the seasonal campaign, Barthel index (ordinal scale used to measure performance in activities of daily living), level of education, obesity, and the presence of other comorbidities. Patients with asthma presented a great risk of influenza (adjusted odds ratio 2.64 [95% confidence interval, 1.77-3.94]). Compared with patients without asthma, patients with asthma had more symptoms, and these had been present for longer before admission but presented a lower hospital or postdischarge mortality. CONCLUSION: This study indicated that asthma was associated with hospitalization from influenza A infection. Although patients with asthma and with influenza had more symptoms, hospital or postdischarge mortality was lower, probably due to a better response to medical treatment</style></abstract><notes><style face="normal" font="default">DA - 20170702IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4060</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668107">PM:28668107</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-277-85.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Proc\2017-38-277-85.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170702, Morales-Suarez-Varela M</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4060</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41793</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lin,C.E.</style></author><author><style face="normal" font="default"> Kaptein,J.S.</style></author><author><style face="normal" font="default"> Sheikh,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Differential expression of microRNAs and their possible roles in patients with chronic idiopathic urticaria and active hives</style></title><secondary-title><style face="normal" font="default">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Rhinol (Providence)</style></abbr-1></periodical><pages end="80" start="67">67-80</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">autoimmune</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic idiopathic urticaria</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> CIU</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> glucocorticoid receptor</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Hives</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microarray</style></keyword><keyword><style face="normal" font="default"> MicroRNAs</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pilot study</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Rna</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Sequence</style></keyword><keyword><style face="normal" font="default"> Sequences</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Transforming Growth Factor beta</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic idiopathic urticaria (CIU) is a complicated skin disease with unknown pathophysiology. MicroRNAs (miRNA) have been shown to be active in cellular regulation. The goal of this pilot study was to examine whether miRNAs may be involved in the regulation of CIU or as biomarkers for CIU. METHODS: Four groups of three patients each were selected: patients with either active hives or no hives and with positive or negative chronic urticaria (CU) index results. MiRNAs were isolated from patient plasma and analyzed by using miRNA microarray technology to determine the amount of each of the 2567 known human miRNAs. RESULTS: A total of 16 miRNAs were found to be differentially expressed in patients with active hives. Among them, five (2355-3p, 4264, 2355-5p, 29c-5p, and 361-3p) were significantly increased in samples with positive CU index results, which could be useful biomarkers for patients with chronic autoimmune urticaria. The miRNA data bases were used to find the targets of these selected miRNA sequences. These potential targets were then compared against a list of 154 urticaria-related genes. Twenty-five genes were found to match. These included eight that were significantly downregulated and eight that were significantly upregulated; however, seven of the eight downregulated genes (FBXL20, OPHN1, YPEL2, STARD9, EZH1, KLHL24, ING4) and five of the eight upregulated genes (BYSL, PNO1, ADAMTS9, STEAP4, SRGN) have no reported roles in signaling. For the 13 genes with reported roles in signaling, the following pathways were found: transforming growth factor beta signaling pathway (NRC31, KITLG, THBS1, CCL2), glucocorticoid receptor signaling pathway (NR3C1, SELE, CCL2), p53 signaling pathway (CCNG2, THBS1, CCL2), p21-activated kinase pathway (PAK1IP1, KITLG, CCL2), phosphoinositide-3 kinase protein kinase B signaling pathway (KITLG, CHRM, THBS1), and neuroactive ligand-receptor interaction (NRC31, HRH1, CHRM), which could play important roles in CIU. CONCLUSION: A better understanding of those genes with undefined function and simultaneous quantitation of both miRNAs and messenger RNAs are needed to fully understand CIU disease</style></abstract><notes><style face="normal" font="default">DA - 20170606IS - 2152-6575 (Print)IS - 2152-6567 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/ar.2017.8.0199</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583230">PM:28583230</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Rhinol (Providence)\2017-8-67-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Rhinol (Providence)\2017-8-67-80.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170606, Lin CE</style></custom2><misc3><style face="normal" font="default">10.2500/ar.2017.8.0199</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41794</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bhardwaj,N.</style></author><author><style face="normal" font="default"> Ishmael,F.</style></author><author><style face="normal" font="default"> Lehman,E.</style></author><author><style face="normal" font="default"> Bethards,D.</style></author><author><style face="normal" font="default"> Ruggiero,F.</style></author><author><style face="normal" font="default"> Ghaffari,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effect of topical beclomethasone on inflammatory markers in adults with eosinophilic esophagitis: A pilot study</style></title><secondary-title><style face="normal" font="default">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Rhinol (Providence)</style></abbr-1></periodical><pages end="94" start="85">85-94</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Beclomethasone</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Budesonide</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default"> Esophagitis</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> fluticasone propionate</style></keyword><keyword><style face="normal" font="default"> Granulocyte-Macrophage Colony-Stimulating Factor</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-3</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Interleukins</style></keyword><keyword><style face="normal" font="default"> Ligands</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pilot study</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Sequence</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Topical corticosteroids</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Topical corticosteroids have proven efficacy in the treatment of eosinophilic esophagitis (EoE) and are considered the cornerstone of therapy. OBJECTIVE: To evaluate the effect of topical beclomethasone dipropionate (BDP) therapy on clinical outcomes, esophageal eosinophilia, and other markers of inflammation in patients with EoE. METHODS: Nine subjects with a biopsy-proven diagnosis of EoE were enrolled. In a cross-over design, the subjects were randomly assigned to a sequence of BDP and placebo. Treatment periods were 8 weeks, with a 4-week washout period. The subjects had endoscopic biopsies and blood tests at baseline and after each treatment period. They were instructed to maintain a diary of symptoms. Immuno-histochemical studies were performed for interleukins IL-4, IL-5, IL-13, granulocyte-macrophage colony-stimulating factor (GM-CSF), and transforming growth factor (TGF) beta. Reverse transcription polymerase chain reaction was performed for IL-3, IL-4, IL-5, IL-10, IL-13, IL-17F, IL-25, IL-33, chemokine ligands (CCL)2, CCL5, CCL11, GM-CSF, and TGF-beta levels. The mast cell tryptase (MCT) level was measured in esophageal tissues. RESULTS: BDP led to a significantly larger decrease in esophageal eosinophilia compared with placebo, but there was no significant change in peripheral eosinophilia and high-sensitivity C-reactive protein between the two groups. The study was not powered enough for us to report a significant improvement in clinical symptoms. There was a significant decrease in tissue IL-13 and MCT levels from baseline to the end of treatment between the treatment and placebo groups. Mean fold decreases in cytokine expression between the baseline and treatment groups were observed for IL-17F, IL-25, CCL2, and CCL5. CONCLUSION: Treatment with topical BDP was associated with significant decrease in esophageal eosinophilia, MCT and IL-13. BDP is a potential alternative to fluticasone propionate and budesonide for treatment of EoE. Larger studies are needed to validate these findings</style></abstract><notes><style face="normal" font="default">DA - 20170606IS - 2152-6575 (Print)IS - 2152-6567 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/ar.2017.8.0202</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583232">PM:28583232</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Rhinol (Providence)\2017-8-85-94.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Rhinol (Providence)\2017-8-85-94.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170606, Bhardwaj N</style></custom2><misc3><style face="normal" font="default">10.2500/ar.2017.8.0202</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41795</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ke,Y.</style></author><author><style face="normal" font="default"> Oskolkova,O.</style></author><author><style face="normal" font="default"> Sarich,N.</style></author><author><style face="normal" font="default"> Tian,Y.</style></author><author><style face="normal" font="default"> Sitikov,A.</style></author><author><style face="normal" font="default"> Tulapurkar,M.</style></author><author><style face="normal" font="default"> Son,S.</style></author><author><style face="normal" font="default"> Birukova,A.A.</style></author><author><style face="normal" font="default"> Birukov,K.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Chicago</style></auth-address><titles><title><style face="normal" font="default">Effects of prostaglandin lipid mediators on agonist-induced lung endothelial permeability and inflammation</style></title><secondary-title><style face="normal" font="default">Am J Physiol Lung Cell Mol Physiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Physiol Lung Cell Mol Physiol</style></full-title></periodical><pages end="L721" start="L710">L710-L721</pages><volume><style face="normal" font="default">313</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic response</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Arachidonic Acid</style></keyword><keyword><style face="normal" font="default"> Barrier dysfunction</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endothelial Cells</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> Interleukin-6</style></keyword><keyword><style face="normal" font="default"> Lipid</style></keyword><keyword><style face="normal" font="default"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="default"> LPS</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Permeability</style></keyword><keyword><style face="normal" font="default"> Prostaglandin</style></keyword><keyword><style face="normal" font="default"> Prostaglandins</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="29" Month="6" Year="2017">2017/6/29</year></dates><abstract><style face="normal" font="default">Prostaglandins (PG), the products of cyclooxygenase-mediated conversion of arachidonic acid, become upregulated in many situations including allergic response, inflammation, injury, and exhibit variety of biological activities. Previous studies described barrier-enhancing and anti-inflammatory effects of PGE2 and PGI2 on vascular endothelial cells (EC). Yet, the effects of other PG members on EC barrier and inflammatory activation have not been systematically analyzed. This study compared effects of PGE2, PGI2, PGF2alpha, PGA2, PGJ2 and PGD2 on human pulmonary EC. EC permeability was assessed by measurements of transendothelial electrical resistance and cell monolayer permeability for FITC-labeled tracer. Anti-inflammatory effects of PGs were evaluated by analysis of expression of adhesion molecule ICAM1 and secretion of soluble ICAM1 and cytokines by EC. PGE2, PGI2, and PGA2 exhibited most potent barrier-enhancing effects and most efficient attenuation of thrombin-induced EC permeability and contractile response, while PGI2 effectively suppressed thrombin-induced permeability but was less efficient in attenuation of prolonged EC hyperpermeability caused by interleukin-6 or bacterial wall lipopolysaccharide, LPS. PGD2 showed modest protective effect on EC inflammatory response, while PGF2alpha and PGJ2 were without effect on agonist-induced EC barrier dysfunction. In vivo, PGE2, PGI2, and PGA2 attenuated LPS-induced lung inflammation, while PGF2alpha and PGJ2 were without effect. Interestingly, PGD2 exhibited protective effect in the in vivo model of LPS-induced lung injury. This study provides comprehensive analysis of barrier-protective and anti-inflammatory effects of different prostaglandins on lung EC in vitro and in vivo and identifies PGE2, PGI2, and PGA2 as prostaglandins with most potent protective properties</style></abstract><notes><style face="normal" font="default">DA - 20170630IS - 1522-1504 (Electronic)IS - 1040-0605 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1152/ajplung.00519.2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28663336">PM:28663336</url></web-urls><related-urls><url ppv-ref="no">presto - 1 anno</url></related-urls></urls><custom2><style face="normal" font="default">20170630, Ke Y</style></custom2><misc3><style face="normal" font="default">10.1152/ajplung.00519.2016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41796</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Agrawal,N.</style></author><author><style face="normal" font="default"> Gogia,A.R.</style></author><author><style face="normal" font="default"> Dayal,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anaesthesia and Intensive Care, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India</style></auth-address><titles><title><style face="normal" font="default">Dilemmas in Anesthetic Management of a Patient with History of Anaphylaxis to Vecuronium</style></title><secondary-title><style face="normal" font="default">Anesth Essays Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Anesth Essays Res</style></full-title></periodical><pages end="527" start="525">525-527</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaesthesia</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Anesthesia</style></keyword><keyword><style face="normal" font="default"> Atracurium</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Fentanyl</style></keyword><keyword><style face="normal" font="default"> General anesthesia</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Injections</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> intradermal test</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Propofol</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">Anaphylaxis during anesthesia is a life-threatening situation that occurs uncommonly. A 60-year-old woman with a history of anaphylaxis during previous anesthesia is scheduled to undergo elective open cholecystectomy. Her skin tests revealed sensitivity to vecuronium and nonsensitivity to injections of midazolam, fentanyl, and propofol. Due to high incidence of cross sensitivity among neuromuscular drugs, it was thought best to avoid general anesthesia. Spinal anesthesia was planned for the patient. The patient refused to give consent for spinal anesthesia, and she had to be taken up for surgery under general anesthesia. The only alternate neuromuscular blocking drug available to us was atracurium, which was tested for sensitivity by intradermal test. Atracurium was found to be not sensitive on intradermal test. We report here the dilemma and the challenges faced during management of general anesthesia in a patient with history of anaphylaxis to vecuronium</style></abstract><notes><style face="normal" font="default">DA - 20170630IS - 0259-1162 (Print)IS - 2229-7685 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/0259-1162.186597</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28663656">PM:28663656</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Anesth Essays Res\2017-11-525-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Anesth Essays Res\2017-11-525-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170630, Agrawal N</style></custom2><misc3><style face="normal" font="default">10.4103/0259-1162.186597</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41797</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zejda,J.E.</style></author><author><style face="normal" font="default"> Farnik,M.</style></author><author><style face="normal" font="default"> Smolka,I.</style></author><author><style face="normal" font="default"> Lawson,J.</style></author><author><style face="normal" font="default"> Brozek,G.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Epidemiology, School of Medicine in Katowice, Medical University of Silesia, Poland.</style></auth-address><titles><title><style face="normal" font="default">Socio-demographic factors related to under-diagnosis of childhood asthma in Upper Silesia, Poland</style></title><secondary-title><style face="normal" font="default">Ann Agric Environ Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Agric Environ Med</style></abbr-1></periodical><pages end="176" start="171">171-176</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Distance</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Raw</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sociodemographic factors</style></keyword><keyword><style face="normal" font="default"> socioeconomic status</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="default">&lt;b>Introduction.&lt;/b> The presented study of 4,535 children aged 7-17 years in the Upper Silesian region of Poland yielded 186 cases of previously known asthma, and 44 children with newly diagnosed asthma. The aim of the presented study was to identify non-medical factors that could explain why children with a newly established diagnosis ('undiagnosed asthma') had not been diagnosed in the past. &lt;b>Materials and method.&lt;/b> The study was performed according to a case-control design. Parents of the children answered questionnaires on socio-economic status and family-related factors. Statistical determinants of undiagnosed asthma were explored using raw (OR) and logistic odds ratios with their 95% confidence intervals (logOR, 95%CI). &lt;b>Results.&lt;/b> Children with undiagnosed asthma were younger compared to the group with previously known asthma (11.3+/-2.1 vs. 12.6+/-2.5 years; p=0.0008). Newly diagnosed cases were more frequent in children who had less parental attention (less than 1 hour/day spent by parent with child - OR=4.36; 95%CI: 1.76-10.81) and who were not registered with specialized health care (OR=2.20; 95%CI: 0.95-5.06). Results of logistic regression analysis suggest that under-diagnosis of asthma is related to age below 12 years - logOR = 3.59 (95%CI: 1.28-10.36), distance to a health centre > 5 km - logOR = 3.45 (95%CI: 1.05-11.36), time spent with child &lt; 1 hour/day - logOR = 6.28 (95%CI: 1.98-19.91). &lt;b>Conclusion.&lt;/b> Among non-medical determinants of undiagnosed asthma the age of a child plays a major role. Another factors of importance is the large distance between residence and health centre, and low parental attention at home</style></abstract><notes><style face="normal" font="default">DA - 20170630IS - 1898-2263 (Electronic)IS - 1232-1966 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28664688">PM:28664688</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Agric Environ Med\2017-24-171-6.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default">20170630, Zejda JE</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41798</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,A.G.</style></author><author><style face="normal" font="default"> Chiu,Y.M.</style></author><author><style face="normal" font="default"> Rosa,M.J.</style></author><author><style face="normal" font="default"> Cohen,S.</style></author><author><style face="normal" font="default"> Coull,B.A.</style></author><author><style face="normal" font="default"> Wright,R.O.</style></author><author><style face="normal" font="default"> Morgan,W.J.</style></author><author><style face="normal" font="default"> Wright,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, New York</style></auth-address><titles><title><style face="normal" font="default">Association of prenatal and early childhood stress with reduced lung function in 7-year-olds</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">African American</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> early childhood</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Lung growth</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Perinatal</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Smoke</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Vital Capacity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="6" Year="2017">2017/6/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: No prior study has examined associations between prenatal and early-life stress on childhood lung function or identified critical windows of exposure. OBJECTIVE: To prospectively examine associations between prenatal and early-life stress and childhood lung function. METHODS: Stress was indexed by a maternal negative life events (NLEs) score ascertained during pregnancy and between 1 and 2 years post partum. Spirometry was performed when children were a mean (SD) of 6.99 (0.89) years old. Associations of prenatal and early postnatal stress with spirometry z scores were examined in 199 children using linear regression. Effect modification by child sex was explored. RESULTS: Most mothers were minorities (65% Hispanic, 21% African American), had 12 years or less of education (67%), and did not smoke prenatally (78%). The highest level of prenatal stress (>/=5 NLEs) was associated with lower levels of forced expiratory volume in 1 second (FEV1) (z score = -0.53, P = .03), forced vital capacity (FVC) (z score = -0.49, P = .04), and forced expiratory flow between 25% and 75% (FEF25%-75%) (z score = -0.68, P = .01) after covariate adjustment; effects were similar for postnatal stress considered separately. In sex-stratified analyses, high postnatal stress (>/=5 NLEs) was associated with lower FEV1 (z score = -0.76, P = .01), FVC (z score = -0.77, P = .01), and FEF25%-75% (z score = -0.67, P = .02) in boys but not girls, although the interaction term was not significant (P for interaction >.10). CONCLUSION: These are the first prospective data that link perinatal stress with reduced child lung function. High levels of stress in the prenatal and postnatal periods were associated with symmetric reductions in FEV1 and FVC consistent with impaired lung growth. Given that lung function growth patterns are established by 7 years of age, these findings have lifelong implications</style></abstract><notes><style face="normal" font="default">DA - 20170702IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.05.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668548">PM:28668548</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170702-Lee AG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170702-Lee AG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170702, Lee AG</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.05.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41799</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shaker,M.</style></author><author><style face="normal" font="default"> Bean,K.</style></author><author><style face="normal" font="default"> Verdi,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Geisel School of Medicine, Hanover, New Hampshire</style></auth-address><titles><title><style face="normal" font="default">Economic evaluation of epinephrine auto-injectors for peanut allergy</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Auto-injectors</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Commercial</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> England</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="default"> EpiPen</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> New England</style></keyword><keyword><style face="normal" font="default"> New Hampshire</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Peanut</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> quality-adjusted life year</style></keyword><keyword><style face="normal" font="default"> Quality-Adjusted Life Years</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Software</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="6" Year="2017">2017/6/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Three commercial epinephrine auto-injectors were available in the United States in the summer of 2016: EpiPen, Adrenaclick, and epinephrine injection, USP auto-injector. OBJECTIVE: To describe the variation in pharmacy costs among epinephrine auto-injector devices in New England and evaluate the additional expense associated with incremental auto-injector costs. METHODS: Decision analysis software was used to evaluate costs of the most and least expensive epinephrine auto-injector devices for children with peanut allergy. To evaluate regional variation in epinephrine auto-injector costs, a random sample of New England national and corporate pharmacies was compared with a convenience sample of pharmacies from 10 Canadian provinces. RESULTS: Assuming prescriptions written for 2 double epinephrine packs each year (home and school), the mean costs of food allergy over the 20-year model horizon totaled $58,667 (95% confidence interval [CI] $57,745-$59,588) when EpiPen was prescribed and $45,588 (95% CI $44,873-$46,304) when epinephrine injection, USP auto-injector was prescribed. No effectiveness differences were evident between groups, with 17.19 (95% CI 17.11-17.27) quality-adjusted life years accruing for each subject. The incremental cost per episode of anaphylaxis treated with epinephrine over the model horizon was $12,576 for EpiPen vs epinephrine injection, USP auto-injector. EpiPen costs were lowest at Canadian pharmacies ($96, 95% CI $85-$107). There was price consistency between corporate and independent pharmacies throughout New England by device brand, with the epinephrine injection, USP auto-injector being the most affordable device. CONCLUSION: Cost differences among epinephrine auto-injectors were significant. More expensive auto-injector brands did not appear to provide incremental benefit</style></abstract><notes><style face="normal" font="default">DA - 20170621IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.05.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28634019">PM:28634019</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170621-ShakerM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170621-ShakerM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170621, Shaker M</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.05.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41800</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Farzan,S.</style></author><author><style face="normal" font="default"> Khan,S.</style></author><author><style face="normal" font="default"> Elera,C.</style></author><author><style face="normal" font="default"> Tsang,J.</style></author><author><style face="normal" font="default"> Akerman,M.</style></author><author><style face="normal" font="default"> DeVoti,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Northwell Health System, Great Neck, New York.</style></auth-address><titles><title><style face="normal" font="default">Effectiveness of montelukast in overweight and obese atopic asthmatics</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> montelukast</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> overweight</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="28" Month="6" Year="2017">2017/6/28</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170702IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.05.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668546">PM:28668546</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170702-FarzanS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170702-FarzanS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170702, Farzan S</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.05.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41801</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lazaro,M.</style></author><author><style face="normal" font="default"> Vazquez,L.</style></author><author><style face="normal" font="default"> Munoz-Bellido,F.J.</style></author><author><style face="normal" font="default"> Gracia,M.T.</style></author><author><style face="normal" font="default"> Arriba-Mendez,S.</style></author><author><style face="normal" font="default"> Davila,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Service, University Hospital, Salamanca, Spain.</style></auth-address><titles><title><style face="normal" font="default">Reproduction of the atopic march in an adult after allogeneic bone marrow transplantation from an atopic sibling</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Bone Marrow</style></keyword><keyword><style face="normal" font="default"> Bone Marrow Transplantation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Reproduction</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="22" Month="6" Year="2017">2017/6/22</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170626IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.05.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28648657">PM:28648657</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170626-LazaroM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170626-LazaroM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170626, Lazaro M</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.05.026</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41802</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,C.</style></author><author><style face="normal" font="default"> Xun,P.</style></author><author><style face="normal" font="default"> Tsinovoi,C.</style></author><author><style face="normal" font="default"> He,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Epidemiology and Biostatistics, School of Public Health-Bloomington, Indiana University, Bloomington, Indiana</style></auth-address><titles><title><style face="normal" font="default">Accumulated evidence on Helicobacter pylori infection and the risk of asthma: A meta-analysis</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma risk</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Helicobacter pylori</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="6" Year="2017">2017/6/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Helicobacter pylori (H pylori) infection has been suggested to be related to a decreased risk of asthma, but findings in the literature are inconsistent. OBJECTIVE: To quantitatively summarize the existing evidence on the association between H pylori infection and asthma risk. METHODS: The PubMed database was searched for observational studies of H pylori infection in relation to the risk of asthma published in English through May 2017. Measurements of association were pooled using a meta-analytic approach and expressed as odds ratios (ORs) with 95% confidence intervals (95% CIs). RESULTS: Twenty-four studies were identified in this meta-analysis, including 8 case-control studies composed of 1,247 cases and 2,410 controls, and 16 cross-sectional studies composed of 50,290 participants (4,185 cases and 46,105 noncases). The average H pylori infection rates were 40.01% and 48.74% in case-control and cross-sectional studies, respectively. Five studies subcategorized H pylori infection according to CagA status, in which 59.37% of H pylori-infected participants were identified as having CagA positivity. Helicobacter pylori infection was significantly inversely associated with the risk of asthma in case-control studies (OR 0.83, 95% CI 0.71-0.98) but was borderline significant in cross-sectional studies (OR 0.88, 95% CI 0.76-1.02). The observed inverse association persisted for CagA-positive H pylori infection (OR 0.77, 95% CI 0.63-0.93, P for interaction = .03) but not for CagA-negative strains (OR 1.08, 95% CI 0.66-1.78). No significant difference was observed across age or region subgroups. CONCLUSION: The accumulated evidence supports that H pylori infection, especially CagA-positive H pylori infection, is inversely associated with the risk of asthma</style></abstract><notes><style face="normal" font="default">DA - 20170621IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.05.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28634020">PM:28634020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170621-ChenC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170621-ChenC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170621, Chen C</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.05.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41803</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Barrick,B.J.</style></author><author><style face="normal" font="default"> Jalan,S.</style></author><author><style face="normal" font="default"> Tollefson,M.M.</style></author><author><style face="normal" font="default"> Milbrandt,T.A.</style></author><author><style face="normal" font="default"> Larson,A.N.</style></author><author><style face="normal" font="default"> Rank,M.A.</style></author><author><style face="normal" font="default"> Lohse,C.M.</style></author><author><style face="normal" font="default"> Davis,D.M.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Mayo Clinic, Rochester, Minnesota</style></auth-address><titles><title><style face="normal" font="default">Associations of self-reported allergic diseases and musculoskeletal problems in children: A US population-based study</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Hay Fever</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Minnesota</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Modeling</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="6" Year="2017">2017/6/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: Previous studies have found increased rates of musculoskeletal problems in adults with allergic disease, but whether this association holds true for children is unknown. OBJECTIVE: To investigate the association of bone, joint, and muscle problems in children with a history of allergic disease. METHODS: Data were obtained from the 2007 Child and Adolescent Health Measurement Initiative. Univariable and multivariable logistic regression models accounting for the sampling design were used to evaluate associations of bone, joint, and muscle problems with allergic diseases, such as asthma, hay fever, food allergies, and eczema. Associations were summarized with odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: The survey included 91,642 individuals aged 0 to 17 years. Multivariable modeling found statistically significant associations between the number of allergic diseases and bone, joint, and muscle problems (1 allergic disease: adjusted OR, 1.28; 95% CI, 1.04-1.56; P = .02; 2 allergic diseases: adjusted OR, 2.55; 95% CI, 1.92-3.39; P &lt; .001; 3 allergic diseases: adjusted OR, 2.70; 95% CI, 1.88-3.86; P &lt; .001; and 4 allergic diseases: adjusted OR, 4.35; 95% CI, 2.46-7.69; P &lt; .001). Severe eczema (but not mild eczema) was associated with bone, joint, and muscle problems (adjusted OR, 2.81; 95% CI, 1.64-4.81; P &lt; .001) and with bone problems (adjusted OR, 6.08; 95% CI, 1.94-19.12; P = .002). CONCLUSION: Self-reported allergic diseases in children were associated with bone, joint, and muscle problems, and associations strengthened with allergic disease severity and number of allergic diseases. Severe eczema may be associated with bone problems in children. Bone, joint, and muscle problems must be considered in children with severe allergic disease, and prospective studies are necessary to define this association</style></abstract><notes><style face="normal" font="default">DA - 20170702IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.06.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668547">PM:28668547</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170702-BarrickBJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170702-BarrickBJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170702, Barrick BJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.06.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41804</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Best,L.G.</style></author><author><style face="normal" font="default"> Azure,C.</style></author><author><style face="normal" font="default"> Segarra,A.</style></author><author><style face="normal" font="default"> Enright,K.J.</style></author><author><style face="normal" font="default"> Hamley,S.</style></author><author><style face="normal" font="default"> Jerome,D.</style></author><author><style face="normal" font="default"> O'Leary,M.A.</style></author><author><style face="normal" font="default"> O'Leary,R.A.</style></author><author><style face="normal" font="default"> Parisien,A.</style></author><author><style face="normal" font="default"> Trottier,K.</style></author><author><style face="normal" font="default"> Yracheta,J.M.</style></author><author><style face="normal" font="default"> Torgerson,D.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Missouri Breaks Industries Research Inc, Eagle Butte, South Dakota</style></auth-address><titles><title><style face="normal" font="default">Genetic variants and risk of asthma in an American Indian population</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="36" start="31">31-36</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Electronic medical records</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic Loci</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Missouri</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is recognized as a complex, multifactorial disease with a genetic component that is well recognized. Certain genetic variants are associated with asthma in a number of populations. OBJECTIVE: To determine whether the same variants increase the risk of asthma among American Indian children. METHODS: The electronic medical records of an Indian Health Service facility identified all children between 6 and 17 years of age with case-defining criteria for asthma (n = 108). Control children (n = 216), matched for age, were also identified. Real-time polymerase chain reaction assays were used to genotype 10 single-nucleotide polymorphisms (SNPs) at 6 genetic loci. Genotypic distributions among cases and controls were evaluated by chi2 and logistic regression methods. RESULTS: A variant at 5q22.1 revealed a statistically significant imbalance in the distribution of genotypes between case-control pairs (rs10056340, P &lt; .001). In logistic regression analyses, the same variant at 5q22.1 and a variant at 17q21 were associated with asthma at P &lt; .05 (rs10056340 and rs9303277). Inclusions of age, body mass index, and atopy in multivariate models revealed significant associations between rs10056340 (odds ratio, 2.020; 95% confidence interval, 1.283-3.180; P = .002) and all 5 17q21 SNPs and asthma in this population. In analyses restricted to atopic individuals, the association of rs10056340 was essentially unchanged, whereas among nonatopic individuals the trend was in the same direction but nonsignificant. The reverse was true for the 17q21 SNPs. CONCLUSION: These findings demonstrate that many variants commonly associated with asthma in other populations also accompany this condition among American Indian children. American Indian children also appear to have an increased risk of asthma associated with obesity</style></abstract><notes><style face="normal" font="default">DA - 20170702IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.05.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668238">PM:28668238</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-31-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-31-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170702, Best LG</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.05.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41805</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Heffler,E.</style></author><author><style face="normal" font="default"> Terranova,G.</style></author><author><style face="normal" font="default"> Chessari,C.</style></author><author><style face="normal" font="default"> Frazzetto,V.</style></author><author><style face="normal" font="default"> Crimi,C.</style></author><author><style face="normal" font="default"> Fichera,S.</style></author><author><style face="normal" font="default"> Picardi,G.</style></author><author><style face="normal" font="default"> Nicolosi,G.</style></author><author><style face="normal" font="default"> Porto,M.</style></author><author><style face="normal" font="default"> Intravaia,R.</style></author><author><style face="normal" font="default"> Crimi,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biomedical Sciences, Humanitas University, Milan, Italy; Personalized Medicine, Allergy and Asthma Clinic, Humanitas Clinical and Research Center, Milan, Italy.</style></auth-address><titles><title><style face="normal" font="default">Point-of-care blood eosinophil count in a severe asthma clinic setting</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="20" start="16">16-20</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Blood Cells</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic asthma</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Personalized medicine</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> Sputum eosinophilia</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: One of the main severe asthma phenotypes is severe eosinophilic or eosinophilic refractory asthma for which novel biologic agents are emerging as therapeutic options. In this context, blood eosinophil counts are one of the most reliable biomarkers. OBJECTIVE: To evaluate the performance of a point-of-care peripheral blood counter in a patients with severe asthma. METHODS: The blood eosinophil counts of 76 patients with severe asthma were evaluated by point-of-care and standard analyzers. RESULTS: A significant correlation between blood eosinophils assessed by the 2 devices was found (R2 = 0.854, P &lt; .001); similar correlations were found also for white blood cells, neutrophils, and lymphocytes. The point-of-care device had the ability to predict blood eosinophil cutoffs used to select patients for biologic treatments for severe eosinophilic asthma and the ELEN index, a composite score useful to predict sputum eosinophilia. CONCLUSION: The results of our study contribute to the validation of a point-of-care device to assess blood eosinophils and open the possibility of using this device for the management of severe asthma management</style></abstract><notes><style face="normal" font="default">DA - 20170702IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.05.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668237">PM:28668237</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-16-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-16-20.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170702, Heffler E</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.05.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41806</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yamamoto-Hanada,K.</style></author><author><style face="normal" font="default"> Yang,L.</style></author><author><style face="normal" font="default"> Narita,M.</style></author><author><style face="normal" font="default"> Saito,H.</style></author><author><style face="normal" font="default"> Ohya,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">Influence of antibiotic use in early childhood on asthma and allergic diseases at age 5</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="58" start="54">54-58</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> early childhood</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> macrolide</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: In the past few decades, the prevalence of allergic diseases has increased rapidly worldwide. At the same time, the overuse of antibiotics has been observed, especially in Japan. OBJECTIVE: To elucidate the association of early childhood antibiotic use with allergic diseases in later childhood at 5 years of age. METHODS: Relevant data were extracted from the hospital-based birth cohort study, the Tokyo Children's Health, Illness and Development Study. To identify signs of asthma and allergic diseases in children, the International Study of Asthma and Allergies in Childhood questionnaire was used. Logistic regression models were applied to estimate the effect of antibiotic use on outcomes in later life. RESULTS: Antibiotic exposure in children within the first 2 years of life was associated with current asthma (adjusted odds ratio [aOR] 1.72, 95% confidence interval [CI] 1.10-2.70), current atopic dermatitis (aOR 1.40, 95% CI 1.01-1.94), and current allergic rhinitis (aOR 1.65, 95% CI 1. 05-2.58) at 5 years of age. Analysis of the associations by type of antibiotics showed that cephem was associated with current asthma (aOR 1.97, 95% CI 1.23-3.16) and current rhinitis (aOR 1.82, 95% CI 1.12-2.93), and macrolide was associated with current atopic dermatitis (aOR 1.58, 95% CI 1.07-2.33). CONCLUSION: Our findings suggest that antibiotic use within the first 2 years of life was a risk factor for current asthma, current atopic dermatitis, and current allergic rhinitis in 5-year-old children</style></abstract><notes><style face="normal" font="default">DA - 20170702IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.05.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668240">PM:28668240</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-54-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-54-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170702, Yamamoto-Hanada K</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.05.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41807</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nabizadeh,E.</style></author><author><style face="normal" font="default"> Jazani,N.H.</style></author><author><style face="normal" font="default"> Bagheri,M.</style></author><author><style face="normal" font="default"> Shahabi,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Medicine, Department of Microbiology, Urmia University of Medical Sciences, Urmia, Iran</style></auth-address><titles><title><style face="normal" font="default">Association of altered gut microbiota composition with chronic urticaria</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="53" start="48">48-53</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Clostridium</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enterobacteriaceae</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> Gut microbiota</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: An altered gut microbiota composition has recently been linked to some types of allergies. OBJECTIVE: To compare the relative amounts of Akkermansia muciniphila, Clostridium leptum, Faecalibacterium prausnitzii, and Enterobacteriaceae as members of gut microbiota among patients with chronic urticaria (CU) and healthy controls. METHODS: A total of 20 patients with CU and 20 healthy individuals matched by age and sex participated in the study. Fresh fecal samples were collected, and DNA extracted from stool samples was analyzed by real-time polymerase chain reaction for the qualitative and quantitative assays of the so-called bacteria. RESULTS: The frequencies of A muciniphila, C leptum, and F prausnitzii in healthy controls' stool samples were significantly more than those of patients with CU (P &lt; .001, P &lt; .01, and P &lt; .05, respectively), whereas the Enterobacteriaceae family was detected in all patients and healthy controls' stool samples. The relative amounts of A muciniphila in healthy control positive samples were significantly higher than those of samples from patients with CU (P &lt; .001). Furthermore, there was a corresponding increase of relative amounts of C leptum and F prausnitzii in healthy control positive samples compared with those of patients with CU (P = .09 and P = .08, respectively). The mean of the relative amounts of Enterobacteriaceae family in the stool samples from patients with CU was more than that of healthy controls; however, the difference was nearly significant (P = .12). CONCLUSION: The results reveal a change of frequency and relative amounts of A muciniphila, C leptum, and F prausnitzii in patients with CU compared with healthy controls. This is the first study, to our knowledge, to show the change of microbiota composition in patients with CU</style></abstract><notes><style face="normal" font="default">DA - 20170702IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.05.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668239">PM:28668239</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-48-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-48-53.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170702, Nabizadeh E</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.05.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41808</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,T.</style></author><author><style face="normal" font="default"> Guo,Z.P.</style></author><author><style face="normal" font="default"> Wang,W.J.</style></author><author><style face="normal" font="default"> Fu,L.X.</style></author><author><style face="normal" font="default"> Sun,Q.M.</style></author><author><style face="normal" font="default"> Zhou,P.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermato-Venereology, Chengdu Second People's Hospital, Chengdu, Sichuan, China</style></auth-address><titles><title><style face="normal" font="default">Increased serum soluble vascular endothelial cadherin levels in patients with chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="709" start="704">704-709</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">angioedema</style></keyword><keyword><style face="normal" font="default"> angiogenesis</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endothelial Cells</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> H1-antihistamine</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Permeability</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> Pretreatment</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Western blot</style></keyword><keyword><style face="normal" font="default"> Wheal</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic spontaneous urticaria (CSU) is a common skin disease characterized by recurrent itchy wheals with or without angioedema that lasts longer than 6 weeks. Vascular endothelial (VE)-cadherin is an endothelial cell-specific adhesion molecule that plays critical roles in angiogenesis and endothelial permeability. OBJECTIVE: To investigate serum levels of soluble VE (sVE)-cadherin in patients with CSU. METHODS: Serum levels of sVE-cadherin in patients with CSU, patients with atopic dermatitis, and healthy controls were determined by enzyme-linked immunosorbent assay. In addition, changes in sVE-cadherin serum levels were compared in patients with CSU before and after H1 antihistamine treatment. Furthermore, the effects of histamine on sVE-cadherin release by HMEC-1 cells were determined by enzyme-linked immunosorbent assay. The inhibition effects of H1 antihistamine and H2 antihistamine on sVE-cadherin release, VE-cadherin phosphorylation, and VE-cadherin disruption were evaluated in histamine-treated HMEC-1 cells by western blot and immunofluorescence. RESULTS: Serum levels of sVE-cadherin in patients with CSU were significantly higher than those in patients with atopic dermatitis and healthy controls. Serum sVE-cadherin levels in patients with CSU were correlated with the severity of CSU according to Urticaria Activity Scores. Furthermore, serum sVE-cadherin levels in patients with CSU at pretreatment decreased after H1 antihistamine treatment. In addition, histamine markedly induced sVE-cadherin release in HMEC-1 cells. Moreover, H1 antihistamine, but not H2 antihistamine, significantly inhibited sVE-cadherin release in histamine-treated HMEC-1 cells. Western blot data showed that histamine induced phosphorylation of VE-cadherin in HMEC-1 cells, which was blocked by H1 antihistamine. CONCLUSION: The present data showed serum levels of sVE-cadherin are increased in patients with CSU. Histamine-induced sVE-cadherin release from endothelial cells could play a role in the pathogenesis of CSU</style></abstract><notes><style face="normal" font="default">DA - 20170606IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.04.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583263">PM:28583263</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-704-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-704-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170606, Chen T</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.04.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41809</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jo,Y.S.</style></author><author><style face="normal" font="default"> Lee,J.</style></author><author><style face="normal" font="default"> Yoon,H.I.</style></author><author><style face="normal" font="default"> Kim,D.K.</style></author><author><style face="normal" font="default"> Yoo,C.G.</style></author><author><style face="normal" font="default"> Lee,C.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Different prevalence and clinical characteristics of asthma-chronic obstructive pulmonary disease overlap syndrome according to accepted criteria</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="703" start="696">696-703</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Asthmatic</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> diagnostic criteria</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> prospective cohort study</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: A unified definition of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) is not available, which makes it difficult to evaluate the prevalence and clinical features of patients with ACOS. OBJECTIVE: To investigate the prevalence and clinical characteristics of ACOS according to the updated widely accepted diagnostic criteria. METHODS: Participants were enrolled from a prospective cohort study conducted between April 2013 and November 2016 in South Korea. We adopted 4 criteria of ACOS: modified Spanish, American Thoracic Society (ATS) Roundtable criteria, the Latin American Project for the Investigation of Obstructive Lung Disease (PLATINO), and the Global Initiative for Asthma/Global Initiative for Chronic Obstructive Lung Disease (GINA/GOLD) criteria. The prevalence, clinical characteristics, and exacerbations of ACOS were investigated. RESULTS: Among 301 patients with chronic obstructive pulmonary disease, 31.3%, 11.9%, 48.3%, and 46.15% were diagnosed with ACOS according to the modified Spanish, ATS Roundtable criteria, PLATINO, and GINA/GOLD criteria, respectively. Compared with other criteria, patients with ACOS diagnosed according to the modified Spanish criteria had better exercise capacity and lung function at baseline but higher risk of moderate to severe (adjusted hazard ratio, 1.97; 95% confidence interval, 1.14-3.41; P = .01) and total (adjusted odds ratio, 2.10; 95% confidence interval, 1.33-3.31; P &lt; .01) exacerbations during at least a 1-year follow-up period than patients without ACOS. CONCLUSION: The prevalence of ACOS varied according to the diagnostic criteria. Among the different criteria, the modified Spanish criteria could identify patients with more asthmatic features and higher risk of exacerbation. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02527486</style></abstract><notes><style face="normal" font="default">DA - 20170606IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.04.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583262">PM:28583262</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-696-703.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-696-703.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170606, Jo YS</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.04.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41810</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Staicu,M.L.</style></author><author><style face="normal" font="default"> Plakosh,M.</style></author><author><style face="normal" font="default"> Ramsey,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Rochester General Hospital, Rochester, New York.</style></auth-address><titles><title><style face="normal" font="default">Prospective evaluation of electronic medical record penicillin allergy documentation at a tertiary community teaching hospital</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="95" start="94">94-95</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Documentation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Teaching</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="31" Month="5" Year="2017">2017/5/31</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170605IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.05.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28578908">PM:28578908</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-94-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-94-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170605, Staicu Ml</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.05.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41811</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Limone,B.A.</style></author><author><style face="normal" font="default"> Jacob,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Loma Linda University, Loma Linda, California</style></auth-address><titles><title><style face="normal" font="default">Insights into the global effect of nickel dermatitis on polysensitization</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="749">749-</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">California</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170606IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.04.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583267">PM:28583267</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-749.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-118-749.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170606, Limone BA</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.04.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41812</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Saito,R.</style></author><author><style face="normal" font="default"> Sawada,Y.</style></author><author><style face="normal" font="default"> Yamaguchi,T.</style></author><author><style face="normal" font="default"> Ohmori,S.</style></author><author><style face="normal" font="default"> Haruyama,S.</style></author><author><style face="normal" font="default"> Yoshioka,M.</style></author><author><style face="normal" font="default"> Okada,E.</style></author><author><style face="normal" font="default"> Nakamura,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan</style></auth-address><titles><title><style face="normal" font="default">Drug eruption caused by memantine</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="90" start="89">89-90</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Dermatology</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug eruption</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170702IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.05.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668245">PM:28668245</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-89-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-89-90.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170702, Saito R</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.05.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41813</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Walters,K.M.</style></author><author><style face="normal" font="default"> Simon,R.A.</style></author><author><style face="normal" font="default"> Woessner,K.M.</style></author><author><style face="normal" font="default"> Wineinger,N.E.</style></author><author><style face="normal" font="default"> White,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Scripps Clinic, San Diego, California.</style></auth-address><titles><title><style face="normal" font="default">Effect of misoprostol on patients with aspirin-exacerbated respiratory disease undergoing aspirin challenge and desensitization</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="76" start="71">71-76</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">5-Lipoxygenase</style></keyword><keyword><style face="normal" font="default"> AERD</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin challenge</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cyclooxygenase 1</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Drug-induced</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Ketorolac</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> mediator release</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Misoprostol</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> Prostaglandin</style></keyword><keyword><style face="normal" font="default"> prostaglandin E2</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Prostaglandin E2 (PGE2) is an anti-inflammatory compound that inhibits 5-lipoxygenase activity. Diminished PGE2 regulation in aspirin-exacerbated respiratory disease (AERD) leads to respiratory reactions on cyclooxygenase 1 inhibition. In vitro studies have found that exogenous PGE2 stabilizes inflammatory mediator release. OBJECTIVE: To examine whether misoprostol (oral prostaglandin E1 analogue) use during aspirin challenge and desensitization might decrease the severity of aspirin-induced symptoms and make desensitization safer for patients with AERD. METHODS: Forty-five patients undergoing aspirin challenge and/or desensitization were randomized to misoprostol (n = 30) or placebo (n = 15) and compared with a group of historical controls (n = 31). Misoprostol (200 mug) was administered at 30 minutes, 90 minutes, and 4 hours after the first dose of nasal ketorolac. Measured end points included change in forced expiratory volume in 1 second (FEV1), peak nasal inspiratory flow rate (PNIF), number of treatments received for induced reactions, and adverse gastrointestinal effects. RESULTS: A difference in FEV1 and PNIF reduction was detected between misoprostol and placebo (P = .03) and misoprostol and historical controls (P = .01), respectively, during nasal ketorolac challenge. No difference was detected among aspirin reactors. Among all reactors, no difference in magnitude was found for FEV1 (P = .13) or PNIF (P = .07) reduction across all 3 groups. Total treatment requirement was similar (P = .14). Patients receiving misoprostol were more likely to report adverse gastrointestinal effects (P = .02). CONCLUSION: The addition of misoprostol to current aspirin challenge and/or desensitization protocols reveals no protective effect in reducing the intensity of nonsteroidal anti-inflammatory drug-induced symptoms and is not recommended based on the findings in this study</style></abstract><notes><style face="normal" font="default">DA - 20170702IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.05.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668243">PM:28668243</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-71-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-71-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170702, Walters KM</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.05.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41814</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chooniedass,R.</style></author><author><style face="normal" font="default"> Temple,B.</style></author><author><style face="normal" font="default"> Becker,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, John Buhler Research Centre, Winnipeg, Manitoba, Canada.</style></auth-address><titles><title><style face="normal" font="default">Epinephrine use for anaphylaxis: Too seldom, too late: Current practices and guidelines in health care</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170705IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.06.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28676208">PM:28676208</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170705-ChooniedassR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170705-ChooniedassR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170705, Chooniedass R</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.06.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41815</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mao,Y.</style></author><author><style face="normal" font="default"> Zhan,Y.</style></author><author><style face="normal" font="default"> Huang,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Epidemiology and Health Statistics, School of Public Health, Kunming Medical University, Kunming, People's Republic of China</style></auth-address><titles><title><style face="normal" font="default">Vitamin D and asthma: A Mendelian randomization study</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="97" start="95">95-97</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Statistics</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170702IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.05.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668249">PM:28668249</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-95-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-95-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170702, Mao Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.05.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41816</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wood,P.R.</style></author><author><style face="normal" font="default"> Kampschmidt,J.C.</style></author><author><style face="normal" font="default"> Dube,P.H.</style></author><author><style face="normal" font="default"> Cagle,M.P.</style></author><author><style face="normal" font="default"> Chaparro,P.</style></author><author><style face="normal" font="default"> Ketchum,N.S.</style></author><author><style face="normal" font="default"> Kannan,T.R.</style></author><author><style face="normal" font="default"> Singh,H.</style></author><author><style face="normal" font="default"> Peters,J.I.</style></author><author><style face="normal" font="default"> Baseman,J.B.</style></author><author><style face="normal" font="default"> Brooks,E.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, UT Health San Antonio, San Antonio, Texas.</style></auth-address><titles><title><style face="normal" font="default">Mycoplasma pneumoniae and health outcomes in children with asthma</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exhaled Breath</style></keyword><keyword><style face="normal" font="default"> exhaled breath condensate</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mycoplasma</style></keyword><keyword><style face="normal" font="default"> Mycoplasma pneumoniae</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> persistence</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> pH</style></keyword><keyword><style face="normal" font="default"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> symptom scores</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Texas</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="6" Year="2017">2017/6/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Acute infections with Mycoplasma pneumoniae (Mp) have been associated with worsening asthma in children. Mp can be present in the respiratory tract for extended periods; it is unknown whether the long-term persistence of Mp in the respiratory tract affects long-term asthma control. OBJECTIVE: To determine the effect of Mp on asthma control. METHODS: We enrolled 31 pediatric subjects 3 to 10 years of age with persistent asthma who completed up to 8 visits over a 24-month period. We detected Mp by antigen capture and polymerase chain reaction. Primary outcome measurements included symptom scores, quality of life, medication scores, oral corticosteroid use, health care usage, school absences, and exhaled breath condensate pH. RESULTS: Low levels of Mp community-acquired respiratory distress syndrome toxin were detected in 20 subjects (64.5%) at enrollment. Subjects with Mp positivity at a given visit had a .579 probability of remaining Mp positive at the subsequent visit, whereas those with Mp negativity had a .348 probability of becoming Mp positive at the following visit. The incidence of Mp overall was higher in the spring and summer months. Overall, we found no significant relation between the detection of Mp and worse outcome measurements at the same visit or at subsequent visits. CONCLUSION: The long-term persistence of Mp in the respiratory tract is common in children with asthma. However, the detection of Mp was not associated significantly with worse asthma symptoms, quality of life, health care usage, school absences, or exhaled breath condensate pH in this pediatric asthma cohort</style></abstract><notes><style face="normal" font="default">DA - 20170621IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.05.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28634021">PM:28634021</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170621-WoodPR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170621-WoodPR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170621, Woo PR</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.05.022</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41817</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Riedl,M.A.</style></author><author><style face="normal" font="default"> Banerji,A.</style></author><author><style face="normal" font="default"> Busse,P.J.</style></author><author><style face="normal" font="default"> Johnston,D.T.</style></author><author><style face="normal" font="default"> Davis-Lorton,M.A.</style></author><author><style face="normal" font="default"> Patel,S.</style></author><author><style face="normal" font="default"> Parr,H.</style></author><author><style face="normal" font="default"> Chiao,J.</style></author><author><style face="normal" font="default"> Watson,D.J.</style></author><author><style face="normal" font="default"> Burrell,E.</style></author><author><style face="normal" font="default"> Machnig,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of California-San Diego, La Jolla, California.</style></auth-address><titles><title><style face="normal" font="default">Patient satisfaction and experience with intravenously administered C1-inhibitor concentrates in the United States</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="64" start="59">59-64</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> C1 esterase inhibitor</style></keyword><keyword><style face="normal" font="default"> C1 INH</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-INH</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> C1Inh</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Internet</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patient Satisfaction</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Thrombosis</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Veins</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hereditary angioedema (HAE) is a rare genetic disorder with substantial morbidity and mortality. Despite expanded choices for effective acute treatment, prophylactic options are more limited. Intravenous C1 esterase inhibitor (C1-INH[IV]) is licensed and used to prevent HAE symptoms. OBJECTIVE: To better understand patient experiences with using C1-INH(IV), including level of satisfaction and types and frequency of complications. METHODS: Fifty adult members (>/=18 years of age) of the US HAE Association who had HAE type I or II completed a self-administered internet survey. Eligible participants were experiencing at least 1 HAE attack per month and must have been receiving treatment with C1-INH(IV) as prophylaxis or acute therapy. RESULTS: Almost all respondents (n = 47; 94%) were using C1-INH(IV) for HAE prophylaxis. Most patients reported administration of C1-INH(IV) through a peripheral vein (n = 34) and 19 were currently (n = 17) or previously (n = 2) using a central venous port. Most respondents (62%) who used a peripheral vein to administer treatment reported having difficulty finding a usable vein or getting the infusion to work properly at least some of the time. Issues accessing veins, exhausted veins, and frequency of attacks were the main reasons physicians recommended ports to respondents. Although ports allow easier administration of therapy, 47% of respondents with ports experienced problems such as occlusion, thrombosis, and infection. Respondents using C1-INH prophylaxis reported a mean of 2.3 attacks per month during the previous 6 months. CONCLUSION: The survey results identified clinical challenges with IV HAE medication use, including venous access issues and ongoing monthly attack occurrence despite prophylactic C1-INH(IV) administration</style></abstract><notes><style face="normal" font="default">DA - 20170702IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.05.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668241">PM:28668241</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-59-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-59-64.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170702, Riedl MA</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.05.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41818</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tiwari,S.M.</style></author><author><style face="normal" font="default"> Gebauer,K.</style></author><author><style face="normal" font="default"> Frydrych,A.M.</style></author><author><style face="normal" font="default"> Burrows,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Fiona Stanley Hospital, Perth, Western Australia, Australia</style></auth-address><titles><title><style face="normal" font="default">Dental patch testing in patients with undifferentiated oral lichen planus</style></title><secondary-title><style face="normal" font="default">Australas J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Australas J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Copper</style></keyword><keyword><style face="normal" font="default"> Dentistry</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epicutaneous</style></keyword><keyword><style face="normal" font="default"> Gold</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypothyroidism</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Lichen Planus</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mercury</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drug</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Potassium</style></keyword><keyword><style face="normal" font="default"> Potassium Dichromate</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Remission</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Western Australia</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="default">BACKGROUND/OBJECTIVES: Distinguishing between oral lichen planus (LP) and lichenoid reactions to dental restorations can be impossible on clinical and histopathological grounds. Epicutaneous patch testing is an investigation that may guide patients and physicians in making timely and costly decisions to replace or cover existing dental restorations. This study aimed to assess the role of epicutaneous patch testing with a battery of dental allergens in patients with undifferentiated oral LP. METHODS: A retrospective review of the medical records of patients with biopsy-proven oral LP referred by an oral medicine specialist and who presented for dental epicutaneous patch testing at a dermatology clinic in Perth, Western Australia between 2009 and 2016 was performed. RESULTS: In total, 68 patients were included, of whom 54 (79%) had positive patch tests. Gold 26 (48%), mercury 24 (44%), nickel 22 (41%), copper 19 (35%), potassium dichromate 14 (26%) and methylhydroquinone 13 (24%) were the most common allergens for which patients tested positive. Hypothyroidism and non-steroidal anti-inflammatory drugs were associated with negative patch tests (P = 0.01 and 0.04, respectively). Smoking history, other medications and comorbidities, the location of the dental restorations and unilateral or bilateral disease were not significantly associated with the patch test results. Restorations were removed in 23 patients: 21 of these (91%) had positive epicutaneous patch tests. Of the 20 patients followed up, 19 (95%) experienced some improvement, among whom 11 (58%) had complete remission. CONCLUSION: Epicutaneous patch testing disclosed a high proportion of relevant positives. This guided the clinical decision to change dental restorations, with high rate of clinical improvement</style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 1440-0960 (Electronic)IS - 0004-8380 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/ajd.12692</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28695565">PM:28695565</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Australas J Dermatol\20170711-TiwariSM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Australas J Dermatol\20170711-TiwariSM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170711, Tiwari SM</style></custom2><misc3><style face="normal" font="default">10.1111/ajd.12692</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41819</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hirunwidchayarat,W.</style></author><author><style face="normal" font="default"> Furusawa,E.</style></author><author><style face="normal" font="default"> Kang,S.</style></author><author><style face="normal" font="default"> Ohno,T.</style></author><author><style face="normal" font="default"> Takeuchi,S.</style></author><author><style face="normal" font="default"> Rungsiyanont,S.</style></author><author><style face="normal" font="default"> Azuma,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Molecular Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">Site-specific regulation of oral mucosa-recruiting CD8+ T cells in a mouse contact allergy model</style></title><secondary-title><style face="normal" font="default">Biochem Biophys Res Commun</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Biochem Biophys Res Commun</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic response</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> CD8+ T cells</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> delayed-type hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Dentistry</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelia</style></keyword><keyword><style face="normal" font="default"> Epithelium</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> immunopathology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> oral mucosa</style></keyword><keyword><style face="normal" font="default"> Recovery</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="7" Year="2017">2017/7/4</year></dates><abstract><style face="normal" font="default">Contact allergy is a T cell-mediated, delayed-type hypersensitivity generated by contact exposure of an allergen to the skin and mucosal surface. The clinical manifestations of allergic responses between the skin and oral mucosa vary and the differences in immunopathology have not been clarified. We generated hapten-induced contact hypersensitivity (CH) of the buccal mucosa (BM) in parallel studies with ear skin (ES) CH, and observed several characteristic findings of BM CH. The BM challenge induced more rapid and more severe inflammation than the ES challenge, with abundant granulocyte and CD8+ T cell infiltration. However, these inflammatory responses diminished quickly. Recruiting CD8+ T cells in the BM had higher ratios of CD62L-CD44low-hi memory-type cells, and showed impaired IFN-gamma, greater PD-1, and comparable Ki-67 expression, suggesting that the recruiting-proliferating CD8+ T cells were unable to differentiate into effector T cells and converted into exhausted T cells at the local site. This finding may explain the rapid recovery of the BM from severe inflammation. Preferentially greater expression of PD-1 ligand (B7-H1), was observed in the BM epithelium under the peak inflammation, and the absence of B7-H1 further accelerated CH responses, suggesting the occurrence of PD-1:B7-H1-mediated immune regulation at the local site. Our results may facilitate the understanding of the unique features of contact allergies in the oral mucosa, and guide the development of new strategies for control of contact allergy</style></abstract><notes><style face="normal" font="default">DA - 20170708IS - 1090-2104 (Electronic)IS - 0006-291X (Linking)LA - engPT - Journal ArticleCO - Japan -CO - Thailand -</style></notes><work-type><style face="normal" font="default">10.1016/j.bbrc.2017.07.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28687491">PM:28687491</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biochem Biophys Res Commun\20170708-HirunwidchayaratW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biochem Biophys Res Commun\20170708-HirunwidchayaratW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170708, Hirunwidchayarat W</style></custom2><misc3><style face="normal" font="default">10.1016/j.bbrc.2017.07.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41820</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,B.H.</style></author><author><style face="normal" font="default"> Kim,H.K.</style></author><author><style face="normal" font="default"> Jang,M.</style></author><author><style face="normal" font="default"> Kim,H.J.</style></author><author><style face="normal" font="default"> Choi,S.H.</style></author><author><style face="normal" font="default"> Hwang,S.H.</style></author><author><style face="normal" font="default"> Kim,H.C.</style></author><author><style face="normal" font="default"> Rhim,H.</style></author><author><style face="normal" font="default"> Cho,I.H.</style></author><author><style face="normal" font="default"> Nah,S.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Ginsentology Research Laboratory and Department of Physiology, College of Veterinary Medicine, Konkuk University</style></auth-address><titles><title><style face="normal" font="default">Effects of Gintonin-Enriched Fraction in an Atopic Dermatitis Animal Model: Involvement of Autotaxin Regulation</style></title><secondary-title><style face="normal" font="default">Biol Pharm Bull</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Biol Pharm Bull</style></full-title></periodical><pages end="1070" start="1063">1063-1070</pages><volume><style face="normal" font="default">40</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal model</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Interferon-gamma</style></keyword><keyword><style face="normal" font="default"> Interleukin-4</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> oral administration</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> veterinary</style></keyword><keyword><style face="normal" font="default"> Veterinary Medicine</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Ginseng extract has been used for prevention of atopic dermatitis (AD) in experimental animal models. However, little is known about its active ingredients and the molecular mechanisms underlying its anti-AD effects. Recently, we isolated a unique lysophosphatidic acid (LPA) receptor ligand, gintonin, from ginseng. Gintonin, the glycolipoprotein fraction of ginseng, contains LPAs, mainly LPA C18 : 2 with other minor lysophospholipid components. A line of evidence showed that serum autotaxin (ATX) activity and level are significantly elevated in human AD patients compared to those in normal controls, which indicates that ATX may be involved in human AD. In a previous study, we demonstrated that gintonin exerted anti-inflammatory effects via inhibition of microglial activation and proinflammatory cytokine production by immune cells and that it strongly inhibited ATX activity. In this study, we investigated whether oral administration of the gintonin-enriched fraction (GEF) could ameliorate the symptoms of 2,4-dinitrofluorobenzene (DNFB)-induced AD in NC/Nga mice. We found that oral administration of GEF to DNFB-induced AD mice for 2 weeks reduced ear swelling and AD skin index. In addition, oral administration of GEF reduced the serum levels of immunoglobulin E, histamine, interleukin-4, and interferon-gamma. Histological examination showed that oral administration of GEF attenuated skin inflammation and significantly reduced eosinophil and mast cell infiltration into the skin. Moreover, oral administration of GEF not only decreased serum ATX level but also reduced serum ATX activity. The present study shows that the anti-AD effects of ginseng might be attributed to GEF-induced anti-inflammatory activity and ATX regulation</style></abstract><notes><style face="normal" font="default">DA - 20170704IS - 1347-5215 (Electronic)IS - 0918-6158 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1248/bpb.b17-00124</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28674249">PM:28674249</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biol Pharm Bull\2017-40-1063-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biol Pharm Bull\2017-40-1063-70.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170704, Lee BH</style></custom2><misc3><style face="normal" font="default">10.1248/bpb.b17-00124</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41821</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,Q.</style></author><author><style face="normal" font="default"> Li,Q.</style></author><author><style face="normal" font="default"> Han,T.</style></author><author><style face="normal" font="default"> Hu,T.</style></author><author><style face="normal" font="default"> Zhang,X.</style></author><author><style face="normal" font="default"> Hu,J.</style></author><author><style face="normal" font="default"> Hu,H.</style></author><author><style face="normal" font="default"> Tan,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Bioscience &amp; Bioengineering, South China University of Technology</style></auth-address><titles><title><style face="normal" font="default">Study of pH stability of R-salbutamol sulfate aerosol solution and its antiasthmatic effects in guinea pigs</style></title><secondary-title><style face="normal" font="default">Biol Pharm Bull</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Biol Pharm Bull</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Animal</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Commercial</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Guinea Pigs</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> nebulized</style></keyword><keyword><style face="normal" font="default"> Particle Size</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pH</style></keyword><keyword><style face="normal" font="default"> pig</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Solutions</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="24" Month="6" Year="2017">2017/6/24</year></dates><abstract><style face="normal" font="default">Currently, all commercial available nebulized Salbutamol in China is in its racemic form. It is known that only R-salbutamol (eutomer) has therapeutic effects, while S-salbutamol (distomer) may exacerbate asthma after chronic use. Therefore, it is an unmet clinical need to develop R-salbutamol as a nebulized product that is more convenient for young and old patients. In our study, a stable aerosol solution of R-salbutamol sulfate was established, and its antiasthmatic effects were confirmed. The decomposition rate and racemization effect of the R-salbutamol sulfate solution were evaluated over a pH range from 1 to 10 (except pH = 7, 8) at 60 . The aerodynamic particle size of the R-salbutamol sulfate solution and commercial RS-salbutamol sulfate solution were both tested in vitro by NGI in 5 . Laser diffractometer was used to characterize the droplet-size distribution (DSD) of both solutions. We next conducted an in vivo animal study to document the antiasthmatic effect of R-salbutamol aerosol sulfate solution and determine the relationship to RS-salbutamol. The results showed that the R-salbutamol sulfate solution was more stable at pH 6. In vitro comparison studies indicated that there was no distribution difference between R-salbutamol sulfate solution and the commercial RS-salbutamol solution. The animal results showed that R-salbutamol was more potent than RS-salbutamol against the same dose of histamine challenge. Unlike commercial RS-salbutamol, which was acidified to a pH of 3.5 to extend bench life but may cause bronchoconstriction in asthmatic patients, the neutralized R-salbutamol solution was more suitable for clinic use</style></abstract><notes><style face="normal" font="default">DA - 20170627IS - 1347-5215 (Electronic)IS - 0918-6158 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1248/bpb.b17-00067</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28652557">PM:28652557</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biol Pharm Bull\20170627-LiuQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biol Pharm Bull\20170627-LiuQ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170627, Liu Q</style></custom2><misc3><style face="normal" font="default">10.1248/bpb.b17-00067</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41822</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pasko,P.</style></author><author><style face="normal" font="default"> Rodacki,T.</style></author><author><style face="normal" font="default"> Domagala-Rodacka,R.</style></author><author><style face="normal" font="default"> Palimonka,K.</style></author><author><style face="normal" font="default"> Marcinkowska,M.</style></author><author><style face="normal" font="default"> Owczarek,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Food Chemistry and Nutrition, Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Krakow, Poland.</style></auth-address><titles><title><style face="normal" font="default">Second generation H1 - antihistamines interaction with food and alcohol-A systematic review</style></title><secondary-title><style face="normal" font="default">Biomed Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Biomed Pharmacother</style></full-title></periodical><pages end="39" start="27">27-39</pages><volume><style face="normal" font="default">93</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Alcohol</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cetirizine</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> desloratadine</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Fexofenadine</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Fruit</style></keyword><keyword><style face="normal" font="default"> H1 antihistamines</style></keyword><keyword><style face="normal" font="default"> H1 receptor</style></keyword><keyword><style face="normal" font="default"> H1-antihistamine</style></keyword><keyword><style face="normal" font="default"> H1-antihistamines</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Loratadine</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> pharmacokinetics</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Publications</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="13" Month="6" Year="2017">2017/6/13</year></dates><abstract><style face="normal" font="default">Histamine is a mediator of many physiological processes. It plays an important role in modulating allergy reactions and immune system responses. H1 receptor is a therapeutic target for drugs applied in allergic diseases such as allergic rhinoconjunctivitis, urticarial, or atopic dermatitis. H1-antihistamines display different chemical structures, pharmacokinetics and a potential for drug-drug and drug-food interactions. Drug-food interactions are known to reduce therapeutic effects of the medicine, as well as to induce a potent adverse drug reactions. Considering it all, a systematic review was conducted to investigate the importance of drug-food interaction for H1-antihistamine drugs. As non-sedating second generation H1-antihistamines remain to be drugs of choice in treating allergic conditions, the review has been focused on this particular class of medicines. The aim of this paper is to examine the evidence of food-drug and food-alcohol interactions for second generation H1-antihistamine drugs. A systematic literature queries were performed in the following databases: Medline (via PubMed), Cochrane Library, Embase and Web of Science (all from their inception date till October 2016). The queries covered nine specific names of second generation anthistamine drugs, namely bilastine, cetirizine, desloratadine, ebastine, fexofenadine, levocetirizine, loratadine, mizolastine, and rupatadine, in combinations with such terms as "food", "juice", "grapefruit", "fruits", "alcohol", "pharmacokinetics", and "meal". Additional publications were found by checking all the reference lists. Where none data on drug-food interaction could be found within the investigated databases, a specific drug prescribing information was used. 2326 publications were identified with the database queries. Articles were subjected to analysis by reviewing their title, abstract and full text; duplicated papers were removed. Having collected a complete set of data, a critical review was undertaken. For selected H1-antihistamines food, fruit juices or alcohol consumption may significantly impact the efficacy and safety of the therapy. This issue shall be well understood to educate patients properly, as it provides the major therapeutic element in allergic diseases</style></abstract><notes><style face="normal" font="default">DA - 20170616IS - 1950-6007 (Electronic)IS - 0753-3322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.biopha.2017.06.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28622592">PM:28622592</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biomed Pharmacother\2017-93-27-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biomed Pharmacother\2017-93-27-39.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170616, Pasko P</style></custom2><misc3><style face="normal" font="default">10.1016/j.biopha.2017.06.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41823</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zheng,R.</style></author><author><style face="normal" font="default"> Qian,L.</style></author><author><style face="normal" font="default"> Yu,J.</style></author><author><style face="normal" font="default"> Li,M.</style></author><author><style face="normal" font="default"> Qian,Q.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Binhai County People's Hospital, Yancheng, Jiangsu 224500, P.R. China</style></auth-address><titles><title><style face="normal" font="default">Analysis of the changes in Th9 cells and related cytokines in the peripheral blood of spontaneous urticaria patients</style></title><secondary-title><style face="normal" font="default">Biomed Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Biomed Rep</style></abbr-1></periodical><pages end="639" start="633">633-639</pages><volume><style face="normal" font="default">6</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> IL-17A</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-9</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> transcription factor</style></keyword><keyword><style face="normal" font="default"> Transforming Growth Factor beta1</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">Spontaneous urticaria (SU) is characterized by immune deregulation of mast cells and T helper (Th) cells. Th9 cells, a subset of Th cells, serve a key role in initiating mast cell accumulation and activation. To understand the role of Th9 cells in the pathogenesis of SU, the authors conducted a control study of 28 patients with acute SU (ASU) and chronic SU (CSU) and 28 healthy controls. The percentage of Th9 cells in peripheral blood was assessed using flow cytometry and levels of Th9 related serum cytokines including interleukin (IL)-4, IL-9, IL-17A, IL-33, IL-1beta and transforming growth factor-beta1 (TGF-beta1) using Luminex 200. ASU patients exhibited higher percentages of Th9 cells and increased serum levels of cytokines IL-9, IL-4 and TGF-beta1 compared to healthy controls. In addition, high mRNA expression of the PU.1 transcription factor was observed in ASU patients. However, the percentage of Th9 cells was similar between patients with CSU and healthy controls. Furthermore, the percentage of Th9 cells demonstrated a positive correlation with IL-4 and IL-9 levels in the peripheral blood of ASU patients, but not with disease severity. The current findings suggested that the numbers of Th9 cells increased in ASU patients and indicated its novel role in the pathogenesis of ASU</style></abstract><notes><style face="normal" font="default">DA - 20170606IS - 2049-9434 (Print)IS - 2049-9434 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.3892/br.2017.904</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28584634">PM:28584634</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biomed Rep\2017-6-633-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biomed Rep\2017-6-633-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170606, Zheng R</style></custom2><misc3><style face="normal" font="default">10.3892/br.2017.904</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41824</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,D.Y.</style></author><author><style face="normal" font="default"> Hwang,C.J.</style></author><author><style face="normal" font="default"> Choi,J.Y.</style></author><author><style face="normal" font="default"> Park,M.H.</style></author><author><style face="normal" font="default"> Song,M.J.</style></author><author><style face="normal" font="default"> Oh,K.W.</style></author><author><style face="normal" font="default"> Son,D.J.</style></author><author><style face="normal" font="default"> Lee,S.H.</style></author><author><style face="normal" font="default"> Han,S.B.</style></author><author><style face="normal" font="default"> Hong,J.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju 28160, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Inhibitory Effect of Carnosol on Phthalic Anhydride-Induced Atopic Dermatitis via Inhibition of STAT3</style></title><secondary-title><style face="normal" font="default">Biomol Ther (Seoul)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Biomol Ther (Seoul)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> COX-2</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> iNOS</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Raw</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rosmarinus</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> suppression</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="27" Month="6" Year="2017">2017/6/27</year></dates><abstract><style face="normal" font="default">Carnosol is a phenolic antioxidant present in rosemary (Rosmarinus officinalis). It is known for anti-inflammatory effects, analgesic activity and anti-cancer effects. However, no study has been dedicated yet to its effect on atopic dermatitis (AD). Here, we show that carnosol effectively inhibited LPS-induced nitric oxide (NO) generation and expression of inflammatory marker proteins (iNOS and COX-2) in RAW 264.7 cells. In addition, carnosol effectively inhibits the phosphorylation of STAT3 and DNA binding activity in RAW 264.7 cells. Pull down assay and docking model analysis showed that carnosol directly binds to the DNA binding domain (DBD) of STAT3. We next examined the anti-atopic activity of carnosol (0.05 microg/cm2) using 5% Phthalic anhydride (PA)-induced AD model in HR1 mice. Carnosol treatment significantly reduced 5% PA-induced AD like skin inflammation in skin tissues compared with control mice. Moreover, carnosol treatment inhibits the expression of iNOS and COX-2 in skin tissue. In addition, the levels of TNF-alpha, IL-1beta, and Immunoglobulin-E in blood serum was significantly decreased in carnosol treated mice compared with those of 5% PA treated group. Furthermore, the activation of STAT3 in skin tissue was decreased in carnosol treated mice compared with control mice. In conclusion, these findings suggest that carnosol exhibited a potential anti-AD activity by inhibiting pro-inflammatory mediators through suppression of STAT3 activation via direct binding to DBD of STAT3</style></abstract><notes><style face="normal" font="default">DA - 20170627IS - 1976-9148 (Print)IS - 1976-9148 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4062/biomolther.2017.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28655070">PM:28655070</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biomol Ther (Seoul)\20170627-LeeDY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biomol Ther (Seoul)\20170627-LeeDY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170627, Lee DY</style></custom2><misc3><style face="normal" font="default">10.4062/biomolther.2017.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41825</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Choi,J.H.</style></author><author><style face="normal" font="default"> Song,Y.S.</style></author><author><style face="normal" font="default"> Lee,H.J.</style></author><author><style face="normal" font="default"> Kim,G.C.</style></author><author><style face="normal" font="default"> Hong,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, School of Korean Medicine, Pusan National University, Yangsan, 626-870, South Korea</style></auth-address><titles><title><style face="normal" font="default">The topical application of low-temperature argon plasma enhances the anti-inflammatory effect of Jaun-ointment on DNCB-induced NC/Nga mice</style></title><secondary-title><style face="normal" font="default">BMC Complement Altern Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Complement Altern Med</style></abbr-1></periodical><pages end="" start="340">340-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Angelica</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Argon</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Dentistry</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> DNCB</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Herbal</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="27" Month="6" Year="2017">2017/6/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Jaun-ointment (JO), also known as Shiunko in Japan, is one of the most popular medicinal formulae used in Korean traditional medicine for the external treatment of skin wound and inflammatory skin conditions. Since JO is composed of crude mixture of two herbal extracts (radix of Lithospermum erythrorhizon Siebold &amp; Zucc and Angelica gigas Nakai), those been proved its anti-inflammatory activities in-vitro and in-vivo, JO has been expected as a good alternative treatment option for atopic dermatitis (AD). However, due to the lack of strategies for the penetrating methods of JO's various anti-inflammatory elements into the skin, an effective and safe transdermal drug delivery system needs to be determined. Here, low-temperature argon plasma (LTAP) was adopted as an ancillary partner of topically applied JO in a mice model of AD and the effectiveness was examined. METHODS: Dorsal skins of NC/Nga mice were challenged with DNCB (2,4-dinitrochlorobenzene) to induce AD. AD-like skin lesions were treated with JO alone, or in combination with LTAP. Inflammatory activity in the skin tissues was evaluated by histological analysis and several molecular biological tests. RESULTS: LTAP enhanced the effect of JO on AD-like skin lesion. Topical application of JO partially inhibited the development of DNCB-induced AD, shown by the moderate reduction of eosinophil homing and pro-inflammatory cytokine level. Combined treatment of JO and LTAP dramatically inhibited AD phenotypes. Interestingly, treatment with JO alone did not affect the activity of nuclear factor (NF)kappaB/RelA in the skin, but combined treatment of LTAP-JO blocked DCNB-mediated NFkappaB/RelA activation. CONCLUSIONS: LTAP markedly enhanced the anti-inflammatory activity of JO on AD-like skin lesions. The effect of LTAP may be attributed to enhancement of drug penetration and regulation of NFkappaB activity. Therefore, the combination treatment of JO and LTAP could be a potential strategy for the treatment of AD</style></abstract><notes><style face="normal" font="default">DA - 20170628IS - 1472-6882 (Electronic)IS - 1472-6882 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1186/s12906-017-1850-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28655324">PM:28655324</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Complement Altern Med\2017-17-340.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Complement Altern Med\2017-17-340.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170628, Choi JH</style></custom2><misc3><style face="normal" font="default">10.1186/s12906-017-1850-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41826</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,S.</style></author><author><style face="normal" font="default"> Jeong,H.H.</style></author><author><style face="normal" font="default"> Kim,D.</style></author><author><style face="normal" font="default"> Wee,K.</style></author><author><style face="normal" font="default"> Park,H.S.</style></author><author><style face="normal" font="default"> Kim,S.H.</style></author><author><style face="normal" font="default"> Sohn,K.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Software and Computer Engineering, Ajou University, Suwon, 16499, South Korea</style></auth-address><titles><title><style face="normal" font="default">Integrative information theoretic network analysis for genome-wide association study of aspirin exacerbated respiratory disease in Korean population</style></title><secondary-title><style face="normal" font="default">BMC Med Genomics</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Med Genomics</style></abbr-1></periodical><pages end="" start="31">31-</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">Suppl 1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AERD</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> association studies</style></keyword><keyword><style face="normal" font="default"> association study</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Computer</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Engineering</style></keyword><keyword><style face="normal" font="default"> epistasis</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genome-wide</style></keyword><keyword><style face="normal" font="default"> genome-wide association</style></keyword><keyword><style face="normal" font="default"> genome-wide association studies</style></keyword><keyword><style face="normal" font="default"> genome-wide association study</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> GWAS</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyposis</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drug</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Polyposis</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> Software</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword></keywords><dates><year Day="24" Month="5" Year="2017">2017/5/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: Aspirin Exacerbated Respiratory Disease (AERD) is a chronic medical condition that encompasses asthma, nasal polyposis, and hypersensitivity to aspirin and other non-steroidal anti-inflammatory drugs. Several previous studies have shown that part of the genetic effects of the disease may be induced by the interaction of multiple genetic variants. However, heavy computational cost as well as the complexity of the underlying biological mechanism has prevented a thorough investigation of epistatic interactions and thus most previous studies have typically considered only a small number of genetic variants at a time. METHODS: In this study, we propose a gene network based analysis framework to identify genetic risk factors from a genome-wide association study dataset. We first derive multiple single nucleotide polymorphisms (SNP)-based epistasis networks that consider marginal and epistatic effects by using different information theoretic measures. Each SNP epistasis network is converted into a gene-gene interaction network, and the resulting gene networks are combined as one for downstream analysis. The integrated network is validated on existing knowledgebase of DisGeNET for known gene-disease associations and GeneMANIA for biological function prediction. RESULTS: We demonstrated our proposed method on a Korean GWAS dataset, which has genotype information of 440,094 SNPs for 188 cases and 247 controls. The topological properties of the generated networks are examined for scale-freeness, and we further performed various statistical analyses in the Allergy and Asthma Portal (AAP) using the selected genes from our integrated network. CONCLUSIONS: Our result reveals that there are several gene modules in the network that are of biological significance and have evidence for controlling susceptibility and being related to the treatment of AERD</style></abstract><notes><style face="normal" font="default">DA - 20170607IS - 1755-8794 (Electronic)IS - 1755-8794 (Linking)LA - engPT - Journal ArticleCO - South Korea -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1186/s12920-017-0266-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28589859">PM:28589859</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Med Genomics\2017-10S-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Med Genomics\2017-10S-31.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170607, Wang S</style></custom2><misc3><style face="normal" font="default">10.1186/s12920-017-0266-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41827</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Torjesen,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">London</style></auth-address><titles><title><style face="normal" font="default">Sugar intake in pregnancy is linked to child's allergy and allergic asthma</style></title><secondary-title><style face="normal" font="default">BMJ</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ</style></abbr-1></periodical><pages end="" start="j3293">j3293-</pages><volume><style face="normal" font="default">358</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="6" Month="7" Year="2017">2017/7/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170707IS - 1756-1833 (Electronic)IS - 0959-535X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1136/bmj.j3293</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28684535">PM:28684535</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ\2017-358-j3293.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ\2017-358-j3293.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170707, Torjesen I</style></custom2><misc3><style face="normal" font="default">10.1136/bmj.j3293</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41828</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Talovic,M.</style></author><author><style face="normal" font="default"> Sheikh,A.</style></author><author><style face="normal" font="default"> McCleary,N.</style></author><author><style face="normal" font="default"> Erkkola,M.</style></author><author><style face="normal" font="default"> Kaila,M.</style></author><author><style face="normal" font="default"> Virtanen,S.M.</style></author><author><style face="normal" font="default"> Nwaru,B.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Asthma UK Centre for Applied Research, Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK</style></auth-address><titles><title><style face="normal" font="default">Periconception endogenous and exogenous maternal sex steroid hormones and risk of asthma and allergy in offspring: protocol for a systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default">BMJ Open</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Open</style></abbr-1></periodical><pages end="" start="e014637">e014637-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Agriculture</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bias</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidemiological studies</style></keyword><keyword><style face="normal" font="default"> ethics</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> Fetus</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Health</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hormones</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Informatics</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nursing</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword></keywords><dates><year Day="12" Month="7" Year="2017">2017/7/12</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Pregnancy is associated with several hormonal changes which influence the developing fetus. Variations in maternal endogenous hormones and prepregnancy use of hormonal preparations have been linked to asthma and allergy in the offspring, but findings are inconsistent. We plan to undertake a systematic review to synthesise the evidence on the association between endogenous and exogenous maternal sex hormones and the risk of asthma and allergy in the offspring. METHODS AND ANALYSIS: We will search Medline, Embase, Cochrane Library, Institute of Scientific Information Web of Science, Cumulative Index of Nursing and Allied Health, Scopus, Google Scholar, Allied and Complementary Medicine Database, Global Health, Psychological Information (PsycINFO), Centre for Agriculture and Bioscience (CAB) International and WHO Global Health Library from inception until 2016 to identify relevant studies on the topic. Additional studies will be identified by searching databases of proceedings of international conferences, contacting international experts in the field and searching the references cited in identified studies. We will include analytical epidemiological studies. Two researchers will independently screen identified studies, undertake data extraction and assess risk of bias in eligible studies, while a third reviewer will arbitrate any disagreement. We will use the Effective Public Health Practice Project tool to assess the risk of bias in the studies. We will perform a random-effects meta-analysis to synthesise the evidence. We will use the Grading of Recommendations Assessment, Development and Evaluation approach to rate the strength and quality of the overall evidence with respect to each outcome. ETHICS AND DISSEMINATION: Ethical approval is not required since the study is a systematic review of published literature. Our findings will be reported in a peer-reviewed scientific journal. PROSPERO REGISTRATION NUMBER: CRD42016048324</style></abstract><notes><style face="normal" font="default">DA - 20170714IS - 2044-6055 (Electronic)IS - 2044-6055 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -CO - Finland -</style></notes><work-type><style face="normal" font="default">10.1136/bmjopen-2016-014637</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28706087">PM:28706087</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Open\2017-7-e014637.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Open\2017-7-e014637.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170714, Talovic M</style></custom2><misc3><style face="normal" font="default">10.1136/bmjopen-2016-014637</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41829</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,Y.H.</style></author><author><style face="normal" font="default"> Lin,C.L.</style></author><author><style face="normal" font="default"> Bau,D.T.</style></author><author><style face="normal" font="default"> Hung,Y.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Endocrinology and Metabolism, Department of Medicine, China Medical University Hospital, Taichung, Taiwan</style></auth-address><titles><title><style face="normal" font="default">Risk of allergic conjunctivitis in patients with type 1 diabetes mellitus: a population-based retrospective cohort study</style></title><secondary-title><style face="normal" font="default">BMJ Open</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Open</style></abbr-1></periodical><pages end="" start="e015795">e015795-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AC</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Conjunctivitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> COX</style></keyword><keyword><style face="normal" font="default"> Diabetes Complications</style></keyword><keyword><style face="normal" font="default"> Diabetes Mellitus</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endocrinology</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective cohort study</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> Taiwan</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="6" Year="2017">2017/6/19</year></dates><abstract><style face="normal" font="default">OBJECTIVE: In accordance with the dichotomy between T helper type 1(Th1) and T helper type 2 (Th2) responses, the occurrence of allergic conjunctivitis (AC) and type 1 diabetes mellitus (T1DM) is, in theory, inversely related in the individual. However, recent studies investigating the association between the two diseases are controversial. DESIGN: Population-based cohort study. SETTING: We used claims data of the National Health Insurance Research Database of Taiwan. PARTICIPANTS: We identified 4160 patients aged 1-30 years with newly diagnosed T1DM and no history of AC at baseline. For each patient with T1DM, four non-T1DM controls (n=16,640) were matched by sex. The mean follow-up time was 6 years. PRIMARY AND SECONDARY OUTCOME MEASURES: Multivariate Cox proportional hazards regression analysis was used to evaluate the risk of AC. We additionally evaluated the association between risk of AC and T1DM progression by examining Diabetes Complications Severity Index (aDCSI) changes from the date of diagnosis until the end of follow-up. RESULTS: The overall incidence of allergic conjunctivitis (AC) was higher in the type 1 diabetes mellitus (T1DM) cohort than in the control cohort (23.0 vs 13.5 per 1000 person-years, adjusted incidence rate ratio (aIRR): 1.59, 95% CI 1.47 to 1.71). Relative to that in patients with mildly progressive T1DM, the risk of AC increased as the adapted Diabetes Complications Severity Index (aDCSI) increased (aIRR: 1.68, 3.78 and 18.8, with yearly changes in aDCSI score: 0.51 to 1.00, 1.01 to 2.00, and >2.00 vs &lt;0.51, respectively; for trend &lt;0.001). CONCLUSION: Patients with T1DM are at an elevated risk of developing AC; this risk increases with T1DM progression. The T helper type 1/T helper type 2 hypothesis is an overly simplistic explanation for this association</style></abstract><notes><style face="normal" font="default">DA - 20170620IS - 2044-6055 (Electronic)IS - 2044-6055 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1136/bmjopen-2016-015795</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28630085">PM:28630085</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Open\2017-7-e015795.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Open\2017-7-e015795.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170620, Chen YH</style></custom2><misc3><style face="normal" font="default">10.1136/bmjopen-2016-015795</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41830</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Alwan,W.</style></author><author><style face="normal" font="default"> Lynch,M.</style></author><author><style face="normal" font="default"> McFadden,J.</style></author><author><style face="normal" font="default"> White,I.R.</style></author><author><style face="normal" font="default"> Banerjee,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Cutaneous Allergy, St. John's Institute of Dermatology, Guy's Hospital, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Patch testing in psoriasis patients: results of a 30-year retrospective study</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> T lymphocyte</style></keyword><keyword><style face="normal" font="default"> T-lymphocyte</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="15" Month="6" Year="2017">2017/6/15</year></dates><abstract><style face="normal" font="default">Psoriasis and allergic contact dermatitis (ACD) are common, chronic T-lymphocyte mediated conditions. Although psoriasis patients are commonly referred for patch testing, there are conflicting views on the relationship between contact allergy and psoriasis. Previous studies have suggested ACD is less common in psoriasis1 and that psoriatics are more difficult to sensitize1,2,3 . This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170615IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - LetterCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15730</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28617935">PM:28617935</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20170615-AlwanW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20170615-AlwanW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170615, Alwan W</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15730</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41831</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fujii,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Shin Kobe Dental Clinic2F Sanyo Building3-9-18 Sannomiya-choChuou-kuKobe650-0021Japan</style></auth-address><titles><title><style face="normal" font="default">Severe dermatitis might be caused by a cross-reaction between nickel and palladium and dental amalgam resolved following removal of dental restorations</style></title><secondary-title><style face="normal" font="default">Clin Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Case Rep</style></abbr-1></periodical><pages end="800" start="795">795-800</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cross Reactions</style></keyword><keyword><style face="normal" font="default"> Cross-reaction</style></keyword><keyword><style face="normal" font="default"> cross-reactions</style></keyword><keyword><style face="normal" font="default"> Crossreactions</style></keyword><keyword><style face="normal" font="default"> Dental Amalgam</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Mercury</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Palladium</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">This report demonstrates a case of atopic dermatitis that was unresponsive to topical steroid therapy. This clinical report highlights the fact that metals used in dental treatment, such as mercury, as well as cross-reactions between nickel and palladium, may cause systemic hypersensitivity or toxicity</style></abstract><notes><style face="normal" font="default">DA - 20170607IS - 2050-0904 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1002/ccr3.938</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28588813">PM:28588813</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Case Rep\2017-5-795-800.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Case Rep\2017-5-795-800.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170607, Fujii Y</style></custom2><misc3><style face="normal" font="default">10.1002/ccr3.938</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41832</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sullivan,M.</style></author><author><style face="normal" font="default"> Silverberg,N.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Mt. Sinai St Luke's-Roosevelt Hospital Center, New York, NY</style></auth-address><titles><title><style face="normal" font="default">Current and emerging concepts in atopic dermatitis pathogenesis</style></title><secondary-title><style face="normal" font="default">Clin Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Dermatol</style></full-title></periodical><pages end="353" start="349">349-353</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">abnormalities</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergen exposure</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> candidate gene</style></keyword><keyword><style face="normal" font="default"> candidate genes</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Ceramides</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evolution</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Filaggrin</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Ichthyosis</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Lipid</style></keyword><keyword><style face="normal" font="default"> Lipids</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> TH17</style></keyword><keyword><style face="normal" font="default"> transepidermal water loss</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Atopic dermatitis is a common skin disorder with a complex, evolving pathogenesis. Research on the pathogenesis has shifted from focusing primarily on generalized immune system abnormalities in T helper 1/T helper 2 (Th1/Th2) activity to more targeted immune and skin barrier abnormalities contributing to the overall phenotype. Specific signaling pathways recently implicated in atopic dermatitis include production of interleukin (IL) 4 and IL-13, which promote immunoglobulin E production, Th17 and Th22 cells, and production of cytokines. Barrier defect abnormalities, such as a shared filaggrin mutation noted in ichthyosis vulgaris and atopic dermatitis, as well as reduced structural proteins and lipids (eg, ceramides), have been discovered as well. These alterations contribute to increased transepidermal water loss in addition to increased allergen exposure, resulting in debate over the "inside out" versus "outside in" theories-that is, the concept that immunity triggers barrier breakdown versus barrier abnormalities triggering immunologic alteration toward atopy. In fact, it is likely that all of these contribute to pathogenesis, with some individuals initially experiencing immunologic abnormalities more strongly than barrier defects and vice versa. Genetic analyses have continued to advance, leading to the discovery of potential candidate genes relating both to the impaired skin barrier and the altered immune system pathways. This review outlines the evolution of the field of current pathogenesis of atopic dermatitis, highlighting the most pertinent recent findings</style></abstract><notes><style face="normal" font="default">DA - 20170715IS - 1879-1131 (Electronic)IS - 0738-081X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.clindermatol.2017.03.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709564">PM:28709564</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Dermatol\2017-35-349-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Dermatol\2017-35-349-53.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170715, Sullivan M</style></custom2><misc3><style face="normal" font="default">10.1016/j.clindermatol.2017.03.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41833</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kramer,O.N.</style></author><author><style face="normal" font="default"> Strom,M.A.</style></author><author><style face="normal" font="default"> Ladizinski,B.</style></author><author><style face="normal" font="default"> Lio,P.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Illinois at Chicago College of Medicine, Chicago</style></auth-address><titles><title><style face="normal" font="default">The history of atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Clin Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Dermatol</style></full-title></periodical><pages end="348" start="344">344-348</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Back</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Illinois</style></keyword><keyword><style face="normal" font="default"> Interpretation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Fred Wise (1881-1950) and Marion Sulzberger (1895-1983) are often credited with introducing the term atopic dermatitis to dermatology in 1933. This definition was based on atopy, a term first created by Arthur Coca (1875-1959) and Robert Cooke (1880-1960) in 1923, when they recognized an association between allergic rhinitis and asthma. Despite its recent introduction into our medical lexicon, historical precursors of atopic dermatitis date back to at least as early as 69-140 ce. In this contribution, we highlight both the prominent individuals credited with shaping the disorder into our current interpretation and the suspected historical precursors of this disease and reported treatments</style></abstract><notes><style face="normal" font="default">DA - 20170715IS - 1879-1131 (Electronic)IS - 0738-081X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">0.1016/j.clindermatol.2017.03.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709563">PM:28709563</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Dermatol\2017-35-344-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Dermatol\2017-35-344-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170715, Kramer ON</style></custom2><misc3><style face="normal" font="default">0.1016/j.clindermatol.2017.03.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41834</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Silverberg,N.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Icahn School of Medicine at Mt. Sinai, Mt Sinai St Luke's-Roosevelt Hospital, New York, NY.</style></auth-address><titles><title><style face="normal" font="default">Selected active naturals for atopic dermatitis: Atopic Dermatitis Part 1</style></title><secondary-title><style face="normal" font="default">Clin Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Dermatol</style></full-title></periodical><pages end="386" start="383">383-386</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Herbal</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">The desire for naturally derived agents is a growing trend for patients, physicians, and pharmaceutical companies. Studies indicate that complementary and alternative medicine is often used by patients and parents of children with atopic dermatitis, not necessarily with beneficial results. A half-dozen natural agents (ie, topical agents: coconut oil, colloidal oatmeal, sunflower oil, mustard oil, glycerin, and oral Chinese herbal therapy) are discussed because they have become popular for their expected activity in the therapy of atopic dermatitis. A critical review of the published literature on these agents is presented with specific focus on potential such side effects as hepatotoxicity with Chinese herbals</style></abstract><notes><style face="normal" font="default">DA - 20170715IS - 1879-1131 (Electronic)IS - 0738-081X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.clindermatol.2017.03.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709569">PM:28709569</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Dermatol\2017-35-383-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Dermatol\2017-35-383-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170714, Silverberg NB</style></custom2><misc3><style face="normal" font="default">10.1016/j.clindermatol.2017.03.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41835</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Silverberg,N.B.</style></author><author><style face="normal" font="default"> Silverberg,J.I.</style></author></authors></contributors><titles><title><style face="normal" font="default">Atopic dermatitis: Part I</style></title><secondary-title><style face="normal" font="default">Clin Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Dermatol</style></full-title></periodical><pages end="343" start="341">341-343</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170715IS - 1879-1131 (Electronic)IS - 0738-081X (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.clindermatol.2017.03.003.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709562">PM:28709562</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Dermatol\2017-35-341-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Dermatol\2017-35-341-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170716, Silverberg NB</style></custom2><misc3><style face="normal" font="default">10.1016/j.clindermatol.2017.03.003.</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41836</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Silverberg,N.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Icahn School of Medicine at Mt Sinai, New York, NY.</style></auth-address><titles><title><style face="normal" font="default">Typical and atypical clinical appearance of atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Clin Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Dermatol</style></full-title></periodical><pages end="359" start="354">354-359</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Alopecia</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatosis</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Infancy</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Lip</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Atopic dermatitis is a complex, systemic inflammatory disorder associated with a variety of clinical features. The original criteria of Hanifin and Rajka include major criteria and a list of about two dozen minor criteria however, even the minor criteria do not include some features of atopic dermatitis noted less commonly but still seen with some frequency. This contribution first reviews the common clinical appearance of atopic dermatitis in infancy, childhood, and adulthood, as well as the less typical appearances, including lichenoid atopic dermatitis; juvenile plantar dermatosis; nummular-type atopic dermatitis; follicular atopic dermatitis; alopecia of atopic dermatitis; eczema coxsackium; and psoriasiform, perineal, and lip licker's dermatitis. The clinician will be able to recognize and treat rarer forms of atopic dermatitis and incorporate this into their daily practice</style></abstract><notes><style face="normal" font="default">DA - 20170715IS - 1879-1131 (Electronic)IS - 0738-081X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.clindermatol.2017.03.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709565">PM:28709565</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Dermatol\2017-35-354-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Dermatol\2017-35-354-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170715, Silverberg NB</style></custom2><misc3><style face="normal" font="default">10.1016/j.clindermatol.2017.03.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41837</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Silverberg,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departments of Dermatology, Preventive Medicine, and Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL.</style></auth-address><titles><title><style face="normal" font="default">Selected comorbidities of atopic dermatitis: Atopy, neuropsychiatric, and musculoskeletal disorders</style></title><secondary-title><style face="normal" font="default">Clin Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Dermatol</style></full-title></periodical><pages end="366" start="360">360-366</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease Management</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Hay Fever</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> mental health</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Osteoporosis</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Preventive Medicine</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Seizures</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Speech</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disease with substantial morbidity and quality of life impairment. There are a number of comorbid health problems that occur in patients with AD, aside from the cutaneous signs and symptoms. Chronic pruritus and inflammation can lead to sleep disturbances and mental health symptoms, which are not mutually exclusive. AD is associated with and may predispose to higher risk of other atopic disorders, including asthma and hay fever. Persons with AD appear to be at higher risk for multiple neuropsychiatric disorders, including depression, attention-deficit/hyperactivity disorder, speech disorders in childhood, headaches, and seizures. There is also a multifactorial association of AD with osteoporosis, injuries, and fractures. Elucidating the comorbidities of AD is important for disease management and improving overall clinical outcomes. This review summarizes recent developments in the atopic and neuropsychiatric comorbidities of AD</style></abstract><notes><style face="normal" font="default">DA - 20170715IS - 1879-1131 (Electronic)IS - 0738-081X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.clindermatol.2017.03.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709566">PM:28709566</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Dermatol\2017-35-360-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Dermatol\2017-35-360-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170715, Silverberg JI</style></custom2><misc3><style face="normal" font="default">10.1016/j.clindermatol.2017.03.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41838</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Udkoff,J.</style></author><author><style face="normal" font="default"> Waldman,A.</style></author><author><style face="normal" font="default"> Ahluwalia,J.</style></author><author><style face="normal" font="default"> Borok,J.</style></author><author><style face="normal" font="default"> Eichenfield,L.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pediatric and Adolescent Dermatology, Rady Children's Hospital, San Diego, 8010 Frost Street, Suite 602, San Diego, CA 92123; Departments of Dermatology and Pediatrics, University of California, San Diego School of Medicine, 9500 Gillman Drive, La Jolla, CA 92093</style></auth-address><titles><title><style face="normal" font="default">Current and emerging topical therapies for atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Clin Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Dermatol</style></full-title></periodical><pages end="382" start="375">375-382</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Barrier dysfunction</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Interleukin-4</style></keyword><keyword><style face="normal" font="default"> Janus kinase</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patient Care</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> topical treatment</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">The pathogenesis of atopic dermatitis (AD) involves epidermal barrier dysfunction and T helper cell type 2 (Th2) lymphocyte-driven inflammation. Cytokines, such as interleukin 4 (IL-4) and IL-13, are important in this reaction. They stimulate B cells to produce immunoglobulin E, causing atopic disease. This process has been well characterized, and new therapies for AD, such as phosphodiesterase 4 (PDE-4) inhibitors, Th2-expressed chemoattractant receptor-homologous molecule antagonists, and Janus kinase inhibitors, work by antagonizing this cellular pathway. Recently, there have been many advances in treatment strategies and novel therapies for AD. This review summarizes the clinical evidence supporting the use of current and emerging topical treatments for AD, as well as their safety and efficacy profiles. Crisaborole, a novel PDE-4 inhibitor, is of particular note because phase III clinical trials were recently completed, as summarized here. It is prudent for dermatologists to be current with updates in the field because therapies are constantly changing. In addition to the academic interest, this results in improvement of patient care and advancement of the field</style></abstract><notes><style face="normal" font="default">DA - 20170715IS - 1879-1131 (Electronic)IS - 0738-081X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.clindermatol.2017.03.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709568">PM:28709568</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Dermatol\2017-35-375-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Dermatol\2017-35-375-82.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170715, Udkoff J</style></custom2><misc3><style face="normal" font="default">10.1016/j.clindermatol.2017.03.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41839</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Renert-Yuval,Y.</style></author><author><style face="normal" font="default"> Guttman-Yassky,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, IsraelDepartment of Dermatology and the Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY.</style></auth-address><titles><title><style face="normal" font="default">Systemic therapies in atopic dermatitis: The pipeline</style></title><secondary-title><style face="normal" font="default">Clin Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Dermatol</style></full-title></periodical><pages end="397" start="387">387-397</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> subtypes</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic therapy</style></keyword><keyword><style face="normal" font="default"> Systemic treatment</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutics</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tolerability</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD), the most prevalent inflammatory skin disease, is characterized by robust T-cell activation. The disease has several subtypes, all having a common T helper type 2 (Th2)/Th22 polarization, but it also displays differential immune skewing, such as increased Th17/interleukin 23 skewing in the skin of intrinsic, Asian, and early pediatric AD patients. Current systemic treatments for moderate to severe AD are largely unsatisfactory, associated with significant adverse effects and low compliance. A large unmet need exists for better therapeutics for moderate to severe AD. The translational revolution, first transforming the psoriasis treatment paradigm, is now becoming applicable for AD, with multiple targeted drugs being investigated in trials. The new treatments often have increased tolerability and specificity and higher efficacy compared with conventional treatments. The clinical testing of these targeted drugs can also provide an opportunity to further elucidate AD pathogenesis by dissecting the contribution of specific cytokines to the disease phenotype. By reviewing developing therapeutics for AD according to their pathway-specific mechanisms, this contribution also outlines the complex molecular characteristics of AD</style></abstract><notes><style face="normal" font="default">DA - 20170715IS - 1879-1131 (Electronic)IS - 0738-081X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.clindermatol.2017.03.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709570">PM:28709570</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Dermatol\2017-35-387-97.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Dermatol\2017-35-387-97.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170715, Renert-Yuval Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.clindermatol.2017.03.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41840</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Weatherburn,C.J.</style></author><author><style face="normal" font="default"> Guthrie,B.</style></author><author><style face="normal" font="default"> Mercer,S.W.</style></author><author><style face="normal" font="default"> Morales,D.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Population Health Sciences, School of Medicine, University of Dundee, Dundee, UK</style></auth-address><titles><title><style face="normal" font="default">Comorbidities in adults with asthma: population-based cross-sectional analysis of 1.4 million adults in Scotland</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bronchiectasis</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic sinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> cross-sectional analysis</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Dyspepsia</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Electronic medical records</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> mental health</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Scotland</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Sinusitis</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="30" Month="6" Year="2017">2017/6/30</year></dates><abstract><style face="normal" font="default">BACKGROUND: Comorbidity in people with asthma can significantly increase asthma morbidity and lower adherence to asthma guidelines. OBJECTIVE: The objective of this study was to comprehensively measure the prevalence of physical and mental health comorbidities in adults with asthma using a large nationally representative population. METHODS: Cross-sectional analysis of routine primary care electronic medical records for 1,424,378 adults in the UK, examining the prevalence of 39 comorbidities in people with and without asthma, before and after adjustment for age, sex, social deprivation and smoking status using logistic regression. RESULTS: Of 39 comorbidities measured, 36 (92%) were significantly more common in adults with asthma. 62.6% of adults with asthma had >/=1 comorbidity vs. 46.2% of those without, and 16.3% had >/=4 comorbidities vs. 8.7% of those without. Comorbidities with the largest absolute increase in prevalence in adults with asthma were: COPD (13.4% vs 3.1%), depression (17.3% vs 9.1%), painful conditions (15.4% vs 8.4%), and dyspepsia (10.9% vs 5.2%). Comorbidities with the largest relative difference in adults with asthma compared to without were: COPD (adjusted odds ratio [aOR] 5.65, 95%CI 5.52-5.79), bronchiectasis (aOR 4.65, 95%CI 4.26-5.08), eczema/psoriasis (aOR 3.30, 95%CI 3.14-3.48), dyspepsia (aOR 2.20, 95%CI 2.15-2.25) and chronic sinusitis (aOR 2.12, 95%CI 1.99-2.26). Depression and anxiety were more common in adults with asthma (aOR 1.60, 95%CI 1.57-1.63, and aOR 1.53, 95%CI 1.48-1.57 respectively). CONCLUSIONS AND CLINICAL RELEVANCE: Physical and mental health comorbidity is the norm in adults with asthma. Appropriate recognition and management should form part of routine asthma care. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170630IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12971</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28665552">PM:28665552</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170630-WeatherburnCJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170630-WeatherburnCJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170630, Weatherburn CJ</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12971</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41841</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hirai,K.</style></author><author><style face="normal" font="default"> Shirai,T.</style></author><author><style face="normal" font="default"> Suzuki,M.</style></author><author><style face="normal" font="default"> Akamatsu,T.</style></author><author><style face="normal" font="default"> Suzuki,T.</style></author><author><style face="normal" font="default"> Hayashi,I.</style></author><author><style face="normal" font="default"> Yamamoto,A.</style></author><author><style face="normal" font="default"> Akita,T.</style></author><author><style face="normal" font="default"> Morita,S.</style></author><author><style face="normal" font="default"> Asada,K.</style></author><author><style face="normal" font="default"> Tsuji,D.</style></author><author><style face="normal" font="default"> Inoue,K.</style></author><author><style face="normal" font="default"> Itoh,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Pharmacology &amp; Genetics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan</style></auth-address><titles><title><style face="normal" font="default">A clustering approach to identify and characterize the asthma and chronic obstructive pulmonary disease overlap phenotype</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Cluster Analysis</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Foxp3</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH17</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> transcription factor</style></keyword><keyword><style face="normal" font="default"> Transcription Factors</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="6" Year="2017">2017/6/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma and chronic obstructive pulmonary disease (COPD) are heterogeneous diseases. The phenotypes that have clinical features of both asthma and COPD are still incompletely understood. OBJECTIVE: To clarify the best discriminators of the asthma-COPD overlap phenotype from asthma and COPD subgroups using a clustering approach. METHODS: This study assessed pathophysiological parameters, including mRNA expression levels of T helper cell-related transcription factors, namely, TBX21 (Th1), GATA3 (Th2), RORC (Th17), and FOXP3 (Treg), in peripheral blood mononuclear cells in asthma patients (n = 152) and in COPD patients (n = 50). Clusters were determined using k-means clustering. Exacerbations of asthma and COPD were recorded during the 1-year follow-up period. RESULTS: The cluster analysis revealed four biological clusters: cluster 1, predominantly patients with COPD; cluster 2, patients with an asthma-COPD overlap phenotype; cluster 3, patients with non-atopic and late-onset asthma; and cluster 4, patients with early-onset atopic asthma. Hazard ratios for exacerbation were 2.5 (95% confidence interval [CI], 1.1-5.6) in cluster 1 and 2.3 (95% CI, 1.0-5.0) in cluster 2 compared with patients in other clusters. Cluster 2 was discriminated from other clusters by total serum IgE level >/= 310 IU/mL, blood eosinophil counts >/= 280 cells/muL, a higher ratio of TBX21/GATA3, FEV1 /FVC ratio &lt; 0.67, and smoking >/= 10 pack-years with an area under the curve of 0.94 (95% CI, 0.90-0.98) in the receiver operating characteristic analysis. CONCLUSIONS &amp; CLINICAL RELEVANCE: The asthma-COPD overlap phenotype was characterized by peripheral blood eosinophilia and higher levels of IgE despite the Th2-low endotype. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170628IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12970</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28658564">PM:28658564</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170628-HiraiK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170628-HiraiK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170628, Hirai K</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12970</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41842</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Villasenor,A.</style></author><author><style face="normal" font="default"> Rosace,D.</style></author><author><style face="normal" font="default"> Obeso,D.</style></author><author><style face="normal" font="default"> Perez-Gordo,M.</style></author><author><style face="normal" font="default"> Chivato,T.</style></author><author><style face="normal" font="default"> Barbas,C.</style></author><author><style face="normal" font="default"> Barber,D.</style></author><author><style face="normal" font="default"> Escribese,M.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Medicine, IMMA, Institute of Applied Molecular Medicine, CEU San Pablo University, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Answer to: "Biomarkers in allergic asthma: Which matrix should we use?"</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="22" Month="6" Year="2017">2017/6/22</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170622IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12968</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28639292">PM:28639292</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170622-VillasenorA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170622-VillasenorA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170622, Villasenor A</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12968</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41843</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ahlroth Pind,C.</style></author><author><style face="normal" font="default"> Gunnbjornsdottir,M.</style></author><author><style face="normal" font="default"> Bjerg,A.</style></author><author><style face="normal" font="default"> Jarvholm,B.</style></author><author><style face="normal" font="default"> Lundback,B.</style></author><author><style face="normal" font="default"> Malinovschi,A.</style></author><author><style face="normal" font="default"> Middelveld,R.</style></author><author><style face="normal" font="default"> Sommar,J.N.</style></author><author><style face="normal" font="default"> Norback,D.</style></author><author><style face="normal" font="default"> Janson,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Sciences, Respiratory, Allergy and Sleep Research, Uppsala University, Uppsala, Sweden</style></auth-address><titles><title><style face="normal" font="default">Patient-reported signs of dampness at home may be a risk factor for chronic rhinosinusitis: A cross-sectional study</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bronchitis</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> dampness</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Iceland</style></keyword><keyword><style face="normal" font="default"> indoor</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Moulds</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Socioeconomic Factors</style></keyword><keyword><style face="normal" font="default"> standards</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: An association between dampness at home and respiratory conditions has been convincingly demonstrated in children. Fewer studies have been performed in adults and data are lacking for chronic rhinosinusitis (CRS). With a prevalence of 10.9% in Europe, CRS imposes a significant burden on quality of life, as well as economy. OBJECTIVE: Our aim was to study CRS and other respiratory conditions in relation to dampness at home in a representative sample of adults. METHODS: The Swedish GA2 LEN questionnaire was answered by 26,577 adults (16-75 y) and included questions on respiratory symptoms, smoking, education and environmental exposure. CRS was defined according to the EP3 OS criteria. Dampness was defined as reporting water damage, floor dampness or visible moulds in the home during the last 12 months. The dampness score was ranked from 0-3, counting the number of signs of dampness reported. RESULTS: Dampness at home was reported by 11.3% and was independently related to respiratory conditions after adjustment for demographic and socio-economic factors and smoking: CRS odds ratio (OR) 1.71; allergic rhinitis OR 1.24; current asthma OR 1.21; wheeze OR 1.37; nocturnal dyspnea OR 1.80; nocturnal coughing OR 1.34 and chronic bronchitis OR 1.64. The risk of CRS and most of the other respiratory conditions was further elevated in subjects reporting multiple signs of dampness. CONCLUSIONS &amp; CLINICAL RELEVANCE: This study demonstrated an independent association between dampness at home and CRS in adults. The high burden of this and the other respiratory conditions studied is a strong argument in favour of countering indoor dampness by improving building standards. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Iceland -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12976</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28695715">PM:28695715</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170711-AhlrothPindC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170711-AhlrothPindC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170711, Ahlroth Pind C</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12976</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41844</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ellis,A.K.</style></author><author><style face="normal" font="default"> Tsitoura,D.C.</style></author><author><style face="normal" font="default"> Quint,D.</style></author><author><style face="normal" font="default"> Powley,W.</style></author><author><style face="normal" font="default"> Lee,L.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Queen's University, Kingston, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="default">Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: a randomized trial</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse events</style></keyword><keyword><style face="normal" font="default"> aeroallergens</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> allergen challenge</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Headache</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Interferon</style></keyword><keyword><style face="normal" font="default"> Interferons</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal challenge</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Ontario</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> Pollen</style></keyword><keyword><style face="normal" font="default"> Probability</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized trial</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Seasons</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> TLR7</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trends</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="5" Month="7" Year="2017">2017/7/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Toll-like receptor 7 (TLR7) stimulation in the airways may reduce responses to aeroallergens by induction of type 1 interferons (IFNs). GSK2245035 is a novel selective TLR7 agonist in pharmaceutical development. OBJECTIVE: Assessment of safety, pharmacodynamics and nasal allergic reactivity following repeated weekly intranasal (i.n.) GSK2245035. METHODS: This randomized, double-blind, placebo-controlled study (TL7116958) was conducted over two pollen seasons (2013-2014) and follow-up study (204509) conducted one year later. Participants with allergic rhinitis (n=42) were randomized to receive eight weekly doses of i.n. GSK2245035 (20 ng [2014 Cohort; n=14] or 80 ng [2013 Cohort; n=14]) or placebo (n=14). Adverse events (AEs), including cytokine release syndrome-AEs (CytoRS-AEs) and nasal symptoms were assessed. Nasal and serum IFN-inducible protein 10 (IP-10) were measured after doses 1 and 8, then 1 (follow-up visit [FUV] 1) and 3 (FUV2) weeks after final dose. Nasal allergen challenges (NAC) and allergic biomarkers assessment (nasal, serum) were conducted at baseline, FUV1, FUV2 and at a follow-up visit 1-year post final dose (FUV3; 2014 Cohort only). A Bayesian framework enabled probability statements for mean effect sizes. RESULTS: GSK2245035 induced CytoRS-AEs (most commonly headache, median duration &lt;1 day) in 93% of participants at 80 ng, while AE incidence at 20 ng was similar to placebo. There was no evidence of nasal inflammation. Dose-related increases in nasal and serum IP-10 were observed 24h after doses 1 and 8 (>95% certainty). Both doses showed a trend in reducing Total Nasal Symptom Score 15 minutes post NAC at FUV1 and FUV2 but there was no reduction evident at FUV3. Nasal levels of selected allergic biomarkers demonstrated trends for reductions at FUV1, FUV2 and FUV3. CONCLUSIONS AND CLINICAL RELEVANCE: Weekly i.n. GSK2245035 20 ng was well-tolerated and reduced allergic reactivity to nasal challenge for 3 weeks post treatment. CLINICALTRIALS. GOV IDENTIFIERS: NCT01788813/NCT02446613 GSK IDENTIFIERS: TL7116958/204509 This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170706IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12974</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28681506">PM:28681506</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170706-EllisAK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170706-EllisAK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170706, Ellis AK</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12974</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41845</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jabbal,S.</style></author><author><style face="normal" font="default"> Manoharan,A.</style></author><author><style face="normal" font="default"> Lipworth,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, University of Dundee, Scotland, UK, DD1 9SY</style></auth-address><titles><title><style face="normal" font="default">Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> cumulative dose</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Down-Regulation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> Mannitol</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> REACH</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Recovery</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Scotland</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="30" Month="6" Year="2017">2017/6/30</year></dates><abstract><style face="normal" font="default">BACKGROUND: Tiotropium is a long acting antimuscarinic (LAMA), licenced as triple therapy with inhaled corticosteroid and long acting beta-agonist (ICS/LABA). There may be a synergistic benefit between LAMA and LABA as a consequence of receptor cross-talk, which in turn could modify beta-2 receptor down-regulation and associated tolerance induced by LABA. OBJECTIVE: We hypothesise this mechanism may result in a reduction of airway hyperresponsiveness (AHR) when using triple therapy. METHODS: We evaluated 14 non-smoking asthmatics using an open-label, randomized crossover design. ICS with Indacaterol and Tiotropium (IND/TIO) vs ICS with Indacaterol (IND) over 4 weeks with challenge performed after 1st and last doses at trough. RESULTS: We found no significant difference in mannitol sensitivity, expressed as the provocative dose of mannitol required to reach a 15% drop in FEV1 , or mannitol reactivity, expressed as the response dose ratio (RDR: max % fall in FEV1 / cumulative dose), when comparing ICS/IND/TIO to ICS/IND. Geometric mean fold differences for RDR comparing single and chronic dosing were 3.26 fold (95%CI 1.46-7.29) and 2.51 fold (95%CI 1.32-4.79) for IND and IND/TIO respectively. Furthermore, salbutamol recovery post challenge was significantly blunted after chronic compared to single dosing with either IND (P&lt;0.005) or IND/TIO (P&lt;0.05). CONCLUSION &amp; CLINICAL RELEVANCE: Our data suggests that concomitant tiotropium does not modify the bronchoprotective tolerance induced by Indacaterol, in turn suggesting that cross-talk may not be clinically relevant when using triple therapy. This study was registered on clinicaltrials. gov as NCT02039011. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170630IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12972</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28665534">PM:28665534</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170630-JabbalS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170630-JabbalS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170630, Jabbal S</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12972</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41846</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pinto,L.A.</style></author><author><style face="normal" font="default"> Guerra,S.</style></author><author><style face="normal" font="default"> Anto,J.M.</style></author><author><style face="normal" font="default"> Postma,D.</style></author><author><style face="normal" font="default"> Koppelman,G.H.</style></author><author><style face="normal" font="default"> de Jongste,J.C.</style></author><author><style face="normal" font="default"> Gehring,U.</style></author><author><style face="normal" font="default"> Smit,H.A.</style></author><author><style face="normal" font="default"> Wijga,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">ISGlobal, Centre for Research and Enviromental Epidemiology (CREAL), Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default">Increased risk of asthma in overweight children born large for gestational age</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Anthropometry</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Gestational Age</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> overweight</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Being born large for gestational age (LGA) is a marker of increased growth velocity in fetal life and a risk factor for childhood overweight. Both being born LGA and childhood overweight may influence the development of asthma, although the role of overweight in the association between LGA and childhood asthma is unclear. Importantly, recent studies have suggested that the association between overweight and asthma may be related to non-allergic pathways. If this also applies to the association between LGA and asthma, the association between being born LGA and asthma may be different for atopic and non-atopic children. OBJECTIVE: We investigated the association of being LGA with the prevalence of asthma at age 8 in atopic and non-atopic children and the role of overweight in this association. METHODS: Complete data on asthma, anthropometry and atopy at age 8 years, and potential confounders were available for 1,608 participants of the PIAMA birth cohort. Odds ratios for the association between LGA and asthma in atopic and non-atopic children were estimated by logistic regression analysis adjusting for potential confounders. Overweight was assessed as a potential modifier of the association between LGA and asthma. RESULTS: Being born LGA was not significantly associated with asthma at age 8 in atopic and non-atopic children. However, overweight at age 8 years modified the association between asthma at age 8 and LGA. In non-atopic children, children who were born LGA and were overweight at age 8 years had a significantly increased odds of asthma compared to non-LGA, non-overweight children (adj OR 7.04; 95% CI 2.2-24). CONCLUSIONS: We observed that non-atopic children born LGA, who were overweight by 8 years have an increased risk of asthma. If confirmed, these findings suggest that non-atopic children born LGA may be identified early in life as a high-risk group for asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170609IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Brazil -CO - United States -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12961</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28599075">PM:28599075</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170609-PintoLA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170609-PintoLA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170609, Pinto LA</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12961</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41847</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gonsalves,N.</style></author><author><style face="normal" font="default"> Berdnikovs,S.</style></author><author><style face="normal" font="default"> Schroeder,H.</style></author><author><style face="normal" font="default"> Zalewski,A.</style></author><author><style face="normal" font="default"> Bryce,P.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Gastroenterology and Hepatology, Northwestern University</style></auth-address><titles><title><style face="normal" font="default">Gender-specific differences in the molecular signatures of adult Eosinophilic Eosophagitis</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="971" start="969">969-971</pages><volume><style face="normal" font="default">47</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Esophagus</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Gastroenterology</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Quantification</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="5" Month="6" Year="2017">2017/6/5</year></dates><abstract><style face="normal" font="default">The influence of gender on the prevalence, presentation and pathogenesis of allergic diseases is being increasingly recognized [1]. Eosinophilic Eosophagitis (EoE) is a chronic inflammatory disorder of the esophagus, seen in both children and adults, and is 3-4 times more common in males than females [2]. Diagnosis of EoE has relied on quantification of eosophageal eosinophils by biopsy and patient-reported symptoms but recent studies have supported the use of tissue-based molecular biomarker assessment, based on gene expression signatures [3], aiding patient diagnosis [4]. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170605IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12960</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28580626">PM:28580626</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\2017-47-969-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\2017-47-969-71.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170605, Gonsalves N</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12960</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41848</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">van der Lee,M.</style></author><author><style face="normal" font="default"> Arabkhazaeli,A.</style></author><author><style face="normal" font="default"> van Erp,F.C.</style></author><author><style face="normal" font="default"> Raaijmakers,J.A.</style></author><author><style face="normal" font="default"> Van der Ent,C.K.</style></author><author><style face="normal" font="default"> Bruijnzeel-Koomen,C.A.F.M.</style></author><author><style face="normal" font="default"> de Bruin-Weller,M.S.</style></author><author><style face="normal" font="default"> Vijverberg,S.J.H.</style></author><author><style face="normal" font="default"> Maitland-van der Zee,A.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht University, Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Atopic dermatitis characteristics and medication-use patterns in school-age children with AD and asthma symptoms</style></title><secondary-title><style face="normal" font="default">Clin Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Dermatol</style></full-title></periodical><pages end="508" start="503">503-508</pages><volume><style face="normal" font="default">42</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Caregivers</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Life quality</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> QOL</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis (AD) and asthma often coexist. Both diseases can have a major impact on the lives of children with AD and their caregivers. AIM: To investigate the association of patient characteristics, comorbidities and impact of AD on children who have both asthma and AD. METHODS: Children with AD (n = 140) were selected from a larger cohort of children with a reported use of asthma medication. The Children's Dermatology Life Quality Index (CDLQI) was used to assess Quality of Life (QoL), and the Self-Assessed Eczema Area and Severity Index (SA-EASI) was used to measure AD severity. Characteristics assessed included: age, sex, and the number and type of atopic comorbidities. Medication use for AD was defined using the total number of AD prescriptions, the number of different topical AD prescriptions and the highest potency topical corticosteroid (TCS) used. Determinants of AD severity and QoL were evaluated using Spearman rank tests. RESULTS: The following factors were most strongly associated with a lower QoL: characteristics of AD lesions (Spearman Rs = 0.61-0.69, P &lt; 0.01), a higher SA-EASI score (Rs = 0.54, P &lt; 0.01) and a larger number of different topical AD prescriptions (Rs = 0.38, P &lt; 0.01). The following factors were correlated with more severe AD: age (Rs = -0.36, P &lt; 0.01), larger number of different TCS preparations used (Rs = 0.27, P &lt; 0.05) and larger number of TCS prescriptions (Rs = 0.25, P &lt; 0.05). CONCLUSION: In children with asthma and AD, the number of TCS preparations used is associated with lower QoL and increased AD severity</style></abstract><notes><style face="normal" font="default">DA - 20170606IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/ced.13111</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28585727">PM:28585727</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Dermatol\2017-42-503-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Dermatol\2017-42-503-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170606, van der Lee M</style></custom2><misc3><style face="normal" font="default">10.1111/ced.13111</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41849</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wu,J.</style></author><author><style face="normal" font="default"> Zhang,L.M.</style></author><author><style face="normal" font="default"> Xiao,T.</style></author><author><style face="normal" font="default"> Chen,H.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, No.1 Hospital of China Medical University, Shenyang, China</style></auth-address><titles><title><style face="normal" font="default">Refractory chronic spontaneous urticaria associated with CD4 lymphocytopenia in a patient with thymoma</style></title><secondary-title><style face="normal" font="default">Clin Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">CD4</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Thymoma</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="22" Month="6" Year="2017">2017/6/22</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170622IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1111/ced.13170</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28639715">PM:28639715</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Dermatol\20170622-WuJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Dermatol\20170622-WuJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170622, Wu J</style></custom2><misc3><style face="normal" font="default">10.1111/ced.13170</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41850</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guevara,B.E.K.</style></author><author><style face="normal" font="default"> Guillano,V.P.</style></author><author><style face="normal" font="default"> Dayrit,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Southern Philippines Medical Center, Davao City, Philippines</style></auth-address><titles><title><style face="normal" font="default">Urticaria pigmentosa with concomitant polycythaemia vera in a 3-year-old boy</style></title><secondary-title><style face="normal" font="default">Clin Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cities</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Philippines</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> Urticaria Pigmentosa</style></keyword></keywords><dates><year Day="14" Month="6" Year="2017">2017/6/14</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170614IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - Journal ArticleCO - Philippines -</style></notes><work-type><style face="normal" font="default">10.1111/ced.13196</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28614617">PM:28614617</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Dermatol\20170614-GuevaraBE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Dermatol\20170614-GuevaraBE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170614, Guevara BE</style></custom2><misc3><style face="normal" font="default">10.1111/ced.13196</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41851</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pagliarello,C.</style></author><author><style face="normal" font="default"> Scrivani,S.</style></author><author><style face="normal" font="default"> Fabrizi,G.</style></author><author><style face="normal" font="default"> Feliciani,C.</style></author><author><style face="normal" font="default"> Di Nuzzo,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Section of Dermatology, Department of Medicine and Surgery, University of Parma, Parma, Italy</style></auth-address><titles><title><style face="normal" font="default">An under-recognized, life-threatening complication of atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Clin Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170609IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/ced.13171</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28597997">PM:28597997</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Dermatol\20170609-PagliarelloC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Dermatol\20170609-PagliarelloC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170609, Pagliarello C</style></custom2><misc3><style face="normal" font="default">10.1111/ced.13171</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41852</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mansoor,E.</style></author><author><style face="normal" font="default"> Saleh,M.A.</style></author><author><style face="normal" font="default"> Cooper,G.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, 11100 Euclid Avenue Cleveland, Ohio 44106.</style></auth-address><titles><title><style face="normal" font="default">Prevalence of Eosinophilic Gastroenteritis and Colitis in a Population-Based Study, From 2012 to 2017</style></title><secondary-title><style face="normal" font="default">Clin Gastroenterol Hepatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Gastroenterol Hepatol</style></abbr-1></periodical><pages end="1741" start="1733">1733-1741</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> African American</style></keyword><keyword><style face="normal" font="default"> African Americans</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Colitis</style></keyword><keyword><style face="normal" font="default"> Commercial</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Esophagitis</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Gastroenteritis</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Records</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Ohio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="8" Month="6" Year="2017">2017/6/8</year></dates><abstract><style face="normal" font="default">BACKGROUND &amp; AIMS: Although eosinophilic esophagitis (EoE) has been extensively studied, there have been few epidemiology studies of other eosinophilic gastrointestinal disorders (EGIDs). Using a large, population-based database, we investigated epidemiologic features of eosinophilic gastroenteritis (EoGE), and colitis (EoC) in the United States (US). METHODS: We collected data from a commercial database (Explorys Inc, Cleveland, OH) that provided electronic health records from 26 major integrated US healthcare systems from 1999 to March 2017. We identified a cohort of adult and pediatric patients with EoGE and EoC from March 2012 through March 2017, based on the Systematized Nomenclature of Medicine - Clinical Terms. We calculated the overall prevalence of EoGE and EoC among different patient groups, and performed age and gender adjusted analyses to assess for differences in the prevalence of associated medical conditions in patients with EoGE and EoC and controls (patients in the database between March 2012 and March 2017 without EGID associated diagnoses). RESULTS: Of the 35,826,830 individuals in the database, we identified 1820 patients with EoGE and 770 with EoC. The overall prevalence rate of EoGE was 5.1/100,000 persons; the overall prevalence rate of EoC was 2.1/100,000 persons. Each of the non-EoE EGIDs were more prevalent in Caucasians than African-Americans and Asians, and in female patients than male patients. Although EoGE was more prevalent in children (under 18 years) than adults, EoC was more prevalent in adults (older than 18 years). Compared with controls, individuals with non-EoE EGIDs were more likely to have been diagnosed with other gastrointestinal or allergic disorders. CONCLUSIONS: In a population-based study in the US, using the Explorys database, we found the overall prevalence rate of EoGE to be 5.1/100,000 persons and the prevalence rate of EoC to be 2.1/100,000; these values are at the lower end of prevalence rates previously reported in the US</style></abstract><notes><style face="normal" font="default">DA - 20170612IS - 1542-7714 (Electronic)IS - 1542-3565 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.cgh.2017.05.050</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28603057">PM:28603057</url></web-urls></urls><custom2><style face="normal" font="default">20170612, Mansoor E</style></custom2><misc3><style face="normal" font="default">10.1016/j.cgh.2017.05.050</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41853</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Imbalzano,E.</style></author><author><style face="normal" font="default"> Quartuccio,S.</style></author><author><style face="normal" font="default"> Di Salvo,E.</style></author><author><style face="normal" font="default"> Crea,T.</style></author><author><style face="normal" font="default"> Casciaro,M.</style></author><author><style face="normal" font="default"> Gangemi,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy</style></auth-address><titles><title><style face="normal" font="default">Association between HMGB1 and asthma: a literature review</style></title><secondary-title><style face="normal" font="default">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Mol Allergy</style></full-title></periodical><pages end="" start="12">12-</pages><volume><style face="normal" font="default">15</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">airflow</style></keyword><keyword><style face="normal" font="default"> airflow obstruction</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Airway hyper-responsiveness</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Employment</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Recently, some studies demonstrated that HMGB1, as proinflammatory mediator belonging to the alarmin family, has a key role in different acute and chronic immune disorders. Asthma is a complex disease characterised by recurrent and reversible airflow obstruction associated to airway hyper-responsiveness and airway inflammation. OBJECTIVE: This literature review aims to analyse advances on HMGB1 role, employment and potential diagnostic application in asthma. METHODS: We reviewed experimental studies that investigated the pathogenetic role of HMGB in bronchial airway hyper-responsiveness, inflammation and the correlation between HMGB1 level and asthma. RESULTS: A total of 19 studies assessing the association between HMGB1 and asthma were identified. CONCLUSIONS: What emerged from this literature review was the confirmation of HMGB-1 involvement in diseases characterised by chronic inflammation, especially in pulmonary pathologies. Findings reported suggest a potential role of the alarmin in being a stadiation method and a marker of therapeutic efficacy; finally, inhibiting HMGB1 in humans in order to contrast inflammation should be the aim for future further studies</style></abstract><notes><style face="normal" font="default">DA - 20170620IS - 1476-7961 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1186/s12948-017-0068-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28630596">PM:28630596</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-12.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170620, Imbalzano E</style></custom2><misc3><style face="normal" font="default">10.1186/s12948-017-0068-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41854</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McLaurin,E.</style></author><author><style face="normal" font="default"> Bergmann,M.</style></author><author><style face="normal" font="default"> Narvekar,A.</style></author><author><style face="normal" font="default"> Adewale,A.</style></author><author><style face="normal" font="default"> Gomes,P.</style></author><author><style face="normal" font="default"> Torkildsen,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, Total Eye Care, PA, Memphis, TN</style></auth-address><titles><title><style face="normal" font="default">Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis</style></title><secondary-title><style face="normal" font="default">Clin Ophthalmol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Ophthalmol</style></abbr-1></periodical><pages end="1097" start="1089">1089-1097</pages><volume><style face="normal" font="default">11</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> allergen challenge</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Conjunctivitis</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Itch</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Ocular</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Ophthalmology</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">PURPOSE: Two individual phase 3 conjunctival allergen challenge (CAC) studies of similar design have assessed the efficacy and safety of olopatadine hydrochloride (HCl) 0.77% for the treatment of allergic conjunctivitis. The purpose of this study is to evaluate the integrated efficacy and safety of olopatadine HCl 0.77% from a larger dataset by pooling data from the two individual CAC studies. METHODS: Data were pooled from two phase 3, randomized, multicenter, double-masked, active- and vehicle-controlled CAC studies. The primary comparison was on ocular itching scores between olopatadine HCl 0.77% versus vehicle (at onset and 24 hours) and olopatadine HCl 0.77% versus olopatadine 0.2% (at 24 hours). Additional end points included conjunctival redness, total redness, and proportion of itching responders at onset and 24-hour duration of CAC. For both primary and secondary analysis, mixed model repeated measures analysis was used, except for proportion of ocular itching responders. Sensitivity analyses were carried out using a two-sample t-test. RESULTS: This analysis included 448 patients. Olopatadine HCl 0.77% was superior to vehicle (P&lt;0.0001) at onset and 24-hour duration of action (difference in means: -1.14 to -1.52) and to olopatadine 0.2% (P=0.0009) at 24-hour duration of action in relieving ocular itch. Additionally, olopatadine HCl 0.77% substantially reduced conjunctival redness and total redness over vehicle and olopatadine 0.2% at onset and 24-hour duration of action. At 24 hours CAC, there were a higher proportion of itching responders with olopatadine HCl 0.77% compared to vehicle or olopatadine 0.2% (difference in proportion of responders: 43.17%, P&lt;0.0001, and 17.25%, P=0.0012, respectively). No safety concerns were identified. CONCLUSION: This analysis confirms the findings from the individual studies. The rapid onset and prolonged duration of action (for 24 hours) of olopatadine HCl 0.77% supports once-daily dosing in the treatment of allergic conjunctivitis</style></abstract><notes><style face="normal" font="default">DA - 20170627IS - 1177-5467 (Print)IS - 1177-5467 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2147/OPTH.S131830</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28652694">PM:28652694</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Ophthalmol\2017-11-1089-97.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Ophthalmol\2017-11-1089-97.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170627, McLaurin E</style></custom2><misc3><style face="normal" font="default">10.2147/OPTH.S131830</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41855</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Louis,B.</style></author><author><style face="normal" font="default"> Bequignon,E.</style></author><author><style face="normal" font="default"> Devars du Mayne,M.</style></author><author><style face="normal" font="default"> Zerah-Lancner,F.</style></author><author><style face="normal" font="default"> Larger,C.</style></author><author><style face="normal" font="default"> Isabey,D.</style></author><author><style face="normal" font="default"> Coste,A.</style></author><author><style face="normal" font="default"> Papon,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">INSERM, U955, E13, Creteil, 94010, France</style></auth-address><titles><title><style face="normal" font="default">Nasal Compliance Measurement for Diagnosis of Idiopathic Non-Allergic Rhinitis: a Prospective Case-Controlled Study of 63 Patients</style></title><secondary-title><style face="normal" font="default">Clin Otolaryngol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Otolaryngol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">acoustic rhinometry</style></keyword><keyword><style face="normal" font="default"> allergen-specific</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic rhinitis</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal Mucosa</style></keyword><keyword><style face="normal" font="default"> Nonallergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword></keywords><dates><year Day="13" Month="7" Year="2017">2017/7/13</year></dates><abstract><style face="normal" font="default">* Idiopathic non allergic rhinitis (i-NAR) is a frequent cause of non-allergic rhinitis and associates nonspecific symptoms. There is no simple direct procedure to establish i-NAR diagnosis. * Diagnosis of i-NAR is currently based on an absence of a definite causal factor and a lack of evidence for IgE-mediated allergy by skin prick tests and allergen-specific serum IgE * Measurement of nasal compliance with acoustic rhinometry evaluates the vasomotricity-related deformability of the nasal mucosa. It has been already suggested that nasal compliance could be abnormal in i-NAR. * In this prospective case-controlled study of 42 patients with chronic rhinitis and 21 control patients, after topical decongestion, compliances in i-NAR group were significantly increased compared to allergic rhinitis (AR) and Control group (n=21) (p&lt;0.01). * Measurement of nasal compliance after topical decongestion allows to objectively and non-invasively discriminating i-NAR from AR. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170713IS - 1749-4486 (Electronic)IS - 1749-4478 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/coa.12935</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28703884">PM:28703884</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Otolaryngol\20170713-LouisB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Otolaryngol\20170713-LouisB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170713, Louis B</style></custom2><misc3><style face="normal" font="default">10.1111/coa.12935</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41856</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arnold,D.H.</style></author><author><style face="normal" font="default"> Bowman,N.</style></author><author><style face="normal" font="default"> Reiss,T.F.</style></author><author><style face="normal" font="default"> Hartert,T.V.</style></author><author><style face="normal" font="default"> Seger,D.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Departments of Pediatrics and Emergency Medicine , Vanderbilt University School of Medicine , Nashville , TN , USA</style></auth-address><titles><title><style face="normal" font="default">Adverse events are rare after single-dose montelukast exposures in children</style></title><secondary-title><style face="normal" font="default">Clin Toxicol (Phila)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Toxicol (Phila)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Abdominal Pain</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic asthma</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Emergency Medicine</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="default"> Logistic Models</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> montelukast</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> single dose</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> Statistics</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="22" Month="6" Year="2017">2017/6/22</year></dates><abstract><style face="normal" font="default">STUDY OBJECTIVE: Montelukast sodium is a leukotriene-receptor antagonist approved as a controller medication for chronic asthma and allergic rhinitis in children and adults. We sought to characterize adverse events associated with single montelukast exposures in children ages 5-17 years and to determine whether adverse events were dose related for all-dose and for ultra-high-dose (>/=50 mg) exposures. METHODS: This is a retrospective analysis of data from the National Poison Data System for exposures that included montelukast in individuals aged 5-17 years for calendar years 2000-2016. Filters were applied to identify exposure events in which montelukast was the primary exposure and for which the exact or lowest-possible ingested dose was recorded. Characteristics of adverse events were examined using descriptive statistics and multivariable logistic models were used to examine whether associations of montelukast and adverse events were dose related. RESULTS: During the 17-year study period, there were 17,069 montelukast exposures available for analyses. Patients were median [interquartile range] age 7 (5, 9) years, and 10,907 (64%) male gender. Abdominal pain was the most common adverse event (0.23%). There were 618 ultra-high-dose exposures (>/=50 mg). These patients had median age 6 (5, 8) years, and 347 (56%) male gender. Abdominal pain was the most common adverse event (1.46%). Increasing ingested dose was associated with abdominal pain (adjusted odds ratio, 1.01, 95% confidence interval 1.01, 1.02) after adjustment for age and gender. No serious or life-threatening events were reported. CONCLUSIONS: Single-dose exposures of montelukast up to 445 mg are rarely associated with any adverse events and are not associated with serious or life-threatening adverse events in children aged 5-17 years</style></abstract><notes><style face="normal" font="default">DA - 20170622IS - 1556-9519 (Electronic)IS - 1556-3650 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/15563650.2017.1337123</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28639856">PM:28639856</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Toxicol (Phila)\20170622-ArnoldDH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Toxicol (Phila)\20170622-ArnoldDH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170622, Arnold DH</style></custom2><misc3><style face="normal" font="default">10.1080/15563650.2017.1337123</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41857</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cingi,C.</style></author><author><style face="normal" font="default"> Gevaert,P.</style></author><author><style face="normal" font="default"> Mosges,R.</style></author><author><style face="normal" font="default"> Rondon,C.</style></author><author><style face="normal" font="default"> Hox,V.</style></author><author><style face="normal" font="default"> Rudenko,M.</style></author><author><style face="normal" font="default"> Muluk,N.B.</style></author><author><style face="normal" font="default"> Scadding,G.</style></author><author><style face="normal" font="default"> Manole,F.</style></author><author><style face="normal" font="default"> Hupin,C.</style></author><author><style face="normal" font="default"> Fokkens,W.J.</style></author><author><style face="normal" font="default"> Akdis,C.</style></author><author><style face="normal" font="default"> Bachert,C.</style></author><author><style face="normal" font="default"> Demoly,P.</style></author><author><style face="normal" font="default"> Mullol,J.</style></author><author><style face="normal" font="default"> Muraro,A.</style></author><author><style face="normal" font="default"> Papadopoulos,N.</style></author><author><style face="normal" font="default"> Pawankar,R.</style></author><author><style face="normal" font="default"> Rombaux,P.</style></author><author><style face="normal" font="default"> Toskala,E.</style></author><author><style face="normal" font="default"> Kalogjera,L.</style></author><author><style face="normal" font="default"> Prokopakis,E.</style></author><author><style face="normal" font="default"> Hellings,P.W.</style></author><author><style face="normal" font="default"> Bousquet,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology, Eskisehir Osmangazi University School of Medicine, Eskisehir, Turkey</style></auth-address><titles><title><style face="normal" font="default">Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report</style></title><secondary-title><style face="normal" font="default">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Transl Allergy</style></full-title></periodical><pages end="" start="17">17-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> Apnea</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Conjunctivitis</style></keyword><keyword><style face="normal" font="default"> Consensus</style></keyword><keyword><style face="normal" font="default"> Croatia</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> Hypertrophy</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Obstructive sleep apnea</style></keyword><keyword><style face="normal" font="default"> Olfaction Disorders</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patient Care</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Romania</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Sleep apnea</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">This report has been prepared by the European Academy of Allergy and Clinical Immunology Task Force on Allergic Rhinitis (AR) comorbidities. The aim of this multidisciplinary European consensus document is to highlight the role of multimorbidities in the definition, classification, mechanisms, recommendations for diagnosis and treatment of AR, and to define the needs in this neglected area by a literature review. AR is a systemic allergic disease and is generally associated with numerous multi-morbid disorders, including asthma, eczema, food allergies, eosinophilic oesophagitis (EoE), conjunctivitis, chronic middle ear effusions, rhinosinusitis, adenoid hypertrophy, olfaction disorders, obstructive sleep apnea, disordered sleep and consequent behavioural and educational effects. This report provides up-to-date usable information to: (1) improve the knowledge and skills of allergists, so as to ultimately improve the overall quality of patient care; (2) to increase interest in this area; and (3) to present a unique contribution to the field of upper inflammatory disease</style></abstract><notes><style face="normal" font="default">DA - 20170602IS - 2045-7022 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Turkey -CO - Belgium -CO - Germany -CO - Spain -CO - United Kingdom -CO - Romania -CO - Netherlands -CO - Switzerland -CO - France -CO - Italy -CO - Greece -CO - Japan -CO - United States -CO - Croatia -</style></notes><work-type><style face="normal" font="default">10.1186/s13601-017-0153-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28572918">PM:28572918</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-17.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-17.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170602, Cingi C</style></custom2><misc3><style face="normal" font="default">10.1186/s13601-017-0153-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41858</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Su,T.</style></author><author><style face="normal" font="default"> Broekhuizen,B.D.L.</style></author><author><style face="normal" font="default"> Verheij,T.J.M.</style></author><author><style face="normal" font="default"> Rockmann,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">The impact of penicillin allergy labels on antibiotic and health care use in primary care: a retrospective cohort study</style></title><secondary-title><style face="normal" font="default">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Transl Allergy</style></full-title></periodical><pages end="" start="18">18-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> and primary</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> General practitioner</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> health care use</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> Primary Health Care</style></keyword><keyword><style face="normal" font="default"> Quinolones</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective cohort study</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Suspected penicillin allergy (Pen-A) is often not verified by diagnostic testing. In third line penicillin allergy labels were associated with prescription of broad spectrum antibiotics, hospital stay duration and readmission. OBJECTIVE: Assess the impact of Pen-A labels on antibiotic and health care use in primary care. METHODS: A retrospective cohort study was conducted in primary care in the Utrecht area, the Netherlands. All patients registered with a penicillin allergy on 31 December 2013 were selected from the General Practitioner Network database. Each patient with a Pen-A label was matched for age, gender, follow-up period with three patients without Pen-A label. Risk (OR) of receiving a reserve and second choice antibiotic, number and type of antibiotics prescribed during follow-up and number of GP contacts were compared between the two cohorts. RESULTS: Of 196,440 patients, 1254 patients (0.6%) with a Pen-A label were identified and matched with 3756 patients without Pen-A label. Pen-A labels resulted in higher risk of receiving >/=1 antibiotic prescription per year (OR 2.56, 95% CI 2.05-3.20), >/=1 s choice antibiotic prescription per year (OR 2.21 95% CI 1.11-4.40), and >/=4 GP contacts per year (OR 1.71 95% CI 1.46-2.00). The chance of receiving tetracyclins (OR 2.24, 95% CI 1.29-3.89), macrolides/lincosamides/streptogamins (OR 8.69, 95% CI 4.26-17.73) and quinolones (OR 2.59, 95% CI 1.22-5.48) was higher in Pen-A patients. CONCLUSIONS: In primary health care Pen-A labels are associated with increased antibiotic use, including second choice antibiotics, and more health care use</style></abstract><notes><style face="normal" font="default">DA - 20170608IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1186/s13601-017-0154-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28593040">PM:28593040</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-18.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-18.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170608, Su T</style></custom2><misc3><style face="normal" font="default">10.1186/s13601-017-0154-y</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41859</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oiso,N.</style></author><author><style face="normal" font="default"> Tatebayashi,M.</style></author><author><style face="normal" font="default"> Hoshiyama,Y.</style></author><author><style face="normal" font="default"> Kawada,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Kindai University Faculty of Medicine, Osaka-Sayama 589-8511, Japan</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by arbutin and dipotassium glycyrrhizate in skin-lightening products</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="53" start="51">51-53</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170614IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12739</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28612442">PM:28612442</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-51-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-51-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170614, Oiso N</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12739</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41860</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ali,L.</style></author><author><style face="normal" font="default"> Foulds,J.S.</style></author><author><style face="normal" font="default"> Abdul Ghaffar,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK</style></auth-address><titles><title><style face="normal" font="default">Severe eyelid allergic contact dermatitis secondary to eyelash tint: two case reports</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="60" start="59">59-60</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eyelid</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170614IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12749</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28612445">PM:28612445</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-59-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-59-60.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170614, Ali L</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12749</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41861</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bonefeld,C.M.</style></author><author><style face="normal" font="default"> Geisler,C.</style></author><author><style face="normal" font="default"> Gimenez-Arnau,E.</style></author><author><style face="normal" font="default"> Lepoittevin,J.P.</style></author><author><style face="normal" font="default"> Uter,W.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Health and Medical Sciences, Department of Immunology and Microbiology, University of Copenhagen, 2200, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default">Immunological, chemical and clinical aspects of exposure to mixtures of contact allergens</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical aspects</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact allergens</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Salts</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="5" Month="7" Year="2017">2017/7/5</year></dates><abstract><style face="normal" font="default">Allergic contact dermatitis is one of the most frequent forms of skin inflammation. Very often, we are exposed to mixtures of allergens with varying potencies, doses/areas, and exposure times. Therefore, improved knowledge about immune responses to combinations of contact allergens is highly relevant. In this article, we provide a general introduction to immune responses to contact allergens, and discuss the literature concerning immune responses to mixtures of allergens. According to the existing evidence, increased responses are induced following sensitization with combinations of allergens as compared with single allergens. The response to a mixture of allergens can be both additive and synergistic, depending on the dose and combination of allergens. Importantly, sensitization with combinations of either fragrance allergens or metal salts can result in increased challenge responses to specific allergens within the mixture. Taken together, the immune responses to mixtures of allergens are complex, and further studies are required to obtain the necessary knowledge to improve consumer safety</style></abstract><notes><style face="normal" font="default">DA - 20170705IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Denmark -CO - France -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12847</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28677261">PM:28677261</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170705-BonefeldCM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170705-BonefeldCM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170705, Bonefeld CM</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12847</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41862</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wuyts,L.</style></author><author><style face="normal" font="default"> van Hoof,T.</style></author><author><style face="normal" font="default"> Lambert,J.</style></author><author><style face="normal" font="default"> Aerts,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Hospital Antwerp (UZA) and University of Antwerp (UA), 2650 Antwerp, Belgium</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by aftershave creams containing Glycyrrhiza inflata</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="51" start="49">49-51</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170614IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12725</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28612439">PM:28612439</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-49-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-49-51.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170614, Wuyts L</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12725</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41863</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Opstrup,M.S.</style></author><author><style face="normal" font="default"> Garvey,L.H.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author><author><style face="normal" font="default"> Bregnbak,D.K.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, National Allergy Research Centre, Herlev and Gentofte Hospital, University of Copenhagen, 2900 Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">A contact allergic reaction to budesonide mimicking immediate-type allergy</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="63" start="62">62-63</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Budesonide</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170614IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12762</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28612436">PM:28612436</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-62-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-62-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170614, Opstrup MS</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12762</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41864</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Assier,H.</style></author><author><style face="normal" font="default"> Wolkenstein,P.</style></author><author><style face="normal" font="default"> Chosidow,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, AP-HP, Hopital Henri-Mondor, 94010 Creteil, France</style></auth-address><titles><title><style face="normal" font="default">First case of contact dermatitis caused by hydroxypropyl tetrahydropyrantriol used in an anti-ageing cream</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="61" start="60">60-61</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170614IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12756</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28612444">PM:28612444</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-60-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-60-1.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170614, Assier H</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12756</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41865</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lagrelius,M.</style></author><author><style face="normal" font="default"> Wahlgren,C.F.</style></author><author><style face="normal" font="default"> Matura,M.</style></author><author><style face="normal" font="default"> Bergstrom,A.</style></author><author><style face="normal" font="default"> Kull,I.</style></author><author><style face="normal" font="default"> Liden,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Environmental Medicine, Karolinska Institutet, 171 77, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default">A population-based study of self-reported skin exposures and symptoms in relation to contact allergy in adolescents</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Fragrance mix</style></keyword><keyword><style face="normal" font="default"> Hair</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand eczema</style></keyword><keyword><style face="normal" font="default"> Hygiene</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Nickel allergy</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Piercing</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Tattooing</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="7" Year="2017">2017/7/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Knowledge about the relations between skin exposures, skin symptoms and contact allergy in adolescents is limited. OBJECTIVES: To explore self-reported skin exposures and skin symptoms in girls and boys, and to assess the associations between exposures, symptoms and contact allergy at age 16 years. PARTICIPANTS AND METHODS: In all, 3115 adolescents from the population-based BAMSE birth cohort answered a questionnaire at age 16 concerning various skin exposures and related skin symptoms. Of these, 2285 were patch tested. RESULTS: The prevalences of self-reported piercing (55.4%), hair dyeing (50.1%) and related skin symptoms were high, particularly in girls. Piercing and itchy rash after contact with metal items were associated with increased risks of nickel allergy [respectively: odds ratio (OR) 1.77, 95%CI: 1.04-3.03, and OR 2.25, 95%CI: 1.57-3.23]. An itchy rash resulting from the use of personal hygiene products or makeup was associated with a positive patch test reaction to fragrance mix I (OR 2.11, 95%CI: 1.02-4.35). CONCLUSIONS: Adolescents are exposed to skin-sensitizing substances, for example because of piercing, hair dyeing, and tattooing. Such early-life skin exposure may lead to lifelong contact allergy and future allergic contact dermatitis and hand eczema</style></abstract><notes><style face="normal" font="default">DA - 20170704IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12816</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28675503">PM:28675503</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170704-LagreliusM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170704-LagreliusM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170704, Lagrelius M</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12816</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41866</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Al Ali,A.</style></author><author><style face="normal" font="default"> Mireault,J.</style></author><author><style face="normal" font="default"> Tremblay,C.</style></author><author><style face="normal" font="default"> Sasseville,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Division of Dermatology, McGill University Health Centre, Montreal, QC H3G 1A4, Canada</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by pentaerythrityl tetracaprylate/tetracaprate</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="59" start="58">58-59</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170614IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12748</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28612437">PM:28612437</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-58-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-58-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170614, Al Ali A</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12748</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41867</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Klasson,M.</style></author><author><style face="normal" font="default"> Lindberg,M.</style></author><author><style face="normal" font="default"> Bryngelsson,I.L.</style></author><author><style face="normal" font="default"> Arvidsson,H.</style></author><author><style face="normal" font="default"> Pettersson,C.</style></author><author><style face="normal" font="default"> Husby,B.</style></author><author><style face="normal" font="default"> Westberg,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Occupational and Environmental Medicine, Orebro University, 701 85, Orebro, SwedeniRiSC - Inflammatory Response and Infection Susceptibility Centre, School of Health and Medical Sciences, Orebro University, 701 82, Orebro, Sweden</style></auth-address><titles><title><style face="normal" font="default">Biological monitoring of dermal and air exposure to cobalt at a Swedish hard metal production plant: does dermal exposure contribute to uptake?</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> lung cancer</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> Plant</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="4" Month="7" Year="2017">2017/7/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Occupational exposure to cobalt is well established in hard metal manufacture. Cobalt is known to cause contact allergy, asthma, hard metal lung disease, and lung cancer. The relationship between skin exposure and uptake determined in blood has not been extensively investigated. OBJECTIVE: To examine whether skin and inhalable air exposure to cobalt contributes to uptake, determined as cobalt in blood, in a hard metal manufacturing factory. METHODS: The amount of cobalt on the skin found with an acid wash technique, the air concentrations of inhalable cobalt and cobalt blood concentrations were determined and correlated in exposed workers. RESULTS: We found a significant rank correlation for cobalt concentrations on the skin, in inhalable air, and in blood (0.376-0.498). Multiple linear regression showed significant regression coefficients for cobalt skin exposure and blood (B = 0.01, p &lt; 0.05) and for inhalable cobalt in air and blood (B = 49.1, p &lt; 0.001). According to our model based on data from the regression analyses, a twofold increase in skin exposure levels at different air concentrations caused a 3-14% increase in blood levels. CONCLUSIONS: Our data suggest that skin exposure to cobalt in the hard metal industry could affect the total uptake at the same order of magnitude as air exposure</style></abstract><notes><style face="normal" font="default">DA - 20170704IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12790</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28675438">PM:28675438</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170704-KlassonM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170704-KlassonM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170704, Klasson M</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12790</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41868</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Amsler,E.</style></author><author><style face="normal" font="default"> Al-Raddadi,R.</style></author><author><style face="normal" font="default"> Frances,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of dermatology and allergology, Tenon Hospital, 75020 Paris, France</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by PEG-22/dodecyl glycol copolymer in a skin-repairing cream</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="55" start="54">54-55</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170614IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12743</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28612438">PM:28612438</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-54-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-54-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170614, Amsler E</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12743</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41869</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bircher,A.J.</style></author><author><style face="normal" font="default"> Sigg,R.</style></author><author><style face="normal" font="default"> Scherer,Hofmeier K.</style></author><author><style face="normal" font="default"> Schlegel,U.</style></author><author><style face="normal" font="default"> Hauri,U.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Unit, Dermatology Clinic, University Hospital Basel and University of Basel 4031, Basel, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by a new temporary blue-black tattoo dye - sensitization to genipin from jagua (Genipa americana L.) fruit extract</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergenic</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fruit</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Internet</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polysaccharides</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> South America</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Temporary tattoo</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="7" Year="2017">2017/7/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Temporary tattoos made with an extract of the jagua fruit (Genipa americana L.) are becoming increasingly popular. It is claimed that it is 'dermatologically tested' and does not contain p-phenylenediamine. Extracts of jagua and gardenia fruits have been used by indigenous people in South America, as well as in traditional Chinese medicine, for centuries. Genipin is currently used for its cross-linking effect in the manufacture of polysaccharides, and is being investigated for its anti-inflammatory and other properties. OBJECTIVES: To report the presence of the allergenic substance genipin in a self-administered temporary tattoo dye made from the fruit juice of jagua (Genipa americana L.). PATIENTS AND METHODS: A 39-year-old female who repeatedly applied 'completely natural and 100% safe' Earth Jagua(R) tattoo, obtained via the internet, to her left hand developed allergic contact dermatitis within 6 weeks. Analysis of the dye showed the presence of geniposide and genipin. RESULTS: Patch tests with the dye and with its main components, including genipin, gave strong positive reactions to the latter. There was no sensitization to other ingredients or p-amino compounds. CONCLUSIONS: We report an extensively evaluated case of allergic contact dermatitis caused by a temporary Earth Jagua(R) tattoo. The allergen identified is genipin, a substance that is increasingly used for tattoos and as a therapeutic agent in medicine. This could result in an increase in the number of allergic reactions in the future</style></abstract><notes><style face="normal" font="default">DA - 20170704IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12844</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28675523">PM:28675523</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170704-BircherAJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170704-BircherAJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170704, Bircher AJ</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12844</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41870</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Siemund,I.</style></author><author><style face="normal" font="default"> Mowitz,M.</style></author><author><style face="normal" font="default"> Zimerson,E.</style></author><author><style face="normal" font="default"> Bruze,M.</style></author><author><style face="normal" font="default"> Hindsen,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Occupational and Environmental Dermatology, Skane University Hospital, Lund University, 20502, Malmo, Sweden</style></auth-address><titles><title><style face="normal" font="default">Variation in aluminium patch test reactivity over time</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> False negative</style></keyword><keyword><style face="normal" font="default"> False Negative Reactions</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Contact allergy to aluminium has been reported more frequently in recent years. It has been pointed out that positive patch test reactions to aluminium may not be reproducible on retesting. OBJECTIVES: To investigate possible variations in patch test reactivity to aluminium over time. METHODS: Twenty-one adults, who had previously reacted positively to aluminium, were patch tested with equimolar dilution series in pet. of aluminium chloride hexahydrate and aluminium lactate, four times over a period of 8 months. RESULTS: Thirty-six of 84 (43%) serial dilution tests with aluminium chloride hexahydrate and 49 of 84 (58%) serial dilution tests with aluminium lactate gave negative results. The range of reactivity varied between a negative reaction to aluminium chloride hexahydrate at 10% and/or to aluminium lactate at 12%, and a positive reaction to aluminium chloride hexahydrate at 0.1% and/or to aluminium lactate at 0.12%. The highest individual difference in test reactivity noticed was 320-fold when the two most divergent minimal eliciting concentrations were compared. CONCLUSIONS: The patch test reactivity to aluminium varies over time. Aluminium-allergic individuals may have false-negative reactions. Therefore, retesting with aluminium should be considered when there is a strong suspicion of aluminium contact allergy</style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12836</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28695639">PM:28695639</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170711-SiemundI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170711-SiemundI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170711, Siemund I</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12836</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41871</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gatica-Ortega,M.E.</style></author><author><style face="normal" font="default"> Pastor-Nieto,M.A.</style></author><author><style face="normal" font="default"> Mercader-Garcia,P.</style></author><author><style face="normal" font="default"> Silvestre-Salvador,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Department, Toledo Hospital Complex, 45071, Toledo, Spain</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by (meth)acrylates in long-lasting nail polish - are we facing a new epidemic in the beauty industry?</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Beauty</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidemic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand dermatitis</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> Methacrylate</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Telephone</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="27" Month="6" Year="2017">2017/6/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic contact dermatitis (ACD) caused by (meth)acrylates has been described both in occupational and in non-occupational settings. OBJECTIVES: To evaluate the clinical patterns, the most frequent allergens and the prognosis in patients sensitized to (meth)acrylates in long-lasting nail polish. METHODS: The files of patients with ACD caused by (meth)acrylates in long-lasting nail polish diagnosed between January 2013 and June 2016 in four dermatology departments in Spain were reviewed. Patients were followed up by telephone interview. RESULTS: Overall, 2353 patients were patch tested. Forty-three (1.82%) were diagnosed with ACD caused by (meth)acrylates in long-lasting nail polish during that period; all were female, and all had hand dermatitis. Patients were mostly less than 40 years old (72.1%), non-atopic (95.4%) and had an occupational cause of their dermatitis (93%), which developed approximately 10.1 months after they had started to use this technique. The most frequent positive allergens were: 2-hydroxypropyl methacrylate, 2-hydroxyethyl methacrylate, and tetrahydrofurfuryl methacrylate. Eight of the 22 interviewed patients were able to improve their working technique and used 4H(R) protective material (fingerstalls/gloves). CONCLUSIONS: Long-lasting nail polishes have become widespread, and it is a matter of concern that we may be facing a new epidemic of ACD caused by these. Policies regulating their use are urgently needed</style></abstract><notes><style face="normal" font="default">DA - 20170628IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12827</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28656588">PM:28656588</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170628-GaticaOrtegaME.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170628-GaticaOrtegaME.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170628, Gatica-Ortega ME</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12827</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41872</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mowitz,M.</style></author><author><style face="normal" font="default"> Svedman,C.</style></author><author><style face="normal" font="default"> Zimerson,E.</style></author><author><style face="normal" font="default"> Isaksson,M.</style></author><author><style face="normal" font="default"> Ponten,A.</style></author><author><style face="normal" font="default"> Bruze,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Lund University, Department of Occupational and Environmental Dermatology, Lund University, Skane University Hospital, 205 02, Malmo, Sweden</style></auth-address><titles><title><style face="normal" font="default">Simultaneous patch testing with fragrance mix I, fragrance mix II and their ingredients in southern Sweden between 2009 and 2015</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Baseline series</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eugenol</style></keyword><keyword><style face="normal" font="default"> Farnesol</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Fragrance mix</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="7" Month="7" Year="2017">2017/7/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Fragrance mix I (FM I) and fragrance mix II (FM II) are included in the European baseline series as screening substances for fragrance contact allergy. OBJECTIVES: To investigate the frequency of allergic reactions to FM I, FM II and their ingredients in consecutively patch tested patients. MATERIALS AND METHODS: A retrospective analysis of data from 4430 patients patch tested between 2009 and 2015 was performed. RESULTS: Of the patients, 6.5% were FM I-positive and 3.2% were FM II-positive. Forty-five per cent of FM I-positive patients did not have positive reactions to FM I ingredients. Thirty-five per cent of those who were FM II-positive did not have positive reactions to FM II ingredients. Twenty-seven per cent of those with positive reactions to one or more of the FM I ingredients were FM I-negative, and 36% of those who had positive reactions to one or more of the FM II ingredients were FM II-negative. The allergens with the highest pick-up rates were Evernia prunastri (1.8%), cinnamal (1.3%), citral (1.2%), and hydroxyisohexyl 3-cyclohexene carboxaldehyde (1.2%). Significant differences were observed in the proportions of positive reactions to FM I, FM II, eugenol, isoeugenol, and farnesol when results from patch testing with materials from different suppliers were compared. CONCLUSIONS: There is a risk of missing fragrance contact allergy when testing with only the fragrance mixes is performed. The use of preparations from different suppliers may affect the patch test results</style></abstract><notes><style face="normal" font="default">DA - 20170707IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12834</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28685882">PM:28685882</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170707-MowitzM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170707-MowitzM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170707, Mowitz M</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12834</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41873</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fujiwara,Y.</style></author><author><style face="normal" font="default"> Inomata,N.</style></author><author><style face="normal" font="default"> Ishida,S.</style></author><author><style face="normal" font="default"> Miyakawa,M.</style></author><author><style face="normal" font="default"> Nomura,Y.</style></author><author><style face="normal" font="default"> Mitani,N.</style></author><author><style face="normal" font="default"> Aihara,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Yokohama City University School of Medicine, Yokohama 236-0004, Japan</style></auth-address><titles><title><style face="normal" font="default">Contact urticaria syndrome caused by sulfamethoxazole sodium contained in eye drops</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="57" start="56">56-57</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cities</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact urticaria</style></keyword><keyword><style face="normal" font="default"> contact urticaria syndrome</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> Sulfamethoxazole</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170614IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12745</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28612443">PM:28612443</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-56-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-56-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170614, Fujiwara Y</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12745</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41874</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ruffner,M.A.</style></author><author><style face="normal" font="default"> Spergel,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Children's Hospital of Philadelphia, Division of Allergy and Immunology, Department of Pediatrics, Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA, USA</style></auth-address><titles><title><style face="normal" font="default">Eosinophilic Esophagitis in Children</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma.Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Allergy Asthma.Rep</style></abbr-1></periodical><pages end="" start="54">54-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Elimination</style></keyword><keyword><style face="normal" font="default"> Elimination diet</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default"> Esophagitis</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pennsylvania</style></keyword><keyword><style face="normal" font="default"> Philadelphia</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: EoE is a significant cause of gastrointestinal morbidity affecting 1:2000. Patients with EoE typically have multiple atopic comorbidities, and additionally, many patients with EoE can be controlled well with elimination diets. The purpose of this review is to summarize the care of pediatric eosinophilic esophagitis patients. RECENT FINDINGS: EoE represents a distinct clinical syndrome which is characterized by esophageal dysfunction and eosinophil-predominant inflammation of the esophageal mucosa. Patients with EoE can present with varying symptoms depending on their age; in this review, we review the presenting features of eosinophilic esophagitis in children as well as a diagnostic algorithm for EoE. The mucosal inflammation in EoE is driven by exposure to food antigens in many patients with EoE. Therefore, for the majority of patients, the mainstays of treatment remain food elimination diets or swallowed steroids. This review summarizes the diagnostic approach to eosinophilic esophagitis (EoE) in pediatric patients, focusing on the importance of accurate diagnosis and selection of appropriate therapy</style></abstract><notes><style face="normal" font="default">DA - 20170627IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0721-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28653125">PM:28653125</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma.Rep\2017-17-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma.Rep\2017-17-54.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170627, Ruffner MA</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0721-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41875</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sanchez-Borges,M.</style></author><author><style face="normal" font="default"> Gonzalez-Aveledo,L.</style></author><author><style face="normal" font="default"> Caballero-Fonseca,F.</style></author><author><style face="normal" font="default"> Capriles-Hulett,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy and Clinical Immunology Department, Centro Medico Docente La Trinidad, Caracas, Venezuela.</style></auth-address><titles><title><style face="normal" font="default">Review of Physical Urticarias and Testing Methods</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma.Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Allergy Asthma.Rep</style></abbr-1></periodical><pages end="" start="51">51-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> subtypes</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> Venezuela</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: This review aims to update the information available on the prevalence, clinical picture, diagnostic methods, and treatment of urticarias induced by external physical stimuli. RECENT FINDINGS: Physical urticarias are present in up to 5% of the general population, and in 10 to 50% of patients with chronic urticaria. Recent investigations have provided evidence that the presence of physical urticaria alone or when comorbid with chronic spontaneous urticaria is associated with a worse prognosis and duration. Most frequent subtypes of physical urticaria are dermographism and delayed pressure urticaria. The diagnosis is established through specific provocation tests and the management encompasses avoidance measures, pharmacologic therapy with nonsedating antihistamines, and alternative medications in refractory cases</style></abstract><notes><style face="normal" font="default">DA - 20170621IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Venezuela -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0722-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28634900">PM:28634900</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma.Rep\2017-17-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma.Rep\2017-17-51.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170621, Sanchez-Borges M</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0722-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41876</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Peters,R.L.</style></author><author><style face="normal" font="default"> Neeland,M.R.</style></author><author><style face="normal" font="default"> Allen,K.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre of Food and Allergy Research, Murdoch Childrens Research Institute, Parkville, VIC, Australia</style></auth-address><titles><title><style face="normal" font="default">Primary Prevention of Food Allergy</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma.Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Allergy Asthma.Rep</style></abbr-1></periodical><pages end="" start="52">52-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergenic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> BCG</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> dog</style></keyword><keyword><style face="normal" font="default"> Dogs</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Immunisation</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Peanut</style></keyword><keyword><style face="normal" font="default"> Peanuts</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Primary Prevention</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: This article summarises recent developments on the prevention of food allergy in terms of the 5 D's of the development of food allergy: dry skin, diet, dogs, dribble, and vitamin D. RECENT FINDINGS: While several advances have improved our understanding of the development of food allergy, few preventive strategies have been implemented beyond changes in infant feeding guidelines. These now state that the introduction of allergenic solids such as peanuts should occur in the first year of life. Results from randomised controlled trials on other allergenic solids, vitamin D supplementation, BCG immunisation at birth and eczema prevention are eagerly anticipated in order to inform further preventative strategies</style></abstract><notes><style face="normal" font="default">DA - 20170621IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0718-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28634899">PM:28634899</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma.Rep\2017-17-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma.Rep\2017-17-52.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170621, Peters RL</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0718-x</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41877</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Turedi,O.</style></author><author><style face="normal" font="default"> Sozener,Z.C.</style></author><author><style face="normal" font="default"> Kendirlinan,R.</style></author><author><style face="normal" font="default"> Bavbek,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Ankara University School of Medicine, Department of Medical Genetics, Ankara. Turkey</style></auth-address><titles><title><style face="normal" font="default">A case of pantoprazole anaphylaxis with cross reactivity to all proton pump inhibitors: finding a safe alternative</style></title><secondary-title><style face="normal" font="default">Curr Drug Saf</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Drug Saf</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy workup</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> cross reactivity</style></keyword><keyword><style face="normal" font="default"> Cross-reactivity</style></keyword><keyword><style face="normal" font="default"> cumulative dose</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> drug allergy work-up</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Famotidine</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> intradermal test</style></keyword><keyword><style face="normal" font="default"> Intradermal Tests</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Lansoprazole</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral provocation test</style></keyword><keyword><style face="normal" font="default"> Oral provocation tests</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> proton pump inhibitor</style></keyword><keyword><style face="normal" font="default"> Proton pump inhibitors</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> Ranitidine</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> tablet</style></keyword><keyword><style face="normal" font="default"> Tablets</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hypersensitivity reactions due to Proton pump inhibitors (PPIs ) are rare, and further anaphylaxis to a PPI with cross-reactivity to all commercially available PPIs is very rare Objective: To present a case of anaphylaxis to pantoprazole with cross-reactivity to all commercially available PPIs Method: Skin prick tests (SPTs), intradermal tests (IDTs) and oral provocation tests (OPTs) were performed with available PPIs according to the method described in previous studies. RESULTS: All tested PPIs except lansoprazole were positive on skin tests either SPT or IDT. The patient was challenged with lansoprazole at increasing doses (7.5 mg, 15 mg, 30 mg capsule) every 60 minutes and she reacted with urticaria to 52.5 mg cumulative dose of lansoprazole. She could tolerate ranitidine and famotidine tablets via OPT. CONCLUSION: In our best knowledge, our case was the first case in this regard and that points the possibility of all cross-reactive pattern in patients with pantoprazole anaphylaxis and the importance of a thorough drug allergy work-up for finding safe alternatives. H2 receptor antagonists are used as safe alternatives in cases with PPI hypersensitivity</style></abstract><notes><style face="normal" font="default">DA - 20170712IS - 2212-3911 (Electronic)IS - 1574-8863 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.2174/1574886312666170711122341</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28699491">PM:28699491</url></web-urls></urls><custom2><style face="normal" font="default">20170712, Turedi O</style></custom2><misc3><style face="normal" font="default">10.2174/1574886312666170711122341</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41878</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lipinska-Ojrzanowska,A.</style></author><author><style face="normal" font="default"> Marcinkiewicz,A.</style></author><author><style face="normal" font="default"> Walusiak-Skorupa,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Occupational Diseases and Environmental Health, Nofer Institute of Occupational Medicine, 8 St. Teresy, 91-348 Lodz, Poland</style></auth-address><titles><title><style face="normal" font="default">Usefulness of Biomarkers in Work-Related Airway Disease</style></title><secondary-title><style face="normal" font="default">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Treat Options Allergy</style></full-title></periodical><pages end="190" start="181">181-190</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> Exhaled Breath</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic Markers</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Inhalant</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational disease</style></keyword><keyword><style face="normal" font="default"> Occupational Diseases</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> Occupational Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Saliva</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> urine</style></keyword><keyword><style face="normal" font="default"> Workplace</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Determination of biomarkers may be useful in the surveillance of occupational exposure and workers' health. The possibility of predicting development/clinical course of specific disorders or current disease, diagnosing in early steps, and health condition monitoring is a real necessity. Various agents present in the workplace environment (or their metabolites) can be measured in samples possessed from human body (blood and urine, saliva, etc.). On the other hand, inhalant exposure may induce specific or non-specific, local or systemic, acute or chronic biological response expressed by synthesis or releasing specific or non-specific substances/mediators that also can be determined in blood, nasal and bronchial lavage or sputum, tear fluid, exhaled breath, etc. The least is known about genetic markers which may predict individual susceptibility to develop some work-related disorders under the influence of occupational exposure. Due to common exposure to inhalant agents at workplace, researches on biomarkers that allow to inspect the impact of exposure to humans' health are still needed. The authors of this article summarize the utility of biomarkers' determination in work-related airway diseases in a recent clinical approach</style></abstract><notes><style face="normal" font="default">DA - 20170706IS - 2196-3053 (Print)LA - engPT - Journal ArticlePT - ReviewCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1007/s40521-017-0121-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28680796">PM:28680796</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-181-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-181-90.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170706, Lipinska-Ojrzanowska A</style></custom2><misc3><style face="normal" font="default">10.1007/s40521-017-0121-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41879</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zheng,Y.</style></author><author><style face="normal" font="default"> Chaudhari,P.R.</style></author><author><style face="normal" font="default"> Maibach,H.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Dermato-Venereology , The Third Affiliated Hospital of Sun Yat-sen University , Guangzhou , Guangdong , China</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis from ophthalmics</style></title><secondary-title><style face="normal" font="default">Cutan Ocul Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cutan Ocul Toxicol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact Lens Solutions</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Solutions</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="6" Month="3" Year="2017">2017/3/6</year></dates><abstract><style face="normal" font="default">In this article we summarize the recently described allergens responsible for allergic contact dermatitis due to ophthalmic drugs and contact lens solutions, and emphaage the need on how to perform diagnostic testing in this special clinical entity</style></abstract><notes><style face="normal" font="default">DA - 20170620IS - 1556-9535 (Electronic)IS - 1556-9527 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/15569527.2017.1295251</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28632093">PM:28632093</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cutan Ocul Toxicol\20170620-ZhengY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cutan Ocul Toxicol\20170620-ZhengY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170620, Zheng Y</style></custom2><misc3><style face="normal" font="default">10.1080/15569527.2017.1295251</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41880</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">AlGhamdi,K.M.</style></author><author><style face="normal" font="default"> Khurrum,H.</style></author><author><style face="normal" font="default"> Gad Al Rab,M.O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia</style></auth-address><titles><title><style face="normal" font="default">Evaluation of patch test reactivities in patients with chronic idiopathic urticaria</style></title><secondary-title><style face="normal" font="default">Cutis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cutis</style></full-title></periodical><pages end="E32" start="E27">E27-E32</pages><volume><style face="normal" font="default">99</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic idiopathic urticaria</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> CIU</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Saudi Arabia</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">Chronic idiopathic urticaria (CIU) is one of the mysteries of dermatology. An association between spontaneous CIU and contact allergy sensitization is possible. In this study, we aimed to test the hypothesis that contact allergy might play a role in disease in CIU patients. Furthermore, we examined if patch testing should be routinely performed in patients with chronic urticaria (CU). Ultimately, we concluded that patch testing should be included among the diagnostic procedures for CU</style></abstract><notes><style face="normal" font="default">DA - 20170707IS - 2326-6929 (Electronic)IS - 0011-4162 (Linking)LA - engPT - Journal ArticleCO - Saudi Arabia -</style></notes><work-type><style face="normal" font="default">10.1080/15569527.2017.1295251</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28686766">PM:28686766</url></web-urls></urls><custom2><style face="normal" font="default">20170707, AlGhamdi KM</style></custom2><misc3><style face="normal" font="default">10.1080/15569527.2017.1295251</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41881</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Warshaw,E.M.</style></author><author><style face="normal" font="default"> Zug,K.A.</style></author><author><style face="normal" font="default"> Belsito,D.V.</style></author><author><style face="normal" font="default"> Fowler,J.F.,Jr.</style></author><author><style face="normal" font="default"> DeKoven,J.G.</style></author><author><style face="normal" font="default"> Sasseville,D.</style></author><author><style face="normal" font="default"> Maibach,H.I.</style></author><author><style face="normal" font="default"> Mathias,C.G.T.</style></author><author><style face="normal" font="default"> Deleo,V.A.</style></author><author><style face="normal" font="default"> Taylor,J.S.</style></author><author><style face="normal" font="default"> Fransway,A.F.</style></author><author><style face="normal" font="default"> Marks,J.G.,Jr.</style></author><author><style face="normal" font="default"> Pratt,M.D.</style></author><author><style face="normal" font="default"> Zirwas,M.J.</style></author><author><style face="normal" font="default"> Geier,J.</style></author><author><style face="normal" font="default"> Uter,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Minneapolis Veterans Affairs Medical Center</style></auth-address><titles><title><style face="normal" font="default">Positive Patch-Test Reactions to Essential Oils in Consecutive Patients: Results From North America and Central Europe</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="252" start="246">246-252</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Baseline series</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Essential oil</style></keyword><keyword><style face="normal" font="default"> Essential oils</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Fragrance mix</style></keyword><keyword><style face="normal" font="default"> Fragrances</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Labeling</style></keyword><keyword><style face="normal" font="default"> Leg</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Melaleuca</style></keyword><keyword><style face="normal" font="default"> Mentha</style></keyword><keyword><style face="normal" font="default"> Mentha piperita</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Myroxylon</style></keyword><keyword><style face="normal" font="default"> Myroxylon pereirae</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> North America</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Oils</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Petrolatum</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Santalum</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Tea</style></keyword><keyword><style face="normal" font="default"> Tea Tree Oil</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Veterans</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="13" Month="6" Year="2017">2017/6/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: Synthetic fragrances and natural essential oils (EOs) are used in perfumery and found in various cosmetics. Essential oils are also increasingly used to promote wellness. In previous studies, the sensitization potential of some EOs has been identified; however, the current prevalence of sensitivity is largely unknown. OBJECTIVES: The aim of this study was to determine frequency of positive patch-test reactions to EOs tested in the baseline series, along with 3 fragrance markers (FMs) (fragrance mix I, fragrance mix II, and Myroxylon pereirae), in consecutive patients in the US/Canadian North American Contact Dermatitis Group (NACDG) (2009-2014) and the central European, trinational Information Network of Departments of Dermatology (IVDK) (2010-2014). METHODS: This study used a retrospective analysis of patch-test results and relevant demographic/clinical data collected electronically by the networks, obtained with Santalum album 10% petrolatum (pet) (IVDK only); Cananga odorata 2% (NACDG) and 10% (IVDK) pet; Jasminum species 2% (NACDG) and 5% (IVDK) pet; Mentha piperita 2% pet; Melaleuca alternifolia, oxidized (tea tree oil), 5% pet; and Lavandula angustifolia 2% pet (latter 3 NACDG only). RESULTS: Overall, 62,354 patients were tested to 3 FMs and EOs (NACDG, 13,398; IVDK, 48,956); 11,568 (18.6%) reacted to at least 1 FM or EO, whereas 857 (1.4%) reacted to 1 or more EOs but none of the 3 FMs. For both the NACDG and IVDK populations, individuals who were positive to 1 or more of the 9 study allergens were significantly less likely to be male, have occupational skin disease, or have hand involvement and significantly more likely to have leg dermatitis and be 40 years and older (P's &lt;/= 0.005). Prevalence rates for EOs were as follows: S. album, 1.4% IVDK; C. odorata, 1.1% NACDG and 2.4% IVDK; Jasminum species, 0.7% NACDG and 1.4% IVDK; M. piperita, 0.9% NACDG; L. angustifolia, 0.3% NACDG; and M. alternifolia, 0.3% NACDG. Of the 140 NACDG patients who reacted to 1 or more of the 5 NACDG EOs but none of the FMs, M. alternifolia yielded most positive reactions (45%); half of these reactions were strong (++ or +++, 50.8%) and of definite/probable clinical relevance (52.4%). Of the 717 IVDK patients who reacted to 1 or more of the 3 IVDK EOs but none of the 3 FMs, 38% were positive to C. odorata, 38% to S. album and 36% to Jasminum species.' CONCLUSIONS: Testing to EOs may be important for detecting sensitivity not detected by FMs alone. In North America, M. alternifolia is an important and clinically relevant sensitizer often not detected by FM. In Europe, as well as in North America, clinical relevance is often difficult to evaluate because (1) labeling of EOs when used as fragrance is not mandatory, and (2) these mixtures may indicate sensitization to 1 or more of their individual constituents from other sources, including synthetic fragrances</style></abstract><notes><style face="normal" font="default">DA - 20170614IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000293</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28614106">PM:28614106</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-246-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-246-52.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170614, Warshaw EM</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000293</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41882</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chou,M.</style></author><author><style face="normal" font="default"> Dhingra,N.</style></author><author><style face="normal" font="default"> Strugar,T.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Icahn School of Medicine at Mount Sinai; and daggerDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York</style></auth-address><titles><title><style face="normal" font="default">Contact Sensitization Due to Allergens in Nail Cosmetics: Identification, Treatment, and Prevention</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="240" start="231">231-240</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acrylate</style></keyword><keyword><style face="normal" font="default"> Acrylates</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergenic</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> contact sensitization</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dibutyl Phthalate</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Formaldehyde</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Methacrylate</style></keyword><keyword><style face="normal" font="default"> Methacrylates</style></keyword><keyword><style face="normal" font="default"> Nails</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Spread</style></keyword><keyword><style face="normal" font="default"> Toluene</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="13" Month="6" Year="2017">2017/6/13</year></dates><abstract><style face="normal" font="default">Ingredients found in the nail cosmetic industry, including but not limited to methacrylate and acrylate monomers, formaldehyde, and toluene sulfonamide-formaldehyde resin, can incite allergic contact dermatitis. An eczematous outbreak presents on areas surrounding the nail plate and may spread through contact transfer of the allergen, commonly to the face and neck. Even components that were originally deemed nonsensitizing, such as the ubiquitous cyanoacrylate adhesive family, have been found to be allergenic. They do not, however, cross-react with methacrylates and acrylates. Alternative options for individuals with allergic contact dermatitis reactions to these ingredients can be avoidance of these procedures or use of products that are "3, 4, 5 free" in which the common allergens dibutyl phthalate, toluene, and formaldehyde are absent. In cases where strengthening of the nail is the sole purpose, nail wraps or preformed nails can be applied for non-cyanoacrylate-sensitive individuals</style></abstract><notes><style face="normal" font="default">DA - 20170614IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000301</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28614110">PM:28614110</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-231-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-231-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170614, Chou M</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000301</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41883</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Silverberg,J.I.</style></author><author><style face="normal" font="default"> Silverberg,N.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Northwestern Medicine Multidisciplinary Eczema Center, Contact Dermatitis Clinic, Northwestern Memorial Hospital, Departments of Dermatology, Preventive Medicine, and Medical Social Sciences, Northwestern University, Feinberg School of Medicine, 676 North Saint Clair Street, Suite 1600, Chicago, IL 60611, USA.</style></auth-address><titles><title><style face="normal" font="default">Atopic Dermatitis: A Heterogeneous Disorder</style></title><secondary-title><style face="normal" font="default">Dermatol Clin</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Dermatol Clin</style></abbr-1></periodical><pages end="x" start="ix">ix-x</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Preventive Medicine</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170604IS - 1558-0520 (Electronic)IS - 0733-8635 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.det.2017.04.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28577808">PM:28577808</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatol Clin\2017-35-ix-x.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatol Clin\2017-35-ix-x.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170604, Silverberg JI</style></custom2><misc3><style face="normal" font="default">10.1016/j.det.2017.04.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41884</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Halling-Overgaard,A.S.</style></author><author><style face="normal" font="default"> Zachariae,C.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Kildegardsvej 28, Hellerup DK-2900, Denmark</style></auth-address><titles><title><style face="normal" font="default">Management of Atopic Hand Dermatitis</style></title><secondary-title><style face="normal" font="default">Dermatol Clin</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Dermatol Clin</style></abbr-1></periodical><pages end="372" start="365">365-372</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Azathioprine</style></keyword><keyword><style face="normal" font="default"> Calcineurin</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical aspects</style></keyword><keyword><style face="normal" font="default"> Coal</style></keyword><keyword><style face="normal" font="default"> Coal Tar</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Cyclosporine</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emollient</style></keyword><keyword><style face="normal" font="default"> Emollients</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand dermatitis</style></keyword><keyword><style face="normal" font="default"> Hand eczema</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritants</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Methotrexate</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prednisolone</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic therapy</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Topical calcineurin</style></keyword><keyword><style face="normal" font="default"> Topical corticosteroids</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">This article provides an overview of clinical aspects of hand eczema in patients with atopic dermatitis. Hand eczema can be a part of atopic dermatitis itself or a comorbidity, for example, as irritant or allergic contact dermatitis. When managing hand eczema, it is important to first categorize the subtype and identify potential culprit allergens or irritants. First-line therapy should be a combination of emollients and topical corticosteroids; possible alternatives include topical calcineurin inhibitors or coal tar. Second-line therapy includes UV therapy and systemic therapy, including azathioprine, cyclosporine, methotrexate, and mycophenolate. Prednisolone should only be very infrequently used</style></abstract><notes><style face="normal" font="default">DA - 20170604IS - 1558-0520 (Electronic)IS - 0733-8635 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1016/j.det.2017.02.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28577805">PM:28577805</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatol Clin\2017-35-365-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatol Clin\2017-35-365-72.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170604, Halling-Overgaard AS</style></custom2><misc3><style face="normal" font="default">10.1016/j.det.2017.02.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41885</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mokhtari,R.</style></author><author><style face="normal" font="default"> Sepaskhah,M.</style></author><author><style face="normal" font="default"> Aslani,F.S.</style></author><author><style face="normal" font="default"> Dastgheib,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Molecular Dermatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.</style></auth-address><titles><title><style face="normal" font="default">Autoimmune progesterone dermatitis presenting as fixed drug eruption: a case report</style></title><secondary-title><style face="normal" font="default">Dermatol Online J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatol Online J</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Buttocks</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Challenge test</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug eruption</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Erythema Multiforme</style></keyword><keyword><style face="normal" font="default"> Fixed drug eruption</style></keyword><keyword><style face="normal" font="default"> Forearm</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> Lip</style></keyword><keyword><style face="normal" font="default"> Luteal Phase</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Menstrual Cycle</style></keyword><keyword><style face="normal" font="default"> Menstruation</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Physical Examination</style></keyword><keyword><style face="normal" font="default"> Prednisolone</style></keyword><keyword><style face="normal" font="default"> Progesterone</style></keyword><keyword><style face="normal" font="default"> Recurrence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="15" Month="6" Year="2017">2017/6/15</year></dates><abstract><style face="normal" font="default">Autoimmune progesterone dermatitis (APD) is a rare disorder characterized by periodic skin lesions that erupt during the luteal phase of the menstrual cycle. Clinical manifestations of APD is caused by an unusual allergy to progesterone and has a wide range of clinical manifestations from eczema and urticaria to angioedema and erythema multiforme. A 46-year-old woman described recurrent, round erythematous plaques on the lower lip, both forearms and buttocks. These skin eruptions waxed and waned for 10 months, reoccurring 3-4 days before menstruation. Based on her medical history and physical examination, APD was suspected and the progesterone challenge test showed positive results. After treatment with oral prednisolone (30 mg/day) before menstruation, the severity of eruptions decreased dramatically but recurrence did not cease completely</style></abstract><notes><style face="normal" font="default">DA - 20170621IS - 1087-2108 (Electronic)IS - 1087-2108 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28633739">PM:28633739</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatol Online J\20170621-MokhtariR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatol Online J\20170621-MokhtariR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170621, Mokhtari R</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41886</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Moreira,J.</style></author><author><style face="normal" font="default"> Goncalves,R.</style></author><author><style face="normal" font="default"> Coelho,P.</style></author><author><style face="normal" font="default"> Maio,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, Hospital Pedro Hispano, Porto, Portugal</style></auth-address><titles><title><style face="normal" font="default">Eyelid Dermatitis Caused by Allergic Contact to Acrylates in Artificial Nails</style></title><secondary-title><style face="normal" font="default">Dermatol Reports</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Dermatol Reports</style></abbr-1></periodical><pages end="" start="7198">7198-</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acrylate</style></keyword><keyword><style face="normal" font="default"> Acrylates</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Artificial nail</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Eyelid</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Nails</style></keyword><keyword><style face="normal" font="default"> Ophthalmology</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword></keywords><dates><year Day="13" Month="3" Year="2017">2017/3/13</year></dates><abstract><style face="normal" font="default">Over the past few years, there has been an increase in cases of allergic contact dermatitis caused by acrylates, because of the growing popularity of artificial nails. Pathological reactions to artificial nails typically occur on or around the nail area. Eyelid contact dermatitis due to artificial nails is rarely seen, especially in a nonoccupational setting. The authors report the case of a 45-year-old female accountant who developed eyelid dermatitis due to artificial nails</style></abstract><notes><style face="normal" font="default">DA - 20170612IS - 2036-7392 (Print)IS - 2036-7392 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.4081/dr.2017.7198</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28603598">PM:28603598</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatol Reports\2017-9-7198.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatol Reports\2017-9-7198.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170612, Moreira J</style></custom2><misc3><style face="normal" font="default">10.4081/dr.2017.7198</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41887</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Young,C.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">What underlies the unconscious negative attitude of healthcare professionals towards patient-reported drug allergies?</style></title><secondary-title><style face="normal" font="default">Drugs Ther Perspect</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Drugs Ther Perspect</style></abbr-1></periodical><pages end="347" start="345">345-347</pages><volume><style face="normal" font="default">33</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Attitude</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1179-1977</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1007/s40267-017-0418-6</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.1007/s40267-017-0418-6</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Drugs Ther Perspect\2017-33-345-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Drugs Ther Perspect\2017-33-345-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170715, Young CJ</style></custom2><misc3><style face="normal" font="default">10.1007/s40267-017-0418-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41888</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Magrone,T.</style></author><author><style face="normal" font="default"> Salvatore,R.</style></author><author><style face="normal" font="default"> Spagnoletta,A.</style></author><author><style face="normal" font="default"> Magrone,M.</style></author><author><style face="normal" font="default"> Russo,M.A.</style></author><author><style face="normal" font="default"> Jirillo,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Basic Medical Sciences, Neuroscience and Sensory Organs, University of Bari, School of Medicine, Bari. Italy</style></auth-address><titles><title><style face="normal" font="default">In vitro effects of nickel on healthy non allergic peripheral blood mononuclear cells. The role of red grape polyphenols</style></title><secondary-title><style face="normal" font="default">Endocr Metab Immune Disord Drug Targets</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Endocr Metab Immune Disord Drug Targets</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL-17</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Natural products</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> PBMCs</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="13" Month="7" Year="2017">2017/7/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: Nickel (Ni) is widely distributed in the environment and continuous exposure to this metal may lead to pathological manifestations, such as the human allergic contact dermatitis. METHODS: The in vitro effects of Ni on human healthy non allergic peripheral blood mononuclear cells (PBMCs) in the absence or presence of red grape polyphenols have been evaluated. In the culture supernatants, levels of cytokines have been determined by ELISA, while nitric oxide (NO) concentration has been evaluated by a colorimetric procedure. RESULTS: Ni per se did not affect release of interferon-g, interleukin (IL)-4 and IL-10. Instead, this metal dramatically reduced production of IL-17 which was restored by supplementation of polyphenols. Finally, while Ni significantly increased generation of NO, polyphenols reduced production of this compound. CONCLUSION: Taken together, all these data may indicate a preventative role of polyphenols against Ni exposure in non allergic to Ni individuals, also confirming the immunomodulating role of these natural products. The interaction Ni/polyphenols/lipopolysaccharides will also be discussed</style></abstract><notes><style face="normal" font="default">DA - 20170714IS - 2212-3873 (Electronic)IS - 1871-5303 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.2174/1871530317666170713145350</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28707594">PM:28707594</url></web-urls></urls><custom2><style face="normal" font="default">20170714, Magrone T</style></custom2><misc3><style face="normal" font="default">10.2174/1871530317666170713145350</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41889</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aleksandrov,A.P.</style></author><author><style face="normal" font="default"> Mirkov,I.</style></author><author><style face="normal" font="default"> Zolotarevski,L.</style></author><author><style face="normal" font="default"> Ninkov,M.</style></author><author><style face="normal" font="default"> Mileusnic,D.</style></author><author><style face="normal" font="default"> Kataranovski,D.</style></author><author><style face="normal" font="default"> Kataranovski,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunotoxicology Group, Department of Ecology, Institute for Biological Research "Sinisa Stankovic", University of Belgrade, Belgrade, Serbia</style></auth-address><titles><title><style face="normal" font="default">Oral warfarin intake affects skin inflammatory cytokine responses in rats</style></title><secondary-title><style face="normal" font="default">Environ Toxicol Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Environ Toxicol Pharmacol</style></abbr-1></periodical><pages end="98" start="93">93-98</pages><volume><style face="normal" font="default">54</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous reaction</style></keyword><keyword><style face="normal" font="default"> Cutaneous reactions</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dinitrochlorobenzene</style></keyword><keyword><style face="normal" font="default"> DNCB</style></keyword><keyword><style face="normal" font="default"> Ecology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> lipopolysaccharide</style></keyword><keyword><style face="normal" font="default"> LPS</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> rat</style></keyword><keyword><style face="normal" font="default"> Rats</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Serbia</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Thromboembolism</style></keyword><keyword><style face="normal" font="default"> TNF</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Warfarin</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="6" Year="2017">2017/6/28</year></dates><abstract><style face="normal" font="default">Warfarin is an anticoagulant used in prevention/prophylaxis of thromboembolism. Besides the effects on coagulation, non-hemorrhagic reactions have also been documented. Although cutaneous reactions were reported in some patients, the impact on skin immunity was not explored. In the present paper, the effect of 30-day oral warfarin intake on skin cytokine responses in rats was analyzed. Increased release of inflammatory cytokines (TNF, IL-1beta and IL-10) was noted by skin explants from rats which received warfarin, but without effect on IL-6. No impact on epidermal cell cytokine secretion was seen, except a tendency of an increase of IL-6 response to stimulation with microbial product lipopolysaccharide (LPS). Topical application of contact allergen dinitrochlorobenzene (DNCB) resulted in slight (numerical solely) increase of TNF release by skin explants of warfarin-treated animals, while epidermal cells responded by increased secretion of all four cytokines examined. The data presented provide new information on the potential of oral warfarin to modulate skin innate immune activity</style></abstract><notes><style face="normal" font="default">DA - 20170713IS - 1872-7077 (Electronic)IS - 1382-6689 (Linking)LA - engPT - Journal ArticleCO - Serbia -</style></notes><work-type><style face="normal" font="default">10.1016/j.etap.2017.06.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28704755">PM:28704755</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Environ Toxicol Pharmacol\2017-54-93-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Environ Toxicol Pharmacol\2017-54-93-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170713, Aleksandrov AP</style></custom2><misc3><style face="normal" font="default">10.1016/j.etap.2017.06.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41890</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Casorati,G.</style></author><author><style face="normal" font="default"> Dellabona,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Experimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milano, ItalyExperimental Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy</style></auth-address><titles><title><style face="normal" font="default">Of self-lipids, CD1-restricted T cells, and contact sensitization</style></title><secondary-title><style face="normal" font="default">Eur J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur J Immunol</style></full-title></periodical><pages end="1122" start="1119">1119-1122</pages><volume><style face="normal" font="default">47</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cells</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> contact sensitization</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> Dinitrochlorobenzene</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Lipid</style></keyword><keyword><style face="normal" font="default"> Lipids</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rodent</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Contact hypersensitivity (CHS) in rodents and contact dermatitis in humans are long-known pathological conditions caused by MHC-restricted T-cell responses. These responses are triggered upon T-cell recognition of neo-antigenic determinants, which are generated by a variety of environmental contact sensitizer (CS) chemicals associating with self-proteins to comprise these neo-antigens. In this issue of the European Journal of Immunology, Betts et al. [Eur. J. Immunol. 2017. 47: 1171-1180] provide intriguing data implying that common small molecule CSs such as dinitrochlorobenzene can also recruit and activate autoreactive CD1-restricted T cells specific for cell-endogenous lipids, which are enriched in human skin. The effects of dinitrochlorobenzene on CD1 T-cell recruitment and function were dependent on newly synthesized CD1 molecules and the presence of endogenous lipids. These findings shed new light on unanticipated mechanisms that have potential clinical relevance on a common and highly distressing disease state</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 1521-4141 (Electronic)IS - 0014-2980 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1002/eji.201747112</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28691226">PM:28691226</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur J Immunol\2017-47-1119-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur J Immunol\2017-47-1119-22.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170710, Casorati G</style></custom2><misc3><style face="normal" font="default">10.1002/eji.201747112</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41891</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,T.</style></author><author><style face="normal" font="default"> Che,D.</style></author><author><style face="normal" font="default"> Liu,R.</style></author><author><style face="normal" font="default"> Han,S.</style></author><author><style face="normal" font="default"> Wang,N.</style></author><author><style face="normal" font="default"> Zhan,Y.</style></author><author><style face="normal" font="default"> Pundir,P.</style></author><author><style face="normal" font="default"> Cao,J.</style></author><author><style face="normal" font="default"> Lv,Y.</style></author><author><style face="normal" font="default"> Yang,L.</style></author><author><style face="normal" font="default"> Wang,J.</style></author><author><style face="normal" font="default"> Ding,M.</style></author><author><style face="normal" font="default"> Dong,X.</style></author><author><style face="normal" font="default"> He,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Pharmacy, Xi'an Jiaotong University, Xi'an, China</style></auth-address><titles><title><style face="normal" font="default">Typical antimicrobials induce mast cell degranulation and anaphylactoid reactions via MRGPRX2 and its murine homologue MRGPRB2</style></title><secondary-title><style face="normal" font="default">Eur J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur J Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic response</style></keyword><keyword><style face="normal" font="default"> Allergiclike reaction</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> anaphylactoid reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Antimicrobials</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Body Temperature</style></keyword><keyword><style face="normal" font="default"> Ca2+</style></keyword><keyword><style face="normal" font="default"> Cell Degranulation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> G protein-coupled receptor</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> imaging</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Temperature</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="8" Month="7" Year="2017">2017/7/8</year></dates><abstract><style face="normal" font="default">Mast cells are unique immune cells that function as sentinels in host defence reactions, including immediate hypersensitivity responses and allergic responses. The mast cell-specific receptor named MAS-related G protein-coupled receptor X2 (MRGPRX2) triggers mast-cell degranulation, a key process in anaphylactoid reactions. It is widely observed that antimicrobials can induce pseudo-allergic reactions (i.e. IgE-independent mechanism) with symptoms ranging from skin inflammation to life-threatening systemic anaphylaxis. However, their direct involvement and the mechanisms underlying anaphylactoid reactions caused by antimicrobials have not been demonstrated. Structurally different antimicrobials were screened by Ca2+ imaging using MRGPRX2 overexpressing HEK293 cells. MRGPRX2 related anaphylactoid reactions induced by these components were investigated by body temperature drop and mast cell degranulation assays. We showed that MRGPRX2 is involved in allergic-like reactions to three types of antimicrobials in a dose-dependent manner. However, mast cells lacking the receptor show reduced degranulation. Furthermore, mice without MAS-related G protein-coupled receptor B2 (the orthologous gene of MRGPRX2) exhibited reduced substance-induced inflammation. Interestingly, beta-lactam and antiviral nucleoside analogues did not induce anaphylactic reactions, which were also observed in vitro. These results should alarm many clinicians that such drugs might induce anaphylactoid reactions and provide guidance on safe dosage of these drugs. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170708IS - 1521-4141 (Electronic)IS - 0014-2980 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1002/eji.201746951</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28688196">PM:28688196</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur J Immunol\20170708-ZhangT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur J Immunol\20170708-ZhangT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170708, Zhang T</style></custom2><misc3><style face="normal" font="default">10.1002/eji.201746951</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41892</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dunican,E.M.</style></author><author><style face="normal" font="default"> Fahy,J.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Airway Clinical Research Center, Division of Pulmonary and Critical Care Medicine, Cardiovascular Research Institute, Sandler Center for Basic Asthma Research, University of California, San Francisco, CA, USAThe Airway Clinical Research Center, Division of Pulmonary and Critical Care Medicine, Cardiovascular Research Institute, Sandler Center for Basic Asthma Research, University of California, San Francisco, CA, USA john.fahy@ucsf.edu</style></auth-address><titles><title><style face="normal" font="default">Asthma and corticosteroids: time for a more precise approach to treatment</style></title><secondary-title><style face="normal" font="default">Eur Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Respir J</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> San Francisco</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170630IS - 1399-3003 (Electronic)IS - 0903-1936 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1183/13993003.01167-2017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28663322">PM:28663322</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170630, Dunican EM</style></custom2><misc3><style face="normal" font="default">10.1183/13993003.01167-2017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41893</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Park,M.S.</style></author><author><style face="normal" font="default"> Song,N.E.</style></author><author><style face="normal" font="default"> Baik,S.H.</style></author><author><style face="normal" font="default"> Pae,H.O.</style></author><author><style face="normal" font="default"> Park,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute for Metabolic Disease, Wonkwang University, Iksan, Jeollabuk 570-749, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Oral administration of lactobacilli isolated from Jeotgal, a salted fermented seafood, inhibits the development of 2,4-dinitrofluorobenzene-induced atopic dermatitis in mice</style></title><secondary-title><style face="normal" font="default">Exp Ther Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Exp Ther Med</style></abbr-1></periodical><pages end="641" start="635">635-641</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Dinitrofluorobenzene</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-12</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Interferon</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Lactic Acid</style></keyword><keyword><style face="normal" font="default"> Lactobacillus</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> oral administration</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Seafood</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> serum IgE levels</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Certain strains of lactobacilli have been reported to exert favorable effects on atopic dermatitis (AD). Jeotgal, a traditional Korean food, is a salted fermented seafood known to harbor many lactic acid bacteria. In the present study, two novel lactobacillus strains were isolated from Jeotgal, and their anti-AD effects were investigated. Lactobacilli isolated from Jeotgal were identified, according to conjugated linoleic acid-producing activity, as Lactobacillus plantarum (JBCC105645 and JBCC105683). AD-like skin lesions were induced in BALB/c mice using dinitrofluorobenzene (DNFB). Ear swelling, histological analysis and serum immunoglobulin E (IgE) levels in mice were evaluated to investigate the anti-AD effects of lactobacilli. Cytokine production of ex vivo cluster of differentiation (CD)4+ T cells, and interleukin (IL)-12 production of in vitro macrophages were also evaluated to establish a putative mechanism of the action of lactobacilli. Administration of JBCC105645 or JBCC105683 suppressed ear swelling and serum IgE levels in DNFB-treated mice (P&lt;0.05). Notably, JBCC105645 was more effective than JBCC105683 (P&lt;0.05). Treatment with the lactobacilli also induced a significant decrease in IL-4 production with concomitant increase in interferon (IFN)-gamma production in DNFB-exposed CD4+ T cells, and an increase in IL-12 production in macrophages (P&lt;0.05). Taken together, the lactobacilli isolated from Jeotgal may suppress the development of AD-like skin inflammation in mice by modulating IL-4 and IFN-gamma production in CD4+ T cells, presumably via enhancing IL-12 production by macrophages</style></abstract><notes><style face="normal" font="default">DA - 20170704IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.3892/etm.2017.4536</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28672978">PM:28672978</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Exp Ther Med\2017-14-635-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Exp Ther Med\2017-14-635-41.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170704, Kim MS</style></custom2><misc3><style face="normal" font="default">10.3892/etm.2017.4536</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41894</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,C.G.</style></author><author><style face="normal" font="default"> Lee,J.E.</style></author><author><style face="normal" font="default"> Jeong,D.G.</style></author><author><style face="normal" font="default"> Lee,Y.H.</style></author><author><style face="normal" font="default"> Park,S.I.</style></author><author><style face="normal" font="default"> Lee,D.G.</style></author><author><style face="normal" font="default"> Han,C.H.</style></author><author><style face="normal" font="default"> Kang,S.J.</style></author><author><style face="normal" font="default"> Song,C.H.</style></author><author><style face="normal" font="default"> Choi,S.H.</style></author><author><style face="normal" font="default"> Lee,Y.J.</style></author><author><style face="normal" font="default"> Ku,S.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Biological Oceanography and Marine Biology Division, KIOST, Ansan, Gyeonggi 15627, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Bathing effects of east saline groundwater concentrates on allergic (atopic) dermatitis-like skin lesions induced by 2,4-dinitrochlorobenzene in hairless mice</style></title><secondary-title><style face="normal" font="default">Exp Ther Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Exp Ther Med</style></abbr-1></periodical><pages end="3466" start="3448">3448-3466</pages><volume><style face="normal" font="default">13</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> Apoptosis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Back</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Body Weight</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> DNCB</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Histopathology</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Keratinocytes</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Oxidative Stress</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Republic of Korea</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> Spleen</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">In the present study, it was evaluated whether east saline groundwater concentration solution (ESGWc) exerted a favorable inhibitory effect on 2,4-dinitrochlorobenzene (DNCB)-induced allergic/atopic-like dermatitis (AD). AD was induced and boosted by sensitization with DNCB via topical application on the dorsal back skins. Mice with DNCB-induced AD were bathed in 100-, 200- and 400-fold diluted ESGWc. After 6 weeks bathing, changes to body weight, clinical skin severity scores, scratching behavior, serum total immunoglobulin (Ig)E levels, submandibular lymph node and spleen weights, splenic cytokine levels, skin cytokine mRNA expressions, antioxidant defense systems and superoxide anion productions were recorded to determine the effects of bathing on the histopathology of dorsal back skin tissues. All DNCB-induced mice demonstrated that the induction of AD through IgE-mediated hypersensitivities, oxidative stresses, activation of MMP and apoptosis of keratinocytes resulted in no significant differences in body weight between the different groups at each time point following initial sensitization. However, markers of DNCB-induced AD were significantly inhibited (P&lt;0.05) in a concentration-dependent manner following bathing in all concentrations of ESGWc. The results obtained in the present study suggest that bathing in ESGWc may have favorable protective effects against DNCB-induced AD due to favorable systemic and local immunomodulatory effects, active cytoprotective anti-apoptotic effects, inhibitory effects of matrix metalloproteinase activity, and anti-inflammatory and antioxidative effects</style></abstract><notes><style face="normal" font="default">DA - 20170607IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.3892/etm.2017.4397</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28587425">PM:28587425</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Exp Ther Med\2017-13-3448-66.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Exp Ther Med\2017-13-3448-66.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170607, Kim CG</style></custom2><misc3><style face="normal" font="default">10.3892/etm.2017.4397</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41895</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bai,Y.</style></author><author><style face="normal" font="default"> Duan,J.</style></author><author><style face="normal" font="default"> Wang,L.</style></author><author><style face="normal" font="default"> Bai,R.</style></author><author><style face="normal" font="default"> Lin,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China</style></auth-address><titles><title><style face="normal" font="default">Clinical analysis of the effect of anti-allergy treatment on pocket-related complications following pacemaker implantation</style></title><secondary-title><style face="normal" font="default">Exp Ther Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Exp Ther Med</style></abbr-1></periodical><pages end="2882" start="2876">2876-2882</pages><volume><style face="normal" font="default">13</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Hematoma</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> Promethazine</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">A total number of 339 patients who received a pacemaker implantation between June 2012 and June 2014 at Tongji Hospital of Tongji Medical College (Wuhan, China) were investigated in the present study. The aims of the present study were to explore the risk factors of pocket hematoma following pacemaker implantation, and to analyze the effect of anti-allergy treatment on pocket-related complications following pacemaker implantation. Predictors of hematoma occurrence were determined and analyzed via a Chi-square test. Patients suffering from pocket hematoma, which were indicated to be partially caused by an allergic reaction to the pacemaker component, were distinguished by routine blood parameters. Furthermore, the pacemaker component was distinguished by histopathological examinations in one patient. Promethazine (25 mg/day) was used to treat allergic patients. The results demonstrated that in patients with a history of allergies, the rate of pocket hematoma was significantly higher when compared with patients without a history of allergies (22.00 vs. 7.61%; P=0.027). A significantly increased incidence of hematoma was indicated in patients with a lower body mass index when compared with patients of normal weight (15.79 vs. 7.38%; P=0.042). Furthermore, implantation of larger-sized devices, such as an implantable cardioverter-defibrillator and cardiac resynchronization therapy, were significantly predictive of hematoma development (29.63 vs. 8.01%; P=0.015). Patients with diabetes were also identified to exhibit a significantly high incidence of hematoma (22.22 vs. 8.25%; P=0.023). Promethazine administration significantly decreased the incidence of re-operating (P=0.017) and the duration of hospital stay (P=0.038) in patients whose pocket hematoma was caused by an allergy. In conclusion, promethazine may be a beneficial agent to treat pocket hematoma caused by allergic reactions following pacemaker surgery</style></abstract><notes><style face="normal" font="default">DA - 20170607IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.3892/etm.2017.4366</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28587353">PM:28587353</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Exp Ther Med\2017-13-2876-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Exp Ther Med\2017-13-2876-82.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170607, Bai Y</style></custom2><misc3><style face="normal" font="default">10.3892/etm.2017.4366</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41896</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fernandez,T.D.</style></author><author><style face="normal" font="default"> Mayorga,C.</style></author><author><style face="normal" font="default"> Salas,M.</style></author><author><style face="normal" font="default"> Barrionuevo,E.</style></author><author><style face="normal" font="default"> Posadas,T.</style></author><author><style face="normal" font="default"> Ariza,A.</style></author><author><style face="normal" font="default"> Laguna,J.J.</style></author><author><style face="normal" font="default"> Moreno,E.</style></author><author><style face="normal" font="default"> Torres,M.J.</style></author><author><style face="normal" font="default"> Dona,I.</style></author><author><style face="normal" font="default"> Montanez,M.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">BIONAND , Malaga , Spain</style></auth-address><titles><title><style face="normal" font="default">Evolution of diagnostic approaches in betalactam hypersensitivity</style></title><secondary-title><style face="normal" font="default">Expert Rev Clin Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Expert Rev Clin Pharmacol</style></abbr-1></periodical><pages end="683" start="671">671-683</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> administration &amp; dosage</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Anti-Bacterial Agents</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Bacterial Infections</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophil activation test</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> beta-Lactams</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Betalactams</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug therapy</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Evolution</style></keyword><keyword><style face="normal" font="default"> Expert</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Haptens</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Immunoassay</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> In vitro tests</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Activation</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Transformation</style></keyword><keyword><style face="normal" font="default"> Lymphocyte transformation test</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nanotechnology</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Proteomics</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Transformation</style></keyword><keyword><style face="normal" font="default"> trends</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Betalactams are the most widely used drugs against infections and the primary cause of antibiotic hypersensitivity reactions. Reaction patterns for different betalactams have been changing in accordance with consumption trends, and vary among countries. As a consequence, in vivo and in vitro tests have had to change with to keep up with new tendencies. Areas covered: This review is focused on advances in betalactam hypersensitivity diagnosis. Changes in in vivo methods have been limited to the inclusion of new haptens. In contrast, major progress has been achieved for in vitro tests since the 1960s, from the first description of immunoassays, the basophil activation test and the lymphocyte transformation test, to the more sophisticated assays developed in last years. Expert commentary: Issues with diagnosis are related to test sensitivity. In vivo tests show higher sensitivity, however they can be risky, especially in severe and life-threatening reactions. Therefore, we believe that in vitro tests should be the preferred method. Current efforts are under way to enhance their sensitivity. Only multidisciplinary approaches involving immunology, proteomics, nanotechnology and chemistry can help us to fully understand conjugate structures and mechanisms involved in hypersensitivity reactions to betalactams, and consequently lead to advances in in vitro methods</style></abstract><notes><style face="normal" font="default">DA - 20170404IS - 1751-2441 (Electronic)IS - 1751-2433 (Linking)LA - engPT - Journal ArticlePT - ReviewRN - 0 (Anti-Bacterial Agents)RN - 0 (beta-Lactams)SB - IMCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1080/17512433.2017.1313110</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28375040">PM:28375040</url></web-urls></urls><custom2><style face="normal" font="default">20170404, Fernandez TD</style></custom2><misc3><style face="normal" font="default">10.1080/17512433.2017.1313110</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41897</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bock,C.N.</style></author><author><style face="normal" font="default"> Babu,S.</style></author><author><style face="normal" font="default"> Breloer,M.</style></author><author><style face="normal" font="default"> Rajamanickam,A.</style></author><author><style face="normal" font="default"> Boothra,Y.</style></author><author><style face="normal" font="default"> Brunn,M.L.</style></author><author><style face="normal" font="default"> Kuhl,A.A.</style></author><author><style face="normal" font="default"> Merle,R.</style></author><author><style face="normal" font="default"> Lohning,M.</style></author><author><style face="normal" font="default"> Hartmann,S.</style></author><author><style face="normal" font="default"> Rausch,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Veterinary Medicine, Institute of Immunology, Freie Universitat BerlinBerlin, Germany</style></auth-address><titles><title><style face="normal" font="default">Th2/1 Hybrid Cells Occurring in Murine and Human Strongyloidiasis Share Effector Functions of Th1 Cells</style></title><secondary-title><style face="normal" font="default">Front Cell Infect Microbiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Cell Infect Microbiol</style></abbr-1></periodical><pages end="" start="261">261-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> expansion</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Spleen</style></keyword><keyword><style face="normal" font="default"> Strongyloides stercoralis</style></keyword><keyword><style face="normal" font="default"> Strongyloidiasis</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> Th1 Cells</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> Th2 Cells</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> TH2 cytokines</style></keyword><keyword><style face="normal" font="default"> Th2 response</style></keyword><keyword><style face="normal" font="default"> Th2 responses</style></keyword><keyword><style face="normal" font="default"> veterinary</style></keyword><keyword><style face="normal" font="default"> Veterinary Medicine</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Infections by the soil-transmitted threadworm Strongyloides stercoralis affect 30-100 million people worldwide, predominantly in tropic and sub-tropic regions. Here we assessed the T helper cell phenotypes in threadworm-infected patients and experimental murine infections with focus on CD4+ T cells co-expressing markers of Th2 and Th1 differentiation. We show that mice infected with the close relative S. ratti generate strong Th2 responses characterized by the expansion of CD4+ GATA-3+ cells expressing IL-4/-5/-13 in blood, spleen, gut-draining lymph nodes, lung and gut tissue. In addition to conventional Th2 cells, significantly increased frequencies of GATA-3+T-bet+ Th2/1-hybrid cells were detected in all organs and co-expressed Th2- and Th1-cytokines at intermediate levels. Assessing the phenotype of blood-derived CD4+ T cells from South Indian patients infected with S. stercoralis and local uninfected control donors we found that GATA-3 expressing Th2 cells were significantly increased in the patient cohort, coinciding with elevated eosinophil and IgE/IgG4 levels. A fraction of IL-4+CD4+ T cells simultaneously expressed IFN-gamma hence displaying a Th2/1 hybrid phenotype. In accordance with murine Th2/1 cells, human Th2/1 cells expressed intermediate levels of Th2 cytokines. Contrasting their murine counterparts, human Th2/1 hybrids were marked by high levels of IFN-gamma and rather low GATA-3 expression. Assessing the effector function of murine Th2/1 cells in vitro we found that Th2/1 cells were qualified for driving the classical activation of macrophages. Furthermore, Th2/1 cells shared innate, cytokine-driven effector functions with Th1 cells. Hence, the key findings of our study are that T helper cells with combined characteristics of Th2 and Th1 cells are integral to immune responses of helminth-infected mice, but also occur in helminth-infected humans and we suggest that Th2/1 cells are poised for the instruction of balanced immune responses during nematode infections</style></abstract><notes><style face="normal" font="default">DA - 20170705IS - 2235-2988 (Electronic)IS - 2235-2988 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - India -</style></notes><work-type><style face="normal" font="default">10.3389/fcimb.2017.00261</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28676845">PM:28676845</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Cell Infect Microbiol\2017-7-261.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Cell Infect Microbiol\2017-7-261.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170705, Bock CN</style></custom2><misc3><style face="normal" font="default">10.3389/fcimb.2017.00261</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41898</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Montanez,M.I.</style></author><author><style face="normal" font="default"> Mayorga,C.</style></author><author><style face="normal" font="default"> Bogas,G.</style></author><author><style face="normal" font="default"> Barrionuevo,E.</style></author><author><style face="normal" font="default"> Fernandez-Santamaria,R.</style></author><author><style face="normal" font="default"> Martin-Serrano,A.</style></author><author><style face="normal" font="default"> Laguna,J.J.</style></author><author><style face="normal" font="default"> Torres,M.J.</style></author><author><style face="normal" font="default"> Fernandez,T.D.</style></author><author><style face="normal" font="default"> Dona,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Laboratory, IBIMA-Regional University Hospital of Malaga-UMA, Malaga, Spain</style></auth-address><titles><title><style face="normal" font="default">Epidemiology, Mechanisms, and Diagnosis of Drug-Induced Anaphylaxis</style></title><secondary-title><style face="normal" font="default">Front Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Immunol</style></abbr-1></periodical><pages end="" start="614">614-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Analgesics</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophil activation test</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> Cell Degranulation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> Complement</style></keyword><keyword><style face="normal" font="default"> Complement Activation</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> Drug-induced</style></keyword><keyword><style face="normal" font="default"> Drug-induced anaphylaxis</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Histamine Release</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE-dependent</style></keyword><keyword><style face="normal" font="default"> Igg</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Platelet Activating Factor</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Quantification</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> sIgE</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Specific IgE</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> Th2 Cells</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Anaphylaxis is an acute, life-threatening, multisystem syndrome resulting from the sudden release of mediators by mast cells and basophils. Although anaphylaxis is often under-communicated and thus underestimated, its incidence appears to have risen over recent decades. Drugs are among the most common triggers in adults, being analgesics and antibiotics the most common causal agents. Anaphylaxis can be caused by immunologic or non-immunologic mechanisms. Immunologic anaphylaxis can be mediated by IgE-dependent or -independent pathways. The former involves activation of Th2 cells and the cross-linking of two or more specific IgE (sIgE) antibodies on the surface of mast cells or basophils. The IgE-independent mechanism can be mediated by IgG, involving the release of platelet-activating factor, and/or complement activation. Non-immunological anaphylaxis can occur through the direct stimulation of mast cell degranulation by some drugs, inducing histamine release and leading to anaphylactic symptoms. Work-up of a suspected drug-induced anaphylaxis should include clinical history; however, this can be unreliable, and skin tests should also be used if available and validated. Drug provocation testing is not recommended due to the risk of inducing a harmful reaction. In vitro testing can help to confirm anaphylaxis by analyzing the release of mediators such as tryptase or histamine by mast cells. When immunologic mechanisms are suspected, serum-sIgE quantification or the use of the basophil activation test can help confirm the culprit drug. In this review, we will discuss multiple aspects of drug-induced anaphylaxis, including epidemiology, mechanisms, and diagnosis</style></abstract><notes><style face="normal" font="default">DA - 20170614IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="default">10.3389/fimmu.2017.00614</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28611774">PM:28611774</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Immunol\2017-8-614.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Immunol\2017-8-614.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170614, Montanez MI</style></custom2><misc3><style face="normal" font="default">10.3389/fimmu.2017.00614</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41899</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McBrien,C.N.</style></author><author><style face="normal" font="default"> Menzies-Gow,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Imperial College London, London, United KingdomRoyal Brompton and Harefield NHS Foundation Trust, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">The Biology of Eosinophils and Their Role in Asthma</style></title><secondary-title><style face="normal" font="default">Front Med (Lausanne)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Med (Lausanne)</style></abbr-1></periodical><pages end="" start="93">93-</pages><volume><style face="normal" font="default">4</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway remodeling</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> cationic protein</style></keyword><keyword><style face="normal" font="default"> cell surface molecules</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Chemokines</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Enzymes</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Granules</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> Mucus</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">This review will describe the structure and function of the eosinophil. The roles of several relevant cell surface molecules and receptors will be discussed. We will also explore the systemic and local processes triggering eosinophil differentiation, maturation, and migration to the lungs in asthma, as well as the cytokine-mediated pathways that result in eosinophil activation and degranulation, i.e., the release of multiple pro-inflammatory substances from eosinophil-specific granules, including cationic proteins, cytokines, chemokines growth factors, and enzymes. We will discuss the current understanding of the roles that eosinophils play in key asthma processes such as airway hyperresponsiveness, mucus hypersecretion, and airway remodeling, in addition to the evidence relating to eosinophil-pathogen interactions within the lungs</style></abstract><notes><style face="normal" font="default">DA - 20170717IS - 2296-858X (Print)IS - 2296-858X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.3389/fmed.2017.00093</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28713812">PM:28713812</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Med (Lausanne)\2017-4-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Med (Lausanne)\2017-4-93.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170717, McBrien CN</style></custom2><misc3><style face="normal" font="default">10.3389/fmed.2017.00093</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41900</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Turner,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Child Health, University of Aberdeen, Aberdeen, UK</style></auth-address><titles><title><style face="normal" font="default">Gene-Environment Interactions-What Can These Tell Us about the Relationship between Asthma and Allergy?</style></title><secondary-title><style face="normal" font="default">Front Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Pediatr</style></abbr-1></periodical><pages end="" start="118">118-</pages><volume><style face="normal" font="default">5</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Gene-Environment Interaction</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Hay Fever</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Asthma is a common condition, which is associated with atopy and allergic conditions including hay fever, eczema, and food allergies. Asthma and atopy are both complex conditions where genetic and environmental factors are implicated in causation. Interactions between genetic and environmental factors, likely via epigenetic mechanisms, are widely thought to be important in determining the risk for developing asthma and atopy. The nature of the relationship between asthma and atopy is unclear and the answer to the question "does atopy cause asthma?" remains unknown. This review explores the relationship between asthma and atopy from a gene-environment interaction perspective and tackles the question "are similar gene-environment interactions present for asthma and atopy?" The main finding is that gene-environment interactions are described for asthma and atopy in children but these interactions are seldom sought for both asthma and atopy in the same population. In the few instances where a gene-environment interaction is related to both asthma and atopy, there is no consistent evidence that similar interactions are common to asthma and atopy. Many plausible gene-environment interactions for asthma and atopy are yet to be explored. Overall, from the gene-environment interaction perspective, there is absence of evidence to better understand the complex relationship between asthma and atopy</style></abstract><notes><style face="normal" font="default">DA - 20170607IS - 2296-2360 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.3389/fped.2017.00118</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28589116">PM:28589116</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Pediatr\2017-5-118.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Pediatr\2017-5-118.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170607, Turner S</style></custom2><misc3><style face="normal" font="default">10.3389/fped.2017.00118</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41901</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martin-Orozco,E.</style></author><author><style face="normal" font="default"> Norte-Munoz,M.</style></author><author><style face="normal" font="default"> Martinez-Garcia,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biochemistry and Molecular Biology B and Immunology, School of Medicine, Murcia Biohealth Research Institute-University of Murcia (IMIB-UMU), Regional Campus of International Excellence "Campus Mare Nostrum", Murcia, Spain</style></auth-address><titles><title><style face="normal" font="default">Regulatory T Cells in Allergy and Asthma</style></title><secondary-title><style face="normal" font="default">Front Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Pediatr</style></abbr-1></periodical><pages end="" start="117">117-</pages><volume><style face="normal" font="default">5</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Biochemistry</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Embryo</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbes</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> Molecular Biology</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> regulatory T cell</style></keyword><keyword><style face="normal" font="default"> regulatory T cells</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> Tregs</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The immune system's correct functioning requires a sophisticated balance between responses to continuous microbial challenges and tolerance to harmless antigens, such as self-antigens, food antigens, commensal microbes, allergens, etc. When this equilibrium is altered, it can lead to inflammatory pathologies, tumor growth, autoimmune disorders, and allergy/asthma. The objective of this review is to show the existing data on the importance of regulatory T cells (Tregs) on this balance and to underline how intrauterine and postnatal environmental exposures influence the maturation of the immune system in humans. Genetic and environmental factors during embryo development and/or early life will result in a proper or, conversely, inadequate immune maturation with either beneficial or deleterious effects on health. We have focused herein on Tregs as a reflection of the maturity of the immune system. We explain the types, origins, and the mechanisms of action of these cells, discussing their role in allergy and asthma predisposition. Understanding the importance of Tregs in counteracting dysregulated immunity would provide approaches to diminish asthma and other related diseases in infants</style></abstract><notes><style face="normal" font="default">DA - 20170607IS - 2296-2360 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="default">10.3389/fped.2017.00117</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28589115">PM:28589115</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Pediatr\2017-5-117.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Pediatr\2017-5-117.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170607, Martin-Orozco E</style></custom2><misc3><style face="normal" font="default">10.3389/fped.2017.00117</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41902</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,Q.U.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Paediatrics and Adolescent Medicine, Princess Margaret Hospital, Laichikok, Hong Kong</style></auth-address><titles><title><style face="normal" font="default">Hypersensitivity to antipyretics: pathogenesis, diagnosis, and management</style></title><secondary-title><style face="normal" font="default">Hong Kong Med J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Hong Kong Med J</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Antipyretics</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophil activation</style></keyword><keyword><style face="normal" font="default"> Basophil activation test</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> Cofactors</style></keyword><keyword><style face="normal" font="default"> Commercial</style></keyword><keyword><style face="normal" font="default"> Cyclooxygenase 2</style></keyword><keyword><style face="normal" font="default"> Cyclooxygenase 2 Inhibitors</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> delayed reaction</style></keyword><keyword><style face="normal" font="default"> desensitisation</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug eruption</style></keyword><keyword><style face="normal" font="default"> Drug Eruptions</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> Drug provocation test</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Fixed drug eruption</style></keyword><keyword><style face="normal" font="default"> Gold</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hong Kong</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Transformation</style></keyword><keyword><style face="normal" font="default"> Lymphocyte transformation test</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> paediatrics</style></keyword><keyword><style face="normal" font="default"> Paracetamol</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Premedication</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Prostaglandin</style></keyword><keyword><style face="normal" font="default"> prostaglandin E2</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Sensitisation</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Stevens-Johnson syndrome/toxic epidermal necrolysis</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Transformation</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword></keywords><dates><year Day="7" Month="7" Year="2017">2017/7/7</year></dates><abstract><style face="normal" font="default">Antipyretics are commonly prescribed drugs and hypersensitivity occurs at rates of 0.01% to 0.3%. Hypersensitivity can be due to immune mechanisms that include type I to IV hypersensitivity. Type I hypersensitivity results from specific immunoglobulin E production following sensitisation on first exposure. Subsequent exposures elicit degranulation of mast cells, culminating an immediate reaction. Non-type I hypersensitivity is a delayed reaction that involves various effector cells, resulting in maculopapular rash, fixed drug eruptions, drug reaction with eosinophilia and systemic symptoms, and Stevens-Johnson syndrome/toxic epidermal necrolysis. Antipyretics also cause non-immune hypersensitivity via cyclooxygenase inhibition. Apart from hypersensitivity to parent compounds, hypersensitivity to excipient has been reported. Clinical manifestations of antipyretic hypersensitivity involve the skin, mucosa, or multiple organs. Diagnosis of hypersensitivity requires a detailed history taking and knowledge of any underlying disorders. Differential diagnoses include infection, inflammatory conditions, and antipyretics acting as co-factors of other allergens. Investigations include specific immunoglobulin E assays, lymphocyte transformation test, basophil activation test, and skin prick test. Lack of standardisation and a scarcity of available commercial reagents, however, limit the utility of these tests. A drug provocation test under close supervision remains the gold standard of diagnosis. A trial of the culprit drug or other structurally different antipyretics can be considered. Patients with confirmed hypersensitivity to antipyretics should consider either avoidance or desensitisation. Other theoretical options include subthreshold or low-dose paracetamol, cyclooxygenase-2 inhibitors, pre-medication with antihistamines with or without a leukotriene receptor antagonist, co-administration of prostaglandin E2 analogue, traditional Chinese medicine, or desensitisation if antipyretics are deemed desirable. Safety and efficacy of unconventional treatments warrant future studies</style></abstract><notes><style face="normal" font="default">DA - 20170707IS - 1024-2708 (Print)IS - 1024-2708 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Hong Kong -</style></notes><work-type><style face="normal" font="default">10.12809/hkmj166186</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28684647">PM:28684647</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Hong Kong Med J\20170707-LeeQU.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Hong Kong Med J\20170707-LeeQU.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170707, Lee QU</style></custom2><misc3><style face="normal" font="default">10.12809/hkmj166186</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41903</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Otsuka,A.</style></author><author><style face="normal" font="default"> Nomura,T.</style></author><author><style face="normal" font="default"> Rerknimitr,P.</style></author><author><style face="normal" font="default"> Seidel,J.A.</style></author><author><style face="normal" font="default"> Honda,T.</style></author><author><style face="normal" font="default"> Kabashima,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan</style></auth-address><titles><title><style face="normal" font="default">The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Immunol Rev</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immunol Rev</style></abbr-1></periodical><pages end="262" start="246">246-262</pages><volume><style face="normal" font="default">278</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Barrier dysfunction</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Filaggrin</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Keratinocytes</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> Skin barrier function</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> Targeted therapy</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> Th2 Cells</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> TH2 cytokines</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a chronic skin disorder characterized by pruritus and recurrent eczematous lesions that are accompanied by T-helper (Th)2-dominated inflammation. AD Etiology is not yet completely understood, but it is multifactorial. Moreover, the disease is characterized by complex interactions between genetic and environmental factors, such as skin barrier dysfunctions, allergy/immunity, and pruritus. For example, filaggrin is a key protein involved in skin barrier function. Th2 cells produce interleukin (IL)-31, which provokes pruritus, and other Th2 cytokines decrease filaggrin expression by keratinocytes. Dupilumab has recently been developed for AD treatment; its mechanism of action is to bind to IL-4 receptor alpha and inhibit downstream signaling induced by IL-4 and IL-13. This review summarizes the etiopathogenesis of AD and provides the rationale for selecting a novel targeted therapy</style></abstract><notes><style face="normal" font="default">DA - 20170628IS - 1600-065X (Electronic)IS - 0105-2896 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -CO - Thailand -CO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1111/imr.12545</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28658541">PM:28658541</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Rev\2017-278-246-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Rev\2017-278-246-62.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170628, Otsuka A</style></custom2><misc3><style face="normal" font="default">10.1111/imr.12545</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41904</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hansbro,P.M.</style></author><author><style face="normal" font="default"> Kim,R.Y.</style></author><author><style face="normal" font="default"> Starkey,M.R.</style></author><author><style face="normal" font="default"> Donovan,C.</style></author><author><style face="normal" font="default"> Dua,K.</style></author><author><style face="normal" font="default"> Mayall,J.R.</style></author><author><style face="normal" font="default"> Liu,G.</style></author><author><style face="normal" font="default"> Hansbro,N.G.</style></author><author><style face="normal" font="default"> Simpson,J.L.</style></author><author><style face="normal" font="default"> Wood,L.G.</style></author><author><style face="normal" font="default"> Hirota,J.A.</style></author><author><style face="normal" font="default"> Knight,D.A.</style></author><author><style face="normal" font="default"> Foster,P.S.</style></author><author><style face="normal" font="default"> Horvat,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute and The University of Newcastle, Newcastle, NSW, Australia</style></auth-address><titles><title><style face="normal" font="default">Mechanisms and treatments for severe, steroid-resistant allergic airway disease and asthma</style></title><secondary-title><style face="normal" font="default">Immunol Rev</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immunol Rev</style></abbr-1></periodical><pages end="62" start="41">41-62</pages><volume><style face="normal" font="default">278</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Endotypes</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> respiratory infection</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Severe, steroid-resistant asthma is clinically and economically important since affected individuals do not respond to mainstay corticosteroid treatments for asthma. Patients with this disease experience more frequent exacerbations of asthma, are more likely to be hospitalized, and have a poorer quality of life. Effective therapies are urgently required, however, their development has been hampered by a lack of understanding of the pathological processes that underpin disease. A major obstacle to understanding the processes that drive severe, steroid-resistant asthma is that the several endotypes of the disease have been described that are characterized by different inflammatory and immunological phenotypes. This heterogeneity makes pinpointing processes that drive disease difficult in humans. Clinical studies strongly associate specific respiratory infections with severe, steroid-resistant asthma. In this review, we discuss key findings from our studies where we describe the development of representative experimental models to improve our understanding of the links between infection and severe, steroid-resistant forms of this disease. We also discuss their use in elucidating the mechanisms, and their potential for developing effective therapeutic strategies, for severe, steroid-resistant asthma. Finally, we highlight how the immune mechanisms and therapeutic targets we have identified may be applicable to obesity-or pollution-associated asthma</style></abstract><notes><style face="normal" font="default">DA - 20170628IS - 1600-065X (Electronic)IS - 0105-2896 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1111/imr.12543</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28658552">PM:28658552</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Rev\2017-278-41-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Rev\2017-278-41-62.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170628, Hansbro PM</style></custom2><misc3><style face="normal" font="default">10.1111/imr.12543</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41905</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gelfand,E.W.</style></author><author><style face="normal" font="default"> Joetham,A.</style></author><author><style face="normal" font="default"> Wang,M.</style></author><author><style face="normal" font="default"> Takeda,K.</style></author><author><style face="normal" font="default"> Schedel,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Cell Biology, Department of Pediatrics, National Jewish Health, Denver, CO, USA</style></auth-address><titles><title><style face="normal" font="default">Spectrum of T-lymphocyte activities regulating allergic lung inflammation</style></title><secondary-title><style face="normal" font="default">Immunol Rev</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immunol Rev</style></abbr-1></periodical><pages end="86" start="63">63-86</pages><volume><style face="normal" font="default">278</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> adaptive</style></keyword><keyword><style face="normal" font="default"> Adaptive immunity</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Optimization</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T lymphocyte</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-lymphocyte</style></keyword><keyword><style face="normal" font="default"> Targeted therapy</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Despite advances in the treatment of asthma, optimization of symptom control remains an unmet need in many patients. These patients, labeled severe asthma, are responsible for a substantial fraction of the disease burden. In these patients, research is needed to define the cellular and molecular pathways contributing to disease which in large part are refractory to corticosteroid treatment. The causes of steroid-resistant asthma are multifactorial and result from complex interactions of genetics, environmental factors, and innate and adaptive immunity. Adaptive immunity, addressed here, integrates the activities of distinct T-cell subsets and by definition is dynamic and responsive to an ever-changing environment and the influences of epigenetic modifications. These T-cell subsets exhibit different susceptibilities to the actions of corticosteroids and, in some, corticosteroids enhance their functional activation. Moreover, these subsets are not fixed in lineage differentiation but can undergo transcriptional reprogramming in a bidirectional manner between protective and pathogenic effector states. Together, these factors contribute to asthma heterogeneity between patients but also in the same patient at different stages of their disease. Only by carefully defining mechanistic pathways, delineating their sensitivity to corticosteroids, and determining the balance between regulatory and effector pathways will precision medicine become a reality with selective and effective application of targeted therapies</style></abstract><notes><style face="normal" font="default">DA - 20170628IS - 1600-065X (Electronic)IS - 0105-2896 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/imr.12561</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28658551">PM:28658551</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Rev\2017-278-63-86.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Rev\2017-278-63-86.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170628, Gelfand EW</style></custom2><misc3><style face="normal" font="default">10.1111/imr.12561</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41906</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ealey,K.N.</style></author><author><style face="normal" font="default"> Moro,K.</style></author><author><style face="normal" font="default"> Koyasu,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory for Innate Immune Systems, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan</style></auth-address><titles><title><style face="normal" font="default">Are ILC2s Jekyll and Hyde in airway inflammation?</style></title><secondary-title><style face="normal" font="default">Immunol Rev</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immunol Rev</style></abbr-1></periodical><pages end="218" start="207">207-218</pages><volume><style face="normal" font="default">278</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adaptive</style></keyword><keyword><style face="normal" font="default"> Adaptive immunity</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway epithelial cell</style></keyword><keyword><style face="normal" font="default"> airway epithelial cells</style></keyword><keyword><style face="normal" font="default"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Helminths</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL-9</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> innate immune system</style></keyword><keyword><style face="normal" font="default"> Innate lymphoid cells</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Mucus</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> nonallergic asthma</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Repair</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> suppression</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral infection</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Asthma is a complex heterogeneous disease of the airways characterized by lung inflammation, airway hyperreactivity (AHR), mucus overproduction, and remodeling of the airways. Group 2 innate lymphoid cells (ILC2s) play a crucial role in the initiation and propagation of type 2 inflammatory programs in allergic asthma models, independent of adaptive immunity. In response to allergen, helminths or viral infection, damaged airway epithelial cells secrete IL-33, IL-25, and thymic stromal lymphopoietin (TSLP), which activate ILC2s to produce type 2 cytokines such as IL-5, IL-13, and IL-9. Furthermore, ILC2s coordinate a network of cellular responses and interact with numerous cell types to propagate the inflammatory response and repair lung damage. ILC2s display functional plasticity in distinct asthma phenotypes, enabling them to respond to very different immune microenvironments. Thus, in the context of non-allergic asthma, triggered by exposure to environmental factors, ILC2s transdifferentiate to ILC1-like cells and activate type 1 inflammatory programs in the lung. In this review, we summarize accumulating evidence on the heterogeneity, plasticity, regulatory mechanisms, and pleiotropic roles of ILC2s in allergic inflammation as well as mechanisms for their suppression in the airways</style></abstract><notes><style face="normal" font="default">DA - 20170628IS - 1600-065X (Electronic)IS - 0105-2896 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/imr.12547</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28658554">PM:28658554</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Rev\2017-278-207-18.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Rev\2017-278-207-18.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170628, Ealey KN</style></custom2><misc3><style face="normal" font="default">10.1111/imr.12547</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41907</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tumes,D.J.</style></author><author><style face="normal" font="default"> Papadopoulos,M.</style></author><author><style face="normal" font="default"> Endo,Y.</style></author><author><style face="normal" font="default"> Onodera,A.</style></author><author><style face="normal" font="default"> Hirahara,K.</style></author><author><style face="normal" font="default"> Nakayama,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan</style></auth-address><titles><title><style face="normal" font="default">Epigenetic regulation of T-helper cell differentiation, memory, and plasticity in allergic asthma</style></title><secondary-title><style face="normal" font="default">Immunol Rev</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immunol Rev</style></abbr-1></periodical><pages end="19" start="8">8-19</pages><volume><style face="normal" font="default">278</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway remodeling</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> allergen-specific</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cell Differentiation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-17</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL-9</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> Methylation</style></keyword><keyword><style face="normal" font="default"> Mucus</style></keyword><keyword><style face="normal" font="default"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="default"> persistence</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH17</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> transcription factor</style></keyword><keyword><style face="normal" font="default"> Transcription Factors</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">An estimated 300 million people currently suffer from asthma, which causes approximately 250 000 deaths a year. Allergen-specific T-helper (Th) cells produce cytokines that induce many of the hallmark features of asthma including airways hyperreactivity, eosinophilic and neutrophilic inflammation, mucus hypersecretion, and airway remodeling. Cytokine-producing Th subsets including Th1 (IFN-gamma), Th2 (IL-4, IL-5, IL-13), Th9 (IL-9), Th17 (IL-17), Th22 (IL-22), and T regulatory (IL-10) cells have all been suggested to play a role in the development of asthma. Th differentiation involves genetic regulation of gene expression through the concerted action of cytokines, transcription factors, and epigenetic regulators. We describe how Th differentiation and plasticity is regulated by epigenetic histone and DNA modifications, with a focus on the regulation of histone methylation by members of the polycomb and trithorax complexes. In addition, we outline environmental influences that could influence epigenetic regulation of Th cells and discuss the potential to regulate Th plasticity and function through drugs targeting the epigenetic machinery. It is also becoming apparent that epigenetic regulation of allergen-specific memory Th cells may be important in the development and persistence of chronic allergies. Finally, we describe how epigenetic modifiers regulate cytokine memory in Th cells and describe recently identified hybrid, plastic, and pathogenic memory Th subsets the context of allergic asthma</style></abstract><notes><style face="normal" font="default">DA - 20170628IS - 1600-065X (Electronic)IS - 0105-2896 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/imr.12560</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28658556">PM:28658556</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Rev\2017-278-8-19.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Rev\2017-278-8-19.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170628, Turnes DJ</style></custom2><misc3><style face="normal" font="default">10.1111/imr.12560</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41908</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Xu,M.</style></author><author><style face="normal" font="default"> Dong,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute for Immunology and School of Medicine, Tsinghua University, Beijing, ChinaInstitute for Immunology and School of Medicine, Tsinghua University, Beijing, China</style></auth-address><titles><title><style face="normal" font="default">IL-25 in allergic inflammation</style></title><secondary-title><style face="normal" font="default">Immunol Rev</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immunol Rev</style></abbr-1></periodical><pages end="191" start="185">185-191</pages><volume><style face="normal" font="default">278</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Beijing</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> IL-17</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">IL-25, also known as IL-17E, is a member of the IL-17 cytokine family mostly produced by epithelial cells and innate immune cells. After binding to the IL-17RB/IL-17RA complex, IL-25 induces downstream signaling responses in epithelial cells and type 2 lymphocytes, which initiates, propagates, and sustains type 2 immunity. The function of IL-25 in allergic diseases such as asthma has been well established, and now also is extended to diseases such as inflammatory bowel disease and cancer. This review summarizes the literature on IL-25 and discusses the unsolved questions. Our knowledge on IL-25 will pave the pathway for targeting this cytokine in inflammatory diseases</style></abstract><notes><style face="normal" font="default">DA - 20170628IS - 1600-065X (Electronic)IS - 0105-2896 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - China -</style></notes><work-type><style face="normal" font="default">10.1111/imr.12558</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28658555">PM:28658555</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Rev\2017-278-185-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Rev\2017-278-185-91.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170628, Xu M</style></custom2><misc3><style face="normal" font="default">10.1111/imr.12558</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41909</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kimura,M.Y.</style></author><author><style face="normal" font="default"> Hayashizaki,K.</style></author><author><style face="normal" font="default"> Tokoyoda,K.</style></author><author><style face="normal" font="default"> Takamura,S.</style></author><author><style face="normal" font="default"> Motohashi,S.</style></author><author><style face="normal" font="default"> Nakayama,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan</style></auth-address><titles><title><style face="normal" font="default">Crucial role for CD69 in allergic inflammatory responses: CD69-Myl9 system in the pathogenesis of airway inflammation</style></title><secondary-title><style face="normal" font="default">Immunol Rev</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immunol Rev</style></abbr-1></periodical><pages end="100" start="87">87-100</pages><volume><style face="normal" font="default">278</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> disease models</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Ligands</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">CD69 has been known as an early activation marker of lymphocytes; whereas, recent studies demonstrate that CD69 also has critical functions in immune responses. Early studies using human samples revealed the involvement of CD69 in various inflammatory diseases including asthma. Moreover, murine disease models using Cd69-/- mice and/or anti-CD69 antibody (Ab) treatment have revealed crucial roles for CD69 in inflammatory responses. However, it had not been clear how the CD69 molecule contributes to the pathogenesis of inflammatory diseases. We recently elucidated a novel mechanism, in which the interaction between CD69 and its ligands, myosin light chain 9, 12a and 12b (Myl9/12) play a critical role in the recruitment of activated T cells into the inflammatory lung. In this review, we first summarize CD69 function based on its structure and then introduce the evidence for the involvement of CD69 in human diseases and murine disease models. Then, we will describe how we discovered CD69 ligands, Myl9 and Myl12, and how the CD69-Myl9 system regulates airway inflammation. Finally, we will discuss possible therapeutic usages of the blocking Ab to the CD69-Myl9 system</style></abstract><notes><style face="normal" font="default">DA - 20170628IS - 1600-065X (Electronic)IS - 0105-2896 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/imr.12559</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28658550">PM:28658550</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Rev\2017-278-87-100.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Rev\2017-278-87-100.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170628, Kimura MY</style></custom2><misc3><style face="normal" font="default">10.1111/imr.12559</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41910</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hirose,K.</style></author><author><style face="normal" font="default"> Iwata,A.</style></author><author><style face="normal" font="default"> Tamachi,T.</style></author><author><style face="normal" font="default"> Nakajima,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan</style></auth-address><titles><title><style face="normal" font="default">Allergic airway inflammation: key players beyond the Th2 cell pathway</style></title><secondary-title><style face="normal" font="default">Immunol Rev</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immunol Rev</style></abbr-1></periodical><pages end="161" start="145">145-161</pages><volume><style face="normal" font="default">278</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Airway Obstruction</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-17A</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mucus</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> Th2 Cells</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> TH2 cytokines</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Allergic asthma is characterized by eosinophilic airway inflammation, mucus hyperproduction, and airway hyperreactivity, causing reversible airway obstruction. Accumulating evidence indicates that antigen-specific Th2 cells and their cytokines such as IL-4, IL-5, and IL-13 orchestrate these pathognomonic features of asthma. However, over the past decade, the understanding of asthma pathogenesis has made a significant shift from a Th2 cell-dependent, IgE-mediated disease to a more complicated heterogeneous disease. Recent studies clearly show that not only Th2 cytokines but also other T cell-related cytokines such as IL-17A and IL-22 as well as epithelial cell cytokines such as IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) are involved in the pathogenesis of asthma. In this review, we focus on the roles of these players beyond Th2 pathways in the pathogenesis of asthma</style></abstract><notes><style face="normal" font="default">DA - 20170628IS - 1600-065X (Electronic)IS - 0105-2896 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/imr.12540</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28658544">PM:28658544</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Rev\2017-278-145-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Rev\2017-278-145-61.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170628, Hirose K</style></custom2><misc3><style face="normal" font="default">10.1111/imr.12540</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41911</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McKenzie,C.</style></author><author><style face="normal" font="default"> Tan,J.</style></author><author><style face="normal" font="default"> Macia,L.</style></author><author><style face="normal" font="default"> Mackay,C.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Infection and Immunity Program, Department of Biochemistry, Biomedicine Discovery Institute, Monash University, Clayton, Vic., Australia</style></auth-address><titles><title><style face="normal" font="default">The nutrition-gut microbiome-physiology axis and allergic diseases</style></title><secondary-title><style face="normal" font="default">Immunol Rev</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immunol Rev</style></abbr-1></periodical><pages end="295" start="277">277-295</pages><volume><style face="normal" font="default">278</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acids</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> Biochemistry</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Biomedicine</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> DC</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Enzymes</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Fatty acid</style></keyword><keyword><style face="normal" font="default"> Fatty Acids</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> histone deacetylase</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Iga</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Lifestyle</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Prebiotics</style></keyword><keyword><style face="normal" font="default"> Probiotics</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Dietary and bacterial metabolites influence immune responses. This raises the question whether the increased incidence of allergies, asthma, some autoimmune diseases, cardiovascular disease, and others might relate to intake of unhealthy foods, and the decreased intake of dietary fiber. In recent years, new knowledge on the molecular mechanisms underpinning a 'diet-gut microbiota-physiology axis' has emerged to substantiate this idea. Fiber is fermented to short chain fatty acids (SCFAs), particularly acetate, butyrate, and propionate. These metabolites bind 'metabolite-sensing' G-protein-coupled receptors such as GPR43, GPR41, and GPR109A. These receptors play fundamental roles in the promotion of gut homeostasis and the regulation of inflammatory responses. For instance, these receptors and their metabolites influence Treg biology, epithelial integrity, gut homeostasis, DC biology, and IgA antibody responses. The SCFAs also influence gene transcription in many cells and tissues, through their inhibition of histone deacetylase expression or function. Contained in this mix is the gut microbiome, as commensal bacteria in the gut have the necessary enzymes to digest dietary fiber to SCFAs, and dysbiosis in the gut may affect the production of SCFAs and their distribution to tissues throughout the body. SCFAs can epigenetically modify DNA, and so may be one mechanism to account for diseases with a 'developmental origin', whereby in utero or post-natal exposure to environmental factors (such as nutrition of the mother) may account for disease later in life. If the nutrition-gut microbiome-physiology axis does underpin at least some of the Western lifestyle influence on asthma and allergies, then there is tremendous scope to correct this with healthy foodstuffs, probiotics, and prebiotics</style></abstract><notes><style face="normal" font="default">DA - 20170628IS - 1600-065X (Electronic)IS - 0105-2896 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/imr.12556</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28658542">PM:28658542</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Rev\2017-278-277-95.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Rev\2017-278-277-95.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170628, McKenzie C</style></custom2><misc3><style face="normal" font="default">10.1111/imr.12556</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41912</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lloyd,C.M.</style></author><author><style face="normal" font="default"> Saglani,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Inflammation, Repair &amp; Development Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College, London, UK</style></auth-address><titles><title><style face="normal" font="default">Development of allergic immunity in early life</style></title><secondary-title><style face="normal" font="default">Immunol Rev</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immunol Rev</style></abbr-1></periodical><pages end="115" start="101">101-115</pages><volume><style face="normal" font="default">278</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> dysregulation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Repair</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">The growth and maturity of the peripheral immune system and subsequent development of pulmonary immunity in early life is dictated by host, environmental and microbial factors. Dysregulation during the critical window of immune development in the postnatal years results in disease which impacts on lifelong lung health. Asthma is a common disease in childhood and is often preceded by wheezing illnesses during the preschool years. However, the mechanisms underlying development of wheeze and how and why only some children progress to asthma is unknown. Human studies to date have generally focused on peripheral immune development, with little assessment of local tissue pathology in young children. Moreover, mechanisms underlying the interactions between inflammation and tissue repair at mucosal surfaces in early life remain unknown. Disappointingly, mechanistic studies in mice have predominantly used adult models. This review will consider the aspects of the neonatal immune system which might contribute to the development of early life wheezing disorders and asthma, and discuss the external environmental factors which may influence this process</style></abstract><notes><style face="normal" font="default">DA - 20170628IS - 1600-065X (Electronic)IS - 0105-2896 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1111/imr.12562</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28658545">PM:28658545</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Rev\2017-278-101-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Rev\2017-278-101-15.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170628, Lloyd CM</style></custom2><misc3><style face="normal" font="default">10.1111/imr.12562</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41913</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zundler,S.</style></author><author><style face="normal" font="default"> Neurath,M.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine 1, University of Erlangen-Nuremberg, Kussmaul Campus for Medical Research &amp; Translational Research Center, Erlangen, Germany</style></auth-address><titles><title><style face="normal" font="default">Pathogenic T cell subsets in allergic and chronic inflammatory bowel disorders</style></title><secondary-title><style face="normal" font="default">Immunol Rev</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immunol Rev</style></abbr-1></periodical><pages end="276" start="263">263-276</pages><volume><style face="normal" font="default">278</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> Apoptosis</style></keyword><keyword><style face="normal" font="default"> Celiac Disease</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> priming</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Targeted therapy</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Homeostasis in the gastrointestinal tract relies on a sensitive equilibrium between permissive and protective functions. This is closely reflected in the regulation of the intestinal immune system and especially T cells in the gut. This balance, however, is susceptible to disturbances as demonstrated by pathological conditions like food allergy, celiac disease, or inflammatory bowel disease. In these allergic and chronic inflammatory bowel disorders, luminal antigens get access to the lamina propria where they trigger a dysregulated immune response with crucial involvement of different T cell subsets. We will begin this review with some comprehensive remarks on current concepts on the pathogenesis of these diseases before taking a closer look at the life cycle of intestinal T cells consisting of priming, homing, differentiation and proliferation and apoptosis respectively. Subsequently we will discuss the specific implication of distinct T cell subsets in allergic and chronic inflammatory conditions of the gastrointestinal tract in detail and comment on current and future approaches to targeted therapy in this context</style></abstract><notes><style face="normal" font="default">DA - 20170628IS - 1600-065X (Electronic)IS - 0105-2896 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/imr.12544</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28658546">PM:28658546</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Rev\2017-278-263-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Rev\2017-278-263-76.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170628, Zundler S</style></custom2><misc3><style face="normal" font="default">10.1111/imr.12544</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41914</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gandhi,R.</style></author><author><style face="normal" font="default"> Sharma,B.</style></author><author><style face="normal" font="default"> Sood,J.</style></author><author><style face="normal" font="default"> Sehgal,R.</style></author><author><style face="normal" font="default"> Chugh,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anaesthesia and Intensive Care, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India</style></auth-address><titles><title><style face="normal" font="default">Anaphylaxis during anaesthesia: Indian scenario</style></title><secondary-title><style face="normal" font="default">Indian J Anaesth</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Indian J Anaesth</style></abbr-1></periodical><pages end="392" start="387">387-392</pages><volume><style face="normal" font="default">61</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaesthesia</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Blood Transfusion</style></keyword><keyword><style face="normal" font="default"> Colloids</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Developed Countries</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Muscle relaxants</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">BACKGROUND AND AIMS: Anaphylaxis during anaesthesia is a rare but serious problem. In contrast to the developed countries where databases of perianaesthetic anaphylaxis are preserved, none exist in India. We conducted a survey amongst Indian anaesthesiologists to study the incidence and aetiology of anaphylaxis during anaesthesia in India. METHODS: A written questionnaire comprising 20 items was mailed electronically or distributed personally to 600 randomly selected Indian anaesthesiologists. The responses were compiled and analysed. RESULTS: We received responses from 242 anaesthesiologists. One hundred and sixty-two (67%) anaesthesiologists had encountered anaphylaxis during anaesthesia. Anaesthetic drugs led to 40% of reactions, and 60% of reactions were attributed to non-anaesthetic drugs. Opioids were the most common anaesthetic drugs implicated in anaphylaxis during anaesthesia, and non-depolarising muscle relaxants were the second most commonly implicated agents. Colloids, antibiotics and blood transfusion were the common non-anaesthetic agents thought to be responsible for anaphylactic reactions during anaesthesia. There were five deaths due to anaphylaxis during anaesthesia. Only 10% of anaesthesiologists ordered for allergy testing subsequently though 38% of anaesthesiologists had access to allergy testing facilities. CONCLUSIONS: Our survey reveals that two-thirds of participating Indian anaesthesiologists had witnessed anaphylaxis during anaesthesia. Commonly implicated anaesthetic drugs were opioids and non-depolarising muscle relaxants while colloids, antibiotics and blood transfusion were the common non-anaesthetic agents causing anaphylactic reactions during anaesthesia. Further, our survey reveals low utilisation and paucity of referral allergy centres to investigate suspected cases of anaphylaxis during anaesthesia</style></abstract><notes><style face="normal" font="default">DA - 20170606IS - 0019-5049 (Print)IS - 0019-5049 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/ija.IJA_80_17</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28584347">PM:28584347</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Anaesth\2017-61-387-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Anaesth\2017-61-387-92.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170606, Gandhi R</style></custom2><misc3><style face="normal" font="default">10.4103/ija.IJA_80_17</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41915</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Raut,M.S.</style></author><author><style face="normal" font="default"> Kar,S.</style></author><author><style face="normal" font="default"> Maheshwari,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Cardiac Anesthesia, Sir Ganga Ram Hospital, New Delhi, India</style></auth-address><titles><title><style face="normal" font="default">Awareness of Allergic Angina Syndrome</style></title><secondary-title><style face="normal" font="default">Indian J Crit Care Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Indian J Crit Care Med</style></abbr-1></periodical><pages end="413" start="412">412-413</pages><volume><style face="normal" font="default">21</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Anesthesia</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170713IS - 0972-5229 (Print)IS - 0972-5229 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/ijccm.IJCCM_58_17</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28701851">PM:28701851</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Crit Care Med\2017-21-412-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Crit Care Med\2017-21-412-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170713, Raut MS</style></custom2><misc3><style face="normal" font="default">10.4103/ijccm.IJCCM_58_17</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41916</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sarkar,T.K.</style></author><author><style face="normal" font="default"> Sil,A.</style></author><author><style face="normal" font="default"> Pal,S.</style></author><author><style face="normal" font="default"> Ghosh,C.</style></author><author><style face="normal" font="default"> Das,N.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Medical College and Hospital, Kolkata, West Bengal, India</style></auth-address><titles><title><style face="normal" font="default">Effectiveness and safety of levocetirizine 10 mg versus a combination of levocetirizine 5 mg and montelukast 10 mg in chronic urticaria resistant to levocetirizine 5 mg: A double-blind, randomized, controlled trial</style></title><secondary-title><style face="normal" font="default">Indian J Dermatol Venereol Leprol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Indian J Dermatol Venereol Leprol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> montelukast</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Sedation</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="27" Month="6" Year="2017">2017/6/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic urticaria is a vexing problem for patients and treating physicians alike. The EAACI/GA2LEN/EDF/WAO guidelines advocate an increased antihistamine dosage up to four times the standard, before adding leukotriene receptor antagonists. Patients are frequently intolerant of these higher dosages. We conducted this study to determine whether the addition of leukotriene receptor antagonists to the standard antihistamine dose was comparable to higher dosages of antihistamines alone, in terms of efficacy, safety and quality of life changes. We compared levocetirizine 10 mg (double dose of standard) versus a combination of levocetirizine 5 mg and montelukast 10 mg in cases of chronic urticaria not responding to single daily dose of 5 mg levocetirizine. METHODS: A single-center, double-blind, randomized, active-controlled, parallel group phase IV trial (CTRI/2014/12/005261) was conducted on 120 patients of chronic urticaria of either sex not responding to 5 mg levocetirizine. Patients were randomized into receiving either levocetirizine 10 mg or levocetirizine 5 mg + montelukast 10 mg for 4 weeks. Primary outcome measures were Urticaria Activity Score (UAS) and Urticaria Total Severity Score (TSS). Routine hematological and biochemical tests and treatment-emergent adverse events were monitored for safety. RESULTS: Fifty-two patients on levocetirizine 10 mg group and 51 patients on levocetirizine 5 mg + montelukast 10 mg group were analyzed. UAS and TSS reduced significantly in both treatment groups and reduction of score were comparable in between the groups (P = 0.628, P = 0.824, respectively). Among adverse effects, sedation was noted significantly more (P = 0.013) in levocetirizine 10 mg group. Quality of life was significantly improved in levocetirizine 5 mg + montelukast 10 mg group (P = 0.031). LIMITATIONS: The limitation of the study was that the follow-up period was 4 weeks. CONCLUSION: EAACI/GA2LEN/EDF/WAO guidelines need to be more flexible in allowing usage of montelukast before escalation of anti-histamine dosage</style></abstract><notes><style face="normal" font="default">DA - 20170628IS - 0973-3922 (Electronic)IS - 0378-6323 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/ijdvl.IJDVL_551_16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28656910">PM:28656910</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Dermatol Venereol Leprol\20170628-SarkarTK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Dermatol Venereol Leprol\20170628-SarkarTK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170628, Sarkar TK</style></custom2><misc3><style face="normal" font="default">10.4103/ijdvl.IJDVL_551_16</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41917</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aygoren-Pursun,E.</style></author><author><style face="normal" font="default"> Soteres,D.</style></author><author><style face="normal" font="default"> Moldovan,D.</style></author><author><style face="normal" font="default"> Christensen,J.</style></author><author><style face="normal" font="default"> Van Leerberghe,A.</style></author><author><style face="normal" font="default"> Hao,J.</style></author><author><style face="normal" font="default"> Schranz,J.</style></author><author><style face="normal" font="default"> Jacobson,K.W.</style></author><author><style face="normal" font="default"> Martinez-Saguer,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department for Children and Adolescents, Angioedema Centre, University Hospital Frankfurt, Goethe University, Frankfurt, Germany</style></auth-address><titles><title><style face="normal" font="default">Preventing Hereditary Angioedema Attacks in Children Using Cinryze(R): Interim Efficacy and Safety Phase 3 Findings</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="119" start="114">114-119</pages><volume><style face="normal" font="default">173</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> C1 INH</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-INH</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> C1Inh</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Romania</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> serious adverse events</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> subcutaneous</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="30" Month="6" Year="2017">2017/6/30</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hereditary angioedema (HAE) is a rare genetic disease causing unpredictable and potentially life-threatening subcutaneous and submucosal edematous attacks. Cinryze(R) (Shire ViroPharma Inc., Lexington, MA, USA), a nanofiltered C1 inhibitor (C1-INH), is approved in Europe for the treatment, preprocedure prevention, and routine prophylaxis of HAE attacks, and for the routine prophylaxis of attacks in the USA. This phase 3 study assessed the safety and efficacy of 2 C1-INH doses in preventing attacks in children aged 6-11 years. METHODS: A randomized single-blind crossover study was initiated in March 2014. Results for the first 6 patients completing the study are reported here. After a 12-week qualifying observation period, patients were randomly assigned to 1 of 2 C1-INH doses, 500 or 1,000 U, every 3-4 days for 12 weeks and crossed over to the alternative dose for a second 12-week period. The primary efficacy endpoint was the number of angioedema attacks per month. RESULTS: Six females with HAE type I and a median age of 10.5 years received 2 doses of C1-INH (500 and 1,000 U). The mean (SD) difference in the number of monthly angioedema attacks between the baseline observation period and the treatment period was -1.89 (1.31) with 500 U and -1.89 (1.11) with 1,000 U. During the treatment periods, cumulative attack severity, cumulative daily severity, and the number of attacks needing acute treatment were lower. No serious adverse events or study drug discontinuations occurred. CONCLUSIONS: Interim findings from this study indicate that routine prevention with intravenous administration of C1-INH is efficacious, safe, and well tolerated in children >/=6 years of age</style></abstract><notes><style face="normal" font="default">DA - 20170629IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Romania -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1159/000477541</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28662509">PM:28662509</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-114-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-114-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170629, Aygoren-Pursun E</style></custom2><misc3><style face="normal" font="default">10.1159/000477541</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41918</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Loo,E.X.L.</style></author><author><style face="normal" font="default"> Ong,L.</style></author><author><style face="normal" font="default"> Goh,A.</style></author><author><style face="normal" font="default"> Chia,A.R.</style></author><author><style face="normal" font="default"> Teoh,O.H.</style></author><author><style face="normal" font="default"> Colega,M.T.</style></author><author><style face="normal" font="default"> Chan,Y.H.</style></author><author><style face="normal" font="default"> Saw,S.M.</style></author><author><style face="normal" font="default"> Kwek,K.</style></author><author><style face="normal" font="default"> Gluckman,P.D.</style></author><author><style face="normal" font="default"> Godfrey,K.M.</style></author><author><style face="normal" font="default"> Van Bever,H.</style></author><author><style face="normal" font="default"> Lee,B.W.</style></author><author><style face="normal" font="default"> Chong,Y.S.</style></author><author><style face="normal" font="default"> Chong,M.F.</style></author><author><style face="normal" font="default"> Shek,L.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Singapore Institute for Clinical Sciences (SICS), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore</style></auth-address><titles><title><style face="normal" font="default">Effect of Maternal Dietary Patterns during Pregnancy on Self-Reported Allergic Diseases in the First 3 Years of Life: Results from the GUSTO Study</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="113" start="105">105-113</pages><volume><style face="normal" font="default">173</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> allergen sensitization</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> Cheese</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Factor analysis</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergens</style></keyword><keyword><style face="normal" font="default"> Fruit</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune Tolerance</style></keyword><keyword><style face="normal" font="default"> Inhalant</style></keyword><keyword><style face="normal" font="default"> Meat</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Recall</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Seafood</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> skin prick testing</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> Vegetables</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="28" Month="6" Year="2017">2017/6/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: Maternal diet during pregnancy has been suggested to be an important early-life exposure that influences immune tolerance and the development of allergic diseases in offspring. METHODS: We examined the relationship between maternal dietary patterns assessed using 24-h recalls and food diaries at 26-28 weeks of pregnancy and the subsequent development of allergic outcomes in the offspring in the Growing Up in Singapore towards Healthy Outcomes (GUSTO) birth cohort. Exploratory factor analysis was used to characterize maternal dietary patterns during pregnancy. During repeated visits in the first 36 months of life, questionnaires were administered to ascertain allergic symptoms, namely, eczema, rhinitis, and wheeze. At ages 18 and 36 months, we administered skin-prick testing to inhalant and food allergens. RESULTS: Of the 3 maternal dietary patterns that emerged, the seafood and noodles pattern was associated with a reduced risk of developing allergen sensitization at both 18 months (odds ratio [95% confidence interval]: 0.7 [0.5-0.9]) and 36 months (0.7 [0.6-0.9]) after adjustment for a family history of allergy, and ethnicity, sex, and maternal education levels. No associations between the patterns vegetables, fruit, and white rice or pasta, cheese, and processed meat were observed with any of the allergic outcomes in the first 18 and 36 months of life. CONCLUSION: Maternal diet during pregnancy can influence the subsequent development of allergic outcomes in offspring</style></abstract><notes><style face="normal" font="default">DA - 20170627IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1159/000475497</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28654921">PM:28654921</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-105-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-105-13.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170627, Loo EX</style></custom2><misc3><style face="normal" font="default">10.1159/000475497</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41919</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cong,M.</style></author><author><style face="normal" font="default"> Wu,Z.</style></author><author><style face="normal" font="default"> Xu,X.</style></author><author><style face="normal" font="default"> Yin,J.</style></author><author><style face="normal" font="default"> Li,H.</style></author><author><style face="normal" font="default"> Zhuang,B.</style></author><author><style face="normal" font="default"> Wang,C.</style></author><author><style face="normal" font="default"> Zhao,X.</style></author></authors></contributors><auth-address><style face="normal" font="default">Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, 266003, ChinaInstitute of Materia Medica, Shandong Academy of Medical Sciences, Jinan Shandong, 250062, China; School of Medicine and Life Sciences, Shandong Academy of Medical SciencesUniversity of Jinan, JinanShandong, 250062China</style></auth-address><titles><title><style face="normal" font="default">Novel Oleyl Amine-modified Polymannuronic Acid Micelle Loading Tacrolimus for Therapy of Allergic Conjunctivitis</style></title><secondary-title><style face="normal" font="default">Int J Biol Macromol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Biol Macromol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AC</style></keyword><keyword><style face="normal" font="default"> adherence</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Conjunctivitis</style></keyword><keyword><style face="normal" font="default"> cytotoxicity</style></keyword><keyword><style face="normal" font="default"> Diffusion</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medication adherence</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> nuclear magnetic resonance</style></keyword><keyword><style face="normal" font="default"> Particle Size</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Tacrolimus</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="24" Month="6" Year="2017">2017/6/24</year></dates><abstract><style face="normal" font="default">Marine polysaccharide-based nanomaterial attracted considerable attention due to its biocompatibility and biodegradability. Here, a novel polymannuronic acid derivative (PM-C18) was synthesized as nanocarrier modified with hydrophobic oleyl amine. Its structure was confirmed by Fourier-transformed infrared spectrometry and nuclear magnetic resonance. To investigate its function, we developed tacrolimus (FK506) loaded nanoparticle by self-assembling PM-C18 and studied its drug loading, cytotoxicity and mechanism of in vitro release. Furthermore, we established a mouse model of allergic conjunctivitis (AC) to evaluate the efficacy of FK506 loaded PM-C18. The results indicated that PM-C18 carrier can encapsule FK506 with high drug loading (18%) and average particle size of 110.34+/-1.6nm. The release mechanism was diffusion initially followed a lasting release induced by swelling and collapse of PM-C18. One-week treatment with FK506 loaded PM-C18 efficiently relieved the symptoms of AC, which indicated it could serve as a potential ophthalmic drug for patients with AC. Compared with FK506 ophthalmic suspension, FK506 loaded PM-C18 improved medication adherence. Most importantly, we developed a novel versatile nanomaterial of PM-C18 which could encapsule other active agents for more applications</style></abstract><notes><style face="normal" font="default">DA - 20170628IS - 1879-0003 (Electronic)IS - 0141-8130 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.ijbiomac.2017.06.064</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28655660">PM:28655660</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Biol Macromol\20170628-CongM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Biol Macromol\20170628-CongM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170628, Cong M</style></custom2><misc3><style face="normal" font="default">10.1016/j.ijbiomac.2017.06.064</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41920</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">de Las Vecillas Sánchez,L.</style></author><author><style face="normal" font="default"> Alenazy,L.A.</style></author><author><style face="normal" font="default"> Garcia-Neuer,M.</style></author><author><style face="normal" font="default"> Castells,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Immunology and Allergy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</style></auth-address><titles><title><style face="normal" font="default">Drug Hypersensitivity and Desensitizations: Mechanisms and New Approaches</style></title><secondary-title><style face="normal" font="default">Int J Mol Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Mol Sci</style></abbr-1></periodical><pages end="" start="E1316">E1316-</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergenic</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cross reactivity</style></keyword><keyword><style face="normal" font="default"> Cross-reactivity</style></keyword><keyword><style face="normal" font="default"> Cystic Fibrosis</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease Management</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drug desensitization</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> Immunoglobuline E</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> late phase</style></keyword><keyword><style face="normal" font="default"> Late phase reaction</style></keyword><keyword><style face="normal" font="default"> late-phase</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> mediator release</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="20" Month="6" Year="2017">2017/6/20</year></dates><abstract><style face="normal" font="default">Drug hypersensitivity reactions (HSRs) are increasing in the 21st Century with the ever expanding availability of new therapeutic agents. Patients with cancer, chronic inflammatory diseases, cystic fibrosis, or diabetes can become allergic to their first line therapy after repeated exposures or through cross reactivity with environmental allergens. Avoidance of the offending allergenic drug may impact disease management, quality of life, and life expectancy. Precision medicine provides new tools for the understanding and management of hypersensitivity reactions (HSRs), as well as a personalized treatment approach for IgE (Immunoglobuline E) and non-IgE mediated HSRs with drug desensitization (DS). DS induces a temporary hyporesponsive state by incremental escalation of sub-optimal doses of the offending drug. In vitro models have shown evidence that IgE desensitization is an antigen-specific process which blocks calcium flux, impacts antigen/IgE/FcepsilonRI complex internalization and prevents the acute and late phase reactions as well as mast cell mediator release. Through a "bench to bedside" approach, in vitro desensitization models help elucidate the molecular pathways involved in DS, providing new insights to improved desensitization protocols for all patients. The aim of this review is to summarize up to date information on the drug HSRs, the IgE mediated mechanisms of desensitization, and their clinical applications</style></abstract><notes><style face="normal" font="default">DA - 20170620IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.3390/ijms18061316</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28632196">PM:28632196</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-E1316.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-E1316.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170620, de Las Vecillas Sánchez L</style></custom2><misc3><style face="normal" font="default">10.3390/ijms18061316</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41921</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Spoerl,D.</style></author><author><style face="normal" font="default"> Nigolian,H.</style></author><author><style face="normal" font="default"> Czarnetzki,C.</style></author><author><style face="normal" font="default"> Harr,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Clinical Immunology and Allergy, Department of Medical Specialties, University Hospital and Faculty of Medicine, University of Geneva, rue Gabrielle-Perret-Gentil 4, CH-1205 Geneva, Switzerland.</style></auth-address><titles><title><style face="normal" font="default">Reclassifying Anaphylaxis to Neuromuscular Blocking Agents Based on the Presumed Patho-Mechanism: IgE-Mediated, Pharmacological Adverse Reaction or "Innate Hypersensitivity"?</style></title><secondary-title><style face="normal" font="default">Int J Mol Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Mol Sci</style></abbr-1></periodical><pages end="" start="E1223">E1223-</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cell Degranulation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Hypotension</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE antibodies</style></keyword><keyword><style face="normal" font="default"> IgE antibody</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Neuromuscular blocking agent</style></keyword><keyword><style face="normal" font="default"> Neuromuscular Blocking Agents</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Perioperative anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="default">Approximately 60% of perioperative anaphylactic reactions are thought to be immunoglobulin IgE mediated, whereas 40% are thought to be non-IgE mediated hypersensitivity reactions (both considered non-dose-related type B adverse drug reactions). In both cases, symptoms are elicited by mast cell degranulation. Also, pharmacological reactions to drugs (type A, dose-related) may sometimes mimic symptoms triggered by mast cell degranulation. In case of hypotension, bronchospasm, or urticarial rash due to mast cell degranulation, identification of the responsible mechanism is complicated. However, determination of the type of the underlying adverse drug reaction is of paramount interest for the decision of whether the culprit drug may be re-administered. Neuromuscular blocking agents (NMBA) are among the most frequent cause of perioperative anaphylaxis. Recently, it has been shown that NMBA may activate mast cells independently from IgE antibodies via the human Mas-related G-protein-coupled receptor member X2 (MRGPRX2). In light of this new insight into the patho-mechanism of pseudo-allergic adverse drug reactions, in which as drug-receptor interaction results in anaphylaxis like symptoms, we critically reviewed the literature on NMBA-induced perioperative anaphylaxis. We challenge the dogma that NMBA mainly cause IgE-mediated anaphylaxis via an IgE-mediated mechanism, which is based on studies that consider positive skin test to be specific for IgE-mediated hypersensitivity. Finally, we discuss the question whether MRGPRX2 mediated pseudo-allergic reactions should be re-classified as type A adverse reactions</style></abstract><notes><style face="normal" font="default">DA - 20170607IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.3390/ijms18061223</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28590439">PM:28590439</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-E1223.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-E1223.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170607, Spoerl D</style></custom2><misc3><style face="normal" font="default">10.3390/ijms18061223</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41922</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mayorga,C.</style></author><author><style face="normal" font="default"> Dona,I.</style></author><author><style face="normal" font="default"> Perez-Inestrosa,E.</style></author><author><style face="normal" font="default"> Fernandez,T.D.</style></author><author><style face="normal" font="default"> Torres,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Laboratory-Allergy Unit, Biomedical Institute of Malaga-IBIMA, Regional University Hospital of Malaga-UMA, Malaga 29009, Spain.</style></auth-address><titles><title><style face="normal" font="default">The Value of In Vitro Tests to DiminishDrug Challenges</style></title><secondary-title><style face="normal" font="default">Int J Mol Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Mol Sci</style></abbr-1></periodical><pages end="" start="1222">1222-</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> In vitro tests</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patient Safety</style></keyword><keyword><style face="normal" font="default"> Predictive values</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe reactions</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="default">Drug hypersensitivity reactions have multiple implications for patient safety and health system costs, thus it is important to perform an accurate diagnosis. The diagnostic procedure includes a detailed clinical history, often unreliable; followed by skin tests, sometimes with low sensitivity or unavailable; and drug provocation testing, which is not risk-free for the patient, especially in severe reactions. In vitro tests could help to identify correctly the responsible agent, thus improving the diagnosis of these reactions, helping the physician to find safe alternatives, and reducing the need to perform drug provocation testing. However, it is necessary to confirm the sensitivity, specificity, negative and positive predictive values for these in vitro tests to enable their implementation in clinical practice. In this review, we have analyzed these parameters from different studies that have used in vitro test for evaluating drug hypersensitivity reactions and estimated the added value of these tests to the in vivo diagnosis</style></abstract><notes><style face="normal" font="default">DA - 20170607IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="default">10.3390/ijms18061222</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28590437">PM:28590437</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-1222.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-1222.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170607, Mayorga C</style></custom2><misc3><style face="normal" font="default">10.3390/ijms18061222</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41923</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Soyer,O.</style></author><author><style face="normal" font="default"> Sahiner,U.M.</style></author><author><style face="normal" font="default"> Sekerel,B.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric Allergy Ankara, School of Medicine, Hacettepe University, Ankara 06100, Turkey.</style></auth-address><titles><title><style face="normal" font="default">Pro and Contra: Provocation Tests in Drug Hypersensitivity</style></title><secondary-title><style face="normal" font="default">Int J Mol Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Mol Sci</style></abbr-1></periodical><pages end="" start="E1437">E1437-</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> Drug provocation test</style></keyword><keyword><style face="normal" font="default"> Efficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Interpretation</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="4" Month="7" Year="2017">2017/7/4</year></dates><abstract><style face="normal" font="default">Drug provocation test (DPT) is the controlled administration of a drug to diagnose immune- or non-immune-mediated drug hypersensitivity and the last step for accurate recognition of drug hypersensitivity reactions when the previous diagnostic evaluations are negative or unavailable. A DPT is performed only if other conventional tests fail to yield conclusive results. In each clinical presentation, "to provoke or not to provoke" a patient should be decided after careful assessment of the risk-benefit ratio. Well-defined benefits of DPT include confirmative exclusion of diagnoses of drug hypersensitivity and provision of safe alternatives. However, disadvantages such as safety, difficulty in interpretations of results, lack of objective biomarkers, risks of resensitization, efficiency in daily practice, and lack of standardized protocols, are poorly debated. This review summarizes the current published research concerning DPT, with particular emphasis on the advantages and disadvantages of DPT in an evidence-based manner</style></abstract><notes><style face="normal" font="default">DA - 20170705IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.3390/ijms18071437</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28677662">PM:28677662</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-E1437.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-E1437.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170705, Soyer O</style></custom2><misc3><style face="normal" font="default">10.3390/ijms18071437</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41924</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Matsubara,R.</style></author><author><style face="normal" font="default"> Kumagai,K.</style></author><author><style face="normal" font="default"> Shigematsu,H.</style></author><author><style face="normal" font="default"> Kitaura,K.</style></author><author><style face="normal" font="default"> Nakasone,Y.</style></author><author><style face="normal" font="default"> Suzuki,S.</style></author><author><style face="normal" font="default"> Hamada,Y.</style></author><author><style face="normal" font="default"> Suzuki,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Oral and Maxillofacial Surgery, School of Dental Medicine, Tsurumi University, 2-3-1 Tsurumi, Tsurumi-ku, Yokohama 230-8501, Japan.</style></auth-address><titles><title><style face="normal" font="default">Fexofenadine Suppresses Delayed-Type Hypersensitivity in the Murine Model of Palladium Allergy</style></title><secondary-title><style face="normal" font="default">Int J Mol Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Mol Sci</style></abbr-1></periodical><pages end="" start="E1357">E1357-</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antigen-presenting cell</style></keyword><keyword><style face="normal" font="default"> Antigen-Presenting Cells</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> delayed-type hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Dental Materials</style></keyword><keyword><style face="normal" font="default"> Dentistry</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fexofenadine</style></keyword><keyword><style face="normal" font="default"> Glucocorticoids</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metal allergies</style></keyword><keyword><style face="normal" font="default"> Metal allergy</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Palladium</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Prednisolone</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> suppression</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="25" Month="6" Year="2017">2017/6/25</year></dates><abstract><style face="normal" font="default">Palladium is frequently used in dental materials, and sometimes causes metal allergy. It has been suggested that the immune response by palladium-specific T cells may be responsible for the pathogenesis of delayed-type hypersensitivity in study of palladium allergic model mice. In the clinical setting, glucocorticoids and antihistamine drugs are commonly used for treatment of contact dermatitis. However, the precise mechanism of immune suppression in palladium allergy remains unknown. We investigated inhibition of the immune response in palladium allergic mice by administration of prednisolone as a glucocorticoid and fexofenadine hydrochloride as an antihistamine. Compared with glucocorticoids, fexofenadine hydrochloride significantly suppressed the number of T cells by interfering with the development of antigen-presenting cells from the sensitization phase. Our results suggest that antihistamine has a beneficial effect on the treatment of palladium allergy compared to glucocorticoids</style></abstract><notes><style face="normal" font="default">DA - 20170704IS - 1422-0067 (Electronic)IS - 1422-0067 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.3390/ijms18071357</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28672829">PM:28672829</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-E1357.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Mol Sci\2017-18-E1357.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170704, Matsubara R</style></custom2><misc3><style face="normal" font="default">10.3390/ijms18071357</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41925</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gutierrez-Cardona,N.</style></author><author><style face="normal" font="default"> Sands,P.</style></author><author><style face="normal" font="default"> Roberts,G.</style></author><author><style face="normal" font="default"> Lucas,J.S.</style></author><author><style face="normal" font="default"> Walker,W.</style></author><author><style face="normal" font="default"> Salib,R.</style></author><author><style face="normal" font="default"> Burgess,A.</style></author><author><style face="normal" font="default"> Ismail-Koch,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Medicine, University of Southampton, Building 85, Life Sciences Building, Highfield Campus, Southampton, SO171BJ, United Kingdom. Electronic address: nag1e14@southamptonalumni.ac.uk</style></auth-address><titles><title><style face="normal" font="default">The acceptability and tolerability of nasal douching in children with allergic rhinitis: A systematic review</style></title><secondary-title><style face="normal" font="default">Int J Pediatr Otorhinolaryngol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Pediatr Otorhinolaryngol</style></abbr-1></periodical><pages end="135" start="126">126-135</pages><volume><style face="normal" font="default">98</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergen avoidance</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immunotherapy</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Publications</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Solutions</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Tolerability</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic rhinitis (AR) is a significant issue in children. Treatment options include allergen avoidance, pharmacotherapy and immunotherapy. The use of nasal saline douching (NSD) in children has recently gained acceptability. However, there is limited data regarding the acceptability and tolerability of NSD in children with AR. METHODS: A search was conducted using Medline and Embase databases from January 1946 until June 2015 on the use of NSD in children aged 4-12 years with AR. All publications identified that assessed the beneficial effects, acceptability and tolerability were included. RESULTS: 40 studies were analyzed. Data varied considerably in terms of saline solutions used, modality of application, participant numbers, study design, follow up and outcomes. Factors that appear to influence the acceptability and tolerability of NSD include parental and health professionals' preconceptions, and characteristics of the solution. CONCLUSIONS: Nasal saline douching appears to be effective, being accepted and tolerated in the majority of children (78-100%). NSD has a significant positive impact on the quality of life in children with allergic rhinitis. When used as an adjunctive treatment having mainly a cleansing property, NSD potentiates the effects and may reduce the dose required of AR medications. Among the principal factors that influence the acceptability and tolerability of NSD are the child's age, delivery system and method, and tonicity. Nasal saline douching provides an accessible, low cost, low morbidity, easy to use treatment in children with allergic rhinitis</style></abstract><notes><style face="normal" font="default">DA - 20170606IS - 1872-8464 (Electronic)IS - 0165-5876 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.ijporl.2017.04.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583489">PM:28583489</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Pediatr Otorhinolaryngol\2017-98-126-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Pediatr Otorhinolaryngol\2017-98-126-35.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170606, Gutierrez-Cardona N</style></custom2><misc3><style face="normal" font="default">10.1016/j.ijporl.2017.04.040</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41926</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chopra,R.</style></author><author><style face="normal" font="default"> Vakharia,P.P.</style></author><author><style face="normal" font="default"> Sacotte,R.</style></author><author><style face="normal" font="default"> Patel,N.</style></author><author><style face="normal" font="default"> Immaneni,S.</style></author><author><style face="normal" font="default"> White,T.</style></author><author><style face="normal" font="default"> Kantor,R.</style></author><author><style face="normal" font="default"> Hsu,D.Y.</style></author><author><style face="normal" font="default"> Silverberg,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Feinberg School of Medicine at Northwestern University, Chicago, IL USA</style></auth-address><titles><title><style face="normal" font="default">Relationship between EASI and SCORAD severity assessments for atopic dermatitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Assessment</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="15" Month="6" Year="2017">2017/6/15</year></dates><abstract><style face="normal" font="default">The present study shows a complex relationship between EASI and SCORAD. The results provide support for inclusion of objective-SCORAD and/or SCORAD in addition to EASI in clinical trials</style></abstract><notes><style face="normal" font="default">DA - 20170619IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.052</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28625808">PM:28625808</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170619-ChopraR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170619-ChopraR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170619, Chopra R</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.052</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41927</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schleimer,R.P.</style></author><author><style face="normal" font="default"> Berdnikovs,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, Ill</style></auth-address><titles><title><style face="normal" font="default">Etiology of epithelial barrier dysfunction in patients with type 2 inflammatory diseases</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="1761" start="1752">1752-1761</pages><volume><style face="normal" font="default">139</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic sensitization</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Barrier dysfunction</style></keyword><keyword><style face="normal" font="default"> Barriers</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> Communication</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endocrine System</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="default"> Hormones</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Protease</style></keyword><keyword><style face="normal" font="default"> proteases</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">Epithelial barriers of the skin, gastrointestinal tract, and airway serve common critical functions, such as maintaining a physical barrier against environmental insults and allergens and providing a tissue interface balancing the communication between the internal and external environments. We now understand that in patients with allergic disease, regardless of tissue location, the homeostatic balance of the epithelial barrier is skewed toward loss of differentiation, reduced junctional integrity, and impaired innate defense. Importantly, epithelial dysfunction characterized by these traits appears to pre-date atopy and development of allergic disease. Despite our growing appreciation of the centrality of barrier dysfunction in initiation of allergic disease, many important questions remain to be answered regarding mechanisms disrupting normal barrier function. Although our external environment (proteases, allergens, and injury) is classically thought of as a principal contributor to barrier disruption associated with allergic sensitization, there is a need to better understand contributions of the internal environment (hormones, diet, and circadian clock). Systemic drivers of disease, such as alterations of the endocrine system, metabolism, and aberrant control of developmental signaling, are emerging as new players in driving epithelial dysfunction and allergic predisposition at various barrier sites. Identifying such central mediators of epithelial dysfunction using both systems biology tools and causality-driven laboratory experimentation will be essential in building new strategic interventions to prevent or reverse the process of barrier loss in allergic patients</style></abstract><notes><style face="normal" font="default">DA - 20170606IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583447">PM:28583447</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-1752-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-1752-61.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170606, Schleimer RP</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41928</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lugogo,N.</style></author><author><style face="normal" font="default"> Green,C.L.</style></author><author><style face="normal" font="default"> Agada,N.</style></author><author><style face="normal" font="default"> Zhang,S.</style></author><author><style face="normal" font="default"> Meghdadpour,S.</style></author><author><style face="normal" font="default"> Zhou,R.</style></author><author><style face="normal" font="default"> Yang,S.</style></author><author><style face="normal" font="default"> Anstrom,K.J.</style></author><author><style face="normal" font="default"> Israel,E.</style></author><author><style face="normal" font="default"> Martin,R.</style></author><author><style face="normal" font="default"> Lemanske,R.F.,Jr.</style></author><author><style face="normal" font="default"> Boushey,H.</style></author><author><style face="normal" font="default"> Lazarus,S.C.</style></author><author><style face="normal" font="default"> Wasserman,S.I.</style></author><author><style face="normal" font="default"> Castro,M.</style></author><author><style face="normal" font="default"> Calhoun,W.</style></author><author><style face="normal" font="default"> Peters,S.P.</style></author><author><style face="normal" font="default"> Dimango,E.</style></author><author><style face="normal" font="default"> Chinchilli,V.</style></author><author><style face="normal" font="default"> Icitovic,N.</style></author><author><style face="normal" font="default"> Kunselman,S.</style></author><author><style face="normal" font="default"> King,T.S.</style></author><author><style face="normal" font="default"> Kraft,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Duke University Medical Center, Durham, NC.</style></auth-address><titles><title><style face="normal" font="default">Obesity's Impact on Asthma Extends to Diagnostic Criteria</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> diagnostic criteria</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> sputum eosinophil</style></keyword><keyword><style face="normal" font="default"> Sputum eosinophilia</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="14" Month="6" Year="2017">2017/6/14</year></dates><abstract><style face="normal" font="default">BACKGROUND: The use of inflammatory biomarkers to delineate the type of lung inflammation present in asthma is increasingly common. However, the impact of obesity on these markers is unknown. OBJECTIVES: We aimed to determine the impact of obesity on conventional markers of inflammation in asthma. METHODS: We performed secondary analysis of data from 652 patients previously enrolled in two ACRN trials. We performed linear correlations between biomarkers and logistic regression analysis to determine the predictive value of IgE, blood eosinophils and FeNO in relationship to sputum eosinophils (>2%), as well as to determine if cut points existed that would maximize the sensitivity and specificity for predicting sputum eosinophilia in the three weight groups. RESULTS: Overall, statistically significant but relatively weak correlations were observed among all four markers of inflammation. Within obese subjects, the only significant correlation found was between IgE and blood eosinophils (r=0.33, p&lt;0.001); furthermore, all other correlations between inflammatory markers were approximately 0, including correlations with sputum eosinophils. In addition, the predictive value of each biomarker alone or in combination was poor in obese subjects. In fact in obese subjects, none of the inflammation biomarkers significantly predicted the presence of high sputum eosinophils. Obese asthma subjects have lower cut points for IgE, (268IU), FeNO (14.5ppb) and blood eosinophils (96 cells/ul) than all other groups. CONCLUSIONS: In obese asthma, conventional biomarkers of inflammation are poorly predictive of eosinophilic airway inflammation. As such, biomarkers currently used to delineate eosinophilic inflammation in asthma should be approached with caution in these patients</style></abstract><notes><style face="normal" font="default">DA - 20170618IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28624608">PM:28624608</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170618-LugogoN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170618-LugogoN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170618, Lugogo N</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.047</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41929</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Galli,S.J.</style></author><author><style face="normal" font="default"> Gaudenzio,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA; Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, CA 94305, USA</style></auth-address><titles><title><style face="normal" font="default">Human mast cells as antigen-presenting cells: when is this role important in vivo?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antigen-presenting cell</style></keyword><keyword><style face="normal" font="default"> Antigen-Presenting Cells</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human mast cells</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="14" Month="6" Year="2017">2017/6/14</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170618IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28624609">PM:28624609</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170618-GalliSJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170618-GalliSJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170618, Galli SJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41930</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lugogo,N.</style></author><author><style face="normal" font="default"> Francisco,D.</style></author><author><style face="normal" font="default"> Addison,K.J.</style></author><author><style face="normal" font="default"> Manne,A.</style></author><author><style face="normal" font="default"> Pederson,W.</style></author><author><style face="normal" font="default"> Ingram,J.L.</style></author><author><style face="normal" font="default"> Green,C.L.</style></author><author><style face="normal" font="default"> Suratt,B.T.</style></author><author><style face="normal" font="default"> Lee,J.J.</style></author><author><style face="normal" font="default"> Sunday,M.E.</style></author><author><style face="normal" font="default"> Kraft,M.</style></author><author><style face="normal" font="default"> Ledford,J.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Duke University Medical Center, Durham, NC</style></auth-address><titles><title><style face="normal" font="default">Obese Asthmatics Have Decreased Surfactant Protein-A Levels: Mechanisms and Implications</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic asthma</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> eotaxin</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Modeling</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> overweight</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> SP-A</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="14" Month="6" Year="2017">2017/6/14</year></dates><abstract><style face="normal" font="default">BACKGROUND: Eosinophils are prominent in some individuals with asthma and are elevated in the submucosa in a subgroup of obese asthmatics. Surfactant protein-A (SP-A) modulates host responses to infectious and environmental insults. OBJECTIVE: To determine if SP-A levels are altered in obese asthma patients compared to a control group and to determine the implications of these alterations in SP-A levels in asthma. METHODS: Bronchoalveolar lavage fluid from 23 lean, 12 overweight and 20 obese subjects were examined for SP-A. Mouse tracheal epithelial cells (MTECs) grown at an air-liquid interface were used for mechanistic studies. SP-A-/- mice were challenged in allergen models and exogenous SP-A therapy was given after the last challenge. Eosinophils were visualized and quantitated in the lung parenchyma by immunostaining. RESULTS: Significantly less SP-A (p=0.002) was detected in samples from obese asthmatics compared to the control group. A univariable regression model found SP-A was significantly negatively correlated with BMI (r= -0.33; p=0.014), while multivariable modeling demonstrated the correlation depended both on asthma status (p=0.017) and the interaction of asthma and BMI (p=0.008). Addition of exogenous TNF-alpha to MTECs was sufficient to attenuate SP-A and eotaxin secretion. Allergen challenged SP-A-/- mice that received SP-A therapy had significantly less tissue eosinophilia compared to mice receiving vehicle. CONCLUSIONS: SP-A functions as an important mediator in resolving tissue and lavage eosinophilia in allergic mouse models. Decreased levels of SP-A in obese asthmatics, which could be due to increased local TNF-alpha, may lead to impaired eosinophil resolution and could contribute to the eosinophilic asthma phenotype</style></abstract><notes><style face="normal" font="default">DA - 20170618IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28624607">PM:28624607</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170619-LugogoN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170619-LugogoN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170619, Lugogo N</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41931</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Frei,R.</style></author><author><style face="normal" font="default"> Ferstl,R.</style></author><author><style face="normal" font="default"> Roduit,C.</style></author><author><style face="normal" font="default"> Dipl-Ing,M.Z.</style></author><author><style face="normal" font="default"> Schiavi,E.</style></author><author><style face="normal" font="default"> Barcik,W.</style></author><author><style face="normal" font="default"> Rodriguez-Perez,N.</style></author><author><style face="normal" font="default"> Wirz,O.F.</style></author><author><style face="normal" font="default"> Wawrzyniak,M.</style></author><author><style face="normal" font="default"> Pugin,B.</style></author><author><style face="normal" font="default"> Nehrbass,D.</style></author><author><style face="normal" font="default"> Jutel,M.</style></author><author><style face="normal" font="default"> Smolinska,S.</style></author><author><style face="normal" font="default"> Konieczna,P.</style></author><author><style face="normal" font="default"> Bieli,C.</style></author><author><style face="normal" font="default"> Loeliger,S.</style></author><author><style face="normal" font="default"> Waser,M.</style></author><author><style face="normal" font="default"> Pershagen,G.</style></author><author><style face="normal" font="default"> Riedler,J.</style></author><author><style face="normal" font="default"> Depner,M.</style></author><author><style face="normal" font="default"> Schaub,B.</style></author><author><style face="normal" font="default"> Genuneit,J.</style></author><author><style face="normal" font="default"> Renz,H.</style></author><author><style face="normal" font="default"> Pekkanen,J.</style></author><author><style face="normal" font="default"> Karvonen,A.M.</style></author><author><style face="normal" font="default"> Dalphin,J.C.</style></author><author><style face="normal" font="default"> Van Hage,M.</style></author><author><style face="normal" font="default"> Doekes,G.</style></author><author><style face="normal" font="default"> Akdis,M.</style></author><author><style face="normal" font="default"> Braun-Fahrlander,C.</style></author><author><style face="normal" font="default"> Akdis,C.A.</style></author><author><style face="normal" font="default"> von Mutius,E.</style></author><author><style face="normal" font="default"> O'Mahony,L.</style></author><author><style face="normal" font="default"> Lauener,R.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Christine Kuhne - Center for Allergy Research and Education (CK-CARE), Davos, Switzerland; Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default">Exposure to non-microbial N-Glycolylneuraminic acid protects farmers' children against airway inflammation and colitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Austria</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Colitis</style></keyword><keyword><style face="normal" font="default"> Cord Blood</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> Foxp3</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Igg</style></keyword><keyword><style face="normal" font="default"> IL-17</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> microbes</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> regulatory T cell</style></keyword><keyword><style face="normal" font="default"> regulatory T cells</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="16" Month="6" Year="2017">2017/6/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Childhood exposure to a farm environment has been shown to protect against the development of inflammatory diseases such as allergy, asthma, and inflammatory bowel disease. OBJECTIVE: We sought to investigate whether besides exposure to microbes also exposure to structures of non-microbial origin such as the sialic acid N-Glycolylneuraminic acid (Neu5Gc) may play a significant role. METHODS: Exposure to Neu5Gc was evaluated by quantifying anti-Neu5Gc antibody levels in the sera of children enrolled in two farm studies: the PARSIFAL study (n=299) and the PASTURE birth cohort (cord blood (n=836), 1 year (n=734), 4.5 years (n=700) and 6 years (n=728)), and we associated them with asthma and wheeze. The effect of Neu5Gc was examined in murine airway inflammation and colitis models and the role of Neu5Gc in regulating immune activation was assessed by T helper cells and regulatory T cell activation in mice. RESULTS: In children, anti-Neu5Gc IgG levels positively correlated with living on a farm and increased peripheral blood Foxp3 expression and inversely correlated with wheezing and asthma in non-atopic subjects. Exposure to Neu5Gc in mice resulted in reduced airway hyperresponsiveness and inflammatory cell recruitment to the lung. Furthermore, Neu5Gc administration to mice reduced the severity of a colitis model. Mechanistically, we found that Neu5Gc exposure reduced IL-17 positive T cells and supported differentiation of regulatory T cells. CONCLUSIONS: In addition to microbial exposure, increased exposure to non-microbial-derived Neu5Gc may contribute to the protective effects associated with the farm environment</style></abstract><notes><style face="normal" font="default">DA - 20170620IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - Poland -CO - Sweden -CO - Austria -CO - Germany -CO - Finland -CO - France -CO - Netherland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.051</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28629745">PM:28629745</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170619-FreiR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170619-FreiR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170620, Frei R</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.051</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41932</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhou,Y.</style></author><author><style face="normal" font="default"> Do,D.C.</style></author><author><style face="normal" font="default"> Ishmael,F.T.</style></author><author><style face="normal" font="default"> Squadrito,M.L.</style></author><author><style face="normal" font="default"> Tang,H.M.</style></author><author><style face="normal" font="default"> Tang,H.L.</style></author><author><style face="normal" font="default"> Hsu,M.H.</style></author><author><style face="normal" font="default"> Qiu,L.</style></author><author><style face="normal" font="default"> Li,C.</style></author><author><style face="normal" font="default"> Zhang,Y.</style></author><author><style face="normal" font="default"> Becker,K.G.</style></author><author><style face="normal" font="default"> Wan,M.</style></author><author><style face="normal" font="default"> Huang,S.K.</style></author><author><style face="normal" font="default"> Gao,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Johns Hopkins Asthma &amp; Allergy Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA</style></auth-address><titles><title><style face="normal" font="default">Mannose Receptor Modulates Macrophage Polarization and Allergic Inflammation through miR-511-3p</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> allergen specific IgE</style></keyword><keyword><style face="normal" font="default"> allergen-specific</style></keyword><keyword><style face="normal" font="default"> allergen-specific IgE</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> allergic sensitization</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Baltimore</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Cockroach</style></keyword><keyword><style face="normal" font="default"> Cockroaches</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> differentially expressed gene</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> gene profiling</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> Maryland</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="6" Year="2017">2017/6/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Mannose receptor (MRC1/CD206) has been suggested to mediate allergic sensitization and asthma to multiple glyco-allergens, including cockroach allergens. OBJECTIVE: Determine the existence of a protective mechanism through which MRC1 limits allergic inflammation through its intronic miR-511-3p. METHODS: We examined the MRC1-mediated cockroach allergen uptake by lung macrophages and lung inflammation using C57BL/6 wild-type (WT) and Mrc1-/- mice. Role of miR-511-3p in macrophage polarization and cockroach allergen-induced lung inflammation in mice transfected with Adeno-Associated Virus (AAV)-miR-511-3p (AAV-CMV-miR-511-3p-eGFP) was analyzed. Gene profiling of macrophages with or without miR-511-3p overexpression was also performed. RESULTS: Mrc1-/- lung macrophages showed significant reduction in cockroach allergen uptake compared with WT mice, and Mrc1-/- mice had an exacerbated lung inflammation with increased levels of cockroach allergen-specific IgE and Th2/Th17 cytokines in a cockroach allergen-induced mouse model compared to WT mice. Macrophages from Mrc1-/- mice showed significantly reduced levels of miR-511-3 and a M1 phenotype whereas over-expression of miR-511-3p rendered macrophages to exhibit a M2 phenotype. Furthermore, mice transfected with AAV-miR-511-3p showed a significant reduction in cockroach allergen-induced inflammation. Profiling of macrophages with or without miR-511-3p over-expression identified 729 differentially expressed genes, wherein the levels of Ptgds and its product PGD2 were significantly down-regulated by miR-511-3p. Ptgds showed a robust binding to miR-511-3p, which might contribute to the protective effect of miR-511-3p. The plasma levels of miR-511-3p were significantly lower in human asthmatics compared to non-asthmatic subjects. CONCLUSION: These studies support a critical but previously unrecognized role of MRC1 and miR-511-3p in protection against allergen-induced lung inflammation</style></abstract><notes><style face="normal" font="default">DA - 20170620IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28629744">PM:28629744</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170620-ZhouY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170620-ZhouY.pdf</url></text-urls><related-urls><url ppv-ref="no">video in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20170620, Zhou Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.049</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41933</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Min,J.Y.</style></author><author><style face="normal" font="default"> Nayak,J.V.</style></author><author><style face="normal" font="default"> Hulse,K.E.</style></author><author><style face="normal" font="default"> Stevens,W.W.</style></author><author><style face="normal" font="default"> Raju,P.A.</style></author><author><style face="normal" font="default"> Huang,J.H.</style></author><author><style face="normal" font="default"> Suh,L.A.</style></author><author><style face="normal" font="default"> Van Roey,G.A.</style></author><author><style face="normal" font="default"> Norton,J.E.</style></author><author><style face="normal" font="default"> Carter,R.G.</style></author><author><style face="normal" font="default"> Price,C.P.E.</style></author><author><style face="normal" font="default"> Weibman,A.R.</style></author><author><style face="normal" font="default"> Rashan,A.R.</style></author><author><style face="normal" font="default"> Ghosn,E.E.</style></author><author><style face="normal" font="default"> Patel,Z.M.</style></author><author><style face="normal" font="default"> Homma,T.</style></author><author><style face="normal" font="default"> Conley,D.B.</style></author><author><style face="normal" font="default"> Welch,K.C.</style></author><author><style face="normal" font="default"> Shintani-Smith,S.</style></author><author><style face="normal" font="default"> Peters,A.T.</style></author><author><style face="normal" font="default"> Grammer,L.C.,III</style></author><author><style face="normal" font="default"> Harris,K.E.</style></author><author><style face="normal" font="default"> Kato,A.</style></author><author><style face="normal" font="default"> Hwang,P.H.</style></author><author><style face="normal" font="default"> Kern,R.C.</style></author><author><style face="normal" font="default"> Herzenberg,L.A.</style></author><author><style face="normal" font="default"> Schleimer,R.P.</style></author><author><style face="normal" font="default"> Tan,B.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA</style></auth-address><titles><title><style face="normal" font="default">Evidence for altered levels of Immunoglobulin D in the nasal airway mucosa of patients with chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> Bacterial Infections</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Igm</style></keyword><keyword><style face="normal" font="default"> IL-2</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Immunoassay</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin D</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> Mucosal immunity</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal lavage</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Otolaryngology</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Respiratory Mucosa</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="15" Month="6" Year="2017">2017/6/15</year></dates><abstract><style face="normal" font="default">BACKGROUND: Immunoglobulin D (IgD) is an enigmatic antibody isotype best known when co-expressed with IgM on naive B cells. However, elevated soluble IgD (sIgD) and increased IgD+IgM- B cell populations have been described in the human upper respiratory mucosa. OBJECTIVE: We assessed whether levels of sIgD and IgD+ B cells are altered in nasal tissue from patients with chronic rhinosinusitis (CRS). We further characterized IgD+ B cell populations and explored clinical and local inflammatory factors associated with tissue sIgD levels. METHODS: sIgD levels were measured by ELISA in nasal tissues, nasal lavages, serum, and supernatants of dissociated nasal tissues. IgD+ cells were identified by immunofluorescence and flow cytometry. Inflammatory mediator levels in tissues were assessed by real-time PCR and multiplex immunoassay. Bacterial cultures from the middle meatus were performed. Underlying medical history and medicine use were obtained from medical records. RESULTS: sIgD levels and the number of IgD+ cells were significantly increased in uncinate tissue (UT) of CRS without nasal polyps (CRSsNP) compared to control (4-fold, P&lt;.05). IgD+ cells were densely scattered in the periglandular regions of CRSsNP UT. We also found that IgD+CD19+CD38bright plasmablasts were significantly elevated in CRSsNP tissues compared to control (P&lt;.05). Among numerous factors tested, IL-2 levels were increased in CRSsNP UT and were positively correlated with tissue IgD levels. Additionally, the supernatants of IL-2-stimulated dissociated CRSsNP tissue had significantly increased sIgD levels compared to IL-2-stimulated dissociated control tissue ex vivo (P&lt;.05). Tissue from CRS patients with preoperative antibiotic use or those with pathogenic bacteria presence showed higher IgD levels compared to tissue from patients absent these variables (P&lt;.05). CONCLUSION: sIgD levels and IgD+CD19+CD38bright plasmablasts were increased in nasal tissue of CRSsNP. IgD levels were associated with increased IL-2 and the presence of pathogenic bacteria. These findings suggest that IgD might contribute to enhance mucosal immunity, inflammation, or respond to bacterial infections in CRS, especially CRSsNP</style></abstract><notes><style face="normal" font="default">DA - 20170619IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28625807">PM:28625807</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170619-MinJY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170619-MinJY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170619, Min JY</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.032</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41934</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Loxham,M.</style></author><author><style face="normal" font="default"> Davies,D.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical and Experimental Sciences and the Southampton NIHR Respiratory Biomedical Research Unit, University of Southampton Faculty of Medicine, Sir Henry Wellcome Laboratories, University Hospital Southampton, Southampton, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Phenotypic and genetic aspects of epithelial barrier function in asthmatic patients</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="1751" start="1736">1736-1751</pages><volume><style face="normal" font="default">139</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">abnormalities</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Biomedical Research</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial epithelium</style></keyword><keyword><style face="normal" font="default"> cell surface molecules</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> disease pathogenesis</style></keyword><keyword><style face="normal" font="default"> dysregulation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelia</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelium</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Gene-Environment Interaction</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune dysregulation</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritants</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Repair</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Toxins</style></keyword><keyword><style face="normal" font="default"> Translating</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">The bronchial epithelium is continuously exposed to a multitude of noxious challenges in inhaled air. Cellular contact with most damaging agents is reduced by the action of the mucociliary apparatus and by formation of a physical barrier that controls passage of ions and macromolecules. In conjunction with these defensive barrier functions, immunomodulatory cross-talk between the bronchial epithelium and tissue-resident immune cells controls the tissue microenvironment and barrier homeostasis. This is achieved by expression of an array of sensors that detect a wide variety of viral, bacterial, and nonmicrobial (toxins and irritants) agents, resulting in production of many different soluble and cell-surface molecules that signal to cells of the immune system. The ability of the bronchial epithelium to control the balance of inhibitory and activating signals is essential for orchestrating appropriate inflammatory and immune responses and for temporally modulating these responses to limit tissue injury and control the resolution of inflammation during tissue repair. In asthmatic patients abnormalities in many aspects of epithelial barrier function have been identified. We postulate that such abnormalities play a causal role in immune dysregulation in the airways by translating gene-environment interactions that underpin disease pathogenesis and exacerbation</style></abstract><notes><style face="normal" font="default">DA - 20170606IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583446">PM:28583446</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-1736-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-139-1736-51.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170606, Loxham M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41935</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Czarnowicki,T.</style></author><author><style face="normal" font="default"> Krueger,J.G.</style></author><author><style face="normal" font="default"> Guttman-Yassky,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and the Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY; Laboratory for Investigative Dermatology, Rockefeller University, New York, NY</style></auth-address><titles><title><style face="normal" font="default">Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="1734" start="1723">1723-1734</pages><volume><style face="normal" font="default">139</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">abnormalities</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> antigen-presenting cell</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Calcineurin</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Immunosuppression</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> priming</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> Spread</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Topical calcineurin</style></keyword><keyword><style face="normal" font="default"> Topical corticosteroids</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">Skin barrier abnormalities have been suggested to play an essential role in initiation of early atopic dermatitis (AD). Antigen penetration through a compromised barrier likely leads to increased innate immune responses, antigen-presenting cell stimulation, and priming of overt cutaneous disease. In a TH2-promoting environment, T-cell/B-cell interactions occurring in regional lymph nodes lead to excessive IgE switch. Concurrent redistribution of memory T cells into the circulation not only leads to exacerbation of AD through T-cell skin infiltration but also spreads beyond the skin to initiate the atopic march, which includes food allergy, asthma, and allergic rhinitis. Possible primary interventions to prevent AD are focusing on improving skin barrier integrity, including supplementing barrier function with moisturizers. As for secondary prophylaxis in children with established AD, this can be stratified into prevention of disease exacerbations by using proactive approaches (with either topical corticosteroids or topical calcineurin inhibitors) in mild AD cases or the prevention of other atopic disorders that will probably mandate systemic immunosuppression in severe AD cases</style></abstract><notes><style face="normal" font="default">DA - 20170606IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583445">PM:28583445</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170606-CzarnowickiT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170606-CzarnowickiT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170606, Czarnowicki T</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41936</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Akdis,C.A.</style></author><author><style face="normal" font="default"> Ballas,Z.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Swiss Institute of Allergy and Asthma Research, University of Zurich (SIAF), Davos, SwitzerlandUniversity of Iowa, and Iowa City VA Medical Center, Iowa City, Iowa</style></auth-address><titles><title><style face="normal" font="default">The future of Allergy/Immunology: Promising Young Investigators</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Iowa</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="14" Month="6" Year="2017">2017/6/14</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170618IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - Switzerland -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28624611">PM:28624611</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170618-AkdisCA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170618-AkdisCA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170618, Akdis CA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41937</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Leiding,J.W.</style></author><author><style face="normal" font="default"> Okada,S.</style></author><author><style face="normal" font="default"> Hagin,D.</style></author><author><style face="normal" font="default"> Abinun,M.</style></author><author><style face="normal" font="default"> Shcherbina,A.</style></author><author><style face="normal" font="default"> Balashov,D.N.</style></author><author><style face="normal" font="default"> Kim,V.H.D.</style></author><author><style face="normal" font="default"> Ovadia,A.</style></author><author><style face="normal" font="default"> Guthery,S.L.</style></author><author><style face="normal" font="default"> Pulsipher,M.</style></author><author><style face="normal" font="default"> Lilic,D.</style></author><author><style face="normal" font="default"> Devlin,L.A.</style></author><author><style face="normal" font="default"> Christie,S.</style></author><author><style face="normal" font="default"> Depner,M.</style></author><author><style face="normal" font="default"> Fuchs,S.</style></author><author><style face="normal" font="default"> van Royen-Kerkhof,A.</style></author><author><style face="normal" font="default"> Lindemans,C.</style></author><author><style face="normal" font="default"> Petrovic,A.</style></author><author><style face="normal" font="default"> Sullivan,K.E.</style></author><author><style face="normal" font="default"> Bunin,N.</style></author><author><style face="normal" font="default"> Kilic,S.S.</style></author><author><style face="normal" font="default"> Arpaci,F.</style></author><author><style face="normal" font="default"> Calle-Martin,O.</style></author><author><style face="normal" font="default"> Martinez-Martinez,L.</style></author><author><style face="normal" font="default"> Aldave,J.C.</style></author><author><style face="normal" font="default"> Kobayashi,M.</style></author><author><style face="normal" font="default"> Ohkawa,T.</style></author><author><style face="normal" font="default"> Imai,K.</style></author><author><style face="normal" font="default"> Iguchi,A.</style></author><author><style face="normal" font="default"> Roifman,C.M.</style></author><author><style face="normal" font="default"> Gennery,A.R.</style></author><author><style face="normal" font="default"> Slatter,M.</style></author><author><style face="normal" font="default"> Ochs,H.D.</style></author><author><style face="normal" font="default"> Morio,T.</style></author><author><style face="normal" font="default"> Torgerson,T.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Department of Pediatrics, University of South Florida, St. Petersburg, Florida, USA</style></auth-address><titles><title><style face="normal" font="default">Hematopoietic stem cell transplantation in patients with Gain of Function STAT1 Mutation</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Autoimmunity</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Data Collection</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> dysregulation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Florida</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hematopoietic Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune dysregulation</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Russia</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> signal transducer and activator of transcription 1</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> STAT1</style></keyword><keyword><style face="normal" font="default"> Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Gain of function mutations in signal transducer and activator of transcription 1 (GOF-STAT1) cause a susceptibility to a range of infections, autoimmunity, immune dysregulation, and combined immunodeficiency. Disease manifestations can be mild or severe and life threatening. Hematopoietic stem cell transplantation (HSCT) has been utilized in some patients with more severe symptoms to treat and cure the disorder. The outcome of HSCT for this disorder is, however, not well established. OBJECTIVE: To aggregate the worldwide experience of HSCT in GOF-STAT1 patients and to assess outcomes including donor engraftment, overall survival, graft versus host disease, and transplant related complications. METHODS: Data were collected from an international cohort of 15 GOF-STAT1 patients that had undergone HSCT using a variety of conditioning regimens and donor sources. Retrospective data collection allowed the outcome of transplantation to be assessed. In vitro functional testing was performed to confirm that each of the identified STAT1 variants was, in-fact, a gain of function mutation. RESULTS: Primary donor engraftment in this cohort of 15 GOF-STAT1 patients was 74% and overall survival was only 40%. Secondary graft failure was common (50%) and post-transplant event free survival was poor (10% by 100 days). A subset of patients developed hemophagocytic lymphohistiocytosis (HLH) prior to their transplant, contributing to their poor outcomes. CONCLUSION: Our data indicate that HSCT for patients with GOF-STAT1 mutations is curative but has significant risk of secondary graft failure and death</style></abstract><notes><style face="normal" font="default">DA - 20170611IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Japan -CO - United Kingdom -CO - Germany -CO - Russia -CO - Canada -CO - Netherlands -CO - Turkey -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28601685">PM:28601685</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170611-LeidingJW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170611-LeidingJW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170611, Leiding JW</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.049</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41938</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yu,C.</style></author><author><style face="normal" font="default"> Fitzpatrick,A.</style></author><author><style face="normal" font="default"> Cong,D.</style></author><author><style face="normal" font="default"> Yao,C.</style></author><author><style face="normal" font="default"> Yoo,J.</style></author><author><style face="normal" font="default"> Turnbull,A.</style></author><author><style face="normal" font="default"> Schwarze,J.</style></author><author><style face="normal" font="default"> Norval,M.</style></author><author><style face="normal" font="default"> Howie,S.E.M.</style></author><author><style face="normal" font="default"> Weller,R.B.</style></author><author><style face="normal" font="default"> Astier,A.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">MRC Centre for Inflammation Research, University of Edinburgh, Queen's Medical Research Institute, Edinburgh EH16 4TJ, UK</style></auth-address><titles><title><style face="normal" font="default">Nitric oxide induces human CLA+CD25+Foxp3+ regulatory T cells with skin homing potential</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> regulatory T cell</style></keyword><keyword><style face="normal" font="default"> regulatory T cells</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="default">Phototherapy releases nitric oxide and can reduce symptoms in Atopic Dermatitis (AD). Nitric oxide induced suppressive regulatory T cells and, post-phototherapy, a clinical improvement in AD correlated with an increased ratio of Tregulatory:Teffector cells</style></abstract><notes><style face="normal" font="default">DA - 20170611IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28601680">PM:28601680</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170611-YuC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170611-YuC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170611, Yu C</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41939</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jensen,E.T.</style></author><author><style face="normal" font="default"> Kuhl,J.T.</style></author><author><style face="normal" font="default"> Martin,L.J.</style></author><author><style face="normal" font="default"> Rothenberg,M.E.</style></author><author><style face="normal" font="default"> Dellon,E.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Wake Forest University Public Health Sciences, Department of Epidemiology and Prevention, Winston-Salem, NC; Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.</style></auth-address><titles><title><style face="normal" font="default">Prenatal, intrapartum, and postnatal factors are associated with pediatric eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Antibiotic</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Esophagitis</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Folic Acid</style></keyword><keyword><style face="normal" font="default"> Gastroenterology</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infancy</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> North Carolina</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Multiple lines of evidence point to the potential importance of early-life environmental factors in the rapid rise in incidence of eosinophilic esophagitis (EoE), but potential exposures have not been extensively studied. OBJECTIVE: To assess the association between prenatal, intrapartum, and postnatal factors and the development of pediatric EoE using a case-control study. METHODS: Cases of EoE were recruited from an existing registry at Cincinnati Children's Hospital Medical Center (CCHMC). Population-based community controls were identified from a separate CCHMC registry. Mothers of study subjects were contacted and completed a web-based questionnaire. Crude and adjusted models were used to estimate associations. RESULTS: Mothers of 127 cases and 121 controls were included. We observed a positive association between several early-life factors and EoE, including prenatal (maternal fever: aOR 3.18; 95% CI 1.27, 7.98; preterm labor: aOR 2.18; 95% CI 1.06, 4.48), intrapartum (Cesarean delivery: aOR 1.77; 95% CI 1.01, 3.09) and infancy factors (antibiotic use: aOR 2.30; 95% CI 1.21, 4.38; use of an acid-suppressant: aOR 6.05; 95% CI 2.55, 14.40). We observed an inverse association between having a furry pet in infancy and EoE (aOR 0.58; 95% CI 0.34, 0.97). No associations were observed for breastfeeding or maternal multivitamin or folic acid supplement use. CONCLUSION: Early-life factors including maternal fever, preterm labor, Cesarean delivery, and antibiotic or acid suppressant use in infancy were associated with risk of pediatric EoE; having a pet in the home was protective. These results add to growing evidence that implicate early-life exposures in EoE pathogenesis</style></abstract><notes><style face="normal" font="default">DA - 20170611IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28601683">PM:28601683</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170611-JensenET.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170611-JensenET.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170611, Jensen ET</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41940</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bitar,M.</style></author><author><style face="normal" font="default"> Boldt,A.</style></author><author><style face="normal" font="default"> Binder,S.</style></author><author><style face="normal" font="default"> Borte,M.</style></author><author><style face="normal" font="default"> Kentouche,K.</style></author><author><style face="normal" font="default"> Borte,S.</style></author><author><style face="normal" font="default"> Sack,U.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Clinical Immunology, Medical Faculty, University of Leipzig, Johannisallee 30, 04103 Leipzig, Germany.</style></auth-address><titles><title><style face="normal" font="default">Flow cytometric measurement of STAT1 and STAT3 phosphorylation in CD4+ and CD8+ T cells - Clinical applications in PID diagnostics</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">CD8+ T cells</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic tool</style></keyword><keyword><style face="normal" font="default"> Diagnostics</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> STAT1</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="default">Flow cytometry-based pSTAT1 and pSTAT3 profiling is an effective diagnostic tool to identify PID patients with aberrations in the STAT1 or STAT3 gene</style></abstract><notes><style face="normal" font="default">DA - 20170611IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28601682">PM:28601682</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170611-BitarM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170611-BitarM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170611, Bitar M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41941</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oue,S.</style></author><author><style face="normal" font="default"> Ramezanpour,M.</style></author><author><style face="normal" font="default"> Paramasivan,S.</style></author><author><style face="normal" font="default"> Miljkovic,D.</style></author><author><style face="normal" font="default"> Cooksley,C.M.</style></author><author><style face="normal" font="default"> Bassiouni,A.</style></author><author><style face="normal" font="default"> Ou,J.</style></author><author><style face="normal" font="default"> Psaltis,A.J.</style></author><author><style face="normal" font="default"> Wormald,P.J.</style></author><author><style face="normal" font="default"> Vreugde,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Surgery-Otorhinolaryngology Head and Neck Surgery, The University of Adelaide, South Australia, Australia</style></auth-address><titles><title><style face="normal" font="default">Increased IL-13 expression is independently associated with neo-osteogenesis in chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Australia</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Remodelling</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="default">CAPSULE SUMMARY: Increased expression of IL-13 is independently affected by the neo-osteogenesis state in CRS. IL-13 protein increased osteoblastic bone mineralization in vitro. Our findings indicate that IL-13 may contribute to pathological bone remodelling in recalcitrant CRS</style></abstract><notes><style face="normal" font="default">DA - 20170611IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28601687">PM:28601687</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170611-OueS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170611-OueS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170611, Oue S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41942</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bafunno,V.</style></author><author><style face="normal" font="default"> Firinu,D.</style></author><author><style face="normal" font="default"> D'Apolito,M.</style></author><author><style face="normal" font="default"> Cordisco,G.</style></author><author><style face="normal" font="default"> Loffredo,S.</style></author><author><style face="normal" font="default"> Leccese,A.</style></author><author><style face="normal" font="default"> Bova,M.</style></author><author><style face="normal" font="default"> Barca,M.P.</style></author><author><style face="normal" font="default"> Santacroce,R.</style></author><author><style face="normal" font="default"> Cicardi,M.</style></author><author><style face="normal" font="default"> Del Giacco,S.</style></author><author><style face="normal" font="default"> Margaglione,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical Genetics, Dept. of Clinical and Experimental Medicine, University of Foggia</style></auth-address><titles><title><style face="normal" font="default">Mutation of Angiopoietin-1 Gene Associates with a New Type of Hereditary Angioedema</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> coagulation Factor XII</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Factor XII</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Recombinant</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hereditary angioedema (HAE) is a rare genetic disease usually due to mutation within the C1 inhibitor or the coagulation Factor XII gene. However, in a series of patients with HAE no causative variants have been described and the pathophysiology of the disease remains unknown (U-HAE). Identification of causative genes in U-HAE is valuable for understanding the cause of the disease. OBJECTIVE: We conducted genetic studies in Italian patients with U-HAE to identify novel causative genes. METHODS: Among patients belonging to 10 independent families and unrelated index patients with U-HAE disease recruited from the Italian network for C1-INH-HAE (ITACA), we selected a large multiplex family with U-HAE and performed whole-exome sequencing. The angiopoietin-1 gene (ANGPT1) was investigated in all patients with familial or sporadic U-HAE. The effect of ANGPT1 variants was investigated by in silico prediction and using patients and control plasmas and transfected cells. RESULTS: We identified a missense mutation (ANGPT1, c.807G>T, p.A119S) in a family with U-HAE. The ANGPT1 p.A119S variant was detected in all members of the index family with U-HAE but not in asymptomatic family members, nor in an additional 20 patients with familial U-HAE, 22 patients with sporadic U-HAE, and 200 controls. Protein analysis of the plasma of patients revealed a reduction of multimeric forms and a reduced ability to bind the natural receptor "tunica interna endothelial cell kinase-2" (TIE2) of the ANGPT1 p.A119S variant. The recombinant mutated ANGPT1 p.A119S formed a reduced amount of multimers and showed a reduced binding capability to its receptor. CONCLUSION: ANGPT1 impairment is associated with angioedema and ANGPT1 variants can be the basis of HAE</style></abstract><notes><style face="normal" font="default">DA - 20170611IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28601681">PM:28601681</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170611-BafunnoV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170611-BafunnoV.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170611, Bafunno V</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41943</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Durack,J.</style></author><author><style face="normal" font="default"> Boushey,H.A.</style></author><author><style face="normal" font="default"> Huang,Y.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of California, Dept. of Medicine, Division of Gastroenterology, San Francisco, CAUniversity of California, Dept. of Medicine, Division of Pulmonary &amp; Critical Care Medicine, San Francisco, CA. Electronic address: homer.boushey@ucsf.eduUniversity of Michigan, Division of Pulmonary &amp; Critical Care Medicine, Ann Arbor, MI</style></auth-address><titles><title><style face="normal" font="default">Incorporating the airway microbiome into asthma phenotyping - moving towards personalized medicine for non-eosinophilic asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotyping</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Gastroenterology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Michigan</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> Non-eosinophilic</style></keyword><keyword><style face="normal" font="default"> Personalized medicine</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> San Francisco</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="13" Month="6" Year="2017">2017/6/13</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170619IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28627361">PM:28627361</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170619-DurackJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170619-DurackJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170619, Durack J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.026</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41944</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kaler,M.</style></author><author><style face="normal" font="default"> Barochia,A.V.</style></author><author><style face="normal" font="default"> Weir,N.A.</style></author><author><style face="normal" font="default"> Cuento,R.A.</style></author><author><style face="normal" font="default"> Stylianou,M.</style></author><author><style face="normal" font="default"> Roth,M.J.</style></author><author><style face="normal" font="default"> Filie,A.C.</style></author><author><style face="normal" font="default"> Vaughey,E.C.</style></author><author><style face="normal" font="default"> Nathan,S.D.</style></author><author><style face="normal" font="default"> Levine,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Asthma and Lung Inflammation, Cardiovascular and Pulmonary Branch, NHLBI, NIH</style></auth-address><titles><title><style face="normal" font="default">A Randomized, Placebo-controlled, Double-blinded, Crossover Trial of Pioglitazone for Severe Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="15" Month="6" Year="2017">2017/6/15</year></dates><abstract><style face="normal" font="default">The PPAR-gamma agonist, pioglitazone, was associated with significant side effects and did not improve the primary outcome measure of the Juniper Asthma Quality of Life Questionnaire (AQLQ) score in severe asthmatics. We conclude that no further studies should be performed with pioglitazone for severe asthma</style></abstract><notes><style face="normal" font="default">DA - 20170619IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28625806">PM:28625806</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170619-KalerM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170619-KalerM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170619, Kaler M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.033</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41945</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mirzakhani,H.</style></author><author><style face="normal" font="default"> O'Connor,G.</style></author><author><style face="normal" font="default"> Bacharier,L.B.</style></author><author><style face="normal" font="default"> Zeiger,R.S.</style></author><author><style face="normal" font="default"> Schatz,M.X.</style></author><author><style face="normal" font="default"> Weiss,S.T.</style></author><author><style face="normal" font="default"> Litonjua,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA</style></auth-address><titles><title><style face="normal" font="default">Asthma Control Status in Pregnancy, BMI, and Maternal Vitamin D Levels</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="default">Higher maternal 25OHD levels at early pregnancy could reduce the associated risk of uncontrolled asthma status during pregnancy. Obesity might attenuate this effect and is a predictor of uncontrolled status during pregnancy</style></abstract><notes><style face="normal" font="default">DA - 20170613IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.053</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28606587">PM:28606587</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170613-MirzakhaniH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170613-MirzakhaniH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170613, Mirzakhani H</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.053</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41946</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brozek,J.L.</style></author><author><style face="normal" font="default"> Bousquet,J.</style></author><author><style face="normal" font="default"> Agache,I.</style></author><author><style face="normal" font="default"> Agarwal,A.</style></author><author><style face="normal" font="default"> Bachert,C.</style></author><author><style face="normal" font="default"> Bosnic-Anticevich,S.</style></author><author><style face="normal" font="default"> Brignardello-Petersen,R.</style></author><author><style face="normal" font="default"> Canonica,G.W.</style></author><author><style face="normal" font="default"> Casale,T.</style></author><author><style face="normal" font="default"> Chavannes,N.H.</style></author><author><style face="normal" font="default"> Correia de Sousa,J.</style></author><author><style face="normal" font="default"> Cruz,A.A.</style></author><author><style face="normal" font="default"> Cuello-Garcia,C.A.</style></author><author><style face="normal" font="default"> Demoly,P.</style></author><author><style face="normal" font="default"> Dykewicz,M.</style></author><author><style face="normal" font="default"> Etxeandia-Ikobaltzeta,I.</style></author><author><style face="normal" font="default"> Florez,I.D.</style></author><author><style face="normal" font="default"> Fokkens,W.</style></author><author><style face="normal" font="default"> Fonseca,J.</style></author><author><style face="normal" font="default"> Hellings,P.W.</style></author><author><style face="normal" font="default"> Klimek,L.</style></author><author><style face="normal" font="default"> Kowalski,S.</style></author><author><style face="normal" font="default"> Kuna,P.</style></author><author><style face="normal" font="default"> Laisaar,K.T.</style></author><author><style face="normal" font="default"> Larenas-Linnemann,D.E.</style></author><author><style face="normal" font="default"> Lodrup Carlsen,K.C.</style></author><author><style face="normal" font="default"> Manning,P.J.</style></author><author><style face="normal" font="default"> Meltzer,E.</style></author><author><style face="normal" font="default"> Mullol,J.</style></author><author><style face="normal" font="default"> Muraro,A.</style></author><author><style face="normal" font="default"> O'Hehir,R.</style></author><author><style face="normal" font="default"> Ohta,K.</style></author><author><style face="normal" font="default"> Panzner,P.</style></author><author><style face="normal" font="default"> Papadopoulos,N.</style></author><author><style face="normal" font="default"> Park,H.S.</style></author><author><style face="normal" font="default"> Passalacqua,G.</style></author><author><style face="normal" font="default"> Pawankar,R.</style></author><author><style face="normal" font="default"> Price,D.</style></author><author><style face="normal" font="default"> Riva,J.J.</style></author><author><style face="normal" font="default"> Roldan,Y.</style></author><author><style face="normal" font="default"> Ryan,D.</style></author><author><style face="normal" font="default"> Sadeghirad,B.</style></author><author><style face="normal" font="default"> Samolinski,B.</style></author><author><style face="normal" font="default"> Schmid-Grendelmeier,P.</style></author><author><style face="normal" font="default"> Sheikh,A.</style></author><author><style face="normal" font="default"> Togias,A.</style></author><author><style face="normal" font="default"> Valero,A.</style></author><author><style face="normal" font="default"> Valiulis,A.</style></author><author><style face="normal" font="default"> Valovirta,E.</style></author><author><style face="normal" font="default"> Ventresca,M.</style></author><author><style face="normal" font="default"> Wallace,D.</style></author><author><style face="normal" font="default"> Waserman,S.</style></author><author><style face="normal" font="default"> Wickman,M.</style></author><author><style face="normal" font="default"> Wiercioch,W.</style></author><author><style face="normal" font="default"> Yepes-Nunez,J.J.</style></author><author><style face="normal" font="default"> Zhang,L.</style></author><author><style face="normal" font="default"> Zhang,Y.</style></author><author><style face="normal" font="default"> Zidarn,M.</style></author><author><style face="normal" font="default"> Zuberbier,T.</style></author><author><style face="normal" font="default"> Schunemann,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada</style></auth-address><titles><title><style face="normal" font="default">Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines - 2016 Revision</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergic Rhinitis and its Impact on Asthma</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> ARIA</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Caregivers</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Colombia</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Czech Republic</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Estonia</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> General practice</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> H1 antihistamines</style></keyword><keyword><style face="normal" font="default"> H1-antihistamine</style></keyword><keyword><style face="normal" font="default"> H1-antihistamines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health care provider</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Intranasal corticosteroid</style></keyword><keyword><style face="normal" font="default"> intranasal corticosteroids</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> Ireland</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mexico</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> office</style></keyword><keyword><style face="normal" font="default"> Office Visits</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Romania</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Slovenia</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="8" Month="6" Year="2017">2017/6/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic rhinitis affects 10 to 40% of the population. It reduces quality of life, school and work performance, and is a frequent reason for office visits in general practice. Medical costs are large but avoidable costs associated with lost work productivity are even larger than those incurred by asthma. New evidence has accumulated since the last revision of the Allergic Rhinitis and its Impact on Asthma - ARIA guidelines in 2010 prompting its update. OBJECTIVE: To provide a targeted update of the ARIA guidelines. METHODS: The ARIA guideline panel identified new clinical questions and selected questions requiring an update. We performed systematic reviews of health effects and the evidence about patient values and preferences, and resource requirements (up to June 2016). We followed the Grading of Recommendations Assessment, Development and Evaluation (GRADE) evidence-to-decision frameworks to develop recommendations. RESULTS: The 2016 revision of the ARIA guidelines provides updated and new recommendations about the pharmacological treatment of allergic rhinitis. It specifically addresses the relative merits of using oral H1-antihistamines, intranasal H1-antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists either alone or their combination. The ARIA guideline panel provides specific recommendations for the choice of treatment, the rationale for the choice, and discusses specific considerations that clinicians and patients may want to review in order to choose the management most appropriate for an individual patient. CONCLUSIONS: Appropriate treatment of allergic rhinitis may improve patients' quality of life, school and work productivity. ARIA recommendations support patients, their caregivers, and health care providers in choosing the optimal treatment</style></abstract><notes><style face="normal" font="default">DA - 20170612IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - France -CO - Romania -CO - Belgium -CO - Netherlands -CO - Australia -CO - Italy -CO - Germany -CO - China -CO - Slovenia -CO - Colombia -CO - Sweden -CO - United States -CO - Finland -CO - Switzerland -CO - Poland -CO - Iran -CO - United Kingdom -CO - Japan -CO - San Martino -CO - South Korea -CO - Czechia -CO - Spain -CO - Ireland -CO - Estonia -CO - Mexico -CO - Portugal -CO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.050</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28602936">PM:28602936</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170612-BrozekJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170612-BrozekJL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170612, Brozek JL</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.050</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41947</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lynch,M.D.</style></author><author><style face="normal" font="default"> McFadden,J.P.</style></author><author><style face="normal" font="default"> White,J.M.</style></author><author><style face="normal" font="default"> Banerjee,P.</style></author><author><style face="normal" font="default"> White,I.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Cutaneous Allergy, St John's Institute of Dermatology.</style></auth-address><titles><title><style face="normal" font="default">Age-specific profiling of cutaneous allergy at high temporal resolution suggests age-related alterations in regulatory immune function</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen-specific</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="default">We report the age-specific prevalence of cutaneous allergy in 45110 patients over a 30 year period. Our analysis reveals complex allergen-specific sensitization profiles which may reflect alterations in T-cell mediated immunity and regulatory immune function</style></abstract><notes><style face="normal" font="default">DA - 20170613IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.054</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28606588">PM:28606588</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170613-LynchMD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170613-LynchMD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170613, Lynch MD</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.054</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41948</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Carter,M.C.</style></author><author><style face="normal" font="default"> Desai,A.</style></author><author><style face="normal" font="default"> Komarow,H.D.</style></author><author><style face="normal" font="default"> Bai,Y.</style></author><author><style face="normal" font="default"> Clayton,S.T.</style></author><author><style face="normal" font="default"> Clark,A.S.</style></author><author><style face="normal" font="default"> Ruiz-Esteves,K.N.</style></author><author><style face="normal" font="default"> Long,L.M.</style></author><author><style face="normal" font="default"> Cantave,D.</style></author><author><style face="normal" font="default"> Wilson,T.M.</style></author><author><style face="normal" font="default"> Scott,L.M.</style></author><author><style face="normal" font="default"> Simakova,O.</style></author><author><style face="normal" font="default"> Jung,M.Y.</style></author><author><style face="normal" font="default"> Hahn,J.</style></author><author><style face="normal" font="default"> Maric,I.</style></author><author><style face="normal" font="default"> Metcalfe,D.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health.</style></auth-address><titles><title><style face="normal" font="default">A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Bone Marrow</style></keyword><keyword><style face="normal" font="default"> Bone Marrow Examination</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hymenoptera</style></keyword><keyword><style face="normal" font="default"> KIT</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mastocytosis</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum tryptase</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic mastocytosis</style></keyword><keyword><style face="normal" font="default"> Systemic reaction</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="6" Year="2017">2017/6/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Clonal mast cell disorders are known to occur in a subset of patients with systemic reactions to Hymenoptera stings. This observation has prompted the question as to whether clonal mast cell disorders also occur in patients with idiopathic anaphylaxis (IA). OBJECTIVE: We sought to determine the prevalence of clonal mast cell disorders among patients with IA, criteria to identify those patients who require a bone marrow biopsy and whether the pathogenesis of IA involves a hyper-responsive mast cell compartment. METHODS: We prospectively enrolled patients with IA (>/=3 episodes/yr) and who then underwent a medical evaluation that included a serum tryptase determination, allele-specific quantitative polymerase chain reaction (ASqPCR) for KIT D816V and a bone marrow examination. Mast cells were cultured from peripheral blood CD34+ cells and examined for releasibility following FcepsilonRI aggregation. RESULTS: Clonal mast cell disease was diagnosed in 14% of patients referred with IA. ASqPCR for the KIT D816V mutation was a useful adjunct in helping identify those with systemic mastocytosis (SM) but not monoclonal mast cell activation syndrome (MMAS). A modified overall clonal prediction model was developed using clinical findings, a serum tryptase determination and ASqPCR. There was no evidence of a hyper-responsive mast cell phenotype in patients with IA. CONCLUSION: Patients with clonal mast cell disease may present as idiopathic anaphylaxis. Distinct clinical and laboratory features may be used to select those patients more likely to have an underlying clonal mast cell disorder (MMAS or SM) and thus candidates for a bone marrow biopsy</style></abstract><notes><style face="normal" font="default">DA - 20170620IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28629749">PM:28629749</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170620-CarterMC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170620-CarterMC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170620, Carter MC</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.036</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41949</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Turner,J.</style></author><author><style face="normal" font="default"> Wang,J.G.</style></author><author><style face="normal" font="default"> Neighbour,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, McMaster University, Hamilton, Ontario, Canada.</style></auth-address><titles><title><style face="normal" font="default">Chronic Eosinophilic Pneumonia: A Diagnostic Challenge</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1738" start="1737">1737-1738</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Canada</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic eosinophilic pneumonia</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> eosinophilic pneumonia</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Ontario</style></keyword><keyword><style face="normal" font="default"> Pneumonia</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="7" Month="7" Year="2017">2017/7/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.05.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28694046">PM:28694046</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170711, Turner J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.05.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41950</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sellaturay,P.</style></author><author><style face="normal" font="default"> Nasser,S.</style></author><author><style face="normal" font="default"> Ewan,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default">Skin testing in gadolinium allergy: 2 case reports</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Gadolinium</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="29" Month="6" Year="2017">2017/6/29</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170703IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.04.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28669891">PM:28669891</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170703, Sellaturay P</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.04.040</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41951</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Carlson,G.S.</style></author><author><style face="normal" font="default"> Wong,P.H.</style></author><author><style face="normal" font="default"> White,K.M.</style></author><author><style face="normal" font="default"> Quinn,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Wilford Hall, Lackland Air Force Base, San Antonio, Texas.</style></auth-address><titles><title><style face="normal" font="default">Evaluation of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy in immunotherapy-associated systemic reactions</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1432" start="1430">1430-1432</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic reaction</style></keyword><keyword><style face="normal" font="default"> Texas</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="7" Month="7" Year="2017">2017/7/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.05.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28694048">PM:28694048</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1430-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1430-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170711, Carlson GS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.05.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41952</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jhun,I.</style></author><author><style face="normal" font="default"> Lai,P.S.</style></author><author><style face="normal" font="default"> Phipatanakul,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Harvard Medical School, Boston, Mass</style></auth-address><titles><title><style face="normal" font="default">Reply (Refers to: Reducing the burden of allergy and asthma in schoolchildren: Air cleaning solutions and microbial diversity-the dark side of the moon?)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1166" start="1165">1165-1166</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schoolchildren</style></keyword><keyword><style face="normal" font="default"> Solutions</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 2213-2201 (Electronic)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.04.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689836">PM:28689836</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1165-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1165-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170710, Jhun I</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.04.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41953</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Casale,T.B.</style></author><author><style face="normal" font="default"> Onder,R.F.</style></author><author><style face="normal" font="default"> Berkowitz,R.B.</style></author><author><style face="normal" font="default"> Korenblat,P.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, University of South Florida Morsani College of Medicine, Tampa, Fla.</style></auth-address><titles><title><style face="normal" font="default">Nasal Carbon Dioxide Used As Needed in the Symptomatic Treatment of Seasonal Allergic Rhinitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse events</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Dioxide</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Florida</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> perennial</style></keyword><keyword><style face="normal" font="default"> perennial allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> SAR</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> serious adverse events</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Nasal, noninhaled carbon dioxide (CO2) was shown to be effective for the treatment of symptoms of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis in single application studies. OBJECTIVE: To assess the efficacy of as-needed treatment with nasal, noninhaled CO2 in patients with SAR. METHODS: Fifty-six ragweed-allergic patients were enrolled at 3 sites in this study. After a 3- to 7-day run-in, 32 eligible patients who had an instantaneous total nasal symptom score of 8 or more out of a maximum of 12 in at least 2 SAR episodes per day were randomized to the CO2 group (n = 19) or to the placebo group (n = 13). A 10-second/nostril application was used as needed for 14 days (maximum 6 times/d). Patients evaluated their symptoms before and 30 minutes after each application. All symptoms were scored on a 0 to 3 scale. RESULTS: Analysis of all treated episodes (CO2 = 816, placebo = 516) showed a statistically significant beneficial change in total nasal symptom score from baseline (effect size = -0.51; P &lt; .001). The effect size was larger with more severe baseline symptoms (baseline severities of >/=6 = -0.98; >/=8 = -1.14; and >/=10 = -1.61; all P &lt; .001). CO2 was well tolerated, with transient nasal discomfort as the most common adverse event reported. There were no serious adverse events, serious adverse device effects, or early discontinuations. CONCLUSIONS: Nasal, noninhaled CO2 is effective for the as-needed treatment of SAR symptoms. The effect is rapid and the effect size is large. It represents a novel potential option for the as-needed treatment of rhinitis symptoms</style></abstract><notes><style face="normal" font="default">DA - 20170714IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.05.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28705451">PM:28705451</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170714, Casale TB</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.05.028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41954</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Smith,T.D.</style></author><author><style face="normal" font="default"> Cunningham-Rundles,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, NY</style></auth-address><titles><title><style face="normal" font="default">Detection of anti-glutamic acid decarboxylase antibodies in immunoglobulin products</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="29" Month="6" Year="2017">2017/6/29</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170703IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.04.042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28669890">PM:28669890</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170703, Smith TD</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.04.042</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41955</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zeiger,R.S.</style></author><author><style face="normal" font="default"> Tran,T.N.</style></author><author><style face="normal" font="default"> Schatz,M.</style></author><author><style face="normal" font="default"> Li,Q.</style></author><author><style face="normal" font="default"> Chen,W.</style></author><author><style face="normal" font="default"> Khatry,D.B.</style></author><author><style face="normal" font="default"> Davis,J.</style></author><author><style face="normal" font="default"> Kawatkar,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departments of Allergy and Research and Evaluation, Kaiser Permanente Southern California, San Diego and Pasadena, Calif. Electronic address: robert.s.zeiger@kp.orgObservational Research Center, AstraZeneca, Gaithersburg, MdDepartments of Allergy and Research and Evaluation, Kaiser Permanente Southern California, San Diego and Pasadena, CalifDepartments of Allergy and Research and Evaluation, Kaiser Permanente Southern California, San Diego and Pasadena, CalifDepartments of Allergy and Research and Evaluation, Kaiser Permanente Southern California, San Diego and Pasadena, CalifStatistical Sciences, MedImmune LLC, Gaithersburg, MdAstraZeneca, Wilmington, DelDepartments of Allergy and Research and Evaluation, Kaiser Permanente Southern California, San Diego and Pasadena, Calif</style></auth-address><titles><title><style face="normal" font="default">Drivers of health care costs for adults with persistent asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Care Costs</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><notes><style face="normal" font="default">DA - 20170715IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Unitesd States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.05.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709819">PM:28709819</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170715, Zeigner RS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.05.026</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41956</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sanchez,J.</style></author><author><style face="normal" font="default"> Zakzuk,J.</style></author><author><style face="normal" font="default"> Cardona,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Group of Experimental and Clinical Allergy, IPS Universitaria, University of Antioquia, Medellin, Colombia</style></auth-address><titles><title><style face="normal" font="default">Evaluation of a Guidelines-Based Approach to the Treatment of Chronic Spontaneous Urticaria</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical guidelines</style></keyword><keyword><style face="normal" font="default"> Colombia</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cyclosporine</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: International scientific associations have made recommendations for the management of chronic spontaneous urticaria (CSU) that have been summarized in clinical guidelines. OBJECTIVE: To evaluate the clinical impact of guideline recommendations for CSU management. METHODS: A multicenter, triple-blinded, prospective, randomized study (the Urticaria Research of Tropical Impact and Control Assessment project; ClinicalTrials.gov identifier: NCT01940393) was performed. Patients older than 12 years and diagnosed with CSU were recruited and treated according to the European Academy of Allergy and Clinical Immunology/Global Allergy and Asthma European Network/European Dermatology Forum/World Allergy Organization guideline recommendations. The Dermatology Quality of Life Index (DLQI) was assessed every 2 weeks. As a first line of treatment, patients received a daily oral dose of antihistamine. After 4 weeks, in those patients without clinical response (DLQI &lt;/= 5), a higher dose (up to 4 times) of antihistamine was administered as a second line of therapy. After 2 months of follow-up, unresponsive patients received omalizumab or cyclosporine (as add-on therapy) for 4 months as a third line of treatment. RESULTS: One hundred fifty patients were enrolled. After the first line of treatment, 88 patients (58.7%) reached a DLQI of 5 or less. With the second line of treatment, disease control rate was 76.7%. With the third line, 12 patients from the omalizumab group (8%) and 11 patients from the cyclosporine group (7.3%) reached a good clinical control (additional 15.3%). Control rate with line 1 treatment was superior at 1 month than at 2 weeks (P &lt; .0001). CONCLUSIONS: The application of these guideline recommendations for CSU led to a high rate of disease control, assessed by scoring severity and patients' perception of quality of life. These results support the usefulness of guideline recommendations</style></abstract><notes><style face="normal" font="default">DA - 20170715IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Colombia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709817">PM:28709817</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170715, Sanchez J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41957</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Patel,P.O.</style></author><author><style face="normal" font="default"> Patel,M.R.</style></author><author><style face="normal" font="default"> Baptist,A.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Clinical Immunology, University of Michigan Health System, Ann Arbor, Mich.</style></auth-address><titles><title><style face="normal" font="default">Depression and Asthma Outcomes in Older Adults: Results from the National Health and Nutrition Examination Survey</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1697" start="1691">1691-1697</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> mental health</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Michigan</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> National Health and Nutrition Examination Survey</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Older adults</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Poisson</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="17" Month="6" Year="2017">2017/6/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Older adults have high rates of asthma morbidity and mortality, as well as increased rates of depression. There are no nationally representative studies describing the association of depression on key asthma outcomes such as emergency department (ED) visits among older adults. OBJECTIVE: The objective of this study was to determine the association of depression with asthma outcomes in older adults (age >/= 55) from the National Health and Nutrition Examination Survey (NHANES). METHODS: Data from the NHANES survey (2007-2012) were analyzed. Bivariate analyses and multivariate Poisson regression models were used to examine associations between depression and asthma outcomes among adults above the age of 55. RESULTS: Approximately 7.01% (n = 509) of the sample reported a physician diagnosis of asthma. Older adults with asthma and depression (n = 196) had increased asthma episodes (prevalence ratio [PR], 1.53; 95% confidence interval [CI], 1.00-2.35), ED/urgent care visits for asthma (PR, 2.24; 95% CI, 1.15-4.34), sleep disturbances due to asthma (PR 2.75; 95% CI, 1.54-4.92), and activity limitation (PR, 1.77; 95% CI, 1.00-3.18; P = .05) compared with older asthmatics without depression. They also reported worse health-related quality of life measures across 4 domains including days of poor general health, physical health, mental health, and inactivity (P &lt; .001 for all). No significant differences in spirometric values were observed. CONCLUSIONS: Older adults with asthma and depression are nearly twice as likely to have poor asthma outcomes across several indicators, including asthma-related ED/urgent care visits compared with those without depression. Screening for depression and providing supportive resources may decrease the burden of asthma among older adults</style></abstract><notes><style face="normal" font="default">DA - 20170621IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28634102">PM:28634102</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170621, Patel PO</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.034</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41958</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Soler,X.</style></author><author><style face="normal" font="default"> Holbrook,J.T.</style></author><author><style face="normal" font="default"> Gerald,L.B.</style></author><author><style face="normal" font="default"> Berry,C.E.</style></author><author><style face="normal" font="default"> Saams,J.</style></author><author><style face="normal" font="default"> Henderson,R.J.</style></author><author><style face="normal" font="default"> Sugar,E.</style></author><author><style face="normal" font="default"> Wise,R.A.</style></author><author><style face="normal" font="default"> Ramsdell,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, UC San Diego, San Diego, Calif</style></auth-address><titles><title><style face="normal" font="default">Validity of the Asthma Control Test Questionnaire among Smoking Asthmatics</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> ACT</style></keyword><keyword><style face="normal" font="default"> ACT Score</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> African American</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Asthma therapy</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> ROC</style></keyword><keyword><style face="normal" font="default"> Roc Curve</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Sensitivity and Specificity</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> smokers</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="29" Month="6" Year="2017">2017/6/29</year></dates><abstract><style face="normal" font="default">BACKGROUND: Smoking asthmatics respond worse to existing asthma therapies and have more asthma symptoms and exacerbations. OBJECTIVE: We evaluated the Asthma Control Test (ACT) for assessing asthma control among smokers. METHODS: Adults with asthma who smoked were enrolled and followed for 6 weeks. The statistical properties, validity, and responsiveness of the ACT were evaluated. Physician global assessment (GS) of asthma was the "gold standard." RESULTS: A total of 151 participants were enrolled: 52% female and 48% male. The median (interquartile ranges) was 35 (27, 43) years for age, 11 (7, 18) for pack-years, and 16 (13, 20) for the ACT score. Participants self-identified as African American (49%), non-Hispanic whites (38%), and Hispanic whites (11%). Participants were classified as well controlled (24%), not well controlled (42%), or very poorly controlled (34%) at enrollment. Cronbach's alpha (95% confidence interval [CI]) for the ACT at enrollment was 0.81 (0.76, 0.85). The intraclass correlation coefficient (95% CI) for agreement of scores at enrollment and 6 weeks was 0.68 (0.57, 0.78) in participant with stable asthma (n = 93). ACT scores were associated with GS (P &lt; .001). Area under the receiver operating characteristic (ROC) curve (95% CI) for an ACT cutoff score of &lt;/=19 (not well controlled) was 0.76 (0.67, 0.84). The ACT score with the maximum area under the ROC curve was 18.6. CONCLUSIONS: The ACT questionnaire was reliable and discriminated between levels of asthma control in smoking asthmatics with similar sensitivity and specificity as nonsmoking asthmatics, which confirms its value as a tool for the management of asthma in this prevalent but understudied subgroup of subjects</style></abstract><notes><style face="normal" font="default">DA - 20170703IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.05.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28669892">PM:28669892</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170703, Soler X</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.05.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41959</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Prieto-Garcia,A.</style></author><author><style face="normal" font="default"> Perez-David,E.</style></author><author><style face="normal" font="default"> Devesa,C.</style></author><author><style face="normal" font="default"> Tornero,P.</style></author><author><style face="normal" font="default"> Schwartz,L.B.</style></author><author><style face="normal" font="default"> Pascual,C.</style></author><author><style face="normal" font="default"> Castells,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy, University Hospital Gregorio Maranon, Health Research Institute Gregorio Maranon, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default">Fatal anaphylaxis caused by gadolinium due to beta-tryptase-induced hemorragic diathesis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1434" start="1433">1433-1434</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Gadolinium</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="17" Month="6" Year="2017">2017/6/17</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170621IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Spain -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.05.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28634099">PM:28634099</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1433-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1433-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170621, Prieto-Garcia A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.05.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41960</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cavaleiro,R.J.</style></author><author><style face="normal" font="default"> Moreira,A.</style></author><author><style face="normal" font="default"> Delgado,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Basic and Clinical Immunology, Faculty of Medicine, University of Porto, Porto, Portugal</style></auth-address><titles><title><style face="normal" font="default">Reducing the burden of allergy and asthma in schoolchildren: Air cleaning solutions and microbial diversity-the dark side of the moon?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1165" start="1164">1164-1165</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Schoolchildren</style></keyword><keyword><style face="normal" font="default"> Solutions</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 2213-2201 (Electronic)LA - engPT - LetterCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.04.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689835">PM:28689835</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1164-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1164-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170710, Cavaleiro RJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.04.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41961</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Castillo,J.R.</style></author><author><style face="normal" font="default"> Peters,S.P.</style></author><author><style face="normal" font="default"> Busse,W.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wis</style></auth-address><titles><title><style face="normal" font="default">Asthma Exacerbations: Pathogenesis, Prevention, and Treatment</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="927" start="918">918-927</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Care Costs</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human rhinovirus</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> respiratory infection</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinovirus</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Wisconsin</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Guideline-based management of asthma focuses on disease severity and choosing the appropriate medical therapy to control symptoms and reduce the risk of exacerbations. However, irrespective of asthma severity and often despite optimal medical therapy, patients may experience acute exacerbations of symptoms and a loss of disease control. Asthma exacerbations are most commonly triggered by viral respiratory infections, particularly with human rhinovirus. Given the importance of these events to asthma morbidity and health care costs, we will review common inciting factors for asthma exacerbations and approaches to prevent and treat these events</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.05.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689842">PM:28689842</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-918-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-918-27.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170710, Castillo JR</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.05.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41962</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hall,C.</style></author><author><style face="normal" font="default"> Nici,L.</style></author><author><style face="normal" font="default"> Sood,S.</style></author><author><style face="normal" font="default"> ZuWallack,R.</style></author><author><style face="normal" font="default"> Castro,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Washington University School of Medicine, St Louis, Mo</style></auth-address><titles><title><style face="normal" font="default">Nonpharmacologic Therapy for Severe Persistent Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="935" start="928">928-935</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway remodeling</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchial thermoplasty</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health care utilization</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory mediators</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Nerve Endings</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Randomized Controlled Trials</style></keyword><keyword><style face="normal" font="default"> rehabilitation</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> Washington</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">The treatment of asthma largely depends on guideline-based pharmacologic therapies. However, nonpharmacologic therapies for asthma such as pulmonary rehabilitation, focused breathing techniques, and bronchial thermoplasty have an important, yet underappreciated, role. Structured pulmonary rehabilitation programs can reduce dyspnea and increase cardiopulmonary fitness. The educational component of these programs can ensure that therapies are being used appropriately, increase compliance, and decrease health care utilization. Studies have demonstrated a reduction in inflammatory mediators in patients with asthma who are engaged in an exercise program. Focused breathing techniques are commonly used by patients with asthma, yet benefit has not been clearly shown in randomized controlled trials. For the patients with severe asthma who are unresponsive to maximum medical therapy and have evidence of airway remodeling, bronchial thermoplasty has demonstrated long-term improvement in quality of life and reduction in severe exacerbations and health care utilization. Recent airway biopsy studies have demonstrated bronchial thermoplasty's disease-modifying effect on smooth muscle, inflammatory mediators, and bronchial nerve endings. These nonpharmacologic therapies are complementary to current guideline-based treatment, including the use of biologic modifiers, for severe asthma</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.04.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689843">PM:28689843</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-928-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-928-35.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170710, Hall C</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.04.030</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41963</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pepper,A.N.</style></author><author><style face="normal" font="default"> Renz,H.</style></author><author><style face="normal" font="default"> Casale,T.B.</style></author><author><style face="normal" font="default"> Garn,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida Morsani College of Medicine and James A. Haley Veterans' Affairs Hospital, Tampa, Fla</style></auth-address><titles><title><style face="normal" font="default">Biologic Therapy and Novel Molecular Targets of Severe Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="916" start="909">909-916</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Biologic therapy</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Endotypes</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Florida</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Indications</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> reslizumab</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Veterans</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Treatment options for severe or uncontrolled asthma are increasing, especially pertaining to novel biologic therapies. The 2 primary asthma endotypes, T2 high and T2 low, are defined by the level of type 2 T helper and innate lymphoid cell activity and mediators. Most therapies for severe asthma target T2 high asthma, including the 3 biologics approved for use in the United States and Europe: omalizumb, mepolizumb, and reslizumab. Other biologics, with various molecular targets, are under investigation. Unfortunately, treatment options for T2 low asthma are limited. Although these therapies may improve asthma symptoms, exacerbation rates, and lung function parameters, they have not been shown to modify the disease process or provide lasting benefits after discontinuation. Biomarkers identified thus far to help guide individualized therapy in severe asthma are helpful, but imperfect discriminators for picking the best option for individual patients. This review will discuss the mechanisms of action, indications, and therapeutic effects of currently available and emerging biologics for the treatment of severe or uncontrolled asthma</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.04.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689841">PM:28689841</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-909-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-909-16.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170710, Pepper AN</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.04.038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41964</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Carr,T.F.</style></author><author><style face="normal" font="default"> Kraft,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Asthma and Airway Disease Research Center, University of Arizona, Tucson, Ariz.</style></auth-address><titles><title><style face="normal" font="default">Management of Severe Asthma before Referral to the Severe Asthma Specialist</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="886" start="877">877-886</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> Arizona</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma specialist</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medication adherence</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Personalized medicine</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Severe asthma is associated with significant morbidity and can be challenging to assess and control, due to heterogeneity of disease, complexity of diagnosis, and impact of comorbidities. A structured approach to the assessment and management of severe asthma may be helpful to the practicing clinician. First, it is important to confirm a diagnosis of asthma. In patients who are either not responding to treatment, or who require high doses of medication to control symptoms, it is highly possible that disease mimickers or comorbidities are present and can inhibit therapeutic responsiveness. The assessment and management of common comorbidities of asthma may dramatically impact disease control and thus medication requirement. Determining medication adherence and optimizing drug dose and delivery may separate out truly severe asthmatics from those not using medications regularly or properly. Next, although true personalized medicine for severe asthma is not yet realized, for those individuals with severe asthma, phenotypic characteristics of each patient may guide which therapeutic options may be most effective for that patient. Finally, evaluation and management of severe asthma at a referral center can add additional phenotyping, therapeutic, and diagnostic strategies</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.04.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689838">PM:28689838</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-877-86.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-877-86.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170710, Carr TF</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.04.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41965</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fitzpatrick,A.M.</style></author><author><style face="normal" font="default"> Moore,W.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Emory University, Atlanta, GaElectronic address: wmoore@wakehealth.edu</style></auth-address><titles><title><style face="normal" font="default">Severe Asthma Phenotypes - How Should They Guide Evaluation and Treatment?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="908" start="901">901-908</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical phenotypes</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Endotypes</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Although patients with "severe" asthma tend to be characterized by ongoing symptoms and airway inflammation despite treatment with high doses of inhaled and systemic corticosteroids, there is increasing recognition of marked phenotypic heterogeneity within affected patients. Although "precision medicine" approaches for patients with severe asthma are needed, there are many hurdles that must be overcome in daily practice. The National Heart, Lung and Blood Institute's Severe Asthma Research Program (SARP) has been at the forefront of phenotype discovery in severe asthma for the past decade. SARP, along with other international groups, has described clinical severe asthma phenotypes in both adults and children that can be evaluated in the clinical setting. Although these clinical phenotypes provide a good "starting point" for addressing disease heterogeneity in severe asthma in everyday practice, more efforts are needed to understand how these phenotypes relate to underlying disease mechanisms and pharmacological treatment responses. This review highlights the clinical asthma phenotypes identified to date, their associations with underlying endotypes and potential biomarkers, and remaining knowledge gaps that must be addressed before precision medicine can become a reality for patients with severe asthma</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.05.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689840">PM:28689840</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-901-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-901-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170710, Fitzpatrick AM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.05.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41966</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Moore,W.C.</style></author><author><style face="normal" font="default"> Castro,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Section of Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NCDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Washington University School of Medicine, St Louis, Mo. Electronic address: castrom@wustl.edu</style></auth-address><titles><title><style face="normal" font="default">The Many "Buckets" of Severe Asthma: Moving Toward Personalized Management</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="937" start="936">936-937</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Washington</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.05.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689844">PM:28689844</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-936-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-936-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170710, Moore WC</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.05.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41967</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guilbert,T.W.</style></author><author><style face="normal" font="default"> Price,D.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary Medicine, Cincinnati Children's Hospital and Medical Center, Cincinnati, Ohio</style></auth-address><titles><title><style face="normal" font="default">Reply (Refers to: Real-Life Outcomes for Patients with Asthma Prescribed Spacers for Use with Either Extrafine- or Fine-Particle Inhaled Corticosteroids)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1164" start="1163">1163-1164</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Ohio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Medicine</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 2213-2201 (Electronic)LA - engPT - LetterCO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.010.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689834">PM:28689834</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1163-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1163-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170710, Guilbert TW</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.010.</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41968</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lipworth,B.</style></author><author><style face="normal" font="default"> Jabbal,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Scottish Centre for Respiratory Research, Molecular &amp; Clinical Medicine, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, Scotland, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default">Impact of Spacers on Therapeutic Ratio with Inhaled Corticosteroids</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="1163">1163-</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical Medicine</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Scotland</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 2213-2201 (Electronic)LA - engPT - LetterCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689833">PM:28689833</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1163.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-1163.pdf</url></text-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170710, Lipworth B</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41969</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Namazy,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Scripps Clinic, Allergy and Immunology, La Jolla, Calif.</style></auth-address><titles><title><style face="normal" font="default">More Reason to Watch Your Weight During Pregnancy</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="989" start="988">988-989</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.05.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689847">PM:28689847</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-988-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-988-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170710, Namazy JA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.05.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41970</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jarjour,N.N.</style></author><author><style face="normal" font="default"> Hogan,M.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wis.</style></auth-address><titles><title><style face="normal" font="default">A Systematic Approach to Evaluating Difficult to Control Asthma: A Little Goes a Long Way</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="966" start="965">965-966</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Wisconsin</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.03.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689845">PM:28689845</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-965-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-965-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170710, Jarjour NN</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.03.038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41971</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Teague,W.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Child Health Research Center, University of Virginia School of Medicine, Charlottesville, Va.</style></auth-address><titles><title><style face="normal" font="default">Up in Smoke: Accelerated Loss of Lung Function in Two Clusters of Smokers Identified in a Longitudinal Cohort Study of Adult-Onset Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="980" start="979">979-980</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult-onset asthma</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Smoke</style></keyword><keyword><style face="normal" font="default"> smokers</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Virginia</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default"> 10.1016/j.jaip.2017.03.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689846">PM:28689846</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-979-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\2017-5-979-80.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170710, Teague WC</style></custom2><misc3><style face="normal" font="default"> 10.1016/j.jaip.2017.03.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41972</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Alroqi,F.J.</style></author><author><style face="normal" font="default"> Charbonnier,L.M.</style></author><author><style face="normal" font="default"> Baris,S.</style></author><author><style face="normal" font="default"> Kiykim,A.</style></author><author><style face="normal" font="default"> Chou,J.</style></author><author><style face="normal" font="default"> Platt,C.D.</style></author><author><style face="normal" font="default"> Algassim,A.</style></author><author><style face="normal" font="default"> Keles,S.</style></author><author><style face="normal" font="default"> Al Saud,B.K.</style></author><author><style face="normal" font="default"> Alkuraya,F.S.</style></author><author><style face="normal" font="default"> Jordan,M.</style></author><author><style face="normal" font="default"> Geha,R.S.</style></author><author><style face="normal" font="default"> Chatila,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunology, The Boston Children's Hospital. Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA</style></auth-address><titles><title><style face="normal" font="default">Exaggerated T Follicular Helper Cell Responses in LRBA Deficiency Due to Failure of CTLA4-Mediated Regulation</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Analyse</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Autoantibodies</style></keyword><keyword><style face="normal" font="default"> Autoimmunity</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Cell Differentiation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Coculture</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> dysregulation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> IL-2</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune dysregulation</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Saudi Arabia</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T lymphocyte</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> T-lymphocyte</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="default">PURPOSE: LRBA (lipopolysaccharide-responsive beige like anchor protein) and CTLA4 (cytotoxic T lymphocyte antigen 4) deficiencies give rise to overlapping phenotypes of immune dysregulation and autoimmunity, with dramatically increased frequencies of circulating T Follicular helper (cTFH) cells. We sought to determine the mechanisms of cTFH cell dysregulation in LRBA deficiency and the utility of monitoring cTFH cells as a correlate of clinical response to CTLA4-Ig therapy. METHODS: cTFH cells and other lymphocyte subpopulations were characterized. Functional analyses included in vitro TFH cell differentiation and cTFH/naive B cell co-cultures. Serum soluble IL-2 receptor alpha chain (sIL-2Ralpha), and in vitro immunoglobulin production by cultured B cells were quantified by ELISA. RESULTS: cTFH cell frequencies in patients with LRBA or CTLA4 deficiency sharply declined with CTLA4-Ig therapy, in parallel with other markers of immune dysregulation including sIL-2Ralpha, CD45RO+CD4+ effector T cells and auto-antibodies, and predictive of favorable clinical responses. cTFH cells in patients with LRBA deficiency were biased towards a TH1-like cell phenotype, which was partially reversed by CTLA4-Ig therapy. LRBA-sufficient but not -deficient regulatory T (Treg) cells suppressed in vitro TFH cell differentiation in a CTLA4-dependent manner. LRBA deficient TFH cells supported in vitro antibody production by naive LRBA-sufficient B cells. CONCLUSIONS: cTFH cell dysregulation in LRBA deficiency reflects impaired control of TFH differentiation due to profoundly decreased CTLA4 expression on Treg cells, and probably contributes to autoimmunity in this disease. Serial monitoring of cTFH cell frequencies is highly useful in gauging the clinical response of LRBA deficient patients to CTLA4-Ig therapy</style></abstract><notes><style face="normal" font="default">DA - 20170611IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Turkey -CO - Saudi Arabia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28601686">PM:28601686</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170611-AlroqiFJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170611-AlroqiFJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170611, Alroqi FJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.022</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41973</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Honda,T.</style></author><author><style face="normal" font="default"> Nomura,T.</style></author><author><style face="normal" font="default"> Kabashima,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.</style></auth-address><titles><title><style face="normal" font="default">Advances in atopic dermatitis and urticaria, 2016</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-31</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> Staphylococcus</style></keyword><keyword><style face="normal" font="default"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="23" Month="6" Year="2017">2017/6/23</year></dates><abstract><style face="normal" font="default">This review highlights recent key advances in the pathology and therapies of inflammatory skin diseases, focusing on atopic dermatitis (AD) and chronic spontaneous urticaria (CSU). Regarding AD, transcriptomic analysis using human samples revealed different immune profiles between childhood AD and adult AD. Phase III clinical trials of dupilumab, an anti-IL4 receptor alpha antibody, on AD have successfully finished, and dupilumab will appear in clinical practice as the first biologics for AD in 2017. In addition, a novel biologics that targets IL-31 shows promising results in a phase II trial. As for the skin microbiome study, novel insights into the mechanisms of microbial dysbiosis such as the colonization of Staphylococcus aureus, a common feature of AD, were proposed. Regarding CSU, autoreactive CD4+ T cells that react to FcepsilonRI were discovered, which may potentially contribute to the development of CSU. These findings give new insights into the pathogenesis of AD and CSU, and will lead to more specific and personalized treatments</style></abstract><notes><style face="normal" font="default">DA - 20170627IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28652155">PM:28652155</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170627-HondaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170627-HondaT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170627, Honda T</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41974</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Heimall,J.</style></author><author><style face="normal" font="default"> Spergel,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Children's Hospital of Philadelphia, Division of Allergy and Immunology, Department of Pediatrics, Perelman School of Medicine at University of Pennsylvania</style></auth-address><titles><title><style face="normal" font="default">New pathways for itching in atopic dermatitis?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pennsylvania</style></keyword><keyword><style face="normal" font="default"> Philadelphia</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="23" Month="6" Year="2017">2017/6/23</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170627IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28652154">PM:28652154</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170627-HeimallJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170627-HeimallJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170627, Heimall J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41975</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Akiyama,M.</style></author><author><style face="normal" font="default"> Takeichi,T.</style></author><author><style face="normal" font="default"> McGrath,J.A.</style></author><author><style face="normal" font="default"> Sugiura,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</style></auth-address><titles><title><style face="normal" font="default">Autoinflammatory keratinization diseases</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="28" Month="6" Year="2017">2017/6/28</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170702IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - Japan -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28668225">PM:28668225</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170702-AkiyamaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170702-AkiyamaM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170702, Akiyama M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41976</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ndika,J.</style></author><author><style face="normal" font="default"> Airaksinen,L.</style></author><author><style face="normal" font="default"> Suojalehto,H.</style></author><author><style face="normal" font="default"> Karisola,P.</style></author><author><style face="normal" font="default"> Fyhrquist,N.</style></author><author><style face="normal" font="default"> Puustinen,A.</style></author><author><style face="normal" font="default"> Alenius,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Bacteriology and Immunology, Medicum, University of Helsinki, Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="default">Epithelial proteome profiling suggests essential role of interferon-inducible proteins in allergic rhinitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> Bacteriology</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Interferon</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal congestion</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pollen</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Protease</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> proteome</style></keyword><keyword><style face="normal" font="default"> Proteomics</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> SAR</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> seasonal allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Seasons</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Sneezing</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="17" Month="6" Year="2017">2017/6/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Seasonal allergic rhinitis (SAR) as a result of intermittent exposure to seasonal pollen, causes itching, nasal congestion and repeated sneezing, with profound effects on the quality of life, work productivity and school performance. While both the genotype and environmental factors may contribute to the immunological basis of allergic reactions, the molecular underpinnings associated with the pathogenesis of allergic rhinitis are not entirely clear. METHODS: To address these questions, nasal epithelial brushings were collected from 29 SAR and 31 Control individuals during and after the pollen season. We then implemented an orbitrap-based, bottom up label free quantitative proteomics approach, followed by multivariate analyses to identify differentially abundant proteins between the four sample groups. RESULTS: We identified a total of 133 differentially abundant proteins for which the most significantly overrepresented functional category was found to be interferon 1 signaling. Two proteins, CST1 and PRNT3, of which the former protects against protease activity of allergens and the latter has a role in epithelial barrier function, were differentially abundant in SAR and Control individuals irrespective of season. Moreover, IFIT1, CST1 and IFIT3 were found to be differentially regulated between SAR and Control individuals, with inverse abundance dynamics during the transition from fall to spring. CONCLUSION: We identified type 1 interferon regulated proteins as biomarkers in SAR, potentially playing an important role in its pathogenesis. Moreover, when compared to SAR patients, healthy individuals exhibit an antagonistic proteome response across seasons, which may yet prove to be a therapeutic target for disease prevention</style></abstract><notes><style face="normal" font="default">DA - 20170621IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28633877">PM:28633877</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170621-NdikaJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170621-NdikaJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170621, Ndika J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.040</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41977</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Petersheim,D.</style></author><author><style face="normal" font="default"> Massaad,M.J.</style></author><author><style face="normal" font="default"> Lee,S.</style></author><author><style face="normal" font="default"> Scarselli,A.</style></author><author><style face="normal" font="default"> Cancrini,C.</style></author><author><style face="normal" font="default"> Moriya,K.</style></author><author><style face="normal" font="default"> Sasahara,Y.</style></author><author><style face="normal" font="default"> Lankester,A.C.</style></author><author><style face="normal" font="default"> Dorsey,M.</style></author><author><style face="normal" font="default"> Di Giovanni,D.</style></author><author><style face="normal" font="default"> Bezrodnik,L.</style></author><author><style face="normal" font="default"> Ohnishi,H.</style></author><author><style face="normal" font="default"> Nishikomori,R.</style></author><author><style face="normal" font="default"> Tanita,K.</style></author><author><style face="normal" font="default"> Kanegane,H.</style></author><author><style face="normal" font="default"> Morio,T.</style></author><author><style face="normal" font="default"> Gelfand,E.W.</style></author><author><style face="normal" font="default"> Jain,A.</style></author><author><style face="normal" font="default"> Secord,E.</style></author><author><style face="normal" font="default"> Picard,C.</style></author><author><style face="normal" font="default"> Casanova,J.L.</style></author><author><style face="normal" font="default"> Albert,M.H.</style></author><author><style face="normal" font="default"> Torgerson,T.R.</style></author><author><style face="normal" font="default"> Geha,R.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA</style></auth-address><titles><title><style face="normal" font="default">Severe disease and greater impairment of NF-kappaB activation in IkappaBa point mutants versus truncation mutants in autosomal dominant anhidrotic ectodermal dysplasia with immune deficiency</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> Argentina</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Degradation</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Ectodermal Dysplasia</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Fibroblasts</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hematopoietic Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Mutant</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> Point Mutation</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="6" Year="2017">2017/6/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Autosomal dominant anhidrotic ectodermal dysplasia with immune deficiency (AD EDA-ID) is caused by heterozygous point mutations at or close to S32 and S36 or N-terminal truncations in IkappaBalpha that impair its phosphorylation and degradation, and thus activation of the canonical NF-kappaB pathway. The outcome of hematopoietic stem cell transplantation is poor in AD EDA-ID despite achievement of chimerism. Mice heterozygous for the S32I mutation in IkappaBalpha have impaired non-canonical NF-kappaB activity and defective lymphorganogenesis. OBJECTIVE: To establish genotype-phenotype correlation in AD EDA-ID. METHODS: A disease severity scoring system was devised. Stability of IkappaBalpha mutants was examined in transfected cells. Immunological, biochemical, and gene expression analyses were performed to evaluate canonical and non-canonical NF-kappaB signaling in skin-derived fibroblasts. RESULTS: Disease severity was greater in patients with IkappaBalpha point mutations than in patients with truncation mutations. IkappaBalpha point mutants were expressed at significantly higher levels in transfectants compared to truncation mutants. Canonical NF-kappaB-dependent IL-6 secretion and upregulation of the NF-kappaB2/p100 and RelB components of the non-canonical NF-kappaB pathway were diminished significantly more in patients with point mutations compared to those with truncations. Non-canonical NF-kappaB-driven generation of the transcriptionally active p100 cleavage product p52, and upregulation of CCL20, ICAM1 and VCAM1, important for lymphorganogenesis, were diminished significantly more in LPS+alpha-LTbetaR-stimulated fibroblasts from patients with point mutations compared to those with truncations. CONCLUSIONS: IkappaBalpha point mutants accumulate at higher levels compared to truncation mutants and are associated with more severe disease and greater impairment of canonical and non-canonical NF-kappaB activity in AD EDA-ID</style></abstract><notes><style face="normal" font="default">DA - 20170620IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Japan -CO - Netherlands -CO - Argentina -CO - France -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28629746">PM:28629746</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170620-PetersheimD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170620-PetersheimD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170620, Petersheim D</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.030</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41978</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Abuabara,K.</style></author><author><style face="normal" font="default"> Hoffstad,O.</style></author><author><style face="normal" font="default"> Troxel,A.B.</style></author><author><style face="normal" font="default"> Gelfand,J.M.</style></author><author><style face="normal" font="default"> McCulloch,C.E.</style></author><author><style face="normal" font="default"> Margolis,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of California San Francisco (UCSF), San Francisco, CA.</style></auth-address><titles><title><style face="normal" font="default">Patterns and predictors of atopic dermatitis disease control past childhood: An observational cohort study</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Age of Onset</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Income</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> race</style></keyword><keyword><style face="normal" font="default"> San Francisco</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="16" Month="6" Year="2017">2017/6/16</year></dates><abstract><style face="normal" font="default">Individuals experience distinct patterns of atopic dermatitis disease control over time; female sex, lower income, non-white race, atopic history and earlier age of onset were highly predictive of persistently active disease into early adulthood</style></abstract><notes><style face="normal" font="default">DA - 20170620IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28629748">PM:28629748</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170620-AbuabaraK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170620-AbuabaraK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170620, Abuabara K</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.031</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41979</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Klemann,C.</style></author><author><style face="normal" font="default"> Ammann,S.</style></author><author><style face="normal" font="default"> Heizmann,M.</style></author><author><style face="normal" font="default"> Fuchs,S.</style></author><author><style face="normal" font="default"> Bode,S.F.</style></author><author><style face="normal" font="default"> Heeg,M.</style></author><author><style face="normal" font="default"> Fuchs,H.</style></author><author><style face="normal" font="default"> Lehmberg,K.</style></author><author><style face="normal" font="default"> Zur,Stadt U.</style></author><author><style face="normal" font="default"> Roll,C.</style></author><author><style face="normal" font="default"> Vraetz,T.</style></author><author><style face="normal" font="default"> Speckmann,C.</style></author><author><style face="normal" font="default"> Lorenz,M.R.</style></author><author><style face="normal" font="default"> Schwarz,K.</style></author><author><style face="normal" font="default"> Rohr,J.</style></author><author><style face="normal" font="default"> Feske,S.</style></author><author><style face="normal" font="default"> Ehl,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany</style></auth-address><titles><title><style face="normal" font="default">Hemophagocytic lymphohistiocytosis as presenting manifestation of profound combined immunodeficiency due to an ORAI1 mutation</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">chronic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="17" Month="6" Year="2017">2017/6/17</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170621IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28633876">PM:28633876</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170621-KlemannC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170621-KlemannC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170621, Klemann C</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.039</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41980</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Renz,H.</style></author><author><style face="normal" font="default"> Holt,P.G.</style></author><author><style face="normal" font="default"> Inouye,M.</style></author><author><style face="normal" font="default"> Logan,A.C.</style></author><author><style face="normal" font="default"> Prescott,S.L.</style></author><author><style face="normal" font="default"> Sly,P.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Laboratory Medicine, Philipps-University Marburg, Marburg, Germany</style></auth-address><titles><title><style face="normal" font="default">An exposome perspective: Early-life events and immune development in a changing world</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="40" start="24">24-40</pages><volume><style face="normal" font="default">140</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Genome</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human health</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metabolomics</style></keyword><keyword><style face="normal" font="default"> microbes</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Personalized medicine</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Proteomics</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Urbanization</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Advances in metagenomics, proteomics, metabolomics, and systems biology are providing a new emphasis in research; interdisciplinary work suggests that personalized medicine is on the horizon. These advances are illuminating sophisticated interactions between human-associated microbes and the immune system. The result is a transformed view of future prevention and treatment of chronic noncommunicable diseases, including allergy. Paradigm-shifting gains in scientific knowledge are occurring at a time of rapid global environmental change, urbanization, and biodiversity losses. Multifactorial and multigenerational implications of total environmental exposures, the exposome, require coordinated interdisciplinary efforts. It is clear that the genome alone cannot provide answers to urgent questions. Here we review the historical origins of exposome research and define a new concept, the metaexposome, which considers the bidirectional effect of the environment on human subjects and the human influence on all living systems and their genomes. The latter is essential for human health. We place the metaexposome in the context of early-life immune functioning and describe how various aspects of a changing environment, especially through microbiota exposures, can influence health and disease over the life course</style></abstract><notes><style face="normal" font="default">DA - 20170704IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28673401">PM:28673401</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-140-24-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-140-24-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170704, Renz H</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41981</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yang,I.V.</style></author><author><style face="normal" font="default"> Lozupone,C.A.</style></author><author><style face="normal" font="default"> Schwartz,D.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, University of Colorado, School of Medicine, Aurora, Colo;</style></auth-address><titles><title><style face="normal" font="default">The environment, epigenome, and asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="23" start="14">14-23</pages><volume><style face="normal" font="default">140</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> North America</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Publications</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Asthma prevalence has been on the increase, especially in North America compared with other continents. However, the prevalence of asthma differs worldwide, and in many countries the prevalence is stable or decreasing. This highlights the influence of environmental exposures, such as allergens, air pollution, and the environmental microbiome, on disease etiology and pathogenesis. The epigenome might provide the unifying mechanism that translates the influence of environmental exposures to changes in gene expression, respiratory epithelial function, and immune cell skewing that are hallmarks of asthma. In this review we will introduce the concept of the environmental epigenome in asthmatic patients, summarize previous publications of relevance to this field, and discuss future directions</style></abstract><notes><style face="normal" font="default">DA - 20170704IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28673400">PM:28673400</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-140-14-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-140-14-23.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170704, Yang IV</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41982</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Burbank,A.J.</style></author><author><style face="normal" font="default"> Sood,A.K.</style></author><author><style face="normal" font="default"> Kesic,M.J.</style></author><author><style face="normal" font="default"> Peden,D.B.</style></author><author><style face="normal" font="default"> Hernandez,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Environmental Medicine, Asthma and Lung Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC</style></auth-address><titles><title><style face="normal" font="default">Environmental determinants of allergy and asthma in early life</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="12" start="1">1-12</pages><volume><style face="normal" font="default">140</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergen exposure</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic sensitization</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> diversity</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Environmental Exposure</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic susceptibility</style></keyword><keyword><style face="normal" font="default"> indoor</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbial</style></keyword><keyword><style face="normal" font="default"> North Carolina</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Primary Prevention</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Allergic disease prevalence has increased significantly in recent decades. Primary prevention efforts are being guided by study of the exposome (or collective environmental exposures beginning during the prenatal period) to identify modifiable factors that affect allergic disease risk. In this review we explore the evidence supporting a relationship between key components of the external exposome in the prenatal and early-life periods and their effect on atopy development focused on microbial, allergen, and air pollution exposures. The abundance and diversity of microbial exposures during the first months and years of life have been linked with risk of allergic sensitization and disease. Indoor environmental allergen exposure during early life can also affect disease development, depending on the allergen type, dose, and timing of exposure. Recent evidence supports the role of ambient air pollution in allergic disease inception. The lack of clarity in the literature surrounding the relationship between environment and atopy reflects the complex interplay between cumulative environmental factors and genetic susceptibility, such that no one factor dictates disease development in all subjects. Understanding the effect of the summation of environmental exposures throughout a child's development is needed to identify cost-effective interventions that reduce atopy risk in children</style></abstract><notes><style face="normal" font="default">DA - 20170704IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28673399">PM:28673399</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-140-1-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-140-1-12.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170704, Burbank AJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41983</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Akdis,C.A.</style></author><author><style face="normal" font="default"> Byrne,J.</style></author><author><style face="normal" font="default"> Ballas,Z.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default">The Journal of Allergy and Clinical Immunology: An update on style and substance</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="62" start="60">60-62</pages><volume><style face="normal" font="default">140</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170704IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - Switzerland -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28673404">PM:28673404</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-140-60-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-140-60-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170704, Akdis CA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41984</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hauck,F.</style></author><author><style face="normal" font="default"> Voss,R.</style></author><author><style face="normal" font="default"> Urban,C.</style></author><author><style face="normal" font="default"> Seidel,M.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunodeficiency Unit and Immunological Diagnostics Laboratory, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University, Munich, Germany</style></auth-address><titles><title><style face="normal" font="default">Intrinsic and Extrinsic Causes of Malignancies in Primary Immunodeficiency Disorders</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Austria</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostics</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> malignancy</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="default"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathomechanisms</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Repair</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Transformation</style></keyword><keyword><style face="normal" font="default"> Viruses</style></keyword></keywords><dates><year Day="29" Month="6" Year="2017">2017/6/29</year></dates><abstract><style face="normal" font="default">Malignancies occur with a higher incidence rate and manifest earlier in life in patients with primary immunodeficiency disorders (PID) than in the general population. However, no universal mechanism of malignancy predisposition in PID can been determined. Despite the strong support for the physiological role of tumor immunosurveillance and increasing success of strategies in immunological tumor therapy, which include checkpoint inhibition, monoclonal antibodies, and engineered T cell antigen receptors, the incidence and pattern of malignancies in PID do not reflect an increased tumor immune escape per se. In contrast, malignancies appear to be restricted to either i) tissue types bearing the same molecular defect that underlies the PID such as syndromes of DNA repair deficiency or immune cell-specific maturation or functional defects that suggest a cell-intrinsic oncogenic basis, or ii) other tissues when they are infected by transforming viruses or chronically inflamed, pointing towards extrinsic causes for transformation that are potentially facilitated by but not predominantly owed to a lack of immunosurveillance. Based on recent studies of preexisting conditions in malignancy patients and on malignancies in large PID cohorts, we conclude that a large part of tumor predisposition in PID is derived from the same molecular defect as the immunodeficiency itself. The presented concept elucidates diverse pathomechanisms and risks of malignancies in PID in the light of current tumor immune therapies</style></abstract><notes><style face="normal" font="default">DA - 20170703IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Austria -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28669558">PM:28669558</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170703-HauckF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170703-HauckF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170703, Hauck F</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41985</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,H.</style></author><author><style face="normal" font="default"> Do,D.C.</style></author><author><style face="normal" font="default"> Liu,J.</style></author><author><style face="normal" font="default"> Wang,B.</style></author><author><style face="normal" font="default"> Qu,J.</style></author><author><style face="normal" font="default"> Ke,X.</style></author><author><style face="normal" font="default"> Luo,X.</style></author><author><style face="normal" font="default"> Tang,H.M.</style></author><author><style face="normal" font="default"> Tang,H.L.</style></author><author><style face="normal" font="default"> Hu,C.</style></author><author><style face="normal" font="default"> Anderson,M.E.</style></author><author><style face="normal" font="default"> Liu,Z.</style></author><author><style face="normal" font="default"> Gao,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA;</style></auth-address><titles><title><style face="normal" font="default">Functional Role of Kynurenine and Aryl hydrocarbon Receptor Axis in Chronic Rhinosinusitis with Nasal Polyps</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> Baltimore</style></keyword><keyword><style face="normal" font="default"> Ca2+</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Intracellular Ca2+</style></keyword><keyword><style face="normal" font="default"> Kynurenine</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> Non-eosinophilic</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Ovalbumin</style></keyword><keyword><style face="normal" font="default"> oxidant</style></keyword><keyword><style face="normal" font="default"> Oxygen</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> ROS</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Tryptophan</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="6" Month="7" Year="2017">2017/7/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with mast cell-mediated inflammation and heightened oxidant stress. Kynurenine (KYN), an endogenous tryptophan metabolite, can promote allergen-induced mast cell activation through the aryl hydrocarbon receptor (AhR). OBJECTIVES: Determine the role of the KYN/AhR axis and oxidant stress in mast cell activation and the development of CRSwNP. METHODS: We measured expression of indoleamine 2, 3-dioxygenase 1 (IDO1), tryptophan 2, 3-dioxygenase (TDO2), KYN, and oxidized calmodulin-dependent protein kinase II (ox-CaMKII) in nasal polyps and controls. KYN-potentiated ovalbumin (OVA)-induced reactive oxygen species (ROS) generation, cell activation, and ox-CaMKII expression were investigated in wild type (WT) and AhR deficient (AhR-/-) mast cells. The role of ox-CaMKII in mast cell activation was further investigated. RESULTS: Nasal polyps in CRSwNP showed an increased expression of IDO1, TDO2, and KYN compared with controls. AhR was predominantly expressed in mast cells in nasal polyps. Activated mast cells and local IgE levels were substantially increased in eosinophilic polyps compared with non-eosinophilic polyps and controls. Furthermore, KYN potentiated OVA-induced ROS generation, intracellular Ca2+ levels, cell activation, and expression of ox-CaMKII in WT, but not in AhR-/- mast cells. Compared with non-eosinophilic polyps and controls, eosinophilic polyps showed increased expression of ox-CaMKII in mast cells. Mast cells from ROS-resistant CaMKII MMVVdelta mice or pre-treated with CaMKII inhibitor showed protection against KYN-promoted OVA-induced mast cell activation. CONCLUSION: These studies support a potentially critical but previously unidentified function of the KYN/AhR axis in regulating IgE-mediated mast cell activation through ROS and ox-CaMKII in CRSwNP</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689792">PM:28689792</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170710-WangH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170710-WangH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170710, Wang H</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41986</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Reddy,V.B.</style></author><author><style face="normal" font="default"> Graham,T.A.</style></author><author><style face="normal" font="default"> Azimi,E.</style></author><author><style face="normal" font="default"> Lerner,E.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129</style></auth-address><titles><title><style face="normal" font="default">A single amino acid in MRGPRX2 necessary for binding and activation by pruritogens</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Amino acid</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Itch</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Substance P</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="6" Month="7" Year="2017">2017/7/6</year></dates><abstract><style face="normal" font="default">Substance P, a neuropeptide associated with itch, atopic dermatitis and inflammation, activates MRGPRX2, a member of the mas-related GPCR family. A specific amino acid in the receptor has been found to be critical for activity</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28689793">PM:28689793</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170710-ReddyVB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170710-ReddyVB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170710, Reddy VB</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.046</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41987</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Semitekolou,M.</style></author><author><style face="normal" font="default"> Morianos,I.</style></author><author><style face="normal" font="default"> Banos,A.</style></author><author><style face="normal" font="default"> Konstantopoulos,D.</style></author><author><style face="normal" font="default"> mou-Tzani,M.</style></author><author><style face="normal" font="default"> Sparwasser,T.</style></author><author><style face="normal" font="default"> Xanthou,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cellular Immunology Laboratory, Center for Basic Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece</style></auth-address><titles><title><style face="normal" font="default">Dendritic cells conditioned by activin A-induced regulatory T cells exhibit enhanced tolerogenic properties and protect against experimental asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> allergic response</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Biomedical Research</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> DC</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Gene Expression Profiling</style></keyword><keyword><style face="normal" font="default"> gene profiling</style></keyword><keyword><style face="normal" font="default"> Genome-wide</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Immunotherapy</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> LPS</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> priming</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> regulatory T cell</style></keyword><keyword><style face="normal" font="default"> regulatory T cells</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Previously, we demonstrated that regulatory T (Treg) cells induced by the cytokine activin-A suppress TH2-mediated allergic responses and linked airway disease. Still, the effects of activin-A-induced regulatory T (Act-A-iTreg) cells on the regulation of dendritic cell (DC)-driven allergic inflammation remain elusive. OBJECTIVE: Here we investigated whether Act-A-iTreg cells can modulate DC responses and endow them with enhanced tolerogenic functions. METHODS: Using adoptive cell transfer studies in mouse models of allergic airway disease, we examined the effects of Act-A-iTreg cells on DC phenotype, maturation status, and TH2 cell priming potential. Genome-wide gene expression profiling characterized the transcriptional networks induced in tolerogenic DCs by Act-A-iTreg cells. The ability of DCs conditioned by Act-A-iTreg cells (Act-A-iTreg cell-modified DCs) to protect against experimental asthma, and the mechanisms involved were also explored. RESULTS: Act-A-iTreg cell-modified DCs exhibited a significantly impaired capacity to uptake allergen and stimulate naive and TH2 effector responses on allergen stimulation in vivo accompanied by markedly attenuated inflammatory cytokine release in response to LPS. Gene-profiling studies revealed that Act-A-iTreg cells dampened crucial TH2-skewing transcriptional networks in DCs. Administration of Act-A-iTreg cell-modified DCs ameliorated cardinal asthma manifestations in preventive and therapeutic protocols through generation of strongly suppressive forkhead box P3+ Treg cells. Finally, programed death protein 1/programmed death ligand 1 signaling pathways were essential in potentiating the generation of DCs with tolerogenic properties by Act-A-iTreg cells. CONCLUSION: Our studies reveal that Act-A-iTreg cells instruct the generation of a highly effective immunoregulatory circuit encompassing tolerogenic DCs and forkhead box P3+ Treg cells that could be targeted for the design of novel immunotherapies for allergic disorders</style></abstract><notes><style face="normal" font="default">DA - 20170605IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Greece -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28579377">PM:28579377</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170605-SemitekolouM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170605-SemitekolouM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170605, Semitekolou M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.047</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41988</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Robb,C.T.</style></author><author><style face="normal" font="default"> McSorley,H.J.</style></author><author><style face="normal" font="default"> Lee,J.</style></author><author><style face="normal" font="default"> Aoki,T.</style></author><author><style face="normal" font="default"> Yu,C.</style></author><author><style face="normal" font="default"> Crittenden,S.</style></author><author><style face="normal" font="default"> Astier,A.</style></author><author><style face="normal" font="default"> Felton,J.M.</style></author><author><style face="normal" font="default"> Parkinson,N.</style></author><author><style face="normal" font="default"> Ayele,A.</style></author><author><style face="normal" font="default"> Breyer,R.M.</style></author><author><style face="normal" font="default"> Anderton,S.M.</style></author><author><style face="normal" font="default"> Narumiya,S.</style></author><author><style face="normal" font="default"> Rossi,A.G.</style></author><author><style face="normal" font="default"> Howie,S.E.</style></author><author><style face="normal" font="default"> Guttman-Yassky,E.</style></author><author><style face="normal" font="default"> Weller,R.B.</style></author><author><style face="normal" font="default"> Yao,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical Research Council (MRC) Centre for Inflammation Research, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh EH16 4TJ, UK</style></auth-address><titles><title><style face="normal" font="default">Prostaglandin E2 stimulates adaptive IL-22 production and promotes allergic contact dermatitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adaptive</style></keyword><keyword><style face="normal" font="default"> Adenosine</style></keyword><keyword><style face="normal" font="default"> Adenosine Monophosphate</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> cAMP</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Haptens</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Increased prevalence</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Oxazolone</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Prostaglandin</style></keyword><keyword><style face="normal" font="default"> prostaglandin E2</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Up-Regulation</style></keyword></keywords><dates><year Day="2" Month="6" Year="2017">2017/6/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis (AD) and allergic contact dermatitis (ACD) are both forms of eczema and are common inflammatory skin diseases with a central role of Th22-derived IL-22 in their pathogenesis. Although prostaglandin E2 (PGE2) is known to promote inflammation, little is known about its role in processes related to AD and ACD development, including IL-22 up-regulation. OBJECTIVES: To investigate whether PGE2 has a role in IL-22 induction and development of ACD, which has increased prevalence in patients with AD. METHODS: T-cell cultures and in vivo sensitization of mice with haptens were used to assess the role of PGE2 in production of IL-22. The involvement of PGE2 receptors and their downstream signals were also examined. The effects of PGE2 were evaluated using the oxazolone (OXA)-induced ACD mouse model. The relationship of PGE2 and IL-22 signaling pathways in skin inflammation were also investigated using genomic profiling in human lesional AD skin. RESULTS: PGE2 induces IL-22 from T cells through its receptors EP2 and EP4 and involves cyclic adenosine monophosphate (cAMP) signaling. Selective deletion of EP4 in T-cells prevents hapten-induced IL-22 production in vivo, and inhibition of PGE2 synthesis limits atopic-like skin inflammation in the OXA-induced ACD model. Moreover, both PGE2 and IL-22 pathway genes were coordinately up-regulated in human AD lesional skin, but were below significant detection levels after corticosteroid or ultraviolet band B (UVB) treatments. CONCLUSIONS: Our results define a crucial role for PGE2 in promoting ACD by facilitating IL-22 production from T-cells. CLINICAL IMPLICATIONS: Allergic contact dermatitis is a common disabling disease characterized by elevated IL-22. The identification of a tightly regulated PGE2 driven pathway controlling IL-22 dysfunction offers a novel target for therapeutic intervention</style></abstract><notes><style face="normal" font="default">DA - 20170606IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -CO - Japan -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583370">PM:28583370</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170606-RobbCT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170606-RobbCT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170606, Robb CT</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.045</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41989</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wilson,S.R.</style></author><author><style face="normal" font="default"> Mulligan,M.J.</style></author><author><style face="normal" font="default"> Ayala,E.</style></author><author><style face="normal" font="default"> Chausow,A.</style></author><author><style face="normal" font="default"> Huang,Q.</style></author><author><style face="normal" font="default"> Knowles,S.B.</style></author><author><style face="normal" font="default"> Gummidipundi,S.</style></author><author><style face="normal" font="default"> Castro,M.</style></author><author><style face="normal" font="default"> Wise,R.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Palo Alto Medical Foundation Research Institute, Palo Alto, CA; Department of Medicine, Stanford University School of Medicine, Stanford, CA.</style></auth-address><titles><title><style face="normal" font="default">A New Measure to Assess Asthma's Impact on Quality of Life from the Patient's Perspective</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> adherence</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> QOL</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> treatment adherence</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: The Asthma Impact on Quality of Life Scale (A-IQOLS) assesses the negative effect of asthma on quality of life (QoL) from the patient's perspective, using dimensions of Flanagan's Quality of Life Scale (QOLS), a measure of current QoL. OBJECTIVES: To determine and compare the psychometric properties of the A-IQOLS and QOLS, including their sensitivities to differences and changes in asthma status. METHODS: In a test-retest design (3-5 week interval), adults with persistent asthma underwent spirometry and were administered the A-IQOLS, other asthma outcome measures (ACT, ASUI, Marks and Juniper AQLQs), and QOLS. RESULTS: Participants' (n = 147) mean age was 49 yrs.; 76% were White; 12% Hispanic; 65% female. A-IQOLS and QOLS scores were significantly correlated with other asthma outcomes scores except FEV1, but shared relatively low common variance with these measures. A-IQOLS, but not QOLS, score changes were significantly correlated with changes in asthma outcomes. The A-IQOLS SEM = 0.27 implies that a within-person score change of >/= +/-0.73 constitutes a true change. The QOLS SEM = 0.43. CONCLUSIONS: A-IQOLS provides a reliable, valid, and unique assessment of the patient-perceived negative effect of asthma on their QoL, suitable for use in asthma clinical research and potentially in clinical care. Further studies are needed in diverse patient populations. QOLS, a measure of current QoL, is less sensitive to disease status changes but may be useful in characterizing study populations, in treatment adherence research, and as a clinical and research tool in patients with multiple, severe, and/or life-limiting chronic conditions</style></abstract><notes><style face="normal" font="default">DA - 20170605IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.02.047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28579376">PM:28579376</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170605-WilsonSR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170605-WilsonSR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170605, Wilson SR</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.02.047</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41990</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wu,M.</style></author><author><style face="normal" font="default"> Woodrick,N.M.</style></author><author><style face="normal" font="default"> Arora,V.M.</style></author><author><style face="normal" font="default"> Farnan,J.M.</style></author><author><style face="normal" font="default"> Press,V.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pritzker School of Medicine, University of Chicago, Chicago, Ill</style></auth-address><titles><title><style face="normal" font="default">Developing a Virtual Teach-To-Goal Inhaler Technique Learning Module: A Mixed Methods Approach</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1736" start="1728">1728-1736</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> Computer</style></keyword><keyword><style face="normal" font="default"> Computers</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Feedback</style></keyword><keyword><style face="normal" font="default"> Focus Groups</style></keyword><keyword><style face="normal" font="default"> Functionality</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Education</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Inpatients</style></keyword><keyword><style face="normal" font="default"> Internet</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Learning</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Self-management</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Teaching</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="6" Month="6" Year="2017">2017/6/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Most hospitalized patients with asthma or chronic obstructive pulmonary disease misuse respiratory inhalers. An in-person educational strategy, teach-to-goal (TTG), improves inpatients' inhaler technique. OBJECTIVE: To develop an effective, portable education intervention that remains accessible to hospitalized patients postdischarge for reinforcement of proper inhaler technique. METHODS: A mixed methods approach at an urban academic hospital was used to iteratively develop, modify, and test a virtual teach-to-goal (V-TTG) educational intervention using patient end-user feedback. A survey examined access and willingness to use technology for self-management education. Focus groups evaluated patients' feedback on access, functionality, and quality of V-TTG. RESULTS: Forty-eight participants completed the survey, with most reporting having Internet access; 77% used the Internet at home and 82% used the Internet at least once every few weeks. More than 80% reported that they were somewhat or very likely to use V-TTG to gain skills to improve their health. Most participants reported smartphone access (73%); half owned laptop computers (52%). Participants with asthma versus chronic obstructive pulmonary disease were more likely to own a smartphone, have a data plan, and have daily Internet use (P &lt; .05). Nine focus groups (n = 25) identified themes for each domain: access-platform and delivery, Internet access, and technological literacy; functionality-usefulness, content, and teaching strategy; and quality-clarity, ease of use, length, and likability. CONCLUSIONS: V-TTG is a promising educational tool for improving patients' inhaler technique, iteratively developed and refined with patient input. Patients in our urban, academic hospital overwhelmingly reported access to platforms and willingness to use V-TTG for health education</style></abstract><notes><style face="normal" font="default">DA - 20170610IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.04.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28600133">PM:28600133</url></web-urls><related-urls><url ppv-ref="no">Presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170610, Wu M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.04.032</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41991</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Takada,S.</style></author><author><style face="normal" font="default"> Kambe,N.</style></author><author><style face="normal" font="default"> Kawasaki,Y.</style></author><author><style face="normal" font="default"> Niwa,A.</style></author><author><style face="normal" font="default"> Honda-Ozaki,F.</style></author><author><style face="normal" font="default"> Kobayashi,K.</style></author><author><style face="normal" font="default"> Osawa,M.</style></author><author><style face="normal" font="default"> Nagahashi,A.</style></author><author><style face="normal" font="default"> Semi,K.</style></author><author><style face="normal" font="default"> Hotta,A.</style></author><author><style face="normal" font="default"> Asaka,I.</style></author><author><style face="normal" font="default"> Yamada,Y.</style></author><author><style face="normal" font="default"> Nishikomori,R.</style></author><author><style face="normal" font="default"> Heike,T.</style></author><author><style face="normal" font="default"> Matsue,H.</style></author><author><style face="normal" font="default"> Nakahata,T.</style></author><author><style face="normal" font="default"> Saito,M.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Application, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan</style></auth-address><titles><title><style face="normal" font="default">Pluripotent stem cell models of Blau syndrome reveal an IFN-gamma-dependent inflammatory response in macrophages</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Autoinflammation</style></keyword><keyword><style face="normal" font="default"> Cell Lineage</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Mutant</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> priming</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rna</style></keyword><keyword><style face="normal" font="default"> Sarcoidosis</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="3" Month="6" Year="2017">2017/6/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Blau syndrome, or early-onset sarcoidosis, is a juvenile-onset systemic granulomatosis associated with a mutation in nucleotide-binding oligomerization domain 2 (NOD2). The underlying mechanisms of Blau syndrome leading to autoinflammation are still unclear, and there is currently no effective specific treatment for Blau syndrome. OBJECTIVES: To elucidate the mechanisms of autoinflammation in patients with Blau syndrome, we sought to clarify the relation between disease-associated mutant NOD2 and the inflammatory response in human samples. METHODS: Blau syndrome-specific induced pluripotent stem cell (iPSC) lines were established. The disease-associated NOD2 mutation of iPSCs was corrected by using a CRISPR-Cas9 system to precisely evaluate the in vitro phenotype of iPSC-derived cells. We also introduced the same NOD2 mutation into a control iPSC line. These isogenic iPSCs were then differentiated into monocytic cell lineages, and the statuses of nuclear factor kappaB pathway and proinflammatory cytokine secretion were investigated. RESULTS: IFN-gamma acted as a priming signal through upregulation of NOD2. In iPSC-derived macrophages with mutant NOD2, IFN-gamma treatment induced ligand-independent nuclear factor kappaB activation and proinflammatory cytokine production. RNA sequencing analysis revealed distinct transcriptional profiles of mutant macrophages both before and after IFN-gamma treatment. Patient-derived macrophages demonstrated a similar IFN-gamma-dependent inflammatory response. CONCLUSIONS: Our data support the significance of ligand-independent autoinflammation in the pathophysiology of Blau syndrome. Our comprehensive isogenic disease-specific iPSC panel provides a useful platform for probing therapeutic and diagnostic clues for the treatment of patients with Blau syndrome</style></abstract><notes><style face="normal" font="default">DA - 20170607IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.04.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28587749">PM:28587749</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170607-TakadaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170607-TakadaS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170607, Takada S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.04.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41992</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hayashi,H.</style></author><author><style face="normal" font="default"> Fukutomi,Y.</style></author><author><style face="normal" font="default"> Mitsui,C.</style></author><author><style face="normal" font="default"> Nakatani,E.</style></author><author><style face="normal" font="default"> Watai,K.</style></author><author><style face="normal" font="default"> Kamide,Y.</style></author><author><style face="normal" font="default"> Sekiya,K.</style></author><author><style face="normal" font="default"> Tsuburai,T.</style></author><author><style face="normal" font="default"> Ito,S.</style></author><author><style face="normal" font="default"> Hasegawa,Y.</style></author><author><style face="normal" font="default"> Taniguchi,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Kanagawa, Japan</style></auth-address><titles><title><style face="normal" font="default">Smoking Cessation as a Possible Risk Factor for the Development of Aspirin-Exacerbated Respiratory Disease in Smokers</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">AERD</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cessation</style></keyword><keyword><style face="normal" font="default"> Cigarette</style></keyword><keyword><style face="normal" font="default"> cigarette smoke</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Control Groups</style></keyword><keyword><style face="normal" font="default"> COX-2</style></keyword><keyword><style face="normal" font="default"> Cyclooxygenase 2</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epithelia</style></keyword><keyword><style face="normal" font="default"> Epithelium</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Outpatients</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Prostaglandin</style></keyword><keyword><style face="normal" font="default"> prostaglandin E2</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Smoke</style></keyword><keyword><style face="normal" font="default"> smokers</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Smoking Cessation</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="6" Year="2017">2017/6/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: The pathogenesis of aspirin-exacerbated respiratory disease (AERD) is characterized by the low expression of cyclooxygenase-2 (COX-2) in airway epithelia, which decreases the production of prostaglandin E2 (PGE2). Conversely, cigarette smoke stimulates COX-2 expression in airway epithelia. Therefore, it was hypothesized that the development of AERD would be suppressed by elevated PGE2 levels in smokers, and smoking cessation might increase susceptibility to AERD. OBJECTIVE: The objective of this study was to evaluate the relationship between smoking and the risk of AERD development. METHODS: The smoking status of patients with AERD (n = 114) was compared with 2 control groups with aspirin-tolerant asthma (ATA), patients diagnosed by a systemic aspirin provocation test (ATA-1, n = 83) and outpatients randomly selected from a large-scale dataset (ATA-2, n = 914), as well as a healthy control group (HC, n = 2313). RESULTS: At the age of asthma onset, there was a low frequency of current smokers (9.7%), but a high frequency of past smokers (20.2%) in the AERD group compared with the ATA-1 (20.5% and 12.0% for current and past smokers, respectively), ATA-2 (24.5% and 10.3%, respectively), and HC group (26.2% and 12.6%, respectively). After adjustment for confounding variables, AERD was positively associated with smoking cessation between 1 and 4 years before disease onset compared with the ATA-2 group (adjusted odds ratio [aOR] 4.63, 95% confidence interval [CI]: 2.16-9.93) and the HC group (aOR 4.09, 95% CI: 2.07-8.05), implying that smoking cessation was followed by the development of AERD. CONCLUSION: Smoking cessation may be a risk factor for the development of AERD</style></abstract><notes><style face="normal" font="default">DA - 20170606IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.04.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28583479">PM:28583479</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170606-HayashiH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170606-HayashiH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170606, Hayashi H</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.04.035</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41993</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Farkas,H.</style></author><author><style face="normal" font="default"> Reshef,A.</style></author><author><style face="normal" font="default"> Aberer,W.</style></author><author><style face="normal" font="default"> Caballero,T.</style></author><author><style face="normal" font="default"> McCarthy,L.</style></author><author><style face="normal" font="default"> Hao,J.</style></author><author><style face="normal" font="default"> Nothaft,W.</style></author><author><style face="normal" font="default"> Schranz,J.</style></author><author><style face="normal" font="default"> Bernstein,J.A.</style></author><author><style face="normal" font="default"> Li,H.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hungarian Angioedema Center, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary.</style></auth-address><titles><title><style face="normal" font="default">Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Austria</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor deficiency</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Hungary</style></keyword><keyword><style face="normal" font="default"> Icatibant</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Puberty</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> subcutaneous</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Clinical manifestations of hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) usually begin in childhood, often intensifying during puberty. Currently there are insufficient efficacy/safety data for HAE therapies in children and adolescents due to the small number of pediatric patients enrolled in studies. OBJECTIVE: The objective of this phase 3 study was to evaluate the efficacy/safety of a single subcutaneous dose of icatibant (0.4 mg/kg; maximum 30 mg) in pediatric patients with C1-INH-HAE. METHODS: Patients aged 2 years to younger than 18 years were categorized as prepubertal (children) and pubertal/postpubertal (adolescents). The primary end point was time to onset of symptom relief-earliest time posttreatment to 20% or more improvement in composite symptom score. RESULTS: Thirty-two patients received icatibant (safety population: 11 children with attack, 10 adolescents without attack, and 11 adolescents with attack). The efficacy population consisted of 11 children and 11 adolescents with edematous attacks. Most attacks in the efficacy population (16 [72.7%]) were cutaneous, 5 (22.7%) were abdominal, and 1 (4.5%) was both cutaneous and abdominal; none was laryngeal. Overall, the median time to onset of symptom relief was 1.0 hour, the same for children and adolescents. Thirty-two treatment-emergent adverse events (all mild or moderate) occurred in 9 (28.1%) patients. Gastrointestinal symptoms were most common (9 events in 3 [9.4%] patients). Injection-site reactions affected most (90.6%) patients (particularly erythema and swelling), but almost all resolved by 6 hours postdose. Icatibant demonstrated a monophasic plasma concentration-time profile. Time to peak concentration was approximately 0.5 hours postdose. CONCLUSIONS: Symptom relief was rapid, and a single icatibant injection in pediatric patients with C1-INH-HAE was well tolerated (ClinicalTrials.gov identifier, NCT01386658)</style></abstract><notes><style face="normal" font="default">DA - 20170611IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Hungary -CO - Israel -CO - Austria -CO - Spain -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.04.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28601641">PM:28601641</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170611-FarkasH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20170611-FarkasH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170611, Farkas H</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.04.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41994</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lagercrantz,B.</style></author><author><style face="normal" font="default"> Persson,A.</style></author><author><style face="normal" font="default"> Kull,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Children and Youth Clinic, Vaxjo Hospital , Vaxjo , Sweden</style></auth-address><titles><title><style face="normal" font="default">"Healthcare seems to vary a lot": A focus group study among parents of children with severe allergy</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Fear</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Interviews</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Qualitative study</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> youth</style></keyword></keywords><dates><year Day="22" Month="2" Year="2017">2017/2/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: Living with an allergic disease has consequences for both affected children and their families. The aim of this qualitative study was to gain deeper knowledge of what life is like for families of children with severe allergic disease, in order to improve care and thereby reduce the consequences of living with a chronic disease. METHODS: Four focus group interviews were performed with Swedish parents of children, aged 6-11 and 12-16 years, with severe allergic disease (from one or more allergic conditions, such as food allergy/eczema/hay fever/asthma). The participants were attending a family support weekend. Interviews were analyzed with a qualitative method. RESULTS: Based on parental experiences, the following themes were presented in the analysis: limitations, control, injustices, and fear and anxiety. It was evident that the families lived isolated lives and experienced different kinds of limitations. Parents felt a need to have control of their child's everyday life and described a feeling of constantly being on guard. They also suggested that understanding of the child's allergies was lacking in preschool/school and that healthcare did not provide adequate support. They felt that the same care should be offered to children and families, no matter where they lived. CONCLUSIONS: Based on parental experiences, having a child with severe allergic disease implies a need to constantly be on guard. In order to improve the care of children with severe allergy and their families, a more person- and family-centered approach is needed</style></abstract><notes><style face="normal" font="default">DA - 20170621IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1258079</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28635547">PM:28635547</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170621-LagercrantzB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170621-LagercrantzB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170621, Lagercrantz B</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1258079</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41995</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Halwani,R.</style></author><author><style face="normal" font="default"> Sultana,A.</style></author><author><style face="normal" font="default"> Vazquez-Tello,A.</style></author><author><style face="normal" font="default"> Jamhawi,A.</style></author><author><style face="normal" font="default"> Al-Masri,A.A.</style></author><author><style face="normal" font="default"> Al-Muhsen,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Prince Naif Center for Immunology Research, Asthma Research Chair, Department of Pediatrics , College of Medicine, King Saud University , Riyadh , Saudi Arabia</style></auth-address><titles><title><style face="normal" font="default">Th-17 regulatory cytokines IL-21, IL-23, and IL-6 enhance neutrophil production of IL-17 cytokines during asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Feedback</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> IL-17</style></keyword><keyword><style face="normal" font="default"> IL-17A</style></keyword><keyword><style face="normal" font="default"> IL-23</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophil Infiltration</style></keyword><keyword><style face="normal" font="default"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Saudi Arabia</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> TH17</style></keyword><keyword><style face="normal" font="default"> TH17 cells</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="3" Year="2017">2017/3/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: In a subset of severe asthma patients, chronic airway inflammation is associated with infiltration of neutrophils, Th-17 cells and elevated expression of Th-17-derived cytokines (e.g., interleukin [IL]-17, IL-21, IL-22). Peripheral neutrophils from allergic asthmatics are known to express higher IL-17 cytokine levels than those from healthy subjects, but the regulatory mechanisms involved are not well understood. We hypothesize that Th-17 regulatory cytokines could modulate IL-17 expression in neutrophils. METHODS: Peripheral blood neutrophils isolated from asthmatics were stimulated with IL-21, IL-23, and IL-6 cytokines and their ability to produce IL-17A and IL-17F was determined relative to healthy controls. Signal transducer and activator of transcription 3 (STAT3) phosphorylation levels were measured in stimulated neutrophil using flow cytometry. The requirement for STAT3 phosphorylation was determined by blocking its activation using a specific chemical inhibitor. RESULTS: Stimulating asthmatic neutrophils with IL-21, 23, and 6 enhanced the production of IL-17A and IL-17F at significantly higher levels comparatively to healthy controls. Stimulating neutrophils with IL-21, IL-23, and IL-6 cytokines enhanced STAT3 phosphorylation, in all cases. Interestingly, inhibiting STAT3 phosphorylation using a specific chemical inhibitor dramatically blocked the ability of neutrophils to produce IL-17, demonstrating that STAT3 activation is the major factor mediating IL-17 gene expression. CONCLUSIONS: These findings suggest that neutrophil infiltration in lungs of severe asthmatics may represent an important source of pro-inflammatory IL-17A and -F cytokines, a production enhanced by Th-17 regulatory cytokines, and thus providing a feedback mechanism that sustains inflammation. Our results suggest that STAT3 pathway could be a potential target for regulating neutrophilic inflammation during severe asthma</style></abstract><notes><style face="normal" font="default">DA - 20170621IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Saudi Arabia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1283696</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28635548">PM:28635548</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170621-HalwaniR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170621-HalwaniR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170621, Halwani R</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1283696</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41996</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McGovern,C.M.</style></author><author><style face="normal" font="default"> Redmond,M.</style></author><author><style face="normal" font="default"> Arcoleo,K.</style></author><author><style face="normal" font="default"> Stukus,D.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">a College of Nursing, The Ohio State University , Columbus , OH , USA</style></auth-address><titles><title><style face="normal" font="default">A missed primary care appointment correlates with a subsequent emergency department visit among children with asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicaid</style></keyword><keyword><style face="normal" font="default"> Medicare</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Nursing</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Ohio</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="3" Year="2017">2017/3/2</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Since the Affordable Care Act's implementation, emergency department (ED) visits have increased. Poor asthma control increases the risk of acute exacerbations and preventable ED visits. The Centers for Medicare and Medicaid Services support the reduction of preventable ED visits to reduce healthcare spending. Implementation of interventions to avoid preventable ED visits has become a priority for many healthcare systems yet little data exist examining children's missed asthma management primary care (PC) appointments and subsequent ED visits. METHODS: Longitudinal, retrospective review at a children's hospital was conducted for children with diagnosed asthma (ICD-9 493.xx), ages 2-18 years, scheduled for a PC visit between January 1, 2010, and June 30, 2012 (N = 3895). Records were cross-referenced with all asthma-related ED visits from January 1, 2010 to December 31, 2012. Logistic regression with maximum likelihood estimation was conducted. RESULTS: None of the children who completed a PC appointment experienced an ED visit in the subsequent 6 months whereas 2.7% of those with missed PC appointments had an ED visit (chi2 = 64.28, p &lt;.0001). Males were significantly more likely to have an ED visit following a missed PC appointment than females (chi2 = 34.37, p &lt;.0001). There was a statistically significant interaction of sex x age. Younger children (&lt;12 years) made more visits than older children. CONCLUSIONS: The importance of adherence to PC appointments for children with asthma as one mechanism for preventing ED visits was demonstrated. Interventions targeting missed visits could decrease asthma-related morbidity, preventable ED visits, and healthcare costs</style></abstract><notes><style face="normal" font="default">DA - 20170621IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1283697</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28635549">PM:28635549</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170621-McGovernCM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170621-McGovernCM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170621, McGovern CM</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1283697</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41997</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Qu,Y.</style></author><author><style face="normal" font="default"> Zhang,C.</style></author><author><style face="normal" font="default"> Gao,W.</style></author><author><style face="normal" font="default"> Ning,Y.</style></author><author><style face="normal" font="default"> Chen,R.</style></author><author><style face="normal" font="default"> Zhang,S.</style></author><author><style face="normal" font="default"> Sun,Y.</style></author><author><style face="normal" font="default"> Shang,Y.</style></author><author><style face="normal" font="default"> Bai,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Respiratory and Critical Care Medicine, Changhai Hospital , Second Military Medical University , Shanghai , China</style></auth-address><titles><title><style face="normal" font="default">Validity of a Chinese version of the Mini Asthma Quality of Life Questionnaire (MiniAQLQ) and a comparison of completion by patients and relatives</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> Reproducibility</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="31" Month="5" Year="2017">2017/5/31</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To test the psychometric properties of the Chinese version of the Mini Asthma Quality of Life Questionnaire (MiniAQLQ) and to investigate the differences between the MiniAQLQ completed by patients (p-MiniAQLQ) and by their relatives (r-MiniAQLQ). METHODS: One hundred and two asthmatic patients and 45 relatives were recruited. The reliability was evaluated using Cronbach's alpha and intraclass correlation coefficient (ICC). The validity of the MiniAQLQ was assessed by comparing it with the Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and lung function measurements. The mean quality of life scores were compared by gender and smoking history, and the p-MiniAQLQ scores were then compared with the r-MiniAQLQ scores. RESULTS: The MiniAQLQ showed high internal consistency (Cronbach's alpha = 0.901) and a high two-week reproducibility (ICC = 0.863). The cross-sectional correlations between the MiniAQLQ and the AQLQ-S were strong. Correlations between the MiniAQLQ and lung function (predicted FEV1% and PEF) ranged from poor to weak at the total or domain levels. The MiniAQLQ scores were not significantly associated with gender or smoking history. There was poor agreement between the p-MiniAQLQ and r-MiniAQLQ scores at the total or domain levels. CONCLUSIONS: The Chinese version of the MiniAQLQ showed good reliability and validity. It is reliable for evaluating the impact of asthma on patients' quality of life. Relatives of the patients did not have a comprehensive grasp of the patients' conditions. Physicians should be cautious when patients' relatives come to the hospital to seek a modified treatment when the patients are not present</style></abstract><notes><style face="normal" font="default">DA - 20170531IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1325491</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28562157">PM:28562157</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170531-QuY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170531-QuY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170531, Qu Y</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1325491</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41998</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Harrington,C.B.</style></author><author><style face="normal" font="default"> Langhans,E.</style></author><author><style face="normal" font="default"> Shelef,D.Q.</style></author><author><style face="normal" font="default"> Savitz,M.</style></author><author><style face="normal" font="default"> Whitmore,C.</style></author><author><style face="normal" font="default"> Teach,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">b Department of Prevention and Community Health , George Washington University Milken Institute School of Public Health, The George Washington University , Washington, DC , USA</style></auth-address><titles><title><style face="normal" font="default">A pilot randomized trial of school-based administration of inhaled corticosteroids for at-risk children with asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> African American</style></keyword><keyword><style face="normal" font="default"> African Americans</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> DC</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health care utilization</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medicaid</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Nurses</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Randomized clinical trial</style></keyword><keyword><style face="normal" font="default"> randomized trial</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Washington</style></keyword></keywords><dates><year Day="8" Month="6" Year="2017">2017/6/8</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To investigate whether high adherence to inhaled corticosteroids (ICS) among disadvantaged urban public school children on public insurance with persistent asthma is achievable by having school nurses administer morning doses on each day that school is in session. DESIGN/METHODS: This was a pilot prospective randomized clinical trial of home versus school nurse-administered ICS among children on Medicaid enrolled in grades K-8. The primary outcome was the proportion of expected morning doses of ICS given to the intervention group in school over the 60-day treatment period. Secondary outcomes included the relative proportions of expected doses (morning, evening, and total), asthma-related morbidity, quality of life, and health-care utilization. RESULTS: A total of 46 patients were enrolled (mean age 8.21 +/- 2.45; 56.5% male; 91.3% non-Hispanic, African-Americans), and follow-up data were available for 44/46 (95.7%) patients. The groups did not differ in age, gender, race/ethnicity, or asthma severity. The intervention group received 91.7% of expected morning doses of ICS at school over the 60-day treatment period (95% CI [87.7, 95.5]). Intervention patients reported significantly less functional limitation (42.9% vs. 73.9%, p = 0.04), adjustment to family life (23.8% vs. 56.5%, p = 0.03), and sleep loss (1.7 vs. 4.1 nights in last 2 weeks, p = 0.035) than control patients at the end of the 60-days study period. There were no differences in unscheduled health-care utilization by group. CONCLUSIONS: These pilot data suggest that school-based administration of ICS has the potential to achieve high adherence to morning doses of ICS on school days among urban, disadvantaged, and largely minority children with asthma</style></abstract><notes><style face="normal" font="default">DA - 20170608IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1323915</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28594249">PM:28594249</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170621-HarringtonCB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170621-HarringtonCB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170621, Harrington CB</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1323915</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>41999</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Marfortt,D.A.</style></author><author><style face="normal" font="default"> Josviack,D.</style></author><author><style face="normal" font="default"> Lozano,A.</style></author><author><style face="normal" font="default"> Cuestas,E.</style></author><author><style face="normal" font="default"> Aguero,L.</style></author><author><style face="normal" font="default"> Castro-Rodriguez,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Institute of Child Respiratory Medicine , Rafaela , Santa Fe , Argentina</style></auth-address><titles><title><style face="normal" font="default">Differences between preschoolers with asthma and allergies in urban and rural environments</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Argentina</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Chile</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Fumigation</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Milk</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Plant</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> recurrent wheezing</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Rural</style></keyword><keyword><style face="normal" font="default"> Schoolchildren</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Siblings</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> Vaginal delivery</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="12" Month="6" Year="2017">2017/6/12</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The influence of living in a rural or urban environment on asthma and allergic diseases in school-children provide conflicting results; moreover none of these studies included exclusively preschoolers. The aim of the present study was to evaluate if recurrent wheezing preschoolers from rural or urban areas differ in asthma, allergic diseases, and atopy. METHODS: A cross-sectional-study in Rafaela, Argentina, on 143 preschoolers with recurrent wheezing from rural and urban settings was performed (2010-2012). Diagnosis of asthma (by positive asthma predictive index [API]), allergic diseases (rhinitis, dermatitis), and atopy (by skin prick test [SPT], peripheral blood eosinophils, and serum total IgE) were evaluated. RESULTS: Preschoolers from rural settings had significantly higher prevalence of vaginal delivery, longer breastfeeding, earlier onset of wheezing, more parental smoking, siblings, shared a bedroom, and more exposure to chemicals used in plant fumigation or farm animals, and unpasteurized milk consumption, in comparison to preschoolers living in urban setting. In contrast, preschoolers from urban areas had significantly higher prevalence of parental history of allergy, positive skin prick test, and positive API. After multivariate analysis adjusting for covariates, maternal smoking (OR = 3.44), and positive SPT (OR = 5.57) significantly increase the risk of asthma diagnosis (positive API); in contrast, living in rural setting (OR = 0.04), and having more siblings (OR = 0.51) decrease their risk. CONCLUSIONS: Recurrent wheezing preschoolers from rural areas had a significant inverse odds of being diagnosed with asthma (type-2 inflammation) when compared to those from urban areas. Exposure to farm animals and consumption of unpasteurized milk might have a role</style></abstract><notes><style face="normal" font="default">DA - 20170612IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Argentina -CO - Chile -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1339800</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28605217">PM:28605217</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170612-MarfortiDA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170612-MarfortiDA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170612, Marforti DA</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1339800</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42000</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Miller-Archie,S.A.</style></author><author><style face="normal" font="default"> Jordan,H.T.</style></author><author><style face="normal" font="default"> Alper,H.</style></author><author><style face="normal" font="default"> Wisnivesky,J.P.</style></author><author><style face="normal" font="default"> Cone,J.E.</style></author><author><style face="normal" font="default"> Friedman,S.M.</style></author><author><style face="normal" font="default"> Brackbill,R.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a World Trade Center Health Registry , New York City Department of Health and Mental Hygiene , New York , NY</style></auth-address><titles><title><style face="normal" font="default">Hospitalizations for asthma among adults exposed to the September 11, 2001 World Trade Center terrorist attack</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Hygiene</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> New York City</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Poisson</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> prospective cohort study</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> sinus</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="6" Month="6" Year="2017">2017/6/6</year></dates><abstract><style face="normal" font="default">OBJECTIVE: We described patterns of asthma hospitalization among persons exposed to the 2001 World Trade Center (WTC) attacks, and assessed whether 9/11-related exposures or comorbidities, including posttraumatic stress disorder (PTSD) and gastroesophageal reflux symptoms (GERS), were associated with an increased rate of hospitalization. METHODS: Data for adult enrollees in the WTC Health Registry, a prospective cohort study, with self-reported physician-diagnosed asthma who resided in New York State on 9/11 were linked to administrative hospitalization data to identify asthma hospitalizations during September 11, 2001-December 31, 2010. Multivariable zero-inflated Poisson regression was used to examine associations between 9/11 exposures, comorbid conditions, and asthma hospitalizations. RESULTS: Of 11 471 enrollees with asthma, 406 (3.5%) had >1 asthma hospitalization during the study period (721 total hospitalizations). Among enrollees diagnosed before 9/11 (n = 6319), those with PTSD or GERS had over twice the rate of hospitalization (adjusted rate ratio (ARR) = 2.5, 95% CI = 1.4-4.1; ARR = 2.1, 95% CI = 1.3-3.2, respectively) compared to those without. This association was not statistically significant in enrollees diagnosed after 9/11. Compared to higher educational attainment, completing less than college was associated with an increased hospitalization rate among participants with both pre-9/11- and post-9/11-onset asthma (ARR = 1.9, 95% CI = 1.2-2.9; ARR = 2.6, 95% CI = 1.6-4.1, respectively). Sinus symptoms, exposure to the dust cloud, and having been a WTC responder were not associated with asthma hospitalization. CONCLUSIONS: Among enrollees with pre-9/11 asthma, comorbid PTSD and GERS were associated with an increase in asthma hospitalizations. Management of these comorbidities may be an important factor in preventing hospitalization</style></abstract><notes><style face="normal" font="default">DA - 20170606IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1337787</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28586254">PM:28586254</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170606-MillerArchieSA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170606-MillerArchieSA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170606, Miller-Archie SA</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1337787</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42001</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Alexander,G.L.</style></author><author><style face="normal" font="default"> Olden,H.A.</style></author><author><style face="normal" font="default"> Troy,T.</style></author><author><style face="normal" font="default"> Miree,C.A.</style></author><author><style face="normal" font="default"> Joseph,C.L.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Henry Ford Health System , Public Health Sciences , Detroit , Michigan , USA</style></auth-address><titles><title><style face="normal" font="default">Overweight adolescents and asthma: Revealing motivations and challenges with adolescent-provider communication</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> African American</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic asthma</style></keyword><keyword><style face="normal" font="default"> Communication</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease Management</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Interviews</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Michigan</style></keyword><keyword><style face="normal" font="default"> Motivation</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> overweight</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Program Development</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword><keyword><style face="normal" font="default"> Weight Loss</style></keyword><keyword><style face="normal" font="default"> youth</style></keyword></keywords><dates><year Day="31" Month="5" Year="2017">2017/5/31</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Among teens with asthma, challenges of disease management may be greater in those with a body mass index (BMI) >85th percentile compared to youth within the parameters for normal weight-for-age. This mixed-methods study assessed teens' awareness of the link between weight and asthma management, and perspectives on how medical providers might open a discussion about managing weight. METHOD: Teens aged 13-18, having BMI >85 percentile and chronic asthma, identified using health system databases and a staff email message board, were invited to complete a semi-structured, in-depth phone interview. Interviews were audio taped, transcribed, and qualitatively analyzed, using the Framework Method. Responses were summarized and themes identified. Descriptive summaries were generated for a 16-item survey of weight conversation starters. RESULTS: Of 35 teens interviewed, 24 (69%) were girls, 11 (31%) boys, 20 (63%) African-American. All teens reported having "the weight conversation" with their doctors, and preferred that parents be present. Half knew from their doctor about the link between being overweight and asthma, others knew from personal experience. Nearly all expressed the importance of providers initiating a weight management conversation. Most preferred conversation starters that recognized challenges and included parents' participation in weight management; least liked referred to "carrying around too much weight." CONCLUSIONS: Most teens responded favorably to initiating weight loss if it impacted asthma management, valued their provider addressing weight and family participation in weight management efforts. Adolescents' views enhance program development fostering more effective communication targeting weight improvement within the overall asthma management plan</style></abstract><notes><style face="normal" font="default">DA - 20170531IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1323921</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28562121">PM:28562121</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170531-AlexanderGL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170531-AlexanderGL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170531, Alexander GL</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1323921</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42002</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,L.K.</style></author><author><style face="normal" font="default"> Obi,E.</style></author><author><style face="normal" font="default"> Paknis,B.</style></author><author><style face="normal" font="default"> Kavati,A.</style></author><author><style face="normal" font="default"> Chipps,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Health Outcomes Research, Kantar Health , Foster City , CA , USA</style></auth-address><titles><title><style face="normal" font="default">Asthma control and disease burden in patients with asthma and allergic comorbidities</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical guidelines</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> long acting beta agonists</style></keyword><keyword><style face="normal" font="default"> long-acting beta-agonists</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Step-up therapy</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> treatment adherence</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Unmet needs</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="6" Month="6" Year="2017">2017/6/6</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To assess asthma control and associations with health-related quality of life (HRQoL) and economic outcomes among patients with asthma and allergic comorbidities treated with inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) combination therapy. METHODS: Data from the 2011-2013 US National Health and Wellness Survey were used to identify patients with asthma currently treated with ICS and LABA combination therapy (N = 1923). Patients were included if they self-reported a physician diagnosis of asthma and at least one allergic/asthma-related comorbid condition (e.g., nasal allergies, atopic dermatitis). Asthma Control Test scores categorized patients as very poorly (scores &lt;/= 15; 29.3%), not well (16-19; 25.1%), or well controlled (20-25; 45.7%). Outcomes included HRQoL (SF-36v2; SF-12v2), work productivity and activity impairment, healthcare utilization (HRU), and annual indirect and direct costs. Generalized linear models, controlling for covariates, examined whether outcomes differed by asthma control. RESULTS: Over half of the patients had very poorly or not well-controlled asthma (54.4%). Patients with very poorly controlled versus well-controlled asthma reported significantly greater decreases in HRQoL, greater overall work impairment, and higher HRU (all, p &lt; 0.05). Very poorly controlled patients incurred over double the indirect costs and nearly one and a half times the direct and total costs of well-controlled patients. CONCLUSIONS: Increasing level of asthma control was related to improved HRQoL and lower costs. The considerably high prevalence of uncontrolled asthma among patients on ICS and LABA suggests poor treatment adherence or unmet needs in current treatment and may require step-up therapy in appropriate patients according to clinical guidelines</style></abstract><notes><style face="normal" font="default">DA - 20170606IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1316394</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28586296">PM:28586296</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170606-LeeLK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170606-LeeLK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170606, Lee LK</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1316394</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42003</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Han,R.T.</style></author><author><style face="normal" font="default"> Kim,S.</style></author><author><style face="normal" font="default"> Choi,K.</style></author><author><style face="normal" font="default"> Jwa,H.</style></author><author><style face="normal" font="default"> Lee,J.</style></author><author><style face="normal" font="default"> Kim,H.Y.</style></author><author><style face="normal" font="default"> Kim,H.J.</style></author><author><style face="normal" font="default"> Kim,H.R.</style></author><author><style face="normal" font="default"> Back,S.K.</style></author><author><style face="normal" font="default"> Na,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Neuroscience Research Institute</style></auth-address><titles><title><style face="normal" font="default">Asthma-like airway inflammation and responses in a rat model of atopic dermatitis induced by neonatal capsaicin treatment</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="189" start="181">181-189</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Airway Resistance</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal model</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> Atopic diseases</style></keyword><keyword><style face="normal" font="default"> BAL</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default"> Capsaicin</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> functional study</style></keyword><keyword><style face="normal" font="default"> Hypertrophy</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Infancy</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Compliance</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Mucus</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polymerase Chain Reaction</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> rat</style></keyword><keyword><style face="normal" font="default"> Rats</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> TH2 cytokines</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Recent studies have shown that approximately 70% of patients with severe atopic dermatitis (AD) develop asthma. Development of AD in infancy and subsequent other atopic diseases such as asthma in childhood is referred to as atopic march. However, a causal link between the diseases of atopic march has remained largely unaddressed, possibly due to lack of a proper animal model. Recently, we developed an AD rat model showing chronically relapsing dermatitis and scratching behaviors induced by neonatal capsaicin treatment. Here, we investigated whether our model also showed asthmatic changes, with the aim of expanding our AD model into an atopic march model. First, we confirmed that capsaicin treatment (50 mg/kg within 24 h after birth) induced dermatitis and scratching behaviors until 6 weeks of age. After that, the mRNA expression of Th1 and Th2 cytokines, such as IFN-gamma and TNF-alpha, and IL-4, IL-5, and IL-13, respectively, was quantified with quantitative real-time polymerase chain reaction in the skin and the lungs. The number of total cells and eosinophils was counted in bronchoalveolar lavage (BAL) fluid. The levels of IgE in the serum and BAL fluid were determined with enzyme-linked immunosorbent assay. Paraffin-embedded sections (4 mum) were stained with hematoxylin/eosin to analyze the morphology of the lung and the airway. Airway responsiveness was measured in terms of airway resistance and compliance using the flexiVent system. In the capsaicin-treated rats, persistent dermatitis developed, and scratching behaviors increased over several weeks. The levels of IgE in the serum and BAL fluid as well as the mRNA expression of Th2 cytokines, including IL-4, IL-5, and IL-13, in both the skin and the lungs were elevated, and the number of eosinophils in the BAL fluid was also increased in the capsaicin-treated rats compared to control rats. Morphological analysis of the airway revealed smooth muscle hypertrophy and extensive mucus plug in the capsaicin-treated rats. Functional studies demonstrated an increment of the airway resistance and a decrement of lung compliance in the capsaicin-treated rats compared to control rats. Taken together, our findings suggested that neonatal capsaicin treatment induced asthma-like airway inflammation and responses in juvenile rats</style></abstract><notes><style face="normal" font="default">DA - 20170602IS - 1178-6965 (Print)IS - 1178-6965 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.2147/JAA.S124902</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28572736">PM:28572736</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-181-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-181-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170602, Han RT</style></custom2><misc3><style face="normal" font="default">10.2147/JAA.S124902</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42004</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Grzybowski,A.</style></author><author><style face="normal" font="default"> Bardeci,L.A.Z.</style></author></authors></contributors><auth-address><style face="normal" font="default">Poznan, PolandBuenos Aires, Argentina</style></auth-address><titles><title><style face="normal" font="default">Relationship between moxifloxacin use and increased antibiotic resistance and possible anaphylactic reactions</style></title><secondary-title><style face="normal" font="default">J Cataract Refract Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Cataract Refract Surg</style></abbr-1></periodical><pages end="" start="711">711-</pages><volume><style face="normal" font="default">43</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Argentina</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170612IS - 1873-4502 (Electronic)IS - 0886-3350 (Linking)LA - engPT - LetterCO - Argentina -</style></notes><work-type><style face="normal" font="default">10.1016/j.jcrs.2017.03.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28602346">PM:28602346</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Cataract Refract Surg\2017-43-711.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Cataract Refract Surg\2017-43-711.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170612, Grzybowski A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jcrs.2017.03.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42005</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,X.</style></author><author><style face="normal" font="default"> Jiang,X.</style></author><author><style face="normal" font="default"> Yu,X.</style></author><author><style face="normal" font="default"> Liu,H.</style></author><author><style face="normal" font="default"> Tao,Y.</style></author><author><style face="normal" font="default"> Jiang,G.</style></author><author><style face="normal" font="default"> Hong,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Jiangsu Key Laboratory of Pediatric Respiratory Disease, Nanjing University of Chinese Medicine, Nanjing, China</style></auth-address><titles><title><style face="normal" font="default">Cimifugin suppresses allergic inflammation by reducing epithelial derived initiative key factors via regulating tight junctions</style></title><secondary-title><style face="normal" font="default">J Cell Mol Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Cell Mol Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electron microscopy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Microscopy</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> tight junctions</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Western blot</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="default">Cimifugin is a bioactive component of Saposhnikovia divaricata, a Chinese herb for treating allergy. Our previous studies demonstrated that cimifugin inhibited allergic inflammation efficiently. This study aims to determine the mechanism of cimifugin on epithelial cells in allergic inflammation. Mice were sensitized and challenged with FITC to establish type 2 atopic dermatitis (AD) model. The initial stage of AD model, in which mice were just sensitized with FITC, was established in vivo and immortalized human epidermal (HaCaT) cells were utilized in vitro. Initiative key cytokines, TSLP and IL-33, were measured by ELISA, the junctions in ECs were observed by electron microscopy and TJs (CLDN-1, occludin and CLDND1) were assessed by Western blot, immunohistochemistry and immunofluorescence. The results showed that TSLP and IL-33 were inhibited significantly by cimifugin in the initial stage of AD model. Simultaneously, cimifugin reduced the separated gap among the epithelial cells and increased the expression of TJs. Similar effects on TSLP/IL-33 and TJs were obtained in vitro. The effect of cimifugin on TSLP decreased significantly when expression of CLDN1 was interfered with siRNA and this implied cimifugin inhibits initiative cytokines through restoring TJs. Furthermore, cimifugin administered only in the initial stage obviously attenuated the ultimate allergic inflammation, which indicate that impacts of cimifugin in the initial stage on TSLP/IL-33 and TJs are sufficient for suppressing allergic inflammation. This study not only revealed the mechanisms of cimifugin, but also indicated the possibility of initiative key cytokines and TJs as therapeutic targets</style></abstract><notes><style face="normal" font="default">DA - 20170609IS - 1582-4934 (Electronic)IS - 1582-1838 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1111/jcmm.13204</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28597545">PM:28597545</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Cell Mol Med\20170609-WangX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Cell Mol Med\20170609-WangX.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170609, Wang X</style></custom2><misc3><style face="normal" font="default">10.1111/jcmm.13204</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42006</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fowler,A.</style></author><author><style face="normal" font="default"> Koenen,R.</style></author><author><style face="normal" font="default"> Hilbert,J.</style></author><author><style face="normal" font="default"> Blatchford,J.</style></author><author><style face="normal" font="default"> Kappeler,D.</style></author><author><style face="normal" font="default"> Benediktus,E.</style></author><author><style face="normal" font="default"> Wood,C.</style></author><author><style face="normal" font="default"> Gupta,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Boehringer Ingelheim Ltd, Bracknell, UK</style></auth-address><titles><title><style face="normal" font="default">Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma</style></title><secondary-title><style face="normal" font="default">J Clin Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Clin Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse events</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> CRTH2</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> pharmacokinetics</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> Prostaglandin</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> single dose</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> Tolerability</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="13" Month="6" Year="2017">2017/6/13</year></dates><abstract><style face="normal" font="default">BI 1021958, a novel antagonist of the chemoattractant-receptor-homologous molecule (CRTH2), targets airway inflammation in asthma by inhibiting prostaglandin binding to CRTH2 receptors. Two phase 1 studies assessed BI 1021958 safety/tolerability and pharmacokinetics (PK)/pharmacodynamics (PD) following single doses in healthy men and multiple doses in men/women with well-controlled asthma. Studies 1 had 2 parts: a placebo-controlled, fixed-sequence, single-blind, single-rising-dose part (n = 56) and a randomized, 2-way crossover, open-label, repeated-dose part studying the food effect on PK/PD (n = 12). Study 2 was a placebo-controlled, single-center, double-blind multiple-rising-dose study (n = 84). Primary end points were safety/tolerability and PK/PD (both studies); secondary end points were eosinophil shape change (ESC; study 1) and dose proportionality/linearity following first dose and at steady state (study 2). BI 1021958 was adequately tolerated in both studies; adverse events were infrequent, generally mild to moderate, and occurred similarly in treatment groups. Maximum measured concentration (Cmax ) was achieved in &lt;/=2.5 hours in study 1 and &lt;/=2.0 hours in study 2. BI 1021958 exposure increased proportionally with dose. In study 1, following a single 60-mg dose, AUC parameters and Cmax were 20% and 15% lower, respectively, after a high-fat meal compared with the fasted state. After >/=60-mg single doses (study 1) and >40-mg multiple doses (study 2), >95% ESC inhibition was observed for >/=24 hours. PK/PD was similar in healthy subjects and subjects with well-controlled asthma. Data support further investigation of CRTH2 antagonists for the treatment of asthma</style></abstract><notes><style face="normal" font="default">DA - 20170613IS - 1552-4604 (Electronic)IS - 0091-2700 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Germany -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1002/jcph.947</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28609567">PM:28609567</url></web-urls></urls><custom2><style face="normal" font="default">20170613, Fowler A</style></custom2><misc3><style face="normal" font="default">10.1002/jcph.947</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42007</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zheng,M.</style></author><author><style face="normal" font="default"> Wang,X.</style></author><author><style face="normal" font="default"> Ge,S.</style></author><author><style face="normal" font="default"> Gu,Y.</style></author><author><style face="normal" font="default"> Ding,X.</style></author><author><style face="normal" font="default"> Zhang,Y.</style></author><author><style face="normal" font="default"> Ye,J.</style></author><author><style face="normal" font="default"> Zhang,L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Allergic and Non-Allergic Rhinitis Are Common in Obstructive Sleep Apnea but Not Associated With Disease Severity</style></title><secondary-title><style face="normal" font="default">J Clin Sleep Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Clin Sleep Med</style></abbr-1></periodical><pages end="966" start="959">959-966</pages><volume><style face="normal" font="default">13</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Analysis of Variance</style></keyword><keyword><style face="normal" font="default"> Apnea</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Arousal</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Efficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nonallergic rhinitis</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Obstructive sleep apnea</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Oxygen</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polysomnography</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Sleep apnea</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="6" Year="2017">2017/6/16</year></dates><abstract><style face="normal" font="default">STUDY OBJECTIVES: Several studies have suggested that rhinitis contributes to the pathogenesis of obstructive sleep apnea (OSA). We aimed to investigate the prevalence and influence of allergic rhinitis (AR) and non-allergic rhinitis (NAR) on severity of OSA. METHODS: Two hundred forty patients with OSA confirmed by standardized polysomnography were assessed for presence of AR and NAR, using validated questionnaires and skin prick tests. Data comparison was carried out by using chi-square test, analysis of variance, and least significant difference test. Associations between severity of OSA and rhinitis, age, sex, and body mass index were assessed with ordinal logistic regression analysis. RESULTS: The prevalence of AR and NAR among patients with OSA was 27.1% and 28.7%, respectively, with no significant differences in the severity of rhinitis. Ordinal logistic regression analysis showed AR and NAR were not the risk factors for severity of OSA. There were significant differences of polysomnography parameters in sleep efficiency (79.7 +/- 2.0 versus 85.2 +/- 1.4 between AR and NAR; 79.7 +/- 2.0 versus 87.2 +/- 1.4 between AR and no-rhinitis) and arousal index (36.8 +/- 4.1 versus 24.7 +/- 3.5 between AR and no-rhinitis). Patients with NAR had lower average arterial oxygen saturation (91.9 +/- 0.6 versus 94.0 +/- 0.6) and minimal arterial oxygen saturation (70.6 +/- 1.7 versus 77.3 +/- 1.8), compared with subjects categorized as no-rhinitis. CONCLUSIONS: This study suggests that despite a comparatively high prevalence in patients with OSA, the presence or severity of AR or NAR does not influence the severity of OSA; however, rhinitis may significantly disturb sleep in patients with OSA</style></abstract><notes><style face="normal" font="default">DA - 20170621IS - 1550-9397 (Electronic)IS - 1550-9389 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28633721">PM:28633721</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170621, Zheng M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42008</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Balmert,S.C.</style></author><author><style face="normal" font="default"> Donahue,C.</style></author><author><style face="normal" font="default"> Vu,J.R.</style></author><author><style face="normal" font="default"> Erdos,G.</style></author><author><style face="normal" font="default"> Falo,L.D.,Jr.</style></author><author><style face="normal" font="default"> Little,S.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15261, United States</style></auth-address><titles><title><style face="normal" font="default">In vivo induction of regulatory T cells promotes allergen tolerance and suppresses allergic contact dermatitis</style></title><secondary-title><style face="normal" font="default">J Control Release</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Control Release</style></abbr-1></periodical><pages end="233" start="223">223-233</pages><volume><style face="normal" font="default">261</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergen exposure</style></keyword><keyword><style face="normal" font="default"> allergen-specific</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact allergens</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> IL-2</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> regulatory T cell</style></keyword><keyword><style face="normal" font="default"> regulatory T cells</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> Topical corticosteroids</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> Tregs</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="8" Month="7" Year="2017">2017/7/8</year></dates><abstract><style face="normal" font="default">Allergic contact dermatitis (ACD) is a common T-cell mediated inflammatory skin condition, characterized by an intensely pruritic rash at the site of contact with allergens like poison ivy or nickel. Current clinical treatments use topical corticosteroids, which broadly and transiently suppress inflammation and symptoms of ACD, but fail to address the underlying immune dysfunction. Here, we present an alternative therapeutic approach that teaches the immune system to tolerate contact allergens by expanding populations of naturally suppressive allergen-specific regulatory T cells (Tregs). Specifically, biodegradable poly(ethylene glycol)-poly(lactic-co-glycolic acid) (PEG-PLGA) microparticles were engineered to release TGF-beta1, Rapamycin, and IL-2, to locally sustain a microenvironment that promotes Treg differentiation. By expanding allergen-specific Tregs and reducing pro-inflammatory effector T cells, these microparticles inhibited destructive hypersensitivity responses to subsequent allergen exposure in an allergen-specific manner, effectively preventing or reversing ACD in previously sensitized mice. Ultimately, this approach to in vivo Treg induction could also enable novel therapies for transplant rejection and autoimmune diseases</style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 1873-4995 (Electronic)IS - 0168-3659 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jconrel.2017.07.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28694031">PM:28694031</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Control Release\2017-261-223-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Control Release\2017-261-223-33.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170711, Balmert SC</style></custom2><misc3><style face="normal" font="default">10.1016/j.jconrel.2017.07.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42009</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Facchini,G.</style></author><author><style face="normal" font="default"> Eberlin,S.</style></author><author><style face="normal" font="default"> Clerici,S.P.</style></author><author><style face="normal" font="default"> Alves Pinheiro,A.L.</style></author><author><style face="normal" font="default"> Costa,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Kosmoscience Group, Campinas, SP, Brazil</style></auth-address><titles><title><style face="normal" font="default">Ultraviolet A photosensitivity profile of dexchlorpheniramine maleate and promethazine-based creams: Anti-inflammatory, antihistaminic, and skin barrier protection properties</style></title><secondary-title><style face="normal" font="default">J Cosmet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Cosmet Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Formulation</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> IL-1</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> Interleukin 1</style></keyword><keyword><style face="normal" font="default"> Interleukin-1</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritation</style></keyword><keyword><style face="normal" font="default"> Keratin</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Leukotriene B4</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Photosensitivity</style></keyword><keyword><style face="normal" font="default"> Phototoxicity</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Promethazine</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Repair</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="7" Month="6" Year="2017">2017/6/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Unwanted side effects such as dryness, hypersensitivity, and cutaneous photosensitivity are challenge for adherence and therapeutical success for patients using treatments for inflammatory and allergic skin response. AIMS: In this study, we compared the effects of two dermatological formulations, which are used in inflammatory and/or allergic skin conditions: dexchlorpheniramine maleate (DCP; 10 mg/g) and promethazine (PTZ; 20 mg/g). METHODS: We evaluated both formulations for phototoxicity potential, skin irritation, anti-inflammatory and antihistaminic abilities, and skin barrier repair in vitro and ex vivo using the standard OECD test guideline n degrees 432, the ECVAM protocol n degrees 78, and cultured skin explants from a healthy patient. Ultraviolet A was chosen as exogenous agent to induce allergic and inflammatory response. RESULTS: Both PTZ and DCP promoted increases in interleukin-1 (IL-1) synthesis in response to ultraviolet A (UVA) radiation compared to control. However, the increase observed with PTZ was significantly greater than the DCP, indicating that the latter has a lower irritant potential. DCP also demonstrated a protective effect on UVA-induced leukotriene B4 and nuclear factor kappa B (NF-kappaB) synthesis. Conversely, PTZ demonstrates more robust UVA antihistaminic activity. Likewise, PTZ promoted a significantly greater increase in the production of involucrin and keratin 14, both associated with protective skin barrier property. CONCLUSION: In conclusion, these data suggest possible diverging UVA response mechanisms of DCP and PTZ, which gives greater insight into the contrasting photosensitizing potential between DCP and PTZ observed in the patients</style></abstract><notes><style face="normal" font="default">DA - 20170608IS - 1473-2165 (Electronic)IS - 1473-2130 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1111/jocd.12349</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28593645">PM:28593645</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Cosmet Dermatol\20170608-FacchiniG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Cosmet Dermatol\20170608-FacchiniG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170608, Facchini G</style></custom2><misc3><style face="normal" font="default">10.1111/jocd.12349</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42010</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Elliott,J.F.</style></author><author><style face="normal" font="default"> Abbas,M.</style></author><author><style face="normal" font="default"> Hull,P.</style></author><author><style face="normal" font="default"> de Gannes,G.</style></author><author><style face="normal" font="default"> Toussi,R.</style></author><author><style face="normal" font="default"> Milani,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Dermatology, Departments of Medicine &amp; Medical Microbiology and Immunology, University of Alberta, Edmonton, AB, Canada</style></auth-address><titles><title><style face="normal" font="default">Decreasing Rates of Neomycin Sensitization in Western Canada</style></title><secondary-title><style face="normal" font="default">J Cutan Med Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Cutan Med Surg</style></full-title></periodical><pages end="452" start="446">446-452</pages><volume><style face="normal" font="default">20</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse effects</style></keyword><keyword><style face="normal" font="default"> Alberta</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Anti-Bacterial Agents</style></keyword><keyword><style face="normal" font="default"> British Columbia</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Colombia</style></keyword><keyword><style face="normal" font="default"> Columbia</style></keyword><keyword><style face="normal" font="default"> Comparative Study</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact sensitization</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Drug Eruptions</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Multicenter Studies</style></keyword><keyword><style face="normal" font="default"> Multicenter study</style></keyword><keyword><style face="normal" font="default"> Neomycin</style></keyword><keyword><style face="normal" font="default"> North America</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Over-the-counter</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Saskatchewan</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Statistics</style></keyword><keyword><style face="normal" font="default"> supply &amp; distribution</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Neomycin contact sensitization rates in North America range from 7% to 13%, whereas in Europe they average approximately 1.9%. OBJECTIVES: Given that topical neomycin products are no longer readily available in Canada, the aim of this study was to examine what influence this may have had on neomycin sensitization rates in the 3 western provinces. METHODS: On the basis of an observation originally communicated by L. M. Parsons and C. Zhang of the University of Calgary, which suggested significantly reduced rates of neomycin sensitization in Calgary, Alberta, Canada, a multicenter study of patch test results from 5690 patient charts was undertaken. Data from 3 other western Canadian Universities (the University of Saskatchewan, the University of Alberta, and the University of British Colombia) were analyzed. Data were available from 2001 to 2013 for the University of Saskatchewan (except 2006), whereas the University of Alberta and the University of British Columbia had data from 2009 to 2013. Descriptive statistics, trend analysis, and risk estimates were determined using SPSS version 20. RESULTS: Sensitization rates for neomycin have decreased in western Canada and are now similar to those of Europe. CONCLUSIONS: This trend is likely influenced by the reduced availability of over-the-counter and prescription neomycin products in Canada</style></abstract><notes><style face="normal" font="default">DA - 20160907IS - 1615-7109 (Electronic)IS - 1203-4754 (Linking)LA - engPT - Comparative StudyPT - Journal ArticlePT - Multicenter StudyPT - ReviewRN - 0 (Anti-Bacterial Agents)RN - 1404-04-2 (Neomycin)SB - IMCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1177/1203475415623512</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="26700538">PM:26700538</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Cutan Med Surg\2016-20-446-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Cutan Med Surg\2016-20-446-52.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160907, Elliott JF</style></custom2><misc3><style face="normal" font="default">10.1177/1203475415623512</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42011</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yang,M.Y.</style></author><author><style face="normal" font="default"> Jin,H.</style></author><author><style face="normal" font="default"> Shim,W.H.</style></author><author><style face="normal" font="default"> Kim,G.W.</style></author><author><style face="normal" font="default"> Kim,H.S.</style></author><author><style face="normal" font="default"> Ko,H.C.</style></author><author><style face="normal" font="default"> Kim,H.J.</style></author><author><style face="normal" font="default"> Suh,H.S.</style></author><author><style face="normal" font="default"> Lee,S.K.</style></author><author><style face="normal" font="default"> Jung,S.Y.</style></author><author><style face="normal" font="default"> Kim,H.S.</style></author><author><style face="normal" font="default"> Lim,K.M.</style></author><author><style face="normal" font="default"> Kim,M.B.</style></author><author><style face="normal" font="default"> Kim,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Dermatology , Pusan National University Hospital , Busan , Korea</style></auth-address><titles><title><style face="normal" font="default">High rates of secondary non-adherence causes decreased efficacy of 0.1% topical tacrolimus in adult eczema patients: results from a multicenter clinical trial</style></title><secondary-title><style face="normal" font="default">J Dermatolog Treat</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatolog Treat</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> adherence</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Iga</style></keyword><keyword><style face="normal" font="default"> Itch</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Tacrolimus</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> VAS</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="3" Month="7" Year="2017">2017/7/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patients tend to apply topical medications less frequently, in improper amounts. Not only frequency but also application amount may influence treatment outcome. However, studies on relationship between application amount and objective treatment outcome have rarely been conducted. OBJECTIVE: To assess efficacy of topical agent according to application amount in adult patients, using the finger-tip unit method Methods: The efficacy of 0.1% topical tacrolimus in adult patients with localised atopic dermatitis was assessed using EASI, TIS, IGA, and PGA scores at baseline, follow-up. Adherence in amount was evaluated after 2 weeks of treatment using the ratio of the actual amount applied to the expected amount applied (A/E). RESULTS: 27 patients (20.93%) used topical tacrolimus in proper amounts (A/E: 0.8-1.2). However, 86 patients (66.67%) underused topical tacrolimus; 16 (12.40%) patients overused topical tacrolimus. Decreases in EASI scores between baseline and 2 weeks of follow-up in each group (under-amount, proper amount, over-amount) were 1.64, 4.65 and 4.21, respectively. Treatment efficacy increased in accordance with application amount. Further, TIS, IGA, PGA, VAS for Itch and DLQI scores improved concomitantly, exhibiting similar tendencies. CONCLUSION: Application amount of topical agent is important in increasing treatment efficacy in adult patients with atopic dermatitis</style></abstract><notes><style face="normal" font="default">DA - 20170703IS - 1471-1753 (Electronic)IS - 0954-6634 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1080/09546634.2017.1350256</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28670943">PM:28670943</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatolog Treat\20170703-YangMY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatolog Treat\20170703-YangMY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170703, Yang MY</style></custom2><misc3><style face="normal" font="default">10.1080/09546634.2017.1350256</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42012</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tolkachjov,S.N.</style></author><author><style face="normal" font="default"> Wetter,D.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Schnitzler Syndrome With Delirium and Vertigo: The Utility of Neurologic Manifestations in Diagnosis</style></title><secondary-title><style face="normal" font="default">J Drugs Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Drugs Dermatol</style></full-title></periodical><pages end="627" start="625">625-627</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Arthralgia</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatosis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Differential diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Neurologic Manifestations</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Schnitzler Syndrome</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> Vertigo</style></keyword></keywords><dates><year Day="1" Month="6" Year="2017">2017/6/1</year></dates><abstract><style face="normal" font="default">&lt;p>Schnitzler syndrome (SS) is an autoinflammatory dermatosis that often goes undiagnosed for 5-6 years. Patients typically carry a diagnosis of urticaria; however, their cutaneous symptoms fail to respond to typical urticaria therapies and lack symptoms such as pruritus. Additionally, patients with SS may see multiple providers for nonspecific complaints of fever, lymphadenopathy, arthralgias, and bone pain. A correct diagnosis is paramount, as close to 20% of patients may develop a lymphoproliferative disorder and appropriate treatment may ameliorate all symptoms.1 We report 2 cases of SS misdiagnosed as urticaria for years in order to illuminate diagnostic pearls, histopathological findings, and treatment modalities. Additionally, we highlight the importance of neurologic disturbances in this rare but important differential diagnosis of urticaria.&lt;/p> &lt;p>&lt;em>J Drugs Dermatol. 2017;16(6):625-627.&lt;/em>&lt;/p></style></abstract><notes><style face="normal" font="default">DA - 20170707IS - 1545-9616 (Print)IS - 1545-9616 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28686783">PM:28686783</url></web-urls></urls><custom2><style face="normal" font="default">20170707, Tolkachjov SN</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42013</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lisante,T.A.</style></author><author><style face="normal" font="default"> Nunez,C.</style></author><author><style face="normal" font="default"> Zhang,P.</style></author><author><style face="normal" font="default"> Mathes,B.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">A 1% Colloidal Oatmeal Cream Alone is Effective in Reducing Symptoms of Mild to Moderate Atopic Dermatitis: Results from Two Clinical Studies</style></title><secondary-title><style face="normal" font="default">J Drugs Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Drugs Dermatol</style></full-title></periodical><pages end="676" start="671">671-676</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse events</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Ceramides</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Itch</style></keyword><keyword><style face="normal" font="default"> Over-the-counter</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> transepidermal water loss</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> VAS</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Water</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="default">&lt;p>BACKGROUND: The epidermal barrier in patients with atopic dermatitis (AD) is deficient in ceramides and cathelicidins. Such epidermal defects may be a trigger for AD, thereby encouraging research toward development of skin-barrier-targeted preventive strategies.&lt;/p> &lt;p>METHODS: Two single-center, single-arm clinical trials were conducted (study 1, age greater than equal to 8 years and study 2, greater than equal to 10 years) in patients with mild to moderate AD to evaluate the effects of an over-the-counter 1% colloidal oatmeal cream administered for 14 days. Study 1 assessed the Eczema Area and Severity Index (EASI) and Investigator's Global Atopic Dermatitis Assessment (IGADA) on day 3, and itch severity using a Visual Analogue Scale (VAS) immediately after application as primary efficacy endpoints. In study 2, the primary efficacy endpoint was change from baseline in patients' assessment of itch. Both studies assessed safety through adverse event (AE) recording.&lt;/p> &lt;p>RESULTS: Study 1: 29 patients were enrolled (mean age [range], 27.07 [8 -67]). Comparing to baseline, EASI, IGADA, and itch were improved after the application, and improvements were maintained until day 14. Improvements of greater than/equal to 20% over baseline were noted in 53.6% and 25.0% patients at day 3 for EASI and IGADA scores, respectively, and in 37.9% patients for itch score immediately after the product application. On day 14, these percentages were 82.8%, 62.1%, and 85.7%, respectively.&lt;/p> &lt;p>STUDY 2: 30 patients were enrolled (mean age [range], 32.9 [10-80]). Itch severity and EASI score were significantly improved after product application and improvements were maintained until day 14. Transepidermal water loss values were significantly reduced and skin hydration was significantly increased at all assessment time points. No adverse events (AEs) were reported in study 2 and 2 AEs were reported by 1 patient in study 1.&lt;/p> &lt;p>CONCLUSIONS: The colloidal oatmeal cream was well tolerated and clinically effective in patients with mild to moderate AD.&lt;/p> &lt;p>&lt;em>J Drugs Dermatol. 2017;16(7):671-676.&lt;/em>&lt;/p></style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 1545-9616 (Print)IS - 1545-9616 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28697218">PM:28697218</url></web-urls></urls><custom2><style face="normal" font="default">20170711, Lisante TA</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42014</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aurich,S.</style></author><author><style face="normal" font="default"> Schuurmann,M.</style></author><author><style face="normal" font="default"> Simon,J.C.</style></author><author><style face="normal" font="default"> Treudler,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Klinik fur Dermatologie, Venerologie und Allergologie, Universitatsklinikum Leipzig</style></auth-address><titles><title><style face="normal" font="default">Anaphylaktischer Schock bei Intrakutantestung auf Cefuroxim</style></title><secondary-title><style face="normal" font="default">J Dtsch Dermatol Ges</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dtsch Dermatol Ges</style></full-title></periodical><pages end="669" start="667">667-669</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergologie</style></keyword><keyword><style face="normal" font="default"> Dermatologie</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170607IS - 1610-0387 (Electronic)IS - 1610-0379 (Linking)LA - engPT - LetterCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/ddg.13246_g</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28591448">PM:28591448</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dtsch Dermatol Ges\2017-15-667-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dtsch Dermatol Ges\2017-15-667-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170607, Aurich S</style></custom2><misc3><style face="normal" font="default">10.1111/ddg.13246_g</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42015</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Boechat Souza,M.</style></author><author><style face="normal" font="default"> Russo,T.</style></author><author><style face="normal" font="default"> Delorenze,L.M.</style></author><author><style face="normal" font="default"> Castro,G.</style></author><author><style face="normal" font="default"> Argenziano,G.</style></author><author><style face="normal" font="default"> Piccolo,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Department, Hospital Universitario Antonio Pedro, Universidade Federal Fluminense, Niteroi-Rio de Janeiro, Brazil</style></auth-address><titles><title><style face="normal" font="default">Cryptogenic cirrhosis: misunderstood cause of yellow urticaria</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Brazil</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cirrhosis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Liver Cirrhosis</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="13" Month="6" Year="2017">2017/6/13</year></dates><abstract><style face="normal" font="default">We read with great interest the paper by Combalia et al recently appeared on Journal of European Academy of Dermatology1 . The authors reported two cases of yellow urticaria related to liver cirrhosis, one due to hemochromatosis, and the other one to alcohol1 . With a total of ten cases reported in literature by now, we considered relevant to report another case we recently came across. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170613IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.14407</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28609562">PM:28609562</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170613-BoechatSouzaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170613-BoechatSouzaM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170613, Boechat Souza M</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.14407</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42016</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Combalia,A.</style></author><author><style face="normal" font="default"> Fusta,X.</style></author><author><style face="normal" font="default"> Guilabert,A.</style></author><author><style face="normal" font="default"> Mascaro,J.M.,Jr.</style></author><author><style face="normal" font="default"> Estrach,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology department, Hospital Clinic, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default">Hyperbilirubinemia: The common denominator of Yellow Urticaria</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cause</style></keyword><keyword><style face="normal" font="default"> Cirrhosis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Liver Cirrhosis</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="13" Month="6" Year="2017">2017/6/13</year></dates><abstract><style face="normal" font="default">Rosso et al recently enlarged to ten the list of patients diagnosed with yellow urticaria (YU). These cases of YU remind clinicians that the skin, besides forming a biological barrier to protect internal organs and systems from the external environment, frequently reflects underlying internal diseases. YU has been described secondary to infective hepatitis1, liver cirrhosis (regardless of the cause) 2, 3, 4, 5, 6 , acute liver failure7 , and metastatic disease of the liver8 . This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170613IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.14397</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28609589">PM:28609589</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170613-CombaliaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170613-CombaliaA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170613, Combalia A</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.14397</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42017</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yun,S.J.</style></author><author><style face="normal" font="default"> Lee,J.Y.</style></author><author><style face="normal" font="default"> Kim,G.H.</style></author><author><style face="normal" font="default"> Kim,T.H.</style></author><author><style face="normal" font="default"> Lee,A.Y.</style></author><author><style face="normal" font="default"> Lee,S.H.</style></author><author><style face="normal" font="default"> Hong,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Dongguk University Ilsan Hospital, College of Medicine, Dongguk University, Goyang, Korea</style></auth-address><titles><title><style face="normal" font="default">Systemic contact dermatitis induced by roots of Hosta plantaginea</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> Asia</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Compositae</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Flower</style></keyword><keyword><style face="normal" font="default"> Flowers</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Rhus</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="default">In East Asia, herbs are not only used by traditional medical practitioners but also commonly eaten by public. Compositae and Rhus are well-known antigens that can cause allergic contact dermatitis, but the other herbs are not well studied for antigenicity. Hosta plantaginea (also known as 'August lily' or 'Plantain lily') is originated from China and usually grown for ornamental purposes (Fig. 1a~c). In traditional medicine, flowers are used as oral medicines for sore throat or dysuria and sometimes topically applied for burn. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.14469</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28696039">PM:28696039</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170711-YunSJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170711-YunSJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170711, Yun SJ</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.14469</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42018</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jannic,A.</style></author><author><style face="normal" font="default"> Servy,A.</style></author><author><style face="normal" font="default"> Chevalier,X.</style></author><author><style face="normal" font="default"> Colin,A.</style></author><author><style face="normal" font="default"> Chosidow,O.</style></author><author><style face="normal" font="default"> Ingen-Housz-Oro,S.</style></author><author><style face="normal" font="default"> Wolkenstein,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology department, AP-HP, Henri Mondor Hospital, Creteil, France</style></auth-address><titles><title><style face="normal" font="default">Self-diagnosed drug allergies: the belief of patients</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Elimination</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword></keywords><dates><year Day="11" Month="6" Year="2017">2017/6/11</year></dates><abstract><style face="normal" font="default">The term of "drug allergy" (DA) may include true hypersensitivity or non-allergic reactions. The rate of self-reporting DA ranges from 4.7% to 11% regardless of age. When patients report a DA, the medical team often decides a full and definitive elimination of the incriminated drug from future therapy, which deeply affects medical care. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170611IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.14392</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28602024">PM:28602024</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170611-JannicA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170611-JannicA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170611, Jannic A</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.14392</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42019</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Christensen,T.J.</style></author><author><style face="normal" font="default"> Samant,S.A.</style></author><author><style face="normal" font="default"> Shin,A.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Reno Orthopaedic Clinic, Reno, NV</style></auth-address><titles><title><style face="normal" font="default">Making Sense of Metal Allergy and Hypersensitivity to Metallic Implants in Relation to Hand Surgery</style></title><secondary-title><style face="normal" font="default">J Hand Surg Am</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Hand Surg Am</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Corrosion</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metal allergies</style></keyword><keyword><style face="normal" font="default"> Metal allergy</style></keyword><keyword><style face="normal" font="default"> metal hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> Vasculitis</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="default">All metals implanted into a biological system undergo some degree of corrosion depending upon its composition. The electrochemical process of corrosion produces free metal ions, which may activate the host's immune system through a variety of mechanisms. Whereas dermal metal hypersensitivity is common, affecting 10% to 15% of the population, the immune reaction from implanted metals is much less common (&lt; 0.1%), but has been associated with metal allergy and hypersensitivity producing a multitude of patient symptoms. Superficial symptoms may be mild to severe forms of dermatitis, urticaria, pruritus, and vasculitis, whereas deep sequelae include metallosis-related pseudotumor, implant loosening, and joint stiffness. Currently, there are clinical tests to evaluate patients for metal hypersensitivity, but there is little agreement regarding the ideal timing and clinical situation prompting the work-up of a patient for a metal allergy or hypersensitivity. An understanding of the epidemiology, etiology, basic science, diagnostic testing, and treatment of patients with suspected metal allergy, as it pertains to the current literature, will aid orthopedic and plastic surgeons of all subspecialties in the management of patients requiring metallic implants</style></abstract><notes><style face="normal" font="default">DA - 20170715IS - 1531-6564 (Electronic)IS - 0363-5023 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jhsa.2017.06.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709788">PM:28709788</url></web-urls></urls><custom2><style face="normal" font="default">20170715, Christensen TJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jhsa.2017.06.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42020</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Floudas,A.</style></author><author><style face="normal" font="default"> Saunders,S.P.</style></author><author><style face="normal" font="default"> Moran,T.</style></author><author><style face="normal" font="default"> Schwartz,C.</style></author><author><style face="normal" font="default"> Hams,E.</style></author><author><style face="normal" font="default"> Fitzgerald,D.C.</style></author><author><style face="normal" font="default"> Johnston,J.A.</style></author><author><style face="normal" font="default"> Ogg,G.S.</style></author><author><style face="normal" font="default"> McKenzie,A.N.</style></author><author><style face="normal" font="default"> Walsh,P.T.</style></author><author><style face="normal" font="default"> Fallon,P.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland</style></auth-address><titles><title><style face="normal" font="default">IL-17 Receptor A Maintains and Protects the Skin Barrier To Prevent Allergic Skin Inflammation</style></title><secondary-title><style face="normal" font="default">J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Immunol</style></full-title></periodical><pages end="717" start="707">707-717</pages><volume><style face="normal" font="default">199</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> dysregulation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Filaggrin</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> IL-17</style></keyword><keyword><style face="normal" font="default"> IL-17A</style></keyword><keyword><style face="normal" font="default"> IL-33</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Ireland</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> Mutant</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> Th2 Cells</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="15" Month="7" Year="2017">2017/7/15</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a common inflammatory skin disease affecting up to 20% of children and 3% of adults worldwide and is associated with dysregulation of the skin barrier. Although type 2 responses are implicated in AD, emerging evidence indicates a potential role for the IL-17A signaling axis in AD pathogenesis. In this study we show that in the filaggrin mutant mouse model of spontaneous AD, IL-17RA deficiency (Il17ra-/- ) resulted in severe exacerbation of skin inflammation. Interestingly, Il17ra-/- mice without the filaggrin mutation also developed spontaneous progressive skin inflammation with eosinophilia, as well as increased levels of thymic stromal lymphopoietin (TSLP) and IL-5 in the skin. Il17ra-/- mice have a defective skin barrier with altered filaggrin expression. The barrier dysregulation and spontaneous skin inflammation in Il17ra-/- mice was dependent on TSLP, but not the other alarmins IL-25 and IL-33. The associated skin inflammation was mediated by IL-5-expressing pathogenic effector Th2 cells and was independent of TCRgammadelta T cells and IL-22. An absence of IL-17RA in nonhematopoietic cells, but not in the hematopoietic cells, was required for the development of spontaneous skin inflammation. Skin microbiome dysbiosis developed in the absence of IL-17RA, with antibiotic intervention resulting in significant amelioration of skin inflammation and reductions in skin-infiltrating pathogenic effector Th2 cells and TSLP. This study describes a previously unappreciated protective role for IL-17RA signaling in regulation of the skin barrier and maintenance of skin immune homeostasis</style></abstract><notes><style face="normal" font="default">DA - 20170615IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - Ireland -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.4049/jimmunol.1602185</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28615416">PM:28615416</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Immunol\2017-199-707-17.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Immunol\2017-199-707-17.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170615, Floudas A</style></custom2><misc3><style face="normal" font="default">10.4049/jimmunol.1602185</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42021</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bechara,R.</style></author><author><style face="normal" font="default"> Antonios,D.</style></author><author><style face="normal" font="default"> Azouri,H.</style></author><author><style face="normal" font="default"> Pallardy,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Inflammation Chimiokines et Immunopathologie, INSERM, Fac. de pharmacie - Univ.Paris-Sud, Universite Paris-Saclay, Chatenay-Malabry, France</style></auth-address><titles><title><style face="normal" font="default">Nickel sulfate promotes IL-17A producing CD4+ T-cells by an IL-23 dependent mechanism regulated by TLR4 and Jak-STAT pathways</style></title><secondary-title><style face="normal" font="default">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Invest Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Chimiokines</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> delayed-type hypersensitivity</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> IL-12</style></keyword><keyword><style face="normal" font="default"> IL-17A</style></keyword><keyword><style face="normal" font="default"> IL-23</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH1</style></keyword><keyword><style face="normal" font="default"> TH17</style></keyword><keyword><style face="normal" font="default"> TH17 cells</style></keyword><keyword><style face="normal" font="default"> TLR4</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="17" Month="6" Year="2017">2017/6/17</year></dates><abstract><style face="normal" font="default">Allergic contact dermatitis, caused by nickel, is a delayed-type hypersensitivity reaction and 14.5% of the general population may be affected in Europe. Among a wide range of cytokines, the IL-12 family has unique structural and immunological characteristics. While IL-12p70 promotes T helper (Th) 1 cells polarization, IL-23 promotes Th17 cells development and both have been isolated from nickel-allergic patients. In this work, we were interested in understanding the mechanism behind nickel-induced Th17 cells development. We showed that nickel induced an early production of IL-23 in human monocyte-derived dendritic cells (MoDCs) along with an increase in the expression of il-23p19 and il-12p40 mRNA. However, the production of a significant level of IL-12p70 required an additional signal such as IFN-gamma. Moreover, nickel-treated MoDCs induced an increase in the percentage of IL-17A+ CD4+ T-cells, an effect reduced by IL-23 neutralization. We, then, investigated the molecular mechanism of IL-23 production. Our results showed that TLR4, p38MAPK and NF-kB were involved in IL-23 production induced by nickel. However, Jak-STAT activation seems to maintain the IL-23/IL-12p70 balance by limiting IL-23 production and promoting Th1 polarization. These results indicate that nickel-induced Th17 cells development is dependent on the production of IL-23 by human MoDCs via TLR4, p38MAPK, NF-kappaB and Jak-STAT pathways</style></abstract><notes><style face="normal" font="default">DA - 20170621IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticleCO - France -CO - Lebanon -</style></notes><work-type><style face="normal" font="default">10.1016/j.jid.2017.05.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28634033">PM:28634033</url></web-urls></urls><custom2><style face="normal" font="default">20170621, Bechara R</style></custom2><misc3><style face="normal" font="default">10.1016/j.jid.2017.05.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42022</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,D.Y.</style></author><author><style face="normal" font="default"> Chong,W.S.</style></author><author><style face="normal" font="default"> Pan,J.Y.</style></author><author><style face="normal" font="default"> Heng,Y.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Skin Centre, Singapore</style></auth-address><titles><title><style face="normal" font="default">First Case Report of Aseptic Meningitis Induced by Adalimumab Administered for Treatment of Chronic Plaque Psoriasis</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="185" start="183">183-185</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Case Report</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Meningitis</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170601IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Singapore -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0148</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28570223">PM:28570223</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-183-97.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-183-97.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170601, Wang DY</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0148</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42023</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">De Pasquale,T.M.</style></author><author><style face="normal" font="default"> Buonomo,A.</style></author><author><style face="normal" font="default"> Di Gennaro,L.</style></author><author><style face="normal" font="default"> Pucci,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Unit, Ospedale di Civitanova Marche, Civitanova Marche, Italy</style></auth-address><titles><title><style face="normal" font="default">Pulmonary Embolism After Ceftriaxone-Induced Anaphylaxis</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="191" start="190">190-191</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Embolism</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170601IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0152</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28570226">PM:28570226</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-183-97.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-183-97.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170601, De Pasquale TM</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0152</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42024</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shim,Y.J.</style></author><author><style face="normal" font="default"> Ha,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Institute for Cancer Research, Keimyung University School of Medicine and Dongsan Medical Center, Daegu, KoreaDepartment of Laboratory Medicine, Keimyung University School of Medicine and Dongsan Medical Center, Daegu, Korea</style></auth-address><titles><title><style face="normal" font="default">Identification of Novel JAK3 Mutations by Whole-Exome Sequencing in a Korean Boy With Severe Combined Immunodeficiency</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="189" start="187">187-189</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cancer</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Severe Combined Immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170601IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0151</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28570225">PM:28570225</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-183-97.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-183-97.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170601, Shim YJ</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0151</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42025</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Alves-Correia,M.</style></author><author><style face="normal" font="default"> Gaspar,A.</style></author><author><style face="normal" font="default"> Borrego,L.M.</style></author><author><style face="normal" font="default"> Mota,I.</style></author><author><style face="normal" font="default"> Morais-Almeida,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunoallergy Department, CUF Descobertas Hospital, Lisbon, Portugal</style></auth-address><titles><title><style face="normal" font="default">Desensitization to Cyanocobalamin: Rush Protocol</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="197" start="196">196-197</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">desensitization</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170601IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0160</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28570229">PM:28570229</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-183-97.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-183-97.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170601, Alves-Correia M</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0160</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42026</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Munoz-Cano,R.</style></author><author><style face="normal" font="default"> Ainsua-Enrich,E.</style></author><author><style face="normal" font="default"> Torres-Atencio,I.</style></author><author><style face="normal" font="default"> Martin,M.</style></author><author><style face="normal" font="default"> Sanchez-Lopez,J.</style></author><author><style face="normal" font="default"> Bartra,J.</style></author><author><style face="normal" font="default"> Picado,C.</style></author><author><style face="normal" font="default"> Mullol,J.</style></author><author><style face="normal" font="default"> Valero,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Unitat d'Al.lergia, Servei de Pneumologia i Al.lergia Respiratoria, Hospital Clinic and Universitat de Barcelona, Barcelona, Catalonia, Spain</style></auth-address><titles><title><style face="normal" font="default">Effects of Rupatadine on Platelet- Activating Factor-Induced Human Mast Cell Degranulation Compared With Desloratadine and Levocetirizine (The MASPAF Study)</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="168" start="161">161-168</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> and primary</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> Anti-H1</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Cell Degranulation</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> desloratadine</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Histamine Release</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lipid</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="default"> mediator release</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Platelet</style></keyword><keyword><style face="normal" font="default"> Platelet Activating Factor</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVE: Platelet-activating factor (PAF) is a lipid mediator involved in the pathophysiology of several allergic diseases, for example, in the ampli fi cation of mast cell (MC) activation in anaphylaxis. Rupatadine is an antihistamine with a demonstrated anti-PAF effect, although its capacity to inhibit PAF-induced MC degranulation has not been fully evaluated. Objectives: To compare the ability of rupatadine to inhibit PAF-induced MC degranulation with that of desloratadine and levocetirizine and to confirm the dual anti-H1 and anti-PAF activity of rupatadine. METHODS: The human MC line LAD2 and primary MCs (human lung tissue MCs [hLMCs]) were used. MC mediator release was evaluated using the b-hexosaminidase and histamine release assay. The effects of rupatadine (H1 antagonist + PAF receptor antagonist), desloratadine, and levocetirizine (H1 antagonists) on LAD2 and hLMCs were compared. The PAF receptor antagonists WEB2086, BN52021, and CV6209 were also tested. PAF receptor protein expression was evaluated in both LAD2 and hLMCs. RESULTS: CV6209 and rupatadine inhibited PAF-induced MC degranulation in both LAD2 and hLMCs. In LAD2, rupatadine (5 and 10 microM) and levocetirizine (5 microM), but not desloratadine, inhibited PAF-induced b-hexosaminidase release. Rupatadine (1-10 microM), levocetirizine (1-10 microM), and desloratadine (10 microM) inhibited PAF-induced histamine release. Rupatadine at 10 microM had an inhibitory effect on hLMC degranulation, but levocetirizine and desloratadine did not. CONCLUSIONS: This study shows that rupatadine and, to a lesser extent, levocetirizine, but not desloratadine, inhibit PAF-induced degranulation in both LAD2 and hLMCs. These findings support the dual antihistamine and anti-PAF effect of rupatadine in allergic disorders</style></abstract><notes><style face="normal" font="default">DA - 20161019IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0117</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27758758">PM:27758758</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-161-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-161-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170601, Munoz-Cano R</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0117</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42027</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ruiz Hornillos,J.</style></author><author><style face="normal" font="default"> Nevot Falco,S.</style></author><author><style face="normal" font="default"> Olaguibel,J.M.</style></author><author><style face="normal" font="default"> Ibanez,M.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Teaching Interest Group of the Child Allergy Committee of the Spanish Society of Allergology and Clinical Immunology, Spain</style></auth-address><titles><title><style face="normal" font="default">Training of Spanish Allergology Residents in Pediatric Allergology: A Survey of the Current Situation</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="" start="203">203-</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> allergology</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Teaching</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170601IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0153</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28570232">PM:28570232</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-203.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-203.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170601, Ruiz Hornillos J</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0153</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42028</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Quiralte-Castillo,J.</style></author><author><style face="normal" font="default"> Avila-Castellano,M.R.</style></author><author><style face="normal" font="default"> Cimbollek,S.</style></author><author><style face="normal" font="default"> Benaixa,P.</style></author><author><style face="normal" font="default"> Leguisamo,S.</style></author><author><style face="normal" font="default"> Baynova,K.</style></author><author><style face="normal" font="default"> Labella,M.</style></author><author><style face="normal" font="default"> Quiralte,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Section, Hospital Universitario Virgen del Rocio, Sevilla, Spain</style></auth-address><titles><title><style face="normal" font="default">Nasal Ketorolac Challenge Using Acoustic Rhinometry in Patients With Aspirin-Exacerbated Respiratory Disease</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="174" start="169">169-174</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">acoustic rhinometry</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> AERD</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin challenge</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> cumulative dose</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Ketorolac</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal Cavity</style></keyword><keyword><style face="normal" font="default"> nasal challenge</style></keyword><keyword><style face="normal" font="default"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> oral challenge</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVE: Safer and less time-consuming alternatives to single-blind placebo-controlled oral challenge (SBPCOC) have been sought for the diagnosis of aspirin-exacerbated respiratory disease (AERD). Nasal challenges with various nonsteroidal anti-inflammatory drugs and assessment methods have been developed. Objective: Our objective was to evaluate the utility and safety of nasal ketorolac challenge (NKC) using acoustic rhinometry in patients with suspected AERD. METHODS: The study population comprised 36 patients with suspected AERD. NKC was performed with placebo (saline) and 13 mg of ketorolac sprayed as aerosol into both nostrils. A positive challenge result was defined as an increase of >/=30% in nasal symptoms (recorded using a visual analog scale) and a 30% drop in the sum of the volumes of both nasal cavities at 2-8 cm. Patients with a negative NKC result underwent SBPCOC with aspirin (cumulative dose of 750 mg). RESULTS: A naso-ocular reaction during NKC was detected in 21 patients. Four patients also developed mild asthma exacerbations (although only 1 experienced a decrease in FEV1 >15%). No other significant adverse events occurred. The remaining 15 patients with a negative NKC result had a negative response during aspirin SBPCOC. CONCLUSIONS: NKC assessed using acoustic rhinometry is a reliable method for the study of patients with AERD. We suggest that NKC assessed with acoustic rhinometry was useful and safe for selection of candidates for safe oral aspirin challenge</style></abstract><notes><style face="normal" font="default">DA - 20161019IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0118</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27758759">PM:27758759</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-169-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-169-74.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161019, Quiralte-Castillo J</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0118</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42029</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Garcia Nunez,I.</style></author><author><style face="normal" font="default"> Algaba Marmol,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Department, Hospital Quironsalud Malaga, Malaga, SpainDCCU Ecija, Osune Primary Care Unit, Osuna, Spain</style></auth-address><titles><title><style face="normal" font="default">A Minimum Difference Between 2 Syndromes</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="202" start="201">201-202</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170601IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0156</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28570231">PM:28570231</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-201-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-201-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170601, Garcia Nunez I</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0156</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42030</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Seecheran,R.</style></author><author><style face="normal" font="default"> Seecheran,V.</style></author><author><style face="normal" font="default"> Persad,S.</style></author><author><style face="normal" font="default"> Lalla,S.</style></author><author><style face="normal" font="default"> Seecheran,N.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">The University of the West Indies, Mt. Hope, Trinidad and Tobago</style></auth-address><titles><title><style face="normal" font="default">Contrast Media-Induced Anaphylaxis Causing a Stress-Related Cardiomyopathy Post Percutaneous Coronary Intervention: Case Report</style></title><secondary-title><style face="normal" font="default">J Investig Med High Impact Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Med High Impact Case Rep</style></full-title></periodical><pages end="" start="2324709617712735">2324709617712735-</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Cardiomyopathies</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> West Indies</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">Anaphylaxis is a sudden-onset, severe hypersensitivity reaction that can be potentially fatal. It can often transition to refractory hemodynamic instability, eventually resulting in death. Stress-related cardiomyopathies (SRCs) have multifactorial etiologies, including being linked to excessive catecholamine release in periods of intense stress. This novel case report recounts a SRC caused by contrast-induced anaphylaxis within 1 hour post percutaneous coronary intervention. Both acutely life-threatening conditions may occur simultaneously and are implicated with devastating complications. Further research is required to understand this cardiac-neuroaxis interplay in SRC to identify risk factors and develop management strategies</style></abstract><notes><style face="normal" font="default">DA - 20170613IS - 2324-7096 (Linking)LA - engPT - Journal ArticleCO - Trinidad and Tobago -</style></notes><work-type><style face="normal" font="default">10.1177/2324709617712735</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28607937">PM:28607937</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Med High Impact Case Rep\2017-5-2324709617712735.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Med High Impact Case Rep\2017-5-2324709617712735.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170613, Seecheran R</style></custom2><misc3><style face="normal" font="default">10.1177/2324709617712735</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42031</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Karn,D.</style></author><author><style face="normal" font="default"> Kc,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Dhulikhel Hospital, Kavre, NepalDepartment of Dermatology, Dhulikhel Hospital, Kavre, Nepal</style></auth-address><titles><title><style face="normal" font="default">Clinical Outcome of Autologous Serum Therapy in Chronic Idiopathic Urticaria</style></title><secondary-title><style face="normal" font="default">J Nepal Health Res Council</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Nepal Health Res Council</style></abbr-1></periodical><pages end="74" start="71">71-74</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">35</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Body Weight</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic idiopathic urticaria</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> H1 antihistamines</style></keyword><keyword><style face="normal" font="default"> H1-antihistamine</style></keyword><keyword><style face="normal" font="default"> H1-antihistamines</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nepal</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Quantification</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Quality of life in chronic idiopathic urticaria is hampered as efficacy of H1-antihistamines is limited. Autologous serum containing tolerance-generating anti-idiotype antibodies is a novel and cost-effective therapy. This study was conducted to evaluate the efficacy of autologous serum therapy (AST) among chronic urticaria patients with autologous skin prick test positive and negative status. METHODS: Untreated 102 patients of chronic urticaria were enrolled in a non-randomized interventional study. Patients were categorized into two groups based on autologous serum skin prick test as test positive (ASST +) and test negative (ASST -). Patients were then treated with intramuscular injection of 0.05ml per kg body weight of autologous serum weekly for 10 weeks. Urticaria activity scoring (UAS) tool was used for quantification of the symptoms. Weekly recording of UAS (range: 0-42) was made before the therapy (baseline) and during the therapy for 10 weeks. RESULTS: Significant improvement with AST in the mean UAS was noted from baseline to 10 weeks in both the group of patients (14.6 +/- 6.3 and 10.2 +/- 5.1 for ASST+ group ; 16.9 +/- 7.8 and 8.6 +/- 4.8 for</style></abstract><notes><style face="normal" font="default">DA - 20170717IS - 1999-6217 (Electronic)IS - 1727-5482 (Linking)LA - engPT - Journal ArticleCO - Nepal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28714496">PM:28714496</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Nepal Health Res Council\2017-15-71-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Nepal Health Res Council\2017-15-71-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170717, Karn D</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42032</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rumchev,K.</style></author><author><style face="normal" font="default"> Brown,H.</style></author><author><style face="normal" font="default"> Wheeler,A.</style></author><author><style face="normal" font="default"> Pereira,G.</style></author><author><style face="normal" font="default"> Spickett,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a School of Public Health, Curtin University</style></auth-address><titles><title><style face="normal" font="default">Behavioural Interventions to Reduce Nickel Exposure in a Nickel Processing Plant</style></title><secondary-title><style face="normal" font="default">J Occup Environ Hyg</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Occup Environ Hyg</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Feedback</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hygiene</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> Plant</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> urine</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Workplace</style></keyword></keywords><dates><year Day="22" Month="6" Year="2017">2017/6/22</year></dates><abstract><style face="normal" font="default">Nickel is a widely used material in many industries. Although, there is enough evidence that occupational exposure to nickel may cause respiratory illnesses, allergies and even cancer, it is not possible to stop the use of nickel in occupational settings. Nickel exposure, however, can be controlled and reduced significantly in workplaces. The main objective of this study was to assess if educational intervention of hygiene behaviour could reduce nickel exposure among Indonesian nickel smelter workers. Participants were randomly assigned to three intervention groups (n = 99). Group one (n = 35) received only an educational booklet about nickel, related potential health effects and preventive measures, group two (n = 35) attended a presentation in addition to the booklet, and group three (n = 29) received personal feedback on their biomarker results in addition to the booklet and presentations. Pre and post intervention air sampling was conducted to measure concentrations of dust and nickel in air along with worker's blood and urine nickel concentrations. The study did not measure significant differences in particles and nickel concentrations in the air between pre and post interventions. However, we achieved significant reductions in the post intervention urine and blood nickel concentrations which can be attributed to changes in personal hygiene behaviour. The median urinary nickel concentration in the pre-intervention period for group one was 52.3 microg/l, for group two 57.4 microg/l and group three 43.2 microg/l which were significantly higher (p&lt; = 0.010) than those measured in the post-intervention period for each of the groups with 8.5 microg/l, 9.6 microg/l and 8.2 microg/l, respectively. A similar pattern was recorded for serum nickel with significantly (p &lt;0.05) higher median concentrations measured in the pre-intervention period for group one 1.7 microg/l, and 2.0 microg/l for group 2 and group 3 compared with the post intervention median serum nickel levels of 0.1 microg/l for all groups. The study showed that educational interventions can significantly reduce personal exposure levels to nickel among Indonesian nickel smelter workers</style></abstract><notes><style face="normal" font="default">DA - 20170622IS - 1545-9632 (Electronic)IS - 1545-9624 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1080/15459624.2017.1335402</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28641054">PM:28641054</url></web-urls><related-urls><url ppv-ref="no">presto - 18 mesi</url></related-urls></urls><custom2><style face="normal" font="default">20170622, Rumchev K</style></custom2><misc3><style face="normal" font="default">10.1080/15459624.2017.1335402</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42033</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mai,W.</style></author><author><style face="normal" font="default"> Liu,X.</style></author><author><style face="normal" font="default"> Su,G.</style></author><author><style face="normal" font="default"> Zhou,W.</style></author><author><style face="normal" font="default"> Wen,Z.</style></author><author><style face="normal" font="default"> Lu,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Prevention and Healthcare, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province, China (Dr Mai, Su); Department of General Surgery, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province, China (Mr Liu); Department of Laboratory Science, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province, China (Ms Zhou); and Department of Dermatology, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province, China (Mr Wen, Mr Lu)</style></auth-address><titles><title><style face="normal" font="default">Elevation of Circulating Th17/Th22 Cells Exposed to Low-Level Formaldehyde and Its Relevance to Formaldehyde-Induced Occupational Allergic Contact Dermatitis</style></title><secondary-title><style face="normal" font="default">J Occup Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Occup Environ Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Formaldehyde</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH17</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="10" Month="7" Year="2017">2017/7/10</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The aim of this study was to investigate the effects of formaldehyde exposure on Th17 and Th22 cells and its relevance to human occupational allergic contact dermatitis (OACD). METHODS: Circulating IL17-/IL22-secreting cells and serum IL17/IL22 levels in formaldehyde-exposed workers at Occupational Exposure Limit and nonexposed controls were assessed. RESULTS: The IL17 and IL22 cell population were detected in both CD3CD8 and CD3CD8 cells. The percentages of circulating IL17 and IL22 T cells in the workers with and without ACD history were all elevated, which were more remarkable in the ones with ACD history. Serum levels of IL17 and IL22 between the workers and controls were not significantly different. CONCLUSIONS: Low-level formaldehyde exposure may increase circulating IL17-/IL22-producing T cells (CD8 and CD8), possibly involved in the development of human OACD. But it may not alter serum levels of IL17/IL22 before the appearance of OACD symptoms</style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 1536-5948 (Electronic)IS - 1076-2752 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1097/JOM.0000000000001074</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28697061">PM:28697061</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Occup Environ Med\20170711-MaiW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Occup Environ Med\20170711-MaiW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170711, Mai W</style></custom2><misc3><style face="normal" font="default">10.1097/JOM.0000000000001074</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42034</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mason,P.</style></author><author><style face="normal" font="default"> Scarpa,M.C.</style></author><author><style face="normal" font="default"> Liviero,F.</style></author><author><style face="normal" font="default"> Guarnieri,G.</style></author><author><style face="normal" font="default"> Maestrelli,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Cardiologic, Thoracic and Vascular Sciences, University of Padova, Padova, Italy</style></auth-address><titles><title><style face="normal" font="default">Distinct Clinical Phenotypes of Occupational Asthma due to Diisocyanates</style></title><secondary-title><style face="normal" font="default">J Occup Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Occup Environ Med</style></full-title></periodical><pages end="542" start="539">539-542</pages><volume><style face="normal" font="default">59</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical phenotypes</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> occupational asthma</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> specific inhalation challenge</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To assess whether diisocyanate occupational asthma represents a unique phenotype. METHODS: We studied 187 patients with diagnosis of asthma due to diisocyanates confirmed by a positive specific inhalation challenge. The simplified algorithm from severe asthma research program (SARP) (Moore et al, 2010) was applied to classify patients into five clusters. RESULTS: Our patients were allocated in three of the five clusters described in common asthma, since the most severe Clusters (4 and 5) were not represented. Cluster 2 was the most populated, as in common asthma, and included the youngest patients with the shortest duration of exposure to the sensitizers. Cluster 3 included older men patients with worse lung function and longer occupational exposure. CONCLUSIONS: Diisocyanate asthma is a heterogeneous disease. Differences across clusters include demographic characteristics, lung function, and chronology of diisocyanate exposure</style></abstract><notes><style face="normal" font="default">DA - 20170609IS - 1536-5948 (Electronic)IS - 1076-2752 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1097/JOM.0000000000001017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28598931">PM:28598931</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Occup Environ Med\2017-59-539-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Occup Environ Med\2017-59-539-42.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170609, Mason P</style></custom2><misc3><style face="normal" font="default">10.1097/JOM.0000000000001017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42035</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Moore,N.A.</style></author><author><style face="normal" font="default"> Czyz,C.N.</style></author><author><style face="normal" font="default"> Carter,T.D.</style></author><author><style face="normal" font="default"> Foster,J.A.</style></author><author><style face="normal" font="default"> Cahill,K.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, Indiana University School of Medicine, 2022 Ruckle St., Indianapolis, IN, 46202, USA.</style></auth-address><titles><title><style face="normal" font="default">Neomycin, polymyxin B, and dexamethasone allergic reactions following periocular surgery</style></title><secondary-title><style face="normal" font="default">J Ophthalmic Inflamm Infect</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Ophthalmic Inflamm Infect</style></full-title></periodical><pages end="" start="15">15-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dexamethasone</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neomycin</style></keyword><keyword><style face="normal" font="default"> Ophthalmology</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polymyxin B</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin reaction</style></keyword><keyword><style face="normal" font="default"> skin reactions</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: The aim of this study was to evaluate the rate of periocular allergic skin reactions to topical neomycin, polymyxin B, and dexamethasone (NPD) ophthalmic ointment. METHODS: A consecutive patient prospective study was performed. A total of 522 patients who had a procedure involving incision of the periocular skin with subsequent postoperative application of NPD ophthalmic ointment were included. Patients were evaluated for signs of allergy at 1 week postoperatively or prior if the patient had complaints. A periocular allergic reaction was defined as any periocular skin pruritus, erythema, edematous papules, vesicles, or plaques at the site of ointment application beyond that of the typical postprocedure presentation. The patients continued to be monitored for 30 days postoperatively. RESULTS: Of the 522 patients who completed the study, eight (1.5%) had a definitive periocular allergic contact dermatitis to the NPD ophthalmic ointment. Allergic presentation ranged from postoperative day 3 to 14. CONCLUSIONS: The rate of periocular allergic reactions to NPD ophthalmic ointment is significantly lower than reported in the literature for other topical preparations of neomycin and polymyxin B. The low rate of allergy in this study suggests that NPD ophthalmic ointment can safely be applied to the periocular skin with a very minimal risk of inciting an allergic reaction</style></abstract><notes><style face="normal" font="default">DA - 20170613IS - 1869-5760 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1186/s12348-017-0133-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28608297">PM:28608297</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Ophthalmic Inflamm Infect\2017-7-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Ophthalmic Inflamm Infect\2017-7-15.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170613, Moore NA</style></custom2><misc3><style face="normal" font="default">10.1186/s12348-017-0133-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42036</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Thomson,H.</style></author><author><style face="normal" font="default"> Seith,R.</style></author><author><style face="normal" font="default"> Craig,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Clinical Sciences at Monash Health, Monash University, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="default">Inaccurate diagnosis of paediatric anaphylaxis in three Australian Emergency Departments</style></title><secondary-title><style face="normal" font="default">J Paediatr Child Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Paediatr Child Health</style></abbr-1></periodical><pages end="704" start="698">698-704</pages><volume><style face="normal" font="default">53</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Consensus</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> diagnostic criteria</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Victoria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">AIM: To determine the accuracy of emergency department (ED) paediatric anaphylaxis diagnosis, and to identify factors associated with misdiagnosis. METHODS: Retrospective chart review of children aged 0-18 years with allergic presentations to three Victorian EDs in 2014. Cases were included if an ED diagnosis of anaphylaxis was recorded, or the presentation met international consensus criteria for anaphylaxis. RESULTS: Of the 60 143 paediatric ED presentations during the study period, 1551 allergy-related presentations were identified and reviewed. One hundred and eighty-seven met consensus criteria for anaphylaxis, and another 24 were diagnosed with anaphylaxis without meeting criteria. Of the 211 presentations, 105 cases were given an ED diagnosis of anaphylaxis and 106 cases were given an alternative diagnosis in ED. ED assessment had a sensitivity of 43.2% (95% confidence interval (CI) 36.1-50.7%) and specificity of 97.9% (95% CI 96.9-98.7%) for anaphylaxis. Multiple logistic regression demonstrated that an ED anaphylaxis diagnosis was associated with previous anaphylaxis (odds ratio (OR) 3.20; 95% CI 1.52-6.75), arrival by ambulance (OR 2.80; 95% CI 1.36-5.74), a high-acuity triage category (OR 4.51; 95% CI 2.20-9.25) and presentation to a tertiary hospital (OR 2.86; 95% CI 1.44-5.67). ED diagnosis of anaphylaxis was less likely in those with resolution of symptoms and signs in at least one organ system prior to arrival (OR 0.27; 95% CI 0.12-0.62). CONCLUSION: In children with allergic presentations, ED assessment has a low sensitivity but high specificity for anaphylaxis. Attention to resolved pre-hospital symptoms and awareness of diagnostic criteria are important considerations for accurate ED diagnosis of anaphylaxis</style></abstract><notes><style face="normal" font="default">DA - 20170703IS - 1440-1754 (Electronic)IS - 1034-4810 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/jpc.13483</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28670809">PM:28670809</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Paediatr Child Health\2017-53-698-704.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Paediatr Child Health\2017-53-698-704.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170703, Thomson H</style></custom2><misc3><style face="normal" font="default">10.1111/jpc.13483</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42037</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mochmer,P.E.</style></author><author><style face="normal" font="default"> Casmaer,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Paul E. Mochmer is a fellow in emergency medicine at the San Antonio Military Medical Center at Fort Sam Houston, Tex. Monica L. Casmaer isthe program director and a faculty member in the US Army/Baylor University Doctor of Science Emergency Medicine Physician Assistant Program at Fort Sam Houston, Tex. The authors have disclosed no potential conflicts of interest, financial or otherwise. This case study does not represent the views or opinions of the Department of Defense or the US Army</style></auth-address><titles><title><style face="normal" font="default">Possible allergic reaction after outpatient surgery</style></title><secondary-title><style face="normal" font="default">JAAPA</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">JAAPA</style></full-title></periodical><pages end="56" start="55">55-56</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Emergency Medicine</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170623IS - 1547-1896 (Print)IS - 0893-7400 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/01.JAA.0000520548.38699.67</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28644226">PM:28644226</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JAAPA\2017-30-55-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JAAPA\2017-30-55-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170623, Mochmer PE</style></custom2><misc3><style face="normal" font="default">10.1097/01.JAA.0000520548.38699.67</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42038</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Trubiano,J.A.</style></author><author><style face="normal" font="default"> Adkinson,N.F.</style></author><author><style face="normal" font="default"> Phillips,E.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Infectious Diseases, Austin Hospital, Melbourne, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="default">Penicillin Allergy Is Not Necessarily Forever</style></title><secondary-title><style face="normal" font="default">JAMA</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">JAMA</style></full-title></periodical><pages end="83" start="82">82-83</pages><volume><style face="normal" font="default">318</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Victoria</style></keyword></keywords><dates><year Day="4" Month="7" Year="2017">2017/7/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170703IS - 1538-3598 (Electronic)IS - 0098-7484 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1001/jama.2017.6510</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28672303">PM:28672303</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JAMA\2017-318-82-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JAMA\2017-318-82-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170703, Trubiano JA</style></custom2><misc3><style face="normal" font="default">10.1001/jama.2017.6510</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42039</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pawlasty,H.M.</style></author><author><style face="normal" font="default"> Thompson,A.J.</style></author><author><style face="normal" font="default"> Chalmers,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pharmacy, School of Medicine, University of Tasmania, Hobart, Tasmania, Australia</style></auth-address><titles><title><style face="normal" font="default">Rates and Consequences of False Penicillin Allergies in Australia</style></title><secondary-title><style face="normal" font="default">JAMA Intern Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JAMA Intern Med</style></abbr-1></periodical><pages end="" start="1061">1061-</pages><volume><style face="normal" font="default">177</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170703IS - 2168-6114 (Electronic)IS - 2168-6106 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1001/jamainternmed.2017.1836</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28672355">PM:28672355</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JAMA Intern Med\2017-177-1061.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JAMA Intern Med\2017-177-1061.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170703, Pawlasty HM</style></custom2><misc3><style face="normal" font="default">10.1001/jamainternmed.2017.1836</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42040</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Juri,M.C.</style></author><author><style face="normal" font="default"> Fernandez Romero,D.S.</style></author><author><style face="normal" font="default"> Larrauri,B.</style></author><author><style face="normal" font="default"> Malbran,E.</style></author><author><style face="normal" font="default"> Torre,G.</style></author><author><style face="normal" font="default"> Malbran,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Unidad de Alergia, Asma e Inmunologia Clinica, Buenos Aires, Argentina.</style></auth-address><titles><title><style face="normal" font="default">[Allergy to drugs. Experience in 771 procedures]</style></title><secondary-title><style face="normal" font="default">Medicina (B Aires)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Medicina (B Aires)</style></abbr-1></periodical><pages end="184" start="180">180-184</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Alergia</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Argentina</style></keyword><keyword><style face="normal" font="default"> Asma</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> Drug provocation test</style></keyword><keyword><style face="normal" font="default"> Drug skin tests</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> Nausea</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Drug hypersensitivity reactions (RHD) are those that present clinically as allergic. They can or cannot involve an immunologic mechanism of lesion. They are frequent and, occasionally, life threatening. Patients with RHD repeat the reaction when they are re-exposed to the drug, limiting the therapeutic options and exposing them to more expensive and toxic drugs. It is difficult to identify the responsible drug when the reaction was not recent or when it occurred in the context of therapy with multiple drugs or confusing concurrent diseases. The diagnosis should be based on clinical history, followed by drug skin tests and drug provocation tests. We describe our experience in 771 procedures, 331 cutaneous and 440 drug provocation tests, 11% of them were positive. Positive symptoms included generalized pruritus, rash, urticaria, angioedema, rhinitis, bronchospasm, nausea and anaphylaxis. All the patients with positive tests had a good response to treatment. It can therefore be concluded that drug tests undertaken on individuals with suspected drug allergy, performed by experienced personnel and in controlled settings, are useful and safe to confirm drug hypersensitivity</style></abstract><notes><style face="normal" font="default">DA - 20170623IS - 0025-7680 (Print)IS - 0025-7680 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Argentina -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28643673">PM:28643673</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Medicina (B Aires)\2017-77-180-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Medicina (B Aires)\2017-77-180-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170623, Juri MC</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42041</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bie,Q.</style></author><author><style face="normal" font="default"> Jin,C.</style></author><author><style face="normal" font="default"> Zhang,B.</style></author><author><style face="normal" font="default"> Dong,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Laboratory Medicine, Affiliated Hospital of Jining Medical University, Jining, Shandong, PR China</style></auth-address><titles><title><style face="normal" font="default">IL-17B: A new area of study in the IL-17 family</style></title><secondary-title><style face="normal" font="default">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Mol Immunol</style></full-title></periodical><pages end="56" start="50">50-56</pages><volume><style face="normal" font="default">90</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> IL-17</style></keyword><keyword><style face="normal" font="default"> IL-17A</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Ligands</style></keyword><keyword><style face="normal" font="default"> malignancy</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> subtypes</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="10" Month="7" Year="2017">2017/7/10</year></dates><abstract><style face="normal" font="default">The interleukin (IL)-17 superfamily, a relatively new family of cytokines, consists of six ligands (from IL-17A to IL-17F), which bind to five receptor subtypes (from IL-17RA to IL-17RE) and induce downstream signaling. IL-17A, a prototype member of this family, has been reported to be involved in the pathogenesis of allergies, autoimmune diseases, allograft transplantations, and malignancies. Unlike IL-17A, which is mainly produced by T helper 17 cells, IL-17B is widely expressed in various tissues. Recently, the biological function of IL-17B in diseases, particularly tumors, has attracted the attention of researchers. We previously reported that the expression of IL-17RB increased in gastric cancer tissues and demonstrated that IL-17B/IL-17RB signaling plays a critical role in gastric tumor progression. However, studies on IL-17B are scant. In this review, we detail the structural characteristics, expression patterns, and biological activities of IL-17B and its potential role in the pathogenesis of diseases</style></abstract><notes><style face="normal" font="default">DA - 20170713IS - 1872-9142 (Electronic)IS - 0161-5890 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.molimm.2017.07.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28704706">PM:28704706</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mol Immunol\2017-90-50-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mol Immunol\2017-90-50-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170713, Bie Q</style></custom2><misc3><style face="normal" font="default">10.1016/j.molimm.2017.07.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42042</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kumar,A.</style></author><author><style face="normal" font="default"> Bicer,E.M.</style></author><author><style face="normal" font="default"> Pfeffer,P.</style></author><author><style face="normal" font="default"> Monopoli,M.P.</style></author><author><style face="normal" font="default"> Dawson,K.A.</style></author><author><style face="normal" font="default"> Eriksson,J.</style></author><author><style face="normal" font="default"> Edwards,K.</style></author><author><style face="normal" font="default"> Lynham,S.</style></author><author><style face="normal" font="default"> Arno,M.</style></author><author><style face="normal" font="default"> Behndig,A.F.</style></author><author><style face="normal" font="default"> Blomberg,A.</style></author><author><style face="normal" font="default"> Somers,G.</style></author><author><style face="normal" font="default"> Hassall,D.</style></author><author><style face="normal" font="default"> Dailey,L.A.</style></author><author><style face="normal" font="default"> Forbes,B.</style></author><author><style face="normal" font="default"> Mudway,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Pharmaceutical Science, Faculty of Life Sciences and Medicine, King's College, London, UK</style></auth-address><titles><title><style face="normal" font="default">Differences in the coronal proteome acquired by particles depositing in the lungs of asthmatic versus healthy humans</style></title><secondary-title><style face="normal" font="default">Nanomedicine</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nanomedicine</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Ireland</style></keyword><keyword><style face="normal" font="default"> Lactoferrin</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> Mucosal immunity</style></keyword><keyword><style face="normal" font="default"> Nanoparticles</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> proteome</style></keyword><keyword><style face="normal" font="default"> Proteomics</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> SP-A</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="22" Month="6" Year="2017">2017/6/22</year></dates><abstract><style face="normal" font="default">Most inhaled nanomedicines in development are for the treatment of lung disease, yet little is known about their interaction with the respiratory tract lining fluids (RTLFs). Here we combined the use of nano-silica, as a protein concentrator, with label-free snapshot proteomics (LC-MS/MS; key findings confirmed by ELISA) to generate a quantitative profile of the RTLF proteome and provided insight into the evolved corona; information that may be used in future to improve drug targeting to the lungs by inhaled medicines. The asthmatic coronal proteome displayed a reduced contribution of surfactant proteins (SP-A and B) and a higher contribution of alpha1-antitrypsin. Pathway analysis suggested that asthmatic RTLFs may also be deficient in proteins related to metal handling (e.g. lactoferrin). This study demonstrates how the composition of the corona acquired by inhaled nanoparticles is modified in asthma and suggests depressed mucosal immunity even in mild airway disease</style></abstract><notes><style face="normal" font="default"> - United KIngdom -CO - Ireland -CO - Sweden -DA - 20170625IS - 1549-9642 (Electronic)IS - 1549-9634 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Ireland -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1016/j.nano.2017.06.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28647590">PM:28647590</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nanomedicine\20170625-KumarA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nanomedicine\20170625-KumarA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170625, Kumar A</style></custom2><misc3><style face="normal" font="default">10.1016/j.nano.2017.06.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42043</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lusi,E.A.</style></author><author><style face="normal" font="default"> Patrissi,T.</style></author><author><style face="normal" font="default"> Guarascio,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Nickel-resistant bacteria isolated in human microbiome</style></title><secondary-title><style face="normal" font="default">New Microb New Infect</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">New Microb New Infect</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Bacteria</style></keyword><keyword><style face="normal" font="default"> Communication</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic Techniques</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human Microbiome</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Ireland</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Nickel allergy</style></keyword><keyword><style face="normal" font="default"> Nickel-resistant bacteria</style></keyword><keyword><style face="normal" font="default"> overweight</style></keyword><keyword><style face="normal" font="default"> Oxygen</style></keyword><keyword><style face="normal" font="default"> Sequence</style></keyword><keyword><style face="normal" font="default"> Sequences</style></keyword><keyword><style face="normal" font="default"> Soil</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2052-2975</style></isbn><abstract><style face="normal" font="default">Abstract Nickel-resistant bacteria have been isolated so far only in contaminated soils and wastewaters polluted with different industrial sources. The aim of our study was to determine if nickel-resistant bacteria could also be isolated from human samples. In this brief communication, we describe how we were able to isolate human bacterial strains that grew without oxygen and in the presence of high concentration of nickel. The identification was made by phenotypic and genetic techniques. The bacterial sequences have been deposited in the NCBI database repository. Our finding shows that there are several different heavy metal tolerant bacteria in humans that should be considered for further studies</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Ireland -CO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.nmni.2017.06.001</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.nmni.2017.06.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\New Microb New Infect\20170704-LusiEA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\New Microb New Infect\20170704-LusiEA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170704, Lusi EA</style></custom2><misc3><style face="normal" font="default">10.1016/j.nmni.2017.06.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42044</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ajiya,A.</style></author><author><style face="normal" font="default"> Salisu,A.D.</style></author><author><style face="normal" font="default"> Nwaorgu,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology, Aminu Kano Teaching Hospital, Kano, Nigeria</style></auth-address><titles><title><style face="normal" font="default">A correlation of symptomatology with lung function in patients with allergic rhinosinusitis</style></title><secondary-title><style face="normal" font="default">Niger J Clin Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Niger J Clin Pract</style></abbr-1></periodical><pages end="651" start="647">647-651</pages><volume><style face="normal" font="default">20</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergen exposure</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Health</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal congestion</style></keyword><keyword><style face="normal" font="default"> Nigeria</style></keyword><keyword><style face="normal" font="default"> Nose</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Software</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> symptom scores</style></keyword><keyword><style face="normal" font="default"> Symptomatology</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Teaching</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> Turbinates</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic rhinosinusitis is clinically defined as a symptomatic disorder of the nose induced by an IgE-mediated inflammation following allergen exposure to the membrane lining of the nose. It constitutes a global health problem. Both allergic rhinosinusitis and bronchial asthma are systemic inflammatory conditions that often coexist. OBJECTIVE: The objectives of the study are to assess the pattern of allergic rhinosinusitis and to correlate nasal symptom score with lung volumes of patients with allergic rhinosinusitis. METHODS: This is a prospective study of all the adult patients with clinically diagnosed allergic rhinosinusitis at the study center. Patients' biodata, symptoms, and signs were obtained using a specially designed form. The symptoms were scored using nasal symptom scoring protocol and the lung volumes determined using spirometry. The data were collated and analyzed using SPSS Version 15 statistical software. RESULTS: There were 300 patients and another 300 nonallergic individuals as control. The most common presenting symptom was nasal congestion (98%), whereas the most common sign was engorged turbinates (91%). The most common trigger of allergic symptoms was dust (72.3%). Spirometric test results were below 90% on average in both sexes and significantly (P &lt; 0.05) below those of the participants in the control group. A large number of patients with abnormal spirometry results have total nasal symptom scores of above 5 (n = 119), whereas few (n = 7) had symptom scores of 5 and below. There was a statistically significant correlation between high total nasal symptom score and abnormal spirometry (chi2 = 72, P = 0.0001). CONCLUSION: There is a significant correlation between nasal symptom score and reduced lung volumes in patients with allergic rhinosinusitis even in the absence of asthma</style></abstract><notes><style face="normal" font="default">DA - 20170628IS - 1119-3077 (Print)LA - engPT - Journal ArticleCO - Nigeria -</style></notes><work-type><style face="normal" font="default">10.4103/1119-3077.187321</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28656916">PM:28656916</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Niger J Clin Pract\2017-20-647-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Niger J Clin Pract\2017-20-647-51.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170628, Ajiya A</style></custom2><misc3><style face="normal" font="default">10.4103/1119-3077.187321</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42045</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Neerven,R.J.J.V.</style></author><author><style face="normal" font="default"> Savelkoul,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Wageningen University &amp; Research, Cell Biology and Immunology, 6709 PG, Wageningen, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default">Nutrition and Allergic Diseases</style></title><secondary-title><style face="normal" font="default">Nutrients</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nutrients</style></abbr-1></periodical><pages end="" start="E762">E762-</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acids</style></keyword><keyword><style face="normal" font="default"> Allergenicity</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic sensitization</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Cow's milk</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fatty acid</style></keyword><keyword><style face="normal" font="default"> Fatty Acids</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> Fruit</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> Milk</style></keyword><keyword><style face="normal" font="default"> Minerals</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vegetables</style></keyword><keyword><style face="normal" font="default"> Vitamins</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="17" Month="7" Year="2017">2017/7/17</year></dates><abstract><style face="normal" font="default">The development of IgE-mediated allergic diseases is influenced by many factors, including genetic and environmental factors such as pollution and farming, but also by nutrition. In the last decade, substantial progress has been made in our understanding of the impact that nutrition can have on allergic diseases. Many studies have addressed the effect of breastfeeding, pre-, pro- and synbiotics, vitamins and minerals, fiber, fruit and vegetables, cow's milk, and n-3 fatty acids, on the development of allergies. In addition, nutrition can also have indirect effects on allergic sensitization. This includes the diet of pregnant and breastfeeding women, which influences intrauterine development, as well as breastmilk composition. These include the diet of pregnant and breastfeeding women that influences intrauterine development as well as breastmilk composition, effects of food processing that may enhance allergenicity of foods, and effects via modulation of the intestinal microbiota and their metabolites. This editorial review provides a brief overview of recent developments related to nutrition and the development and management of allergic diseases</style></abstract><notes><style face="normal" font="default">DA - 20170717IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - EditorialCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.3390/nu9070762</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28714911">PM:28714911</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nutrients\2017-9-E762.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nutrients\2017-9-E762.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170717, Neerven RJ</style></custom2><misc3><style face="normal" font="default">10.3390/nu9070762</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42046</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">D'Alcamo,A.</style></author><author><style face="normal" font="default"> Mansueto,P.</style></author><author><style face="normal" font="default"> Soresi,M.</style></author><author><style face="normal" font="default"> Iacobucci,R.</style></author><author><style face="normal" font="default"> Blasca,F.</style></author><author><style face="normal" font="default"> Geraci,G.</style></author><author><style face="normal" font="default"> Cavataio,F.</style></author><author><style face="normal" font="default"> Fayer,F.</style></author><author><style face="normal" font="default"> Arini,A.</style></author><author><style face="normal" font="default"> Di Stefano,L.</style></author><author><style face="normal" font="default"> Iacono,G.</style></author><author><style face="normal" font="default"> Bosco,L.</style></author><author><style face="normal" font="default"> Carroccio,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dipartimento di Biologia e Medicina Interna e Specialistica (DiBiMIS), Internal Medicine Unit, University Hospital, Palermo 90100, Italy.</style></auth-address><titles><title><style face="normal" font="default">Contact Dermatitis Due to Nickel Allergy in Patients Suffering from Non-Celiac Wheat Sensitivity</style></title><secondary-title><style face="normal" font="default">Nutrients</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nutrients</style></abbr-1></periodical><pages end="" start="E103">E103-</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous manifestations</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Double-Blind Method</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> IBS</style></keyword><keyword><style face="normal" font="default"> Ingestion</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Nickel allergy</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Triticum</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wheat</style></keyword><keyword><style face="normal" font="default"> Wheat Hypersensitivity</style></keyword></keywords><dates><year Day="2" Month="2" Year="2017">2017/2/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Non-celiac wheat sensitivity (NCWS) is a new clinical entity in the world of gluten-related diseases. Nickel, the most frequent cause of contact allergy, can be found in wheat and results in systemic nickel allergy syndrome and mimics irritable bowel syndrome (IBS). Objective: To evaluate the frequency of contact dermatitis due to nickel allergy in NCWS patients diagnosed by a double-blind placebo-controlled(DBPC)challenge,and to identify the characteristics of NCWS patients with nickel allergy. Methods: We performed a prospective study of 60 patients (54 females, 6 males; mean age 34.1 +/- 8.1 years) diagnosed with NCWS from December 2014 to November 2016; 80 age- and sex-matched subjects with functional gastrointestina l symptoms served as controls. Patients reporting contact dermatitis related to nickel-containing objects underwent nickel patch test (Clinicaltrials.gov registration number: NCT02750735). RESULTS: Six out of sixty patients (10%) with NCWS suffered from contact dermatitis and nickel allergy and this frequency was statistically higher (p = 0.04)than observed in the control group(5%. The main clinical characteristic of NCWS patients with nickel allergy was a higher frequency of cutaneous symptoms after wheat ingestion compared to NCWS patients who did not suffer from nickel allergy (p &lt; 0.0001. CONCLUSIONS: Contact dermatitis and nickel allergy are more frequent in NCWS patients than in subjects with functional gastrointestinal disorders;furthermore, these patients had a very high frequency of cutaneous manifestations after wheat ingestion. Nickel allergy should be evaluated in NCWS patients who have cutaneous manifestations after wheat ingestion</style></abstract><notes><style face="normal" font="default">DA - 20170203IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticleRN - 7OV03QG267 (Nickel)SB - IMCO - Italy -</style></notes><work-type><style face="normal" font="default">10.3390/nu9020103</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28157173">PM:28157173</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nutrients\2017-9-E103.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nutrients\2017-9-E103.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170203, D'Alcamo A</style></custom2><misc3><style face="normal" font="default">10.3390/nu9020103</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42047</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Iahn-Aun,M.</style></author><author><style face="normal" font="default"> Aun,M.V.</style></author><author><style face="normal" font="default"> Motta,A.A.</style></author><author><style face="normal" font="default"> Kalil,J.</style></author><author><style face="normal" font="default"> Giavina-Bianchi,P.</style></author><author><style face="normal" font="default"> Hayashida,S.A.</style></author><author><style face="normal" font="default"> Baracat,E.C.</style></author><author><style face="normal" font="default"> Maciel,G.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Gynecologist/Obstetrician, Disciplina de Ginecologia</style></auth-address><titles><title><style face="normal" font="default">The Complex Interaction Between Polycystic Ovary Syndrome and Hereditary Angioedema: Case Reports and Review of the Literature</style></title><secondary-title><style face="normal" font="default">Obstet Gynecol Surv</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Obstet Gynecol Surv</style></full-title></periodical><pages end="424" start="417">417-424</pages><volume><style face="normal" font="default">72</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Abdominal Pain</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> C1 INH</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-INH</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> C1Inh</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Estradiol</style></keyword><keyword><style face="normal" font="default"> estrogen</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hormones</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laryngeal Edema</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> normal C1-INH</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> type III</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Importance: Hereditary angioedema (HAE) is a rare but severe disease, with high risk of death, and attacks have been associated to high estrogen levels. Polycystic ovary syndrome (PCOS) is a common hyperandrogenic condition, which is frequently treated with combined oral contraceptives. Objective: The aim of this study was to describe 2 clinical cases of young women diagnosed as having PCOS who developed HAE attacks after the introduction of combined estrogen-progestin pills to treat PCOS symptoms. Evidence Acquisition: Literature review of sex hormones' role in genesis of HAE attacks and possible mechanisms involved. Results: In the cases reported, after initiation of combined contraceptives, patients presented with facial swelling with airway involvement (laryngeal edema) and abdominal pain. They had a familial history of angioedema and normal C1 inhibitor (C1-INH) levels, leading to the diagnosis of HAE with normal C1-INH (HAEnC1-INH) or HAE type III. After suspension of exogenous estrogen, patients remained asymptomatic from HAE. Conclusions and Relevance: HAEnC1-INH is an estrogen-dependent form of HAE. It is well established that exogenous estrogen triggers attacks of all types of HAE. However, this is the first description of the association between PCOS and HAE, in which PCOS could be masking HAE symptoms. We propose that PCOS might have a protective role regarding HAE attacks, because of its particular hormonal features, that is, hyperandrogenism and relative stable levels of estradiol. The use of combined estrogen-progestin compounds in women with PCOS and HAE must be avoided, and treatment must be individualized</style></abstract><notes><style face="normal" font="default">DA - 20170717IS - 1533-9866 (Electronic)IS - 0029-7828 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1097/OGX.0000000000000457</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28715060">PM:28715060</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Obstet Gynecol Surv\2017-72-417-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Obstet Gynecol Surv\2017-72-417-24.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170717, Iahn-Aun M</style></custom2><misc3><style face="normal" font="default">10.1097/OGX.0000000000000457</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42048</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Andersen,H.H.</style></author><author><style face="normal" font="default"> Elberling,J.</style></author><author><style face="normal" font="default"> Solvsten,H.</style></author><author><style face="normal" font="default"> Yosipovitch,G.</style></author><author><style face="normal" font="default"> rendt-Nielsen,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Laboratory of Experimental Cutaneous Pain Research, SMI, Faculty of Medicine, Aalborg University, Denmark; 2 Department of Dermato-Allergology, Copenhagen University Hospital, Gentofte, Copenhagen, Denmark; 3 Dermatology Center North, Aalborg, Denmark; 4 Department of Clinical Medicine, Faculty of Medicine, Aalborg University, Denmark; 5 Department of Dermatology and Itch Center, University of Miami Miller School of Medicine, Miami, Florida, USA</style></auth-address><titles><title><style face="normal" font="default">Non-histaminergic and mechanical itch sensitization in atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Pain</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pain</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">area</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical Medicine</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Florida</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Itch</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Threshold</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="default">Chronic or episodic severe itch is recurrent in atopic dermatitis (AD). Non-histaminergic neuronal itch pathways are suggested to dominate in AD itch, contributing to an "itch-scratch-itch cycle" that prolongs and worsens itch, pain, and skin lesions. We hypothesized that non-histaminergic neuronal sensitization contributes to itch in AD. Hence, we compared sensitivity to thermal, mechanical, and chemical pruritic stimuli in AD patients and controls. The study comprised 25 AD patients with chronic itch and 25 healthy controls. Questionnaires on itch characteristics were administered, and sensory tests were conducted intra-lesionally, extra-lesionally, and in homologous areas of controls. Thermal and mechanical quantitative sensory testing (QST) as well as histamine and cowhage provocations were performed. Subsequently, hyperknesis and vasomotor reactivity were assessed. Average itch and associated pain among AD patients were 60.7+/-4.3 and 39.7+/-5.2 (VAS0-100), respectively. Patients experienced significantly higher itch from cowhage both intra- and extra-lesionally compared to controls, whereas histamine-evoked itch intensity was not significantly different between groups. No group differences were found for thermal QSTs or pain evoked by itch provocations. Patients had decreased mechanical detection thresholds intra-lesionally and increased mechanical pain sensitivity intra- and extra-lesionally. Lastly, patients exhibited intra- and extra-lesional hyperknesis prior to chemical itch provocations and augmented hyperknesis following itch provocations. Increased itch to a non-histaminergic pruritogen (but not histamine) suggests pathway-specific itch sensitization in AD while increased susceptibility to mechanically-evoked itch and pain, particularly intra-lesionally, suggests sensitization of normally non-pruritic mechano-sensitive circuitry. Drugs targeting the non-histaminergic (PAR2/TRPA1) itch-pathway and itch sensitization are promising for treating AD itch</style></abstract><notes><style face="normal" font="default">DA - 20170614IS - 1872-6623 (Electronic)IS - 0304-3959 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/j.pain.0000000000000980</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28614190">PM:28614190</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pain\20170614-AndersenHH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pain\20170614-AndersenHH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170614, Andersen HH</style></custom2><misc3><style face="normal" font="default">10.1097/j.pain.0000000000000980</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42049</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kessel,A.</style></author><author><style face="normal" font="default"> Farkas,H.</style></author><author><style face="normal" font="default"> Kivity,S.</style></author><author><style face="normal" font="default"> Veszeli,N.</style></author><author><style face="normal" font="default"> Kohalmi,K.V.</style></author><author><style face="normal" font="default"> Engel-Yeger,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Technion Faculty of Medicine, Haifa, Israel</style></auth-address><titles><title><style face="normal" font="default">The relationship between anxiety and quality of life in children with hereditary angioedema</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor deficiency</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Hungary</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="10" Month="7" Year="2017">2017/7/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: The severe life-threatening characteristics of hereditary angioedema (HAE) with C1-inhibitor deficiency (C1-INH-HAE) can affect anxiety levels among pediatric patients. This emotional burden together with the physical restrictions of C1-INH-HAE may decrease children's health-related quality of life (HRQoL). OBJECTIVE: (1) To compare anxiety state and trait between children with C1-INH-HAE and healthy controls (2) To examine the relationship between the level of anxiety of children with C1-INH-HAE, their disease activity/affected sites and their HRQoL (3) To predict the HRQoL of children with C1-INH-HAE based on their anxiety level and disease activity/affected sites. METHODS: Thirty-three children with C1-INH-HAE (aged 5-18 years) and 52 healthy controls were recruited from Israel and Hungary. All children completed the State Trait Anxiety Inventory for Children (STAIC), the Pediatric Quality of Life Inventory (Peds-QL) demographic questionnaire and a disease activity and site questionnaire. Disease activity was defined as the number of attacks in last year. RESULTS: Both anxiety state and trait were significantly higher among children with C1-INH-HAE as compared to the controls (44.74+/-10.56 vs. 38.76+/-10.67, p&lt;0.01, 29.21+/-5.16 vs. 25.23+/-4.09, p&lt;0.001 in comparison). Significant differences were found between C1-INH-HAE patients with HAE attacks, asymptomatic C1-INH-HAE patients and healthy controls in both anxiety state (F56,2=4.69, p=.001) and trait (F56,2=9.06, p&lt;.0001). A higher anxiety trait was correlated with the number of angioedema affected sites (r=.52, p=.003). The presence of HAE attacks and higher anxiety trait predicted a lower HRQoL in children with C1-INH-HAE. CONCLUSIONS: C1-INH-HAE children have higher anxiety trait and state which correlate with reduced HRQoL domains. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Israel -CO - Hungary -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12758</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28692169">PM:28692169</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170710-KesselA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170710-KesselA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170710, Kessel A</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12758</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42050</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wahn,V.</style></author><author><style face="normal" font="default"> von Bernuth,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric Pneumology, Immunology and Intensive Care Medicine, Charite University Medicine, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="default">Short review: IgG subclass deficiencies in children: facts and fiction</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Children</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Igg</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric Pneumology</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="7" Month="7" Year="2017">2017/7/7</year></dates><abstract><style face="normal" font="default">The chance to analyze the four IgG subclasses arose with the publication of Terry WD and Fahey JL (1964). Since then a lot of new information on the role of subclasses and their deficiency states in humans has been obtained. This review tries to analyze critically our current knowledge of subclass deficiencies in children. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170707IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12757</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28686792">PM:28686792</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170707-WahnV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170707-WahnV.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170707, Wahn V</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12757</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42051</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rodrigo,G.J.</style></author><author><style face="normal" font="default"> Neffen,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departamento de Emergencia, Hospital Central de las Fuerzas Armadas. Montevideo UruguayCentro de Alergia, Inmunologia y Enfermedades Respiratorias Santa Fe, Argentina</style></auth-address><titles><title><style face="normal" font="default">Efficacy and safety of tiotropium in school-age children with moderate to severe symptomatic asthma: A Systematic Review</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="578" start="575">575-578</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Alergia</style></keyword><keyword><style face="normal" font="default"> Argentina</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> bronchodilation</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Controller medications</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> rescue medication</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="10" Month="7" Year="2017">2017/7/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Recently published data support the benefits and safety of the once-daily (OD) long-acting anticholinergic tiotropium bromide bronchodilator for the treatment of uncontrolled moderate to severe asthma in adults and adolescents. However, its role for the treatment of school-age asthmatics has not yet been clearly defined. The aim of this systematic review was to assess the efficacy and safety of tiotropium Respimat(R) in children aged 6-11 years with moderate to severe symptomatic asthma. METHODS: Randomized, placebo-controlled trials were included. Primary outcomes were peak forced expiratory volume in 1 second measured within 3 hours post-dosing) [FEV1 (0-3h) ] and trough FEV1 measured at the end of the dosing interval. RESULTS: Three studies (more than 900 patients) were selected. Tiotropium was associated with significant improvements in FEV1 peak (mean change from baseline) by 102 mL (p&lt;0.0001) and trough by 82 ml (p&lt;0.0001) compared with placebo. Tiotropium 5 mcg dose presented a trend (statistically non-significant) toward a greater bronchodilation in comparison with 2.5 mcg dose. Tiotropium significantly increased the rate of the Asthma Control Questionnaire (ACQ-7) responders compared with placebo (82.2% vs. 75.4%, number needed to treat for benefit [NN TB] = 15), and significantly decreased the number of patients with at least one exacerbation in comparison with placebo (17.6 vs. 23.8%, with a NNTB of 16). There were no significant differences in rescue medication use, withdrawals, and adverse events. CONCLUSIONS: OD tiotropium Respimat(R) is efficacious and well tolerated as add-on to ICS plus one or more controller medications in school-age symptomatic asthmatics. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Uruguay -CO - Argentina -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12759</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28692145">PM:28692145</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170710-RodrigoGJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170710-RodrigoGJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170710, Rodrigo GJ</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12759</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42052</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mori,F.</style></author><author><style face="normal" font="default"> Fili,L.</style></author><author><style face="normal" font="default"> Barni,S.</style></author><author><style face="normal" font="default"> Sarti,L.</style></author><author><style face="normal" font="default"> Montemaggi,A.</style></author><author><style face="normal" font="default"> Bassi,A.</style></author><author><style face="normal" font="default"> Filippeschi,C.</style></author><author><style face="normal" font="default"> Galli,L.</style></author><author><style face="normal" font="default"> Parronchi,P.</style></author><author><style face="normal" font="default"> Novembre,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Unit, Department of Pediatric Medicine, Anna Meyer Children's University Hospital, Florence, Italy</style></auth-address><titles><title><style face="normal" font="default">T-cell activation in two cases of Stevens-Johnson syndrome after receiving amoxicillin-clavulanic acid</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="606" start="602">602-606</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Amoxicillin-clavulanic acid</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Anticonvulsants</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drug</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillins</style></keyword><keyword><style face="normal" font="default"> Publications</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default"> Stevens-Johnson Syndrome</style></keyword><keyword><style face="normal" font="default"> Sulfonamides</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="default">Stevens-Johnson syndrome (SJS) is a rare life-threatening condition attributed almost exclusively to drug exposure (1). The main etiologic factor for SJS is treatment with drugs, primarily sulfonamides and anticonvulsants, followed by penicillins and non-steroidal anti-inflammatory drugs (1). Among penicillins, amoxicillin/clavulanic acid (AMX/CLV), despite generally being a well-tolerated antimicrobial, has been reported as a risk factor for SJS in adults and children in several publications (2, 3). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170609IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12741</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28599076">PM:28599076</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170609-MoriF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170609-MoriF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170609, Mori F</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12741</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42053</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stenberg-Hammar,K.</style></author><author><style face="normal" font="default"> Hedlin,G.</style></author><author><style face="normal" font="default"> Soderhall,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default">Rhinovirus and pre-school wheeze</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Airway Obstruction</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cold</style></keyword><keyword><style face="normal" font="default"> Common Cold</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostics</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> preschool children</style></keyword><keyword><style face="normal" font="default"> respiratory infection</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Respiratory viruses</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinovirus</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> Viruses</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="9" Month="6" Year="2017">2017/6/9</year></dates><abstract><style face="normal" font="default">Rhinovirus (RV) known as the common cold virus generally only causes a mild upper respiratory infection, but severe lower respiratory symptoms have been associated with RV infections especially in asthmatic individuals. Wheezing is a symptom of airway obstruction, and preschool children wheezing with RV have been associated with increased risk of asthma at school age. There are however conflicting opinions as to whether there are differences in response to RV infection or if wheezing with RV reveals a preexisting impairment that promotes asthma mainly in predisposed children. The advent of molecular diagnostics to detect respiratory viruses has led to new insights into the role of RV infections. This review will discuss recent information concerning the role of RV as an important respiratory pathogen related to early onset wheeze and exacerbation of established asthma in preschool children. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170609IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12740</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28599066">PM:28599066</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170609-StenbergHammarK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170609-StenbergHammarK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170609, Stenberg-Hammar K</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12740</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42054</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Apfelbacher,C.J.</style></author><author><style face="normal" font="default"> Heinl,D.</style></author><author><style face="normal" font="default"> Smith,H.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical Sociology, Institute of Epidemiology and Preventive Medicine, University of Regensburg, Dr.-Gessler-Str. 17, 93051, Regensburg, GermanyLee Kong Chian School of Medicine, Nanyang Technological University Singapore, Novena, Singapore</style></auth-address><titles><title><style face="normal" font="default">Several PROMs exist for children with atopic eczema / dermatitis but their validity is largely unknown</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic eczema</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Preventive Medicine</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword></keywords><dates><year Day="7" Month="7" Year="2017">2017/7/7</year></dates><abstract><style face="normal" font="default">There is a current paradigm shift to the inclusion of patient-reported outcome measures (PROMs), such as health-related quality of life or functioning, in clinical trials and evaluative healthcare research. Before incorporating PROMS into studies it is important to review their qualities and characteristics objectively. It is for this reason we welcome Soyiri et al.'s review of PROMs for children with asthma and allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170707IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Germany -CO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12755</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28686314">PM:28686314</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170707-ApfelbacherCJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170707-ApfelbacherCJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170707, Apfelbacher CJ</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12755</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42055</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Looman,K.I.M.</style></author><author><style face="normal" font="default"> Jansen,M.A.E.</style></author><author><style face="normal" font="default"> Voortman,T.</style></author><author><style face="normal" font="default"> van den Heuvel,D.</style></author><author><style face="normal" font="default"> Jaddoe,V.W.V.</style></author><author><style face="normal" font="default"> Franco,O.H.</style></author><author><style face="normal" font="default"> van Zelm,M.C.</style></author><author><style face="normal" font="default"> Moll,H.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Generation R Study Group, Erasmus MC, University Medical Center, Rotterdam, the Netherlands</style></auth-address><titles><title><style face="normal" font="default">The Role of Vitamin D on Circulating Memory T Cells in Children: The Generation R Study</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cord Blood</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> herpes</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Immunophenotyping</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Lifestyle</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Subsets</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Memory</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T lymphocyte</style></keyword><keyword><style face="normal" font="default"> T lymphocytes</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> T-lymphocyte</style></keyword><keyword><style face="normal" font="default"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="7" Month="7" Year="2017">2017/7/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Previous studies have demonstrated that vitamin D affects T cell function and maturation via the vitamin D receptor. However, no studies in children have been performed on this topic. Because most of the T cell memory is formed in the first five years of life, we aimed to determine the association between serum 25-hydroxyvitamin D (25(OH)D) levels and numbers of circulatory naive, central memory (Tcm) and effector memory (Tem) T lymphocytes in a large population of healthy children. METHODS: Among 3,189 children participating in a population-based prospective cohort, we measured 25(OH)D levels and performed detailed immuno-phenotyping of naive and memory T-lymphocytes at a median age of 6.0 years (95% range 5.7 to 7.9). Detailed lymphocyte subsets were available in 986 children. Multivariable linear regression analyses were performed to determine the association between 25(OH)D and the maturation of T lymphocytes in children adjusted for cord blood 25(OH)D levels, herpes seropositivity, sociodemographic and lifestyle confounders. Furthermore, multivariable logistic regression analyses were performed to determine associations between 25(OH)D and childhood infections. RESULTS: Higher 25(OH)D levels were associated with higher numbers of Tem lymphocytes. Every 10 nmol/L higher 25(OH)D was associated with 2.20% (95% CI 0.54-3.89; p=0.009) higher CD4TemRA, 1.50% (95% CI 0.38-2.62; p=0.008) higher CD4TemRO and 1.82% (95% CI 0.11-3.56; p=0.037) higher CD8TemRA cell numbers. Generally, stronger associations were observed among boys. 25(OH)D levels were not significantly associated with naive, Tcm cell numbers, herpes seropositivity or URTIs. CONCLUSIONS: Our results suggest that vitamin D enhances cellular immunity in young children. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170707IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12754</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28686349">PM:28686349</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170707-LoomanKI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170707-LoomanKI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170707, Looman KI</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12754</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42056</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arabkhazaeli,A.</style></author><author><style face="normal" font="default"> Vijverberg,S.J.H.</style></author><author><style face="normal" font="default"> Van der Ent,C.K.</style></author><author><style face="normal" font="default"> Raaijmakers,J.A.M.</style></author><author><style face="normal" font="default"> Maitland-van der Zee,A.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pharmacoepidemiology &amp; Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, Universiteitsweg 99, Utrecht, 3508 TB, the Netherlands</style></auth-address><titles><title><style face="normal" font="default">Asthma treatment patterns in Dutch children using medication dispensing data</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> REACH</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Step down</style></keyword><keyword><style face="normal" font="default"> Step-down</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="29" Month="6" Year="2017">2017/6/29</year></dates><abstract><style face="normal" font="default">Asthma medicines (e.g. inhaled corticosteroids (ICS) and inhaled beta-agonists) are the most commonly chronically used medication in children.(1) In the Netherlands, asthma is treated according to a stepwise approach, which is mainly derived from the British Thoracic Society (BTS) guidelines.(2, 3) The guidelines advice to start treatment at the most appropriate step according to clinical severity. Step up of asthma treatment is advised if a child does not reach asthma control in the current step, and step down is advised if a child is well controlled for a period of 3 months.(2, 4) Little is known about how well the stepwise approach in the guidelines is followed in clinical practice. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170629IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12751</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28661552">PM:28661552</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170629-ArabkhazaeliA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170629-ArabkhazaeliA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170629, Arabkhazaeli A</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12751</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42057</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Koistinen,A.</style></author><author><style face="normal" font="default"> Lukkarinen,M.</style></author><author><style face="normal" font="default"> Turunen,R.</style></author><author><style face="normal" font="default"> Vuorinen,T.</style></author><author><style face="normal" font="default"> Vahlberg,T.</style></author><author><style face="normal" font="default"> Camargo,C.A.,Jr.</style></author><author><style face="normal" font="default"> Gern,J.</style></author><author><style face="normal" font="default"> Ruuskanen,O.</style></author><author><style face="normal" font="default"> Jartti,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland</style></auth-address><titles><title><style face="normal" font="default">Prednisolone for the first rhinovirus-induced wheezing and 4-year asthma risk: a randomized trial</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma risk</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Genome</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> paediatrics</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> Prednisolone</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized trial</style></keyword><keyword><style face="normal" font="default"> recurrent wheezing</style></keyword><keyword><style face="normal" font="default"> Rhinovirus</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="29" Month="6" Year="2017">2017/6/29</year></dates><abstract><style face="normal" font="default">BACKGROUND: Previous findings show that corticosteroid treatment during the first acute wheezing episode may reduce recurrent wheezing in children with high rhinovirus genome load at 12-month follow-up. Longer-term effects have not been investigated prospectively. METHODS: After PCR-confirmation of rhinovirus from nasopharyngeal aspirate, 79 children with the first acute wheezing episode were randomized to receive orally prednisolone or placebo for three days. The initiation of asthma control medication before the age of 5 years was confirmed from medical record and/or from parental interview. The outcome was the time to initiation of regular asthma control medication. Interaction analysis examined rhinovirus genome load. RESULTS: Fifty-nine (75%) children completed the follow-up. Asthma control medication was initiated in 40 (68%) children at the median age of 20 months. Overall, prednisolone did not affect the time to initiation of asthma control medication when compared to placebo (p=0.99). Rhinovirus load modified the effect of prednisolone regarding the time to initiation of asthma control medication (p-value for interaction=0.04). In children with high rhinovirus load (>7000 copies/mL)(n=23), the risk for initiation of medication was lower in the prednisolone group compared to the placebo group (p=0.05). In the placebo group asthma medication was initiated to all children with high rhinovirus load (n=9) during the 14 months after the first wheezing episode. CONCLUSIONS: Overall, prednisolone did not affect the time to initiation of asthma control medication when compared to placebo. However, prednisolone may be beneficial in first-time wheezing children whose episode was severe and associated with high rhinovirus load. (ClinicalTrials. gov, NCT00731575). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170629IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Finland -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12749</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28660720">PM:28660720</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170629-KoistinenA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170629-KoistinenA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170629, Koistinen A</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12749</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42058</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sharma,N.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Moore College University of Georgia, 108 Herty Drive, Athens, GA, 30602, USA</style></auth-address><titles><title><style face="normal" font="default">Breastfeeding and the Risk of Childhood Asthma: A Two-Stage Instrumental Variable Analysis to Address Endogeneity</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="572" start="564">564-572</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bias</style></keyword><keyword><style face="normal" font="default"> Causality</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Georgia</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Modeling</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Selection Bias</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="29" Month="6" Year="2017">2017/6/29</year></dates><abstract><style face="normal" font="default">BACKGROUND: Several explanations for the inconsistent results on the effects of breastfeeding on childhood asthma have been suggested. The purpose of this study is to investigate one unexplored explanation, which is the presence of a potential endogenous relationship between breastfeeding and childhood asthma. Endogeneity exists when an explanatory variable is correlated with the error term for reasons such as selection bias, reverse causality, and unmeasured confounders. Unadjusted endogeneity will bias the effect of breastfeeding on childhood asthma. METHODS: To investigate potential endogeneity, a cross-sectional study of breastfeeding practices and incidence of childhood asthma in 87 pediatric patients in Georgia, USA was conducted using generalized linear modeling (GLM) and a two-stage instrumental variable analysis. First, the relationship between breastfeeding and childhood asthma was analysed without considering endogeneity. Second, tests for presence of endogeneity were performed and having detected endogeneity between breastfeeding and childhood asthma, a two-stage instrumental variable analysis was performed. The first stage of this analysis estimated the duration of breastfeeding and the second-stage estimated the risk of childhood asthma. RESULTS: When endogeneity was not taken into account, duration of breastfeeding was found to significantly increase the risk of childhood asthma (relative risk ratio (RR) = 2.020, 95% CI (1.143-3.570)). After adjusting for endogeneity, duration of breastfeeding significantly reduced the risk of childhood asthma (RR = 0.003, 95% CI (0.000-0.240)). CONCLUSIONS: The findings suggest that researchers should consider evaluating how the presence of endogeneity could affect the relationship between duration of breastfeeding and the risk of childhood asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170629IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12750</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28660698">PM:28660698</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170629-SharmaND.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170629-SharmaND.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170629, Sharma ND</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12750</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42059</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sung,M.</style></author><author><style face="normal" font="default"> Lee,K.S.</style></author><author><style face="normal" font="default"> Ha,E.G.</style></author><author><style face="normal" font="default"> Lee,S.J.</style></author><author><style face="normal" font="default"> Kim,M.A.</style></author><author><style face="normal" font="default"> Lee,S.W.</style></author><author><style face="normal" font="default"> Jee,H.M.</style></author><author><style face="normal" font="default"> Shin,Y.H.</style></author><author><style face="normal" font="default"> Jung,Y.H.</style></author><author><style face="normal" font="default"> Han,M.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Inje University Haeundae Paik Hospital, Busan, Korea</style></auth-address><titles><title><style face="normal" font="default">An association between periostin levels with the severity and chronicity of atopic dermatitis in children</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Periostin</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="20" Month="6" Year="2017">2017/6/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: Serum periostin might be a biomarker of the pathogenesis of T helper 2-type allergic diseases. The aim of this study is to investigate the relationship between serum periostin levels and the severity and chronicity of atopic dermatitis (AD) in children. METHODS: This population-based study examined 4,076 children from aged 4 to 13 years between June 2015 and July 2015. Of the 4,076 children, 196 including 137 with a history of AD in the AD group and 59 without allergic diseases history in the healthy control (HC) group were included for the final analysis. RESULTS: Serum periostin levels were higher in the AD group than in the HC group (P &lt; 0.001) and were found to be positively associated with SCORAD score (Spearman's rho [r] = 0.24, P = 0.001). Children with AD onset time &lt; 2 years had significantly higher periostin levels (P = 0.030) compared to those with AD onset time >/= 2 years. The total eosinophil (P = 0.189) and IgE levels (P = 0.140) were comparable between children with AD onset time &lt; 2 years and those with AD onset time >/= 2 years. After adjustment for age, gender, and parental allergic history, serum periostin level (OR 1.03, 95% CI 1.00 - 1.06, P = 0.046) contributed to the development of AD in children with AD onset time &lt; 2 years. CONCLUSION: Serum periostin level may play a role in the severity and chronicity of AD in children. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170620IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12744</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28631851">PM:28631851</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170620-SungM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170620-SungM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170620, Sung M</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12744</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42060</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,Y.M.</style></author><author><style face="normal" font="default"> Kim,J.</style></author><author><style face="normal" font="default"> Lee,J.Y.</style></author><author><style face="normal" font="default"> Kim,M.</style></author><author><style face="normal" font="default"> Kim,H.</style></author><author><style face="normal" font="default"> Jung,K.</style></author><author><style face="normal" font="default"> Eo,S.</style></author><author><style face="normal" font="default"> Ahn,M.</style></author><author><style face="normal" font="default"> Ahn,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">the Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Impact of solar ultraviolet radiation on atopic dermatitis symptoms in young children: A longitudinal study</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="556" start="551">551-556</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Heat</style></keyword><keyword><style face="normal" font="default"> Humidity</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Radiation</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Temperature</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="20" Month="6" Year="2017">2017/6/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: There are controversial data about the effects of sun exposure on atopic dermatitis (AD). We evaluated the association between solar ultraviolet radiation (UVR) exposure and AD symptoms in children. METHODS: Eighty two children under 6 years (48 boys and 34 girls) with AD living in Seoul, Korea were enrolled and followed for 12 months between September 2013 and August 2014. Daily symptoms were recorded to describe the degree of itching, sleep disturbance, erythema, dryness, oozing and edema. We assessed solar UVR by measuring radiation heat flux over the 290-400 nm wavelength range using thermopiles. A generalized linear mixed model and a generalized additive mixed model were used to evaluate the effects of UVR exposure on AD symptoms after adjusting for age, sex, outdoor temperature, outdoor humidity, and ambient air pollution. RESULTS: Symptom records of 12,915 person-days were analyzed. UVR showed a significantly positive relationship with AD symptoms. Over the study period, an increase in UVR by 10 W/cm2 was associated with a 1.46% increase in AD symptoms (95% CI: 0.85-2.07) on the exposure day. An increase in the 6-day average level of UVR of the previous 5 days and the current day by 10 W/cm2 was associated with a 3.58% (95% CI: 2.60-4.56) increase in AD symptoms. UVR exposure significantly increased AD symptoms in autumn, but decreased them in winter. CONCLUSIONS: AD symptoms in children are likely to be affected by exposure to solar UVR with a cumulative effect, and this effect is different according to season. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170620IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12746</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28631848">PM:28631848</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170620-KimM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170620-KimM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170620, Kim YM</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12746</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42061</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dilley,M.A.</style></author><author><style face="normal" font="default"> Petty,C.R.</style></author><author><style face="normal" font="default"> Sheehan,W.J.</style></author><author><style face="normal" font="default"> Gaffin,J.M.</style></author><author><style face="normal" font="default"> Hauptman,M.</style></author><author><style face="normal" font="default"> Phipatanakul,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Boston Children's Hospital, Boston, MA</style></auth-address><titles><title><style face="normal" font="default">Adherence and Stress in a Population of Inner-City Children with Asthma</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> inner city</style></keyword><keyword><style face="normal" font="default"> inner-city</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> socioeconomic status</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="7" Month="7" Year="2017">2017/7/7</year></dates><abstract><style face="normal" font="default">Asthma is the most common chronic disease in children, (1) with many modifiable risk factors impacting asthma morbidity, including adherence to medications. Despite research demonstrating the importance of adherence to asthma medication regimens, poor and variable adherence persists,(2) with patients receiving 30-70% of prescribed doses of inhaled corticosteroids.(3) Non-adherence may be especially prevalent in minorities and those of lower socioeconomic status, which may contribute to higher morbidity in these groups.(4). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170707IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12756</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28686791">PM:28686791</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170707-DilleyMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170707-DilleyMA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170707, Dilley MA</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12756</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42062</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stensballe,L.G.</style></author><author><style face="normal" font="default"> Klanso,L.</style></author><author><style face="normal" font="default"> Jensen,A.</style></author><author><style face="normal" font="default"> Haerskjold,A.</style></author><author><style face="normal" font="default"> Thomsen,S.F.</style></author><author><style face="normal" font="default"> Simonsen,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Child and Adolescent Clinic 4072, Juliane Marie Centret, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK-2100, Copenhagen O, Denmark</style></auth-address><titles><title><style face="normal" font="default">The validity of register-data to identify children with atopic dermatitis, asthma or allergic rhinoconjunctivitis</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Algorithms</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> Atopic diseases</style></keyword><keyword><style face="normal" font="default"> Bronchitis</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidemiological studies</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Gold</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Interviews</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> recurrent wheezing</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Telephone</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="20" Month="6" Year="2017">2017/6/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: The incidence of atopic dermatitis, wheezing, asthma and allergic rhinoconjunctivitis have been increasing. Register-based studies are essential for research in subpopulations with specific diseases, and facilitate epidemiological studies to identify causes and evaluate interventions. Algorithms have been developed to identify children with atopic dermatitis, asthma or allergic rhinoconjunctivitis using register information on disease-specific dispensed prescribed medication and hospital contacts, but the validity of the algorithms has not been evaluated. The present study validated the algorithms versus gold standard deep telephone interviews with the caretaker about physician-diagnosed atopic dermatitis, wheezing, asthma, or allergic rhinoconjunctivitis in the child. METHODS: The algorithms defined each of the three atopic diseases using register-based information on disease specific hospital contacts and/or filled prescriptions of disease specific medication. Confirmative answers to questions about physician-diagnosed atopic disease were used as the gold standard for the comparison with the algorithms, resulting in sensitivities and specificities and 95% confidence intervals. The interviews with the caretaker of the included 454 Danish children born 1997-2003 were carried out May-September 2015; the mean age of the children at the time of the interview being 15.2 years (standard deviation 1.3 years). RESULTS: For the algorithm capturing children with atopic dermatitis, the sensitivity was 74.1% (95-% confidence interval: 66.9-80.2%) and the specificity 73.0% (67.3-78.0%). For the algorithm capturing children with asthma, both the sensitivity of 84.1% (78.0-88.8%) and the specificity of 81.6% (76.5-85.8%) were high compared with physician-diagnosed asthmatic bronchitis (recurrent wheezing). The sensitivity remained high when capturing physician-diagnosed asthma: 83.3% (74.3-89.6%), however, the specificity declined to 66.0% (60.9-70.8%). For allergic rhino-conjunctivitis, the sensitivity was 84.4% (78.0-89.2) and the specificity 81.6% (75.0-84.4). CONCLUSION: The algorithms are valid and valuable tools to identify children with atopic dermatitis, wheezing, asthma or allergic rhinoconjunctivitis on a population level using register data. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170620IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12743</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28632331">PM:28632331</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170620-StensballeLG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170620-StensballeLG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170620, Stensballe LG</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12743</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42063</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mohammed,J.</style></author><author><style face="normal" font="default"> Mehrotra,S.</style></author><author><style face="normal" font="default"> Schulz,H.</style></author><author><style face="normal" font="default"> Lim,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Departments of Paediatrics and Medicine, Schulich School of Medicine, Western University, Children's Hospital, London Health Sciences Centre, London, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="default">Severe Infant Rash Resistant to Therapy Due to Zinc Deficiency: A Case Report</style></title><secondary-title><style face="normal" font="default">Pediatr Emerg Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Emerg Care</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Emergency Medicine</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Ontario</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> paediatrics</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Zinc</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="default">Pediatric skin diseases are a common presenting complaint to emergency medicine physicians but often pose a significant diagnostic challenge. Skin eruptions that are unusually severe for the diagnosis in question, lasting beyond the typical time of resolution, or not responding to conventional therapy should raise concern of a misdiagnosis. We present the case of a severe rash not responding to conventional atopic dermatitis therapy that led to a diagnosis of transient neonatal zinc deficiency. Clinicians caring for children should be aware of zinc deficiency and its corresponding clinical presentation, because it is readily treatable and may lead to the avoidance of unnecessary treatments and prevention of serious complications</style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 1535-1815 (Electronic)IS - 0749-5161 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1097/PEC.0000000000001218</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28697160">PM:28697160</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Emerg Care\20170711-MohammedJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Emerg Care\20170711-MohammedJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170711, Mohammed J</style></custom2><misc3><style face="normal" font="default">10.1097/PEC.0000000000001218</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42064</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">van Veen,W.J.</style></author><author><style face="normal" font="default"> Driessen,J.M.M.</style></author><author><style face="normal" font="default"> Kersten,E.T.G.</style></author><author><style face="normal" font="default"> van Leeuwen,J.C.</style></author><author><style face="normal" font="default"> Brusse-Keizer,M.G.J.</style></author><author><style face="normal" font="default"> van Aalderen,W.M.C.</style></author><author><style face="normal" font="default"> Thio,B.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Medisch Spectrum Twente, Enschede, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">BMI predicts exercise induced bronchoconstriction in asthmatic boys</style></title><secondary-title><style face="normal" font="default">Pediatr Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Pulmonol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Challenge test</style></keyword><keyword><style face="normal" font="default"> Challenge tests</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> overweight</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Exercise induced bronchoconstriction (EIB) is a frustrating morbidity of asthma in children. Obesity has been associated with asthma and with more severe EIB in asthmatic children. OBJECTIVES: To quantify the effect of BMI on the risk of the occurrence of EIB in children with asthma. METHODS: Data were collected from six studies in which exercise challenge tests were performed according to international guidelines. We included 212 Children aged 7-18 years, with a pediatrician-diagnosed mild-to-moderate asthma. RESULTS: A total of 103 of 212 children (49%) had a positive exercise challenge (fall of FEV1 >/= 13%). The severity of EIB, as measured by the maximum fall in FEV1 , was significantly greater in overweight and obese children compared to normal weight children (respectively 23.9% vs 17.9%; P = 0.045). Asthmatic children with a BMI z-score around +1 had a 2.9-fold higher risk of the prevalence of EIB compared to children with a BMI z-score around the mean (OR 2.9; 95%CI: 1.3-6.1; P &lt; 0.01). An increase in BMI z-score of 0.1 in boys led to a 1.4-fold increased risk of EIB (OR 1.4; 95%CI: 1.0-1.9; P = 0.03). A reduction in pre-exercise FEV1 was associated with a higher risk of EIB (last quartile six times higher risk compared to highest quartile (OR 6.1 [95%CI 2.5-14.5]). CONCLUSIONS: The severity of EIB is significantly greater in children with overweight and obesity compared to non-overweight asthmatic children. Furthermore, this study shows that the BMI-z-score, even with a normal weight, is strongly associated with the incidence of EIB in asthmatic boys</style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 1099-0496 (Electronic)IS - 1099-0496 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1002/ppul.23758</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28696535">PM:28696535</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Pulmonol\20170711-vanVeenWJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Pulmonol\20170711-vanVeenWJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170711, van Veen WJ</style></custom2><misc3><style face="normal" font="default">10.1002/ppul.23758</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42065</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vyles,D.</style></author><author><style face="normal" font="default"> Adams,J.</style></author><author><style face="normal" font="default"> Chiu,A.</style></author><author><style face="normal" font="default"> Simpson,P.</style></author><author><style face="normal" font="default"> Nimmer,M.</style></author><author><style face="normal" font="default"> Brousseau,D.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Emergency Medicine</style></auth-address><titles><title><style face="normal" font="default">Allergy Testing in Children With Low-Risk Penicillin Allergy Symptoms</style></title><secondary-title><style face="normal" font="default">Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatrics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Emergency Medicine</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="3" Month="7" Year="2017">2017/7/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Penicillin allergy is commonly reported in the pediatric emergency department (ED). True penicillin allergy is rare, yet the diagnosis results from the denial of first-line antibiotics. We hypothesize that all children presenting to the pediatric ED with symptoms deemed to be low-risk for immunoglobulin E-mediated hypersensitivity will return negative results for true penicillin allergy. METHODS: Parents of children aged 4 to 18 years old presenting to the pediatric ED with a history of parent-reported penicillin allergy completed an allergy questionnaire. A prespecified 100 children categorized as low-risk on the basis of reported symptoms completed penicillin allergy testing by using a standard 3-tier testing process. The percent of children with negative allergy testing results was calculated with a 95% confidence interval. RESULTS: Five hundred ninety-seven parents completed the questionnaire describing their child's reported allergy symptoms. Three hundred two (51%) children had low-risk symptoms and were eligible for testing. Of those, 100 children were tested for penicillin allergy. The median (interquartile range) age at testing was 9 years (5-12). The median (interquartile range) age at allergy diagnosis was 1 year (9 months-3 years). Rash (97 [97%]) and itching (63 [63%]) were the most commonly reported allergy symptoms. Overall, 100 children (100%; 95% confidence interval 96.4%-100%) were found to have negative results for penicillin allergy and had their labeled penicillin allergy removed from their medical record. CONCLUSIONS: All children categorized as low-risk by our penicillin allergy questionnaire were found to have negative results for true penicillin allergy. The utilization of this questionnaire in the pediatric ED may facilitate increased use of first-line penicillin antibiotics</style></abstract><notes><style face="normal" font="default">DA - 20170704IS - 1098-4275 (Electronic)IS - 0031-4005 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1542/peds.2017-0471</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28674112">PM:28674112</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170704, Vyles D</style></custom2><misc3><style face="normal" font="default">10.1542/peds.2017-0471</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42066</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Devos,F.C.</style></author><author><style face="normal" font="default"> Pollaris,L.</style></author><author><style face="normal" font="default"> Cremer,J.</style></author><author><style face="normal" font="default"> Seys,S.</style></author><author><style face="normal" font="default"> Hoshino,T.</style></author><author><style face="normal" font="default"> Ceuppens,J.</style></author><author><style face="normal" font="default"> Talavera,K.</style></author><author><style face="normal" font="default"> Nemery,B.</style></author><author><style face="normal" font="default"> Hoet,P.H.M.</style></author><author><style face="normal" font="default"> Vanoirbeek,J.A.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Environment and Health, Department of Public Health and Primary Care, University of Leuven, Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="default">IL-13 is a central mediator of chemical-induced airway hyperreactivity in mice</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0180690">e0180690-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperreactivity</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> and primary</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immune-mediated</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TDI</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: While the importance of the Th2 cytokine IL-13 as a central mediator of airway hyperreactivity (AHR) has been described in allergic protein-induced asthma, this has never been investigated in chemical-induced asthma. OBJECTIVE: We examined the importance of IL-13 in a mouse model of chemical-induced AHR, using toluene-2,4-diisocyanate (TDI). METHODS: In a first set-up, wild type (WT) and IL-13 knockout (KO) C57Bl/6 mice were dermally treated on days 1 and 8 with 1% TDI or vehicle (acetone/olive oil) on both ears. On day 15, mice received an intranasal instillation with 0.1% TDI or vehicle. In a second set-up, WT mice sensitized with 1% TDI or vehicle, received i.v. either anti-IL-13 or control antibody prior to the intranasal challenge. RESULTS: TDI-sensitized and TDI-challenged WT mice showed AHR to methacholine, in contrast to TDI-sensitized and TDI-challenged IL-13 KO mice, which also showed lower levels of total serum IgE. TDI-sensitized and TDI-challenged IL-13 KO mice had lower numbers of T-cells in the auricular lymph nodes. TDI-treated WT mice, receiving anti-IL-13, showed no AHR, in contrast to those receiving control antibody, despite increased levels of IgE. Anti-IL-13 treatment in TDI-treated WT mice resulted in lower levels of serum IL-13, but did not induce changes in T- and B-cell numbers, and in the cytokine production profile. CONCLUSION AND CLINICAL RELEVANCE: We conclude that IL-13 plays a critical role in the effector phase of chemical-induced, immune-mediated AHR. This implicates that anti-IL-13 treatment could have a beneficial effect in patients with this asthma phenotype</style></abstract><notes><style face="normal" font="default">DA - 20170713IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Japan -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0180690</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28704401">PM:28704401</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0180690.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0180690.pdf</url></text-urls><related-urls><url ppv-ref="no">xls in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20170713, Devos FC</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0180690</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42067</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brigham,E.P.</style></author><author><style face="normal" font="default"> Matsui,E.C.</style></author><author><style face="normal" font="default"> Appel,L.J.</style></author><author><style face="normal" font="default"> Bull,D.A.</style></author><author><style face="normal" font="default"> Curtin-Brosnan,J.</style></author><author><style face="normal" font="default"> Zhai,S.</style></author><author><style face="normal" font="default"> White,K.</style></author><author><style face="normal" font="default"> Charleston,J.B.</style></author><author><style face="normal" font="default"> Hansel,N.N.</style></author><author><style face="normal" font="default"> Diette,G.B.</style></author><author><style face="normal" font="default"> McCormack,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America</style></auth-address><titles><title><style face="normal" font="default">A pilot feeding study for adults with asthma: The healthy eating better breathing trial</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0180068">e0180068-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> African American</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Baltimore</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Carotenoids</style></keyword><keyword><style face="normal" font="default"> Cholesterol</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> dietary intervention</style></keyword><keyword><style face="normal" font="default"> Eating</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fatty acid</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fruit</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Maryland</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pilot study</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Self Report</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">RATIONALE: Evidence from observational studies and to a lesser extent clinical trials suggest that a healthy diet may improve symptoms and lung function in patients with asthma. We conducted a pilot study to determine the feasibility of conducting a larger scale dietary trial and to provide preliminary evidence on the impact of a healthy diet on asthma outcomes. METHODS: In a randomized, two period cross-over trial, participants with asthma received a 4-week dietary intervention followed by a usual diet (or vice versa), separated by a 4-week washout. The dietary intervention was a healthy diet rich in unsaturated fat. During the dietary intervention, participants ate three meals per week on site at the Johns Hopkins ProHealth Research Center. All remaining meals and snacks were provided for participants to consume off-site. During the control diet, participants were instructed to continue their usual dietary intake. Relevant biomarkers and asthma clinical outcomes were assessed at 0, 2, and 4 weeks after starting each arm of the study. RESULTS: Eleven participants were randomized, and seven completed the full study protocol. Among these seven participants, average age was 42 years, six were female, and six were African American. Participant self-report of dietary intake revealed significant increases in fruit, vegetable, and omega-3 fatty acid intake with the dietary intervention compared to usual diet. Serum carotenoids (eg. lutein and beta-cryptoxanthin) increased in the intervention versus control. Total cholesterol decreased in the intervention versus control diet. There was no consistent effect on asthma outcomes. CONCLUSIONS: The findings suggest that a feeding trial in participants with asthma is feasible. Larger trials are needed to definitively assess the potential benefits of dietary interventions on pulmonary symptoms and function in patients with asthma</style></abstract><notes><style face="normal" font="default">DA - 20170713IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0180068</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28704419">PM:28704419</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0180068.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0180068.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170713, Brigham EP</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0180068</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42068</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chin,M.C.</style></author><author><style face="normal" font="default"> Sivasampu,S.</style></author><author><style face="normal" font="default"> Khoo,E.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Healthcare Statistics Unit, National Clinical Research Centre, Kuala Lumpur, Malaysia</style></auth-address><titles><title><style face="normal" font="default">Prescription of oral short-acting beta 2-agonist for asthma in non-resource poor settings: A national study in Malaysia</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0180443">e0180443-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Malaysia</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral corticosteroids</style></keyword><keyword><style face="normal" font="default"> Oral steroids</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> respiratory infection</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Statistics</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Use of oral short-acting beta 2-agonist (SABA) persists in non-resource poor countries despite concerns for its lower efficacy and safety. Utilisation and reasons for such use is needed to support the effort to discourage the use of oral SABA in asthma. This study examined the frequency of oral short-acting Beta 2-agonist (SABA) usage in the management of asthma in primary care and determined correlates of its usage. METHODS: Data used were from the 2014 National Medical Care Survey in Malaysia, a nationally representative survey of primary care encounters (weighted n = 325818). Using methods of analysis of data for complex surveys, we determined the frequency of asthma diagnosis in primary care and the rate of asthma medication prescription, which includes oral SABA. Multivariate logistic regression models were built to assess associations with the prescription of oral SABA. RESULTS: A weighted estimate of 9241 encounters presented to primary care with asthma in 2014. The mean age of the patients was 39.1 years. The rate of oral SABA, oral steroids, inhaled SABA and inhaled corticosteroids prescriptions were 33, 33, 50 and 23 per 100 asthma encounters, respectively. It was most commonly used in patients with the age ranged between 20 to less than 40 years. Logistic regression models showed that there was a higher odds of oral SABA usage in the presence of respiratory infection, prescription of oral corticosteroids and in the private sector. CONCLUSION: Oral SABA use in asthma is found to be common in a non- resource poor setting and its use could be attributed to a preference for oral medicines along undesirable clinical practices within a fragmented health system</style></abstract><notes><style face="normal" font="default">DA - 20170629IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Malaysia -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0180443</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28662193">PM:28662193</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0180443.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0180443.pdf</url></text-urls><related-urls><url ppv-ref="no">xls in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20170629, Chin MC</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0180443</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42069</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,L.</style></author><author><style face="normal" font="default"> Gao,S.</style></author><author><style face="normal" font="default"> Yu,M.</style></author><author><style face="normal" font="default"> Sheng,Z.</style></author><author><style face="normal" font="default"> Tan,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of E.N.T, Weifang People's Hospital, Weifang, China</style></auth-address><titles><title><style face="normal" font="default">Association of asthma with coronary heart disease: A meta analysis of 11 trials</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0179335">e0179335-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult-onset asthma</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">PURPOSE: While the relationship of asthma and coronary heart disease (CHD) (a specific manifestation of cardiovascular disease) has not been described consistently, we tried to defined this relation and explore the influence of gender and asthma status (child- and adult-onset asthma) on this issue. METHODS: We searched published reports that described the relationship of asthma and CHD. RESULTS: Eleven trials were identified, covering 666,355 subjects. Asthma overall was significantly associated with CHD both for prospective trials (HR 1.34 [1.09,1.64], P = 0.005) and for retrospective trials(OR 1.29 [1.13,1.46], P = 0.001), when compared to individuals without asthma. Subgroup analysis split by gender indicated that females with asthma were significantly associated with CHD (HR 1.40 [1.20,1.62], P&lt;0.001), but males with asthma were not significantly related with CHD (HR 1.19 [0.98,1.44], P = 0.07). For the four subgroups (Females with adult-onset asthma,males with adult-onset asthma,females with child-onset asthma,and males with child-onset asthma), pooled analysis of two trials indicated that only females with adult-onset asthma were significantly associated with CHD (HR 2.06 [1.32,3.19], P&lt;0.001). CONCLUSIONS: Our data indicated that asthma was associated with CHD, and the relationship between them seemed to derived mostly from females with adult-onset asthma. Considering the limits of our study, these findings should be taken with caution</style></abstract><notes><style face="normal" font="default">DA - 20170613IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0179335</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28609456">PM:28609456</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0179335.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0179335.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170613, Wang L</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0179335</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42070</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brown,K.R.</style></author><author><style face="normal" font="default"> Krouse,R.Z.</style></author><author><style face="normal" font="default"> Calatroni,A.</style></author><author><style face="normal" font="default"> Visness,C.M.</style></author><author><style face="normal" font="default"> Sivaprasad,U.</style></author><author><style face="normal" font="default"> Kercsmar,C.M.</style></author><author><style face="normal" font="default"> Matsui,E.C.</style></author><author><style face="normal" font="default"> West,J.B.</style></author><author><style face="normal" font="default"> Makhija,M.M.</style></author><author><style face="normal" font="default"> Gill,M.A.</style></author><author><style face="normal" font="default"> Kim,H.</style></author><author><style face="normal" font="default"> Kattan,M.</style></author><author><style face="normal" font="default"> Pillai,D.</style></author><author><style face="normal" font="default"> Gern,J.E.</style></author><author><style face="normal" font="default"> Busse,W.W.</style></author><author><style face="normal" font="default"> Togias,A.</style></author><author><style face="normal" font="default"> Liu,A.H.</style></author><author><style face="normal" font="default"> Khurana Hershey,G.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, United States of America</style></auth-address><titles><title><style face="normal" font="default">Endotypes of difficult-to-control asthma in inner-city African American children</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0180778">e0180778-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">African American</style></keyword><keyword><style face="normal" font="default"> African Americans</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Controller medications</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Endotypes</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-17A</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inner city</style></keyword><keyword><style face="normal" font="default"> inner-city</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> Ohio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">African Americans have higher rates of asthma prevalence, morbidity, and mortality in comparison with other racial groups. We sought to characterize endotypes of childhood asthma severity in African American patients in an inner-city pediatric asthma population. Baseline blood neutrophils, blood eosinophils, and 38 serum cytokine levels were measured in a sample of 235 asthmatic children (6-17 years) enrolled in the NIAID (National Institute of Allergy and Infectious Diseases)-sponsored Asthma Phenotypes in the Inner City (APIC) study (ICAC (Inner City Asthma Consortium)-19). Cytokines were quantified using a MILLIPLEX panel and analyzed on a Luminex analyzer. Patients were classified as Easy-to-Control or Difficult-to-Control based on the required dose of controller medications over one year of prospective management. A multivariate variable selection procedure was used to select cytokines associated with Difficult-to-Control versus Easy-to-Control asthma, adjusting for age, sex, blood eosinophils, and blood neutrophils. In inner-city African American children, 12 cytokines were significant predictors of Difficult-to-Control asthma (n = 235). CXCL-1, IL-5, IL-8, and IL-17A were positively associated with Difficult-to-Control asthma, while IL-4 and IL-13 were positively associated with Easy-to-Control asthma. Using likelihood ratio testing, it was observed that in addition to blood eosinophils and neutrophils, serum cytokines improved the fit of the model. In an inner-city pediatric population, serum cytokines significantly contributed to the definition of Difficult-to-Control asthma endotypes in African American children. Mixed responses characterized by TH2 (IL-5) and TH17-associated cytokines were associated with Difficult-to-Control asthma. Collectively, these data may contribute to risk stratification of Difficult-to-Control asthma in the African American population</style></abstract><notes><style face="normal" font="default">DA - 20170707IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0180778</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28686637">PM:28686637</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0180778.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0180778.pdf</url></text-urls><related-urls><url ppv-ref="no">csv in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20170707, Brown KR</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0180778</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42071</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nejad,M.M.</style></author><author><style face="normal" font="default"> Nejad,G.S.</style></author><author><style face="normal" font="default"> Tavakol,H.</style></author><author><style face="normal" font="default"> Cheraghi,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Social Determinant of Health Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran</style></auth-address><titles><title><style face="normal" font="default">The effect of the training program on the quality of life in patients with asthma based on the Precede model in Ahvaz, Iran</style></title><secondary-title><style face="normal" font="default">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Postepy Dermatol Alergol</style></full-title></periodical><pages end="223" start="216">216-223</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Control Groups</style></keyword><keyword><style face="normal" font="default"> Data Collection</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Software</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">AIM: The aim of the study was to determine the effect of the training program based on the Precede model and its main components on improving the quality of life in patients with asthma. MATERIAL AND METHODS: It was a randomized quasi-experimental study done on 120 patients with asthma who were referred to the Imam Khomeini hospital in Ahvaz who were selected using the convenience sampling method and were randomly divided into intervention and control groups. The data collection tool consisted of two questionnaires. The first questionnaire evaluated the quality of life in patients with asthma and the other one was developed by the researcher based on the structures of the Precede model. Training intervention was conducted during four sessions twice a week and each session was carried out for an hour based on the structures of the Precede model. In order to achieve the results, SPSS software, even t-test, and chi2 were used. RESULTS: The results showed that after the training intervention in the experimental group, the mean scores of predisposing factors (p &lt; 0.001), enabling factors, reinforcing factors and behavioral factors were significantly increased (p &lt; 0.001) as compared to the control group. A significant difference was observed in the mean scores of quality of life in two groups after the intervention (p &lt; 0.001), and the quality of life of patients in the experimental group was improved after the training intervention. CONCLUSIONS: The design and implementation of the training program based on the Precede model can have a positive effect on the improvement of quality of life in patients with asthma</style></abstract><notes><style face="normal" font="default">DA - 20170703IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">10.5114/ada.2017.67844</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28670249">PM:28670249</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-216-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-216-23.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170703, Nejad MM</style></custom2><misc3><style face="normal" font="default">10.5114/ada.2017.67844</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42072</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Su,O.</style></author><author><style face="normal" font="default"> Bahali,A.G.</style></author><author><style face="normal" font="default"> Demir,A.D.</style></author><author><style face="normal" font="default"> Ozkaya,D.B.</style></author><author><style face="normal" font="default"> Uzuner,S.</style></author><author><style face="normal" font="default"> Dizman,D.</style></author><author><style face="normal" font="default"> Onsun,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Medical Faculty, Bezmialem Vakif University, Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="default">The relationship between severity of disease and vitamin D levels in children with atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Postepy Dermatol Alergol</style></full-title></periodical><pages end="227" start="224">224-227</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disorder. Vitamin D is a liposoluble vitamin synthesized mainly in the skin. Vitamin D has several effects on the skin. AIM: To assess the serum level of vitamin D in children with AD and determine its relation to AD severity. MATERIAL AND METHODS: Sixty patients with AD were enrolled in the study. We evaluated disease severity using the SCORing Atopic Dermatitis (SCORAD) index. The control group consisted of 37 healthy subjects. RESULTS: The mean serum concentration of 25(OH)D3 in patients with AD was not statistically different from control subjects (p = 0.065). The vitamin D level was significantly lower in moderate and severe AD compared with mild AD, and this difference was statistically significant (p = 0.001 and p = 0.004). Vitamin D showed a negative correlation with serum total IgE levels (p = 0.007). There was no significant correlation between total IgE levels and SCORAD scores (p = 0.089). CONCLUSIONS: This study suggests that a low serum vitamin D level is inversely associated with severity of AD in children. Vitamin D has not been included in the routine treatment of AD because of the conflicting results of various studies. Thus, there is a need for more detailed and prospective studies</style></abstract><notes><style face="normal" font="default">DA - 20170703IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.5114/pdia.2017.66054</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28670250">PM:28670250</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-224-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-224-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170703, Su O</style></custom2><misc3><style face="normal" font="default">10.5114/pdia.2017.66054</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42073</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kot,M.</style></author><author><style face="normal" font="default"> Bogaczewicz,J.</style></author><author><style face="normal" font="default"> Krecisz,B.</style></author><author><style face="normal" font="default"> Wozniacka,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Venereology, Medical University of Lodz, Lodz, Poland</style></auth-address><titles><title><style face="normal" font="default">Contact allergy in the population of patients with chronic inflammatory dermatoses and contact hypersensitivity to corticosteroids</style></title><secondary-title><style face="normal" font="default">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Postepy Dermatol Alergol</style></full-title></periodical><pages end="259" start="253">253-259</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Balsam of Peru</style></keyword><keyword><style face="normal" font="default"> Baseline series</style></keyword><keyword><style face="normal" font="default"> Betamethasone</style></keyword><keyword><style face="normal" font="default"> Budesonide</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clobetasol</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> contact eczema</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dermatoses</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> GC</style></keyword><keyword><style face="normal" font="default"> glucocorticosteroids</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Haptens</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Leg</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Peru</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Salts</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Topical corticosteroids</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Clinical studies indicate that contact allergy to glucocorticosteroids (GCS) is not rare and has been increasingly reported over the past decade. Among the risk factors for developing contact hypersensitivity to topical corticosteroids, chronic inflammatory skin diseases and polyvalent contact allergy seem to be most important. AIM: To present the structure of contact allergy in the population of patients with chronic inflammatory dermatoses (CID) and contact hypersensitivity to corticosteroids. MATERIAL AND METHODS: Twenty-seven patients with contact allergy to GCS and chronic inflammatory dermatoses were patch tested with 28 European Baseline Series allergens and 8 corticosteroid allergens. This study group consisted of 5 patients with atopic dermatitis (AD), 15 patients with contact eczema (CE) and 7 with chronic leg eczema (CLE). Nineteen (70.4%) patients were females and 8 (29.6%) were males. RESULTS: In the study group, the most sensitizing non-steroidal allergens were nickel sulfate (51.8%), cobalt chloride (33.3%) and balsam of Peru (29.6%). The most sensitizing corticosteroid allergens were budesonide (77.8%), betamethasone valerate and clobetasol propionate (55.5% each). A total of 77.8% of patients allergic to GCS also showed sensitivity to at least one non-steroidal allergen from the European Baseline Series. CONCLUSIONS: The most important risk factors for developing contact allergy to corticosteroids appear to be chronic inflammatory dermatoses, long disease duration, extended on-and-off topical corticosteroid use, patients presenting two or more positive patch test results and polyvalent contact allergy to metal salts and to other non-steroidal haptens</style></abstract><notes><style face="normal" font="default">DA - 20170703IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.5114/ada.2017.67848</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28670256">PM:28670256</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-253-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-253-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170703, Kot M</style></custom2><misc3><style face="normal" font="default">10.5114/ada.2017.67848</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42074</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Almutairi,N.</style></author><author><style face="normal" font="default"> Almutawa,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Faculty of Medicine, Kuwait University, KuwaitDepartment of Dermatology, Farwaniya Hospital, KuwaitDepartment of Medicine, Faculty of Medicine, Kuwait University, KuwaitDepartment of Dermatology, Farwaniya Hospital, Kuwait</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis pattern in Kuwait: nickel leads the pack. In-depth analysis of nickel allergy based on the results from a large prospective patch test series report</style></title><secondary-title><style face="normal" font="default">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Postepy Dermatol Alergol</style></full-title></periodical><pages end="215" start="207">207-215</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> contact sensitization</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dermatosis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Kuwait</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Nickel allergy</style></keyword><keyword><style face="normal" font="default"> Occupation</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword><keyword><style face="normal" font="default"> Wrist</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Contact dermatitis is a relatively common dermatosis reported among several population groups from all around the globe. However, the data from Kuwait is unavailable. Patch tests are essential for the diagnosis of contact sensitization. AIM: To determine a relative frequency and pattern of sensitizers to different allergens in patients of suspected contact dermatitis in Kuwait and, also to study the role of the commonest sensitizer in detail. MATERIAL AND METHODS: Patch tests were performed in 2461 consecutive patients with a clinical diagnosis of contact dermatitis seen at our hospital between September 1, 2014 and August 31, 2015. Out of the total of 1381 (56.1%) patients with positive patch test results to at least one allergen, 546 (22.2%) patients with a single positive reaction to nickel only (single largest sensitizer) were selected as the study population for further detailed analysis. RESULTS: At least one positive patch test reaction was found in 1381 (56.12%) patients. Nickel was found to be the most common sensitizer seen in 546 (40%) patients. The mean age was 37.3 +/-13.8 years and the mean duration of disease was 27.3 +/-13.8 months. Most (387/546) patients sensitized were females. The forearms/hands and wrists were the most prevalent sites (52.56% of the participants). In 58.91% of women, dermatitis was more often confined to other sites, mostly ears and the neck due to earrings and necklaces. Just more than half of the number (51.09%) of nickel allergic patients were found in the age group of 15-25 years. Hairdressers/beauticians were the most affected group followed by house workers (housewives, cleaners, housekeepers). CONCLUSIONS: Nickel is the single most common sensitizer found in our patients, and female sex, young age, occupation with long hours of contact to nickel are high risk factors. We recommend that a directive, which limits the release of nickel from products with extended skin contact, be approved in Kuwait</style></abstract><notes><style face="normal" font="default">DA - 20170703IS - 1642-395X (Print)IS - 1642-395X (Linking)LA - engPT - Journal ArticleCO - Kuwait -</style></notes><work-type><style face="normal" font="default">10.5114/ada.2017.67843</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28670248">PM:28670248</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-207-15.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-207-15.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170703, Almutairi N</style></custom2><misc3><style face="normal" font="default">10.5114/ada.2017.67843</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42075</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gan,W.Q.</style></author><author><style face="normal" font="default"> Sanderson,W.T.</style></author><author><style face="normal" font="default"> Browning,S.R.</style></author><author><style face="normal" font="default"> Mannino,D.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Preventive Medicine and Environmental Health, University of Kentucky College of Public Health, Lexington, KY, USA</style></auth-address><titles><title><style face="normal" font="default">Different types of housing and respiratory health outcomes</style></title><secondary-title><style face="normal" font="default">Prev Med Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Prev Med Rep</style></abbr-1></periodical><pages end="129" start="124">124-129</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bronchitis</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> confounding factors</style></keyword><keyword><style face="normal" font="default"> Construction Materials</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> Emphysema</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Housing</style></keyword><keyword><style face="normal" font="default"> indoor</style></keyword><keyword><style face="normal" font="default"> Indoor environment</style></keyword><keyword><style face="normal" font="default"> Kentucky</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> National Health and Nutrition Examination Survey</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Preventive Medicine</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Respiratory diseases</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Evidence has shown that housing conditions may substantially influence the health of residents. Different types of housing have different structures and construction materials, which may affect indoor environment and housing conditions. This study aimed to investigate whether people living in different types of housing have different respiratory health outcomes. The data from the 1999-2006 National Health and Nutrition Examination Survey were used for the analyses. The types of housing included houses, townhouses, apartments, and mobile homes. Respiratory symptoms included wheezing, coughing, sputum, and dyspnea; respiratory diseases included asthma, chronic bronchitis, emphysema, and chronic obstructive pulmonary disease (COPD). Multiple logistic regression was used to calculate odds ratio (OR) and 95% confidence interval (CI) after adjustment for potential confounding factors. A total of 11,785 participants aged 40 years and older were included in the analyses. Compared with those living in single family houses, participants living in mobile homes were more likely to have respiratory conditions, the OR (95% CI) was 1.38 (1.13-1.69) for wheezing, and 1.49 (1.25-1.78) for dyspnea; whereas participants living in apartments were less likely to have respiratory conditions, the OR (95% CI) was 0.58 (0.36-0.91) for chronic bronchitis, and 0.69 (0.49-0.97) for COPD. Compared with living in single family houses, living in mobile home was associated with worse, whereas living in apartments was associated with better, respiratory health outcomes. Further research is needed to better understand the underlying mechanisms and prevent adverse respiratory effects associated with living in mobile homes</style></abstract><notes><style face="normal" font="default">DA - 20170629IS - 2211-3355 (Print)IS - 2211-3355 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.pmedr.2017.05.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28660119">PM:28660119</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Prev Med Rep\2017-7-124-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Prev Med Rep\2017-7-124-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170629, Can WQ</style></custom2><misc3><style face="normal" font="default">10.1016/j.pmedr.2017.05.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42076</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vatankhah,V.</style></author><author><style face="normal" font="default"> Khazraei,H.</style></author><author><style face="normal" font="default"> Iranpoor,H.</style></author><author><style face="normal" font="default"> Lotfizadeh,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Impact of high body mass index on allergic rhinitis patients</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Consensus</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Control Groups</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Indice de masse corporelle</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">AbstractBackground Allergic rhinitis is one of the most prevalent diseases in the world and many studies have been done to find its risk factors. Several studies have shown that there is an association between suffering from allergic rhinitis and increased body mass index (BMI), but no consensus has been yet achieved. Materials and methods There is a case</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çôcontrol study conducted in Imam Ali Clinic in Shahrekord during 2014</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô2015. Fifty-four participants with allergic rhinitis and 54 healthy persons were selected and their body mass index values were measured. Also, demographic data were collected by a questionnaire and analyzed by SPSS. Results The mean body mass index in the case and control groups were 25.03 -¦ 3.5 kg/m2 and 23.32 -¦ 2.80 kg/m2 respectively, with a significant difference between the two groups (P = 0.006). In the case group, 53.7% of participants have high body mass indexes but in the control group, 33.3% of participants have high body mass indexes, with a statistically difference between two groups according to ¤ç2 test (P = 0.04). Conclusion These results indicate a significant association between high body mass index value and allergic rhinitis. We underline that this relationship is more prominent in women</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Iran -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.05.001</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.05.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170712-VatankhahV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170712-VatankhahV.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170712, Vatankhah V</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.05.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42077</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fihmi,N.</style></author><author><style face="normal" font="default"> Alouani,I.</style></author><author><style face="normal" font="default"> Alami,Z.</style></author><author><style face="normal" font="default"> Zizi,N.</style></author><author><style face="normal" font="default"> Dikhaye,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cutaneous reaction due to allopurinol: Vigilant prescribing is needed!</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allopurinol</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous reaction</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> DRESS</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Gout</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Hyperuricemia</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Indications</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Lyell syndrome</style></keyword><keyword><style face="normal" font="default"> Misuse</style></keyword><keyword><style face="normal" font="default"> Morocco</style></keyword><keyword><style face="normal" font="default"> Myocarditis</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Serious toxic dermal reactions</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Allopurinol is the most widely used agent to treat hyperuricemia. However, its misuse can lead to severe toxic dermal reactions. Herein we report four retrospective cases of cutaneous reaction due to allopurinol: drug reaction with eosinophilia and systemic symptoms (DRESS) (n = 3), and Lyell syndrome (n = 1). The median time from introduction of the drug to onset of reaction was four weeks. Incrimination of the drug was probable in all 4 cases. Allopurinol was stopped immediately and a favorable outcome was observed in two cases. Two deaths were recorded due to septic shock and myocarditis. Many studies have shown a lack of knowledge concerning the indications and dosage of this agent. Like with all drugs, it should be used in a rational manner and the guidelines should be followed. Control of its misuse is the only way to reduce the rate of severe toxic dermal reactions</style></abstract><notes><style face="normal" font="default">LA - FRECO - Morocco -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.03.006</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.03.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170712-FihmiN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170712-FihmiN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170712, Fihmi N</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.03.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42078</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pineiro-Hermida,S.</style></author><author><style face="normal" font="default"> Lopez,I.P.</style></author><author><style face="normal" font="default"> Alfaro-Arnedo,E.</style></author><author><style face="normal" font="default"> Torrens,R.</style></author><author><style face="normal" font="default"> Iniguez,M.</style></author><author><style face="normal" font="default"> Alvarez-Erviti,L.</style></author><author><style face="normal" font="default"> Ruiz-Martinez,C.</style></author><author><style face="normal" font="default"> Pichel,J.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Lung Cancer and Respiratory Diseases Unit, Centro de Investigacion Biomedica de La Rioja (CIBIR), Fundacion Rioja Salud, Logrono, Spain</style></auth-address><titles><title><style face="normal" font="default">IGF1R deficiency attenuates acute inflammatory response in a bleomycin-induced lung injury mouse model</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="4290">4290-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">alveolar macrophage</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bone Marrow</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> differentially expressed gene</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Down-Regulation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> Epigenetics</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Deletion</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> lung cancer</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Lung Diseases</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> Mutant</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> Oxidative Stress</style></keyword><keyword><style face="normal" font="default"> Permeability</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> redox</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Respiratory diseases</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> Transcriptome</style></keyword><keyword><style face="normal" font="default"> Tyrosine</style></keyword><keyword><style face="normal" font="default"> tyrosine kinase</style></keyword><keyword><style face="normal" font="default"> Up-Regulation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="27" Month="6" Year="2017">2017/6/27</year></dates><abstract><style face="normal" font="default">IGF1R (Insulin-like Growth Factor 1 Receptor) is a tyrosine kinase with pleiotropic cellular functions. IGF activity maintains human lung homeostasis and is implicated in pulmonary diseases such as cancer, ARDS, COPD, asthma and fibrosis. Here we report that lung transcriptome analysis in mice with a postnatally-induced Igf1r gene deletion showed differentially expressed genes with potentially protective roles related to epigenetics, redox and oxidative stress. After bleomycin-induced lung injury, IGF1R-deficient mice demonstrated improved survival within a week. Three days post injury, IGF1R-deficient lungs displayed changes in expression of IGF system-related genes and reduced vascular fragility and permeability. Mutant lungs presented reduced inflamed area, down-regulation of pro-inflammatory markers and up-regulation of resolution indicators. Decreased inflammatory cell presence in BALF was reflected in diminished lung infiltration mainly affecting neutrophils, also corroborated by reduced neutrophil numbers in bone marrow, as well as reduced lymphocyte and alveolar macrophage counts. Additionally, increased SFTPC expression together with hindered HIF1A expression and augmented levels of Gpx8 indicate that IGF1R deficiency protects against alveolar damage. These findings identify IGF1R as an important player in murine acute lung inflammation, suggesting that targeting IGF1R may counteract the inflammatory component of many lung diseases</style></abstract><notes><style face="normal" font="default">DA - 20170628IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1038/s41598-017-04561-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28655914">PM:28655914</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Rep\2017-7-4290.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Rep\2017-7-4290.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170628, Pineiro-Hermida S</style></custom2><misc3><style face="normal" font="default">10.1038/s41598-017-04561-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42079</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aleid,N.M.</style></author><author><style face="normal" font="default"> Fertig,R.</style></author><author><style face="normal" font="default"> Maddy,A.</style></author><author><style face="normal" font="default"> Tosti,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia</style></auth-address><titles><title><style face="normal" font="default">Common Allergens Identified Based on Patch Test Results in Patients with Suspected Contact Dermatitis of the Scalp</style></title><secondary-title><style face="normal" font="default">Skin Appendage Disord</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Skin Appendage Disord</style></full-title></periodical><pages end="14" start="7">7-14</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Balsam of Peru</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> Fragrance mix</style></keyword><keyword><style face="normal" font="default"> Gel</style></keyword><keyword><style face="normal" font="default"> Gels</style></keyword><keyword><style face="normal" font="default"> Hair</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Peru</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Preservatives</style></keyword><keyword><style face="normal" font="default"> Propylene Glycol</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Saudi Arabia</style></keyword><keyword><style face="normal" font="default"> Scalp</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Contact dermatitis of the scalp is common and might be caused by many chemicals including metals, ingredients of shampoos and conditioners, dyes, or other hair treatments. Eliciting a careful history and patch tests are necessary to identify the responsible allergen and prevent relapses. OBJECTIVES: To identify allergens that may cause contact dermatitis of the scalp by reviewing patch test results. METHODS: We reviewed the records of 1,015 patients referred for patch testing at the Dermatology Department of the University of Miami. A total of 226 patients (205 females and 21 males) with suspected scalp contact dermatitis were identified, and the patch test results and clinical data for those patients were analyzed. Most patients were referred for patch testing from a specialized hair clinic at our institution. RESULTS: The most common allergens in our study population were nickel (23.8%), cobalt (21.0%), balsam of Peru (18.2%), fragrance mix (14.4%), carba mix (11.6%), and propylene glycol (PG) (8.8%). The majority of patients were females aged 40-59 years, and scalp itching or burning were reported as the most common symptom. CONCLUSION: Frequent sources of allergens for metals include hair clasps, pins, and brushes, while frequent sources of allergens for preservatives, fragrance mix, and balsam of Peru include shampoos, conditioners, and hair gels. Frequent sources of allergens for PG include topical medications</style></abstract><notes><style face="normal" font="default">DA - 20170614IS - 2296-9195 (Print)IS - 2296-9160 (Linking)LA - engPT - Journal ArticleCO - Saudi Arabia -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1159/000453530</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28611994">PM:28611994</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Skin Appendage Disord\2017-3-7-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Skin Appendage Disord\2017-3-7-14.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170614, Aleid NM</style></custom2><misc3><style face="normal" font="default">10.1159/000453530</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42080</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zajdel,N.J.</style></author><author><style face="normal" font="default"> Smith,W.A.</style></author><author><style face="normal" font="default"> Taintor,A.R.</style></author><author><style face="normal" font="default"> Jacob,S.E.</style></author><author><style face="normal" font="default"> Olasz,E.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI</style></auth-address><titles><title><style face="normal" font="default">Chemical Tattoo Treatment Leading to Systemic Cobalt Hypersensitivity</style></title><secondary-title><style face="normal" font="default">Skinmed</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Skinmed</style></full-title></periodical><pages end="222" start="221">221-222</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Ankle</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Physical Examination</style></keyword><keyword><style face="normal" font="default"> Prednisone</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trichloroacetic Acid</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wisconsin</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">An otherwise healthy 36-year-old Caucasian woman, without prior history of atopic dermatitis or eczema, presented to an outside dermatologist with a generalized, severely pruritic eruption involving the entire body except the face. One month previously, she had used a 50% trichloroacetic acid tattoo removal solution on a blue-colored tattoo on the medial aspect of the left ankle. The patient's eruption persisted for 7 months, and after several attempts to slowly taper her prednisone dose, she presented to our institution. On physical examination, there was a 3-cm erythematous, lichenified plaque surrounding the tattoo (Figure). On the trunk and upper regions of the arms, there were scattered, 1- to 2-cm, nummular patches and plaques. Biopsy of a truncal lesion revealed spongiotic pustules with a mixed dermal infiltrate and scattered eosinophils, consistent with subacute spongiotic dermatitis</style></abstract><notes><style face="normal" font="default">DA - 20170714IS - 1540-9740 (Print)IS - 1540-9740 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28705288">PM:28705288</url></web-urls></urls><custom2><style face="normal" font="default">20170714, Zajdel NJ</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42081</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Maspero,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Fundacion Cidea Allergy and Respiratory Research Unit, Paraguay 2035, 2*SS, Ciudad de Buenos Aires, Argentina</style></auth-address><titles><title><style face="normal" font="default">Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects</style></title><secondary-title><style face="normal" font="default">Ther Adv Respir Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ther Adv Respir Dis</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> Affinity</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Argentina</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic asthma</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Formulation</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Interleukin-5</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> maturation</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> reslizumab</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> subcutaneous</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tolerability</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="default">Eosinophils have long been implicated as playing a central role in the pathophysiology of asthma in many patients, and eosinophilic asthma is now recognized as an important asthma endotype. Eosinophil differentiation, maturation, migration, and survival are primarily under the control of interleukin-5 (IL-5). Reslizumab is a humanized monoclonal (immunoglobulin G4/kappa) antibody that binds with high affinity to circulating human IL-5 and downregulates the IL-5 signaling pathway, potentially disrupting the maturation and survival of eosinophils. In 2016, an intravenous formulation of reslizumab was approved in the USA, Canada, and Europe as add-on maintenance treatment for patients aged 18 years with severe asthma and with an eosinophilic phenotype. The efficacy of reslizumab as add-on intravenous therapy has been reported in several phase III studies in patients with inadequately controlled moderate-to-severe asthma and elevated blood eosinophil counts (400 cells/microl). Compared with placebo, reslizumab was associated with significant improvements in clinical exacerbation rate, forced expiratory volume in 1 s, asthma symptoms and quality of life, and significant reductions in blood eosinophil counts. Reslizumab also demonstrated a favorable tolerability profile similar to that of placebo, with reported adverse events being mostly mild to moderate in severity. Ongoing studies are focusing on the evaluation of a subcutaneous formulation of reslizumab in patients with asthma and elevated eosinophil levels. This review discusses the preclinical and clinical trial data available on reslizumab, potential opportunities for predicting an early response to reslizumab, and future directions in the field of anti-IL-5 antibody therapy</style></abstract><notes><style face="normal" font="default">DA - 20170707IS - 1753-4666 (Electronic)IS - 1753-4658 (Linking)LA - engPT - Journal ArticleCO - Argentina -</style></notes><work-type><style face="normal" font="default">10.1177/1753465817717134</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28683596">PM:28683596</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ther Adv Respir Dis\20170707-MasperoJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ther Adv Respir Dis\20170707-MasperoJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170707, Maspero J</style></custom2><misc3><style face="normal" font="default">10.1177/1753465817717134</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42082</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ameline,A.</style></author><author><style face="normal" font="default"> Farrugia,A.</style></author><author><style face="normal" font="default"> Tortel,M.C.</style></author><author><style face="normal" font="default"> Eibel,A.</style></author><author><style face="normal" font="default"> Oertel,L.</style></author><author><style face="normal" font="default"> Raul,J.S.</style></author><author><style face="normal" font="default"> Kintz,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Medico-legal aspects of rocuronium anaphylactic shock</style></title><secondary-title><style face="normal" font="default">Toxicol Anal Clin</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Toxicol Anal Clin</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Accidents</style></keyword><keyword><style face="normal" font="default"> Allergie</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Anesthesia</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Autopsy</style></keyword><keyword><style face="normal" font="default"> Bile</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Chromatography</style></keyword><keyword><style face="normal" font="default"> Curare</style></keyword><keyword><style face="normal" font="default"> Curares</style></keyword><keyword><style face="normal" font="default"> Cyanides</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Ethanol</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> General anesthesia</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Intubation</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> pH</style></keyword><keyword><style face="normal" font="default"> Potassium</style></keyword><keyword><style face="normal" font="default"> Potassium Iodide</style></keyword><keyword><style face="normal" font="default"> Quantification</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Rocuronium</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2352-0078</style></isbn><abstract><style face="normal" font="default">Summary Rocuronium is an aminosteroid non-depolarizing neuromuscular blocker used during general anesthesia. Due to its brief action time, about 90 seconds, this drug is an excellent muscle relaxant, used to facilitate endotracheal intubation. Rocuronium has a good safety index, but like all curares it is subject to therapeutic accidents, such as anaphylactic shock. In 2016, the incidence of anaphylaxis was evaluated in France between 1:3500 and 1:20,000 anesthesia, responsible for one death for 100,000 interventions in 2016. These accidents are non-dose-dependent, and rocuronium appears as the most frequently muscle relaxant involved. We report the case of a 44-year-old man hospitalized for the establishment of a gastric bypass. In the immediate aftermath of the anesthetic induction using rocuronium, the patient developed a rash, a bronchospasm, followed by a cardiorespiratory arrest. After 24 hours of hospitalization in the medical reanimation department, the subject died as a result of multiple organ failure. The external examination of the body and the forensic autopsy did not detect the presence of suspected traumatic lesion, excluding reanimation stigma, and intense multiple organ congestion. Toxicological investigations were unremarkable: absence of ethanol in blood, cyanides below 80 ng/mL, carboxyhemoglobin at 1.9%, absence of both volatiles substance and drug of abuse. Pharmaceutical screening of the peripheral blood demonstrated the presence of midazolam at 356 ng/mL and the presence of an antibiotic, levofloxacin (not dosed). Although used for anesthetic induction, rocuronium was not detected during these initial analyses. A rocuronium-specific method was developed by high performance liquid chromatography coupled with tandem mass spectrometry after liquid</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çôliquid extraction at pH = 5.4 and potassium iodide ion pairing. This method allowed the identification and quantification of rocuronium at 325 and 2219 ng/mL in peripheral blood and bile, respectively. The presence of rocuronium, even at a sub-therapeutic concentration, confirms the anaphylactic shock, in agreement with thanatological and pathological findings</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.toxac.2017.04.002</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.toxac.2017.04.002</url></web-urls></urls><custom2><style face="normal" font="default">20170712, Ameline A</style></custom2><misc3><style face="normal" font="default">10.1016/j.toxac.2017.04.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42083</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kounis,N.G.</style></author><author><style face="normal" font="default"> Koniari,I.</style></author><author><style face="normal" font="default"> Velissaris,D.</style></author><author><style face="normal" font="default"> Patsuras,N.</style></author><author><style face="normal" font="default"> Hahalis,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Cardiology, University of Patras Medical School, Rion, Patras, Achaia, Greece. ngkounis@otenet.gr</style></auth-address><titles><title><style face="normal" font="default">Amoxicillin/clavulanate allergic reaction, implantable defibrillator shock, and Kounis syndrome: Pathophysiological considerations</style></title><secondary-title><style face="normal" font="default">Turk Kardiyol Dern Ars</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Turk Kardiyol Dern Ars</style></abbr-1></periodical><pages end="492" start="490">490-492</pages><volume><style face="normal" font="default">45</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> Kounis syndrome</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 1308-4488 (Electronic)IS - 1016-5169 (Linking)LA - engPT - LetterCO - Greece -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.5543/tkda.2017.00671</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28694411">PM:28694411</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Turk Kardiyol Dern Ars\2017-45-490-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Turk Kardiyol Dern Ars\2017-45-490-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170711, Kounis NG</style></custom2><misc3><style face="normal" font="default">10.5543/tkda.2017.00671</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42084</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Canpolat,U.</style></author><author><style face="normal" font="default"> Kocyigit,D.</style></author><author><style face="normal" font="default"> Aytemir,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey.</style></auth-address><titles><title><style face="normal" font="default">Interesting presentation of Kounis syndrome secondary to amoxicillin/ clavulanate use: Coronary vasospasm and simultaneous appropriate implantable defibrillator shock</style></title><secondary-title><style face="normal" font="default">Turk Kardiyol Dern Ars</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Turk Kardiyol Dern Ars</style></abbr-1></periodical><pages end="469" start="466">466-469</pages><volume><style face="normal" font="default">45</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acute Coronary Syndrome</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Coronary Vasospasm</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Kounis syndrome</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Kounis syndrome (KS) is defined as concurrent acute coronary syndrome and allergic or hypersensitivity reactions. Despite being increasingly reported, it is still an underdiagnosed entity. Several medications are already known to result in KS. Amoxicillin/clavulanic acid is a frequently used antibiotic, and its use has been linked with KS. The aim of the present report was to draw attention to rare clinical manifestation of KS following peroral amoxicillin/clavulanate use</style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 1308-4488 (Electronic)IS - 1016-5169 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.5543/tkda.2017.38845</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28694403">PM:28694403</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Turk Kardiyol Dern Ars\2017-45-466-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Turk Kardiyol Dern Ars\2017-45-466-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170711, Canpolat U</style></custom2><misc3><style face="normal" font="default">10.5543/tkda.2017.38845</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42085</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Achdout,H.</style></author><author><style face="normal" font="default"> Lustig,S.</style></author><author><style face="normal" font="default"> Israely,T.</style></author><author><style face="normal" font="default"> Erez,N.</style></author><author><style face="normal" font="default"> Politi,B.</style></author><author><style face="normal" font="default"> Tamir,H.</style></author><author><style face="normal" font="default"> Israeli,O.</style></author><author><style face="normal" font="default"> Waner,T.</style></author><author><style face="normal" font="default"> Melamed,S.</style></author><author><style face="normal" font="default"> Paran,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Infectious Diseases, Israel Institute for Biological Research (IIBR), Ness-Ziona, Israel</style></auth-address><titles><title><style face="normal" font="default">Induction, treatment and prevention of eczema vaccinatum in atopic dermatitis mouse models</style></title><secondary-title><style face="normal" font="default">Vaccine</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Vaccine</style></full-title></periodical><pages end="4254" start="4245">4245-4254</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">33</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Barrier dysfunction</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> humoral</style></keyword><keyword><style face="normal" font="default"> Hyperplasia</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Israel</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> Rash</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin lesion</style></keyword><keyword><style face="normal" font="default"> Smallpox</style></keyword><keyword><style face="normal" font="default"> Smallpox Vaccine</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutics</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Vaccination</style></keyword><keyword><style face="normal" font="default"> vaccine</style></keyword><keyword><style face="normal" font="default"> Vaccinia</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral Load</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword></keywords><dates><year Day="20" Month="6" Year="2017">2017/6/20</year></dates><abstract><style face="normal" font="default">Eczema vaccinatum is a severe and occasionally lethal complication of smallpox vaccine, characterized by systemic viral dissemination, distant from the initial inoculation site of the vaccine. A major risk factor for eczema vaccinatum is a background of atopic dermatitis, a chronic, common allergic, relapsing disorder, manifested by dry and inflamed skin, itchy rash, Th2 biased immune response and hypersensitivity to various antigens. Unlike the severe manifestations of eczema vaccinatum in humans, current models present only mild symptoms that limits examination of potential therapeutics for eczema vaccinatum. The atopic dermatitis and eczema vaccinatum models we present here, are the first to simulate the severity of the diseases in humans. Indeed, dermatitic mice display persistent severe dermatitis, characterized by dry and inflamed skin with barrier dysfunction, epidermal hyperplasia and significant elevation of serum IgE. By exposing atopic dermatitis mice to ectromelia virus, we generated eczema vaccinatum that mimic the human disease better than known eczema vaccinatum models. Similarly to humans, eczematous mice displayed enlarged and disseminated skin lesions, which correlated with elevated viral load. Cidofovir and antiviral antibodies conferred protection even when treatment started at a late eczematous stage. Moreover, we are the first to demonstrate that despite a severe background of atopic dermatitis, modified vaccinia Ankara virus (MVA) vaccination protects against lethal ectromelia virus exposure. We finally show that protection by MVA vaccination is dependent on CD4+ T cells and is associated with significant activation of CD8+ cytotoxic T cells and induction of humoral immunity</style></abstract><notes><style face="normal" font="default">DA - 20170619IS - 1873-2518 (Electronic)IS - 0264-410X (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">10.1016/j.vaccine.2017.06.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28625523">PM:28625523</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Vaccine\2017-35-4245-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Vaccine\2017-35-4245-54.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170619, Achdout H</style></custom2><misc3><style face="normal" font="default">10.1016/j.vaccine.2017.06.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42086</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Carr,T.F.</style></author><author><style face="normal" font="default"> Altisheh,R.</style></author><author><style face="normal" font="default"> Zitt,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Medicine, University of Arizona, Tucson, Arizona USA</style></auth-address><titles><title><style face="normal" font="default">Small airways disease and severe asthma</style></title><secondary-title><style face="normal" font="default">World Allergy Organ J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">World Allergy Organ J</style></abbr-1></periodical><pages end="" start="20">20-</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Adult asthma</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Airways disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Arizona</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> bronchodilators</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> imaging</style></keyword><keyword><style face="normal" font="default"> impulse oscillometry</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Nitrogen</style></keyword><keyword><style face="normal" font="default"> Oscillometry</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Plethysmography</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> REACH</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> small airways</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The small airways of the lungs are commonly affected in pediatric and adult asthma. Small airways disease has been related to asthma control, severity, and risk of exacerbation. Diagnosis of small airways disease can be best made through evaluation of surgical lung specimens. Noninvasive techniques including spirometry, plethysmography, nitrogen washout, impulse oscillometry, and cross-sectional imaging have been utilized to assess and infer the extent of small airways disease in asthma and can be used longitudinally to assess response to treatment. Patients with small airways disease seem to benefit from inhaled asthma medications that have improved capacity to reach the distal lung compartment. This is especially important for patients with severe asthma, who rely upon high doses of inhaled corticosteroid and bronchodilators for asthma control. This review will describe the techniques which may be utilized to assess small airways disease, discuss the prevalence and characteristics of small airways disease in severe asthma, and highlight how small airway disease may complicate severe asthma treatment</style></abstract><notes><style face="normal" font="default">DA - 20170626IS - 1939-4551 (Print)IS - 1939-4551 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1186/s40413-017-0153-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28649293">PM:28649293</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\World Allergy Organ J\2017-10-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\World Allergy Organ J\2017-10-20.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170626, Carr TF</style></custom2><misc3><style face="normal" font="default">10.1186/s40413-017-0153-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42087</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hettick,J.M.</style></author><author><style face="normal" font="default"> Law,B.F.</style></author><author><style face="normal" font="default"> Lin,C.C.</style></author><author><style face="normal" font="default"> Wisnewski,A.V.</style></author><author><style face="normal" font="default"> Siegel,P.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Allergy and Clinical Immunology Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health , 1095 Willowdale Road , Morgantown , WV 26505</style></auth-address><titles><title><style face="normal" font="default">Mass spectrometry-based analysis of murine bronchoalveolar lavage fluid following respiratory exposure to 4,4'-methylene diphenyl diisocyanate aerosol</style></title><secondary-title><style face="normal" font="default">Xenobiotica</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Xenobiotica</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">albumin</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> disease pathogenesis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Mass Spectrometry</style></keyword><keyword><style face="normal" font="default"> MDI</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Health</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Proteomics</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum Albumin</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Tandem Mass Spectrometry</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Western blot</style></keyword><keyword><style face="normal" font="default"> Xenobiotic</style></keyword></keywords><dates><year Day="20" Month="6" Year="2017">2017/6/20</year></dates><abstract><style face="normal" font="default">Diisocyanates are highly reactive electrophiles utilized in the manufacture of a wide range of polyurethane products, and have been identified as causative agents of occupational allergic respiratory disease. However, in spite of the significant occupational health burden associated with diisocyanate-induced asthma, the mechanism of disease pathogenesis remains largely unknown. To better understand the fate of inhaled diisocyanates, a nose-only aerosol exposure system was constructed and utilized to expose a BALB/c mouse model to aerosol generated from 4,4'-methylene diphenyl diisocyanate (MDI). Tissue and bronchoalveolar lavage samples were evaluated 4 hours and 24 hours post-exposure for evidence of diisocyanate-protein haptenation, and a label-free quantitative proteomics strategy was employed to evaluate relative changes to protein content of the cellular fraction of the lavage fluid. Following MDI aerosol exposure, expression of a number of proteins with immunological or xenobiotic metabolism relevance is increased, including endoplasmin, cytochrome P450 and argininosuccinate synthase. Western blot analysis indicated MDI-conjugated protein in the lavage fluid, which was identified as serum albumin. Tandem mass spectrometry analysis of MDI-albumin revealed MDI conjugation occurs at a dilysine motif at Lys525, as well as at a glutamine-lysine motif at Lys414, in good agreement with previously published in vitro data on diisocyanate-conjugated serum albumin</style></abstract><notes><style face="normal" font="default">DA - 20170620IS - 1366-5928 (Electronic)IS - 0049-8254 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/00498254.2017.1344791</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28629263">PM:28629263</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Xenobiotica\20170620-HettickJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Xenobiotica\20170620-HettickJM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170620, Hettick JM</style></custom2><misc3><style face="normal" font="default">10.1080/00498254.2017.1344791</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42088</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Qiu,S.B.</style></author><author><style face="normal" font="default"> Shi,Q.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">[A case of severe allergic reaction induced by NA rectangleDMPS]</style></title><secondary-title><style face="normal" font="default">Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi</style></full-title></periodical><pages end="307" start="306">306-307</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword></keywords><dates><year Day="20" Month="4" Year="2017">2017/4/20</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170615IS - 1001-9391 (Print)IS - 1001-9391 (Linking)LA - chiPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.3760/cma.j.issn.1001-9391.2017.04.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28614937">PM:28614937</url></web-urls></urls><custom2><style face="normal" font="default">20170615, Qiu SB</style></custom2><misc3><style face="normal" font="default">10.3760/cma.j.issn.1001-9391.2017.04.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42089</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Okawa,T.</style></author><author><style face="normal" font="default"> Yamaguchi,Y.</style></author><author><style face="normal" font="default"> Kou,K.</style></author><author><style face="normal" font="default"> Ono,J.</style></author><author><style face="normal" font="default"> Azuma,Y.</style></author><author><style face="normal" font="default"> Komitsu,N.</style></author><author><style face="normal" font="default"> Inoue,Y.</style></author><author><style face="normal" font="default"> Kohno,M.</style></author><author><style face="normal" font="default"> Matsukura,S.</style></author><author><style face="normal" font="default"> Kambara,T.</style></author><author><style face="normal" font="default"> Ohta,S.</style></author><author><style face="normal" font="default"> Izuhara,K.</style></author><author><style face="normal" font="default"> Aihara,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan</style></auth-address><titles><title><style face="normal" font="default">Serum levels of squamous cell carcinoma antigens 1 and 2 reflect disease severity and clinical type of atopic dermatitis in adult patients</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Candida</style></keyword><keyword><style face="normal" font="default"> Carcinoma</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical phenotypes</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatophagoides</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Epidermis</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Keratinocytes</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Malassezia</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Pollen</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Specific IgE</style></keyword><keyword><style face="normal" font="default"> Staphylococcal enterotoxin B</style></keyword><keyword><style face="normal" font="default"> TARC</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: Recent studies have indicated that serum levels of squamous cell carcinoma antigen (SCCA) 1 and 2 induced by type 2 cytokines such as IL-4 and IL-13, are increased in patients with atopic dermatitis (AD). However, no clinical studies have analyzed serum levels of SCCA2 in larger series of AD patients or their association with various clinical characteristics. This study was performed to clarify whether serum levels of SCCA2 are associated with disease severity and clinical phenotypes of adult AD patients. METHODS: An enzyme-linked immunosorbent assay was performed to examine serum SCCA2 levels in 240 adult patients with AD and 25 healthy controls in this study. Serum SCCA2 levels were analyzed with clinical characteristics and laboratory parameters including thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), blood eosinophils, total IgE, and specific IgE (Japanese cedar pollen, Dermatophagoides farina, Candida, malassezia, Staphylococcal enterotoxin B). Expression of SCCA2 in AD eruption was examined by immunohistochemistry. The effect of treatment on serum SCCA2 was also assessed. RESULTS: Serum SCCA2 level showed a positive correlation with disease severity, levels of TARC, LDH, eosinophil counts, and IgE levels. Robust expression of SCCA2 was detected in the supra basal keratinocytes in the epidermis of AD patients. Serial measurements of serum SCCA2 revealed decreased levels of SCCA2 after treatment for AD. CONCLUSIONS: Serum SCCA2 levels reflected disease severity and clinical type of AD. Serum SCCA2 may thus be a relevant biomarker for AD</style></abstract><notes><style face="normal" font="default">DA - 20170723IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.06.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28734739">PM:28734739</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170723-OkawaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170723-OkawaT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170723, Okawa T</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.06.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42090</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nakamura,N.</style></author><author><style face="normal" font="default"> Tamagawa-Mineoka,R.</style></author><author><style face="normal" font="default"> Masuda,K.</style></author><author><style face="normal" font="default"> Katoh,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan</style></auth-address><titles><title><style face="normal" font="default">Immediate-type allergic reactions to local anesthetics</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Anesthetics</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> local anesthetics</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170723IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.07.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28734740">PM:28734740</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170723-NakamuraN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170723-NakamuraN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170723,Nakamura N</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.07.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42091</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dunn,R.M.</style></author><author><style face="normal" font="default"> Busse,P.J.</style></author><author><style face="normal" font="default"> Wechsler,M.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonary and Critical Care Medicine, University of Colorado School of Medicine Aurora, Colorado. National Jewish Health DenverColoradoDivision of Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, NYDepartment of Pulmonary and Critical Care Medicine, National Jewish Health, Denver, Co</style></auth-address><titles><title><style face="normal" font="default">Asthma in the Elderly and Late-onset Adult Asthma</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Adult asthma</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma therapy</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> elderly</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="default">Elderly asthmatics are at a higher risk for morbidity and mortality from their asthma than younger patients. There are important age-related physiologic and immunologic changes that complicate the presentation, diagnosis and management of asthma in the aged population. Evidence suggests that elderly asthmatics are more likely to be under-diagnosed and under-treated. Additionally, elderly patients with asthma have highest rates of morbidity and mortality from their disease than younger patients. The underlying airway inflammation of asthma in this age group likely differs from younger patients and is felt to be non-Type 2 mediated. While elderly patients are underrepresented in clinical trials, subgroup analysis of large clinical trials suggests they may be less likely to respond to traditional asthma therapies (i.e., corticosteroids). As the armamentarium of pharmacologic asthma therapies expands, it will be critical to include elderly asthmatics in large clinical trials so that therapy may be better tailored to this at-risk and growing population. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170719IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.13258</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28722758">PM:28722758</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170719-DunnRM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170719-DunnRM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170719, Dunn RM</style></custom2><misc3><style face="normal" font="default">10.1111/all.13258</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42092</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Simon,D.</style></author><author><style face="normal" font="default"> Page,B.</style></author><author><style face="normal" font="default"> Vogel,M.</style></author><author><style face="normal" font="default"> Bussmann,C.</style></author><author><style face="normal" font="default"> Blanchard,C.</style></author><author><style face="normal" font="default"> Straumann,A.</style></author><author><style face="normal" font="default"> Simon,H.U.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Inselspital, Bern University Hospital, University of Bern</style></auth-address><titles><title><style face="normal" font="default">Evidence of an abnormal epithelial barrier in active, untreated and corticosteroid-treated eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Candida</style></keyword><keyword><style face="normal" font="default"> Candida albicans</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Esophagitis</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Filaggrin</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Kallikrein</style></keyword><keyword><style face="normal" font="default"> Kallikreins</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Protease</style></keyword><keyword><style face="normal" font="default"> proteases</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> TSLP</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="7" Year="2017">2017/7/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Eosinophilic esophagitis (EoE) is a chronic, immune/antigen-mediated disease characterized by symptoms related to esophageal dysfunction and an eosinophil-predominant inflammation. This study has aimed to investigate whether the recently observed sensitization to Candida albicans in EoE patients is owing to pre-existing disease and its underlying abnormal epithelial barrier or, alternatively, is linked to corticosteroid (CS) therapy. METHODS: Medical histories, as well as serum and tissue samples of 60 EoE patients (15 CS-naive, 45 with current or previous CS therapy) and 20 controls, stored in the Swiss Eosinophilic Esophagitis Database (SEED) and Biobank, were analyzed. We applied ImmunoCAP to measure IgE levels and immunofluorescence techniques to examine epithelial barrier components. RESULTS: EoE patients had higher total IgE levels and were more frequently sensitized to Candida albicans than controls. In EoE tissue specimens, increased numbers of eosinophils and mast cells, a higher expression levels of thymic stromal lymphopoietin (TSLP), cathelicidin, proteases, i.e. the kallikreins (KLK)-5 and KLK-7, were observed as compared with controls, while reduced expression of lympho-epithelial Kazal-type-related inhibitor (LEKTI), filaggrin, E-cadherin, claudin, occludin, demoglein-1 was found, independent of CS therapy. In CS-treated EoE, significantly lower numbers of CD1a+ cells and cathelicidin expression were noted as compared to CS-naive EoE. CONCLUSION: This study provides further evidence that EoE is associated with an abnormal epithelial barrier and postulates that CS therapy, by reducing innate immune mechanisms, may promote Candida albicans colonization and likely subsequent sensitization. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170716IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1111/all.13244</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28712126">PM:28712126</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170716-SimonD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170716-SimonD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170716, Simon D</style></custom2><misc3><style face="normal" font="default">10.1111/all.13244</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42093</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Van Gerven,L.</style></author><author><style face="normal" font="default"> Steelant,B.</style></author><author><style face="normal" font="default"> Alpizar,Y.A.</style></author><author><style face="normal" font="default"> Talavera,K.</style></author><author><style face="normal" font="default"> Hellings,P.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical division of Otorhinolaryngology, Head &amp; Neck Surgery, University Hospitals Leuven, Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="default">Therapeutic effect of capsaicin nasal treatment in patients with mixed rhinitis unresponsive to intranasal steroids</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Belgium</style></keyword><keyword><style face="normal" font="default"> Capsaicin</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Head</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Intranasal steroids</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="16" Month="7" Year="2017">2017/7/16</year></dates><abstract><style face="normal" font="default">Literature is convincing regarding the efficacy of capsaicin nasal treatment in idiopathic rhinitis (IR). However, up to 50% of IR patients do not meet the strict inclusion criteria of the trials conducted so far. As a consequence, the efficacy of capsaicin is unknown in a significant number of IR patients that do not meet the strict inclusion/exclusion criteria (1)(2). 'Mixed rhinitis' (MR) patients have more than one major etiologic factor involved in the mucosal pathology. We have no idea about the efficacy of capsaicin nasal spray in these patients nor about the time interval to seek a second application. We report here that capsaicin nasal spray is effective in a broader group of IR than the purely selected ones described before, that subjective nasal hyperreactivity is a good predictor of positive outcome and that the time interval for seeking a second treatment is likely to be shorter in MR patients than in the strictly selected IR patients. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170716IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/all.13245</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28712109">PM:28712109</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170716-VanGervenL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170716-VanGervenL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170716, Van Gerven L</style></custom2><misc3><style face="normal" font="default">10.1111/all.13245</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42094</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Edwards,M.R.</style></author><author><style face="normal" font="default"> Walton,R.P.</style></author><author><style face="normal" font="default"> Jackson,D.J.</style></author><author><style face="normal" font="default"> Feleszko,W.</style></author><author><style face="normal" font="default"> Skevaki,C.</style></author><author><style face="normal" font="default"> Jartti,T.</style></author><author><style face="normal" font="default"> Makrinoti,H.</style></author><author><style face="normal" font="default"> Nikonova,A.</style></author><author><style face="normal" font="default"> Shilovskiy,I.</style></author><author><style face="normal" font="default"> Schwarze,J.</style></author><author><style face="normal" font="default"> Johnston,S.L.</style></author><author><style face="normal" font="default"> Khaitov,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Airway Disease Infection Section, National Heart Lung Institute, Imperial College London</style></auth-address><titles><title><style face="normal" font="default">The potential of anti-infectives and immunomodulators as therapies for asthma and asthma exacerbations</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic asthma</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> immunomodulators</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Russia</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="default">Asthma is responsible for approximately 25,000 deaths annually in Europe despite available medicines that maintain asthma control and reduce asthma exacerbations. Better treatments are urgently needed for the control of chronic asthma and reduction of asthma exacerbations, the major cause of asthma mortality. Much research spanning >20 years shows a strong association between microorganisms including pathogens in asthma onset, severity and exacerbation, yet with the exception of antibiotics, few treatments are available that specifically target the offending pathogens. Recent insights into the microbiome suggest that modulating commensal organisms within the gut or lung may also be a possible way to treat/prevent asthma. The European Academy of Allergy &amp; Clinical Immunology Task Force on Anti-infectives in Asthma was initiated to investigate the potential of anti-infectives and immunomodulators in asthma. This review provides a concise summary of the current literature and aims to identify and address key questions that concern the use of anti-infectives and both microbe and host based immunomodulators and their feasibility for use in asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170719IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Finland -CO - Russia -CO - Germany -CO - Poland -</style></notes><work-type><style face="normal" font="default">10.1111/all.13257</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28722755">PM:28722755</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170716-EdwardsMR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170716-EdwardsMR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170719, Edwards MR</style></custom2><misc3><style face="normal" font="default">10.1111/all.13257</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42095</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Katzka,D.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA</style></auth-address><titles><title><style face="normal" font="default">Eosinophilic Esophagitis: Leaky Gullet or Leaky Gut?</style></title><secondary-title><style face="normal" font="default">Am J Gastroenterol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Gastroenterol</style></full-title></periodical><pages end="1073" start="1072">1072-1073</pages><volume><style face="normal" font="default">112</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> and primary</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default"> epithelia</style></keyword><keyword><style face="normal" font="default"> Epithelium</style></keyword><keyword><style face="normal" font="default"> Esophagitis</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Gastroenterology</style></keyword><keyword><style face="normal" font="default"> gastrointestinal</style></keyword><keyword><style face="normal" font="default"> Gastrointestinal Tract</style></keyword><keyword><style face="normal" font="default"> Gut</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Minnesota</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> Permeability</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Eosinophilic esophagitis (EoE) is a food allergen disorder driven by antigen recognition in the gastrointestinal tract. The study by Warners et al., strongly supports the esophageal epithelium as the area of disturbed permeability and primary target for initiation of the TH2-induced allergic pathway. In contrast, small bowel assessment reveals a lack of clear change in aspects of permeability compared to controls. It is not clear, however, if the available testing used for this purpose accurately assesses the mechanisms by which antigen recognition may occur in this organ. As a result, the role of the small bowel in EoE remains unclear</style></abstract><notes><style face="normal" font="default">DA - 20170720IS - 1572-0241 (Electronic)IS - 0002-9270 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1038/ajg.2017.136</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28725075">PM:28725075</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Gastroenterol\2017-112-1072-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Gastroenterol\2017-112-1072-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170720, Katzka DA</style></custom2><misc3><style face="normal" font="default">10.1038/ajg.2017.136</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42096</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">DelGaudio,J.M.</style></author><author><style face="normal" font="default"> Loftus,P.A.</style></author><author><style face="normal" font="default"> Hamizan,A.W.</style></author><author><style face="normal" font="default"> Harvey,R.J.</style></author><author><style face="normal" font="default"> Wise,S.K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Central compartment atopic disease</style></title><secondary-title><style face="normal" font="default">Am J Rhinol Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Am J Rhinol Allergy</style></abbr-1></periodical><pages end="234" start="228">228-234</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Edema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endoscopy</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhalant</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal Cavity</style></keyword><keyword><style face="normal" font="default"> Nasal Septum</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> sinus</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Turbinates</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Isolated polypoid changes of the middle turbinate were recently reported as having a high association with inhalant allergy. A more advanced manifestation of this association may present as polypoid changes of the entire central sinonasal compartment (i.e., the middle and superior turbinates, and the posterosuperior nasal septum), while the lateral sinus mucosa remains relatively normal. OBJECTIVE: To introduce and describe this newly recognized variant of chronic rhinosinusitis (CRS), termed central compartment atopic disease (CCAD). METHODS: A case series of 15 patients from two institutions who presented with sinonasal symptoms and demonstrated central compartment polypoid mucosal changes on computed tomography (CT). The endoscopic appearance of central compartment edema was assessed. Allergy status was determined by skin or serum in vitro testing. RESULTS: The mean +/- standard deviation patient age was 42.4 +/- 14.8 years, and 47% of the patients were women. All 15 patients had a diagnosis of allergic rhinitis symptomatically, and those who underwent allergy assessment (14/15) tested positive. All the patients had central compartment polypoid edema on endoscopy and central nasal soft-tissue thickening with peripheral clearing on CT. Even with more severe sinus disease, a central focus of inflammatory change existed. CONCLUSION: CCAD may represent a local inhalant allergy process that affects the central nasal structures of ethmoid origin. Although inhalant allergy changes mainly appear within the nasal cavity, medial-to-lateral progression to involve the sinuses can occur as a simple obstructive phenomenon. This is a pattern of CRS distinct from the more diffuse sinonasal inflammatory disease and likely requires allergy management as a core component</style></abstract><notes><style face="normal" font="default">DA - 20170718IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/ajra.2017.31.4443</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28716173">PM:28716173</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Rhinol Allergy\2017-31-228-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Rhinol Allergy\2017-31-228-34.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170718, DelGaudio JM</style></custom2><misc3><style face="normal" font="default">10.2500/ajra.2017.31.4443</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42097</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Geng,B.</style></author><author><style face="normal" font="default"> Eastman,J.J.</style></author><author><style face="normal" font="default"> Mori,K.</style></author><author><style face="normal" font="default"> Braskett,M.</style></author><author><style face="normal" font="default"> Riedl,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Allergy and Immunology, University of California-San Diego, La Jolla, California.</style></auth-address><titles><title><style face="normal" font="default">Utility of minor determinants for skin testing in inpatient penicillin allergy evaluation</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergenic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Amoxicillin</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Flare</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Inpatients</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Penicillin allergy</style></keyword><keyword><style face="normal" font="default"> Penicillin G</style></keyword><keyword><style face="normal" font="default"> Polylysine</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick testing</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> skin testing</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wheal</style></keyword></keywords><dates><year Day="22" Month="7" Year="2017">2017/7/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: Most patients with a history of penicillin allergy can tolerate penicillin. Skin testing can identify tolerant patients, but not all known allergenic determinants are commercially available. Protocols exist that use only available reagents, but the sensitivity and safety of these protocols, particularly for hospitalized patients, are controversial. OBJECTIVE: To determine the number of hospitalized patients referred for penicillin skin testing who showed unique positivity to the minor determinants penicilloate and penilloate. METHODS: A retrospective chart review was conducted of all inpatients who underwent penicillin skin testing at 1 institution. Patients were referred by their treating physician. All patients underwent skin prick testing to benzylpenicilloyl polylysine (major determinant), penicillin G, penicilloate, penilloate (minor determinants), amoxicillin, and positive and negative controls. If the result was negative, then intradermal testing was done with the same penicillin determinants and the negative control. A 4-mm wheal with flare was considered a positive reaction. RESULTS: Inpatient penicillin skin testing was done in 528 subjects. Any positive test reaction was found in 107 subjects (20%). Three subjects (3%) reacted to penilloate only, 25 (23%) reacted to penicilloate only, 2 (2%) reacted to penicillin G only, and 8 (8%) reacted to amoxicillin only. Sixty-eight subjects (64%) reacted to a compound other than the major determinant. CONCLUSION: This study found a high rate of exclusively positive skin test reactions to the minor determinants penicilloate and penilloate. Because patients with positive test reactions are at increased risk of reaction to drug challenge, these data support the use of these reagents for penicillin skin testing in hospitalized patients</style></abstract><notes><style face="normal" font="default">DA - 20170726IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.06.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28743423">PM:28743423</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170726-GengB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170726-GengB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170726, Geng B</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.06.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42098</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brescia,G.</style></author><author><style face="normal" font="default"> Barion,U.</style></author><author><style face="normal" font="default"> Zanotti,C.</style></author><author><style face="normal" font="default"> Cinetto,F.</style></author><author><style face="normal" font="default"> Giacomelli,L.</style></author><author><style face="normal" font="default"> Martini,A.</style></author><author><style face="normal" font="default"> Marioni,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Neurosciences DNS, Otolaryngology Section, Padova University, Padova, Italy.</style></auth-address><titles><title><style face="normal" font="default">Blood eosinophil-to-basophil ratio in patients with sinonasal polyps: Does it have a clinical role?</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> aspirin exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> aspirin-exacerbated respiratory disease</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Endotypes</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Otolaryngology</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="22" Month="7" Year="2017">2017/7/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: In a recent preliminary study, eosinophil and basophil counts were calculated in chronic rhinosinusitis with nasal polyps (CRSwNP) using conventional histologic and immunohistochemical methods. The tissue eosinophil-to-basophil ratio differed in the CRSwNP endotypes considered. OBJECTIVE: To compare the blood eosinophil-to-basophil ratio (bEBR) in a large series of patients with CRSwNP with that in a control group of consecutive rhinological patients with no evidence of nasal, paranasal, or systemic inflammatory disorders. METHODS: A retrospective study was performed on 334 patients with CRSwNP to compare the preoperative bEBR among different endotypes and with controls (69 cases). RESULTS: The mean bEBR was significantly higher in the CRSwNP group than in the control group (P = .0006). The eosinophil and basophil counts were significantly and directly correlated in the CRSwNP cases (P = .0000). The mean bEBR was significantly higher in the sub-cohorts of CRSwNP with allergy (P = .0007), asthma (P = .0000), and aspirin-exacerbated respiratory disease (P = .0153). The mean bEBR was significantly higher in the sub-cohort with eosinophilic CRSwNP than in the sub-cohort with noneosinophilic CRSwNP (P = .0000). CONCLUSION: This study confirms the increasingly interesting role emerging for blood eosinophils and basophils in different CRSwNP endotypes. The bEBR seems to be a parameter worth investigating in different CRSwNP endotypes, because it is significantly higher in patients with allergy, asthma, and aspirin-exacerbated respiratory disease</style></abstract><notes><style face="normal" font="default">DA - 20170726IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.06.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28743424">PM:28743424</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170726-BresciaG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170726-BresciaG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170726, Brescia G</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.06.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42099</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Robinson,M.</style></author><author><style face="normal" font="default"> Greenhawt,M.</style></author><author><style face="normal" font="default"> Stukus,D.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Section of Allergy and Immunology, National Jewish Hospital, Denver, Colorado</style></auth-address><titles><title><style face="normal" font="default">Factors associated with epinephrine administration for anaphylaxis in children before arrival to the emergency department</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Awareness</style></keyword><keyword><style face="normal" font="default"> Caregivers</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Electronic medical records</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="30" Month="6" Year="2017">2017/6/30</year></dates><abstract><style face="normal" font="default">BACKGROUND: Epinephrine is the first-line treatment for anaphylaxis but may be underused by patients and medical personnel. OBJECTIVE: To evaluate factors associated with anaphylaxis management before arrival at the emergency department (ED) or urgent care center (UCC). METHODS: We performed a retrospective review of electronic medical records for all patients aged 0 to 25 years presenting with anaphylaxis to the ED or UCC at a pediatric academic referral center during 2009 to 2013. RESULTS: A total of 408 patients (mean age, 7.25 years; 62% male) were included for analysis. Only 148 patients (36.3%) received epinephrine before arrival at the ED or UCC. Reactions occurring at home (n = 36/114) were less likely to be treated with epinephrine compared with reactions occurring at school (n = 30/49) (odds ratio [OR], 0.29; 95% confidence interval [CI], 0.15-0.59). The odds of receiving epinephrine before arrival at the ED or UCC were significantly lower with a 2-organ system (OR, 0.50; 95% CI, 0.30-0.85) or 3-organ system (OR, 0.41; 95% CI, 0.21-0.81) presentation compared with 1-organ system involvement. Foods (342 [83.8%]) were the most commonly reported provoking trigger. Patients who did not receive epinephrine before arrival at the ED or UCC were significantly less likely to be discharged to home (OR, 0.56; 95% CI, 0.37-0.86; P = .01). CONCLUSION: This study identifies factors associated with prehospital management of anaphylaxis for children, which highlight that epinephrine administration may be occurring with considerable delay. Increased awareness and education of caregivers, patients, and medical professionals are necessary to provide optimal management</style></abstract><notes><style face="normal" font="default">DA - 20170716IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.06.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28711194">PM:28711194</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170716-RobinsonM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170716-RobinsonM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170716, Robinson M</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.06.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42100</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Foot,H.</style></author><author><style face="normal" font="default"> La Caze,A.</style></author><author><style face="normal" font="default"> Cottrell,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Pharmacy, The University of Queensland, Woolloongabba, Queensland, Australia.</style></auth-address><titles><title><style face="normal" font="default">Identifying the relationship between beliefs and medication adherence in asthma</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medication adherence</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="22" Month="7" Year="2017">2017/7/22</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170726IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.06.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28743425">PM:28743425</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170726-FootH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170726-FootH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170726, Foot H</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.06.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42101</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Havan,M.</style></author><author><style face="normal" font="default"> Razi,C.H.</style></author><author><style face="normal" font="default"> Bulus,A.D.</style></author><author><style face="normal" font="default"> Koksal,A.O.</style></author><author><style face="normal" font="default"> Andiran,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatrics, Kecioren Research and Educational Hospital, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="default">Effects of 25 hydroxy vitamin D levels on the severity and asthma control in school age asthma patients</style></title><secondary-title><style face="normal" font="default">Arch Argent Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Arch Argent Pediatr</style></abbr-1></periodical><pages end="342" start="336">336-342</pages><volume><style face="normal" font="default">115</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Alkaline Phosphatase</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Control Groups</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="default"> Healthy Volunteers</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Phosphorus</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> Vitamin D Deficiency</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: The objective was to determine vitamin D levels in patients between the ages 6 and 18 years, followed for asthma, and the relation between vitamin D levels and asthma control and severity. MATERIALS AND METHODS: Patients with asthma and healthy volunteers between the ages 6 and 18 years were enrolled into the study as patient and control groups, respectively. Patient demographic information and clinical findings were recorded; a respiratory function test was performed. Body mass index (BMI), 25(OH) D,calcium, phosphorus, alkaline phosphatase, total IgE and eosinophil levels were determined for all patients. Asthma severity and control conditions were established based on GINA (Global Initiative for Asthma) criteria. RESULTS: Seventy two patients with asthma and 66 healthy children were included. Compared to the control group, decreased serum vitamin D levels were detected in patient group. Thirty eight (52.8%) patients in asthma patient group had vitamin D defficiency; in this group, asthma control was poor and asthma severity was significantly higher. No significant correlation was found between vitamin D levels and gender, obesity, respiratory functions, skin test, serum eosinophil and total IgE levels. CONCLUSION: The frequency of vitamin D deficiency and insufficiency was higher in children with asthma, compared to the controls. Lower levels of vitamin D are associated with poor asthma control and increased asthma severity</style></abstract><notes><style face="normal" font="default">DA - 20170724IS - 1668-3501 (Electronic)IS - 0325-0075 (Linking)LA - engLA - spaPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.5546/aap.2017.eng.336</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28737861">PM:28737861</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Arch Argent Pediatr\2017-115-336-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Arch Argent Pediatr\2017-115-336-42.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170724, Havan M</style></custom2><misc3><style face="normal" font="default">10.5546/aap.2017.eng.336</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42102</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Enriquez,D.</style></author><author><style face="normal" font="default"> Lamborizio,M.J.</style></author><author><style face="normal" font="default"> Firenze,L.</style></author><author><style face="normal" font="default"> Jaureguizar,M.P.</style></author><author><style face="normal" font="default"> Diaz Pumara,E.</style></author><author><style face="normal" font="default"> Szyld,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centro de Simulacion Medica de Roemmers (SIMMER), Olivos, Pcia. de Buenos Aires.</style></auth-address><titles><title><style face="normal" font="default">[Training of resident physicians in the recognition and treatment of an anaphylaxis case in pediatrics with simulation models]</style></title><secondary-title><style face="normal" font="default">Arch Argent Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Arch Argent Pediatr</style></abbr-1></periodical><pages end="403" start="399">399-403</pages><volume><style face="normal" font="default">115</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Argentina</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Optimization</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="default">OBJETIVE: To evaluate the performance of resident physicians in diagnosing and treating a case of anaphylaxis, six months after participating in simulation training exercises. METHODS: Initially, a group of pediatric residents were trained using simulation techniques in the management of critical pediatric cases. Based on their performance in this exercise, participants were assigned to one of 3 groups. At six months post-training, 4 residents were randomly chosen from each group to be re-tested, using the same performance measure as previously used. RESULTS: During the initial training session, 56 of 72 participants (78%) correctly identified and treated the case. Six months after the initial training, all 12 (100%) resident physicians who were re-tested successfully diagnosed and treated the simulated anaphylaxis case. CONCLUSIONS: The training through simulation techniques allowed correction or optimization of the treatment of simulated anaphylaxis cases in resident physicians evaluated after 6 months of the initial training</style></abstract><notes><style face="normal" font="default">DA - 20170724IS - 1668-3501 (Electronic)IS - 0325-0075 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Argentina -CO - United States -</style></notes><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28737882">PM:28737882</url></web-urls><related-urls><url ppv-ref="no">presto - su sito</url></related-urls></urls><custom2><style face="normal" font="default">20170724, Enriquez D</style></custom2></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42103</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McConnell,K.</style></author><author><style face="normal" font="default"> Shields,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Paediatric Respiratory Medicine, Royal Belfast Hospital for Sick Children, Belfast, UKRoyal Belfast Hospital for Sick Children, Belfast, UK</style></auth-address><titles><title><style face="normal" font="default">Azithromycin for episodes with asthma-like symptoms in young children aged 1-3 years</style></title><secondary-title><style face="normal" font="default">Arch Dis Child Educ Pract Ed</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Arch Dis Child Educ Pract Ed</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Azithromycin</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="22" Month="7" Year="2017">2017/7/22</year></dates><abstract><style face="normal" font="default">N/A</style></abstract><notes><style face="normal" font="default">DA - 20170723IS - 1743-0593 (Electronic)IS - 1743-0585 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1136/archdischild-2016-311409</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28735295">PM:28735295</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Arch Dis Child Educ Pract Ed\20170723-McConnellK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Arch Dis Child Educ Pract Ed\20170723-McConnellK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170723, McConnell K</style></custom2><misc3><style face="normal" font="default">10.1136/archdischild-2016-311409</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42104</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rodriguez-Sanz,A.</style></author><author><style face="normal" font="default"> Sanchez-Villanueva,R.</style></author><author><style face="normal" font="default"> Dominguez-Ortega,J.</style></author><author><style face="normal" font="default"> Fiandor,A.M.</style></author><author><style face="normal" font="default"> Ruiz,M.P.</style></author><author><style face="normal" font="default"> Trocoli,F.</style></author><author><style face="normal" font="default"> Diaz-Tejeiro,R.</style></author><author><style face="normal" font="default"> Cadenillas,C.</style></author><author><style face="normal" font="default"> Gonzalez,E.</style></author><author><style face="normal" font="default"> Martinez,V.</style></author><author><style face="normal" font="default"> Lopez-Trascasa,M.</style></author><author><style face="normal" font="default"> Quirce,S.</style></author><author><style face="normal" font="default"> Selgas,R.</style></author><author><style face="normal" font="default"> Bellon,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hospital La Paz Health Research Institute-IdiPAZ-Research, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Mechanisms Involved in Hypersensitivity Reactions to Polysulfone Hemodialysis Membranes</style></title><secondary-title><style face="normal" font="default">Artif Organs</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Artif Organs</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cellulose</style></keyword><keyword><style face="normal" font="default"> Complement</style></keyword><keyword><style face="normal" font="default"> Complement Activation</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Leukocytes</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Membranes</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> priming</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum tryptase</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic reaction</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="default">Several cases of patients with anaphylactic or systemic hypersensitivity reactions to polysulfone (PS) hemodialysis (HD) membranes and tolerance to cellulose triacetate (CTA) membranes have recently been reported. To investigate the mechanisms involved in PS hypersensitivity, basophil, T cell, and complement activation were analyzed in acute-phase samples from two patients with systemic reactions to PS-based membranes. Basophil and T cell activation, as well as higher serum tryptase levels were detected in acute-phase samples compared with basal levels. Complement levels (C3 and C4) were decreased in acute-phase samples from PS-allergic patients to a higher extent than in samples from control donors taken at the same time points, indicating complement activation during the acute reactions. An experimental external circuit was established on pediatric membranes after rinsing with low or high priming volumes of saline solution, to analyze basophils, T cells, and complement activation in blood samples from 10 PS-allergic and 8 nonallergic HD patients upon contact with PS-based or CTA membranes. Predialysis and postdialysis samples were collected. Basophils from PS-allergic patients exhibited increased degranulation, and T cells showed significantly increased activation after contact with PS-based membranes primed with low volumes of saline. No activation was detected in leukocytes from nonallergic patients under the same experimental conditions. Membrane priming with high volumes of saline abrogated activation of basophils and T cells. However, basophils from allergic donors showed significantly higher responses to Fcepsilonc stimulation after contact with PS membranes. Basophil degranulation and elevated serum tryptase levels in allergic patients during acute reactions support the systemic activation of mast cells and basophils during hypersensitivity reactions to PS-based membranes. A leachable component of the membranes might be responsible for cell activation in some patients</style></abstract><notes><style face="normal" font="default">DA - 20170719IS - 1525-1594 (Electronic)IS - 0160-564X (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/aor.12954</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28722144">PM:28722144</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Artif Organs\20170719-RodriguezSanzA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Artif Organs\20170719-RodriguezSanzA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170719, Rodriguez-Sanz A</style></custom2><misc3><style face="normal" font="default">10.1111/aor.12954</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42105</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Amaral,L.</style></author><author><style face="normal" font="default"> Martins,C.</style></author><author><style face="normal" font="default"> Coimbra,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Servico de Imunoalergologia, Centro Hospitalar Sao Joao, Porto, Portugal</style></auth-address><titles><title><style face="normal" font="default">Use of the Control of Allergic Rhinitis and Asthma Test and pulmonary function tests to assess asthma control in pregnancy</style></title><secondary-title><style face="normal" font="default">Aust N Z J Obstet Gynaecol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Aust N Z J Obstet Gynaecol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Records</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> Mites</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> pulmonary function test</style></keyword><keyword><style face="normal" font="default"> Pulmonary function tests</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Sensitisation</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Upper airways</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="27" Month="7" Year="2017">2017/7/27</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Asthma is one of the most prevalent chronic medical conditions to complicate pregnancy. Similarly, active management strategies that prioritise asthma control in this vulnerable population can have a far-reaching impact. AIM: To describe lung function parameters and results of the Control of Allergic Rhinitis and Asthma Test (CARAT) questionnaire in pregnant asthmatics and to analyse correlations between lung function tests and CARAT results. METHODS: All pregnant asthmatics who performed spirometry and CARAT between September 2014 and August 2015 were included. A medical records review was performed and data regarding demographics, sensitisation and medical prescriptions were recorded. Control of asthma and rhinitis was defined by CARAT total score (CARAT (T)) >/= 24; upper airways (U) control if CARAT (U) > 8; lower airways (L) control if CARAT (L) > 15. RESULTS: Forty-two pregnant asthmatics were included, with a median age (interquartile range)of 32 (27-34) years; all had a previous medical diagnosis of asthma and rhinitis, 76% were atopic, 94% sensitised to dust mites and 43% were polissensitised. More than 80% presented poor control (CARAT (T) &lt; 24) in the first assessment and 15% had a percentage forced expiratory volume in the first second &lt; 80%. There were significant negative correlations between CARAT (L) and CARAT (T) scores and step-up of controller medication, (correlation coefficients = -0.453 and -0.392, respectively). CONCLUSION: The use of tools such as spirometry and validated questionnaires to objectively assess asthma control during pregnancy should be routinely applied to assist in the management of these patients. These data reinforce the importance of close monitoring of pregnant asthmatics to achieve and maintain better disease control</style></abstract><notes><style face="normal" font="default">DA - 20170727IS - 1479-828X (Electronic)IS - 0004-8666 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.1111/ajo.12673</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28749014">PM:28749014</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Aust N Z J Obstet Gynaecol\20170727AmaralL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Aust N Z J Obstet Gynaecol\20170727AmaralL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170727, Amaral L</style></custom2><misc3><style face="normal" font="default">10.1111/ajo.12673</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42106</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Haldar,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, UK</style></auth-address><titles><title><style face="normal" font="default">Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma</style></title><secondary-title><style face="normal" font="default">Biologics</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Biologics</style></abbr-1></periodical><pages end="95" start="81">81-95</pages><volume><style face="normal" font="default">11</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Biomedical Research</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Cost-effectiveness</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic asthma</style></keyword><keyword><style face="normal" font="default"> European Union</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Interpretation</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> mepolizumab</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Trajectory</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Mepolizumab (Nucala(R)) is an effective and specific anti-eosinophil molecular therapy that has recently been approved as add-on therapy for the management of severe eosinophilic asthma by the US Food and Drug Administration (FDA), European Medicines Agency (EMA; European Union) and more recently National Institute for Health and Care Excellence (NICE; UK). It is one of several molecular therapies in development for this indication and is illustrative of the strategic trajectory for pharmaceutical drug development taken over the past decade in several disease areas. Molecular therapies offer the prospect of improved specificity and effectiveness of biological effect. However, this necessitates a clear understanding of the underlying mechanistic pathways underpinning pathological processes, to inform drug development that yields novel more efficacious treatment options with a better clinical profile than existing agents. For the first time, utilization of molecular therapies in clinical trials is providing a novel in vivo model to characterize the association between specific pathways and clinical disease expression. It is increasingly recognized that asthma exhibits both clinical and pathological heterogeneity. It follows that a one-size-fits-all approach will not be appropriate and cost-effectiveness may only be achieved by identifying responder subgroups. This so-called personalized approach to therapy is being supported by the parallel development of companion biomarkers for clinical application. In this review, the author summarizes the clinical studies, their interpretation and the lessons learnt with mepolizumab that have informed our understanding of the approach to personalized molecular therapy in asthma</style></abstract><notes><style face="normal" font="default">DA - 20170719IS - 1177-5475 (Print)IS - 1177-5475 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.2147/BTT.S93954</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28721009">PM:28721009</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biologics\2017-11-81-95.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biologics\2017-11-81-95.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170719, Haldar P</style></custom2><misc3><style face="normal" font="default">10.2147/BTT.S93954</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42107</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hamnerius,N.</style></author><author><style face="normal" font="default"> Svedman,C.</style></author><author><style face="normal" font="default"> Bergendorff,O.</style></author><author><style face="normal" font="default"> Bjork,J.</style></author><author><style face="normal" font="default"> Bruze,M.</style></author><author><style face="normal" font="default"> Ponten,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Lund University, Skane University Hospital, Department of Occupational and Environmental Dermatology, Malmo, Sweden</style></auth-address><titles><title><style face="normal" font="default">Wet work exposure and hand eczema among healthcare workers - a cross-sectional study</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> confounding factors</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disinfectants</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Gloves</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand eczema</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Healthcare workers</style></keyword><keyword><style face="normal" font="default"> Hygiene</style></keyword><keyword><style face="normal" font="default"> Life Style</style></keyword><keyword><style face="normal" font="default"> Lifestyle</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> Nurses</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Regulations</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hand eczema is more common in healthcare workers compared to the general population. The hands are subject to changing occupational exposures due to mandatory hygiene regulations for health care workers. OBJECTIVES: To describe the exposure due to hygiene procedures and investigate the associations between occupational hand washing, use of non-sterile gloves, and hand disinfectant and self-reported hand eczema. METHODS: Cross-sectional study with an electronic questionnaire distributed to 28 762 hospital employees in southern Sweden. Respondents working as nurses, assistant nurses or physicians constituted the group of healthcare workers analysed. Adjustments were made for gender, age, wet work at home, life-style factors and atopic dermatitis. RESULTS: 12 288 (43%) responded including 9051 healthcare workers. In this group the 1-year prevalence of self-reported hand eczema was 21%. On a daily basis, 30% reported hand washing with soap >20 times at work, 45% used hand disinfectants >50 times, and 54% used non-sterile gloves > 2 hours. After adjustment for confounding factors, a dose-dependent association with self-reported hand eczema was found for the daily number of hand washes with soap at work and time working with disposable gloves, but not for alcoholic disinfectant use. Hand washing outside work was not associated with self-reported hand eczema in the adjusted multivariate analysis. CONCLUSIONS: In this study, we found a higher 1-year prevalence of self-reported hand eczema among Swedish healthcare workers than reported in the general population. Hand washing with soap and use of disposable gloves were associated with the occurrence of self-reported hand eczema in a dose-dependent way. Use of hand disinfectant was not associated with self-reported hand eczema. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170719IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15813</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28722122">PM:28722122</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20170719-HamneriusN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20170719-HamneriusN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170719, Hamnerius N</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15813</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42108</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brown,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Skin Research Group, School of Medicine, University of Dundee, Dundee, DD1 9SY, U.KDepartment of Dermatology, Ninewells Hospital, Dundee, DD1 9SY, U.K</style></auth-address><titles><title><style face="normal" font="default">What progress have we made in the treatment of atopic eczema? Putting the new biological therapies into a wider context</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="6" start="4">4-6</pages><volume><style face="normal" font="default">177</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> atopic eczema</style></keyword><keyword><style face="normal" font="default"> Biological Therapy</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - EditorialCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15646</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731235">PM:28731235</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\2017-177-4-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\2017-177-4-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170721, Brown SJ</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15646</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42109</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jacob,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Loma Linda University, Loma Linda, CA, U.S.A</style></auth-address><titles><title><style face="normal" font="default">Percutaneous absorption risks in atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="12" start="11">11-12</pages><volume><style face="normal" font="default">177</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Absorption</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15439</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731252">PM:28731252</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\2017-177-11-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\2017-177-11-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170721, Jacob SE</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15439</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42110</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Boyle,R.J.</style></author><author><style face="normal" font="default"> Umasunthar,T.</style></author><author><style face="normal" font="default"> Smith,J.G.</style></author><author><style face="normal" font="default"> Hanna,H.</style></author><author><style face="normal" font="default"> Procktor,A.</style></author><author><style face="normal" font="default"> Phillips,K.</style></author><author><style face="normal" font="default"> Pinto,C.</style></author><author><style face="normal" font="default"> Gore,C.</style></author><author><style face="normal" font="default"> Cox,H.E.</style></author><author><style face="normal" font="default"> Warner,J.O.</style></author><author><style face="normal" font="default"> Vickers,B.</style></author><author><style face="normal" font="default"> Hodes,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Section of Paediatrics, Imperial College London</style></auth-address><titles><title><style face="normal" font="default">A brief psychological intervention for mothers of children with food allergy can change risk perception and reduce anxiety: outcomes of a randomised controlled trial</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> Behavioural therapy</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cognitive behavioural therapy</style></keyword><keyword><style face="normal" font="default"> Communication</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cortisol</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> paediatrics</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> Psychological intervention</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="15" Month="7" Year="2017">2017/7/15</year></dates><abstract><style face="normal" font="default">BACKGROUND: Mothers of children with food allergy have increased anxiety, which may be influenced by healthcare professionals' communication of risk. OBJECTIVE: To evaluate a brief psychological intervention for reducing anxiety in mothers of children with food allergy. METHODS: Two hundred mothers of children with food allergy were recruited from allergy clinics. A computer-generated randomization list was used to allocate participants to a single-session Cognitive Behavioural Therapy intervention including a risk communication module, or standard care. Anxiety and risk perception were assessed at 6 weeks and 1 year. Primary outcome was state anxiety at 6 weeks. Secondary outcomes included state anxiety at 1 year, risk perception at 6 weeks and 1 year, and salivary cortisol response to a simulated anaphylaxis scenario at 1 year. RESULTS: We found no significant difference in the primary outcome state anxiety at 6 weeks, with mean 31.9 (sd 10.2) intervention, 34.0 (10.2) control; mean difference 2.1 (95%CI -0.9, 5.0; P=0.17). There was significantly reduced state anxiety at 6 weeks in the intervention group, in the subgroup of participants with moderate/high anxiety at enrolment (103/200, 52%), with mean 33.0 (sd 9.3) intervention, 37.8 (sd 10.0) control; mean difference 4.8 (95% CI 0.9, 8.7; P=0.016; Cohen's d effect size 0.50). The psychological intervention also reduced risk perception and salivary cortisol response (P=0.032; effect size 0.36). CONCLUSION: We found evidence that a brief psychological intervention which incorporates accurate risk information may impact on anxiety, risk perception and physiological stress response in mothers of children with food allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170715IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12981</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28710902">PM:28710902</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170715-BoyleRJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170715-BoyleRJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170715, Boyle RJ</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12981</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42111</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Perper,M.</style></author><author><style face="normal" font="default"> Cervantes,J.</style></author><author><style face="normal" font="default"> Eber,A.E.</style></author><author><style face="normal" font="default"> Tosti,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Cutaneous Surgery, University of Miami Hospital, Miami, FL, 33136, USA</style></auth-address><titles><title><style face="normal" font="default">Airborne contact dermatitis caused by fragrance diffusers in Uber cars</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="117" start="116">116-117</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fragrance</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170713IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12804</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28703349">PM:28703349</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-116-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-116-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170713, Perper M</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12804</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42112</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fukuda,R.</style></author><author><style face="normal" font="default"> Ouchi,T.</style></author><author><style face="normal" font="default"> Hirai,I.</style></author><author><style face="normal" font="default"> Funakoshi,T.</style></author><author><style face="normal" font="default"> Honda,A.</style></author><author><style face="normal" font="default"> Tanese,K.</style></author><author><style face="normal" font="default"> Tanikawa,A.</style></author><author><style face="normal" font="default"> Amagai,M.</style></author><author><style face="normal" font="default"> Takahashi,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Keio University School of Medicine, Tokyo, 160-8582, Japan</style></auth-address><titles><title><style face="normal" font="default">Non-pigmenting fixed drug eruption with mixed features of acute generalized exanthematous pustulosis induced by pseudoephedrine: a case report</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="126" start="123">123-126</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acute Generalized Exanthematous Pustulosis</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug eruption</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fixed drug eruption</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170713IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12754</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28703347">PM:28703347</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-123-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-123-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170713, Fukuda R</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12754</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42113</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Horton,E.</style></author><author><style face="normal" font="default"> Montgomery,R.</style></author><author><style face="normal" font="default"> Wilkinson,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Leeds, LS7 4SA, UK</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by copper in a malachite necklace</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="121" start="120">120-121</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Copper</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Teaching</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170713IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12791</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28703344">PM:28703344</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-120-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-120-1.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170713, Horton E</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12791</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42114</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Washio,K.</style></author><author><style face="normal" font="default"> Ijuin,K.</style></author><author><style face="normal" font="default"> Fukunaga,A.</style></author><author><style face="normal" font="default"> Nagai,H.</style></author><author><style face="normal" font="default"> Nishigori,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Nishi Kobe Medical Centre, Kobe, 651-2273, Japan</style></auth-address><titles><title><style face="normal" font="default">Contact anaphylaxis caused by Basic Blue 99 in hair dye</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="123" start="122">122-123</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hair</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170713IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12740</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28703343">PM:28703343</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-122-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-122-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170713, Washio K</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12740</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42115</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aerts,O.</style></author><author><style face="normal" font="default"> Naessens,T.</style></author><author><style face="normal" font="default"> Dandelooy,J.</style></author><author><style face="normal" font="default"> Leysen,J.</style></author><author><style face="normal" font="default"> Lambert,J.</style></author><author><style face="normal" font="default"> Apers,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Contact Allergy Unit, Department of Dermatology, University Hospital Antwerp (UZA) and University of Antwerp (UA), 2650, Edegem, Antwerp, Belgium</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by wet wipes containing steareth-10: Is stearyl alcohol to blame?</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="119" start="117">117-119</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Alcohol</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170713IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12776</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28703348">PM:28703348</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-117-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-117-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170713, Aerts O</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12776</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42116</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Uter,W.</style></author><author><style face="normal" font="default"> Lessmann,H.</style></author><author><style face="normal" font="default"> Geier,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Informatics, Biometry and Epidemiology, University of Erlangen-Nurnberg, 91054, Erlangen, Germany</style></auth-address><titles><title><style face="normal" font="default">Is octocrylene a frequent contact allergen?</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="128" start="127">127-128</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Biometry</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medical Informatics</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170713IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12761</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28703345">PM:28703345</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-127-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-127-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170713, Uter W</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12761</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42117</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Assier,H.</style></author><author><style face="normal" font="default"> Valeyrie-Allanore,L.</style></author><author><style face="normal" font="default"> Gener,G.</style></author><author><style face="normal" font="default"> Verlinde Carvalh,M.</style></author><author><style face="normal" font="default"> Chosidow,O.</style></author><author><style face="normal" font="default"> Wolkenstein,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Referral Centre for Toxic Bullous Diseases, AP-HP, Hopital Henri-Mondor, UPEC, 94010, Creteil, France</style></auth-address><titles><title><style face="normal" font="default">Patch testing in non-immediate cutaneous adverse drug reactions: value of extemporaneous patch tests</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Commercial</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Cutaneous adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nonimmediate</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword></keywords><dates><year Day="21" Month="7" Year="2017">2017/7/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patch testing following a standardized protocol is reliable for identifying the culprit drug in cutaneous adverse drug reactions (CADRs). However, these patch tests (PTs) require pharmaceutical material and staff, which are not always easily available. OBJECTIVES: To evaluate an extemporaneous PT method in CADRs. METHODS: We retrospectively analysed data for all patients referred to our department between March 2009 and June 2013 for patch testing after a non-immediate CADR. The patients who supplied their own suspected drugs were tested both with extemporaneous PTs and with conventional PTs. Extemporaneous PTs involved a nurse crushing and diluting the drug in pet. in a ratio of approximately one-third to two-thirds. Standardized PTs were performed according to guidelines, with commercial drugs diluted to 30% or with active ingredients diluted to 10%. We analysed the data for the two PT methods in terms of the number of positive test reactions, drugs tested, and type of CADR for patients in whom the two PT methods were used. RESULTS: In total, 75 of 156 patients underwent the two PT procedures, including 91 double tests. Overall, 21 tests gave positive reactions with the two methods, and 69 other tests gave negative results with the two methods. CONCLUSION: Our series yielded results similar to those of published series concerning the types of CADR and the drugs responsible. Our results suggest that, for CADRs, if a patient supplies a suspected drug but if the pharmaceutical material and staff are not available for conventional PTs, extemporaneous PTs performed by the nurse with the commercial drug used by the patient can be useful and reliable</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12842</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28730661">PM:28730661</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170721-AssierH.pdfF:\A&amp;H LMW Papers\Contact Dermatitis\20170721-AssierH.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default">20170721, Assier H</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12842</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42118</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ahlstrom,M.G.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author><author><style face="normal" font="default"> Menne,T.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, National Allergy Research Centre, Herlev and Gentofte Hospital, University of Copenhagen, 2900, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Prevalence of nickel allergy in Europe following the EU Nickel Directive - a review</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Nickel allergy</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="21" Month="7" Year="2017">2017/7/21</year></dates><abstract><style face="normal" font="default">Nickel contact allergy remains a problem in EU countries, despite the EU Nickel Directive. To study the prevalence of nickel allergy in EU countries following the implementation of the EU Nickel Directive, we performed a systematic search in PubMed for studies that examined the prevalence of nickel allergy in EU countries published during 2005-2016. We identified 46 studies: 10 in the general population and 36 in patch tested dermatitis patients. A significantly lower prevalence of nickel allergy after than before the implementation of the EU Nickel Directive was found in women aged 18-35 years (11.4% versus 19.8%) (p = 0.02), in female dermatitis patients aged &lt;/=17 years (14.3% versus 29.2%) (p &lt; 0.0001), and in dermatitis patients aged 18-30 years (women: 20.2% versus 36.6%) (p &lt; 0.0001) (men: 4.9% versus 6.6%) (p &lt; 0.0001). Overall, the prevalence was higher in southern than in northern EU countries, and generally remained high, affecting 8-18% of the general population. A consistent pattern of decreasing prevalence of nickel allergy in some EU countries was observed, although the prevalence among young women remains high. Steps should be taken for better prevention of nickel allergy in EU countries</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12846</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28730624">PM:28730624</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170721-AhlstromMG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170721-AhlstromMG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170721, Ahlstrom MG</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12846</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42119</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Agudo-Mena,J.L.</style></author><author><style face="normal" font="default"> Romero-Perez,D.</style></author><author><style face="normal" font="default"> Encabo-Duran,B.</style></author><author><style face="normal" font="default"> Alvarez-Chinchilla,P.J.</style></author><author><style face="normal" font="default"> Silvestre-Salvador,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Complejo Hospitalario Universitario de Albacete, University of Castilla La Mancha, 02006, Albacete, Spain</style></auth-address><titles><title><style face="normal" font="default">Photoallergic contact dermatitis caused by quinidine sulfate in a caregiver</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="132" start="131">131-132</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Quinidine</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170713IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12774</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28703350">PM:28703350</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-131-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-131-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170713, Agudo-Mena JL</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12774</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42120</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Saito,R.</style></author><author><style face="normal" font="default"> Sawada,Y.</style></author><author><style face="normal" font="default"> Nakamura,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, 807-8555, Japan</style></auth-address><titles><title><style face="normal" font="default">Two cases of eczematous drug eruption caused by oral tacrolimus administration</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="130" start="128">128-130</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug eruption</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Tacrolimus</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170713IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12772</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28703346">PM:28703346</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-128-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-128-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170713, Saito R</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12772</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42121</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Newberry,C.</style></author><author><style face="normal" font="default"> Lynch,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Can We Use Diet to Effectively Treat Esophageal Disease? A Review of the Current Literature</style></title><secondary-title><style face="normal" font="default">Curr Gastroenterol Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Gastroenterol Rep</style></full-title></periodical><pages end="" start="38">38-</pages><volume><style face="normal" font="default">19</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenocarcinoma</style></keyword><keyword><style face="normal" font="default"> Algorithms</style></keyword><keyword><style face="normal" font="default"> Anatomy</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophilic esophagitis</style></keyword><keyword><style face="normal" font="default"> Esophagitis</style></keyword><keyword><style face="normal" font="default"> Esophagus</style></keyword><keyword><style face="normal" font="default"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="default"> Gastroesophageal reflux disease</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1534-312X</style></isbn><abstract><style face="normal" font="default">Esophageal diseases represent a wide variety of conditions affecting esophageal anatomy, physiology, and motility. Therapy focuses on pharmacotherapy and endoscopic or surgical management. Dietary therapy can be considered in management algorithms for specific esophageal diseases. This review focuses on outlining the literature related to dietary therapy in gastroesophageal reflux disease, eosinophilic esophagitis, Barrett</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖs esophagus, and esophageal adenocarcinoma</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11894-017-0578-5</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s11894-017-0578-5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Gastroenterol Rep\2017-19-38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Gastroenterol Rep\2017-19-38.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Newberry C</style></custom2><misc3><style face="normal" font="default">10.1007/s11894-017-0578-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42122</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gomes Rebelo,E.</style></author><author><style face="normal" font="default"> Kuyucu,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Epidemiology and Risk Factors in Drug Hypersensitivity Reactions</style></title><secondary-title><style face="normal" font="default">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Treat Options Allergy</style></full-title></periodical><pages end="257" start="239">239-257</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Betalactams</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> elderly</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> NSAID</style></keyword><keyword><style face="normal" font="default"> NSAIDs</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2196-3053</style></isbn><abstract><style face="normal" font="default">Data on adverse drug reactions (ADRs) is abundant, especially regarding prevalence and incidence among hospital-based populations. Most studies, however, do not differentiate between drug hypersensitivity reactions (DHRs) and other kinds of ADR, and in those ones where this information is available, the diagnosis of DHR or drug allergy is mostly based on a suspected clinical history or self-reporting as the majority of patients are not referred for an allergy diagnostic workup. Large studies in drug allergy clinics revealed that only 10 to 20% of the initial DHR suspicions are actually confirmed after investigation. Diagnosis based only on clinical histories largely overestimates drug hypersensitivity, so specific data on DHR is scarce and generally of low quality. Epidemiological data, although limited, can help researchers to identify potential risk factors for DHR. Females seem to be more susceptible than males to ADR and DHRs in adult populations, while the female gender is not a risk factor among children. ADRs have also a higher incidence among young children and among the elderly. The role of atopy as a risk factor for DHR is still debatable; however, recent evidence shows that it can actually be important considering reactions to betalactams and NSAIDs. Comorbidities as infections and underlying chronic diseases are known risk factors both for ADR in general and for DHR. The most recent investigation concentrates on the importance of genetic risk factors, and many gene polymorphisms have been identified with strong associations to particular kind of DHR and/or to reactions to specific drugs. This article will discuss general limitations of the available epidemiological data on DHR and will present an in-depth review of the main identified risk factors for drug reactions with special focus on genetic findings</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Portugal -CO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1007/s40521-017-0128-2</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40521-017-0128-2</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-239-57.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-239-57.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Gomes Rebelo E</style></custom2><misc3><style face="normal" font="default">10.1007/s40521-017-0128-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42123</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dona,I.</style></author><author><style face="normal" font="default"> Salas,M.</style></author><author><style face="normal" font="default"> Barrionuevo,E.</style></author><author><style face="normal" font="default"> Campo,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Management of Respiratory Symptoms Induced by Non-Steroidal Anti-Inflammatory Drugs</style></title><secondary-title><style face="normal" font="default">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Treat Options Allergy</style></full-title></periodical><pages end="282" start="268">268-282</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Cardiovascular</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> COX-1</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Gold</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Ketorolac</style></keyword><keyword><style face="normal" font="default"> Lysine</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> Nasal surgery</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drug</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> NSAID</style></keyword><keyword><style face="normal" font="default"> NSAIDs</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2196-3053</style></isbn><abstract><style face="normal" font="default">Non-steroidal anti-inflammatory drugs (NSAIDs)-exacerbated respiratory disease (NERD) is defined by the combination of chronic rhinosinusitis, nasal polyps, bronchial asthma, and hypersensitivity reactions involving upper and/or lower airways after the exposure to acetylsalicylic acid (ASA) and other NSAIDs. However, airway inflammation occurs even in the absence of exposure to these drugs, leading to disease progression with aggressive polyp formation and non-optimal controlled asthma and rhinosinusitis. In this review, we discuss current and potential management strategies of NERD. This management should be multidisciplinary and comprise medical and surgical treatment of the underlying diseases. In order to prevent reactions due to NSAIDs, avoidance of COX-1 inhibitors with provision of safe therapeutic alternatives should be indicated. However, avoidance of NSAIDs does not ensure disappearance of the airway inflammation and this progresses and persists for life. ASA desensitization followed by daily ASA therapy remains the gold standard of NERD treatment. It is indicated in patients with uncontrolled bronchial and nasal symptoms as well as in patients who require NSAID treatment for specific diseases, such as rheumatic or cardiovascular conditions. ASA desensitization improves upper and lower respiratory symptoms, reduces the need for new nasal surgeries and increases quality of life. Different ASA desensitization protocols have been reported, although the addition of intranasal ketorolac and lysine aspirin prior to an oral ASA schedule has made ASA desensitization safer and more efficient. New therapeutic strategies are being investigated and may provide an alternative treatment for those patients in which ASA desensitization are contraindicated or continuous ASA therapy is discontinued because of adverse effects. Among them, biologic agents are an important treatment option, useful for controlling symptoms of the upper and lower airways. More investigation studies into the mechanisms involved in NERD are needed in order to identify additional therapeutic targets</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1007/s40521-017-0129-1</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40521-017-0129-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-268-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-268-82.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Dona I</style></custom2><misc3><style face="normal" font="default">10.1007/s40521-017-0129-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42124</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bonadonna,P.</style></author><author><style face="normal" font="default"> Zanotti,R.</style></author><author><style face="normal" font="default"> Varani Bisoffi,A.</style></author><author><style face="normal" font="default"> Pagani,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Mast Cell Diseases and Drug Hypersensitivity Reactions</style></title><secondary-title><style face="normal" font="default">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Treat Options Allergy</style></full-title></periodical><pages end="267" start="258">258-267</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Bone Marrow</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> cutaneous mastocytosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hymenoptera</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mastocytosis</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drug</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Perioperative</style></keyword><keyword><style face="normal" font="default"> Physical Examination</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Serum tryptase</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic mastocytosis</style></keyword><keyword><style face="normal" font="default"> Tryptase</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2196-3053</style></isbn><abstract><style face="normal" font="default">Mastocytosis is a clonal disorder characterized by the proliferation and accumulation of mast cells (MCs) in different tissues, with a preferential localization in skin and bone marrow (BM). Patients with cutaneous and systemic mastocytosis could present symptoms, including immediate and severe hypersensitivity reactions, related to the increase of MC releasability and to the excess of mast cell in the tissues. Mastocytosis in adults is associated with a history of anaphylaxis in 22</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô49%. Hymenoptera stings represent the more frequent elicitor of anaphylaxis, sometimes fatal, in mastocytosis patients. Moreover, anaphylaxis after intake of drugs such as non-steroidal anti-inflammatory drugs, opioids and drugs in the perioperative setting is occasionally described in mastocytosis. However, data on the frequency of drug hypersensitivity in mastocytosis and vice versa are scarce and evidence for an association appears to be limited. Nevertheless, clonal MC disorders should be ruled out in cases of severe anaphylaxis based on the evaluation of basal serum tryptase determination, physical examination for cutaneous Mastocytosis lesions, and clinical characteristics of anaphylactic reaction. In this paper, we focused on the most relevant evidence about the association between mastocytosis and hypersensitivity to some classes of drugs. In addition, we tried to give recommendations, based on available literature data, about the use of these drugs in patients with diagnosed mastocytosis</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1007/s40521-017-0130-8</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40521-017-0130-8</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-258-67.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-258-67.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Bonadonna P</style></custom2><misc3><style face="normal" font="default">10.1007/s40521-017-0130-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42125</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tarlo,S.M.</style></author><author><style face="normal" font="default"> Liss,G.M.</style></author><author><style face="normal" font="default"> Lipszyc,J.C.</style></author><author><style face="normal" font="default"> Gupta,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Rationale for Development of Work-Related Asthma Educational Tools for Asthmatics</style></title><secondary-title><style face="normal" font="default">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Treat Options Allergy</style></full-title></periodical><pages end="117" start="111">111-117</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Educational tools</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Internet</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> occupational asthma</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword><keyword><style face="normal" font="default"> Work-related asthma</style></keyword><keyword><style face="normal" font="default"> Workplace</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2196-3053</style></isbn><abstract><style face="normal" font="default">Currently, young asthmatics have little knowledge of the potential effects of work exposures on their asthma. We expect that education of young asthmatics about the potential effects of the working environment on their asthma and appropriate steps to reduce work-related exacerbations will provide these individuals with skills to better control their asthma. Currently, there is no formal process for this education to our knowledge. Since the Internet is readily available and widely used by most young asthmatics, it may provide a useful forum for such education. Our preliminary studies with development and early validation of a Web-based educational tool for work-related asthma suggest that this can provide education and may prove to be a useful resource. Additional studies are needed to determine whether this can be easily used in high schools or trade schools or in the workplace, and whether the knowledge gained can translate into reduction of morbidity. Potentially, benefit may also accrue to older working adults with asthma or those at increased risk of developing occupational asthma</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1007/s40521-017-0119-3</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40521-017-0119-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-111-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-111-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Tarlo SM</style></custom2><misc3><style face="normal" font="default">10.1007/s40521-017-0119-3</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42126</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bellon,T.</style></author><author><style face="normal" font="default"> Cabanas,R.</style></author><author><style face="normal" font="default"> Gonzalez-Herrada,C.</style></author><author><style face="normal" font="default"> Ramirez,E.</style></author><author><style face="normal" font="default"> Gonzalez-Ramos,J.</style></author><author><style face="normal" font="default"> Lopez San Martin,M.</style></author><author><style face="normal" font="default"> Gonzalez-Valle,O.</style></author><author><style face="normal" font="default"> Fiandor,A.M.</style></author><author><style face="normal" font="default"> Lerma,V.</style></author><author><style face="normal" font="default"> Roustan,G.</style></author><author><style face="normal" font="default"> de Abajo,F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Approach to Severe Cutaneous Adverse Drug Reactions</style></title><secondary-title><style face="normal" font="default">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Treat Options Allergy</style></full-title></periodical><pages end="221" start="201">201-221</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acute Generalized Exanthematous Pustulosis</style></keyword><keyword><style face="normal" font="default"> adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Algorithms</style></keyword><keyword><style face="normal" font="default"> Causality</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cross reactivity</style></keyword><keyword><style face="normal" font="default"> Cross-reactivity</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Cutaneous adverse drug reactions</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> DRESS</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Drug-induced</style></keyword><keyword><style face="normal" font="default"> drug-induced hypersensitivity syndrome</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity syndrome</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> In vitro tests</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Rare Diseases</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default"> Stevens-Johnson Syndrome</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Toxic epidermal necrolysis</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2196-3053</style></isbn><abstract><style face="normal" font="default">Severe cutaneous adverse drug reactions (SCARs) can occur at any age and can be life threatening, although some drugs have been more frequently reported than others. The spectrum of SCARs includes acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, also known as drug-induced hypersensitivity syndrome (DiHS) or hypersensitivity syndrome (HSS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). Immediate withdrawal of the offending drug is the mainstay treatment in SCARs, and rechallenge often leads to recurrent reactions. Cross reactivity and multiple sensitivities have also been reported. The identification of the offending medication at the onset of the disease is therefore essential to avoid future exposures to the same or chemically related compounds. Various algorithms can be useful to identify the culprit drug in the acute stage. Delayed onset from the initiation of treatment differs in the various clinical entities. Therefore, a prompt, accurate diagnosis is crucial for proper identification of the offending agent. After resolution of the disease, cutaneous tests and in vitro tests can be useful for confirmation of drug causality and investigation of possible cross-reactivity. SCARs are rare diseases, given the incidence is extremely low. Multidisciplinary and international teams are required to study these diseases. Further research is needed to fully understand etiopathogenesis and for the development of specific treatments</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1007/s40521-017-0127-3</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40521-017-0127-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-201-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-201-21.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Bellon T</style></custom2><misc3><style face="normal" font="default">10.1007/s40521-017-0127-3</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42127</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Caubet,J.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">How to Manage Drug-Induced Exanthema in Children</style></title><secondary-title><style face="normal" font="default">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Treat Options Allergy</style></full-title></periodical><pages end="238" start="222">222-238</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> betalactam allergy</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> Drug provocation test</style></keyword><keyword><style face="normal" font="default"> Drug-induced</style></keyword><keyword><style face="normal" font="default"> Exanthema</style></keyword><keyword><style face="normal" font="default"> Fear</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> In vitro tests</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2196-3053</style></isbn><abstract><style face="normal" font="default">Exanthemas are frequently encountered in the pediatric population and often occur while patients concomitantly receive a drug, leading to a high prevalence of suspicion of drug allergy in children. Although the vast majority of these exanthemas are due to the underlying infection, most of those patients are falsely labeled as </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç£drug allergic</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇØ without appropriate testing, mostly due to fear of life-threatening reactions. Overdiagnosis of drug allergy constitutes a major public health problem by increasing health costs and by contributing to overall antibiotic resistance. Thus, an accurate diagnosis is considered as a major contribution to cost-effective health care and will be based on a complete allergic workup (i.e., clinical history, skin tests, in vitro tests, and/or drug provocation test). Specific aspects of the management of drug allergy have been highlighted recently, particularly regarding the importance and safety of the drug provocation test as well as the low diagnostic value of skin tests in the diagnosis of betalactam allergy</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1007/s40521-017-0131-7</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40521-017-0131-7</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-222-38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-222-38.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Caubet JC</style></custom2><misc3><style face="normal" font="default">10.1007/s40521-017-0131-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42128</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Xu,S.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author><author><style face="normal" font="default"> Paller,A.S.</style></author><author><style face="normal" font="default"> Silverberg,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL; daggerDepartment of Dermatology, Gentofte University Hospital, Hellerup, Denmark; and Departments of double daggerPediatrics, section signPreventive Medicine, and parallelMedical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL</style></auth-address><titles><title><style face="normal" font="default">Eczema, Atopic Dermatitis, or Atopic Eczema: Analysis of Global Search Engine Trends</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="279" start="276">276-279</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> atopic eczema</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> Communication</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Language</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patient Education</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> trends</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: The lack of standardized nomenclature for atopic dermatitis (AD) creates challenges for scientific communication, patient education, and advocacy. OBJECTIVE: We sought to determine the relative popularity of the terms eczema, AD, and atopic eczema (AE) using global search engine volumes. METHODS: A retrospective analysis of average monthly search volumes from 2014 to 2016 of Google, Bing/Yahoo, and Baidu was performed for eczema, AD, and AE in English and 37 other languages. Google Trends was used to determine the relative search popularity of each term from 2006 to 2016 in English and the top foreign languages, German, Turkish, Russian, and Japanese. RESULTS: Overall, eczema accounted for 1.5 million monthly searches (84%) compared with 247 000 searches for AD (14%) and 44 000 searches for AE (2%). For English language, eczema accounted for 93% of searches compared with 6% for AD and 1% for AE. Search popularity for eczema increased from 2006 to 2016 but remained stable for AD and AE. CONCLUSIONS: Given the ambiguity of the term eczema, we recommend the universal use of the next most popular term, AD</style></abstract><notes><style face="normal" font="default">DA - 20170719IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">0.1097/DER.0000000000000273</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28722692">PM:28722692</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-276-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-276-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170719, Xu S</style></custom2><misc3><style face="normal" font="default">0.1097/DER.0000000000000273</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42129</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chou,M.</style></author><author><style face="normal" font="default"> Dhingra,N.</style></author><author><style face="normal" font="default"> Strugar,T.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Icahn School of Medicine at Mount Sinai; and daggerDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York</style></auth-address><titles><title><style face="normal" font="default">Contact Sensitization to Allergens in Nail Cosmetics</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="240" start="231">231-240</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acrylate</style></keyword><keyword><style face="normal" font="default"> Acrylates</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergenic</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> contact sensitization</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dibutyl Phthalate</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Formaldehyde</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> Ingredients</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Methacrylate</style></keyword><keyword><style face="normal" font="default"> Methacrylates</style></keyword><keyword><style face="normal" font="default"> Nails</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Spread</style></keyword><keyword><style face="normal" font="default"> Toluene</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Ingredients found in the nail cosmetic industry, including but not limited to methacrylate and acrylate monomers, formaldehyde, and toluene sulfonamide-formaldehyde resin, can incite allergic contact dermatitis. An eczematous outbreak presents on areas surrounding the nail plate and may spread through contact transfer of the allergen, commonly to the face and neck. Even components that were originally deemed nonsensitizing, such as the ubiquitous cyanoacrylate adhesive family, have been found to be allergenic. They do not, however, cross-react with methacrylates and acrylates. Alternative options for individuals with allergic contact dermatitis reactions to these ingredients can be avoidance of these procedures or use of products that are "3, 4, 5 free" in which the common allergens dibutyl phthalate, toluene, and formaldehyde are absent. In cases where strengthening of the nail is the sole purpose, nail wraps or preformed nails can be applied for non-cyanoacrylate-sensitive individuals</style></abstract><notes><style face="normal" font="default">DA - 20170718IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000301</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28719472">PM:28719472</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-231-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-231-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170718, Chou M</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000301</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42130</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Raessler,F.</style></author><author><style face="normal" font="default"> Schliemann,S.</style></author><author><style face="normal" font="default"> Elsner,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Hospital Jena, Germany, franziska.raessler@med.uni-jena.de Department of Dermatology, University Hospital Jena, Germany</style></auth-address><titles><title><style face="normal" font="default">A Rare Case of Contact Urticaria and Allergic Contact Dermatitis to Maleic and Fumaric Acids</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="295" start="294">294-295</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acids</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact urticaria</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170718IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000299</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28719476">PM:28719476</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-294-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-294-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170718, Raessler F</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000299</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42131</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Goodier,M.C.</style></author><author><style face="normal" font="default"> Ljungberg,L.</style></author><author><style face="normal" font="default"> Persson,C.</style></author><author><style face="normal" font="default"> Engfeldt,M.</style></author><author><style face="normal" font="default"> Bruze,M.</style></author><author><style face="normal" font="default"> Warshaw,E.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Department of Dermatology, University of Minnesota Medical School; daggerHCMC Parkside Occupational and Contact Dermatitis Clinic; and double daggerMinneapolis Veterans Affairs Medical Center, Department of Dermatology, Minneapolis, MN; and section signDepartment of Occupational and Environmental Dermatology, Lund University, Skane University Hospital, Malmo, Sweden</style></auth-address><titles><title><style face="normal" font="default">Allergic Contact Dermatitis From Methylisothiazolinone in Residential Wall Paint</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="287" start="284">284-287</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Benzisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Chromatography</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Minnesota</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Paint</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Veterans</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">A 33-year-old woman presented to our clinic for suspected photoallergic contact dermatitis with a recent episode of severe, vesicular dermatitis involving exposed skin and correlating with relocation to a new home. Biopsy results showed spongiotic and lichenoid dermatitis with eosinophils. Patch test results showed a very strong (+++) reaction to methylisothiazolinone (MI), mild (+) reaction to MI/methylchloroisothiazolinone, and no reaction to benzisothiazolinone. These allergens were found in several personal products. However, the patient was suspicious of 4 wall paints recently used in her home. Semiopen patch tests to 3 Behr interior paints showed positive results. Nine controls showed negative results. High-performance liquid chromatography demonstrated MI and benzisothiazolinone in all 4 paints at concentrations ranging from 50 to 100 ppm and 290 to 340 ppm, respectively. Although MI has been reported to cause occupational airborne contact dermatitis in European household painters, to our knowledge, this is the first documented case of paint-related MI allergy in the United States</style></abstract><notes><style face="normal" font="default">DA - 20170718IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000294</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28719475">PM:28719475</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-284-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-284-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170718, Goodier MC</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000294</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42132</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chaudhry,H.M.</style></author><author><style face="normal" font="default"> Drage,L.A.</style></author><author><style face="normal" font="default"> El-Azhary,R.A.</style></author><author><style face="normal" font="default"> Hall,M.R.</style></author><author><style face="normal" font="default"> Killian,J.M.</style></author><author><style face="normal" font="default"> Prakash,A.V.</style></author><author><style face="normal" font="default"> Yiannias,J.A.</style></author><author><style face="normal" font="default"> Davis,M.D.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Mayo Clinic School of Medicine, Mayo Clinic College of Medicine and Science; and daggerDivision of Clinical Dermatology, Mayo Clinic, Rochester, MN; double daggerDepartment of Dermatology, Mayo Clinic, Jacksonville, FL; section signDivision of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN; and parallelDivision of Clinical Dermatology, Mayo Clinic, Scottsdale, AZ</style></auth-address><titles><title><style face="normal" font="default">Delayed Patch-Test Reading After 5 Days: An Update From the Mayo Clinic Contact Dermatitis Group</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="260" start="253">253-260</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Bacitracin</style></keyword><keyword><style face="normal" font="default"> Beryllium</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> delayed reaction</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Gold</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metals</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neomycin</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Palladium</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Preservatives</style></keyword><keyword><style face="normal" font="default"> Propolis</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Reading</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Statistics</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Topical corticosteroids</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patch-test readings after day 5 have previously been used to identify delayed reactions to metals and topical antibiotics. OBJECTIVE: The aims of this study were to identify allergens for which late readings (beyond day 5) would be most valuable and to compare our results with our previous study on delayed patch-test readings. METHODS: This was a retrospective study of 298 patients who underwent metal and corticosteroid series patch testing from January 1, 2007, through December 31, 2013. Patch-test readings were conducted on days 3 and 5 and at least once sometime between days 7 and 14. All reactions were examined at each reading. CONCLUSIONS: These results were concordant with our previous findings that additional readings after day 7 are particularly useful for identifying reactions to metals (gold, cobalt, beryllium, palladium), specific preservatives (dodecyl gallate, propolis), and the topical antibiotic neomycin. New delayed reactions to bacitracin, p-phenylenediamine, and topical corticosteroids were not seen in this cohort</style></abstract><notes><style face="normal" font="default">DA - 20170718IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000297</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28719473">PM:28719473</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-253-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-253-60.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170718, Chaudhry HM</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000297</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42133</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Balp,M.M.</style></author><author><style face="normal" font="default"> Lopes da,Silva N.</style></author><author><style face="normal" font="default"> Vietri,J.</style></author><author><style face="normal" font="default"> Tian,H.</style></author><author><style face="normal" font="default"> Esina,L.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Novartis Pharma AG, Basel, Switzerland.</style></auth-address><titles><title><style face="normal" font="default">The Burden of Chronic Urticaria from Brazilian Patients' Perspective</style></title><secondary-title><style face="normal" font="default">Dermatol Ther (Heidelb)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Dermatol Ther (Heidelb)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Status</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="26" Month="7" Year="2017">2017/7/26</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Chronic urticaria (CU), a proxy for chronic spontaneous urticaria, has been associated with a negative impact on health-related quality of life (HRQoL) and costs, but there is limited evidence on the burden of CU in Brazil. The objective of this study was to estimate the prevalence of CU and assess the burden of CU on HRQoL and healthcare resource utilization (HRU) among adults in Brazil. METHODS: This retrospective, cross-sectional study, pooled data from the 2011, 2012, and 2015 National Health and Wellness Survey in Brazil (n = 36,000). Respondents (aged >/=18 years) diagnosed with and treated for CU provided data on demographics, health history, HRQoL (mental and physical health status) on Short-Form SF-36v2, presence of psychological complaints, work impairment, activity impairment, and HRU. Generalized linear models, controlling for covariates, examined differences between those treated for CU and matched controls on the outcome variables. RESULTS: The prevalence of diagnosed CU was 0.41% (n = 249) and treated CU was 0.21% (n = 127). After adjustments, CU (currently treated for CU) was associated with worse mental functioning, physical functioning, and health utilities compared with controls (all p &lt; 0.01). CU had over twice the odds of anxiety and sleep difficulties, over 1.5 times the work and activity impairment, twice the number of total physician visits, eight times the number of allergist visits, and twice the number of emergency room visits as controls (all p &lt; 0.01). CONCLUSIONS: Many CU patients using prescription treatment experienced anxiety and sleep disturbances, poorer HRQoL, significant work and activity impairment, and high HRU, compared with matched general population controls. Findings suggest an unmet need for more effective treatment and management of CU in Brazil. FUNDING: Novartis Pharma AG and Genentech</style></abstract><notes><style face="normal" font="default">DA - 20170727IS - 2193-8210 (Print)LA - engPT - Journal ArticleCO - Switzerland -CO - Brazil -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s13555-017-0191-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28748405">PM:28748405</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatol Ther (Heidelb)\20170727-BalpMM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatol Ther (Heidelb)\20170727-BalpMM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170727, Balp MM</style></custom2><misc3><style face="normal" font="default">10.1007/s13555-017-0191-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42134</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kolkhir,P.</style></author><author><style face="normal" font="default"> Pogorelov,D.</style></author><author><style face="normal" font="default"> Olisova,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.</style></auth-address><titles><title><style face="normal" font="default">CRP, D-dimer, fibrinogen and ESR as predictive markers of response to standard doses of levocetirizine in patients with chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="192" start="189">189-192</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Discriminant Analysis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Fibrinogen</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> H1 antihistamines</style></keyword><keyword><style face="normal" font="default"> H1-antihistamine</style></keyword><keyword><style face="normal" font="default"> H1-antihistamines</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Moscow</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Russia</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Summary: According to current guidelines, non-sedative H1-antihistamines (nsAH) are the first-line therapy of chronic spontaneous urticaria (CSU). But even up-dosed antihistamines (to four times the standard dose) produce symptom resolution in less than 50% of patients. Biomarkers that can predict the response to nsAH are still unknown. We carried out a prospective study and used discriminant analysis to evaluate the combination of D-dimer, fibrinogen, C-reactive protein and ESR values for predicting the outcome of treatment with levocetirizine in 84 CSU patients. We found that elevation of these parameters is associated with more active disease, low quality of life and lack of response to standard doses of levocetirizine. Thus, evaluation of these markers may be considered useful before starting treatment with nsAH. The mechanisms behind the increase in these parameters in CSU patients need to be elucidated in further studies</style></abstract><notes><style face="normal" font="default">DA - 20170728IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Russia -</style></notes><work-type><style face="normal" font="default">10.23822/EurAnnACI.1764-1489.05</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28752724">PM:28752724</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-189-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-189-92.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170728, Kolkhir P</style></custom2><misc3><style face="normal" font="default">10.23822/EurAnnACI.1764-1489.05</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42135</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Semik-Orzech,A.</style></author><author><style face="normal" font="default"> Skoczynski,S.</style></author><author><style face="normal" font="default"> Pierzchala,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pneumology, School of Medicine, Medical University of Silesia, Katowice, Poland.</style></auth-address><titles><title><style face="normal" font="default">Serum estradiol concentration, estradiol-to-progesterone ratio and sputum IL-5 and IL-8 concentrations are increased in luteal phase of the menstrual cycle in perimenstrual asthma patients</style></title><secondary-title><style face="normal" font="default">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="170" start="161">161-170</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Cell Count</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cortisol</style></keyword><keyword><style face="normal" font="default"> Estradiol</style></keyword><keyword><style face="normal" font="default"> Hormones</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Luteal Phase</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Menstrual Cycle</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Progesterone</style></keyword><keyword><style face="normal" font="default"> Prolactin</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Testosterone</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Summary: Background. The results of the research on perimenstrual asthma (PMA) pathophysiology are inconsistent, and the role of sex hormones remains inconclusive. The aim of the study was to evaluate the influence of serum sex steroid (and other) hormones concentrations on lower airway inflammation of PMA patients. Methods. Thirty-three women of childbearing age diagnosed as: PMA (n = 13), non-PMA asthmatics (n = 10), and healthy controls (n = 10) were prospectively followed for 12 weeks over 2 consecutive menstrual cycles. On the 10th and 26th day of each cycle serum 17beta-estradiol, progesterone, testosterone, androstendion, dehydroepiandrosteron, cortisol, thyroid-stimulating hormone and prolactin were measured, and sputum was induced. Sputum inflammatory cell count and IL-5, -6, -8, -10 concentrations were determined. Results. When compared to non-PMA asthmatics, the luteal phase of the cycle in PMA subjects was associated with increased serum estradiol concentration, estradiol-to-progesterone ratio (p &lt; 0.001, p = 0.001, respectively) and sputum IL-5 and IL-8 concentrations (p = 0.045, p = 0.039, respectively). Decreased serum testosterone levels (p &lt; 0.05) and a trend to increased serum prolactin levels in both phases of the menstrual cycle in PMA subjects were observed. Sputum analysis in PMA patients revealed increased total inflammatory cell count in both phases of the menstrual cycle (p &lt; 0.05), when compared to non-PMA asthmatics. Conclusions. The luteal phase of the cycle in PMA patients is associated with increased serum estradiol levels with concurrent higher sputum concentration of IL-5 and IL-8. Serum testosterone levels are decreased, and total number of sputum inflammatory cells is increased in PMA patients in both phases of the menstrual cycle</style></abstract><notes><style face="normal" font="default">DA - 20170728IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.23822/EurAnnACI.1764-1489.09</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28752719">PM:28752719</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-161-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-161-70.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170728, Semik-Orzech A</style></custom2><misc3><style face="normal" font="default">10.23822/EurAnnACI.1764-1489.09</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42136</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Becerra-Diaz,M.</style></author><author><style face="normal" font="default"> Wills-Karp,M.</style></author><author><style face="normal" font="default"> Heller,N.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USADepartment of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USADepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA</style></auth-address><titles><title><style face="normal" font="default">New perspectives on the regulation of type II inflammation in asthma</style></title><secondary-title><style face="normal" font="default">F1000Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">F1000Res</style></abbr-1></periodical><pages end="" start="1014">1014-</pages><volume><style face="normal" font="default">6</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anesthesiology</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Baltimore</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> diversity</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Endotypes</style></keyword><keyword><style face="normal" font="default"> Engineering</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-5</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immunosuppression</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Interleukin</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Periostin</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Primary Prevention</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> TH2 cytokines</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Therapeutics</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Asthma is a chronic inflammatory disease of the lungs which has been thought to arise as a result of inappropriately directed T helper type-2 (Th2) immune responses of the lungs to otherwise innocuous inhaled antigens. Current asthma therapeutics are directed towards the amelioration of downstream consequences of type-2 immune responses (i.e. beta-agonists) or broad-spectrum immunosuppression (i.e. corticosteroids). However, few approaches to date have been focused on the primary prevention of immune deviation. Advances in molecular phenotyping reveal heterogeneity within the asthmatic population with multiple endotypes whose varying expression depends on the interplay between numerous environmental factors and the inheritance of a broad range of susceptibility genes. The most common endotype is one described as "type-2-high" (i.e. high levels of interleukin [IL]-13, eosinophilia, and periostin). The identification of multiple endotypes has provided a potential explanation for the observations that therapies directed at typical Th2 cytokines (IL-4, IL-5, and IL-13) and their receptors have often fallen short when they were tested in a diverse group of asthmatic patients without first stratifying based on disease endotype or severity. However, despite the incorporation of endotype-dependent stratification schemes into clinical trial designs, variation in drug responses are still apparent, suggesting that additional genetic/environmental factors may be contributing to the diversity in drug efficacy. Herein, we will review recent advances in our understanding of the complex pathways involved in the initiation and regulation of type-2-mediated immune responses and their modulation by host factors (genetics, metabolic status, and the microbiome). Particular consideration will be given to how this knowledge could pave the way for further refinement of disease endotypes and/or the development of novel therapeutic strategies for the treatment of asthma</style></abstract><notes><style face="normal" font="default">DA - 20170719IS - 2046-1402 (Print)IS - 2046-1402 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.12688/f1000research.11198.1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28721208">PM:28721208</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\F1000Res\2017-6-1014.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\F1000Res\2017-6-1014.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170719, Becerra-Diaz M</style></custom2><misc3><style face="normal" font="default">10.12688/f1000research.11198.1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42137</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martin Alonso,A.</style></author><author><style face="normal" font="default"> Saglani,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Inflammation, Repair and Development Section, National Heart and Lung Institute, Imperial College London, London, United KingdomInflammation, Repair and Development Section, National Heart and Lung Institute, Imperial College London, London, United KingdomRespiratory Pediatrics, The Royal Brompton Hospital, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Mechanisms Mediating Pediatric Severe Asthma and Potential Novel Therapies</style></title><secondary-title><style face="normal" font="default">Front Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Pediatr</style></abbr-1></periodical><pages end="" start="154">154-</pages><volume><style face="normal" font="default">5</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway remodeling</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung growth</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Personalized medicine</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Repair</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> serum IgE levels</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Although a rare disease, severe therapy-resistant asthma in children is a cause of significant morbidity and results in utilization of approximately 50% of health-care resources for asthma. Improving control for children with severe asthma is, therefore, an urgent unmet clinical need. As a group, children with severe asthma have severe and multiple allergies, steroid resistant airway eosinophilia, and significant structural changes of the airway wall (airway remodeling). Omalizumab is currently the only add-on therapy that is licensed for use in children with severe asthma. However, limitations of its use include ineligibility for approximately one-third of patients because of serum IgE levels outside the recommended range and lack of clinical efficacy in a further one-third. Pediatric severe asthma is thus markedly heterogeneous, but our current understanding of the different mechanisms underpinning various phenotypes is very limited. We know that there are distinctions between the factors that drive pediatric and adult disease since pediatric disease develops in the context of a maturing immune system and during lung growth and development. This review summarizes the current data that give insight into the pathophysiology of pediatric severe asthma and will highlight potential targets for novel therapies. It is apparent that in order to identify novel treatments for pediatric severe asthma, the challenge of undertaking mechanistic studies using age appropriate experimental models and airway samples from children needs to be accepted to allow a targeted approach of personalized medicine to be achieved</style></abstract><notes><style face="normal" font="default">DA - 20170720IS - 2296-2360 (Print)IS - 2296-2360 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.3389/fped.2017.00154</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28725641">PM:28725641</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Pediatr\2017-5-154.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Pediatr\2017-5-154.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170720, Martin Alonso A</style></custom2><misc3><style face="normal" font="default">10.3389/fped.2017.00154</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42138</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guido,M.V.</style></author><author><style face="normal" font="default"> Jithpratuck,W.</style></author><author><style face="normal" font="default"> Parks,G.E.</style></author><author><style face="normal" font="default"> Krishnaswamy,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Wake Forest Baptist Medical Center, Winston Salem, NC, USA</style></auth-address><titles><title><style face="normal" font="default">Nafcillin-Induced Allergic Eosinophilic Cholestatic Hepatitis</style></title><secondary-title><style face="normal" font="default">Gastroenterology Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Gastroenterology Res</style></abbr-1></periodical><pages end="207" start="202">202-207</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotic allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Arthritis</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Enzymes</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> expansion</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glucocorticoids</style></keyword><keyword><style face="normal" font="default"> Hepatitis</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Jaundice</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Nafcillin</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Recovery</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">A 71-year-old female with no history of liver disease or antibiotic allergy developed jaundice with elevated liver enzymes and eosinophilia following treatment with nafcillin for septic arthritis. Further workup demonstrated hepatocellular dysfunction and liver biopsy showed expansion of portal tracts by lymphocytes and eosinophils consistent with a hypersensitivity reaction. Nafcillin and related antibiotics were withdrawn, and her symptoms resolved 3 months later. We searched PubMed using terms of "nafcillin cholestasis" and "nafcillin hepatitis", and a review of the literature showed other reports of nafcillin-induced hepatitis and cholestasis. Avoidance and on occasion the guarded use of glucocorticoids can lead to recovery from the insult. This case report shows that while rare, nafcillin can cause cholestatic hepatitis through a likely eosinophil-mediated hypersensitivity reaction. Further studies are needed to elucidate the mechanism of this reaction</style></abstract><notes><style face="normal" font="default">DA - 20170720IS - 1918-2805 (Print)IS - 1918-2805 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.14740/gr824w</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28725311">PM:28725311</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Gastroenterology Res\2017-10-202-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Gastroenterology Res\2017-10-202-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170720, Guido MV</style></custom2><misc3><style face="normal" font="default">10.14740/gr824w</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42139</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Philips,N.</style></author><author><style face="normal" font="default"> Samuel,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Inhibition of Interleukin-4 Signalling in the Treatment of Atopic Dermatitis and Allergic Asthma</style></title><secondary-title><style face="normal" font="default">Global J Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Global J Allergy</style></full-title></periodical><pages end="021" start="019">019-021</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">adaptive</style></keyword><keyword><style face="normal" font="default"> Adaptive immunity</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> Atopic diseases</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical symptom</style></keyword><keyword><style face="normal" font="default"> clinical symptoms</style></keyword><keyword><style face="normal" font="default"> Conjunctivitis</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IgE antibodies</style></keyword><keyword><style face="normal" font="default"> IgE antibody</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Interleukin-4</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Leukotrienes</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> Th2 Cells</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Atopic dermatitis and allergic asthma result from amplifi ed immune response to environmentalantigens, and allergic reactions from released IgE, histamine, leukotrienes and cytokines. Environmentalantigens immune cells, of innate and adaptive immunity, to stimulate interleukin-4 (IL-4) mediatedactivation of Th2 cells and subsequent isotype switching of B cells to produce IgE antibodies, responsiblefor the clinical manifestation of atopic diseases. The IL-4 receptor alpha chain (IL4Ra), which mediatesIL-4 signaling, is common to IL-4 and IL-13 receptors, with IL-13 being an associated cytokine in theallergic response. US Food and Drug Administration recently approved dupilumab, which blocks IL4Ra forthe treatment of moderate to severe atopic dermatitis. In controlled trials, dupilumab counteracted theallergic response and the clinical symptoms of dermatitis and asthma, and dupilumab was more effectivethan other available treatments. The primary safety concern of dupilumab is conjunctivitis and its longtermsafety, which is unknown.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.17352/2455-8141.000019</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.17352/2455-8141.000019</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Global J Allergy\2017-3-019-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Global J Allergy\2017-3-019-21.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Philips N</style></custom2><misc3><style face="normal" font="default">10.17352/2455-8141.000019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42140</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kaplan,A.P.</style></author><author><style face="normal" font="default"> Joseph,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425, USA.</style></auth-address><titles><title><style face="normal" font="default">Pathogenesis of Hereditary Angioedema: The Role of the Bradykinin-Forming Cascade</style></title><secondary-title><style face="normal" font="default">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="525" start="513">513-525</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">angioedema</style></keyword><keyword><style face="normal" font="default"> Bradykinin</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Kallikrein</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> South Carolina</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">Hereditary angioedema (HAE) is an autosomal-dominant disorder owing to mutations in the C1 inhibitor gene. Type I is characterized by a low C1 inhibitor protein level and diminished functional activity, whereas type II has a normal (or elevated) protein level but diminished function. When functional levels drop beyond 40% of normal, attacks of swelling are likely to occur due to overproduction of bradykinin. Angioedema can be peripheral, abdominal, or laryngeal. The typical duration of episodes is 3 days. Therapies include C1 inhibitor replacement for prophylaxis or acute therapy, whereas inhibition of kallikrein or blockade at the bradykinin receptor level can interrupt acute episodes of swelling</style></abstract><notes><style face="normal" font="default">DA - 20170708IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.iac.2017.04.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28687106">PM:28687106</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-513-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-513-25.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170708, Kaplan AP</style></custom2><misc3><style face="normal" font="default">10.1016/j.iac.2017.04.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42141</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Christiansen,S.C.</style></author><author><style face="normal" font="default"> Zuraw,B.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, University of California, 9500 Gilman Drive, Mailcode 0732, La Jolla, CA 92093, USA</style></auth-address><titles><title><style face="normal" font="default">Laboratory Approaches for Assessing Contact System Activation</style></title><secondary-title><style face="normal" font="default">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="539" start="527">527-539</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> subcutaneous</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">Hereditary angioedema (HAE) is a rare autosomal dominant disease clinically characterized by recurrent, often unpredictable attacks of subcutaneous and mucosal swelling. Acute episodes are debilitating, painful, disfiguring, and potentially fatal. HAE type I and type II result from a deficiency in the plasma level of functional C1 inhibitor. HAE with normal levels of C1 inhibitor has been recognized. There is evidence that contact activation underlies the recurrent attacks of swelling. This article reviews laboratory parameters to detect contact system activation and implications for diagnosis of HAE and other forms of bradykinin-mediated angioedema</style></abstract><notes><style face="normal" font="default">DA - 20170708IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.iac.2017.04.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28687107">PM:28687107</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-527-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-527-39.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170708, Christiansen SC</style></custom2><misc3><style face="normal" font="default">10.1016/j.iac.2017.04.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42142</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Otani,I.M.</style></author><author><style face="normal" font="default"> Banerji,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, UCSF Medical Center, 400 Parnassus Avenue, Box 0359, San Francisco, CA 94143, USA.</style></auth-address><titles><title><style face="normal" font="default">Acquired C1 Inhibitor Deficiency</style></title><secondary-title><style face="normal" font="default">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="511" start="497">497-511</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Androgens</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Autoimmunity</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Bradykinin</style></keyword><keyword><style face="normal" font="default"> C1 INH</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor deficiency</style></keyword><keyword><style face="normal" font="default"> C1-INH</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> C1Inh</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Ecallantide</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Icatibant</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Lymphoma</style></keyword><keyword><style face="normal" font="default"> Lymphoproliferative Disorders</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> San Francisco</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tranexamic Acid</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">Acquired angioedema due to C1-INH deficiency (C1-INH-AAE) can occur when there are acquired (not inherited) deficiencies of C1-INH. A quantitative or functional C1-INH deficiency with negative family history and low C1q is diagnostic of C1-INH-AAE. The most common conditions associated with C1-INH-AAE are autoimmunity and B-cell lymphoproliferative disorders. A diagnosis of C1-INH-AAE can precede a diagnosis of lymphoproliferative disease and confers an increased risk for developing non-Hodgkin lymphoma. Treatment focuses on symptom control with therapies that regulate bradykinin activity (C1-INH concentrate, icatibant, ecallantide, tranexamic acid, androgens) and treatment of any underlying conditions</style></abstract><notes><style face="normal" font="default">DA - 20170708IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.iac.2017.03.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28687105">PM:28687105</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-497-511.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-497-511.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170708, Otani IM</style></custom2><misc3><style face="normal" font="default">10.1016/j.iac.2017.03.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42143</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Busse,P.J.</style></author><author><style face="normal" font="default"> Smith,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Clinical Immunology, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029-6574, USA.</style></auth-address><titles><title><style face="normal" font="default">Histaminergic Angioedema</style></title><secondary-title><style face="normal" font="default">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="481" start="467">467-481</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Histaminergic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">Angioedema is frequently categorized into histamine- or bradykinin-mediated disease. It is critical to determine the underlying mediator of symptoms as it directs treatment. Histaminergic angioedema is the most frequent cause of angioedema. It is classified as either acute (lasting &lt;6 weeks) or chronic (symptoms >6 weeks). It is further classified into angioedema presenting with or without urticaria. Some patients with acute angioedema may have disease that becomes chronic. Mast cells and basophils are central to the underlying pathophysiology of histamine-mediated angioedema. The underlying treatments of histamine-mediated angioedema are antihistamines, corticosteroids, and epinephrine</style></abstract><notes><style face="normal" font="default">DA - 20170708IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.iac.2017.03.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28687103">PM:28687103</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-467-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-467-81.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170708, Busse PJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.iac.2017.03.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42144</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stone,C.,Jr.</style></author><author><style face="normal" font="default"> Brown,N.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, 1161 21st Avenue South T-1218, Medical Center North, Nashville, TN 37232-2650, USA</style></auth-address><titles><title><style face="normal" font="default">Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema</style></title><secondary-title><style face="normal" font="default">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="495" start="483">483-495</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Angiotensin converting enzyme inhibitors</style></keyword><keyword><style face="normal" font="default"> Angiotensin-Converting Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> Beta-lactam antibiotics</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Bradykinin</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cessation</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug-induced</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Enzyme Inhibitors</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Leukotrienes</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prostaglandin</style></keyword><keyword><style face="normal" font="default"> Prostaglandins</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Substance P</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">Nonsteroidal antiinflammatory agents, beta-lactam antibiotics, non-beta lactam antibiotics, and angiotensin-converting enzyme inhibitors are the most common classes of drugs that cause angioedema. Drug-induced angioedema is known to occur via mechanisms mediated by histamine, bradykinin, or leukotriene, and an understanding of these mechanisms is crucial in guiding therapeutic decisions. Nonallergic angioedema occurs in patients with genetic variants that affect metabolism or synthesis of bradykinin, substance P, prostaglandins, or leukotrienes, or when patients are taking drugs that have synergistic mechanisms. The mainstay in treatment of nonallergic drug-induced angioedema is cessation of the offending agents</style></abstract><notes><style face="normal" font="default">DA - 20170708IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.iac.2017.04.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28687104">PM:28687104</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-483-95.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-483-95.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170708, Stone C Jr</style></custom2><misc3><style face="normal" font="default">10.1016/j.iac.2017.04.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42145</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Katelaris,C.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunology and Allergy Unit, Department of Medicine, Campbelltown Hospital, Therry Road, Campbelltown, Sydney, New South Wales 2560, Australia.</style></auth-address><titles><title><style face="normal" font="default">Acute Management of Hereditary Angioedema Attacks</style></title><secondary-title><style face="normal" font="default">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="556" start="541">541-556</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Developing Countries</style></keyword><keyword><style face="normal" font="default"> Ecallantide</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> New South Wales</style></keyword><keyword><style face="normal" font="default"> North America</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> Recombinant</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Wales</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">Several treatment modalities have become available for management of acute hereditary angioedema (HAE) attacks in the last 15 years. Most are now available to patients in North America, Europe, United Kingdom, and Australia, but few options exist in developing countries. Preferred contemporary use of the treatments to be discussed is "on demand," because control remains with the patient and delays in treatment access avoided. Four treatments-plasma-derived C1 inhibitor concentrate, recombinant C1 inhibitor concentrate, ecallantide, and icatibant-are reviewed in this article. All have been shown to be superior to placebo and effective in the management of all HAE attacks</style></abstract><notes><style face="normal" font="default">DA - 20170708IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.iac.2017.04.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28687108">PM:28687108</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-541-56.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-541-56.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170708, Katelaris CH</style></custom2><misc3><style face="normal" font="default">10.1016/j.iac.2017.04.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42146</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Caballero,T.</style></author><author><style face="normal" font="default"> Prior,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Department, Hospital La Paz Institute for Health Research (IdiPaz), Paseo de la Castellana 261, Madrid 28046, Spain; CIBERER (U754), Allergy Department, Hospital La Paz Institute for Health Research (IdiPaz), Paseo de la Castellana 261, Madrid 28046, Spain. Electronic address: mteresa.caballero@idipaz.esAllergy Department, Hospital Universitario Severo Ochoa, Avenida de Orellana s/n, Leganes, Madrid 28911, Spain</style></auth-address><titles><title><style face="normal" font="default">Burden of Illness and Quality-of-Life Measures in Angioedema Conditions</style></title><secondary-title><style face="normal" font="default">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="616" start="597">597-616</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor deficiency</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Hereditary angioedema with normal C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Psychiatric disorder</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">Burden of illness studies and evaluation of health-related quality of life using validated questionnaires have become an important task in the comprehensive management of angioedema conditions, mainly angioedema associated with chronic spontaneous urticaria and hereditary angioedema caused by C1-inhibitor deficiency. A review of the principal tools and studies is presented. Both diseases present a higher proportion of psychiatric disorders, impair work and studies productivity, and produce high direct and indirect costs. These assessments also have been useful to evaluate the positive impact of new drugs and interventions. More studies are desirable, especially in other types of angioedema disorders, such as hereditary angioedema with normal C1 inhibitor</style></abstract><notes><style face="normal" font="default">DA - 20170708IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.iac.2017.04.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28687112">PM:28687112</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-597-616.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-597-616.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170708, Caballero T</style></custom2><misc3><style face="normal" font="default">10.1016/j.iac.2017.04.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42147</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lumry,W.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Internal Medicine/Allergy/Immunology Division, University of Texas Southwestern Medical School, Dallas, TX, USA</style></auth-address><titles><title><style face="normal" font="default">Pharmacoeconomics of Orphan Disease Treatment with a Focus on Hereditary Angioedema</style></title><secondary-title><style face="normal" font="default">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="628" start="617">617-628</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">angioedema</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pharmacoeconomics</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Texas</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">This article discusses orphan diseases, their prevalence, legislative incentives to encourage development of therapies, and the impact of treatment on health care payment systems. Specifically, the cost burden of hereditary angioedema on patients, health care systems, and society is reviewed. The impact of availability of and access to novel and specific therapies on morbidity, mortality, and overall burden of disease is explored. Changes in treatment paradigms to improve effect and reduce cost of treatment are presented</style></abstract><notes><style face="normal" font="default">DA - 20170708IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.iac.2017.03.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28687113">PM:28687113</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-617-28.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-617-28.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170708, Lumry WR</style></custom2><misc3><style face="normal" font="default">10.1016/j.iac.2017.03.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42148</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,M.</style></author><author><style face="normal" font="default"> Riedl,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Department of Medicine, Allergy &amp; Immunology, University of California San Diego, 8899 University City Lane, Suite 230, San Diego, CA 92122, USA.</style></auth-address><titles><title><style face="normal" font="default">Emerging Therapies in Hereditary Angioedema</style></title><secondary-title><style face="normal" font="default">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="595" start="585">585-595</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> California</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Solutions</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">Remarkable progress has been made in the treatment of bradykinin-mediated angioedema with the advent of multiple new therapies. Patients now have effective medications available for prophylaxis and treatment of acute attacks. However, hereditary angioedema is a burdensome disease that can lead to debilitating and dangerous angioedema episodes associated with significant costs for individuals and society. The burden of treatment must be addressed regarding medication administration difficulties, treatment complications, and adverse side effects. New therapies are being investigated and may offer solutions to these challenges. This article reviews the emerging therapeutic options for the treatment of HAE</style></abstract><notes><style face="normal" font="default">DA - 20170708IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.iac.2017.03.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28687111">PM:28687111</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-585-95.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-585-95.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170708, Chen M</style></custom2><misc3><style face="normal" font="default">10.1016/j.iac.2017.03.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42149</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Longhurst,H.</style></author><author><style face="normal" font="default"> Zinser,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology, Barts Health NHS Trust, Pathology and Pharmacy Building, 80 Newark Street, London E1 2HS, UK.</style></auth-address><titles><title><style face="normal" font="default">Prophylactic Therapy for Hereditary Angioedema</style></title><secondary-title><style face="normal" font="default">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="570" start="557">557-570</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Androgens</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Long-term prophylaxis</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tranexamic Acid</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">Long-term prophylaxis is needed in many patients with hereditary angioedema and poses many challenges. Attenuated androgens are effective in many but are limited by side effect profiles. There is less evidence for efficacy of tranexamic acid and progestagens; however, the small side effect profile makes tranexamic acid an option for prophylaxis in children and progestagens an option for women. C1 inhibitor is beneficial, but at present requires intravenous delivery and may need dose titration for maximum efficacy. Short-term prophylaxis should be considered for all procedures. New therapies are promising in overcoming many problems encountered with current options for long-term prophylaxis</style></abstract><notes><style face="normal" font="default">DA - 20170708IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.iac.2017.04.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28687109">PM:28687109</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-557-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-557-70.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170708, Longhurst H</style></custom2><misc3><style face="normal" font="default">10.1016/j.iac.2017.04.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42150</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Magerl,M.</style></author><author><style face="normal" font="default"> Germenis,A.E.</style></author><author><style face="normal" font="default"> Maas,C.</style></author><author><style face="normal" font="default"> Maurer,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Allergie-Centrum-Charite/ECARF, Charite - Universitatsmedizin Berlin, Chariteplatz 1, Berlin 10117, Germany.</style></auth-address><titles><title><style face="normal" font="default">Hereditary Angioedema with Normal C1 Inhibitor: Update on Evaluation and Treatment</style></title><secondary-title><style face="normal" font="default">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="584" start="571">571-584</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> C1 INH</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-INH</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> C1Inh</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> HAE</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Hereditary angioedema with normal C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> normal C1-INH</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">A new form of hereditary angioedema (HAE) was identified in the year 2000. Its clinical appearance resembles HAE types I and II, which are caused by mutations that result in a deficiency of C1 inhibitor (C1-INH). In patients with the new form of HAE, C1-INH plasma levels and function values are normal, so it's termed HAE with normal C1-INH (HAE-nC1). HAE-nC1, in a subgroup of patients, is thought to be caused by mutations that affect the F12 gene. The diagnosis of HAE-nC1 is based on history and clinical criteria. There are no licensed drugs with proven treatment effects for HAE-nC1</style></abstract><notes><style face="normal" font="default">DA - 20170708IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.iac.2017.04.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28687110">PM:28687110</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-571-84.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-571-84.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170708, Magerl M</style></custom2><misc3><style face="normal" font="default">10.1016/j.iac.2017.04.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42151</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gill,P.</style></author><author><style face="normal" font="default"> Betschel,S.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Clinical Immunology, St. Joseph's Hospital, Western University, 268 Grosvenor Street, London, ON N6A 4V2, Canada</style></auth-address><titles><title><style face="normal" font="default">The Clinical Evaluation of Angioedema</style></title><secondary-title><style face="normal" font="default">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="466" start="449">449-466</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">angioedema</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> London</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">The clinical evaluation of angioedema is reliant on obtaining a thorough patient and family history with an assessment of risk factors and presenting symptoms unique to each subtype. It is important to distinguish between angioedema with and without urticaria as a primary step in the evaluation; thereafter, laboratory parameters and investigations allow for subsequent stratification. There is a significant disease burden associated with angioedema and thus it is essential for health care practitioners to establish a prompt and accurate diagnosis, and a comprehensive care plan that addresses the patient's physical and mental well-being alike</style></abstract><notes><style face="normal" font="default">DA - 20170708IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.iac.2017.04.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28687102">PM:28687102</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-449-66.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-449-66.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170708, Gill P</style></custom2><misc3><style face="normal" font="default">10.1016/j.iac.2017.04.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42152</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Conti,P.</style></author><author><style face="normal" font="default"> Carinci,F.</style></author><author><style face="normal" font="default"> Lessiani,G.</style></author><author><style face="normal" font="default"> Spinas,E.</style></author><author><style face="normal" font="default"> Kritas,S.K.</style></author><author><style face="normal" font="default"> Ronconi,G.</style></author><author><style face="normal" font="default"> Caraffa,A.</style></author><author><style face="normal" font="default"> Theoharides,T.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunology Division, Postgraduate Medical School, University of Chieti-Pescara, Viale Unita dell'Italia 73, 66013, Chieti, Italy.</style></auth-address><titles><title><style face="normal" font="default">Potential therapeutic use of IL-37: a key suppressor of innate immunity and allergic immune responses mediated by mast cells</style></title><secondary-title><style face="normal" font="default">Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immunol Res</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> activation</style></keyword><keyword><style face="normal" font="default"> adaptive</style></keyword><keyword><style face="normal" font="default"> Adaptive immunity</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> anti-allergic activity</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Caspase 1</style></keyword><keyword><style face="normal" font="default"> caspase-1</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cysteine</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> IL-1</style></keyword><keyword><style face="normal" font="default"> IL-10</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate immunity</style></keyword><keyword><style face="normal" font="default"> Interleukin 1</style></keyword><keyword><style face="normal" font="default"> Interleukin-1</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Monocyte</style></keyword><keyword><style face="normal" font="default"> Monocytes</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Organ</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Plasma Cells</style></keyword><keyword><style face="normal" font="default"> Protease</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapeutic use</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="26" Month="7" Year="2017">2017/7/26</year></dates><abstract><style face="normal" font="default">The host response to either exogenous or endogenous insults produces a series of changes, characterized by alterations in immunological functions and generation of mediators called cytokines which include the interleukin-1 (IL-1) family members. IL-1 acts as a hormone mediating the host responses to infection and inflammation. Blocking inflammatory IL-1 family members can be effective against inflammatory disorders, including allergies. IL-37, (formerly IL-1 family member 7), emerges as an inhibitor of innate and adaptive immunity by reducing circulating and organ cytokine levels. IL-37, mainly expressed in dendritic cells, monocytes, and plasma cells after TIR ligand activation, inhibits inflammatory cytokines and augments the level of anti-inflammatory IL-10. IL-37 is involved in allergic reaction and its expression in dendritic cells causes tollerogenicity and inhibits inflammatory response. Mast cells (MCs) are ubiquitous in the body, reside in numerous mucosal tissues, and are mediators of allergic reaction, and innate and adaptive immunity. MCs are important regulators of cytokine generation in the course of inflammatory responses and allergy, and are implicated in the pathophysiology of allergic asthma. Cysteine protease caspase-1 activation leads to the cleavage of pro-form of IL-1 into active mature IL-1 which is present in stimulated and unstimulated inflammatory MCs. Inflammatory cytokine inhibition, along with the augmentation of anti-inflammatory IL-10 by IL-37, is certainly beneficial and improves the pathogenesis of allergic disorders. However, in these studies, the exact mechanism(s) of IL-37-induced anti-inflammatory and anti-allergic activity along with its side effect(s) remain to be determined</style></abstract><notes><style face="normal" font="default">DA - 20170727IS - 1559-0755 (Electronic)IS - 0257-277X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -CO - Greece -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s12026-017-8938-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28748328">PM:28748328</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Res\20170727-ContiP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Res\20170727-ContiP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170727, Conti P</style></custom2><misc3><style face="normal" font="default">10.1007/s12026-017-8938-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42153</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kumaran,M.S.</style></author><author><style face="normal" font="default"> Arora,A.K.</style></author><author><style face="normal" font="default"> Parsad,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, IndiaDepartment of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, IndiaDepartment of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India</style></auth-address><titles><title><style face="normal" font="default">Cholinergic urticaria: Clinicoepidemiological paradigms from a tertiary care center in North India</style></title><secondary-title><style face="normal" font="default">Indian J Dermatol Venereol Leprol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Indian J Dermatol Venereol Leprol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Dermatology</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 0973-3922 (Electronic)IS - 0378-6323 (Linking)LA - engPT - LetterCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/ijdvl.IJDVL_735_16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731013">PM:28731013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Dermatol Venereol Leprol\20170721-KumaranMS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Dermatol Venereol Leprol\20170721-KumaranMS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170721, Kumaran MS</style></custom2><misc3><style face="normal" font="default">10.4103/ijdvl.IJDVL_735_16</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42154</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Srivastava,P.R.</style></author><author><style face="normal" font="default"> Vaggu,A.K.</style></author><author><style face="normal" font="default"> Kasoju,S.</style></author><author><style face="normal" font="default"> Khare,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Krishna Institute of Medical Sciences, Secunderabad, Telangana, India</style></auth-address><titles><title><style face="normal" font="default">Palmoplantar aquagenic urticaria: A case report</style></title><secondary-title><style face="normal" font="default">Indian J Dermatol Venereol Leprol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Indian J Dermatol Venereol Leprol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Case Report</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword></keywords><dates><year Day="20" Month="7" Year="2017">2017/7/20</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 0973-3922 (Electronic)IS - 0378-6323 (Linking)LA - engPT - LetterCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/ijdvl.IJDVL_577_16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731018">PM:28731018</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Dermatol Venereol Leprol\20170721-SrivastavaPR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Dermatol Venereol Leprol\20170721-SrivastavaPR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170721, Srivastava PR</style></custom2><misc3><style face="normal" font="default">10.4103/ijdvl.IJDVL_577_16</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42155</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chakraborty,S.</style></author><author><style face="normal" font="default"> Kar,N.</style></author><author><style face="normal" font="default"> Kumari,L.</style></author><author><style face="normal" font="default"> De,A.</style></author><author><style face="normal" font="default"> Bera,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Nanomedicine, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, India</style></auth-address><titles><title><style face="normal" font="default">Inhibitory effect of a new orally active cedrol-loaded nanostructured lipid carrier on compound 48/80-induced mast cell degranulation and anaphylactic shock in mice</style></title><secondary-title><style face="normal" font="default">Int J Nanomedicine</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Nanomedicine</style></abbr-1></periodical><pages end="4868" start="4849">4849-4868</pages><volume><style face="normal" font="default">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="default"> anaphylactoid reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal model</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> Anti-allergic effect</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Ca2+</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Cell Degranulation</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cromolyn Sodium</style></keyword><keyword><style face="normal" font="default"> degranulation</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Glucocorticoids</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Histamine Release</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lipid</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast cell degranulation</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Platelet Activating Factor</style></keyword><keyword><style face="normal" font="default"> Prednisolone</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Selectivity</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> vehicle</style></keyword><keyword><style face="normal" font="default"> Vitamin E</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Type I hypersensitivity is an allergic reaction characterized by the overactivity of the immune system provoked by normally harmless substances. Glucocorticoids, anti-histamines, or mast cell stabilizers are the choices of treatment for type I hypersensitivity. Even though these drugs have the anti-allergic effect, they can have several side effects in prolong use. Cedrol is the main bioactive compound of Cedrus atlantica with anti-tumor, anti-oxidative, and platelet-activating factor inhibiting properties. METHODS: In this study, the preparation and anti-anaphylactic effect of cedrol-loaded nanostructured lipid carriers (NLCs) were evaluated. NLCs were prepared using Compritol(R) 888 ATO and triolein as lipid phase and vitamin E d-alpha-tocopherylpolyethyleneglycol 1000 succinate, soya lecithin, and sodium deoxycholate as nanoparticle stabilizers. RESULTS: The average diameter of cedrol-NLCs (CR-NLCs) was 71.2 nm (NLC-C1) and 91.93 nm (NLC-C2). The particle had negative zeta potential values of -31.9 mV (NLC-C1) and -44.5 mV (NLC-C2). Type I anaphylactoid reaction in the animal model is significantly reduced by cedrol and cedrol-NLC. This in vivo activity of cedrol resulted that cedrol suppressed compound 48/80-induced peritoneal mast cell degranulation and histamine release from mast cells. Furthermore, compound 48/80-evoked Ca2+ uptake into mast cells was reduced in a dose-dependent manner by cedrol and cedrol-NLC. Studies confirmed that the inhibition of type I anaphylactoid response in vivo in mice and compound 48/80-induced mast cell activation in vitro are greatly enhanced by the loading of cedrol into the NLCs. The safety of cedrol and CR-NLC was evaluated as selectivity index (SI) with prednisolone and cromolyn sodium as positive control. SI of CR-NLC-C2 was found to be 11.5-fold greater than both prednisolone and cromolyn sodium. CONCLUSION: Administration of CR-NLC 24 hours before the onset of anaphylaxis can prevent an anaphylactoid reaction. NLCs could be a promising vehicle for the oral delivery of cedrol to protect anaphylactic reactions</style></abstract><notes><style face="normal" font="default">DA - 20170726IS - 1178-2013 (Electronic)IS - 1176-9114 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.2147/IJN.S132114</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28744120">PM:28744120</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Nanomedicine\2017-12-4849-68.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Nanomedicine\2017-12-4849-68.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170726, Chakraborty S</style></custom2><misc3><style face="normal" font="default">10.2147/IJN.S132114</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42156</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kiec-Swierczynska,M.</style></author><author><style face="normal" font="default"> Swierczynska-Machura,D.</style></author><author><style face="normal" font="default"> Chomiczewska-Skora,D.</style></author><author><style face="normal" font="default"> Krecisz,B.</style></author><author><style face="normal" font="default"> Walusiak-Skorupa,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Nofer Institute of Occupational Medicine, Lodz, Poland (Department of Occupational Diseases and Environmental Health).</style></auth-address><titles><title><style face="normal" font="default">Screening survey of ocular, nasal, respiratory and skin symptoms in manicurists in Poland</style></title><secondary-title><style face="normal" font="default">Int J Occup Med Environ Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Occup Med Environ Health</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acrylate</style></keyword><keyword><style face="normal" font="default"> Acrylates</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> aeroallergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> Atopic diseases</style></keyword><keyword><style face="normal" font="default"> Baseline series</style></keyword><keyword><style face="normal" font="default"> Beauty</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Gloves</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand eczema</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritation</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mucosal</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Nickel allergy</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational disease</style></keyword><keyword><style face="normal" font="default"> Occupational Diseases</style></keyword><keyword><style face="normal" font="default"> Occupational Medicine</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Ocular</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patch-tests</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin Care</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="12" Month="7" Year="2017">2017/7/12</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Manicurists are exposed to various chemicals in nail and skin care products and may develop ocular, nasal, respiratory or skin adverse reactions to them. To investigate the occurrence of ocular, nasal, respiratory and skin problems among manicurists and to identify their causal factors, particularly allergic etiology and occupational origin. MATERIAL AND METHODS: Manicurists employed in beauty salons in the central region of Poland were invited to fill in the questionnaire and undergo medical examination, skin prick tests with common aeroallergens, patch tests with European Baseline Series and (Meth)Acrylates Series-Nails and spirometry. RESULTS: In the questionnaire adverse nasal symptoms were reported by 70%, ocular - by 58%, respiratory - by 42%, hand eczema - by 43% of manicurists. In the medical interview, the frequency of those complaints was lower: nasal ones - 41%, ocular - 24%, cough - 18%, hand skin dryness - 20%, hand eczema - 6%. Cough and hand skin dryness occurred significantly more frequently than in the case of controls. Contact allergy was found for 41% of manicurists and 35% of controls. The prevalence of nickel sensitization was high in both groups (38% and 27%, respectively). Only 3 manicurists reacted to (meth)acrylates. The frequency of atopic diseases was similar in compared groups. Irritant nasal and respiratory reactions were significantly more prevalent among manicurists (nasal - 18% vs. 2%, p &lt; 0.01; respiratory - 18% vs. 1%, p &lt; 0.001). Work-related nasal irritant reactions were finally diagnosed for 19%, ocular ones - for 13%, respiratory - for 18% and within hand skin - for 23% of manicurists. CONCLUSIONS: The frequency of workattributed irritant mucosal and skin symptoms among manicurists is high. Exposure to acrylates is an important source of mucosal irritant reactions while occlusive gloves cause irritation of hand skin. The prevalence of nickel allergy among Polish females is high. Int J Occup Med Environ Health 2017;30(6)</style></abstract><notes><style face="normal" font="default">DA - 20170724IS - 1896-494X (Electronic)IS - 1232-1087 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.13075/ijomeh.1896.00961</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28736450">PM:28736450</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Occup Med Environ Health\20170724-KiecSwierczynskaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Occup Med Environ Health\20170724-KiecSwierczynskaM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170724, Kiec-Swierczynska M</style></custom2><misc3><style face="normal" font="default">10.13075/ijomeh.1896.00961</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42157</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,M.B.</style></author><author><style face="normal" font="default"> Kim,J.H.</style></author><author><style face="normal" font="default"> Lee,K.H.</style></author><author><style face="normal" font="default"> Hong,S.C.</style></author><author><style face="normal" font="default"> Lee,H.S.</style></author><author><style face="normal" font="default"> Kang,J.W.</style></author></authors></contributors><titles><title><style face="normal" font="default">The association between the parenting stress of the mother and the incidence of allergic rhinitis in their children</style></title><secondary-title><style face="normal" font="default">Int J Pediatr Otorhinolaryngol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Pediatr Otorhinolaryngol</style></abbr-1></periodical><pages end="40" start="37">37-40</pages><volume><style face="normal" font="default">101</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Counseling</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Income</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> Parenting</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><isbn><style face="normal" font="default">0165-5876</style></isbn><abstract><style face="normal" font="default">AbstractObjectives The prevalence of allergic rhinitis and the social burden related to the management of allergic rhinitis have persistently increased. There are many studies investigating the association between the allergic diseases of children and the stress of their parent. However, the relationship between parenting stress and the incidence of allergic rhinitis among children requires further investigation. We aimed to investigate the significance of parenting stress for mothers with children treated for allergic rhinitis. Methods The mothers of 250 children in the second and third grade of elementary school were involved in this study. The Parenting Stress Index-Short Form (PSI-SF) was used to measure parenting stress. Additionally, the monthly household income, treatment history for allergic diseases (atopic dermatitis, asthma, and allergic rhinitis) during the past 12 months, and maternal education status were investigated using the questionnaire. Results Parenting stress index score was significantly higher among the mothers of children treated for allergic rhinitis (76.41-á-¦-á9.35) compared with the parents of children without treatment history for allergic rhinitis (70.06-á-¦-á13.74). Nonetheless, there were no significant differences between the cases of children with atopic dermatitis and those with asthma. We analyzed the association between allergic rhinitis and parenting stress adjusted for the monthly household income, and maternal education status, and showed that a treatment history of allergic rhinitis was significantly associated with parenting stress (coefficient 7.477, 95% interval 1.703</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô13.252; p-á=-á0.011). Conclusion Treatment of the children for allergic rhinitis significantly affects the parenting stress of their mother. We recommend that mothers with children with allergic rhinitis should receive appropriate counseling about parenting stress</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.ijporl.2017.07.023</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.ijporl.2017.07.023</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Pediatr Otorhinolaryngol\2017-101-37-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Pediatr Otorhinolaryngol\2017-101-37-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Kim MB</style></custom2><misc3><style face="normal" font="default">10.1016/j.ijporl.2017.07.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42158</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yu,J.</style></author><author><style face="normal" font="default"> Wan,K.</style></author><author><style face="normal" font="default"> Sun,X.</style></author></authors></contributors><auth-address><style face="normal" font="default">Key Laboratory of Drug Targeting and Novel Drug Delivery System, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, PR China</style></auth-address><titles><title><style face="normal" font="default">Improved transdermal delivery of morin efficiently inhibits allergic contact dermatitis</style></title><secondary-title><style face="normal" font="default">Int J Pharm</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Pharm</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cornea</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Gel</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Natural products</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Permeability</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> stratum corneum</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> T lymphocyte</style></keyword><keyword><style face="normal" font="default"> T lymphocytes</style></keyword><keyword><style face="normal" font="default"> T-lymphocyte</style></keyword><keyword><style face="normal" font="default"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="21" Month="7" Year="2017">2017/7/21</year></dates><abstract><style face="normal" font="default">The skin is an important site for local or systemic application of drugs. However, most of the drugs have poor permeability through the skin's outermost layer, stratum corneum. The aim of this study was to develop a method to enable transdermal delivery of morin (3, 5, 7, 2, 4-pentahydroxyflavone), which is a poorly water-soluble drug with anti-inflammatory properties obtained from natural products. Morin phospholipid complex (MPC) was prepared and then loaded in Carbopol 940 hydrogel (MPC-gel), which can significantly increase the transdermal flux of morin based on the in vitro skin penetration data presented in this paper. To further enhance permeation, different compositions of penetration enhancers were dispersed in the gel and screened. After applied onto the mouse skin, MPC-gel showed apparent reduction of ear swelling in 2, 4-dinitrofluorobenzene (DNFB)-induced allergic contact dermatitis (ACD). Further determination of cytokines levels, histopathological analysis and T lymphocytes proliferation indicates that the MPC-gel is potent enough to reduce the inflammatory response mediated by the DNFB in ACD mice model. Collectively, we anticipate that such an approach may provide a new treatment for topical ACD</style></abstract><notes><style face="normal" font="default">DA - 20170725IS - 1873-3476 (Electronic)IS - 0378-5173 (Linking)LA - engPT - Journal ArticleCO - China -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.ijpharm.2017.07.062</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28739503">PM:28739503</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Pharm\20170725-YuJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Pharm\20170725-YuJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170725, Yu J</style></custom2><misc3><style face="normal" font="default">10.1016/j.ijpharm.2017.07.062</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42159</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jannesar,M.</style></author><author><style face="normal" font="default"> Sharif Shoushtari,M.</style></author><author><style face="normal" font="default"> Majd,A.</style></author><author><style face="normal" font="default"> Pourpak,Z.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="default">Bee Pollen Flavonoids as a Therapeutic Agent in Allergic and Immunological Disorders</style></title><secondary-title><style face="normal" font="default">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Iran J Allergy Asthma Immunol</style></abbr-1></periodical><pages end="182" start="171">171-182</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aging</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anemia</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bee pollen</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Cold</style></keyword><keyword><style face="normal" font="default"> Colitis</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Flavonoids</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Nutrients</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Phytotherapy</style></keyword><keyword><style face="normal" font="default"> Plant</style></keyword><keyword><style face="normal" font="default"> Plants</style></keyword><keyword><style face="normal" font="default"> Pollen</style></keyword><keyword><style face="normal" font="default"> Pollens</style></keyword><keyword><style face="normal" font="default"> premature</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Ulcer</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">Bee pollen grains, as the male reproductive part of seed-bearing plants contain considerable concentrations of various phytochemicals and nutrients. Since antiquity, people throughout the world used pollens to cure colds, flu, ulcers, premature aging, anemia and colitis. It is now well-documented that some bee pollen secondary metabolites (e.g. flavonoid) may have positive health effects. In recent years, the flavonoids have attracted much interest because of their wide range of biological properties and their beneficial effects on human health. The current review, points out potential therapeutic effects of bee pollen flavonoids as one of the main bee pollen bioactive compounds in allergic and immunological diseases. Due to the fact that some types of flavonoid components in bee pollen have anti-allergic, anti-oxidant and anti-inflammatory properties, bee pollen flavonoids can be excellent candidates for future studies including phytotherapy, molecular pharmacology and substitutes for chemicals used in treating allergic and immunological disorders</style></abstract><notes><style face="normal" font="default">DA - 20170722IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28732430">PM:28732430</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2017-16-171-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2017-16-171-82.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170722, Jannesar M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42160</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Isik,S.</style></author><author><style face="normal" font="default"> Uzuner,N.</style></author><author><style face="normal" font="default"> Karaman,M.</style></author><author><style face="normal" font="default"> Karaman,O.</style></author><author><style face="normal" font="default"> Kiray,M.</style></author><author><style face="normal" font="default"> Kozanoglu,I.</style></author><author><style face="normal" font="default"> Alper Bagriyanik,H.</style></author><author><style face="normal" font="default"> Arikan-Ayyildiz,Z.</style></author><author><style face="normal" font="default"> Kartal Yandim,M.</style></author><author><style face="normal" font="default"> Baran,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric Allergy and Immunology, Dokuz Eylul University, Izmir, Turkey</style></auth-address><titles><title><style face="normal" font="default">Effects of Intraperitoneal Injection of Allogeneic Bone Marrow-derived Mesenchymal Stem Cells on Bronchiolitis Obliterans in Mice Model</style></title><secondary-title><style face="normal" font="default">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Iran J Allergy Asthma Immunol</style></abbr-1></periodical><pages end="218" start="205">205-218</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bronchiolitis</style></keyword><keyword><style face="normal" font="default"> Bronchiolitis Obliterans</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage Fluid</style></keyword><keyword><style face="normal" font="default"> CD4</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Collagen</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> Histopathology</style></keyword><keyword><style face="normal" font="default"> IFN-gamma</style></keyword><keyword><style face="normal" font="default"> IL-2</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Lung Diseases</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Microscopy</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> murine model</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> Staining</style></keyword><keyword><style face="normal" font="default"> Stem Cells</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">Bone marrow-derived mesenchymal stem cells (BMSCs) can ameliorate a variety of lung diseases such as asthma, lung fibrosis, and acute lung injury by its anti-inflammatory and immunmodulatory effects. In this study, we developed a mouse model of bronchiolitis obliterans (BO) and evaluated the effects of the intraperitoneal administration of BMSCs on lung histopathology and cytokine levels. 25 BALB/c mice were divided into four groups; control group (Group I), BO developed and 1x106 BMSCs-injected group (Group II), non-BO, 1x106 BMSCs-injected group (Group III), and BO developed and saline-injected group (Group IV). Histological and immunohistochemical findings of the lung tissue and the migration of BMSCs to the lung were evaluated using light and confocal microscopy techniques. Confocal microscopy evaluations showed that there was no noteworthy amount of BMSCs in the lung tissue of group III while significant amount of BMSCs was detected in group II. Wall thicknesses of terminal bronchiole and periterminal bronchiolar collagen deposition were significantly lower in group II compared to the group IV (p&lt;0.05). Furthermore, according to the immunohistochemical staining results, CD3, CD4, CD8, CD20, CD68 and neutrophil elastase positive immune cells of group II were stained more positive than group IV cells (p&lt;0.05). IFN-gamma IL-2 and TNF-alpha levels in bronchoalveolar lavage fluid (BALF) were significantly lower in group II compared to group IV (p&lt;0.05). The findings of this study indicate that intraperitoneally administered BMSCs have potent effects on histopatological changes of the lung tissue and cytokine levels in the murine model of BO</style></abstract><notes><style face="normal" font="default">DA - 20170722IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28732434">PM:28732434</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2017-16-205-18.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2017-16-205-18.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170722, Isik S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42161</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mazloomzadeh,S.</style></author><author><style face="normal" font="default"> Bakhshi,N.</style></author><author><style face="normal" font="default"> Ahmadiafshar,A.</style></author><author><style face="normal" font="default"> Gholami,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Social Determinants of Health Research Center, Zanjan University of Medical Sciences, Zanjan, Iran</style></auth-address><titles><title><style face="normal" font="default">The Effect of Salt Space on Clinical Findings and Peak Expiratory Flow in Children with Mild to Moderate Asthma: A Randomized Crossover Trial</style></title><secondary-title><style face="normal" font="default">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Iran J Allergy Asthma Immunol</style></abbr-1></periodical><pages end="204" start="198">198-204</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Peak expiratory flow</style></keyword><keyword><style face="normal" font="default"> Peak Expiratory Flow Rate</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> rescue medication</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">The asthma treatment and control might be associated with significant burden on family and community' thus exploring other therapeutic plans could be desirable. The aim of this study was to investigate the effect of salt space on clinical findings and peak expiratory flow rate among children with asthma. In this randomized crossover trial, 34 patients aged 6-14 years old with mild to moderate asthma were selected and randomly divided into two groups. The first group went through a period of salt therapy by staying in the salt room for one hour, three times a week for 3 consecutive weeks and then was under observation for three weeks. This process was reversed for the second group (three weeks under observation followed by salt therapy). The wash-out period was one week. During the study, the morning and evening peak expiratory flow (PEF), the frequency of coughing, wheezing, dyspnea and use of rescue medications were measured. Salt therapy had a significant effect on raising the morning and evening PEF in the second week in both groups (p=0.028 and p=0.032, respectively). However, there was no significant effect on PEF variabilities' cough' wheezing, dyspnea, and the frequency of rescue medication (p>0.05). No side effect was observed during salt therapy. This study showed the significant effect of salt therapy on PEF rate of the patients in the second week. However, further studies with different frequency and time of salt therapy on respiratory disorders are recommended</style></abstract><notes><style face="normal" font="default">DA - 20170722IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28732433">PM:28732433</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2017-16-198-204.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2017-16-198-204.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170722, Mazloomzadeh S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42162</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhong,Y.</style></author><author><style face="normal" font="default"> Liu,X.</style></author><author><style face="normal" font="default"> Li,Y.</style></author><author><style face="normal" font="default"> Liang,H.</style></author><author><style face="normal" font="default"> Li,J.</style></author><author><style face="normal" font="default"> Chen,C.</style></author><author><style face="normal" font="default"> Li,K.</style></author><author><style face="normal" font="default"> Liu,X.</style></author><author><style face="normal" font="default"> Zhong,S.</style></author><author><style face="normal" font="default"> Li,L.</style></author><author><style face="normal" font="default"> Wang,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effects of Acupuncture on 1-chloro-2,4-dinitrochlorobenzene Induced Allergic Contact Dermatitis in Mice</style></title><secondary-title><style face="normal" font="default">J Acupunct Meridian Stud</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Acupunct Meridian Stud</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acupuncture</style></keyword><keyword><style face="normal" font="default"> Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> alternative therapy</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> DNCB</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> NF-+¦B</style></keyword><keyword><style face="normal" font="default"> Phosphorylation</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> serum IgE levels</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Topical corticosteroids</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2005-2901</style></isbn><abstract><style face="normal" font="default">Abstract Allergic contact dermatitis (ACD) is a chronic inflammatory skin disease. Topical corticosteroids are the first-line therapy for ACD although their significant adverse effects. Acupuncture has been widely used in the treatment of various skin diseases, but its underlying mechanism remains unrevealed. In this study, we investigated the characteristics of acupuncture treatment based on effectiveness and mechanism. BALB/c mice received 1-chloro-2,4-dinitrobenzene (DNCB) application to build AD like model. Results showed that acupuncture treatment was a effective method in inhibiting inflammatory conditions, serum IgE levels, and expression of proinflammatory cytokineTh2 (IL-4, IL-6), Th2 (IL-1+¦,TNF-+¦) mRNA compared with DNCB group. Acupuncture treatment also inhibited NF-+¦B p65, phosphorylation of I+¦B+¦, and phosphorylation of occludin proteins expression. In addition, acupuncture treatment could improve EGF expression both in mRNA and protein levels. These results suggest that acupuncture, as an alternative therapy treatment for its no significant side effects, was effective in alleviating allergic contact dermatitis by reducing pro-inflammatory cytokines and changing proteins expression</style></abstract><notes><style face="normal" font="default">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="ArialUnicodeMS">10.1016/j.jams.2017.06.004</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jams.2017.06.004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Acupunct Meridian Stud\20170720-ZhongY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Acupunct Meridian Stud\20170720-ZhongY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170720, Zhong Y</style></custom2><misc3><style face="normal" font="ArialUnicodeMS">10.1016/j.jams.2017.06.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42163</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mommert,S.</style></author><author><style face="normal" font="default"> Gregor,K.</style></author><author><style face="normal" font="default"> Rossbach,K.</style></author><author><style face="normal" font="default"> Schaper,K.</style></author><author><style face="normal" font="default"> Witte,T.</style></author><author><style face="normal" font="default"> Gutzmer,R.</style></author><author><style face="normal" font="default"> Werfel,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany</style></auth-address><titles><title><style face="normal" font="default">Histamine H2 receptor stimulation up-regulates Th2 chemokine CCL17 production in human M2a macrophages</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Monocyte</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword></keywords><dates><year Day="17" Month="7" Year="2017">2017/7/17</year></dates><abstract><style face="normal" font="default">Stimulation of the histamine H2 receptor significantly increased CCL17 production in human monocyte derived M2a macrophages. These results may be helpful to identify novel therapeutical target structures in diseases driven at least in part by histamine</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28728999">PM:28728999</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170721-MommertS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170721-MommertS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170721, Mommert S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42164</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mahlaoui,N.</style></author><author><style face="normal" font="default"> Jais,J.P.</style></author><author><style face="normal" font="default"> Brosselin,P.</style></author><author><style face="normal" font="default"> Mignot,C.</style></author><author><style face="normal" font="default"> Beaurain,B.</style></author><author><style face="normal" font="default"> Brito,C.</style></author><author><style face="normal" font="default"> Costes,L.</style></author><author><style face="normal" font="default"> Courteille,V.</style></author><author><style face="normal" font="default"> de Vergnes,N.</style></author><author><style face="normal" font="default"> Alcais,A.</style></author><author><style face="normal" font="default"> Fischer,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">French National Reference Center for Primary Immune Deficiencies (CEREDIH), Necker-Enfants Malades University Hospital, Assistance Publique-Hopitaux de Paris, Paris, France</style></auth-address><titles><title><style face="normal" font="default">Prevalence of Primary Immunodeficiencies in France is underestimated</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">deficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="18" Month="7" Year="2017">2017/7/18</year></dates><abstract><style face="normal" font="default">Prevalence of PID has not been precisely determined. A field epidemiology study shows that prevalence of PIDs in registries is under-estimated and that minimal prevalence is 11 per 100,000 inhabitants instead of 8 per 100,000 inhabitants</style></abstract><notes><style face="normal" font="default">DA - 20170722IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28732644">PM:28732644</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170722-MahlaouiN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170722-MahlaouiN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170722, Mahlaoui N</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42165</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Silkoff,P.E.</style></author><author><style face="normal" font="default"> Flavin,S.</style></author><author><style face="normal" font="default"> Gordon,R.</style></author><author><style face="normal" font="default"> Loza,M.J.</style></author><author><style face="normal" font="default"> Sterk,P.J.</style></author><author><style face="normal" font="default"> Lutter,R.</style></author><author><style face="normal" font="default"> Diamant,Z.</style></author><author><style face="normal" font="default"> Turner,R.B.</style></author><author><style face="normal" font="default"> Lipworth,B.J.</style></author><author><style face="normal" font="default"> Proud,D.</style></author><author><style face="normal" font="default"> Singh,D.</style></author><author><style face="normal" font="default"> Eich,A.</style></author><author><style face="normal" font="default"> Backer,V.</style></author><author><style face="normal" font="default"> Gern,J.E.</style></author><author><style face="normal" font="default"> Herzmann,C.</style></author><author><style face="normal" font="default"> Halperin,S.A.</style></author><author><style face="normal" font="default"> Mensinga,T.T.</style></author><author><style face="normal" font="default"> Del Vecchio,A.M.</style></author><author><style face="normal" font="default"> Branigan,P.</style></author><author><style face="normal" font="default"> San Mateo,L.</style></author><author><style face="normal" font="default"> Baribaud,F.</style></author><author><style face="normal" font="default"> Barnathan,E.S.</style></author><author><style face="normal" font="default"> Johnston,S.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Janssen Research &amp; Development LLC, 1400 McKean Rd, Spring House, PA, 19477, USA.</style></auth-address><titles><title><style face="normal" font="default">TLR3 Blockade in Rhinovirus-Induced Experimental Asthma Exacerbations: A Randomized Controlled Study</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Antiviral Agents</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Cold</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="default"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> North America</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> Protection</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Rhinoviruses</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> symptom scores</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral Load</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: Human rhinoviruses (HRV) commonly precipitate asthma exacerbations. TLR3, an innate pattern-recognition receptor, is triggered by HRV driving inflammation that may worsen asthma. OBJECTIVE: To evaluate an inhibitory monoclonal antibody to TLR3, CNTO3157, on experimental HRV-16 inoculation in healthy and asthmatic subjects. METHODS: In this double-blind multicenter randomized parallel-group study in North America and Europe, healthy and mild-moderate stable asthmatic subjects received single or multiple doses of CNTO 3157 or placebo, respectively, and were then inoculated with HRV-16 within 72 hours. All subjects were monitored for respiratory symptoms, lung function, and nasal viral load. The primary endpoint was maximal decline in forced expired volume in 1 second (FEV1) during 10-days post-inoculation. RESULTS: In asthmatic subjects (N=63), CNTO3157 provided no protection against FEV1 decline (LS mean [SE]: CNTO3157 (n=30) = -7.08 [8.15] % and placebo (n=25) = -5.98 [8.56] %), or symptoms post- inoculation. In healthy subjects (N=12), CNTO3157 versus placebo significantly attenuated upper (p=0.03) and lower (p=0.02) airway symptom scores, with area-under-the-curve increases of 9.1(15.1) vs 34.9 (17.6) and 13.0 (18.4) vs 50.4 (25.9) for the CNTO3157 group (n=8) and placebo group (n=4), respectively, after inoculation. All of the severe and three of the four non-serious asthma exacerbations occurred on CNTO3157. CONCLUSION: In summary, CNTO3157 was ineffective in attenuating the impact of HRV-16 challenge on lung function, asthma control, and symptoms in asthma, but suppressed cold symptoms in healthy subjects. Other approaches, including blockade of multiple pathways, or antiviral agents, need to be sought for this high unmet medical need</style></abstract><notes><style face="normal" font="default">DA - 20170723IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Netherlands -CO - United Kingdom -CO - Canada -CO - Germany -CO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28734844">PM:28734844</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170723-SilkoffPE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170723-SilkoffPE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170723, Silkoff PE</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42166</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yadlapati,R.</style></author><author><style face="normal" font="default"> Kahrilas,P.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA</style></auth-address><titles><title><style face="normal" font="default">The "Dangers" of Chronic Proton Pump Inhibitor Use</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Chicago</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Gastroenterology</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> proton pump inhibitor</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="17" Month="7" Year="2017">2017/7/17</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28729001">PM:28729001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170721-YadlapatiR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170721-YadlapatiR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170721, Yadlapati R</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42167</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Versluys,B.</style></author><author><style face="normal" font="default"> Bierings,M.</style></author><author><style face="normal" font="default"> Murk,J.L.</style></author><author><style face="normal" font="default"> Wolfs,T.</style></author><author><style face="normal" font="default"> Lindemans,C.</style></author><author><style face="normal" font="default"> Ent,K.V.</style></author><author><style face="normal" font="default"> Boelens,J.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Blood and Marrow Transplantation Program, Department of Pediatrics, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: a.b.versluys@umcutrecht.nlBlood and Marrow Transplantation Program, Department of Pediatrics, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of virology and microbiology, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of pediatric infectious diseases, department of Pediatrics, University Medical Center Utrecht, Utrecht, The NetherlandsBlood and Marrow Transplantation Program, Department of Pediatrics, University Medical Center Utrecht, Utrecht, The NetherlandsDepartment of Pediatric Pulmonology, University Medical Center Utrecht, Utrecht, The NetherlandsBlood and Marrow Transplantation Program, Department of Pediatrics, University Medical Center Utrecht, Utrecht, The Netherlands; U-DANCE Laboratory of Translational Immunology, University Medical Center Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Respiratory Virus prior to Hematopoietic Cell Transplantation is associated with allo-immune mediated lung syndromes</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> BAL</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Bronchiolitis</style></keyword><keyword><style face="normal" font="default"> Bronchiolitis Obliterans</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> COX</style></keyword><keyword><style face="normal" font="default"> Detection</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Pneumonia</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Rhinovirus</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> virology</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="14" Month="7" Year="2017">2017/7/14</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allo-immune mediated lung syndromes (allo-LS) are life-threatening complications after hematopoietic cell transplantation (HCT). Respiratory virus (RV) has been suggested to play a role in the pathogenesis. OBJECTIVE: We studied the relation between RV-DNA/RNA detection in upper/lower airway before HCT and the occurrence of allo-LS. METHODS: We retrospectively analyzed all HCT recipients between 2004 and 2014, in whom Real-Time PCR for RV was done from Nasal-Pharyngeal-Aspirates (NPA) and Broncho-Alveolar- Lavage (BAL) before HCT. Main outcome of interest was allo-LS, defined as Idiopathic Pneumonia Syndrome or Bronchiolitis Obliterans Syndrome. Other outcomes were overall survival and treatment related mortality (TRM). We used Cox proportional hazard models, logistic regression models and Fine-Gray competing risk regression for analyses. RESULTS: 179 children (median age 6.8 years) were included. RV was found in 61% (41% in BAL/NPA, 20% in NPA-only). Rhinovirus was the most frequently detected RV (42%). Allo-LS occurred in 13 %. RV-positivity in BAL was a predictor for allo-LS (HR 3.8, 95% CI 1.4 - 10.7; p=0.01), while RV-positivity in NPA-only was not. No other predictors were found. Acute Graft-Versus-Host-Disease grade 2-4, related with steroid treatment, shows a trend towards a protective effect (OR 0.16, 95%CI 0.0-1.3; p=0.08). Allo-LS significantly increased TRM (52 +/- 10% in allo-LS, 20 +/- 4% in non-allo-LS, p= 0.007). CONCLUSIONS: These results show that pre-HCT BAL RV-positivity was a predictor for allo-LS. Screening for RV before HCT may identify patients at risk for allo-LS. This may have implications for prevention and treatment and may subsequently influence the outcomes of HCT</style></abstract><notes><style face="normal" font="default">DA - 20170718IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.03.055</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28716387">PM:28716387</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170718-VersluysB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170718-VersluysB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170718, Versluys B</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.03.055</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42168</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,X.</style></author><author><style face="normal" font="default"> Agerbo,E.</style></author><author><style face="normal" font="default"> Schlunssen,V.</style></author><author><style face="normal" font="default"> Wright,R.J.</style></author><author><style face="normal" font="default"> Li,J.</style></author><author><style face="normal" font="default"> Munk-Olsen,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">The National Center for Register-based Research, Aarhus University, Aarhus, Denmark.</style></auth-address><titles><title><style face="normal" font="default">Maternal asthma severity and control during pregnancy and risk of offspring asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">area</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Increased prevalence</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> linkage</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Perinatal</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="27" Month="6" Year="2017">2017/6/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Severe and uncontrolled asthma during pregnancy has been linked to several unfavorable perinatal outcomes. However, current knowledge on the association between the severity and control of maternal asthma and offspring asthma is sparse. OBJECTIVE: We sought to investigate the extent to which offspring asthma is influenced by maternal asthma severity and control during pregnancy. METHODS: We performed a prospective population-based cohort study. Using linkage of Danish national registers, we constructed a cohort of 675,379 singletons, of which 15,014 children were born to asthmatic mothers. Among them, 7,188 children were born to mothers with active asthma during pregnancy. We categorized mothers with active asthma into 4 groups based on dispensed antiasthma prescriptions and on use of medical services: mild controlled, mild uncontrolled, moderate-to-severe controlled, and moderate-to-severe uncontrolled asthma. The outcomes were offspring early-onset transient, early-onset persistent, and late-onset asthma. We estimated prevalence ratios (PRs) of each phenotype of asthma using a log-binomial model with 95% CIs. RESULTS: Higher prevalence of early-onset persistent asthma was observed among children of asthmatic mothers with mild uncontrolled (PR, 1.19; 95% CI, 1.05-1.35), moderate-to-severe controlled (PR, 1.33; 95% CI, 1.09-1.63), and moderate-to-severe uncontrolled asthma (PR, 1.37; 95% CI, 1.17-1.61) compared with those of mothers with mild controlled asthma. A borderline increased prevalence of early-onset transient asthma was observed among children of mothers with uncontrolled asthma. CONCLUSION: Maternal uncontrolled asthma increases the risk of early-onset persistent and transient asthma. If replicated, this could suggest that maintaining asthma control in pregnancy is an area for possible prevention of specific phenotypes of offspring asthma</style></abstract><notes><style face="normal" font="default">DA - 20170717IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28712803">PM:28712803</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170717-LiuX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170717-LiuX.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170717, Liu X</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42169</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Anderson,W.C.,III</style></author><author><style face="normal" font="default"> Apter,A.</style></author><author><style face="normal" font="default"> Dutmer,C.M.</style></author><author><style face="normal" font="default"> Searing,D.A.</style></author><author><style face="normal" font="default"> Szefler,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy &amp; Immunology Section, Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, CO</style></auth-address><titles><title><style face="normal" font="default">Advances in Asthma 2016: Designing Individualized Approaches to Management</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Air quality</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic sensitization</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Climate</style></keyword><keyword><style face="normal" font="default"> Colorado</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Dust</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> environmental tobacco smoke</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic Association</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> microbiome</style></keyword><keyword><style face="normal" font="default"> Mite</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Smoke</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Tobacco</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral infection</style></keyword><keyword><style face="normal" font="default"> Viral infections</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="default">In this years Advances in Asthma review we discuss viral infections in asthma and potential therapeutic agents, the microbiome, novel genetic associations with asthma, air quality and climate effects on asthma, exposures during development and long term sequelae of childhood asthma, patient centered outcome research, and precision medicine. In addition, we discuss application of biomarkers to precision medicine, and new information on asthma medications. New evidence indicates that rhinovirus-triggered asthma exacerbations become more severe as the degree of sensitization to dust mite and mouse increase. The two biggest drivers of asthma severity were an allergy pathway starting with allergic sensitization and an environmental tobacco smoke pathway. In addition, allergic sensitization and blood eosinophils can be used to select medications for management of early asthma in young children. These current findings, among others covered in this review, represent significant steps towards addressing rapidly advancing areas of knowledge that have implications for asthma management</style></abstract><notes><style face="normal" font="default">DA - 20170715IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28709967">PM:28709967</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170715-AndersonWCIII.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170715-AndersonWCIII.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170715, Anderson WC III</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42170</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Qiu,W.</style></author><author><style face="normal" font="default"> Guo,F.</style></author><author><style face="normal" font="default"> Glass,K.</style></author><author><style face="normal" font="default"> Guo,C.Y.</style></author><author><style face="normal" font="default"> Quackenbush,J.</style></author><author><style face="normal" font="default"> Zhou,X.</style></author><author><style face="normal" font="default"> Tantisira,K.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA</style></auth-address><titles><title><style face="normal" font="default">Differential Connectivity of Gene Regulatory Networks Distinguishes Corticosteroid Response in Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> cAMP</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Gene Expression</style></keyword><keyword><style face="normal" font="default"> Gene Regulatory Networks</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetic factors</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> transcription factor</style></keyword><keyword><style face="normal" font="default"> Transcription Factors</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword></keywords><dates><year Day="20" Month="7" Year="2017">2017/7/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: Variations in drug response between individuals have prevented us from achieving high drug efficacy in treating many complex diseases, including asthma. Genetics plays an important role in accounting for such inter-individual variations in drug response. However, systematic approaches for addressing how genetic factors and their regulators determine variations in drug response in asthma treatment are lacking. METHODS: We used PANDA (Passing Attributes between Networks for Data Assimilations) to construct the gene regulatory networks associated with good responders and poor responders to inhaled corticosteroids based on a subset of 145 Caucasian asthmatic children who participated in the Childhood Asthma Management Cohort (CAMP). PANDA utilizes gene expression profiles and published relationships among genes, transcription factors (TFs), and proteins to construct the directed networks of TFs and genes. We assessed the differential connectivity between the gene regulatory network of good responders vs. that of poor responders. RESULTS: When compared to poor responders, the network of good responders has differential connectivity and distinct ontologies (e.g., pro-apoptosis enriched in network of good responders and anti-apoptosis enriched in network of poor responders). Many of the key hubs identified in conjunction with clinical response are also cellular response hubs. Functional validation demonstrated abrogation of differences in corticosteroid treated cell viability following siRNA knockdown of two TFs and differential downstream expression between good-responders and poor-responders. CONCLUSIONS: We have identified and validated multiple transcription factors influencing asthma treatment response. Our results show that differential connectivity analysis can provide new insights into the heterogeneity of drug treatment effects</style></abstract><notes><style face="normal" font="default">DA - 20170724IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.052</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28736268">PM:28736268</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170724-QiuW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170724-QiuW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170724, Qiu W</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.052</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42171</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Papadopoulos,N.G.</style></author><author><style face="normal" font="default"> Megremis,S.</style></author><author><style face="normal" font="default"> Kitsioulis,N.A.</style></author><author><style face="normal" font="default"> Vangelatou,O.</style></author><author><style face="normal" font="default"> West,P.</style></author><author><style face="normal" font="default"> Xepapadaki,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Infection, Immunity &amp; Respiratory Medicine, The University of Manchester, Manchester, UK</style></auth-address><titles><title><style face="normal" font="default">Promising approaches for treatment and prevention of viral respiratory illnesses</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Burden</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Policy</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immunisation</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> Immunomodulatory drugs</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Influenza</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> REACH</style></keyword><keyword><style face="normal" font="default"> respiratory infection</style></keyword><keyword><style face="normal" font="default"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="default"> Respiratory viruses</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinoviruses</style></keyword><keyword><style face="normal" font="default"> RSV</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> subtypes</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> transmission</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> vaccine</style></keyword><keyword><style face="normal" font="default"> Vaccines</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> Viruses</style></keyword></keywords><dates><year Day="21" Month="7" Year="2017">2017/7/21</year></dates><abstract><style face="normal" font="default">Viral respiratory infections are the most common human ailments, leading to enormous health and economic burden. Hundreds of virus species and subtypes have been associated with these conditions, with influenza viruses (IFV), respiratory syncytial virus (RSV) and the rhinoviruses (RV) being the most frequent and with the highest burden. When considering prevention or treatment of viral respiratory infections, potential targets include the causative pathogens themselves but also the immune response, disease transmission or even just the symptoms. Strategies targeting all these aspects are concurrently developing and several novel and promising approaches are emerging. In this perspective, we overview the entire range of options and highlight some of the most promising approaches, including new antivirals, symptomatic or immunomodulatory drugs, the re-emergence of natural remedies, as well as vaccines and public health policies towards prevention. Wide scale prevention through immunisation appears to be within reach for RSV and promising for IFV, while additional effort is needed in regard to RV, as well as other respiratory viruses</style></abstract><notes><style face="normal" font="default">DA - 20170725IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Greece -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.07.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28739285">PM:28739285</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170725-PapadopoulosNG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170725-PapadopoulosNG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170725, Papadopoulos NG</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.07.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42172</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guerra,S.</style></author><author><style face="normal" font="default"> Melen,E.</style></author><author><style face="normal" font="default"> Sunyer,J.</style></author><author><style face="normal" font="default"> Xu,C.J.</style></author><author><style face="normal" font="default"> Lavi,I.</style></author><author><style face="normal" font="default"> Benet,M.</style></author><author><style face="normal" font="default"> Bustamante,M.</style></author><author><style face="normal" font="default"> Carsin,A.E.</style></author><author><style face="normal" font="default"> Dobano,C.</style></author><author><style face="normal" font="default"> Guxens,M.</style></author><author><style face="normal" font="default"> Tischer,C.</style></author><author><style face="normal" font="default"> Vrijheid,M.</style></author><author><style face="normal" font="default"> Kull,I.</style></author><author><style face="normal" font="default"> Bergstrom,A.</style></author><author><style face="normal" font="default"> Kumar,A.</style></author><author><style face="normal" font="default"> Soderhall,C.</style></author><author><style face="normal" font="default"> Gehring,U.</style></author><author><style face="normal" font="default"> Dijkstra,D.J.</style></author><author><style face="normal" font="default"> van der Blies,P.</style></author><author><style face="normal" font="default"> Wickman,M.</style></author><author><style face="normal" font="default"> Bousquet,J.</style></author><author><style face="normal" font="default"> Postma,D.S.</style></author><author><style face="normal" font="default"> Anto,J.M.</style></author><author><style face="normal" font="default"> Koppelman,G.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">ISGlobal, Center for Research in Environmental Epidemiology (CREAL), Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default">Genetic and epigenetic regulation of YKL-40 in childhood</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Alleles</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> birth cohort</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> early childhood</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Methylation</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="21" Month="7" Year="2017">2017/7/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: Circulating levels of the chitinase-like protein YKL-40 are influenced by genetic variation in its encoding gene (CHI3L1) and are increased in several diseases, including asthma. Epigenetic regulation of circulating YKL-40 early in life is unknown. OBJECTIVE: To determine (1) whether methylation levels at CHI3L1 CpG sites mediate the association of CHI3L1 single nucleotide polymorphisms (SNPs) with YKL-40 levels in the blood; and (2) whether these biomarkers (CHI3L1 SNPs, methylation profiles, and YKL-40 levels) are associated with asthma in early childhood. METHODS: We used data from up to 2405 participants from the INMA, BAMSE, and PIAMA birth cohorts. Associations between 68 CHI3L1 SNPs, methylation levels at 14 CHI3L1 CpG sites in whole blood DNA, and circulating YKL-40 levels at 4 years of age were tested using correlation analysis, multivariable regression, and mediation analysis. Each of these biomarkers was also tested for association with asthma at 4 years of age using multivariable logistic regression. RESULTS: YKL-40 levels were significantly associated with seven SNPs and with methylation at five CpG sites. Consistent associations between these seven SNPs (particularly rs10399931 and rs4950928) and five CpG sites were observed. Alleles linked to lower YKL-40 levels were associated with higher methylation levels. Participants with high YKL-40 levels (defined as the highest YKL-40 tertile) had increased odds for asthma as compared with subjects with low YKL-40 levels [meta-analyzed adjusted odds ratio (adjOR): 1.90, 1.08-3.36]. In contrast, neither SNPs nor methylation levels at CpG sites in CHI3L1 were associated with asthma. CONCLUSIONS: The effects of CHI3L1 genetic variation on circulating YKL-40 are partly mediated by methylation profiles. In our study, YKL-40 levels, but not CHI3L1 SNPs or methylation levels, were associated with childhood asthma</style></abstract><notes><style face="normal" font="default">DA - 20170725IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Sweden -CO - United States -CO - Netherlands -CO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28739286">PM:28739286</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170725-GuerraS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170725-GuerraS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170725, Guerra S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.030</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42173</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Burbank,A.J.</style></author><author><style face="normal" font="default"> Duran,C.G.</style></author><author><style face="normal" font="default"> Pan,Y.</style></author><author><style face="normal" font="default"> Burns,P.</style></author><author><style face="normal" font="default"> Jones,S.</style></author><author><style face="normal" font="default"> Jiang,Q.</style></author><author><style face="normal" font="default"> Yang,C.</style></author><author><style face="normal" font="default"> Jenkins,S.</style></author><author><style face="normal" font="default"> Wells,H.</style></author><author><style face="normal" font="default"> Alexis,N.</style></author><author><style face="normal" font="default"> Kesimer,M.</style></author><author><style face="normal" font="default"> Bennett,W.D.</style></author><author><style face="normal" font="default"> Zhou,H.</style></author><author><style face="normal" font="default"> Peden,D.B.</style></author><author><style face="normal" font="default"> Hernandez,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Environmental Medicine, Asthma and Lung Biology, University of North Carolina, Chapel Hill, NC</style></auth-address><titles><title><style face="normal" font="default">Gamma tocopherol-enriched supplement reduces sputum eosinophilia and endotoxin-induced sputum neutrophilia in volunteers with asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> airway response</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal model</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> antioxidant</style></keyword><keyword><style face="normal" font="default"> Arm</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Biology</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> endotoxin</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> isoform</style></keyword><keyword><style face="normal" font="default"> LPS</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Mucins</style></keyword><keyword><style face="normal" font="default"> Mucociliary Clearance</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> North Carolina</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> sputum eosinophil</style></keyword><keyword><style face="normal" font="default"> Sputum eosinophilia</style></keyword><keyword><style face="normal" font="default"> Supplements</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vitamin E</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="7" Year="2017">2017/7/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: We and others have shown that the gamma tocopherol (gammaT) isoform of vitamin E has multiple anti-inflammatory and antioxidant actions and that gammaT supplementation reduces eosinophilic and endotoxin (LPS)-induced neutrophilic airway inflammation in animal models and healthy human volunteers. OBJECTIVE: To determine if gammaT supplementation reduces eosinophilic airway inflammation and acute neutrophilic response to inhaled LPS challenge in volunteers with asthma. METHODS: Participants with mild asthma were enrolled in a double-blinded, placebo controlled crossover study to assess the effect of 1200 mg of gammaT daily for 14 days on sputum eosinophils, mucins and cytokines. We also assessed the effect on acute inflammatory response to inhaled LPS challenge following gammaT treatment, focusing on changes in sputum neutrophilia, mucins and cytokines. Mucociliary clearance was measured using gamma scintigraphy. RESULTS: Fifteen subjects with mild asthma completed both arms of the study. Compared to placebo, gammaT notably reduced pre-LPS challenge sputum eosinophils and mucins, including MUC5AC, and reduced LPS-induced airway neutrophil recruitment 6 and 24-hours after challenge. Mucociliary clearance was slowed 4-hours post-challenge in the placebo group but not in the gammaT treatment group. Total sputum mucins (but not MUC5AC) were reduced at 24-hours post-challenge during gammaT treatment compared to placebo. CONCLUSION: gammaT supplementation for 14 days reduced inflammatory features of asthma, including sputum eosinophils and mucins, as well as acute airway response to inhaled LPS challenge when compared to placebo. Larger scale clinical trials are needed to assess the efficacy of gammaT supplements as a complementary or steroid-sparing treatment for asthma</style></abstract><notes><style face="normal" font="default">DA - 20170724IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28736267">PM:28736267</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170724-BurbankAJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170724-BurbankAJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170724, Burbank AJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42174</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">O'Sullivan,J.A.</style></author><author><style face="normal" font="default"> Carroll,D.J.</style></author><author><style face="normal" font="default"> Cao,Y.</style></author><author><style face="normal" font="default"> Salicru,A.N.</style></author><author><style face="normal" font="default"> Bochner,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy-Immunology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA</style></auth-address><titles><title><style face="normal" font="default">Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> basophil</style></keyword><keyword><style face="normal" font="default"> Basophils</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cell Death</style></keyword><keyword><style face="normal" font="default"> Cell Line</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endocytosis</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Leukemia</style></keyword><keyword><style face="normal" font="default"> Ligands</style></keyword><keyword><style face="normal" font="default"> Lipid</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Microscopy</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Tyrosine</style></keyword><keyword><style face="normal" font="default"> tyrosine kinase</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: Sialic acid-binding immunoglobulin-like lectin (Siglec)-8 is a cell-surface protein expressed selectively on human eosinophils, mast cells, and basophils, making it an ideal target for the treatment of diseases involving these cell types. However, the effective delivery of therapeutic agents to these cells requires an understanding of the dynamics of Siglec-8 surface expression. OBJECTIVE: To determine whether Siglec-8 is endocytosed in human eosinophils and malignant mast cells, identify mechanisms underlying its endocytosis, and demonstrate whether a toxin can be targeted to Siglec-8-bearing cells to kill these cells. METHODS: Siglec-8 surface dynamics were examined by flow cytometry using peripheral blood eosinophils, mast cell lines, and Siglec-8-transduced cells in the presence of inhibitors targeting components of endocytic pathways. Siglec-8 intracellular trafficking was followed by confocal microscopy. The ribosome-inhibiting protein saporin was conjugated to a Siglec-8-specific antibody to examine targeting of an agent to these cells through Siglec-8 endocytosis. RESULTS: Siglec-8 endocytosis required actin rearrangement, tyrosine kinase and PKC activities, and both clathrin and lipid rafts. Internalized Siglec-8 localized to the lysosomal compartment. Maximal endocytosis in Siglec-8-transduced HEK293T cells required an intact immunoreceptor tyrosine-based inhibitory motif. Siglec-8 was also shuttled to the surface via a distinct pathway. Sialidase treatment of eosinophils revealed that Siglec-8 is partially masked by sialylated cis ligands. Targeting saporin to Siglec-8 consistently caused extensive cell death in eosinophils and the human mast cell leukemia cell line HMC-1.2. CONCLUSION: Therapeutic payloads can be targeted selectively to eosinophils and malignant mast cells by exploiting this endocytic pathway</style></abstract><notes><style face="normal" font="default">DA - 20170723IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28734845">PM:28734845</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170723-OSullivanJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170723-OSullivanJA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170723, O'Sullivan JA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42175</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,Q.</style></author></authors></contributors><titles><title><style face="normal" font="default">The Utilization of Needle-Free Acupuncture and Chinese Traditional Medicine Theory to Cure Two Patients Suffering from Different Types of Chronic Urticaria</style></title><secondary-title><style face="normal" font="default">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Ther</style></full-title></periodical><pages end="" start="249">249-</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Acupuncture</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.4172/2155-6121.1000249</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000249</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Ther\2017-8-249.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Ther\2017-8-249.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Chen Q</style></custom2><misc3><style face="normal" font="default">10.4172/2155-6121.1000249</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42176</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Melo dos Santos,V.</style></author><author><style face="normal" font="default"> Machado,H.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Antibiotic Allergy: A Clinical Review</style></title><secondary-title><style face="normal" font="default">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Ther</style></full-title></periodical><pages end="" start="248">248-</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotic allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic test</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> Drug provocation test</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> immediate reactions</style></keyword><keyword><style face="normal" font="default"> Immunochemistry</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> In vitro tests</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Labeling</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> non-immediate reactions</style></keyword><keyword><style face="normal" font="default"> nonimmediate</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Introduction: Antibiotics are commonly associated with hypersensitivity reactions. These can be expressed through clinical manifestations that range from mild symptoms to severe life-threating reactions. Nevertheless, these are often mistaken with adverse events. Incorrect labeling off a patient as allergic, leads to increase in costs and morbidity in the health care setting.Objectives: Review currently available information on evaluation, diagnosis and treatment of allergic antibiotic reactions.Methods: A search was conducted in the PubMed, filtering results to articles published in the last ten years, in English, in adults and with full texts available. Out of the eight hundred and twenty-six results, seventy-three were selected.Results: Diagnosis of allergic events requires a detailed anamnesis. Confirmation of the diagnosis is influenced by the clinical features and the type of reaction, immediate or nonimmediate. The first can be evaluated with skin tests and drug provocation tests. The latter are studied with delayed-reading skin tests and drug provocation tests. Management of these patients should follow avoidance and application of an alternative tolerated drug. However, if the drug in question is indispensable for the treatment of the patient, then desensitization can be tried.Discussion: Clinical history is a fundamental component in the management of these patients. Skin tests are less well validated to antibiotics other than ß-lactam. In vitro tests have not been fully validated in large samples of subjects. Desensitization has been validated for patients with ß-lactam immediate reactions, but further investigation is required for non-immediate reactions, as well as, for non ß-lactam antimicrobials.Conclusion: Management of antimicrobial hypersensitivity follows specific considerations in function of the type of allergic reaction and antibiotic class. Further investigation regarding immunochemistry and validation of diagnostic tests for non ß-lactam antibiotics is required.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.4172/2155-6121.1000248</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000248</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Ther\2017-8-248.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Ther\2017-8-248.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Melo dos Santos V</style></custom2><misc3><style face="normal" font="default">10.4172/2155-6121.1000248</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42177</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yalcin,A.D.</style></author><author><style face="normal" font="default"> Goney,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Asthma and Smoking</style></title><secondary-title><style face="normal" font="default">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Ther</style></full-title></periodical><pages end="" start="e120">e120-</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.4172/2155-6121.1000e120</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000e120</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Ther\2017-8-e120.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Ther\2017-8-e120.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Yalcin AD</style></custom2><misc3><style face="normal" font="default">10.4172/2155-6121.1000e120</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42178</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Minhajat,R.</style></author><author><style face="normal" font="default"> Djaharuddin,I.</style></author><author><style face="normal" font="default"> Halim,R.</style></author><author><style face="normal" font="default"> Fachruddin Benyamin,A.</style></author><author><style face="normal" font="default"> Bakri,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Drugs Hypersensitivity Reaction in Patient with Human Immunodeficiency Virus (HIV) Infection</style></title><secondary-title><style face="normal" font="default">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Ther</style></full-title></periodical><pages end="" start="252">252-</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Acupuncture</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Antituberculosis drugs</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Differential diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> dysregulation</style></keyword><keyword><style face="normal" font="default"> Hiv</style></keyword><keyword><style face="normal" font="default"> HIV infection</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human immunodeficiency virus</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Indonesia</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pneumonia</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Tuberculosis</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">A case of male, 34 years old with a diagnosis of immunodeficiency syndrome resulting from HIV infection with suspected pneumonia in the differential diagnosis of pulmonary tuberculosis relapse, in the course of the disease, patients experienced hypersensitivity reactions to some antibiotics and antituberculosis drugs. Hypersensitivity reactions were exaggerated by immune response to an allergen in a normal immune system. In this case, we found the drug hypersensitivity reactions in patients with immunodeficiency. Until now, the exact underlying mechanism is not fully known but may be due to multifactorial and the dysregulation of the immune system due to HIV infection.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Indonesia -</style></notes><work-type><style face="normal" font="default">10.4172/2155-6121.1000252</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000252</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Ther\2017-8-252.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Ther\2017-8-252.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Minhajat R</style></custom2><misc3><style face="normal" font="default">10.4172/2155-6121.1000252</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42179</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Balo-Banga,J.M.</style></author><author><style face="normal" font="default"> Schweitzer,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">In Vitro Diagnosis of Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs (NSAID) Comparison of Two Methods</style></title><secondary-title><style face="normal" font="default">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Ther</style></full-title></periodical><pages end="" start="255">255-</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy workup</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> anaphylactic reaction</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical phenotypes</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> COX</style></keyword><keyword><style face="normal" font="default"> COX-1</style></keyword><keyword><style face="normal" font="default"> COX-2</style></keyword><keyword><style face="normal" font="default"> cross-intolerance</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Diagnostic tool</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Formulation</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> HSA</style></keyword><keyword><style face="normal" font="default"> Hungary</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immune reaction</style></keyword><keyword><style face="normal" font="default"> Immunoassay</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> Isoenzymes</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drug</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> NSAID</style></keyword><keyword><style face="normal" font="default"> NSAIDs</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> PBMCs</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Specific IgE</style></keyword><keyword><style face="normal" font="default"> Standardization</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Objective: Current concept distinguishes between cross intolerance (non-immune) and single or multiple hypersensitivity based (immune) adverse reactions of non-steroidal anti-inflammatory drugs (NSAID) due to their potential to inhibit cyclooxygenase (COX) isoenzymes (COX-1, COX-2). Recently we described a rapid IL-6 release assay using blood mononuclear cells of patients with various clinical forms of drug hypersensitivity. Here we present data of a comprehensive analysis if the IL-6 release test and the classical IgE immuno-assay for their sensitivity in cases with adverse reactions to NSAIDs grouped according to the new clinical classification.Methods: Total and specific serum IgE against 9 different HSA coupled-NSAIDs were determined by manual ELISA tests (55 cases) and compared to drug-specific release from preformed IL-6 pool of PBMCs of patients sensitized to the same NSAIDs after short (20') incubation of 4 standardized concentrations (51 cases and 9 controls) and IL-6 measurement from their cell free supernatants including positive and negative intraassay controls.Results: The ratio of cross intolerant to specific hypersensitive (HS) cases was higher in the IgE group (and total IgE too,) than in the IL-6 release tested ones. There was no difference, however, in the overall ratio of early and accelerated plus late onset adverse events based on individual histories. Nine NSAIDs were tested in both groups which represented all major COX-1 inhibitors. The positivity of validated test results was double within the IL-6 tested group (65.4% vs. 36.9%). In some cases non-drug components of NSAID formulations were responsible for the observed (mainly) anaphylactic reactions. Positive results in both groups were scattered amongst cross intolerant and single to multiple hypersensitive (HS) subgroups. To our knowledge no comprehensive analysis had been performed before either on clinical phenotypes dependent IgE immunoassays or on NSAID-induced "early" Tcell activation after those specified adverse events.Conclusion: Specific HS and multiple non cross-reactive NSAID sensitizations exceeded non- immune reactions in both in vitro tested groups. Some intolerant patients revealed detectable ASA antibodies of IgE type. Preformed IL-6 release by PBMC was more sensitive than specific IgE immunoassays as an in vitro diagnostic tool. The results indicate that checking of non-drug components should be considered in allergy workups. ASA in vivo provocations need further standardization.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Hungary -</style></notes><work-type><style face="normal" font="default">10.4172/2155-6121.1000255</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000255</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Ther\2017-8-255.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Ther\2017-8-255.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Balo-Banga JM</style></custom2><misc3><style face="normal" font="default">10.4172/2155-6121.1000255</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42180</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mizuyoshi,T.</style></author><author><style face="normal" font="default"> Asano,M.</style></author><author><style face="normal" font="default"> Furuta,A.</style></author><author><style face="normal" font="default"> Asano,K.</style></author><author><style face="normal" font="default"> Kobayashi,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Influence of Histamine H1 Receptor Antagonists on Thioredoxin Production In vitro and In vivo</style></title><secondary-title><style face="normal" font="default">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Ther</style></full-title></periodical><pages end="" start="257">257-</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Anti-inflammatory effects</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cetirizine</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Enzyme</style></keyword><keyword><style face="normal" font="default"> Fexofenadine</style></keyword><keyword><style face="normal" font="default"> H1 receptor</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> histamine H1 receptor</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pollen</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> secretion</style></keyword><keyword><style face="normal" font="default"> Thioredoxin</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Thioredoxin (TRX), a 12-kDa oxidoreductase enzyme, is well known to be a redox-active protein that regulates reactive oxidative metabolism. TRX is also accepted to be a protein with anti-inflammatory effects and reported to attenuate the development of allergic airway inflammatory diseases such as allergic rhinitis (AR) and asthma. Although histamine H1 receptor antagonists are frequently used for the treatment of AR, the influence of the agents on TRX production is not well understood. In the present study, we examined the influence of fexofenadine (FEX), cetirizine (CT), and levocetirizine (LCT), which are classified into histamine H1 receptor antagonists, on TRX production in vitro and in vivo.Methods: Macrophages derived from THP-1 cells (1 × 105 cells/ml) were cultured with 50 µM H2O2 in combination with/without the agents for 24 h. Nasal secretions were obtained from patients with Japanese cedar pollen-sensitized rhinitis, who were treated with FEX or LCT for four weeks during pollen season. TRX contents in both culture supernatants and nasal secretions were examined by ELISA.Results: Addition of FEX, CT and LCT into macrophage cultures increased TRX levels in supernatants. The minimum concentration of the agents that caused significant increase was 0.3 µM for FEX, 0.4 µM for CT and LCT. Treatment of patients with FEX and LCT also caused increase in TRX levels in nasal secretions along with attenuation of clinical symptoms.Conclusion: Histamine H1 receptor antagonists may increase the ability of macrophages to produce TRX, and results in favorable modification of clinical conditions of AR.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="default">10.4172/2155-6121.1000257</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000257</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Ther\2017-8-257.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Ther\2017-8-257.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Mizuyoshi T</style></custom2><misc3><style face="normal" font="default">10.4172/2155-6121.1000257</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42181</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Asano,M.</style></author><author><style face="normal" font="default"> Mizuyoshi,T.</style></author><author><style face="normal" font="default"> Ishikawa,S.</style></author><author><style face="normal" font="default"> Asano,K.</style></author><author><style face="normal" font="default"> Kobayashi,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Suppressive Activity of Histamine H1 Receptor Antagonists, Desloratadine and Levocetirizine, on the Production of Periostin from Nasal Epithelial Cells In vitro</style></title><secondary-title><style face="normal" font="default">J Allergy Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Ther</style></full-title></periodical><pages end="" start="253">253-</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cetirizine</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> desloratadine</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="default"> H1 receptor</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> histamine H1 receptor</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> human nasal epithelial cells</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Loratadine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal epithelial cell</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Periostin</style></keyword><keyword><style face="normal" font="default"> persistence</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> suppression</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> transcription factor</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Periostin, a 90-kDa endogenous extracellular matrix protein, is well known to be involved in the development and persistence of allergic rhinitis. Although histamine H1 receptor antagonists are recommended as first choice of agents in the treatment of allergic rhinitis, the influence of the agents on periostin production is not well understood. The present study was undertaken to examine the influence of histamine H1 receptor antagonists on periostin production from nasal epithelial cells after IL-4 stimulation in vitro.Methods: Human nasal epithelial cells (HNEpC) at a concentration of 1 × 105 cells/ml were stimulated with 10.0 ng/ml IL-4 in combination with either desloratadine (DLT), loratadine (LT), levocetirizine (LCT) or cetirizine (CT). After 48 h, culture supernatants were collected and assayed for periostin levels by ELISA. The influence of LCT on transcription factor, STAT6, activation and periostin mRNA expression were also examined by ELISA and real-time RT-PCR, respectively.Results: Treatment of cells with DLT, LT, LCT and CT suppressed the ability of HNEpC to produce periostin in response to IL-4 stimulation in dose-dependent manner. The minimum concentration that caused significant suppression is 0.01 mM for DLT, 0.05 mM for LT, 0.05 mM for LCT and 0.1 mM for CT. Treatment of HNEpC with LCT at more than 0.05 mM also suppressed STAT6 activation and periostin mRNA expression induced by IL-4 stimulation.Conclusion: The present results strongly suggest that histamine H1 receptor antagonists favorably modify the clinical conditions of allergic rhinitis through the suppression of periostin production from nasal epithelial cells after IL-4 stimulation.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="default">10.4172/2155-6121.1000253</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4172/2155-6121.1000253</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Ther\2017-8-253.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Ther\2017-8-253.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Asano M</style></custom2><misc3><style face="normal" font="default">10.4172/2155-6121.1000253</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42182</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chalmers,B.P.</style></author><author><style face="normal" font="default"> Melugin,H.P.</style></author><author><style face="normal" font="default"> Sculco,P.K.</style></author><author><style face="normal" font="default"> Schoch,J.J.</style></author><author><style face="normal" font="default"> Sierra,R.J.</style></author><author><style face="normal" font="default"> Pagnano,M.W.</style></author><author><style face="normal" font="default"> Stuart,M.J.</style></author><author><style face="normal" font="default"> Taunton,M.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Characterizing the Diagnosis and Treatment of Allergic Contact Dermatitis to 2-octyl Cyanoacrylate Utilized for Skin Closure in Elective Orthopedic Surgery</style></title><secondary-title><style face="normal" font="default">J Arthroplasty</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Arthroplasty</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">2-Octyl-cyanoacrylate</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Knee</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Oral corticosteroids</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe reactions</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Topical corticosteroids</style></keyword><keyword><style face="normal" font="default"> total joint arthroplasty</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wound Healing</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0883-5403</style></isbn><abstract><style face="normal" font="default">AbstractIntroduction While studies have shown that postoperative wound complications can predispose to deep infection following orthopedic surgery, the best form of skin closure has not been elucidated. Further, the unique risks and benefits of each type of wound closure have not been studied. The goal of this study is to present the diagnosis and treatment of patients with allergic contact dermatitis (ACD) from 2-octyl cyanoacrylate, a skin adhesive commonly utilized in wound closure. Methods Twenty-nine patients with ACD to 2-octyl cyanoacrylate (Prineo-«, Ethicon, NJ) following elective orthopedic surgeries from 2013- 2016 were retrospectively reviewed; this occurred in 29 of 6,088 units of Prineo-« utilized at our institution, for an estimated incidence of 0.5%. Nineteen patients (66%) had knee operations. Mean age was 55 years (range, 15</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô92 years). We classified patients by symptom severity and treatment requirements into mild, moderate, and severe reactions. Results Most reactions were moderate (48%) or severe (38%) reactions. Mean time from surgery to diagnosis was 11.8 days (range, 2</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô42 days). All patients underwent removal of the Prineo-« dressing and daily dressing changes with a specific protocol. Twenty patients (69%) received oral antihistamines, sixteen patients (55%) required topical corticosteroids, and five patients (17%) required oral corticosteroids. All cases of ACD ultimately resolved at a mean of 22 days (range, 13</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô56 days) postoperatively. Conclusion 2-octyl cyanoacrylate skin adhesive occurs in an estimated 0.5% of cases and can lead to severe postoperative ACD when used following orthopedic operations. However, with early recognition and appropriate treatment, patients</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖ symptoms resolve without a significant impact on wound healing</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.arth.2017.07.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28811110">PM:28811110</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Arthroplasty\20170803-ChalmersBP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Arthroplasty\20170803-ChalmersBP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170803, Chalmers BP</style></custom2><misc3><style face="normal" font="default">10.1016/j.arth.2017.07.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42183</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ekerljung,L.</style></author><author><style face="normal" font="default"> Mincheva,R.</style></author><author><style face="normal" font="default"> Hagstad,S.</style></author><author><style face="normal" font="default"> Bjerg,A.</style></author><author><style face="normal" font="default"> Telg,G.</style></author><author><style face="normal" font="default"> Stratelis,G.</style></author><author><style face="normal" font="default"> Lotvall,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Institution for Medicine/Department for Internal medicine and Nutrition/Krefting Research , Centre at University of Gothenburg , Gothenburg , Sweden</style></auth-address><titles><title><style face="normal" font="default">Prevalence, clinical characteristics and morbidity of the Asthma-COPD overlap in a general population sample</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Bronchitis</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical signs</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="default">Objective Although asthma and COPD have been regarded as distinct conditions, emerging literature suggests that overlapping phenotypes exists, asthma-COPD overlap (ACO). The aim of this study was to describe prevalence, patient characteristics and morbidity of ACO. Methods From a cross-sectional population sample, the West Sweden Asthma Study, subjects with suspected asthma, chronic bronchitis or COPD, and a random sample, were invited to clinical examinations. ACO was defined as doctors diagnosed asthma, or clear clinical signs of asthma at examination, with a FEV1/FVC&lt;0.7. Results Subjects were categorised as ACO (N = 181), COPD only (N = 89), asthma only (N = 651), or healthy (n = 1036) based on clinical examinations. Prevalence of ACO was 3.4% in the random sample (N = 1172) and 18.1% among asthmatics (N = 138) in the random sample. Subjects with ACO (mean age 59 years, 54% women) had an age and gender distribution in between asthma only (45 years, 63% women) and COPD only (62 years, 41% women). Ever-smoking was reported by 71%, 48% and 74% in the ACO, asthma only and COPD only groups, respectively. Subjects with ACO had worse lung function (mean FEV1% of predicted normal 76%) than asthma only (100%) and COPD only (87%) and reported more respiratory symptoms. Also respiratory related emergency visits were more common in ACO compared to asthma only and COPD only, respectively. Conclusions ACO is present in 3.4% of the population and common among subjects with both asthma and COPD. Subjects with ACO had worse lung function and more symptoms than subjects with asthma or COPD only</style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1339799</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28696811">PM:28696811</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170711-EkerljungL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170711-EkerljungL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170711, Ekerljung L</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1339799</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42184</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tsai,M.K.</style></author><author><style face="normal" font="default"> Lin,Y.C.</style></author><author><style face="normal" font="default"> Huang,M.Y.</style></author><author><style face="normal" font="default"> Lee,M.S.</style></author><author><style face="normal" font="default"> Kuo,C.H.</style></author><author><style face="normal" font="default"> Kuo,P.L.</style></author><author><style face="normal" font="default"> Lin,C.H.</style></author><author><style face="normal" font="default"> Hung,C.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Division of Nephrology, Department of internal Medicine , Kaohsiung Armed Forces General Hospital , Kaohsiung , Taiwan</style></auth-address><titles><title><style face="normal" font="default">The effects of asthma medications on reactive oxygen species production in human monocytes</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">agonists</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Budesonide</style></keyword><keyword><style face="normal" font="default"> Cell Line</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> fluticasone</style></keyword><keyword><style face="normal" font="default"> formoterol</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human monocytes</style></keyword><keyword><style face="normal" font="default"> Hydrogen</style></keyword><keyword><style face="normal" font="default"> Hydrogen Peroxide</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="default"> LTRA</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Monocyte</style></keyword><keyword><style face="normal" font="default"> Monocytes</style></keyword><keyword><style face="normal" font="default"> montelukast</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Oxygen</style></keyword><keyword><style face="normal" font="default"> pollutants</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Reactive Oxygen Species</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> ROS</style></keyword><keyword><style face="normal" font="default"> salmeterol</style></keyword><keyword><style face="normal" font="default"> Taiwan</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Asthma is a chronic inflammatory airway disease induced by many environmental factors. The inhalation of allergens and pollutants promotes the production of reactive oxygen species (ROS) leading to airway inflammation, hyper-responsiveness, and remodeling in allergic asthma. The effects of asthma medications on ROS production are unclear. The present study investigated the anti-ROS effects of current asthma medications including inhaled corticosteroid (ICS; budesonide and fluticasone), leukotriene receptor antagonist (LTRA; montelukast), long-acting beta2 agonists (LABAs; salmeterol and formoterol), and a new extra-LABA (indacaterol). METHODS: The human monocyte cell line THP-1 cells were pre-treated with different concentrations of the asthma medications at different time points after hydrogen peroxide (H2O2) stimulation. H2O2 production was measured with DCFH-DA by flow cytometry. RESULTS: Montelukast, fluticasone, and salmeterol suppressed H2O2-induced ROS production. Indacaterol enhanced H2O2-induced ROS production. Budesonide and formoterol alone had no anti-ROS effects, but the combination of these two drugs significantly suppressed H2O2-induced ROS production. CONCLUSIONS: Different asthma medications have different anti-ROS effects on monocytes. The combination therapy with LABA and ICS seemed not to be the only choice for asthma control. Montelukast may also be a good supplemental treatment for the poorly controlled asthma because of its powerful anti-ROS effects. Our findings provide a novel therapeutic view in asthma</style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1339798</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28696794">PM:28696794</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170711-TsaiMK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170711-TsaiMK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170711, Tsai MK</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1339798</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42185</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kamalaporn,H.</style></author><author><style face="normal" font="default"> Chawalitdamrong,P.</style></author><author><style face="normal" font="default"> Preutthipan,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Division of Pulmonology, Department of Pediatrics, Ramathibodi Hospital, Faculty of Medicine , Mahidol University , Bangkok , Thailanda Division of Pulmonology, Department of Pediatrics, Ramathibodi Hospital, Faculty of Medicine , Mahidol University , Bangkok , Thailanda Division of Pulmonology, Department of Pediatrics, Ramathibodi Hospital, Faculty of Medicine , Mahidol University , Bangkok , Thailand</style></auth-address><titles><title><style face="normal" font="default">Thai pediatricians' current practice toward childhood asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> bronchodilators</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Compliance</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> investigations</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> leukotriene receptor antagonist</style></keyword><keyword><style face="normal" font="default"> LTRA</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatricians</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Childhood asthma is a substantial health burden in Thailand. Due to a lack of pediatric respiratory specialists (pediatric pulmonologists and allergists; RS), most Thai children are cared for by general pediatricians (pediatric primary care providers (PCP)). OBJECTIVES: We investigated whether current practices of Thai pediatricians complied with asthma guidelines and compared practices (diagnosis and treatments) provided by PCP and RS. METHODS: A cross-sectional study was conducted using electronic surveys including four case scenarios of different asthma phenotypes distributed to Thai pediatricians. Asthma diagnosis and management were evaluated for compliance with standard guidelines. The practices of PCP and RS were compared. RESULTS: From 800 surveys distributed, there were 405 respondents (51%). Most respondents (81%) were PCP, who preferred to use clinical diagnosis rather than laboratory investigations to diagnose asthma. For acute asthmatic attacks, 58% of the pediatricians prescribed a systemic corticosteroid. For uncontrolled asthma, 89% of the pediatricians prescribed at least one controller. For exercise-induced bronchospasm, 55% of the pediatricians chose an inhaled bronchodilator, while 38% chose a leukotriene receptor antagonist (LTRA). For virus-induced wheeze, 40% of the respondents chose an LTRA, while 15% chose inhaled corticosteroids (ICS). PCP prescribed more oral bronchodilators (31% vs. 18%, p = 0.02), antibiotics (20% vs. 6%, p &lt; 0.001), and antihistamines (13% vs. 0%, p = 0.02) than RS for the management of an acute asthmatic attack. CONCLUSIONS: Most of the Thai pediatricians' practices toward diagnosis and treatment of acute asthmatic attack and uncontrolled asthma conform to the guidelines. PCP prescribed more oral bronchodilators, antibiotics, and antihistamines than RS</style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1338724</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28696803">PM:28696803</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170711-KamalapornH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170711-KamalapornH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170711, Kamalaporn H</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1338724</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42186</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Reznik,M.</style></author><author><style face="normal" font="default"> Islamovic,F.</style></author><author><style face="normal" font="default"> Choi,J.</style></author><author><style face="normal" font="default"> Leu,C.S.</style></author><author><style face="normal" font="default"> Rowlands,A.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatrics , Children's Hospital at Montefiore, Albert Einstein College of Medicine , Bronx , NY , USA</style></auth-address><titles><title><style face="normal" font="default">Factors associated with in-school physical activity among urban children with asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma impairment</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Impairment</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Light</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> overweight</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schoolchildren</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="default">OBJECTIVE: A cross-sectional study was conducted to determine if in-school physical activity (PA) varied by age, gender, weight and asthma status, participation in physical education (PE), outdoor recess, and other in-school PA among urban schoolchildren with asthma. METHODS: PA was measured by tri-axial accelerometers. Height and mass were measured and overweight defined as BMI >/=85th percentile. Asthma impairment and risk were assessed as per national guidelines, and asthma status variable with three categories (mild, moderate, and severe) was created. Multivariable generalized linear mixed models adjusting for clustering due to school and student were fitted to identify variables predictive of PA. RESULTS: 108 children with asthma participated. Children spent 374 minutes in school, of which 253 minutes were sedentary, 105 minutes in light PA, and 16 minutes in moderate-to-vigorous PA (MVPA). Only 3 participants reached the recommended >/=30 minutes/day of MVPA. Multivariable analysis revealed age, gender, participation in PE class, outdoor recess, and other in-school PA as independent predictors of PA. BMI and asthma status were not associated with PA. CONCLUSIONS: Children with asthma were mostly sedentary at school. Older children and girls were particularly at risk for inactivity. PE, recess, and other in-school PA participation are modifiable factors that should be targeted in school-based interventions aimed at increasing PA in this population</style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1340482</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28696842">PM:28696842</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170711-ReznikM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170711-ReznikM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170711, Reznik M</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1340482</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42187</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Quast,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">a College of Public Health , University of South Florida , Tampa , FL , USA</style></auth-address><titles><title><style face="normal" font="default">Healthcare utilization by children with asthma displaced by Hurricane Katrina</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Control Groups</style></keyword><keyword><style face="normal" font="default"> Controller medications</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Florida</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Louisiana</style></keyword><keyword><style face="normal" font="default"> Medicaid</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> office</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Texas</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To assess the performance of TexKat, the largest Hurricane Katrina Medicaid Emergency Waiver, in providing care to asthmatic children. METHODS: Medicaid enrollment and encounter data for 2004 and 2006 from Louisiana and Texas were analyzed in a pre-post comparison. Changes in utilization by children in the waiver were compared to changes in utilization by children in Medicaid in three control groups: children in Louisiana counties that were designated as a disaster assistance area but who were not displaced; children in Louisiana counties that were not designated as a disaster assistance area, and children in Texas. The analysis included prescriptions for controller and quick-relief medications as well as encounters in inpatient, emergency, outpatient, and office settings. RESULTS: The sample proportion of TexKat enrollees who had a prescription filled for controller medications fell from 0.37 to 0.28 between 2004 and 2006. By contrast, the sample proportions for the three control groups were relatively unchanged or increased. The inferential analysis indicated that the 2004-2006 change in proportions for the TexKat group differed from the changes for each of the three control groups (p-value &lt; 0.001). For office and emergency department visits, the 2004-2006 decreases in both the proportion of subjects with a visit and the average number of visits for the TexKat group were greater than the changes for the control groups (p-value &lt; 0.001). CONCLUSIONS: While TexKat appears to have largely been successful in preventing extreme utilization disruptions, the analysis suggests that children in the program may have received inadequate care</style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1339244</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28696804">PM:28696804</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170711-QuastT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170711-QuastT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170711, Quast T</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1339244</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42188</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Suarez-Varela,M.M.</style></author><author><style face="normal" font="default"> Llopis,A.</style></author><author><style face="normal" font="default"> Fernandez-Fabrellas,E.</style></author><author><style face="normal" font="default"> Sanz,F.</style></author><author><style face="normal" font="default"> Perez-Lozano,M.J.</style></author><author><style face="normal" font="default"> Martin,V.</style></author><author><style face="normal" font="default"> Astray,J.</style></author><author><style face="normal" font="default"> Castilla,J.</style></author><author><style face="normal" font="default"> Egurrola,M.</style></author><author><style face="normal" font="default"> Force,L.</style></author><author><style face="normal" font="default"> Toledo,D.</style></author><author><style face="normal" font="default"> Dominguez,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Area de Medicina Preventiva y Salud Publica, Departamento de Medicina Preventiva , Universidad de Valencia , Burjasot, Valencia , Spain</style></auth-address><titles><title><style face="normal" font="default">Asthma and influenza vaccination in elderly hospitalized patients: Matched case-control study in Spain</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> elderly</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evolution</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Influenza</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Records</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Vaccination</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="21" Month="6" Year="2017">2017/6/21</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Influenza infection is an exacerbating factor for asthma, and its prevention is critical in managing asthmatic patients. We investigated the effect of influenza vaccination on asthmatic and non-asthmatic patients hospitalized with laboratory-confirmed influenza in Spain. METHODS: We made a matched case-control study to assess the frequency of hospitalization for influenza in people aged >/=65 years. Hospitalized patients with unplanned hospital admissions were recruited from 20 hospitals representing seven Spanish regions. Cases were defined as those hospitalized due to a laboratory-confirmed influenza infection and controls were matched by age, sex, and hospital. Data were obtained from clinical records, and patients stratified by clinical asthma history. Vaccination status and asthma due to influenza infection were analyzed according to sociodemographic variables and medical risk conditions. Multivariable analysis was made using conditional logistic regression models. RESULTS: 582 hospitalized patients with influenza (15.8% asthmatic) and 1,570 hospitalized patients without influenza (7.9% asthmatic) were included. In the multivariable conditional logistic regression using unvaccinated and non-asthmatic patients as the reference group, vaccination significantly prevented influenza in non-asthmatic patients (aOR = 0.63; 95% CI: 0.45, 0.88) and also showed a trend for a possibly protective effect in asthmatic patients (aOR = 0.79; 95% CI: 0.34, 1.81). CONCLUSION: Our results suggest that influenza vaccination could be a protective factor for asthmatic patients, although the results are inconclusive and further research is required. Practically, given the better clinical evolution of vaccinated asthma cases, and the lack of better evidence, the emphasis on vaccination of this group should continue</style></abstract><notes><style face="normal" font="default">DA - 20170621IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1332204</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28636411">PM:28636411</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170721-SuarezVarelaMM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170721-SuarezVarelaMM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170621, Suarez-Varela MM</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1332204</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42189</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Albers,F.C.</style></author><author><style face="normal" font="default"> Mullerova,H.</style></author><author><style face="normal" font="default"> Gunsoy,N.B.</style></author><author><style face="normal" font="default"> Shin,J.Y.</style></author><author><style face="normal" font="default"> Nelsen,L.M.</style></author><author><style face="normal" font="default"> Bradford,E.S.</style></author><author><style face="normal" font="default"> Cockle,S.M.</style></author><author><style face="normal" font="default"> Suruki,R.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Respiratory Medical Franchise, GSK , Research Triangle Park , NC , USA</style></auth-address><titles><title><style face="normal" font="default">Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> anti-IgE</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> Endotypes</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> mepolizumab</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> reslizumab</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="16" Month="6" Year="2017">2017/6/16</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Severe asthma comprises several distinct phenotypes. Consequently, patients with severe asthma can be eligible for more than one biologic treatment targeting Th2 inflammation, such as anti-interleukin (IL)-5 and anti-immunoglobulin (Ig) E. The objective of this study was to describe treatment eligibility and overlap in treatment eligibility for mepolizumab (anti-IL-5), omalizumab (anti-IgE) and reslizumab (anti-IL-5) in patients with severe asthma, who were recruited from clinical practice. METHODS: This cross-sectional, single-visit, observational study in six countries enrolled patients with severe asthma (defined by American Thoracic Society/European Respiratory Society guidelines). Assessable patients were analysed as a total cohort and a sub-cohort, who were not currently receiving omalizumab. Treatment eligibility was defined according to the local prescribing information or protocol-defined inclusion/exclusion criteria. Patients currently receiving omalizumab were automatically categorised as omalizumab-eligible. RESULTS: The total cohort comprised 670 patients who met the analysis criteria, of whom 20% were eligible for mepolizumab, 31-41% were eligible for omalizumab (depending on eligibility criteria used), and 5% were eligible for reslizumab. In patients not currently receiving omalizumab (n = 502), proportions eligible for each biologic were similar (mepolizumab: 20%, reslizumab 6%) or lower (omalizumab 7-21%) than those for the total cohort. Overlap in treatment eligibility varied; in mepolizumab-eligible patients not currently receiving omalizumab (n = 101), 27-37% were omalizumab-eligible and 18% were reslizumab-eligible. CONCLUSIONS: Treatment eligibility for mepolizumab and omalizumab was higher than that for reslizumab. Although there was some overlap in treatment eligibility, the patient groups eligible for treatment with anti-IL-5 or anti-IgE therapies were often distinct, emphasising the different phenotypes and endotypes in severe asthma</style></abstract><notes><style face="normal" font="default">DA - 20170616IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -CO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1322611</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28622052">PM:28622052</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170616-AlbersFC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170616-AlbersFC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170616, Albers FC</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1322611</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42190</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kansal,P.</style></author><author><style face="normal" font="default"> Nandan,D.</style></author><author><style face="normal" font="default"> Agarwal,S.</style></author><author><style face="normal" font="default"> Patharia,N.</style></author><author><style face="normal" font="default"> Arya,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatrics , PGIMER and RML Hospital , Delhi , India</style></auth-address><titles><title><style face="normal" font="default">Correlation of induced sputum eosinophil levels with clinical parameters in mild and moderate persistent asthma in children aged 7-18 years</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma in children</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Budesonide</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> induced sputum</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> rescue medication</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> sputum eosinophil</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="11" Month="7" Year="2017">2017/7/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Treatment decisions in asthma are currently based on clinical assessment and spirometry. Sputum eosinophil, being a marker of airway inflammation, can serve as a tool for assessing severity and response to treatment in asthma patients. OBJECTIVES: To measure eosinophil percentage in induced sputum in children with asthma and correlate it with clinical asthma parameters. METHODS: A prospective observational study was performed at tertiary care hospital on 91 children aged 7-18 years with newly diagnosed mild or moderate persistent asthma. Theinduced sputum eosinophil percentage was obtained at the time of enrollment and three months after treatment with inhaled budesonide. Patients were specifically evaluated for five clinical parameters of asthma, i.e., days of acute exacerbations, use of salbutamol as rescue medication, emergency visits, nighttime cough and days of school absence. RESULTS: Sputum eosinophil percentage was high (3.1 +/- 0.515%) at the time of enrollment which reduced significantly after three months of inhaled budesonide therapy [0.06 +/- 0.164% (p &lt; 0.0005)]. Children with moderate persistent asthma had significantly higher values of sputum eosinophil levels than children with mild persistent asthma at the time of enrollment (3.38 +/- 0.64% vs. 2.99 +/- 0.42%, p = 0.001) but the difference was not significant after three months of inhaled steroid therapy (0.07 +/- 0.18 vs. 0.04 +/- 0.12, p = 0.5104). A significant negative correlation was found between reduction in sputum eosinophil levels and improvement in FEV1 (r = -0.400, p = 0.0001). All the clinical asthma parameters also correlated significantly with the reduction in sputum eosinophil levels after three months of inhaled steroid therapy. CONCLUSION: Eosinophil levels in induced sputum correlate well with clinical asthma parameters and asthma severity in children. It is a simple, noninvasive and cheap method which can be used for the monitoring of asthma in a resource-limited setting</style></abstract><notes><style face="normal" font="default">DA - 20170711IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1338725</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28696802">PM:28696802</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170711-KansalP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170711-KansalP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170711, Kansal P</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1338725</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42191</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Banerjee,D.</style></author><author><style face="normal" font="default"> Gelaye,B.</style></author><author><style face="normal" font="default"> Zhong,Q.Y.</style></author><author><style face="normal" font="default"> Sanchez,S.E.</style></author><author><style face="normal" font="default"> Williams,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Epidemiology , Harvard T.H. Chan School of Public Health , Boston , MA , USA</style></auth-address><titles><title><style face="normal" font="default">Childhood Abuse and Adult Onset Asthma among Peruvian Women</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Adult-onset asthma</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Confidence Intervals</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Income</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Peru</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="26" Month="6" Year="2017">2017/6/26</year></dates><abstract><style face="normal" font="default">Objective Childhood abuse has been found to be associated with adult-onset asthma; however, this association has not been studied in low and middle income countries with a high burden of gender-based violence, including childhood abuse. We examined the odds of asthma diagnosed at age 18 or older in relation to history of physical and sexual abuse among Peruvian pregnant women. Methods This cross-sectional study collected demographic characteristics, history of abuse and asthma diagnoses from 3081 pregnant women. Logistic regression procedures estimated adjusted odds ratios and 95% confidence intervals (aOR,[95%CI]) for asthma diagnoses in relation to abuse. Results Overall, 71% of women reported a history of abuse (&lt;18 years), and asthma was diagnosed among 2.6% of cohort participants. The prevalence of physical only, sexual only and both physical and sexual childhood abuse was 38%, 8% and 25%, respectively. History of physical only (1.16,[0.63-2.17]), sexual only (2.11,[0.92-4.84]) or both physical and sexual childhood abuse (1.75,[0.94-3.29]) were positively associated with increased odds of asthma, although the associations were not statistically significant in the multivariate analysis. However, the odds of asthma increased with increasing numbers of abuse events (ptrend = 0.01). Women who reported >/=3 abuse events had an increased odds of asthma (1.88,[1.06-3.34]). Conclusion Our results do not provide convincing evidence that childhood abuse is associated with asthma among pregnant Peruvian women; however, we were able to demonstrate that an increased number of abuse events are associated with asthma. Further research is required to better understand the effects of abuse on asthma</style></abstract><notes><style face="normal" font="default">DA - 20170626IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Peru -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1339243</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28650748">PM:28650748</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170626-BanerjeeD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170626-BanerjeeD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170626, Banerjee D</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1339243</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42192</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tubby,C.</style></author><author><style face="normal" font="default"> Negm,O.H.</style></author><author><style face="normal" font="default"> Harrison,T.</style></author><author><style face="normal" font="default"> Tighe,P.J.</style></author><author><style face="normal" font="default"> Todd,I.</style></author><author><style face="normal" font="default"> Fairclough,L.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">a School of Life Sciences, University of Nottingham , Nottingham , UK</style></auth-address><titles><title><style face="normal" font="default">Peripheral killer cells do not differentiate between asthma patients with or without fixed airway obstruction</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="466" start="456">456-466</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Airway Obstruction</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> CD8+ T cells</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> cytotoxicity</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Egypt</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Killer Cells</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> NK cells</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> subset</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The three main types of killer cells - CD8+ T cells, NK cells and NKT cells - have been linked to asthma and chronic obstructive pulmonary disease (COPD). However, their role in a small subset of asthma patients displaying fixed airway obstruction (FAO), similar to that seen in COPD, has not been explored. The objective of the present study was to investigate killer cell numbers, phenotype and function in peripheral blood from asthma patients with FAO, asthma patients without FAO, and healthy individuals. METHODS: Peripheral CD8+ T cells (CD8+CD3+CD56-), NK cells (CD56+CD3-) and NKT-like cells (CD56+CD3+) of 14 asthma patients with FAO (post-bronchodilator FEV/FVC &lt;0.7, despite clinician-optimised treatment), 7 asthma patients without FAO (post-bronchodilator FEV/FVC >/= 0.7), and 9 healthy individuals were studied. RESULTS: No significant differences were seen between the number, receptor expression, MAPK signalling molecule expression, cytotoxic mediator expression, and functional cytotoxicity of peripheral killer cells from asthma patients with FAO, asthma patients without FAO and healthy individuals. CONCLUSIONS: Peripheral killer cell numbers or functions do not differentiate between asthma patients with or without fixed airway obstruction</style></abstract><notes><style face="normal" font="default">DA - 20161013IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Egypt -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1236941</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27736259">PM:27736259</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-456-66.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-456-66.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161013, Tubby C</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1236941</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42193</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Udesen,P.B.</style></author><author><style face="normal" font="default"> Westergaard,C.G.</style></author><author><style face="normal" font="default"> Porsbjerg,C.</style></author><author><style face="normal" font="default"> Backer,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Respiratory Research Unit , Bispebjerg University Hospital , Copenhagen , Denmark</style></auth-address><titles><title><style face="normal" font="default">Stability of FeNO and airway hyperresponsiveness to mannitol in untreated asthmatics</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="536" start="530">530-536</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Mannitol</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> symptom scores</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Airway hyperresponsiveness and airway inflammation are important hallmarks of asthma and are useful in asthma diagnosing, monitoring and treatment. The aim of the study was to assess whether two commonly used clinical tests, the mannitol challenge and Fraction of exhaled NO (FeNO), were stable clinical indicators over time in stable untreated asthmatics. METHODS: 54 non-smoking, asthma patients not treated with steroids were enrolled in the study and assessed at baseline and a median of 6 months later. At baseline and follow-up, FeNO and airway hyperesponsiveness to mannitol were measured, and asthma control was assessed with the Asthma Control Questionnaire (ACQ). RESULTS: A total of 41 subjects completed both visits. Mean (SD) FEV1% at baseline was 94.1% (17.7) and at re-examination 94.6% (19.7) (ns). The ACQ score was unchanged from baseline (Mean (SD): 0.90 (+/- 0.73)) to follow-up 0.90 (+/- 0.74) (ns), as was the FEV1% (94.1% (+/-17.1%) vs 94.6% (19.7%)(ns) indicating that patients were clinically stable during follow-up. The response to mannitol was unchanged at follow-up (Geometric mean (CI) of Response Dose Ratio (RDR) to mannitol: 0.026(0.013-0.046) vs 0.026(0.012-0.050) (ns). There was a slight decrease in FeNO at follow-up (25.5 ppb (19.7-32.9) to 21.9 ppb (17.1-28.2) (p &lt; 0.001). CONCLUSIONS: In steroid-free non-smoking asthmatics with constant symptom scores and lung function, airway responsiveness to mannitol remained at the same level over a period of months, while a minor change in exhaled FeNO was reported. These results suggest that mannitol is a stable, reliable marker of clinical disease activity</style></abstract><notes><style face="normal" font="default">DA - 20160926IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1238928</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27668981">PM:27668981</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-530-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-530-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160926, Udesen PB</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1238928</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42194</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wong,A.</style></author><author><style face="normal" font="default"> Tavakoli,H.</style></author><author><style face="normal" font="default"> Sadatsafavi,M.</style></author><author><style face="normal" font="default"> Carlsten,C.</style></author><author><style face="normal" font="default"> Fitzgerald,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Faculty of Medicine, University of British Columbia , Vancouver , Canada</style></auth-address><titles><title><style face="normal" font="default">Asthma control and productivity loss in those with work-related asthma: A population-based study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="542" start="537">537-542</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Absenteeism</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> British Columbia</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Columbia</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Initiative for Asthma</style></keyword><keyword><style face="normal" font="default"> Linear Models</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword><keyword><style face="normal" font="default"> Work-related asthma</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">OBJECTIVE: In Canada, asthma is the third leading cause of work loss, yet little is known about the associated productivity loss. The goal of this study was to look at the relationship between asthma control and productivity loss, particularly contrasting those with work-related asthma (WRA) and non-work-related asthma (NWRA). METHODS: A population-based random sample of adults with asthma in British Columbia, Canada, was prospectively recruited. Asthma control was graded according to Global Initiative for Asthma classification, while productivity loss and presence of WRA was assessed using questionnaires. Ordinal regression models were then used to associate WRA with asthma control. Generalized linear models were applied to estimate the average productivity loss associated with different levels of asthma control among those with WRA and NWRA. RESULTS: The study included 300 employed adults. Sixty (20%) had WRA. The odds of being controlled were significantly lower in those with WRA (OR = 0.23, 95% CI: 0.09, 0.56; P &lt; 0.01). Those with WRA and uncontrolled asthma had a significant difference in productivity loss due to presenteeism ($659.1 [95% CI: 12.9, 1581.5; P = 0.04]), but not absenteeism ($88.7 [95% CI: -86.5, 279.6; P = 0.35]), when compared to those with NWRA and uncontrolled asthma. There was no significant difference when a similar comparison was made for those with controlled or partially controlled asthma. CONCLUSIONS: WRA is associated with worse asthma control and increased productivity loss. Presenteeism makes a significant contribution to productivity loss and should be considered when evaluating the overall economic burden of asthma, particularly WRA</style></abstract><notes><style face="normal" font="default">DA - 20160805IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1220011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27494107">PM:27494107</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-537-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-537-42.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160805, Wong A</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1220011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42195</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Porpodis,K.</style></author><author><style face="normal" font="default"> Domvri,K.</style></author><author><style face="normal" font="default"> Kontakiotis,T.</style></author><author><style face="normal" font="default"> Fouka,E.</style></author><author><style face="normal" font="default"> Kontakioti,E.</style></author><author><style face="normal" font="default"> Zarogoulidis,K.</style></author><author><style face="normal" font="default"> Papakosta,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pulmonary Medicine , Aristotle University of Thessaloniki , Thessaloniki , Greece</style></auth-address><titles><title><style face="normal" font="default">Comparison of diagnostic validity of mannitol and methacholine challenges and relationship to clinical status and airway inflammation in steroid-naive asthmatic patients</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="529" start="520">520-529</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Challenge test</style></keyword><keyword><style face="normal" font="default"> Challenge tests</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Mannitol</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> Methacholine challenge</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Physical Examination</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Medicine</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The purpose of this study was to demonstrate and compare the diagnostic validity of two bronchial challenges and to investigate their correlation with patient clinical status, atopy and inflammation markers. METHODS: Eighty-eight patients, 47 women and 41 men, mean age 38.56 +/- 16.73 years who presented with asthma related symptoms and were not on any anti-asthma medication, were challenged with mannitol and methacholine on separate days. Medical history regarding asthmatic symptoms, physical examination, skin prick tests and FeNO levels were also assessed. The clinical diagnosis of asthma was based on bronchodilator reversibility test. RESULTS: Sixty-seven patients were diagnosed with asthma and 21 without asthma. Both methacholine (P &lt; 0.014) and mannitol (P &lt; 0.000) challenges were significant in diagnosing asthma. The positive/negative predictive value was 93.33%/41.86% for methacholine, 97.72%/45.45% for mannitol and 97.05%/45.45%. for both methods assessed together. Worthy of note that 22% of asthmatics had both tests negative. There was a negative correlation between PC20 of methacholine and the FeNO level P &lt; 0.001, and positive with the PD15 of mannitol P &lt; 0.001 and the pre-test FEV1% pred P &lt; 0.005, whereas PD15 of mannitol was negatively correlated with the FeNO level P &lt; 0.001. Furthermore, dyspnea was the only asthmatic symptom associated with FeNO level P &lt; 0.035 and the positivity of mannitol P &lt; 0.014 and methacholine P &lt; 0.04. CONCLUSIONS: Both challenge tests were equivalent in diagnosing asthma. Nevertheless, specificity appeared to be slightly higher in mannitol challenge</style></abstract><notes><style face="normal" font="default">DA - 20160930IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1238926</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27686218">PM:27686218</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-520-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-520-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160930, Porpodis K</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1238926</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42196</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Taniguchi,H.</style></author><author><style face="normal" font="default"> Furuse,H.</style></author><author><style face="normal" font="default"> Nakanishi,Y.</style></author><author><style face="normal" font="default"> Tsuda,T.</style></author><author><style face="normal" font="default"> Totsuka,K.</style></author><author><style face="normal" font="default"> Masaki,Y.</style></author><author><style face="normal" font="default"> Suzuki,K.</style></author><author><style face="normal" font="default"> Ishizawa,S.</style></author><author><style face="normal" font="default"> Miyazawa,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">a The Department of Internal Medicine , Toyama Prefectural Central Hospital , 2-2-78 Nishinage, Toyama , Japan</style></auth-address><titles><title><style face="normal" font="default">Bronchial biopsy and reactivity in patients with chest tightness relieved with bronchodilator</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="487" start="479">479-487</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> Bronchoscopy</style></keyword><keyword><style face="normal" font="default"> Chest Pain</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Constriction</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Internal Medicine</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> reactivity</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">OBJECTIVE: It has been hypothesized that some patients with chest tightness of unknown origin can be successfully treated with a bronchodilator and that they should be diagnosed with chest pain variant asthma. We conducted a prospective study to characterize newly diagnosed patients with chest tightness relieved with bronchodilator use and without characteristic bronchial asthma attacks. METHODS: Eleven patients were registered following recurrent positive responses of chest tightness to inhalation of a ss2-agonist. These patients underwent assessments of airway responsiveness to methacholine, bronchial biopsy and bronchial lavage under fiber-optic bronchoscopy before receiving treatment. RESULTS: For the patients with chest tightness relieved with bronchodilator use, the bronchial biopsy specimens exhibited significant increases in lymphocyte and macrophage infiltration (p &lt; 0.05) and no significant increase in eosinophils (p = 0.2918) compared with the control subjects. The bronchial responsiveness to methacholine was increased in two of the patients with chest tightness, and it was not increased in seven; in addition, increased percentages of eosinophils were detected in bronchial lavage fluid (5% or more) from two patients, but no increase was detected in eight patients. CONCLUSIONS: We suspect that the chest tightness was induced by airway constriction in these patients, but further study is necessary to validate this hypothesis. We propose that the chest tightness relieved with bronchodilator use was attributed to airway constriction resulting from inflammation with lymphocytes and macrophages and/or that the chest tightness was directly attributed to airway inflammation. This clinical trial is registered at www.umin.ac.jp (UMIN13994 and UMIN 16741)</style></abstract><notes><style face="normal" font="default">DA - 20161123IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1236940</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27880056">PM:27880056</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-479-87.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-479-87.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161123, Taniguchi H</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1236940</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42197</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hall,A.B.</style></author><author><style face="normal" font="default"> Novotny,A.</style></author><author><style face="normal" font="default"> Bhisitkul,D.M.</style></author><author><style face="normal" font="default"> Melton,J.</style></author><author><style face="normal" font="default"> Regan,T.</style></author><author><style face="normal" font="default"> Leckie,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Emergency Medicine , Lakeland Regional Health , Lakeland , FL , USA</style></auth-address><titles><title><style face="normal" font="default">Association of emergency department albuterol dispensing with pediatric asthma revisits and readmissions</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="503" start="498">498-503</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Albuterol</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Emergency Medicine</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> MDI</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Metered Dose Inhalers</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Regression Analysis</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective cohort study</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Although pediatric asthma continues to be a highly studied disease, data to suggest clear strategies to decrease asthma related revisits or readmissions is lacking. The purpose of our study was to assess the effect of emergency department (ED) direct dispensing of beta-agonist metered dose inhalers on pediatric asthma ED revisit and readmission rates. METHODS: We conducted a retrospective cohort study of pediatric patients discharged from the pediatric ED with a diagnosis of asthma. Our primary outcome measured the rate of asthma revisits to the ED or admissions to the hospital within 28 days. Logistic regression analysis was used to assess ED beta-agonist MDI dispensing and revisit and/or readmission as the outcome. RESULTS: A total of 853 patients met eligibility for inclusion in the study, with 657 enrolled in the Baseline group and 196 enrolled in the ED-MDI group. The Baseline group experienced a revisit and readmission rate of 7.0% (46/657) versus 2.6% (5/196) in the ED-MDI group, (p = 0.026). ED direct dispensing of MDIs was found to be independently associated with a decreased risk of revisit or readmission (odds ratio 0.37; 95% confidence interval 0.14-0.95). CONCLUSIONS: In our study, ED direct dispensing of beta-agonist MDIs resulted in a reduction in 28-day revisit and readmission to the hospital. Further studies should be performed to evaluate the economic impact of reducing these revisits and readmissions against the costs of maintaining a dispensing program. Our findings may support modification of asthma programs to include dispensing MDIs from the emergency department</style></abstract><notes><style face="normal" font="default">DA - 20161007IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1236942</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27715361">PM:27715361</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-498-503.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-498-503.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161007, Hall AB</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1236942</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42198</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Janevic,M.R.</style></author><author><style face="normal" font="default"> Baptist,A.P.</style></author><author><style face="normal" font="default"> Bryant-Stephens,T.</style></author><author><style face="normal" font="default"> Lara,M.</style></author><author><style face="normal" font="default"> Persky,V.</style></author><author><style face="normal" font="default"> Ramos-Valencia,G.</style></author><author><style face="normal" font="default"> Uyeda,K.</style></author><author><style face="normal" font="default"> Hazan,R.</style></author><author><style face="normal" font="default"> Garrity,A.</style></author><author><style face="normal" font="default"> Malveaux,F.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a School of Public Health, University of Michigan , Ann Arbor , MI , USA</style></auth-address><titles><title><style face="normal" font="default">Effects of pediatric asthma care coordination in underserved communities on parent perceptions of care and asthma-management confidence</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="519" start="514">514-519</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Caregivers</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Communication</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Los Angeles</style></keyword><keyword><style face="normal" font="default"> low income</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Michigan</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Perception</style></keyword><keyword><style face="normal" font="default"> Philadelphia</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> race</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> socioeconomic status</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Disparities by race and socioeconomic status persist in pediatric asthma morbidity, mortality, and treatment. Improving parent/provider communication and parents' asthma-management confidence may result in better asthma control in vulnerable populations. The Merck Childhood Asthma Network, Inc. funded an initiative to implement medical-social care coordination to improve asthma outcomes at sites in four low-income, urban communities (Los Angeles, CA; Philadelphia, PA; Chicago, IL; and San Juan, PR.) As part of a cross-site evaluation of this effort, pre- post-program changes in parents' reports of asthma care and management were assessed. METHODS: Across sites, 805 parents or other caregivers responded to a baseline survey that was repeated one year later following their child's participation in care coordination. Parents' asthma-management confidence, as well as their perceptions of provider access, trust, and communication, were measured with Likert scales. Linear mixed models were used to assess improvement in these variables, across and within sites, adjusting for sociodemographics. RESULTS: Pooled across sites, the adjusted mean estimate for all outcomes showed a significant improvement (p &lt;.05) from baseline to follow-up. Knowledge and Between-Provider Communication improved significantly (p &lt;.05) within all four sites; Access improved significantly in Chicago, Philadelphia, and Puerto Rico; Trust improved significantly in Chicago, Los Angeles, and Philadelphia; and Patient-Provider Communication improved significantly in Philadelphia only. CONCLUSION: Pediatric asthma care coordination, as implemented variously in diverse settings, was associated with improvement in parents' perceptions of asthma care and self-reported asthma-management knowledge and confidence. This positive impact on parents may help sustain care coordination's impact on children</style></abstract><notes><style face="normal" font="default">DA - 20161130IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1242136</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27901627">PM:27901627</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-514-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-514-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161130, Janevic MR</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1242136</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42199</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dodd,K.E.</style></author><author><style face="normal" font="default"> Mazurek,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Respiratory Health Division, National Institute for Occupational Safety and Health , Centers for Disease Control and Prevention (CDC) , Morgantown , West Virginia , USAa Respiratory Health Division, National Institute for Occupational Safety and Health , Centers for Disease Control and Prevention (CDC) , Morgantown , West Virginia , USA</style></auth-address><titles><title><style face="normal" font="default">Asthma medication use among adults with current asthma by work-related asthma status, Asthma Call-back Survey, 29 states, 2012-2013</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Beta-agonist</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> leukotriene</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Virginia</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> West Virginia</style></keyword><keyword><style face="normal" font="default"> Work-related asthma</style></keyword><keyword><style face="normal" font="default"> Workplace</style></keyword></keywords><dates><year Day="13" Month="7" Year="2017">2017/7/13</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Asthma severity is defined as the intensity of treatment required to achieve good control of asthma symptoms. Studies have shown that work-related asthma (WRA) can be associated with poorer asthma control and more severe symptoms than non-WRA. Associations between asthma medications and WRA status were assessed using data from the 2012-2013 Asthma Call-back Survey among ever-employed adults (>/=18 years) with current asthma from 29 states. METHODS: Persons with WRA had been told by a physician that their asthma was work-related. Persons with possible WRA had asthma caused or made worse by their current or previous job, but did not have physician-diagnosed WRA. Asthma medications were classified as controller (i.e., long-acting beta-agonist, inhaled corticosteroid, oral corticosteroid, cromolyn/nedocromil, leukotriene pathway inhibitor, methylxanthine, anti-cholinergics) and rescue (i.e., short-acting beta-agonist). Demographic and clinical characteristics were examined. Associations between asthma medications and WRA status were assessed using a multivariate logistic regression to calculate adjusted prevalence ratios (PRs). RESULTS: Among an estimated 15 million ever-employed adults with current asthma, 14.7% had WRA and an additional 40.4% had possible WRA. Compared with adults with non-WRA, those with WRA were more likely to have taken anti-cholinergics (PR = 1.80), leukotriene pathway inhibitor (PR = 1.59), and methylxanthine (PR = 4.76), and those with possible WRA were more likely to have taken methylxanthine (PR = 2.85). CONCLUSIONS: Results provide additional evidence of a higher proportion of severe asthma among adults with WRA compared to non-WRA. To achieve optimal asthma control, adults with WRA may require additional intervention, such as environmental controls or removal from the workplace exposure</style></abstract><notes><style face="normal" font="default">DA - 20170713IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1339245</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28704107">PM:28704107</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170713-DoddKE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170713-DoddKE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170713, Dodd KE</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1339245</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42200</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martin,M.A.</style></author><author><style face="normal" font="default"> Press,V.G.</style></author><author><style face="normal" font="default"> Erwin,K.</style></author><author><style face="normal" font="default"> Margellos-Anast,H.</style></author><author><style face="normal" font="default"> Ignoffo,S.</style></author><author><style face="normal" font="default"> McMahon,K.S.</style></author><author><style face="normal" font="default"> Mosnaim,G.</style></author><author><style face="normal" font="default"> Ramsay,J.</style></author><author><style face="normal" font="default"> Paik,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatrics , University of Illinois at Chicago , Chicago , IL , USA</style></auth-address><titles><title><style face="normal" font="default">Engaging end-users in intervention research study design</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Caregivers</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Chicago</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> community health worker</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Fatigue</style></keyword><keyword><style face="normal" font="default"> Focus Groups</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Illinois</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Interviews</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patient Education</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> Protocols</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="12" Month="7" Year="2017">2017/7/12</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Coordinated Healthcare Interventions for Childhood Asthma Gaps in Outcomes (CHICAGO) Plan is a 3-arm multicenter pragmatic trial to evaluate asthma interventions in high-risk Chicago children presenting to emergency departments (ED) with asthma. A formative evaluation with end-users to provide input into the trial design and outcome instruments was conducted prior to trial initiation. METHODS: A multi-level data gathering framework from the field of design and standard qualitative methods was employed. This included one focus group with asthma Community Health Workers (N = 8), two focus groups with caregivers of children with asthma (N = 9), in-home interviews with caregivers (N = 9), key informant interviews at six EDs and outpatient clinical sites (N = 19), and ED tours and observations (N = 6). Data were presented, discussed, and organized into themes. RESULTS: Data indicated that changes to the study design and discharge tool were warranted. A key insight was that ED discharge protocols typically place patient education at a single inopportune time, as families are preparing to leave the ED. At this point in time, families are less receptive to education due to fatigue and a desire to expedite the discharge process. The trial design was modified to reposition the discharge asthma plan to occur at earlier "teachable moments." Delivery of the asthma discharge plan was assigned to study-employed ED coordinators instead of ED providers and staff. Other potential challenges to study recruitment and implementation were raised and addressed. CONCLUSIONS: Engagement of end-users in the design phase of implementation research is critical to improve research feasibility and relevance</style></abstract><notes><style face="normal" font="default">DA - 20170712IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1342256</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28699825">PM:28699825</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170712-MartinMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170712-MartinMA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170712, Martin MA</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1342256</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42201</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kovacikova,Z.</style></author><author><style face="normal" font="default"> Neumannova,K.</style></author><author><style face="normal" font="default"> Rydlova,J.</style></author><author><style face="normal" font="default"> Bizovska,L.</style></author><author><style face="normal" font="default"> Janura,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Sports Kinanthropology, Faculty of Physical Education and Sports , Comenius University in Bratislava , Slovakia</style></auth-address><titles><title><style face="normal" font="default">The effect of balance training intervention on postural stability in children with asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Breathing Exercises</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Czech Republic</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exercise</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> rehabilitation</style></keyword><keyword><style face="normal" font="default"> Slovakia</style></keyword><keyword><style face="normal" font="default"> Sport</style></keyword><keyword><style face="normal" font="default"> Sports</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="12" Month="7" Year="2017">2017/7/12</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Pulmonary rehabilitation is mainly focused on exercise training and breathing retraining in children with asthma. Conversely, balance training is not usually recommended for the treatment, although postural deficits were found in these patients. Therefore, this study assessed the effect of balance training intervention on postural stability in children with asthma. METHODS: Nineteen children with mild intermittent asthma (age 11.1 +/- 2.1 years, height 147.6 +/- 13.9 cm, weight 41.8 +/- 13.3 kg) were randomly assigned to an experimental group or a control group and completed a four-week physiotherapy program including breathing exercises and aerobic physical training (six times/week, 45 minutes). Both groups performed the same training, but only the experimental group underwent exercises on balance devices. The center of pressure (CoP) velocity in the anteroposterior (Vy) and mediolateral (Vx) directions, and total CoP velocity (Vtot) were recorded before and after training in the preferred and the adjusted stances under eyes open (EO) and eyes closed (EC) conditions. RESULTS: The addition of balance intervention led to significant improvements of Vtot (p = 0.02, p = 0.04) in both types of stance, Vx in the preferred stance (p = 0.03) and Vy in the adjusted stance (p = 0.01) under EO conditions. Significant improvements were also found in Vy in the adjusted stance (p = 0.01) under EC conditions. CONCLUSIONS: Results of this study support the effectiveness of balance training as a part of physiotherapy treatment for improving balance performance, predominantly under EO conditions, in children with mild asthma</style></abstract><notes><style face="normal" font="default">DA - 20170712IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Slovakia -CO - Czechia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1342257</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28699850">PM:28699850</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170712-KovacikovaZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170712-KovacikovaZ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170712, Kovacikova Z</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1342257</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42202</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rajabi,S.</style></author><author><style face="normal" font="default"> Keshavarz,E.</style></author><author><style face="normal" font="default"> Dehghani,Y.</style></author><author><style face="normal" font="default"> Keshavarz,M.</style></author><author><style face="normal" font="default"> AliMoradi,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Psychology, Faculty of Literature and Humanities , Persian Gulf University , Bushehr , Iran</style></auth-address><titles><title><style face="normal" font="default">Comparing executive functions between patients with chronic asthma and healthy subjects</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic asthma</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> psychology</style></keyword><keyword><style face="normal" font="default"> Software</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wisconsin</style></keyword></keywords><dates><year Day="14" Month="7" Year="2017">2017/7/14</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Allergic diseases have different levels of prevalence all over the world. Among them, asthma is the most common chronic disease. Up to now, little attention has been paid to the impact of this chronic disease on people's executive functions. The present study aimed at comparing the executive functions in patients with chronic asthma and healthy subjects. METHODS: The study population was patients with chronic asthma who were referred to Al-Zahra hospital in Isfahan Province and their visitors who were assigned as the control group. Thirty patients with chronic asthma and 30 patient visitors were enrolled in this study, and three software programs (Wisconsin, Stroop, and Continuous Performance Tests) were used. RESULTS: The results of multivariate variance analysis showed that there is a significant difference between patients with chronic asthma and healthy subjects in terms of set shifting, inhibition, and attention performance. CONCLUSIONS: This study revealed that the executive functions of patients with chronic asthma have significant defects</style></abstract><notes><style face="normal" font="default">DA - 20170714IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1337786</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28708949">PM:28708949</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170714-RajabiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170714-RajabiS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170714, Rajabi S</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1337786</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42203</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kanagalingam,S.</style></author><author><style face="normal" font="default"> Shehab,S.S.</style></author><author><style face="normal" font="default"> Kaminsky,D.A.</style></author><author><style face="normal" font="default"> Wise,R.A.</style></author><author><style face="normal" font="default"> Lang,J.E.</style></author><author><style face="normal" font="default"> Dixon,A.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">a University of Vermont, Burlington Vermont</style></auth-address><titles><title><style face="normal" font="default">Effect of obesity on sinonasal disease in asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> eosinophilic inflammation</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> Increased prevalence</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mometasone</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal corticosteroids</style></keyword><keyword><style face="normal" font="default"> nasal lavage</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> overweight</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="24" Month="7" Year="2017">2017/7/24</year></dates><abstract><style face="normal" font="default">Sinonasal disease can contribute to poor asthma control. There are reports that link obesity with an increased prevalence of sinonasal disease, but no studies evaluating the severity of sinonasal disease in obese asthmatics, and how this impacts asthma control. The purpose of the current study was to determine if obesity is associated with increased severity of sinonasal disease, and/or affects response to nasal corticosteroid treatment in asthma. METHODS: This study included 236 adults participating in a 24-week randomized, double-masked, placebo-controlled study of nasal mometasone for the treatment of poorly controlled asthma. Sinonasal disease severity was assessed using validated questionnaires, and compared in participants of differing BMI. Eosinophilic inflammation was assessed using markers in nasal lavage, serum and exhaled nitric oxide. Response to treatment was compared in the different BMI groups. RESULTS: Obesity had no effect on the severity of sinonasal disease symptoms in asthmatics (Sino-Nasal Outcomes Test 22 score [mean +/- SD] 35.4+/-18.5, 40.2+/-22.8, 39.1+/-21.7, p = 0.43, in lean, overweight and obese participants), nor on nasal, bronchial or systemic markers of allergic inflammation. Nasal steroids had some limited effects on symptoms, lung function and inflammatory markers in lean participants, but no detectable effect in obese patients. CONCLUSIONS: Obesity does not affect severity of sinonasal disease in patients with asthma; the association of sinonasal disease symptoms with increased asthma severity, and markers of Type 2 inflammation are consistent across all BMI groups. The response of obese patients to nasal corticosteroids requires further study</style></abstract><notes><style face="normal" font="default">DA - 20170724IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1341522</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28737966">PM:28737966</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170724-KanagalingamS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170724-KanagalingamS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170724, Kanagalingam S</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1341522</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42204</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Trivedi,M.</style></author><author><style face="normal" font="default"> Fung,V.</style></author><author><style face="normal" font="default"> Kharbanda,E.O.</style></author><author><style face="normal" font="default"> Larkin,E.K.</style></author><author><style face="normal" font="default"> Butler,M.G.</style></author><author><style face="normal" font="default"> Horan,K.</style></author><author><style face="normal" font="default"> Lieu,T.A.</style></author><author><style face="normal" font="default"> Wu,A.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Division of Pediatric Pulmonology and Quantitative Health Sciences , University of Massachusetts Medical School , Worcester , MA , USA</style></auth-address><titles><title><style face="normal" font="default">Racial disparities in family-provider interactions for pediatric asthma care</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Analyse</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Decision Making</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Latino</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Lung Diseases</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> race</style></keyword><keyword><style face="normal" font="default"> racial disparities</style></keyword><keyword><style face="normal" font="default"> Racial disparity</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> white</style></keyword></keywords><dates><year Day="14" Month="7" Year="2017">2017/7/14</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Black and Latino children experience significantly worse asthma morbidity than their white peers for multifactorial reasons. This study investigated differences in family-provider interactions for pediatric asthma, based on race/ethnicity. METHODS: This was a cross-sectional study of parent surveys of asthmatic children within the Population-Based Effectiveness in Asthma and Lung Diseases Network. Our study population comprised 647 parents with survey response data. Data on self-reported race/ethnicity of the child were collected from parents of the children with asthma. Outcomes studied were responses to the questions about family-provider interactions in the previous 12 months: (1) number of visits with asthma provider; (2) number of times provider reviewed asthma medications with patient/family; (3) review of a written asthma treatment plan with provider; and (4) preferences about making asthma decisions. RESULTS: In multivariate adjusted analyses controlling for asthma control and other co-morbidities, black children had fewer visits in the previous 12 months for asthma than white children: OR 0.63 (95% CI 0.40, 0.99). Additionally, black children were less likely to have a written asthma treatment plan given/reviewed by a provider than their white peers, OR 0.44 (95% CI 0.26, 0.75). There were no significant differences by race in preferences about asthma decision-making nor in the frequency of asthma medication review. CONCLUSION: Black children with asthma have fewer visits with their providers and are less likely to have a written asthma treatment plan than white children. Asthma providers could focus on improving these specific family-provider interactions in minority children</style></abstract><notes><style face="normal" font="default">DA - 20170714IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Bermuda -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1337790</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28708958">PM:28708958</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170714-TrivediM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170714-TrivediM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170714, Trivedi M</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1337790</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42205</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hatziagorou,E.</style></author><author><style face="normal" font="default"> Kirvassilis,F.</style></author><author><style face="normal" font="default"> Kouroukli,E.</style></author><author><style face="normal" font="default"> Avramidou,V.</style></author><author><style face="normal" font="default"> Papanikolaou,D.</style></author><author><style face="normal" font="default"> Terzi,D.</style></author><author><style face="normal" font="default"> Karailidou,M.</style></author><author><style face="normal" font="default"> Tsanakas,J.</style></author><author><style face="normal" font="default"> Papagianni,M.</style></author><author><style face="normal" font="default"> Panagiotakos,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Aristotle University of Thessaloniki, Greece, 1Paediatric Pulmonology Unit , 3rd Paediatric Dept, Hippokration Hospital, Thessaloniki, Greece , 49 Konstantinoupoleo str, Thessaloniki , 54642 Greeced Harokopio University, School of Health Science and Education , Athens , 176 71 Greece</style></auth-address><titles><title><style face="normal" font="default">A "real-life" study on height in prepubertal asthmatic children receiving inhaled steroids</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> Caregivers</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="14" Month="7" Year="2017">2017/7/14</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Asthma is the most common chronic respiratory disease in children and inhaled corticosteroids (ICS) constitute the first line of treatment for these patients. However, the potential growth-inhibiting effect of ICS has often been a cause of concern for both caregivers as well as physicians, and there still remains conflict regarding their safety profile. OBJECTIVE: To assess whether the administration of ICS in low or medium doses is associated with height reduction in prepubertal children. METHODS: We performed a retrospective study to examine the association between ICS treatment and growth deceleration in children with mild persistent asthma. The comparison of height measurements every 6 months from 3 to 8 years of age was conducted among three groups of patients: patients not receiving ICS, patients being treated with low dose of ICS and patients being treated with medium dose of ICS (GINA Guidelines 2015). RESULTS: This study included 284 patients (198 male, 86 female) aged 3 to 8 years; 75 patients were not receiving ICS, 63 patients were on low-dose ICS and 146 patients were on medium-dose ICS. The measured height every 6 months did not differ significantly (p>0.05) among the three groups while the difference remained stable (p>0.05), even when we evaluated males and females separately. CONCLUSIONS: In this "real-life" study we found that a long-term treatment with ICS in low or medium doses is not associated with height reduction in prepubertal children with asthma</style></abstract><notes><style face="normal" font="default">DA - 20170714IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1336243</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28708950">PM:28708950</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170714-HatziagorouE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170714-HatziagorouE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170714, Hatziagorou E</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1336243</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42206</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Banasiak,N.C.</style></author><author><style face="normal" font="default"> Meadows-Oliver,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Nurse Practitioner Specialty, Yale University School of Nursing, New Haven, CT, USA</style></auth-address><titles><title><style face="normal" font="default">Evaluating asthma websites using the Brief DISCERN instrument</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="196" start="191">191-196</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Caregivers</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Internet</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Nursing</style></keyword><keyword><style face="normal" font="default"> office</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Reading</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Software</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">PURPOSE: The primary purpose of this study was to examine the quality of sponsored and unsponsored asthma websites using the Brief DISCERN instrument and to evaluate whether the Health On the Net Code of Conduct (HONcode) logo was present, thereby indicating that the site met the criteria. The Internet is an important source of health information for patients and their families. The primary purpose of this study was to examine the quality of sponsored and unsupported asthma websites. A secondary aim was to determine the readability and reading ease of the materials for each website along with the grade level. METHODS: We queried seven Internet search engines using the keyword "asthma." The websites were evaluated using the six-item Brief DISCERN instrument and by ascertaining whether the HONcode quality label was present. The websites were also evaluated for readability employing Flesch-Kincaid grade level and Flesch reading ease tools using Microsoft Office Word 2013 software. RESULTS: A total of 22 unique websites were included in the study. Approximately 68% of the websites reviewed had a Brief DISCERN cutoff score of >/=16. The overall Brief DISCERN scores ranged from 6 to 30, and the mean score was 17.32 (SD =6.71). The Flesch-Kincaid grade level scores ranged from 2.9 to 15.4, and the average reading grade score was 9.49 (SD =2.7). The Flesch reading ease scores ranged from 17 to 82.7, with a mean reading ease score of 53.57 (SD =15.03). Sites with a HONcode quality label had significantly higher Brief DISCERN scores than those without one (t=2.3795; df=20; p=0.02). CONCLUSION: Brief DISCERN scores revealed that there is quality asthma information for children and their families available on the Internet. The grade level ranged between 2.9 and 15.4 among the websites. However, the mean grade level scores were 9.3-9.89, which is high for the average consumer. Access to accurate information via the Internet, with appropriate readability, may enable pediatric asthma patients and their caregivers to better control and manage asthma</style></abstract><notes><style face="normal" font="default">DA - 20170703IS - 1178-6965 (Print)IS - 1178-6965 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2147/JAA.S133536</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28670135">PM:28670135</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-191-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-191-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170703, Banasiak NC</style></custom2><misc3><style face="normal" font="default">10.2147/JAA.S133536</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42207</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gheorghe-Cetean,S.</style></author><author><style face="normal" font="default"> Cainap,C.</style></author><author><style face="normal" font="default"> Oprean,L.</style></author><author><style face="normal" font="default"> Hangan,A.</style></author><author><style face="normal" font="default"> Virag,P.</style></author><author><style face="normal" font="default"> Fischer-Fodor,E.</style></author><author><style face="normal" font="default"> Gherman,A.</style></author><author><style face="normal" font="default"> Cainap,S.</style></author><author><style face="normal" font="default"> Constantin,A.M.</style></author><author><style face="normal" font="default"> Laszlo,I.</style></author><author><style face="normal" font="default"> Vlad,C.</style></author><author><style face="normal" font="default"> Oprean,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Iuliu Hatieganu University of Medicine and Pharmacy, Dept. of General and Inorganic Chemistry , Cluj-Napoca</style></auth-address><titles><title><style face="normal" font="default">Platinum derivatives: a multidisciplinary approach</style></title><secondary-title><style face="normal" font="default">J BUON</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J BUON</style></full-title></periodical><pages end="577" start="568">568-577</pages><volume><style face="normal" font="default">22</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Evolution</style></keyword><keyword><style face="normal" font="default"> Greece</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Platinum</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Repair</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> Rna</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Tumor Suppressor Protein p53</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Cancer is one of the most difficult diseases to be treated. The particularities regarding the tumors' occurrence mechanism, their evolution under chemotherapy, disease-free interval, but also the increasing number of patients make cancer an intensively studied health domain. Although introduced in therapy since the early 80s, platinum derivatives play an essential role in anticancer therapy. Their use in therapy resulted in improving the patient quality of life and prolonging disease-free interval, which makes them still a benchmark for other anticancer compounds. However, adverse reactions and allergic reactions are a major impediment in therapy with platinum derivatives. This paper summarizes data about platinum derivatives through a multidisciplinary approach, starting from a chemical point of view and on to their mechanism of action, mechanism of cellular resistance, predictive factors for the outcome of chemotherapy such as micro RNAs (miRNAs), tumor suppressor protein p53, and the excision repair cross-complementing 1 protein (ERCC1)</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 1107-0625 (Print)IS - 1107-0625 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28730758">PM:28730758</url></web-urls></urls><custom2><style face="normal" font="default">20170721, Gheorghe-Cetean S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42208</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,H.</style></author><author><style face="normal" font="default"> Zhang,X.</style></author><author><style face="normal" font="default"> Wang,D.</style></author><author><style face="normal" font="default"> Sun,H.</style></author><author><style face="normal" font="default"> Lan,Y.</style></author><author><style face="normal" font="default"> Jiang,H.</style></author><author><style face="normal" font="default"> Chen,S.</style></author><author><style face="normal" font="default"> Lin,Z.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Pharmaceutical Sciences, Peking University, Beijing 100191, China</style></auth-address><titles><title><style face="normal" font="default">An on-line analytical approach for detecting haptens in Shuang-huang-lian powder injection</style></title><secondary-title><style face="normal" font="default">J Chromatogr A</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Chromatogr A</style></abbr-1></periodical><pages end="139" start="126">126-139</pages><volume><style face="normal" font="default">1513</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acids</style></keyword><keyword><style face="normal" font="default"> Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Allergenic</style></keyword><keyword><style face="normal" font="default"> Bacterial Infections</style></keyword><keyword><style face="normal" font="default"> Beijing</style></keyword><keyword><style face="normal" font="default"> Bronchitis</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Chinese</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Flavonoids</style></keyword><keyword><style face="normal" font="default"> Glycosides</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Haptens</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Reproducibility</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Structure activity relationship</style></keyword><keyword><style face="normal" font="default"> Structure-Activity Relationship</style></keyword><keyword><style face="normal" font="default"> structure-activity relationships</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="13" Month="7" Year="2017">2017/7/13</year></dates><abstract><style face="normal" font="default">Shuang-huang-lian powder injection (SHLPI) is a traditional Chinese medicine injection (TCMI) frequently used in the clinical treatment of faucitis, bronchitis, and other viral and bacterial infections of upper respiratory tract. However, its allergenic reactions, being the main adverse effects (AEs) of SHLPI, have been a serious problem of its clinical safety. This problem has not been solved due to short of methods for detecting haptens in complex TCMIs. In this study, an on-line high-performance liquid chromatography-diode-array detector-mass spectrometry combined with bovine serum albumin-fluorescence detector (HPLC-DAD-MS-BSA-FLD) system was established for the first time, validated and applied for identification of haptens in SHLPI. Fourteen of 35 identified compounds showed BSA binding activity, and they were six flavonoids, six caffeoylquinic acids (CQAs), and two phenylethanoid glycosides. The structure-activity relationships of 10 active components were studied, and their ability of sensitization together with that of two CQAs were further verified by ELISA assay. It was found that 10 compounds had sensitization, and flavonoids showed stronger sensitizability than CQAs while the diCQAs were slightly stronger than caffeoylquinic acids. The system was validated using 3-CQA as a positive control, and was proved to have good reproducibility, stability, precision (RSD&lt;0.1%) and linearity (R2>0.9993). This online system is fast, sensitive and efficient for screening haptens in traditional Chinese medicine injection (TCMI), provides a new approach to reveal the chemical basis of haptens in TCMIs</style></abstract><notes><style face="normal" font="default">DA - 20170725IS - 1873-3778 (Electronic)IS - 0021-9673 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.chroma.2017.07.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28739272">PM:28739272</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Chromatogr A\2017-1513-126-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Chromatogr A\2017-1513-126-39.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170725, Wang H</style></custom2><misc3><style face="normal" font="default">10.1016/j.chroma.2017.07.031</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42209</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ferreira Vasconcelos,L.M.</style></author><author><style face="normal" font="default"> Rodrigues,R.O.</style></author><author><style face="normal" font="default"> Albuquerque,A.A.</style></author><author><style face="normal" font="default"> Barroso,G.D.</style></author><author><style face="normal" font="default"> Sasahara,G.L.</style></author><author><style face="normal" font="default"> Severo Ferreira,J.F.</style></author><author><style face="normal" font="default"> Francelino,E.V.</style></author><author><style face="normal" font="default"> Cardoso,C.C.</style></author><author><style face="normal" font="default"> Barem Rabenhorst,S.H.</style></author><author><style face="normal" font="default"> de Almeida,T.L.P.</style></author><author><style face="normal" font="default"> Nagao-Dias,A.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Universidade Federal do Ceara, Fortaleza, Brazil</style></auth-address><titles><title><style face="normal" font="default">Polymorphism of IL10, IL4, CTLA4, and DAO Genes in Cross-Reactive Nonsteroidal Anti-inflammatory Drug Hypersensitivity</style></title><secondary-title><style face="normal" font="default">J Clin Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Clin Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Complement</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> IL10</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> polymorphisms</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> single nucleotide polymorphism</style></keyword><keyword><style face="normal" font="default"> SNP</style></keyword><keyword><style face="normal" font="default"> SNPs</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> targets</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="27" Month="7" Year="2017">2017/7/27</year></dates><abstract><style face="normal" font="default">Our aim was to evaluate genetic polymorphism of molecules involved in immunoregulatory/allergic processes in patients who presented with cutaneous hypersensitivity caused by chemically unrelated nonsteroidal anti-inflammatory drugs. Polymorphisms at IL10 (-1082 G>A), IL4 (-589 C>T), CTLA4 (+49A>G), and DAO (+8956 C>G) genes were studied in 55 cases and 97 controls by the polymerase chain reaction-restriction fragment length polymorphism technique. With regard to the polymorphism at IL10 -1082, higher frequencies of the AG genotype (57% vs 39%) and G allele carriers (70% vs 48%) were found among the patients, indicating a risk effect (odds ratio [OR] = 2.56 and P = .01 for AG genotype and OR = 2.52; P = .01 for AG/GG). For the CTLA4 +49 A/G single-nucleotide polymorphism (SNP), AG genotype (31.0%) (P = .02) and G carrier (54.0%) (P = .05) frequencies were found to be significantly lower in the patient group compared with the control group (51.0% and 69.0%, respectively). The SNP DAO +8956 C>G was associated with a strong protective effect, with OR values of 0.83 for CG and 0.11 for GG genotype (P = .04 for the codominant model), suggesting an allele dose effect. The combination of IL10 and DAO SNPs in a multivariate model did not alter the OR values, suggesting independent effects for both SNPs. The results are striking. In conclusion, these results suggest that polymorphisms in regulatory targets of the immune response and in DAO gene could modulate an individual's susceptibility to nonsteroidal anti-inflammatory drug hypersensitivity reactions. Further studies will be necessary to complement our results</style></abstract><notes><style face="normal" font="default">DA - 20170727IS - 1552-4604 (Electronic)IS - 0091-2700 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1002/jcph.986</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28750137">PM:28750137</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Pharmacol\20170727-FerreiraVasconcelosLM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Pharmacol\20170727-FerreiraVasconcelosLM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170727, Ferreira Vasconcelos LM</style></custom2><misc3><style face="normal" font="default">10.1002/jcph.986</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42210</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Puri,B.K.</style></author><author><style face="normal" font="default"> Howard,J.M.</style></author><author><style face="normal" font="default"> Monro,J.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Desensitization to chemical and food sensitivities by low-dose immunotherapy ascertained by provocation neutralization is associated with reduced influx of calcium ions into lymphocytes</style></title><secondary-title><style face="normal" font="default">J Complement Integr Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Complement Integr Med</style></abbr-1></periodical><pages end="" start="">-</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergen specific immunotherapy</style></keyword><keyword><style face="normal" font="default"> allergen-specific</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium Channels</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> cell signaling</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Fluorescence</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Formaldehyde</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immunotherapy</style></keyword><keyword><style face="normal" font="default"> Ions</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocytes</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> natural course</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Nitrosamines</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="26" Month="4" Year="2017">2017/4/26</year></dates><abstract><style face="normal" font="default">Background Food and chemical sensitivities have detrimental effects on health and the quality of life. The natural course of such sensitivities can potentially be altered through various types of allergen-specific immunotherapy, including low-dose immunotherapy. The molecular mechanism by which low-dose immunotherapy causes desensitization has not thus far been elucidated. While resting lymphocytes maintain a low cytosolic calcium ion concentration, antigen receptor signaling results in calcium ion influx, predominantly via store-operated calcium channels. We therefore hypothesized that desensitization by low-dose immunotherapy is associated with reduced influx of calcium ions into lymphocytes. The aim of this study was to test this hypothesis. Methods Intracellular lymphocytic calcium ion concentrations were assayed in a total of 47 patients, following incubation with picogram amounts of the test allergens, using a cell-permeable calcium-sensing ratiometric fluorescent dye and fluorescence spectroscopy, both at baseline and following successful provocation neutralization treatment with low-dose immunotherapy. Results Low-dose immunotherapy was associated with a reduction in lymphocytic intracellular calcium ion concentration following treatment of: 23% for metabisulfite sensitivity (p&lt;0.0004); 12% for salicylate sensitivity (p&lt;0.01); 23% for benzoate sensitivity (p&lt;0.01); 30% for formaldehyde sensitivity (p&lt;0.0001); 16% for sensitivity to petrol exhaust (p&lt;0.003); 16% for natural gas sensitivity (p&lt;0.001); 13% for nickel sensitivity (p&lt;0.05); 30% for sensitivity to organophosphates (p&lt;0.01); and 24% for sensitivity to nitrosamines (p&lt;0.05). Conclusions Low-dose immunotherapy may affect baseline levels of intracellular calcium in lymphocytes, supporting the premise that allergens affect cell signaling in immune cells and provocation neutralization immunotherapy helps to promote more normal immune cell signaling</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 1553-3840 (Electronic)IS - 1553-3840 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1515/jcim-2016-0010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731314">PM:28731314</url></web-urls></urls><custom2><style face="normal" font="default">20170721, Puri BK</style></custom2><misc3><style face="normal" font="default">10.1515/jcim-2016-0010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42211</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chu,C.Y.</style></author><author><style face="normal" font="default"> Cho,Y.T.</style></author><author><style face="normal" font="default"> Jiang,J.H.</style></author><author><style face="normal" font="default"> Lin,E.I.</style></author><author><style face="normal" font="default"> Tang,C.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan</style></auth-address><titles><title><style face="normal" font="default">Epidemiology and comorbidities of patients with chronic urticaria in Taiwan: A nationwide population-based study</style></title><secondary-title><style face="normal" font="default">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">antihistamine</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic urticaria</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistence</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Psychiatric disorder</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rheumatic Diseases</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Taiwan</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="15" Month="7" Year="2017">2017/7/15</year></dates><abstract><style face="normal" font="default">BACKGROUND: Comprehensive data regarding the epidemiology of chronic urticaria (CU) in general populations are scant. OBJECTIVES: To investigate the prevalence, incidence, and comorbidities of CU in general population. METHODS: The data were sourced from the National Health Insurance Research Database (NHIRD) for 2009-2012. Patients who had a primary/secondary ICD-9-CM diagnosis code of 708.1, 708.8, or 708.9 during the year with at least two outpatient visits and an antihistamine prescription, were identified as the cases of CU for each year. The incidence, persistence and comorbidities of CU were examined. RESULTS: The prevalence of CU ranged from 0.69% to 0.79% for each year from 2009 to 2012, and the incidence was around 0.50% per year from 2010 to 2012. Comparing to the Standard Population, the standardized prevalence ratios (SPRs) for the rheumatic diseases, thyroid disorders, inflammatory diseases, and psychiatric disorders among CU patients were 2.74, 1.81, 1.57 and 1.87, respectively. CONCLUSION: The prevalence of CU in Taiwan is about 0.69-0.79%. CU is associated with a significantly increased risk of psychiatric disorders, inflammatory diseases, thyroid disorders, and rheumatic diseases. Except for thyroid disorders, the prevalence of these comorbidities tends to increase the longer CU persists</style></abstract><notes><style face="normal" font="default">DA - 20170726IS - 1873-569X (Electronic)IS - 0923-1811 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jdermsci.2017.07.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28743610">PM:28743610</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatol Sci\20170726-ChuCY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatol Sci\20170726-ChuCY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170726, Chu CY</style></custom2><misc3><style face="normal" font="default">10.1016/j.jdermsci.2017.07.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42212</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Suwanpradid,J.</style></author><author><style face="normal" font="default"> Shih,M.</style></author><author><style face="normal" font="default"> Pontius,L.</style></author><author><style face="normal" font="default"> Yang,B.</style></author><author><style face="normal" font="default"> Birukova,A.</style></author><author><style face="normal" font="default"> Guttman-Yassky,E.</style></author><author><style face="normal" font="default"> Corcoran,D.L.</style></author><author><style face="normal" font="default"> Que,L.G.</style></author><author><style face="normal" font="default"> Tighe,R.M.</style></author><author><style face="normal" font="default"> Macleod,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Duke University, Durham, NC 27710</style></auth-address><titles><title><style face="normal" font="default">Arginase1 Deficiency in Monocytes/Macrophages Upregulates Inducible Nitric Oxide Synthase To Promote Cutaneous Contact Hypersensitivity</style></title><secondary-title><style face="normal" font="default">J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> IL-6</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> iNOS</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide Synthase</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="26" Month="7" Year="2017">2017/7/26</year></dates><abstract><style face="normal" font="default">The innate immune components that modulate allergic contact hypersensitivity (CHS) responses are poorly defined. Using human skin from contact dermatitis patients and a mouse model of CHS, we find that hapten allergens disrupt the Arginase1 (Arg1) and inducible NO synthase (iNOS) dynamic in monocytes/macrophages (mono/MPhi), which renders those cells ineffectual in suppressing skin inflammation. Mice lacking Arg1 in MPhi develop increased CHS characterized by elevated ear thickening, mono/MPhi-dominated dermal inflammation, and increased iNOS and IL-6 expression compared with control mice. Treatment of Arg1flox/flox; LysMCre+/- mice with a selective NOS inhibitor or knockout of Nos2, encoding iNOS, significantly ameliorates CHS. Our findings suggest a critical role for Arg1 in mono/MPhi in suppressing CHS through dampening Nos2 expression. These results support that increasing Arg1 may be a potential therapeutic avenue in treating allergic contact dermatitis</style></abstract><notes><style face="normal" font="default">DA - 20170727IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.4049/jimmunol.1700739</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28747341">PM:28747341</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Immunol\20170727-SuwanpradidJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Immunol\20170727-SuwanpradidJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170727, Suwanpradid J</style></custom2><misc3><style face="normal" font="default">10.4049/jimmunol.1700739</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42213</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mahnke,K.</style></author><author><style face="normal" font="default"> Useliene,J.</style></author><author><style face="normal" font="default"> Ring,S.</style></author><author><style face="normal" font="default"> Kage,P.</style></author><author><style face="normal" font="default"> Jendrossek,V.</style></author><author><style face="normal" font="default"> Robson,S.C.</style></author><author><style face="normal" font="default"> Bylaite-Bucinskiene,M.</style></author><author><style face="normal" font="default"> Steinbrink,K.</style></author><author><style face="normal" font="default"> Enk,A.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Ruprecht-Karls-University Heidelberg, Department of Dermatology, Im Neuenheimer Feld 440, 69120 Heidelberg, Germany.</style></auth-address><titles><title><style face="normal" font="default">Down-Regulation of CD62L Shedding in T Cells by CD39+ Regulatory T Cells Leads to Defective Sensitization in Contact Hypersensitivity Reactions</style></title><secondary-title><style face="normal" font="default">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Invest Dermatol</style></full-title></periodical><pages end="114" start="106">106-114</pages><volume><style face="normal" font="default">137</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenosine</style></keyword><keyword><style face="normal" font="default"> Adenosine Triphosphate</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> Antigens,CD</style></keyword><keyword><style face="normal" font="default"> Apyrase</style></keyword><keyword><style face="normal" font="default"> Blotting,Western</style></keyword><keyword><style face="normal" font="default"> CD8+ T cells</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cells,Cultured</style></keyword><keyword><style face="normal" font="default"> Comparative Study</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> cytology</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Down-Regulation</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidermis</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> Immunization</style></keyword><keyword><style face="normal" font="default"> immunologic</style></keyword><keyword><style face="normal" font="default"> Immunologic Factors</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> L-Selectin</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Lymph</style></keyword><keyword><style face="normal" font="default"> Lymph node</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Mice,Inbred C57BL</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Protease</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Reference Values</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> regulatory T cell</style></keyword><keyword><style face="normal" font="default"> regulatory T cells</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> surface</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> T-Lymphocytes,Regulatory</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> Tregs</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">Injection of regulatory T cells (Tregs) followed by sensitization with 2,4,6-trinitrochlorobenzene induced a transient increase in size and cellularity of skin-draining lymph nodes (LNs) in mice. This led us to hypothesize that Tregs may affect the trafficking of T cells from and to peripheral LNs. Two to three hours after sensitization, we found fewer CD8+ T cells expressing CD62L in LNs compared with untreated controls. Injection of wild-type Tregs prevented this down-regulation of CD62L. In contrast, Tregs devoid of the adenosine triphosphate (ATP)-degrading ecto-enzyme CD39 were unable to do so. As for the mechanism of CD62L regulation, we found that ATP, which is released in skin upon hapten-exposure, is inducing the protease ADAM17 in LN-residing T cells via engagement of P2X7 ATP receptors. ADAM17 cleaves CD62L from the surface of CD8+ T cells, which in turn provide a signal for T cells to leave the LNs. This regulation of CD62L is disturbed by the presence of Tregs, because Tregs remove extracellular ATP from the tissue by activity of CD39 and, therefore, abrogate the shedding of CD62L. Thus, these data indicate that the regulation of ATP turnover by Tregs in skin and LNs is an important modulator for immune responses</style></abstract><notes><style face="normal" font="default">DA - 20160913IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Comparative StudyPT - Journal ArticleRN - 0 (Antigens, CD)RN - 0 (Immunologic Factors)RN - 126880-86-2 (L-Selectin)RN - 8L70Q75FXE (Adenosine Triphosphate)RN - EC 3.6.1.5 (Apyrase)RN - EC 3.6.1.5 (CD39 antigen)SB - IMCO - Germany -CO - Lithuania -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jid.2016.08.023.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27623510">PM:27623510</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Invest Dermatol\2017-137-106-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Invest Dermatol\2017-137-106-14.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160913, Mahnke K</style></custom2><misc3><style face="normal" font="default">10.1016/j.jid.2016.08.023.</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42214</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Perez Gonzalez,E.L.</style></author><author><style face="normal" font="default"> Medina Alfaro,I.</style></author><author><style face="normal" font="default"> Iglesias Cadarso,A.</style></author><author><style face="normal" font="default"> Boteanu,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Section, Hospital Universitario Puerta de Hierro, Majadahonda, Spain</style></auth-address><titles><title><style face="normal" font="default">An Unusual Case of Contact Dermatitis Caused by a Pacemaker Implanted for Neurostimulation</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="273" start="272">272-273</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0168</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731418">PM:28731418</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-261-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-261-75.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170721, Perez Gonzalez EL</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0168</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42215</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oda,T.</style></author><author><style face="normal" font="default"> Sawada,Y.</style></author><author><style face="normal" font="default"> Okada,E.</style></author><author><style face="normal" font="default"> Yamaguchi,T.</style></author><author><style face="normal" font="default"> Ohmori,S.</style></author><author><style face="normal" font="default"> Haruyama,S.</style></author><author><style face="normal" font="default"> Yoshioka,M.</style></author><author><style face="normal" font="default"> Nakamura,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu City, Fukuoka, Japan</style></auth-address><titles><title><style face="normal" font="default">Stevens-Johnson Syndrome After Influenza Vaccine Injection</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="275" start="274">274-275</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cities</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Influenza</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default"> Stevens-Johnson Syndrome</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> vaccine</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0169</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731419">PM:28731419</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-261-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-261-75.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170721, Oda T</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0169</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42216</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mota,I.</style></author><author><style face="normal" font="default"> Martins,C.</style></author><author><style face="normal" font="default"> Borrego,L.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunoallergy Department, CUF Descobertas Hospital, Lisbon, Portugal</style></auth-address><titles><title><style face="normal" font="default">Regulatory B cells and Allergy: uncovering the link</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Regulatory B cell</style></keyword></keywords><dates><year Day="27" Month="3" Year="2017">2017/3/27</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170327IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0157</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28345522">PM:28345522</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\20170327-MotaI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\20170327-MotaI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170327, Mota I</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0157</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42217</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gu,W.</style></author><author><style face="normal" font="default"> Shi,D.</style></author><author><style face="normal" font="default"> Mi,N.</style></author><author><style face="normal" font="default"> Pang,X.</style></author><author><style face="normal" font="default"> Liu,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, General Hospital of Air Force, Beijing, China</style></auth-address><titles><title><style face="normal" font="default">Physician, Beware! Drug Fever Without Skin Rashes Can Be Caused by Minocycline</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="269" start="268">268-269</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Beijing</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Minocycline</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0164</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731416">PM:28731416</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-261-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-261-75.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170721, Gu W</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0164</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42218</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pola-Bibian,B.</style></author><author><style face="normal" font="default"> Dominguez-Ortega,J.</style></author><author><style face="normal" font="default"> Vila-Nadal,G.</style></author><author><style face="normal" font="default"> Entrala,A.</style></author><author><style face="normal" font="default"> Gonzalez-Cavero,L.</style></author><author><style face="normal" font="default"> Barranco,P.</style></author><author><style face="normal" font="default"> Cancelliere,N.</style></author><author><style face="normal" font="default"> Diaz-Almiron,M.</style></author><author><style face="normal" font="default"> Quirce,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid. Spain</style></auth-address><titles><title><style face="normal" font="default">Asthma exacerbations in a tertiary hospital: clinical features, triggers, and risk factors for hospitalization</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> respiratory infection</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Trigger</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Risk factors for asthma exacerbations are not fully understood. The aim of this study was to determine the epidemiological and clinical characteristics of patients with an asthma exacerbation, potential triggers, and possible predictors of hospitalization. METHODS: A retrospective, non-interventional cohort study was conducted in adult patients who attended the Emergency Department of a tertiary hospital with an asthma exacerbation during 2014. RESULTS: 831 patients (888 events) were included. The highest number of episodes occurred in January and May. Respiratory infection was considered the trigger in 523 events. 34.21% had >/=260 eosinophils/mm3 (20.7%>/=400 eosinophils/mm3), significantly associated with allergic asthma (p&lt;0.0001). Risk factors for hospitalization were: older age [OR:1.58 (95% CI 1.46-1.71)]; no previous diagnosis of asthma [OR:1.40(95% CI 1.06-1.86)]; poorly controlled asthma[OR:1.78 (95% CI 1.10-2.88)]; respiratory infection [OR:2.65 (95% CI 1.95-3.62)]; and severe crisis with more treatment requirements. Of those asthmatics with >/=400 eosinophils/mm3, the rate of hospitalization was lower (p&lt;0.001). CONCLUSION: Older age, absence of a previous asthma diagnosis, uncontrolled disease or concomitant COPD are frequent among patients presenting to the ED with asthma exacerbations. There were some features associated with higher risk of admission. Blood eosinophilia should be considered as a marker of asthma, but not as a predictor of hospitalization</style></abstract><notes><style face="normal" font="default">DA - 20161215IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0128</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27973326">PM:27973326</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\20161215-PolaBibianB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\20161215-PolaBibianB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161215, Pola-Bibian B</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0128</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42219</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shimoda,T.</style></author><author><style face="normal" font="default"> Obase,Y.</style></author><author><style face="normal" font="default"> Nagasaka,Y.</style></author><author><style face="normal" font="default"> Nakano,H.</style></author><author><style face="normal" font="default"> Kishikawa,R.</style></author><author><style face="normal" font="default"> Iwanaga,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical Research Center, Fukuoka National Hospital, Fukuoka, Japan</style></auth-address><titles><title><style face="normal" font="default">Lung Sound Analysis Is Useful for Monitoring Therapy in Patients With Bronchial Asthma</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="251" start="246">246-251</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">abnormalities</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Airway Obstruction</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Budesonide</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> Fractional exhaled nitric oxide</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung sound analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Multivariate Analysis</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Nitric Oxide</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Pressure</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> sputum eosinophil</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVE: Lung sound analysis (LSA) has been reported to be useful for predicting airway obstruction and inflammation in patients with bronchial asthma. Objectives: We examined whether the exhalation-to-inhalation sound pressure ratio in the middle frequency range (200-400 Hz) (E/I MF) is useful for monitoring therapy in patients with asthma. METHODS: The study population comprised 84 patients with mild to moderate asthma whose LSA data were available before and after 1 year of daily treatment with (budesonide 800 mug). We analyzed whether the E/I MF before and after treatment was associated with the fractional exhaled nitric oxide (FeNO) level, sputum eosinophil percentage, respiratory function, and airway hyperresponsiveness. RESULTS: Prior to treatment with budesonide, the E/I MF was significantly correlated with respiratory function, airway hyperresponsiveness, FeNO, and sputum eosinophil percentage. The cutoff values for the E/I MF to detect the abnormalities of respiratory function, FeNO, and sputum eosinophil percentage were 0.367, 0.358, and 0.363, respectively. With respect to the reference value, the E/I MF improved significantly in patients whose respiratory function and FeNO benefited from therapy with budesonide compared with patients whose respiratory function did not benefit from budesonide (odds ratios of 6.39 and 4.78, respectively). According to the multivariate analysis, patients whose E/I MF did not improve had a longer history of smoking (P=.038), poorer posttreatment respiratory function (P=.028), and higher posttreatment FeNO (P=.0095). CONCLUSIONS: Similar to respiratory function and FeNO, E/I MF based on LSA is a useful indicator for monitoring the efficacy of therapy in asthmatic patients</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0132</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731412">PM:28731412</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-246-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-246-51.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170721, Shimoda T</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0132</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42220</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yazdani,R.</style></author><author><style face="normal" font="default"> Abolhassani,H.</style></author><author><style face="normal" font="default"> Asgardoon,M.</style></author><author><style face="normal" font="default"> Shaghaghi,M.</style></author><author><style face="normal" font="default"> Modaresi,M.</style></author><author><style face="normal" font="default"> Azizi,G.</style></author><author><style face="normal" font="default"> Aghamohammadi,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran</style></auth-address><titles><title><style face="normal" font="default">Infectious and Noninfectious Pulmonary Complications in Patients With Primary Immunodeficiency Disorders</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="224" start="213">213-224</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adverse reaction</style></keyword><keyword><style face="normal" font="default"> Adverse reactions</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway disease</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Bronchiectasis</style></keyword><keyword><style face="normal" font="default"> Bronchitis</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Early Diagnosis</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> interstitial lung disease</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Lung Diseases</style></keyword><keyword><style face="normal" font="default"> malignancy</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Otitis</style></keyword><keyword><style face="normal" font="default"> Otitis Media</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pneumonia</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Respiratory disease</style></keyword><keyword><style face="normal" font="default"> Respiratory diseases</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Sinusitis</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Primary immunodeficiency disorders (PIDs) are caused by 1 or more defects of the immune system. Patients are more likely to experience recurrent and/or severe infections and tend to develop a wide range of complications. Respiratory diseases are the main and initial manifestation in most cases and the most common complication. Pulmonary complications cause significant morbidity and mortality in patients with PIDs. Early diagnosis and appropriate treatment can prevent or at least slow the development of respiratory complications. Since the spectrum of pulmonary complications in PIDs is broad, we divided pulmonary complications into upper respiratory complications (eg, sinusitis, otitis media, and laryngeal angioedema) and lower respiratory complications (eg, pneumonia, bronchitis, bronchiectasis, interstitial lung diseases, organizing pneumonia, pulmonary adenopathies and malignancies, hyperreactive airway diseases, pulmonary dysgenesis, and adverse reactions to treatment). This review covers the main respiratory manifestations in patients with PIDs</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Iran -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0166</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731410">PM:28731410</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-213-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-213-24.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170721, Yazdani R</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0166</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42221</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Megna,M.</style></author><author><style face="normal" font="default"> Patruno,C.</style></author><author><style face="normal" font="default"> Balato,A.</style></author><author><style face="normal" font="default"> Napolitano,M.</style></author><author><style face="normal" font="default"> Balato,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy</style></auth-address><titles><title><style face="normal" font="default">Adult Atopic Dermatitis: Less Certainty, More Challenges</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="277" start="276">276-277</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical Medicine</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0155</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731420">PM:28731420</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-261-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-261-75.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170721, Megna M</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0155</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42222</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Silvestre-Salvador,J.F.</style></author><author><style face="normal" font="default"> Romero-Perez,D.</style></author><author><style face="normal" font="default"> Encabo-Duran,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Hospital General Universitario de Alicante, Alicante, SpainDepartment of Dermatology, Hospital General Universitario de Alicante, Alicante, SpainDepartment of Dermatology, Hospital General Universitario de Alicante, Alicante, Spain</style></auth-address><titles><title><style face="normal" font="default">Reply to "Adult Atopic Dermatitis: Less Certainty, More Challenges"</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="" start="278">278-</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0165</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28731421">PM:28731421</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-261-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-261-75.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170721, Silvestre-Salvador JF</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0165</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42223</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Taponen,S.</style></author><author><style face="normal" font="default"> Lehtimaki,L.</style></author><author><style face="normal" font="default"> Karvala,K.</style></author><author><style face="normal" font="default"> Luukkonen,R.</style></author><author><style face="normal" font="default"> Uitti,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Finla Occupational Health, Satakunnankatu 18 B, 33210 Tampere, Finland</style></auth-address><titles><title><style face="normal" font="default">Correlates of employment status in individuals with asthma: a cross-sectional survey</style></title><secondary-title><style face="normal" font="default">J Occup Med Toxicol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Occup Med Toxicol</style></abbr-1></periodical><pages end="" start="19">19-</pages><volume><style face="normal" font="default">12</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Employment</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> gender</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Behavior</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Health</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Smoking</style></keyword><keyword><style face="normal" font="default"> Socioeconomic Factors</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: This study aims to elucidate factors that among adults with asthma are associated with working full-time. METHODS: This cross-sectional survey of 2613 working-age adults with asthma included questions on asthma history, symptoms and use of asthma medication, socioeconomic factors and health behavior. Full-time workers were compared to groups according to employment status: unemployed, work disability and retired due to age. RESULTS: Adults with asthma working full time were younger and more often nonmanual workers, experienced less asthma symptoms, used less asthma medication and smoked less than subjects with work disability. After adjusting for age, gender, smoking and professional status, having frequent symptoms of asthma during last month was associated with an increase in the risk of unemployment (OR 2.3, 95% CI 1.3-4.2) and with an increase in the risk of work disability (OR 4.4, 95% CI 2.3-8.2). CONCLUSIONS: Among adults with asthma, full-time work was associated with younger age, less symptomatic asthma despite of less medication, nonmanual work and less smoking. Having more severe symptoms of asthma was associated with undesirable employment status such as unemployment or work disability. Possibilities to change from manual to nonmanual work may be important in preventing work disability and early exit from work</style></abstract><notes><style face="normal" font="default">DA - 20170727IS - 1745-6673 (Print)IS - 1745-6673 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="default">10.1186/s12995-017-0165-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28747990">PM:28747990</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Occup Med Toxicol\2017-12-19.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Occup Med Toxicol\2017-12-19.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170727, Taponen S</style></custom2><misc3><style face="normal" font="default">10.1186/s12995-017-0165-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42224</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sonney,J.</style></author><author><style face="normal" font="default"> Insel,K.C.</style></author><author><style face="normal" font="default"> Segrin,C.</style></author><author><style face="normal" font="default"> Gerald,L.B.</style></author><author><style face="normal" font="default"> Ki,Moore,I</style></author></authors></contributors><titles><title><style face="normal" font="default">Association of Asthma Illness Representations and Reported Controller Medication Adherence Among School-Aged Children and Their Parents</style></title><secondary-title><style face="normal" font="default">J Pediatr Health Care</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Pediatr Health Care</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medication adherence</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="7" Year="2017">2017/7/20</year></dates><abstract><style face="normal" font="default">This study examined the relationship between asthma illness representations and reported controller medication adherence of school-aged children (6-11 years) with persistent asthma and their parents. Thirty-four parent-child dyads independently reported on asthma controller medication adherence and asthma illness representations. Hierarchical regression analyses were used to test parent and child illness representation domain variables as predictors of reported medication adherence. Parent beliefs about medication necessity versus concerns was a significant predictor of parent-reported adherence (beta = .55, p &lt; .01), and child treatment control was also a significant predictor of parent-reported adherence (beta = -.50, p &lt; .01). Child beliefs about medication necessity versus concerns was a significant predictor of child-reported adherence (beta = .50, p &lt; .01), and no parent variables reached significance. Although there are similarities between parent and child asthma illness representations, findings indicate that school-aged children develop illness representations somewhat independently from their parents and, therefore, are critical participants in both asthma care and research</style></abstract><notes><style face="normal" font="default">DA - 20170723IS - 1532-656X (Electronic)IS - 0891-5245 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.pedhc.2017.06.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28734618">PM:28734618</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Pediatr Health Care\20170723-SonneyJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Pediatr Health Care\20170723-SonneyJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170723, Sonney J</style></custom2><misc3><style face="normal" font="default">10.1016/j.pedhc.2017.06.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42225</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ekim,A.</style></author><author><style face="normal" font="default"> Hecan,M.</style></author><author><style face="normal" font="default"> Oren,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Nursing, Faculty of Health Sciences, Istanbul Bilgi University, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="default">Psychometric Properties of the Turkish Version of Caregiver Burden Index (CBI) for Parents of Children with Allergies</style></title><secondary-title><style face="normal" font="default">J Pediatr Nurs</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Pediatr Nurs</style></abbr-1></periodical><pages end="82" start="78">78-82</pages><volume><style face="normal" font="default">35</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Factor analysis</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> Nursing</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> reliability</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> structure</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> validity</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Childhood chronic diseases have a great impact, including physiological, social and financial burdens, on parents. The concept of "caregiver burden" is gaining importance to understand the effects of allergic diseases and plan family-centered strategies. PURPOSE: The purpose of this study was to examine the psychometric properties of the Caregiver Burden Index (CBI) in Turkish mothers of children with allergies. METHOD: The participants of this methodological study were 213 mothers of children with allergies between 6 and 12years. Construct validity was evaluated through factor analysis and reliability was evaluated through internal consistency and item-total correlation. RESULTS: In reliability analysis, the overall Cronbach's alpha value (0.85) demonstrated a high level of reliability. The corrected item-total correlation varied between 0.63 and 0.84. In exploratory factor analysis, it was detected that 3 factors structure explained 73.6% of the total variance. CONCLUSION: This study indicated that the CBI is a valid and reliable tool to assess the caregiver burden of mothers of Turkish children with allergies. IMPLICATION FOR PRACTICES: The results of this study contribute to the development and implementation of evidence based models of care that address the caregiver burden needs of parents whose children have allergies</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 1532-8449 (Electronic)IS - 0882-5963 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1016/j.pedn.2017.03.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28728773">PM:28728773</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Pediatr Nurs\2017-35-78-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Pediatr Nurs\2017-35-78-82.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170721, Ekim A</style></custom2><misc3><style face="normal" font="default">10.1016/j.pedn.2017.03.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42226</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cobb,H.K.</style></author><author><style face="normal" font="default"> Shinohara,M.M.</style></author><author><style face="normal" font="default"> Huss,J.T.</style></author><author><style face="normal" font="default"> Welch,M.P.</style></author><author><style face="normal" font="default"> Gardner,J.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Systemic contact dermatitis to a surgical implant presenting as red decorative tattoo reaction</style></title><secondary-title><style face="normal" font="default">JAAD Case Reports</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JAAD Case Reports</style></abbr-1></periodical><pages end="350" start="348">348-350</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">cobalt chromium</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Metal allergy</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Tattoo</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><isbn><style face="normal" font="default">2352-5126</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jdcr.2017.05.003</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jdcr.2017.05.003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JAAD Case Reports\2017-3-348-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JAAD Case Reports\2017-3-348-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170803, Cobb HK</style></custom2><misc3><style face="normal" font="default">10.1016/j.jdcr.2017.05.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42227</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McCracken,J.L.</style></author><author><style face="normal" font="default"> Veeranki,S.P.</style></author><author><style face="normal" font="default"> Ameredes,B.T.</style></author><author><style face="normal" font="default"> Calhoun,W.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Clinical Immunology, University of Texas Medical Branch, Galveston</style></auth-address><titles><title><style face="normal" font="default">Diagnosis and Management of Asthma in Adults: A Review</style></title><secondary-title><style face="normal" font="default">JAMA</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">JAMA</style></full-title></periodical><pages end="290" start="279">279-290</pages><volume><style face="normal" font="default">318</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway inflammation</style></keyword><keyword><style face="normal" font="default"> Airway Obstruction</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergen sensitivity</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma specialist</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Bronchodilator</style></keyword><keyword><style face="normal" font="default"> bronchodilators</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Controller medications</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Dyspnea</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroids</style></keyword><keyword><style face="normal" font="default"> Long-acting bronchodilator</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> mepolizumab</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Muscarinic antagonist</style></keyword><keyword><style face="normal" font="default"> Muscarinic Antagonists</style></keyword><keyword><style face="normal" font="default"> Observation</style></keyword><keyword><style face="normal" font="default"> omalizumab</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> reslizumab</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Texas</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword></keywords><dates><year Day="18" Month="7" Year="2017">2017/7/18</year></dates><abstract><style face="normal" font="default">Importance: Asthma affects about 7.5% of the adult population. Evidence-based diagnosis, monitoring, and treatment can improve functioning and quality of life in adult patients with asthma. Observations: Asthma is a heterogeneous clinical syndrome primarily affecting the lower respiratory tract, characterized by episodic or persistent symptoms of wheezing, dyspnea, and cough. The diagnosis of asthma requires these symptoms and demonstration of reversible airway obstruction using spirometry. Identifying clinically important allergen sensitivities is useful. Inhaled short-acting beta2-agonists provide rapid relief of acute symptoms, but maintenance with daily inhaled corticosteroids is the standard of care for persistent asthma. Combination therapy, including inhaled corticosteroids and long-acting beta2-agonists, is effective in patients for whom inhaled corticosteroids alone are insufficient. The use of inhaled long-acting beta2-agonists alone is not appropriate. Other controller approaches include long-acting muscarinic antagonists (eg, tiotropium), and biological agents directed against proteins involved in the pathogenesis of asthma (eg, omalizumab, mepolizumab, reslizumab). Conclusions and Relevance: Asthma is characterized by variable airway obstruction, airway hyperresponsiveness, and airway inflammation. Management of persistent asthma requires avoidance of aggravating environmental factors, use of short-acting beta2-agonists for rapid relief of symptoms, and daily use of inhaled corticosteroids. Other controller medications, such as long-acting bronchodilators and biologics, may be required in moderate and severe asthma. Patients with severe asthma generally benefit from consultation with an asthma specialist for consideration of additional treatment, including injectable biologic agents</style></abstract><notes><style face="normal" font="default">DA - 20170718IS - 1538-3598 (Electronic)IS - 0098-7484 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1001/jama.2017.8372</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28719697">PM:28719697</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JAMA\2017-318-279-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JAMA\2017-318-279-90.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170718, McCracken JL</style></custom2><misc3><style face="normal" font="default">10.1001/jama.2017.8372</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42228</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ricklefs,I.</style></author><author><style face="normal" font="default"> Barkas,I.</style></author><author><style face="normal" font="default"> Duvall,M.G.</style></author><author><style face="normal" font="default"> Cernadas,M.</style></author><author><style face="normal" font="default"> Grossman,N.L.</style></author><author><style face="normal" font="default"> Israel,E.</style></author><author><style face="normal" font="default"> Bleecker,E.R.</style></author><author><style face="normal" font="default"> Castro,M.</style></author><author><style face="normal" font="default"> Erzurum,S.C.</style></author><author><style face="normal" font="default"> Fahy,J.V.</style></author><author><style face="normal" font="default"> Gaston,B.M.</style></author><author><style face="normal" font="default"> Denlinger,L.C.</style></author><author><style face="normal" font="default"> Mauger,D.T.</style></author><author><style face="normal" font="default"> Wenzel,S.E.</style></author><author><style face="normal" font="default"> Comhair,S.A.</style></author><author><style face="normal" font="default"> Coverstone,A.M.</style></author><author><style face="normal" font="default"> Fajt,M.L.</style></author><author><style face="normal" font="default"> Hastie,A.T.</style></author><author><style face="normal" font="default"> Johansson,M.W.</style></author><author><style face="normal" font="default"> Peters,M.C.</style></author><author><style face="normal" font="default"> Phillips,B.R.</style></author><author><style face="normal" font="default"> Levy,B.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pulmonary and Critical Care Medicine Division, Department of Medicine, Brigham and Women's Hospital</style></auth-address><titles><title><style face="normal" font="default">ALX receptor ligands define a biochemical endotype for severe asthma</style></title><secondary-title><style face="normal" font="default">JCI Insight</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">JCI Insight</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Annexin A1</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> BAL</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Bronchoalveolar Lavage</style></keyword><keyword><style face="normal" font="default"> Bronchoscopy</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Critical Care</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Endotype</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Gastroesophageal Reflux</style></keyword><keyword><style face="normal" font="default"> Gastroesophageal reflux disease</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Heart</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory response</style></keyword><keyword><style face="normal" font="default"> Ligands</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Lipoxin</style></keyword><keyword><style face="normal" font="default"> lipoxin A4</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric Pneumology</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Receptors</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Sinusitis</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="20" Month="7" Year="2017">2017/7/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: In health, inflammation resolution is an active process governed by specialized proresolving mediators and receptors. ALX/FPR2 receptors (ALX) are targeted by both proresolving and proinflammatory ligands for opposing signaling events, suggesting pivotal roles for ALX in the fate of inflammatory responses. Here, we determined if ALX expression and ligands were linked to severe asthma (SA). METHODS: ALX expression and levels of proresolving ligands (lipoxin A4 [LXA4], 15-epi-LXA4, and annexin A1 [ANXA1]), and a proinflammatory ligand (serum amyloid A [SAA]) were measured in bronchoscopy samples collected in Severe Asthma Research Program-3 (SA [n = 69], non-SA [NSA, n = 51] or healthy donors [HDs, n = 47]). RESULTS: Bronchoalveolar lavage (BAL) fluid LXA4 and 15-epi-LXA4 were decreased and SAA was increased in SA relative to NSA. BAL macrophage ALX expression was increased in SA. Subjects with LXA4loSAAhi levels had increased BAL neutrophils, more asthma symptoms, lower lung function, increased relative risk for asthma exacerbation, sinusitis, and gastroesophageal reflux disease, and were assigned more frequently to SA clinical clusters. SAA and aliquots of LXA4loSAAhi BAL fluid induced IL-8 production by lung epithelial cells expressing ALX receptors, which was inhibited by coincubation with 15-epi-LXA4. CONCLUSIONS: Together, these findings have established an association between select ALX receptor ligands and asthma severity that define a potentially new biochemical endotype for asthma and support a pivotal functional role for ALX signaling in the fate of lung inflammation. TRIAL REGISTRATION: Severe Asthma Research Program-3 (SARP-3; ClinicalTrials.gov NCT01606826)FUNDING Sources. National Heart, Lung and Blood Institute, the NIH, and the German Society of Pediatric Pneumology</style></abstract><notes><style face="normal" font="default">DA - 20170720IS - 2379-3708 (Electronic)IS - 2379-3708 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1172/jci.insight.93534</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28724795">PM:28724795</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JCI Insight\20170720-RickefsI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JCI Insight\20170720-RickefsI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170720, Rickefs I</style></custom2><misc3><style face="normal" font="default">10.1172/jci.insight.93534</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42229</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Campbell,M.S.</style></author><author><style face="normal" font="default"> Gregory,S.W.</style></author><author><style face="normal" font="default"> Weaver,A.L.</style></author><author><style face="normal" font="default"> Mara,K.C.</style></author><author><style face="normal" font="default"> Kumar,S.</style></author><author><style face="normal" font="default"> Boyce,T.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Impact of Asthma on the Association between Childhood Obesity and Influenza</style></title><secondary-title><style face="normal" font="default">JSM Allergy Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">JSM Allergy Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Influenza</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> vaccine</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Despite long-standing recommendations for influenza vaccine in patients with asthma, whether asthma is a risk factor for medically-attended influenza is unclear. Obesity has more recently been found to be a risk factor for severe influenza in adults. Its role in children is less certain. Materials and methods: We conducted a 1:1 matched case-control study of all 185 children 2 to 18 years old with PCR-confirmed influenza at our institution from 2010 to 2013. Results: Having a prior history of asthma was 2 times more common (95% CI, 1.24-3.23) among the influenza cases than the controls. Obesity was not associated with influenza overall (OR 0.94, 95% CI 0.49-1.83). However, among patients with asthma, influenza cases were 4.4 times more likely to be obese compared with subjects without influenza (95% CI, 0.93-20.58). Conclusion: In our population, a prior diagnosis of asthma was associated with a two-fold increased risk of medically-attended influenza. In addition, among patients with asthma there was a trend toward obesity increasing the risk of influenza.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.jscimedcentral.com/Allergy/index.php</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JSM Allergy Asthma\20170801-CampbellMS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JSM Allergy Asthma\20170801-CampbellMS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Campbell MS</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42230</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kabego,L.</style></author><author><style face="normal" font="default"> de Beer,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association between Respiratory Syncytial Virus Infection in Infancy and Subsequent Asthma: A Meta-Analysis of Observational Studies</style></title><secondary-title><style face="normal" font="default">JSM Allergy Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">JSM Allergy Asthma</style></full-title></periodical><pages end="" start="1009">1009-</pages><volume><style face="normal" font="default">2</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Africa</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma risk</style></keyword><keyword><style face="normal" font="default"> Bronchiolitis</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> Infancy</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> respiratory syncytial virus</style></keyword><keyword><style face="normal" font="default"> Rest</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> RSV</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Software</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> virus infection</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: It has been shown that respiratory syncytial virus (RSV) bronchiolitis in infancy can increase the risk of asthma. This review will aim to describe the association between RSV bronchiolitis in infancy and subsequent asthma.Methodology: Relevant articles were retrieved from PubMed and Web of Science. A random effect meta-analysis was done using the Open Meta Analyst software to evaluate the influence of RSV bronchiolitis as a risk factor of subsequent asthma.Results: Five studies met the inclusion criteria and showed that people who had suffered RSV bronchiolitis in infancy had a higher risk to develop asthma (OR: 4.03; 95% confidence interval (CI): 2.23 to 8.31, p-value&lt;0.001) comparing to those who did not have bronchiolitis in infancy.The heterogeneity of this meta-analysis was moderate (Q=11.28, p-value &lt;0.024, I2=64.56%). Two outlying studies were found that had results that diverged with the rest of the studies. After removing these two outlying studies, the heterogeneity of the study becomes null (I2=0) and the asthma risk in the RSV group becomes higher (OR=8.01; 95% CI: 4.30 to 14.93, p-value &lt;0.001).Conclusion: The results from this meta-analysis suggest that RSV bronchiolitis in infancy can precipitate subsequent asthma. Further studies are needed to confirm this association. However, prevention of RSV bronchiolitis is suggested to be able to decrease the risk of asthma.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -CO - Congo -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.jscimedcentral.com/Allergy/currentissue.php</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JSM Allergy Asthma\2017-2-1009.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JSM Allergy Asthma\2017-2-1009.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Kabego L</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42231</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bordon,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Asthma and allergy: Vitamin D primes neonatal immune system</style></title><secondary-title><style face="normal" font="default">Nat Rev Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nat Rev Immunol</style></abbr-1></periodical><pages end="" start="467">467-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword></keywords><dates><year Day="27" Month="7" Year="2017">2017/7/27</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170727IS - 1474-1741 (Electronic)IS - 1474-1733 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1038/nri.2017.82</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28749460">PM:28749460</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nat Rev Immunol\2017-17-467.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nat Rev Immunol\2017-17-467.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170727, Bordon Y</style></custom2><misc3><style face="normal" font="default">10.1038/nri.2017.82</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42232</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dvorakova,V.</style></author><author><style face="normal" font="default"> O'Regan,G.M.</style></author><author><style face="normal" font="default"> Irvine,A.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Dermatology Department, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland</style></auth-address><titles><title><style face="normal" font="default">Methotrexate for Severe Childhood Atopic Dermatitis: Clinical Experience in a Tertiary Center</style></title><secondary-title><style face="normal" font="default">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Calcineurin</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emollient</style></keyword><keyword><style face="normal" font="default"> Emollients</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Iga</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Ireland</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Life quality</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Methotrexate</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic treatment</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Topical calcineurin</style></keyword><keyword><style face="normal" font="default"> Topical corticosteroids</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="21" Month="7" Year="2017">2017/7/21</year></dates><abstract><style face="normal" font="default">BACKGROUND/OBJECTIVES: Atopic dermatitis (AD) affects up to 20% of children. Although the majority of patients are adequately controlled using emollients, topical corticosteroids, topical calcineurin inhibitors, or phototherapy, children with moderate to severe AD may require systemic treatment for control. The objective of the current study was to evaluate the efficacy and safety of methotrexate in children with severe AD attending a tertiary referral center. METHODS: A retrospective chart review was undertaken of all children who received methotrexate for severe AD at our tertiary referral center from November 2010 to August 2015. RESULTS: Forty-seven children were started on methotrexate for AD during this period. The mean Investigator Global Assessment (IGA) at the 3- to 5-month follow-up improved from 4.25 to 2.8, with further improvement to 1.9 in the patients that continued therapy beyond 10 months. Changes in the Children's Dermatology Life Quality Index (CDLQI) mirrored changes in the IGA, with improvement in the mean CDLQI from 14.4 at the start of the treatment to 7.5 at the 3- to 5-month follow-up. Further improvement in the CDLQI to 6.6 in patients who continued methotrexate beyond 10 months confirmed continued improvement in disease control beyond medium-term therapy. The treatment was well tolerated. CONCLUSIONS: Methotrexate appears to be an effective, safe treatment for severe pediatric AD. Its therapeutic effects continue beyond the medium-term treatment period, as reflected by further improvement in IGA and CDLQI scores in patients who continued methotrexate therapy beyond 10 months</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Journal ArticleCO - Ireland -</style></notes><work-type><style face="normal" font="default">10.1111/pde.13209</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28730617">PM:28730617</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Dermatol\20170721-DvorakovaV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Dermatol\20170721-DvorakovaV.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170721, Dvorakova V</style></custom2><misc3><style face="normal" font="default">10.1111/pde.13209</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42233</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ortiz-Salvador,J.M.</style></author><author><style face="normal" font="default"> Esteve-Martinez,A.</style></author><author><style face="normal" font="default"> Garcia-Rabasco,A.</style></author><author><style face="normal" font="default"> Subiabre-Ferrer,D.</style></author><author><style face="normal" font="default"> Martinez-Leborans,L.</style></author><author><style face="normal" font="default"> Zaragoza-Ninet,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Department, Valencia University General Hospital, Valencia, Spain</style></auth-address><titles><title><style face="normal" font="default">Dermatitis of the Foot: Epidemiologic and Clinical Features in 389 Children</style></title><secondary-title><style face="normal" font="default">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic eczema</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> Cobalt</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Dermatosis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Foot</style></keyword><keyword><style face="normal" font="default"> Irritant</style></keyword><keyword><style face="normal" font="default"> Irritant contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Mercury</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Origin</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Potassium</style></keyword><keyword><style face="normal" font="default"> Potassium Dichromate</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Shoe</style></keyword><keyword><style face="normal" font="default"> Shoes</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Thimerosal</style></keyword><keyword><style face="normal" font="default"> Tinea</style></keyword><keyword><style face="normal" font="default"> Tinea Pedis</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="21" Month="7" Year="2017">2017/7/21</year></dates><abstract><style face="normal" font="default">BACKGROUND/OBJECTIVES: Footwear dermatitis is a form of contact dermatitis resulting from exposure to shoes. There have been only small studies regarding foot contact dermatitis in children. The present study was undertaken to define the prevalence and epidemiologic and clinical features of shoe dermatitis in children. METHODS: A retrospective study was undertaken of all children referred for patch testing between 1996 and 2015. Children with dermatitis limited to the feet were selected. RESULTS: We collected data from 389 children younger than 16 years, 52 of whom (13.4%) were referred with dermatitis exclusively on the feet. Diagnosis after patch testing was allergic contact dermatitis in 23 children (44.2%), atopic eczema in 12 (23.1%), juvenile plantar dermatosis in 8 (15.4%), dyshidrotic eczema in 6 (11.5%), irritant contact dermatitis in 2 (3.8%), and tinea pedis in 1 (1.9%). The most frequent allergens were potassium dichromate, thimerosal, cobalt chloride, mercapto mix, colophonium, mercury, and nickel(II) sulfate. CONCLUSION: Allergic contact dermatitis caused by footwear is a common cause of foot dermatitis in children. Children with foot dermatitis should be referred for patch testing when an allergic origin is suspected</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/pde.13203</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28730653">PM:28730653</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Dermatol\20170721-OrtizSalvadorJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Dermatol\20170721-OrtizSalvadorJM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170721, Ortiz-Salvador JM</style></custom2><misc3><style face="normal" font="default">10.1111/pde.13203</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42234</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tsai,J.D.</style></author><author><style face="normal" font="default"> Chen,H.J.</style></author><author><style face="normal" font="default"> Ku,M.S.</style></author><author><style face="normal" font="default"> Chen,S.M.</style></author><author><style face="normal" font="default"> Hsu,C.C.</style></author><author><style face="normal" font="default"> Tung,M.C.</style></author><author><style face="normal" font="default"> Lin,C.C.</style></author><author><style face="normal" font="default"> Chang,H.Y.</style></author><author><style face="normal" font="default"> Sheu,J.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan</style></auth-address><titles><title><style face="normal" font="default">Association between allergic disease, sleep-disordered breathing, and childhood nocturnal enuresis: a population-based case-control study</style></title><secondary-title><style face="normal" font="default">Pediatr Nephrol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Nephrol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic conjunctivitis</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Apnea</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> confounding factors</style></keyword><keyword><style face="normal" font="default"> Conjunctivitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Nocturnal Enuresis</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Obstructive sleep apnea</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Sleep apnea</style></keyword><keyword><style face="normal" font="default"> Snoring</style></keyword><keyword><style face="normal" font="default"> Taiwan</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="22" Month="7" Year="2017">2017/7/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: Little is known about the associations between allergic disease, sleep-disordered breathing (SDB), and childhood nocturnal enuresis (NE). We examined whether allergic disease and SDB were associated with childhood NE. METHODS: Data were assessed from the 2007-2012 Taiwan National Health Insurance Research Database. We enrolled 4308 children aged 5-18 years having NE diagnosis and age- and sex-matched 4308 children as the control group. The odds ratios of NE were calculated to determine an association with preexisting allergic disease and SDB. RESULTS: A total of 8616 children were included in the analysis. Prevalence of allergic diseases and SDB was significantly higher for the NE group than the control group (all p &lt; 0.001). After adjusting odds ratios for potential confounding factors, except asthma, children with allergic rhinitis, atopic dermatitis, allergic conjunctivitis, and obstructive sleep apnea (OSA) had significantly higher odds of NE compared with children never diagnosed. With stratification for sex, girls with allergic rhinitis, atopic dermatitis, allergic conjunctivitis, OSA, and snoring had significantly higher odds of NE, compared with girls never diagnosed. Only boys with allergic rhinitis and OSA were associated with increased odds of NE. With stratification for age, children aged 5-12 years with allergic rhinitis, atopic dermatitis, allergic conjunctivitis, and OSA had significantly higher odds of NE compared with those never diagnosed. Odds of NE increased with the number of comorbid allergic diseases. CONCLUSIONS: Allergic diseases and SDB are associated with increased odds of childhood NE. The odds of NE increased with the number of comorbid allergic diseases present</style></abstract><notes><style face="normal" font="default">DA - 20170723IS - 1432-198X (Electronic)IS - 0931-041X (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1007/s00467-017-3750-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28735503">PM:28735503</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Nephrol\20170723-TsaiJD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Nephrol\20170723-TsaiJD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170723, Tsai JD</style></custom2><misc3><style face="normal" font="default">10.1007/s00467-017-3750-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42235</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dudeney,J.</style></author><author><style face="normal" font="default"> Sharpe,L.</style></author><author><style face="normal" font="default"> Jaffe,A.</style></author><author><style face="normal" font="default"> Jones,E.B.</style></author><author><style face="normal" font="default"> Hunt,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Psychology, University of Sydney, Sydney, New South Wales, Australia</style></auth-address><titles><title><style face="normal" font="default">Anxiety in youth with asthma: A meta-analysis</style></title><secondary-title><style face="normal" font="default">Pediatr Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Pulmonol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">analysis</style></keyword><keyword><style face="normal" font="default"> Anxiety</style></keyword><keyword><style face="normal" font="default"> Anxiety Disorders</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Maintenance</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> New South Wales</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> psychology</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Symptomatology</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Wales</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> youth</style></keyword></keywords><dates><year Day="27" Month="7" Year="2017">2017/7/27</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Anxiety often presents comorbidly with asthma in youth under 18; however, prevalence rates are unclear. The aim of this review was to provide an up-to-date analysis of the literature investigating the prevalence of anxiety disorders, and comparisons of anxiety disorders and symptomatology in youth with asthma, compared to those without. METHODS: A systematic search was conducted using the databases PsycINFO, MEDLINE, EMBASE, and CINAHL. RESULTS: The search process produced 15 studies (n = 7443) reporting data on youth with asthma and anxiety disorders, 11 studies (n = 10 332) reporting data on youth with and without asthma and anxiety disorders, and 28 studies (n = 5848) reporting data on youth with and without asthma and anxiety symptomatology. Youth with asthma had an anxiety disorder prevalence rate of 22.7%. Youth with asthma also had a greater number of anxiety disorders, compared to those without asthma (d = 0.37, 95%CI: 0.24-0.50, P &lt; 0.001), and higher levels of anxiety symptomatology than youth without asthma (d = 0.29, 95%CI: 0.19-0.39, P &lt; 0.001). CONCLUSIONS: Youth with asthma display a prevalence rate for anxiety disorders that is more than three times higher than the prevalence in healthy youth. For the specific anxiety disorders investigated, elevated prevalence rates for youth with asthma were also found. Future research needs to focus on the factors that mediate or predict the development and maintenance of anxiety in youth with asthma and the development of clinically efficacious treatments</style></abstract><notes><style face="normal" font="default">DA - 20170727IS - 1099-0496 (Electronic)IS - 1099-0496 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1002/ppul.23689</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28749088">PM:28749088</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Pulmonol\20170727-DudeneyJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Pulmonol\20170727-DudeneyJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170727, Dudeney J</style></custom2><misc3><style face="normal" font="default">10.1002/ppul.23689</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42236</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Davis,J.S.</style></author><author><style face="normal" font="default"> Sun,M.</style></author><author><style face="normal" font="default"> Kho,A.T.</style></author><author><style face="normal" font="default"> Moore,K.G.</style></author><author><style face="normal" font="default"> Sylvia,J.M.</style></author><author><style face="normal" font="default"> Weiss,S.T.</style></author><author><style face="normal" font="default"> Lu,Q.</style></author><author><style face="normal" font="default"> Tantisira,K.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America</style></auth-address><titles><title><style face="normal" font="default">Circulating microRNAs and association with methacholine PC20 in the Childhood Asthma Management Program (CAMP) cohort</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0180329">e0180329-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> airway smooth muscle</style></keyword><keyword><style face="normal" font="default"> airway smooth muscle cells</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> Boston</style></keyword><keyword><style face="normal" font="default"> cAMP</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human airway smooth muscle</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Massachusetts</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> MicroRNAs</style></keyword><keyword><style face="normal" font="default"> Muscle Cells</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Circulating microRNAs (miRNA) are promising biomarkers for human diseases. Our study hypothesizes that circulating miRNA would reveal candidate biomarkers related to airway hyperresponsiveness (AHR) and provide biologic insights into asthma epigenetic influences. METHODS: Serum samples obtained at randomization for 160 children in the Childhood Asthma Management Program were profiled using a TaqMan miRNA array set. The association of the isolated miRNA with methacholine PC20 was assessed. Network and pathway analyses were performed. Functional validation of two significant miRNAs was performed in human airway smooth muscle cells (HASMs). RESULTS: Of 155 well-detected circulating miRNAs, eight were significantly associated with PC20 with the strongest association with miR-296-5p. Pathway analysis revealed miR-16-5p as a network hub, and involvement of multiple miRNAs interacting with genes in the FoxO and Hippo signaling pathways by KEGG analysis. Functional validation of two miRNA in HASM showed effects on cell growth and diameter. CONCLUSION: Reduced circulatory miRNA expression at baseline is associated with an increase in PC20. These miRNA provide biologic insights into, and may serve as biomarkers of, asthma severity. miR-16-5p and -30d-5p regulate airway smooth muscle phenotypes critically involved in asthma pathogenesis, supporting a mechanistic link to these findings. Functional ASM phenotypes may be directly relevant to AHR</style></abstract><notes><style face="normal" font="default">DA - 20170727IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0180329</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28749975">PM:28749975</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0180329.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0180329.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170727, Davis JS</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0180329</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42237</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Alexander,K.L.</style></author><author><style face="normal" font="default"> Katz,J.</style></author><author><style face="normal" font="default"> Elson,C.O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America</style></auth-address><titles><title><style face="normal" font="default">CBirTox is a selective antigen-specific agonist of the Treg-IgA-microbiota homeostatic pathway</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0181866">e0181866-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Alabama</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> antigen</style></keyword><keyword><style face="normal" font="default"> Antigens</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Cholera Toxin</style></keyword><keyword><style face="normal" font="default"> DC</style></keyword><keyword><style face="normal" font="default"> dendritic cell</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> dysregulation</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Foxp3</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Iga</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin A</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> regulatory T cell</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> signaling</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin disease</style></keyword><keyword><style face="normal" font="default"> Skin Diseases</style></keyword><keyword><style face="normal" font="default"> Subunit</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Treg</style></keyword><keyword><style face="normal" font="default"> Tregs</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Cultivating an environment of mutualism between host cells and the microbiota is vital, and dysregulation of this relationship is associated with multiple immune disorders including metabolic and skin diseases, asthma, allergy, and Inflammatory Bowel Disease (IBD). One prominent mechanism for maintaining homeostasis is the protective regulatory T cell (Treg)- Immunoglobulin A (IgA) pathway toward microbiota antigens, in which Tregs maintain homeostasis and provide critical survival factors to IgA+ B cells. In order to amplify the Treg-IgA pathway, we have generated a fusion protein, CBirTox, comprised of a portion of the carboxy terminus of CBir1, a microbiota flagellin, genetically coupled to Cholera Toxin B subunit (CTB) via the A2 linker of CT. Both dendritic cells (DCs) and B cells pulsed with CBirTox selectively induced functional CD4+Foxp3+ Tregs in vitro, and CBirTox augmented CD4+Foxp3+ cell numbers in vivo. The induced Foxp3 expression was independent of retinoic acid (RA) signaling but was inhibited by neutralization of TGF-beta. CBirTox treatment of B cells downregulated mammalian target of rapamycin (mTOR) signaling. Furthermore, CBirTox-pulsed DCs induced substantial production of IgA from naive B cells. Collectively these data demonstrate that CBirTox represents a novel approach to bolstering the Treg-IgA pathway at the host-microbiota interface</style></abstract><notes><style face="normal" font="default">DA - 20170727IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0181866</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28750075">PM:28750075</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0181866.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0181866.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170727, Alexander KL</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0181866</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42238</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Matysiak,K.</style></author><author><style face="normal" font="default"> Matuszewski,M.</style></author><author><style face="normal" font="default"> Feleszko,W.</style></author></authors></contributors><titles><title><style face="normal" font="default">Calcium prepartions do not inhibit allergic reactions. A randomized controlled trial</style></title><secondary-title><style face="normal" font="default">Pol Arch Intern Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pol Arch Intern Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Absorption</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> Anti-allergic</style></keyword><keyword><style face="normal" font="default"> anti-allergic drug</style></keyword><keyword><style face="normal" font="default"> anti-allergic drugs</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Calcium Carbonate</style></keyword><keyword><style face="normal" font="default"> Dietary Supplements</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Minerals</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> placebo</style></keyword><keyword><style face="normal" font="default"> placebo controlled</style></keyword><keyword><style face="normal" font="default"> placebo-controlled</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Preparation</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Pruritus</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> Salts</style></keyword><keyword><style face="normal" font="default"> scale</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin reaction</style></keyword><keyword><style face="normal" font="default"> skin reactions</style></keyword><keyword><style face="normal" font="default"> Supplements</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> VAS</style></keyword><keyword><style face="normal" font="default"> Vitamins</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wheal</style></keyword></keywords><dates><year Day="27" Month="6" Year="2017">2017/6/27</year></dates><abstract><style face="normal" font="default">INTRODUCTION Massive consumption of dietary supplements, including vitamins and minerals, has recently became a serious public issue in Europe. When ingested, they may negatively affect pharmacological activity of various medications, including anti-allergic drugs. Calcium preparations are well-known and commonly used in some European countries as a popular remedy for allergy-related skin reactions, such as itching, erythema and wheals, as well as insect bites. However, their action has not been reliably proven yet. OBJECTIVES The aim of this study is to investigate the efficacy of calcium salts in allergic reactions using the allergen-induced skin prick test (SPT) in a randomized, double-blind, placebo-controlled approach. PATIENTS AND METHODS Forty adult volunteers with allergic rhinoconjunctivitis and/or asthma were recruited and received oral calcium carbonate (1000 mg) or placebo t.i.d. for 3 days. SPTs were performed with 11 aeroallergen extracts at baseline, 4 and 72 hours after drug administration. The diameter of wheal was measured. We also evaluated pruritus intensity based on the visual analog scale (VAS). RESULTS There was no difference in the wheal size or pruritus between patients receiving calcium or placebo at any of the time points (P > 0.05). Calcium preparations were well tolerated. CONCLUSIONS We found no evidence to support the efficacy of calcium preparations in allergy-related skin reactions associated with itching and wheals. Calcium preparations do not suppress SPT responses; moreover their use in allergic patients should be discouraged due to their possible interference with the absorption of anti-allergic medications</style></abstract><notes><style face="normal" font="default">DA - 20170720IS - 1897-9483 (Electronic)IS - 0032-3772 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.20452/pamw.4049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28724883">PM:28724883</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pol Arch Intern Med\20170720-MatysiakK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pol Arch Intern Med\20170720-MatysiakK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170720, Matysiak K</style></custom2><misc3><style face="normal" font="default">10.20452/pamw.4049</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42239</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bielecki,P.é</style></author><author><style face="normal" font="default"> Sieskiewicz,A.</style></author><author><style face="normal" font="default"> Garkowski,M.</style></author><author><style face="normal" font="default"> Rogowski,M.</style></author><author><style face="normal" font="default"> Kowal,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Chronic rhinosinusitis: allergologis and laryngologist points of view</style></title><secondary-title><style face="normal" font="default">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pol J Allergol</style></full-title></periodical><pages end="76" start="68">68-76</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Affect</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Aspirin</style></keyword><keyword><style face="normal" font="default"> aspirin intolerance</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> astma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> Intranasal</style></keyword><keyword><style face="normal" font="default"> Intranasal steroids</style></keyword><keyword><style face="normal" font="default"> Irrigation</style></keyword><keyword><style face="normal" font="default"> mucosa</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasal Cavity</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year><pub-dates><date Day="0" Month="6" Year="2017">2017/6</date></pub-dates></dates><isbn><style face="normal" font="default">2353-3854</style></isbn><abstract><style face="normal" font="default">Abstract Chronic rhinosinusitis (CRS) is an inflammatory disorder which affects mucosa of nasal cavity and sinuses and lasts for at least 12-week duration. Many studies exploring association between allergy and CRS have been conducted. The most frequent allergic diseases which co-exist with CRS are asthma, allergic rhinitis and aspirin intolerance. Appropriate therapy of CRS should include both severity of symptoms and histopathologic characteristics. Initial treatment should relay on pharmacological control of symptoms using intranasal steroids, local irrigations and systemic antibiotics. Surgical interventions are usually performed whenever initial therapy fails. Despite appropriate therapy symptoms of CRS tend to recur. Therefore patients with CRS should be systematically evaluated by allergists and laryngologists. New pharmacological options including biologics may allow for more effective treatment</style></abstract><notes><style face="normal" font="default">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.alergo.2017.06.002</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.alergo.2017.06.002</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170801, Bielecki P</style></custom2><misc3><style face="normal" font="default">10.1016/j.alergo.2017.06.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42240</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bugova,G.</style></author><author><style face="normal" font="default"> Uhliarova,B.</style></author><author><style face="normal" font="default"> Jesenak,M.</style></author><author><style face="normal" font="default"> Hajtman,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">The presence of atopy and its effect on bacterial colonization of the upper airways in children with adenoid vegetation</style></title><secondary-title><style face="normal" font="default">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pol J Allergol</style></full-title></periodical><pages end="52" start="46">46-52</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenoid hypertrophy</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> Hypertrophy</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Moraxella</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Nasopharynx</style></keyword><keyword><style face="normal" font="default"> Pathogenic bacteria</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Slovakia</style></keyword><keyword><style face="normal" font="default"> Staphylococcus</style></keyword><keyword><style face="normal" font="default"> Staphylococcus aureus</style></keyword><keyword><style face="normal" font="default"> Streptococcus</style></keyword><keyword><style face="normal" font="default"> Streptococcus pneumoniae</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Upper airways</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year><pub-dates><date Day="0" Month="6" Year="2017">2017/6</date></pub-dates></dates><isbn><style face="normal" font="default">2353-3854</style></isbn><abstract><style face="normal" font="default">Abstract Background: The aim of this study was to determine the frequency of atopy and the influence of atopy on bacterial colonization of upper airway in children with adenoid hypertrophy. Material and methods: Forty children were enrolled in the prospective study. Presence of atopy was diagnosed by skin-prick test. Differences in bacterial colonization of middle nasal meatus and nasopharynx according to the presence of atopy were analyzed. Results: Atopy was diagnosed in 75% children with adenoid hypertrophy. Presence of atopy was associated with significantly more often colonization of pathogenic bacteria (Streptococcus pneumoniae, Hemophillus influaenzae, Moraxella catarrhalis, Staphylococcus aureus) in the middle nasal meatus but not in nasopharynx (P = 0.045, P = 0.483, respectively). Identification of pathogenic bacteria in middle nasal meatus did not correlate with isolation of pathogenic bacteria in nasopharynx in both groups of children. Conclusion: There is a high incidence of atopy in children with adenoid hypertrophy. Atopy is related to increased colonization by pathogenic bacteria in middle nasal meatus but not in nasopharynx</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Slovakia -</style></notes><work-type><style face="normal" font="default">10.1016/j.alergo.2017.04.002</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.alergo.2017.04.002</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170801, Bugova G</style></custom2><misc3><style face="normal" font="default">10.1016/j.alergo.2017.04.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42241</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ray,A.</style></author><author><style face="normal" font="default"> Nangia,V.</style></author><author><style face="normal" font="default"> Chatterji,R.</style></author><author><style face="normal" font="default"> Dalal,N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Unusual pulmonary manifestations in hepatitis B associated polyarteritis nodosa</style></title><secondary-title><style face="normal" font="default">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pol J Allergol</style></full-title></periodical><pages end="57" start="53">53-57</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Abdomen</style></keyword><keyword><style face="normal" font="default"> Arteries</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Bronchoscopy</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Circulating immune complexes</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Hemorrhage</style></keyword><keyword><style face="normal" font="default"> Hepatitis</style></keyword><keyword><style face="normal" font="default"> Hepatitis B</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> imaging</style></keyword><keyword><style face="normal" font="default"> immune complexes</style></keyword><keyword><style face="normal" font="default"> Immunosuppressants</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Intrabronchial mass</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Polyarteritis Nodosa</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Artery</style></keyword><keyword><style face="normal" font="default"> Pulmonary artery thrombosis</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Thrombosis</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year><pub-dates><date Day="0" Month="6" Year="2017">2017/6</date></pub-dates></dates><isbn><style face="normal" font="default">2353-3854</style></isbn><abstract><style face="normal" font="default">Abstract A young male recently diagnosed as a case of hepatitis B related chronic liver disease and portal hypertension presented with fever, shortness of breath and hemoptysis for the last one month. Chest and abdomen imaging revealed left main pulmonary artery thrombosis with evidence of nodular infiltrates in the right lung,collapse of the left lung (due to profuse pulmonary hemorrhage) and splenic infarcts. Bronchoscopy revealed nodular lesions in left main bronchus with cut-off. Routine anti-microbial screens were all negative. Serum C1q level was raised suggesting likely presence of circulating immune-complexes. As per American College of Rheumatology criteria the patient was labeled as a case of PAN with supportive endobronchial biopsy result. The patient showed dramatic improvement to immunosuppressants and pulmonary lesions showed near resolution. It is thus important to consider PAN as a possible cause of pulmonary manifestations in relation with HBV infection</style></abstract><notes><style face="normal" font="default">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="default">10.1016/j.alergo.2017.04.001</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.alergo.2017.04.001</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170801, Ray A</style></custom2><misc3><style face="normal" font="default">10.1016/j.alergo.2017.04.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42242</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Marko,M.</style></author><author><style face="normal" font="default"> Pawliczak,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">The role of microbiota in allergy development</style></title><secondary-title><style face="normal" font="default">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pol J Allergol</style></full-title></periodical><pages end="62" start="58">58-62</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Bacteria</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Digestive System</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Hay Fever</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human health</style></keyword><keyword><style face="normal" font="default"> hygiene hypothesis</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Probiotics</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year><pub-dates><date Day="0" Month="6" Year="2017">2017/6</date></pub-dates></dates><isbn><style face="normal" font="default">2353-3854</style></isbn><abstract><style face="normal" font="default">Abstract The increase of allergic diseases incidence has been noticed in industrialized countries. The reason for that is sought in increasing environment pollution and hygienisation of life. Diseases including asthma, hay fever, eczema and food allergies have dramatically increased over the last century. Microbiota (intestinal microflora) is a community of microorganisms, mainly bacteria that forms in the human digestive system a complex ecosystem. Recently more and more attention is paid to the connection of intestinal microflora with the occurrence of allergic diseases. Microbiota and the beneficial effects of probiotic bacteria on human health is becoming increasingly important in allergy development. However, the importance of probiotics in the prevention of these diseases has not been proven. It is a necessity to design and carry out thorough and detailed research to confirm significance of treatment with using probiotics strains</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.alergo.2017.03.002</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.alergo.2017.03.002</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170801, Marko M</style></custom2><misc3><style face="normal" font="default">10.1016/j.alergo.2017.03.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42243</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gawlik,R.</style></author><author><style face="normal" font="default"> Zagorny,G.</style></author><author><style face="normal" font="default"> Bozek,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Pharmacoeconomic assessment of allergic rhinitis and asthma treatment with specific immunotherapy</style></title><secondary-title><style face="normal" font="default">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pol J Allergol</style></full-title></periodical><pages end="67" start="63">63-67</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergen immunotherapy</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis and asthma</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Cost-effectiveness</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Health-related quality of life</style></keyword><keyword><style face="normal" font="default"> Immunotherapy</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> QOL</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> specific immunotherapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year><pub-dates><date Day="0" Month="6" Year="2017">2017/6</date></pub-dates></dates><isbn><style face="normal" font="default">2353-3854</style></isbn><abstract><style face="normal" font="default">Abstract Allergic rhinitis is a most common allergic disease affecting 40% of the population. The impact of AR on health-related quality of life (QoL) and productivity results in a significant economic burden. Allergen immunotherapy is the only causative treatment of allergic rhinitis and asthma. However, it is still unclear whether AIT is more cost-effective than the other treatments of AR without long-term cost-effectiveness studies. There is a need for further economic evaluations comparing different ways of immunotherapy and immunotherapy with pharmacotherapy</style></abstract><notes><style face="normal" font="default">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.alergo.2017.05.002</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.alergo.2017.05.002</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170801, Gawlik R</style></custom2><misc3><style face="normal" font="default">10.1016/j.alergo.2017.05.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42244</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Leszczynski,P.</style></author><author><style face="normal" font="default"> Sokol-Leszczynska,B.</style></author><author><style face="normal" font="default"> Pietrzak,B.</style></author><author><style face="normal" font="default"> Sawicka-Grzelak,A.</style></author><author><style face="normal" font="default"> Wielgos,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Microbiology, Warsaw Medical University of Warsaw, Warsaw, Poland</style></auth-address><titles><title><style face="normal" font="default">Erythromycin or Clindamycin - is it Still an Empirical Therapy against Streptococcus agalactiae in Patients Allergic to Penicillin?</style></title><secondary-title><style face="normal" font="default">Pol J Microbiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pol J Microbiol</style></abbr-1></periodical><pages end="268" start="265">265-268</pages><volume><style face="normal" font="default">66</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Clindamycin</style></keyword><keyword><style face="normal" font="default"> Erythromycin</style></keyword><keyword><style face="normal" font="default"> hospitalized</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> microbiology</style></keyword><keyword><style face="normal" font="default"> newborn</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Poland</style></keyword><keyword><style face="normal" font="default"> resistance</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Streptococcus</style></keyword><keyword><style face="normal" font="default"> Streptococcus agalactiae</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="6" Month="7" Year="2017">2017/7/6</year></dates><abstract><style face="normal" font="default">Retrospective analysis of Streptococcus agalactiae antibiotic susceptibility isolated in 2010-2013 was performed. Penicillin was still the first-line antibiotic. Due to the high percentage of strains resistant to erythromycin and clindamycin empirical treatment with these antibiotics may not be effective. Lower resistance rate to erythromycin and clindamycin among strains isolated from infected pregnant women and newborns were observed than among strains isolated from samples from patients hospitalized in other departments (29% and 47% v. 46% and 63%). The increasing resistance rate might give a rise to a new epidemiological situation</style></abstract><notes><style face="normal" font="default">DA - 20170723IS - 1733-1331 (Print)IS - 1733-1331 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28735311">PM:28735311</url></web-urls><related-urls><url ppv-ref="no">presto - su sito</url></related-urls></urls><custom2><style face="normal" font="default">20170723, Leszczynski P</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42245</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Underner,M.</style></author><author><style face="normal" font="default"> Perriot,J.</style></author><author><style face="normal" font="default"> Peiffer,G.</style></author><author><style face="normal" font="default"> Jaafari,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universite de Poitiers, unite de recherche clinique Pierre-Deniker, centre hospitalier Henri-Laborit, 370, avenue Jacques-Coeur, CS 10587, 86021 Poitiers cedex, France.</style></auth-address><titles><title><style face="normal" font="default">[Asthma and heroin use]</style></title><secondary-title><style face="normal" font="default">Presse Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Presse Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">acute asthma</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Alcohol</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchial Hyperreactivity</style></keyword><keyword><style face="normal" font="default"> Cannabis</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Case-Control Studies</style></keyword><keyword><style face="normal" font="default"> case-control study</style></keyword><keyword><style face="normal" font="default"> Clinique</style></keyword><keyword><style face="normal" font="default"> Cocaine</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> cross-sectional</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> English Abstract</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Heroin</style></keyword><keyword><style face="normal" font="default"> Intensive Care</style></keyword><keyword><style face="normal" font="default"> intensive care unit</style></keyword><keyword><style face="normal" font="default"> Intensive Care Units</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Intubation</style></keyword><keyword><style face="normal" font="default"> Language</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> longitudinal</style></keyword><keyword><style face="normal" font="default"> Longitudinal Studies</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Observance</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Overdose</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Reading</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Sex Ratio</style></keyword><keyword><style face="normal" font="default"> Tobacco</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> Ventilation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Heroin use can be responsible for many respiratory complications including asthma. OBJECTIVES: Systematic literature review of data on asthma in heroin users. DOCUMENTARY SOURCES: Medline(R), on the period 1980-2017 with the following keywords: keywords: "asthma" or "bronchospasm" and "heroin" or "opiate" or "opiates", limits "title/abstract"; the selected languages were English or French. Among 97 articles, 67 abstracts have given use to a dual reading to select 23 studies. RESULTS: The seven case reports included 21 patients (mean age: 28 years [19-46 years]; sex-ratio: 2.5 [males: 71.5%]). Heroin was inhaled (71.4%), sniffed (19%) or injected by intravenous route (9.5%). Associated addictive substances were tobacco (81%), cannabis (38%), alcohol (4.7%) and cocaine (4.7%). Outcome was fatal in 3 subjects (14.3%). Other studies included one cross-sectional study, 3 case-control studies and 12 longitudinal studies (11 retrospective studies and one prospective study). The proportion of heroin users was higher in asthmatic subjects and the prevalence of asthma and bronchial hyperreactivity was higher in heroin users. Heroin use can be responsible for asthma onset, with a temporal relationship between the onset of heroin use and asthma onset in 28 to 31% of subjects. A positive association between inhaled heroin use and acute asthma exacerbation was observed. Asthma treatment observance was lower in heroin users. In case of asthma exacerbation, heroin users were more likely to seek care in the emergency department, to be admitted in intensive care units and to require intubation and invasive ventilation. Asthma deaths related to heroin use mainly occurred following an intravenous injection (especially in the case of overdose), but also following heroin use by nasal (sniff) or pulmonary route. CONCLUSION: Heroin use may be responsible for asthma onset, acute asthma exacerbations (which may require intubation and invasive ventilation) or deaths related to asthma. Heroin use must be sought in case of asthma exacerbation in young persons and practitioners must help heroin users to stop their consumption</style></abstract><notes><style face="normal" font="default">DA - 20170723IS - 2213-0276 (Electronic)IS - 0755-4982 (Linking)LA - frePT - English AbstractPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.lpm.2017.06.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28734637">PM:28734637</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Presse Med\20170723-UrdenerM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Presse Med\20170723-UrdenerM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170723, Underner M</style></custom2><misc3><style face="normal" font="default">10.1016/j.lpm.2017.06.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42246</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mervak,B.M.</style></author><author><style face="normal" font="default"> Cohan,R.H.</style></author><author><style face="normal" font="default"> Ellis,J.H.</style></author><author><style face="normal" font="default"> Khalatbari,S.</style></author><author><style face="normal" font="default"> Davenport,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departments of Radiology, University of Michigan Health System, 1500 E Medical Center Dr, Room B2 A209P, Ann Arbor, MI 48109-5030</style></auth-address><titles><title><style face="normal" font="default">Intravenous Corticosteroid Premedication Administered 5 Hours Before CT Compared with a Traditional 13-Hour Oral Regimen</style></title><secondary-title><style face="normal" font="default">Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Radiology</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cohort</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> cohort study</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> Contrast material</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroid prophylaxis</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Informed Consent</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Michigan</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Premedication</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Radiology</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="26" Month="7" Year="2017">2017/7/26</year></dates><abstract><style face="normal" font="default">Purpose To determine if the allergic-like breakthrough reaction rate of intravenous corticosteroid prophylaxis administered 5 hours before contrast material-enhanced computed tomography (CT) is noninferior to that of a traditional 13-hour oral regimen. Materials and Methods Institutional review board approval was obtained and informed consent waived for this retrospective noninferiority cohort study. Subjects (n = 202) who completed an accelerated 5-hour intravenous corticosteroid premedication regimen before low-osmolality contrast-enhanced CT for a prior allergic-like or unknown-type reaction to iodine-based contrast material from June 1, 2008, to June 30, 2016, were identified. The breakthrough reaction rate was compared by using the Farrington and Manning noninferiority likelihood score to test subjects premedicated with a traditional 13-hour oral regimen (2.1% [13 of 626]). All subjects were premedicated for a prior allergic-like or unknown-type reaction to iodine-based contrast material. A noninferiority margin of 4.0% was selected to allow for no more than a clinically negligible 6.0% breakthrough reaction rate in the cohort that received 5-hour intravenous corticosteroid prophylaxis. Results The breakthrough reaction rate for 5-hour intravenous prophylaxis was 2.5% (five of 202 patients; 95% confidence interval: 0.8%, 5.7%), which was noninferior to the 2.1% (13 of 626 patients; 95% confidence interval: 1.1%, 3.5%) rate for the 13-hour regimen (P = .0181). The upper limits of the confidence interval for the difference between the two rates was 3.7% (0.4%; 95% confidence interval: -1.6%, 3.7%), which was within the 4.0% noninferiority margin. All breakthrough reactions were of equal or lesser severity to those of the index reactions (two severe, one moderate, and one mild reaction). Conclusion Accelerated intravenous premedication with corticosteroids beginning 5 hours before contrast-enhanced CT has a breakthrough reaction rate noninferior to that of a 13-hour oral premedication regimen. (c) RSNA, 2017</style></abstract><notes><style face="normal" font="default">DA - 20170726IS - 1527-1315 (Electronic)IS - 0033-8419 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1148/radiol.2017170107</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28745940">PM:28745940</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Radiology\20170726-MervakBM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Radiology\20170726-MervakBM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170726, Mervak BM</style></custom2><misc3><style face="normal" font="default">10.1148/radiol.2017170107</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42247</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arts,J.</style></author><author><style face="normal" font="default"> Kimber,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">AkzoNobel NV, Velperweg 76, 6824 BM, Arnhem, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default">Azodicarbonamide (ADCA): A reconsideration of classification as a respiratory sensitiser</style></title><secondary-title><style face="normal" font="default">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> occupational asthma</style></keyword><keyword><style face="normal" font="default"> pig</style></keyword><keyword><style face="normal" font="default"> Respiratory allergies</style></keyword><keyword><style face="normal" font="default"> Respiratory allergy</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Sensitisation</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Workplace</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="default">Azodicarbonamide (ADCA) is widely used by industry in the manufacture of a variety of products. ADCA has been classified as a respiratory allergen, and the purpose of this article was to consider whether this classification is appropriate based upon the available data. Here both clinical experience and relevant experimental data have been reviewed. Although there have been reports of an association between workplace exposure to ADCA and symptoms of respiratory allergy and occupational asthma, the evidence is less than persuasive, with in many instances a lack of properly controlled and executed diagnostic procedures. In addition, ADCA fails to elicit positive responses in mouse and guinea pig predictive tests for skin sensitisation; a lack of activity that is regarded as being inconsistent with respect to respiratory sensitising potential. Collectively, the data reviewed here do not provide an adequate basis for the classification of ADCA as a respiratory allergen</style></abstract><notes><style face="normal" font="default">DA - 20170723IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.yrtph.2017.07.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28734852">PM:28734852</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\20170723-ArtsJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\20170723-ArtsJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170723, Arts J</style></custom2><misc3><style face="normal" font="default">10.1016/j.yrtph.2017.07.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42248</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,H.</style></author><author><style face="normal" font="default"> Zeng,Q.S.</style></author><author><style face="normal" font="default"> Zhang,M.</style></author><author><style face="normal" font="default"> Chen,R.C.</style></author><author><style face="normal" font="default"> Xia,T.T.</style></author><author><style face="normal" font="default"> Wang,W.</style></author><author><style face="normal" font="default"> Xu,X.</style></author><author><style face="normal" font="default"> Guan,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China</style></auth-address><titles><title><style face="normal" font="default">Quantitative Low-Dose Computed Tomography of the Lung Parenchyma and Airways for the Differentiation between Chronic Obstructive Pulmonary Disease and Asthma Patients</style></title><secondary-title><style face="normal" font="default">Respiration</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Respiration</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Control Groups</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Differential diagnosis</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emphysema</style></keyword><keyword><style face="normal" font="default"> imaging</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> pulmonary function</style></keyword><keyword><style face="normal" font="default"> pulmonary function test</style></keyword><keyword><style face="normal" font="default"> Pulmonary function tests</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Radiology</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> small airways</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="25" Month="7" Year="2017">2017/7/25</year></dates><abstract><style face="normal" font="default">BACKGROUND: It is difficult to differentiate between chronic obstructive pulmonary disease (COPD) and asthma in clinics; therefore, for diagnostic purposes, imaging-based measurements could be beneficial to differentiate between the two diseases. OBJECTIVES: We aim to analyze quantitative measurements of the lung and bronchial parameters that are provided by low-dose computed tomography (CT) to differentiate COPD and asthma from an imaging perspective. MATERIALS AND METHODS: 69 COPD patients, 52 asthma patients, and 20 healthy subjects were recruited to participate in CT imaging and pulmonary function tests (PFTs). Comparative analysis was performed to identify differences between COPD and asthma in CT measurements. PFT measurements enabled validation of the differentiation between COPD and asthma patients. RESULTS: There were significant differences among the COPD, asthma, and healthy control groups. The differences were more significant among the following: inspiratory emphysema index (EI)-950 (%), expiratory lung volume, expiratory mean lung density (MLD), and expiratory EI-950 (%) and EI-850 (%). The COPD group had a significantly higher EI-950 (%) than the asthma group (p = 0.008). There were significant differences among the three groups in lumen area (LA), wall area (WA), total area, and Pi10WA. The asthma group had significantly higher WA%/WV% than both the COPD (p = 0.002) and the control group (p = 0.012). There was high sensitivity in EI-950 (%), EI-850 (%) and expiratory MLD in the parenchyma and high sensitivity in LA and Pi10WA in small airways in the differential diagnosis of COPD and asthma. CONCLUSION: To aid the diagnosis, CT can provide quantitative measurements to differentiate between COPD and asthma patients</style></abstract><notes><style face="normal" font="default">DA - 20170724IS - 1423-0356 (Electronic)IS - 0025-7931 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1159/000478531</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28738344">PM:28738344</url></web-urls><related-urls><url ppv-ref="no">presto - 1 anno</url></related-urls></urls><custom2><style face="normal" font="default">20170724, Chen H</style></custom2><misc3><style face="normal" font="default">10.1159/000478531</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42249</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Habukawa,C.</style></author><author><style face="normal" font="default"> Murakami,K.</style></author><author><style face="normal" font="default"> Endoh,M.</style></author><author><style face="normal" font="default"> Horii,N.</style></author><author><style face="normal" font="default"> Nagasaka,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Paediatrics, Minami Wakayama Medical Center, Tanabe, Japan</style></auth-address><titles><title><style face="normal" font="default">Treatment evaluation using lung sound analysis in asthmatic children</style></title><secondary-title><style face="normal" font="default">Respirology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respirology</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Airway Obstruction</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> inhaled corticosteroid</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung sound analysis</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> paediatric</style></keyword><keyword><style face="normal" font="default"> paediatrics</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Predictive values</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVE: Non-invasive assessment of treatment and prediction of attacks in asthmatic children do not yet exist. Lung sound analysis can non-invasively evaluate airway obstruction. We used a recently developed technology for analysing lung sounds using ic700 (index of the chest wall at 700 Hz, sound intensity at 700 Hz) to evaluate response to inhaled corticosteroid (ICS) in asthmatic children. METHOD: Seventy asthmatic children, including infants, underwent lung sound recording in the asymptomatic state prior to and 1, 2, 4, 6 and 8 weeks after ICS treatment, and asthma control was assessed at 10 weeks. The ic700 scores at 4, 6 and 8 weeks were compared with the presence of attack during the following 2 weeks. Subjects were divided into uncontrolled and well-controlled groups. RESULTS: The mean ic700 scores of all subjects significantly reduced after 8 weeks of treatment. The mean scores of the uncontrolled group were significantly higher than those of the well-controlled group at 4, 6 and 8 weeks after starting treatment. The ic700 cut-off value for predicting asthma attacks within 2 weeks following the evaluation was set at 0.0. After 6 weeks of treatment, the area under the curve was 0.92 +/- 0.04; the sensitivity, specificity and positive and negative predictive values were 83%, 88% and 88% and 84%, respectively. Similar results were observed at 4 and 8 weeks. CONCLUSION: The ic700 score is useful in assessing the effects of ICS treatment, predicting attack symptoms and identifying asymptomatic asthmatic children at a high risk for asthma attack</style></abstract><notes><style face="normal" font="default">DA - 20170719IS - 1440-1843 (Electronic)IS - 1323-7799 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/resp.13109</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28722791">PM:28722791</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respirology\20170719-HabukawaC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respirology\20170719-HabukawaC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170719, Habukawa C</style></custom2><misc3><style face="normal" font="default">10.1111/resp.13109</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42250</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bazouti,S.</style></author><author><style face="normal" font="default"> Fihmi,N.</style></author><author><style face="normal" font="default"> Zizi,N.</style></author><author><style face="normal" font="default"> Dikhaye,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Black henna tattoos: Beware!</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Black henna</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Henna</style></keyword><keyword><style face="normal" font="default"> Morocco</style></keyword><keyword><style face="normal" font="default"> P-phenylenediamine</style></keyword><keyword><style face="normal" font="default"> Tatouage</style></keyword><keyword><style face="normal" font="default"> Tattoo</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - FRECO - Morocco -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.04.001</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.04.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170803-BazoutiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170803-BazoutiS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170803, Bazouti S</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.04.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42251</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Man,M.A.</style></author><author><style face="normal" font="default"> Man,S.C.</style></author><author><style face="normal" font="default"> Motoc,N.S.</style></author><author><style face="normal" font="default"> Pop,C.M.</style></author><author><style face="normal" font="default"> Trofor,A.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Mother and Child, Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania; claudiu.man@umfcluj.ro</style></auth-address><titles><title><style face="normal" font="default">Fatal hypersensitivity pneumonitis after chemical occupational exposure</style></title><secondary-title><style face="normal" font="default">Rom J Morphol Embryol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rom J Morphol Embryol</style></full-title></periodical><pages end="634" start="627">627-634</pages><volume><style face="normal" font="default">58</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Biopsy</style></keyword><keyword><style face="normal" font="default"> Bronchiectasis</style></keyword><keyword><style face="normal" font="default"> Bronchoscopy</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> Carbon Monoxide</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> Cough</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Early Diagnosis</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Fatigue</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Fibrosis</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity Pneumonitis</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune response</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> Inhalation Exposure</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> lung biopsy</style></keyword><keyword><style face="normal" font="default"> Lung disease</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Exposure</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Pharmacies</style></keyword><keyword><style face="normal" font="default"> Pharmacy</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Romania</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Transfer Factor</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword><keyword><style face="normal" font="default"> Weight Loss</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Hypersensitivity pneumonitis (HP; extrinsic allergic alveolitis) is a rare non-immunoglobulin E (IgE)-mediated inflammatory lung disease caused by inhalation exposure (occupational, recreational or ordinary home exposure). A 36-year-old female patient, without significant medical history, is referred to an outpatient pulmonology clinic for dry cough, shortness of breath, fever, fatigue and weight loss. Chest high-resolution computed tomography (HRCT) was performed, and significant lung fibrosis (especially centrilobular and interlobular in bilateral "thick lines"), traction bronchiectasis and alveolitis in both superior lobes are described. Lung function tests showed severe restrictive dysfunction. Transfer factor of the lung for carbon monoxide (TLCO) being very low, the flexible bronchoscopy was contraindicated. Surgical lung biopsy was performed. Histopathological examination showed characteristic lesions of chronic bilateral hypersensitivity pneumonitis. The patient died four days after the surgical intervention due to post-operative complications. Exposure to various chemical substances can form bonds with human proteins molecules and induce an exaggerated immune response in susceptible individuals. A high index of suspicion of occupational exposure can determine an early diagnosis with a better outcome</style></abstract><notes><style face="normal" font="default">DA - 20170721IS - 1220-0522 (Print)IS - 1220-0522 (Linking)LA - engPT - Journal ArticleCO - Romania -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28730253">PM:28730253</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rom J Morphol Embryol\2017-58-627-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rom J Morphol Embryol\2017-58-627-34.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170721, Man MA</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42252</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Frisch,N.B.</style></author><author><style face="normal" font="default"> Jacobs,J.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hypersensitivity: Doc, Am I Allergic to My Implant?</style></title><secondary-title><style face="normal" font="default">Semin Arthroplasty</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Semin Arthroplasty</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Arthroplasty</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Device Removal</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> immune reaction</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Intolerance</style></keyword><keyword><style face="normal" font="default"> Jewelry</style></keyword><keyword><style face="normal" font="default"> Knee</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Lymphocyte</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Transformation</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> metal</style></keyword><keyword><style face="normal" font="default"> Metal allergy</style></keyword><keyword><style face="normal" font="default"> metal hypersensitivity</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> total hip arthroplasty</style></keyword><keyword><style face="normal" font="default"> total knee arthroplasty</style></keyword><keyword><style face="normal" font="default"> Transformation</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> validation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1045-4527</style></isbn><abstract><style face="normal" font="default">Abstract There is controversy regarding the clinical significance of metal hypersensitivity in total knee arthroplasty (TKA). Given the current state of the art, metal hypersensitivity, if it exists at all, is a diagnosis of exclusion. Clinical presentation may involve a cutaneous response, but current diagnostic methods do not have robust clinical validation and should be used with caution. The two most commonly used tests include cutaneous patch testing and in vitro lymphocyte transformation testing. Initially, conservative management is indicated and other more common causes of a symptomatic total knee replacement should be fully explored. In rare cases, device removal may be undertaken but this should be considered a last resort. Pre-operative testing prior to a primary total joint replacement may be helpful when there</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç¦s a patient-reported history of intolerance to jewelry or of an allergic reaction to a prior metal implant, but routine lab screening is not supported by the literature</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1053/j.sart.2017.07.005</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1053/j.sart.2017.07.005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Semin Arthroplasty\20170801-FrischNB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Semin Arthroplasty\20170801-FrischNB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Frisch NB</style></custom2><misc3><style face="normal" font="default">10.1053/j.sart.2017.07.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42253</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Saito,K.</style></author><author><style face="normal" font="default"> Takenouchi,O.</style></author><author><style face="normal" font="default"> Nukada,Y.</style></author><author><style face="normal" font="default"> Miyazawa,M.</style></author><author><style face="normal" font="default"> Sakaguchi,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Kao Corporation, R&amp;D, Safety Science Research, 2606 Akabane Ichikai-Machi Haga-Gun, Tochigi 321-3497, Japan.</style></auth-address><titles><title><style face="normal" font="default">An in vitro skin sensitization assay termed EpiSensA for broad sets of chemicals including lipophilic chemicals and pre/pro-haptens</style></title><secondary-title><style face="normal" font="default">Toxicol In Vitro</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Toxicol In Vitro</style></full-title></periodical><pages end="25" start="11">11-25</pages><volume><style face="normal" font="default">40</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine</style></keyword><keyword><style face="normal" font="default"> Activating Transcription Factor 3</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> analogs &amp; derivatives</style></keyword><keyword><style face="normal" font="default"> Animal Testing Alternatives</style></keyword><keyword><style face="normal" font="default"> antagonist</style></keyword><keyword><style face="normal" font="default"> antagonists</style></keyword><keyword><style face="normal" font="default"> Biological Assay</style></keyword><keyword><style face="normal" font="default"> Cell Survival</style></keyword><keyword><style face="normal" font="default"> Cells,Cultured</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Dinitrochlorobenzene</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidermis</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> Glutamate-Cysteine Ligase</style></keyword><keyword><style face="normal" font="default"> hapten</style></keyword><keyword><style face="normal" font="default"> Haptens</style></keyword><keyword><style face="normal" font="default"> HSP40 Heat-Shock Proteins</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> IL-8</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Interleukin-8</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Keratinocytes</style></keyword><keyword><style face="normal" font="default"> L-Lactate Dehydrogenase</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> NF-E2-Related Factor 2</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Purinergic P2X Receptor Antagonists</style></keyword><keyword><style face="normal" font="default"> Receptor</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rna</style></keyword><keyword><style face="normal" font="default"> RNA,Small Interfering</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Subunit</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> transcription factor</style></keyword><keyword><style face="normal" font="default"> Up-Regulation</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">To evaluate chemicals (e.g. lipophilic chemicals, pre/pro-haptens) that are difficult to correctly evaluate using in vitro skin sensitization tests (e.g. DPRA, KeratinoSens or h-CLAT), we developed a novel in vitro test termed "Epidermal Sensitization Assay: EpiSensA" that uses reconstructed human epidermis. This assay is based on the induction of multiple marker genes (ATF3, IL-8, DNAJB4 and GCLM) related to two keratinocyte responses (inflammatory or cytoprotective) in the induction of skin sensitization. Here, we first confirmed the mechanistic relevance of these marker genes by focusing on key molecules that regulate keratinocyte responses in vivo (P2X7 for inflammatory and Nrf2 for cytoprotective responses). The up-regulation of ATF3 and IL-8, or DNAJB4 and GCLM induced by the representative sensitizer 2,4-dinitrochlorobenzene in human keratinocytes was significantly suppressed by a P2X7 specific antagonist KN-62, or by Nrf2 siRNA, respectively, which supported mechanistic relevance of marker genes. Moreover, the EpiSensA had sensitivity, specificity and accuracy of 93%, 100% and 93% for 29 lipophilic chemicals (logKow>/=3.5), and of 96%, 75% and 88% for 43 hydrophilic chemicals including 11 pre/pro-haptens, compared with the LLNA. These results suggested that the EpiSensA could be a mechanism-based test applicable to broad sets of chemicals including lipophilic chemicals and pre/pro-haptens</style></abstract><notes><style face="normal" font="default">DA - 20161214IS - 1879-3177 (Electronic)IS - 0887-2333 (Linking)LA - engPT - Journal ArticleRN - 0 (ATF3 protein, human)RN - 0 (Activating Transcription Factor 3)RN - 0 (Allergens)RN - 0 (DNAJB4 protein, human)RN - 0 (HSP40 Heat-Shock Proteins)RN - 0 (Haptens)RN - 0 (Interleukin-8)RN - 0 (NF-E2-Related Factor 2)RN - 0 (NFE2L2 protein, human)RN - 0 (Purinergic P2X Receptor Antagonists)RN - 0 (RNA, Small Interfering)RN - 63HM46XPOW (KN 62)RN - 84477-87-2 (1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine)RN - EC 1.1.1.27 (L-Lactate Dehydrogenase)RN - EC 6.3.2.2 (Glutamate-Cysteine Ligase)RN - EC 6.3.2.2 (glutamate-cysteine ligase modifier subunit, human)RN - GE3IBT7BMN (Dinitrochlorobenzene)SB - IMCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.tiv.2016.12.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27965148">PM:27965148</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicol in Vitro\2017-40-11-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicol in Vitro\2017-40-11-25.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161214, Saito K</style></custom2><misc3><style face="normal" font="default">10.1016/j.tiv.2016.12.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42254</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chalmers,J.R.</style></author><author><style face="normal" font="default"> Haines,R.H.</style></author><author><style face="normal" font="default"> Mitchell,E.J.</style></author><author><style face="normal" font="default"> Thomas,K.S.</style></author><author><style face="normal" font="default"> Brown,S.J.</style></author><author><style face="normal" font="default"> Ridd,M.</style></author><author><style face="normal" font="default"> Lawton,S.</style></author><author><style face="normal" font="default"> Simpson,E.L.</style></author><author><style face="normal" font="default"> Cork,M.J.</style></author><author><style face="normal" font="default"> Sach,T.H.</style></author><author><style face="normal" font="default"> Bradshaw,L.E.</style></author><author><style face="normal" font="default"> Montgomery,A.A.</style></author><author><style face="normal" font="default"> Boyle,R.J.</style></author><author><style face="normal" font="default"> Williams,H.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.</style></auth-address><titles><title><style face="normal" font="default">Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial</style></title><secondary-title><style face="normal" font="default">Trials</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Trials</style></abbr-1></periodical><pages end="" start="343">343-</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergic sensitisation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> Atopic diseases</style></keyword><keyword><style face="normal" font="default"> atopic eczema</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Cost Savings</style></keyword><keyword><style face="normal" font="default"> Cost-effectiveness</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Definition</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> diagnostic criteria</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> effectiveness</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emollient</style></keyword><keyword><style face="normal" font="default"> Emollients</style></keyword><keyword><style face="normal" font="default"> England</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> Fever</style></keyword><keyword><style face="normal" font="default"> Filaggrin</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Genotype</style></keyword><keyword><style face="normal" font="default"> Hay Fever</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health care provider</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Registry</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Sensitisation</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin barrier</style></keyword><keyword><style face="normal" font="default"> Skin Care</style></keyword><keyword><style face="normal" font="default"> Term</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="21" Month="7" Year="2017">2017/7/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic eczema (AE) is a common skin problem that impairs quality of life and is associated with the development of other atopic diseases including asthma, food allergy and allergic rhinitis. AE treatment is a significant cost burden for health care providers. The purpose of the trial is to investigate whether daily application of emollients for the first year of life can prevent AE developing in high-risk infants (first-degree relative with asthma, AE or allergic rhinitis). METHODS: This is a protocol for a pragmatic, two-arm, randomised controlled, multicentre trial. Up to 1400 term infants at high risk of developing AE will be recruited through the community, primary and secondary care in England. Participating families will be randomised in a 1:1 ratio to receive general infant skin-care advice, or general skin-care advice plus emollients with advice to apply daily to the infant for the first year of life. Families will not be blinded to treatment allocation. The primary outcome will be a blinded assessment of AE at 24 months of age using the UK Working Party Diagnostic Criteria for Atopic Eczema. Secondary outcomes are other definitions of AE, time to AE onset, severity of AE (EASI and POEM), presence of other allergic diseases including food allergy, asthma and hay fever, allergic sensitisation, quality of life, cost-effectiveness and safety of the emollients. Subgroup analyses are planned for the primary outcome according to filaggrin genotype and the number of first-degree relatives with AE and other atopic diseases. Families will be followed up by online and postal questionnaire at 3, 6, 12 and 18 months with a face-to-face visit at 24 months. Long-term follow-up until 60 months will be via annual questionnaires. DISCUSSION: This trial will demonstrate whether skin-barrier enhancement through daily emollient for the first year of life can prevent AE from developing in high-risk infants. If effective, this simple and cheap intervention has the potential to result in significant cost savings for health care providers throughout the world by preventing AE and possibly other associated allergic diseases. TRIAL REGISTRATION: ISRCTN registry; ID: ISRCTN21528841 . Registered on 25 July 2014</style></abstract><notes><style face="normal" font="default">DA - 20170722IS - 1745-6215 (Electronic)IS - 1745-6215 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1186/s13063-017-2031-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28732519">PM:28732519</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Trials\2017-18-343.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Trials\2017-18-343.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170722, Chalmers JR</style></custom2><misc3><style face="normal" font="default">10.1186/s13063-017-2031-3</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42255</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dilek,F.</style></author><author><style face="normal" font="default"> Emin,O.</style></author><author><style face="normal" font="default"> Gultepe,B.</style></author><author><style face="normal" font="default"> Yazici,M.</style></author><author><style face="normal" font="default"> Cakir,E.</style></author><author><style face="normal" font="default"> Gedik,A.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Division of Pediatric Allergy and Immunology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="default">Evaluation of nasal fluid beta-defensin 2 levels in children with allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Turk Pediatri Ars</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Turk Pediatri Ars</style></full-title></periodical><pages end="84" start="79">79-84</pages><volume><style face="normal" font="default">52</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Absorption</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Allergy and Immunology</style></keyword><keyword><style face="normal" font="default"> Chemotaxis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Control Groups</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> Defensins</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Enzyme-Linked Immunosorbent Assay</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Fungal infection</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Immunity</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> innate immune system</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> peptide</style></keyword><keyword><style face="normal" font="default"> Peptides</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> symptom scores</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Turkey</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wound Healing</style></keyword></keywords><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">AIM: Knowledge about the role of the innate immune system in the pathogenesis of allergic diseases has been expanding in recent years. Defensins are antimicrobial peptides that are components of the innate immune system. Defensins have strong efficacy against bacterial, viral, and fungal infections. Moreover, they have regulatory functions in many physiologic processes such as antitumoral immunity, chemotaxis, inflammation, and wound healing. In this study, we aimed to investigate beta-defensin 2 levels in the nasal fluids of children with allergic rhinitis. MATERIAL AND METHODS: Study and control groups consisted of 28 patients with newly diagnosed allergic rhinitis who were not taking any medication, and 23 healthy children. Skin prick tests were performed on patients with allergic rhinitis and disease severity was assessed using the total symptom score. Nasal fluid samples were obtained using a modified polyurethane sponge absorption method from patients and control subjects. Nasal fluid beta-defensin 2 levels were determined using an enzyme-linked immunosorbent assay (ELISA). RESULTS: The median value of nasal fluid beta-defensin 2 levels were 173.8 pg/mL (interquartile range; 54.8-205.9 pg/mL) in allergic rhinitis group and 241.6 pg/mL (163.5-315.2 pg/mL) in the control group. There was a statistically significant difference between the two groups (p=0.01). Moreover, nasal fluid beta-defensin 2 levels showed a significant negative correlation with total symptom scores (rho= -0.78, p&lt;0.001). CONCLUSIONS: Children with allergic rhinitis have reduced nasal fluid beta-defensin 2 levels compared with controls, and beta-defensin 2 levels were negatively correlated with disease severity. A more definite understanding of the roles of defensins and other antimicrobial peptides in allergic inflammation can open up new horizons in the management and treatment of these common diseases</style></abstract><notes><style face="normal" font="default">DA - 20170727IS - 1306-0015 (Print)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.5152/TurkPediatriArs.2017.4497</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28747838">PM:28747838</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Turk Pediatri Ars\2017-52-79-84.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Turk Pediatri Ars\2017-52-79-84.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170727, Dilek F</style></custom2><misc3><style face="normal" font="default">10.5152/TurkPediatriArs.2017.4497</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42256</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Toledo,M.F.</style></author><author><style face="normal" font="default"> Saraiva-Romanholo,B.M.</style></author><author><style face="normal" font="default"> Oliveira,R.C.</style></author><author><style face="normal" font="default"> da Silva,L.F.</style></author><author><style face="normal" font="default"> Sole,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, University of Taubate (UNITAU), Taubate, Sao Paulo, Brazil.</style></auth-address><titles><title><style face="normal" font="default">Air pollution and its relationship to lung function among adolescents from Taubate, Sao Paulo, Brazil</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> adolescents</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> alveolar macrophage</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Brazil</style></keyword><keyword><style face="normal" font="default"> Carbon</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Evaluation</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> FEV1</style></keyword><keyword><style face="normal" font="default"> Inhalation</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> macrophage</style></keyword><keyword><style face="normal" font="default"> Macrophages</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Paper</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> Sputum</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="27" Month="7" Year="2017">2017/7/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: This paper sought to evaluate individual exposure to air pollution by quantifying the carbon in alveolar macrophages (AMs) and its relationship to lung function. We also examined the proximity of participants' residences to the Presidente Dutra highway (PDH) in adolescents with asthma from Taubate, Sao Paulo, Brazil. METHODS: This descriptive study examined fifty 13- to 14-year-old adolescents with asthma identified by the International Study of Asthma and Allergies in Childhood (ISAAC) in Taubate. These adolescents underwent spirometry and sputum induction via the inhalation of 3% hypertonic saline (HSS). Sputum was collected after each nebulisation, and forced expiratory flow in one second (FEV1) was measured. The collected sputum was stored and transported to the laboratory; it was then processed and analysed for ultrafine particles (&lt;/=100nm). This analysis was correlated with the residence location and FEV1 of each adolescent. RESULTS: A total of 39 adolescents completed the study. The comparison of the carbon fraction within macrophages (CA/MA) showed no differences according to residence in relation to the PDH (p=0.758). After adjustment, a mixed linear model with FEV1 as the dependent variable and CA/MA, location, and evaluation condition as the predictors found that the interactions among the variables were not significant. CONCLUSIONS: The amount of carbon present within the AMs of adolescents with asthma was not correlated with either lung function or residence location. Evaluations of the topography and local climatic conditions in Taubate should be considered in future studies</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.04.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28757196">PM:28757196</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170731-ToledoMF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20170731-ToledoMF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170731, Toledo MF</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.04.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42257</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ito,K.</style></author><author><style face="normal" font="default"> Ono,M.</style></author><author><style face="normal" font="default"> Kando,N.</style></author><author><style face="normal" font="default"> Matsui,T.</style></author><author><style face="normal" font="default"> Nakagawa,T.</style></author><author><style face="normal" font="default"> Sugiura,S.</style></author><author><style face="normal" font="default"> Ebisawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy, Aichi Children's Health and Medical Center, Aichi, Japan</style></auth-address><titles><title><style face="normal" font="default">Surveillance of the use of adrenaline auto-injectors in Japanese children</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adrenaline</style></keyword><keyword><style face="normal" font="default"> Adrenaline auto-injector</style></keyword><keyword><style face="normal" font="default"> Adrenaline autoinjector</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Auto-injectors</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Cow's milk</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> egg</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> fish</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> food allergies</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Food Labeling</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Labeling</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Milk</style></keyword><keyword><style face="normal" font="default"> Nurseries</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Peanut</style></keyword><keyword><style face="normal" font="default"> Peanuts</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pediatric allergy</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Schools</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Wheat</style></keyword></keywords><dates><year Day="4" Month="8" Year="2017">2017/8/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: The appropriate usage of an adrenaline auto-injector (AAI, Epipen(R)) is a key aspect of patient and social education in the management of anaphylaxis. However, although AAIs are being prescribed increasingly frequently, there are few reports on their actual use. METHODS: The Anaphylaxis Working Group of the Japanese Society of Pediatric Allergy and Clinical Immunology requested that society members register cases in which AAIs were used. Two hundred and sixty-six cases were collected from March 2014 to March 2016. RESULTS: The cases included 240 events of immediate-type food allergies caused by cow's milk (n = 100), hen's egg (n = 42), wheat (n = 40), and peanuts (n = 11). Exercise-related events were reported in 19 cases; however, the diagnosis of food-dependent exercise-induced anaphylaxis with a specific causative food was only made in 4 cases (wheat, n = 2; fish, n = 1; squid, n = 1). The frequent reasons for the causative intake included programmed intake (n = 48), failure to check the food labeling (n = 43), and consuming an inappropriate food (n = 26). AAIs were used at schools or nurseries in 67 cases, with school or nursery staff members administering the AAI in 39 cases (58%). On arriving at the hospital, the symptom grade was improved in 71% of the cases, while grade 4 symptoms remained in 20% of the cases. No lethal cases or sequelae were reported. CONCLUSIONS: AAIs were used effectively, even by school teachers. The need to visit a hospital after the use of an AAI should be emphasized because additional treatment might be required</style></abstract><notes><style face="normal" font="default">DA - 20170808IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.07.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28784272">PM:28784272</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170808-ItoK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170808-ItoK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170808, Ito K</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.07.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42258</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Iikura,M.</style></author><author><style face="normal" font="default"> Hojo,M.</style></author><author><style face="normal" font="default"> Nagano,N.</style></author><author><style face="normal" font="default"> Sakamoto,K.</style></author><author><style face="normal" font="default"> Kobayashi,K.</style></author><author><style face="normal" font="default"> Yamamoto,S.</style></author><author><style face="normal" font="default"> Hashimoto,M.</style></author><author><style face="normal" font="default"> Ishii,S.</style></author><author><style face="normal" font="default"> Izumi,S.</style></author><author><style face="normal" font="default"> Sugiyama,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default">Bronchial thermoplasty for severe uncontrolled asthma in Japan</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchial thermoplasty</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Global Health</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Tokyo</style></keyword></keywords><dates><year Day="29" Month="7" Year="2017">2017/7/29</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170802IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.07.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28764942">PM:28764942</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170802-IikuraM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170802-IikuraM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Iikura M</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.07.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42259</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hong,H.Y.</style></author><author><style face="normal" font="default"> Chen,F.H.</style></author><author><style face="normal" font="default"> Sun,Y.Q.</style></author><author><style face="normal" font="default"> Hu,X.T.</style></author><author><style face="normal" font="default"> Wei,Y.</style></author><author><style face="normal" font="default"> Fan,Y.P.</style></author><author><style face="normal" font="default"> Zhang,J.</style></author><author><style face="normal" font="default"> Wang,D.H.</style></author><author><style face="normal" font="default"> Xu,R.</style></author><author><style face="normal" font="default"> Li,H.B.</style></author><author><style face="normal" font="default"> Shi,J.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Center, Otorhinolaryngology Hospital, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou</style></auth-address><titles><title><style face="normal" font="default">Local IL-25 contributes to Th2-biased inflammatory profiles in nasal polyps</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> computed tomography</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> innate</style></keyword><keyword><style face="normal" font="default"> Innate lymphoid cells</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Polyps</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Staining</style></keyword><keyword><style face="normal" font="default"> subtypes</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> TH2 cell</style></keyword><keyword><style face="normal" font="default"> Th2 Cells</style></keyword><keyword><style face="normal" font="default"> TH2 cytokine</style></keyword><keyword><style face="normal" font="default"> Th2 response</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="3" Month="8" Year="2017">2017/8/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: IL-25 has been proposed to play a key role in the pathogenesis of chronic rhinosinusitis with nasal polyps (CRSwNP). This study aims to evaluate the association of IL-25 with the Th2-biased inflammatory profiles in CRSwNP. METHODS: Nasal polyp (NP) tissues and control uncinate process tissues were collected from 92 patients with CRSwNP, 20 patients with chronic rhinosinusitis without nasal polyps (CRSsNP), and 16 normal control subjects. IL-25 expression was examined using immunohistochemistry and immunofluorescence staining, flow cytometry, RT-qPCR, and ELISA. The inflammatory profiles and clinical characteristics of 2 NP subtypes (IL-25high and IL-25low ) were evaluated, and the effects of IL-25 on Th2 cytokine production in cultured dispersed polyp cells were examined in vitro. RESULTS: The mRNA and protein levels of IL-25 were significantly increased in the polyp tissues compared with the control uncinate process tissues. The IL-25high subtype showed greater computed tomography scores, endoscopic scores, and Th2 response. Exposure to IL-25 activated type 2 innate lymphoid cells and Th2 cells in NP simultaneously which further increased Th2 cytokine production in vitro. CONCLUSIONS: Local IL-25 plays a crucial role in promoting Th2-biased inflammatory profiles in NP, and may serve as a promising therapeutic target in CRSwNP patients. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170803IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1111/all.13267</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28771767">PM:28771767</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170803-HongHY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170803-HongHY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170803, Hong HY</style></custom2><misc3><style face="normal" font="default">10.1111/all.13267</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42260</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Watanabe,T.</style></author><author><style face="normal" font="default"> Chibana,K.</style></author><author><style face="normal" font="default"> Shiobara,T.</style></author><author><style face="normal" font="default"> Tei,R.</style></author><author><style face="normal" font="default"> Koike,R.</style></author><author><style face="normal" font="default"> Nakamura,Y.</style></author><author><style face="normal" font="default"> Arai,R.</style></author><author><style face="normal" font="default"> Horigane,Y.</style></author><author><style face="normal" font="default"> Shimizu,Y.</style></author><author><style face="normal" font="default"> Takemasa,A.</style></author><author><style face="normal" font="default"> Fukuda,T.</style></author><author><style face="normal" font="default"> Wenzel,S.E.</style></author><author><style face="normal" font="default"> Ishii,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine, Tochigi, Japan</style></auth-address><titles><title><style face="normal" font="default">Expression of intelectin-1 in bronchial epithelial cells of asthma is correlated with T-helper 2 (Type-2) related parameters and its function</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Clin Immunol</style></full-title></periodical><pages end="" start="35">35-</pages><volume><style face="normal" font="default">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> BAL</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchial epithelial cells</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chemokine</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> CXCL10</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> epithelial</style></keyword><keyword><style face="normal" font="default"> Epithelial Cells</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> Fibroblasts</style></keyword><keyword><style face="normal" font="default"> Goblet Cells</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> IL-13</style></keyword><keyword><style face="normal" font="default"> IL13</style></keyword><keyword><style face="normal" font="default"> Immunohistochemistry</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inhibition</style></keyword><keyword><style face="normal" font="default"> iNOS</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mometasone</style></keyword><keyword><style face="normal" font="default"> mometasone furoate</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mRNA</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> PCR</style></keyword><keyword><style face="normal" font="default"> Periostin</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Pulmonary Medicine</style></keyword><keyword><style face="normal" font="default"> Quantitative</style></keyword><keyword><style face="normal" font="default"> Recombinant</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> T helper</style></keyword><keyword><style face="normal" font="default"> T-helper-2</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Intelectin-1 (ITLN-1) is secreted by intestinal goblet cells and detectable in blood. Its expression is increased in IL-13-overexpressing mouse airways. However, its expression and function in human airways is poorly understood. METHODS: Distal and proximal bronchial epithelial cells (BECs) were isolated from bronchoscopic brushings of disease control (D-CON), COPD, inhaled corticosteroid-treated asthma (ST-Asthma) and inhaled corticosteroid-naive asthma (SN-Asthma) patients. ITLN-1 mRNA expression in freshly isolated BECs, primary cultured BECs with or without IL-13 and inhibition effects of mometasone furoate (MF) were investigated by quantitative real-time PCR (qPCR). Correlations between ITLN-1 mRNA and Type-2 related parameters (e.g. FeNO, IgE, iNOS, CCL26, periostin and DPP4 mRNA) were analyzed. ITLN-1 protein distribution in asthmatic airway tissue was assessed by immunohistochemistry. Bronchial alveolar lavage (BAL) and serum ITLN-1 protein were measured by ELISA. The effect of recombinant human (rh) ITLN-1 on stimulated production of CXCL10 and phospho(p)-STAT1 expression examined in lung fibroblasts. RESULTS: ITLN-1 mRNA was expressed in freshly isolated BECs and was correlated with Type-2 related parameters. ITLN-1 protein was increased in goblet cells in SN-Asthmatics and increased in SN-Asthmatic BAL fluid. There were no any differences in serum ITLN-1 concentration between ST and SN-Asthma. IL-13 enhanced ITLN-1 expression and inhibited by MF from BECs in vitro, while rhITLN-1 inhibited CXCL10 production and p-STAT1 expression in HFL-1 cells. CONCLUSION: ITLN-1 is induced by IL-13 and expressed mainly in goblet cells in untreated asthma where its levels correlate with known Type-2 related parameters. Further, ITLN-1 inhibits Type-1 chemokine expression</style></abstract><notes><style face="normal" font="default">DA - 20170804IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1186/s13223-017-0207-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28775743">PM:28775743</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-35.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default">20170804, Watanabe T</style></custom2><misc3><style face="normal" font="default">10.1186/s13223-017-0207-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42261</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Marc,M.M.</style></author><author><style face="normal" font="default"> Rozman,A.</style></author><author><style face="normal" font="default"> Skrgat,S.</style></author><author><style face="normal" font="default"> Silar,M.</style></author><author><style face="normal" font="default"> Selb,J.</style></author><author><style face="normal" font="default"> Flezar,M.</style></author><author><style face="normal" font="default"> Korosec,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pulmonology Department, University Clinic for Respiratory and Allergic Diseases, Golnik, Slovenia.</style></auth-address><titles><title><style face="normal" font="default">Bronchial thermoplasty induces immunomodulation with a significant increase in pulmonary CD4+25+ regulatory T cells</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchial thermoplasty</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Immunomodulation</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Regulatory</style></keyword><keyword><style face="normal" font="default"> regulatory T cell</style></keyword><keyword><style face="normal" font="default"> regulatory T cells</style></keyword><keyword><style face="normal" font="default"> Slovenia</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170805IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Slovenia -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.06.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28778660">PM:28778660</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170805-MarcMM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170805-MarcMM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170805, Marc MM</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.06.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42262</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Maatta,A.M.</style></author><author><style face="normal" font="default"> Kotaniemi-Syrjanen,A.</style></author><author><style face="normal" font="default"> Malmstrom,K.</style></author><author><style face="normal" font="default"> Malmberg,L.P.</style></author><author><style face="normal" font="default"> Sundvall,J.</style></author><author><style face="normal" font="default"> Pelkonen,A.S.</style></author><author><style face="normal" font="default"> Makela,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.</style></auth-address><titles><title><style face="normal" font="default">Vitamin D, high-sensitivity C-reactive protein, and airway hyperresponsiveness in infants with recurrent respiratory symptoms</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airway hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> C-Reactive Protein</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Challenge test</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> early childhood</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulin E</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> linked</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> Lung function testing</style></keyword><keyword><style face="normal" font="default"> methacholine</style></keyword><keyword><style face="normal" font="default"> Methacholine challenge</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> respiratory symptom</style></keyword><keyword><style face="normal" font="default"> respiratory symptoms</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Vitamin D</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheezing</style></keyword><keyword><style face="normal" font="default"> young children</style></keyword></keywords><dates><year Day="28" Month="7" Year="2017">2017/7/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: Vitamin D insufficiency might be associated with biased T-cell responses resulting in inflammatory conditions such as atopy and asthma. Little is known about the role of vitamin D in low-grade systemic inflammation and airway hyperresponsiveness (AHR) in young children. OBJECTIVE: To evaluate whether vitamin D insufficiency and increased serum high-sensitivity C-reactive protein (hs-CRP) are linked to AHR in symptomatic infants. METHODS: Seventy-nine infants with recurrent or persistent lower respiratory tract symptoms underwent comprehensive lung function testing and a bronchial methacholine challenge test. In addition, skin prick tests were performed and serum 25-hydroxyvitamin D (S-25-OHD), hs-CRP, total immunoglobulin E, and blood eosinophil levels were determined. RESULTS: S-25-OHD was lowest in infants with blood eosinophilia and AHR (n = 10) compared with those with eosinophilia only (n = 6) or AHR only (n = 50) or those with neither (n = 13; P = .035). Moreover, vitamin D insufficiency (S-25-OHD &lt;50 nmol/L) was most common in infants with blood eosinophilia and AHR (P = .041). Serum hs-CRP was lower in infants with recurrent physician-diagnosed wheezing (P = .048) and in those with blood eosinophilia (P = .015) than in infants without these characteristics and was not associated with S-25-OHD or AHR. S-25-OHD levels were significantly lower (median 54 nmol/L) during the autumn-winter season than in the spring-summer season (median 63 nmol/L; P = .026). CONCLUSION: Vitamin D insufficiency could underlie eosinophilia and AHR in infants with troublesome lung symptoms, whereas hs-CRP-mediated low-grade systemic inflammation is rare in early childhood wheezing</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.06.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28757230">PM:28757230</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170731-MaattaAM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170731-MaattaAM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170731, Maatta AM</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.06.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42263</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rosa,M.J.</style></author><author><style face="normal" font="default"> Just,A.C.</style></author><author><style face="normal" font="default"> Kloog,I.</style></author><author><style face="normal" font="default"> Pantic,I.</style></author><author><style face="normal" font="default"> Schnaas,L.</style></author><author><style face="normal" font="default"> Lee,A.</style></author><author><style face="normal" font="default"> Bose,S.</style></author><author><style face="normal" font="default"> Chiu,Y.M.</style></author><author><style face="normal" font="default"> Hsu,H.L.</style></author><author><style face="normal" font="default"> Coull,B.</style></author><author><style face="normal" font="default"> Schwartz,J.</style></author><author><style face="normal" font="default"> Cohen,S.</style></author><author><style face="normal" font="default"> Tellez Rojo,M.M.</style></author><author><style face="normal" font="default"> Wright,R.O.</style></author><author><style face="normal" font="default"> Wright,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai, New York, New York</style></auth-address><titles><title><style face="normal" font="default">Prenatal particulate matter exposure and wheeze in Mexican children: effect modification by prenatal psychosocial stress</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mexico</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mothers</style></keyword><keyword><style face="normal" font="default"> New York</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Particulate matter</style></keyword><keyword><style face="normal" font="default"> PM2.5</style></keyword><keyword><style face="normal" font="default"> Poisson</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Prediction</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Stress</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> wheeze</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="27" Month="7" Year="2017">2017/7/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Air pollution exposure in childhood is associated with greater incidence and exacerbation of asthma, particularly in children whose parents report high levels of psychological stress. However, this interaction has not been completely elucidated in pregnancy. OBJECTIVE: To examine whether the association between prenatal exposure to particulate matter no larger than 2.5 mum in diameter (PM2.5) and wheeze in children is modified by prenatal stress. METHODS: Mexican women were recruited during pregnancy (N = 552). Residential prenatal daily exposure to PM2.5 was estimated using a satellite-based spatiotemporally resolved prediction model and averaged over trimesters. Maternal stress was indexed by maternal negative life events (NLE) score (range 0-11) ascertained during mid to late pregnancy. NLE scores were dichotomized at the median as low (NLE score &lt;/= 3) and high (NLE score > 3) stress. Reports of ever wheeze and wheeze in the past 12 months (current wheeze) for children were obtained using the International Study of Asthma and Allergies in Childhood survey at 48 months. The association between prenatal PM2.5 and wheeze was analyzed using a modified Poisson regression and stratified by low vs high stress. RESULTS: Greater PM2.5 exposure during the first trimester was associated with increased risk of current wheeze among children with mothers reporting high prenatal stress (relative risk 1.35, 95% confidence interval 1.00-1.83, per interquartile range increase 3.8 mug/m3) but not among those reporting low stress (relative risk 0.84, 95% confidence interval 0.61-1.16, per interquartile range increase 3.8 mug/m3; P for interaction = .04). CONCLUSION: Increased prenatal stress enhanced the association between PM2.5 exposure in early pregnancy, and child wheeze at 48 months of age. It is important to consider chemical and nonchemical stressors together to more comprehensively characterize children's environmental risk</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Mexico -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.06.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28757229">PM:28757229</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170731-RosaMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170731-RosaMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170731, Rosa MJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.06.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42264</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sousa-Pinto,B.</style></author><author><style face="normal" font="default"> Fonseca,J.A.</style></author><author><style face="normal" font="default"> Gomes,E.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">MEDCIDS-Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal</style></auth-address><titles><title><style face="normal" font="default">Frequency of self-reported drug allergy: A systematic review and meta-analysis with meta-regression</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anesthetics</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Class</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Clinical manifestations</style></keyword><keyword><style face="normal" font="default"> community</style></keyword><keyword><style face="normal" font="default"> Consequences</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous manifestations</style></keyword><keyword><style face="normal" font="default"> Databases</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> Drug provocation test</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> frequency</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Inpatient</style></keyword><keyword><style face="normal" font="default"> Inpatients</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Meta-Analysis</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> observational study</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Outpatients</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Provocation test</style></keyword><keyword><style face="normal" font="default"> Provocation tests</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> systematic review</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic reaction</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="8" Year="2017">2017/8/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patients reporting drug allergy are treated with second-line therapies, with possible negative clinical and health consequences. OBJECTIVE: To assess the prevalence of self-reported drug allergy. METHODS: We performed a systematic review of observational studies assessing the prevalence of self-reported drug allergy. We searched 4 electronic databases. From selected studies, we extracted data on self-reported drug allergy prevalence, study design, participants' demographic characteristics, reported clinical manifestations, and suspected culprit drugs. We performed a random-effects meta-analysis followed by a meta-regression. RESULTS: Fifty-three studies were included in the systematic review, assessing a total of 126,306 participants, of whom 8.3% (range across studies 0.7-38.5%) self-reported drug allergy. Cutaneous manifestations were reported by 68.2% of participants, and anaphylactic or systemic reactions were reported by 10.8%. Antibiotics, nonsteroidal anti-inflammatory drugs, and anesthetics were the most frequently reported culprit drug classes. The frequency of self-reported drug allergy was higher in female (11.4%) than in male (7.2%) patients, adults (10.0%) than in children (5.1%), and in studies in the medical setting (15.9% in inpatients, 11.4% in outpatients) than in the general population (5.9%). The meta-analysis rendered a pooled prevalence of 7.9% (95% confidence interval 6.4-9.6), and the meta-regression identified study region, participants' age group, and study setting as factors associated with significant heterogeneity. Confirmation tests (including skin, in vitro, and drug provocation tests) were performed in only 3 studies. CONCLUSION: The prevalence of self-reported drug allergy is highly variable and is higher in female patients, adults, and inpatients. To overcome this variability, further studies using confirmation tests are needed</style></abstract><notes><style face="normal" font="default">DA - 20170806IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28779998">PM:28779998</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170806-SousaPintoB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170806-SousaPintoB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170806, Sousa-Pinto B</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42265</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sanchez Salguero,C.A.</style></author><author><style face="normal" font="default"> Sanchez Chacon,A.I.</style></author></authors></contributors><titles><title><style face="normal" font="default">Atopic Conjunctivitis in Children: Influence of Treatment with Topical Cyclosporin 0.05% in the Quality of Life</style></title><secondary-title><style face="normal" font="default">Arch Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arch Asthma Allergy Immunol</style></full-title></periodical><pages end="008" start="001">001-008</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Calcineurin</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Conjunctivitis</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Cyclosporine</style></keyword><keyword><style face="normal" font="default"> Eye</style></keyword><keyword><style face="normal" font="default"> Fatigue</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Ocular</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> rhinoconjunctivitis</style></keyword><keyword><style face="normal" font="default"> Sleep</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Introduction: Forty-six per cent children have allergic rhinoconjunctivitis (Allergologica 2005).Working hypothesis: Ocular topical cyclosporine improves the quality of life for these patients.Material, methods, design: 2-year prospective study (2015-16), 40 patients with topical corticosteroidswithout improvement, followed 20 and 20 switched to corticosteroids cyclosporine 0.05%. Interview withQuality of Life Questionnaire in Children with rhinoconjunctivitis (PRQLQ) before and at the end of treatment.Mean age of 10.3 years with 60% male-40% female. Treatments were applied from January to March. Therewere 15 questions divided into two blocks. Children responded using a card with responses rated from zero(not bothered at all) to 6 (quite upset).Results: Before the 100% reported that, the itching was very bothersome. In the group of 40 children,80% showed symptoms of epiphora and 60% showed symptoms of ocular infl ammation. 100% complainedof signifi cant discomfort in rubbing their eyes, 30% did not like to take medications. Headaches affected 20%.100% stated that they cannot play normally. 80% showed decreased concentration in class.Continuing with corticosteroids did not show statistically signifi cant changes.Patients with cyclosporine improved the results by 3 points, with decreased itching, tearing, swelling, pain,eye rubbing, medication and headaches. In the 2nd questionnaire there was limited variation in the resultsrelated to fatigue, malaise, and irritability but with substantially improved balance of sleep, insomnia andconcentration at school.Conclusion: Cyclosporine A is a cyclic polypeptide calcineurin inhibitor developed from the fungusTolypocladium infl atum. The fi rst dilution was 2% but it is currently used at a dilution of 0.05% and recentpublications suggest nanosuspensions. Our study showed improvement in parameters related to symptoms,especially itching and lower improvement of psychological aspects, this achieves a better quality of life forchildren and more willingness to adhere to the treatment.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.heighpubs.org/haard/articles.php?volume=1&amp;issue=1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Arch Asthma Allergy Immunol\2017-1-001-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Arch Asthma Allergy Immunol\2017-1-001-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170805, Sanchez Salguero CA</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42266</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ospelnikova,T.P.</style></author><author><style face="normal" font="default"> Gevorkyan,O.V.</style></author><author><style face="normal" font="default"> Mironova,T.V.</style></author><author><style face="normal" font="default"> Andreeva,S.A.</style></author><author><style face="normal" font="default"> Kolodyazhnaya,L.V.</style></author><author><style face="normal" font="default"> Ershov,F.I.</style></author></authors></contributors><titles><title><style face="normal" font="default">Features of Interferon and Cytokine Status in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">Arch Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arch Asthma Allergy Immunol</style></full-title></periodical><pages end="014" start="009">009-014</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">atopic</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> herpes</style></keyword><keyword><style face="normal" font="default"> Herpes virus</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Interferon</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Russia</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> virus</style></keyword><keyword><style face="normal" font="default"> virus infection</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="Roboto-Regular">The insuffi ciency of interferon production and the cytokine imbalance in patients with atopic dermatitis, especially in combination with persistent herpes virus infection, has been identifi ed. The expediency of the useof interferon inducer Cycloferon in the treatment of chronic atopic dermatitis has been shown.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Russia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.heighpubs.org/haard/articles.php?volume=1&amp;issue=1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Arch Asthma Allergy Immunol\2017-1-009-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Arch Asthma Allergy Immunol\2017-1-009-14.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170805, Ospelnikova TP</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42267</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Midoro-Horiuti,T.</style></author><author><style face="normal" font="default"> Goldblum,R.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">The effects of early low dose exposures to the Environmental Estrogen Bisphenol A on the Development of Childhood Asthma</style></title><secondary-title><style face="normal" font="default">Arch Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arch Asthma Allergy Immunol</style></full-title></periodical><pages end="027" start="015">015-027</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> allergic asthma</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Animal model</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Bisphenol A</style></keyword><keyword><style face="normal" font="default"> Breast</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Epidemiological studies</style></keyword><keyword><style face="normal" font="default"> estrogen</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Fetus</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Medline</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> Placenta</style></keyword><keyword><style face="normal" font="default"> Plastics</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Production</style></keyword><keyword><style face="normal" font="default"> Publications</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> urine</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Exposure to environmental chemicals is a potential cause for the rapid increase in the prevalence of allergicasthma over the last few decades. The production of the environmental estrogen bisphenol A, the monomer ofpolycarbonate plastics, has increased rapidly over the last 50 years, such that bisphenol A is one of the mosthighly produced chemicals. It is detectable in the urine of the vast majority of the human population. Whilethe relationship between the increase of bisphenol A in our environment and the prevalence of asthma doesnot prove a cause and effect relationship, it provides a strong rationale for experiments that have tested thehypothesis. Because of its small molecular size and hydrophobicity, bisphenol A is easily transferred from themother to the fetus, via the placenta and in breast milk.We have reviewed all the publications available on medline on the human epidemiological studies of theearly bisphenol A exposure on the development of allergic asthma and experimental studies using mousemodel of the effects of early bisphenol A exposure on the development of asthma. There are eight humanepidemiological studies and fi ve mouse model studies currently published.The human studies suggest that bisphenol A exposure in early life enhances the likelihood of developingasthma on at least one of the study groups. The effects of early bisphenol A exposure were observed as anenhanced development of asthma before adolescent in the animal model.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.heighpubs.org/haard/articles.php?volume=1&amp;issue=1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Arch Asthma Allergy Immunol\2017-1-015-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Arch Asthma Allergy Immunol\2017-1-015-27.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170805, Midoro-Horiuti T</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42268</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Callero,A.</style></author><author><style face="normal" font="default"> Perez-Rodriguez,E.</style></author><author><style face="normal" font="default"> Heras-Mendaza,F.</style></author><author><style face="normal" font="default"> Martinez-Tadeo,J.A.</style></author><author><style face="normal" font="default"> Garcia-Robaina,J.C.</style></author><author><style face="normal" font="default"> Conde-Salazar,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universitary Hospital Nuestra Senora de Candelaria, Allergy Unit. 38010 Santa Cruz de Tenerife, Spain</style></auth-address><titles><title><style face="normal" font="default">Is Euxyl K400 patch testing useful in the general population?</style></title><secondary-title><style face="normal" font="default">Asia Pac Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asia Pac Allergy</style></abbr-1></periodical><pages end="172" start="171">171-172</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> general population</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170802IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.5415/apallergy.2017.7.3.171</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28765822">PM:28765822</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-171-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-171-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Callero A</style></custom2><misc3><style face="normal" font="default">10.5415/apallergy.2017.7.3.171</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42269</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bedolla-Barajas,M.</style></author><author><style face="normal" font="default"> Puente-Fernandez,C.</style></author><author><style face="normal" font="default"> Flores-Merino,M.V.</style></author><author><style face="normal" font="default"> Morales-Romero,J.</style></author><author><style face="normal" font="default"> Dominguez-Garcia,M.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Servicio de Alergia e Inmunologia Clinica, Hospital Civil de Guadalajara "Dr. Juan I. Menchaca", 44340 Guadalajara, Mexico</style></auth-address><titles><title><style face="normal" font="default">Self-report prevalence and associated factors to drug hypersensitivity in Mexican young adults</style></title><secondary-title><style face="normal" font="default">Asia Pac Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asia Pac Allergy</style></abbr-1></periodical><pages end="162" start="156">156-162</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Alergia</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic disease</style></keyword><keyword><style face="normal" font="default"> Atopic diseases</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immune System</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mexico</style></keyword><keyword><style face="normal" font="default"> nonsteroidal anti-inflammatory drugs</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Self Report</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Drug hypersensitivity is defined as any unfavorable reaction that occurs after the administration of any drug. It may or may not be mediated by the involvement of the immune system. Epidemiological data related to drug hypersensitivity reactions in our country are scarce. OBJECTIVE: To determine the prevalence of drug hypersensitivity in a group of young adults, as well as to identify associated factors. METHODS: A structured questionnaire was applied to young people aged 18 to 25 years. The instrument was oriented to identify reactions of drug hypersensitivity, as well as the most prevalent drugs involved. In addition, a personal and family history of atopic diseases was included. Analysis for associations between variables was been done through logistic regression. RESULTS: The prevalence of drug hypersensitivity reactions was 12% (144 of 1,200). The antibiotics were the agents most related to hypersensitivity reactions (9.8%) followed by nonsteroidal anti-inflammatory drugs (1.6%). Factors associated with drug hypersensitivity were a personal history of asthma, odds ratio (OR) 3.15 (95% confidence interval [CI], 1.44-6.91), maternal and paternal history of drug hypersensitivity, OR 2.33 (95% CI, 1.21-4.48) and OR 3.11 (95% CI, 1.22-7.92), respectively. CONCLUSION: The results of this research show that drug hypersensitivity in young adults is a highly prevalent event and it is associated with personal history of asthma and history of drug hypersensitivity in parents</style></abstract><notes><style face="normal" font="default">DA - 20170802IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="default">10.5415/apallergy.2017.7.3.156</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28765820">PM:28765820</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-156-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-156-62.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Bedolla-Barajas M</style></custom2><misc3><style face="normal" font="default">10.5415/apallergy.2017.7.3.156</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42270</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kang,D.Y.</style></author><author><style face="normal" font="default"> Ahn,K.M.</style></author><author><style face="normal" font="default"> Kang,H.R.</style></author><author><style face="normal" font="default"> Cho,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Drug Safety Monitoring Center, Seoul National University Hospital, Seoul 03080, Korea</style></auth-address><titles><title><style face="normal" font="default">Past, present, and future of pharmacovigilance in Korea</style></title><secondary-title><style face="normal" font="default">Asia Pac Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asia Pac Allergy</style></abbr-1></periodical><pages end="178" start="173">173-178</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">27</style></keyword><keyword><style face="normal" font="default"> adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> Distribution</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Monitoring</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> global</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> insurance</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> network</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patient Safety</style></keyword><keyword><style face="normal" font="default"> Pharmacovigilance</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk Management</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Societies</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> World Health</style></keyword><keyword><style face="normal" font="default"> World Health Organization</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">As an essential part of patient safety, pharmacovigilance is of worldwide interest and should expand its scope and focus on new emerging issues. South Korea has been making continuous efforts in the field of pharmacovigilance for the last 3 decades since voluntary adverse drug reaction (ADR) reporting system was first launched in 1988. Korea joined the World Health Organization Program for International Drug Monitoring in 1992, and the activities of Pharmacovigilance Research Network, Korean Society for Pharmacoepidemiology and Risk Management, and Regional Pharmacovigilance Center (RPVC) have contributed to the remarkable progress in the pharmacovigilance area and global status. RPVCs have played pivotal roles in establishment of pharmacovigilance system in Korea by monitoring voluntary ADR reports. RPVCs started with 3 hospitals in 2006 and have now expanded to 27 hospitals nationwide. The Korea Institute of Drug Safety &amp; Risk Management was established in 2012 and in charge of operating the decentralized national pharmacovigilance system. The voluntary report of ADR, which is the basis of current pharmacovigilance system, has various limitations and an active surveillance system can be the overarching alternative. This change in pharmacovigilance paradigm is a global trend and Korea has excellent infrastructure such as broad distribution of electronic medical recording systems and a nationwide single healthcare insurance. As a result, the pharmacovigilance in Korea is now expected to progress to a new active surveillance system from traditional spontaneous reporting system</style></abstract><notes><style face="normal" font="default">DA - 20170802IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.5415/apallergy.2017.7.3.173</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28765823">PM:28765823</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-173-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-173-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Kang DY</style></custom2><misc3><style face="normal" font="default">10.5415/apallergy.2017.7.3.173</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42271</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cho,S.W.</style></author><author><style face="normal" font="default"> Kim,D.W.</style></author><author><style face="normal" font="default"> Kim,J.W.</style></author><author><style face="normal" font="default"> Lee,C.H.</style></author><author><style face="normal" font="default"> Rhee,C.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Korea</style></auth-address><titles><title><style face="normal" font="default">Classification of chronic rhinosinusitis according to a nasal polyp and tissue eosinophilia: limitation of current classification system for Asian population</style></title><secondary-title><style face="normal" font="default">Asia Pac Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asia Pac Allergy</style></abbr-1></periodical><pages end="130" start="121">121-130</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> Asia</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> eosinophilic</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Korea</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> nasal polyp</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Neck</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> remodeling</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Chronic rhinosinusitis (CRS) can be classified according to the presence of a nasal polyp (NP): CRS with NP (CRSwNP) and CRS without NP (CRSsNP). CRSwNP has characteristics with high infiltration of tissue eosinophilia with a burst of Th2 inflammatory cytokine. However recent findings in Eastern Asia countries suggest that CRSwNP can be divided according to the presence of tissue eosinophilia. Thus, CRSwNP can be classified into eosinophilic and noneosinophilic. Eosinophilic CRSwNP seems to have different immunological and clinical feature compared to noneosinophilic CRSwNP. From the same point of view, CRSsNP can also be divided according to tissue eosinophilia. However, the meaning of this dichotomous categorization in CRS seems to be not quite clear. This review focus on the limitations in current subclassification of CRS according to the presence of NP and tissue eosinophilia and discuss other factors related to tissue remodeling and NP generation which may provide clues for the further understanding of CRS pathogenesis</style></abstract><notes><style face="normal" font="default">DA - 20170802IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.5415/apallergy.2017.7.3.121</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28765816">PM:28765816</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-121-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-121-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Cho SW</style></custom2><misc3><style face="normal" font="default">10.5415/apallergy.2017.7.3.121</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42272</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Timalsena,S.</style></author><author><style face="normal" font="default"> Pluangnooch,P.</style></author><author><style face="normal" font="default"> Wongkajornsilp,A.</style></author><author><style face="normal" font="default"> Soontrapa,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">An additional CD28 costimulatory signal enhances proliferation and cytotoxicity of murine T cell-derived CIK cells</style></title><secondary-title><style face="normal" font="default">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="74" start="67">67-74</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">activation</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> cell activation</style></keyword><keyword><style face="normal" font="default"> Cell cytotoxicity</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Culture</style></keyword><keyword><style face="normal" font="default"> Cytokine</style></keyword><keyword><style face="normal" font="default"> cytokines</style></keyword><keyword><style face="normal" font="default"> cytotoxicity</style></keyword><keyword><style face="normal" font="default"> expression</style></keyword><keyword><style face="normal" font="default"> Flow Cytometry</style></keyword><keyword><style face="normal" font="default"> IL-2</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Interferon</style></keyword><keyword><style face="normal" font="default"> Interleukin-2</style></keyword><keyword><style face="normal" font="default"> Killer Cells</style></keyword><keyword><style face="normal" font="default"> Lymphoma</style></keyword><keyword><style face="normal" font="default"> monoclonal antibodies</style></keyword><keyword><style face="normal" font="default"> Monoclonal antibody</style></keyword><keyword><style face="normal" font="default"> murine</style></keyword><keyword><style face="normal" font="default"> Natural</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> peripheral blood</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> proliferation</style></keyword><keyword><style face="normal" font="default"> Propidium</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T cells</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> T-cells</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword><keyword><style face="normal" font="default"> Tumor Necrosis Factor-alpha</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Objective: Cytokine induced killer (CIK) cells are ex-vivo expanded T cells endowed with both T and Natural Killer cellproperties. The standard protocol for generation of CIK cells is to culture peripheral blood mononuclear cells (PBMC) inthe presence of interferon- gamma (IFN-ƒÁ), monoclonal antibody (mAb) against CD3 and interleukin-2 (IL-2). However,this protocol lacks costimulatory signal (CD28), crucial for T cell activation. Herein, the proliferation and functionalproperties of murine thymocytes derived CIK cells generated with or without costimulatory activation provided byanti-CD28 mAb were examined.Method: The proportion of CIK (Thy1.2+NK1.1+ and CD8+NK1.1+) cells in culture and the expression of cytotoxicgranules (granzyme B and perforin) and proinflammatory cytokines (IFN-ƒÁ and tumor necrosis factor-alpha (TNF-ƒ¿))were determined by flow cytometry. Additionally, CIK cell cytotoxicity against YAC-1 murine lymphoma cells wasmeasured by a propidium iodide-based assay.Results: The addition of anti-CD28 to standard CIK culture conditions increased the number of Thy1.2+ NK1.1+ and CD8+NK1.1+ (the major effector population) cells by almost 40% and 32%, respectively. Furthermore, the cytotoxic potentialof CIK cells cultured with the addition of anti-CD28 mAb was also enhanced, with a corresponding increase in CIK cellsexpressing granzyme B, perforin, IFN-ƒÁ and TNF-ƒ¿.Conclusions: The addition of anti-CD28 mAb generated more effective murine T cell-derived CIK cells.Keywords: CD28 monoclonal antibody; CD3 monoclonal antibody, Cytokine-induced killer cells; Murine thymocytes,Immunostimulation</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Thailand -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://apjai-journal.org/volume-35-number-2-june-2017/</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2017-35-67-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2017-35-67-74.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170805, Timalsena S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42273</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Daengsuwan,T.</style></author><author><style face="normal" font="default"> Watanatham,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">A comparative pilot study of the efficacy and safety of nebulized magnesium sulfate and intravenous magnesium sulfate in children with severe acute asthma</style></title><secondary-title><style face="normal" font="default">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="112" start="108">108-112</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">acute asthma</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Adverse effect</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Magnesium</style></keyword><keyword><style face="normal" font="default"> Magnesium Sulfate</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> nebulized</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Pilot study</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Sample Size</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Introduction: Severe asthma attacks are life-threatening, and require serious medical attention. Intravenous MgSO4 isan efficient medication, proven to improve outcomes. To date, most research has focused on administration of nebulizedMgSO4 in adults with critical asthma. However, its benefits for treating childhood asthma has been little investigated. Thisstudy compared the clinical efficacy and adverse effects of nebulized MgSO4 and intravenous MgSO4 in the treatment ofchildren with severe acute asthma.Method: A prospective, open-label, randomized, controlled pilot study was conducted in children with severe asthmaexacerbation admitted at the Queen Sirikit National Institute of Child Health. Twenty-eight patients were randomizedto receive three intermittent doses of nebulized or intravenous MgSO4. The Modified Woodfs Clinical Asthma Score wasdetermined prior to, and at 20, 40, 60, 120, 180 and 240 minutes after treatment administration. The length of hospital staywas also recorded.Results: Fifteen patients received nebulized isotonic MgSO4 and 13 were administered intravenous MgSO4. There were nodifferences in the baseline characteristics of the two groups, including their initial asthma severity scores (4.87 } 0.92 vs. 5.0+0.82; p = 0.69). No statistically significant differences between the two groups were identified at 60 minutes (2.47 } 0.83vs. 2.77 } 0.93; p = 0.37) until 240 minutes. The length of hospital stay for both groups was also similar (4.0 }1.2 vs. 4.54 }2.7; p = 0.51). No adverse effects from MgSO4 administration were observed among the participants.Conclusions: In this small sample size we demonstrated that nebulized MgSO4 and intravenous MgSO4 are both clinicallybeneficial and safe for Thai children suffering from severe asthma exacerbation.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Thailand -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://apjai-journal.org/volume-35-number-2-june-2017/</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2017-35-108-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2017-35-108-12.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170805, Daengsuwan T</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42274</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Satdhabudha,A.</style></author><author><style face="normal" font="default"> Utispan,K.</style></author><author><style face="normal" font="default"> Monthanapisut,P.</style></author><author><style face="normal" font="default"> Poachannukoon,O.</style></author></authors></contributors><titles><title><style face="normal" font="default">A randomized controlled study comparing the efficacy of nasal saline irrigation devices in children with acute rhinosinusitis</style></title><secondary-title><style face="normal" font="default">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="107" start="102">102-107</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Amoxicillin-clavulanic acid</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Irrigation</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> nasal</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Parents</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> randomized</style></keyword><keyword><style face="normal" font="default"> Rhinosinusitis</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> Side effect</style></keyword><keyword><style face="normal" font="default"> side effects</style></keyword><keyword><style face="normal" font="default"> Sinusitis</style></keyword><keyword><style face="normal" font="default"> Thailand</style></keyword><keyword><style face="normal" font="default"> use</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Objective: To evaluate the efficacy of positive-pressure nasal irrigation devices in children with acute sinusitis, in additionto bacterial colonization of the irrigation device.Method: We performed a randomized, prospective, controlled study of 80 children with acute sinusitis, aged between 3 and15 years. Participants were randomly separated into two groups, where one group was treated using a squeezable bottle andthe other group treated using a syringe. All patients were instructed to use a 1.25% buffered hypertonic solution for nasalirrigation twice daily for 2 weeks, in addition to amoxicillin-clavulanic acid. During this period, all participants recordeda 5S score, satisfaction score, any side effects and use of antihistamines. Parents were instructed to clean the device withsoap after each use. After this period, the nasal irrigation devices were sent to a microbiological laboratory for bacterialidentification.Results: At the 2-week follow-up, improvement in both 5S and satisfaction scores were observed in both groups comparedto baseline, which were significantly higher in the group treated with the squeezable bottle compared to the syringe. Fewcomplaints were reported, and side effects were equal in both groups. The overall rate of bacterial contamination for bothtreatments was approximately 80%, but this did not translate into higher rates of infection amongst patients.Conclusions: The use of a squeezable bottle for nasal irrigation in children with acute sinusitis was associated with furtherimprovements in 5S and satisfaction scores compared to syringe use, and there were no significant differences in bacterialcontamination between methods.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Thailand -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://apjai-journal.org/volume-35-number-2-june-2017/</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2017-35-102-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asian Pac J Allergy Immunol\2017-35-102-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170805, Satdhabudha A</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42275</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gupta,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Flaws in GINA Guidelines and the Solutions Thereof</style></title><secondary-title><style face="normal" font="default">Austin J Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Austin J Allergy</style></full-title></periodical><pages end="" start="1027">1027-</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> Solutions</style></keyword><keyword><style face="normal" font="default"> Step down</style></keyword><keyword><style face="normal" font="default"> Step-down</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Asthma continues to be the commonest chronic respiratory illness and its prevalence is on the rise. Further, its control remains poor in spite of the wide availability and practice of GINA guidelines. Based on literature, the author is of the opinion that asthma can be better controlled with "Step in-Step down approach" (Initiating treatment of asthma with optimal dose of ICS along with LABA, withdrawal of LABA first during step down and finally reducing dose of ICS once control of asthma is sustained) rather than the Step up-step down approach" suggested by GINA.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="default">10.26420/austinjallergy.2017.1027</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.26420/austinjallergy.2017.1027</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Austin J Allergy\2017-4-1027.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Austin J Allergy\2017-4-1027.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170805, Gupta P</style></custom2><misc3><style face="normal" font="default">10.26420/austinjallergy.2017.1027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42276</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tuluri,F.</style></author><author><style face="normal" font="default"> Gorai,A.K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Asthma Trends in Mississippi Coastal Region with Air Pollutants and Meteorological Factors</style></title><secondary-title><style face="normal" font="default">Austin J Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Austin J Allergy</style></full-title></periodical><pages end="" start="1026">1026-</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Air</style></keyword><keyword><style face="normal" font="default"> Air Pollutants</style></keyword><keyword><style face="normal" font="default"> Air quality</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Continuous</style></keyword><keyword><style face="normal" font="default"> correlation</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Human health</style></keyword><keyword><style face="normal" font="default"> Humidity</style></keyword><keyword><style face="normal" font="default"> India</style></keyword><keyword><style face="normal" font="default"> Indium</style></keyword><keyword><style face="normal" font="default"> Industry</style></keyword><keyword><style face="normal" font="default"> Meteorological Factors</style></keyword><keyword><style face="normal" font="default"> Mexico</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> monitoring</style></keyword><keyword><style face="normal" font="default"> Nitrogen</style></keyword><keyword><style face="normal" font="default"> Nitrogen Dioxide</style></keyword><keyword><style face="normal" font="default"> NO2</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Ozone</style></keyword><keyword><style face="normal" font="default"> Particulate matter</style></keyword><keyword><style face="normal" font="default"> PM2.5</style></keyword><keyword><style face="normal" font="default"> Poisson</style></keyword><keyword><style face="normal" font="default"> pollutants</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Selective</style></keyword><keyword><style face="normal" font="default"> Temperature</style></keyword><keyword><style face="normal" font="default"> Transportation</style></keyword><keyword><style face="normal" font="default"> trends</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Weather</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">An understanding of interplay between asthma, criteria air pollutants, and meteorological factors is essential to predicting human health and reducing the capital costs on controlling asthma prevalence. A systematic relationship between asthma and variables related to air quality and weather in a location will help mitigate or reduce impact of asthma over the people in it. The impact of industries, transportation, and weather on health is complex and needs continuous monitoring for controlling health disorders. The present study examines Poisson Regression Model of the daily data of asthma admissions, Particulate Matter (PM2.5), Ozone (O3), Nitrogen dioxide (NO2), temperature, and humidity in selective locations of Mississippi coastal region of Gulf of Mexico for the period 2003 to 2011. The study region consists of three locations, namely Gulfport, Pascagoula, and Waveland because of the extent of data availability. Overall, the results indicate a negative correlation of asthma with temperature and the effect was statistically significant (p &lt; 0.05) in all the regions. The correlation of other variables was not consistent uniformly, and their influence on asthma was not statistically significant except in few cases.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -CO - India -</style></notes><work-type><style face="normal" font="default">10.26420/austinjallergy.2017.1026</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.26420/austinjallergy.2017.1026</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Austin J Allergy\2017-4-1026.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Austin J Allergy\2017-4-1026.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170805, Tuluri F</style></custom2><misc3><style face="normal" font="default">10.26420/austinjallergy.2017.1026</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42277</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Barton,S.</style></author><author><style face="normal" font="default"> Ngo,S.</style></author><author><style face="normal" font="default"> Costello,P.</style></author><author><style face="normal" font="default"> Garratt,E.</style></author><author><style face="normal" font="default"> El-Heis,S.</style></author><author><style face="normal" font="default"> Antoun,E.</style></author><author><style face="normal" font="default"> Clarke-Harris,R.</style></author><author><style face="normal" font="default"> Murray,R.</style></author><author><style face="normal" font="default"> Bhatt,T.</style></author><author><style face="normal" font="default"> Burdge,G.</style></author><author><style face="normal" font="default"> Cooper,C.</style></author><author><style face="normal" font="default"> Inskip,H.</style></author><author><style face="normal" font="default"> van der Beek,E.M.</style></author><author><style face="normal" font="default"> Sheppard,A.</style></author><author><style face="normal" font="default"> Godfrey,K.M.</style></author><author><style face="normal" font="default"> Lillycrop,K.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">MRC Lifecourse Epidemiology Unit, University of Southampton, UK</style></auth-address><titles><title><style face="normal" font="default">DNA methylation of Th2 lineage determination genes at birth is associated with allergic outcomes in childhood</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">age</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> atopic eczema</style></keyword><keyword><style face="normal" font="default"> Atopy</style></keyword><keyword><style face="normal" font="default"> Cell Line</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> epigenetic</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> Genes</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> IL-4</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Methylation</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> New Zealand</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Promoter</style></keyword><keyword><style face="normal" font="default"> regulation</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> TH2</style></keyword><keyword><style face="normal" font="default"> transcription</style></keyword><keyword><style face="normal" font="default"> transcription factor</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> Umbilical Cord</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="30" Month="7" Year="2017">2017/7/30</year></dates><abstract><style face="normal" font="default">BACKGROUND: There is now increasing evidence that asthma and atopy originate in part in utero, with disease risk being associated with the altered epigenetic regulation of genes. OBJECTIVE AND METHODS: To determine the relationship between variations in DNA methylation at birth and the development of allergic disease, we examined the methylation status of CpG loci within the promoter regions of Th1/2 lineage commitment genes (GATA3, IL-4, IL-4R, STAT4 and TBET) in umbilical cord DNA at birth in a cohort of infants from the Southampton Women's Survey (n=696) who were later assessed for asthma, atopic eczema and atopy. RESULTS: We found that higher methylation of GATA3 CpGs -2211/-2209 at birth was associated with a reduced risk of asthma at ages 3 (median ratio [median methylation in asthma group/median methylation in non-asthma group] =0.74, p=0.006) and 6 (median ratio 0.90, p=0.048) years. Furthermore, we demonstrated that the GATA3 CpG loci associated with later risk of asthma lie within a NF-kappaB binding site, and that methylation here blocks transcription factor binding to the GATA3 promoter in the Human Jurkat T cell line. Associations between umbilical cord methylation of CpG loci within IL-4R with atopic eczema at 12 months (median ratio 1.02, p=0.028), and TBET with atopy (median ratio 0.98, p=0.017) at 6-7 years of age were also observed. CONCLUSIONS AND CLINICAL RELEVANCE: Our findings provides further evidence of a developmental contribution to the risk of later allergic disorders, and suggests that involvement of epigenetic mechanisms in childhood asthma is already demonstrable at birth. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170730IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - New Zealand -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12988</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28756630">PM:28756630</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170730-BartonS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170730-BartonS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170730, Barton S</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12988</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42278</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Raison-Peyron,N.</style></author><author><style face="normal" font="default"> Amsler,E.</style></author><author><style face="normal" font="default"> Pecquet,C.</style></author><author><style face="normal" font="default"> Du-Thanh,A.</style></author><author><style face="normal" font="default"> Naessens,T.</style></author><author><style face="normal" font="default"> Apers,S.</style></author><author><style face="normal" font="default"> Aerts,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Hopital Saint-Eloi, CHU de Montpellier, 34295 Montpellier, France</style></auth-address><titles><title><style face="normal" font="default">Severe allergic contact dermatitis caused by octylisothiazolinone in a leather sofa: two new cases</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="178" start="176">176-178</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Leather</style></keyword><keyword><style face="normal" font="default"> Octylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170802IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - France -CO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12793</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28766805">PM:28766805</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-176-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-176-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Raison-Peyron N</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12793</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42279</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hennen,J.</style></author><author><style face="normal" font="default"> Blomeke,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Environmental Toxicology, University Trier, 54296 Trier, GermanyDepartment of Environmental Toxicology, University Trier, 54296 Trier, Germany</style></auth-address><titles><title><style face="normal" font="default">Assessment of skin sensitization potency of hair dye molecules in vitro</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="180" start="179">179-180</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Assessment</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hair</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> Toxicology</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170802IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12780</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28766798">PM:28766798</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-179-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-179-80.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Hennen J</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12780</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42280</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Romita,P.</style></author><author><style face="normal" font="default"> Ettorre,G.</style></author><author><style face="normal" font="default"> Corazza,M.</style></author><author><style face="normal" font="default"> Borghi,A.</style></author><author><style face="normal" font="default"> Foti,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biomedical Science and Human Oncology, Dermatological Clinic, University of Bari, 70124 Bari, Italy</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by clindamycin mimicking 'retinoid flare'</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="182" start="181">181-182</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Clindamycin</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Flare</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170802IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12784</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28766800">PM:28766800</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-181-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-181-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Romita P</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12784</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42281</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Andersson,A.M.</style></author><author><style face="normal" font="default"> Opstrup,M.S.</style></author><author><style face="normal" font="default"> Zachariae,C.</style></author><author><style face="normal" font="default"> Friis,U.F.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, 2900 Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">The importance of a complete declaration of isothiazolinones in products beyond cosmetics</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="172" start="171">171-172</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Isothiazolinones</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170802IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12755</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28766801">PM:28766801</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-171-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-171-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Andersson AM</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12755</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42282</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Todberg,T.</style></author><author><style face="normal" font="default"> Opstrup,M.S.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author><author><style face="normal" font="default"> Hald,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, 2900 Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Occupational facial contact dermatitis caused by methylchloroisothiazolinone/methylisothiazolinone in a stainless steel aerosol spray</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="174" start="173">173-174</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Stainless Steel</style></keyword><keyword><style face="normal" font="default"> Steel</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170802IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12773</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28766799">PM:28766799</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-173-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-173-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Todberg T</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12773</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42283</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Silva,C.A.</style></author><author><style face="normal" font="default"> El-Houri,R.B.</style></author><author><style face="normal" font="default"> Christensen,L.P.</style></author><author><style face="normal" font="default"> Andersen,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy Center, Odense University Hospital, University of Southern Denmark, 5000 Odense C, Denmark</style></auth-address><titles><title><style face="normal" font="default">Contact allergy caused by methylisothiazolinone in shoe glue</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="176" start="175">175-176</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Shoe</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170802IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12785</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28766796">PM:28766796</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-175-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-175-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Silva CA</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12785</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42284</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aalto-Korte,K.</style></author><author><style face="normal" font="default"> Suuronen,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Occupational Medicine, Finnish Institute of Occupational Health (FIOH), 00250 Helsinki, FinlandOccupational Medicine, Finnish Institute of Occupational Health (FIOH), 00250 Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="default">Patterns of concomitant allergic reactions in patients suggest cross-sensitization between octylisothiazolinone and methylisothiazolinone</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> Benzisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> cross reactivity</style></keyword><keyword><style face="normal" font="default"> Cross-reactivity</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidemic</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Isothiazolinones</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Occupation</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Health</style></keyword><keyword><style face="normal" font="default"> Occupational Medicine</style></keyword><keyword><style face="normal" font="default"> Occupations</style></keyword><keyword><style face="normal" font="default"> Octylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch-test</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="28" Month="7" Year="2017">2017/7/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: Recent animal tests have indicated cross-reactivity between methylisothiazolinone (MI), octylisothiazolinone (OIT), and benzisothiazolinone (BIT). OBJECTIVES: To retrospectively analyse concomitant reactions to different isothiazolinones in patients in an occupational dermatology clinic during the ongoing MI contact allergy epidemic. METHODS: We searched patch test files (January 2012 to February 2017) for patients with allergic reactions to OIT, BIT, and MI, and analysed their patch test results, occupations, exposure, and diagnoses. RESULTS: We found 61 (9.4%) allergic reactions to MI, 19 (2.9%) reactions to OIT and nine (1.4%) reactions to BIT in a total of 647 consecutively tested patients. Seventeen (89%) of the OIT-positive patients had concomitant reactions to MI, whereas only 3 (33%) BIT-positive patients had allergic reactions to MI. The MI reactions in OIT-positive patients were almost exclusively extreme reactions (+++). Exposure to OIT was identified in 26% of the OIT-positive patients, and 56% of the BIT-positive patients had been exposed to BIT. CONCLUSIONS: Allergic reactions to OIT were strongly associated with extreme reactions to MI, which suggests cross-sensitization. However, BIT reactions were mostly independent</style></abstract><notes><style face="normal" font="default">DA - 20170728IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12855</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28752892">PM:28752892</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170728-AaltoKorteK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170728-AaltoKorteK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170728, Aalto-Korte K</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12855</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42285</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mitsuyama,S.</style></author><author><style face="normal" font="default"> Abe,F.</style></author><author><style face="normal" font="default"> Kimura,M.</style></author><author><style face="normal" font="default"> Higuchi,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Sakura Medical Centre, School of Medicine, Toho University, Sakura 285-0841, Japan</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by -aminocaproic acid in a purified sodium hyaluronate ophthalmic solution</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="192" start="191">191-192</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Japan</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Sodium</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170802IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12808</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28766795">PM:28766795</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-191-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-191-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Mitsuyama S</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12808</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42286</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schuttelaar,M.L.</style></author><author><style face="normal" font="default"> Meijer,J.M.</style></author><author><style face="normal" font="default"> Engfeldt,M.</style></author><author><style face="normal" font="default"> Lapeere,H.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author><author><style face="normal" font="default"> Bruze,M.</style></author><author><style face="normal" font="default"> Persson,C.</style></author><author><style face="normal" font="default"> Bergendorff,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Groningen, University Medical Centre Groningen, 9700 RB, Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by dimethylthiocarbamylbenzothiazole sulfide (DMTBS) in canvas shoes: in search of the culprit allergen</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acetone</style></keyword><keyword><style face="normal" font="default"> allergen</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Baseline series</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> Chromatography</style></keyword><keyword><style face="normal" font="default"> components</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> cross reactivity</style></keyword><keyword><style face="normal" font="default"> Cross-reactivity</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Identification</style></keyword><keyword><style face="normal" font="default"> Materials</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Rubber</style></keyword><keyword><style face="normal" font="default"> Shoe</style></keyword><keyword><style face="normal" font="default"> Shoes</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Thiuram mix</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="4" Month="8" Year="2017">2017/8/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: During rubber vulcanization, new compounds can be formed. OBJECTIVES: To report a case of allergic shoe dermatitis in which the search for the allergen ultimately led to the identification of dimethylthiocarbamylbenzothiazole sulfide (DMTBS). METHODS: A female presented with eczema on her feet after wearing Sperry Top Sider(R) canvas sneakers. Patch testing was performed with the European baseline series, additional series, shoe materials, and extracts of shoe materials. Thin-layer chromatography (TLC) was performed for additional patch testing, and high-performance liquid chromatography and gas chromatography-mass spectometry were used for chemical analysis. RESULTS: Positive reactions were found to thiuram mix (+), tetramethylthiuram monosulfide (TMTM) (+), shoe material (+), and shoe extracts in eth. (++) and acetone (+). The extracts did not contain TMTM or other components of thiuram mix. TLC strips yielded a positive reaction (+) to one spot, whereas chemical analysis gave a negative result. Thereafter, a similar sneaker from another patient with shoe dermatitis was analysed, and DMBTS was identified. New extracts of the shoe of our first patient were then also shown to contain DMTBS. DMTBS as culprit allergen was confirmed by positive patch testing with a dilution series with DMTBS. CONCLUSION: DMBTS was identified as the culprit allergen in shoe dermatitis, giving rise to compound allergy. The positive reaction to TMTM was considered to represent cross-reactivity</style></abstract><notes><style face="normal" font="default">DA - 20170804IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Sweden -CO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12857</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28776709">PM:28776709</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170804-SchuttelaarML.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170804-SchuttelaarML.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170804, Schuttelaar ML</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12857</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42287</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Crepy,M.N.</style></author><author><style face="normal" font="default"> Lecuen,J.</style></author><author><style face="normal" font="default"> Ratour-Bigot,C.</style></author><author><style face="normal" font="default"> Stocks,J.</style></author><author><style face="normal" font="default"> Bensefa-Colas,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Occupational and Environmental Diseases, University Hospital of Centre of Paris, Hotel-Dieu Hospital, AP-HP, 75004 Paris, France</style></auth-address><titles><title><style face="normal" font="default">Accelerator-free gloves as alternatives in cases of glove allergy in healthcare workers</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergen</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> contact allergens</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> efficacy</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Gloves</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Hand eczema</style></keyword><keyword><style face="normal" font="default"> Healthcare workers</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Paris</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Rubber</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> Secondary Prevention</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="27" Month="7" Year="2017">2017/7/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Accelerators in rubber gloves constitute an important group of contact allergens, particularly in healthcare workers. OBJECTIVES: To assess the efficacy of accelerator-free medical gloves in the secondary prevention of allergic contact dermatitis caused by rubber accelerators in healthcare workers. METHODS: Nine healthcare workers with hand eczema were advised to use accelerator-free rubber gloves after a diagnosis of allergic contact dermatitis caused by rubber accelerators. RESULTS: Switching from conventional medical single-use gloves containing accelerators to accelerator-free medical gloves led to improvement in all cases, and more than two-thirds of the patients were completely free of symptoms. CONCLUSION: The use of accelerator-free medical gloves can be an effective alternative in healthcare workers who are allergic to rubber accelerators</style></abstract><notes><style face="normal" font="default">DA - 20170727IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - France -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12860</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28748553">PM:28748553</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170727-CrepyMN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170727-CrepyMN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170727, Crepy MN</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12860</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42288</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Malinauskiene,L.</style></author><author><style face="normal" font="default"> Bruze,M.</style></author><author><style face="normal" font="default"> Isaksson,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center of Pulmonology ans Allergology, Clinic of Infectious and Chest Diseases, Dermatovenereology and Allergology, Vilnius University, 08661, Vilnius, Lithuania</style></auth-address><titles><title><style face="normal" font="default">Patch testing with the Swedish baseline series supplemented with a textile dye mix and gold in Vilnius, Lithuania and Malmo, Sweden</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="190" start="189">189-190</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergology</style></keyword><keyword><style face="normal" font="default"> Baseline series</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> dye</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Gold</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170802IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Lithuania -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12802</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28766803">PM:28766803</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-189-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-189-90.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Malinauskiene L</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12802</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42289</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tong,P.L.</style></author><author><style face="normal" font="default"> Chow,E.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Liverpool Hospital, 2170, Sydney, New South Wales, Australia</style></auth-address><titles><title><style face="normal" font="default">Isopropyl myristate contact allergy: could your moisturizer be the culprit?</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="185" start="184">184-185</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Australia</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> New South Wales</style></keyword><keyword><style face="normal" font="default"> Wales</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170802IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12799</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28766802">PM:28766802</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-184-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-184-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Tong PL</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12799</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42290</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Romita,P.</style></author><author><style face="normal" font="default"> Foti,C.</style></author><author><style face="normal" font="default"> Stingeni,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biomedical Science and Human Oncology, Dermatological Clinic, University of Bari, 70124, Bari, Italy</style></auth-address><titles><title><style face="normal" font="default">Photoallergy to promazine hydrochloride</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="183" start="182">182-183</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Electronic</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Photoallergy</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170802IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12797</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28766806">PM:28766806</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-182-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-182-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Romita P</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12797</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42291</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ormerod,E.</style></author><author><style face="normal" font="default"> Hughes,T.M.</style></author><author><style face="normal" font="default"> Stone,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Department, Bristol Royal Infirmary, Bristol BS2 8HW, UK</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by resorcinol following a temporary black henna tattoo</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="188" start="187">187-188</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Black henna</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Henna</style></keyword><keyword><style face="normal" font="default"> Tattoo</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170802IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12801</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28766804">PM:28766804</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-187-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-187-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Ormerod E</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12801</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42292</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martinez-Gonzalez,M.I.</style></author><author><style face="normal" font="default"> Gonzalez-Perez,R.</style></author><author><style face="normal" font="default"> Garcia-Rio,I.</style></author><author><style face="normal" font="default"> Heras-Gonzalez,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology and Venereology Service, Araba University Hospital, 01009, Vitoria, Spain</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by benzoic acid and lauryl glucoside in a sunscreen</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="187" start="186">186-187</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Benzoic Acid</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Lauryl glucoside</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170802IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12810</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28766797">PM:28766797</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-186-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-186-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Martinez-Gonzalez MI</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12810</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42293</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dona,I.</style></author><author><style face="normal" font="default"> Moreno,E.</style></author><author><style face="normal" font="default"> Perez-Sanchez,N.</style></author><author><style face="normal" font="default"> Andreu,I.</style></author><author><style face="normal" font="default"> Hernandez Fernandez de Rojas,D.</style></author><author><style face="normal" font="default"> Torres,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Unit, Pabellon 6, primera planta, IBIMA Regional University Hospital of Malaga-UMA (Pavillion C, Hospital Civil), Plaza del Hospital Civil, 29009, Malaga, Spain.</style></auth-address><titles><title><style face="normal" font="default">Update on Quinolone Allergy</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="56">56-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Avoidance</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical history</style></keyword><keyword><style face="normal" font="default"> Commercial</style></keyword><keyword><style face="normal" font="default"> cross reactivity</style></keyword><keyword><style face="normal" font="default"> Cross-reactivity</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> desensitization</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug provocation</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Exanthema</style></keyword><keyword><style face="normal" font="default"> Gold</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> mechanisms</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Neuromuscular blocking agent</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> provocation</style></keyword><keyword><style face="normal" font="default"> Quinolones</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> use</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Quinolones are a group of synthetic antibiotics widely use as first-line treatment for many infections. There has been an increase in the incidence of hypersensitivity reactions to quinolones in recent years, likely due to increased prescription. The purpose of this review is to summarize the clinical pictures, the methods used for diagnosing and the management of allergic reactions to quinolones. RECENT FINDINGS: Allergic reactions to quinolones can be immediate or delayed, being anaphylaxis and maculopapular exanthema respectively the most frequent clinical entities. A precise diagnosis is particularly difficult since clinical history is often unreliable, skin tests can induce false-positive results, and commercial in vitro test are not well validated. Therefore, drug provocation testing is considered the gold standard to establish diagnosis, which is not a risk-free procedure. Cross-reactivity between quinolones is difficult to predict due to the small number of patients included in the few published studies. Moreover, hypersensitivity to quinolones has also been associated with beta-lactam and neuromuscular blocking agent allergies, although further studies are needed to understand the underlying mechanisms. Avoidance of the culprit quinolone is indicated in patients with a diagnosis of hypersensitivity to these drugs. When quinolone treatment is the only therapeutic option available, desensitization is necessary. This review summarizes the complex diagnostic approach and management of allergic reactions to quinolones</style></abstract><notes><style face="normal" font="default">DA - 20170728IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0725-y.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28752367">PM:28752367</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-56.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default">20170728, Dona I</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0725-y.</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42294</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gomez-Traseira,C.</style></author><author><style face="normal" font="default"> Caballero,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Angioedema after caesarean delivery in a patient with hereditary angioedema with normal c1 inhibitor and p.Thr309lys mutation in the f12 gene - is it always bradykinin-mediated?</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="96" start="94">94-96</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> antihistamine</style></keyword><keyword><style face="normal" font="default"> Antihistamines</style></keyword><keyword><style face="normal" font="default"> C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> C1-inhibitor</style></keyword><keyword><style face="normal" font="default"> Commercial</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Delivery</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Eyelid</style></keyword><keyword><style face="normal" font="default"> Eyelids</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Hereditary angioedema with normal C1 inhibitor</style></keyword><keyword><style face="normal" font="default"> Icatibant</style></keyword><keyword><style face="normal" font="default"> Lip</style></keyword><keyword><style face="normal" font="default"> Lipid</style></keyword><keyword><style face="normal" font="default"> mother</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> Nuts</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Pregnancy</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> sIgE</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> Tongue</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">A 27-year-old pregnant female patient with a non-pruritic, non-erythematous facial angioedema episodeunresponsive to a high dose of parenteral corticosteroids and antihistamines was referred to our clinic. Shehad previously had six episodes of facial and upper airway oedema while she was under treatment withethinylestradiol-drospirenone. Her mother referred only a facial angioedema after dental extraction and hermaternal grandmother had had angioedema attacks in two out of the three pregnancies. The p.Thr309Lysmutation in the F12 gene occurred in all of them. She received short-term prophylaxis with pdhC1INH1 500U before caesarean delivery and no oedema occurred. However, 21 hours after caesarean deliveryshe developed oedema of the lips, tongue and eyelids, along with dysphagia and dysphonia. Treatmentwith pdhC1INH 1 500U and icatibant acetate ten minutes later was unsuccessful. Thirty minutes laterdexchlorpheniramine, corticosteroids and epinephrine were administered and the patient improved within15 minutes. The anamnesis revealed that she had eaten a peeled peach in syrup 15 minutes prior to thereaction. Commercial skin-prick tests (SPTs) were positive to peach, apple, cherry, plum, several nuts andpollens. Her sIgE was positive to peach, apple, rPru p 3 and other lipid transfer proteins.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/Journal/J2017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-94-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-94-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170410, Gomez-Traseira C</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42295</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Beyer,A.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Simulation-based education in allergology training: A South African perspective</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="23" start="16">16-23</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">allergology</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> area</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Communication</style></keyword><keyword><style face="normal" font="default"> Curriculum</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease Management</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Employment</style></keyword><keyword><style face="normal" font="default"> Environment</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Learning</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Process</style></keyword><keyword><style face="normal" font="default"> Running</style></keyword><keyword><style face="normal" font="default"> Teaching</style></keyword><keyword><style face="normal" font="default"> Techniques</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> Training</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">In the past two decades, simulation-based education has moved medical teaching out of the lecture rooms,wards and emergency departments by creating a safe environment that provides the learners with life-likeexperiences, while shielding patients from novicesf potentially unsafe medical practices.Developing a curriculum based on simulation is a complex process that involves the acquisition ofinfrastructure and equipment as well as the employment of qualified personnel and faculty in order to supportthe training programme. Learning objectives are achieved by running simulated case scenarios followedby debriefing. The cases must be both realistic and relevant to the learnersf practice area to motivateself-driven learning and, at the same time, to provide state-of-the-art training to the required competencystandards. Debriefing through various techniques, such as the advocacy-and-inquiry with egood judgementfapproach is an essential component of the educational experience, focused on the learning phases ofdescription, analysis and application of newly-acquired knowled ge and skills.Simulation-based education is particularly useful in fields of medical practice such as allergology, wheretrainees are not routinely exposed to critical cases and where communication skills are essential forsuccessful chronic disease management through the development of a solid relationship between themedical team and the patient.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/Journal/J2017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-16-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-16-23.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170601, Beyer AM</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42296</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Munblit,D.</style></author><author><style face="normal" font="default"> Korsunskiy,I.</style></author><author><style face="normal" font="default"> Asmanov,A.</style></author><author><style face="normal" font="default"> Hanna,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">The role of breastfeeding and weaning practices in allergic disease development</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="81" start="76">76-81</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Allergenic</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> Allergic sensitisation</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> Burden</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Foods</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> infants</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Prevalence</style></keyword><keyword><style face="normal" font="default"> protective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Russia</style></keyword><keyword><style face="normal" font="default"> Sensitisation</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Weaning</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Data from many studies demonstrate that allergy prevalence has been on the increase in the past fewdecades. This alarming burden of allergic disease highlights the importance of the development of primaryprevention strategies. Breastfeeding is well known for its beneficial short- and long-term effects on a varietyof health outcomes. However, there is still no agreement on the protective role of breastfeeding in relationto allergic sensitisation and disease development. Exclusive breastfeeding for six months is recommendedbut it is unclear whether a unified approach should be used in all children or if weaning should be initiatedearlier in infants with a high risk for allergy development. The timing of solid food introduction is currently amatter of discussion, with emerging evidence suggesting the potential benefits of the early introduction of'highly allergenic foods'. This review summarises the evidence about breastfeeding and food introduction ininfancy and their association with the development of allergic disease later in life.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United Kingdom -CO - Russia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/Journal/J2017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-76-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-76-81.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170410, Munblit D</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42297</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liebrich,W.</style></author><author><style face="normal" font="default"> Esser,M.</style></author><author><style face="normal" font="default"> Emanuel,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">PID 123: Wiskott-Aldrich Syndrome (WAS)</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="39" start="38">38-39</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Africa</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/Journal/J2017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-38-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-38-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170601, Liebrich W</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42298</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Carman,H.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Multiple chemical sensitivity - two illustrative case reports</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="43" start="40">40-43</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Africa</style></keyword><keyword><style face="normal" font="default"> Attention</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Case reports</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> chemical</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Ear</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Multiple Chemical Sensitivity</style></keyword><keyword><style face="normal" font="default"> Nose</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Occupational</style></keyword><keyword><style face="normal" font="default"> Occupational Health</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> sensitivity</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Multiple Chemical Sensitivity was first proposed as a disease entity 50 years ago and, although still surroundedby controversy, is increasingly being accepted as such. The condition is also known as Idiopathic EnvironmentalIntolerance. It is a chronic disease in which low levels of chemicals invoke a multiplicity of unrelated symptoms.The cause is not known but the condition will present to physicians, allergologists, ear, nose and throat surgeonsand, most especially, occupational health practitioners. Symptoms may be mild or totally disabling, and multipleorgans may be affected. No objective or measurable features aid the diagnosis and no definitive managementoptions are available. Two case histories are presented which conform to the criteria that were established in1999 and modified in 2005. In both cases the condition caused severe disability, with devastating consequencesfor the sufferers, especially their ability to continue working. This article aims to bring the existence of thiscondition to the attention of health practitioners.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/Journal/J2017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-40-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-40-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170601, Carman HA</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42299</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tang,M.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Key determinants of the intestinal microbiota in early childhood</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="74" start="70">70-74</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Australia</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Determinant</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> diversity</style></keyword><keyword><style face="normal" font="default"> early childhood</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Long term</style></keyword><keyword><style face="normal" font="default"> Microbiota</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Tolerance</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The intestinal microbiota develops rapidly after birth, determined by the maternal microbiota, mode ofdelivery, early infant feeding patterns and the subsequent long-term diet. While short-term dietary changesare associated with rapid effects on the intestinal microbiota, changes are transient and modest in magnitude.A healthy intestinal microbiota with high diversity can support a balanced immune homeostasis, allowingappropriate tolerance responses while simultaneously protecting against harmful exposures. Disruption ofthe intestinal microbiota in early life leads to a degraded stable microbiota that has been associated withincreased risk of disease, particularly chronic non-communicable diseases that have increased in prevalencealongside progressive industrialisation. Strategies that support the establishment of a healthy microbiotain the first years of life and beyond may offer an approach to the prevention of chronic non-communicablediseases.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Australia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/Journal/J2017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-70-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-70-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170410, Tang ML</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42300</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">van der Berg,S.</style></author><author><style face="normal" font="default"> van Rooyen,C.</style></author><author><style face="normal" font="default"> Green,R.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">We can do more to identify patients with primary immunodeficiencies</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="52" start="44">44-52</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Africa</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> South Africa</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/Journal/J2017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-44-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-44-52.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170601, van den Berg S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42301</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liao,S.L.</style></author><author><style face="normal" font="default"> Tseng,Y.H.</style></author><author><style face="normal" font="default"> Chu,C.Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Contact allergy to methylisothiazolinone/methylchloroisothiazolinone: A retrospective case series in a referral center in northern Taiwan</style></title><secondary-title><style face="normal" font="default">Dermatol Sin</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatol Sin</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic contact</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Aromatherapist</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Essential oil</style></keyword><keyword><style face="normal" font="default"> Essential oils</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Face</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hand</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> methylchloroisothiazolinone</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Oils</style></keyword><keyword><style face="normal" font="default"> Patch test</style></keyword><keyword><style face="normal" font="default"> Patch testing</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Taiwan</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> Time</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1027-8117</style></isbn><abstract><style face="normal" font="default">Background/ObjectiveSince 2005, there has been a significant increase in contact allergy to methylisothiazolinon (MI)/methylchloroisothiazolinone (MCI) incidences in European countries, but there has been no documented large-scale studies of such incidences in Taiwan.MethodsFrom 1987 to 2015, a total of 2590 patients received patch testing in our Contact Dermatitis Clinic. Analyzed were patients with positive reactions to MI/MCI (Kathon CG) in patch testing and with suspected allergy to MI/MCI.ResultsAmong the total 2590 patients, 2388 received patch testing during 1987-2005, while 202 received patch testing during 2006-2015. Because Kathon CG was not routinely patch tested for all patients from 1987 to 2005, the incidence of contact allergy to MI/MCI was thus corrected to 3/145 (2.1%) for this time period. After 2005, there were 11 patients (11/202, 5.4%) who showed positive reactions to MI/MCI. Amongst the 14 patients who showed positive reactions to MI/MCI, 12 of them were females (85.7%). The majority of the lesions was located on the hands (10 patients, 71.4%), along with the face (3 patients, 21.4%). Interestingly, 6 patients (42.9%) who showed positive reactions to MI/MCI were associated with contact allergy to essential oils, and five of them were aromatherapists.ConclusionAccording to our study, the incidence of MI/MCI contact allergy in a referral center in Taiwan was 5.4%. A trend of increasing incidence of contact allergy to MI/MCI was noted after 2005, which is consistent with the findings in Europe. Allergic contact dermatitis to MI/MCI should be suspected in patients who have eczema on the hands and face, especially those who are aromatherapists.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1016/j.dsi.2017.06.006</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.dsi.2017.06.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatol Sin\20170811-LiaoSL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatol Sin\20170811-LiaoSL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170811, Liao SL</style></custom2><misc3><style face="normal" font="default">10.1016/j.dsi.2017.06.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42302</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Morad Abbassi,J.</style></author><author><style face="normal" font="default"> Farhadi,M.</style></author><author><style face="normal" font="default"> Badamchi,A.</style></author><author><style face="normal" font="default"> Tabatabaei,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Soluble programmed death-1 ligand-1 (PD-L1) is decreased in allergic rhinitis patients</style></title><secondary-title><style face="normal" font="default">J Adv Allergy Immunol Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Adv Allergy Immunol Dis</style></full-title></periodical><pages end="6" start="1">1-6</pages><volume><style face="normal" font="default">2</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> AR</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> autoimmune</style></keyword><keyword><style face="normal" font="default"> Autoimmune Diseases</style></keyword><keyword><style face="normal" font="default"> Cancer</style></keyword><keyword><style face="normal" font="default"> Commercial</style></keyword><keyword><style face="normal" font="default"> Criteria</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> diagnostic criteria</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> ELISA</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Ige</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Iran</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> KIT</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> Serum</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> total IgE</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Programmed death-1 ligand-1 (PD-L1) is a member of co-signaling molecules involved in fine-tuning of T-cell mediated inflammatory conditions. Soluble PD-L1 (sPD-L1) is recognized in healthy individuals and patients with some kinds of cancers or autoimmune diseases. However, a few studies have been conducted on the role of sPD-L1 in allergic disorders. Objectives: The aim of this survey was to evaluate the sPD-L1 level and its association with IgE in allergic rhinitis (AR) patients. Patients and Methods: Subjects with AR (n=43) were selected according to AR diagnostic criteria and considering the exclusive benchmarks. Patients' serum samples were prepared and stored at -20°C until measurements. Normal serum samples were also obtained from normal volunteers (n=18) with no symptoms or family history of allergy. The serum concentration of IgE and sPD-L1 in patients and normal individuals was determined by commercial ELI-SA kits. Results: The serum levels of sPD-L1 in AR patients (mean=3.73±2.05) were significantly (P=0.010) lower than normal individuals (mean=10.96±8.66). Moreover, sPD-L1 was not correlated with total IgE in AR patients (r=- 0.036, P=0.815). Conclusion: Soluble B7-H1 may present a down-regulatory function against allergic reactions in the course of allergic rhini-tis development. Therefore, it can be assumed that the modulation of sPD-L1 may be an efficient therapeutic strategy together with current treatments in AR patients.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Iran -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.siftdesk.org/home/archive_articles/61/2/1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Adv Allergy Immunol Dis\2017-2-1-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Adv Allergy Immunol Dis\2017-2-1-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170805, Morad Abbassi J</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42303</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schubert,D.</style></author><author><style face="normal" font="default"> Klein,M.C.</style></author><author><style face="normal" font="default"> Hassdenteufel,S.</style></author><author><style face="normal" font="default"> Caballero-Oteyza,A.</style></author><author><style face="normal" font="default"> Yang,L.</style></author><author><style face="normal" font="default"> Proietti,M.</style></author><author><style face="normal" font="default"> Bulashevska,A.</style></author><author><style face="normal" font="default"> Kemming,J.</style></author><author><style face="normal" font="default"> Kuhn,J.</style></author><author><style face="normal" font="default"> Winzer,S.</style></author><author><style face="normal" font="default"> Rusch,S.</style></author><author><style face="normal" font="default"> Fliegauf,M.</style></author><author><style face="normal" font="default"> Schaffer,A.A.</style></author><author><style face="normal" font="default"> Pfeffer,S.</style></author><author><style face="normal" font="default"> Geiger,R.</style></author><author><style face="normal" font="default"> Cavalie,A.</style></author><author><style face="normal" font="default"> Cao,H.</style></author><author><style face="normal" font="default"> Yang,F.</style></author><author><style face="normal" font="default"> Li,Y.</style></author><author><style face="normal" font="default"> Rizzi,M.</style></author><author><style face="normal" font="default"> Eibel,H.</style></author><author><style face="normal" font="default"> Kobbe,R.</style></author><author><style face="normal" font="default"> Marks,A.L.</style></author><author><style face="normal" font="default"> Peppers,B.P.</style></author><author><style face="normal" font="default"> Hostoffer,R.W.</style></author><author><style face="normal" font="default"> Puck,J.M.</style></author><author><style face="normal" font="default"> Zimmermann,R.</style></author><author><style face="normal" font="default"> Grimbacher,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany</style></auth-address><titles><title><style face="normal" font="default">Plasma cell deficiency in humans with heterozygous mutations in SEC61A1</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Antibodies</style></keyword><keyword><style face="normal" font="default"> Antibody</style></keyword><keyword><style face="normal" font="default"> B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> Cause</style></keyword><keyword><style face="normal" font="default"> Cell Differentiation</style></keyword><keyword><style face="normal" font="default"> Cell Line</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Characterization</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> differentiation</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> functional study</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Genetic mutations</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Hela Cells</style></keyword><keyword><style face="normal" font="default"> Homeostasis</style></keyword><keyword><style face="normal" font="default"> Human</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> In Vitro</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Multiple Myeloma</style></keyword><keyword><style face="normal" font="default"> Mutation</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> Plasma Cells</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Protein</style></keyword><keyword><style face="normal" font="default"> Respiratory tract infection</style></keyword><keyword><style face="normal" font="default"> Respiratory Tract Infections</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Subunit</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="3" Month="8" Year="2017">2017/8/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Primary antibody deficiencies (PAD) are the most frequent primary immunodeficiencies in humans. The genetic causes for PADs are largely unknown. Sec61 translocon alpha 1 subunit (SEC61A1) is the major subunit of the Sec61 complex, which is the main polypeptide-conducting channel in the endoplasmic reticulum (ER) membrane. SEC61A1 is a target gene of XBP1s and strongly induced during plasma cell differentiation. OBJECTIVE: Characterization of a novel genetic defect and its pathological mechanism in eleven patients from two unrelated families with PAD. METHODS: Whole exome sequencing (WES) and targeted sequencing were conducted to identify novel genetic mutations. Functional studies were carried out ex vivo in primary cells of patients and in vitro in different cell lines to assess the effect of SEC61A1 mutations on B cell differentiation and survival. RESULTS: We investigated two families with patients suffering from hypogammaglobulinemia, severe recurrent respiratory tract infections and normal peripheral B- and T cell subpopulations. Upon in vitro stimulation, B cells showed an intrinsic deficiency to develop into plasma cells (PCs). Genetic analysis and targeted sequencing identified novel heterozygous missense (c.254T>A, p.V85D) and nonsense (c.1325G>T, p.E381*) mutations in SEC61A1, segregating with the disease phenotype. SEC61A1-V85D was deficient in co-translational protein translocation and it disturbed the cellular calcium homeostasis in HeLa cells. Moreover, SEC61A1-V85D triggered the terminal unfolded protein response (UPR) in multiple myeloma (MM) cell lines. CONCLUSION: We describe a monogenic defect leading to a specific plasma cell deficiency in humans, expanding our knowledge about the pathogenesis of antibody deficiencies</style></abstract><notes><style face="normal" font="default">DA - 20170807IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United States -CO - Switzerland -CO - China -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28782633">PM:28782633</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170807-SchubertD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170807-SchubertD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170807, Schubert D</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.042</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42304</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lugthart,G.</style></author><author><style face="normal" font="default"> Goedhart,M.</style></author><author><style face="normal" font="default"> van Leeuwen,M.M.</style></author><author><style face="normal" font="default"> Melsen,J.E.</style></author><author><style face="normal" font="default"> Jol-van der Zijde,C.M.</style></author><author><style face="normal" font="default"> Vervat,C.</style></author><author><style face="normal" font="default"> van Ostaijen-Ten Dam,M.M.</style></author><author><style face="normal" font="default"> Jansen-Hoogendijk,A.M.</style></author><author><style face="normal" font="default"> van Tol,M.J.D.</style></author><author><style face="normal" font="default"> Lankester,A.C.</style></author><author><style face="normal" font="default"> Schilham,M.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Leiden University Medical Center, Department of Pediatrics, Leiden, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default">Expansion of cytotoxic CD56bright NK cells during T cell deficiency after allogeneic hematopoietic stem cell transplantation</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cells</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> expansion</style></keyword><keyword><style face="normal" font="default"> Hematopoietic Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> NK cells</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> T cell</style></keyword><keyword><style face="normal" font="default"> T-cell</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="default">We describe a compensatory expansion of activated cytotoxic CD56bright NK cells during T-cell deficiency after hematopoietic stem cell transplantation. This mimics the situation in severe inborn T-cell deficiencies and unmasks the functional and phenotypic versatility of NK cells</style></abstract><notes><style face="normal" font="default">DA - 20170805IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28778795">PM:28778795</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170805-LugthartG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170805-LugthartG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170805, Lugthart G</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.039</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42305</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chand,H.S.</style></author><author><style face="normal" font="default"> Mebratu,Y.A.</style></author><author><style face="normal" font="default"> Kuehl,P.J.</style></author><author><style face="normal" font="default"> Tesfaigzi,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">COPD Program, Lovelace Respiratory Research Institute, Albuquerque, NM</style></auth-address><titles><title><style face="normal" font="default">Blocking Bcl-2 resolves IL-13-mediated mucous cell hyperplasia in a Bik-dependent manner</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">COPD</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hyperplasia</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Research institute</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="22" Month="7" Year="2017">2017/7/22</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170808IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28784260">PM:28784260</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170808-ChandHS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170808-ChandHS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170808, Chand HS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42306</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hofman,Z.L.M.</style></author><author><style face="normal" font="default"> de Maat,S.</style></author><author><style face="normal" font="default"> Suffritti,C.</style></author><author><style face="normal" font="default"> Zanichelli,A.</style></author><author><style face="normal" font="default"> van Doorn,C.</style></author><author><style face="normal" font="default"> Sebastian,S.A.E.</style></author><author><style face="normal" font="default"> Veszeli,N.</style></author><author><style face="normal" font="default"> Csuka,D.</style></author><author><style face="normal" font="default"> Renne,T.</style></author><author><style face="normal" font="default"> Pasterkamp,G.</style></author><author><style face="normal" font="default"> Cicardi,M.</style></author><author><style face="normal" font="default"> Farkas,H.</style></author><author><style face="normal" font="default"> Hack,C.E.</style></author><author><style face="normal" font="default"> Maas,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Chemistry and Haematology, Germany</style></auth-address><titles><title><style face="normal" font="default">Cleaved kininogen as a biomarker for bradykinin release in hereditary angioedema</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">angioedema</style></keyword><keyword><style face="normal" font="default"> biomarker</style></keyword><keyword><style face="normal" font="default"> Bradykinin</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> hereditary angioedema</style></keyword><keyword><style face="normal" font="default"> Hungary</style></keyword><keyword><style face="normal" font="default"> Immunoassay</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> Kininogen</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Plasma</style></keyword><keyword><style face="normal" font="default"> weight</style></keyword></keywords><dates><year Day="3" Month="8" Year="2017">2017/8/3</year></dates><abstract><style face="normal" font="default">Cleaved high-molecular weight kininogen (cHK) in plasma is a biomarker for bradykinin formation. We developed an immuno-assay to detect cHK in plasma. cHK plasma levels are increased in asymptomatic C1-INH-HAE patients, and increase further during angioedema attacks</style></abstract><notes><style face="normal" font="default">DA - 20170807IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Netherlands -CO - Italy -CO - Hungary -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.07.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28782632">PM:28782632</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170808-HofmanZL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170808-HofmanZL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170807, Hofman ZL</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.07.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42307</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shah,R.M.</style></author><author><style face="normal" font="default"> Elfeky,R.</style></author><author><style face="normal" font="default"> Nademi,Z.</style></author><author><style face="normal" font="default"> Qasim,W.</style></author><author><style face="normal" font="default"> Amrolia,P.</style></author><author><style face="normal" font="default"> Chiesa,R.</style></author><author><style face="normal" font="default"> Rao,K.</style></author><author><style face="normal" font="default"> Lucchini,G.</style></author><author><style face="normal" font="default"> Silva,J.M.F.</style></author><author><style face="normal" font="default"> Worth,A.</style></author><author><style face="normal" font="default"> Barge,D.</style></author><author><style face="normal" font="default"> Ryan,D.</style></author><author><style face="normal" font="default"> Conn,J.</style></author><author><style face="normal" font="default"> Cant,A.J.</style></author><author><style face="normal" font="default"> Skinner,R.</style></author><author><style face="normal" font="default"> Abd Hamid,I.J.</style></author><author><style face="normal" font="default"> Flood,T.</style></author><author><style face="normal" font="default"> Abinun,M.</style></author><author><style face="normal" font="default"> Hambleton,S.</style></author><author><style face="normal" font="default"> Gennery,A.R.</style></author><author><style face="normal" font="default"> Veys,P.</style></author><author><style face="normal" font="default"> Slatter,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology and BMT, Great North Children's Hospital, Royal Victoria Infirmary, Newcastle Upon Tyne, UK</style></auth-address><titles><title><style face="normal" font="default">TCRalphabeta+ and CD19+ cell depleted Haploidentical and Mismatched Hematopoietic Stem Cell Transplantation in Primary Immune Deficiency</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cells</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> GRADE</style></keyword><keyword><style face="normal" font="default"> Hematopoietic Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> Immune</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Prophylaxis</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword><keyword><style face="normal" font="default"> UK</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Victoria</style></keyword><keyword><style face="normal" font="default"> viral</style></keyword><keyword><style face="normal" font="default"> Viral infection</style></keyword><keyword><style face="normal" font="default"> Viral infections</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="2" Month="8" Year="2017">2017/8/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allogeneic hematopoietic stem cell transplantation (HSCT) is used as a therapeutic approach for primary immunodeficiencies (PIDs). The best outcomes have been achieved using HLA-matched donors, but when a matched donor is not available, a haploidentical or mismatched unrelated donor (mMUD) can be useful. Various strategies are used to mitigate the risk of graft versus host disease (GvHD) and rejection associated with such transplants. OBJECTIVE: We sought to evaluate the outcomes of haploidentical or mMUD HSCT after depleting GvHD causing TCRalphabetaCD3+ cells from the graft. METHODS: CD3+TCRalphabeta+/CD19+ depleted grafts were given in conditioned (except three) children with PIDs. Treosulfan (busulfan in one), fludarabine, thiotepa and ATG or alemtuzumab conditioning was used in 77% cases, and all but four received GvHD prophylaxis. RESULTS: 25 patients with 12 types of PIDs received 26 HSCTs. Three were transplanted for refractory GvHD developing after first cord transplantation. At 20.8 months (5 month- 3.3 years) median follow up, 21/25 patients survived and were cured of underlying immunodeficiency. Overall and Event Free Survival at 3 years was 83.9% and 80.4% respectively. Cumulative incidence (CI) of Grade II-IV acute GvHD was 22+/-8.7%. No case of visceral or chronic GvHD was seen. CI of graft failure, CMV or/and adeno viral infections and transplant related mortality at 1 year were 4.2+/-4.1%, 58.8+/-9.8% and 16.1+/-7.4% respectively. Patients going into transplant with systemic viral infections had poor survival in comparison to those with absent or resolved infection (33.3% vs.100%). CONCLUSION: CD3+TCRalphabeta+ and CD19+ depleted haploidentical or mMUD HSCT is a practical and viable alternative for children with a range of PIDs</style></abstract><notes><style face="normal" font="default">DA - 20170806IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.07.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28780238">PM:28780238</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170806-ShahRM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170806-ShahRM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170806, Shah RM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.07.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42308</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Persson,C.</style></author><author><style face="normal" font="default"> Ueki,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory Medicine, Clinical Pharmacology, University Hospital, Lund, Sweden.</style></auth-address><titles><title><style face="normal" font="default">Lytic eosinophils produce extracellular DNA traps as well as free eosinophil granules</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Clinical</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Granules</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="3" Month="8" Year="2017">2017/8/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170807IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28780970">PM:28780970</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170807-PerssonC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170807-PerssonC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170807, Persson C</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.047</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42309</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Frisoli,M.L.</style></author><author><style face="normal" font="default"> Harris,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Massachuestts Medical School, Department of Dermatology, 364 Plantation St., LRB 225, Worcester, MA 01605, USAUniversity of Massachuestts Medical School, Department of Dermatology, 364 Plantation St., LRB 225, Worcester, MA 01605, USA</style></auth-address><titles><title><style face="normal" font="default">Vitiligo: Mechanistic Insights Lead to Novel Treatments</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">autoimmune</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> Clinical Trials</style></keyword><keyword><style face="normal" font="default"> Dermatology</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> disease pathogenesis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Melanocytes</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> Regeneration</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> Targeted therapy</style></keyword><keyword><style face="normal" font="default"> Targeted treatment</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> USA</style></keyword><keyword><style face="normal" font="default"> Vitiligo</style></keyword></keywords><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="default">Vitiligo is an autoimmune disease of the skin characterized by patchy depigmentation. Current treatments are moderately effective at reversing disease by suppressing autoimmune inflammation in the skin and promoting the regeneration of melanocytes. Recent basic and translational research studies have significantly improved our understanding of disease pathogenesis, which is now leading to emerging treatment strategies based on targeted therapy. Here we discuss important clinical characteristics of vitiligo, current therapies, their limitations, advances in understanding disease pathogenesis, emerging targeted treatments, and strategies to optimize clinical trials to efficiently and effectively test these new treatments</style></abstract><notes><style face="normal" font="default">DA - 20170805IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.07.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28778794">PM:28778794</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170805-FrisoliML.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170805-FrisoliML.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170805, Frisoli ML</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.07.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42310</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Husby,A.</style></author><author><style face="normal" font="default"> Pasanen,A.</style></author><author><style face="normal" font="default"> Waage,J.</style></author><author><style face="normal" font="default"> Sevelsted,A.</style></author><author><style face="normal" font="default"> Hodemaekers,H.</style></author><author><style face="normal" font="default"> Janssen,R.</style></author><author><style face="normal" font="default"> Karjalainen,M.K.</style></author><author><style face="normal" font="default"> Stokholm,J.</style></author><author><style face="normal" font="default"> Chawes,B.L.</style></author><author><style face="normal" font="default"> Korppi,M.</style></author><author><style face="normal" font="default"> Wennergren,G.</style></author><author><style face="normal" font="default"> Heinzmann,A.</style></author><author><style face="normal" font="default"> Bont,L.</style></author><author><style face="normal" font="default"> Bisgaard,H.</style></author><author><style face="normal" font="default"> Bonnelykke,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Faculty of Health and Medical Sciences, University of Copenhagen &amp; Danish Pediatric Asthma Center, Gentofte Hospital, University of Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default">CDHR3 gene variation and childhood bronchiolitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Bronchiolitis</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Denmark</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Finland</style></keyword><keyword><style face="normal" font="default"> gene</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatric asthma</style></keyword><keyword><style face="normal" font="default"> polymorphism</style></keyword><keyword><style face="normal" font="default"> prospective</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> prospective study</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> RSV</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> variation</style></keyword></keywords><dates><year Day="3" Month="8" Year="2017">2017/8/3</year></dates><abstract><style face="normal" font="default">This genetic study combining data from five countries shows that the CDHR3 rs6967330 polymorphism is not associated to bronchiolitis triggered by RSV but might increase risk of bronchiolitis triggered by other infectious agents</style></abstract><notes><style face="normal" font="default">DA - 20170807IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - Netherlands -CO - Finland -CO - Sweden -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28782631">PM:28782631</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170807-HusbyA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170807-HusbyA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170807, Husby A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.044</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42311</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gevaert,E.</style></author><author><style face="normal" font="default"> Yousefi,S.</style></author><author><style face="normal" font="default"> Bachert,C.</style></author><author><style face="normal" font="default"> Simon,H.U.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Medicine, Upper Airways Research Laboratory, Ghent University, Ghent, Belgium</style></auth-address><titles><title><style face="normal" font="default">Reply (Refers to: Lytic eosinophils produce extracellular DNA traps as well as free eosinophil granules)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> Belgium</style></keyword><keyword><style face="normal" font="default"> Dna</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Granules</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> Upper airways</style></keyword></keywords><dates><year Day="3" Month="8" Year="2017">2017/8/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170807IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Belgium -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.048</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28780969">PM:28780969</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170807-GevaertE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170807-GevaertE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170807, Gevaert E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.048</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42312</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hsu,J.</style></author><author><style face="normal" font="default"> Chen,J.</style></author><author><style face="normal" font="default"> Mirabelli,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Air Pollution and Respiratory Health Branch, Division of Environmental Hazards and Health Effects, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Ga.</style></auth-address><titles><title><style face="normal" font="default">Asthma Morbidity, Comorbidities, and Modifiable Factors among Older Adults</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> Air</style></keyword><keyword><style face="normal" font="default"> Air Pollution</style></keyword><keyword><style face="normal" font="default"> Arteries</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Barriers</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> chronic obstructive pulmonary disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cockroach</style></keyword><keyword><style face="normal" font="default"> Cockroaches</style></keyword><keyword><style face="normal" font="default"> Columbia</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> COPD</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> District of Columbia</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Environmental Health</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hospitalization</style></keyword><keyword><style face="normal" font="default"> Hospitalizations</style></keyword><keyword><style face="normal" font="default"> Intervention</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> obstructive</style></keyword><keyword><style face="normal" font="default"> Older adults</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pollution</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> pulmonary</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Risk factor</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> secondary</style></keyword><keyword><style face="normal" font="default"> sex</style></keyword><keyword><style face="normal" font="default"> sex differences</style></keyword><keyword><style face="normal" font="default"> Surveillance</style></keyword><keyword><style face="normal" font="default"> survey</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Women</style></keyword></keywords><dates><year Day="19" Month="7" Year="2017">2017/7/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma morbidity is increased among older adults, especially older adult women. Interventions to improve asthma control in this population are not well described. OBJECTIVE: The objective of this study was to identify risk factors (including modifiable factors) associated with asthma-related hospitalizations and emergency department or urgent care center visits (ED/UCV) among older adults. A secondary objective was to investigate sex differences in variables relevant to asthma control. METHODS: Data were obtained from 14,076 older adults >/=65 years with active asthma participating in the 2006-2010 Behavioral Risk Factor Surveillance System Asthma Call-back Survey (a random-digit dialed survey) in 40 US states, the District of Columbia, and Puerto Rico, representative of >2.6 million persons. Weighted, adjusted logistic regression was conducted. RESULTS: One or more asthma-related hospitalizations in the past year were reported by 5.7% (95% confidence interval [95% CI] = 5.0% to 6.4%) of participants; 10.6% (95% CI = 9.7% to 11.5%) reported >/=1 asthma-related ED/UCV. Compared with older adults without asthma-related hospitalizations, adjusted odds were higher among those with >/=1 asthma-related hospitalization for chronic obstructive pulmonary disease (COPD), coronary artery disease, depression, cockroaches or mold in the home, and cost barriers to asthma-related health care or medication. All these factors, except for cockroaches, were associated with asthma-related ED/UCV. Compared with males, adjusted odds were higher among females for COPD, depression, obesity, and cost barriers to asthma-related health care or medication. CONCLUSIONS: Among older adults, asthma-related hospitalizations and ED/UCV were associated with clinical comorbidities, mold in the home, and financial barriers to asthma-related health care. Interventions addressing modifiable factors could reduce asthma morbidity among older adults</style></abstract><notes><style face="normal" font="default">DA - 20170730IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28756082">PM:28756082</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170730, Hsu J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42313</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Motosue,M.S.</style></author><author><style face="normal" font="default"> Bellolio,M.F.</style></author><author><style face="normal" font="default"> Van Houten,H.K.</style></author><author><style face="normal" font="default"> Shah,N.D.</style></author><author><style face="normal" font="default"> Bellamkonda,V.R.</style></author><author><style face="normal" font="default"> Nestler,D.M.</style></author><author><style face="normal" font="default"> Campbell,R.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergic Diseases, Mayo Clinic, Rochester, Minn</style></auth-address><titles><title><style face="normal" font="default">Temporal Trends in Epinephrine Dispensing and Allergy/Immunology Follow-up Among Emergency Department Anaphylaxis Patients in the United States, 2005-2014</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1279" start="1272">1272-1279</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic disease</style></keyword><keyword><style face="normal" font="default"> allergic diseases</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Decrease</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> discharge</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> emergency department</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> follow up</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> trends</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="26" Month="7" Year="2017">2017/7/26</year></dates><abstract><style face="normal" font="default">BACKGROUND: Anaphylaxis is a potentially life-threatening allergic reaction; measures including prescription of an epinephrine autoinjector (EAI) and allergy/immunology (A/I) follow-up may prevent future morbidity. OBJECTIVE: The objective of this study was to evaluate trends in outpatient management of anaphylaxis by studying EAI dispensing and A/I follow-up among patients seen in the emergency department (ED) for anaphylaxis from 2005 through 2014. METHODS: We analyzed administrative claims data from the OptumLabs Data Warehouse database using an expanded International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code algorithm. RESULTS: The study cohort comprised 18,279 patients with a mean age of 39 years; 58% were female, and 86% were discharged from an ED. Within 1 year after discharge, 46% had filled an EAI prescription and 29% had A/I follow-up. Overall, from 2005 to 2014, annual rates of filled EAI prescriptions and A/I follow-up did not change. Among children (aged &lt;18 years), rates increased for filled EAI prescriptions (16.1% increase; P = .02 for trend) and A/I follow-up (18.8% increase; P = .048 for trend). Rates decreased for A/I follow-up among adults (15.4% decrease; P = .002 for trend). Overall rates of filled EAI prescriptions were highest in those with venom-induced (73.9 per 100 ED visits) and food-induced anaphylaxis (69.4 per 100 ED visits); the lowest rates were among those with medication-related anaphylaxis (18.2 per 100 ED visits). CONCLUSIONS: Over the past decade, rates of EAI dispensing and A/I follow-up after an ED visit for anaphylaxis have remained low, suggesting that patients may not be prepared to manage future episodes</style></abstract><notes><style face="normal" font="default">DA - 20170730IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28756081">PM:28756081</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1272-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1272-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170730, Motosue MS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42314</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,P.</style></author><author><style face="normal" font="default"> Zhao,W.</style></author><author><style face="normal" font="default"> Sun,J.</style></author><author><style face="normal" font="default"> Tao,T.</style></author><author><style face="normal" font="default"> Chen,X.</style></author><author><style face="normal" font="default"> Zheng,Y.Y.</style></author><author><style face="normal" font="default"> Zhang,C.H.</style></author><author><style face="normal" font="default"> Chen,Z.</style></author><author><style face="normal" font="default"> Gao,Y.Q.</style></author><author><style face="normal" font="default"> She,F.</style></author><author><style face="normal" font="default"> Li,Y.Q.</style></author><author><style face="normal" font="default"> Wei,L.S.</style></author><author><style face="normal" font="default"> Lu,P.</style></author><author><style face="normal" font="default"> Chen,C.P.</style></author><author><style face="normal" font="default"> Zhou,J.</style></author><author><style face="normal" font="default"> Wang,D.Q.</style></author><author><style face="normal" font="default"> Chen,L.</style></author><author><style face="normal" font="default"> Shi,X.H.</style></author><author><style face="normal" font="default"> Deng,L.</style></author><author><style face="normal" font="default"> ZhuGe,R.</style></author><author><style face="normal" font="default"> Chen,H.Q.</style></author><author><style face="normal" font="default"> Zhu,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Model Animal Research Center and MOE Key Laboratory of Model Animal for Disease Study and the Medical School of Nanjing University, Nanjing 210061, China</style></auth-address><titles><title><style face="normal" font="default">Inflammatory Mediators Mediate Airway Smooth Muscle Contraction through a GPCR-TMEM16A-VDCC Axis and Contribute to Bronchial Hyperresponsiveness in Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acetylcholine</style></keyword><keyword><style face="normal" font="default"> agonists</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> airway smooth muscle</style></keyword><keyword><style face="normal" font="default"> Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Animal</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> bronchial hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Ca2+</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> hyperresponsiveness</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Induced</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory mediators</style></keyword><keyword><style face="normal" font="default"> ITS</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Mediators</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> mouse</style></keyword><keyword><style face="normal" font="default"> mouse model</style></keyword><keyword><style face="normal" font="default"> Muscle Contraction</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="25" Month="7" Year="2017">2017/7/25</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic inflammation has long been implicated in asthmatic hyperresponsiveness of airway smooth muscle (ASM), but its mechanism underlying remains incompletely understood. Serving as GPCR agonists, several inflammatory mediators can induce membrane depolarization, contract ASM and augment cholinergic contractile response. We hypothesized that the signal cascade integrating on membrane depolarization by the mediators might involve asthmatic hyperresponsiveness. OBJECTIVE: We sought to investigate the signalling transduction of inflammatory mediators in ASM contraction and assess its contribution in the genesis of hyperresponsiveness. METHODS: We assessed the capacity of inflammatory mediators to induce depolarization currents by electrophysiological analysis. We analysed the phenotypes of TMEM16A knockout mice, applied pharmacological reagents and measured the Ca2+ signal during ASM contraction. To study the role of the depolarization signalling in asthmatic hyperresponsiveness, we measured the synergistic contraction by acetylcholine and inflammatory mediators both ex vivo and in OVA-induced mouse model RESULTS: Inflammatory mediators, such as 5-HT, histamine, U46619 and LTD4, are capable of inducing ClCa currents in ASM cells, and these currents are mediated by TMEM16A. A combination of multiple analysis revealed that a GPCR-TMEM16A-VDCC signalling axis was required for ASM contraction induced by inflammatory mediators. Block of TMEM16A activity may significantly inhibit the synergistic contraction of acetylcholine and the mediators, and hence reduces hypersensitivity. CONCLUSIONS: A GPCR-TMEM16A-VDCC axis contributes to inflammatory mediator-induced ASM contraction, and synergistically activating TMEM16A by allergic inflammatory mediators with cholinergic stimuli</style></abstract><notes><style face="normal" font="default">DA - 20170729IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.053</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28754608">PM:28754608</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170729-WangP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170729-WangP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170729, Wang P</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.053</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42315</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Azzu,V.</style></author><author><style face="normal" font="default"> Kennard,L.</style></author><author><style face="normal" font="default"> Morillo-Gutierrez,B.</style></author><author><style face="normal" font="default"> Slatter,M.</style></author><author><style face="normal" font="default"> Edgar,J.D.M.</style></author><author><style face="normal" font="default"> Kumararatne,D.S.</style></author><author><style face="normal" font="default"> Griffiths,W.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Liver Unit, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ.</style></auth-address><titles><title><style face="normal" font="default">Liver disease predicts mortality in patients with XHIM but can be prevented by early hematopoietic stem cell transplantation</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Hematopoietic Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> Hospitals</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Liver</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> progression</style></keyword><keyword><style face="normal" font="default"> Stem Cell Transplantation</style></keyword><keyword><style face="normal" font="default"> survival</style></keyword><keyword><style face="normal" font="default"> transplantation</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="26" Month="7" Year="2017">2017/7/26</year></dates><abstract><style face="normal" font="default">In the largest detailed study of liver disease in X-linked immunodeficiency with hyper-IgM, we show that liver disease is commoner than generally recognized and that early hematopoietic stem cell transplantation may prevent liver disease progression and improve survival</style></abstract><notes><style face="normal" font="default">DA - 20170730IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28756297">PM:28756297</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170730-AzzuV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170730-AzzuV.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170730, Azzu V</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.036</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42316</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Khoury,P.</style></author><author><style face="normal" font="default"> Abiodun,A.O.</style></author><author><style face="normal" font="default"> Holland-Thomas,N.</style></author><author><style face="normal" font="default"> Fay,M.P.</style></author><author><style face="normal" font="default"> Klion,A.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, Bethesda, Md.</style></auth-address><titles><title><style face="normal" font="default">Hypereosinophilic Syndrome Subtype Predicts Responsiveness to Glucocorticoids</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> alternative therapy</style></keyword><keyword><style face="normal" font="default"> Assessment</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Cohort</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Dose</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> GC</style></keyword><keyword><style face="normal" font="default"> Glucocorticoids</style></keyword><keyword><style face="normal" font="default"> Growth</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Hypereosinophilic Syndrome</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> Laboratories</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> model</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Parasitic Diseases</style></keyword><keyword><style face="normal" font="default"> Platelet-Derived Growth Factor</style></keyword><keyword><style face="normal" font="default"> predict</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> Prednisone</style></keyword><keyword><style face="normal" font="default"> Protocol</style></keyword><keyword><style face="normal" font="default"> response</style></keyword><keyword><style face="normal" font="default"> retrospective</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> variants</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="27" Month="7" Year="2017">2017/7/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Glucocorticoids (GCs) are considered first-line treatment for platelet-derived growth factor alpha (PDGFRA)-negative hypereosinophilic syndromes (HESs). Despite this, little is known about clinical predictors of GC responsiveness in HES. OBJECTIVE: Knowledge of clinical and laboratory predictors of GC response before initiation of GC could lead to more rational selection of subjects with HES for whom earlier institution of second-line and alternative therapies would be appropriate. METHODS: Response to GC, as defined by the reduction of the absolute eosinophil count to below 1000/mm3 and control of symptoms, was assessed by a retrospective chart review of subjects with PDGFRA-negative HES evaluated on an institutional review board-approved protocol. Demographic, clinical, and laboratory parameters obtained before institution of GC, as well as final diagnosis, were evaluated to determine predictors of GC response. Proportional odds models were used for univariate and multivariate assessment of predictors with permutation adjusted P values to correct for multiple comparisons. RESULTS: A total of 164 subjects with PDGFRA-negative HES were categorized according to GC response. Of them, 39% of the subjects responded to low dose (&lt;/=10 mg) prednisone, 9% did not respond to GC, and the remainder (52%) had variable responses to GC. The HES subtype diagnosis was the best predictor of response to GC with myeloid forms and lymphocytic variants of HES being the least responsive to GC. CONCLUSIONS: In a large cohort of well-characterized subjects with HES, the odds of response to GC was predicted by HES subtype. Using this model, clinicians may more readily proceed to second-line agents in subjects with confirmed lymphocytic or myeloid forms of HES</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28757367">PM:28757367</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170731, Khoury P</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42317</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tam,H.</style></author><author><style face="normal" font="default"> Simons,F.E.R.</style></author><author><style face="normal" font="default"> Simons,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada</style></auth-address><titles><title><style face="normal" font="default">Are dispensing patterns for epinephrine autoinjectors age-appropriate in children?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1437" start="1435">1435-1437</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> Canada</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> Epinephrine autoinjector</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="27" Month="7" Year="2017">2017/7/27</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28757368">PM:28757368</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1435-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol Pract\2017-5-1435-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170731, Tam H</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42318</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Phillips,A.</style></author><author><style face="normal" font="default"> Hoyte,F.C.L.</style></author><author><style face="normal" font="default"> Leung,D.Y.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Clinical Immunology, Department of Pediatrics, National Jewish Health, Denver, Colo</style></auth-address><titles><title><style face="normal" font="default">Dystonia as an unusual presentation of systemic mastocytosis: possible link between histamine release and movement disorders</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Histamine</style></keyword><keyword><style face="normal" font="default"> Histamine Release</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Mastocytosis</style></keyword><keyword><style face="normal" font="default"> Movement</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> Systemic mastocytosis</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="27" Month="7" Year="2017">2017/7/27</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28757371">PM:28757371</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170731, Phillips A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42319</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Baptist,A.P.</style></author><author><style face="normal" font="default"> Hao,W.</style></author><author><style face="normal" font="default"> Karamched,K.R.</style></author><author><style face="normal" font="default"> Kaur,B.</style></author><author><style face="normal" font="default"> Carpenter,L.</style></author><author><style face="normal" font="default"> Song,P.X.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Mich; Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, Mich.</style></auth-address><titles><title><style face="normal" font="default">Distinct Asthma Phenotypes among Older Adults with Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">ACT</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adults</style></keyword><keyword><style face="normal" font="default"> age</style></keyword><keyword><style face="normal" font="default"> Airway</style></keyword><keyword><style face="normal" font="default"> Airway Obstruction</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> allergy and clinical immunology</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> Asthma Control Test</style></keyword><keyword><style face="normal" font="default"> asthma phenotype</style></keyword><keyword><style face="normal" font="default"> asthma phenotypes</style></keyword><keyword><style face="normal" font="default"> atopic</style></keyword><keyword><style face="normal" font="default"> Behavior</style></keyword><keyword><style face="normal" font="default"> BMI</style></keyword><keyword><style face="normal" font="default"> Body Mass Index</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical immunology</style></keyword><keyword><style face="normal" font="default"> Cluster Analysis</style></keyword><keyword><style face="normal" font="default"> Comorbidities</style></keyword><keyword><style face="normal" font="default"> Comorbidity</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Depression</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> education</style></keyword><keyword><style face="normal" font="default"> elderly</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health Behavior</style></keyword><keyword><style face="normal" font="default"> Health Education</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Michigan</style></keyword><keyword><style face="normal" font="default"> Morbidity</style></keyword><keyword><style face="normal" font="default"> mortality</style></keyword><keyword><style face="normal" font="default"> objective</style></keyword><keyword><style face="normal" font="default"> Older adults</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Phenotype</style></keyword><keyword><style face="normal" font="default"> Phenotypes</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Public Health</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Quality of Life</style></keyword><keyword><style face="normal" font="default"> Quality-of-life</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Questionnaires</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> Score</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> severe asthma</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick testing</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Spirometry</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> testing</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword><keyword><style face="normal" font="default"> Work</style></keyword></keywords><dates><year Day="27" Month="7" Year="2017">2017/7/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Older adults have high rates of asthma morbidity and mortality. Asthma is now recognized as a heterogeneous disease, yet the distinct phenotypes among older adults are unknown. OBJECTIVE: The objective of this study was to identify asthma phenotypes in a diverse population of elderly patients with asthma. METHODS: Using cluster analysis, 180 older adults with persistent asthma were analyzed. Subjects completed detailed questionnaires, skin prick testing, and spirometry with reversibility. Twenty-four core variables were analyzed. RESULTS: Four groups were identified. Subjects in cluster 1 (n = 69) typically had asthma diagnosed after the age of 40 and the shortest duration of asthma. Cluster 2 (n = 40) had the mildest asthma defined by spirometry, Asthma Control test (ACT), and Asthma Quality of Life Questionnaire (AQLQ). They also had the lowest body mass index (BMI), lowest depression score, and least number of comorbidities. Cluster 3 (n = 46) had the longest duration of asthma (56 years) and the highest atopic skin test sensitization (74%). Cluster 4 (n = 25) had the most severe asthma, with extremely low FEV1% predicted (37.8%), lowest ACT, and lowest AQLQ scores. They were more likely to be black and had the highest comorbidities. Using BMI, posttreatment FEV1% predicted, and duration of asthma, 95.6% of subjects were able to be correctly classified. CONCLUSIONS: In older adults with asthma, distinct phenotypes vary on key features that are more pronounced among the elderly, including comorbidities, fixed airway obstruction, and duration of asthma >/=40 years. Further work is required to determine the clinical and therapeutic implications for different asthma phenotypes in older adults</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28757370">PM:28757370</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170731, Baptist AP</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42320</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Price,D.</style></author><author><style face="normal" font="default"> Bjermer,L.</style></author><author><style face="normal" font="default"> Bergin,D.A.</style></author><author><style face="normal" font="default"> Martinez,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Asthma referrals: a key component of asthma management that needs to be addressed</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="223" start="209">209-223</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> asthma management</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical outcomes</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Health care provider</style></keyword><keyword><style face="normal" font="default"> Health Status</style></keyword><keyword><style face="normal" font="default"> Ireland</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> management</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Singapore</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Sweden</style></keyword><keyword><style face="normal" font="default"> Switzerland</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Uncertainty</style></keyword><keyword><style face="normal" font="default"> United Kingdom</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Heterogeneity of asthma and difficulty in achieving optimal control are the major challenges in the management of asthma. To help attain the best possible clinical outcomes in patients with asthma, several guidelines provide recommendations for patients who will require a referral to a specialist. Such referrals can help in clearing the uncertainty from the initial diagnosis, provide tailored treatment options to patients with persistent symptoms and offer the patients access to health care providers with expertise in the management of the asthma; thus, specialist referrals have a substantial impact on disease prognosis and the patient's health status. Hurdles in implementing these recommendations include lack of their dissemination among health care providers and nonadherence to these guidelines; these hurdles considerably limit the implementation of specialist referrals, eventually affecting the rate of referrals. In this review, recommendations for specialist referrals from several key international and national asthma guidelines and other relevant published literature are evaluated. Furthermore, we highlight why referrals are not happening, how this can be improved, and ultimately, what should be done in the specialist setting, based on existing evidence in published literature.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United Kingdom -CO - Singapore -CO - Sweden -CO - Ireland -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.2147/JAA.S134300</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.2147/JAA.S134300</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-209-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-209-23.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170810, Price D</style></custom2><misc3><style face="normal" font="default">10.2147/JAA.S134300</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42321</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tan,L.D.</style></author><author><style face="normal" font="default"> Kenyon,N.</style></author><author><style face="normal" font="default"> Yoneda,K.Y.</style></author><author><style face="normal" font="default"> Louie,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Bronchial thermoplasty: implementing best practice in the era of cost containment</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="" start="230">230-</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">225</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">adherence</style></keyword><keyword><style face="normal" font="default"> administration</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Barriers</style></keyword><keyword><style face="normal" font="default"> bronchial</style></keyword><keyword><style face="normal" font="default"> Bronchial thermoplasty</style></keyword><keyword><style face="normal" font="default"> Bronchoscopy</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical trial</style></keyword><keyword><style face="normal" font="default"> contraindications</style></keyword><keyword><style face="normal" font="default"> cost</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Food</style></keyword><keyword><style face="normal" font="default"> Guideline</style></keyword><keyword><style face="normal" font="default"> Health</style></keyword><keyword><style face="normal" font="default"> Indication</style></keyword><keyword><style face="normal" font="default"> Indications</style></keyword><keyword><style face="normal" font="default"> information</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> national</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> persistent asthma</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Safety</style></keyword><keyword><style face="normal" font="default"> Specialist</style></keyword><keyword><style face="normal" font="default"> Strategies</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Technology</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> trial</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Increasing dependence on advanced technologies in the 21st century has created a dilemma between the practice and business of medicine. From information technology to robotic surgery, new technologies have expanded treatment possibilities and have potentially improved patient outcomes and safety. Simultaneously, their escalating costs limit access for certain patients and health care facilities. Nevertheless, medical decisions should not simply be based on cost. Input from physicians and other health care specialists as well as adherence to best practice position statements, are vital to implementing truly cost-effective strategies in medicine. Bronchial thermoplasty (BT), a US Food and Drug Administration approved bronchoscopy procedure in difficult-to-control persistent asthma, is a prime example of a new technology facing cost and implementation challenges. We discuss the specific indications and contraindications for BT and review recent real-world experiences that can provide the foundation for building a comprehensive asthma program that provides BT for difficult-to-control asthma patients who fail national guideline treatment recommendations after an adequate clinical trial of one. We also offer insight into the barriers to implementing a successful BT program and strategies for overcoming them.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.2147/JAA.S135291</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.2147/JAA.S135291</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-225-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-225-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170810, Tan LD</style></custom2><misc3><style face="normal" font="default">10.2147/JAA.S135291</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42322</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ahmadizar,F.</style></author><author><style face="normal" font="default"> Vijverberg,S.J.H.</style></author><author><style face="normal" font="default"> Arets,H.G.M.</style></author><author><style face="normal" font="default"> de Boer,A.</style></author><author><style face="normal" font="default"> Garssen,J.</style></author><author><style face="normal" font="default"> Kraneveld,A.D.</style></author><author><style face="normal" font="default"> Maitland-van der Zee,A.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands</style></auth-address><titles><title><style face="normal" font="default">Breastfeeding is associated with a decreased risk of childhood asthma exacerbations later in life</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Analyse</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> asthma exacerbation</style></keyword><keyword><style face="normal" font="default"> Asthma exacerbations</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> asthma symptoms</style></keyword><keyword><style face="normal" font="default"> Asthmatic</style></keyword><keyword><style face="normal" font="default"> Asthmatic children</style></keyword><keyword><style face="normal" font="default"> childhood</style></keyword><keyword><style face="normal" font="default"> Childhood asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Control</style></keyword><keyword><style face="normal" font="default"> Duration</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Epidemiological studies</style></keyword><keyword><style face="normal" font="default"> Exacerbation</style></keyword><keyword><style face="normal" font="default"> exacerbations</style></keyword><keyword><style face="normal" font="default"> Exposure</style></keyword><keyword><style face="normal" font="default"> Family</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Logistic regression</style></keyword><keyword><style face="normal" font="default"> medication</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Netherlands</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> Odds Ratio</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> questionnaire</style></keyword><keyword><style face="normal" font="default"> Risk</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> symptoms</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="29" Month="7" Year="2017">2017/7/29</year></dates><abstract><style face="normal" font="default">BACKGROUND: Breastfeeding has been suggested to influence the risk of asthma and asthma severity in children. However, the conclusions from epidemiological studies are inconsistent. METHODS: We used data from 960 children (aged 4-12 years) using regular asthma medication who participated in the PACMAN study. Breastfeeding exposure was based on questionnaire data and stratified into: 1) ever versus never, and 2) >/=6 versus &lt;6 months duration of breastfeeding. Asthma severity was based on the occurrence of asthma exacerbations in the preceding year and/or poorly controlled asthma symptoms during the last week of study visit. Odds ratios (ORs) were derived from univariate and multivariable logistic regression analyses. RESULTS: Breastfeeding was associated with a decreased risk of asthma exacerbations; adjusted (adj.) OR: 0.55 (95% confidence interval (CI): 0.35-0.87). After stratification for duration of breastfeeding the adj. ORs were 0.48 (95% CI: 0.27-0.84) for duration &lt;6 months and 0.71 (95% CI: 0.43-1.20) for duration >/=6 months breastfeeding. When we stratified the analysis by family history of asthma, the association between breastfeeding and asthma exacerbations was strong and statistically significant only in children with a positive family history of asthma; adj. OR: 0.34 (95% CI: 0.18-0.66). There was no association between breastfeeding and risk of poor asthma control; adj. OR: 1.04 (95% CI: 0.76-1.41). CONCLUSION: In a pediatric population with asthma, children who had been breastfed had a statistically significantly lower risk of asthma exacerbations later in life compared to asthmatic children who had not been breastfed. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170729IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12760</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28755494">PM:28755494</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170729-AhmadizarF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170729-AhmadizarF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170729, Ahmadizar F</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12760</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42323</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tegtmeyer,D.</style></author><author><style face="normal" font="default"> Seidl,M.</style></author><author><style face="normal" font="default"> Gerner,P.</style></author><author><style face="normal" font="default"> Baumann,U.</style></author><author><style face="normal" font="default"> Klemann,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics and Adolescent Medicine, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany</style></auth-address><titles><title><style face="normal" font="default">Inflammatory bowel disease caused by primary immunodeficiencies-Clinical presentations, review of literature, and proposal of a rational diagnostic algorithm</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="429" start="412">412-429</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Chronic granulomatous disease</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> Colitis</style></keyword><keyword><style face="normal" font="default"> Common Variable Immunodeficiency</style></keyword><keyword><style face="normal" font="default"> deficiency</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Early Diagnosis</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> Faculty</style></keyword><keyword><style face="normal" font="default"> Germany</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Immunosuppressive therapy</style></keyword><keyword><style face="normal" font="default"> Infection</style></keyword><keyword><style face="normal" font="default"> Infections</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> inflammatory bowel disease</style></keyword><keyword><style face="normal" font="default"> Inflammatory Bowel Diseases</style></keyword><keyword><style face="normal" font="default"> interaction</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Medical</style></keyword><keyword><style face="normal" font="default"> Medicine</style></keyword><keyword><style face="normal" font="default"> NEMO</style></keyword><keyword><style face="normal" font="default"> Nutrition</style></keyword><keyword><style face="normal" font="default"> Onset</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathogenesis</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> predictor</style></keyword><keyword><style face="normal" font="default"> predictors</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiencies</style></keyword><keyword><style face="normal" font="default"> primary immunodeficiency</style></keyword><keyword><style face="normal" font="default"> Rare Diseases</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> susceptibility</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">Inflammatory bowel diseases (IBD) including Crohn's disease (CD) and ulcerative colitis have a multifactorial pathogenesis with complex interactions between polygenetic predispositions and environmental factors. However, IBD can also be caused by monogenic diseases, such as primary immunodeficiencies (PID). Recently, an increasing number of these altogether rare diseases have been described to present often primarily, or solely, as IBD. Early recognition of these conditions enables adaption of therapies and thus directly benefits the course of IBDs. Here, we discuss the different clinical presentations in IBD and characteristic features of patient's history, clinical findings, and diagnostic results indicative for a causative PID. Possible predictors are early onset of disease, necessity of parenteral nutrition, failure to respond to standard immunosuppressive therapy, parental consanguinity, increased susceptibility for infections, certain histopathologic findings, and blood tests that are atypical for classic IBD. We illustrate this with exemplary case studies of IBD due to NEMO deficiency, chronic granulomatous disease, common variable immunodeficiency, CTLA-4 and LRBA deficiency. Taking these factors into account, we propose a diagnostic pathway to enable early diagnosis of IBD due to PID</style></abstract><notes><style face="normal" font="default">DA - 20170517IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12734</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28513998">PM:28513998</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\2017-28-412-29.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\2017-28-412-29.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170517, Tegtmeyer D</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12734</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42324</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lodi,L.</style></author><author><style face="normal" font="default"> Ricci,S.</style></author><author><style face="normal" font="default"> Romano,F.</style></author><author><style face="normal" font="default"> Ghiori,F.</style></author><author><style face="normal" font="default"> Canessa,C.</style></author><author><style face="normal" font="default"> Lippi,F.</style></author><author><style face="normal" font="default"> Bianchi,L.</style></author><author><style face="normal" font="default"> Azzari,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Immunology Division, Department of Pediatrics, Anna Meyer Children's University Hospital, Florence, Italy</style></auth-address><titles><title><style face="normal" font="default">Newborn screening for PIDs using both TREC and KREC identifies late occurrence of B cells</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="500" start="498">498-500</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">B cell</style></keyword><keyword><style face="normal" font="default"> B cells</style></keyword><keyword><style face="normal" font="default"> B-cell</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> Electronic</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Italy</style></keyword><keyword><style face="normal" font="default"> newborn</style></keyword><keyword><style face="normal" font="default"> Newborn screening</style></keyword><keyword><style face="normal" font="default"> occurrence</style></keyword><keyword><style face="normal" font="default"> pediatric</style></keyword><keyword><style face="normal" font="default"> Pediatrics</style></keyword><keyword><style face="normal" font="default"> Screening</style></keyword><keyword><style face="normal" font="default"> Universities</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170518IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12733</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28517432">PM:28517432</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\2017-28-498-500.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\2017-28-498-500.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170518, Lodi L</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12733</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42325</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Villani,A.P.</style></author><author><style face="normal" font="default"> Vocanson,M.</style></author><author><style face="normal" font="default"> Laoubi,L.</style></author><author><style face="normal" font="default"> Jullien,D.</style></author><author><style face="normal" font="default"> Berard,F.</style></author><author><style face="normal" font="default"> Nicolas,J.F.</style></author><author><style face="normal" font="default"> Bensaid,B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Toxic epidermal necrolysis: Pathophysiology and therapeutic advances</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> associations</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> complication</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> cutaneous</style></keyword><keyword><style face="normal" font="default"> Cutaneous adverse drug reaction</style></keyword><keyword><style face="normal" font="default"> Cyclosporine</style></keyword><keyword><style face="normal" font="default"> Cytotoxic T lymphocyte</style></keyword><keyword><style face="normal" font="default"> Death</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Development</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> drug hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Drug reaction</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Epidermis</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> genetic</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> immunoglobulin</style></keyword><keyword><style face="normal" font="default"> Immunoglobulins</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> Maculo-papular exanthema</style></keyword><keyword><style face="normal" font="default"> Necrosis</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> Pathophysiology</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> steroid</style></keyword><keyword><style face="normal" font="default"> Steroids</style></keyword><keyword><style face="normal" font="default"> Stevens Johnson syndrome</style></keyword><keyword><style face="normal" font="default"> Stevens-Johnson Syndrome</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword><keyword><style face="normal" font="default"> Systemic</style></keyword><keyword><style face="normal" font="default"> T lymphocyte</style></keyword><keyword><style face="normal" font="default"> T lymphocytes</style></keyword><keyword><style face="normal" font="default"> T-lymphocyte</style></keyword><keyword><style face="normal" font="default"> T-Lymphocytes</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> TNF-alpha</style></keyword><keyword><style face="normal" font="default"> Toxic epidermal necrolysis</style></keyword><keyword><style face="normal" font="default"> Toxiderma</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Toxic epidermal necrolysis is a rare and severe cutaneous adverse drug reaction. The histologic hallmark of this reaction is necrosis with detachment of the epidermis resulting in skin blistering. This is a life-threatening emergency with up to 30-á% deaths in the acute phase. The percentage of blistering skin determines two clinical entities: Stevens-Johnson syndrome, in which detachment is less than 10-á%, and Lyell's syndrome, in which it is greater than 30-á%. The development of late complications, notably mucous synechiae, is frequent and must be systematically prevented. The pathophysiologic mechanism consists of a delayed drug hypersensitivity reaction in which cytotoxic T-lymphocytes play a major role. Genetic background is also very important with HLA-drug associations having been reported, notably in Asian populations. Treatment remains highly debated, with systemic steroids, cyclosporine or intravenous immunoglobulins all being commonly used. Some studies also suggest that TNF-alpha inhibitors are of value in treating this disease</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.06.002</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.06.002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170808-VillaniAP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170808-VillaniAP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170808, Villani AP</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.06.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42326</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Amsler,E.</style></author><author><style face="normal" font="default"> Soria,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hypersensitivity reactions to beta-lactam antibiotics</style></title><secondary-title><style face="normal" font="default">Rev Med Interne</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Med Interne</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergie</style></keyword><keyword><style face="normal" font="default"> Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylactic shock</style></keyword><keyword><style face="normal" font="default"> Antibiotic</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> Beta lactam</style></keyword><keyword><style face="normal" font="default"> beta-lactam</style></keyword><keyword><style face="normal" font="default"> Beta-lactam antibiotics</style></keyword><keyword><style face="normal" font="default"> beta-Lactams</style></keyword><keyword><style face="normal" font="default"> betalactam</style></keyword><keyword><style face="normal" font="default"> betalactam allergy</style></keyword><keyword><style face="normal" font="default"> Betalactams</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> clinical features</style></keyword><keyword><style face="normal" font="default"> delayed</style></keyword><keyword><style face="normal" font="default"> Delayed hypersensitivity</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> DRESS</style></keyword><keyword><style face="normal" font="default"> Exanthema</style></keyword><keyword><style face="normal" font="default"> France</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> hypersensitivity reaction</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity reactions</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> Or</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> oral challenge</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> penicillin</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> severe</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0248-8663</style></isbn><abstract><style face="normal" font="default">Allergy to beta-lactam antibiotics is a common condition and about 10% of patients report being allergic to penicillin. However, this diagnosis is largely overestimated. Two types of allergy should be distinguished and include immediate hypersensitivity that can lead to anaphylactic shock and delayed hypersensitivity, ranging from the most common maculopapular exanthema to severe bullous toxidermia or life-threatening DRESS. Allergy challenge with oriented skin tests according to the clinical features, supplemented with oral challenge in the absence of contraindication, will confirm or invalidate the diagnosis of beta-lactam allergy and will help to identify if necessary safe alternatives to beta-lactams.</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.revmed.2017.06.020</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.revmed.2017.06.020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Med Interne\20170812-AmslerE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Med Interne\20170812-AmslerE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170812, Amsler E</style></custom2><misc3><style face="normal" font="default">10.1016/j.revmed.2017.06.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42327</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Carolino,F.</style></author><author><style face="normal" font="default"> Silva,D.</style></author><author><style face="normal" font="default"> Dias de Castro,E.</style></author><author><style face="normal" font="default"> Rodrigues Cernads,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Challenges in the diagnosis of hypersensitivity to proton-pump inhibitors.</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="225" start="219">219-225</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Allergies</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Challenge</style></keyword><keyword><style face="normal" font="default"> cross reactivity</style></keyword><keyword><style face="normal" font="default"> Cross-reactivity</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diagnostic</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> Drug allergies</style></keyword><keyword><style face="normal" font="default"> Drug allergy</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Formulation</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> immediate</style></keyword><keyword><style face="normal" font="default"> immediate reactions</style></keyword><keyword><style face="normal" font="default"> in vivo</style></keyword><keyword><style face="normal" font="default"> Incidence</style></keyword><keyword><style face="normal" font="default"> Inhibitors</style></keyword><keyword><style face="normal" font="default"> intradermal test</style></keyword><keyword><style face="normal" font="default"> Intradermal Tests</style></keyword><keyword><style face="normal" font="default"> Lansoprazole</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Omeprazole</style></keyword><keyword><style face="normal" font="default"> oral</style></keyword><keyword><style face="normal" font="default"> outcome</style></keyword><keyword><style face="normal" font="default"> outcomes</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Patients</style></keyword><keyword><style face="normal" font="default"> patterns</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Prick test</style></keyword><keyword><style face="normal" font="default"> prick tests</style></keyword><keyword><style face="normal" font="default"> Prick-test</style></keyword><keyword><style face="normal" font="default"> Prick-tests</style></keyword><keyword><style face="normal" font="default"> proton pump inhibitor</style></keyword><keyword><style face="normal" font="default"> Proton pump inhibitors</style></keyword><keyword><style face="normal" font="default"> Proton-pump inhibitor</style></keyword><keyword><style face="normal" font="default"> quality</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> recommendation</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> skin prick test</style></keyword><keyword><style face="normal" font="default"> Skin prick tests</style></keyword><keyword><style face="normal" font="default"> Skin test</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Skin-tests</style></keyword><keyword><style face="normal" font="default"> Specificity</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tests</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Background: The incidence of hypersensitivity (HS) to proton-pump inhibitors (PPI) seems to be increasing. Current recommendations for skin tests with PPI are weak and based on moderate quality evidence. Aims: To review the outcomes of in vivo diagnostic procedures and to assess the cross-reactivity (CR) patterns in patients evaluated for suspected PPI HS. Methods: This is a descriptive study of patients assessed in the Drug Allergy Unit from January/2007 to December/2014 for suspected PPI HS. We reviewed the outcomes of skin prick tests (SPT) and intradermal tests (IDTs) performed with commercially available parenteral PPI formulations (omeprazole, esomeprazole e pantoprazole); oral presentations of lansoprazole and rabeprazole were also used for SPT only. Results: We evaluated 19 patients (58% females; mean age±SD 51±14 years) and the main incriminated PPI was omeprazole (68%). A total of 11 patients (5 with immediate reactions) had positive skin tests, 4 of them to more than one PPI. The 3 patients with positive SPT (cases of omeprazole anaphylaxis) had skin CR (1 to omeprazole/esomeprazole and 2 to omeprazole/pantoprazole). Two patients with positive IDT to omeprazole 4 mg/ml tolerated oral omeprazole posteriorly. Specificity of skin tests was 80% (IC95%: 44%-98%). Conclusions: Omeprazol 4 mg/ml may be an irritative concentration for IDTs (1/10 of that currently recommended). No clear CR pattern emerged</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.spaic.pt/rpia/arquivos?ano_publicacao=2016&amp;volume_publicacao=24&amp;numero_publicacao=4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-219-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-219-25.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161210, Carolino F</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42328</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Almeida,J.P.</style></author><author><style face="normal" font="default"> Lopes,A.</style></author><author><style face="normal" font="default"> Pedro,E.</style></author><author><style face="normal" font="default"> Pereira Barbosa,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">A case report of perioperatory hypersensitivity to non-steroidal anti-inflammatory drug.</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="233" start="227">227-233</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Allergic</style></keyword><keyword><style face="normal" font="default"> Allergic reaction</style></keyword><keyword><style face="normal" font="default"> allergic reactions</style></keyword><keyword><style face="normal" font="default"> anti-inflammatory</style></keyword><keyword><style face="normal" font="default"> Antiinflammatory</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Bupivacaine</style></keyword><keyword><style face="normal" font="default"> Captopril</style></keyword><keyword><style face="normal" font="default"> Case Report</style></keyword><keyword><style face="normal" font="default"> Cefazolin</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diazepam</style></keyword><keyword><style face="normal" font="default"> Diclofenac</style></keyword><keyword><style face="normal" font="default"> drug</style></keyword><keyword><style face="normal" font="default"> drugs</style></keyword><keyword><style face="normal" font="default"> Emergencies</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword><keyword><style face="normal" font="default"> Enoxaparin</style></keyword><keyword><style face="normal" font="default"> Ephedrine</style></keyword><keyword><style face="normal" font="default"> Generalized urticaria</style></keyword><keyword><style face="normal" font="default"> Granisetron</style></keyword><keyword><style face="normal" font="default"> history</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Hypertension</style></keyword><keyword><style face="normal" font="default"> IgE mediated</style></keyword><keyword><style face="normal" font="default"> IgE-Mediated</style></keyword><keyword><style face="normal" font="default"> Insulin</style></keyword><keyword><style face="normal" font="default"> intradermal test</style></keyword><keyword><style face="normal" font="default"> Intravenous</style></keyword><keyword><style face="normal" font="default"> investigation</style></keyword><keyword><style face="normal" font="default"> Knee</style></keyword><keyword><style face="normal" font="default"> Knee Prosthesis</style></keyword><keyword><style face="normal" font="default"> Non-steroidal anti-inflammatory drug</style></keyword><keyword><style face="normal" font="default"> Pain</style></keyword><keyword><style face="normal" font="default"> Paracetamol</style></keyword><keyword><style face="normal" font="default"> Patient</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Reaction</style></keyword><keyword><style face="normal" font="default"> reactions</style></keyword><keyword><style face="normal" font="default"> Repair</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Test</style></keyword><keyword><style face="normal" font="default"> Tramadol</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Background: Several drugs may be responsible for perioperatory allergic reactions. The authors document one case report of IgE-mediated hypersensitivity to a nonsteroidal anti-inflammatory drug in the perioperatory period. Case report: 74 year-old woman, with a past history of blood hypertension and hypotiroidism. This patient has a history of generalized urticaria related to three surgeries. The first reaction (2010) occurred 24h after a knee artroscopy and she was medicated with: bupivacaine, paracoxib, diclofenac, metamizol, esomeprazole, metoclopramide, enoxaparin, cefazolin and diazepam. The second reaction (2012) occurred 8 hours after a cystocele repair and the drugs used were: bupivacaine, sufentanyl, midazolam, cefoxitine, ephedrine, paracetamol, metamizole and insulin. The third reaction (2013) occurred 6 hours after knee prosthesis implantation and the drugs used were: enoxaparin, esomeprazole, captopril, cefazolin, diazepam, levotiroxine, hidroxizine, granisetron, cetorolac, paracetamol, metamizol, tramadol and metoclopramide. The diagnosis workup revealed a positive intradermal test for metamizol, and the patient tolerated other anti-inflammatory drugs. Additionally, due to muscular pain, this patient was mistakenly administered with intravenous metamizol at emergency room, and a reproducible reaction has been observed. Conclusion: This reports a case of metamizol IgE-mediated hypersensitivity in a patient with multiple surgeries and several culprit drugs, which complicated our investigation</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.spaic.pt/rpia/arquivos?ano_publicacao=2016&amp;volume_publicacao=24&amp;numero_publicacao=4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-227-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-227-33.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161210, Almeida JP</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42329</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rosmaninho,I.</style></author><author><style face="normal" font="default"> Moreira,A.</style></author><author><style face="normal" font="default"> Moreira da Silva,J.P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Contact Dermatitis: Literature review.</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="209" start="197">197-209</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords><keyword><style face="normal" font="default">Allergist</style></keyword><keyword><style face="normal" font="default"> Allergists</style></keyword><keyword><style face="normal" font="default"> and primary</style></keyword><keyword><style face="normal" font="default"> Contact</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Literature</style></keyword><keyword><style face="normal" font="default"> Physicians</style></keyword><keyword><style face="normal" font="default"> Portugal</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> therapeutic</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">Contact dermatitis is a common disease seen by allergists, dermatologists and primary care physicians. It is an entity that should always be considered in the presence of eczema not responding to treatment. The purpose of this article is to review the literature on contact dermatitis in which the authors discuss the main types of contact dermatitis, diagnosis, some specific groups and some therapeutic considerations</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.spaic.pt/rpia/arquivos?ano_publicacao=2016&amp;volume_publicacao=24&amp;numero_publicacao=4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-197-209.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Port Imunoalergol\2016-24-197-209.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161210, Rosmaninho I</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42330</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ray,A.</style></author><author><style face="normal" font="default"> Kolls,J.K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Neutrophilic Inflammation in Asthma and Association with Disease Severity</style></title><secondary-title><style face="normal" font="default">Trends Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Trends Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Airway</style></keyword><keyword><style face="normal" font="default"> airways</style></keyword><keyword><style face="normal" font="default"> association</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Asthma severity</style></keyword><keyword><style face="normal" font="default"> Asthma treatment</style></keyword><keyword><style face="normal" font="default"> Cells</style></keyword><keyword><style face="normal" font="default"> chronic</style></keyword><keyword><style face="normal" font="default"> Clinical</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword><keyword><style face="normal" font="default"> Disease</style></keyword><keyword><style face="normal" font="default"> Disease severity</style></keyword><keyword><style face="normal" font="default"> Eosinophil</style></keyword><keyword><style face="normal" font="default"> Eosinophils</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> inflammatory</style></keyword><keyword><style face="normal" font="default"> Knowledge</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mast Cells</style></keyword><keyword><style face="normal" font="default"> Neutrophil</style></keyword><keyword><style face="normal" font="default"> Neutrophil Infiltration</style></keyword><keyword><style face="normal" font="default"> Neutrophilic inflammation</style></keyword><keyword><style face="normal" font="default"> Neutrophils</style></keyword><keyword><style face="normal" font="default"> Population</style></keyword><keyword><style face="normal" font="default"> Refractory</style></keyword><keyword><style face="normal" font="default"> Research</style></keyword><keyword><style face="normal" font="default"> Review</style></keyword><keyword><style face="normal" font="default"> Role</style></keyword><keyword><style face="normal" font="default"> severity</style></keyword><keyword><style face="normal" font="default"> subtypes</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword><keyword><style face="normal" font="default"> WAS</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1471-4906</style></isbn><abstract><style face="normal" font="default">Asthma is a chronic inflammatory disorder of the airways. While the local infiltration of eosinophils and mast cells, and their role in the disease have long been recognized, neutrophil infiltration has also been assessed in many clinical studies. In these studies, airway neutrophilia was associated with asthma severity. Importantly, neutrophilia also correlates with asthma that is refractory to corticosteroids, the mainstay of asthma treatment. However, it is now increasingly recognized that neutrophils are a heterogeneous population, and a more precise phenotyping of these cells may help delineate different subtypes of asthma. Here, we review current knowledge of the role of neutrophils in asthma and highlight future avenues of research in this field.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.it.2017.07.003</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.it.2017.07.003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Trends Immunol\20170810-RayA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Trends Immunol\20170810-RayA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170810, Ray A</style></custom2><misc3><style face="normal" font="default">10.1016/j.it.2017.07.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42331</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kolesnik,M.</style></author><author><style face="normal" font="default"> Franke,I.</style></author><author><style face="normal" font="default"> Lux,A.</style></author><author><style face="normal" font="default"> Quist,S.R.</style></author><author><style face="normal" font="default"> Gollnick,H.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Venereology, Otto-von-Guericke-University Magdeburg, Leipziger Str. 44, DE-39120 Magdeburg, Germany.</style></auth-address><titles><title><style face="normal" font="default">Differential Diagnosis of Palmoplantar Eczema in Psoriatico: Chronic Allergic Contact Dermatitis and/or Psoriasis?</style></title><secondary-title><style face="normal" font="default">Acta Derm Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Acta Derm Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="default">Differential diagnosis of palmoplantar non-pustular psoriasis and chronic allergic contact dermatitis (ACD) and the combination of these conditions, termed "eczema in psoriatico" (EIP), is difficult, especially in cases of isolated involvement. A blind re-evaluation of 63 archived formalin-fixed palmoplantar samples, previously diagnosed clinically as either psoriasis or chronic ACD, was performed. Samples were allocated to histopathological diagnoses of psoriasis, contact dermatitis or EIP. Immunohistological stainings were performed for better characterization. Immunochemistry of EIP revealed features that overlapped contemporarily with psoriasis (cytokeratin 17 (CK17), Ki67, interleukin (IL)-8, IL-17, IL-23) and with ACD (CD1a, major histocompatibility complex (MHC) class I, MHC class II, epidermal T-cell subsets). Surprisingly, a significantly much higher number of dermal CD8+ T cells was found in EIP than in ACD and psoriasis. In conclusion, this study provides insight into the immunohistological differentiation of palmoplantar psoriasis, chronic ACD and EIP</style></abstract><notes><style face="normal" font="default">DA - 20170830IS - 1651-2057 (Electronic)IS - 0001-5555 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.2340/00015555-2779</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28853491">PM:28853491</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Acta Derm Venereol\20170830-KolesnikM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Acta Derm Venereol\20170830-KolesnikM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170830, Kolesnik M</style></custom2><misc3><style face="normal" font="default">10.2340/00015555-2779</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42332</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dugonik,A.</style></author><author><style face="normal" font="default"> Kalac,P.M.</style></author><author><style face="normal" font="default"> Vok,M.</style></author><author><style face="normal" font="default"> Dugonik,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Aleksandra Dugonik, MD, Department of Dermatology and Venereology, University Medical Centre, Ljubljanska street 2, 2000 Maribor, Slovenia</style></auth-address><titles><title><style face="normal" font="default">Development and Significance of the E-surveillance System for Contact Allergies in Slovenia</style></title><secondary-title><style face="normal" font="default">Acta Dermatovenerol Croat</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Acta Dermatovenerol Croat</style></full-title></periodical><pages end="98" start="91">91-98</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">This paper describes the development and significance of online systems for the collection and analysis of medical data (patch test results) with a web application. Modern digital tools greatly aid in collecting, combining, and preserving the data in a way that is friendly, undemanding and time-efficient for the dermatologist. Creating a central database for the results of patch testing provides a better picture of contact sensitivity and characteristics of allergic contact dermatitis in Slovenia. An electronic database and connected network was started in Slovenia in 2010. Data from skin allergy units since 2000 has also been included retrospectively. At present (Oct 2016), the database contains the data of 19,772 patch tests performed by seven skin allergy units. Creating a central database of the results of patch testing provides a larger and therefore more credible collection of data. Immediate integration and data processing enable a current overview of contact sensitivity for each participating center as well as at the national level. Data can be easily transferred to other databases or edited with other software tools. This on-line register has worked flawlessly for more than five years. We have contributed data to the European Surveillance System on Contact Allergies (ESSCA) network database since 2012, which, along with the Deutsche Kontaktallergie-Gruppe system of collecting patch test data for German-speaking countries, represents the only multicenter surveillance system of patch test results in Europe</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1847-6538 (Electronic)IS - 1330-027X (Linking)LA - engPT - Journal ArticleCO - Slovenia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28871922">PM:28871922</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Acta Dermatovenerol Croat\2017-25-91-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Acta Dermatovenerol Croat\2017-25-91-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Dugonik A</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42333</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tanaka,M.</style></author><author><style face="normal" font="default"> Nakayama,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Bioscience and Biotechnology, Faculty of Agriculture, Graduate School, Kyushu University, Fukuoka, Japan</style></auth-address><titles><title><style face="normal" font="default">Development of the gut microbiota in infancy and its impact on health in later life</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="8" Year="2017">2017/8/17</year></dates><abstract><style face="normal" font="default">Gut microbial ecology and function are dynamic in infancy, but are stabilized in childhood. The 'new friends' have a great impact on the development of the digestive tract and host immune system. In the first year of life, especially, the gut microbiota dramatically changes through interactions with the developing immune system in the gut. The process of establishing the gut microbiota is affected by various environmental factors, with the potential to be a main determinant of life-long health. In this review, we summarize recent findings regarding gut microbiota establishment, including the importance of various factors related to the development of the immune system and allergic diseases later in life</style></abstract><notes><style face="normal" font="default">DA - 20170822IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.07.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28826938">PM:28826938</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170822-TanakaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170822-TanakaM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170822, Tanaka M</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.07.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42334</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yamazaki,Y.</style></author><author><style face="normal" font="default"> Nakamura,Y.</style></author><author><style face="normal" font="default"> Nunez,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Chiba University Graduate School of Medicine, Chiba, Japan</style></auth-address><titles><title><style face="normal" font="default">Role of the microbiota in skin immunity and atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="9" Year="2017">2017/9/4</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a chronic inflammatory skin disease that affects 15-20% of children and 2-5% of adults in industrialized countries. The pathogen Staphylococcus aureus selectively colonizes the lesional skin of AD patients while this bacterium is absent in the skin of the majority of healthy individuals. However, the role of S. aureus in the pathogenesis of AD remains poorly understood. In addition to S. aureus, recent studies show a contribution of the skin microbiota to the regulation of immune responses in the skin as well as to the development of inflammatory skin disease. This review summarizes current knowledge about the role of the microbiota in skin immune responses and the role of S. aureus virulent factors in the pathogenesis of AD</style></abstract><notes><style face="normal" font="default">DA - 20170908IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.08.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28882556">PM:28882556</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170908-YamazakiY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170908-YamazakiY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170908, Yamazaki Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.08.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42335</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tohda,Y.</style></author><author><style face="normal" font="default"> Hozawa,S.</style></author><author><style face="normal" font="default"> Tanaka,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine, Osakasayama, Japan.</style></auth-address><titles><title><style face="normal" font="default">Development of a questionnaire to evaluate asthma control in Japanese asthma patients</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="8" Year="2017">2017/8/31</year></dates><abstract><style face="normal" font="default">BACKGROUND: The asthma control questionnaires used in Japan are Japanese translations of those developed outside Japan, and have some limitations; a questionnaire designed to optimally evaluate asthma control levels for Japanese may be necessary. The present study was conducted to validate the Japan Asthma Control Survey (JACS) questionnaire in Japanese asthma patients. METHODS: A total of 226 adult patients with mild to severe persistent asthma were enrolled and responded to the JACS questionnaire, asthma control questionnaire (ACQ), and Mini asthma quality of life questionnaire (Mini AQLQ) at Weeks 0 and 4. The reliability, validity, and sensitivity/responsiveness of the JACS questionnaire were evaluated. RESULTS: The intra-class correlation coefficients (ICCs) were within the range of 0.55-0.75 for all JACS scores, indicating moderate/substantial reproducibility. For internal consistency, Cronbach's alpha coefficients ranged from 0.76 to 0.92 in total and subscale scores, which were greater than the lower limit of internal consistency. As for factor validity, the cumulative contribution ratio of four main factors was 0.66. For criterion-related validity, the correlation coefficients between the JACS total score and ACQ5, ACQ6, and Mini AQLQ scores were -0.78, -0.78, and 0.77, respectively, showing a significant correlation (p &lt; 0.0001). CONCLUSIONS: The JACS questionnaire was validated in terms of reliability and validity. It will be necessary to evaluate the therapeutic efficacy measured by the JACS questionnaire and calculate cutoff values for the asthma control status in a higher number of patients. CLINICAL TRIAL REGISTRATION: UMIN000016589</style></abstract><notes><style face="normal" font="default">DA - 20170904IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.06.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28867215">PM:28867215</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170904-TohdaY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170904-TohdaY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170904, Tohda Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.06.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42336</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rodriguez-Fernandez,A.</style></author><author><style face="normal" font="default"> Sanchez-Dominguez,M.</style></author><author><style face="normal" font="default"> Noguerado-Mellado,B.</style></author><author><style face="normal" font="default"> Rojas-Perez-Ezquerra,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Urticaria by thiamine (vitamin B1)</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="8" Year="2017">2017/8/23</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170827IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.07.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28843441">PM:28843441</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20170827-RodriguezFernandezA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20170827-RodriguezFernandezA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170827, Rodriguez-Fernandez A</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.07.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42337</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ro,M.</style></author><author><style face="normal" font="default"> Lee,A.J.</style></author><author><style face="normal" font="default"> Kim,J.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Life Sciences and Biotechnology, Korea University, Seoul, 02841, Korea</style></auth-address><titles><title><style face="normal" font="default">5-/12-lipoxygenase-linked cascade contributes to the IL-33-induced synthesis of IL-13 in mast cells, thus promoting asthma development</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="default">BACKGROUND: As asthma progresses, the levels of IL-33 in serum are markedly increased and contribute to asthmatic development and exacerbation. Mast cells, one of the principal effector cells in the pathogenesis of asthma, express high levels of the IL-33 receptor ST2 and have been shown to be activated by IL-33. Thus, IL-33 stimulates mast cells to produce Th2-type cytokines such as IL-13, thus contributing to asthmatic development. However, the signaling mechanism for IL-33-induced synthesis of Th2 cytokines, particularly IL-13, has not been fully elucidated in mast cells. METHODS: The role of 5- or 12-LO in the IL-33-induced synthesis of IL-13 was investigated using knockdown or pharmacological inhibitors in BMMCs and animal model. RESULTS: Blockade of 5- or 12-LO significantly suppressed IL-33-induced synthesis of IL-13 in BMMCs. The subsequent action of 5- and 12-LO metabolites through their specific receptor, BLT2, was also critical for IL-33-induced synthesis of IL-13. We also demonstrated that the MyD88-p38 kinase cascade lies upstream of 5-/12-LO and that NF-kappaB lies downstream of 5-/12-LO to mediate the IL-33-induced synthesis of IL-13 in mast cells. Consistent with these findings, we observed that in an IL-33-administered asthmatic airway inflammation model, IL-13 levels were markedly increased in bronchoalveolar lavage fluid, but its levels were markedly suppressed by treatment with inhibitors of 5-LO, 12-LO or BLT2, further suggesting roles of 5-/12-LO in IL-33-induced IL-13 production. CONCLUSION: Our results suggest that 'MyD88-5-/12-LO-BLT2-NF-kappaB' cascade significantly contributes to the IL-33-induced synthesis of IL-13 in mast cells, thus potentially contributing to asthmatic development and exacerbation. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170831IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1111/all.1329</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28857185">PM:28857185</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170831-RoM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170831-RoM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170831, Ro M</style></custom2><misc3><style face="normal" font="default">10.1111/all.1329</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42338</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bork,K.</style></author><author><style face="normal" font="default"> Wulff,K.</style></author><author><style face="normal" font="default"> Steinmuller-Magin,L.</style></author><author><style face="normal" font="default"> Braenne,I.</style></author><author><style face="normal" font="default"> Staubach-Renz,P.</style></author><author><style face="normal" font="default"> Witzke,G.</style></author><author><style face="normal" font="default"> Hardt,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Johannes Gutenberg University, Mainz, GermanyUniversity Medicine, Ernst Moritz Arndt University, Greifswald, Germany</style></auth-address><titles><title><style face="normal" font="default">Hereditary angioedema with a mutation in the plasminogen gene</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="8" Year="2017">2017/8/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hereditary angioedema (HAE) with normal C1-INH (HAEnCI) may be linked to specific mutations in the coagulation factor 12 (FXII) gene (HAE-FXII) or functional mutations in other genes that are still unknown. We sought to identify and characterize a hitherto unknown type of HAE with normal C1-INH and without mutation in the F12 gene. METHODS: The study comprised analysis of whole exome sequencing, Sanger sequencing, and clinical data of patients. RESULTS: We detected a mutation in the plasminogen gene in patients with HAEnCI. The mutation c.9886A>G was located in exon 9 leading to the missense mutation p.Lys330Glu (K330E) in the kringle 3 domain of the plasminogen protein. The mutation was identified by next generation sequencing in 14 patients with HAEnCI belonging to 4 of 7 families. Family studies revealed that this type of HAE was transmitted as an autosomal dominant trait. The plasminogen gene mutation was present in all studied symptomatic patients and was also found in 9 out of 38 index patients from 38 further families with HAEnCI. Most patients had swelling of face/lips (78.3%) and tongue (78.3%). 331 out of all 3.795 tongue swellings (8.7%) were associated with dyspnea, voice changes and imminent asphyxiation. Two women died by asphyxiation due to a tongue swelling. CONCLUSIONS: HAE with a mutation in the plasminogen gene is a novel type of HAE. It is associated with a high risk of tongue swellings. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170810IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.13270</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28795768">PM:28795768</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170810-BorkK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170810-BorkK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170810, Bork K</style></custom2><misc3><style face="normal" font="default">10.1111/all.13270</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42339</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">De Servi,B.</style></author><author><style face="normal" font="default"> Ranzini,F.</style></author><author><style face="normal" font="default"> Pique,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">VitroScreen Srl, Via Mose Bianchi 103, 20149 Milan, Italy</style></auth-address><titles><title><style face="normal" font="default">Protective barrier properties of Rhinosectan(R) spray (containing xyloglucan) on an organotypic 3D airway tissue model (MucilAir): results of an in vitro study</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Clin Immunol</style></full-title></periodical><pages end="" start="37">37-</pages><volume><style face="normal" font="default">13</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergens</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: To evaluate barrier protective properties of Rhinosectan(R) spray, a medical device containing xyloglucan, on nasal epithelial cells (MucilAir). METHODS: MucilAir-Nasal, a three-dimensional organotypic (with different cell types) airway tissue model, was treated with the medical device Rhinosectan(R) (30 microL) or with controls (Rhinocort-budesonide-or saline solution). The protective barrier effects of Rhinosectan(R) were evaluated by: TEER (trans-epithelial electrical resistance) (preservation of tight junctions), Lucifer Yellow assay (preservation of paracellular flux) and confocal immunofluorescence microscopy (localization of tight junction proteins). RESULTS: Exposure of MucilAir with Rhinosectan(R) protected cell tight junctions (increases in TEER of 13.1% vs -6.3% with saline solution after 1 h of exposure), and preserved the paracellular flux, even after exposure with pro-inflammatory compounds (TNF-alpha and LPS from Pseudomonas aeruginosa 10). Results of confocal immunofluorescence microscopy demonstrated that, after treatment with the pro-inflammatory mixture, Rhinosectan(R) produced a slight relocation of zona occludens-1 in the cytosol compartment (while Rhinocort induced expression of zona-occludens-1), maintaining the localization of occludin (similarly to negative control). CONCLUSIONS: Results of our study indicates that Rhinosectan(R) creates a protective physical barrier on nasal epithelial cells in vitro, allowing the avoidance of allergens and triggering factors, thus confirming the utility of this medical device in the management of nasal respiratory diseases, as rhinitis or rhinosinusitis</style></abstract><notes><style face="normal" font="default">DA - 20170816IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1186/s13223-017-0209-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28811823">PM:28811823</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-37.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-37.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170816, De Servi B</style></custom2><misc3><style face="normal" font="default">10.1186/s13223-017-0209-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42340</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bellanti,J.A.</style></author><author><style face="normal" font="default"> Settipane,R.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Primum adiuvare ... primum non nocere ... and the practice of allergy</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="332" start="331">331-332</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170817IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4082</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28814354">PM:28814354</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170817, Bellanti JA</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4082</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42341</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cavkaytar,O.</style></author><author><style face="normal" font="default"> Karaatmaca,B.</style></author><author><style face="normal" font="default"> Cetinkaya,P.G.</style></author><author><style face="normal" font="default"> Esenboga,S.</style></author><author><style face="normal" font="default"> Arik,Y.E.</style></author><author><style face="normal" font="default"> Sahiner,U.M.</style></author><author><style face="normal" font="default"> Sekerel,B.E.</style></author><author><style face="normal" font="default"> Soyer,O.</style></author></authors></contributors><titles><title><style face="normal" font="default">Characteristics of drug-induced anaphylaxis in children and adolescents</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="63" start="56">56-63</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergens</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Although data on anaphylaxis in the general population exist for different allergens, there is still lack of detailed etiologic data on drug-induced anaphylaxis (DIA), particularly in children. OBJECTIVE: To define the etiology of DIA, to determine the accuracy of drug-related anaphylaxis histories, along with the severity and culprit drug associations among individuals &lt;18 years old. METHODS: Patients with a history of drug hypersensitivity reaction (DHR) referred to our center between January 2012 and February 2016 were included. After the collection of European Network for Drug Allergy questionnaire results, initial skin tests and/or provocation tests were performed for the offending drug. RESULTS: Among 561 children and adolescents referred due to a suspected DHR, 113 (19%) (median age [interquartile range], 9.6 years [5.4-13.8 years]; 55% boys) had anaphylaxis in their history. At the end of diagnostic evaluation of the patients, 84 (74% of the patients with a history of DIA) were actually hypersensitive to the offending drug. Major drugs that resulted in DIA were antibiotics (33%), nonsteroidal anti-inflammatory drugs (25%), and chemotherapeutics (19%). The majority of patients reported grade 2 (moderate) (45%) and grade 3 (severe) (33%) anaphylactic reactions. A history of systemic illness (41.7 versus 7.1%; p = 0.001), concomitant intake of other drugs regularly (36.9 versus 10.3%; p = 0.007), and the use of chemotherapeutics as the culprit drug (19 versus 0%; p = 0.011) were more frequent, whereas the use of antibiotics was less frequent (34.5 versus 75.9%; p &lt; 0.001) among patients with actual DIA compared to drug tolerant patients. CONCLUSION: Three-fourths of the children and adolescents referred due to a suspected history of DIA were found to actually be drug hypersensitive. Prediagnosed systemic illness and different types of drugs would have an impact on the risk of DIA; however, atopic disease or a family history of drug hypersensitivity did not have an impact on actual DIA</style></abstract><notes><style face="normal" font="default">DA - 20170817IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4064</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28814352">PM:28814352</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170817, Cavkaytar O</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4064</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42342</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Misirlioglu,E.D.</style></author><author><style face="normal" font="default"> Guvenir,H.</style></author><author><style face="normal" font="default"> Toyran,M.</style></author><author><style face="normal" font="default"> Vezir,E.</style></author><author><style face="normal" font="default"> Capanoglu,M.</style></author><author><style face="normal" font="default"> Civelek,E.</style></author><author><style face="normal" font="default"> Buyuktiryaki,B.</style></author><author><style face="normal" font="default"> Ginis,T.</style></author><author><style face="normal" font="default"> Kocabas,C.N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Frequency of selective immediate responders to aminopenicillins and cephalosporins in Turkish children</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="382" start="376">376-382</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Skin</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Beta-lactam antibiotics (BLA) are the most commonly prescribed antibiotics and are responsible for the majority of immediate hypersensitivity reactions to drugs in children. Cross-reactivity is important in hypersensitivity to BLAs because these drugs all share a common beta-lactam structure and some share similar side chains. OBJECTIVE: The aim of this study was to evaluate the clinical characteristics of patients who are diagnosed with immediate-type BLA hypersensitivity and frequency of patients with side chain hypersensitivity, "selective responders." METHODS: The study included patients who were diagnosed with immediate-type BLA hypersensitivity between January 2011 and May 2016 in a pediatric allergy outpatient clinic. The patients who had negative penicillin test (minor determinant mixture, benzylpenicilloylpoly-L-lysine, penicillin G) results and could tolerate penicillin V and/or BLAs with dissimilar side chains but had positive skin and/or provocation test results with the suspected drug were diagnosed as selective responders. RESULTS: During the study period, 357 patients (55.2% girls) were admitted to our clinic with suspected immediate-type BLA hypersensitivity. Parents of 11 patients did not give consent for an allergy workup with the suspected drug. Forty-five of the patients were diagnosed (45/346 [13%]) based on skin test or drug provocation test results. The most common susceptible agent was amoxicillin-clavulanate. Of the patients, 71.4% with a reaction to sulbactam-ampicillin /or amoxicillin-clavulanate and 93.7% with a reaction to cephalosporin were classified as selective responders. CONCLUSION: Among children with immediate BLA hypersensitivity, selective responders constituted an important group. Most of the patients with reactions to aminopenicillin and cephalosporins safely tolerated penicillin V and BLAs with dissimilar side chains after negative allergy workup results</style></abstract><notes><style face="normal" font="default">DA - 20170817IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4065</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28814358">PM:28814358</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170817, Misirlioglu ED</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4065</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42343</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nassiri,M.</style></author><author><style face="normal" font="default"> Bahna,S.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Skin rash in a 2-week-old infant</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="393" start="390">390-393</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">diagnosis</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword></keywords><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="default">We presented a case of a male infant with annular patchy rash on his torso since 2 weeks of age. This was initially diagnosed as tinea corporis but did not respond to oral antifungal treatment. Because of the appearance of the rash and a history of a certain disease in a maternal aunt, we suspected the most probable cause of the rash and the diagnosis was confirmed by laboratory testing. Furthermore, laboratory screening of the mother, who was asymptomatic, revealed that she was seropositive for the disease and was counseled on the importance of follow-up. The infant's rash gradually improved and completely disappeared, without any sequalae by 8 months of age</style></abstract><notes><style face="normal" font="default">DA - 20170817IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28814360">PM:28814360</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170817, Nassiri M</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4044</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42344</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kwong,K.Y.</style></author><author><style face="normal" font="default"> Redjal,N.</style></author><author><style face="normal" font="default"> Scott,L.</style></author><author><style face="normal" font="default"> Li,M.</style></author><author><style face="normal" font="default"> Thobani,S.</style></author><author><style face="normal" font="default"> Yang,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Los Angeles County+University of Southern California Medical Center, Division of Allergy-Immunology, Department of Pediatrics, 1801 East Marengo St, Rm 1G1, Los Angeles, CA 90033.</style></auth-address><titles><title><style face="normal" font="default">Adaptation of an asthma management program to a small clinic</style></title><secondary-title><style face="normal" font="default">Am J Manag Care</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Am J Manag Care</style></abbr-1></periodical><pages end="e237" start="e231">e231-e237</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Asthma management programs, such as the Breathmobile program, have been extremely effective in reducing asthma morbidity and increasing disease control; however, their high start-up costs may preclude their implementation in smaller health systems. In this study, we extended validated asthma disease management principles from the Breathmobile program to a smaller clinic system utilizing existing resources and compared clinical outcomes. STUDY DESIGN: Cox-regression analyses were conducted to determine the cumulative probability that a new patient entering the program would achieve improved clinical control of asthma with each subsequent visit to the program. METHODS: A weekly asthma disease management clinic was initiated in an existing multi-specialty pediatric clinic in collaboration with the Breathmobile program. Existing nursing staff was utilized in conjunction with an asthma specialist provider. Patients were referred from a regional healthcare maintenance organization and patients were evaluated and treated every 2 months. Reduction in emergency department (ED) visits and hospitalizations, and improvements in asthma control were assessed at the end of 1 year. RESULTS: A total of 116 patients were enrolled over a period of 1 year. Mean patient age was 6.4 years at the time of their first visit. Patient ethnicity was self-described predominantly as Hispanic or African American. Initial asthma severity for most patients, classified in accordance with national guidelines, was "moderate persistent." After 1 year of enrollment, there was a 69% and 92% reduction in ED/urgent care visits and hospitalizations, respectively, compared with the year before enrollment. Up to 70% of patients achieved asthma control by the third visit. Thirty-six different patients were seen during 1 year for a total of $15,938.70 in contracted reimbursements. CONCLUSIONS: A large-scale successful asthma management program can be adapted to a stationary clinic system and achieve comparable results</style></abstract><notes><style face="normal" font="default">DA - 20170829IS - 1936-2692 (Electronic)IS - 1088-0224 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28850792">PM:28850792</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Manag Care\2017-23-e231-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Manag Care\2017-23-e231-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170829, Kwong KY</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42345</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Salter,B.M.A.</style></author><author><style face="normal" font="default"> Smith,S.G.</style></author><author><style face="normal" font="default"> Mukherjee,M.</style></author><author><style face="normal" font="default"> Plante,S.</style></author><author><style face="normal" font="default"> Krisna,S.</style></author><author><style face="normal" font="default"> Nusca,G.</style></author><author><style face="normal" font="default"> Oliveria,J.P.</style></author><author><style face="normal" font="default"> Irshad,A.</style></author><author><style face="normal" font="default"> Gauvreau,G.M.</style></author><author><style face="normal" font="default"> Chakir,J.</style></author><author><style face="normal" font="default"> Nair,P.</style></author><author><style face="normal" font="default"> Sehmi,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">McMaster University, Medicine, Hamilton, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="default">Human Bronchial Epithelial Cell-Derived Factors from Severe Asthmatic Subjects Stimulate Eosinophil Differentiation</style></title><secondary-title><style face="normal" font="default">Am J Respir Cell Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Cell Mol Biol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="default">RATIONALE: Activated bronchial epithelial cells release alarmins, including thymic stromal lymphopoietin (TSLP) that drive type 2 inflammatory responses. We hypothesize that bronchial epithelial-derived factors enhance in situ eosinophil differentiation and maturation from myeloid precursors, a process that is driven by an IL-5 rich micro-environment within asthma airways. METHODS: To assess the eosinophilopoietic potential of epithelial-derived factors, eosinophil/basophil colony forming units (Eo/B-CFU) were enumerated in 14-day methylcellulose cultures of blood-derived mononuclear cells (NAMNCs) incubated with bronchial epithelial cell supernatants (BECSN) from healthy non-atopic controls (NC; n = 8), mild atopic asthmatics (MA; n = 9) and severe asthmatics (SA; n = 5). Receptor blocking antibodies were used to evaluate the contribution of alarmins. Modulation of mRNA expression of transcription factors crucial for eosinophil differentiation was evaluated. RESULTS: BECSN stimulated the clonogenic expansion of eosinophil progenitors, in vitro. In the presence of IL-5, Eo/B-CFU growth was significantly greater in co-cultures of BESCN from SA, compared to MA and NC. This effect was attenuated by a TSLP receptor blocking antibody but not by an ST2 antibody. Recombinant human TSLP (optimal at 100 pg/ml) stimulated significant Eo/B-CFU growth, which was significantly enhanced in presence of IL-5 (1 ng/ml). Overnight culture of CD34+ cells with IL-5 and TSLP synergistically increased GATA-2 and CEBP-alpha mRNA expression. CONCLUSIONS: The eosinophilopoietic potential of factors derived from bronchial epithelial cells is increased in severe asthma. Our data suggest that TSLP is a key alarmin produced by bronchial epithelial cells, which promotes in situ eosinophilopoiesis in a type 2 rich microenvironment</style></abstract><notes><style face="normal" font="default">DA - 20170830IS - 1535-4989 (Electronic)IS - 1044-1549 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1165/rcmb.2016-0262OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28853918">PM:28853918</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170830, Salter BM</style></custom2><misc3><style face="normal" font="default">10.1165/rcmb.2016-0262OC</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42346</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Johal,K.</style></author><author><style face="normal" font="default"> Welch,K.</style></author><author><style face="normal" font="default"> Peters,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Immunoglobulin G4 sinusitis in association with aspirin-exacerbated respiratory disease</style></title><secondary-title><style face="normal" font="default">Am J Rhinol Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Am J Rhinol Allergy</style></abbr-1></periodical><pages end="304" start="302">302-304</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Immunoglobulin G4 (IgG4) related disease is a systemic inflammatory disease characterized by tumor-like tissue infiltration with IgG4 positive (IgG4+) plasma cells. Aspirin-exacerbated respiratory disease (AERD) is defined as asthma, chronic rhinosinusitis with nasal polyposis, and hypersensitivity to cyclooxygenase-1 inhibitors. OBJECTIVE: We described a case of a non-smoking 61-year-old male with prior NSAID sensitivity who presented with a 1-year history of left eye proptosis associated with chronic nasal symptoms, ultimately identified as concurrent AERD and IgG4 sinusitis. METHODS: The patient was evaluated in the clinic and diagnosed by using clinical, radiographic, and surgical biopsy findings. RESULTS: Although initial concern was greatest for malignancy, a biopsy specimen confirmed the presence of a dense lymphoplasmacytic infiltrate and storiform fibrosis, associated with increased IgG4+ plasma cells. Therefore, IgG4-related disease (RD) was identified in this patient with AERD. CONCLUSION: Shared type II inflammation may be responsible for the coexistence of IgG4-RD and AERD as observed in our patient. Health care workers must be cognizant of the simultaneous presentation of both IgG4-RD and AERD</style></abstract><notes><style face="normal" font="default">DA - 20170901IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/ajra.2017.31.4455</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28859705">PM:28859705</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Rhinol Allergy\2017-31-302-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Rhinol Allergy\2017-31-302-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170901, Johal K</style></custom2><misc3><style face="normal" font="default">10.2500/ajra.2017.31.4455</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42347</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">White,A.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">An update on the epidemiology of aspirin-exacerbated respiratory disease</style></title><secondary-title><style face="normal" font="default">Am J Rhinol Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Am J Rhinol Allergy</style></abbr-1></periodical><pages end="301" start="299">299-301</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Aspirin-exacerbated respiratory disease (AERD) is a disorder of nasal polyposis, asthma, and hypersensitivity respiratory reactions when on systemic cyclooxygenase 1 blockade. METHODS: AERD warrants specific evaluation as an endotype of asthma and chronic sinus disease due to unique therapeutic opportunities. Currently, aspirin therapy is uniquely beneficial as an anti-inflammatory therapy in AERD, with multiple additional therapies currently in early to late clinical studies, which might also show exceptional benefit in AERD. RESULTS: Yet, given the lack of a simple diagnostic test, opportunities to identify patients with AERD are still frequently neglected. CONCLUSION: Identifying the prevalence and population characteristics necessary to determine appropriate candidates in whom to perform diagnostic aspirin challenge remains critically important and was the purpose of this article</style></abstract><notes><style face="normal" font="default">DA - 20170901IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/ajra.2017.31.4462</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28859704">PM:28859704</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Rhinol Allergy\2017-31-299-301.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Rhinol Allergy\2017-31-299-301.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170901, White AA</style></custom2><misc3><style face="normal" font="default">10.2500/ajra.2017.31.4462</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42348</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jones,B.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Divisions of Allergy/Asthma/Immunology and Pediatric Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Hospital, University of Missouri, Kansas City, MO.</style></auth-address><titles><title><style face="normal" font="default">Understanding the biology of disease in underserved children with asthma: The missing piece of the health disparity puzzle</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="100" start="99">99-100</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">pharmacology</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170812IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.06.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28801022">PM:28801022</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-99-100.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-99-100.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170812, Jones BL</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.06.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42349</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tam,H.</style></author><author><style face="normal" font="default"> Simons,F.E.R.</style></author><author><style face="normal" font="default"> Simons,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics and Child Health, University of Manitoba, Winnipeg, Manitoba, Canada</style></auth-address><titles><title><style face="normal" font="default">Uptake of EpiPen and Allerject (Auvi-Q) epinephrine auto-injectors in Manitoba children</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="193" start="192">192-193</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword></keywords><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170812IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.06.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28801017">PM:28801017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-192-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-192-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170812, Tam H</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.06.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42350</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Manti,S.</style></author><author><style face="normal" font="default"> Amorini,M.</style></author><author><style face="normal" font="default"> Cuppari,C.</style></author><author><style face="normal" font="default"> Salpietro,A.</style></author><author><style face="normal" font="default"> Porcino,F.</style></author><author><style face="normal" font="default"> Leonardi,S.</style></author><author><style face="normal" font="default"> Giudice,M.M.D.</style></author><author><style face="normal" font="default"> Marseglia,G.</style></author><author><style face="normal" font="default"> Caimmi,D.P.</style></author><author><style face="normal" font="default"> Salpietro,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Unit of Pediatric Genetics and Immunology, University of Messina, Messina, Italy.</style></auth-address><titles><title><style face="normal" font="default">Filaggrin mutations and Molluscum contagiosum skin infection in patients with atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="default">BACKGROUND: Although mutations in the filaggrin (FLG) gene have been reported to predispose patients with atopic dermatitis (AD) skin infection susceptibility, to date, the data reported in the literature are still controversial. OBJECTIVE: To evaluate the role of FLG polymorphisms expression and risk of developing a concomitant Molluscum contagiosum sustained skin infection in the pediatric population with AD. METHODS: A total of 100 children with AD and 97 healthy children were enrolled. AD was diagnosed and assessed according to the validated European Task Force on Atopic Dermatitis. DNA samples of patients were analyzed for allelic variants in the promoter and coding exon of FLG. Genotyping was performed with polymerase chain reaction amplification and direct sequencing. RESULTS: Sixteen FLG variants have been detected in 29% of patients with AD: 2 synonymous (rs79808464 and rs116222149), 12 missense (rs11584340, rs113136594, rs145828067, rs374910442, rs747005144, rs145627745, rs144209313, rs74129443, rs192455877, rs150957860, rs138055273, rs147472105), 1 stop gained (rs183942200), and 1 frameshift (rs 558269137). In contrast, only 13% of the control group reported FLG mutations (22 heterozygous variants). In addition, the age at disease onset correlated significantly with FLG variants (P &lt; .001). In addition, the AD with FLG gene variants (rs145627745, rs79808464, rs150957860, rs145828067, rs747005144, rs374910442, rs138055273, rs183942200, rs11584340, and rs113136594) reported moderate to severe Scoring Atopic Dermatitis scores. Finally, the AD group and the AD plus M contagiosum skin infection group had a significant association with FLG mutations when compared with the control group (P &lt; .01). CONCLUSION: FLG mutations are associated with early onset of AD, more severe clinical course of disease, and a significantly increased risk of M contagiosum sustained skin infection</style></abstract><notes><style face="normal" font="default">DA - 20170903IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28866311">PM:28866311</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170903-MantiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170903-MantiS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170903, Manti S</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42351</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,L.</style></author><author><style face="normal" font="default"> Liang,R.</style></author><author><style face="normal" font="default"> Zhou,T.</style></author><author><style face="normal" font="default"> Zheng,J.</style></author><author><style face="normal" font="default"> Liang,B.M.</style></author><author><style face="normal" font="default"> Zhang,H.P.</style></author><author><style face="normal" font="default"> Luo,F.M.</style></author><author><style face="normal" font="default"> Gibson,P.G.</style></author><author><style face="normal" font="default"> Wang,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pneumology Group, Department of Integrated Traditional Chinese and Western Medicine, State Key Laboratory of Biotherapy of China, West China Hospital, Sichuan University, Chengdu, People's Republic of China</style></auth-address><titles><title><style face="normal" font="default">Identification and validation of asthma phenotypes in Chinese population using cluster analysis</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is a heterogeneous airway disease, so it is crucial to clearly identify clinical phenotypes to achieve better asthma management. OBJECTIVE: To identify and prospectively validate asthma clusters in a Chinese population. METHODS: Two hundred eighty-four patients were consecutively recruited and 18 sociodemographic and clinical variables were collected. Hierarchical cluster analysis was performed by the Ward method followed by k-means cluster analysis. Then, a prospective 12-month cohort study was used to validate the identified clusters. RESULTS: Five clusters were successfully identified. Clusters 1 (n = 71) and 3 (n = 81) were mild asthma phenotypes with slight airway obstruction and low exacerbation risk, but with a sex differential. Cluster 2 (n = 65) described an "allergic" phenotype, cluster 4 (n = 33) featured a "fixed airflow limitation" phenotype with smoking, and cluster 5 (n = 34) was a "low socioeconomic status" phenotype. Patients in clusters 2, 4, and 5 had distinctly lower socioeconomic status and more psychological symptoms. Cluster 2 had a significantly increased risk of exacerbations (risk ratio [RR] 1.13, 95% confidence interval [CI] 1.03-1.25), unplanned visits for asthma (RR 1.98, 95% CI 1.07-3.66), and emergency visits for asthma (RR 7.17, 95% CI 1.26-40.80). Cluster 4 had an increased risk of unplanned visits (RR 2.22, 95% CI 1.02-4.81), and cluster 5 had increased emergency visits (RR 12.72, 95% CI 1.95-69.78). Kaplan-Meier analysis confirmed that cluster grouping was predictive of time to the first asthma exacerbation, unplanned visit, emergency visit, and hospital admission (P &lt; .0001 for all comparisons). CONCLUSION: We identified 3 clinical clusters as "allergic asthma," "fixed airflow limitation," and "low socioeconomic status" phenotypes that are at high risk of severe asthma exacerbations and that have management implications for clinical practice in developing countries</style></abstract><notes><style face="normal" font="default">DA - 20170903IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - China -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28866310">PM:28866310</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170903-WangL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170903-WangL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170903, Wang L</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42352</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jose,J.</style></author><author><style face="normal" font="default"> Virojanapa,A.</style></author><author><style face="normal" font="default"> Lehman,E.B.</style></author><author><style face="normal" font="default"> Horwitz,A.</style></author><author><style face="normal" font="default"> Fausnight,T.</style></author><author><style face="normal" font="default"> Jhaveri,P.</style></author><author><style face="normal" font="default"> Alexander,C.</style></author><author><style face="normal" font="default"> Jhaveri,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Hershey, Pennsylvania.</style></auth-address><titles><title><style face="normal" font="default">Parental perception of anxiety in children with eosinophilic esophagitis in a tertiary care center</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170903IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28866305">PM:28866305</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170903-JoseJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170903-JoseJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170903, Jose J</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42353</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hermans,M.A.W.</style></author><author><style face="normal" font="default"> Arends,N.J.T.</style></author><author><style face="normal" font="default"> Gerth van Wijk,R.</style></author><author><style face="normal" font="default"> van Hagen,P.M.</style></author><author><style face="normal" font="default"> Kluin-Nelemans,H.C.</style></author><author><style face="normal" font="default"> Oude Elberink,H.N.G.</style></author><author><style face="normal" font="default"> Pasmans,S.G.M.A.</style></author><author><style face="normal" font="default"> van Daele,P.L.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Section of Allergy, Erasmus University Medical Center, Rotterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Management around invasive procedures in mastocytosis: An update</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Mastocytosis is a chronic hematologic disorder that is characterized by the accumulation of aberrant mast cells and typically involves the skin and/or bone marrow. Patients with mastocytosis are at increased risk of anaphylaxis. Based on theoretical assumptions, medical procedures requiring general anesthesia or radiocontrast media are deemed hazardous for patients with mastocytosis. The objective of this article is to provide a comprehensive overview of the actual risk of iatrogenic anaphylaxis and provide recommendations for daily practice. DATA SOURCES: Various scientific search engines were used (eg, PubMed and Medline). STUDY SELECTIONS: Because of the paucity of high-level studies on this topic, all available evidence was considered, including case reports. RESULTS: Reliable data on the incidence of iatrogenic anaphylaxis in mastocytosis are lacking. However, although the incidence as reported in (retrospective) cohort studies is higher than in the general population, it is still lower than commonly anticipated, with an incidence of 5.4% in 1 study. Adequate premedication and avoidance of certain physical stimuli can further decrease this risk by 10-fold. The role of drugs as elicitors of anaphylaxis is perhaps overestimated, and physical stimuli are at least as important in inducing release of mast cell mediators. CONCLUSION: This article provides practical recommendations for the management of invasive procedures in patients with mastocytosis based on current knowledge of this topic</style></abstract><notes><style face="normal" font="default">DA - 20170903IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28866309">PM:28866309</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170903-HermansMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170903-HermansMA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170903, Hermans MA</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.022</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42354</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pena-Zarza,J.A.</style></author><author><style face="normal" font="default"> Osona,B.</style></author><author><style face="normal" font="default"> Sailer,S.</style></author><author><style face="normal" font="default"> Gil-Sanchez,J.A.</style></author><author><style face="normal" font="default"> Figuerola,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, University Hospital Son Espases, Palma de Mallorca, Spain.</style></auth-address><titles><title><style face="normal" font="default">Assessing hypoxia risk during air travel after a severe asthma exacerbation in children</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28870449">PM:28870449</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170905-PenaZarzaJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170905-PenaZarzaJA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Pena-Zarza JA</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.034</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42355</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Iammatteo,M.</style></author><author><style face="normal" font="default"> Keskin,T.</style></author><author><style face="normal" font="default"> Jerschow,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York</style></auth-address><titles><title><style face="normal" font="default">Evaluation of periprocedural hypersensitivity reactions</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="default">BACKGROUND: Identifying the cause of periprocedural hypersensitivity reactions (HSRs) remains challenging because of the multitude of medications involved. Antibiotics are the most common cause in the United States, whereas neuromuscular blocking agents are most common in Europe. OBJECTIVE: To identify causative agents for periprocedural HSRs. METHODS: This study was a 7-year retrospective medical record review of patients evaluated between December 2009 and January 2017 at a drug allergy center in Bronx, New York for periprocedural HSRs, defined as occurring soon before, during, or soon after a medical procedure or operation with or without general anesthesia. Demographics, description of historical HSRs, results of testing to potential causative medications, and tolerance of subsequent anesthesia were reviewed. RESULTS: Thirty-four patients completed a comprehensive evaluation. Skin testing identified an IgE-mediated cause in 22 patients (64.7%). The most common causative class of medications was induction agents (n = 9 [36%]), with midazolam being the most frequently implicated (n = 6 [3 positive skin test results, 3 equivocal skin test results]). Cefazolin was the most common agent identified (n = 8 [32%]) followed by ondansetron (n = 3 [12%]). Sixteen of 22 contacted patients were exposed to subsequent anesthesia, including 3 patients with negative evaluations. One patient experienced a mild urticarial HSR. CONCLUSION: Induction agents were the most common causative agents in our patients, which differs from other studies. Given the variability in evaluations of periprocedural HSRs across the United States with data published on small sample sizes, there is a need to establish national guidelines to standardize evaluations and to create a national registry to allow for data sharing</style></abstract><notes><style face="normal" font="default">DA - 20170903IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28866307">PM:28866307</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170903-IammatteoM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170903-IammatteoM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170903, Iammatteo M</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42356</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,H.S.</style></author><author><style face="normal" font="default"> Kim,J.H.</style></author><author><style face="normal" font="default"> Seo,Y.M.</style></author><author><style face="normal" font="default"> Chun,Y.H.</style></author><author><style face="normal" font="default"> Yoon,J.S.</style></author><author><style face="normal" font="default"> Kim,H.H.</style></author><author><style face="normal" font="default"> Lee,J.S.</style></author><author><style face="normal" font="default"> Kim,J.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Eosinophil-derived neurotoxin as a biomarker for disease severity and relapse in recalcitrant atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="default">BACKGROUND: Eosinophils are encountered in many skin diseases, but the role of eosinophils in atopic dermatitis (AD) remains uncertain. OBJECTIVE: To examine the role of serum eosinophil-derived neurotoxin (EDN), eosinophil cationic protein (ECP), and total IgE as a biomarker of disease severity and relapse in severe recalcitrant AD. METHODS: We enrolled 99 patients with AD: 37 with severe recalcitrant AD, 20 with severe AD, and 42 with mild to moderate AD. We examined the difference in serum level of total IgE, ECP, and EDN between the groups and whether any correlation existed between disease severity and ECP or EDN. Lastly, difference in levels of ECP or EDN between those who experienced relapse was examined in the severe recalcitrant group. RESULTS: Serum levels of total IgE, ECP, and EDN were significantly higher in the severe recalcitrant AD group and severe AD group compared with the mild to moderate AD group. No significant difference was found in serum levels of total IgE, ECP, and EDN between the severe recalcitrant group and severe group. EDN had a significant positive correlation with the SCORing Atopic Dermatitis. No significant correlation was found between EDN and ECP. In the severe recalcitrant group, 29.7% of patients experienced relapse, and EDN was significantly higher in those who experienced relapse. The cutoff value of EDN for predicting relapse was 64.5. CONCLUSION: EDN correlated with the disease severity of AD. EDN may predict relapse in severe recalcitrant AD. The EDN serum level could be considered a candidate molecule as a clinical biomarker for evaluating AD disease activity and a predictor of relapse</style></abstract><notes><style face="normal" font="default">DA - 20170903IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.06.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28866306">PM:28866306</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170903-KimHS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170903-KimHS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170903, Kim HS</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.06.022</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42357</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,F.</style></author><author><style face="normal" font="default"> Hong,H.</style></author><author><style face="normal" font="default"> Sun,Y.</style></author><author><style face="normal" font="default"> Hu,X.</style></author><author><style face="normal" font="default"> Zhang,J.</style></author><author><style face="normal" font="default"> Xu,G.</style></author><author><style face="normal" font="default"> Zhao,W.</style></author><author><style face="normal" font="default"> Li,H.</style></author><author><style face="normal" font="default"> Shi,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Otorhinolaryngology Hospital, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China</style></auth-address><titles><title><style face="normal" font="default">Nasal interleukin 25 as a novel biomarker for patients with chronic rhinosinusitis with nasal polyps and airway hypersensitiveness: A pilot study</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory disease of the upper airway and is tightly linked with airway hyperresponsiveness (AHR) and asthma. However, the surrogate biomarkers for indicating AHR and asthma in patients with CRSwNP remain elusive. OBJECTIVE: To investigate the surrogate biomarkers for indicating AHR and asthma in patients with CRSwNP. METHODS: In this study, sinonasal tissues were collected from 42 patients with CRSwNP (asthma, n = 17; asymptomatic AHR, n = 11; non-AHR, n = 14), 11 patients with chronic rhinosinusitis without nasal polyps (CRSsNP), and 13 controls. The protein and messenger RNA levels of interleukin (IL) 25 and other cytokines in nasal polyp (NP) and control sinonasal tissues were determined by quantitative real-time polymerase chain reaction and multiplex immunoassay, respectively. Multivariate logistic regression and receiver operating characteristic curve analysis were performed to assess the clinical relevance of IL-25. RESULTS: We found that the protein and messenger RNA levels of IL-25 were significantly increased in NP tissues compared with the control sinonasal tissues from patients with CRSwNP, patients with CRSsNP, and controls. Multivariate logistic regression revealed that the nasal IL-25 protein level and nasal and blood eosinophil counts were independent risk factors for AHR in patients with CRSwNP. According to receiver operating characteristic curve analysis, nasal tissue IL-25 had a sensitivity of 91.4% and a specificity of 62.8% (area under the curve, 0.845) at the cutoff level of 5 pg/muL for indicating AHR in this CRSwNP cohort. CONCLUSION: Our findings indicated that IL-25 was significantly increased in NP tissues and may be considered as the molecular indicator for AHR in patients with CRSwNP. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02110654</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28870448">PM:28870448</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170905-ChenF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170905-ChenF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Chen F</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42358</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">You,H.R.</style></author><author><style face="normal" font="default"> Yun,S.J.</style></author><author><style face="normal" font="default"> Kim,S.J.</style></author><author><style face="normal" font="default"> Lee,S.C.</style></author><author><style face="normal" font="default"> Won,Y.H.</style></author><author><style face="normal" font="default"> Lee,J.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Chonnam National University Medical School, Gwangju, Korea</style></auth-address><titles><title><style face="normal" font="default">Three Cases of Autoimmune Progesterone Dermatitis</style></title><secondary-title><style face="normal" font="default">Ann Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Dermatol</style></abbr-1></periodical><pages end="482" start="479">479-482</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">Autoimmune progesterone dermatitis is a rare cyclic premenstrual reaction to progesterone produced during the luteal phase of the menstrual cycle. The clinical symptoms of autoimmune progesterone dermatitis overlap with other forms of dermatosis such as erythema multiforme, eczema, fixed drug eruption, urticaria, and angioedema. We experienced 3 cases of autoimmune progesterone dermatitis. All patients had a recurrent history of monthly skin eruptions. Skin lesions normally began a few days before menstruation and resolved a few days later. Patients were confirmed to have autoimmune progesterone dermatitis by the results of the progesterone intradermal test. All three patients had different clinical findings such as erythema annulare centrifugum, urticaria, contact dermatitis, and rosacea. Because patients presented with variable clinical manifestations, they could have been easily misdiagnosed. The patients were treated with oral contraceptive, antihistamine and steroids for symptom control. We propose that dermatologists should consider autoimmune progesterone dermatitis in cases of recurrent cyclic skin eruptions in female patients. Further, if this condition is suspected, thorough history taking including that on menstrual cycle and intradermal progesterone test should be performed</style></abstract><notes><style face="normal" font="default">DA - 20170801IS - 1013-9087 (Print)IS - 1013-9087 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.5021/ad.2017.29.4.479</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28761298">PM:28761298</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Dermatol\2017-29-479-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Dermatol\2017-29-479-82.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, You HR</style></custom2><misc3><style face="normal" font="default">10.5021/ad.2017.29.4.479</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42359</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Son,J.H.</style></author><author><style face="normal" font="default"> Park,S.Y.</style></author><author><style face="normal" font="default"> Cho,Y.S.</style></author><author><style face="normal" font="default"> Byun,Y.S.</style></author><author><style face="normal" font="default"> Chung,B.Y.</style></author><author><style face="normal" font="default"> Cho,H.J.</style></author><author><style face="normal" font="default"> Kim,H.O.</style></author><author><style face="normal" font="default"> Park,C.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Two Cases of Successful Treatment of Refractory Chronic Inflammatory Skin Disease, Atopic Dermatitis and Psoriasis with Oral Alitretinoin</style></title><secondary-title><style face="normal" font="default">Ann Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Dermatol</style></abbr-1></periodical><pages end="506" start="503">503-506</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170801IS - 1013-9087 (Print)IS - 1013-9087 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.5021/ad.2017.29.4.503</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28761307">PM:28761307</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Dermatol\2017-29-503-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Dermatol\2017-29-503-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Son JH</style></custom2><misc3><style face="normal" font="default">10.5021/ad.2017.29.4.503</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42360</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kikuchi,S.</style></author><author><style face="normal" font="default"> Yanaba,K.</style></author><author><style face="normal" font="default"> Nobeyama,Y.</style></author><author><style face="normal" font="default"> Yabe,S.</style></author><author><style face="normal" font="default"> Kiso,M.</style></author><author><style face="normal" font="default"> Saeki,H.</style></author><author><style face="normal" font="default"> Tada,Y.</style></author><author><style face="normal" font="default"> Nakagawa,H.</style></author><author><style face="normal" font="default"> Okochi,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">Suppressive Effects of Mesenchymal Stem Cells in Adipose Tissue on Allergic Contact Dermatitis</style></title><secondary-title><style face="normal" font="default">Ann Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Dermatol</style></abbr-1></periodical><pages end="399" start="391">391-399</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic contact dermatitis (ACD), which is accelerated by interferon (IFN)-gamma and suppressed by interleukin (IL)-10 as regulators, is generally self-limited after removal of the contact allergen. Adipose tissue-derived multipotent mesenchymal stem cells (ASCs) potentially exert immunomodulatory effects. Considering that subcutaneous adipose tissue is located close to the site of ACD and includes mesenchymal stem cells (MSCs), the MSCs in adipose tissue could contribute to the self-limiting course of ACD. OBJECTIVE: The aims of the present study were to elucidate the effects of MSCs in adipose tissue on ACD and to examine any cytokine-mediated mechanisms involved. METHODS: Ear thickness in a C57BL/6 mouse model of ACD using contact hypersensitivity (CHS) elicited by 2,4,6-trinitro-1-chlorobenzene was evaluated as a marker of inflammation level. Five and nine mice were injected with ASCs and phosphate-buffered saline (PBS), respectively. After ASC or PBS injection, real-time reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay were performed. RESULTS: Histology showed that CHS was self-limited and ear thickness was suppressed by ASCs in a dose-dependent manner. IFN-gamma expression in the elicited skin site and regional lymph nodes was significantly lower in ASC-treated mice than in control mice. IL-10 expression did not differ between treated and control mice. The suppressive effects of ASCs on CHS response did not differ between IL-10 knock-out C57BL/6 mice and wild-type mice. CONCLUSION: The present findings suggest that MSCs in adipose tissue may contribute to the self-limiting course of ACD through decreased expression of IFN-gamma, but not through increased expression of IL-10</style></abstract><notes><style face="normal" font="default">DA - 20170801IS - 1013-9087 (Print)IS - 1013-9087 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.5021/ad.2017.29.4.391</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28761285">PM:28761285</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Dermatol\2017-29-391-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Dermatol\2017-29-391-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Kikuchi S</style></custom2><misc3><style face="normal" font="default">10.5021/ad.2017.29.4.391</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42361</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Al-Ahmad,M.</style></author><author><style face="normal" font="default"> Bouza,T.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Mona Al-Ahmad, Department of Microbiology,, Faculty of Medicine, Kuwait University,, PO Box 24923,, Safat 13110, Kuwait, T: +965-24636515, F: +965-25332719, Alahmadm@hsc.edu.kw, ORCID: orcid.org/0000-0003-3720-7032</style></auth-address><titles><title><style face="normal" font="default">Successful desensitization to radiocontrast media in two high-risk cardiac patients</style></title><secondary-title><style face="normal" font="default">Ann Saudi Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Saudi Med</style></abbr-1></periodical><pages end="335" start="333">333-335</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Hypersensitivity reactions to radiocontrast media (RCM) are common and in severe cases may present a challenge for treating physician in cases when premedication fails or the patient presents with severe comorbidities. We describe two cases in need of radiocontrast media after a severe reaction on previous exposure to iohexol. One presented anaphylactic reaction to RCM despite premedication and another presented with angina. Both cases were treated with a desensitization protocol to iodixanol. In conclusion, desensitization to radiocontrast media may be considered in patients with previously unsuccessful premedication and/or severe acute comorbidities. SIMILAR CASES PUBLISHED: 14</style></abstract><notes><style face="normal" font="default">DA - 20170801IS - 0975-4466 (Electronic)IS - 0256-4947 (Linking)LA - engPT - Journal ArticleCO - Kuwait -</style></notes><work-type><style face="normal" font="default">10.5144/0256-4947.2017.333</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28761034">PM:28761034</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Saudi Med\2017-37-333-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Saudi Med\2017-37-333-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Al-Ahmad M</style></custom2><misc3><style face="normal" font="default">10.5144/0256-4947.2017.333</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42362</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tan,J.W.</style></author><author><style face="normal" font="default"> Israf,D.A.</style></author><author><style face="normal" font="default"> Md Hashim,N.F.</style></author><author><style face="normal" font="default"> Cheah,Y.K.</style></author><author><style face="normal" font="default"> Harith,H.H.</style></author><author><style face="normal" font="default"> Shaari,K.</style></author><author><style face="normal" font="default"> Tham,C.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biomedical Science, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang 43300, Malaysia</style></auth-address><titles><title><style face="normal" font="default">LAT is essential for the mast cell stabilising effect of tHGA in IgE-mediated mast cell activation</style></title><secondary-title><style face="normal" font="default">Biochem Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Biochem Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="8" Year="2017">2017/8/13</year></dates><abstract><style face="normal" font="default">Mast cells play a central role in the pathogenesis of allergic reaction. Activation of mast cells by antigens is strictly dependent on the influx of extracellular calcium that involves a complex interaction between signalling molecules located within the cells. We have previously reported that tHGA, an active compound originally isolated from a local shrub known as Melicope ptelefolia, prevented IgE-mediated mast cell activation and passive systemic anaphylaxis by suppressing the release of interleukin-4 (IL-4) and tumour necrosis factor (TNF)-alpha from activated rat basophilic leukaemia (RBL)-2H3 cells. However, the mechanism of action (MOA) as well as the molecular target underlying the mast cell stabilising effect of tHGA has not been previously investigated. In this study, DNP-IgE-sensitised RBL-2H3 cells were pre-treated with tHGA before challenged with DNP-BSA. To dissect the MOA of tHGA in IgE-mediated mast cell activation, the effect of tHGA on the transcription of IL-4 and TNF-alpha mRNA was determined using Real Time-Polymerase Chain Reaction (qPCR) followed by Calcium Influx Assay to confirm the involvement of calcium in the activation of mast cells. The protein lysates were analysed by using Western Blot to determine the effect of tHGA on various important signalling molecules in the LAT-PLCgamma-MAPK and PI3K-NFkappaB pathways. In order to identify the molecular target of tHGA in IgE-mediated mast cell activation, the LAT and LAT2 genes in RBL-2H3 cells were knocked-down by using RNA interference to establish a LAT/LAT2 competition model. The results showed that tHGA inhibited the transcription of IL-4 and TNF-alpha as a result of the suppression of calcium influx in activated RBL-2H3 cells. The results from Western Blot revealed that tHGA primarily inhibited the LAT-PLCgamma-MAPK pathway with partial inhibition on the PI3K-p65 pathway without affecting Syk. The results from RNAi further demonstrated that tHGA failed to inhibit the release of mediators associated with mast cell degranulation under the LAT/LAT2 competition model in the absence of LAT. Collectively, this study concluded that the molecular target of tHGA could be LAT and may provide a basis for the development of a mast cell stabiliser which targets LAT</style></abstract><notes><style face="normal" font="default">DA - 20170816IS - 1873-2968 (Electronic)IS - 0006-2952 (Linking)LA - engPT - Journal ArticleCO - Malaysia -</style></notes><work-type><style face="normal" font="default">10.1016/j.bcp.2017.08.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28813645">PM:28813645</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biochem Pharmacol\20170816-TanJW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biochem Pharmacol\20170816-TanJW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170816, Tan JW</style></custom2><misc3><style face="normal" font="default">10.1016/j.bcp.2017.08.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42363</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hussain,M.</style></author><author><style face="normal" font="default"> Xu,C.</style></author><author><style face="normal" font="default"> Lu,M.</style></author><author><style face="normal" font="default"> Wu,X.</style></author><author><style face="normal" font="default"> Tang,L.</style></author><author><style face="normal" font="default"> Wu,X.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacology, School of Medicine, Zhejiang University, Hangzhou City, 310058, China</style></auth-address><titles><title><style face="normal" font="default">Wnt/beta-catenin signaling links embryonic lung development and asthmatic airway remodeling</style></title><secondary-title><style face="normal" font="default">Biochim Biophys Acta</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Biochim Biophys Acta</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="default">Embryonic lung development requires reciprocal endodermal-mesodermal interactions; mediated by various signaling proteins. Wnt/beta-catenin is a signaling protein that exhibits the pivotal role in lung development, injury and repair while aberrant expression of Wnt/beta-catenin signaling leads to asthmatic airway remodeling: characterized by hyperplasia and hypertrophy of airway smooth muscle cells, alveolar and vascular damage goblet cells metaplasia, and deposition of extracellular matrix; resulting in decreased lung compliance and increased airway resistance. The substantial evidence suggests that Wnt/beta-catenin signaling links embryonic lung development and asthmatic airway remodeling. Here, we summarized the recent advances related to the mechanistic role of Wnt/beta-catenin signaling in lung development, consequences of aberrant expression or deletion of Wnt/beta-catenin signaling in expansion and progression of asthmatic airway remodeling, and linking early-impaired pulmonary development and airway remodeling later in life. Finally, we emphasized all possible recent potential therapeutic significance and future prospectives, that are adaptable for therapeutic intervention to treat asthmatic airway remodeling</style></abstract><notes><style face="normal" font="default">DA - 20170903IS - 0006-3002 (Print)IS - 0006-3002 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.bbadis.2017.08.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28866134">PM:28866134</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biochim Biophys Acta\20170903-HussainM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biochim Biophys Acta\20170903-HussainM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170903, Hussain M</style></custom2><misc3><style face="normal" font="default">10.1016/j.bbadis.2017.08.031</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42364</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dean,K.</style></author><author><style face="normal" font="default"> Niven,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">University Hospital South Manchester, Manchester, UKManchester Academic Health Science Centre, The University of Manchester and University Hospital South Manchester, Manchester, UK.</style></auth-address><titles><title><style face="normal" font="default">Asthma Phenotypes and Endotypes: Implications for Personalised Therapy</style></title><secondary-title><style face="normal" font="default">BioDrugs</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BioDrugs</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="9" Year="2017">2017/9/6</year></dates><abstract><style face="normal" font="default">Asthma is increasingly recognised as a heterogeneous group of diseases with similar clinical presentations rather than a singular disease entity. Asthma was historically categorised by clinical symptoms; however, newer methods of subgrouping, describing and categorising the disease have sub-defined asthma. These sub-definitions are intermittently called phenotypes or endotypes, but the real meanings of these words are poorly understood. Novel treatments are currently and increasingly available, partly in the monoclonal antibody environment, and also some physical therapies (bronchial thermoplasty), but additionally small molecules are not far away from clinical practice. Understanding the disease pathogenesis and the mechanism of action more completely may enable identification of treatable traits, biomarkers, mediators and modifiable therapeutic targets. However, there remains a danger that clinicians become preoccupied with the concept of endotypes and biomarkers, ignoring therapies that are hugely effective but have no companion biomarker. This review discusses our understanding of the concept of phenotypes and endotypes in appreciating and managing the heterogeneous condition that is asthma. We consider the role of functional imaging, physiology, blood-, sputum- and breath-based biomarkers and clinical manifestations that could be used to produce a personalised asthma profile, with implications on prognosis, pathophysiology and most importantly specific therapeutic responses. With the advent of increasing numbers of biological therapies and other interventional options such as bronchial thermoplasty, the importance of targeting expensive therapies to patients with the best chance of clinical response has huge health economic importance</style></abstract><notes><style face="normal" font="default">DA - 20170907IS - 1179-190X (Electronic)IS - 1173-8804 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1007/s40259-017-0242-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28879503">PM:28879503</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BioDrugs\20170907-DeanK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BioDrugs\20170907-DeanK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170907, Dean K</style></custom2><misc3><style face="normal" font="default">10.1007/s40259-017-0242-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42365</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Okamoto-Uchida,Y.</style></author><author><style face="normal" font="default"> Nakamura,R.</style></author><author><style face="normal" font="default"> Sai,K.</style></author><author><style face="normal" font="default"> Imatoh,T.</style></author><author><style face="normal" font="default"> Matsunaga,K.</style></author><author><style face="normal" font="default"> Aihara,M.</style></author><author><style face="normal" font="default"> Saito,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Medicinal Safety Science, National Institute of Health Sciences</style></auth-address><titles><title><style face="normal" font="default">Effect of Infectious Diseases on the Pathogenesis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis</style></title><secondary-title><style face="normal" font="default">Biol Pharm Bull</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Biol Pharm Bull</style></full-title></periodical><pages end="1580" start="1576">1576-1580</pages><volume><style face="normal" font="default">40</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse drug reactions. Recent studies have revealed that the prevalence of SJS/TEN is associated with genetic backgrounds, such as polymorphisms in human leukocyte antigens (HLAs). However, non-genetic factors contributing to the etiology of SJS/TEN are largely unknown. This study aimed to assess the involvement of concurrent infection on the pathological states of SJS/TEN, examining the severity of cutaneous symptoms and ocular involvement as well as the time to onset in drug-induced SJS/TEN patients. We recruited 257 Japanese SJS/TEN patients from June 2006 to September 2013 through a nationwide case collection network and participating hospitals and reviewed the clinical information including patient backgrounds, primary disease and medication status. Association between infection and pathological states of SJS/TEN was assessed using univariate and multivariate analyses. The concurrent infectious group of SJS/TEN patients showed a significantly higher rate of exhibiting severer dermatological and ophthalmological phenotypes and an earlier onset of SJS/TEN than the non-infectious group. Our results suggest that the infection could be a risk factor to cause severer symptoms and earlier onset of SJS/TEN</style></abstract><notes><style face="normal" font="default">DA - 20170904IS - 1347-5215 (Electronic)IS - 0918-6158 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1248/bpb.b17-00207</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28867742">PM:28867742</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biol Pharm Bull\20170904-OkamotoUchidaY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biol Pharm Bull\20170904-OkamotoUchidaY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170904, Okamoto-Uchida Y</style></custom2><misc3><style face="normal" font="default">10.1248/bpb.b17-00207</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42366</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fernandez-Mendez,F.</style></author><author><style face="normal" font="default"> Saez-Gallego,N.M.</style></author><author><style face="normal" font="default"> Barcala-Furelos,R.</style></author><author><style face="normal" font="default"> Abelairas-Gomez,C.</style></author><author><style face="normal" font="default"> Padron-Cabo,A.</style></author><author><style face="normal" font="default"> Perez-Ferreiros,A.</style></author><author><style face="normal" font="default"> Garcia-Magan,C.</style></author><author><style face="normal" font="default"> Moure-Gonzalez,J.</style></author><author><style face="normal" font="default"> Contreras-Jordan,O.</style></author><author><style face="normal" font="default"> Rodriguez-Nunez,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">University College of Nursing, University of Vigo, Pontevedra, Spain</style></auth-address><titles><title><style face="normal" font="default">Learning and Treatment of Anaphylaxis by Laypeople: A Simulation Study Using Pupilar Technology</style></title><secondary-title><style face="normal" font="default">Biomed Res Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Biomed Res Int</style></abbr-1></periodical><pages end="" start="9837508">9837508-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">An anaphylactic shock is a time-critical emergency situation. The decision-making during emergencies is an important responsibility but difficult to study. Eye-tracking technology allows us to identify visual patterns involved in the decision-making. The aim of this pilot study was to evaluate two training models for the recognition and treatment of anaphylaxis by laypeople, based on expert assessment and eye-tracking technology. A cross-sectional quasi-experimental simulation study was made to evaluate the identification and treatment of anaphylaxis. 50 subjects were randomly assigned to four groups: three groups watching different training videos with content supervised by sanitary personnel and one control group who received face-to-face training during paediatric practice. To evaluate the learning, a simulation scenario represented by an anaphylaxis' victim was designed. A device capturing eye movement as well as expert valuation was used to evaluate the performance. The subjects that underwent paediatric face-to-face training achieved better and faster recognition of the anaphylaxis. They also used the adrenaline injector with better precision and less mistakes, and they needed a smaller number of visual fixations to recognise the anaphylaxis and to make the decision to inject epinephrine. Analysing the different video formats, mixed results were obtained. Therefore, they should be tested to evaluate their usability before implementation</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 2314-6141 (Electronic)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1155/2017/9837508</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28758128">PM:28758128</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biomed Res Int\2017-2017-9837508.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biomed Res Int\2017-2017-9837508.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170731, Fernandez-Mendez F</style></custom2><misc3><style face="normal" font="default">10.1155/2017/9837508</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42367</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Koo,S.M.</style></author><author><style face="normal" font="default"> Kim,Y.</style></author><author><style face="normal" font="default"> Park,C.</style></author><author><style face="normal" font="default"> Park,G.W.</style></author><author><style face="normal" font="default"> Lee,M.</style></author><author><style face="normal" font="default"> Won,S.</style></author><author><style face="normal" font="default"> Yang,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Respiratory Medicine, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Effect of Pregnancy on Quantitative Medication Use and Relation to Exacerbations in Asthma</style></title><secondary-title><style face="normal" font="default">Biomed Res Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Biomed Res Int</style></abbr-1></periodical><pages end="" start="8276190">8276190-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: The quantification of asthma medication reduction and its relation to an aggravation of asthma during pregnancy at an individual level are unclear. METHODS: We conducted a nationwide retrospective cohort study of asthmatic pregnant women in South Korea. All of the asthma medications were ranked from 1 to 4 according to the guideline-based stepwise approach. We assessed the daily sums of the ranks of the asthma medications and their association with exacerbations during three phases based on the individual's delivery date: before, during, and after pregnancy. RESULTS: The study cohort included 115,169 asthmatic pregnant women who gave birth between 2011 and 2013. The subjects were clustered into four groups according to the daily rank sums of their asthma medication. Asthma medications were rapidly reduced at the beginning of the pregnancy and then slowly increased after delivery. Exacerbations were more frequent in the group with higher rank-sum values than in the group with lower values. Overall exacerbations were reduced during pregnancy compared to before or after delivery. CONCLUSIONS: Asthmatic pregnant women tended to reduce their asthma medication use during pregnancy. This led to a greater number of exacerbations in a small part of the study population</style></abstract><notes><style face="normal" font="default">DA - 20170815IS - 2314-6141 (Electronic)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1155/2017/8276190</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28808663">PM:28808663</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biomed Res Int\2017-2017-8276190.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biomed Res Int\2017-2017-8276190.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170815, Koo SM</style></custom2><misc3><style face="normal" font="default">10.1155/2017/8276190</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42368</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Totty,J.</style></author><author><style face="normal" font="default"> Forsyth,J.</style></author><author><style face="normal" font="default"> Mekako,A.</style></author><author><style face="normal" font="default"> Chetter,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Academic Vascular Surgery, Hull York Medical School, Hull, UK</style></auth-address><titles><title><style face="normal" font="default">Life-threatening intraoperative anaphylaxis as a result of chlorhexidine present in Instillagel</style></title><secondary-title><style face="normal" font="default">BMJ Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword></keywords><dates><year Day="21" Month="8" Year="2017">2017/8/21</year></dates><abstract><style face="normal" font="default">A 70-year-old man with left lower limb critical ischaemia was admitted to our vascular unit for a femoral-popliteal bypass. He had experienced a skin reaction to chlorhexidine 6 months previously during an angioplasty procedure. After intubation, once in the operating theatre, the patient had a urinary catheter inserted using Instillagel. Around 30 min later the patient had a full-blown anaphylactic reaction that required aggressive medical management and the abandoning of surgery. Postoperative allergy testing confirmed that the suspected primary trigger for the anaphylaxis was indeed chlorhexidine, which was present in Instillagel. The patient was also found to have allergies to atracurium and teicoplanin, which had been given on induction. This case report highlights the importance of recognising that Instillagel contains chlorhexidine, and that indeed intraurethral use during routine urinary catheterisation can be a cause of life-threatening anaphylaxis</style></abstract><notes><style face="normal" font="default">DA - 20170823IS - 1757-790X (Electronic)IS - 1757-790X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1136/bcr-2017-221443</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28830892">PM:28830892</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Case Rep\20170823-TottyJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Case Rep\20170823-TottyJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170823, Totty J</style></custom2><misc3><style face="normal" font="default">10.1136/bcr-2017-221443</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42369</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bahal,S.</style></author><author><style face="normal" font="default"> Sharma,S.</style></author><author><style face="normal" font="default"> Garvey,L.H.</style></author><author><style face="normal" font="default"> Nagendran,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology, Barts Health NHS Trust, London, UK</style></auth-address><titles><title><style face="normal" font="default">Anaphylaxis after disinfection with 2% chlorhexidine wand applicator</style></title><secondary-title><style face="normal" font="default">BMJ Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword></keywords><dates><year Day="8" Month="8" Year="2017">2017/8/8</year></dates><abstract><style face="normal" font="default">A 54-year-old man with end-stage renal failure attended for dialysis. Within seconds of applying 2% w/v chlorhexidine (ChloraPrep 3 mL Wand Applicator) to the skin surrounding the insertion point of his dialysis catheter (Tesio catheter), he developed pruritus, urticaria, shortness of breath, hypotension and reduced responsiveness. Treatment for anaphylaxis was initiated with rapid improvement of his symptoms, and he made a full recovery. Allergy to chlorhexidine was confirmed with skin testing, and the patient was warned against all future exposure to chlorhexidine. Subsequent dialysis without chlorhexidine was uneventful</style></abstract><notes><style face="normal" font="default">DA - 20170809IS - 1757-790X (Electronic)IS - 1757-790X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1136/bcr-2017-219794</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28790050">PM:28790050</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Case Rep\20170809-BahalS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Case Rep\20170809-BahalS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170809, Bahal S</style></custom2><misc3><style face="normal" font="default">10.1136/bcr-2017-219794</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42370</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hounsome,N.</style></author><author><style face="normal" font="default"> Fitzsimmons,D.</style></author><author><style face="normal" font="default"> Phillips,C.</style></author><author><style face="normal" font="default"> Patel,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Asthma UK Centre for Applied Research, Centre ofPrimary Care and Public Health, Queen Mary Universityof London, London, UK</style></auth-address><titles><title><style face="normal" font="default">Developing core economic outcome sets for asthma studies: a protocol for a systematic review</style></title><secondary-title><style face="normal" font="default">BMJ Open</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Open</style></abbr-1></periodical><pages end="" start="e017054">e017054-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="8" Year="2017">2017/8/11</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Core outcome sets are standardised lists of outcomes, which should be measured and reported in all clinical studies of a specific condition. This study aims to develop core outcome sets for economic evaluations in asthma studies. Economic outcomes include items such as costs, resource use or quality-adjusted life years. The starting point in developing core outcome sets will be conducting a systematic literature review to establish a preliminary list of reporting items to be considered for inclusion in the core outcome set. METHODS AND ANALYSIS: We will conduct literature searches of peer-reviewed studies published from January 1990 to January 2017. These will include any comparative or observational studies (including economic models) and systematic reviews reporting economic outcomes. All identified economic outcomes will be tabulated together with the major study characteristics, such as population, study design, the nature and intensity of the intervention, mode of data collection and instrument(s) used to derive an outcome. We will undertake a 'realist synthesis review' to analyse the identified economic outcomes. The outcomes will be summarised in the context of evaluation perspectives, types of economic evaluation and methodological approaches. Parallel to undertaking a systematic review, we will conduct semistructured interviews with stakeholders (including people with personal experience of asthma, health professionals, researchers and decision makers) in order to explore additional outcomes which have not been considered, or used, in published studies. The list of outcomes generated from the systematic review and interviews with stakeholders will form the basis of a Delphi survey to refine the identified outcomes into a core outcome set. ETHICS AND DISSEMINATION: The review will not involve access to individual-level data. Findings from our systematic review will be communicated to a broad range of stakeholders including clinical guideline developers, research funders, trial registries, ethics committees and other regulators</style></abstract><notes><style face="normal" font="default">DA - 20170812IS - 2044-6055 (Electronic)IS - 2044-6055 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1136/bmjopen-2017-017054</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28801433">PM:28801433</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Open\2017-7-e017054.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Open\2017-7-e017054.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170812, Hounsome N</style></custom2><misc3><style face="normal" font="default">10.1136/bmjopen-2017-017054</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42371</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Todkill,D.</style></author><author><style face="normal" font="default"> Loveridge,P.</style></author><author><style face="normal" font="default"> Elliot,A.J.</style></author><author><style face="normal" font="default"> Morbey,R.</style></author><author><style face="normal" font="default"> Lusignan,S.</style></author><author><style face="normal" font="default"> Edeghere,O.</style></author><author><style face="normal" font="default"> Smith,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Field Epidemiology Service, National Infection Service, Public Health England, Birmingham, UK</style></auth-address><titles><title><style face="normal" font="default">Socioeconomic and geographical variation in general practitioner consultations for allergic rhinitis in England, 2003-2014: an observational study</style></title><secondary-title><style face="normal" font="default">BMJ Open</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Open</style></abbr-1></periodical><pages end="" start="e017038">e017038-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Female</style></keyword></keywords><dates><year Day="11" Month="8" Year="2017">2017/8/11</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Allergic rhinitis (AR) is a global health problem, potentially impacting individuals' sleep, work and social life. We aimed to use a surveillance network of general practitioners (GPs) to describe the epidemiology of AR consultations in England. SETTING: A large GP surveillance network covering approximately 53% of the English population. METHODS: GP consultations for AR across England between 30 December 2002 and 31 December 2014 were analysed. Using more granular data available between 2 April 2012 and 31 December 2014 rates and rate ratios (RR) of AR were further analysed in different age groups, gender, rural-urban classification and index of multiple deprivation score quintile of location of GP. RESULTS: The mean weekly rate for AR consultations was 19.8 consultations per 100 000 GP registered patients (range 1.13-207), with a regular peak occurring during June (weeks 24-26), and a smaller peak during April. Between 1 April 2012 and 31 December 2014, the highest mean daily rates of consultations per 1 00 000 were: in age group 5-14 years (rate=8.02, RR 6.65, 95% CI 6.38 to 6.93); females (rate=4.57, RR 1.12 95% CI 1.12 to 1.13); persons registered at a GP in the most socioeconomically deprived quintile local authority (rate=5.69, RR 1.48, 95% CI 1.47 to 1.49) or in an urban area with major conurbation (rate=5.91, RR 1.78, 95% CI 1.69 to 1.87). CONCLUSIONS: AR rates were higher in those aged 5-14 years, females and in urban and socioeconomically deprived areas. This needs to be viewed in the context of this study's limitations but should be considered in health promotion and service planning</style></abstract><notes><style face="normal" font="default">DA - 20170812IS - 2044-6055 (Electronic)IS - 2044-6055 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1136/bmjopen-2017-017038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28801431">PM:28801431</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Open\2017-7-e017038.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Open\2017-7-e017038.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170812, Todkill D</style></custom2><misc3><style face="normal" font="default">10.1136/bmjopen-2017-017038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42372</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Weidinger,S.</style></author><author><style face="normal" font="default"> Baurecht,H.</style></author><author><style face="normal" font="default"> Schmitt,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Venereology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Schittenhelmstrasse 7, 24105, Kiel, Germany</style></auth-address><titles><title><style face="normal" font="default">A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="9" Year="2017">2017/9/4</year></dates><abstract><style face="normal" font="default">AIM: The PETITE study (Sigurgeirsson et al.) aimed to compare safety and efficacy of pimecrolimus 1% cream (PIM) and low-to-medium-potency topical corticosteroids (TCS) in children with mild-to-moderate atopic dermatitis (AD). SETTING AND DESIGN: Participants of this 5-year drug-company sponsored multicentre, open-label, parallel-group trial were recruited between April 2004 and October 2005. No details are reported regarding the study sites. STUDY EXPOSURE: Infants aged >/= 3 to &lt; 12 months with mild-to-moderate AD were randomly assigned in a 1 : 1 ratio to receive either PIM or a low- or medium-potency TCS cream/ointment for 5 years. No information on specific TCS products used was provided. The topical treatment was applied twice daily 'until complete AD clearance or for as long as allowed by the label of the specific TCS', and was reinitiated at the occurrence of first signs and symptoms of AD flares. In the PIM group, exacerbations not controlled by PIM were treated with short-term TCSs. OUTCOMES: Adverse events (AEs) and serious AEs (SAEs) were recorded 'during clinic visits'. In a proportion of the patients, various immunological assessments including antibody titres to common vaccine antigens, immunoglobulin levels, B and T lymphocyte cell counts, and T-cell proliferation tests were performed. The children's growth was assessed by measuring height and weight. AD severity was measured using the Investigator Global Assessment (IGA) score and the percentage of the total body surface area affected. No specific information was provided on the number and scheduling of study visits. Primary outcomes were the incidence of AEs 'of primary clinical interest' and those with a crude incidence of >/= 5% in either treatment group. Secondary outcome was 'long-term efficacy' defined as IGA &lt;/= 1 at week 3 and year 5. RESULTS: Patients in the PIM group experienced significantly more AEs [bronchitis (P = 0.02), infected eczema (P &lt;/= 0.001), impetigo (P = 0.045), nasopharyngitis (P = 0.04)]. No significant differences were seen for the other AEs. The overall incidence of SAEs was slightly higher for PIM (20.5% vs. 17.3%; P = 0.046). The proportion of participants with IGA &lt;/= 1 at year 5 was 88.7% for PIM and 92.3% for TCS, a success rate difference of 3.6% (95% confidence interval 0.8-6.4) favouring TCS. CONCLUSIONS: Sigurgeirsson et al. conclude that the long-term management of mild-to-moderate AD in children with both TCS and PIM is safe, and that PIM has similar efficacy to TCS. Further, they conclude that their data support the use of PIM as a first-line treatment of mild-to-moderate AD in children</style></abstract><notes><style face="normal" font="default">DA - 20170904IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15827</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28868633">PM:28868633</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20170904-WeidingerS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20170904-WeidingerS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170904, Weidinger S</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15827</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42373</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Charman,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Royal Devon and Exeter NHS Foundation Trust, Exeter, U.K</style></auth-address><titles><title><style face="normal" font="default">A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal - comment</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="8" Year="2017">2017/8/31</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170831IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15848</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28858382">PM:28858382</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20170831-CharmanC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20170831-CharmanC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170831, Charman C</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15848</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42374</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Drucker,A.M.</style></author><author><style face="normal" font="default"> Eyerich,K.</style></author><author><style face="normal" font="default"> de Bruin-Weller,M.S.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author><author><style face="normal" font="default"> Spuls,P.I.</style></author><author><style face="normal" font="default"> Irvine,A.D.</style></author><author><style face="normal" font="default"> Girolomoni,G.</style></author><author><style face="normal" font="default"> Dhar,S.</style></author><author><style face="normal" font="default"> Flohr,C.</style></author><author><style face="normal" font="default"> Murrell,D.F.</style></author><author><style face="normal" font="default"> Paller,A.S.</style></author><author><style face="normal" font="default"> Guttman-Yassky,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Alpert Medical School of Brown University, Providence, RI, USA</style></auth-address><titles><title><style face="normal" font="default">Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="2" Month="9" Year="2017">2017/9/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Guidelines discourage the use of systemic corticosteroids for atopic dermatitis but their use remains widespread. OBJECTIVE: To reach consensus among an international group of atopic dermatitis experts on the use of systemic corticosteroids for atopic dermatitis. METHODS: A survey consisting of statements accompanied by visual analog scales ranging from "strongly disagree" to "neutral" to "strongly agree" was distributed to the International Eczema Council (IEC). Consensus was reached in agreement on a statement if &lt;30% of respondents marked to the left of "neutral" towards "strongly disagree." RESULTS: Sixty of 77 (79%) IEC members participated. Consensus was reached on 12 statements, including that systemic corticosteroids should generally be avoided but can be used rarely for severe atopic dermatitis under certain circumstances, including a lack of other treatment options, as a bridge to other systemic therapies or phototherapy, during acute flares in need of immediate relief, in anticipation of a major life event or in the most severe cases. If used, treatment should be limited to short-term. Most respondents agreed that systemic corticosteroids should never be used in children, but consensus was not reached on that statement. The conclusions of our expert group are limited by a dearth of high-quality published evidence. If more stringent consensus criteria were applied (e.g., requiring &lt;20% of respondents marking towards "strongly disagree," consensus would have been reached on fewer statements. CONCLUSIONS: Based on expert opinion from the IEC, routine use of systemic corticosteroids for atopic dermatitis is generally discouraged and should be reserved for special circumstances. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170902IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - United states -CO - Germany -CO - Netherlands -CO - Denmark -CO - Ireland -CO - Italy -CO - India -CO - United Kingdom -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15928</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28865094">PM:28865094</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20170902-DruckerAM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20170902-DruckerAM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170902, Drucker AM</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15928</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42375</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Boehm,I.</style></author><author><style face="normal" font="default"> Nairz,K.</style></author><author><style face="normal" font="default"> Morelli,J.</style></author><author><style face="normal" font="default"> Silva Hasembank,K.P.</style></author><author><style face="normal" font="default"> Heverhagen,J.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital, University of Bern, Bern, Switzerland</style></auth-address><titles><title><style face="normal" font="default">General anaesthesia for patients with a history of a contrast medium-induced anaphylaxis: a useful prophylaxis?</style></title><secondary-title><style face="normal" font="default">Br J Radiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Br J Radiol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="9" Year="2017">2017/9/6</year></dates><abstract><style face="normal" font="default">Contrast-enhanced radiological examinations are important diagnostic tools in modern medicine. Currently, all approved and available iodinated and gadolinium-based contrast agents are safe and well tolerated by most patients. However, approximately 2% of patients receiving iodinated contrast media (CM) exhibit hypersensitivity reactions. Patients with a history of such a reaction are at increased risk upon re-exposure. Therefore, they are subjected to a prophylaxis such as injection of anti-allergy drugs or general anesthesia. The latter procedure is expensive, can burden the patients organism, and besides lacks objective verification. Therefore, the purpose of our review paper is to present and discuss the background and the previous practice, as well as to provide a proposal for a safe individual patient management</style></abstract><notes><style face="normal" font="default">DA - 20170906IS - 1748-880X (Electronic)IS - 0007-1285 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1259/bjr.20160647</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28876979">PM:28876979</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Radiol\20170906-BoehmI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Radiol\20170906-BoehmI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170906, Boehm I</style></custom2><misc3><style face="normal" font="default">10.1259/bjr.20160647</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42376</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,Q.</style></author><author><style face="normal" font="default"> Fu,Z.</style></author><author><style face="normal" font="default"> Dai,J.</style></author><author><style face="normal" font="default"> Geng,G.</style></author><author><style face="normal" font="default"> Fu,W.</style></author><author><style face="normal" font="default"> Tian,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing 400014, China</style></auth-address><titles><title><style face="normal" font="default">Recurrent Wheezing and Cough Caused by Double Aortic Arch, Not Asthma</style></title><secondary-title><style face="normal" font="default">Case Rep Cardiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Case Rep Cardiol</style></abbr-1></periodical><pages end="" start="8079851">8079851-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">diagnosis</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Double aortic arch is a congenital vascular abnormality in which the connected segments and their branches course between and compress the trachea and esophagus, often resulting in invariable airway compression. CASE PRESENTATION: A 4-year-old boy with a history of recurrent wheezing was admitted to our hospital for evaluation of asthma based on his past medical history, persistent cough, wheezing, and airway hyperresponsiveness by lung function test. Double aortic arch was diagnosed with computed tomography angiogram. After surgery, the respiratory infection improved strikingly. Early diagnosis and treatment may prevent chronic, irreversible complications. CONCLUSION: We present a case of double aortic arch masquerading as asthma</style></abstract><notes><style face="normal" font="default">DA - 20170816IS - 2090-6404 (Print)IS - 2090-6404 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1155/2017/8079851</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28811940">PM:28811940</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Case Rep Cardiol\2017-2017-8079851.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Case Rep Cardiol\2017-2017-8079851.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170816, Zhang Q</style></custom2><misc3><style face="normal" font="default">10.1155/2017/8079851</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42377</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yu,J.F.</style></author><author><style face="normal" font="default"> Feng,Y.Y.</style></author><author><style face="normal" font="default"> Shen,X.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Dermatology, The Fifth affiliated Hospital of Xinjiang Medical University, China</style></auth-address><titles><title><style face="normal" font="default">Potential immunotoxic effects of trichloroethylene-induced IV allergic reaction in renal impairment</style></title><secondary-title><style face="normal" font="default">Cent Eur J Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cent Eur J Immunol</style></abbr-1></periodical><pages end="149" start="140">140-149</pages><volume><style face="normal" font="default">42</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Trichloroethylene (TCE) is known to induce allergic contact dermatitis and subsequent occupational medicamentosa-like dermatitis (OMLD) with multi-system injuries, including liver, kidney, and skin injuries. However, the mechanisms underlying immune system dysfunction that result in organ injury have not yet been clearly elucidated. In the present study, we measured the levels of secreted cytokines by effect or T cells in TCE-treated guinea pigs to better understand the contribution of allergic disorders in renal injuries. We immunized guinea pigs with trichloroethylene using the Guinea Pig Maximization Test (GPMT) and scored the inflammation on the guinea pigs' skin. The kidney function and ultra-structural changes in the kidneys were detected using biochemical methods and electron microscopy. The deposition of cytokines was determined using immunohistochemistry. The sensitization rate was 63.16% in the TCE-sensitized groups. The electron microscopy results showed tubular epithelial cell mitochondrial swelling, vacuolar degeneration, and atrophy of the microvillus in the sensitized groups. A high degree of cytokine deposition was observed in the renal tubular proximal epithelial cells in the TCE-sensitized groups. As observed in this study, the variation in the level of immune system activation not only indicates that TCE can largely magnify the immune reaction but also suggests a potential role of immune dysfunction in renal impairment</style></abstract><notes><style face="normal" font="default">DA - 20170904IS - 1426-3912 (Print)IS - 1426-3912 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.5114/ceji.2017.69354</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28867961">PM:28867961</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cent Eur J Immunol\2017-42-140-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cent Eur J Immunol\2017-42-140-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170904, Yu JF</style></custom2><misc3><style face="normal" font="default">10.5114/ceji.2017.69354</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42378</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Linde,S.J.L.</style></author><author><style face="normal" font="default"> Franken,A.</style></author><author><style face="normal" font="default"> Du Plessis,J.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Occupational respiratory exposure to platinum group metals: A review and recommendations</style></title><secondary-title><style face="normal" font="default">Chem Res Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chem Res Toxicol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="8" Year="2017">2017/8/31</year></dates><abstract><style face="normal" font="default">Platinum Group Metals (PGMs) is a group of metals that include platinum, palladium, rhodium, ruthenium, iridium and osmium. Occupational respiratory exposure to platinum has been reported since 1945 but studies investigating occupational exposure to palladium, rhodium, ruthenium, iridium and osmium are scarce. This review provides a summation of the information available on the respiratory exposure to PGMs in various industrial settings, methods used to assess exposure and the possible adverse health effects resulting from occupational exposure to PGMs. Of these effects, respiratory sensitization caused by soluble PGMs is of most importance. Metallic PGMs have not been shown to cause allergic reactions. This review reiterates that occupational respiratory exposure to PGMs is dependent on the type of industry where exposure takes place, the chemical form (soluble or insoluble) of the PGMs present in the workplace air and the tasks performed by workers in the specific work areas. Sensitization to soluble platinum is associated with the degree of exposure to soluble platinum compounds and the highest concentrations of soluble PGMs in workplace air have been reported for precious metals refineries where personal exposures frequently exceed the occupational exposure limit for soluble platinum (2 microg/m3). Additionally, this review emphasizes that personal exposure monitoring is preferred over area monitoring when assessing workers' exposure to PGMs. The legislation applicable to occupational exposure to PGMs is also discussed and it is highlighted that the occupational exposure limit for soluble platinum has remained unchanged, in most countries, since 1970 and that too few countries have classified PGM compounds as respiratory and/or skin sensitizers. Finally, recommendations are made to ensure that future investigations are comparable in terms of the type of exposure monitoring (personal or area) conducted, the type of tasks included in the exposure monitoring program and the format in which results are reported</style></abstract><notes><style face="normal" font="default">DA - 20170831IS - 1520-5010 (Electronic)IS - 0893-228X (Linking)LA - engPT - Journal ArticleCO - South Africa -</style></notes><work-type><style face="normal" font="default">10.1021/acs.chemrestox.7b00184</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28858470">PM:28858470</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Chem Res Toxicol\20170831-LindeSJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Chem Res Toxicol\20170831-LindeSJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170831, Linde SJ</style></custom2><misc3><style face="normal" font="default">10.1021/acs.chemrestox.7b00184</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42379</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Murota,H.</style></author><author><style face="normal" font="default"> Azukizawa,H.</style></author><author><style face="normal" font="default"> Katayama,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Course of Integrated Medicine, Graduate School of Medicine, Osaka University, Suita, Osaka, 575-0871, Japan.</style></auth-address><titles><title><style face="normal" font="default">Impact of Jumihaidokuto (Shi-Wei-Bai-Du-Tang) on treatment of chronic spontaneous urticaria: A randomized controlled study</style></title><secondary-title><style face="normal" font="default">Chin J Integr Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Chin J Integr Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="8" Year="2017">2017/8/17</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To study the effect of Jumihaidokuto (Shi-Wei-Bai-Du-Tang, ) in the management of chronic spontaneous urticaria. METHODS: A randomized two-arm, parallel group study was conducted to compare the effect of Jumihaidokuto (6 g daily) with a control for 8 weeks. Concomitant therapy (e.g., antihistamines) was continued. Twenty-one subjects with severe chronic urticaria were enrolled in this study. The primary treatment outcome was the severity score proposed by the Japanese Dermatological Association. Secondary outcomes were quality of life (Skindex-16), itch intensity (Visual Analogue Scale), and patients' subjective disability due to wheal or itch. After the subjects were randomly assigned to groups by block randomization, 10 received Jumihaidokuto, and 11 did not. All subjects had already taken antihistamines. RESULTS: Improvement was significant when comparing the severity score of the Jumihaidokuto group with that of the control group (P&lt;0.01). Skindex-16 values for both groups gradually decreased in the same fashion. CONCLUSION: Concomitant use of Jumihaidokuto with antihistamine was more effective than antihistamine alone in the management of chronic idiopathic urticaria. (Trial Registration No. UMIN000007251)</style></abstract><notes><style face="normal" font="default">DA - 20170818IS - 1672-0415 (Print)IS - 1672-0415 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1007/s11655-017-2950-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28819778">PM:28819778</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Chin J Integr Med\20170818-MurotaH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Chin J Integr Med\20170818-MurotaH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170818, Murota H</style></custom2><misc3><style face="normal" font="default">10.1007/s11655-017-2950-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42380</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Imbernon-Moya,A.</style></author><author><style face="normal" font="default"> Vargas-Laguna,E.</style></author><author><style face="normal" font="default"> Burgos,F.</style></author><author><style face="normal" font="default"> Fernandez-Cogolludo,E.</style></author><author><style face="normal" font="default"> Aguilar-Martinez,A.</style></author><author><style face="normal" font="default"> Gallego-Valdes,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of DermatologyHospital Universitario Severo OchoaAvenida de Orellana28911LeganesMadridSpain</style></auth-address><titles><title><style face="normal" font="default">Urticaria vasculitis in a child: a case report and literature review</style></title><secondary-title><style face="normal" font="default">Clin Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Case Rep</style></abbr-1></periodical><pages end="1257" start="1255">1255-1257</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">Annular urticarial lesions in a child must establish a main differential diagnosis with urticaria multiforme, common urticaria, acute hemorrhagic edema of infancy, erythema marginatum, erythema annulare centrifugum, annular erythema in childhood, erythema multiforme, Sweet's syndrome, Schonlein-Henoch purpura, erythematosus lupus, several systemic vasculitis, and serum sickness</style></abstract><notes><style face="normal" font="default">DA - 20170807IS - 2050-0904 (Print)IS - 2050-0904 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1002/ccr3.1027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28781836">PM:28781836</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Case Rep\2017-5-1255-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Case Rep\2017-5-1255-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170807, Imbernon-Moya A</style></custom2><misc3><style face="normal" font="default">10.1002/ccr3.1027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42381</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tanno,L.K.</style></author><author><style face="normal" font="default"> Simons,F.E.R.</style></author><author><style face="normal" font="default"> Sanchez-Borges,M.</style></author><author><style face="normal" font="default"> Cardona,V.</style></author><author><style face="normal" font="default"> Moon,H.B.</style></author><author><style face="normal" font="default"> Calderon,M.A.</style></author><author><style face="normal" font="default"> Sisul,J.C.</style></author><author><style face="normal" font="default"> Muraro,A.</style></author><author><style face="normal" font="default"> Casale,T.</style></author><author><style face="normal" font="default"> Demoly,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hospital Sirio Libanes, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="default">Applying prevention concepts to anaphylaxis: A call for worldwide availability of adrenaline auto-injectors</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="1114" start="1108">1108-1114</pages><volume><style face="normal" font="default">47</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170831IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - EditorialCO - Brazil -CO - France -CO - Canada -CO - Venezuela -CO - Spain -CO - Korea -CO - United Kingdom -CO - Paraguay -CO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12973</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28856836">PM:28856836</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\2017-47-1108-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\2017-47-1108-14.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170831, Tanno LK</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12973</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42382</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Deliu,M.</style></author><author><style face="normal" font="default"> Yavuz,T.S.</style></author><author><style face="normal" font="default"> Sperrin,M.</style></author><author><style face="normal" font="default"> Belgrave,D.</style></author><author><style face="normal" font="default"> Sahiner,U.M.</style></author><author><style face="normal" font="default"> Sackesen,C.</style></author><author><style face="normal" font="default"> Kalayci,O.</style></author><author><style face="normal" font="default"> Custovic,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Informatics, Imaging and Data Sciences, Faculty of Biology, Medicine and Health University of Manchester, Manchester, UK</style></auth-address><titles><title><style face="normal" font="default">Features of asthma which provide meaningful insights for understanding the disease heterogeneity</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="8" Year="2017">2017/8/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: Data-driven methods such as hierarchical clustering (HC) and principal component analysis (PCA) have been used to identify asthma subtypes, with inconsistent results. OBJECTIVE: To develop a framework for the discovery of stable and clinically meaningful asthma subtypes. METHODS: We performed HC in a rich dataset from 613 asthmatic children, using 45 clinical variables (Model 1), and after PCA dimensionality reduction (Model 2). Clinical experts then identified a set of asthma features/domains which informed clusters in the two analyses. In Model 3, we re-clustered the data using these features to ascertain whether this improved the discovery process. RESULTS: Cluster stability was poor in Models 1 and 2. Clinical experts highlighted four asthma features/domains which differentiated the clusters in two models: age of onset, allergic sensitization, severity, and recent exacerbations. In Model 3 (HC using these four features), cluster stability improved substantially. The cluster assignment changed, providing more clinically interpretable results. In a 5-cluster model, we labelled the clusters as: "Difficult asthma" (n=132); "Early-onset mild atopic" (n=210); "Early-onset mild non-atopic: (n=153); "Late-onset" (n=105); and "Exacerbation-prone asthma" (n=13). Multinomial regression demonstrated that lung function was significantly diminished among children with "Difficult asthma"; blood eosinophilia was a significant feature of "Difficult", "Early-onset mild atopic", and "Late-onset asthma". Children with moderate-severe asthma were present in each cluster. CONCLUSIONS AND CLINICAL RELEVANCE: An integrative approach of blending the data with clinical expert domain knowledge identified four features, which may be informative for ascertaining asthma endotypes. These findings suggests that variables which are key determinants of asthma presence, severity or control, may not be the most informative for determining asthma subtypes. Our results indicate that exacerbation-prone asthma may be a separate asthma endotype, and that severe asthma is not a single entity, but an extreme end of the spectrum of several different asthma endotypes. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170823IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Turkey -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28833810">PM:28833810</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170823-DeliuM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170823-DeliuM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170823, Deliu M</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42383</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lachowicz-Scroggins,M.E.</style></author><author><style face="normal" font="default"> Finkbeiner,W.E.</style></author><author><style face="normal" font="default"> Gordon,E.D.</style></author><author><style face="normal" font="default"> Yuan,S.</style></author><author><style face="normal" font="default"> Zlock,L.</style></author><author><style face="normal" font="default"> Bhakta,N.R.</style></author><author><style face="normal" font="default"> Woodruff,P.G.</style></author><author><style face="normal" font="default"> Fahy,J.V.</style></author><author><style face="normal" font="default"> Boushey,H.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, 94143</style></auth-address><titles><title><style face="normal" font="default">Corticosteroid and Long-Acting ss-Agonist Therapy Reduces Epithelial Goblet Cell Metaplasia</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="8" Year="2017">2017/8/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: Bronchial epithelial goblet cell metaplasia (GCM) with hyperplasia is a prominent feature of asthma, but the effects of treatment with corticosteroids, alone or in combination with a long-acting beta2 -adrenergic receptor agonist (LABA) on GCM in the bronchial epithelium are unknown. OBJECTIVES: To determine if corticosteroid alone or in combination with a LABA alter protein and gene expression pathways associated with IL-13-induced goblet cell metaplasia. RESULTS: We evaluated the effects of Fluticasone Propionate (FP) and of Salmeterol (SM), on the response of well-differentiated cultured bronchial epithelial cells to interleukin-13 (IL-13). Outcome measures included gene expression of SPDEF/FOXa2, gene expression and protein production of MUC5AC/MUC5B, and morphologic appearance of cultured epithelial cell sheets. We additionally analyzed expression of these genes in bronchial epithelial brushings from healthy, steroid-naive asthmatic, and steroid-treated asthmatic subjects. In cultured airway epithelial cells, FP treatment inhibited IL-13-induced suppression of FOXa2 gene expression and upregulation of SPDEF, alterations in gene and protein measures of MUC5AC and MUC5B, and induction of GCM. The addition of SM synergistically modified the effects of FP modestly-only for gel-forming mucin MUC5AC. In bronchial epithelial cells recovered from asthmatic vs. healthy human subjects, we found FOXa2 and MUC5B gene expression to be reduced and SPEDF and MUC5AC gene expression to be increased; these alterations were not observed in bronchial epithelial cells recovered after treatment with inhaled corticosteroids. CONCLUSION AND CLINICAL RELEVANCE: Corticosteroid treatment inhibits IL-13-induced GCM of the airways in asthma, possibly through its effects on SPDEF and FOXa2 regulation of mucin gene expression. These effects are modestly augmented by the addition of a long-acting ss-agonist. As we found evidence for drug treatment counter-acting the effects of IL-13 on the epithelium, we conclude that further exploration into the mechanisms by which corticosteroids and long-acting beta2 -adrenergic agonists confer protection against pathologic airway changes is warranted. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170823IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28833774">PM:28833774</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170823-LachowiczScrogginsME.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170823-LachowiczScrogginsME.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170823, Lachowicz-Scroggins ME</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42384</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bratke,K.</style></author><author><style face="normal" font="default"> Fritz,L.</style></author><author><style face="normal" font="default"> Nokodian,F.</style></author><author><style face="normal" font="default"> Geissler,K.</style></author><author><style face="normal" font="default"> Garbe,K.</style></author><author><style face="normal" font="default"> Lommatzsch,M.</style></author><author><style face="normal" font="default"> Virchow,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pneumology, University of Rostock, Rostock, Germany</style></auth-address><titles><title><style face="normal" font="default">Differential regulation of PD-1 and its ligands in allergic asthma</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="2" Month="9" Year="2017">2017/9/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Targeting PD-1/PD-1 ligand signalling is an established treatment option for cancer. The role of these molecules in allergic asthma has been investigated in several mouse studies yielding conflicting results. However, human studies investigating the expression and regulation of PD-1 and its ligands in allergic inflammation are lacking. OBJECTIVE: To analyse the expression and regulation of PD-1 and its ligands in human allergic asthma. METHODS: The well-established human asthma model of segmental allergen challenge (SAC) was used to analyse the regulation of PD-1 and its ligands PD-L1 and PD-L2 on T lymphocytes and dendritic cells by flow cytometry. The impact of immunoglobulin E (IgE)-mediated signalling on PD-L1 expression was analysed on isolated plasmacytoid dendritic cells (pDCs). RESULTS: PD-1 expression by blood CD4+ T cells was negatively associated with total and specific (against the allergen used for provocation) IgE serum concentrations. 24 hours after SAC, a small decrease in endobronchial PD-1+ CD4+ T cells was accompanied by an increase of PD-L1 expression on endobronchial myeloid dendritic cells (mDCs) and pDCs. The PD-L1 up-regulation on pDCs was not induced by IgE-mediated mechanisms. In contrast, PD-L2 was only detected on endobronchial mDCs and was significantly down-regulated 24 hours after SAC. CONCLUSION AND CLINICAL RELEVANCE: This study shows, for the first time, an association of a low PD-1 expression by circulating CD4+ T cells with high total and specific (against the allergen used for provocation) IgE concentrations in allergic asthma. In addition, we demonstrate a differential regulation of PD-1 ligands on endobronchial DCs after allergen challenge which may favour Th2-inflammation. Therefore, modulating PD-1 ligand-mediated pathways might be a promising target in allergic asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170902IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28865147">PM:28865147</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170902-BratkeK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170902-BratkeK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170902, Bratke K</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42385</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Egner,W.</style></author><author><style face="normal" font="default"> Cook,T.</style></author><author><style face="normal" font="default"> Harper,N.</style></author><author><style face="normal" font="default"> Garcez,T.</style></author><author><style face="normal" font="default"> Marinho,S.</style></author><author><style face="normal" font="default"> Kong,K.L.</style></author><author><style face="normal" font="default"> Nasser,S.</style></author><author><style face="normal" font="default"> Thomas,M.</style></author><author><style face="normal" font="default"> Warner,A.</style></author><author><style face="normal" font="default"> Hitchman,J.</style></author><author><style face="normal" font="default"> Floss,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Sheffield Teaching Hospitals NHS Foundation Trust, Clinical Immunology and Allergy Unit, Sheffield</style></auth-address><titles><title><style face="normal" font="default">Specialist Peri-Operative Allergy Clinic Services in the UK 2016: Results from the Royal College of Anaesthetists Sixth National Audit Project (NAP6)</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword></keywords><dates><year Day="8" Month="8" Year="2017">2017/8/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Guidelines for investigation of perioperative drug allergy exist, but the quality of services is unknown. Specialist perioperative anaphylaxis services were surveyed through the Royal College of Anaesthetists 6th National Audit Project. OBJECTIVES: We compare self-declared UK practice in specialist perioperative allergy services with national recommendations. METHODS: A SurveyMonkey questionnaire was distributed to providers of allergy services in the UK. Responses were assessed for adherence to the best practice recommendations of the British Society for Allergy and Clinical Immunology, the Association of Anaesthetists of Great Britain and Ireland and the National Institute for Health and Care Excellence (NICE) Guidance on Drug Allergy - CG183. RESULTS: Over 1200 patients were evaluated in 44 centres annually. Variation in workload, waiting times, access, staffing and diagnostic approach was noted. Paediatric centres had the longest routine waiting times (most wait >13 weeks) in contrast to adult centres (most wait &lt;12 weeks). Service leads are allergists/immunologists (91%) or anaesthetists (7%). Potentially important differences were seen in: testing repertoire [10/44 (23%) lacked BSACI compliant NMBA panels and 17/44 (39%) lacked a NAP6-defined extended panel; many failed to screen all cases for chlorhexidine 19/44 (43%) or latex 21/44 (48%)], staffing [only 26/44 (59%) had specialist nurses and 18/44 (41%) an anaesthetist], and provision of information [18/44 (41%) gave immediate information in clinic, and 5/44 (11%) on support groups]. Most centres were able to provide diagnostic challenges to antibiotics [40/44 (91%]) and local anaesthetics [41/44 (93%)]. CONCLUSIONS AND CLINICAL RELEVANCE: Diagnostic testing is not harmonised, with marked variability in the NMBA panels used to identify safe alternatives. Chlorhexidine and latex are not part of routine testing in many centres. Poor access to services and patient information provision require attention. Harmonisation of diagnostic approach is desirable, particularly with regard to a minimum NMBA panel for identification of safe alternatives. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170808IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cea.12993</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28787764">PM:28787764</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170808-EgnerW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170808-EgnerW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170808, Egner W</style></custom2><misc3><style face="normal" font="default">10.1111/cea.12993</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42386</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ghannam,M.</style></author><author><style face="normal" font="default"> Mansour,S.</style></author><author><style face="normal" font="default"> Nabulsi,A.</style></author><author><style face="normal" font="default"> Abdoh,Q.</style></author></authors></contributors><auth-address><style face="normal" font="default">AN-Najah National University Teaching Hospital, Asira, Nablus, West bank Palestine</style></auth-address><titles><title><style face="normal" font="default">Anticonvulsant hypersensitivity syndrome after phenytoin administration in an adolescent patient: a case report and review of literature</style></title><secondary-title><style face="normal" font="default">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Mol Allergy</style></full-title></periodical><pages end="" start="14">14-</pages><volume><style face="normal" font="default">15</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">diagnosis</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hypersensitivity is a rare adverse drug reaction (ADR) associated with anti-epileptic medications. Phenytoin is one of the commonly used drugs for treatment of epilepsy that encounters a hypersensitivity reaction. This reaction can be ranged from mild cutaneous rash to anticonvulsant hypersensitivity syndrome (AHS) or drug reaction with eosinophilia and systemic symptoms (DRESS) that includes fever, rash, eosinophilia and involvement of multiple internal organs. CASE PRESENTATION: A 15 year old middle eastern female patient from Gaza strip with free past medical and allergic history. She presented to An-Najah National University Hospital (NNUH) in Nablus with intermittent high grade fever, jaundice, rash and skin peeling. On examination, she had axillary and inguinal lymphadenopathy, moderate splenomegaly and diffuse maculopapular rash. The patient was on phenytoin which started 1 month prior to her presentation as a seizure prophylaxis due to previous head injury. Eventually, the patient was diagnosed with AHS/DRESS. CONCLUSIONS: AHS is a diagnosis of exclusion and it is significantly underreported that requires a high index of suspicion. We liked to share this case and shed the light in more details on AHS/DRESS. Our goal was to help making AHS more reported in the literature in adolescent patients, as well as to make physicians more alert of this condition's seriousness when they prescribe antiepileptic medications in particular. In this report, we included the first case of AHS which was reported in an adolescent patient in Palestine. Moreover, we reviewed the available literature for a better understanding of the pathophysiology and management of AHS. We still believe that the full understanding of the pathogenesis of AHS is lacking, and also we are lacking a clinical tool or scoring system to determine the severity of AHS/DRESS</style></abstract><notes><style face="normal" font="default">DA - 20170622IS - 1476-7961 (Print)IS - 1476-7961 (Linking)LA - engPT - Journal ArticleCO - Palestine -</style></notes><work-type><style face="normal" font="default">10.1186/s12948-017-0069-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28638280">PM:28638280</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-14.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170622, Ghannam M</style></custom2><misc3><style face="normal" font="default">10.1186/s12948-017-0069-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42387</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rota,A.P.</style></author><author><style face="normal" font="default"> Bacharier,L.B.</style></author><author><style face="normal" font="default"> Jaffee,K.</style></author><author><style face="normal" font="default"> Visness,C.M.</style></author><author><style face="normal" font="default"> Kattan,M.</style></author><author><style face="normal" font="default"> O'Connor,G.T.</style></author><author><style face="normal" font="default"> Wood,R.A.</style></author><author><style face="normal" font="default"> Gergen,P.J.</style></author><author><style face="normal" font="default"> Gern,J.E.</style></author><author><style face="normal" font="default"> Bloomberg,G.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Stony Brook School of Medicine, Stony Brook, NY, USA</style></auth-address><titles><title><style face="normal" font="default">Screen Time Engagement Is Increased in Urban Children With Asthma</style></title><secondary-title><style face="normal" font="default">Clin Pediatr (Phila)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Pediatr (Phila)</style></abbr-1></periodical><pages end="1053" start="1048">1048-1053</pages><volume><style face="normal" font="default">56</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Physical activity in children has been shown to play a role in its relationship to asthma, both in terms of prevalence and incidence. One measure of physical activity in children is sedentary behavior, which might be measured by the degree of engagement with media electronic screens. We found that children with asthma, as compared with children without asthma, engage in significantly more hours of screen time (median 35 vs 26 h/wk, P = .004). In this birth cohort, those who developed a diagnosis of asthma at 8 years of age were significantly more engaged in electronic screen time than their peers. No other clinical or lifestyle behaviors were significantly associated with a diagnosis of asthma. Further study will be needed to determine directionality of this finding</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1938-2707 (Electronic)IS - 0009-9228 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/0009922817698801</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28871879">PM:28871879</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Pediatr (Phila)\2017-56-1048-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Pediatr (Phila)\2017-56-1048-53.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Rota AP</style></custom2><misc3><style face="normal" font="default">10.1177/0009922817698801</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42388</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Baverel,P.</style></author><author><style face="normal" font="default"> White,N.</style></author><author><style face="normal" font="default"> Vicini,P.</style></author><author><style face="normal" font="default"> Karlsson,M.O.</style></author><author><style face="normal" font="default"> Agoram,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical Pharmacology, Drug Metabolism and Pharmacokinetics, MedImmune, Cambridge, UK</style></auth-address><titles><title><style face="normal" font="default">Dose-Exposure-Response Relationship of the Investigational Anti-IL-13 Monoclonal Antibody Tralokinumab in Patients with Severe, Uncontrolled Asthma</style></title><secondary-title><style face="normal" font="default">Clin Pharmacol Ther</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Pharmacol Ther</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="7" Year="2017">2017/7/30</year></dates><abstract><style face="normal" font="default">Interleukin (IL)-13 is involved in the pathogenesis of some types of asthma. Tralokinumab is a human IgG4 monoclonal antibody that specifically binds to IL-13. Two placebo-controlled Phase 2 studies (Phase 2a, NCT00873860 and Phase 2b, NCT01402986) have been conducted in which tralokinumab was administered subcutaneously (SC). This investigation aimed to characterize tralokinumab's dose-exposure-response (forced expiratory volume in one second [FEV1 ]) relationship in patients with asthma and to predict the most appropriate dose for Phase 3. An integrated population pharmacokinetic-pharmacodynamic modeling analysis was required for Phase 3 dose selection, due to differing Phase 2 patient populations, designs, and regimens. Analysis of combined datasets enabled the identification of tralokinumab's dose-exposure-FEV1 response relationship in patients with asthma. Near-maximal FEV1 increase was predicted at a dose of 300 mg SC Q2W. This dose was chosen for tralokinumab in the Phase 3 clinical development program for treatment of severe, uncontrolled asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 1532-6535 (Electronic)IS - 0009-9236 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1002/cpt.803</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28758192">PM:28758192</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Pharmacol Ther\20170731-BaverelP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Pharmacol Ther\20170731-BaverelP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170731, Baverel P</style></custom2><misc3><style face="normal" font="default">10.1002/cpt.803</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42389</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bucher,M.C.</style></author><author><style face="normal" font="default"> Petkovic,T.</style></author><author><style face="normal" font="default"> Helbling,A.</style></author><author><style face="normal" font="default"> Steiner,U.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Immunology, University Hospital Zurich, Gloriastrasse 23, 8091 Zurich, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published clinical trials</style></title><secondary-title><style face="normal" font="default">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Transl Allergy</style></full-title></periodical><pages end="" start="27">27-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Idiopathic non-histaminergic acquired angioedema (InH-AAE) is a rare disease for which there are no available laboratory parameters to clearly define the disorder. Therapy is often difficult and various treatment options have been proposed. In this paper, we have evaluated the most effective therapies for InH-AAE on the basis of current literature and report the therapeutic effect of omalizumab in three patients with InH-AAE. METHODS: Literature was searched with a combination of MeSH/EMTREE terms and freetext search for angioedema and therapy/omalizumab in the databases Medline (Ovid), PubMed/Premedline, Embase, Cochrane library and Scopus with no time or language restrictions. In three patients affected by InH-AAE the therapeutic effect of omalizumab was demonstrated by clinical outcome. In one patient the FcepsilonRI receptor density on basophils was monitored under therapy with omalizumab. RESULTS: From the review of the current literature, 25 out of 286 publications dealing with relevant therapeutic recommendations for InH-AAE were analyzed. Six publications with 98 patients referred to tranexamic acid, of which 27 had a complete, 70 a partial and 1 no response. In three case reports ecallantide showed 2 patients with a complete and 1 a partial response. In four case reports for Icatibant 2 had a complete and 3 a partial response. When evaluated in three reports, C1-INH found complete and partial responses in 2 patients each. One patient had a complete response to progestin. Omalizumab was described in 6 reports with 20 patients, all of whom showed a complete response. All three patients described in our study responded to omalizumab with a complete remission. Density of FcepsilonRI receptors on basophils, monitored in patient 1 on a long-term course of 31 months, decreased from 74,051.61 to a minimal level of 1907 receptors per cell. CONCLUSIONS: Omalizumab seems to be the most effective therapy in InH-AAE. The continuous decrease of FcepsilonRI-receptor density on basophils under therapy with omalizumab along with clinical improvement observed in one patient, could serve as a new approach for further studies to evaluate FcepsilonRI-receptor density as a surrogate marker for therapeutic efficacy and for dosing and determining injection intervals of omalizumab. Trial registration BASEC-Nr. Req-2016-00692. Retrospectively registered 24.11.2016</style></abstract><notes><style face="normal" font="default">DA - 20170901IS - 2045-7022 (Print)IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1186/s13601-017-0164-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28861213">PM:28861213</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-27.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170901, Bucher MC</style></custom2><misc3><style face="normal" font="default">10.1186/s13601-017-0164-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42390</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Colantonio,S.</style></author><author><style face="normal" font="default"> Kirshen,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Dermatology, Department of Medicine, University of Ottawa, Ottawa, Ont</style></auth-address><titles><title><style face="normal" font="default">Severe allergic contact dermatitis due to Polysporin</style></title><secondary-title><style face="normal" font="default">CMAJ</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">CMAJ</style></abbr-1></periodical><pages end="" start="E1018">E1018-</pages><volume><style face="normal" font="default">189</style></volume><number><style face="normal" font="default">31</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="8" Year="2017">2017/8/8</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170809IS - 1488-2329 (Electronic)IS - 0820-3946 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1503/cmaj.161214</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28790058">PM:28790058</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\CMAJ\2017-189-E1018.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\CMAJ\2017-189-E1018.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170809, Colantonio S</style></custom2><misc3><style face="normal" font="default">10.1503/cmaj.161214</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42391</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kuster,D.</style></author><author><style face="normal" font="default"> Haufe,E.</style></author><author><style face="normal" font="default"> Rethberg,C.</style></author><author><style face="normal" font="default"> Bauer,A.</style></author><author><style face="normal" font="default"> Seidler,A.</style></author><author><style face="normal" font="default"> Schmitt,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre of Evidence-Based Healthcare, University Hospital and Medical Faculty Carl Gustav Carus, TU Dresden, 01307 Dresden, Germany</style></auth-address><titles><title><style face="normal" font="default">Health utilities for controlled and uncontrolled chronic hand eczema in healthcare employees</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="8" Year="2017">2017/8/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: Health utilities provide a universally applicable method for measuring the relative preferences or values of specific health states. Health economic studies use health utilities to estimate disease burden and the cost-effectiveness of interventions. Chronic hand eczema (CHE) affects many individuals and adversely affects work productivity. Health utilities for CHE from the perspective of healthcare professionals are lacking. OBJECTIVES: To assess health utilities for CHE from the perspectives of employees in the healthcare sector and affected patients. METHODS: A cross-sectional study with volunteers from the healthcare sector (n = 126) and patients (n = 32) was conducted to establish health utilities (ranging from 1 = perfect health to 0 = death) for mild and severe CHE. RESULTS: The median health utilities of the healthy volunteers derived with the time trade-off method were 0.97 (mean: 0.92) for mild CHE and 0.77 (mean: 0.75) for severe CHE. The median health utilities for mild and severe CHE from the perspective of affected patients were 0.98 (mean: 0.91) and 0.82 (mean: 0.77), respectively. Differences in health utilities between the two study groups were not significant. CONCLUSION: CHE constitutes a considerable burden from the perspective of healthcare employees. Effective control of CHE constitutes an important public health goal</style></abstract><notes><style face="normal" font="default">DA - 20170823IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12863</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28833233">PM:28833233</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170823-KusterD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170823-KusterD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170823, Kuster D</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12863</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42392</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Eber,A.E.</style></author><author><style face="normal" font="default"> Sanchez,M.</style></author><author><style face="normal" font="default"> Lee,N.</style></author><author><style face="normal" font="default"> Perper,M.</style></author><author><style face="normal" font="default"> Cervantes,J.</style></author><author><style face="normal" font="default"> Tosti,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, 33136, USA</style></auth-address><titles><title><style face="normal" font="default">Confocal microscopy in the diagnosis of fibreglass dermatitis</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="267" start="266">266-267</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12818</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28872201">PM:28872201</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-266-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-266-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Eber AE</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12818</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42393</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Desroche,T.</style></author><author><style face="normal" font="default"> Barbaud,A.</style></author><author><style face="normal" font="default"> Bauvin,O.</style></author><author><style face="normal" font="default"> Poreaux,C.</style></author><author><style face="normal" font="default"> Schmutz,J.L.</style></author><author><style face="normal" font="default"> Waton,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergology, University Hospital of Nancy, 54500 Vandoeuvre-les-Nancy, France</style></auth-address><titles><title><style face="normal" font="default">Care of pets entails the risk of allergic contact dermatitis caused by plants</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="266" start="264">264-266</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12815</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28872199">PM:28872199</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-264-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-264-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Desroche T</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12815</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42394</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Prasertvit,P.</style></author><author><style face="normal" font="default"> Chareonyingwattana,A.</style></author><author><style face="normal" font="default"> Wattanakrai,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Medicine, Division of Dermatology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand 10400</style></auth-address><titles><title><style face="normal" font="default">Nevirapine patch testing in Thai human immunodeficiency virus infected patients with nevirapine drug hypersensitivity</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Skin</style></keyword></keywords><dates><year Day="6" Month="8" Year="2017">2017/8/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Antiretroviral drug hypersensitivity in HIV patients is common. Publications have shown that Abacavir (ABC) patch testing is useful in confirming ABC hypersensitivity in 24-50% of cases with a 100% sensitivity of HLA-B*5701 in patch test positive cases. However, Nevirapine (NVP) patch testing has not been reported. OBJECTIVES: (1) To evaluate the usefulness and safety of NVP patch testing in Thai HIV patients with NVP hypersensitivity. (2) To assess the correlation of positive patch tests with HLA-B*3505. PATIENTS, MATERIALS AND METHODS: Patients were classified into two groups: (1) study group of 20 HIV NVP hypersensitivity patients and (2) control group of 15 volunteers without NVP hypersensitivity. Both groups were patch tested with purified and commercialized form of NVP in various vehicles. RESULTS: Two HIV patients with NVP hypersensitivity were patch test positive. All controls tested negative. Three HIV patients were positive for HLA-B*3505 and the two patients with positive patch testing were both HLA-B*3505 positive. CONCLUSIONS: NVP patch testing in Thai HIV patients is safe and can be used to help confirm the association between NVP and hypersensitivity skin reactions. NVP patch test results significantly correlated with HLA-B*3505. The sensitivity of HLA-B*3505 for positive patch test was 100%</style></abstract><notes><style face="normal" font="default">DA - 20170807IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12849</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28782122">PM:28782122</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170807-PrasertvitP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170807-PrasertvitP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170807, Prasertvit P</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12849</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42395</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Herman,A.</style></author><author><style face="normal" font="default"> Aerts,O.</style></author><author><style face="normal" font="default"> Baeck,M.</style></author><author><style face="normal" font="default"> Bruze,M.</style></author><author><style face="normal" font="default"> De Block,C.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author><author><style face="normal" font="default"> Hamnerius,N.</style></author><author><style face="normal" font="default"> Huygens,S.</style></author><author><style face="normal" font="default"> Maiter,D.</style></author><author><style face="normal" font="default"> Tennstedt,D.</style></author><author><style face="normal" font="default"> Vandeleene,B.</style></author><author><style face="normal" font="default"> Mowitz,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Cliniques Universitaires Saint-Luc, 1200, Brussels, Belgium</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by isobornyl acrylate in Freestyle(R) Libre, a newly introduced glucose sensor</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergens</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword></keywords><dates><year Day="14" Month="8" Year="2017">2017/8/14</year></dates><abstract><style face="normal" font="default">BACKGROUND: Glucose sensors, such as FreeStyle(R) Libre, are innovative medical devices developed for diabetes patients as a replacement for classic glucose meters, ensuring continuous glucose monitoring without the disadvantage of regular skin finger pricks. OBJECTIVES: To report several cases of allergic contact dermatitis caused by FreeStyle(R) Libre, and to report on isobornyl acrylate as a culprit allergen. PATIENTS AND METHODS: Fifteen patients presented with allergic contact dermatitis caused by FreeStyle(R) Libre. All but 1 were patch tested with a baseline series, and with pieces and/or ultrasonic bath extracts of (the adhesive part of) the glucose sensor. Isobornyl acrylate was patch tested, in various concentrations and vehicles, in 13 patients. Gas chromatography-mass spectrometry (GC-MS) of the sensors was performed. RESULTS: All patients reacted to the adhesive part of the sensor, and 12 patients were shown to be sensitized to isobornyl acrylate. Simultaneous reactions to other allergens were rarely observed. GC-MS showed the presence of isobornyl acrylate in the sensors. CONCLUSIONS: Cases of allergic contact dermatitis caused by FreeStyle(R) Libre are increasingly being observed, and isobornyl acrylate is a relevant culprit allergen. Cross-reactivity to other acrylates was infrequently observed, but other, hitherto unidentified, contact allergens may still be present in the device</style></abstract><notes><style face="normal" font="default">DA - 20170814IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12866</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28804907">PM:28804907</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170814-HermanA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170814-HermanA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170814, Herman A</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12866</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42396</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">de Cuyper,C.</style></author><author><style face="normal" font="default"> Lodewick,E.</style></author><author><style face="normal" font="default"> Schreiver,I.</style></author><author><style face="normal" font="default"> Hesse,B.</style></author><author><style face="normal" font="default"> Seim,C.</style></author><author><style face="normal" font="default"> Castillo-Michel,H.</style></author><author><style face="normal" font="default"> Laux,P.</style></author><author><style face="normal" font="default"> Luch,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, AZ Sint-Jan Brugge-Oostende AV, 8000 Brugge, Belgium</style></auth-address><titles><title><style face="normal" font="default">Are metals involved in tattoo-related hypersensitivity reactions? A case report</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Skin</style></keyword></keywords><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic reactions to tattoos are not uncommon. However, identification of the culprit allergen(s) remains challenging. OBJECTIVES: We present a patient with papulo-nodular infiltration of 20-year-old tattoos associated with systemic symptoms that disappeared within a week after surgical removal of metal osteosynthesis implants from his spine. We aimed to explore the causal relationship between the metal implants and the patient's clinical presentation. METHODS: Metal implants and a skin biopsy of a reactive tattoo were analysed for elemental contents by inductively coupled plasma mass spectrometry and synchrotron-based X-ray fluorescence (XRF) spectroscopy. RESULTS: Nickel (Ni) and chromium (Cr) as well as high levels of titanium (Ti) and aluminium were detected in both the skin biopsy and the implants. XRF analyses identified Cr(III), with Cr(VI) being absent. Patch testing gave negative results for Ni and Cr. However, patch tests with an extract of the implants and metallic Ti on the tattooed skin evoked flare-up of the symptoms. CONCLUSION: The patient's hypersensitivity reaction and its spontaneous remission after removal of the implants indicate that Ti, possibly along with some of the other metals detected, could have played a major role in this particular case of tattoo-related allergy</style></abstract><notes><style face="normal" font="default">DA - 20170810IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Netherlands -CO - Germany -CO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12862</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28795428">PM:28795428</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170810-deCuyperC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170810-deCuyperC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170810, de Cuyper C</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12862</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42397</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lind,M.L.</style></author><author><style face="normal" font="default"> Johnsson,S.</style></author><author><style face="normal" font="default"> Liden,C.</style></author><author><style face="normal" font="default"> Meding,B.</style></author><author><style face="normal" font="default"> Boman,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Environmental Medicine, Karolinska Institutet, 171 77, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default">Hairdressers' skin exposure to hair dyes during different hair dyeing tasks</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Skin</style></keyword></keywords><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: The high risk of occupational skin disease among hairdressers, caused by skin exposure to irritants and sensitizers, such as hair dye substances, is of great concern. OBJECTIVES: The aim of the present study was to assess how the various tasks involved in hair dyeing contribute to hairdressers' exposure to hair dye, in order to enable the formulation of well-founded recommendations on working routines that will reduce exposure and prevent occupational disease. METHODS: Skin exposure to hair dye was measured for 20 hairdressers applying highlights and all-over hair colour with the hand rinsing technique. Resorcinol was used as a proxy for hair dye exposure. RESULTS: Applying hair dye and cutting the newly dyed hair were the tasks that contributed most to exposure in treatments for highlights. After cutting all-over-coloured hair, all hairdressers had measurable amounts of hair dyes on both hands. CONCLUSIONS: Hairdressers are exposed to hair dye ingredients during all steps of the hair dyeing procedure. Cutting newly dyed hair contributes significantly to exposure. As initial steps for the prevention of occupational disease resulting from hair dye exposure, we suggest cutting hair before dyeing it, and wearing gloves during all other work tasks</style></abstract><notes><style face="normal" font="default">DA - 20170810IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12833</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28795423">PM:28795423</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170810-LindML.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170810-LindML.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170810, Lind ML</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12833</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42398</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chaubal,T.V.</style></author><author><style face="normal" font="default"> Bapat,R.A.</style></author><author><style face="normal" font="default"> Shetty,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Periodontics, D. Y. Patil School of Dentistry, Nerul, Navi Mumbai, 400706, India</style></auth-address><titles><title><style face="normal" font="default">Allergic contact stomatitis caused by camphorquinone in a light cure periodontal dressing</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="252" start="251">251-252</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - India -CO - Malaysia -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12794</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28872204">PM:28872204</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-251-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-251-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Chaubal TV</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12794</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42399</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Haisma,M.S.</style></author><author><style face="normal" font="default"> Schuttelaar,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Medical Centre Groningen, University of Groningen, 9700 RB, Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Contact urticaria caused by the ultraviolet absorber octocrylene in sunscreens</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="256" start="254">254-256</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12806</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28872203">PM:28872203</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-254-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-254-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Haisma MS</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12806</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42400</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kamstrup,M.R.</style></author><author><style face="normal" font="default"> Bandier,J.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, 2900, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Contact allergy to methyldibromo glutaronitrile is still of clinical relevance</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="251" start="250">250-251</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12768</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28872197">PM:28872197</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-250-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-250-1.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Kamstrup MR</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12768</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42401</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Montgomery,R.</style></author><author><style face="normal" font="default"> Wilkinson,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Leeds, LS7 4SA, UK</style></auth-address><titles><title><style face="normal" font="default">Allergic contact urticaria secondary to hair dye use</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="259" start="257">257-259</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12811</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28872198">PM:28872198</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-257-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-257-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Montgomery R</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12811</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42402</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Garnica Velandia,D.R.</style></author><author><style face="normal" font="default"> Dalmau,Duch G.</style></author><author><style face="normal" font="default"> Gazquez,Garcia,V</style></author><author><style face="normal" font="default"> Indiveri,M.</style></author><author><style face="normal" font="default"> Gaig,Jane P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Seccion de Alergologia Hospital Universitario Joan XXIII, 43005 Tarragona, Spain</style></auth-address><titles><title><style face="normal" font="default">Fixed drug eruption induced by ciprofloxacin and cross-reactivity to other quinolones</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="262" start="261">261-262</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12813</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28872202">PM:28872202</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-261-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-261-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Garnica-Velandia DR</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12813</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42403</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lamoureux,A.</style></author><author><style face="normal" font="default"> Meharon,M.</style></author><author><style face="normal" font="default"> Durand,A.L.</style></author><author><style face="normal" font="default"> Darrigade,A.S.</style></author><author><style face="normal" font="default"> Doutre,M.S.</style></author><author><style face="normal" font="default"> Milpied,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Department, Saint Andre Hospital, 33075 Bordeaux, France</style></auth-address><titles><title><style face="normal" font="default">A first case of erythema multiforme-like contact dermatitis caused by propolis</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="264" start="263">263-264</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12814.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28872200">PM:28872200</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-263-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-263-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Lamoureux A</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12814.</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42404</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mertens,M.</style></author><author><style face="normal" font="default"> Gilissen,L.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author><author><style face="normal" font="default"> Lambert,J.</style></author><author><style face="normal" font="default"> Vermander,E.</style></author><author><style face="normal" font="default"> Aerts,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Hospital Antwerp (UZA) and University of Antwerp (UA), 2650 Antwerp, Belgium</style></auth-address><titles><title><style face="normal" font="default">Generalized systemic allergic dermatitis caused by Cinnamomum zeylanicum in a herbal tea</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="261" start="259">259-261</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12812</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28872206">PM:28872206</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-259-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-259-61.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Mertens M</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12812</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42405</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ozturk,A.B.</style></author><author><style face="normal" font="default"> Turturice,B.A.</style></author><author><style face="normal" font="default"> Perkins,D.L.</style></author><author><style face="normal" font="default"> Finn,P.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy and Immunology, Koc University Hospital, Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="default">The Potential for Emerging Microbiome-Mediated Therapeutics in Asthma</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="62">62-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword></keywords><dates><year Day="10" Month="8" Year="2017">2017/8/10</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: In terms of immune regulating functions, analysis of the microbiome has led the development of therapeutic strategies that may be applicable to asthma management. This review summarizes the current literature on the gut and lung microbiota in asthma pathogenesis with a focus on the roles of innate molecules and new microbiome-mediated therapeutics. RECENT FINDINGS: Recent clinical and basic studies to date have identified several possible therapeutics that can target innate immunity and the microbiota in asthma. Some of these drugs have shown beneficial effects in the treatment of certain asthma phenotypes and for protection against asthma during early life. Current clinical evidence does not support the use of these therapies for effective treatment of asthma. The integration of the data regarding microbiota with technologic advances, such as next generation sequencing and omics offers promise. Combining comprehensive bioinformatics, new molecules and approaches may shape future asthma treatment</style></abstract><notes><style face="normal" font="default">DA - 20170816IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Turkey -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0730-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28812256">PM:28812256</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-62.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170816, Ozturk AB</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0730-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42406</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pattanaik,D.</style></author><author><style face="normal" font="default"> Lieberman,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Division of Rheumatology, The University of Tennessee Health Science Center, 51 North Dunlap, Suite 400, Memphis, TN, 38105, USA</style></auth-address><titles><title><style face="normal" font="default">Pediatric Angioedema</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="60">60-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword></keywords><dates><year Day="8" Month="8" Year="2017">2017/8/8</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: The aims of this study are to update the clinician on current understanding of angioedema as it presents in the pediatric population and to review proper diagnostic techniques and treatment modalities for various types of angioedema. RECENT FINDINGS: Angioedema is still best classified by whether it is likely histaminergic or kinin-mediated. New guidelines have been published around the world to help diagnose and treat both forms (urticaria/angioedema and hereditary angioedema). The vast majority of the studies on treatment have been conducted in the adult population; however, there are data available in the pediatric population. In the realm of hereditary angioedema, there are multiple new therapies that have been studied in the pediatric population (down to 2 years in some studies) in recent years and offer the clinician options for treatment. Angioedema (whether occurring with or without urticaria) is common in the pediatric population. The majority of the recent studies has been conducted in hereditary angioedema, and now, the clinician should have various options to treat all forms of angioedema. Many treatment options, especially for hereditary angioedema, are further being examined specifically in the pediatric population</style></abstract><notes><style face="normal" font="default">DA - 20170809IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0729-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28791569">PM:28791569</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-60.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170809, Pattanaik D</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0729-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42407</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Atanaskovic-Markovic,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Multiple Drug Allergy</style></title><secondary-title><style face="normal" font="default">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Treat Options Allergy</style></full-title></periodical><pages end="400" start="395">395-400</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2196-3053</style></isbn><abstract><style face="normal" font="default">The tendency to develop multiple drug hypersensitivity (MDH), defined as a hypersensitivity to two or more structurally unrelated drugs, occurs in up to 10% of people who have a severe and proven immune-mediated drug hypersensitivity reaction (DHR). There are two subtypes of MDH: in the first type, MDH develops if different drugs are administered simultaneously; in the second, MDH develops if different drugs are administered sequentially, sometimes years apart. MDH presents clinically as immediate and/or non-immediate reactions. The main drugs responsible for MDH are antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), antiepileptics, hypnotics, antidepressants, corticosteroids, and local anesthetics. There are two pathogenic mechanisms of developing MDH: the first is T cell mediated and the second is IgE mediated. Activated T cells are directed against the culprit drug or its metabolites. MDH can be proven by positive responses to patch tests and/or delayed-reading intradermal tests as well as a positive lymphocyte transformation test. During the first DHR, the immune stimulation may lower the threshold of T cell reactivity to that drug and facilitate the immune response to the second drug, similar to viral infections. The drug-reactive T cells in patients with MDH display an enhanced state of activation. Less frequently, the pathogenic mechanism is IgE mediated. This can be proven by positive responses to an immediate-reading intradermal test and provocation test, as well as with positive specific IgE to culprit drug and a basophil activation test (BAT). A T cell-mediated reaction might be built on the IgE-mediated reaction. It is well-known that the tolerance mechanism to small molecular compounds fails in MDH patients, although the pathogenic mechanisms of this syndrome are still unknown</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Serbia -</style></notes><work-type><style face="normal" font="default">10.1007/s40521-017-0139-z</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40521-017-0139-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-395-400.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-395-400.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170901, Atanaskovic-Markovic M</style></custom2><misc3><style face="normal" font="default">10.1007/s40521-017-0139-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42408</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aun,M.V.</style></author><author><style face="normal" font="default"> Ribeiro,M.R.</style></author><author><style face="normal" font="default"> Kalil,J.</style></author><author><style face="normal" font="default"> Giavina-Bianchi,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">NSAIDs-Induced Anaphylaxis</style></title><secondary-title><style face="normal" font="default">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Treat Options Allergy</style></full-title></periodical><pages end="328" start="320">320-328</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2196-3053</style></isbn><abstract><style face="normal" font="default">Drugs are between the main triggers of anaphylaxis. They have been described as major cause of fatal anaphylaxis. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most frequently prescribed drugs around the world because of their analgesic, anti-inflammatory, antipyretic, and antithrombotic effects. This class of drug is the first or the second after antibiotics as the cause of drug hypersensitivity reactions, including anaphylaxis. However, frequency of NSAIDs as the drug implicated in anaphylactic reactions is too variable among different countries. We believe there are discrepancies between genetics, frequency of exposure and mainly between classification of hypersensitivity reactions to NSAIDs and definition of anaphylaxis. Actual classification of NSAIDs hypersensitivity considers as anaphylaxis only those severe reactions presented by selective responders, probably IgE-mediated. Blended reactions, when respiratory plus mucocutaneous symptoms are presented after intaking NSAIDs from different groups (cross-intolerant), are not included in this classification. It can lead to underdiagnosis of non-immunological anaphylaxis. International groups of researchers must try to better define phenotypes of hypersensitivity reactions to NSAIDs, in order to include those blended reactions and better manage these cases</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1007/s40521-017-0137-1</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40521-017-0137-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-320-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-320-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170901, Aun MV</style></custom2><misc3><style face="normal" font="default">10.1007/s40521-017-0137-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42409</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fajt,M.L.</style></author><author><style face="normal" font="default"> Traister,R.S.</style></author><author><style face="normal" font="default"> Petrov,A.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Vocal Cord Dysfunction and Asthma</style></title><secondary-title><style face="normal" font="default">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Treat Options Allergy</style></full-title></periodical><pages end="341" start="329">329-341</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2196-3053</style></isbn><abstract><style face="normal" font="default">Vocal cord dysfunction (VCD) is a functional disorder of the vocal cords characterized by exaggerated adduction of vocal cords during inspiration and/or expiration causing respiratory and laryngeal symptoms. VCD can exist in isolation and coexist with asthma, or it can mimic asthma. The missteps during the VCD and asthma diagnostic process and subsequent faulty clinical conclusions can lead to mistreatment and increased health care utilization that can last for years. Therefore, diagnostic precision in conjunction with optimal therapeutics is a prerequisite for the best patient outcomes in this patient population. An integrated approach is frequently required using multiple diagnostic modalities to make a correct diagnosis. The treatment options, usually applied in a step-wise progression, depend on the severity of presentation and the underlying type of VCD. Future studies should address the better identification of specific phenotypes of VCD and their corresponding treatments</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s40521-017-0138-0</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40521-017-0138-0</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-329-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-329-41.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170901, Fajt ML</style></custom2><misc3><style face="normal" font="default">10.1007/s40521-017-0138-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42410</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nwaru,B.I.</style></author><author><style face="normal" font="default"> Dhami,S.</style></author><author><style face="normal" font="default"> Sheikh,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Idiopathic Anaphylaxis</style></title><secondary-title><style face="normal" font="default">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Treat Options Allergy</style></full-title></periodical><pages end="319" start="312">312-319</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2196-3053</style></isbn><abstract><style face="normal" font="default">Idiopathic anaphylaxis is a rare life-threatening disorder with symptoms similar to other forms of anaphylaxis. There is lack of a robust evidence base underpinning the treatment of anaphylaxis and even less so for idiopathic anaphylaxis. Much of the evidence therefore comes from relatively small case series and expert opinion. Idiopathic anaphylaxis is a diagnosis of exclusion, requiring a thorough history and careful diagnostic work-up investigating possible triggers and underlying predisposing factors. Key diagnostic tests include skin-prick testing, tests for specific-IgE, component-resolved diagnostics, and in some cases for allergen challenge tests. Other recognized causes of anaphylaxis, such as foods, medications, insect stings, latex, and exercise, should all be considered, as should differential diagnoses such as asthma. While the cause of idiopathic anaphylaxis remains unknown, prompt treatment with intramuscular epinephrine (adrenaline) administered into the anterolateral aspect of the thigh is associated with good prognosis. There may also be a role for H1-antihistamines and corticosteroids as second-line agents. Patients need to be carefully monitored for signs of deterioration and/or a possible protracted or biphasic reaction. Patients with frequent episodes of anaphylaxis (e.g., six or more episodes/year) should be considered for preventive therapy, which may include corticosteroids, H1- and H2-antihistamines, and, in some cases, mast cell stabilizers such as ketotifen. Alternative immune-suppressants (e.g., methotrexate) and anti-IgE may rarely also need to be considered. In many cases, the frequency of anaphylaxis declines such that regular use of corticosteroids can be discontinued after 9</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô12-ámonths. Pediatric patients should be treated with similar regimens as adults, but with appropriate dose adjustments. Patients should carry their self-injectable epinephrine and other emergency medications at all times in order to deal with emergency situations</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1007/s40521-017-0136-2</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40521-017-0136-2</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-312-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-312-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170901, Nwaru BI</style></custom2><misc3><style face="normal" font="default">10.1007/s40521-017-0136-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42411</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tavares,M.</style></author><author><style face="normal" font="default"> Dias,J.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Eosinophilic Oesophagitis in Children: Disease Modulation by Topical Steroids</style></title><secondary-title><style face="normal" font="default">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Treat Options Allergy</style></full-title></periodical><pages end="354" start="342">342-354</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2196-3053</style></isbn><abstract><style face="normal" font="default">Eosinophilic oesophagitis (EoE) is a chronic inflammatory disease, and effective treatment for paediatric EoE is still evolving. There is no consensual standard therapy for adults or children, as evolving concepts still need to be properly validated and there has been continuous update from published trials. This paper summarizes the current knowledge about inflammatory background and corticosteroid therapy in paediatric eosinophilic oesophagitis</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.1007/s40521-017-0142-4</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40521-017-0142-4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-342-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Treat Options Allergy\2017-4-342-54.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170901, Tavares M</style></custom2><misc3><style face="normal" font="default">10.1007/s40521-017-0142-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42412</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Takasugi,M.</style></author><author><style face="normal" font="default"> Muta,E.</style></author><author><style face="normal" font="default"> Yamada,K.</style></author><author><style face="normal" font="default"> Arai,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Applied Chemistry and Biochemistry, Faculty of Engineering, Kyushu Sangyo University, 2-3-1 Matsukadai, Higashi-ku, Fukuoka, 813-8503, Japan</style></auth-address><titles><title><style face="normal" font="default">A new method to evaluate anti-allergic effect of food component by measuring leukotriene B4 from a mouse mast cell line</style></title><secondary-title><style face="normal" font="default">Cytotechnology</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cytotechnology</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="8" Year="2017">2017/8/29</year></dates><abstract><style face="normal" font="default">Leukotrienes (LTs), chemical mediators produced by mast cells, play an important role in allergic symptoms such as food allergies and hay fever. We tried to construct an evaluation method for the anti-LTB4 activity of chemical substances using a mast cell line, PB-3c. PB-3c pre-cultured with or without arachidonic acid (AA) was stimulated by calcium ionophore (A23187) for 20 min, and LTB4 production by the cells was determined by HPLC with UV detection. LTB4 was not detected when PB-3c was pre-cultured without AA. On the other hand, LTB4 production by PB-3c pre-cultured with AA was detectable by HPLC, and the optimal conditions of PB-3c for LTB4 detection were to utilize the cells pre-cultured with 50 microM AA for 48 h. MK-886 (5-lipoxygenase inhibitor) completely inhibited LTB4 production, but AACOCF3 (phospholipase A2 inhibitor) slightly increased LTB4 production, suggesting that LTB4 was generated from exogenous free AA through 5-lipoxygenase pathway. We applied this technique to the evaluation of the anti-LTB4 activity of food components. PB-3c pre-cultured with 50 microM AA for 48 h was stimulated with A23187 in the presence of 50 microM soybean isoflavones (daidzin, genistin, daidzein, and genistein), equol, quercetin, or kaempferol. Genistein, equol, quercetin, and kaempferol strongly inhibited LTB4 production without cytotoxicity. These results suggest that a new assay system using PB-3c is convenient to evaluate LTB4 inhibition activity by food components. This method could be utilized for elucidation of the mechanisms of LTB4 release suppression by food components such as flavonoids and the structure-activity relationship</style></abstract><notes><style face="normal" font="default">DA - 20170830IS - 0920-9069 (Print)IS - 0920-9069 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1007/s10616-017-0129-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28852902">PM:28852902</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cytotechnology\20170830-TakasugiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cytotechnology\20170830-TakasugiM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170830, Takasugi M</style></custom2><misc3><style face="normal" font="default">10.1007/s10616-017-0129-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42413</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bygum,A.</style></author><author><style face="normal" font="default"> Martinez-Saguer,I.</style></author><author><style face="normal" font="default"> Bas,M.</style></author><author><style face="normal" font="default"> Rosch,J.</style></author><author><style face="normal" font="default"> Edelman,J.</style></author><author><style face="normal" font="default"> Rojavin,M.</style></author><author><style face="normal" font="default"> Williams-Herman,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">HAE Centre Denmark, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark</style></auth-address><titles><title><style face="normal" font="default">Use of a C1 Inhibitor Concentrate in Adults >/=65 Years of Age with Hereditary Angioedema: Findings from the International Berinert(R) (C1-INH) Registry</style></title><secondary-title><style face="normal" font="default">Drugs Aging</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Drugs Aging</style></abbr-1></periodical><pages end="827" start="819">819-827</pages><volume><style face="normal" font="default">33</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">administration &amp; dosage</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Angioedemas,Hereditary</style></keyword><keyword><style face="normal" font="default"> chemically induced</style></keyword><keyword><style face="normal" font="default"> Complement C1 Inactivator Proteins</style></keyword><keyword><style face="normal" font="default"> drug therapy</style></keyword><keyword><style face="normal" font="default"> Europe</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Gastrointestinal Hemorrhage</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Infusions,Intravenous</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Registries</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword><keyword><style face="normal" font="default"> therapeutic use</style></keyword><keyword><style face="normal" font="default"> United States</style></keyword></keywords><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Treatment of hereditary angioedema (HAE) in 'older adults' (those aged >/=65 years) has not been well studied. The international Berinert Patient Registry collected data on the use of intravenous plasma-derived, pasteurized, nanofiltered C1-inhibitor concentrate (pnfC1-INH; Berinert(R)/CSL Behring) in patients of any age, including many older adults. METHODS: This observational registry, conducted from 2010 to 2014 at 30 US and seven European sites, gathered prospective (post-enrollment) and retrospective (pre-enrollment) usage and adverse event (AE) data on subjects treated with pnfC1-INH. RESULTS: The registry documented 1701 pnfC1-INH infusions in 27 older adults. A total of 1511 HAE attacks treated with pnfC1-INH administration were reported among 25 of the 27 (92.6 %) older adults. Among the older adults, mean (standard deviation [SD]) (8.8 [4.1] IU/kg) and median (6.4 IU/kg) pnfC1-INH doses were lower than those reported for 252 'younger adults' (those aged &lt;65 years: 12.9 [6.2], 12.5 IU/kg, respectively). A total of 19 AEs occurred in 8 of 23 (34.8 %) older adults with prospective data, for rates of 0.83 events per subject and 0.02 events per infusion, similar to corresponding rates in younger adults (0.91 and 0.03, respectively). None of the AEs were considered related to pnfC1-INH, and all but two events (prostatectomy, gastrointestinal bleeding) were mild or moderate in severity. Administration of pnfC1-INH outside of a healthcare setting was reported for 1609 infusions in 16 older adults, representing 94.6 % of all pnfC1-INH infusions in this age group. There were no recorded instances of difficulty with self-administration of intravenous pnfC1-INH. CONCLUSIONS: These findings suggest a high degree of safety with intravenous pnfC1-INH use in older adults with HAE, regardless of administration setting. Trial Registration Clinicaltrials.gov NCT01108848</style></abstract><notes><style face="normal" font="default">DA - 20161004IS - 1179-1969 (Electronic)IS - 1170-229X (Linking)LA - engPT - Journal ArticlePT - Multicenter StudyPT - Observational StudyRN - 0 (Complement C1 Inactivator Proteins)RN - 0 (SERPING1 protein, human)SB - IMCO - Denmark -CO - Germany -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s40266-016-0403-010.1007/s40266-016-0403-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27699634">PM:27699634</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Drugs Aging\2016-33-819-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Drugs Aging\2016-33-819-27.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161004, Bygum A</style></custom2><misc3><style face="normal" font="default">10.1007/s40266-016-0403-010.1007/s40266-016-0403-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42414</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Paulin,L.M.</style></author><author><style face="normal" font="default"> Williams,D.L.</style></author><author><style face="normal" font="default"> Peng,R.</style></author><author><style face="normal" font="default"> Diette,G.B.</style></author><author><style face="normal" font="default"> McCormack,M.C.</style></author><author><style face="normal" font="default"> Breysse,P.</style></author><author><style face="normal" font="default"> Hansel,N.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Johns Hopkins Pulmonary/Critical Care, Baltimore, MD, United States.</style></auth-address><titles><title><style face="normal" font="default">24-h Nitrogen dioxide concentration is associated with cooking behaviors and an increase in rescue medication use in children with asthma</style></title><secondary-title><style face="normal" font="default">Environ Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Environ Res</style></abbr-1></periodical><pages end="123" start="118">118-123</pages><volume><style face="normal" font="default">159</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="8" Year="2017">2017/8/7</year></dates><abstract><style face="normal" font="default">Exposure to nitrogen dioxide (NO2), a byproduct of combustion, is associated with poor asthma control in children. We sought to determine whether gas-fueled kitchen appliance use is associated with 24-h indoor NO2 concentrations and whether these concentrations are associated with asthma morbidity in children. Children aged 5-12 years old with asthma were eligible. Mean 24-h NO2 concentration was measured in the kitchen over a four-day sampling period and gas stove use was captured in time activity diaries. The relationship between stove and oven use and daily NO2 concentration was analyzed. Longitudinal analysis assessed the effect of daily NO2 exposure on symptoms, inhaler use, and lung function. Multivariate models were adjusted for age, sex, season, and maternal education. Thirty children contributed 126 participant days of sampling. Mean indoor 24-h NO2 concentration was 58(48)ppb with a median (range) of 45(12-276)ppb. All homes had gas stoves and furnaces. Each hour of kitchen appliance use was associated with an 18ppb increase in 24-h NO2 concentration. In longitudinal multivariate analysis, each ten-fold increase in previous-day NO2 was associated with increased nighttime inhaler use (OR = 4.9, p = 0.04). There were no associations between NO2 and lung function or asthma symptoms. Higher previous-day 24-h concentration of NO2 is associated with increased nighttime inhaler use in children with asthma</style></abstract><notes><style face="normal" font="default">DA - 20170811IS - 1096-0953 (Electronic)IS - 0013-9351 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.envres.2017.07.052</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28797886">PM:28797886</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Environ Res\2017-159-118-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Environ Res\2017-159-118-23.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170811, Paulin LM</style></custom2><misc3><style face="normal" font="default">10.1016/j.envres.2017.07.052</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42415</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Uphoff,E.P.</style></author><author><style face="normal" font="default"> Bird,P.K.</style></author><author><style face="normal" font="default"> Anto,J.M.</style></author><author><style face="normal" font="default"> Basterrechea,M.</style></author><author><style face="normal" font="default"> Von Berg,A.</style></author><author><style face="normal" font="default"> Bergstrom,A.</style></author><author><style face="normal" font="default"> Bousquet,J.</style></author><author><style face="normal" font="default"> Chatzi,L.</style></author><author><style face="normal" font="default"> Fantini,M.P.</style></author><author><style face="normal" font="default"> Ferrero,A.</style></author><author><style face="normal" font="default"> Gehring,U.</style></author><author><style face="normal" font="default"> Gori,D.</style></author><author><style face="normal" font="default"> Heinrich,J.</style></author><author><style face="normal" font="default"> Keil,T.</style></author><author><style face="normal" font="default"> Kull,I.</style></author><author><style face="normal" font="default"> Lau,S.</style></author><author><style face="normal" font="default"> Maier,D.</style></author><author><style face="normal" font="default"> Momas,I.</style></author><author><style face="normal" font="default"> Narduzzi,S.</style></author><author><style face="normal" font="default"> Porta,D.</style></author><author><style face="normal" font="default"> Ranciere,F.</style></author><author><style face="normal" font="default"> Roumeliotaki,T.</style></author><author><style face="normal" font="default"> Schikowski,T.</style></author><author><style face="normal" font="default"> Smit,H.A.</style></author><author><style face="normal" font="default"> Standl,M.</style></author><author><style face="normal" font="default"> Sunyer,J.</style></author><author><style face="normal" font="default"> Wright,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Bradford Institute for Health Research, Bradford, UK</style></auth-address><titles><title><style face="normal" font="default">Variations in the prevalence of childhood asthma and wheeze in MeDALL cohorts in Europe</style></title><secondary-title><style face="normal" font="default">ERJ Open Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">ERJ Open Res</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Europe</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">While there is evidence for variations in prevalence rates of childhood wheeze and asthma between countries, longitudinal, individual-level data are needed to understand these differences. The aim of this study was to examine variations in prevalence rates of childhood asthma, wheeze and wheeze with asthma in Europe. We analysed datasets from 10 MeDALL (Mechanisms of the Development of ALLergy) cohorts in eight countries, representing 26 663 children, to calculate prevalence rates of wheeze and asthma by child age and wheeze with asthma at age 4 years. Harmonised variables included outcomes parent-reported wheeze and parent-reported doctor-diagnosed asthma, and covariates maternal education, parental smoking, pets, parental asthma, doctor-diagnosed allergic rhinitis, doctor-diagnosed eczema and wheeze severity. At age 4 years, asthma prevalence varied from 1.72% in Germany to 13.48% in England and the prevalence of wheeze varied from 9.82% in Greece to 55.37% in Spain. Adjusted estimates of the proportion of 4-year-old children with wheeze diagnosed with asthma remained highest in England (38.14%, 95% CI 31.38-44.90%) and lowest in Spain (15.94%, 95% CI 6.16-25.71%). The large differences in prevalence rates of asthma, wheeze and wheeze with asthma at age 4 years between European cohorts may indicate that childhood asthma is more readily diagnosed in some countries while going unrecognised elsewhere</style></abstract><notes><style face="normal" font="default">DA - 20170828IS - 2312-0541 (Print)IS - 2312-0541 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -CO - Spain -CO - Sweden -CO - Italy -CO - France -CO - Greece -CO - Netherlands -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1183/23120541.00150-2016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28845428">PM:28845428</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\ERJ Open Res\20170828-UphoffEP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\ERJ Open Res\20170828-UphoffEP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170828, Uphoff EP</style></custom2><misc3><style face="normal" font="default">10.1183/23120541.00150-2016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42416</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nygaard,L.</style></author><author><style face="normal" font="default"> Henriksen,D.P.</style></author><author><style face="normal" font="default"> Madsen,H.</style></author><author><style face="normal" font="default"> Davidsen,J.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Odense University Hospital, Odense C, Denmark</style></auth-address><titles><title><style face="normal" font="default">Appropriate selection for omalizumab treatment in patients with severe asthma?</style></title><secondary-title><style face="normal" font="default">Eur Clin Respir J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Eur Clin Respir J</style></abbr-1></periodical><pages end="" start="1359477">1359477-</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">pharmacology</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Omalizumab improves asthma control in patients with uncontrolled severe allergic asthma; however, appropriate patient selection is crucial. Information in this field is sparse. Objective: We aimed to estimate whether potential omalizumab candidates were appropriately selected according to guidelines, and the clinical effect of omalizumab treatment over time. Design: We performed a retrospective observational study on adult patients with asthma treated with omalizumab during 2006-2015 at the Department of Respiratory Medicine at Odense University Hospital (OUH), Denmark. Data were obtained from the Electronic Patient Journal of OUH and Odense Pharmaco-Epidemiological Database. Guideline criteria for omalizumab treatment were used to evaluate the appropriateness of omalizumab candidate selection, and the Asthma Control Test (ACT) to assess the clinical effects of omalizumab at weeks 16 and 52 from treatment initiation. Results: During the observation period, 24 patients received omalizumab, but only 10 patients (42%) fulfilled criteria recommended by international guidelines. The main reasons for not fulfilling the criteria were inadequately reduced lung function, insufficient number of exacerbations, and asthma standard therapy below Global Initiative for Asthma (GINA) step 4-5. Seventeen and 11 patients completed treatment at weeks 16 and 52, with a statistically significant increase in ACT score of 5.1 points [95% confidence interval (CI) 3.1-7.2, p = 0.0001] and 7.7 points (95% CI 4.3-11.1, p = 0.0005), respectively. Conclusion: Only 42% of the omalizumab-treated patients were appropriately selected according to current guidelines. Still, as omalizumab showed significant improvement in asthma control over time, it is important to keep this drug in mind as an add-on to asthma therapy in well-selected patients</style></abstract><notes><style face="normal" font="default">DA - 20170817IS - 2001-8525 (Print)IS - 2001-8525 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1080/20018525.2017.1359477</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28815007">PM:28815007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Clin Respir J\2017-4-1359477.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Clin Respir J\2017-4-1359477.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170817, Nygaard L</style></custom2><misc3><style face="normal" font="default">10.1080/20018525.2017.1359477</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42417</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Poluzzi,E.</style></author><author><style face="normal" font="default"> Diemberger,I.</style></author><author><style face="normal" font="default"> De Ridder,M.</style></author><author><style face="normal" font="default"> Koci,A.</style></author><author><style face="normal" font="default"> Clo,M.</style></author><author><style face="normal" font="default"> Oteri,A.</style></author><author><style face="normal" font="default"> Pecchioli,S.</style></author><author><style face="normal" font="default"> Bezemer,I.</style></author><author><style face="normal" font="default"> Schink,T.</style></author><author><style face="normal" font="default"> Pilgaard,Ulrichsen S.</style></author><author><style face="normal" font="default"> Boriani,G.</style></author><author><style face="normal" font="default"> Sturkenboom,M.C.J.</style></author><author><style face="normal" font="default"> De Ponti,F.</style></author><author><style face="normal" font="default"> Trifiro,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.</style></auth-address><titles><title><style face="normal" font="default">Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project</style></title><secondary-title><style face="normal" font="default">Eur J Clin Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur J Clin Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="8" Year="2017">2017/8/22</year></dates><abstract><style face="normal" font="default">PURPOSE: After regulatory restrictions for terfenadine and astemizole in '90s, only scarce evidence on proarrhythmic potential of antihistamines has been published. We evaluate the risk of ventricular tachyarrhythmia (VA) related to the use of individual antihistamines. METHODS: A matched case-control study nested in a cohort of new users of antihistamines was conducted within the EU-funded ARITMO project. Data on 1997-2010 were retrieved from seven healthcare databases: AARHUS (Denmark), GEPARD (Germany), HSD and ERD (Italy), PHARMO and IPCI (Netherlands) and THIN (UK). Cases of VA were selected and up to 100 controls were matched to each case. The odds ratio (OR) of current use for individual antihistamines (AHs) was estimated using conditional logistic regression. RESULTS: For agents largely used to prevent allergic symptoms, such as cetirizine, levocetirizine, loratadine, desloratadine and fexofenadine, we found no VA risk. A statistically significant, increased risk of VA was found only for current use of cyclizine in the pooled analysis (ORadj, 5.3; 3.6-7.6) and in THIN (ORadj, 5.3; 95% CI, 3.7-7.6), for dimetindene in GEPARD (ORadj, 3.9; 1.1-14.7) and for ebastine in GEPARD (ORadj, 3.3; 1.1-10.8) and PHARMO (ORadj, 4.6; 1.3-16.2). CONCLUSIONS: The risk of VA associated with a few specific antihistamines could be ascribable to heterogeneity in pattern of use or in receptor binding profile</style></abstract><notes><style face="normal" font="default">DA - 20170823IS - 1432-1041 (Electronic)IS - 0031-6970 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Netherlands -CO - Germany -CO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1007/s00228-017-2317-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28831527">PM:28831527</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur J Clin Pharmacol\20170823-PoluzziE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur J Clin Pharmacol\20170823-PoluzziE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170823, Poluzzi E</style></custom2><misc3><style face="normal" font="default">10.1007/s00228-017-2317-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42418</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martin,A.A.</style></author><author><style face="normal" font="default"> Fainardi,V.</style></author><author><style face="normal" font="default"> Saglani,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Inflammation, Repair and Development , NHLI, Imperial College London , London , UK</style></auth-address><titles><title><style face="normal" font="default">Severe therapy resistant asthma in children: translational approaches to uncover sub-phenotypes</style></title><secondary-title><style face="normal" font="default">Expert Rev Respir Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Expert Rev Respir Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergens</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword></keywords><dates><year Day="21" Month="8" Year="2017">2017/8/21</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Paediatric severe therapy resistant asthma (STRA) affects a very small proportion of all children with asthma, but results in significant morbidity, has a high risk of mortality and utilises approximately half of all healthcare resources for childhood asthma. children with STRA need add-on 'beyond guidelines' therapies because of poor control despite maximal conventional treatments and optimisation of basic asthma management. however, STRA is heterogeneous with marked phenotypic variation between patients and mechanisms from adult severe asthma cannot be extrapolated to children. Areas covered: This review will cover our current knowledge of paediatric STRA pathophysiology, with examples of translational approaches that have been used to define sub-phenotypes including; 1. pre-clinical age-appropriate models using clinically relevant allergens, 2. in vitro techniques incorporating complex co-cultures of structural and inflammatory cells, and 3. techniques that allow detailed cellular immunophenotyping of small airway samples will be discussed. Studies using these approaches that have demonstrated the importance of the innate mediator IL-33 and vitamin D deficiency in severe steroid resistant disease will also be discussed. Expert commentary: These experimental approaches allow investigation of age and disease specific molecular pathways and the development of personalised therapies that can be stratified and targeted to sub-phenotypes of paediatric STRA</style></abstract><notes><style face="normal" font="default">DA - 20170822IS - 1747-6356 (Electronic)IS - 1747-6348 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1080/17476348.2017.1368391</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28826280">PM:28826280</url></web-urls></urls><custom2><style face="normal" font="default">20170822, Martin AA</style></custom2><misc3><style face="normal" font="default">10.1080/17476348.2017.1368391</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42419</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chuenjit,W.</style></author><author><style face="normal" font="default"> Engchuan,V.</style></author><author><style face="normal" font="default"> Yuenyongviwat,A.</style></author><author><style face="normal" font="default"> Sangsupawanich,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand</style></auth-address><titles><title><style face="normal" font="default">Achieving good adherence to inhaled corticosteroids after weighing canisters of asthmatic children</style></title><secondary-title><style face="normal" font="default">F1000Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">F1000Res</style></abbr-1></periodical><pages end="" start="266">266-</pages><volume><style face="normal" font="default">6</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: The metered-dose inhalers (MDIs) currently available for inhaled corticosteroid delivery do not offer an integrated dose counter; therefore, it is difficult to evaluate adherence of patients. The present authors developed a linear regression equation using canister weight to calculate the number of doses actuated from the MDIs. This study aimed to assess medical adherence after the integration of regular weighing of the canisters into the routine service. Methods: A cohort study was carried out between May 2013 and April 2014. Children aged less than 8 years with a diagnosis of asthma were recruited. The duration of adherence assessment was 24 weeks. Participants had a regular schedule every 8 weeks to obtain a new FLIXOTIDE(R) 125 inhaler. Parents were asked to collect the discarded MDI canisters, which were then weighed by a laboratory scale. The weight of each canister was replaced in the regression equation to calculate the number of doses actuated from the MDIs. Results: A total of 52 asthmatic children participated in the study. The median age was 52.7 months. At the end of 24 weeks, 44, 33, and 23 discarded MDI canisters were collected from visits 1, 2, and 3, respectively. The median percentages of adherence were 96.8%, 96.3%, and 96.3%, respectively. In 11 discarded canisters (11%), the remaining medication was more than 30% of the labeled doses. Approximately 90% of the participants had no asthma exacerbation during 24-week study period. Conclusion: High adherence rates were achieved after integration of canister weighing into the asthma care service</style></abstract><notes><style face="normal" font="default">DA - 20170904IS - 2046-1402 (Print)IS - 2046-1402 (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="default">10.12688/f1000research.10710.1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28868133">PM:28868133</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\F1000Res\2017-6-266.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\F1000Res\2017-6-266.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170904, Chuenjit W</style></custom2><misc3><style face="normal" font="default">10.12688/f1000research.10710.1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42420</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mennini,M.</style></author><author><style face="normal" font="default"> Dahdah,L.</style></author><author><style face="normal" font="default"> Artesani,M.C.</style></author><author><style face="normal" font="default"> Fiocchi,A.</style></author><author><style face="normal" font="default"> Martelli,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Bambino Gesu Children's Hospital, Vatican City, Vatican City</style></auth-address><titles><title><style face="normal" font="default">Probiotics in Asthma and Allergy Prevention</style></title><secondary-title><style face="normal" font="default">Front Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Pediatr</style></abbr-1></periodical><pages end="" start="165">165-</pages><volume><style face="normal" font="default">5</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Interest in probiotic research and its potential benefits in infant foods are relatively recent but significantly increasing. The evolution of the knowledge in the last 20 years demonstrated that alterations in the microbiome may be a consequence of events occurring during infancy or childhood, including prematurity, cesarean section, and nosocomial infections. Several pieces of evidence prove that a "healthy" intestinal microbiota facilitates the development of immune tolerance. Interventional studies suggest that probiotics could be protective against the development of many diseases. Nevertheless, many factors complicate the analysis of dysbiosis in subjects with food allergy. Comparison in-between studies are difficult, because of considerable heterogeneity in study design, sample size, age at fecal collection, methods of analysis of gut microbiome, and geographic location. Currently, there is no positive recommendation from scientific societies to use pre- or probiotics for treatment of food allergy or other allergic manifestations, while their use in prevention is being custom-cleared. However, the recommendation is still based on little evidence. Although there is valid scientific evidence in vitro, there is no sufficient information to suggest the use of specific probiotics in allergy and asthma prevention</style></abstract><notes><style face="normal" font="default">DA - 20170821IS - 2296-2360 (Print)IS - 2296-2360 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Vatican City -CO - Italy -</style></notes><work-type><style face="normal" font="default">10.3389/fped.2017.00165</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28824889">PM:28824889</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Pediatr\2017-5-165.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Pediatr\2017-5-165.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170821, Mennini M</style></custom2><misc3><style face="normal" font="default">10.3389/fped.2017.00165</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42421</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pickles,K.</style></author><author><style face="normal" font="default"> Eassey,D.</style></author><author><style face="normal" font="default"> Reddel,H.K.</style></author><author><style face="normal" font="default"> Locock,L.</style></author><author><style face="normal" font="default"> Kirkpatrick,S.</style></author><author><style face="normal" font="default"> Smith,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Values, Ethics &amp; the Law in Medicine, University of Sydney, Sydney, NSW, Australia</style></auth-address><titles><title><style face="normal" font="default">"This illness diminishes me. What it does is like theft": A qualitative meta-synthesis of people's experiences of living with asthma</style></title><secondary-title><style face="normal" font="default">Health Expect</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Health Expect</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="2" Month="8" Year="2017">2017/8/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: What matters to people in their everyday experiences of living with asthma is influenced by a diverse range of personal, social, medical and environmental factors. Previous reviews of the asthma literature have largely focused on medical aspects of asthma or specific population groups with particular needs. OBJECTIVE: To identify, describe and synthesize from the available qualitative literature the views and experiences of adults living with asthma. METHOD: We systematically searched for qualitative studies reporting on the personal experience of living with asthma. A meta-synthesis approach was used to analyse and interpret the data. Key themes relating to personal perspectives on asthma were identified and grouped into overarching concepts. RESULTS: We identified 26 studies. There was a paucity of literature on the physical burden of asthma symptoms and the role of social support. Our synthesis generated a central concept of the "work" associated with living with asthma: work was of a personal nature, and at times an intensely emotional experience. Individuals tailored their behaviour in response to demands of the physical and social environment, including interactions with health-care professionals. CONCLUSION: This is the first systematic review of the qualitative literature reporting on people's own perspectives of living with asthma. Our findings draw attention to the nuances and sensitivities surrounding patient experiences of self-management. Medical care is a central plank of managing chronic conditions, but our health-care systems are now expected to deliver patient-centred care. Considering the broader aspects of asthma management, beyond that of symptoms and treatment, will help to facilitate comprehensive care</style></abstract><notes><style face="normal" font="default">DA - 20170802IS - 1369-7625 (Electronic)IS - 1369-6513 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/hex.12605</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28768067">PM:28768067</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Health Expect\20170802-PicklesK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Health Expect\20170802-PicklesK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Pickles K</style></custom2><misc3><style face="normal" font="default">10.1111/hex.12605</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42422</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vazquez Guillamet,L.J.</style></author><author><style face="normal" font="default"> Malinis,M.F.</style></author><author><style face="normal" font="default"> Meyer,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Yale New Haven Health-Bridgeport Hospital, 267 Grant St., Bridgeport, CT, 06610, USASection of Infectious Diseases, Yale School of Medicine, New Haven, CT USAYale AIDS Program, New Haven, CT, USA</style></auth-address><titles><title><style face="normal" font="default">Emerging role of Actinomyces meyeri in brain abscesses: A case report and literature review</style></title><secondary-title><style face="normal" font="default">IDCases</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">IDCases</style></full-title></periodical><pages end="29" start="26">26-29</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">We describe a case of a 29-year-old man from Pakistan who presented with progressive neurologic symptoms over 1 week and was found to have a right parietal cerebral abscess. Neurosurgical drainage cultures showed growth of Actinomyces meyeri, Streptococcus intermedius, and Parvimonas micra. An abscessed molar was identified as the likely port of entry and was extracted. The patient was treated with metronidazole, vancomycin, and doxycycline because of prior anaphylaxis to penicillin. At 6-month follow-up, repeat magnetic resonance imaging showed no signs of residual abscess. Culture-independent identification techniques (e.g., ribosomal sequencing) increasingly identify Actinomyces meyeri as a causative agent and significant pathogen in spontaneous brain abscesses. As understanding about Actinomyces meyeri's prevalence and pathogenesis improves, questions arise about optimal treatment strategy, which we discuss based on a literature review</style></abstract><notes><style face="normal" font="default">DA - 20170823IS - 2214-2509 (Print)IS - 2214-2509 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.idcr.2017.07.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28831384">PM:28831384</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\IDCases\2017-10-26-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\IDCases\2017-10-26-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170823, Vazquez Guillamet LJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.idcr.2017.07.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42423</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kambara,R.</style></author><author><style face="normal" font="default"> Minami,T.</style></author><author><style face="normal" font="default"> Akazawa,H.</style></author><author><style face="normal" font="default"> Tsuji,F.</style></author><author><style face="normal" font="default"> Sasaki,T.</style></author><author><style face="normal" font="default"> Inohara,H.</style></author><author><style face="normal" font="default"> Horii,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology, Suita Municipal Hospital, Suita, Japan</style></auth-address><titles><title><style face="normal" font="default">Lower Airway Inflammation in Eosinophilic Chronic Rhinosinusitis as Determined by Exhaled Nitric Oxide</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="232" start="225">225-232</pages><volume><style face="normal" font="default">173</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="8" Year="2017">2017/8/29</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic rhinosinusitis (CRS) is classified into eosinophilic CRS (ECRS) and non-ECRS. The objectives of this study were to evaluate lower airway inflammation by measuring the fractional concentration of exhaled nitric oxide (FeNO) and to examine the effects of endoscopic sinus surgery (ESS) on FeNO in patients with ECRS compared to non-ECRS. METHODS: CRS patients with nasal polyps (23 with ECRS and 22 with non-ECRS) were enrolled into this study. ECRS was diagnosed based on the definition proposed by the Japanese Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis (JESREC) study group. Several clinical markers including blood eosinophil counts, percent of eosinophils in white blood cells (WBC), number of eosinophils in nasal polyps, JESREC scores, total IgE, FeNO, and Lund-Mackay paranasal sinus CT scores were compared between ECRS and non-ECRS. These markers were also tested before and 2 months after ESS. RESULTS: FeNO was significantly higher in patients with ECRS than in non-ECRS patients. When all CRS patients were tested, a significant correlation was found between FeNO and eosinophilic markers including blood eosinophil counts, percent of eosinophils in WBC, number of eosinophils in nasal polyps, and JESREC scores. FeNO showed a significant correlation with Lund-Mackay scores only in ECRS patients. Blood eosinophil counts, percent of eosinophils in WBC, and FeNO decreased after ESS only in ECRS patients. CONCLUSIONS: ECRS patients had lower airway inflammation as revealed by an elevated FeNO, which was parallel to the Lund-Mackay CT scores. ESS decreased the blood eosinophils and FeNO, leading to an improvement of the occult pulmonary dysfunction in ECRS patients</style></abstract><notes><style face="normal" font="default">DA - 20170829IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1159/000479387</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28848094">PM:28848094</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-225-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-225-32.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170829, Kambara R</style></custom2><misc3><style face="normal" font="default">10.1159/000479387</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42424</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Padovan,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biomedicine, University Hospital, University of Basel, Basel, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Modulation of CD4+ T Helper Cell Memory Responses in the Human Skin</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="137" start="121">121-137</pages><volume><style face="normal" font="default">173</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Skin</style></keyword></keywords><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="default">Immunological memory is defined as the capacity to mount faster and more effective immune responses against antigenic challenges that have been previously encountered by the host. CD4+ T helper (Th) cells play central roles in the establishment of immunological memory as they assist the functions of other leukocytes. Th cells express polarized cytokine profiles and distinct migratory and seeding capacities, but also retain a certain functional plasticity that allows them to modulate their proliferation, activity, and homing behaviour upon need. Thus, in healthy individuals, T cell immunomodulation fulfils the task of eliciting protective immune responses where they are needed. At times, however, Th plasticity can lead to collateral tissue damage and progression to autoimmune diseases or, conversely, incapacity to reject malignant tissues and clear chronic infections. Furthermore, common immune players and molecular pathways of diseases can lead to different outcomes in different individuals. A mechanistic understanding of those pathways is therefore crucial for developing precise and curative medical interventions. Here, I focus on the skin microenvironment and comprehensively describe some of the cellular and molecular determinants of CD4+ T cell memory responses in homeostatic and pathological conditions. In discussing the cellular network orchestrating cutaneous immunity, I comprehensively describe the bidirectional interaction of skin antigen-presenting cells and mononuclear phagocytes with Th17 lymphocytes, and examine how the outcome of this interaction is influenced by endogenous skin molecules, including sodium salts and neuropeptides</style></abstract><notes><style face="normal" font="default">DA - 20170808IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1159/000477728</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28787717">PM:28787717</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-121-37.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-121-37.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170808, Padovan E</style></custom2><misc3><style face="normal" font="default">10.1159/000477728</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42425</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lam,S.C.</style></author><author><style face="normal" font="default"> Yeung,C.C.Y.</style></author><author><style face="normal" font="default"> Chan,J.H.M.</style></author><author><style face="normal" font="default"> Lam,D.W.C.</style></author><author><style face="normal" font="default"> Lam,A.H.Y.</style></author><author><style face="normal" font="default"> Annesi-Maesano,I.</style></author><author><style face="normal" font="default"> Bousquet,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Nursing and Health Studies, School of Science and Technology, The Open University of Hong Kong, and School of Nursing, The University of Hong Kong, Hong Kong, SAR, China</style></auth-address><titles><title><style face="normal" font="default">Adaptation of the Score for Allergic Rhinitis in the Chinese Population: Psychometric Properties and Diagnostic Accuracy</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="224" start="213">213-224</pages><volume><style face="normal" font="default">173</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic rhinitis (AR) is a worldwide health problem with rising prevalence. To enhance the estimation of AR prevalence in epidemiological studies, the Score for AR (SFAR), a screening tool, has been developed and widely used. An 8-item SFAR is a handy, self-administered instrument assessing the information on nasal and eye symptoms, seasonal increase in symptoms, skin test results, and previous AR diagnoses. This study aimed to adapt the SFAR to the Chinese population (CSFAR) and validate it by testing its psychometric properties and diagnostic accuracy. METHODS: This methodological study involved translation and validation phases. Different batches of participants were recruited for the above purposes. RESULTS: In phase 1, the CSFAR obtained satisfactory item (80-100%) and scale level (97.8%) semantic equivalence, content validity index (96.7%), comprehensibility (100%), cross-language testing (kappa = 0.44-0.83 for item-to-item agreement; intraclass correlation coefficient [ICC] = 0.95, p &lt; 0.05-0.001). In phase 2, CSFAR showed satisfactory internal consistency (alpha = 0.83), 1-month (ICC = 0.88) and 1-year stability (ICC = 0.85), and construct validity (significant correlation between CSFAR and impairments induced by AR: r = 0.47, p &lt; 0.001). Based on the receiver-operating characteristic curve, comparing the CSFAR with diagnosis made by specialists, an optimal cutoff value was 6 (sensitivity 81.8% and specificity 80.3%). CONCLUSION: SFAR was translated into a Chinese version, the CSFAR. Satisfactory results were obtained for its equivalence, appropriateness, comprehensibility, and relevance, as well as its reliability and validity. A cutoff value of 6 was recommended to increase the diagnostic accuracy in environments with less pollen. This study provides evidence that the SFAR we adapted for the Chinese population is a valuable tool in AR screening</style></abstract><notes><style face="normal" font="default">DA - 20170829IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Hong Kong -CO - China -</style></notes><work-type><style face="normal" font="default">10.1159/000477727</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28850947">PM:28850947</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-213-24.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-213-24.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170829, Lam SC</style></custom2><misc3><style face="normal" font="default">10.1159/000477727</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42426</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Singh,U.</style></author><author><style face="normal" font="default"> Bernstein,J.A.</style></author><author><style face="normal" font="default"> Lorentz,H.</style></author><author><style face="normal" font="default"> Sadoway,T.</style></author><author><style face="normal" font="default"> Nelson,V.</style></author><author><style face="normal" font="default"> Patel,P.</style></author><author><style face="normal" font="default"> Salapatek,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Cincinnati Medical Center, Cincinnati, OH, USA</style></auth-address><titles><title><style face="normal" font="default">A Pilot Study Investigating Clinical Responses and Biological Pathways of Azelastine/Fluticasone in Nonallergic Vasomotor Rhinitis before and after Cold Dry Air Provocation</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="164" start="153">153-164</pages><volume><style face="normal" font="default">173</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">diagnosis</style></keyword></keywords><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Nonallergic vasomotor rhinitis (NAVMR) has been considered a diagnosis by exclusion due to unknown mechanisms or lack of diagnostic biomarkers. METHODS: To determine clinical responses and biological pathways in NAVMR subjects challenged to cold dry air (CDA) in an environmental exposure chamber (EEC) pre- and posttreatment with azelastine/fluticasone (AzeFlu), 30 NAVMR subjects, prescreened for CDA-induced symptoms (approx. 14 degrees C, &lt;15% relative humidity, x1 h) were randomized to treatment with AzeFlu (n = 20) or placebo (n = 10) for 2 weeks. Total nasal symptoms scores, minimum cross-sectional area, cough, and conjunctival redness were recorded at visit 1 (pretreatment) and visit 2 (posttreatment) before, during, and after CDA challenge. At both visits, nasal lavage fluid (NLF) and nasal scrapings (NS) were collected pre- and post-CDA challenge. Substance P, neurokinin-A, and calcitonin gene-related peptide concentrations in NLF were analyzed pre- and postchallenge at each visit. Their relationship with CDA-induced symptoms was determined by statistical analysis. MicroRNA sequencing from NS determined differentially expressed miRNA between the treatment groups post-CDA challenge at each visit. RESULTS: The minimum cross-sectional area (p &lt; 0.05), cough count (p &lt; 0.05), and substance P (p &lt; 0.01) improved posttreatment with AzeFlu versus placebo. Gene targets for differentially expressed miRNAs at visit 1 were enriched for biological pathways regulating epithelial ciliogenesis and cell integrity that were modified in the AzeFlu-treated group versus placebo posttreatment. CONCLUSIONS: This study demonstrated the feasibility of an EEC model to investigate CDA-induced clinical responses and pathobiology in NAVMR subjects pre- and posttreatment with AzeFlu. NAVMR disease mechanisms for other nonallergic triggers can be investigated similarly</style></abstract><notes><style face="normal" font="default">DA - 20170808IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1159/000478698</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28787742">PM:28787742</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-153-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-153-64.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170808, Singh U</style></custom2><misc3><style face="normal" font="default">10.1159/000478698</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42427</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schunter,J.A.</style></author><author><style face="normal" font="default"> Stocker,B.</style></author><author><style face="normal" font="default"> Brehler,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Hospital Munster, Munster, Germany</style></auth-address><titles><title><style face="normal" font="default">A Case of Severe Anaphylaxis to Polyhexanide: Cross-Reactivity between Biguanide Antiseptics</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="236" start="233">233-236</pages><volume><style face="normal" font="default">173</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="8" Year="2017">2017/8/29</year></dates><abstract><style face="normal" font="default">We present the case of a 77-year-old female patient who suffered from severe anaphylaxis during wound care. Allergologic evaluation yielded specific IgE antibodies to chlorhexidine, but anaphylaxis to chlorhexidine was not congruent with the patient history and dermal provocation tests. However, skin prick tests provided evidence for a sensitization to polyhexanide that was further supported by the detection of specific IgE antibodies to polyhexanide, the results of basophil activation tests and IgE inhibition analysis. We presume cross-reactive IgE antibodies binding to both biguanide antiseptics and identified polyhexanide as the likely cause of the anaphylactic reaction. We recognize polyhexanide as an emerging allergen that has to be considered as a cause of anaphylaxis</style></abstract><notes><style face="normal" font="default">DA - 20170829IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1159/000478700</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28848174">PM:28848174</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-233-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-233-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170829, Schunter JA</style></custom2><misc3><style face="normal" font="default">10.1159/000478700</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42428</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cardona,V.</style></author><author><style face="normal" font="default"> Ferre-Ybarz,L.</style></author><author><style face="normal" font="default"> Guilarte,M.</style></author><author><style face="normal" font="default"> Moreno-Perez,N.</style></author><author><style face="normal" font="default"> Gomez-Galan,C.</style></author><author><style face="normal" font="default"> Acoceba-Borras,E.</style></author><author><style face="normal" font="default"> Delavalle,M.B.</style></author><author><style face="normal" font="default"> Garriga-Baraut,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Section, Department of Internal Medicine, Hospital Universitari Vall d'Hebron, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default">Safety of Adrenaline Use in Anaphylaxis: A Multicentre Register</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="177" start="171">171-177</pages><volume><style face="normal" font="default">173</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse effects</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword></keywords><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: The use of intramuscular adrenaline to treat anaphylaxis is suboptimal, despite being the first-line treatment recommended by national and international anaphylaxis guidelines. Fear of potentially severe side effects may be one of the underlying factors. The aim of this study was to assess the incidence and severity of adverse side effects after the use of adrenaline in anaphylaxis, as well as potential risk factors. METHODS: Observational study based on a multicenter online registry of cases of adrenaline administration for suspected anaphylaxis. RESULTS: 277 registered valid cases were included: 138 (51.49%) female, median age 29 years (12-47), and 6 children under 2 years with a median age of 9 months (1-21). Side effects occurred in 58 cases (21.64%), with tremors, palpitations, and anxiety being the most frequent. There was a significant association of developing side effects with older age, higher dose of adrenaline, or use of the intravenous route. Potentially severe adverse effects (high blood pressure, chest discomfort, or ECG alterations) occurred only in 8 cases (2.99%); in these cases, no differences were found according to age or adrenaline dose, but again, intravenous administration was associated with more severe adverse events. CONCLUSION: This study shows that side effects affect less than 1 in 5 patients who receive adrenaline for an anaphylactic reaction, and are usually mild and transient. Therefore, in an emergency situation such as anaphylaxis, restricting adrenaline administration due to potential adverse effects would, in general, not be justified</style></abstract><notes><style face="normal" font="default">DA - 20170809IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1159/000477566</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28793302">PM:28793302</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-171-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-173-171-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170809, Cardona V</style></custom2><misc3><style face="normal" font="default">10.1159/000477566</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42429</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cheung,M.</style></author><author><style face="normal" font="default"> Seres,T.</style></author><author><style face="normal" font="default"> Cleveland,J.</style></author><author><style face="normal" font="default"> Kounis,N.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesiology, University of Colorado Denver, Colorado, USA.</style></auth-address><titles><title><style face="normal" font="default">Kounis syndrome, a coronary hypersensitivity disorder: A rare case of amiodarone-induced coronary vasospasm and simultaneous peripheral vasodilation intraoperatively</style></title><secondary-title><style face="normal" font="default">Int J Cardiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Cardiol</style></full-title></periodical><pages end="268" start="267">267-268</pages><volume><style face="normal" font="default">218</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse effects</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Amiodarone</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> chemically induced</style></keyword><keyword><style face="normal" font="default"> Coronary Vasospasm</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Intraoperative Complications</style></keyword><keyword><style face="normal" font="default"> Vasodilation</style></keyword></keywords><dates><year Day="1" Month="9" Year="2016">2016/9/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20160614IS - 1874-1754 (Electronic)IS - 0167-5273 (Linking)LA - engPT - Case ReportsPT - Journal ArticleRN - N3RQ532IUT (Amiodarone)SB - IMCO - United States -CO - Greece -</style></notes><work-type><style face="normal" font="default">10.1016/j.ijcard.2016.05.058</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27236126">PM:27236126</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Cardiol\20170614-CheungM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Cardiol\20170614-CheungM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160614, Cheung M</style></custom2><misc3><style face="normal" font="default">10.1016/j.ijcard.2016.05.058</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42430</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Koureas,M.</style></author><author><style face="normal" font="default"> Rachiotis,G.</style></author><author><style face="normal" font="default"> Tsakalof,A.</style></author><author><style face="normal" font="default"> Hadjichristodoulou,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, 22 Papakyriazi Street, 41222 Larissa, Greece.</style></auth-address><titles><title><style face="normal" font="default">Increased Frequency of Rheumatoid Arthritis and Allergic Rhinitis among Pesticide Sprayers and Associations with Pesticide Use</style></title><secondary-title><style face="normal" font="default">Int J Environ Res Public Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Environ Res Public Health</style></abbr-1></periodical><pages end="" start="E865">E865-</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="default">Objective: The aim of this study was to identify diseases linked with the pesticide sprayer occupation and explore possible associations with exposure history data. Methods: Alpha cross sectional study was conducted among pesticide sprayers (n = 80) and the general population (n = 90) in Thessaly (Greece). Medical history, demographic characteristics and detailed exposure history were recorded by conducting personal interviews. Lifetime exposure indicators were calculated for several pesticide chemical subclasses. Moreover, organophosphate metabolite levels were quantified in urine samples of all participants by using gas chromatography -mass spectrometry (GC-MS). Multinomial analysis was used to determine associations between occupational pesticide exposure and diseases or disorders. Results: In the pesticide sprayers group, significantly higher frequencies for rheumatoid arthritis (RA) and allergic rhinitis were observed compared with the control group (p = 0.002 and p = 0.024 respectively). Within the pesticide sprayers group, high lifetime pesticide exposure was associated with increased risk for reporting RA (OR: 43.07 95% CI: 3.09-600.67) and allergic rhinitis (OR: 9.72 95% CI: 2.31-40.89), compared with low pesticide exposure. Exposure to organophsphate, guanidine and quinone pesticides were associated with RA while organophosphates, pyrethroids and paraquat were associated with allergic rhinitis. Despite the higher levels of certain pesticide metabolites observed among participants with rheumatoid arthritis, the differences were not statistically significant. One metabolite (diethylthiophosphate) was found to be significantly increased in allergic rhinitis cases (p = 0.037). Conclusions: The results from the current study suggest a possible association of occupational pesticide exposure with RA and allergic rhinitis that should be further investigated</style></abstract><notes><style face="normal" font="default">DA - 20170801IS - 1660-4601 (Electronic)IS - 1660-4601 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="default">10.3390/ijerph14080865</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28763046">PM:28763046</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Environ Res Public Health\2017-14-E865.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Environ Res Public Health\2017-14-E865.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Koureas M</style></custom2><misc3><style face="normal" font="default">10.3390/ijerph14080865</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42431</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Choi,E.</style></author><author><style face="normal" font="default"> Kim,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesiology and Pain Medicine, College of Medicine, Yeungnam University, Daegu, Republic of KoreaDepartment of Anesthesiology and Pain Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Anaphylactic reaction following reversal of nondepolarizing muscle relaxant during general anesthesia: a case report</style></title><secondary-title><style face="normal" font="default">Int Med Case Rep J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Med Case Rep J</style></abbr-1></periodical><pages end="274" start="271">271-274</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">An anaphylactic reaction during general anesthesia may cause fatal complications. Perioperative anaphylaxis can occur in response to different medications. To our knowledge, pyridostigmine or combination of pyridostigmine with glycopyrrolate-induced anaphylactic reaction during general anesthesia has not been reported. We report a case of a suspected anaphylactic reaction to these drugs. To reduce the risk of complicated perioperative anaphylactic events, prompt assessment and treatment are needed. Moreover, any undesirable exposure to confirmed allergens should be avoided as part of secondary prevention</style></abstract><notes><style face="normal" font="default">DA - 20170829IS - 1179-142X (Print)IS - 1179-142X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.2147/IMCRJ.S142597</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28848366">PM:28848366</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Med Case Rep J\2017-10-271-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Med Case Rep J\2017-10-271-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170829, Choi E</style></custom2><misc3><style face="normal" font="default">10.2147/IMCRJ.S142597</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42432</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mubarak,B.</style></author><author><style face="normal" font="default"> Afzal,N.</style></author><author><style face="normal" font="default"> Javaid,K.</style></author><author><style face="normal" font="default"> Talib,R.</style></author><author><style face="normal" font="default"> Aslam,R.</style></author><author><style face="normal" font="default"> Latif,W.</style></author><author><style face="normal" font="default"> Khaliq,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Frequency of HLA DQ+¦1*0201 and DQ+¦1*0301 Alleles and Total Serum IgE in Patients with Bronchial Asthma: A Pilot Study from Pakistan</style></title><secondary-title><style face="normal" font="default">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Iran J Allergy Asthma Immunol</style></abbr-1></periodical><pages end="320" start="313">313-320</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Asthma,HLA-DQ+¦1,Immunoglobulin E,Human leukocyte antigen (HLA)</style></keyword></keywords><dates><year Day="12" Month="8" Year="2017">2017/8/12</year></dates><abstract><style face="normal" font="default">In Pakistan about 3.7% of the population is suffering from asthma, a chronic inflammatory disorder of airways. Asthma has wide spectrum of predisposing factors including environment and genetics. Many studies have been performed to determine association of asthma with serum IgE and major histocompatibility complex (MHC) alleles but conflicting results were reported. Therefore, present study was designed to determine frequency of HLA-DQ+¦1*0201 and DQ+¦1*0301 alleles in patients with bronchial asthma. This case control study included 85 asthmatic patients and 85 healthy controls. HLA-DQ+¦1*0201 and DQ+¦1*0301 alleles were detected by allele specific PCR and serum IgE was determined by ELISA. Median and inter-quartile range (IQR) of total IgE level were more increased in asthma patients (585.7 IU/mL and 247.2-848.1 IU/mL) compared to healthy controls (65.1 IU/mL and 28.1-181.3 IU/mL) ( p &amp;lt;0.001). Frequency of HLA-DQ+¦1*0201 and -DQ+¦1*0301 alleles was more in healthy controls (32% and 38%, p =0.616) as compared to bronchial asthma patients (28% and 26%, p = 0.09). There was a significant association of IgE levels and HLA-DQ+¦1*0201 allele. Patients positive for HLA-DQ+¦1*0201 allele had low level of serum IgE 357.2 IU/mL (153.9-634.3 IU/mL) compared to the patients negative for this HLA allele i.e. 642.9 IU/mL (289.8-1299.5IU/mL) ( p =0.005), whereas, HLA-DQ+¦1*0301 allele was not associated with total serum IgE level ( p =0.865). Our findings show that HLA-DQ+¦1*0201 and -DQ+¦1*0301 alleles were not associated with asthma; however, HLA-DQ+¦1*0201 allele was associated with low levels of total serum IgE in the study population</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Pakistan -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://ijaai.tums.ac.ir/index.php/ijaai/article/view/896</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2017-16-313-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2017-16-313-20.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170830, Mubarak B</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42433</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yang,H.</style></author><author><style face="normal" font="default"> Yang,M.</style></author><author><style face="normal" font="default"> Wang,Y.</style></author><author><style face="normal" font="default"> Huang,X.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association between Fc+ÁRIB Polymorphisms and Asthma in Asian Population: a Meta-analysis</style></title><secondary-title><style face="normal" font="default">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Iran J Allergy Asthma Immunol</style></abbr-1></periodical><pages end="369" start="367">367-369</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Asthma,Fc+ÁRIB,Meta-analysis,Polymorphism</style></keyword></keywords><dates><year Day="12" Month="8" Year="2017">2017/8/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://ijaai.tums.ac.ir/index.php/ijaai/article/view/1042</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2017-16-367-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2017-16-367-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170830, Yang H</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42434</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Berghi,N.O.</style></author></authors></contributors><titles><title><style face="normal" font="default">Immunological Mechanisms Implicated in the Pathogenesis of Chronic Urticaria and Hashimoto Thyroiditis</style></title><secondary-title><style face="normal" font="default">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Iran J Allergy Asthma Immunol</style></abbr-1></periodical><pages end="366" start="358">358-366</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">CD 4+CD25+Tcells,Chronic urticaria,Hashimoto thyroiditis,Interleukin 6</style></keyword></keywords><dates><year Day="12" Month="8" Year="2017">2017/8/12</year></dates><abstract><style face="normal" font="default">Autoimmunity represents the attack of the immune system of an organism against its own cells and tissues. Autoimmune diseases may affect one organ (Hashimoto thyroiditis) or can be systemic (chronic urticaria). Many factors are implicated in the pathogenesis of autoimmunity (white cells, cytokines, chemokines). Hashimoto thyroiditis has been associated with chronic urticaria in the last 3 decades in a number of clinical studies. Anti-thyroid antibodies have been documented in a proportion ranging from 10% to 30% in chronic urticaria patients in different countries from 3 continents. Two of the factors involved in the mechanism of autoimmunity are present both in the pathophysiology of Hashimoto thyroiditis and chronic urticaria. According to recent studies, IL6 is implicated in the pathogenesis of both diseases. TregsCD 4+ CD 25+ Foxp 3+ cells have also been implicated in the pathological mechanisms of these 2 entities. This review offers an explanation of the clinical and statistical association between these two diseases from the pathophysiological point of view</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Romania -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://ijaai.tums.ac.ir/index.php/ijaai/article/view/984</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2017-16-358-66.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default">20170830, Berghi NO</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42435</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sadri,M.</style></author><author><style face="normal" font="default"> Ganjalikhani-Hakemi,M.</style></author><author><style face="normal" font="default"> Akbari,P.</style></author><author><style face="normal" font="default"> Salehi,R.</style></author><author><style face="normal" font="default"> Rastaghi,S.</style></author><author><style face="normal" font="default"> Ghasemi,R.</style></author><author><style face="normal" font="default"> Meshkat,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association between +4259 T>G and -574 G>T Polymorphisms of TIM-3 with Asthma in an Iranian Population</style></title><secondary-title><style face="normal" font="default">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Iran J Allergy Asthma Immunol</style></abbr-1></periodical><pages end="328" start="321">321-328</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Asthma,Immunoglobulin E,Iranian population,Single nucleotide polymorphism,T cell immunoglobulin and mucin domain 3 (TIM-3)</style></keyword></keywords><dates><year Day="12" Month="8" Year="2017">2017/8/12</year></dates><abstract><style face="normal" font="default">T-cell immunoglobulin and mucin domain (TIM)-3 have been shown to negatively regulate Th1 cell-mediated immunity. Activation of TIM-3 by galectin-9 induces Th1 cell apoptosis, which may contribute to skewing of immune response towards Th2-dominant immunity. The aim of this study was to determine whether certain genetic variations of TIM-3 influence predisposition to asthma in a sample of Iranian population. This case-control study was conducted on 209 patients with asthma and 200 healthy controls. The +4259 T&amp;gt;G and -574 G&amp;gt;T polymorphisms were detected using polymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP) and amplification refractory mutation system-PCR(ARMS-PCR). Total serum IgE was further measured with ELISA. Notably, +4259T &amp;gt; G and-574G&amp;gt;T polymorphisms of TIM-3 were significantly associated with the susceptibility to asthma. In addition, the present study showed a significant difference between the distribution frequency of the GT + TT genotype and T allele on the +4259 T&amp;gt;G and -574 G&amp;gt;T locus between the groups.However, no correlation between the +4259 T &amp;gt; G and -574G &amp;gt; T polymorphisms and total serum IgE levels were observed. Together these results suggest that the TIM-3 +4259 T&amp;gt;G and -574 G&amp;gt;T polymorphisms are greatly associated with the susceptibility of Iranian population to asthma, which could open up new horizons for-á better understanding of the pathophysiology, diagnostic, prognostic and therapeutic approaches of asthma.-á</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Iran -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://ijaai.tums.ac.ir/index.php/ijaai/article/view/1026</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2017-16-321-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2017-16-321-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170830, Sadri M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42436</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chipps,B.E.</style></author><author><style face="normal" font="default"> Haselkorn,T.</style></author><author><style face="normal" font="default"> Paknis,B.</style></author><author><style face="normal" font="default"> Ortiz,B.</style></author><author><style face="normal" font="default"> Bleecker,E.R.</style></author><author><style face="normal" font="default"> Kianifard,F.</style></author><author><style face="normal" font="default"> Foreman,A.J.</style></author><author><style face="normal" font="default"> Szefler,S.J.</style></author><author><style face="normal" font="default"> Zeiger,R.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Capital Allergy and Respiratory Disease Center, Sacramento, California.</style></auth-address><titles><title><style face="normal" font="default">More Than a Decade Follow-up in Severe or Difficult-to-Treat Asthma: TENOR II</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="8" Year="2017">2017/8/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR I) study demonstrated high morbidity in patients with severe/difficult-to-treat asthma, despite standard-of-care treatment. OBJECTIVE: To determine the long-term natural history of disease and outcomes in patients in TENOR I, after more than a decade. METHODS: TENOR I was a multicenter, observational study (2001-2004) of 4756 patients with severe/difficult-to-treat asthma. TENOR II was a follow-up study of TENOR I patients using a single, cross-sectional visit in 2013/2014. Overall, the sites participating in TENOR II originally enrolled 1230 patients in TENOR I. Clinical and patient-reported outcomes were assessed, including very poorly controlled (VPC) asthma based on National Heart, Lung, and Blood Institute (NHLBI) guidelines. RESULTS: A total of 341 (27.7%) patients were enrolled in TENOR II and were representative of the TENOR I cohort. Most frequent comorbidities were rhinitis (84.0%), sinusitis (47.8%) and gastroesophageal reflux disease (46.3%). Mean (SD) percent predicted pre- and post-bronchodilator FEV1 were 72.7% (21.4%) and 78.2% (20.7%), respectively. A total of 231/317 (72.9%) tested positive for >/=1 allergen-specific IgE. Mean (SD) blood eosinophil count was 200 muL (144). Eighty-eight (25.8%) patients experienced an asthma exacerbation in the prior 3 months requiring hospital attention and/or oral corticosteroids. Over half (197/339; 58.1%) had VPC asthma. Medication use suggested undertreatment. CONCLUSION: TENOR II provides longitudinal data to characterize disease progression, heterogeneity and severity in severe/difficult-to-treat asthma. Findings show continued morbidity, including a high degree of comorbid conditions, allergic sensitization, exacerbations and VPC asthma, including reduced lung function</style></abstract><notes><style face="normal" font="default">DA - 20170811IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.07.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28797732">PM:28797732</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170811-ChippsBE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170811-ChippsBE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170811, Chipps BE</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.07.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42437</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Seo,S.H.</style></author><author><style face="normal" font="default"> Jang,M.S.</style></author><author><style face="normal" font="default"> Kim,D.J.</style></author><author><style face="normal" font="default"> Kim,S.M.</style></author><author><style face="normal" font="default"> Oh,S.C.</style></author><author><style face="normal" font="default"> Jung,C.R.</style></author><author><style face="normal" font="default"> Park,Y.</style></author><author><style face="normal" font="default"> Ha,S.J.</style></author><author><style face="normal" font="default"> Jung,H.</style></author><author><style face="normal" font="default"> Park,Y.J.</style></author><author><style face="normal" font="default"> Yoon,S.R.</style></author><author><style face="normal" font="default"> Choi,I.</style></author><author><style face="normal" font="default"> Kim,T.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunotherapy Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Korea</style></auth-address><titles><title><style face="normal" font="default">MicroRNA-150 controls differentiation of intraepithelial lymphocytes via TGF-beta receptor II regulation</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Mice</style></keyword></keywords><dates><year Day="7" Month="8" Year="2017">2017/8/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Intraepithelial lymphocytes (IELs) in the intestines play pivotal roles in maintaining the integrity of the mucosa, regulating the immune cells, and protecting against pathogenic invasion. Although several extrinsic factors such as transforming growth factor-beta (TGF-beta) have been identified to contribute to IEL generation, intrinsic regulatory factors have not been fully determined. OBJECTIVE: Here, we investigated the regulation of IEL differentiation and the underlying mechanisms in mice. METHODS: We analyzed IELs and the expression of molecules associated with IEL differentiation in wildtype control and microRNA-150-knockout mice. Methotrexate (MTX) was administered to mice lacking microRNA (miR)-150 and control mice. RESULTS: miR-150 deficiency reduced the IEL population in the small intestine and increased susceptibility to MTX-induced mucositis. Evaluation of expression of IEL differentiation-associated molecules showed that miR-150-deficient IELs exhibited decreased expression of TGF-beta receptor II (TGF-betaRII), CD103, CD8alphaalpha, and RUNX3 in all the IEL subpopulations. The reduced expression of TGF-betaRII in miR-150-deficient IELs was caused by the increased expression of c-Myb/miR-20a. Restoration of miR-150 or inhibition of miR-20a recovered the TGF-betaRII expression. CONCLUSION: miR-150 is an intrinsic regulator of IEL differentiation through TGF-betaRII regulation. miR-150-mediated IEL generation is crucial for maintaining intestinal integrity against anticancer drug-induced mucositis</style></abstract><notes><style face="normal" font="default">DA - 20170811IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.07.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28797734">PM:28797734</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170811-SeoSH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170811-SeoSH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170811, Seo SH</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.07.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42438</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bjorkman,A.</style></author><author><style face="normal" font="default"> Du,L.</style></author><author><style face="normal" font="default"> van der Burg,M.</style></author><author><style face="normal" font="default"> Cormier-Daire,V.</style></author><author><style face="normal" font="default"> Borck,G.</style></author><author><style face="normal" font="default"> Pie,J.</style></author><author><style face="normal" font="default"> Anderlid,B.M.</style></author><author><style face="normal" font="default"> Hammarstrom,L.</style></author><author><style face="normal" font="default"> Strom,L.</style></author><author><style face="normal" font="default"> Villartay,J.P.</style></author><author><style face="normal" font="default"> Kipling,D.</style></author><author><style face="normal" font="default"> Walters,D.D.</style></author><author><style face="normal" font="default"> Pan-Hammarstrom,Q.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Laboratory Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default">Reduced immunoglobulin gene diversity in patients with Cornelia de Lange syndrome</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword></keywords><dates><year Day="4" Month="8" Year="2017">2017/8/4</year></dates><abstract><style face="normal" font="default">Altered IGH repertoires with reduced diversity, skewed VH gene usage and reduced frequency of somatic hypermutation were observed in CdLS patients</style></abstract><notes><style face="normal" font="default">DA - 20170822IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - France -CO - Germany -CO - Spain -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28826797">PM:28826797</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170822-BjorkmanA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170822-BjorkmanA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170822, Bjorkman A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.043</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42439</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,A.</style></author><author><style face="normal" font="default"> Leon Hsu,H.H.</style></author><author><style face="normal" font="default"> Mathilda Chiu,Y.H.</style></author><author><style face="normal" font="default"> Bose,S.</style></author><author><style face="normal" font="default"> Rosa,M.J.</style></author><author><style face="normal" font="default"> Kloog,I.</style></author><author><style face="normal" font="default"> Wilson,A.</style></author><author><style face="normal" font="default"> Schwartz,J.</style></author><author><style face="normal" font="default"> Cohen,S.</style></author><author><style face="normal" font="default"> Coull,B.A.</style></author><author><style face="normal" font="default"> Wright,R.O.</style></author><author><style face="normal" font="default"> Wright,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA</style></auth-address><titles><title><style face="normal" font="default">Prenatal fine particulate exposure and early childhood asthma: effect of maternal stress and fetal gender</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="8" Year="2017">2017/8/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: The impact of prenatal ambient air pollution on child asthma may be modified by maternal stress, child sex and exposure dose and timing. OBJECTIVE: We prospectively examined associations between co-exposure to prenatal particulate matter with an aerodynamic diameter of less than 2.5 microns (PM2.5) and maternal stress on childhood asthma (n=736). METHODS: Daily PM2.5 exposure during pregnancy was estimated using a validated satellite-based spatio-temporally resolved prediction model. Prenatal maternal negative life events (NLEs) were dichotomized around the median (high: NLE>/=3; low: NLE&lt;3). We employed Bayesian distributed lag interaction models (BDLIMs) to identify sensitive windows for prenatal PM2.5 exposure on children's asthma by age 6, and determine effect modification by maternal stress and child sex. RESULTS: BDLIMs identified a critical window of exposure (19-23 weeks gestation, cumulative OR=1.15, 95%CI=1.03-1.26; per IQR (1.7 mug/m3) increase in prenatal PM2.5 level) during which children concomitantly exposed to prenatal PM2.5 and maternal stress had increased risk of asthma. No significant association was seen in children born to women reporting low prenatal stress. When examining modifying effects of prenatal stress and fetal sex, we found that boys born to mothers with higher prenatal stress were most vulnerable (19-21 weeks gestation, cumulative OR=1.28, 95%CI=1.15-1.41; per IQR increase in PM2.5). CONCLUSION: Prenatal PM2.5 exposure during sensitive windows is associated with increased risk of child asthma, especially in boys concurrently exposed to elevated maternal stress</style></abstract><notes><style face="normal" font="default">DA - 20170812IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.07.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28801196">PM:28801196</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170812-LeeA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170812-LeeA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170812, Lee A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.07.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42440</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Essaidi-Laziosi,M.</style></author><author><style face="normal" font="default"> Brito,F.</style></author><author><style face="normal" font="default"> Benaoudia,S.</style></author><author><style face="normal" font="default"> Royston,L.</style></author><author><style face="normal" font="default"> Cagno,V.</style></author><author><style face="normal" font="default"> Fernandes-Rocha,M.</style></author><author><style face="normal" font="default"> Piuz,I.</style></author><author><style face="normal" font="default"> Zdobnov,E.</style></author><author><style face="normal" font="default"> Huang,S.</style></author><author><style face="normal" font="default"> Constant,S.</style></author><author><style face="normal" font="default"> Boldi,M.O.</style></author><author><style face="normal" font="default"> Kaiser,L.</style></author><author><style face="normal" font="default"> Tapparel,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Microbiology and Molecular Medicine, University of Geneva Medical School, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Propagation of respiratory viruses in human airway epithelia reveals persistent virus-specific signatures</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">etiology</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword></keywords><dates><year Day="7" Month="8" Year="2017">2017/8/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Leading etiologies of acute illnesses, respiratory viruses typically cause self-limited diseases, though severe complications can occur in fragile patients. Rhinoviruses, respiratory enteroviruses, influenza virus, respiratory syncytial viruses and coronaviruses are highly prevalent respiratory pathogens, but due to the lack of reliable animal models, their differential pathogenesis remains poorly characterized. OBJECTIVE: To compare infections by respiratory viruses isolated from clinical specimens using reconstituted human airway epithelia. METHODS: Tissues were infected with rhinoviruses RV-A55, RV-A49, RV-B48, RV-C8 and RV-C15, respiratory enterovirus EV-D68, influenza virus H3N2, respiratory syncytial virus RSV-B and coronavirus HCoV-OC43. Replication kinetics, cell tropism, impact on tissue integrity and cytokine secretion were compared. Virus adaptation and tissue response were assessed through RNA-sequencing. RESULTS: Rhinoviruses, RSV-B and HCoV-OC43 infected ciliated cells and caused no major cell death while H3N2 and EV-D68 induced ciliated cell loss and tissue integrity disruption. H3N2 was also detected in rare goblet and basal cells. All viruses except RV-B48 and HCoV-OC43 altered cilia beating and MCC. H3N2 was the strongest cytokine-inducer and HCoV-OC43 the weakest. Persistent infection was observed in all cases. RNA-sequencing highlighted perturbation of tissue metabolism and induction of a transient but important immune response at 4-days post-infection. No majority mutations emerged in the viral population. CONCLUSION: Our results highlight the differential in vitro pathogenesis of respiratory viruses during the acute infection-phase and their ability to persist under immune tolerance. These data help to appreciate the range of disease severity observed in vivo and the occurrence of chronic respiratory infections in immunocompromised hosts</style></abstract><notes><style face="normal" font="default">DA - 20170811IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.07.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28797733">PM:28797733</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170811-EssaidiLaziosiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170811-EssaidiLaziosiM.pdf</url></text-urls><related-urls><url ppv-ref="no">.xlsx in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20170811, Essaidi-Laziosi M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.07.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42441</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pandey,R.</style></author><author><style face="normal" font="default"> Kapur,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202, USA</style></auth-address><titles><title><style face="normal" font="default">Kinase inhibitors in clinical practice: An expanding world</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword></keywords><dates><year Day="8" Month="8" Year="2017">2017/8/8</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170812IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United states -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.07.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28801197">PM:28801197</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170812-PandeyR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170812-PandeyR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170812, Pandey R</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.07.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42442</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cuervo-Pardo,N.</style></author><author><style face="normal" font="default"> Gonzalez-Estrada,A.</style></author><author><style face="normal" font="default"> Cuervo-Pardo,L.</style></author><author><style face="normal" font="default"> Reddy,K.</style></author><author><style face="normal" font="default"> Gonzalez-Estrada,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universidad del Valle, Cali, Colombia</style></auth-address><titles><title><style face="normal" font="default">Bullous Fixed Drug Eruption Secondary to Chlorthalidone</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword></keywords><dates><year Day="12" Month="8" Year="2017">2017/8/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170816IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Colombia -CO - Spain -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28811176">PM:28811176</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170816, Cuervo-Pardo N</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.037</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42443</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sheen,Y.H.</style></author><author><style face="normal" font="default"> Rolfes,M.C.</style></author><author><style face="normal" font="default"> Wi,C.I.</style></author><author><style face="normal" font="default"> Crowson,C.S.</style></author><author><style face="normal" font="default"> Pendegraft,R.S.</style></author><author><style face="normal" font="default"> King,K.S.</style></author><author><style face="normal" font="default"> Ryu,E.</style></author><author><style face="normal" font="default"> Juhn,Y.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minn</style></auth-address><titles><title><style face="normal" font="default">Association of Asthma with Rheumatoid Arthritis: A Population-Based Case-Control Study</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Female</style></keyword></keywords><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: TH1 and TH2 cells have counterregulatory relationships. However, the relationship between asthma, a TH2-predominant condition, and risk of systemic inflammatory diseases such as rheumatoid arthritis (RA), a TH1 condition, is poorly understood. OBJECTIVE: We aimed to determine whether asthma was associated with increased risks of incident RA among adults. METHODS: We conducted a retrospective population-based case-control study that examined existing incident RA cases and controls matched by age, sex, and registration year from the general population in Olmsted County, Minnesota, between January 2002 and December 2007. We performed comprehensive medical record reviews to ascertain asthma status using predetermined asthma criteria. The frequency of a history of asthma before the index date was compared between cases and controls. Logistic regression models were used to adjust for confounding factors. RESULTS: We enrolled 221 RA cases and 218 controls. Of the 221 RA cases, 156 (70.6%) were females, 207 (93.7%) were white, the median age at the index date was 52.5 years, and 53 (24.0%) had a history of asthma. Controls had similar characteristics except that 35 of 218 controls (16.1%) had a history of asthma. After adjustment for sex, age, smoking, body mass index, socioeconomic status, and comorbidity, asthma was significantly associated with increased risks of RA (adjusted odds ratio, 1.74; 95% CI, 1.05-2.90; P = .03). CONCLUSIONS: Despite the counterregulatory relationship between TH1 and TH2 cells, patients with asthma had a significantly higher risk of developing RA than healthy individuals</style></abstract><notes><style face="normal" font="default">DA - 20170813IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28803184">PM:28803184</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170813, Sheen YH</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.022</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42444</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Matsusaka,M.</style></author><author><style face="normal" font="default"> Fukunaga,K.</style></author><author><style face="normal" font="default"> Kabata,H.</style></author><author><style face="normal" font="default"> Izuhara,K.</style></author><author><style face="normal" font="default"> Asano,K.</style></author><author><style face="normal" font="default"> Betsuyaku,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">Subphenotypes of type 2 severe asthma in adults</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170813IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28803182">PM:28803182</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170813, Matsusaka M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42445</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Li,P.H.</style></author><author><style face="normal" font="default"> Wagner,A.</style></author><author><style face="normal" font="default"> York,M.</style></author><author><style face="normal" font="default"> Rutkowski,R.</style></author><author><style face="normal" font="default"> Haque,R.</style></author><author><style face="normal" font="default"> Rutkowski,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Blue dye allergy: Pitfalls in diagnosis and how to avoid them</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">diagnosis</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword></keywords><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170813IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Hong Kong -CO - United Kingdom -CO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28803181">PM:28803181</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170813, Li PH</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42446</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dorman,S.M.</style></author><author><style face="normal" font="default"> Seth,S.</style></author><author><style face="normal" font="default"> Khan,D.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Family Allergy &amp; Asthma Consultants, Jacksonville, Fla</style></auth-address><titles><title><style face="normal" font="default">Risk of Allergic Reactions to Recurrent Intravenous Penicillin Administration in Penicillin Skin Test Negative Patients</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword></keywords><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patients with a history of penicillin allergy who are found to be skin test negative to penicillin are able to tolerate repeated oral doses of penicillin with low rates of resensitization. However, the resensitization rate after repeated doses of intravenous penicillin is less clear. OBJECTIVE: We sought to evaluate the risk of allergic reactions to repeated doses of intravenous penicillin in patients who previously reported penicillin allergy and were found to be penicillin skin test and oral challenge negative. METHODS: A retrospective review was conducted between 2010 and 2016 of adult patients who were treated at our academically affiliated hospitals. Patients included in the review had negative penicillin allergy testing and were treated with 2 or more courses of intravenous penicillins. Charts were evaluated to identify any adverse drug reactions. RESULTS: Thirty-two patients met our inclusion criteria. The index penicillin-associated reactions ranged from rash to hypotension and were, for the most part, remote as 75% had reported reactions more than 10 years previously. More than 50% of patients received 3 or more courses of intravenous penicillins. The most frequently repeated intravenous penicillin overall was piperacillin/tazobactam. Thirty-two patients received a total of 111 courses of intravenous penicillins and none developed an immediate hypersensitivity reaction. CONCLUSIONS: In patients who report penicillin allergy and have negative penicillin allergy testing, repeated administration of intravenous penicillin antibiotics appears to be safe. Larger prospective studies should be performed to confirm these observations</style></abstract><notes><style face="normal" font="default">DA - 20170813IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28803185">PM:28803185</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170813, Dorman SM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42447</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shams,M.R.</style></author><author><style face="normal" font="default"> Bruce,A.C.</style></author><author><style face="normal" font="default"> Fitzpatrick,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Emory University Department of Pediatrics, Atlanta, Ga</style></auth-address><titles><title><style face="normal" font="default">Anxiety Contributes to Poorer Asthma Outcomes in Inner-City Black Adolescents</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: The factors associated with poor asthma control, exacerbations, and health care utilization in black adolescents are complex and not well understood. Although psychological comorbidities such as anxiety are common in patients with asthma, these have not been studied in this population. OBJECTIVE: This study characterized anxiety and associated asthma features in a cohort of black inner-city adolescents with persistent asthma and determined the association between anxiety symptoms, persistent uncontrolled asthma, and prospective health care utilization over 1 year. METHODS: Eighty-six black adolescents were enrolled, phenotyped, and screened for anxiety symptoms with the Hospital Anxiety and Depression Scale anxiety subscale (HADS-A). Participants were telephoned every 2 months and a second study visit was completed at 1 year. Primary outcomes included persistent uncontrolled asthma, asthma exacerbations requiring systemic corticosteroids, and unscheduled health care utilization during the 1-year study period. RESULTS: A total of 31% (n = 27) of adolescents had probable anxiety (ie, HADS-A score >7) and 27% (n = 23) had possible anxiety (ie, HADS-A score 5-7) at the baseline visit. Anxiety symptoms were associated with poorer asthma control, more impaired quality of life, and more insomnia symptoms. Adolescents with probable anxiety disorders also had increased odds of persistent uncontrolled asthma and emergency department utilization, with no differences in physician visits or systemic corticosteroid receipt. CONCLUSIONS: Inner-city black adolescents with persistent asthma have a high prevalence of anxiety symptoms associated with poorer asthma control, impaired quality of life, insomnia, and increased prospective emergency department utilization for asthma. Routine screening for anxiety disorders may be useful in the clinical management of adolescents with asthma</style></abstract><notes><style face="normal" font="default">DA - 20170813IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28803180">PM:28803180</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170813, Shams MR</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.034</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42448</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chipps,B.E.</style></author><author><style face="normal" font="default"> Haselkorn,T.</style></author><author><style face="normal" font="default"> Rosen,K.</style></author><author><style face="normal" font="default"> Mink,D.R.</style></author><author><style face="normal" font="default"> Trzaskoma,B.L.</style></author><author><style face="normal" font="default"> Luskin,A.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Capital Allergy and Respiratory Disease Center, Sacramento, Calif.</style></auth-address><titles><title><style face="normal" font="default">Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Data examining associations between asthma exacerbations, triggers, and asthma-related quality of life (QOL) in children with severe/difficult-to-treat asthma are unavailable. OBJECTIVE: To evaluate real-world data on relationships between asthma exacerbations, triggers, and QOL in children using data from TENOR (The Epidemiology and Natural History of Asthma Outcomes and Treatment Regimens), a 3-year observational study of patients with severe/difficult-to-treat asthma, including those aged 6 to 12 years. METHODS: QOL was examined using the Pediatric Asthma Quality of Life Questionnaire (PAQLQ) and defined exacerbations hierarchically (descending order of severity): hospitalization, emergency department visit, steroid burst, no exacerbation, using the highest value from months 6 and 12. One-way ANOVA was used to test for differences in PAQLQ domain scores at month 12 across exacerbation severity, total number of asthma exacerbations, and number of baseline asthma triggers. Mantel-Haenszel chi-square test was used to test the association between the number of triggers and exacerbation hierarchy. RESULTS: Greater severity of asthma exacerbations was associated with significantly (P &lt; .001) lower mean PAQLQ domain scores, indicating poorer QOL. A higher number of asthma exacerbations was associated with significantly (P &lt; .001) lower mean PAQLQ domain scores. PAQLQ scores were significantly lower with higher numbers of baseline triggers. Higher baseline number of asthma triggers was associated with greater severity (P = .05) and number of asthma exacerbations (P &lt; .001). CONCLUSIONS: A higher number of asthma triggers at baseline was associated with greater asthma severity and number of asthma exacerbations and lower QOL in children with severe/difficult-to-treat asthma</style></abstract><notes><style face="normal" font="default">DA - 20170813IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.05.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28803186">PM:28803186</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170813-ChippsBE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170813-ChippsBE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170813, Chipps BE</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.05.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42449</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Luo,J.</style></author><author><style face="normal" font="default"> Feng,J.</style></author><author><style face="normal" font="default"> Yu,G.</style></author><author><style face="normal" font="default"> Yang,P.</style></author><author><style face="normal" font="default"> Mack,M.R.</style></author><author><style face="normal" font="default"> Du,J.</style></author><author><style face="normal" font="default"> Yu,W.</style></author><author><style face="normal" font="default"> Qian,A.</style></author><author><style face="normal" font="default"> Zhang,Y.</style></author><author><style face="normal" font="default"> Liu,S.</style></author><author><style face="normal" font="default"> Yin,S.</style></author><author><style face="normal" font="default"> Xu,A.</style></author><author><style face="normal" font="default"> Cheng,J.</style></author><author><style face="normal" font="default"> Liu,Q.</style></author><author><style face="normal" font="default"> O'Neil,R.G.</style></author><author><style face="normal" font="default"> Xia,Y.</style></author><author><style face="normal" font="default"> Ma,L.</style></author><author><style face="normal" font="default"> Carlton,S.M.</style></author><author><style face="normal" font="default"> Kim,B.S.</style></author><author><style face="normal" font="default"> Renner,K.</style></author><author><style face="normal" font="default"> Liu,Q.</style></author><author><style face="normal" font="default"> Hu,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for the Study of Itch, Department of Anesthesiology, Washington University School of Medicine, St Louis, Mo</style></auth-address><titles><title><style face="normal" font="default">Transient receptor potential vanilloid 4-expressing macrophages and keratinocytes contribute differentially to allergic and nonallergic chronic itch</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Mice</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword></keywords><dates><year Day="5" Month="8" Year="2017">2017/8/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic itch is a highly debilitating symptom that underlies many medical disorders with no universally effective treatments. Although unique neuronal signaling cascades in the sensory ganglia and spinal cord have been shown to critically promote the pathogenesis of chronic itch, the role of skin-associated cells remains poorly understood. OBJECTIVE: We sought to examine the cutaneous mechanisms underlying transient receptor potential vanilloid 4 (TRPV4)-mediated allergic and nonallergic chronic itch. METHODS: Expression of TRPV4 in chronic itch and healthy control skin preparations was examined by using real-time RT-PCR. Trpv4eGFP mice were used to study the expression and function of TRPV4 in the skin by means of immunofluorescence staining, flow cytometry, calcium imaging, and patch-clamp recordings. Genetic and pharmacologic approaches were used to examine the role and underlying mechanisms of TRPV4 in mouse models of dry skin-associated chronic itch and spontaneous scratching associated with squaric acid dibutylester-induced allergic contact dermatitis. RESULTS: TRPV4 is selectively expressed by dermal macrophages and epidermal keratinocytes in mice. Lineage-specific deletion of TRPV4 in macrophages and keratinocytes reduces allergic and nonallergic chronic itch in mice, respectively. Importantly, TRPV4 expression is significantly increased in skin biopsy specimens from patients with chronic idiopathic pruritus in comparison with skin from healthy control subjects. Moreover, TRPV4-dependent chronic itch requires 5-hydroxytryptamine (5-HT) signaling secondary to activation of distinct 5-HT receptors in both patients with allergic and those with nonallergic chronic itch conditions. CONCLUSION: Our study reveals previously unrecognized mechanisms by which TRPV4-expressing epithelial and immune cells in the skin critically and dynamically mediate chronic itch and unravels novel targets for therapeutics in the setting of chronic itch</style></abstract><notes><style face="normal" font="default">DA - 20170815IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.05.051</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28807414">PM:28807414</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170815-LuoJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170815-LuoJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170815, Luo J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.05.051</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42450</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Thijs,J.L.</style></author><author><style face="normal" font="default"> Drylewicz,J.</style></author><author><style face="normal" font="default"> Fiechter,R.</style></author><author><style face="normal" font="default"> Strickland,I.</style></author><author><style face="normal" font="default"> Sleeman,M.A.</style></author><author><style face="normal" font="default"> Herath,A.</style></author><author><style face="normal" font="default"> May,R.D.</style></author><author><style face="normal" font="default"> Bruijnzeel-Koomen,C.A.F.M.</style></author><author><style face="normal" font="default"> Knol,E.F.</style></author><author><style face="normal" font="default"> Giovannone,B.</style></author><author><style face="normal" font="default"> de Bruin-Weller,M.S.</style></author><author><style face="normal" font="default"> Nierkens,S.</style></author><author><style face="normal" font="default"> Hijnen,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergology, University Medical Center Utrecht, The Netherlands; Laboratory of Translational Immunology, Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">EASI p-EASI: Utilising a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword></keywords><dates><year Day="16" Month="8" Year="2017">2017/8/16</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170821IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28823810">PM:28823810</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170821-ThijsJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170821-ThijsJL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170821, Thijs JL</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.046</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42451</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shefler,I.</style></author><author><style face="normal" font="default"> Salamon,P.</style></author><author><style face="normal" font="default"> Levi-Schaffer,F.</style></author><author><style face="normal" font="default"> Mor,A.</style></author><author><style face="normal" font="default"> Hershko,A.Y.</style></author><author><style face="normal" font="default"> Mekori,Y.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Herbert Mast Cell Disorders Center, Laboratory of Allergy and Clinical Immunology, Meir Medical Center, Kfar Saba, Israel</style></auth-address><titles><title><style face="normal" font="default">miR-4443 Regulates Mast Cell Activation By T Cell - Derived Microvesicles</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword></keywords><dates><year Day="16" Month="8" Year="2017">2017/8/16</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170821IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Israel -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28823811">PM:28823811</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170821-SheflerI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170821-SheflerI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170821, Shefler I</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.045</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42452</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Prencipe,G.</style></author><author><style face="normal" font="default"> Caiello,I.</style></author><author><style face="normal" font="default"> Pascarella,A.</style></author><author><style face="normal" font="default"> Grom,A.A.</style></author><author><style face="normal" font="default"> Bracaglia,C.</style></author><author><style face="normal" font="default"> Chatel,L.</style></author><author><style face="normal" font="default"> Ferlin,W.G.</style></author><author><style face="normal" font="default"> Marasco,E.</style></author><author><style face="normal" font="default"> Strippoli,R.</style></author><author><style face="normal" font="default"> de Min,C.</style></author><author><style face="normal" font="default"> De Benedetti,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Bambino Gesu Children's Hospital IRCCS, Rome, Italy</style></auth-address><titles><title><style face="normal" font="default">Neutralization of interferon-gamma reverts clinical and laboratory features in a mouse model of macrophage activation syndrome</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Mice</style></keyword></keywords><dates><year Day="11" Month="8" Year="2017">2017/8/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: The pathogenesis of macrophage activation syndrome (MAS) is not clearly understood: a large body of evidence supports the involvement of mechanisms similar to those implicated in primary hemophagocytic lymphohistiocytosis. OBJECTIVE: To investigate the pathogenic role of interferon-gamma (IFNgamma) and the therapeutic efficacy of IFNgamma neutralization in an animal model of macrophage activation syndrome. METHODS: We used a MAS model established in mice transgenic for human interleukin-6 (IL-6TG) challenged with LPS (MAS mice). Levels of IFNgamma and IFNgamma-inducible chemokines were evaluated by real-time PCR in liver and spleen and by ELISA in plasma. IFNgamma neutralization was achieved using the anti-IFNgamma antibody XMG1.2 in vivo. RESULTS: MAS mice showed a significant upregulation of the IFNgamma pathway, as demonstrated by increased mRNA levels of Ifngamma and by higher levels of phospho-STAT1 in liver and spleen and by increased expression of IFNgamma-inducible chemokines Cxcl9 and Cxcl10 in liver and spleen as well as in plasma. A marked increase in Il-12a and Il-12b expression was also found in liver and spleen from MAS mice. In addition, MAS mice showed a significant increase in liver CD68 positive macrophages. MAS mice treated with an anti-IFNgamma antibody showed a significant improvement in survival and in body weight recovery, associated to a significant amelioration of ferritin, fibrinogen and alanine aminotransferase levels. In MAS mice, treatment with the anti-IFNgamma antibody significantly decreased circulating levels of CXCL9, CXCL10 and downstream proinflammatory cytokines. The decrease in CXCL9 and CXCL10 levels paralleled the decrease in the serum levels of proinflammatory cytokines and ferritin. CONCLUSION: These results provide evidence for a pathogenic role of IFNgamma in MAS</style></abstract><notes><style face="normal" font="default">DA - 20170815IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.07.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28807602">PM:28807602</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170815-PrencipeG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170815-PrencipeG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170815, Prencipe G</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.07.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42453</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Holland,T.</style></author><author><style face="normal" font="default"> Wohlleber,D.</style></author><author><style face="normal" font="default"> Marx,S.</style></author><author><style face="normal" font="default"> Kreutzberg,T.</style></author><author><style face="normal" font="default"> Vento-Asturias,S.</style></author><author><style face="normal" font="default"> Schmitt-Mbamunyo,C.</style></author><author><style face="normal" font="default"> Welz,M.</style></author><author><style face="normal" font="default"> Janas,M.</style></author><author><style face="normal" font="default"> Komander,K.</style></author><author><style face="normal" font="default"> Eickhoff,S.</style></author><author><style face="normal" font="default"> Brewitz,A.</style></author><author><style face="normal" font="default"> Hasenberg,M.</style></author><author><style face="normal" font="default"> Mann,L.</style></author><author><style face="normal" font="default"> Gunzer,M.</style></author><author><style face="normal" font="default"> Wilhelm,C.</style></author><author><style face="normal" font="default"> Kastenmuller,W.</style></author><author><style face="normal" font="default"> Knolle,P.</style></author><author><style face="normal" font="default"> Abdullah,Z.</style></author><author><style face="normal" font="default"> Kurts,C.</style></author><author><style face="normal" font="default"> Garbi,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Experimental Immunology, University of Bonn, Germany</style></auth-address><titles><title><style face="normal" font="default">Rescue of T-cell function during persistent pulmonary adenoviral infection by TLR9 activation</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword></keywords><dates><year Day="18" Month="8" Year="2017">2017/8/18</year></dates><abstract><style face="normal" font="default">Pulmonary persistent adenoviral infections induce an immunosuppressive environment in the lung that renders CD8 T-cells dysfunctional. Innate cell activation during persistent infection re-invigorates effector T cell function leading to viral clearance and immune homeostasis</style></abstract><notes><style face="normal" font="default">DA - 20170822IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.048</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28826775">PM:28826775</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170822-HollandT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170822-HollandT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170822, Holland T</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.048</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42454</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dadi,H.</style></author><author><style face="normal" font="default"> Jones,T.A.</style></author><author><style face="normal" font="default"> Merico,D.</style></author><author><style face="normal" font="default"> Sharfe,N.</style></author><author><style face="normal" font="default"> Ovadia,A.</style></author><author><style face="normal" font="default"> Schejter,Y.</style></author><author><style face="normal" font="default"> Reid,B.</style></author><author><style face="normal" font="default"> Sun,M.</style></author><author><style face="normal" font="default"> Vong,L.</style></author><author><style face="normal" font="default"> Atkinson,A.</style></author><author><style face="normal" font="default"> Lavi,S.</style></author><author><style face="normal" font="default"> Pomerantz,J.L.</style></author><author><style face="normal" font="default"> Roifman,C.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunology and Allergy, Department of Pediatrics, The Hospital for Sick Children and the University of Toronto, Toronto, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="default">Combined immunodeficiency and atopy caused by a dominant negative mutation in CARD11</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">diagnosis</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword></keywords><dates><year Day="18" Month="8" Year="2017">2017/8/18</year></dates><abstract><style face="normal" font="default">BACKGROUND: Combined immunodeficiency is a T cell defect frequently presenting with recurrent infections as well as associated immune dysregulation manifesting as autoimmunity or allergic inflammation. OBJECTIVE: We sought to identify the genetic aberration in four related patients with combined immunodeficiency, early onset asthma, eczema and food allergies, as well as autoimmunity. METHODS: Whole exome sequencing (WES) followed by Sanger confirmation, assessment of the genetic variant impact on cell signaling and evaluation of the resultant immune function. RESULTS: A heterozygous novel c.C88T one base pair substitution resulting in the amino acid change R30W in CARD11 was identified by WES and segregated perfectly to family members with severe atopy only, but was not found in healthy individuals. We demonstrate that the R30W mutation results in a loss of function while also exerting a dominant negative effect on wild-type CARD11. The CARD11 defect altered the classical Nuclear Factor-kappaB (NF-kappaB) pathway, resulting in poor in vitro T cell responses to mitogens and antigens caused by reduced secretion of IFNgamma and IL-2. CONCLUSION: Unlike patients with biallelic mutations in CARD11 causing severe combined immunodeficiency, the R30W defect results in a less profound yet prominent susceptibility to infections as well as multi-organ atopy and autoimmunity</style></abstract><notes><style face="normal" font="default">DA - 20170822IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28826773">PM:28826773</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170822-DadiH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170822-DadiH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170822, Dadi H</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.047</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42455</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chinen,J.</style></author><author><style face="normal" font="default"> Badran,Y.</style></author><author><style face="normal" font="default"> Geha,R.S.</style></author><author><style face="normal" font="default"> Chou,J.S.</style></author><author><style face="normal" font="default"> Fried,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunology, Allergy and Rheumatology Section, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas.</style></auth-address><titles><title><style face="normal" font="default">Advances in Basic and Clinical Immunology 2016</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword></keywords><dates><year Day="18" Month="8" Year="2017">2017/8/18</year></dates><abstract><style face="normal" font="default">Advances in basic immunology in 2016 included studies that further characterized the role of different proteins in the differentiation of effector T cells and B cells, including cytokines and proteins involved in actin cytoskeleton. The regulation of granule formation and secretion in cytotoxic cells was also further described by examining patients with familial hemophagocytic lymphohystiocytosis. The role of prenylation in mevalonate kinase deficiency leading to inflammation has been established. We reviewed advances in clinical immunology as well as new approaches of whole genome sequencing and genes newly reported to be associated with immunodeficiency, such as linker of activation of T cells (LAT), B cell lymphoma 11B (BCL11B), RLTPR, moesin and JAK1. Trials of Hematopoietic stem cells transplantation and gene therapy for primary immunodeficiency have had relative success; the use of autologous viral specific cytotoxic T cells has proven effective. New medications are being explored, such as pioglitazone and its role in enhancing the oxidative burst in chronic granulomatous disease. Development of vaccines for HIV infection continues to provide insight into the immune response against a virus with an extraordinary mutation rate</style></abstract><notes><style face="normal" font="default">DA - 20170822IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.07.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28826774">PM:28826774</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170822-ChinenJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170822-ChinenJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170822, Chinen J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.07.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42456</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Armentia,A.</style></author><author><style face="normal" font="default"> Martin-Armentia,B.</style></author><author><style face="normal" font="default"> Martin-Armentia,S.</style></author><author><style face="normal" font="default"> Ruiz-Munoz,P.</style></author><author><style face="normal" font="default"> Quesada,J.M.</style></author><author><style face="normal" font="default"> Postigo,I.</style></author><author><style face="normal" font="default"> Conde,R.</style></author><author><style face="normal" font="default"> Gonzalez-Sagrado,M.</style></author><author><style face="normal" font="default"> Pineda,F.</style></author><author><style face="normal" font="default"> Castillo,M.</style></author><author><style face="normal" font="default"> Palacios,R.</style></author><author><style face="normal" font="default"> Tejedor,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Unit, Rio Hortega University Hospital, University of Valladolid, Valladolid, Spain.</style></auth-address><titles><title><style face="normal" font="default">Cocaine Allergy in Drug-Dependent Patients and Allergic People</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="8" Year="2017">2017/8/29</year></dates><abstract><style face="normal" font="default">BACKGROUND: Adverse reactions to local anesthetics (LAs), especially esters, are not uncommon, but true allergy is rarely diagnosed. To our knowledge, currently there is no reliable method of determining IgE-mediated hypersensitivity to LAs and cocaine. OBJECTIVE: To assess the clinical value of allergy tests (prick, IgE, challenges, and arrays) in people suffering hypersensitivity reactions (asthma and anaphylaxis) during local anesthesia with cocaine derivatives and drug abusers with allergic symptoms after cocaine inhalation. METHODS: We selected cocaine-dependent patients and allergic patients who suffered severe reactions during local anesthesia from a database of 23,873 patients. The diagnostic yield (sensitivity, specificity, and predictive value) of allergy tests using cocaine and coca leaf extracts in determining cocaine allergy was assessed, taking a positive challenge as the criterion standard. RESULTS: After prick tests, specific IgE, and challenge with cocaine extract, 41 of 211 patients (19.4%) were diagnosed as sensitized to cocaine. Prick tests and IgE to coca leaves (coca tea) had a good sensitivity (95.1% and 92.7%, respectively) and specificity (92.3 and 98.8%, respectively) for the diagnosis of cocaine allergy and LA-derived allergy. CONCLUSIONS: Cocaine may be an important allergen. Drug abusers and patients sensitized to local anesthesia and tobacco are at risk. Both prick tests and specific IgE against coca leaf extract detected sensitization to cocaine. The highest levels were related to severe clinical profiles</style></abstract><notes><style face="normal" font="default">DA - 20170902IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28863944">PM:28863944</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170902, Armentia A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42457</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dequidt,L.</style></author><author><style face="normal" font="default"> Milpied,B.</style></author><author><style face="normal" font="default"> Chauvel,A.</style></author><author><style face="normal" font="default"> Seneschal,J.</style></author><author><style face="normal" font="default"> Taieb,A.</style></author><author><style face="normal" font="default"> Darrigade,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Adult and Pediatric Dermatology, Bordeaux University Hospitals, Bordeaux, France</style></auth-address><titles><title><style face="normal" font="default">A case of lichenoid and pigmented drug eruption to acetazolamide confirmed by a lichenoid patch test</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="8" Year="2017">2017/8/25</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170829IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28847654">PM:28847654</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170829, Dequidt L</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42458</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Trubiano,J.A.</style></author><author><style face="normal" font="default"> Stone,C.A.</style></author><author><style face="normal" font="default"> Lindsay,G.M.</style></author><author><style face="normal" font="default"> Urbancic,K.</style></author><author><style face="normal" font="default"> Slavin,M.A.</style></author><author><style face="normal" font="default"> Thursky,K.A.</style></author><author><style face="normal" font="default"> Phillips,E.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="default">The 3 Cs of Antibiotic Allergy-Classification, Cross-Reactivity, and Collaboration</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1542" start="1532">1532-1542</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="8" Year="2017">2017/8/23</year></dates><abstract><style face="normal" font="default">Antibiotic allergy labeling is highly prevalent and negatively impacts patient outcomes and antibiotic appropriateness. Reducing the prevalence and burden of antibiotic allergies requires the engagement of key stakeholders such as allergists, immunologists, pharmacists, and infectious diseases physicians. To help address this burden of antibiotic allergy overlabeling, we review 3 key antibiotic allergy domains: (1) antibiotic allergy classification, (2) antibiotic cross-reactivity, and (3) multidisciplinary collaboration. We review the available evidence and research gaps of currently used adverse drug reaction classification systems, antibiotic allergy cross-reactivity, and current and future models of antibiotic allergy care</style></abstract><notes><style face="normal" font="default">DA - 20170827IS - 2213-2201 (Electronic)LA - engPT - Journal ArticlePT - ReviewCO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28843343">PM:28843343</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170827, Trubiano JA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42459</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wallington,J.C.</style></author><author><style face="normal" font="default"> Williams,A.P.</style></author><author><style face="normal" font="default"> Staples,K.J.</style></author><author><style face="normal" font="default"> Wilkinson,T.M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical &amp; Experimental Sciences, University of Southampton Faculty of Medicine, Sir Henry Wellcome Laboratories, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD</style></auth-address><titles><title><style face="normal" font="default">IL-12 and IL-7 synergise to control MAIT cell cytotoxic responses to bacterial infection</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Bacterial respiratory tract infections and exacerbations of chronic lung diseases are commonly caused by nontypeable Haemophilus influenzae (NTHi). Cell-mediated cytotoxicity may be key to controlling infection, but the responses of NTHi-specific T cell populations are not well understood. Mucosal-associated invariant T (MAIT) cells are a recently-discovered, innate-like subset of T cells with cytotoxic function, whose role in lung immunity is unclear. OBJECTIVE: The aim of this study was to determine the mechanisms behind conventional T and MAIT cell cytotoxic responses to NTHi. METHODS: Human ex vivo lung explants were infected with a clinical strain of NTHi. Monocyte-derived macrophages were also infected with NTHi in vitro and co-cultured with autologous T cells. Cytotoxic responses of T cell subsets were measured by flow cytometry. RESULTS: We found significant upregulation of the cytotoxic markers, CD107a and granzyme B, in lung CD4+, CD8+ and MAIT cell populations. We show that MAIT cell cytotoxic responses were upregulated by a combination of both time-dependent antigen presentation and through a novel mechanism by which IL-12 and IL-7 synergistically control granzyme B through upregulation of the IL-12 receptor. CONCLUSIONS: Overall our data provide evidence for a cytotoxic role of MAIT cells in the lung and highlight important differences in the control of adaptive and innate-like T cell responses. Understanding these mechanisms may lead to new therapeutic opportunities to modulate the anti-bacterial response and improve clinical outcome</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.08.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28870466">PM:28870466</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170905-WallingtonJC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170905-WallingtonJC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Wallington JC</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.08.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42460</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Szentpetery,S.E.</style></author><author><style face="normal" font="default"> Han,Y.Y.</style></author><author><style face="normal" font="default"> Brehm,J.M.</style></author><author><style face="normal" font="default"> Acosta-Perez,E.</style></author><author><style face="normal" font="default"> Forno,E.</style></author><author><style face="normal" font="default"> Boutaoui,N.</style></author><author><style face="normal" font="default"> Canino,G.</style></author><author><style face="normal" font="default"> Alcorn,J.F.</style></author><author><style face="normal" font="default"> Celedon,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pediatric Pulmonary Medicine, Allergy, and Immunology, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh, Pittsburgh, Pa</style></auth-address><titles><title><style face="normal" font="default">Vitamin D insufficiency, plasma cytokines, and severe asthma exacerbations in school-aged children</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="8" Year="2017">2017/8/25</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170829IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - Puerto Rico -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28847651">PM:28847651</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170829, Szentpetery SE</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42461</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sullivan,P.W.</style></author><author><style face="normal" font="default"> Ghushchyan,V.</style></author><author><style face="normal" font="default"> Navaratnam,P.</style></author><author><style face="normal" font="default"> Friedman,H.S.</style></author><author><style face="normal" font="default"> Kavati,A.</style></author><author><style face="normal" font="default"> Ortiz,B.</style></author><author><style face="normal" font="default"> Lanier,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacy Practice, Regis University School of Pharmacy, Denver, Colo.</style></auth-address><titles><title><style face="normal" font="default">National Prevalence of Poor Asthma Control and Associated Outcomes among School-Aged Children in the United States</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="8" Year="2017">2017/8/25</year></dates><abstract><style face="normal" font="default">BACKGROUND: The degree of asthma control among school-aged children (SAC) nationally is not well understood. OBJECTIVE: The objective of this study was to characterize poor control among SAC (aged 6-17 years) in the United States. METHODS: This was a retrospective analysis of the 2007-2013 Medical Expenditure Panel Survey. Indicators of poor control included exacerbation in previous year; use of >3 canisters of short-acting beta-agonist (SABA) in 3 months; and asthma-specific (AS) emergency department (ED) or inpatient (IP) visits. Treatment indicators included daily controller medication and peak flow meter use. Negative binomial regression was used for health resource utilization (HRU); generalized linear models with log-link were used for health care expenditures. RESULTS: There were 44,320 SAC, of whom 5,890 had asthma. The prevalence of poor control and treatment among SAC with asthma were as follows: exacerbation (59%), >3 canisters of SABA (4%), ED/IP visit (3%), daily controller (19%), peak flow (12%). In 2013, 3.4 million SAC had an asthma exacerbation and 200,000 had an AS ED/IP visit. SAC with asthma and an exacerbation had 18.9 times more annual AS ED visits (and 43.3 times more AS hospitalizations) than SAC with asthma but no exacerbation. SAC with asthma and an indicator of poor control incurred greater annual all-cause expenditures than SAC without asthma ($US 2015): $1,144 (exacerbation), $1,859 (>/=3 canisters of SABA), and $3,063 (ED/IP visit). Use of daily controller medication was low even among SAC with poor control (27% to 61%). CONCLUSION: Renewed and vigilant asthma management and treatment is necessary to mitigate the current and long-term public health effects and expenditures associated with poor asthma control</style></abstract><notes><style face="normal" font="default">DA - 20170829IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28847656">PM:28847656</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170829, Sullivan PW</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.039</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42462</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Blais,L.</style></author><author><style face="normal" font="default"> Kettani,F.Z.</style></author><author><style face="normal" font="default"> Forget,A.</style></author><author><style face="normal" font="default"> Beauchesne,M.F.</style></author><author><style face="normal" font="default"> Lemiere,C.</style></author><author><style face="normal" font="default"> Rey,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Pharmacy, Universite de Montreal, Montreal, Quebec, Canada</style></auth-address><titles><title><style face="normal" font="default">Long-Acting beta2-Agonists and Risk of Hypertensive Disorders of Pregnancy: A Cohort Study</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="8" Year="2017">2017/8/25</year></dates><abstract><style face="normal" font="default">BACKGROUND: Maternal asthma has been found to be associated with an increased risk of hypertensive disorders of pregnancy (HDP), that is, gestational hypertension, preeclampsia, and eclampsia. There is limited data, however, regarding the relationship between the use of long-acting beta-agonists (LABAs) during pregnancy and these outcomes. OBJECTIVE: To investigate whether exposure to a LABA in addition to an inhaled corticosteroid increases the risk of HDP or preeclampsia/eclampsia, as compared with nonexposure to LABAs, in pregnant women with asthma. METHODS: A cohort of 8,936 pregnancies in women with asthma who delivered between 1998 and 2010 was reconstructed using Quebec (Canada) health administrative databases. Cox proportional hazard regression models, adjusted for potential confounders, were used for statistical analyses. The primary exposure was LABA use (yes/no) measured on the first day of the 20th week of pregnancy. HDP were identified on the basis of recorded diagnoses and on prescriptions of antihypertensive drugs filled on or after the first day of week 20 of gestation. RESULTS: There were 567 (6.3%) cases of HDP and 256 (2.9%) cases of preeclampsia/eclampsia in the cohort, and the rates of both disorders were similar in women exposed or not exposed to LABAs. LABA use was not associated with increased risks of HDP (adjusted hazard ratio, 0.96; 95% CI, 0.69-1.33) or preeclampsia/eclampsia (adjusted hazard ratio, 0.89; 95% CI, 0.53-1.50). CONCLUSIONS: The results of this study provide evidence suggesting the safety of LABAs for the treatment of asthma in pregnancy, in terms of the risks of HDP and preeclampsia/eclampsia</style></abstract><notes><style face="normal" font="default">DA - 20170829IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28847655">PM:28847655</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170829, Blais L</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42463</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Simpson,E.L.</style></author><author><style face="normal" font="default"> Bruin-Weller,M.</style></author><author><style face="normal" font="default"> Flohr,C.</style></author><author><style face="normal" font="default"> Ardern-Jones,M.R.</style></author><author><style face="normal" font="default"> Barbarot,S.</style></author><author><style face="normal" font="default"> Deleuran,M.</style></author><author><style face="normal" font="default"> Bieber,T.</style></author><author><style face="normal" font="default"> Vestergaard,C.</style></author><author><style face="normal" font="default"> Brown,S.J.</style></author><author><style face="normal" font="default"> Cork,M.J.</style></author><author><style face="normal" font="default"> Drucker,A.M.</style></author><author><style face="normal" font="default"> Eichenfield,L.F.</style></author><author><style face="normal" font="default"> Foelster-Holst,R.</style></author><author><style face="normal" font="default"> Guttman-Yassky,E.</style></author><author><style face="normal" font="default"> Nosbaum,A.</style></author><author><style face="normal" font="default"> Reynolds,N.J.</style></author><author><style face="normal" font="default"> Silverberg,J.I.</style></author><author><style face="normal" font="default"> Schmitt,J.</style></author><author><style face="normal" font="default"> Seyger,M.M.B.</style></author><author><style face="normal" font="default"> Spuls,P.I.</style></author><author><style face="normal" font="default"> Stalder,J.F.</style></author><author><style face="normal" font="default"> Su,J.C.</style></author><author><style face="normal" font="default"> Takaoka,R.</style></author><author><style face="normal" font="default"> Traidl-Hoffmann,C.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author><author><style face="normal" font="default"> van der Schaft,J.</style></author><author><style face="normal" font="default"> Wollenberg,A.</style></author><author><style face="normal" font="default"> Irvine,A.D.</style></author><author><style face="normal" font="default"> Paller,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Oregon Health and Science University, Portland, Oregon.</style></auth-address><titles><title><style face="normal" font="default">When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council</style></title><secondary-title><style face="normal" font="default">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword></keywords><dates><year Day="10" Month="8" Year="2017">2017/8/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Although most patients with atopic dermatitis (AD) are effectively managed with topical medication, a significant minority require systemic therapy. Guidelines for decision making about advancement to systemic therapy are lacking. OBJECTIVE: To guide those considering use of systemic therapy in AD and provide a framework for evaluation before making this therapeutic decision with the patient. METHODS: A subgroup of the International Eczema Council determined aspects to consider before prescribing systemic therapy. Topics were assigned to expert reviewers who performed a topic-specific literature review, referred to guidelines when available, and provided interpretation and expert opinion. RESULTS: We recommend a systematic and holistic approach to assess patients with severe signs and symptoms of AD and impact on quality of life before systemic therapy. Steps taken before commencing systemic therapy include considering alternate or concomitant diagnoses, avoiding trigger factors, optimizing topical therapy, ensuring adequate patient/caregiver education, treating coexistent infection, assessing the impact on quality of life, and considering phototherapy. LIMITATIONS: Our work is a consensus statement, not a systematic review. CONCLUSION: The decision to start systemic medication should include assessment of severity and quality of life while considering the individual's general health status, psychologic needs, and personal attitudes toward systemic therapies</style></abstract><notes><style face="normal" font="default">DA - 20170814IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Netherlands -CO - United Kingdom -CO - France -CO - Denmark -CO - Germany -CO - Australia -CO - Brazil -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaad.2017.06.042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28803668">PM:28803668</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am Acad Dermatol\20170814-SimpsonEl.pdf</url></pdf-urls><text-urls><url ppv-ref="no">f:\A&amp;H LMW Papers\J Am Acad Dermatol\20170814-SimpsonEl.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170814, Simpson EL</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaad.2017.06.042</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42464</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rosychuk,R.J.</style></author><author><style face="normal" font="default"> Ospina,M.</style></author><author><style face="normal" font="default"> Zhang,J.</style></author><author><style face="normal" font="default"> Leigh,R.</style></author><author><style face="normal" font="default"> Cave,A.</style></author><author><style face="normal" font="default"> Rowe,B.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatrics , University of Alberta, Rm 3-524, Edmonton Clinic Health Academy (ECHA) , 11405 87 Avenue NW, Edmonton , Alberta T6G 1C9 , Canada</style></auth-address><titles><title><style face="normal" font="default">Sex Differences in Outcomes After Discharge from Alberta Emergency Departments for Asthma: A Large Population-based Study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="9" Year="2017">2017/9/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Asthma exacerbations frequently result in emergency department (ED) visits. While sex differences have been identified in some asthma studies, there is a paucity of literature on sex differences in the ED setting, especially population-based ones. This study examines sex differences in important outcomes of patients discharged from EDs for acute asthma in Alberta, Canada. METHODS: Alberta residents aged 2 to 55 years discharged from EDs with a primary diagnosis of asthma during</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1373805</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28872981">PM:28872981</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170905-RosychukRJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170905-RosychukRJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Rosychuk RJ</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1373805</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42465</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Harris,D.A.</style></author><author><style face="normal" font="default"> Mainardi,A.</style></author><author><style face="normal" font="default"> Iyamu,O.</style></author><author><style face="normal" font="default"> Rosenthal,M.S.</style></author><author><style face="normal" font="default"> Bruce,R.D.</style></author><author><style face="normal" font="default"> Pisani,M.A.</style></author><author><style face="normal" font="default"> Redlich,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Division of Pulmonary and Critical Care Medicine, Yale University</style></auth-address><titles><title><style face="normal" font="default">Improving the asthma disparity gap with legal advocacy? A qualitative study of patient-identified challenges to improve social and environmental factors that contribute to poorly controlled asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="9" Year="2017">2017/9/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To identify challenges disadvantaged adults with asthma face in mitigating social and environmental factors associated with poor symptom control. METHODS: Using a community-engaged approach, we partnered with a community health center in New Haven, CT to conduct in-person interviews and a written survey of asthmatic adults with poor symptom control. Using the constant comparative method, we analyzed participant interviews to establish emerging themes and identify common barriers to improved outcomes. Through a written survey utilizing clinically validated questions, we assessed information on access to medical care, asthma control and selected social and environmental risk factors. RESULTS: Twenty-one patients (mean age 47, 62% female, 71% Black, 95% insured by Medicaid) participated. The average Asthma Control Test (ACT) score was 11.6. Seventy-six percent of participants were currently employed and of those, 75% reported work-related symptoms. Among participants currently in housing, 59% reported exposure to domiciliary mice and 47% to mold. We identified three themes that summarize the challenges the study participants face: 1) Lack of knowledge about home and workplace asthma triggers; 2) Lack of awareness of legal rights or resources available to mitigate adverse conditions in the home or work environment; and 3) Fear of retaliation from landlords or employers, including threats of eviction, sexual assault and job loss. CONCLUSION: Patients with poorly controlled asthma in a disadvantaged urban northeast community identified common barriers in both the domestic and work environments that impeded attainment of symptom control. These challenges may best be addressed through legal advocacy for those most at risk</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1373393</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28872933">PM:28872933</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170905-HarrisDA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170905-HarrisDA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Harris DA</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1373393</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42466</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pade,K.H.</style></author><author><style face="normal" font="default"> Seik-Ismail,S.T.</style></author><author><style face="normal" font="default"> Chang,T.P.</style></author><author><style face="normal" font="default"> Wang,V.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Emergency Medicine and Transport , Children's Hospital Los Angeles , Los Angeles</style></auth-address><titles><title><style face="normal" font="default">Utilization of Just-in-time Training for Nursing Education using the LA Phonospirometry Asthma Tool</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="28" Month="8" Year="2017">2017/8/28</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Just-in-time training (JITT) has been used to teach and re-teach known medical techniques, but has not been used to teach novel techniques. We aimed to assess the performance retention of JITT on a novel asthma exacerbation severity assessment technique known as Los Angeles (LA) Phonospirometry. METHODS: This was a prospective cohort study using a convenience sample of pediatric emergency department registered nurses (RNs) who were asked to watch a brief instructional digital video on LA Phonospirometry, and then asked to practice the technique on a research assistant (RA). A checklist was used to evaluate proficiency with the primary outcome being the number correct on the checklist. The secondary outcome included whether or not they could identify a common error demonstrated by the RA. RNs were re-tested after 4-6 months to assess skill retention. RESULTS: Forty RNs were enrolled in the study and 6 were lost to follow-up. The mean time from the first to second testing was 5.4 months +/- 0.5 months. The mean score of the first part of the checklist on the initial testing was 4.6 +/- 0.7 and on second testing was 3.8 +/- 1.5 (p = 0.008). This represented a drop in scores and thus minimal knowledge decay of 18% (from 91% to 73%). The mean for number of errors picked up for the first test and second test were 1.3 and 1.5, respectively (p = 0.2). CONCLUSIONS: JITT demonstrated feasibility as a rapid instructional tool for RNs, with a limited decay in cognitive knowledge surrounding the LA Phonospirometry technique</style></abstract><notes><style face="normal" font="default">DA - 20170828IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1366507</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28846445">PM:28846445</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170828-PadeKH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170828-PadeKH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170828, Pade KH</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1366507</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42467</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Veeranki,S.P.</style></author><author><style face="normal" font="default"> Ohabughiro,M.U.</style></author><author><style face="normal" font="default"> Moran,J.</style></author><author><style face="normal" font="default"> Mehta,H.B.</style></author><author><style face="normal" font="default"> Ameredes,B.T.</style></author><author><style face="normal" font="default"> Kuo,Y.F.</style></author><author><style face="normal" font="default"> Calhoun,W.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Preventive Medicine and Community Health , University of Texas Medical Branch , Galveston , TX</style></auth-address><titles><title><style face="normal" font="default">National estimates of 30-day readmissions among children hospitalized for asthma in the United States</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="24" Month="8" Year="2017">2017/8/24</year></dates><abstract><style face="normal" font="default">Objective Previous single-center studies have reported that up to 40% of children hospitalized for asthma will be readmitted. The study objectives are to investigate the prevalence and timing of 30-day readmissions in children hospitalized with asthma, and to identify factors associated with 30-day readmissions. Methods Data (n = 12,842) for children aged 6-18 years hospitalized for asthma were obtained from the 2013 Nationwide Readmission Database (NRD). The primary study outcome was time to readmission within 30 days after discharge attributable to any cause. Several predictors associated with risk of admission were included: patient (age, sex, median household income, insurance type, county location, pediatric chronic complex condition), admission (type, day, emergency services utilization, length of stay (LOS), discharge disposition) and hospital (ownership, bed size, teaching status). Cox's Proportional Hazards model was used to identify predictors. Results Of 12,842 asthma-related index hospitalizations, 2.5% were readmitted within 30 days post discharge. Time to event models identified significantly higher risk of readmission among asthmatic children aged 12-18 years, those who resided in in micropolitan counties, those with >4 days LOS during index hospitalization, those who were hospitalized in urban hospital, who had unfavorable discharge (HR 2.53, 95% CI 1.33-4.79), and those who were diagnosed with PCCC, respectively than children in respective referent categories. Conclusion A multi-dimensional approach including effective asthma discharge action plans and follow-up processes, home-based asthma education, and neighborhood/community-level efforts to address disparities should be integrated into routine clinical care of asthma children</style></abstract><notes><style face="normal" font="default">DA - 20170824IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1365888</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28837382">PM:28837382</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170824-VeerankiSP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170824-VeerankiSP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170824, Veeranki SP</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1365888</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42468</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Drewek,R.</style></author><author><style face="normal" font="default"> Mirea,L.</style></author><author><style face="normal" font="default"> Touresian,P.</style></author><author><style face="normal" font="default"> Adelson,P.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Phoenix Children's Hospital</style></auth-address><titles><title><style face="normal" font="default">Asthma treatment and outcomes for children in the emergency department and hospital</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="8" Year="2017">2017/8/18</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To describe and compare the treatment of acute asthma exacerbations in children seen in the emergency department (ED) and admitted to acute care floor in the hospital or intensive care unit (ICU). METHODS: Retrospective chart review of visits for acute exacerbation of asthma treated at Phoenix Children's Hospital between January 1, 2014 and December 31, 2016. RESULTS: A total of 287 asthma exacerbation cases were identified including 106 (37%) ED visits, 134 (47%) hospital floor and 47 (16%) ICU admissions. History of a previous ED visit (ED 88%, Floor 60% and ICU 68%; p&lt;0.0001) and prior pulmonology inpatient consult (ED 30%, Floor 19% and ICU 15%; p = 0.05) varied significantly. Pulmonology inpatient consults were performed more frequently in the ICU than on hospital floor (54% vs 8%; p&lt;0.0001). Although overall 145 (51%) of cases were already on inhaled corticosteroids (ICS) at time of visit with no differences across locations, ICS initiation/step-up was greater in the ICU (72%) than hospital floor (54%) and ED (2%) (p&lt;0.0001). A recommendation given to the family for follow-up with pulmonology was more frequent for patients who had been admitted to the ICU (68%) as compared to those only admitted to the floor (31%) or ED (4%) (p&lt;0.0001). Readmission rates were similar for patients previously admitted to hospital (Floor 42%, ICU 40%), but significantly higher for previous ED visits (77%) (p&lt;0.0001). CONCLUSIONS: Physicians in the ED have an opportunity to provide preventative care in the acute care setting and should be encouraged to initiate treatment with ICS. Consideration should be given to developing a program or clinical pathway focused on long-term asthma management and maintenance to reduce readmissions and long hospital stays</style></abstract><notes><style face="normal" font="default">DA - 20170818IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1355381</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28820610">PM:28820610</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170818-DrewekR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170818-DrewekR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170818, Drewek R</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1355381</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42469</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rasulnia,M.</style></author><author><style face="normal" font="default"> Burton,B.S.</style></author><author><style face="normal" font="default"> Ginter,R.P.</style></author><author><style face="normal" font="default"> Wang,T.Y.</style></author><author><style face="normal" font="default"> Pleasants,R.A.</style></author><author><style face="normal" font="default"> Green,C.L.</style></author><author><style face="normal" font="default"> Lugogo,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Pack Health, Strategic Partnerships , 3613 6th Ave S, Birmingham , 35222 United States</style></auth-address><titles><title><style face="normal" font="default">Assessing the Impact of a Remote Digital Coaching Engagement Program on Patient Reported Outcomes in Asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="8" Year="2017">2017/8/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Low adherence and poor outcomes provide opportunity for digital coaching to engage patients with uncontrolled asthma in their care to improve outcomes. OBJECTIVES: To examine the impact of a remote digital coaching program on asthma control and patient experience. METHODS: We recruited 51 adults with uncontrolled asthma, denoted by albuterol use of > 2 times per week and/or exacerbations requiring corticosteroids, and applied a 12-week patient-centered remote digital coaching program using a combination of educational pamphlets, symptom trackers, best peak flow establishment, physical activity, and dietary counseling, as well as coaches who implemented emotional enforcement to motivate disease self-management through telephone, text, and email. Baseline and post-intervention measures were quality of life (QOL), spirometry, Asthma Control Test (ACT), Asthma Symptom Utility Index (ASUI), rescue albuterol use, and exacerbation history. RESULTS: Among 51 patients recruited, 40 completed the study. Eight subjects required assistance reading medical materials. Significant improvements from baseline were observed for PROMIS mental status (p = 0.010), body weight and outpatient exacerbation frequency (p = 0.028). The changes from baseline in ACT (p = 0.005) was statistically significant but did not achieve the pre-specified minimum clinically important difference (MCID). Whereas for ASUI, the MCID and statistical significance were achieved. Spirometry and rescue albuterol use were no different. CONCLUSION: A patient-oriented, remote digital coaching program that utilized trained health coaches and digital materials led to statistically significant improvement in mental status, outpatient exacerbations, body weight, and ASUI. Digital coaching programs may improve some outcomes in adults with uncontrolled asthma</style></abstract><notes><style face="normal" font="default">DA - 20170811IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1362430</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28800273">PM:28800273</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170811-RasulniaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170811-RasulniaM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170811, Rasulnia M</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1362430</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42470</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Alzayer,R.</style></author><author><style face="normal" font="default"> Chaar,B.</style></author><author><style face="normal" font="default"> Basheti,I.</style></author><author><style face="normal" font="default"> Saini,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Building A15, Science Road, The University of Sydney Camperdown , NSW 2006 , Australia</style></auth-address><titles><title><style face="normal" font="default">Asthma management experiences of Australians who are native Arabic-speakers</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="8" Year="2017">2017/8/11</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The aim of this study was to explore the asthma management experiences of people with asthma within the Arabic-speaking community in Australia. METHODS: Semi-structured interviews guided by a schedule of questions were conducted with 25 Arabic-speaking women with asthma/carer of a child with asthma, recruited from medical practices and community centers in Melbourne, Australia. RESULTS: Twenty-five Arabic-speaking participants with asthma or caring for those with asthma were interviewed. Interviews lasted on average 25 minutes. Most participants or those they were caring for did not have well-controlled asthma. Thematic analyses of the interview transcripts highlighted five key emergent themes: stigma, health literacy, non-adherence, expectations and coping styles. Findings indicated that many participants were not conversant about local information avenues or healthcare or facilities such as the Asthma Foundation or availability of Arabic translators during general practitioner (GP) consults. Many recent migrants were generally non-adherent with treatment; preferring to follow traditional folk medicine rather than consulting a GP or pharmacist. Some unrealistic expectations from doctors/treatment goals were expressed by a few participants. Some parents of children with asthma reported disappointment with the fact that their children did not grow out of asthma. CONCLUSION: Low health literacy and in particular knowledge about asthma, cultural beliefs, language, and migration-related issues may all be affecting the level of asthma control in the Arabic-speaking population in Australia. Measures to enhance asthma and health system literacy designed to be culturally concordant with the beliefs, expectations, and experiences of such populations may be key to improving asthma management</style></abstract><notes><style face="normal" font="default">DA - 20170811IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - Jordan -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1362702</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28800268">PM:28800268</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170811-AlzayerR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170811-AlzayerR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170811, Alzayer R</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1362702</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42471</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Warman,K.L.</style></author><author><style face="normal" font="default"> Silver,E.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a The Children's Hospital at Montefiore, Albert Einstein College of Medicine , Bronx , NY</style></auth-address><titles><title><style face="normal" font="default">Are Inner-City Children with Asthma Receiving Specialty Care as Recommended in National Asthma Guidelines?</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="8" Year="2017">2017/8/16</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To examine whether children with asthma in an urban healthcare network are receiving asthma specialty care, and which factors, if any, are associated with receipt of this care, including: child's racial/ethnic group, age, socio-economic status (SES), insurance, and/or acute care utilization. METHODS: This study is a retrospective cohort study of children ages 7- 17 years old who received primary care in an urban medical center in 2012 and had a primary or secondary ICD9 code for asthma. Data on asthma-related health care utilization from 1997-2012 were accessed using a software application linked to the electronic medical record. Analyses included descriptive statistics (means and percentages) as well as bivariate and multivariable logistic regression. RESULTS: The participants were 4959 children (59% Hispanic and 37% Black, NH) with a mean age = 11.1 year +/- 3.05, 56.8% male. Only 19% of children had outpatient asthma specialist care: pulmonary (16%) and/or allergy (7%). Only 42% with an asthma-related hospitalization had an outpatient asthma specialist visit. Receipt of specialty care did not vary by race/ethnicity, SES or private vs. public insurance, but was more likely with hospitalization for asthma (OR 3.4) or >/=2 lifetime ED visits (OR 2.6) and less likely for those uninsured (OR 0.7). CONCLUSIONS: In contrast to guideline recommendations, few inner-city children with high asthma morbidity in this sample had seen asthma specialists. Efforts are needed to ensure that inner-city children with asthma are receiving guideline recommended asthma specialty care</style></abstract><notes><style face="normal" font="default">DA - 20170816IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1350966</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28813166">PM:28813166</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170816-WarmanKL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170816-WarmanKL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170816, Warman KL</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1350966</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42472</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Myung,J.</style></author><author><style face="normal" font="default"> Lee,H.</style></author><author><style face="normal" font="default"> Kim,T.H.</style></author><author><style face="normal" font="default"> Han,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Graduate School of Public Health, Yonsei University , Seoul , South Korea</style></auth-address><titles><title><style face="normal" font="default">Relationships between self-reported asthma and pulmonary function and various measures of obesity</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="8" Year="2017">2017/8/11</year></dates><abstract><style face="normal" font="default">OBJECTIVE: We explore the association with self-reported asthma and pulmonary function based on spirometry measurements using different measures to determine obesity because body mass index (BMI) is limited in not differentiating fat and muscle mass. METHODS: A multi-year cross-sectional study using Korean National Health and Nutrition Examination Survey data was conducted between July 2008 and May 2011. A total of 9409 subjects were included in the final analysis. RESULTS: Obesity was associated with self-reported asthma and pulmonary function limitations mainly in adult women aged between 40 and 65 years and elderly men aged 65 or older. The association was stronger when the measurement of obesity was based on body fat percentage or waist-to-height ratio, compared to BMI. There was a higher self-reported asthma risk among obese women according to the waist-to-height ratio (OR = 1.817, 95% CI: [1.208, 2.735]). There was an increased risk of pulmonary function limitation with abdominal obesity (OR 1.418, 95% CI [1.020, 1.972]), weight-to-height ratio (OR 1.467, 95% CI [1.058, 2.034]), and obesity with regards to body fat percentage (OR 1.753, 95% CI [1.251, 2.457]) in adult women. In elderly men, obesity based on body fat percentage was associated with an increased risk of pulmonary function limitation (OR 1.93, 95% CI [1.098, 3.388]). CONCLUSIONS: Measures other than BMI should be examined when investigating the effect of obesity on self-reported asthma and pulmonary function limitation</style></abstract><notes><style face="normal" font="default">DA - 20170811IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1362701</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28800274">PM:28800274</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170811-MyungJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170811-MyungJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170811, Myung J</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1362701</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42473</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Con,W.</style></author><author><style face="normal" font="default"> Ka,M.</style></author><author><style face="normal" font="default"> Wtb,E.</style></author><author><style face="normal" font="default"> G S</style></author><author><style face="normal" font="default"> Am,W.</style></author><author><style face="normal" font="default"> Jy,R.</style></author><author><style face="normal" font="default"> Ijm,D.</style></author><author><style face="normal" font="default"> Ma,M.</style></author><author><style face="normal" font="default"> Ga,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Swansea University Medical School</style></auth-address><titles><title><style face="normal" font="default">Perceptions of asthma and exercise in adolescents with and without asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To elicit the views of adolescents, with and without asthma, about exercise and asthma, and the perceived benefits of and barriers to participation. The adolescent views elicited would subsequently inform the design of a high-intensity exercise intervention to improve asthma control. METHODS: Fifty-four adolescents (age 13.1+/-0.9years; 26 with asthma) participated in twelve semi-structured group interviews. Questions were structured around knowledge, attitudes and beliefs towards asthma and its impact on exercise participation and lifestyle. The interviews were transcribed verbatim, thematically analysed and presented via diagrams of emergent themes. Ethical approval was granted by the institutional research ethics committee. RESULTS: Fear of an asthma attack emerged as the main barrier to exercise, with many adolescents with asthma withdrawing from exercise as a coping strategy; many healthy adolescents perceived this withdrawal as laziness or an excuse. Despite this, the majority (81%) of adolescents with asthma reported exercise to be their most enjoyable activity. Adolescents suggested incorporating mixed activities, such as team games (e.g., rounders, football, netball), for future interventions to ensure adherence. CONCLUSIONS: Whilst exercise is important in the management of asthma, the tendency of those with asthma to withdraw from exercise to avoid adverse events could be addressed through a games-based high-intensity exercise intervention. Furthermore, educating all adolescents on asthma could simultaneously reduce stigmatisation and enhance exercise engagement</style></abstract><notes><style face="normal" font="default">DA - 20170830IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1369992</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28853952">PM:28853952</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170830-ConW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170830-ConW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170830, Con W</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1369992</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42474</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Snyder,D.A.</style></author><author><style face="normal" font="default"> Thomas,O.W.</style></author><author><style face="normal" font="default"> Gleeson,S.P.</style></author><author><style face="normal" font="default"> Stukus,D.R.</style></author><author><style face="normal" font="default"> Jones,L.M.</style></author><author><style face="normal" font="default"> Regan,C.</style></author><author><style face="normal" font="default"> Shamansky,A.</style></author><author><style face="normal" font="default"> Allen,E.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Section of Ambulatory Pediatrics , Nationwide Children's Hospital , Columbus , OH , United States</style></auth-address><titles><title><style face="normal" font="default">Reducing Emergency Department Visits Utilizing a Primary Care Asthma Specialty Clinic in a High Risk Patient Population</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Asthma is a leading cause of pediatric emergency department(ED) use. Optimizing asthma outcomes is a goal of Nationwide Children's Hospital(NCH) and its affiliated Accountable Care Organization. NCH's Primary Care Network, comprised of 12 offices serving a predominantly Medicaid population, sought to determine whether an Asthma Specialty Clinic (ASC) operated within a single primary care office could reduce ED asthma rates and improve quality measures, relative to all other network offices. METHODS: An ASC was piloted with four components: patient monitoring, provider continuity, standardized assessment, and multi-disciplinary education. A registry was established to contact patients at recommended intervals. At extended-length visits, a general pediatrician evaluated patients and a multi-disciplinary team provided education. Novel educational tools, were utilized, guideline-based templates recorded and spirometry obtained. ED asthma rate, spirometry utilization, and controller fills by intervention office patients were compared to all other network offices before and after ASC initiation. RESULTS: At baseline, asthma ED visits by intervention and usual care populations were similar(p = 0.43). After, rates were significantly lower for intervention office patients versus usual care office patients(p &lt;0.001), declining in the intervention population by 26.2%, 25.2% and 31.8% in 2013, 2014, and 2015, respectively, from 2012 baseline, versus increases of 3.8%, 16.2%, and 9.5% in the usual care population. Spirometry completion, controller fills, and patients with favorable Asthma Medication Ratios significantly increased for intervention office patient relative to the usual care population. CONCLUSIONS: A primary care-based asthma clinic was associated with a significant and sustainable reduction in ED utilization versus usual care. What's new:This study describes a comprehensive, multi-disciplinary and innovative model for an asthma management program within the medical home that demonstrated a significant reduction in emergency department visits, an increase in spirometry utilization and an increase in controller fills in a high-risk asthma population versus comparison group</style></abstract><notes><style face="normal" font="default">DA - 20170830IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1369989</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28853957">PM:28853957</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170830-SnyderDA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170830-SnyderDA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170830, Snyder DA</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1369989</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42475</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Paudyal,P.</style></author><author><style face="normal" font="default"> Jones,C.</style></author><author><style face="normal" font="default"> Grindey,C.</style></author><author><style face="normal" font="default"> Dawood,R.</style></author><author><style face="normal" font="default"> Smith,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Primary Care and Public Health , Brighton and Sussex Medical School , Brighton , United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Meditation for asthma: Systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To conduct a comprehensive review and meta-analysis of the effectiveness of meditation on a variety of asthma outcomes. METHODS: We searched MEDLINE, EMBASE, CINAHL, PsycINFO and AMED in June 2016 to identify randomised controlled trials (RCTs) investigating the effectiveness of meditation in adults with asthma. No restriction was put on language or year of publication. Study quality was assessed using The Cochrane Risk of Bias Assessment Tool. Meta-analysis was carried out using RevMan 5.3. RESULTS: Four RCTS involving 201 patients met the inclusion criteria. Quality of studies was inconsistent with only one study reporting adequate allocation concealment. Disease-specific quality of life was assessed in two trials; a pooled result involving 62 intervention and 65 control participants indicated a significant improvement in quality of life in the meditation group compared to the control group (SMD 0.40, 95% CI 0.05 to 0.76). A pooled result from all four studies indicated the uncertain effect of meditation in forced expiratory volume in one second (FEV1) (SMD -0.67, 95% CI -2.17 to 0.82). Results from the individual trials suggest that meditation may be helpful in reducing perceived stress and the use of short-term rescue medication. CONCLUSION: Our review suggests that there is some evidence that meditation is beneficial in improving quality of life in asthma patients. As two out of four studies in our review were of poor quality, further trials with better methodological quality are needed to support or refute this finding</style></abstract><notes><style face="normal" font="default">DA - 20170830IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1365887</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28853958">PM:28853958</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170830-PaudyalP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170830-PaudyalP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170830, Paudyal P</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1365887</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42476</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chung,J.H.</style></author><author><style face="normal" font="default"> Kim,T.H.</style></author><author><style face="normal" font="default"> Han,C.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Internal Medicine , International St. Mary`s Hospital, Catholic Kwandong University College of Medicine , Incheon , Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Association between Asthma and Falls: A Nationwide Population-Based Study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="default">OBJECTIVES: We evaluated the relationship between asthma and falls in Koreans using data from a large population-based cross-sectional survey. METHODS: Data were obtained from 228,642 participants, of whom 6,372 had asthma, who participated in the 2013 Korean Community Health Survey. We explored the risk of falls after adjusting for sociodemographic factors and comorbidities. Logistic regression was used to identify risk factors for falls in asthmatics. Patients with asthma who had been diagnosed by a physician were included after excluding those who did not respond to the self-reported questionnaire. RESULTS: In all, 1,733/6,372 (27.1%) asthma patients and 258/788 (32.7%) patients with uncontrolled asthma (who had visited the emergency room because of asthma exacerbation in the prior 12 months) reported histories of falls. In asthmatics, the crude odds ratio (OR) for falls was 1.57 (95% confidence interval [CI]: 1.48-1.67); the OR for falls in the group with uncontrolled asthma was 2.13 (95% CI: 1.83-2.47). The multivariate OR for falls in the asthma group (compared to the non-asthma group) was 1.27 (95% CI, 1.18-1.35) and the OR for falls in the uncontrolled asthma group (again compared to the non-asthma group) was 1.55 (95% CI, 1.32-1.82). Subgroup analysis of the adjusted ORs for falls in asthmatics by age group revealed a significant difference between the presence of asthma and uncontrolled asthma, and falls, in each age group, similar to the relationship evident in the total adult population. CONCLUSION: Asthma is associated with falls, even after adjusting for sociodemographic and comorbid variables</style></abstract><notes><style face="normal" font="default">DA - 20170830IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1369990</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28853959">PM:28853959</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170830-ChungJH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170830-ChungJH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170830, Chung JH</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1369990</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42477</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhao,D.H.</style></author><author><style face="normal" font="default"> Smith,L.</style></author><author><style face="normal" font="default"> Saini,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Faculty of Pharmacy, The University of Sydney , Sydney , NSW , Australia</style></auth-address><titles><title><style face="normal" font="default">Exploring Asthma in the Workplace: A Triangulation of Perspectives from Management, Employees and People with Asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="8" Year="2017">2017/8/31</year></dates><abstract><style face="normal" font="default">OBJECTIVES: People with asthma spend a significant amount of time in the workplace but little is known about the current state of disease management in such contexts. The aim of the current study is to explore the experiences, attitudes and perceptions of asthma across different stakeholders in the workplace to help inform potential recommendations for workplace asthma policies. METHODS: Using a purposive convenience sampling method, in-depth semi-structured interviews were conducted in Australia with 5 human resource personnel, 10 employees with asthma and 10 employees without asthma. Interviews were guided by a schedule of questions focusing on attitudes and experiences of asthma in the workplace, which were audio recorded, transcribed verbatim and thematically analysed. RESULTS: Analysis of the qualitative dataset revealed three key themes: Beliefs and Attitudes about Asthma, Asthma Solutions in the Workplace and Workplace Obstacles. Findings suggest employees with asthma experience problems managing their asthma at work and there is a lack of workplace support in relation to asthma emergency management. CONCLUSION: Key recommendations for workplace asthma policies have been made to provide better support for employees with asthma. However, further investigation into the experience of managing asthma is required in a wider variety of occupations and work experiences to inform the development of a workplace asthma policy</style></abstract><notes><style face="normal" font="default">DA - 20170831IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1369991</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28858530">PM:28858530</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170831-ZhaoDH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170831-ZhaoDH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170831, Zhao DH</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1369991</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42478</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Feng-Jia,C.</style></author><author><style face="normal" font="default"> Xin-Yan,H.</style></author><author><style face="normal" font="default"> Geng-Peng,L.</style></author><author><style face="normal" font="default"> Yang-Li,L.</style></author><author><style face="normal" font="default"> Can-Mao,X.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Respiratory Disease , The First Affiliated Hospital, Sun Yet-Sen University , Guangzhou 510080 , China</style></auth-address><titles><title><style face="normal" font="default">Validity of Fractional Exhaled Nitric Oxide and Small Airway Function Indices in Diagnosis of Cough Variant Asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="28" Month="8" Year="2017">2017/8/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: Fractional exhaled nitric oxide (FeNO) is a non-invasive method used to reveal the eosinophilic inflammation of airway and to diagnose and manage asthma. The diagnostic value of FeNO in patients with cough variant asthma (CVA) is poorly understood. Small airways remain an important aspect of CVA. The use of FeNO measurement or its combination with the small airway function in differentiating CVA patients from chronic cough patients is unexplored. METHODS: From December 2012 to June 2016, patients with chronic nonproductive cough for more than 8 weeks without any wheezing or dyspnea, fever or blood-stained sputum, and abnormalities on X-ray or larger airways function based on physician's opinion were subjected to FeNO, pulmonary function, and bronchial hyperresponsiveness (BHR) tests. Patients who obtained positive BHR were diagnosed with CVA. Receiver operating characteristic (ROC) curves were obtained to evaluate the clinical value of FeNO and small airways indices in CVA diagnosis. The optimal cutoff point for the level of FeNO was also determined. RESULTS: A total of 450 patients were enrolled, among which 150 patients had CVA. The FeNO value in CVA was significantly higher than that in NCVA group [42(41) parts per billion (ppb) vs. (16(11) ppb), P&lt;0.05]. The area under the ROC curve was estimated as 0.874 for FeNO. An optimal cutoff point of 25 ppb had respective sensitivity and specificity values of 81.3% and 84.0% in differentiating CVA patients from NCVA patients. The CVA group showed small airway dysfunction, and the small airway resistance was significantly higher than in the NCVA group. The area under the ROC curve of FeNO combined with MEF (% predicted) was 0.883, and that combined with MEF50 (% predicted) was 0.886. CONCLUSIONS: The measurement of FeNO is a noninvasive, reproducible, and sensitive method of differentiating CVA patients from NCVA patients. A combination of the level of FeNO (>/=25 ppb) and the abnormal small airway function suggested higher CVA possibility, thereby resulting in a rapid diagnosis. Unnecessary treatments are avoided. This finding provides a new perspective for the management of patients with CVA</style></abstract><notes><style face="normal" font="default">DA - 20170828IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1366509</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28846444">PM:28846444</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170828-FengJiaC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170828-FengJiaC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170828, Feng-Jia C</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1366509</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42479</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Heikkinen,S.A.M.</style></author><author><style face="normal" font="default"> Makikyro,E.M.S.</style></author><author><style face="normal" font="default"> Hugg,T.T.</style></author><author><style face="normal" font="default"> Jaakkola,M.S.</style></author><author><style face="normal" font="default"> Jaakkola,J.J.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Oulun Yliopisto Laaketieteellisen tiedekunta,Center for Environmental and Respiratory Research , Oulu , 90014 Finland</style></auth-address><titles><title><style face="normal" font="default">Effects of regular exercise on asthma control in young adults</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="28" Month="8" Year="2017">2017/8/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: According to our systematic literature review, no previous study has assessed potential effects of regular exercise on asthma control among young adults. We hypothesized that regular exercise improves asthma control among young adults. METHODS: We studied 162 subjects with current asthma recruited from a population-based cohort study of 1623 young adults 20-27 years of age. Asthma control was assessed by the occurrence of asthma-related symptoms, including wheezing, shortness of breath, cough, and phlegm production, during the past 12 months. Asthma symptom score was calculated based on reported frequencies of these symptoms (range 0-12). Exercise was assessed as hours/week. RESULTS: In Poisson regression, adjusting for gender, age, smoking, environmental tobacco smoke exposure, and education, the asthma symptom score reduced by 0.09 points per 1 hour of exercise/week (95% CI: 0.00 to 0.17). Applying the "Low exercise" quartile as the reference, "Medium exercise" reduced the asthma symptom score by 0.66 (-0.39 to 1.72), and "High exercise" reduced it significantly by 1.13 (0.03 to 2.22). The effect was strongest among overweight subjects. CONCLUSIONS: Our results provide new evidence that regular exercising among young adults improves their asthma control. Thus, advising about exercise should be included as an important part of asthma self-management in clinical practise</style></abstract><notes><style face="normal" font="default">DA - 20170828IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1366510</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28846458">PM:28846458</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170828-HeikkinenSA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170828-HeikkinenSA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170828, Heikkinen SA</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1366510</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42480</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Carew,C.</style></author><author><style face="normal" font="default"> Cox,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Respiratory department , Our Lady's Children's Hospital , Crumlin, Dublin , Ireland</style></auth-address><titles><title><style face="normal" font="default">Laps or lengths? The effects of different exercise programmes on asthma control in children</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="9" Year="2017">2017/9/5</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Exercise training has been shown in numerous studies to improve lung function and asthma control in children with asthma. Swimming has been shown to be of benefit in children with asthma, but which form of exercise is better for asthmatics has not been determined to date. The aim of this study was to examine if swimming improved lung function and asthma symptoms in asthmatic children when compared with different forms of exercise and a control group. METHODS: Subjects with asthma were randomly assigned to either one of three different exercise training groups (swimming, football and basketball) or a control group. Spirometry was performed before and after and the subjects were asked to keep asthma diaries and perform daily peak flow measurements. RESULTS: 41 children and adolescents between the ages of nine and 16 participated in the study. After completing the training, children across all three exercise programmes had significantly higher forced vital capacity (FVC) percentage values when compared to the control group. The swimming group demonstrated a significant increase in the percentage peak expiratory flow (PEF) following the exercise programme when compared with the control group (78.3 +/- 9.3 versus 89.0 +/- 14.9, p = 0.04). All children on exercise training programmes reported an improvement in their asthma symptoms via asthma diaries. CONCLUSION: This study suggests that a swimming training programme is more beneficial in terms of peak flow measurements when compared with other exercise training programmes</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Ireland -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1373806</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28872938">PM:28872938</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170905-CarewC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170905-CarewC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Carew C</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1373806</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42481</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mukadam,S.</style></author><author><style face="normal" font="default"> Zacharias,J.</style></author><author><style face="normal" font="default"> Henao,M.P.</style></author><author><style face="normal" font="default"> Kraschnewski,J.</style></author><author><style face="normal" font="default"> Terrence,I.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Pennsylvania State University College of Medicine,Medicine , 500 University Dr, H171, Hershey , 17033 United States</style></auth-address><titles><title><style face="normal" font="default">Differential Effects of Obesity on Eosinophilic vs. Non-Eosinophilic Asthma Subtypes</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="28" Month="8" Year="2017">2017/8/28</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Asthma is a heterogeneous disease composed of multiple disease subtypes. Obesity may worsen asthma, although the mechanism is poorly understood and its effects on different subtypes are not well characterized. We sought to determine whether obesity affects eosinophilic asthma differently from non-eosinophilic asthma. METHODS: Charts of 196 persistent asthmatics were reviewed. Subjects were categorized by BMI (obese >/= 30 kg/m2) and blood eosinophilia based on two different cutoffs (>/=200 or >/=400 cells/microl): eosinophilic, non-obese (E-NO), eosinophilic, obese (E-O), non-eosinophilic, non-obese (NE-NO), and non-eosinophilic, obese (NE-O). We analyzed clinical parameters across these groups to determine associations with obesity and/or eosinophilia. RESULTS: Obesity was highly prevalent in our population (50.5%, 99/196). The majority of asthmatics were female (75.5%), though the ratio was lower in the E-NO group (56%). The NE-NO group was associated with lowest asthma severity, lower atopy, and less medication use. Regardless of eosinophilia, obesity was associated higher ICS doses and lower FVC%-predicted than their non-obese counterparts. Obesity was associated with reduced FEV1% only in the non-eosinophilic group. Eosinophilia was also associated with reduced FEV1% in the non-obese subjects, but FEV1% was not further reduced in the E-O group compared to the E-NO and NE-O groups. Similar findings were observed regardless of whether the blood eosinophil cutoff was 200 or 400 cells/ microl. CONCLUSION: Multiple clinical features of asthma are adversely affected by obesity, which may affect eosinophilic and non-eosinophilic subtypes differently</style></abstract><notes><style face="normal" font="default">DA - 20170828IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1365886</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28846451">PM:28846451</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170828-MukadamS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170828-MukadamS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170828, Mukadam S</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1365886</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42482</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Paciej,P.</style></author><author><style face="normal" font="default"> Dziankowska-Zaborszczyk,E.</style></author><author><style face="normal" font="default"> Ciabiada,B.</style></author><author><style face="normal" font="default"> Bryla,M.</style></author><author><style face="normal" font="default"> Maniecka-Bryla,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Epidemiology and Biostatistics , Medical University of Lodz</style></auth-address><titles><title><style face="normal" font="default">Years of Life Lost Due to Bronchial Asthma in Poland Between 1999-2013</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Female</style></keyword></keywords><dates><year Day="31" Month="7" Year="2017">2017/7/31</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The aim of this study was to analyze the years of life lost due to asthma in Poland between 1999-2013, with the use of the SEYLL measure (Standard Expected Years of Life Lost). METHODS: The study was based on a dataset of 5 606 516 records gathered from death certificates of Polish residents from 1999-2013. The data on the deaths due to bronchial asthma and status asthmaticus (J45 and J46 according to ICD-10) were used for the analysis. The SEYLL, SEYLLp (SEYLL per person) and SEYLLd (SEYLL per death) were implemented to assess lost life years. The analysis of time trends was performed with the use of the joinpoint model. RESULTS: In 1999-2013, asthma and status asthmaticus were the cause of 11 380 deaths of Poles (0.20% of all deaths), resulting in 4.23 prematurely lost life years per 10 000 males and 3.22 years per 10 000 females. Over the analyzed years, the value of SEYLL decreased both for men and for women. A man who died due to asthma in the studied period, lost on average 19.12 years of life, and a woman 18.20 years. CONCLUSIONS: The analysis of SEYLL indicated that premature mortality due to asthma is still a meaningful problem in the Polish population and a constant challenge for public health activities</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1355382</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28759291">PM:28759291</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170731-PaciejP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170731-PaciejP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170731, Paciej P</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1355382</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42483</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gillette,C.</style></author><author><style face="normal" font="default"> Rockich-Winston,N.</style></author><author><style face="normal" font="default"> Shepherd,M.</style></author><author><style face="normal" font="default"> Flesher,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Wingate University School of Pharmacy</style></auth-address><titles><title><style face="normal" font="default">Children with asthma and their caregivers help improve written asthma action plans: A pilot mixed-methods study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="0">0-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="7" Year="2017">2017/7/31</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The objectives of this study were to (a) qualitatively examine caregiver and child feedback about a gold standard written asthma action plan (WAAP), and (b) determine whether having an asthma action plan was associated with child and caregiver self-efficacy in managing an exacerbation. METHODS: This was a cross-sectional analysis of structured interviews with 22 children with persistent asthma that collected feedback about the WAAP as well as self-efficacy. Analysis of interviews used the constant comparative method to identify themes of child and caregiver statements. Caregivers completed a questionnaire that measured asthma management self-efficacy, barriers to managing asthma, and belief in treatment efficacy using validated scales. RESULTS: Approximately 36% of caregivers reported having a written asthma action plan for their child from their child's pediatrician. Most caregivers stated that having pictures would improve the written asthma action plan while most children stated that the layout needed to be improved by adding more space between the sections. Caregivers who reported knowing what the asthma action plan was had greater self-efficacy than caregivers who did not (z = -1.99, p = 0.047). CONCLUSIONS: Re-designing the current WAAP layout and including pictures of inhalers may promote patient understanding. Future research needs to examine if a re-designed WAAP improves asthma management of children with asthma and their caregivers</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1355379</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28759273">PM:28759273</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170731-GilletteC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170731-GilletteC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170731, Gillette C</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1355379</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42484</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Watanabe,J.I.</style></author><author><style face="normal" font="default"> Tanaka,K.</style></author><author><style face="normal" font="default"> Nagata,C.</style></author><author><style face="normal" font="default"> Furukawa,S.</style></author><author><style face="normal" font="default"> Arakawa,M.</style></author><author><style face="normal" font="default"> Miyake,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Epidemiology and Preventive Medicine , Ehime University Graduate School of Medicine , Ehime , Japan</style></auth-address><titles><title><style face="normal" font="default">Breastfeeding duration is inversely associated with asthma in Japanese children aged 3 years</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="7" Year="2017">2017/7/31</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Recent meta-analyses found an inverse relationship between breastfeeding duration and asthma in children. The present cross-sectional study investigated the associations between breastfeeding duration and the prevalence of wheeze and asthma in Japanese children aged 3 years. METHODS: Subjects were 6412 children who participated in the Kyushu Okinawa Child Health Study. Data were collected using a self-administered questionnaire. Wheeze was defined according to the criteria of the International Study of Asthma and Allergies in Childhood. Asthma was considered present if the child had been diagnosed by a physician as having asthma. Associations of breastfeeding duration with wheeze and asthma were estimated using multivariate generalized estimating equation methods adjusted for maternal, family, and health characteristics. RESULTS: The prevalence values of wheeze and asthma were 19.5% and 7.0%, respectively. Compared with &lt;4 months of exclusive breastfeeding, exclusive breastfeeding for >/=4 months was not significantly associated with wheeze or asthma. Compared with &lt;10 months of breastfeeding duration regardless of exclusivity, 10 to &lt;14 months, 14 to &lt;19 months, and 19 months or more of breastfeeding duration regardless of exclusivity were independently inversely related to asthma: the adjusted odds ratios [ORs; 95% confidence intervals (CIs)] were 0.69 (0.52-0.91, p = 0.01), 0.73 (0.56-0.97, p = 0.03), and 0.67 (0.51-0.88, p = 0.004), respectively. No association was found between breastfeeding duration regardless of exclusivity and wheeze. CONCLUSIONS: We confirmed an inverse association between breastfeeding duration regardless of exclusivity and asthma</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Jpan -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1349793</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28759280">PM:28759280</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170731-WatanabeJI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170731-WatanabeJI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170731, Watanabe JI</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1349793</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42485</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Clawson,A.H.</style></author><author><style face="normal" font="default"> McQuaid,E.L.</style></author><author><style face="normal" font="default"> Borrelli,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Centers for Behavioral and Preventive Medicine, Alpert Medical School of Brown University and The Miriam Hospital . Providence , RI , USA</style></auth-address><titles><title><style face="normal" font="default">Smokers who have children with asthma: Perceptions about child secondhand smoke exposure and tobacco use initiation and parental willingness to participate in child-focused tobacco interventions</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="7" Year="2017">2017/7/31</year></dates><abstract><style face="normal" font="default">OBJECTIVE: This study examined, among parents who smoke and have children with asthma, perceptions about child secondhand smoke exposure (SHSe), child tobacco use initiation, and parent willingness to participate in child-focused tobacco interventions. METHODS: Participants were 300 caregivers who smoked and had a child with asthma (ages 10-14). Parents completed an online survey and self-reported perceptions about child SHSe elimination, child tobacco use prevention, and willingness to participate in three types of interventions with and without their child (SHSe reduction intervention, tobacco prevention intervention, and the combination of the two). Correlates of perceptions and willingness were examined. RESULTS: Parents who were ready to quit smoking and who reported home smoking bans (HSBs) were more motivated to eliminate SHSe (p's &lt; .05). Being white, younger, ready to quit, and having HSBs were associated with greater confidence to eliminate SHSe (p's &lt; .05). Parents with HSBs reported higher perceived importance about preventing child tobacco use (p's &lt; .05). Parents were less confident about preventing male children from using tobacco (p = 0.001). Parents were highly willing to participate in all of the described intervention approaches, with or without their child. CONCLUSIONS: Parents were willing to participate in child-focused tobacco interventions, with or without their child with asthma, including interventions that address both child SHSe and tobacco use prevention. This research demonstrates the acceptability of child-focused tobacco interventions among a high-risk population and may be a foundational step for intervention development</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1339797</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28759279">PM:28759279</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170731-ClawsonAH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170731-ClawsonAH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170731, Clawson AH</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1339797</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42486</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rodriguez-Martinez,C.E.</style></author><author><style face="normal" font="default"> Sossa-Briceno,M.P.</style></author><author><style face="normal" font="default"> Castro-Rodriguez,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatrics, School of Medicine , Universidad Nacional de Colombia , Bogota , Colombiab Department of Pediatric Pulmonology and Pediatric Critical Care Medicine, School of Medicine , Universidad El Bosque , Bogota , Colombiac Department of Internal Medicine, School of Medicine , Universidad Nacional de Colombia , Bogota , Colombiad Division of Pediatrics, School of Medicine , Pontificia Universidad Catolica de Chile , Santiago , Chile</style></auth-address><titles><title><style face="normal" font="default">A cost-effectiveness threshold analysis of a multidisciplinary structured educational intervention in pediatric asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="7" Year="2017">2017/7/31</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Asthma educational interventions have been shown to improve several clinically and economically important outcomes. However, these interventions are costly in themselves and could lead to even higher disease costs. A cost-effectiveness threshold analysis would be helpful in determining the threshold value of the cost of educational interventions, leading to these interventions being cost-effective. The aim of the present study was to perform a cost-effectiveness threshold analysis to determine the level at which the cost of a pediatric asthma educational intervention would be cost-effective and cost-saving. METHODS: A Markov-type model was developed in order to estimate costs and health outcomes of a simulated cohort of pediatric patients with persistent asthma treated over a 12-month period. Effectiveness parameters were obtained from a single uncontrolled before-and-after study performed with Colombian asthmatic children. Cost data were obtained from official databases provided by the Colombian Ministry of Health. The main outcome was the variable "quality-adjusted life-years" (QALYs). RESULTS: A deterministic threshold sensitivity analysis showed that the asthma educational intervention will be cost-saving to the health system if its cost is under US$513.20. Additionally, the analysis showed that the cost of the intervention would have to be below US$967.40 in order to be cost-effective. CONCLUSIONS: This study identified the level at which the cost of a pediatric asthma educational intervention will be cost-effective and cost-saving for the health system in Colombia. Our findings could be a useful aid for decision makers in efficiently allocating limited resources when planning asthma educational interventions for pediatric patients</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Colombia -CO - Chile -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1348512</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28759278">PM:28759278</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170731-RodriguezMartinezCE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170731-RodriguezMartinezCE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170731, Rodriguez-Martinez CE</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1348512</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42487</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Machluf,Y.</style></author><author><style face="normal" font="default"> Farkash,R.</style></author><author><style face="normal" font="default"> Fink,D.</style></author><author><style face="normal" font="default"> Chaiter,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Medical Corps, IDF , Israel</style></auth-address><titles><title><style face="normal" font="default">Asthma severity and heterogeneity: Insights from prevalence trends and associated demographic variables and anthropometric indices among Israeli adolescents</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="9" Year="2017">2017/9/5</year></dates><abstract><style face="normal" font="default">OBJECTIVES: While asthma presents various clinical forms with different levels of severity, it is unclear whether asthma severities are a consequence of disease management or varied etiologies. We sought to investigate this question. METHODS: This paper presents a cross-sectional study of 113,671 Israeli adolescents. Prevalence rates of mild and moderate-to-severe asthma over a 24-year period were calculated and multivariate regression models (outcomes: different asthma severity, reference: subjects without asthma) were performed to analyze associations with anthropometric indices and socio-demographic variables, in males and females separately. RESULTS: The prevalence of mild asthma increased until birth years 1976-1980 and then steadily decreased. In contrast, the prevalence of moderate-to-severe asthma was relatively stable until birth years 1976-1980, then rose steeply until 1986-1990 and subsequently plateaued in the early 1990s. Obesity was positively associated with both mild and moderate-to-severe asthma in males (Odds Ratio [95%CIs]: 1.61 [1.37-1.89] and 1.63 [1.34-1.98], respectively) and females (1.54 [1.10-2.16] and 1.54 [1.20-1.98], respectively). Family size greater than 3 siblings was negatively associated with both mild and moderate-to-severe asthma in males (0.62 [0.56-0.68] and 0.59 [0.52-0.68]) and females (0.71 [0.60-0.83] and 0.73 [0.63-0.83]). In contrast, in males, underweight was only associated with mild asthma (1.54 [1.22-1.94]) but not with moderate-to-severe asthma. In females, overweight was only associated with moderate-to-severe asthma (1.21 [1.00-1.46]) and rural residence was only associated with mild asthma (1.26 [1.09-1.47]). CONCLUSIONS: The differences between mild and moderate-to-severe asthma enhance asthma phenotype characterization, with respect to secular trends and associated variables, and indicate varied etiologies</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1373809</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28872935">PM:28872935</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170905-MachlufY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170905-MachlufY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Machluf Y</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1373809</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42488</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Toennesen,L.L.</style></author><author><style face="normal" font="default"> Bjerregaard,A.</style></author><author><style face="normal" font="default"> Porsbjerg,C.</style></author><author><style face="normal" font="default"> Ulrik,C.S.</style></author><author><style face="normal" font="default"> Harmsen,L.</style></author><author><style face="normal" font="default"> Backer,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Respiratory Medicine , Respiratory Research Unit, Bispebjerg Hospital , Copenhagen , Denmarkb Institute of Clinical Medicine, University of Copenhagen , Copenhagen , Denmark</style></auth-address><titles><title><style face="normal" font="default">Overweight in childhood and adolescence: Does it lead to airway hyperresponsiveness in adulthood?</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="7" Year="2017">2017/7/31</year></dates><abstract><style face="normal" font="default">BACKGROUND: Obesity is increasing worldwide among children and adolescents, and has been associated with an increased incidence of asthma. However, the mechanisms underlying this association are incompletely understood. OBJECTIVE: In this cohort study we aimed to investigate whether being overweight in childhood and adolescence is associated with an increased risk of airway hyperresponsiveness (AHR), a hallmark of asthma, in early adulthood. METHODS: Of 527 subjects from a random population sample of children and adolescents (7-17 years) examined at baseline, a total of 184 subjects completed the follow-up visit 20 years later and were included in the present analysis. Both visits included assessment of height and weight, case history and spirometry. At both visits, bronchial provocation tests were performed using either histamine (baseline) or methacholine (follow-up). In addition, fractional exhaled nitric oxide (FeNO) was measured at follow-up. RESULTS: No significant difference in the prevalence of AHR at follow-up was found between subjects who were overweight or obese at baseline visit (n = 26) (pediatric definition, body mass index >/= 85%percentile) and normal weight subjects (n = 158) (positive bronchial provocation tests: 15.4% vs. 22.2%, respectively, p = 0.35). Likewise, follow-up FeNO levels did not differ significantly between subjects who were lean and those who were overweight or obese at baseline (geometric mean (95% confidence interval [CI]) 15.1 (13.7, 16.6) parts per billion (ppb) versus 13.0 (10.6, 15.9) ppb, p = 0.23). CONCLUSION: In children and adolescents, being obese or overweight seems not to be associated with an increased risk of AHR or increased FeNO levels in early adulthood</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1318143</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28758814">PM:28758814</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170731-ToennesenLL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170731-ToennesenLL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170731, Toennesen LL</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1318143</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42489</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shlomi,D.</style></author><author><style face="normal" font="default"> Katz,I.</style></author><author><style face="normal" font="default"> Segel,M.J.</style></author><author><style face="normal" font="default"> Oberman,B.</style></author><author><style face="normal" font="default"> Peled,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Clalit Health Services , Dan-Petah-Tiqwa District , Israel</style></auth-address><titles><title><style face="normal" font="default">Determination of asthma control using administrative data regarding short-acting beta-agonist inhaler purchase</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="7" Year="2017">2017/7/31</year></dates><abstract><style face="normal" font="default">BACKGROUND: Symptom control is a primary goal in asthma. We hypothesized that administrative data regarding rescue inhaler purchases may correlate with asthma symptom control. METHODS: We identified all patients who purchased short-acting beta-agonist (SABA) inhalers during the course of one year in the database of a Health Maintenance Organization (HMO). Primary physicians identified asthma patients and classified their asthma symptom control into three groups according to the Global Initiative for Asthma (GINA) guidelines. Asthma patients were asked to answer symptom questionnaires and grade their asthma control. SABA inhaler purchases were compared between asthma control groups as classified by the guidelines, the physicians and the patients. We also compared the agreement on asthma control between the three methods of classification. RESULTS: Of 241 asthma patients, 83 completed the questionnaires. Using the GINA guidelines criteria, 26 were symptom controlled, 46 were partially controlled and 11 were uncontrolled. SABA inhaler purchases were not significantly lower in the controlled group. Using patients' overall impression of their asthma control, the mean numbers of SABA inhalers purchased were 1.5, 4.4 and 6.4 per year in the controlled, partially controlled and uncontrolled groups, respectively (p = 0.03). Patients' classification of asthma control had better agreement (kappa = 0.34) with GINA guidelines than physician's' agreement (kappa = 0.05). CONCLUSION: When using administrative data for asthma patients, 2 or more SABA inhaler purchases in one year should alert the physician for the need for asthma control evaluation. Purchase of at least 4 SABA inhalers a year may be regarded as a marker for asthma that is not controlled</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1348513</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28759272">PM:28759272</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170731-ShlomiD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170731-ShlomiD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170731, Shlomi D</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1348513</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42490</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fitzgerald,K.</style></author><author><style face="normal" font="default"> Pang,T.C.</style></author><author><style face="normal" font="default"> Kritikos,V.</style></author><author><style face="normal" font="default"> Saini,B.</style></author><author><style face="normal" font="default"> Moles,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Faculty of Pharmacy, University of Sydney Building A15, Faculty of Pharmacy, Science Road, University of Sydney , Camperdown Campus, NSW , 2006 Australia</style></auth-address><titles><title><style face="normal" font="default">Systematic Review and Content Analysis of Asthma Knowledge Questionnaires: A Focus on Knowledge Surrounding Acute Exacerbation Management</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="7" Year="2017">2017/7/31</year></dates><abstract><style face="normal" font="default">Objectives Asthma education is a key component of asthma management. Asthma education around management of a person who is having an acute exacerbation of asthma (often referred to as asthma first-aid training) is important, particularly in a school setting. There is no gold standard assessment of asthma knowledge and no specific tool to measure knowledge of asthma first-aid. Our aim was to identify asthma knowledge questionnaires and perform a content analysis. We were interested in evaluating the number, the type and the format of asthma first aid questions. Method A literature search was performed to identify instruments able to assess asthma knowledge of people with asthma and/or caregivers of people with asthma. An electronic database search was performed in EMBASE, IPA, MEDLINE and PUBMED. Articles which described the development or psychometric testing of an asthma knowledge questionnaire were included. The content of questions in each instrument were analysed and categorized using N Vivo software, and a secondary analysis was performed to identify knowledge questions relevant to the management of an acute asthma exacerbation. Results Forty four papers with 37 different instruments met the inclusion criteria. The majority of the instruments contained a relatively low proportion of questions related to management of acute asthma, only 162 of the 780 questions (21%). No questionnaire had sufficient specific emphasis on acute asthma management knowledge to test the impact of asthma first-aid training. Conclusion There is scope to develop an up-to-date validated acute asthma management knowledge questionnaire for use in research and clinical settings</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1355380</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28759285">PM:28759285</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170731-FitzGeraldK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170731-FitzGeraldK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170731, FitzGerald K</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1355380</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42491</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lougheed,M.D.</style></author><author><style face="normal" font="default"> Thomas,N.J.</style></author><author><style face="normal" font="default"> Wasilewski,N.V.</style></author><author><style face="normal" font="default"> Morra,A.H.</style></author><author><style face="normal" font="default"> Minard,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Medicine , Queen's University , 102 Stuart Street, Kingston , Ontario , K7L 2V6 , Canada</style></auth-address><titles><title><style face="normal" font="default">Use of SNOMED CT(R) and LOINC(R) to Standardize Terminology for Primary Care Asthma Electronic Health Records</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="8" Year="2017">2017/8/11</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The burden of asthma ranks among the highest for chronic diseases. Interoperable EHRs can improve the management of chronic diseases such as asthma by facilitating sharing of data between health care settings along the continuum of care. Terminology such as SNOMED CT(R) (Systematized Nomenclature of Medicine-Clinical Terms) and LOINC(R) (Logistical Observation Identifier Names and Codes) are prerequisites for interoperability of electronic health records (EHRs). We sought to determine the extent to which data elements in a validated asthma care map (ACM) are congruent with these terminologies. METHODS: A certified asthma educator entered all 169 elements in the ACM into the SNOMED CT(R) browser. Matched elements were assigned a concept name, an identification number and classified into a hierarchy. LOINC(R) terminology was reviewed for asthma-related pulmonary function tests (PFT). RESULTS: Forty-two % of the ACM elements were complete matches to existing SNOMED CT(R) concepts, 24% partial matches and 34% unmatched. Specific asthma control parameters were either complete (n = 3) or partial (n = 4) matches, but overall 'asthma control' was unmatched. There were 92% complete or partial matches for PFT elements to SNOMED CT(R) and 83% to LOINC(R). Conclusions: The majority of ACM elements are congruent with standardized terminology, enabling EHR interoperability. Future requests for new concepts in SNOMED CT(R) and LOINC(R) should be pursed for asthma control parameters paramount to evidence-based practice</style></abstract><notes><style face="normal" font="default">DA - 20170811IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1362424</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28800265">PM:28800265</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170811-LougheedMD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170811-LougheedMD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170811, Lougheed MD</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1362424</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42492</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kerwin,E.</style></author><author><style face="normal" font="default"> Barnes,N.</style></author><author><style face="normal" font="default"> Gibbs,M.</style></author><author><style face="normal" font="default"> Leather,D.</style></author><author><style face="normal" font="default"> Forth,R.</style></author><author><style face="normal" font="default"> Jacques,L.</style></author><author><style face="normal" font="default"> Yates,L.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Clinical Research Institute of Southern Oregon , Medford , OR , USA</style></auth-address><titles><title><style face="normal" font="default">Fluticasone furoate/vilanterol once daily improves night-time awakenings in asthma patients with night symptoms; post-hoc analyses of three randomized controlled trials</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="8" Year="2017">2017/8/7</year></dates><abstract><style face="normal" font="default">Symptoms, including night-time awakenings, affect the quality of life of people with asthma. Fluticasone furoate/vilanterol (FF/VI) reduces exacerbations, improves lung function, and rescue-free and symptom-free 24-hour periods in patients with asthma. These post-hoc analyses compared daytime and night-time symptoms in patients with asthma who received FF/VI, versus FF, fluticasone propionate (FP) or placebo. Daytime and night-time symptoms were collected via electronic daily diary cards in three Phase III randomized studies of once-daily FF/VI in patients with uncontrolled asthma on inhaled corticosteroids (ICS) +/-long-acting beta2-agonists (LABA) (n = 609/1039/586). Endpoints included: change from baseline in symptom-free days and nights (analyzed by Analysis of Covariance, covariates: baseline, region, sex, age, treatment), time for patients to achieve 7 consecutive symptom-free nights (analyzed by Cox proportional hazards model, covariates as above), and proportion of patients experiencing 100% symptom-free nights per week (analyzed by logistic regression, covariates: percentage of symptom-free nights, sex, age, treatment). Improvements in symptom-free days and nights were generally observed for all treatments. More patients who received FF/VI experienced 100% symptom-free nights in the last week of the treatment period than patients who received ICS alone or placebo. FF/VI also reduced time to 7 consecutive symptom-free nights. Patients with at least one night of symptoms at baseline experienced an additional 2.7 and 2.0 symptom-free nights per week with FF/VI 100/25 microg, versus 1.9 and 1.7 with FF alone; similar findings were seen with FF/VI 200/25 microg. Benefits in terms of symptom-free days and nights were observed for patients receiving FF/VI versus comparators in these post-hoc analyses</style></abstract><notes><style face="normal" font="default">DA - 20170807IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United states -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1362429</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28783413">PM:28783413</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170807-KerwinE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170807-KerwinE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170807, Kerwin E</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1362429</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42493</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Goedken,A.M.</style></author><author><style face="normal" font="default"> Brooks,J.M.</style></author><author><style face="normal" font="default"> Milavetz,G.</style></author><author><style face="normal" font="default"> Rudzianski,N.J.</style></author><author><style face="normal" font="default"> Chrischilles,E.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a College of Pharmacy, University of Iowa , Iowa City , IA , USA</style></auth-address><titles><title><style face="normal" font="default">Geographic variation in inhaled corticosteroid use for children with persistent asthma in Medicaid</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="8" Year="2017">2017/8/11</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Geographic variation in the rates of inhaled corticosteroid (ICS) use for children with persistent asthma in Medicaid has been reported, but the source of the variation is unknown. The objective of this study was to quantify the geographic variation in ICS use for children with persistent asthma in Medicaid that remains after adjusting for the characteristics of children in an area. METHODS: Data from the 2005-2007 Medicaid Analytic eXtract files were used. Frequent fills of short-acting beta2-agonist (SABA) were used to identify children 5-18 years old with persistent asthma across the United States. A child was considered to have used an ICS if the child initially filled an ICS following frequent SABA use. Areas were determined using published methods, and the unadjusted ICS rate and the area treatment ratio for ICS, which adjusted for demographic and clinical characteristics, were calculated for each area. RESULTS: Of 15,917 children, 13% used an ICS. The median unadjusted ICS rate for all areas was 10% but ranged from 0-64%. ICS use was less than expected for more than half of the areas based on the characteristics of the children in the area, but use was nearly five times what was expected in some areas. Areas with higher than expected ICS use were found contiguous to areas with lower than expected use. CONCLUSIONS: Geographic variation in ICS not attributable to the demographic and clinical characteristics of the children in an area exists and could prove useful in the struggle to reduce asthma exacerbation rates</style></abstract><notes><style face="normal" font="default">DA - 20170811IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1362428</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28800267">PM:28800267</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170811-GoedkenAM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170811-GoedkenAM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170811, Goedken AM</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1362428</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42494</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Taylor,Y.J.</style></author><author><style face="normal" font="default"> Tapp,H.</style></author><author><style face="normal" font="default"> Shade,L.E.</style></author><author><style face="normal" font="default"> Liu,T.L.</style></author><author><style face="normal" font="default"> Mowrer,J.L.</style></author><author><style face="normal" font="default"> Dulin,M.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Carolinas HealthCare System , Charlotte , North Carolina</style></auth-address><titles><title><style face="normal" font="default">Impact of Shared Decision Making on Asthma Quality of Life and Asthma Control among Children</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">diagnosis</style></keyword></keywords><dates><year Day="11" Month="8" Year="2017">2017/8/11</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Few studies have examined the effectiveness of shared decision making (SDM) in clinical practice. This study evaluated the impact of SDM on quality of life and symptom control in children with asthma. METHODS: We conducted a prospective 3-year study in six community-based practices serving a low-income patient population. Practices received training on SDM using an evidence-based toolkit. Patients aged 2 to 17 with a diagnosis of asthma were identified from scheduling and billing data. At approximate 6-month intervals, patients completed a survey consisting of the Mini Pediatric Asthma Quality of Life Questionnaire (range 1-7) and the control domain of the Pediatric Asthma Therapy Assessment Questionnaire (range 0-7). We used propensity scores to match 46 children receiving SDM to 46 children receiving usual care with decision support. Included children had completed a baseline survey and at least one follow-up survey. Random coefficient models incorporated repeated measures to assess the effect of SDM on asthma quality of life and asthma control. RESULTS: The sample was primarily of non-White patients (94.6%) with Medicaid insurance (92.4%). Receipt of SDM using an evidence-based toolkit was associated with higher asthma quality of life (mean difference 0.9; 95% confidence interval [CI] 0.4-1.4) and fewer asthma control problems (mean difference -0.9; 95% CI -1.6--0.2) compared to usual care with decision support. CONCLUSIONS: Implementation of SDM within clinical practices using a standardized toolkit is associated with improved asthma quality of life and asthma control for low-income children with asthma when compared to usual care with decision support</style></abstract><notes><style face="normal" font="default">DA - 20170811IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1362423</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28800266">PM:28800266</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170811-TaylorYJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170811-TaylorYJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170811, Taylor YJ</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1362423</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42495</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhou,Q.</style></author><author><style face="normal" font="default"> Fu,Y.</style></author><author><style face="normal" font="default"> Hu,L.</style></author><author><style face="normal" font="default"> Li,Q.</style></author><author><style face="normal" font="default"> Jin,M.</style></author><author><style face="normal" font="default"> Jiang,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Respiratory and Critical Care Medicine , The First Affiliated Hospital of Chongqing Medical University , Chongqing 40016 , China</style></auth-address><titles><title><style face="normal" font="default">Relationship of circulating chemerin and omentin levels with Th17 and Th9 cell immune responses in patients with asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="3" Month="8" Year="2017">2017/8/3</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Adipokines are correlated with immune response in asthma, but data on the roles of chemerin and omentin in asthmaare limited. This studyexplored the relationship of chemerin and omentin levels with Th17 and Th9 cells in asthma. METHODS: Seventy-six asthmatics were divided into the intermittent to mild persistent (n = 28), moderate persistent (n = 26) and severe persistent (n = 22) and enrolled in the study. Additionally, 20 healthy subjects were enrolled as controls. Clinical characteristics of the subjects, the Asthma Control Test (ACT), lung function, fractional exhaled nitric oxide (FeNO) score, plasma chemerin and omentin levels were evaluated, and the percentage of Th17 and Th9 cells were determined by flow cytometry. RESULTS: The percentage of Th17 and Th9 cells were higher in the moderate to severe persistent asthmatics than in the intermittent to mild persistent asthmatics or healthy controls (p&lt; 0.05). The severe persistent asthma group had higher chemerin level but lower omentin levels than control group (p&lt; 0.05). Chemerin levels were positively correlated with Th17 and Th9 cell percentages, while omentin levels were negatively correlated with Th17 and Th9 cell percentages (p&lt; 0.01). CONCLUSIONS: The regulatory functions of adipokines on immune responses may be associated with pathogenesis and processes of asthma</style></abstract><notes><style face="normal" font="default">DA - 20170803IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1355378</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28771382">PM:28771382</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170803-ZhouQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170803-ZhouQ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170803, Zhou Q</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1355378</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42496</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pateraki,E.</style></author><author><style face="normal" font="default"> Morris,P.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Paediatric Psychology (CAMHS), Wishaw General Hospital, NHS Lanarkshire</style></auth-address><titles><title><style face="normal" font="default">Effectiveness of cognitive behavioural therapy in reducing anxiety in adults and children with asthma: a systematic review</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">diagnosis</style></keyword></keywords><dates><year Day="31" Month="7" Year="2017">2017/7/31</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Asthma and anxiety are known to interact, leading to exacerbations for both conditions. This systematic review summarised evidence regarding the effectiveness of cognitive-behavioural therapy (CBT) in reducing anxiety for individuals with asthma, with results presented separately for adults and children. DATA SOURCES: PRISMA statement and CRD guidance was followed to conduct and report the current review. Three major electronic databases (Ovid Medline, PsycINFO, and EMBASE) and manual searches were used to find relevant published and unpublished research. STUDY SELECTIONS: Sixteen trials (twelve adult and four child) met inclusion criteria, and were evaluated with adapted quality criteria. Both controlled trials and repeated-measure designs were eligible. All CBT intervention formats were eligible (group, individual, computerised, self-help). Nine studies (eight adult and one child) focused upon participants with either an anxiety condition diagnosis or above threshold anxiety scores on a validated measure of anxiety at baseline. RESULTS: The review indicates tentative preliminary support for the use of CBT for anxiety in adults with asthma, with the evidence-base for interventions with children appearing promising, but under-developed. Studies were more likely to indicate beneficial effects where anxiety-focused (rather than illness-focused) intervention protocols were utilised, asthma-related education was provided and where the trials focused on individuals with likely clinical levels of anxiety at baseline. CONCLUSION: Whilst further high quality research is needed, available evidence is supportive of anxiety-focused CBT interventions tailored to target the particular mechanisms thought to maintain this comorbidity in asthma</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1350967</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28759284">PM:28759284</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170731-PaterakiE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170731-PaterakiE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170731, Pateraki E</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1350967</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42497</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mangold,R.</style></author><author><style face="normal" font="default"> Salzman,G.A.</style></author><author><style face="normal" font="default"> Williams,K.B.</style></author><author><style face="normal" font="default"> Hanania,N.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Saint Luke's Hospital , Kansas City , Missouri</style></auth-address><titles><title><style face="normal" font="default">Factors Associated with Depressive Symptoms in Uncontrolled Asthmatics</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="7" Year="2017">2017/7/31</year></dates><abstract><style face="normal" font="default">RATIONALE: Recent epidemiological data indicate that approximately 6.7% of U.S. adults suffer from depression in any given year. The purpose of the study is to identify factors associated with depressive symptoms in a large diverse group of patients with poorly controlled asthma. The factors include quality of life, lung function, asthma knowledge, attitudes, self-efficacy, symptoms and control of disease. METHODS: Baseline characteristics of a cohort of 599 subjects with asthma recruited from twenty Asthma Clinical Research Centers across the U.S. were examined. The Center for Epidemiologic Studies Depression Scale (CES-D) was used to stratify subjects into those with depressive symptoms (CES-D score > = 16) and those without depressive symptoms (CES-D &lt;16). Bivariate statistics were used to compare the two groups; additionally, logistic regression was used to determine factors that have the greatest association with depressive symptoms. RESULTS: Subjects with depressive symptoms had significantly lower quality of life (QOL) scores and less knowledge about their disease than subjects with no depression; however, lung function (FEV1%) and asthma control were not significantly associated with depressive symptoms in the logistic regression analysis. Subjects, who were non-white, had lower household income, high school diploma or less and those who were unemployed or disabled had significantly higher scores for depressive symptoms. CONCLUSION: Subjects with depressive symptoms have significantly less knowledge of their disease and poorer quality of life compared to those without depressive symptoms. Evaluating depressive symptoms in subjects with asthma will provide a more complete picture of their overall condition. The role of asthma education on depressive symptoms in this population needs to be further investigated. The effect on quality of life of treating depression in asthma patients also needs to be studied</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1350968</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28759275">PM:28759275</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170731-MangoldR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170731-MangoldR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170731, Mangold R</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1350968</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42498</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Raphael,G.</style></author><author><style face="normal" font="default"> Yiu,G.</style></author><author><style face="normal" font="default"> Sakov,A.</style></author><author><style face="normal" font="default"> Liu,S.</style></author><author><style face="normal" font="default"> Caracta,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Bethesda Allergy, Asthma and Research Center , Bethesda , MD , USA</style></auth-address><titles><title><style face="normal" font="default">Randomized, double-blind trial evaluating the efficacy and safety of fluticasone propionate and fluticasone propionate/salmeterol delivered via multidose dry powder inhalers in patients with persistent asthma aged 12 years and older</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="0">0-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="8" Year="2017">2017/8/1</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To assess the efficacy and safety of fluticasone propionate (Fp) and Fp/salmeterol (FS) administered via a novel multidose dry powder inhaler (MDPI) that is easy to use correctly in asthma patients. METHODS: This phase 3, multicenter, double-blind, parallel-group study evaluated asthmatic patients (>/=12 years of age) previously treated with either low- or mid-dose inhaled corticosteroids (ICS) or ICS/long-acting beta-agonists. After a 14- to 21-day run-in, patients were randomized to Fp MDPI 50 mcg, Fp MDPI 100 mcg, FS MDPI 50/12.5 mcg, FS MDPI 100/12.5 mcg, or placebo twice daily for 12 weeks. Change from baseline in forced expiratory volume in 1 second (FEV1; primary endpoint) was evaluated at week 12, and serial spirometry was collected at day 1 and week 12 (subset of patients). Safety was assessed by adverse events (AEs). RESULTS: The full analysis and serial spirometry subset included 640 and 312 patients, respectively. At week 12, FS MDPI significantly improved FEV1 from baseline at each dose versus corresponding Fp MDPI doses (p&lt;0.05). Change from baseline in FEV1 for active treatment groups was significantly greater versus placebo (p&lt;0.05). After 12 weeks, serial spirometry was significantly greater at all time points in the FS MDPI groups versus corresponding Fp MDPI groups (p&lt;0.05). Improvements in serial spirometry on day 1 were maintained through week 12. AEs were similar across groups. CONCLUSIONS: Pulmonary function was significantly improved with Fp MDPI and FS MDPI versus placebo and FS MDPI versus Fp MDPI. Active treatments had a safety profile comparable to placebo</style></abstract><notes><style face="normal" font="default">DA - 20170801IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1350971</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28763243">PM:28763243</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170801-RaphaelG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170801-RaphaelG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Raphael G</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1350971</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42499</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Miadich,S.A.</style></author><author><style face="normal" font="default"> Everhart,R.S.</style></author><author><style face="normal" font="default"> Heron,K.E.</style></author><author><style face="normal" font="default"> Cobb,C.O.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Psychology , Virginia Commonwealth University , Richmond , VA , USA</style></auth-address><titles><title><style face="normal" font="default">Medication use, sleep, and caregiver smoking status among urban children with asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="7" Year="2017">2017/7/31</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Children living in urban settings from low-income, minority families are at a high risk for experiencing asthma morbidity. Environmental tobacco smoke (ETS, i.e., secondhand) exposure, typically from caregiver smoking, has been associated with increased quick-relief medication use and child nocturnal awakenings due to increased asthma symptoms as well as worse sleep quality in children with asthma. This study investigated the moderating role of caregiver smoking status on the association between quick-relief medication use and child's sleep quality in urban children with persistent asthma. METHODS: Fifty-four urban children with persistent asthma and their primary caregivers completed a baseline research session. Caregivers then completed ecological momentary assessment surveys via smartphones twice daily for two weeks in which smoking behaviors, child quick-relief medication use, and child's sleep quality were assessed. RESULTS: Twenty caregivers (37%) reported smoking at least one day across the two-week period. The caregiver smoking status significantly moderated the association between quick-relief medication use and child's sleep quality after controlling for child age and monthly household income. The caregiver smoking status exacerbated the association between quick-relief medication use and child's sleep quality, such that more medication usage was associated with worse sleep quality. CONCLUSIONS: Findings suggest that in urban families with a caregiver who smokes, more daily quick-relief medication use may put children at an increased risk for worse sleep quality. The effects of ETS exposure on child's sleep quality in addition to child asthma symptoms should be an integral part of discussions between pediatric healthcare providers and families of children with asthma</style></abstract><notes><style face="normal" font="default">DA - 20170731IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1350969</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28759271">PM:28759271</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170731-MiadichSA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170731-MiadichSA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170731, Miadich SA</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1350969</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42500</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McIvor,E.R.</style></author><author><style face="normal" font="default"> McIvor,R.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Queen's University, Belfast, UKDepartment of Medicine, McMaster University, Firestone Institute for Respiratory Health, Hamilton, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="default">The evolving role of tiotropium in asthma</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="236" start="231">231-236</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Tiotropium is a long-acting muscarinic antagonist (LAMA) that exerts its bronchodilatory effect by blocking endogenous acetylcholine receptors in the airways. Its safety and efficacy are well established for the treatment of COPD, and it is now being recognized for its role in improving lung function and control in asthma. This review discusses the evolving role of tiotropium delivered by the Respimat(R) in patients across the range of asthma severities and ages, and provides an overview of safety and efficacy data. Tiotropium is the only LAMA currently approved for the treatment of asthma, and evidence from a large-scale clinical trial program, including several Phase III studies in adults, has demonstrated that tiotropium improves lung function and asthma control, with a safety profile comparable with that of placebo. Clinical trials in adolescent patients (aged 12-17 years) have also shown improvements in lung function and trends toward improved asthma control. Of note, the efficacy and safety profiles are consistent regardless of baseline characteristics and phenotype. Given the large and growing body of evidence, it is likely that as clinical experience with tiotropium increases, this treatment may possibly emerge as the key choice for add-on therapy to inhaled corticosteroids/long-acting beta2-agonists, and in patients who do not tolerate long-acting bronchodilators or other medications, in the future</style></abstract><notes><style face="normal" font="default">DA - 20170901IS - 1178-6965 (Print)IS - 1178-6965 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.2147/JAA.S140577</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28860828">PM:28860828</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-231-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-231-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170901, McIvor ER</style></custom2><misc3><style face="normal" font="default">10.2147/JAA.S140577</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42501</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sim,D.W.</style></author><author><style face="normal" font="default"> Yu,J.E.</style></author><author><style face="normal" font="default"> Jeong,J.</style></author><author><style face="normal" font="default"> Koh,Y.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Asthma and Clinical Immunology, Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea</style></auth-address><titles><title><style face="normal" font="default">Ciprofloxacin-induced immune-mediated thrombocytopenia: No cross-reactivity with gemifloxacin</style></title><secondary-title><style face="normal" font="default">J Clin Pharm Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Clin Pharm Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword></keywords><dates><year Day="8" Month="8" Year="2017">2017/8/8</year></dates><abstract><style face="normal" font="default">WHAT IS KNOWN AND OBJECTIVE: Fluoroquinolone-induced immune-mediated thrombocytopenia is uncommon, and no reports of cross-reactivity among fluoroquinolones exist. Here, we describe a case of ciprofloxacin-induced immune thrombocytopenia with no cross-reactivity with gemifloxacin. CASE DESCRIPTION: A 77-year-old woman showed profound thrombocytopenia immediately after two ciprofloxacin injections for pneumonia. Platelet counts recovered rapidly after ciprofloxacin discontinuation. She had experienced thrombocytopenia after ciprofloxacin administration 4 years earlier, which was assumed to be ciprofloxacin-induced immune-related. Interestingly, no thrombocytopenia occurred following the subsequent exposure to another fluoroquinolone, gemifloxacin. WHAT IS NEW AND CONCLUSION: No cross-reactivity occurred between ciprofloxacin and gemifloxacin in this fluoroquinolone-induced immune thrombocytopenia case</style></abstract><notes><style face="normal" font="default">DA - 20170809IS - 1365-2710 (Electronic)IS - 0269-4727 (Linking)LA - engPT - Case ReportsCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1111/jcpt.12596</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28791716">PM:28791716</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Pharm Ther\20170809-SimDW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Pharm Ther\20170809-SimDW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170809, Sim DW</style></custom2><misc3><style face="normal" font="default">10.1111/jcpt.12596</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42502</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yanagishita-Nakatsuji,S.</style></author><author><style face="normal" font="default"> Fukai,K.</style></author><author><style face="normal" font="default"> Ohyama,A.</style></author><author><style face="normal" font="default"> Umekoji,A.</style></author><author><style face="normal" font="default"> Sowa-Osako,J.</style></author><author><style face="normal" font="default"> Tsuruta,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Osaka City University Graduate School of Medicine, Osaka, Japan</style></auth-address><titles><title><style face="normal" font="default">Probable allergic contact dermatitis from hydroquinone presenting as leukomelanoderma: Report of two cases</style></title><secondary-title><style face="normal" font="default">J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="8" Year="2017">2017/8/16</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170817IS - 1346-8138 (Electronic)IS - 0385-2407 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/1346-8138.14011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28815722">PM:28815722</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatol\20170817-YanagishitaNakatsujiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatol\20170817-YanagishitaNakatsujiS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170817, Yanagishita-Nakatsuji S</style></custom2><misc3><style face="normal" font="default">10.1111/1346-8138.14011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42503</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Amagai,Y.</style></author><author><style face="normal" font="default"> Katsuta,C.</style></author><author><style face="normal" font="default"> Nomura,Y.</style></author><author><style face="normal" font="default"> Oida,K.</style></author><author><style face="normal" font="default"> Matsuda,K.</style></author><author><style face="normal" font="default"> Jang,H.</style></author><author><style face="normal" font="default"> Ahn,G.</style></author><author><style face="normal" font="default"> Hamasaki,T.</style></author><author><style face="normal" font="default"> Matsuda,H.</style></author><author><style face="normal" font="default"> Tanaka,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Graduate School of Bio-Applications and System Engineering, Tokyo University of Agriculture and Technology, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">Amelioration of atopic-like skin conditions in NC/Tnd mice by topical application with distilled Alpinia intermedia Gagnep extracts</style></title><secondary-title><style face="normal" font="default">J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse effects</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword></keywords><dates><year Day="16" Month="8" Year="2017">2017/8/16</year></dates><abstract><style face="normal" font="default">Alpinia intermedia, a perennial plant that belongs to the Zingiberaceae family, has been used in folk medicine for a long time in the southern region of Japan. Because skin care is an effective approach that enables patients to manage their atopic dermatitis (AD), various herbal ingredients with few adverse effects have been evaluated for use in AD patients in recent years. In this study, we examined whether distilled extracts obtained from A. intermedia were beneficial for AD-like skin conditions in NC/Tnd mice. Topical application with the A. intermedia extracts significantly reduced the severity of AD, transepidermal water loss and scratching behavior in the mice. Supplementation of the extracts to cell cultures suppressed the expression of Tslp mRNA in PAM212 keratinocytes, degranulation in bone marrow-derived cultured mast cells (BMCMC), and neurite outgrowth in PC12 cells and dorsal root ganglia. In addition, the component analysis revealed that beta-pinene was a major constituent of the A. intermedia extracts. The inhibitory effects of beta-pinene both in vivo and in vitro were also demonstrated. These results indicate that topical application with the A. intermedia extract to the skin of NC/Tnd mice improved the condition of the skin by suppressing multiple inflammatory responses. The extracts may become novel skin-care remedies for AD patients</style></abstract><notes><style face="normal" font="default">DA - 20170817IS - 1346-8138 (Electronic)IS - 0385-2407 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/1346-8138.13995</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28815692">PM:28815692</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatol\20170817-AmagaiY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatol\20170817-AmagaiY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170817, Amagai Y</style></custom2><misc3><style face="normal" font="default">10.1111/1346-8138.13995</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42504</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Amano,W.</style></author><author><style face="normal" font="default"> Nakajima,S.</style></author><author><style face="normal" font="default"> Yamamoto,Y.</style></author><author><style face="normal" font="default"> Tanimoto,A.</style></author><author><style face="normal" font="default"> Matsushita,M.</style></author><author><style face="normal" font="default"> Miyachi,Y.</style></author><author><style face="normal" font="default"> Kabashima,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan</style></auth-address><titles><title><style face="normal" font="default">JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation</style></title><secondary-title><style face="normal" font="default">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatol Sci</style></full-title></periodical><pages end="265" start="258">258-265</pages><volume><style face="normal" font="default">84</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Administration,Oral</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Antigen Presentation</style></keyword><keyword><style face="normal" font="default"> Cell Differentiation</style></keyword><keyword><style face="normal" font="default"> Cell Movement</style></keyword><keyword><style face="normal" font="default"> Cell Proliferation</style></keyword><keyword><style face="normal" font="default"> Croton Oil</style></keyword><keyword><style face="normal" font="default"> cytology</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> Drug Evaluation,Preclinical</style></keyword><keyword><style face="normal" font="default"> drug therapy</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Haptens</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Interferon-gamma</style></keyword><keyword><style face="normal" font="default"> Interleukin-13</style></keyword><keyword><style face="normal" font="default"> Interleukin-17</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> Lymphocyte Activation</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Mice,Inbred C57BL</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Protein Kinase Inhibitors</style></keyword><keyword><style face="normal" font="default"> Pyrroles</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> T-Lymphocytes</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Using JAK inhibitors to inhibit cytokine signaling is presumed to be a possible means of treating skin inflammatory disorders such as contact dermatitis. OBJECTIVE: To clarify the action site of JAK inhibitors in skin inflammatory disorders. METHODS: We analyzed the mechanism of action of the JAK inhibitor JTE-052 using murine skin inflammation models, including contact hypersensitivity (CHS) and irritant contact dermatitis. Cells isolated from ear tissue or lymph node (LN) were analyzed by flow cytometry. The amounts of cytokines in the culture medium were measured by ELISA or bead array system. Proliferation of LN cells was evaluated by measurement of tritiated thymidine incorporation. RESULTS: Oral administration of JTE-052 during both sensitization and elicitation phase attenuated CHS, but did not affect croton oil-induced irritant contact dermatitis. JTE-052 potently inhibited T cell proliferation and activation by antigen presentation in vitro, and attenuated skin inflammation in a sensitized-lymphocyte transfer model without suppressing T cell migration. JTE-052 did not affect hapten-induced cutaneous dendritic cell migration into draining lymph nodes or their costimulatory molecule expressions. CONCLUSION: The JAK inhibitor JTE-052 exerts an inhibitory effect on antigen-specific T cell activation and subsequent inflammation in acquired skin immunity, such as CHS</style></abstract><notes><style face="normal" font="default">DA - 20160925IS - 1873-569X (Electronic)IS - 0923-1811 (Linking)LA - engPT - Journal ArticleRN - 0 (Haptens)RN - 0 (Interleukin-13)RN - 0 (Interleukin-17)RN - 0 (JTE-052)RN - 0 (Protein Kinase Inhibitors)RN - 0 (Pyrroles)RN - 8001-28-3 (Croton Oil)RN - 82115-62-6 (Interferon-gamma)SB - IMCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jdermsci.2016.09.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27665390">PM:27665390</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatol Sci\2016-84-258-65.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatol Sci\2016-84-258-65.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160925, Amano W</style></custom2><misc3><style face="normal" font="default">10.1016/j.jdermsci.2016.09.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42505</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Elliott,G.</style></author><author><style face="normal" font="default"> Vanwersch,R.</style></author><author><style face="normal" font="default"> Soeberdt,M.</style></author><author><style face="normal" font="default"> Metze,D.</style></author><author><style face="normal" font="default"> Lotts,T.</style></author><author><style face="normal" font="default"> Stander,S.</style></author><author><style face="normal" font="default"> Abels,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Derphartox BV, Rotterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default">Topical nalfurafine exhibits anti-inflammatory and anti-pruritic effects in a murine model of AD</style></title><secondary-title><style face="normal" font="default">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatol Sci</style></full-title></periodical><pages end="354" start="351">351-354</pages><volume><style face="normal" font="default">84</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Administration,Topical</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Anti-Inflammatory Agents</style></keyword><keyword><style face="normal" font="default"> Antipruritics</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Atopic</style></keyword><keyword><style face="normal" font="default"> Disease Models,Animal</style></keyword><keyword><style face="normal" font="default"> drug therapy</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword><keyword><style face="normal" font="default"> Ligands</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> Mice,Inbred BALB C</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Receptors,Opioid,kappa</style></keyword><keyword><style face="normal" font="default"> Receptors,Opioid,mu</style></keyword></keywords><dates><year Day="0" Month="12" Year="2016">2016/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20160925IS - 1873-569X (Electronic)IS - 0923-1811 (Linking)LA - engPT - LetterRN - 0 (Anti-Inflammatory Agents)RN - 0 (Antipruritics)RN - 0 (Ligands)RN - 0 (Receptors, Opioid, kappa)RN - 0 (Receptors, Opioid, mu)SB - IMCO - Netherlands -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jdermsci.2016.09.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27665389">PM:27665389</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatol Sci\2016-84-351-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatol Sci\2016-84-351-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160925, Elliott G</style></custom2><misc3><style face="normal" font="default">10.1016/j.jdermsci.2016.09.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42506</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yasuike,R.</style></author><author><style face="normal" font="default"> Tamagawa-Mineoka,R.</style></author><author><style face="normal" font="default"> Ueta,M.</style></author><author><style face="normal" font="default"> Nakamura,N.</style></author><author><style face="normal" font="default"> Kinoshita,S.</style></author><author><style face="normal" font="default"> Katoh,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departments of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.</style></auth-address><titles><title><style face="normal" font="default">The role of toll-like receptor 3 in chronic contact hypersensitivity induced by repeated elicitation</style></title><secondary-title><style face="normal" font="default">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Mice</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword></keywords><dates><year Day="4" Month="8" Year="2017">2017/8/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Accumulating evidence suggests that Toll-like receptor (TLR)-3 signaling is involved in non-infectious immune and inflammatory reactions as well as in viral infections. The skin of patients with atopic dermatitis (AD) is often infected with virus and bacteria, leading to the aggravation of atopic symptoms. These findings suggest TLR3 signaling may be involved in the pathogenesis of AD, but the exact role of TLR3 in AD remains to be defined. OBJECTIVE: The purpose of this study was to investigate the role of TLR3 in chronic contact hypersensitivity reactions induced by repeated elicitation, resembling the features of AD. METHODS: Wild-type (WT) and Toll-like receptor 3 knockout (Tlr3 KO) mice were sensitized, and chronic contact hypersensitivity reactions were elicited in their ear skin via repeated application of a hapten, 2,4,6-trinitro-1-chlorobenzene (TNCB) or oxazolone. RESULTS: The Tlr3 KO mice exhibited less ear swelling, less leukocyte infiltration into the skin, and lower serum total IgE levels than WT mice after hapten challenge. The Tlr3 KO mice also displayed lower expression levels of inflammatory cytokines (interleukin (IL)-33, IL-4, IL-10, and interferon- in their TNCB-treated ear skin than WT mice. CONCLUSION: These results showed that TLR3 deficiency suppressed the development of chronic contact hypersensitivity reactions, suggesting that TLR3 signaling may participate in the pathogenesis of AD</style></abstract><notes><style face="normal" font="default">DA - 20170815IS - 1873-569X (Electronic)IS - 0923-1811 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jdermsci.2017.07.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28807557">PM:28807557</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatol Sci\20170815-YasuikeR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatol Sci\20170815-YasuikeR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170815, Yasuike R</style></custom2><misc3><style face="normal" font="default">10.1016/j.jdermsci.2017.07.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42507</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bennike,N.H.</style></author><author><style face="normal" font="default"> Oturai,N.B.</style></author><author><style face="normal" font="default"> Muller,S.</style></author><author><style face="normal" font="default"> Kirkeby,C.S.</style></author><author><style face="normal" font="default"> Jorgensen,C.</style></author><author><style face="normal" font="default"> Christensen,A.B.</style></author><author><style face="normal" font="default"> Zachariae,C.</style></author><author><style face="normal" font="default"> Duus,J.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Allergy Research Centre Department of Dermatology and Allergy, Herlev-Gentofte Hospital University of Copenhagen, 2900, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Fragrance contact allergens in 5,588 cosmetic products identified through a novel smartphone application</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergens</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword></keywords><dates><year Day="10" Month="8" Year="2017">2017/8/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: More than 25% of the adult European population suffers from contact allergy, with fragrance substances recognized as one of the main causes. Since 2005, 26 fragrance contact allergens have been mandatory to label in cosmetic products within the EU if present at 10 ppm or above in leave-on and 100 ppm or above in wash-off cosmetics. OBJECTIVE: To examine exposure, based on ingredient labelling, to the 26 fragrances in a sample of 5,588 fragranced cosmetic products. METHODS: The investigated products were identified through a novel, non-profit smartphone application (app), designed to provide information to consumers about chemical substances in cosmetic products. Products registered through the app between December 2015 and October 2016 were label checked according to International Nomenclature of Cosmetic Ingredients (INCI) for the presence of the 26 fragrance substances or the wording "fragrance/parfum/aroma". RESULTS: The largest product categories investigated were "cream, lotion and oil" (n=1192), "shampoo and conditioner" (n=968) and "deodorants" (n=632). Among cosmetic products labelled to contain at least one of the 26 fragrances, 85.5% and 73.9% contained at least two and at least three of the 26 fragrances, respectively. Linalool (49.5%) and limonene (48.5%) were labelled most often among all investigated products. Hydroxyisohexyl 3-cyclohexene carboxaldehyde (HICC/Lyral(R) ) was found in 13.5% of deodorants. Six of the 26 fragrance substances were labelled on less than one percent of all products, including the natural extracts Evernia furfuracea (tree moss) and Evernia prunastri (oak moss). 329 (5.9%) products had one or more of the 26 fragrance substances labelled, but did not have "parfum/fragrance/aroma" listed on the label. CONCLUSIONS: Consumers are widely exposed to, often multiple, well-established fragrance contact allergens through various cosmetic products intended for daily use. Several fragrance substances that are common causes of contact allergy were rarely labelled in this large sample of cosmetic products. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170810IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.14513</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28796916">PM:28796916</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170810-BennikeNH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170810-BennikeNH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170810, Bennike NH</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.14513</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42508</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Norreslet,L.B.</style></author><author><style face="normal" font="default"> Ebbehoj,N.E.</style></author><author><style face="normal" font="default"> Bonde,J.P.E.</style></author><author><style face="normal" font="default"> Thomsen,S.F.</style></author><author><style face="normal" font="default"> Agner,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Copenhagen, Bispebjerg Hospital, 2400, Copenhagen, NV, Denmark</style></auth-address><titles><title><style face="normal" font="default">The impact of atopic dermatitis on work life - a systematic review</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="8" Year="2017">2017/8/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis (AD) has considerable multidimensional personal and societal costs. However, the extent to which the patient's work life is affected due to AD is more sparsely described in the literature. OBJECTIVE: To examine the impact on work life for patients with AD, with a specific focus on choice of education and occupation, sick leave, social compensations and change of job due to AD. METHODS: A systematic literature search was performed in PubMed, EMBASE and Web of Science up to 7th February 2017 for articles on the impact on work life for patients with atopic dermatitis. Results were summarized taking several measures of study quality into account. RESULTS: 23 articles were found eligible. 5 studies assessed the influence of AD on educational or job choice, without any consistent conclusion, while 8 out of 9 studies with respect to sick leave and 2 on disability pensions found AD to have a negative impact. Studies of change or loss of job and AD showed more diverse results, as not all studies documented a negative effect of AD on work life. CONCLUSIONS: AD imposes a burden extending beyond personal, emotional and financial costs. This review strongly implies that AD affects sick leave, and though not fully clarified, possible also job choice, change or loss of job and even disability pensions for the more severe cases. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170823IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.14523</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28833648">PM:28833648</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170823-NorresletRB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20170823-NorresletRB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170823, Norreslet LB</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.14523</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42509</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schneider,T.M.</style></author><author><style face="normal" font="default"> Bence,T.</style></author><author><style face="normal" font="default"> Brettner,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of intensive care medicine, Krankenhaus Barmherzige Brueder Munich, Muenchen, Germany</style></auth-address><titles><title><style face="normal" font="default">"Awake" ECCO2R superseded intubation in a near-fatal asthma attack</style></title><secondary-title><style face="normal" font="default">J Intensive Care</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Intensive Care</style></abbr-1></periodical><pages end="" start="53">53-</pages><volume><style face="normal" font="default">5</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Near-fatal asthma attacks are life threatening events that often require mechanical ventilation. Extracorporeal carbon dioxide removal (ECCO2R) is, beside extracorporeal membrane oxygenation (ECMO), a well-established rescue option whenever ventilation gets to its limits. But there seems to be very rare experience with those techniques in avoiding mechanical ventilation in severe asthma attacks. CASE PRESENTATION: A 67-year-old man with a near-fatal asthma attack deteriorated under non-invasive ventilation conditions. Beside pharmacological treatment, the intensivists decided to use an extracorporeal carbon dioxide removal system (ECCO2R) to avoid sedation and intubation. Within only a few hours, there was a breakthrough and the patient's status improved continuously. One and a half days later, weaning from ECCO2R was already completed. CONCLUSIONS: The discussion deals with several advantages of extracorporeal lung support in acute asthma, the potential of avoiding intubation and sedation, as well as the benefits of a conscious and spontaneously breathing patient. Extracorporeal membrane oxygenation (ECMO) in general and ECCO2R in particular is a highly effective method for the treatment of an acute near-fatal asthma attack. Pathophysiological aspects favor the "awake" approach, without sedation, intubation, and mechanical ventilation. Therefore, experienced clinicians might consider "awake" ECCO2R in similar cases</style></abstract><notes><style face="normal" font="default">DA - 20170815IS - 2052-0492 (Print)IS - 2052-0492 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1186/s40560-017-0247-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28808576">PM:28808576</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Intensive Care\2017-5-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Intensive Care\2017-5-53.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170815, Schneider TM</style></custom2><misc3><style face="normal" font="default">10.1186/s40560-017-0247-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42510</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Van Hoover,C.</style></author><author><style face="normal" font="default"> Rademayer,C.A.</style></author><author><style face="normal" font="default"> Farley,C.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Body Piercing: Motivations and Implications for Health</style></title><secondary-title><style face="normal" font="default">J Midwifery Womens Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Midwifery Womens Health</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="8" Year="2017">2017/8/14</year></dates><abstract><style face="normal" font="default">Body piercing has evolved from a behavior once considered extreme to an accepted choice among the general population. Earlobe piercing is so common that it is now considered a normative behavior. The motivations for choosing body piercing have changed and are associated with piercing site and number of piercings chosen by the individual. Meanings ascribed to body piercing were traditionally related to enhanced sexual desirability and experience, but now range from the innocuous, such as a fashion statement, to the risk laden, such as nonsuicidal self-injury. Professional piercers are the primary providers of piercing services, and people will first turn to their professional piercer for advice when complications of the site arise, thus delaying entry into needed health care. Health care providers are often perceived as uninformed, dismissive, and biased against individuals, who are pierced particularly those with multiple piercings and piercings in intimate areas of the body. Common complications of piercing include infection, bleeding, and problems relating to tissue trauma and scarring, and are reported by nearly 50% of individuals who are pierced. Metal allergies can develop as a result of piercing, making the type of jewelry used for body adornment an important consideration. Additionally, management of the piercing site becomes critical under certain conditions, such as during pregnancy and birth, lactation, or surgery. This article provides information supporting midwives and other health care providers to offer anticipatory guidance and health care services in a nonjudgmental and supportive manner to individuals choosing body piercing</style></abstract><notes><style face="normal" font="default">DA - 20170814IS - 1542-2011 (Electronic)IS - 1526-9523 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/jmwh.12630</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28806494">PM:28806494</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Midwifery Womens Health\20170814-VanHHooverC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Midwifery Womens Health\20170814-VanHHooverC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170814, Van Hoover C</style></custom2><misc3><style face="normal" font="default">10.1111/jmwh.12630</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42511</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kumagai,K.</style></author><author><style face="normal" font="default"> Matsubara,R.</style></author><author><style face="normal" font="default"> Nakasone,Y.</style></author><author><style face="normal" font="default"> Shigematsu,H.</style></author><author><style face="normal" font="default"> Kitaura,K.</style></author><author><style face="normal" font="default"> Suzuki,S.i</style></author><author><style face="normal" font="default"> Haneji,K.</style></author><author><style face="normal" font="default"> Hamada,Y.</style></author><author><style face="normal" font="default"> Suzuki,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Possible involvement of invariant natural killer T cells and mucosal-associated invariant T cells in a murine model of titanium allergy</style></title><secondary-title><style face="normal" font="default">J Oral Maxillofac Surg Med Pathol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Oral Maxillofac Surg Med Pathol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">CDR</style></keyword><keyword><style face="normal" font="default"> Titanium allergy</style></keyword><keyword><style face="normal" font="default"> allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Metal allergy</style></keyword><keyword><style face="normal" font="default"> MAIT cells</style></keyword><keyword><style face="normal" font="default"> NK T cells</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2212-5558</style></isbn><abstract><style face="normal" font="default">Titanium alloy has long been regarded as a biocompatible material, and is widely used for implants in medicine and dentistry. Titanium is thought to be a potential cause of metal allergy, however, accumulating T cells during development of titanium allergy have been poorly characterized because basic research based on a suitable animal model has not been performed. This study aimed to investigate the skewing of the T-cell receptor repertoire and cytokine profiles of accumulated T cells in inflamed skin during titanium allergy. A novel model of titanium allergy was induced by two sensitizations by injection of TiCl3 plus lipopolysaccharide solution into the mouse groin followed by two challenges with TiCl3 into the footpad. Cytokine expression profiles, T cell phenotypes, and T-cell receptor repertoire were determined in the titanium-induced allergic footpads. Significant swelling and pathological features, such as spongiosis of the dermis, were histologically evident at 7days after challenge in mice with titanium allergy. Characterization of the TCR repertoire revealed the presence of the TRAV10/TRAJ18 clonotype, indicative of natural killer T cells, and TRAV1/TRAJ33, associated with mucosal-associated invariant T (MAIT) cells in the inflamed skin of both the irritant and allergic mice models. Our murine model of titanium-induced hypersensitivity shows that NKT cells and MAIT cells participate in titanium allergy</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.ajoms.2017.08.001</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.ajoms.2017.08.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Oral Maxillofac Surg Med Pathol\20170905-KumagaiK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Oral Maxillofac Surg Med Pathol\20170905-KumagaiK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Kumagai K</style></custom2><misc3><style face="normal" font="default">10.1016/j.ajoms.2017.08.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42512</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ben-Shoshan,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Montreal Children's Hospital Montreal, Quebec, Canada</style></auth-address><titles><title><style face="normal" font="default">Most children labeled as penicillin allergic are at low risk for true penicillin allergy</style></title><secondary-title><style face="normal" font="default">J Pediatr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Pediatr</style></full-title></periodical><pages end="311" start="308">308-311</pages><volume><style face="normal" font="default">188</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170827IS - 1097-6833 (Electronic)IS - 0022-3476 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jpeds.2017.06.061</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28843308">PM:28843308</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Pediatr\2017-188-308-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Pediatr\2017-188-308-11.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170827, Ben-Shoshan M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jpeds.2017.06.061</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42513</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Xu,Y.</style></author><author><style face="normal" font="default"> Wang,D.</style></author><author><style face="normal" font="default"> Tang,L.</style></author><author><style face="normal" font="default"> Wang,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Zhejiang University of Technology, Hangzhou 310014, China</style></auth-address><titles><title><style face="normal" font="default">Separation and characterization of allergic polymerized impurities in cephalosporins by 2D-HPSECxLC-IT-TOF MS</style></title><secondary-title><style face="normal" font="default">J Pharm Biomed Anal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Pharm Biomed Anal</style></full-title></periodical><pages end="750" start="742">742-750</pages><volume><style face="normal" font="default">145</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="2" Month="8" Year="2017">2017/8/2</year></dates><abstract><style face="normal" font="default">Eleven unknown allergic impurities in cefodizime, cefmenoxime and cefonicid were separated and characterized by a trap-free two-dimensional high performance size exclusion chromatography (HPSEC) and reversed phase liquid chromatography (RP-HPLC) coupled to high resolution ion trap/time-of-flight mass spectrometry (2D-HPSECxLC-IT-TOF MS) with positive and negative modes of electrospray ionization method. Separation and characterization the allergic polymerized impurities in beta-lactam antibiotics were on the basis of column-switching technique which effectively combined the advantages of HPSEC and the ability of RP-HPLC to identify the special impurities. In the first dimension HPSEC, the column was Xtimate SEC-120 analytical column (7.8mmx30cm, 5mum), and the gradient elution used pH 7.0 buffer-acetonitrile as mobile phase And the second dimension analytical column was ZORBAX SB-C18 (4.6x150mm, 3.5mum) with ammonium formate solution (10mM) and ammonium formate (8mM) in [acetonitrile-water (4:1, v/v)] solution as mobile phase. Structures of eleven unknown impurities were deduced based on the high resolution MSn data with both positive and negative modes, in which nine impurities were polymerized impurities. The forming mechanism of beta-lactam antibiotic polymerization in cephalosporins was also studied. The question on incompatibility between non-volatile salt mobile phase and mass spectrometry was solved completely by multidimensional heart-cutting approaches and online demineralization technique, which was worthy of widespread use and application for the advantages of stability and repeatability</style></abstract><notes><style face="normal" font="default">DA - 20170814IS - 1873-264X (Electronic)IS - 0731-7085 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.jpba.2017.07.063</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28806571">PM:28806571</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Pharm Biomed Anal\2017-145-742-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Pharm Biomed Anal\2017-145-742-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170814, Xu Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.jpba.2017.07.063</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42514</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,H.</style></author><author><style face="normal" font="default"> Shi,Y.</style></author><author><style face="normal" font="default"> Wang,C.</style></author><author><style face="normal" font="default"> Zhao,K.</style></author><author><style face="normal" font="default"> Zhang,S.</style></author><author><style face="normal" font="default"> Wei,L.</style></author><author><style face="normal" font="default"> Dong,L.</style></author><author><style face="normal" font="default"> Gu,W.</style></author><author><style face="normal" font="default"> Xu,Y.</style></author><author><style face="normal" font="default"> Ruan,H.</style></author><author><style face="normal" font="default"> Zhi,H.</style></author><author><style face="normal" font="default"> Yang,X.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Toxicology, National Institute of Environmental Health, Chinese Center for Desease Control and Prevention, China</style></auth-address><titles><title><style face="normal" font="default">An improvement of LLNA:DA to assess the skin sensitization potential of chemicals</style></title><secondary-title><style face="normal" font="default">J Toxicol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Toxicol Sci</style></full-title></periodical><pages end="136" start="129">129-136</pages><volume><style face="normal" font="default">42</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adenosine Triphosphate</style></keyword><keyword><style face="normal" font="default"> Allergens</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> cytology</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Local Lymph Node Assay</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Mice,Inbred BALB C</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">We developed a modified local lymph node assay based on ATP (LLNA:DA), termed the Two-Stage LLNA:DA, to further reduce the animal numbers in the identification of sensitizers. In the Two-Stage LLNA:DA procedure, 13 chemicals ranging from non-sensitizers to extreme sensitizers were selected. The first stage used reduced LLNA:DA (rLLNA:DA) to screen out sensitive chemicals. The second stage used LLNA:DA based on OECD 442 (A) to classify those potential sensitizers screened out in the first stage. In the first stage, the SIs of the methyl methacrylate, salicylic acid, methyl salicylate, ethyl salicylate, isopropanol and propanediol were below 1.8 and need not to be tested in the second step. Others continued to be tested by LLNA:DA. In the second stage, sodium lauryl sulphate and xylene were classified as weak sensitizers. a-hexyl cinnamic aldehyde and eugenol were moderate sensitizers. Benzalkonium chloride and glyoxal were strong sensitizers, and phthalic anhydride was an extreme sensitizer. The 9/9, 11/12, 10/11, and 8/13 (positive or negative only) categories of the Two-Stage LLNA:DA were consistent with those from the other methods (LLNA, LLNA:DA, GPMT/BT and HMT/HPTA), suggesting that Two-Stage LLNA:DA have a high coincidence rate with reported data. In conclusion, The Two-Stage LLNA:DA is in line with the "3R" rules, and can be a modification of LLNA:DA but needs more study</style></abstract><notes><style face="normal" font="default">DA - 20170321IS - 1880-3989 (Electronic)IS - 0388-1350 (Linking)LA - engPT - Journal ArticleRN - 0 (Allergens)RN - 8L70Q75FXE (Adenosine Triphosphate)SB - IMCO - China -</style></notes><work-type><style face="normal" font="default">10.2131/jts.42.129</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28321039">PM:28321039</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Toxicol Sci\2017-42-129-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Toxicol Sci\2017-42-129-36.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170321, Zhang H</style></custom2><misc3><style face="normal" font="default">10.2131/jts.42.129</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42515</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bartenstein,D.W.</style></author><author><style face="normal" font="default"> Diven,D.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA</style></auth-address><titles><title><style face="normal" font="default">Shelf life considerations as EpiPen price increases</style></title><secondary-title><style face="normal" font="default">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Lancet</style></full-title></periodical><pages end="" start="2871">2871-</pages><volume><style face="normal" font="default">388</style></volume><number><style face="normal" font="default">10062</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Commerce</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword></keywords><dates><year Day="10" Month="12" Year="2016">2016/12/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20161216IS - 1474-547X (Electronic)IS - 0140-6736 (Linking)LA - engPT - LetterPT - CommentRN - YKH834O4BH (Epinephrine)SB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/S0140-6736(16)32469-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27979405">PM:27979405</url></web-urls></urls><custom2><style face="normal" font="default">20161216, Bartenstein DW</style></custom2><misc3><style face="normal" font="default">10.1016/S0140-6736(16)32469-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42516</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ebmeier,S.</style></author><author><style face="normal" font="default"> Thayabaran,D.</style></author><author><style face="normal" font="default"> Braithwaite,I.</style></author><author><style face="normal" font="default"> Benamara,C.</style></author><author><style face="normal" font="default"> Weatherall,M.</style></author><author><style face="normal" font="default"> Beasley,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical Research Institute of New Zealand, Wellington, New Zealand</style></auth-address><titles><title><style face="normal" font="default">Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012)</style></title><secondary-title><style face="normal" font="default">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Lancet</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="8" Year="2017">2017/8/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: International time trends in asthma mortality have been strongly affected by changes in management and in particular drug treatments. However, little is known about how asthma mortality has changed over the past decade. In this study, we assessed these international trends. METHODS: We collated age-standardised country-specific asthma mortality rates in the 5-34 year age group from the online WHO Mortality Database for 46 countries. To be included in the analysis, we specified that a country must have 10 years of complete data in the WHO Mortality Database between 1993 and 2012. In the absence of consistent and accurate asthma prevalence and prescribing data, we chose to use a locally weighted scatter plot smoother (LOESS) curve, weighted by the individual country population in the 5-34-year age group to show the global trends in asthma mortality rates with time. FINDINGS: Of the 46 countries included in the analysis of asthma mortality, 36 were high-income countries, and 10 were middle-income countries. The LOESS estimate of the global asthma mortality rate was 0.44 deaths per 100 000 people (90% CI 0.39-0.48) in 1993 and 0.19 deaths per 100 000 people (0.18-0.21) in 2006. Despite apparent further reductions in some countries and regions of the world, there was no appreciable change in global asthma mortality rates from 2006 through to 2012, when the LOESS estimate was also 0.19 deaths per 100 000 people (0.16-0.21). INTERPRETATION: The trend for reduction in global asthma mortality observed since the late 1980s might have stalled, with no appreciable difference in a smoothed LOESS curve of asthma mortality from 2006 to 2012. Although better implementation of established management strategies that have been shown to reduce mortality risk is needed, to achieve a further substantive reduction in global asthma mortality novel strategies will also be required. FUNDING: The Medical Research Institute of New Zealand, which is supported by Health Research Council of New Zealand Independent Research Organisation</style></abstract><notes><style face="normal" font="default">DA - 20170811IS - 1474-547X (Electronic)IS - 0140-6736 (Linking)LA - engPT - Journal ArticleCO - New Zealand -</style></notes><work-type><style face="normal" font="default">10.1016/S0140-6736(17)31448-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28797514">PM:28797514</url></web-urls></urls><custom2><style face="normal" font="default">20170811, Ebmeier S</style></custom2><misc3><style face="normal" font="default">10.1016/S0140-6736(17)31448-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42517</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jenkins,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">The George Institute for Global Health, University of New South Wales, Sydney, NSW 2042, Australia.</style></auth-address><titles><title><style face="normal" font="default">Eliminating asthma deaths: have we stalled?</style></title><secondary-title><style face="normal" font="default">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Lancet</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="8" Year="2017">2017/8/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170811IS - 1474-547X (Electronic)IS - 0140-6736 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/S0140-6736(17)31587-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28797515">PM:28797515</url></web-urls></urls><custom2><style face="normal" font="default">20170811, Jenkins C</style></custom2><misc3><style face="normal" font="default">10.1016/S0140-6736(17)31587-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42518</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Golinska-Zach,A.</style></author><author><style face="normal" font="default"> Wiszniewska,M.</style></author><author><style face="normal" font="default"> Walusiak-Skorupa,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Instytut Medycyny Pracy im. prof. J. Nofera / Nofer Institute of Occupational Medicine, Lodz, Poland</style></auth-address><titles><title><style face="normal" font="default">[Guidelines for the preventive health care of hairdressing apprentices]</style></title><secondary-title><style face="normal" font="default">Med Pr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Med Pr</style></full-title></periodical><pages end="687" start="677">677-687</pages><volume><style face="normal" font="default">68</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="7" Year="2017">2017/7/26</year></dates><abstract><style face="normal" font="default">Hairdressing is one of the most developing branch of the service industry in Poland. Providing representatives of this occupational group with preventive health care services it should be remembered that they are at risk of skin and respiratory diseases, which occur due to a quite frequent exposure to harmful agents in the work environment of hairdressers and hairdressing apprentices. Interestingly, a much lower number of researches concentrate on respiratory symptoms than on skin disorders in hairdressers. The authors of this article have carried out the first Polish follow-up study focused not only on skin disorders but also on respiratory tract symptoms in hairdressing apprentices. The results of the study have been reported in other publications while this paper presents a literature review based on EBSCO and PubMed databases, Elsevier and contained articles (on the subject discussed in this paper). On the basis of information obtained from the authors' own research evidence and from the literature review, the guidelines for the preventive health care of hairdressing apprentices were developed. It was confirmed that neither determination of allergen-specific immunoglobulin E (IgE) nor performance of skin prick tests (SPTs) and patch tests for hairdressing factors are necessary. They should be performed as a part of preventive medical examination only in those apprentice candidates and trainees in this profession who report work-related symptoms and it is suspected that they result from exposure to particular factor in the work environment. Med Pr 2017;68(5):677-687</style></abstract><notes><style face="normal" font="default">DA - 20170804IS - 0465-5893 (Print)IS - 0465-5893 (Linking)LA - polPT - English AbstractPT - GuidelineCO - Poland -</style></notes><work-type><style face="normal" font="default">10.13075/mp.5893.00530</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28775385">PM:28775385</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Med Pr\2017-68-677-87.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Med Pr\2017-68-677-87.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170804, Golinska-Zach A</style></custom2><misc3><style face="normal" font="default">10.13075/mp.5893.00530</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42519</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,M.H.</style></author><author><style face="normal" font="default"> Song,W.J.</style></author><author><style face="normal" font="default"> Yang,M.S.</style></author><author><style face="normal" font="default"> Lee,S.H.</style></author><author><style face="normal" font="default"> Kwon,J.W.</style></author><author><style face="normal" font="default"> Kim,S.H.</style></author><author><style face="normal" font="default"> Kang,H.R.</style></author><author><style face="normal" font="default"> Park,H.W.</style></author><author><style face="normal" font="default"> Cho,Y.J.</style></author><author><style face="normal" font="default"> Cho,S.H.</style></author><author><style face="normal" font="default"> Min,K.U.</style></author><author><style face="normal" font="default"> Kim,Y.Y.</style></author><author><style face="normal" font="default"> Chang,Y.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Clinical course of asthma patients with H1N1 influenza infection and oseltamivir</style></title><secondary-title><style face="normal" font="default">Minerva Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Minerva Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="9" Year="2017">2017/9/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: H1N1 influenza virus prevailed throughout the world in 2009. However, there are few reports on the clinical features of H1N1 influenza infection in adult asthma patients. We evaluated the clinical features in asthma patients with H1N1 influenza infection who took oseltamivir and compared them to those with other upper respiratory infections. METHODS: We reviewed asthma patients over 15 years of age who had visited Seoul National University Hospital and Seoul National University Bundang Hospital for suspected H1N1 influenza infection from August 2009 to March 2010. Various clinical features such as hospital admission days, respiratory symptoms, basal lung function, and past history was compared between H1N1 influenza PCR positive and negative groups. RESULTS: A total of 111 asthmatics were enrolled. All patients took oseltamivir. H1N1 RT- PCR was positive in 62 patients (55.9%), negative in 49 patients (44.1%). Wheezing developed more frequently in the H1N1 positive group. (43.5 vs 16.7%, p=0.044). The rate of acute asthma exacerbations and pneumonia development were higher in the H1N1 positive group (59.7 vs 51%, p=0.015, 25.0% vs 0%, p&lt;0.001). The rates for emergency room visit, hospital admissions, intensive care unit admissions, hospital days were not different between the groups. Underlying medical conditions were accompanied more frequently in the H1N1 negative patients (21.6% vs 30.6%, p=0.002), especially cardiac disease (7.2% vs 15.3%, p=0.011). CONCLUSIONS: H1N1 influenza infection may affect the clinical course of asthma combined with more severe manifestations; however, Oseltamivir could have affected the clinical course of H1N1 infected patients and made it milder than expected</style></abstract><notes><style face="normal" font="default">DA - 20170907IS - 1827-1669 (Electronic)IS - 0026-4806 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.23736/S0026-4806.17.05329-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28880061">PM:28880061</url></web-urls></urls><custom2><style face="normal" font="default">20170907, Kim MH</style></custom2><misc3><style face="normal" font="default">10.23736/S0026-4806.17.05329-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42520</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Koch,A.</style></author><author><style face="normal" font="default"> Tchernev,G.</style></author><author><style face="normal" font="default"> Wollina,U.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Friedrichstrasse 41, 01067, Dresden, Germany</style></auth-address><titles><title><style face="normal" font="default">Allergic Maculo-Papular Exanthema Due To Terbinafine</style></title><secondary-title><style face="normal" font="default">Open Access Maced J Med Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Open Access Maced J Med Sci</style></full-title></periodical><pages end="536" start="535">535-536</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="7" Year="2017">2017/7/25</year></dates><abstract><style face="normal" font="default">We report on a 76-year-old male patient who developed a maculopapular generalised exanthema due to terbinafine. Prick test was negative; patch test revealed a positive reaction after 48 h confirming the delayed-type allergic reaction. Non-pustular exanthema has only rarely been reported for terbinafine</style></abstract><notes><style face="normal" font="default">DA - 20170808IS - 1857-9655 (Print)IS - 1857-9655 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.3889/oamjms.2017.105</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28785353">PM:28785353</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Open Access Maced J Med Sci\2017-5-535-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Open Access Maced J Med Sci\2017-5-535-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170808, Koch A</style></custom2><misc3><style face="normal" font="default">10.3889/oamjms.2017.105</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42521</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">no authors</style></author></authors></contributors><titles><title><style face="normal" font="default">AAOM Clinical Practice Statement: Subject: Oral Contact Allergy</style></title><secondary-title><style face="normal" font="default">Oral Surg Oral Med Oral Pathol Oral Radiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Oral Surg Oral Med Oral Pathol Oral Radiol</style></abbr-1></periodical><pages end="52" start="50">50-52</pages><volume><style face="normal" font="default">122</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">adverse effects</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> Dental Materials</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Risk Factors</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Stomatitis</style></keyword></keywords><dates><year Day="0" Month="7" Year="2016">2016/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20160604IS - 2212-4411 (Electronic)LA - engPT - EditorialPT - Practice GuidelineRN - 0 (Cosmetics)RN - 0 (Dental Materials)SB - DSB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.oooo.2016.02.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27184929">PM:27184929</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Oral Surg Oral Med Oral Pathol Oral Radiol\2016-122-50-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Oral Surg Oral Med Oral Pathol Oral Radiol\2016-122-50-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160604, no authors</style></custom2><misc3><style face="normal" font="default">10.1016/j.oooo.2016.02.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42522</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Labrosse,R.</style></author><author><style face="normal" font="default"> Graham,F.</style></author><author><style face="normal" font="default"> Begin,P.</style></author><author><style face="normal" font="default"> Samaan,K.</style></author><author><style face="normal" font="default"> Paradis,L.</style></author><author><style face="normal" font="default"> Des Roches,A.</style></author><author><style face="normal" font="default"> Lacombe-Barrios,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Allergy &amp; Clinical Immunology, CHU Sainte-Justine, University of Montreal, 3175 Chemin de la Cote-Sainte-Catherine, Montreal, QC, Canada, H3T 1C5</style></auth-address><titles><title><style face="normal" font="default">A Pediatric Case of Selective Fixed Drug Eruption to Amoxicillin</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="28" Month="8" Year="2017">2017/8/28</year></dates><abstract><style face="normal" font="default">Fixed drug eruption (FDE) is a distinctive type of delayed drug hypersensitivity that presents with dermal inflammation of limited involvement recurring at the same location upon exposure to the culprit drug. It is typically characterized by an erythematous single lesion with sharp margins, even though multiple-site involvement can also occur. Appropriate testing to confirm diagnosis is still debated, although graded drug provocation test (DPT) seems to be more sensitive (1). Drugs most frequently associated with FDE include analgesics, antimalarials, barbiturates and antibiotics, including amoxicillin (2, 3). However, the evaluation of cross-reactivity of the culprit drug to others agents with similar chemical structure has been poorly studied. We present here a rare case of FDE to amoxicillin reproducible with a DPT in which we also assessed cross-reactivity with other beta-lactams both with and without identical lateral chains. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170828IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12776</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28846156">PM:28846156</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170828-LabrosseR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170828-LabrosseR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170828, Labrosse R</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12776</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42523</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tan,J.W.</style></author><author><style face="normal" font="default"> Turner,P.J.</style></author><author><style face="normal" font="default"> Valerio,C.</style></author><author><style face="normal" font="default"> Sertori,R.</style></author><author><style face="normal" font="default"> Barnes,E.H.</style></author><author><style face="normal" font="default"> Campbell,D.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Discipline of Child and Adolescent Health, University of Sydney, Sydney, New South Wales, Australia</style></auth-address><titles><title><style face="normal" font="default">Striking the balance between primary prevention of allergic disease and optimal infant growth and nutrition</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword></keywords><dates><year Day="17" Month="8" Year="2017">2017/8/17</year></dates><abstract><style face="normal" font="default">The timing of introduction of solids and/or complementary feeds continues to be an area of intense interest with respect to allergy prevention and general optimal infant nutrition. There is recent evidence from RCTs (1-3) and a meta-analysis(1), that the earlier introduction of peanut (between 4 and 11 months) and egg (between 4 and 6 months), in infants at higher risk of allergic disease, may be beneficial. However, concerns have been raised over the impact this may have on duration of breastfeeding, nutrition and growth, when a high protein and calorie-containing food, such as egg or peanut, is introduced. Duration of breast feeding appears to have little impact on development of allergic disease, but is important for protection against overweight and obesity, diabetes and childhood infections (particularly in resource poor settings)(4). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170817IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12775</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28815797">PM:28815797</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170817-TanJW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170817-TanJW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170817, Tan JW</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12775</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42524</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Meincke,R.</style></author><author><style face="normal" font="default"> Pokladnikova,J.</style></author><author><style face="normal" font="default"> Straznicka,J.</style></author><author><style face="normal" font="default"> Meyboom,R.H.B.</style></author><author><style face="normal" font="default"> Niedrig,D.</style></author><author><style face="normal" font="default"> Russmann,S.</style></author><author><style face="normal" font="default"> Jahodar,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Social and Clinical Pharmacy, Faculty of Pharmacy, Charles University, Prague, Hradec Kralove, Czech Republic</style></auth-address><titles><title><style face="normal" font="default">Allergy-like Immediate Reactions with Herbal Medicines in Children:A Retrospective Study Using Data from VigiBase(R)</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="28" Month="8" Year="2017">2017/8/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: The use of herbal medicines in children and the general population is continually on the rise with an overall herbal lifetime and current use ranging between 0.8-85.5% and 2.2-8.9%, respectively. Although acute hypersensitivity reactions are generally considered to be rare, little knowledge exists on the frequency and type of these reactions especially in specific populations like children. OBJECTIVES: To assess the patterns of acute hypersensitivity reactions to herbal medicines reported to the WHO global individual case safety report (ICSR) database VigiBase(R) in children. STUDY DESIGN: From the original VigiBase(R) extract for the time between 1968 and 2014, we included all reports with adverse drug reactions (ADR) associated with herbal medicines in children where WHO-ART reaction terms were indicative of acute hypersensitivity reactions. RESULTS: VigiBase(R) contained 2,646 ICSRs with 14,860 distinct adverse reactions reported in association with herbal medicine in children. Among those, 79 cases with 107 allergy-like reactions met our inclusion criteria. The most commonly reported WHO-ART terms were urticaria or rash/rash erythematous (59.8%), and allergic reaction (8.4%). The most frequently reported suspected herbal medicines were mixed herbal products (51.4%), Hedera helix (15.0%), and Echinacea purpurea (5.6%). Most frequent routes of administration were oral (75.9%), topical (8.9%), and rectal (3.8%). Over 30% of cases were reported in the age group from 7 to 12 years. The majority of reports were received from Germany (29.1%), Thailand (21.5%), and Australia (11.4%). CONCLUSION: VigiBase(R) contains a considerable number of acute hypersensitivity reactions in children associated with herbal medicines, including life-threatening reactions such as anaphylactic shock. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170828IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Czechia -CO - Sweden -CO - Netherlands -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12778</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28846157">PM:28846157</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170828-MeinckeR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170828-MeinckeR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170828, Meincke R</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12778</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42525</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rosenfeld,L.</style></author><author><style face="normal" font="default"> Marques,A.M.</style></author><author><style face="normal" font="default"> Niendorf,S.</style></author><author><style face="normal" font="default"> Hofmann,J.</style></author><author><style face="normal" font="default"> Gratopp,A.</style></author><author><style face="normal" font="default"> Kuhl,J.S.</style></author><author><style face="normal" font="default"> Schulte,J.H.</style></author><author><style face="normal" font="default"> von Bernuth,H.</style></author><author><style face="normal" font="default"> Voigt,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric Pneumology and Immunology, Charite-Universitatsmedizin Berlin, Germany</style></auth-address><titles><title><style face="normal" font="default">Life-threatening systemic rotavirus infection after vaccination in Severe Combined Immunodeficiency (SCID)</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword></keywords><dates><year Day="17" Month="8" Year="2017">2017/8/17</year></dates><abstract><style face="normal" font="default">Rotavirus (RV) infections are the major cause of severe gastroenteritis in children under five years of age, causing 215,000 deaths per year worldwide mainly due to dehydration in countries with weak economic resources (1). In the immunocompetent host RV infections are self-limiting and mortality is low in high-income countries. Notifications of RV cases have declined from 49,000 in season 2012/2013 to 25,000 in season 2015/2016 (2) since RV vaccination has been recommended by the Standing Committee on Vaccination (STIKO) in Germany in 2013. The recommendation was based on systematic reviews and meta-analyses of studies showing efficacy and safety of RV vaccination (3). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170817IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12771</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28815852">PM:28815852</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170817-RosenfeldL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170817-RosenfeldL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170817, Rosenfeld L</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12771</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42526</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kruger,R.</style></author><author><style face="normal" font="default"> Zappe,S.M.</style></author><author><style face="normal" font="default"> Stolzel,K.</style></author><author><style face="normal" font="default"> von Bernuth,H.</style></author><author><style face="normal" font="default"> Wahn,V.</style></author><author><style face="normal" font="default"> Knopke,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric Pneumology and Immunology, Charite Universitatsmedizin Berlin, Germany</style></auth-address><titles><title><style face="normal" font="default">Fatal case of ataxia telangiectasia complicated by severe epistaxis due to nasal telangiectasia in a 12 year old boy</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword></keywords><dates><year Day="7" Month="8" Year="2017">2017/8/7</year></dates><abstract><style face="normal" font="default">Ataxia telangiectasia (AT) is a rare autosomal inherited disorder with progressive ataxia, cutaneous and ocular telangiectasia, and an increased risk for malignancies due to chromosomal instability and varying degrees of immunodeficiency. Telangiectasia mostly occurs in eyes and sun exposed skin areas. However, mucosal bleeding due to telangiectasia within the vesical bladder has been reported. We, for the first time, report massive epistaxis in a 12 year old boy with AT due to multiple endonasal telangiectasias. Bleeding was refractory to a combined tamponade but could successfully be controlled using laser vaporization. Despite control of bleeding the boy -who had suffered from progressive chronic liver disease of unknown origin- died from liver failure 15 days after laser treatment. In conclusion, telangiectasias in mucous membranes have to be considered in AT patients with bleeding events. In particular, epistaxis in patients with AT should prompt for ENT examination to diagnose and treat endonasal telangiectasia. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170807IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12766</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28782291">PM:28782291</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170807-KrugerR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170807-KrugerR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170807, Kruger R</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12766</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42527</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nwaru,B.I.</style></author><author><style face="normal" font="default"> Hadkhale,K.</style></author><author><style face="normal" font="default"> Hamalainen,N.</style></author><author><style face="normal" font="default"> Takkinen,H.M.</style></author><author><style face="normal" font="default"> Ahonen,S.</style></author><author><style face="normal" font="default"> Ilonen,J.</style></author><author><style face="normal" font="default"> Toppari,J.</style></author><author><style face="normal" font="default"> Niemela,O.</style></author><author><style face="normal" font="default"> Haapala,A.M.</style></author><author><style face="normal" font="default"> Veijola,R.</style></author><author><style face="normal" font="default"> Knip,M.</style></author><author><style face="normal" font="default"> Virtanen,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Social Sciences/Health, University of Tampere, Finland</style></auth-address><titles><title><style face="normal" font="default">Vitamin D intake during the first 4 years and onset of asthma by age 5: a nested case-control study</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="8" Year="2017">2017/8/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Early life vitamin D intake has been linked to asthma risk in childhood, but the role of longitudinal vitamin D exposure has not been previously evaluated. We investigated the association between vitamin D intake during the first 4 years of life and asthma risk by age 5. METHODS: Within a Finnish population-based birth cohort, 182 incident asthma cases were matched to 728 controls on sex, genetic risk for type 1 diabetes, delivery hospital, and time of birth. Vitamin D intake was assessed by age-specific 3-day food records. Parents completed a validated version of the International Study of Asthma and Allergies in Childhood questionnaire at 5 years. RESULTS: At 3 months, supplements were the main source of vitamin D intake; intake from foods increased from 3 months on, mainly from fortified milk products. Vitamin D intake at each specific age was associated with an increased risk of any asthma, atopic and non-atopic asthma, but only intake at 1 and 2 years was statistically significantly associated with asthma. Longitudinal vitamin D intake was associated with an increased risk of asthma (OR 1.24; 95%CI 1.00-1.53) CONCLUSIONS: Increased vitamin D intake in childhood, particularly intake at 1 and 2 years of age, may increase risk of childhood asthma. This might reflect a true effect or residual confounding by lifestyle or environmental factors. Repeated assessment of vitamin D intake allowed evaluation of the longitudinal and age-dependent impact of vitamin D on the risk of asthma. Further longitudinal studies are required to confirm or question these findings. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170817IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Finland -CO - United Kingdom -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12773</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28815786">PM:28815786</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170817-NwaruBI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170817-NwaruBI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170817, Nwaru BI</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12773</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42528</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ferreira de Magalhaes,M.J.</style></author><author><style face="normal" font="default"> Amaral,R.D.S.</style></author><author><style face="normal" font="default"> Pereira,A.M.</style></author><author><style face="normal" font="default"> de Sa E Sousa Santos,A.I.A.</style></author><author><style face="normal" font="default"> de Azevedo,M.I.A.</style></author><author><style face="normal" font="default"> de Azevedo,L.F.R.</style></author><author><style face="normal" font="default"> Fonseca,J.A.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Centro Hospitalar de S. Joao, Porto, Portugal</style></auth-address><titles><title><style face="normal" font="default">Cost of asthma in children: a nationwide, population-based, cost-of-illness study</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="8" Year="2017">2017/8/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Childhood asthma is very prevalent and costs can be high, especially in severe disease. This study aimed to estimate the cost of asthma in Portuguese children and the variations by level of asthma control. METHODS: A nationwide, population- and prevalence-based cost-of-illness study with a societal perspective was conducted. We measured direct and indirect costs using a bottom-up approach and a human capital method, respectively, for 208 children (&lt;18 years), from two national repositories. Generalised linear modelling for analysis of asthma costs' determinants and sensitivity analysis to assess uncertainty were performed. RESULTS: The mean annualised asthma cost per child was euro929.35 (95%CI, 809.65-1,061.11): euro698.65 (95%CI, 600.88-798.27) for direct costs, and euro230.70 (95%CI, 197.36-263.81) for indirect costs. Extrapolations for the Portuguese children amounted to euro161,410,007.61 (95%CI, 140,620,769.55-184,293,968.55) for total costs. Direct costs represent 75.2% with the costliest domain (51.1% of total costs) being the healthcare service use: 20.7% for scheduled medical visits and 30.4% for acute asthma care - non-scheduled medical visits (7.9%, euro12,766,203.20), emergency department visits (11.7%, euro18,932,464.80) and hospitalisations (10.8%, euro17,406,946.00). Children with partly controlled and uncontrolled asthma had higher mean costs per year (adjusted coefficients: 1.46 [95%CI, 1.12-1.90] and 2.25 [95%CI, 1.56-3.24], respectively). CONCLUSIONS: Costs of childhood asthma are high (0.9% of the healthcare expenditures in Portugal). Direct costs represented 3/4 of total costs, mainly related to the use of healthcare services for acute asthma care. Policies and interventions to improve asthma control and reduce acute use of healthcare services have the potential to reduce asthma costs. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170817IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12772</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28815837">PM:28815837</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170817-FerreiradeMagalhaesMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170817-FerreiradeMagalhaesMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170817, Ferreira de Magalhaes MJ</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12772</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42529</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Soyiri,I.N.</style></author><author><style face="normal" font="default"> Nwaru,B.I.</style></author><author><style face="normal" font="default"> Sheikh,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Asthma UK Centre for Applied Research, Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK</style></auth-address><titles><title><style face="normal" font="default">Response to validity of PROMS in atopic eczema/dermatitis</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="8" Year="2017">2017/8/17</year></dates><abstract><style face="normal" font="default">We welcome the critique by Apfelbacher and colleagues 1 of our overview of patient-reported outcome measures (PROMS) in allergy and asthma clinical studies in children 2 . Our focus was on identifying valid instruments and in so doing we relied on our own detailed systematic reviews in relation to asthma and food allergy 3-5 , recent evidence-based guidelines on PROMS in allergy 6 , and systematic reviews undertaken by others in atopic eczema/dermatitis and allergic rhinitis 7 . We agree that on a closer look at the primary evidence in relation to PROMs for atopic eczema/dermatitis, whilst there is some evidence of validation work in relation to Infants' Dermatitis Quality of Life Index (IDQOL) 8 9 , the overall validity of this instrument still remains to be established. his article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170817IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12774</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28815809">PM:28815809</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170817-SoyiriIN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170817-SoyiriIN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170817, Soyiri IN</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12774</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42530</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hill,D.A.</style></author><author><style face="normal" font="default"> Leahy,A.B.</style></author><author><style face="normal" font="default"> Sciasci,J.</style></author><author><style face="normal" font="default"> O'Neill,S.P.</style></author><author><style face="normal" font="default"> Reilly,A.</style></author><author><style face="normal" font="default"> Balamuth,N.</style></author><author><style face="normal" font="default"> Seeholzer,S.H.</style></author><author><style face="normal" font="default"> Spergel,J.M.</style></author><author><style face="normal" font="default"> Brown-Whitehorn,T.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Division of Allergy and Immunology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania</style></auth-address><titles><title><style face="normal" font="default">Medication contaminants as a potential cause of anaphylaxis to vincristine</style></title><secondary-title><style face="normal" font="default">Pediatr Blood Cancer</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Blood Cancer</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword></keywords><dates><year Day="22" Month="8" Year="2017">2017/8/22</year></dates><abstract><style face="normal" font="default">Vincristine (VCR) is a vinca alkaloid and common chemotherapeutic that is used to treat multiple pediatric and adult malignancies. Despite its common use, cases of anaphylaxis to VCR are rare and typically isolated to a single individual. We report a series of eight patients with adverse reactions to VCR over the course of 11 months at a single institution, four of which progressed to anaphylaxis and one of which resulted in cardiac arrest. Mass spectrometry analysis of medication lots was performed to test for possible contaminant(s). Our findings highlight the risk of anaphylaxis during therapy with VCR</style></abstract><notes><style face="normal" font="default">DA - 20170823IS - 1545-5017 (Electronic)IS - 1545-5009 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1002/pbc.26761</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28834048">PM:28834048</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Blood Cancer\20170823-HillDA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Blood Cancer\20170823-HillDA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170823, Hill DA</style></custom2><misc3><style face="normal" font="default">10.1002/pbc.26761</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42531</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Isidoro-Garcia,M.</style></author><author><style face="normal" font="default"> Sanchez-Martin,A.</style></author><author><style face="normal" font="default"> Garcia-Sanchez,A.</style></author><author><style face="normal" font="default"> Sanz,C.</style></author><author><style face="normal" font="default"> Garcia-Berrocal,B.</style></author><author><style face="normal" font="default"> Davila,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Biochemistry, Pharmacogenetics Unit, University Hospital of Salamanca, Salamanca, Spain</style></auth-address><titles><title><style face="normal" font="default">Pharmacogenetics and the treatment of asthma</style></title><secondary-title><style face="normal" font="default">Pharmacogenomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pharmacogenomics</style></full-title></periodical><pages end="1280" start="1271">1271-1280</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">13</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">Heterogeneity defines both the natural history of asthma as well as patient's response to treatment. Pharmacogenomics contribute to understand the genetic basis of drug response and thus to define new therapeutic targets or molecular biomarkers to evaluate treatment effectiveness. This review is initially focused on different genes so far involved in the pharmacological response to asthma treatment. Specific considerations regarding allergic asthma, the pharmacogenetics aspects of polypharmacy and the application of pharmacogenomics in new drugs in asthma will also be addressed. Finally, future perspectives related to epigenetic regulatory elements and the potential impact of systems biology in pharmacogenetics of asthma will be considered</style></abstract><notes><style face="normal" font="default">DA - 20170804IS - 1744-8042 (Electronic)IS - 1462-2416 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.2217/pgs-2017-0024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28776467">PM:28776467</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pharmacogenomics\2017-18-1271-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pharmacogenomics\2017-18-1271-80.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170804, Isidoro-Garcia M</style></custom2><misc3><style face="normal" font="default">10.2217/pgs-2017-0024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42532</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Park,J.H.</style></author><author><style face="normal" font="default"> Lee,B.</style></author><author><style face="normal" font="default"> Kim,H.K.</style></author><author><style face="normal" font="default"> Kim,E.Y.</style></author><author><style face="normal" font="default"> Kim,J.H.</style></author><author><style face="normal" font="default"> Min,J.H.</style></author><author><style face="normal" font="default"> Kim,S.</style></author><author><style face="normal" font="default"> Sohn,Y.</style></author><author><style face="normal" font="default"> Jung,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anatomy, College of Korean Medicine, Kyung Hee University, Kyungheedae-ro, Dongdaemun-gu, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Peimine Inhibits the Production of Proinflammatory Cytokines Through Regulation of the Phosphorylation of NF-kappaB and MAPKs in HMC-1 Cells</style></title><secondary-title><style face="normal" font="default">Pharmacogn Mag</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pharmacogn Mag</style></full-title></periodical><pages end="S364" start="S359">S359-S364</pages><volume><style face="normal" font="default">13</style></volume><number><style face="normal" font="default">Suppl 2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Inflammation</style></keyword></keywords><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Peimine is a major biologically active component of Fritillaria ussuriensis. Peimine was investigated in chronic inflammation response, but it has not been studied in mast cell-related immediate allergic reaction. The present study aimed to evaluate anti-allergic effect of peimine in human mast cell (HMC-1). MATERIALS AND METHODS: The effect of peimine on cell viability was measured by MTS assay in HMC-1. Histamine release was investigated in rat peritoneal mast cells (RPMCs). Interleukin (IL)-6, IL-8, and tumor necrosis factor-alpha (TNF-alpha) expressions were measured by ELISA assay and reverse transcription-polymerase chain reaction. Mitogen-activated protein kinases (MAPKs) and nuclear factor-kappaB (NF-kappaB) were examined by Western blot. Passive cutaneous anaphylaxis (PCA) reactions were evaluated using Sprague-Dawley (SD) rats. RESULTS: Peimine inhibited the production of pro-inflammatory cytokines, such as IL-6, IL-8, and TNF-alpha. Moreover, peimine reduced MAPKs phosphorylation and the nuclear NF-kappaB expression in PMACI-induced HMC-1. Peimine decreased PCA reactions in rats as well. CONCLUSION: Our study proved that peimine might be suitable for the treatment of mast cell-derived allergic inflammatory reactions. SUMMARY: Peimine inhibited the production of pro-inflammatory cytokines, such as IL-6, IL-8, and TNF-alphaPeimine reduced MAPKs phosphorylation and the nuclear NF-kappaB expression in PMACI-induced HMC-1Peimine decreased PCA reactions in ratsPeimine has anti-allergic effect through regulation of pro-inflammatory mechanism on mast cell. Abbreviations used: HMC-1: Human mast cell, MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetr azolium, RPMCs: Rat peritoneal mast cells. IL-6: Interleukin 6, IL-8: Interleukin 8, TNF-alpha: Tumor necrosis factor-alpha, MAPKs: Mitogen-activated protein kinases; NF-kappaB: Nuclear factor-kappaB, PCA: Passive cutaneous anaphylaxis reactions, SD: Sprague-Dawley</style></abstract><notes><style face="normal" font="default">DA - 20170815IS - 0973-1296 (Print)IS - 0973-1296 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4103/0973-1296.210173</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28808406">PM:28808406</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pharmacogn Mag\2017-13S2-359-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pharmacogn Mag\2017-13S2-359-64.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170815, Park JH</style></custom2><misc3><style face="normal" font="default">10.4103/0973-1296.210173</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42533</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Huang,L.</style></author><author><style face="normal" font="default"> Dong,Y.</style></author><author><style face="normal" font="default"> Wu,J.</style></author><author><style face="normal" font="default"> Wang,P.</style></author><author><style face="normal" font="default"> Zhou,H.</style></author><author><style face="normal" font="default"> Li,T.</style></author><author><style face="normal" font="default"> Liu,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau, China</style></auth-address><titles><title><style face="normal" font="default">Sinomenine-induced histamine release-like anaphylactoid reactions are blocked by tranilast via inhibiting NF-kappaB signaling</style></title><secondary-title><style face="normal" font="default">Pharmacol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pharmacol Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="8" Year="2017">2017/8/31</year></dates><abstract><style face="normal" font="default">Zhengqing Fengtongning (ZQFTN), the pharmaceutical preparation of sinomenine (SIN) derived from the medicinal plant Sinmenium acutum, is well-known in China as an effective treatment for rheumatoid arthritis (RA). However, its histamine-release anaphylactoid reactions (HRARs) occur often in some patients. Therefore, it is desirable to establish effective clinical protocols to manage such HRARs. In the study, rat models with systemic HRARs and local HRARs of the skin were established. The level of vascular permeability and mast cell numbers was determined by quantitative analysis using Evans blue dye and histological assays. The levels of histamine, leukotriene B4 (LTB4) and IL-33 in plasma were detected by UHPLC-SPE-MS, ELISA and immunohistochemistry assays, respectively. The results demonstrated that SIN significantly induced both systemic and local HRARs in rats, showing significant decrease of body temperature, increases in vascular permeability in skin, injury of lung tissues and mast cell infiltration and IL-33 expression in skin and lung tissues. Mechanistic study showed that tranilast could prevent SIN-triggered HRARs via inhibition of H1 receptor gene expression and NF-kappaB signaling. Our findings provide evidence that mast cell membrane stabilizers and H1 receptor blockers effectively prevent SIN-induced HRARs, and cromolyn, cetirizine and tranilast can be used in the clinic for the management of HRARs induced by ZQFTN</style></abstract><notes><style face="normal" font="default">DA - 20170904IS - 1096-1186 (Electronic)IS - 1043-6618 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.phrs.2017.08.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28867637">PM:28867637</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pharmacol Res\20170904-HuangL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pharmacol Res\20170904-HuangL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170904, Huang L</style></custom2><misc3><style face="normal" font="default">10.1016/j.phrs.2017.08.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42534</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Leung,J.S.</style></author><author><style face="normal" font="default"> Johnson,D.W.</style></author><author><style face="normal" font="default"> Sperou,A.J.</style></author><author><style face="normal" font="default"> Crotts,J.</style></author><author><style face="normal" font="default"> Saude,E.</style></author><author><style face="normal" font="default"> Hartling,L.</style></author><author><style face="normal" font="default"> Stang,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pediatric Emergency Medicine, Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="default">A systematic review of adverse drug events associated with administration of common asthma medications in children</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0182738">e0182738-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">pharmacology</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To systematically review the literature and determine frequencies of adverse drug events (ADE) associated with pediatric asthma medications. METHODS: Following PRISMA guidelines, we systematically searched six bibliographic databases between January 1991 and January 2017. Study eligibility, data extraction and quality assessment were independently completed and verified by two reviewers. We included randomized control trials (RCT), case-control, cohort, or quasi-experimental studies where the primary objective was identifying ADE in children 1 month- 18 years old exposed to commercial asthma medications. The primary outcome was ADE frequency. FINDINGS: Our search identified 14,540 citations. 46 studies were included: 24 RCT, 15 cohort, 4 RCT pooled analyses, 1 case-control, 1 open-label trial and 1 quasi-experimental study. Studies examined the following drug classes: inhaled corticosteroids (ICS) (n = 24), short-acting beta-agonists (n = 10), long-acting beta-agonists (LABA) (n = 3), ICS + LABA (n = 3), Leukotriene Receptor Antagonists (n = 3) and others (n = 3). 29 studies occurred in North America, and 29 were industry funded. We report a detailed index of 406 ADE descriptions and frequencies organized by drug class. The majority of data focuses on ICS, with 174 ADE affecting 13 organ systems including adrenal and growth suppression. We observed serious ADE, although they were rare, with frequency ranging between 0.9-6% per drug. There were no confirmed deaths, except for 13 potential deaths in a LABA study including combined adult and pediatric participants. We identified substantial methodological concerns, particularly with identifying ADE and determining severity. No studies utilized available standardized causality, severity or preventability assessments. CONCLUSION: The majority of studies focus on ICS, with adrenal and growth suppression described. Serious ADE are relatively uncommon, with no confirmed pediatric deaths. We identify substantial methodological concerns, highlighting need for standardization with future research examining pediatric asthma medication safety</style></abstract><notes><style face="normal" font="default">DA - 20170809IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0182738</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28793336">PM:28793336</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0182738.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0182738.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170809, Leung JS</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0182738</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42535</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhu,R.</style></author><author><style face="normal" font="default"> Zheng,Y.</style></author><author><style face="normal" font="default"> Dirks,N.L.</style></author><author><style face="normal" font="default"> Vadhavkar,S.</style></author><author><style face="normal" font="default"> Jin,J.Y.</style></author><author><style face="normal" font="default"> Peng,K.</style></author><author><style face="normal" font="default"> Holweg,C.T.J.</style></author><author><style face="normal" font="default"> Olsson,J.</style></author><author><style face="normal" font="default"> Matthews,J.G.</style></author><author><style face="normal" font="default"> Putnam,W.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Genentech, Inc., South San Francisco, CA, USA</style></auth-address><titles><title><style face="normal" font="default">Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma</style></title><secondary-title><style face="normal" font="default">Pulm Pharmacol Ther</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pulm Pharmacol Ther</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Inflammation</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword></keywords><dates><year Day="23" Month="8" Year="2017">2017/8/23</year></dates><abstract><style face="normal" font="default">Lebrikizumab is a humanized monoclonal antibody that binds to interleukin-13 and has been evaluated as a treatment for moderate-to-severe asthma. Objectives of this work were to characterize lebrikizumab pharmacokinetics (PK), identify influential covariates, and graphically explore exposure-response relationships in moderate-to-severe asthmatics. Pooled PK data from 11 studies were used in the population PK model development. Full covariate modeling was used to evaluate the impact of pre-specified covariates. Response data (exacerbation rate, forced expiratory volume in 1 s [FEV1], and fractional exhaled nitric oxide [FeNO]) were obtained from moderate-to-severe asthmatics (n = 2148) who received placebo, lebrikizumab 37.5 mg or 125 mg every 4 weeks (Q4W) in two replicate phase 3 studies. Graphical exposure-response analyses were stratified by numerous covariates, including biomarker subgroups defined by serum periostin level and blood eosinophil count at baseline. Lebrikizumab PK was described by a two-compartment model with first-order absorption. Population typical values were estimated as 0.156 L/day for clearance (CL), 4.10 L for central volume (Vc), and 0.239 day-1 for absorption rate (ka), 85.6% for bioavailability (inter-subject variability: CL, 33.3%; Vc, 36.3%; ka, 40.8%). The estimated mean terminal half-life was 25.7 days. Body weight was the most influential covariate. Generally, the exposure-response analyses of FEV1 and FeNO showed increased response at higher exposure quartiles, while flat or unclear exposure-response relationships were observed in exacerbation rate. Lebrikizumab PK is as expected for a typical immunoglobulin G4 monoclonal antibody. Results from the exposure-response analyses suggested that, compared to 125 mg Q4W, the 37.5 mg Q4W dose did not achieve the maximum responses for FEV1 and FeNO, although it appeared to maximize the effect on exacerbation reduction. This suggests that the antibody levels needed to improve these outcomes may not be the same. In addition, the role of IL-13 in airflow obstruction/airway inflammation and asthma exacerbations might be different and targeting multiple pathways may be required to treat this heterogeneous disease and provide clinically meaningful benefits to asthma patients</style></abstract><notes><style face="normal" font="default">DA - 20170827IS - 1522-9629 (Electronic)IS - 1094-5539 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.pupt.2017.08.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28843617">PM:28843617</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pulm Pharmacol Ther\20170827-ZhuR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pulm Pharmacol Ther\20170827-ZhuR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170827, Zhu R</style></custom2><misc3><style face="normal" font="default">10.1016/j.pupt.2017.08.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42536</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vincent,M.J.</style></author><author><style face="normal" font="default"> Bernstein,J.A.</style></author><author><style face="normal" font="default"> Basketter,D.</style></author><author><style face="normal" font="default"> LaKind,J.S.</style></author><author><style face="normal" font="default"> Dotson,G.S.</style></author><author><style face="normal" font="default"> Maier,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department Environmental Health, University Cincinnati College of Medicine, Cincinnati, OH, United States.</style></auth-address><titles><title><style face="normal" font="default">Chemical-induced asthma and the role of clinical, toxicological, exposure and epidemiological research in regulatory and hazard characterization approaches</style></title><secondary-title><style face="normal" font="default">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="8" Year="2017">2017/8/30</year></dates><abstract><style face="normal" font="default">Uncertainties in understanding all potential modes-of-action for asthma induction and elicitation hinders design of hazard characterization and risk assessment methods that adequately screen and protect against hazardous chemical exposures. To address this challenge and identify current research needs, the University of Cincinnati and the American Cleaning Institute hosted a webinar series to discuss the current state-of-science regarding chemical-induced asthma. The general consensus is that the available database, comprised of data collected from routine clinical and validated toxicological tests, is inadequate for predicting or determining causal relationships between exposures and asthma induction for most allergens. More research is needed to understand the mechanism of asthma induction and elicitation in the context of specific chemical exposures and exposure patterns, and the impact of population variability and patient phenotypes. Validated tools to predict respiratory sensitization and to translate irritancy assays to asthma potency are needed, in addition to diagnostic biomarkers that assess and differentiate allergy versus irritant-based asthmatic responses. Diagnostic methods that encompass the diverse etiologies of asthmatic responses and incorporate robust exposure measurements capable of capturing different temporal patterns of complex chemical mixtures are needed. In the absence of ideal tools, risk assessors apply hazard-based safety assessment methods, in conjunction with active risk management, to limit potential asthma concerns, proactively identify new concerns, and ensure deployment of approaches to mitigate asthma-related risks</style></abstract><notes><style face="normal" font="default">DA - 20170903IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.yrtph.2017.08.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28866265">PM:28866265</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\20170903-VincentMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\20170903-VincentMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170903, Vincent MJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.yrtph.2017.08.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42537</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ade,S.</style></author><author><style face="normal" font="default"> Awanou,B.</style></author><author><style face="normal" font="default"> Wachinou,A.P.</style></author><author><style face="normal" font="default"> Kouchade,V.</style></author><author><style face="normal" font="default"> Adjobimey,M.</style></author><author><style face="normal" font="default"> Adjibode,O.</style></author><author><style face="normal" font="default"> Dovonou,A.C.</style></author><author><style face="normal" font="default"> Agodokpessi,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Treatment of "severe" asthma in Benin, a country with limited resources</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">severe asthma</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword><keyword><style face="normal" font="default"> Improvement</style></keyword><keyword><style face="normal" font="default"> Follow-up</style></keyword><keyword><style face="normal" font="default"> Benin</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Objective To assess treatment outcomes of patients with severe diagnosed asthma among those treated in the two major pulmonology-tuberculosis centers involved in an asthma management programme in Benin. Patients and methods This was retrospective cohort study that included all patients enrolled between January 2013 and November 2015. Data on patient's characteristics, asthma severity, compliance with planned control visits, and annual evaluation results were collected, entered and analyzed using the EpiData and SPSS 21 software packages. Results Of the 491 asthmatic patients presenting at least one weekly attack, 194 (40%) had a severe form, with a male-female ratio of 0.81 and a median age of 47 years (interquartile range = 32</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô60 years). The proportion of those adhering to control visits gradually fell: 98% (2 weeks), 74% (1 month), 63% (3 months), 54% (6 months), 51% (9 months) and 41% (1 year). The annual assessment of 52 (27%) patients showed no improvement. In addition, of the 115 (59%) not attending this appointment, 82 (42%) did not improve, based on their last assessment in the programme. The only factor associated with lack of improvement was being aged over 41 years (adjusted relative risk = 2.14; 95% CI = 1.11</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô4.13; P = 0.02). Conclusion Many patients in the project were diagnosed with severe asthma. Their attendance of follow-up gradually decreased during and their condition showed little improvement at their annual evaluation visits. Application of the GINA recommendations and subsidizing other drugs would doubtless help to improve their condition</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -CO - Benin -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.07.008</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.07.008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20170906-AdeS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20170906-AdeS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170906, Ade S</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.07.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42538</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Herteman,N.</style></author><author><style face="normal" font="default"> Vargas,A.</style></author><author><style face="normal" font="default"> Lavoie,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Sciences, Faculty of Veterinary Medicine, Universite de Montreal. 3200 Rue Sicotte, Saint-Hyacinthe, J2S 2M2, QC, Canada</style></auth-address><titles><title><style face="normal" font="default">Characterization of Circulating Low-Density Neutrophils Intrinsic Properties in Healthy and Asthmatic Horses</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="7743">7743-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Animals</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword></keywords><dates><year Day="10" Month="8" Year="2017">2017/8/10</year></dates><abstract><style face="normal" font="default">Low-density neutrophils (LDNs) are a subset of neutrophils first described in the bloodstream upon pathological conditions, and recently, in the blood of healthy humans. LDNs may have an enhanced pro-inflammatory (low-density granulocytes, LDGs) or an immunosuppressive (Granulocytic myeloid-derived suppressor cells, G-MDSCs) profile. Whether these characteristics are specific to LDNs or related to disease states is unknown. Thus, we sought to investigate the properties of LDNs in both health and disease states, and to compare them to those of autologous normal-density neutrophils (NDNs). We studied 8 horses with severe equine asthma and 11 healthy animals. LDNs were smaller and contained more N-formylmethionine-leucyl-phenylalanine receptors than NDNs, but the myeloperoxidase content was similar in both cell populations. They also had an increased capacity to produce neutrophil extracellular traps, and were more sensitive to activation by phorbol-12-myristate-13-acetate. This profile is suggestive of LDGs. These characteristics were similar in both healthy and diseased animals, indicating that these are intrinsic properties of LDNs. Furthermore, these results suggest that LDNs represent a population of primed and predominantly mature cells. This study is the first to characterize LDNs in health, and to compare their properties with those of NDNs and of animals with a naturally occurring disease</style></abstract><notes><style face="normal" font="default">DA - 20170811IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1038/s41598-017-08089-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28798364">PM:28798364</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Rep\2017-7-7743.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Rep\2017-7-7743.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170811, Herteman N</style></custom2><misc3><style face="normal" font="default">10.1038/s41598-017-08089-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42539</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brunner,P.M.</style></author><author><style face="normal" font="default"> Suarez-Farinas,M.</style></author><author><style face="normal" font="default"> He,H.</style></author><author><style face="normal" font="default"> Malik,K.</style></author><author><style face="normal" font="default"> Wen,H.C.</style></author><author><style face="normal" font="default"> Gonzalez,J.</style></author><author><style face="normal" font="default"> Chan,T.C.</style></author><author><style face="normal" font="default"> Estrada,Y.</style></author><author><style face="normal" font="default"> Zheng,X.</style></author><author><style face="normal" font="default"> Khattri,S.</style></author><author><style face="normal" font="default"> Dattola,N.</style></author><author><style face="normal" font="default"> Krueger,J.G.</style></author><author><style face="normal" font="default"> Guttman-Yassky,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA</style></auth-address><titles><title><style face="normal" font="default">The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="8707">8707-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Skin</style></keyword></keywords><dates><year Day="18" Month="8" Year="2017">2017/8/18</year></dates><abstract><style face="normal" font="default">Beyond classic "allergic"/atopic comorbidities, atopic dermatitis (AD) emerges as systemic disease with increased cardiovascular risk. To better define serum inflammatory and cardiovascular risk proteins, we used an OLINK high-throughput proteomic assay to analyze moderate-to-severe AD (n = 59) compared to psoriasis (n = 22) and healthy controls (n = 18). Compared to controls, 10 proteins were increased in serum of both diseases, including Th1 (IFN-gamma, CXCL9, TNF-beta) and Th17 (CCL20) markers. 48 proteins each were uniquely upregulated in AD and psoriasis. Consistent with skin expression, AD serum showed up-regulation of Th2 (IL-13, CCL17, eotaxin-1/CCL11, CCL13, CCL4, IL-10), Th1 (CXCL10, CXCL11) and Th1/Th17/Th22 (IL-12/IL-23p40) responses. Surprisingly, some markers of atherosclerosis (fractalkine/CX3CL1, CCL8, M-CSF, HGF), T-cell development/activation (CD40L, IL-7, CCL25, IL-2RB, IL-15RA, CD6) and angiogenesis (VEGF-A) were significantly increased only in AD. Multiple inflammatory pathways showed stronger enrichment in AD than psoriasis. Several atherosclerosis mediators in serum (e.g. E-selectin, PI3/elafin, CCL7, IL-16) correlated with SCORAD, but not BMI. Also, AD inflammatory mediators (e.g. MMP12, IL-12/IL-23p40, CXCL9, CCL22, PI3/Elafin) correlated between blood and lesional as well as non-lesional skin. Overall, the AD blood signature was largely different compared to psoriasis, with dysregulation of inflammatory and cardiovascular risk markers, strongly supporting its systemic nature beyond atopic/allergic association</style></abstract><notes><style face="normal" font="default">DA - 20170819IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1038/s41598-017-09207-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28821884">PM:28821884</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Rep\2017-7-8707.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Rep\2017-7-8707.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170819, Brunner PM</style></custom2><misc3><style face="normal" font="default">10.1038/s41598-017-09207-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42540</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hsieh,H.T.</style></author><author><style face="normal" font="default"> Chang,H.M.</style></author><author><style face="normal" font="default"> Lin,W.J.</style></author><author><style face="normal" font="default"> Hsu,Y.T.</style></author><author><style face="normal" font="default"> Mai,F.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Graduate Institute of Medical Science, College of Medicine, Taipei Medical University, No. 250 Wuxing St., Taipei, 11031, Taiwan</style></auth-address><titles><title><style face="normal" font="default">Poly-Methyl Methacrylate/Polyvinyl Alcohol Copolymer Agents Applied on Diabetic Wound Dressing</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="9531">9531-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cities</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword></keywords><dates><year Day="25" Month="8" Year="2017">2017/8/25</year></dates><abstract><style face="normal" font="default">Due to the difficulty of healing chronic wound, in the process of changing dressing, secondary damage on the tissue caused by adhesion should be prevented. In this study, the new dressing of particle hydrogels synthesized with poly-methyl methacrylate and poly-vinyl alcohol precursors were proposed. In addition, cell safety tests, animal's allergic stimulation, and animal's wound healing experiments were conducted for particle hydrogels. On one hand, in L929 cell experiment, the results of particle hydrogels extract 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide tests and lactate dehydrogenase test trial show that there are no safety concerns over particle hydrogels. On the other hand, New Zealand white rabbits were chosen for skin sensitization tests in animal trials, which show the consistent results. At last, wound healing tests used diabetes induction with 10-week-old rats and three-month-old Landrace pigs, with the tissue histology. In short, through this experiment, it is found that in the early phase of the diabetic rats and pigs' wound healing, using particle hydrogels can enhance collagen formation, and achieve the goal of faster wound healing</style></abstract><notes><style face="normal" font="default">DA - 20170826IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1038/s41598-017-10193-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28842691">PM:28842691</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Rep\2017-7-9531.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Rep\2017-7-9531.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170826, Hsieh HT</style></custom2><misc3><style face="normal" font="default">10.1038/s41598-017-10193-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42541</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chinnaswamy,S.</style></author><author><style face="normal" font="default"> Wardzynska,A.</style></author><author><style face="normal" font="default"> Pawelczyk,M.</style></author><author><style face="normal" font="default"> Makowska,J.</style></author><author><style face="normal" font="default"> Skaaby,T.</style></author><author><style face="normal" font="default"> Mercader,J.M.</style></author><author><style face="normal" font="default"> Ahluwalia,T.S.</style></author><author><style face="normal" font="default"> Grarup,N.</style></author><author><style face="normal" font="default"> Guindo-Martinez,M.</style></author><author><style face="normal" font="default"> Bisgaard,H.</style></author><author><style face="normal" font="default"> Torrents,D.</style></author><author><style face="normal" font="default"> Linneberg,A.</style></author><author><style face="normal" font="default"> Bonnelykke,K.</style></author><author><style face="normal" font="default"> Kowalski,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Institute of Biomedical Genomics, PO:N.S.S, Kalyani, 741251, West Bengal, India.</style></auth-address><titles><title><style face="normal" font="default">A functional IFN-lambda4-generating DNA polymorphism could protect older asthmatic women from aeroallergen sensitization and associate with clinical features of asthma</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="10500">10500-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="9" Year="2017">2017/9/5</year></dates><abstract><style face="normal" font="default">Lambda interferons (IFNLs) have immunomodulatory functions at epithelial barrier surfaces. IFN-lambda4, a recent member of this family is expressed only in a subset of the population due to a frameshift-causing DNA polymorphism rs368234815. We examined the association of this polymorphism with atopy (aeroallergen sensitization) and asthma in a Polish hospital-based case-control cohort comprising of well-characterized adult asthmatics (n = 326) and healthy controls (n = 111). In the combined cohort, we saw no association of the polymorphism with asthma and/or atopy. However, the IFN-lambda4-generating DeltaG allele protected older asthmatic women (>50 yr of age) from atopic sensitization. Further, DeltaG allele significantly associated with features of less-severe asthma including bronchodilator response and corticosteroid usage in older women in this Polish cohort. We tested the association of related IFNL locus polymorphisms (rs12979860 and rs8099917) with atopy, allergic rhinitis and presence/absence of asthma in three population-based cohorts from Europe, but saw no significant association of the polymorphisms with any of the phenotypes in older women. The polymorphisms associated marginally with lower occurrence of asthma in men/older men after meta-analysis of data from all cohorts. Functional and well-designed replication studies may reveal the true positive nature of these results</style></abstract><notes><style face="normal" font="default">DA - 20170906IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - India -CO - Poland -CO - Denmark -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1038/s41598-017-10467-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28874741">PM:28874741</url></web-urls><related-urls><url ppv-ref="no">presto - pdf non funzionante</url></related-urls></urls><custom2><style face="normal" font="default">20170906, Chinnaswamy S</style></custom2><misc3><style face="normal" font="default">10.1038/s41598-017-10467-y</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42542</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cousins,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Infection, Immunity and Inflammation, National Institute for Health Research Leicester Biomedical Research Centre, Leicester Institute for Lung Health, University of Leicester, Leicester LE3 9QP, UK. Email: dc282@leicester.ac.uk</style></auth-address><titles><title><style face="normal" font="default">Pinning allergies on pathogenic TH2 cells</style></title><secondary-title><style face="normal" font="default">Sci Transl Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Transl Med</style></abbr-1></periodical><pages end="" start="eaao0392">eaao0392-</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">401</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="2" Month="8" Year="2017">2017/8/2</year></dates><abstract><style face="normal" font="default">A new proinflammatory subtype of antigen-specific TH2 cell that expresses CD161 emerges as the pathogenic cell type in allergic disease and is deleted during allergen-specific immunotherapy (Wambre et al, this issue)</style></abstract><notes><style face="normal" font="default">DA - 20170803IS - 1946-6242 (Electronic)IS - 1946-6234 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1126/scitranslmed.aao0392</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28768801">PM:28768801</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Transl Med\2017-9-eaao0392.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Transl Med\2017-9-eaao0392.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170803, Cousins DJ</style></custom2><misc3><style face="normal" font="default">10.1126/scitranslmed.aao0392</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42543</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Morales,M.K.</style></author><author><style face="normal" font="default"> Harris,C.</style></author><author><style face="normal" font="default"> Shoham,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Transplant &amp; Oncology Infectious Diseases Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA</style></auth-address><titles><title><style face="normal" font="default">Graded isavuconazole introduction in a patient with voriconazole allergy</style></title><secondary-title><style face="normal" font="default">Transpl Infect Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Transpl Infect Dis</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="8" Year="2017">2017/8/29</year></dates><abstract><style face="normal" font="default">Triazole antifungal drugs may rarely cause serious allergic reactions including angioedema. No standardized tests are available to predict cross-reactivity within the azole class and little guiding information on whether to change therapy within the class or to another class after a serious allergic reaction. Herein we report the first successful use, to our knowledge, of graded isavuconazole introduction for treatment of aspergillosis in a liver transplant recipient with severe voriconazole allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170829IS - 1399-3062 (Electronic)IS - 1398-2273 (Linking)LA - engPT - Case ReportsCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/tid.12772</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28851131">PM:28851131</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Transpl Infect Dis\20170829-MoralesMK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Transpl Infect Dis\20170829-MoralesMK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170829, Morales MK</style></custom2><misc3><style face="normal" font="default">10.1111/tid.12772</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42544</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Prescott,S.L.</style></author><author><style face="normal" font="default"> Larcombe,D.L.</style></author><author><style face="normal" font="default"> Logan,A.C.</style></author><author><style face="normal" font="default"> West,C.</style></author><author><style face="normal" font="default"> Burks,W.</style></author><author><style face="normal" font="default"> Caraballo,L.</style></author><author><style face="normal" font="default"> Levin,M.</style></author><author><style face="normal" font="default"> Etten,E.V.</style></author><author><style face="normal" font="default"> Horwitz,P.</style></author><author><style face="normal" font="default"> Kozyrskyj,A.</style></author><author><style face="normal" font="default"> Campbell,D.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Paediatrics and Child Health, University of Western Australia and Princess Margaret Hospital for Children, PO Box D184, Perth, WA 6001 Australia</style></auth-address><titles><title><style face="normal" font="default">The skin microbiome: impact of modern environments on skin ecology, barrier integrity, and systemic immune programming</style></title><secondary-title><style face="normal" font="default">World Allergy Organ J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">World Allergy Organ J</style></abbr-1></periodical><pages end="" start="29">29-</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Skin barrier structure and function is essential to human health. Hitherto unrecognized functions of epidermal keratinocytes show that the skin plays an important role in adapting whole-body physiology to changing environments, including the capacity to produce a wide variety of hormones, neurotransmitters and cytokine that can potentially influence whole-body states, and quite possibly, even emotions. Skin microbiota play an integral role in the maturation and homeostatic regulation of keratinocytes and host immune networks with systemic implications. As our primary interface with the external environment, the biodiversity of skin habitats is heavily influenced by the biodiversity of the ecosystems in which we reside. Thus, factors which alter the establishment and health of the skin microbiome have the potential to predispose to not only cutaneous disease, but also other inflammatory non-communicable diseases (NCDs). Indeed, disturbances of the stratum corneum have been noted in allergic diseases (eczema and food allergy), psoriasis, rosacea, acne vulgaris and with the skin aging process. The built environment, global biodiversity losses and declining nature relatedness are contributing to erosion of diversity at a micro-ecological level, including our own microbial habitats. This emphasises the importance of ecological perspectives in overcoming the factors that drive dysbiosis and the risk of inflammatory diseases across the life course</style></abstract><notes><style face="normal" font="default">DA - 20170831IS - 1939-4551 (Print)IS - 1939-4551 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -CO - United States -CO - Sweden -CO - Colombia -CO - South Africa -CO - Canada -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1186/s40413-017-0160-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28855974">PM:28855974</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\World Allergy Organ J\2017-10-29.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\World Allergy Organ J\2017-10-29.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170831, Prescott SL</style></custom2><misc3><style face="normal" font="default">10.1186/s40413-017-0160-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42545</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hossny,E.</style></author><author><style face="normal" font="default"> Caraballo,L.</style></author><author><style face="normal" font="default"> Casale,T.</style></author><author><style face="normal" font="default"> el-Gamal,Y.</style></author><author><style face="normal" font="default"> Rosenwasser,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Allergy and Immunology Unit, Children's Hospital Ain Shams University, 40A Baghdad Street, Cairo, 11341 Egypt</style></auth-address><titles><title><style face="normal" font="default">Severe asthma and quality of life</style></title><secondary-title><style face="normal" font="default">World Allergy Organ J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">World Allergy Organ J</style></abbr-1></periodical><pages end="" start="28">28-</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Severe asthma has a great impact on the quality of life (QOL) of patients and their families. The magnitude of this morbidity is affected by several personal factors including age. Appropriate asthma control and modifications of social roles and activities are expected to improve QOL. Biologics, primarily monoclonal antibodies, have been developed to target specific pathways and molecules important in the pathogenesis of asthma. The use of biologics has shown some promising effects on the QOL of patients with severe recalcitrant asthma. Other potential measures involve targeting risk factors and comorbidities and improving the levels of adherence to therapy. This article briefly reviews the impact of severe asthma on QOL and the potential methods to combat this morbidity including the available therapeutic biologics</style></abstract><notes><style face="normal" font="default">DA - 20170831IS - 1939-4551 (Print)IS - 1939-4551 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Egypt -CO - Colombia -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1186/s40413-017-0159-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28855973">PM:28855973</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\World Allergy Organ J\2017-10-28.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\World Allergy Organ J\2017-10-28.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170831, Hossny E</style></custom2><misc3><style face="normal" font="default">10.1186/s40413-017-0159-y</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42546</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Perren,S.M.</style></author><author><style face="normal" font="default"> Regazzoni,P.</style></author><author><style face="normal" font="default"> Fernandez,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Davos, Switzerland</style></auth-address><titles><title><style face="normal" font="default">How to Choose between the Implant Materials Steel and Titanium in Orthopedic Trauma Surgery: Part 2 - Biological Aspects</style></title><secondary-title><style face="normal" font="default">Acta Chir Orthop Traumatol Cech</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Acta Chir Orthop Traumatol Cech</style></abbr-1></periodical><pages end="90" start="85">85-90</pages><volume><style face="normal" font="default">84</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">pathology</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BIOLOGICAL ASPECTS OF STEEL AND TITANIUM AS IMPLANT MATERIAL IN ORTHOPEDIC TRAUMA SURGERY The following case from the ICUC database, where a titanium plate was implanted into a flourishing infection, represents the clinical experience leading to preferring titanium over steel. (Fig. 1) (6). Current opinions regarding biological aspects of implant function. The "street" opinions regarding the biological aspects of the use of steel versus titanium as a surgical trauma implant material differ widely. Statements of opinion leaders range from "I do not see any difference in the biological behavior between steel and titanium in clinical application" to "I successfully use titanium implants in infected areas in a situation where steel would act as foreign body "sustaining" infection." Furthermore, some comments imply that clinical proof for the superiority of titanium in human application is lacking. The following tries to clarify the issues addressing the different aspects more through a practical clinical approach than a purely scientific one, this includes simplifications. Today's overall biocompatibility of implant materials is acceptable but: As the vast majority of secondary surgeries are elective procedures this allows the selection of implant materials with optimal infection resistance. The different biological reactions of stainless steel and titanium are important for this segment of clinical pathologies. Biological tole - rance (18) depends on the toxicity and on the amount of soluble implant material released. Release, diffusion and washout through blood circulation determine the local concentration of the corrosion products. Alloying components of steel, especially nickel and chromium, are less than optimal in respect to tissue tolerance and allergenicity. Titanium as a pure metal provides excellent biological tolerance (3, 4, 16). Better strength was obtained by titanium alloys like TiAl6V4. The latter found limited application as surgical implants. It contains Vanadium (9). Today's high strength titanium alloys contain well tolerated alloying components1 like Zr, Nb, Mo and Ta (ISO 5832-14) (7, 15). The corrosion rate of surgical implants is kept low by the passive layer formed when immerged in body fluids (13, 14). The passive layer may be locally destroyed, for instance, by mechanical fretting or by local corrosion conditions like in pitting; it is renewed by an electrochemical corrosion process which releases alloying components like Ni and Cr (Fig. 2) (10). The amount of soluble component may vary markedly depending on the local electrochemical conditions (see below)</style></abstract><notes><style face="normal" font="default">DA - 20170815IS - 0001-5415 (Print)IS - 0001-5415 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28809623">PM:28809623</url></web-urls></urls><custom2><style face="normal" font="default">20170815, Perren SM</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42547</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pasmatzi,E.</style></author><author><style face="normal" font="default"> Monastirli,A.</style></author><author><style face="normal" font="default"> Badavanis,G.</style></author><author><style face="normal" font="default"> Tsambaos,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Patras, Rio-Patras,Greece</style></auth-address><titles><title><style face="normal" font="default">Angioedema without urticaria caused by oral acitretin</style></title><secondary-title><style face="normal" font="default">Acta Dermatovenerol Alp Pannonica Adriat</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Acta Dermatovenerol Alp Pannonica Adriat</style></full-title></periodical><pages end="68" start="67">67-68</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">The efficacy of oral acitretin in the systemic treatment of severe and recalcitrant dermatoses has been established in a large number of clinical trials. Its mucocutaneous and ocular adverse reactions are common or relatively common, whereas systemic side effects are either uncommon or rare and include teratogenesis, hyperlipidemia, hepatotoxicity, intracranial hypertension, myopathy, and peripheral neuropathy. Angioedema is a term used to describe an acute, solitary or multiple, circumscribed, and non-pitting mucocutaneous swelling that affects the dermis and the subcutaneous tissue, lasts 24 to 72 hours, and may become potentially life-threatening when the pharynx and/or the larynx are involved. We report here the case of a 51-year old female psoriatic patient with angioedema (without urticaria) due to oral acitretin, confirmed by a positive oral provocation test. To the best of our knowledge, this is the second description of such an adverse reaction to acitretin</style></abstract><notes><style face="normal" font="default">DA - 20170923IS - 1581-2979 (Electronic)IS - 1318-4458 (Linking)LA - engPT - Journal ArticleCO - Greece -CO - Cyprus -</style></notes><work-type><style face="normal" font="default">10.15570/actaapa.2017.21</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28941265">PM:28941265</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Acta Dermatovenerol Alp Pannonica Adriat\2017-26-67-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Acta Dermatovenerol Alp Pannonica Adriat\2017-26-67-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170923, Pasmatzi E</style></custom2><misc3><style face="normal" font="default">10.15570/actaapa.2017.21</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42548</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jamshidi,S.</style></author><author><style face="normal" font="default"> Rahmati,K.M.</style></author><author><style face="normal" font="default"> Mirzaie,M.</style></author><author><style face="normal" font="default"> Sarrafan,A.</style></author><author><style face="normal" font="default"> Khafri,S.</style></author><author><style face="normal" font="default"> Parsian,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Faculty of Dentistry , Babol University of Medical Science , Babol , Iran</style></auth-address><titles><title><style face="normal" font="default">Evaluation of scalp hair nickel and chromium level changes in patients with fixed orthodontic appliance: a one-year follow-up study</style></title><secondary-title><style face="normal" font="default">Acta Odontol Scand</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Acta Odontol Scand</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="9" Year="2017">2017/9/9</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVES: The release of metal ions from orthodontic appliances is part of the dissolution and biomechanical processes of alloys. Nickel (Ni) and chromium (Cr) are the elements commonly used in the manufacture of various components of fixed orthodontic appliances, including bands, brackets and wires. This study was aimed to measure the Ni and Cr ions levels in the scalp hair of patients treated with fixed orthodontic appliances in comparison of the control group. MATERIALS AND METHODS: The patient group consisted of 24 patients treated with fixed orthodontic appliances for one year, while the control group included 28 healthy individuals without orthodontic appliances. Analysis of the Cr and Ni was performed using atomic absorption spectrophotometer by graphite furnace method. The data were analyzed via student and paired samples t-test and ANOVA repeated measurement test. RESULTS: After one year, the levels of Ni and Cr in two groups showed significant differences (0.086 +/- 0.007 and 0.258 +/- 0.009 microg/g for control group and 0.149 +/- 0.010 and 0.339 +/- 0.013 microg/g for patient group, respectively for Ni and Cr, p &lt; .001). ANCOVA test by removing the effects of age, gender and the baseline levels of Ni and Cr showed that changes in these ions in the scalp hair of both groups after one year were statistically significant. CONCLUSION: Due to the slightly elevated levels of Ni and Cr ions in the scalp hair of patients treated with fixed orthodontic appliances and considering the cytotoxic and allergic effects of these ions, changing the ingredients in fixed orthodontic appliances is suggested for the future</style></abstract><notes><style face="normal" font="default">DA - 20170911IS - 1502-3850 (Electronic)IS - 0001-6357 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">10.1080/00016357.2017.1372624</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28889787">PM:28889787</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Acta Odontol Scand\20170911-JamshidiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Acta Odontol Scand\20170911-JamshidiS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170911, Jamshidi S</style></custom2><misc3><style face="normal" font="default">10.1080/00016357.2017.1372624</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42549</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Giacaman-von der Weth,M.</style></author><author><style face="normal" font="default"> Perez-Ferriols,A.</style></author><author><style face="normal" font="default"> Sierra-Talamantes,C.</style></author><author><style face="normal" font="default"> Zaragoza-Ninet,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Servicio de Dermatologia, Hospital General, Valencia, Espana.</style></auth-address><titles><title><style face="normal" font="default">Allergic Sensitization to Isothiazolinones in Patients Referred for Photobiologic Study</style></title><secondary-title><style face="normal" font="default">Actas Dermosifiliogr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Actas Dermosifiliogr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="9" Year="2017">2017/9/26</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170930IS - 1578-2190 (Electronic)IS - 0001-7310 (Linking)LA - engLA - spaPT - LetterCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.ad.2017.02.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28963026">PM:28963026</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170930, Giacaman-von der Weth M</style></custom2><misc3><style face="normal" font="default">10.1016/j.ad.2017.02.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42550</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,L.C.</style></author><author><style face="normal" font="default"> Tseng,H.M.</style></author><author><style face="normal" font="default"> Kuo,M.L.</style></author><author><style face="normal" font="default"> Chiu,C.Y.</style></author><author><style face="normal" font="default"> Liao,S.L.</style></author><author><style face="normal" font="default"> Su,K.W.</style></author><author><style face="normal" font="default"> Tsai,M.H.</style></author><author><style face="normal" font="default"> Hua,M.C.</style></author><author><style face="normal" font="default"> Lai,S.H.</style></author><author><style face="normal" font="default"> Yao,T.C.</style></author><author><style face="normal" font="default"> Yeh,K.W.</style></author><author><style face="normal" font="default"> Wu,A.H.</style></author><author><style face="normal" font="default"> Huang,J.L.</style></author><author><style face="normal" font="default"> Huang,S.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Asthma and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan</style></auth-address><titles><title><style face="normal" font="default">A composite of exhaled LTB4 , LXA4 , FeNO and FEV1 as an "asthma classification ratio" characterizes childhood asthma</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="9" Year="2017">2017/9/25</year></dates><abstract><style face="normal" font="default">BACKGROUND: Aberrant generation of eicosanoids is associated with asthma, but the evidence remains incomplete and its potential utility as biomarkers is unclear. Major eicosanoids in exhaled breath condensates (EBCs) were assessed as candidate markers for childhood asthma. METHODS: Ten exhaled eicosanoid species was evaluated using ELISA in the discovery phase, followed by prediction model-building and validation phases. RESULTS: Exhaled LTB4 , LTE4 , PGE2 and LXA4 showed significant difference between asthmatics (N=60) and controls (N=20). For validation, an expanded study population consisting of 626 subjects with asthma and 161 healthy controls were partitioned into a training subset to establish a prediction model and a test sample subset for validation. Receiver Operating Characteristic (ROC) analyses of the training subset revealed the level of exhaled LTB4 to be the most discriminative among all parameters, including FeNO, and a composite of exhaled LTB4 , LXA4 , together with FeNO and FEV1 , distinguishing asthma with high sensitivity and specificity. Further, the Youden index (J) indicated the cut point value of 0.598 for this composite of markers as having the strongest discriminatory ability (sensitivity = 85.2% and specificity = 83.6%). The predictive algorithm as "asthma classification ratio" was further validated in an independent test sample with sensitivity and specificity being 84.4% and 84.8%, respectively. CONCLUSIONS: In a pediatric study population in Taiwan, the levels of exhaled LTB4 , LTE4 , LXA4 and PGE2 in asthmatic children were significantly different from those of healthy controls, and the combination of exhaled LTB4 and LXA4 , together with FeNO and FEV1 , best characterized childhood asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170925IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Taiwan -CO - China -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.13318</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28944471">PM:28944471</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170925-ChenLC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170925-ChenLC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170925, Chen LC</style></custom2><misc3><style face="normal" font="default">10.1111/all.13318</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42551</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ueta,M.</style></author><author><style face="normal" font="default"> Hamuro,J.</style></author><author><style face="normal" font="default"> Nishigaki,H.</style></author><author><style face="normal" font="default"> Nakamura,N.</style></author><author><style face="normal" font="default"> Shinomiya,K.</style></author><author><style face="normal" font="default"> Mizushima,K.</style></author><author><style face="normal" font="default"> Hitomi,Y.</style></author><author><style face="normal" font="default"> Tamagawa-Mineoka,R.</style></author><author><style face="normal" font="default"> Yokoi,N.</style></author><author><style face="normal" font="default"> Naito,Y.</style></author><author><style face="normal" font="default"> Tokunaga,K.</style></author><author><style face="normal" font="default"> Katoh,N.</style></author><author><style face="normal" font="default"> Sotozono,C.</style></author><author><style face="normal" font="default"> Kinoshita,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan</style></auth-address><titles><title><style face="normal" font="default">Mucocutaneous Inflammation in the Ikaros Family Zinc Finger 1 (IKZF1) - keratin 5 specifc transgenic mice</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="15" Month="9" Year="2017">2017/9/15</year></dates><abstract><style face="normal" font="default">BACKGROUND: Our genome-wide association study documented an association between cold medicine related Stevens-Johnson syndrome / toxic epidermal necrolysis (CM-SJS/TEN) and Ikaros Family Zinc Finger 1 (IKZF1). Few studies examined biological and pathological functions of IKZF1 in mucosal immunity. We hypothesized that IKZF1 contributes to the mucocutaneous inflammation. METHODS: Human skin and conjunctival tissues were obtained for immunohistological studies. Primary human conjunctival epithelial cells (PHCjECs) and adult human epidermal keratinocytes (HEKa) also used for gene expression analysis. We also generated K5-Ikzf1-EGFP transgenic mice (Ikzf1 Tg) by introducing the Ik1 isoform into cells expressing keratin 5, which is expressed in epithelial tissues such as the epidermis and conjunctiva and then examined them histologically and investigated gene expression of the epidermis. Moreover, Ikzf1 Tg were induced allergic contact dermatitis. RESULTS: We found that human epidermis and conjunctival epithelium expressed IKZF1, and in PHCjECs and HEKa, the expression of IKZF1 mRNA was up-regulated by stimulation with polyI:C, a TLR3 ligand. In Ikzf1 Tg, we observed dermatitis and mucosal inflammation including the ocular surface. In contact dermatitis model, inflammatory infiltrates in the skin of Ikzf1 Tg were significantly increased compared with wild type. Microarray analysis showed that Lcn2, Adh7, Epgn, Ifi202b, Cdo1, Gpr37, Duoxa1, Tnfrsf4, and Enpp5 genes were significantly up-regulated in the epidermis of Ikzf1 Tg compared with wild-type. CONCLUSION: Our findings support the hypothesis that Ikaros might participate in mucocutaneous inflammation. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170915IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/all.13308</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28914974">PM:28914974</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170915-UetaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170915-UetaM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170915, Ueta M</style></custom2><misc3><style face="normal" font="default">10.1111/all.13308</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42552</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yilmaz,I.</style></author><author><style face="normal" font="default"> Terl,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Chest Diseases, Division of Immunology and Allergy, Erciyes University School of Medicine, Kayseri, Turkey</style></auth-address><titles><title><style face="normal" font="default">Asthma management: A new phenotype-based approach using presence of eosinophilia and allergy</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="1589" start="1587">1587-1589</pages><volume><style face="normal" font="default">72</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170914IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - LetterCO - Turkey -CO - Czechia -</style></notes><work-type><style face="normal" font="default">10.1111/all.13188</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28905457">PM:28905457</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\2017-72-1587-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\2017-72-1587-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170914, Yilmaz I</style></custom2><misc3><style face="normal" font="default">10.1111/all.13188</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42553</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Agache,I.</style></author><author><style face="normal" font="default"> Rogozea,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Medicine, Department of Allergy and Clinical Immunology, Transylvania University of Brasov, Brasov, Romania.</style></auth-address><titles><title><style face="normal" font="default">Asthma Biomarkers: Do They Bring Precision Medicine Closer to the Clinic?</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="476" start="466">466-476</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">Measurement of biomarkers has been incorporated within clinical research of asthma to characterize the population and to associate the disease with environmental and therapeutic effects. Regrettably, at present, there are no specific biomarkers, none is validated or qualified, and endotype-driven choices overlap. Biomarkers have not yet reached clinical practice and are not included in current asthma guidelines. Last but not least, the choice of the outcome upholding the value of the biomarkers is extremely difficult, since it has to reflect the mechanistic intervention while being relevant to both the disease and the particular person. On the verge of a new age of asthma healthcare standard, we must embrace and adapt to the key drivers of change. Disease endotypes, biomarkers, and precision medicine represent an emerging model of patient care building on large-scale biologic databases, omics and diverse cellular assays, health information technology, and computational tools for analyzing sizable sets of data. A profound transformation of clinical and research pattern from population to individual risk and from investigator-imposed subjective disease clustering (hypothesis driven) to unbiased, data-driven models is facilitated by the endotype/biomarker-driven approach</style></abstract><notes><style face="normal" font="default">DA - 20170915IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Romania -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.6.466</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28913985">PM:28913985</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-466-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-466-76.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170915, Agache I</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.6.466</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42554</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,M.A.</style></author><author><style face="normal" font="default"> Shin,S.W.</style></author><author><style face="normal" font="default"> Park,J.S.</style></author><author><style face="normal" font="default"> Uh,S.T.</style></author><author><style face="normal" font="default"> Chang,H.S.</style></author><author><style face="normal" font="default"> Bae,D.J.</style></author><author><style face="normal" font="default"> Cho,Y.S.</style></author><author><style face="normal" font="default"> Park,H.S.</style></author><author><style face="normal" font="default"> Yoon,H.J.</style></author><author><style face="normal" font="default"> Choi,B.W.</style></author><author><style face="normal" font="default"> Kim,Y.H.</style></author><author><style face="normal" font="default"> Park,C.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonology, Allergy and Critical Care Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea.</style></auth-address><titles><title><style face="normal" font="default">Clinical Characteristics of Exacerbation-Prone Adult Asthmatics Identified by Cluster Analysis</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="490" start="483">483-490</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">PURPOSE: Asthma is a heterogeneous disease characterized by various types of airway inflammation and obstruction. Therefore, it is classified into several subphenotypes, such as early-onset atopic, obese non-eosinophilic, benign, and eosinophilic asthma, using cluster analysis. A number of asthmatics frequently experience exacerbation over a long-term follow-up period, but the exacerbation-prone subphenotype has rarely been evaluated by cluster analysis. This prompted us to identify clusters reflecting asthma exacerbation. METHODS: A uniform cluster analysis method was applied to 259 adult asthmatics who were regularly followed-up for over 1 year using 12 variables, selected on the basis of their contribution to asthma phenotypes. After clustering, clinical profiles and exacerbation rates during follow-up were compared among the clusters. RESULTS: Four subphenotypes were identified: cluster 1 was comprised of patients with early-onset atopic asthma with preserved lung function, cluster 2 late-onset non-atopic asthma with impaired lung function, cluster 3 early-onset atopic asthma with severely impaired lung function, and cluster 4 late-onset non-atopic asthma with well-preserved lung function. The patients in clusters 2 and 3 were identified as exacerbation-prone asthmatics, showing a higher risk of asthma exacerbation. CONCLUSIONS: Two different phenotypes of exacerbation-prone asthma were identified among Korean asthmatics using cluster analysis; both were characterized by impaired lung function, but the age at asthma onset and atopic status were different between the two</style></abstract><notes><style face="normal" font="default">DA - 20170915IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.6.483</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28913987">PM:28913987</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-483-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-483-90.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170915, Kim MA</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.6.483</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42555</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cho,Y.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Clinical Immunology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</style></auth-address><titles><title><style face="normal" font="default">Effective Strategies for Managing Asthma Exacerbations for Precision Medicine</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="465" start="463">463-465</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170915IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - EditorialCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.6.463</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28913984">PM:28913984</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-463-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-463-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170915, Cho YS</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.6.463</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42556</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,J.H.</style></author><author><style face="normal" font="default"> Ye,Y.M.</style></author><author><style face="normal" font="default"> Ban,G.Y.</style></author><author><style face="normal" font="default"> Shin,Y.S.</style></author><author><style face="normal" font="default"> Lee,H.Y.</style></author><author><style face="normal" font="default"> Nam,Y.H.</style></author><author><style face="normal" font="default"> Lee,S.K.</style></author><author><style face="normal" font="default"> Cho,Y.S.</style></author><author><style face="normal" font="default"> Jang,S.H.</style></author><author><style face="normal" font="default"> Jung,K.S.</style></author><author><style face="normal" font="default"> Park,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea</style></auth-address><titles><title><style face="normal" font="default">Effects of Immunoglobulin Replacement on Asthma Exacerbation in Adult Asthmatics with IgG Subclass Deficiency</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="533" start="526">526-533</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">PURPOSE: Recurrent respiratory tract infection is a common manifestation of primary immunodeficiency disease, and respiratory viruses or bacteria are important triggers of asthma exacerbations. Asthma often coexists with humoral immunodeficiency in adults, and some asthmatics with immunoglobulin (Ig) G subclass deficiency (IgGSCD) suffer from recurrent exacerbations. Although some studies suggest a benefit from Ig replacement, others have failed to support its use. This study aimed to assess the effect of Ig replacement on asthma exacerbation caused by respiratory infection as well as the asthma control status of adult asthmatics with IgGSCD. METHODS: This is a multi-center, open-label study of adult asthmatics with IgGSCD. All patients received monthly intravenous immunoglobulin (IVIG) for 6 months and were evaluated regarding asthma exacerbation related to infection, asthma control status, quality of life, and lung function before and after IVIG infusion. RESULTS: A total of 30 patients were enrolled, and 24 completed the study. Most of the patients had a moderate degree of asthma severity with partly (52%) or uncontrolled (41%) status at baseline. IVIG significantly reduced the proportion of patients with asthma exacerbations, lowered the number of respiratory infections, and improved asthma control status, compared to the baseline values (P&lt;0.001). The mean asthma-specific quality of life and asthma control test scores were improved significantly (P=0.009 and P=0.053, respectively); however, there were no significant changes in lung function. CONCLUSIONS: IVIG reduced the frequency of asthma exacerbations and improved asthma control status in adult asthmatics with IgGSCD, suggesting that IVIG could be an effective treatment option in this population</style></abstract><notes><style face="normal" font="default">DA - 20170915IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.6.526</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28913992">PM:28913992</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-526-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-526-33.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170915, Kim JH</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.6.526</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42557</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,S.W.</style></author><author><style face="normal" font="default"> Lee,S.</style></author><author><style face="normal" font="default"> Sheen,Y.H.</style></author><author><style face="normal" font="default"> Ha,E.K.</style></author><author><style face="normal" font="default"> Choi,S.H.</style></author><author><style face="normal" font="default"> Yang,M.S.</style></author><author><style face="normal" font="default"> Hwang,S.</style></author><author><style face="normal" font="default"> Kim,S.S.</style></author><author><style face="normal" font="default"> Choi,J.H.</style></author><author><style face="normal" font="default"> Han,M.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, CHA University School of Medicine, Seongnam, Korea</style></auth-address><titles><title><style face="normal" font="default">Seasonal Cycle and Relationship of Seasonal Rhino- and Influenza Virus Epidemics With Episodes of Asthma Exacerbation in Different Age Groups</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="525" start="517">517-525</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">PURPOSE: Seasonal variations in asthma exacerbation (AE) are associated with respiratory virus outbreaks and the return of children to school after vacation. This study aims to elucidate the period, phase, and amplitude of seasonal cycles of AE in 5 different age groups with regard to rhino- and influenza virus epidemics in Korea. METHODS: The number of daily emergency department (ED) visits for AE in all age groups of Korea and the nationwide weekly incidence of rhino- and influenza virus, were obtained for 2008-2012. Fourier regression was used to model rhythmicity, and the Cosinor method was used to determine the amplitude and phase of the cycles in each age group. The cross-correlation function (CCF) between AE and the rhino- and influenza virus epidemics was also calculated. RESULTS: There were 157,559 events of AE (0.62 events/1,000 individuals/year) during the study period. There were spring and fall peaks of AE in children and adults, but only 1 winter peak in the elderly. The amplitude of the AE peak in infants was higher in spring than in fall (9.16 vs 3.04, P&lt;0.010), and the fall peak was approximately 1 month later in infants than in school children (October 11 vs November 13, P&lt;0.010). The association between AE and rhinovirus was greatest in school children (rho=0.331), and the association between AE and influenza virus was greatest in those aged >/=60 years (rho=0.682). CONCLUSIONS: The rhythmicity, amplitude, and phase of the annual cycle of AE differed among different age groups. The patterns of AE were related to the annual rhino- and influenza virus epidemics</style></abstract><notes><style face="normal" font="default">DA - 20170915IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2017.9.6.517</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28913991">PM:28913991</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-517-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2017-9-517-25.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170915, Lee SW</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2017.9.6.517</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42558</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mancuso,J.B.</style></author><author><style face="normal" font="default"> Maruthi,R.</style></author><author><style face="normal" font="default"> Wang,S.Q.</style></author><author><style face="normal" font="default"> Lim,H.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Henry Ford Hospital, Detroit, MI, USA.</style></auth-address><titles><title><style face="normal" font="default">Sunscreens: An Update</style></title><secondary-title><style face="normal" font="default">Am J Clin Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Clin Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="5" Year="2017">2017/5/16</year></dates><abstract><style face="normal" font="default">Sunscreens have been widely used by the general public for their photoprotective properties, including prevention of photocarcinogenesis and photoaging and management of photodermatoses. It is important to emphasize to consumers the necessity of broad-spectrum protection, with coverage of both ultraviolet A (320-400 nm) and ultraviolet B (290-320 nm) radiation. This review discusses the benefits of sunscreen, different ultraviolet filters, sunscreen regulations and controversies, the importance of broad-spectrum protection, issues of photostability and formulation, and patient education and compliance</style></abstract><notes><style face="normal" font="default">DA - 20170516IS - 1179-1888 (Electronic)IS - 1175-0561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s40257-017-0290-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28510141">PM:28510141</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Clin Dermatol\20170516-MancusoJB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Clin Dermatol\20170516-MancusoJB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170516, Mancuso JB</style></custom2><misc3><style face="normal" font="default">10.1007/s40257-017-0290-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42559</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ojiaku,C.A.</style></author><author><style face="normal" font="default"> Cao,G.</style></author><author><style face="normal" font="default"> Zhu,W.</style></author><author><style face="normal" font="default"> Yoo,E.J.</style></author><author><style face="normal" font="default"> Shumyatcher,M.</style></author><author><style face="normal" font="default"> Himes,B.E.</style></author><author><style face="normal" font="default"> An,S.S.</style></author><author><style face="normal" font="default"> Panettieri,R.A.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Pennsylvania, Department of Systems Pharmacology and Translational Therapeutics, Philadelphia, Pennsylvania, United States</style></auth-address><titles><title><style face="normal" font="default">TGF-beta1 Evokes Human Airway Smooth Muscle Cell Shortening and Hyperresponsiveness via Smad3</style></title><secondary-title><style face="normal" font="default">Am J Respir Cell Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Cell Mol Biol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="10" Year="2017">2017/10/6</year></dates><abstract><style face="normal" font="default">Transforming growth factor beta 1 (TGF-beta1), a cytokine whose levels are elevated in the airways of patients with asthma, perpetuates airway inflammation and modulates airway structural cell remodeling. However, the role of TGF-beta1 in excessive airway narrowing in asthma, or airway hyperresponsiveness (AHR), remains unclear. In this study, we set out to investigate the direct effects of TGF-beta1 on human airway smooth muscle (HASM) cell shortening and hyperresponsiveness. The dynamics of AHR and single-cell excitation-contraction (E-C) coupling were measured in human precision-cut lung slices (hPCLS) and in isolated HASM cells using supravital microscopy and magnetic twisting cytometry (MTC), respectively. In hPCLS, overnight treatment with TGF-beta1 significantly augmented basal and carbachol-induced bronchoconstriction. In isolated HASM cells, TGF-beta1 increased basal and methacholine-induced cytoskeletal stiffness in a dose- and time-dependent manner. TGF-beta1-induced single-cell contraction was corroborated by concomitant increases in myosin light chain (MLC) and myosin phosphatase target subunit 1 (MYPT1) phosphorylation levels, which were attenuated by siRNA-mediated knockdown of Smad3 and pharmacological inhibition of Rho kinase. Strikingly, these physiologic effects of TGF-beta1 occurred through a RhoA-independent mechanism with little effect on HASM cell [Ca2+]i levels. Together, our data suggest that TGF-beta1 enhances HASM E-C coupling pathways to induce HASM cell shortening and hyperresponsiveness. These findings reveal a potential link between airway injury-repair responses and bronchial hyperreactivity in asthma, and define TGF-beta1 signaling as a potential target to reduce AHR in asthma</style></abstract><notes><style face="normal" font="default">DA - 20171006IS - 1535-4989 (Electronic)IS - 1044-1549 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1165/rcmb.2017-0247OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28984468">PM:28984468</url></web-urls><related-urls><url ppv-ref="no">presto - 1 anno</url></related-urls></urls><custom2><style face="normal" font="default">20171006, Ojiaku CA</style></custom2><misc3><style face="normal" font="default">10.1165/rcmb.2017-0247OC</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42560</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McDonald,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary, Allergy and Critical Care Medicine University of Alabama at Birmingham Birmingham, AL</style></auth-address><titles><title><style face="normal" font="default">Multiomics Approach to Asthma: Navigating the Network</style></title><secondary-title><style face="normal" font="default">Am J Respir Cell Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Cell Mol Biol</style></full-title></periodical><pages end="382" start="381">381-382</pages><volume><style face="normal" font="default">57</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 1535-4989 (Electronic)IS - 1044-1549 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1165/rcmb.2017-0220ED</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28960106">PM:28960106</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Respir Cell Mol Biol\2017-57-381-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Respir Cell Mol Biol\2017-57-381-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, McDonald ML</style></custom2><misc3><style face="normal" font="default">10.1165/rcmb.2017-0220ED</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42561</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shah,S.</style></author><author><style face="normal" font="default"> Patel,K.</style></author><author><style face="normal" font="default"> Gambhir,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, State University of New York, Upstate Medical University, Syracuse, NY</style></auth-address><titles><title><style face="normal" font="default">Oxymetazoline-Induced Asthma</style></title><secondary-title><style face="normal" font="default">Am J Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="24" Month="8" Year="2017">2017/8/24</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170913IS - 1536-3686 (Electronic)IS - 1075-2765 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/MJT.0000000000000628</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28901959">PM:28901959</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Ther\20170913-ShahS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Ther\20170913-ShahS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170913, Shah S</style></custom2><misc3><style face="normal" font="default">10.1097/MJT.0000000000000628</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42562</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,F.</style></author><author><style face="normal" font="default"> Hu,W.</style></author><author><style face="normal" font="default"> Liu,H.</style></author><author><style face="normal" font="default"> Zhang,M.</style></author><author><style face="normal" font="default"> Sang,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Jinling Hospital affiliated to Nanjing University School of Medicine - Jiangsu, China</style></auth-address><titles><title><style face="normal" font="default">Episodic angioedema associated with eosinophilia</style></title><secondary-title><style face="normal" font="default">An Bras Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">An Bras Dermatol</style></full-title></periodical><pages end="536" start="534">534-536</pages><volume><style face="normal" font="default">92</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">We report a 12-year-old girl who presented with recurrent angioedema on the face, trunk, and extremities, and concomitant marked weight gain for 5 years. During the episode, her white blood cell count increased to 47.7x109/L with 89.9% eosinophils, followed by elevated serum level of IL-5, IgE, IgM, and LDH. Histopathology showed perivascular eosinophilic infiltration and diffuse eosinophilic infiltration throughout the dermis. Possible causes of hypereosinophilia and eosinophilic infiltration of vital organs were ruled out. We also tested the FIP1L1/PDGFRa and ETV6/PDGFRb fusion gene to exclude the possibility of myeloid and lymphatic vessel neoplasms. The patient was treated with methylprednisolone and discharged with an oral prednisolone taper, which resulted in complete remission of the edema and normalization of peripheral blood eosinophil count, serum IL-5 level, IgE, IgM, and LDH</style></abstract><notes><style face="normal" font="default">DA - 20170927IS - 1806-4841 (Electronic)IS - 0365-0596 (Linking)LA - engPT - Case ReportsCO - China -</style></notes><work-type><style face="normal" font="default">10.1590/abd1806-4841.20174351</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28954105">PM:28954105</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\An Bras Dermatol\2017-92-534-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\An Bras Dermatol\2017-92-534-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170927, Liu F</style></custom2><misc3><style face="normal" font="default">10.1590/abd1806-4841.20174351</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42563</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oliveira,L.M.L.</style></author><author><style face="normal" font="default"> Souza,M.V.</style></author><author><style face="normal" font="default"> Guedes,A.C.M.</style></author><author><style face="normal" font="default"> Araujo,M.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Service, Hospital das Clinicas, Universidade Federal de Minas Gerais - Belo Horizonte(MG), Brazil</style></auth-address><titles><title><style face="normal" font="default">Case for diagnosis. Infective dermatitis associated with HTLV-1: differential diagnosis of atopic dermatitis</style></title><secondary-title><style face="normal" font="default">An Bras Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">An Bras Dermatol</style></full-title></periodical><pages end="574" start="573">573-574</pages><volume><style face="normal" font="default">92</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Infective dermatitis associated with HTLV-1 (IDH) is the main cutaneous marker of HTLV-1 infection. This disease occurs primarily in children and should be differentiated from other eczemas, especially from atopic dermatitis. The largest series of IDH are from Jamaica and Brazil. There are an estimated 15 to 20 million infected people in the world, and Brazil is one of the endemic regions. Studies suggest that IDH in children may be a marker for the development of T-cell leukemia/lymphoma (ATL) or myelopathy associated with HTLV-1/tropical spastic paraparesis (HAM / TSP) in adulthood</style></abstract><notes><style face="normal" font="default">DA - 20170927IS - 1806-4841 (Electronic)IS - 0365-0596 (Linking)LA - engPT - Case ReportsCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1590/abd1806-4841.20176684</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28954118">PM:28954118</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\An Bras Dermatol\2017-92-573-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\An Bras Dermatol\2017-92-573-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170927, Oliveira ML</style></custom2><misc3><style face="normal" font="default">10.1590/abd1806-4841.20176684</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42564</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Scolaro,R.J.</style></author><author><style face="normal" font="default"> Crilly,H.M.</style></author><author><style face="normal" font="default"> Maycock,E.J.</style></author><author><style face="normal" font="default"> McAleer,P.T.</style></author><author><style face="normal" font="default"> Nicholls,K.A.</style></author><author><style face="normal" font="default"> Rose,M.A.</style></author><author><style face="normal" font="default"> The,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Member of Australiasian Society of Clinical Immunology and Allergy; European Academy of Allergy and Clinical Immunology</style></auth-address><titles><title><style face="normal" font="default">Australian and New Zealand Anaesthetic Allergy Group Perioperative Anaphylaxis Investigation Guidelines</style></title><secondary-title><style face="normal" font="default">Anaesth Intensive Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Anaesth Intensive Care</style></full-title></periodical><pages end="555" start="543">543-555</pages><volume><style face="normal" font="default">45</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">These guidelines are a consensus document developed by a working party of the Australian and New Zealand Anaesthetic Allergy Group (ANZAAG) to provide an approach to the investigation of perioperative anaphylaxis. They focus primarily on the use of skin testing as it is the investigation with the greatest clinical utility for the identification of the likely causative agent and potentially safer alternatives. The practicalities and process of skin testing, its limitations, and the place of other tests are discussed. These guidelines also address the roles of graded challenge and in vitro testing. The implications of anaphylaxis associated with neuromuscular blocking agents, beta-lactam antibiotics, local anaesthetic agents and chlorhexidine are discussed. Evidence for the recommendations is derived from literature searches using the words skin test, allergy, anaphylaxis, anaesthesia, and each of the individual agents listed in these guidelines. The individual articles were then reviewed for suitability for inclusion in these guidelines. Where evidence was not strong, as is the situation for many perioperative agents, expert consensus from the ANZAAG working party was used. These guidelines are intended for use by specialists involved in the investigation of perioperative allergy. They have been approved following peer review by members of ANZAAG and are available on the ANZAAG website: http://www.anzaag.com/anaphylaxis-management/testing-guidelines.pdf</style></abstract><notes><style face="normal" font="default">DA - 20170915IS - 0310-057X (Print)IS - 0310-057X (Linking)LA - engPT - Journal ArticleCO - Australia -CO - New Zealand -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28911283">PM:28911283</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Anaesth Intensive Care\2017-45-543-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Anaesth Intensive Care\2017-45-543-55.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170915, Scolaro RJ</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42565</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bruzzoniti,M.C.</style></author><author><style face="normal" font="default"> Abollino,O.</style></author><author><style face="normal" font="default"> Pazzi,M.</style></author><author><style face="normal" font="default"> Rivoira,L.</style></author><author><style face="normal" font="default"> Giacomino,A.</style></author><author><style face="normal" font="default"> Vincenti,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Chemistry, University of Turin, Via P. Giuria 5, 10125, Turin, Italy.</style></auth-address><titles><title><style face="normal" font="default">Chromium, nickel, and cobalt in cosmetic matrices: an integrated bioanalytical characterization through total content, bioaccessibility, and Cr(III)/Cr(VI) speciation</style></title><secondary-title><style face="normal" font="default">Anal Bioanal Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Anal Bioanal Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="9" Year="2017">2017/9/25</year></dates><abstract><style face="normal" font="default">The presence of certain metals naturally contained inside raw materials (e.g., pigments) used to produce cosmetics for make-up may represent a serious concern for the final quality and safety of the product. The knowledge of the total concentration of metals is not sufficient to predict their reactivity and their toxicological profile. For these reasons, we set up a comprehensive approach to characterize the content of Co, Cr, and Ni in two raw materials for cosmetic production, a black iron oxide and a pearly pigment, and in a finished product, pearly powder eye shadow. Namely, besides the total metal concentrations, the speciation of chromium and the bioaccessibility of the three metals were assessed. Since no standard method is so far available for hexavalent chromium extraction from cosmetic samples, three approaches were compared (EPA 3060A method, IRSA 16 method, and a Na3PO4 extraction). Results show that Na3PO4 extraction is the most selective one. Cr(VI) was undetectable in black iron oxide and present at very low concentrations (about 0.3 mg/kg) in pearly pigment and in the pearly powder eye shadow samples. The extracted Cr(VI) concentrations are not related to the total Cr content in the samples. Bioaccessibility studies were performed by in vitro extractions with synthetic lacrimal fluids and sweat. Despite the wide range of metal concentrations in the samples, the amounts of bioaccessible elements were undetectable or very low (less than 0.4 mg/kg), thus suggesting that metals in the three samples are present in inert forms. Graphical abstract The possible leaching of metals from cosmetics to biological fluids. Spectroscopic and chromatographic techniques provide complementary information for an integrated bioanalytical approach to risk characterization</style></abstract><notes><style face="normal" font="default">DA - 20170926IS - 1618-2650 (Electronic)IS - 1618-2642 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1007/s00216-017-0644-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28948317">PM:28948317</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Anal Bioanal Chem\20170926-BruzzonitiMC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Anal Bioanal Chem\20170926-BruzzonitiMC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170926, Bruzzoniti MC</style></custom2><misc3><style face="normal" font="default">10.1007/s00216-017-0644-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42566</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dang,A.T.</style></author><author><style face="normal" font="default"> Schwartz,G.</style></author><author><style face="normal" font="default"> Jones,L.</style></author><author><style face="normal" font="default"> Absalon,M.J.</style></author><author><style face="normal" font="default"> McMasters,R.L.</style></author><author><style face="normal" font="default"> Assa'ad,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. Electronic address: andrew.dang@cchmc.org</style></auth-address><titles><title><style face="normal" font="default">An unusual cause of fever in a patient with common variable immunodeficiency</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="213" start="210">210-213</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170911IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890017">PM:28890017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-210-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-210-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170911, Dang AT</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42567</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Suzuki,Y.</style></author><author><style face="normal" font="default"> Oyama,Y.</style></author><author><style face="normal" font="default"> Hozumi,H.</style></author><author><style face="normal" font="default"> Imokawa,S.</style></author><author><style face="normal" font="default"> Toyoshima,M.</style></author><author><style face="normal" font="default"> Yokomura,K.</style></author><author><style face="normal" font="default"> Nakamura,H.</style></author><author><style face="normal" font="default"> Kuroishi,S.</style></author><author><style face="normal" font="default"> Karayama,M.</style></author><author><style face="normal" font="default"> Furuhashi,K.</style></author><author><style face="normal" font="default"> Enomoto,N.</style></author><author><style face="normal" font="default"> Fujisawa,T.</style></author><author><style face="normal" font="default"> Nakamura,Y.</style></author><author><style face="normal" font="default"> Inui,N.</style></author><author><style face="normal" font="default"> Koshimizu,N.</style></author><author><style face="normal" font="default"> Yamada,T.</style></author><author><style face="normal" font="default"> Mori,K.</style></author><author><style face="normal" font="default"> Masuda,M.</style></author><author><style face="normal" font="default"> Shirai,T.</style></author><author><style face="normal" font="default"> Hayakawa,H.</style></author><author><style face="normal" font="default"> Sumikawa,M.</style></author><author><style face="normal" font="default"> Johkoh,T.</style></author><author><style face="normal" font="default"> Suda,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan. Electronic address: yuzosuzu@hama-med.ac.jp</style></auth-address><titles><title><style face="normal" font="default">Persistent impairment on spirometry in chronic eosinophilic pneumonia: a longitudinal observation study (Shizuoka-CEP study)</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic eosinophilic pneumonia (CEP) is characterized by the accumulation of eosinophils in the lung with unknown etiology. Although systemic corticosteroid administration leads to dramatic improvement, nearly half the patients with CEP experience relapse and some develop persistent impairment of pulmonary function. However, predictive factors for this persistent impairment have not been determined. OBJECTIVE: To investigate the occurrence of persistent impairment of pulmonary function in CEP and determine its predictive factors. METHODS: This observational study consisted of 133 consecutive patients with CEP who were followed for longer than 1 year. Spirometry was performed at the time of diagnosis and at follow-up. RESULTS: During the observational period (6.1 +/- 4.1 years), relapse occurred in 75 patients (56.4%). Remarkably, 42 patients (31.6%) had a persistent pulmonary function defect (27 obstructive, 10 restrictive, and 4 obstructive and restrictive cases) at the last evaluation. Logistic analyses showed that the relapse was associated with neither persistent obstructive nor restrictive defects. Persistent obstructive defect was significantly associated with the comorbidity of asthma and obstructive defect at the initial CEP diagnosis, whereas persistent restrictive defect was significantly related to reticulation at high-resolution computer tomography and restrictive defect at diagnosis. CONCLUSION: Persistent impairment of pulmonary function is common in CEP. Concurrent asthma and obstructive defects at diagnosis were predictors for persistent obstructive impairments, whereas reticulation at high-resolution computer tomography and restrictive defect at diagnosis predicted persistent restrictive impairment. Attention should be paid to these persistent impairments in the management of CEP</style></abstract><notes><style face="normal" font="default">DA - 20170925IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.08.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28942952">PM:28942952</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170925-SuzukiY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20170925-SuzukiY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170925, Suzuki Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.08.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42568</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Solensky,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Corvallis Clinic, Oregon State University, Oregon Health Science University College of Pharmacy, Corvallis, Oregon. Electronic address: roland.solensky@corvallisclinic.com</style></auth-address><titles><title><style face="normal" font="default">Penicillin skin testing: The devil is in the details</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="200" start="199">199-200</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170911IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890015">PM:28890015</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-199-200.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-199-200.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170911, Solensky R</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42569</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Endo,Y.</style></author><author><style face="normal" font="default"> Shirai,T.</style></author><author><style face="normal" font="default"> Akamatsu,T.</style></author><author><style face="normal" font="default"> Asada,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan. Electronic address: toshihiro-shirai@i.shizuoka-pho.jp</style></auth-address><titles><title><style face="normal" font="default">Comparison of fractional exhaled nitric oxide levels measured using the NIOX VERO and NOA 280i</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="385" start="383">383-385</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958377">PM:28958377</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-383-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-383-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Endo Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.026</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42570</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Greenberger,P.A.</style></author><author><style face="normal" font="default"> Wallace,D.V.</style></author><author><style face="normal" font="default"> Lieberman,P.L.</style></author><author><style face="normal" font="default"> Gregory,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Division of Allergy-Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois   Electronic address: phillieberman@hotmail.com</style></auth-address><titles><title><style face="normal" font="default">Contemporary issues in anaphylaxis and the evolution of epinephrine autoinjectors: What will the future bring?</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="338" start="333">333-338</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Food allergy and anaphylaxis appear to be increasing in the United States, especially in young children, and preparedness is paramount to successful emergency management in the community. Although the treatment of choice for anaphylaxis is epinephrine delivered by autoinjection, some devices are challenged by less user-friendly designs or pose the risk of injury, especially in young patients. Human factors engineering has played a larger role in the development of more recent epinephrine autoinjector technologies and will continue to play a role in the evolution and future design of epinephrine autoinjectors. OBJECTIVE: To discuss contemporary issues related to the identification and management of anaphylaxis, current and future epinephrine autoinjector design, and unmet needs for the treatment of special populations, namely, young children weighing less than 15 kg. METHODS: The literature was reviewed and select articles retrieved to support expert clinical opinions on the need for improved recognition of anaphylaxis, epinephrine autoinjector design, and unmet needs in special populations. RESULTS: Anaphylaxis may be underrecognized and poorly defined in infant- and toddler-aged children, current devices may not be adequate to safely treat these patients (ie, inappropriate needle length), and health care professionals may not be aware of these issues. CONCLUSION: As epinephrine autoinjector technology continues to evolve, device characteristics that promote safe, user-friendly experiences and give clinicians and their patients confidence to successfully treat anaphylaxis during an emergency, without injury, will be favored</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958374">PM:28958374</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-333-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-333-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Greenberger PA</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.030</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42571</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sokoya,M.</style></author><author><style face="normal" font="default"> Ramakrishnan,V.R.</style></author><author><style face="normal" font="default"> Frank,D.N.</style></author><author><style face="normal" font="default"> Rahkola,J.</style></author><author><style face="normal" font="default"> Getz,A.</style></author><author><style face="normal" font="default"> Kingdom,T.T.</style></author><author><style face="normal" font="default"> Kofonow,J.M.</style></author><author><style face="normal" font="default"> Nguyen,Q.</style></author><author><style face="normal" font="default"> Janoff,E.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine, Denver, Colorado  Electronic address: Edward.Janoff@ucdenver.edu</style></auth-address><titles><title><style face="normal" font="default">Expression of immunoglobulin D is increased in chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="323" start="317">317-323</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Immunoglobulin (Ig) D is largely localized to the upper airway and reacts with colonizing respiratory pathogens. OBJECTIVE: To determine whether chronic rhinosinusitis (CRS) is associated with increased IgD expression. METHODS: We performed immunofluorescent staining for cytoplasmic IgD, IgA, IgM, and surface plasma cell marker CD138 (syndecan-1) in sinus tissue of patients with CRS with and without nasal polyps (CRSwNP and CRSsNP, respectively) and control subjects without CRS (n = 6 each). Sinonasal mucus antibody levels of patients with CRSwNP or CRSsNP and control subjects were measured by enzyme-linked immunosorbent assay (n = 13, 11, and 9 subjects, respectively). Cells per square millimeter and antibody levels were compared by analysis of variance. Histopathology was performed with sinus tissue from subjects in the 3 groups (n = 6, 8, and 13 subjects respectively). RESULTS: Cells expressing cytoplasmic IgD exceeded those with cytoplasmic IgA and IgM and represented most CD138+ plasma cells in the lamina propria. The frequencies of IgD+ plasma cells were significantly higher in patients with CRSsNP and CRSwNP compared with control subjects (P &lt; .01). Only patients with CRSwNP showed increased frequencies of IgM and IgA plasma cells (P &lt; .01). In contrast to high plasma cell frequencies in tissues, the levels of secreted IgD were lower than those of IgA, IgM, and IgG but were highest in the CRSwNP group compared with the other groups (P &lt; .05). CONCLUSION: IgD plasma cells are prominent in sinus tissues and are increased in CRS. That IgD protein also shows the lowest concentration of antibodies in secretions suggests that its activity might be targeted to the tissue rather than secretions</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958373">PM:28958373</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-317-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-317-23.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Sokoya M</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42572</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Perez-Lopez,C.J.</style></author><author><style face="normal" font="default"> Arroyo,E.</style></author><author><style face="normal" font="default"> Rodriguez,M.</style></author><author><style face="normal" font="default"> Ortiz,D.</style></author><author><style face="normal" font="default"> Nazario,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, VA Caribbean Health Care System, San Juan, Puerto Rico. Electronic address: cjperez737@gmail.com</style></auth-address><titles><title><style face="normal" font="default">Disseminated Mycobacterium avium intracellulare leading to protein-losing enteropathy in an elderly man with idiopathic CD4 lymphocytopenia</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="391" start="390">390-391</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958380">PM:28958380</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-390-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-390-1.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Perez-Lopez CJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.035</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42573</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wilson,R.</style></author><author><style face="normal" font="default"> Greenhawt,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Central Michigan University College of Medicine, Mt Pleasant, Michigan</style></auth-address><titles><title><style face="normal" font="default">Influence of rhinitis control and inspiratory loop flattening on perceived asthma control</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="389" start="387">387-389</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.08.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958379">PM:28958379</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-387-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-387-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Wilson R</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.08.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42574</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zagar,B.</style></author><author><style face="normal" font="default"> Jiroutek,M.R.</style></author><author><style face="normal" font="default"> Hancock,T.</style></author><author><style face="normal" font="default"> Kelly,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Campbell University College of Pharmacy &amp; Health Sciences, Buies Creek, North Carolina; Cape Fear Valley Health System, Fayetteville, North Carolina. Electronic address: zagar@campbell.edu</style></auth-address><titles><title><style face="normal" font="default">An analysis of insurance and other factors associated with asthma-related emergency department visits, 2009-2014</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="386" start="385">385-386</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958378">PM:28958378</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-385-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-385-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Zagar B</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42575</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ayubi,E.</style></author><author><style face="normal" font="default"> Safiri,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Epidemiology, School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="default">Predictors of granulomatous lymphocytic interstitial lung disease in common variable immunodeficiency: Methodological issues</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="296">296-</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170911IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - LetterCO - Iran -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.06.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890025">PM:28890025</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-296-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-296-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170911, Ayubi E</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.06.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42576</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brunet,B.A.</style></author><author><style face="normal" font="default"> Rodriguez,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Divisions of Clinical Immunology and Allergy, Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi. Electronic address: bbrunet2000@yahoo.com</style></auth-address><titles><title><style face="normal" font="default">Unusual presentation of combined immunodeficiency in a child with homozygous DOCK8 mutation</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="295" start="294">294-295</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170911IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890024">PM:28890024</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-294-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-294-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170911, Brunet BA</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42577</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sullivan,P.W.</style></author><author><style face="normal" font="default"> Ghushchyan,V.</style></author><author><style face="normal" font="default"> Navaratnam,P.</style></author><author><style face="normal" font="default"> Friedman,H.S.</style></author><author><style face="normal" font="default"> Kavati,A.</style></author><author><style face="normal" font="default"> Ortiz,B.</style></author><author><style face="normal" font="default"> Lanier,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacy Practice, Regis University School of Pharmacy, Denver, Colorado.</style></auth-address><titles><title><style face="normal" font="default">The national cost of asthma among school-aged children in the United States</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="252" start="246">246-252</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Recent research has quantified the national health care resource use (HCRU) and health care expenditure (HCE) burden associated with adult asthma; however, estimates specific to school-aged children are more than 2 decades old. OBJECTIVE: To estimate the national HCRU and HCEs attributable to asthma among school-aged children in the United States. METHODS: This was a cross-sectional retrospective analysis of school-aged children (aged 6-17 years) in the nationally representative 2007-2013 Medical Expenditure Panel Survey. All-cause HCRU and HCEs of school-aged children with asthma were compared with school-aged children without asthma, controlling for sociodemographics and comorbidities. HCRU encounters included emergency department (ED) and outpatient visits, hospitalizations, and prescriptions. Expenditures included total, medical, ED, inpatient, outpatient, and pharmacy. Negative binomial regression analyses were used for HCRU and Heckman selection with logarithmic transformation, and smearing retransformation was used for HCEs. RESULTS: There were 44,320 school-aged children of whom 5,890 had asthma. Children with asthma incurred a higher rate of all-cause annual ED visits (incidence rate ratio [IRR], 1.5; P &lt; .001), hospitalizations (IRR, 1.4; P &lt; .05), outpatient visits (IRR, 1.4; P &lt; .001), and prescription drugs (IRR, 3.3; P &lt; .001) compared with school-aged children without asthma. They incurred US$847 (2015 dollars) more annually in all-cause expenditures (P &lt; .001). Private insurance and Medicaid paid the largest share of expenditures. Pharmacy and outpatient costs represented the largest proportion of total expenditures. On the basis of the nationally representative Medical Expenditure Panel Survey sample weights from 2013, the total annual HCEs attributable to asthma for school-aged children in the United States was US$5.92 billion (2015 dollars). CONCLUSION: Childhood asthma continues to represent a prevalent and significant clinical and economic burden in the United States. More aggressive treatment and asthma management programs are needed to address this national financial and resource burden</style></abstract><notes><style face="normal" font="default">DA - 20170911IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890020">PM:28890020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-246-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-246-52.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170911, Sullivan PW</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42578</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hartono,S.</style></author><author><style face="normal" font="default"> Motosue,M.S.</style></author><author><style face="normal" font="default"> Khan,S.</style></author><author><style face="normal" font="default"> Rodriguez,V.</style></author><author><style face="normal" font="default"> Iyer,V.N.</style></author><author><style face="normal" font="default"> Divekar,R.</style></author><author><style face="normal" font="default"> Joshi,A.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Mayo Medical School, Rochester, Minnesota</style></auth-address><titles><title><style face="normal" font="default">Author's response (Predictors of granulomatous lymphocytic interstitial lung disease in common variable immunodeficiency: Methodological issues)</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="297" start="296">296-297</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170911IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890026">PM:28890026</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-296-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-296-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170911, Hartono S</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42579</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ballow,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy &amp; Immunology, Department of Pediatrics, University of South Florida Morsani College of Medicine, and Johns Hopkins All Children's Hospital, St Petersburg, Florida. Electronic address: mballow@health.usf.edu</style></auth-address><titles><title><style face="normal" font="default">Practical aspects of immunoglobulin replacement</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="303" start="299">299-303</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958372">PM:28958372</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-299-303.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-299-303.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Ballow M</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42580</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Soria,A.</style></author><author><style face="normal" font="default"> Autegarden,E.</style></author><author><style face="normal" font="default"> Amsler,E.</style></author><author><style face="normal" font="default"> Gaouar,H.</style></author><author><style face="normal" font="default"> Vial,A.</style></author><author><style face="normal" font="default"> Frances,C.</style></author><author><style face="normal" font="default"> Autegarden,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Dermatology and Allergology , Tenon Hospital, APHP , Paris , France</style></auth-address><titles><title><style face="normal" font="default">A clinical decision-making algorithm for penicillin allergy</style></title><secondary-title><style face="normal" font="default">Ann Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Med</style></abbr-1></periodical><pages end="717" start="710">710-717</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword></keywords><dates><year Day="26" Month="8" Year="2017">2017/8/26</year></dates><abstract><style face="normal" font="default">BACKGROUND: About 10% of subjects report suspected penicillin allergy, but 85-90% of these patients are not truly allergic and could safely receive beta-lactam antibiotics Objective: To design and validate a clinical decision-making algorithm, based on anamnesis (chronology, severity, and duration of the suspected allergic reactions) and reaching a 100% sensitivity and negative predictive value, to assess allergy risk related to a penicillin prescription in general practise. STUDY DESIGN AND METHODS: All patients were included prospectively and explorated based on ENDA/EAACI recommendations. Results of penicillin allergy work-up (gold standard) were compared with results of the algorithm. RESULTS: Allergological work-up diagnosed penicillin hypersensitivity in 41/259 patients (15.8%) [95% CI: 11.5-20.3]. Three of these patients were diagnosed as having immediate-type hypersensitivity to penicillin, but had been misdiagnosed as low risk patients using the clinical algorithm. Thus, the sensitivity and negative predictive value of the algorithm were 92.7% [95% CI: 80.1-98.5] and 96.3% [95% CI: 89.6-99.2], respectively, and the probability that a patient with true penicillin allergy had been misclassified was 3.7% [95% CI: 0.8-10.4]. CONCLUSIONS: Although the risk of misclassification is low, we cannot recommend the use of this algorithm in general practice. However, the algorithm can be useful in emergency situations in hospital settings. Key messages True penicillin allergy is considerably lower than alleged penicillin allergy (15.8%; 41 of the 259 patients with suspected penicillin allergy). A clinical algorithm based on the patient's clinical history of the supposed allergic event to penicillin misclassified 3/41 (3.7%) truly allergic patients</style></abstract><notes><style face="normal" font="default">DA - 20170828IS - 1365-2060 (Electronic)IS - 0785-3890 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1080/07853890.2017.1370125</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28844171">PM:28844171</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Med\2017-49-710-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Med\2017-49-710-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170828, Soria A</style></custom2><misc3><style face="normal" font="default">10.1080/07853890.2017.1370125</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42581</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jansen,J.W.</style></author><author><style face="normal" font="default"> Moenster,R.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 SCL Saint Vincent Healthcare, Billings, MT, USA</style></auth-address><titles><title><style face="normal" font="default">Rate and Incidence of Adverse Reactions Associated With Ceftaroline Exposure: Importance of Cutaneous Manifestations</style></title><secondary-title><style face="normal" font="default">Ann Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Pharmacother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="10" Year="2017">2017/10/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Ceftaroline is a broad-spectrum, methicillin-resistant Staphylococcus aureus (MRSA)-active beta-lactam approved for acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired pneumonia. Because of its favorable spectrum and pharmacokinetics, ceftaroline is frequently utilized for infections such as osteomyelitis and endocarditis. Ceftaroline has been associated with neutropenia, but evaluation of other adverse events remains limited. OBJECTIVE: To describe the rates and types of ceftaroline-associated adverse events and determine if patients' baseline allergies affect the rates of an adverse event. METHODS: A single-center, retrospective, observational analysis was conducted of all patients who received ceftaroline between November 4, 2011, and March 28, 2017, at the VA Saint Louis Health Care System. The Naranjo algorithm was utilized as a standardized method to evaluate likelihood that the adverse events were caused by ceftaroline therapy. Ceftaroline dose, duration, indication, and baseline allergy information were collected for all patients. RESULTS: There were 75 patients who received 78 courses of ceftaroline identified for inclusion. The most common indications were osteomyelitis (51.3%) and ABSSSI (16.7%). Overall, 13/75 (17.3%) patients developed an adverse event, and 10/75 (13.3%) required discontinuation of ceftaroline. Rash was the most common adverse reaction and occurred in 7/75 (9.3%) patients, followed by neutropenia in 3/75 (4.0%) patients. There were no differences in baseline allergy characteristics between patients who experienced an adverse reaction to ceftaroline and those who did not. CONCLUSIONS: When compared with clinical trials, ceftaroline use appears to be associated with an increased rate of overall adverse events, which is driven by cutaneous reactions</style></abstract><notes><style face="normal" font="default">DA - 20171005IS - 1542-6270 (Electronic)IS - 1060-0280 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/1060028017735629</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28980484">PM:28980484</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Pharmacother\20171005-JansenJW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Pharmacother\20171005-JansenJW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171005, Jansen JW</style></custom2><misc3><style face="normal" font="default">10.1177/1060028017735629</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42582</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tugrul,A.B.</style></author><author><style face="normal" font="default"> Mustu,K.O.</style></author><author><style face="normal" font="default"> Yildirm,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Aksaray University, Aksaray Training and Research Hospital, Department of Dermatology and Venereology. Aksaray, Turkey.</style></auth-address><titles><title><style face="normal" font="default">Serum prolactin levels in atopic dermatitis and the relationship with disease severity</style></title><secondary-title><style face="normal" font="default">Arch Argent Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Arch Argent Pediatr</style></abbr-1></periodical><pages end="496" start="493">493-496</pages><volume><style face="normal" font="default">115</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="10" Year="2017">2017/10/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Prolactin performs as a neuroendocrine modulator of skin epithelial cell proliferation and the skin immune system. OBJETIVE: The aim was to assess the serum prolactin levels in patients with atopic dermatitis and the relationship with disease severity. METHODS: The study was performed on 46 patients with atopic dermatitis and 100 healthy controls aged between 0.5 years and 19.5 years. The diagnosis of atopic dermatitis was based on clinical findings and the severity of the disease was documented. Venous blood sampling was performed in order to measure prolactin levels. RESULTS: Prolactin levels in atopic dermatitis were not different from controls and there was no relationship between the severity of atopic dermatitis and serum prolactin levels. Prolactin may not have a role in the pathogenesis of atopic dermatitis. Further studies with larger sample sizes and measurement of prolactin levels in the skin may help to understand the role of prolactin in the pathogenesis of atopic dermatitis</style></abstract><notes><style face="normal" font="default">DA - 20170912IS - 1668-3501 (Electronic)IS - 0325-0075 (Linking)LA - engLA - spaPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.5546/aap.2017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28895698">PM:28895698</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Arch Argent Pediatr\2017-115-493-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Arch Argent Pediatr\2017-115-493-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170912, Tugrul AB</style></custom2><misc3><style face="normal" font="default">10.5546/aap.2017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42583</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wruhs,M.</style></author><author><style face="normal" font="default"> Gleiss,A.</style></author><author><style face="normal" font="default"> Steiner,A.</style></author><author><style face="normal" font="default"> Sator,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Municipal Hospital Hietzing, Wolkersbergenstrasse 1, 1130, Vienna, Austria.</style></auth-address><titles><title><style face="normal" font="default">Quantity and quality of sweating in atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Arch Dermatol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arch Dermatol Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="default">Sweat may be an important factor in triggering an exacerbation of atopic dermatitis. It was the aim of this study to evaluate a possible correlation between atopic patients and hyperhidrosis-measured by a questionnaire-and to find out whether there are qualitative differences in sweat response-measured by sudomotor activity (sympathetic skin response test, SSR). Included were 100 study participants, of whom 50 were patients with atopic dermatitis and 50 were serving as control group. The frequency of hyperhidrosis is higher in atopic patients than in the control group (30 vs. 16%), but has no statistical significance. In addition, patients with hyperhidrosis and atopic dermatitis have a significantly higher exacerbation rate of atopic dermatitis in summertime. The group of atopic patients shows a statistically significant prolonged SSR latency period, which indicates an insufficient sympathetic innervation. In our tests, type IV allergic patients showed clear differences in terms of SSR latency and amplitude. Atopic patients have a higher incidence of hyperhidrosis. The study clearly shows that there is a dysfunction of sudomotor activity in the sympathetic nervous system of atopic patients. Our findings suggest that a deficient innervation of sweat glands in atopic patients may lead to an increase in the development of type IV allergies</style></abstract><notes><style face="normal" font="default">DA - 20170922IS - 1432-069X (Electronic)IS - 0340-3696 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="default">10.1007/s00403-017-1770-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28936748">PM:28936748</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Arch Dermatol Res\20170922-WruhsM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Arch Dermatol Res\20170922-WruhsM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170922, Wruhs M</style></custom2><misc3><style face="normal" font="default">10.1007/s00403-017-1770-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42584</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liendo,V.L.</style></author><author><style face="normal" font="default"> Vola,M.E.</style></author><author><style face="normal" font="default"> Barreiro,T.P.</style></author><author><style face="normal" font="default"> Wakamatsu,T.H.</style></author><author><style face="normal" font="default"> Gomes,J.A.P.</style></author><author><style face="normal" font="default"> Santos,M.S.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, Universidade Federal de Sao Paulo Sao Paulo, SP, Brazil</style></auth-address><titles><title><style face="normal" font="default">Topical tacrolimus for the treatment of severe allergic keratoconjunctivitis in children</style></title><secondary-title><style face="normal" font="default">Arq Bras Oftalmol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arq Bras Oftalmol</style></full-title></periodical><pages end="214" start="211">211-214</pages><volume><style face="normal" font="default">80</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Purpose:: Administration of eye drops containing antihistamines or sodium cromoglycate and its derivatives for the treatment of allergic keratoconjunctivitis is often insufficient and usually requires the addition of corticosteroids. However, the risk of complications, such as glaucoma and cataract, limits the use of corticosteroids to short courses, resulting in inadequate long-term treatment response. Immunosuppressive drugs have been considered as a valid alternative to steroids for atopic keratoconjunctivitis and vernal keratoconjunctivitis. This study aimed to evaluate the use of topical tacrolimus (TCL) in improving the clinical signs of severe allergic keratoconjuctivitis in children. Methods:: Patients with severe allergic keratoconjunctivitis associated with corneal epitheliopathy, gelatinous limbal infiltrates, and/or papillary reaction, along with a history of recurrences and resistance to conventional topical anti-allergy agents, were included in this open clinical trial. Patients were treated with 0.03% TCL ointment for ocular use. A severity score ranging from 0 to 9, with 9 being the highest and 0 being the lowest, was assigned based on signs observed on biomicroscopy prior to and following TCL treatment. Results:: Analyses included 66 eyes of 33 patients. After a mean follow-up period of 13 months (range, 12-29 months), TCL treatment significantly decreased the mean symptom score severity for the right (from 5.56 +/- 1.18 to 2.76 +/- 1.5; p&lt;0.001) and left (from 5.94 +/- 1.16 to 2.86 +/- 1.64; p&lt;0.001). Conclusion:: Topical TCL was effective and significantly improved the clinical signs of allergic keratoconjuctivitis in children. Thus, it is a potential new option for severe and challenging cases of ocular allergy</style></abstract><notes><style face="normal" font="default">DA - 20170927IS - 1678-2925 (Electronic)IS - 0004-2749 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/0004-2749.20170052</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28954018">PM:28954018</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Arq Bras Oftalmol\2017-80-211-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Arq Bras Oftalmol\2017-80-211-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170927, Liendo VL</style></custom2><misc3><style face="normal" font="default">10.5935/0004-2749.20170052</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42585</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kutlug,S.</style></author><author><style face="normal" font="default"> Sogut,A.</style></author><author><style face="normal" font="default"> Ceiiksoy,M.H.</style></author><author><style face="normal" font="default"> Paksu,M.S.</style></author><author><style face="normal" font="default"> Guner,S.N.</style></author><author><style face="normal" font="default"> Murat,N.</style></author><author><style face="normal" font="default"> Ozturk,F.</style></author><author><style face="normal" font="default"> Sancak,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Mean Platelet Volume in Children with Chronic Spontaneous Urticaria</style></title><secondary-title><style face="normal" font="default">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asthma Allergy Immunol</style></full-title></periodical><pages end="92" start="87">87-92</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Objective: It has been suggested that mean platelet volume can beused as a marker of inflammation in some inflammatory diseases.This marker has not been investigated adequately in children withallergic disease. The aim of this study was to evaluate mean plateletvolume in children with chronic spontaneous urticaria.Materials and Methods: Fifty-four children with chronicspontaneous urticaria (26 boys and 28 girls, mean age 13.70±3.66years) were included in this retrospective study. The demographiccharacteristics, complete blood count, serum total IgE, erythrocytesedimentation rate, and skin prick tests results of the patientswere recorded. Sixty healthy children were included as the controlgroup. Only complete blood count results of the control group wererecorded. Platelet count, mean platelet volume, platelet distributionwidth, leukocyte count, and hemoglobin values were comparedbetween the two groups. Correlations between mean platelet volumewith age, disease duration, atopy, serum total IgE, and erythrocytesedimentation rate were analyzed in the patient group.Results: There was no statistically significant difference in terms ofage and sex between the two groups (p=0.09, p=0.60, respectively).Mean platelet volume and platelet count in the patient group weresignificantly higher than those in the control group (p=0.005, p=0.01,respectively). Platelet distribution widths in the patient group weresignificantly lower than those in the control group (p&lt;0.001). Therewas no significant difference in leukocyte count and hemoglobinvalues between the two groups (p>0.05). Mean platelet volumes inthe patient group were not correlated with age, disease duration,atopy, serum total IgE, and erythrocyte sedimentation rate. Conclusion: Mean platelet volumes and platelet counts are increasedin children with chronic spontaneous urticaria. However, the meanplatelet volume does not appear to be associated with the erythrocytesedimentation rate and atopy.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.aai.org.tr/index.php/aai/article/view/73/270</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Allergy Immunol\2017-15-87-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Allergy Immunol\2017-15-87-92.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Kutlug S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42586</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mansuroglu,U.</style></author><author><style face="normal" font="default"> Altintas,D.U.</style></author><author><style face="normal" font="default"> Dogruel,D.</style></author></authors></contributors><titles><title><style face="normal" font="default">The Relationship Between Vitamin D Deficiency and Wheezing in Young Children; A Randomized Study</style></title><secondary-title><style face="normal" font="default">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asthma Allergy Immunol</style></full-title></periodical><pages end="102" start="93">93-102</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Objective: Vitamin D (VD) plays a critical role in immunologicalprocesses and studies have been conducted to investigate its role inthe development of several allergic and infectious diseases. The aimof this study was to determine the factors that affect the 25(OH)Dlevel in children, and also to assess the relationship between VD andwheezing, allergy, and infection.Materials and Methods: Sixty-four children between 18-24 monthsof age were included in this study. At the beginning and at the endof the study, a physical examination was performed, blood sampleswere taken, and parents completed the questionnaire. Half of thechildren had been recommended at the first visit to take daily 400units of VD. Follow-up visits were scheduled at the 3rd, 6th and 12thmonths of the study.Results: The mean age of the infants participating in the study was20.3±1.5 months. 46.9% (n=30) of the infants were female and 53.1%(n=34) were male. While the 25(OH)D level was 29.8±10.8 ng/mlat the beginning of the study, it was 26.5±10.3 ng/ml (p=0.017) atthe end of the study. The percentage of patients with sufficient 25(OH) D levels was 48.4% (n = 31) at the beginning of the studyand 29.7% (n = 19) at the end of the study (p=0.010). A statisticallysignificant relationship was determined between VD intake andserum 25(OH)D level. At the beginning and at the end of thestudy, the 25(OH)D level was statistically inversely correlated withwheezing. Low 25(OH)D levels were also found to be a risk factor forthe development of wheezing. No statistically significant relationshipwas determined between the serum 25(OH)D level and allergic andrespiratory outcomes.Conclusion: When the factors which effect 25(OH)D level wereexamined, it was only associated with VD supplementation.VD deficiency showed a significant relationship with wheezingdevelopment, regardless of supplementation of VD.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.aai.org.tr/index.php/aai/article/view/350/291</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Allergy Immunol\2017-15-93-102.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Allergy Immunol\2017-15-93-102.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Mansuroglu U</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42587</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Elizalde-Beiras,I.</style></author><author><style face="normal" font="default"> Guillen-Grima,F.</style></author><author><style face="normal" font="default"> Aguinaga-Ontoso,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Atencion Primaria, Servicio Navarro de Salud, Pamplona, Navarra, Espana.</style></auth-address><titles><title><style face="normal" font="default">[Factors associated with asthma in children and adolescents in rural areas of Navarre (Spain)]</style></title><secondary-title><style face="normal" font="default">Aten Primaria</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Aten Primaria</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="9" Year="2017">2017/9/18</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To determine the factors associated with asthma and asthma-related symptoms in children and adolescents in rural areas of Navarre (Spain). PARTICIPANTS AND METHODS: A cross-sectional study using the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire, as well as additional variables, was conducted on 797 children and adolescents. These provided prevalence data on asthma symptoms and associated factors without further diagnostic testing. LOCATION: Primary Care setting, through the basic health areas and in the corresponding education centres. MEASUREMENTS AND RESULTS: The prevalence of referred asthma is 11.7% in children, and 13.4% in adolescents. The prevalence in the female population is 13.7% and in males it is 11.3%. As for the related factors according to the values of OR, an OR=9.5 was found between wheezing and asthma, and an OR=3.5 between recent rhinitis and asthma. As regards recent wheezing, an OR=11.5 was found between awakenings due to wheezing and recent wheezing, and an OR=3.4 between recent rhinitis and wheezing. CONCLUSIONS: Referred asthma is a prevalent disease in children and adolescents in rural areas. It is more prevalent in adolescence and in the female population. Rhinitis and other asthma symptoms are related to asthma and wheezing, as well as the use of emergency services, in the case of asthma</style></abstract><notes><style face="normal" font="default">DA - 20170922IS - 1578-1275 (Electronic)IS - 0212-6567 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.aprim.2017.05.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28935380">PM:28935380</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Aten Primaria\20170922-ElizaldeBeirasI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Aten Primaria\20170922-ElizaldeBeirasI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170922, Elizalde-Beiras I</style></custom2><misc3><style face="normal" font="default">10.1016/j.aprim.2017.05.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42588</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ziyab,A.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Community Medicine and Behavioral Sciences, Faculty of Medicine, Kuwait University, Kuwait, Kuwait</style></auth-address><titles><title><style face="normal" font="default">Prevalence and Risk Factors of Asthma, Rhinitis, and Eczema and Their Multimorbidity among Young Adults in Kuwait: A Cross-Sectional Study</style></title><secondary-title><style face="normal" font="default">Biomed Res Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Biomed Res Int</style></abbr-1></periodical><pages end="" start="2184193">2184193-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To estimate the prevalence of allergic diseases and allergic multimorbidity (coexistence) among young adults in Kuwait and to examine associations between risk factors with allergic diseases and allergic multimorbidity. METHODS: A cross-sectional study was conducted by enrolling 1,154 students, aged 18-26 years, attending Kuwait University. Participants self-completed a questionnaire on symptoms and clinical history of allergic diseases. Prevalence ratios (PRs) and 95% confidence intervals (CIs) were estimated by applying Poisson regression with robust variance estimation. RESULTS: The prevalence of current asthma, rhinitis, and eczema was estimated to be 11.9% (135/1135), 20.4% (232/1138), and 9.2% (105/1143), respectively. The coexistence of "asthma and rhinitis" (5.1%, 57/1125) was the most frequent allergic multimorbidity. Both maternal history (PR = 3.97, 95% CI: 2.32-6.80) and paternal history (PR = 1.72, 95% CI: 1.10-2.68) of allergy were independently associated with having two or more coexisting allergic diseases. The joint effect of having both maternal and paternal history of allergy was associated with 8.16 times (95% CI: 4.19-15.90) higher risk of allergic multimorbidity. CONCLUSION: Allergic diseases and allergic multimorbidity are common among young adults in Kuwait and their burden mirrors that of westernized countries. Parental history of allergy is a strong predisposing factor for allergic multimorbidity</style></abstract><notes><style face="normal" font="default">DA - 20170927IS - 2314-6141 (Electronic)LA - engPT - Journal ArticleCO - Kuwait -</style></notes><work-type><style face="normal" font="default">10.1155/2017/2184193</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28951868">PM:28951868</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biomed Res Int\2017-2017-2184193.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biomed Res Int\2017-2017-2184193.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170927, Ziyab AH</style></custom2><misc3><style face="normal" font="default">10.1155/2017/2184193</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42589</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Procopiou,P.A.</style></author><author><style face="normal" font="default"> Ford,A.J.</style></author><author><style face="normal" font="default"> Gore,P.M.</style></author><author><style face="normal" font="default"> Hancock,A.P.</style></author><author><style face="normal" font="default"> Hodgson,S.T.</style></author><author><style face="normal" font="default"> Holmes,D.S.</style></author><author><style face="normal" font="default"> Looker,B.E.</style></author><author><style face="normal" font="default"> Vile,S.</style></author><author><style face="normal" font="default"> Clark,K.L.</style></author><author><style face="normal" font="default"> Saunders,K.A.</style></author><author><style face="normal" font="default"> Slack,R.J.</style></author><author><style face="normal" font="default"> Watts,C.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Bioorg Med Chem Lett</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Bioorg Med Chem Lett</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Histamine H receptor antagonist</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> Once-daily dosing</style></keyword><keyword><style face="normal" font="default"> Topical application</style></keyword><keyword><style face="normal" font="default"> Quinoline</style></keyword><keyword><style face="normal" font="default"> Sulfone</style></keyword><keyword><style face="normal" font="default"> Sulfonamide</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0960-894X</style></isbn><abstract><style face="normal" font="default">Abstract A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, and was turned over to five major metabolites. Furthermore, 33b had longer duration of action than azelastine in guinea pigs, lower rat brain-penetration, and did not cause time dependent inhibition of CYP2D6 or CYP3A4. The clinical dose in humans is expected to be low (approximately 0.5 mg per day) based on the clinical dose used for azelastine and a comparison of efficacy data from animal models for 33b and azelastine</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.bmcl.2017.09.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958623">PM:28958623</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Bioorg Med Chem Lett\20171010-ProcopiouPA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Bioorg Med Chem Lett\20171010-ProcopiouPA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Procopiou PA</style></custom2><misc3><style face="normal" font="default">10.1016/j.bmcl.2017.09.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42590</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tessier,L.</style></author><author><style face="normal" font="default"> Cote,O.</style></author><author><style face="normal" font="default"> Clark,M.E.</style></author><author><style face="normal" font="default"> Viel,L.</style></author><author><style face="normal" font="default"> Diaz-Mendez,A.</style></author><author><style face="normal" font="default"> Anders,S.</style></author><author><style face="normal" font="default"> Bienzle,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pathobiology, University of Guelph, 50 Stone Road East, Guelph, ON, N1G 2W1, Canada</style></auth-address><titles><title><style face="normal" font="default">Impaired response of the bronchial epithelium to inflammation characterizes severe equine asthma</style></title><secondary-title><style face="normal" font="default">BMC Genomics</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Genomics</style></abbr-1></periodical><pages end="" start="708">708-</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="9" Year="2017">2017/9/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Severe equine asthma is a naturally occurring lung inflammatory disease of mature animals characterized by neutrophilic inflammation, bronchoconstriction, mucus hypersecretion and airway remodeling. Exacerbations are triggered by inhalation of dust and microbial components. Affected animals eventually are unable of aerobic performance. In this study transcriptomic differences between asthmatic and non-asthmatic animals in the response of the bronchial epithelium to an inhaled challenge were determined. RESULTS: Paired endobronchial biopsies were obtained pre- and post-challenge from asthmatic and non-asthmatic animals. The transcriptome, determined by RNA-seq and analyzed with edgeR, contained 111 genes differentially expressed (DE) after challenge between horses with and without asthma, and 81 of these were upregulated. Genes involved in neutrophil migration and activation were in central location in interaction networks, and related gene ontology terms were significantly overrepresented. Relative abundance of specific gene products as determined by immunohistochemistry was correlated with differential gene expression. Gene sets involved in neutrophil chemotaxis, immune and inflammatory response, secretion, blood coagulation and apoptosis were overrepresented among up-regulated genes, while the rhythmic process gene set was overrepresented among down-regulated genes. MMP1, IL8, TLR4 and MMP9 appeared to be the most important proteins in connecting the STRING protein network of DE genes. CONCLUSIONS: Several differentially expressed genes and networks in horses with asthma also contribute to human asthma, highlighting similarities between severe human adult and equine asthma. Neutrophil activation by the bronchial epithelium is suggested as the trigger of the inflammatory cascade in equine asthma, followed by epithelial injury and impaired repair and differentiation. Circadian rhythm dysregulation and the sonic Hedgehog pathway were identified as potential novel contributory factors in equine asthma</style></abstract><notes><style face="normal" font="default">DA - 20170909IS - 1471-2164 (Electronic)IS - 1471-2164 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -CO - Australia -CO - Finland -</style></notes><work-type><style face="normal" font="default">10.1186/s12864-017-4107-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28886691">PM:28886691</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Genomics\2017-18-708.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Genomics\2017-18-708.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170909, Tessier L</style></custom2><misc3><style face="normal" font="default">10.1186/s12864-017-4107-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42591</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Olaniyan,T.</style></author><author><style face="normal" font="default"> Jeebhay,M.</style></author><author><style face="normal" font="default"> Roosli,M.</style></author><author><style face="normal" font="default"> Naidoo,R.</style></author><author><style face="normal" font="default"> Baatjies,R.</style></author><author><style face="normal" font="default"> Kunzil,N.</style></author><author><style face="normal" font="default"> Tsai,M.</style></author><author><style face="normal" font="default"> Davey,M.</style></author><author><style face="normal" font="default"> de Hoogh,K.</style></author><author><style face="normal" font="default"> Berman,D.</style></author><author><style face="normal" font="default"> Parker,B.</style></author><author><style face="normal" font="default"> Leaner,J.</style></author><author><style face="normal" font="default"> Dalvie,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Environmental and Occupational Health Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.</style></auth-address><titles><title><style face="normal" font="default">A prospective cohort study on ambient air pollution and respiratory morbidities including childhood asthma in adolescents from the western Cape Province: study protocol</style></title><secondary-title><style face="normal" font="default">BMC Public Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Public Health</style></abbr-1></periodical><pages end="" start="712">712-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="9" Year="2017">2017/9/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: There is evidence from existing literature that ambient air pollutant exposure in early childhood likely plays an important role in asthma exacerbation and other respiratory symptoms, with greater effect among asthmatic children. However, there is inconclusive evidence on the role of ambient air pollutant exposures in relation to increasing asthma prevalence as well as asthma induction in children. At the population level, little is known about the potential synergistic effects between pollen allergens and air pollutants since this type of association poses challenges in uncontrolled real life settings. In particular, data from sub-Sahara Africa is scarce and virtually absent among populations residing in informal residential settlements. METHODS/DESIGN: A prospective cohort study of 600 school children residing in four informal settlement areas with varying potential ambient air pollutant exposure levels in the Western Cape in South Africa is carried-out. The study has two follow-up periods of at least six-months apart including an embedded panel study in summer and winter. The exposure assessment component models temporal and spatial variability of air quality in the four study areas over the study duration using land-use regression modelling (LUR). Additionally, daily pollen levels (mould spores, tree, grass and weed pollen) in the study areas are recorded. In the panel study asthma symptoms and serial peak flow measurements is recorded three times daily to determine short-term serial airway changes in relation to varying ambient air quality and pollen over 10-days during winter and summer. The health outcome component of the cohort study include; the presence of asthma using a standardised ISAAC questionnaire, spirometry, fractional exhaled nitric-oxide (FeNO) and the presence of atopy (Phadiatop). DISCUSSION: This research applies state of the art exposure assessment approaches to characterize the effects of ambient air pollutants on childhood respiratory health, with a specific focus on asthma and markers of airway inflammation (FeNO) in South African informal settlement areas by considering also pollen counts and meteorological factors. The study will generate crucial data on air pollution and asthma in low income settings in sub-Sahara Africa that is lacking in the international literature</style></abstract><notes><style face="normal" font="default">DA - 20170916IS - 1471-2458 (Electronic)IS - 1471-2458 (Linking)LA - engPT - Journal ArticleCO - South Africa -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1186/s12889-017-4726-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28915873">PM:28915873</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Public Health\2017-17-712.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Public Health\2017-17-712.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170916, Olaniyan T</style></custom2><misc3><style face="normal" font="default">10.1186/s12889-017-4726-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42592</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sigurgeirsson,B.</style></author><author><style face="normal" font="default"> Luger,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Medicine, Department of Dermatology, University of Iceland, Reykjavik, IcelandDepartment of Dermatology, University of Munster, Von Esmarchstrasse 58, 48149, Munster, Germany</style></auth-address><titles><title><style face="normal" font="default">A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal - author response</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170923IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - Iceland -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15849</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28940181">PM:28940181</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20170923-SigurgeirssonB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20170923-SigurgeirssonB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170923, Sigurgeirsson B</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15849</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42593</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ung,C.Y.</style></author><author><style face="normal" font="default"> White,J.M.L.</style></author><author><style face="normal" font="default"> White,I.R.</style></author><author><style face="normal" font="default"> Banerjee,P.</style></author><author><style face="normal" font="default"> McFadden,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Guy's and St, Thomas' University Hospital, St John's Institute of Dermatology, London, UK</style></auth-address><titles><title><style face="normal" font="default">Patch testing with the European baseline series fragrance markers: A 2016 update</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Fragrance contact allergy is common and is currently screened for with the European baseline series fragrance markers: Fragrance Mix 1, Fragrance Mix 2, Myroxylon pereirae and hydroxyisohexyl 3-cyclohexene carboxaldehyde. OBJECTIVES: To investigate the validity of patch testing with these fragrance markers in detecting fragrance allergy to 26 individual fragrance substances for which cosmetic ingredient labelling is mandatory in the European Union. METHODS: We conducted a retrospective review of the patch test records of all eczema patients who underwent testing with the European baseline series extended with the individual fragrance substances during the period 2015-2016. RESULTS: 359 patients (17.2%) reacted to one or more allergens from the labelled fragrance substance series and/or a fragrance marker from the European baseline series. The allergens that were positive with the greatest frequencies were oxidised linalool (154; 7.4%, 95% CI 6.3%-8.6%), oxidised limonene (89; 4.3%, 95% CI 3.4%-5.2%) and Evernia furfuracea (44; 2.1%, 95% CI 1.5%-2.8%). Of the 319 patients who reacted to any of the labelled fragrance substances, only 130 (40.8%) also reacted to a baseline series fragrance marker. The sensitivity of our history-taking for fragrance allergy was 25.7%. CONCLUSIONS: With the evolving trends in fragrance allergy patch testing with Fragrance Mix 1, Fragrance Mix 2, Myroxylon pereirae and hydroxyisohexyl 3-cyclohexene carboxaldehyde are no longer sufficient for screening for fragrance allergy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15949</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28960261">PM:28960261</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20170929-UngCY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20170929-UngCY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Ung CY</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15949</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42594</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nakagawa,H.</style></author><author><style face="normal" font="default"> Nemoto,O.</style></author><author><style face="normal" font="default"> Igarashi,A.</style></author><author><style face="normal" font="default"> Nagata,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: A phase 2, multi-centre, randomised, vehicle-controlled clinical study</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="28" Month="9" Year="2017">2017/9/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: JTE-052 is a novel Janus kinase inhibitor presently under clinical development for the topical treatment of atopic dermatitis (AD). OBJECTIVES: To evaluate the efficacy and safety of JTE-052 ointment in Japanese adult patients with AD. Methods Patients with moderate-to-severe AD were randomised (2:2:2:2:1:1) to receive JTE-052 ointment at 0.25%, 0.5%, 1% or 3%, the vehicle ointment or 0.1% tacrolimus ointment (reference) twice daily for 4 weeks. The primary efficacy endpoint was the percent change in modified Eczema Area Severity Index (m-EASI) score from the baseline at the end of treatment (EOT). Secondary efficacy endpoints included change from baseline in the pruritus numeric rating scale (NRS) score. RESULTS: A total of 327 patients were enrolled. At EOT, the least-squares mean percent change from baseline in m-EASI score for JTE-052 0.25%, 0.5%, 1%, 3% and the vehicle ointment was -41.7%, -57.1%, -54.9%, -72.9% and -12.2%, respectively. All JTE-052 groups showed significant reductions of m-EASI score versus the vehicle group (p &lt;0.001 for all). In the tacrolimus group, the mean percent change in m-EASI score was -62.0%. JTE-052 groups also showed significant improvement in other parameters; notably, the pruritus NRS score was reduced as early as Day 1 night-time. JTE-052 ointment at doses up to 3% was safe and well tolerated. CONCLUSIONS: Topical JTE-052 markedly and rapidly improved clinical signs and symptoms in Japanese adult patients with moderate-to-severe AD with a favourable safety profile. The study results indicate that topical JTE-052 is a promising therapeutic option for AD. This article is protected by copyright. All rights reserved. TRIAL REGISTRATION NUMBER: JAPICCTI-152887</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.16014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28960254">PM:28960254</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20170929-NakagawaH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20170929-NakagawaH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Nakagawa H</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.16014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42595</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arents,B.W.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical Affairs &amp; Health Care, Dutch Association for People with Atopic Dermatitis (VMCE: Vereniging voor Mensen met Constitutioneel Eczeem), Nijkerk, the Netherlands</style></auth-address><titles><title><style face="normal" font="default">Eczema treatment: it takes time to do no harm</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="614" start="613">613-614</pages><volume><style face="normal" font="default">177</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170923IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15788</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28940275">PM:28940275</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\2017-177-613-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\2017-177-613-4.pdf</url></text-urls><related-urls><url ppv-ref="no">.mp3 in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20170923, Arents BW</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15788</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42596</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bechaalani,P.</style></author><author><style face="normal" font="default"> Aun-Pereira,V.</style></author><author><style face="normal" font="default"> Pescadinha de Carvalho,A.</style></author><author><style face="normal" font="default"> Tartuce Aun,W.</style></author><author><style face="normal" font="default"> Ferreira de Mello,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Profile of patients with urticaria and angioedema caused by nonsteroidal anti-inflammatory drugs in the Allergy and Immunology Division of Hospital do Servidor Público Estadual de São Paulo</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="205" start="201">201-205</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Objectives: To identify patients with a history of urticaria andangioedema caused by nonsteroidal anti-inflammatory drugs(NSAIDs) at the Allergy and Immunology Division of Hospitaldo Servidor Público Estadual de São Paulo, to classify themas selective or nonselective, and to evaluate their tolerability tocyclooxygenase-2 inhibitors (etoricoxib 90 mg). Methods: Patientswith multiple reactions induced by NSAIDs, from different groups,were subjected to oral provocation test with etoricoxib 90 mg.Patients with a history of urticaria and/or angioedema inducedby only one group of NSAIDs, or experiencing their first episode,were subjected to oral provocation test with another NSAIDgroup to classify them as selective or non-selective. Results:A total of 43 patients aged 18-71 years, predominantly female(77%), were studied. The majority of patients showed reactionsto multiple NSAIDs (non-selective); only 2 (4.6%) reacted to onlyone NSAID (selective). Allergic symptoms were observed in 53%of the patients, mainly rhinitis (61%). The drugs most frequentlyinvolved were dipyrone (39%), diclofenac (18%) and acetylsalicylicacid (14%). The etoricoxib 90 mg test resulted negative for allpatients. Conclusion: The majority of patients showed non-selective reactions, and all of them showed negative etoricoxib90 mg tests, demonstrating the safety and appropriateness ofthis treatment option.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170024</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170024</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-201-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-201-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Bechaalani P</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42597</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Morandi Lopes,M.</style></author><author><style face="normal" font="default"> Diogo-Salles,P.</style></author><author><style face="normal" font="default"> Dantas,P.</style></author><author><style face="normal" font="default"> Kalil,J.</style></author><author><style face="normal" font="default"> Abilio Motta,A.</style></author><author><style face="normal" font="default"> Camara Agondi,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Nonsteroidal anti-inflammatory drug-exacerbated chronic urticaria and response to antileukotrienes</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="211" start="206">206-211</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Introduction: Patients with chronic spontaneous urticaria(CSU) frequently show symptom exacerbation after the use ofnonsteroidal anti-inflammatory drugs (NSAIDs) - drugs that inhibitcyclooxygenase-1 (COX-1) and affect leukotriene production.Antileukotrienes are considered a therapeutic option for patientswho do not respond to antihistamines (AH1). Objective: The aimof this study was to assess the effectiveness of antileukotrienesin patients with CSU exacerbated or not by NSAIDs. Methods: Inthis retrospective study, the electronic charts of CSU outpatientswere analyzed. All patients were inquired about history of CSUexacerbation or not by NSAIDs. In addition to AH1, treatment withmontelukast was introduced to all patients at some point duringfollow-up. Response to antileukotriene treatment and associationbetween treatment response and history of NSAID exacerbationwere evaluated. Results: A total of 62 patients participated in thestudy. Mean age was 48.4 years, and 82.3% were female. Thirty-five patients (56.5%) reported worsening of urticaria with the useof NSAIDs; 77.1% of these patients responded to antileukotrienecombined with AH1. Of the 27 patients with no history of CSUexacerbation with NSAIDs, 48.1% showed a favorable responseto antileukotrienes associated with AH1. Conclusion: Responseto antileukotriene treatment was higher and statistically significant(p=0.031) in patients with NSAID-exacerbated CSU. Therefore,the association of antileukotrienes with AH1 could be a safe andeffective treatment option, especially for patients with NSAID-exacerbated CSU.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170025</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170025</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-15-206-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-15-206-11.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Morandi Lopes M</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42598</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">D'Onofrio-Silva,A.C.</style></author><author><style face="normal" font="default"> Longen,E.</style></author><author><style face="normal" font="default"> Abilio Motta,A.</style></author><author><style face="normal" font="default"> Kalil,J.</style></author><author><style face="normal" font="default"> Giavina-Bianchi,P.</style></author><author><style face="normal" font="default"> Vivolo Aun,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Persistence of positive skin test 25 years after penicillin-induced anaphylaxis</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="234" start="231">231-234</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Skin tests are important in the investigation of hypersensitivityreactions to beta-lactams, but sensitivity decreases with time andis generally negative within 5 years from the initial reaction. Wedescribe a case of persistent positive skin test 25 years after ananaphylactic reaction induced by penicillin. A 39-year old womanwas referred to the allergy service due to gestational syphilis and ahistory of penicillin-induced anaphylaxis, to evaluate the possibilityof performing desensitization. The patient had experienced twohypersensitivity reactions 25 years earlier, the first one consisting ofimmediate urticaria after the use of benzathine penicillin, followedby an anaphylactic reaction in the subsequent week after receivinganother dose of the medication. She had not taken any other beta-lactam since then, but reported contact urticaria when preparingoral amoxicillin to her children. Skin tests were performed withbenzylpenicillin 10,000 IU/mL. The skin prick test resulted negative,but the intradermal test was positive, confirming the presence ofspecific IgE. She was subjected to desensitization, with success,but presented a grade I hypersensitivity reaction (urticaria) duringthe procedure. At the end, she received 2,400,000 IU benzathinepenicillin in 3 weekly doses, with no reactions. Skin tests shouldbe performed in the investigation of penicillin allergy, even longafter the initial reaction, as it allows to predict the risk of reactionrecurrence upon re-exposure.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170029</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170029</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-15-231-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-15-231-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, D'Onofrio-Silva AC</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42599</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fernandes Costa,A.J.</style></author><author><style face="normal" font="default"> Veras de Araujo,G.</style></author><author><style face="normal" font="default"> Cavalcante Sarinho,E.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Paracetamol use and the incidence of asthma</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="236" start="235">235-236</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170030</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170030</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-15-235-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-15-235-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Fernades Costa AJ</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170030</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42600</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rosário Filho,N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Pollution, global warming, and allergy</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="238" start="236">236-238</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170031</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170031</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-15-236-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-15-236-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Rosário Filho N</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170031</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42601</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oliveira Mendonça,L.</style></author><author><style face="normal" font="default"> Biegelmeyer,J.</style></author><author><style face="normal" font="default"> Paulo de Assis,J.</style></author><author><style face="normal" font="default"> Costa Amorim,L.</style></author><author><style face="normal" font="default"> Levy-Neto,M.</style></author><author><style face="normal" font="default"> Kalil,J.</style></author><author><style face="normal" font="default"> de Arruda Martins,M.</style></author><author><style face="normal" font="default"> Morato Castro,F.</style></author><author><style face="normal" font="default"> Toledo de Barros,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">IgG4-related systemic disease associated with lymphopenia: case report and brief literature review</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="230" start="226">226-230</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">IgG4-related systemic disease is a recently described, emergingcondition, clinically characterized by partial or total enlargementof an organ, with a broad spectrum of clinical manifestations. It isa systemic fibroinflammatory condition caused by the infiltration ofIgG4-positive plasmablasts that lead to eosinophilic inflammationof tissues and consequently storiform fibrosis. When diagnosis isearly, clinical improvement and maintained response achievedwith systemic corticosteroids is impressive. Diagnosis is basedon pathological criteria, but recent papers have described thatserum plasmablasts may serve as an independent factor to aidin diagnosis. This paper describes an atypical presentation ofIgG4-related disease in a lymphopenic patient with inconclusiveserum plasmablast measurement.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170028</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170028</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-15-226-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-15-226-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Oliveira Mendonça L</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42602</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Camara Agondi,R.</style></author><author><style face="normal" font="default"> Crispim,L.</style></author><author><style face="normal" font="default"> Almonfrey,F.B.</style></author><author><style face="normal" font="default"> Kalil,J.</style></author><author><style face="normal" font="default"> Abilio Motta,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Antihistamine-refractory chronic spontaneous urticaria: opting for cyclosporine</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="216" start="212">212-216</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Introduction: Second-generation antihistamines (sgAH1) are thetreatment of choice for patients with chronic spontaneous urticaria(CSU). However, about 50% of the patients do not respond to thistreatment. Cyclosporine is an option for more severe presentations.This drug has potent immunosuppressive properties. Despite itseffectiveness, use is limited due to several serious side effects.Objective: The aim of this study was to assess response to cyclos-porine in patients with antihistamine-refractory CSU. Method:This retrospective study was based on the electronic recordsof patients with sgAH1-refractory CSU who did not respond tothe introduction of other drugs to control urticaria. Cyclosporinewas indicated for all patients. D-dimer dosage was performed insome patients. Results: Thirty patients participated in the study.Of these, 80% were female and the mean age was 42.8 years.Prior to the introduction of cyclosporine, all patients were usingAH1, 60% AH2, 67% montelukast, 33.3% hydroxychloroquine,and 56.7% oral corticosteroids. Median time of cyclosporine usewas 11.5 months. Regarding efficacy, 40% of the patients showedimprovement of symptoms, 40% did not respond to treatment,and in 20% response was not evaluated because the medicationwas withdrawn due to side effects or was not introduced basedon previous clinical or laboratory abnormalities. There was anincrease in blood pressure levels in 9 patients (30%) and nephro-toxicity in 5 (16.7%). Conclusions: Even though cyclosporine isa good therapeutic option for patients with AH1-refractory CSU,side effects are frequent and should be monitored.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170026</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170026</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-15-212-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-15-212-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Camara Agondi R</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170026</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42603</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kraft Köhler Ribeiro,M.L.</style></author><author><style face="normal" font="default"> Barcellos,A.C.</style></author><author><style face="normal" font="default"> Ferreira Silva,H.G.</style></author><author><style face="normal" font="default"> Mattei Carletto,L.H.</style></author><author><style face="normal" font="default"> Bet,M.C.</style></author><author><style face="normal" font="default"> Zorze Rossetto,N.</style></author><author><style face="normal" font="default"> Rosario,N.A.</style></author><author><style face="normal" font="default"> Chong-Neto,H.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Anaphylaxis in the emergency room: still a long way to go</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="225" start="217">217-225</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Objective: Anaphylaxis is the most dramatic clinical presentationof allergy in the emergency setting. The aim of this study was toassess knowledge on anaphylaxis management among physiciansworking at emergency services. Methods: A cross-sectional studywas carried out and a written questionnaire was applied to 119physicians working at eight hospitals (Hospital group) and to 210physicians working at nine emergency services/mobile emergencyservices (UPA/SAMU group) between April and September 2016.Results: Among the respondents, 79 (66.4%) physicians workedat hospitals and 78 (37.1%) at emergency services. One hundredtwenty-two participants (78.7%) had graduated less than tenyears earlier. Sixty-nine physicians (43.9%) correctly diagnosedanaphylaxis, and only 29 (18.5%) identified the systems that couldbe affected in an anaphylactic reaction. Intramuscular adrenalinewas reported as the first treatment option for anaphylaxis by 64physicians (40.7%), and glucagon was chosen as an option inpatients using ß-blockers by 19 (12.1%). The use of auto-injectorswas referred by 71 (45.3%) of the physicians. Conclusion: Thelevel of medical knowledge on anaphylaxis management inemergency departments is low. Guidelines are not followed andmay result in an unfavorable outcome for patients presenting withan anaphylactic reaction.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170027</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170027</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-15-217-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-15-217-25.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Kraft Köhler Ribeiro ML</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42604</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Touil,N.</style></author><author><style face="normal" font="default"> van der Rest,E.</style></author><author><style face="normal" font="default"> Van Boven,M.</style></author><author><style face="normal" font="default"> Momeni,M.</style></author><author><style face="normal" font="default"> Veevaete,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesiology, Cliniques Universitaires Saint-Luc, Universite catholique de Louvain, Brussels, Belgium</style></auth-address><titles><title><style face="normal" font="default">Anesthetic management of a patient allergic to ethylene oxide: a case report</style></title><secondary-title><style face="normal" font="default">Can J Anaesth</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Can J Anaesth</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170928IS - 1496-8975 (Electronic)IS - 0832-610X (Linking)LA - engPT - LetterCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1007/s12630-017-0981-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28956277">PM:28956277</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Can J Anaesth\20170928-TouilN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Can J Anaesth\20170928-TouilN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170928, Touil N</style></custom2><misc3><style face="normal" font="default">10.1007/s12630-017-0981-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42605</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rodriguez,T.A.</style></author><author><style face="normal" font="default"> Camara,H.C.</style></author><author><style face="normal" font="default"> Garcia-Trujillo,J.A.</style></author><author><style face="normal" font="default"> Magriz,T.I.</style></author><author><style face="normal" font="default"> Fernandez Pereira,L.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Department, Nuestra Senora del Prado Hospital, Talavera de la Reina, Toledo, Spain</style></auth-address><titles><title><style face="normal" font="default">A Case of Immediate Hypersensitivity Reaction to Maltitol</style></title><secondary-title><style face="normal" font="default">Case Rep Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Case Rep Med</style></abbr-1></periodical><pages end="" start="2127167">2127167-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Maltitol is a sugar alcohol that is frequently used as a noncaloric sweetener, although it is also used as an excipient, a plasticizer in gelatin capsules, and an emollient. It has not been previously described as an agent involved in immediate hypersensitivity reactions. METHODS: We report on an anaphylactoid reaction with pharyngeal occlusion suffered by a 60-year-old man after ingestion of a candy containing maltitol syrup. A prick-to-prick test was performed with the candy and maltitol powder. Other allergens were excluded as causative agents of the adverse reaction, although the patient refused to undergo an oral challenge test with the candy. A basophil activation test (BAT) was performed with maltitol powder, and a dose-response curve was generated. The test was also performed in 3 healthy controls. RESULTS: Both prick-to-prick tests were negative. The result of the BAT was positive at all the concentrations tested in the patient's blood and negative in all the controls. CONCLUSIONS: The BAT can help to clarify the agents implicated in an adverse reaction and can reduce the risk involved in diagnosis. The BAT can also prove useful in the study of reactions caused by low-molecular-weight antigens, for which routine diagnostic tests are not feasible</style></abstract><notes><style face="normal" font="default">DA - 20170912IS - 1687-9627 (Print)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1155/2017/2127167</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28894468">PM:28894468</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Case Rep Med\2017-2017-2127167.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Case Rep Med\2017-2017-2127167.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170912, Rodriguez TA</style></custom2><misc3><style face="normal" font="default">10.1155/2017/2127167</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42606</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Reinhart,R.</style></author><author><style face="normal" font="default"> Rohner,L.</style></author><author><style face="normal" font="default"> Wicki,S.</style></author><author><style face="normal" font="default"> Fux,M.</style></author><author><style face="normal" font="default"> Kaufmann,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Pharmacology, University of Bern, Bern, SwitzerlandUniversity Institute of Clinical Chemistry, University of Bern, Bern, SwitzerlandInstitute of Pharmacology, University of Bern, Bern, SwitzerlandUniversity Institute of Clinical Chemistry, University of Bern, Bern, SwitzerlandInstitute of Pharmacology, University of Bern, Bern, Switzerland</style></auth-address><titles><title><style face="normal" font="default">BH3 mimetics efficiently induce apoptosis in mouse basophils and mast cells</style></title><secondary-title><style face="normal" font="default">Cell Death Differ</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cell Death Differ</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="9" Year="2017">2017/9/29</year></dates><abstract><style face="normal" font="default">Basophil granulocytes and mast cells are recognized for their roles in immunity and are central effectors of diverse immunological disorders. Despite their similarities, there is emerging evidence for non-redundant roles of the circulating yet scarce basophils and tissue-resident mast cells, respectively. Because of their importance in allergic pathogenesis, specific induction of apoptosis in basophils and mast cells may represent an interesting novel treatment strategy. The pro-inflammatory cytokine interleukin-3 serves as a key factor for basophil and mouse mast cell survival. Interleukin-3 increases the expression of anti-apoptotic BCL-2 family members, such as BCL-2, BCL-XL or MCL-1; however, little is known how strongly these individual proteins contribute to basophil survival. Here, we were applying small molecule inhibitors called BH3 mimetics, some of which show remarkable success in cancer treatments, to neutralize the function of anti-apoptotic BCL-2 family members. We observed that expression levels of anti-apoptotic BCL-2 proteins do not necessarily correlate with their respective importance for basophil survival. Whereas naive in vitro-differentiated mouse basophils efficiently died upon BCL-2 or BCL-XL inhibition, interleukin-3 priming rendered the cells highly resistant toward apoptosis, and this could only be overcome upon combined targeting of BCL-2 and BCL-XL. Of note, human basophils differed from mouse basophils as they depended on BCL-2 and MCL-1, but not on BCL-XL, for their survival at steady state. On the other hand, and in contrast to mouse basophils, MCL-1 proved critical in mediating survival of interleukin-3 stimulated mouse mast cells, whereas BCL-XL seemed dispensable. Taken together, our results indicate that by choosing the right combination of BH3 mimetic compounds, basophils and mast cells can be efficiently killed, even after stimulation with potent pro-survival cytokines such as interleukin-3. Because of the tolerable side effects of BH3 mimetics, targeting basophils or mast cells for apoptosis opens interesting possibilities for novel treatment approaches.Cell Death and Differentiation advance online publication, 29 September 2017; doi:10.1038/cdd.2017.154</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 1476-5403 (Electronic)IS - 1350-9047 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1038/cdd.2017.154</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28960207">PM:28960207</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cell Death Differ\20170929-ReinhartR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cell Death Differ\20170929-ReinhartR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Reinhart R</style></custom2><misc3><style face="normal" font="default">10.1038/cdd.2017.154</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42607</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yang,Q.</style></author><author><style face="normal" font="default"> Xu,W.</style></author><author><style face="normal" font="default"> Long,Y.</style></author><author><style face="normal" font="default"> Kuang,J.</style></author><author><style face="normal" font="default"> Li,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China</style></auth-address><titles><title><style face="normal" font="default">STAT3 regulates cytokine expression in peripheral blood mononuclear cells from asthma patients</style></title><secondary-title><style face="normal" font="default">Cell Mol Biol (Noisy le grand)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cell Mol Biol (Noisy le grand)</style></abbr-1></periodical><pages end="74" start="71">71-74</pages><volume><style face="normal" font="default">63</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="9" Year="2017">2017/9/30</year></dates><abstract><style face="normal" font="default">Asthma is a common long term inflammatory disease of the airways. This disease affected millions of people worldwide. Recently, it is demonstrated that signal transducer and activator of transcription 3 (STAT3) plays critical role in asthma occurrence. In the current study, we isolated peripheral blood mononuclear cells (PBMCs) from patients with mild and moderate asthma, and then determined the correlation between STAT3 and cytokine expression. We found that the concentration and mRNA level of cytokines was increased in PBMCs from asthma patients. The concentration and mRNA level of cytokines was altered by the regulation of STAT3 expression and the concentration and mRNA expression level of cytokines was positively correlated with STAT3 activation. Furthermore, phosphorylated STAT3 expression in PBMCs from asthma patients was increased compared with the control. Collectively, this study directly proved that STAT3 was correlated with cytokine expression in PBMCs from asthma patients, providing a potential linkage between STAT3 and pathogenesis of asthma</style></abstract><notes><style face="normal" font="default">DA - 20171005IS - 1165-158X (Electronic)IS - 0145-5680 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.14715/cmb/2017.63.9.13</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28980924">PM:28980924</url></web-urls></urls><custom2><style face="normal" font="default">20171005, Yang Q</style></custom2><misc3><style face="normal" font="default">10.14715/cmb/2017.63.9.13</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42608</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Izuhara,K.</style></author><author><style face="normal" font="default"> Nunomura,S.</style></author><author><style face="normal" font="default"> Nanri,Y.</style></author><author><style face="normal" font="default"> Ogawa,M.</style></author><author><style face="normal" font="default"> Ono,J.</style></author><author><style face="normal" font="default"> Mitamura,Y.</style></author><author><style face="normal" font="default"> Yoshihara,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, 5-1-1, Nabeshima, Saga, 849-8501, Japan</style></auth-address><titles><title><style face="normal" font="default">Periostin in inflammation and allergy</style></title><secondary-title><style face="normal" font="default">Cell Mol Life Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cell Mol Life Sci</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="9" Year="2017">2017/9/8</year></dates><abstract><style face="normal" font="default">We found for the first time that IL-4 and IL-13, signature type 2 cytokines, are able to induce periostin expression. We and others have subsequently shown that periostin is highly expressed in chronic inflammatory diseases-asthma, atopic dermatitis, eosinophilc chronic sinusitis/chronic rhinosinusitis with nasal polyp, and allergic conjunctivitis-and that periostin plays important roles in the pathogenesis of these diseases. The epithelial/mesenchymal interaction via periostin is important for the onset of allergic inflammation, in which periostin derived from fibroblasts acts on epithelial cells or fibroblasts, activating their NF-kappaB. Moreover, the immune cell/non-immune cell interaction via periostin may be also involved. Now the significance of periostin has been expanded into other inflammatory or fibrotic diseases such as scleroderma and pulmonary fibrosis. The cross-talk of periostin with TGF-beta or pro-inflammatory cytokines is important for the underlying mechanism of these diseases. Because of its pathogenic importance and broad expression, diagnostics or therapeutic drugs can be potentially developed to target periostin as a means of treating these diseases</style></abstract><notes><style face="normal" font="default">DA - 20170909IS - 1420-9071 (Electronic)IS - 1420-682X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1007/s00018-017-2648-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28887633">PM:28887633</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cell Mol Life Sci\20170909-IzuharaK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cell Mol Life Sci\20170909-IzuharaK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170909, Izuhara K</style></custom2><misc3><style face="normal" font="default">10.1007/s00018-017-2648-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42609</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Boulet,L.P.</style></author><author><style face="normal" font="default"> Robitaille,C.</style></author><author><style face="normal" font="default"> Deschesnes,F.</style></author><author><style face="normal" font="default"> Villeneuve,H.</style></author><author><style face="normal" font="default"> Boulay,M.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institut universitaire de cardiologie et de pneumologie de Quebec-Universite Laval, Quebec, Canada.</style></auth-address><titles><title><style face="normal" font="default">Comparative clinical, physiological and inflammatory characteristics of elderly subjects with or without asthma and young asthmatics</style></title><secondary-title><style face="normal" font="default">Chest</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chest</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma seems to present in the elderly as a specific phenotype that remains to be further described. AIM: In this prospective observational study, we aimed to assess the multidimensional aspects of asthma in the elderly. METHODS: In young (18 to 35 years old) mildly to moderately asthmatic subjects and elderly subjects (aged >/=60 years) either with or without mild to moderate asthma, we compared asthma control, healthcare and medication use, lung function, markers of airway and systemic inflammation, and adherence to therapy. RESULTS: Fifty subjects were recruited in each group. Elderly asthmatics showed more marked airway obstruction compared to young asthmatics and elderly non-asthmatics. They also had poorer asthma control, mainly associated with a lower FEV1, as compared to young asthmatics, although airway responsiveness, healthcare use, prescribed doses of inhaled corticosteroids and adherence to treatment were similar in both groups. Elderly subjects had an increase in some markers of systemic inflammation and bronchial epithelial dysfunction compared to young asthmatics. Blood eosinophils were higher in both asthmatic groups, particularly in elderly asthmatics. Sputum neutrophils were increased in both groups of elderly subjects and sputum eosinophils were increased in elderly asthmatics compared to the two other groups. CONCLUSION: Asthma in the elderly presents as a specific phenotype associated with increased airway obstruction and mixed airway inflammation in addition to signs of systemic inflammation</style></abstract><notes><style face="normal" font="default">DA - 20170924IS - 1931-3543 (Electronic)IS - 0012-3692 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.chest.2017.09.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28941741">PM:28941741</url></web-urls></urls><custom2><style face="normal" font="default">20170924, Boulet LP</style></custom2><misc3><style face="normal" font="default">10.1016/j.chest.2017.09.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42610</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cifuentes,M.</style></author><author><style face="normal" font="default"> Davari,P.</style></author><author><style face="normal" font="default"> Rogers,R.S.,III</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Faculty of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile.</style></auth-address><titles><title><style face="normal" font="default">Contact stomatitis</style></title><secondary-title><style face="normal" font="default">Clin Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Dermatol</style></full-title></periodical><pages end="440" start="435">435-440</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Contact stomatitis occurs in up to 10% of the population. Mechanical or chemical irritation, ill-fitting dentures, and dental fillings can induce irritant contact stomatitis. Type I hypersensitivity and type IV hypersensitivity to dental products and foods are frequently responsible for the allergic types of contact stomatitis. We review the causal agents of contact stomatitis, the differential diagnoses, diagnostic testing, and potential treatment</style></abstract><notes><style face="normal" font="default">DA - 20170916IS - 1879-1131 (Electronic)IS - 0738-081X (Linking)LA - engPT - Journal ArticleCO - Chile -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.clindermatol.2017.06.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28916024">PM:28916024</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Dermatol\2017-35-435-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Dermatol\2017-35-435-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170916, Cifuentes M</style></custom2><misc3><style face="normal" font="default">10.1016/j.clindermatol.2017.06.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42611</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ali,Z.</style></author><author><style face="normal" font="default"> Nilas,L.</style></author><author><style face="normal" font="default"> Ulrik,C.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonary Medicine, Hvidovre Hospital</style></auth-address><titles><title><style face="normal" font="default">Determinants of low risk of asthma exacerbation during pregnancy</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: Assessment of asthma control every 4-6 weeks during pregnancy is recommended to reduce risk of exacerbation, and by that improve outcome. OBJECTIVE: To identify determinants of pregnancies with low risk of asthma exacerbation. METHODS: All pregnant women enrolled into the Management of Asthma during Pregnancy (MAP) program at Hvidovre Hospital since 2007. Assessment of asthma control, adjustment of treatment, spirometry and measurement of exhaled nitric oxide (FE NO) were performed, and baseline characteristics and exacerbation history was collected at enrolment. Determinants of low-exacerbation risk pregnancies were identified by logistic regression analysis (stepwise backward elimination). RESULTS: In 1,283 pregnancies, 107 exacerbations were observed. Multiple regression analysis revealed that no history of pre-pregnancy exacerbations (p&lt;0.001), no prescribed controller medication (p&lt;0.001), and clinically stable asthma at enrolment (p=0.002)were significantly associated with low risk of exacerbation during pregnancy, with these combined characteristics only two out of 385 pregnancies were complicated by an exacerbation (OR 0.04, 95% CI 0.01-0.18, p&lt;0.001). CONCLUSION AND CLINICAL RELEVANCE: Clinically stable asthma at enrolment, together with no history of previous exacerbations and no prescribed controller medication, are determinants of low risk of an asthma exacerbation during pregnancy, which may guide clinicians in individualising surveillance of asthma during pregnancy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170919IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28925525">PM:28925525</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170919-AliZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170919-AliZ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170919, Ali Z</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13033</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42612</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lodge,C.J.</style></author><author><style face="normal" font="default"> Braback,L.</style></author><author><style face="normal" font="default"> Lowe,A.J.</style></author><author><style face="normal" font="default"> Dharmage,S.C.</style></author><author><style face="normal" font="default"> Olsson,D.</style></author><author><style face="normal" font="default"> Forsberg,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy and Lung Health Unit Centre for Epidemiology and Biostatistics, School of Population Health University of Melbourne, 3010, Australia</style></auth-address><titles><title><style face="normal" font="default">Grandmaternal smoking increases asthma risk in grandchildren: a nationwide Swedish cohort</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: There is growing interest in exposures prior to conception as possible risk factors for offspring asthma. Although partially supported by evidence from limited human studies, current evidence is inconsistent, and based on recall of exposure status. OBJECTIVE: We aimed to investigate grandmaternal smoking during pregnancy and the risk of asthma in grandchildren using prospectively collected population-based data. METHODS: Information on grandmaternal and maternal smoking during pregnancy and grandchild use of asthma medications was collected from national Swedish registries. Associations between grandmaternal smoking during pregnancy (10-12 weeks), and asthma medication use in grandchildren were investigated using generalized estimating equations. Ages at which asthma medications were prescribed classified childhood asthma into never, early transient (0-3years), late onset (3-6 years) and early persistent (0-3 and 3-6 years) phenotypes. RESULTS: From 1982 to 1986, 44,583 grandmothers gave birth to 46,197 mothers, who gave birth to 66,271 grandchildren (born 1996-2010). Children aged 1-6 years had an increased asthma risk if their grandmothers had smoked during pregnancy, with a higher risk for more exposure (10+ cigs/day; adjusted OR 1.23; 1.17, 1.30). Maternal smoking did not modify this relationship. CONCLUSIONS &amp; CLINICAL RELEVANCE: Children had an increased risk of asthma in the first six years of life if their grandmothers smoked during early pregnancy, independent of maternal smoking. Importantly this exhibited a dose-response relationship and was associated with a persistent childhood asthma phenotype. These findings support possible epigenetic transmission of risk from environmental exposures in previous generations. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170919IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28925522">PM:28925522</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170919-LodgeCJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170919-LodgeCJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170919, Lodge CJ</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13031</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42613</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Heijkenskjold-Rentzhog,C.</style></author><author><style face="normal" font="default"> Janson,C.</style></author><author><style face="normal" font="default"> Berglund,L.</style></author><author><style face="normal" font="default"> Borres,M.P.</style></author><author><style face="normal" font="default"> Nordvall,L.</style></author><author><style face="normal" font="default"> Alving,K.</style></author><author><style face="normal" font="default"> Malinovschi,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Uppsala University, Dept. of Women's and Children's Health, Uppsala, Sweden</style></auth-address><titles><title><style face="normal" font="default">Overall and peripheral lung function assessment by spirometry and forced oscillation technique in relation to asthma diagnosis and control</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: Classic spirometry is effort-dependent and of limited value in assessing small airways. Peripheral airway involvement, and relation to poor control, in asthma, has been highlighted recently. Forced oscillation technique (FOT) offers an effort-independent assessment of overall and peripheral lung mechanics. We studied the association between lung function variables, obtained either by spirometry or multi-frequency (5, 11 and 19 Hz) FOT, and asthma diagnosis and control. METHODS: Spirometry measures, resistance at 5 (R5) and 19 Hz (R19), reactance at 5 Hz (X5), resonant frequency (fres ), resistance difference between 5-19 Hz (R5-R19) and Asthma Control Test scores were determined in 234 asthmatic and 60 healthy subjects (aged 13-39 years). We used standardised lung function variables in logistic regression analyses, unadjusted and adjusted for age, height, gender, weight. RESULTS: Lower FEV1 /FVC (OR (95% CI) 0.47 (0.32, 0.69)) and FEF50 (0.62 (0.46, 0.85)) per standard deviation increase, and higher R5 (3.31 (1.95, 5.62)) and R19 (2.54 (1.65, 3.91)) were associated with asthma diagnosis. Independent predictive effects of FEV1 /FVC and R5 or R19, respectively, were found for asthma diagnosis. Lower FEV1 /FVC and altered peripheral FOT measures (X5, fres and R5-R19) were associated with uncontrolled asthma (p-values &lt; 0.05). CONCLUSIONS: Resistance FOT measures were equally informative as spirometry, related to asthma diagnosis, and furthermore, offered additive information to FEV1 /FVC, supporting a complementary role for FOT. Asthma control was related to FOT measures of peripheral airways, suggesting a potential use in identifying such involvement. Further studies are needed to determine a clinical value, and relevant reference values in children, for the multi-frequency FOT measurements. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170923IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28940832">PM:28940832</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170923-HeijkenskjoldRentzhogC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170923-HeijkenskjoldRentzhogC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170923, Heijkenskjold-Rentzhog C</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13035</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42614</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stenberg,H.</style></author><author><style face="normal" font="default"> Diamant,Z.</style></author><author><style face="normal" font="default"> Ankerst,J.</style></author><author><style face="normal" font="default"> Bjermer,L.</style></author><author><style face="normal" font="default"> Tufvesson,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Respiratory Medicine and Allergology, Lund, Sweden</style></auth-address><titles><title><style face="normal" font="default">Small airway involvement in the late allergic response in asthma</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergy and asthma are closely linked. Inhalation of allergen induces an early allergic response (EAR) within the airways of allergic asthmatic subjects, which is followed by a late allergic response (LAR) in approximately 50% of the subjects. The LAR is defined as a drop in forced expiratory volume in 1 s (FEV1 ) from baseline usually occurring 4-8 h after exposure, and is believed to affect small airways. However, FEV1 is insensitive to changes in small airway physiology. OBJECTIVE: Our aim was to investigate and compare the pathophysiological processes in large and small airways during the EAR and the LAR, and to characterize subjects with both an EAR and a LAR (dual responders) versus those with an EAR only (single responders). METHODS: Thirty-four subjects with allergic asthma underwent an inhaled allergen challenge. Lung physiology was assessed by spirometry, impulse oscillometry (IOS), body plethysmography, inert gas washout, single breath methane dilution carbon monoxide diffusion and exhaled breath temperature, at baseline and repeatedly for 23 h post-allergen challenge. RESULTS: Peripheral airway resistance, air trapping and ventilation heterogeneity were significantly increased in dual responders (n=15) compared to single responders (n=19) 6-8 h post-challenge. Parameters of peripheral airway resistance and ventilation heterogeneity, measured with IOS and inert gas washout, respectively, correlated at baseline and during the allergic airway response in all subjects. CONCLUSION: The LAR involves increased resistance and ventilation defects within the peripheral airways. Alternative definitions of the LAR including small airways pathophysiology could be considered. CLINICAL RELEVANCE: Small airway dysfunction during the LAR suggests that dual responders may have more extensive airway pathology and underscores the relevance of small airways assessment in asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170923IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28940836">PM:28940836</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20170923-StenbergH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20170923-StenbergH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170923, Stenberg H</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13036</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42615</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kwon,H.J.</style></author><author><style face="normal" font="default"> Kim,J.M.</style></author><author><style face="normal" font="default"> Oh,W.J.</style></author><author><style face="normal" font="default"> Park,K.Y.</style></author><author><style face="normal" font="default"> Kim,M.N.</style></author><author><style face="normal" font="default"> Seo,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Chung-Ang University College of Medicine, Chung Ang University Hospital, 224-1 Heukseok-dong, Dongjak-ku, Seoul, 156-755, South Korea</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by a moisturizer containing iodopropynyl butylcarbamate</style></title><secondary-title><style face="normal" font="default">Clin Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="9" Year="2017">2017/9/22</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170923IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - LetterCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1111/ced.13242</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28940475">PM:28940475</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Dermatol\20170923-KwonHJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Dermatol\20170923-KwonHJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170923, Kwon HJ</style></custom2><misc3><style face="normal" font="default">10.1111/ced.13242</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42616</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Twardziok,M.</style></author><author><style face="normal" font="default"> Schroder,P.C.</style></author><author><style face="normal" font="default"> Krusche,J.</style></author><author><style face="normal" font="default"> Casaca,V.I.</style></author><author><style face="normal" font="default"> Illi,S.</style></author><author><style face="normal" font="default"> Bock,A.</style></author><author><style face="normal" font="default"> Loss,G.J.</style></author><author><style face="normal" font="default"> Kabesch,M.</style></author><author><style face="normal" font="default"> Toncheva,A.</style></author><author><style face="normal" font="default"> Roduit,C.</style></author><author><style face="normal" font="default"> Depner,M.</style></author><author><style face="normal" font="default"> Genuneit,J.</style></author><author><style face="normal" font="default"> Renz,H.</style></author><author><style face="normal" font="default"> Roponen,M.</style></author><author><style face="normal" font="default"> Weber,J.</style></author><author><style face="normal" font="default"> Braun-Fahrlander,C.</style></author><author><style face="normal" font="default"> Riedler,J.</style></author><author><style face="normal" font="default"> Lauener,R.</style></author><author><style face="normal" font="default"> Vuitton,D.A.</style></author><author><style face="normal" font="default"> Dalphin,J.C.</style></author><author><style face="normal" font="default"> Pekkanen,J.</style></author><author><style face="normal" font="default"> von Mutius,E.</style></author><author><style face="normal" font="default"> Schaub,B.</style></author><author><style face="normal" font="default"> Hyvarinen,A.</style></author><author><style face="normal" font="default"> Karvonen,A.M.</style></author><author><style face="normal" font="default"> Kirjavainen,P.</style></author><author><style face="normal" font="default"> Remes,S.</style></author><author><style face="normal" font="default"> Kaulek,V.</style></author><author><style face="normal" font="default"> Dalphin,M.L.</style></author><author><style face="normal" font="default"> Ege,M.</style></author><author><style face="normal" font="default"> Pfefferle,P.</style></author><author><style face="normal" font="default"> Doekes,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">LMU Munich, University Children's Hospital, Munich, Germany</style></auth-address><titles><title><style face="normal" font="default">Asthmatic farm children show increased CD3+CD8low T-cells compared to non-asthmatic farm children</style></title><secondary-title><style face="normal" font="default">Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="9" Year="2017">2017/9/13</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170917IS - 1521-7035 (Electronic)IS - 1521-6616 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United States -CO - Switzerland -CO - Finland -CO - Austria -CO - France -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.clim.2017.09.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28917722">PM:28917722</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Immunol\20170917-TwardziokM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Immunol\20170917-TwardziokM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170917, Twardziok M</style></custom2><misc3><style face="normal" font="default">10.1016/j.clim.2017.09.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42617</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Elieh Ali,K.D.</style></author><author><style face="normal" font="default"> Grauwet,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran</style></auth-address><titles><title><style face="normal" font="default">Role of Mast Cells in Regulation of T Cell Responses in Experimental and Clinical Settings</style></title><secondary-title><style face="normal" font="default">Clin Rev Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Rev Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="default">Mast cells secrete a wide spectrum of stored or newly synthesized pro-inflammatory, anti-inflammatory, and/or immunosuppressive mediators and express several costimulatory and inhibitory surface molecules. Mast cells finely tune activities of T cells, B cells, and regulatory cells and effectively contribute to the development of different T cell-associated responses by influencing their recruitment, activation, proliferation, and differentiation. The interaction between mast cells and T cells, with regard to cellular functionality and immune responses, can be assessed in both activating and inhibitory regulations. While Th2 cytokines, including IL-5 and IL-9, stimulate stem cell factor (SCF)-dependent proliferation of mast cells, Th1 cytokine IFN-gamma suppresses SCF-mediated differentiation of mast cell progenitors. Mast cell mediators such as CCL5 have a role in the recruitment of CD8+ T cells to viral infection sites where their ability in clearance of viral reservoirs is needed. The capacity of mast cells in presenting antigens by classes I and II MHC molecules to CD4+ and CD8+ T cells respectively is considered one of the main antigen-dependent interactions of mast cells with T cells. Interestingly, Tregs recruit mast cells to different sites through secretion of IL-9, while the OX40L (expressed on mast cell)-OX40(expressed on T cell) interaction inhibits the extent of the mast cell degranulation. Recently, the capability of exosomes to carry regulatory receptors of the mast cell surface and their role in T cell activation has been investigated. Functional interplay between mast cells and T cell subsets has been suggested primarily by investigating their co-localization in inflamed tissues and involvement of mast cells in autoimmune diseases. In this review, the interactions of mast cells with T cells are reviewed in cell-to-cell, cytokine, and exosome categories</style></abstract><notes><style face="normal" font="default">DA - 20170920IS - 1559-0267 (Electronic)IS - 1080-0549 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Iran -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s12016-017-8646-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28929455">PM:28929455</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Rev Allergy Immunol\20170920-EliehAliKD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Rev Allergy Immunol\20170920-EliehAliKD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170920, Elieh Ali KD</style></custom2><misc3><style face="normal" font="default">10.1007/s12016-017-8646-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42618</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kraus,L.F.</style></author><author><style face="normal" font="default"> Scheurmann,N.</style></author><author><style face="normal" font="default"> Frenzel,D.F.</style></author><author><style face="normal" font="default"> Tasdogan,A.</style></author><author><style face="normal" font="default"> Weiss,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, University of Ulm, 89081, Ulm, Germany</style></auth-address><titles><title><style face="normal" font="default">9-cis-Retinoic acid induces a distinct regulatory dendritic cell phenotype that modulates murine delayed-type allergy</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="9" Year="2017">2017/9/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hand eczema, which is frequently caused by delayed-type allergy, is treated with 9-cis-retinoic acid (9cisRA). However, knowledge on how 9cisRA modulates skin immunity is sparse. OBJECTIVE: As dendritic cells (DCs) are central in the pathogenesis of contact allergy, we investigated 9cisRA modulation of DC function in murine contact hypersensitivity (CHS). METHODS: 9cisRA-differentiated DCs (9cisRA-DCs) were analysed for phenotype and function. In vivo 9cisRA-DCs were tested in the CHS model. RESULTS: 9cisRA induces the differentiation of a distinct C</style></abstract><notes><style face="normal" font="default">DA - 20170912IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12868</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28895168">PM:28895168</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170912-KrausLF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170912-KrausLF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170912, Kraus LF</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12868</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42619</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hassan,I.</style></author><author><style face="normal" font="default"> Rasool,F.</style></author><author><style face="normal" font="default"> Akhtar,S.</style></author><author><style face="normal" font="default"> Kamili,A.</style></author><author><style face="normal" font="default"> Rather,P.</style></author><author><style face="normal" font="default"> Kanth,R.</style></author><author><style face="normal" font="default"> Bhat,Y.</style></author><author><style face="normal" font="default"> Rather,S.</style></author><author><style face="normal" font="default"> Mubashir,S.</style></author><author><style face="normal" font="default"> Yaseen,A.</style></author><author><style face="normal" font="default"> Bashir,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Sexually Transmitted Diseases &amp; Leprosy, Government Medical College and Associated Hospitals, 190010, Srinagar, India</style></auth-address><titles><title><style face="normal" font="default">Contact dermatitis caused by tulips: identification of contact sensitizers in tulip workers of Kashmir Valley in North India</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: Tulip, belonging to the genus Tulipa and family Liliaceae, is a spring-blooming perennial that grows from bulbs. Owing to manual handling, contact dermatitis can occur in professionals at any stage of the growth cycle of the tulip plant. OBJECTIVES: To determine the clinical pattern of contact dermatitis resulting from tulip plant cultivation, and to assess contact allergy in workers coming into contact with this plant. METHODS: One hundred and sixty-four tulip workers were screened, and 48 patients with suspected contact dermatitis were patch tested with 39 allergens, including haptens from the Indian baseline series, a plant series, and extracts from different parts of the tulip plant. RESULTS: Thirty-nine positive patch test reactions were observed in 21 patients. Seventeen patients showed positive reactions to either alpha-methylene-gamma-butyrolactone or to tulip plant extract. Clinical relevance was observed for 13 of 17 positive patch test reactions. CONCLUSIONS: Contact dermatitis is an important health hazard in workers dealing with tulip bulbs. Further studies to identify and isolate other possible tulip allergens, and to quantify the amounts of allergens in different parts of the tulip plant, are recommended</style></abstract><notes><style face="normal" font="default">DA - 20170923IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12870</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28940507">PM:28940507</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170923-HassanI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170923-HassanI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170923, Hassan I</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12870</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42620</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fransen,M.</style></author><author><style face="normal" font="default"> Overgaard,L.E.K.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, National Allergy Research Centre, Herlev and Gentofte Hospital, University of Copenhagen, 2900 Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Contact allergy to lanolin: temporal changes in prevalence and association with atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: Lanolin has been tested as lanolin alcohols (30% pet.) in baseline patch test series since 1969, and this has shown clinically relevant allergic contact dermatitis cases. OBJECTIVES: To investigate the temporal development of lanolin allergy (i.e. positive reaction to lanolin alcohols and/or Amerchol L-101), and the association between contact allergy to lanolin and patient characteristics from the MOAHLFA index. METHODS: A retrospective observational study of consecutively patch tested dermatitis patients (n = 9577) between 1 January 2004 and 31 December 2015 with lanolin alcohols 30% pet. and Amerchol L-101 50% pet. was performed. RESULTS: The prevalence of lanolin allergy increased from 0.45% in 2004 to 1.81% in 2015. In age-adjusted and sex-adjusted analyses, weak, significant associations were found between atopic dermatitis and lanolin and lanolin alcohols allergy, respectively, but no association with Amerchol L-101 allergy was found. Among 9286 dermatitis patients who were tested with both allergens, 108 had a positive test reaction to either lanolin alcohols or Amerchol L-101, whereas only 29 patients had positive test reactions to both markers. CONCLUSIONS: The prevalence of lanolin contact allergy has increased over a 12-year period, and inclusion of Amerchol L-101 will increase the chance of detecting lanolin contact allergy. Patch testing with lanolin is helpful in atopics with dermatitis and suspected cosmetic allergy</style></abstract><notes><style face="normal" font="default">DA - 20170923IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12872</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28940210">PM:28940210</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170923-FransenM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170923-FransenM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170923, Fransen M</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12872</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42621</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Louisias,M.</style></author><author><style face="normal" font="default"> Phipatanakul,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, USA</style></auth-address><titles><title><style face="normal" font="default">Managing Asthma in Low-Income, Underrepresented Minority, and Other Disadvantaged Pediatric Populations: Closing the Gap</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="68">68-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="15" Month="9" Year="2017">2017/9/15</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: In this article, we review current understanding of the epidemiology and etiology of disparities in asthma. We also highlight current and emerging literature on solutions to tackle disparities while underscoring gaps and pressing future directions. RECENT FINDINGS: Tailored, multicomponent approaches including the home, school, and clinician-based interventions show great promise. Managing asthma in disadvantaged populations can be challenging as they tend to have disproportionately worse outcomes due to a multitude of factors. However, multifaceted, innovative interventions that are sustainable and scalable are key to improving outcomes</style></abstract><notes><style face="normal" font="default">DA - 20170915IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United states -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0734-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28914405">PM:28914405</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-68.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-68.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170915, Louisias M</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0734-x</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42622</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Medrek,S.K.</style></author><author><style face="normal" font="default"> Parulekar,A.D.</style></author><author><style face="normal" font="default"> Hanania,N.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Section of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, 1504 Taub Loop, Houston, TX, 77030, USA</style></auth-address><titles><title><style face="normal" font="default">Predictive Biomarkers for Asthma Therapy</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="69">69-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Asthma is a heterogeneous disease characterized by multiple phenotypes. Treatment of patients with severe disease can be challenging. Predictive biomarkers are measurable characteristics that reflect the underlying pathophysiology of asthma and can identify patients that are likely to respond to a given therapy. This review discusses current knowledge regarding predictive biomarkers in asthma. RECENT FINDINGS: Recent trials evaluating biologic therapies targeting IgE, IL-5, IL-13, and IL-4 have utilized predictive biomarkers to identify patients who might benefit from treatment. Other work has suggested that using composite biomarkers may offer enhanced predictive capabilities in tailoring asthma therapy. Multiple biomarkers including sputum eosinophil count, blood eosinophil count, fractional concentration of nitric oxide in exhaled breath (FeNO), and serum periostin have been used to identify which patients will respond to targeted asthma medications. Further work is needed to integrate predictive biomarkers into clinical practice</style></abstract><notes><style face="normal" font="default">DA - 20170920IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0739-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28929293">PM:28929293</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-69.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-69.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170920, Medrek SK</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0739-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42623</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Muglia,C.</style></author><author><style face="normal" font="default"> Oppenheimer,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Rutgers New Jersey Medical School, The State University of New Jersey, 90 Bergen Street, Newark, NJ, 07103, USA</style></auth-address><titles><title><style face="normal" font="default">Wheezing in Infancy: An Overview of Recent Literature</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="67">67-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Wheezing in infancy is a common presentation with many potential causes. In writing this review, we sought to summarize the newest recommendations and testing available for the more common etiologies of wheezing. RECENT FINDINGS: Regarding the diagnosis of asthma, the modified asthma predictive index has recently been established as a useful predictive tool. Non-breath held multidetector CT with 3D volume rendering airway images is also a newer helpful diagnostic tool for tracheomalacia due to ease of use and its 100% positive predictive value. We found vaccines have greatly reduced the prevalence of epiglottitis, while advances in surgery are improving outcomes in infants with vascular rings. Wheezing in infants is a common problem with an extensive differential diagnosis from relatively benign to life threatening. To prevent over-looking a diagnosis that potentially requires surgical correction or emergent care, we recommend a structured approach to the history and physical exam with targeted testing directed towards the most likely diagnoses as outlined in this review</style></abstract><notes><style face="normal" font="default">DA - 20170912IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United states -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0737-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28895039">PM:28895039</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-67.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-67.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170912, Muglia C</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0737-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42624</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cosmi,L.</style></author><author><style face="normal" font="default"> Liotta,F.</style></author><author><style face="normal" font="default"> Maggi,L.</style></author><author><style face="normal" font="default"> Annunziato,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Experimental and Clinical Medicine and DENOTHE Center, University of Florence, 50134, Florence, Italy</style></auth-address><titles><title><style face="normal" font="default">Role of Type 2 Innate Lymphoid Cells in Allergic Diseases</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="66">66-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: The adaptive immune response orchestrated by type 2 T helper (Th2) lymphocytes, strictly cooperates with the innate response of group 2 innate lymphoid cells (ILC2), in the protection from helminths infection, as well as in the pathogenesis of allergic disease. The aim of this review is to explore the pathogenic role of ILC2 in different type 2-mediated disorders. RECENT FINDINGS: Recent studies have shown that epithelial cell-derived cytokines and their responding cells, ILC2, play a pathogenic role in bronchial asthma, chronic rhinosinusitis, and atopic dermatitis. The growing evidences of the contribution of ILC2 in the induction and maintenance of allergic inflammation in such disease suggest the possibility to target them in therapy. Biological therapies blocking ILC2 activation or neutralizing their effector cytokines are currently under evaluation to be used in patients with type 2-dominated diseases</style></abstract><notes><style face="normal" font="default">DA - 20170912IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0735-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28895020">PM:28895020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-66.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-66.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170912, Cosmi L</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0735-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42625</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shastri,M.D.</style></author><author><style face="normal" font="default"> Peterson,G.M.</style></author><author><style face="normal" font="default"> Patel,R.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Health Sciences, Faculty of Health, University of Tasmania, Launceston, TAS, Australia.</style></auth-address><titles><title><style face="normal" font="default">Redefining Approaches to Asthma: Bridging the Gap Between Heparin and Its Anti-inflammatory Activities</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="70">70-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Heparin is widely used as an anticoagulant. Currently, this macromolecule is at the forefront in the field of glycobiology because of the recognition of its therapeutic potential in a wide range of medical conditions including inflammation. Heparin is composed of anticoagulant and non-anticoagulant molecules. A large body of evidence suggests that the anti-inflammatory activities of heparin are attributed to its non-anticoagulant molecules and are therefore independent to its anticoagulant effect. However, the potential therapeutic use of heparin in inflammatory conditions is hindered by the presence of anticoagulant molecules causing the risk of bleeding. Therefore, there is an emerging interest in identifying non-anticoagulant molecules of heparin responsible for the anti-inflammatory effects of the parent molecule. The present editorial commentary focuses on the non-anticoagulant applications of heparin for the management of asthma. The commentary concisely describes the plausible mechanisms of action of heparin involved in the therapy of asthma. It also discusses various approaches that are utilised for the development of novel non-anticoagulant analogues of heparin that possess the potent anti-asthmatic activity of the parent molecule but are devoid of anticoagulant effect. We also briefly outline potential future approaches for the use of this molecule as an effective anti-inflammatory agent</style></abstract><notes><style face="normal" font="default">DA - 20170920IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0738-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28929391">PM:28929391</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-70.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170920, Shastri MD</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0738-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42626</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kling,S.</style></author><author><style face="normal" font="default"> Kruger,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Can children refuse medical treatment?</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="182" start="179">179-182</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Children are increasingly recognised as being capable of making decisions regarding their own healthcare.This is reflected in international guidelines as well as South African legislation, where children as young as12 years of age may consent to medical treatment. However, when it comes to treatment refusal, clinicianshave a moral obligation to investigate and, if necessary, contest treatment refusal by the child and/orparents. Usually the best interests principle serves as guidance to clinicians in the choice of healthcareinterventions, but in this case it is probably more apt to apply the harm principle.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/Journal/J2017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-179-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-179-82.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Kling S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42627</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Warner,J.</style></author><author><style face="normal" font="default"> Spitters,S.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Integrating care for children with allergic diseases: the United Kingdom experience</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="178" start="172">172-178</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/Journal/J2017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-172-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-172-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Warner J</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42628</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Peter,J.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">NSAID hypersensitivity - an allergist's pain</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="169" start="162">162-169</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Non-steroidal anti-inflammatory drugs (NSAIDs) are a chemically diverse class of drugs that inhibit the cyclo-oxygenase pathway, decreasing pro-inflammatory prostenoid synthesis. They cause a number of adversereactions and are one of the most common causes of drug hypersensitivity with ~2% of the general adult populationreporting an NSAID allergy. Accurate diagnosis and clinical phenotyping is necessary to ensure patient safety,initiate appropriate therapy and limit the unnecessary restriction of different NSAIDs. Detailed history and oralprovocation testing is usually sufficient for diagnosis and management, with in vitro and skin testing of verylimited added value. Classification requires that the allergist distinguish immediate and delayed reactions; single-drug reactors from COX-1 cross-intolerance; as well as the presence of any associated cutaneous or respiratorydisease. Management involves either specific NSAIDs or avoidance of all COX-1 inhibitors; guideline-drivenmanagement of associated cutaneous and respiratory disease, and, where indicated, aspirin desensitisation.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/Journal/J2017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-162-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-162-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Peter JG</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42629</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Al Badri,F.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Surgical mask contact dermatitis and epidemiology of contact dermatitis in healthcare workers</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="188" start="183">183-188</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Although contact dermatitis in healthcare workers is common, there are very few case reports about surgicalmask dermatitis. Contact dermatitis due to N95 masks during the severe acute respiratory syndrome (SARS)pandemic has been documented in a few studies. It has been attributed to free formaldehyde which wasconfirmed to be present in certain types of N95 mask. None of the cases studied was found to be related todibromodicyanobutane, which is found predominantly as a preservative in detergents used in the healthcareenvironment. In this article a case is presented to illustrate important aspects of contact dermatitis in healthcareworkers, particularly surgical face-mask contact dermatitis. The article further explores dibromodicyanobutaneas a known cause of allergic contact dermatitis (ACD).</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/Journal/J2017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-183-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Clin Immunol\2017-30-183-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Al Badri FM</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42630</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Andersen,Y.M.F.</style></author><author><style face="normal" font="default"> Egeberg,A.</style></author><author><style face="normal" font="default"> Skov,L.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Kildegardsvej 28, 2900 Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Comorbidities of Atopic Dermatitis: Beyond Rhinitis and Asthma</style></title><secondary-title><style face="normal" font="default">Curr Dermatol Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Dermatol Rep</style></full-title></periodical><pages end="41" start="35">35-41</pages><volume><style face="normal" font="default">6</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: In this review article, we summarize the current evidence about atopic dermatitis (AD)-associated comorbidities, beyond the traditional atopic and allergic conditions. RECENT FINDINGS: Patients with AD may have an increased risk of cardiovascular diseases, certain malignancies, autoimmune diseases, and neuropsychiatric diseases. The causes of these associations are likely multifactorial and may include genetic predispositions, systemic low-grade inflammation, environmental exposures, medication, and lifestyle and behavioral risk factors. There appears to be geographical variations in prevalence of comorbidities in patients with AD, indicating that differences in ethnicity and lifestyle factors may significantly influence the risk of certain comorbidities. SUMMARY: The reported comorbidities in recent literature emphasize the burden of disease in patients with AD. Early appropriate AD therapy, in combination with reduction of risk factors, may help prevention of certain comorbidities. The reported observations may generate hypotheses for future investigations in underlying risk factors for AD-associated comorbidities</style></abstract><notes><style face="normal" font="default">DA - 20170911IS - 2162-4933 (Print)IS - 2162-4933 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1007/s13671-017-0168-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890845">PM:28890845</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Dermatol Rep\2017-6-35-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Dermatol Rep\2017-6-35-41.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170911, Andersen YM</style></custom2><misc3><style face="normal" font="default">10.1007/s13671-017-0168-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42631</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Su,X.</style></author><author><style face="normal" font="default"> Ren,Y.</style></author><author><style face="normal" font="default"> Li,M.</style></author><author><style face="normal" font="default"> Zhao,X.</style></author><author><style face="normal" font="default"> Kong,L.</style></author><author><style face="normal" font="default"> Kang,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Respiratory Medicine , Institute of Respiratory Diseases, The First Affiliated Hospital of China Medical University , Shenyang 110001 , People's Republic of China</style></auth-address><titles><title><style face="normal" font="default">Association between lipid profile and the prevalence of asthma: a meta-analysis and systemic review</style></title><secondary-title><style face="normal" font="default">Curr Med Res Opin</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Med Res Opin</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="9" Year="2017">2017/9/25</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To explore the association of asthma with serum levels of high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol, and triglyceride. METHODS: PubMed, Cochrane, and Embase databases were systematically searched through November 2015 using the following search terms: dyslipidemia, HDL, LDL, triglyceride, cholesterol, and asthma. Eligible studies included randomized controlled trials (RCTs), retrospective, cohort, and cross-sectional studies. Sensitivity analysis and publication bias were performed. RESULTS: Twenty studies were included in the analysis with a total 32,604 patients (3,458 in the asthma group and 29,146 in the control group). The pooled analysis found that the mean difference between groups was significantly higher in the asthma group for levels of LDL (6.026 mg/dL, 95%CI = 2.696 to 9.356, P&lt;.001) and total cholesterol (8.161 mg/dL, 95%CI = 3.006 to 13.316, P = 0.002) compared with the control group. No association was observed between asthma and control groups for levels of HDL (mean difference, -0.728, 95%CI=-3.146 to 1.691, P = 0.555) or triglycerides (mean difference, 1.436, 95%CI=-2.768 to 5.640, P = 0.503). CONCLUSIONS: Levels of LDL and total cholesterol were higher in patients with asthma than non-asthmatic patients</style></abstract><notes><style face="normal" font="default">DA - 20170925IS - 1473-4877 (Electronic)IS - 0300-7995 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1080/03007995.2017.1384371</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28945108">PM:28945108</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Med Res Opin\20170925-SuX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Med Res Opin\20170925-SuX.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170925, Su X</style></custom2><misc3><style face="normal" font="default">10.1080/03007995.2017.1384371</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42632</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Api,A.M.</style></author><author><style face="normal" font="default"> Parakhia,R.</style></author><author><style face="normal" font="default"> O'Brien,D.</style></author><author><style face="normal" font="default"> Basketter,D.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Research Institute for Fragrance Materials, Woodcliff Lake, NJ; and daggerDABMEB Consultancy Ltd, Sharnbrook, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Fragrances Categorized According to Relative Human Skin Sensitization Potency</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="307" start="299">299-307</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: The development of non-animal alternatives for skin sensitization potency prediction is dependent upon the availability of a sufficient dataset whose human potency is well characterized. Previously, establishment of basic categorization criteria for 6 defined potency categories, allowed 131 substances to be allocated into them entirely on the basis of human information. OBJECTIVES: To supplement the original dataset with an extended range of fragrance substances. METHODS: A more fully described version of the original criteria was used to assess 89 fragrance chemicals, allowing their allocation into one of the 6 potency categories. RESULTS: None of the fragrance substances were assigned to the most potent group, category 1, whereas 11 were category 2, 22 were category 3, 37 were category 4, and 19 were category 5. Although none were identified as non-sensitizing, note that substances in category 5 also do not pass the threshold for regulatory classification. CONCLUSIONS: The combined datasets of >200 substances placed into potency categories solely on the basis of human data provides an essential resource for the elaboration and evaluation of predictive non-animal methods</style></abstract><notes><style face="normal" font="default">DA - 20170710IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000304</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28691948">PM:28691948</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-299-307.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-299-307.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170710, Api AM</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000304</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42633</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aschenbeck,K.A.</style></author><author><style face="normal" font="default"> Warshaw,E.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Minnesota School of Medicine, Minneapolis, Department of Dermatology, Minneapolis Veterans Affairs Medical Center, MN, HCMC Parkside Occupational and Contact Dermatitis Clinic, Minneapolis, MN Department of Dermatology, Minneapolis Veterans Affairs Medical Center, MN, HCMC Parkside Occupational and Contact Dermatitis Clinic, Minneapolis, MN, Department of Dermatology, University of Minnesota, Minneapolis</style></auth-address><titles><title><style face="normal" font="default">Allergenic Ingredients in Hand Wet Wipes</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="330" start="329">329-330</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170908IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000311</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28885311">PM:28885311</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-329-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-329-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170908, Aschenbeck KA</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000311</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42634</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Isaac,J.</style></author><author><style face="normal" font="default"> Scheinman,P.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Tufts University School of Medicine and daggerDepartment of Dermatology, Brigham and Women's Hospital, Boston, MA</style></auth-address><titles><title><style face="normal" font="default">Benzalkonium Chloride: An Irritant and Sensitizer</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="9" Year="2017">2017/9/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Benzalkonium chloride (BAK) is a known irritant, and potentially cross-reacting quaternary ammonium compounds are commonly used as preservatives in personal care products. OBJECTIVE: The aim of the study was to review positive reactions to BAK in 615 patients patch tested for suspected allergic contact dermatitis. METHODS: A retrospective chart review was performed in 615 patients patch tested from June 2015 to October 2016. All patients were tested to a Modified American Contact Dermatitis Society core series of 70 allergens including BAK (0.1% aqueous). Initial readings were performed at 48 hours with final readings performed between 72 and 168 hours. Results were graded as + (weak: papules and erythema), ++ (strong: papules and edema or vesicles), or +++ (extreme: coalescing vesicles, spreading or bullous reactions). RESULTS: A total of 141 men (23%) and 475 women (77%) were tested (mean age, 49 years). Four hundred thirty-two (70%) were atopic. Of 615 patients, 198 (32%) tested positive to BAK, and 64 (10%) had ++ or +++ reactions at their final reading. On average, BAK-positive patients were using at least 1 product containing BAK or possible cross-reactors. CONCLUSIONS: Widespread exposure to irritants in dermatitis patients can predispose to sensitization. Products containing BAK or potential cross-reactors should be used carefully in patients with compromised skin barriers</style></abstract><notes><style face="normal" font="default">DA - 20170908IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000316</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28885313">PM:28885313</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\20170908-IsaacJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\20170908-IsaacJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170908, Isaac J</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000316</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42635</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Filon,F.L.</style></author><author><style face="normal" font="default"> Bongiorni,L.</style></author><author><style face="normal" font="default"> Prodi,A.</style></author><author><style face="normal" font="default"> Rui,F.</style></author><author><style face="normal" font="default"> Fortina,A.B.</style></author><author><style face="normal" font="default"> Corradin,M.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical Unit of Occupational Medicine, University of Trieste, Italy larese@units.it Sezione di Dermatologia Pediatrica, Dipartimento di Salute della Donna e del Bambino, Padova, Italy Divisione di Dermatologia, Ospedale Santa Maria degli Angeli, Pordenone, Italy</style></auth-address><titles><title><style face="normal" font="default">Effectiveness of European Regulation on Euxyl K400 Sensitization in Northeastern Italy From 1996 to 2012 and Occupation</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="328" start="327">327-328</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170908IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000296</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28885309">PM:28885309</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-327-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-327-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170908, Filon FL</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000296</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42636</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hsu,C.Y.</style></author><author><style face="normal" font="default"> Liu,D.</style></author><author><style face="normal" font="default"> Lee,W.R.</style></author><author><style face="normal" font="default"> Shih,Y.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Department of Dermatology, Taipei Medical University Shuang Ho Hospital; and daggerDepartment of Dermatology, School of Medicine, and double daggerGraduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taiwan</style></auth-address><titles><title><style face="normal" font="default">Lichen Planus Pigmentosus Inversus Caused by Occupational Systemic Sensitization to Metals in a Semiconductor Factory Worker</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="326" start="324">324-326</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170614IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000292</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28614105">PM:28614105</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-324-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-324-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170614, Hsu CY</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000292</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42637</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Awosika,O.</style></author><author><style face="normal" font="default"> Kao,S.</style></author><author><style face="normal" font="default"> Rengifo-Pardo,M.</style></author><author><style face="normal" font="default"> Ehrlich,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Department of Dermatology, The George Washington Medical Faculty Associates; and daggerThe George Washington University School of Medicine &amp; Health Sciences, DC</style></auth-address><titles><title><style face="normal" font="default">Angioedema, Stomatitis, and Urticaria Caused by Contact Allergy to Invisalign</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="324" start="323">323-324</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170908IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000314</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28885312">PM:28885312</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-323-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-323-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170908, Awosika O</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000314</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42638</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nath,N.S.</style></author><author><style face="normal" font="default"> Liu,B.</style></author><author><style face="normal" font="default"> Green,C.</style></author><author><style face="normal" font="default"> Atwater,A.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Duke University School of Medicine and Departments of daggerBiostatistics and Bioinformatics and double daggerDermatology, Duke University Medical Center, Durham, NC</style></auth-address><titles><title><style face="normal" font="default">Contact Allergy to Hydroperoxides of Linalool and D-Limonene in a US Population</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="316" start="313">313-316</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Linalool and D-limonene are common fragrance ingredients that readily oxidize on exposure to air. The resulting hydroperoxides of linalool and D-limonene have been shown to have high frequencies of positive patch test reactions in several European and international studies. OBJECTIVE: The aim of the study was to investigate the prevalence of contact allergy to the hydroperoxides of linalool and D-limonene in a US population. METHODS: In this retrospective study, 103 patients with suspected fragrance allergy were patch tested to linalool 10% petrolatum (pet), hydroperoxides of linalool 1% pet, D-limonene 10% pet, and/or the hydroperoxides of D-limonene 0.3% pet between July 9, 2014, and October 25, 2016. CONCLUSIONS: In this study, the frequency of positive patch test reactions to the hydroperoxides of linalool is 20% (19/96), and the frequency of positive reactions to the hydroperoxides of D-limonene is 8% (7/90). These high frequencies suggest that patch testing to the hydroperoxides of linalool and limonene should be performed in all patients with suspected fragrance allergy</style></abstract><notes><style face="normal" font="default">DA - 20170908IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000318</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28885310">PM:28885310</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-313-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-313-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170908, Nath NS</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000318</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42639</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kawada,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">Atopic Dermatitis and Sleep Disturbance in Adults</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="" start="328">328-</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170524IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000286</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28538008">PM:28538008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-328.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-328.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170524, Kawada T</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000286</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42640</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Silverberg,J.I.</style></author><author><style face="normal" font="default"> Yu,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departments of Dermatology Preventive Medicine, and Medical Social Sciences, Feinberg School of Medicine at Northwestern University, Northwestern Medicine, Multidisciplinary Eczema Center, Chicago, IL JonathanISilverberg@gmail.com Department of Dermatology, Case Western Reserve University, Cleveland, OH</style></auth-address><titles><title><style face="normal" font="default">Measuring Sleep Disturbance in Atopic Dermatitis: Patient-Reported Versus Objective Outcomes</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="329" start="328">328-329</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170524IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000284</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28538010">PM:28538010</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-328-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-328-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170524, Silverberg JI</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000284</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42641</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sheikhi,A.</style></author><author><style face="normal" font="default"> Giti,H.</style></author><author><style face="normal" font="default"> Heibor,M.R.</style></author><author><style face="normal" font="default"> Jafarzadeh,A.</style></author><author><style face="normal" font="default"> Shakerian,M.</style></author><author><style face="normal" font="default"> Baharifar,N.</style></author><author><style face="normal" font="default"> Niruzad,F.</style></author><author><style face="normal" font="default"> Moghaddam,A.S.</style></author><author><style face="normal" font="default"> Kokhaei,P.</style></author><author><style face="normal" font="default"> Baghaeifar,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dpartment of Immunology, Faculty of Medicine, Dezful University of Medical Sciences, Dezful, Iran</style></auth-address><titles><title><style face="normal" font="default">Lactobacilus Delbrueckii subsp. Bulgaricus Modulates the Secretion of Th1/Th2 and Treg Cell-Related Cytokines by PBMCs from Patients with Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">Drug Res (Stuttg)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Drug Res (Stuttg)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="9" Year="2017">2017/9/12</year></dates><abstract><style face="normal" font="default">Background Atopic dermatitis (AD) is an inflammatory skin disease which may be due to the imbalance between Th1-, Th2 and Treg cell-related immune responses. Evidences suggest that appropriate stimulation with probiotics may correct the skewed immune response in children with AD. The aim was to determine the effects of the yogurt culture lactobacillus Bulgaricus on the secretion of Th1/Th2/Treg type cytokines by PBMCs from children with AD. MethodsL. Bulgaricus was cultivated on MRS broth. The PBMCs from 20 children with AD were separated by Ficoll-Hypaque centrifugation and co-cultured with different concentrations of UV killed bacteria in RPMI-1640 plus 10% FCS for 48/72 h. The levels of IL-10, IL-4, IL-12 and IFN-gamma were measured in supernatant of PBMCs by ELISA. ResultsL. Bulgaricus significantly up-regulated the secretion of IL-10, IL-12 and IFN-gamma, whereas decreased the secretion of IL-4 by PBMCs at both incubation times 48 h/72 h and both bacteria:PBMCs ratios 100:1/50:1, compared to control (p&lt;0.05). There were no significant differences between incubation times 48 h and 72 h regarding the secretion levels of IL-12, IFN-gamma and IL-4. However, the secretion of IL-10 by L. Bulgaricus-stimulated PBMCs at incubation time 72 h and in the presence of bacteria:PBMCs ratio 100:1 was significantly higher than in incubation time 48 h and in the presence of bacteria:PBMCs ratio 50:1 (P&lt;0.000 and P&lt;0.00, respectively). Conclusion These data show that L. Bulgaricus may modulate the secretion of Th1-, Th2-Treg-related cytokines in AD patients. Therefore, the possible potential therapeutic of L. Bulgaricus for treatment of AD should be consider in further investigation</style></abstract><notes><style face="normal" font="default">DA - 20170912IS - 2194-9387 (Electronic)IS - 2194-9379 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">10.1055/s-0043-117612</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28898911">PM:28898911</url></web-urls></urls><custom2><style face="normal" font="default">20170912, Sheikhi A</style></custom2><misc3><style face="normal" font="default">10.1055/s-0043-117612</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42642</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kia,N.S.</style></author><author><style face="normal" font="default"> Malek,F.</style></author><author><style face="normal" font="default"> Ghods,E.</style></author><author><style face="normal" font="default"> Fathi,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Community Medicine, Research Centre for Social Determinants of Health, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Islamic Republic of Iran</style></auth-address><titles><title><style face="normal" font="default">Health-related quality of life of patients with asthma: a cross-sectional study in Semnan, Islamic Republic of Iran</style></title><secondary-title><style face="normal" font="default">East Mediterr Health J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">East Mediterr Health J</style></abbr-1></periodical><pages end="506" start="500">500-506</pages><volume><style face="normal" font="default">23</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="8" Year="2017">2017/8/27</year></dates><abstract><style face="normal" font="default">Asthma can profoundly affect the quality of life of individuals with the disease. There are limited data on the quality of life of people with asthma in the Islamic Republic of Iran. This cross-sectional study aimed to evaluate quality of life in adults with asthma in Semnan using the 36-item short form health survey (SF-36). The effect of sociodemographic characteristics on quality of life scores was examined. The study included a convenience sample of 385 outpatients with asthma attending a pulmonary clinic from June to December 2013. The mean physical and mental component scores were 58.8 (SD 18.3) and 57.3 (SD 17.0) respectively. The study sample had lower quality of life scores in all the fields than the reference population (P &lt; 0.05). Patients with lower education, urban residents, widowed/divorced patients and manual workers had lower quality of life scores (P &lt; 0.05). Efforts are needed to improve the quality of life of people with asthma in parallel with precise management plans</style></abstract><notes><style face="normal" font="default">DA - 20170830IS - 1020-3397 (Print)IS - 1020-3397 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28853134">PM:28853134</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\East Mediterr Health J\2017-23-500-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\East Mediterr Health J\2017-23-500-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170830, Kia NS</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42643</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Moustaki,M.</style></author><author><style face="normal" font="default"> Tsabouri,S.</style></author><author><style face="normal" font="default"> Priftis,K.</style></author><author><style face="normal" font="default"> Douros,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Allergy and Respiratory Unit, 3rd Department of Pediatrics, "Attikon" Hospital, University of Athens School of Medicine, Athens. Greece</style></auth-address><titles><title><style face="normal" font="default">Prenatal stress enhances susceptibility to allergic diseases of offspring</style></title><secondary-title><style face="normal" font="default">Endocr Metab Immune Disord Drug Targets</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Endocr Metab Immune Disord Drug Targets</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="9" Year="2017">2017/9/12</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVES: Maternal prenatal stress (MPS) may result in a range of long-term consequences in the offspring among which is susceptibility to allergic diseases. This review presents the current knowledge on the pathways through which MPS may affect the fetus, and the existing evidence regarding the association between MPS and development of allergy in the offspring. RESULT AND DISCUSSION: A pivotal mediator triggered in response to stress is the release of glucocorticoids (GC). GC may affect gene expression through binding to GC receptors, thus affecting fetal development in general, and allergic vulnerability in particular. A series of recent findings also indicate that MPS may affect the fetus programming of immune functions and lead to vulnerability of the immune system. MPS may hinder the gradual process in the offspring's cytokine production towards a Th1 type immune response. Prenatal factors may also influence the intrauterine microbiome and thereby the maternal bacteria transferred into the fetal gastrointestinal tract. The imbalances of intestinal microbiota in infancy could result in deviations in the development of systemic immune function, predisposing to allergic sensitization. Epidemiological studies in humans also suggest that there is an association of MPS and allergic vulnerability of the offspring. CONCLUSION: Although the existing evidence support a relationship of MPS with allergic predisposition of the offspring, further studies are needed to elucidate whether the association is dependent on the type of stress and whether it involves any type of allergic predisposition or not</style></abstract><notes><style face="normal" font="default">DA - 20170913IS - 2212-3873 (Electronic)IS - 1871-5303 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="default">10.2174/1871530317666170912160646</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28901864">PM:28901864</url></web-urls></urls><custom2><style face="normal" font="default">20170913, Moustaki M</style></custom2><misc3><style face="normal" font="default">10.2174/1871530317666170912160646</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42644</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Magrone,T.</style></author><author><style face="normal" font="default"> Romita,P.</style></author><author><style face="normal" font="default"> Verni,P.</style></author><author><style face="normal" font="default"> Salvatore,R.</style></author><author><style face="normal" font="default"> Spagnoletta,A.</style></author><author><style face="normal" font="default"> Magrone,M.</style></author><author><style face="normal" font="default"> Russo,M.A.</style></author><author><style face="normal" font="default"> Jirillo,E.</style></author><author><style face="normal" font="default"> Foti,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Basic Medical Sciences, Neuroscience and Sensory Organs, University of Bari, School of Medicine, Bari. Italy</style></auth-address><titles><title><style face="normal" font="default">In vitro effects of polyphenols on the peripheral immune responses in nickel-sensitized patients</style></title><secondary-title><style face="normal" font="default">Endocr Metab Immune Disord Drug Targets</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Endocr Metab Immune Disord Drug Targets</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="3" Month="10" Year="2017">2017/10/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Nickel (Ni) is a metal largely present in the environment and prolonged exposure to it may lead to multiple pathological conditions in human subjects. Among these, the most frequent is allergic contact dermatitis. METHODS: Peripheral blood mononuclear cells isolated from 25 patients with Ni-dependent contact dermatitis were evaluated in terms of cytokine release and nitric oxide (NO) production in the presence or absence of two doses (3 and 5 mug, respectively) of polyphenols. RESULTS: Polyphenols were able to reduce the increased release of interferon-g and interleukin (IL)-4, while maintaining the equilibrium between IL-10 and IL-17. At the same time, exaggerated release of NO was reduced by polyphenol supplementation. CONCLUSION: In view of their anti-inflammatory activities, polyphenols may represent a potential therapeutic tool to treat Ni-sensitized patients</style></abstract><notes><style face="normal" font="default">DA - 20171006IS - 2212-3873 (Electronic)IS - 1871-5303 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.2174/1871530317666171003161314</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28982342">PM:28982342</url></web-urls></urls><custom2><style face="normal" font="default">20171006, Magrone T</style></custom2><misc3><style face="normal" font="default">10.2174/1871530317666171003161314</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42645</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Noonan,C.W.</style></author><author><style face="normal" font="default"> Semmens,E.O.</style></author><author><style face="normal" font="default"> Smith,P.</style></author><author><style face="normal" font="default"> Harrar,S.W.</style></author><author><style face="normal" font="default"> Montrose,L.</style></author><author><style face="normal" font="default"> Weiler,E.</style></author><author><style face="normal" font="default"> McNamara,M.</style></author><author><style face="normal" font="default"> Ward,T.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Public and Community Health Sciences, University of Montana , Missoula, Montana, USA</style></auth-address><titles><title><style face="normal" font="default">Randomized Trial of Interventions to Improve Childhood Asthma in Homes with Wood-burning Stoves</style></title><secondary-title><style face="normal" font="default">Environ Health Perspect</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Environ Health Perspect</style></full-title></periodical><pages end="" start="097010">097010-</pages><volume><style face="normal" font="default">125</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="9" Year="2017">2017/9/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: Household air pollution due to biomass combustion for residential heating adversely affects vulnerable populations. Randomized controlled trials to improve indoor air quality in homes of children with asthma are limited, and no such studies have been conducted in homes using wood for heating. OBJECTIVES: Our aims were to test the hypothesis that household-level interventions, specifically improved-technology wood-burning appliances or air-filtration devices, would improve health measures, in particular Pediatric Asthma Quality of Life Questionnaire (PAQLQ) scores, relative to placebo, among children living with asthma in homes with wood-burning stoves. METHODS: A three-arm placebo-controlled randomized trial was conducted in homes with wood-burning stoves among children with asthma. Multiple preintervention and postintervention data included PAQLQ (primary outcome), peak expiratory flow (PEF) monitoring, diurnal peak flow variability (dPFV, an indicator of airway hyperreactivity) and indoor particulate matter (PM) PM2.5. RESULTS: Relative to placebo, neither the air filter nor the woodstove intervention showed improvement in quality-of-life measures. Among the secondary outcomes, dPFV showed a 4.1 percentage point decrease in variability [95% confidence interval (CI)=-7.8 to -0.4] for air-filtration use in comparison with placebo. The air-filter intervention showed a 67% (95% CI: 50% to 77%) reduction in indoor PM2.5, but no change was observed with the improved-technology woodstove intervention. CONCLUSIONS: Among children with asthma and chronic exposure to woodsmoke, an air-filter intervention that improved indoor air quality did not affect quality-of-life measures. Intent-to-treat analysis did show an improvement in the secondary measure of dPFV. TRIAL REGISTRATION: ClincialTrials.gov NCT00807183. https://doi.org/10.1289/EHP849</style></abstract><notes><style face="normal" font="default">DA - 20170922IS - 1552-9924 (Electronic)IS - 0091-6765 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1289/EHP849</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28935614">PM:28935614</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Environ Health Perspect\2017-125-097010.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Environ Health Perspect\2017-125-097010.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170922, Noonan CW</style></custom2><misc3><style face="normal" font="default">10.1289/EHP849</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42646</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hehua,Z.</style></author><author><style face="normal" font="default"> Qing,C.</style></author><author><style face="normal" font="default"> Shanyan,G.</style></author><author><style face="normal" font="default"> Qijun,W.</style></author><author><style face="normal" font="default"> Yuhong,Z.</style></author></authors></contributors><auth-address><style face="normal" font="default">Shengjing Hospital of China Medical University, Huaxiang Road No. 39, Tiexi District, China</style></auth-address><titles><title><style face="normal" font="default">The impact of prenatal exposure to air pollution on childhood wheezing and asthma: A systematic review</style></title><secondary-title><style face="normal" font="default">Environ Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Environ Res</style></abbr-1></periodical><pages end="530" start="519">519-530</pages><volume><style face="normal" font="default">159</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="9" Year="2017">2017/9/6</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVES: There has been no clear consensus about whether prenatal exposure to air pollution contributes to the development of wheezing and asthma in children. We conducted a systematic review to analyze the association between exposure to different pollutants during pregnancy and the development of childhood wheezing and asthma. METHODS: We systematically reviewed epidemiological studies published through June 6, 2017 available in the MEDLINE and Web of Science databases. We included studies that examined the association between prenatal exposure to any air pollutants except tobacco smoke and the incidence or prevalence of "wheezing" or "asthma" from birth to 14 years of age. We extracted key characteristics of each included study using a template of predefined data items. We used the Critical Appraisal Skills Programme checklists to assess the validity of each included study. We conducted overall and subgroup meta-analyses for each summary exposure-outcome association. Pooled odds ratios (OR) with 95% confidence intervals (CI) were estimated by using a random effects model. RESULTS: Eighteen studies met our eligibility criteria. There was notable variability in exposure assessment methods. The overall random effects risk estimates (95% CI) of different pollutants were 1.04 (0.94-1.15) aromatic hydrocarbons (PAH), 1.04 (1.01-1.07) NO2, 1.4 (0.97-2.03) PM2.5 for childhood wheeze and 1.07 (1.01-1.14) NO2, 1 (0.97-1.03) PM2.5, 1.02 (0.98-1.07) SO2, 1.08 (1.05-1.12) PM10 for childhood asthma. Minimal heterogeneity was seen for PAH and SO2, while some heterogeneity was observed for PM10, PM2.5 and NO2. CONCLUSIONS: The overall and subgroup risk estimates from the meta-analyses showed statistically significant associations between prenatal exposures to NO2, SO2, and PM10 and the risk of wheezing and asthma development in childhood. There is insufficient evidence to show an effect of prenatal exposure to BC, CO, and O3 on childhood wheezing and asthma. Further studies are needed to examine the individual compounds' effects</style></abstract><notes><style face="normal" font="default">DA - 20170909IS - 1096-0953 (Electronic)IS - 0013-9351 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.envres.2017.08.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888196">PM:28888196</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Environ Res\2017-159-519-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Environ Res\2017-159-519-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170909, Hehua Z</style></custom2><misc3><style face="normal" font="default">10.1016/j.envres.2017.08.038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42647</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Andrusaityte,S.</style></author><author><style face="normal" font="default"> Grazuleviciene,R.</style></author><author><style face="normal" font="default"> Petraviciene,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Environmental Sciences, Vytauto Didziojo Universitetas, K. Donelaicio str. 58, Kaunas 44248, Lithuania.</style></auth-address><titles><title><style face="normal" font="default">Effect of diet and maternal education on allergies among preschool children: A case-control study</style></title><secondary-title><style face="normal" font="default">Environ Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Environ Res</style></abbr-1></periodical><pages end="380" start="374">374-380</pages><volume><style face="normal" font="default">159</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword><keyword><style face="normal" font="default"> Cities</style></keyword><keyword><style face="normal" font="default"> Diet</style></keyword><keyword><style face="normal" font="default"> Science</style></keyword></keywords><dates><year Day="24" Month="8" Year="2017">2017/8/24</year></dates><abstract><style face="normal" font="default">INTRODUCTION: The prevalence of asthma and allergy has increased among children. This increase in prevalence might be related to dietary patterns. AIMS: The present epidemiological study investigated the relationship between the consumption of fruit, vegetables, nuts, meat and fish, and the prevalence of wheeze, asthma, and eczema among preschool children. METHODS: This nested case-control study included 1489 children aged 4-6 years and residing in Kaunas city, Lithuania. The subjects were recruited to the KANC newborn cohort study during 2007-2009. Parents' responses to questionnaires were used to collect information on allergic diseases, diet, and other variables. The association between dietary patterns and children's allergic diseases were tested by using logistic regressions, after adjustment for maternal education level, smoking during pregnancy, parental asthma, children's sex, parity, and antibiotic usage during the first year of life. RESULTS: In this study, 83.3% of all children consumed fresh fruit and/or vegetables at least three times per week. A significantly lower adjusted odds ratio (aOR) of wheeze was found among children who ate fruit than among those who did not (aOR: 0.48; 95% CI: 0.22-0.96). The consumption of nuts was also associated with a lower 61% risk of eczema among 4-6 years old children. CONCLUSION: The results indicated a beneficial effect of a frequent consumption of fresh fruit and nuts on the prevalence of allergies among children. These results might have important implications for children's health</style></abstract><notes><style face="normal" font="default">DA - 20170827IS - 1096-0953 (Electronic)IS - 0013-9351 (Linking)LA - engPT - Journal ArticleCO - Lithuania -</style></notes><work-type><style face="normal" font="default">10.1016/j.envres.2017.08.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28843990">PM:28843990</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Environ Res\2017-159-374-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Environ Res\2017-159-374-80.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170827, Andrusaityte S</style></custom2><misc3><style face="normal" font="default">10.1016/j.envres.2017.08.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42648</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Azizi,G.</style></author><author><style face="normal" font="default"> Abolhassani,H.</style></author><author><style face="normal" font="default"> Yazdani,R.</style></author><author><style face="normal" font="default"> Mohammadikhajehdehi,S.</style></author><author><style face="normal" font="default"> Parvaneh,N.</style></author><author><style face="normal" font="default"> Negahdari,B.</style></author><author><style face="normal" font="default"> Mohammadi,J.</style></author><author><style face="normal" font="default"> Aghamohammadi,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Laboratory Medicine, Imam Hassan Mojtaba Hospital, Alborz University of Medical Sciences, Karaj, Iran. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran. Primary Immunodeficiency Diseases Network (PIDNet), Universal Scientific Education and Research Network (USERN), Tehran, IranResearch Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.</style></auth-address><titles><title><style face="normal" font="default">New therapeutic approach by sirolimus for enteropathy treatment in patients with LRBA deficiency</style></title><secondary-title><style face="normal" font="default">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="239" start="235">235-239</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Summary: Purpose. To report the successful use of sirolimus for management of enteropathy in four patients with LPS-responsive beige-like anchor protein (LRBA) deficiency. Methods. Case series. Results. sirolimus therapy led to a complete improvement of symptoms including decrease in frequency and severity of diarrhea, as well as patients' weight gain. No signs of abdominal cramps and anorexia were also detected during the follow up period after treatment. Conclusions. sirolimus with its potential efficacy and immunomodulatory properties may be recommended for the treatment of severe enteropathy refractory to conventional therapy in patients with LRBA deficiency</style></abstract><notes><style face="normal" font="default">DA - 20170908IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Iran -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.23822/EurAnnACI.1764-1489.22</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28884992">PM:28884992</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-235-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-235-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170908, Azizi G</style></custom2><misc3><style face="normal" font="default">10.23822/EurAnnACI.1764-1489.22</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42649</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Caminati,M.</style></author><author><style face="normal" font="default"> Senna,G.</style></author><author><style face="normal" font="default"> Segala,N.</style></author><author><style face="normal" font="default"> Bacchini,M.</style></author><author><style face="normal" font="default"> Stefanizzi,G.</style></author><author><style face="normal" font="default"> Bovo,C.</style></author><author><style face="normal" font="default"> Schiappoli,M.</style></author><author><style face="normal" font="default"> Canonica,G.W.</style></author><author><style face="normal" font="default"> Passalacqua,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Asthma Center and Allergy Unit, Verona University and General Hospital, Verona, Italy.</style></auth-address><titles><title><style face="normal" font="default">Evaluation of asthma control in the pharmacy: an Italian cross-sectional study</style></title><secondary-title><style face="normal" font="default">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="230" start="225">225-230</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Summary: Background. In Western countries a large proportion of asthmatic patients remain uncontrolled, despite the availability of effective drugs. An involvement of pharmacies / pharmacists in asthma management has been suggested in guidelines, since this could provide a relevant support. Objective. The present cross-sectional study aimed at assessing the level of asthma control, by using ACT questionnaire, in the community pharmacies in the County of Verona, North East of Italy. Methods. A call for participation was sent by Verona Pharmacists' Association to all the pharmacies located in the Verona municipality. Patients with a medical prescription and an asthma exemption code were recruited in pharmacies. They were asked to fill the ACT questionnaire and to answer some additional questions on asthma treatment, smoke habits and comorbidities. Results. Thirty-seven community pharmacies recruited 239 patients. According to the ACT score, more than 50% of patients had a controlled asthma but 20% of them were totally uncontrolled and 12% were using oral steroid. Only 2.9% of patients had received an asthma action plan. Asthma was intermittent in 17.6% of patients, mild persistent in 13.8%, moderate persistent in 63.1% and severe in 5.4%. Discordance was observed between the self-perceived asthma control and objective parameters, when available. Of note, in the severe asthma group, most patients had an ACT > 20. Conclusion. This is the first Italian pharmacy-based study on asthma control. A better asthma control was recorded in this study in comparison with other trials, but about 50% of patients were insufficiently controlled. The community pharmacies can play a relevant role in the preliminary assessment of asthma control by using easy and not time consuming tools, such as ACT</style></abstract><notes><style face="normal" font="default">DA - 20170908IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.23822/EurAnnACI.1764-1489.03</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28884990">PM:28884990</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-225-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-225-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170908, Caminati M</style></custom2><misc3><style face="normal" font="default">10.23822/EurAnnACI.1764-1489.03</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42650</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,T.H.</style></author><author><style face="normal" font="default"> Yoon,S.H.</style></author><author><style face="normal" font="default"> Lee,S.Y.</style></author><author><style face="normal" font="default"> Choi,Y.H.</style></author><author><style face="normal" font="default"> Park,C.M.</style></author><author><style face="normal" font="default"> Kang,H.R.</style></author><author><style face="normal" font="default"> Cho,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiology, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, 03080, Korea</style></auth-address><titles><title><style face="normal" font="default">Biphasic and protracted anaphylaxis to iodinated contrast media</style></title><secondary-title><style face="normal" font="default">Eur Radiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Eur Radiol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To investigate the prevalence of biphasic and protracted anaphylaxis to iodinated contrast media (ICM), their risk factors and practical observation duration for detecting biphasic reaction. METHODS: 145 patients with ICM anaphylaxis from January 2005-February 2016 were retrospectively categorised into uniphasic, biphasic (anaphylaxis recurrence within 72 h after resolution of initial anaphylaxis) and protracted (anaphylaxis >5 h) reaction groups. Multivariate regression analyses of potential risk factors were performed. We calculated negative predictive value (NPV) for biphasic reactions and additional person-hours required to detect one case during post-anaphylaxis observation. RESULTS: Fifteen patients had biphasic reactions with secondary reactions with similar or milder severity and six had protracted reactions. Most significant risk factors were anaphylaxis duration >40 min for biphasic reactions (odds ratio (OR), 8.65 [95 % CI, 1.05-70.71]; P=0.044), and additional epinephrine administration within 1 h of initial dosing for protracted reactions (OR, 102.0 [95 % CI, 3.40-3057.25]; P=0.008). A 6-h post-anaphylaxis observation produced NPV of 96.4 %, while requiring a minimum of 65.5 additional person-hours to detect one additional case. CONCLUSION: Biphasic and protracted ICM anaphylaxis developed in 10.3 % and 4.1 %, respectively, with revealing risk factors. Six hours could be practical for post-anaphylaxis observation to detect biphasic reaction. KEY POINTS: * Incidence of biphasic anaphylaxis in iodinated contrast media anaphylaxis is 10.3 %. * Incidence of protracted anaphylaxis in iodinated contrast media anaphylaxis is 4.1 %. * Initial anaphylaxis >40 min can predict for biphasic anaphylaxis development. * A 6-h post-anaphylactic observation in ICM-related anaphylaxis seems practical</style></abstract><notes><style face="normal" font="default">DA - 20170928IS - 1432-1084 (Electronic)IS - 0938-7994 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1007/s00330-017-5052-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28956131">PM:28956131</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Radiol\20170928-KimTH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Radiol\20170928-KimTH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170928, Kim TH</style></custom2><misc3><style face="normal" font="default">10.1007/s00330-017-5052-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42651</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Beinart,D.</style></author><author><style face="normal" font="default"> Ren,D.</style></author><author><style face="normal" font="default"> Pi,C.</style></author><author><style face="normal" font="default"> Poulton,S.</style></author><author><style face="normal" font="default"> Holzknecht,Z.E.</style></author><author><style face="normal" font="default"> Swanson,C.</style></author><author><style face="normal" font="default"> Parker,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Duke University Medical Center, Box 2605, Department of Surgery, Durham, NC 27710</style></auth-address><titles><title><style face="normal" font="default">Immunization enhances the natural antibody repertoire</style></title><secondary-title><style face="normal" font="default">EXCLI J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">EXCLI J</style></full-title></periodical><pages end="1030" start="1018">1018-1030</pages><volume><style face="normal" font="default">16</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The role of immunization in the production of antibodies directed against immunogens is widely appreciated in laboratory animals and in humans. However, the role of immunization in the development of "natural antibodies" has not been investigated. Natural antibodies are those antibodies present without known history of infection or immunization, and react to a wide range of targets, including "cryptic" self-antigens that are exposed upon cell death. In this study, the ability of immunization to elicit the production of natural antibodies in laboratory rats was evaluated. Laboratory rats were immunized with a series of injections using peanut extracts (a common allergen), a high molecular weight protein conjugated to hapten (FITC-KLH), and a carbohydrate conjugated to hapten (DNP-Ficall). Significantly greater binding of antibodies from immunized animals compared to controls was observed to numerous autologous organ extracts (brain, kidney, liver, lung, prostate, and spleen) for both IgM and IgG, although the effect was more pronounced for IgM. These studies suggest that immunization may have at least one unforeseen benefit, enhancing networks of natural antibodies that may be important in such processes as wound repair and tumor surveillance. Such enhancement of natural antibody function may be particularly important in Western society, where decreased exposure to the environment may be associated with a weakened natural antibody repertoire</style></abstract><notes><style face="normal" font="default">DA - 20170913IS - 1611-2156 (Print)IS - 1611-2156 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.17179/excli2017-500</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28900382">PM:28900382</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\EXCLI J\2017-16-1018-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\EXCLI J\2017-16-1018-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170913, Beinart D</style></custom2><misc3><style face="normal" font="default">10.17179/excli2017-500</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42652</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Park,J.H.</style></author><author><style face="normal" font="default"> Yeo,I.J.</style></author><author><style face="normal" font="default"> Han,J.H.</style></author><author><style face="normal" font="default"> Suh,J.W.</style></author><author><style face="normal" font="default"> Lee,H.P.</style></author><author><style face="normal" font="default"> Hong,J.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">College of Pharmacy and Medical Research Center, Chungbuk National University, 194-31 Osongsaengmyeong 1-ro, Osong-eup, Heungduk-gu, Cheongju, Chungbuk, 361-951, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Anti-inflammatory effect of Astaxanthin in phthalic anhydride-induced atopic dermatitis animal model</style></title><secondary-title><style face="normal" font="default">Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="9" Year="2017">2017/9/8</year></dates><abstract><style face="normal" font="default">In this study, we investigated anti-dermatitic effects of Astaxanthin (AST) in phthalic anhydride (PA)-induced atopic dermatitis (AD) animal model as well as in vitro model. AD-like lesion was induced by the topical application of 5% PA to the dorsal skin or ear of Hos:HR-1 mouse. After AD induction, 100 mul of 1 mg/ml and 2 mg/ml of AST (10 mug or 20 mug/cm2 ) was spread on the dorsum of ear or back skin three times a week for four weeks. We evaluated dermatitis severity, histopathological changes and changes in protein expression by Western blotting for inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and nuclear factor-kappaB (NF-kappaB) activity. We also measured tumor necrosis factor- alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and immunoglobulinE (IgE) concentration in the blood of AD mice by enzyme-linked immunosorbent assay (ELISA). AST treatment attenuated the development of PA-induced AD. Histological analysis showed that AST inhibited hyperkeratosis, mast cells and infiltration of inflammatory cells. AST treatment inhibited expression of iNOS and COX-2, and NF-kappaB activity as well as release of TNF-alpha, IL-1beta, IL-6, and IgE. In addition, AST (5, 10, and 20muM) potently inhibited lipopolysaccharide (LPS) (1 mug/ml)-induced nitric oxide (NO) production, expression of iNOS and COX-2, and NF-kappaB DNA binding activities in RAW 264.7 macrophage cells. Our data demonstrated that AST could be a promising agent for AD by inhibition of NF-kappaB signaling. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170909IS - 1600-0625 (Electronic)IS - 0906-6705 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1111/exd.13437</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28887839">PM:28887839</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Exp Dermatol\20170909-ParkJH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Exp Dermatol\20170909-ParkJH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170909, Park JH</style></custom2><misc3><style face="normal" font="default">10.1111/exd.13437</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42653</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shimoda-Komatsu,Y.</style></author><author><style face="normal" font="default"> Sato,Y.</style></author><author><style face="normal" font="default"> Yamazaki,Y.</style></author><author><style face="normal" font="default"> Takahashi,R.</style></author><author><style face="normal" font="default"> Shiohara,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Kyorin University School of Medicine, Mitaka city, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">A novel method to assess the potential role of sweating abnormalities in the pathogenesis of AD</style></title><secondary-title><style face="normal" font="default">Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="9" Year="2017">2017/9/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: Although atopic dry skin is believed to be caused by defects in skin genes important for maintaining skin barrier function, the role of sweat in atopic dermatitis (AD) has been apparently underestimated. Given the great capacity of sweat to maintain and increase skin hydration, defective sweating responses may be a logical place to look for changes that predispose individuals to the disease. METHODS: We investigated how disease process and sweating defects progress from early asymptomatic stages to the onset of clinically apparent disease by employing the impression mold technique, which allows an accurate quantification of individual sweat gland/duct activity in relation to skin surface topography. Insensible and sensible sweating responses under baseline conditions and after thermal stimulus, respectively, were measured in various stages of AD patients and healthy controls. RESULTS: In controls, under baseline conditions sweat ducts/glands at the dermal folds secreted basal levels of sweat (insensible sweating), thereby maintaining skin hydration. Not only such insensible sweating but also sensible sweating markedly decreased even in the earliest asymptomatic stage and the decrease was followed by compensatory hyperhidrosis at the ridge: leakage of sweat into the dermis could represent the initial event resulting in the decreased sweating and inflammation. The defects eventually progressed involving all of the ducts/glands to develop systemic dry skin. CONCLUSION: AD skin is characterized by varying degrees of functional impairment of sweat ducts/glands depending on the stage and this defect would be among the reasons for the inability of AD patients to maintain skin hydration. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170923IS - 1600-0625 (Electronic)IS - 0906-6705 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/exd.13448</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28940663">PM:28940663</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Exp Dermatol\20170923-ShimodaKomatsuY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Exp Dermatol\20170923-ShimodaKomatsuY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170923, Shimoda-Komatsu Y</style></custom2><misc3><style face="normal" font="default">10.1111/exd.13448</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42654</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Choi,H.</style></author><author><style face="normal" font="default"> Kim,D.J.</style></author><author><style face="normal" font="default"> Nam,S.</style></author><author><style face="normal" font="default"> Lim,S.</style></author><author><style face="normal" font="default"> Hwang,J.S.</style></author><author><style face="normal" font="default"> Park,K.S.</style></author><author><style face="normal" font="default"> Hong,H.S.</style></author><author><style face="normal" font="default"> Shin,M.K.</style></author><author><style face="normal" font="default"> Chung,E.</style></author><author><style face="normal" font="default"> Son,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Genetic Engineering, College of Life Science and Graduate School of Biotechnology, Yong In, 446-701 R&amp;D center, Cell &amp; Bio, Seoul</style></auth-address><titles><title><style face="normal" font="default">Manifestation of atopic dermatitis-like skin in TNCB-induced NC/Nga mice is ameliorated by topical treatment of substance P, possibly through blockade of allergic inflammation</style></title><secondary-title><style face="normal" font="default">Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Inflammation</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> Mice</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword></keywords><dates><year Day="20" Month="8" Year="2017">2017/8/20</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by intense pruritus and eczematous lesion. In this study, topically applied substance P (SP) significantly alleviated AD-like clinical symptoms in 2, 4, 6-trinitrochlorobenzene (TNCB)-induced dermatitis in NC/Nga mice. This effect was nullified by pre-treatment of the neurokinin-1 receptor (NK-1R) antagonist CP99994. SP treatment significantly reduced the infiltration of mast cells and CD3-positive T cells as well as inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and thymic stromal lymphopoietin (TSLP), in AD-like skin lesions and decreased the levels of IgE and thymus and activation-regulated chemokine in serum. This SP-induced alleviation of allergic inflammatory responses was also confirmed as reduced activation in the axillary lymph nodes (aLN) and spleen, suggesting the systemic effect of SP on immune responses in TNCB-induced NC/Nga mice. Furthermore, SP-mediated TSLP reduction was confirmed in human keratinocyte culture under pro-inflammatory TNF-alpha stimulation. Taken together, these results suggest that topically administered SP may have potential as a medication for atopic dermatitis. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170823IS - 1600-0625 (Electronic)IS - 0906-6705 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1111/exd.13421</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28833499">PM:28833499</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Exp Dermatol\20170823-ChoiH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Exp Dermatol\20170823-ChoiH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170823, Choi H</style></custom2><misc3><style face="normal" font="default">10.1111/exd.13421</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42655</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mangano,K.</style></author><author><style face="normal" font="default"> Vergalito,F.</style></author><author><style face="normal" font="default"> Mammana,S.</style></author><author><style face="normal" font="default"> Mariano,A.</style></author><author><style face="normal" font="default"> De Pasquale,R.</style></author><author><style face="normal" font="default"> Meloscia,A.</style></author><author><style face="normal" font="default"> Bartollino,S.</style></author><author><style face="normal" font="default"> Guerra,G.</style></author><author><style face="normal" font="default"> Nicoletti,F.</style></author><author><style face="normal" font="default"> Di Marco,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biomedical and Biotechnological Sciences, University of Catania, I-95124 Catania, Italy</style></auth-address><titles><title><style face="normal" font="default">Evaluation of hyaluronic acid-P40 conjugated cream in a mouse model of dermatitis induced by oxazolone</style></title><secondary-title><style face="normal" font="default">Exp Ther Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Exp Ther Med</style></abbr-1></periodical><pages end="2444" start="2439">2439-2444</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">P40 is a particulate fraction or fragment isolated from Corynebacterium granulosum, which exhibits a wide spectrum of pharmacological functions including antitumor, antibacterial, phagocytic, antiviral and cytokine induction effects. In the present study, the immunomodulatory potential of P40-conjugated with hyaluronic acid was assessed in a mouse model of dermatitis induced by oxazolone. Oxazolone-induced allergic contact dermatitis is a T cell-mediated Th2-like hypersensitivity reaction, which mimics the corresponding reaction in humans. Female cluster of differentiation-1 mice were sensitized on days 0 and 1 by the application of 2% oxazolone onto a shaved back. The disease was induced by re-challenge on day 7 using 15% oxazolone in the inner and outer of the left ears of the mice. Mice were topically treated with hyaluronic acid-P40 conjugate cream or with placebo to the inner and outer surface of the left ear for 7 consecutive days starting from 1 h after the sensitization. A significant reduction in ear thickness and weight and in edema and leukocyte recruitment were observed in the mice treated with hyaluronic-P40 conjugate cream compared with mice treated with the cream base alone (P&lt;0.05). Thus, P40-conjugated with hyaluronic acid may constitute an innovative dermatitis treatment</style></abstract><notes><style face="normal" font="default">DA - 20170930IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.3892/etm.2017.4810</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28962179">PM:28962179</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Exp Ther Med\2017-14-2439-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Exp Ther Med\2017-14-2439-44.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170930, Mangano K</style></custom2><misc3><style face="normal" font="default">10.3892/etm.2017.4810</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42656</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Blanca-Lopez,N.</style></author><author><style face="normal" font="default"> Perez-Alzate,D.</style></author><author><style face="normal" font="default"> Canto,G.</style></author><author><style face="normal" font="default"> Blanca,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Hospital Infanta Leonor , Madrid , Spain</style></auth-address><titles><title><style face="normal" font="default">Practical approach to the treatment of NSAID hypersensitivity</style></title><secondary-title><style face="normal" font="default">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Expert Rev Clin Immunol</style></full-title></periodical><pages end="1027" start="1017">1017-1027</pages><volume><style face="normal" font="default">13</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="9" Year="2017">2017/9/12</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Non-steroidal anti-inflammatory drugs (NSAIDs) are the most frequently involved in drug hypersensitivity reactions (DHR). NSAIDs are prescribed for different processes and some NSAIDs can be obtained over the counter. Areas covered: We analyse the practical approaches for managing and treating NSAID-DHR considering the five major groups of entities recognised, divided into two categories: those responding to strong COX-1 inhibitors and possibly weak COX-1 or selective COX-2 inhibitors named cross-intolerant (CI), and those induced by a single drug or drug group with good tolerance to strong COX-1 inhibitors, known as allergic reactions (SR). An analysis of the recent literature indicates that two approaches can be followed for CI: to give acetyl salicylic acid to confirm NSAID hypersensitivity or to give alternative drugs to provide a solution for the treatment of pain, fever, inflammation or other conditions. Desensitisation approaches have been undertaken, but mainly for CI cases with respiratory airway involvement and they are very rarely used for CI with cutaneous involvement or SR. Expert commentary: DHR to NSAIDs are now recognised as one of the most important problems in the evaluation and management of drug allergy. Because no diagnostic tests exist, important resources are needed to evaluate these patients</style></abstract><notes><style face="normal" font="default">DA - 20170912IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1080/1744666X.2017.1377072</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28893093">PM:28893093</url></web-urls></urls><custom2><style face="normal" font="default">20170912, Blanca-Lopez N</style></custom2><misc3><style face="normal" font="default">10.1080/1744666X.2017.1377072</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42657</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Douros,K.</style></author><author><style face="normal" font="default"> Moustaki,M.</style></author><author><style face="normal" font="default"> Tsabouri,S.</style></author><author><style face="normal" font="default"> Papadopoulou,A.</style></author><author><style face="normal" font="default"> Papadopoulos,M.</style></author><author><style face="normal" font="default"> Priftis,K.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">3rd Department of Pediatrics, "Attikon" University General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece</style></auth-address><titles><title><style face="normal" font="default">Prenatal Maternal Stress and the Risk of Asthma in Children</style></title><secondary-title><style face="normal" font="default">Front Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Pediatr</style></abbr-1></periodical><pages end="" start="202">202-</pages><volume><style face="normal" font="default">5</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Emerging evidence indicate that maternal prenatal stress (MPS) can result in a range of long-term adverse effects in the offspring. The underlying mechanism of MPS is not fully understood. However, its complexity is emphasized by the number of purportedly involved pathways namely, placental deregulated metabolism of maternal steroids, impaired maturation of fetal HPA axis, imbalanced efflux of commensal bacteria across the placenta, and skewed immune development toward Th2. Fetal programming probably exerts a pivotal role in the end result of the above pathways through the modulation of gene expression. In this review, we highlight the current knowledge from epidemiological and experimental studies regarding the effects of MPS on asthma development in the offspring</style></abstract><notes><style face="normal" font="default">DA - 20171005IS - 2296-2360 (Print)IS - 2296-2360 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Greece -</style></notes><work-type><style face="normal" font="default">10.3389/fped.2017.00202</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28979893">PM:28979893</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Pediatr\2017-5-202.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Pediatr\2017-5-202.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171005, Douros K</style></custom2><misc3><style face="normal" font="default">10.3389/fped.2017.00202</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42658</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mohamed,A.R.</style></author><author><style face="normal" font="default"> Georgey,H.H.</style></author><author><style face="normal" font="default"> George,R.F.</style></author><author><style face="normal" font="default"> El-Eraky,W.I.</style></author><author><style face="normal" font="default"> Saleh,D.O.</style></author><author><style face="normal" font="default"> Abdel Gawad,N.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo 11829, Egypt</style></auth-address><titles><title><style face="normal" font="default">Identification of some novel xanthine-based derivatives with bronchodilator activity</style></title><secondary-title><style face="normal" font="default">Future Med Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Future Med Chem</style></abbr-1></periodical><pages end="1747" start="1731">1731-1747</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">15</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="9" Year="2017">2017/9/5</year></dates><abstract><style face="normal" font="default">AIM: The discovery of new bronchodilators with higher efficacy than theophylline is an important issue for asthmatic patients. MATERIALS &amp; METHODS: Theophylline 2, 8-bromotheophylline 4 and theobromine 6 were reacted with different 2/3-chloro-N-phenylacetamides 1a-d or their propanamide analogs 1e-g to obtain 3a-g, 5a-g and 7a-g, respectively. The target compounds were screened for their in vitro bronchodilator activity using isolated guinea pig tracheal rings precontracted with histamine and compared with their precursors. RESULTS: Many compounds exhibited promising activity especially 3d, 3f, 5d, 7d and 7e. 2D-QSAR study resulted in a significant model (N = 24, n = 5, R 2 = 0.848, R 2cvOO = 0.748, R 2cvMO = 0.745, F = 21.215, s 2 = 0.0002) using CODESSA-Pro software. CONCLUSION: These compounds can be considered as promising hits for potent bronchodilators that may be useful for further investigations. [Formula: see text]</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1756-8927 (Electronic)IS - 1756-8919 (Linking)LA - engPT - Journal ArticleCO - Egypt -</style></notes><work-type><style face="normal" font="default">10.4155/fmc-2017-0092</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28871831">PM:28871831</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Future Med Chem\2017-9-1731-47.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Future Med Chem\2017-9-1731-47.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Mohamed AR</style></custom2><misc3><style face="normal" font="default">10.4155/fmc-2017-0092</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42659</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Philips,N.</style></author><author><style face="normal" font="default"> Samuel,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Inhibition of Interleukin-4 Signalling in the Treatment of Atopic Dermatitis and Allergic Asthma</style></title><secondary-title><style face="normal" font="default">Glob J Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Glob J Allergy</style></full-title></periodical><pages end="021" start="019">019-021</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Atopic dermatitis and allergic asthma result from amplifi ed immune response to environmentalantigens, and allergic reactions from released IgE, histamine, leukotrienes and cytokines. Environmentalantigens immune cells, of innate and adaptive immunity, to stimulate interleukin-4 (IL-4) mediatedactivation of T h 2 cells and subsequent isotype switching of B cells to produce IgE antibodies, responsiblefor the clinical manifestation of atopic diseases. The IL-4 receptor alpha chain (IL4Ra), which mediatesIL-4 signaling, is common to IL-4 and IL-13 receptors, with IL-13 being an associated cytokine in theallergic response. US Food and Drug Administration recently approved dupilumab, which blocks IL4Ra forthe treatment of moderate to severe atopic dermatitis. In controlled trials, dupilumab counteracted theallergic response and the clinical symptoms of dermatitis and asthma, and dupilumab was more effectivethan other available treatments. The primary safety concern of dupilumab is conjunctivitis and its long-term safety, which is unknown.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.17352/2455-8141.000019</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.17352/2455-8141.000019</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Glob J Allergy\2017-3-019-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Glob J Allergy\2017-3-019-21.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Philips N</style></custom2><misc3><style face="normal" font="default">10.17352/2455-8141.000019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42660</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Garg,T.</style></author><author><style face="normal" font="default"> Agarwal,S.</style></author><author><style face="normal" font="default"> Rana,S.</style></author><author><style face="normal" font="default"> Chander,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and STD, Lady Hardinge Medical College, New Delhi, India</style></auth-address><titles><title><style face="normal" font="default">Patch Testing in Patients with Suspected Footwear Dermatitis: A Retrospective Study</style></title><secondary-title><style face="normal" font="default">Indian Dermatol Online J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Indian Dermatol Online J</style></abbr-1></periodical><pages end="327" start="323">323-327</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Footwear dermatitis represents a common but often undiagnosed or misdiagnosed condition. Patch testing aids in its confirmation and identification of the offending allergen. AIMS: This study aimed to find the frequency of positive patch test reactions in cases with suspected allergic contact dermatitis (ACD) to footwear, as well as the common responsible allergens. MATERIALS AND METHODS: This is a retrospective record based study of 37 patients, with suspected ACD to footwear, who underwent patch testing with Indian standard series and Indian footwear series from July 2012 to July 2015. RESULTS: The majority of patients (45.94%) belonged to the age group of 20-40 years. Dorsal aspects of feet (81.08%) and soles (18.92%) were the common sites involved. Patch test was positive in 18.92% patients. The most common causative allergens were hydroquinone monobenzylether (8.11%) and 4-aminoazobenzene (5.41%). CONCLUSION: Common chemicals implicated in ACD were rubber, rubber additives, and dyes. The principal culprit allergens were hydroquinone monobenzylether and 4-aminoazobenzene</style></abstract><notes><style face="normal" font="default">DA - 20171005IS - 2229-5178 (Print)IS - 2229-5178 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/idoj.IDOJ_254_16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28979863">PM:28979863</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian Dermatol Online J\2017-8-323-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian Dermatol Online J\2017-8-323-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171005, Garg T</style></custom2><misc3><style face="normal" font="default">10.4103/idoj.IDOJ_254_16</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42661</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Godse,K.V.</style></author><author><style face="normal" font="default"> Nadkarni,N.</style></author><author><style face="normal" font="default"> Patil,S.</style></author><author><style face="normal" font="default"> Mehta,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, D. Y. Patil Hospital, Navi Mumbai, Maharashtra, India</style></auth-address><titles><title><style face="normal" font="default">Subcutaneous Autologous Serum Therapy in Chronic Spontaneous Urticaria</style></title><secondary-title><style face="normal" font="default">Indian J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Indian J Dermatol</style></abbr-1></periodical><pages end="507" start="505">505-507</pages><volume><style face="normal" font="default">62</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: There is a felt need for trying newer therapeutic modalities in patients with chronic spontaneous urticaria, especially in the subset of patients classified as non-responders to antihistamines. Autologous serum therapy is an upcoming modality of treatment, and we decided to study its efficacy by subcutaneous route. AIMS: To evaluate the effectiveness of subcutaneous autologous serum therapy (AST) in CSU. METHODS: This was a single blind, placebo-controlled parallel group, randomized, controlled study. Twenty-four patients with CSU (11M: 13 F) were given subcutaneous AST and seventeen patients (7 M: 10F) patients were given subcutaneous injection normal saline (placebo), along with levocetirizine in an on-demand basis in both groups. RESULTS: Urticaria activity score (UAS) came down from 35.74 to 7 at the end of 9 weeks and the patients' requirement of antihistamines also reduced remarkably from 5.8 to 1.7 per week in the serum group. Sub-cutaneous saline group did not show statistically significant fall in UAS. Saline group showed UAS 32.8 at zero week to 22.1 at the end of 9 weeks. DLQI showed significant fall in serum group, from 14.26 to 4 at the end of 9 weeks. CONCLUSION: Subcutaneous autoserum therapy is effective in treatment of CSU</style></abstract><notes><style face="normal" font="default">DA - 20171005IS - 1998-3611 (Electronic)IS - 0019-5154 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/ijd.IJD_710_16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28979013">PM:28979013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Dermatol\2017-62-505-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Dermatol\2017-62-505-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171005, Godse KV</style></custom2><misc3><style face="normal" font="default">10.4103/ijd.IJD_710_16</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42662</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Balai,M.</style></author><author><style face="normal" font="default"> Ansari,F.</style></author><author><style face="normal" font="default"> Gupta,L.K.</style></author><author><style face="normal" font="default"> Khare,A.K.</style></author><author><style face="normal" font="default"> Mittal,A.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Venereology and Leprology, RNT Medical College, Udaipur, Rajasthan, India.</style></auth-address><titles><title><style face="normal" font="default">Urticaria and Angioedema Associated with Haloperidol</style></title><secondary-title><style face="normal" font="default">Indian J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Indian J Dermatol</style></abbr-1></periodical><pages end="540" start="539">539-540</pages><volume><style face="normal" font="default">62</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171005IS - 1998-3611 (Electronic)IS - 0019-5154 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/ijd.IJD_257_17</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28979025">PM:28979025</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Dermatol\2017-62-539-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Dermatol\2017-62-539-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171005, Balai M</style></custom2><misc3><style face="normal" font="default">10.4103/ijd.IJD_257_17</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42663</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Valkonen,M.</style></author><author><style face="normal" font="default"> Taubel,M.</style></author><author><style face="normal" font="default"> Pekkanen,J.</style></author><author><style face="normal" font="default"> Tischer,C.</style></author><author><style face="normal" font="default"> Rintala,H.</style></author><author><style face="normal" font="default"> Zock,J.P.</style></author><author><style face="normal" font="default"> Casas,L.</style></author><author><style face="normal" font="default"> Probst-Hensch,N.</style></author><author><style face="normal" font="default"> Forsberg,B.</style></author><author><style face="normal" font="default"> Holm,M.</style></author><author><style face="normal" font="default"> Janson,C.</style></author><author><style face="normal" font="default"> Pin,I.</style></author><author><style face="normal" font="default"> Gislason,T.</style></author><author><style face="normal" font="default"> Jarvis,D.</style></author><author><style face="normal" font="default"> Heinrich,J.</style></author><author><style face="normal" font="default"> Hyvarinen,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Institute for Health and Welfare, Living Environment and Health Unit, Kuopio, Finland</style></auth-address><titles><title><style face="normal" font="default">"Microbial characteristics in homes of asthmatic and non-asthmatic adults in the ECRHS cohort"</style></title><secondary-title><style face="normal" font="default">Indoor Air</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Indoor Air</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Microbial exposures in homes of asthmatic adults have been rarely investigated; specificities and implications for respiratory health are not well understood. OBJECTIVE: The objectives of this study were to investigate associations of microbial levels with asthma status, asthma symptoms, bronchial hyperresponsiveness (BHR), and atopy. MATERIAL AND METHODS: Mattress dust samples of 199 asthmatics and 198 control subjects from seven European countries participating in the European Community Respiratory Health Survey II study were analysed for fungal and bacterial cell wall components and individual taxa. RESULTS: We observed trends for protective associations of higher levels of mostly bacterial markers. Increased levels of muramic acid, a cell wall component predominant in Gram positive bacteria, tended to be inversely associated with asthma [OR's for different quartiles: II 0.71 (0.39-1.30), III 0.44 (0.23-0.82) and IV 0.60 (0.31-1.18) p for trend 0.07] and with asthma score (p for trend 0.06) and with atopy (p for trend 0.02). These associations were more pronounced in Northern Europe. CONCLUSIONS: This study among adults across Europe supports a potential protective effect of Gram positive bacteria in mattress dust and points out that this may be more pronounced in areas where microbial exposure levels are generally lower. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 1600-0668 (Electronic)IS - 0905-6947 (Linking)LA - engPT - Journal ArticleCO - Finland -CO - Spain -CO - Belgium -CO - Switzerland -CO - Sweden -CO - France -CO - Iceland -CO - United Kingdom -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/ina.12427</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28960492">PM:28960492</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indoor Air\20170929-ValkonenM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indoor Air\20170929-ValkonenM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Valkonen M</style></custom2><misc3><style face="normal" font="default">10.1111/ina.12427</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42664</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Peng,G.</style></author><author><style face="normal" font="default"> Mu,Z.</style></author><author><style face="normal" font="default"> Cui,L.</style></author><author><style face="normal" font="default"> Liu,P.</style></author><author><style face="normal" font="default"> Wang,Y.</style></author><author><style face="normal" font="default"> Wu,W.</style></author><author><style face="normal" font="default"> Han,X.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Shengjing Hospital of China Medical University, No. 36 Sanhao St., Heping Area, Shenyang, Liaoning, 110004, China</style></auth-address><titles><title><style face="normal" font="default">Anti-IL-33 Antibody Has a Therapeutic Effect in an Atopic Dermatitis Murine Model Induced by 2, 4-Dinitrochlorobenzene</style></title><secondary-title><style face="normal" font="default">Inflammation</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Inflammation</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="9" Year="2017">2017/9/26</year></dates><abstract><style face="normal" font="default">IL-33 is a new member of the IL-1 family that plays a role in allergic disease. In this study, we evaluated the potential on the inhibition of atopic dermatitis (AD) of anti-mouse IL-33 antibody (alphaIL-33Ab) using 2, 4-dinitrochlorobenzene (DNCB)-induced AD mice model. We treated mice with alphaIL-33Ab via subcutaneous injection of each DNCB treatment 1 h later from day 1 to day 33 for 14 times. A control group received tacrolimus. Skin lesion and scratching behavior were compared. Ear thickness, dermatitis score, eosinophils and mast cells infiltration, and serum IgE levels were also analyzed. Correlations between serum IL-33 as well as soluble(s) ST2 and AD disease activity index in human AD were also investigated. DNCB-induced AD-like mice treated with alphaIL-33Ab showed improved AD-like symptoms. Eosinophils and mast cells infiltration and serum IgE levels were also significantly reduced by alphaIL-33Ab. Our study suggests that blockade of IL-33 has a curative effect on AD</style></abstract><notes><style face="normal" font="default">DA - 20170927IS - 1573-2576 (Electronic)IS - 0360-3997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1007/s10753-017-0673-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28952069">PM:28952069</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Inflammation\20170927-PengG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Inflammation\20170927-PengG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170927, Peng G</style></custom2><misc3><style face="normal" font="default">10.1007/s10753-017-0673-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42665</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bohadana,A.</style></author><author><style face="normal" font="default"> Arish,N.</style></author><author><style face="normal" font="default"> Rokach,A.</style></author><author><style face="normal" font="default"> Izbicki,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Asthma Education Delivered in the Emergency Department: Does it Encourage Asthma Self-management?</style></title><secondary-title><style face="normal" font="default">Insights Allergy Asthma Bronchitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Insights Allergy Asthma Bronchitis</style></full-title></periodical><pages end="" start="20">20-</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: The rates of optimal asthma control and compliance to treatmentin Israel are reportedly low. We postulated that adults attending our emergencydepartment (ED) with asthma exacerbation were not using self-managementstrategies optimally.Objectives: This pilot study aims to: (a) verify the above hypothesis and, ifapplicable, (b) determine whether an asthma education intervention (AEI)administered in the ED would encourage post-discharge use of a written asthmaaction plan (AAP).Methods: Thirty-eight adults (>18 yr.) visiting the ED with asthma exacerbationreceived a 30-min AEI including a written AAP. Prior asthma education wasassessed by questionnaire. Follow-up, carried out by phone = 12 months afterdischarge, assessed AAP use, asthma control (GINA), and exacerbations in the pastyear.Results: At baseline, participants denied previous education on asthma self-management and AAP use. Of 27 patients available for follow-up, only 5 (18.5%)were using the AAP, assisted by their care-provider. Eighteen subjects (66.7%)presented uncontrolled asthma while, as a whole, the group reported significantlymore exacerbation episodes than at enrolment (mean (SD)=5.1 (6.5) vs. 2.7 (3.0)(p=0.0498)). Finally, compared with AAP non-users (n=22) AAP users (n=5) tendedto have better asthma control (60% vs. 18%) and fewer episodes of exacerbations(mean (SD)=2.8 (2.2) vs 5.9 (6.9)) but the differences did not reach significance.Conclusion: Delivery to adults of a short AEI in the ED was of limited efficiencyin post-discharge boosting of patient/doctor partnership, resulting in sub-optimalAAP use. Feasibility of the AEI in a crowded ED, however, justifies further researchon AEI delivery coupled with alternative follow-up strategies targeting patient anddoctor perception of AAPs.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Israel -</style></notes><work-type><style face="normal" font="default">10.21767/2471-304X.100020</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.21767/2471-304X.100020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Insights Allergy Asthma Bronchitis\2017-3-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Insights Allergy Asthma Bronchitis\2017-3-20.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Bohadana A</style></custom2><misc3><style face="normal" font="default">10.21767/2471-304X.100020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42666</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Najmuddin,F.</style></author><author><style face="normal" font="default"> Lahiri,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Vitamin D in Pediatric Asthma and Allergic Rhinitis: Benefits beyond Skeletal Health</style></title><secondary-title><style face="normal" font="default">Insights Allergy Asthma Bronchitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Insights Allergy Asthma Bronchitis</style></full-title></periodical><pages end="" start="19">19-</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Deficiency of Vitamin D in the Indian subcontinent is emerging as a major non-infectious epidemic. To correlate vitamin D deficient children with the asthmaand allergic rhinitis classification and pulmonary function tests. We studied 66children with asthma and allergic rhinitis between 6 to 12 years of whom 33 caseswere administered Vitamin D and 33 controls who were not given Vitamin D.The ethical committee approval was taken. It was a prospective, randomised andcomparative study. Data was analysed using mean, standard deviation and paired-t test. The study revealed 42 (63.6%) males and 24 (36.4%) females. The Asthmaclassification depicted mild persistent in 37 (56.1%) followed by intermittent 16(24.2%) and moderate persistent 12 (18.2%). Maximum cases of allergic rhinitiswere moderate persistent 42 (63.6%). The Children who received vitamin D hadsignificant improvement of Forced Expiratory Volume in the first second (FEV1,p-0.000), Forced Vital Capacity (FVC, p-0.005), FEV1: FVC% (p-0.002) and PeakExpiratory Flow Rate (PEFR, p-0.000). The control group showed significantimprovement in the PEFR parameter (p- 0.0077). The case group showed markedimprovement in the lung functions. Adherence to the duration of therapy for aperiod of 10 weeks with Vitamin D is mandatory.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="default">10.21767/2471-304X.100019</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.21767/2471-304X.100019</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Insights Allergy Asthma Bronchitis\2017-3-19.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Insights Allergy Asthma Bronchitis\2017-3-19.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Najmuddin F</style></custom2><misc3><style face="normal" font="default">10.21767/2471-304X.100019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42667</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Grumach,A.S.</style></author><author><style face="normal" font="default"> Ferraroni,N.</style></author><author><style face="normal" font="default"> Olivares,M.M.</style></author><author><style face="normal" font="default"> Lopez-Serrano,M.C.</style></author><author><style face="normal" font="default"> Bygum,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculdade de Medicina ABC, Santo Andre, Brazil</style></auth-address><titles><title><style face="normal" font="default">An ABC of the Warning Signs of Hereditary Angioedema</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="6" start="1">1-6</pages><volume><style face="normal" font="default">174</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="default">Hereditary angioedema (HAE) with C1 inhibitor deficiency is a genetic disorder that clinically manifests with attacks of angioedema in the subcutaneous and submucosal tissues, mainly in the extremities, abdomen, and upper airway. During attacks, vascular permeability is increased due to increased bradykinin (BK). This means that special therapies are needed for attacks that do not respond to traditional antiallergic therapies involving antihistamines, corticosteroids, and epinephrine. The recurring attacks may disable patients and lead to frequent visits to emergency rooms where misdiagnoses are common. HAE attacks may be fatal when upper-airway edema occurs, if proper treatment with a C1 inhibitor concentrate or BK receptor antagonist is not administered or an emergency tracheostomy is not performed. We propose a mnemonic method for the warning signs of HAE for the use as a diagnostic tool, i.e., the so-called "ABC" of the warning signs of HAE. The letters represent the following: A = Angioedema, B = Bradykinin, C = C1 inhibitor, D = Distress factors, E = Epinephrine nonresponsive, F = Family history, and G = Glottis/Gastrointestinal edema. To avoid fatalities, medical staff and patients, including family members, must be aware of HAE. An alphabetical mnemonic method has been developed and we hope it may benefit patients</style></abstract><notes><style face="normal" font="default">DA - 20170926IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1159/000479839</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28950264">PM:28950264</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-174-1-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-174-1-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170926, Grumach AS</style></custom2><misc3><style face="normal" font="default">10.1159/000479839</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42668</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Scangas,G.A.</style></author><author><style face="normal" font="default"> Remenschneider,A.K.</style></author><author><style face="normal" font="default"> Su,B.M.</style></author><author><style face="normal" font="default"> Shrime,M.G.</style></author><author><style face="normal" font="default"> Metson,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology, Harvard Medical School, Boston, MA</style></auth-address><titles><title><style face="normal" font="default">The impact of asthma on the cost effectiveness of surgery for chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Forum Allergy Rhinol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="9" Year="2017">2017/9/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: The objective of this work was to evaluate the impact of asthma on the cost-effectiveness profile of endoscopic sinus surgery (ESS) compared to medical therapy for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). METHODS: The study design consisted of a cohort-style Markov decision-tree cost utility analysis with a 35-year time horizon. Matched cohorts of CRSwNP patients with (n = 95) and without (n = 95) asthma who underwent ESS were compared with cohorts of patients from the national Medical Expenditures Survey Panel (MEPS) database who underwent medical management for chronic rhinosinusitis (CRS). Baseline, 1-year, and 2-year health utility values were calculated from responses to the EuroQol-5 Dimension (EQ-5D) instrument in both cohorts. The primary outcome measure was the incremental cost effectiveness ratio (ICER) for each cohort. RESULTS: The reference cases for CRSwNP patients with and without asthma yielded ICERs for ESS vs medical therapy alone of $12,066 per quality-adjusted life year (QALY) and $7,369 per QALY, respectively. At a willingness-to-pay threshold of $50,000/QALY, the ICER scatter plots demonstrated 86% and 99% certainty that the ESS strategy was the most cost-effective option for CRSwNP patients with and without asthma, respectively. ESS was not significantly more cost effective for CRSwNP patients without asthma (p = 0.494). CONCLUSION: ESS remains cost effective compared to medical therapy for patients both with and without asthma. While the comorbidity of asthma results in an inferior ICER result, it does not result in a statistically significant negative impact on the overall cost effectiveness of ESS</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1002/alr.22013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28873286">PM:28873286</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Forum Allergy Rhinol\20170905-ScangasGA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Forum Allergy Rhinol\20170905-ScangasGA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Scangas GA</style></custom2><misc3><style face="normal" font="default">10.1002/alr.22013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42669</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zimmer,K.A.</style></author><author><style face="normal" font="default"> Armbrecht,E.S.</style></author><author><style face="normal" font="default"> Burkemper,N.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Resident, Medical University of South Carolina, Charleston, SC, USA</style></auth-address><titles><title><style face="normal" font="default">The association of smoking with contact dermatitis and hand eczema - a review</style></title><secondary-title><style face="normal" font="default">Int J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="default">Given the high prevalence of allergic contact dermatitis (ACD), irritant contact dermatitis (ICD), hand eczema (HE), and smoking, and the impact that smoking has on skin disease, the authors reviewed the existing literature to assess the association between smoking and contact dermatitis or hand eczema. Using the PubMed and SCOPUS databases, a literature search identified articles related to allergic contact dermatitis, irritant contact dermatitis, and hand eczema and a possible association with smoking. The search period included articles prior to and including April 2016. Seven of eight articles described a positive relationship between smoking and allergic or irritant contact dermatitis, while nine of nineteen articles found a positive association between smoking and hand eczema. Published studies document that smoking may be an important risk factor for both allergic and irritant contact dermatitis as well as hand eczema</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 1365-4632 (Electronic)IS - 0011-9059 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/ijd.13777</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28960277">PM:28960277</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Dermatol\20170929-ZimmerKA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Dermatol\20170929-ZimmerKA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Zimmer KA</style></custom2><misc3><style face="normal" font="default">10.1111/ijd.13777</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42670</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Newell,K.</style></author><author><style face="normal" font="default"> Corrigan,C.</style></author><author><style face="normal" font="default"> Punshon,G.</style></author><author><style face="normal" font="default"> Leary,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Central London Community Healthcare NHS Trust, London, UK</style></auth-address><titles><title><style face="normal" font="default">Severe asthma: emergency care patient driven solutions</style></title><secondary-title><style face="normal" font="default">Int J Health Care Qual Assur</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Health Care Qual Assur</style></abbr-1></periodical><pages end="637" start="628">628-637</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="8" Year="2017">2017/8/14</year></dates><abstract><style face="normal" font="default">Purpose Patients with severe asthma were choosing not to use the emergency department (ED) in extremis and were self-medicating when experiencing severe asthma, putting their lives at risk. This local issue reflected a nationwide situation. The purpose of this paper is to better understand the reasons behind patients' reluctance to attend ED and to consider practical solutions in a structured way. Design/methodology/approach Systems thinking (soft systems methodology) was used to examine the issues resulting in this reluctance to attend the ED. Once this tame (well-defined) problem was revealed, a potential solution was developed in co-production with patients. Findings Patients feared attending the ED and felt vulnerable while in the ED for several reasons. This appeared to be a well-defined and solvable problem. The solution proposed was an asthma patient passport (APP), which increased patient's confidence in their ability to communicate their needs while in severe distress. The APP decreases (from 12 to 5 steps) the work patients had to do to achieve care. The APP project is currently being evaluated. Practical implications The APP should be offered to all people with severe asthma. Originality/value By revisiting systems thinking and identifying problems, a solution was identified. Although methods such as soft systems methodology have limitations when used in wicked (difficult or impossible to resolve) problems, such methods still have merit in tame problems and were applicable in this case to fully understand the issues, and to design practical solutions</style></abstract><notes><style face="normal" font="default">DA - 20170815IS - 0952-6862 (Print)IS - 0952-6862 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1108/IJHCQA-09-2016-0127</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28809587">PM:28809587</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Health Care Qual Assur\2017-30-628-37.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Health Care Qual Assur\2017-30-628-37.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170815, Newell K</style></custom2><misc3><style face="normal" font="default">10.1108/IJHCQA-09-2016-0127</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42671</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Boyle,V.T.</style></author><author><style face="normal" font="default"> Thorstensen,E.B.</style></author><author><style face="normal" font="default"> Thompson,J.M.D.</style></author><author><style face="normal" font="default"> McCowan,L.M.E.</style></author><author><style face="normal" font="default"> Mitchell,E.A.</style></author><author><style face="normal" font="default"> Godfrey,K.M.</style></author><author><style face="normal" font="default"> Poston,L.</style></author><author><style face="normal" font="default"> Wall,C.R.</style></author><author><style face="normal" font="default"> Murphy,R.</style></author><author><style face="normal" font="default"> Cutfield,W.</style></author><author><style face="normal" font="default"> Kenealy,T.</style></author><author><style face="normal" font="default"> Kenny,L.C.</style></author><author><style face="normal" font="default"> Baker,P.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Gravida: National Centre for Growth and Development and The Liggins Institute, University of Auckland, New Zealand</style></auth-address><titles><title><style face="normal" font="default">The relationship between maternal 25-hydroxyvitamin D status in pregnancy and childhood adiposity and allergy: An observational study</style></title><secondary-title><style face="normal" font="default">Int J Obes (Lond)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Obes (Lond)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="8" Year="2017">2017/8/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Vitamin D insufficiency (defined as &lt;75 nmol/l) is widespread amongst pregnant women around the world and has been proposed to influence offspring outcomes in childhood and into adult life, including adiposity and allergy. Disorders including asthma and eczema are on the rise amongst children. Our aim was to investigate the relationship between maternal 25-hydroxyvitamin D status in pregnancy and offspring adiposity, asthma and eczema in childhood. SUBJECTS AND METHODS: Maternal 25-hydroxyvitamin D concentrations were analysed in serum samples collected at 15 weeks' gestation from 1710 participants of the prospective Screening for Pregnancy Endpoints (SCOPE) cohort study. The offspring of 1208 mothers were followed up at age 5-6 years. Data collected included height, weight, percentage body fat (PBF, measured by bioimpedence) and history of asthma and eczema. Multivariable analysis controlled for maternal BMI, age and sex of the child and season of serum sampling. RESULTS: Complete data were available for 922 mother-child pairs. Each 10 nmol/l increase in maternal 25-hydroxyvitamin D concentration at 15 weeks' gestation was associated with a decrease in offspring PBF of 0.2% (95% CI 0.04-0.36% P=0.01) after adjustment for confounders, but was not related to child BMI z-score. Maternal mean (+/-s.d.) 25-hydroxyvitamin D concentration was similar in children who did and did not have asthma (71.7+/-26.1 vs 73.3+/-27.1 nmol/l P=0.5), severe asthma (68.6+/-28.6 vs 73.3+/-26.8 nmol/l P=0.2) and eczema (71.9+/-27.0 vs 73.2+/-27.0 nmol/l P=0.5). CONCLUSIONS: The finding of a relationship between maternal vitamin D status and adiposity in childhood is important, particularly because vitamin D insufficiency in pregnancy is highly prevalent. The association between maternal vitamin D supplementation in pregnancy and adiposity in the offspring merits examination in randomised controlled trials.International Journal of Obesity accepted article preview online, 04 August 2017. doi:10.1038/ijo.2017.182</style></abstract><notes><style face="normal" font="default">DA - 20170804IS - 1476-5497 (Electronic)IS - 0307-0565 (Linking)LA - engPT - Journal ArticleCO - New Zealand -CO - Australia -CO - Ireland -</style></notes><work-type><style face="normal" font="default">10.1038/ijo.2017.182</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28775375">PM:28775375</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Obes (Lond)\20170804-BoyleVT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Obes (Lond)\20170804-BoyleVT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170804, Boyle VT</style></custom2><misc3><style face="normal" font="default">10.1038/ijo.2017.182</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42672</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sinha,K.R.</style></author><author><style face="normal" font="default"> Duckwiler,G.</style></author><author><style face="normal" font="default"> Rootman,D.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA</style></auth-address><titles><title><style face="normal" font="default">Urticarial reaction following endovascular embolization of an orbital arteriovenous malformation (AVM) with n-butyl cyanoacrylate (nBCA) glue</style></title><secondary-title><style face="normal" font="default">Interv Neuroradiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Interv Neuroradiol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="default">Orbital arteriovenous malformations (AVMs) are rare vascular lesions that may be managed with endovascular embolization followed by surgical resection. Embolization is often accomplished with n-butyl-2-cyanoacrylate (nBCA), which is considered to be a safe and effective liquid occlusive agent. Localized vascular inflammation has been associated with endovascular nBCA use in histopathologic studies, but reports of systemic hypersensitivity reactions following endovascular embolization with nBCA are rare. We present a case of a 26-year-old male who developed an intermittent systemic urticarial reaction without cardiopulmonary compromise beginning four weeks after nBCA embolization of an orbital AVM. Subsequent skin allergy testing performed by an allergist confirmed hypersensitivity to nBCA glue and the patient has since been successfully managed with daily oral antihistamines. Awareness of this rare potential complication of endovascular embolization with nBCA will aid in the counseling and management of patients with AVMs</style></abstract><notes><style face="normal" font="default">DA - 20170912IS - 2385-2011 (Electronic)IS - 1591-0199 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/1591019917728400</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28893128">PM:28893128</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Interv Neuroradiol\20170912-SinhaKR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Interv Neuroradiol\20170912-SinhaKR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170912, Sinha KR</style></custom2><misc3><style face="normal" font="default">10.1177/1591019917728400</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42673</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,C.</style></author><author><style face="normal" font="default"> Liu,X.</style></author><author><style face="normal" font="default"> Li,Y.</style></author><author><style face="normal" font="default"> Liang,H.</style></author><author><style face="normal" font="default"> Li,K.</style></author><author><style face="normal" font="default"> Li,J.</style></author><author><style face="normal" font="default"> Cheng,C.</style></author><author><style face="normal" font="default"> Liu,X.</style></author><author><style face="normal" font="default"> Zhong,S.</style></author><author><style face="normal" font="default"> Li,L.</style></author><author><style face="normal" font="default"> Wang,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Guangzhou Youdi Biotechnology Company, Guangzhou, Guangdong, China</style></auth-address><titles><title><style face="normal" font="default">Effects of Acupuncture on 1-chloro-2,4-dinitrochlorobenzene-induced Allergic Contact Dermatitis in Mice</style></title><secondary-title><style face="normal" font="default">J Acupunct Meridian Stud</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Acupunct Meridian Stud</style></full-title></periodical><pages end="260" start="252">252-260</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">Allergic contact dermatitis (ACD) is a chronic inflammatory skin disease. Topical corticosteroids are the first-line therapy for ACD despite their significant adverse effects. Acupuncture has been widely used in the treatment of various skin diseases, but its underlying mechanism remains unrevealed. In this study, we investigated the characteristics of acupuncture treatment based on effectiveness and mechanism. BALB/c mice received 1-chloro-2,4-dinitrobenzene (DNCB) application to build AD-like model. Results showed that acupuncture was an effective treatment method in inhibiting inflammatory conditions, serum IgE levels, and expression of proinflammatory cytokine Th2 (IL-4, IL-6), and Th2 (IL-1beta, TNF-alpha) mRNA compared with DNCB treatment. Acupuncture treatment also inhibited nuclear factor-kappaB p65, phosphorylation of IkappaBalpha, and phosphorylation of occludin proteins expression. Furthermore, it could improve the expression of epidermal growth factor in both mRNA and protein levels. These results suggest that acupuncture, as an alternative therapy treatment for its no significant side effects, was effective in alleviating ACD by reducing proinflammatory cytokines and changing proteins' expression</style></abstract><notes><style face="normal" font="default">DA - 20170911IS - 2093-8152 (Electronic)IS - 2005-2901 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.jams.2017.06.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28889842">PM:28889842</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Acupunct Meridian Stud\2017-10-252-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Acupunct Meridian Stud\2017-10-252-60.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170911, Chen C</style></custom2><misc3><style face="normal" font="default">10.1016/j.jams.2017.06.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42674</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gold,D.R.</style></author><author><style face="normal" font="default"> Litonjua,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA.</style></auth-address><titles><title><style face="normal" font="default">Long-term Benefits of Optimal Asthma Control in Pregnancy</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.08.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28870459">PM:28870459</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170905-GoldDR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170905-GoldDR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Gold DR</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.08.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42675</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mincheva,R.</style></author><author><style face="normal" font="default"> Ekerljung,L.</style></author><author><style face="normal" font="default"> Bossios,A.</style></author><author><style face="normal" font="default"> Lundback,B.</style></author><author><style face="normal" font="default"> Lotvall,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Krefting Research Centre, Institute of Medicine, University of Gothenburg, BOX 424, SE 40530, Gothenburg, Sweden.</style></auth-address><titles><title><style face="normal" font="default">High prevalence of severe asthma in a large random population study</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: The prevalence of asthma severity is not well described at a population level. OBJECTIVE: To determine the prevalence of phenotypic signs of asthma severity among individuals with asthma in a general population, and to describe risk factors for asthma severity. METHODS: Epidemiological study conducted between 2008 and 2012 (West Sweden Asthma Study). A postal questionnaire was sent to random population (N = 30,000) in West Sweden, with 18,087 responses. A total of 2,006 individuals were carefully phenotyped. Only individuals with "active asthma" (symptoms or medication in the last year, N = 744) were analyzed in this study, to determine degree of severity of the disease within an asthma cohort. Phenotypes of severity were calculated based on: 1) multiple symptoms during the day despite the ongoing use of asthma medications, 2) FEV1 below 70% of predicted value, 3) daily or almost daily use of rescue medications, 4) nighttime symptoms once a week or more, and 5) oral corticosteroid use/emergency room visits. Asthmatics were grouped as non-severe, one sign of severity or two or more signs of severity. RESULTS: A total of 36.2% of asthmatics expressed at least one sign of asthma severity, and 13.2% had two or more signs. The group with two or more signs was older in age, had higher BMI, a higher rate of tobacco smoking and lower lung function. Bronchial hyperreactivity, airway inflammation and sensitization were significantly different among the three groups. At a population level, the prevalence of asthma severity was 3.1% for one sign, and 1.3% for at least two signs. CONCLUSION: More than one in three asthmatics show at least one sign of asthma severity. The phenotypes of asthma severity are highly diverse, which is important to consider when implementing personalized medicine in asthma. CLINICAL IMPLICATIONS: Our data is based on a random population, which results in minimal bias vs patient selection, and argues that asthma severity is present in 13% to 36% of asthmatics</style></abstract><notes><style face="normal" font="default">DA - 20170923IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.07.047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28939411">PM:28939411</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170923-MinchevaR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170923-MinchevaR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170923, Mincheva R</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.07.047</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42676</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ludka-Gaulke,T.</style></author><author><style face="normal" font="default"> Ghera,P.</style></author><author><style face="normal" font="default"> Waring,S.C.</style></author><author><style face="normal" font="default"> Keifer,M.</style></author><author><style face="normal" font="default"> Seroogy,C.</style></author><author><style face="normal" font="default"> Gern,J.E.</style></author><author><style face="normal" font="default"> Kirkhorn,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Marshfield Clinic Department of Medicine-Pediatrics, Marshfield, Wis</style></auth-address><titles><title><style face="normal" font="default">Farm exposure in early childhood is associated with a lower risk of severe respiratory illnesses</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.07.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28870458">PM:28870458</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170905-LudkaGaulkeT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170905-LudkaGaulkeT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Ludka-Gaulke T</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.07.032</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42677</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ebo,D.G.</style></author><author><style face="normal" font="default"> Van Gasse,A.L.</style></author><author><style face="normal" font="default"> Sabato,V.</style></author><author><style face="normal" font="default"> Bartholomeus,E.</style></author><author><style face="normal" font="default"> Reyniers,E.</style></author><author><style face="normal" font="default"> Vanbellinghen,J.F.</style></author><author><style face="normal" font="default"> Poirel,H.A.</style></author><author><style face="normal" font="default"> Mortier,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology-Allergology-Rheumatology, Faculty of Medicine and Health Sciences, University of Antwerp, and Antwerp University Hospital, Antwerp, Belgium.</style></auth-address><titles><title><style face="normal" font="default">Hereditary angioedema in 2 sisters due to paternal gonadal mosaicism</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="9" Year="2017">2017/9/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170910IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888847">PM:28888847</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170910, Ebo DG</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42678</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ameratunga,R.</style></author><author><style face="normal" font="default"> Gillis,D.</style></author><author><style face="normal" font="default"> Gold,M.</style></author><author><style face="normal" font="default"> Linneberg,A.</style></author><author><style face="normal" font="default"> Elwood,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Virology and Immunology, Auckland Hospital, Auckland, New Zealand.</style></auth-address><titles><title><style face="normal" font="default">Evidence Refuting the Existence of Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (ASIA)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1555" start="1551">1551-1555</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="9" Year="2017">2017/9/6</year></dates><abstract><style face="normal" font="default">Autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA) was described in 2011. Over time the condition and its triggers have broadened to include several autoimmune disorders, the macrophagic myofasciitis syndrome, the Gulf war syndrome, the sick building syndrome, siliconosis, and the chronic fatigue syndrome. The aluminum-containing adjuvants in the hepatitis B vaccine and the human papillomavirus vaccine in particular have been stated to be the major causes of the disorder. Here, we review the specificity of the diagnostic criteria for ASIA. We also examine relevant human data, pertaining to causation, particularly from patients undergoing allergen-specific immunotherapy (IT). Patients undergoing allergen-specific IT receive 100 to 500 times more injected aluminum over 3 to 5 years, compared with hepatitis B and human papillomavirus vaccine recipients. In a large pharmacoepidemiological study, in contrast to case series of ASIA, patients receiving aluminum-containing allergen IT preparations were shown to have a lower incidence of autoimmune disease. In another clinical trial, there were no increases in exacerbations in a cohort of patients with systemic lupus erythematosus immunized with the hepatitis B vaccine. Current data do not support the causation of ASIA by vaccine adjuvants containing aluminum, which should be of reassurance to patients undergoing routine immunizations as well as to those undergoing allergen-specific IT</style></abstract><notes><style face="normal" font="default">DA - 20170910IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - New Zealand -CO - Australia -CO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888842">PM:28888842</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170910, Ameratunga R</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.033</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42679</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Werder,R.B.</style></author><author><style face="normal" font="default"> Sci,B.B.</style></author><author><style face="normal" font="default"> Zhang,V.</style></author><author><style face="normal" font="default"> Lynch,J.P.</style></author><author><style face="normal" font="default"> Snape,N.</style></author><author><style face="normal" font="default"> Upham,J.W.</style></author><author><style face="normal" font="default"> Spann,K.</style></author><author><style face="normal" font="default"> Phipps,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Biomedical Sciences, University of Queensland, Queensland 4072, Australia</style></auth-address><titles><title><style face="normal" font="default">Chronic IL-33 expression predisposes to viral-induced exacerbations of asthma by increasing type-2 inflammation and dampening antiviral immunity</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="9" Year="2017">2017/9/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: Rhinovirus infection triggers acute exacerbations of asthma. IL-33 is an instructive cytokine of type-2 inflammation whose expression is associated with viral load during experimental rhinovirus infection of asthmatic subjects. OBJECTIVE: To determine whether anti-IL-33 therapy is effective during disease progression, established disease, or viral exacerbation using a preclinical model of chronic asthma and in vivo human primary airway epithelial cells (AECs). METHODS: To model disease onset, progression, and chronicity, mice were exposed to pneumonia virus of mouse and cockroach extract in early-life and later-life, then challenged with rhinovirus. Interventions included anti-IL-33 or dexamethasone at various stages of disease. AECs were obtained from asthmatic and healthy patients, and treated with anti-IL-33 following RV infection. RESULTS: Anti-IL-33 decreased type-2 inflammation in all phases of disease; however, the ability to prevent airway smooth muscle growth was lost after the progression phase. After the chronic phase, IL-33 levels were persistently high and rhinovirus challenge exacerbated the type-2 inflammatory response. Treatment with anti-IL-33 or dexamethasone diminished exacerbation severity and anti-IL-33, but not dexamethasone, promoted antiviral IFN expression and decreased viral load. RV replication was higher and IFN-lambda lower in asthmatic compared to healthy AECs. Anti-IL-33 lowered RV replication and increased IFN-lambda at the gene and protein level. CONCLUSION: Anti-IL-33 or dexamethasone suppressed the magnitude of type-2 inflammation during a rhinovirus-induced acute exacerbation, however only anti-IL-33 boosted antiviral immunity and lowered viral replication. The latter phenotype was replicated in RV infected human AECs, suggesting that anti-IL-33 therapy has the additional benefit of enhancing host defence</style></abstract><notes><style face="normal" font="default">DA - 20170926IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.07.051</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28947081">PM:28947081</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170926-WerderRB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170926-WerderRB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170926, Werder RB</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.07.051</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42680</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lai,P.S.</style></author><author><style face="normal" font="default"> Massoud,A.H.</style></author><author><style face="normal" font="default"> Xia,M.</style></author><author><style face="normal" font="default"> Petty,C.R.</style></author><author><style face="normal" font="default"> Cunningham,A.</style></author><author><style face="normal" font="default"> Chatila,T.A.</style></author><author><style face="normal" font="default"> Phipatanakul,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary and Critical Care, Massachusetts General Hospital, Boston, Massachusetts; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, Massachusetts; Harvard Medical School, Boston, MassachusettsHarvard Medical School, Boston, Massachusetts; Allergy and Immunology, Boston Children's Hospital, Boston, Massachusetts</style></auth-address><titles><title><style face="normal" font="default">Gene-environment interaction between an IL4R variant and school endotoxin exposure contributes to asthma symptoms in inner-city children</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="default">An interleukin 4 receptor genetic variant (IL4Ralpha-Q576R) is common in children of African ancestry. There is a gene-environment interaction between this variant, school endotoxin exposure, and asthma symptoms</style></abstract><notes><style face="normal" font="default">DA - 20170925IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.08.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28943468">PM:28943468</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170925-LaiPS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170925-LaiPS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170925, Lai PS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.08.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42681</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Na,H.</style></author><author><style face="normal" font="default"> Lim,H.</style></author><author><style face="normal" font="default"> Choi,G.</style></author><author><style face="normal" font="default"> Kim,B.K.</style></author><author><style face="normal" font="default"> Kim,S.H.</style></author><author><style face="normal" font="default"> Chang,Y.S.</style></author><author><style face="normal" font="default"> Nurieva,R.</style></author><author><style face="normal" font="default"> Dong,C.</style></author><author><style face="normal" font="default"> Chang,S.H.</style></author><author><style face="normal" font="default"> Chung,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Immune Regulation, Institute of Pharmaceutical Sciences; BK21 Plus program, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Concomitant suppression of Th2 and Th17 cell responses in allergic asthma by targeting RORgammat</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic asthma is a heterogeneous chronic inflammatory disease in the airway with a massive infiltration of eosinophils or neutrophils mediated by allergen-specific Th2 cells and Th17 cells, respectively. Successful treatment of allergic asthma will therefore require suppression of both Th2 and Th17 cells. OBJECTIVE: We sought to investigate the role of Th17 cell pathway in regulating Th2 cell responses in allergic asthma. METHODS: Allergic asthma was induced by intranasal challenges with proteinase allergens in C57BL/6, Il17a-/-Il17f- /-and RORgammatgfp/gfp mice. Pharmacological RORgammat inhibitor was used to evaluate its preventive and therapeutic effects in allergic asthma. Characteristics of allergic airway inflammation were analyzed by flow cytometry, histology, qRT-PCR and ELISA. Mixed bone marrow chimeric mice, fate mapping analysis, shRNA transduction and in vitro T cell differentiation were employed for mechanistic studies. RESULTS: Mice deficient in IL-17A and IL-17F as well as in RORgammat exhibited a significant reduction not only in Th17 cell responses, but also in Th2 cell responses in an animal model of allergic asthma. Similarly, mice treated with an RORgammat inhibitor showed significantly diminished Th17 as well as Th2 cell responses, leading to reduced numbers of neutrophils and eosinophils in the airway. RORgammat-deficient T cells were intrinsically defective in differentiating into Th2 cells and expressed increased level of Bcl6. Knock-down of Bcl6 resulted in a remarkable restoration of Th2 cell differentiation in RORgammat-deficient T cells. Blockade of RORgammat also significantly hampered the differentiation of human Th2 cells and Th17 cells from naive CD4+ T cells. CONCLUSION: RORgammat in T cells is required for optimal Th2 cell differentiation by suppressing Bcl6 expression; this finding suggests that targeting RORgammat might be a promising approach for the treatment of allergic asthma by concomitantly suppressing Th17 and Th2 cell responses in the airway</style></abstract><notes><style face="normal" font="default">DA - 20170925IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - South Korea -CO - China -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.07.050</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28943467">PM:28943467</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170925-NaH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170925-NaH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170925, Na H</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.07.050</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42682</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">O'Connor,G.T.</style></author><author><style face="normal" font="default"> Lynch,S.V.</style></author><author><style face="normal" font="default"> Bloomberg,G.R.</style></author><author><style face="normal" font="default"> Kattan,M.</style></author><author><style face="normal" font="default"> Wood,R.A.</style></author><author><style face="normal" font="default"> Gergen,P.J.</style></author><author><style face="normal" font="default"> Jaffee,K.F.</style></author><author><style face="normal" font="default"> Calatroni,A.</style></author><author><style face="normal" font="default"> Bacharier,L.B.</style></author><author><style face="normal" font="default"> Beigelman,A.</style></author><author><style face="normal" font="default"> Sandel,M.T.</style></author><author><style face="normal" font="default"> Johnson,C.C.</style></author><author><style face="normal" font="default"> Faruqi,A.</style></author><author><style face="normal" font="default"> Santee,C.</style></author><author><style face="normal" font="default"> Fujimura,K.E.</style></author><author><style face="normal" font="default"> Fadrosh,D.</style></author><author><style face="normal" font="default"> Boushey,H.</style></author><author><style face="normal" font="default"> Visness,C.M.</style></author><author><style face="normal" font="default"> Gern,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Boston University School of Medicine, Boston, Mass.</style></auth-address><titles><title><style face="normal" font="default">Early-life home environment and risk of asthma among inner-city children</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="9" Year="2017">2017/9/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Environmental exposures in early life appear to play an important role in the pathogenesis of childhood asthma, but the potentially modifiable exposures that lead to asthma remain uncertain. OBJECTIVE: We sought to identify early-life environmental risk factors for childhood asthma in a birth cohort of high-risk inner-city children. METHODS: We examined the relationship of prenatal and early-life environmental factors to the occurrence of asthma at 7 years of age among 442 children. RESULTS: Higher house dust concentrations of cockroach, mouse, and cat allergens in the first 3 years of life were associated with lower risk of asthma (for cockroach allergen: odds ratio per interquartile range increase in concentration, 0.55; 95% CI, 0.36-0.86; P &lt; .01). House dust microbiome analysis using 16S ribosomal RNA sequencing identified 202 and 171 bacterial taxa that were significantly (false discovery rate &lt; 0.05) more or less abundant, respectively, in the homes of children with asthma. A majority of these bacteria were significantly correlated with 1 of more allergen concentrations. Other factors associated significantly positively with asthma included umbilical cord plasma cotinine concentration (odds ratio per geometric SD increase in concentration, 1.76; 95% CI, 1.00-3.09; P = .048) and maternal stress and depression scores. CONCLUSION: Among high-risk inner-city children, higher indoor levels of pet or pest allergens in infancy were associated with lower risk of asthma. The abundance of a number of bacterial taxa in house dust was associated with increased or decreased asthma risk. Prenatal tobacco smoke exposure and higher maternal stress and depression scores in early life were associated with increased asthma risk</style></abstract><notes><style face="normal" font="default">DA - 20170923IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28939248">PM:28939248</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170923-OConnorGT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170923-OConnorGT.pdf</url></text-urls><related-urls><url ppv-ref="no">xlsx in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20170923, O'Connor GT</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.040</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42683</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Blumenthal,K.G.</style></author><author><style face="normal" font="default"> Li,Y.</style></author><author><style face="normal" font="default"> Banerji,A.</style></author><author><style face="normal" font="default"> Yun,B.J.</style></author><author><style face="normal" font="default"> Long,A.A.</style></author><author><style face="normal" font="default"> Walensky,R.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass</style></auth-address><titles><title><style face="normal" font="default">The Cost of Penicillin Allergy Evaluation</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="9" Year="2017">2017/9/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: Unverified penicillin allergy leads to adverse downstream clinical and economic sequelae. Penicillin allergy evaluation can be used to identify true, IgE-mediated allergy. OBJECTIVE: To estimate the cost of penicillin allergy evaluation using time-driven activity-based costing (TDABC). METHODS: We implemented TDABC throughout the care pathway for 30 outpatients presenting for penicillin allergy evaluation. The base-case evaluation included penicillin skin testing and a 1-step amoxicillin drug challenge, performed by an allergist. We varied assumptions about the provider type, clinical setting, procedure type, and personnel timing. RESULTS: The base-case penicillin allergy evaluation costs $220 in 2016 US dollars: $98 for personnel, $119 for consumables, and $3 for space. In sensitivity analyses, lower cost estimates were achieved when only a drug challenge was performed (ie, no skin test, $84) and a nurse practitioner provider was used ($170). Adjusting for the probability of anaphylaxis did not result in a changed estimate ($220); although other analyses led to modest changes in the TDABC estimate ($214-$246), higher estimates were identified with changing to a low-demand practice setting ($268), a 50% increase in personnel times ($269), and including clinician documentation time ($288). In a least/most costly scenario analyses, the lowest TDABC estimate was $40 and the highest was $537. CONCLUSIONS: Using TDABC, penicillin allergy evaluation costs $220; even with varied assumptions adjusting for operational challenges, clinical setting, and expanded testing, penicillin allergy evaluation still costs only about $540. This modest investment may be offset for patients treated with costly alternative antibiotics that also may result in adverse consequences</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958738">PM:28958738</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170929, Blumenthal KG</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42684</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chanoine,S.</style></author><author><style face="normal" font="default"> Pin,I.</style></author><author><style face="normal" font="default"> Sanchez,M.</style></author><author><style face="normal" font="default"> Temam,S.</style></author><author><style face="normal" font="default"> Pison,C.</style></author><author><style face="normal" font="default"> Le Moual,N.</style></author><author><style face="normal" font="default"> Severi,G.</style></author><author><style face="normal" font="default"> Boutron-Ruault,M.C.</style></author><author><style face="normal" font="default"> Fournier,A.</style></author><author><style face="normal" font="default"> Bousquet,J.</style></author><author><style face="normal" font="default"> Bedouch,P.</style></author><author><style face="normal" font="default"> Varraso,R.</style></author><author><style face="normal" font="default"> Siroux,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Team of Environmental Epidemiology Applied to Reproduction and Respiratory Health, Institute for Advanced Biosciences, Institut National de la Sante et de la Recherche Medicale U1209, Centre National de la Recherche Scientifique - Unite Mixte de Recherche 5309, Universite Grenoble Alpes, Grenoble, France</style></auth-address><titles><title><style face="normal" font="default">Asthma Medication Ratio Phenotypes in Elderly Women</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="9" Year="2017">2017/9/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: With population aging, further asthma research is needed in the elderly. OBJECTIVE: We assessed the relevance of the controller-to-total asthma medication ratio and its fluctuations over time to identify participants with a subsequent risk of poor asthma-related outcomes among well-characterized elderly women. METHODS: We studied 4,328 women with ever asthma (69.6 +/- 6.1 years) from the Asthma-E3N study (Etude Epidemiologique aupres des femmes de la Mutuelle Generale de l'Education Nationale), which combined drug claims data since 2004 with prospective individual characteristics. The levels of the yearly controller-to-total asthma medication ratio from 2004 to 2011 were included in latent class analysis to identify groups of women characterized by specific long-term fluctuations of the ratio. Multiple regression models estimated the subsequent risk of uncontrolled asthma, asthma attacks, asthma exacerbations, and poor asthma-related quality of life associated with the level and the fluctuations of the ratio. RESULTS: A short-term (12 months) ratio below 0.5 was associated with a higher risk of subsequent uncontrolled asthma, asthma attacks, asthma exacerbations (odds ratio [95% confidence interval (CI)] = 2.13 [1.41; 3.23], 1.51 [1.01; 2.26], and 2.18 [1.37; 3.44], respectively), and a lower total asthma quality of life questionnaire score (beta [95% CI] = -0.49 [-0.68; -0.29]). The analysis of the long-term fluctuations of the ratio identified 5 profiles ("Never regular treatment," 53.2%; "Persistent high ratio," 21.8%; "Increasing ratio," 4.4%; "Initiating treatment," 8.8%; "Treatment discontinuation," 11.8%). The subsequent risk of poor asthma-related outcomes was significantly higher in profiles characterized by no or interrupted asthma maintenance therapy over time, compared with the "Persistent high ratio" group. CONCLUSIONS: The level and the long-term fluctuations of the controller-to-total asthma medication ratio predict poor asthma-related outcomes in elderly women</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958739">PM:28958739</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170929, Chanoine S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42685</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Derrick,M.I.</style></author><author><style face="normal" font="default"> Williams,K.B.</style></author><author><style face="normal" font="default"> Shade,L.M.P.</style></author><author><style face="normal" font="default"> Phillips,E.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Vanderbilt University Medical Center, Nashville, Tenn</style></auth-address><titles><title><style face="normal" font="default">A survey of drug allergy training opportunities in the United States</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="9" Year="2017">2017/9/22</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958742">PM:28958742</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170929, Derrick MI</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42686</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Macy,E.</style></author><author><style face="normal" font="default"> Blumenthal,K.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy, Southern California Permanente Medical Group, San Diego Medical Center, San Diego, Calif.</style></auth-address><titles><title><style face="normal" font="default">Are Cephalosporins Safe for Use in Penicillin Allergy Without Prior Allergy Evaluation?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="9" Year="2017">2017/9/22</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 2213-2201 (Electronic)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958745">PM:28958745</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170929, Macy E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.033</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42687</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sonnappa,S.</style></author><author><style face="normal" font="default"> McQueen,B.</style></author><author><style face="normal" font="default"> Postma,D.S.</style></author><author><style face="normal" font="default"> Martin,R.J.</style></author><author><style face="normal" font="default"> Roche,N.</style></author><author><style face="normal" font="default"> Grigg,J.</style></author><author><style face="normal" font="default"> Guilbert,T.</style></author><author><style face="normal" font="default"> Gouder,C.</style></author><author><style face="normal" font="default"> Pizzichini,E.</style></author><author><style face="normal" font="default"> Niimi,A.</style></author><author><style face="normal" font="default"> Phipatanakul,W.</style></author><author><style face="normal" font="default"> Chisholm,A.</style></author><author><style face="normal" font="default"> Dandurand,R.J.</style></author><author><style face="normal" font="default"> Kaplan,A.</style></author><author><style face="normal" font="default"> Israel,E.</style></author><author><style face="normal" font="default"> Papi,A.</style></author><author><style face="normal" font="default"> van Aalderen,W.M.C.</style></author><author><style face="normal" font="default"> Usmani,O.S.</style></author><author><style face="normal" font="default"> Price,D.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Observational and Pragmatic Research Institute Pte Ltd, Singapore; Department of Respiratory Paediatrics, Rainbow Children's Hospital, Bengaluru, India</style></auth-address><titles><title><style face="normal" font="default">Extrafine Versus Fine Inhaled Corticosteroids in Relation to Asthma Control: A Systematic Review and Meta-Analysis of Observational Real-Life Studies</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: The particle size of inhaled corticosteroids (ICSs) may affect airway drug deposition and effectiveness. OBJECTIVE: To compare the effectiveness of extrafine ICSs (mass median aerodynamic diameter, &lt;2 mum) versus fine-particle ICSs administered as ICS monotherapy or ICS-long-acting beta-agonist combination therapy by conducting a meta-analysis of observational real-life asthma studies to estimate the treatment effect of extrafine ICSs. METHODS: MEDLINE and EMBASE databases were reviewed for asthma observational comparative effectiveness studies from January 2004 to June 2016. Studies were included if they reported odds and relative risk ratios and met all inclusion criteria (Respiratory Effectiveness Group/European Academy of Allergy and Clinical Immunology quality standards, comparison of extrafine ICSs with same or different ICS molecule, >/=12-month follow-up). End-point data (asthma control, exacerbations, prescribed ICS dose) were pooled. Random-effects meta-analysis modeling was used. The study protocol is published in the PROSPERO register CRD42016039137. RESULTS: Seven studies with 33,453 subjects aged 5 to 80 years met eligibility criteria for inclusion. Six studies used extrafine beclometasone propionate and 1 study used both extrafine beclometasone propionate and extrafine ciclesonide as comparators with fine-particle ICSs. The overall odds of achieving asthma control were significantly higher for extrafine ICSs compared with fine-particle ICSs (odds ratio, 1.34; 95% CI, 1.22-1.46). Overall exacerbation rate ratios (0.84; 95% CI, 0.73-0.97) and ICS dose (weighted mean difference, -170 mug; 95% CI, -222 to -118 mug) were significantly lower for extrafine ICSs compared with fine-particle ICSs. CONCLUSIONS: This meta-analysis demonstrates that extrafine ICSs have significantly higher odds of achieving asthma control with lower exacerbation rates at significantly lower prescribed doses than fine-particle ICSs</style></abstract><notes><style face="normal" font="default">DA - 20170924IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - India -CO - United States -CO - Netherlands -CO - France -CO - United Kingdom -CO - Malta -CO - Brazil -CO - Japan -CO - Canada -CO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28941668">PM:28941668</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170924, Sonnappa S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.032</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42688</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stone,C.</style></author><author><style face="normal" font="default"> Gebretsadik,T.</style></author><author><style face="normal" font="default"> Lee,R.L.</style></author><author><style face="normal" font="default"> Evans,A.M.</style></author><author><style face="normal" font="default"> Hartert,T.V.</style></author><author><style face="normal" font="default"> Mitchel,E.</style></author><author><style face="normal" font="default"> Morrow,J.</style></author><author><style face="normal" font="default"> Wu,A.C.</style></author><author><style face="normal" font="default"> Iribarren,C.</style></author><author><style face="normal" font="default"> Butler,M.G.</style></author><author><style face="normal" font="default"> Larkin,E.K.</style></author><author><style face="normal" font="default"> Turi,K.N.</style></author><author><style face="normal" font="default"> Wu,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn</style></auth-address><titles><title><style face="normal" font="default">Trends in health care utilization for asthma exacerbations among diverse populations with asthma in the United States</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="9" Year="2017">2017/9/18</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170922IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28935525">PM:28935525</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170922, Stone C</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42689</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bochenek,G.</style></author><author><style face="normal" font="default"> Stachura,T.</style></author><author><style face="normal" font="default"> Szafraniec,K.</style></author><author><style face="normal" font="default"> Plutecka,H.</style></author><author><style face="normal" font="default"> Sanak,M.</style></author><author><style face="normal" font="default"> Nizankowska-Mogilnicka,E.</style></author><author><style face="normal" font="default"> Sladek,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland.</style></auth-address><titles><title><style face="normal" font="default">Diagnostic Accuracy of Urinary LTE4 Measurement to Predict Aspirin-Exacerbated Respiratory Disease in Patients with Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="9" Year="2017">2017/9/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patients with aspirin-exacerbated respiratory disease (AERD) are distinguished from patients with aspirin-tolerant asthma (ATA) by significantly higher baseline concentrations of urinary leukotriene E4 (uLTE4). However, an overlap between the individual values of the groups exists. OBJECTIVE: The objective of this study was to estimate the discriminative value of uLTE4 concentration in differentiating between patients with AERD and patients with ATA and evaluate the diagnostic accuracy of uLTE4 measurement alone and added to clinical parameters to predict AERD diagnosis in patients with asthma. METHODS: Clinical data were collected from questionnaires. Spirometry, skin prick tests, total IgE, and blood eosinophilia were evaluated. ULTE4 concentrations were measured in morning urine samples by enzyme-linked immune assay (ELISA). RESULTS: Patients with AERD (n = 247) had significantly higher uLTE4 concentrations than those with ATA (n = 239). The uLTE4 concentration of 800.0 pg/mg creatinine as measured by ELISA on a spot sample best discriminated the 2 groups (area under the curve 0.7; 95% confidence interval 0.66-0.74, sensitivity 49%, specificity 81%). The positive predictive value and negative predictive value (NPV), after considering the prevalence of AERD in the population of asthmatics, were 16% and 96%, respectively. Nasal polyps, upper airway symptoms, nasal corticosteroid treatment, asthma exacerbations, forced expiratory volume in the 1 second predicted, and age of asthma onset were independent predictors of AERD diagnosis. The addition of elevated uLTE4 concentration to the set of clinical parameters enhanced slightly the prediction of AERD diagnosis beyond the level predicted by clinical parameters (P = .036). CONCLUSIONS: A set of typical clinical parameters has a superior accuracy in prediction of AERD diagnosis than the measurement of uLTE4 concentration alone. The addition of uLTE4 concentration to clinical parameters slightly enhances the prediction of AERD diagnosis, especially due to a high NPV</style></abstract><notes><style face="normal" font="default">DA - 20170910IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888846">PM:28888846</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170910, Bochenek G</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42690</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Watts,T.J.</style></author><author><style face="normal" font="default"> Li,P.H.</style></author><author><style face="normal" font="default"> Ue,K.L.</style></author><author><style face="normal" font="default"> Haque,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Adult Allergy, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default">Chronic Allergic Contact Dermatitis Due to Chlorhexidine</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170923IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United Kingdom -CO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28939138">PM:28939138</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170923, Watts TJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42691</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Coattrenec,Y.</style></author><author><style face="normal" font="default"> Spoerl,D.</style></author><author><style face="normal" font="default"> Jandus,P.</style></author><author><style face="normal" font="default"> Harr,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunology and Allergology, Department of Medical Specialties, University Hospital and Medical Faculty, Geneva, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Anaphylactic shock to H1 antihistamine drug bilastine: A case report</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170923IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28939141">PM:28939141</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170923, Coattrenec Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.042</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42692</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rojas-Perez-Ezquerra,P.</style></author><author><style face="normal" font="default"> Noguerado-Mellado,B.</style></author><author><style face="normal" font="default"> Saenz de Santamaria,G.M.</style></author><author><style face="normal" font="default"> Roa-Medellin,D.</style></author><author><style face="normal" font="default"> Hernandez-Aragues,I.</style></author><author><style face="normal" font="default"> Zubeldia Ortuno,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Service, Hospital General Universitario Gregorio Maranon, Madrid, Spain; Gregorio Maranon Health Research Institute (IiSGM), Madrid, Spain.  Spain</style></auth-address><titles><title><style face="normal" font="default">Sweet syndrome caused by sensitization to gabapentin</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="9" Year="2017">2017/9/22</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958741">PM:28958741</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170929, Rojas-Perez-Ezquerra P</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42693</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">De Pasquale,T.M.A.</style></author><author><style face="normal" font="default"> Buonomo,A.</style></author><author><style face="normal" font="default"> Pucci,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Unit, Ospedale Civile di Civitanova Marche (MC), Civitanova Marche, Italy</style></auth-address><titles><title><style face="normal" font="default">Delayed-type allergy to articaine with cross-reactivity to other local anesthetics from the amide group</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="9" Year="2017">2017/9/22</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958747">PM:28958747</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170929, De Pasquale TM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.046</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42694</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Unal,D.</style></author><author><style face="normal" font="default"> Demir,S.</style></author><author><style face="normal" font="default"> Gelincik,A.</style></author><author><style face="normal" font="default"> Olgac,M.</style></author><author><style face="normal" font="default"> Coskun,R.</style></author><author><style face="normal" font="default"> Colakoglu,B.</style></author><author><style face="normal" font="default"> Buyukozturk,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="default">Diagnostic Value of Oral Challenge Testing in the Diagnosis of Macrolide Hypersensitivity</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="9" Year="2017">2017/9/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hypersensitivity reactions (HRs) to macrolides are rare. OBJECTIVE: The aim of this study was to evaluate the diagnostic value of in vivo tests in the diagnosis of HRs to macrolides and also to assess cross-reactivity between 4 different macrolides (clarithromycin, dirithromycin, spiramycin, and azithromycin) belonging to 3 different groups. METHODS: Twenty-five patients with a history of immediate or delayed-type HRs to at least 1 macrolide and 20 healthy control subjects underwent skin testing for both the culprit and alternative macrolides. Then, all subjects underwent single-blind drug provocation tests (SBDPTs) with these drugs. RESULTS: Twenty-one patients (84%) described an early reaction, whereas the remaining 4 (16%) had delayed-type reactions. Skin prick test results with culprit macrolides were positive in only 2 patients who had experienced anaphylaxis. These 2 and another 4 patients with anaphylaxis history and 6 patients with negative skin test results who did not give consent were not challenged. A total of 13 patients with negative skin test results were challenged with the culprit drugs and all of them experienced HRs during the SBDPTs. Skin test results with alternative drugs were positive in only 2 patients with negative SBDPT results. Conversely, 5 patients with negative skin test results reacted to SBDPTs with alternative macrolides. In healthy control subjects, the skin test results were positive in 3 patients (1 positivity with clarithromycin, 2 positivity with spiramycin) whereas all DPT results were negative. CONCLUSIONS: Our results suggested that DPT is the only reliable method to predict macrolide hypersensitivity as well as to detect cross-reactivity between macrolides</style></abstract><notes><style face="normal" font="default">DA - 20170919IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28923488">PM:28923488</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170919, Unal D</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.036</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42695</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sugier,P.E.</style></author><author><style face="normal" font="default"> Brossard,M.</style></author><author><style face="normal" font="default"> Sarnowski,C.</style></author><author><style face="normal" font="default"> Vaysse,A.</style></author><author><style face="normal" font="default"> Morin,A.</style></author><author><style face="normal" font="default"> Pain,L.</style></author><author><style face="normal" font="default"> Margaritte-Jeannin,P.</style></author><author><style face="normal" font="default"> Dizier,M.H.</style></author><author><style face="normal" font="default"> Cookson,W.O.C.M.</style></author><author><style face="normal" font="default"> Lathrop,M.</style></author><author><style face="normal" font="default"> Moffatt,M.F.</style></author><author><style face="normal" font="default"> Laprise,C.</style></author><author><style face="normal" font="default"> Demenais,F.</style></author><author><style face="normal" font="default"> Bouzigon,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Genetic Variation and Human Diseases Unit, INSERM, Universite Paris Diderot, Universite Sorbonne Paris Cite, Paris, France</style></auth-address><titles><title><style face="normal" font="default">A novel role for cilia function in atopy: ADGRV1 and DNAH5 interactions</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="9" Year="2017">2017/9/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopy, an endotype underlying allergic diseases, has a substantial genetic component. OBJECTIVE: Our goal was to identify novel genes associated with atopy in asthma-ascertained families. METHODS: We implemented a three-step analysis strategy in three datasets: The Epidemiological study on the Genetics and Environment of Asthma (EGEA) dataset: 1,660 subjects; The Saguenay-Lac-Saint-Jean (SLSJ) dataset: 1,138 subjects; and The Medical Research Council (MRC) dataset: 446 subjects). This strategy included a single-SNP genome-wide association study (GWAS), the selection of related gene pairs based on statistical filtering of GWAS results and text-mining filtering using GRAIL and SNP-SNP interaction analysis of selected gene pairs. RESULTS: We identified the 5q14 locus, harboring the adhesion G protein-coupled receptor V1 (ADGRV1) gene, that showed genome-wide significant association with atopy (rs4916831; Pmeta=6.8x10-9). Statistical filtering of GWAS results followed by text-mining filtering revealed relationships between ADGRV1 and three genes showing suggestive association with atopy (P&lt;/=10-4). SNP-SNP interaction analysis between ADGRV1 and these three genes showed significant interaction between ADGRV1 rs17554723 and two correlated SNPs (rs2134256 and rs1354187) within dynein axonemal heavy chain 5 (DNAH5) gene (Pmeta-int=3.6x10-5 and 6.1x10-5, that met the multiple-testing corrected threshold of 7.3x10-5). Further conditional analysis indicated that rs2134256 alone accounted for the interaction signal with rs17554723. CONCLUSION: As both DNAH5 and ADGRV1 contribute to function of cilia, this study suggests that cilia dysfunction may represent a novel mechanism underlying atopy. Combining GWAS and epistasis analysis driven by statistical and knowledge-based evidence represents a promising approach for identifying new genes involved in complex traits</style></abstract><notes><style face="normal" font="default">DA - 20170920IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - France -CO - Canada -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.06.050</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28927820">PM:28927820</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170920-SugierPE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170920-SugierPE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170920, Sugier PE</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.06.050</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42696</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mirzakhani,H.</style></author><author><style face="normal" font="default"> Carey,V.J.</style></author><author><style face="normal" font="default"> McElrath,T.F.</style></author><author><style face="normal" font="default"> Laranjo,N.</style></author><author><style face="normal" font="default"> O'Connor,G.</style></author><author><style face="normal" font="default"> Iverson,R.E.</style></author><author><style face="normal" font="default"> Lee-Parritz,A.</style></author><author><style face="normal" font="default"> Strunk,R.C.</style></author><author><style face="normal" font="default"> Bacharier,L.B.</style></author><author><style face="normal" font="default"> Macones,G.A.</style></author><author><style face="normal" font="default"> Zeiger,R.S.</style></author><author><style face="normal" font="default"> Schatz,M.</style></author><author><style face="normal" font="default"> Hollis,B.W.</style></author><author><style face="normal" font="default"> Litonjua,A.A.</style></author><author><style face="normal" font="default"> Weiss,S.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Mass; Harvard Medical School, Boston, Mass</style></auth-address><titles><title><style face="normal" font="default">The Association of Maternal Asthma and Early Pregnancy Vitamin D with Risk of Preeclampsia: An Observation From Vitamin D Antenatal Asthma Reduction Trial (VDAART)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="9" Year="2017">2017/9/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Maternal asthma, uncontrolled asthma, and low vitamin D levels during pregnancy have been individually linked to increased risk of preeclampsia. OBJECTIVE: To investigate the association of history of physician-diagnosed asthma and uncontrolled asthma status during pregnancy with the risk of preeclampsia and the effects of early pregnancy vitamin D concentrations on this relationship. METHODS: A total of 816 subjects with available pregnancy outcome data and risk factors of interest were analyzed. A group of experienced obstetricians and gynecologists from 3 study centers validated the preeclampsia diagnoses. Vitamin D was measured using the DiaSorin method at 10 to 18 weeks of gestation. The Pregnancy-Asthma Control Test was used to assess asthma control during pregnancy. Criterion-based stepwise variable selection algorithm was applied to investigate the relationships of risk factors of interest (history of asthma diagnosis, uncontrolled asthma during pregnancy, and vitamin D) to preeclampsia. RESULTS: The incidence of preeclampsia was not related to the presence of asthma diagnosis (8.9% with vs 7.4% without). The adjusted odds of preeclampsia controlled for maternal serum 25-hydroxyvitamin D (25OHD) concentrations was higher for women with a higher proportion of uncontrolled asthma months per visit during pregnancy (adjusted odds ratio, 3.55; 95% CI, 1.15-13.0). Adjusting for asthma control status during pregnancy, an additional decrease in the associated preeclampsia risk by 7% was observed for a 10-unit (ng/mL) increase in early pregnancy 25OHD levels (adjusted odds ratio10-unit, 0.60; 95% CI, 0.43-0.82) as compared with the previous risk estimate of preeclampsia associated with low maternal 25OHD unadjusted for asthma control status. CONCLUSIONS: Uncontrolled asthma during pregnancy is associated with an increased risk of preeclampsia. Early pregnancy 25OHD contributes to the association of uncontrolled asthma status with preeclampsia</style></abstract><notes><style face="normal" font="default">DA - 20170919IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28923490">PM:28923490</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170919, Mirzakhani H</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42697</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Butz,A.M.</style></author><author><style face="normal" font="default"> Bellin,M.</style></author><author><style face="normal" font="default"> Tsoukleris,M.</style></author><author><style face="normal" font="default"> Mudd,S.S.</style></author><author><style face="normal" font="default"> Kub,J.</style></author><author><style face="normal" font="default"> Ogborn,J.</style></author><author><style face="normal" font="default"> Morphew,T.</style></author><author><style face="normal" font="default"> Lewis-Land,C.</style></author><author><style face="normal" font="default"> Bollinger,M.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Md.</style></auth-address><titles><title><style face="normal" font="default">Very Poorly Controlled Asthma in Urban Minority Children: Lessons Learned</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="9" Year="2017">2017/9/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: Very poorly controlled (VPC) asthma in children is associated with ongoing acute exacerbations but factors associated with VPC are understudied. OBJECTIVE: To examine the risk factors associated with VPC asthma in urban minority children. METHODS: This descriptive study examined asthma control levels (well-controlled [WC], not well-controlled [NWC], and VPC) at baseline and 6 months in children participating in an ongoing randomized controlled trial of an emergency department/home environmental control intervention. Data collection occurred during the index emergency department visit and included allergen-specific IgE and salivary cotinine testing and caregiver interview of sociodemographic and child health characteristics. Follow-up data were collected at 6 months. Unadjusted analyses examined the association of sociodemographic and health characteristics by level of asthma control. Multivariate analysis tested significant factors associated with VPC asthma at 6 months. RESULTS: At baseline most children were categorized with VPC asthma (WC, 0%; NWC, 47%; VPC, 53%) and rates of VPC minimally improved at 6 months (WC, 13%; NWC, 41%; VPC, 46%). Risk for VPC asthma was twice as likely in children with allergic rhinitis (odds ratio [OR], 2.42), having 2 or more primary care provider asthma visits within the past 3 months (OR, 2.77), or caregiver worry about medication side effects (OR, 2.13) and 3 to 4 times more likely when asthma control was assessed during the fall or spring season (OR: fall, 3.32; spring, 4.14). CONCLUSIONS: Improving asthma control in low-income, high-risk children with VPC asthma requires treatment of comorbidities, attention to caregiver medication beliefs, and adept use of stepwise therapy</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28958744">PM:28958744</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170929, Butz AM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42698</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Garzorz-Stark,N.</style></author><author><style face="normal" font="default"> Lauffer,F.</style></author><author><style face="normal" font="default"> Krause,L.</style></author><author><style face="normal" font="default"> Thomas,J.</style></author><author><style face="normal" font="default"> Atenhan,A.</style></author><author><style face="normal" font="default"> Franz,R.</style></author><author><style face="normal" font="default"> Roenneberg,S.</style></author><author><style face="normal" font="default"> Boehner,A.</style></author><author><style face="normal" font="default"> Jargosch,M.</style></author><author><style face="normal" font="default"> Batra,R.</style></author><author><style face="normal" font="default"> Mueller,N.S.</style></author><author><style face="normal" font="default"> Haak,S.</style></author><author><style face="normal" font="default"> Gross,C.</style></author><author><style face="normal" font="default"> Gross,O.</style></author><author><style face="normal" font="default"> Traidl-Hoffmann,C.</style></author><author><style face="normal" font="default"> Theis,F.J.</style></author><author><style face="normal" font="default"> Schmidt-Weber,C.B.</style></author><author><style face="normal" font="default"> Biedermann,T.</style></author><author><style face="normal" font="default"> Eyerich,S.</style></author><author><style face="normal" font="default"> Eyerich,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.</style></auth-address><titles><title><style face="normal" font="default">TLR7/8 agonists stimulate plasmacytoid dendritic cells to initiate a Th17-deviated acute contact dermatitis in humans</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="9" Year="2017">2017/9/18</year></dates><abstract><style face="normal" font="default">BACKGROUND: A standardized human model to study early pathogenic events in psoriasis is missing. Activation of Toll-like receptor 7/8 by topical application of imiquimod is the most commonly used mouse model of psoriasis. OBJECTIVE: To investigate the potential of a human imiquimod patch test model to resemble human psoriasis. METHODS: Imiquimod (Aldara(R) 5% cream) was applied twice a week onto the back of volunteers (n=18) and the development of skin lesions was monitored over a time period of four weeks. Consecutive biopsies were taken for whole genome expression analysis, histology and T cell isolation. pDC were isolated from whole blood, stimulated with TLR7 agonist and analysed by extracellular flux analysis and real time PCR. RESULTS: We demonstrate imiquimod induces a monomorphic and self-limited inflammatory response in healthy individuals as well as psoriasis or eczema patients, respectively. The clinical and histologic phenotype as well as transcriptome of imiquimod-induced inflammation in human skin resembles an acute contact dermatitis rather than psoriasis. Nevertheless, the imiquimod model mimics hallmarks of psoriasis. Namely, plasmacytoid dendritic cells (pDC) are primary sensors of imiquimod, responding with production of pro-inflammatory and Th17-skewing cytokines. This results in a Th17 immune response with IL-23 as a key driver. In a proof-of-concept setting, systemic treatment with ustekinumab diminished the imiquimod-induced inflammation. CONCLUSION: In humans, imiquimod induces contact dermatitis with the distinctive feature that pDC are the primary sensors, leading to an IL-23/Th17 deviation. Despite these shortcomings, the human imiquimod model might be useful to investigate early pathogenic events and prove molecular concepts in psoriasis</style></abstract><notes><style face="normal" font="default">DA - 20170922IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.07.045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28935206">PM:28935206</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170922-GarzorzStarkN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170922-GarzorzStarkN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170922, Garzorz-Stark N</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.07.045</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42699</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Roberts,T.T.</style></author><author><style face="normal" font="default"> Haines,C.M.</style></author><author><style face="normal" font="default"> Uhl,R.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Neurological Institute, Cleveland Clinic, Cleveland, OH (Dr. Roberts and Dr. Haines) and the Division of Orthopaedic Surgery, Albany Medical Center, Albany, NY (Dr. Uhl)</style></auth-address><titles><title><style face="normal" font="default">Allergic or Hypersensitivity Reactions to Orthopaedic Implants</style></title><secondary-title><style face="normal" font="default">J Am Acad Orthop Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Am Acad Orthop Surg</style></abbr-1></periodical><pages end="702" start="693">693-702</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Allergic or hypersensitivity reactions to orthopaedic implants can pose diagnostic and therapeutic challenges. Although 10% to 15% of the population exhibits cutaneous sensitivity to metals, deep-tissue reactions to metal implants are comparatively rare. Nevertheless, the link between cutaneous sensitivity and clinically relevant deep-tissue reactions is unclear. Most reactions to orthopaedic devices are type IV, or delayed-type hypersensitivity reactions. The most commonly implicated allergens are nickel, cobalt, and chromium; however, reactions to nonmetal compounds, such as polymethyl methacrylate, antibiotic spacers, and suture materials, have also been reported. Symptoms of hypersensitivity to implants are nonspecific and include pain, swelling, stiffness, and localized skin reactions. Following arthroplasty, internal fixation, or implantation of similarly allergenic devices, the persistence or early reappearance of inflammatory symptoms should raise suspicions for hypersensitivity. However, hypersensitivity is a diagnosis of exclusion. Infection, as well as aseptic loosening, particulate synovitis, instability, and other causes of failure must first be eliminated</style></abstract><notes><style face="normal" font="default">DA - 20170927IS - 1940-5480 (Electronic)IS - 1067-151X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.5435/JAAOS-D-16-00007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28953084">PM:28953084</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am Acad Orthop Surg\2017-25-693-702.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Am Acad Orthop Surg\2017-25-693-702.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170927, Roberts TT</style></custom2><misc3><style face="normal" font="default">10.5435/JAAOS-D-16-00007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42700</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Duncan,C.L.</style></author><author><style face="normal" font="default"> Walker,H.A.</style></author><author><style face="normal" font="default"> Brabson,L.</style></author><author><style face="normal" font="default"> Williford,D.N.</style></author><author><style face="normal" font="default"> Hynes,L.</style></author><author><style face="normal" font="default"> Hogan,M.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Psychology , West Virginia University , Morgantown , WV , USA</style></auth-address><titles><title><style face="normal" font="default">Developing pictorial asthma action plans to promote self-management and health in rural youth with asthma: A qualitative study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Asthma action plans (AAPs) provide asthma management instructions to families; however, AAPs typically are written at a 7th-9th grade reading level, making them less useful in lower literacy families. There is a need to develop simpler AAP formats and content to optimize their utility across all families, including those who are rural and may be at a risk for literacy concerns. Because using pictures can simplify and enhance health education, our study's aim was to develop a pictorial AAP through a series of focus groups with key stakeholders - youth with asthma, caregivers, and physicians. METHODS: Fourteen caregiver/youth dyads and four physicians participated in separate focus groups where their preferences for pictorial AAP structure and content were obtained. Focus groups were audio recorded, transcribed, coded with ATLAS.ti, and analyzed for themes. RESULTS: Youth and their caregivers prefer that the AAPs include simple, cartoon-like pictures customized to the patient. Physicians emphasized AAP's capability to display pictures of controller medication given its importance in preventing asthma exacerbations. A stoplight format, currently used in most written AAPs, received positive reviews. Specific suggestions for pictures showing symptoms, medications, and how to take medication were suggested. Words and short phrases accompanying the pictures were thought to add clarity. CONCLUSIONS: Key stakeholders viewed pictorial AAPs as positive and potentially effective alternatives to standard written AAPs. It is expected that low literacy youth and caregivers would more easily understand a pictorial AAP presentation, which should facilitate better medication adherence and asthma outcomes in these children</style></abstract><notes><style face="normal" font="default">DA - 20170921IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1371743</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28933570">PM:28933570</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170921-DuncanCL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170921-DuncanCL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170921, Duncan CL</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1371743</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42701</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Self,T.H.</style></author><author><style face="normal" font="default"> Shah,S.P.</style></author><author><style face="normal" font="default"> March,K.L.</style></author><author><style face="normal" font="default"> Sands,C.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Clinical Pharmacy , University of Tennessee Health Science Center , Memphis , TN , USA</style></auth-address><titles><title><style face="normal" font="default">Asthma associated with the use of cocaine, heroin, and marijuana: A review of the evidence</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="722" start="714">714-722</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">OBJECTIVE: A review of the evidence was conducted regarding asthma associated with the use of cocaine, heroin, and marijuana. DATA SOURCES: A search of the English literature was performed via PubMed/Medline and EMBASE using the search terms asthma AND cocaine, heroin, and marijuana. When pertinent articles were found, salient references in those articles were assessed. STUDY SELECTION: Due to the relatively small number of studies, we included all studies and cases. RESULTS: For several decades, case reports, retrospective studies, and laboratory investigations have demonstrated that inhalation of cocaine or heroin is associated with increased asthma symptoms and reduced pulmonary function. Smoking crack cocaine, nasal insufflation of cocaine or heroin, and smoking heroin increases the risk of emergency department visits and hospitalizations for asthma. Although frequent smoking of marijuana may cause symptoms of cough, sputum production, and wheezing in the general population, more studies are needed specifically in patients with asthma. Smoking marijuana with concomitant tobacco use is common and further worsens the respiratory symptoms. CONCLUSIONS: Use of cocaine and heroin in patients with asthma should be avoided. Pending further studies, it would be prudent for patients with asthma to avoid smoking marijuana. Clinicians need to be vigilant regarding use of these drugs in their patients with hyperreactive airway disease</style></abstract><notes><style face="normal" font="default">DA - 20161118IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1259420</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27858495">PM:27858495</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-714-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-714-22.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161118, Self TH</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1259420</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42702</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,T.L.</style></author><author><style face="normal" font="default"> Taylor,Y.J.</style></author><author><style face="normal" font="default"> Mahabaleshwarkar,R.</style></author><author><style face="normal" font="default"> Blanchette,C.M.</style></author><author><style face="normal" font="default"> Tapp,H.</style></author><author><style face="normal" font="default"> Dulin,M.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Center for Outcomes Research and Evaluation , Carolinas HealthCare System</style></auth-address><titles><title><style face="normal" font="default">Shared Decision Making and Time to Exacerbation in Children with Asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Although shared decision making (SDM) is a promising approach for improving outcomes for patients with chronic diseases, no evidence currently supports the use of SDM to delay asthma exacerbations. We evaluated the impact of an SDM intervention implemented by providers in a real-world setting on time to exacerbation in children with asthma. METHODS: This study used a prospective cohort observed between 2011-2013 at five primary care practices that serve vulnerable populations (e.g. Medicaid and uninsured patients) in Charlotte, NC. Patients aged 1 to 17 receiving SDM were matched to those receiving usual care using propensity scores. Time to asthma exacerbation (asthma hospitalization, emergency department visit or oral steroid prescription in the outpatient setting), was compared between groups using Kaplan Meier curves and conditional Cox proportional hazards models. RESULTS: The cohort included 746 children, 60.5% male and 54.2% African American, with a mean age of 8.6 years. Of these, 625 received usual care and 121 received SDM. The final analysis included 100 matched pairs of children. Kaplan Meier curves showed longer exacerbation-free time for patients in the SDM intervention compared to those in usual care (p = 0.005). The difference in risk of experiencing an exacerbation was marginally significant between the two groups (HR = 0.56, 95% C.I. = 0.29-1.08, p = 0.08). CONCLUSIONS: SDM was found to delay exacerbations among children with asthma. Clinicians should consider incorporating patient preferences in treatment decisions through SDM as a means for longer exacerbation free time among children with poor asthma control</style></abstract><notes><style face="normal" font="default">DA - 20170911IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1378357</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28892418">PM:28892418</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170911-TiuTL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170911-TiuTL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170911, Liu TL</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1378357</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42703</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nugent,C.</style></author><author><style face="normal" font="default"> Yiu,G.</style></author><author><style face="normal" font="default"> Song,S.</style></author><author><style face="normal" font="default"> Caracta,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Teva Pharmaceuticals, Inc. , Malvern , PA , USA</style></auth-address><titles><title><style face="normal" font="default">The Pharmacokinetics, Safety, and Tolerability of Single, High-Strength Doses of Fluticasone Propionate and Fluticasone Propionate/Salmeterol Delivered Via a Novel Multidose Dry Powder Inhaler in Adolescents and Adults with Persistent Asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Characterize fluticasone propionate (Fp) and combination fluticasone propionate and salmeterol (FS) pharmacokinetic and safety profiles, delivered via a novel, inhalation-driven, multidose dry powder inhaler (MDPI). METHODS: This multicenter, open-label, 4-period crossover, single-dose study randomized patients aged >/=12 years with persistent asthma to Fp MDPI 200 mcg, FS MDPI 200/12.5 mcg, Fp dry powder inhaler (DPI) 500 mcg (250 mcg x 2 inhalations), or FS DPI 500/50 mcg. Blood samples for determination of Fp and salmeterol pharmacokinetic parameters including Cmax, AUC0-t, AUC0-inf, tmax, and t(1/2) were collected predose through 36 hours postdose (14 time points). Safety assessments comprised adverse events, vital signs, and physical examinations. The Institutional Review Board approved the study protocol. RESULTS: The pharmacokinetic analysis set and safety population each included 40 patients. Fp systemic exposure (Cmax, AUC0-t, and AUC0-inf) was highest for Fp DPI 500 mcg and similar for Fp MDPI 200 mcg, FS MDPI 200/12.5 mcg, and FS DPI 500/50 mcg. Fp geometric mean t(1/2) values were similar across treatments. Salmeterol Cmax was 20% lower and AUC0-t and AUC0-inf were approximately 50% lower with FS MDPI versus FS DPI. Median tmax and geometric mean t(1/2) were similar between FS MDPI and FS DPI. Adverse events were similar across treatments with no relevant changes in vital signs, physical examinations, or hematology test results. CONCLUSIONS: Fp MDPI and FS MDPI produced similar or lower systemic exposure to Fp and salmeterol, despite lower doses, versus conventional DPI devices, suggesting improved efficiency due to formulation and device differences</style></abstract><notes><style face="normal" font="default">DA - 20170921IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1373392</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28933971">PM:28933971</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170921-NugentC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170921-NugentC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170921, Nugent C</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1373392</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42704</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yilmaz,O.</style></author><author><style face="normal" font="default"> Turkeli,A.</style></author><author><style face="normal" font="default"> Onur,E.</style></author><author><style face="normal" font="default"> Bilge,S.</style></author><author><style face="normal" font="default"> Yuksel,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatric Allergy and Pulmonology , Celal Bayar University Medical Faculty , Manisa , Turkey</style></auth-address><titles><title><style face="normal" font="default">Secondhand tobacco smoke and severity in wheezing children: Nasal oxidant stress and inflammation</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Prenatal and postnatal smoke exposures are associated with many lung diseases in children due to impaired lung function, increased inflammation, and oxidative stress. We aimed to determine the influence of secondhand tobacco smoke exposure on the levels of nasal glutathione, IL-8, IL-17, MMP-9, and TIMP-1, as well as serum surfactant protein-D (SP-D) in wheezy children. METHODS: We enrolled 150 children with recurrent wheezing and recorded wheezing characteristics at enrollment. We measured the levels of serum cotinine, SP-D, nasal glutathione, IL-8, IL-17, MMP-9, and TIMP-1. Serum cotinine levels between 3 and 12 ng/mL, and above 12 ng/mL were defined as lower and higher level secondhand tobacco smoke exposure, respectively. The ANOVA test, Pearson's correlation analysis and multivariate analysis with a linear regression test were used for the statistical analysis. RESULTS: Ninety-one children had been exposed to lower level secondhand tobacco smoke, while 24 children were exposed to higher level secondhand tobacco smoke. Thirty-five children were not exposed to cigarette smoke. Wheezing symptom scores were higher in exposed children (p = 0.03). Levels of other biomarkers showed no significant difference. CONCLUSIONS: Secondhand tobacco smoke exposure is associated with more severe respiratory symptoms in wheezing children. However, levels of nasal or serum inflammatory markers fail to explain this association, either because of different mechanical factors in the process or due to low levels of the biomarkers especially in nasal secretions</style></abstract><notes><style face="normal" font="default">DA - 20170907IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1350970</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28881145">PM:28881145</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170907-YilmazO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170907-YilmazO.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170907, Yilmaz O</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1350970</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42705</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bosnic-Anticevich,S.</style></author><author><style face="normal" font="default"> Kritikos,V.</style></author><author><style face="normal" font="default"> Carter,V.</style></author><author><style face="normal" font="default"> Yan,K.Y.</style></author><author><style face="normal" font="default"> Armour,C.</style></author><author><style face="normal" font="default"> Ryan,D.</style></author><author><style face="normal" font="default"> Price,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Woolcock Institute of Medical Research , Quality Use of Respiratory Medicines , Glebe , Australia</style></auth-address><titles><title><style face="normal" font="default">Lack of asthma and rhinitis control in general practitioner-managed patients prescribed fixed-dose combination therapy in Australia</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="9" Year="2017">2017/9/8</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The first aim of the study (i) assess the current asthma status of general-practitioner-managed patients receiving regular fixed-dose combination inhaled corticosteroid and long-acting beta2 agonist (FDC ICS/LABA) therapy and (ii) explore patients' perceptions of asthma control and attitudes/behaviors regarding preventer inhaler use. METHODS: A cross-sectional observational study of Australian adults with a current physician diagnosis of asthma receiving >/=2 prescriptions of FDC ICS/LABA therapy in the previous year, who were recruited through general practice to receive a structured in-depth asthma review between May 2012 and January 2014. Descriptive statistics and Chi-Square tests for independence were used for associations across asthma control levels. RESULTS: Only 11.5% of the patients had controlled asthma based on guideline-defined criteria. Contrarily, 66.5% of the patients considered their asthma to be well controlled. Incidence of acute asthma exacerbations in the previous year was 26.5% and 45.6% of the patients were without a diagnosis of rhinitis. Asthma medication use and inhaler technique were sub-optimal; only 41.0% of the preventer users reported everyday use. The side effects of medication were common and more frequently reported among uncontrolled and partially controlled patients. CONCLUSIONS: The study revealed the extent to which asthma management needs to be improved in this patient cohort and the numerous unmet needs regarding the current state of asthma care. Not only there is a need for continuous education of patients, but also education of health care practitioners to better understand the way in which patient's perceptions impact on asthma management practices, incorporating these findings into clinical decision making</style></abstract><notes><style face="normal" font="default">DA - 20170908IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - Ireland -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1353611</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28886264">PM:28886264</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170908-BosnicAnticevichS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170908-BosnicAnticevichS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170908, Bosnic-Anticevich S</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1353611</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42706</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Johnson,M.D.</style></author><author><style face="normal" font="default"> Nkoy,F.L.</style></author><author><style face="normal" font="default"> Sheng,X.</style></author><author><style face="normal" font="default"> Greene,T.</style></author><author><style face="normal" font="default"> Stone,B.L.</style></author><author><style face="normal" font="default"> Garvin,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatrics , University of Utah School of Medicine , Salt Lake City , UT , USA</style></auth-address><titles><title><style face="normal" font="default">Direct concurrent comparison of multiple pediatric acute asthma scoring instruments</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="753" start="741">741-753</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Appropriate delivery of Emergency Department (ED) treatment to children with acute asthma requires clinician assessment of acute asthma severity. Various clinical scoring instruments exist to standardize assessment of acute asthma severity in the ED, but their selection remains arbitrary due to few published direct comparisons of their properties. Our objective was to test the feasibility of directly comparing properties of multiple scoring instruments in a pediatric ED. METHODS: Using a novel approach supported by a composite data collection form, clinicians categorized elements of five scoring instruments before and after initial treatment for 48 patients 2-18 years of age with acute asthma seen at the ED of a tertiary care pediatric hospital ED from August to December 2014. Scoring instruments were compared for inter-rater reliability between clinician types and their ability to predict hospitalization. RESULTS: Inter-rater reliability between clinician types was not different between instruments at any point and was lower (weighted kappa range 0.21-0.55) than values reported elsewhere. Predictive ability of most instruments for hospitalization was higher after treatment than before treatment (p &lt; 0.05) and may vary between instruments after treatment (p = 0.054). CONCLUSIONS: We demonstrate the feasibility of comparing multiple clinical scoring instruments simultaneously in ED clinical practice. Scoring instruments had higher predictive ability for hospitalization after treatment than before treatment and may differ in their predictive ability after initial treatment. Definitive conclusions about the best instrument or meaningful comparison between instruments will require a study with a larger sample size</style></abstract><notes><style face="normal" font="default">DA - 20161110IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">0.1080/02770903.2016.1258081</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27831833">PM:27831833</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-741-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-741-53.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161110, Johnson MD</style></custom2><misc3><style face="normal" font="default">0.1080/02770903.2016.1258081</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42707</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Soo,Y.Y.</style></author><author><style face="normal" font="default"> Luckie,K.H.</style></author><author><style face="normal" font="default"> Saini,B.</style></author><author><style face="normal" font="default"> Kritikos,V.</style></author><author><style face="normal" font="default"> Brannan,J.D.</style></author><author><style face="normal" font="default"> Moles,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a National Prescribing Service , Learning Specialist Program &amp; Product Development , Surry Hills , Australia</style></auth-address><titles><title><style face="normal" font="default">Improving childcare staff management of acute asthma exacerbation - An Australian pilot study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="740" start="732">732-740</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">OBJECTIVE: This study aimed to evaluate the effectiveness of an asthma first-aid training tool for childcare staff in Australia. The effects of training on both asthma knowledge and skills were assessed. METHODS: A pre/post-study design was utilised to assess changes in asthma knowledge and asthma first-aid skills in childcare staff before and after an educational intervention. Asthma first-aid skills were assessed from the participant's response to two scenarios in which a child was having a severe exacerbation of asthma. Asthma knowledge and asthma skills scores were collected at base-line and 3 weeks post the education session, which involved feedback on each individual's skills and a brief lecture on asthma delivered via PowerPoint presentation. RESULTS: There was a significant improvement after intervention in asthma knowledge (Z = -3.638, p &lt; 0.001) and asthma first-aid skills for both scenario 1 (Z = -6.012, p &lt; 0.001) and scenario 2 (Z = -6.018, p &lt; 0.001). In scenario 1 and 2, first-aid skills improved by 65% (p &lt; 0.001) and 57% (p &lt; 0.001), respectively. Asthma knowledge was high at baseline (79%) and increased by 7% (p &lt; 0.001) after the educational intervention. These asthma knowledge results were not significant when adjusted for prior knowledge. Results suggest that knowledge assessment alone may not predict the practical skills needed for asthma first-aid. CONCLUSIONS: Skills assessment is a useful adjunct to knowledge assessment when gauging the ability of childcare staff to manage acute asthma exacerbation. Skills assessment could be considered for incorporation into future educational interventions to improve management of acute asthma exacerbation</style></abstract><notes><style face="normal" font="default">DA - 20161111IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1258076</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27834496">PM:27834496</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-732-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-732-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161111, Soo YY</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1258076</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42708</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Baker,M.A.</style></author><author><style face="normal" font="default"> Butler,M.G.</style></author><author><style face="normal" font="default"> Seymour,S.</style></author><author><style face="normal" font="default"> Zhang,F.</style></author><author><style face="normal" font="default"> Wu,Y.</style></author><author><style face="normal" font="default"> Wu,A.C.</style></author><author><style face="normal" font="default"> Levenson,M.S.</style></author><author><style face="normal" font="default"> Wu,P.</style></author><author><style face="normal" font="default"> Iyer,A.</style></author><author><style face="normal" font="default"> Toh,S.</style></author><author><style face="normal" font="default"> Iyasu,S.</style></author><author><style face="normal" font="default"> Zhou,E.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Population Medicine , Harvard Medical School and Harvard Pilgrim Health Care Institute , Boston , MA</style></auth-address><titles><title><style face="normal" font="default">The Impact of FDA Regulatory Activities on Incident Dispensing of LABA-Containing Medication: 2005-2011</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="9" Year="2017">2017/9/14</year></dates><abstract><style face="normal" font="default">BACKGROUND: Evidence of safety issues associated with long-acting beta2-agonist (LABA) treatment has led to multiple regulatory activities by the U.S. Food and Drug Administration (FDA) on this class of medications. OBJECTIVE: This study describes the impact of the regulatory activities on incident LABA-containing medication dispensing. METHODS: A monthly rolling cohort of asthma patients who were eligible to initiate a LABA-containing product was created in the Mini-Sentinel Distributed Database between January 2005 and June 2011. Cohorts of individuals who initiated LABA were examined for the changes in the proportions of single-ingredient to fixed-dose inhaled corticosteroid (ICS)-LABA initiators, appropriate initiation of LABA-containing products, and use of controller medications. The impact of the 2005 and 2010 FDA regulatory activities associated with LABA-containing products were measured using interrupted time series with segmented regression. RESULTS: LABA-containing product initiation was declining prior to the 2005 regulatory activities and continued to decline over the study period, accompanied by increased initiation of fixed dose ICS-LABA among LABA initiators. While the 2010 regulatory activities had no immediate impact on the proportion of LABA initiation in patients with prior controller medication dispensing and/or poor asthma control, there was an increasing positive trend toward LABA initiation in the appropriate patient population after the regulatory activities. CONCLUSION: The 2005 and 2010 FDA regulatory activities likely had an impact on communicating the safety concerns of LABA products. However, the impact cannot be viewed independent of scientific publications, guidelines for asthma treatment and other regulatory activities</style></abstract><notes><style face="normal" font="default">DA - 20170914IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Bermuda -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1378355</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28910559">PM:28910559</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170914-BakerMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170914-BakerMA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170914, Baker MA</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1378355</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42709</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,Q.</style></author><author><style face="normal" font="default"> Lamichhane,R.</style></author><author><style face="normal" font="default"> Diggs,L.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a School of Community and Environmental Health, Old Dominion University , Norfolk , VA , USAb Department of Mathematics , Texas A&amp;M University-Kingsville , Kingsville , TX , USAa School of Community and Environmental Health, Old Dominion University , Norfolk , VA , USA</style></auth-address><titles><title><style face="normal" font="default">Disparities in emergency department visits in American children with asthma: 2006-2010</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="686" start="679">679-686</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">OBJECTIVE: This article was to examine the trends in emergency department (ED) visits for asthma among American children in 2006-2010 across sociodemographic factors, parental smoking status, and children's body weight status. METHODS: We analyzed 5,535 children aged 2-17 years with current asthma in the Asthma Call-Back Survey in 2006-2010. Multivariate log binomial regression was used to examine the disparities of ED visits by demographics, socioeconomic status, parental smoking status, children's body weight status, and the level of asthma control. We controlled for average state-level air pollutants. Prevalence ratios (PRs) and 95% confidence intervals (CIs) were reported. RESULTS: Minority children with current asthma had higher risks of ED visits compared with white children in 2009 and 2010, e.g., the PR (95% CI) for black children in 2009 was 3.64 (1.79, 7.41). Children who had current asthma and more highly educated parents experienced a higher risk of ED visits in 2007 (PRs [95% CI] = 2.15 [1.02, 4.53] and 2.97 [1.29, 6.83] for children with some college or college-graduated parents), but not significant in other years. Children with uncontrolled asthma were significantly more likely to visit the ED in 2008 (PRs [95% CI] = 2.79 [1.44, 5.41] and 6.96 [3.55, 13.64] for not-well-controlled and very poorly controlled children with asthma). CONCLUSIONS: Minority children with current asthma or children with uncontrolled asthma were more likely to visit EDs for asthma treatment. However, the disparities in ED visits across sociodemographics, health status, or asthma control vary in scale and significance across time. More research is needed to explain these differences</style></abstract><notes><style face="normal" font="default">DA - 20161123IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1263315</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27880053">PM:27880053</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-679-86.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-679-86.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161123, Zhang Q</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1263315</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42710</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sheikh,S.I.</style></author><author><style face="normal" font="default"> Pitts,J.</style></author><author><style face="normal" font="default"> Ryan-Wenger,N.A.</style></author><author><style face="normal" font="default"> Kotha,K.</style></author><author><style face="normal" font="default"> McCoy,K.S.</style></author><author><style face="normal" font="default"> Stukus,D.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatrics , The Ohio State University College of Medicine , Columbus , OH , USA</style></auth-address><titles><title><style face="normal" font="default">Improved quality-of-life of caregivers of children with asthma through guideline-based management</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="776" start="768">768-776</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The quality of life (QOL) of caregivers of children with asthma may be related to children's responses to asthma management. AIM: To evaluate change in QOL over time of caregivers of children with asthma through guideline-based management. DESIGN: This was a 3-year prospective cohort study of children with asthma referred to our pediatric asthma center. Families completed Pediatric Asthma Caregiver's Quality of Life Questionnaire (PACQLQ), the Asthma Control Test (ACT), and reported the number of days/month of albuterol use and wheezing at each clinic visit. RESULTS: We enrolled 143 children, ages 7-17 years (mean = 10.6 +/- 2.9), 56.6% male, 70.6% Caucasian. Patients were managed by the same MD (n = 65,45.5%) or APN (n = 78,54.5%) over time. The mean total PACQLQ significantly increased over the 3-year period (F = 67.418, p &lt; .001). Total scores at the first visit were 4.8 +/- 1.6, which improved to 6.1 +/- 1 at the 3-month follow-up visit. This improvement was sustained at the 1, 2, and 3-year clinic visits. PACQLQ emotional function (F = 60.798, p &lt; .001) and activity limitation (F = 41.517, p &lt; .001) domains significantly improved as well. PACQLQ scores were significantly associated with improved ACT scores (r = .37 to .47, p &lt; .05), fewer days/month of albuterol use (r = -.25 to -.36., p &lt; .05), and wheezing (r = -.28 to -.33, p &lt; .05). There were no significant differences in PACQLQ, or asthma clinical outcome measures between MD and APN providers. CONCLUSION: Use of National Asthma Education and Prevention Program (NAEPP) guidelines significantly improved QOL of caregivers of children with asthma and in asthma-related symptoms. Improvements over time were independent of type of providers</style></abstract><notes><style face="normal" font="default">DA - 20161110IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1258077</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27831828">PM:27831828</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-768-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-768-76.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161110, Sheikh S</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1258077</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42711</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hollenbach,J.P.</style></author><author><style face="normal" font="default"> Cushing,A.</style></author><author><style face="normal" font="default"> Melvin,E.</style></author><author><style face="normal" font="default"> McGowan,B.</style></author><author><style face="normal" font="default"> Cloutier,M.M.</style></author><author><style face="normal" font="default"> Manice,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatrics , University of Connecticut School of Medicine, Asthma Center, CT Children's Medical Center , Hartford , CT , USA</style></auth-address><titles><title><style face="normal" font="default">Understanding clinicians' attitudes toward a mobile health strategy to childhood asthma management: A qualitative study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="760" start="754">754-760</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Mobile technology for childhood asthma can provide real-time data to enhance care. What real-time adherence information clinicians want, how they may use it, and if the data meet their clinical needs have not been fully explored. Our goal was to determine whether pediatric primary care and pulmonary clinicians believe if a sensor-based mobile intervention is useful in caring for patients with asthma. METHODS: We recruited participants from 3 urban, primary care and 1 pulmonary practice from July to September 2015 in Hartford, CT. Forty-one participated in four focus groups, which included a demonstration of the technology. Participants were probed with open-ended questions on the type, frequency, and format of inter-visit patient information they found useful. RESULTS: 41 participants (mean age 49 (+/-13.7) years) were board-certified clinicians (41% MDs and 20% mid-level practitioners), practiced medicine on an average of 19 (+/-14) years, were primarily white (59%) and women (78%). Clinicians wanted 1) adherence to prescribed inhaler therapy and 2) data on inhaler technique. Clinicians wanted it at the time of a scheduled clinic visit but also wanted inter-visit alerts for excessive use of rescue therapy. Pulmonologists liked the mobile spirometer's provision of inter-visit lung function data; pediatricians did not share this view. Concerns with data accuracy were raised due to families who shared inhalers, access to smartphones, and protection of health information. CONCLUSIONS: Overall, clinicians view an asthma mobile health technology as enhancing the patient-centered medical home. Pediatric primary care clinicians and pulmonologists want different information from a mobile app</style></abstract><notes><style face="normal" font="default">DA - 20161123IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2016.1263649</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27880049">PM:27880049</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-754-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-754-60.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161123, Hollenbach JP</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2016.1263649</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42712</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mindlis,I.</style></author><author><style face="normal" font="default"> Morales-Raveendran,E.</style></author><author><style face="normal" font="default"> Goodman,E.</style></author><author><style face="normal" font="default"> Xu,K.</style></author><author><style face="normal" font="default"> Vila-Castelar,C.</style></author><author><style face="normal" font="default"> Keller,K.</style></author><author><style face="normal" font="default"> Crawford,G.</style></author><author><style face="normal" font="default"> James,S.</style></author><author><style face="normal" font="default"> Katz,C.L.</style></author><author><style face="normal" font="default"> Crowley,L.E.</style></author><author><style face="normal" font="default"> de la Hoz,R.E.</style></author><author><style face="normal" font="default"> Markowitz,S.</style></author><author><style face="normal" font="default"> Wisnivesky,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Division of General Internal Medicine , Icahn School of Medicine at Mount Sinai , New York , NY , USA</style></auth-address><titles><title><style face="normal" font="default">Post-traumatic stress disorder dimensions and asthma morbidity in World Trade Center rescue and recovery workers</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="731" start="723">723-731</pages><volume><style face="normal" font="default">54</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Using data from a cohort of World Trade Center (WTC) rescue and recovery workers with asthma, we assessed whether meeting criteria for post-traumatic stress disorder (PTSD), sub-threshold PTSD, and for specific PTSD symptom dimensions are associated with increased asthma morbidity. METHODS: Participants underwent a Structured Clinical Interview for Diagnostic and Statistical Manual to assess the presence of PTSD following DSM-IV criteria during in-person interviews between December 2013 and April 2015. We defined sub-threshold PTSD as meeting criteria for two of three symptom dimensions: re-experiencing, avoidance, or hyper-arousal. Asthma control, acute asthma-related healthcare utilization, and asthma-related quality of life data were collected using validated scales. Unadjusted and multiple regression analyses were performed to assess the relationship between sub-threshold PTSD and PTSD symptom domains with asthma morbidity measures. RESULTS: Of the 181 WTC workers with asthma recruited into the study, 28% had PTSD and 25% had sub-threshold PTSD. Patients with PTSD showed worse asthma control, higher rates of inpatient healthcare utilization, and poorer asthma quality of life than those with sub-threshold or no PTSD. After adjusting for potential confounders, among patients not meeting the criteria for full PTSD, those presenting symptoms of re-experiencing exhibited poorer quality of life (p = 0.003). Avoidance was associated with increased acute healthcare use (p = 0.05). Sub-threshold PTSD was not associated with asthma morbidity (p > 0.05 for all comparisons). CONCLUSIONS: There may be benefit in assessing asthma control in patients with sub-threshold PTSD symptoms as well as those with full PTSD to more effectively identify ongoing asthma symptoms and target management strategies</style></abstract><notes><style face="normal" font="default">DA - 20161201IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default"> 10.1080/02770903.2016.1263650</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27905829">PM:27905829</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\2017-54-723-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\2017-54-723-31.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161201, Mindlis I</style></custom2><misc3><style face="normal" font="default"> 10.1080/02770903.2016.1263650</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42713</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Daugherty,J.</style></author><author><style face="normal" font="default"> Lin,X.</style></author><author><style face="normal" font="default"> Baxter,R.</style></author><author><style face="normal" font="default"> Suruki,R.</style></author><author><style face="normal" font="default"> Bradford,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy , University of North Carolina , Chapel Hill , NC , USA</style></auth-address><titles><title><style face="normal" font="default">The impact of long-term systemic glucocorticoid use in severe asthma: A UK retrospective cohort analysis</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Systemic glucocorticoids (SGCs) are a treatment option for severe asthma but are associated with the development of adverse events (AEs). Evidence on the extent of SGC use and the relationship between SGC dose and AE risk in severe asthma is limited. METHODS: Patients with severe asthma (Global Initiative for Asthma step 4/5), with no SGC use during the &lt;6-12 months before severe asthma determination (index date) were identified in the UK-based Clinical Practice Research Datalink database (2004-2012). Patients were assessed for SGC exposure and an incident diagnosis of an SGC-related AE (cataracts, diabetes, myocardial infarction [MI], osteoporosis, peptic ulcer or stroke) during the 8-year observation phase. The dose-related risk of an SGC-related AE was determined using AE-specific Cox proportional hazards models. RESULTS: Overall, 75% of 60,418 patients identified with severe asthma received SGC during the 8-year follow-up, with the majority receiving an average of >0-&lt;/=2.5 mg/day. The risk of diabetes (hazard ratio [HR]:1.20 [95% confidence interval (CI): 1.11, 1.30]), MI (HR: 1.25 [95% CI: 1.09, 1.43]) and osteoporosis (HR: 1.64 [95% CI: 1.51, 1.78]) was increased at low SGC doses (0-2.5 mg/day), with further risk increases at doses >2.5 mg/day versus no SGC use. Compared with no SGC use, SGC increased the risk of peptic ulcer in a non-dose-dependent manner, but the risk of stroke was unchanged. CONCLUSIONS: Most patients with severe asthma are exposed to SGC, which increases SGC-related AE risk. This suggests that SGC exposure should be minimized as recommended by asthma treatment guidelines</style></abstract><notes><style face="normal" font="default">DA - 20170919IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1353612</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28925768">PM:28925768</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170919-DaughertyJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170919-DaughertyJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170919, Daugherty J</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1353612</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42714</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Johnston,C.F.</style></author><author><style face="normal" font="default"> Broom,M.</style></author><author><style face="normal" font="default"> Shadbolt,B.</style></author><author><style face="normal" font="default"> Todd,D.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Australian National University (ANU) Medical School , Canberra , ACT , Australia</style></auth-address><titles><title><style face="normal" font="default">Smoking in the family is most predictive of the development of childhood asthma in preterm babies &lt;30 weeks gestation: Results of the Respiratory Outcomes Study 2 (REPOS2)</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="9" Year="2017">2017/9/13</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The Respiratory Outcomes Study 2 (RESPOS2) investigated the relationship between neonatal outcomes (specifically, chronic lung disease [CLD]) and environmental factors on the development of asthma and atopic outcomes at primary school age for preterm babies (PBs) &lt;30 weeks gestational age (GA). METHODS: The study included all surviving PBs &lt;30 weeks GA admitted to the Neonatal Intensive Care Unit at Canberra Hospital, Australian Capital Territory between 2007-2009. Parents were sent a questionnaire regarding asthma and atopy symptoms when the PBs were aged 5-7 years old. Data were compared based on CLD status. RESULTS: There were 103 PBs included in the study with a 68.9% response rate to the respiratory questionnaire (71/103). Of these PBs, 15/71 (21.1%) received a diagnosis of CLD. There were no significant differences with regards to asthma, hay fever or eczema in PBs either with or without CLD. The most significant predictor for the development of asthma was smoking in the family (Odds Ratio [OR]: 11.66, 95% Confidence Interval [CI]: 2.01-67.56) with a trend towards significance for family history of asthma (OR: 3.83, 95% CI: 0.85-17.25). CONCLUSION: The RESPOS2 has confirmed previous reports that CLD in PBs &lt;30 weeks GA is not associated with the development of childhood asthma, hay fever or eczema. In our group of PBs the strongest predictor of the development of asthma was smoking in the family</style></abstract><notes><style face="normal" font="default">DA - 20170913IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1366508</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28902527">PM:28902527</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170913-JohnstonCF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170913-JohnstonCF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170913, Johnston CF</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1366508</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42715</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Trent,S.A.</style></author><author><style face="normal" font="default"> Hasegawa,K.</style></author><author><style face="normal" font="default"> Ramratnam,S.K.</style></author><author><style face="normal" font="default"> Bittner,J.C.</style></author><author><style face="normal" font="default"> Camargo,C.A.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Emergency Medicine , Denver Health Medical Center , Denver , CO ; University of Colorado School of Medicine , Aurora</style></auth-address><titles><title><style face="normal" font="default">Variation in Asthma Care at Hospital Discharge by Race/Ethnicity Groups</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="default">INTRODUCTION: While asthma disproportionately affects minorities, little is known about racial/ethnic differences in asthma care at hospital discharge. METHODS: Design: Secondary data analysis of multicenter retrospective study using standardized medical record review. POPULATION: Random sample of patients age 2-54 years, who were hospitalized for asthma at 25 hospitals from 2012-2013. Outcomes and Analysis: We categorized patients into three race/ethnicity groups: non-Hispanic white (NHW), non-Hispanic black (NHB), and Hispanic. Multivariable logistic regression using generalized estimating equations were used to examine the relationship between race/ethnicity and the provision of guideline-concordant asthma care at hospital discharge including: the provision of asthma action plans, provision of new prescription of an inhaled corticosteroid, and referral to asthma specialist. RESULTS: 913 patients (39% children, 71% minorities) hospitalized for asthma were included. In adjusted models, NHB children were significantly less likely to receive a written asthma action plan (OR 0.48; 95% CI 0.31-0.76) than NHW children. In contrast, amongst adults, we found no statistically significant difference in the provision of asthma action plan. Additionally, we found no difference in the provision of a new inhaled corticosteroid prescription or referral to asthma specialist amongst children or adults. CONCLUSIONS: NHB and Hispanic patients represent the majority of patients hospitalized for acute asthma in our cohort and were more likely than NHW patients to have increased markers of asthma severity. Despite this, the only significant racial/ethnic difference in asthma care at hospital discharge was among NHB children, who were less likely to receive a written asthma action plan</style></abstract><notes><style face="normal" font="default">DA - 20170911IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1378356</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28892408">PM:28892408</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170911-TrentSA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170911-TrentSA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170911, Trent SA</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1378356</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42716</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Menzella,F.</style></author><author><style face="normal" font="default"> Galeone,C.</style></author><author><style face="normal" font="default"> Bertolini,F.</style></author><author><style face="normal" font="default"> Castagnetti,C.</style></author><author><style face="normal" font="default"> Facciolongo,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Specialties, Pneumology Unit, I</style></auth-address><titles><title><style face="normal" font="default">Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="247" start="237">237-247</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The increasing understanding of the molecular biology and the etiopathogenetic mechanisms of asthma helps in identification of numerous phenotypes and endotypes, particularly for severe refractory asthma. For a decade, the only available biologic therapy that met the unmet needs of a specific group of patients with severe uncontrolled allergic asthma has been omalizumab. Recently, new biologic therapies with different mechanisms of action and targets have been approved for marketing, such as mepolizumab. Other promising drugs will be available in the coming years, such as reslizumab, benralizumab, dupilumab and lebrikizumab. Moreover, since 2010, bronchial thermoplasty has been successfully introduced for a limited number of patients. This is a nonpharmacologic endoscopic procedure which is considered a promising therapy, even though several aspects still need to be clarified. Despite the increasing availability of new therapies, one of the major problems of each treatment is still the identification of the most suitable patients. This sudden abundance of therapeutic options, sometimes partially overlapping with each other, increases the importance to identify new biomarkers useful to guide the clinician in selecting the most appropriate patients and treatments, without forgetting the drug-economic aspects seen in elevated direct cost of new therapies. The aim of this review is, therefore, to update the clinician on the state of the art of therapies available for refractory asthma and, above all, to give useful directions that will help understand the different choices that sometimes partially overlap and to dispel the possible doubts that still exist</style></abstract><notes><style face="normal" font="default">DA - 20170918IS - 1178-6965 (Print)IS - 1178-6965 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.2147/JAA.S144100</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28919788">PM:28919788</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-237-47.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-237-47.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170918, Menzella F</style></custom2><misc3><style face="normal" font="default">10.2147/JAA.S144100</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42717</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sharma,S.</style></author><author><style face="normal" font="default"> Kaur,T.</style></author><author><style face="normal" font="default"> Malhotra,S.K.</style></author><author><style face="normal" font="default"> Rai,J.</style></author><author><style face="normal" font="default"> Chaudhari,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Junior Resident, Department of Dermatology, Venereology and Leprosy, Govt. Medical College, Amritsar, Punjab, India</style></auth-address><titles><title><style face="normal" font="default">Correlation of Vitamin D3 Levels and SCORAD Index in Atopic Dermatits: A Case Control Study</style></title><secondary-title><style face="normal" font="default">J Clin Diagn Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Clin Diagn Res</style></abbr-1></periodical><pages end="WC03" start="WC01">WC01-WC03</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Atopic Dermatitis (AD) is a common chronic inflammatory condition characterized clinically by pruritus and eczematous lesions. An inverse relationship has been suggested between serum 25-hydroxyvitamin D concentration and severity of atopic dermatitis. AIM: We carried out this controlled cross-sectional study to evaluate the association between the serum vitamin D3 levels and SCORAD index. MATERIALS AND METHODS: For this study, 40 patients with clinical diagnosis of AD based on UK diagnostic criteria were enrolled and 40 patients with minor ailments like superficial bacterial, fungal or viral infections and not suffering from atopic dermatitis were taken as controls. Salient presentations were recorded in a pre-set proforma. Serum 25-hydroxyvitamin D levels were determined through Sandwich-ELISA technique. SCORAD (Scoring AD) index was used to evaluate the severity of the disease. RESULTS: Mean value of serum 25-hydroxyvitamin D levels in cases was 30.38 nmol/l whereas in controls, it was 53.46 nmol/l. The decrease in serum levels in cases was statistically highly significant (p-value &lt;0.001). Mean+/-S.D of serum vitamin D levels in mild disease was 33.29+/-5.89 nmol/l, in moderate disease was 31.52+/-6.04 nmol/l and in severe form of disease was 21.24+/-3.17nmol/l. The correlation between SCORAD and serum 25-hydroxyvitamin D levels was also statistically significant. CONCLUSION: The data suggests an inverse relationship between serum levels of vitamin D3 and the SCORAD Index</style></abstract><notes><style face="normal" font="default">DA - 20170912IS - 2249-782X (Print)IS - 0973-709X (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.7860/JCDR/2017/27188.10223</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28893022">PM:28893022</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Diagn Res\2017-11-WC01-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Diagn Res\2017-11-WC01-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170912, Sharma S</style></custom2><misc3><style face="normal" font="default">10.7860/JCDR/2017/27188.10223</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42718</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sandre,M.</style></author><author><style face="normal" font="default"> Skotnicki-Grant,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Division of Dermatology, University of Toronto, Toronto, ON, Canada</style></auth-address><titles><title><style face="normal" font="default">A Case of a Paediatric Patient With Allergic Contact Dermatitis to Benzoyl Peroxide</style></title><secondary-title><style face="normal" font="default">J Cutan Med Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Cutan Med Surg</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="default">Allergic contact dermatitis to benzoyl peroxide can occur in up to 6.5% of those with a history of exposure to this potential allergen. Conversely, irritant contact dermatitis is very common with benzoyl peroxide and can be differentiated from allergic contact dermatitis based on the patient's history and clinical signs and symptoms. We present a case of a paediatric patient with patch test-confirmed severe allergic contact dermatitis to benzoyl peroxide requiring hospitalisation and systemic treatment</style></abstract><notes><style face="normal" font="default">DA - 20170919IS - 1615-7109 (Electronic)IS - 1203-4754 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1177/1203475417733462</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28922933">PM:28922933</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Cutan Med Surg\20170919-SandreM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Cutan Med Surg\20170919-SandreM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170919, Sandre M</style></custom2><misc3><style face="normal" font="default">10.1177/1203475417733462</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42719</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cavagnero,K.</style></author><author><style face="normal" font="default"> Doherty,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, University of California San Diego, USADepartment of Medicine, University of California San Diego, USA</style></auth-address><titles><title><style face="normal" font="default">Cytokine and Lipid Mediator Regulation of Group 2 Innate Lymphoid Cells (ILC2s) in Human Allergic Airway Disease</style></title><secondary-title><style face="normal" font="default">J Cytokine Biol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Cytokine Biol</style></abbr-1></periodical><pages end="" start="116">116-</pages><volume><style face="normal" font="default">2</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">The recent discovery of group 2 innate lymphoid cells (ILC2s) has caused a paradigm shift in the understanding of allergic airway disease pathogenesis. Prior to the discovery of ILC2s, Th2 cells were largely thought to be the primary source of type 2 cytokines; however, activated ILC2s have since been shown to contribute significantly, and in some cases, dominantly to type 2 cytokine production. Since the discovery of ILC2s in 2010, many mediators have been shown to regulate their effector functions. Initial studies identified the epithelial derived cytokines IL-25, IL-33, and TSLP as activators of ILC2s, and recent studies have identified many additional cytokine and lipid mediators that are involved in ILC2 regulation. ILC2s and their mediators represent novel therapeutic targets for allergic airway diseases and intensive investigation is underway to better understand ILC2 biology and upstream and downstream pathways that lead to ILC2-driven airway pathology. In this review, we will focus on the cytokine and lipid mediators that regulate ILC2s in human allergic airway disease, as well as highlight newly discovered mediators of mouse ILC2s that may eventually translate to humans</style></abstract><notes><style face="normal" font="default">DA - 20170929LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28959799">PM:28959799</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Cytokine Biol\2017-2-116.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Cytokine Biol\2017-2-116.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Cavagnero K</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42720</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,J.</style></author><author><style face="normal" font="default"> Lee,J.Y.</style></author><author><style face="normal" font="default"> Kim,H.J.</style></author><author><style face="normal" font="default"> Seo,K.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Oral and Maxillofacial Surgery, School of Dentistry, Seoul National University, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Dental anesthesia for patients with allergic reactions to lidocaine: two case reports</style></title><secondary-title><style face="normal" font="default">J Dent Anesth Pain Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Dent Anesth Pain Med</style></abbr-1></periodical><pages end="212" start="209">209-212</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="default">Lidocaine, a local anesthetic commonly used in dental treatments, is capable of causing allergies or adverse effects similar to allergic reactions. However, the frequency of such occurrences in actual clinical settings is very rare, and even clinical tests on patients with known allergies to local anesthetics may often show negative results. When adverse effects, such as allergy to lidocaine, are involved, patients can be treated by testing other local anesthetics and choosing a local anesthetic without any adverse effects, or by performing dental treatment under general anesthesia in cases in which no local anesthetic without adverse effects is available. Along with a literature review, the authors of the present study report on two cases of patients who tested positive on allergy skin tests for lidocaine and bupivacaine and subsequently underwent successful dental treatments with either general anesthesia or a different local anesthetic</style></abstract><notes><style face="normal" font="default">DA - 20170908IS - 2383-9309 (Print)IS - 2383-9309 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.17245/jdapm.2016.16.3.209</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28884155">PM:28884155</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dent Anesth Pain Med\2016-16-209-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dent Anesth Pain Med\2016-16-209-12.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170908, Lee J</style></custom2><misc3><style face="normal" font="default">10.17245/jdapm.2016.16.3.209</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42721</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hon,K.L.</style></author><author><style face="normal" font="default"> Kung,J.S.C.</style></author><author><style face="normal" font="default"> Tsang,K.Y.</style></author><author><style face="normal" font="default"> Yu,J.W.</style></author><author><style face="normal" font="default"> Wong,N.</style></author><author><style face="normal" font="default"> Leung,T.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">a The Chinese University of Hong Kong, Prince of Wales Hospital , Hong Kong</style></auth-address><titles><title><style face="normal" font="default">Do we need another symptom score for childhood eczema?</style></title><secondary-title><style face="normal" font="default">J Dermatolog Treat</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatolog Treat</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="8" Year="2017">2017/8/29</year></dates><abstract><style face="normal" font="default">AIM: It is important to objectively measure the severity of atopic dermatitis (AD). This study aims to investigate correlations among various clinical severity scores and determine how a severity score based on symptoms alone performs. METHODS: A modified symptom score based on Patient-Oriented Eczema Measure (POEM, a short-term subjective-symptom score), Scoring Atopic Dermatitis (SCORAD, a short-term subjective-symptom and objective-sign score), Nottingham Eczema Severity Score (NESS, a long-term subjective-symptom score), Children Dermatology Life Quality Index (CDLQI, a short-term subjective-symptom score), skin hydration (SH) and transepidermal water loss (TEWL) were compared and Spearman's rho correlations evaluated. RESULTS: 126 sets of clinical scores from eczema patients (mean age: 11.4+/-5.6years; 34.7% male) were evaluated. The modified-POEM, objective SCORAD, NESS, CDLQI correlated well with each other. All round, best correlations were obtained with POEM: Objective SCORAD (rho = 0.7, p &lt; 0.001), NESS (rho = 0.69, p &lt; 0.001), SCORAD symptom of itch (rho = 0.75, p &lt; 0.01), SCORAD symptom of sleep loss (rho = 0.64, p &lt; 0.01), CDLQI (rho = 0.77, p &lt; 0.001) and SH (rho= -0.043, p &lt; 0.05). Linear stepwise-backward regression demonstrated that POEM was independently associated with CDLQI parameters of pruritus (B: 2.16; p = 0.018), activities (B: 1.80; p= 0.009), sleep disturbance (B: 2.78; p &lt; 0.001)], and NESS parameter of sleep disturbance (B: 1.02; p = 0.003). CONCLUSION: Clinical scores for acute, chronic, subjective symptoms and objective signs correlated well with each other. The symptom measures by modified POEM is easy to perform by parents or patients and correlated better with most other clinical scores, making it an all-round ideal symptom-based severity score for research</style></abstract><notes><style face="normal" font="default">DA - 20170829IS - 1471-1753 (Electronic)IS - 0954-6634 (Linking)LA - engPT - Journal ArticleCO - Hong Kong -</style></notes><work-type><style face="normal" font="default">10.1080/09546634.2017.1373734</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28849683">PM:28849683</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatolog Treat\20170829-ZhanPP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatolog Treat\20170829-ZhanPP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170829, Hon KL</style></custom2><misc3><style face="normal" font="default">10.1080/09546634.2017.1373734</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42722</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Riha,H.M.</style></author><author><style face="normal" font="default"> Summers,B.B.</style></author><author><style face="normal" font="default"> Rivera,J.V.</style></author><author><style face="normal" font="default"> Van Berkel,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacy, Erlanger Health System, Chattanooga, Tennessee</style></auth-address><titles><title><style face="normal" font="default">Novel Therapies for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema: A Systematic Review of Current Evidence</style></title><secondary-title><style face="normal" font="default">J Emerg Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Emerg Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="9" Year="2017">2017/9/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: Angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema can occur at any point during therapy and, when severe, can require mechanical ventilation. Standard agents for anaphylactic reactions have limited efficacy for bradykinin-mediated angioedema and, therefore, agents approved for hereditary angioedema are increasingly prescribed for these patients. OBJECTIVE OF THE REVIEW: This systematic review critically evaluates evidence describing the off-label use of fresh frozen plasma (FFP), prothrombin complex concentrate (PCC), complement 1 esterase inhibitor (C1-INH), icatibant, and ecallantide for treatment of ACEI-induced angioedema. DISCUSSION: A PubMed search was conducted and articles were cross-referenced for additional citations. All full-text clinical trials, case series, and case reports published in the English language describing pharmacologic treatment of ACEI-induced angioedema were included. Thirty-seven publications detailing FFP, PCC, and regimens approved for hereditary angioedema, including icatibant, ecallantide, and C1-INH, are reviewed extensively. CONCLUSIONS: While findings of decreased time to symptom resolution or a cessation in symptom progression have been reported with each of these therapies, additional data showing clinically relevant implications, such as reduced intensive care unit length of stay or avoidance of mechanical ventilation, are warranted, especially when taking cost into consideration. FFP has limited evidence demonstrating a benefit for treatment of ACEI-induced angioedema without consistent dosing strategies. However, given its wide availability and low potential for adverse reactions, FFP therapy may be reasonable. Of the novel agents traditionally used for hereditary angioedema, icatibant has the highest level of evidence and has been reported to be successful in limiting the progression of angioedema</style></abstract><notes><style face="normal" font="default">DA - 20170923IS - 0736-4679 (Print)IS - 0736-4679 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jemermed.2017.05.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28939396">PM:28939396</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Emerg Med\20170923-RihaHM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Emerg Med\20170923-RihaHM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170923, Riha HM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jemermed.2017.05.037</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42723</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kosumi,H.</style></author><author><style face="normal" font="default"> Yanagi,T.</style></author><author><style face="normal" font="default"> Izumi,K.</style></author><author><style face="normal" font="default"> Ito,T.</style></author><author><style face="normal" font="default"> Shimizu,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, Sapporo, Japan</style></auth-address><titles><title><style face="normal" font="default">Unusual post-patch testing erythema: a late, granulomatous, non-eczematous reaction to gold sodium thiosulfate</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="10" Year="2017">2017/10/6</year></dates><abstract><style face="normal" font="default">In patch testing, delayed reactions at day 7 or later are regarded as "late reactions".1 Neomycin, corticosteroids, paraphenylendiamin and gold are well-known allergens of late reactions.1,2 Of these, reactions to gold sodium thiosulfate (GSTS) can be significantly delayed, and some cases have been reported to be accompanied with granulomatous changes.3,4 Clinical reports of this reaction to GSTS are very limited. Here, we report a case of granulomatous reaction to GSTS, and we review the literature to reveal the features of this phenomenon. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171006IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.14615</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28983965">PM:28983965</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20171006-KosumiH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20171006-KosumiH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171006, Kosumi H</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.14615</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42724</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ebell,M.</style></author><author><style face="normal" font="default"> Marchello,C.</style></author><author><style face="normal" font="default"> O'Connor,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Epidemiology, College of Public Health, University of Georgia, Athens, GADepartment of Epidemiology, College of Public Health, University of Georgia, Athens, GAChronic Disease Prevention Director, Georgia Department of Public Health, Atlanta, GA</style></auth-address><titles><title><style face="normal" font="default">The burden and social determinants of asthma for adults in the state of Georgia</style></title><secondary-title><style face="normal" font="default">J Ga Public Health Assoc</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Ga Public Health Assoc</style></abbr-1></periodical><pages end="434" start="426">426-434</pages><volume><style face="normal" font="default">6</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is a serious chronic health condition, and social determinants may affect its prevalence. METHODS: Data from the Behavioral Risk Factors Surveillance Survey (BRFSS), the Georgia Asthma Call-back Survey (ACBS), and the Georgia hospital and emergency department survey for patients with a diagnosis of asthma were used. All data were from the years 2011 through 2014. SAS and SUDAAN software were used to calculate weighted prevalence estimates and to perform univariate and multivariate analyses of the association between social determinants, other risk factors, and asthma outcomes. RESULTS: The prevalence of asthma was highest among non-Hispanic blacks, women, and persons with less than a high school education, with an annual household income below $25,000, and in rural parts of the state (south and northwest Georgia). Those without insurance for more than three years had a higher prevalence of asthma than those who had insurance or had been uninsured less than 6 months. Although the percentage without insurance declined from 2012 to 2014, more than 1 in 5 adults of working age with asthma still lacked health insurance, and more than half had been without it for more than 3 years. One-third of Georgians with asthma could not see a doctor, at least on one occasion, because of cost, and more than a third were currently paying off medical bills. Approximately one quarter did not report having a personal physician, and a similar percentage reported having more than one year since their last check-up. In multivariate analyses, women (adjusted odds ratio [aOR] 1.61), smokers (aOR 1.54), and persons with a higher BMI (aOR 1.56) were all independently associated with having asthma. CONCLUSIONS: For the state of Georgia, there are associations between social determinants, such as education, income, and geography, and the prevalence of asthma, and many patients lack access to care. Addressing social determinants, including having affordable health insurance, is necessary to improve management of asthma</style></abstract><notes><style face="normal" font="default">DA - 20170922IS - 2471-9773 (Print)IS - 2471-9773 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.21633/jgpha.6.406</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28936486">PM:28936486</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Ga Public Health Assoc\2017-6-426-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Ga Public Health Assoc\2017-6-426-34.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170922, Ebell M</style></custom2><misc3><style face="normal" font="default">10.21633/jgpha.6.406</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42725</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dai,J.</style></author><author><style face="normal" font="default"> Choo,M.K.</style></author><author><style face="normal" font="default"> Park,J.M.</style></author><author><style face="normal" font="default"> Fisher,D.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cutaneous Biology Research Center, Massachusetts General Hospital, Charlestown, MA, USA</style></auth-address><titles><title><style face="normal" font="default">Topical ROR inverse agonists suppress inflammation in mouse models of atopic dermatitis and acute irritant dermatitis</style></title><secondary-title><style face="normal" font="default">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Invest Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="7" Year="2017">2017/7/31</year></dates><abstract><style face="normal" font="default">The retinoic acid receptor-related orphan receptors RORalpha and RORgamma are critical for the functions of specific subsets of T cells and innate lymphoid cells, which are key drivers of inflammatory disease in barrier tissues. Here, we investigate the anti-inflammatory potential of SR1001, a synthetic RORalpha/gamma inverse agonist, in mouse models of atopic dermatitis and acute irritant dermatitis. Topical treatment with SR1001 reduces epidermal and dermal features of MC903-induced atopic dermatitis-like disease, and suppresses the production of type 2 cytokines and other inflammatory mediators in lesional skin. In the epidermis, SR1001 treatment blocks MC903-induced expression of thymic stromal lymphopoietin (TSLP) and reverses impaired keratinocyte differentiation. SR1001 is also effective in alleviating acute dermatitis triggered by 12-O-tetradecanoylphorbol-13-acetate (TPA). Overall, our results suggest RORalpha/gamma as important therapeutic targets for cutaneous inflammation, and topical usage of inhibitory ligands as a novel approach to treating skin diseases of inflammatory etiology</style></abstract><notes><style face="normal" font="default">DA - 20170804IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jid.2017.07.819</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28774591">PM:28774591</url></web-urls></urls><custom2><style face="normal" font="default">20170804, Dai J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jid.2017.07.819</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42726</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shaked,E.</style></author><author><style face="normal" font="default"> Wainstock,T.</style></author><author><style face="normal" font="default"> Sheiner,E.</style></author><author><style face="normal" font="default"> Walfisch,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Joyce and Irving Goldman Medical School , Faculty of Health Sciences , Ben-Gurion University of the Negev , Beer - Sheva , Israel</style></auth-address><titles><title><style face="normal" font="default">Maternal asthma: pregnancy course and outcome</style></title><secondary-title><style face="normal" font="default">J Matern Fetal Neonatal Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Matern Fetal Neonatal Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="28" Month="8" Year="2017">2017/8/28</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To evaluate the association between maternal asthma and perinatal outcome. STUDY DESIGN: In this retrospective population-based cohort study, all pregnancies occurring between 1991-2014 in a tertiary medical center, were included. Multiple pregnancies and congenital malformations were excluded. Pregnancy course and outcomes were compared between women with and without asthma, and multivariable generalized estimating equations were used to control for confounders. RESULTS: During the study period, 243 363 deliveries met the inclusion criteria, 1.35% of which (n = 3283) occurred in women diagnosed with asthma. Multiple perinatal complications were found to be associated with maternal asthma, including hypertensive disorders, preterm delivery, and cesarean delivery. However, no significant differences between the groups were noted in neonatal outcomes, including perinatal mortality rates and low Apgar scores. In the regression model, maternal asthma was noted as an independent risk factor for preterm delivery, hypertensive disorders of pregnancy, and cesarean delivery (aOR = 1.21, 95%CI 1.1-1.4, p = 0.007, aOR = 1.35, 95%CI 1.2-1.6, p &lt; 0.001 and aOR = 1.27, 95%CI 1.2-1.4, p &lt; 0.001, respectively) while controlling for multiple confounders. CONCLUSION: Maternal asthma is associated with an increased risk for adverse pregnancy outcome. This association remains significant while controlling for variables considered to coexist with maternal asthma. Nevertheless, perinatal outcome is generally favorable</style></abstract><notes><style face="normal" font="default">DA - 20170829IS - 1476-4954 (Electronic)IS - 1476-4954 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">10.1080/14767058.2017.1372414</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28847192">PM:28847192</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Matern Fetal Neonatal Med\20170829-ShakedE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Matern Fetal Neonatal Med\20170829-ShakedE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170829, Shaked E</style></custom2><misc3><style face="normal" font="default">10.1080/14767058.2017.1372414</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42727</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sand,F.L.</style></author><author><style face="normal" font="default"> Thomsen,S.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Dermatology , Bispebjerg Hospital , Copenhagen , Denmark</style></auth-address><titles><title><style face="normal" font="default">Skin diseases of the vulva: eczematous diseases and contact urticaria</style></title><secondary-title><style face="normal" font="default">J Obstet Gynaecol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Obstet Gynaecol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Skin</style></keyword></keywords><dates><year Day="7" Month="8" Year="2017">2017/8/7</year></dates><abstract><style face="normal" font="default">Skin diseases in the vulvar area include a variety of disorders many of which have a chronic course with significant morbidity. It is important to be aware of the symptoms, signs and diagnostic tools in order to optimise treatment. Herein, the most common eczematous diseases of the vulvar area, i.e. lichen simplex chronicus, seborrhoeic dermatitis, atopic dermatitis, irritant contact dermatitis, and non-systemic and systemic allergic contact dermatitis are reviewed. Allergic contact urticaria is also described</style></abstract><notes><style face="normal" font="default">DA - 20170807IS - 1364-6893 (Electronic)IS - 0144-3615 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1080/01443615.2017.1329283</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28780897">PM:28780897</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Obstet Gynaecol\20170807-SandFL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Obstet Gynaecol\20170807-SandFL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170807, Sand FL</style></custom2><misc3><style face="normal" font="default">10.1080/01443615.2017.1329283</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42728</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Moraschini,V.</style></author><author><style face="normal" font="default"> deAlbuquerque Calasans-Maia,J.</style></author><author><style face="normal" font="default"> Diuana Calasans-Maia,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Periodontology, School of Dentistry, Fluminense Federal University, Niteroi, Rio de Janeiro, Brazil</style></auth-address><titles><title><style face="normal" font="default">Association Between Asthma and Periodontal Disease: A Systematic Review and Meta-Analysis</style></title><secondary-title><style face="normal" font="default">J Periodontol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Periodontol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="9" Year="2017">2017/9/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: The aim of this systematic review is to evaluate the association between asthma and periodontal disease. METHODS: An electronic search without date or language restrictions was carried out in MEDLINE, Cochrane, Web of Science, and LILACS until May 2016. In addition, manual search and in the grey literature were also conducted. The search process, data analysis, and quality assessment were performed by two independent reviewing authors. Eligibility criteria included prospective and retrospective cohort studies, case-controls, and randomized clinical trials. RESULTS: The search and selection process yielded 21 studies, published between 1979 and 2017. The meta-analysis showed a statistically significant difference for the parameters of gingival bleeding, plaque index, and gingival index for asthmatic participants with P&lt;0.0001, P&lt;0.0001, and P= 0.0005, respectively. CONCLUSIONS: The data from this systematic review strongly suggest the association of asthma with periodontal disease</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1943-3670 (Electronic)IS - 0022-3492 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1902/jop.2017.170363</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28871892">PM:28871892</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Periodontol\20170905-MoraschiniV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Periodontol\20170905-MoraschiniV.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Moraschini V</style></custom2><misc3><style face="normal" font="default">10.1902/jop.2017.170363</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42729</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhan,P.P.</style></author><author><style face="normal" font="default"> Zhang,Y.</style></author><author><style face="normal" font="default"> Liu,J.C.</style></author><author><style face="normal" font="default"> Zhu,Y.</style></author><author><style face="normal" font="default"> Zhao,Y.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Marine Sciences, Ningbo University, Ningbo, Zhejiang, China</style></auth-address><titles><title><style face="normal" font="default">Directly-coupled-column ultra-fast liquid chromatography with diode array detection method for the rapid quantification of allergenic disperse dyes in water preconcentrated by magnetic solid-phase extraction</style></title><secondary-title><style face="normal" font="default">J Sep Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Sep Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="default">A directly-coupled-column ultra-fast liquid chromatography coupled with diode array detection method for the determination of 12 allergenic disperse dyes in river water at sub-ppb levels has been developed and successfully validated. The analytical method is based on the use of two different reversed-phased columns connected through a two-position switching valve. A baseline separation was achieved by proper selection of stationary phases, mobile phases, and the use of a gradient elution in both dimensions. Furthermore, an easy-to-handle magnetic solid-phase extraction procedure was developed for the preconcentration of 12 allergenic disperse dyes from river water. An enrichment factor of 100 times was obtained. The results showed excellent performance in terms of trueness (76.8-99.0%), precision (intraday: 2.2-8.0%, interday: 3.3-8.2%), and sensitivity (limits of determination, 0.027-1.46 mug/L). Twenty real samples collected from the outfalls in the Yaojiang, Yongjiang and Fenghuajiang estuary were analyzed, and three of the studied compounds were found in one collected sample (12.6 mug/L for disperse blue 7, 11.6 mug/L for disperse blue 106, and 0.22 mug/L for disperse blue 3)</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 1615-9314 (Electronic)IS - 1615-9306 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1002/jssc.201700578</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28960918">PM:28960918</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Sep Sci\20170929-ZhanPP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Sep Sci\20170929-ZhanPP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Zhan PP</style></custom2><misc3><style face="normal" font="default">10.1002/jssc.201700578</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42730</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bitterman,A.</style></author><author><style face="normal" font="default"> Sandhu,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Allergic contact dermatitis to 2-octyl cyanoacrylate after surgical repair: Humidity as a potential factor</style></title><secondary-title><style face="normal" font="default">JAAD Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JAAD Case Rep</style></abbr-1></periodical><pages end="481" start="480">480-481</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy</style></keyword><keyword><style face="normal" font="default"> Contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Dermabond</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> sensitization</style></keyword><keyword><style face="normal" font="default"> surgical glue</style></keyword></keywords><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><isbn><style face="normal" font="default">2352-5126</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jdcr.2017.07.006</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jdcr.2017.07.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JAAD Case Rep\2017-3-480-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JAAD Case Rep\2017-3-480-1.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Bitterman A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jdcr.2017.07.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42731</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Xu,S.</style></author><author><style face="normal" font="default"> Kwa,M.</style></author><author><style face="normal" font="default"> Lohman,M.E.</style></author><author><style face="normal" font="default"> Evers-Meltzer,R.</style></author><author><style face="normal" font="default"> Silverberg,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois</style></auth-address><titles><title><style face="normal" font="default">Consumer Preferences, Product Characteristics, and Potentially Allergenic Ingredients in Best-Selling Moisturizers</style></title><secondary-title><style face="normal" font="default">JAMA Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JAMA Dermatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="9" Year="2017">2017/9/6</year></dates><abstract><style face="normal" font="default">Importance: Because moisturizer use is critical for the prevention and treatment of numerous dermatological conditions, patients frequently request product recommendations from dermatologists. Objective: To determine the product performance characteristics and ingredients of best-selling moisturizers. Design and Setting: This cohort study involved publicly available data of the top 100 best-selling whole-body moisturizing products at 3 major online retailers (Amazon, Target, and Walmart). Products marketed for use on a specific body part (eg, face, hands, eyelids) were excluded. Main Outcomes and Measures: Pairwise comparisons of median price per ounce on the basis of marketing claims (eg, dermatologist recommended, fragrance free, hypoallergenic) and presence of ingredients represented in the North American Contact Dermatitis Group (NACDG) series were conducted using Wilcoxon rank sum tests. The effect of vehicle type (eg, ointment, lotion, cream, butter) was assessed using the Kruskal-Wallis test. Cross-reactors and botanicals for fragrances were derived from the American Contact Dermatitis Society's Contact Allergen Management Program database. Results: A total of 174 unique best-selling moisturizer products were identified, constituting 109713 reviews as of August 2016. The median price per ounce was $0.59 (range, $0.10-$9.51 per ounce) with a wide range (9400%). The most popular vehicles were lotions (102 [59%]), followed by creams (22 [13%]), oils (21 [12%]), butters (14 [8%]), and ointments (3 [2%]). Only 12% (n = 21) of best-selling moisturizer products were free of NACDG allergens. The 3 most common allergens were fragrance mix (n = 87), paraben mix (n = 75), and tocopherol (n = 74). Products with the claim "dermatologist recommended" had higher median price per ounce ($0.79; interquartile range [IQR], $0.56-$1.27) than products without the claim ($0.59; IQR, $0.34-$0.92). Products with the claim "phthalate free" had higher median price per ounce ($1.38; IQR, $0.86-$1.63) than products without the claim ($0.59; IQR, $0.35-$0.91). Lotions (median, $0.49; IQR, $0.31-0.68) were statistically less expensive per ounce than butters (median, $1.20; IQR, $0.76-$1.63), creams (median, $0.80; IQR, $0.69-$1.25) and oils (median, $1.30; IQR, $0.64-$2.43). For products with a claim of "fragrance free," 18 (45%) had at least 1 fragrance cross-reactor or botanical ingredient. Products without any ingredients in the NACDG (median, $0.83; IQR, $0.47-$1.69) were not statistically more expensive per ounce than products with 1 or more allergens (median, $0.60; IQR, $0.35-$1.06). Conclusions and Relevance: Best-selling moisturizers vary widely by price and product characteristics. Given the lack of readily available comparison data on moisturizer efficacy, dermatologists should balance consumer preference, price, and allergenicity in their recommendations</style></abstract><notes><style face="normal" font="default">DA - 20170906IS - 2168-6084 (Electronic)IS - 2168-6068 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1001/jamadermatol.2017.3046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28877310">PM:28877310</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JAMA Dermatol\20170906-XuS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JAMA Dermatol\20170906-XuS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170906, Xu S</style></custom2><misc3><style face="normal" font="default">10.1001/jamadermatol.2017.3046</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42732</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lavin,J.</style></author><author><style face="normal" font="default"> Min,J.Y.</style></author><author><style face="normal" font="default"> Lidder,A.K.</style></author><author><style face="normal" font="default"> Huang,J.H.</style></author><author><style face="normal" font="default"> Kato,A.</style></author><author><style face="normal" font="default"> Lam,K.</style></author><author><style face="normal" font="default"> Meen,E.</style></author><author><style face="normal" font="default"> Chmiel,J.S.</style></author><author><style face="normal" font="default"> Norton,J.</style></author><author><style face="normal" font="default"> Suh,L.</style></author><author><style face="normal" font="default"> Mahdavinia,M.</style></author><author><style face="normal" font="default"> Hulse,K.E.</style></author><author><style face="normal" font="default"> Conley,D.B.</style></author><author><style face="normal" font="default"> Chandra,R.K.</style></author><author><style face="normal" font="default"> Shintani-Smith,S.</style></author><author><style face="normal" font="default"> Kern,R.C.</style></author><author><style face="normal" font="default"> Schleimer,R.P.</style></author><author><style face="normal" font="default"> Tan,B.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology-Head and Neck SurgeryDivision of Pediatric Otolaryngology, Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois, U.S.A</style></auth-address><titles><title><style face="normal" font="default">Superior turbinate eosinophilia correlates with olfactory deficit in chronic rhinosinusitis patients</style></title><secondary-title><style face="normal" font="default">Laryngoscope</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Laryngoscope</style></full-title></periodical><pages end="2218" start="2210">2210-2218</pages><volume><style face="normal" font="default">127</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Chemokine CCL11</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Cross-Sectional Studies</style></keyword><keyword><style face="normal" font="default"> Eosinophil Cationic Protein</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Eosinophilia</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Glycoproteins</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Interleukin-5</style></keyword><keyword><style face="normal" font="default"> Lysophospholipase</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Nasal Polyps</style></keyword><keyword><style face="normal" font="default"> Olfaction Disorders</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Prospective Studies</style></keyword><keyword><style face="normal" font="default"> Rhinitis</style></keyword><keyword><style face="normal" font="default"> Sinusitis</style></keyword><keyword><style face="normal" font="default"> Turbinates</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To evaluate if molecular markers of eosinophilia in olfactory-enriched mucosa are associated with olfactory dysfunction. STUDY DESIGN: Cross-sectional study of tissue biopsies from 99 patients, and an additional 30 patients who underwent prospective olfactory testing prior to sinonasal procedures. METHODS: Tissue biopsies were processed for analysis of inflammatory markers using quantitative real time polymerase chain reaction (qRT-PCR). Ipsilateral olfactory performance was assessed using the Sniffin' Sticks (Burghart, Wedel, Germany) threshold component and the University of Pennsylvania Smell Identification Test (Sensonics, Haddon Heights, NJ). Age-adjusted data was correlated with inflammatory marker expression and clinical measures of obstruction from computed tomography and endoscopy. RESULTS: Gene expression of the eosinophil marker CLC (Charcot Leyden crystal protein) was elevated in superior turbinate (ST) tissue in chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) compared to ST and inferior turbinate tissue in CRS without nasal polyps (CRSsNP) and control patients (all P &lt; 0.001, respectively). CLC in ST tissue was correlated with IL-5 and eotaxin-1 expression (all P &lt; 0.001; P = 0.65, and 0.49, respectively). CLC expression was strongly correlated with eosinophilic cationic protein levels (P &lt; 0.001; r = -0.76), and ST CLC expression was inversely related to olfactory threshold (P = 0.002, r = -0.57) and discrimination scores (P = 0.05, r = -0.42). In multiple linear regression of CLC gene expression, polyp status, and radiographic and endoscopic findings with olfactory threshold, CLC was the only significantly correlated variable (P &lt; 0.05). CONCLUSION: Markers of eosinophils are elevated in the ST of patients with CRSwNP and correlate with olfactory loss. These findings support the hypothesis that olfactory dysfunction in CRS correlates local eosinophil influx into the olfactory cleft. LEVEL OF EVIDENCE: NA. Laryngoscope, 127:2210-2218, 2017</style></abstract><notes><style face="normal" font="default">DA - 20170321IS - 1531-4995 (Electronic)IS - 0023-852X (Linking)LA - engPT - Evaluation StudiesPT - Journal ArticleRN - 0 (CCL11 protein, human)RN - 0 (Chemokine CCL11)RN - 0 (Glycoproteins)RN - 0 (IL5 protein, human)RN - 0 (Interleukin-5)RN - EC 3.1.1.5 (Lysophospholipase)RN - EC 3.1.1.5 (lysolecithin acylhydrolase)RN - EC 3.1.27.- (Eosinophil Cationic Protein)SB - IMCO - United states -</style></notes><work-type><style face="normal" font="default">10.1002/lary.26555</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28322448">PM:28322448</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Laryngoscope\2017-127-2210-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Laryngoscope\2017-127-2210-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170321, Lavin J</style></custom2><misc3><style face="normal" font="default">10.1002/lary.26555</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42733</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">de Moura,B.H.</style></author><author><style face="normal" font="default"> Migliavacca,R.O.</style></author><author><style face="normal" font="default"> Lima,R.K.</style></author><author><style face="normal" font="default"> Dolci,J.E.L.</style></author><author><style face="normal" font="default"> Becker,M.</style></author><author><style face="normal" font="default"> Feijo,C.</style></author><author><style face="normal" font="default"> Brauwers,E.</style></author><author><style face="normal" font="default"> Lavinsky-Wolff,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Graduate Program in SurgeryDepartment of Otolaryngology, Hospital de Clinicas de Porto Alegre (HCPA), Porto Alegre, RS</style></auth-address><titles><title><style face="normal" font="default">Partial inferior turbinectomy in rhinoseptoplasty has no effect in quality-of-life outcomes: A randomized clinical trial</style></title><secondary-title><style face="normal" font="default">Laryngoscope</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Laryngoscope</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aged</style></keyword></keywords><dates><year Day="16" Month="8" Year="2017">2017/8/16</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Evaluate the impact of endoscopic partial inferior turbinectomy (EPIT) associated with primary rhinoseptoplasty on quality-of-life outcomes (QOL), complications, and surgical duration. STUDY DESIGN: Randomized clinical trial. METHODS: Individuals with nasal obstruction aged >/= 16 years who were candidates for functional and aesthetics primary rhinoseptoplasty were evaluated from March 2014 through May 2015. Eligible participants were randomly allocated to rhinoseptoplasty with or without EPIT (excision of one-third of the inferior turbinates). RESULTS: Fifty patients were studied. Most were Caucasian and had moderate/severe allergic rhinitis symptoms. Mean age was 36 ( +/- 14.5) years. Rhinoseptoplasty was associated with improvement in all QOL scores irrespective of turbinate intervention (P &lt; 0.001). Analysis of covariance was conducted to control for potential confounders. There was no difference between the groups in absolute score changes for Nasal Obstruction Symptom Evaluation-Portuguese (NOSE-p) (-50.5 vs. -47.6; P = 0.723), Rhinoplasty Outcome Evaluation (ROE) (47 vs. 44.8; P = 0.742), and all World Health Organization Quality of Life Scale-Abbreviated (WHOQOL-bref) score domains (P > 0.05). There were no differences between the groups regarding presence of the complications. Surgical duration was higher in the EPIT group (212 minutes +/- 7.8 vs. 159.1 +/- 5.6; P ? 0.001). CONCLUSIONS: Turbinate reduction through EPIT during primary rhinoseptoplasty did not improve short-term general and specific QOL outcomes. The use of EPIT increases surgical time considerably without improving QOL scores. There was no difference in postoperative incidence of complications, suggesting that EPIT is a safe technique. LEVEL OF EVIDENCE: 1b. Laryngoscope, 2017</style></abstract><notes><style face="normal" font="default">DA - 20170817IS - 1531-4995 (Electronic)IS - 0023-852X (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1002/lary.26831</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28815717">PM:28815717</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Laryngoscope\20170817-deMouraBH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Laryngoscope\20170817-deMouraBH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170817, de Moura BH</style></custom2><misc3><style face="normal" font="default">10.1002/lary.26831</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42734</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ramalho,M.</style></author><author><style face="normal" font="default"> Ramalho,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Gadolinium-Based Contrast Agents: Associated Adverse Reactions</style></title><secondary-title><style face="normal" font="default">Magn Reson Imaging Clin N Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Magn Reson Imaging Clin N Am</style></full-title></periodical><pages end="764" start="755">755-764</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Gadolinium-based contrast agents (GBCAs)</style></keyword><keyword><style face="normal" font="default"> Adverse events</style></keyword><keyword><style face="normal" font="default"> Acute allergic reactions</style></keyword><keyword><style face="normal" font="default"> Contrast Media</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1064-9689</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.1016/j.mric.2017.06.006</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.mric.2017.06.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Magn Reson Imaging Clin N Am\2017-25-755-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Magn Reson Imaging Clin N Am\2017-25-755-64.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Ramalho M</style></custom2><misc3><style face="normal" font="default">10.1016/j.mric.2017.06.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42735</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Roshi,D.</style></author><author><style face="normal" font="default"> Toci,E.</style></author><author><style face="normal" font="default"> Burazeri,G.</style></author><author><style face="normal" font="default"> Schroder-Back,P.</style></author><author><style face="normal" font="default"> Malaj,L.</style></author><author><style face="normal" font="default"> Brand,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of International Health, School CAPHRI, Care and Public Health Research Institute, Maastricht University Maastricht, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Users' Knowledge About Adverse Effects of Non-steroidal Anti-inflammatory Drugs in Tirana, Albania</style></title><secondary-title><style face="normal" font="default">Mater Sociomed</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Mater Sociomed</style></abbr-1></periodical><pages end="142" start="138">138-142</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="6" Year="2017">2017/6</year></dates><abstract><style face="normal" font="default">AIM: To assess the level of knowledge of the adult users of non-steroidal anti-inflammatory drugs (NSAIDs) regarding their side effects and the socio-demographic factors associated with the use of these drugs in the adult population of Albania. METHODS: This was a cross-sectional study including a representative sample of 199 individuals aged >/=18 years (77% women; overall mean age: 30.3+/-10.0 years; overall response rate: 90%) who were users of NSAIDs recruited in ten different pharmacies in Tirana municipality during April-May 2015. A self-administered questionnaire contained basic socio-demographic information and questions about NSAIDs use, their types, participants' knowledge about NSAIDs side effects and their interaction with other drugs. RESULTS: In 56% of the cases, NSAIDs were taken by participants' own decisions, whereas in about 29% of the cases these drugs were prescribed by physicians. Acetaminophen, ketoprofen and ibuprofen were the most frequently used NSAIDs. Overall, 51% of participants thought NSAIDs could cause allergic reactions, whereas one third or fewer were aware of each of the following side effects: upper and lower gastrointestinal bleeding, hypertension, gastritis, kidney failure, myopathy, osteoporosis. About one third of participants were aware of NSAIDs-other drug interactions, whereas some of them were already taking contraindicated drugs. No significant differences were noticed regarding sex, age, educational level, employment status and marital status, with very few exceptions. CONCLUSION: Our findings indicate limited knowledge about NSAIDs side effects and their interaction with other drugs among the Albania adult population, which is a cause of concern</style></abstract><notes><style face="normal" font="default">DA - 20170908IS - 1512-7680 (Print)IS - 1512-7680 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Albania -</style></notes><work-type><style face="normal" font="default">10.5455/msm.2017.29.138-142</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28883779">PM:28883779</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mater Sociomed\2017-29-138-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mater Sociomed\2017-29-138-42.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170908, Roshi D</style></custom2><misc3><style face="normal" font="default">10.5455/msm.2017.29.138-142</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42736</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Duerr,C.U.</style></author><author><style face="normal" font="default"> Fritz,J.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Microbiology and Immunology, McGill University Research Centre on Complex Traits (MRCCT), McGill University, 3649 Promenade-Sir-William Osler, Bellini Pavilion Room 371, Montreal, QC, Canada, H3G 0B1</style></auth-address><titles><title><style face="normal" font="default">Isolation of Group 2 Innate Lymphoid Cells from Mouse Lungs</style></title><secondary-title><style face="normal" font="default">Methods Mol Biol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Methods Mol Biol</style></abbr-1></periodical><pages end="261" start="253">253-261</pages><volume><style face="normal" font="default">1656</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The recently described group 2 innate lymphoid cells (ILC2) exert critical roles in type 2 immune responses, epithelial repair at mucosal tissues and metabolic homeostasis. ILC2 release large amounts of type 2 cytokines such as interleukin 4 (IL-4), IL-5, and IL-13, driving type 2 immunity such as the defense against helminths. However, if not tightly regulated ILC2 can trigger unwanted type 2 immunopathologies including allergic airway inflammation, airway hyper-responsiveness, and atopic dermatitis. Viral respiratory tract infections, archetypal triggers of type 1 immune responses, often give rise to pulmonary type 2 immunopathologies such as asthma and asthma exacerbations. Interestingly, pulmonary viral infections induce the release of IL-33, followed by induction of ILC2-mediated pulmonary type 2 immunopathology independent of the adaptive immune system. Due to their scarcity at steady state but also after infection and inflammation, pulmonary ILC2 are challenging to work with. In this chapter, we describe the detection and isolation procedure of pulmonary mouse ILC2 by flow cytometry and compare four distinct enzymatic mouse lung tissue processing protocols for optimized cell yield</style></abstract><notes><style face="normal" font="default">DA - 20170815IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1007/978-1-4939-7237-1_16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28808975">PM:28808975</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Methods Mol Biol\2017-1656-253-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Methods Mol Biol\2017-1656-253-61.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170815, Duerr CU</style></custom2><misc3><style face="normal" font="default">10.1007/978-1-4939-7237-1_16</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42737</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wakefield,D.L.</style></author><author><style face="normal" font="default"> Holowka,D.</style></author><author><style face="normal" font="default"> Baird,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York 14853</style></auth-address><titles><title><style face="normal" font="default">The FcepsilonRI Signaling Cascade and Integrin Trafficking Converge at Patterned Ligand Surfaces</style></title><secondary-title><style face="normal" font="default">Mol Biol Cell</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Mol Biol Cell</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Ligands</style></keyword></keywords><dates><year Day="9" Month="8" Year="2017">2017/8/9</year></dates><abstract><style face="normal" font="default">We examined the spatial targeting of early and downstream signaling mediated by the IgE receptor (FcepsilonRI) in RBL mast cells utilizing surface-patterned 2,4 dinitrophenyl (DNP) ligands. Micron-sized features of DNP are presented as densely immobilized conjugates of bovine serum albumin (DNP-BSA) or mobile in a supported lipid bilayer (DNP-SLB). Although soluble anti-DNP IgE binds uniformly across features for both pattern types, IgE bound to FcepsilonRI on cells shows distinctive distributions: uniform for DNP-SLB and edge-concentrated for DNP-BSA. These distributions of IgE-FcepsilonRI propagate to the spatial recruitment of early signaling proteins, including spleen tyrosine kinase (Syk), linker for activation of T cells (LAT), and activated phospholipase C gamma 1 (PLCgamma1), which all localize with engaged receptors. We found stimulated polymerization of F-actin is not required for Syk recruitment but is progressively involved in the recruitment of LAT and PLCgamma1. We further found beta1- and beta3-integrins colocalize with IgE-FcepsilonRI at patterned ligand surfaces as cells spread. This recruitment corresponds to directed exocytosis of recycling endosomes (REs) containing these integrins and their fibronectin ligand. Together, our results show targeting of signaling components, including integrins, to regions of clustered IgE-FcepsilonRI in processes that depend on stimulated actin polymerization and outward trafficking of REs</style></abstract><notes><style face="normal" font="default">DA - 20170810IS - 1939-4586 (Electronic)IS - 1059-1524 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1091/mbc.E17-03-0208</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28794269">PM:28794269</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mol Biol Cell\20170810-WakefieldDL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mol Biol Cell\20170810-WakefieldDL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170810, Wakefield DL</style></custom2><misc3><style face="normal" font="default">10.1091/mbc.E17-03-0208</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42738</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hassan,M.R.</style></author><author><style face="normal" font="default"> Kabir,S.</style></author><author><style face="normal" font="default"> Basher,A.E.</style></author><author><style face="normal" font="default"> Rahman,M.A.</style></author><author><style face="normal" font="default"> Islam,M.A.</style></author><author><style face="normal" font="default"> Khan,M.K.</style></author><author><style face="normal" font="default"> Basher,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dr Mohammad Rashedul Hassan, Lecturer, Department of Community Medicine, Mymensingh Medical College (MMC), Mymensingh, Bangladesh</style></auth-address><titles><title><style face="normal" font="default">Quality of Life in Children with Asthma in Bangladesh</style></title><secondary-title><style face="normal" font="default">Mymensingh Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Mymensingh Med J</style></full-title></periodical><pages end="476" start="471">471-476</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Asthma is a public health problem that adversely affects different aspects of quality of life. Childhood asthma is common in Bangladesh affecting their lifestyle. The objective of the study was to assess health-related quality of life in children with bronchial asthma. A descriptive, cross-sectional study was carried out from January 2014 to December 2014 at the Outpatient Department of National Asthma Centre, Mohakhali, Dhaka among hundred sixty-two purposively selected children of both sexes with bronchial asthma aged from 7 to 17 years. Data were collected through interview with children or their parents using an interviewer-administered questionnaire based on Pediatric Asthma Quality of Life Questionnaire (PAQLQ). Data were analyzed by computer software SPSS version 16.0. The mean age was 12.5 years with a standard deviation (SD) of 2.9 years. Overwhelming majority 157(96.9%) of children were literate, while only 5(3.1%) children were illiterate. Eighty (49.4%) children were male, while 82(50.6%) female. As many as 148(91.4%) children were students, while 10(6.2%) children were engaged in some type of job and 4(2.5%) children had no occupation. Parents of 145(89.5%) children were currently married, while 10(6.2%) children had single parent and 7(4.3%) children's parents were divorced or separated. Quality of life in children with asthma decreases with age as the disease intensity increases with age. Female asthmatic children had lower overall score of Quality of life (p=0.017), as well as lower activity domain score (p&lt;0.001). Emotional domain score was found lower in children with single parent (p=0.021) and low monthly family income (p&lt;0.001). Furthermore, children with lower monthly family income and working children had lower Quality of life score in all domains</style></abstract><notes><style face="normal" font="default">DA - 20170918IS - 1022-4742 (Print)IS - 1022-4742 (Linking)LA - engPT - Journal ArticleCO - Bangladesh -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28919597">PM:28919597</url></web-urls></urls><custom2><style face="normal" font="default">20170918, Hassan MR</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42739</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kocer,N.</style></author><author><style face="normal" font="default"> Mondel,P.K.</style></author><author><style face="normal" font="default"> Yamac,E.</style></author><author><style face="normal" font="default"> Kavak,A.</style></author><author><style face="normal" font="default"> Kizilkilic,O.</style></author><author><style face="normal" font="default"> Islak,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiology, Division of Neuroradiology, Cerrahpasa Medical Faculty, Istanbul University, Kocamustafapasa, 34098, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="default">Is there an association between flow diverter fish mouthing and delayed-type hypersensitivity to metals?-a case-control study</style></title><secondary-title><style face="normal" font="default">Neuroradiology</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Neuroradiology</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="9" Year="2017">2017/9/5</year></dates><abstract><style face="normal" font="default">PURPOSE: Flow diverters are increasingly used in the treatment of complex and giant intracranial aneurysms. However, they are associated with complications like late aneurysmal rupture. Additionally, flow diverters show focal structural decrease in luminal diameter without any intimal hyperplasia. This resembles a "fish mouth" when viewed en face. In this pilot study, we tested the hypothesis of a possible association between flow diverter fish-mouthing and delayed-type hypersensitivity to its metal constituents. METHODS: We retrospectively reviewed patient records from our center between May 2010 and November 2015. A total of nine patients had flow diverter fish mouthing. A control group of 25 patients was selected. All study participants underwent prospective patch test to detect hypersensitivity to flow diverter metal constituents. Analysis was performed using logistic regression analysis and Wilcoxon sign rank sum test. Univariate and multivariate analyses were performed to test variables to predict flow diverter fish mouthing. RESULTS: The association between flow diverter fish mouthing and positive patch test was not statistically significant. In multivariate analysis, history of allergy and maximum aneurysm size category was associated with flow diverter fish mouthing. This was further confirmed on Wilcoxon sign rank sum test. CONCLUSION: The study showed statistically significant association between flow diverter fish mouthing and history of contact allergy and a small aneurysmal size. Further large-scale studies are needed to detect a statistically significant association between flow diverter fish mouthing and patch test. We recommend early and more frequent follow-up imaging in patients with contact allergy to detect flow diverter fish mouthing and its subsequent evolution</style></abstract><notes><style face="normal" font="default">DA - 20170906IS - 1432-1920 (Electronic)IS - 0028-3940 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1007/s00234-017-1910-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28875355">PM:28875355</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Neuroradiology\20170906-KocerN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Neuroradiology\20170906-KocerN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170906, Kocer N</style></custom2><misc3><style face="normal" font="default">10.1007/s00234-017-1910-3</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42740</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chima,E.I.</style></author><author><style face="normal" font="default"> Iroezindu,M.O.</style></author><author><style face="normal" font="default"> Uchenna,N.R.</style></author><author><style face="normal" font="default"> Mbata,G.O.</style></author><author><style face="normal" font="default"> Okwuonu,C.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Federal Medical Centre, Umuahia, Nigeria</style></auth-address><titles><title><style face="normal" font="default">A survey of asthma management practices and implementation of Global Initiative for Asthma guidelines among doctors in a resource-limited setting in Nigeria</style></title><secondary-title><style face="normal" font="default">Niger J Clin Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Niger J Clin Pract</style></abbr-1></periodical><pages end="991" start="984">984-991</pages><volume><style face="normal" font="default">20</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Bronchial asthma is a global health problem that causes significant morbidity and mortality in all age groups. Global Initiative for Asthma (GINA) seeks to standardize the care asthma patients receive. We assessed the knowledge, attitude, and practices of doctors in Umuahia, Southeast Nigeria, regarding asthma and determined the extent to which they abide by GINA guidelines in their management of asthma. METHODOLOGY: It was a descriptive cross-sectional study. A pretested self-administered questionnaire was used to obtain information from the participants regarding knowledge of asthma prevalence, asthma risk factors, and management practices. RESULTS: Out of 142 questionnaires administered, 117 were retrieved giving a response rate of 82%. About 70% were men, and the most common age group was 30-39 years (57.3%). The median duration of medical practice was 6 (3-12) years. About 77% reported asthma prevalence to be on the increase. While 105 (89.7%) respondents had seen a spirometer, only 28 (23.9%) use spirometry in asthma diagnosis. Similarly, 95 (81.2%) had seen a peak flow meter, but only 41 (35.5%) use it in asthma diagnosis. Only 7 (6.0%) respondents reported that their patients keep a peak flow diary. Of 117 respondents, 94 (80.3%) know about GINA guidelines for asthma control, 45 (38.5%) apply GINA guidelines in patient care, 86 (73.5%) regularly review patient inhaler technique, 33 (28.2%) use adult asthma control test while 17 (14.5%) regularly review asthma action plan with patients. CONCLUSION: There is a wide gap between GINA guidelines and the knowledge, attitude, and practices of doctors in Umuahia regarding asthma management. Improvement and standardization of asthma care are recommended</style></abstract><notes><style face="normal" font="default">DA - 20170911IS - 1119-3077 (Print)LA - engPT - Journal ArticleCO - Nigeria -</style></notes><work-type><style face="normal" font="default">10.4103/njcp.njcp_88_16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28891543">PM:28891543</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Niger J Clin Pract\2017-20-984-91.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Niger J Clin Pract\2017-20-984-91.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170911, Chima EI</style></custom2><misc3><style face="normal" font="default">10.4103/njcp.njcp_88_16</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42741</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pichardo-Geisinger,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Wake Forest University School of Medicine, 4618 Country Club Road, Winston-Salem, NC 27104, USA.</style></auth-address><titles><title><style face="normal" font="default">Atopic and Contact Dermatitis of the Vulva</style></title><secondary-title><style face="normal" font="default">Obstet Gynecol Clin North Am</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Obstet Gynecol Clin North Am</style></abbr-1></periodical><pages end="378" start="371">371-378</pages><volume><style face="normal" font="default">44</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Pruritus, or itch, is a common vulvar complaint that is often treated empirically as a yeast infection; however, yeast infections are just one of the many conditions that can cause vulvar itch. Ignoring other conditions can prolong pruritus unnecessarily. Atopic dermatitis, irritant contact dermatitis, and allergic contact dermatitis are extremely common noninfectious causes of vulvar itch that are often underdiagnosed by nondermatologists. Identifying these conditions and treating them appropriately can significantly improve a patient's quality of life and appropriately decrease health care expenditures by preventing unnecessary additional referrals or follow-up visits and decreasing pharmaceutical costs</style></abstract><notes><style face="normal" font="default">DA - 20170805IS - 1558-0474 (Electronic)IS - 0889-8545 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.ogc.2017.05.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28778637">PM:28778637</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Obstet Gynecol Clin North Am\2017-44-371-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Obstet Gynecol Clin North Am\2017-44-371-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170805, Pichardo-Geisinger R</style></custom2><misc3><style face="normal" font="default">10.1016/j.ogc.2017.05.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42742</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Luo,W.</style></author><author><style face="normal" font="default"> Xu,W.</style></author><author><style face="normal" font="default"> Xia,L.</style></author><author><style face="normal" font="default"> Xie,D.</style></author><author><style face="normal" font="default"> Wang,L.</style></author><author><style face="normal" font="default"> Guo,Z.</style></author><author><style face="normal" font="default"> Cheng,Y.</style></author><author><style face="normal" font="default"> Liu,Y.</style></author><author><style face="normal" font="default"> Li,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, PR China</style></auth-address><titles><title><style face="normal" font="default">Family-based whole exome sequencing of atopic dermatitis complicated with cataracts</style></title><secondary-title><style face="normal" font="default">Oncotarget</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Oncotarget</style></abbr-1></periodical><pages end="59454" start="59446">59446-59454</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">35</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="8" Year="2017">2017/8/29</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis (AD) is a common skin disorder with elevated prevalence. Cataract induced by AD rarely occurs in adolescent and young adult patients, which is also called atopic cataract. Using whole exome sequencing, we aimed to explore genetic alterations among AD and atopic cataract. RESULT: We recruited a 19 year-old Chinese male with AD accompanied with cataracts, his father with AD and his mother without AD or cataract. Through analysis of the exomic sequence of the 3 individuals from the same family, we identified that with respect to AD, there were 162 genes mutated in both this patient and his father but not in his mother. In addition, we found 10 genes mutated in this patient only without in his parents according to cataract. CONCLUSION: This research suggests that coinheritance of mutations in these genes may correlate with AD, and the pathogenesis of AD complicated with cataracts was related to genetic factors</style></abstract><notes><style face="normal" font="default">DA - 20170923IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.18632/oncotarget.19739</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28938649">PM:28938649</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Oncotarget\2017-8-59446-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Oncotarget\2017-8-59446-54.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170923, Luo W</style></custom2><misc3><style face="normal" font="default">10.18632/oncotarget.19739</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42743</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gawad,A.T.</style></author><author><style face="normal" font="default"> Kamel,T.B.</style></author><author><style face="normal" font="default"> Abd Al-Aziz,M.M.</style></author><author><style face="normal" font="default"> Abou-Sekin,T.A.</style></author><author><style face="normal" font="default"> Alfy Ramzy,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Is Serum Tryptase a Valuable Marker for Obesity-Bronchial Asthma Interrelationship in Children?</style></title><secondary-title><style face="normal" font="default">Open J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Open J Asthma</style></full-title></periodical><pages end="020" start="017">017-020</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Asthma among obese represents a unique phenotype. Mast cells are more abundant inobese. Serum tryptase (ST) is a marker of mast cell numbers or activity. Since obesity and asthma havebeen linked in epidemiological studies, a possible higher mast cell activity in obesity could be a factorbetween the two conditions. This study was to investigate ST and its potential association between obesityand childhood asthma.Methods: Study recruited 60 asthmatic children, their age ranged from 5-16 years. They were dividedaccording to BMI centile to 30 obese and 30 non-obese asthmatics. Thirty healthy non-asthmatic, non-atopic and non-obese children; were included as a healthy control. Serum tryptase, atopy (skin prick testreactivity) and spirometry were assessed.Results: Frequency of atopy and positive skin prick test signifi cantly increased among obese morethan non-obese asthmatics (P&lt;0.05, OR = 1.96, 95% CI = 1.27-3.24). FEV1% of predicted mean levels werelower among obese than non-obese asthmatics (p&lt;0.05). ST was signifi cantly higher in asthmatics thanin controls with a mean ±SD of 53.3±13.78 ng/ml and 10.06±4.39 ng/ml respectively. ST was higher inobese than non-obese asthmatics with a mean ±SD of 71.73±19.17 ng/ml and 34.5±8.68 ng/ml respectively(P&lt;0.05). There was a negative correlation between ST and FEV1 % of predicted and positive correlationsbetween ST and age, BMI, and waist circumference among asthmatics.Conclusion: Mast cells play a role in both obesity and asthma, serum tryptase, being a marker of mastcell activation, could represent a link between them.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Egypt -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.peertechz.com/journals/open-journal-of-asthma/articles/volume-1/issue-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Open J Asthma\2017-1-017-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Open J Asthma\2017-1-017-20.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Gawad AT</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42744</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Solis-Soto,M.T.</style></author><author><style face="normal" font="default"> Patino,A.</style></author><author><style face="normal" font="default"> Nowak,D.</style></author><author><style face="normal" font="default"> Radon,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Diet and Current Asthma Symptoms in School-Aged Children from Oropeza Province -Chuquisaca, Bolivia</style></title><secondary-title><style face="normal" font="default">Open J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Open J Asthma</style></full-title></periodical><pages end="016" start="009">009-016</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Several studies have linked dietary intake and asthma symptoms, nevertheless theresults are still inconclusive and data from developing country are scarce.Objective: To assess the association of Food patterns and current asthma symptoms in school-agedchildren from rural and urban areas of Oropeza Province - Bolivia.Methods: A total of 1655 children attending the fi fth elementary grade were invited to participate ina cross-sectional study in rural and urban areas of Oropeza province. Current Asthma symptoms weredefi ned following the International Study of Asthma and Allergies in Childhood (ISSAC) recommendation(written and video questionnaire). Food patterns were defi ned using the ISAAC environmentalquestionnaire. The Mediterranean diet (MD) score was calculated based on this information. Crude andadjusted logistic regression models were calculated including age, sex and place of living.Results: The age range was between 9 - 15 years (Median 11), and 47.9% were male. Current asthmasymptoms were reported in a 17% considering the written questionnaire (WQ) and in a 6% considering thevideo questionnaire (VQ). Higher consumption of nuts [(p=0.01, aOR= 1.6(1.1-2.2)], corn [(p=0.03, aOR=1.5(1.0-2.2)] and fast food [(p=0.06, aOR= 1.4(1.0-2.0)] showed positive association with current asthmasymptoms. Greater adherence to the MD was associated with lower risk of asthma symptoms.Conclusion: Promotion of healthy food patterns in children is needed in order to avoid the rapidincrease of non-communicable diseases in this region.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Bolivia -CO - Germany -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.peertechz.com/journals/open-journal-of-asthma/articles/volume-1/issue-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Open J Asthma\2017-1-009-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Open J Asthma\2017-1-009-16.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Solis-Soto MT</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42745</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Frieri,M.</style></author><author><style face="normal" font="default"> Kumar,K.</style></author><author><style face="normal" font="default"> Boutin,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Stress, Trauma, Sepsis, Inflammation, Management in Asthma</style></title><secondary-title><style face="normal" font="default">Open J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Open J Asthma</style></full-title></periodical><pages end="006" start="001">001-006</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">This review paper covered stress, management related to asthma, trauma, sepsis, infl ammationalong with anxiety, and depression that occurs both in women with asthma, traumatic children andadult patients. These areas, induce immune function changes, which can lead to both trauma and pro-infl ammatory activation known as systemic infl ammation response syndrome (SIRS). Related to sepsis.Stress management in trauma is based upon the notion that stress causes an immune imbalance insusceptible individuals. Various topics also covered were the neuroimmune system, oxidative stress,infl ammation, innate immunity, the role of NF-kappa B related to infl ammation, cytokines, procalcitoninrelated to sepsis.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.peertechz.com/journals/open-journal-of-asthma/articles/volume-1/issue-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Open J Asthma\2017-1-001-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Open J Asthma\2017-1-001-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Frieri M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42746</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kopac,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Calculation of Predicted Peak Expiratory Flow in Children with a Formula</style></title><secondary-title><style face="normal" font="default">Open J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Open J Asthma</style></full-title></periodical><pages end="008" start="007">007-008</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: To determine whether a child has asthma exacerbation, we should obtain the valueof peak expiratory fl ow. It is useful in a diagnostic procedure, in evaluation of response to therapy andfollowing the course of asthma.The context and purpose of the study: On the basis of published relations between body height andpeak expiratory fl ow in children I developed a formula for calculation of predicted peak expiratory fl ow inchildren according to body height.Results: Formula for estimation of predicted peak expiratory fl ow in children according to body heightreads as follows:Peak expiratory fl ow [L/min] = (Body height [cm] x 5.3) - 433.Conclusions: In some situations, especially in emergency settings, the presented formula may proveuseful in predicting peak expiratory fl ow knowing only a child's body height.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Slovenia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.peertechz.com/journals/open-journal-of-asthma/articles/volume-1/issue-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Open J Asthma\2017-1-007-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Open J Asthma\2017-1-007-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Kopac M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42747</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Convocar,J.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Moving away persons with Asthma from Geopathic Zone (Dowsing Technique): How are they after?</style></title><secondary-title><style face="normal" font="default">Open J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Open J Asthma</style></full-title></periodical><pages end="036" start="021">021-036</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No one really knows what exactly caused asthma. However, recent studies revealed that exposureto magnetic fi elds increases asthma risk and make asthma victims worst. This case study was aimedat determining the extent of the symptoms of asthma among victims when they stayed within and weremoved away from the geopathic zone. A combined qualitative-quantitative technique employed thequestionnaire checklist, interview, observation, and medical reports in gathering data. Likewise, Y-dowsingrod was used to locate the crossing points of earth grids where geopathic zone is found. The mean wasused to describe the extent of the health problems and matrices for the comparison of commonalities,patterns and variances in the analysis and interpretation of qualitative data. The fi ndings revealed thatasthma is triggered when one's head and breast is directly exposed within geopathic zone for a longertime. The illness remains incurable or become unresponsive to any medical treatment while the victimsstayed within the zone of radiation. However, when one moved away from the said zone it ceases to bea problem. Thus, asthma is a disease of location primarily triggered by geopathic stress and could beeffectively addressed when a victim moved away. Unless the people recognized the existence this unseennegative earth energy in selected location and its adverse effect on their health, the exact cause and cureof asthma remained a mystery.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Philippines -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.peertechz.com/journals/open-journal-of-asthma/articles/volume-1/issue-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Open J Asthma\2017-1-021-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Open J Asthma\2017-1-021-36.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Convocar JL</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42748</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">de Angelo Calsaverini Leal,R.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Inhalation Devices: Various forms of administration for Therapeutic Optimization</style></title><secondary-title><style face="normal" font="default">Open J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Open J Asthma</style></full-title></periodical><pages end="044" start="037">037-044</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Introduction: Aerosol therapy consists of spraying liquid particles suspended for therapeuticpurposes in the respiratory tract. With direct absorption and deposition at the lung level, avoiding sideeffects and presenting fast response time. Several factors infl uence the drug action, such as size, particlemovement, ventilatory fl ow, pulmonary expansion, anatomy, respiratory mechanics and the nebulizer andpatient interface. The therapeutic optimization depends on the type of nebulizer differentiating itself bythe physical principle that generates the mist.Objectives: Check advantages and disadvantages of different inhalation devices. Methodology. Thisis a review of the PubMed database using descriptors: ultrasonic and jet nebulizer, aerosol deposition inthe lung, metered dose inhaler and dry, inhaler therapy.Results: Different devices are mentioned in the literature: pneumatic and ultrasonic nebulizers(administering solutions), metered pressurized inhalers - pMDI used with or without expander chamber(administering suspensions) and dry powder inhalers - DPI (administering powder).Discussion and Conclusion: The US has advantages: quiet, does not require coordinating abilities,without propellant gases and quick nebulization with small amount of solution. Disadvantages: changein the active principle of thermosensitive drugs, deposition in the oropharynx and VAI of 2% of inhaledparticles. The NJ has 10% VAI drug deposition. Disadvantages: longer use time, need energy source,hinders molecular transport and has variable fl ow rate. DPI has advantages: portable, simple, activated byinspiration and the dose deposited varies from 15 to 40%. Disadvantage: requires respiratory coordination.The pMDI offers advantages: deposition in VAI of 37%, practical, allows a micropulverization. Disadvantage:Required high inspiratory fl ow. Aerosol therapy aims at deposition of particles with a diameter of less than5 µm in VAI. To achieve a concentration similar to the inhaled route in VA tissues, a higher dose of oralmedication is required. For each patient there is a suitable inhaler.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Brazil -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.peertechz.com/journals/open-journal-of-asthma/articles/volume-1/issue-2</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Open J Asthma\2017-1-037-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Open J Asthma\2017-1-037-44.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, de Angelo Calsaverini Leal RC</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42749</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lake,N.H.</style></author><author><style face="normal" font="default"> Barlow,B.T.</style></author><author><style face="normal" font="default"> Toledano,J.E.</style></author><author><style face="normal" font="default"> Valentine,J.</style></author><author><style face="normal" font="default"> McDonald,L.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Contact Dermatitis Reaction to 2-Octyl Cyanoacrylate Following 3 Orthopedic Procedures</style></title><secondary-title><style face="normal" font="default">Orthopedics</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Orthopedics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="9" Year="2017">2017/9/21</year></dates><abstract><style face="normal" font="default">Two-octyl cyanoacrylate is a popular skin adhesive used for closing surgical incisions. Since Food and Drug Administration approval in 1998, the few reports of adverse reactions following its use have primarily been limited to the nonorthopedic literature. The authors present a case series of contact dermatitis associated with 2-octyl cyanoacrylate following orthopedic surgery and a review of the literature on the diagnosis and treatment of this complication. All 3 patients presented with blistering around their incisions within 2 weeks of surgery and responded to treatment involving removal of the offending agent and use of oral diphenhydramine and hydroxyzine and topical triamcinolone. One case was complicated by a draining hematoma, requiring irrigation and debridement. Complete resolution occurred in all cases. This case series is intended to increase awareness in the orthopedic community of allergic contact dermatitis to 2-octyl cyanoacrylate and its appropriate treatment. [Orthopedics. 201x; xx(x):xx-xx.]</style></abstract><notes><style face="normal" font="default">DA - 20170921IS - 1938-2367 (Electronic)IS - 0147-7447 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.3928/01477447-20170918-08</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28934541">PM:28934541</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Orthopedics\20170921-LakeNH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Orthopedics\20170921-LakeNH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170921, Lake NH</style></custom2><misc3><style face="normal" font="default">10.3928/01477447-20170918-08</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42750</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Campbell,A.P.</style></author><author><style face="normal" font="default"> Phillips,K.M.</style></author><author><style face="normal" font="default"> Hoehle,L.P.</style></author><author><style face="normal" font="default"> Gaudin,R.A.</style></author><author><style face="normal" font="default"> Caradonna,D.S.</style></author><author><style face="normal" font="default"> Gray,S.T.</style></author><author><style face="normal" font="default"> Sedaghat,A.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Department of Otolaryngology, Harvard Medical School, Boston, Massachusetts, USA</style></auth-address><titles><title><style face="normal" font="default">Association between Asthma and Chronic Rhinosinusitis Severity in the Context of Asthma Control</style></title><secondary-title><style face="normal" font="default">Otolaryngol Head Neck Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Otolaryngol Head Neck Surg</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="9" Year="2017">2017/9/1</year></dates><abstract><style face="normal" font="default">Objective Comorbid asthma is associated with decreased quality of life (QOL) in chronic rhinosinusitis (CRS). It is unclear whether this association is independent of the patients' clinical asthma status. We therefore sought to determine if asthma is associated with lower QOL in CRS, independent of asthma control. Study Design Cross-sectional cohort study of 350 patients with CRS. Setting Tertiary academic rhinology clinic. Subjects and Methods In total, 350 participants with CRS were recruited and 28.3% were asthmatic. CRS-specific QOL was measured using the 22-item Sinonasal Outcome Test (SNOT-22). Asthma control was assessed with the Asthma Control Test (ACT). General health-related QOL was assessed with the EuroQoL 5-dimensional general health-related quality of life survey visual analog scale (EQ-5D VAS). Associations were sought between SNOT-22 and EQ-5D VAS (dependent variables) and asthma (independent variable), while controlling for ACT. ACT score for patients with CRS without asthma was set at 25 (indicating completely controlled, asymptomatic asthma). Results Comorbid asthma was associated with SNOT-22 (beta = 11.8; 95% confidence interval [CI], 6.2-17.3; P &lt; .001) and EQ-5D VAS (beta = -6.2; 95% CI, -11.2 to -1.3; P = .014). After controlling for ACT, asthma was no longer associated with SNOT-22 ( P = .147) or EQ-5D VAS ( P = .994). Instead, ACT score was associated with SNOT-22 (beta = -2.1; 95% CI, -3.2 to -1.1; P &lt; .001) and EQ-5D VAS (beta = 2.1; 95% CI, 1.1 to 3.0; P &lt; .001). ACT score completely drove the association between asthma and worse QOL. Conclusion Comorbid asthma is not necessarily reflective of decreased QOL in CRS. The association of comorbid asthma with lower QOL in CRS is related to the clinical status (eg, control) of asthma</style></abstract><notes><style face="normal" font="default">DA - 20170905IS - 1097-6817 (Electronic)IS - 0194-5998 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1177/0194599817728920</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28871839">PM:28871839</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Otolaryngol Head Neck Surg\20170905-CampbellAP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Otolaryngol Head Neck Surg\20170905-CampbellAP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170905, Campbell AP</style></custom2><misc3><style face="normal" font="default">10.1177/0194599817728920</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42751</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sucic,L.</style></author><author><style face="normal" font="default"> Galati-Fournier,V.</style></author><author><style face="normal" font="default"> Kym,U.</style></author><author><style face="normal" font="default"> Pfeifle,V.</style></author><author><style face="normal" font="default"> Gros,S.</style></author><author><style face="normal" font="default"> Schafer,K.H.</style></author><author><style face="normal" font="default"> Holland-Cunz,S.</style></author><author><style face="normal" font="default"> Keck,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department Pediatric Surgery, University Children's Hospital Basel (UKBB), Spitalstrasse 33, 4056, Basel, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Increased regulatory T cells in pediatric acute appendicitis</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="default">Appendectomy of an inflamed appendix has been reported to be protective in the pathogenesis of ulcerative colitis (UC) in both mice and human (1, 2). In mice, the contribution of a suppressive T cell subset has been described. However, no human prospective study has investigated the generation of those protective cells. Using immunofluorescence microscopy we evaluate for the first time the generation of suppressor T cells during pediatric acute appendicitis in a small control-matched cohort study. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170907IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Switzerland -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12797</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28881058">PM:28881058</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170907-SucicL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170907-SucicL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170907, Sucic L</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12797</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42752</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dermendzhiev,S.M.</style></author><author><style face="normal" font="default"> Sokolova,R.</style></author><author><style face="normal" font="default"> Chokoeva,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Occupational Diseases and Toxicology, 2nd Department of Internal Medicine, Medical University of Plovdiv, Medical Faculty, 15A Vasil Aprilov blvd, 4002, Plovdiv, Bulgaria</style></auth-address><titles><title><style face="normal" font="default">Acquired Arnold-Chiary malformation in a 16-year-old patient with hereditary angioedema</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="9" Year="2017">2017/9/7</year></dates><abstract><style face="normal" font="default">A 16-year-old male patient, presented with one month-history of complaints of an acute pain in the neck, accompanied by relapsing acute headache, sometimes irradiating forward the left arm. The patient had been diagnosed with hereditary angioedema (HAE) type I at age of 7, because of recurrent, non-pruritic edemas, affecting the skin of the face, neck, chest and abdomen, accompanied by colic-like intestinal spasms and relapsing bronchospasms, occurring without provocation and laboratory confirmed low serum levels of C1 inhibitor (Fig. 1a,b). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170907IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Bulgaria -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12777</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28881398">PM:28881398</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170907-DermendzhievSM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170907-DermendzhievSM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170907, Dermendzhiev SM</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12777</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42753</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ogawa,K.</style></author><author><style face="normal" font="default"> Tanaka,S.</style></author><author><style face="normal" font="default"> Yang,L.</style></author><author><style face="normal" font="default"> Arata,N.</style></author><author><style face="normal" font="default"> Sago,H.</style></author><author><style face="normal" font="default"> Yamamoto-Hanada,K.</style></author><author><style face="normal" font="default"> Narita,M.</style></author><author><style face="normal" font="default"> Ohya,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center of Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">Beta-2 receptor agonist exposure in the uterus associated with subsequent risk of childhood asthma</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Although the beta-2 receptor agonist (B2RA) is occasionally prescribed in the prenatal period for women with preterm labor, few studies have referred to the long-term effects of intrauterine exposure to B2RA on fetus. We examined the association between intrauterine exposure to B2RA and asthma in the offspring. METHODS: We obtained data from a hospital-based birth cohort study conducted in Tokyo, Japan. The outcomes of interest were three indicators, consisting of current wheeze, current asthma and ever asthma at 5 years of age, based on the International Study of Asthma and Allergies in Childhood questionnaire. Logistic regression analysis was used to evaluate the association between intrauterine B2RA exposure and outcomes. To evaluate dose-dependent risk, we categorized children into three groups according to both the cumulative dose and duration (days) and conducted trend analysis. RESULTS: Of 1158 children, 94 (8.1%) were exposed to B2RA in utero, and 191 (16.5%), 111 (9.6%) and 168 (14.5%) children experienced current wheeze, current asthma and ever asthma, respectively. After adjusting for confounders, we found an increased risk of current asthma caused by B2RA exposure with an adjusted odds ratio of 2.04 (95% confidence interval: 1.02-4.05). Trend analysis showed that B2RA exposure in utero was associated with a dose-dependent increased risk of current asthma in terms of both cumulative dose and duration (p values for trend were 0.015 and 0.017, respectively). These results were similar to those for other outcome measures. CONCLUSION: Exposure to B2RA in utero could be a risk for childhood asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170911IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12805</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28892561">PM:28892561</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170911-OgawaK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170911-OgawaK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170911, Ogawa K</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12805</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42754</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Abelius,M.S.</style></author><author><style face="normal" font="default"> Jedenfalk,M.</style></author><author><style face="normal" font="default"> Ernerudh,J.</style></author><author><style face="normal" font="default"> Janefjord,C.</style></author><author><style face="normal" font="default"> Berg,G.</style></author><author><style face="normal" font="default"> Matthiesen,L.</style></author><author><style face="normal" font="default"> Jenmalm,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Unit of Autoimmunity and Immune Regulation, Department of Clinical and Experimental Medicine, Linkoping University, Linkoping, Sweden</style></auth-address><titles><title><style face="normal" font="default">Pregnancy modulates the allergen-induced cytokine production differently in allergic and non-allergic women</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: The immunological environment during pregnancy may differ between allergic and non-allergic women. This study investigates the effect of maternal allergy on the allergen-induced cytokine and chemokine levels and if pregnancy modulates these immune responses differently in allergic and non-allergic women. METHODS: The birch-, cat-, phytohemagglutinin- and tetanus toxoid-induced interferon-gamma (IFN-gamma), interleukin-4 (IL)-4, IL-5, IL-10, IL-13, the T-helper 1 (Th1)-associated chemokine CXCL10 and the Th2-associated chemokine CCL17 levels were quantified in 20 women with allergic symptoms (sensitised, n=13) and 36 women without allergic symptoms (non-sensitised, n=30) at gestational weeks 10-12, 15-16, 25, 35 and 2 and 12 months postpartum. RESULTS: Birch-, but not cat-induced, IL-5, IL-13 and CCL17 levels were increased during pregnancy as compared with postpartum in the sensitised women with allergic symptoms. In contrast, cat-, but not birch-induced, IL-5 and IL-13 levels were increased during pregnancy as compared with postpartum in the non-sensitised women without allergic symptoms. Furthermore, IFN-gamma secretion was increased in the first and decreased in the second and third trimesters in response to birch and decreased in the third trimester in response to cat as compared with postpartum in the non-sensitised women without allergic symptoms. Increased allergen-induced IL-4, IL-5 and IL-13 levels were associated with allergic symptoms and sensitisation. CONCLUSIONS: Pregnancy had a clear effect on the allergen-induced IL-5, IL-13, CCL17, IFN-gamma and CXCL10 production, with distinct enhanced Th2-responses to birch in the allergic group and to cat in the non-allergic group. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170911IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12802</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28892576">PM:28892576</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170911-AbeliusMS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170911-AbeliusMS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170911, Abelius MS</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12802</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42755</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Moral,L.</style></author><author><style face="normal" font="default"> Caubet,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Allergy and Respiratory Unit. Hospital General Universitario de Alicante. Alicante, SpainPediatric Allergy Unit, Department of Child and Adolescent, University Hospitals of Geneva, Geneva, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Oral challenge without skin tests in children with non-severe betalactam hypersensitivity: time to change the paradigm?</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="default">Suspected allergy to penicillins and cephalosporins is very common in childhood. After a proper evaluation, allergy will be confirmed only in a small portion of them. Intradermal tests are usually part of the allergy workup, but they are painful for children and time-consuming, and their role has been debated. A systematic review found only two studies reporting a positive predictive value of skin tests in children of 36% and 33%, respectively, leading to a high rate of inaccurate diagnosis. Moreover, considering that skin tests are negative in more than 90-95% of cases, an oral provocation test (OPT) is finally needed to confirm tolerance in most of these children. Positive OPT are rare and even where children demonstrate reproducible signs on challenge, they rarely constitute immediate or serious symptoms. Therefore, OPT to the index antibiotic without skin tests are increasingly being considered an accepted procedure for children with a suspected mild non-immediate reaction related to a betalactam antibiotic. Furthermore, a recent research has taken the same approach including children with suspected mild immediate reactions, with similar safety and positive results. In the light of recent evidence highlighted, it is now the time for large and multicentric studies to confirm that OPT with the index antibiotic, without skin tests, are safe and convenient for children with a history of a mild reaction with a betalactam antibiotic before it can be recommended in pediatric allergy guidelines. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170911IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12800</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28892222">PM:28892222</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170911-MoralL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170911-MoralL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170911, Moral L</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12800</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42756</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Raissy,H.</style></author><author><style face="normal" font="default"> Blake,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Acetaminophen and Asthma in Children: Association or Causality?</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="131" start="129">129-131</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="5" Year="2017">2017/5/12</year><pub-dates><date Day="26" Month="8" Year="2017">2017/8/26</date></pub-dates></dates><publisher><style face="normal" font="default">Mary Ann Liebert, Inc., publishers</style></publisher><isbn><style face="normal" font="default">2151-321X</style></isbn><abstract><style face="normal" font="default">Use of acetaminophen and increasing risk of asthma have been reported in the epidemiological studies. Despite lack of controlled prospective clinical trials evaluating these associations in children, avoidance of acetaminophen in children with asthma has become controversial. This review presents data from observational studies and a recent prospective clinical trial investigating the association with use of acetaminophen in children with mild asthma and on asthma control.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1089/ped.2017.0767</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1089/ped.2017.0767</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-129-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-129-31.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Raissy H</style></custom2><misc3><style face="normal" font="default">10.1089/ped.2017.0767</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42757</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dinatale,M.</style></author><author><style face="normal" font="default"> Sahin,L.</style></author><author><style face="normal" font="default"> Johnson,T.</style></author><author><style face="normal" font="default"> Howard,T.B.</style></author><author><style face="normal" font="default"> Yao,L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Medication Use During Pregnancy and Lactation: Introducing the Pregnancy and Lactation Labeling Rule</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="134" start="132">132-134</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="6" Year="2017">2017/6/1</year><pub-dates><date Day="26" Month="8" Year="2017">2017/8/26</date></pub-dates></dates><publisher><style face="normal" font="default">Mary Ann Liebert, Inc., publishers</style></publisher><isbn><style face="normal" font="default">2151-321X</style></isbn><abstract><style face="normal" font="default">On June 30, 2015, the U.S. Food and Drug Administration implemented the Pregnancy and Lactation Labeling Rule (PLLR). The PLLR was issued to address the shortcomings of pregnancy and lactation information in prescription drug and biological product labeling. The new labeling format under PLLR is structured to better help providers communicate important information about the risks and benefits of taking a specific medication to their pregnant or breastfeeding patients.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1089/ped.2017.0772</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1089/ped.2017.0772</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-132-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol Pulmonol\2017-30-132-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Dinatale M</style></custom2><misc3><style face="normal" font="default">10.1089/ped.2017.0772</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42758</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martins,C.</style></author><author><style face="normal" font="default"> Silva,D.</style></author><author><style face="normal" font="default"> Severo,M.</style></author><author><style face="normal" font="default"> Rufo,J.</style></author><author><style face="normal" font="default"> Paciencia,I.</style></author><author><style face="normal" font="default"> Madureira,J.</style></author><author><style face="normal" font="default"> Padrao,P.</style></author><author><style face="normal" font="default"> Moreira,P.</style></author><author><style face="normal" font="default"> Delgado,L.</style></author><author><style face="normal" font="default"> Oliveira,F.E.</style></author><author><style face="normal" font="default"> Barros,H.</style></author><author><style face="normal" font="default"> Malmberg,P.</style></author><author><style face="normal" font="default"> Moreira,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunoallergology, Centro Hospitalar de Sao Joao, Porto, Portugal</style></auth-address><titles><title><style face="normal" font="default">Spirometry adjusted exhaled nitric oxide increases accuracy for assessment of asthma control in children</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="default">Spirometry and exhaled nitric oxide are two important complimentary tools to identify and assess asthma control in children. We aimed to determine the ability of a new suggested spirometry adjusted exhaled nitric oxide (NO) index in doing that. A random sample of 1602 schoolchildren were screened by a health questionnaire, skin-prick tests, spirometry with bronchodilation and exhaled NO. A total of 662 children were included with median (IQR) exhaled NO 11(14) ppb. ROC curves using exhaled NO equations from Malmberg, Kovesi and Buchvald, and spirometry adjusted exhaled NO values were applied to identify asthmatic children and uncontrolled asthma. ROC curves failed to identify asthmatic children (all AUC&lt;0.700). Spirometry adjusted exhaled NO/FEV1 (AUC=0.712; p=0.010) and NO/FEF25-75% (AUC=0.735 p=0.004) had a fair and increased ability to identify uncontrolled disease compared with exhaled NO (AUC=0.707; p=0.011) or the Malmberg equation (AUC=0.701; p=0.014). Sensitivity and specificity identifying non-controlled asthma was of 59% and 81%, respectively, for the cut-off value of 9.7 ppb/L for exhaled NO/FEV1 , and 40% and 100% for 15.7 ppb/L/s for exhaled NO/FEF25-75% . Exhaled NO did not allow to identify childhood asthma. Spirometry adjusted fraction of exhaled NO performed better assessing asthma control in children. Thus, despite more validation studies are needed, we suggest its use in epidemiological studies to assess asthma control</style></abstract><notes><style face="normal" font="default">DA - 20170911IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12803</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28892559">PM:28892559</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170911-MartinsC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20170911-MartinsC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170911, Martins C</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12803</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42759</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lohman,M.E.</style></author><author><style face="normal" font="default"> Lio,P.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Feinberg School of Medicine, Northwestern University, Chicago, IL, USAFeinberg School of Medicine, Northwestern University, Chicago, IL, USA</style></auth-address><titles><title><style face="normal" font="default">Comparison of psoriasis and atopic dermatitis guidelines-an argument for aggressive atopic dermatitis management</style></title><secondary-title><style face="normal" font="default">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="9" Year="2017">2017/9/25</year></dates><abstract><style face="normal" font="default">The development of effective systemic treatments has revolutionized the treatment of inflammatory skin diseases. The availability of safe new treatments and the understanding of psoriasis as a systemic disease with comorbidities and effects on quality of life have driven the current aggressive treatment paradigm of psoriasis. Historically the morbidity of atopic dermatitis (AD) has been dismissed, given the perception of AD as "just" a rash. Differences in the guidelines for psoriasis and AD management may suggest variations in the current conceptualization of disease severity and effects on quality of life. Published guidelines from the American Academy of Dermatology for the management of psoriasis and AD were reviewed. We recorded the similarities and differences in disease assessment and therapy. The threshold to use biologic agents for moderate to severe psoriasis highlights the aggressive nature of modern psoriasis treatment. AD guidelines include an assessment of quality of life but do not designate a disease severity threshold for systemic treatment. AD and psoriasis have a tremendous effect on quality of life. The AD guidelines have a less aggressive approach to disease management than the psoriasis guidelines. We should think critically about rapid advancement to systemic agents in AD management, especially now that more and better agents are being developed</style></abstract><notes><style face="normal" font="default">DA - 20170925IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pde.13282</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28944965">PM:28944965</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Dermatol\20170925-LohmanME.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Dermatol\20170925-LohmanME.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170925, Lohman ME</style></custom2><misc3><style face="normal" font="default">10.1111/pde.13282</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42760</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">van Meel,E.R.</style></author><author><style face="normal" font="default"> Jaddoe,V.W.V.</style></author><author><style face="normal" font="default"> Bonnelykke,K.</style></author><author><style face="normal" font="default"> de Jongste,J.C.</style></author><author><style face="normal" font="default"> Duijts,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Generation R Study Group, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">The role of respiratory tract infections and the microbiome in the development of asthma: A narrative review</style></title><secondary-title><style face="normal" font="default">Pediatr Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Pulmonol</style></full-title></periodical><pages end="1370" start="1363">1363-1370</pages><volume><style face="normal" font="default">52</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="9" Year="2017">2017/9/4</year></dates><abstract><style face="normal" font="default">Asthma is a common disease in childhood, and might predispose for chronic obstructive respiratory morbidity in adolescence and adulthood. Various early-life risk factors might influence the risk of wheezing, asthma, and lower lung function in childhood. Cohort studies demonstrated that lower respiratory tract infections in the first years of life are associated with an increased risk of wheezing and asthma, while the association with lung function is less clear. Additionally, the gut and airway microbiome might influence the risk of wheezing and asthma. The interaction between respiratory tract infections and the microbiome complicates studies of their associations with wheezing, asthma, and lung function. Furthermore, the causality behind these observations is still unclear, and several other factors such as genetic susceptibility and the immune system might be of importance. This review is focused on the association of early-life respiratory tract infections and the microbiome with wheezing, asthma, and lung function, it is possible influencing factors and perspectives for future studies</style></abstract><notes><style face="normal" font="default">DA - 20170904IS - 1099-0496 (Electronic)IS - 1099-0496 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Netherlands -CO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1002/ppul.23795</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28869358">PM:28869358</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Pulmonol\2017-52-1363-70.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Pulmonol\2017-52-1363-70.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170904, van Meel ER</style></custom2><misc3><style face="normal" font="default">10.1002/ppul.23795</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42761</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Song,E.H.</style></author><author><style face="normal" font="default"> Chung,K.S.</style></author><author><style face="normal" font="default"> Kang,Y.M.</style></author><author><style face="normal" font="default"> Lee,J.H.</style></author><author><style face="normal" font="default"> Lee,M.</style></author><author><style face="normal" font="default"> An,H.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Eupatilin suppresses the allergic inflammatory response in vitro and in vivo</style></title><secondary-title><style face="normal" font="default">Phytomedicine</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Phytomedicine</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic inflammation</style></keyword><keyword><style face="normal" font="default"> Eupatilin</style></keyword><keyword><style face="normal" font="default"> Human mast cell</style></keyword><keyword><style face="normal" font="default"> NF-+¦B,Cytokine</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0944-7113</style></isbn><abstract><style face="normal" font="default">Introduction : Eupatilin, a pharmacologically active ingredient found in Artemisia asiatica, has been reported to have anti-oxidative, anti-inflammatory, and anti-apoptotic activities. However, molecular mechanisms underlying its anti-allergic properties are not yet clear. In this study, we investigated the effects of eupatilin on allergic inflammation in phorbol 12-myristate 13-acetate plus calcium ionophore A23187 (PMACI)-stimulated human mast cells and a compound 48/80-induced anaphylactic shock model. Methods : Cytokine assays, histamine assays, quantitative real-time polymerase chain reaction analysis, western blot analysis and compound 48/80-induced anaphylactic shock model were used in this study. Results : Eupatilin significantly suppresses the expression and production of pro-inflammatory cytokines, such as interleukin (IL)-1+¦, tumor necrosis factor (TNF)-+¦, and IL-6 in vitro and in vivo. In addition, eupatilin inhibits nuclear factor kappa B (NF-+¦B) activation by regulating the phosphorylation and degradation of I+¦B+¦ via the Akt/IKK(+¦/+¦) pathway. Eupatilin treatment also attenuates the phosphorylation of p38, ERK, and JNK MAPKs. Furthermore, eupatilin blocked anaphylactic shock and decreased the release of histamine. Conclusions: Anti-allergic inflammation may involve the expression and production of regulating pro-inflammatory cytokines via Akt/IKK(+¦/+¦) and MAPK activation of NF-+¦B. On the basis of these data, eupatilin is a potential candidate for the treatment of allergic diseases</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.phymed.2017.08.027</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.phymed.2017.08.027</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Phytomedicine\20171010-SongEH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Phytomedicine\20171010-SongEH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Song EH</style></custom2><misc3><style face="normal" font="default">10.1016/j.phymed.2017.08.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42762</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Clerc,A.</style></author><author><style face="normal" font="default"> Reynaud,Q.</style></author><author><style face="normal" font="default"> Durupt,S.</style></author><author><style face="normal" font="default"> Chapuis-Cellier,C.</style></author><author><style face="normal" font="default"> Nove-Josserand,R.</style></author><author><style face="normal" font="default"> Durieu,I.</style></author><author><style face="normal" font="default"> Lega,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departement de medecine interne et Centre de Reference Mucoviscidose, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France</style></auth-address><titles><title><style face="normal" font="default">Elevated IgG4 serum levels in patients with cystic fibrosis</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0181888">e0181888-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Serum immunoglobulin (Ig) G4 elevation has been associated with several pathological conditions other than IgG4-related disease (IgG4-RD). In cystic fibrosis (CF), an elevation of specific IgG4 has been associated with colonization and infection by Pseudomonas aeruginosa. IgG4 elevation may be a marker of chronic infection or inflammatory stimulation. The aim of this study was to explore the prevalence of elevated IgG4 levels in CF and its correlation with the major clinical and microbiological features found in CF patients. METHODS: In a cross-sectional study, we analyzed data from a large cohort of adult CF patients attending the CF center of Lyon University Hospital. An elevated IgG4 level was defined as being above the cut-off value of 135 mg/dL. RESULTS: One hundred and sixty-five CF patients were analyzed. An IgG4 elevation was detected in 43 patients (26%). Compared with the control group (&lt;/= 135 mg/dL), high IgG4 patients exhibited a greater prevalence of Staphylococcus aureus colonization and higher IgG, IgG1, IgG2 and IgE levels. No significant differences were observed in terms of pulmonary function, colonization with Pseudomonas aeruginosa, or the annual rate of bronchial exacerbations. CONCLUSION: An elevated IgG4 serum level was frequently detected in adult CF patients and did not appear to be associated with poor lung function. We suggest that IgG4 elevation is a marker of the activation of tolerance. Its clinical significance remains to be demonstrated</style></abstract><notes><style face="normal" font="default">DA - 20170918IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0181888</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28922375">PM:28922375</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0181888.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0181888.pdf</url></text-urls><related-urls><url ppv-ref="no">xlsx in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20170918, Clerc A</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0181888</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42763</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Poninska,J.K.</style></author><author><style face="normal" font="default"> Samolinski,B.</style></author><author><style face="normal" font="default"> Tomaszewska,A.</style></author><author><style face="normal" font="default"> Raciborski,F.</style></author><author><style face="normal" font="default"> Samel-Kowalik,P.</style></author><author><style face="normal" font="default"> Walkiewicz,A.</style></author><author><style face="normal" font="default"> Lipiec,A.</style></author><author><style face="normal" font="default"> Piekarska,B.</style></author><author><style face="normal" font="default"> Krzych-Falta,E.</style></author><author><style face="normal" font="default"> Namyslowski,A.</style></author><author><style face="normal" font="default"> Kostrzewa,G.</style></author><author><style face="normal" font="default"> Pawlik,A.</style></author><author><style face="normal" font="default"> Jasek,M.</style></author><author><style face="normal" font="default"> Wisniewski,A.</style></author><author><style face="normal" font="default"> Kusnierczyk,P.</style></author><author><style face="normal" font="default"> Majewski,S.</style></author><author><style face="normal" font="default"> Ploski,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Biology, Institute of Cardiology, Warsaw, PolandDepartment of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland</style></auth-address><titles><title><style face="normal" font="default">Haplotype dependent association of rs7927894 (11q13.5) with atopic dermatitis and chronic allergic rhinitis: A study in ECAP cohort</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0183922">e0183922-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The T allele of rs7927894 (at 11q13.5) was associated with atopic dermatitis and other allergic diseases. Our purpose was to replicate the association with allergic phenotypes and explore the role of rs7927894 in predisposing to persistent allergic rhinitis and atopic asthma. We also wanted to explore if other SNPs at 11q13.5 contributed to effect of rs7927894. We studied patients with atopic dermatitis (N = 270), atopic asthma (N = 486), persistent allergic rhinitis (N = 589) and controls matched for age, sex and region (N = 540, N = 372 and N = 1178, respectively). We found that rs7927894 T was associated with atopic dermatitis (OR = 1.39, CI: 1.12-1.73, P = 0.003) and independently with persistent allergic rhinitis (OR = 1.24, CI:1.07-1.43, P = 0.0043, Pcorrected = 0.013) but not atopic asthma. Analysis of additional tagging SNPs (rs7930763, rs2513517, rs7125552) showed that effect of rs7927894 T was limited to haplotypes encoding G at rs7125552. In conclusion, rs7927894 T is associated not only with atopic dermatitis but also persistent allergic rhinitis. Since these effects are haplotype dependent rs7927894 alone does not account for the association between 11q13.5 and atopic dermatitis/persistent allergic rhinitis</style></abstract><notes><style face="normal" font="default">DA - 20170908IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0183922</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28886043">PM:28886043</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0183922.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0183922.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170908, Poninska JK</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0183922</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42764</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chu,S.</style></author><author><style face="normal" font="default"> Chen,Q.</style></author><author><style face="normal" font="default"> Chen,Y.</style></author><author><style face="normal" font="default"> Bao,Y.</style></author><author><style face="normal" font="default"> Wu,M.</style></author><author><style face="normal" font="default"> Zhang,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Laboratory of Respiratory Disease, Affiliated Hospital of Guilin Medical University, Guilin, China</style></auth-address><titles><title><style face="normal" font="default">Cesarean section without medical indication and risk of childhood asthma, and attenuation by breastfeeding</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0184920">e0184920-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Previous studies suggest that caesarean section (CS) may increase the risk of asthma in children, but none of them could preclude potential confounding effects of underlying medical indications for CS. We aim to assess the association between CS itself (without medical indications) and risk of childhood asthma. METHODS: We conducted a hospital-based case-control study on childhood asthma with 573 cases and 812 controls in Shanghai. Unconditional logistic regression models in SAS were employed to control for potential confounders. RESULTS: Our study found that CS without medical indication was significantly associated with elevated asthma risk (adjusted OR = 1.58 [95% CI 1.17-2.13]). However, this risk was attenuated in children fed by exclusive breastfeeding in the first six months after birth (adjusted OR = 1.39 [95% CI 0.92-2.10]). In contrast, the risk was more prominent in children with non-exclusive breastfeeding or bottle feeding (adjusted OR = 1.91 [95% CI 1.22-2.99]). CONCLUSIONS: CS without medical indication was associated with an increased risk of childhood asthma. Exclusive breastfeeding in infancy may attenuate this risk</style></abstract><notes><style face="normal" font="default">DA - 20170918IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0184920</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28922410">PM:28922410</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0184920.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0184920.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170918, Chu S</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0184920</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42765</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dmochowski,M.</style></author><author><style face="normal" font="default"> Gornowicz-Porowska,J.</style></author><author><style face="normal" font="default"> Bowszyc-Dmochowska,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Dew drops on spider web appearance: a newly named pattern of IgG4 deposition in pemphigus with direct immunofluorescence</style></title><secondary-title><style face="normal" font="default">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Postepy Dermatol Alergol</style></full-title></periodical><pages end="298" start="295">295-298</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Novel appearances in cutaneous pathology as well as mucocutaneous clinical signs are being described whichindicate that this is still an attractive area for exploration. The H + E histology terms of "decorated tomb stoning"and "undecorated tomb stoning", advocated by some pathologists, are misleading and as such should be avoided.Here, an appearance of IgG4 pemphigus deposits examined cost-effectively with direct immunofluorescence andsuggested to be called "dew drops on spider web" is depicted in depth.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="default">10.5114/ada.2017.69306</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.5114/ada.2017.69306</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-295-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-295-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Dmochowski M</style></custom2><misc3><style face="normal" font="default">10.5114/ada.2017.69306</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42766</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Almutairi,N.</style></author><author><style face="normal" font="default"> Almutawa,F.</style></author></authors></contributors><titles><title><style face="normal" font="default">The role of nickel allergy in hand dermatitis and its impact on handling cupronickel currency coins. A comparative cohort study from Kuwait</style></title><secondary-title><style face="normal" font="default">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Postepy Dermatol Alergol</style></full-title></periodical><pages end="321" start="313">313-321</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Introduction: Contact with nickel-releasing coins as a cause of hand dermatitis has been debated.Aim: Studying a hand dermatitis risk from handling Kuwaiti cupronickel coins among nickel-allergic and nickelnon-allergic subjects.Material and methods: One hundred hand dermatitis patients (group I: nickel-allergic) and 100 matched patients(group II: nickel non-allergic) were selected from over 500 hand dermatitis cases seen between September 2014and September 2015. Nickel released from Kuwaiti cupronickel coins immersed in a standardized artificial sweatsolution was measured at 1, 24, 48, 144 and 168 h at room temperature. Subjects in both groups were exposed tonickel releasing coins. The process was repeated after 3 months using nickel coated coins as controls.Results: Nickel released from 20, 50 and 100 fils Kuwaiti cupronickel coins at 1 week was 28.64, 32.76, 35.76 µg/cm 2 /week, respectively. Ninety-one patients (29 males, 62 females) in group I and 87 patients (38 males, 49 females)in group II completed the study. 47.3% in group I vs. 13.8% in group II developed dermatitis on exposure to nickelreleasing coins. Nickel coated coins resulted in dermatitis in 8.8% of group I vs. 5.7% in group II.Conclusions: Nickel is released significantly from cupronickel Kuwaiti coins. Handling of coins caused dermatitismore often in patients with nickel-allergy compared to nickel non-allergic patients.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Kuwait -</style></notes><work-type><style face="normal" font="default">10.5114/ada.2017.69309</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.5114/ada.2017.69309</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-313-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-313-21.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Almutairi N</style></custom2><misc3><style face="normal" font="default">10.5114/ada.2017.69309</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42767</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Panaszek,B.</style></author><author><style face="normal" font="default"> Nowak,D.</style></author><author><style face="normal" font="default"> Cieslik,K.</style></author><author><style face="normal" font="default"> Dziemieszonek,P.</style></author><author><style face="normal" font="default"> Gomulka,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Systemic contact dermatitis caused by cobalt chloride and palladium in a 26-year-old woman with allergic type I reactions, non-steroidal anti-inflammatory drug hypersensitivity and autoimmune thyroiditis</style></title><secondary-title><style face="normal" font="default">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Postepy Dermatol Alergol</style></full-title></periodical><pages end="390" start="388">388-390</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="default">10.5114/ada.2017.69324</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.5114/ada.2017.69324</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-388-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-388-90.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Panaszek B</style></custom2><misc3><style face="normal" font="default">10.5114/ada.2017.69324</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42768</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sundquist,B.K.</style></author><author><style face="normal" font="default"> Bowen,B.J.</style></author><author><style face="normal" font="default"> Otabor,U.</style></author><author><style face="normal" font="default"> Celestin,J.</style></author><author><style face="normal" font="default"> Sorum,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Medicine, Division of Allergy, Asthma, and Immunology , Albany Medical College , Albany , NY , USA</style></auth-address><titles><title><style face="normal" font="default">Proactive penicillin allergy testing in primary care patients labeled as allergic: outcomes and barriers</style></title><secondary-title><style face="normal" font="default">Postgrad Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Postgrad Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword></keywords><dates><year Day="24" Month="8" Year="2017">2017/8/24</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To promote penicillin allergy testing in an outpatient setting in patients labeled as penicillin allergic, to determine the number of those who are truly allergic, evaluate patient satisfaction with the testing, and educate both patients and clinicians about testing. METHODS: Patients with a history of penicillin allergy listed in their EHR were screened and recruited by their primary care office and referred for penicillin allergy testing. The results of allergy testing and patient satisfaction after testing were the main outcomes. We also surveyed the primary care physicians about perceived barriers to recruitment. RESULTS: A total of 82 patients were recruited, although only 37 actually underwent testing. None of these 37 had a positive skin test, and none of 36 had a positive oral challenge (1 refused it). Following testing, 2 patients (5%) had subjective reactions within 24 h. Thirty-one patients (84%) responded to a post-testing follow-up questionnaire; 3 (10%) were subsequently treated with a beta-lactam, and all reported that testing provided important information to their medical history. Providers identified time constraints, either their or their patients lack of time, as the major barrier to recruitment. CONCLUSIONS: Penicillin allergy testing safely evaluates patients labeled as penicillin allergic. It is well tolerated, and embraced by the patients who undergo testing. In our study, none of the patients tested had an allergic reaction, but we identified multiple barriers to developing a protocol for testing patients from the primary care setting</style></abstract><notes><style face="normal" font="default">DA - 20170822IS - 1941-9260 (Electronic)IS - 0032-5481 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/00325481.2017.1370360</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28829234">PM:28829234</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Postgrad Med\20170822-SundquistBK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Postgrad Med\20170822-SundquistBK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170822, Sundquist BK</style></custom2><misc3><style face="normal" font="default">10.1080/00325481.2017.1370360</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42769</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rajcani,J.</style></author><author><style face="normal" font="default"> Solarikova,P.</style></author><author><style face="normal" font="default"> Brezina,I.</style></author></authors></contributors><titles><title><style face="normal" font="default">Effects of allergy and trait anxiety on heart rate variability: A naturalistic design study</style></title><secondary-title><style face="normal" font="default">Psychoneuroendocrinology</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Psychoneuroendocrinology</style></abbr-1></periodical><pages end="" start="40">40-</pages><volume><style face="normal" font="default">83</style></volume><number><style face="normal" font="default">Supplement</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0306-4530</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Slovak Republic -</style></notes><work-type><style face="normal" font="default">10.1016/j.psyneuen.2017.07.347</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.psyneuen.2017.07.347</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Psychoneuroendocrinology\2017-83S-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Psychoneuroendocrinology\2017-83S-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Rajcani J</style></custom2><misc3><style face="normal" font="default">10.1016/j.psyneuen.2017.07.347</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42770</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hom,S.</style></author><author><style face="normal" font="default"> Pisano,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Reslizumab (Cinqair): An Interleukin-5 Antagonist for Severe Asthma of the Eosinophilic Phenotype</style></title><secondary-title><style face="normal" font="default">PT</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PT</style></abbr-1></periodical><pages end="568" start="564">564-568</pages><volume><style face="normal" font="default">42</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Reslizumab (Cinqair), an interleukin-5 antagonist for severe eosinophilic asthma</style></abstract><notes><style face="normal" font="default">DA - 20170911IS - 1052-1372 (Print)IS - 1052-1372 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28890642">PM:28890642</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PT\2017-42-564-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PT\2017-42-564-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170911, Hom S</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42771</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Papamichael,M.M.</style></author><author><style face="normal" font="default"> Itsiopoulos,C.</style></author><author><style face="normal" font="default"> Susanto,N.H.</style></author><author><style face="normal" font="default"> Erbas,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">1School of Allied Health,Department of Rehabilitation,Nutrition and Sport,La Trobe University,Melbourne,VIC 3086,Australia</style></auth-address><titles><title><style face="normal" font="default">Does adherence to the Mediterranean dietary pattern reduce asthma symptoms in children? A systematic review of observational studies</style></title><secondary-title><style face="normal" font="default">Public Health Nutr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Public Health Nutr</style></abbr-1></periodical><pages end="2734" start="2722">2722-2734</pages><volume><style face="normal" font="default">20</style></volume><number><style face="normal" font="default">15</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Diet</style></keyword></keywords><dates><year Day="14" Month="8" Year="2017">2017/8/14</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The purpose of the present systematic review was to synthesize evidence from the literature to assess efficacy of the Mediterranean dietary pattern in childhood asthma. Design/Setting A systematic search of six databases, three clinical trial registries and hand-search of peer-reviewed articles was conducted up to 29 October 2016. Inclusion criteria included exposure to a Mediterranean dietary pattern, measurement of asthma symptoms and study population of children aged &lt;18 years. Quality assessment was conducted. Due to significant heterogeneity, meta-analysis was not feasible. RESULTS: Of the 436 articles identified, after removal of duplicates and based on inclusion criteria, fifteen observational studies conducted in Mediterranean and non-Mediterranean countries were relevant. No randomized controlled trials were retrieved. Twelve studies reported an inverse association between adherence to a Mediterranean dietary pattern and asthma in children, two studies showed no association and one study showed an increase in asthma symptoms. In fourteen out of fifteen studies, quality assessment checks revealed good reliability and validity among study methodologies. CONCLUSIONS: The current systematic review revealed a consistent inverse relationship (protective) between a Mediterranean dietary pattern and asthma in children. Future well-designed randomized controlled trials are needed to provide solid evidence. Nevertheless, the existing level of evidence adds to the public health message relating to the beneficial effects of a Mediterranean-type diet in children suffering with asthma</style></abstract><notes><style face="normal" font="default">DA - 20170814IS - 1475-2727 (Electronic)IS - 1368-9800 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1017/S1368980017001823</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28803594">PM:28803594</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Public Health Nutr\2017-20-2722-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Public Health Nutr\2017-20-2722-34.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170814, Papamichael MM</style></custom2><misc3><style face="normal" font="default">10.1017/S1368980017001823</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42772</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Heshmatzadeh,B.A.</style></author><author><style face="normal" font="default"> Zhao,Y.</style></author><author><style face="normal" font="default"> Farooq,Z.</style></author><author><style face="normal" font="default"> Prince,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Department of Radiology, Weill Cornell Medical Center, 416 E 55th St, New York, NY 10022</style></auth-address><titles><title><style face="normal" font="default">Immediate Allergic Reactions to Gadolinium-based Contrast Agents: A Systematic Review and Meta-Analysis</style></title><secondary-title><style face="normal" font="default">Radiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Radiology</style></full-title></periodical><pages end="" start="162740">162740-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="8" Year="2017">2017/8/25</year></dates><abstract><style face="normal" font="default">Purpose To perform a systematic review and meta-analysis to determine if there are differences in rates of immediate allergic events between classes of gadolinium-based contrast agents (GBCAs). Materials and Methods PubMed and Google Scholar databases were searched for studies in which rates of immediate adverse events to GBCAs were reported. The American College of Radiology classification system was used to characterize allergic-like events as mild, moderate, or severe, and the total number of administrations of each GBCA was recorded. Where necessary, authors of studies were contacted to clarify data and eliminate physiologic reactions. Relative risks of GBCA types were estimated by using the Mantel-Haenszel type method. Results Nine studies in which immediate reactions to GBCA were recorded from a total of 716 978 administrations of GBCA met the criteria for inclusion and exclusion. The overall and severe rates of GBCA allergic-like adverse events were 9.2 and 0.052 per 10 000 administrations, respectively: 81% (539 of 662) were mild, 13% (86 of 662) were moderate, and 6% (37 of 662) were severe reactions. The nonionic linear chelate gadodiamide had the lowest rate of reactions, at 1.5 (95% confidence interval [CI]: 0.74, 2.4) per 10 000 administrations, which was significantly less than that of linear ionic GBCAs at 8.3 (95% CI: 7.5, 9.2) per 10 000 administrations (relative risk, 0.19 [95% CI: 0.099, 0.36]; P &lt; .00001) and less than that for nonionic macrocyclic GBCAs at 16 (95% CI: 14, 19) per 10 000 administrations (relative risk, 0.12 [95% CI: 0.05, 0.31]; P &lt; .001). GBCAs known to be associated with protein binding had a higher rate of reactions, at 17 (95% CI: 15, 20) per 10 000 administrations compared with the same chelate classification without protein binding, at 5.2 (95% CI: 4.5, 6.0) per 10 000 administrations (relative risk, 3.1 [95% CI: 2.4, 3.8]; P &lt; .0001). Conclusion These data show the lowest rate of immediate allergic adverse events with use of the nonionic linear GBCA gadodiamide in comparison with those of ionic linear or nonionic macrocyclic GBCAs. A higher rate of immediate allergic adverse events was associated with ionicity, protein binding, and macrocyclic structure. (c) RSNA, 2017</style></abstract><notes><style face="normal" font="default">DA - 20170828IS - 1527-1315 (Electronic)IS - 0033-8419 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1148/radiol.2017162740</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28846495">PM:28846495</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Radiology\2017-162740.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Radiology\2017-162740.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170828, Heshmatzadeh BA</style></custom2><misc3><style face="normal" font="default">10.1148/radiol.2017162740</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42773</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Agrahari,V.F.</style></author><author><style face="normal" font="default"> Aulgur,Z.</style></author><author><style face="normal" font="default"> Thukral,S.</style></author><author><style face="normal" font="default"> Dhall,N.</style></author><author><style face="normal" font="default"> Conely,R.</style></author><author><style face="normal" font="default"> Mitra,A.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, 64108. United States</style></auth-address><titles><title><style face="normal" font="default">Recent Patents and Emerging Therapeutics on Ocular Inflammation and Allergy</style></title><secondary-title><style face="normal" font="default">Recent Pat Inflamm Allergy Drug Discov</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Recent Pat Inflamm Allergy Drug Discov</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="9" Year="2017">2017/9/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Ocular inflammation and allergic eye diseases range from mild to severe may disturbs visual function and affects quality of life. Since these diseases require intensive therapies, the pathophysiology and treatments of these conditions are highlighted. OBJECTIVE: The ocular diseases caused by inflammation and allergy are extensively studied in this review to provide an overview of the newer compounds, novel delivery approaches, preclinical and clinical trials for treatment of the allergic conjunctivitis, dry eye syndrome, and uveitis. METHOD: The eye is divided into two segments; anterior and posterior. Both segments of the eye i.e. anterior and posterior provide barriers to the eye. Despite many efforts by scientists, several potential drug candidates are often dropped from the initial screening portfolio due to failure in overcoming these barriers. Thus to overcome unmet challenges remarkable progresses have been made towards the design of novel ocular therapeutics with enhanced activity and minimal toxicity to ocular tissue. A comprehensible understanding of the diseased conditions, physiological barriers and pharmacokinetics of the eye would significantly accelerate the development of new therapeutics. Moreover, identification of new targets drives the discovery of novel drug molecules for the ocular disease treatment. RESULTS: The advancement in the drug discovery and dosage from design showcases the increasing number of patent applications being filed and issued for allergic conjunctivitis, dry eye syndrome, and uveitis. In addition, preclinical and clinical trials are now becoming available showing the newer generation of ocular drugs. CONCLUSION: This review presented a brief background on the disease condition, types, treatment, advancement in the delivery approaches, focus on emerging therapeutics, related patents and clinical trials for the treatment of the allergic conjunctivitis, dry eye syndrome, and uveitis</style></abstract><notes><style face="normal" font="default">DA - 20170913IS - 1872-213X (Print)IS - 1872-213X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2174/1872213X11666170913150146</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28901856">PM:28901856</url></web-urls></urls><custom2><style face="normal" font="default">20170913, Agrahari VF</style></custom2><misc3><style face="normal" font="default">10.2174/1872213X11666170913150146</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42774</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vincent,M.J.</style></author><author><style face="normal" font="default"> Parker,A.</style></author><author><style face="normal" font="default"> Maier,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department Environmental Health, University Cincinnati College of Medicine, Cincinnati, OH, USA.</style></auth-address><titles><title><style face="normal" font="default">Cleaning and asthma: A systematic review and approach for effective safety assessment</style></title><secondary-title><style face="normal" font="default">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="9" Year="2017">2017/9/13</year></dates><abstract><style face="normal" font="default">Research indicates a correlative relationship between asthma and use of consumer cleaning products. We conduct a systematic review of epidemiological literature on persons who use or are exposed to cleaning products, both in occupational and domestic settings, and risk of asthma or asthma-like symptoms to improve understanding of the causal relationship between exposure and asthma. A scoring method for assessing study reliability is presented. Although research indicates an association between asthma and the use of cleaning products, no study robustly investigates exposure to cleaning products or ingredients along with asthma risk. This limits determination of causal relationships between asthma and specific products or ingredients in chemical safety assessment. These limitations, and a lack of robust animal models for toxicological assessment of asthma, create the need for a weight-of-evidence (WoE) approach to examine an ingredient or product's asthmatic potential. This proposed WoE method organizes diverse lines of data (i.e., asthma, sensitization, and irritation information) through a systematic, hierarchical framework that provides qualitatively categorized conclusions using hazard bands to predict a specific product or ingredient's potential for asthma induction. This work provides a method for prioritizing chemicals as a first step for quantitative and scenario-specific safety assessments based on their potential for inducing asthmatic effects. Acetic acid is used as a case study to test this framework</style></abstract><notes><style face="normal" font="default">DA - 20170917IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.yrtph.2017.09.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28918194">PM:28918194</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\20170917-VincentMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\20170917-VincentMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170917, Vincent MJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.yrtph.2017.09.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42775</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bakirtas,A.</style></author><author><style face="normal" font="default"> Kutlu,A.</style></author><author><style face="normal" font="default"> Baccioglu,A.</style></author><author><style face="normal" font="default"> Erkekol,F.O.</style></author><author><style face="normal" font="default"> Bavbek,S.</style></author><author><style face="normal" font="default"> Kalayci,O.</style></author></authors></contributors><titles><title><style face="normal" font="default">Physicians' preference for controller medication in mild persistent asthma</style></title><secondary-title><style face="normal" font="default">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respir Med</style></full-title></periodical><pages end="240" start="236">236-240</pages><volume><style face="normal" font="default">131</style></volume><number><style face="normal" font="default">Supplement C</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Mild</style></keyword><keyword><style face="normal" font="default"> Persistent</style></keyword><keyword><style face="normal" font="default"> Physician</style></keyword><keyword><style face="normal" font="default"> Preference</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0954-6111</style></isbn><abstract><style face="normal" font="default">Abstract Although the asthma guidelines recommend inhaled corticosteroids(ICS) or leukotriene receptor antagonists-(LTRAs) for the treatment of mild persistent asthma, factors governing the physicians' preference are unknown. We aimed to investigate the preference of physicians for the controller medication and the factors governing their choice. A self-administered questionnaire composed of 16 questions that aimed to determine the preference of the physicians for the first choice controller medication in mild persistent asthma and physician and patient related factors that may be associated with this selection was e-mailed to the members of the Turkish National Society of Allergy and Clinical Immunology and distributed to participants in the 21st congress. Of the 670 questionnaires, there were 51% participants and 336 of them were complete enough to be included in the analysis. Low dose ICS was preferred as the first choice controller medication for mild persistent asthma by 84.5% of the physicians. The reasons for physicians' preference were different for ICS and LTRA. In the logistic regression analysis, use of asthma guidelines (OR:3.5, 95%CI:1.3</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô9.3, p-á=-á0.01), alignment in guidelines (OR:2.9, 95%CI:1.4</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô5.8, p-á=-á0.002) and the opinion that it is a more effective (OR:2.3, 95%CI:1.1</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô4.8, p-á=-á0.02) were independently associated with ICS preference. Being a pediatrician (OR:5.4, 95%CI: 2.7</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô10.5, p-á&lt;-á0.001) and the opinion that it has better patient compliance (OR:4.4, 95%CI: 1.6</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô12.0, p-á=-á0.004) were independently associated with LTRA preference. Surveyed Turkish physicians, the majority of whom were specialists, preferred ICS over LTRA as controller medication in mild persistent asthma. Asthma guidelines, training background (pediatrician versus not) and perceived efficacy and patient compliance appeared to influence their preferences</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1016/j.rmed.2017.08.029</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.rmed.2017.08.029</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respir Med\2017-131SC-236-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respir Med\2017-131SC-236-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Bakirtas A</style></custom2><misc3><style face="normal" font="default">10.1016/j.rmed.2017.08.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42776</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Toraih,E.A.</style></author><author><style face="normal" font="default"> Hussein,M.H.</style></author><author><style face="normal" font="default"> Al Ageeli,E.</style></author><author><style face="normal" font="default"> Riad,E.</style></author><author><style face="normal" font="default"> AbdAllah,N.B.</style></author><author><style face="normal" font="default"> Helal,G.M.</style></author><author><style face="normal" font="default"> Fawzy,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Genetics Unit, Department of Histology and Cell Biology, Faculty of Medicine, Suez Canal University, Ismailia, P.O. 41522, Egypt.</style></auth-address><titles><title><style face="normal" font="default">Structure and functional impact of seed region variant in MIR-499 gene family in bronchial asthma</style></title><secondary-title><style face="normal" font="default">Respir Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Respir Res</style></abbr-1></periodical><pages end="" start="169">169-</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="9" Year="2017">2017/9/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Small non-coding RNAs (microRNAs) have been evolved to master numerous cellular processes. Genetic variants within microRNA seed region might influence microRNA biogenesis and function. The study aimed at determining the role of microRNA-499 (MIR-499) gene family polymorphism as a marker for susceptibility and progression of bronchial asthma and to analyze the structural and functional impact of rs3746444 within the seed region. METHODS: Genotyping for 192 participants (96 patients and 96 controls) in the discovery phase and 319 subjects (115 patients and 204 controls) in the replication phase was performed via Real Time-Polymerase Chain Reaction technology. Patients underwent the methacholine challenge test and biochemical analysis. Gene structural and functional analysis, target prediction, annotation clustering, and pathway enrichment analysis were executed. Predicted functional effect of rs37464443 SNP was analyzed. RESULTS: miR-499 gene family is highly implicated in inflammation-related signaling pathways. Rs374644 (A > G) in MIR499A and MIR499B within the seed region could disrupt target genes and create new genes. The G variant was associated with high risk of developing asthma under all genetic association models (G versus A: OR = 3.27, 95% CI = 2.53-4.22; GG versus AA: OR = 9.52, 95% CI = 5.61-16.5; AG versus AA: OR = 2.13, 95% CI = 1.24-3.46; GG + AG versus AA: OR = 4.43, 95% CI = 2.88-6.82). GG genotype was associated with poor pre-bronchodilator FEV1 (p = 0.047) and the worst bronchodilator response after Salbutamol inhalation, represented in low peaked expiratory flow rate (p = 0.035). CONCLUSIONS: miR-499 rs3746444 (A > G) polymorphism was associated with asthma susceptibility and bronchodilator response in Egyptian children and adolescents. Further functional analysis is warranted to develop more specific theranostic agents for selecting targeted therapy</style></abstract><notes><style face="normal" font="default">DA - 20170909IS - 1465-993X (Electronic)IS - 1465-9921 (Linking)LA - engPT - Journal ArticleCO - Egypt -CO - Saudi Arabia -</style></notes><work-type><style face="normal" font="default">10.1186/s12931-017-0648-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28886711">PM:28886711</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respir Res\2017-18-169.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respir Res\2017-18-169.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170909, Toraih EA</style></custom2><misc3><style face="normal" font="default">10.1186/s12931-017-0648-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42777</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vega-Robledo,G.B.</style></author><author><style face="normal" font="default"> Rico-Rosillo,M.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Senescence of the immune system and alterations related with asthma</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="219" start="206">206-219</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Senescence is an irreversible process by which cells enter to a permanent cell cycle arrest withgeneralized molecular changes. Senescent cells remain metabolically active and most of themshow a secretory phenotype; through its secretion may induce senescence or cancer in othercells. The secretory cells in the so-called transient senescence may participate in embryogenesis,tissue regeneration and immune response. The deleterious changes associated with age affectthe immune system members and the immune senescence cause poor response to vaccinesand susceptibility to cancer and infections. These latter are a frequent cause of asthma mostly inthe elderly, the incidence is increasing in old people, and it may be related with those anatomical,physiological and immune changes caused by age, asthma chronicity and external agents.Comorbidity in the elderly worsens the ailment and hinders diagnosis, therefore, knowledge andhandling of these clinical entities must be in control by the physicians responsible of the first levelattention to old patients.</style></abstract><notes><style face="normal" font="default">LA - SPACO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://revistaalergia.mx/ojs/index.php/ram/issue/view/22/showToc</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-206-19.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-206-19.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Vega-Robledo GB</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42778</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Galicia-Negrete,G.</style></author><author><style face="normal" font="default"> Falfan-Valencia,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Mediators of inflammatory response in asthma and its association with obesity</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="205" start="198">198-205</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">There is an increase in the prevalence of asthma and obesity, constituting a public health problem atnational and global levels. The association between the two pathologies has not been clearly determined;however, a certain synergy has been proposed, which leads to more severe bronchospasms, longerrecovery time, and more prolonged use of medications in obese asthmatic patients. The discoveryof leptin, an adipokine that is directly related to the amount of total body fat and the production ofproinflammatory cytokines, has generated greater interest in white adipose tissue. Our objective wasto describe the possible mechanisms involved and the association between obesity and asthma.A bibliographic search was conducted in the scientific literature using the National BiotechnologyInformation Center (NCBI) database of the USA as a search tool; keywords used were: asthma,leptin, obesity and inflammation. There are numerous clinical and experimental studies that explorethe role of obesity as an inflammatory entity in asthma, some of which have evaluated the role of"shared" genetic polymorphisms in both pathologies. Apparently, the interaction between asthmaand obesity is complex, there are mechanisms that link both pathologies, these can influence theimprovement or exacerbation of symptoms.</style></abstract><notes><style face="normal" font="default">LA - SPACO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://revistaalergia.mx/ojs/index.php/ram/issue/view/22/showToc</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-198-205.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-198-205.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Galicia-Negrete G</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42779</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rendon-Macias,M.E.</style></author><author><style face="normal" font="default"> Villasis-Keever,M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">The research protocol V: The calculation of sample size</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="227" start="220">220-227</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Sample size refers to the number of participants to be included in a research study. If the calculationis carried out properly, not only conclusions will be established with statistical support and thepotential risks to the subjects included in the investigation will be limited, but also the study canbe properly planned to optimize economic and time costs. Calculation of sample size requiresinformation that must be supported by the research protocol. This information includes that theobjectives (descriptive study or a study to establish differences between groups) and hypothesesare well elaborated (with magnitude and direction), the scale of measurement of the outcomevariable(s) must be defined, and type I error and type II error appropriately identified. This reviewdescribes how to specify the requirements needed for sample size calculation, including examplesin clinical research designs.</style></abstract><notes><style face="normal" font="default">LA - SPACO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://revistaalergia.mx/ojs/index.php/ram/issue/view/22/showToc</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-220-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-220-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Rendon-Macias ME</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42780</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Herrera-Sanchez,D.A.</style></author><author><style face="normal" font="default"> Leon-Pedroza,J.I.</style></author><author><style face="normal" font="default"> Vargas-Camano,M.E.</style></author><author><style face="normal" font="default"> Castrejon-Vazquez,M.I.</style></author></authors></contributors><titles><title><style face="normal" font="default">Good's syndrome. Report of case</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="240" start="235">235-240</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Good's syndrome is an association of thymoma and immunodeficiency. The symptomsare recurrent sinopulmonary infections in addition to the compressive side of thymoma. A laboratoryfinding is notable for the absence or decrease of B lymphocytes, hypogammaglobulinemia,inversion ratio CD4/CD8 and abnormal proliferative response to mitogens.Clinical case: Female, 49-year-old started five months earlier with lower limb edema, postprandialvomiting, dysphagia, chronic diarrhea and weight loss. A second endoscopy ruled gastricneoplasia. Chest radiography with mediastinal widening, Thoraco-abdominal CT with bilateralpleural effusion and a mass in the anterior mediastinum, histopathological report of the tumor:B1 thymoma. Laboratory findings: IgG 349 mg/dL, IgA 70.3 mg/dL, 37.1 IgM mg/dL, Ca125 631UI/mL, leukocytes 7890 mm 3 , hemoglobin 13.2 g/dL, lymphocytes 2060 mm 3 , CD16+CD56+ 122cells/µL, CD19 77 cells/µL, CD3 2052 cells/µL, CD4 977 cells/µL, CD8 998 cells/µL; ratio CD4/CD8 0.98, hepatitis C, B and HIV negative. They requested valuation to Clinical Immunologyand Allergy due to hypogammaglobulinemia, the diagnosis of Good's syndrome was confirmedand initiated with intravenous gamma globulin replacement to immunomodulatory dose of 1 g/kg, she reached replacement goal in the third dose of immunoglobulin intravenous, with clinicalimprovement. She died four months later from cardiac complications.Conclusions: Despite the variability of presentation, Good's syndrome should be suspected as partof the paraneoplastic manifestations of thymoma.</style></abstract><notes><style face="normal" font="default">LA - SPACO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://revistaalergia.mx/ojs/index.php/ram/issue/view/22/showToc</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-235-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-235-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Herrera-Sanchez DA</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42781</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lopez-Rocha,E.</style></author><author><style face="normal" font="default"> O'Farril-Romanillos,P.</style></author><author><style face="normal" font="default"> Cerda-Reyes,S.</style></author><author><style face="normal" font="default"> Medina-Torres,E.A.</style></author><author><style face="normal" font="default"> Espinosa-Padilla,S.E.</style></author><author><style face="normal" font="default"> Huerta-Lopez,J.G.</style></author><author><style face="normal" font="default"> Blanxas-Galicia,L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Angioedema as initial manifestation of hypogammaglobulinemia</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="234" start="228">228-234</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Common variable immunodeficiency is characterized by hypogammaglobulinemia and the inabilityto respond to vaccines. Patients mostly manifest infections, however only less than 5 % havepathological conditions as autoimmunity, granulomatous inflammation, and splenomegaly orlymphoproliferative disease among others, without showing infections. We report the case of awoman who debuted with localized cutaneous affection, facial angioedema, without other earlysymptoms. After diagnosis splenomegaly and bronchiectasis were documented. Angioedema andbronchiectasis responded with IVIG replacement. We also review the dermatological manifestationsassociated with CVID.</style></abstract><notes><style face="normal" font="default">LA - SPACO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://revistaalergia.mx/ojs/index.php/ram/issue/view/22/showToc</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-228-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-228-34.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, LOpez-Rocha E</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42782</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ocampo,J.</style></author><author><style face="normal" font="default"> Gaviria,R.</style></author><author><style face="normal" font="default"> Sanchez,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prevalence of asthma in Latin America. Critical look at ISAAC and other studies</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="197" start="188">188-197</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Currently, the ISAAC (International Study of Asthma and Allergies in Childhood) project is aglobal approach to assess the prevalence of asthma and other allergies in different latitudes.One of the great advantages of this project is that it compares using the same methodology, theprevalence of asthma in more than 50 cities during the same period of time, nevertheless thereproducibility of these results when compared with other studies of prevalence in each regionhas not been evaluated. In this review we aim to compare the epidemiological data providedby the ISAAC against the data identified in some regional cohort studies and by means of acritical evaluation to highlight the main similarities and to analyze the differences between theseepidemiological data.</style></abstract><notes><style face="normal" font="default">LA - SPACO - Colombia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://revistaalergia.mx/ojs/index.php/ram/issue/view/22/showToc</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-188-97.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-188-97.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Ocampo J</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42783</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bedolla-Barajas,M.</style></author><author><style face="normal" font="default"> Lopez-Hernandez,J.C.</style></author><author><style face="normal" font="default"> Garcia-Padilla,L.F.</style></author><author><style face="normal" font="default"> Morales-Romero,J.</style></author><author><style face="normal" font="default"> Velarde-Rivera,F.A.</style></author><author><style face="normal" font="default"> Robles-Figueroa,M.</style></author><author><style face="normal" font="default"> Ortiz-Peregrina,J.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prevalence of vitamin D insufficiency and deficiency in Mexican adults with allergic asthma</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="187" start="178">178-187</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Hypovitaminosis D has been associated with various chronic diseases such asinfections, autoimmune diseases, chronic obstructive pulmonary disease, cancer and asthmaObjective: The objective at hand is to determine the prevalence of vitamin D (VD) insufficiency anddeficiency in adults with allergic asthma.Methods: Through a cross-sectional study, we analyzed corresponding data amongst 135 patients.VD concentration was categorized as sufficient (= 30 ng/mL), insufficient (21-29 ng/mL), and deficient(= 20 ng/mL). The level of VD deficiency was measured through chemo-luminescence. We estimatedthe prevalence of VD alterations and their respective confidence intervals at 95 % (CI 95 %).Results: Within the analyzed population, there were 99/135 women (73.3 %); the mean age was 34.5± 10.3 years. The mean concentration of VD was 17.9 ± 6.9 ng/mL and the median was 17 ng/mL.The prevalence of VD insufficiency and deficiency was 25.2 % (CI 95 %, 18.6-33.2 %) and 71.1 %(CI 95 %, 62.9-78.1 %), respectively; VD concentrations = 10 ng/mL had 13.3 % (CI 95 %, 8.5-20.2 %) and = 30 ng/mL at 3.7 % (CI 95 %: 1.4-8.6 %). When we contrasted the men to the women,the median concentration of VD did not differ significantly (16 ng/mL vs. 18 ng/mL, p = 0.71).Conclusions: In this study, patients with allergic asthma had distinctively reduced VD concentrationlevels; future research will determine if and how VD affects the severity of asthma.</style></abstract><notes><style face="normal" font="default">LA - SPACO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://revistaalergia.mx/ojs/index.php/ram/issue/view/22/showToc</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-178-87.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-178-87.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Bedolla-Barajas M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42784</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dalle,J.</style></author><author><style face="normal" font="default"> Ramos,M.C.</style></author><author><style face="normal" font="default"> Jimenez,M.F.</style></author><author><style face="normal" font="default"> Escobar,F.G.</style></author><author><style face="normal" font="default"> Antonello,V.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Prevention and Infection Control, Hospital Femina, Porto Alegre, RS, Brazil</style></auth-address><titles><title><style face="normal" font="default">Oral Desensitization to Penicillin for the Treatment of Pregnant Women with Syphilis: A Successful Program</style></title><secondary-title><style face="normal" font="default">Rev Bras Ginecol Obstet</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Rev Bras Ginecol Obstet</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="8" Year="2017">2017/8/31</year></dates><abstract><style face="normal" font="default">Gestational syphilis is a prevalent disease in Brazil and other low and medium income countries. Desensitization to penicillin is recommended for pregnant women with syphilis who are allergic to beta-lactams. This is a descriptive study utilizing outpatient medical records from 2011 to 2015 from a mother and child hospital that is part of the national healthcare system in the South of Brazil, which performs an average of 3,600 birth assistances per year. All cases of pregnant women with syphilis and presumptive diagnosis of beta-lactam allergy during the study period were included. The patients referred for desensitization originated from the hospital prenatal care service, as well as from municipal/state antenatal care services. Oral desensitization was performed in the obstetric emergency room, and adult and pediatric intensive care units were available at all times. Ten patients underwent desensitization during the period of study. Personal history of urticaria was the most common reaction that demanded desensitization. All patients tolerated the procedure well, and showed no adverse reactions. We report a successful program of oral desensitization. None of the patients presented adverse reactions or complications, a fact that corroborates the feasibility and safety of the desensitization protocol. Oral administration of penicillin comes at a low cost, and optimizes the use of time and resources</style></abstract><notes><style face="normal" font="default">DA - 20170831IS - 1806-9339 (Electronic)IS - 0100-7203 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1055/s-0037-1606274</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28859210">PM:28859210</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170831, Dalle J</style></custom2><misc3><style face="normal" font="default">10.1055/s-0037-1606274</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42785</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Parthasarathi,K.</style></author><author><style face="normal" font="default"> Christensen,J.M.</style></author><author><style face="normal" font="default"> Alvarado,R.</style></author><author><style face="normal" font="default"> Barham,H.P.</style></author><author><style face="normal" font="default"> Sacks,R.</style></author><author><style face="normal" font="default"> Harvey,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">1. Rhinology and Skull Base Research Group, St Vincents Centre for Applied Medical Research, University of New South Wales, Sydney, Australia</style></auth-address><titles><title><style face="normal" font="default">Airflow and symptom outcomes between allergic and non-allergic rhinitis patients from turbinoplasty</style></title><secondary-title><style face="normal" font="default">Rhinology</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Rhinology</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="9" Year="2017">2017/9/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Inferior turbinate procedures are applied to relieve medically refractory nasal obstruction. However, the nature of congestion differs between allergic(AR) and non-allergic rhinitis(NAR). This study compares surgical outcomes between AR and NAR patients. METHODOLOGY: A case-control study of patients undergoing turbinate with or without septoplasty surgery for nasal obstruction was performed. Patient reported outcomes were: nasal obstruction, global nasal function(GNF), and sino-nasal outcome test(SNOT-22) with rhinitis, facial symptom, sleep and psychological sub-scores. Nasal peak inspiratory flow(NPIF) assessed nasal airflow. Measurements were obtained preoperatively and 3 months postoperatively. RESULTS: 190 patients were assessed. AR had worse obstruction and worse GNF. All outcomes improved post-surgery; nasal obstruction, GNF, SNOT-22, rhinitis-symptoms, facial-symptoms, sleep-function, psychological-function and NPIF. GNF improvement was greater in AR. NPIF improvement was similar between groups. CONCLUSIONS: Both AR and NAR patients gained benefit from surgery to relieve nasal obstruction. AR patients demonstrate greater improvement in GNF score but allergy management may contribute to this</style></abstract><notes><style face="normal" font="default">DA - 20170909IS - 0300-0729 (Print)IS - 0300-0729 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.4193/Rhin16.210</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28888024">PM:28888024</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170909, Parthasarathi K</style></custom2><misc3><style face="normal" font="default">10.4193/Rhin16.210</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42786</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shakoor,Z.</style></author><author><style face="normal" font="default"> Al-Mutairi,A.S.</style></author><author><style face="normal" font="default"> Al-Shenaifi,A.M.</style></author><author><style face="normal" font="default"> Al-Abdulsalam,A.M.</style></author><author><style face="normal" font="default"> Al-Shirah,B.Z.</style></author><author><style face="normal" font="default"> Al-Harbi,S.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pathology, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia.</style></auth-address><titles><title><style face="normal" font="default">Screening for skin-sensitizing allergens among patients with clinically suspected allergic contact dermatitis</style></title><secondary-title><style face="normal" font="default">Saudi Med J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Saudi Med J</style></abbr-1></periodical><pages end="927" start="922">922-927</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To detect common skin-sensitizing agents among patients experiencing allergic contact dermatitis (ACD). Methods: This was a retrospective study of 152 patients with clinically suspected ACD who underwent patch testing in an allergy clinic at King Khalid University Hospital, Riyadh, Kingdom of Saudi Arabia between January 2012 and February 2015. Of these patients, only 74 (48%) patients reacted to one or more contact allergens. This group of patients included 58 (78.4%) women and 16 (21.6%) men (mean age: 37.8+/-13.8 years). Patch testing was performed using the thin-layer rapid-use epicutaneous patch test panels. Results: Nickel sulfate was the most common sensitizing agent, with 26 (35.1%) patients yielding a positive result; followed by p-phenylenediamine in 17 (22.9%), butyl-tetra-phenol formaldehyde in 12 (16.2%), gold sodium thiosulfate in 10 (13.5%), and thimerosal in 6 (8.1%) patients. Nickel reactivity was significantly higher among women (41.4%) than among men (12.5%) (p less than 0.0001). Similarly, gold reactivity among women (15.5%) was also higher than among men (6.2%) (p&lt;/=0.02). Conclusion: The high level of skin sensitization due to nickel, PPD, and gold in patients with ACD emphasizes the need for measures to decrease exposure to these sensitizing agents</style></abstract><notes><style face="normal" font="default">DA - 20170910IS - 0379-5284 (Print)IS - 0379-5284 (Linking)LA - engPT - Journal ArticleCO - Saudi Arabia -</style></notes><work-type><style face="normal" font="default">10.15537/smj.2017.9.20505</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28889150">PM:28889150</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Saudi Med J\2017-38-922-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Saudi Med J\2017-38-922-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170910, Shakoor Z</style></custom2><misc3><style face="normal" font="default">10.15537/smj.2017.9.20505</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42787</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kajisa,T.</style></author><author><style face="normal" font="default"> Yamaguchi,T.</style></author><author><style face="normal" font="default"> Hu,A.</style></author><author><style face="normal" font="default"> Suetake,N.</style></author><author><style face="normal" font="default"> Kobayashi,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Hospital Administration, School of Medicine, Juntendo University, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default">Hydrogen water ameliorates the severity of atopic dermatitis-like lesions and decreases interleukin-1beta, interleukin-33, and mast cell infiltration in NC/Nga mice</style></title><secondary-title><style face="normal" font="default">Saudi Med J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Saudi Med J</style></abbr-1></periodical><pages end="933" start="928">928-933</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To examine the effect of hydrogen water (HW) on the severity of atopic dermatitis (AD) and elucidate the underlying pathophysiological mechanisms. METHODS: For this experimental study between March 2015 and December 2015, NC/Nga mice characterized by mild AD severity were given either HW (n=11) or purified water (PW) (n=9) ad libitum; specific-pathogen-free mice (n=9) were used as AD-free control. Atopic dermatitis severity score and transepidermal water loss (TEWL) were examined at baseline (0 week), and after 4 weeks of HW/PW treatment. Levels of serum thymus and activation-regulated chemokine (TARC) and cytokines in the AD lesion were measured by ELISA; and mRNA expression of TARC and aquaporin (AQP-3) genes in the skin was examined by real-time polymerase chain reaction. Results: Mice treated with HW for 4 weeks demonstrated a significant decrease in the AD severity score compared with PW-treated mice (p less than 0.01). Hydrogen water administration also significantly reduced TEWL and serum TARC levels (p less than 0.01), infiltration of mast cells (p less than 0.05), and secretion of the proinflammatory cytokines interleukin (IL)-1beta and IL-33 (p less than 0.05) in skin lesions compared with PW. However, no difference was observed between PW and HW groups in interferon-gamma secretion and expression of AQP-3 and TARC genes. Conclusion: Hydrogen water suppressed inflammation in AD mice, leading to amelioration of disease severity, which suggests the therapeutic potential of HW in AD treatment</style></abstract><notes><style face="normal" font="default">DA - 20170910IS - 0379-5284 (Print)IS - 0379-5284 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.15537/smj.2017.9.20807</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28889151">PM:28889151</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Saudi Med J\2017-38-928-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Saudi Med J\2017-38-928-33.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170910, Kajisa T</style></custom2><misc3><style face="normal" font="default">10.15537/smj.2017.9.20807</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42788</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Duvall,M.G.</style></author><author><style face="normal" font="default"> Barnig,C.</style></author><author><style face="normal" font="default"> Cernadas,M.</style></author><author><style face="normal" font="default"> Ricklefs,I.</style></author><author><style face="normal" font="default"> Krishnamoorthy,N.</style></author><author><style face="normal" font="default"> Grossman,N.L.</style></author><author><style face="normal" font="default"> Bhakta,N.R.</style></author><author><style face="normal" font="default"> Fahy,J.V.</style></author><author><style face="normal" font="default"> Bleecker,E.R.</style></author><author><style face="normal" font="default"> Castro,M.</style></author><author><style face="normal" font="default"> Erzurum,S.C.</style></author><author><style face="normal" font="default"> Gaston,B.M.</style></author><author><style face="normal" font="default"> Jarjour,N.N.</style></author><author><style face="normal" font="default"> Mauger,D.T.</style></author><author><style face="normal" font="default"> Wenzel,S.E.</style></author><author><style face="normal" font="default"> Comhair,S.A.</style></author><author><style face="normal" font="default"> Coverstone,A.M.</style></author><author><style face="normal" font="default"> Fajt,M.L.</style></author><author><style face="normal" font="default"> Hastie,A.T.</style></author><author><style face="normal" font="default"> Johansson,M.W.</style></author><author><style face="normal" font="default"> Peters,M.C.</style></author><author><style face="normal" font="default"> Phillips,B.R.</style></author><author><style face="normal" font="default"> Israel,E.</style></author><author><style face="normal" font="default"> Levy,B.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pulmonary and Critical Care Medicine Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA</style></auth-address><titles><title><style face="normal" font="default">Natural killer cell-mediated inflammation resolution is disabled in severe asthma</style></title><secondary-title><style face="normal" font="default">Sci Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Immunol</style></abbr-1></periodical><pages end="" start=" eaam5446"> eaam5446-</pages><volume><style face="normal" font="default">2</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">immunology</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword></keywords><dates><year Day="10" Month="3" Year="2017">2017/3/10</year></dates><abstract><style face="normal" font="default">Severe asthma is typically characterized by chronic airway inflammation that is refractory to corticosteroids and associated with excess morbidity. Patients were recruited into the National Heart, Lung, and Blood Institute-sponsored Severe Asthma Research Program and comprehensively phenotyped by bronchoscopy. Bronchoalveolar lavage (BAL) cells were analyzed by flow cytometry. Compared with healthy individuals (n = 21), patients with asthma (n = 53) had fewer BAL natural killer (NK) cells. Patients with severe asthma (n = 29) had a marked increase in the ratios of CD4+ T cells to NK cells and neutrophils to NK cells. BAL NK cells in severe asthma were skewed toward the cytotoxic CD56dim subset, with significantly increased BAL fluid levels of the cytotoxic mediator granzyme A. The numbers of BAL CD56dim NK cells and CCR6-</style></abstract><notes><style face="normal" font="default">DA - 20170807IS - 2470-9468 (Electronic)IS - 2470-9468 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1126/sciimmunol.aam5446</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28783702">PM:28783702</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Immunol\2017-2- eaam5446.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Immunol\2017-2- eaam5446.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170807, Duvall MG</style></custom2><misc3><style face="normal" font="default">10.1126/sciimmunol.aam5446</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42789</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Davis,D.M.</style></author><author><style face="normal" font="default"> Waldman,A.</style></author><author><style face="normal" font="default"> Jacob,S.</style></author><author><style face="normal" font="default"> LeBovidge,J.</style></author><author><style face="normal" font="default"> Ahluwalia,J.</style></author><author><style face="normal" font="default"> Tollefson,M.</style></author><author><style face="normal" font="default"> Jetter,N.</style></author><author><style face="normal" font="default"> Spergel,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USADivision of Pediatric and Adolescent Dermatology, Rady Children's Hospital, San Diego, California, USA</style></auth-address><titles><title><style face="normal" font="default">Diagnosis, comorbidity, and psychosocial impact of atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Semin Cutan Med Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Semin Cutan Med Surg</style></abbr-1></periodical><pages end="99" start="95">95-99</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a chronic inflammatory skin disease, with a remitting relapsing course. The central diagnostic features of AD include pruritus, xerosis, eczematous lesions with a characteristic morphology and distribution, and a personal or family history of atopic disease. Several clinical studies have emphasized the link between AD and other atopic disorders including asthma, allergic rhinitis, and food allergies. More recent studies indicate possible links between AD and other nonatopic disorders, including ADHD, sleep disturbance, and mental health disorders, suggesting an even more profound impact of this disease. Furthermore, the social, emotional, and personal impact of AD for patients and their caregivers is substantial. Understanding both the clinical characteristics and implications of AD is critical to lessening the psychosocial, clinical, and economic burden of this disease</style></abstract><notes><style face="normal" font="default">DA - 20170912IS - 1085-5629 (Print)IS - 1085-5629 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.12788/j.sder.2017.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28895954">PM:28895954</url></web-urls></urls><custom2><style face="normal" font="default">20170912, Davis DM</style></custom2><misc3><style face="normal" font="default">10.12788/j.sder.2017.028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42790</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Eichenfield,L.F.</style></author><author><style face="normal" font="default"> Ahluwalia,J.</style></author><author><style face="normal" font="default"> Davis,D.M.</style></author><author><style face="normal" font="default"> Fleischer,D.M.</style></author><author><style face="normal" font="default"> Waldman,A.</style></author><author><style face="normal" font="default"> Spergel,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pediatric and Adolescent Dermatology, Rady Children's Hospital, San Diego, California, USA.</style></auth-address><titles><title><style face="normal" font="default">Curriculum United for Better Eczema Care: why, how, and what?</style></title><secondary-title><style face="normal" font="default">Semin Cutan Med Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Semin Cutan Med Surg</style></abbr-1></periodical><pages end="94" start="93">93-94</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">While various medical specialties treat eczema patients, care for these patients is largely fragmented and disorganized. Moreover, standardized treatment protocols that incorporate upcoming eczema therapies and emerging guidelines have yet to be established. Thus, there is both a need and an opportunity to equip clinicians to succeed in this novel and changing era of eczema care. The National Eczema Association's (NEA) strategic plan-developed through extensive discussions with patients who have atopic dermatitis and their caregivers, industry, and providers representing different specialties-called for the creation of an interdisciplinary coalition to steer this initiative. The Coalition United for Better Eczema Care (CUBE-C) is a network of cross-specialty leaders working to help construct an educational curriculum based on standards of effective treatment and disease management</style></abstract><notes><style face="normal" font="default">DA - 20170912IS - 1085-5629 (Print)IS - 1085-5629 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.12788/j.sder.2017.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28895953">PM:28895953</url></web-urls></urls><custom2><style face="normal" font="default">20170912, Eichenfield LF</style></custom2><misc3><style face="normal" font="default">10.12788/j.sder.2017.033</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42791</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ahluwalia,J.</style></author><author><style face="normal" font="default"> Davis,D.M.</style></author><author><style face="normal" font="default"> Jacob,S.</style></author><author><style face="normal" font="default"> Waldman,A.</style></author><author><style face="normal" font="default"> Ong,P.Y.</style></author><author><style face="normal" font="default"> Cohen,S.</style></author><author><style face="normal" font="default"> Friedman,A.</style></author><author><style face="normal" font="default"> Lio,P.</style></author><author><style face="normal" font="default"> Jetter,N.</style></author><author><style face="normal" font="default"> Bienstock,J.</style></author><author><style face="normal" font="default"> LeBovidge,J.</style></author><author><style face="normal" font="default"> Spergel,J.</style></author><author><style face="normal" font="default"> Fonacier,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pediatric and Adolescent Dermatology, Rady Children's Hospital, San Diego, California, USA</style></auth-address><titles><title><style face="normal" font="default">Atopic dermatitis: addressing allergy, infection, itch and complementary therapies</style></title><secondary-title><style face="normal" font="default">Semin Cutan Med Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Semin Cutan Med Surg</style></abbr-1></periodical><pages end="117" start="112">112-117</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a complex condition that results from the dynamic interplay between genetic predisposition, skin barrier defects, environmental factors, and a dysfunctional immune system. As a result, AD can be complicated by irritant and allergic contact dermatitis and imbalances in the skin microbiome, which can subsequently exacerbate the severity and complicate the course of preexisting atopic disease. Itch is an important symptom of AD, as it plays a large role in the quality of life of patients and their families. Since AD is a chronic, inflammatory disease that recrudesces throughout life, many have utilized alternative and/or complementary therapies, as monotherapy or in conjunction with conventional therapies, as a form of management</style></abstract><notes><style face="normal" font="default">DA - 20170912IS - 1085-5629 (Print)IS - 1085-5629 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.12788/j.sder.2017.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28895957">PM:28895957</url></web-urls></urls><custom2><style face="normal" font="default">20170912, Ahluwalia J</style></custom2><misc3><style face="normal" font="default">10.12788/j.sder.2017.038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42792</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Davis,D.M.</style></author><author><style face="normal" font="default"> Borok,J.</style></author><author><style face="normal" font="default"> Udkoff,J.</style></author><author><style face="normal" font="default"> Lio,P.</style></author><author><style face="normal" font="default"> Spergel,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Pediatrics, Mayo Clinic Rochester, Minnesota, USA.</style></auth-address><titles><title><style face="normal" font="default">Atopic dermatitis: phototherapy and systemic therapy</style></title><secondary-title><style face="normal" font="default">Semin Cutan Med Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Semin Cutan Med Surg</style></abbr-1></periodical><pages end="123" start="118">118-123</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">The majority of atopic dermatitis (AD) patients respond satisfactorily to gentle bathing, frequent moisturizing, and topical medications. Second-line therapies for AD should be used in recalcitrant cases or in patients with uncontrolled disease despite compliance with first-line measures and avoidance of allergens. Recommended advanced therapies include phototherapy, especially narrowband ultraviolet B, systemic immunosuppressants, and a new biologic agent. Few studies have compared head-to-head efficacy of the different immunosuppressant therapies such as cyclosporine, methotrexate, azathioprine and mycophenolate mofetil. Therefore, the agent used is based on provider and patient preferences and can be decided on a case-by-case basis</style></abstract><notes><style face="normal" font="default">DA - 20170912IS - 1085-5629 (Print)IS - 1085-5629 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.12788/j.sder.2017.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28895958">PM:28895958</url></web-urls></urls><custom2><style face="normal" font="default">20170912, Davis DM</style></custom2><misc3><style face="normal" font="default">10.12788/j.sder.2017.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42793</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guttman-Yassky,E.</style></author><author><style face="normal" font="default"> Waldman,A.</style></author><author><style face="normal" font="default"> Ahluwalia,J.</style></author><author><style face="normal" font="default"> Ong,P.Y.</style></author><author><style face="normal" font="default"> Eichenfield,L.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, New York, USA.</style></auth-address><titles><title><style face="normal" font="default">Atopic dermatitis: pathogenesis</style></title><secondary-title><style face="normal" font="default">Semin Cutan Med Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Semin Cutan Med Surg</style></abbr-1></periodical><pages end="103" start="100">100-103</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Atopic Dermatitis (AD) is a complex inflammatory cutaneous disorder characterized by immune mediated inflammation and epidermal barrier dysfunction. Arising from a complex interplay between environmental and genetic factors, the definitive etiology of AD is perplexing and controversial. Advances in molecular medicine are radically transforming our understanding of AD pathogenesis. Increasing knowledge on the pathogenesis of AD results in novel therapeutic targets and pathways. This article details the pathogenesis section of the Curriculum United for Better Eczema Care (CUBE-C), facilitating primary care and sub-specialist education on the scientific advances driving recent AD therapeutic innovations</style></abstract><notes><style face="normal" font="default">DA - 20170912IS - 1085-5629 (Print)IS - 1085-5629 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.12788/j.sder.2017.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28895955">PM:28895955</url></web-urls></urls><custom2><style face="normal" font="default">20170912, Guttman-Yassky E</style></custom2><misc3><style face="normal" font="default">10.12788/j.sder.2017.036</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42794</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fleischer,D.M.</style></author><author><style face="normal" font="default"> Udkoff,J.</style></author><author><style face="normal" font="default"> Borok,J.</style></author><author><style face="normal" font="default"> Friedman,A.</style></author><author><style face="normal" font="default"> Nicol,N.</style></author><author><style face="normal" font="default"> Bienstock,J.</style></author><author><style face="normal" font="default"> Lio,P.</style></author><author><style face="normal" font="default"> Tollefson,M.M.</style></author><author><style face="normal" font="default"> Eichenfield,L.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Children's Hospital Colorado, University of Colorado Denver School of Medicine, Aurora, Colorado, USA.</style></auth-address><titles><title><style face="normal" font="default">Atopic dermatitis: skin care and topical therapies</style></title><secondary-title><style face="normal" font="default">Semin Cutan Med Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Semin Cutan Med Surg</style></abbr-1></periodical><pages end="110" start="104">104-110</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) pathogenesis is strongly influenced by Type 2 innate lymphoid cell and T-helper cell type 2 lymphocyte-driven inflammation and skin barrier dysfunction. AD therapies attempt to correct this pathology, and guidelines suggest suggest basics of AD therapy, which include repair of the skin barrier through bathing practices and moisturizers, infection control, and further lifestyle modifications to avoid and reduce AD triggers.While some patients' AD may be controlled using these measures, inflammatory eczema including acute flares and maintenance therapy in more severe patients are treated with topical pharmacologic agents such as topical corticosteroids, topical calcineurin inhibitors, and, more recently, topical PDE-4 inhibitors. This model of basic skin therapy and, as needed, topical pharmacologic agents may be used to treat the vast majority of patients with AD and remains the staple of AD therapy</style></abstract><notes><style face="normal" font="default">DA - 20170912IS - 1085-5629 (Print)IS - 1085-5629 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.12788/j.sder.2017.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28895956">PM:28895956</url></web-urls></urls><custom2><style face="normal" font="default">20170912, Fleischer DM</style></custom2><misc3><style face="normal" font="default">10.12788/j.sder.2017.035</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42795</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Simpson,E.</style></author><author><style face="normal" font="default"> Udkoff,J.</style></author><author><style face="normal" font="default"> Borok,J.</style></author><author><style face="normal" font="default"> Tom,W.</style></author><author><style face="normal" font="default"> Beck,L.</style></author><author><style face="normal" font="default"> Eichenfield,L.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Oregon Health &amp; Science University, Portland, Oregon, USA.</style></auth-address><titles><title><style face="normal" font="default">Atopic dermatitis: emerging therapies</style></title><secondary-title><style face="normal" font="default">Semin Cutan Med Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Semin Cutan Med Surg</style></abbr-1></periodical><pages end="130" start="124">124-130</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Crisaborole and dupilumab represent the first 2 Food and Drug Administration (FDA)-approved therapies for atopic dermatitis (AD) in more than 15 years, and there are many promising drugs currently in development. This new wave of therapeutics capitalizes on the large body of work clarifying the pathogenesis of AD over the last several decades. In particular, type 2 cytokine-driven inflammation and skin barrier dysfunction are key processes underlying AD pathogenesis</style></abstract><notes><style face="normal" font="default">DA - 20170912IS - 1085-5629 (Print)IS - 1085-5629 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.12788/j.sder.2017.0137</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28895959">PM:28895959</url></web-urls></urls><custom2><style face="normal" font="default">20170912, Simpson E</style></custom2><misc3><style face="normal" font="default">10.12788/j.sder.2017.0137</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42796</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">LeBovidge,J.</style></author><author><style face="normal" font="default"> Borok,J.</style></author><author><style face="normal" font="default"> Udkoff,J.</style></author><author><style face="normal" font="default"> Yosipovitch,G.</style></author><author><style face="normal" font="default"> Eichenfield,L.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">1Allergy Program, Division of Immunology, Boston Children's Hospital, Boston, Massachusetts, USA.</style></auth-address><titles><title><style face="normal" font="default">Atopic dermatitis: therapeutic care delivery: therapeutic education, shared decision-making, and access to care</style></title><secondary-title><style face="normal" font="default">Semin Cutan Med Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Semin Cutan Med Surg</style></abbr-1></periodical><pages end="136" start="131">131-136</pages><volume><style face="normal" font="default">36</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a chronic skin condition affecting children and adults, with a significant negative impact on patient and caregiver quality of life (QOL). Although effective treatments for AD are available, outcomes are often limited by poor adherence to treatment plans. Effective patient and caregiver education about the disease and its management is a necessary and important component of AD care. Therapeutic patient education (TPE) is a patient-centered process that aims to transfer information and skills necessary to manage and cope with a disease from health care professionals to patients and caregivers. Shared decision making between the health care provider and the patient/caregiver is an integral component of the TPE process and recognizes the importance of both the medical provider's clinical expertise, as well as the patient/caregiver's preferences and experiences regarding their own medical condition and its treatment. TPE programs for patients with AD and their caregivers are typically provided by multidisciplinary teams and utilize a number of different methods and tools to facilitate the transfer of knowledge and skills through both individual care and group-based educational sessions. TPE has been demonstrated to improve outcomes such as AD disease severity, treatment adherence, QOL, and coping with itch. It is important to consider strategies to reduce barriers to cost-effective accessible AD education and treatment</style></abstract><notes><style face="normal" font="default">DA - 20170912IS - 1085-5629 (Print)IS - 1085-5629 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.12788/j.sder.2017.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28895960">PM:28895960</url></web-urls></urls><custom2><style face="normal" font="default">20170912, LeBovidge J</style></custom2><misc3><style face="normal" font="default">10.12788/j.sder.2017.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42797</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hughes,O.B.</style></author><author><style face="normal" font="default"> Maderal,A.D.</style></author><author><style face="normal" font="default"> Tosti,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA</style></auth-address><titles><title><style face="normal" font="default">An Unusual Case of Contact Dermatitis</style></title><secondary-title><style face="normal" font="default">Skin Appendage Disord</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Skin Appendage Disord</style></full-title></periodical><pages end="165" start="163">163-165</pages><volume><style face="normal" font="default">3</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="8" Year="2017">2017/8</year></dates><abstract><style face="normal" font="default">We report a case of acute psoriasiform contact dermatitis of the forehead and scalp related to the use of a low-laser light cap. The patient had a positive patch test to dimethylol dihydroxyethyleneurea (DMDE), methylisothiazolinone, kathon CG, and cobalt. We believe that DMDE in the fabric of the cap was responsible for the allergic contact dermatitis in this case as the lesions resolved with cessation of cap use</style></abstract><notes><style face="normal" font="default">DA - 20170907IS - 2296-9195 (Print)IS - 2296-9160 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1159/000466703</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28879194">PM:28879194</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Skin Appendage Disord\2017-3-163-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Skin Appendage Disord\2017-3-163-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170907, Hughes OB</style></custom2><misc3><style face="normal" font="default">10.1159/000466703</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42798</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bock,S.</style></author><author><style face="normal" font="default"> Said,A.</style></author><author><style face="normal" font="default"> Muller,G.</style></author><author><style face="normal" font="default"> Schafer-Korting,M.</style></author><author><style face="normal" font="default"> Zoschke,C.</style></author><author><style face="normal" font="default"> Weindl,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Pharmacy (Pharmacology and Toxicology), Freie Universitat Berlin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="default">Characterization of reconstructed human skin containing Langerhans cells to monitor molecular events in skin sensitization</style></title><secondary-title><style face="normal" font="default">Toxicol In Vitro</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Toxicol In Vitro</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="default">Human cell-based approaches to assess defined key events in allergic contact dermatitis (ACD) are well-established, but lack cutaneous penetration and biotransformation as well as cellular cross-talk. Herein, we integrated in vitro-generated immature MUTZ-3-derived Langerhans-like cells (MUTZ-LCs) or monocyte-derived LC-like cells (MoLCs) into reconstructed human skin (RHS), consistent of a stratified epidermis formed by primary keratinocytes on a dermal compartment with collagen-embedded primary fibroblasts. LC-like cells were mainly localized in the epidermal compartment and distributed homogenously in accordance with native human skin. Topical application of the strong contact sensitizer 2,4-dinitrochlorobenzene (DNCB) induced IL-6 and IL-8 secretion in RHS with LC-like cells, whereas no change was observed in reference models. Increased gene expression of CD83, PD-L1, and CXCR4 in the dermal compartment indicated LC maturation. Importantly, exposure to DNCB enhanced mobility of the LC-like cells from epidermal to dermal compartments. In response to the moderate sensitizer isoeugenol and irritant sodium dodecyl sulphate, the obtained response was less pronounced. In summary, we integrated immature and functional MUTZ-LCs and MoLCs into RHS and provide a unique comparative experimental setting to monitor early events during skin sensitization</style></abstract><notes><style face="normal" font="default">DA - 20170924IS - 1879-3177 (Electronic)IS - 0887-2333 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.tiv.2017.09.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28941582">PM:28941582</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicol In Vitro\20170924-BockS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicol In Vitro\20170924-BockS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170924, Bock S</style></custom2><misc3><style face="normal" font="default">10.1016/j.tiv.2017.09.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42799</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wareing,B.</style></author><author><style face="normal" font="default"> Urbisch,D.</style></author><author><style face="normal" font="default"> Kolle,S.N.</style></author><author><style face="normal" font="default"> Honarvar,N.</style></author><author><style face="normal" font="default"> Sauer,U.G.</style></author><author><style face="normal" font="default"> Mehling,A.</style></author><author><style face="normal" font="default"> Landsiedel,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">BASF SE, Experimental Toxicology and Ecology, Ludwigshafen, Germany</style></auth-address><titles><title><style face="normal" font="default">Prediction of skin sensitization potency sub-categories using peptide reactivity data</style></title><secondary-title><style face="normal" font="default">Toxicol In Vitro</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Toxicol In Vitro</style></full-title></periodical><pages end="145" start="134">134-145</pages><volume><style face="normal" font="default">45</style></volume><number><style face="normal" font="default">Pt 1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="9" Year="2017">2017/9/4</year></dates><abstract><style face="normal" font="default">While the skin sensitization hazard of substances can already be identified using non-animal methods, the classification of potency sub-categories GHS-1A and 1B is still challenging. Potency can be measured by the dose at which an effect is observed; since the protein-adduct formation is determining the dose of the allergen in the skin, peptide reactivity was used to assess the potency. The Direct Peptide Reactivity Assay (DPRA; one concentration and reaction-time) did not sufficiently discriminate between sub-categories 1A and 1B (56% accuracy compared to LLNA data, n=124). An extended protocol termed 'quantitative DPRA' (three concentrations and one reaction-time), discriminated sub-categories GHS 1A and 1B with an accuracy of 81% or 57% compared to LLNA (n=36) or human (n=14) data, respectively. The analysis of the Cys-adducts was already sufficient; additional analysis of Lys-adducts did not improve the predictivity. An additional modification, the 'kinetic DPRA' (several concentrations and reaction-times) was used to approximate the rate constant of Cys-peptide-adduct formation. 35 of 38 substances were correctly assigned to the potency sub-categories (LLNA data), and the predictivity for 14 human data was equally high. These results warrant the kinetic DPRA for further validation in order to fully replace in vivo testing for assessing skin sensitization including potency sub-classification</style></abstract><notes><style face="normal" font="default">DA - 20170908IS - 1879-3177 (Electronic)IS - 0887-2333 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.tiv.2017.08.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28882705">PM:28882705</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicol In Vitro\2017-45-134-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicol In Vitro\2017-45-134-45.pdf</url></text-urls><related-urls><url ppv-ref="no">xlsx in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20170908, Wareing B</style></custom2><misc3><style face="normal" font="default">10.1016/j.tiv.2017.08.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42800</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ogi,K.</style></author><author><style face="normal" font="default"> Takabayashi,T.</style></author><author><style face="normal" font="default"> Yamada,T.</style></author><author><style face="normal" font="default"> Sakashita,M.</style></author><author><style face="normal" font="default"> Kanno,M.</style></author><author><style face="normal" font="default"> Narita,N.</style></author><author><style face="normal" font="default"> Fujieda,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Otorhinolaryngology Head and Neck Surgery, Department of Sensory and Locomotor Medicine, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan</style></auth-address><titles><title><style face="normal" font="default">Trimellitic anhydride induces low-grade mast cell degranulation without specific IgE</style></title><secondary-title><style face="normal" font="default">Toxicol Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Toxicol Rep</style></abbr-1></periodical><pages end="707" start="701">701-707</pages><volume><style face="normal" font="default">3</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2016">2016</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Low-molecular-weight (LMW) substances are known to be causative agents of occupational asthma (OA) and occupational rhinitis (OR). Although most LMW substances are irritants or allergens, some can cause immediate type immunoglobulin E (IgE)-mediated allergic reactions. Trimellitic anhydride (TMA) is one such LMW substance, which is known as an immunological sensitizer. However, the exact molecular biological details of the effects of TMA remain unclear. METHODS: We measured the beta-hexosaminidase release from mast cells after directly exposing the cells to various LMW substances. The tyrosine phosphorylation of whole cellular molecules and the phosphorylation of extracellular signal-regulated kinase (ERK) were assessed by immunoblot assay. RESULTS: Among the LMW substances tested, only TMA induced beta-hexosaminidase release. However, the mast cell degranulation induced by TMA was lower than that induced by an antigen or a calcium ionophore. Moreover, the pattern of tyrosine phosphorylation of whole cellular molecules was quite different between IgE-mediated antigen stimulation and TMA exposure. The TMA effect on mast cells was independent of not only IgE but also Ca2+ influx. ERK phosphorylation was not detected in mast cells exposed to TMA. CONCLUSIONS: TMA induced mild degranulation of mast cells without IgE, even though the phosphorylation of ERK was not detected. This reaction suggests that TMA affects humans even upon first exposure. Therefore, it is imperative to avoid human exposure to high concentrations of TMA. In order to stop the development of severe asthma in individuals with OR, we need to be able to identify cases of OR caused by TMA as soon as possible</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 2214-7500 (Print)IS - 2214-7500 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.toxrep.2016.09.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28959595">PM:28959595</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicol Rep\2016-3-701-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicol Rep\2016-3-701-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Ogi K</style></custom2><misc3><style face="normal" font="default">10.1016/j.toxrep.2016.09.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42801</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Richard,E.J.</style></author><author><style face="normal" font="default"> Murugan,S.</style></author><author><style face="normal" font="default"> Bethapudi,B.</style></author><author><style face="normal" font="default"> Illuri,R.</style></author><author><style face="normal" font="default"> Mundkinajeddu,D.</style></author><author><style face="normal" font="default"> Chinampudur,V.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biology, R&amp;D Centre, Natural Remedies Private Limited, Bangalore, 560 100, Karnataka, India</style></auth-address><titles><title><style face="normal" font="default">Is Andrographis paniculata extract and andrographolide anaphylactic?</style></title><secondary-title><style face="normal" font="default">Toxicol Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Toxicol Rep</style></abbr-1></periodical><pages end="437" start="431">431-437</pages><volume><style face="normal" font="default">4</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Andrographis paniculata, "King of bitters" is a popularly known medicinal plant extensively used in many parts of the world for treatment of various diseases. Since recent past, anaphylactic/allergic type adverse events were reported upon A. paniculata usage, the study aimed to evaluate the anaphylactic and anaphylactoid potential of A. paniculata extract and andrographolide (a major phytoactive of A. paniculata). The anaphylactic potential was evaluated using active systemic anaphylaxis (ASA) assay in guinea pigs. Further, the release of allergic mediators was measured in immunoglobulin E (IgE) sensitized and non-IgE sensitized Rat Basophilic Leukemia (RBL-2H3) cell lines in-vitro. A. paniculata extract or andrographolide sensitized guinea pigs following the challenge antigen administration orally and intravenously did not demonstrate any clinical signs of anaphylaxis. IgE sensitized and non- IgE sensitized RBL-2H3 cells treated with A. paniculata extract did not induce release of allergic mediators. Whereas IgE sensitized and non- IgE sensitized RBL-2H3 cells treated with andrographolide demonstrated mild to moderate release of allergic mediators. A. paniculata extract has no anaphylactic and anaphylactoid potential in in-vivo and in-vitro studies. Whereas, andrographolide effects on allergic mediators in in-vitro studies needs to be scrutinized if they are of biologically important</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 2214-7500 (Print)IS - 2214-7500 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.1016/j.toxrep.2017.07.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28959670">PM:28959670</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicol Rep\2016-3-431-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicol Rep\2016-3-431-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Richard EJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.toxrep.2017.07.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42802</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sadanshiv,M.</style></author><author><style face="normal" font="default"> George,A.A.</style></author><author><style face="normal" font="default"> Mishra,A.K.</style></author><author><style face="normal" font="default"> Kuriakose,C.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Christian Medical College and Hospital, Vellore, Tamil Nadu, India</style></auth-address><titles><title><style face="normal" font="default">Rifampicin-induced immune allergic reaction</style></title><secondary-title><style face="normal" font="default">Trop Doct</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Trop Doct</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170802IS - 1758-1133 (Electronic)IS - 0049-4755 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.1177/0049475517724689</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28764592">PM:28764592</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Trop Doct\20170802-SadanshivM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Trop Doct\20170802-SadanshivM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170802, Sadanshiv M</style></custom2><misc3><style face="normal" font="default">10.1177/0049475517724689</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42803</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rozas-Munoz,E.</style></author><author><style face="normal" font="default"> Game,D.</style></author><author><style face="normal" font="default"> Serra-Baldrich,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Servicio de Dermatologia, Hospital de la Sant Creu i Sant Pau, Barcelona, Espana.</style></auth-address><titles><title><style face="normal" font="default">Allergic Contact Dermatitis by Anatomical Regions: Diagnostic Clues</style></title><secondary-title><style face="normal" font="default">Actas Dermosifiliogr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Actas Dermosifiliogr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="10" Year="2017">2017/10/11</year></dates><abstract><style face="normal" font="default">Allergic contact dermatitis (ACD) is a common disease in daily clinical practice, and its prevalence has increased in recent years. It is characterized clinically by varying degrees of erythema, vesiculation, flaking, and lichenification, though these signs can also be present in other eczematous diseases. Patch testing is the main diagnostic tool to confirm ACD, but its accurate interpretation requires correct correlation with the medical history (details of exposure) and physical examination. We provide a practical and instructive description of the most common clinical patters of ACD depending on the area affected. Knowledge of these patterns will not only help the clinician reach the diagnosis but will suggest possible allergens and forms of contact</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 1578-2190 (Electronic)IS - 0001-7310 (Linking)LA - engLA - spaPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.ad.2017.05.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29031485">PM:29031485</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171016, Rozas-Munoz E</style></custom2><misc3><style face="normal" font="default">10.1016/j.ad.2017.05.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42804</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Weschenfelder,A.K.</style></author><author><style face="normal" font="default"> Klimek,L.</style></author><author><style face="normal" font="default"> Mulleneisen,N.</style></author><author><style face="normal" font="default"> Renz,H.</style></author><author><style face="normal" font="default"> Wehrmann,W.</style></author><author><style face="normal" font="default"> Werfel,T.</style></author><author><style face="normal" font="default"> Hamelmann,E.</style></author><author><style face="normal" font="default"> Wasem,J.</style></author><author><style face="normal" font="default"> Biermann,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute for Health Care Management and Research, University of Duisburg-Essen, Essen, Germany</style></auth-address><titles><title><style face="normal" font="default">Course of respiratory allergy by treatment strategy based on German routine data</style></title><secondary-title><style face="normal" font="default">Allergo J Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergo J Int</style></abbr-1></periodical><pages end="203" start="195">195-203</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">PURPOSE: Allergic respiratory diseases represent a global health problem. The two major treatment strategies are symptom treatment and specific immunotherapy (SIT). SIT is considered the only causal treatment option available with the ability to alter the course of the disease. This study aims to describe the course of disease and medication of respiratory allergy across treatment strategies and disease groups. METHODS: The analysis is based on routine data from a German statutory health insurance. The patient cohort is observed from 2007-2012. For each year based on assured outpatient diagnoses patients are assigned to a disease group: rhinitis, asthma or both diseases. Additionally, prescribed medication is considered. Treatment comparisons are based on matched pairs. RESULTS: The study population comprises 165,446 patients with respiratory allergy. In 2007 the most frequent disease group is rhinitis (70%), followed by asthma (16%) and both diseases (14%). During the observation period a second allergic respiratory diagnosis occurs only in about 12% of rhinitis patients and 28% of asthma patients. In about 50% of patients with both diseases one of the diagnoses is omitted. These patients are more likely to no longer report their asthma diagnosis when receiving immunotherapy compared to symptom treatment. Furthermore immunotherapy reduces the frequency of asthma medication use. CONCLUSIONS: Results of detailed analysis of diagnoses reflect the alternating nature of allergic diseases. Although limited by accuracy of documentation and the lack of clinical information, the comparison of treatment strategies shows some advantages of immunotherapy regarding course of disease and asthma medication use</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 2197-0378 (Print)IS - 2197-0378 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1007/s40629-017-0027-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29034146">PM:29034146</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergo J Int\2017-26-195-203.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergo J Int\2017-26-195-203.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171016, Weschenfelder AK</style></custom2><misc3><style face="normal" font="default">10.1007/s40629-017-0027-x</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42805</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ren,M.Q.</style></author><author><style face="normal" font="default"> Zhou,Y.T.</style></author><author><style face="normal" font="default"> Chen,H.X.</style></author><author><style face="normal" font="default"> Li,T.Y.</style></author><author><style face="normal" font="default"> Vajandar,S.K.</style></author><author><style face="normal" font="default"> Osipowicz,T.</style></author><author><style face="normal" font="default"> Watt,F.</style></author><author><style face="normal" font="default"> Li,C.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Ion Beam Applications, Department of Physics, National University of Singapore, Singapore</style></auth-address><titles><title><style face="normal" font="default">Quantitative analysis of multiple elements in healthy and remodeled epithelium from human upper airway mucosa by using nuclear microscopy</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="10" Year="2017">2017/10/11</year></dates><abstract><style face="normal" font="default">Elements are vital in airway mucosal physiology and pathology; but their distribution and levels in the mucosa remain unclear. The present study uses the state-of-the-art nuclear microscopy facility to map and quantify multiple elements in the histology sections of nasal mucosa from patients with nasal polyps or inverted papilloma. Our results demonstrate that P and Ca are the most abundant elements in mucosa and their distinct difference between epithelial and sub-epithelial regions; more importantly, our results reveal decreased amounts of Cu and Zn in the remodelled epithelium as compared to the normal epithelium. These findings suggest that Cu and Zn may be beneficial targets to regulate aberrant epithelial remodeling in airway inflammation. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171012IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Singapore -CO - China -</style></notes><work-type><style face="normal" font="default">10.1111/all.13329</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29023780">PM:29023780</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171012-RenMQ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171012-RenMQ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171012, Ren MQ</style></custom2><misc3><style face="normal" font="default">10.1111/all.13329</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42806</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ferreira,D.S.</style></author><author><style face="normal" font="default"> Carvalho-Pinto,R.M.</style></author><author><style face="normal" font="default"> Gregorio,M.G.</style></author><author><style face="normal" font="default"> Annoni,R.</style></author><author><style face="normal" font="default"> Teles,A.M.</style></author><author><style face="normal" font="default"> Buttignol,M.</style></author><author><style face="normal" font="default"> Araujo-Paulino,B.B.</style></author><author><style face="normal" font="default"> Katayama,E.H.</style></author><author><style face="normal" font="default"> Oliveira,B.L.</style></author><author><style face="normal" font="default"> Del Frari,H.S.</style></author><author><style face="normal" font="default"> Cukier,A.</style></author><author><style face="normal" font="default"> Dolhnikoff,M.</style></author><author><style face="normal" font="default"> Stelmach,R.</style></author><author><style face="normal" font="default"> Rabe,K.F.</style></author><author><style face="normal" font="default"> Mauad,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pathology, University of Sao Paulo Medical School</style></auth-address><titles><title><style face="normal" font="default">Airway pathology in severe asthma is related to airflow obstruction but not symptom control</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patients with asthma present structural and inflammatory alterations that are believed to play a role in disease severity. However, airway remodeling and inflammation have not been extensively investigated in relation to both symptom control and airflow obstruction in severe asthmatics. We aimed to investigate several inflammatory and structural pathological features in bronchial biopsies of severe asthmatics that could be related to symptom control and airflow obstruction after standardized treatment. METHODS: 50 severe asthmatics received prednisone 40 mg/day for 2 weeks and maintenance therapy with budesonide/formoterol 400/12 mug twice daily + budesonide/formoterol 200/6 mug as needed for 12 weeks. Endobronchial biopsies were performed at the end of 12 weeks. We performed extensive immunopathological analyses of airway tissue inflammation and remodeling features in patients stratified by asthma symptom control and by airflow obstruction. RESULTS: Airway tissue inflammation and remodeling were not associated with symptom control. Asthmatics with persistent airflow obstruction had greater airway smooth muscle (Asm) area with decreased periostin and transforming growth factor beta positive cells within Asm bundles, in addition to lower numbers of chymase positive mast cells in the submucosa compared to patients with non-persistent obstruction. CONCLUSIONS: Symptom control in severe asthmatics was not associated with airway tissue inflammation and remodeling, although persistent airflow obstruction in these patients was associated with bronchial inflammation and airway structural changes. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/all.13323</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28960335">PM:28960335</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20170929-FerreiraDS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20170929-FerreiraDS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Ferreira DS</style></custom2><misc3><style face="normal" font="default">10.1111/all.13323</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42807</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schmitt,J.</style></author><author><style face="normal" font="default"> Buske-Kirschbaum,A.</style></author><author><style face="normal" font="default"> Tesch,F.</style></author><author><style face="normal" font="default"> Trikojat,K.</style></author><author><style face="normal" font="default"> Stephan,V.</style></author><author><style face="normal" font="default"> Abraham,S.</style></author><author><style face="normal" font="default"> Bauer,A.</style></author><author><style face="normal" font="default"> Nemat,K.</style></author><author><style face="normal" font="default"> Plessow,F.</style></author><author><style face="normal" font="default"> Roessner,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Evidence-based Healthcare, Medizinische Fakultat Carl Gustav Carus, TU, Dresden, Germany</style></auth-address><titles><title><style face="normal" font="default">Increased attention-deficit/hyperactivity symptoms in atopic dermatitis are associated with history of antihistamine use</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="10" Year="2017">2017/10/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Epidemiologic evidence indicates a relevant association between atopic dermatitis (AD) and attention-deficit/hyperactivity disorder (ADHD). Underlying mechanisms and ways to best identify subgroups of AD patients at risk for ADHD are poorly understood. AIMS OF THE STUDY: To compare sociodemographic, clinical, and psychosocial characteristics of children with AD, ADHD, comorbid AD/ADHD, and age-matched healthy controls. To investigate aspects of AD related to ADHD symptoms. METHODS: Applying a factorial design we investigated 4 groups of children age 6 to 12 years: AD-only (i.e. without ADHD), ADHD-only (i.e. without AD), AD+ADHD, healthy controls (HC; i.e. no AD/no ADHD). Using validated instruments, ADHD symptoms and other behavioural problems, quality of life, parenting stress, and sleeping problems were compared between groups. In children with AD-only, clinical signs (objective SCORAD), symptoms (POEM, VAS pruritus, VAS sleeping problems), and previous treatment of AD were assessed to investigate disease patterns related to ADHD symptoms. RESULTS: Compared to HC (n=47), children with AD-only (n=42), ADHD-only (n=34) and comorbid AD+ADHD (n=31) had significantly increased behavioural problems and decreased quality of life. Children with AD-only had significantly higher levels of ADHD symptoms than HC. In children with AD-only, previous use of antihistamines was significantly associated with increased ADHD symptoms (OR 1.88; 95%-CI 1.04-3.39). Current clinical signs and AD-symptoms were unrelated to the level of ADHD symptoms. CONCLUSIONS: Even if the clinical diagnosis of ADHD is excluded, children with AD show increased levels of ADHD symptoms. Further investigations need to determine whether early antihistamine exposure is a major risk factor for ADHD or a surrogate for previous AD severity and/or associated sleeping problems. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171004IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.13326</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28975640">PM:28975640</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171004-SchmittJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171004-SchmittJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171004, Schmitt J</style></custom2><misc3><style face="normal" font="default">10.1111/all.13326</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42808</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Veszeli,N.</style></author><author><style face="normal" font="default"> Kohalmi,K.V.</style></author><author><style face="normal" font="default"> Kajdacsi,E.</style></author><author><style face="normal" font="default"> Gulyas,D.</style></author><author><style face="normal" font="default"> Temesszentandrasi,G.</style></author><author><style face="normal" font="default"> Cervenak,L.</style></author><author><style face="normal" font="default"> Farkas,H.</style></author><author><style face="normal" font="default"> Varga,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Laboratory, 3rd Department of Internal Medicine, Semmelweis University, Hungary</style></auth-address><titles><title><style face="normal" font="default">Complete kinetic follow-up of symptoms and complement parameters during a hereditary angioedema attack</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="10" Year="2017">2017/10/7</year></dates><abstract><style face="normal" font="default">We studied the kinetics of C1-inhibitor (C1-INH) and other complement parameters in a self-limited edematous attack (EA) in a patient with hereditary angioedema due to C1-INH deficiency to better understand the pathomechanism of the evolution, course, and complete resolution of EAs. C1-INH concentration and functional activity (C1-INHc+f ), C1(q,r,s), C3, C4, C3a, C4a, C5a and SC5b-9 levels were measured in blood samples obtained during the 96-hour observation period. The highest C1-INHc+f , C4, and C1(q,r,s) levels were measured at baseline, and their continuous decrease was observed during the entire observation period. C4 depletion started at prodromal phase and C4 was lowest after the maximum severity peak. Compared to baseline, C4a level was four times higher 7 hours before the onset of the attack. C1-INH did not increase after resolution of the attack suggesting that factors other than C1-INH may be important in this process. C4a may be a useful biomarker for the prediction of EAs. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171007IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Hungary -</style></notes><work-type><style face="normal" font="default">10.1111/all.13327</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28986975">PM:28986975</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171007-VeszeliN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171007-VeszeliN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171007, Veszeli N</style></custom2><misc3><style face="normal" font="default">10.1111/all.13327</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42809</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hennen,J.</style></author><author><style face="normal" font="default"> Blomeke,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Environmental Toxicology, University Trier, Trier, GermanyDepartment of Environmental Toxicology, University Trier, Trier, Germany</style></auth-address><titles><title><style face="normal" font="default">Keratinocytes improve prediction of sensitization potential and potency of chemicals with THP-1 cells</style></title><secondary-title><style face="normal" font="default">ALTEX</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">ALTEX</style></full-title></periodical><pages end="288" start="279">279-288</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergens</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> Animal Testing Alternatives</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Antigens,CD86</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Cell Culture Techniques</style></keyword><keyword><style face="normal" font="default"> Cell Line</style></keyword><keyword><style face="normal" font="default"> Coculture Techniques</style></keyword><keyword><style face="normal" font="default"> Dendritic Cells</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Keratinocytes</style></keyword><keyword><style face="normal" font="default"> Skin Irritancy Tests</style></keyword><keyword><style face="normal" font="default"> Up-Regulation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">In vitro approaches to address key steps of chemical-induced skin sensitization have been developed, but there is uncertainty how keratinocytes, which play a crucial role not only regarding xenobiotic metabolism but also skin inflammation, impact on a chemical's potential and potency to activate dendritic cells. We investigated these aspects by coculturing THP-1 cells, as surrogate dendritic cells, with HaCaT keratinocytes. We tested our HaCaT/THP-1 model with a set of 14 sensitizers, containing 7 prohaptens, and 10 non-sensitizers. Compared to exposing THP-1 alone, coculturing resulted in up to 3.1-fold enhanced maximal CD86 and/or CD54 upregulation on THP-1, and improved concentration-dependency. All 14 sensitizers were found positive for CD86 and/or CD54 upregulation based on mean fluorescence intensity (MFI) >/= 10 for CD86 and MFI >/= 50 for CD54. Only 1 of 10 non-sensitizers was false-positive. Remarkably, coculture with HaCaT keratinocytes improved the rank correlation of the estimated minimum chemical concentrations inducing a positive response in vitro with in vivo data on sensitization potency, especially for CD54 (Spearman: r = 0.739, p = 0.006; CD86: r = 0.571, p = 0.041). These promising data suggest that the coculture model has the potential to support the prediction of sensitization potency based on in vitro data</style></abstract><notes><style face="normal" font="default">DA - 20161021IS - 1868-596X (Print)IS - 1868-596X (Linking)LA - engPT - Journal ArticleRN - 0 (Allergens)RN - 0 (Antigens, CD86)SB - IMCO - Germany -</style></notes><work-type><style face="normal" font="default">10.14573/altex.1606171</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27768804">PM:27768804</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\ALTEX\2017-34-279-88.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\ALTEX\2017-34-279-88.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20161021, Hennen J</style></custom2><misc3><style face="normal" font="default">10.14573/altex.1606171</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42810</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chiu,K.Y.</style></author><author><style face="normal" font="default"> Li,J.G.</style></author><author><style face="normal" font="default"> Lin,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong, China</style></auth-address><titles><title><style face="normal" font="default">Calcium channel blockers for lung function improvement in asthma: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="10" Year="2017">2017/10/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: For decades, calcium channel blockers (CCBs) have been believed to play a role in asthma treatment. However, the clinical efficacy of CCBs for lung function improvement in patients with asthma has not been qualitatively evaluated. OBJECTIVE: To assess the effect of CCBs vs placebo on lung function test results in adults with asthma. METHODS: Various databases were systematically searched to identify all randomized clinical trials with adults with asthma. We aimed to assess the influence of CCBs on forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), peak expiratory flow rate (PEFR), and provocative concentration of bronchoconstrictive agents causing a 20% decrease in FEV1 (PC20) compared with a placebo. All effect estimates were pooled by the generic inverse variance method with random-effects meta-analysis. Subgroup analysis, sensitivity analysis, and heterogeneity investigation were performed. RESULTS: Thirty eligible articles with 301 patients were included in this meta-analysis. Our results revealed that in a standard exercise test CCBs could produce a mean maximal percentage decrease in FEV1 of 11.56% (95% confidence interval, 8.97%-14.16%; P &lt; .001) and an increase in postdose FEV1 by 80 mL (95% confidence interval, 0.02-0.15 mL; P = .01). However, there was no statistical significance for CCBs in postdose FVC, PEFR, or PC20 of histamine and methacholine. CONCLUSION: CCBs may be beneficial for lung function improvement in asthma, especially in exercise-induced asthma. However, there is a lack of evidence for CCBs protecting asthma patients from chemical irritation</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.08.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29032888">PM:29032888</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171016-ChiuKY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171016-ChiuKY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171016, Chiu KY</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.08.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42811</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Morales-Cabeza,C.</style></author><author><style face="normal" font="default"> Roa-Medellin,D.</style></author><author><style face="normal" font="default"> Torrado,I.</style></author><author><style face="normal" font="default"> De Barrio,M.</style></author><author><style face="normal" font="default"> Fernandez-Alvarez,C.</style></author><author><style face="normal" font="default"> Montes-Acenero,J.F.</style></author><author><style face="normal" font="default"> De La Riva,I.</style></author><author><style face="normal" font="default"> Prieto-Garcia,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Department, Hospital General Universitario Gregorio Maranon, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Immediate reactions to iodinated contrast media</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="10" Year="2017">2017/10/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Immediate hypersensitivity reactions (IHRs) to iodinated contrast media (ICMs) remain a common clinical concern. Positive skin test and basophil activation test results suggest a specific IgE-mediated mechanism in some cases. Skin test and controlled challenge test (CCT) are useful to manage these patients. OBJECTIVE: To study clinical and allergologic features of IHRs to ICMs in a Spanish tertiary hospital during a 7-year period. METHODS: Demographic and clinical data concerning the reaction were recorded. Patients treated at the Allergy Department of Hospital General Universitario Gregorio Maranon, Madrid, Spain, underwent skin tests. In those with positive results, CCTs with an alternative skin-test-negative ICM was performed. Global reaction rate was calculated and compared for each ICM. RESULTS: A total of 342 reactions occurred in 329 patients. Cutaneous symptoms were the most common (87.7%). A total of 196 patients underwent an allergy workup, 15 (7.6%) of whom had positive skin test results. Reactions were more severe in patients with positive vs negative skin test results (grade 1, 46.7% vs 73.6%; grade 2, 33.3% vs 20.9%; grade 3, 20% vs 5.46%; P &lt; .05). Three patients had cross-reactivity to 3 ICMs, all including ioversol and iomeprol. Six patients allergic to iopamidol tolerated ioversol and 1 tolerated iomeprol. Four patients allergic to ioversol and 1 allergic to iomeprol tolerated iopamidol. The global reaction rate was 0.2%, differing for each ICM (iopamidol, 0.14%; ioversol, 0.2%; and iomeprol, 0.4%; P &lt; .001). Positive skin test results were found in a low percentage of patients in whom skin test-based CCT identified an alternative non-cross-reactive ICM. Low-grade cross-reactivity was found, especially between iopamidol and ioversol. Reactions were more severe in patients with positive skin test results. The reaction rate was greater for iomeprol compared with iopamidol (reaction rate, 2.8%) and ioversol (reaction rate, 2%). CONCLUSIONS: This study identified a possible underlying specific IgE-mediated mechanism by positive skin test result in a low percentage of patients with IHRs to ICMs. In these patients, the CCT based on skin test results was useful for identifying an alternative non-cross-reactive ICM. More studies are needed to investigate the underlying mechanism in patients with IHRs and negative skin test results</style></abstract><notes><style face="normal" font="default">DA - 20171011IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.08.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29017901">PM:29017901</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171011-MoralesCabezaC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171011-MoralesCabezaC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171011, Morales-Cabeza C</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.08.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42812</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gibbons,K.R.</style></author><author><style face="normal" font="default"> Abraham,T.</style></author><author><style face="normal" font="default"> Sandhu,M.</style></author><author><style face="normal" font="default"> Peppers,B.P.</style></author><author><style face="normal" font="default"> Girzhel,J.F.</style></author><author><style face="normal" font="default"> Hostoffer,R.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">University Hospitals, Cleveland, Cleveland, Ohio.</style></auth-address><titles><title><style face="normal" font="default">Successful perinatal management of hereditary angioedema with normal C1 esterase inhibitor and factor XII mutation using C1 esterase inhibitor therapy</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="10" Year="2017">2017/10/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171011IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.08.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29017903">PM:29017903</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171011-GibbonsKR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171011-GibbonsKR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171011, Gibbons KR</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.08.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42813</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Demoulin,R.</style></author><author><style face="normal" font="default"> Poyet,R.</style></author><author><style face="normal" font="default"> Capilla,E.</style></author><author><style face="normal" font="default"> Cardinale,M.</style></author><author><style face="normal" font="default"> Tortat,A.V.</style></author><author><style face="normal" font="default"> Pons,F.</style></author><author><style face="normal" font="default"> Brocq,F.X.</style></author><author><style face="normal" font="default"> Jego,C.</style></author><author><style face="normal" font="default"> Foucault,G.</style></author><author><style face="normal" font="default"> Cellarier,G.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Service de cardiologie, hopital d'instruction des armees Sainte-Anne, BCRM, boulevard Sainte-Anne, BP 600, 83600 Toulon cedex 9, France.</style></auth-address><titles><title><style face="normal" font="default">[Inferior myocardial infarction complicated by complete heart block and cardiac arrest following a gadolinium injection: A case of Kounis syndrome]</style></title><secondary-title><style face="normal" font="default">Ann Cardiol Angeiol (Paris)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Cardiol Angeiol (Paris)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="default">Kounis syndrome is an allergic acute coronary syndrome. It occurs on healthy or pathological arteries. Its complications, although often benign, can lead to cardiac arrest and death. Its triggering factors are multiple and include contrast products used in diagnostic imaging. We report the case of an 81 years old patient affected by hepatocellular carcinoma, who presented a type 2 Kounis syndrome with inferior myocardial infarction, complicated by cardiac arrest related to complete heart block following a gadoteric acid injection</style></abstract><notes><style face="normal" font="default">DA - 20171020IS - 1768-3181 (Electronic)IS - 0003-3928 (Linking)LA - frePT - English AbstractPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.ancard.2017.09.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29050735">PM:29050735</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Cardiol Angeiol (Paris)\20171020-DemoulinR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Cardiol Angeiol (Paris)\20171020-DemoulinR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171020, Demoulin R</style></custom2><misc3><style face="normal" font="default">10.1016/j.ancard.2017.09.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42814</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Alharethy,S.</style></author><author><style face="normal" font="default"> Wedami,M.A.</style></author><author><style face="normal" font="default"> Syouri,F.</style></author><author><style face="normal" font="default"> Alqabbani,A.A.</style></author><author><style face="normal" font="default"> Baqays,A.</style></author><author><style face="normal" font="default"> Mesallam,T.</style></author><author><style face="normal" font="default"> Aldrees,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Correspondence: Dr. Turki Mohammed Aldrees Medical College, Prince Sattam bin Abdulaziz University, Alkharj, Saudi Arabia</style></auth-address><titles><title><style face="normal" font="default">Validation of the Arabic version of the score for allergic rhinitis tool</style></title><secondary-title><style face="normal" font="default">Ann Saudi Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Saudi Med</style></abbr-1></periodical><pages end="361" start="357">357-361</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic rhinitis (AR) is a common inflammation of the nasal mucosa in response to allergen exposure. We translated and validated the Score for Allergic Rhinitis (SFAR) into an Arabic version so that the disease can be studied in an Arabic population. OBJECTIVES: SFAR is a non-invasive self-administered tool that evaluates eight items related to AR. This study aimed to translate and culturally adapt the SFAR questionnaire into Arabic, and assess the validity, consistency, and reliability of the translated version in an Arabic-speaking population of patients with suspected AR. STUDY DESIGN: Cross-sectional. SETTING: Tertiary care hospital in Riyadh. PARTICIPANTS AND METHODS: The Arabic version of the SFAR was administered to patients with suspected AR and control participants. MAIN OUTCOME MEASURE: Comparison of the AR and control groups to determine the test-retest reliability and internal consistency of the instrument. RESULTS: The AR (n=173) and control (n=75) groups had significantly different Arabic SFAR scores (P &lt; .0001). The instrument provided satisfactory internal consistency (Cronbach's alpha value of 0.7). The test-retest reliability was excellent for the total Arabic SFAR score (r =0.836, P &lt; .0001). CONCLUSION: These findings demonstrate that the Arabic version of the SFAR is a valid tool that can be used to screen Arabic speakers with suspected AR. LIMITATIONS: The absence of objective allergy testing</style></abstract><notes><style face="normal" font="default">DA - 20171008IS - 0975-4466 (Electronic)IS - 0256-4947 (Linking)LA - engPT - Journal ArticleCO - Saudi Arabia -</style></notes><work-type><style face="normal" font="default">10.5144/0256-4947.2017.357</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28988249">PM:28988249</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Saudi Med\2017-37-357-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Saudi Med\2017-37-357-61.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171008, Alharethy S</style></custom2><misc3><style face="normal" font="default">10.5144/0256-4947.2017.357</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42815</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hu,J.</style></author><author><style face="normal" font="default"> Cantrell,P.</style></author><author><style face="normal" font="default"> Nand,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Chemical Analysis Branch, TestSafe, SafeWork NSW, AustraliaHygiene and Toxicology Unit, SafeWork NSW, AustraliaHygiene and Toxicology Unit, SafeWork NSW, Australia</style></auth-address><titles><title><style face="normal" font="default">Comprehensive Biological Monitoring to Assess Isocyanates and Solvents Exposure in the NSW Australia Motor Vehicle Repair Industry</style></title><secondary-title><style face="normal" font="default">Ann Work Expo Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Work Expo Health</style></abbr-1></periodical><pages end="1023" start="1015">1015-1023</pages><volume><style face="normal" font="default">61</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="10" Year="2017">2017/10/1</year></dates><abstract><style face="normal" font="default">Urethane products that contain isocyanates are extensively used in the motor vehicle repair (MVR) industry and other industries such as furniture and cabinet-making as two-pack spray paints, clears, and adhesives. Attention has recently been refocussed on isocyanate-containing chemicals, particularly in paints. The spray painters in the MVR industry had a propensity to develop industrial asthma at a rate 80 times higher than the general public, which was previously reported in the UK. To track workers exposure to isocyanates, urine samples were collected from 196 spray painters who worked mainly in 78 MVR shops across 54 New South Wales (NSW) towns and suburbs. The biological monitoring also covered exposure testing to a wide variety of solvents including aromatic hydrocarbons, ketones, and alcohols. The main finding of the study was that 2.6% of the spray painters surveyed in the MVR industry in NSW that handled isocyanate-containing paints showed exposure to isocyanates; with 1.0% being moderately exposed, which is more than twice the current UK's Health and Safety Executive (HSE) Biological Monitoring Guidance Value (BMGV) of 1 micromol mol-1 creatinine. Potential exposures to toluene (a solvent often found in paint thinners) was monitored via hippuric acid (HA) urine levels and showed 2.6% of the spray painters surveyed to be over the US' American Conference of Government Industrial Hygienists (ACGIH) Biological Exposure Index (BEI) of 1010 mmol/mole creatinine for HA. The other solvents or their metabolites were all below their respective BEI; these comprised benzene, xylene, ethyl benzene, methyl ethyl ketone, acetone, methanol, and ethanol. These findings indicate that isocyanates and certain solvents exposure were occurring in the NSW Australia vehicle repair industry, albeit at lower levels than previous occupational biological monitoring studies that showed higher exposure levels, particularly for isocyanates. One reason for this could be the increasing use of water-based paints in the industry, resulting in lower than expected isocyanate and solvent metabolite levels detected in this more recent study. Further, the completion of sample context form, along with spot urine collection in relation to the isocyanate exposure monitoring work details will provide crucial information to interpret the biological analysis results. The development of new biomarkers of isocyanate oligomer-derived triamines should be incorporated in the assessment of isocyanate exposure in the MVR industry to provide a more complete picture of isocyanate exposure</style></abstract><notes><style face="normal" font="default">DA - 20171013IS - 2398-7316 (Electronic)IS - 2398-7308 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1093/annweh/wxx064</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29028250">PM:29028250</url></web-urls></urls><custom2><style face="normal" font="default">20171013, Hu J</style></custom2><misc3><style face="normal" font="default">10.1093/annweh/wxx064</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42816</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yu,H.</style></author><author><style face="normal" font="default"> Li,H.</style></author><author><style face="normal" font="default"> Li,Y.</style></author><author><style face="normal" font="default"> Li,M.</style></author><author><style face="normal" font="default"> Chen,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Affiliated Qingdao Municipal Hospital of Qingdao University, No. 1 Jiaozhou Road, Qingdao, 266011, China</style></auth-address><titles><title><style face="normal" font="default">Effect of isoliquiritigenin for the treatment of atopic dermatitis-like skin lesions in mice</style></title><secondary-title><style face="normal" font="default">Arch Dermatol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arch Dermatol Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a common chronic inflammatory skin disease characterized with high heterogeneity. Recent studies have suggested that it is driven by both terminal keratinocyte differentiation defects and type 2 immune responses. The mainstay steroid topical therapy has severe side effect and new treatment is in demand. Isoliquiritigenin (ISLG) is a small phenolic bioactive molecule from licorice that has shown multiple pharmacological effects against cancer, inflammatory disorder, and cardiovascular diseases. ISLG was evaluated in AD-like lesion model induced by the repetitive application of 2,4-dinitrochlorobenzene (DNCB) in BALB/c mice. Overall symptom score, serological and molecular changes of the skin lesions were evaluated. ISLG could ameliorate the overall manifestation of AD-like symptoms including scratching behavior incidence and skin lesion severity. At blood level, ISLG significantly suppressed the DNCB-induced IgE and Th2 cytokines up-regulation. At skin lesion site, ISLG also inhibited DNCB-induced pro-inflammatory cytokines like TNF-alpha, IL-6 as well as IL-4 expressions. In a human monocyte model THP-1, ISLG suppressed the up-regulation of CD86 and CD54 and abolished the DNCB-induced p38-alpha and ERK activation, suggesting a molecular mechanism for ISLG therapy. This study indicated that ISLG could be a potential therapeutic agent for the treatment of AD</style></abstract><notes><style face="normal" font="default">DA - 20171013IS - 1432-069X (Electronic)IS - 0340-3696 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1007/s00403-017-1787-3.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29026975">PM:29026975</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Arch Dermatol Res\20171013-YuH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Arch Dermatol Res\20171013-YuH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171013, Yu H</style></custom2><misc3><style face="normal" font="default">10.1007/s00403-017-1787-3.</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42817</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sharma,S.</style></author><author><style face="normal" font="default"> Joske,D.</style></author><author><style face="normal" font="default"> Watson,D.</style></author><author><style face="normal" font="default"> Caccetta,T.</style></author><author><style face="normal" font="default"> Baltic,S.</style></author><author><style face="normal" font="default"> Kumarasinghe,S.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Fiona Stanley Hospital, Perth, Western Australia, Australia</style></auth-address><titles><title><style face="normal" font="default">Schnitzler syndrome: A rare cause of chronic recalcitrant urticaria successfully treated with Anakinra</style></title><secondary-title><style face="normal" font="default">Australas J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Australas J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171013IS - 1440-0960 (Electronic)IS - 0004-8380 (Linking)LA - engPT - LetterCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/ajd.12731</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29027204">PM:29027204</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Australas J Dermatol\20171013-SharmaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Australas J Dermatol\20171013-SharmaS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171013, Sharma S</style></custom2><misc3><style face="normal" font="default">10.1111/ajd.12731</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42818</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Low,J.S.Y.</style></author><author><style face="normal" font="default"> Soh,S.E.</style></author><author><style face="normal" font="default"> Lee,Y.K.</style></author><author><style face="normal" font="default"> Kwek,K.Y.C.</style></author><author><style face="normal" font="default"> Holbrook,J.D.</style></author><author><style face="normal" font="default"> van der Beek,E.M.</style></author><author><style face="normal" font="default"> Shek,L.P.</style></author><author><style face="normal" font="default"> Goh,A.E.N.</style></author><author><style face="normal" font="default"> Teoh,O.H.</style></author><author><style face="normal" font="default"> Godfrey,K.M.</style></author><author><style face="normal" font="default"> Chong,Y.S.</style></author><author><style face="normal" font="default"> Knol,J.</style></author><author><style face="normal" font="default"> Lay,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Nutricia Research, Danone Nutricia Early Life Nutrition, Matrix Building #05-01B, 30 Biopolis Street, 138671 Singapore, Singapore</style></auth-address><titles><title><style face="normal" font="default">Ratio of Klebsiella/Bifidobacterium in early life correlates with later development of paediatric allergy</style></title><secondary-title><style face="normal" font="default">Benef Microbes</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Benef Microbes</style></abbr-1></periodical><pages end="695" start="681">681-695</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="default">Several studies have reported that intestinal microbial colonisation patterns differ between non-allergic and allergic infants. However, the microbial signature underlying the pathogenesis of allergies remains unclear. We aim to gain insight into the development of the intestinal microbiota of healthy infants and infants who develop allergy in early life, and identify potential microbiota biomarkers of later allergic disease. Using a case-control design in a Chinese sub-cohort of a Singaporean birth cohort (GUSTO), we utilised 16S rRNA gene sequencing to assess intestinal microbial composition and diversity of 21 allergic and 18 healthy infants at 3 weeks, 3 months and 6 months of age, and correlated the microbiota with allergy at ages 18 and 36 months. Pronounced differences in intestinal microbiota composition between allergic and healthy infants were observed at 3 months of age. The intestine of healthy infants was colonised with higher abundance of commensal Bifidobacterium. Conversely, Klebsiella, an opportunistic pathogen, was significantly enriched in the allergic infants. Interestingly, infants with a high Klebsiella/Bifidobacterium (K/B) ratio (above the population median K/B ratio) at age 3 months had an odds ratio of developing allergy by 3 years of age of 9.00 (95% confidence interval 1.46-55.50) compared to those with low K/B ratio. This study demonstrated a relationship between the ratio of genera Klebsiella and Bifidobacterium during early infancy and development of paediatric allergy in childhood. Our study postulates that an elevated K/B ratio in early infancy could be a potential indicator of an increased risk of allergy development. This line of research might enable future intervention strategies in early life to prevent or treat allergy. Our study provides new insights into microbial signatures associated with childhood allergy, in particular, suggests that an elevated K/B ratio could be a potential early-life microbiota biomarker of allergic disease</style></abstract><notes><style face="normal" font="default">DA - 20171012IS - 1876-2891 (Electronic)IS - 1876-2883 (Linking)LA - engPT - Journal ArticleCO - Singapore -CO - United Kingdom -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.3920/BM2017.0020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29022383">PM:29022383</url></web-urls></urls><custom2><style face="normal" font="default">20171012, Low JS</style></custom2><misc3><style face="normal" font="default">10.3920/BM2017.0020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42819</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Prakoeswa,C.R.S.</style></author><author><style face="normal" font="default"> Herwanto,N.</style></author><author><style face="normal" font="default"> Prameswari,R.</style></author><author><style face="normal" font="default"> Astari,L.</style></author><author><style face="normal" font="default"> Sawitri,S.</style></author><author><style face="normal" font="default"> Hidayati,A.N.</style></author><author><style face="normal" font="default"> Indramaya,D.M.</style></author><author><style face="normal" font="default"> Kusumowidagdo,E.R.</style></author><author><style face="normal" font="default"> Surono,I.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Dermatology and Venereology Department, Faculty of Medicine, Universitas Airlangga, Dr Soetomo Teaching Hospital, Prof Dr. Moestopo No.47, 60131 Surabaya, East Java, Indonesia</style></auth-address><titles><title><style face="normal" font="default">Lactobacillus plantarum IS-10506 supplementation reduced SCORAD in children with atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Benef Microbes</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Benef Microbes</style></abbr-1></periodical><pages end="840" start="833">833-840</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="default">Lactobacillus plantarum IS-10506 is a novel probiotic isolated from dadih, an Indonesian traditional fermented buffalo milk. It's in vitro and in vivo probiotic properties have been assessed. Probiotic function has been shown in vivo by the suppression of allergic reactions in BALB/c mice through the action of T-regulatory cells cytokines by balancing Th1 and Th2 immune response. Atopic dermatitis (AD) is a chronic recurrent inflammatory skin disease characterised by the imbalance of Th1 and Th2. The aim of the study was to assess the probiotic function of L. plantarum IS-10506 in children with mild and moderate AD. A randomised double-blind placebo-controlled trial comparing microencapsulated L. plantarum IS-10506 (1010 cfu/day) and placebo (skim milk-Avicel) twice daily for 12 weeks was conducted in an outpatient clinic on children with mild and moderate AD. The trial included 22 AD children divided into intervention and control groups of n=12 and n=10 patients, respectively. Scoring Atopic Dermatitis Index (SCORAD) and serum immunoglobulin E (IgE), interleukin (IL)-4, interferon gamma (IFN-gamma), forkhead box P3 (Foxp3+)/IL-10, and IL-17 levels were assessed. Demographic and baseline characteristics were not significantly different between the two groups. SCORAD and levels of IL-4, IFN-gamma, and IL-17 were significantly lower in the probiotic group than those in the placebo group, while the IgE levels were not significantly changed. The ratio of Foxp3+ to IL-10 was significantly higher in the probiotic group than that in placebo group. Supplementation with the probiotic L. plantarum IS-10506 offered a potential treatment for children with AD. Further long-term studies with a larger sample size are required to confirm the therapeutic efficacy of L. plantarum IS-10506 in AD</style></abstract><notes><style face="normal" font="default">DA - 20171012IS - 1876-2891 (Electronic)IS - 1876-2883 (Linking)LA - engPT - Journal ArticleCO - Indonesia -</style></notes><work-type><style face="normal" font="default">10.3920/BM2017.0011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29022387">PM:29022387</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Benef Microbes\2017-8-833-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Benef Microbes\2017-8-833-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171012, Prakoeswa CR</style></custom2><misc3><style face="normal" font="default">10.3920/BM2017.0011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42820</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,R.</style></author><author><style face="normal" font="default"> Che,D.</style></author><author><style face="normal" font="default"> Zhao,T.</style></author><author><style face="normal" font="default"> Pundir,P.</style></author><author><style face="normal" font="default"> Cao,J.</style></author><author><style face="normal" font="default"> Lv,Y.</style></author><author><style face="normal" font="default"> Wang,J.</style></author><author><style face="normal" font="default"> Ma,P.</style></author><author><style face="normal" font="default"> Fu,J.</style></author><author><style face="normal" font="default"> Wang,N.</style></author><author><style face="normal" font="default"> Wang,X.</style></author><author><style face="normal" font="default"> Zhang,T.</style></author><author><style face="normal" font="default"> Dong,X.</style></author><author><style face="normal" font="default"> He,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Pharmacy, Xi'an Jiaotong University, Xi'an 710061, China</style></auth-address><titles><title><style face="normal" font="default">MRGPRX2 is Essential for Sinomenine HydrochlorideInduced Anaphylactoid Reactions</style></title><secondary-title><style face="normal" font="default">Biochem Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Biochem Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="10" Year="2017">2017/10/4</year></dates><abstract><style face="normal" font="default">Mast cells are unique immunocytes that function as sentinel cells in host defense reactions such as immediate hypersensitivity responses and anaphylactic responses. The mast cell specific receptor MRGPRX2 (Mas-related G protein-coupled receptor X2) triggers mast cell degranulation-a key process in anaphylactic reactions. We sought to better understand anaphylactic reaction induced by Sinomenine Hydrochloride (SH). MRGPRX2-related pseudo-allergic reactions induced by SH were investigated using the hindpaw swelling and extravasation assay in vivo and mast cell degranulation assays in vitro. Mice knockout MrgprB2 exhibit a reduced SH-induced inflammation effect. Furthermore, MRGPRX2 (the orthologous gene of MrgprB2) related human mast cells are activated by SH in a dose-dependent manner; however, mast cells knockdown MRGPRX2 showed reduced degranulation. The results showed a kind of mechanism that SH-induced anaphylactoid reactions were mediated by MRGPRX2 via activating PLC molecular signaling pathways to provoke mast cells Ca2+ mobilization and degranulation</style></abstract><notes><style face="normal" font="default">DA - 20171008IS - 1873-2968 (Electronic)IS - 0006-2952 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.bcp.2017.09.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28987593">PM:28987593</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biochem Pharmacol\20171008-LiuR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biochem Pharmacol\20171008-LiuR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171008, Liu R</style></custom2><misc3><style face="normal" font="default">10.1016/j.bcp.2017.09.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42821</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">von Kobyletzki,L.B.</style></author><author><style face="normal" font="default"> Beckman,L.</style></author><author><style face="normal" font="default"> Smeeth,L.</style></author><author><style face="normal" font="default"> McKee,M.</style></author><author><style face="normal" font="default"> Quint,J.K.</style></author><author><style face="normal" font="default"> Abuabara,K.</style></author><author><style face="normal" font="default"> Langan,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Lund University, Skane University Hospital, Malmo, Sweden</style></auth-address><titles><title><style face="normal" font="default">Association between childhood allergic diseases, educational attainment and occupational status in later life: systematic review protocol</style></title><secondary-title><style face="normal" font="default">BMJ Open</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Open</style></abbr-1></periodical><pages end="" start="e017245">e017245-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="10" Year="2017">2017/10/11</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Childhood allergic diseases may prevent affected children from achieving their academic potential. Potential mechanisms include absence from school due to illness and medical appointments. Experience of symptoms in classes or leisure time, and stigma associated with visible signs and symptoms, including skin disease, requirements for medication during school time or the need for specific diets, may also contribute to reduced educational attainment. Studies have investigated the association between specific allergic diseases and educational attainment. The aim of this study is to systematically review the literature on allergic diseases, educational attainment and occupational status, and if possible, calculate meta-analytic summary estimates for the associations. METHODS: Systematic electronic searches in Medline, EMBASE, Cochrane, Cumulative Index to Nursing &amp; Allied Health Literature (CINAHL), PsycINFO and education Resources Information Center (ERIC); hand search in reference lists of included papers and conference reports; search for unpublished studies in clinical trial registers and the New York Academy of Medicine Grey Literature Report; data extraction; and study quality assessment (Newcastle-Ottawa Scale) will be performed. ANALYSIS: Data will be summarised descriptively, and meta-analysis including meta-regression to explore sources of heterogeneities will be performed if possible. ETHICS AND DISSEMINATION: Dissemination in a peer-reviewed, open-access, international scientific journal is planned. PROSPERO REGISTRATION NUMBER: CRD42017058036</style></abstract><notes><style face="normal" font="default">DA - 20171013IS - 2044-6055 (Electronic)IS - 2044-6055 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1136/bmjopen-2017-017245</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29025838">PM:29025838</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Open\2017-7-e017245.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Open\2017-7-e017245.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171013, von Kobyletzki LB</style></custom2><misc3><style face="normal" font="default">10.1136/bmjopen-2017-017245</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42822</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fedorowicz,Z.</style></author><author><style face="normal" font="default"> Van Zuuren,E.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cochrane Bahrain, PO Box 25438, Awali, Bahrain.</style></auth-address><titles><title><style face="normal" font="default">Eczema symptoms scores: are we getting closer to HOME?</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="668" start="667">667-668</pages><volume><style face="normal" font="default">175</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Dermatitis,Atopic</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20160921IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticlePT - CommentSB - IMCO - Bahrain -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.14786</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27650737">PM:27650737</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\2016-175-667-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\2016-175-667-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160921, Fedorowicz Z</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.14786</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42823</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hamann,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">SmartPractice, 3400 E McDowell Road, Phoenix, AZ, 85008, U.S.A.</style></auth-address><titles><title><style face="normal" font="default">New Fragrance Mix I formulation in TRUE Test</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="824">824-</pages><volume><style face="normal" font="default">175</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergens</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Perfume</style></keyword></keywords><dates><year Day="0" Month="10" Year="2016">2016/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20160921IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - LetterPT - CommentRN - 0 (Allergens)RN - 0 (Perfume)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.14663</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27061714">PM:27061714</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\2016-175-824.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\2016-175-824.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160921, Hamann C</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.14663</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42824</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Decaesteker,T.</style></author><author><style face="normal" font="default"> Seys,S.</style></author><author><style face="normal" font="default"> Hox,V.</style></author><author><style face="normal" font="default"> Dilissen,E.</style></author><author><style face="normal" font="default"> Marijsse,G.</style></author><author><style face="normal" font="default"> Manhaeghe,L.</style></author><author><style face="normal" font="default"> Hellings,P.</style></author><author><style face="normal" font="default"> Vanoirbeek,J.</style></author><author><style face="normal" font="default"> Bullens,D.</style></author><author><style face="normal" font="default"> Dupont,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical and Experimental Medicine, Laboratory of Pneumology, KU Leuven, Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="default">Serum and sputum calprotectin, a reflection of neutrophilic airway inflammation in asthmatics after high altitude exposure</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="10" Year="2017">2017/10/9</year></dates><abstract><style face="normal" font="default">Until recently, asthma has been characterized as a T(h)2-disorder with eosinophilic airway inflammation. However, several studies showed the existence of patients with asthma characterized by neutrophilic airway inflammation.[1] Seys et al. showed an increased proportion of sputum neutrophils in asthmatic patients after exposure to environmental conditions at high altitude (HA) and in elite athletes after intensive exercise (swimming).[2,3] As patients with neutrophilic asthma poorly respond to classic therapies such as inhaled corticosteroids, it is crucial to identify these patients to predict their medication response and to provide them with an appropriate therapy.[4] This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171009IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28992401">PM:28992401</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20171009-DecaestekerT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20171009-DecaestekerT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171009, Decaesteker T</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13043</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42825</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chang,H.Y.</style></author><author><style face="normal" font="default"> Seo,J.H.</style></author><author><style face="normal" font="default"> Kwon,J.W.</style></author><author><style face="normal" font="default"> Suh,D.I.</style></author><author><style face="normal" font="default"> Cho,H.J.</style></author><author><style face="normal" font="default"> Yoon,J.</style></author><author><style face="normal" font="default"> Kim,E.J.</style></author><author><style face="normal" font="default"> Lee,J.S.</style></author><author><style face="normal" font="default"> Shin,Y.J.</style></author><author><style face="normal" font="default"> Hong,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Psychiatry and Behavioral Sciences, Ajou University School of Medicine, Suwon, Korea</style></auth-address><titles><title><style face="normal" font="default">Independent association among suicidal ideation, asthma, and bronchial hyperresponsiveness in adolescents</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="10" Year="2017">2017/10/6</year></dates><abstract><style face="normal" font="default">Asthma is a known risk factor for suicide-related behaviors in adolescents.1 In particular, an association between asthma and suicidal behaviors has been reported in US high school students2 and Taiwanese3 adolescents. However, most previous studies have used self-reported questionnaires to determine whether asthma was present2 , and others used hospital registries.3 Moreover, the role of potential confounders has not been fully investigated. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171006IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28985451">PM:28985451</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20171006-ChangHY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20171006-ChangHY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171006, Chang HY</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13041</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42826</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Braman,S.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box #1232, New York, NY 10029, USA. sidney.braman@mssm.edu</style></auth-address><titles><title><style face="normal" font="default">Asthma in the Elderly</style></title><secondary-title><style face="normal" font="default">Clin Geriatr Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Geriatr Med</style></abbr-1></periodical><pages end="537" start="523">523-537</pages><volume><style face="normal" font="default">33</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">The older population has seen the greatest increase in the prevalence of current asthma in recent years. Asthma may begin at any age and when it occurs at an advanced as opposed to a young age, it is often nonatopic, severe, and unremitting. Unfortunately, geriatric-specific guidelines are not available for the diagnosis and treatment of asthma. However, with objective monitoring, avoidance of asthma triggers, appropriate pharmacotherapy, and patient education, the disease can be managed successfully</style></abstract><notes><style face="normal" font="default">DA - 20171009IS - 1879-8853 (Electronic)IS - 0749-0690 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.cger.2017.06.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28991648">PM:28991648</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Geriatr Med\2017-33-523-37.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Geriatr Med\2017-33-523-37.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171009, Braman SS</style></custom2><misc3><style face="normal" font="default">10.1016/j.cger.2017.06.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42827</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">De Luca,F.</style></author><author><style face="normal" font="default"> Losappio,L.M.</style></author><author><style face="normal" font="default"> Mirone,C.</style></author><author><style face="normal" font="default"> Schroeder,J.W.</style></author><author><style face="normal" font="default"> Citterio,A.</style></author><author><style face="normal" font="default"> Aversano,M.G.</style></author><author><style face="normal" font="default"> Scibilia,J.</style></author><author><style face="normal" font="default"> Pastorello,E.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergology and Immunology, Ospedale Metropolitano Niguarda Ca' Granda, Piazza Ospedale Maggiore, 3, 20162 Milan, Italy</style></auth-address><titles><title><style face="normal" font="default">Tolerated drugs in subjects with severe cutaneous adverse reactions (SCARs) induced by anticonvulsants and review of the literature</style></title><secondary-title><style face="normal" font="default">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Mol Allergy</style></full-title></periodical><pages end="" start="16">16-</pages><volume><style face="normal" font="default">15</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Anticonvulsant hypersensitivity syndrome represents a rare but potentially fatal kind of adverse drug reaction. This clinical picture often hampers the flexibility with which alternative anticonvulsants or even other classes of drugs are prescribed in these patients, negatively affecting the efficacy of treatment and the course of the disease. The aim of this study was to analyse a group of six patients with severe cutaneous drug reactions induced by anticonvulsants and to report which alternative antiepileptic drugs and which drugs of other classes were tolerated. CASE PRESENTATION: A total of six patients (2 males and 4 females, age 11-73 years) are described in this study. In all the patients the onset of the severe cutaneous drug reactions was 2-4 weeks after initiating the anticonvulsant therapy: 2 out of 6 patients presented with a drug reaction with eosinophilia and systemic symptoms under therapy with phenytoin; 2 out of 6 presented with Stevens-Johnson syndrome under therapy with lamotrigine; and 2 out of 6 presented with a toxic epidermal necrolysis, one of them under therapy with valproic acid, and the other one under therapy with lamotrigine. Alternative anticonvulsants tolerated after the reaction were: clonazepam, levetiracetam, diazepam, delorazepam and lormetazepam. CONCLUSIONS: In our cases we observed that non aromatic anticonvulsants and benzodiazepines were well tolerated as alternative treatments in six patients with reactions to aromatic anticonvulsivants and that the risk of hypersensitivity reactions to other drug classes was not increased as compared to general population</style></abstract><notes><style face="normal" font="default">DA - 20171013IS - 1476-7961 (Print)IS - 1476-7961 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1186/s12948-017-0072-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29026345">PM:29026345</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-16.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-16.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171013, De Luca F</style></custom2><misc3><style face="normal" font="default">10.1186/s12948-017-0072-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42828</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Conway,E.L.</style></author><author><style face="normal" font="default"> Lin,K.</style></author><author><style face="normal" font="default"> Sellick,J.A.</style></author><author><style face="normal" font="default"> Kurtzhalts,K.</style></author><author><style face="normal" font="default"> Carbo,J.</style></author><author><style face="normal" font="default"> Ott,M.C.</style></author><author><style face="normal" font="default"> Mergenhagen,K.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Veterans Affairs Western New York Healthcare System, Buffalo, New York</style></auth-address><titles><title><style face="normal" font="default">Impact of Penicillin Allergy on Time to First Dose of Antimicrobial Therapy and Clinical Outcomes</style></title><secondary-title><style face="normal" font="default">Clin Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="10" Year="2017">2017/10/9</year></dates><abstract><style face="normal" font="default">PURPOSE: The objective of this study was to evaluate the impact of a listed penicillin allergy on the time to first dose of antibiotic in a Veterans Affairs hospital. Additional clinical outcomes of patients with penicillin allergies were compared with those of patients without a penicillin allergy. METHODS: A retrospective chart review of veterans admitted through the emergency department with a diagnosis of pneumonia, urinary tract infection, bacteremia, and sepsis from January 2006 to December 2015 was conducted. The primary outcome was time to first dose of antibiotic treatment, defined as the time from when the patient presented to the emergency department to the medication administration time. Secondary outcomes included total antibiotic therapy duration and treatment outcomes, including mortality, length of stay, and 30-day readmission rate. FINDINGS: A total of 403 patients were included in the final analysis; 57 patients (14.1%) had a listed penicillin allergy. The average age of the population was 75 years and 99% of the population was male. The mean time to first dose of antibiotic treatment for patients with a penicillin allergy was prolonged compared with those without a penicillin allergy (236.1 vs 186.6 minutes; P = 0.03), resulting in an approximately 50-minute delay. Penicillin-allergic patients were more likely to receive a carbapenem or fluoroquinolone antibiotic (P &lt; 0.0001). IMPLICATIONS: Patients with a penicillin allergy had a prolonged time to first dose of antibiotic therapy. No significant differences were found in total antibiotic duration, length of stay, or 30-day readmission rate. The small sample size, older population, and single-center nature of this study may limit the generalizability of the present findings to other populations</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 1879-114X (Electronic)IS - 0149-2918 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.clinthera.2017.09.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29032850">PM:29032850</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Ther\20171016-ConwayEL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Ther\20171016-ConwayEL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171016, Conway EL</style></custom2><misc3><style face="normal" font="default">10.1016/j.clinthera.2017.09.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42829</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Riedl,M.A.</style></author><author><style face="normal" font="default"> Bernstein,J.A.</style></author><author><style face="normal" font="default"> Craig,T.</style></author><author><style face="normal" font="default"> Banerji,A.</style></author><author><style face="normal" font="default"> Magerl,M.</style></author><author><style face="normal" font="default"> Cicardi,M.</style></author><author><style face="normal" font="default"> Longhurst,H.J.</style></author><author><style face="normal" font="default"> Shennak,M.M.</style></author><author><style face="normal" font="default"> Yang,W.H.</style></author><author><style face="normal" font="default"> Schranz,J.</style></author><author><style face="normal" font="default"> Baptista,J.</style></author><author><style face="normal" font="default"> Busse,P.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of California - San Diego School of Medicine, 8899 University Center Lane, Suite 230, San Diego, CA 92122 USA</style></auth-address><titles><title><style face="normal" font="default">An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension</style></title><secondary-title><style face="normal" font="default">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Transl Allergy</style></full-title></periodical><pages end="" start="36">36-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hereditary angioedema (HAE) is characterized by recurrent attacks of subcutaneous or submucosal edema. Attacks are unpredictable, debilitating, and have a significant impact on quality of life. Patients may be prescribed prophylactic therapy to prevent angioedema attacks. Current prophylactic treatments may be difficult to administer (i.e., intravenously), require frequent administrations or are not well tolerated, and breakthrough attacks may still occur frequently. Lanadelumab is a subcutaneously-administered monoclonal antibody inhibitor of plasma kallikrein in clinical development for prophylaxis of hereditary angioedema attacks. A Phase 1b study supported its efficacy in preventing attacks. A Phase 3, randomized, double-blind, placebo-controlled, parallel-arm study has been completed and an open-label extension is currently ongoing. METHODS/DESIGN: The primary objective of the open-label extension is to evaluate the long-term safety of repeated subcutaneous administrations of lanadelumab in patients with type I/II HAE. Secondary objectives include evaluation of efficacy and time to first angioedema attack to determine outer bounds of the dosing interval. The study will also evaluate immunogenicity, pharmacokinetics/pharmacodynamics, quality of life, characteristics of breakthrough attacks, ease of self-administration, and safety/efficacy in patients who switch to lanadelumab from another prophylactic therapy. The open-label extension will enroll patients who completed the double-blind study ("rollover patients") and those who did not participate in the double-blind study ("non-rollover patients"), which includes patients who may or may not be currently using another prophylactic therapy. Rollover patients will receive a single 300 mg dose of lanadelumab on Day 0 and the second dose after the patient's first confirmed angioedema attack. Thereafter, lanadelumab will be administered every 2 weeks. Non-rollover patients will receive 300 mg lanadelumab every 2 weeks regardless of the first attack. All patients will receive their last dose on Day 350 (maximum of 26 doses), and will then undergo a 4-week follow-up. DISCUSSION: Prevention of attacks can reduce the burden of illness associated with HAE. Prophylactic therapy requires extended, repeated dosing and the results of this study will provide important data on the long-term safety and efficacy of lanadelumab, a monoclonal antibody inhibitor of plasma kallikrein for subcutaneous administration for the treatment of HAE. Trial registration NCT02741596</style></abstract><notes><style face="normal" font="default">DA - 20171018IS - 2045-7022 (Print)IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Germany -CO - Italy -CO - United Kingdom -CO - Jordan -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1186/s13601-017-0172-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29043014">PM:29043014</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-36.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-36.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171018, Riedl MA</style></custom2><misc3><style face="normal" font="default">10.1186/s13601-017-0172-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42830</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Friis,U.F.</style></author><author><style face="normal" font="default"> Goosens,A.</style></author><author><style face="normal" font="default"> Gimenez-Arnau,A.M.</style></author><author><style face="normal" font="default"> Liden,C.</style></author><author><style face="normal" font="default"> Gimenez-Arnau,E.</style></author><author><style face="normal" font="default"> White,I.R.</style></author><author><style face="normal" font="default"> Alfonso,J.H.</style></author><author><style face="normal" font="default"> Uter,W.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Copenhagen University Hospital Gentofte, Research Centre for Hairdressers and Beauticians, 2900, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Self-testing for contact allergy to hair dyes - a 5-year follow-up multicentre study</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="9" Year="2017">2017/9/29</year></dates><abstract><style face="normal" font="default">BACKGROUND: In 2011, a multicentre study was conducted in order to determine how hair dye manufacturers instructed consumers to perform a self-test prior to dyeing their hair, in order to identify individuals who are likely to react upon subsequent hair dyeing. A number of concerns were raised concerning the variability in instructions between products and producers, and the safety and validity of this tool. OBJECTIVES: To perform a 5-year follow-up study in order to determine whether manufacturers still recommend a self-test, and if so, whether the procedures have been changed. METHODS: During March 2016, a total of 40 oxidative hair dye products from 21 different manufacturers were bought in retail stores in 8 European countries. RESULTS: The consumers were instructed to perform a self-test prior to hair dyeing for 39 of the products; however, the procedures varied greatly regarding the method of application, the amount of hair dye applied, the location and size of the application area, the number of applications, whether or not rinsing was performed after application, the reading times, and how a positive reaction was defined. CONCLUSIONS: Self-testing is still recommended by almost all manufacturers of permanent hair dyes. There are major variations in the instructions, even in products from the same manufacturer. The previously raised concerns regarding safety and validity still remain</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - Belgium -CO - Spain -CO - Sweden -CO - France -CO - United Kingdom -CO - Norway -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12882</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28961320">PM:28961320</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170929-FriisUF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170929-FriisUF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Friis UF</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12882</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42831</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mercader-Garcia,P.</style></author><author><style face="normal" font="default"> Pastor-Nieto,M.A.</style></author><author><style face="normal" font="default"> Garcia-Doval,I.</style></author><author><style face="normal" font="default"> Gimenez-Arnau,A.</style></author><author><style face="normal" font="default"> Gonzalez-Perez,R.</style></author><author><style face="normal" font="default"> Fernandez-Redondo,V.</style></author><author><style face="normal" font="default"> Serra-Baldrich,E.</style></author><author><style face="normal" font="default"> Cordoba-Guijarro,S.</style></author><author><style face="normal" font="default"> Gatica-Ortega,M.E.</style></author><author><style face="normal" font="default"> Silvestre-Salvador,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Department, Hospital General Universitario Jose M feminine Morales Meseguer, 30008, Murcia, Spain</style></auth-address><titles><title><style face="normal" font="default">Are the Spanish baseline series markers sufficient to detect contact allergy to corticosteroids in Spain? A GEIDAC prospective study</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Corticosteroids are among the most commonly used topical drugs. Contact allergy to these exists, but can be easily missed. Corticosteroid screening markers have been included in the baseline series with the aim of detecting most of the sensitized patients. OBJECTIVES: To assess the prevalence of contact allergy to topical corticosteroids in Spain and examine the usefulness of corticosteroid markers to detect contact allergy to corticosteroids. METHODS: In total, 3699 patients referred to 20 dermatology departments across Spain for patch testing with the baseline series, including budesonide and tixocortol pivalate, were also tested with six supplementary corticosteroids (methylprednisolone aceponate, mometasone furoate, prednicarbate, clobetasol propionate, betamethasone 17-valerate, and betamethasone 17,21-dipropionate). Additionally, 2547 (68.8%) patients were tested with hydrocortisone 17-butyrate. RESULTS: Fifty-four patients showed positive reactions to at least one of all tested corticosteroids (1.46%). Thirty-nine (1.05%) reacted to at least one of the additionally tested corticosteroids; among these, 24 of 39 (61.5%) did not react to any of the corticosteroid allergy screening markers tested. CONCLUSIONS: More than half of the patients who were allergic to the additionally tested corticosteroids were not detected with the corticosteroid allergy markers. An update of the corticosteroid allergy screening markers is encouraged, with consideration of group 3 corticosteroids</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12874</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28960334">PM:28960334</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20170929-MercaderGarciaP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20170929-MercaderGarciaP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Mercader-Garcia P</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12874</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42832</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Clapp,P.W.</style></author><author><style face="normal" font="default"> Jaspers,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Curriculum in Toxicology, School of Medicine, University of North Carolina, Chapel Hill, NC, USA</style></auth-address><titles><title><style face="normal" font="default">Electronic Cigarettes: Their Constituents and Potential Links to Asthma</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="79">79-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="10" Year="2017">2017/10/5</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Vaping is gaining popularity in the USA, particularly among teens and young adults. While e-cigs are commonly represented as safer alternatives to tobacco cigarettes, little is known regarding the health effects of their short- or long-term use, especially in individuals with pre-existing respiratory diseases such as asthma. Flavored e-cig liquids (e-liquids) and e-cig aerosols contain airway irritants and toxicants that have been implicated in the pathogenesis and worsening of lung diseases. In this review, we will summarize existing data on potential health effects of components present in e-cig aerosols, such as propylene glycol, vegetable glycerin, nicotine, and flavorings, and discuss their relevance in the context of asthma. RECENT FINDINGS: Recent survey data indicate that adolescents with asthma had a higher prevalence of current e-cig use (12.4%) compared to their non-asthmatics peers (10.2%) and conveyed positive beliefs about tobacco products, especially e-cigs. Similarly, a study conducted among high school students from Ontario, Canada, indicated a greater likelihood of e-cig use in asthmatics as compared to their non-asthmatic peers. Availability of different flavorings is often cited as the main reason among youth/adolescents for trying e-cigs or switching from cigarettes to e-cigs. Occupational inhalation of some common food-safe flavoring agents is reported to cause occupational asthma and worsen asthmatic symptoms. Moreover, workplace inhalation exposures to the flavoring agent diacetyl have caused irreversible obstructive airway disease in healthy workers. Additionally, recent studies report that thermal decomposition of propylene glycol (PG) and vegetable glycerin (VG), the base constituents of e-liquids, produces reactive carbonyls, including acrolein, formaldehyde, and acetaldehyde, which have known respiratory toxicities. Furthermore, recent nicotine studies in rodents reveal that prenatal nicotine exposures lead to epigenetic reprogramming in the offspring, abnormal lung development, and multigenerational transmission of asthmatic-like symptoms. Comparisons of the toxicity and health effects of e-cigs and conventional cigarettes often focus on toxicants known to be present in cigarette smoke (CS) (i.e., formaldehyde, nitrosamines, etc.), as well as smoking-associated clinical endpoints, such as cancer, bronchitis, and chronic obstructive pulmonary disease (COPD). However, this approach disregards potential toxicity of components unique to flavored e-cigs, such as PG, VG, and the many different flavoring chemicals, which likely induce respiratory effects not usually observed in cigarette smokers</style></abstract><notes><style face="normal" font="default">DA - 20171006IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0747-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28983782">PM:28983782</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-79.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-79.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171006, Clapp PW</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0747-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42833</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Klaiber,N.</style></author><author><style face="normal" font="default"> Kumar,S.</style></author><author><style face="normal" font="default"> Irani,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Division of Allergy and Immunology, Virginia Commonwealth University Health Systems, 1000 E Broad Street, Richmond, VA, 23219, USA</style></auth-address><titles><title><style face="normal" font="default">Mastocytosis in Children</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="80">80-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="10" Year="2017">2017/10/7</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: In this review, we examine the current understanding of the pathogenesis, clinical presentations, diagnostic tools, and treatment options of pediatric mastocytosis as well as the natural history of the disease. RECENT FINDINGS: We discuss the emerging concept of mast cell activation syndrome. Mastocytosis in children presents most commonly as isolated cutaneous lesions and is a relatively rare occurrence with excellent prognosis and spontaneous regression often occurring by adolescence. Systemic mastocytosis with organ system involvement is a more serious condition and is likely to persist into adulthood</style></abstract><notes><style face="normal" font="default">DA - 20171008IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0748-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28988349">PM:28988349</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-80.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171008, Klaiber N</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0748-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42834</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,H.I.</style></author><author><style face="normal" font="default"> Lin,Y.T.</style></author><author><style face="normal" font="default"> Jung,C.R.</style></author><author><style face="normal" font="default"> Hwang,B.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the aDepartment of Occupational Safety and Health, College of Public Health, China Medical University, Taichung, Taiwan, Republic of China; bDepartment of Occupational Therapy, College of Medical and Health Science, Asia University, Taichung, Taiwan, Republic of China</style></auth-address><titles><title><style face="normal" font="default">Interaction Between Catalase Gene Promoter Polymorphisms and Indoor Environmental Exposure in Childhood Allergic Rhinitis</style></title><secondary-title><style face="normal" font="default">Epidemiology</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Epidemiology</style></abbr-1></periodical><pages end="S132" start="S126">S126-S132</pages><volume><style face="normal" font="default">28 Suppl 1</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic rhinitis (AR) is a highly prevalent chronic inflammatory disease affecting nearly 40% of the children in Taiwan. Genetic susceptibility may interact with specific environmental factors leading to allergic disease development. METHODS: To assess the interactions between catalase gene promoter polymorphisms and environmental factors on the risk of AR, we conducted a case-control study in Taiwan. Data on AR and environmental factors were collected from 800 children using the ISSAC questionnaire. The case group consisted of 263 children with AR, and the control group consisted of =537 healthy children. Genotyping was performed for rs1001179 and rs769214 polymorphisms, and environmental exposure was assessed using four indicators including dwelling visible molds, mold odor, moisture on surfaces, and water damage. RESULTS: We found that the presence of visible molds, mold odor, and moisture was associated with AR. An apparent joint effect of the GG genotype and mold odor, compared with the AA and AG combined genotypes and without any exposure indicator (adjusted odds ratio [OR] = 1.95 [95% confidence interval (CI) = 1.20, 3.18]; interaction adjusted odds ratio = 2.59 [95% CI = 1.27, 5.30]), was observed. CONCLUSIONS: Our findings suggest that gene-environment interactions between the catalase polymorphism rs769214 and mold odor may play an important role in childhood AR development</style></abstract><notes><style face="normal" font="default">DA - 20171013IS - 1531-5487 (Electronic)IS - 1044-3983 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1097/EDE.0000000000000741</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29028686">PM:29028686</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Epidemiology\2017-28S1-126-32.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Epidemiology\2017-28S1-126-32.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171013, Chen HI</style></custom2><misc3><style face="normal" font="default">10.1097/EDE.0000000000000741</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42835</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gomez,J.L.</style></author><author><style face="normal" font="default"> Yan,X.</style></author><author><style face="normal" font="default"> Holm,C.T.</style></author><author><style face="normal" font="default"> Grant,N.</style></author><author><style face="normal" font="default"> Liu,Q.</style></author><author><style face="normal" font="default"> Cohn,L.</style></author><author><style face="normal" font="default"> Nezgovorova,V.</style></author><author><style face="normal" font="default"> Meyers,D.A.</style></author><author><style face="normal" font="default"> Bleecker,E.R.</style></author><author><style face="normal" font="default"> Crisafi,G.M.</style></author><author><style face="normal" font="default"> Jarjour,N.N.</style></author><author><style face="normal" font="default"> Rogers,L.</style></author><author><style face="normal" font="default"> Reibman,J.</style></author><author><style face="normal" font="default"> Chupp,G.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Section of Pulmonary, Critical Care Medicine and Sleep and Dept of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA</style></auth-address><titles><title><style face="normal" font="default">Characterisation of asthma subgroups associated with circulating YKL-40 levels</style></title><secondary-title><style face="normal" font="default">Eur Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Respir J</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="default">50</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">The chitinase-like protein YKL-40 mediates airway inflammation and serum levels are associated with asthma severity. However, asthma phenotypes associated with YKL-40 levels have not been precisely defined.We conducted an unsupervised cluster analysis of asthma patients treated at the Yale Center for Asthma and Airways Disease (n=156) to identify subgroups according to YKL-40 level. The resulting YKL-40 clusters were cross-validated in cohorts from the Severe Asthma Research Programme (n=167) and the New York University/Bellevue Asthma Repository (n=341). A sputum transcriptome analysis revealed molecular pathways associated with YKL-40 subgroups.Four YKL-40 clusters (C1-C4) were identified. C3 and C4 had high serum YKL-40 levels compared with C1 and C2. C3 was associated with earlier onset and longer duration of disease, severe airflow obstruction, and near-fatal asthma exacerbations. C4 had the highest serum YKL-40 levels, adult onset and less airflow obstruction, but frequent exacerbations. An airway transcriptome analysis in C3 and C4 showed activation of non-type 2 inflammatory pathways.Elevated serum YKL-40 levels were associated with two distinct clinical asthma phenotypes: one with irreversible airway obstruction and another with severe exacerbations. The YKL-40 clusters are potentially useful for identification of individuals with severe or exacerbation-prone asthma</style></abstract><notes><style face="normal" font="default">DA - 20171013IS - 1399-3003 (Electronic)IS - 0903-1936 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1183/13993003.00800-2017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29025889">PM:29025889</url></web-urls><related-urls><url ppv-ref="no">presto - 18 mesi</url></related-urls></urls><custom2><style face="normal" font="default">20171013, Gomez JL</style></custom2><misc3><style face="normal" font="default">10.1183/13993003.00800-2017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42836</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martinez-Moragon,E.</style></author><author><style face="normal" font="default"> Romero-Falcon,A.</style></author><author><style face="normal" font="default"> Garcia-Rivero,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Pulmonology Department , Hospital Universitario Dr. Peset , Valencia , Spainb Unidad de Asma. Unidad Medico-Quirurgica de Enfermedades Respiratorias , Hospital Universitario Virgen del Rocio , Sevilla , Spainc Pneumology Department , Hospital de Laredo , Laredo , Spain</style></auth-address><titles><title><style face="normal" font="default">Algorithm for the management of asthma in pregnant women: a protocol to optimize processes in healthcare</style></title><secondary-title><style face="normal" font="default">Expert Rev Respir Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Expert Rev Respir Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="10" Year="2017">2017/10/10</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Asthma is the most common chronic disease in pregnant women. Its evolution during pregnancy could improve, stay the same or worsen, especially in cases where there is a loss of clinical control. This can lead to maternal and fetal hypoxia with serious adverse perinatal outcomes. Areas covered: This article reviews physiological modifications in pregnancy, effects of pregnancy on asthma, and possible consequences on fetus development. Furthermore, it reviews evidence on assessment and both pharmacological and non-pharmacological management of asthma in pregnant and breastfeeding women as well as in acute exacerbations. Electronic databases, such as PUBMED, were searched for terms pregnan* or perinat* or obstet* and breastfeeding or asthma or wheeze, as well as a book published by the present authors. Expert commentary: A patient-centered multidisciplinary approach, where the respiratory specialists have a key role in assessing and achieving control, as well as the education interventions for self-monitoring and adherence are at least as important as adequate pharmacological treatment</style></abstract><notes><style face="normal" font="default">DA - 20171010IS - 1747-6356 (Electronic)IS - 1747-6348 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1080/17476348.2017.1391094</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29016232">PM:29016232</url></web-urls></urls><custom2><style face="normal" font="default">20171010, Martinez-Moragon E</style></custom2><misc3><style face="normal" font="default">10.1080/17476348.2017.1391094</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42837</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mazzotta,C.</style></author><author><style face="normal" font="default"> Traversi,C.</style></author><author><style face="normal" font="default"> Mellace,P.</style></author><author><style face="normal" font="default"> Bagaglia,S.A.</style></author><author><style face="normal" font="default"> Zuccarini,S.</style></author><author><style face="normal" font="default"> Mencucci,R.</style></author><author><style face="normal" font="default"> Jacob,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine (C.M., C.T., P.M.), Surgery and Neurosciences, Siena University, Siena, Italy</style></auth-address><titles><title><style face="normal" font="default">Keratoconus Progression in Patients With Allergy and Elevated Surface Matrix Metalloproteinase 9 Point-of-Care Test</style></title><secondary-title><style face="normal" font="default">Eye Contact Lens</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Eye Contact Lens</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="10" Year="2017">2017/10/4</year></dates><abstract><style face="normal" font="default">PURPOSE: To assess keratoconus (KC) progression in patients with allergies who also tested positive to surface matrix metalloproteinase 9 (MMP-9) point-of-care test. METHODS: Prospective comparative study including 100 stage I-II keratoconic patients, mean age 16.7+/-4.6 years. All patients underwent an anamnestic questionnaire for concomitant allergic diseases and were screened with the MMP-9 point-of-care test. Patients were divided into two groups: patients KC with allergies (KC AL) and patients KC without allergies (KC NAL). Severity of allergy was established by papillary subtarsal response grade and KC progression assessed by Scheimpflug corneal tomography, corrected distance visual acuity (CDVA) measurement in a 12-month follow-up. RESULTS: The KC AL group included 52 patients and the KC NAL group 48. In the KC AL group, 42/52 of patients (81%) were positive to MMP-9 point-of-care test versus two positive patients in the KC NAL group (4%). The KC AL group data showed a statistically significant decrease of average CDVA, from 0.155+/-0.11 to 0.301+/-0.2 logarithm of the minimum angle of resolution (P&lt;0.005) at 12 months; Kmax value increased significantly, from 50.2 D+/-2.7 to 55.2 D+/-1.9 on average. The KC NAL group revealed a slight KC progression without statistically significant changes. Pearson correlation test showed a high correlation between Kmax worsening and severity of PSR in the KC AL group. CONCLUSIONS: The study demonstrated a statistically significant progression of KC in patients with concomitant allergies, positive to MMP-9 point-of-care test versus negative. A high correlation between severity of allergy and KC progression was documented</style></abstract><notes><style face="normal" font="default">DA - 20171009IS - 1542-233X (Electronic)IS - 1542-2321 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - India -</style></notes><work-type><style face="normal" font="default">10.1097/ICL.0000000000000432</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28991055">PM:28991055</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eye Contact Lens\20171009-MazzottaC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eye Contact Lens\20171009-MazzottaC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171009, Mazzotta C</style></custom2><misc3><style face="normal" font="default">10.1097/ICL.0000000000000432</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42838</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Plenzig,S.</style></author><author><style face="normal" font="default"> Heinbuch,S.</style></author><author><style face="normal" font="default"> Held,H.</style></author><author><style face="normal" font="default"> Verhoff,M.A.</style></author><author><style face="normal" font="default"> Lux,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Legal Medicine, University Hospital Frankfurt, Kennedyallee 104, 60596, Frankfurt am Main, Germany.</style></auth-address><titles><title><style face="normal" font="default">A case of fatal perimyocarditis due to a rare disease</style></title><secondary-title><style face="normal" font="default">Forensic Sci Med Pathol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Forensic Sci Med Pathol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="10" Year="2017">2017/10/11</year></dates><abstract><style face="normal" font="default">Although myocarditis is caused by viral infections in about 50% of cases in European countries, various other causative agents are known. We report the case of a 51-year-old man who died several months after being diagnosed with asthma by his general practitioner. This diagnosis had been confirmed by a pulmonologist approximately 6 weeks before the man's death. To rule out the possibility of medical malpractice the prosecuting authority ordered a forensic autopsy. At autopsy macroscopic indicators for perimyocarditis and pneumonia were found. Microbiological and histological examination of tissue samples confirmed a diagnosis of Churg-Strauss syndrome, also known as Eosinophilic Granulomatosis with Polyangiitis (EGPA). The cause of death was determined to be cardiac involvement in Churg-Strauss syndrome. The presence of this disease also accounted for the man's recent medical history. There were no findings to indicate that a medical error had been made. The reported case illustrates why accessory histological and microbiological examinations should always be performed when macroscopic findings at autopsy suggest myocarditis. Determining the etiology of myocarditis is a necessary step to prevent overlooking rare diseases with inflammatory myocardial involvement, especially in the clarification of alleged medical malpractice</style></abstract><notes><style face="normal" font="default">DA - 20171012IS - 1556-2891 (Electronic)IS - 1547-769X (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1007/s12024-017-9920-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29022232">PM:29022232</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Forensic Sci Med Pathol\20171012-PlenzigS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Forensic Sci Med Pathol\20171012-PlenzigS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171012, Plenzig S</style></custom2><misc3><style face="normal" font="default">10.1007/s12024-017-9920-3</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42839</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Svenningsen,S.</style></author><author><style face="normal" font="default"> Nair,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, McMaster University, Hamilton, ON, Canada</style></auth-address><titles><title><style face="normal" font="default">Asthma Endotypes and an Overview of Targeted Therapy for Asthma</style></title><secondary-title><style face="normal" font="default">Front Med (Lausanne)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Med (Lausanne)</style></abbr-1></periodical><pages end="" start="158">158-</pages><volume><style face="normal" font="default">4</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Guidelines for the management of severe asthma do not emphasize the measurement of the inflammatory component of airway disease to indicate appropriate treatments or to monitor response to treatment. Inflammation is a central component of asthma and contributes to symptoms, physiological, and structural abnormalities. It can be assessed by a number of endotyping strategies based on "omics" technology such as proteomics, transcriptomics, and metabolomics. It can also be assessed using simple cellular responses by quantitative cytometry in sputum. Bronchitis may be eosinophilic, neutrophilic, mixed-granulocytic, or paucigranulocytic (eosinophils and neutrophils not elevated). Eosinophilic bronchitis is usually a Type 2 (T2)-driven process and therefore a sputum eosinophilia of greater than 3% usually indicates a response to treatment with corticosteroids or novel therapies directed against T2 cytokines such as IL-4, IL-5, and IL-13. Neutrophilic bronchitis represents a non-T2-driven disease, which is generally a predictor of response to antibiotics and may be a predictor to therapies targeted at pathways that lead to neutrophil recruitment such as TNF, IL-1, IL-6, IL-8, IL-23, and IL-17. Paucigranulocytic disease may not warrant anti-inflammatory therapy. These patients, whose symptoms may be driven largely by airway hyper-responsiveness may benefit from smooth muscle-directed therapies such as bronchial thermoplasty or mast-cell directed therapies. This review will briefly summarize the current knowledge regarding "omics-based signatures" and cellular endotyping of severe asthma and give an overview of segmentation of asthma therapeutics guided by the endotype</style></abstract><notes><style face="normal" font="default">DA - 20171011IS - 2296-858X (Print)IS - 2296-858X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Canada -</style></notes><work-type><style face="normal" font="default">10.3389/fmed.2017.00158</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29018800">PM:29018800</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Med (Lausanne)\2017-4-158.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Med (Lausanne)\2017-4-158.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171011, Svenningsen S</style></custom2><misc3><style face="normal" font="default">10.3389/fmed.2017.00158</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42840</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tikhonova,I.V.</style></author><author><style face="normal" font="default"> Kosyakova,N.I.</style></author><author><style face="normal" font="default"> Grinevich,A.A.</style></author><author><style face="normal" font="default"> Nadeev,A.D.</style></author><author><style face="normal" font="default"> Chemeris,N.K.</style></author><author><style face="normal" font="default"> Safronova,V.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Accelerated reactivity of blood granulocytes in patients with atopic bronchial asthma out of exacerbation</style></title><secondary-title><style face="normal" font="default">Immunobiology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunobiology</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Phagocyte</style></keyword><keyword><style face="normal" font="default"> Respiratory Burst</style></keyword><keyword><style face="normal" font="default"> Kinetics</style></keyword><keyword><style face="normal" font="default"> Receiver operating characteristic</style></keyword><keyword><style face="normal" font="default"> priming</style></keyword><keyword><style face="normal" font="default"> Adhesion</style></keyword><keyword><style face="normal" font="default"> Allergic bronchial asthma</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0171-2985</style></isbn><abstract><style face="normal" font="default">Abstract Reactive oxygen species (ROS) are important in bronchial asthma (BA) pathogenesis owing to accumulation of activated granulocytes in the lungs. But the ROS-producing activity of the cells is insufficiently understood in the blood of BA patients. This study analyzes the kinetics of phagocyte respiratory burst in the blood to improve the methods of BA patients monitoring. Patients with atopic BA out of exacerbation (n=60) and healthy controls (n=43) were recruited. The time-course of respiratory response to opsonized zymosan (OZ) was recorded in the whole blood using luminol-dependent chemiluminescence (CL), and its activation kinetics (lag-time, rate, amplitude, ROS production) was calculated. The discriminative power of ROS generation kinetics was defined by Receiver Operating Characteristic (ROC) curve analysis. Standard physiological respiratory parameters of patients did not differ from the controls. More rapid response to OZ was recorded in BA patient samples versus the controls. The primed state of phagocytes in the blood of BA patients was corroborated by significant weakening formyl peptide priming effect. The adhesion of granulocytes to cultured human endothelial cells was two-fold higher in BA patients versus controls. ROC curve analysis exhibited good discriminative effectiveness of the CL kinetics to compare BA individuals with the controls. The highest power (86% sensitivity and 90% specificity) was achieved at a linear combination of the parameters. We assume that the assessment of phagocyte reactivity based on the analysis of the response kinetic profile is a good test for monitoring of the state in BA patients</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Russia -</style></notes><work-type><style face="normal" font="default">10.1016/j.imbio.2017.10.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29032837">PM:29032837</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunobiology\20171011-TikhonovaIV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunobiology\20171011-TikhonovaIV.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171016, Tikhonova IV</style></custom2><misc3><style face="normal" font="default">10.1016/j.imbio.2017.10.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42841</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Modena,B.</style></author><author><style face="normal" font="default"> White,A.A.</style></author><author><style face="normal" font="default"> Woessner,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Asthma and Immunology, Scripps Clinic, 3811 Valley Centre Drive, S99, San Diego, CA 92130, USA</style></auth-address><titles><title><style face="normal" font="default">Aspirin and Nonsteroidal Antiinflammatory Drugs Hypersensitivity and Management</style></title><secondary-title><style face="normal" font="default">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="749" start="727">727-749</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">Aspirin and nonsteroidal antiinflammatory drugs (NSAIDs) are widely used in the United States and throughout the world for a variety of indications. Several unique hypersensitivity syndromes exist to this class of medications, making them one of the common reasons for consultation to the allergist. The lack of any laboratory-based diagnostic studies to assist in identifying the culprits in these reactions make evaluation of aspirin and NSAID hypersensitivity challenging. Identifying patients appropriate for oral challenge and/or desensitization protocols is the standard pragmatic approach to this issue when it arises</style></abstract><notes><style face="normal" font="default">DA - 20171002IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.iac.2017.07.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28965637">PM:28965637</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-727-49.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-727-49.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171002, Modena B</style></custom2><misc3><style face="normal" font="default">10.1016/j.iac.2017.07.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42842</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McNulty,C.M.G.</style></author><author><style face="normal" font="default"> Park,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergic Diseases, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USADivision of Allergic Diseases, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA. Electronic address: park.miguel@mayo.edu</style></auth-address><titles><title><style face="normal" font="default">Delayed Cutaneous Hypersensitivity Reactions to Antibiotics: Management with Desensitization</style></title><secondary-title><style face="normal" font="default">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="760" start="751">751-760</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">Successful desensitization to mild to moderate delayed cutaneous adverse reaction to antibiotics has been described in a limited number of antibiotics and found to be safe. However, there are ample opportunities to standardize protocols for delayed cutaneous adverse reactions to antibiotics</style></abstract><notes><style face="normal" font="default">DA - 20171002IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.iac.2017.07.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28965638">PM:28965638</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-751-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-751-60.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171002, McNulty CM</style></custom2><misc3><style face="normal" font="default">10.1016/j.iac.2017.07.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42843</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pavlos,R.</style></author><author><style face="normal" font="default"> White,K.D.</style></author><author><style face="normal" font="default"> Wanjalla,C.</style></author><author><style face="normal" font="default"> Mallal,S.A.</style></author><author><style face="normal" font="default"> Phillips,E.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute for Immunology and Infectious Diseases, Murdoch University, 6150 Murdoch, Western Australia, Australia</style></auth-address><titles><title><style face="normal" font="default">Severe Delayed Drug Reactions: Role of Genetics and Viral Infections</style></title><secondary-title><style face="normal" font="default">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="815" start="785">785-815</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">Adverse drug reactions (ADRs) are a significant source of patient morbidity and mortality and represent a major burden to health care systems and drug development. Up to 50% of such reactions are preventable. Although many ADRs can be predicted based on the on-target pharmacologic activity, ADRs arising from drug interactions with off-target receptors are recognized. Off-target ADRs include the immune-mediated ADRs (IM-ADRs) and pharmacologic drug effects. In this review, we discuss what is known about the immunogenetics and pathogenesis of IM-ADRs and the hypothesized role of heterologous immunity in the development of IM-ADRs</style></abstract><notes><style face="normal" font="default">DA - 20171002IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.iac.2017.07.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28965641">PM:28965641</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-785-815.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-785-815.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171002, Pavlos R</style></custom2><misc3><style face="normal" font="default">10.1016/j.iac.2017.07.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42844</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Picard,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Division of Allergy and Immunology, Hopital Maisonneuve-Rosemont, Universite de Montreal, 5415 boulevard de l'Assomption, Montreal, Quebec H1T 2M4, Canada.</style></auth-address><titles><title><style face="normal" font="default">Management of Hypersensitivity Reactions to Taxanes</style></title><secondary-title><style face="normal" font="default">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="693" start="679">679-693</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">Taxanes are an important class of antineoplastic agents used in the treatment of a wide variety of cancers. However, paclitaxel and docetaxel, which are the most commonly used taxanes, elicit immediate hypersensitivity reactions (HSRs) in 5% to 10% of patients. Almost all patients that experience these reactions can be safely re-exposed to taxanes either through desensitization or challenge. This article describes the clinical presentation, diagnosis, and management of HSRs to taxanes and discusses the different options for their safe readministration</style></abstract><notes><style face="normal" font="default">DA - 20171002IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.iac.2017.07.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28965634">PM:28965634</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-679-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-679-93.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171002, Picard M</style></custom2><misc3><style face="normal" font="default">10.1016/j.iac.2017.07.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42845</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Har,D.</style></author><author><style face="normal" font="default"> Solensky,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, USA</style></auth-address><titles><title><style face="normal" font="default">Penicillin and Beta-Lactam Hypersensitivity</style></title><secondary-title><style face="normal" font="default">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="662" start="643">643-662</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">Ten percent of patients report penicillin allergy, but more than 90% of these individuals can tolerate penicillins. Skin testing remains the optimal method for evaluation of possible IgE-mediated penicillin allergy and is recommended by professional societies, as the harms for alternative antibiotics include antimicrobial resistance, prolonged hospitalizations, readmissions, and increased costs. Removal of penicillin allergy leads to decreased utilization of broad-spectrum antibiotics, such as fluoroquinolones and vancomycin. There is minimal allergic cross-reactivity between penicillins and cephalosporins. IgE-mediated allergy to cephalosporins is usually side-chain specific and may warrant graded challenge with cephalosporins containing dissimilar R1 or R2 group side chains</style></abstract><notes><style face="normal" font="default">DA - 20171002IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.iac.2017.07.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28965632">PM:28965632</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-643-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-643-62.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171002, Har D</style></custom2><misc3><style face="normal" font="default">10.1016/j.iac.2017.07.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42846</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aun,M.V.</style></author><author><style face="normal" font="default"> Kalil,J.</style></author><author><style face="normal" font="default"> Giavina-Bianchi,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Avenida Eneas de Carvalho Aguiar 155, 8th Floor, Predio dos Ambulatorios, Bloco 03, 05403-900, Sao Paulo, Brasil.</style></auth-address><titles><title><style face="normal" font="default">Drug-Induced Anaphylaxis</style></title><secondary-title><style face="normal" font="default">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="641" start="629">629-641</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">Drugs are among the main triggers of anaphylaxis, but identification of the culprit drug is frequently difficult. To confirm diagnosis of the causative agent, medical records and clinical history are fundamental. There are a few in vitro tests available in clinical practice, such as serum-specific IgE and basophil activation test. Skin tests are often useful for the diagnosis, although drug challenge is indicated in patients with inconclusive clinical history or to provide safe alternatives. Treatment of anaphylaxis is standard and intramuscular epinephrine is the main agent to prevent morbidity and mortality. Rapid desensitization may be indicated in selected cases</style></abstract><notes><style face="normal" font="default">DA - 20171002IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1016/j.iac.2017.06.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28965631">PM:28965631</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-629-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-629-41.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171002, Aun MV</style></custom2><misc3><style face="normal" font="default">10.1016/j.iac.2017.06.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42847</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Otani,I.M.</style></author><author><style face="normal" font="default"> Wong,J.</style></author><author><style face="normal" font="default"> Banerji,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, UCSF Medical Center, 400 Parnassus Avenue, Fifth Floor, San Francisco, CA 94143, USA.</style></auth-address><titles><title><style face="normal" font="default">Platinum Chemotherapy Hypersensitivity: Prevalence and Management</style></title><secondary-title><style face="normal" font="default">Immunol Allergy Clin North Am</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immunol Allergy Clin North Am</style></full-title></periodical><pages end="677" start="663">663-677</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">Hypersensitivity reactions to platinum agents are common. For carboplatin and cisplatin, the first hypersensitivity reaction typically occurs around the second and third re-exposure during the second line of therapy (eighth and ninth courses overall). For oxaliplatin, the first hypersensitivity reaction can occur throughout the treatment course. Skin testing helps risk stratify patients to appropriate desensitization protocols and assess risk for breakthrough HSRs during desensitization. A risk-stratification protocol using 3 serial skin tests and desensitization protocols enables patients with platinum agent hypersensitivity to receive first-line chemotherapy treatment safely</style></abstract><notes><style face="normal" font="default">DA - 20171002IS - 1557-8607 (Electronic)IS - 0889-8561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.iac.2017.06.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28965633">PM:28965633</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-663-77.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Allergy Clin North Am\2017-37-663-77.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171002, Otani IM</style></custom2><misc3><style face="normal" font="default">10.1016/j.iac.2017.06.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42848</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Xu,Z.</style></author><author><style face="normal" font="default"> Crooks,J.L.</style></author><author><style face="normal" font="default"> Davies,J.M.</style></author><author><style face="normal" font="default"> Khan,A.F.</style></author><author><style face="normal" font="default"> Hu,W.</style></author><author><style face="normal" font="default"> Tong,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Public Health and Social Work &amp; Institute of Health and Biomedical Innovation, Queensland University of Technology, Kelvin Grove, 4059, Australia.</style></auth-address><titles><title><style face="normal" font="default">The association between ambient temperature and childhood asthma: a systematic review</style></title><secondary-title><style face="normal" font="default">Int J Biometeorol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Biometeorol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="10" Year="2017">2017/10/11</year></dates><abstract><style face="normal" font="default">The objectives of this study are to review available information on the association between ambient temperature and childhood asthma, and to elucidate the possible underlying mechanisms of this relationship. A systematic review was conducted based on the papers retrieved from four databases, including PubMed, ProQuest, ScienceDirect, and Scopus. Papers examining the association of absolute temperature or temperature variation with childhood asthma published from 1 January 2000 to 31 December 2016 were included. Thirteen papers have quantified the effect of absolute temperature on childhood asthma, and six papers have examined the effect of intra- or inter-day temperature variation on childhood asthma. All studies were conducted in urban areas. Aeroallergen sensitizations were only considered in the analyses of one study. Discrepancy existed in the significance of the relationship between absolute temperature and childhood asthma, and also in the shape of this relationship (i.e. linear or non-linear) and whether temperature effects were lagged. Increasing evidence is suggesting non-linear relationship between absolute temperature and childhood asthma. Future research should investigate the burden of childhood asthma specifically attributable to extreme temperatures and temperature variation using advanced statistical approach, particularly in rural areas, after properly considering aeroallergens and air pollution. Projecting future burden of childhood asthma under climate change scenarios is also warranted</style></abstract><notes><style face="normal" font="default">DA - 20171012IS - 1432-1254 (Electronic)IS - 0020-7128 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -CO - Bangladesh -CO - China -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s00484-017-1455-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29022096">PM:29022096</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Biometeorol\20171012-XuZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Biometeorol\20171012-XuZ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171012, Xu Z</style></custom2><misc3><style face="normal" font="default">10.1007/s00484-017-1455-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42849</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vandenplas,O.</style></author><author><style face="normal" font="default"> Vinnikov,D.</style></author><author><style face="normal" font="default"> Blanc,P.D.</style></author><author><style face="normal" font="default"> Agache,I.</style></author><author><style face="normal" font="default"> Bachert,C.</style></author><author><style face="normal" font="default"> Bewick,M.</style></author><author><style face="normal" font="default"> Cardell,L.O.</style></author><author><style face="normal" font="default"> Cullinan,P.</style></author><author><style face="normal" font="default"> Demoly,P.</style></author><author><style face="normal" font="default"> Descatha,A.</style></author><author><style face="normal" font="default"> Fonseca,J.</style></author><author><style face="normal" font="default"> Haahtela,T.</style></author><author><style face="normal" font="default"> Hellings,P.W.</style></author><author><style face="normal" font="default"> Jamart,J.</style></author><author><style face="normal" font="default"> Jantunen,J.</style></author><author><style face="normal" font="default"> Kalayci,O.</style></author><author><style face="normal" font="default"> Price,D.</style></author><author><style face="normal" font="default"> Samolinski,B.</style></author><author><style face="normal" font="default"> Sastre,J.</style></author><author><style face="normal" font="default"> Tian,L.</style></author><author><style face="normal" font="default"> Valero,A.L.</style></author><author><style face="normal" font="default"> Zhang,X.</style></author><author><style face="normal" font="default"> Bousquet,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Universite Catholique de Louvain, Yvoir, Belgium.</style></auth-address><titles><title><style face="normal" font="default">Impact of Rhinitis on Work Productivity: A Systematic Review</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="10" Year="2017">2017/10/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic rhinitis (AR) is increasingly acknowledged as having a substantial socioeconomic impact associated with impaired work productivity, although available information remains fragmented. OBJECTIVE: This systematic review summarizes recently available information to provide a quantitative estimate of the burden of AR on work productivity including lost work time (ie, absenteeism) and reduced performance while working (ie, presenteeism). METHODS: A Medline search retrieved original studies from 2005 to 2015 pertaining to the impact of AR on work productivity. A pooled analysis of results was carried out with studies reporting data collected through the validated Work Productivity and Activity Impairment (WPAI) questionnaire. RESULTS: The search identified 19 observational surveys and 9 interventional studies. Six studies reported economic evaluations. Pooled analysis of WPAI-based studies found an estimated 3.6% (95% confidence interval [CI], 2.4; 4.8%) missed work time and 35.9% (95% CI, 29.7; 42.1%) had impairment in at-work performance due to AR. Economic evaluations indicated that indirect costs associated with lost work productivity are the principal contributor to the total AR costs and result mainly from impaired presenteeism. The severity of AR symptoms was the most consistent disease-related factor associated with a greater impact of AR on work productivity, although ocular symptoms and sleep disturbances may independently affect work productivity. Overall, the pharmacologic treatment of AR showed a beneficial effect on work productivity. CONCLUSIONS: This systematic review provides summary estimates of the magnitude of work productivity impairment due to AR and identifies its main determinant factors. This information may help guide both clinicians and health policy makers</style></abstract><notes><style face="normal" font="default">DA - 20171011IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Belgium -CO - Kazakhstan -CO - United States -CO - Romania -CO - United KIngdom -CO - Sweden -CO - France -CO - Finland -CO - Portugal -CO - Turkey -CO - Poland -CO - Spain -CO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.09.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29017832">PM:29017832</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171011, Vandebplas O</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.09.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42850</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ayubi,E.</style></author><author><style face="normal" font="default"> Safiri,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Epidemiology, School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Epidemiology &amp; Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="default">Comments on clinical predictors of remission and persistence of adult-onset asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="9" Year="2017">2017/9/26</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171002IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Iran -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.08.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28967479">PM:28967479</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171002-AyubiE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171002-AyubiE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171002, Ayubi E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.08.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42851</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">el-Gamal,Y.M.</style></author><author><style face="normal" font="default"> Hossny,E.M.</style></author><author><style face="normal" font="default"> El-Sayed,Z.A.</style></author><author><style face="normal" font="default"> Reda,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Allergy and Immunology Unit, Children's Hospital, Ain Shams University</style></auth-address><titles><title><style face="normal" font="default">Allergy and immunology in Africa: Challenges and unmet needs</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="9" Year="2017">2017/9/26</year></dates><abstract><style face="normal" font="default">The tremendous increase in allergy in the African continent cannot simply be explained by the change in public hygiene. There are many "prehygiene" communities with sewage-contaminated water supplies, helminth infestations, bare footedness, and poor housing, and still there is a high prevalence of allergic disease. Africans can be exposed to many risk factors facilitating severe asthma and wheezing, including airborne viruses, smoke, indoor dampness, cockroaches, and poor access to health care. Although the reporting on food allergy is inadequate to perform systematic reviews or meta-analyses, the available data suggest that food allergy is underdiagnosed. The rate of new HIV infections in high-prevalence settings in Africa remains unacceptably high. Although the annual number of new HIV infections in Sub-Saharan Africa has decreased lately, new HIV infections in the Middle East and North Africa region have increased; however, the current prevalence of 0.1% is still among the lowest globally. Africa is densely populated, and consanguineous mating is high in some areas of North and Sub-Saharan Africa. This allows for emergence of many autosomal recessive primary immunodeficiency diseases. There is urgent need for the establishment of primary immunodeficiency disease registries, stem cell transplantation facilities, and neonatal screening programs. To address these expanding problems and perform local cutting-edge research, Africans need to be empowered by motivated governments, dedicated funds, and compassionate scientific partnership</style></abstract><notes><style face="normal" font="default">DA - 20170930IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Egypt -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.09.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28962920">PM:28962920</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170930-ElGamalYM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20170930-ElGamalYM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170930, El-Gamal YM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.09.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42852</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kvisselgaard,A.D.</style></author><author><style face="normal" font="default"> Mosbech,H.F.</style></author><author><style face="normal" font="default"> Fransson,S.</style></author><author><style face="normal" font="default"> Garvey,L.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Clinic, Department of Dermatology and Allergology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.</style></auth-address><titles><title><style face="normal" font="default">Risk of Immediate-Type Allergy to Local Anesthetics is Overestimated-Results from 5 Years of Provocation Testing in a Danish Allergy Clinic</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="10" Year="2017">2017/10/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Local anesthetics (LAs) are used in many health care settings and exposure during a lifetime is almost inevitable. Immediate-type allergy to LAs is considered rare among allergy experts but is commonly suspected by health care workers from other specialties, and by patients. OBJECTIVE: The main aim of this study was to investigate the incidence of immediate-type allergy to LAs in our regional allergy clinic over the 5-year period 2010 to 2014. METHODS: This was a retrospective single-center study of patients referred to a regional allergy clinic (excluding patients with perioperative reactions) with suspected immediate allergy to LAs, who had undergone subcutaneous provocation with 1 or more LAs. Patients were identified in the hospital clinical coding system and clinical information about the reaction and investigation results was obtained from their medical records. RESULTS: A total of 164 patients (123 women/41 men; median age, 56 years; range, 7-89 years) who had 189 provocations with LAs were included over the 5-year period 2010 to 2014. All 164 patients had negative subcutaneous provocations to all 189 tests with LAs (95% CI, 0%-1.83%). Another allergen was identified in 10% (n = 17) of the patients. CONCLUSIONS: None of the 164 patients with suspected immediate-type allergy to LAs reacted on provocation. Thus, no patients have been diagnosed with an immediate allergy to LAs in our regional allergy clinic in the 5-year period studied, and allergy to LAs must be considered very rare. Alternative mechanisms should be considered, but if symptoms are consistent with allergy, other potential allergens should be investigated</style></abstract><notes><style face="normal" font="default">DA - 20171009IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28988784">PM:28988784</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171009, Kvisselgaard AD</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42853</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rejno,G.</style></author><author><style face="normal" font="default"> Lundholm,C.</style></author><author><style face="normal" font="default"> Larsson,K.</style></author><author><style face="normal" font="default"> Larsson,H.</style></author><author><style face="normal" font="default"> Lichtenstein,P.</style></author><author><style face="normal" font="default"> D'Onofrio,B.M.</style></author><author><style face="normal" font="default"> Saltvedt,S.</style></author><author><style face="normal" font="default"> Almqvist,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default">Adverse Pregnancy Outcomes in Asthmatic Women: A Population-Based Family Design Study</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="9" Year="2017">2017/9/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is associated with several adverse pregnancy and perinatal outcomes. Familial factors may confound these associations. OBJECTIVE: To examine the role of measured and unmeasured confounding by conducting a study that compared differentially exposed cousins and siblings from the same families. METHODS: We retrieved data on adverse pregnancy outcomes, prescribed drugs, and physician-diagnosed asthma from nationwide registers for all women in Sweden with singleton births between 2001 and 2013. Logistic and linear regression estimated the association between maternal asthma and several outcomes in the whole population and within differently exposed pregnant relatives. RESULTS: In total, 1,075,153 eligible pregnancies were included and 10.1% of the study population had asthma. We identified 475,200 cousin and 341,205 sister pregnancies. Women with asthma had increased risks for preeclampsia (adjusted odds ratio [aOR], 1.17; 95% CI, 1.13-1.21), emergency cesarean section (aOR, 1.24; 95% CI, 1.22-1.27), and having a child small for gestational age (aOR, 1.18; 95% CI, 1.12-1.23). In the conditional regression analyses, after adjustment for familial factors, the associations remained: preeclampsia in cousins (aOR, 1.16; 95% CI, 1.07-1.25) and siblings (aOR, 1.23; 95% CI, 1.08-1.38), emergency cesarean section in cousins (aOR, 1.28) and siblings (aOR, 1.21), and small for gestational age in cousins (aOR, 1.17) and siblings (aOR, 1.13). CONCLUSIONS: Factors shared by siblings and cousins do not seem to explain the observed association between maternal asthma and adverse pregnancy outcomes. This implies that targeting the asthma disease will continue to be important in reducing risks for adverse outcomes in pregnancy</style></abstract><notes><style face="normal" font="default">DA - 20171009IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Sweden -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28988783">PM:28988783</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171009, Rejno G</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.036</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42854</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zagursky,R.J.</style></author><author><style face="normal" font="default"> Pichichero,M.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Rochester General Hospital Research Institute, Center for Infectious Diseases and Immunology, Rochester, NY</style></auth-address><titles><title><style face="normal" font="default">Cross-reactivity in beta-Lactam Allergy</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="10" Year="2017">2017/10/7</year></dates><abstract><style face="normal" font="default">beta-Lactam drugs (penicillins, amoxicillin, and cephalosporins) account for 42.6% of all severe drug-induced anaphylaxis. In this review, we focus on clinically significant immunologic cross-reactivity in patients with confirmed penicillin allergy to cephalosporins, and the structural involvement of the R1 and R2 chemical side chains of the cephalosporins causing IgE-mediated cross-reactivity with penicillin and other cephalosporins. Skin tests predict IgE-mediated reactions and showed cross-reactivity between penicillins and early generation cephalosporins that shared side chains, but confirmatory challenge data are lacking. Later-generation cephalosporins, which have distinct side chains, do not have any skin test cross-reactivity with penicillin/amoxicillin. There is debate as to the involvement of R2 side chains as the antigenic determinants that cause IgE-mediated hypersensitivity with various cephalosporins. Avoidance of cephalosporins, when they are the drug of choice in a penicillin-allergic individual, results in significant morbidity that outweighs the low risk of anaphylaxis. We conclude that there is ample evidence to allow the safe use of cephalosporins in patients with isolated confirmed penicillin or amoxicillin allergy</style></abstract><notes><style face="normal" font="default">DA - 20171011IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29017833">PM:29017833</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171011, Zagursky RJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42855</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Song,W.J.</style></author><author><style face="normal" font="default"> Wong,G.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Changing trends and challenges in the management of asthma in Asia</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171001IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - South Korea -CO - Hong Kong -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.09.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28964883">PM:28964883</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171001-SongWJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171001-SongWJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171001, Song WJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.09.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42856</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gaffin,J.M.</style></author><author><style face="normal" font="default"> Hauptman,M.</style></author><author><style face="normal" font="default"> Petty,C.R.</style></author><author><style face="normal" font="default"> Sheehan,W.J.</style></author><author><style face="normal" font="default"> Lai,P.S.</style></author><author><style face="normal" font="default"> Wolfson,J.M.</style></author><author><style face="normal" font="default"> Gold,D.R.</style></author><author><style face="normal" font="default"> Coull,B.A.</style></author><author><style face="normal" font="default"> Koutrakis,P.</style></author><author><style face="normal" font="default"> Phipatanakul,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Respiratory Diseases, Boston Children's Hospital, Boston, MA, USA</style></auth-address><titles><title><style face="normal" font="default">Nitrogen Dioxide Exposure in School Classrooms of Inner-City Children with Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="10" Year="2017">2017/10/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Ambient and home exposure to nitrogen dioxide (NO2) causes asthma symptoms and decreased lung function in children with asthma. Little is known about the health effects of school classroom pollution exposure. OBJECTIVE: We aimed to determine the effect of indoor classroom NO2 on lung function and symptoms of inner-city schoolchildren with asthma. METHODS: Children enrolled in the School Inner City Asthma Study were followed for one academic year. Subjects performed spirometry and fractional exhaled nitric oxide (FeNO) twice during the school year, at school. Classroom NO2 was collected by passive sampling for 1 week periods, twice per year coinciding with lung function testing. Generalized estimating equation models assessed lung function and symptom relationships with the temporally nearest classroom NO2 level. RESULTS: NO2 mean values were 11.1ppb (range 4.3 - 29.7ppb). In total, exposure data was available for 296 subjects; 188 with complete spirometry data. Above a threshold of 8ppb NO2, and after adjusting for race and season (spirometry standardized by age, height, and gender), NO2 was highly associated with airflow obstruction such that each 10ppb rise in NO2 was associated with a 5% decline in FEV1/FVC (beta: -0.05, 95% confidence interval (CI) [-0.08, -0.02], p=0.01). FEF25-75% predicted was also inversely associated with higher NO2 exposure (beta: -22.8, 95%CI [-36.0, -9.7], p=0.01). There was no significant association of NO2 with FEV1% predicted, FeNO or asthma symptoms. Additionally, there was no effect modification of atopy on lung function or symptom outcomes. CONCLUSION: In children with asthma, indoor classroom NO2 may be associated with increased airflow obstruction</style></abstract><notes><style face="normal" font="default">DA - 20171009IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.08.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28988796">PM:28988796</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171009-GaffinJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171009-GaffinJM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171009, Gaffin JM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.08.028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42857</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,Y.</style></author><author><style face="normal" font="default"> Gevaert,E.</style></author><author><style face="normal" font="default"> Lou,H.</style></author><author><style face="normal" font="default"> Wang,X.</style></author><author><style face="normal" font="default"> Zhang,L.</style></author><author><style face="normal" font="default"> Bachert,C.</style></author><author><style face="normal" font="default"> Zhang,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology Head and Neck Surgery, Beijing TongRen Hospital; Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology</style></auth-address><titles><title><style face="normal" font="default">Chronic rhinosinusitis in Asia</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="10" Year="2017">2017/10/4</year></dates><abstract><style face="normal" font="default">Chronic rhinosinusitis (CRS), although possibly overdiagnosed, is associated with a high burden of disease and is often difficult to treat in those truly affected. Recent research has demonstrated that inflammatory signatures of CRS vary around the world, with less eosinophilic and more neutrophilic inflammation found in Asia compared with Europe and North America. Although in the Western world about 80% of nasal polyps carry a type 2 signature, this might be between 20% and 60% in China and Korea or Thailand, respectively. These differences are associated with a lower asthma comorbidity and risk of disease recurrence after surgery in the Asian population. As a hallmark of severe type 2 inflammation, eosinophils attacking Staphylococcus aureus at the epithelial barrier have been described recently; they also can be found in a subgroup of Asian patients with nasal polyps. Furthermore, the percentage of type 2 signature disease in patients with CRS is dramatically increasing ("eosinophilic shift") in several Asian countries over the last 20 years. Establishing an accurate diagnosis along with considering the current and shifting patterns of inflammation seen in Asia will enable more effective selection of appropriate pharmacotherapy, surgical therapy, and eventually biotherapy. Determining the causes and pathophysiology for this eosinophilic shift will require additional research</style></abstract><notes><style face="normal" font="default">DA - 20171008IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - China -CO - Sweden -CO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.09.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28987810">PM:28987810</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171008-ZhangY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171008-ZhangY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171008, Zhang Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.09.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42858</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Agache,I.</style></author><author><style face="normal" font="default"> Strasser,D.S.</style></author><author><style face="normal" font="default"> Pierlot,G.M.</style></author><author><style face="normal" font="default"> Farine,H.</style></author><author><style face="normal" font="default"> Izuhara,K.</style></author><author><style face="normal" font="default"> Akdis,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Medicine, Transylvania University, Brasov, Romania.</style></auth-address><titles><title><style face="normal" font="default">Monitoring the inflammatory heterogeneity with multiple biomarkers for multidimensional endotyping of asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="10" Year="2017">2017/10/5</year></dates><abstract><style face="normal" font="default">The complexity of type 2 and non-type 2 asthma requires monitoring with multiple biomarkers. We evaluated the potential of multidimensional endotyping to characterise physio-pathological clusters based on asthma severity and intensity of the blood eosinophilia</style></abstract><notes><style face="normal" font="default">DA - 20171008IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Romania -CO - Switzerland -CO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.08.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28987809">PM:28987809</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171008-AgacheI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171008-AgacheI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171008, Agache I</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.08.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42859</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Westerhof,G.A.</style></author><author><style face="normal" font="default"> Bel,E.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default">Reply (Refers to: Comments on clinical predictors of remission and persistence of adult-onset asthma)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="9" Year="2017">2017/9/26</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171002IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.07.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28967480">PM:28967480</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171002-WesterhofGA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171002-WesterhofGA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171002, Westerhof GA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.07.037</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42860</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Harford,T.J.</style></author><author><style face="normal" font="default"> Rezaee,F.</style></author><author><style face="normal" font="default"> Scheraga,R.G.</style></author><author><style face="normal" font="default"> Olman,M.A.</style></author><author><style face="normal" font="default"> Piedimonte,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Pediatric Research, Pediatric Institute and Children's Hospital, The Cleveland Clinic, Cleveland, Ohio</style></auth-address><titles><title><style face="normal" font="default">Asthma predisposition and respiratory syncytial virus infection modulate transient receptor potential vanilloid 1 function in children's airways</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="9" Year="2017">2017/9/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171006IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.07.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28982576">PM:28982576</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171006-HarfordTJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171006-HarfordTJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171006, Harford TJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.07.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42861</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lajunen,T.K.</style></author><author><style face="normal" font="default"> Jaakkola,J.J.K.</style></author><author><style face="normal" font="default"> Jaakkola,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Environmental and Respiratory Health Research (CERH), University of Oulu, P.O. Box 5000, FI-90014 Oulu, Finland</style></auth-address><titles><title><style face="normal" font="default">Interleukin 6 polymorphisms modify the effects of smoking on the risk of adult asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="10" Year="2017">2017/10/5</year></dates><abstract><style face="normal" font="default">Our findings highlight the importance of IL-6 in the pathogenesis of asthma and imply that the GG genotype in rs1800797 and/or rs1800795 polymorphism may predispose to the adverse effects of smoking on adult asthma</style></abstract><notes><style face="normal" font="default">DA - 20171008IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.09.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28987812">PM:28987812</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171008-LajunenTK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171008-LajunenTK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171008, Lajunen TK</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.09.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42862</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,H.K.</style></author><author><style face="normal" font="default"> Yoon,K.C.</style></author><author><style face="normal" font="default"> Seo,K.Y.</style></author><author><style face="normal" font="default"> Ueta,M.</style></author><author><style face="normal" font="default"> Kim,M.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea; Laboratory of Ocular Regenerative Medicine and Immunology, Seoul Artificial Eye Center, Seoul National University Hospital Clinical Research Institute, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Chronic ocular complications of Stevens-Johnson syndrome associated with causative medications in Korea</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="10" Year="2017">2017/10/4</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171009IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - South Korea -CO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.09.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28988785">PM:28988785</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171009, Lee HK</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.09.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42863</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Salas,M.</style></author><author><style face="normal" font="default"> Fernandez-Santamaria,R.</style></author><author><style face="normal" font="default"> Mayorga,C.</style></author><author><style face="normal" font="default"> Barrionuevo,E.</style></author><author><style face="normal" font="default"> Ariza,A.</style></author><author><style face="normal" font="default"> Posadas,T.</style></author><author><style face="normal" font="default"> Laguna,J.J.</style></author><author><style face="normal" font="default"> Montanez,M.I.</style></author><author><style face="normal" font="default"> Molina,N.</style></author><author><style face="normal" font="default"> Fernandez,T.D.</style></author><author><style face="normal" font="default"> Torres,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Unit, IBIMA-Regional University Hospital of Malaga UMA, Malaga, Spain</style></auth-address><titles><title><style face="normal" font="default">Use of the Basophil Activation Test May Reduce the Need for Drug Provocation in Amoxicillin-Clavulanic Allergy</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Reports of selective reactions to clavulanic acid (CLV) have increased in recent decades because of its increased prescription in combination with amoxicillin (AX) as AX-CLV. Basophil activation test (BAT) is used for diagnosing beta-lactam immediate hypersensitivity and is the only available in vitro assay for diagnosing patients with immediate hypersensitivity to CLV. However, few studies, and with limited numbers of patients have been published. OBJECTIVE: The aim of this study was to establish the sensitivity, specificity, and negativization rates of BAT to AX and CLV. METHODS: We studied 115 patients with immediate allergic reactions after AX-CLV treatment, 57 with selective reactions to AX (group A), 58 with selective reactions to CLV (group B), and 28 tolerant subjects. BAT was performed with AX in group A and with CLV in group B. A 4-year follow-up study was performed in patients with an initial positive BAT result. RESULTS: The overall sensitivity of BAT was 55%, specificity 89%, and positive predictive value (PPV) 96%. For group A, sensitivity was 47%, specificity 93%, and PPV 93%; for group B, sensitivity was 62%, specificity 89%, and PPV 92%. Follow-up study showed a faster negativization rate of BAT for group A, with around 40% of patients becoming negative at 12 months in both groups. CONCLUSIONS: The high PPV of BAT to CLV shows its potential value as a complementary tool to the allergological workup of patients with immediate allergic reactions after AX-CLV treatment. Importantly, the assay should be done within the first 12 months after the reaction to reduce false-negative results</style></abstract><notes><style face="normal" font="default">DA - 20171001IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28964705">PM:28964705</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171001, Salas M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42864</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Forno,E.</style></author><author><style face="normal" font="default"> Han,Y.Y.</style></author><author><style face="normal" font="default"> Mullen,J.</style></author><author><style face="normal" font="default"> Celedon,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary Medicine, Allergy and Immunology, Department of Pediatrics, Children's Hospital of Pittsburgh of UPMC, University of Pittsburgh, Pittsburgh, Pa.</style></auth-address><titles><title><style face="normal" font="default">Overweight, Obesity, and Lung Function in Children and Adults-A Meta-analysis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="9" Year="2017">2017/9/26</year></dates><abstract><style face="normal" font="default">BACKGROUND: There is conflicting evidence on the effect of obesity on lung function in adults and children with and without asthma. We aimed to evaluate the relation between overweight or obesity and lung function, and whether such relationship varies by age, sex, or asthma status. METHODS: We searched PubMed, Scopus, CINAHL, Cochrane, and EMBASE for all studies (in English) reporting on obesity status (by body mass index) and lung function, from 2005 to 2017. Main outcomes were forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC, forced expiratory flow between 25th and 75th percentile of the forced vital capacity (FEF25-75), total lung capacity (TLC), residual volume (RV), and functional residual capacity (FRC). Random-effects models were used to calculate the pooled risk estimates; each study was weighed by the inverse effect size variance. For each outcome, we compared overweight or obese ("obese") subjects with those of normal weight. RESULTS: All measures of lung function were decreased among obese subjects. Obese adults showed a pattern (lower FEV1, FVC, TLC, and RV) different from obese children (more pronounced FEV1/FVC deficit with unchanged FEV1 or FVC). There were also seemingly different patterns by asthma status, in that subjects without asthma had more marked decreases in FEV1, TLC, RV, and FRC than subjects with asthma. Subjects who were obese (as compared with overweight) had even further decreased FEV1, FVC, TLC, RV, and FRC. CONCLUSIONS: Obesity is detrimental to lung function, but specific patterns differ between children and adults. Physicians should be aware of adverse effects of obesity on lung function, and weight control should be considered in the management of airway disease among the obese</style></abstract><notes><style face="normal" font="default">DA - 20171002IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28967546">PM:28967546</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171002, Forno E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42865</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Goujon,C.</style></author><author><style face="normal" font="default"> Viguier,M.</style></author><author><style face="normal" font="default"> Staumont-Salle,D.</style></author><author><style face="normal" font="default"> Bernier,C.</style></author><author><style face="normal" font="default"> Guillet,G.</style></author><author><style face="normal" font="default"> Lahfa,M.</style></author><author><style face="normal" font="default"> Ferrier Le Bouedec,M.C.</style></author><author><style face="normal" font="default"> Cambazard,F.</style></author><author><style face="normal" font="default"> Bottigioli,D.</style></author><author><style face="normal" font="default"> Grande,S.</style></author><author><style face="normal" font="default"> Dahel,K.</style></author><author><style face="normal" font="default"> Berard,F.</style></author><author><style face="normal" font="default"> Rabilloud,M.</style></author><author><style face="normal" font="default"> Mercier,C.</style></author><author><style face="normal" font="default"> Nicolas,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergology and Immunology, Clinical Research Unit, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Benite, France.</style></auth-address><titles><title><style face="normal" font="default">Methotrexate Versus Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="9" Year="2017">2017/9/26</year></dates><abstract><style face="normal" font="default">BACKGROUND: Methotrexate is currently used to treat atopic dermatitis but has never been assessed versus cyclosporine in adults. OBJECTIVE: This study evaluated the efficacy and safety of methotrexate versus cyclosporine in patients with moderate-to-severe atopic dermatitis. METHODS: Patients were randomized to receive either oral methotrexate (15 mg/wk) or cyclosporine (2.5 mg/kg/d) for 8 weeks. The primary end point was a patient achieving 50% improvement in the SCORing Atopic Dermatitis index (SCORAD 50) at week 8. When the primary end point was not achieved, methotrexate was increased to 25 mg and cyclosporine to 5 mg during the next 16 weeks. The secondary end points were a patient achieving a 50% reduction in the Eczema Area Severity Intensity index (EASI 50) and SCORAD 50 at each visit (ClinicalTrials.gov no. NCT00809172). RESULTS: A total of 97 patients received methotrexate 15 mg (n = 50) or cyclosporine 2.5 mg (n = 47). Regarding the primary end point at week 8, methotrexate was inferior to cyclosporine because the proportion of patients with SCORAD 50 was 8% (4 of 50) in the methotrexate arm versus 42% (18 of 43) in the cyclosporine arm. The difference in percentages for the 2 treatment groups (2-sided 90% CI) was -34% (-48% to -20%). At week 8, methotrexate and cyclosporine dosages were increased in 56% and 49% of the patients, respectively. Regarding EASI 50, the noninferiority end point was reached at week 20 in 92% (22 of 24) of patients in the methotrexate arm and 87% (26 of 30) of patients in the cyclosporine arm. The treatment-related adverse events were more frequent with cyclosporine (P &lt; .0001). CONCLUSIONS: Methotrexate 15 mg/wk was inferior to cyclosporine 2.5 mg/kg/d at week 8. Increasing the doses of methotrexate to 25 mg/wk induced a significant improvement versus cyclosporine at week 20</style></abstract><notes><style face="normal" font="default">DA - 20171002IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28967549">PM:28967549</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171002, Goujon C</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42866</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lindstrom,I.</style></author><author><style face="normal" font="default"> Karvonen,H.</style></author><author><style face="normal" font="default"> Suuronen,K.</style></author><author><style face="normal" font="default"> Suojalehto,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Occupational Medicine, Finnish Institute of Occupational Health, Helsinki, Finland.</style></auth-address><titles><title><style face="normal" font="default">Occupational asthma from biological pest control in greenhouses</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="10" Year="2017">2017/10/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171014IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29030000">PM:29030000</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171014, Lindstrom I</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.034</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42867</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sullivan,K.E.</style></author><author><style face="normal" font="default"> Crowley,T.B.</style></author><author><style face="normal" font="default"> Maurer,K.</style></author><author><style face="normal" font="default"> Goldmuntz,E.</style></author><author><style face="normal" font="default"> Gaynor,J.W.</style></author><author><style face="normal" font="default"> Zackai,E.</style></author><author><style face="normal" font="default"> Donald-McGinn,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy Immunology, Department of Pediatrics, the Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine, Philadelphia, Pa.</style></auth-address><titles><title><style face="normal" font="default">T-cell lymphopenia in 22q11.2 deletion syndrome: Relationship to cardiac disease</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171001IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28964704">PM:28964704</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171001, Sullivan KE</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42868</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,C.H.</style></author><author><style face="normal" font="default"> Dilokthornsakul,P.</style></author><author><style face="normal" font="default"> Campbell,J.D.</style></author><author><style face="normal" font="default"> van Boven,J.F.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Denver, Colo</style></auth-address><titles><title><style face="normal" font="default">Asthma Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in Estimating Value?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="9" Year="2017">2017/9/26</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma medication cost-effectiveness analyses (CEAs) lack the qualitative assessment regarding whether they capture the National Institutes for Health (NIH) 2012 recommended outcomes necessary to allow robust cross-study comparisons. OBJECTIVE: We aimed to assess the current asthma outcomes used in CEAs and recommend a direction for improvement. METHODS: We performed a systematic search using electronic databases including PubMed, EMBASE, Tufts CEA registry, Cochrane, and NHSEED from January 2010 through December 2015. Key words included (1) cost-effectiveness, cost-utility, economic evaluation, health economics, or cost-benefit AND (2) asthma. All CEA studies evaluating 1 or more asthma medication were included. Authors assessed each CEA study with respect to asthma-specific NIH outcome recommendations including core (hospitalizations, emergency department visits, outpatient visits, medication, interventions costs), supplemental (visit categories and work/school absence), and emerging (academic/job-related) asthma outcomes. Besides outcomes of each CEA, issues that could prevent robust cross-study comparison were identified and thematically summarized. RESULTS: A total of 12 pre-NIH and 14 post-NIH recommendation CEAs were included. Eleven (91.7%) and 14 (100%) of the pre-/post-NIH studies included at least 1 core outcome, respectively. Of the 26 total studies, 7 (26.9%) included asthma-specific outpatient visit categories, 6 (23.1%) included asthma school or work absences, 5 (19.2%) included respiratory health care use, and none of the studies included emerging outcomes. Other issues that hamper cross-study comparison include lack of standardized cost data, time frames, quality-of-life measures, and incorporation of adherence. CONCLUSIONS: Although the use of NIH-recommended asthma core outcomes has improved, there is still room for improvement in using supplemental and emerging outcomes. To allow robust cross-study comparisons, future work should focus on further standardizing of data sources and methods</style></abstract><notes><style face="normal" font="default">DA - 20171002IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28967548">PM:28967548</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171002, Kim CH</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42869</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rogers,L.</style></author><author><style face="normal" font="default"> Sugar,E.A.</style></author><author><style face="normal" font="default"> Blake,K.</style></author><author><style face="normal" font="default"> Castro,M.</style></author><author><style face="normal" font="default"> Dimango,E.</style></author><author><style face="normal" font="default"> Hanania,N.A.</style></author><author><style face="normal" font="default"> Happel,K.I.</style></author><author><style face="normal" font="default"> Peters,S.P.</style></author><author><style face="normal" font="default"> Reibman,J.</style></author><author><style face="normal" font="default"> Saams,J.</style></author><author><style face="normal" font="default"> Teague,W.G.</style></author><author><style face="normal" font="default"> Wise,R.A.</style></author><author><style face="normal" font="default"> Holbrook,J.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Icahn School of Medicine at Mt Sinai, New York, NY</style></auth-address><titles><title><style face="normal" font="default">Step-Down Therapy for Asthma Well Controlled on Inhaled Corticosteroid and Long-Acting Beta-Agonist: A Randomized Clinical Trial</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="9" Year="2017">2017/9/30</year></dates><abstract><style face="normal" font="default">BACKGROUND: Stepping down therapy when asthma is well controlled on combination inhaled corticosteroids (ICSs) and long-acting beta-agonists (LABAs) is recommended, but it is not known whether lowering the ICS dose or stopping LABA is superior. OBJECTIVE: To evaluate whether step-down therapy with LABA is superior to one without; and, secondarily, to evaluate whether reducing the ICS dose while maintaining LABA is noninferior to remaining on stable-ICS/LABA. METHODS: The study was a randomized, double-masked 3-arm parallel group trial in participants aged 12 years or older. Following an 8-week run-in, 459 participants were randomly assigned to continue medium-dose ICS/LABA, reduced-dose ICS/LABA, or ICS alone (LABA-step-off) and followed for 48 weeks. The primary outcome was time to treatment failure, a composite of health care utilization, systemic corticosteroid use, increase in rescue therapy, decline in lung function, or participant or physician decision. RESULTS: Time to treatment failure did not differ significantly between reduced- ICS/LABA and LABA-step-off (hazard ratio, 1.07; 95.3% CI, 0.69-1.65, P = .76). Nor was there a difference between stable-ICS/LABA and reduced-ICS/LABA (hazard ratio, 1.11; 95% CI, 0.70-1.76; P = .67), but the 10% noninferiority margin was exceeded. Lung function declines and hospitalization rates were significantly greater in the LABA-step-off group. CONCLUSIONS: The 2 step-down regimens did not differ in terms of treatment failure, although stopping LABA was associated with a decline in lung function and more hospitalizations. There was no evidence to support the noninferiority of reduced-ICS/LABA as compared with stable-ICS/LABA</style></abstract><notes><style face="normal" font="default">DA - 20171004IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28974349">PM:28974349</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171004, Rogers L</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.030</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42870</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Otani,I.M.</style></author><author><style face="normal" font="default"> Lax,T.</style></author><author><style face="normal" font="default"> Long,A.A.</style></author><author><style face="normal" font="default"> Slawski,B.R.</style></author><author><style face="normal" font="default"> Camargo,C.A.,Jr.</style></author><author><style face="normal" font="default"> Banerji,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, University of California San Francisco, San Francisco, Calif.</style></auth-address><titles><title><style face="normal" font="default">Utility of Risk Stratification for Paclitaxel Hypersensitivity Reactions</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="3" Month="10" Year="2017">2017/10/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hypersensitivity reactions (HSRs) are a common impediment to paclitaxel therapy. Management strategies to guide care after a paclitaxel-induced HSR are needed. OBJECTIVE: The objective was to evaluate the utility and safety of risk stratification on the basis of severity of the initial HSR. METHODS: A risk stratification pathway was developed on the basis of a retrospective review of the management and outcome of 130 patients with paclitaxel-induced HSRs at Massachusetts General Hospital. This pathway was then studied prospectively in patients referred to Allergy/Immunology with paclitaxel-induced HSRs. RESULTS: The study population (n = 35) had a mean age of 56.1 +/- 12 years and most were women (n = 33 [94%]). All 5 patients (15%) with grade 1 initial HSRs were successfully reexposed to paclitaxel, 1 patient at the standard infusion rate and 4 patients at 50% of the standard infusion rate. Thirty patients (85%) with grade 2 to 4 initial HSRs underwent initial paclitaxel desensitization based on the risk stratification pathway. No patients developed severe HSRs using the pathway. Eleven (31%) patients had HSRs that were mild to moderate in nature (grade 1, n = 4 [11%]; grade 2, n = 6 [17%]; grade 3, n = 1 [3%]) during their first desensitization. Sixteen (46%) of the 35 patients safely returned to the outpatient infusion setting for paclitaxel treatment at 50% of the standard infusion rate. Seven (20%) discontinued paclitaxel before the completion of the risk stratification pathway because of disease progression, completion of therapy, or death. CONCLUSIONS: A management strategy using the initial HSR severity for risk stratification allowed patients to receive paclitaxel safely</style></abstract><notes><style face="normal" font="default">DA - 20171007IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28986119">PM:28986119</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171007, Otani IM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42871</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Blanca-Lopez,N.</style></author><author><style face="normal" font="default"> Haroun-Diaz,E.</style></author><author><style face="normal" font="default"> Ruano,F.J.</style></author><author><style face="normal" font="default"> Perez-Alzate,D.</style></author><author><style face="normal" font="default"> Somoza,M.L.</style></author><author><style face="normal" font="default"> Vazquez de la Torre Gaspar,M.</style></author><author><style face="normal" font="default"> Rivas-Ruiz,F.</style></author><author><style face="normal" font="default"> Garcia-Martin,E.</style></author><author><style face="normal" font="default"> Blanca,M.</style></author><author><style face="normal" font="default"> Canto,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Service, Infanta Leonor University Hospital, Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default">Acetyl Salicylic Acid Challenge in Children with Hypersensitivity Reactions to Nonsteroidal Anti-Inflammatory Drugs Differentiates Between Cross-Intolerant and Selective Responders</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="3" Month="10" Year="2017">2017/10/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) in children are becoming a great concern. Most studies have focused on adults, with noted discrepancies observed in the classification of hypersensitivity reactions to NSAIDs in children when compared with adults. OBJECTIVE: To phenotype a group of children with hypersensitivity reactions to NSAIDs, including paracetamol, and analyze the degree of agreement with the entities reported in adults and how they fit the proposed classifications. METHODS: The study comprised 116 children aged 0.5 to 14 years, with a clinical history indicative of hypersensitivity reactions to NSAIDs. They all underwent a single-blind oral provocation test with acetyl salicylic acid, except in those cases when this was the suspected drug, in which case the challenge was done first with ibuprofen. If positive, cross-intolerance was established and if negative, an oral provocation test with the culprit drug was performed to establish a selective response or exclude allergy. RESULTS: Of the 26% diagnosed as hypersensitive to NSAIDs, 83% were cross-intolerant and 17% selective reactors. The highest significant differences between reactors and nonreactors were observed in the time to reaction after drug intake and the clinical entity (P &lt; .0001), followed by drug involved and age (P &lt; .01). CONCLUSIONS: From the total number of cases confirmed with NSAID hypersensitivity, 83% were cross-intolerant. In cross-intolerant reactions, both cutaneous and respiratory manifestations are common. Acetyl salicylic acid challenge as the first approach proved to be safe and useful to establish the diagnosis</style></abstract><notes><style face="normal" font="default">DA - 20171007IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28986120">PM:28986120</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171007, Blanca-Lopez N</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42872</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Panganiban,C.M.</style></author><author><style face="normal" font="default"> Pourang,D.</style></author><author><style face="normal" font="default"> Samant,S.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Kaiser Permanente Los Angeles Medical Center, Los Angeles, Calif.</style></auth-address><titles><title><style face="normal" font="default">A novel 2-day desensitization protocol to oral mesalamine</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="9" Year="2017">2017/9/30</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171004IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28974350">PM:28974350</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171004, Panganiban CM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.036</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42873</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arroyo,A.J.C.</style></author><author><style face="normal" font="default"> Chee,C.P.</style></author><author><style face="normal" font="default"> Camargo,C.A.,Jr.</style></author><author><style face="normal" font="default"> Wang,N.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass.</style></auth-address><titles><title><style face="normal" font="default">Where do children die from asthma? National data from 2003 to 2015</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="9" Year="2017">2017/9/29</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171003IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28970087">PM:28970087</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171003, Arroyo AJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.032</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42874</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Goodwin,J.L.</style></author><author><style face="normal" font="default"> Gerald,L.B.</style></author><author><style face="normal" font="default"> Johnson,J.L.H.</style></author><author><style face="normal" font="default"> Gerald,J.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Asthma and Airways Disease Research Center, University of Arizona, Tucson, Ariz.</style></auth-address><titles><title><style face="normal" font="default">Use of a disposable valved-holding chamber (spacer) in a school-based asthma trial</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="9" Year="2017">2017/9/29</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171003IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28970085">PM:28970085</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171003, Goodwin JL</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42875</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Boozalis,E.</style></author><author><style face="normal" font="default"> Patel,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA</style></auth-address><titles><title><style face="normal" font="default">"Allergen of the Year" alkyl glucoside is an ingredient in top-selling sunscreens and facial moisturizers</style></title><secondary-title><style face="normal" font="default">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="10" Year="2017">2017/10/14</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171018IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaad.2017.10.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29042229">PM:29042229</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am Acad Dermatol\20171018-BoozalisE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Am Acad Dermatol\20171018-BoozalisE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171018, Boozalis E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaad.2017.10.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42876</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Karampitsakos,T.</style></author><author><style face="normal" font="default"> Protopapas,A.</style></author><author><style face="normal" font="default"> Gianoloudi,M.</style></author><author><style face="normal" font="default"> Papadopoulos,V.P.</style></author><author><style face="normal" font="default"> Bouros,D.</style></author><author><style face="normal" font="default"> Chatzimichael,A.</style></author><author><style face="normal" font="default"> Paraskakis,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Paediatrics , University Hospital of Alexandroupolis, Democritus University of Thrace , Alexandroupolis , Greece</style></auth-address><titles><title><style face="normal" font="default">The effect of bronchodilation and spirometry on fractional exhaled nitric oxide (FeNO50), bronchial NO flux (JawNO) and alveolar NO concentration (CANO) in children and young adults</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="9" Year="2017">2017/9/26</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Fractional exhaled nitric oxide (FeNO), bronchial nitric oxide (JawNO) and alveoar nitric oxide (CANO) are biomarkers of eosinophilic inflammation, usually measured simultaneously with spirometry and bronchodilation. Our aim was to investigate the effect of bronchodilation and spirometry on FeNO, CANO and JawNO in children and young adults with well-controlled asthma and in healthy volunteers. METHODS: FeNO was measured in 95 subjects (62 controls, 33 asthmatics). CANO and JawNO were assessed in 41 of the subjects (35 healthy, 6 asthmatics.) Measurements were performed before spirometry (1), right after spirometry (2), 20 min after the first spirometry and bronchodilation (3), right after the post-bronchodilation spirometry (4) and 30 min after the last spirometry (5). RESULTS: The presence of well-controlled asthma was not associated with different pattern of reaction after spirometry and bronchodilation. A statistically significant difference was observed only between FeNO4 and FeNO5, as well as between CANO1 and CANO3 (19.14 +/- 1.68 vs 20.62 +/- 1.85 ppb, p = 0.001 and 4.42 +/- 0.40 vs 3.09+/-0.32 ppb, p = 0.001, respectively). CONCLUSIONS: Spirometry and bronchodilation have an insignificant effect on FeNO and JawNO. Even if a slight change occurs in FeNO and JawNO, this does not modify clinician's decision and therapeutic strategy. CANO values (CANO1) are significantly decreased 20 min after spirometry and bronchodilation</style></abstract><notes><style face="normal" font="default">DA - 20170926IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1373807</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28949783">PM:28949783</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170926-KarampitsakosT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170926-KarampitsakosT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170926, Karampitsakos T</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1373807</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42877</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chung,J.H.</style></author><author><style face="normal" font="default"> Han,C.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Internal Medicine , International St. Mary`s Hospital, Catholic Kwandong University College of Medicine , Incheon , Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Health Related Quality of Life in relation to Asthma - Data from a Cross Sectional Study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="10" Year="2017">2017/10/4</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The aim of this study was to examine the effect of adult asthma on health-related quality of life (HRQoL) and psychological factors using the results of a cross-sectional nationwide survey. METHODS: Data were obtained from 229,131 participants (5,989 with asthma and 223,142 without asthma) in the 2010 Korean Community Health Survey. We compared EuroQol (EQ)-5D and EQ-visual analogue scale (VAS) scores after adjusting for sociodemographic and psychosocial factors, as well as for comorbidities. Multiple logistic regression analysis was used to explore determinants of the lowest quartile HRQoL in the asthma group. RESULTS: The mean EQ-5D and EQ-VAS scores were significantly lower in the asthma group (EQ-5D, 0.82; EQ-VAS, 64.2) compared with the non-asthma group (EQ-5D, 0.90; EQ-VAS, 73.2) (P &lt; 0.001). The multivariate odds ratio (OR) for the lowest quartile of EQ-VAS in the asthma group versus the non-asthma group was 1.17 (95% confidence interval (CI), 1.04-1.32) and the OR for the lowest quartile of EQ-5D in the asthma group versus the non-asthma group was 1.47 (95% CI, 1.18-1.84). Asthma subjects were more likely than those without asthma to have some or severe problems with pain (OR, 1.34; 95% CI, 1.16-1.56) and anxiety/depression (OR, 1.08; 95% CI, 1.03-1.56)</style></abstract><notes><style face="normal" font="default">DA - 20171004IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1387266</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28976222">PM:28976222</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171004-ChungJH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171004-ChungJH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171004, Chung JH</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1387266</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42878</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ferreira,D.S.</style></author><author><style face="normal" font="default"> Kaushik,S.</style></author><author><style face="normal" font="default"> Smith,C.L.</style></author><author><style face="normal" font="default"> Dharmage,S.C.</style></author><author><style face="normal" font="default"> Benke,G.P.</style></author><author><style face="normal" font="default"> Thompson,B.R.</style></author><author><style face="normal" font="default"> Walters,E.H.</style></author><author><style face="normal" font="default"> Wolfe,R.</style></author><author><style face="normal" font="default"> Abramson,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a School of Public Health &amp; Preventive Medicine, Monash University , Melbourne , Australia</style></auth-address><titles><title><style face="normal" font="default">Associations Of Atopy And Asthma During Aging Of An Adult Population Over A 20-year Follow-up</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="10" Year="2017">2017/10/4</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Atopy is associated with asthma, but cross-sectional studies suggest this association may be weaker in older adults. It remains unclear if atopy predicts asthma later in adult life. We aimed to investigate whether atopy in young adults predicted asthma 20 years later and to quantify the contemporaneous relationship of atopy and asthma as adults age. METHODS: Participants of the European Community Respiratory Health Survey (ECRHS) in [city; data removed for double-blind peer review] aged 20-44 years were followed for 20 years and completed questionnaires, skin prick tests (SPT) and allergen specific immunoglobulin E measurement at a baseline and two subsequent surveys. Using logistic regression and generalized estimating equations, we tested if atopy at baseline predicted current asthma later in life and estimated the association between current atopy measured at each survey and current asthma, while adjusting for potential confounders. RESULTS: The analysis included 220 participants: 50.9% male. Mean (SD) age at baseline was 35.7 (5.7) years. Asthma and atopy prevalence remained stable over 20 years. Baseline atopy (SPT) was associated with current asthma (OR 9.74, 95%CI 4.22, 22.5) over 20 years, and current atopy (SPT) with concurrent asthma (3.12; 1.70, 5.74). CONCLUSIONS: Atopy remains strongly associated with current asthma in 40 to 64 year-old adults, both prospectively and contemporaneously, but the prospective association is stronger</style></abstract><notes><style face="normal" font="default">DA - 20171004IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1386669</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28976229">PM:28976229</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171004-FerreiraDS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171004-FerreiraDS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171004, Ferreira DS</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1386669</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42879</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bernstein,D.</style></author><author><style face="normal" font="default"> Andersen,L.</style></author><author><style face="normal" font="default"> Forth,R.</style></author><author><style face="normal" font="default"> Jacques,L.</style></author><author><style face="normal" font="default"> Yates,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">a University of Cincinnati College of Medicine and Bernstein Clinical Research Center , Cincinnati , OH , USA</style></auth-address><titles><title><style face="normal" font="default">Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="9" Year="2017">2017/9/29</year></dates><abstract><style face="normal" font="default">OBJECTIVE: We aimed to demonstrate non-inferiority of once-daily fluticasone furoate/vilanterol 100/25 mug (FF/VI) to twice-daily fluticasone propionate/salmeterol 250/50 mug (FP/SAL) in adults/adolescents with asthma well controlled on inhaled corticosteroid/long-acting beta2 agonist (ICS/LABA). METHODS: This was a randomized, double-blind, double-dummy, parallel-group, 24-week study (NCT02301975/GSK study 201378). Patients whose asthma met study-defined criteria for control were randomized 1:1:1 to receive FF/VI, FP/SAL or twice-daily FP 250 mug for 24 weeks. Primary endpoint was change from baseline in evening trough forced expiratory volume in 1 second (FEV1). Secondary endpoints included rescue-/symptom-free 24-hour periods. Safety was also assessed. RESULTS: The intent-to-treat (ITT) population included 1504 randomized and treated patients (504 FF/VI; 501 FP/SAL; 499 FP); mean age 43.5 years, 64% female. FF/VI demonstrated non-inferiority (using a margin of -100 mL) to FP/SAL for evening trough FEV1 at Week 24 (ITT: 19 mL [95% confidence interval (CI) -11 to 49]; per protocol population [N = 1336]: 6 mL [95% CI -27 to 40]). Improvement in evening trough FEV1 at Week 24 for both FF/VI (123 mL; p &lt; 0.001) and FP/SAL (104 mL; p &lt; 0.001) was greater than FP. FF/VI increased rescue-/symptom-free 24-hour periods by 1.2%/1.2% compared with FP/SAL. All treatments were well tolerated. On-treatment adverse event (AE) rates were 43% to 45% across arms; there were no drug-related serious AEs. CONCLUSIONS: FF/VI was non-inferior to FP/SAL for evening trough FEV1 at 24 weeks. These data suggest that patients well controlled on FP/SAL could step across to FF/VI without loss of control</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1386214</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28961020">PM:28961020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170929-BernsteinD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170929-BernsteinD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Bernstein D</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1386214</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42880</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Xia,M.</style></author><author><style face="normal" font="default"> Xu,H.</style></author><author><style face="normal" font="default"> Dai,W.</style></author><author><style face="normal" font="default"> Zhu,C.</style></author><author><style face="normal" font="default"> Wu,L.</style></author><author><style face="normal" font="default"> Yan,S.</style></author><author><style face="normal" font="default"> Ge,X.</style></author><author><style face="normal" font="default"> Zhou,W.</style></author><author><style face="normal" font="default"> Chen,C.</style></author><author><style face="normal" font="default"> Dai,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pulmonary Medicine , Hangzhou Hospital of Traditional Chinese Medicine , Hangzhou , China</style></auth-address><titles><title><style face="normal" font="default">The role of HDAC2 in cigarette smoke-induced airway inflammation in a murine model of asthma and the effect of intervention with roxithromycin</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="9" Year="2017">2017/9/29</year></dates><abstract><style face="normal" font="default">BACKGROUND: Cigarette smoke is well known to worsen asthma symptoms in asthmatic patients and to make them refractory to treatment, but the underling molecular mechanism is unclear. We hypothesized that cigarette smoke can reduce the expression of HDAC2 in asthma and the process was achieved by activating the PI3K-delta/Akt signaling pathway. We further hypothesized that roxithromycin (RXM) can alleviate the impacts by cigarette smoke. METHODS: A murine model of asthma induced by ovalbumin (OVA) and cigarette smoke has been established. The infiltration of inflammatory cells and inflammatory factors was examined in this model. Finally, we evaluated the expression of HDAC2, Akt phosphorylation levels, and the effects of RXM treatment on the model described earlier. RESULTS: Cigarette smoke exposure reduced HDAC2 protein expression by enhancing the phosphorylation of Akt in PI3K-delta/Akt signaling pathway. Furthermore, RMX reduced the airway inflammation and improved the level of expression of HDAC2 in the cigarette smoke-exposed asthma mice. CONCLUSIONS: This study provides a novel insight into the mechanism of cigarette smoke exposure in asthma and the effects of RXM treatment on this condition. These results may be helpful for treating refractory asthma and emphasizing the need for a smoke-free environment for asthmatic patients</style></abstract><notes><style face="normal" font="default">DA - 20170929IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1337788</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28960099">PM:28960099</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20170929-XiaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20170929-XiaM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170929, Xia M</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1337788</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42881</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vianello,A.</style></author><author><style face="normal" font="default"> Caminati,M.</style></author><author><style face="normal" font="default"> Chieco-Bianchi,F.</style></author><author><style face="normal" font="default"> Marchi,M.R.</style></author><author><style face="normal" font="default"> Vio,S.</style></author><author><style face="normal" font="default"> Arcaro,G.</style></author><author><style face="normal" font="default"> Iovino,S.</style></author><author><style face="normal" font="default"> Braccioni,F.</style></author><author><style face="normal" font="default"> Molena,B.</style></author><author><style face="normal" font="default"> Turato,C.</style></author><author><style face="normal" font="default"> Peditto,P.</style></author><author><style face="normal" font="default"> Battistella,L.</style></author><author><style face="normal" font="default"> Gallan,F.</style></author><author><style face="normal" font="default"> Senna,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Respiratory Pathophysiology Division , University-City Hospital of Padova , Padova , Italy</style></auth-address><titles><title><style face="normal" font="default">Spontaneous Pneumomediastinum Complicating Severe Acute Asthma Exacerbation in Adult Patients</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="10" Year="2017">2017/10/9</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The real incidence of pneumomediastinum (PNM) in adult patients with severe acute asthma exacerbation continues to be unknown. The current study aims to investigate the occurrence of PNM in an adult population of patients presenting a severe asthma attack and to evaluate the risk factors associated to its development. METHODS: The 45 consecutive subjects who were admitted to our Division between January 1, 2015 and December 31, 2016 for severe acute asthma exacerbation underwent a diagnostic protocol including a standard chest X-ray and continuous monitoring of arterial oxygen saturation (SaO2) during the first 24 hours following admission. The patients showing persistence or deterioration of oxyhemoglobin desaturation were prescribed a chest Computed Tomographic (CT) scan. RESULTS: Five out of the 45 patients (11.1%) with severe acute asthma exacerbation were diagnosed with PNM, in one case on the basis of an X-ray image and in 4 on the basis of a chest CT scan. Data analysis showed that the PNM patients were younger [21(17-21) vs 49.5 (20-73) yrs; p&lt;0.001] and more likely to show sensitization to Alternaria (2/5 vs 0/40; p = 0.0101) with respect to their non-PNM counterparts. The duration of hospital stay was similar in the two groups [8 (4-12) vs 7 (3-15) days; p = 0.6939]. CONCLUSIONS: PNM is a common clinical entity in young adults with severe acute asthma exacerbation, particularly in those with unsatisfactory response to initial medical therapy. Although generally benign, patients with suspected PNM should be closely monitored because of the risk of developing severe hypoxemia</style></abstract><notes><style face="normal" font="default">DA - 20171009IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1388392</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28991498">PM:28991498</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171009-VianelloA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171009-VianelloA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171009, Vianello A</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1388392</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42882</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sullivan,P.W.</style></author><author><style face="normal" font="default"> Ghushchyan,V.H.</style></author><author><style face="normal" font="default"> Globe,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Regis University School of Pharmacy , Denver , CO</style></auth-address><titles><title><style face="normal" font="default">Estimating Asthma Control Questionnaire (ACQ) Scores from Claims Data</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="10" Year="2017">2017/10/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma control is the main focus of treatment guidelines. Valid instruments such as the Asthma Control Questionnaire (ACQ) require prospective survey. These surveys may be challenging for large population health applications. OBJECTIVE: To develop an algorithm for estimating ACQ-5 scores from commonly available claims data. METHODS: Data was derived from four prospective surveys including the ACQ-5 combined with retrospective claims of Kaiser Permanente of Colorado (KPCO) patients. The statistical approach consisted of derivation and validation of a prediction algorithm including medical and pharmacy claims data using stepwise regression elimination. Validation was conducted by estimating mean squared error (MSE) and mean absolute error (MAE) in one hundred split-sample iterations. Ordinary least squares (OLS), Tobit and Median regression were used. RESULTS: There were 2,657 individuals with valid ACQ-5 scores, claims and eligibility at baseline. The following had statistically significant associations with ACQ-5 scores: gender, use of oral corticosteroids and short-acting beta agonists, the number of asthma drug classes, and emergency and outpatient visits. Average MSE and MAE were similar for the estimation and validation samples. CONCLUSION: This research provides preliminary results of the feasibility of predicting ACQ-5 scores using commonly available medical and pharmacy claims data. The resulting algorithm may facilitate public health and population level analyses of asthma control. Future studies in different populations will be important to validate the algorithm</style></abstract><notes><style face="normal" font="default">DA - 20171004IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Armenia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1386670</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28976789">PM:28976789</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171004-SullivanPW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171004-SullivanPW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171004, Sullivan PW</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1386670</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42883</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,Z.G.</style></author><author><style face="normal" font="default"> Meng,P.</style></author><author><style face="normal" font="default"> Li,H.T.</style></author><author><style face="normal" font="default"> Li,M.</style></author><author><style face="normal" font="default"> Yang,L.F.</style></author><author><style face="normal" font="default"> Yan,Y.</style></author><author><style face="normal" font="default"> Li,Y.T.</style></author><author><style face="normal" font="default"> Zou,X.L.</style></author><author><style face="normal" font="default"> Wang,D.Y.</style></author><author><style face="normal" font="default"> Zhang,T.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pulmonary Diseases , The Third Affiliated Hospital of Sun Yat-Sen University, Institute of Respiratory Diseases of Sun Yat-Sen University , Guangzhou , China</style></auth-address><titles><title><style face="normal" font="default">Thymic stromal lymphopoietin contribution to the recruitment of circulating fibrocytes to the lung in a mouse model of chronic allergic asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="3" Month="10" Year="2017">2017/10/3</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Fibrocyte localization to the airways and thymic stromal lymphopoietin (TSLP) overexpression in the lung are features of severe asthma. The aim of this study was to determine whether TSLP contributes to fibrocyte trafficking and airway remodelling in a mouse model of allergic asthma. METHODS: We established a chronic asthma animal model by administering house dust mite (HDM) extracts intranasally for up to 5 consecutive weeks. Mouse anti-TSLP monoclonal antibody (mAb) was given intraperitoneally starting the 4th week. Fluorescence-labeled CD34/collagen I (Col I)-dual-positive fibrocytes were examined by confocal microscopy. The level of TGF-beta1 in the bronchoalveolar lavage (BAL) fluid was determined by ELISA. RESULTS: We found significantly increased levels of TSLP and TGF-beta1 in the lung of the mice subjected to repeated allergen exposure, which was accompanied by increased number of fibrocytes in the sub-epithelial zone and the BAL fluid. However, blocking TSLP markedly decreased the production of TGF-beta1, reduced the number of fibrocytes and subsequently prevented alterations of both airway and vascular structures. CONCLUSIONS: Our data suggested that TSLP might function in airway remodelling by promoting circulating fibrocyte recruitment to the lung in the mice subjected to chronic allergen exposure. These results provide a better rationale for targeting the interaction between TSLP and fibrocytes as a therapeutic approach for chronic allergic asthma</style></abstract><notes><style face="normal" font="default">DA - 20171003IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - China -CO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1386213</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28972433">PM:28972433</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171003-ChenZG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171003-ChenZG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171003, Chen ZG</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1386213</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42884</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sullivan,P.W.</style></author><author><style face="normal" font="default"> Ghushchyan,V.</style></author><author><style face="normal" font="default"> Navaratnam,P.</style></author><author><style face="normal" font="default"> Friedman,H.S.</style></author><author><style face="normal" font="default"> Kavati,A.</style></author><author><style face="normal" font="default"> Ortiz,B.</style></author><author><style face="normal" font="default"> Lanier,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Rueckert-Hartman College for Health Professions , Regis University School of Pharmacy , Denver , CO , USA</style></auth-address><titles><title><style face="normal" font="default">The national burden of poorly controlled asthma, school absence and parental work loss among school-aged children in the United States</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="10" Year="2017">2017/10/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The degree of poorly controlled asthma and its association with missed school days and parental missed work days is not well understood. METHODS: This was a retrospective analysis of missed school days and missed work days for school-aged children (SAC; aged 6-17) and their caregivers in the nationally representative 2007-2013 Medical Expenditure Panel Survey (MEPS). Indicators of poor asthma control included: exacerbation in previous 12 months; use of >3 canisters of short-acting beta agonist (SABA) in 3 months; and annual asthma-specific (AS) Emergency Department (ED) or inpatient (IP) visits. Negative binomial regression was used for missed school days, and a Heckman two-step selection model was used for missed work days. All analyses controlled for sociodemographics and other covariates. RESULTS: There were 44,320 SAC in MEPS, of whom 5,890 had asthma. SAC with asthma and an indicator of poor control missed more school days than SAC without asthma: exacerbation (1.8 times more; p &lt; 0.001); >3 canisters SABA (2.7 times more; p &lt; 0.001) and ED/IP visit (3.8 times more; p &lt; 0.001). The parents/caregivers of SAC with asthma and an exacerbation missed 1.2 times more work days (p &lt; 0.05), while those with SAC with asthma and an ED/IP visit missed 1.8 times more work days (p &lt; 0.01) than the parents of SAC without asthma. CONCLUSIONS: This study provides evidence of the significant national burden of poorly controlled asthma due to missed school and work days in the United States. More effective and creative asthma management strategies, with collaboration across clinical, community and school-based outreach, may help address this burden</style></abstract><notes><style face="normal" font="default">DA - 20171005IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Armenia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1350972</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28981368">PM:28981368</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171005-SullivanPW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171005-SullivanPW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171005, Sullivan PW</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1350972</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42885</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ali,Z.</style></author><author><style face="normal" font="default"> Nilas,L.</style></author><author><style face="normal" font="default"> Ulrik,C.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonary Medicine</style></auth-address><titles><title><style face="normal" font="default">Postpartum airway responsiveness and exacerbation of asthma during pregnancy - a pilot study</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="267" start="261">261-267</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Airway responsiveness and inflammation are associated with the clinical manifestations of asthma and the response to pharmacological therapy. OBJECTIVE: To investigate if airway responsiveness and inflammatory characteristics are related to asthma exacerbations during pregnancy. MATERIALS AND METHODS: In women with asthma who were prescribed controller medication and monitored closely during pregnancy, the risk of exacerbations was analyzed in relation to postpartum measures of fractional exhaled nitric oxide (FENO), skin prick test reactivity, static and dynamic lung volumes, diffusing capacity for carbon monoxide, bronchial responsiveness to inhaled mannitol, and inflammatory characteristics in induced sputum. Obtained data were analyzed in relation to exacerbation status during pregnancy. The PD15 is defined as the cumulative administered dose causing a 15% decline in forced expiratory volume in the first second (FEV1). RESULTS: Fifty women (mean age +/- standard deviation of 32+/-5 years) were enrolled over an 11-month period and examined on average 4 months postpartum. During pregnancy, 13 women had a total of 16 exacerbations (8 mild and 8 severe). Women with asthma exacerbation during pregnancy had more pronounced airway responsiveness to inhaled mannitol (geometric mean PD15 82 vs 171 mg, p=0.04) and were less likely to be atopic (62% vs 86%, respectively; p=0.04) than the non-exacerbators. No statistically significant difference was found between the 2 groups of women with regard to type of airway inflammation in sputum and fractional exhaled nitric oxide (FENO). CONCLUSION: More pronounced airway hyperresponsiveness together with nonatopic status appears to characterize women at high risk of exacerbation of asthma during pregnancy</style></abstract><notes><style face="normal" font="default">DA - 20171018IS - 1178-6965 (Print)IS - 1178-6965 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.2147/JAA.S137847</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29042800">PM:29042800</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-261-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-261-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171018, Ali Z</style></custom2><misc3><style face="normal" font="default">10.2147/JAA.S137847</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42886</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Romberg,K.</style></author><author><style face="normal" font="default"> Tufvesson,E.</style></author><author><style face="normal" font="default"> Bjermer,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory Medicine and Allergology, Department of Clinical Sciences, Lund, Lund University, Lund</style></auth-address><titles><title><style face="normal" font="default">Asthma symptoms, mannitol reactivity and exercise-induced bronchoconstriction in adolescent swimmers versus tennis players</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="260" start="249">249-260</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Strenuous physical activity at an elite level is associated with an increased risk for asthma and, in some sports, also prevalence of allergies. The aim of this study was to investigate the prevalence of asthma and allergy among elite swimmers and tennis players and compare airway hyperreactivity to mannitol and exercise. MATERIALS AND METHODS: One hundred and one adolescent swimmers and 86 tennis players answered a questionnaire about respiratory symptoms and allergy and performed mannitol challenge and sport-specific exercise challenge. Atopy was assessed and fractional exhaled nitric oxide was measured. Mannitol positivity was defined as drop in FEV1 >/=15% (ordinary criteria) and/or beta2-reversibility (>/=15%) after provocation (extended criteria). A positive exercise test was defined as a drop in FEV1 >/=10% (ordinary criteria) and/or beta2-reversibility (>/=15%) after provocation (extended criteria). Club cell protein (CC16) was measured in urine before and after the challenges. RESULTS: Asthma symptoms were common in both groups. More swimmers had exercise-induced symptoms (77% versus 50%) and current asthma symptoms (56% versus 38%), compared to the tennis players. More swimmers also had a positive mannitol challenge test both using ordinary (26% versus 6%) and extended criteria (43% versus 17%), while the number of positive exercise tests did not differ. After exercise (but not mannitol) challenge, CC16 level was increased in both groups, but to a higher extent in tennis players. There were no differences in atopy, rhinitis or fractional exhaled nitric oxide. CONCLUSION: We found a high prevalence of asthma among elite swimmers and tennis players and a higher frequency of current asthma and positive mannitol challenge tests among the swimmers. This indicates an unfavorable exercise environment</style></abstract><notes><style face="normal" font="default">DA - 20171018IS - 1178-6965 (Print)IS - 1178-6965 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.2147/JAA.S134794</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29042799">PM:29042799</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-249-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-249-60.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171018, Romberg K</style></custom2><misc3><style face="normal" font="default">10.2147/JAA.S134794</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42887</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Akil,S.</style></author><author><style face="normal" font="default"> Newman,J.M.</style></author><author><style face="normal" font="default"> Shah,N.V.</style></author><author><style face="normal" font="default"> Ahmed,N.</style></author><author><style face="normal" font="default"> Deshmukh,A.J.</style></author><author><style face="normal" font="default"> Maheshwari,A.V.</style></author></authors></contributors><titles><title><style face="normal" font="default">Metal hypersensitivity in total hip and knee arthroplasty: Current concepts</style></title><secondary-title><style face="normal" font="default">J Clin Orthop Trauma</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Clin Orthop Trauma</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">total joint arthroplasty</style></keyword><keyword><style face="normal" font="default"> total knee arthroplasty</style></keyword><keyword><style face="normal" font="default"> total hip arthroplasty</style></keyword><keyword><style face="normal" font="default"> Metal allergy</style></keyword><keyword><style face="normal" font="default"> metal hypersensitivity</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0976-5662</style></isbn><abstract><style face="normal" font="default">Abstract Metal hypersensitivity (MHS) is a rare complication of total joint arthroplasty that has been linked to prosthetic device failure when other potential causes have been ruled out. The purpose of this review was to conduct an analysis of existing literature in order to get a better understanding of the pathophysiology, presentation, diagnosis, and management of MHS. It has been described as a type IV hypersensitivity reaction to the metals comprising prosthetic implants, often nickel and cobalt-chromium. Patients suffering from this condition have reported periprosthetic joint pain and swelling as well as cutaneous, eczematous dermatitis. There is no standard for diagnosis MHS, but tests such as patch testing and lymphocyte transformation testing have demonstrated utility, among others. Treatment options that have demonstrated success include administration of steroids and revision surgery, in which the existing metal implant is replaced with one of less allergenic materials. Moreover, the definitive resolution of symptoms has most commonly required revision surgery with the use of different implants. However, more studies are needed in order to understand the complexity of this subject</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.jcot.2017.10.003</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jcot.2017.10.003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Orthop Trauma\20171020-AkilS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Orthop Trauma\20171020-AkilS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171020, Akil S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jcot.2017.10.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42888</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Matas,S.</style></author><author><style face="normal" font="default"> Broto,M.</style></author><author><style face="normal" font="default"> Corominas,M.</style></author><author><style face="normal" font="default"> Lleonart,R.</style></author><author><style face="normal" font="default"> Babington,R.</style></author><author><style face="normal" font="default"> Marco,M.P.</style></author><author><style face="normal" font="default"> Galve,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Nanobiotechnology for Diagnostics (Nb4D), Department of Chemical and Biomolecular Nanotechnology, Institute for Advanced Chemistry of Catalonia (IQAC) of the Spanish Council for Scientific Research (CSIC), Spain; CIBER de Bioingenieria, Biomateriales y Nanomedicina (CIBER-BBN), Jordi Girona 18-26, 08034 Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default">Immediate hypersensitivity to penicillins. Identification of a new antigenic determinant</style></title><secondary-title><style face="normal" font="default">J Pharm Biomed Anal</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Pharm Biomed Anal</style></full-title></periodical><pages end="23" start="17">17-23</pages><volume><style face="normal" font="default">148</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="9" Year="2017">2017/9/18</year></dates><abstract><style face="normal" font="default">The study of adverse drug reactions (ADRs) constitutes a challenge in the area of Medicine. Drugs generate a large number of the total registered hypersensitivity reactions, where penicillins are responsible for more than half of them. In vitro tests in the market are not efficient enough since they lack in sensitivity and specificity. This is the reason why in vivo tests are carried out, with the subsequent danger to the patient's life. It is essential to discover new beta-lactam antigenic determinants to develop more effective detection systems and thus, obtain better explanations of the allergic mechanisms related to these drugs. We propose a strategy based on the use of "peptide probes", small labeled and chemical active peptides which have been structurally modified for reacting with the beta-lactam moiety at different conditions. The probes also contain a biotin group for application in an immunoassay format. Three different amoxicillin adducts have been obtained, purified and characterized by HPLC-MS and NMR techniques. These results have helped us to elucidate and propose a new antigenic determinant for beta-lactams, named the "penamidyl" epitope. All the adducts have been validated and evaluated with sera from different penicillin allergic patients by means of a Magneto-ELISA, immunochemical technique that has allowed us to detect specific IgEs in a very high percentage of the serum samples. An immunoassay has been developed, validated and applied as a diagnostic tool for the detection of specific IgEs in the sera of penicillin allergic patients using a new antigenic determinant</style></abstract><notes><style face="normal" font="default">DA - 20171008IS - 1873-264X (Electronic)IS - 0731-7085 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.jpba.2017.08.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28987997">PM:28987997</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Pharm Biomed Anal\2017-148-17-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Pharm Biomed Anal\2017-148-17-23.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171008, Matas S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jpba.2017.08.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42889</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Han,R.T.</style></author><author><style face="normal" font="default"> Back,S.K.</style></author><author><style face="normal" font="default"> Lee,J.</style></author><author><style face="normal" font="default"> Kim,H.Y.</style></author><author><style face="normal" font="default"> Kim,H.J.</style></author><author><style face="normal" font="default"> Na,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Neuroscience Research Institute &amp; Department of Physiology, College of Medicine, Korea University</style></auth-address><titles><title><style face="normal" font="default">Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment</style></title><secondary-title><style face="normal" font="default">J Vis Exp</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Vis Exp</style></abbr-1></periodical><pages end="" start="">-</pages><number><style face="normal" font="default">127</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="9" Year="2017">2017/9/27</year></dates><abstract><style face="normal" font="default">Atopic dermatitis is chronically relapsing pruritic eczema and prevails around the world especially in developed countries. Complex interactions between genetic and environmental factors are known to play an important role in the pathophysiology of atopic dermatitis. However, we still lack a detailed picture of the pathogenesis of this disease. Thus, it is of importance to develop appropriate animal models for elucidating the progression of atopic dermatitis. Moreover, investigating the effect of environmental factors such as air pollutants on atopic dermatitis expands understanding of the disease. Here, we describe a method for inducing atopic dermatitis in rats with neonatal capsaicin treatment and a protocol for exposure of a constant concentration of formaldehyde to rats to reveal effects on the development of atopic dermatitis in infantile and adolescent periods. These protocols have been successfully applied to several experiments and can be used for other substances</style></abstract><notes><style face="normal" font="default">DA - 20171010IS - 1940-087X (Electronic)IS - 1940-087X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.3791/55987</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28994767">PM:28994767</url></web-urls></urls><custom2><style face="normal" font="default">20171010, Han RT</style></custom2><misc3><style face="normal" font="default">10.3791/55987</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42890</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kow,R.Y.</style></author><author><style face="normal" font="default"> Low,C.L.</style></author><author><style face="normal" font="default"> Ruben,J.K.</style></author><author><style face="normal" font="default"> Zaharul-Azri,M.Z.</style></author><author><style face="normal" font="default"> Ng,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Orthopaedics, Kuala Lipis Hospital, Kuala Lipis, Malaysia</style></auth-address><titles><title><style face="normal" font="default">Life-threatening Chlorhexidine Anaphylaxis: A Case Report</style></title><secondary-title><style face="normal" font="default">Malays Orthop J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Malays Orthop J</style></abbr-1></periodical><pages end="74" start="72">72-74</pages><volume><style face="normal" font="default">11</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Chlorhexidine is a common antiseptic and disinfectant used in the medical field. Allergy to chlorhexidine has been reported in the literature but life-threatening anaphylactic shock is rare. We present a case of severe anaphylactic shock due to chlorhexidine occurring during surgery. Literatures suggest that profound anaphylactic shock to chlorhexidine is commonly preceded by milder, non-specific reactions. These mild symptoms are often dismissed by both the patient and physicians alike. Direct questioning of these symptoms is necessary as a part of the pre-operative assessment and the patient should be referred for further immunology testing if indicated</style></abstract><notes><style face="normal" font="default">DA - 20171012IS - 1985-2533 (Print)IS - 1985-2533 (Linking)LA - engPT - Journal ArticleCO - Malaysia -</style></notes><work-type><style face="normal" font="default">10.5704/MOJ.1707.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29021884">PM:29021884</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Malays Orthop J\2017-11-72-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Malays Orthop J\2017-11-72-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171012, Kow RY</style></custom2><misc3><style face="normal" font="default">10.5704/MOJ.1707.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42891</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Solidoro,P.</style></author><author><style face="normal" font="default"> Verri,G.</style></author><author><style face="normal" font="default"> Patrucco,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonology, Cardiothoracic and Vascular Department, AOU Citta della Salute e della Scienza di Torino, University of Turin, Turin, Italy</style></auth-address><titles><title><style face="normal" font="default">Management of H1N1 influenza infection in asthmatic patients</style></title><secondary-title><style face="normal" font="default">Minerva Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Minerva Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="10" Year="2017">2017/10/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171010IS - 1827-1669 (Electronic)IS - 0026-4806 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.23736/S0026-4806.17.05449-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28994568">PM:28994568</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Minerva Med\20171010-SolidoroP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Minerva Med\20171010-SolidoroP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, Solidoro P</style></custom2><misc3><style face="normal" font="default">10.23736/S0026-4806.17.05449-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42892</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Choi,Y.A.</style></author><author><style face="normal" font="default"> Choi,J.K.</style></author><author><style face="normal" font="default"> Jang,Y.H.</style></author><author><style face="normal" font="default"> Lee,S.</style></author><author><style face="normal" font="default"> Lee,S.R.</style></author><author><style face="normal" font="default"> Choi,J.H.</style></author><author><style face="normal" font="default"> Park,J.H.</style></author><author><style face="normal" font="default"> Shin,T.Y.</style></author><author><style face="normal" font="default"> Kim,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Antiinflammatory effect of Amomum xanthioides in a mouse atopic dermatitis model</style></title><secondary-title><style face="normal" font="default">Mol Med Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Mol Med Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="3" Month="10" Year="2017">2017/10/3</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disorder. The present study investigated the effects of Amomum xanthioides extract (AXE) on ADlike skin inflammation using a Dermatophagoides farinae extract (DFE) and 2,4dinitrochlorobenzene (DNCB)induced mouse AD model. Hematoxylin and eosin staining results demonstrated that repeated DFE/DNCB exposure markedly increased the thickening of the dermis and epidermis, in addition to the infiltration of eosinophils and mast cells. However, oral administration of AXE reduced these histopathological alterations in a dosedependent manner. Elevated serum histamine, total and DFEspecific immunoglobulin E (IgE), and IgG2a were also decreased by treatment with AXE. In addition, reverse transcriptionquantitative polymerase chain reaction (RTqPCR) results demonstrated that the mRNA expression of tumor necrosis factor (TNF)alpha, interferon (IFN)gamma, interleukin (IL)4, IL13, IL31 and IL17A was reduced in ear skin following AXE administration in AD mice. Fluorescenceactivated cell sorting demonstrated that the population of CD4+/IL4+, CD4+/IFNgamma+ and CD4+/IL17A+ cells in draining lymph nodes was also significantly decreased in AXEtreated mice compared with AD mice without AXE treatment. Furthermore, keratinocytes that were stimulated with TNFalpha and IFNgamma exhibited increased gene expression of proinflammatory cytokines and chemokines, including TNFalpha, IL1beta, IL6, IL8, CC motif chemokine ligand (CCL)17 and CCL22, as determined by RTqPCR. However, upregulation of these genes was reduced by AXE pretreatment. Based on these results, we hypothesize that AXE may be useful in the treatment of allergic skin inflammation, particularly AD</style></abstract><notes><style face="normal" font="default">DA - 20171009IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.3892/mmr.2017.7695</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28990098">PM:28990098</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171009, Choi YA</style></custom2><misc3><style face="normal" font="default">10.3892/mmr.2017.7695</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42893</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dorea,J.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Professor Emeritus, Faculty of Health Sciences, Universidade de Brasilia, 70919-970, Brasilia, DF, Brazil.</style></auth-address><titles><title><style face="normal" font="default">Abating Mercury Exposure in Young Children Should Include Thimerosal-Free Vaccines</style></title><secondary-title><style face="normal" font="default">Neurochem Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Neurochem Res</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="24" Month="4" Year="2017">2017/4/24</year></dates><abstract><style face="normal" font="default">Pediatric immunization is essential to prevent, control and eradicate children`s infectious diseases. Newborns and infants in less developed countries have a concentrated schedule of Thimerosal-containing vaccines (TCVs); pregnant mothers are also immunized with TCVs. Metabolic changes during early development are demonstrably an important risk factor for ethylmercury (EtHg) effects on neurodevelopment, while exposure to Thimerosal sensitizes susceptible individuals to life-long contact dermatitis. Concerns regarding toxicity of Hg have moved rich nations to withdraw it from medicines and, in particular, Thimerosal from pediatric vaccines; it has been more than 20 years since rich countries started using Thimerosal-free vaccines. TCVs and Thimerosal-free vaccines show dissimilar profiles of adverse effects. Thimerosal-free vaccines have shown a decrease in contact dermatitis, while TCVs showed a significant association with increased risk of tic disorders; in some circumstances, EtHg in combination with other neurotoxic substances negatively impacted neurobehavioral tests. In studies that explored vaccines and risk of tics, Thimerosal was a necessary factor. However, when the binary exposure to organic Hg forms (TCV-EtHg and fish-MeHg) was considered, effects on neurobehavioral tests were inconsistent. CONCLUSIONS: (a) The indiscriminate use of pediatric-TCVs in less developed countries carries an unjustifiable and excessive EtHg exposure with an unnecessary risk of neurotoxicity to the developing brain; (b) measurable benefits (of Thimerosal-free) and measurable risks of tic disorders have been associated with the (Thimerosal-containing) type of vaccine;</style></abstract><notes><style face="normal" font="default">DA - 20170425IS - 1573-6903 (Electronic)IS - 0364-3190 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1007/s11064-017-2277-x</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28439753">PM:28439753</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Neurochem Res\20170425-DoreaJG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Neurochem Res\20170425-DoreaJG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170425, Dorea JG</style></custom2><misc3><style face="normal" font="default">10.1007/s11064-017-2277-x</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42894</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">House,R.</style></author><author><style face="normal" font="default"> Rajaram,N.</style></author><author><style face="normal" font="default"> Tarlo,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Occupational Medicine, Department of Medicine, St. Michael's Hospital, Toronto, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="default">Case report of asthma associated with 3D printing</style></title><secondary-title><style face="normal" font="default">Occup Med (Lond)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Occup Med (Lond)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="8" Year="2017">2017/8/23</year></dates><abstract><style face="normal" font="default">Background: Three-dimensional (3D) printing is being increasingly used in manufacturing and by small business entrepreneurs and home hobbyists. Exposure to airborne emissions during 3D printing raises the issue of whether there may be adverse health effects associated with these emissions. Aims: We present a case of a worker who developed asthma while using 3D printers, which illustrates that respiratory problems may be associated with 3D printer emissions. Case report: The patient was a 28-year-old self-employed businessman with a past history of asthma in childhood, which had resolved completely by the age of eight. He started using 10 fused deposition modelling 3D printers with acrylonitrile-butadiene-styrene filaments in a small work area of approximately 3000 cubic feet. Ten days later, he began to experience recurrent chest tightness, shortness of breath and coughing at work. After 3 months, his work environment was modified by reducing the number of printers, changing to polylactic acid filaments and using an air purifier with an high-efficiency particulate air filter and organic cartridge. His symptoms improved gradually, although he still needed periodic treatment with a salbutamol inhaler. While still symptomatic, a methacholine challenge indicated a provocation concentration causing a 20% fall in FEV1 (PC20) of 4 mg/ml, consistent with mild asthma. Eventually, his symptoms resolved completely and a second methacholine challenge after symptom resolution was normal (PC20 > 16 mg/ml). Conclusions: This case indicates that workers may develop respiratory problems, including asthma when using 3D printers. Further investigation of the specific airborne emissions and health problems from 3D printing is warranted</style></abstract><notes><style face="normal" font="default">DA - 20171010IS - 1471-8405 (Electronic)IS - 0962-7480 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1093/occmed/kqx129</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29016991">PM:29016991</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Occup Med (Lond)\20171010-HouseR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Occup Med (Lond)\20171010-HouseR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171010, House R</style></custom2><misc3><style face="normal" font="default">10.1093/occmed/kqx129</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42895</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">London,N.R.,Jr.</style></author><author><style face="normal" font="default"> Ramanathan,M.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins, Baltimore, MD, USA</style></auth-address><titles><title><style face="normal" font="default">The Role of the Sinonasal Epithelium in Allergic Rhinitis</style></title><secondary-title><style face="normal" font="default">Otolaryngol Clin North Am</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Otolaryngol Clin North Am</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="10" Year="2017">2017/10/5</year></dates><abstract><style face="normal" font="default">The sinonasal epithelial barrier is comprised of tight and adherens junction proteins. Disruption of epithelial barrier function has been hypothesized to contribute to allergic disease such as allergic rhinitis through increased passage of antigens and exposure of underlying tissue to these stimuli. Several mechanisms of sinonasal epithelial barrier disruption include antigen proteolytic activity, inflammatory cytokine-mediated tight junction breakdown, or exacerbation from environmental stimuli. Mechanisms of sinonasal epithelial barrier stabilization include corticosteroids and nuclear erythroid 2-related factor 2 (Nrf2) cytoprotective pathway activation. Additional studies will aid in determining the contribution of epithelial barrier function in allergic rhinitis pathophysiology and treatment</style></abstract><notes><style face="normal" font="default">DA - 20171009IS - 1557-8259 (Electronic)IS - 0030-6665 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.otc.2017.08.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28988814">PM:28988814</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Otolaryngol Clin North Am\20171009-LondonNRJr.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Otolaryngol Clin North Am\20171009-LondonNRJr.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171009, London NR Jr</style></custom2><misc3><style face="normal" font="default">10.1016/j.otc.2017.08.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42896</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Krouse,J.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Medicine, University of Texas Rio Grande Valley, 1201 West, University Drive, Edinburg, Texas 78539, USA.</style></auth-address><titles><title><style face="normal" font="default">Asthma Management for the Otolaryngologist</style></title><secondary-title><style face="normal" font="default">Otolaryngol Clin North Am</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Otolaryngol Clin North Am</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="10" Year="2017">2017/10/5</year></dates><abstract><style face="normal" font="default">Asthma is a chronic inflammatory disease that will frequently be encountered by otolaryngologists as they manage their patients with upper respiratory diseases. Symptoms such as cough should alert otolaryngologists to consider more broadly the potential role of asthma in the differential diagnosis. It is critical for otolaryngologists to appreciate that patients with allergic rhinitis and chronic rhinosinusitis will often have asthma, and that many of them may not be diagnosed at the time of presentation. Appropriate diagnosis of the patient with asthma, as well as effective treatment for its symptoms, will improve patient function and enhance quality of life</style></abstract><notes><style face="normal" font="default">DA - 20171009IS - 1557-8259 (Electronic)IS - 0030-6665 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.otc.2017.08.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28988813">PM:28988813</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Otolaryngol Clin North Am\20171009-KrouseJH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Otolaryngol Clin North Am\20171009-KrouseJH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171009, Krouse JH</style></custom2><misc3><style face="normal" font="default">10.1016/j.otc.2017.08.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42897</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mims,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA.</style></auth-address><titles><title><style face="normal" font="default">Advancements and Dilemmas in the Management of Allergy</style></title><secondary-title><style face="normal" font="default">Otolaryngol Clin North Am</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Otolaryngol Clin North Am</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="10" Year="2017">2017/10/5</year></dates><abstract><style face="normal" font="default">Recent advances in the diagnosis and management of allergic disease also lead to new clinical decisions for providers. Advances in component (or molecular) diagnostic testing for allergy continue to build in the literature, but diagnosing inhalant allergy remains largely unchanged clinically. Prevention of allergy has been demonstrated by preventing peanut allergy in high-risk infants by intentional oral exposure to promote tolerance. Immunotherapy options have increased, with literature supporting sublingual drops, sublingual tablets, and subcutaneous immunotherapy. Expanded options create clinical questions such as the role of monotherapy in polysensitized patients. This article explores recent advances and their clinical implications</style></abstract><notes><style face="normal" font="default">DA - 20171009IS - 1557-8259 (Electronic)IS - 0030-6665 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.otc.2017.08.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28988815">PM:28988815</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Otolaryngol Clin North Am\20171009-MimsJW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Otolaryngol Clin North Am\20171009-MimsJW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171009, Mims JW</style></custom2><misc3><style face="normal" font="default">10.1016/j.otc.2017.08.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42898</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wolf,S.</style></author><author><style face="normal" font="default"> Perez,G.F.</style></author><author><style face="normal" font="default"> Mukharesh,L.</style></author><author><style face="normal" font="default"> Isaza,N.</style></author><author><style face="normal" font="default"> Preciado,D.</style></author><author><style face="normal" font="default"> Freishtat,R.J.</style></author><author><style face="normal" font="default"> Pillai,D.</style></author><author><style face="normal" font="default"> Rose,M.C.</style></author><author><style face="normal" font="default"> Nino,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Genetic Research Medicine, Children's National Medical Center, Washington, DC</style></auth-address><titles><title><style face="normal" font="default">Conditional reprogramming of pediatric airway epithelial cells: a new human model to investigate early life respiratory disorders</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="10" Year="2017">2017/10/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Airway epithelial cells (AEC) are quite difficult to access in newborns and infants. It is critically important to develop robust life-extended models to conduct translational studies in this age group. We propose the use of a recently described cell-culture technology (conditionally reprogrammed cells - CRC) to generate continuous primary cell cultures from nasal and bronchial AEC of young children. METHODS: We collected nasal and/or bronchial AEC from a total of 23 subjects of different ages including newborns/infants/toddlers (0-2 years; N=9), school age children (4-11 years; N=6), and a group of adolescent/adult donors (N=8). For CRC generation, we used conditioned medium from mitotically inactivated 3T3 fibroblasts and Rho-associated kinase (ROCK) inhibitor (Y-27632). Antiviral immune responses were studied using 25 key antiviral genes and protein production of type III epithelial interferon (IFN lambda1) after double stranded (ds) RNA exposure. RESULTS: CRC derived from primary AEC of neonates/infants and young children exhibited: 1) augmented proliferative capacity and life-extension, 2) preserved airway epithelial phenotype after multiple passages, 3) robust immune responses characterized by expression of innate antiviral genes and parallel nasal/bronchial production of IFN lambda1 after exposure to dsRNA, and 4) induction of airway epithelial inflammatory and remodeling responses to dsRNA (e.g. CXCL8 and MMP9). CONCLUSION: Conditional reprogramming of AEC from young children is a feasible and powerful translational approach to investigate early-life airway epithelial immune responses in humans. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171005IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12810</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28981980">PM:28981980</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171005-WolfS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171005-WolfS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171005, Wolf S</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12810</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42899</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rodriguez del Rio,P.</style></author><author><style face="normal" font="default"> Andion,M.</style></author><author><style face="normal" font="default"> Ruano,D.</style></author><author><style face="normal" font="default"> Escudero Diez,C.</style></author><author><style face="normal" font="default"> Mendez Brea,P.</style></author><author><style face="normal" font="default"> Sanchez-Garcia,S.</style></author><author><style face="normal" font="default"> Ibanez,M.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Department, Hospital Infantil Universitario Nino JesusIIS-La Princesa</style></auth-address><titles><title><style face="normal" font="default">Initial experience with carboplatin desensitization: A case series in a paediatric hospital</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="10" Year="2017">2017/10/5</year></dates><abstract><style face="normal" font="default">For several years, carboplatin has been the most efficacious and safest first-line treatment for paediatric low-grade gliomas (LGGs), although very recently vinblastine has been proven to display a better safety profile with similar efficacy (1). Classically, hypersensitivity reactions to carboplatin appeared in around 27% to 42% of cases (2). These reactions are especially frequent as of the seventh cycle (3) in adults and the ninth in children (4), leading to treatment withdrawal and the use of second-line drugs. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171005IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12816</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28981992">PM:28981992</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171005-RodriguezDelRioP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171005-RodriguezDelRioP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171005, Rodriguez Del Rio P</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12816</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42900</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bersuch,E.</style></author><author><style face="normal" font="default"> Graf,F.</style></author><author><style face="normal" font="default"> Renner,E.D.</style></author><author><style face="normal" font="default"> Jung,A.</style></author><author><style face="normal" font="default"> Traidl-Hoffmann,C.</style></author><author><style face="normal" font="default"> Lauener,R.</style></author><author><style face="normal" font="default"> Roduit,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">CK-CARE, Christine Kuhne Center for Allergy Research and Education, Davos-Wolfgang, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Lung function improvement and airways inflammation reduction in asthmatic children after a rehabilitation program at moderate altitude</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="10" Year="2017">2017/10/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Rehabilitational programs at moderate altitude (1500m to 2500m) showed improvement of lung function and reduction of airways inflammation in asthmatic adults. Allergen avoidance was postulated as the major cause of these improvements. METHODS: Spirometries of 344 and fractional exhaled nitric oxide measurements (FeNO) of 124 asthmatic children and adolescents, staying in a rehabilitation hospital in Davos (1590m) with at least 14 days between admission and discharge, were analysed in associations with atopic sensitisation (skin-prick testing and/or specific IgE), level of asthma control, and inhalative corticosteroid (ICS) dose. RESULTS: Pulmonary conditions improved significantly on average during the sojourn. Uncontrolled asthmatics benefited most with an absolute increase of predicted FEV1, MEF25 and MEF75 of 7.7, 9.9 12.7%, respectively (p&lt;0.001). FeNO decreased by 36.9ppb for uncontrolled, by 26.9ppb for partly-controlled and by 11.8ppb for controlled asthmatics. In uncontrolled subjects, pulmonary improvement was comparable between patients with and without house dust mites (HDM)-sensitisation. Pulmonary improvements of pollen sensitised patients were not dependent on the season of the sojourn. For the group with constant ICS level the absolute increase of FEV1 was 4.9% (p&lt;0.001) with a FeNO decreased by 32.7ppb (p&lt;0.001). When the ICS dose was elevated by one GINA-level, the absolute increase of FEV1 was slightly higher (6.6%,p&lt;0.001), with a FeNO decrease of 31.4ppb (p&lt;0.001). CONCLUSION: Inpatient rehabilitation at moderate altitude improved pulmonary conditions in asthmatic children and adolescents independent of sensitisation status to HDM or pollen. A positive effect was also observed in patients without change in medication. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171005IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12808</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28981975">PM:28981975</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171005-BersuchE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171005-BersuchE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171005, Bersuch E</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12808</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42901</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fortmann,C.</style></author><author><style face="normal" font="default"> Goen,T.</style></author><author><style face="normal" font="default"> Kruger,M.</style></author><author><style face="normal" font="default"> Ure,B.M.</style></author><author><style face="normal" font="default"> Petersen,C.</style></author><author><style face="normal" font="default"> Kubler,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric Surgery, Hannover Medical School, Hannover, Germany</style></auth-address><titles><title><style face="normal" font="default">Trace metal release after minimally-invasive repair of pectus excavatum</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0186323">e0186323-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Several studies have shown a high incidence of metal allergy after minimally-invasive repair of pectus excavatum (MIRPE). We postulated that MIRPE is associated with a significant release of trace metal ions, possibly causing the allergic symptoms. METHODS: We evaluated the concentration with chromium, cobalt and nickel in blood, urine and tissue in patients prior to MIRPE and in patients who underwent an explantation of the stainless-steel bar(s) after three years. RESULTS: Our study group consisted of 20 patients (mean age 19 years) who had bar explantation and our control group included 20 patients (mean age 16 years) prior to MIRPE. At the time of bar removal we detected significantly elevated concentrations of chromium and nickel in the tissue compared to patients prior to the procedure (p&lt;0,001). We also found a significant increase in the levels of chromium in urine and nickel in blood in patients three years post MIRPE (p&lt;0,001). Four patients temporarily developed symptoms of metal allergy, all had elevated metal values in blood and urine at explantation. CONCLUSIONS: Minimally-invasive repair of pectus excavatum can lead to a significant trace metal exposure</style></abstract><notes><style face="normal" font="default">DA - 20171012IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0186323</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29023602">PM:29023602</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0186323.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0186323.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171012, Fortmann C</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0186323</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42902</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,X.</style></author><author><style face="normal" font="default"> Biagini Myers,J.M.</style></author><author><style face="normal" font="default"> Yadagiri,V.K.</style></author><author><style face="normal" font="default"> Ulm,A.</style></author><author><style face="normal" font="default"> Chen,X.</style></author><author><style face="normal" font="default"> Weirauch,M.T.</style></author><author><style face="normal" font="default"> Khurana Hershey,G.K.</style></author><author><style face="normal" font="default"> Ji,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America</style></auth-address><titles><title><style face="normal" font="default">Nasal DNA methylation differentiates corticosteroid treatment response in pediatric asthma: A pilot study</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0186150">e0186150-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Treatment response to systemic corticosteroid in asthmatic children is heterogeneous and may be mediated by epigenetic mechanism(s). We aim to identify DNA methylation (DNAm) changes responsive to steroid, and DNAm biomarkers that distinguish treatment response. MATERIALS AND METHODS: We followed 33 children (ages 5-18) presenting to the Emergency Department (ED) for asthma exacerbation. Based on whether they met discharge criteria in &lt;/=24 hours, participants were grouped into good and poor responders to steroid treatment. Nasal samples were collected upon presentation to the ED (T0) and 18-24 hours later (T1). Genome-wide DNAm was measured for both time points in 20 subjects, and compared between T0 and T1 in good and poor responders respectively. DNAm at T1 was also compared between two responder groups. DNAm of selected CpGs was verified in the complete cohort, and expression of associated genes was examined. Interactions between DNAm, common single nucleotide polymorphism (SNP) located at the CpG sites and treatment responses were assessed. RESULTS: Three CpGs located in the OTX2 promoter showed responder-specific DNAm changes from T0 to T1, in which DNAm decreased in good but not in poor responders. Good and poor responders showed differential DNAm at T1 in 127 CpGs without and 182 CpGs with common SNP co-localization. Negative correlations between DNAm and gene expression were observed at CpGs located within the LDHC promoter, suggesting an impact of DNAm on gene regulation. Interactions between SNPs, DNAm and treatment response were detected. CONCLUSION: Acute systemic steroid treatment modifies nasal DNAm in good responders. Nasal DNAm, dependent or independent of SNPs, can differentiate response to treatment in acute asthmatic children</style></abstract><notes><style face="normal" font="default">DA - 20171013IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0186150</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29028809">PM:29028809</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0186150.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0186150.pdf</url></text-urls><related-urls><url ppv-ref="no">xlsx in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20171013, Zhang X</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0186150</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42903</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Carsin,A.</style></author><author><style face="normal" font="default"> Baravalle-Einaudi,M.</style></author><author><style face="normal" font="default"> Dubus,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Pulmonology, University Hospital Timone-Enfants, Aix-Marseille University, Marseille, France</style></auth-address><titles><title><style face="normal" font="default">When Christmas decoration goes hand in hand with bronchial aspiration ...</style></title><secondary-title><style face="normal" font="default">Respir Med Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Respir Med Case Rep</style></abbr-1></periodical><pages end="267" start="266">266-267</pages><volume><style face="normal" font="default">22</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">We report the case of a 14-month-old girl suffering from cough and wheeze around Christmas. She was treated with anti-asthmatic drugs with no success, and 3 weeks later a chest X-ray revealed a LED bulb in the left main bronchus. This LED bulb came from a Christmas light garland decorating the Christmas tree. We discuss the different Christmas objects that can be inhaled by young children, the challenge to diagnose bronchial inhalation during this winter period, and the emergence of new foreign bodies, such as LED bulbs, with a particularly aerodynamic shape</style></abstract><notes><style face="normal" font="default">DA - 20171012IS - 2213-0071 (Print)IS - 2213-0071 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.rmcr.2017.09.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29021955">PM:29021955</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respir Med Case Rep\2017-22-266-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respir Med Case Rep\2017-22-266-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171012, Carsin A</style></custom2><misc3><style face="normal" font="default">10.1016/j.rmcr.2017.09.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42904</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bogen,K.T.</style></author><author><style face="normal" font="default"> Garry,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Exponent Health Sciences, Oakland, CA, USAExponent Health Sciences, Bellevue, WA, USA</style></auth-address><titles><title><style face="normal" font="default">Risks of Allergic Contact Dermatitis Elicited by Nickel, Chromium, and Organic Sensitizers: Quantitative Models Based on Clinical Patch Test Data</style></title><secondary-title><style face="normal" font="default">Risk Anal</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Risk Anal</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="10" Year="2017">2017/10/11</year></dates><abstract><style face="normal" font="default">Risks of allergic contact dermatitis (ACD) from consumer products intended for extended (nonpiercing) dermal contact are regulated by E.U. Directive EN 1811 that limits released Ni to a weekly equivalent dermal load of &lt;/=0.5 mug/cm2 . Similar approaches for thousands of known organic sensitizers are hampered by inability to quantify respective ACD-elicitation risk levels. To help address this gap, normalized values of cumulative risk for eliciting a positive (">/=+") clinical patch test response reported in 12 studies for a total of n = 625 Ni-sensitized patients were modeled in relation to observed ACD-eliciting Ni loads, yielding an approximate lognormal (LN) distribution with a geometric mean and standard deviation of GMNi = 15 mug/cm2 and GSDNi = 8.0, respectively. Such data for five sensitizers (including formaldehyde and 2-hydroxyethyl methacrylate) were also approximately LN distributed, but with a common GSD value equal to GSDNi and with heterogeneous sensitizer-specific GM values each defining a respective ACD-eliciting potency GMNi /GM relative to Ni. Such potencies were also estimated for nine (meth)acrylates by applying this general LN ACD-elicitation risk model to respective sets of fewer data. ACD-elicitation risk patterns observed for Cr(VI) (n = 417) and Cr(III) (n = 78) were fit to mixed-LN models in which approximately 30% and approximately 40% of the most sensitive responders, respectively, were estimated to exhibit a LN response also governed by GSDNi . The observed common LN-response shape parameter GSDNi may reflect a common underlying ACD mechanism and suggests a common interim approach to quantitative ACD-elicitation risk assessment based on available clinical data</style></abstract><notes><style face="normal" font="default">DA - 20171012IS - 1539-6924 (Electronic)IS - 0272-4332 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/risa.12902</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29023909">PM:29023909</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Risk Anal\20171012-BogenKT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Risk Anal\20171012-BogenKT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171012, Bogen KT</style></custom2><misc3><style face="normal" font="default">10.1111/risa.12902</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42905</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vuillermin,P.J.</style></author><author><style face="normal" font="default"> Macia,L.</style></author><author><style face="normal" font="default"> Nanan,R.</style></author><author><style face="normal" font="default"> Tang,M.L.</style></author><author><style face="normal" font="default"> Collier,F.</style></author><author><style face="normal" font="default"> Brix,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Deakin University, Geelong, Australia.</style></auth-address><titles><title><style face="normal" font="default">The maternal microbiome during pregnancy and allergic disease in the offspring</style></title><secondary-title><style face="normal" font="default">Semin Immunopathol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Semin Immunopathol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="default">There is substantial epidemiological and mechanistic evidence that the increase in allergic disease and asthma in many parts of the world in part relates to changes in microbial exposures and diet acting via the composition and metabolic products of the intestinal microbiome. The majority of research in this field has focused on the gut microbiome during infancy, but it is increasingly clear that the maternal microbiome during pregnancy also has a key role in preventing an allergy-prone immune phenotype in the offspring. The mechanisms by which the maternal microbiome influences the developing fetal immune system include alignment between the maternal and infant regulatory immune status and transplacental passage of microbial metabolites and IgG. Interplay between microbial stimulatory factors such as lipopolysaccharides and regulatory factors such as short-chain fatty acids may also influence on fetal immune development. However, our understanding of these pathways is at an early stage and further mechanistic studies are needed. There are also no data from human studies relating the composition and metabolic activity of the maternal microbiome during pregnancy to the offspring's immune status at birth and risk of allergic disease. Improved knowledge of these pathways may inform novel strategies for tackling the increase in allergic disorders in the modern world</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 1863-2300 (Electronic)IS - 1863-2297 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -CO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1007/s00281-017-0652-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29038841">PM:29038841</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Semin Immunopathol\20171017-VuillerminPJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Semin Immunopathol\20171017-VuillerminPJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Vuillermin PJ</style></custom2><misc3><style face="normal" font="default">10.1007/s00281-017-0652-y</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42906</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Raffalli,C.</style></author><author><style face="normal" font="default"> Clouet,E.</style></author><author><style face="normal" font="default"> Kuresepi,S.</style></author><author><style face="normal" font="default"> Damiens,M.H.</style></author><author><style face="normal" font="default"> Lepoittevin,J.P.</style></author><author><style face="normal" font="default"> Pallardy,M.</style></author><author><style face="normal" font="default"> Ferret,P.J.</style></author><author><style face="normal" font="default"> Gimenez-Arnau,E.</style></author><author><style face="normal" font="default"> Kerdine-Romer,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pierre Fabre Dermo-Cosmetique Research &amp; Development, Toxicology Division, Safety Department, Toulouse, FranceUMR</style></auth-address><titles><title><style face="normal" font="default">Fragrance allergens linalool and limonene allylic hydroperoxides in skin allergy: mechanisms of action focusing on transcription factor Nrf2</style></title><secondary-title><style face="normal" font="default">Toxicol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Toxicol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="9" Year="2017">2017/9/29</year></dates><abstract><style face="normal" font="default">Allergic contact dermatitis (ACD) is regarded as the most frequent expression of immunotoxicity in humans. Many odorant terpenes commonly used in fragrance compositions are considered as weak skin sensitizers, whereas some of their autoxidation products, allylic hydroperoxides, are classified as strong sensitizers according to the Local Lymph Node Assay (LLNA). However, the mechanism of their effects on the immune system remains unclear. Since dendritic cells play a key role in ACD, we studied their activation by the frequently used linalool (LINA) and limonene (LIMO), and their respective sensitizing allylic hydroperoxides (LINA-OOH, LIMO-OOH). The THP-1 cell line was used as a surrogate for dendritic cells, the model currently employed in the validated h-CLAT in vitro test.Our data showed that allylic hydroperoxides behave differently. Both LINA-OOH and LIMO-OOH, oxidized cell surface thiols 30 min after stimulation. However, the oxidative stress induced by LINA-OOH was stronger, with a higher decreased GSH/GSSG ratio and a stronger reactive species production. Moreover, LINA-OOH induced a stronger Nrf2 accumulation in correlation with nqo1 and ho-1 gene expression, two Nrf2 target genes. Regarding signaling pathways involved in these effects, P38 MAPK and P-ERK were activated in response to LINA-OOH but not with LIMO-OOH. CD54 and CD86 were induced 24 h post exposure. In contrast LINA and LIMO did not modify THP-1 phenotype.This work underlies that autoxidation forming allylic hydroperoxide (ROOH) does not lead to equal chemical reactivity since LINA-OOH appears to be a stronger activator than LIMO-OOH, in regard to oxidative stress and Nrf2 pathway activation</style></abstract><notes><style face="normal" font="default">DA - 20171013IS - 1096-0929 (Electronic)IS - 1096-0929 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1093/toxsci/kfx207</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29029310">PM:29029310</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicol Sci\20171013-RaffalliC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicol Sci\20171013-RaffalliC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171013, Raffalli C</style></custom2><misc3><style face="normal" font="default">10.1093/toxsci/kfx207</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42907</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mori,H.</style></author><author><style face="normal" font="default"> Suzuki,H.</style></author><author><style face="normal" font="default"> Matsuzaki,J.</style></author><author><style face="normal" font="default"> Masaoka,T.</style></author><author><style face="normal" font="default"> Kanai,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients</style></title><secondary-title><style face="normal" font="default">United European Gastroenterol J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">United European Gastroenterol J</style></abbr-1></periodical><pages end="804" start="796">796-804</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">BACKGROUND AND AIM: Helicobacter pylori (H. pylori) eradication regimen has not been standardized for patients with penicillin allergy. We investigated the association between the efficacy of a 10-day sitafloxacin, metronidazole, and esomeprazole triple regimen and antibiotic resistance, in patients with penicillin allergy. METHODS: Penicillin-allergic patients infected with H. pylori were enrolled between March 2014 and November 2015. The minimum inhibitory concentrations (MICs) of sitafloxacin and metronidazole, and the gyrA mutation status of the H. pylori strains were determined before treatment. The cut-off points for antimicrobial resistance were defined as 8.0 microg/ml for metronidazole and 0.12 microg/ml for sitafloxacin. The patients received the triple therapy (20 mg esomeprazole, bid; 250 mg metronidazole, bid; and 100 mg sitafloxacin, bid) for 10 days. Successful eradication was evaluated using the [13C] urea breath test or the H. pylori stool antigen test. RESULTS: Fifty-seven patients were analyzed, and the overall eradication rate was 89.5%. The eradication rate in cases of double antibiotic resistance to metronidazole and sitafloxacin was 40.0%, whereas for other combinations of resistance, this was above 90.0%. Finally, the eradication rate of gyrA mutation-negative strains was 96.2%, whereas for gyrA mutation-positive strains, it was 83.9%. Adverse events were reported in 31.6% of cases, all of which were mild and tolerable. CONCLUSION: Ten days of sitafloxacin and metronidazole triple therapy was safe and highly effective in eradicating H. pylori in penicillin-allergic patients. Double resistance to metronidazole and sitafloxacin was an important predicting factor for eradication failure. However, 10 days of the sitafloxacin and metronidazole triple therapy was highly effective if the strain was susceptible to either sitafloxacin or metronidazole</style></abstract><notes><style face="normal" font="default">DA - 20171013IS - 2050-6406 (Print)IS - 2050-6406 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1177/2050640616688995</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29026593">PM:29026593</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\United European Gastroenterol J\2017-5-796-804.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\United European Gastroenterol J\2017-5-796-804.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171013, Mori H</style></custom2><misc3><style face="normal" font="default">10.1177/2050640616688995</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42908</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Manrique Espinel,A.M.</style></author><author><style face="normal" font="default"> Feldman,J.M.</style></author><author><style face="normal" font="default"> Nelson,S.</style></author><author><style face="normal" font="default"> Smaliak,T.</style></author><author><style face="normal" font="default"> Flynn,J.M.</style></author><author><style face="normal" font="default"> Nicolson,S.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pennsylvania</style></auth-address><titles><title><style face="normal" font="default">Anaphylaxis to Surgiflo During Posterior Spinal Fusion in an Adolescent Status Post Truncus Arteriosus Repair: A Case Report</style></title><secondary-title><style face="normal" font="default">A A Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">A A Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="24" Month="10" Year="2017">2017/10/24</year></dates><abstract><style face="normal" font="default">Anaphylactic reaction to gelatin-containing hemostatic agents has been reported in the orthopedic literature, most commonly during scoliosis repair in adolescents. However, the risk, differential diagnosis, and management of anaphylaxis in patients with complex congenital heart disease undergoing noncardiac procedures have not been previously reported. We describe the case of an adolescent with a history of repaired truncus arteriosus undergoing posterior spinal fusion who developed sudden and profound hypotension that was ultimately confirmed to be an anaphylactic reaction to Surgiflo. Echocardiography was used to aid in diagnosis and management of the cardiovascular effects of anaphylaxis in this patient with residual cardiac pathophysiology</style></abstract><notes><style face="normal" font="default">DA - 20171025IS - 2325-7237 (Electronic)IS - 2325-7237 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.1213/XAA.0000000000000646</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29068803">PM:29068803</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\A A Case Rep\20171025-ManriqueEspinelAM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\A A Case Rep\20171025-ManriqueEspinelAM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171025, Manrique Espinel AM</style></custom2><misc3><style face="normal" font="default">10.1213/XAA.0000000000000646</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42909</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cui,T.T.</style></author><author><style face="normal" font="default"> Wang,G.X.</style></author><author><style face="normal" font="default"> Wei,N.N.</style></author><author><style face="normal" font="default"> Wang,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacology, Qingdao University School of Pharmacy, Qingdao 266021, China</style></auth-address><titles><title><style face="normal" font="default">A pivotal role for the activation of TRPV3 channel in itch sensations induced by the natural skin sensitizer carvacrol</style></title><secondary-title><style face="normal" font="default">Acta Pharmacol Sin</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Acta Pharmacol Sin</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="2" Month="11" Year="2017">2017/11/2</year></dates><abstract><style face="normal" font="default">Itching is an intricate, common symptom of dermatologic and systemic diseases, and both TRPV3 and TRPA1 channels have been suggested to function as downstream effector targets. But the relative contributions of TRPV3 and TRPA1 to itch sensation in vivo remain unclear. To dissect the role of TRPA1 or TRPV3 in the cutaneous sensation of itching, we took the advantage of a natural compound carvacrol from oregano, and examined its effect on the induction of scratching behavior in mice. We showed that the intradermal injection of carvacrol (0.01%, 0.1% and 1%, 50 muL) induced scratching in a concentration-dependent manner. But in TRPV3-knockout mice, the scratching induced by carvacrol (1%, 50 muL) was markedly decreased by approximately 64% (from 275 scratching bouts down to 90) within 60 min. Further analysis revealed that TRPV3-knockout caused a reduction of scratching bouts for approximately 40% in the first 20 min (the initial phase), whereas the scratching bouts were reduced by approximately 90% in the last 40 min (the sustained phase). These results were in consistence with those in our whole-cell recordings in HEK-293T cells expressing either TRPA1 or TRPV3: carvacrol exhibited similar potencies in activating either TRPA1 or TRPV3, but carvacrol-activated TRPA1 current showed a rapid desensitization, which was reduced by approximately 90% within 5 min before a complete washout, whereas carvacrol-induced TRPV3 current showed a slow desensitization that caused less than 30% of current reduction in 10 min and left a significant residual TRPV3 current after washout. Our results demonstrate that carvacrol from plant oregano is a skin sensitizer or allergen; TRPV3 is involved in the initial phase and the sustained phase of pruritus, whereas TRPA1 likely contributes to the initial phase</style></abstract><notes><style face="normal" font="default">DA - 20171102IS - 1745-7254 (Electronic)IS - 1671-4083 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1038/aps.2017.152</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29094727">PM:29094727</url></web-urls><related-urls><url ppv-ref="no">presto - 1 anno</url></related-urls></urls><custom2><style face="normal" font="default">20171102, Cui TT</style></custom2><misc3><style face="normal" font="default">10.1038/aps.2017.152</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42910</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hervella,M.</style></author><author><style face="normal" font="default"> Garcia-Gavin,J.</style></author><author><style face="normal" font="default"> Silvestre,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Servicio de Dermatologia, Complejo Hospitalario de Navarra, Pamplona, Navarra, Espana.</style></auth-address><titles><title><style face="normal" font="default">The Spanish Standard Patch Test Series</style></title><secondary-title><style face="normal" font="default">Actas Dermosifiliogr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Actas Dermosifiliogr</style></full-title></periodical><pages end="550" start="547">547-550</pages><volume><style face="normal" font="default">107</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> standards</style></keyword><keyword><style face="normal" font="default"> Spain</style></keyword></keywords><dates><year Day="0" Month="9" Year="2016">2016/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20160829IS - 1578-2190 (Electronic)IS - 0001-7310 (Linking)LA - engLA - spaPT - Journal ArticleSB - IMCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.ad.2016.04.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27180004">PM:27180004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Actas Dermosifiliogr\2016-107-547-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Actas Dermosifiliogr\2016-107-547-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160829, Hervella M</style></custom2><misc3><style face="normal" font="default">10.1016/j.ad.2016.04.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42911</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sanchez-Gilo,A.</style></author><author><style face="normal" font="default"> Nuno,G.A.</style></author><author><style face="normal" font="default"> Gutierrez,P.M.</style></author><author><style face="normal" font="default"> Vicente Martin,F.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Servicio de Dermatologia, Hospital Universitario Rey Juan Carlos, Mostoles, Madrid, Espana.</style></auth-address><titles><title><style face="normal" font="default">Airborne Allergic Contact Dermatitis Caused by Neem Oil</style></title><secondary-title><style face="normal" font="default">Actas Dermosifiliogr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Actas Dermosifiliogr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="10" Year="2017">2017/10/23</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171027IS - 1578-2190 (Electronic)IS - 0001-7310 (Linking)LA - engLA - spaPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.ad.2017.05.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29074140">PM:29074140</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171027, Sanchez-Gilo A</style></custom2><misc3><style face="normal" font="default">10.1016/j.ad.2017.05.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42912</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,B.S.</style></author><author><style face="normal" font="default"> Lee,E.</style></author><author><style face="normal" font="default"> Lee,M.J.</style></author><author><style face="normal" font="default"> Kang,M.J.</style></author><author><style face="normal" font="default"> Yoon,J.</style></author><author><style face="normal" font="default"> Cho,H.J.</style></author><author><style face="normal" font="default"> Park,J.</style></author><author><style face="normal" font="default"> Won,S.</style></author><author><style face="normal" font="default"> Lee,S.Y.</style></author><author><style face="normal" font="default"> Hong,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Life Science, Multidisciplinary Genome Institute Hallym University, Chuncheon, 24252, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Different Functional Genes of Upper Airway Microbiome Associated with Natural Course of Childhood Asthma</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="10" Year="2017">2017/10/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: Microbial colonization of the airway plays a role in the pathogenesis of asthma; however, the effect of the upper airway microbiome on childhood asthma is not fully understood. We analyzed the metagenome of airway microbiome to understand the associated role of upper airway microbiome with the natural course of childhood asthma. METHODS: Nasopharyngeal swabs were collected from children with asthma, those in asthma remission, and control groups. High-throughput sequencing was used to examine the structure and functional dynamics of the airway microbiome with respect to asthma phenotypes. RESULTS: The composition of microbiota differed among healthy control, asthma, and remission groups. The relative abundance of Streptococcus was negatively associated with FEV1% predicted (p = 0.023), and that of Staphylococcus was negatively associated with methacholine PC20 (p = 0.013). Genes related to arachidonic acid metabolites, lysine residues, and glycosaminoglycans in the microbiome could be associated with airway inflammation. In particular, genes related to synthesis of anti-inflammatory prostaglandin E2 were not detected from the airway microbiome in the asthma group. CONCLUSIONS: These data suggest that alterations in the composition and function of the upper airway microbiome could be related with the natural course of asthma in children. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171020IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1111/all.13331</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29052232">PM:29052232</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171020-KimBS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171020-KimBS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171020, Kim BS</style></custom2><misc3><style face="normal" font="default">10.1111/all.13331</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42913</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Huang,F.</style></author><author><style face="normal" font="default"> Yin,J.N.</style></author><author><style face="normal" font="default"> Wang,H.B.</style></author><author><style face="normal" font="default"> Liu,S.Y.</style></author><author><style face="normal" font="default"> Li,Y.N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association of imbalance of effector T cells and regulatory cells with the severity of asthma and allergic rhinitis in children</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="77" start="70">70-77</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="default">PURPOSE: This study investigated the frequency and absolute numbers of different subsets of peripheral blood cells, including CD4+ T cells and CD19+ interleukin (IL) 10+ B regulatory cells (Breg) and their potential association with clinical laboratory measurements in children diagnosed with simple asthma or asthma plus allergic rhinitis (AR). METHOD: The frequency and numbers of peripheral blood CD4+ interferon (IFN) gamma+ T-helper (Th) type 1, CD4+ IL-4+ Th2, CD4+ IL-17A+ Th17, CD4+CD25+ Forkhead Box P3+ regulatory T cells (Treg) and CD19+ IL-10+ Bregs in 22 children with asthma, 17 children with asthma and AR, and 25 healthy controls were determined by flow cytometry. The levels of serum cytokines were determined by enzyme-linked immunosorbent assay. RESULTS: In comparison with healthy controls, patients with asthma alone had significantly increased numbers of Th1, Th2, and Th17 cells, and their cytokines but decreased numbers of Tregs and Bregs, and the cytokines IL-10 and transforming growth factor beta 1. This imbalance between effector and regulatory cells and their cytokines further increased in patients with asthma and AR. The ratios of percentage effector T cells (Th1 + Th2 + Th17) to regulatory cells (Treg + Breg) were positively correlated with fractional exhaled nitric oxide but negatively correlated with forced expiratory volume in 1 second in patients with asthma or asthma plus AR. CONCLUSION: The imbalance of effector T cells and regulatory cells contributed to the pathogenesis of airway inflammation of asthma and AR in children</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4076</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29046188">PM:29046188</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171019, Huang F</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4076</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42914</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gangemi,S.</style></author><author><style face="normal" font="default"> Quartuccio,S.</style></author><author><style face="normal" font="default"> Casciaro,M.</style></author><author><style face="normal" font="default"> Trapani,G.</style></author><author><style face="normal" font="default"> Minciullo,P.L.</style></author><author><style face="normal" font="default"> Imbalzano,E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Interleukin 31 and skin diseases: A systematic review</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="408" start="401">401-408</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Although the pathophysiology of pruritus has been extensively studied in recent years, with many resultant advancements, management of pruritus is still enigmatic, particularly in chronic cutaneous diseases, such as atopic dermatitis, chronic urticaria, allergic contact dermatitis, cutaneous T-cell lymphoma, and uremic pruritus. The recent finding of the involvement of interleukin (IL) 31 in the pathogenesis of chronic pruritus has provided a novel approach to the management of chronic inflammatory skin disorders. The present report provided an in-depth overview of the role of IL-31 in chronic skin diseases and the possible diagnostic and therapeutic applications in the management of these diseases. METHODS: A systematic review of IL-31 was conducted by using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. RESULTS: A review of a total of 45 published research articles revealed that the majority of these articles focused on the role of IL-31 in causation of pruritus and in the worsening of the disease in atopic dermatitis. Other publications examined interleukin in other pruritic diseases (cutaneous T-cell lymphoma, uremic pruritus, allergic contact dermatitis, chronic urticaria). In almost every disease, IL-31 levels were reported to be correlated with the pathology and often with pruritus. The cutaneous injection of IL-31 resulted in a long-lasting itching sensation, and the use of monoclonal antibodies that targeted IL-31 led to a reduction in pruritus. CONCLUSION: The use of monoclonal antibodies against mediators involved in the pathogenesis of chronic skin diseases has shown promising results. Antibodies that target IL-31, in particular, its receptor A, showed interesting results in atopic dermatitis and decreased pruritus. In subsequent years, the use of these new therapeutic strategies could change the scenario of pruritic skin diseases. However, further studies are needed to more rigorously examine the effects of IL-31 cascade blockage in different chronic skin diseases and to confirm efficacy and the safety of these new therapeutic approaches</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4080</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29046191">PM:29046191</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171019, Gangemi S</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4080</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42915</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aabom,A.</style></author><author><style face="normal" font="default"> Nguyen,D.</style></author><author><style face="normal" font="default"> Fisker,N.</style></author><author><style face="normal" font="default"> Bygum,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Health-related quality of life in Danish children with hereditary angioedema</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="446" start="440">440-446</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: The potentially life-threatening disease hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) can have considerable impact on the health-related quality of life (HRQoL) in adult patients. Half the patients with C1-INH-HAE develop symptoms before the age of 10 years. However, the HRQoL in children with C1-INH-HAE is almost unexplored. OBJECTIVE: To investigate HRQoL in Danish children with C1-INH-HAE, including possible correlations to disease severity and attack frequency. METHODS: All Danish children ages 2-18 years with C1-INH-HAE were invited to complete questionnaires regarding HRQoL; 14 (93%) agreed. Child self-report forms were used for children ages >/=5 years. The instruments used were the PedsQL (Child Self-Report and Parent Proxy-Report forms); the Children's Dermatology Life Quality Index; a nonvalidated, disease-specific quality-of-life questionnaire; and two visual analog scales that rated general health. RESULTS: The HRQoL scores in our study were comparable with the normal scores for healthy children and better than the scores in the only other study dedicated to HRQoL in children. Children with recent attacks had lower scores, whereas HRQoL scores were not correlated to overall disease severity or age. Surprisingly, home therapy was associated with lower HRQoL; however, home therapy was also correlated to a higher overall severity score and more frequent attacks. There was a strong child-parent agreement in the PedsQL forms, but scores were independent of whether the child had a family history of C1-INH-HAE or sporadic C1-INH-HAE and whether the parent completing the Parent Proxy-Report form carried the disease. CONCLUSION: Overall, the children assessed on average had a normal HRQoL and better than those with other common skin disorders. However, according to our findings, health care providers should be especially attentive to HRQoL when children with C1-INH-HAE become symptomatic</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4093</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29046193">PM:29046193</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171019, Aabom A</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4093</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42916</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bellanti,J.A.</style></author><author><style face="normal" font="default"> Settipane,R.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hereditary angioneurotic edema ... a disease has been described</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="400" start="399">399-400</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4102</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29046190">PM:29046190</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171019, Bellanti JA</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4102</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42917</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sullivan,P.W.</style></author><author><style face="normal" font="default"> Ghushchyan,V.</style></author><author><style face="normal" font="default"> Navaratnam,P.</style></author><author><style face="normal" font="default"> Friedman,H.S.</style></author><author><style face="normal" font="default"> Kavati,A.</style></author><author><style face="normal" font="default"> Ortiz,B.</style></author><author><style face="normal" font="default"> Lanier,B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Indicators of poorly controlled asthma and health-related quality of life among school-age children in the United States</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="439" start="431">431-439</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="11" Year="2017">2017/11/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Poorly controlled asthma has far-reaching effects on school-age children and their parents, but little is known about the national impact on health-related quality of life (HRQoL). OBJECTIVE: To examine HRQoL associated with asthma and indicators of poorly controlled asthma in the United States. METHODS: This was a cross-sectional analysis of HRQoL among school-age children (age range, 6-17 years) with asthma in the nationally representative 2007-2013 Medical Expenditure Panel Survey (MEPS). Indicators of poor asthma control included the following: exacerbation in the previous 12 months, use of more than three canisters of short-acting beta agonist in 3 months, and annual asthma-specific emergency department or inpatient visits. Health status and HRQoL instruments included the following: the Columbia Impairment Scale (CIS), Child Health Questionnaire (CHQ), Children with Special Health Care Needs Screener (CSHCN), and self-perceived physical and mental health. Ordered logistic regression was used for ordered categorical variables, and logistic regression was used for binary variables. All regressions controlled for sociodemographics and other covariates. RESULTS: There were 44,320 school-age children in the MEPS, of whom 5890 had asthma. School-age children with indicators of poorly controlled asthma had higher odds of feeling unhappy and/or sad or nervous and/or afraid, and of having problems with sports and/or hobbies and schoolwork on the CIS. Results from the CHQ showed that parents of school-age children with asthma and indicators of poorly controlled asthma had higher odds of worrying about their child's health and future. Results from the CSHCN showed that school-age children with asthma and indicators of poorly controlled asthma were more likely to have special health care needs. School-age children with asthma and indicators of poorly controlled asthma had higher odds of having poor perceived physical health. CONCLUSION: This nationally representative study provided novel information on the burden of poorly controlled asthma on emotional problems, school-related and activity limitations, general health status, and worry among school-age children and their families as measured by validated instruments</style></abstract><notes><style face="normal" font="default">DA - 20170812IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4084</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28800789">PM:28800789</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170812, Sullivan PW</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4084</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42918</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hampel,F.C.,Jr.</style></author><author><style face="normal" font="default"> Carr,W.</style></author><author><style face="normal" font="default"> Gillespie,M.</style></author><author><style face="normal" font="default"> Small,C.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Evaluation of beclomethasone dipropionate (80 and 160 micrograms/day) delivered via a breath-actuated inhaler for persistent asthma</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="430" start="419">419-430</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="11" Year="2017">2017/11/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Breath-actuated inhalers (BAI) may simplify the delivery of inhaled medications compared with other devices. OBJECTIVE: To evaluate the efficacy and safety of beclomethasone dipropionate BAI versus matching placebo in adolescent and adult patients with persistent asthma. METHODS: This phase III, 12-week, double-blind study enrolled patients with asthma aged >/=12 years who were previously treated with a stable dose of inhaled corticosteroid or noncorticosteroid therapy. After a run-in period of 14 to 21 days, patients were randomly assigned in a 1:1:1 ratio to beclomethasone dipropionate BAI 80 or 160 micrograms/day (40 or 80 micrograms twice daily) or placebo BAI. The primary end point was the standardized baseline-adjusted trough morning forced expiratory volume in 1 second (FEV1) area under the effect curve from time 0 to 12 weeks (AUEC[0-12 weeks]). Secondary end points included peak expiratory flow, rescue medication use, asthma symptoms, and the time to withdrawal due to meeting predefined criteria for worsening asthma. Additional end points evaluated quality of life, instructions for use, and safety. RESULTS: The full analysis and the safety sets included 270 and 273 patients, respectively. Patients who received beclomethasone dipropionate BAI 80 or 160 micrograms/day had significant improvements in FEV1 AUEC(0-12 weeks) versus placebo (p &lt;/= 0.001). Improvements in secondary end points were also apparent in patients who received beclomethasone dipropionate BAI 80 or 160 micrograms/day compared with placebo. Patients who received beclomethasone dipropionate BAI 80 or 160 micrograms/day had greater increases in Asthma Quality of Life Questionnaire scores versus placebo patients at week 12. Of 98 patients who participated in the instructions-for-use substudy, 87 (88.8%) used the inhaler successfully on their first attempt. Treatment was generally safe and well tolerated. CONCLUSION: Beclomethasone dipropionate BAI 80 and 160 micrograms/day were effective and well-accepted treatments in patients with asthma, with safety comparable to beclomethasone dipropionate delivered via a metered-dose inhaler.Clinical trial NCT02040779, &lt;ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov&lt;/ext-link></style></abstract><notes><style face="normal" font="default">DA - 20170909IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4089</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28886758">PM:28886758</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170909, Hampel FC Jr</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4089</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42919</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Li,H.H.</style></author><author><style face="normal" font="default"> Reshef,A.</style></author><author><style face="normal" font="default"> Baker,J.W.</style></author><author><style face="normal" font="default"> Harper,J.R.</style></author><author><style face="normal" font="default"> Relan,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Efficacy of recombinant human C1 esterase inhibitor for the treatment of severe hereditary angioedema attacks</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="461" start="456">456-461</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="11" Year="2017">2017/11/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Severe attacks of hereditary angioedema (HAE) are debilitating and potentially life threatening, and can increase anxiety and the use of medical resources. OBJECTIVE: This post hoc assessment evaluated recombinant human C1 esterase inhibitor (rhC1-INH) used to treat acute severe HAE attacks. METHODS: In a double-blind, randomized-controlled trial (RCT), patients with an HAE attack (baseline visual analog scale score of >/=50 mm, with severe attacks defined as >/=75 mm) were randomly assigned to receive rhC1-INH (50 IU/kg for patients who weighed &lt;84 kg; 4200 IU for patients who weighed >/=84 kg) or placebo. Also, in an open-label extension (OLE) study of rhC1-INH, oropharyngeal-laryngeal attacks were analyzed. Rescue therapy with rhC1-INH 50 IU/kg (&lt;/=4200 IU) was permitted after 4 hours or for life-threatening symptoms (in the RCT) or after 1 hour (in the OLE study). The primary end point measured the time to the beginning of symptom relief by using the Treatment Effects Questionnaire. RESULTS: Of 75 adults in the RCT, 43 had severe attacks and received either rhC1-INH (n = 24) or placebo (n = 19). The median (95% confidence interval) time to the onset of symptom relief totaled 90.0 minutes (95% confidence interval, 47.0-120.0 minutes) versus 334.0 minutes (95% confidence interval, 105.0 to not calculable minutes; hazard ratio, 2.5; p = 0.02), for rhC1-INH and placebo, respectively. Open-label rhC1-INH rescue therapy was administered to 1 of 24 in the rhC1-INH group (4.2%) and 10 of 19 in the placebo group (52.6%). During the OLE study, the median onset of symptom relief with rhC1-INH for eight oropharyngeal-laryngeal HAE attacks was 69.0 minutes (95% confidence interval, 59.0-91.0 minutes). CONCLUSION: In the current study, rhC1-INH was efficacious in resolving severe HAE attacks, including oropharyngeal-laryngeal attacks. The rhC1-INH rescue treatment rapidly improved symptoms for patients who received placebo and who experienced worsening or sustained symptoms</style></abstract><notes><style face="normal" font="default">DA - 20170906IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4088</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28874235">PM:28874235</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170906, Li HH</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4088</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42920</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nordenfelt,P.</style></author><author><style face="normal" font="default"> Nilsson,M.</style></author><author><style face="normal" font="default"> Lindfors,A.</style></author><author><style face="normal" font="default"> Wahlgren,C.F.</style></author><author><style face="normal" font="default"> Bjorkander,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Health-related quality of life in relation to disease activity in adults with hereditary angioedema in Sweden</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="455" start="447">447-455</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="11" Year="2017">2017/11/30</year></dates><abstract><style face="normal" font="default">BACKGROUND: Health-related quality of life (HR-QoL) is impaired in patients with hereditary angioedema (HAE) but has not yet been satisfactorily described. OBJECTIVE: To study HR-QoL in patients with HAE by combining different HR-QoL instruments with disease activity assessment. METHODS: All adults in the Swedish HAE registry were invited to take part in this questionnaire study, which used the generic HR-QoL instruments, EuroQol 5 Dimensions 5 Level (EQ-5D-5L) and the RAND Corporation Short Form 36 (RAND-36), the disease-specific Angioedema Quality of Life instrument (AE-QoL), the recently introduced Angioedema Activity Score (AAS) form, and questionnaires on sick leave and prophylactic medication. RESULTS: Sixty-four of 133 adults (26 men, 38 women) between 18 and 91 years old responded. The most affected HR-QoL dimensions in the EQ-5D-5L were pain/discomfort and anxiety/depression; in the RAND-36, energy/fatigue, general health, pain; and, in the AE-QoL, fears/shame and fatigue/mood. Women had lower HR-QoL in the RAND-36 for general health and energy/fatigue (p &lt; 0.05). Patients who reported any AAS of >0 had significantly impaired HR-QoL. There were significant associations (p &lt; 0.05) between the AAS and EQ-5D-5L, between the AAS and all dimensions of the RAND-36 except physical function, and between the AAS and AE-QoL in all dimensions. Nine of 36 patients who reported sick leave during the previous 4 weeks had significantly impaired HR-QoL in all the instruments (p &lt; 0.05). There was no significant difference in HR-QoL in the patients with and the patients without prophylactic medication, except for the nutrition dimension of the AE-QoL (p &lt; 0.05). CONCLUSION: Comprehensive information is obtained by combining different HR-QoL instruments. Pain, anxiety/depression, and fatigue/mood are important aspects of HAE but the AE-QoL disregards pain. HR-QoL was not significantly affected by prophylaxis. Increased disease activity was associated with impaired HR-QoL, which justifies more active disease management</style></abstract><notes><style face="normal" font="default">DA - 20170831IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4087</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28855002">PM:28855002</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170831, Nordenfelt P</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4087</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42921</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Riedl,M.A.</style></author><author><style face="normal" font="default"> Li,H.H.</style></author><author><style face="normal" font="default"> Cicardi,M.</style></author><author><style face="normal" font="default"> Harper,J.R.</style></author><author><style face="normal" font="default"> Relan,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Recombinant human C1 esterase inhibitor for acute hereditary angioedema attacks with upper airway involvement</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="466" start="462">462-466</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="11" Year="2017">2017/11/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: Recombinant human C1 esterase inhibitor (rhC1-INH) is approved for treatment of hereditary angioedema (HAE) in adolescents and adults. HAE attacks that involve the upper airway can be life threatening, and data on the administration of rhC1-INH for these types of attacks are currently limited. OBJECTIVE: To evaluate the efficacy and safety of rhC1-INH for treatment of acute HAE attacks with upper airway involvement. METHODS: A pooled analysis of data from three clinical trials with open-label extensions examined rhC1-INH for treatment of acute HAE attacks with upper airway involvement. Patients with functional plasma C1 esterase inhibitor &lt;50% of normal who had experienced an acute upper airway HAE attack and received rhC1-INH were identified retrospectively based on severity of breathing or swallowing symptoms. The primary end point was the time to beginning of relief (time at which the overall visual analog scale score [0-100 mm] decreased from baseline by >/=20 mm for two consecutive time points [persistence]). RESULTS: Of 683 acute HAE attacks treated with rhC1-INH, data for 45 attacks with upper airway involvement were included. The median time to the beginning of symptom relief was 67 minutes (95% confidence interval, 60-120 minutes) and did not differ by attack number or by baseline breathing or swallowing symptom severity. Most attacks (91.1%) achieved the beginning of relief within 4 hours of rhC1-INH treatment. All attacks resolved without the need for any additional medication, and no patients required intubation or tracheostomy. Treatment with rhC1-INH was well tolerated, with no adverse events reported in more than one patient (except HAE reported as an adverse event [n = 2]). CONCLUSION: This pooled analysis of clinical trial data supports the efficacy of rhC1-INH for treatment of acute HAE attacks with upper airway involvement</style></abstract><notes><style face="normal" font="default">DA - 20170914IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal Article</style></notes><work-type><style face="normal" font="default">10.2500/aap.2017.38.4090.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28903805">PM:28903805</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20170914, Riedl MA</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2017.38.4090.</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42922</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hoy,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand.</style></auth-address><titles><title><style face="normal" font="default">Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">Am J Clin Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Clin Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="10" Year="2017">2017/10/26</year></dates><abstract><style face="normal" font="default">Crisaborole ointment 2% (Eucrisa) is a novel, anti-inflammatory inhibitor of phosphodiesterase 4 (PDE4) that is available in the USA for the topical treatment of mild to moderate atopic dermatitis in patients aged >/= 2 years. In two short-term (28 days), identically designed, multicentre, phase III studies in this patient population, topical therapy with crisaborole ointment 2% reduced disease severity and pruritus severity compared with vehicle, with the effect established early and sustained over the course of treatment. Improvements in the other signs of atopic dermatitis (erythema, exudation, excoriation, induration/papulation, and lichenification) were also seen. Crisaborole ointment 2% was generally well tolerated in the short-term studies, with its favorable safety profile maintained over the longer term (up to 52 weeks) in a multicentre, extension study. Most treatment-emergent adverse events (TEAEs) were of mild to moderate severity and considered unrelated to the study medication. Moreover, the incidence of application-site pain following short- and longer-term topical therapy with crisaborole ointment 2% was low. In conclusion, crisaborole ointment 2% is an effective and generally well tolerated new topical option for the management of mild to moderate atopic dermatitis in patients aged >/= 2 years, with the potential to effectively treat this patient population over the longer term without the safety concerns associated with other current topical anti-inflammatory agents</style></abstract><notes><style face="normal" font="default">DA - 20171027IS - 1179-1888 (Electronic)IS - 1175-0561 (Linking)LA - engPT - Journal ArticleCO - New Zealand -</style></notes><work-type><style face="normal" font="default">10.1007/s40257-017-0327-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29076116">PM:29076116</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Clin Dermatol\20171027-HoySM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Clin Dermatol\20171027-HoySM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171027, Hoy SM</style></custom2><misc3><style face="normal" font="default">10.1007/s40257-017-0327-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42923</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dean,R.K.</style></author><author><style face="normal" font="default"> Subedi,R.</style></author><author><style face="normal" font="default"> Christiano,P.</style></author><author><style face="normal" font="default"> Ghimire,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, United States.</style></auth-address><titles><title><style face="normal" font="default">More than a drink: A rare anaphylactic reaction to sparkling water</style></title><secondary-title><style face="normal" font="default">Am J Emerg Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Emerg Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="10" Year="2017">2017/10/7</year></dates><abstract><style face="normal" font="default">Anaphylaxis is a potentially life threatening, type I hypersensitivity reaction which can occur within seconds to minutes after exposure to an allergen. Sulfites have been implicated in causing such reactions with symptoms ranging from mild to potentially life threatening. Here we present a patient who had an anaphylactic reaction secondary to exposure to sulfites found in sparkling water</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 1532-8171 (Electronic)IS - 0735-6757 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.ajem.2017.10.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29031480">PM:29031480</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Emerg Med\20171016-DeanKR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Emerg Med\20171016-DeanKR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171016, Dean KR</style></custom2><misc3><style face="normal" font="default">10.1016/j.ajem.2017.10.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42924</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Papi,A.</style></author><author><style face="normal" font="default"> Beghe,B.</style></author><author><style face="normal" font="default"> Fabbri,L.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Ferrara, Research Centre on Asthma and COPD , Via Savonarola 9 , Ferrara, Italy</style></auth-address><titles><title><style face="normal" font="default">We Have to Learn to Do Without Knowing Enough: Anti-Eosinophilic Treatments for Severe Asthma</style></title><secondary-title><style face="normal" font="default">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Crit Care Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="10" Year="2017">2017/10/18</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171018IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1164/rccm.201710-1970ED</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29043835">PM:29043835</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171018, Papi A</style></custom2><misc3><style face="normal" font="default">10.1164/rccm.201710-1970ED</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42925</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rusconi,F.</style></author><author><style face="normal" font="default"> Gagliardi,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Anna Meyer Children's University Hospital, Epidemiology Unit, Florence, Italy</style></auth-address><titles><title><style face="normal" font="default">Pregnancy Complications and Wheezing and Asthma in Childhood</style></title><secondary-title><style face="normal" font="default">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Crit Care Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="24" Month="10" Year="2017">2017/10/24</year></dates><abstract><style face="normal" font="default">This review focuses on recent advances in the field of several frequent maternal complications in pregnancy and asthma and wheezing in childhood, for which large birth cohort studies have recently provided clues. Within the framework of epidemiologic studies, we discuss potential mechanisms, mediators and confounders involved in associations, in an attempt to discern causal pathways. Preeclampsia, a pregnancy-specific multiorgan disease that affects 2-4% of women in developed countries, is characterized by placental dysfunction and is associated with preterm delivery, fetal growth restriction and vascular and lung effects in the fetus. Recent cohort studies have found an association with asthma and wheezing in offspring, probably partly mediated by being preterm or small for gestational age. Obesity, diabetes, maternal depression, anxiety and psychological stress are increasingly complicating the course of pregnancy. With the exception of diabetes, for the other conditions, several studies have found associations especially with wheezing in early childhood. Biologically plausible mechanisms acting on the developing lung and on the modulation of immune function have been suggested. The importance of prenatal and postnatal confounders and mediators still needs to be fully ascertained. Cesarean deliveries are increasing in many countries, and available epidemiological evidence indicates that children born by cesarean delivery suffer from an increased risk of asthma. Recent studies suggest that the association between planned cesarean delivery - often an avoidable condition- and asthma development in childhood is stronger than that of emergency caesarean delivery, however consensus has still not been reached</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1164/rccm.201704-0744PP</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29064265">PM:29064265</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171024, Rusconi F</style></custom2><misc3><style face="normal" font="default">10.1164/rccm.201704-0744PP</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42926</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bhakta,N.R.</style></author><author><style face="normal" font="default"> Christenson,S.A.</style></author><author><style face="normal" font="default"> Nerella,S.</style></author><author><style face="normal" font="default"> Solberg,O.D.</style></author><author><style face="normal" font="default"> Nguyen,C.P.</style></author><author><style face="normal" font="default"> Choy,D.F.</style></author><author><style face="normal" font="default"> Jung,K.L.</style></author><author><style face="normal" font="default"> Garudadri,S.</style></author><author><style face="normal" font="default"> Bonser,L.R.</style></author><author><style face="normal" font="default"> Pollack,J.L.</style></author><author><style face="normal" font="default"> Zlock,L.T.</style></author><author><style face="normal" font="default"> Erle,D.J.</style></author><author><style face="normal" font="default"> Langelier,C.</style></author><author><style face="normal" font="default"> Derisi,J.L.</style></author><author><style face="normal" font="default"> Arron,J.R.</style></author><author><style face="normal" font="default"> Fahy,J.V.</style></author><author><style face="normal" font="default"> Woodruff,P.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of California San Francisco, 8785, San Francisco, California, United States</style></auth-address><titles><title><style face="normal" font="default">Interferon-stimulated Gene Expression, Type-2 Inflammation and Endoplasmic Reticulum Stress in Asthma</style></title><secondary-title><style face="normal" font="default">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Crit Care Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="24" Month="10" Year="2017">2017/10/24</year></dates><abstract><style face="normal" font="default">RATIONALE: Quantification of type-2 inflammation provided a molecular basis for heterogeneity in asthma. Non-type-2 pathways that contribute to asthma pathogenesis are not well understood. OBJECTIVES: To identify dysregulated pathways beyond type-2 inflammation. METHODS: We applied RNA sequencing to airway epithelial brushings obtained from stable mild asthmatics not on corticosteroids (n=19) and healthy controls (n=16). Sequencing reads were mapped to human and viral genomes. In the same cohort, and in a separate group with severe asthma (n=301), we profiled blood gene expression with microarrays. MEASUREMENTS AND MAIN RESULTS: In airway brushings from mild asthma on inhaled corticosteroids, RNA sequencing yielded 1379 differentially expressed genes (FDR&lt;0.01). Pathway analysis revealed increased expression of type-2 markers, interferon-stimulated gene (ISGs) and endoplasmic reticulum (ER) stress-related genes. Airway epithelial ISG expression was not associated with type-2 inflammation in asthma or with viral transcripts, but was associated with reduced lung function by FEV1 (rho=-0.72, p=0.0004). ER stress was confirmed by an increase in XBP1 splicing in mild asthma and was associated with both type-2 inflammation and ISG expression. ISGs were also the most activated genes in blood cells in asthma and were correlated with airway ISG expression (rho=0.55 p=0.030). High blood ISG expression in severe asthma was similarly unrelated to type-2 inflammation. CONCLUSIONS: ISG activation is prominent in asthma, independent of viral transcripts, orthogonal to type-2 inflammation, and associated with distinct clinical features. ER stress is associated with both type-2 inflammation and ISG expression</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1164/rccm.201706-1070OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29064281">PM:29064281</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171024, Bhakta NR</style></custom2><misc3><style face="normal" font="default">10.1164/rccm.201706-1070OC</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42927</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martinez,F.D.</style></author><author><style face="normal" font="default"> Guerra,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Arizona HSC, Tucson, Arizona, United States</style></auth-address><titles><title><style face="normal" font="default">Early Origins of Asthma: Role of Microbial Dysbiosis and Metabolic Dysfunction</style></title><secondary-title><style face="normal" font="default">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Crit Care Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="default">Asthma is a developmental disease that affects airway growth and is characterized by inappropriate responses to a variety of environmental stimuli. Recent advances point to two altered early life pathways as major determinants of asthma risk. In the "microbial" pathway, pre- and post-natal exposures to microbiota-loaded farm environments block gene-virus interactions (e.g., interactions between risk alleles in chromosome 17q21 and lower respiratory illnesses [LRI] by rhinovirus) that are associated with asthma development. Early colonization of the airway by pathogenic bacteria such as Streptococci and Moraxella may predispose for recurrent wheezing LRIs and subsequent asthma. Abnormal patterns of gut microbial colonization (dysbiosis) in the first months of life are associated with production of deleterious metabolic products that predispose for the development of asthma and reduction of beneficial metabolites, such as short-chain fatty acids, that may protect from the disease. The "metabolic" pathway is triggered by maternal obesity, excessive weight gain during pregnancy, and accelerated body mass index growth in the first years of life, which in turn predispose for early development of both metabolic alterations and asthma phenotypes. Notably, early gut dysbiosis is also associated with subsequent development of obesity, although it is currently unknown whether there are common intestinal microbial patterns in obesity- and asthma-associated dysbiosis. Promising avenues for asthma prevention could entail manipulating these two pathways with microbes, surrogates of animal farm exposures, or dietary supplements such as n-3 long-chain polyunsaturated fatty acids</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1164/rccm.201706-1091PP</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29048927">PM:29048927</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171019, Martinez FD</style></custom2><misc3><style face="normal" font="default">10.1164/rccm.201706-1091PP</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42928</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sadleir,P.H.M.</style></author><author><style face="normal" font="default"> Clarke,R.C.</style></author><author><style face="normal" font="default"> Bozic,B.</style></author><author><style face="normal" font="default"> Platt,P.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Sir Charles Gairdner Hospital, Nedlands, Australia</style></auth-address><titles><title><style face="normal" font="default">Consequences of proceeding with surgery after resuscitation from intra-operative anaphylaxis</style></title><secondary-title><style face="normal" font="default">Anaesthesia</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Anaesthesia</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="2" Month="11" Year="2017">2017/11/2</year></dates><abstract><style face="normal" font="default">Intra-operative acute hypersensitivity reactions require a decision to be made regarding whether to proceed with or abandon the planned surgical procedure once the patient has stabilised. Using retrospective case controls, we examined all cases (223) of proven acute hypersensitivity reactions from 2005 to 2014 in Western Australia, in which the syndrome was recognised by the treating clinician before or during surgery, to determine whether recovery outcomes were adversely affected by proceeding with the planned procedure. Surgery proceeded in 104 patients (47%) and was abandoned in 119 (53%). The severity of acute hypersensitivity reactions was Societe Francaise d'Anesthesie et de Reanimation grade 1 or 2 in 56 patients (25%), grade 3 in 128 (56%) and grade 4 in 39 (17%). Abandoning surgery was more common in patients with increasing severity of hypersensitivity. The rate of major hypersensitivity-related complications for all patients was zero for grade 1 and 2 reactions, 4.7% for grade 3 and 12.8% for grade 4. There were no deaths. Patients in whom surgery was completed were not observed to have a higher frequency of major hypersensitivity-related complications when compared with cases of similar severity in whom surgery was abandoned. For patients admitted to the intensive care unit, proceeding with surgery was not associated with an increased duration of mechanical ventilation of the lungs. Our results suggest that, once initial resuscitation has been achieved and if resuscitative efforts can be re-instituted if required, continuing with planned surgery in grade 1, 2 and 3 immediate hypersensitivity was not associated with poorer outcomes. After grade 3 reactions, there was a significant incidence of complications attributable to acute hypersensitivity regardless of whether surgery proceeded or was abandoned. Surgery was frequently abandoned in grade 4 immediate hypersensitivity and was associated with a high rate of complications</style></abstract><notes><style face="normal" font="default">DA - 20171102IS - 1365-2044 (Electronic)IS - 0003-2409 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/anae.14106</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29094752">PM:29094752</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Anaesthesia\20171102-SadleirPH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Anaesthesia\20171102-SadleirPH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171102, Sadleir PH</style></custom2><misc3><style face="normal" font="default">10.1111/anae.14106</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42929</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pfutzner,W.</style></author><author><style face="normal" font="default"> Wulf,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">[Perioperative Anaphylaxia on Drugs]</style></title><secondary-title><style face="normal" font="default">Anasthesiol Intensivmed Noftallmed Schmerzther</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Anasthesiol Intensivmed Noftallmed Schmerzther</style></abbr-1></periodical><pages end="715" start="704">704-715</pages><volume><style face="normal" font="default">52</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">The diagnostic evaluation of perioperative anaphylaxia is of great importance for the medical care of the affected persons in the context of renewed interventions in general anesthesia. The most frequent triggers include muscle relaxants, antibiotics, latex and analgesics of the type of the cyclooxygenase inhibitors, but other perioperatively administered drugs such as opioids, anesthetics, benzodiazepines, dyes, disinfectants and even corticosteroids or drug additives may also be the cause in rare cases. The most important aim is therefore the identification of the responsible drug, for which a near-time allergological diagnosis should be carried out within the first 4 weeks to 6 months after the reaction. At the end of the examinations, the patient receives a structured allergy passport, which includes information on the drug reaction, the triggers and alternative medicines, as well as possible preventive measures for future surgical procedures. It should be noted, however, that the latter are not a guarantee that, upon renewed exposure to the causative medicinal product, there will be no, possibly even heavier, anaphylactic reaction</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 1439-1074 (Electronic)IS - 0939-2661 (Linking)LA - gerPT - English AbstractPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1055/s-0043-100231</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29050061">PM:29050061</url></web-urls></urls><custom2><style face="normal" font="default">20171019, Pfutzner W</style></custom2><misc3><style face="normal" font="default">10.1055/s-0043-100231</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42930</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Miyazaki,Y.</style></author><author><style face="normal" font="default"> Sunaga,H.</style></author><author><style face="normal" font="default"> Kida,K.</style></author><author><style face="normal" font="default"> Hobo,S.</style></author><author><style face="normal" font="default"> Inoue,N.</style></author><author><style face="normal" font="default"> Muto,M.</style></author><author><style face="normal" font="default"> Uezono,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Department of Anesthesiology, Jikei University School of Medicine, Tokyo, Japan; and daggerDepartment of Anesthesiology, Mitsui Memorial Hospital, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">Incidence of Anaphylaxis Associated With Sugammadex</style></title><secondary-title><style face="normal" font="default">Anesth Analg</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Anesth Analg</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="default">We retrospectively investigated the incidence of potential sugammadex-induced anaphylaxis at a single center in Japan over a period of 3 years. The overall incidence of intraoperative hypersensitivity reaction was 0.22% (95% confidence interval [CI], 0.17%-0.29%), and the incidence of anaphylaxis was 0.059% (95% CI, 0.032%-0.10%). The total number of patients who received sugammadex during the study period was 15,479, and the incidence of anaphylaxis associated with sugammadex was 0.039% (n = 6; 95% CI, 0.014%-0.084%). This result implies that the incidence of sugammadex-associated anaphylaxis could be as high as that for succinylcholine or rocuronium. A prospective study, including testing for identification of cause, is necessary to confirm the exact incidence of sugammadex-induced anaphylaxis; however, the present finding calls attention to this potential</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1526-7598 (Electronic)IS - 0003-2999 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1213/ANE.0000000000002562</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29064876">PM:29064876</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Anesth Analg\20171024-MiyazakiY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Anesth Analg\20171024-MiyazakiY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171024, Miyazaki Y</style></custom2><misc3><style face="normal" font="default">10.1213/ANE.0000000000002562</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42931</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Caraballo,J.</style></author><author><style face="normal" font="default"> Binkley,E.</style></author><author><style face="normal" font="default"> Han,I.</style></author><author><style face="normal" font="default"> Dowden,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy and Immunology, University of Iowa Hospitals and Clinics, Iowa City, Iowa.</style></auth-address><titles><title><style face="normal" font="default">Intraoperative anaphylaxis to bacitracin during scleral buckle surgery</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="10" Year="2017">2017/10/14</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171018IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.09.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29042173">PM:29042173</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171018-CaraballoJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171018-CaraballoJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171018, Caraballo J</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.09.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42932</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ross,M.K.</style></author><author><style face="normal" font="default"> Yoon,J.</style></author><author><style face="normal" font="default"> van der Schaar,A.</style></author><author><style face="normal" font="default"> van der Schaar,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of California, Los Angeles, Pediatrics, Division of Pulmonary and Sleep Medicine, Los Angeles, California, United States</style></auth-address><titles><title><style face="normal" font="default">Discovering Pediatric Asthma Phenotypes Based on Response to Controller Medication Using Machine Learning</style></title><secondary-title><style face="normal" font="default">Ann Am Thorac Soc</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Am Thorac Soc</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="default">RATIONALE: Pediatric asthma has variable underlying inflammation and symptom control. Approaches to address this heterogeneity such as clustering methods to find phenotypes and predicting outcomes have been investigated. However, clustering based upon the relationship between treatment and clinical outcome has not been performed. Also, machine learning approaches for long-term outcome prediction in pediatric asthma have not been studied in depth. OBJECTIVES: Our objectives were to use our novel machine learning algorithm, Predictor Pursuit (PP) to discover pediatric asthma phenotypes based on treatment response to different asthma controller medications, to predict outcomes of children with asthma over time, and to identify the most indicative features of asthma control for the discovered pediatric phenotypes. METHODS: We applied PP to the Childhood Asthma Management Program (CAMP) study data (n=1,019) to discover phenotypes based on treatment outcome (budesonide vs. nedocromil). We confirmed PP's ability to discover phenotypes using the Asthma Clinical Research Network (ACRN)/Childhood Asthma Research and Education (CARE) network data. We next predicted children's asthma outcomes over time and compared PP's performance to traditional prediction methods. Last, we determined the clinical features most correlated with asthma control in the discovered phenotypes. RESULTS: Four phenotypes were discovered in both datasets: allergic-not-obese (A(+)/O(-)), obese-not-allergic (A(-)/O(+)), allergic-and-obese (A(+)/O(+)), and neither-obese-nor-allergic (A(-)/O(-)). Of the well-controlled children in the CAMP dataset, we found more non-obese children treated with budesonide than nedocromil (p=0.015) and more obese children treated with nedocromil than budesonide (p=0.008). Within the obese group, more A(+)/O(+) children were well-controlled with nedocromil than budesonide (p=0.022) or placebo (p=0.011). The PP algorithm performed significantly better (p&lt;0.001) than traditional machine learning algorithms for both short and long-term asthma control prediction. In the short-term (four months), control state followed by airways hyperreactivity was most predictive of outcome regardless of treatment or phenotype. In the long-term (one year), less airways hyperreactivity and serum eosinophils were most predictive of better control regardless of phenotype or assigned medication. CONCLUSIONS: Advanced statistical machine learning approaches can be a powerful tool to discover phenotypes based upon treatment response and to predict outcomes in complex medical conditions such as asthma</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 2325-6621 (Electronic)IS - 2325-6621 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1513/AnnalsATS.201702-101OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29048949">PM:29048949</url></web-urls></urls><custom2><style face="normal" font="default">20171019, Ross MK</style></custom2><misc3><style face="normal" font="default">10.1513/AnnalsATS.201702-101OC</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42933</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Garval,E.</style></author><author><style face="normal" font="default"> Vuiblet,V.</style></author><author><style face="normal" font="default"> Durlach,A.</style></author><author><style face="normal" font="default"> Perceau,G.</style></author><author><style face="normal" font="default"> Anuset,D.</style></author><author><style face="normal" font="default"> Bernard,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Service de dermatologie, hopital Robert-Debre, CHU de Reims, avenue du General-Koenig, 51092 Reims cedex, France.</style></auth-address><titles><title><style face="normal" font="default">[Skin pigmentation induced by meropenem and levofloxacin]</style></title><secondary-title><style face="normal" font="default">Ann Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="10" Year="2017">2017/10/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Various cutaneous side-effects, including, exanthema, pruritus, urticaria and Lyell or Stevens-Johnson syndrome, have been reported with meropenem (carbapenem), a rarely-prescribed antibiotic. Levofloxacin (fluoroquinolone), a more frequently prescribed antibiotic, has similar cutaneous side-effects, as well as photosensitivity. We report a case of cutaneous hyperpigmentation induced by meropenem and levofloxacin. PATIENTS AND METHODS: A 67-year-old male was treated with meropenem (1gx4 daily), levofloxacin (500mg twice daily) and amikacin (500mg daily) for 2 weeks, followed by meropenem, levofloxacin and rifampicin (600mg twice daily) for 4 weeks for osteitis of the fifth metatarsal. Three weeks after initiation of antibiotic therapy, dark hyperpigmentation appeared on the lower limbs, predominantly on the anterior aspects of the legs. Histology revealed dark, perivascular and interstitial deposits throughout the dermis, which stained with both Fontana-Masson and Perls stains. Infrared microspectroscopy revealed meropenem in the dermis of involved skin. After withdrawal of the antibiotics, the pigmentation subsided slowly. DISCUSSION: Similar cases of cutaneous hyperpigmentation have been reported after use of minocycline. In these cases, histological examination also showed iron and/or melanin deposits within the dermis, but the nature of the causative pigment remains unclear. In our case, infrared spectroscopy enabled us to identify meropenem in the dermis. Two cases of cutaneous hyperpigmentation have been reported following use of levofloxacin, and the results of histological examination were similar. This is the first case of cutaneous hyperpigmentation induced by meropenem</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 0151-9638 (Print)IS - 0151-9638 (Linking)LA - frePT - English AbstractPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.annder.2017.05.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29031417">PM:29031417</url></web-urls></urls><custom2><style face="normal" font="default">20171016, Garval E</style></custom2><misc3><style face="normal" font="default">10.1016/j.annder.2017.05.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42934</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stanbrook,M.B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Azithromycin reduced exacerbations and improved QoL in symptomatic asthma despite inhaled maintenance therapy</style></title><secondary-title><style face="normal" font="default">Ann Intern Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Intern Med</style></abbr-1></periodical><pages end="" start="JC42">JC42-</pages><volume><style face="normal" font="default">167</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="10" Year="2017">2017/10/17</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 1539-3704 (Electronic)IS - 0003-4819 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.7326/ACPJC-2017-167-8-042</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29049761">PM:29049761</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Intern Med\2017-167-JC42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Intern Med\2017-167-JC42.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Stanbrook MB</style></custom2><misc3><style face="normal" font="default">10.7326/ACPJC-2017-167-8-042</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42935</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chary,A.</style></author><author><style face="normal" font="default"> Hennen,J.</style></author><author><style face="normal" font="default"> Klein,S.G.</style></author><author><style face="normal" font="default"> Serchi,T.</style></author><author><style face="normal" font="default"> Gutleb,A.C.</style></author><author><style face="normal" font="default"> Blomeke,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Environmental Research and Innovation (ERIN) Department, Luxembourg Institute of Science and Technology (LIST), 5 Avenue des Hauts-Fourneaux, 4362, Esch-sur-Alzette, Grand Duchy of Luxembourg</style></auth-address><titles><title><style face="normal" font="default">Respiratory sensitization: toxicological point of view on the available assays</style></title><secondary-title><style face="normal" font="default">Arch Toxicol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Arch Toxicol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="default">Respiratory sensitization as a consequence of exposure to chemical products has increased over the last decades, leading to an increase of morbidity. The increased use of synthetic compounds resulted in an exponential growth of substances to which we are potentially exposed on a daily basis. Some of them are known to induce respiratory sensitization, meaning that they can trigger the development of allergies. In the past, animal studies provided useful results for the understanding of mechanisms involved in the development of respiratory allergies. However, the mechanistic understanding of the involved cellular effects is still limited. Currently, no in vitro or in vivo models are validated to identify chemical respiratory sensitizers. Nonetheless, chemical respiratory sensitizers elicit a positive response in validated assays for skin sensitization. In this review, we will discuss how these assays could be used for respiratory sensitization and if necessary, what can be learnt from these assays to develop a model to assess the respiratory sensitizing potential of chemicals. In the last decades, much work has been done to study the respiratory toxicity of inhaled compounds especially in developing in vitro assays grown at the air-liquid interface. We will discuss how possibly the tests currently used to investigate general particle toxicity could be transformed to investigate respiratory sensitization. In the present review, we describe the most known mechanism involved in the sensitization process and the experimental in vivo and alternative in vitro models, which are currently available and how to adapt and improve existing models to study respiratory sensitization</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 1432-0738 (Electronic)IS - 0340-5761 (Linking)LA - engPT - Journal ArticleCO - Luxembourg -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1007/s00204-017-2088-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29038838">PM:29038838</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Arch Toxicol\20171017-CharyA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Arch Toxicol\20171017-CharyA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Chary A</style></custom2><misc3><style face="normal" font="default">10.1007/s00204-017-2088-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42936</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,J.</style></author><author><style face="normal" font="default"> Lee,B.S.</style></author><author><style face="normal" font="default"> Kim,B.</style></author><author><style face="normal" font="default"> Na,I.</style></author><author><style face="normal" font="default"> Lee,J.</style></author><author><style face="normal" font="default"> Lee,J.Y.</style></author><author><style face="normal" font="default"> Park,M.R.</style></author><author><style face="normal" font="default"> Kim,H.</style></author><author><style face="normal" font="default"> Sohn,I.</style></author><author><style face="normal" font="default"> Ahn,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnamgu, Seoul 06351, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Identification of atopic dermatitis phenotypes with good responses to probiotics (Lactobacillus plantarum CJLP133) in children</style></title><secondary-title><style face="normal" font="default">Benef Microbes</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Benef Microbes</style></abbr-1></periodical><pages end="761" start="755">755-761</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="10" Year="2017">2017/10/13</year></dates><abstract><style face="normal" font="default">The therapeutic effect of probiotics in atopic dermatitis (AD) remains controversial and varies according to the individual patient. We aimed to identify a population of AD patients with a good clinical response to probiotic treatment. We recruited 76 children with a median age of 7.1 years who suffered from moderate to severe AD. After a 2-week washout period, all patients were given Lactobacillus plantarum CJLP133 at a dosage of 1x1010 colony-forming units once a day for 12 weeks. We measured eosinophil counts in the peripheral blood, the proportion of CD4+CD25+Foxp3+ regulatory T (Treg) cells in CD4+ T cells, serum total immunoglobulin E (IgE) levels, and specific IgE against common allergens before the start of the treatment (T1) and at discontinuation (T2). Responders were defined as patients with at least a 30% reduction in the SCORing of AD (SCORAD) index after treatment. There were 36 responders and 40 non-responders after probiotic treatment. The median SCORAD was reduced from 29.5 (range 20.6-46.3) at T1 to 16.4 (range 6.3-30.8) at T2 in the responder group (P&lt;0.001). In multivariable logistic regression analysis, a good clinical response was significantly associated with high total IgE levels (aOR 5.1, 95% CI 1.1-23.6), increased expression of transforming growth factor (TGF)-beta (aOR 4.6, 95% CI 1.3-15.9), and a high proportion of Treg cells in CD4+ T cells (aOR 3.7, 95% CI 1.1-12.7) at T1. In the responder group, the proportion of Treg cells was significantly increased after 12 weeks of treatment (P=0.004), while TGF-beta mRNA expression was decreased (P=0.017). Our results suggest that a subgroup of patients with a specific AD phenotype showing an immunologically active state (high total IgE, increased expression of TGF-beta, high numbers of Treg cells) may benefit from probiotic treatment with L. plantarum CJLP133</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 1876-2891 (Electronic)IS - 1876-2883 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.3920/BM2017.0034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29035111">PM:29035111</url></web-urls></urls><custom2><style face="normal" font="default">20171016, Kim J</style></custom2><misc3><style face="normal" font="default">10.3920/BM2017.0034</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42937</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Li,L.</style></author><author><style face="normal" font="default"> Wang,X.</style></author><author><style face="normal" font="default"> Meng,H.</style></author><author><style face="normal" font="default"> Liu,G.</style></author><author><style face="normal" font="default"> Liu,C.</style></author><author><style face="normal" font="default"> Dong,Y.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">In vitro and in vivo anti-allergic effects of an extract of a traditional Chinese medicine preparation</style></title><secondary-title><style face="normal" font="default">Biomed Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Biomed Dermatol</style></full-title></periodical><pages end="" start="5">5-</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2398-8460</style></isbn><abstract><style face="normal" font="default">The present research was conducted to investigate the in vivo and in vitro anti-allergic activity of a traditional Chinese medicine formulation comprising Ampelopsis grossedentata, Saposhnikovia divaricata, Sophora flavescens, Angelica sinensis, Ophiopogon japonicus, and Cornus officinalis</style></abstract><notes><style face="normal" font="default">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="default">10.1186/s41702-017-0005-4</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1186/s41702-017-0005-4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biomed Dermatol\20171031-LiL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biomed Dermatol\20171031-LiL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171031, Li L</style></custom2><misc3><style face="normal" font="default">10.1186/s41702-017-0005-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42938</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gionfriddo,M.R.</style></author><author><style face="normal" font="default"> Hagan,J.B.</style></author><author><style face="normal" font="default"> Rank,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Pharmacy Innovation and Outcomes, Geisinger Health System, Forty Fort, PA, USA</style></auth-address><titles><title><style face="normal" font="default">Why and how to step down chronic asthma drugs</style></title><secondary-title><style face="normal" font="default">BMJ</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ</style></abbr-1></periodical><pages end="" start="j4438">j4438-</pages><volume><style face="normal" font="default">359</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Administration,Inhalation</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> drug therapy</style></keyword><keyword><style face="normal" font="default"> prevention &amp; control</style></keyword><keyword><style face="normal" font="default"> Bronchodilator Agents</style></keyword><keyword><style face="normal" font="default"> administration &amp; dosage</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Dose-Response Relationship,Drug</style></keyword><keyword><style face="normal" font="default"> Drug Substitution</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Pulmonary Disease,Chronic Obstructive</style></keyword><keyword><style face="normal" font="default"> Randomized Controlled Trials as Topic</style></keyword></keywords><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="default">Asthma is a common chronic airways disease. The goal of asthma management is to control symptoms while minimizing the side effects of treatment. Following a period of stable asthma, clinicians should consider stepping down treatment. This approach is recommended by current guidelines. Step-down has been studied for several types of asthma drug regimens, and certain approaches may have lower risk than others. Systematic reviews of multiple trials support the following specific step-down approaches: optimizing inhaled corticosteroid dosing when stepping down oral corticosteroid, reducing inhaled corticosteroid from a higher dose, lowering inhaled corticosteroid-long acting bronchodilator (ICS-LABA) dose while adding ICS-LABA on-demand, adding leukotriene receptor antagonist (LTRA) while lowering inhaled corticosteroid dose, and using allergen immunotherapy when reducing inhaled corticosteroid from a higher dose. Systematic reviews of multiple trials support an increased risk of asthma exacerbation for patients who completely stop taking inhaled corticosteroid or long acting bronchodilator. Strategies to implement step-down in practice include the use of risk prediction as well as tools to support shared decision making and communication about risk between clinicians and patients</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 1756-1833 (Electronic)IS - 0959-535X (Linking)LA - engPT - Journal ArticlePT - ReviewRN - 0 (Bronchodilator Agents)SB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.1136/bmj.j4438</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29038166">PM:29038166</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ\2017-359-j4438.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ\2017-359-j4438.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Gionfriddo MR</style></custom2><misc3><style face="normal" font="default">10.1136/bmj.j4438</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42939</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Namiki,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Yonaguni Municipal Clinic, Japan Association for Development of Community Medicine, Okinawa, Japan</style></auth-address><titles><title><style face="normal" font="default">Exercise-induced anaphylaxis in an elderly patient</style></title><secondary-title><style face="normal" font="default">BMJ Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="24" Month="10" Year="2017">2017/10/24</year></dates><abstract><style face="normal" font="default">A 75-year-old Japanese woman presented with acute flushing pruritus and a feeling of diffuse warmth followed by collapse while dancing. After resting for 30 min and receiving a rapid infusion of 0.9% sodium chloride, her condition stabilised. She admitted that she had a similar experience 2 years earlier while dancing. Based on her history, her symptoms were attributed to exercise-induced anaphylaxis. None of the episodes was associated with any other suspicious cotriggers of anaphylaxis. She was successfully discharged from the clinic without any complications after receiving careful guidance on how to prevent this condition</style></abstract><notes><style face="normal" font="default">DA - 20171025IS - 1757-790X (Electronic)IS - 1757-790X (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1136/bcr-2017-222297</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29066661">PM:29066661</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Case Rep\20171025-NamikiH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Case Rep\20171025-NamikiH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171025, Namiki H</style></custom2><misc3><style face="normal" font="default">10.1136/bcr-2017-222297</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42940</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pabreja,K.</style></author><author><style face="normal" font="default"> Gibson,P.</style></author><author><style face="normal" font="default"> Lochrin,A.J.</style></author><author><style face="normal" font="default"> Wood,L.</style></author><author><style face="normal" font="default"> Baines,K.J.</style></author><author><style face="normal" font="default"> Simpson,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Priority Research Centre for Healthy Lungs, School of Medicine and Public Health, Hunter Medical Research Institute, The University of Newcastle, Newcastle, New South Wales, Australia</style></auth-address><titles><title><style face="normal" font="default">Sputum colour can identify patients with neutrophilic inflammation in asthma</style></title><secondary-title><style face="normal" font="default">BMJ Open Respir Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Open Respir Res</style></abbr-1></periodical><pages end="" start="e000236">e000236-</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Sputum colour is associated with neutrophilic inflammation in chronic bronchitis and chronic obstructive pulmonary disease (COPD). Neutrophilia and sputum expectoration is notable in asthma, but whether sputum colour is associated with and predicts the presence of neutrophilic inflammation in asthma is unknown. The objective of the study is to assess the ability of sputum colour in distinguishing asthma inflammatory phenotypes. METHODS: Induced sputum samples collected from 271 adults with stable asthma were retrospectively assessed. Sputum colour was determined using the BronkoTest sputum colour chart and correlated to differential cell counts and CXCL-8 concentration. Neutrophilic inflammation was defined as an age-corrected sputum neutrophil proportion (>/=61.6% for age 20-40 years; >/=63.2% for age 40-60 and >/=67.2% for age >60 years), whereas neutrophilic bronchitis (NB) was defined as high total cell count (>/=5.1x106 cells/mL) plus an increased age-corrected neutrophil proportion. The optimal cut-off for sputum colour to predict neutrophilic inflammation and NB was determined using receiver operator characteristic curve analysis. RESULTS: A sputum colour score of >/=3 represented and predicted neutrophilic inflammation with modest accuracy (area under the curve (AUC)=0.64; p&lt;0.001, specificity=78.4%, sensitivity=49.2%). Participants with a sputum colour score of >/=3 had significantly (p&lt;0.05) higher CXCL-8, total cells and neutrophil number and proportion. Sputum colour score was also positively correlated with these factors. Sputum colour score >/=3 predicted NB with reasonably good accuracy (AUC=0.79, p&lt;0.001, specificity=79.3%, sensitivity=70.7%). CONCLUSIONS: Visual gradation of sputum colour in asthma relates to high total cell count and neutrophilic inflammation. Assessment of sputum colour can identify adults with asthma who are likely to have NB without the need for sputum processing and differential cell count, which may facilitate asthma management</style></abstract><notes><style face="normal" font="default">DA - 20171026IS - 2052-4439 (Print)IS - 2052-4439 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1136/bmjresp-2017-000236</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29071085">PM:29071085</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Open Respir Res\2017-4-e000236.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Open Respir Res\2017-4-e000236.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171026, Pabreja K</style></custom2><misc3><style face="normal" font="default">10.1136/bmjresp-2017-000236</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42941</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rose,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anaesthesia, Royal North Shore Hospital, NSW 2065, AustraliaUniversity of Sydney, NSW 2006, Australia</style></auth-address><titles><title><style face="normal" font="default">Low end-tidal carbon dioxide as a marker of severe anaesthetic anaphylaxis: the missing piece of the puzzle?</style></title><secondary-title><style face="normal" font="default">Br J Anaesth</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Anaesth</style></full-title></periodical><pages end="862" start="859">859-862</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171027IS - 1471-6771 (Electronic)IS - 0007-0912 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1093/bja/aex264.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29077815">PM:29077815</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Anaesth\2017-119-859-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Anaesth\2017-119-859-62.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171027, Rose MA</style></custom2><misc3><style face="normal" font="default">10.1093/bja/aex264.</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42942</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gouel-Cheron,A.</style></author><author><style face="normal" font="default"> de Chaisemartin,L.</style></author><author><style face="normal" font="default"> Jonsson,F.</style></author><author><style face="normal" font="default"> Nicaise-Roland,P.</style></author><author><style face="normal" font="default"> Granger,V.</style></author><author><style face="normal" font="default"> Sabahov,A.</style></author><author><style face="normal" font="default"> Guinnepain,M.T.</style></author><author><style face="normal" font="default"> Chollet-Martin,S.</style></author><author><style face="normal" font="default"> Bruhns,P.</style></author><author><style face="normal" font="default"> Neukirch,C.</style></author><author><style face="normal" font="default"> Longrois,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institut Pasteur, Department of Immunology, Unit of Antibodies in Therapy and Pathology, Paris, France</style></auth-address><titles><title><style face="normal" font="default">Low end-tidal CO2 as a real-time severity marker of intra-anaesthetic acute hypersensitivity reactions</style></title><secondary-title><style face="normal" font="default">Br J Anaesth</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Anaesth</style></full-title></periodical><pages end="917" start="908">908-917</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="default">Background: Prompt diagnosis of intra-anaesthetic acute hypersensitivity reactions (AHR) is challenging because of the possible absence and/or difficulty in detecting the usual clinical signs and because of the higher prevalence of alternative diagnoses. Delayed epinephrine administration during AHR, because of incorrect/delayed diagnosis, can be associated with poor prognosis. Low end-tidal CO2 (etCO2) is known to be linked to low cardiac output. Yet, its clinical utility during suspected intra-anaesthetic AHR is not well documented. Methods: Clinical data from the 86 patients of the Neutrophil Activation in Systemic Anaphylaxis (NASA) multicentre study were analysed. Consenting patients with clinical signs consistent with intra-anaesthetic AHR to a neuromuscular blocking agent were included. Severe AHR was defined as a Grade 3-4 of the Ring and Messmer classification. Causes of AHR were explored following recommended guidelines. Results: Among the 86 patients, 50% had severe AHR and 69% had a confirmed/suspected IgE-mediated event. Occurrence and minimum values of arterial hypotension, hypocapnia and hypoxaemia increased significantly with the severity of AHR. Low etCO2 was the only factor able to distinguish mild [median 3.5 (3.2;3.9) kPa] from severe AHR [median 2.4 (1.6;3.0) kPa], without overlap in inter-quartile range values, with an area under the receiver operator characteristic curve of 0.92 [95% confidence interval: 0.79-1.00]. Among the 41% of patients who received epinephrine, only half received it as first-line therapy despite international guidelines. Conclusions: An etCO2 value below 2.6 kPa (20 mm Hg) could be useful for prompt diagnosis of severe intra-anaesthetic AHR, and could facilitate early treatment with titrated doses of epinephrine. Clinical trial registration: NCT01637220</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 1471-6771 (Electronic)IS - 0007-0912 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1093/bja/aex260</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29040433">PM:29040433</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Anaesth\2017-119-908-17.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Anaesth\2017-119-908-17.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Gouel-Cheron A</style></custom2><misc3><style face="normal" font="default">10.1093/bja/aex260</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42943</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Asero,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy</style></auth-address><titles><title><style face="normal" font="default">Towards a better categorization of patients with chronic urticaria</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="904" start="903">903-904</pages><volume><style face="normal" font="default">177</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171020IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15806</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29052900">PM:29052900</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\2017-177-903-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\2017-177-903-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171020, Asero R</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15806</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42944</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Caroe,T.K.</style></author><author><style face="normal" font="default"> Ebbehoj,N.E.</style></author><author><style face="normal" font="default"> Bonde,J.P.E.</style></author><author><style face="normal" font="default"> Vejlstrup,S.G.</style></author><author><style face="normal" font="default"> Agner,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Copenhagen, Bispebjerg Hospital, Bispebjerg Bakke 23, 2400, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default">Job change facilitates healing in a cohort of patients with occupational hand eczema</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="10" Year="2017">2017/10/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Occupational hand eczema is a frequent and often chronic disease and knowledge of the consequences of change of profession is sparse. OBJECTIVES: To compare severity of hand eczema and health related QoL HR-QoL in patients who after 5 years were still in the same profession and those who were not. METHODS: The study is a register-based cohort study including patients with recognised occupational hand eczema in Denmark in 2010 and 2011. Outcomes were eczema related parameters and Dermatology Life Quality Index (DLQI) obtained from a follow-up questionnaire after 5 years. RESULTS: A total of 1496 participants were included in the study. More participants who changed or ended profession reported complete healing of hand eczema at follow up, compared to participants still in the same profession (OR=1.62 (1.06-2.47) and OR=2.85 (1.83-4.42), respectively), as well as increased improvement at follow-up (OR=1.91(1.44-2.54) and OR=1.51(1.09-2.10), respectively), while DLQI for participants who changed or ended profession was increased at follow up, (Incidence Rate Ratio (IRR)= 1.12 (0.98-1.28) and IRR= 1.29 (1.11-1.51), respectively). Subgroup analyses of patients with irritant or allergic occupational hand eczema did not differ markedly from this result. Change of work procedures was positively associated with improvement (OR=2.31(1.51-3.54)), and did not markedly influence DLQI. CONCLUSION: Change of profession has a beneficial effect on eczema parameters, but a negative effect on HR-QoL, indicated by increased DLQI. Change of work procedures while staying in the same profession positively influenced improvement, with no marked influence on HR-QoL, and should be considered as an alternative to job change. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171027IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.16095</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29078013">PM:29078013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20171027-CaroeTK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20171027-CaroeTK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171027, Caroe TK</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.16095</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42945</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vakharia,P.P.</style></author><author><style face="normal" font="default"> Chopra,R.</style></author><author><style face="normal" font="default"> Sacotte,R.</style></author><author><style face="normal" font="default"> Patel,N.</style></author><author><style face="normal" font="default"> Immaneni,S.</style></author><author><style face="normal" font="default"> White,T.</style></author><author><style face="normal" font="default"> Kantor,R.</style></author><author><style face="normal" font="default"> Hsu,D.Y.</style></author><author><style face="normal" font="default"> Simpson,E.L.</style></author><author><style face="normal" font="default"> Silverberg,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departments of Dermatology, Preventive Medicine and Medical Social Sciences, Feinberg School of Medicine at Northwestern University, Chicago, IL, USA</style></auth-address><titles><title><style face="normal" font="default">Severity strata for five patient-reported outcomes in adults with atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: Multiple patient-reported outcomes have been used to assess the burden of atopic dermatitis (AD). Some are disease specific, e.g. the Patient Oriented Eczema Measure (POEM). While others pertain to itch, e.g. Numerical Rating Scale (NRS)-itch, ItchyQoL and 5-D itch, or dermatologic disease in general, e.g. Dermatology Life Quality Index (DLQI). Development of severity strata is essential for proper interpretability of these assessments. We sought to confirm previously developed strata for POEM, DLQI and raw ItchyQoL, and develop strata for the NRS-itch, mean ItchyQOL and 5-D itch scale for use in adults with AD. METHODS: Self-administered questionnaires were completed by 210 adults with AD in a dermatology practice setting. Strata were selected using an anchoring approach based on patient-reported disease severity. RESULTS: We confirmed the existing strata for POEM (mild=0-7, moderate=8-16, severe=17-28) (kappa=0.440), DLQI (mild=0-5, moderate=6-10, severe=11-30) (kappa=0.398) and NRS-itch (mild=0-3, moderate=4-6, severe=7-10) (kappa=0.499). However, the preferred band for raw ItchyQoL was mild=22-58, moderate=59-74 and severe=75-110 (kappa=0.379) and mean ItchyQOL was mild=1-2.9, moderate=3.0-3.9, severe=4.0-5.0 (kappa=0.374). The preferred band for 5-D itch scale was mild=0-11, moderate=12-17 and severe=18-25 (kappa=0.331). CONCLUSIONS: Existing strata for POEM and DLQI perform well in adult AD. Previously reported strata for VAS-itch performed best for NRS-itch. We identified banding for the raw ItchyQoL for our AD population that varies slightly from the banding published for a more heterogeneous population. Finally, we proposed strata for mean ItchyQOL and 5-D itch scale in adult AD. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.16078</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29048751">PM:29048751</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20171019-VakhariaPP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20171019-VakhariaPP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Vakharia PP</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.16078</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42946</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jones,N.R.</style></author><author><style face="normal" font="default"> Wang,K.</style></author><author><style face="normal" font="default"> Yang,Y.</style></author><author><style face="normal" font="default"> Heneghan,C.</style></author><author><style face="normal" font="default"> Price,C.P.</style></author><author><style face="normal" font="default"> Van den Bruel,A.</style></author><author><style face="normal" font="default"> Pluddemann,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford</style></auth-address><titles><title><style face="normal" font="default">Fractional exhaled nitric oxide monitoring in paediatric asthma management</style></title><secondary-title><style face="normal" font="default">Br J Gen Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Br J Gen Pract</style></abbr-1></periodical><pages end="532" start="531">531-532</pages><volume><style face="normal" font="default">67</style></volume><number><style face="normal" font="default">664</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171027IS - 1478-5242 (Electronic)IS - 0960-1643 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.3399/bjgp17X693449</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29074699">PM:29074699</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171027, Jones NR</style></custom2><misc3><style face="normal" font="default">10.3399/bjgp17X693449</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42947</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sole,D.</style></author><author><style face="normal" font="default"> Pastorino,A.C.</style></author><author><style face="normal" font="default"> Kuschnir,F.</style></author><author><style face="normal" font="default"> Camelo-Nunes,I.C.</style></author><author><style face="normal" font="default"> Paes-Barreto,B.A.</style></author><author><style face="normal" font="default"> Porto,A.C.</style></author><author><style face="normal" font="default"> Coelho,M.A.</style></author><author><style face="normal" font="default"> Toledo,E.C.</style></author><author><style face="normal" font="default"> Furlan,F.P.</style></author><author><style face="normal" font="default"> Casagrande,R.R.</style></author><author><style face="normal" font="default"> Palvo,F.</style></author><author><style face="normal" font="default"> Freitas,M.S.</style></author><author><style face="normal" font="default"> Santos,S.L.</style></author><author><style face="normal" font="default"> Cardozo,C.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Are the factors associated with asthma in children and adolescents universal? A systematic multicenter Brazilian study</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="278" start="272">272-278</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Objective: To compare factors associated with the development ofasthma in Brazilian schoolchildren residing in different geographicalregions. Method: Children and adolescents (4-8 years, n = 4,262;10-14 years, n = 10,603) enrolled in public or private schools at 11centers from 9 Brazilian cities were screened using the protocolof the International Study of Asthma and Allergies in Childhood(ISAAC). After obtaining asthma prevalence rates, schoolchildrenwith active asthma (positive response for wheezing in the past 12months) and without asthma (negative response) were randomlyselected at a ratio of 1:2. Then, their parents or guardians wereasked to answer the supplementary ISAAC questionnaire on riskfactors. Multivariate logistic regression analysis identified factorsassociated with the expression of asthma among schoolchildren at each center. Results: Among children, having a history of rhinitisor atopic eczema, having a family history of allergic diseases,and being exposed to tobacco were identified as risk factors atmost centers. Among adolescents, similar results were found:having allergic rhinitis (8/11 centers), having a family history ofallergic diseases (6/11), being passively exposed to tobacco(6/11), being exposed to domestic animals, especially cat (5/11),having been born preterm, and having a low intake of vegetablesand fruit juice were the main factors identified. Conclusion: Riskfactors for the development of asthma in Brazilian schoolchildrenwere not unanimous. Genetic factors, such as having anotherallergic disease, or having family members with allergic disease,were identified by most of the participating centers. Exposureto tobacco, as well as to domestic animals, also showed to beclinically important.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170038</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170038</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-272-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-272-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171025, Sole D</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42948</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oliveira Pereira,C.</style></author><author><style face="normal" font="default"> Saraiva dos Santos,D.H.</style></author><author><style face="normal" font="default"> Silva Fernandes,A.</style></author><author><style face="normal" font="default"> de Sousa Vela Cunha,F.I.</style></author></authors></contributors><titles><title><style face="normal" font="default">Tattoos: from temporary to permanent</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="324" start="321">321-324</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Temporary tattoos are quite popular, and they are perceivedas harmless. The ink used in temporary tattoos is made fromhenna, a reddish-brown coloring pigment obtained from a shrub.However, in order to obtain "black henna" and facilitate the tattooingprocess, other compounds are added to the mixture, especiallyp-phenylenediamine. This compound is associated with allergicreactions that are sometimes severe and may leave sequelae.The authors describe a case of a 10-year old child presentingwith allergic reaction and probable bacterial superinfection ina temporary tattoo area. The patient had a history of prior skinsensitization, and therefore the reaction was early and moreaggressive. The severity of the inflammatory signs motivatedhospital admission for systemic corticosteroid therapy andintravenous antibiotic therapy. Despite the good clinical evolution, ahypopigmented lesion persisted. Our goal is to raise awareness onthe dangers of this practice and to highlight the lack of legislationin the area.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170047</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170047</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-321-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-321-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171025, Oliveira Pereira C</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170047</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42949</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">de Carvalho,S.L.</style></author><author><style face="normal" font="default"> Boguchewski,A.P.</style></author><author><style face="normal" font="default"> Nascimento,F.L.</style></author><author><style face="normal" font="default"> Dalmas,L.M.</style></author><author><style face="normal" font="default"> Carvalho,V.O.</style></author></authors></contributors><titles><title><style face="normal" font="default">Impact of atopic dermatitis on the quality of life of the family</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="310" start="305">305-310</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Objective: To study the impact of atopic dermatitis severity onthe quality of life of the patient's caregivers. Methods: This wasan analytical cross-sectional study in which questionnaires wereapplied to caregivers of patients with atopic dermatitis seenconsecutively from August to December 2015. Disease severitywas determined according to the Scoring Atopic Dermatitis(SCORAD) index and graded as mild (score = 20), moderate (> 20to = 40), or severe (> 40). The questionnaire used to evaluatethe quality of life of caregivers was the Dermatitis Family Impact(DFI), validated to Portuguese. Results: One hundred and onecaregivers participated in the study; 31.7% of them took careof patients with mild atopic dermatitis, 36.6% of moderate, and31.7% of patients with severe atopic dermatitis. The mean qualityof life score was 9.1±6.7. Quality of life indexes worsened withatopic dermatitis severity (Spearman correlation 0.53; p &lt; 0.0001).The domains most strongly affected were treatment expenses,sleep, and fatigue/exhaustion. The mean monthly expense withtreatment was 200 reais, accounting for 7.5% of the family'smonthly income. There was a significant difference in the expense/income percentage according to disease severity as measured bythe SCORAD index (5% in mild, 7.2% in moderate, and 10% insevere atopic dermatitis). Conclusion: Quality of life indexes forcaregivers of patients with atopic dermatitis worsen as the severityof the disease increases, mainly because of treatment expenses,lack of sleep, and exhaustion.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170043</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170043</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-305-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-305-10.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171025, de Carvalho SL</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170043</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42950</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Maraldi Freire,L.</style></author><author><style face="normal" font="default"> Santos Souza,P.</style></author><author><style face="normal" font="default"> Augusta Sella,J.</style></author><author><style face="normal" font="default"> Paes Leme Ferriani,M.</style></author><author><style face="normal" font="default"> Arruda,L.K.</style></author><author><style face="normal" font="default"> Lima Melo,J.M.</style></author><author><style face="normal" font="default"> Padua Menezes,U.</style></author></authors></contributors><titles><title><style face="normal" font="default">Anaphylaxis to benzydamine hydrochloride: a case report</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="318" start="316">316-318</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Hypersensitivity drug reactions (HDRs) may induce mild tosevere heterogeneous clinical manifestations. They are classifiedas immunological or allergic when mediated by antibodies orT lymphocytes, and non-immunological when resulting frompharmacological effects of the drug, including inhibition of thecyclooxygenase (Cox) enzyme. The two groups of drugs mostfrequently implicated in HDRs are non-steroidal anti-inflammatorydrugs (NSAIDs) and beta-lactam antibiotics. Appropriatemanagement of NSAID reactions depends on identification ofthe pathophysiological mechanism involved, which will allow toclassify the patient as selective reactor (patient reacting to asingle drug and others with similar chemical structure) or multipleor cross-intolerant reactor (patient reacting to multiple drugs withunrelated chemical structure). Benzydamine hydrochloride (BZH)is a frequently used, relatively safe NSAID for which descriptionsof severe reactions are not available. BZH acts inhibiting theenzymes prostaglandin endoperoxide H synthase (PGHS) 1 and/or 2 and phospholipase A2. In patients with a history of NSAIDreactions, the challenge test is the gold standard diagnostic tool toconfirm or exclude cross-reactivity to other NSAIDs, and to definea safe alternative drug. In this paper, we describe a rare case ofanaphylaxis to BZH during an oral drug provocation test.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170045</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170045</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-316-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-316-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171025, Maraldi Freire L</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170045</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42951</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Moreira Boralli,C.F.</style></author><author><style face="normal" font="default"> Duarte Dortas Júnior,S.</style></author><author><style face="normal" font="default"> Carvalho Oliveira,B.E.</style></author><author><style face="normal" font="default"> Tavares Franca,A.</style></author><author><style face="normal" font="default"> Rodrigues Valle,S.O.</style></author></authors></contributors><titles><title><style face="normal" font="default">Evaluation of autologous serum skin test and autologous plasma skin test in chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="286" start="279">279-286</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Objective: To compare the autologous serum skin test (ASST)and the autologous plasma skin test (APST) for the diagnosis ofautoimmunity in patients with chronic spontaneous urticaria (CSU)and to evaluate their relationship with antithyroid autoantibodies.Methods: Fifty patients with CSU and 50 sex- and age-matchedhealthy controls were compared in relation to ASST and APSTresults and thyroid autoimmunity. Results: Twenty-three (46%)patients and 5 (10%) controls had positive ASST; 16 (32%)patients and 7 (14%) controls had positive APST. There was anassociation between thyroid function and ASST results in patientswith CSU. Euthyroid patients with CSU had a higher rate of positiveASST. Conclusion: ASST is a simple, cost-effective test thatsignificantly contributes to elucidate the pathogenesis of CSUand can demonstrate the presence of functional autoantibodies.Some authors suggest that APST is more sensitive than ASST. Allrelevant studies published so far report that both can be used asdiagnostic methods in patients with CSU. In conclusion, ASST andAPST can both be used to evaluate autoreactivity in the etiology ofCSU, and antithyroid autoantibodies should be investigated evenwhen thyroid function tests are normal.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170039</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170039</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-279-86.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-279-86.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171025, Moreira Boralli CF</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170039</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42952</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">El-Yakub,A.I.</style></author><author><style face="normal" font="default"> Bello,U.M.</style></author><author><style face="normal" font="default"> Sheshe,A.A.</style></author><author><style face="normal" font="default"> Naaya,H.U.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Surgery, Aminu Kano Teaching Hospital, Kano, Nigeria</style></auth-address><titles><title><style face="normal" font="default">Delayed Presentation of Posttraumatic Diaphragmatic Hernia Masquerading as Recurrent Acute Asthmatic Attack</style></title><secondary-title><style face="normal" font="default">Case Rep Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Case Rep Med</style></abbr-1></periodical><pages end="" start="5037619">5037619-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Diaphragmatic hernia following blunt abdominal injury is extremely rare and often diagnosed late. Missed diagnosis is also common with this condition. We herein present a delayed presentation of diaphragmatic hernia following blunt abdominal injury that was initially misdiagnosed as recurrent acute asthmatic attack due to repeated presentation with episodic difficulty in breathing</style></abstract><notes><style face="normal" font="default">DA - 20171023IS - 1687-9627 (Print)LA - engPT - Journal ArticleCO - Nigeria -</style></notes><work-type><style face="normal" font="default">10.1155/2017/5037619</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29056971">PM:29056971</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Case Rep Med\2017-2017-5037619.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Case Rep Med\2017-2017-5037619.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171023, El-Yakub AI</style></custom2><misc3><style face="normal" font="default">10.1155/2017/5037619</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42953</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">O'Dwyer,D.N.</style></author><author><style face="normal" font="default"> Moore,B.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, 4053 BSRB, 109 Zina Pitcher Place, Ann Arbor, MI, 48109-2200, USA</style></auth-address><titles><title><style face="normal" font="default">The role of periostin in lung fibrosis and airway remodeling</style></title><secondary-title><style face="normal" font="default">Cell Mol Life Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cell Mol Life Sci</style></abbr-1></periodical><pages end="4314" start="4305">4305-4314</pages><volume><style face="normal" font="default">74</style></volume><number><style face="normal" font="default">23</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">airway remodeling</style></keyword><keyword><style face="normal" font="default"> genetics</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> biomarkers</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Cell Adhesion Molecules</style></keyword><keyword><style face="normal" font="default"> Cell Differentiation</style></keyword><keyword><style face="normal" font="default"> Collagen Type I</style></keyword><keyword><style face="normal" font="default"> Extracellular Matrix</style></keyword><keyword><style face="normal" font="default"> Fibroblasts</style></keyword><keyword><style face="normal" font="default"> Gene Expression Regulation</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Pulmonary Fibrosis</style></keyword><keyword><style face="normal" font="default"> Signal Transduction</style></keyword><keyword><style face="normal" font="default"> Th2 Cells</style></keyword></keywords><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">Periostin is a protein that plays a key role in development and repair within the biological matrix of the lung. As a matricellular protein that does not contribute to extracellular matrix structure, periostin interacts with other extracellular matrix proteins to regulate the composition of the matrix in the lung and other organs. In this review, we discuss the studies exploring the role of periostin to date in chronic respiratory diseases, namely asthma and idiopathic pulmonary fibrosis. Asthma is a major health problem globally affecting millions of people worldwide with significant associated morbidity and mortality. Periostin is highly expressed in the lungs of asthmatic patients, contributes to mucus secretion, airway fibrosis and remodeling and is recognized as a biomarker of Th2 high inflammation. Idiopathic pulmonary fibrosis is a fatal interstitial lung disease characterized by progressive aberrant fibrosis of the lung matrix and respiratory failure. It predominantly affects adults over 50 years of age and its incidence is increasing worldwide. Periostin is also highly expressed in the lungs of idiopathic pulmonary fibrosis patients. Serum levels of periostin may predict clinical progression in this disease and periostin promotes myofibroblast differentiation and type 1 collagen production to contribute to aberrant lung fibrosis. Studies to date suggest that periostin is a key player in several pathogenic mechanisms within the lung and may provide us with a useful biomarker of clinical progression in both asthma and idiopathic pulmonary fibrosis</style></abstract><notes><style face="normal" font="default">DA - 20170917IS - 1420-9071 (Electronic)IS - 1420-682X (Linking)LA - engPT - Journal ArticlePT - ReviewRN - 0 (Biomarkers)RN - 0 (Cell Adhesion Molecules)RN - 0 (Collagen Type I)RN - 0 (POSTN protein, human)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s00018-017-2649-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28918442">PM:28918442</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cell Mol Life Sci\2017-74-4305-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cell Mol Life Sci\2017-74-4305-14.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170917, O'Dwyer DN</style></custom2><misc3><style face="normal" font="default">10.1007/s00018-017-2649-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42954</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wong-McGrath,K.</style></author><author><style face="normal" font="default"> Denlinger,L.C.</style></author><author><style face="normal" font="default"> Bleecker,E.R.</style></author><author><style face="normal" font="default"> Castro,M.</style></author><author><style face="normal" font="default"> Gaston,B.</style></author><author><style face="normal" font="default"> Israel,E.</style></author><author><style face="normal" font="default"> Jarjour,N.N.</style></author><author><style face="normal" font="default"> Mauger,D.T.</style></author><author><style face="normal" font="default"> Peters,S.</style></author><author><style face="normal" font="default"> Phillips,B.R.</style></author><author><style face="normal" font="default"> Wenzel,S.E.</style></author><author><style face="normal" font="default"> Fahy,J.V.</style></author><author><style face="normal" font="default"> Peters,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary and Critical Care Medicine, Department of Medicine and the Cardiovascular Research Institute, University of California San Francisco. 505 Parnassus Avenue, San Francisco, CA 94143-0130</style></auth-address><titles><title><style face="normal" font="default">Internet-based monitoring in the Severe Asthma Research Program identifies a subgroup of patients with labile asthma control</style></title><secondary-title><style face="normal" font="default">Chest</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chest</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="10" Year="2017">2017/10/25</year></dates><abstract><style face="normal" font="default">BACKGROUND: We designed an Internet-based Monitoring Systems (IBS) survey to facilitate monitoring of asthma symptoms and asthma exacerbations in the Severe Asthma Research Program (SARP). Our objective was to evaluate compliance with the IBS survey tool and to explore how data from an IBS tool can inform understanding of asthma phenotypes. METHODS: We invited adult subjects in the SARP III cohort (n=528) to complete a monthly IBS asthma control survey. We compared the characteristics of subjects who did or did not participant with the IBS survey tool. Among subjects who participated with IBS (IBS+), we identified participants with low, medium, and high ACT score variability, and we explored asthma morbidity in these three participant subgroups. RESULTS: 259 subjects participated with the IBS (IBS+). Compared to subjects who did not engage with IBS (IBS-), IBS+ subjects were older, more likely to be of white race, be college educated, have an annual household income >$25,000, and have controlled asthma. Among IBS+ participants, the subgroup with the highest ACT score variability was more likely to have severe asthma, had lower ACT score at baseline, and had increased asthma related healthcare utilization (often precipitated by cold and flu-like illnesses). Participants with high ACT variability were also characterized by metabolic dysfunction, as evidenced by obesity and hypertension. CONCLUSIONS: Active participation with an internet-based symptom survey tool in patients with severe asthma is influenced by race, socio-economic status, and asthma control. Among survey participants, a group with highly variable (labile) asthma control is identifiable as a specific subgroup with unmet treatment needs. The association of asthma lability, increased susceptibility to adverse asthma effects of cold and flu-like Illnesses, and metabolic dysfunction provides clues for potentially effective intervention strategies</style></abstract><notes><style face="normal" font="default">DA - 20171029IS - 1931-3543 (Electronic)IS - 0012-3692 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.1016/j.chest.2017.10.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29080709">PM:29080709</url></web-urls></urls><custom2><style face="normal" font="default">20171029, Wong-McGrath K</style></custom2><misc3><style face="normal" font="default">10.1016/j.chest.2017.10.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42955</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tan,S.P.</style></author><author><style face="normal" font="default"> Brown,S.B.</style></author><author><style face="normal" font="default"> Griffiths,C.E.</style></author><author><style face="normal" font="default"> Weller,R.B.</style></author><author><style face="normal" font="default"> Gibbs,N.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">MRC Centre for Inflammation Research</style></auth-address><titles><title><style face="normal" font="default">Feeding filaggrin: effects of l-histidine supplementation in atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Clin Cosmet Investig Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Cosmet Investig Dermatol</style></abbr-1></periodical><pages end="411" start="403">403-411</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD), also known as eczema, is one of the most common chronic skin conditions worldwide, affecting up to 16% of children and 10% of adults. It is incurable and has significant psychosocial and economic impacts on the affected individuals. AD etiology has been linked to deficiencies in the skin barrier protein, filaggrin. In mammalian skin, l-histidine is rapidly incorporated into filaggrin. Subsequent filaggrin proteolysis releases l-histidine as an important natural moisturizing factor (NMF). In vitro studies were conducted to investigate the influence of l-histidine on filaggrin processing and barrier function in human skin-equivalent models. Our further aim was to examine the effects of daily oral l-histidine supplementation on disease severity in adult AD patients. We conducted a randomized, double-blind, placebo-controlled, crossover, nutritional supplementation pilot study to explore the effects of oral l-histidine in adult AD patients (n=24). In vitro studies demonstrated that l-histidine significantly increased both filaggrin formation and skin barrier function (P&lt;0.01, respectively). Data from the clinical study indicated that once daily oral l-histidine significantly reduced (P&lt;0.003) AD disease severity by 34% (physician assessment using the SCORingAD tool) and 39% (patient self-assessment using the Patient Oriented Eczema Measure tool) after 4 weeks of treatment. No improvement was noted with the placebo (P>0.32). The clinical effect of oral l-histidine in AD was similar to that of mid-potency topical corticosteroids and combined with its safety profile suggests that it may be a safe, nonsteroidal approach suitable for long-term use in skin conditions that are associated with filaggrin deficits such as AD</style></abstract><notes><style face="normal" font="default">DA - 20171018IS - 1178-7015 (Print)IS - 1178-7015 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.2147/CCID.S146760</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29042806">PM:29042806</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Cosmet Investig Dermatol\2017-10-403-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Cosmet Investig Dermatol\2017-10-403-11.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171018, Tan SP</style></custom2><misc3><style face="normal" font="default">10.2147/CCID.S146760</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42956</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arathimos,R.</style></author><author><style face="normal" font="default"> Suderman,M.</style></author><author><style face="normal" font="default"> Sharp,G.C.</style></author><author><style face="normal" font="default"> Burrows,K.</style></author><author><style face="normal" font="default"> Granell,R.</style></author><author><style face="normal" font="default"> Tilling,K.</style></author><author><style face="normal" font="default"> Gaunt,T.R.</style></author><author><style face="normal" font="default"> Henderson,J.</style></author><author><style face="normal" font="default"> Ring,S.</style></author><author><style face="normal" font="default"> Richmond,R.C.</style></author><author><style face="normal" font="default"> Relton,C.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Social and Community Medicine, University of Bristol, Bristol, UK</style></auth-address><titles><title><style face="normal" font="default">Epigenome-wide association study of asthma and wheeze in childhood and adolescence</style></title><secondary-title><style face="normal" font="default">Clin Epigenetics</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Epigenetics</style></abbr-1></periodical><pages end="" start="112">112-</pages><volume><style face="normal" font="default">9</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma heritability has only been partially explained by genetic variants and is known to be sensitive to environmental factors, implicating epigenetic modifications such as DNA methylation in its pathogenesis. METHODS: Using data collected in the Avon Longitudinal Study of Parents and Children (ALSPAC), we assessed associations of asthma and wheeze with DNA methylation at 7.5 and 16.5 years, at over 450,000 CpG sites in DNA from the peripheral blood of approx. 1000 participants. We used Mendelian randomization (MR), a method of causal inference that uses genetic variants as instrumental variables, to infer the direction of association between DNA methylation and asthma. RESULTS: We identified 302 CpGs associated with current asthma status (FDR-adjusted P value &lt; 0.05) and 445 with current wheeze status at 7.5 years, with substantial overlap between the two. Genes annotated to the 302 associated CpGs were enriched for pathways related to movement of cellular/subcellular components, locomotion, interleukin-4 production and eosinophil migration. All associations attenuated when adjusted for eosinophil and neutrophil cell count estimates. At 16.5 years, two sites were associated with current asthma after adjustment for cell counts. The CpGs mapped to the AP2A2 and IL5RA genes, with a - 2.32 [95% CI - 1.47, - 3.18] and - 2.49 [95% CI - 1.56, - 3.43] difference in percentage methylation in asthma cases respectively. Two-sample bi-directional MR indicated a causal effect of asthma on DNA methylation at several CpG sites at 7.5 years. However, associations did not persist after adjustment for multiple testing. There was no evidence of a causal effect of asthma on DNA methylation at either of the two CpG sites at 16.5 years. CONCLUSION: The majority of observed associations are driven by higher eosinophil cell counts in asthma cases, acting as an intermediate phenotype, with important implications for future studies of DNA methylation in atopic diseases</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 1868-7083 (Electronic)IS - 1868-7075 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1186/s13148-017-0414-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29046734">PM:29046734</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Epigenetics\2017-9-112.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Epigenetics\2017-9-112.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Arathimos R</style></custom2><misc3><style face="normal" font="default">10.1186/s13148-017-0414-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42957</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Krishna,M.T.</style></author><author><style face="normal" font="default"> Huissoon,A.P.</style></author><author><style face="normal" font="default"> Li,M.</style></author><author><style face="normal" font="default"> Richter,A.</style></author><author><style face="normal" font="default"> Pillay,D.G.</style></author><author><style face="normal" font="default"> Sambanthan,D.</style></author><author><style face="normal" font="default"> Raman,S.C.</style></author><author><style face="normal" font="default"> Nasser,S.</style></author><author><style face="normal" font="default"> Misbah,S.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy and Immunology, Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UK</style></auth-address><titles><title><style face="normal" font="default">Enhancing antibiotic stewardship by tackling "spurious" penicillin allergy</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="1373" start="1362">1362-1373</pages><volume><style face="normal" font="default">47</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">Approximately 90-99% of patients with a label of penicillin allergy (PenA) are not allergic when comprehensively investigated. An inaccurate label of PenA has major public health implications-longer hospital stay, more frequent hospital admissions, greater use of fluoroquinolones, glycopeptides, cephalosporins and other expensive antibiotics resulting in significantly higher costs to the health service and predisposing to Clostridium difficile, methicillin-resistant Staphylococcus aureus infections and vancomycin-resistant enterococcus. We describe lessons learnt from recent studies regarding possible reasons contributing to an inaccurate label of PenA as well as propose a concerted multidisciplinary approach to address this important public health problem. Given the unmet need for allergy services in the UK and several other countries and knowledge gaps regarding PenA amongst healthcare professionals, we describe the potential role for a computerized clinical decision support system to enable non-specialists rapidly identify and de-label "low-risk" hospitalized patients with a label of PenA thereby obviating the need for allergy tests. This approach however needs rigorous evaluation for feasibility, safety, patient and physician acceptability, cost-effectiveness and its compatibility with information technology systems currently employed in the health service</style></abstract><notes><style face="normal" font="default">DA - 20171013IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -CO - India -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29028276">PM:29028276</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\2017-47-1362-73.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\2017-47-1362-73.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171013, Krishna MT</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13044</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42958</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dickison,P.</style></author><author><style face="normal" font="default"> Smith,S.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Royal North Shore Hospital, St Leonards, NSW, Australia</style></auth-address><titles><title><style face="normal" font="default">Itching for nail fashion: chronic urticaria and chronic hand dermatitis secondary to acrylate and methacrylate allergy in gel nail varnish</style></title><secondary-title><style face="normal" font="default">Clin Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="10" Year="2017">2017/10/23</year></dates><abstract><style face="normal" font="default">Allergic contact dermatitis (ACD) secondary to acrylates and methacrylates is a well- described occurrence, particularly in those who wear or handle gel nail varnish. Management involves avoidance of the identified allergen. The cause of chronic urticaria (CI) is often not identified, and CU is not known to be associated with acrylates or methacrylates. We report a case of a 50-year-old woman who initially presented with hand dermatitis exacerbated by gel nail varnish on a background of CU. Avoiding all nail varnishes because of her ACD also resulted in improvement of her CU. To our knowledge, this is the first documented case of CU secondary to the acrylates and methacrylates found in nail cosmetics</style></abstract><notes><style face="normal" font="default">DA - 20171023IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/ced.13252</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29058325">PM:29058325</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Dermatol\20171023-DickisonP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Dermatol\20171023-DickisonP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171023, Dickison P</style></custom2><misc3><style face="normal" font="default">10.1111/ced.13252</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42959</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vu,M.</style></author><author><style face="normal" font="default"> Heyes,C.</style></author><author><style face="normal" font="default"> Robertson,S.J.</style></author><author><style face="normal" font="default"> Varigos,G.A.</style></author><author><style face="normal" font="default"> Ross,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="default">Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo</style></title><secondary-title><style face="normal" font="default">Clin Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/ced.13290</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29034491">PM:29034491</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Dermatol\20171016-VuM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Dermatol\20171016-VuM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171016, Vu M</style></custom2><misc3><style face="normal" font="default">10.1111/ced.13290</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42960</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Terhorst,D.</style></author><author><style face="normal" font="default"> Koti,I.</style></author><author><style face="normal" font="default"> Krause,K.</style></author><author><style face="normal" font="default"> Metz,M.</style></author><author><style face="normal" font="default"> Maurer,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergie-Centrum-Charite, Department of Dermatology and Allergy, Charite-Universitatsmedizin Berlin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="default">In chronic spontaneous urticaria, high numbers of dermal endothelial cells, but not mast cells, are linked to recurrent angio-oedema</style></title><secondary-title><style face="normal" font="default">Clin Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="24" Month="10" Year="2017">2017/10/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic spontaneous urticaria (CSU) is an inflammatory skin disorder characterized by recurrent weals, angio-oedema or both. Recent studies have shown that the number of endothelial cells is increased in the skin of patients with CSU, but the underlying mechanisms and clinical implications of this are unclear. AIM: To evaluate whether mast cell (MC) or endothelial cell (EC) numbers correlate with CSU and whether they are relevant for disease duration, disease activity or the presence of clinical features. METHODS: We determined the numbers of CD31+ ECs and MCs in nonlesional skin of 30 patients with CSU using quantitative histomorphometry, and assessed their correlation with each other and with clinical features such as disease duration, disease activity and occurrence of angio-oedema. RESULTS: The numbers of MCs and ECs were high in the nonlesional skin of patients with CSU, but did not correlate with each other. Neither MC number nor EC number correlated with disease duration or disease activity. Interestingly, patients with high numbers of cutaneous CD31+ ECs had higher rates of recurrent angio-oedema and vice versa. CONCLUSIONS: Based on these findings, we speculate that vascular remodelling and MC hyperplasia in patients with CSU occurs independently and via different mechanisms. Targeting of the mechanisms that drive neoangiogenesis in CSU may result in novel therapeutic strategies for the management of patients with angio-oedema</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/ced.13254</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29064119">PM:29064119</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Dermatol\20171024-TerhorstD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Dermatol\20171024-TerhorstD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171024, Terhorst D</style></custom2><misc3><style face="normal" font="default">10.1111/ced.13254</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42961</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tuman,T.C.</style></author><author><style face="normal" font="default"> Tuman,B.</style></author><author><style face="normal" font="default"> Polat,M.</style></author><author><style face="normal" font="default"> Cakir,U.</style></author></authors></contributors><auth-address><style face="normal" font="default">Izzet Baysal Teaching and State Hospital for Psychiatry, Bolu, TurkeyDepartment of Dermatology, Faculty of Medicine, Abant Izzet Baysal University, Bolu, TurkeyDepartment of Dermatology, Faculty of Medicine, Abant Izzet Baysal University, Bolu, TurkeyDepartment of Psychiatry, Faculty of Medicine, Abant Izzet Baysal University, Bolu, Turkey</style></auth-address><titles><title><style face="normal" font="default">Urticaria and Angioedema Associated with Fluoxetine</style></title><secondary-title><style face="normal" font="default">Clin Psychopharmacol Neurosci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Psychopharmacol Neurosci</style></abbr-1></periodical><pages end="419" start="418">418-419</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="11" Year="2017">2017/11/30</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171027IS - 1738-1088 (Print)IS - 1738-1088 (Linking)LA - engPT - LetterCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.9758/cpn.2017.15.4.418</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29073757">PM:29073757</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Psychopharmacol Neurosci\2017-15-418-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Psychopharmacol Neurosci\2017-15-418-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171027, Tuman TC</style></custom2><misc3><style face="normal" font="default">10.9758/cpn.2017.15.4.418</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42962</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sinha,A.</style></author><author><style face="normal" font="default"> Sterk,P.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, F5-158, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, 1100 AZ, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default">Proteomics in asthma: the clinicians were right after all, were not they?</style></title><secondary-title><style face="normal" font="default">Clin Transl Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Transl Med</style></abbr-1></periodical><pages end="" start="39">39-</pages><volume><style face="normal" font="default">6</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="10" Year="2017">2017/10/27</year></dates><abstract><style face="normal" font="default">Clinical disease phenotypes with underlying information of molecular and biological signatures for the same, is a prerequisite for improving medical care and developing more effective, stratified management strategies. This commentary reviews the research carried out by Cao et al. to unravel biological networks associated with different clinical categories of asthma. It finally comments on the utility of using data from multiple platforms aided by integrated systems approaches to effectively find out the obvious underlying physiological disease signatures related to clinical disease sub-types</style></abstract><notes><style face="normal" font="default">DA - 20171028IS - 2001-1326 (Print)LA - engPT - LetterCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1186/s40169-017-0170-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29080192">PM:29080192</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Transl Med\2017-6-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Transl Med\2017-6-39.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171028, Sinha A</style></custom2><misc3><style face="normal" font="default">10.1186/s40169-017-0170-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42963</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lerner,M.</style></author><author><style face="normal" font="default"> Pal,R.S.</style></author><author><style face="normal" font="default"> Borici-Mazi,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Respirology (Lerner), Department of Medicine, McMaster University, Hamilton, Ont.; Department of Medicine (Pal, Borici-Mazi), Queens University, Kingston, Ont</style></auth-address><titles><title><style face="normal" font="default">Kounis syndrome and systemic mastocytosis in a 52-year-old man having surgery</style></title><secondary-title><style face="normal" font="default">CMAJ</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">CMAJ</style></abbr-1></periodical><pages end="E211" start="E208">E208-E211</pages><volume><style face="normal" font="default">189</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Coronary Angiography</style></keyword><keyword><style face="normal" font="default"> Coronary Artery Disease</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lipectomy</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Mastocytosis,Systemic</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Syndrome</style></keyword></keywords><dates><year Day="6" Month="2" Year="2017">2017/2/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20160803IS - 1488-2329 (Electronic)IS - 0820-3946 (Linking)LA - engPT - Case ReportsPT - Journal ArticleSB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.1503/cmaj.151314</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27486207">PM:27486207</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\CMAJ\2017-189-E208-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\CMAJ\2017-189-E208-11.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160803, Lerner M</style></custom2><misc3><style face="normal" font="default">10.1503/cmaj.151314</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42964</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">DeKoven,S.</style></author><author><style face="normal" font="default"> Holness,D.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Doctor of Medicine Program (DeKoven), Schulich School of Medicine and Dentistry, London, Ont.; Division of Occupational Medicine (DeKoven, Holness), Department of Medicine, St. Michael's Hospital; Dalla Lana School of Public Health and Department of Medicine (Holness), University of Toronto; Centre for Urban Health Solutions (Holness), Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ont. sdekoven2018@meds.uwo.caDoctor of Medicine Program (DeKoven), Schulich School of Medicine and Dentistry, London, Ont.; Division of Occupational Medicine (DeKoven, Holness), Department of Medicine, St. Michael's Hospital; Dalla Lana School of Public Health and Department of Medicine (Holness), University of Toronto; Centre for Urban Health Solutions (Holness), Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ont</style></auth-address><titles><title><style face="normal" font="default">Contact dermatitis caused by methacrylates in nail products</style></title><secondary-title><style face="normal" font="default">CMAJ</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">CMAJ</style></abbr-1></periodical><pages end="" start="E1193">E1193-</pages><volume><style face="normal" font="default">189</style></volume><number><style face="normal" font="default">37</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Cosmetics</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Methacrylates</style></keyword><keyword><style face="normal" font="default"> Nails</style></keyword></keywords><dates><year Day="18" Month="9" Year="2017">2017/9/18</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170919IS - 1488-2329 (Electronic)IS - 0820-3946 (Linking)LA - engPT - Case ReportsPT - Journal ArticleRN - 0 (Cosmetics)RN - 0 (Methacrylates)SB - AIMSB - IMCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1503/cmaj.170264</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28923798">PM:28923798</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\CMAJ\2017-189-E1193.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\CMAJ\2017-189-E1193.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170919, DeKoven S</style></custom2><misc3><style face="normal" font="default">10.1503/cmaj.170264</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42965</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kalambay,J.</style></author><author><style face="normal" font="default"> Ghazanfar,H.</style></author><author><style face="normal" font="default"> Martes Pena,K.A.</style></author><author><style face="normal" font="default"> Munshi,R.A.</style></author><author><style face="normal" font="default"> Zhang,G.</style></author><author><style face="normal" font="default"> Patel,J.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medicine, University SetifInternal Medicine, Newark Beth Israel Medical CenterInternal Medicine, Newark Beth Israel Medical CenterInternal Medicine, Chittagong Medical College &amp; HospitalInternal Medicine, Shanghai Medical College, Fudan UniversityInternal Medicine, Pramukhswami Medical College, Anand,Gujarat</style></auth-address><titles><title><style face="normal" font="default">Pathogenesis of Drug Induced Non-Allergic Angioedema: A Review of Unusual Etiologies</style></title><secondary-title><style face="normal" font="default">Cureus</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cureus</style></abbr-1></periodical><pages end="" start="e1598">e1598-</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">8</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="8" Year="2017">2017/8/23</year></dates><abstract><style face="normal" font="default">Angioedema is the swelling of mucosal and sub-mucosal tissue. Typically, it manifests as the swelling of the face, lips, and tongue. Angioedema can be severe and life threatening when it involves the respiratory tract. Drug induced allergic angioedema and drug induced non-allergic angioedema differ in their mediator, their clinical presentations, and their management. In drug induced non-allergic angioedema, symptoms are resistant to antihistamine and corticosteroid treatment. The aim of the analysis was to identify which medications are associated with drug-induced non-allergic angioedema and to understand the mechanism of action via which of these medication cause angioedema</style></abstract><notes><style face="normal" font="default">DA - 20171025IS - 2168-8184 (Print)IS - 2168-8184 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Algeria -CO - United States -CO - Bangladesh -CO - China -CO - India -</style></notes><work-type><style face="normal" font="default">10.7759/cureus.1598</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29067222">PM:29067222</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cureus\2017-9-e1598.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cureus\2017-9-e1598.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171025, Kalambay J</style></custom2><misc3><style face="normal" font="default">10.7759/cureus.1598</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42966</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Boulet,L.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institut universitaire de cardiologie et de pneumologie de Quebec, Universite Laval, Quebec, Canada</style></auth-address><titles><title><style face="normal" font="default">Airway remodeling in asthma: update on mechanisms and therapeutic approaches</style></title><secondary-title><style face="normal" font="default">Curr Opin Pulm Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Opin Pulm Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="10" Year="2017">2017/10/25</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: The term 'airway remodeling' reflects changes in the type, quantity, and nature of airway wall components and their organization. The purpose of this review is to look at recent publications on airway remodeling in asthma. RECENT FINDINGS: Animal models and in-vitro studies have confirmed the involvement of airway epithelium, airway smooth muscle (ASM), and extracellular matrix components in asthma-related airway remodeling. They report influences on proliferation of ASM cells, and how their orientation or morphology, in addition to the heterogeneity of ASM mass at different levels of airways could influence their effects. Clinical benefits have been observed following reduction of ASM following bronchial thermoplasty. Asthmatic epithelial cell transcriptome alterations were found to involve metabolism and epigenetics, beyond epithelial mesenchymal trophic unit driven by injury and repair in chronic inflammation. New ways to explore airway remodeling such as imaging or endoscopic techniques have been evaluated. Finally, new data support the role of eosinophils and mast cells in remodeling and show the influence of new asthma drugs on this process. SUMMARY: As recently stated by an American Thoracic Society task force, we need more research on airway remodeling, its determinants and clinical relevance, and on the effects of asthma drugs on its various components</style></abstract><notes><style face="normal" font="default">DA - 20171027IS - 1531-6971 (Electronic)IS - 1070-5287 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1097/MCP.0000000000000441</style></work-type><urls><web-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Pulm Med\20171027-BouletLP.pdf</url></web-urls><pdf-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Pulm Med\20171027-BouletLP.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default">20171027, Boulet LP</style></custom2><misc3><style face="normal" font="default">10.1097/MCP.0000000000000441</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42967</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Braido,F.</style></author><author><style face="normal" font="default"> Baiardini,I.</style></author><author><style face="normal" font="default"> Canonica,G.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">aDepartment of Internal Medicine, IRCCS San Martino di Genova University Hospital, Genoa bDepartment of Biomedical Science, Personalized Medicine Clinic Asthma &amp; Allergy, Humanitas Clinical and Research Center, Humanitas University, Rozzano, Milano, Italy</style></auth-address><titles><title><style face="normal" font="default">Patient-reported outcomes in asthma clinical trials</style></title><secondary-title><style face="normal" font="default">Curr Opin Pulm Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Opin Pulm Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="10" Year="2017">2017/10/13</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: The review provides an overview of the results of asthma clinical trials published in peer review journals in the last 18 months that evaluated patient-reported outcomes (PROs). RECENT FINDINGS: In the last 10 years, health care moved toward a patient-centered approach, which includes patients' perspectives reflecting the impact of a disease and its treatment. SUMMARY: Surprisingly, among the almost 300 clinical trials published in the last one and a half year, PRO evaluation was performed in only 20 studies, and none of them held in a real-life setting. The effort of applying the scientific methods of PRO investigations in asthma clinical trials following a rigorous and systematic approach needs to be highly improved to allow better understanding of patient reported factors. Some recommendations are drawn particularly about PRO assessment in personalized medicine research. The ability of an individual PRO to evaluate choice of treatment and its effectiveness remains to be achieved</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 1531-6971 (Electronic)IS - 1070-5287 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1097/MCP.0000000000000440</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29036017">PM:29036017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Pulm Med\20171016-BraidoF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Pulm Med\20171016-BraidoF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171016, Braido F</style></custom2><misc3><style face="normal" font="default">10.1097/MCP.0000000000000440</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42968</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chung,K.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">aNational Heart and Lung Institute, Imperial College London bRespiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Trust, Imperial College London, London, UK</style></auth-address><titles><title><style face="normal" font="default">Precision medicine in asthma: linking phenotypes to targeted treatments</style></title><secondary-title><style face="normal" font="default">Curr Opin Pulm Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Opin Pulm Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="10" Year="2017">2017/10/13</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Asthma is a heterogeneous disease consisting of different phenotypes that are driven by different mechanistic pathways. The purpose of this review is to emphasize the important role of precision medicine in asthma management. RECENT FINDINGS: Despite asthma heterogeneity, the approach to management has been on the basis of disease severity, with the most severe patients reserved for the maximum treatments with corticosteroids and bronchodilators. At the severe end, the recent availability of biologic therapies in the form of anti-IgE (omalizumab) and anti-IL5 therapies (mepolizumab and reslizumab) has driven the adaptation of precision medicine. These therapies are reserved for severe asthma with defined either allergic or eosinophilic background, respectively. SUMMARY: Unbiased definition of phenotypes or endotypes (which are phenotypes defined by mechanisms) is an important step towards the use of precision medicine in asthma. Although T2-high asthma has been defined with targets becoming available for treating allergic or eosinophilic asthma, the definition of non-T2 phenotypes remains a priority. Precision medicine is also dependent on the definition of biomarkers that can help differentiate between these phenotypes and pinpoint patients suitable for specific-targeted therapies. Thus, precision medicine links phenotypes (endotypes) to targeted treatments for better outcomes</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 1531-6971 (Electronic)IS - 1070-5287 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1097/MCP.0000000000000434</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29036018">PM:29036018</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Pulm Med\20171016-ChungKF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Pulm Med\20171016-ChungKF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171016, Chung KF</style></custom2><misc3><style face="normal" font="default">10.1097/MCP.0000000000000434</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42969</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hanania,N.A.</style></author><author><style face="normal" font="default"> Diamant,Z.</style></author></authors></contributors><auth-address><style face="normal" font="default">aSection of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, Texas, USA bDepartment of Respiratory Medicine &amp; Allergology, Institute for Clinical Science, Skane University Hospital, Lund, Sweden cDepartment of General Practice and Elderly Care Medicine, University of Groningen, University Medical Center Groningen dQPS-NL, Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">The road to precision medicine in asthma: challenges and opportunities</style></title><secondary-title><style face="normal" font="default">Curr Opin Pulm Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Opin Pulm Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="10" Year="2017">2017/10/17</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171018IS - 1531-6971 (Electronic)IS - 1070-5287 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1097/MCP.0000000000000444</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29045293">PM:29045293</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Pulm Med\20171018-HananiaNA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Pulm Med\20171018-HananiaNA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171018, Hanania NA</style></custom2><misc3><style face="normal" font="default">10.1097/MCP.0000000000000444</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42970</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Humbert,M.</style></author><author><style face="normal" font="default"> Busse,W.</style></author><author><style face="normal" font="default"> Hanania,N.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">aFaculte de Medecine, Univ. Paris-Sud, Universite Paris-Saclay, Le Kremlin-Bicetre bService de Pneumologie, Assistance Publique Hopitaux de Paris, Hopital Bicetre, Le Kremlin-Bicetre, France cDepartment of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin dSection of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, Houston, Texas, USA</style></auth-address><titles><title><style face="normal" font="default">Controversies and opportunities in severe asthma</style></title><secondary-title><style face="normal" font="default">Curr Opin Pulm Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Opin Pulm Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="10" Year="2017">2017/10/20</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Despite currently available treatments, many asthma patients remain inadequately controlled, but identifying distinct patient populations (phenotypes/endotypes) may optimize their management. This review discusses some of the controversies and opportunities for improved disease control in severe asthma. RECENT FINDINGS: Currently approved anti-immunoglobulin E and anti-interleukin 5 biologics, which target specific pathways instead of using a 'one size fits all' strategy, are efficacious and well tolerated therapies for severe asthma. The appropriate use of these biologics, and of those in development (e.g., benralizumab and dupilumab), should be aided by further understanding of asthma phenotypes and endotypes, utilizing appropriate biomarkers.Oral corticosteroids are often added as maintenance therapy for patients with severe uncontrolled asthma, but their use is associated with significant adverse effects and should be considered a last option. The true cost of this therapy, including the cost of morbidities associated with its use, remains to be determined.Severe asthma in pediatrics poses a unique opportunity for possible prevention strategies and the potential for primary prevention. Although several avenues for primary prevention are being explored and are out of the scope of this review, we focus our discussion on the use of omalizumab, which has been recently explored in clinical trials. SUMMARY: Appropriate use of biologics in severe asthma should be supported by further understanding of biomarkers predicting response to targeted therapy. Because of their association with significant adverse effects, add-on oral corticosteroids should be considered a last treatment option for patients with uncontrolled severe asthma. Finally, severe asthma in pediatrics poses a unique opportunity for potential prevention strategies</style></abstract><notes><style face="normal" font="default">DA - 20171023IS - 1531-6971 (Electronic)IS - 1070-5287 (Linking)LA - engPT - Journal ArticleCO - France -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/MCP.0000000000000438</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29059087">PM:29059087</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Pulm Med\20171023-HumbertM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Pulm Med\20171023-HumbertM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171023, Humbert M</style></custom2><misc3><style face="normal" font="default">10.1097/MCP.0000000000000438</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42971</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pite,H.</style></author><author><style face="normal" font="default"> Morais-Almeida,M.</style></author><author><style face="normal" font="default"> Rocha,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">aAllergy Center, CUF Descobertas Hospital and CUF Infante Santo Hospital bCEDOC, Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciencias Medicas, Universidade Nova de Lisboa, Lisbon cDepartment of Chemistry &amp; QOPNA, University of Aveiro, Aveiro, Portugal</style></auth-address><titles><title><style face="normal" font="default">Metabolomics in asthma: where do we stand?</style></title><secondary-title><style face="normal" font="default">Curr Opin Pulm Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Opin Pulm Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="10" Year="2017">2017/10/20</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Metabolomics has been used to uncover the metabolic signatures of asthma, both for biomarker identification and pathophysiologic mechanisms research. We aimed to review recent advances in this field, published since 2016, and discuss these findings implications to future research and application into clinical practice. RECENT FINDINGS: Experimental asthma models and clinical studies in both children and adults supported independent metabolic signatures of asthma. Common reported pathways included purine, glycerophospholipid, glutathione, fatty acids, and arginine and proline metabolism. Metabolomics-based studies identified candidate biomarkers related to asthma severity and corticosteroid resistance, and supported the definition of the obesity-related phenotype at the molecular level. A systematic review with meta-analysis and recent prospective studies favored exhaled volatile organic compounds as one of the most promising biomarkers in asthma diagnosis and monitoring. SUMMARY: Metabolomics has provided unique and novel insights into asthma profiling at the molecular level. Current challenges include procedures standardization and control of potentially confounding variables for external validation. Point-of-care technology developments bring metabolomics closer to clinical practice. In addition to biomarkers identification, relating metabolites to their biologic role will serve as critical foundations for understanding the biology underpinning asthma heterogeneity and for specific-targeted therapies.Video Abstract: http://links.lww.com/COPM/A22</style></abstract><notes><style face="normal" font="default">DA - 20171023IS - 1531-6971 (Electronic)IS - 1070-5287 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.1097/MCP.0000000000000437</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29059088">PM:29059088</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Pulm Med\20171023.PiteH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Pulm Med\20171023.PiteH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171023, Pite H</style></custom2><misc3><style face="normal" font="default">10.1097/MCP.0000000000000437</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42972</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nojkov,B.</style></author><author><style face="normal" font="default"> Amin,M.</style></author><author><style face="normal" font="default"> Ghaith,G.</style></author><author><style face="normal" font="default"> Cappell,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Gastroenterology and Hepatology, University of Michigan Health System, Ann Arbor, MI, USA</style></auth-address><titles><title><style face="normal" font="default">A Statistically Significant Association Between Esophageal Granular Cell Tumors and Eosinophilic Esophagitis: A 16-year Analysis at Two Large Hospitals of 167,434 EGDs</style></title><secondary-title><style face="normal" font="default">Dig Dis Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Dig Dis Sci</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="24" Month="10" Year="2017">2017/10/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: Esophageal granular cell tumor (eGCT) is a rare, usually benign, neoplasm of neuroectodermic origin. Eosinophilic esophagitis (EoE) is a relatively uncommon, immune-mediated, chronic disease. Both diseases commonly present with dysphagia. One case has been reported of simultaneous occurrence of both diseases. AIMS: To determine the association between diseases. METHODS: The present study was an IRB-approved, retrospective review of esophagogastroduodenoscopies (EGDs) with esophageal biopsies from two large hospitals, 1999-2014. RESULTS: Among 29,235 EGDs with esophageal biopsies for 16 years (167,434 total EGDs), 16 patients had pathologically diagnosed eGCT, and 1225 patients had pathologically diagnosed EoE. Five (31%) of 16 patients with eGCT had concomitant EoE (p = 0.001, OR 10.43, 95% ORCI 3.16-32.44, Fisher's exact test). Patients with simultaneous eGCT and EoE were young (mean age = 33.6 +/- 12.9 years). Three were female. Dysphagia was presenting symptom in 4 (80%) of patients. Three had asthma. All five patients had > 20 eosinophils/hpf in esophageal biopsy specimens. Three patients had endoscopic esophageal abnormalities suggesting EoE. Four patients were treated with a PPI (before and after diagnosis of EoE), and 2 patients underwent six-food-elimination diet with partial symptomatic improvement. The eGCTs averaged 13.4 +/- 4.2 mm in maximal diameter and were located in upper-2, middle-2, and lower esophagus-2 (1 patient had 2 eGCTs). eGCTs were endoscopically resected-3 patients, and monitored-2 patients. Surveillance endoscopies revealed no recurrence or growth of eGCTs after resection (mean follow-up = 4.6 years). CONCLUSIONS: This novel report of 5 patients with simultaneous EoE and eGCT adds to one, previously published case and suggests these two diseases are associated, and have a common pathophysiologic link, despite apparently different pathogenesis. Large, prospective, endoscopic and pathologic studies are warranted to further investigate this association</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1573-2568 (Electronic)IS - 0163-2116 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s10620-017-4802-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29064014">PM:29064014</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dig Dis Sci\20171024-NojkovB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dig Dis Sci\20171024-NojkovB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171024, Nojkov B</style></custom2><misc3><style face="normal" font="default">10.1007/s10620-017-4802-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42973</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mierzejewska,A.</style></author><author><style face="normal" font="default"> Jung,A.</style></author><author><style face="normal" font="default"> Kalicki,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Pediatric Nephrology and Allergology, Central Clinical Hospital of the Ministry of Defence, Military Institute of Medicine, Warsaw, Poland</style></auth-address><titles><title><style face="normal" font="default">Nasal Cytology as a Marker of Atopy in Children</style></title><secondary-title><style face="normal" font="default">Dis Markers</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Dis Markers</style></abbr-1></periodical><pages end="" start="4159251">4159251-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The aim of this study was to evaluate the cytological picture of nasal mucosa in children with atopic diseases and to determine the diagnostic value of the test for the diagnosis of atopic diseases. The study included 140 children from 4 months to 17 years old. Among children with a history of atopy, there were 30 children with atopic dermatitis, 30 children with asthma, and 46 children with allergic rhinitis. The control group consisted of 34 healthy children. The nasal scraping technique has been used to collect samples from the nasal cavity. The samples were evaluated under light microscope. Epithelial cells as well as infiltrating cells were assessed. The only statistically significant group of cells differentiating children with atopic disease and without atopy were eosinophils, which in children with atopy were significantly more common. Assuming a significant eosinophilia value of at least 5% of all cells in cytogram, the sensitivity of nasal cytology in allergic rhinitis was 52.2%, in asthma 33.3%, and in atopic dermatitis 13.3%. The specificity of the test in atopic diseases was 94.1%. It can be concluded that nasal cytology with eosinophilia assessment can be a useful tool for an early diagnosis of atopic disease in children</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 1875-8630 (Electronic)IS - 0278-0240 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1155/2017/4159251</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29038613">PM:29038613</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dis Markers\2017-2017-4159251.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dis Markers\2017-2017-4159251.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Mierzejewska A</style></custom2><misc3><style face="normal" font="default">10.1155/2017/4159251</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42974</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arjona-Aguilera,C.</style></author><author><style face="normal" font="default"> Jimenez-Gallo,D.</style></author><author><style face="normal" font="default"> Ossorio-Garcia,L.</style></author><author><style face="normal" font="default"> Linares-Barrios,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Unidad de Gestion Clinica Dermatologia y Venereologia, Hospital Universitario Puerta del Mar, Servicio Andaluz de Salud, Cadiz, Espana</style></auth-address><titles><title><style face="normal" font="default">[Refractory urticaria: Schnitzler syndrome]</style></title><secondary-title><style face="normal" font="default">Emergencias</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Emergencias</style></abbr-1></periodical><pages end="" start="137">137-</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171027IS - 2386-5857 (Electronic)IS - 1137-6821 (Linking)LA - spaPT - LetterCO - Spain -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29077281">PM:29077281</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Emergencias\2017-29-137.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Emergencias\2017-29-137.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171027, Arjona-Aguilera C</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42975</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Barrett,J.R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Warm, Cozy Woodstoves . . . and the PM They Produce: Home Interventions Show Mixed Results in Protecting Children with Asthma</style></title><secondary-title><style face="normal" font="default">Environ Health Perspect</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Environ Health Perspect</style></full-title></periodical><pages end="" start="104004">104004-</pages><volume><style face="normal" font="default">125</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="10" Year="2017">2017/10/17</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171018IS - 1552-9924 (Electronic)IS - 0091-6765 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1289/EHP2598</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29043979">PM:29043979</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Environ Health Perspect\2017-125-104004.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Environ Health Perspect\2017-125-104004.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171018, Barrett JR</style></custom2><misc3><style face="normal" font="default">10.1289/EHP2598</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42976</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oh,I.</style></author><author><style face="normal" font="default"> Lee,J.</style></author><author><style face="normal" font="default"> Ahn,K.</style></author><author><style face="normal" font="default"> Kim,J.</style></author><author><style face="normal" font="default"> Kim,Y.M.</style></author><author><style face="normal" font="default"> Sun,Sim C.</style></author><author><style face="normal" font="default"> Kim,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Environmental Health Center, University of Ulsan College of Medicine, Ulsan, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Association between particulate matter concentration and symptoms of atopic dermatitis in children living in an industrial urban area of South Korea</style></title><secondary-title><style face="normal" font="default">Environ Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Environ Res</style></abbr-1></periodical><pages end="468" start="462">462-468</pages><volume><style face="normal" font="default">160</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="24" Month="10" Year="2017">2017/10/24</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Increased exposure to particulate matter (PM) appears to increase the development of atopic diseases and allergic sensitization. This study evaluated the association between daily levels of PM with diameters less than 10microm (PM10) and PM2.5 and symptoms of atopic dermatitis (AD) in children living in an industrial urban area. METHODS: Indoor PM10 and PM2.5 concentrations were measured with an optical particle counter in two preschools near large industrial complexes in Ulsan, South Korea during two 6-month periods (May-October of 2012 and 2013). Twenty-one children with AD from these preschools were enrolled and observed daily for AD symptoms during the same periods. Indoor and outdoor PM concentrations were used to estimate PM exposure based on time activity patterns. RESULTS: Analysis of PM10 and PM2.5 concentrations showed that indoor and outdoor PM10 levels varied similarly throughout each 6-month period. In addition, indoor concentration of PM2.5 had high correlation with ambient outdoor concentration of PM10. Correlation analysis also indicated a significant positive correlation between the exacerbation of AD symptoms and daily mean exposure to PM10 and PM2.5. Based on a generalized linear mixed model (GLMM), PM exposure was significantly associated with the exacerbation of AD symptoms, with a maximum adjusted odds ratio (aOR) of 1.399 for a 10microg/m3 increase of PM2.5 (95% CI: 1.216-1.610). DISCUSSION: Our findings suggest that short-term exposure to PM can exacerbate AD in young children living in an industrial urban area. PM2.5 had a stronger effect than PM10 on exacerbation of AD symptoms</style></abstract><notes><style face="normal" font="default">DA - 20171027IS - 1096-0953 (Electronic)IS - 0013-9351 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.envres.2017.10.030</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29078139">PM:29078139</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Environ Res\2017-160-462-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Environ Res\2017-160-462-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171027, Oh I</style></custom2><misc3><style face="normal" font="default">10.1016/j.envres.2017.10.030</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42977</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Agusti,A.</style></author><author><style face="normal" font="default"> Bafadhel,M.</style></author><author><style face="normal" font="default"> Beasley,R.</style></author><author><style face="normal" font="default"> Bel,E.H.</style></author><author><style face="normal" font="default"> Faner,R.</style></author><author><style face="normal" font="default"> Gibson,P.G.</style></author><author><style face="normal" font="default"> Louis,R.</style></author><author><style face="normal" font="default"> McDonald,V.M.</style></author><author><style face="normal" font="default"> Sterk,P.J.</style></author><author><style face="normal" font="default"> Thomas,M.</style></author><author><style face="normal" font="default"> Vogelmeier,C.</style></author><author><style face="normal" font="default"> Pavord,I.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory Institute, Hospital Clinic, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default">Precision medicine in airway diseases: moving to clinical practice</style></title><secondary-title><style face="normal" font="default">Eur Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Respir J</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="default">50</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">On February 21, 2017, a European Respiratory Society research seminar held in Barcelona discussed how to best apply precision medicine to chronic airway diseases such as asthma and chronic obstructive pulmonary disease. It is now clear that both are complex and heterogeneous diseases, that often overlap and that both require individualised assessment and treatment. This paper summarises the presentations and discussions that took place during the seminar. Specifically, we discussed the need for a new taxonomy of human diseases, the role of different players in this scenario (exposome, genes, endotypes, phenotypes, biomarkers and treatable traits) and a number of unanswered key questions in the field. We also addressed how to deploy airway precision medicine in clinical practice today, both in primary and specialised care. Finally, we debated the type of research needed to move the field forward</style></abstract><notes><style face="normal" font="default">DA - 20171020IS - 1399-3003 (Electronic)IS - 0903-1936 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - United Kingdom -CO - Netherlands -CO - New Zealand -CO - Australia -CO - Belgium -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1183/13993003.01655-2017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29051276">PM:29051276</url></web-urls></urls><custom2><style face="normal" font="default">20171020, Agusti A</style></custom2><misc3><style face="normal" font="default">10.1183/13993003.01655-2017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42978</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Heederik,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Occupational exposure and asthma control</style></title><secondary-title><style face="normal" font="default">Eur Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Respir J</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="default">50</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171027IS - 1399-3003 (Electronic)IS - 0903-1936 (Linking)LA - engPT - EditorialCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1183/13993003.01951-2017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29074549">PM:29074549</url></web-urls></urls><custom2><style face="normal" font="default">20171027, Heederik D</style></custom2><misc3><style face="normal" font="default">10.1183/13993003.01951-2017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42979</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pavon-Romero,G.F.</style></author><author><style face="normal" font="default"> Ramirez-Jimenez,F.</style></author><author><style face="normal" font="default"> Roldan-Alvarez,M.A.</style></author><author><style face="normal" font="default"> Teran,L.M.</style></author><author><style face="normal" font="default"> Falfan-Valencia,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Departamento de Investigacion en Inmunogenetica y Alergia</style></auth-address><titles><title><style face="normal" font="default">Physiopathology and genetics in aspirin-exacerbated respiratory disease</style></title><secondary-title><style face="normal" font="default">Exp Lung Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Exp Lung Res</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Aspirin-exacerbated respiratory disease (AERD) is a clinical entity characterized by hypersensitivity to aspirin leading to asthma and chronic rhinosinusitis with nasosinusal polyposis. The pathophysiology of the disease involves disruption at the level of arachidonic acid metabolism. Therefore, genetic association studies have been focused on the genes coding this pathway. As other mechanisms involved in the genesis of the disease were elucidated, the corresponding genes were also explored. AIM: To describe the association reported in the literature between gene polymorphisms involved in the pathophysiology or therapeutic processes of AERD. RESULTS: There is a genetic association between polymorphisms of genes involved in the synthesis of proteins related to arachidonic acid metabolism (LTC4S, ALOX5), antigen presentation (HLA), inflammation (IL5, IL17), and aspirin metabolism (CYP2C19). CONCLUSIONS: Genetic association research in AERD has evaluated studies of SNPs in metabolic pathways related to arachidonic acid. Recently, whole genome analysis strategies have allowed the detection of new genetic variants that were previously not considered. Furthermore, these studies have identified SNPs that are associated with inflammatory processes, which could serve as diagnostic markers or predictors of the therapeutic response</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 1521-0499 (Electronic)IS - 0190-2148 (Linking)LA - engPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="default">10.1080/01902148.2017.1358776</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29035123">PM:29035123</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Exp Lung Res\20171016-PavonRomeroGF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Exp Lung Res\20171016-PavonRomeroGF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171016, Pavon-Romero GF</style></custom2><misc3><style face="normal" font="default">10.1080/01902148.2017.1358776</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42980</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Licari,A.</style></author><author><style face="normal" font="default"> Castagnoli,R.</style></author><author><style face="normal" font="default"> Brambilla,I.</style></author><author><style face="normal" font="default"> Marseglia,A.</style></author><author><style face="normal" font="default"> Tosca,M.A.</style></author><author><style face="normal" font="default"> Marseglia,G.L.</style></author><author><style face="normal" font="default"> Ciprandi,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Pediatric Clinic , Fondazione IRCCS San Matteo , Pavia , Italy</style></auth-address><titles><title><style face="normal" font="default">New approaches for identifying and testing potential new anti-asthma agents</style></title><secondary-title><style face="normal" font="default">Expert Opin Drug Discov</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Expert Opin Drug Discov</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="10" Year="2017">2017/10/27</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Asthma is a chronic disease with significant heterogeneity in clinical features, disease severity, pattern of underlying disease mechanisms, and responsiveness to specific treatments. While the majority of asthmatic patients are controlled by standard pharmacological strategies, a significant subgroup has limited therapeutic options representing a major unmet need. Ongoing asthma research aims to better characterize distinct clinical phenotypes, molecular endotypes, associated reliable biomarkers, and also to develop a series of new effective targeted treatment modalities. Areas covered: The expanding knowledge on the pathogenetic mechanisms of asthma has allowed researchers to investigate a range of new treatment options matched to patient profiles. The aim of this review is to provide a comprehensive and updated overview of the currently available, new and developing approaches for identifying and testing potential treatment options for asthma management. Expert opinion: Future therapeutic strategies for asthma require the identification of reliable biomarkers that can help with diagnosis and endotyping, in order to determine the most effective drug for the right patient phenotype. Furthermore, in addition to the identification of clinical and inflammatory phenotypes, it is expected that a better understanding of the mechanisms of airway remodeling will likely optimize asthma targeted treatment</style></abstract><notes><style face="normal" font="default">DA - 20171027IS - 1746-045X (Electronic)IS - 1746-0441 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1080/17460441.2018.1396315</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29077521">PM:29077521</url></web-urls></urls><custom2><style face="normal" font="default">20171027, Licari A</style></custom2><misc3><style face="normal" font="default">10.1080/17460441.2018.1396315</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42981</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Furue,M.</style></author><author><style face="normal" font="default"> Kadono,T.</style></author><author><style face="normal" font="default"> Tsuji,G.</style></author><author><style face="normal" font="default"> Nakahara,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Dermatology , Kyushu University , Fukuoka , Japan</style></auth-address><titles><title><style face="normal" font="default">Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Expert Opin Investig Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Expert Opin Investig Drugs</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="10" Year="2017">2017/10/25</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Local adverse effects of steroid use and the burning sensation of calcineurin inhibitors impair patients' adherence to treatment and decrease the treatment response in atopic dermatitis (AD). Steroid phobia appears to be a psychological problem in patients with AD. Topical non-steroidal remedies are in demand. Areas covered: This manuscript reviews the current literature on preclinical and clinical studies regarding topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor. We also discuss the mechanistic background of E6005/RVT-501 in the treatment of AD. Expert opinion: Topical E6005/RVT-501 improves skin eruption and pruritus of pediatric and adult AD patients without any serious side effects. It is useful for mild to moderate lesions of AD in pediatric and adult patients. Topical E6005/RVT-501 is non-steroidal agent but its potency is equal to that of mild rank topical steroid, therefore, it may fit the demand of patients with steroid phobia. Its steroid-sparing effects may also be investigated in future clinical trials and may minimize the dose and frequency of topical steroids</style></abstract><notes><style face="normal" font="default">DA - 20171025IS - 1744-7658 (Electronic)IS - 1354-3784 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1080/13543784.2017.1397626</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29068253">PM:29068253</url></web-urls></urls><custom2><style face="normal" font="default">20171025, Furue M</style></custom2><misc3><style face="normal" font="default">10.1080/13543784.2017.1397626</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42982</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ruscitti,P.</style></author><author><style face="normal" font="default"> Cipriani,P.</style></author><author><style face="normal" font="default"> Di Benedetto,P.</style></author><author><style face="normal" font="default"> Liakouli,V.</style></author><author><style face="normal" font="default"> Carubbi,F.</style></author><author><style face="normal" font="default"> Berardicurti,O.</style></author><author><style face="normal" font="default"> Ciccia,F.</style></author><author><style face="normal" font="default"> Guggino,G.</style></author><author><style face="normal" font="default"> Triolo,G.</style></author><author><style face="normal" font="default"> Giacomelli,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Division of Rheumatology , University of L'Aquila , L'Aquila , Italy</style></auth-address><titles><title><style face="normal" font="default">Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?</style></title><secondary-title><style face="normal" font="default">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Expert Rev Clin Immunol</style></full-title></periodical><pages end="1047" start="1041">1041-1047</pages><volume><style face="normal" font="default">13</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Macrophage activation syndrome (MAS) is a severe, hyperinflammatory life-threatening syndrome, generally complicating different rheumatic diseases. Despite the severity of the disease, little is known about the pathogenic mechanisms and, thus, possible targeted therapies in the management of these patients. Areas covered: In this review, we aimed to update the current pathogenic knowledge of MAS, during rheumatic diseases, focusing mainly on immunologic abnormalities and on new possible therapeutic strategies. Expert commentary: The difficult pathogenic scenario of MAS, in which genetic defects, predisposing diseases, and triggers are mixed together with the high mortality rate, make it difficult to manage these patients. Although most efforts have been focused on investigating the disease in children, in recent years, several studies are trying to elucidate the possible pathogenic mechanism in adult MAS patients. In this context, genetic and immunological studies might lead to advances in the knowledge of pathogenic mechanisms and possible new therapeutic targets. In the future, the results of ongoing clinical trials are awaited in order to improve the management and, thus, the survival of these patients</style></abstract><notes><style face="normal" font="default">DA - 20170824IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1080/1744666X.2017.1372194</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28837367">PM:28837367</url></web-urls></urls><custom2><style face="normal" font="default">20170824, Ruscitti P</style></custom2><misc3><style face="normal" font="default">10.1080/1744666X.2017.1372194</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42983</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Choi,J.K.</style></author><author><style face="normal" font="default"> Jang,Y.H.</style></author><author><style face="normal" font="default"> Lee,S.</style></author><author><style face="normal" font="default"> Lee,S.R.</style></author><author><style face="normal" font="default"> Choi,Y.A.</style></author><author><style face="normal" font="default"> Jin,M.</style></author><author><style face="normal" font="default"> Choi,J.H.</style></author><author><style face="normal" font="default"> Park,J.H.</style></author><author><style face="normal" font="default"> Park,P.H.</style></author><author><style face="normal" font="default"> Choi,H.</style></author><author><style face="normal" font="default"> Kwon,T.K.</style></author><author><style face="normal" font="default"> Khang,D.</style></author><author><style face="normal" font="default"> Kim,S.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cell &amp; Matrix Research Center, Department of Pharmacology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Chrysin attenuates atopic dermatitis by suppressing inflammation of keratinocytes</style></title><secondary-title><style face="normal" font="default">Food Chem Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Food Chem Toxicol</style></full-title></periodical><pages end="150" start="142">142-150</pages><volume><style face="normal" font="default">110</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="default">We previously reported the inhibitory effect of chrysin, a natural flavonoid plentifully contained in propolis, vegetables and fruits, on the mast cell-mediated allergic reaction. In this study, we evaluated the effect of chrysin on atopic dermatitis (AD) and defined underlying mechanisms of action. We used an AD model in BALB/c mice by the repeated local exposure of 2,4-dinitrochlorobenzene (DNCB) and house dust mite (Dermatophagoides farinae extract, DFE) to the ears. Repeated alternative treatment of DNCB/DFE caused AD-like skin lesions. Oral administration of chrysin diminished AD symptoms such as ear thickness and histopathological analysis, in addition to serum IgE and IgG2a levels. Chrysin decreased infiltration of mast cells, and reduced serum histamine level. Chrysin also suppressed AD by inhibiting the inflammatory responses of Th1, Th2, and Th17 cells in mouse lymph node and ear. Interestingly, chrysin significantly inhibited the production of cytokines, Th2 chemokines, CCL17 and CCL22 by the down-regulation of p38 MAPK, NF-kappaB, and STAT1 in tumor necrosis factor (TNF)-alpha/interferon (IFN)-gamma-stimulated human keratinocytes (HaCaT). Chrysin also inhibited TNF-alpha/IFN-gamma-stimulated IL-33 expression in HaCaT cells and mouse primary keratinocytes. Taken together, the results indicate that chrysin suppressed AD symptoms, suggesting that chrysin might be a candidate for the treatment of AD and skin allergic diseases</style></abstract><notes><style face="normal" font="default">DA - 20171020IS - 1873-6351 (Electronic)IS - 0278-6915 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.fct.2017.10.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29050978">PM:29050978</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Food Chem Toxicol\2017-110-142-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Food Chem Toxicol\2017-110-142-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171020, Choi JK</style></custom2><misc3><style face="normal" font="default">10.1016/j.fct.2017.10.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42984</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Roviezzo,F.</style></author><author><style face="normal" font="default"> Sorrentino,R.</style></author><author><style face="normal" font="default"> Terlizzi,M.</style></author><author><style face="normal" font="default"> Riemma,M.A.</style></author><author><style face="normal" font="default"> Iacono,V.M.</style></author><author><style face="normal" font="default"> Rossi,A.</style></author><author><style face="normal" font="default"> Spaziano,G.</style></author><author><style face="normal" font="default"> Pinto,A.</style></author><author><style face="normal" font="default"> D'Agostino,B.</style></author><author><style face="normal" font="default"> Cirino,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacy, School of Medicine, University of Naples Federico II, Naples, Italy</style></auth-address><titles><title><style face="normal" font="default">Toll-Like Receptor 4 Is Essential for the Expression of Sphingosine-1-Phosphate-Dependent Asthma-Like Disease in Mice</style></title><secondary-title><style face="normal" font="default">Front Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Immunol</style></abbr-1></periodical><pages end="" start="1336">1336-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Sphingosine-1-phosphate (S1P) levels significantly increase in bronchoalveolar lavage (BAL) of asthmatic patients following segmental allergen challenge and this increase well correlates with pulmonary inflammation. Epidemiological, genetic, clinical, and experimental data indicate a potential for the toll-like receptor 4 (TLR4) to initiate and exacerbate allergic airway diseases. The aim of this study was to evaluate the contribution of TLR4 in S1P-dependent asthma-like disease in mice. BALB/c or TLR4 defective (C3H/HeJ) mice received S1P (10 ng/mouse), LPS (0.1 mug/mouse) or S1P + LPS. Furthermore, S1P-treated BALB/c mice were injected with the purified rabbit anti-TLR4 antibody (10 mug/mouse). S1P administration induced airway hyperreactivity and pulmonary inflammation associated to an increase in the percentage of dendritic cells (DCs) and macrophages into the lung of BALB/c mice. These effects were coupled to a reduction of DCs in the mediastinic lymph node. All these S1P-mediated effects were absent in TLR4 defective mice or reversed by treatment with a purified rabbit anti-TLR4 antibody. Confocal analysis of pulmonary sections showed a significant increase in TLR4+ cells and a similar presence of S1P1 and TLR4 following S1P challenge. Accordingly, the immunoprecipitation evidenced an increased S1P1/TLR4 interaction. In conclusion, our findings suggest that a functional interaction between S1P1 and TLR4 leads to an enhanced allergic inflammatory response. Thus, S1P pathway contributes to the sentinel role played by innate immunity providing new targets for prevention and treatment of allergic airway diseases</style></abstract><notes><style face="normal" font="default">DA - 20171102IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.3389/fimmu.2017.01336</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29093714">PM:29093714</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Immunol\2017-8-1336.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Immunol\2017-8-1336.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171102, Roviezzo F</style></custom2><misc3><style face="normal" font="default">10.3389/fimmu.2017.01336</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42985</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mitson-Salazar,A.</style></author><author><style face="normal" font="default"> Prussin,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunobiology, Yale University School of Medicine, New Haven, CT, United StatesKnopp Biosciences LLC, Pittsburgh, PA, United States</style></auth-address><titles><title><style face="normal" font="default">Pathogenic Effector Th2 Cells in Allergic Eosinophilic Inflammatory Disease</style></title><secondary-title><style face="normal" font="default">Front Med (Lausanne)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Med (Lausanne)</style></abbr-1></periodical><pages end="" start="165">165-</pages><volume><style face="normal" font="default">4</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">There is an absolute requirement for Th2 cells in the pathogenesis of allergen-driven eosinophil-rich type 2 inflammation. Although Th2 cells are generally regarded as a homogeneous population, in the past decade there has been increasing evidence for a minority subpopulation of IL-5+ Th2 cells that have enhanced effector function. This IL-5+ Th2 subpopulation has been termed pathogenic effector Th2 (peTh2), as it exhibits greater effector function and disease association than conventional Th2 cells. peTh2 cells have a different expression profile, differentially express transcription factors, and preferentially use specific signaling pathways. As such, peTh2 cells are a potential target in the treatment of allergic eosinophilic inflammation. This review examines peTh2 cells, both in mouse models and human disease, with an emphasis on their role in the pathogenesis of allergic eosinophilic inflammation</style></abstract><notes><style face="normal" font="default">DA - 20171023IS - 2296-858X (Print)IS - 2296-858X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.3389/fmed.2017.00165</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29057225">PM:29057225</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Food Chem Toxicol\2017-4-165.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Food Chem Toxicol\2017-4-165.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171023, Mitson-Salazar A</style></custom2><misc3><style face="normal" font="default">10.3389/fmed.2017.00165</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42986</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Doran,E.</style></author><author><style face="normal" font="default"> Cai,F.</style></author><author><style face="normal" font="default"> Holweg,C.T.J.</style></author><author><style face="normal" font="default"> Wong,K.</style></author><author><style face="normal" font="default"> Brumm,J.</style></author><author><style face="normal" font="default"> Arron,J.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunology Discovery, Genentech, Inc., South San Francisco, CA, United States</style></auth-address><titles><title><style face="normal" font="default">Interleukin-13 in Asthma and Other Eosinophilic Disorders</style></title><secondary-title><style face="normal" font="default">Front Med (Lausanne)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Med (Lausanne)</style></abbr-1></periodical><pages end="" start="139">139-</pages><volume><style face="normal" font="default">4</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Asthma is characterized by episodic, reversible airflow obstruction associated with variable levels of inflammation. Over the past several decades, there has been an increasing appreciation that the clinical presentation of asthma comprises a diverse set of underlying pathologies. Rather than being viewed as a single disease entity, asthma is now thought of as a clinical syndrome with the involvement of multiple pathological mechanisms. While it is appreciated that eosinophilia is present in only a subset of patients, it remains a key feature of asthma and other eosinophilic disorders such as atopic dermatitis, eosinophilic esophagitis, and chronic rhinosinusitis with nasal polyps. Eosinophils are bone marrow-derived leukocytes present in low numbers in health; however, during disease the type 2 cytokines [interleukins (IL)-4, -5, and -13] can induce rapid eosinophilopoiesis, prolonged eosinophil survival, and trafficking to the site of injury. In diseases such as allergic asthma there is an aberrant inflammatory response leading to eosinophilia, tissue damage, and airway pathology. IL-13 is a pleiotropic type 2 cytokine that has been shown to be integral in the pathogenesis of asthma and other eosinophilic disorders. IL-13 levels are elevated in animal models of eosinophilic inflammation and in the blood and tissue of patients diagnosed with eosinophilic disorders. IL-13 signaling elicits many pathogenic mechanisms including the promotion of eosinophil survival, activation, and trafficking. Data from preclinical models and clinical trials of IL-13 inhibitors in patients have revealed mechanistic insights into the role of this cytokine in driving eosinophilia. Promising results from clinical trials further support a key mechanistic role of IL-13 in asthma and other eosinophilic disorders. Here, we provide a perspective on the role of IL-13 in asthma and other eosinophilic disorders and describe ongoing clinical trials targeting this pathway in patients with significant unmet medical needs</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 2296-858X (Print)IS - 2296-858X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.3389/fmed.2017.00139</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29034234">PM:29034234</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Food Chem Toxicol\2017-4-139.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Food Chem Toxicol\2017-4-139.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171016, Doran E</style></custom2><misc3><style face="normal" font="default">10.3389/fmed.2017.00139</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42987</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ioan,I.</style></author><author><style face="normal" font="default"> Tatopoulos,A.</style></author><author><style face="normal" font="default"> Metche,S.</style></author><author><style face="normal" font="default"> Coutier,L.</style></author><author><style face="normal" font="default"> Houriez,E.</style></author><author><style face="normal" font="default"> Kiefer,S.</style></author><author><style face="normal" font="default"> Blonde,A.</style></author><author><style face="normal" font="default"> Bonabel,C.</style></author><author><style face="normal" font="default"> Marchal,F.</style></author><author><style face="normal" font="default"> Derelle,J.</style></author><author><style face="normal" font="default"> Schweitzer,C.E.</style></author><author><style face="normal" font="default"> Demoulin-Alexikova,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Service d'explorations Fonctionnelles Pediatriques, Hopital d'enfants, CHRU de Nancy, Vandoeuvre-les-Nancy, France</style></auth-address><titles><title><style face="normal" font="default">More Relaxation by Deep Breath on Methacholine- Than on Exercise-Induced bronchoconstriction during the Routine Testing of Asthmatic Children</style></title><secondary-title><style face="normal" font="default">Front Physiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Physiol</style></abbr-1></periodical><pages end="" start="768">768-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Deep inspiration (DI) dilates normal airway precontracted with methacholine. The fact that this effect is diminished or absent in asthma could be explained by the presence of bronchial inflammation. The hypothesis was tested that DI induces more relaxation in methacholine induced bronchoconstriction-solely determined by the smooth muscle contraction-than in exercise induced bronchoconstriction, which is contributed to by both smooth muscle contraction and airway wall inflammation. The respiratory conductance (Grs) response to DI was monitored in asthmatic children presenting a moderately positive airway response to challenge by methacholine (n = 36) or exercise (n = 37), and expressed as the post- to pre-DI Grs ratio (GrsDI). Both groups showed similar change in FEV1 after challenge and performed a DI of similar amplitude. GrsDI however was significantly larger in methacholine than in exercise induced bronchoconstriction (p &lt; 0.02). The bronchodilatory effect of DI is thus less during exercise- than methacholine-induced bronchoconstriction. The observation is consistent with airway wall inflammation-that characterizes exercise induced bronchoconstriction-rendering the airways less responsive to DI. More generally, it is surmised that less relief of bronchoconstriction by DI is to be expected during indirect than direct airway challenge. The current suggestion that airway smooth muscle constriction and airway wall inflammation may result in opposing effects on the bronchomotor action of DI opens important perspective to the routine testing of asthmatic children. New crossover research protocols comparing the mechanical consequences of the DI maneuver are warranted during direct and indirect bronchial challenges</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 1664-042X (Print)IS - 1664-042X (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.3389/fphys.2017.00768</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29046644">PM:29046644</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Physiol\2017-8-768.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Physiol\2017-8-768.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Ioan I</style></custom2><misc3><style face="normal" font="default">10.3389/fphys.2017.00768</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42988</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,X.</style></author><author><style face="normal" font="default"> Li,X.</style></author><author><style face="normal" font="default"> Shen,Y.</style></author><author><style face="normal" font="default"> Wang,X.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Department, Beijing Shijitan Hospital, Capital Medical University, Beijing, China</style></auth-address><titles><title><style face="normal" font="default">The association between serum vitamin D levels and urticaria: a meta-analysis of observational studies</style></title><secondary-title><style face="normal" font="default">G Ital Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">G Ital Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="10" Year="2017">2017/10/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: Despite the recent studies revealed Vitamin D may play a role in urticaria, no meta-analysis providing definite conclusions in this field has been reported. METHODS: A systematic search up to 30thJune 2017 was conducted in MEDLINE (via PubMed) and Excerpta Medica database (EMBASE) to identify relevant articles. Search terms included ''vitamin D'' or "25-hydroxyvitamin D" or ''25hydroxy-vitaminD" or "25(OH)D" or "1,25-dihydroxyvitamin D" combined with ''urticaria". RESULTS: Initial searches yielded 30 citations. Of these original results, 10 met specific selection criteria and were included in the meta-analysis with 547 urticaria cases and 517 controls.The vitamin D levels was significantly decreased in the urticarial cases (WMD -9.8 mg/L, 95% CI: -12.57 to -7.04 mg/L, from a random effects model), with a significant heterogeneity (I2 =85.9%, P=0.000). When divide the Vitamin D level into two subgroups, the pooled OR comparing Vitamin D insufficiency vs normal level was 1.64 (95%CI:0.71-3.77). Meanwhile, Vitamin D deficiency vs normal level was4.09 (95%CI: 1.32-12.73). CONCLUSIONS: The study demonstrated that patients with urticaria had a lower Vitamin D level than healthy controls. Vitamin D deficiency rather than insufficiency has a positive relationship with urticaria. However, larger-scale studies over alonger duration of treatment are needed to confirm this conclusion</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1827-1820 (Electronic)IS - 0392-0488 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.23736/S0392-0488.17.05774-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29064205">PM:29064205</url></web-urls></urls><custom2><style face="normal" font="default">20171024, Wang X</style></custom2><misc3><style face="normal" font="default">10.23736/S0392-0488.17.05774-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42989</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lipowska,A.M.</style></author><author><style face="normal" font="default"> Kavitt,R.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dr Lipowska is a gastroenterology fellow and Dr Kavitt is an assistant professor of medicine and director of the Center for Esophageal Diseases in the Section of Gastroenterology, Hepatology, and Nutrition at The University of Chicago Medicine in Chicago, Illinois</style></auth-address><titles><title><style face="normal" font="default">Current Diagnostic and Treatment Strategies for Eosinophilic Esophagitis</style></title><secondary-title><style face="normal" font="default">Gastroenterol Hepatol (N Y)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Gastroenterol Hepatol (N Y)</style></abbr-1></periodical><pages end="535" start="527">527-535</pages><volume><style face="normal" font="default">13</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder of the esophagus diagnosed by the presence of esophageal symptoms accompanied by an esophageal eosinophilic infiltrate. EoE has an increasing worldwide prevalence and can be a cause of dysphagia and food impactions. There is an important role for the use of proton pump inhibitors in the diagnostic pathway of EoE. Treatment paradigms for EoE aim to minimize esophageal inflammation and improve symptom control. Dietary therapy targets dietary allergens and encompasses the elemental diet, the allergy testing-directed elimination diet, and the empiric elimination diet. Pharmacologic options include topical corticosteroids as the standard first-line treatment. Multiple other pharmacologic interventions are currently under investigation and are not recommended in the most recent guidelines. Endoscopic dilation is usually reserved for patients who relapse on pharmacologic or dietary regimens or who have symptomatic stricturing disease. This article provides a comprehensive discussion of existing diagnostic and management strategies for EoE</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 1554-7914 (Print)IS - 1554-7914 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29038643">PM:29038643</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Gastroenterol Hepatol (N Y)\2017-13-527-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Gastroenterol Hepatol (N Y)\2017-13-527-35.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Lipowska AM</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42990</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gabrielli,S.</style></author><author><style face="normal" font="default"> Clarke,A.E.</style></author><author><style face="normal" font="default"> Eisman,H.</style></author><author><style face="normal" font="default"> Morris,J.</style></author><author><style face="normal" font="default"> Joseph,L.</style></author><author><style face="normal" font="default"> La Vieille,S.</style></author><author><style face="normal" font="default"> Small,P.</style></author><author><style face="normal" font="default"> Lim,R.</style></author><author><style face="normal" font="default"> Enarson,P.</style></author><author><style face="normal" font="default"> Zelcer,M.</style></author><author><style face="normal" font="default"> Chan,E.S.</style></author><author><style face="normal" font="default"> Mill,C.</style></author><author><style face="normal" font="default"> Ben-Shoshan,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pediatric Allergy and Clinical Immunology, Department of Pediatrics, McGill University Health Centre, Montreal, Quebec, Canada</style></auth-address><titles><title><style face="normal" font="default">Disparities in rate, triggers, and management in pediatric and adult cases of suspected drug-induced anaphylaxis in Canada</style></title><secondary-title><style face="normal" font="default">Immun Inflamm Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immun Inflamm Dis</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Data is sparse on drug-induced anaphylaxis (DIA) and there have not been studies assessing the differences in clinical characteristics and management of DIA between adults and children. OBJECTIVE: We assessed the percentage, diagnosis, and management of DIA among all anaphylaxis visits in three pediatric and one adult emergency departments (ED) across Canada. METHODS: Children presenting to the Montreal Children's Hospital (MCH), British Columbia Children's Hospital (BCCH), and Children's Hospital at London Health Sciences Center and adults presenting to Hopital du Sacre-Coeur with anaphylaxis were recruited as part of the Cross-Canada Anaphylaxis Registry. A standardized data form documenting the reaction and management was completed and patients were followed annually to determine assessment by allergist and use of confirmatory tests. RESULTS: From June 2012 to May 2016, 51 children were recruited from the pediatric centers and 64 adults from the adult center with drug-induced anaphyalxis. More than half the cases were prospectively recruited. The percentage of DIA among all cases of anaphylaxis was similar in all three pediatric centers but higher in the adult center in Montreal. Most reactions in children were triggered by non-antibiotic drugs, and in adults, by antibiotics. The majority of adults and a third of children did not see an allergist after the initial reaction. In those that did see an allergist, diagnosis was established by either a skin test or an oral challenge in less than 20% of cases. CONCLUSIONS: Our results reveal disparities in rate, culprit, and management of DIA in children versus adults. Further, most cases of suspected drug allergy are not appropriately diagnosed. Guidelines to improve assessment and diagnosis of DIA are required</style></abstract><notes><style face="normal" font="default">DA - 20171102IS - 2050-4527 (Electronic)IS - 2050-4527 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1002/iid3.201</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29094518">PM:29094518</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171102, Gabrielli S</style></custom2><misc3><style face="normal" font="default">10.1002/iid3.201</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42991</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chang,Y.</style></author><author><style face="normal" font="default"> Kang,S.Y.</style></author><author><style face="normal" font="default"> Kim,J.</style></author><author><style face="normal" font="default"> Kang,H.R.</style></author><author><style face="normal" font="default"> Kim,H.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Korea</style></auth-address><titles><title><style face="normal" font="default">Functional Defects in Type 3 Innate Lymphoid Cells and Classical Monocytes in a Patient with Hyper-IgE Syndrome</style></title><secondary-title><style face="normal" font="default">Immune Netw</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immune Netw</style></abbr-1></periodical><pages end="364" start="352">352-364</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Hyper-IgE syndrome (HIES) is a very rare primary immune deficiency characterized by elevated serum IgE levels, recurrent bacterial infections, chronic dermatitis, and connective tissue abnormalities. Autosomal dominant (AD) HIES involves a mutation in signal transducer and activator of transcription 3 (STAT3) that leads to an impaired TH17 response. STAT3 signaling is also involved in the function of RORgammat+ type 3 innate lymphoid cells (ILC3s) and RORgammat+TH17 cells. The aim of this study was to investigate the role of innate immune cells such as innate lymphoid cells (ILCs), granulocytes, and monocytes in a patient with HIES. Peripheral blood mononuclear cells (PBMCs) from a patient with HIES and three age-matched healthy controls were obtained for the analysis of the innate and adaptive immune cells. The frequencies of ILCs in PBMCs were lower in the patient with HIES than in the controls. Moreover, granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-17A produced by ILC3s in PBMCs were lower in the patient with HIES than the controls. Compared with the controls, classical monocytes (CD14+CD16low), which have a high antimicrobial capability, were also lower in the patient with HIES, while non-classical monocytes (CD14lowCD16+) as well as intermediate monocytes (CD14+CD16intermediate) were higher. Taken together, these results indicate that the impaired immune defense against pathogenic microbes in the patient with HIES might be partially explained by functional defects in ILC3s and inflammatory monocytes</style></abstract><notes><style face="normal" font="default">DA - 20171102IS - 1598-2629 (Print)IS - 1598-2629 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4110/in.2017.17.5.352</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29093656">PM:29093656</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immune Netw\2017-17-352-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immune Netw\2017-17-352-64.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171102, Chang Y</style></custom2><misc3><style face="normal" font="default">10.4110/in.2017.17.5.352</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42992</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wu,S.</style></author><author><style face="normal" font="default"> Li,H.</style></author><author><style face="normal" font="default"> Yu,L.</style></author><author><style face="normal" font="default"> Wang,N.</style></author><author><style face="normal" font="default"> Li,X.</style></author><author><style face="normal" font="default"> Chen,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Translational Medicine, The First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi, China</style></auth-address><titles><title><style face="normal" font="default">IL-1beta upregulates Muc5ac expression via NF-kappaB-induced HIF-1alpha in asthma</style></title><secondary-title><style face="normal" font="default">Immunol Lett</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immunol Lett</style></abbr-1></periodical><pages end="26" start="20">20-26</pages><volume><style face="normal" font="default">192</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="default">The manifest and important feature in respiratory diseases, including asthma and COPD (chronic obstructive pulmonary disease), is the increased numbers and hypersecretion of goblet cells and overexpression of mucins, especially Muc5ac. Many proinflammatory cytokines play important roles in goblet cell metaplasia and overproduction of Muc5ac. However, the effect of IL-1beta on Muc5ac expression in asthma remains unknown. Here, we detected the correlation between IL-1beta and Muc5ac in asthma patients and further explored the mechanism of IL-1beta-induced Muc5ac overexpression. Our results showed that Muc5ac and IL-1beta were up-regulated in 41 patients with asthma and that Muc5ac overexpression was related with IL-1beta in asthma (R2=0.668, p&lt;&lt;0.001). Furthermore, the correlation between IL-1beta and Muc5ac is higher in severe group than that in moderate group. In vitro experiments with normal human bronchial epithelial cells (NHBECs) showed that IL-1beta up-regulated Muc5ac expression in NHBEC in a time- and dosage-dependent manner. Hypoxia-induced HIF-1alpha was responsible for Muc5ac expression mediated by IL-1beta. Knocking down HIF-1alpha by siRNA decreased Muc5ac expression under hypoxia even in IL-1beta-treated NHBEC cells. Luciferase reporter assay showed that HIF-1alpha enhanced Muc5ac promoter activity in HEK293T cells. HIF-1alpha could specifically bind to the promoter of Muc5ac by EMSA. The correlation among IL-1beta, HIF-1alpha and Muc5ac was observed in patients with asthma. Mechanically, NF-kappaB activation was essential to IL-1beta-induced HIF-1alpha upregulation via the canonical pathway of NF-kappaB. The level of nuclear p65, a subunit of NF-kappaB, was obviously increased in NHBEC cells under IL-1beta treatment. IL-1beta did not change either HIF-1alpha or Muc5ac expression when inhibiting NF-kappaB signaling with Bay11-7082, an inhibitor of NF-kappaB. Collectively, we concluded that IL-1beta up-regulated Muc5ac expression via NF-kappaB-induced HIF-1alpha in asthma and provided a potential therapeutic target for asthma</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 1879-0542 (Electronic)IS - 0165-2478 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.imlet.2017.10.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29031476">PM:29031476</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunol Lett\2017-192-20-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunol Lett\2017-192-20-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171016, Wu S</style></custom2><misc3><style face="normal" font="default">10.1016/j.imlet.2017.10.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42993</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Khawaji,A.</style></author><author><style face="normal" font="default"> Basudan,A.</style></author><author><style face="normal" font="default"> Moafa,A.</style></author><author><style face="normal" font="default"> Faqihi,M.</style></author><author><style face="normal" font="default"> Alhazmi,M.</style></author><author><style face="normal" font="default"> Mahnashi,T.</style></author><author><style face="normal" font="default"> Haddadi,Y.</style></author><author><style face="normal" font="default"> Yassin,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Epidemiology of bronchial asthma among children in Jazan Region, Saudi Arabia</style></title><secondary-title><style face="normal" font="default">Indian J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Indian J Allergy Asthma Immunol</style></full-title></periodical><pages end="75" start="69">69-75</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="default">&lt;b>Context:&lt;/b> Asthma is a global problem, its prevalence varies among different countries and cities and age groups. In children, asthma is one of the most common chronic diseases and one of the leading causes of morbidity and mortality. &lt;b>Aims:&lt;/b> This study was conducted to estimate the prevalence of asthma among children in Jazan Region (JR), Saudi Arabia. &lt;b>Settings And Design:&lt;/b> This is study conducted in Jazan region, saudi arabia among school age children. It is a cross-sectional study used a modified international study os asthma and allergy in children questionnaire. &lt;b>Subjects And Methods:&lt;/b> The target study population were school age, witth sample size of 1200 distributed to all geographical areas. &lt;b>Statistical Analysis Used:&lt;/b> The data had been entered and analyzed using Statistical Package for Social Sciences software version 22.0. Descriptive statistics (e.g., number, percentage) and analytic statistics using Chi-square tests (&lt;i>&amp;#967;&lt;/i>&lt;sup>2&lt;/sup>) to test for the association and/or the difference between two categorical variables will be applied. A &lt;i>P&lt;/i> &amp;#60; 0.05 was considered statistically significant. &lt;b>Results:&lt;/b> The total study population was 1400, most of them were Saudi (1273, 90.9&amp;#37;). Male students were 840 (60.0&amp;#37;), and female students were 560 (40.0&amp;#37;). According to the residency, 811 (57.9&amp;#37;) students were lived in rural, 64.7&amp;#37; of them were male, and 589 (42.1&amp;#37;) of participants lived in urban area. Most of the students lived in plain area (840, 60.0&amp;#37;), and only 16.4&amp;#37; of them lived in mountain area in which 63.5&amp;#37; of them were male. Elementary school students account 54.1&amp;#37; of total students; about 63&amp;#37; of them were male. The prevalence of life-long wheezes was 17.7&amp;#37;. The prevalence of exercise-induced wheeze and wheeze during the last 12 months was 206 (14.7&amp;#37;) and 159 (11.4&amp;#37;), respectively. Students with the past medical history of bronchial asthma were 212 (15.1&amp;#37;), with no clear statistical significant difference in frequency between male and female (&lt;i>P&lt;/i> &amp;#61; 0.161). Asthma was confirmed by doctor in 10&amp;#37; of participants. &lt;b>Conclusions:&lt;/b> The prevalence of asthma among children in JR is slightly higher than those reported from local and regional reports</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Saudi Arabia -</style></notes><work-type><style face="normal" font="default">10.4103/ijaai.ijaai_18_17</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4103/ijaai.ijaai_18_17</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Allergy Asthma Immunol\2017-31-69-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Allergy Asthma Immunol\2017-31-69-75.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171025, Khawaji A</style></custom2><misc3><style face="normal" font="default">10.4103/ijaai.ijaai_18_17</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42994</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">John,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Pediatric peak expiratory flow rate nomograms for Ernakulam district</style></title><secondary-title><style face="normal" font="default">Indian J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Indian J Allergy Asthma Immunol</style></full-title></periodical><pages end="86" start="83">83-86</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="default">&lt;b>Objective:&lt;/b> To obtain the normal reference values of peak expiratory flow rates (PEFRs) among healthy school-going children between 8 and 12 years and thereby construct a nomogram. &lt;b>Materials And Methods:&lt;/b> A cross-sectional study was conducted among healthy children attending schools in Ernakulam district over a period of 1 year. PEFR values were recorded using a Mini-Wright peak flow meter, and the best of three readings was documented. &lt;b>Results:&lt;/b> Nine hundred and fifty-four students were studied. PEFR increases as the age increases. A similar trend was observed across various heights. Nomograms based on age and height were constructed separately for boys and girls. &lt;b>Conclusion:&lt;/b> Established baseline values of PEFR in this study can be useful in diagnosing and following asthmatic children in Ernakulam district</style></abstract><notes><style face="normal" font="default">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/ijaai.ijaai_6_17</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4103/ijaai.ijaai_6_17</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Allergy Asthma Immunol\2017-31-83-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Allergy Asthma Immunol\2017-31-83-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171025, John J</style></custom2><misc3><style face="normal" font="default">10.4103/ijaai.ijaai_6_17</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42995</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Naik,P.</style></author><author><style face="normal" font="default"> Ravikumar,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Study of prevalence of bronchial asthma in school children of 6&amp;#8211;12 years of age in rural schools of Tumakuru district</style></title><secondary-title><style face="normal" font="default">Indian J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Indian J Allergy Asthma Immunol</style></full-title></periodical><pages end="60" start="56">56-60</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="default">&lt;b>Context:&lt;/b> Pediatric asthma is a serious global health problem. The recent rise in the prevalence of asthma was associated with environmental pollution, urbanization, and the change in demography. &lt;b>Aims:&lt;/b> The present study was undertaken to determine the prevalence of asthma in school children of rural parts of Tumakuru district and to study its association with different epidemiological factors. &lt;b>Settings And Design:&lt;/b> This study is a questionnaire-based study (International Study of Asthma and Allergies in Childhood-Questionnaire) carried out in four randomly selected rural schools of Tumakuru district. &lt;b>Subjects And Methods:&lt;/b> The questionnaire was distributed to all the children (&lt;i>n&lt;/i> &amp;#61; 1750) and asked to fill the questionnaire with the help of their parents. These questionnaires were given standard scores to diagnose asthma. Other epidemiological factors were also recorded in the questionnaire and studied. &lt;b>Statistical Analysis Used:&lt;/b> The statistical analysis was done using MSTAT software. Chi-square test was used to get the &lt;i>P&lt;/i> value. &lt;i>P&lt;/i> &amp;#60; 0.05 was considered statistically significant. &lt;b>Results:&lt;/b> The prevalence of asthma in our study was 3.12&amp;#37; (&lt;i>n&lt;/i> &amp;#61; 51). Boys had a slightly higher prevalence 3.36&amp;#37; (&lt;i>n&lt;/i> &amp;#61; 32) than girls 2.8&amp;#37; (&lt;i>n&lt;/i> &amp;#61; 19). We found 58.8&amp;#37; (&lt;i>n&lt;/i> &amp;#61; 30) of these asthmatics had allergic rhinitis and 19.6&amp;#37; (&lt;i>n&lt;/i> &amp;#61; 10) had a history of atopy. Overall prevalence of allergic rhinitis was 8.3&amp;#37; (&lt;i>n&lt;/i> &amp;#61; 137) and atopy was 1.13&amp;#37; (&lt;i>n&lt;/i> &amp;#61; 23). &lt;b>Conclusions:&lt;/b> The study showed 3.12&amp;#37; of children are affected with asthma, and its prevalence is significantly associated with epidemiological factors such as family history of allergy, high socioeconomic status, and use of fire wood for cooking</style></abstract><notes><style face="normal" font="default">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/ijaai.ijaai_35_16</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4103/ijaai.ijaai_35_16</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Allergy Asthma Immunol\2017-31-56-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Allergy Asthma Immunol\2017-31-56-60.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171025, Naik P</style></custom2><misc3><style face="normal" font="default">10.4103/ijaai.ijaai_35_16</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42996</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Meher,B.</style></author><author><style face="normal" font="default"> Pradhan,D.</style></author><author><style face="normal" font="default"> Pradeep,S.</style></author><author><style face="normal" font="default"> Das,L.</style></author><author><style face="normal" font="default"> Beriha,S.</style></author><author><style face="normal" font="default"> Panigrahi,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Factors influencing age of onset of wheezing among children with recurrent wheezing and the association of Vitamin D status with atopic manifestations</style></title><secondary-title><style face="normal" font="default">Indian J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Indian J Allergy Asthma Immunol</style></full-title></periodical><pages end="82" start="76">76-82</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="default">&lt;b>Background:&lt;/b> Onset of wheezing before 3 years of age is concerning due to its potential for the development of asthma. Different risk factors, atopic manifestations, and Vitamin D deficiency are attributed to it. &lt;b>Aims:&lt;/b> The aim of this study is to assess the factors influencing the age of wheezing onset among children with early-onset recurrent wheezing and the association of Vitamin D status with different atopic manifestations. &lt;b>Subjects And Methods:&lt;/b> This cross-sectional observational study included 141 children aged from 1 month to 14 years with recurrent wheezing. Onset of wheezing after 36 months was excluded from the study. Different risk factors and atopic manifestations were recorded, and Vitamin D levels were measured. Descriptive analysis, independent &lt;i>t&lt;/i>-test, analysis of variance, and regression analysis were done using SPSS version 24.0. &lt;b>Results:&lt;/b> Of 141 children, 65 (46.0&amp;#37;) had onset of wheezing at &amp;#60;1 year of age. Children with onset of wheezing &amp;#60;1 year had early age of presentation (29.38 &amp;#177; 29.35 vs. 46.25 &amp;#177; 27.77 months) were predominately male (52.1&amp;#37; vs. 47.9&amp;#37;) and had a low birth weight (2688.46 &amp;#177; 608.84 vs. 2904.61 &amp;#177; 510.96 g) and high Vitamin D level (22.01 &amp;#177; 12.63 vs. 16.65 &amp;#177; 9.05 ng/mL; &lt;i>P&lt;/i> &amp;#60; 0.05). In the regression analysis, birth weight, family with &amp;#62;1 sibling, and atopic dermatitis had regression coefficients of 0.393 (&lt;i>P&lt;/i> &amp;#60; 0.01), 4.525 (&lt;i>P&lt;/i> &amp;#60; 0.01), and &amp;#8722;2.970, respectively (&lt;i>P&lt;/i> &amp;#62; 0.05). &lt;b>Conclusions:&lt;/b> Children with onset of wheezing before 1 year were predominantly male and had a lower birth weight. Vitamin D deficiency does not hasten the onset of wheezing; however, a low birth weight and associated atopic dermatitis hasten the onset of wheezing, and being part of a family with &amp;#62;1 sibling delays onset</style></abstract><notes><style face="normal" font="default">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/ijaai.ijaai_29_17</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4103/ijaai.ijaai_29_17</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Allergy Asthma Immunol\2017-31-76-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Allergy Asthma Immunol\2017-31-76-82.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171025, Meher B</style></custom2><misc3><style face="normal" font="default">10.4103/ijaai.ijaai_29_17</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42997</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Agarwal,D.</style></author><author><style face="normal" font="default"> Gupta,P.</style></author><author><style face="normal" font="default"> Sood,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Improvement in pulmonary functions and clinical parameters due to addition of breathing exercises in asthma patients receiving optimal treatment</style></title><secondary-title><style face="normal" font="default">Indian J Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Indian J Allergy Asthma Immunol</style></full-title></periodical><pages end="68" start="61">61-68</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="7" Year="2017">2017/7/1</year></dates><abstract><style face="normal" font="default">&lt;b>Background:&lt;/b> Breathing exercises have been described to be useful in asthma management. &lt;b>Objective:&lt;/b> The aim of this study is to detect the efficacy of breathing exercises (&lt;i>Pranayamas&lt;/i>) in asthma patients using spirometric indices, clinical symptoms parameters, and requirement of rescue medications. &lt;b>Methods:&lt;/b> A total of 60 stable asthma patients (34 females) diagnosed and received optimal asthma treatment for 3 months or more according to the GINA guidelines were enrolled. All patients continued their respective medications and in addition performed seven breathing exercises (&lt;i>Surya Bhedana Pranayama, Nadi Shuddi Pranayama, Bhramari Pranayama, Surya Nadi Pranayama, Kapal Bhati, Bhastrika&lt;/i>, and &lt;i>Om Chanting&lt;/i>) under supervision at Yoga center at our Institute for 3 months after inclusion to study. Spirometry, nocturnal symptoms, and the requirement of rescue medicines were assessed before and after breathing exercise intervention. Visual analog scale (VAS) was used to assess the dyspnea and wheezing in the study participants. &lt;b>Results:&lt;/b> The mean age of asthma patients was 25.45 &amp;#177; 5.41 years. After breathing exercise intervention, mean forced expired volume in one second increased from 2.492 &amp;#177; 0.358 L to 2.745 &amp;#177; 0.343 L and mean peak expiratory flow rate increased from 283.82 &amp;#177; 51.12 L/min to 336.23 &amp;#177; 51.47 L/min; the increases were statistically significant. The mean nocturnal symptoms score decreased significantly from 1.416 &amp;#177; 1.619 to 0.067 &amp;#177; 0.362. The requirement of rescue medications decreased significantly from 6.23 &amp;#177; 2.95 to 0.90 &amp;#177; 1.25 puffs/week. VAS scores for breathlessness and wheezing were significantly decreased. &lt;b>Conclusions:&lt;/b> Breathing exercises provided significant improvements in spirometric parameters and significant reduction in breathlessness, wheezing, and nocturnal symptoms as well as requirements of rescue medicines in asthma patients who were receiving optimal asthma treatment</style></abstract><notes><style face="normal" font="default">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/ijaai.ijaai_34_16</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.4103/ijaai.ijaai_34_16</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Allergy Asthma Immunol\2017-31-61-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Allergy Asthma Immunol\2017-31-61-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171025, Agarwal D</style></custom2><misc3><style face="normal" font="default">10.4103/ijaai.ijaai_34_16</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42998</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Demirturk,M.</style></author><author><style face="normal" font="default"> Akpinar,T.S.</style></author><author><style face="normal" font="default"> Kose,M.</style></author><author><style face="normal" font="default"> Gelincik,A.</style></author><author><style face="normal" font="default"> Colakoglu,B.</style></author><author><style face="normal" font="default"> Buyukozturk,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunology and Allergy Unit, Yedikule Education and Training Hospital, Istanbul University, Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="default">Endocan: A Novel Marker of Endothelial Dysfunction in C1-Inhibitor-Deficient Hereditary Angioedema</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="107" start="104">104-107</pages><volume><style face="normal" font="default">174</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="24" Month="10" Year="2017">2017/10/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hereditary angioedema (HAE) related to C1-inhibitor deficiency is a rare autosomal dominant disorder. Vascular cell adhesion molecules (VCAM) are known as endothelial activation markers. Endocan (also called ESM-1) is proposed as an endothelial dysfunction indicator. We aimed to investigate endothelial activation in attack-free periods in HAE patients by measuring their levels of endocan and VCAM-1. METHODS: Twenty-six HAE patients (22 female, mean age 40 +/- 13 years) and 38 healthy control patients (13 female, mean age 36.9 +/- 12 years) were included in the study. Peripheral blood samples were collected from HAE patients during symptom-free periods and control subjects. Endocan and VCAM-1 levels were measured using the enzyme-linked immunosorbent assay method. RESULTS: The median serum levels of endocan (647 +/- 101 ng/mL) and VCAM-1 (500 +/- 79 ng/mL) in the HAE patients were significantly higher than in the control patients (391 +/- 41 and 325 +/- 4; p &lt; 0.001 for both). CONCLUSION: The increased endocan and VCAM-1 levels may reflect an endothelial activation even in attack-free periods in HAE patients</style></abstract><notes><style face="normal" font="default">DA - 20171023IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1159/000481256</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29059678">PM:29059678</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-174-104-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-174-104-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171023, Demiturk M</style></custom2><misc3><style face="normal" font="default">10.1159/000481256</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>42999</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhao,Y.</style></author><author><style face="normal" font="default"> Sun,S.</style></author><author><style face="normal" font="default"> Li,X.</style></author><author><style face="normal" font="default"> Ma,X.</style></author><author><style face="normal" font="default"> Tang,H.</style></author><author><style face="normal" font="default"> Sun,L.</style></author><author><style face="normal" font="default"> Zhai,S.</style></author><author><style face="normal" font="default"> Wang,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacy, Peking University Third Hospital, Beijing, China</style></auth-address><titles><title><style face="normal" font="default">Drug-induced anaphylaxis in China: a 10 year retrospective analysis of the Beijing Pharmacovigilance Database</style></title><secondary-title><style face="normal" font="default">Int J Clin Pharm</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Clin Pharm</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="10" Year="2017">2017/10/31</year></dates><abstract><style face="normal" font="default">Background Few studies on the causes of drug-induced anaphylaxis (DIA) in the hospital setting are available. Objective We aimed to use the Beijing Pharmacovigilance Database (BPD) to identify the causes of DIA in Beijing, China. Setting Anaphylactic case reports from the BPD provided by the Beijing Center for Adverse Drug Reaction Monitoring. Method DIA cases collected by the BPD from January 2004 to December 2014 were adjudicated. Cases were analyzed for demographics, causative drugs and route of administration, and clinical signs and outcomes. Main outcome measure Drugs implicated in DIAs were identified and the signs and symptoms of the DIA cases were analyzed. Results A total of 1189 DIA cases were analyzed. The mean age was 47.6 years, and 732 (61.6%) were aged from 18 to 59 years. A total of 627 patients (52.7%) were females. There was a predominance of cardiovascular (83.8%) followed by respiratory (55.4%), central nervous (50.1%), mucocutaneous (47.4%), and gastrointestinal symptoms (31.3%). A total of 249 different drugs were involved. DIAs were mainly caused by antibiotics (39.3%), traditional Chinese medicines (TCM) (11.9%), radiocontrast agents (11.9%), and antineoplastic agents (10.3%). Cephalosporins accounted for majority (34.5%) of antibiotic-induced anaphylaxis, followed by fluoroquinolones (29.6%), beta-lactam/beta-lactamase inhibitors (15.4%) and penicillins (7.9%). Blood products and biological agents (3.1%), and plasma substitutes (2.1%) were also important contributors to DIAs. Conclusion A variety of drug classes were implicated in DIAs. Patients should be closely monitored for signs and symptoms of anaphylaxis when medications are administered especially with antibiotics, TCM, radiocontrast and antineoplastic agents</style></abstract><notes><style face="normal" font="default">DA - 20171031IS - 2210-7711 (Electronic)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11096-017-0535-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29086147">PM:29086147</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Clin Pharm\20171031-ZhaoY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Clin Pharm\20171031-ZhaoY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171031, Zhao Y</style></custom2><misc3><style face="normal" font="default">10.1007/s11096-017-0535-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43000</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brew,B.K.</style></author><author><style face="normal" font="default"> Lundholm,C.</style></author><author><style face="normal" font="default"> Viktorin,A.</style></author><author><style face="normal" font="default"> Lichtenstein,P.</style></author><author><style face="normal" font="default"> Larsson,H.</style></author><author><style face="normal" font="default"> Almqvist,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default">Longitudinal depression or anxiety in mothers and offspring asthma: a Swedish population-based study</style></title><secondary-title><style face="normal" font="default">Int J Epidemiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Epidemiol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="9" Year="2017">2017/9/23</year></dates><abstract><style face="normal" font="default">Background: Previous research has found that maternal stress during pregnancy increases the risk of offspring asthma. However, whether this association is consistent with a causal interpretation has never been tested. The objective is to determine whether there is a critical exposure period for maternal depression or anxiety on offspring asthma or whether cumulative exposure is most important, and to investigate evidence of confounding. Methods: The study population included all children born in Sweden from July 2006 to December 2009 (n = 360 526). Information about childhood asthma, maternal depression or anxiety (diagnosis or medication) and covariates was obtained from the Swedish national health registers. The associations between exposure periods (pre-conception, pregnancy, postnatal or current) and childhood asthma were estimated using structured life course approach hypothesis testing. Paternal and cousin analyses were used to test for evidence of confounding from shared genes and environment. Results: For childhood asthma, cumulative exposure best described the effect of exposure to maternal depression or anxiety up to a maximum of any two exposure periods [adjusted odds ratio 1.44, 95% confidence interval (CI) 1.38, 1.52]. The hypotheses of a critical period were not supported. The paternal and cousin analyses indicated minimal influence from familial confounding. Conclusions: These findings support an association between cumulative exposure to maternal depression or anxiety and asthma development in offspring. This association is unique for maternal depression or anxiety and not due to familial confounding. The clinical implication is that effective psychological management of women with chronic distress may reduce offspring asthma risk</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 1464-3685 (Electronic)IS - 0300-5771 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1093/ije/dyx208</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29040553">PM:29040553</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Epidemiol\20171017-BrewBK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Epidemiol\20171017-BrewBK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Brew BK</style></custom2><misc3><style face="normal" font="default">10.1093/ije/dyx208</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43001</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nguyen,V.N.</style></author><author><style face="normal" font="default"> Nguyen,Q.N.</style></author><author><style face="normal" font="default"> Le,A.P.</style></author><author><style face="normal" font="default"> Chavannes,N.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, the NetherlandsDepartment of Family Medicine, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, VietnamAsthma and COPD Clinic, University Medical Center, Ho Chi Minh City, VietnamDepartment of Family Medicine, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, VietnamDepartment of Family Medicine, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, VietnamDepartment of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands</style></auth-address><titles><title><style face="normal" font="default">Implementation of GINA guidelines in asthma management by primary care physicians in Vietnam</style></title><secondary-title><style face="normal" font="default">Int J Gen Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Gen Med</style></abbr-1></periodical><pages end="355" start="347">347-355</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma control is suboptimal in Vietnam. Lack of knowledge of primary care physicians (PCPs) for asthma management may potentially be one of the causes. PURPOSE: The aim of this study was to assess the knowledge and practice of PCPs' asthma management based on the Global Initiative for Asthma (GINA) guidelines (2015 update). METHODS: A cross-sectional study with convenience sampling was conducted among PCPs in an urban and rural area of Vietnam using questionnaires related to asthma patients daily practice: use of spirometry and the asthma control test (ACT), prescription of asthma medications, and frequency of consultations. Five asthma case scenarios were also used to ask participants to classify GINA-defined levels of asthma control and to choose the initial or adjusted treatment options based on the current situation. All scenarios are common in Vietnam, ie, three cases for adults, one case for children, and one case for pregnant women. RESULTS: Of the 327 completed questionnaires, 201 questionnaires could be analyzed. Most PCPs consulted their asthma patients on a weekly to monthly basis. Approximately 50% used spirometry for asthma care and only 25% used ACT. For asthma treatment, oral short-acting beta agonists and oral steroids were still commonly used and long-acting beta agonists alone were prescribed by 70%. Regarding GINA-defined levels of asthma control, 24% of the responders had >/=50% of correct answers, 21% had no correct answers, 2% had all five correct answers, and 20-42% had a correct answer for each of the five questions. Regarding treatment choice, 22% had >/=50% of correct answers, 14% had a wrong answer for all nine questions, and no respondent had a correct answer for >/=8 questions. CONCLUSION: The percentage of PCPs in Vietnam who had implemented GINA 2015 was low. Some drugs with a high risk of side effects were still being prescribed. There is a need to improve both knowledge and daily practice. Additional studies should determine why these guidelines are not largely adopted by PCPs in Vietnam</style></abstract><notes><style face="normal" font="default">DA - 20171018IS - 1178-7074 (Print)IS - 1178-7074 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Vietnam -</style></notes><work-type><style face="normal" font="default">10.2147/IJGM.S147752</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29042809">PM:29042809</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Gen Med\2017-10-347-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Gen Med\2017-10-347-55.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171018, Nguyen VN</style></custom2><misc3><style face="normal" font="default">10.2147/IJGM.S147752</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43002</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ibrahim,W.H.</style></author><author><style face="normal" font="default"> Mushtaq,K.</style></author><author><style face="normal" font="default"> Raza,T.</style></author><author><style face="normal" font="default"> Kartha,A.</style></author><author><style face="normal" font="default"> Saleh,A.O.</style></author><author><style face="normal" font="default"> Malik,R.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Hamad General Hospital and Weill-Cornell Medical College, Doha, Qatar.</style></auth-address><titles><title><style face="normal" font="default">Effects of procalcitonin-guided treatment on antibiotic use and need for mechanical ventilation in patients with acute asthma exacerbation: Meta-analysis of randomized controlled trials</style></title><secondary-title><style face="normal" font="default">Int J Infect Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Infect Dis</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="10" Year="2017">2017/10/13</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The primary outcome was to determine whether serum procalcitonin-guided antibiotic therapy can reduce antibiotic exposure in patients with an acute exacerbation of asthma presenting to the primary care facility, emergency department or during hospital admission. The secondary outcome was the need for mechanical ventilation. METHODS: In this meta-analysis, we performed extensive literature search for randomized controlled clinical trials (published in English) that compared serum procalcitonin-guided antibiotic therapy versus antibiotic use according to physician's discretion for adult participants with mild, moderate or severe acute asthma exacerbations. RESULTS: Four randomized controlled trials evaluating 457 patients were included in this meta-analysis with significant homogeneity observed among these studies. Procalcitonin-based protocols decreased antibiotic prescriptions (Relative risk 0.58, 95% CI, 0.50-0.67). The conclusion concerning the difference between both groups with regard to the need for mechanical ventilation (Relative risk 1.10, 95% CI, 0.62-1.94) was guarded due to inadequate power and the potential for Type II error. The overall quality of evidence was also limited by the lack of double-blindness. CONCLUSION: Our data suggest a potential benefit for the use of serum procalcitonin in guiding antibiotic therapy in patients with an acute asthma exacerbation and advocates the need for more randomized controlled trials</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 1878-3511 (Electronic)IS - 1201-9712 (Linking)LA - engPT - Journal ArticleCO - Qatar -</style></notes><work-type><style face="normal" font="default">10.1016/j.ijid.2017.10.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29038045">PM:29038045</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Infect Dis\20171017-IbrahimWH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Infect Dis\20171017-IbrahimWH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Ibrahim WH</style></custom2><misc3><style face="normal" font="default">10.1016/j.ijid.2017.10.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43003</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lin,H.</style></author><author><style face="normal" font="default"> Luo,Y.</style></author><author><style face="normal" font="default"> Wang,L.</style></author><author><style face="normal" font="default"> Deng,K.</style></author><author><style face="normal" font="default"> Sun,Q.</style></author><author><style face="normal" font="default"> Fang,R.</style></author><author><style face="normal" font="default"> Wei,X.</style></author><author><style face="normal" font="default"> Zha,S.</style></author><author><style face="normal" font="default"> Wang,Z.</style></author><author><style face="normal" font="default"> Huang,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Shanghai Key Laboratory of Forensic Medicine, Shanghai Forensic Service Platform, Institute of Forensic Science, Ministry of Justice, Shanghai, 200063, China</style></auth-address><titles><title><style face="normal" font="default">Identification of pulmonary edema in forensic autopsy cases of fatal anaphylactic shock using Fourier transform infrared microspectroscopy</style></title><secondary-title><style face="normal" font="default">Int J Legal Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Legal Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="10" Year="2017">2017/10/30</year></dates><abstract><style face="normal" font="default">Anaphylaxis is a rapid allergic reaction that may cause sudden death. Currently, postmortem diagnosis of anaphylactic shock is sometimes difficult and often achieved through exclusion. The aim of our study was to investigate whether Fourier transform infrared (FTIR) microspectroscopy combined with pattern recognition methods would be complementary to traditional methods and provide a more accurate postmortem diagnosis of fatal anaphylactic shock. First, the results of spectral peak area analysis showed that the pulmonary edema fluid of the fatal anaphylactic shock group was richer in protein components than the control group, which included mechanical asphyxia, brain injury, and acute cardiac death. Subsequently, principle component analysis (PCA) was performed and showed that the anaphylactic shock group contained more turn and alpha-helix protein structures as well as less tyrosine-rich proteins than the control group. Ultimately, a partial least-square discriminant analysis (PLS-DA) model combined with a variables selection method called the genetic algorithm (GA) was built and demonstrated good separation between these two groups. This pilot study demonstrates that FTIR microspectroscopy has the potential to be an effective aid for postmortem diagnosis of fatal anaphylactic shock</style></abstract><notes><style face="normal" font="default">DA - 20171031IS - 1437-1596 (Electronic)IS - 0937-9827 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1007/s00414-017-1721-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29086053">PM:29086053</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Legal Med\20171031-LinH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Legal Med\20171031-LinH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171031, Lin H</style></custom2><misc3><style face="normal" font="default">10.1007/s00414-017-1721-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43004</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martin,M.</style></author><author><style face="normal" font="default"> Sauer,T.</style></author><author><style face="normal" font="default"> Alarcon,J.A.</style></author><author><style face="normal" font="default"> Vinoles,J.</style></author><author><style face="normal" font="default"> Walter,E.C.</style></author><author><style face="normal" font="default"> Ton,T.G.</style></author><author><style face="normal" font="default"> Zunt,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Fogarty International Clinical Research Training Program, Bethesda, Maryland, Stanford University, Stanford, California, USA, Universidad Nacional Mayor de San Marcos, Lima, Peru</style></auth-address><titles><title><style face="normal" font="default">Prevalence and impact of asthma among school-aged students in Lima, Peru</style></title><secondary-title><style face="normal" font="default">Int J Tuberc Lung Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Tuberc Lung Dis</style></full-title></periodical><pages end="1205" start="1201">1201-1205</pages><volume><style face="normal" font="default">21</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="default">SETTING AND OBJECTIVE: The International Study of Asthma and Allergies in Childhood (ISAAC) reported asthma prevalence in Peru to be among the highest in the world. We assessed the prevalence and morbidity of self-reported asthma in an underserved, peri-urban area of Lima, Peru, with limited medical access. DESIGN: The study was conducted in the outskirts of Lima from March to May 2011. Five hundred children aged 6-18 years were selected through cluster sampling. Parents completed a modified version of the ISAAC questionnaire. Children underwent spirometry testing. Those with a forced expiratory volume in one second (FEV1% predicted) &lt;/=80% were tested for reversibility using salbutamol. RESULTS: Of the 500 children selected, 71% participated. The prevalence of asthma was 16.7%. Asthma symptoms were associated with self-reported asthma (P &lt; 0.001); 52.5% of children with asthma had ever used an inhaler (P &lt; 0.001), and 27.1% had never been to the doctor for respiratory problems (P &lt; 0.001). CONCLUSION: We found a high prevalence of self-reported asthma and high morbidity related to asthma symptoms in the previous 12 months among the study cohort. Symptoms were poorly controlled due to limited availability of medication and access to medical services</style></abstract><notes><style face="normal" font="default">20171017IS - 1815-7920 (Electronic)IS - 1027-3719 (Linking)LA - engPT - Journal ArticleCO - Peru -CO - United States -</style></notes><work-type><style face="normal" font="default">10.5588/ijtld.17.0282</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29037303">PM:29037303</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Tuberc Lung Dis\2017-21-1201-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Tuberc Lung Dis\2017-21-1201-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Martin M</style></custom2><misc3><style face="normal" font="default">10.5588/ijtld.17.0282</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43005</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fan,X.J.</style></author><author><style face="normal" font="default"> Yang,C.</style></author><author><style face="normal" font="default"> Zhang,L.</style></author><author><style face="normal" font="default"> Fan,Q.</style></author><author><style face="normal" font="default"> Li,T.</style></author><author><style face="normal" font="default"> Bai,X.</style></author><author><style face="normal" font="default"> Zhao,Z.H.</style></author><author><style face="normal" font="default"> Zhang,X.</style></author><author><style face="normal" font="default"> Norback,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">College of Chemistry and Chemical Engineering, Taiyuan University of Technology, Taiyuan, Shanx</style></auth-address><titles><title><style face="normal" font="default">Asthma symptoms among Chinese children: the role of ventilation and PM10 exposure at school and home</style></title><secondary-title><style face="normal" font="default">Int J Tuberc Lung Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Tuberc Lung Dis</style></full-title></periodical><pages end="1193" start="1187">1187-1193</pages><volume><style face="normal" font="default">21</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="default">SETTING: Respiratory symptoms in relation to environment in Taiyuan, China. OBJECTIVE: To study associations between school/home exposure and prevalence of respiratory symptoms and self-reported respiratory infections (RIs) among students. DESIGN: A total of 2134 pupils from 10 schools answered a questionnaire; air pollution at school was measured. RESULTS: The prevalence of current wheeze, daytime attacks of breathlessness, nocturnal cough, nocturnal respiratory symptoms and RI was respectively 4.4%, 18.7%, 11.6%, 3.6% and 32.3%. Environmental tobacco smoke (ETS) at home was associated with daytime attacks of breathlessness (OR 1.41), nocturnal cough (OR 1.41) and RI (OR 1.26). Redecoration or indoor painting at home was associated with wheeze (OR 2.02), daytime attacks of breathlessness (OR 1.57) and nocturnal symptoms (OR 1.83). Dampness or mould at home was associated with daytime attacks of breathlessness (OR 1.68), nocturnal cough (OR 1.68) and RI (OR 1.69). Particulate matter of diameter &lt;/= 10 microns (PM10) in the classroom was associated with nocturnal cough (OR 1.20/10 mug/m3). PM10 outside school was associated with daytime attacks of breathlessness (OR 1.07/10 mug/m3) and nocturnal cough (OR 1.13/10 mug/m3). Indoor carbon dioxide, a marker of poor ventilation (OR 1.52/1000 parts per million), and relative humidity (RH) (OR 1.33/10%) were associated with nocturnal cough. CONCLUSION: Dampness, redecoration and ETS at home, as well as poor ventilation flow, and high RH and PM10 concentration at school may influence respiratory health</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 1815-7920 (Electronic)IS - 1027-3719 (Linking)LA - engPT - Journal ArticleCO - China -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.5588/ijtld.17.0196</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29037301">PM:29037301</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Tuberc Lung Dis\2017-21-1187-93.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Tuberc Lung Dis\2017-21-1187-93.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Fan XJ</style></custom2><misc3><style face="normal" font="default">10.5588/ijtld.17.0196</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43006</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lautenbacher,L.</style></author><author><style face="normal" font="default"> Perzanowski,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonology, Department of Pediatrics Columbia University College of Physicians and SurgeonsDepartment of Environmental Health Sciences Mailman School of Public Health, Columbia University, New York, NY, USA</style></auth-address><titles><title><style face="normal" font="default">Global asthma burden and poverty in the twenty-first century</style></title><secondary-title><style face="normal" font="default">Int J Tuberc Lung Dis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Tuberc Lung Dis</style></full-title></periodical><pages end="" start="1093">1093-</pages><volume><style face="normal" font="default">21</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 1815-7920 (Electronic)IS - 1027-3719 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.5588/ijtld.17.0638</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29037288">PM:29037288</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Tuberc Lung Dis\2017-21-1093.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Tuberc Lung Dis\2017-21-1093.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Lautenbacher L</style></custom2><misc3><style face="normal" font="default">10.5588/ijtld.17.0638</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43007</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ohsawa,I.</style></author><author><style face="normal" font="default"> Honda,D.</style></author><author><style face="normal" font="default"> Hisada,A.</style></author><author><style face="normal" font="default"> Inoshita,H.</style></author><author><style face="normal" font="default"> Onda-Tsueshita,K.</style></author><author><style face="normal" font="default"> Mano,S.</style></author><author><style face="normal" font="default"> Sato,N.</style></author><author><style face="normal" font="default"> Nakamura,Y.</style></author><author><style face="normal" font="default"> Shimizu,T.</style></author><author><style face="normal" font="default"> Gotoh,H.</style></author><author><style face="normal" font="default"> Goto,Y.</style></author><author><style face="normal" font="default"> Suzuki,Y.</style></author><author><style face="normal" font="default"> Tomino,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Nephrology Unit, Saiyu Soka Hospital, Japan</style></auth-address><titles><title><style face="normal" font="default">Clinical Features of Hereditary and Mast Cell-mediated Angioedema Focusing on the Differential Diagnosis in Japanese Patients</style></title><secondary-title><style face="normal" font="default">Intern Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Intern Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="default">Background The present study was designed to identify the clinical characteristics that permit the differential diagnosis of hereditary angioedema (HAE) and mast cell-mediated angioedema (Mast-AE) during the first consultation. Methods The medical histories and laboratory data of 46 patients with HAE and 41 patients with Mast-AE were compared. Results The average age of onset in the HAE group (19.8+/-9.0 years) was significantly lower than that in the Mast-AE group (35.2+/-12.0 years). The incidence of familial angioedema (AE) in the HAE group (73.9%) was significantly higher than that in the Mast-AE group (9.7%). The frequency of history of AE in the extremities, larynx, or gastrointestinal tract was significantly higher in the HAE group. The frequency of AE episodes of the lips and eyelids was significantly lower in the HAE group. The serum C4 concentration and CH50 titer were lower than the normal limit in 91.3% and 45.6% of the patients in the HAE group, respectively; in Mast-AE group the serum C4 concentration and CH50 titer were significantly lower than the normal limit in 4.8% and 0% of the patients, the difference between the two groups was statistically significant. A C1-inhibitor (C1-INH) activity level of &lt;50% was observed in all of the HAE patients, but none of the Mast-AE patients. The mean serum IgE titer in the HAE group (120.8+/-130.5 IU/mL) was significantly lower than that in the Mast-AE group (262.2+/-314.9 IU/mL). Conclusion The parameters within the patients' medical histories, such as the age at the onset of AE, a family history of AE, and the locations of past AE episodes are critical for the successful diagnosis of the disease. Measurements of the C4 and C1-INH activity are very useful for differential diagnosis of HAE from Mast-AE</style></abstract><notes><style face="normal" font="default">DA - 20171102IS - 1349-7235 (Electronic)IS - 0918-2918 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.2169/internalmedicine.8624-16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29093383">PM:29093383</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Intern Med\20171102-OhsawaI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Intern Med\20171102-OhsawaI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171102, Ohsawa I</style></custom2><misc3><style face="normal" font="default">10.2169/internalmedicine.8624-16</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43008</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Garcia-Neuer,M.</style></author><author><style face="normal" font="default"> Lynch,D.M.</style></author><author><style face="normal" font="default"> Marquis,K.</style></author><author><style face="normal" font="default"> Dowdall,J.</style></author><author><style face="normal" font="default"> Castells,M.</style></author><author><style face="normal" font="default"> Sloane,D.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Allergy and Immunology, Brigham and Women's Hospital, Boston, Mass</style></auth-address><titles><title><style face="normal" font="default">Drug-Induced Paradoxical Vocal Fold Motion</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="10" Year="2017">2017/10/13</year></dates><abstract><style face="normal" font="default">Vocal cord dysfunction, also known as paradoxical vocal fold motion (PVFM), is a disorder characterized by abnormal vocal cord adduction during inspiration. PVFM is commonly misdiagnosed as asthma because of the similarity of symptoms: cough, wheezing, chest pain, and dyspnea. We present the clinical vignette of a 36-year-old woman with juvenile rheumatoid arthritis and multiple adverse drug reactions who presented with recurrent episodes of unrecognized PVFM during skin testing for drug allergy, omalizumab treatment, and tocilizumab desensitization. Before the diagnosis of PVFM, these episodes were treated as anaphylaxis, including the administration of epinephrine. Once diagnosed and treated for PVFM, the patient did not present any further events and continued treatment for drug allergy. PVFM may be underreported in hypersensitivity reactions because of the similarity to Type 1-mediated respiratory symptoms and comorbid asthma</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29037819">PM:29037819</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171017, Garcia-Neuer M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43009</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">O'Sullivan,J.A.</style></author><author><style face="normal" font="default"> Bochner,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA</style></auth-address><titles><title><style face="normal" font="default">Eosinophils and Eosinophil-Associated Diseases: an Update</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="15" Month="10" Year="2017">2017/10/15</year></dates><abstract><style face="normal" font="default">The goal of this series is to offer a survey of the latest literature for clinicians and scientists alike, providing a list of important recent advances relevant to the broad field of allergy and immunology. This particular assignment was to cover the topic of eosinophils. In an attempt to highlight major ideas, themes, trends and advances relevant to basic and clinical aspects of eosinophil biology, a search of papers published since 2015 in JACI and other high impact journals was performed. Manuscripts were then reviewed and organized, and then key findings were summarized. Given space limitations, many outstanding papers could not be included, but the hope is that what follows provides a succinct overview of recently published work that has significantly added to our knowledge of eosinophils and eosinophil-associated diseases</style></abstract><notes><style face="normal" font="default">DA - 20171018IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.09.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29045815">PM:29045815</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171018-OSullivanJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171018-OSullivanJA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171018, O'Sullivan JA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.09.022</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43010</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Goldman,D.L.</style></author><author><style face="normal" font="default"> Chen,Z.</style></author><author><style face="normal" font="default"> Shankar,V.</style></author><author><style face="normal" font="default"> Tyberg,M.</style></author><author><style face="normal" font="default"> Vicencio,A.</style></author><author><style face="normal" font="default"> Burk,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Children's Hospital at Montefiore, Maimonides Hospital, Brooklyn, New York</style></auth-address><titles><title><style face="normal" font="default">Lower Airway Microbiota and Mycobiota in Children with Severe Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Hong Kong -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.09.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29031597">PM:29031597</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171016-GoldmanDL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171016-GoldmanDL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171016, Goldman DL</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.09.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43011</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hanjra,P.</style></author><author><style face="normal" font="default"> Lee,C.R.</style></author><author><style face="normal" font="default"> Maric,I.</style></author><author><style face="normal" font="default"> Carter,M.</style></author><author><style face="normal" font="default"> Olivera,A.</style></author><author><style face="normal" font="default"> Metcalfe,D.D.</style></author><author><style face="normal" font="default"> Komarow,H.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md</style></auth-address><titles><title><style face="normal" font="default">Chromogranin A is not a biomarker of mastocytosis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29033257">PM:29033257</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171016, Hanjra P</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.022</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43012</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rothenberg,M.E.</style></author><author><style face="normal" font="default"> Saito,H.</style></author><author><style face="normal" font="default"> Peebles,R.S.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center,Cincinnati, Ohio.</style></auth-address><titles><title><style face="normal" font="default">Advances in mechanisms of allergic disease in 2016</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="10" Year="2017">2017/10/13</year></dates><abstract><style face="normal" font="default">This review highlights advances in mechanisms of allergic disease, particularly type 2 innate lymphoid cells; TH2 lymphocytes; eicosanoid regulation of inflammation; extracellular vesicles in allergic responses; IL-33; microbiome properties, especially as they relate to mucosal barrier function; and a series of findings concerning the allergic inflammatory cells eosinophils, basophils, and mast cells. During the last year, mechanistic advances occurred in understanding type 2 innate lymphoid cells, particularly related to their response to ozone, involvement with experimental food allergy responses, and regulation by IL-33. Novel ways of regulating TH2 cells through epigenetic regulation of GATA-3 through sirtuin-1, a class III histone deacetylase, were published. The understanding of eicosanoid regulation of inflammation increased and focused on additional properties of phospholipase A2 and the role of prostaglandin D2 and its receptors and inhibitory prostaglandin E2 pathways. Mechanisms through which extracellular vesicles are released and contribute to allergic responses were reported. There was a deeper appreciation of mucosal barrier function, the epithelial alarmin IL-33, and the microbiome. Finally, there were advances concerning allergic inflammatory cells (mast cells, basophils, and eosinophils) that will undoubtedly have an effect on disease understanding and new therapeutic strategies</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.08.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29038009">PM:29038009</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171017-RothenbergME.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171017-RothenbergME.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Rothenberg ME</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.08.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43013</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cho,M.</style></author><author><style face="normal" font="default"> Lee,J.E.</style></author><author><style face="normal" font="default"> Lim,H.</style></author><author><style face="normal" font="default"> Shin,H.W.</style></author><author><style face="normal" font="default"> Khalmuratova,R.</style></author><author><style face="normal" font="default"> Choi,G.</style></author><author><style face="normal" font="default"> Kim,H.S.</style></author><author><style face="normal" font="default"> Choi,W.S.</style></author><author><style face="normal" font="default"> Park,Y.J.</style></author><author><style face="normal" font="default"> Shim,I.</style></author><author><style face="normal" font="default"> Kim,B.S.</style></author><author><style face="normal" font="default"> Kang,C.Y.</style></author><author><style face="normal" font="default"> Kim,J.O.</style></author><author><style face="normal" font="default"> Tanaka,S.</style></author><author><style face="normal" font="default"> Kubo,M.</style></author><author><style face="normal" font="default"> Chung,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Immune Regulation, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826</style></auth-address><titles><title><style face="normal" font="default">Fibrinogen-cleavage products and TLR4 promote the generation of programmed cell death 1 ligand 2(PD-L2)+ dendritic cells in allergic asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="10" Year="2017">2017/10/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: Inhaled protease allergens preferentially trigger Th2-mediated inflammation in allergic asthma. The role of dendritic cells (DCs) on the induction of Th2 cell responses in allergic asthma has been well documented; however, the mechanism by which protease allergens induce Th2-favorable DCs in the airway remains unclear. OBJECTIVE: We sought to determine a subset of DCs responsible for Th2 cell responses in allergic asthma and the mechanism by which protease allergens induce the DC subset in the airway. METHODS: Mice were intranasally challenged with protease allergens or fibrinogen-cleavage product (FCP) to induce allergic airway inflammation. DCs isolated from the mediastinal lymph nodes were analyzed for surface phenotype and T cell stimulatory function. Anti-Thy1.2 and Mas-TRECK mice were used to deplete innate lymphoid cells and mast cells, respectively. Adoptive cell transfer, bone marrow DC culture, anti-IL-13, and TLR4-deficient mice were used for further mechanistic studies. RESULTS: Protease allergens induced a remarkable accumulation of Th2-favorable PD-L2+ DCs in the mediastinal lymph nodes, which was significantly abolished in mice depleted of mast cells and, to a lesser extent, innate lymphoid cells. Mechanistically, FCP generated by protease allergens triggered IL-13 production from wild-type mast cells but not from TLR4-deficient mast cells, which resulted in the increase of PD-L2+ DCs. Intranasal administration of FCP induced an increase of PD-L2+ DCs in the airway, which was significantly abolished in</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - South Korea -CO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.09.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29038008">PM:29038008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171017-ChoM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171017-ChoM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Cho M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.09.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43014</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schussler,E.</style></author><author><style face="normal" font="default"> Yang,A.</style></author><author><style face="normal" font="default"> Lyons,J.J.</style></author><author><style face="normal" font="default"> Milner,J.D.</style></author><author><style face="normal" font="default"> Wang,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonology, Allergy &amp; Immunology, Department of Pediatrics, Weill Cornell Medical College, New York, NY.</style></auth-address><titles><title><style face="normal" font="default">Persistent tryptase elevation in a patient with Gaucher disease</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29033258">PM:29033258</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171016, Schussler E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.039</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43015</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tsoi,L.C.</style></author><author><style face="normal" font="default"> Yang,J.</style></author><author><style face="normal" font="default"> Liang,Y.</style></author><author><style face="normal" font="default"> Sarkar,M.K.</style></author><author><style face="normal" font="default"> Xing,X.</style></author><author><style face="normal" font="default"> Beamer,M.A.</style></author><author><style face="normal" font="default"> Aphale,A.</style></author><author><style face="normal" font="default"> Raja,K.</style></author><author><style face="normal" font="default"> Kozlow,J.H.</style></author><author><style face="normal" font="default"> Getsios,S.</style></author><author><style face="normal" font="default"> Voorhees,J.J.</style></author><author><style face="normal" font="default"> Kahlenberg,J.M.</style></author><author><style face="normal" font="default"> Elder,J.T.</style></author><author><style face="normal" font="default"> Gudjonsson,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Michigan Medical School, Ann Arbor, MI, USA</style></auth-address><titles><title><style face="normal" font="default">Transcriptional determinants of individualized inflammatory responses at anatomically separate sites</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.07.054</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29031600">PM:29031600</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171016-TsoiLC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171016-TsoiLC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171016, Tsoi LC</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.07.054</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43016</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chairakaki,A.D.</style></author><author><style face="normal" font="default"> Saridaki,M.I.</style></author><author><style face="normal" font="default"> Pyrillou,K.</style></author><author><style face="normal" font="default"> Mouratis,M.A.</style></author><author><style face="normal" font="default"> Koltsida,O.</style></author><author><style face="normal" font="default"> Walton,R.P.</style></author><author><style face="normal" font="default"> Bartlett,N.W.</style></author><author><style face="normal" font="default"> Stavropoulos,A.</style></author><author><style face="normal" font="default"> Boon,L.</style></author><author><style face="normal" font="default"> Rovina,N.</style></author><author><style face="normal" font="default"> Papadopoulos,N.G.</style></author><author><style face="normal" font="default"> Johnston,S.L.</style></author><author><style face="normal" font="default"> Andreakos,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece</style></auth-address><titles><title><style face="normal" font="default">Plasmacytoid dendritic cells drive acute exacerbations of asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="10" Year="2017">2017/10/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Although acute exacerbations, mostly triggered by viruses, account for the majority of hospitalizations in asthma, there is still very little known about the pathophysiological mechanisms involved. Plasmacytoid DCs (pDCs), prominent cells of antiviral immunity, exhibit pro-inflammatory or tolerogenic functions depending on the context, yet their involvement in asthma exacerbations remains unexplored. OBJECTIVES: We sought to investigate the role of pDCs in allergic airway inflammation and acute exacerbations of asthma. METHODS: Animal models of allergic airway disease (AAD) and virus-induced AAD exacerbations were employed to dissect pDC function in vivo and unwind potential mechanisms involved. Sputum from asthma patients with stable disease or acute exacerbations was further studied to determine pDC presence and correlation with inflammation. RESULTS: pDCs were key mediators of the immuno-inflammatory cascade that drives asthma exacerbations. In animal models of AAD and RV-induced AAD exacerbations, pDCs were recruited to the lung during inflammation and migrated to the draining lymph nodes to boost Th2-mediated effector responses. Accordingly, pDC depletion post-allergen challenge or during RV infection abrogated exacerbation of inflammation and disease. Central to this process was IL-25, induced by allergen challenge or RV infection that conditioned pDCs for pro-inflammatory function. Consistently, in asthma patients pDCs were markedly increased during exacerbations, and correlated with the severity of inflammation and the risk for asthmatic attacks. CONCLUSIONS: Our studies uncover a previously unsuspected role of pDCs in asthma exacerbations with potential diagnostic and prognostic implications. They also propose the therapeutic targeting of pDCs and IL-25 for the treatment of acute asthma</style></abstract><notes><style face="normal" font="default">DA - 20171021IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Greece -CO - United Kingdom -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.08.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29054692">PM:29054692</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171021-ChairakakiAD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171021-ChairakakiAD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171021, Chairakaki AD</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.08.032</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43017</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wong,X.F.C.C.</style></author><author><style face="normal" font="default"> Denil,S.L.I.J.</style></author><author><style face="normal" font="default"> Foo,J.N.</style></author><author><style face="normal" font="default"> Chen,H.</style></author><author><style face="normal" font="default"> Ling Tay,A.S.</style></author><author><style face="normal" font="default"> Haines,R.L.</style></author><author><style face="normal" font="default"> Tang,M.B.Y.</style></author><author><style face="normal" font="default"> McLean,W.H.I.</style></author><author><style face="normal" font="default"> Sandilands,A.</style></author><author><style face="normal" font="default"> Smith,F.J.D.</style></author><author><style face="normal" font="default"> Lane,E.B.</style></author><author><style face="normal" font="default"> Liu,J.</style></author><author><style face="normal" font="default"> Common,J.E.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Medical Biology, A*STAR, Singapore 138648, Singapore</style></auth-address><titles><title><style face="normal" font="default">Array-based sequencing of filaggrin gene for comprehensive detection of disease-associated variants</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="default">Comprehensive sequencing of FLG is a challenging endeavour. We have developed a method using array-based amplicon PCR and NGS for a robust and cost efficient method to analyze this major atopic dermatitis risk factor</style></abstract><notes><style face="normal" font="default">DA - 20171023IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Singapore -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.10.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29056476">PM:29056476</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171023-WongXF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171023-WongXF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171023, Wong XF</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.10.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43018</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Geerdink,R.J.</style></author><author><style face="normal" font="default"> Hennus,M.P.</style></author><author><style face="normal" font="default"> Westerlaken,G.H.A.</style></author><author><style face="normal" font="default"> Abrahams,A.C.</style></author><author><style face="normal" font="default"> Albers,K.I.</style></author><author><style face="normal" font="default"> Walk,J.</style></author><author><style face="normal" font="default"> Wesselink,E.</style></author><author><style face="normal" font="default"> Janssen,R.</style></author><author><style face="normal" font="default"> Bont,L.</style></author><author><style face="normal" font="default"> Meyaard,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory for Translational Immunology, Department of Immunology, University Medical Center Utrecht, 3584 EA Utrecht, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">LAIR-1 limits neutrophil extracellular trap formation in viral bronchiolitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171020IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.08.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29050972">PM:29050972</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171020-GeerdinkRJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171020-GeerdinkRJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171020, Geerdink RJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.08.031</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43019</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hsu,C.Y.</style></author><author><style face="normal" font="default"> Lee,W.R.</style></author><author><style face="normal" font="default"> Shih,Y.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Taipei Medical University-Shuang Ho Hospital, New Taipei City, Taiwan</style></auth-address><titles><title><style face="normal" font="default">Recalcitrant chronic leg ulcer: An indication for patch testing for hydrocolloid dressing</style></title><secondary-title><style face="normal" font="default">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am Acad Dermatol</style></full-title></periodical><pages end="e98" start="e97">e97-e98</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Bandages,Hydrocolloid</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Dermatitis,Allergic Contact</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> immunology</style></keyword><keyword><style face="normal" font="default"> Disease Progression</style></keyword><keyword><style face="normal" font="default"> Follow-Up Studies</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Leg Ulcer</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Patch Tests</style></keyword><keyword><style face="normal" font="default"> Risk Assessment</style></keyword><keyword><style face="normal" font="default"> Withholding Treatment</style></keyword><keyword><style face="normal" font="default"> Wound Healing</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword></keywords><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20170917IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Case ReportsPT - Journal ArticleSB - IMCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaad.2017.03.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28917483">PM:28917483</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am Acad Dermatol\2017-77-e97-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Am Acad Dermatol\2017-77-e97-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170917, Hsu CY</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaad.2017.03.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43020</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rickstrew,J.</style></author><author><style face="normal" font="default"> Wang,T.</style></author><author><style face="normal" font="default"> Liu,D.</style></author><author><style face="normal" font="default"> Rajpara,A.</style></author><author><style face="normal" font="default"> Aires,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Kansas Medical Center, Division of Dermatology, Kansas City, Kansas</style></auth-address><titles><title><style face="normal" font="default">Mitigation or prevention of mild hair dye contact dermatitis after pretreatment with clobetasol foam</style></title><secondary-title><style face="normal" font="default">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="e129">e129-</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171014IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaad.2017.07.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29029920">PM:29029920</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am Acad Dermatol\2017-77-e129.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Am Acad Dermatol\2017-77-e129.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171014, Rickstrew J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaad.2017.07.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43021</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Katoh,S.</style></author><author><style face="normal" font="default"> Ikeda,M.</style></author><author><style face="normal" font="default"> Shirai,R.</style></author><author><style face="normal" font="default"> Abe,M.</style></author><author><style face="normal" font="default"> Ohue,Y.</style></author><author><style face="normal" font="default"> Kobashi,Y.</style></author><author><style face="normal" font="default"> Oka,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Respiratory Medicine , Kawasaki Medical School , 577 Matsushima, Kurashiki , Okayama 701-0192 , Japan</style></auth-address><titles><title><style face="normal" font="default">Biomarkers for differentiation of patients with asthma and chronic obstructive pulmonary disease</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Asthma and chronic obstructive pulmonary disease (COPD) are airflow limitation diseases with similar clinical manifestations but different pathophysiologic mechanisms. To implement the appropriate treatment, it is important to distinguish between asthma and COPD which sometimes might result difficult in clinical practice. We evaluated biomarkers to distinguish between asthma and COPD. METHODS: Blood eosinophil counts and fractional exhaled nitric oxide (FeNO) levels were analyzed. Serum periostin, interleukin-25 (IL-25), and immunoglobulin E (IgE) concentrations were compared between patients with asthma (n = 60), including atopic-asthma (n = 30) and non-atopic asthma (n = 30), and patients with COPD (n = 30). RESULTS: Significantly higher peripheral blood eosinophil counts (p&lt;0.001), FeNO levels (p&lt;0.001), and total serum IgE (P = 0.003) concentrations, but not serum periostin (p = 0.584) or serum IL-25 (p = 0.085) concentrations, were detected in patients with asthma compared to patients with COPD. Serum periostin and IgE concentrations were increased in patients with atopic-asthma compared with those with non-atopic asthma and COPD (p&lt;0.05). The FeNO levels were significantly correlated with the peripheral blood eosinophil counts (r = 0.430, p = 0.001) and serum IL-25 concentrations (r = 0.338, p = 0.009) in patients with asthma. The serum periostin concentrations were also correlated with the serum IgE concentrations (r = 0.375, p = 0.003) and FeNO levels (r = 0.291, p = 0.024) in patients with asthma. Asthma patients were effectively differentiated from COPD patients based on the FeNO levels (p&lt;0.001) and peripheral blood eosinophil counts (p&lt;0.001). CONCLUSIONS: FeNO levels and peripheral blood eosinophil counts were useful biomarkers for distinguishing between patients with asthma and COPD. Serum periostin and IgE concentrations could be biomarkers for atopic asthma</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1391281</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29035604">PM:29035604</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171016-KatohS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171016-KatohS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171016, Katoh S</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1391281</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43022</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lambert,K.A.</style></author><author><style face="normal" font="default"> Prendergast,L.A.</style></author><author><style face="normal" font="default"> Dharmage,S.C.</style></author><author><style face="normal" font="default"> Tang,M.</style></author><author><style face="normal" font="default"> O'Sullivan,M.</style></author><author><style face="normal" font="default"> Tran,T.</style></author><author><style face="normal" font="default"> Druce,J.</style></author><author><style face="normal" font="default"> Bardin,P.</style></author><author><style face="normal" font="default"> Abramson,M.J.</style></author><author><style face="normal" font="default"> Erbas,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">a School of Psychology and Public Health , La Trobe University , Victoria , Melbourne , Australia</style></auth-address><titles><title><style face="normal" font="default">The role of human rhinovirus (HRV) species on asthma exacerbation severity in children and adolescents</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="10" Year="2017">2017/10/11</year></dates><abstract><style face="normal" font="default">OBJECTIVE: It is recognized that human rhinovirus (HRV) infection is an important factor in asthma exacerbations requiring hospitalization in children. However, previous studies have disagreed on the differential impact of various HRV species. We sought to assess the impact of HRV species on the severity of asthma exacerbations in children and adolescents. We also examined whether the effect of HRV species on severity was modified by age and gender. METHODS: Virus strain was determined for 113 children with HRV detectable at the time of admission for asthma exacerbation. Patient characteristics were collected on admission and exacerbation severity was scored using several validated scales. RESULTS: HRV species by itself was not associated with moderate/severe vs. mild exacerbations. Boys with HRV-C infections were more likely (OR: 3.7, 95% CI: 1.2-13.4) to have a moderate/severe exacerbation than girls with HRV-C (p = 0.04 for interaction term). Higher odds were observed in younger boys (3 years old: OR: 9.1, 95% CI: 1.8-47.1 vs 5 years old: OR: 3.3, 95% CI: 0.9-11.8 vs 7 years old: OR: 1.2, 95% CI: 0.2-6.6). In contrast, children with HRV-C infection and sensitized to pollen during the pollen season were less likely to have moderate/severe exacerbations (p = 0.01 for the interaction term). CONCLUSION: Acute asthma exacerbations are more likely to be moderate/severe in boys under 5 years of age who had HRV-C infection on admission. The opposite was found in children with sensitization to pollen during pollen season</style></abstract><notes><style face="normal" font="default">DA - 20171011IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1362425</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29020463">PM:29020463</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171011-LambertKA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171011-LambertKA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171011, Lambert KA</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1362425</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43023</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Boulay,M.E.</style></author><author><style face="normal" font="default"> Pruneau-Pomerleau,C.</style></author><author><style face="normal" font="default"> Villeneuve,H.</style></author><author><style face="normal" font="default"> Deschesnes,F.</style></author><author><style face="normal" font="default"> Ringuette,L.</style></author><author><style face="normal" font="default"> Boulet,L.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institut Universitaire de Cardiologie et de Pneumologie de Quebec-Universite Laval , Quebec , QC , Canada</style></auth-address><titles><title><style face="normal" font="default">Comparative features of Asthma with frequent or infrequent exacerbations: A longitudinal study of retrospective and prospective events</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="10" Year="2017">2017/10/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: A "frequent exacerbator phenotype" has been described, mostly in the population of patients with severe asthma. Further data are needed on such exacerbation-prone patients in milder asthma. AIM: To compare the characteristics of frequent and nonfrequent exacerbators in asthma of different severities and to assess the stability of the exacerbator status. METHODS: This was an observational study comparing baseline data from frequent (>/=2 exacerbations in the past year) and nonfrequent (&lt;2 exacerbations in the past year) exacerbators. Patients were also followed up for one year. Information regarding clinical, physiologic, and inflammatory characteristics was collected at baseline and one-year follow-up. RESULTS: Forty-seven frequent and 53 nonfrequent exacerbators were recruited. No specific clinical, physiologic, or inflammatory characteristic was observed in the frequent as compared to the nonfrequent exacerbators at baseline. Fifty-eight percent of patients reporting frequent exacerbations at baseline remained in this group after one year of follow-up. Forty-two and 62% of patients with, respectively, mild-to-moderate asthma and severe asthma had frequent exacerbations. In a post hoc analysis according to asthma severity, frequent exacerbators with severe asthma had a higher body mass index and poorer asthma control, although they reported higher adherence to medication, in comparison to frequent exacerbators with mild-to-moderate asthma. No specific characteristics could discriminate between frequent and nonfrequent exacerbators of the same asthma severity. CONCLUSIONS: Frequent exacerbators with severe asthma present some specific characteristics not observed in frequent exacerbators with mild-to-moderate disease. However, the latter group should be identified to reassess treatment needs and potential contributing factors</style></abstract><notes><style face="normal" font="default">DA - 20171011IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO -. Canada -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1323918</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29020468">PM:29020468</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171011-BoulayME.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171011-BoulayME.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171011, Boulay ME</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1323918</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43024</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Afshar,M.</style></author><author><style face="normal" font="default"> Press,V.G.</style></author><author><style face="normal" font="default"> Robison,R.G.</style></author><author><style face="normal" font="default"> Kho,A.N.</style></author><author><style face="normal" font="default"> Bandi,S.</style></author><author><style face="normal" font="default"> Biswas,A.</style></author><author><style face="normal" font="default"> Avila,P.C.</style></author><author><style face="normal" font="default"> Kumar,H.V.M.</style></author><author><style face="normal" font="default"> Yu,B.</style></author><author><style face="normal" font="default"> Naureckas,E.T.</style></author><author><style face="normal" font="default"> Nyenhuis,S.M.</style></author><author><style face="normal" font="default"> Codispoti,C.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Division of Pulmonary and Critical Care, Loyola University Chicago Stritch School of Medicine , Maywood , IL USA</style></auth-address><titles><title><style face="normal" font="default">A computable phenotype for asthma case identification in adult and pediatric patients: External validation in The Chicago Area Patient-Outcomes Research Network (CAPriCORN)</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="10" Year="2017">2017/10/13</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Comprehensive, rapid, and accurate identification of patients with asthma for clinical care and engagement in research efforts is needed. The original development and validation of a computable phenotype for asthma case identification occurred at a single institution in Chicago and demonstrated excellent test characteristics. However, its application in a diverse payer mix, across different health systems and multiple electronic health record vendors, and in both children and adults was not examined. The objective of this study is to externally validate the computable phenotype across diverse Chicago institutions to accurately identify pediatric and adult patients with asthma. METHODS: A cohort of 900 asthma and control patients was identified from the electronic health record between January 1, 2012 and November 30, 2014. Two physicians at each site independently reviewed the patient chart to annotate cases. RESULTS: The inter-observer reliability between the physician reviewers had a kappa-coefficient of 0.95 (95% CI 0.93-0.97). The accuracy, sensitivity, specificity, negative predictive value, and positive predictive value of the computable phenotype were all above 94% in the full cohort. CONCLUSIONS: The excellent positive and negative predictive values in this multi-center external validation study establish a useful tool to identify asthma cases in in the electronic health record for research and care. This computable phenotype could be used in large-scale comparative-effectiveness trials</style></abstract><notes><style face="normal" font="default">DA - 20171013IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1389952</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29027824">PM:29027824</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171013-AfsharM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171013-AfsharM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171013, Afshar M</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1389952</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43025</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Meuwissen,J.M.J.E.</style></author><author><style face="normal" font="default"> Heynens,J.</style></author><author><style face="normal" font="default"> Dauven,T.</style></author><author><style face="normal" font="default"> Crasborn,L.</style></author><author><style face="normal" font="default"> Smeenk,F.W.J.M.</style></author><author><style face="normal" font="default"> van der Weijden,T.</style></author><author><style face="normal" font="default"> Muris,J.W.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department Family Medicine , Maastricht University , Maastricht , The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Interprofessional Pulmocheck care pathway: An innovative approach to managing pediatric asthma care in the Netherlands</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="10" Year="2017">2017/10/13</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Under-diagnosis and suboptimal asthma control in children persists. An innovative care pathway was developed by a hospital department of pediatrics with the aim to detect pulmonary problems in children and provide appropriate treatment possibilities through systematic feedback towards the referring primary care physician. Primary care physicians can use this pathway to refer children with asthma-like symptoms for a one-day assessment. Goals are to measure the usage of the pathway by primary care general practitioners (GPs), the outcomes in terms of new diagnoses of asthma, the reduction in regular referrals, generated recommendations/therapy and the adequacy of asthma follow-up. METHODS: We collected all feedback letters sent to the GP concerning children who underwent the Pulmocheck in 2010, 2011 and 2012. Furthermore, all GPs, who had referred a child to the Pulmocheck in this period and that subsequently was diagnosed with asthma and was further managed in primary care, were sent a follow-up questionnaire in 2014. RESULTS: There were 121 referrals from 51 GPs in 3 years to this pathway. In 59.5% of these referrals a new diagnosis of asthma was established. In 90.9% one or more changes in clinical management were advised. The response rate to the follow-up questionnaires was 65.7% of which 4.8% of the children with new established asthma were reviewed four times or more in the follow-up period, 17.4% two times, 65.2% once, and in 8.7% were not followed. CONCLUSIONS: The specialty pediatric asthma care pathway revealed a high number of children with newly diagnosed asthma, but was also helpful to exclude this diagnosis. However, the referral rate of GPs to this pathway was low, but in the children, that were referred several changes in the clinical management were advised and the frequency of monitoring of the children with diagnosed asthma was not in accordance with the asthma guidelines</style></abstract><notes><style face="normal" font="default">DA - 20171013IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1363893</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29028376">PM:29028376</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171013-MeuwissenJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171013-MeuwissenJM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171013, Meuwissen JM</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1363893</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43026</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Good,J.</style></author><author><style face="normal" font="default"> Dogra,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Subjective responses to Sprint Interval Exercise in adults with and without Exercise-Induced Bronchoconstriction</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Little is known of the subjective response to exercise that involves short "all out" bursts of effort, separated by recovery periods (sprint interval exercise (SPRINT)) among adults with exercise-induced bronchoconstriction (EIBC). The purpose of this study was to compare subjective responses to SPRINT and moderate intensity continuous exercise (MOD) among adults with EIBC, and to compare these responses between adults with EIBC and those without EIBC. METHODS: Eight adults (22.3 +/- 3.0 years) with EIBC, and eight adults (22.3 +/- 3.0 years) without EIBC completed a SPRINT (4 x 30 second sprints separated by 4.5 minutes of active recovery) and MOD (20 minutes at 65% peak power output) session in random order. Self-reported affect, perceived breathlessness, and perceived exertion were recorded throughout exercise using validated scales. Enjoyment was assessed following exercise. RESULTS: Differences between SPRINT and MOD were observed such that affect and perceived breathlessness were worse during the initial stages of SPRINT than MOD; however differences disappeared by the end of exercise. Enjoyment was similar for SPRINT and MOD in the EIBC group (SPRINT: 72.9 +/- 20.0 vs. MOD: 79.5 +/- 20.5, p = 0.25), and between groups for SPRINT and MOD. CONCLUSIONS: Perceived breathlessness may impact affect during the early stages of exercise among those with EIBC. Post-exercise enjoyment appears to be similar between SPRINT and MOD. Future research is needed to better understand the relationship between ventilation patterns, exercise intensity, and enjoyment of exercise among those with EIBC</style></abstract><notes><style face="normal" font="default">DA - 20171012IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1391282</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29023174">PM:29023174</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171012-GoodJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171012-GoodJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171012, Good J</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1391282</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43027</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mazalovic,K.</style></author><author><style face="normal" font="default"> Jacoud,F.</style></author><author><style face="normal" font="default"> Dima,A.L.</style></author><author><style face="normal" font="default"> Van Ganse,E.</style></author><author><style face="normal" font="default"> Nolin,M.</style></author><author><style face="normal" font="default"> Cannet,D.</style></author><author><style face="normal" font="default"> Zabawa,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of General Medicine , UFR Sciences de Sante, University of Burgundy , France</style></auth-address><titles><title><style face="normal" font="default">Asthma exacerbations and socio-economic status in French adults with persistent asthma: a prospective cohort study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Adults disadvantaged by poor socio-economic status (SES) are more severely affected by asthma compared to those with better SES. We aimed to determine whether the frequency of asthma exacerbations (AEx), as well as aspects related to AEx management, differed based on SES in patients treated with daily treatments. METHODS: This study, part of the prospective observational cohort ASTRO-LAB, included French adult patients with persistent asthma. Patients were considered as low SES if they benefited from publicly funded special health insurance and/or were perceived as low SES by their general practitioner. AEx was defined as at least one of the following: asthma-related oral corticosteroid course, medical contact, hospitalization, and death. We examined associations between SES and AEx frequency, perceived triggering factors and type of medical contact after AEx. RESULTS: In our sample of 255 patients, 11.40% were considered as low SES. Patients with low SES did not report significantly more AEx than medium/high SES patients during one-year follow-up (0.79 versus 0.55, p = 0.38). The type of medical contact during AEx differed significantly between the two groups (p = 0.03): patients with medium/high SES consulted their general practitioner more frequently (OR = 2.23, 95% CI = 0.91-5.50, p = 0.08) and were less likely to visit an emergency department or be hospitalized (OR = 0.27, 95% CI = 0.09-0.84, p = 0.02). CONCLUSIONS: AEx frequency did not differ significantly between low and medium/high SES patients, but differences were found in the management of AEx. Studies are needed to better understand the relation between precariousness and management of asthma</style></abstract><notes><style face="normal" font="default">DA - 20171012IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - France -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1391280</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29023163">PM:29023163</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171012-MazalovicK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171012-MazalovicK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171012, Mazalovic K</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1391280</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43028</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Crespo-Lessmann,A.</style></author><author><style face="normal" font="default"> Mateus,E.</style></author><author><style face="normal" font="default"> Torrejon,M.</style></author><author><style face="normal" font="default"> Belda,A.</style></author><author><style face="normal" font="default"> Giner,J.</style></author><author><style face="normal" font="default"> Vidal,S.</style></author><author><style face="normal" font="default"> Sibila,O.</style></author><author><style face="normal" font="default"> Plaza,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Service of Pneumology, Hospital de la Santa Ceu i Sant Pau, Institute of Sant Pau Biomedical Research (IBB Sant Pau), Universitat Autonoma de Barcelona, Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES)</style></auth-address><titles><title><style face="normal" font="default">Asthma with bronchial hypersecretion: expression of mucins and toll-like receptors in sputum and blood</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="276" start="269">269-276</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Asthma with bronchial hypersecretion is a type of asthma that is poorly studied. Its pathogenesis is not well understood, but is probably related to innate impaired immunity, particularly with toll-like receptors (TLRs) and secretory mucins (MUC). OBJECTIVES: 1) Define the clinical and inflammatory phenotype of asthma with bronchial hypersecretion of mucus. 2) Compare the type of mucin present in induced sputum (IS) of patients with and without bronchial hypersecretion. 3) Determine the expression of TLRs in IS and blood of asthmatics with and without bronchial hypersecretion. MATERIALS AND METHODS: Cross-sectional study which included 43 non-smoking asthmatic patients without bronchiectasis, 19 with bronchiectasis, and 24 without bronchial hypersecretion. All patients underwent the following: IS, spirometry, fractional exhaled nitric oxide, prick test, total immunoglobulin E (IgE), and blood albumin. Analysis of mucins was determined by ELISA and expression of TLR2 and TLR4 by flow cytometry. The level of asthma control was determined by the Asthma Control Test (ACT) questionnaire and quality of life was assessed by the reduced version of the Asthma Quality of Life Questionnaire (mini-AQLQ). RESULTS: Asthmatics with bronchial hypersecretion were significantly older (62.6 years vs 48.5 years; p=0.02); had greater severity (persistent severe asthma 94.7% vs 29.2%; p=0.000); a higher proportion of nasal polyposis (36.8% vs 8.3%; p=0.022); less control of asthma (73.7% vs 8.3%; p=0,000); a higher proportion of asthma with negative prick test (68.4% vs 16.6%; p=0.001), and lower levels of IgE (113.4 IU/mL vs 448 IU/mL; p=0.007), compared with asthmatics without bronchial hypersecretion. Significant differences were observed neither in the expression of TLRs 2 and 4 in inflammatory cells of IS or peripheral blood, nor in the expression of mucins between both groups. CONCLUSION: Asthma patients with bronchial hypersecretion have more severe and uncontrolled disease, with poor quality of life as well as a non-allergic inflammatory phenotype. Within the mechanisms involving these differences, it does not appear that mucins and TLRs play an important role</style></abstract><notes><style face="normal" font="default">DA - 20171025IS - 1178-6965 (Print)IS - 1178-6965 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.2147/JAA.S142200</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29066918">PM:29066918</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-269-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-269-76.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171025, Crespo-Lessmann A</style></custom2><misc3><style face="normal" font="default">10.2147/JAA.S142200</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43029</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fretzayas,A.</style></author><author><style face="normal" font="default"> Moustaki,M.</style></author><author><style face="normal" font="default"> Loukou,I.</style></author><author><style face="normal" font="default"> Douros,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Third Department of Pediatrics, Athens University Medical School, "Attikon" University Hospital, Haidari, Greece</style></auth-address><titles><title><style face="normal" font="default">Differentiating vocal cord dysfunction from asthma</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="283" start="277">277-283</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Vocal cord dysfunction (VCD)-associated symptoms are not rare in pediatric patients. Dyspnea, wheezing, stridor, chest pain or tightness and throat discomfort are the most commonly encountered symptoms. They may occur either at rest or more commonly during exercise in patients with VCD, as well as in asthmatic subjects. The phase of respiration (inspiration rather than expiration), the location of the wheezing origin, the rapid resolution of symptoms, and the timing occurring in relation to exercise, when VCD is exercise induced, raise the suspicion of VCD in patients who may have been characterized as merely asthmatics and, most importantly, had not responded to the appropriate treatment. The gold standard method for the diagnosis of VCD is fiberoptic laryngoscopy, which may also identify concomitant laryngeal abnormalities other than VCD. However, as VCD is an intermittent phenomenon, the procedure should be performed while the patient is symptomatic. For this reason, challenges that induce VCD symptoms should be performed, such as exercise tests. Recently, for the evaluation of patients with exercise-induced VCD, continuous laryngoscopy during exercise (such as treadmill, bicycle ergometer, swimming) was used. A definite diagnosis of VCD is of importance, especially for those patients who have been erroneously characterized as asthmatics, without adequate response to treatment. In these cases, another therapeutic approach is necessary, which will depend on whether they suffer solely from VCD or from both conditions</style></abstract><notes><style face="normal" font="default">DA - 20171025IS - 1178-6965 (Print)IS - 1178-6965 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Greece -</style></notes><work-type><style face="normal" font="default">10.2147/JAA.S146007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29066919">PM:29066919</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-277-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-277-83.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171025, Fretzayas A</style></custom2><misc3><style face="normal" font="default">10.2147/JAA.S146007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43030</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shrestha,S.K.</style></author><author><style face="normal" font="default"> Drews,A.</style></author><author><style face="normal" font="default"> Sharma,L.</style></author><author><style face="normal" font="default"> Pant,S.</style></author><author><style face="normal" font="default"> Shrestha,S.</style></author><author><style face="normal" font="default"> Neopane,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Internal Medicine , Kathmandu Medical College, Sinamangal, Kathmandu, Bagmati, Kathmandu, NEPAL</style></auth-address><titles><title><style face="normal" font="default">Relationship between total serum immunoglobulin E levels, fractional exhaled breath Nitric Oxide levels and absolute blood eosinophil counts in atopic and non-atopic asthma: a controlled comparative study</style></title><secondary-title><style face="normal" font="default">J Breath Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Breath Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="10" Year="2017">2017/10/25</year></dates><abstract><style face="normal" font="default">ABSTRACT&amp;#13; &amp;#13; Introduction&amp;#13; Asthma is a prevalent non communicable disease both in low and high income countries, including Nepal. Total serum immunoglobulin E levels and peripheral blood absolute eosinophil counts are known inflammatory markers of asthma. And Fractional Exhaled Nitric Oxide measure in breath has also been proposed as a non-invasive biomarker to assess eosinophilic airway inflammation. This study explores the correlation between these three variables with intent that one may replace the other in resource limited setup. &amp;#13; &amp;#13; Method&amp;#13; This prospective controlled trial evaluated 314 subjects with and without asthma, with asthma group sub-divided into atopic and non-atopic category. Total serum Immunoglobulin E level, absolute eosinophil count in peripheral blood and fractional exhaled nitric oxide level were measured in all categories.&amp;#13; &amp;#13; Results&amp;#13; The geometric mean of Immunoglobulin E levels, absolute eosinophil count and fractional exhaled nitric oxide were 221.07+774.55 IU/mL, 214+360/uL and 37+49 ppb in asthma group and 59.13+174.32IU/mL, 164+137/uL and 12+21 ppb in control group, respectively. Significant higher levels were seen in asthma group for total serum immunoglobulin E (p&amp;lt;0.001), AEC (p=0.002) and FENO (p&amp;lt;0.001) levels. &amp;#13; Total serum immunoglobulin E levels, absolute eosinophil count and fractional exhaled nitric oxide were 436.79+822.40 IU/mL, 269+395/uL and 76+52 ppb in atopic asthma group. Similarly, total serum immunoglobulin E levels, absolute eosinophil count and fractional exhaled nitric oxide were 131.17+692.96 IU/mL, 182+328/uL and 23+22.5 ppb in non-atopic asthma group. Significant higher levels were seen in all three variables: tIgE (p&amp;lt;0.001), AEC (p=0.008) and FENO (p&amp;lt;0.001). &amp;#13; Moderate degree of positive correlation was identified between tIgE and FENO50 (Spearman's rho=0.461) and tIgE and AEC (Spearman's rho of 0.315) with only small correlation between FENO50 and AEC (spearman's rho of 0.299).&amp;#13; &amp;#13; Conclusion&amp;#13; tIgE levels, FENO50 and AEC levels are higher in asthma specifically in atopic phenotype as compared to normal. Total serum IgE levels have moderate correlation with FENO50 and AEC but FENO50 and AEC are weakly correlated.&amp;#13; &amp;#13</style></abstract><notes><style face="normal" font="default">DA - 20171025IS - 1752-7163 (Electronic)IS - 1752-7155 (Linking)LA - engPT - Journal ArticleCO - Nepal -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1088/1752-7163/aa95da</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29068321">PM:29068321</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Breath Res\20171025-ShresthaSK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Breath Res\20171025-ShresthaSK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171025, Shrestha SK</style></custom2><misc3><style face="normal" font="default">10.1088/1752-7163/aa95da</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43031</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Perez-Outeiral,J.</style></author><author><style face="normal" font="default"> Elcoroaristizabal,S.</style></author><author><style face="normal" font="default"> Amigo,J.M.</style></author><author><style face="normal" font="default"> Vidal,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Applied Chemistry, Faculty of Chemistry, University of the Basque Country (UPV/EHU), P.O. Box 1072, 20080 San Sebastian, Spain.</style></auth-address><titles><title><style face="normal" font="default">Development and validation of a method for the determination of regulated fragrance allergens by High-Performance Liquid Chromatography and Parallel Factor Analysis 2</style></title><secondary-title><style face="normal" font="default">J Chromatogr A</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Chromatogr A</style></abbr-1></periodical><pages end="92" start="82">82-92</pages><volume><style face="normal" font="default">1526</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="10" Year="2017">2017/10/14</year></dates><abstract><style face="normal" font="default">This work presents the development and validation of a multivariate method for quantitation of 6 potentially allergenic substances (PAS) related to fragrances by ultrasound-assisted emulsification microextraction coupled with HPLC-DAD and PARAFAC2 in the presence of other 18 PAS. The objective is the extension of a previously proposed univariate method to be able to determine the 24 PAS currently considered as allergens. The suitability of the multivariate approach for the qualitative and quantitative analysis of the analytes is discussed through datasets of increasing complexity, comprising the assessment and validation of the method performance. PARAFAC2 showed to adequately model the data facing up different instrumental and chemical issues, such as co-elution profiles, overlapping spectra, unknown interfering compounds, retention time shifts and baseline drifts. Satisfactory quality parameters of the model performance were obtained (R2>/=0.94), as well as meaningful chromatographic and spectral profiles (r>/=0.97). Moreover, low errors of prediction in external validation standards (below 15% in most cases) as well as acceptable quantification errors in real spiked samples (recoveries from 82 to 119%) confirmed the suitability of PARAFAC2 for resolution and quantification of the PAS. The combination of the previously proposed univariate approach, for the well-resolved peaks, with the developed multivariate method allows the determination of the 24 regulated PAS</style></abstract><notes><style face="normal" font="default">DA - 20171023IS - 1873-3778 (Electronic)IS - 0021-9673 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Ireland -</style></notes><work-type><style face="normal" font="default">10.1016/j.chroma.2017.10.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29056274">PM:29056274</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Chromatogr A\2017-1526-82-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Chromatogr A\2017-1526-82-92.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171023, Perez-Outeiral J</style></custom2><misc3><style face="normal" font="default">10.1016/j.chroma.2017.10.034</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43032</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Landsem,L.M.</style></author><author><style face="normal" font="default"> Ross,F.J.</style></author><author><style face="normal" font="default"> Eisses,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, WA, United States.</style></auth-address><titles><title><style face="normal" font="default">A case of midazolam anaphylaxis during a pediatric patient's first anesthetic</style></title><secondary-title><style face="normal" font="default">J Clin Anesth</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Clin Anesth</style></full-title></periodical><pages end="76" start="75">75-76</pages><volume><style face="normal" font="default">43</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 1873-4529 (Electronic)IS - 0952-8180 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jclinane.2017.08.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29049905">PM:29049905</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Anesth\2017-43-75-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Anesth\2017-43-75-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Landsem LM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jclinane.2017.08.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43033</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Capelle,H.</style></author><author><style face="normal" font="default"> Tummino,C.</style></author><author><style face="normal" font="default"> Greillier,L.</style></author><author><style face="normal" font="default"> Gouitaa,M.</style></author><author><style face="normal" font="default"> Birnbaum,J.</style></author><author><style face="normal" font="default"> Ausias,N.</style></author><author><style face="normal" font="default"> Barlesi,F.</style></author><author><style face="normal" font="default"> Montana,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Aix Marseille Univ, AP-HM, Oncopharma, Hopital Nord, Marseille, France</style></auth-address><titles><title><style face="normal" font="default">Retrospective study of hypersensitivity reactions to chemotherapeutic agents in a thoracic oncology service</style></title><secondary-title><style face="normal" font="default">J Clin Pharm Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Clin Pharm Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="default">WHAT IS KNOWN AND OBJECTIVE: With the increasing use of cancer chemotherapy agents, hypersensitivity reactions are commonly encountered. The allergic clinical symptoms are variable and unpredictable. The aim of this study was to identify the characteristics of hypersensitivity reactions and to assess the value of skin tests for platinum salts and pemetrexed in the treatment of patients with non-small cell lung cancers or malignant pleural mesothelioma. METHODS: A single-centre retrospective study was performed for 2 years. Patients treated with the drugs of interest for an advanced or metastatic non-small cell lung cancers or malignant pleural mesothelioma and who experienced hypersensitivity reactions symptoms were eligible for this study. Clinical symptoms of hypersensitivity reactions, population characteristics and administered chemotherapy regimens were identified. RESULTS: The hypersensitivity reactions frequency was rare (1.2%) and concerned 17 patients in our study. Typical clinical features of immediate hypersensitivity reactions associated with treatment were observed for nine patients (anaphylactic reactions for three cases, angioedema and hypotension associated with asthenia and heat in one case, respectively, and other cutaneous symptoms in the remaining four cases). Skin tests were positive in three patients, but only for platinum salts. The outcome after reintroduction of a negatively tested platinum salt allowed us to calculate a negative predictive value for platinum salt skin tests of 100%. For pemetrexed, skin tests were negative for all patients. WHAT IS NEW AND CONCLUSION: Skin tests could be used to diagnose hypersensitivity reactions with platinum salts or to evaluate the possibility of cross-reactions between two platinum salts. A negative skin test may predict with reasonable reliability the absence of future hypersensitivity reactions in case of reintroduction of drug infusion. Because the IgE-mediated mechanism has never been demonstrated for pemetrexed, skin tests are not valid and have no diagnostic value for this molecule. Because hypersensitivity reactions are potentially fatal adverse events, we recommend that patients who experience a hypersensitivity reactions onset should be monitored closely and clinicians must be aware of hypersensitivity reaction signs</style></abstract><notes><style face="normal" font="default">DA - 20171101IS - 1365-2710 (Electronic)IS - 0269-4727 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/jcpt.12645</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29092096">PM:29092096</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Pharm Ther\20171101-CapelleH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Pharm Ther\20171101-CapelleH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171101, Capelle H</style></custom2><misc3><style face="normal" font="default">10.1111/jcpt.12645</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43034</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhou,L.L.</style></author><author><style face="normal" font="default"> Pratt,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada2 Division of Dermatology, University of Ottawa, Ottawa, ON, Canada</style></auth-address><titles><title><style face="normal" font="default">Allergic Contact Cheilitis From a Variety of Lip Balm Ingredients</style></title><secondary-title><style face="normal" font="default">J Cutan Med Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Cutan Med Surg</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="10" Year="2017">2017/10/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 1615-7109 (Electronic)IS - 1203-4754 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1177/1203475417738969</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29039219">PM:29039219</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Cutan Med Surg\20171017-ZhouLL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Cutan Med Surg\20171017-ZhouLL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Zhou LL</style></custom2><misc3><style face="normal" font="default">10.1177/1203475417738969</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43035</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Steuer,A.B.</style></author><author><style face="normal" font="default"> Scherl,S.</style></author><author><style face="normal" font="default"> Ashinoff,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Autoimmune Progesterone Dermatitis: A Diagnosis to Consider in a Patient With Cyclical Cutaneous Eruptions</style></title><secondary-title><style face="normal" font="default">J Drugs Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Drugs Dermatol</style></full-title></periodical><pages end="1042" start="1040">1040-1042</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="10" Year="2017">2017/10/1</year></dates><abstract><style face="normal" font="default">Autoimmune progesterone dermatitis (APD) is a cyclical cutaneous reaction to progesterone, with symptoms that typically begin 3-10 days before the onset of menstrual flow and end 1-2 days into menses. The symptoms vary in severity from barely visible to anaphylaxis, but most often include an eczematous eruption, erythema multiforme, urticaria, folliculitis, and angioedema. This is a rare disorder with only a handful of documented cases. The pathogenesis of this condition remains unknown and significant variations in the presentation and severity of symptoms complicates its diagnosis. Treatment seeks to inhibit progesterone secretion through suppression of ovulation, but it may be unsuccessful. We present a case of autoimmune progesterone dermatitis that eluded diagnosis for several years, and subsequently the patient was completely controlled with oral contraceptive pills. &lt;p>&lt;em>J Drugs Dermatol. 2017;16(10):1040-1042.&lt;/em>&lt;/p></style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 1545-9616 (Print)IS - 1545-9616 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29036259">PM:29036259</url></web-urls></urls><custom2><style face="normal" font="default">20171016, Steuer AB</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43036</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jang,E.</style></author><author><style face="normal" font="default"> Nguyen,Q.T.</style></author><author><style face="normal" font="default"> Kim,S.</style></author><author><style face="normal" font="default"> Kim,D.</style></author><author><style face="normal" font="default"> Le,T.H.N.</style></author><author><style face="normal" font="default"> Keslar,K.</style></author><author><style face="normal" font="default"> Dvorina,N.</style></author><author><style face="normal" font="default"> Aronica,M.A.</style></author><author><style face="normal" font="default"> Min,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195</style></auth-address><titles><title><style face="normal" font="default">Lung-Infiltrating Foxp3+ Regulatory T Cells Are Quantitatively and Qualitatively Different during Eosinophilic and Neutrophilic Allergic Airway Inflammation but Essential To Control the Inflammation</style></title><secondary-title><style face="normal" font="default">J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="default">Understanding functions of Foxp3+ regulatory T cells (Tregs) during allergic airway inflammation remains incomplete. In this study, we report that, during cockroach Ag-induced allergic airway inflammation, Foxp3+ Tregs are rapidly mobilized into the inflamed lung tissues. However, the level of Treg accumulation in the lung was different depending on the type of inflammation. During eosinophilic airway inflammation, approximately 30% of lung-infiltrating CD4 T cells express Foxp3, indicative of Tregs. On the contrary, only approximately 10% of infiltrating CD4 T cells express Foxp3 during neutrophilic airway inflammation. Despite the different accumulation, the lung inflammation and inflammatory T cell responses were aggravated following Treg depletion, regardless of the type of inflammation, suggesting regulatory roles for Tregs. Interestingly, however, the extent to which inflammatory responses are aggravated by Treg depletion was significantly greater during eosinophilic airway inflammation. Indeed, lung-infiltrating Tregs exhibit phenotypic and functional features associated with potent suppression. Our results demonstrate that Tregs are essential regulators of inflammation, regardless of the type of inflammation, although the mechanisms used by Tregs to control inflammation may be shaped by environmental cues available to them</style></abstract><notes><style face="normal" font="default">DA - 20171102IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.4049/jimmunol.1700211</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29093062">PM:29093062</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Immunol\20171102-JangE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Immunol\20171102-JangE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171102, Jang E</style></custom2><misc3><style face="normal" font="default">10.4049/jimmunol.1700211</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43037</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sasso,O.</style></author><author><style face="normal" font="default"> Summa,M.</style></author><author><style face="normal" font="default"> Armirotti,A.</style></author><author><style face="normal" font="default"> Pontis,S.</style></author><author><style face="normal" font="default"> De Mei,C.</style></author><author><style face="normal" font="default"> Piomelli,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Drug Discovery and Development, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genova, Italy</style></auth-address><titles><title><style face="normal" font="default">The N-acylethanolamine acid amidase inhibitor ARN077 suppresses inflammation and pruritus in a mouse model of allergic dermatitis</style></title><secondary-title><style face="normal" font="default">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Invest Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="10" Year="2017">2017/10/17</year></dates><abstract><style face="normal" font="default">N-acylethanolamine acid amidase (NAAA), a cysteine hydrolase highly expressed in macrophages and B-lymphocytes, catalyzes the degradation of palmitoylethanolamide (PEA). PEA is an agonist of peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and an important regulator of pain and innate immunity. In the present study, we investigated the properties of the NAAA inhibitor, ARN077, in a mouse model of allergic contact dermatitis. Acute topical applications of ARN077 attenuated key signs of DNFB-induced dermatitis in a dose-dependent manner. Moreover, ARN077 increased tissue PEA content and normalized circulating levels of cytokines and immunoglobulin E. No such effect was seen in PPAR-alpha-deficient mice. Moreover, mice lacking NAAA failed to develop edema or scratching behavior after challenge with DNFB, confirming that this enzyme plays an important role in dermatitis. Consistent with this conclusion, subchronic applications of ARN077 suppressed DNFB-induced inflammation when administered either before or after the DNFB challenge. The effects of subchronic ARN077 were dose-dependent and comparable in size to those produced by the steroids clobetasol and dexamethasone. Unlike the latter, however, ARN077 did not cause skin atrophy. The results identify NAAA as a promising target for the development of effective and safe treatments for atopic dermatitis and other inflammatory disorders of the skin</style></abstract><notes><style face="normal" font="default">DA - 20171021IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticleCO - Italy -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jid.2017.07.853</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29054595">PM:29054595</url></web-urls></urls><custom2><style face="normal" font="default">20171021, Sasso O</style></custom2><misc3><style face="normal" font="default">10.1016/j.jid.2017.07.853</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43038</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bruhs,A.</style></author><author><style face="normal" font="default"> Proksch,E.</style></author><author><style face="normal" font="default"> Schwarz,T.</style></author><author><style face="normal" font="default"> Schwarz,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergology, University Kiel, 24105 Kiel, Germany</style></auth-address><titles><title><style face="normal" font="default">Disruption of the epidermal barrier induces regulatory T cells via IL-33 in mice</style></title><secondary-title><style face="normal" font="default">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Invest Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="15" Month="10" Year="2017">2017/10/15</year></dates><abstract><style face="normal" font="default">Disturbance of the epidermal barrier by UV radiation (UVR) is associated with the release of antimicrobial peptides and inflammatory cytokines for the purpose of a danger response. On the other hand, UVR causes immunosuppression via regulatory T cells (Treg) which limit the inflammatory reaction. The concurrent induction of antimicrobial peptides and Treg by UVR may represent a counter-regulatory mechanism in response to barrier disruption, preventing microbial superinfection and sensitization to contact allergens, respectively, both of which cross impaired epidermis more easily. Thus, using a model of murine contact hypersensitivity (CHS) we examined if disruption of the epidermal barrier only initiates similar counter-regulatory mechanisms via generation of Treg. Sensitization through tape-stripped skin induced a weaker CHS response than in control mice. This was due to the induction of antigen-specific Treg, as demonstrated in adoptive transfer and depletion experiments utilizing DEREG mice. Treg induction by tape stripping was linked to the expression of the alarmin IL-33, as blockade of IL-33 exacerbated CHS, while injection of IL-33 inhibited CHS and induced Treg. These results demonstrate that epidermal barrier disruption, in addition to danger signals, induces regulatory events that prevent exaggerated skin inflammation and that IL-33 appears to be critically involved in this process</style></abstract><notes><style face="normal" font="default">DA - 20171018IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jid.2017.09.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29045819">PM:29045819</url></web-urls></urls><custom2><style face="normal" font="default">20171018, Bruhs A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jid.2017.09.032</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43039</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Habernau,M.A.</style></author><author><style face="normal" font="default"> Del Pozo Abejon,V.</style></author><author><style face="normal" font="default"> Rodriguez Vidigal,F.F.</style></author><author><style face="normal" font="default"> Bobadilla,G.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departament of Biomedical Sciences, University Hospital, Badajoz, Spain</style></auth-address><titles><title><style face="normal" font="default">Role of Periostin in Uncontrolled Asthma in Children (DADO study)</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="298" start="291">291-298</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVE: Asthma is the most common chronic disease in children. Cases of severe asthma (SA) are underdiagnosed. Periostin is a biomarker for SA in adults, but its role in children is poorly understood. Objectives: The aims of the study were to estimate the percentage of cases of uncontrolled severe asthma (UcSA) in children with poorly controlled asthma and to evaluate the role of periostin as a biomarker. MATERIAL AND METHODS: We performed an observational study in children aged 5 to 14 years with poorly controlled asthma. Demographic and clinical data were collected in addition to the results of the lung function test, the fraction of exhaled nitric oxide, the skin prick test, total IgE, specific IgE, blood eosinophil count, serum periostin, treatment, asthma control, and quality of life. Variables were compared between the group with UcSA and the other children. RESULTS: Fifty children with poorly controlled asthma (72% male) were included. Nineteen children (38%) had UcSA. Most children had limitations in their activities of daily living and had visited the emergency department. In addition, 38% were hospitalized. Quality of life was poor. Only 42% of the children received appropriate treatment. The UcSA group was more likely to have a total IgE >500 kUA/mL (52.6% vs 19%, P=.02) and less likely to have serum periostin >1000 ng/mL (31.2% vs 63%, P=.04). CONCLUSIONS: In our setting, 38% of children with poorly controlled asthma have UcSA, which is associated with higher levels of total serum IgE and lower levels of serum periostin</style></abstract><notes><style face="normal" font="default">DA - 20170127IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0144</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28128098">PM:28128098</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Pharm Ther\2017-27-291-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Pharm Ther\2017-27-291-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170127, Habernau MA</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0144</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43040</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Okazaki,S.</style></author><author><style face="normal" font="default"> Murai,H.</style></author><author><style face="normal" font="default"> Kidoguchi,S.</style></author><author><style face="normal" font="default"> Nomura,E.</style></author><author><style face="normal" font="default"> Itoh,N.</style></author><author><style face="normal" font="default"> Hashimoto,N.</style></author><author><style face="normal" font="default"> Hamada,T.</style></author><author><style face="normal" font="default"> Kawakita,A.</style></author><author><style face="normal" font="default"> Yasutomi,M.</style></author><author><style face="normal" font="default"> Ohshima,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Faculty of Medial Sciences, University of Fukui, Fukui, Japan</style></auth-address><titles><title><style face="normal" font="default">The Biomarker Salivary SP-D May Indicate Small Airway Inflammation and Asthma Exacerbation</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="312" start="305">305-312</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Noninvasive and child-friendly biomarkers are important tools for understanding the various phenotypes of childhood asthma. Objective: The aim of this study was to examine the usefulness of salivary surfactant protein (SP) D in assessing the pathophysiology of childhood asthma. METHODS: We measured salivary concentrations of SP-D and forced oscillation technique (FOT) indexes in 19 healthy controls and 21 asthmatic children. Regression equations for the predictive values of FOT indexes were generated from healthy controls. We analyzed the correlations between salivary SP-D concentration and percentages of the predictive values of FOT indexes, as well as the severity of exacerbation. RESULTS: We found that salivary SP-D levels were higher in asthmatic children than in healthy controls. In the asthmatic children, salivary SP-D levels correlated with the percentages of predicted differences in resistance between 5 Hz and 20 Hz (%R5-R20), which represented the resistance of peripheral airways, and with the severity of asthma exacerbation. CONCLUSIONS: Salivary SP-D may reflect asthmatic inflammation in peripheral small airways and may be a useful marker for monitoring the degree of exacerbation in childhood asthma</style></abstract><notes><style face="normal" font="default">DA - 20170606IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0174</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28585516">PM:28585516</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Pharm Ther\2017-27-305-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Pharm Ther\2017-27-305-12.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170606, Okazaki S</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0174</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43041</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Solano-Solares,E.</style></author><author><style face="normal" font="default"> Madrigal-Burgaleta,R.</style></author><author><style face="normal" font="default"> Carpio-Escalona,L.V.</style></author><author><style face="normal" font="default"> Bernal-Rubio,L.</style></author><author><style face="normal" font="default"> Berges-Gimeno,M.P.</style></author><author><style face="normal" font="default"> Alvarez-Cuesta,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Division, Ramon y Cajal University Hospital, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Chemotherapy in Mastocytosis: Administration Issues, Hypersensitivity, and Rapid Drug Desensitization</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="317" start="315">315-317</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171023IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0171</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29057738">PM:29057738</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Pharm Ther\2017-27-313-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Pharm Ther\2017-27-313-35.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171023, Solano-Solares E</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0171</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43042</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mendez Alcalde,J.D.</style></author><author><style face="normal" font="default"> Cabrerizo Ballesteros,S.</style></author><author><style face="normal" font="default"> Garcia Villamuza,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Unidad de Alergologia, Hospital Rio Carrion, Palencia, SpainUnidad de Alergologia, Hospital Rio Carrion, Palencia, SpainUnidad de Alergologia, Hospital Rio Carrion, Palencia, Spain</style></auth-address><titles><title><style face="normal" font="default">Palpebral Edema and Eosinophilia</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="331" start="330">330-331</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171023IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0183</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29057745">PM:29057745</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Pharm Ther\2017-27-313-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Pharm Ther\2017-27-313-35.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171023, Mendez Alcalde JD</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0183</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43043</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pasic,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric Immunology, Mother and Child Health Institute, School of Medicine, University of Belgrade, Serbia</style></auth-address><titles><title><style face="normal" font="default">Reversible Hypogammaglobulinemia in 2 Pediatric Patients With Primary Immunodeficiency</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="321" start="320">320-321</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171023IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Serbia -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0173</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29057740">PM:29057740</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Pharm Ther\2017-27-313-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Pharm Ther\2017-27-313-35.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171023, Pasic S</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0173</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43044</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Machado,A.M.</style></author><author><style face="normal" font="default"> Pires,R.M.</style></author><author><style face="normal" font="default"> Martins,R.O.</style></author><author><style face="normal" font="default"> Grumach,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Medicine ABC, Santo Andre, Brazil</style></auth-address><titles><title><style face="normal" font="default">Pregnancy and Postpartum in Hereditary Angioedema With C1 Inhibitor Deficit in Women Who Have No Access to Therapy</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="323" start="322">322-323</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171023IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0175</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29057741">PM:29057741</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Pharm Ther\2017-27-313-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Pharm Ther\2017-27-313-35.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171023, Machado AM</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0175</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43045</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gomez,T.E.</style></author><author><style face="normal" font="default"> Cortina de la Calle,M.P.</style></author><author><style face="normal" font="default"> Mendez,D.Y.</style></author><author><style face="normal" font="default"> Moreno,L.L.</style></author><author><style face="normal" font="default"> Extremera,O.A.</style></author><author><style face="normal" font="default"> Galindo Bonilla,P.A.</style></author><author><style face="normal" font="default"> Alfaya,A.T.</style></author><author><style face="normal" font="default"> Garcia,R.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Section, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain</style></auth-address><titles><title><style face="normal" font="default">Acute Localized Exanthematous Pustulosis Due to Bemiparin</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="329" start="328">328-329</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171023IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0181</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29057744">PM:29057744</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Pharm Ther\2017-27-313-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Pharm Ther\2017-27-313-35.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171023, Gomez TE</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0181</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43046</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Munjal,A.</style></author><author><style face="normal" font="default"> Al-Sabban,A.</style></author><author><style face="normal" font="default"> Bull-Henry,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Georgetown University Hospital, Washington, DC, USA</style></auth-address><titles><title><style face="normal" font="default">Eosinophilic Enteritis: A Delayed Diagnosis</style></title><secondary-title><style face="normal" font="default">J Investig Med High Impact Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Med High Impact Case Rep</style></full-title></periodical><pages end="" start="2324709617734246">2324709617734246-</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Eosinophilic gastrointestinal disorders are a rare and complex group of disorders that are characterized by eosinophilic infiltration of the gastrointestinal tract. Patients often present with a wide range of signs and symptoms as any length or layer of the GI tract can be involved such as mucosal, muscular, or serosal. As a part of the workup, patients frequently undergo computed tomography scans and multiple endoscopies before the diagnosis is finally made as was true in our case of a 59-year-old male patient presenting with 2 months of nausea, abdominal pain, and weight loss. He underwent esophagogastroduodenoscopies, colonoscopies, video capsule study, and balloon enteroscopy before the diagnosis was confirmed histologically. Endoscopic and radiographic findings can be variable and are usually unpredictable. The diagnosis is confirmed on histopathological examination of biopsies that must show >15-50 eosinophils/high-power field based on the location in the GI tract. In our patient, erythema, scalloping, whitish exudate, and patches of villous blunting were noted in the duodenum to proximal ileum endoscopically with >50 eosinophils/high-power field confirming the diagnosis of eosinophilic enteritis. This class of diseases is often found in patients with a history of allergic disorders suggestive of hypersensitivity in the etiology of the disease although our patient had no such known history. Elimination diets and steroids are the mainstay of therapy and often lead to complete resolution of symptoms as well as endoscopic and radiographic findings in up to 90% of patients as was seen in our patient, although some patients have a chronic remitting course</style></abstract><notes><style face="normal" font="default">DA - 20171020IS - 2324-7096 (Print)IS - 2324-7096 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/2324709617734246</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29051893">PM:29051893</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Med High Impact Case Rep\2017-5-2324709617734246.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Med High Impact Case Rep\2017-5-2324709617734246.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171020, Munjal A</style></custom2><misc3><style face="normal" font="default">10.1177/2324709617734246</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43047</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Geier,D.A.</style></author><author><style face="normal" font="default"> Kern,J.K.</style></author><author><style face="normal" font="default"> Geier,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">a The Institute of Chronic Illnesses, Inc , 14 Redgate Ct , Silver Spring , Maryland , USA</style></auth-address><titles><title><style face="normal" font="default">Demographic and neonatal risk factors for childhood asthma in the USA</style></title><secondary-title><style face="normal" font="default">J Matern Fetal Neonatal Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Matern Fetal Neonatal Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Asthma is the most common chronic condition diagnosed among children worldwide according to the World Health Organization (WHO). This study evaluated on a longitudinal basis prospectively collected medical records for demographic and neonatal information among USA (USA) children diagnosed with childhood asthma in comparison to controls. DESIGN: The vaccine safety data link (VSD) database was examined to identify cases (n = 5907) diagnosed with International Classification of Disease, ninth revision (ICD-9) healthcare provider diagnosed childhood asthma (493.xx) and controls (n = 11 662). PATIENTS: All cases and controls were health maintenance organization (HMO)-enrolled from birth until diagnosis or sufficient time to ensure that they were unlikely to receive a diagnosis, respectively. MAIN OUTCOME MEASURES: Child's gestational age in weeks at birth, birth weight in grams, maternal age in years at birth, Appearance-Pulse-Grimace-Activity-Respiration (APGAR) score at 1 minute and 5 minutes, gender, and race. RESULTS: The study results revealed childhood asthma was diagnosed significantly more frequently among males than females, and significantly more frequently among minority populations (Black > Hispanic > Native American > Asian) than White populations. Cases diagnosed with childhood asthma had significantly decreased mean values for the following neonatal risk factors: gestational age, maternal age, birth weight, and Apgar scores at 1 and 5 minutes in comparison to controls. CONCLUSION: This study offers healthcare providers important demographic and neonatal factors significantly associated with childhood asthma, and should help aid in the early diagnosis and treatment of childhood asthma</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 1476-4954 (Electronic)IS - 1476-4954 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/14767058.2017.1393068</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29034748">PM:29034748</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Matern Fetal Neonatal Med\20171016-GeierDA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Matern Fetal Neonatal Med\20171016-GeierDA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171016, Geier DA</style></custom2><misc3><style face="normal" font="default">10.1080/14767058.2017.1393068</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43048</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McCallister,A.</style></author><author><style face="normal" font="default"> So,T.Y.</style></author><author><style face="normal" font="default"> Stewart,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacy (AM, T-YS), Moses H. Cone Memorial Hospital, Greensboro, North Carolina, University of North Carolina at Chapel Hill Eshelman School of Pharmacy (JS), Chapel Hill, North Carolina</style></auth-address><titles><title><style face="normal" font="default">Evaluation of the Efficacy of a Onetime Injectable Dexamethasone Administered Orally in the Pediatric Emergency Department for Asthma Exacerbation</style></title><secondary-title><style face="normal" font="default">J Pediatr Pharmacol Ther</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Pediatr Pharmacol Ther</style></abbr-1></periodical><pages end="331" start="326">326-331</pages><volume><style face="normal" font="default">22</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">OBJECTIVE: This study assessed the efficacy of injectable dexamethasone administered orally in pediatric patients who presented to the emergency department with asthma exacerbation. METHODS: This was a retrospective study of patients 0 to 18 years of age who presented to and who were directly discharged from the emergency department at Moses H. Cone Memorial Hospital between September 1, 2012, and September 30, 2015, for the diagnosis of asthma or asthma exacerbation. Patients had to receive a onetime dose of injectable dexamethasone orally prior to discharge. Patients were followed for a 30-day period to identify the number of asthma relapses. RESULTS: Ninety-nine patients were included in this study. The average weight-based dose +/- SD of dexamethasone was 0.35 +/- 0.18 mg/kg (range, 0.08-0.62 mg/kg) and the actual dose +/- SD was 10.58 +/- 1.92 mg (range, 5-16 mg). Over a 30-day period, 6 patients (6%) had one repeated emergency department visit, 6 patients (6%) were admitted to the hospital, and 3 patients (3%) presented to an outpatient clinic for asthma-related symptoms. CONCLUSIONS: Injectable dexamethasone administered orally may be an efficacious treatment for asthma exacerbation in pediatric patients. A randomized control trial comparing injectable dexamethasone administered orally to other dexamethasone formulations/routes of administration should be performed to adequately assess the bioequivalence and effectiveness of the former formulation</style></abstract><notes><style face="normal" font="default">DA - 20171018IS - 1551-6776 (Print)IS - 1551-6776 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.5863/1551-6776-22.5.326</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29042832">PM:29042832</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Pediatr Pharmacol Ther\2017-22-326-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Pediatr Pharmacol Ther\2017-22-326-31.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171018, McCallister A</style></custom2><misc3><style face="normal" font="default">10.5863/1551-6776-22.5.326</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43049</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rochman,M.</style></author><author><style face="normal" font="default"> Travers,J.</style></author><author><style face="normal" font="default"> Abonia,J.P.</style></author><author><style face="normal" font="default"> Caldwell,J.M.</style></author><author><style face="normal" font="default"> Rothenberg,M.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Synaptopodin is upregulated by IL-13 in eosinophilic esophagitis and regulates esophageal epithelial cell motility and barrier integrity</style></title><secondary-title><style face="normal" font="default">JCI Insight</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">JCI Insight</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="default">Eosinophilic esophagitis (EoE) is an allergic inflammatory disease of the esophagus mediated by an IL-13-driven epithelial cell transcriptional program. Herein, we show that the cytoskeletal protein synaptopodin (SYNPO), previously associated with podocytes, is constitutively expressed in esophageal epithelium and induced during allergic inflammation. In addition, we show that the SYNPO gene is transcriptionally and epigenetically regulated by IL-13 in esophageal epithelial cells. SYNPO was expressed in the basal layer of homeostatic esophageal epithelium, colocalized with actin filaments, and expanded into the suprabasal epithelium in EoE patients, where expression was elevated 25-fold compared with control individuals. The expression level of SYNPO in esophageal biopsies correlated with esophageal eosinophil density and was improved following anti-IL-13 treatment in EoE patients. In esophageal epithelial cells, SYNPO gene silencing reduced epithelial motility in a wound healing model, whereas SYNPO overexpression impaired epithelial barrier integrity and reduced esophageal differentiation. Taken together, we demonstrate that SYNPO is induced by IL-13 in vitro and in vivo, is a nonredundant regulator of epithelial cell barrier function and motility, and is likely involved in EoE pathogenesis</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 2379-3708 (Electronic)IS - 2379-3708 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1172/jci.insight.96789</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29046486">PM:29046486</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JCI Insight\20171019-RochmanM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JCI Insight\20171019-RochmanM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Rochman M</style></custom2><misc3><style face="normal" font="default">10.1172/jci.insight.96789</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43050</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Park,S.H.</style></author><author><style face="normal" font="default"> Im,M.J.</style></author><author><style face="normal" font="default"> Eom,S.Y.</style></author><author><style face="normal" font="default"> Hahn,Y.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Medical Research Institute, Chungbuk National University College of Medicine, Cheongju, Korea</style></auth-address><titles><title><style face="normal" font="default">Accuracy of maximal expiratory flow-volume curve curvilinearity and fractional exhaled nitric oxide for detection of children with atopic asthma</style></title><secondary-title><style face="normal" font="default">Korean J Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Korean J Pediatr</style></abbr-1></periodical><pages end="295" start="290">290-295</pages><volume><style face="normal" font="default">60</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">PURPOSE: Airway pathology in children with atopic asthma can be reflected by the concave shape of the maximal expiratory flow-volume (MEFV) curve and high fractional exhaled nitric oxide (FeNO) values. We evaluated the capacity of the curvilinearity of the MEFV curve, FeNO, and their combination to distinguish subjects with atopic asthma from healthy individuals. METHODS: FeNO and angle beta, which characterizes the general configuration of the MEFV curve, were determined in 119 steroid-naive individuals with atopic asthma aged 8 to 16 years, and in 92 age-matched healthy controls. Receiver operating characteristic (ROC) curve analyses were performed to determine the cutoff points of FeNO and angle beta that provided the best combination of sensitivity and specificity for asthma detection. RESULTS: Asthmatic patients had a significantly smaller angle beta and higher FeNO compared with healthy controls (both, P&lt;0.001). For asthma detection, the best cutoff values of angle beta and FeNO were observed at 189.3 degrees and 22 parts per billion, respectively. The area under the ROC curve for the combination of angle beta and FeNO improved to 0.91 (95% confidence interval [CI], 0.87-0.95) from 0.80 (95% CI, 0.75-0.86; P&lt;0.001) for angle beta alone and 0.86 (95% CI, 0.82-0.91; P=0.002) for FeNO alone. In addition, the combination enhanced sensitivity with no significant decrease in specificity. CONCLUSION: These data suggest that the combined use of the curvilinearity of the MEFV curve and FeNO is a useful tool to differentiate between children with and without atopic asthma</style></abstract><notes><style face="normal" font="default">DA - 20171018IS - 1738-1061 (Print)IS - 1738-1061 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.3345/kjp.2017.60.9.290</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29042872">PM:29042872</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Korean J Pediatr\2017-60-290-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Korean J Pediatr\2017-60-290-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171018, Park SH</style></custom2><misc3><style face="normal" font="default">10.3345/kjp.2017.60.9.290</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43051</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bush,A.</style></author><author><style face="normal" font="default"> Saglani,S.</style></author><author><style face="normal" font="default"> Fleming,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Heart and Lung Institute, Imperial College London, London, UK; Royal Brompton Hospital, London SW3 6NP, UK.</style></auth-address><titles><title><style face="normal" font="default">Severe asthma: looking beyond the amount of medication</style></title><secondary-title><style face="normal" font="default">Lancet Respir Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Lancet Respir Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="10" Year="2017">2017/10/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 2213-2619 (Electronic)IS - 2213-2600 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/S2213-2600(17)30379-X</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29031948">PM:29031948</url></web-urls></urls><custom2><style face="normal" font="default">20171016, Bush A</style></custom2><misc3><style face="normal" font="default">10.1016/S2213-2600(17)30379-X</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43052</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Puxeddu,I.</style></author><author><style face="normal" font="default"> Pratesi,F.</style></author><author><style face="normal" font="default"> Ribatti,D.</style></author><author><style face="normal" font="default"> Migliorini,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy</style></auth-address><titles><title><style face="normal" font="default">Mediators of Inflammation and Angiogenesis in Chronic Spontaneous Urticaria: Are They Potential Biomarkers of the Disease?</style></title><secondary-title><style face="normal" font="default">Mediators Inflamm</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Mediators Inflamm</style></full-title></periodical><pages end="" start="4123694">4123694-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">In chronic spontaneous urticaria (CSU), different pathophysiological mechanisms, potentially responsible for the development of the disease, have been recently described. It is likely that the activation of skin mast cells with consequent release of histamine and other proinflammatory mediators is responsible for vasodilation in the lesional skin of CSU. However, the underlying causes of mast cell activation in the disease are largely unknown and remain to be identified. Thus, in this review, we discuss new insights in the pathogenesis of CSU, focusing on inflammation and angiogenesis. The understanding of these mechanisms will enable the identification of biomarkers useful for the diagnosis, follow-up, and management of CSU and will allow the development of novel, more specific, and patient-tailored therapies</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 1466-1861 (Electronic)IS - 0962-9351 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1155/2017/4123694</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29038618">PM:29038618</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mediators Inflamm\2017-2017-4123694.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mediators Inflamm\2017-2017-4123694.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Puxeddu I</style></custom2><misc3><style face="normal" font="default">10.1155/2017/4123694</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43053</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Saraya,T.</style></author><author><style face="normal" font="default"> Kimura,H.</style></author><author><style face="normal" font="default"> Kurai,D.</style></author><author><style face="normal" font="default"> Ishii,H.</style></author><author><style face="normal" font="default"> Takizawa,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">aKyorin University School of Medicine, Department of Respiratory Medicine, Mitaka City bInfectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">The molecular epidemiology of respiratory viruses associated with asthma attacks: A single-center observational study in Japan</style></title><secondary-title><style face="normal" font="default">Medicine (Baltimore)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Medicine (Baltimore)</style></abbr-1></periodical><pages end="" start="e8204">e8204-</pages><volume><style face="normal" font="default">96</style></volume><number><style face="normal" font="default">42</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Few reports have described the significance of viral respiratory infections (VRIs) in exacerbation of asthma in adult patients. The aim of this study was to elucidate the profiles of VRIs in adult patients with asthma along with their molecular epidemiology.A cross-sectional observational study was conducted at Kyorin University Hospital from August 2012 to May 2015. To identify respiratory pathogens in inpatients and outpatients suffering from asthma attacks, RT-PCR/sequencing/phylogenetic analysis methods were applied alongside conventional microbiological methods. Phylogenetic and pairwise distance analyses of 10 viruses were performed.A total of 106 asthma attack patients enrolled in this study in both inpatient (n = 49) and outpatient (n = 57) settings. The total 106 respiratory samples were obtained from nasopharyngeal swab (n = 68) or sputum (n = 38). Among these, patients with virus alone (n = 39), virus and bacterial (n = 5), and bacterial alone (n = 5) were identified. The ratio of virus-positive patients in inpatient or outpatient to the total cases were 31.1% (n = 33) and 10.4% (n = 11), respectively. The frequency of virus-positive patients was significantly higher in inpatients (75.3%, n = 33) than in outpatients (19.3%, n = 11). Major VRIs included human rhinovirus (HRV) (n = 24), human metapneumovirus (hMPV) (n = 9), influenza virus (Inf-V) (n = 8), and respiratory syncytial virus (RSV) (n = 3) infections with seasonal variations. HRV-A and HRV-C were the most commonly detected viruses, with wide genetic divergence on phylogenetic analysis.Asthmatic exacerbations in adults are highly associated with VRIs such as HRV-A or HRV-C, hMPV, RSV, and Inf-V infections with seasonal variations and genetic divergence, but similar frequencies of VRIs occurred in asthma attack patients throughout the seasons</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 1536-5964 (Electronic)IS - 0025-7974 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1097/MD.0000000000008204</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29049206">PM:29049206</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Medicine (Baltimore)\2017-96-E8204.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Medicine (Baltimore)\2017-96-E8204.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Saraya T</style></custom2><misc3><style face="normal" font="default">10.1097/MD.0000000000008204</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43054</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Potter,T.M.</style></author><author><style face="normal" font="default"> Neun,B.W.</style></author><author><style face="normal" font="default"> Dobrovolskaia,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cancer Research Technology Program, Nanotechnology Characterization Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, P.O. Box B, Frederick, MD, 21702, USAmarina@mail.nih.gov</style></auth-address><titles><title><style face="normal" font="default">In Vitro and In Vivo Methods for Analysis of Nanoparticle Potential to Induce Delayed-Type Hypersensitivity Reactions</style></title><secondary-title><style face="normal" font="default">Methods Mol Biol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Methods Mol Biol</style></abbr-1></periodical><pages end="210" start="197">197-210</pages><volume><style face="normal" font="default">1682</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="default">Delayed-type hypersensitivity (DTH) reactions are among the common reasons for drug withdrawal from clinical use during the post-marketing stage. Several in vivo methods have been developed to test DTH responses in animal models. They include the local lymph node assay (LLNA) and local lymph node proliferation assay (LLNP). While LLNA is instrumental in testing topically administered formulations (e.g., creams), the LLNP was proven to be predictive of drug-mediated DTH in response to small molecule pharmaceuticals. Global efforts in reducing the use of research animals lead to the development of in vitro models to predict test-material-mediated DTH. Two such models include analysis of surface marker expression in human cell lines THP-1 and U-937. These tests are known as the human cell line activation test (hCLAT) and myeloid U937 skin sensitization test (MUSST or U-SENS), respectively. Here we describe experimental procedures for all these methods, discuss their in vitro-in vivo correlation, and suggest a strategy for applying these tests to analyze engineered nanomaterials and nanotechnology-formulated drug products</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/978-1-4939-7352-1_17</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29039104">PM:29039104</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Methods Mol Biol\2018-1682-210.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Methods Mol Biol\2018-1682-210.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Potter TM</style></custom2><misc3><style face="normal" font="default">10.1007/978-1-4939-7352-1_17</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43055</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Neun,B.W.</style></author><author><style face="normal" font="default"> Ilinskaya,A.N.</style></author><author><style face="normal" font="default"> Dobrovolskaia,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cancer Research Technology Program, Nanotechnology Characterization Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, P.O. Box B, Frederick, MD, 21702, USAmarina@mail.nih.gov</style></auth-address><titles><title><style face="normal" font="default">Analysis of Complement Activation by Nanoparticles</style></title><secondary-title><style face="normal" font="default">Methods Mol Biol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Methods Mol Biol</style></abbr-1></periodical><pages end="160" start="149">149-160</pages><volume><style face="normal" font="default">1682</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="default">The complement system is a group of proteins, which function in plasma to assist the innate immunity in rapid clearance of pathogens. The complement system also contributes to coordination of the adaptive immune response. Complement Activation Related Pseudo Allergy or CARPA is a life-threatening condition commonly reported with certain types of drugs and nanotechnology-based combination products. While CARPA symptoms are similar to that of anaphylaxis, the mechanism behind this pathology does not involve IgE and is mediated by the complement system. In vitro assays using serum or plasma derived from healthy donor volunteers correlate with the in vivo complement-mediated reactions, and therefore are helpful in understanding the propensity of a given drug formulation to cause CARPA in patients. In the first edition of this book, we have described an in vitro method for qualitative assessment of the complement activation by nanomaterials using western blotting. Herein, we present a similar method utilizing enzyme-linked immunoassay for quantitative analysis of the complement activation, and we compare the performance of this approach to that of the qualitative western blotting technique. The revised chapter also includes new details about nanoparticle sample preparation</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 1940-6029 (Electronic)IS - 1064-3745 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/978-1-4939-7352-1_13</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29039100">PM:29039100</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Methods Mol Biol\2018-1682-149-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Methods Mol Biol\2018-1682-149-60.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Neun BW</style></custom2><misc3><style face="normal" font="default">10.1007/978-1-4939-7352-1_13</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43056</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fang,F.</style></author><author><style face="normal" font="default"> Pan,J.</style></author><author><style face="normal" font="default"> Li,Y.</style></author><author><style face="normal" font="default"> Li,Y.</style></author><author><style face="normal" font="default"> Feng,X.</style></author><author><style face="normal" font="default"> Wang,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Pediatric Research, Children's Hospital of Soochow University, 92 Zhongnan Street, Suzhou 215025, China.</style></auth-address><titles><title><style face="normal" font="default">Identification of potential transcriptomic markers in developing asthma: An integrative analysis of gene expression profiles</style></title><secondary-title><style face="normal" font="default">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Mol Immunol</style></full-title></periodical><pages end="44" start="38">38-44</pages><volume><style face="normal" font="default">92</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="default">The goal of this study was to identify potential transcriptomic markers in developing asthma by an integrative analysis of multiple public microarray data sets. Using the R software and bioconductor packages, we performed a statistical analysis to identify differentially expressed (DE) genes in asthma, and further performed functional interpretation (enrichment analysis and co-expression network construction) and classification quality evaluation of the DE genes identified. 3 microarray datasets (192 cases and 91 controls in total) were collected for this analysis. 62 DE genes were identified in asthma, among which 43 genes were up-regulated and 19 genes were down-regulated. The up-regulated gene with the highest Log2 Fold Change (LFC) was CLCA1 (LFC=2.81). The down-regulated gene with the highest absolute LFC was BPIFA1 (LFC=-1.45). Enrichment analysis revealed that those DE genes strongly associated with proteolysis, retina homeostasis, humoral immune response, and salivary secretion. A support vector machine classifier (asthma versus healthy control) was also trained based on DE genes. In conclusion, the consistently DE genes identified in this study are suggested as candidate transcriptomic markers for asthma diagnosis, and provide novel insights into the pathogenesis of asthma</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 1872-9142 (Electronic)IS - 0161-5890 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.molimm.2017.09.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29031950">PM:29031950</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mol Immunol\2017-92-38-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mol Immunol\2017-92-38-44.pdf</url></text-urls><related-urls><url ppv-ref="no">xlsx in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20171016, Fang F</style></custom2><misc3><style face="normal" font="default">10.1016/j.molimm.2017.09.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43057</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Xiong,J.</style></author><author><style face="normal" font="default"> Zhao,W.Q.</style></author><author><style face="normal" font="default"> Huang,G.H.</style></author><author><style face="normal" font="default"> Yao,L.H.</style></author><author><style face="normal" font="default"> Dong,H.M.</style></author><author><style face="normal" font="default"> Yu,C.H.</style></author><author><style face="normal" font="default"> Zhao,H.J.</style></author><author><style face="normal" font="default"> Cai,S.X.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Chronic Airway Diseases, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.</style></auth-address><titles><title><style face="normal" font="default">[Receptor for advanced glycation end products upregulates MUC5AC expression and promotes mucus overproduction in mice with toluene diisocyanate-induced asthma]</style></title><secondary-title><style face="normal" font="default">Nan Fang Yi Ke Da Xue Xue Bao</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Nan Fang Yi Ke Da Xue Xue Bao</style></full-title></periodical><pages end="1307" start="1301">1301-1307</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="10" Year="2017">2017/10/20</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To explore the role of the receptor for advanced glycation end products (RAGE) in regulating the expression of MUC5AC and mucus production in a mouse model of toluene diisocyanate (TDI)?induced asthma. METHODS: BALB/c mice were randomly divided into control group, vehicle (AOO) group, TDI?induced asthma group and RAGE inhibitor (FPS?ZM1) group. PAS staining, Western blotting, and immunohistochemistry were used to analyze the changes in mucus production and MUC5AC expression in the airway of the mice, and the expression of p?ERK was detected with Western blotting. In vitro cultured human bronchial epithelial cell line 16HBE was transfected with lentiviral vector carrying short hairpin RNA targeting RAGE (shRNA?RAGE) and subsequently challenged with a TDI?human serum albumin (TDI-HSA) conjugate, and the changes in cellular MUC5AC mRNA expression as detected using RT-PCR; the protein expressions of ERK and p?ERK in the cells were examined with Western blotting. The effect of ERK inhibitor U0126 pretreatment on MUC5AC mRNA expression was also analyzed in the cells. RESULTS: Compared with the control mice, TDI-induced asthmatic mice showed significantly higher rates of PAS positivity and increased MUC5AC and p?ERK expressions in the airway (P&lt;0.05). Treatment with FPS?ZM1 significantly decreased PAS positivity and lowered MUC5AC and p?ERK expressions in the airway of the asthmatic mice (P&lt;0.05). Exposure of 16HBE cells to TDI?HSA caused a significant increase in MUC5AC mRNA expression and p?ERK protein expression (P&lt;0.05), while RAGE knockdown obviously suppressed TDI?HSA-induced upregulation of p-ERK and MUC5AC mRNA (P&lt;0.05). Treatment with the ERK inhibitor U0126 also lowered TDI?HSA?induced up?regulation of MUC5AC mRNA in the cells (P&lt;0.05). CONCLUSION: RAGE signaling induces MUC5AC expression via extracellular signal-regulated kinase pathway to promote mucus overproduction in mice with TDI-induced asthma</style></abstract><notes><style face="normal" font="default">DA - 20171026IS - 1673-4254 (Print)IS - 1673-4254 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29070458">PM:29070458</url></web-urls></urls><custom2><style face="normal" font="default">20171026, Xiong J</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43058</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ferreira,M.A.</style></author><author><style face="normal" font="default"> Vonk,J.M.</style></author><author><style face="normal" font="default"> Baurecht,H.</style></author><author><style face="normal" font="default"> Marenholz,I.</style></author><author><style face="normal" font="default"> Tian,C.</style></author><author><style face="normal" font="default"> Hoffman,J.D.</style></author><author><style face="normal" font="default"> Helmer,Q.</style></author><author><style face="normal" font="default"> Tillander,A.</style></author><author><style face="normal" font="default"> Ullemar,V.</style></author><author><style face="normal" font="default"> van Dongen,J.</style></author><author><style face="normal" font="default"> Lu,Y.</style></author><author><style face="normal" font="default"> Ruschendorf,F.</style></author><author><style face="normal" font="default"> Esparza-Gordillo,J.</style></author><author><style face="normal" font="default"> Medway,C.W.</style></author><author><style face="normal" font="default"> Mountjoy,E.</style></author><author><style face="normal" font="default"> Burrows,K.</style></author><author><style face="normal" font="default"> Hummel,O.</style></author><author><style face="normal" font="default"> Grosche,S.</style></author><author><style face="normal" font="default"> Brumpton,B.M.</style></author><author><style face="normal" font="default"> Witte,J.S.</style></author><author><style face="normal" font="default"> Hottenga,J.J.</style></author><author><style face="normal" font="default"> Willemsen,G.</style></author><author><style face="normal" font="default"> Zheng,J.</style></author><author><style face="normal" font="default"> Rodriguez,E.</style></author><author><style face="normal" font="default"> Hotze,M.</style></author><author><style face="normal" font="default"> Franke,A.</style></author><author><style face="normal" font="default"> Revez,J.A.</style></author><author><style face="normal" font="default"> Beesley,J.</style></author><author><style face="normal" font="default"> Matheson,M.C.</style></author><author><style face="normal" font="default"> Dharmage,S.C.</style></author><author><style face="normal" font="default"> Bain,L.M.</style></author><author><style face="normal" font="default"> Fritsche,L.G.</style></author><author><style face="normal" font="default"> Gabrielsen,M.E.</style></author><author><style face="normal" font="default"> Balliu,B.</style></author><author><style face="normal" font="default"> Nielsen,J.B.</style></author><author><style face="normal" font="default"> Zhou,W.</style></author><author><style face="normal" font="default"> Hveem,K.</style></author><author><style face="normal" font="default"> Langhammer,A.</style></author><author><style face="normal" font="default"> Holmen,O.L.</style></author><author><style face="normal" font="default"> Loset,M.</style></author><author><style face="normal" font="default"> Abecasis,G.R.</style></author><author><style face="normal" font="default"> Willer,C.J.</style></author><author><style face="normal" font="default"> Arnold,A.</style></author><author><style face="normal" font="default"> Homuth,G.</style></author><author><style face="normal" font="default"> Schmidt,C.O.</style></author><author><style face="normal" font="default"> Thompson,P.J.</style></author><author><style face="normal" font="default"> Martin,N.G.</style></author><author><style face="normal" font="default"> Duffy,D.L.</style></author><author><style face="normal" font="default"> Novak,N.</style></author><author><style face="normal" font="default"> Schulz,H.</style></author><author><style face="normal" font="default"> Karrasch,S.</style></author><author><style face="normal" font="default"> Gieger,C.</style></author><author><style face="normal" font="default"> Strauch,K.</style></author><author><style face="normal" font="default"> Melles,R.B.</style></author><author><style face="normal" font="default"> Hinds,D.A.</style></author><author><style face="normal" font="default"> Hubner,N.</style></author><author><style face="normal" font="default"> Weidinger,S.</style></author><author><style face="normal" font="default"> Magnusson,P.K.E.</style></author><author><style face="normal" font="default"> Jansen,R.</style></author><author><style face="normal" font="default"> Jorgenson,E.</style></author><author><style face="normal" font="default"> Lee,Y.A.</style></author><author><style face="normal" font="default"> Boomsma,D.I.</style></author><author><style face="normal" font="default"> Almqvist,C.</style></author><author><style face="normal" font="default"> Karlsson,R.</style></author><author><style face="normal" font="default"> Koppelman,G.H.</style></author><author><style face="normal" font="default"> Paternoster,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia</style></auth-address><titles><title><style face="normal" font="default">Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology</style></title><secondary-title><style face="normal" font="default">Nat Genet</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nat Genet</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="10" Year="2017">2017/10/30</year></dates><abstract><style face="normal" font="default">Asthma, hay fever (or allergic rhinitis) and eczema (or atopic dermatitis) often coexist in the same individuals, partly because of a shared genetic origin. To identify shared risk variants, we performed a genome-wide association study (GWAS; n = 360,838) of a broad allergic disease phenotype that considers the presence of any one of these three diseases. We identified 136 independent risk variants (P &lt; 3 x 10-8), including 73 not previously reported, which implicate 132 nearby genes in allergic disease pathophysiology. Disease-specific effects were detected for only six variants, confirming that most represent shared risk factors. Tissue-specific heritability and biological process enrichment analyses suggest that shared risk variants influence lymphocyte-mediated immunity. Six target genes provide an opportunity for drug repositioning, while for 36 genes CpG methylation was found to influence transcription independently of genetic effects. Asthma, hay fever and eczema partly coexist because they share many genetic risk variants that dysregulate the expression of immune-related genes</style></abstract><notes><style face="normal" font="default">DA - 20171030IS - 1546-1718 (Electronic)IS - 1061-4036 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - Netherland -CO - Germany -CO - United States -CO - Sweden -CO - Norway -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1038/ng.3985</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29083406">PM:29083406</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nat Genet\20171030-FerreiraMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nat Genet\20171030-FerreiraMA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171030, Ferreira MA</style></custom2><misc3><style face="normal" font="default">10.1038/ng.3985</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43059</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jeong,H.J.</style></author><author><style face="normal" font="default"> Nam,S.Y.</style></author><author><style face="normal" font="default"> Kim,H.Y.</style></author><author><style face="normal" font="default"> Jin,M.H.</style></author><author><style face="normal" font="default"> Kim,M.H.</style></author><author><style face="normal" font="default"> Roh,S.S.</style></author><author><style face="normal" font="default"> Kim,H.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Food Science &amp; Technology and Research Institute for Basic Science , Hoseo University , Asan , Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Anti-allergic inflammatory effect of vanillic acid through regulating thymic stromal lymphopoietin secretion from activated mast cells</style></title><secondary-title><style face="normal" font="default">Nat Prod Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nat Prod Res</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="default">Vanillic acid, which is well known as a benzoic acid derivative, has been used as a flavouring agent. Currently, we ascertained the therapeutic potential action of vanillic acid on allergic inflammatory reaction in human mast cell line, HMC-1. Treatment with vanillic acid resulted in a significant decrease in levels of thymic stromal lymphopoietin and pro-inflammatory cytokines compared to phorbol 12-myristate 13-acetate and calcium ionophore A23187 (PMACI)-treated HMC-1 cells. In PMACI-stimulated cells, treatment with vanillic acid also dramatically inhibited activities of caspase-1 and nuclear factor-kB (p65). Furthermore, treatment with vanillic acid suppressed phosphorylation of mitogen-activated protein kinases in PMACI-treated HMC-1 cells. Taken together, these findings suggest that vanillic acid has a beneficial effect on allergic inflammatory disorders</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 1478-6427 (Electronic)IS - 1478-6419 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1080/14786419.2017.1389938</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29034737">PM:29034737</url></web-urls><related-urls><url ppv-ref="no">presto - 18 mesi</url></related-urls></urls><custom2><style face="normal" font="default">20171016, Jeong HJ</style></custom2><misc3><style face="normal" font="default">10.1080/14786419.2017.1389938</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43060</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rafeeq,M.M.</style></author><author><style face="normal" font="default"> Murad,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacology, Faculty of Medicine, Rabigh Campus, King Abdulaziz University, Jeddah, Saudi ArabiaDepartment of Pharmacology, Faculty of Medicine, Rabigh Campus, King Abdulaziz University, Jeddah, Saudi Arabia</style></auth-address><titles><title><style face="normal" font="default">Evaluation of drug utilization pattern for patients of bronchial asthma in a government hospital of Saudi Arabia</style></title><secondary-title><style face="normal" font="default">Niger J Clin Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Niger J Clin Pract</style></abbr-1></periodical><pages end="1105" start="1098">1098-1105</pages><volume><style face="normal" font="default">20</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Bronchial asthma is a social and economic healthcare burden. Drug utilization studies are important tools to assess current prescription practices against standard guidelines and help in rationalizing the management. MATERIALS AND METHODS: This retrospective cross-sectional study was designed to evaluate the pattern of drug utilization in bronchial asthma patients in a government hospital of Saudi Arabia. Retrospective prescribing information of patients of all ages and both sexes diagnosed with bronchial asthma being treated with at least one of the anti-asthmatic medications was utilized. Demographic details, brand/generic name, indication, route, dosage, frequency, and date of starting the drug were recorded. Prescriptions were examined for order, number, and therapeutic class of drugs in addition to poly-pharmacy and appropriateness. Patients having other respiratory disorders such as chronic obstructive pulmonary disorder (COPD), bronchitis, emphysema, or any comorbidity such as diabetes, hypertension, and peptic ulcer were excluded. The Statistical Package for the Social Sciences was used for statistical analysis. RESULTS: A total of 380 prescriptions were studied. Patients were aged from 4 months to 79 years, with 55.3% males and 44.7% females. Pediatric prescriptions were 47.4%. Bronchodilators followed by steroids were the most common drug groups. Salbutamol and budesonide were the most common from each group, respectively. 89.5% of the patients were having at least two drugs. Number of drugs per prescription averaged 3.18 +/- 1.22, however, no correlation was found between different age groups and number of drugs. 61.3% drugs were administered by inhalational route and 34.8% by oral route. Approximately 77.2% prescriptions were found to be appropriate. CONCLUSION: Prescription pattern was mainly in accordance with standard guidelines with some knowledge and technical gaps in prescription writing methodology</style></abstract><notes><style face="normal" font="default">DA - 20171026IS - 1119-3077 (Print)LA - engPT - Journal ArticleCO - Saudi Arabia -</style></notes><work-type><style face="normal" font="default">10.4103/njcp.njcp_378_16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29072231">PM:29072231</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Niger J Clin Pract\2017-20-1098-105.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Niger J Clin Pract\2017-20-1098-105.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171026, Tafeeq MM</style></custom2><misc3><style face="normal" font="default">10.4103/njcp.njcp_378_16</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43061</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vandenplas,O.</style></author><author><style face="normal" font="default"> Rifflart,C.</style></author><author><style face="normal" font="default"> Evrard,G.</style></author><author><style face="normal" font="default"> Thimpont,J.</style></author><author><style face="normal" font="default"> Seed,M.</style></author><author><style face="normal" font="default"> Agius,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Universite Catholique de Louvain, Yvoir B-5530, Belgium</style></auth-address><titles><title><style face="normal" font="default">Occupational asthma caused by an epoxy amine hardener</style></title><secondary-title><style face="normal" font="default">Occup Med (Lond)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Occup Med (Lond)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="default">We describe a 43-year-old epoxy floor layer who developed work-related asthma while exposed to an epoxy hardener based on isophorone diamine (IPDA). Challenge exposures to the curing of the epoxy resin system and subsequently to the polyfunctional amine hardener containing IPDA both elicited delayed asthmatic reactions. This report further indicates that exposure to epoxy hardeners containing polyfunctional amines should be considered as a potential cause of occupational asthma. Appropriate work hygiene measures should be implemented to minimize airborne exposure to these volatile compounds</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 1471-8405 (Electronic)IS - 0962-7480 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1093/occmed/kqx151</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29040709">PM:29040709</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Occup Med (Lond)\20171017-VandenplasO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Occup Med (Lond)\20171017-VandenplasO.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Vandenplas O</style></custom2><misc3><style face="normal" font="default">10.1093/occmed/kqx151</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43062</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sood,A.B.</style></author><author><style face="normal" font="default"> Pearce,W.A.</style></author><author><style face="normal" font="default"> Workowski,K.A.</style></author><author><style face="normal" font="default"> Lockwood,J.</style></author><author><style face="normal" font="default"> Yeh,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Ophthalmology , Harvard Medical School, Massachusetts Eye and Ear Infirmary , Boston , Massachusetts , USA</style></auth-address><titles><title><style face="normal" font="default">Combined Intravitreal and Systemic Antibiotic Therapy in a Patient with Syphilitic Uveitis</style></title><secondary-title><style face="normal" font="default">Ocul Immunol Inflamm</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ocul Immunol Inflamm</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="10" Year="2017">2017/10/20</year></dates><abstract><style face="normal" font="default">PURPOSE: To report the novel use of combined intravitreal and systemic antibiotic therapy in a patient with syphilitic panuveitis and discuss the management of ocular syphilis. METHODS: Case report Results: A 45-year old heterosexual male with human immunodeficiency virus (HIV) presented with 1 month of blurry vision in both eyes. Clinical examination revealed a bilateral panuveitis. The patient denied history of genital lesions or rash, but did complain of difficulty hearing bilaterally. Treponemal EIA was positive, the RPR titer greater than 1:512 dilution, and CSF VDRL 1:4. A diagnosis of neurosyphilis and ocular syphilis was made based on the clinical and laboratory findings. The patient was admitted for systemic intravenous antibiotic therapy, but was noted to have a penicillin allergy. Intravitreal ceftazidime was promptly administered bilaterally to achieve treponemacidal levels of antibiotic therapy. After penicillin desensitization protocol, the patient received 14 days of intravenous penicillin with clinical resolution. CONCLUSIONS: There are increasing reports of ocular syphilis in the United States and delay in diagnosis and management can lead to severe visual impairment and blindness. We report the first case of adjunct intravitreal antibiotic therapy in a penicillin allergic patient. As ocular syphilis is a form of bacterial endophthalmitis, combination intravitreal and systemic antibiotics may be considered</style></abstract><notes><style face="normal" font="default">DA - 20171020IS - 1744-5078 (Electronic)IS - 0927-3948 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/09273948.2017.1385817</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29053397">PM:29053397</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ocul Immunol Inflamm\20171020-SoodAB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ocul Immunol Inflamm\20171020-SoodAB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171020, Sood AB</style></custom2><misc3><style face="normal" font="default">10.1080/09273948.2017.1385817</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43063</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Maxfield,A.Z.</style></author><author><style face="normal" font="default"> Landegger,L.D.</style></author><author><style face="normal" font="default"> Brook,C.D.</style></author><author><style face="normal" font="default"> Lehmann,A.E.</style></author><author><style face="normal" font="default"> Campbell,A.P.</style></author><author><style face="normal" font="default"> Bergmark,R.W.</style></author><author><style face="normal" font="default"> Stankovic,K.M.</style></author><author><style face="normal" font="default"> Metson,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Division of Otolaryngology, Brigham and Women's Hospital, Boston, Massachusetts, USA</style></auth-address><titles><title><style face="normal" font="default">Periostin as a Biomarker for Nasal Polyps in Chronic Rhinosinusitis</style></title><secondary-title><style face="normal" font="default">Otolaryngol Head Neck Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Otolaryngol Head Neck Surg</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="10" Year="2017">2017/10/1</year></dates><abstract><style face="normal" font="default">Objective Periostin is an extracellular matrix protein that is elevated in the sinonasal tissues of patients with chronic rhinosinusitis (CRS). The purpose of this study was to determine whether serum periostin could serve as a molecular biomarker of nasal polyp burden in sinonasal disease. Study Design Prospective cohort study. Setting Academic medical center. Subjects and Methods Serum periostin levels were measured by ELISA on blood samples collected from patients undergoing sinus surgery for CRS (n = 71), further stratified by phenotype as defined by nasal polyps and asthma. Results were compared with assays performed on control subjects (n = 62). Results Mean serum periostin levels were markedly elevated in patients with CRS versus controls (66.1 ng/mL [95% CI, 51.6-80.6] vs 38.7 ng/mL [95% CI, 34.4-42.9], respectively, P = .004). In addition, mean periostin levels were significantly higher in CRS patients with nasal polyps as compared with those without polyps (94.8 ng/mL [95% CI, 67.3-122.4] vs 41.1 ng/mL [95% CI, 35.2-47.0], respectively, P &lt; .001). Periostin levels did not correlate with sex ( P = .473), smoking history ( P = .748), aspirin-exacerbated respiratory disease status ( P = .136), oral steroid use within 1 month of surgery ( P = .281), use of topical steroid nasal spray ( P = .864), or number of prior sinus operations ( P = .973). Conclusion Serum periostin appears to be a novel molecular biomarker for the presence of nasal polyps and may serve as an indicator of CRS endotypes</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 1097-6817 (Electronic)IS - 0194-5998 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/0194599817737967</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29040053">PM:29040053</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Otolaryngol Head Neck Surg\20171017-MaxfieldAZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Otolaryngol Head Neck Surg\20171017-MaxfieldAZ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Maxfield AZ</style></custom2><misc3><style face="normal" font="default">10.1177/0194599817737967</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43064</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,M.</style></author><author><style face="normal" font="default"> Chen,Z.</style></author><author><style face="normal" font="default"> Yang,Y.</style></author><author><style face="normal" font="default"> Cheng,H.</style></author><author><style face="normal" font="default"> Li,C.</style></author><author><style face="normal" font="default"> He,Q.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Oncology, Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, China</style></auth-address><titles><title><style face="normal" font="default">Pretreatment with different doses of dexamethasone in the prevention of docetaxel-induced hypersensitivity</style></title><secondary-title><style face="normal" font="default">Pak J Pharm Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pak J Pharm Sci</style></abbr-1></periodical><pages end="65" start="61">61-65</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Administration,Oral</style></keyword><keyword><style face="normal" font="default"> Adolescent</style></keyword><keyword><style face="normal" font="default"> Adult</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Anti-Allergic Agents</style></keyword><keyword><style face="normal" font="default"> administration &amp; dosage</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Antineoplastic Agents</style></keyword><keyword><style face="normal" font="default"> China</style></keyword><keyword><style face="normal" font="default"> Dexamethasone</style></keyword><keyword><style face="normal" font="default"> Drug Administration Schedule</style></keyword><keyword><style face="normal" font="default"> Drug Hypersensitivity</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> prevention &amp; control</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Taxoids</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Treatment Outcome</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="0" Month="1" Year="2017">2017/1</year></dates><abstract><style face="normal" font="default">This study aimed to evaluate the efficacy and safety of dexamethasone pretreatment regimen with different doses in the prevention of docetaxel-induced hypersensitivity reaction (HSR). One hundred and sixty-two patients who had malignant tumors as determined by histology and/or cytology and received docetaxel treatments at least 2 cycles, were randomized into two groups. There were 90 patients in the study group and 72 patients in the control group. In the study group, patients received 4.5mg of oral dexamethasone once a day. Patients in the control group received 8 mg of dexamethasone twice a day. All patients received dexamethasone for 3 days, from the day before docetaxel treatment to the day after docetaxel treatment. The endpoints were hypersensitivity reaction (HSR) and other adverse effects, which were determined according to common terminology criteria for adverse event v3.0 (CTCAE 3.0). In the study group, 10 patients had HSRs (11.1%). While in the control group, 7 patients had HSRs (9.7%), and the main clinical symptoms of HSR were rash (3.1%), fever/chill (2.5%), angioedema (1.9%), chest discomfort (1.9%) and hypotension (0.6%). There was no statistically significant difference between these two groups (P=0.774). There was no significant difference in the incidence rate of adverse effect between patients in the study group and in the control group. Those adverse effects included neutropenia, decreased hemoglobin, nausea, vomiting, fatigue and fluid retention. Since no significant difference in the HSR incidence between these two groups has been found, 4.5mg of dexamethasone (qd) is as efficient and safe as 8mg (bid)</style></abstract><notes><style face="normal" font="default">DA - 20170612IS - 1011-601X (Print)IS - 1011-601X (Linking)LA - engPT - Journal ArticlePT - Randomized Controlled TrialRN - 0 (Anti-Allergic Agents)RN - 0 (Antineoplastic Agents)RN - 0 (Taxoids)RN - 15H5577CQD (docetaxel)RN - 7S5I7G3JQL (Dexamethasone)SB - IMCO - China -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28603114">PM:28603114</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pak J Pharm Sci\2017-30-61-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pak J Pharm Sci\2017-30-61-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170612, Zhang M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43065</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Landgraf-Rauf,K.</style></author><author><style face="normal" font="default"> Boeck,A.</style></author><author><style face="normal" font="default"> Raedler,D.</style></author><author><style face="normal" font="default"> Klucker,E.</style></author><author><style face="normal" font="default"> Vogelsang,V.</style></author><author><style face="normal" font="default"> Schmidt,S.</style></author><author><style face="normal" font="default"> Kunze,S.</style></author><author><style face="normal" font="default"> Weissenbacher,C.</style></author><author><style face="normal" font="default"> Graessel,A.</style></author><author><style face="normal" font="default"> Schmidt-Weber,C.</style></author><author><style face="normal" font="default"> von Mutius,E.</style></author><author><style face="normal" font="default"> Schedel,M.</style></author><author><style face="normal" font="default"> Schaub,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">University Children's Hospital Munich, Department of Pulmonary &amp; Allergy, LMU, Munich, Germany</style></auth-address><titles><title><style face="normal" font="default">IRF-1 SNPs influence the risk for childhood allergic asthma: a critical role for pro-inflammatory immune regulation</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic and non-allergic childhood asthma has been characterized by distinct immune mechanisms. While interferon regulating factor 1 (IRF-1) polymorphisms (SNPs) influence atopy risk, the effect of SNPs on asthma phenotype-specific immune mechanisms is unclear. We assessed whether IRF-1 SNPs modify distinct immune regulatory pathways in allergic and non-allergic childhood asthma (AA/NA). METHODS: In the CLARA study, asthma was characterized by doctor's diagnosis and AA vs NA by positive or negative specific IgE. Children were genotyped for four tagging SNPs within IRF-1 (n=172). mRNA expression was measured with qRT-PCR. Gene expression was analyzed depending on genetic variants within IRF-1 and phenotype including haplotype estimation and an allelic risk-score. RESULTS: Carrying the risk alleles of IRF-1 in rs10035166, rs2706384 or rs2070721 was associated with increased risk for AA. Carrying the non-risk allele in rs17622656 was associated with lower risk for AA but not NA. In AA carrying the risk alleles, an increased pro-inflammatory expression of ICAM3, IRF-8, XBP-1, IFN-gamma, RGS13, RORC, and TSC2 was observed. NOD2 expression was decreased in AA with risk alleles in rs2706384 and rs10035166 and with risk-haplotype. Further, AA with risk-haplotype showed increased IL-13 secretion. NA with risk allele in rs2070721 compared to non-risk allele in rs17622656 showed significantly upregulated calcium, innate, mTOR, neutrophil and inflammatory associated genes. CONCLUSION: IRF-1 polymorphisms influence the risk for childhood allergic asthma being associated with increased pro-inflammatory gene-regulation. Thus, it is critical to implement IRF-1 genetics in immune assessment for childhood asthma phenotypes. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12821</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29047170">PM:29047170</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171019-LandgrafRaufK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171019-LandgrafRaufK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Landgraf-Rauf K</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12821</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43066</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wong,G.W.</style></author><author><style face="normal" font="default"> Li,J.</style></author><author><style face="normal" font="default"> Bao,Y.X.</style></author><author><style face="normal" font="default"> Wang,J.Y.</style></author><author><style face="normal" font="default"> Leung,T.F.</style></author><author><style face="normal" font="default"> Li,L.L.</style></author><author><style face="normal" font="default"> Shao,J.</style></author><author><style face="normal" font="default"> Huang,X.Y.</style></author><author><style face="normal" font="default"> Liu,E.M.</style></author><author><style face="normal" font="default"> Kun-Ling,S.</style></author><author><style face="normal" font="default"> Yu-Zhi,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Paediatrics, Prince of Wales Hospital Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region</style></auth-address><titles><title><style face="normal" font="default">Pediatric allergy and immunology in China</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="default">Over the past thirty years, China has enjoyed rapid economic development along with urbanization at a massive scale that the world has not experienced before. Such development has also been associated with a rapid rise in the prevalence of allergic disorders. Because of the large childhood population in the country, the burden of childhood allergic disorders has become one of the major challenges in the health care system. Among the Chinese centers participating in the International Study of Asthma and Allergies in Childhood clearly, the data showed a continuing rise in the prevalence of asthma, allergic rhinitis and atopic eczema. However, the discipline of pediatric allergy in mainland China is still in it's infancy due to the lack of formal training program and subspecialty certification. Clinicians and researchers are increasingly interested in providing better care for patients with allergies by establishing pediatric allergy centers in different regions of the country. Many of them have also participated in national or international collaborative projects hoping to answer the various research questions related to the discipline of pediatric allergy and immunology. It is our hope that the research findings from China will not only improve the quality of care of affected children within this country but also the millions of patients with allergies worldwide. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Hong Kong -CO - China -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12819</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29047174">PM:29047174</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171019-WongGW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171019-WongGW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Wong GW</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12819</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43067</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lezmi,G.</style></author><author><style face="normal" font="default"> Alrowaishdi,F.</style></author><author><style face="normal" font="default"> Bados-Albiero,A.</style></author><author><style face="normal" font="default"> Scheinmann,P.</style></author><author><style face="normal" font="default"> de Blic,J.</style></author><author><style face="normal" font="default"> Ponvert,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">AP-HP, Hopital Necker-Enfants Malades, service de pneumologie et d'allergologie pediatriques, Paris, France</style></auth-address><titles><title><style face="normal" font="default">Non-immediate-reading skin tests and prolonged challenges in non-immediate hypersensitivity to beta-lactams in children</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: A minority of children reporting non-immediate reactions to beta-lactams (BLs) are allergic. Allergy workup usually includes late-reading (48-72h) skin tests (ST) and short (1-3 days) drug provocation tests (DPT), regardless of the chronology of the index reaction. The sensitivity of hyper-late-reading (>/= 6-7 days) ST and of prolonged DPT for the diagnosis of non-immediate hypersensitiviy to BLs are yet to be determined. OBJECTIVES: To establish the diagnostic values of late- and hyper-late-reading ST and of prolonged DPT in children reporting non-immediate reactions to BLs. METHODS: Prospective assessment of children reporting non-immediate reactions to BLs with late- and additional hyper-late-reading intradermal (ID) and patch-tests, and if negative, with prolonged DPT. RESULTS: Five hundred and fifty children reporting reactions to a single or several BLs (674 suspected BLs) were included. Non-immediate hypersensitivity to BLs was diagnosed in 63 children (11.5%), reporting 66 reactions (9.8%), based on responses in ST (n = 17, 25.8% : 5 to ID, 8 to patch-tests, and 4 to both tests), DPT (n = 43, 65.2%), and clinical history (n = 6, 9.1%), including 3/9 children with severe cutaneous adverse reactions. Skin test positivity was observed after the 6th -7th day in 14/17 children, and DPT positivity after a median time of 3 days. No severe reaction was observed after ST or during prolonged DPT. CONCLUSION: Additional hyper-late-reading of ST enhanced their positivity. However their overall sensitivity remained weak, especially in non-severe cases. Prolonged DPT are safe and may improve the performance of DPT in the diagnosis of non-immediate hypersensitivity to BLs. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12826</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29047169">PM:29047169</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171019-LezmiG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171019-LezmiG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Lezmi G</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12826</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43068</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Keskin,O.</style></author><author><style face="normal" font="default"> Arik,Y.E.</style></author><author><style face="normal" font="default"> Motzkus,C.</style></author><author><style face="normal" font="default"> Sackesen,C.</style></author><author><style face="normal" font="default"> Lilly,C.M.</style></author><author><style face="normal" font="default"> Kalayci,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Gaziantep University School of Medicine, Department of Pediatric Allergy, Gaziantep, Turkey</style></auth-address><titles><title><style face="normal" font="default">The effect of montelukast on early life wheezing: a randomized, double-blinded placebo-controlled study</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: Cysteinyl-leukotrienes are increased in the airways of infants with virus-associated wheezing. We aimed to determine the effects of a cysteinyl-leukotriene-1 receptor antagonist on symptoms during an early-life wheezing illness and to investigate the factors that affect the response to this drug. METHOD: This placebo-controlled double-blinded randomized controlled trial recruited children aged 3-36 months with wheezing illness and randomized to active drug or placebo for 56 days. A symptom score diary (SSD) was kept by the children's caregivers. RESULTS: One-hundred patients completed the study, and 62 (30 montelukast, 32 placebo) were analyzed. There were no significant differences in the percent of symptom-free days, symptom scores and the need for rescue salbutamol between the two groups. However, the percent of symptom-free days within the first week was significantly higher for the montelukast than for the placebo group (13.8+/-4.1% vs. 5.4+/-3.4%; p=0.028); wheezing score at 7th day was significantly lower for the montelukast than for the placebo group (0.5+/-0.1 vs. 1.4+/-0.2; p=0.002). In addition, the number of inhaled ss2 -agonist rescue episodes per day during the first week was significantly lower for the montelukast compared to the placebo group (12.7+/-1.8 vs. 19.2+/-1.6; p=0.013). CONCLUSIONS: Our results indicate that montelukast may be effective for reducing caregiver observed wheezing and the need for salbutamol during the first week of treatment for early-life wheezing. The impact for caregivers and the optimal duration of treatment will need to be explored in studies of larger size. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Turkey -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12822</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29047178">PM:29047178</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171019-KeskinO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171019-KeskinO.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Keskin O</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12822</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43069</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ben Mansour,A.</style></author><author><style face="normal" font="default"> Bellon,N.</style></author><author><style face="normal" font="default"> Frassati-Biaggi,A.</style></author><author><style face="normal" font="default"> Sermet-Gaudelus,I.</style></author><author><style face="normal" font="default"> Ponvert,C.</style></author><author><style face="normal" font="default"> de Blic,J.</style></author><author><style face="normal" font="default"> Lezmi,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">HP, Bechir Hamza hospital's Bab Saadoun, Tunisia</style></auth-address><titles><title><style face="normal" font="default">Multifocal Fixed Drug Eruption to ceftazidime in a child with cystic fibrosis</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="default">Fixed drug eruption (FDE) is a cutaneous adverse drug reaction characterized by well-delimited pigmented lesions of the skin and/or mucosa [1,2]. FDE is rare and frequently misdiagnosed leading to recurrent eruptions after the offending drug is re-administered [1,2]. The diagnosis hallmark is its recurrence in previously affected sites leading to a residual hyperpigmentation, however some cases without residual pigmentation have been described [2]. Many drugs have been shown to induce FDE, especially antibiotics and non-steroidal anti-inflammatory drugs (NSAIDs) [3]. To our knowledge, there is no report of FDE to ceftazidime. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Tunisia -CO - France -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12829</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29047164">PM:29047164</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171019-BenMansourA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171019-BenMansourA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Ben Mansour A</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12829</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43070</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sobkowiak,P.</style></author><author><style face="normal" font="default"> Wojsyk-Banaszak,I.</style></author><author><style face="normal" font="default"> Kowalewska,M.</style></author><author><style face="normal" font="default"> Wasilewska,E.</style></author><author><style face="normal" font="default"> Langwinski,W.</style></author><author><style face="normal" font="default"> Kycler,Z.</style></author><author><style face="normal" font="default"> Skibinska,M.</style></author><author><style face="normal" font="default"> Breborowicz,A.</style></author><author><style face="normal" font="default"> Jassem,E.</style></author><author><style face="normal" font="default"> Szczepankiewicz,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Paediatric Pulmonology, Allergy and Clinical Immunology, Laboratory of Molecular and Cell Biology, Poznan University of Medical Sciences, Pozna, Poland</style></auth-address><titles><title><style face="normal" font="default">Interleukin 1beta polymorphism and serum level are associated with pediatric asthma</style></title><secondary-title><style face="normal" font="default">Pediatr Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Pulmonol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="default">BACKGROUND AND AIM: Interleukin-1 is a pro-inflammatory cytokine found in two forms (alpha and beta). The alpha form is mainly cell-bound, whereas IL-1beta is primarily secreted by macrophages in response to immune system stimulation. We hypothesized that polymorphic variants of interleukin 1 genes may play a role in childhood asthma risk. The aim of this study was to investigate if IL-1alpha and beta polymorphism is associated with asthma in a pediatric population and if the genotype affects its serum level. METHODS: The studied population included 310 children aged 6-18 years old (152 with asthma and 158 healthy children). Genotypes were determined with real-time PCR method using TaqMan Genotyping Assays. Serum level was measured with ELISA Set. Statistical analysis was done in Statistica v.12.0. Linkage disequilibrium and haplotype analysis was done in Haploview v. 4.2. RESULTS: We found that three IL-1beta polymorphisms rs1143634, rs1143633, and rs1143643 were associated with allergic asthma risk (P = 0.034; OR = 1.523; P = 0.024, OR = 1.477; 0.044, OR = 1.420, respectively). We also found a strong linkage disequilibrium between these polymorphisms and CAC haplotype was associated significantly with asthma risk (P = 0.023). For IL1alpha, we did not observe association with asthma. We then analyzed if IL-1beta expression was altered in serum and we found that asthmatic children showed significantly higher IL-1beta levels than healthy controls (P = 0.047). No association with asthma was observed for IL-1 alpha variants. CONCLUSIONS: This study indicates that IL-1beta gene polymorphism may affect allergic asthma risk in children</style></abstract><notes><style face="normal" font="default">DA - 20171016IS - 1099-0496 (Electronic)IS - 1099-0496 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1002/ppul.23893</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29034996">PM:29034996</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Pulmonol\20171016-SobkowiakP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Pulmonol\20171016-SobkowiakP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171016, Sobkowiak P</style></custom2><misc3><style face="normal" font="default">10.1002/ppul.23893</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43071</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,S.Y.</style></author><author><style face="normal" font="default"> Sim,S.</style></author><author><style face="normal" font="default"> Choi,H.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology-Head &amp; Neck Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea</style></auth-address><titles><title><style face="normal" font="default">Atopic dermatitis is associated with active and passive cigarette smoking in adolescents</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0187453">e0187453-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The relationship between passive smoking and atopic dermatitis has previously been reported, but few studies have simultaneously evaluated the association of atopic dermatitis with active and passive smoking. METHODS: The relationships between atopic dermatitis and active and passive smoking were evaluated in Korean adolescents. We used a large, representative, population-based survey (The Korea Youth Risk Behavior Web-based Survey) conducted in 2011 and 2012. Active smoking was classified into 3 groups (0 days, 1-19 days, and >/= 20 days/month). Passive smoking was categorized into 3 groups (0 days, 1-4 days, and >/= 5 days/week). Atopic dermatitis diagnosed by a medical doctor either during the past 1 month or during the participant's lifetime was surveyed. Age, sex, obesity status, region of residence, economic level, and parental educational level of the participants were adjusted as confounders. Adjusted odds ratios (AORs) and 95% confidence intervals (CI) were calculated using multiple logistic regression analysis with complex sampling. RESULTS: A total of 6.8% (10,020/135,682) of the participants reported atopic dermatitis during the last 12 months. Active smoking was significantly associated with atopic dermatitis (previous 12 months) (AOR [95% CI] of smoking >/= 20 days/month = 1.18 [1.07-1.29]; 1-19 days/month = 1.11 [0.99-1.23], P = 0.002). Passive smoking was also related to atopic dermatitis (previous 12 months) (AOR [95% CI] of smoking >/= 5 days/week = 1.12 [1.05-1.20]; 1-4 days/week = 1.08 [1.03-1.13], P &lt; 0.001). CONCLUSION: Atopic dermatitis was significantly associated with active and passive smoking in Korean adolescents</style></abstract><notes><style face="normal" font="default">DA - 20171101IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0187453</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29091936">PM:29091936</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0187453.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0187453.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171101, Kim SY</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0187453</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43072</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kumar,P.</style></author><author><style face="normal" font="default"> Ram,U.</style></author></authors></contributors><auth-address><style face="normal" font="default">International Institute for Population Sciences, Mumbai, Maharashtra, IndiaDepartment of Public Health and Mortality Studies, International Institute for Population Sciences, Mumbai, Maharashtra, India</style></auth-address><titles><title><style face="normal" font="default">Patterns, factors associated and morbidity burden of asthma in India</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0185938">e0185938-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is a non-curable but preventable disease, responsible for higher morbidity worldwide. According to recent WHO report, nearly 235 million people are suffering from asthma leading to 383000 deaths in 2015. The burden of asthma morbidity is higher in developed countries and is increasing in developing countries. OBJECTIVE: The present study was aimed at studying the change in prevalence rate of asthma, associated risk factors and estimation of morbidity burden and avoidable cases of asthma in India. METHODS: The second round of Indian Human Development Survey (IHDS-II), 2011-12, was used for the study. For the present study, asthma was defines as ever diagnosed with asthma or having cough with short breath. Multiple-logistic regression was used to identify the possible risk factors associated with prevalence of reporting asthma. Population attributable fractions (PAFs) were computed to estimate the overall and risk factors specific burden of morbidity due to asthma using the extrapolated population of year 2015 using 2011 census. RESULTS: Overall prevalence rate of asthma increased from 41.9 (per 1000 population) in 2004-05 to 54.9 (per 1000 population) in 2011-12. The prevalence rate of reporting asthma was higher in poorer states compared to richer states, and also varied by sub-geographies, with higher prevalence rate in northern states of the country and lower rates in north-eastern states of the country. The odds of reporting asthma was higher for younger and older ages, individual with fewer years of schooling (OR: 1.41; 95% CI: 1.21-1.64) for individual with zero years of schooling compared to those with 11 or more years of schooling, individual from lower economic status, individual living in household using unclean fuels (OR:1.21; 95% CI: 1.08-1.34) and smokers (OR: 1.34; 95% CI: 1.17-1.55) compared to their counterparts. In the year 2015, the overall morbidity burden of asthma was estimated at nearly 65 million and more than 82 thousand deaths were attributed due to asthma. The burden was highest among individuals living in households using solid fuels (firewood~80%, Kerosene~78%). One-third of the cases could be eliminated by minimising the use of any solid fuels. Around 17% of all the asthma cases in population could be attributed to underweight. CONCLUSION: Eliminating the modifiable risk factors could help reduce in huge amount of asthma cases for example by providing education, cessation in smoking, and schemes like Pradhan Mantri Ujjwala Yojana (PMUY), by providing clean fuel (LPG) to poor and vulnerable households</style></abstract><notes><style face="normal" font="default">DA - 20171026IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0185938</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29073132">PM:29073132</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0185938.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0185938.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171026, Kumar P</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0185938</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43073</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oh,S.</style></author><author><style face="normal" font="default"> Yap,G.C.</style></author><author><style face="normal" font="default"> Hong,P.Y.</style></author><author><style face="normal" font="default"> Huang,C.H.</style></author><author><style face="normal" font="default"> Aw,M.M.</style></author><author><style face="normal" font="default"> Shek,L.P.</style></author><author><style face="normal" font="default"> Liu,W.T.</style></author><author><style face="normal" font="default"> Lee,B.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Civil Engineering, Kyung Hee University, Yongin-si, Gyeonggi-do, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Immune-modulatory genomic properties differentiate gut microbiota of infants with and without eczema</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0184955">e0184955-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Gut microbiota play an important role in human immunological processes, potentially affecting allergic diseases such as eczema. The diversity and structure of gut microbiota in infants with eczema have been previously documented. This study aims to evaluate by comparative metagenomics differences in genetic content in gut microbiota of infants with eczema and their matched controls. Stools were collected at the age of one month old from twelve infants from an at risk birth cohort in a case control manner. Clinical follow up for atopic outcomes were carried out at the age of 12 and 24 months. Microbial genomic DNA were extracted from stool samples and used for shotgun sequencing. Comparative metagenomic analysis showed that immune-regulatory TCAAGCTTGA motifs were significantly enriched in the six healthy controls (C) communities compared to the six eczema subjects (E), with many encoded by Bifidobacterium (38% of the total motifs in the C communities). Draft genomes of five Bifidobacterium species populations (B. longum, B. bifidum, B. breve, B. dentium, and B. pseudocatenulatum) were recovered from metagenomic datasets. The B. longum BFN-121-2 genome encoded more TCAAGCTTGA motifs (4.2 copies per one million genome sequence) than other Bifidobacterium genomes. Additionally, the communities in the stool of controls (C) were also significantly enriched in functions associated with tetrapyrrole biosynthesis compared to those of eczema (E). Our results show distinct immune-modulatory genomic properties of gut microbiota in infants associated with eczema and provide new insights into potential role of gut microbiota in affecting human immune homeostasis</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - South Korea -CO - Saudi Arabia -CO - Singapore -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0184955</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29049378">PM:29049378</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0184955.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0184955.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Oh S</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0184955</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43074</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wolsk,H.M.</style></author><author><style face="normal" font="default"> Chawes,B.L.</style></author><author><style face="normal" font="default"> Litonjua,A.A.</style></author><author><style face="normal" font="default"> Hollis,B.W.</style></author><author><style face="normal" font="default"> Waage,J.</style></author><author><style face="normal" font="default"> Stokholm,J.</style></author><author><style face="normal" font="default"> Bonnelykke,K.</style></author><author><style face="normal" font="default"> Bisgaard,H.</style></author><author><style face="normal" font="default"> Weiss,S.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default">Prenatal vitamin D supplementation reduces risk of asthma/recurrent wheeze in early childhood: A combined analysis of two randomized controlled trials</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0186657">e0186657-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: We recently published two independent randomized controlled trials of vitamin D supplementation during pregnancy, both indicating a >20% reduced risk of asthma/recurrent wheeze in the offspring by 3 years of age. However, neither reached statistical significance. OBJECTIVE: To perform a combined analysis of the two trials and investigate whether maternal 25-hydroxy-vitamin D (25(OH)D) level at trial entry modified the intervention effect. METHODS: VDAART (N = 806) and COPSAC2010. (N = 581) randomized pregnant women to daily high-dose vitamin D3 (4,000 IU/d and 2,400 IU/d, respectively) or placebo. All women also received a prenatal vitamin containing 400 IU/d vitamin D3. The primary outcome was asthma/recurrent wheeze from 0-3yrs. Secondary end-points were specific IgE, total IgE, eczema and lower respiratory tract infections (LRTI). We conducted random effects combined analyses of the treatment effect, individual patient data (IPD) meta-analyses, and analyses stratified by 25(OH)D level at study entry. RESULTS: The analysis showed a 25% reduced risk of asthma/recurrent wheeze at 0-3yrs: adjusted odds ratio (aOR) = 0.74 (95% CI, 0.57-0.96), p = 0.02. The effect was strongest among women with 25(OH)D level >/=30ng/ml at study entry: aOR = 0.54 (0.33-0.88), p = 0.01, whereas no significant effect was observed among women with 25(OH)D level &lt;30ng/ml at study entry: aOR = 0.84 (0.62-1.15), p = 0.25. The IPD meta-analyses showed similar results. There was no effect on the secondary end-points. CONCLUSIONS: This combined analysis shows that vitamin D supplementation during pregnancy results in a significant reduced risk of asthma/recurrent wheeze in the offspring, especially among women with 25(OH)D level >/= 30 ng/ml at randomization, where the risk was almost halved. Future studies should examine the possibility of raising 25(OH)D levels to at least 30 ng/ml early in pregnancy or using higher doses than used in our studies. TRIAL REGISTRATION: COPSAC2010: ClinicalTrials.gov NCT00856947; VDAART: ClinicalTrials.gov NCT00920621</style></abstract><notes><style face="normal" font="default">DA - 20171027IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0186657</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29077711">PM:29077711</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0186657.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0186657.pdf</url></text-urls><related-urls><url ppv-ref="no">pdf non unificabile in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20171027, Wolsk HM</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0186657</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43075</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Turturice,B.A.</style></author><author><style face="normal" font="default"> McGee,H.S.</style></author><author><style face="normal" font="default"> Oliver,B.</style></author><author><style face="normal" font="default"> Baraket,M.</style></author><author><style face="normal" font="default"> Nguyen,B.T.</style></author><author><style face="normal" font="default"> Ascoli,C.</style></author><author><style face="normal" font="default"> Ranjan,R.</style></author><author><style face="normal" font="default"> Rani,A.</style></author><author><style face="normal" font="default"> Perkins,D.L.</style></author><author><style face="normal" font="default"> Finn,P.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Division of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois at Chicago, Chicago, IL, United States of America</style></auth-address><titles><title><style face="normal" font="default">Atopic asthmatic immune phenotypes associated with airway microbiota and airway obstruction</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0184566">e0184566-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Differences in asthma severity may be related to inflammation in the airways. The lower airway microbiota has been associated with clinical features such as airway obstruction, symptom control, and response to corticosteroids. OBJECTIVE: To assess the relationship between local airway inflammation, severity of disease, and the lower airway microbiota in atopic asthmatics. METHODS: A cohort of young adult, atopic asthmatics with intermittent or mild/moderate persistent symptoms (n = 13) were assessed via bronchoscopy, lavage, and spirometry. These individuals were compared to age matched non-asthmatic controls (n = 6) and to themselves after six weeks of treatment with fluticasone propionate (FP). Inflammation of the airways was assessed via a cytokine and chemokine panel. Lower airway microbiota composition was determined by metagenomic shotgun sequencing. RESULTS: Unsupervised clustering of cytokines and chemokines prior to treatment with FP identified two asthmatic phenotypes (AP), termed AP1 and AP2, with distinct bronchoalveolar lavage inflammatory profiles. AP2 was associated with more obstruction, compared to AP1. After treatment with FP reduced MIP-1beta and TNF-alpha and increased IL-2 was observed. A module of highly correlated cytokines that include MIP-1beta and TNF-alpha was identified that negatively correlated with pulmonary function. Independently, IL-2 was positively correlated with pulmonary function. The airway microbiome composition correlated with asthmatic phenotypes. AP2, prior to FP treatment, was enriched with Streptococcus pneumoniae. Unique associations between IL-2 or the cytokine module and the microbiota composition of the airways were observed in asthmatics subjects prior to treatment but not after or in controls. CONCLUSION: The underlying inflammation in atopic asthma is related to the composition of microbiota and is associated with severity of airway obstruction. Treatment with inhaled corticosteroids was associated with changes in the airway inflammatory response to microbiota</style></abstract><notes><style face="normal" font="default">DA - 20171020IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0184566</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29053714">PM:29053714</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0184566.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0184566.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171020, Turturice BA</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0184566</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43076</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Micozzi,S.</style></author><author><style face="normal" font="default"> Perez-Ezquerra,P.R.</style></author><author><style face="normal" font="default"> Morales-Cabeza,C.</style></author><author><style face="normal" font="default"> Diez,C.</style></author><author><style face="normal" font="default"> De Barrio,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Gregorio Maranon Health Research Institute, Madrid. Spain</style></auth-address><titles><title><style face="normal" font="default">Stevens Johnson Syndrome versus Jarisch Herxheimer Reaction in an HIV positive patient with secondary syphilis</style></title><secondary-title><style face="normal" font="default">Recent Pat Inflamm Allergy Drug Discov</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Recent Pat Inflamm Allergy Drug Discov</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="10" Year="2017">2017/10/26</year></dates><abstract><style face="normal" font="default">BACKGROUND: HIV positive patients can suffer many complications due to infectious diseases. A severe reaction to some of the drugs involved in the treatment can overlap with the symptoms of infections, making diagnosis very difficult. We present the case of an HIV positive 28-year-old-man, , with secondary syphilis, who developed a Stevens Johnson Syndrome (SJS) caused by one of the many drugs he was receiving. The SJS overlapped with a possible Jarisch Herxheimer Reaction, which complicated diagnosis of the skin reaction. OBJECTIVE: in HIV+ patients the overlapping of severe drug reactions and infectious diseases could be fatal, thus an accurate diagnosis is mandatory. MATERIALS AND METHODS: a Rapid Plasma Reagin Test (RPR), an ELISA test, a blood laboratory test, a chest radiography and a skin biopsy were carried out in order to diagnose the infectious disease and the cause of skin lesions. Intradermal tests and double blind challenge tests were conducted in the allergy study. RESULTS: the laboratory tests confirmed the diagnosis of syphilis; the skin biopsy confirmed the cause of lesions as being a severe allergy reaction due to aSJS. The allergy study discounted all the drugs involved, excepted dypirone which wasn't tested in the study because of the severity of reaction, the high possibility of it being the causative drug and the alternative similar drugs that are available. For the inflammatory response, HIV+ patients are especially susceptible to severe reactions, both infectious and allergic, as in this case. Thus, recent patents focus on the inflammatory molecules that cause inflammatory symptoms. CONCLUSIONS: although the diagnosis of SJS has established criteria, the possibility of overlap with infectious illness and/or with its treatment, may complicate the diagnosis</style></abstract><notes><style face="normal" font="default">DA - 20171027IS - 1872-213X (Print)IS - 1872-213X (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.2174/1872213X11666171026111648</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29076438">PM:29076438</url></web-urls></urls><custom2><style face="normal" font="default">20171027, Micozzi S</style></custom2><misc3><style face="normal" font="default">10.2174/1872213X11666171026111648</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43077</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rothe,H.</style></author><author><style face="normal" font="default"> Ryan,C.A.</style></author><author><style face="normal" font="default"> Page,L.</style></author><author><style face="normal" font="default"> Vinall,J.</style></author><author><style face="normal" font="default"> Goebel,C.</style></author><author><style face="normal" font="default"> Scheffler,H.</style></author><author><style face="normal" font="default"> Toner,F.</style></author><author><style face="normal" font="default"> Roper,C.</style></author><author><style face="normal" font="default"> Kern,P.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Coty, Berliner Allee 65, 64295 Darmstadt, Germany</style></auth-address><titles><title><style face="normal" font="default">Application of in vitro skin penetration measurements to confirm and refine the quantitative skin sensitization risk assessment of methylisothiazolinone</style></title><secondary-title><style face="normal" font="default">Regul Toxicol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Regul Toxicol Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="10" Year="2017">2017/10/25</year></dates><abstract><style face="normal" font="default">Use of quantitative risk assessment (QRA) for assessing the skin sensitization potential of chemicals present in consumer products requires an understanding of hazard and product exposure. In the absence of data, consumer exposure is based on relevant habits and practices and assumes 100% skin uptake of the applied dose. To confirm and refine the exposure, a novel design for in vitro skin exposure measurements was conducted with the preservative, methylisothiazolinone (MI), in beauty care (BC) and household care (HHC) products using realistic consumer exposure conditions. A difference between measured exposure levels (MELs) for MI in leave-on versus rinse-off BC products, and lower MELs for MI in HHC rinse-off compared to BC products was demonstrated. For repeated product applications, the measured exposure was lower than estimations based on summation of applied amounts. Compared to rinse-off products, leave-on applications resulted in higher MELs, correlating with the higher incidences of allergic contact dermatitis associated with those product types. Lower MELs for MI in rinse-off products indicate a lower likelihood to induce skin sensitization, also after multiple daily applications. These in vitro skin exposure measurements indicate conservatism of default exposure estimates applied in skin sensitization QRA and might be helpful in future risk assessments</style></abstract><notes><style face="normal" font="default">DA - 20171029IS - 1096-0295 (Electronic)IS - 0273-2300 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.yrtph.2017.10.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29080845">PM:29080845</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\20171029-RotheH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Regul Toxicol Pharmacol\20171029-RotheH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171029, Rothe H</style></custom2><misc3><style face="normal" font="default">10.1016/j.yrtph.2017.10.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43078</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Smejda,K.</style></author><author><style face="normal" font="default"> Polanska,K.</style></author><author><style face="normal" font="default"> Merecz-Kot,D.</style></author><author><style face="normal" font="default"> Krol,A.</style></author><author><style face="normal" font="default"> Hanke,W.</style></author><author><style face="normal" font="default"> Jerzynska,J.</style></author><author><style face="normal" font="default"> Stelmach,W.</style></author><author><style face="normal" font="default"> Majak,P.</style></author><author><style face="normal" font="default"> Stelmach,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics and Allergy, Medical University of Lodz, Copernicus Memorial Hospital in Lodz, Poland</style></auth-address><titles><title><style face="normal" font="default">Maternal Stress During Pregnancy and Allergic Diseases in Children During the First Year of Life</style></title><secondary-title><style face="normal" font="default">Respir Care</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Respir Care</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="10" Year="2017">2017/10/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Many recent studies indicate that prenatal maternal distress increases the risk of allergic diseases in children. The mechanisms that favor it are still unclear. OBJECTIVES: We aimed to assess the association between exposure to different kinds of prenatal stress and the occurrence of atopic dermatitis, food allergy, wheezing, and recurrent respiratory tract infections in children. METHODS: The study population consisted of 370 mother-child pairs from a Polish Mother and Child Cohort (REPRO_PL). The analysis was restricted to the women who worked at least one month during the pregnancy period. Maternal psychological stress during pregnancy was assessed based on the Subjective Work Characteristics Questionnaire, the Perceived Stress Scale, and the Social Readjustment Rating Scale. The presence of atopic dermatitis, food allergy, wheezing, and recurrent respiratory tract infections in children was evaluated by doctors at 12 months of age. RESULTS: In a univariate model, we showed significant association between maternal life stress (according to the Perceived Stress Scale) and stressful life events (according to the Social Readjustment Rating Scale) and infant wheezing (at least 1 episode of wheezing during the first year of life). A multivariate model of logistic regression analysis revealed that maternal stress during pregnancy, described by the Social Readjustment Rating Scale, increased the risk of wheezing in children (OR 1.09, 95% CI 1.01-1.02) independently from other predictors of wheezing previously determined in this cohort, such as the number of infections and maternal smoking. We observed also significant positive association between maternal life stress during pregnancy measured by the Perceived Stress Scale and the risk of recurrent respiratory tract infections in the first year of life, however it was not significant after adjustment for confounding variables. CONCLUSIONS: Maternal stress during pregnancy increases the risk of childhood wheezing. The effects of stress during pregnancy on the onset of allergic diseases in children should be developed and translated into early prevention strategies</style></abstract><notes><style face="normal" font="default">DA - 20171018IS - 1943-3654 (Electronic)IS - 0020-1324 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.4187/respcare.05692</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29042485">PM:29042485</url></web-urls><related-urls><url ppv-ref="no">oresto - ISS</url></related-urls></urls><custom2><style face="normal" font="default">20171018, Smejda K</style></custom2><misc3><style face="normal" font="default">10.4187/respcare.05692</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43079</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ko,F.W.</style></author><author><style face="normal" font="default"> Hui,D.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong KongDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong</style></auth-address><titles><title><style face="normal" font="default">Many patients labelled as having mild asthma do not have well-controlled asthma</style></title><secondary-title><style face="normal" font="default">Respirology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respirology</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="10" Year="2017">2017/10/20</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171020IS - 1440-1843 (Electronic)IS - 1323-7799 (Linking)LA - engPT - EditorialCO - Hong Kong -</style></notes><work-type><style face="normal" font="default">10.1111/resp.13198</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29052922">PM:29052922</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respirology\20171020-KoFW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respirology\20171020-KoFW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171020, Ko FW</style></custom2><misc3><style face="normal" font="default">10.1111/resp.13198</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43080</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ding,B.</style></author><author><style face="normal" font="default"> Small,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical Evidence and Observational Research, AstraZeneca Gothenburg, Molndal, SwedenRespiratory Research, Adelphi Real World, Macclesfield, UK</style></auth-address><titles><title><style face="normal" font="default">Disease burden of mild asthma in China</style></title><secondary-title><style face="normal" font="default">Respirology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respirology</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="10" Year="2017">2017/10/20</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVE: The impact, treatment patterns and control of mild asthma are poorly understood for Chinese patients. This study describes the characteristics, therapeutic interventions and burden of mild asthma on patients residing in major cities of China. METHODS: The Respiratory Disease Specific Program 2015, a cross-sectional survey, was conducted with Chinese physicians and their patients. The survey assessed clinical characteristics, asthma symptoms, exacerbations, rescue inhaler usage, treatment adherence, asthma control, work and activity impairments and healthcare utilization for patients prescribed Global Initiative for Asthma (GINA) Step 1 or 2 treatment defined mild asthma. RESULTS: From a total sample of 988 patients, 229 patients met the criteria for mild asthma, with 25.3% classified as Step 1 and 74.7% as Step 2. Overall, 12.6% of patients were considered of high adherence to prescribed treatment. Physicians reported that 75% of patients overall were well controlled, although well-controlled asthma as defined by GINA was achieved in only 14.2% of patients. 26.5% of patients indicated daily use of as-needed rescue medication in the last 4 weeks. 17.8% of patients experienced >/=1 exacerbations in the last 12 months and impaired work productivity was 27.2% overall. CONCLUSION: Less than 15% of patients were well controlled according to GINA criteria despite physicians reporting the majority of patients were well controlled. Over one-fourth of patients relied on daily rescue inhaler medication, while exacerbation frequency and work and activity impairment were higher than might reasonably be expected in a mild asthmatic population</style></abstract><notes><style face="normal" font="default">DA - 20171020IS - 1440-1843 (Electronic)IS - 1323-7799 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/resp.13189</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29052915">PM:29052915</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respirology\20171020-DingB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respirology\20171020-DingB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171020, Ding B</style></custom2><misc3><style face="normal" font="default">10.1111/resp.13189</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43081</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Malinovsky,J.M.</style></author><author><style face="normal" font="default"> Tacquard,C.</style></author><author><style face="normal" font="default"> Chiriac,A.M.</style></author><author><style face="normal" font="default"> Perotin,J.M.</style></author><author><style face="normal" font="default"> Demoly,P.</style></author><author><style face="normal" font="default"> Mertes,P.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">News on anaphylaxis related to neuromuscular blocking agents</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Pholcodine</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Anaesthesia</style></keyword><keyword><style face="normal" font="default"> Neuromuscular Blocking Agents</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Anaphylaxis related to neuromuscular blocking agents (NMBA) is a life-threatening complication occurring during anaesthesia. It is an immediate hypersensitivity reaction that is mediated by IgE in more than 60% of cases. Amongst NMBAs, rocuronium and suxamethonium induce anaphylactic reactions more frequently than any other agents. Anaphylaxis related to NMBA is unpredictable other than in patients previously presenting unexplained severe reaction during anaesthesia. The fact that most patients affected have no previous history of NMBA use suggests cross-sensitization with other substances containing the epitope of the quaternary ammonium ion. Different modes of sensitization are currently under investigation. The cough-suppressant pholcodine could constitute an important pathway for sensitization. While the antidote to rocuronium has been reported as exerting beneficial effects on rocuronium-induced anaphylactic reactions, it has nevertheless already induced anaphylactic reactions. When anaphylactic shock occurs, allergy screening is mandatory to investigate cross-sensitization amongst NMBAs and to identify a safe NMBA for subsequent anaesthesia</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.08.006</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.08.006</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20171107-MalinovskyJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20171107-MalinovskyJM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171107, Malinovsky JM</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.08.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43082</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ciprandi,G.</style></author><author><style face="normal" font="default"> Gallo,F.</style></author><author><style face="normal" font="default"> Cirillo,I.</style></author></authors></contributors><titles><title><style face="normal" font="default">Asthma symptom perception does not relate with type-2 bronchial inflammation</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Lung function</style></keyword><keyword><style face="normal" font="default"> FENO</style></keyword><keyword><style face="normal" font="default"> Symptom perception</style></keyword><keyword><style face="normal" font="default"> Asthme</style></keyword><keyword><style face="normal" font="default"> Fonction respiratoire</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.07.001</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.07.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20171107-CiprandiG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20171107-CiprandiG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171107, Ciprandi G</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.07.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43083</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sabouraud-Leclerc,D.</style></author><author><style face="normal" font="default"> Pouessel,G.</style></author><author><style face="normal" font="default"> Beaudouin,E.</style></author><author><style face="normal" font="default"> Bradatan,E.</style></author><author><style face="normal" font="default"> Sullerot,I.</style></author><author><style face="normal" font="default"> Le Pape-Brouillet,F.</style></author><author><style face="normal" font="default"> Dumond,P.</style></author><author><style face="normal" font="default"> Renaudin,J.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Anaphylactic emergencies in schools: A guide to practical management</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Food allergy</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> school</style></keyword><keyword><style face="normal" font="default"> School meals</style></keyword><keyword><style face="normal" font="default"> PMP</style></keyword><keyword><style face="normal" font="default"> TEAP</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">The incidence of anaphylaxis due to food allergy (FA) is steadily rising. Despite the introduction of the Personalized Meal Plan (PMP), anaphylactic shock in school settings is by no means rare and is life-threatening for allergic children. In this article, using data from the French Allergy Surveillance Network (RAV) and from the findings of studies by different groups within the French Allergology Society (SFA), we have identified a number of approaches to prevent and better deal with such accidents: improved training of doctors in anaphylaxis, the importance of Therapeutic Education for Allergic Patients (TEAP) and those around them, harmonization of the literature on personalized plans, diffusion of the recommendations concerning indications for implementation of the PMP in France and the prescription of auto-injectable adrenaline syringes requires allergy training for all persons caring for children with allergies</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.08.010</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.08.010</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20171107-SabouraudLeclercD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20171107-SabouraudLeclercD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171107, Sabouraud-Leclerc D</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.08.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43084</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cruz,M.C.</style></author><author><style face="normal" font="default"> Carvalho,R.S.</style></author><author><style face="normal" font="default"> Daniel,P.M.</style></author><author><style face="normal" font="default"> Ferreira,R.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cardiology Departament, Hospital de Santa Marta, Centro Hospitalar Lisboa Central, Lisbon, Portugal</style></auth-address><titles><title><style face="normal" font="default">A rash decision. The hazards of the wrongful use of adrenaline</style></title><secondary-title><style face="normal" font="default">Rom J Anaesth Intensive Care</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Rom J Anaesth Intensive Care</style></abbr-1></periodical><pages end="166" start="163">163-166</pages><volume><style face="normal" font="default">24</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Anaphylaxis is life-threatening and should be addressed urgently. Its treatment is not without side effects and an accurate diagnosis must be made to prevent potential harm by the wrongful use of medication. A 46-year-old woman with hypertension treated with angiotensin converting enzyme inhibitor (ACEI) presented to the emergency department with non-pitting oedema of the face and limbs. A hasty diagnosis of anaphylaxis was made and intravenous adrenaline administered. The patient developed a myocardial infarction caused by coronary artery spasm that required invasive intervention. The initial clinical picture was resolved when the ACEI was discontinued unmasking a case of ACEI-induced angioedema. The correct differentiation of these two apparently similar clinical entities is of utmost importance in the management of emergency department patients</style></abstract><notes><style face="normal" font="default">DA - 20171101IS - 2392-7518 (Print)IS - 2392-7518 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.21454/rjaic.7518.242.crz</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29090269">PM:29090269</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rom J Anaesth Intensive Care\2017-24-163-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rom J Anaesth Intensive Care\2017-24-163-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171101, Cruz MC</style></custom2><misc3><style face="normal" font="default">10.21454/rjaic.7518.242.crz</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43085</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Han,S.</style></author><author><style face="normal" font="default"> Lv,Y.</style></author><author><style face="normal" font="default"> Kong,L.</style></author><author><style face="normal" font="default"> Che,D.</style></author><author><style face="normal" font="default"> Liu,R.</style></author><author><style face="normal" font="default"> Fu,J.</style></author><author><style face="normal" font="default"> Cao,J.</style></author><author><style face="normal" font="default"> Wang,J.</style></author><author><style face="normal" font="default"> Wang,C.</style></author><author><style face="normal" font="default"> He,H.</style></author><author><style face="normal" font="default"> Zhang,T.</style></author><author><style face="normal" font="default"> Dong,X.</style></author><author><style face="normal" font="default"> He,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Pharmacy, Xi'an Jiaotong University, Xi'an, 710061, China</style></auth-address><titles><title><style face="normal" font="default">Use of the relative release index for histamine in LAD2 cells to evaluate the potential anaphylactoid effects of drugs</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="13714">13714-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="10" Year="2017">2017/10/20</year></dates><abstract><style face="normal" font="default">Anaphylactoid reactions are common clinical acute adverse drug reactions that can exacerbate a patient's condition and produce effects that may become life-threatening. Therefore, it is important to establish a novel method to evaluate drugs for anaphylactoid reactions. In this study, we developed a sensitive and rapid method to detect histamine release from LAD2 cells using liquid chromatography-tandem mass spectrometry (LC-MS/MS) and constructed a relative release index based on various release curve parameters, including allergen release time and sudden change rate, to evaluate the potential and strength of allergen-induced anaphylactoid reactions. This LAD2 release model was used to evaluate anaphylactoid reactions induced by ciprofloxacin, norfloxacin, lomefloxacin, moxifloxacin, and baicalin. The results positively correlated with those obtained with an Evans blue ear test and negatively correlated with the Ca2+ influx EC50. In summary, the current study established a novel in vitro method to analyze the properties of histamine release from LAD2 cells and characterize the sensitization and strength of sensitization of drugs or components that may induce anaphylactoid reactions</style></abstract><notes><style face="normal" font="default">DA - 20171023IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1038/s41598-017-14224-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29057927">PM:29057927</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Rep\2017-7-13714.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Rep\2017-7-13714.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171023, Han S</style></custom2><misc3><style face="normal" font="default">10.1038/s41598-017-14224-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43086</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,F.</style></author><author><style face="normal" font="default"> Su,X.</style></author><author><style face="normal" font="default"> Huang,G.</style></author><author><style face="normal" font="default"> Xin,X.F.</style></author><author><style face="normal" font="default"> Cao,E.H.</style></author><author><style face="normal" font="default"> Shi,Y.</style></author><author><style face="normal" font="default"> Song,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonary Medicine, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China.</style></auth-address><titles><title><style face="normal" font="default">sRAGE alleviates neutrophilic asthma by blocking HMGB1/RAGE signalling in airway dendritic cells</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="14268">14268-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="10" Year="2017">2017/10/27</year></dates><abstract><style face="normal" font="default">Receptor for advanced glycation end products (RAGE) plays a role in inflammatory reactions. The soluble form of RAGE (sRAGE) acts as a decoy to inhibit interactions of RAGE with advanced glycation end products such as High mobility group box 1 (HMGB1). We have demonstrated that HMGB1 directs Th17 skewing by regulating dendritic cell (DC) functions in a previous study. However, the protective effects of HMGB1 blockade with sRAGE in the development of neutrophilic asthma remain unclear. Here, we showed that allergen challenge decreased expression of sRAGE in a murine model of neutrophilic asthma, correlating well with neutrophil counts and interleukin (IL)-17 production. When HMGB1 signalling was blocked by intratracheal administration of sRAGE before sensitisation, HMGB1 expression, neutrophilic inflammation, and Th17-type responses were reduced significantly. Anti-asthma effects of sRAGE were achieved by inhibition of RAGE and IL-23 expression in airway CD11c+ antigen-presenting cells. Finally, we showed that sRAGE inhibited Th17 polarisation induced by recombinant HMGB1 (rHMGB1)-activated dendritic cells (DCs) in vitro. Adoptive transfer of rHMGB1-activated DCs was sufficient to restore airway inflammation, whereas transfer of rHMGB1 plus sRAGE-activated DCs significantly reduced neutrophilic inflammation. Thus, sRAGE prevents Th17-mediated airway inflammation in neutrophilic asthma at least partly by blocking HMGB1/RAGE signalling in DCs</style></abstract><notes><style face="normal" font="default">DA - 20171028IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1038/s41598-017-14667-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29079726">PM:29079726</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Rep\2017-7-14268.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Rep\2017-7-14268.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171028, Zhang F</style></custom2><misc3><style face="normal" font="default">10.1038/s41598-017-14667-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43087</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ait,B.Y.</style></author><author><style face="normal" font="default"> Miyashita,C.</style></author><author><style face="normal" font="default"> Araki,A.</style></author><author><style face="normal" font="default"> Nakajima,T.</style></author><author><style face="normal" font="default"> Sasaki,S.</style></author><author><style face="normal" font="default"> Kishi,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Environmental and Health Sciences, Hokkaido University, North 12, West 7, Kita-ku, Sapporo 060-0812, Japan</style></auth-address><titles><title><style face="normal" font="default">Effects of prenatal di(2-ethylhexyl) phthalate exposure on childhood allergies and infectious diseases: The Hokkaido Study on Environment and Children's Health</style></title><secondary-title><style face="normal" font="default">Sci Total Environ</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Sci Total Environ</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="28" Month="10" Year="2017">2017/10/28</year></dates><abstract><style face="normal" font="default">Phthalates are widely used in consumer products, and experimental studies suggest that exposure to phthalates increase the risk of allergies. However, epidemiologic evidence on the associations between prenatal phthalate exposure and allergies/infectious diseases and cord blood immunoglobulin E (IgE) levels is limited. This study aimed to evaluate the associations between maternal mono(2-ethylhexyl) phthalate (MEHP) levels and cord blood IgE levels at birth (n=127), as well as the risk of allergies/infectious diseases in participants up to 7years of age; the participants were 1.5 (n=248), 3.5 (n=222), 7 (n=184) years of age. Maternal blood MEHP level in the second trimester was measured using gas chromatography-mass spectrometry. Participant characteristics were obtained from the medical birth records and self-administered questionnaires during pregnancy and after delivery. Wheeze and eczema were defined according to the Japanese version of the International Study of Asthma and Allergies in Childhood and the American Thoracic Society-Division of Lung Diseases questionnaire, respectively. Infectious diseases were defined using questionnaires for each specified age. To evaluate the associations between maternal MEHP and allergies or infectious diseases, we used logistic regression analysis and generalized estimating equations analysis. Maternal MEHP levels were negatively associated with cord blood IgE levels and increased risks of allergies and infectious diseases up to 7years of age. This is the first study to investigate the effects of prenatal MEHP exposure on IgE levels at birth and allergies/infectious diseases up to 7years of age. Further epidemiological studies should focus on other phthalate metabolites and their health effects on larger populations</style></abstract><notes><style face="normal" font="default">DA - 20171101IS - 1879-1026 (Electronic)IS - 0048-9697 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.scitotenv.2017.09.270</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29089129">PM:29089129</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Total Environ\20171101-AilBY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Total Environ\20171101-AilBY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171101, Ail BY</style></custom2><misc3><style face="normal" font="default">10.1016/j.scitotenv.2017.09.270</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43088</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sparks,J.A.</style></author><author><style face="normal" font="default"> Lin,T.C.</style></author><author><style face="normal" font="default"> Camargo,C.A.,Jr.</style></author><author><style face="normal" font="default"> Barbhaiya,M.</style></author><author><style face="normal" font="default"> Tedeschi,S.K.</style></author><author><style face="normal" font="default"> Costenbader,K.H.</style></author><author><style face="normal" font="default"> Raby,B.A.</style></author><author><style face="normal" font="default"> Choi,H.K.</style></author><author><style face="normal" font="default"> Karlson,E.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA.</style></auth-address><titles><title><style face="normal" font="default">Rheumatoid arthritis and risk of chronic obstructive pulmonary disease or asthma among women: A marginal structural model analysis in the Nurses' Health Study</style></title><secondary-title><style face="normal" font="default">Semin Arthritis Rheum</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Semin Arthritis Rheum</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="9" Year="2017">2017/9/18</year></dates><abstract><style face="normal" font="default">OBJECTIVE: We investigated whether RA increases risk for chronic obstructive pulmonary disease (COPD) or asthma independent of factors occurring before RA onset or mediating these respiratory morbidities after diagnosis, such as cigarette smoking. METHODS: Within the prospective Nurses' Health Study (n = 121,701 women; 1976-2014), we identified an incident RA cohort and matched each woman with RA to 10 comparators without RA by age and year at index date of RA diagnosis, excluding women with COPD or asthma at baseline. Data were obtained through biennial questionnaires and medical records. We used marginal structural models to determine the independent effect of RA on incident COPD or asthma adjusting for confounders and time-varying mediators through inverse probability weighting. RESULTS: We identified 843 women with RA, matched to 8,399 comparators without RA. Mean age was 59.8 years and mean follow-up after index date was 18.6 years (SD = 9.0) for women with RA, and 18.8 years (SD = 9.5) for comparators. We identified 68 (8.1%) incident COPD and 40 (4.7%) asthma cases among women with RA, and 459 (5.5%) COPD and 268 (3.2%) asthma cases among comparators. RA was associated with increased risk of COPD (HR = 1.52, 95% CI: 1.17-1.97) and asthma (HR = 1.55, 95% CI: 1.11-2.16) compared to comparators adjusted for the matching factors of age and calendar year at index date. After further adjustment for confounders and time-varying mediators occurring after index date, including smoking, RA was significantly associated with COPD (HR = 1.68, 95% CI: 1.36-2.07), but not asthma (HR = 1.11, 95% CI: 0.59-2.09) compared to non-RA comparators. Women with seropositive RA (HR = 1.60, 95% CI: 1.17-2.19) and seronegative RA (HR = 1.62, 95% CI: 1.09-2.40) had similar increased risk for COPD compared to non-RA comparators. CONCLUSION: In this prospective cohort study, RA was associated with increased risk for incident COPD, independent of lifestyle confounders and mediators after diagnosis, including smoking</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 1532-866X (Electronic)IS - 0049-0172 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.semarthrit.2017.09.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29037522">PM:29037522</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Semin Arthritis Rheum\20171017-SparksJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Semin Arthritis Rheum\20171017-SparksJA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Sparks JA</style></custom2><misc3><style face="normal" font="default">10.1016/j.semarthrit.2017.09.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43089</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liyanage,H.</style></author><author><style face="normal" font="default"> Hoang,U.</style></author><author><style face="normal" font="default"> Ferreira,F.</style></author><author><style face="normal" font="default"> Alexander,D.</style></author><author><style face="normal" font="default"> Rigby,M.</style></author><author><style face="normal" font="default"> Blair,M.</style></author><author><style face="normal" font="default"> De Lusignan,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical &amp; Experimental Medicine, University of Surrey, UK</style></auth-address><titles><title><style face="normal" font="default">Availability of Computerised Medical Record System Data to Compare Models of Child Health Care in Primary Care Across Europe</style></title><secondary-title><style face="normal" font="default">Stud Health Technol Inform</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Stud Health Technol Inform</style></abbr-1></periodical><pages end="12" start="8">8-12</pages><volume><style face="normal" font="default">244</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Computerised medical record (CMR) system data can be used to compare different models of health care for children. We identified sources of data from the Models of Child Health Appraised (MOCHA) project that compares family doctor led with paediatrician led and mixed models of child care using index conditions. Asthma and immunisation coverage are the first of these. We explored the extent to which an established Patient Registries Initiative (PARENT); MOCHA's own survey (MIROI); the European Centre for Disease Control (ECDC) immunisation information system survey and the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) registry of data sources provided data to make comparisons of child health care. Five countries had data repositories for our index conditions from paediatrician lead services, compared with 14 for mixed, and 11 for family doctor led services. PARENT identified 212 sources, MIROI 148 sources, ECDC 17 sources and ENCePP 42; with immunisation related data sources found in all four but asthma in only three. There are less sources of electronic data available to study paediatrician led systems than other models; this risks unequal sample size bias</style></abstract><notes><style face="normal" font="default">DA - 20171017IS - 0926-9630 (Print)IS - 0926-9630 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.3233/978-1-61499-824-2-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29039367">PM:29039367</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Stud Health Technol Inform\2017-244-8-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Stud Health Technol Inform\2017-244-8-12.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171017, Liyanage H</style></custom2><misc3><style face="normal" font="default">10.3233/978-1-61499-824-2-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43090</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bloom,C.I.</style></author><author><style face="normal" font="default"> Nissen,F.</style></author><author><style face="normal" font="default"> Douglas,I.J.</style></author><author><style face="normal" font="default"> Smeeth,L.</style></author><author><style face="normal" font="default"> Cullinan,P.</style></author><author><style face="normal" font="default"> Quint,J.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Epidemiology, Occupational Medicine and Public Health, NHLI, Imperial College London, London, UK</style></auth-address><titles><title><style face="normal" font="default">Exacerbation risk and characterisation of the UK's asthma population from infants to old age</style></title><secondary-title><style face="normal" font="default">Thorax</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Thorax</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="10" Year="2017">2017/10/26</year></dates><abstract><style face="normal" font="default">BACKGROUND: Few studies have examined the characteristics of a general asthma population; most have focused on more severe patients or severe exacerbations. METHODS: This population-based cohort study, from April 2007 to September 2015, used linked primary and secondary care electronic healthcare records (Clinical Practice Research Datalink, Hospital Episode Statistics). Characteristics of four age cohorts, 'Under 5s', '5 to 17s', '18 to 54s', '55+', were described. Exacerbation risk factors, including asthma severity (measured by the British Thoracic Society (BTS) stepwise approach), were assessed using Poisson regression. RESULTS: 424 326 patients with current asthma were eligible (n, median follow-up: 'Under 5s'=17 320, 1 year; '5 to 17s'=82 707, 3.3 years; '18 to 54s'=210 724, 4 years; '55+'=113 575, 5.1 years). Over 60% of the total study population had mild asthma (BTS steps 1/2). There were differences between the cohort's characteristics, including by gender, disease severity and exacerbation pattern. The rate of exacerbations was highest in the oldest cohort and lowest in the '5 to 17s' cohort (rate per 10 person-years (95% CI), 'Under 5s'=4.27 (4.18 to 4.38), '5 to 17s'=1.48 (1.47 to 1.50), '18 to 54s'=3.22 (3.21 to 3.24), '55+'=9.40 (9.37 to 9.42)). In all cohorts, exacerbation rates increased with increasing asthma severity, after adjusting for confounders including gender, socioeconomic status, smoking, body mass index, atopy, rhinitis, gastro-oesophageal reflux, anxiety, depression and COPD. CONCLUSION: The majority of UK patients with asthma had mild asthma and did not experience an exacerbation during follow-up. Patients aged >/=55 years had the lowest proportion with mild asthma and highest rate of exacerbations; the opposite was found in patients aged between 5 and 18 years</style></abstract><notes><style face="normal" font="default">DA - 20171027IS - 1468-3296 (Electronic)IS - 0040-6376 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1136/thoraxjnl-2017-210650</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29074814">PM:29074814</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Thorax\20171017-BloomCI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Thorax\20171017-BloomCI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171027, Bloom CI</style></custom2><misc3><style face="normal" font="default">10.1136/thoraxjnl-2017-210650</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43091</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ohtake,T.</style></author><author><style face="normal" font="default"> Maeda,Y.</style></author><author><style face="normal" font="default"> Hayashi,T.</style></author><author><style face="normal" font="default"> Yamanaka,H.</style></author><author><style face="normal" font="default"> Nakai,M.</style></author><author><style face="normal" font="default"> Takeyoshi,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Chemicals Assessment and Research Center, Chemicals Evaluation and Research Institute (CERI), 1600, Shimotakano, Sugito-machi, Kitakatsushika-gun, Saitama 345-0043, Japan.</style></auth-address><titles><title><style face="normal" font="default">Applicability of an Integrated Testing Strategy consisting of in silico, in chemico and in vitro assays for evaluating the skin sensitization potencies of isocyanates</style></title><secondary-title><style face="normal" font="default">Toxicology</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Toxicology</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="10" Year="2017">2017/10/31</year></dates><abstract><style face="normal" font="default">The skin sensitization potential of chemicals has been traditionally assessed using regulatory accepted in vivo methods, such as guinea pig or mouse local lymph node assays (LLNAs). A huge effort to refine and reduce the use of animals for safety assessments of chemicals because of regulatory requirements and ethical issues is presently underway, and alternative non-animal methods have been greatly developed. So far, a few studies have investigated the sensitization potencies of isocyanates which is a group of highly reactive chemicals that are known to be occupational allergens. The present study evaluated nine commonly used isocyanates using an in vivo LLNA and assessed the applicability of an Integrated Testing Strategy (ITS) consisting of an in silico Derek Nexus prediction, an in chemico direct peptide reactivity assay (DPRA), and an in vitro human Cell Line Activation Test (h-CLAT) to isocyanates. All nine isocyanates were evaluated as positive using the LLNA, Derek Nexus and DPRA, whereas seven chemicals tested positive using the h-CLAT: hexamethylene diisocyanate tested negative, and 1,5-diisocyanatonaphthalene could not be examined because of a solubility issue. When assessed using the ITS, the positive/negative evaluations of skin sensitization hazard were consistent with those assessed using the LLNA for all nine chemicals. However, the potency prediction results of the ITS tended to be underestimated, compared with those of the LLNA. The data presented in this work provide insights into the performance of non-animal testing approaches for evaluating the skin sensitization potencies of isocyanates</style></abstract><notes><style face="normal" font="default">DA - 20171104IS - 1879-3185 (Electronic)IS - 0300-483X (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.tox.2017.10.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29100879">PM:29100879</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Toxicology\20171104-OhtakeT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Toxicology\20171104-OhtakeT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171104, Ohtake T</style></custom2><misc3><style face="normal" font="default">10.1016/j.tox.2017.10.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43092</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Soffer,G.</style></author><author><style face="normal" font="default"> Cohen,B.</style></author><author><style face="normal" font="default"> Toh,J.</style></author><author><style face="normal" font="default"> Edelman,D.</style></author><author><style face="normal" font="default"> Garg,K.</style></author><author><style face="normal" font="default"> Jariwala,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Division of Allergy and Immunology, Montefiore Medical Center, Bronx, NY, USA</style></auth-address><titles><title><style face="normal" font="default">Successful Graded Dose Challenge to Iodixanol Radiocontrast Media in a Patient With Delayed Anaphylaxis to Iohexol</style></title><secondary-title><style face="normal" font="default">Vasc Endovascular Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Vasc Endovascular Surg</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="default">We present a case of an 82-year-old male with known radiocontrast media (RCM) hypersensitivity who was admitted to our hospital with gangrene of his right toe. The plan for revascularization of his lower extremity required an angiogram. This presented a management challenge as the patient had experienced 2 episodes of delayed anaphylaxis to Omnipaque (iohexol) RCM, and based on a literature review, there was no known or established precedent on a safe procedure in these situations. The patient was premedicated and given a graded dose challenge of an alternative RCM (iodixanol) prior to the radiographic study. He was given 1% of the total expected dose 1 hour before to the procedure and an additional 10% for the 30 minutes prior. He was then given the final dose in the operating room. Following angiogram, the patient was monitored for 18 hours in the postanesthesia care unit, with no adverse reactions. He was placed on a prednisone taper for 1 week, with daily diphenhydramine. The patient remained asymptomatic throughout the hospital course. This novel approach to RCM hypersensitivity management lends itself to a hope that graded dose challenges may play a greater role in the management of these patients</style></abstract><notes><style face="normal" font="default">DA - 20171031IS - 1938-9116 (Electronic)IS - 1538-5744 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/1538574417736420</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29084492">PM:29084492</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Vasc Endovascular Surg\20171031-SofferG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Vasc Endovascular Surg\20171031-SofferG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171031, Soffer G</style></custom2><misc3><style face="normal" font="default">10.1177/1538574417736420</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43093</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Koch,S.N.</style></author><author><style face="normal" font="default"> Torres,S.M.F.</style></author><author><style face="normal" font="default"> Diaz,S.</style></author><author><style face="normal" font="default"> Gilbert,S.</style></author><author><style face="normal" font="default"> Rendahl,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Veterinary Clinical Sciences, University of Minnesota, 1365 Gortner Avenue, Saint Paul, MN, 55018, USA</style></auth-address><titles><title><style face="normal" font="default">Subcutaneous administration of ciclosporin in 11 allergic cats - a pilot open-label uncontrolled clinical trial</style></title><secondary-title><style face="normal" font="default">Vet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Vet Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="10" Year="2017">2017/10/25</year></dates><abstract><style face="normal" font="default">BACKGROUND: Oral ciclosporin has been reported to be efficacious for feline inflammatory skin diseases; however, cats are often difficult to medicate orally. HYPOTHESIS/OBJECTIVE: To evaluate the efficacy and tolerability of subcutaneous ciclosporin administered to cats with allergic skin disease. ANIMALS: Eleven client-owned cats with nonseasonal clinical signs. METHODS: Prospective open label trial. Ciclosporin 50 mg/mL solution for injection (Sandimune(R), Novartis; NJ, USA) was administered subcutaneously for 60 days with initial doses ranging from 2.5 mg/kg once daily (one cat) to every other day (five cats) and 5 mg/kg once daily (four cats) to every other day (one cat). Dosages were adjusted monthly if needed based on clinical response. Clinical response was assessed using a modified FeDESI (feline Dermatitis Extent and Severity Index) and PVAS (pruritus Visual Analog Scale) between days (D) 0, 30 and 60. RESULTS: Six cats completed the study and four of five cats withdrawn from the study were included in an intention-to-treat analysis. There was significant decrease in FeDESI and PVAS scores between D0 and D30, D0 and D60 and D30 and D60 (P &lt; 0.05) in all ten cats. CONCLUSIONS AND CLINICAL IMPORTANCE: Ciclosporin administered subcutaneously at initial doses of 2.5-5 mg/kg, once daily to alternate days, appears to be an efficacious therapy for feline allergic dermatitis and may be an alternative therapy for cats that cannot be treated orally. Randomized and controlled long term studies which include a larger number of cats are needed to confirm these findings</style></abstract><notes><style face="normal" font="default">DA - 20171025IS - 1365-3164 (Electronic)IS - 0959-4493 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1111/vde.12505</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29068099">PM:29068099</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Vet Dermatol\20171025-KochSN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Vet Dermatol\20171025-KochSN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171025, Koch SN</style></custom2><misc3><style face="normal" font="default">10.1111/vde.12505</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43094</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lavergne,L.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Veterinary Clinical Medicine, College of Veterinary Medicine, University of Illinois-Urbana-Champaign, 2001 South Lincoln Av, Urbana, IL 61802, USA. sidolavergne@hotmail.com</style></auth-address><titles><title><style face="normal" font="default">In Vitro Research Tools in the Field of Human Immediate Drug Hypersensitivity and Their Present Use in Small Animal Veterinary Medicine</style></title><secondary-title><style face="normal" font="default">Vet Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Vet Sci</style></abbr-1></periodical><pages end="" start="E1">E1-</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="12" Year="2016">2016/12/22</year></dates><abstract><style face="normal" font="default">Drug hypersensitivity reactions (DHR) are immune-mediated idiosyncratic adverse drug events. Type I DHR are often referred to as "immediate" and involve B lymphocyte-secreted IgE that bind to the membrane of basophils and mast cells, inducing their degranulation. This review presents various in vitro tests that were developed in the field of human type I HS and implemented as clinical diagnostic tools in human cases of immediate DHR. The respective strengths and weaknesses of each test will be discussed in parallel of validation data such as specificity and sensitivity whenever available. Some of them have also been used as diagnostic tools in veterinary medicine, but not in cases of immediate DHR. Most of these diagnostic tools can be categorized into humoral and cellular tests. The former tests measure serum concentrations of factors, such as histamine, tryptase, and drug-specific IgE. The latter assays quantify markers of drug-induced basophil activation or drug-specific lymphocyte proliferation. Pharmacogenetic markers have also been investigated in immediate DHR, but not as extensively as in non-immediate ones. Throughout, practical aspects and limitations of the tests, as well as sensitivity and specificity parameters, will be presented. In addition, the experience of veterinary medicine with these diagnostic tools will be summarized. However, to date, none of them has ever been reported in a veterinary case of type I DHR</style></abstract><notes><style face="normal" font="default">DA - 20171023IS - 2306-7381 (Electronic)IS - 2306-7381 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.3390/vetsci4010001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29056660">PM:29056660</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Vet Sci\2016-4-E1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Vet Sci\2016-4-E1.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171023, Lavergne LS</style></custom2><misc3><style face="normal" font="default">10.3390/vetsci4010001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43095</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oland,A.A.</style></author><author><style face="normal" font="default"> Booster,G.D.</style></author><author><style face="normal" font="default"> Bender,B.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">1400 Jackson St, Denver, CO 80206 USA</style></auth-address><titles><title><style face="normal" font="default">Psychological and lifestyle risk factors for asthma exacerbations and morbidity in children</style></title><secondary-title><style face="normal" font="default">World Allergy Organ J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">World Allergy Organ J</style></abbr-1></periodical><pages end="" start="35">35-</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Asthma is the most common childhood illness and disproportionately affects low-income, minority children who live in urban areas. A range of risk factors are associated with asthma morbidity and mortality, such as treatment non-adherence, exposure to environmental triggers, low-income households, exposure to chronic stress, child psychological problems, parental stress, family functioning, obesity, physical inactivity, and unhealthy diets. These risk factors often have complex interactions and inter-relationships. Comprehensive studies that explore the inter-relationships of these factors in accounting for asthma morbidity and mortality are needed and would help to inform clinical intervention. Considerable research has focused on interventions to improve adherence, asthma management, asthma symptoms, and quality of life for patients with asthma. Educational interventions combined with psychosocial interventions, such as behavioral, cognitive-behavioral, or family interventions, are beneficial and provide care in schools, homes, and emergency rooms can help to address barriers to accessing care for children and families. Additional recent research has explored the use of multidisciplinary, collaborative, integrated care with pediatric asthma patients, providing promising results. Integrated care could be ideal for addressing the multitude of complex psychosocial and wellness factors that play a role in childhood asthma, for increasing patient-centered care, and for promoting collaborative patient-provider relationships. Further research in this area is essential and would be beneficial</style></abstract><notes><style face="normal" font="default">DA - 20171027IS - 1939-4551 (Print)IS - 1939-4551 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1186/s40413-017-0169-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29075362">PM:29075362</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\World Allergy Organ J\2017-10-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\World Allergy Organ J\2017-10-35.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171027, Oland AA</style></custom2><misc3><style face="normal" font="default">10.1186/s40413-017-0169-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43096</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chapman,E.</style></author><author><style face="normal" font="default"> Leal,D.</style></author><author><style face="normal" font="default"> Alvarez,L.</style></author><author><style face="normal" font="default"> Duarte,M.</style></author><author><style face="normal" font="default"> Garcia,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Fundacion Santa Fe de Bogota, Carrera 7 N 117-15, Bogota, Colombia</style></auth-address><titles><title><style face="normal" font="default">Two case reports of desensitization in patients with hypersensitivity to iron</style></title><secondary-title><style face="normal" font="default">World Allergy Organ J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">World Allergy Organ J</style></abbr-1></periodical><pages end="" start="38">38-</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Iron deficiency anemia is a disease that can significantly compromise a patient's quality of life. Desensitization is a safe and effective treatment option for iron-deficient anemic patients who require intravenous iron despite their hypersensitivity to iron. This report describes a safe desensitization protocol for patients with iron hypersensitivity who require iron treatment for their clinical improvement. CASE PRESENTATION: Two patients of 20 and 46-year-old diagnosed with secondary iron deficiency anemia hipermenorreas and a clinical history of fail treatment with oral iron, who presented a reaction of the anaphylactic type while they receive iron parenteral sucrose. Therefore, the patients were treated with the desensitization protocol applied for patients with hypersensitivity to iron. CONCLUSION: Iron deficiency anemia is a disease that can significantly compromise the quality of life of patients. The desensitization protocol for patients with hypersensitivity to iron is a safe and effective treatment option for patients with a history of allergy to intravenous iron. This case report shows the usefulness to use the desensitization protocol for patients with hypersensitivity to iron</style></abstract><notes><style face="normal" font="default">DA - 20171027IS - 1939-4551 (Print)IS - 1939-4551 (Linking)LA - engPT - Journal ArticleCO - Colombia -</style></notes><work-type><style face="normal" font="default">10.1186/s40413-017-0166-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29075363">PM:29075363</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\World Allergy Organ J\2017-10-38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\World Allergy Organ J\2017-10-38.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171027, Chapman E</style></custom2><misc3><style face="normal" font="default">10.1186/s40413-017-0166-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43097</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cherrez-Ojeda,I.</style></author><author><style face="normal" font="default"> Robles-Velasco,K.</style></author><author><style face="normal" font="default"> Bedoya-Riofrio,P.</style></author><author><style face="normal" font="default"> Schmid-Grendelmeier,P.</style></author><author><style face="normal" font="default"> Cherrez,S.</style></author><author><style face="normal" font="default"> Colbatzky,F.</style></author><author><style face="normal" font="default"> Cardona,R.</style></author><author><style face="normal" font="default"> Barberan-Torres,P.</style></author><author><style face="normal" font="default"> Calero,E.</style></author><author><style face="normal" font="default"> Calderon,J.C.</style></author><author><style face="normal" font="default"> Larco,J.I.</style></author><author><style face="normal" font="default"> Cherrez,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universidad Espiritu Santo, Samborondon, Ecuador. ivancherrez@gmail.com</style></auth-address><titles><title><style face="normal" font="default">[Is it possible for chronic urticaria diagnostic approach to be simplified? A clinical data checklist]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="326" start="309">309-326</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Existing clinical guidelines do not offer an efficient alternative for the collection of data on relevant clinical traits during history and physical of the patient with chronic urticaria. OBJECTIVE: Our aim was to provide a clinical data checklist together with its guide to allow for thorough information to be obtained and for a physical exam that identifies the main features and triggering factors of the disease to be carried out. METHODS: A search was conducted for relevant literature on chronic urticaria in Medline, the Cochrane library and PubMed. RESULTS: We developed an easy-to-use clinical data checklist with its corresponding clinical guide, comprised by 42 items based on two components: essential clues for history taking and chronic urticaria diagnosis (typical symptoms according to subgroups, etiology and laboratory results). Some components are the time of disease onset, wheals' duration, shape, size, color and distribution, associated angioedema, atopy, triggering factors and others. CONCLUSION: The clinical data checklist and its guide constitute a tool to focus, guide and save time in medical consultation, with the main purpose to aid physicians in providing better diagnosis and management of the disease</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleLA - SPACO - Ecuador -CO - Germany -CO - Switzerland -CO - Colombia -CO - Peru -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29046029">PM:29046029</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-309-26.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-309-26.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Cherrez-Ojeda I</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43098</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Anthofer,J.</style></author><author><style face="normal" font="default"> Herbst,A.</style></author><author><style face="normal" font="default"> Janzen,A.</style></author><author><style face="normal" font="default"> Lange,M.</style></author><author><style face="normal" font="default"> Brawanski,A.</style></author><author><style face="normal" font="default"> Schlaier,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Neurosurgery, Medical Centre, University of Regensburg, Franz-Josef-Strauss Allee 11, 93053, Regensburg, Germany.</style></auth-address><titles><title><style face="normal" font="default">Deep brain stimulation: custom-made silicone-coated pulse-generator implantation after allergic reaction to generator compounds</style></title><secondary-title><style face="normal" font="default">Acta Neurochir (Wien)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Acta Neurochir (Wien)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="11" Year="2017">2017/11/7</year></dates><abstract><style face="normal" font="default">Deep brain stimulation for Parkinson's disease has become an established treatment option in recent years. The method and its application in clinical practice has proved to be safe and effective. Nevertheless, procedure-related and hardware-related complications occur. We present a rare case of a patient with an allergic reaction to the impulse generator. The patient suffered from delayed wound-healing deficits with several wound revisions and generator repositionings. After diagnosis of an allergic reaction to components of the generator, a custom-made silicon-coated model was implanted. Hereafter, no wound healing-deficit occurred throughout long-term follow-up. Allergic reaction to hardware components may lead to wound-healing deficits. In such cases, custom-made silicon-coated models may be an effective treatment option</style></abstract><notes><style face="normal" font="default">DA - 20171108IS - 0942-0940 (Electronic)IS - 0001-6268 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1007/s00701-017-3373-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29116383">PM:29116383</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Acta Neurochir (Wien)\20171108-AnthoferJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Acta Neurochir (Wien)\20171108-AnthoferJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171108, Anthofer J</style></custom2><misc3><style face="normal" font="default">10.1007/s00701-017-3373-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43099</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gatica-Ortega,M.E.</style></author><author><style face="normal" font="default"> Pastor-Nieto,M.A.</style></author><author><style face="normal" font="default"> Silvestre-Salvador,J.F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Allergic Contact Dermatitis Caused by Acrylates in Long-Lasting Nail Polish</style></title><secondary-title><style face="normal" font="default">Actas Dermosifiliogr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Actas Dermosifiliogr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergic contact dermatitis</style></keyword><keyword><style face="normal" font="default"> Occupacional</style></keyword><keyword><style face="normal" font="default"> Acrylates</style></keyword><keyword><style face="normal" font="default"> Permanent nail polish</style></keyword><keyword><style face="normal" font="default"> Acrylic nails</style></keyword><keyword><style face="normal" font="default"> Beauticians</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0001-7310</style></isbn><abstract><style face="normal" font="default">The first reported cases of allergic contact dermatitis from acrylates in manicure procedures in relation to the application of porcelain nails-áwere published decades ago. The frequency of sensitization has increased due to the introduction of the so-called permanent nail polish containing photo-bonded acrylates, mainly involving the beauticians who apply them, and to a lesser extent, the consumers. The recent commercialized permanent polish kits for domestic use could trigger even-áhigher degrees of sensitization. In this article, the clinical features, diagnostic procedures, treatment and preventive measures are described. Acrylates are present in a wide range of sources including multiple medical materials. Sensitization caused by a merely aesthetic procedure might end up having an eventual important impact in the future consumer's health which is why restrictive policies should be implemented limiting its use to qualified professionals and banning the indiscriminate sale of domestic kits</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.ad.2017.08.010</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.ad.2017.08.010</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171113, Gatica-Ortega ME</style></custom2><misc3><style face="normal" font="default">10.1016/j.ad.2017.08.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43100</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tsuzuki,Y.</style></author><author><style face="normal" font="default"> Narita,M.</style></author><author><style face="normal" font="default"> Nawa,M.</style></author><author><style face="normal" font="default"> Nakagawa,U.</style></author><author><style face="normal" font="default"> Wakai,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics and AllergySapporo Tokushukai HospitalSapporoHokkaidoJapan</style></auth-address><titles><title><style face="normal" font="default">Management of maternal anaphylaxis in pregnancy: a case report</style></title><secondary-title><style face="normal" font="default">Acute Med Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Acute Med Surg</style></abbr-1></periodical><pages end="204" start="202">202-204</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">Case: A 26-year-old woman (gravida 2, para 1) at 25 weeks' gestation was brought to the emergency department because of anaphylactic symptoms. She reported eating Japanese soba and developed symptoms of dyspnea, generalized itchy rash, abdominal pain, and severe uterine contractions within 15-30 min of eating. She was immediately treated by normal saline infusion, two injections of epinephrine (intramuscularly), and a nebulized short-acting beta2-receptor agonist, followed by H1-antihistamine and methylprednisolone. Obstetrical management was undertaken by an obstetrician. Outcome: The patient recovered rapidly without a biphasic reaction of anaphylaxis. After 11 weeks, a healthy, neurologically intact baby was born. Conclusion: Management of anaphylaxis in pregnant patients is basically the same of that in non-pregnant ones. Treatment should commence immediately to prevent further development of the anaphylaxis reaction and fetal neurological deficiency</style></abstract><notes><style face="normal" font="default">DA - 20171110IS - 2052-8817 (Print)IS - 2052-8817 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1002/ams2.238</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29123862">PM:29123862</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Acute Med Surg\2017-4-202-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Acute Med Surg\2017-4-202-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171110, Tsuzuki Y</style></custom2><misc3><style face="normal" font="default">10.1002/ams2.238</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43101</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Takazawa,T.</style></author><author><style face="normal" font="default"> Oshima,K.</style></author><author><style face="normal" font="default"> Saito,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Intensive Care UnitGunma University HospitalMaebashiGunmaJapanDepartment of Emergency MedicineGunma University Graduate School of MedicineMaebashiGunmaJapanDepartment of AnesthesiologyGunma University Graduate School of MedicineMaebashiGunmaJapan</style></auth-address><titles><title><style face="normal" font="default">Drug-induced anaphylaxis in the emergency room</style></title><secondary-title><style face="normal" font="default">Acute Med Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Acute Med Surg</style></abbr-1></periodical><pages end="245" start="235">235-245</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">Anaphylaxis is a life-threatening, systemic allergic reaction that presents unique challenges for emergency care practitioners. Anaphylaxis occurs more frequently than previously believed. Therefore, proper knowledge regarding the epidemiology, mechanisms, symptoms, diagnosis, and treatment of anaphylaxis is essential. In particular, the initial treatment strategy, followed by correct diagnosis, in the emergency room is critical for preventing fatal anaphylaxis, although making a diagnosis is not easy because of the broad and often atypical presentation of anaphylaxis. To this end, the clinical criteria proposed by the National Institute of Allergy and Infectious Diseases and the Food Allergy and Anaphylaxis Network are useful, which, together with a differential diagnosis, could enable a more accurate diagnosis. Additional in vitro tests, such as plasma histamine and tryptase measurements, are also helpful. It should be emphasized that adrenaline is the only drug recommended as first-line therapy in all published national anaphylaxis guidelines. Most international anaphylaxis guidelines recommend injecting adrenaline by the intramuscular route in the mid-anterolateral thigh, whereas i.v. adrenaline is an option for patients with severe hypotension or cardiac arrest unresponsive to intramuscular adrenaline and fluid resuscitation. In addition to the route of administration, choosing the appropriate dose of adrenaline is essential, because serious adverse effects can potentially occur after an overdose of adrenaline. Furthermore, to avoid future recurrence of anaphylaxis, providing adrenaline auto-injectors and making an etiological diagnosis, including confirmation of the offending trigger, are recommended for patients at risk of anaphylaxis before their discharge from the emergency room</style></abstract><notes><style face="normal" font="default">DA - 20171110IS - 2052-8817 (Print)IS - 2052-8817 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1002/ams2.282</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29123869">PM:29123869</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Acute Med Surg\2017-4-235-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Acute Med Surg\2017-4-235-45.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171110, Takazawa T</style></custom2><misc3><style face="normal" font="default">10.1002/ams2.282</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43102</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Douros,K.</style></author><author><style face="normal" font="default"> Boutopoulou,B.</style></author><author><style face="normal" font="default"> Fouzas,S.</style></author><author><style face="normal" font="default"> Loukou,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">3rd Department of Paediatrics, "Attikon" Hospital, University of Athens School of Medicine, Athens, Greece.</style></auth-address><titles><title><style face="normal" font="default">Asthma and Allergy "Epidemic" and the Role of Vitamin D Deficiency</style></title><secondary-title><style face="normal" font="default">Adv Exp Med Biol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Adv Exp Med Biol</style></abbr-1></periodical><pages end="183" start="169">169-183</pages><volume><style face="normal" font="default">996</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The increase in asthma and allergies prevalence that has been recorded in many countries during the last decades, and the reemergence of vitamin D (VD) deficiency in many populations worldwide, renders fairly plausible the assumption of an underlying association between these two conditions and justifies the research effort invented in this issue. Indeed, there is growing body of evidence from epidemiological, laboratory, and clinical studies, suggesting that such an association does exist. The hypothesis of low levels of VD leading to compromised fetal programming and impairment of various immune functions involved in asthma and allergic disorders, stands as the most credible explanation of this presumed association. However, the evidence is not yet definite and there are some conflicting results among studies. As a consequence, no safe conclusions can be drawn yet, and more research is required in order to fully clarify the involvement of VD deficiency in the pathogenesis of asthma and allergies, and decide if VD has a role to play in the prevention and therapy of these disorders</style></abstract><notes><style face="normal" font="default">DA - 20171110IS - 0065-2598 (Print)IS - 0065-2598 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="default">10.1007/978-3-319-56017-5_14</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29124699">PM:29124699</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Adv Exp Med Biol\2017-996-169-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Adv Exp Med Biol\2017-996-169-83.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171110, Douros K</style></custom2><misc3><style face="normal" font="default">10.1007/978-3-319-56017-5_14</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43103</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Crossman-Barnes,C.J.</style></author><author><style face="normal" font="default"> Peel,A.</style></author><author><style face="normal" font="default"> Fong-Soe-Khioe,R.</style></author><author><style face="normal" font="default"> Sach,T.</style></author><author><style face="normal" font="default"> Wilson,A.</style></author><author><style face="normal" font="default"> Barton,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Norwich Medical School, University of East Anglia, UK</style></auth-address><titles><title><style face="normal" font="default">Economic evidence for non-pharmacological asthma management interventions: A systematic review</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="11" Year="2017">2017/11/6</year></dates><abstract><style face="normal" font="default">Asthma management, education and environmental interventions have been reported as cost effective in a previous review, (Yong and Shafie et al, 2014), but methods used to estimate costs and outcomes were not discussed in detail. This review updates the previous review by providing economic evidence on the cost effectiveness of studies identified after 2012, and a detailed assessment of the methods used in all identified studies. Twelve databases were searched from 1990 to January 2016, and studies included economic evaluations, asthma subjects, and non-pharmacological interventions written in English. Sixty-four studies were included. Of these, fifteen were found in addition to the earlier review; 53% were rated fair in quality and 47% high. Education and self-management interventions were the most cost effective, in line with the earlier review. Self-reporting was the most common method used to gather resource use data, accompanied with bottom-up approaches to estimate costs. Main outcome measures were asthma-related hospitalizations (69%), quality of life (41%) and utility (38%), with AQLQ and the EQ-5D being the most common questionnaires measured prospectively at fixed time points. More rigorous costing methods are needed with a more common quality of life tool to aid greater replicability and comparability amongst asthma studies. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/all.13337</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29105788">PM:29105788</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171106-CrossmanBarnesCJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171106-CrossmanBarnesCJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Crossman-Barnes CJ</style></custom2><misc3><style face="normal" font="default">10.1111/all.13337</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43104</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tanno,L.K.</style></author><author><style face="normal" font="default"> Torres,M.J.</style></author><author><style face="normal" font="default"> Castells,M.</style></author><author><style face="normal" font="default"> Demoly,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hospital Sirio Libanes, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="default">What can we learn in drug allergy management from World Health Organization's International Classifications?</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="11" Year="2017">2017/11/6</year></dates><abstract><style face="normal" font="default">Drug hypersensitivity reactions (DHRs) represent growing health problem worldwide, affecting more than 7% of the general population and represent an important public health problem. However, knowledge in DHRs morbidity and mortality epidemiological data is still not optimal and international comparable standards remain poorly accessed. Institutional databases worldwide increasingly use the WHO International Classification of Diseases (ICD) system to classify diagnoses, health services utilization and death data. The misclassification of disorders in the ICD system contributes to a lack of ascertainment and recognition of their importance for healthcare planning and resource allocation. It also hampers clinical practice and prevention actions. To further inform the allergy community and to ensure that the revision process is transparent as advised in the WHO ICD-11 revision agenda, we report the advances and use of the pioneering "Drug hypersensitivity" subsection of ICD-11 and implementation in the WHO International Classification of Health Interventions (ICHI). The new classification addressed to DHRs will enable the collection of more accurate epidemiological data to support quality management of patients with drug allergies, and better facilitate health care planning and decision-making and public health measures to prevent and reduce the morbidity and mortality attributable to DHRs. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Brazil -CO - France -CO - Spain -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.13335</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29105793">PM:29105793</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171106-TannoLK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171106-TannoLK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Tanno LK</style></custom2><misc3><style face="normal" font="default">10.1111/all.13335</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43105</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schwarze,J.</style></author><author><style face="normal" font="default"> Openshaw,P.</style></author><author><style face="normal" font="default"> Jha,A.</style></author><author><style face="normal" font="default"> Del Giacco,S.</style></author><author><style face="normal" font="default"> Firinu,D.</style></author><author><style face="normal" font="default"> Tsilochristou,O.</style></author><author><style face="normal" font="default"> Roberts,G.</style></author><author><style face="normal" font="default"> Selby,A.</style></author><author><style face="normal" font="default"> Akdis,C.</style></author><author><style face="normal" font="default"> Agache,I.</style></author><author><style face="normal" font="default"> Custovic,A.</style></author><author><style face="normal" font="default"> Heffler,E.</style></author><author><style face="normal" font="default"> Pinna,G.</style></author><author><style face="normal" font="default"> Khaitov,M.</style></author><author><style face="normal" font="default"> Nikonova,A.</style></author><author><style face="normal" font="default"> Papadopoulos,N.</style></author><author><style face="normal" font="default"> Akhlaq,A.</style></author><author><style face="normal" font="default"> Nurmatov,U.</style></author><author><style face="normal" font="default"> Renz,H.</style></author><author><style face="normal" font="default"> Sheikh,A.</style></author><author><style face="normal" font="default"> Skevaki,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Inflammation Research, University of Edinburgh, The Queens Medical Research Institute, Edinburgh, UK</style></auth-address><titles><title><style face="normal" font="default">Influenza burden, prevention and treatment in asthma - a scoping review by the EAACI Influenza in Asthma Task Force</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="11" Year="2017">2017/11/6</year></dates><abstract><style face="normal" font="default">To address uncertainties in the prevention and management of influenza in people with asthma, we performed a scoping review of the published literature on influenza burden; current vaccine recommendations; vaccination coverage; immunogenicity, efficacy, effectiveness and safety of influenza vaccines; and the benefits of antiviral drugs in people with asthma. We found significant variation in the reported rates of influenza detection in individuals with acute asthma exacerbations making it unclear to what degree influenza causes exacerbations of underlying asthma. The strongest evidence of an association was seen in studies of children. Countries in the European Union currently recommend influenza vaccination of adults with asthma; however, coverage varied between regions. Coverage was lower among children with asthma. Limited data suggest that good seroprotection and seroconversion can be achieved in both children and adults with asthma and that vaccination confers a degree of protection against influenza illness and asthma related morbidity to children with asthma. There were insufficient data to determine efficacy in adults. Overall, influenza vaccines appeared to be safe for people with asthma. We identify knowledge gaps and make recommendations on future research needs in relation to influenza in patients with asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -CO - Italy -CO - Switzerland -CO - Romania -CO - Greece -CO - Russia -CO - Pakistan -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/all.13333</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29105786">PM:29105786</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171106-SchwarzeJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171106-SchwarzeJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Schwarze J</style></custom2><misc3><style face="normal" font="default">10.1111/all.13333</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43106</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tormanen,S.</style></author><author><style face="normal" font="default"> Lauhkonen,E.</style></author><author><style face="normal" font="default"> Riikonen,R.</style></author><author><style face="normal" font="default"> Koponen,P.</style></author><author><style face="normal" font="default"> Huhtala,H.</style></author><author><style face="normal" font="default"> Helminen,M.</style></author><author><style face="normal" font="default"> Korppi,M.</style></author><author><style face="normal" font="default"> Nuolivirta,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Child Health Research, Tampere University and University Hospital, Tampere, Finland</style></auth-address><titles><title><style face="normal" font="default">Risk factors for asthma after infant bronchiolitis</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="11" Year="2017">2017/11/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Five studies carried out after bronchiolitis at less than 24 months of age, with a follow up of more than 10 years, reported that atopic dermatitis, family asthma, early-life exposure to tobacco smoke and rhinovirus aetiology were early-life risk factors for later asthma. This study evaluated the long-term outcome at 11-13 years of age of children who were hospitalised for bronchiolitis in early infancy. METHODS: We previously prospectively followed 166 children hospitalised for bronchiolitis at less than six months of age until 5-7 years of age. The current study included a structured questionnaire, parental interviews, clinical examinations and bronchodilation test of 138 of those children at 11-13 years of age. RESULTS: Respiratory syncytial virus caused 66% of the bronchiolitis cases and nearly half of the patients were exposed to tobacco smoke in early life. Doctor-diagnosed asthma was present in 13% of the former bronchiolitis patients at 11-13 years of age. Maternal asthma was the only independently significant risk factor in early life (adjusted OR 3.45, 95% CI 1.07-11.74), as was allergic rhinitis at 5-7 years of age (adjusted OR 4.06, 95% CI 1.35-12.25). CONCLUSIONS: After bronchiolitis at less than six months of age, the risk of doctor-diagnosed asthma at 11-13 years was about twice that of the general Finnish population. Maternal asthma was the only independently significant early-life risk factor for current asthma at 11-13 years of age. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="default">10.1111/all.13347</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29105099">PM:29105099</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171106-TormanenS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171106-TormanenS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Tormanen S</style></custom2><misc3><style face="normal" font="default">10.1111/all.13347</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43107</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ahmadizar,F.</style></author><author><style face="normal" font="default"> Vijverberg,S.J.H.</style></author><author><style face="normal" font="default"> Arets,H.G.M.</style></author><author><style face="normal" font="default"> de Boer,A.</style></author><author><style face="normal" font="default"> Lang,J.E.</style></author><author><style face="normal" font="default"> Garssen,J.</style></author><author><style face="normal" font="default"> Kraneveld,A.</style></author><author><style face="normal" font="default"> Maitland-van der Zee,A.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, the Netherlands</style></auth-address><titles><title><style face="normal" font="default">Early life antibiotic exposure increases the risk of developing allergic symptoms later in life: A meta-analysis</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="11" Year="2017">2017/11/6</year></dates><abstract><style face="normal" font="default">This study systematically reviewed and quantified the relationship between exposure to antibiotics during the first 2 years of life and the risk of allergies/atopies including hay fever, eczema, food allergy, positive skin prick testing (SPT) or elevated allergen-specific serum/plasma immunoglobulin (Ig) E levels later in life. PubMed and Web of Science databases were searched for observational studies published from January 1966 through November 11, 2015. Overall pooled estimates of the odds ratios (ORs) were obtained using fixed or random-effects models. Early life exposure to antibiotics appears to be related with an increased risk of allergic symptoms of hay fever, eczema and food allergy later in life. The summary OR for the risk of hay fever (22 studies) was 1.23, 95% confidence interval (CI):1.13-1.34; I2 : 77.0%. The summary OR for the risk of eczema (22 studies) was 1.26, 95% CI: 1.15-1.37; I2 : 74.2% and the summary OR for food allergy (3 studies) was 1.42, 95% CI: 1.08-1.87; I2 : 80.8%. However, no association was found for antibiotics exposure early in life and objective atopy measurements including positive SPT or elevated allergen-specific serum/plasma IgE levels. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Netherlands -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.13332</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29105784">PM:29105784</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171106-AhmadizarF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171106-AhmadizarF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Ahmadizar F</style></custom2><misc3><style face="normal" font="default">10.1111/all.13332</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43108</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aly,M.A.G.</style></author><author><style face="normal" font="default"> El Tabbakh,M.T.</style></author><author><style face="normal" font="default"> Heissam,W.F.</style></author><author><style face="normal" font="default"> Abbadi,S.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">The study of a possible correlation between serum levels of interleukin 17 and clinical severity in patients with allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Rhinol (Providence)</style></abbr-1></periodical><pages end="131" start="126">126-131</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="10" Year="2017">2017/10/1</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Allergic rhinitis (AR) is one of the most common allergic diseases, which affects approximately 20% of the world's population. T-helper (Th) type 2 cells produce interleukin (IL) 4 and IL-13, and mediate allergic responses, and these cytokines have been extensively studied as key players in the atopic airway diseases. However, the involvement of Th17 cells and IL-17 in AR has not been clearly examined. AIM: To reevaluate AR clinical severity with serum IL-17, whether IL-17 affects the disease alone or in contribution with the atopic predisposition. PATIENTS AND METHODS: During an 18-month period, 39 individuals were divided into three groups: A, (13 control), B (13 with mild-to-moderate AR), and C (13 with severe AR). Both group B and group C patients (26) were subjected to clinical examination and allergy skin testing, and to measurement of both total serum immunoglobulin E (IgE) and IL-17 levels. Eleven patients with AR then were exposed to 6 months of cluster immunotherapy, whereas the rest of the patients were not exposed. RESULTS: Revealed a significant elevation of serum IL-17 levels with an associated increase in serum IgE in the patients with AR compared with controls and revealed that the serum levels of both total serum IgE and IL-17 decreased significantly after cluster immunotherapy. CONCLUSION: These preliminary results added new data about the use of injective immunotherapy as well as reported on the use of sublingual immunotherapy</style></abstract><notes><style face="normal" font="default">DA - 20171026IS - 2152-6575 (Print)IS - 2152-6567 (Linking)LA - engPT - Journal ArticleCO - Egypt -</style></notes><work-type><style face="normal" font="default">10.2500/ar.2017.8.0207</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29070269">PM:29070269</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Rhinol (Providence)\2017-8-126-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Rhinol (Providence)\2017-8-126-31.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171026, Aly MA</style></custom2><misc3><style face="normal" font="default">10.2500/ar.2017.8.0207</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43109</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ickrath,P.</style></author><author><style face="normal" font="default"> Kleinsasser,N.</style></author><author><style face="normal" font="default"> Ding,X.</style></author><author><style face="normal" font="default"> Ginzkey,C.</style></author><author><style face="normal" font="default"> Beyersdorf,N.</style></author><author><style face="normal" font="default"> Hagen,R.</style></author><author><style face="normal" font="default"> Kerkau,T.</style></author><author><style face="normal" font="default"> Hackenberg,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Characterization of T-cell subpopulations in patients with chronic rhinosinusitis with nasal polyposis</style></title><secondary-title><style face="normal" font="default">Allergy Rhinol (Providence)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Rhinol (Providence)</style></abbr-1></periodical><pages end="147" start="139">139-147</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="10" Year="2017">2017/10/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: There is an ongoing discussion concerning the potential origins of chronic rhinosinusitis with nasal polyposis (CRSwNP). OBJECTIVE: The aim of this study was to quantify subpopulations of T cells in peripheral blood and nasal polyps in CRSwNP to examine their influence on the etiology of this disease. METHODS: Tissue and blood samples were collected from 11 patients who underwent nasal sinus surgery, and these samples were analyzed by multicolor flow cytometry. RESULTS: There was a significantly lower frequency of CD4+ T-helper (Th) cells and a significantly higher frequency of CD8+ T cells among lymphocytes isolated from nasal polyps compared with peripheral blood mononuclear cells (PBMC). In both T-cell subpopulations, a shift mainly from naive T cells among peripheral blood lymphocytes toward an effector memory and terminally differentiated subtype predominance in nasal polyps was observed. Among CD4+ T cells, the frequencies of cluster of differentiation (CD) 45RA- Forkhead-Box-Protein P3high (FoxP3high) cytotoxic T-lymphocyte-associated Protein 4high (CTLA-4high) activated regulatory T (Treg) cells, and CD45RA- Forkhead-Box-Protein P3low (FoxP3low) memory T cells were significantly increased in nasal polyps compared with PBMC. CONCLUSION: In this study, we presented a detailed characterization of CD4+ and CD8+ T-cell subpopulations in patients with CRSwNP. CD8+ T cells were more prominent in nasal polyps than in CD4+ T cells. Both nasal CD8+ T cells and CD4+ T cells predominantly had an effector memory phenotype. Among CD4+ T cells, activated Treg cells were increased in nasal polyps compared with PBMC. The data point toward a local regulation of T-cell composition within the microenvironment of nasal polyps, which might be further exploited in the future to develop novel immunotherapeutic strategies</style></abstract><notes><style face="normal" font="default">DA - 20171026IS - 2152-6575 (Print)IS - 2152-6567 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.2500/ar.2017.8.0214</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29070271">PM:29070271</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Rhinol (Providence)\2017-8-139-47.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Rhinol (Providence)\2017-8-139-47.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171026, Ickrath P</style></custom2><misc3><style face="normal" font="default">10.2500/ar.2017.8.0214</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43110</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Merget,R.</style></author><author><style face="normal" font="default"> Sander,I.</style></author><author><style face="normal" font="default"> Fartasch,M.</style></author><author><style face="normal" font="default"> van Kampen,V</style></author><author><style face="normal" font="default"> Roseler,S.</style></author><author><style face="normal" font="default"> Merk,H.</style></author><author><style face="normal" font="default"> Wurpts,G.</style></author><author><style face="normal" font="default"> Raulf,M.</style></author><author><style face="normal" font="default"> Bruning,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany</style></auth-address><titles><title><style face="normal" font="default">Occupational generalized urticaria and anaphylaxis after inhalation of cefuroxime in a nurse</style></title><secondary-title><style face="normal" font="default">Am J Ind Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Ind Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="11" Year="2017">2017/11/8</year></dates><abstract><style face="normal" font="default">We present the case of a 53 years old nonatopic female nurse who experienced repeated anaphylactic reactions at work without involvement in drug-specific tasks such as crushing of tablets or preparation of injections. The causal allergen was not identified until a further severe anaphylactic reaction occurred after oral use of cefuroxime during a respiratory infection. Sensitization to cefuroxime was demonstrated by specific IgE, basophil activation test and skin prick test. An inhalation challenge with a dosimeter induced generalized urticaria after a cumulative dose of about 10 mug of the drug, but no asthmatic reaction. Complete exposure cessation was initiated and a 1-year follow-up was without further allergic reactions. We conclude that work-related systemic allergic reactions to beta-lactam antibiotics may occur in nurses after inhalation of low doses and without perceived association with drug-specific tasks like handling of antibiotics</style></abstract><notes><style face="normal" font="default">DA - 20171108IS - 1097-0274 (Electronic)IS - 0271-3586 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1002/ajim.22788</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29114903">PM:29114903</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Ind Med\20171108-MergetR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Ind Med\20171108-MergetR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171108, Merget R</style></custom2><misc3><style face="normal" font="default">10.1002/ajim.22788</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43111</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ramiro,G.M.D.</style></author><author><style face="normal" font="default"> Ortiz,M.H.</style></author><author><style face="normal" font="default"> Arana Canedo-Arguelles,C.</style></author><author><style face="normal" font="default"> Esparza Olcina,M.J.</style></author><author><style face="normal" font="default"> Cortes,R.O.</style></author><author><style face="normal" font="default"> Terol,C.M.</style></author><author><style face="normal" font="default"> Ordobas,G.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Servicio de Admision, Hospital General Universitario Gregorio Maranon, Madrid, Espana</style></auth-address><titles><title><style face="normal" font="default">[Prevalence of breastfeeding and factors associated with the start and duration of exclusive breastfeeding in the Community of Madrid among participants in the ELOIN]</style></title><secondary-title><style face="normal" font="default">An Pediatr (Barc)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">An Pediatr (Barc)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="2" Month="11" Year="2017">2017/11/2</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Breastfeeding has important benefits for population health. The aims of this study are: (i)to determine the prevalence and duration of breastfeeding and exclusive breastfeeding; (ii)analyse the reasons for not starting or abandoning of breastfeeding, and (iii)describe the factors associated with the initiation and duration of exclusive breastfeeding. MATERIAL AND METHODS: Cross sectional study using the baseline data of the ELOIN cohort, obtained using an epidemiological questionnaire. A sample of 2,627 children born in 2008-2009 from the Community of Madrid was studied. Logistic regression models were used. RESULTS: Prevalence of exclusive breastfeeding and breastfeeding was 77.6% and 88% respectively; prevalence of exclusive breastfeeding at 6months 25.4%, and prevalence of breastfeeding at 2years was 7.7%. The most common reasons for abandoning breastfeeding were insufficient milk (36%), and incorporation to work (25.9%). The variables associated with starting or maintaining of exclusive breastfeeding were: mother older than 35years, medium-high economic status, foreigner residing in Spain less than 10 years, and having participated in a breastfeeding workshop. CONCLUSIONS: Breastfeeding prevalence in the Community of Madrid did not reach the international recommendations in 2008-2009. It is necessary to intensify strategies for breastfeeding promotion, protection, and support, including their periodic monitoring</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 1695-9531 (Electronic)IS - 1695-4033 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.anpedi.2017.09.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29103921">PM:29103921</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\An Pediatr (Barc)\20171106-RamiroGM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\An Pediatr (Barc)\20171106-RamiroGM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Ramiro GM</style></custom2><misc3><style face="normal" font="default">10.1016/j.anpedi.2017.09.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43112</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arnold,D.H.</style></author><author><style face="normal" font="default"> Johnson,D.P.</style></author><author><style face="normal" font="default"> Yang,C.L.</style></author><author><style face="normal" font="default"> Hartert,T.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Emergency Medicine, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee</style></auth-address><titles><title><style face="normal" font="default">Forced expiratory values in 1 second corresponding to Pediatric Respiratory Assessment Measure and Acute Asthma Intensity Research Score values during pediatric acute asthma exacerbations</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="10" Year="2017">2017/10/26</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.09.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29107465">PM:29107465</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171106-ArnoldDH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171106-ArnoldDH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Arnold DH</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.09.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43113</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Howell,C.R.</style></author><author><style face="normal" font="default"> Thompson,L.A.</style></author><author><style face="normal" font="default"> Gross,H.E.</style></author><author><style face="normal" font="default"> Reeve,B.B.</style></author><author><style face="normal" font="default"> Huang,S.W.</style></author><author><style face="normal" font="default"> DeWalt,D.A.</style></author><author><style face="normal" font="default"> Huang,I.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee</style></auth-address><titles><title><style face="normal" font="default">Association of consistently suboptimal quality of life with consistently poor asthma control in children with asthma</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="10" Year="2017">2017/10/26</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.09.053</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29107463">PM:29107463</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171106-HowellCR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171106-HowellCR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Howell CR</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.09.053</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43114</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vinnakota,S.</style></author><author><style face="normal" font="default"> Salonen,B.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Mayo Clinic,Rochester, Minnesota.</style></auth-address><titles><title><style face="normal" font="default">Linear IgA bullous dermatosis: a rare manifestation of vancomycin hypersensitivity</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="11" Year="2017">2017/11/8</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171112IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.10.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29128161">PM:29128161</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171112-VinnakotaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171112-VinnakotaS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171112, VinnakotaS</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.10.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43115</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brunner,P.M.</style></author><author><style face="normal" font="default"> Leung,D.Y.M.</style></author><author><style face="normal" font="default"> Guttman-Yassky,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York</style></auth-address><titles><title><style face="normal" font="default">Immunologic, microbial, and epithelial interactions in atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="11" Year="2017">2017/11/7</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To provide an overview of studies contributing to the understanding of immunologic, microbial, and epithelial interactions in atopic dermatitis. DATA SOURCES: PubMed literature review (2000-2017) and meeting abstracts from recent international dermatology conferences. STUDY SELECTIONS: Articles discussing primarily human disease. RESULTS: Clinical studies showed that atopic dermatitis is a type 2 immune-centered disease with a systemic inflammatory component but with heterogeneous treatment responses. This suggests that other factors are likely involved in shaping the skin disease phenotype, including microbial dysbiosis and epidermal barrier dysfunction. CONCLUSION: Recent clinical investigation has significantly expanded our knowledge on disease pathogenesis in atopic dermatitis, and current and future clinical trials will most likely further help to elucidate this complex, heterogeneous skin disease</style></abstract><notes><style face="normal" font="default">DA - 20171111IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.09.055</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29126710">PM:29126710</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171111-BrunnerPM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171111-BrunnerPM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171111, Brunner PM</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.09.055</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43116</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chomiciene,A.</style></author><author><style face="normal" font="default"> Stankeviciute,R.</style></author><author><style face="normal" font="default"> Malinauskiene,L.</style></author><author><style face="normal" font="default"> Grigaitiene,J.</style></author><author><style face="normal" font="default"> Blaziene,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinic of Infectious and Chest Diseases, Dermatovenereology and Allergology, Center of Pulmonology and Allergology, Vilnius University, Vilnius, Lithuania</style></auth-address><titles><title><style face="normal" font="default">Rare cause of periorbital and eyelids lesions: discoid lupus erythematosus misdiagnosed as allergy</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="10" Year="2017">2017/10/25</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171105IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Lithuania -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.09.062</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29102423">PM:29102423</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171105-ChomiceneA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171105-ChomiceneA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171105, Chomiciene A</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.09.062</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43117</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sato,S.</style></author><author><style face="normal" font="default"> Saito,J.</style></author><author><style face="normal" font="default"> Fukuhara,A.</style></author><author><style face="normal" font="default"> Uematsu,M.</style></author><author><style face="normal" font="default"> Suzuki,Y.</style></author><author><style face="normal" font="default"> Togawa,R.</style></author><author><style face="normal" font="default"> Sato,Y.</style></author><author><style face="normal" font="default"> Nikaido,T.</style></author><author><style face="normal" font="default"> Wang,X.</style></author><author><style face="normal" font="default"> Tanino,Y.</style></author><author><style face="normal" font="default"> Munakata,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonary Medicine, School of Medicine, Fukushima Medical University, Fukushima City, Japan.</style></auth-address><titles><title><style face="normal" font="default">The clinical role of fractional exhaled nitric oxide in asthma control</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="10" Year="2017">2017/10/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: The potential role and characteristics of fractional exhaled nitric oxide (FeNO) remain unclear in the treatment of asthma. OBJECTIVE: To explore the clinical role of FeNO in asthmatic treatment. METHODS: We evaluated whether the mean or change of FeNO levels in the treatment period is associated with other conventional control parameters and predicted some clinical outcomes of asthma. We retrospectively analyzed the mean and percentage change of FeNO levels in the first 5 measurements at our hospital. RESULTS: The study found a significantly strong correlation between FeNO level at diagnosis and the largest changes of FeNO values from diagnosis. No significant correlations were observed between FeNO levels and other parameters (Asthma Control Test [ACT] score or forced expiratory volume in one second [FEV1]) in mean and percentage change of values under treatment of asthma; however, significant positive correlations were found between ACT scores and FEV1. The mean FeNO level revealed a significant negative correlation with an annual change in FEV1 in individuals with asthma who were followed up for more than 2 years. Both the mean ACT score and percent predicted FEV1 revealed a significant negative correlation with occasional use of systemic corticosteroids. CONCLUSION: During conventional treatment of asthma, the largest changes of FeNO values from diagnosis were strongly correlated with FeNO levels at diagnosis. As for the unlikely conventional parameters, no significant associations were observed between FeNO levels and deterioration of asthma during the treatment periods. An elevated mean FeNO level may be a marker of decreased lung function in individuals with asthma</style></abstract><notes><style face="normal" font="default">DA - 20171107IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.09.059</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29110960">PM:29110960</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171107-SatoS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171107-SatoS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171107, Sato S</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.09.059</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43118</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lehrer,P.M.</style></author><author><style face="normal" font="default"> Irvin,C.G.</style></author><author><style face="normal" font="default"> Lu,S.E.</style></author><author><style face="normal" font="default"> Scardella,A.</style></author><author><style face="normal" font="default"> Roehmheld-Hamm,B.</style></author><author><style face="normal" font="default"> Aviles-Velez,M.</style></author><author><style face="normal" font="default"> Graves,J.</style></author><author><style face="normal" font="default"> Vaschillo,E.G.</style></author><author><style face="normal" font="default"> Vaschillo,B.</style></author><author><style face="normal" font="default"> Hoyte,F.</style></author><author><style face="normal" font="default"> Nelson,H.</style></author><author><style face="normal" font="default"> Wamboldt,F.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Psychiatry, Rutgers - Robert Wood Johnson Medical School, 671 Hoes Lane, Piscataway, NJ, 08854, USA.</style></auth-address><titles><title><style face="normal" font="default">Heart Rate Variability Biofeedback Does Not Substitute for Asthma Steroid Controller Medication</style></title><secondary-title><style face="normal" font="default">Appl Psychophysiol Biofeedback</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Appl Psychophysiol Biofeedback</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="11" Year="2017">2017/11/9</year></dates><abstract><style face="normal" font="default">Despite previous findings of therapeutic effects for heart rate variability biofeedback (HRVB) on asthma, it is not known whether HRVB can substitute either for controller or rescue medication, or whether it affects airway inflammation. Sixty-eight paid volunteer steroid naive study participants with mild or moderate asthma were given 3 months of HRVB or a comparison condition consisting of EEG alpha biofeedback with relaxing music and relaxed paced breathing (EEG+), in a two-center trial. All participants received a month of intensive asthma education prior to randomization. Both treatment conditions produced similar significant improvements on the methacholine challenge test (MCT), asthma symptoms, and asthma quality of life (AQOL). MCT effects were of similar size to those of enhanced placebo procedures reported elsewhere, and were 65% of those of a course of a high-potency inhaled steroid budesonide given to a sub-group of participants following biofeedback training. Exhaled nitric oxide decreased significantly only in the HRVB group, 81% of the budesonide effect, but with no significant differences between groups. Participants reported becoming more relaxed during practice of both techniques. Administration of albuterol after biofeedback sessions produced a large improvement in pulmonary function test results, indicating that neither treatment normalized pulmonary function as a potent controller medication would have done. Impulse oscillometry showed increased upper airway (vocal cord) resistance during biofeedback periods in both groups. These data suggest that HRVB should not be considered an alternative to asthma controller medications (e.g., inhaled steroids), although both biofeedback conditions produced some beneficial effects, warranting further research, and suggesting potential complementary effects. Various hypotheses are presented to explain why HRVB effects on asthma appeared smaller in this study than in earlier studies. Clinical Trial Registration NCT02766374</style></abstract><notes><style face="normal" font="default">DA - 20171110IS - 1573-3270 (Electronic)IS - 1090-0586 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s10484-017-9382-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29124506">PM:29124506</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Appl Psychophysiol Biofeedback\20171110-LehrerPM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Appl Psychophysiol Biofeedback\20171110-LehrerPM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171110, Lehrer PM</style></custom2><misc3><style face="normal" font="default">10.1007/s10484-017-9382-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43119</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rangamuwa,K.B.</style></author><author><style face="normal" font="default"> Young,A.C.</style></author><author><style face="normal" font="default"> Thien,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory and Sleep Medicine, Box Hill Hospital, Eastern Health and Monash University, Melbourne, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="default">An epidemic of thunderstorm asthma in Melbourne 2016: asthma, rhinitis, and other previous allergies</style></title><secondary-title><style face="normal" font="default">Asia Pac Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asia Pac Allergy</style></abbr-1></periodical><pages end="198" start="193">193-198</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Background: On 21st November 2016, Melbourne experienced an epidemic of 'thunderstorm asthma.' Although previously described in the literature, risk factors and natural history remain incompletely understood. Objective: Our aim was to follow up those presenting to the 3 Emergency Departments (EDs) in our health service during the epidemic, and assess their history for previous asthma, rhinitis, and allergies. Methods: ED notes of all respiratory presentations within 48 hours of the thunderstorm event were reviewed and patients with acute asthma included. A standardised questionnaire was devised encompassing asthma diagnosis, undiagnosed asthma symptoms and rhinitis severity. Patients were contacted by phone within 30 days of the event. Results: Three hundred forty-four patients were identified overall; 263 patients were contactable and completed a phone or mail questionnaire. The mean age was 32.7 +/- 19.2 years (range, 6 months-87 years; 25% &lt; 18 years) with 58% male sex. A previous diagnosis of asthma was present in 42% (n = 111), and there was no previous asthma diagnosis in 58% (n = 152). Of those who had no asthma diagnosis 53% had probable undiagnosed asthma. Overall, rhinitis prevalence was 88%, of which 72% were moderate or severe (Allergic Rhinitis and its Impact on Asthma guidelines) and 51% (n = 133) reported a history of grass pollen allergy. Conclusion: Our data highlights the importance of atopy and rhinitis as risk factors for epidemic thunderstorm asthma. Better identification of undiagnosed asthma, and implementing treatment of asthma and rhinitis may be important</style></abstract><notes><style face="normal" font="default">DA - 20171102IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.5415/apallergy.2017.7.4.193</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29094016">PM:29094016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-193-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-193-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171102, Rangamuwa KB</style></custom2><misc3><style face="normal" font="default">10.5415/apallergy.2017.7.4.193</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43120</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kumar,A.</style></author><author><style face="normal" font="default"> Kunal,S.</style></author><author><style face="normal" font="default"> Shah,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi 110 007, India</style></auth-address><titles><title><style face="normal" font="default">Frequency and effect of type 1 hypersensitivity in patients from India with chronic obstructive pulmonary disease and associated upper airways symptoms</style></title><secondary-title><style face="normal" font="default">Asia Pac Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asia Pac Allergy</style></abbr-1></periodical><pages end="205" start="199">199-205</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Background: Chronic obstructive pulmonary disease (COPD) is now recognized as a systemic disorder with many comorbidities. Atopy in patients with COPD and upper airways symptoms has not been characterized. Objective: We investigated the occurrence and impact of aeroallergen sensitisation in patients with COPD and upper airways symptoms. Methods: All 41 subjects with COPD diagnosed as per Global Initiative for Chronic Obstructive Lung Disease guidelines, underwent spirometry with reversibility, computed tomography of the paranasal sinuses (CT-PNS), skin prick test (SPT) against common aeroallergens and responded to St. George's Respiratory Questionnaire (SGRQ) and Sino Nasal Outcome Test - 22 (SNOT-22) questionnaires. Upper airways symptoms were assessed as per the Allergic Rhinitis and its Impact on Asthma guidelines. Results: As documented earlier, 27 of the 41 patients (65.9%) with COPD had upper airways symptoms. Of these 27 patients, 11 had SPT positivity against at least one aeroallergen (group 1). One patient had monosensitisation to pollens of grass Imperata while polysensitisation was seen in 10/11 patients commonly to weeds, trees, and insects. Fungal sensitisation to Aspergillus fumigatus was seen in 3 of 11 patients (27.2%). In group 1, all 11 patients (100%) had radiological sinusitis as compared to 8 of 16 (50%) in group 2. The mean CT-PNS scores were significantly higher in group 1 as compared to group 2. Similarly, the SNOT-22 scores were significantly higher in group 1 as compared to group 2. However, there was no difference in SGRQ scores between the 2 groups. In group 1, there was a significant correlation between CT-PNS and SNOT-22 scores. Conclusion: Patients with COPD, associated upper airways symptoms and a positive SPT had a significantly higher frequency of radiological sinusitis on CT-PNS. They even had worse quality of life as compared to those with a negative SPT. The study suggested that atopic patients with COPD and upper airways involvement were more symptomatic. It is therefore possible that upper airways symptoms, if left untreated, would result in less than desirable control of the disease</style></abstract><notes><style face="normal" font="default">DA - 20171102IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.5415/apallergy.2017.7.4.199</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29094017">PM:29094017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-199-205.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-199-205.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171102, Kumar A</style></custom2><misc3><style face="normal" font="default">10.5415/apallergy.2017.7.4.199</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43121</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Loh,W.</style></author><author><style face="normal" font="default"> Wright,K.M.</style></author><author><style face="normal" font="default"> Chiou,F.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Paediatric Medicine, Allergy Service, KK Women's and Children's Hospital, Singapore</style></auth-address><titles><title><style face="normal" font="default">Absence of esophageal eosinophilia in a toddler with severe eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default">Asia Pac Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asia Pac Allergy</style></abbr-1></periodical><pages end="246" start="243">243-246</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Eosinophilic esophagitis (EoE) is a clinicopathologic disease characterised by esophageal dysfunction and eosinophil-predominant inflammation. Diagnosing EoE in children is particularly challenging as they tend to present with nonspecific symptoms and their mucosal specimens may have less than the threshold number of eosinophils. Reluctance to subject children to multiple endoscopic procedures and anesthesia often results in treatment with a proton pump inhibitor (PPI) first to evaluate clinical response. This approach presents a problem as a diagnosis of EoE may be missed. Here we present a case of a child with severe EoE whose initial biopsy did not show esophageal eosinophilia but progressed on to advance dis ease despite clinical response to PPI therapy</style></abstract><notes><style face="normal" font="default">DA - 20171102IS - 2233-8276 (Print)IS - 2233-8276 (Linking)LA - engPT - Journal ArticleCO - Singapore -</style></notes><work-type><style face="normal" font="default">10.5415/apallergy.2017.7.4.243</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29094023">PM:29094023</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-243-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asia Pac Allergy\2017-7-243-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171102, Loh W</style></custom2><misc3><style face="normal" font="default">10.5415/apallergy.2017.7.4.243</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43122</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,H.</style></author><author><style face="normal" font="default"> Archer,N.K.</style></author><author><style face="normal" font="default"> Dillen,C.A.</style></author><author><style face="normal" font="default"> Wang,Y.</style></author><author><style face="normal" font="default"> Ashbaugh,A.G.</style></author><author><style face="normal" font="default"> Ortines,R.V.</style></author><author><style face="normal" font="default"> Kao,T.</style></author><author><style face="normal" font="default"> Lee,S.K.</style></author><author><style face="normal" font="default"> Cai,S.S.</style></author><author><style face="normal" font="default"> Miller,R.J.</style></author><author><style face="normal" font="default"> Marchitto,M.C.</style></author><author><style face="normal" font="default"> Zhang,E.</style></author><author><style face="normal" font="default"> Riggins,D.P.</style></author><author><style face="normal" font="default"> Plaut,R.D.</style></author><author><style face="normal" font="default"> Stibitz,S.</style></author><author><style face="normal" font="default"> Geha,R.S.</style></author><author><style face="normal" font="default"> Miller,L.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA</style></auth-address><titles><title><style face="normal" font="default">Staphylococcus aureus Epicutaneous Exposure Drives Skin Inflammation via IL-36-Mediated T Cell Responses</style></title><secondary-title><style face="normal" font="default">Cell Host Microbe</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cell Host Microbe</style></abbr-1></periodical><pages end="666" start="653">653-666</pages><volume><style face="normal" font="default">22</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="11" Year="2017">2017/11/8</year></dates><abstract><style face="normal" font="default">Staphylococcus aureus colonization contributes to skin inflammation in diseases such as atopic dermatitis, but the signaling pathways involved are unclear. Herein, epicutaneous S. aureus exposure to mouse skin promoted MyD88-dependent skin inflammation initiated by IL-36, but not IL-1alpha/beta, IL-18, or IL-33. By contrast, an intradermal S. aureus challenge promoted MyD88-dependent host defense initiated by IL-1beta rather than IL-36, suggesting that different IL-1 cytokines trigger MyD88 signaling depending on the anatomical depth of S. aureus cutaneous exposure. The bacterial virulence factor PSMalpha, but not alpha-toxin or delta-toxin, contributed to the skin inflammation, which was driven by IL-17-producing gammadelta and CD4+ T cells via direct IL-36R signaling in the T cells. Finally, adoptive transfer of IL-36R-expressing T cells to IL-36R-deficient mice was sufficient for mediating S. aureus-induced skin inflammation. Together, this study defines a previously unknown pathway by which S. aureus epicutaneous exposure promotes skin inflammation involving IL-36R/MyD88-dependent IL-17 T cell responses</style></abstract><notes><style face="normal" font="default">DA - 20171109IS - 1934-6069 (Electronic)IS - 1931-3128 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.chom.2017.10.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29120743">PM:29120743</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cell Host Microbe\2017-22-653-66.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cell Host Microbe\2017-22-653-66.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171109, Liu H</style></custom2><misc3><style face="normal" font="default">10.1016/j.chom.2017.10.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43123</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Williams,M.R.</style></author><author><style face="normal" font="default"> Nakatsuji,T.</style></author><author><style face="normal" font="default"> Gallo,R.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of California, San Diego, La Jolla, CA, USA</style></auth-address><titles><title><style face="normal" font="default">Staphylococcus aureus: Master Manipulator of the Skin</style></title><secondary-title><style face="normal" font="default">Cell Host Microbe</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cell Host Microbe</style></abbr-1></periodical><pages end="581" start="579">579-581</pages><volume><style face="normal" font="default">22</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="11" Year="2017">2017/11/8</year></dates><abstract><style face="normal" font="default">Skin colonization by Staphylococcus aureus is associated with severity of atopic dermatitis (AD). Two papers in this issue of Cell Host &amp; Microbe by Nakagawa et al. (2017) and Liu et al. (2017) define a pathway by which epicutaneous Staphylococcus aureus promotes skin inflammation and may contribute to AD</style></abstract><notes><style face="normal" font="default">DA - 20171109IS - 1934-6069 (Electronic)IS - 1931-3128 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.chom.2017.10.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29120738">PM:29120738</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cell Host Microbe\2017-22-579-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cell Host Microbe\2017-22-579-81.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171109, Williams MR</style></custom2><misc3><style face="normal" font="default">10.1016/j.chom.2017.10.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43124</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Roberts,G.</style></author><author><style face="normal" font="default"> Boyle,R.</style></author><author><style face="normal" font="default"> Crane,J.</style></author><author><style face="normal" font="default"> Hogan,S.P.</style></author><author><style face="normal" font="default"> Saglani,S.</style></author><author><style face="normal" font="default"> Wickman,M.</style></author><author><style face="normal" font="default"> Woodfolk,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton</style></auth-address><titles><title><style face="normal" font="default">Developments in the field of allergy in 2016 through the eyes of Clinical and Experimental Allergy</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="10" Year="2017">2017/10/25</year></dates><abstract><style face="normal" font="default">In this paper we described the development in the field of allergy as described by Clinical and Experimental Allergy in 2016. Experimental models of allergic disease, basic mechanisms, clinical mechanisms, allergens, asthma and rhinitis and clinical allergy are all covered. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171025IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - New Zealand -CO - United States -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29068551">PM:29068551</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20171025-RobertsG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20171025-RobertsG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171025, Roberts G</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13049</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43125</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Recto,M.T.</style></author><author><style face="normal" font="default"> Gabriel,M.T.</style></author><author><style face="normal" font="default"> Kulthanan,K.</style></author><author><style face="normal" font="default"> Tantilipikorn,P.</style></author><author><style face="normal" font="default"> Aw,D.C.</style></author><author><style face="normal" font="default"> Lee,T.H.</style></author><author><style face="normal" font="default"> Chwen,C.C.</style></author><author><style face="normal" font="default"> Mutusamy,S.</style></author><author><style face="normal" font="default"> Hao,N.T.</style></author><author><style face="normal" font="default"> Quang,V.T.</style></author><author><style face="normal" font="default"> Canonica,G.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of the Philippines-Philippine General Hospital, Manila, Philippines</style></auth-address><titles><title><style face="normal" font="default">Selecting optimal second-generation antihistamines for allergic rhinitis and urticaria in Asia</style></title><secondary-title><style face="normal" font="default">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Mol Allergy</style></full-title></periodical><pages end="" start="19">19-</pages><volume><style face="normal" font="default">15</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Allergic diseases are on the rise in many parts of the world, including the Asia-Pacific (APAC) region. Second-generation antihistamines are the first-line treatment option in the management of allergic rhinitis and urticaria. International guidelines describe the management of these conditions; however, clinicians perceive the additional need to tailor treatment according to patient profiles. This study serves as a consensus of experts from several countries in APAC (Hong Kong, Malaysia, the Philippines, Singapore, Thailand, Vietnam), which aims to describe the unmet needs, practical considerations, challenges, and key decision factors when determining optimal second-generation antihistamines for patients with allergic rhinitis and/or urticaria. Methods: Specialists from allergology, dermatology, and otorhinolaryngology were surveyed on practical considerations and key decision points when treating patients with allergic rhinitis and/or urticaria. Results: Clinicians felt the need for additional tools for diagnosis of these diseases and a single drug with all preferred features of an antihistamine. Challenges in treatment include lack of clinician and patient awareness and compliance, financial constraints, and treatment for special patient populations such as those with concomitant disease. Selection of optimal second-generation antihistamines depends on many factors, particularly drug safety and efficacy, impact on psychomotor abilities, and sedation. Country-specific considerations include drug availability and cost-effectiveness. Survey results reveal bilastine as a preferred choice due to its high efficacy and safety, suitability for special patient populations, and the lack of sedative effects. Conclusions: Compliance to the international guidelines is present among allergists, dermatologists and otorhinolaryngologists; however, this is lower amongst general practitioners (GPs). To increase awareness, allergy education programs targeted at GPs and patients may be beneficial. Updates to the existing international guidelines are suggested in APAC to reflect appropriate management for different patient profiles and varying symptoms of allergic rhinitis and urticaria</style></abstract><notes><style face="normal" font="default">DA - 20171109IS - 1476-7961 (Print)IS - 1476-7961 (Linking)LA - engPT - Journal ArticleCO - Philippines -CO - Thailand -CO - Singapore -CO - Hong Kong -CO - Malaysia -CO - Vietnam -CO - Italy -</style></notes><work-type><style face="normal" font="default">10.1186/s12948-017-0074-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29118675">PM:29118675</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-19.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-19.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171109, Recto MT</style></custom2><misc3><style face="normal" font="default">10.1186/s12948-017-0074-3</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43126</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bousquet,J.</style></author><author><style face="normal" font="default"> Onorato,G.L.</style></author><author><style face="normal" font="default"> Bachert,C.</style></author><author><style face="normal" font="default"> Barbolini,M.</style></author><author><style face="normal" font="default"> Bedbrook,A.</style></author><author><style face="normal" font="default"> Bjermer,L.</style></author><author><style face="normal" font="default"> de Sousa,J.C.</style></author><author><style face="normal" font="default"> Chavannes,N.H.</style></author><author><style face="normal" font="default"> Cruz,A.A.</style></author><author><style face="normal" font="default"> De Manuel Keenoy,E.</style></author><author><style face="normal" font="default"> Devillier,P.</style></author><author><style face="normal" font="default"> Fonseca,J.</style></author><author><style face="normal" font="default"> Hun,S.</style></author><author><style face="normal" font="default"> Kostka,T.</style></author><author><style face="normal" font="default"> Hellings,P.W.</style></author><author><style face="normal" font="default"> Illario,M.</style></author><author><style face="normal" font="default"> Ivancevich,J.C.</style></author><author><style face="normal" font="default"> Larenas-Linnemann,D.</style></author><author><style face="normal" font="default"> Millot-Keurinck,J.</style></author><author><style face="normal" font="default"> Ryan,D.</style></author><author><style face="normal" font="default"> Samolinski,B.</style></author><author><style face="normal" font="default"> Sheikh,A.</style></author><author><style face="normal" font="default"> Yorgancioglu,A.</style></author><author><style face="normal" font="default"> Agache,I.</style></author><author><style face="normal" font="default"> Arnavielhe,S.</style></author><author><style face="normal" font="default"> Bewick,M.</style></author><author><style face="normal" font="default"> Annesi-Maesano,I.</style></author><author><style face="normal" font="default"> Anto,J.M.</style></author><author><style face="normal" font="default"> Bergmann,K.C.</style></author><author><style face="normal" font="default"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="default"> Bosnic-Anticevich,S.</style></author><author><style face="normal" font="default"> Bouchard,J.</style></author><author><style face="normal" font="default"> Caimmi,D.P.</style></author><author><style face="normal" font="default"> Camargos,P.</style></author><author><style face="normal" font="default"> Canonica,G.W.</style></author><author><style face="normal" font="default"> Cardona,V.</style></author><author><style face="normal" font="default"> Carriazo,A.M.</style></author><author><style face="normal" font="default"> Cingi,C.</style></author><author><style face="normal" font="default"> Colgan,E.</style></author><author><style face="normal" font="default"> Custovic,A.</style></author><author><style face="normal" font="default"> Dahl,R.</style></author><author><style face="normal" font="default"> Demoly,P.</style></author><author><style face="normal" font="default"> De Vries,G.</style></author><author><style face="normal" font="default"> Fokkens,W.J.</style></author><author><style face="normal" font="default"> Fontaine,J.F.</style></author><author><style face="normal" font="default"> Gemicioglu,B.</style></author><author><style face="normal" font="default"> Guldemond,N.</style></author><author><style face="normal" font="default"> Gutter,Z.</style></author><author><style face="normal" font="default"> Haahtela,T.</style></author><author><style face="normal" font="default"> Hellqvist-Dahl,B.</style></author><author><style face="normal" font="default"> Jares,E.</style></author><author><style face="normal" font="default"> Joos,G.</style></author><author><style face="normal" font="default"> Just,J.</style></author><author><style face="normal" font="default"> Khaltaev,N.</style></author><author><style face="normal" font="default"> Keil,T.</style></author><author><style face="normal" font="default"> Klimek,L.</style></author><author><style face="normal" font="default"> Kowalski,M.L.</style></author><author><style face="normal" font="default"> Kull,I.</style></author><author><style face="normal" font="default"> Kuna,P.</style></author><author><style face="normal" font="default"> Kvedariene,V.</style></author><author><style face="normal" font="default"> Laune,D.</style></author><author><style face="normal" font="default"> Louis,R.</style></author><author><style face="normal" font="default"> Magnan,A.</style></author><author><style face="normal" font="default"> Malva,J.</style></author><author><style face="normal" font="default"> Mathieu-Dupas,E.</style></author><author><style face="normal" font="default"> Melen,E.</style></author><author><style face="normal" font="default"> Menditto,E.</style></author><author><style face="normal" font="default"> Morais-Almeida,M.</style></author><author><style face="normal" font="default"> Mosges,R.</style></author><author><style face="normal" font="default"> Mullol,J.</style></author><author><style face="normal" font="default"> Murray,R.</style></author><author><style face="normal" font="default"> Neffen,H.</style></author><author><style face="normal" font="default"> O'Hehir,R.</style></author><author><style face="normal" font="default"> Palkonen,S.</style></author><author><style face="normal" font="default"> Papadopoulos,N.G.</style></author><author><style face="normal" font="default"> Passalacqua,G.</style></author><author><style face="normal" font="default"> Pepin,J.L.</style></author><author><style face="normal" font="default"> Portejoie,F.</style></author><author><style face="normal" font="default"> Price,D.</style></author><author><style face="normal" font="default"> Pugin,B.</style></author><author><style face="normal" font="default"> Raciborski,F.</style></author><author><style face="normal" font="default"> Simons,F.E.R.</style></author><author><style face="normal" font="default"> Sova,M.</style></author><author><style face="normal" font="default"> Spranger,O.</style></author><author><style face="normal" font="default"> Stellato,C.</style></author><author><style face="normal" font="default"> Todo Bom,A.</style></author><author><style face="normal" font="default"> Tomazic,P.V.</style></author><author><style face="normal" font="default"> Triggiani,M.</style></author><author><style face="normal" font="default"> Valero,A.</style></author><author><style face="normal" font="default"> Valovirta,E.</style></author><author><style face="normal" font="default"> Vandenplas,O.</style></author><author><style face="normal" font="default"> Valiulis,A.</style></author><author><style face="normal" font="default"> van Eerd,M.</style></author><author><style face="normal" font="default"> Ventura,M.T.</style></author><author><style face="normal" font="default"> Wickman,M.</style></author><author><style face="normal" font="default"> Young,I.</style></author><author><style face="normal" font="default"> Zuberbier,T.</style></author><author><style face="normal" font="default"> Zurkuhlen,A.</style></author><author><style face="normal" font="default"> Senn,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Contre les MAladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France</style></auth-address><titles><title><style face="normal" font="default">CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report</style></title><secondary-title><style face="normal" font="default">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Transl Allergy</style></full-title></periodical><pages end="" start="37">37-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">A Good Practice is a practice that works well, produces good results, and is recommended as a model. MACVIA-ARIA Sentinel Network (MASK), the new Allergic Rhinitis and its Impact on Asthma (ARIA) initiative, is an example of a Good Practice focusing on the implementation of multi-sectoral care pathways using emerging technologies with real life data in rhinitis and asthma multi-morbidity. The European Union Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS) has developed a checklist of 28 items for the evaluation of Good Practices. SUNFRAIL (Reference Sites Network for Prevention and Care of Frailty and Chronic Conditions in community dwelling persons of EU Countries), a European Union project, assessed whether MASK is in line with the 28 items of JA-CHRODIS. A short summary was proposed for each item and 18 experts, all members of ARIA and SUNFRAIL from 12 countries, assessed the 28 items using a Survey Monkey-based questionnaire. A visual analogue scale (VAS) from 0 (strongly disagree) to 100 (strongly agree) was used. Agreement equal or over 75% was observed for 14 items (50%). MASK is following the JA-CHRODIS recommendations for the evaluation of Good Practices</style></abstract><notes><style face="normal" font="default">DA - 20171027IS - 2045-7022 (Print)IS - 2045-7022 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - France -CO - Belgium -CO - Italy -CO - Sweden -CO - Portugal -CO - Netherlands -CO - Brazil -CO - Spain -CO - United Kingdom -CO - Poland -CO - Argentina -CO - Mexico -CO - Turkey -CO - Romania -CO - Germany -CO - Denmark -CO - Australia -CO - Canada -CO - Czechia -CO - Finland -CO - Argentina -CO - Switzerland -CO - Lithuania -CO - Ireland -CO - Greece -CO - Austria -CO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1186/s13601-017-0173-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29075437">PM:29075437</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-37.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-37.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171027, Bousquet J</style></custom2><misc3><style face="normal" font="default">10.1186/s13601-017-0173-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43127</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Madsen,M.T.</style></author><author><style face="normal" font="default"> Andersen,F.</style></author><author><style face="normal" font="default"> Paulsen,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Occupational and Environmental Medicine, Odense University Hospital, 5000 Odense C, Denmark</style></auth-address><titles><title><style face="normal" font="default">Concomitant immediate and delayed sensitization by philodendron (Philodendron scandens) in a plant keeper</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="328" start="326">326-328</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12821</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29063689">PM:29063689</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-326-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-326-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171024, Madsen MT</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12821</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43128</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chaubal,T.V.</style></author><author><style face="normal" font="default"> Bapat,R.A.</style></author><author><style face="normal" font="default"> Bapat,P.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Periodontics, D.Y. Patil School of Dentistry, Nerul, Navi Mumbai 400706, IndiaDivision of Clinical Dentistry, School of Dentistry, International Medical University, Kuala Lumpur 57000, MalaysiaCosmetic Dentist, Mumbai 400091, India</style></auth-address><titles><title><style face="normal" font="default">Allergic contact stomatitis caused Salvadora persica in toothpaste</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="326" start="325">325-326</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - India -CO - Malaysia -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12819</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29063688">PM:29063688</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-325-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-325-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171024, Chaubal TV</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12819</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43129</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ozkaya,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Istanbul Medical Faculty, Department of Dermatology and Venereology, Istanbul University, 34093 Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="default">Linear eczema on the amputation stump as a clinical clue to the diagnosis</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="330" start="328">328-330</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12824</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29063694">PM:29063694</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-328-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-328-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171024, Ozkaya E</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12824</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43130</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Montgomery,R.L.</style></author><author><style face="normal" font="default"> Agius,R.</style></author><author><style face="normal" font="default"> Wilkinson,S.M.</style></author><author><style face="normal" font="default"> Carder,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Leeds Teaching Hospitals NHS Trust - Centre for Dermatology, Chapel Allerton Hospital, Leeds, LS7 4SA, UK</style></auth-address><titles><title><style face="normal" font="default">UK trends of allergic occupational skin disease attributed to fragrances 1996-2015</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="10" Year="2017">2017/10/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Fragrances are well known to cause allergic contact dermatitis (ACD). Occupationally related cases occur, with certain groups being at higher risk. OBJECTIVE: To investigate the incidence of occupationally related cases of cutaneous fragrance allergy and to evaluate trends. METHOD: Data on incident cases of occupational ACD caused by fragrances between 1996 and 2015 (inclusive) reported to the EPIDERM surveillance scheme were analysed. RESULTS: Of the cases reported to EPIDERM during the study period, 5.2% had ACD attributed to fragrances. The highest annual incidence rates were observed in women. Hairdressers, beauticians and people working in related occupations had a 47-fold higher incidence rate ratio than the reference category (the average of all other occupations combined). Trends analysis suggested a non-significant increase in fragrance allergy over the study period among all occupations, and beauty and food workers, and a slight decrease in healthcare workers. CONCLUSIONS: Fragrance allergy is a significant problem in an occupational setting. Although there was no significant change in the incidence of fragrance-related allergic occupational contact dermatitis (OCD) during the 20-year study period, this does not mirror the trend in OCD, which is falling. Fragrance allergy continues to be a major contributor to OCD, and contributes to a greater proportion of cases</style></abstract><notes><style face="normal" font="default">DA - 20171027IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12902</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29076574">PM:29076574</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20171027-MontgomeryRL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20171027-MontgomeryRL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171027, Montgomery RL</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12902</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43131</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gilissen,L.</style></author><author><style face="normal" font="default"> Huygens,S.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Contact Allergy Unit, Department of Dermatology, University Hospitals KU Leuven, 3000, Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by calcipotriol</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="11" Year="2017">2017/11/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Calcipotriol, a synthetic vitamin D analogue, is widely used for the topical treatment of psoriasis. It often causes irritant reactions, whereas allergic contact dermatitis has less commonly been reported. OBJECTIVES: To report on 6 patients (among them an 11-year-old child) who presented with eczematous lesions complicating pre-existing dermatitis, observed in our tertiary referral patch test clinic between 2004 and 2016. METHODS: Patch tests were performed with the commercial preparation used by the patients and/or its ingredients, including calcipotriol (2 or 10 microg/ml in isopropyl alcohol), according to ESCD patch test guidelines. RESULTS: Allergic contact dermatitis was confirmed in all cases, and the lesions improved following treatment with topical corticosteroids and/or oral medication. CONCLUSIONS: When topical treatment with calcipotriol fails to improve, or even worsens, existing skin lesions, contact allergy should be suspected. A patch test concentration of 2 microg/ml in isopropyl alcohol seems to be the most suitable. According to the literature, patients sensitized to calcipotriol may tolerate topical therapy with other vitamin D3 analogues, particularly tacalcitol</style></abstract><notes><style face="normal" font="default">DA - 20171108IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12910</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29114901">PM:29114901</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20171108-GilissenL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20171108-GilissenL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171108, Gilissen L</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12910</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43132</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hulstaert,E.</style></author><author><style face="normal" font="default"> Bergendorff,O.</style></author><author><style face="normal" font="default"> Persson,C.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author><author><style face="normal" font="default"> Gilissen,L.</style></author><author><style face="normal" font="default"> Engfeldt,M.</style></author><author><style face="normal" font="default"> Bruze,M.</style></author><author><style face="normal" font="default"> Schuttelaar,M.L.</style></author><author><style face="normal" font="default"> Meijer,J.M.</style></author><author><style face="normal" font="default"> Lapeere,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Hospital Gent, 9000, Ghent, Belgium</style></auth-address><titles><title><style face="normal" font="default">Contact dermatitis caused by a new rubber compound detected in canvas shoes</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="10" Year="2017">2017/10/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: In 2015 and 2016, female patients in Flanders consulted a dermatologist because they developed skin lesions after wearing a specific brand of canvas shoes. OBJECTIVES: To identify the culprit allergen in the shoes. METHODS: Eighteen young females aged 14-22 years presented with itching and erythematous to purple-coloured eczematous lesions on both feet. They were patch tested by 10 dermatologists with the European baseline series. Some patients underwent testing with additional series. Pieces of the shoe fabrics were tested in 11 of 18 patients. Chemical analysis of the shoe materials was performed. Finally, patients were tested with a thin-layer chromatogram of the shoe extracts and dilutions of the suspected rubber compound. RESULTS: All 18 patients showed positive reactions to thiuram mix. Ten of 11 patients reacted to a piece of shoe fabric. Chemical analysis showed the presence of dimethylthiocarbamylbenzothiazole sulfide (DMTBS). No thiurams were detected. Four patients tested with the chromatogram developed positive reactions to DMTBS. Positive reactions to low concentrations were observed in the 4 patients tested with a DMTBS dilution series; one patient reacted to 0.00001% in acetone. CONCLUSIONS: DMTBS, the culprit allergen, is a component formed during rubber vulcanization that probably cross-reacts with the thiuram mix</style></abstract><notes><style face="normal" font="default">DA - 20171018IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Sweden -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12886</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29044554">PM:29044554</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20171018-HulstaertE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20171018-HulstaertE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171018, Hulstaert E</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12886</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43133</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Caroe,T.K.</style></author><author><style face="normal" font="default"> Ebbehoj,N.E.</style></author><author><style face="normal" font="default"> Bonde,J.P.</style></author><author><style face="normal" font="default"> Agner,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Bispebjerg University Hospital, 2400, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default">Occupational hand eczema and/or contact urticaria: factors associated with change of profession or not remaining in the workforce</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="10" Year="2017">2017/10/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Occupational hand eczema and/or contact urticaria may have social consequences such as change of profession or not remaining in the workforce. OBJECTIVES: To identify factors associated with job change in a cohort of participants with recognised occupational hand eczema/contact urticaria METHODS: A registry-based study including 2703 employees with recognised occupational hand eczema/contact urticaria in Denmark in 2010/2011. Four to five years later the participants received a follow-up questionnaire, comprising questions on current job situation (response rate 58.0%). RESULTS: At follow-up, 51.3% of the participants were no longer in the same profession. 32.5% had changed profession and 18.8% were no longer in employment. Change of profession was associated with young age, positive patch test, low educational level and severity of hand eczema/contact urticaria. With regard to specific professions, cleaning personnel changed profession significantly more often than other workers [71.4% (OR = 2.26)], health care workers significantly less often than other workers [34.0% (OR = 0.36)]. CONCLUSION: Job change occurs frequently during the first years after recognition of occupational hand eczema/contact urticaria and more often among patients with positive patch test reactions, with severe hand eczema/contact urticaria. Whether job changes improve the prognosis of occupational hand eczema/contact urticaria remains to be established</style></abstract><notes><style face="normal" font="default">DA - 20171027IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12869</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29076572">PM:29076572</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20171027-CaroeTK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20171027-CaroeTK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171027, Caroe TK</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12869</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43134</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Creytens,K.</style></author><author><style face="normal" font="default"> Gilissen,L.</style></author><author><style face="normal" font="default"> Huygens,S.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Hospitals KU Leuven, 3000 Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="default">A new application for epoxy resins resulting in occupational allergic contact dermatitis: the three-dimensional printing industry</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="351" start="349">349-351</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12840</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29063685">PM:29063685</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-349-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-349-51.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171024, Creytens K</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12840</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43135</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bianchi,L.</style></author><author><style face="normal" font="default"> Hansel,K.</style></author><author><style face="normal" font="default"> Romita,P.</style></author><author><style face="normal" font="default"> Foti,C.</style></author><author><style face="normal" font="default"> Stingeni,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Section of Clinical, Allergological and Venereological Dermatology, Department of Medicine, University of Perugia, 06123 Perugia, Italy</style></auth-address><titles><title><style face="normal" font="default">Erythema multiforme-like eruption induced by risedronate</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="349" start="348">348-349</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12839</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29063697">PM:29063697</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-348-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-348-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171024, Bianchi L</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12839</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43136</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Amschler,K.</style></author><author><style face="normal" font="default"> Fuchs,T.</style></author><author><style face="normal" font="default"> Geier,J.</style></author><author><style face="normal" font="default"> Buhl,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Venereology and Allergology, University Medical Centre Gottingen, 37075 Gottingen, Germany</style></auth-address><titles><title><style face="normal" font="default">In search of a better patch test concentration for povidone-iodine</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="347" start="346">346-347</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12838</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29063684">PM:29063684</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-346-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-346-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171024, Amschler K</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12838</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43137</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Suomela,S.</style></author><author><style face="normal" font="default"> Molsa,K.</style></author><author><style face="normal" font="default"> Aalto-Korte,K.</style></author><author><style face="normal" font="default"> Suuronen,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Occupational Medicine, Finnish Institute of Occupational Health (FIOH), 00250, Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="default">Occupational contact dermatitis caused by hydrogenated formaldehyde-benzenamine polymer (FBAP) in epoxy hardeners</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="343" start="341">341-343</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12835</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29063695">PM:29063695</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-341-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-341-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171024, Suomela S</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12835</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43138</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pastor-Nieto,M.A.</style></author><author><style face="normal" font="default"> Gatica-Ortega,M.E.</style></author><author><style face="normal" font="default"> Melgar-Molero,V.</style></author><author><style face="normal" font="default"> Gonzalez-Munoz,P.</style></author><author><style face="normal" font="default"> Mollejo,M.</style></author><author><style face="normal" font="default"> Schoendorff,C.</style></author><author><style face="normal" font="default"> De Eusebio-Murillo,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Hospital of Guadalajara, 19002 Guadalajara, Spain</style></auth-address><titles><title><style face="normal" font="default">Erythema multiforme-like reaction resulting from vitamin K1 oxide (phytomenadione epoxide)</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="345" start="343">343-345</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12837</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29063687">PM:29063687</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-343-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-343-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171024, Pastor-Nieto MA</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12837</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43139</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Maor,D.</style></author><author><style face="normal" font="default"> Little,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Occupational Dermatology Research and Education Centre, Skin &amp; Cancer Foundation Inc., Melbourne 3053, AustraliaEmergency Department, Cairns Hospital, Cairns 4870, AustraliaCollege of Public Health, Medical and Veterinary Sciences, James Cook University Cairns, Cairns 4878, Australia</style></auth-address><titles><title><style face="normal" font="default">Skin contact with a stinging tree requiring intensive care unit admission</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="337" start="335">335-337</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12830</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29063683">PM:29063683</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-335-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-335-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171024, Maor D</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12830</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43140</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Corazza,M.</style></author><author><style face="normal" font="default"> Amendolagine,G.</style></author><author><style face="normal" font="default"> Cristofaro,D.</style></author><author><style face="normal" font="default"> Bernardi,T.</style></author><author><style face="normal" font="default"> Foti,C.</style></author><author><style face="normal" font="default"> Romita,P.</style></author><author><style face="normal" font="default"> Borghi,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Section of Dermatology, Department of Medical Science, University of Ferrara, 44121 Ferrara, Italy</style></auth-address><titles><title><style face="normal" font="default">Occupational allergic contact dermatitis caused by isothiazolinones in ultrasound gel: 2 cases</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="338" start="337">337-338</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12831</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29063693">PM:29063693</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-337-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-337-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171024, Corazza M</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12831</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43141</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Herman,A.</style></author><author><style face="normal" font="default"> Baeck,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Cliniques Universitaires St Luc, UCL, 1200 Brussels, Belgium</style></auth-address><titles><title><style face="normal" font="default">Airborne contact dermatitis in a patient with type I and IV sensitivity to chicory</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="335" start="333">333-335</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12828</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29063696">PM:29063696</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-333-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-333-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171024, Herman A</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12828</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43142</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Longuenesse,C.</style></author><author><style face="normal" font="default"> Lepelletier,D.</style></author><author><style face="normal" font="default"> Dessomme,B.</style></author><author><style face="normal" font="default"> Le Hir,F.</style></author><author><style face="normal" font="default"> Bernier,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Occupational Health Department, Nantes University Hospital, 44000 Nantes, France</style></auth-address><titles><title><style face="normal" font="default">Hand dermatitis: hand hygiene consequences among healthcare workers</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="331" start="330">330-331</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12825</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29063692">PM:29063692</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-330-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-330-1.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171024, Longuenesse C</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12825</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43143</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tous-Romero,F.</style></author><author><style face="normal" font="default"> Velasco-Tamariz,V.</style></author><author><style face="normal" font="default"> Prieto-Barrios,M.</style></author><author><style face="normal" font="default"> Ortiz de Frutos,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Hospital Universitario 12 de Octubre, I+12 Research Institute, Universidad Complutense, 28041 Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Active sensitization to cadmium, tin, and indium</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="333" start="332">332-333</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12826</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29063686">PM:29063686</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-332-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-332-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171024, Tous-Romero F</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12826</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43144</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yoo,J.</style></author><author><style face="normal" font="default"> Jue,M.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Veterans Health Service Medical Centre, Seoul 05368, Korea</style></auth-address><titles><title><style face="normal" font="default">Intractable pruritus with chronic eczema in an elderly patient caused by long-term intake of calcium channel blocker</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="340" start="339">339-340</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12832</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29063690">PM:29063690</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-339-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-339-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171024, Yoo J</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12832</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43145</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rutt,V.L.</style></author><author><style face="normal" font="default"> Reed,K.X.</style></author><author><style face="normal" font="default"> Liu,X.</style></author><author><style face="normal" font="default"> Richard,E.G.</style></author><author><style face="normal" font="default"> Purcell,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Lehigh Valley Health Network, Allentown, Pennsylvania, USA</style></auth-address><titles><title><style face="normal" font="default">Photosensitive atopic dermatitis exacerbated by UVB exposure</style></title><secondary-title><style face="normal" font="default">Cutis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cutis</style></full-title></periodical><pages end="184" start="180">180-184</pages><volume><style face="normal" font="default">100</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Photosensitive atopic dermatitis (AD) is a rare disease entity that many physicians are not familiar with, thus it often is misdiagnosed. It can be life altering, as patients often strictly avoid the sun and may only leave the house at night. Effective treatments are available, and therefore diagnosis is key to improve quality of life for these patients. We describe a case of photosensitive AD exacerbated by UVB exposure. The diagnosis was made with phototesting, and the patient was able to begin treatment with narrowband UVB (NB-UVB) hardening while on immunosuppression. The literature on photosensitive AD is limited, and this entity typically is not found in the main dermatology textbooks. Our case emphasizes the diagnostic problems and complexity of photosensitive AD. Histopathologic findings are nonspecific. A thorough history and physical examination can provide the necessary clues for further workup. Phototesting should be performed to confirm the diagnosis and evaluate the degree of sensitivity to UV light and the specific wavelength eliciting the cutaneous response. Photoprovocation and photopatch testing also can be useful to confirm the diagnosis</style></abstract><notes><style face="normal" font="default">DA - 20171109IS - 2326-6929 (Electronic)IS - 0011-4162 (Linking)LA - engPT - Journal ArticleCO - United States .</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29121122">PM:29121122</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171109, Rutt VL</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43146</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Silverberg,N.B.</style></author><author><style face="normal" font="default"> Silverberg,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Mt Sinai West of the Icahn School of Medicine, New York, New York, USADepartments of Dermatology, Preventive Medicine, and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA</style></auth-address><titles><title><style face="normal" font="default">The atopic dermatitis biologic era has begun</style></title><secondary-title><style face="normal" font="default">Cutis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cutis</style></full-title></periodical><pages end="146" start="145">145-146</pages><volume><style face="normal" font="default">100</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171109IS - 2326-6929 (Electronic)IS - 0011-4162 (Linking)LA - engPT - Journal ArticleCO - United States .</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29121126">PM:29121126</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171108, Silverberg NB</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43147</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Silverberg,N.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Mt Sinai West of the Icahn School of Medicine, New York, New York, USA</style></auth-address><titles><title><style face="normal" font="default">Atopic dermatitis prevention and treatment</style></title><secondary-title><style face="normal" font="default">Cutis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cutis</style></full-title></periodical><pages end="" start="173">173-</pages><volume><style face="normal" font="default">100</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is the cause of substantial morbidity including severe pruritus and impaired personal and familial quality of life. Furthermore, the rising incidence and familial association of AD have highlighted the need for disease prevention. It is largely genetic in nature and cannot be avoided in all cases. However, low-risk prevention strategies have been attempted to reduce triggering of first onset of AD in predisposed individuals. Therapeutics for active disease include trigger avoidance, barrier repair, topical medicaments including topical corticosteroids (TCs) and nonsteroidal agents, phototherapy, and antibacterial interventions</style></abstract><notes><style face="normal" font="default">DA - 20171109IS - 2326-6929 (Electronic)IS - 0011-4162 (Linking)LA - engPT - Journal ArticleCO - United States .</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29121124">PM:29121124</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171109, Silverberg NB</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43148</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">no authors</style></author></authors></contributors><titles><title><style face="normal" font="default">Allergic contact stomatitis</style></title><secondary-title><style face="normal" font="default">Dental Abstracts</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Dental Abstracts</style></abbr-1></periodical><pages end="329" start="328">328-329</pages><volume><style face="normal" font="default">62</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year><pub-dates><date Day="0" Month="12" Year="2017">2017/12</date></pub-dates></dates><isbn><style face="normal" font="default">0011-8486</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENG</style></notes><work-type><style face="normal" font="default">10.1016/j.denabs.2017.07.010</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.denabs.2017.07.010</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dental Abstracts\2017-62-328-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dental Abstracts\2017-62-328-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171110, no authors</style></custom2><misc3><style face="normal" font="default">10.1016/j.denabs.2017.07.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43149</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wong,A.</style></author><author><style face="normal" font="default"> Seger,D.L.</style></author><author><style face="normal" font="default"> Slight,S.P.</style></author><author><style face="normal" font="default"> Amato,M.G.</style></author><author><style face="normal" font="default"> Beeler,P.E.</style></author><author><style face="normal" font="default"> Fiskio,J.M.</style></author><author><style face="normal" font="default"> Bates,D.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of General Internal Medicine and Primary Care, The Center for Patient Safety Research and Practice, Brigham and Women's Hospital, 1620 Tremont Street, 75 Francis Street, Boston, MA, 02115, USA</style></auth-address><titles><title><style face="normal" font="default">Evaluation of 'Definite' Anaphylaxis Drug Allergy Alert Overrides in Inpatient and Outpatient Settings</style></title><secondary-title><style face="normal" font="default">Drug Saf</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Drug Saf</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="11" Year="2017">2017/11/9</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Drug-allergy interaction (DAI) alerts are generated when a known adverse sensitivity-inducing substance is prescribed. A recent study at our institution showed that providers overrode most DAI alerts, including those that warned against potentially life-threatening 'anaphylaxis'. OBJECTIVE: The aim of this study was to determine the rate of anaphylaxis overrides, the reasons for these overrides, whether the overrides were appropriate, and if harm occurred from overrides. METHODS: All DAI alerts, with a reaction of 'anaphylaxis', were analysed for inpatients and outpatients within our health system between January 2009 and December 2011. Only alerts that were triggered by 'definite' alerts (i.e. same ordered medication as documented allergen) were included. Patient charts were reviewed to assess the appropriateness of overrides and potential harm, according to a predetermined set of criteria. RESULTS: A total of 202 inpatient and 16 outpatient alerts met the inclusion criteria. The rate of overrides for 'definite' anaphylaxis DAI alerts was high (inpatient: n = 93, 46.0%; outpatient: n = 11, 68.8%) but appropriate for most overrides in the inpatient (n = 78, 83.9%) and outpatient settings (n = 11, 100%). The most common override reasons in the inpatient and outpatient settings were 'administer per desensitization protocol' (n = 64, 31.7%) and 'patient does not have this allergy' (n = 7, 63.6%), respectively. No harm was associated with overrides in either setting, particularly because many medications were not administered. CONCLUSIONS: Overrides of 'definite' anaphylaxis DAI alerts were common and often appropriate. Most overrides were due to desensitizations. Allergy reconciliation for patients could further improve critical decision support</style></abstract><notes><style face="normal" font="default">DA - 20171110IS - 1179-1942 (Electronic)IS - 0114-5916 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1007/s40264-017-0615-1.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29124665">PM:29124665</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Drug Saf\20171110-WongA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Drug Saf\20171110-WongA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171110, Wong A</style></custom2><misc3><style face="normal" font="default">10.1007/s40264-017-0615-1.</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43150</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ghozikali,M.G.</style></author><author><style face="normal" font="default"> Ansarin,K.</style></author><author><style face="normal" font="default"> Naddafi,K.</style></author><author><style face="normal" font="default"> Nodehi,R.N.</style></author><author><style face="normal" font="default"> Yaghmaeian,K.</style></author><author><style face="normal" font="default"> Hassanvand,M.S.</style></author><author><style face="normal" font="default"> Yunesian,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Environmental Health Engineering, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="default">Prevalence of asthma and associated factors among male late adolescents in Tabriz, Iran</style></title><secondary-title><style face="normal" font="default">Environ Sci Pollut Res Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Environ Sci Pollut Res Int</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="11" Year="2017">2017/11/8</year></dates><abstract><style face="normal" font="default">Asthma is an important chronic disease all over the world. The aim of this study was to determine the prevalence of asthma in a population of male late adolescents and its association with some contributing risk factors in northwest of Iran. This cross-sectional study was carried out in selected high schools of Tabriz, Iran, in 2016. The asthma prevalence and patient background information were examined using a questionnaire that prepared by the ISAAC. One hundred forty-two out of 1134 subjects (12.4%) identified to have asthma, 23.3% had history of current wheeze, and 16.3% had wheezing in the previous year. Family history of asthma was present in 17.1% of the participants; prevalence of active smoking in the study subjects was 3.1%; 25.1% of all subjects had exposure to secondhand tobacco smoke and keeping pets at home was present in 9.1%. Excess weight (overweight and obesity) was positively associated with prevalence of asthma (p &lt; 0.001). No statistically significant associations were observed between asthma and father's education level (p = 0.570), mother's education level (p = 0.584), type of birth subjects (p = 0.571), and time spent outdoors during a full day (p = 0.863). Our results suggest that family history of asthma and atopy, exposure to secondhand tobacco smoke, active smoking, amount of automobile traffic around subjects' home, and keeping pets at homes are important risk factors for asthma, while time spent outdoors, educations of parents, and delivery type (normal vaginal delivery vs. C-section) subjects are not. Therefore, decreased of exposure to some environmental risk factors could be effective to reduce rate of the prevalence of asthma and wheeze</style></abstract><notes><style face="normal" font="default">DA - 20171108IS - 1614-7499 (Electronic)IS - 0944-1344 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">10.1007/s11356-017-0553-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29116535">PM:29116535</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Environ Sci Pollut Res Int\20171108-GhozikaliMG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Environ Sci Pollut Res Int\20171108-GhozikaliMG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171108, Ghozikali MG</style></custom2><misc3><style face="normal" font="default">10.1007/s11356-017-0553-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43151</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ivancevich,J.C.</style></author><author><style face="normal" font="default"> Neffen,H.</style></author><author><style face="normal" font="default"> Zernotti,M.E.</style></author><author><style face="normal" font="default"> Asayag,E.</style></author><author><style face="normal" font="default"> Blua,A.</style></author><author><style face="normal" font="default"> Ciceran,A.</style></author><author><style face="normal" font="default"> Jares,E.J.</style></author><author><style face="normal" font="default"> Lavrut,A.J.</style></author><author><style face="normal" font="default"> Maspero,J.F.</style></author><author><style face="normal" font="default"> Agache,I.</style></author><author><style face="normal" font="default"> Bachert,C.</style></author><author><style face="normal" font="default"> Bedbrook,A.</style></author><author><style face="normal" font="default"> Canonica,G.W.</style></author><author><style face="normal" font="default"> Casale,T.B.</style></author><author><style face="normal" font="default"> Cruz,A.A.</style></author><author><style face="normal" font="default"> Fokkens,W.J.</style></author><author><style face="normal" font="default"> Hellings,P.W.</style></author><author><style face="normal" font="default"> Samolinski,B.</style></author><author><style face="normal" font="default"> Bousquet,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Facultad de Medicina, Universidad del Salvador, Buenos Aires, Argentina.</style></auth-address><titles><title><style face="normal" font="default">[ARIA 2016 executive summary: Integrated care pathways for predictive medicine throughout the life cycle in Argentina]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="308" start="298">298-308</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">The ARIA initiative was started during a World Health Organization workshop in 1999. The initial goals were to propose a new classification for allergic rhinitis, to promote the concept of multi-morbidity in asthma and rhinitis and to develop guidelines with stakeholders for world-wide use. ARIA is now focused on the implementation of emerging technologies for individualized and predictive medicine. MASK: MACVIA-Aria Sentinel Network uses mobile technology to develop care pathways that enable management by a multidisciplinary group or by patients themselves. An App for iOS and Android uses a visual analogue scale to assess symptom control and work productivity, as well as a clinical decision support system; it is associated with an interoperable tablet for health professionals. The escalation strategy uses recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of ARIA's new approach is to provide an active and healthy life to people affected by rhinitis, regardless of age, gender or socioeconomic status, in order to reduce social and health inequalities caused by the disease</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleLA - SPACO - Argentina -CO - Romania -CO - Belgium -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29046028">PM:29046028</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-298-308.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-298-308.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Ivancevich JC</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43152</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gaido,C.M.</style></author><author><style face="normal" font="default"> Granland,C.</style></author><author><style face="normal" font="default"> Laing,I.A.</style></author><author><style face="normal" font="default"> Souef,P.N.L.</style></author><author><style face="normal" font="default"> Thomas,W.R.</style></author><author><style face="normal" font="default"> Currie,A.J.</style></author><author><style face="normal" font="default"> Hales,B.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Telethon Kids Institute, The University of Western Australia, Perth, Australia</style></auth-address><titles><title><style face="normal" font="default">T-cell responses against rhinovirus species A and C in asthmatic and healthy children</style></title><secondary-title><style face="normal" font="default">Immun Inflamm Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immun Inflamm Dis</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="11" Year="2017">2017/11/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Infections by rhinovirus (RV) species A and C are the most common causes of exacerbations of asthma and a major cause of exacerbations of other acute and chronic respiratory diseases. Infections by both species are prevalent in pre-school and school-aged children and, particularly for RV-C, can cause severe symptoms and a need for hospitalization. While associations between RV infection and asthma are well established, the adaptive immune-mechanisms by which RV infections influence asthma exacerbations are yet to be defined. OBJECTIVE: The aim of this study was to characterize and compare T-cell responses between RV-A and RV-C and to test the hypothesis that T-cell responses would differ between asthmatic children and healthy controls. METHODS: A multi-parameter flow cytometry assay was used to characterize the in vitro recall T-cell response against RV-A and RV-C in PBMCs from children with acute asthma (n = 22) and controls (n = 26). The responses were induced by pools of peptides containing species-specific VP1 epitopes of RV-A and RV-C. RESULTS: Regardless of children's clinical status, all children that responded to the in vitro stimulation (>90%) had a similar magnitude of CD4+ T-cell responses to RV-A and RV-C. However, asthmatic children had a significantly lower number of circulating regulatory T cells (Tregs), and healthy controls had significantly more Tregs induced by RV-A than RV-C. CONCLUSIONS AND CLINICAL RELEVANCE: The comparable recall memory T-cell responses in asthmatic and control children to both RV-A and RV-C show that differences in the antibody and inflammatory responses previously described are likely to be due to regulation, with a demonstrated candidate being reduced regulatory T-cells. The reduced Treg numbers demonstrated here could explain the asthmatic's inability to appropriately control immunopathological responses to RV infections</style></abstract><notes><style face="normal" font="default">DA - 20171110IS - 2050-4527 (Electronic)IS - 2050-4527 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1002/iid3.206</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29124902">PM:29124902</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immun Inflamm Dis\20171110-GaidoCM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immun Inflamm Dis\20171110-GaidoCM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171110, Gaido CM</style></custom2><misc3><style face="normal" font="default">10.1002/iid3.206</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43153</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mohamed,A.F.</style></author><author><style face="normal" font="default"> El-Yamany,M.F.</style></author><author><style face="normal" font="default"> El-Batrawy,F.A.</style></author><author><style face="normal" font="default"> Abdel-Aziz,M.T.</style></author></authors></contributors><titles><title><style face="normal" font="default">JNJ7777120 Ameliorates Inflammatory and Oxidative Manifestations in a Murine Model of Contact Hypersensitivity via Modulation of TLR and Nrf2 Signaling</style></title><secondary-title><style face="normal" font="default">Inflammation</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Inflammation</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1573-2576</style></isbn><abstract><style face="normal" font="default">JNJ7777120, a histamine H4 receptor antagonist, was shown to be effective in different experimental settings of allergic inflammation, including contact hypersensitivity. Toll-like receptors (TLRs) are thought to function as a link between innate and adaptive immune responses to various haptens. Here, we studied the suppression of TLR signaling as a possible mechanism by which JNJ7777120 exerts its anti-inflammatory effects against the chemical hapten, fluorescein isothiocyanate (FITC). The potential anti-oxidant effect of JNJ7777120 in this model was also examined. Mice subjected to FITC sensitization and challenge showed significantly elevated plasma immunoglobulin E (IgE) level, ear interleukin-4 (IL-4), tumor necrosis factor-alpha (TNF-+¦), and thiobarbituric acid reactive substance (TBARS) contents as well as increased myeloid differentiation factor 88 (MyD88) gene expression, nuclear factor-kappa B p65 (NF-+¦B p65), and phospho-p38 mitogen-activated protein kinase (p-p38 MAPK) protein expression. This was accompanied by enhanced ear myeloperoxidase (MPO) and eosinophil peroxidase (EPO) activities as well as diminished glutathione (GSH) content and superoxide dismutase (SOD) activity. JNJ7777120 treatment perceivably reversed these effects, denoting profound anti-inflammatory and anti-oxidant character of JNJ7777120 which was confirmed by its mitigation of FITC-induced pathological changes in mouse ear. JNJ7777120 additionally enhanced the expression of nuclear factor erythroid 2-related factor 2 (Nrf2), providing a novel mechanism by which JNJ7777120 functions as an anti-oxidant in this model. To conclude, JNJ7777120 afforded a remarkable amendment of FITC skin insult by virtue of its anti-inflammatory and anti-oxidant effects; the mechanistic basis of these effects may include modulation of TLR and Nrf2 pathways</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Egypt -</style></notes><work-type><style face="normal" font="default">10.1007/s10753-017-0693-3</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s10753-017-0693-3</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Inflammation\20171114-MohamedAF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Inflammation\20171114-MohamedAF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171114, Mohamed AF</style></custom2><misc3><style face="normal" font="default">10.1007/s10753-017-0693-3</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43154</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tajmir-Riahi,A.</style></author><author><style face="normal" font="default"> Worl,P.</style></author><author><style face="normal" font="default"> Harrer,T.</style></author><author><style face="normal" font="default"> Schliep,S.</style></author><author><style face="normal" font="default"> Schuler,G.</style></author><author><style face="normal" font="default"> Simon,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departmens of Dermatology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nurnberg, Erlangen, Germany</style></auth-address><titles><title><style face="normal" font="default">Life-Threatening Atypical Case of Acute Generalized Exanthematous Pustulosis</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="111" start="108">108-111</pages><volume><style face="normal" font="default">174</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="10" Year="2017">2017/10/25</year></dates><abstract><style face="normal" font="default">Antibiotics are known to cause severe cutaneous adverse reactions, such as the rare acute generalized exanthematous pustulosis (AGEP). Unlike Stevens-Johnson syndrome or toxic epidermal necrolysis, AGEP is rarely life-threatening. Systemic involvement is not typical, and if present usually coincides with a mild elevation of the hepatic enzymes and a decrease in renal function. Hence, AGEP is known to have a good prognosis and to be life-threatening only in elderly patients or patients with chronic diseases. Herein, we report a case of AGEP in a young healthy male leading to systemic inflammatory response syndrome and to treatment in an intensive care unit after being treated with 5 different antibiotics. Initial symptoms were not indicative for AGEP and the patient's course of disease led promptly to critical cardiorespiratory symptoms and systemic inflammatory response syndrome. We assume that the administration of the 5 different antibiotics resulted in type IV allergy as well as secondary infection with Enterococcus faecium and Staphylococcus aureus, while the underlying periodontitis also contributed to the severity of this case</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1159/000480700</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29065395">PM:29065395</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-174-108-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-174-108-11.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171024, Tajmir-Riahi A</style></custom2><misc3><style face="normal" font="default">10.1159/000480700</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43155</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Adappa,N.D.</style></author><author><style face="normal" font="default"> Ranasinghe,V.J.</style></author><author><style face="normal" font="default"> Trope,M.</style></author><author><style face="normal" font="default"> Brooks,S.G.</style></author><author><style face="normal" font="default"> Glicksman,J.T.</style></author><author><style face="normal" font="default"> Parasher,A.K.</style></author><author><style face="normal" font="default"> Palmer,J.N.</style></author><author><style face="normal" font="default"> Bosso,J.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rhinology, Department of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA</style></auth-address><titles><title><style face="normal" font="default">Outcomes after complete endoscopic sinus surgery and aspirin desensitization in aspirin-exacerbated respiratory disease</style></title><secondary-title><style face="normal" font="default">Int Forum Allergy Rhinol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Forum Allergy Rhinol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="3" Month="11" Year="2017">2017/11/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: In this study we assessed patient outcomes after complete endoscopic sinus surgery (ESS) and aspirin desensitization for patients with aspirin-exacerbated respiratory disease (AERD). METHODS: A retrospective chart review was conducted for patients with aspirin challenge-proven AERD who underwent complete ESS followed by aspirin desensitization. Outcomes assessed included need for revision surgery and quality-of-life measures using the 22-item Sino-Nasal Outcomes Test (SNOT-22). Data were collected preoperatively, postoperatively prior to desensitization, and then at intervals post-desensitization through 30 months after aspirin desensitization. A longitudinal linear mixed-effects model was used for data analysis. RESULTS: Thirty-four patients met the inclusion criteria for this study. Thirty-two patients successfully completed aspirin desensitization and were subsequently followed for 30 months after desensitization. Two patients were unable to complete desensitization. Five patients discontinued aspirin maintenance therapy due to gastrointestinal and respiratory side effects. Within the follow-up period, there were only 3 (9.4%) revision sinus surgeries. Notably, 1 of these revision cases occurred in a patient who had discontinued aspirin maintenance therapy. After surgical treatment and prior to desensitization patients had significant reductions in SNOT-22 scores. Our results demonstrate that total SNOT-22 scores remained statistically unchanged from immediate post-desensitization throughout the 30-month follow-up period. CONCLUSION: Complete sinus surgery followed by timely aspirin desensitization and maintenance therapy is an effective combination in the long-term management of sinus disease in patients with AERD</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 2042-6984 (Electronic)IS - 2042-6976 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1002/alr.22036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29105347">PM:29105347</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Forum Allergy Rhinol\20171106-AdappaND.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Forum Allergy Rhinol\20171106-AdappaND.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Adappa ND</style></custom2><misc3><style face="normal" font="default">10.1002/alr.22036</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43156</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Javaud,N.</style></author><author><style face="normal" font="default"> Fain,O.</style></author><author><style face="normal" font="default"> Adnet,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">AP-HP, Urgences, Samu 93, Hopital Avicenne, Universite Paris 13, Bobigny, France</style></auth-address><titles><title><style face="normal" font="default">Icatibant for ACE-inhibitor angioedema, an opportunity to treat the patients?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="1803">1803-</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171110IS - 2213-2201 (Electronic)LA - engPT - LetterCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29122163">PM:29122163</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171110, Javaud N</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.039</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43157</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ungkanont,K.</style></author><author><style face="normal" font="default"> Jirapongsananuruk,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Medicine, Department of Oto-rhino-laryngology, Siriraj Hospital, Mahidol University, Bangkok, Thailand</style></auth-address><titles><title><style face="normal" font="default">Reply (Refers to: Revisiting recurrent acute rhinosinusitis prevention by azithromycin in children)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1803" start="1802">1802-1803</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171110IS - 2213-2201 (Electronic)LA - engPT - LetterCO - Thailand -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29122161">PM:29122161</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171110, Ungkanont K</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43158</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stevens,W.W.</style></author><author><style face="normal" font="default"> Suh,L.</style></author><author><style face="normal" font="default"> Peters,A.T.</style></author><author><style face="normal" font="default"> Schleimer,R.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill.</style></auth-address><titles><title><style face="normal" font="default">Reply (Refers to: Eosinophilic asthma with nasal polyposis march: Is aspirin-exacerbated respiratory disease the last station?)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1809" start="1808">1808-1809</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171110IS - 2213-2201 (Electronic)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29122170">PM:29122170</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171110, Stevens WW</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43159</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bakshi,S.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of ENT and Head &amp; Neck Surgery, Mahatma Gandhi Medical College and Research Institute, Pillaiyarkuppam, Pondicherry, India.</style></auth-address><titles><title><style face="normal" font="default">Revisiting recurrent acute rhinosinusitis prevention by azithromycin in children</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="1802">1802-</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171110IS - 2213-2201 (Electronic)LA - engPT - LetterCO - India -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29122162">PM:29122162</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171110, Bakshi SS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43160</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sinert,R.</style></author><author><style face="normal" font="default"> Levy,P.</style></author><author><style face="normal" font="default"> Bernstein,J.A.</style></author><author><style face="normal" font="default"> Body,R.</style></author><author><style face="normal" font="default"> Sivilotti,M.L.A.</style></author><author><style face="normal" font="default"> Moellman,J.</style></author><author><style face="normal" font="default"> Schranz,J.</style></author><author><style face="normal" font="default"> Baptista,J.</style></author><author><style face="normal" font="default"> Kimura,A.</style></author><author><style face="normal" font="default"> Nothaft,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Emergency Medicine, SUNY Downstate Medical Center/Kings County Hospital Medical Center, Brooklyn, NY.</style></auth-address><titles><title><style face="normal" font="default">Reply (Refers to: Icatibant for ACE-inhibitor angioedema, an opportunity to treat the patients?)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1804" start="1803">1803-1804</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171110IS - 2213-2201 (Electronic)LA - engPT - LetterCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29122164">PM:29122164</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171110, Sinert R</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.040</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43161</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schroeder,S.</style></author><author><style face="normal" font="default"> Ochkur,S.I.</style></author><author><style face="normal" font="default"> Shim,K.P.</style></author><author><style face="normal" font="default"> Galvin,K.M.</style></author><author><style face="normal" font="default"> Bauer,C.S.</style></author><author><style face="normal" font="default"> Lee,J.J.</style></author><author><style face="normal" font="default"> Wright,B.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Phoenix Children's Hospital, Phoenix, Ariz</style></auth-address><titles><title><style face="normal" font="default">Throat-derived eosinophil peroxidase is not a reliable biomarker of pediatric eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1805" start="1804">1804-1805</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171110IS - 2213-2201 (Electronic)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29122165">PM:29122165</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171110, Schroeder S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.043</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43162</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Saffari,H.</style></author><author><style face="normal" font="default"> Baer,K.</style></author><author><style face="normal" font="default"> Boynton,K.K.</style></author><author><style face="normal" font="default"> Gleich,G.J.</style></author><author><style face="normal" font="default"> Peterson,K.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Utah, Salt Lake City, Utah.</style></auth-address><titles><title><style face="normal" font="default">Reply (Refers to: Throat-derived eosinophil peroxidase is not a reliable biomarker of pediatric eosinophilic esophagitis)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="1805">1805-</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171110IS - 2213-2201 (Electronic)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29122166">PM:29122166</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171110, Saffari H</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.044</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43163</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yilmaz,I.</style></author><author><style face="normal" font="default"> Turk,M.</style></author><author><style face="normal" font="default"> Bahcecioglu,S.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunology and Allergy, Department of Chest Diseases, Erciyes University School of Medicine, Kayseri, Turkey.</style></auth-address><titles><title><style face="normal" font="default">Eosinophilic asthma with nasal polyposis march: Is aspirin-exacerbated respiratory disease the last station?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1808" start="1807">1807-1808</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171110IS - 2213-2201 (Electronic)LA - engPT - LetterCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.048</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29122169">PM:29122169</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171110, Yilmaz I</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.048</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43164</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Van Gasse,A.L.</style></author><author><style face="normal" font="default"> Sabato,V.</style></author><author><style face="normal" font="default"> Faber,M.A.</style></author><author><style face="normal" font="default"> Hagendorens,M.M.</style></author><author><style face="normal" font="default"> Ebo,D.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Medicine and Health Science, Department of Immunology-Allergology-Rheumatology, University of Antwerp, Antwerp University Hospital, Antwerpen, Belgium</style></auth-address><titles><title><style face="normal" font="default">An alternative explanation for immediate hypersensitivity reactions to opioids</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="1806">1806-</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171110IS - 2213-2201 (Electronic)LA - engPT - LetterCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29122168">PM:29122168</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171110, Van Gasse AL</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43165</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Li,P.H.</style></author><author><style face="normal" font="default"> Ue,K.L.</style></author><author><style face="normal" font="default"> Wagner,A.</style></author><author><style face="normal" font="default"> Rutkowski,R.</style></author><author><style face="normal" font="default"> Rutkowski,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Reply (Refers to: An alternative explanation for immediate hypersensitivity reactions to opioids)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1807" start="1806">1806-1807</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171110IS - 2213-2201 (Electronic)LA - engPT - LetterCO - United Kingdom -CO - Hong Kong -CO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29122167">PM:29122167</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171110, Li PH</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43166</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Trubiano,J.A.</style></author><author><style face="normal" font="default"> Strautins,K.</style></author><author><style face="normal" font="default"> Redwood,A.J.</style></author><author><style face="normal" font="default"> Pavlos,R.</style></author><author><style face="normal" font="default"> Konvinse,K.C.</style></author><author><style face="normal" font="default"> Aung,A.K.</style></author><author><style face="normal" font="default"> Slavin,M.A.</style></author><author><style face="normal" font="default"> Thursky,K.A.</style></author><author><style face="normal" font="default"> Grayson,M.L.</style></author><author><style face="normal" font="default"> Phillips,E.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia</style></auth-address><titles><title><style face="normal" font="default">The Combined Utility of Ex vivo IFN-gamma Release Enzyme-Linked ImmunoSpot Assay and In vivo Skin Testing in Patients With Antibiotic-Associated Severe Cutaneous Adverse Reactions</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="10" Year="2017">2017/10/31</year></dates><abstract><style face="normal" font="default">BACKGROUND: For severe cutaneous adverse reactions (SCARs) associated with multiple antibiotics dosed concurrently, clinical causality is challenging and diagnostic approaches are limited, leading to constricted future antibiotic choices. OBJECTIVE: To examine the combined utility of in vivo and ex vivo diagnostic approaches at assigning drug causality in a cohort of patients with antibiotic-associated (AA)-SCARs. METHODS: Patients with AA-SCARs were prospectively recruited between April 2015 and February 2017. In vivo testing (patch testing or delayed intradermal testing) was performed to the implicated antibiotic(s) at the highest nonirritating concentration and read at 24 hours through 1 week. Ex vivo testing used patient peripheral blood mononuclear cells (PBMCs) stimulated with a range of pharmacologically relevant concentrations of implicated antibiotics to measure dose-dependent IFN-gamma release from CD4+ and CD8+ T cells via an enzyme-linked immunoSpot assay. RESULTS: In 19 patients with AA-SCARs, combined in vivo and ex vivo testing assigned antibiotic causality in 15 (79%) patients. Ten patients (53%) with AA-SCARs were positive on IFN-gamma release enzyme-linked immunoSpot assay, with an overall reported sensitivity of 52% (95% CI, 29-76) and specificity of 100% (95% CI, 79-100), with improved sensitivity noted in acute (within 1 day to 6 weeks after SCAR onset) testing (75%) and in patients with higher phenotypic scores (59%). There was increased use of narrow-spectrum beta-lactams and antibiotics from within the implicated class following testing in patients with a positive ex vivo or in vivo test result. CONCLUSIONS: We demonstrate the potential utility of combined in vivo and ex vivo testing in patients with AA-SCARs to assign drug causality with high specificity</style></abstract><notes><style face="normal" font="default">DA - 20171104IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.09.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29100867">PM:29100867</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171104, Trubiano JA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.09.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43167</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wu,D.</style></author><author><style face="normal" font="default"> Bleier,B.S.</style></author><author><style face="normal" font="default"> Li,L.</style></author><author><style face="normal" font="default"> Zhan,X.</style></author><author><style face="normal" font="default"> Zhang,L.</style></author><author><style face="normal" font="default"> Lv,Q.</style></author><author><style face="normal" font="default"> Wang,J.</style></author><author><style face="normal" font="default"> Wei,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Department of Otorhinolaryngology, Beijing Anzhen Hospital, Capital Medical University, Beijing, PR China</style></auth-address><titles><title><style face="normal" font="default">Clinical Phenotypes of Nasal Polyps and Comorbid Asthma Based on Cluster Analysis of Disease History</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="10" Year="2017">2017/10/31</year></dates><abstract><style face="normal" font="default">BACKGROUND: Nasal polyps and comorbid asthma (NPcA) is a common united airway disease and is highly heterogeneous with respect to clinical, physiologic, and pathologic parameters. The clinical phenotypes of NPcA are poorly understood. OBJECTIVE: We sought to explore clinical phenotypes in patients with NPcA. METHODS: Patients first diagnosed with NPcA were recruited from Rhinological Clinics and Respiratory Clinics. We clustered patients with NPcA based on parameters regarding natural courses and demographic characteristics. Patients were also evaluated with respect to clinical, functional, and inflammatory parameters in both upper and lower airways. RESULTS: Clustering of 110 cases resulted in 3 clusters: cluster 1 (n = 16, 14.55%, atopic NPcA) was predominantly atopic patients with child-onset airway symptoms, intermediate disease duration, history of family asthma, better lung function, and less severe asthma; cluster 2 (n = 32, 29.09%, smoking NPcA) was characterized by more smokers, short disease duration, adult-onset airway symptoms, less atopy, nonsteroidal anti-inflammatory drug sensitivity, prior sinus surgery history, eosinophilic airway phenotypes, worse lung function, and severe computed tomography appearance; and cluster 3 (n = 62, 56.36%, older NPcA) consisted mostly of older patients with long disease duration, adult-onset airway symptoms, less atopy, more noneosinophilic airway phenotypes, and prior sinus surgery history. CONCLUSIONS: Patients with NPcA with 3 distinct natural courses had different inflammatory status and disease severity. Determining the natural course of a patient might help clinicians predict the clinical aspects of NPcA and contribute to phenotype-guided management approaches in the future</style></abstract><notes><style face="normal" font="default">DA - 20171104IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.09.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29100865">PM:29100865</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171104, Wu D</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.09.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43168</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Veronez,C.L.</style></author><author><style face="normal" font="default"> Moreno,A.S.</style></author><author><style face="normal" font="default"> Constantino-Silva,R.N.</style></author><author><style face="normal" font="default"> Maia,L.S.M.</style></author><author><style face="normal" font="default"> Ferriani,M.P.L.</style></author><author><style face="normal" font="default"> Castro,F.F.M.</style></author><author><style face="normal" font="default"> Valle,S.R.</style></author><author><style face="normal" font="default"> Nakamura,V.K.</style></author><author><style face="normal" font="default"> Cagini,N.</style></author><author><style face="normal" font="default"> Goncalves,R.F.</style></author><author><style face="normal" font="default"> Mansour,E.</style></author><author><style face="normal" font="default"> Serpa,F.S.</style></author><author><style face="normal" font="default"> Coelho Dias,G.A.</style></author><author><style face="normal" font="default"> Piccirillo,M.A.</style></author><author><style face="normal" font="default"> Toledo,E.</style></author><author><style face="normal" font="default"> de Souza,B.M.</style></author><author><style face="normal" font="default"> Cichon,S.</style></author><author><style face="normal" font="default"> Stieber,C.</style></author><author><style face="normal" font="default"> Arruda,L.K.</style></author><author><style face="normal" font="default"> Pesquero,J.B.</style></author><author><style face="normal" font="default"> Grumach,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Research and Molecular Diagnostic of Genetic Diseases, Department of Biophysics, Federal University of Sao Paulo, Sao Paulo, SP, Brazil</style></auth-address><titles><title><style face="normal" font="default">Hereditary Angioedema with Normal C1 Inhibitor and F12 Mutations in 42 Brazilian Families</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="11" Year="2017">2017/11/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hereditary angioedema (HAE) with normal C1 inhibitor (C1-INH) is a rare condition with clinical features similar to those of HAE with C1-INH deficiency. Mutations in the F12 gene have been identified in subsets of patients with HAE with normal C1-INH, mostly within families of European descent. OBJECTIVES: Our aim was to describe clinical characteristics observed in Brazilians from 42 families with HAE and F12 gene mutations (FXII-HAE), and to compare these findings with those from other populations. METHODS: We evaluated a group of 195 individuals, which included 102 patients clinically diagnosed with FXII-HAE and their 93 asymptomatic relatives. RESULTS: Genetic analysis revealed that of the 195 subjects, 134 individuals (77.6% females) carried a pathogenic mutation in F12. The T328K substitution was found in 132 individuals, and the c.971_1018+24del72 deletion was found in 2 patients. The mean age at onset of symptoms in patients with FXII-HAE was 21.1 years. The most common symptoms were subcutaneous edema (85.8% of patients), abdominal pain attacks (69.7%), and upper airway edema (32.3%). Of male individuals carrying F12 mutations, 53.3% (16 of 30) were symptomatic. Compared with reports from Europe, fewer female patients (68.6%) reported an influence of estrogen on symptoms. CONCLUSIONS: Our study included a large number of patients with FXII-HAE, and, as the first such study conducted in a South American population, it highlighted significant differences between this and other study populations. The high number of symptomatic males and patients with estrogen-independent FXII-HAE found here suggests that male sex and the absence of a hormonal influence should not discourage clinicians from searching for F12 mutations in cases of HAE with normal C1-INH</style></abstract><notes><style face="normal" font="default">DA - 20171112IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Brazil -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.09.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29128335">PM:29128335</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171112, Veronez CL</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.09.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43169</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Duvauchelle,T.</style></author><author><style face="normal" font="default"> Robert,P.</style></author><author><style face="normal" font="default"> Donazzolo,Y.</style></author><author><style face="normal" font="default"> Loyau,S.</style></author><author><style face="normal" font="default"> Orlandini,B.</style></author><author><style face="normal" font="default"> Lehert,P.</style></author><author><style face="normal" font="default"> Lecomte,J.M.</style></author><author><style face="normal" font="default"> Schwartz,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Bioprojet Pharma, Paris, France.</style></auth-address><titles><title><style face="normal" font="default">Bioavailability and Cardiovascular Effects of Adrenaline Administered by Anapen Autoinjector in Healthy Volunteers</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="3" Month="11" Year="2017">2017/11/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: The administration of adrenaline is a life-saving intervention for anaphylactic reactions. However, it has been questioned whether the needle length of the autoinjectors is sufficient to achieve genuine intramuscular delivery and optimal bioavailability. OBJECTIVE: To assess the adequacy of Anapen, which has a relatively short needle length (10.5 mm), through a comparison of the depot localization, plasma pharmacokinetics, and cardiovascular responses of adrenaline delivered via Anapen versus a prefilled syringe with a 25.4-mm needle, which is generally used for intramuscular injections. METHODS: This randomized, open-label, crossover study compared the impact of adrenaline administration at 2 sites in the thigh of 18 normal weight male volunteers, using either Anapen or the prefilled syringe; in addition, we studied the treatment of 12 overweight women with Anapen. The depot depth was measured by ultrasonography, plasma adrenaline level was evaluated by ultra performance liquid chromatography-mass spectrometry (UPLC-MS), and heart rates were measured using a Holter monitor. RESULTS: Intramuscular injections were given with both devices at both thigh sites in nonobese men, but not in overweight women. Adrenaline levels showed a double peak, with parallel changes in the heart rate. The first peak, of potential vital importance in anaphylaxis treatment, occurred at approximately 10 minutes postinjection, with maximum concentration and area under the curve significantly higher with Anapen than with prefilled syringes; the magnitude of the second peak did not differ among the various conditions. Unexpectedly, in overweight women treated with Anapen, the magnitude of the first peak was similar to that observed in men, despite the injection being subcutaneous, and the overall bioavailability was enhanced. CONCLUSIONS: Needle length and intramuscular injection are not absolute requirements for autoinjector efficacy, but the monitoring of injection location, biphasic adrenaline levels, and cardiovascular responses is important for the assessment of their therapeutic relevance in anaphylaxis</style></abstract><notes><style face="normal" font="default">DA - 20171107IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - France -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.09.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29109047">PM:29109047</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171107, Duvauchelle T</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.09.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43170</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bashir,H.</style></author><author><style face="normal" font="default"> Grindle,K.</style></author><author><style face="normal" font="default"> Vrtis,R.</style></author><author><style face="normal" font="default"> Vang,F.</style></author><author><style face="normal" font="default"> Kang,T.</style></author><author><style face="normal" font="default"> Salazar,L.</style></author><author><style face="normal" font="default"> Anderson,E.</style></author><author><style face="normal" font="default"> Pappas,T.</style></author><author><style face="normal" font="default"> Gangnon,R.</style></author><author><style face="normal" font="default"> Evans,M.D.</style></author><author><style face="normal" font="default"> Jackson,D.J.</style></author><author><style face="normal" font="default"> Lemanske,R.F.,Jr.</style></author><author><style face="normal" font="default"> Bochkov,Y.A.</style></author><author><style face="normal" font="default"> Gern,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departments of Pediatrics, University of Wisconsin-Madison</style></auth-address><titles><title><style face="normal" font="default">Association of Rhinovirus Species with Common Cold and Asthma Symptoms and Bacterial Pathogens</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="10" Year="2017">2017/10/27</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171107IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.09.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29111214">PM:29111214</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171107-BashirH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171107-BashirH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171107, Bashir H</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.09.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43171</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gurrola,J.</style></author><author><style face="normal" font="default"> Borish,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, San Francisco, CA 94115. Electronic address: jose.gurrola@ucsf.eduDepartments of Medicine and Microbiology, University of Virginia Health Systems, Charlottesville VA 22908</style></auth-address><titles><title><style face="normal" font="default">Chronic Rhinosinusitis: Endotypes, Biomarkers and Treatment Response</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="10" Year="2017">2017/10/26</year></dates><abstract><style face="normal" font="default">It is increasingly recognized that chronic rhinosinusitis (CRS) comprises a spectrum of different diseases with distinct clinical presentations and pathogenic mechanisms. Defining the distinct phenotypes and endotypes of CRS impacts prognosis and most importantly is necessary as the basis for making therapeutic decisions. The need for individualized defining of pathogenic mechanisms prior to initiating therapy extends to virtually all therapeutic considerations. This is clearly crucial with antibiotics where, barring an influence from their off-target anti-inflammatory pharmacological effects, an understanding of the role of individual biome predicts likelihood of therapeutic benefit. But this need for identifying individual phenotypes and endotypes also extends to the agent that is currently considered the mainstay of treatment of CRS, specifically glucocorticoids (GCS). As with asthma, it is recognized that a large minority of CRS patients have a steroid-resistant phenotype, identification of which will preclude use of these agents with their potential side effects. Identification of endotypes is also becoming increasingly imperative as targeted biotherapeutic agents, such as anti-IgE and anti-cytokine antibodies are becoming available. These agents are likely to benefit patients in whom the targeted mediator is not only expressed but demonstrably driving a central mechanism in that individual. In summary, the treatment of CRS is at an exciting crossroad. On the positive side, numerous therapeutics are in development that seem likely to positively impact our patients who suffer from this condition. The challenge is that these therapies will require targeted individualized treatments based upon identifying subjects with the relevant endotype</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.10.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29106996">PM:29106996</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171106-GurrolaJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171106-GurrolaJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Gurrola J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.10.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43172</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jimenez-Reinoso,A.</style></author><author><style face="normal" font="default"> Marin,A.V.</style></author><author><style face="normal" font="default"> Subias,M.</style></author><author><style face="normal" font="default"> Lopez-Lera,A.</style></author><author><style face="normal" font="default"> Roman-Ortiz,E.</style></author><author><style face="normal" font="default"> Payne,K.</style></author><author><style face="normal" font="default"> Ma,C.S.</style></author><author><style face="normal" font="default"> Arbore,G.</style></author><author><style face="normal" font="default"> Kolev,M.</style></author><author><style face="normal" font="default"> Freeley,S.J.</style></author><author><style face="normal" font="default"> Kemper,C.</style></author><author><style face="normal" font="default"> Tangye,S.G.</style></author><author><style face="normal" font="default"> Fernandez-Malave,E.</style></author><author><style face="normal" font="default"> Rodriguez de Cordoba,S.</style></author><author><style face="normal" font="default"> Lopez-Trascasa,M.</style></author><author><style face="normal" font="default"> Regueiro,J.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology, Complutense University School of Medicine and 12 de Octubre Health Research Institute (imas12), Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Human plasma C3 is essential for the development of memory B, but not T, lymphocytes</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="11" Year="2017">2017/11/4</year></dates><abstract><style face="normal" font="default">Primary or secondary plasma C3 deficiency due to mutations in C3 or in complement Factor I impairs memory B, but not T, cell differentiation, but does not preclude intracellular C3 fragment expression in lymphocytes</style></abstract><notes><style face="normal" font="default">DA - 20171108IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - United KIngdom -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.09.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29113906">PM:29113906</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171108-JimenezReinosoA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171108-JimenezReinosoA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171108, Jimenez-Reinoso A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.09.037</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43173</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Roekevisch,E.</style></author><author><style face="normal" font="default"> Schram,M.E.</style></author><author><style face="normal" font="default"> Leeflang,G.M.M.</style></author><author><style face="normal" font="default"> Brouwer,D.M.W.</style></author><author><style face="normal" font="default"> Gerbens,A.L.A.</style></author><author><style face="normal" font="default"> Bos,J.D.</style></author><author><style face="normal" font="default"> Spuls,P.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Academic Medical Center, Amsterdam, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default">Methotrexate versus azathioprine in patients with atopic dermatitis: two years follow-up data</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="10" Year="2017">2017/10/27</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171107IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.09.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29111215">PM:29111215</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171107-RoekevischE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171107-RoekevischE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171107, Roekevisch E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.09.033</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43174</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Caperton,C.</style></author><author><style face="normal" font="default"> Bernstein,D.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy, Asthma &amp; Immunology Center, Willis-Knighton Health System, Shreveport, La</style></auth-address><titles><title><style face="normal" font="default">Contact Dermatitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1793" start="1792">1792-1793</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171110IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.06.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29122160">PM:29122160</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171110, Caperton C</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.06.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43175</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Huo,N.</style></author><author><style face="normal" font="default"> Qian,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Health Outcomes Research and Policy, Auburn University Harrison School of Pharmacy, Auburn, Ala.</style></auth-address><titles><title><style face="normal" font="default">Associations of Herbs and Nonvitamin Dietary Supplements Use with Clinical Outcomes among Adult and Pediatric Patients with Asthma in the United States</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Herbs and nonvitamin dietary supplements (NVDS) have been commonly used among patients with asthma, yet evidence of their impact on patients' clinical outcomes is limited. OBJECTIVE: This study examined the associations of herbs and NVDS use with asthma episodes and asthma-related emergency department (ED) visits among US adults and pediatric patients with asthma. METHODS: A cross-sectional analysis of the 2012 National Health Interview Survey data included 2,930 US adults and 1923 children with self-reported asthma. We estimated the prevalence and type of herbs and/or NVDS use and identified factors associated with their use. We then used multivariable logistic regression models to examine the associations between these supplemental medications use and asthma outcomes, controlling for patient-related covariates. All results were weighted to represent national estimates. RESULTS: Approximately 7.20% of American children and 21.17% of adults with asthma used herbs and/or NVDS in 2012. Herb and/or NVDS users were more likely to be female, non-Hispanic white, living in the West region, having higher family income, and having comorbidities compared with nonusers. Herbs and/or NVDS use was associated with lower likelihood of having asthma-related ED visit (adjusted odds ratio = 0.48; 95% confidence interval: 0.31, 0.75) among adult patients with asthma, but not for pediatric patients with asthma. No association between herbs and/or NVDS use and having an asthma episode was observed in either adults or children. CONCLUSIONS: This study found high prevalence of herbs and/or NVDS use among US patients with asthma. Potential benefit of these supplemental medications use on asthma-related ED visits might exist for adult patients with asthma</style></abstract><notes><style face="normal" font="default">DA - 20171105IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.09.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29102746">PM:29102746</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171105, Huo N</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.09.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43176</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Watts,T.J.</style></author><author><style face="normal" font="default"> Haque,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Adult Allergy, Guy's and St Thomas' NHS Foundation Trust, London, UK.</style></auth-address><titles><title><style face="normal" font="default">DRESS Syndrome Induced by Ranitidine</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="10" Year="2017">2017/10/25</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171105IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.09.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29102410">PM:29102410</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171105, Watts TJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.09.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43177</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Baldo,B.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Molecular Immunology Unit, Kolling Institute of Medical Research, Royal North Shore Hospital of Sydney, Sydney, New South Wales, Australia; Department of Medicine, University of Sydney, Sydney, New South Wales, Australia.</style></auth-address><titles><title><style face="normal" font="default">Opioid Analgesic Drugs: Misuse, Toxicity, and Hypersensitivity</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1608" start="1607">1607-1608</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171110IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.04.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29122159">PM:29122159</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171110, Baldo A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.04.028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43178</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hawro,T.</style></author><author><style face="normal" font="default"> Ohanyan,T.</style></author><author><style face="normal" font="default"> Schoepke,N.</style></author><author><style face="normal" font="default"> Metz,M.</style></author><author><style face="normal" font="default"> Peveling-Oberhag,A.</style></author><author><style face="normal" font="default"> Staubach,P.</style></author><author><style face="normal" font="default"> Maurer,M.</style></author><author><style face="normal" font="default"> Weller,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Allergie-Centrum-Charite, Charite - Universitatsmedizin Berlin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="default">The Urticaria Activity Score-Validity, Reliability, and Responsiveness</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="11" Year="2017">2017/11/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic spontaneous urticaria is characterized by fluctuating symptoms. Its activity is assessed with the urticaria activity score (UAS). Two versions of the urticaria activity score used for 7 consecutive days (UAS7) are available: (1) The guideline-recommended UAS7, with once-daily documentation, and (2) the UAS7TD, with twice-daily documentation. OBJECTIVE: To better characterize both UAS7 versions with regard to their validity, reliability, sensitivity to change, minimal important difference (MID), and smallest detectable change (SDC). METHODS: One hundred thirty adult patients with chronic spontaneous urticaria completed both UAS7 versions, the Patients Global Assessment (PatGA) of disease activity, the Urticaria Control Test (UCT), the Chronic Urticaria Quality of Life Questionnaire, and the Dermatology Life Quality Index before and after the initiation of omalizumab therapy. Physicians completed a Physician Global Assessment of disease activity. RESULTS: The UAS7 and the UAS7TD showed high correlation with the activity anchor PatGA (r = 0.568, P &lt; .001 and r = 0.605, P &lt; .001) and the UCT (r = -0.580, P &lt; .001 and r = -0.585, P &lt; .001). The wheal and pruritus scores of the UAS7 and the UAS7TD exhibited respectable internal consistency and, in each UAS7 version, correlated well with each other (Cronbach alpha = 0.78, r = 0.640, P &lt; .001, and Cronbach alpha = 0.77, r = 0.626, P &lt; .001). Changes in the UAS7 and UAS7TD correlated well with PatGA changes (r = 639, P &lt; .001, and r = .763, P &lt; .001) and with UCT changes (r = -0.642, P &lt; .001, and r = -0.703, P &lt; .001). The MID was 11 for the UAS7 (SDC = 12) and 12 for the UAS7TD (SDC = 11). CONCLUSIONS: The UAS7 and UAS7TD show good and comparable clinimetric properties, including good sensitivity to change, and similar MIDs</style></abstract><notes><style face="normal" font="default">DA - 20171112IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.10.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29128337">PM:29128337</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171112, Hawro T</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.10.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43179</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bao,W.</style></author><author><style face="normal" font="default"> Zhang,X.</style></author><author><style face="normal" font="default"> Lv,C.</style></author><author><style face="normal" font="default"> Bao,L.</style></author><author><style face="normal" font="default"> Yin,J.</style></author><author><style face="normal" font="default"> Huang,Z.</style></author><author><style face="normal" font="default"> Wang,B.</style></author><author><style face="normal" font="default"> Zhou,X.</style></author><author><style face="normal" font="default"> Zhang,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China</style></auth-address><titles><title><style face="normal" font="default">The Value of Fractional Exhaled Nitric Oxide and Forced Mid-Expiratory Flow as Predictive Markers of Bronchial Hyperresponsiveness in Adults With Chronic Cough</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="11" Year="2017">2017/11/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Bronchial provocation tests are standard for diagnosing the etiology of chronic cough, but they are time consuming and can induce severe bronchospasm. A safer and faster clinical examination to predict bronchial hyperresponsiveness (BHR) is needed. OBJECTIVE: The objective of this study was to investigate whether small-airway function tests can predict BHR in adult patients with chronic cough. METHODS: A retrospective, cross-sectional study of diagnoses made using spirometry and bronchial provocation test results was performed in 290 patients with chronic nonproductive cough. BHR-predictive values were analyzed via the area under receiver operating characteristic curves (AUCs). Optimal cutoff values were determined by maximizing the sum of sensitivity and specificity. RESULTS: Patients with chronic cough with BHR showed lower forced expiratory flow between 25% and 75% (FEF25%-75%), higher fractional exhaled nitric oxide (FENO), and a higher percentage of eosinophils in blood than patients without BHR (P &lt; .0001 for all). The AUCs of FENO and FEF25%-75% for a BHR diagnosis were 0.788 (95% CI, 0.725-0.851) and 0.702 (95% CI, 0.641-0.763), respectively. Optimal cutoff values were 43 ppb for FENO and 78.5% for FEF25%-75%, with negative predictive values of 85.38% and 81.34%, respectively. The combined use of FENO and FEF25%-75% increased the AUC to 0.843 (95% CI, 0.794-0.892), significantly higher than either FENO (P = .012) or FEF25%-75% (P &lt; .0001) alone. CONCLUSIONS: Small-airway dysfunction is present in patients with chronic cough and BHR. FEF25%-75% has value as a negative predictive parameter for BHR, especially when combined with FENO. FENO > 43 ppb and FEF25%-75% &lt; 78.5% strongly predicted a positive bronchial provocation test</style></abstract><notes><style face="normal" font="default">DA - 20171112IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.09.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29128336">PM:29128336</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171112, Bao W</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.09.026</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43180</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ben Said,B.</style></author><author><style face="normal" font="default"> Gerfaud-Valentin,M.</style></author><author><style face="normal" font="default"> Seve,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Severe Cutaneous Drug Reaction Unit-CCR2A, Hopital Edouard Herriot, Hospices civils de Lyon, Inserm U851, Universite Claude Bernard Lyon 1, Lyon, France.</style></auth-address><titles><title><style face="normal" font="default">Fatal DRESS syndrome under tocilizumab treatment for seronegative polyarthritis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="11" Year="2017">2017/11/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171111IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29126664">PM:29126664</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171111, Ben Said B</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.041</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43181</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Di Sabatino,A.</style></author><author><style face="normal" font="default"> Aronico,N.</style></author><author><style face="normal" font="default"> Giuffrida,P.</style></author><author><style face="normal" font="default"> Cococcia,S.</style></author><author><style face="normal" font="default"> Lenti,M.V.</style></author><author><style face="normal" font="default"> Vanoli,A.</style></author><author><style face="normal" font="default"> Guerci,M.</style></author><author><style face="normal" font="default"> Di Stefano,M.</style></author><author><style face="normal" font="default"> Corazza,G.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">First Department of Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy.</style></auth-address><titles><title><style face="normal" font="default">Association between defective spleen function and primary eosinophilic gastrointestinal disorders</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="11" Year="2017">2017/11/8</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171112IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.10.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29128338">PM:29128338</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171112, Di Sabatino A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.10.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43182</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Colorafi,K.</style></author><author><style face="normal" font="default"> Moua,L.</style></author><author><style face="normal" font="default"> Shaw,M.</style></author><author><style face="normal" font="default"> Ricker,D.</style></author><author><style face="normal" font="default"> Postma,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Assessing the value of the Meaningful Use Clinical Summary for patients and families with pediatric asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="11" Year="2017">2017/11/6</year></dates><abstract><style face="normal" font="default">Electronic clinical summaries are innovations supported by the Electronic Health Record Incentive Program, known as "Meaningful Use" (MU). The MU clinical summary documents the shared understanding of the plan of care for patients and assists families in managing asthma-related health care. The purpose of this analysis was to identify the communicative value of the summaries to patients and families. Readability measurements, content analysis, and descriptive statistics were employed in a review of twenty clinical summaries and compared with provider encounter notes. The average age of the patients from whom we collected clinical summaries was six years old. The average reading level of the summaries was ninth grade. Neither summaries or health education contained visual images. There was a total of nine different asthma diagnoses. A full list of diagnoses was present in 45% of summaries. The average medications per patient was 5.75, and there were multiple medication changes noted (dosage adjustment, add, discontinued, and add). Allergies, vital signs, and smoking status were reliably reported (99-100%). Provider orders present included medication, follow up, and return to the clinic instructions. The plan of care was replicated on 45% of summaries. There was variable reporting of various asthma guidelines. Opportunities to improve the clinical summary include using plain language to promote readability, action, understanding, and health literacy, training providers to standardize their documentation and include asthma action plans, and configuring EHR settings to ensure diagnoses and plan of care is carried over from provider notes to the summary</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1391283</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29106306">PM:29106306</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171106-ColorafiK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171106-ColorafiK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Colorafi K</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1391283</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43183</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Beaurivage,D.</style></author><author><style face="normal" font="default"> Boulet,L.P.</style></author><author><style face="normal" font="default"> Foster,J.M.</style></author><author><style face="normal" font="default"> Gibson,P.G.</style></author><author><style face="normal" font="default"> McDonald,V.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Institut universitaire de cardiologie et de pneumologie de Quebec (IUCPQ), Laval University , Quebec , Qc , Canadaa Institut universitaire de cardiologie et de pneumologie de Quebec (IUCPQ), Laval University , Quebec , Qc , Canadab Woolcock Institute of Medical Research , University of Sydney , Sydney , NSW , Australiac The Priority Research Centre for Healthy Lungs and Centre of Excellence in Severe Asthma , The University of Newcastle , NSW , Australiad Viruses, Infections/Immunity, Vaccines and Asthma Research Program , Hunter Medical Research Institute , Newcastle , NSW , Australiac The Priority Research Centre for Healthy Lungs and Centre of Excellence in Severe Asthma , The University of Newcastle , NSW , Australiad Viruses, Infections/Immunity, Vaccines and Asthma Research Program , Hunter Medical Research Institute , Newcastle , NSW , Australia</style></auth-address><titles><title><style face="normal" font="default">Validation of the patient-completed asthma knowledge questionnaire (PAKQ)</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="10" Year="2017">2017/10/26</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is often suboptimally controlled, in part due to patients' disease knowledge. Understanding patients' knowledge, prior to education may help in individualizing content. However, there are no well validated or internationally relevant patient asthma knowledge questionnaires available. OBJECTIVE: To translate and validate the rigorously validated Questionnaire de connaissances sur l'asthme destine aux patients adultes (QCA-PA) based on key points related to asthma knowledge and self-management accordingly to the Global Initiative for Asthma report. METHODS: Based on Vallerand's methodology, a preliminary version of the "Patient-completed Asthma Knowledge Questionnaire" (PAKQ) was back-translated and evaluated by an expert committee. A sample of 20 individuals with asthma pretested the questionnaire, after which 62 adults were recruited. Sociodemographic data were collected and the PAKQ together with a comparator questionnaire (Consumer Questionnaire (CQ)) were completed. Fourteen days after the first visit, participants returned to recomplete both questionnaires; half were randomly selected to receive a one-on-one asthma education session and again completed both questionnaires immediately after education, and at 10 days follow-up. RESULTS: The PAKQ showed good internal consistency (KR-20 = 0.77). Moderate correlation with CQ (r = 0.596, p = 0.01) attested to its concurrent validity. Confirmatory factor analyses confirmed a single factor structure. A repeated measures ANOVA showed its reproducibility (n = 21:F(1) = 3.578, p = 0.07, etap2 = 0.152) and responsiveness (n = 21:F(1) = 26.041, P &lt; 0.05, etap2 = 0.566). CONCLUSION: The PAKQ is a valid asthma knowledge questionnaire which is based on international asthma recommendations and could help healthcare professionals in individualizing educational interventions for people with asthma</style></abstract><notes><style face="normal" font="default">DA - 20171026IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1318914</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29072971">PM:29072971</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171026-BeaurivageD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171026-BeaurivageD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171026, Beaurivage D</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1318914</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43184</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Davis,S.R.</style></author><author><style face="normal" font="default"> Peters,D.</style></author><author><style face="normal" font="default"> Calvo,R.A.</style></author><author><style face="normal" font="default"> Sawyer,S.M.</style></author><author><style face="normal" font="default"> Foster,J.M.</style></author><author><style face="normal" font="default"> Smith,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Faculty of Pharmacy, University of Sydney , NSW , Australiab School of Electrical and Information Engineering, University of Sydney , Sydney , NSW Australia</style></auth-address><titles><title><style face="normal" font="default">"Kiss myAsthma": Using a participatory design approach to develop a self-management app with young people with asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="24" Month="10" Year="2017">2017/10/24</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Young people with asthma often lack engagement in self-management. Smartphone apps offer an attractive, immediate method for obtaining asthma information and self-management support. In this research we developed an evidence-based asthma app tailored to young people's needs, created using a participatory design approach to optimise user-engagement. This paper describes the participatory design process. METHODS: This multi-phased research included concept generation and ideation of app design by young people with asthma, and development of asthma information by the research team. Clinical review was sought regarding safety and accuracy of app content. Participant's suggestions for improvement and any problems with the app were logged throughout. Our young co-designers were invited back to test a high fidelity prototype app using a "think aloud" process and completed a usability questionnaire. RESULTS: Twenty asthma patients aged 15-24 years contributed to the initial app design. Three respiratory specialists and two pharmacists suggested minor corrections to clinical terminology in the app which were all incorporated. Nine co-designers acted as expert reviewers of the prototype app, of whom eight completed a usability questionnaire. Median usability scores (maximum score 6) indicated high satisfaction with app content, usefulness and ease of use [median item score 5.3 (range 4.7-6.0)]. All feedback was incorporated to create an updated prototype app. CONCLUSIONS: A clinically sound asthma app has been developed which is considered highly acceptable to the young co-designers. A six-week test of the engagement, acceptability, and usefulness of the app in young people not involved in the participatory design will follow</style></abstract><notes><style face="normal" font="default">DA - 20171024IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1388391</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29064746">PM:29064746</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171024-DavisSR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171024-DavisSR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171024, Davis SR</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1388391</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43185</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arsenault,B.J.</style></author><author><style face="normal" font="default"> Petrides,F.</style></author><author><style face="normal" font="default"> Tabet,F.</style></author><author><style face="normal" font="default"> Bao,W.</style></author><author><style face="normal" font="default"> Hovingh,G.K.</style></author><author><style face="normal" font="default"> Boekholdt,S.M.</style></author><author><style face="normal" font="default"> Ramin-Mangata,S.</style></author><author><style face="normal" font="default"> Meilhac,O.</style></author><author><style face="normal" font="default"> DeMicco,D.</style></author><author><style face="normal" font="default"> Rye,K.A.</style></author><author><style face="normal" font="default"> Waters,D.D.</style></author><author><style face="normal" font="default"> Kastelein,J.J.P.</style></author><author><style face="normal" font="default"> Barter,P.</style></author><author><style face="normal" font="default"> Lambert,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec, Quebec, Canada</style></auth-address><titles><title><style face="normal" font="default">Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk</style></title><secondary-title><style face="normal" font="default">J Clin Lipidol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Clin Lipidol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Proprotein subtilisin kexin type 9 (PCSK9) and lipoprotein (a) [Lp(a)] levels are causative risk factors for coronary heart disease. OBJECTIVES: The objective of the study was to determine the impact of lipid-lowering treatments on circulating PCSK9 and Lp(a). METHODS: We measured PCSK9 and Lp(a) levels in plasma samples from Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events trial patients with coronary heart disease and/or type II diabetes (T2D) mellitus. Patients received atorvastatin, which was titrated (10, 20, 40, or 80 mg/d) to achieve low-density lipoprotein cholesterol levels &lt;100 mg/dL (baseline) and were subsequently randomized either to atorvastatin + torcetrapib, a cholesterol ester transfer protein inhibitor, or to atorvastatin + placebo. RESULTS: At baseline, both plasma PCSK9 and Lp(a) were dose-dependently increased with increasing atorvastatin doses. Compared with patients without T2D, those with T2D had higher PCSK9 (357 +/- 123 vs 338 +/- 115 ng/mL, P = .0012) and lower Lp(a) levels (28 +/- 32 vs 32 +/- 33 mg/dL, P = .0005). Plasma PCSK9 levels significantly increased in patients treated with torcetrapib (+13.1 +/- 125.3 ng/mL [+3.7%], P = .005), but not in patients treated with placebo (+2.6 +/- 127.9 ng/mL [+0.7%], P = .39). Plasma Lp(a) levels significantly decreased in patients treated with torcetrapib (-3.4 +/- 10.7 mg/dL [-11.1%], P &lt; .0001), but not in patients treated with placebo (+0.3 +/- 9.4 mg/dL [+0.1%], P = .92). CONCLUSION: In patients at high cardiovascular disease risk, PCSK9 and Lp(a) are positively and dose-dependently correlated with atorvastatin dosage, whereas the presence of T2D is associated with higher PCSK9 but lower Lp(a) levels. Cholesterol ester transfer protein inhibition with torcetrapib slightly increases PCSK9 levels and decreases Lp(a) levels</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 1933-2874 (Print)IS - 1876-4789 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - United States -CO - Netherlands -CO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jacl.2017.10.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29103916">PM:29103916</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Lipidol\20171106-ArsenaultBJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Lipidol\20171106-ArsenaultBJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Arsenault BJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jacl.2017.10.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43186</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chin,W.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Pharmacy, Monash University Malaysia, Subang Jaya, Malaysia</style></auth-address><titles><title><style face="normal" font="default">Leukotriene receptor antagonism may not be effective in atopic dermatitis treatment after all</style></title><secondary-title><style face="normal" font="default">J Clin Pharm Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Clin Pharm Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="11" Year="2017">2017/11/7</year></dates><abstract><style face="normal" font="default">WHAT IS KNOWN AND OBJECTIVE: Literature evidence suggests leukotriene involvement in the pathogenesis of atopic dermatitis. This article aimed to discuss whether the off-label use of montelukast, a leukotriene receptor antagonist, is justifiable for the treatment of atopic dermatitis. COMMENT: Most non-randomized studies supported the use of montelukast for atopic dermatitis treatment. However, evidence from these studies should be interpreted with caution as it is relatively weak due to the absence of randomization, control groups and blinding processes, subjecting the results to high risk of selection and reporting biases. The inconsistent findings across RCTs may be related to the limited number of patients, nuances in study designs, varying severity of disease and the concomitant use of steroids in some of the studies. WHAT IS NEW AND CONCLUSION: Current literature evidence is limited to rationally support the use of montelukast in atopic dermatitis treatment. For now, the conventional treatments should be preferred in the clinical setting</style></abstract><notes><style face="normal" font="default">DA - 20171108IS - 1365-2710 (Electronic)IS - 0269-4727 (Linking)LA - engPT - Journal ArticleCO - Malaysia -</style></notes><work-type><style face="normal" font="default">10.1111/jcpt.12648</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29114905">PM:29114905</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Clin Pharm Ther\20171108-ChinWK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Clin Pharm Ther\20171108-ChinWK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171108, Chin WK</style></custom2><misc3><style face="normal" font="default">10.1111/jcpt.12648</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43187</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,X.</style></author><author><style face="normal" font="default"> Tan,L.</style></author><author><style face="normal" font="default"> Yu,I.T.S.</style></author><author><style face="normal" font="default"> Zhang,Z.</style></author><author><style face="normal" font="default"> Wong,C.C.</style></author><author><style face="normal" font="default"> Guo,C.</style></author><author><style face="normal" font="default"> Ho,K.F.</style></author><author><style face="normal" font="default"> Lau,A.P.S.</style></author><author><style face="normal" font="default"> Yeoh,E.K.</style></author><author><style face="normal" font="default"> Lee,A.</style></author><author><style face="normal" font="default"> Lao,X.Q.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Public Health, Sun Yat-sen University, Guangzhou, China</style></auth-address><titles><title><style face="normal" font="default">Household cleaning products and the risk of allergic dermatitis: A prospective cohort study with primary-school children</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="11" Year="2017">2017/11/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Household cleaning products are widely used by the public, but limited data have been obtained on whether their use induces allergic dermatitis in children. OBJECTIVE: This study investigated the association between exposure to household cleaning products and allergic dermatitis in primary-school children. METHODS: A prospective cohort study of Hong Kong primary-school children was conducted between 2012 and 2014. A baseline survey was administered to 1,812 students who did not have allergic dermatitis. Information on respiratory symptoms, exposure to household chemical cleaning products and other topics was collected using a self-designed questionnaire. A cumulative chemical burden (CCB) score was calculated for each student by summing the duration of exposure to 14 chemical cleaning products. Principal component analysis was used to identify patterns in the use of these cleaning products. Logistic regression was performed to calculate relative risk (RR) with 95% confidence intervals (CIs) after adjusting for potential confounders. RESULTS: Eighty-nine (4.9%) of the students surveyed had dermatitis during the follow-up. However, exposure to individual chemical cleaning products was not found to be associated with the children's allergic dermatitis (all P > 0.05). In contrast to those in the lowest tertile, neither CCB scores in the middle tertile (RR: 1.16, 95% CI: 0.67 to 2.00) nor those in the highest tertile (RR: 1.24, 95% CI: 0.73 to 2.14) were significantly associated with the risk of allergic dermatitis. The adjusted RR for every 5-unit increment in CCB score was 1.01 (95% CI: 0.98 to 1.03). Four patterns of cleaning-product use were derived, but none were found to be associated with the risk of dermatitis (all P > 0.05). CONCLUSION: The use of household chemical cleaning products is not associated with the risk of dermatitis in primary-school children. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171108IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - China -CO - Hong Kong -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.14680</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29114947">PM:29114947</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20171108-LiuX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Eur Acad Dermatol Venereol\20171108-LiuX.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171108, Liu X</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.14680</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43188</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wendl,B.</style></author><author><style face="normal" font="default"> Wiltsche,H.</style></author><author><style face="normal" font="default"> Lankmayr,E.</style></author><author><style face="normal" font="default"> Winsauer,H.</style></author><author><style face="normal" font="default"> Walter,A.</style></author><author><style face="normal" font="default"> Muchitsch,A.</style></author><author><style face="normal" font="default"> Jakse,N.</style></author><author><style face="normal" font="default"> Wendl,M.</style></author><author><style face="normal" font="default"> Wendl,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Oral Surgery and Orthodontics, Department of Dental Medicine and Oral Health, Medical University, Graz, Austria.</style></auth-address><titles><title><style face="normal" font="default">Metal release profiles of orthodontic bands, brackets, and wires: an in vitro study</style></title><secondary-title><style face="normal" font="default">J Orofac Orthop</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Orofac Orthop</style></full-title></periodical><pages end="503" start="494">494-503</pages><volume><style face="normal" font="default">78</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">AIM: The present study evaluated the temporal release of Co Cr, Mn, and Ni from the components of a typical orthodontic appliance during simulated orthodontic treatment. MATERIALS AND METHODS: Several commercially available types of bands, brackets, and wires were exposed to an artificial saliva solution for at least 44 days and the metals released were quantified in regular intervals using inductively coupled plasma quadrupole mass spectrometry (ICP-MS, Elan DRC+, Perkin Elmer, USA). Corrosion products encountered on some products were investigated by a scanning electron microscope equipped with an energy dispersive X-ray microanalyzer (EDX). RESULTS: Bands released the largest quantities of Co, Cr, Mn, and Ni, followed by brackets and wires. Three different temporal metal release profiles were observed: (1) constant, though not necessarily linear release, (2) saturation (metal release stopped after a certain time), and (3) an intermediate release profile that showed signs of saturation without reaching saturation. These temporal metal liberation profiles were found to be strongly dependent on the individual test pieces. The corrosion products which developed on some of the bands after a 6-month immersion in artificial saliva and the different metal release profiles of the investigated bands were traced back to different attachments welded onto the bands. CONCLUSION: The use of constant release rates will clearly underestimate metal intake by the patient during the first couple of days and overestimate exposure during the remainder of the treatment which is usually several months long. While our data are consistent with heavy metal release by orthodontic materials at levels well below typical dietary intake, we nevertheless recommend the use of titanium brackets and replacement of the band with a tube in cases of severe Ni or Cr allergy</style></abstract><notes><style face="normal" font="default">DA - 20170915IS - 1615-6714 (Electronic)IS - 1434-5293 (Linking)LA - engPT - Journal ArticleCO - Austria -</style></notes><work-type><style face="normal" font="default">10.1007/s00056-017-0107-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28913542">PM:28913542</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Orofac Orthop\2017-78-494-503.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Orofac Orthop\2017-78-494-503.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170915, Wendl B</style></custom2><misc3><style face="normal" font="default">10.1007/s00056-017-0107-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43189</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shields,N.</style></author><author><style face="normal" font="default"> Downs,J.</style></author><author><style face="normal" font="default"> de Haan,J.B.</style></author><author><style face="normal" font="default"> Taylor,N.F.</style></author><author><style face="normal" font="default"> Torr,J.</style></author><author><style face="normal" font="default"> Fernhall,B.</style></author><author><style face="normal" font="default"> Kingsley,M.</style></author><author><style face="normal" font="default"> Mnatzaganian,G.</style></author><author><style face="normal" font="default"> Leonard,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Allied Health, La Trobe University, Australia; Northern Health, Australia.</style></auth-address><titles><title><style face="normal" font="default">What effect does regular exercise have on oxidative stress in people with Down syndrome? A systematic review with meta-analyses</style></title><secondary-title><style face="normal" font="default">J Sci Med Sport</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Sci Med Sport</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="10" Year="2017">2017/10/19</year></dates><abstract><style face="normal" font="default">OBJECTIVE: What effect does regular exercise have on oxidative stress in people with Down syndrome? DESIGN: Systematic review with meta-analyses. METHODS: A systematic review with meta-analyses was conducted. Six databases were searched from inception until August 2017. Studies where included if participants with Down syndrome (any age) had completed an exercise program of at least 6 weeks duration and at least one biomarker measured the generation or removal of reactive oxidative species. Data were extracted using a customised form. Risk of bias was assessed using the Cochrane Collaborations Risk of Bias assessment tool. Effect sizes were calculated and meta-analyses completed for clinically homogeneous data using a random effects model. RESULTS: Seven studies (11 articles) involving 144 inactive participants investigated the effect of moderate intensity aerobic exercise. No pattern emerged for how most biomarkers responded with non-significant pooled effect sizes and high levels of heterogeneity observed. The exception was catalase which increased significantly after exercise (standardised mean difference 0.39, 95%CI 0.040.75; I2 15%). Available studies were at high risk of bias. Two of five studies that measured more than one biomarker reported a decrease in oxidative stress with increased antioxidant activity after exercise but the other three (including one small randomised controlled trial) reported increased oxidative stress with variable change in antioxidant activity. CONCLUSIONS: There remains uncertainty about the effect of exercise on oxidative stress in people with Down syndrome. REVIEW REGISTRATION: PROSPERO CRD42016048492</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 1878-1861 (Electronic)IS - 1878-1861 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jsams.2017.10.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29103914">PM:29103914</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Sci Med Sport\20171106-ShieldsN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Sci Med Sport\20171106-ShieldsN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Shields N</style></custom2><misc3><style face="normal" font="default">10.1016/j.jsams.2017.10.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43190</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wardle,S.L.</style></author><author><style face="normal" font="default"> Greeves,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Applied Human Physiology, Army Personnel Research Capability, Army Headquarters, Andover, UK.</style></auth-address><titles><title><style face="normal" font="default">Mitigating the risk of musculoskeletal injury: A systematic review of the most effective injury prevention strategies for military personnel</style></title><secondary-title><style face="normal" font="default">J Sci Med Sport</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Sci Med Sport</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="9" Year="2017">2017/9/23</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To update the current injury prevention strategy evidence base for making recommendations to prevent physical training-related musculoskeletal injury. DESIGN: We conducted a systematic review to update the evidence base on injury prevention strategies for military personnel. METHODS: Literature was systematically searched and extracted from five databases, and reported according to PRISMA guidelines. Sixty one articles meeting the inclusion criteria and published during the period 2008-2015 were selected for systematic review. RESULTS: The retrieved articles were broadly categorised into six injury prevention strategies; (1) conditioning, (2) footwear modifications, (3) bracing, (4) physical activity volume, (5) physical fitness, and (6) leadership/supervision/awareness. The majority of retrieved articles (n=37 (of 61) evaluated or systematically reviewed a conditioning intervention of some nature. However, the most well-supported strategies were related to reducing physical activity volume and improving leadership/supervision/awareness of injuries and injury prevention efforts. CONCLUSIONS: Several injury prevention strategies effectively reduce musculoskeletal injury rates in both sexes, and many show promise for utility with military personnel. However, further evaluation, ideally with prospective randomised trials, is required to establish the most effective injury prevention strategies, and to understand any sex-specific differences in the response to these strategies</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 1878-1861 (Electronic)IS - 1878-1861 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jsams.2017.09.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29103913">PM:29103913</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Sci Med Sport\20171106-WardleSL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Sci Med Sport\20171106-WardleSL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Wardle SL</style></custom2><misc3><style face="normal" font="default">10.1016/j.jsams.2017.09.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43191</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Samuriwo,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Chair of the Tissue Viability Society Board of Trustees, UK</style></auth-address><titles><title><style face="normal" font="default">Grand convergence in wound healing - The imperative for collaboration in research, innovation and quality improvement</style></title><secondary-title><style face="normal" font="default">J Tissue Viability</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Tissue Viability</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="2" Month="11" Year="2017">2017/11/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 0965-206X (Print)IS - 0965-206X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="underline" font="default">20171106-SamuriwoR.pdf</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29103915">PM:29103915</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Tissue Viability\20171106-SamuriwoR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Tissue Viability\20171106-SamuriwoR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Samuriwo R</style></custom2><misc3><style face="underline" font="default">20171106-SamuriwoR.pdf</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43192</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Trubiano,J.A.</style></author><author><style face="normal" font="default"> Adkinson,N.F.</style></author><author><style face="normal" font="default"> Phillips,E.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, AustraliaJohn Hopkins Asthma and Allergy Center, Baltimore, MarylandDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee</style></auth-address><titles><title><style face="normal" font="default">Persistence of Penicillin Allergy-Reply</style></title><secondary-title><style face="normal" font="default">JAMA</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">JAMA</style></full-title></periodical><pages end="1715" start="1714">1714-1715</pages><volume><style face="normal" font="default">318</style></volume><number><style face="normal" font="default">17</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="11" Year="2017">2017/11/7</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171108IS - 1538-3598 (Electronic)IS - 0098-7484 (Linking)LA - engPT - LetterPT - CommentCO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1001/jama.2017.13763</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29114827">PM:29114827</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JAMA\2017-318-1714-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JAMA\2017-318-1714-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171108, Trubiano JA</style></custom2><misc3><style face="normal" font="default">10.1001/jama.2017.13763</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43193</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fang-Mercado,L.C.</style></author><author><style face="normal" font="default"> Urrego-Alvarez,J.R.</style></author><author><style face="normal" font="default"> Merlano-Baron,A.E.</style></author><author><style face="normal" font="default"> Meza-Torres,C.</style></author><author><style face="normal" font="default"> Hernandez-Bonfante,L.</style></author><author><style face="normal" font="default"> Lopez-Kleine,L.</style></author><author><style face="normal" font="default"> Marrugo-Cano,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universidad de Cartagena, Facultad de Odontologia, Grupo de Investigaciones GITOUC, Cartagena de Indias, Colombia.</style></auth-address><titles><title><style face="normal" font="default">[Influence of lifestyle, diet and vitamin D on atopy in a population of Afro-descendant Colombian children]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="290" start="277">277-290</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic conditions have shown an increase in the past few decades. Hygiene, changes in lifestyle, diet and vitamin D have been blamed for this increase. OBJECTIVE: To determine the role of environment, diet and vitamin D in atopic diseases in a population of Colombian Afro-descendant children. METHODS: Cross-sectional, descriptive, observational study in 200 Afro-descendant children of rural and urban areas from northern Colombia. Lifestyle and diet were established by questionnaires, atopy was assessed with skin tests and total and specific IgE and vitamin D levels were determined by ELISA. RESULTS: Results: Atopy was more prevalent in the urban population (24 % versus 7 %, p &lt; 0.001). Blomia tropicalis was the most common allergen (80.6 %). The PCA indicated two dietary patterns. In the rural area children, the consumption of dairy products and fruit/vegetables was higher, and related with a protective effect on atopy (OR, 0.21 [p &lt; 0.027] and OR, 0.11 [ p &lt; 0.04]). A similar pattern was observed with total IgE and vitamin D levels (2450.73 versus 777.56 kU/mL [p &lt; 0.01] and 59.32 ng/mL versus 31.14 ng/mL [p &lt; 0.001], respectively). CONCLUSION: Allergic conditions were less prevalent in rural area residents, possibly owing to higher consumption of unpasteurized dairy products and fruit/vegetables, as well as higher levels of vitamin D</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleLA - SPACO - Colombia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29046026">PM:29046026</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-277-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-277-90.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Fang-Mercado LC</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43194</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Podgorski,M.</style></author><author><style face="normal" font="default"> Kupczyk,M.</style></author><author><style face="normal" font="default"> Grzelak,P.</style></author><author><style face="normal" font="default"> Bochenska-Marciniak,M.</style></author><author><style face="normal" font="default"> Polguj,M.</style></author><author><style face="normal" font="default"> Kuna,P.</style></author><author><style face="normal" font="default"> Stefanczyk,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Radiology and Diagnostic Imaging, Barlicki Hospital, Medical University of Lodz, Lodz, Poland</style></auth-address><titles><title><style face="normal" font="default">Inhaled Corticosteroids in Asthma: Promoting or Protecting Against Atherosclerosis?</style></title><secondary-title><style face="normal" font="default">Med Sci Monit</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Med Sci Monit</style></abbr-1></periodical><pages end="5344" start="5337">5337-5344</pages><volume><style face="normal" font="default">23</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="11" Year="2017">2017/11/9</year></dates><abstract><style face="normal" font="default">BACKGROUND Bronchial asthma is an inflammatory disease of the respiratory system. However, it may also induce systemic effects. Although reports suggest patients with asthma are at increased risk of cardiovascular events, the association between asthma and atherosclerosis is unclear. The aim of the present study was to compare the progression of atherosclerosis between patients with asthma treated with inhaled corticosteroids and healthy controls. MATERIAL AND METHODS In 102 adult patients with asthma, markers of arterial stiffness (pulse wave velocity and augmentation index) were evaluated by applanation tonometry. Structural atherosclerotic changes (intima-media complex thickness and presence of atherosclerotic plaque) were assessed sonographically. Lipid profile and fasting glucose level were measured. Clinical data concerning the course of asthma, its severity, and management strategy were obtained. A group of 102 healthy, age-matched controls were examined according to the same protocol. RESULTS The majority of patients presented well-controlled asthma of moderate severity. When adjusted for weight, age, and systolic blood pressure, no significant differences were observed in pulse wave velocity, in augmentation index, or in intima-media complex thickness between groups. In controls, atherosclerotic plaque occurred significantly more often than in patients with asthma (p=0.0226). Moreover, in patients with asthma, the intima-media complex thickness of the right common carotid artery was significantly correlated with forced expiratory volume in 1 second (R(2)=-0.2951, p=0.0083). There was no significant difference in any of the atherosclerosis markers between different types and doses of administered inhaled corticosteroids. CONCLUSIONS Patients with bronchial asthma presented a decreased risk of atherosclerosis in comparison to healthy controls</style></abstract><notes><style face="normal" font="default">DA - 20171109IS - 1643-3750 (Electronic)IS - 1234-1010 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.12659/MSM.904469</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29120994">PM:29120994</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Med Sci Monit\2017-23-5337-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Med Sci Monit\2017-23-5337-44.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171109, Podgorski M</style></custom2><misc3><style face="normal" font="default">10.12659/MSM.904469</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43195</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,S.S.</style></author><author><style face="normal" font="default"> Rait,A.</style></author><author><style face="normal" font="default"> Garrido-Sanabria,E.R.</style></author><author><style face="normal" font="default"> Pirollo,K.F.</style></author><author><style face="normal" font="default"> Harford,J.B.</style></author><author><style face="normal" font="default"> Chang,E.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA</style></auth-address><titles><title><style face="normal" font="default">Nanotherapeutics for Gene Modulation that Prevents Apoptosis in the Brain and Fatal Neuroinflammation</style></title><secondary-title><style face="normal" font="default">Mol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Mol Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="10" Year="2017">2017/10/10</year></dates><abstract><style face="normal" font="default">The failure of therapeutic agents to cross the blood-brain barrier (BBB) has been a major impediment in the treatment of neurological disorders and brain tumors. We have addressed this issue using an immunoliposome nanocomplex (designated scL) that delivers therapeutic nucleic acids across the BBB into the deep brain via transcytosis mediated by transferrin receptors. We validated brain delivery of payloads after systemic administration by monitoring uptake of fluorescently labeled payloads and by confirming up- or down-modulation of specific target gene expression in the brain, mainly in neuronal cells. As proof of concept for the therapeutic potential of our delivery system, we employed scL delivering an siRNA targeting tumor necrosis factor alpha to suppress neuroinflammation and neuronal apoptosis and to protect mice in lethal endotoxemia triggered by bacterial lipopolysaccharide. Brain delivery of therapeutic payloads via scL has major implications for the development of treatments for neurological disorders and brain tumors</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 1525-0024 (Electronic)IS - 1525-0016 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.ymthe.2017.10.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29103910">PM:29103910</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171106, Kim SS</style></custom2><misc3><style face="normal" font="default">10.1016/j.ymthe.2017.10.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43196</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fulle,L.</style></author><author><style face="normal" font="default"> Steiner,N.</style></author><author><style face="normal" font="default"> Funke,M.</style></author><author><style face="normal" font="default"> Gondorf,F.</style></author><author><style face="normal" font="default"> Pfeiffer,F.</style></author><author><style face="normal" font="default"> Siegl,J.</style></author><author><style face="normal" font="default"> Opitz,F.V.</style></author><author><style face="normal" font="default"> Hassel,S.K.</style></author><author><style face="normal" font="default"> Erazo,A.B.</style></author><author><style face="normal" font="default"> Schanz,O.</style></author><author><style face="normal" font="default"> Stunden,H.J.</style></author><author><style face="normal" font="default"> Blank,M.</style></author><author><style face="normal" font="default"> Grober,C.</style></author><author><style face="normal" font="default"> Handler,K.</style></author><author><style face="normal" font="default"> Beyer,M.</style></author><author><style face="normal" font="default"> Weighardt,H.</style></author><author><style face="normal" font="default"> Latz,E.</style></author><author><style face="normal" font="default"> Schultze,J.L.</style></author><author><style face="normal" font="default"> Mayer,G.</style></author><author><style face="normal" font="default"> Forster,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunology and Environment, Life and Medical Sciences (LIMES) Institute, University of Bonn, Carl-Troll-Strasse 31, 53115 Bonn, Germany</style></auth-address><titles><title><style face="normal" font="default">RNA Aptamers Recognizing Murine CCL17 Inhibit T Cell Chemotaxis and Reduce Contact Hypersensitivity In Vivo</style></title><secondary-title><style face="normal" font="default">Mol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Mol Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="10" Year="2017">2017/10/13</year></dates><abstract><style face="normal" font="default">The chemokine CCL17, mainly produced by dendritic cells (DCs) in the immune system, is involved in the pathogenesis of various inflammatory diseases. As a ligand of CCR4, CCL17 induces chemotaxis and facilitates T cell-DC interactions. We report the identification of two novel RNA aptamers, which were validated in vitro and in vivo for their capability to neutralize CCL17. Both aptamers efficiently inhibited the directed migration of the CCR4+ lymphoma line BW5147.3 toward CCL17 in a dose-dependent manner. To study the effect of these aptamers in vivo, we used a murine model of contact hypersensitivity. Systemic application of the aptamers significantly prevented ear swelling and T cell infiltration into the ears of sensitized mice after challenge with the contact sensitizer. The results of this proof-of-principle study establish aptamers as potent inhibitors of CCL17-mediated chemotaxis. Potentially, CCL17-specific aptamers may be used therapeutically in humans to treat or prevent allergic and inflammatory diseases</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 1525-0024 (Electronic)IS - 1525-0016 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.ymthe.2017.10.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29103909">PM:29103909</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mol Ther\20171106-FulleL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mol Ther\20171106-FulleL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Fulle L</style></custom2><misc3><style face="normal" font="default">10.1016/j.ymthe.2017.10.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43197</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brown,C.E.</style></author><author><style face="normal" font="default"> Aguilar,B.</style></author><author><style face="normal" font="default"> Starr,R.</style></author><author><style face="normal" font="default"> Yang,X.</style></author><author><style face="normal" font="default"> Chang,W.C.</style></author><author><style face="normal" font="default"> Weng,L.</style></author><author><style face="normal" font="default"> Chang,B.</style></author><author><style face="normal" font="default"> Sarkissian,A.</style></author><author><style face="normal" font="default"> Brito,A.</style></author><author><style face="normal" font="default"> Sanchez,J.F.</style></author><author><style face="normal" font="default"> Ostberg,J.R.</style></author><author><style face="normal" font="default"> D'Apuzzo,M.</style></author><author><style face="normal" font="default"> Badie,B.</style></author><author><style face="normal" font="default"> Barish,M.E.</style></author><author><style face="normal" font="default"> Forman,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Hematology &amp; Hematopoietic Cell Transplantation, T Cell Therapeutics Research Laboratory, City of Hope Beckman Research Institute and Medical Center, Duarte, CA 91010, USA</style></auth-address><titles><title><style face="normal" font="default">Optimization of IL13Ralpha2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma</style></title><secondary-title><style face="normal" font="default">Mol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Mol Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="10" Year="2017">2017/10/5</year></dates><abstract><style face="normal" font="default">T cell immunotherapy is emerging as a powerful strategy to treat cancer and may improve outcomes for patients with glioblastoma (GBM). We have developed a chimeric antigen receptor (CAR) T cell immunotherapy targeting IL-13 receptor alpha2 (IL13Ralpha2) for the treatment of GBM. Here, we describe the optimization of IL13Ralpha2-targeted CAR T cells, including the design of a 4-1BB (CD137) co-stimulatory CAR (IL13BBzeta) and a manufacturing platform using enriched central memory T cells. Utilizing orthotopic human GBM models with patient-derived tumor sphere lines in NSG mice, we found that IL13BBzeta-CAR T cells improved anti-tumor activity and T cell persistence as compared to first-generation IL13zeta-CAR CD8+ T cells that had shown evidence for bioactivity in patients. Investigating the impact of corticosteroids, given their frequent use in the clinical management of GBM, we demonstrate that low-dose dexamethasone does not diminish CAR T cell anti-tumor activity in vivo. Furthermore, we found that local intracranial delivery of CAR T cells elicits superior anti-tumor efficacy as compared to intravenous administration, with intraventricular infusions exhibiting possible benefit over intracranial tumor infusions in a multifocal disease model. Overall, these findings help define parameters for the clinical translation of CAR T cell therapy for the treatment of brain tumors</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 1525-0024 (Electronic)IS - 1525-0016 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.ymthe.2017.10.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29103912">PM:29103912</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171106, Brown CE</style></custom2><misc3><style face="normal" font="default">10.1016/j.ymthe.2017.10.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43198</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jirka,S.M.G.</style></author><author><style face="normal" font="default"> 't Hoen,P.A.C.</style></author><author><style face="normal" font="default"> Diaz Parillas,V</style></author><author><style face="normal" font="default"> Tanganyika-de Winter,C.L.</style></author><author><style face="normal" font="default"> Verheul,R.C.</style></author><author><style face="normal" font="default"> Aguilera,B.</style></author><author><style face="normal" font="default"> de Visser,P.C.</style></author><author><style face="normal" font="default"> Aartsma-Rus,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Human Genetics, Leiden University Medical Center, 2300 RC Leiden, the Netherlands</style></auth-address><titles><title><style face="normal" font="default">Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy</style></title><secondary-title><style face="normal" font="default">Mol Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Mol Ther</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="10" Year="2017">2017/10/12</year></dates><abstract><style face="normal" font="default">Duchenne muscular dystrophy (DMD) is a severe, progressive muscle wasting disorder caused by reading frame disrupting mutations in the DMD gene. Exon skipping is a therapeutic approach for DMD. It employs antisense oligonucleotides (AONs) to restore the disrupted open reading frame, allowing the production of shorter, but partly functional dystrophin protein as seen in less severely affected Becker muscular dystrophy patients. To be effective, AONs need to be delivered and effectively taken up by the target cells, which can be accomplished by the conjugation of tissue-homing peptides. We performed phage display screens using a cyclic peptide library combined with next generation sequencing analyses to identify candidate muscle-homing peptides. Conjugation of the lead peptide to 2'-O-methyl phosphorothioate AONs enabled a significant, 2-fold increase in delivery and exon skipping in all analyzed skeletal and cardiac muscle of mdx mice and appeared well tolerated. While selected as a muscle-homing peptide, uptake was increased in liver and kidney as well. The homing capacity of the peptide may have been overruled by the natural biodistribution of the AON. Nonetheless, our results suggest that the identified peptide has the potential to facilitate delivery of AONs and perhaps other compounds to skeletal and cardiac muscle</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 1525-0024 (Electronic)IS - 1525-0016 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.ymthe.2017.10.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29103911">PM:29103911</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mol Ther\20171106-JirkaSM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mol Ther\20171106-JirkaSM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Jirka SM</style></custom2><misc3><style face="normal" font="default">10.1016/j.ymthe.2017.10.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43199</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guilleminault,L.</style></author><author><style face="normal" font="default"> Williams,E.J.</style></author><author><style face="normal" font="default"> Scott,H.A.</style></author><author><style face="normal" font="default"> Berthon,B.S.</style></author><author><style face="normal" font="default"> Jensen,M.</style></author><author><style face="normal" font="default"> Wood,L.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, University of Newcastle, Callaghan, NSW 2308, Australia.</style></auth-address><titles><title><style face="normal" font="default">Diet and Asthma: Is It Time to Adapt Our Message?</style></title><secondary-title><style face="normal" font="default">Nutrients</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nutrients</style></abbr-1></periodical><pages end="" start="E1227">E1227-</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="11" Year="2017">2017/11/8</year></dates><abstract><style face="normal" font="default">Asthma is a chronic respiratory disorder which is associated with airway inflammation. Environmental factors, in association with genetic susceptibility, play a critical role in asthma pathophysiology. Inhaled allergens, smoke exposure, indoor and outdoor air pollution are common triggers of asthma symptoms. Although the role of diet has clearly established mechanisms in diseases such as cardiovascular disease, type 2 diabetes, and cancer, it is not commonly identified as a causal factor in asthma. However, some dietary patterns, such as the Western diet, which includes a high intake of refined grains, processed and red meats, and desserts, have pro-inflammatory effects. On the contrary, the Mediterranean diet, with high intake of fruits and vegetables has anti-inflammatory properties. The influence of food on asthma outcomes is of growing interest, but dietary habits of asthma patients are not commonly investigated in clinical practice. In this review, we focus on the impact of diet on asthma risk and asthma control. We also detail the influence of diet on obese patients with asthma</style></abstract><notes><style face="normal" font="default">DA - 20171108IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="default">10.3390/nu9111227</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29117118">PM:29117118</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nutrients\2017-9-E1227.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nutrients\2017-9-E1227.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171108, Guilleminault L</style></custom2><misc3><style face="normal" font="default">10.3390/nu9111227</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43200</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,S.Y.</style></author><author><style face="normal" font="default"> Kim,J.D.</style></author><author><style face="normal" font="default"> Sol,I.S.</style></author><author><style face="normal" font="default"> Kim,M.J.</style></author><author><style face="normal" font="default"> Kim,M.N.</style></author><author><style face="normal" font="default"> Hong,J.Y.</style></author><author><style face="normal" font="default"> Kim,H.R.</style></author><author><style face="normal" font="default"> Kim,Y.H.</style></author><author><style face="normal" font="default"> Lee,Y.J.</style></author><author><style face="normal" font="default"> Kim,K.W.</style></author><author><style face="normal" font="default"> Sohn,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Severance Hospital, Institute of Allergy, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Sputum TWEAK Expression Correlates with Severity and Degree of Control in Noneosinophilic Childhood Asthma</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="25" Month="10" Year="2017">2017/10/25</year></dates><abstract><style face="normal" font="default">BACKGROUND: Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is known to play a role in the pathogenesis of various inflammatory diseases. However, no study has been performed on childhood asthma. METHODS: Ninety-five children with asthma and 78 controls aged 5-18 years were included. Sputum induction, pulmonary function test (PFT), and methacholine challenge test were performed. The subjects were divided into the eosinophilic airway (EA) and non-EA (NEA) groups based on sputum analysis and into the high and low TWEAK groups according to the TWEAK cutoff level (263.0 pg/mL). TWEAK in induced sputum supernatant was measured through enzyme-linked immunosorbent assay. RESULTS: Children with asthma had higher TWEAK levels than healthy controls [493.0 (157.1-904.3) vs. 118.2 (67.5-345.5) pg/mL, P &lt; 0.001]. Sputum TWEAK levels were significantly correlated with PFT parameters reflecting airway obstruction. This association was particularly prominent in subjects with NEA inflammation. Significant differences in FEF25-75 (maximum midexpiratory flow, % predicted; P = 0.017), AX (reactance area; P &lt; 0.001), R5-R20 (difference between resistance at 5 and 20 Hz; P = 0.025), and X5 (reactance at 5 Hz, % predicted; P &lt; 0.001) were noted between the high and low TWEAK groups within the NEA group. Sputum TWEAK level also showed significant positive correlations with asthma severity (r = 0.358, P = 0.001) and control status (r = 0.470, P &lt; 0.001), distinctively in subjects with NEA inflammation. CONCLUSIONS: Airway TWEAK may play a role in small airway inflammation especially in children with noneosinophilic asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171025IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12827</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29068159">PM:29068159</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171025-KimSY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171025-KimSY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171025, Kim SY</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12827</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43201</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Raigosa,M.</style></author><author><style face="normal" font="default"> Toro,Y.</style></author><author><style face="normal" font="default"> Sanchez,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universidad de Antioquia, IPS Universitaria, Grupo de Alergologia Clinica y Experimental, Medellin, Colombia. jotamsc@yahoo.co</style></auth-address><titles><title><style face="normal" font="default">[Solar urticaria. Case report and literature review]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="375" start="371">371-375</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Solar urticaria is a rare type of inducible urticaria characterized by wheal and erythema formation shortly after exposure to sunlight or to an artificial light source; its pathophysiology is not yet entirely understood. The treatment of choice, in addition to exposure avoidance, consists in antihistamine administration. CLINICAL CASE: This is the case of a 27-year-old woman with no personal history of allergic diseases and with a 2-year history of erythema and wheals in photo-exposed areas associated with sunlight exposure for periods longer than 10 minutes. A provocation test was carried out; she was started on fexofenadine at 4-fold the standard dose (720 mg/day). Six weeks later, a new challenge was carried out without the antihistamine being discontinued; the reaction was less severe, but she continued with erythema for the first 60 minutes post-exposure. After 3 months on high-dose antihistamines, she referred marked improvement in her quality of life and tolerance to brief sunlight exposure (for less than 15 minutes). CONCLUSIONS: Solar urticaria is a rare process but with a high impact on the patient. The use of antihistamines partially relieves symptoms and allows better tolerance to lighting expositions</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleLA - SPACO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29046033">PM:29046033</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-371-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-371-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Raigosa M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43202</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ramos-Rios,J.A.</style></author><author><style face="normal" font="default"> Ramirez-Hernandez,E.</style></author><author><style face="normal" font="default"> Vazquez-Rodriguez,E.M.</style></author><author><style face="normal" font="default"> Vazquez-Nava,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universidad Veracruzana, Campus Minatitlan, Facultad Odontologia, Minatitlan, Veracruz, Mexico.</style></auth-address><titles><title><style face="normal" font="default">[Asthma-associated oral and dental health repercussions in children aged 6 to 12 years]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="276" start="270">270-276</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma, which is characterized by mouth breathing and by the use of drugs for its treatment, affects between 1 and 30% of children and adolescents. There are only few studies reporting its impact on the oral cavity. OBJECTIVE: To find out the most common asthma-associated repercussions in 6 to 12-year-old children. METHODS: Cross-sectional, comparative, analytical study carried out in 2 primary schools from Coclique, Veracruz, Mexico, in 6 to 12-year-old children. The International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire for parents was used. RESULTS: In a population of 409 children, a prevalence of asthma of 6.84% (n = 28) was found, which was higher in males (15, 54%); boys aged 6, 7 and 11 years and girls aged 8, 9 and 10 years were most affected. Risk factors for oral manifestations were acidic pH (OR = 170), caries (OR = 4.29), anterior open bite (OR = 66.78), gingivitis (OR = 9.75), atypical swallowing (OR = 15.70) and high-arched palate (OR = 45.60). CONCLUSION: Children with chronic conditions such as asthma require an oral and dental preventive program as part of their interdisciplinary care</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleLA - SPACO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29046025">PM:29046025</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-270-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-270-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Ramos-Rios JA</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43203</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sanchez,J.</style></author><author><style face="normal" font="default"> Toro,Y.</style></author><author><style face="normal" font="default"> Cardona,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universidad de Antioquia, IPS Universitaria. Grupo de Alergia Clinica y Experimental. Medellin, Antioquia, Colombia.</style></auth-address><titles><title><style face="normal" font="default">Clinical impact in the real life of guidelines recommendations for atopic dermatitis in a tropical population (TECCEMA cohort)</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="269" start="260">260-269</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Real-life impact of guidelines for the management of atopic dermatitis has been poorly studied. OBJECTIVE: To assess atopic dermatitis clinical control in residents of a tropical area managed according to international consensuses. METHODS: Prospective study with a 24-month follow-up. Clinical response was assessed with SCORAD, DLQI and a subjective scale (SS) on severity perception by the patient. RESULTS: Two-hundred and thirty-three patients were stratified according to SCORAD: 53 had mild severity (22%), 116 moderate (49%) and 64 severe (27%). Baseline SCORAD mean was 33 (15-41), for DLQI, it was 14 (11-20), and for the subjective scale, 85% (67-99). At 6 months, there was significant reduction (p &lt; 0.5): SCORAD 29 (14-41), DLQI 12 (8-16) and subjective scale 62% (45-80). At 2 years, SCORAD was 21 (9-34), DLQI 7 (4-10) and subjective scale 41% (27-56); only 33% achieved complete control (SCORAD &lt; 15%, DLQI &lt; 5, subjective scale &lt; 20%). CONCLUSIONS: Following international guidelines' recommendations reduces eczema severity and improves quality of life, although only 33% achieved complete control after 2 years</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - engPT - Journal ArticleLA - ENGCO - Colombia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29046024">PM:29046024</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-260-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-260-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Sanchez J</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43204</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mancilla-Hernandez,E.</style></author><author><style face="normal" font="default"> Gonzalez-Solorzano,E.V.M.</style></author><author><style face="normal" font="default"> Medina-Avalos,M.A.</style></author><author><style face="normal" font="default"> Barnica-Alvarado,R.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centro de Investigacion en el Area de la Salud. Puebla, Puebla, Mexico. manele05@yahoo.com.mx</style></auth-address><titles><title><style face="normal" font="default">[Prevalence of allergic rhinitis and its symptoms in the school children population of Cuernavaca, Morelos, Mexico]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="249" start="243">243-249</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Studies on allergic rhinitis prevalence have found significant variations in their results, even in closely-living populations. OBJECTIVE: To determine and compare the prevalence of allergic rhinitis and its symptoms in schoolchildren from Cuernavaca, Morelos, Mexico. METHODS: Cross-sectional, descriptive study on the prevalence of allergic rhinitis diagnosis and symptoms, where the "Diagnostic questionnaire for epidemiological studies" was used between June and December 2015 in pre-school and primary and secondary school population, after authorization was granted by parents and school authorities. RESULTS: In 7866 surveys in a population aged between 3 and 15 years, 939 cases of allergic rhinitis (11.94%) were identified, with 53% belonging to the female gender. The symptom with the highest prevalence was cold-induced nasal congestion (56.8%), followed by rhinitis accompanied by ocular symptoms (35.8%) and recurrent flu-like symptoms (20), which was the most common symptom in allergic rhinitis (100%). CONCLUSION: A significant variation was observed in the prevalence of symptoms, notably higher than that of questionnaire-obtained allergic rhinitis diagnosis (11.94%), which suggests that the independent prevalence of symptoms is not a good parameter to detect the prevalence of allergic rhinitis</style></abstract><notes><style face="normal" font="default">DA - 20171019IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29046022">PM:29046022</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-243-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-243-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171019, Mancilla-Hernandez E</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43205</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Corriger,J.</style></author><author><style face="normal" font="default"> Beaudouin,E.</style></author><author><style face="normal" font="default"> Rothmann,C.</style></author><author><style face="normal" font="default"> Penven,E.</style></author><author><style face="normal" font="default"> Haumonte,Q.</style></author><author><style face="normal" font="default"> Thomas,H.</style></author><author><style face="normal" font="default"> Picaud,J.</style></author><author><style face="normal" font="default"> Nguyen-Grosjean,V.M.</style></author><author><style face="normal" font="default"> Corriger-Ippolito,J.</style></author><author><style face="normal" font="default"> Braun,F.</style></author><author><style face="normal" font="default"> De Talance,M.</style></author><author><style face="normal" font="default"> Auburtin,B.</style></author><author><style face="normal" font="default"> Atain-Kouadio,P.</style></author><author><style face="normal" font="default"> Borsa-Dorion,A.</style></author><author><style face="normal" font="default"> Baugnon,D.</style></author><author><style face="normal" font="default"> De Carvalho,M.</style></author><author><style face="normal" font="default"> Jaussaud,R.</style></author><author><style face="normal" font="default"> Nguyen-Thi,P.L.</style></author><author><style face="normal" font="default"> Bollaert,P.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Anaphylaxis and emergency: Regional data in Lorraine and management</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> angioedema</style></keyword><keyword><style face="normal" font="default"> Adrenaline</style></keyword><keyword><style face="normal" font="default"> Allergy</style></keyword><keyword><style face="normal" font="default"> Immediate hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Urticaria</style></keyword><keyword><style face="normal" font="default"> Antihistaminic</style></keyword><keyword><style face="normal" font="default"> corticosteroid</style></keyword><keyword><style face="normal" font="default"> emergency</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Anaphylaxis is an allergic emergency, and its frequency increases in all countries since the 2000s. Epinephrine administration and allergist-emergency room interactions are the key points of its management. The objective of the study was to determine the incidence of anaphylaxis in 2015, to describe its main characteristics and to evaluate practices in Lorraine for this period. Four hospitals in Lorraine were selected. Medical records from each center's adult and pediatric emergency rooms, from 1st January to 31th December 2015, were classified based on their admission cause and diagnosis code. When data were consistent for an anaphylaxis (95 selected ICD-10 codes) record was analyzed by an allergist practitioner and included if confirmed. Epidemiological data, clinical characteristics, management assessment and orientation were provided through a standardized questionnaire. Anaphylaxis is responsible for 0.16% emergency rooms</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖ admissions in the participating centers in 2015; the estimated incidence in Lorraine is 34 per 100,000 person-years. Clinical presentation depends on age, etiologic agent, several cofactors (asthma, cardiovascular comorbidities, treatments) and reaction's gravity. When anaphylaxis was serious (Ring-Messmer's grade </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ëÑ3), epinephrine use was only 32.4% (48/148) and observation duration was less than 6hours 4 times on 10. An allergist referral was proposed in 57.9% (187/323) patients. Anaphylaxis is not a rare cause for emergency rooms</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖ admission in Lorraine. Therefore guidelines are insufficiently followed and a better knowledge of the pathology and its management is necessary for emergency healthcare practitioners</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.09.004</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.09.004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20171015-CorrigerJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20171015-CorrigerJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171015, Corriger J</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.09.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43206</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brun,M.</style></author><author><style face="normal" font="default"> Sarrat,A.</style></author><author><style face="normal" font="default"> Vitte,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Laboratory work-up of mast cell disorders</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Tryptase</style></keyword><keyword><style face="normal" font="default"> Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> mast cell</style></keyword><keyword><style face="normal" font="default"> Mastocytosis</style></keyword><keyword><style face="normal" font="default"> Mast cell activation syndrome</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Mast cell disorders are underlain by abnormal numbers and/or activity of mast cells, either organ-specific or systemic. Clonal expansion of mast cells, with or without abnormal mast cell activation, belong to the WHO category of mastocytosis, a myeloid neoplasm in its systemic variant. Mast cell activation syndromes have recently become a subject of intense research. We performed a literature review on mastocytosis and mast cell activation syndromes, with special focus on laboratory work-up as a tool for allergists</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.08.008</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.08.008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20171015-BrunM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20171015-BrunM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171115, Brun M</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.08.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43207</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Munoz Borras,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Consulta Donis Munoz, Gandia, Valencia, Espana.</style></auth-address><titles><title><style face="normal" font="default">Allergic Reactions to Tattoo Inks: A New Diagnostic Challenge</style></title><secondary-title><style face="normal" font="default">Actas Dermosifiliogr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Actas Dermosifiliogr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="11" Year="2017">2017/11/26</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1578-2190 (Electronic)IS - 0001-7310 (Linking)LA - engLA - spaPT - LetterCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.ad.2017.10.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29187285">PM:29187285</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171126, Munoz Borras D</style></custom2><misc3><style face="normal" font="default">10.1016/j.ad.2017.10.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43208</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fukuoka,A.</style></author><author><style face="normal" font="default"> Yoshimoto,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology, Hyogo College of Medicine, Hyogo, JapanDepartment of Immunology, Hyogo College of Medicine, Hyogo, Japan; Laboratory of Allergic Diseases, Institute for Advanced Medical Sciences, Hyogo College of Medicine, Hyogo, Japan.</style></auth-address><titles><title><style face="normal" font="default">Barrier dysfunction in the nasal allergy</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="11" Year="2017">2017/11/14</year></dates><abstract><style face="normal" font="default">Epithelial cells form the first physiological barrier against invasion by pathogens and the infiltration of allergens. Tight junctions (TJ), a cell-cell junctional complex located on the apical side of epithelial cells, have a critical role in the maintenance of epithelial barrier function. Impaired TJ structures are observed in patients with asthma, atopic dermatitis and nasal allergy; therefore, the dysfunction of epithelial barriers might be involved in the initiation or progression of allergic diseases. Protease-containing allergens and environmental pollutants enhance paracellular transport in epithelial cells through disruption of epithelial barrier function. This suggests that the disruption of TJ leads to the promotion of allergen delivery into the subepithelia, resulting in the progression of allergic diseases. Thus, protection of the epithelial barrier function might prevent or inhibit the development or exacerbation of allergic diseases. Recently, we reported that diesel exhaust particles (DEP), the main component of particulate patter 2.5, exacerbated allergic rhinitis (AR) in a mouse model through TJ disruption. In addition, we revealed that the oxidative stress-mediated pathway is involved in the effects caused by DEP and that nasal treatment with a reactive oxygen species (ROS) scavenger suppressed DEP-induced TJ disruption and exacerbation of AR. In this review, we focus on the relationship between TJ disruption and allergic disease. Furthermore, we discuss our recent findings regarding TJ disruption and the exacerbation of AR</style></abstract><notes><style face="normal" font="default">DA - 20171118IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.10.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29150353">PM:29150353</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20171114-FukuokaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20171114-FukuokaA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171114, Fukuoka A</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.10.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43209</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Egawa,G.</style></author><author><style face="normal" font="default"> Kabashima,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.</style></auth-address><titles><title><style face="normal" font="default">Barrier dysfunction in the skin allergy</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="11" Year="2017">2017/11/16</year></dates><abstract><style face="normal" font="default">The skin is continuously exposed to external pathogens, and its barrier function is critical for skin homeostasis. Previous studies have shown that the barrier dysfunction is one of the most predisposing factors for the development of skin allergic diseases such as atopic dermatitis. In this article, we summarize how the physical barrier of the skin is organized and review its link to the pathomechanism of skin allergic diseases. We describe the formation of the SC barrier in terms of the following five categories: 1) filaggrin metabolism; 2) cornified envelope; 3) intercellular lipids; 4) corneodesmosome; and 5) corneocyte desquamation. New approaches to restoring the skin barrier function are also discussed</style></abstract><notes><style face="normal" font="default">IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.10.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29153780">PM:29153780</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Int\20171116-EgawaG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Int\20171116-EgawaG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171116. Egawa G</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.10.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43210</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liedtke,J.P.</style></author><author><style face="normal" font="default"> Mandl,A.</style></author><author><style face="normal" font="default"> Kother,J.</style></author><author><style face="normal" font="default"> Chwieralski,J.</style></author><author><style face="normal" font="default"> Shah-Hosseini,K.</style></author><author><style face="normal" font="default"> Pieper-Furst,U.</style></author><author><style face="normal" font="default"> Allekotte,S.</style></author><author><style face="normal" font="default"> Mosges,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Medical Statistics, Informatics and Epidemiology, Faculty of Medicine, University of Cologne, Cologne, Germany</style></auth-address><titles><title><style face="normal" font="default">RCAT reflects symptom control and quality of life in allergic rhinoconjunctivitis patients</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="11" Year="2017">2017/11/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: The Global Allergy and Asthma European Network (GA(2) LEN) Taskforce has requested more data on correlations between various Patient Reported Outcomes (PROs) in clinical trials on allergy. We compared three tools-the Rhinitis Control Assessment Test (RCAT), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), and Rhinitis Total Symptom Score (RTSS)-to determine whether the RCAT alone is a sufficient primary outcome parameter in clinical trials on allergic rhinoconjunctivitis. METHODS: In two double-blind, placebo-controlled immunotherapy studies, 33 patients allergic to grass pollen and 94 to birch pollen completed two questionnaires (RCAT and RQLQ) and kept their own symptom diary from which the RTSS was calculated. RESULTS: Upon comparing RCAT and RQLQ results, we found strong correlations of r = -0.871 for grass pollen-allergic patients and r = -0.795 for birch pollen-allergic patients. The comparison between RCAT and RTSS results showed a strong correlation of r = -0.811 (grass pollen-allergic patients) and a moderate correlation of r = -0.539 (birch pollen-allergic patients). In the RCAT, 69.7% of grass pollen-allergic patients and 45.7% of birch pollen-allergic patients receiving guideline-concordant therapy were regarded as having insufficiently controlled symptoms. CONCLUSION: The strong correlation suggests that the RCAT alone is equivalent to the RQLQ with respect to patients' symptom control and quality of life. Patients with uncontrolled symptoms can be identified using the RCAT. Hence, the physician can decide whether symptomatic therapy can be intensified or allergy immunotherapy should be administered. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/all.13362</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29159975">PM:29159975</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171121-LiedtkeJP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171121-LiedtkeJP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171121, Liedtke JP</style></custom2><misc3><style face="normal" font="default">10.1111/all.13362</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43211</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Andersen,Y.M.F.</style></author><author><style face="normal" font="default"> Egeberg,A.</style></author><author><style face="normal" font="default"> Hamann,C.R.</style></author><author><style face="normal" font="default"> Skov,L.</style></author><author><style face="normal" font="default"> Gislason,G.H.</style></author><author><style face="normal" font="default"> Skaaby,T.</style></author><author><style face="normal" font="default"> Linneberg,A.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Poor agreement in questionnaire-based diagnostic criteria for adult atopic dermatitis is a challenge when examining cardiovascular comorbidity</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="11" Year="2017">2017/11/18</year></dates><abstract><style face="normal" font="default">BACKGROUND: The association between atopic dermatitis (AD) and cardio-metabolic risk factors is not yet established. Furthermore, no validated questionnaire-based method of identifying adults with AD is currently available. OBJECTIVES: To assess the cardio-metabolic risk in adults with a history of AD by using three different questionnaire-based diagnostic criteria. METHODS: We utilized data from a general population study including questionnaire data and objective measurements of 9,656 Danish adults. To identify adults with a history of AD, we used a question regarding physician-diagnosed AD, and two versions of the UK Working Party Diagnostic Criteria. Associations between AD status and cardio-metabolic endpoints were estimated using survey weighted logistic and linear regression analysis. RESULTS: We identified 462 (4.8%) adults with self-reported physician-diagnosed AD, whereas 903 (9.4%) and 226 (2.3%) had AD according to the UK Working Party Criteria when at least two and three of four minor criteria were fulfilled. The populations were not comparable in terms of occurrence of cardio-metabolic risk factors. For example, the prevalence of obesity was lower in participants with physician-diagnosed AD but overall higher in UK 2/4 and UK 3/4. CONCLUSION: Due to the heterogeneity in the captured study populations in terms of the studied outcomes and absence of a gold standard, no conclusions regarding the cardio-metabolic risk in adults with AD in a general population could be made. This study serves as an example of the challenges that are often encountered in questionnaire-based epidemiologic studies and highlights the need of better definitions for this patient group. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171118IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/all.13360</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29150853">PM:29150853</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171118-AndersenYM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171118-AndersenYM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171118, Andersen YM</style></custom2><misc3><style face="normal" font="default">10.1111/all.13360</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43212</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Surda,P.</style></author><author><style face="normal" font="default"> Putala,M.</style></author><author><style face="normal" font="default"> Siarnik,P.</style></author><author><style face="normal" font="default"> Walker,A.</style></author><author><style face="normal" font="default"> Bernic,A.</style></author><author><style face="normal" font="default"> Fokkens,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology, Guy's and St, Thomas' University Hospital, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Rhinitis and its Impact on Quality of Life in Swimmers</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="11" Year="2017">2017/11/18</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Limited data suggest that swimmers might be affected by rhinitis significantly more often than the general population. This can have impact on quality of life but also on performance. The aim of the present study was to determine the prevalence and impact of QOL of rhinitis in swimming compared to non-swimming athletes and controls. MATERIALS AND METHODS: This was an observational case control, questionnaire based study involving elite (n=101) and non-elite swimming athletes (n=107), non-swimming athletes (n = 38) and sex and age-matched controls (n = 50). The survey instrument consisted of a general and the miniRQLQ questionnaire. Main question used to assess the prevalence of rhinitis was from the ISAAC study. RESULTS: Rhinitis was reported significantly more often by the elite swimmers (45%) than non-elite swimmers (31%), non-swimming athletes (32%) and controls (24%). Allergic rhinitis prevalence was similar in all groups (12-18%). The prevalence of non-allergic rhinitis was significantly higher in elite swimmers (33%) and non-elite swimmers (22%) compared to non-swimming athlethes and controls. Overall mean miniRQLQ score and all subdomains except the "eye" domain showed significantly reduced QOL in elite and non-elite swimmers compared to non-swimming athletes and controls. Regular nasal medication was used significantly less by elite swimmers (18%) compared to controls (67%) and non-swimming athletes (42%). CONCLUSION: This study revealed a high prevalence of non-allergic rhinitis in swimmers and related impact on QoL. These findings highlight the importance to increase the awareness toward upper airway disorders in the swimming athletes and to ensure adequate management. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171118IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Slovakia -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/all.13359</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29150854">PM:29150854</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171118-SurdaP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171118-SurdaP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171118, Surda P</style></custom2><misc3><style face="normal" font="default">10.1111/all.13359</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43213</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Samitas,K.</style></author><author><style face="normal" font="default"> Carter,A.</style></author><author><style face="normal" font="default"> Kariyawasam,H.H.</style></author><author><style face="normal" font="default"> Xanthou,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cellular Immunology Laboratory, Division of Cell Biology, Centre for Basic Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, 11527, Greece</style></auth-address><titles><title><style face="normal" font="default">Upper and lower airway remodelling mechanisms in asthma, allergic rhinitis and chronic rhinosinusitis: the one airway concept revisited</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="12" Year="2017">2017/12/1</year></dates><abstract><style face="normal" font="default">Allergic rhinitis (AR), chronic rhinosinusitis (CRS) and asthma often co-exist. The one airway model proposes that disease mechanisms occurring in the upper airway may mirror lower airway events. Airway remodelling is the term used to describe tissue structural changes that occur in a disease setting and reflect the dynamic process of tissue restructuring during wound repair. Remodelling has been long identified in the lower airways in asthma and is characterized by epithelial shedding, goblet cell hyperplasia, basement membrane thickening, subepithelial fibrosis, airway smooth muscle hyperplasia and increased angiogenesis. The concept of upper airway remodelling has only recently been introduced, and data so far is limited and often conflicting, an indication that more detailed studies are needed. Whilst remodelling changes in AR are limited, CRS phenotypes demonstrate epithelial hyperplasia, increased matrix deposition and degradation along with accumulation of plasma proteins. Despite extensive research over the past years, the precise cellular and molecular mechanisms involved in airway remodelling remain incompletely defined. This review describes our current rather limited understanding of airway remodelling processes in AR, CRS and asthma, and presents mechanisms both shared and distinct between the upper and lower airways. Delineation of shared and disease-specific pathogenic mechanisms of remodelling between the sinonasal system and the lung may guide the rational design of more effective therapeutic strategies targeting upper and lower airways concomitantly and improving the health of individuals with inflammatory airway diseases. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Greece -CO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1111/all.13373</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29197105">PM:29197105</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171201-SamitasK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171201-SamitasK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Samitas K</style></custom2><misc3><style face="normal" font="default">10.1111/all.13373</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43214</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tanaka,H.</style></author><author><style face="normal" font="default"> Nakatani,E.</style></author><author><style face="normal" font="default"> Fukutom,Y.</style></author><author><style face="normal" font="default"> Sekiya,K.</style></author><author><style face="normal" font="default"> Kaneda,H.</style></author><author><style face="normal" font="default"> Iikura,M.</style></author><author><style face="normal" font="default"> Yoshida,M.</style></author><author><style face="normal" font="default"> Takahashi,K.</style></author><author><style face="normal" font="default"> Tomii,K.</style></author><author><style face="normal" font="default"> Nishikawa,M.</style></author><author><style face="normal" font="default"> Kaneko,N.</style></author><author><style face="normal" font="default"> Sugino,Y.</style></author><author><style face="normal" font="default"> Shinkai,M.</style></author><author><style face="normal" font="default"> Ueda,T.</style></author><author><style face="normal" font="default"> Tanikawa,Y.</style></author><author><style face="normal" font="default"> Shirai,T.</style></author><author><style face="normal" font="default"> Hirabayashi,M.</style></author><author><style face="normal" font="default"> Aoki,T.</style></author><author><style face="normal" font="default"> Kato,T.</style></author><author><style face="normal" font="default"> Iizuka,K.</style></author><author><style face="normal" font="default"> Fujii,M.</style></author><author><style face="normal" font="default"> Taniguchi,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">NPO Sapporo Cough Asthma, and Allergy Center, Sapporo, Japan</style></auth-address><titles><title><style face="normal" font="default">Identification of patterns of factors preceding severe or life-threating asthma exacerbations in a nationwide study</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="12" Year="2017">2017/12/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Reducing near-fatal asthma exacerbations is a critical problem in asthma management. OBJECTIVES: To determine patterns of factors preceding asthma exacerbations in a real-world setting. METHODS: In a nationwide prospective study of 190 patients who had experienced near-fatal asthma exacerbation, cluster analysis was performed using asthma symptoms over the two-week period before admission. RESULTS: Three distinct clusters of symptoms were defined employing the self-reporting of a visual analogue scale. Cluster A (42.1%): rapid worsening within 7.4 hours from moderate attack to admission, young to middle-aged patients with low BMI and tendency to depression who had stopped anti-asthma medications, smoked, were hypersensitive to environmental triggers and furred pets. Cluster B (40.0%): fairly-rapid worsening within 48 hours, mostly middle-aged and older, relatively good ICS or ICS/LABA compliance, and low perception of dyspnea. Cluster C (17.9%): slow worsening over 10 days before admission, high perception of dyspnea, smokers, and chronic daily mild-moderate symptoms. There were no differences in overuse of short-acting beta-agonists, baseline asthma severity, or outcomes after admission for patients in these three clusters. CONCLUSION: To reduce severe or life-threatening asthma exacerbation, personalized asthma management plans should be considered for each cluster. Improvement of ICS and ICS/LABA compliance and cessation of smoking are important in cluster A. To compensate for low perception of dyspnea, asthma monitoring of peak expiratory flow rate and/or exhaled nitric oxide would be useful for patients in cluster B. Avoidance of environmental triggers, increased standard therapy or new anti-type 2 response-targeted therapies should be considered for cluster C. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/all.13374</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29197099">PM:29197099</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171201-TanakaH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171201-TanakaH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Tanaka H</style></custom2><misc3><style face="normal" font="default">10.1111/all.13374</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43215</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tay,T.R.</style></author><author><style face="normal" font="default"> Hew,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy, Asthma and Clinical Immunology, The Alfred Hospital, Melbourne, AUSTRALIADepartment of Respiratory and Critical Care Medicine, Changi General Hospital, SINGAPOREAllergy, Asthma and Clinical Immunology, The Alfred Hospital, Melbourne, AUSTRALIADepartment of Respiratory and Critical Care Medicine, Changi General Hospital, SINGAPORE</style></auth-address><titles><title><style face="normal" font="default">Comorbid 'treatable traits' in difficult asthma: Current evidence and clinical evaluation</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="11" Year="2017">2017/11/27</year></dates><abstract><style face="normal" font="default">The care of patients with difficult-to-control asthma ('difficult asthma') is challenging and costly. Despite high-intensity asthma treatment, these patients experience poor asthma control and face the greatest risk for asthma morbidity and mortality. Poor asthma control is often driven by severe asthma biology, which has appropriately been the focus of intense research and phenotype-driven therapies. However, it is increasing apparent that extra-pulmonary comorbidities also contribute substantially to poor asthma control and a heightened disease burden. These comorbidities have been proposed as "treatable traits" in chronic airways disease, adding impetus to their evaluation and management in difficult asthma. In this review, eight major asthma-related comorbidities are discussed; rhinitis, chronic rhinosinusitis, gastroesophageal reflux, obstructive sleep apnoea, vocal cord dysfunction, obesity, dysfunctional breathing, and anxiety/depression. We describe the prevalence, impact, and treatment-effects of these comorbidities in the difficult asthma population, emphasizing gaps in the current literature. We examine the associations between individual comorbidities, and highlight the potential for comorbidity clusters to exert combined effects on asthma outcomes. We conclude by outlining a pragmatic clinical approach to assess comorbidities in difficult asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -CO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1111/all.13370</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29178130">PM:29178130</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171127-TayTR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171127-TayTR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171127, Tay TR</style></custom2><misc3><style face="normal" font="default">10.1111/all.13370</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43216</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,X.</style></author><author><style face="normal" font="default"> Andersen,S.L.</style></author><author><style face="normal" font="default"> Olsen,J.</style></author><author><style face="normal" font="default"> Agerbo,E.</style></author><author><style face="normal" font="default"> Schlunssen,V.</style></author><author><style face="normal" font="default"> Dharmage,S.C.</style></author><author><style face="normal" font="default"> Munk-Olsen,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">The National Center for Register-based Research, Aarhus University, Aarhus, Denmark</style></auth-address><titles><title><style face="normal" font="default">Maternal hypothyroidism in the perinatal period and childhood asthma in the offspring</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="11" Year="2017">2017/11/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: There is increasing interest in the possible link between maternal hypothyroidism in the perinatal period and childhood asthma risk. We explored this in the present study while accounting for the timing of hypothyroidism diagnosis. Further, we evaluated whether the risk was moderated by thyroid hormone treatment during pregnancy. METHODS: We conducted a population-based cohort study using Danish national registers. All liveborn singletons in Denmark from 1998 to 2007 were identified. Maternal hypothyroidism and asthma in the children were defined by data from the Patient Register and Prescription Registry. We estimated incidence rate ratios (IRRs) of asthma among children born to hypothyroid mothers versus children born to mothers with no recorded thyroid dysfunction using Poisson regression models. RESULTS: Of 595,669 children, 3,524 children were born to mothers with hypothyroidism diagnosed before delivery and 4,664 diagnosed after delivery. Overall 48,990 children received treatment for asthma. The IRRs of asthma was 1.16 (95% confidence interval (CI): 1.03-1.30) and 1.12 (95% CI: 1.02-1.24) for children born to mothers with hypothyroidism diagnosed before and after delivery, compared to children born to mothers with no thyroid dysfunction. The highest risk was observed among children born to mothers with hypothyroidism diagnosed before delivery who did not receive thyroid hormone treatment during pregnancy (IRR=1.37, 95% CI: 1.04-1.80). CONCLUSION: Our findings suggest that maternal hypothyroidism, especially when it is untreated, increases childhood asthma risk. Early detection and appropriate treatment of hypothyroidism in pregnant women may be an area for possible prevention of childhood asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - United States -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/all.13365</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29159833">PM:29159833</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171121-LiuX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171121-LiuX.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171121, Liu X</style></custom2><misc3><style face="normal" font="default">10.1111/all.13365</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43217</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sharma,N.</style></author><author><style face="normal" font="default"> Akkoyunlu,M.</style></author><author><style face="normal" font="default"> Rabin,R.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Bacterial, Parasitic and Allergenic Products, Center for Biologics Evaluation and Research, Office of Vaccines Research and Review, U.S. Food and Drug Administration, Silver Spring, MD, USA</style></auth-address><titles><title><style face="normal" font="default">Macrophages-common culprit in obesity and asthma</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="11" Year="2017">2017/11/27</year></dates><abstract><style face="normal" font="default">Macrophages are essential innate immune cells that also regulate local metabolism. Endogenous or exogenous stimuli may polarize macrophages towards phenotypes that serve distinct innate immunological metabolic functions. IFNgamma or lipopolysaccharide (LPS) polarizes macrophages towards the M1, or "classically activated" phenotype that participates in defense against intracellular pathogens. IL-4, IL-13, or chitin polarizes macrophages towards the M2, or "alternatively activated" phenotype, which defends against multicellular nematodes and fungi. Since macrophages polarize in local environments, M1 and M2 macrophages may coexist in different organs and may differentially affect asthma and obesity, two comorbid diseases where polarized macrophages contribute to their pathogenesis. While M1 macrophages are considered beneficial in asthma and contribute to the pathology of obesity, M2 macrophages contribute to the pathology of asthma, but limit metabolic syndrome associated with obesity. Here we discuss the roles for M1 and M2 macrophages in asthma and obesity, and propose a model by which M1-mediated inflammation in adipose tissue enhances M2-mediated inflammation in the asthmatic lung. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.13369</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29178573">PM:29178573</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171127-SharmaN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171127-SharmaN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171127, Sharma N</style></custom2><misc3><style face="normal" font="default">10.1111/all.13369</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43218</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Segboer,C.L.</style></author><author><style face="normal" font="default"> Terreehorst,I.</style></author><author><style face="normal" font="default"> Gevorgyan,A.</style></author><author><style face="normal" font="default"> Hellings,P.W.</style></author><author><style face="normal" font="default"> van Drunen,C.M.</style></author><author><style face="normal" font="default"> Fokkens,W.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Quality of life is significantly impaired in non-allergic rhinitis patients</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="11" Year="2017">2017/11/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: In contrast to the well-known significant impairment of quality of life (QoL) in allergic rhinitis (AR), the degree of impairment in QoL in non-allergic rhinitis (NAR) remained unknown for a long time, due to a lack of a validated questionnaire to assess QoL in the NAR patient group. In this study a validation for the mini-RQLQ questionnaire in NAR patients was performed, followed by an assessment of QoL in NAR patients compared to AR and healthy controls. Secondly, use of medication and treatment satisfaction in AR and NAR was assessed. METHODS: The study was an observational cohort study in 287 AR and 160 NAR patients. Patients with symptoms of rhinitis were recruited from a tertiary care outpatient clinic of the Otorhinolaryngology Department. AR was defined as one or more positive results on skin prick testing and clinically relevant symptoms of rhinitis related to their sensitization. NAR was defined as clinically relevant symptoms of rhinitis but without positive results on skin prick testing. The mini-RQLQ was successfully validated in this study for NAR patients. RESULTS: QoL in NAR patients was equally -and for some aspects even more- impaired compared to AR. More than half of both AR and NAR patients were unsatisfied with treatment. CONCLUSION: These results demonstrate a significant impairment in both AR and NAR patients in their QoL combined with a low treatment satisfaction, emphasizing the need for adequate treatment, especially in the NAR patient group. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171113IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/all.13356</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29131364">PM:29131364</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171113-SegboerCL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171113-SegboerCL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171113, Segboer CL</style></custom2><misc3><style face="normal" font="default">10.1111/all.13356</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43219</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kolkhir,P.</style></author><author><style face="normal" font="default"> Altrichter,S.</style></author><author><style face="normal" font="default"> Hawro,T.</style></author><author><style face="normal" font="default"> Maurer,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">I.M. Sechenov First Moscow State Medical University, Division of Immune-mediated skin diseases, Department of Dermatology and Venereology, Moscow, Russian Federation</style></auth-address><titles><title><style face="normal" font="default">CRP is linked to disease activity, impact and response to treatment in patients with chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="11" Year="2017">2017/11/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Elevated levels of C-reactive protein (CRP), a sensitive marker of inflammation, have been consistently reported in chronic spontaneous urticaria. Here, we retrospectively analyzed data from 1,253 CSU patients from two centers to answer the following questions: 1) What is the prevalence of elevated levels of CRP in CSU? 2) Why do CSU patients show elevated levels of CRP? 3) Are elevated CRP levels relevant? METHODS: Serum levels of CRP were measured by the nephelometric method. We collected information regarding various laboratory tests including ESR, CBC with differential, D-dimer, fibrinogen, C3, C4, IL-6 etc. For most patients, we also collected data on age, gender, duration of CSU, presence of angioedema, activity (UAS at the time of blood sampling and for 7 days), quality of life (CU-Q2oL and/or DLQI), comorbidities and possible causes of CSU, and autologous serum skin test (ASST) response. The efficacy of second generation antihistamines was evaluated at the day of blood collecting. RESULTS: One third of CSU patients had elevated levels of CRP. Higher levels of CRP were associated with ASST positivity (p=0.009) and arterial hypertension (p=0.005), but not with other possible causes or comorbidities of CSU. CRP correlated with urticaria activity (p&lt;0.001), quality of life impairment (p=0.026), inflammatory and coagulation markers (p&lt;0.001). CRP levels were significantly higher in non-responders to antihistamines as compared to responders (p&lt;0.001). CONCLUSION: Elevated levels of CRP are common and relevant in CSU patients. The assessment of CRP levels may help to optimize the management of patients with CSU. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171113IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Russia -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/all. 13352</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29130488">PM:29130488</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171112-KolkhirP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171112-KolkhirP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171112, Kolkhir P</style></custom2><misc3><style face="normal" font="default">10.1111/all. 13352</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43220</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ghosh,D.</style></author><author><style face="normal" font="default"> Clay,C.</style></author><author><style face="normal" font="default"> Bernstein,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Cincinnati College of Medicine, Department of Internal Medicine, Division of Immunology/Allergy Section</style></auth-address><titles><title><style face="normal" font="default">The Utility Of Monitoring Trimellitic Anhydride (TMA)-Specific IgG To Predict IgE-mediated Sensitization in An Immunosurveillance Program</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="11" Year="2017">2017/11/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Workplace exposure to Trimellitic Anhydride (TMA) can elicit TMA-specific IgE (sIgE), which may lead to occupational asthma (OA). An occupational immunosurveillance program (OISP) has been implemented to monitor TMA exposure and immunologic outcomes. The purpose of this study was to determine whether TMA-specific IgG (sIgG) responses can discriminate between TMA-exposed workers with and without sIgE responses. METHODS: Serum TMA-specific antibody (IgG, IgG4 and IgE) levels were estimated longitudinally (years 2006 to 2014) in TMA-exposed workers recruited in low, medium and high exposure areas. sIgG and sIgE titers plotted against exposure duration were compared between workers with (a) sIgG only and (b) with sIgG who developed sIgE. RESULTS: Among 92 TMA-exposed workers continuously monitored for sIgG and sIgE, 38 developed sIgG; 11 developed a sIgE response 342.38 +/- 186.03 days post-hire and were removed from exposure. The average detection time of sIgG in removed workers (159+/-92 days) was significantly shorter than for actively exposed workers with only sIgG (346+/-187 days). Workers with earlier sIgG responses of higher titer (mean value 42.25 ug/ml) compared to delayed responders with lower sIgG titers (mean value 14.79 ug/ml) more frequently developed sIgE responses. Hierarchical clustering showed the initial magnitude and exposure time required for detectable sIgG production discriminated between workers with only sIgG from workers who subsequently produced sIgE. CONCLUSIONS: This study demonstrates the utility of longitudinally monitoring TMA-specific antibodies in an OISP as exposed workers with early sIgG responses and of higher magnitude are more likely to develop TMA sIgE sensitization. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171108IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.13348</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29117440">PM:29117440</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20171108-GhoshD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20171108-GhoshD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171108, Ghosh D</style></custom2><misc3><style face="normal" font="default">10.1111/all.13348</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43221</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Abrams,E.M.</style></author><author><style face="normal" font="default"> Singer,A.G.</style></author><author><style face="normal" font="default"> Lix,L.</style></author><author><style face="normal" font="default"> Katz,A.</style></author><author><style face="normal" font="default"> Yogendran,M.</style></author><author><style face="normal" font="default"> Simons,F.E.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Section of Allergy and Clinical Immunology, University of Manitoba, FE125-685 William Avenue, Winnipeg, MB R3E 0Z2 Canada.0000 0004 1936 9609grid.21613.37Department of Family Medicine, University of Manitoba, Winnipeg, Canada.0000 0004 1936 9609grid.21613.37Department of Community Health Sciences, University of Manitoba, Winnipeg, Canada.0000 0004 1936 9609grid.21613.37Department of Family Medicine and Community Health Sciences, University of Manitoba, Winnipeg, Canada.0000 0004 1936 9609grid.21613.37Manitoba Centre for Health Policy, University of Manitoba, Winnipeg, Canada.0000 0004 1936 9609grid.21613.37Department of Pediatrics, Section of Allergy and Clinical Immunology, University of Manitoba, FE125-685 William Avenue, Winnipeg, MB R3E 0Z2 Canada.0000 0004 1936 9609grid.21613.37</style></auth-address><titles><title><style face="normal" font="default">Adherence with epinephrine autoinjector prescriptions in primary care</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Clin Immunol</style></full-title></periodical><pages end="" start="46">46-</pages><volume><style face="normal" font="default">13</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: The aim of this study was to estimate primary adherence for epinephrine autoinjector (EA) prescriptions in primary care practices in Manitoba, Canada. Methods: A retrospective analysis of electronic medical record and administrative data was performed to determine primary adherence, defined as dispensation of a new EA prescription within 90 days of the date the prescription was written. Multivariable logistic regression models were used to test predictors of filling an EA prescription. Results: Of 1212 EA prescriptions written between 2012 and 2014, only 69.9% (N = 847) were filled. An increased number of prescriptions for non-EA mediations was associated with an increased odds ratio of not filling an EA prescription. Interpretation: This is the first study in Canada to examine adherence for EA prescriptions. The non-adherence rate identified is higher than rates previously reported in the literature, and indicates that many EA prescriptions for adults seen in primary care may never be filled. It also suggests that prescriptions of EAs for all patients at risk of anaphylaxis in community settings should consistently be accompanied by concise information about the importance of having the EA prescription filled and having the EA readily available</style></abstract><notes><style face="normal" font="default">IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1186/s13223-017-0218-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29151840">PM:29151840</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-46.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-46.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171110, Abrams EM</style></custom2><misc3><style face="normal" font="default">10.1186/s13223-017-0218-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43222</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,H.</style></author><author><style face="normal" font="default"> Ellis,A.K.</style></author><author><style face="normal" font="default"> Fischer,D.</style></author><author><style face="normal" font="default"> Noseworthy,M.</style></author><author><style face="normal" font="default"> Olivenstein,R.</style></author><author><style face="normal" font="default"> Chapman,K.R.</style></author><author><style face="normal" font="default"> Lee,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Clinical Immunology &amp; Allergy, Department of Medicine, Western University, 1151 Richmond St, London, ON N6A 5C1 Canada.</style></auth-address><titles><title><style face="normal" font="default">Asthma biomarkers in the age of biologics</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Clin Immunol</style></full-title></periodical><pages end="" start="48">48-</pages><volume><style face="normal" font="default">13</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The heterogeneous nature of asthma has been understood for decades, but the precise categorization of asthma has taken on new clinical importance in the era of specific biologic therapy. The simple categories of allergic and non-allergic asthma have given way to more precise phenotypes that hint at underlying biologic mechanisms of variable airflow limitation and airways inflammation. Understanding these mechanisms is of particular importance for the approximately 10% of patients with severe asthma. Biomarkers that aid in phenotyping allow physicians to "personalize" treatment with targeted biologic agents. Unfortunately, testing for these biomarkers is not routine in patients whose asthma is refractory to standard therapy. Scientific advances in the recognition of sensitive and specific biomarkers are steadily outpacing the clinical availability of reliable and non-invasive assessment methods designed for the prompt and specific diagnosis, classification, treatment, and monitoring of severe asthma patients. This article provides a practical overview of current biomarkers and testing methods for prompt, effective management of patients with severe asthma that is refractory to standard therapy</style></abstract><notes><style face="normal" font="default">IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1186/s13223-017-0219-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29176991">PM:29176991</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-48.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Clin Immunol\2017-13-48.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171117, Kim H</style></custom2><misc3><style face="normal" font="default">10.1186/s13223-017-0219-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43223</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jin,H.J.</style></author><author><style face="normal" font="default"> Park,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea</style></auth-address><titles><title><style face="normal" font="default">Claudin may be a Potential Biomarker for Epithelial Barrier Dysfunction in Asthma</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="5" start="4">4-5</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - EditorialCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2018.10.1.4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29178671">PM:29178671</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2018-10-4-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2018-10-4-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Jin HJ</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2018.10.1.4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43224</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kennedy,M.D.</style></author><author><style face="normal" font="default"> Faulhaber,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Physical Education and Recreation, University of Alberta, Edmonton, Canada.</style></auth-address><titles><title><style face="normal" font="default">Respiratory Function and Symptoms Post Cold Air Exercise in Female High and Low Ventilation Sport Athletes</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="51" start="43">43-51</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">PURPOSE: Cold weather exercise is common in many regions of the world; however, it is unclear whether respiratory function and symptom worsen progressively with colder air temperatures. Furthermore, it is unclear whether high-ventilation sport background exacerbates dysfunction and symptoms. METHODS: Seventeen active females (measure of the maximum volume of oxygen [VO(2max)]: 49.6+/-6.6 mL.kg(-)(1).min(-)(1)) completed on different days in random order 5 blinded running trials at 0 degrees C, -5 degrees C, -10 degrees C, -15 degrees C, and -20 degrees C (humidity 40%) in an environmental chamber. Distance, heart rate, and rating of perceived exertion (RPE) were measured within each trial; forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), forced expiratory flow at 25%-75% (FEF(2)(5)(-)(7)(5)), and forced expiratory flow at 50% (FEF(5)(0)) were measured pre- and post-test (3, 6, 10, 15, and 20 minutes). Respiratory symptoms and global effort were measured post-test spirometry. RESULTS: Mean decreases were found in FEV1 (4%-5% at 0 degrees C, -5 degrees C, -10 degrees C, and -15 degrees C; 7% at -20 degrees C). FEF(2)(5)(-)(7)(5) and FEF(5)(0) decreased 7% and 11% at -15 degrees C and -20 degrees C, respectively. Post-exertion spirometry results were decreased most at 3 to 6 minutes, recovering back to baseline at 20 minutes. Respiratory symptoms and global effort significantly increased at -15 degrees C and -20 degrees C with decreased heart rate. High-ventilation sports decreased function more than low-ventilation participants but had fewer symptoms. CONCLUSIONS: These results indicate that intense exercise at cold air temperatures up to -20 degrees C is achievable; however, greater effort along with transient acute bronchoconstriction and symptoms of cough after exercising in temperatures colder than -15 degrees C are likely. It is recommended that individuals cover their mouth and reduce exercise intensity to ameliorate the effects of cold weather exercise</style></abstract><notes><style face="normal" font="default">IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - Austria -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2018.10.1.43</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29178677">PM:29178677</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2018-10-43-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2018-10-43-51.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Kennedy MD</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2018.10.1.43</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43225</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,C.K.</style></author><author><style face="normal" font="default"> Callaway,Z.</style></author><author><style face="normal" font="default"> Gern,J.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Asthma and Allergy Center, Inje University Sanggye Paik Hospital, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Viral Infections and Associated Factors That Promote Acute Exacerbations of Asthma</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="17" start="12">12-17</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">Despite asthma being the most common chronic childhood ailment, there is still much to learn about the disease. Early childhood infections with well-known or emerging viruses can lay the pathophysiologic framework for asthma development and exacerbation later in life, which may be due partly to alteration of the airway microbiome. Once asthma is established, acute exacerbations are usually associated with infections with respiratory viruses, such as rhinoviruses (RVs). Once again, there are bidirectional interactions between viruses and airway bacteria that appear to influence the severity of illness and the likelihood of exacerbation. Studies employing recent advances in viral and bacterial identification analytic techniques will clarify these new concepts and may provide the basis for new treatments or prevention or respiratory infection-associated exacerbation. This paper is a review of the associations among respiratory viruses, bacteria, inflammatory mechanisms, and asthma exacerbation</style></abstract><notes><style face="normal" font="default">IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - South Korea -CO - United States -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2018.10.1.12</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29178673">PM:29178673</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2018-10-12-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2018-10-12-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Kim CK</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2018.10.1.12</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43226</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,X.</style></author><author><style face="normal" font="default"> Lan,F.</style></author><author><style face="normal" font="default"> Zhang,Y.</style></author><author><style face="normal" font="default"> Zhang,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology Head and Neck Surgery and Department of allergy, Beijing TongRen Hospital, Capital Medical University, Beijing, China</style></auth-address><titles><title><style face="normal" font="default">Chinese Herbal Medicine to Treat Allergic Rhinitis: Evidence From a Meta-Analysis</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="42" start="34">34-42</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">PURPOSE: Chinese herbal medicine (CHM) has been widely used in China to treat allergic rhinitis (AR). However, several studies have produced conflicting data with regard to the efficacy of the medicine. Our aim was to perform a meta-analysis of randomized clinical trials (RCTs) to evaluate the relative efficacy of CHM. METHODS: We systematically searched the PubMed, Medline, and Springer electronic databases up to March 2017 for RCTs comparing the efficacy of CHM versus placebo for the treatment of patients with AR. Total nasal symptoms and quality of life were assessed through pooling mean difference (MD) with its 95% confidence interval (CI). Moreover, sensitivity and subgroup analyses according to control design and quality of life assessment were performed to evaluate the source of heterogeneity. RESULTS: Eleven RCTs were enrolled in the meta-analysis. Assessment of overall heterogeneity indicated significant heterogeneity among the individual studies (I(2)=100%, P&lt;0.00001), and thus ransomed effects model was used to pool data. CHM was found to significantly enhance quality of life compared with placebo (MD=-0.88, (95% CI: -1.55, -0.21); P=0.01). The symptom of itchy nose, sneezing or total nasal symptoms scores were not significantly improved after CHM treatment, although the improvement in itchy nose just failed to reach significance (MD=0.09, (95% CI: 0.00, 0.18); P=0.06). CONCLUSIONS: This study suggests that CHM appears to improve the quality of life of AR patients. However, these findings, as well as the findings for the effect of CHM on sneezing, total nasal symptoms, and the symptom of itchy nose, need to be substantiated in larger cohorts of AR patients by further well-designed studies</style></abstract><notes><style face="normal" font="default">IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2018.10.1.34</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29178676">PM:29178676</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2018-10-34-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2018-10-34-42.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Zhang X</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2018.10.1.34</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43227</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,Y.H.</style></author><author><style face="normal" font="default"> Nakayama,T.</style></author><author><style face="normal" font="default"> Nayak,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology-Head and Neck Surgery, Inha University College of Medicine, Incheon, Korea.</style></auth-address><titles><title><style face="normal" font="default">Glycolysis and the Hexosamine Biosynthetic Pathway as Novel Targets for Upper and Lower Airway Inflammation</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="11" start="6">6-11</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">Glycolysis is a process that rapidly converts glucose to lactate to produce adenosine triphosphate (ATP) under anaerobic conditions and occurs in all eukaryotic and prokaryotic cells. On the other hand, the hexosamine biosynthetic pathway (HBP) converts glucose to intermediate products like UDP-N-acetylglucosamine, which is critical for post-translational modifications of proteins, such as protein glycosylation. These 2 pathways are well known to contribute to glucose metabolism, but recent studies indicate modulation of these pathways can alter immune system function. In this review article, the authors present results suggesting how cellular metabolism, including glycolysis and the HBP, occurs in immune cells, and the immunologic significances of such activities. In addition, they provide a review of the literature on the effects of glycolysis and the HBP on various autoimmune, immunologic, and allergic diseases. Finally, the authors briefly introduce the results of their research on the immunologic effects of HBP supplementation (glucosamine) in animal models of allergic disease</style></abstract><notes><style face="normal" font="default">IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - South Korea -CO - Japan -CO - United States -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2018.10.1.6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29178672">PM:29178672</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2018-10-6-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2018-10-6-11.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Kim YH</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2018.10.1.6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43228</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,S.H.</style></author><author><style face="normal" font="default"> Kim,T.B.</style></author><author><style face="normal" font="default"> Kim,S.H.</style></author><author><style face="normal" font="default"> Park,H.W.</style></author><author><style face="normal" font="default"> Song,S.H.</style></author><author><style face="normal" font="default"> Jeong,J.W.</style></author><author><style face="normal" font="default"> Jee,Y.K.</style></author><author><style face="normal" font="default"> Park,S.W.</style></author><author><style face="normal" font="default"> Kim,M.S.</style></author><author><style face="normal" font="default"> Yoon,H.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Eulji University School of Medicine, Daejeon, Korea</style></auth-address><titles><title><style face="normal" font="default">Real-Life Clinical Use of Symbicort(R) Maintenance and Reliever Therapy for Asthmatic Patients in Korea</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Immunol Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergy Asthma Immunol Res</style></abbr-1></periodical><pages end="94" start="88">88-94</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">The aim of this study was to examine the daily practice patterns of Symbicort(R) Maintenance and Reliever Therapy (SMART) in Korean asthmatic patients and to analyze clinical signs related to overuse. This study used an observational, multicenter, noninterventional, prospective, uncontrolled design for examining asthmatic patients prescribed SMART to assess the frequency and pattern of Symbicort(R) usage as a maintenance and reliever medication. The characteristics of patients showing signs of overuse (frequency of inhalation: 8 or more times per day) were also analyzed. Among the 1,518 patients analyzed, 1,292 (85.1%) completed the trial. The number of mean inhalations per day was 2.14+/-1.15; the number of patients who had at least 1 as needed usage (PRN) inhalation per day was 843 (55.5%); the mean frequency of PRN use was 0.25+/-0.67 inhalations per day. The number of patients who overused for at least 1 day was 260 (17.1%). In particular, young patients, patients with limited physical activity, and patients with nocturnal symptoms demonstrated high frequency of overuse. The frequency of overuse during SMART was not high in Korean asthmatic patients and the asthma status of follow-up outpatients improved overall. However, there is a need for careful education targeted toward younger patients, patients with limited physical activity, and patients with nocturnal symptoms owing to their tendency to frequently overuse</style></abstract><notes><style face="normal" font="default">IS - 2092-7355 (Print)IS - 2092-7355 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.4168/aair.2018.10.1.88</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29178682">PM:29178682</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2018-10-88-94.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy Asthma Immunol Res\2018-10-88-94.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Kim SH</style></custom2><misc3><style face="normal" font="default">10.4168/aair.2018.10.1.88</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43229</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tucker,A.</style></author><author><style face="normal" font="default"> Hopkins,M.</style></author><author><style face="normal" font="default"> Hammett,E.</style></author><author><style face="normal" font="default"> Clinton,C.</style></author><author><style face="normal" font="default"> Heine,R.P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Penicillin skin testing in pregnant women with a history of penicillin allergy</style></title><secondary-title><style face="normal" font="default">Am J Obstetr Gynecol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Obstetr Gynecol</style></full-title></periodical><pages end="" start="723">723-</pages><volume><style face="normal" font="default">217</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><isbn><style face="normal" font="default">0002-9378</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.ajog.2017.08.053</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.ajog.2017.08.053</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Obstetr Gynecol\2017-217-723.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Obstetr Gynecol\2017-217-723.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Tucker A</style></custom2><misc3><style face="normal" font="default">10.1016/j.ajog.2017.08.053</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43230</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gracy,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Delaney Gracy is with Children's Health Fund, New York, NY</style></auth-address><titles><title><style face="normal" font="default">Managing Childhood Asthma as a Strategy to Break the Cycle of Poverty</style></title><secondary-title><style face="normal" font="default">Am J Public Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Am J Public Health</style></abbr-1></periodical><pages end="22" start="21">21-22</pages><volume><style face="normal" font="default">108</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1541-0048 (Electronic)IS - 0090-0036 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2105/AJPH.2017.304195</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29211530">PM:29211530</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Public Health\2018-108-21-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Public Health\2018-108-21-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171129, Gracy D</style></custom2><misc3><style face="normal" font="default">10.2105/AJPH.2017.304195</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43231</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hinks,T.S.C.</style></author><author><style face="normal" font="default"> Batty,P.</style></author><author><style face="normal" font="default"> Klenerman,P.</style></author><author><style face="normal" font="default"> Pavord,I.D.</style></author><author><style face="normal" font="default"> Xue,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 University of Oxford Oxford, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Cytometric Gating Stringency Impacts Studies of Type 2 Innate Lymphoid Cells in Asthma</style></title><secondary-title><style face="normal" font="default">Am J Respir Cell Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Cell Mol Biol</style></full-title></periodical><pages end="747" start="745">745-747</pages><volume><style face="normal" font="default">57</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1535-4989 (Electronic)IS - 1044-1549 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1165/rcmb.2017-0201LE</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29192833">PM:29192833</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171205, Hinks TS</style></custom2><misc3><style face="normal" font="default">10.1165/rcmb.2017-0201LE</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43232</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sannes,P.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Department of Molecular Biomedical Sciences North Carolina State University Raleigh, North Carolina</style></auth-address><titles><title><style face="normal" font="default">Hyaluronan: Local Climate Change in Asthma?</style></title><secondary-title><style face="normal" font="default">Am J Respir Cell Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Cell Mol Biol</style></full-title></periodical><pages end="636" start="635">635-636</pages><volume><style face="normal" font="default">57</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1535-4989 (Electronic)IS - 1044-1549 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1165/rcmb.2017-0276ED</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29192830">PM:29192830</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171205, Sannes PL</style></custom2><misc3><style face="normal" font="default">10.1165/rcmb.2017-0276ED</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43233</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kantor,D.B.</style></author><author><style face="normal" font="default"> Phipatanakul,W.</style></author><author><style face="normal" font="default"> Hirschhorn,J.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Boston Children's Hospital, Division of Critical Care Medicine, Boston, Massachusetts, United States</style></auth-address><titles><title><style face="normal" font="default">Gene-environment Interactions Associated with the Severity of Acute Asthma Exacerbation in Children</style></title><secondary-title><style face="normal" font="default">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Crit Care Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="11" Year="2017">2017/11/21</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1164/rccm.201711-2166ED</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29160726">PM:29160726</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171205, Kantor DB</style></custom2><misc3><style face="normal" font="default">10.1164/rccm.201711-2166ED</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43234</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lima,F.C.D.R.</style></author><author><style face="normal" font="default"> Cerqueira,A.M.M.</style></author><author><style face="normal" font="default"> Guimaraes,M.B.S.</style></author><author><style face="normal" font="default"> Padilha,C.B.S.</style></author><author><style face="normal" font="default"> Craide,F.H.</style></author><author><style face="normal" font="default"> Bombardelli,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Service of the General Polyclinic of Rio de Janeiro (PGRJ) - Rio de Janeiro (RJ), Brazil</style></auth-address><titles><title><style face="normal" font="default">Crusted scabies due to indiscriminate use of glucocorticoid therapy in infant</style></title><secondary-title><style face="normal" font="default">An Bras Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">An Bras Dermatol</style></full-title></periodical><pages end="385" start="383">383-385</pages><volume><style face="normal" font="default">92</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Crusted or Norwegian scabies is a parasitic infectious disease caused by Sarcoptes scabiei var. hominis that mainly affects immunocompromised individuals and those with neurological patients. We report a case of crusted scabies in a 4-month-old infant who had been treated erroneously for atopic dermatitis with high doses of corticosteroids. This initial misdiagnosis associated with the abusive use of corticosteroid facilitated the evolution of scabies to crusted scabies and its main complications of secondary infection and sepsis</style></abstract><notes><style face="normal" font="default">IS - 1806-4841 (Electronic)IS - 0365-0596 (Linking)LA - engPT - Case ReportsCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1590/abd1806-4841.20174433</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29186253">PM:29186253</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\An Bras Dermatol\2017-92-383-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\An Bras Dermatol\2017-92-383-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170610, Lima FC</style></custom2><misc3><style face="normal" font="default">10.1590/abd1806-4841.20174433</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43235</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,S.H.</style></author><author><style face="normal" font="default"> Tang,S.E.</style></author><author><style face="normal" font="default"> Li,Y.H.</style></author><author><style face="normal" font="default"> Wei,K.Y.</style></author><author><style face="normal" font="default"> Chang,C.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center - Taipei, Taiwan, Republic of China</style></auth-address><titles><title><style face="normal" font="default">Pneumocystis jirovecii pneumonia induced by low-dose methotrexate in a patient with chronic urticaria</style></title><secondary-title><style face="normal" font="default">An Bras Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">An Bras Dermatol</style></full-title></periodical><pages end="403" start="401">401-403</pages><volume><style face="normal" font="default">92</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">Methotrexate has immunosuppressive effects and is administered for refractory chronic urticaria. We present a case of Pneumocystis jirovecii pneumonia in a patient with refractory chronic urticaria managed by low-dose weekly methotrexate treatment (total cumulative dose 195mg). Our study highlights the importance of providing prompt diagnosis and treatment of Pneumocystis jirovecii pneumonia in patients with chronic urticaria under methotrexate therapy</style></abstract><notes><style face="normal" font="default">IS - 1806-4841 (Electronic)IS - 0365-0596 (Linking)LA - engPT - Case ReportsCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1590/abd1806-4841.20175392</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29186259">PM:29186259</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\An Bras Dermatol\2017-92-401-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\An Bras Dermatol\2017-92-401-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170610, Wang SH</style></custom2><misc3><style face="normal" font="default">10.1590/abd1806-4841.20175392</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43236</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lazzarini,R.</style></author><author><style face="normal" font="default"> Hafner,M.F.S.</style></author><author><style face="normal" font="default"> Lopes,A.S.A.</style></author><author><style face="normal" font="default"> Oliari,C.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Clinic, Irmandade da Santa Casa de Misericordia de Sao Paulo - Sao Paulo (SP) Brazil</style></auth-address><titles><title><style face="normal" font="default">Allergy to hypoallergenic nail polish: does this exist?</style></title><secondary-title><style face="normal" font="default">An Bras Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">An Bras Dermatol</style></full-title></periodical><pages end="422" start="421">421-422</pages><volume><style face="normal" font="default">92</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="5" Year="2017">2017/5</year></dates><abstract><style face="normal" font="default">The main allergen responsible for contact dermatitis to nail polish is tosylamide-formaldehyde resin. The so-called hypoallergenic nail polishes are suposedly free of agents that commonly trigger reactions. The commercially available products and their compositions were studied. It was observed that most brands present at least one component capable of triggering the disease; therefore, allergic reaction may occur even when hypoallergenic polishes are used. There should be a proper investigation of the specific allergen through a patch test, because more than one component can cause an allergy, and we need to check the exact composition of each product</style></abstract><notes><style face="normal" font="default">IS - 1806-4841 (Electronic)IS - 0365-0596 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1590/abd1806-4841.20175889</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29186266">PM:29186266</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\An Bras Dermatol\2017-92-421-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\An Bras Dermatol\2017-92-421-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170610, Lazzarini R</style></custom2><misc3><style face="normal" font="default">10.1590/abd1806-4841.20175889</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43237</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Suzuki,N.M.</style></author><author><style face="normal" font="default"> Duarte,I.A.G.</style></author><author><style face="normal" font="default"> Hafner,M.F.S.</style></author><author><style face="normal" font="default"> Lazzarini,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Clinic of the Santa Casa de Sao Paulo - Sao Paulo (SP), Brazil</style></auth-address><titles><title><style face="normal" font="default">Nickel exposure from keys: a Brazilian issue</style></title><secondary-title><style face="normal" font="default">An Bras Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">An Bras Dermatol</style></full-title></periodical><pages end="735" start="734">734-735</pages><volume><style face="normal" font="default">92</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Keys are a significant source of exposure to metal allergens and can be a relevant problem for nickel-allergic individuals. This study aimed to perform nickel and cobalt spot testing among the 5 most common Brazilian brands of keys. Among the tested keys, 100% showed positive result to nickel spot test, 83,3% presented strong positive reaction. 50% exhibited cobalt release as well. Nickel release from keys is very common in our country and may cause a negative impact on sensitized individual's quality of life. Study's results highlight the importance of establishing directives to regulate nickel release in Brazil</style></abstract><notes><style face="normal" font="default">IS - 1806-4841 (Electronic)IS - 0365-0596 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1590/abd1806-4841.20175754</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29166522">PM:29166522</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\An Bras Dermatol\2017-92-734-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\An Bras Dermatol\2017-92-734-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170610, Suzuki NM</style></custom2><misc3><style face="normal" font="default">10.1590/abd1806-4841.20175754</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43238</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wisnewski,A.V.</style></author><author><style face="normal" font="default"> Liu,J.</style></author><author><style face="normal" font="default"> Redlich,C.A.</style></author><author><style face="normal" font="default"> Nassar,A.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Yale University, New Haven, CT 06520, United States.</style></auth-address><titles><title><style face="normal" font="default">Polymerization of hexamethylene diisocyanate in solution and a 260.23 m/z [M+H](+) ion in exposed human cells</style></title><secondary-title><style face="normal" font="default">Anal Biochem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Anal Biochem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="11" Year="2017">2017/11/23</year></dates><abstract><style face="normal" font="default">Hexamethylene diisocyanate (HDI) is an important industrial chemical that can cause asthma, however pathogenic mechanisms remain unclear. Upon entry into the respiratory tract, HDI's N=C=O groups may undergo nucleophilic addition (conjugate) to host molecules (e.g. proteins), or instead react with water (hydrolyze), releasing CO2 and leaving a primary amine in place of the original N=C=O. We hypothesized that (primary amine groups present on) hydrolyzed or partially hydrolyzed HDI may compete with proteins and water as a reaction target for HDI in solution, resulting in polymers that could be identified and characterized using LC-MS and LC-MS/MS. Analysis of the reaction products formed when HDI was mixed with a pH buffered, isotonic, protein containing solution identified multiple [M+H](+) ions with m/z's and collision-induced dissociation (CID) fragmentation patterns consistent with those expected for dimers (259.25/285.23 m/z), and trimers (401.36/427.35 m/z) of partially hydrolyzed HDI (e.g. ureas/oligoureas). Human peripheral blood mononuclear cells (PBMCs) and monocyte-like U937, but not airway epithelial NCI-H292 cell lines cultured with these HDI ureas contained a novel 260.23 m/z [M+H](+) ion. LC-MS/MS analysis of the 260.23 m/z [M+H](+) ion suggest the formula C13H29N3O2 and a structure containing partially hydrolyzed HDI, however definitive characterization will require further orthogonal analyses</style></abstract><notes><style face="normal" font="default">IS - 1096-0309 (Electronic)IS - 0003-2697 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.ab.2017.11.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29175138">PM:29175138</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Anal Biochem\20171124-WisnewskiAV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Anal Biochem\20171124-WisnewskiAV.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171124, Wisnewski AV</style></custom2><misc3><style face="normal" font="default">10.1016/j.ab.2017.11.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43239</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Koski,R.</style></author><author><style face="normal" font="default"> Kennedy,K.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pharmacy Practice, Ferris State University College of Pharmacy, Marquette, Michigan. Walgreens, Marquette, Michigan</style></auth-address><titles><title><style face="normal" font="default">Treatment with omalizumab or cyclosporine for resistant chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="401" start="397">397-401</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171118IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29150066">PM:29150066</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-397-401.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-397-401.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171118, Koski R</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43240</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Paul,M.</style></author><author><style face="normal" font="default"> Geller,L.</style></author><author><style face="normal" font="default"> Nowak-Wegrzyn,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Winthrop University Hospital, Mineola, New YorkDivision of Dermatology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New YorkJaffe Food Allergy Institute, Division of Allergy and Immunology, Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: anna.nowak-wegrzyn@mssm.edu</style></auth-address><titles><title><style face="normal" font="default">Blepharochalasis: A rare cause of eye swelling</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="407" start="402">402-407</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171118IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29150067">PM:29150067</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-402-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-402-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171118, Paul M</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.036</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43241</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hu,Y.</style></author><author><style face="normal" font="default"> Chen,Z.</style></author><author><style face="normal" font="default"> Jin,L.</style></author><author><style face="normal" font="default"> Wang,M.</style></author><author><style face="normal" font="default"> Liao,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">The First Affiliated Hospital of the Third Military Medical University, Chongqing, China</style></auth-address><titles><title><style face="normal" font="default">Decreased expression of indolamine 2,3-dioxygenase in childhood allergic asthma and its inverse correlation with fractional concentration of exhaled nitric oxide</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="434" start="429">429-434</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: The tryptophan metabolic pathway mediated by indolamine 2,3-dioxygenase (IDO), a tryptophan-degrading enzyme, plays an important role in controlling the development of allergic inflammation. The fractional concentration of exhaled nitric oxide (FeNO) is closely associated with the allergic state and is extensively used for the clinical evaluation of airway allergic inflammation. Clinical trials have rarely assessed the expression of IDO in childhood allergic asthma and its correlation with FeNO. OBJECTIVE: To evaluate the IDO level in children with childhood allergic asthma and the relation between IDO levels and FeNO. METHODS: Thirty children older than 5 years who were diagnosed the first time with allergic asthma were selected from the pediatric outpatient department. Another 30 healthy children were selected as controls. The subjects were evaluated by complete medical history, pulmonary function test results, skin prick test reaction, FeNO concentration test result, eosinophil count, and a disease severity score. Peripheral venous blood and induced sputum were obtained to measure the concentrations of IDO metabolites (ie, tryptophan and kynurenine). RESULTS: The IDO levels in the peripheral blood and induced sputum were significantly lower in patients with childhood allergic asthma than in children in the control group. The IDO level was negatively correlated with FeNO but was not significantly correlated with age, sex, blood eosinophil count, or disease severity scale. CONCLUSION: The expression of IDO was significantly lower in childhood allergic asthma, particularly in children with high FeNO levels. There was no significant relation between IDO levels and asthma severity. TRIAL REGISTRATION: Chinese Clinical Trial Register (www.chictr.org.cn) Identifier: ChiCTR-COC-15006080</style></abstract><notes><style face="normal" font="default">DA - 20171118IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.07.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29150070">PM:29150070</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-429-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-429-34.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171118, Hu Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.07.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43242</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chopra,R.</style></author><author><style face="normal" font="default"> Vakharia,P.P.</style></author><author><style face="normal" font="default"> Sacotte,R.</style></author><author><style face="normal" font="default"> Silverberg,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois</style></auth-address><titles><title><style face="normal" font="default">Efficacy of bleach baths in reducing severity of atopic dermatitis: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="440" start="435">435-440</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Bleach baths have been proposed as a treatment for decreasing the severity of atopic dermatitis (AD). However, conflicting results have been found regarding their efficacy. OBJECTIVE: To determine the efficacy of bleach vs water baths at decreasing AD severity. METHODS: We performed a systematic review of all studies evaluating the efficacy of bleach baths for AD. Cochrane, EMBASE, GREAT, LILACS, MEDLINE, and Scopus were searched. Two authors independently performed study selection and data extraction. RESULTS: Five studies were included in the review. Four studies reported significantly decreased AD severity in patients treated with bleach on at least 1 time point. However, of 4 studies comparing bleach with water baths, only 2 found significantly greater decreases in AD severity with bleach baths, 1 found greater decreases with water baths, and 1 found no significant differences. In pooled analyses, there were no significant differences observed between bleach vs water baths at 4 weeks vs baseline for the Eczema Area and Severity Index (I2 = 98%; random effect regression model, P = .16) or body surface area (I2 = 96%; P = .36). CONCLUSION: Although bleach baths are effective in decreasing AD severity, they do not appear to be more effective than water baths alone. Future larger-scale, well-designed randomized controlled trials are needed</style></abstract><notes><style face="normal" font="default">DA - 20171118IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.08.289</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29150071">PM:29150071</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-435-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-435-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171118, Chopra R</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.08.289</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43243</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ciprandi,G.</style></author><author><style face="normal" font="default"> Fuchs,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Ospedale Policlinico San Martino, Genoa, Italy.</style></auth-address><titles><title><style face="normal" font="default">Tryptophan metabolic pathway, airway nitric oxide, and allergy</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="396" start="395">395-396</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171118IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - EditorialCO - Italy -CO - Austria -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.08.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29150065">PM:29150065</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-395-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-395-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171118, Ciprandi G</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.08.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43244</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ellis,A.K.</style></author><author><style face="normal" font="default"> Tenn,M.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Research Unit, Kingston General Hospital, Kingston, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="default">Advances in rhinitis-models and mechanisms</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="11" Year="2017">2017/11/18</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To summarize studies highlighting recent advances in rhinitis-related research in the past 2 years. DATA SOURCES: Original research articles were procured and examined from the Rhinitis and Upper Airway Disease section of the 2015 to 2017 Annals of Allergy, Asthma &amp; Immunology issues. Additional original research articles were identified from PubMed and Google Scholar using the following search terms: allergic rhinitis, rhinitis, chronic rhinosinusitis, environmental exposure unit, and nasal allergen challenge. Only research articles published in the past 2 years were procured. STUDY SELECTIONS: Articles conducting research in allergic rhinitis (AR) or chronic rhinosinusitis or using controlled allergen challenge facilities or the nasal allergen challenge model were selected. RESULTS: Studies in the past 2 years have focused on using skin prick tests and early-life phenotyping to predict AR development in children. They also have elucidated the role of a subset of CD4(+) T cells, basophils, and mast cells in non-eosinophilic chronic rhinosinusitis with nasal polyps, a relatively new chronic rhinosinusitis subtype in the Asian population. Several advances have been made in understanding the role of several cytokines and peripheral cell mitochondrial function in AR using controlled allergen challenge facilities and direct nasal allergen challenges. CONCLUSION: Findings from the recent literature highlight the utility of early-life predictors of AR in possibly targeting high-risk groups for prophylactic interventions. Studies also emphasize the use of controlled allergen challenge facilities and the nasal allergen challenge model as robust experimental models to study AR pathogenesis</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.10.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29157860">PM:29157860</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171201-EllisAK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171201-EllisAK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Elli AK</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.10.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43245</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vereen,S.</style></author><author><style face="normal" font="default"> Kocak,M.</style></author><author><style face="normal" font="default"> Potukuchi,P.K.</style></author><author><style face="normal" font="default"> Hartman,T.J.</style></author><author><style face="normal" font="default"> Tylavsky,F.</style></author><author><style face="normal" font="default"> Carroll,K.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Vanderbilt University Medical Center,Nashville, Tennessee</style></auth-address><titles><title><style face="normal" font="default">The association of maternal prenatal vitamin D levels and child current wheeze</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="11" Year="2017">2017/11/18</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.10.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29162316">PM:29162316</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171201-VereenS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171201-VereenS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Vereen S</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.10.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43246</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Villarreal,R.S.</style></author><author><style face="normal" font="default"> VandenBoom,T.</style></author><author><style face="normal" font="default"> Gonzalez-Gonzalez,F.J.</style></author><author><style face="normal" font="default"> Carter,R.G.</style></author><author><style face="normal" font="default"> Peters,N.T.</style></author><author><style face="normal" font="default"> Peters,A.T.</style></author><author><style face="normal" font="default"> Chiarella,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Northwestern University Feinberg School of Medicine,Chicago, Illinois</style></auth-address><titles><title><style face="normal" font="default">Schnitzler syndrome with IgG gammopathy and elevated IL-1beta and IL-17 in skin biopsy</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="11" Year="2017">2017/11/18</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.10.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29162318">PM:29162318</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171201-VillarealRS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171201-VillarealRS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Villareal RS</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.10.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43247</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rhee,H.</style></author><author><style face="normal" font="default"> Love,T.M.</style></author><author><style face="normal" font="default"> Harrington,D.</style></author><author><style face="normal" font="default"> Grape,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Rochester School of Nursing, Rochester, New York.</style></auth-address><titles><title><style face="normal" font="default">Comorbidity of atopy in urban adolescents with asthma</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="467" start="466">466-467</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171118IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.08.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29150074">PM:29150074</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-466-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-466-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171118, Rhee H</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.08.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43248</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">LaHood,N.</style></author><author><style face="normal" font="default"> Sokol,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Beth Israel Deaconess Medical Center, Boston, Massachusetts.</style></auth-address><titles><title><style face="normal" font="default">DRESS syndrome associated with splenic thrombosis</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="464" start="463">463-464</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171118IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.08.288</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29150073">PM:29150073</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-463-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-463-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171118, LaHood N</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.08.288</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43249</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Iweala,O.I.</style></author><author><style face="normal" font="default"> Copenhaver,C.</style></author><author><style face="normal" font="default"> Wu,E.Y.</style></author><author><style face="normal" font="default"> Moran,T.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Division of Allergy, Immunology, and Rheumatology, University of North Carolina School of Medicine,Chapel Hill, North Carolina.</style></auth-address><titles><title><style face="normal" font="default">Hydroxychloroquine as a steroid-sparing agent in an infant with chronic urticaria</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="11" Year="2017">2017/11/17</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.10.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29157861">PM:29157861</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171201-IwealaOI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171201-IwealaOI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Iweala OI</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.10.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43250</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schend,J.</style></author><author><style face="normal" font="default"> Doll,R.</style></author><author><style face="normal" font="default"> Sandhu,M.</style></author><author><style face="normal" font="default"> Rodgers,M.</style></author><author><style face="normal" font="default"> Hostoffer,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Mercy Health Hospital, Mercy Campus,Muskegon, Michigan.</style></auth-address><titles><title><style face="normal" font="default">Mannose-binding lectin deficiency associated with numerous paraspinal neurofibromas</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="11" Year="2017">2017/11/18</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.10.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29162315">PM:29162315</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171201-SchendJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171201-SchendJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Schend J</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.10.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43251</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Seghezzo,S.</style></author><author><style face="normal" font="default"> Arnold,D.H.</style></author><author><style face="normal" font="default"> Gay,J.C.</style></author><author><style face="normal" font="default"> Moore,P.E.</style></author><author><style face="normal" font="default"> Johnson,D.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Monroe Carell Jr. Children's Hospital, Vanderbilt University School of Medicine, Nashville, Tennessee.</style></auth-address><titles><title><style face="normal" font="default">Dexamethasone for inpatient childhood asthma exacerbations is as effective as short-acting corticosteroid treatment</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="11" Year="2017">2017/11/18</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.10.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29162317">PM:29162317</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171201-SeghezzoS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\20171201-SeghezzoS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Seghezzo S</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.10.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43252</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bates,J.H.T.</style></author><author><style face="normal" font="default"> Poynter,M.E.</style></author><author><style face="normal" font="default"> Frodella,C.M.</style></author><author><style face="normal" font="default"> Peters,U.</style></author><author><style face="normal" font="default"> Dixon,A.E.</style></author><author><style face="normal" font="default"> Suratt,B.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, University of Vermont College of Medicine, Burlington, VermontDepartment of Medicine, University of Vermont College of Medicine, Burlington, VermontDepartment of Medicine, University of Vermont College of Medicine, Burlington, VermontDepartment of Medicine, University of Vermont College of Medicine, Burlington, VermontDepartment of Medicine, University of Vermont College of Medicine, Burlington, VermontDepartment of Medicine, University of Vermont College of Medicine, Burlington, Vermont</style></auth-address><titles><title><style face="normal" font="default">Pathophysiology to Phenotype in the Asthma of Obesity</style></title><secondary-title><style face="normal" font="default">Ann Am Thorac Soc</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Am Thorac Soc</style></abbr-1></periodical><pages end="S398" start="S395">S395-S398</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">Supplement_5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">Obesity affects numerous diseases, including asthma, for reasons that remain incompletely understood. Recent research suggests that the asthma of obesity is not a single disease, and that it breaks out into at least two distinct phenotypes. One phenotype is conventional allergic asthma modulated by obesity, whereas another arises solely due to the presence of obesity. The latter is postulated to be a consequence of the chronic lung compression caused by the obese chest wall in individuals with particularly collapsible lungs. Allergic obese asthma, on the other hand, appears to result from the way that obesity affects the immune system, which we hypothesize can be understood in terms of effects on the dynamic regulation of the inflammatory response</style></abstract><notes><style face="normal" font="default">IS - 2325-6621 (Electronic)IS - 2325-6621 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1513/AnnalsATS.201702-122AW</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29161090">PM:29161090</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Am Thorac Soc\2017-14S5-395-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Am Thorac Soc\2017-14S5-395-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171207, Bates JH</style></custom2><misc3><style face="normal" font="default">10.1513/AnnalsATS.201702-122AW</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43253</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Boutin,R.C.T.</style></author><author><style face="normal" font="default"> Petersen,C.</style></author><author><style face="normal" font="default"> Finlay,B.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Michael Smith Laboratories2 Department of Microbiology and Immunology, and1 Michael Smith Laboratories2 Department of Microbiology and Immunology, and1 Michael Smith Laboratories2 Department of Microbiology and Immunology, and3 Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada</style></auth-address><titles><title><style face="normal" font="default">Microbial Insights into Asthmatic Immunopathology. A Forward-Looking Synthesis and Commentary</style></title><secondary-title><style face="normal" font="default">Ann Am Thorac Soc</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Am Thorac Soc</style></abbr-1></periodical><pages end="S325" start="S316">S316-S325</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">Supplement_5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">Asthma is an aberrant inflammatory condition of the airways affecting approximately 1 in 10 children in affluent countries. An increasing body of evidence suggests that microbial exposures during a "critical window" of development in early life play a central role in determining future asthma susceptibility. However, like the disease itself, considerable heterogeneity exists among studies in which researchers have investigated the associations between particular microbial taxa and asthma immunology. As our understanding of asthmatic pathology evolves to enable clearer definition of asthma endotypes, it will be important to consider the impact of various environmental factors on each endotype. Given the strong evidence in support of the hypothesis that early-life microbial exposures predict later disease states such as asthma, consideration of these endotypes when establishing experimental outcomes in epidemiological studies could allow for increased precision when determining exposure-outcome associations and engaging in more focused follow-up mechanistic investigations</style></abstract><notes><style face="normal" font="default">IS - 2325-6621 (Electronic)IS - 2325-6621 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1513/AnnalsATS.201707-534AW</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29161080">PM:29161080</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Am Thorac Soc\2017-14S5-316-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Am Thorac Soc\2017-14S5-316-25.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171207, Boutin RC</style></custom2><misc3><style face="normal" font="default">10.1513/AnnalsATS.201707-534AW</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43254</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shore,S.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, Massachusetts</style></auth-address><titles><title><style face="normal" font="default">Mechanistic Basis for Obesity-related Increases in Ozone-induced Airway Hyperresponsiveness in Mice</style></title><secondary-title><style face="normal" font="default">Ann Am Thorac Soc</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Am Thorac Soc</style></abbr-1></periodical><pages end="S362" start="S357">S357-S362</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">Supplement_5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">Obesity is a risk factor for asthma, especially nonallergic asthma. Ozone, a common air pollutant, is a nonallergic asthma trigger. Importantly, ozone-induced decrements in lung function are greater in obese and overweight human subjects than in lean individuals. Obese mice also exhibit exaggerated pulmonary responses to ozone. Ozone causes greater increases in pulmonary resistance, in bronchoalveolar lavage neutrophils, and in airway hyperresponsiveness in obese than in lean mice. Our data indicate that IL-33 plays a role in mediating these events. Ozone causes greater release of IL-33 into bronchoalveolar lavage fluid in obese than in lean mice. Furthermore, an antibody blocking the IL-33 receptor, ST2, attenuates ozone-induced airway hyperresponsiveness in obese but not in lean mice. Our data also indicate a complex role for tumor necrosis factor (TNF)-alpha in obesity-related effects on the response to ozone. In obese mice, genetic deficiency in either TNF-alpha or TNF-alpha receptor 2 augments ozone-induced airway hyperresponsiveness, whereas TNF-alpha receptor 2 deficiency virtually abolishes ozone-induced airway hyperresponsiveness in lean mice. Finally, obesity is known to alter the gut microbiome. In female mice, antibiotics attenuate obesity-related increases in the effect of ozone on airway hyperresponsiveness, possibly by altering microbial production of short-chain fatty acids. Asthma control is often difficult to achieve in obese patients with asthma. Our data suggest that therapeutics directed against IL-33 may ultimately prove effective in these patients. The data also suggest that dietary manipulations and other strategies (prebiotics, probiotics) that alter the microbiome and/or its metabolic products may represent a new frontier for treating asthma in obese individuals</style></abstract><notes><style face="normal" font="default">IS - 2325-6621 (Electronic)IS - 2325-6621 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1513/AnnalsATS.201702-140AW</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29161088">PM:29161088</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Am Thorac Soc\2017-14S5-357-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Am Thorac Soc\2017-14S5-357-62.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171207, Shore SA</style></custom2><misc3><style face="normal" font="default">10.1513/AnnalsATS.201702-140AW</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43255</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ege,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dr. von Hauner Children's Hospital, Ludwig Maximilians University Munich and Comprehensive Pneumology Centre Munich, German Centre for Lung Research, Munich, Germany</style></auth-address><titles><title><style face="normal" font="default">The Hygiene Hypothesis in the Age of the Microbiome</style></title><secondary-title><style face="normal" font="default">Ann Am Thorac Soc</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Am Thorac Soc</style></abbr-1></periodical><pages end="S353" start="S348">S348-S353</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">Supplement_5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">The original version of the hygiene hypothesis suggested that infections transmitted early in life by "unhygienic contact" prevented allergies. Examples were endemic fecal-oral infections by viral, bacterial, or protozoic pathogens, such as hepatitis A virus, Helicobacter pylori, or Toxoplasma gondii. Later, this concept also included microorganisms beyond pathogens, such as commensals and symbionts, and the hygiene hypothesis was extended to inflammatory diseases in general. An impressive illustration of the hygiene hypothesis was found in the consistent farm effect on asthma and allergies, which has partly been attributed to immunomodulatory properties of endotoxin as emitted by livestock. Assessment of environmental microorganisms by molecular techniques suggested an additional protective effect of microbial diversity on asthma beyond atopy. Whether microbial diversity stands for a higher probability to encounter protective clusters of microorganisms or whether it is a proxy of a balanced environmental exposure remains elusive. Diversity of the mucosal microbiome of the upper airways probably reflects an undisturbed balance of beneficial microorganisms and pathogens, such as Moraxella catarrhalis, which has been associated with subsequent development of asthma and pneumonia. In addition, specific fermenters of plant fibers, such as the genera Ruminococcus and Bacteroides, have been implied in asthma protection through production of short-chain fatty acids, volatile substances with the capability to reduce T-helper cell type 2-mediated allergic airway inflammation. Evolutionary thinking may offer a key to understanding noncommunicable inflammatory diseases as delayed adaptation to a world of fast and profound environmental changes. Better adaptation may be fostered by growing insight into the interplay between man and microbiome and an adequate choice of the environmental exposure</style></abstract><notes><style face="normal" font="default">IS - 2325-6621 (Electronic)IS - 2325-6621 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1513/AnnalsATS.201702-139AW</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29161087">PM:29161087</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Am Thorac Soc\2017-14S5-348-53.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Am Thorac Soc\2017-14S5-348-53.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171207, Ege MJ</style></custom2><misc3><style face="normal" font="default">10.1513/AnnalsATS.201702-139AW</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43256</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Barsky,E.E.</style></author><author><style face="normal" font="default"> Giancola,L.M.</style></author><author><style face="normal" font="default"> Baxi,S.N.</style></author><author><style face="normal" font="default"> Gaffin,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Children's Hospital Boston, 1862, Respiratory , 300 Longwood Ave , LO-570 , Boston, Massachusetts, United States</style></auth-address><titles><title><style face="normal" font="default">A Practical Approach to Severe Asthma in Children</style></title><secondary-title><style face="normal" font="default">Ann Am Thorac Soc</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Am Thorac Soc</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="12" Year="2017">2017/12/8</year></dates><abstract><style face="normal" font="default">Severe asthma accounts for only a small proportion of the children with asthma, but a disproportionately high amount of resource utilization and morbidity. It is a heterogeneous entity and requires a step-wise, evidence based approach to evaluation and management by pediatric subspecialists. The first step is to confirm the diagnosis by eliciting confirmatory history and objective evidence of asthma and excluding possible masquerading diagnoses. The next step is to differentiate difficult-to-treat asthma, asthma which can be controlled with appropriate management, from asthma which requires the highest level of therapy to maintain control or remains uncontrolled despite management optimization. Evaluation of difficult-to-treat asthma includes an assessment of medication delivery, the home environment and if possible the school and other frequented locations, the psychosocial situation, and comorbid conditions. Once identified, aggressive management of issues related to poor adherence and drug delivery, remediation of environmental triggers, and treatment of comorbid conditions are necessary to characterize the degree of control that can be achieved with standard therapies. For the small proportion of patients that remain poorly controlled with these interventions, the clinician may assess steroid responsiveness and determine the inflammatory pattern and eligibility for biologic therapies. Management of severe asthma refractory to traditional therapies involves considering the various biologic and other newly approved treatments, as well as emerging therapies based on the individual patient characteristics</style></abstract><notes><style face="normal" font="default">IS - 2325-6621 (Electronic)IS - 2325-6621 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1513/AnnalsATS.201708-637FR</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29220200">PM:29220200</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Am Thorac Soc\20171207-BarskyEE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Am Thorac Soc\20171207-BarskyEE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171207, Barsky EE</style></custom2><misc3><style face="normal" font="default">10.1513/AnnalsATS.201708-637FR</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43257</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wright,L.S.</style></author><author><style face="normal" font="default"> Rifas-Shiman,S.L.</style></author><author><style face="normal" font="default"> Oken,E.</style></author><author><style face="normal" font="default"> Litonjua,A.A.</style></author><author><style face="normal" font="default"> Gold,D.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Brigham and Women's Hospital and Harvard Medical School, Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Boston, Massachusetts, United States</style></auth-address><titles><title><style face="normal" font="default">Prenatal and Early-Life Fructose, Fructose-Containing Beverages, and Mid-Childhood Asthma</style></title><secondary-title><style face="normal" font="default">Ann Am Thorac Soc</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Am Thorac Soc</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="12" Year="2017">2017/12/8</year></dates><abstract><style face="normal" font="default">RATIONALE: Cross-sectional studies have linked intake of high fructose corn syrup sweetened beverages with asthma in school children. OBJECTIVE: To examine associations of maternal prenatal and early childhood intake of sugar sweetened beverages and fructose with current asthma in mid-childhood (median 7.7years). METHODS: We assessed maternal pregnancy (1st and 2nd trimester average) and child (median 3.3years) intake of sugar sweetened beverages and total fructose using food frequency questionnaires in 1068 mother-child pairs from Project Viva, a prospective pre-birth cohort. In a multivariable analysis, we examined associations of quartiles of maternal and child sugar sweetened beverage, juice, and total fructose intake with child current asthma in mid-childhood, assessed by questionnaire as ever doctor-diagnosed asthma plus taking asthma medications or reporting wheezing in the past 12months. RESULTS: Higher maternal pregnancy sugar sweetened beverage consumption (mean 0.6 servings/day; range 0-5) was associated with younger maternal age, non-white race/ethnicity, lower education and income, and higher pre-pregnancy BMI. Adjusting for pre-pregnancy BMI and other covariates, comparing quartile 4 v. quartile 1, higher maternal pregnancy intake of sugar sweetened beverages (OR 1.70; 95%CI 1.08, 2.67) and total fructose (OR 1.58; 0.98, 2.53) were associated with greater odds of mid-childhood current asthma (prevalence=19%). Higher early childhood fructose intake (quartile 4 v. quartile 1) was also associated with mid-childhood current asthma in models adjusted for maternal sugar sweetened beverages (OR 1.79; 1.07, 2.97) and after additional adjustment for mid-childhood BMI z-score (OR 1.77; 1.06, 2.95). CONCLUSION: Higher sugar sweetened beverage and fructose intake during pregnancy and in early childhood may influence childhood asthma development, in part through mechanisms apart from adiposity</style></abstract><notes><style face="normal" font="default">IS - 2325-6621 (Electronic)IS - 2325-6621 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1513/AnnalsATS.201707-530OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29219619">PM:29219619</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Am Thorac Soc\20171207-WrightLS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Am Thorac Soc\20171207-WrightLS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171207, Wright LS</style></custom2><misc3><style face="normal" font="default">10.1513/AnnalsATS.201707-530OC</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43258</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Forno,E.</style></author><author><style face="normal" font="default"> Han,Y.Y.</style></author><author><style face="normal" font="default"> Libman,I.M.</style></author><author><style face="normal" font="default"> Muzumdar,R.H.</style></author><author><style face="normal" font="default"> Celedon,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Children's Hospital of Pittsburgh, Pediatric Pulmonary , 4401 Penn Ave , Rangos Research Center , Room #9130 , Pittsburgh, Pennsylvania, United States</style></auth-address><titles><title><style face="normal" font="default">Adiposity and Asthma in a Nationwide Study of Children and Adults in the United States</style></title><secondary-title><style face="normal" font="default">Ann Am Thorac Soc</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Am Thorac Soc</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="11" Year="2017">2017/11/16</year></dates><abstract><style face="normal" font="default">RATIONALE: While obesity has been associated with asthma, body mass index (BMI) is suboptimal to fully characterize adiposity. OBJECTIVES: We examined the relation between adiposity and asthma in a large sample of the U.S. population, using indices defined by dual energy X-ray absorptiometry (DXA). METHODS: We analyzed data from 8,886 children (aged 8-19 years) and 12,795 adults (aged 20-69 years) from the 2001-2006 National Health and Nutrition Examination Survey (NHANES). In addition to BMI, percent body fat (PBF), waist circumference (WC), and waist-to-height ratio (WHtR), DXA was used to calculate whole-body and local adiposity indices: fat mass index (FMI); total, trunk, and legs fat percent (TF%, TrF%, LF%); and trunk-to-total (Tr/Tot), legs-to-total (L/Tot), and trunk-to-legs (Tr/L) fat mass ratios. Logistic regression was used for the analysis of adiposity measures and asthma. RESULTS: Among children, general adiposity was significantly associated with asthma, with no major differences by gender. Results were driven by non-atopic children, in whom trunk-predominant (central) adiposity (assessed by WC, WHtR, Tr/Tot, and Tr/L) was also associated with asthma. There were no significant associations among atopic children. Among adults, all adiposity indices were associated with asthma, with central adiposity significant only among women. The results in adults were driven by atopy, especially in women. CONCLUSIONS: Adiposity measured by DXA provides similar information to that obtained by using anthropometric indices among children of both genders, and among adult men. However, DXA provides additional information in adult women, in whom DXA-measured central adiposity is significantly associated with asthma, particularly atopic asthma</style></abstract><notes><style face="normal" font="default">DA - 20171117IS - 2325-6621 (Electronic)IS - 2325-6621 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1513/AnnalsATS.201709-723OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29144884">PM:29144884</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Am Thorac Soc\20171207-FornoE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Am Thorac Soc\20171207-FornoE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171207, Forno E</style></custom2><misc3><style face="normal" font="default">10.1513/AnnalsATS.201709-723OC</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43259</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Levine,M.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Erythema resulting from suberythemogenic doses of ultraviolet radiation and methotrexate</style></title><secondary-title><style face="normal" font="default">Arch Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arch Dermatol</style></full-title></periodical><pages end="658" start="656">656-658</pages><volume><style face="normal" font="default">117</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">DNA Repair</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> Erythema</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methotrexate</style></keyword><keyword><style face="normal" font="default"> adverse effects</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> PUVA Therapy</style></keyword><keyword><style face="normal" font="default"> Photochemotherapy</style></keyword><keyword><style face="normal" font="default"> Psoriasis</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Skin</style></keyword><keyword><style face="normal" font="default"> Time Factors</style></keyword><keyword><style face="normal" font="default"> Ultraviolet Therapy</style></keyword></keywords><dates><year Day="0" Month="10" Year="1981">1981/10</year></dates><abstract><style face="normal" font="default">A tender diffuse erythema developed in a 47-year-old man who had psoriasis when he was treated with either suberythemogenic oral methoxsalen photochemotherapy or ultraviolet (UV)-B phototherapy and intramuscular methotrexate (MTX). Phototests with middle- and long-wavelength UV fluorescent lamps indicated that the sequence and timing of each therapeutic exposure were important to the development of the erythema. Histologic examination of the erythematous area demonstrated an increased number of pyknotic keratinocytes (sunburn cells) in the upper epidermis. It is possible that MTX prevented the repair of DNA damage caused by UV exposure, leading to the appearance of the sunburn cells and erythema. Care must be exercised when using UV radiation and MTX in combination</style></abstract><notes><style face="normal" font="default">IS - 0003-987X (Print)IS - 0003-987X (Linking)LA - engPT - Case ReportsPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - YL5FZ2Y5U1 (Methotrexate)SB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="7283458">PM:7283458</url></web-urls></urls><custom2><style face="normal" font="default">19810504, LeVine MJ</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43260</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kondo,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">1st Department of Medicine, Tokyo Women's Medical University</style></auth-address><titles><title><style face="normal" font="default">[AIRWAY EPITHELIAL CELL DIFFERENTIATION AND HYPERSECRETION -THE ROLE OF IL-13, CLCA1 AND TMEM16A]</style></title><secondary-title><style face="normal" font="default">Arerugi</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Arerugi</style></abbr-1></periodical><pages end="1160" start="1155">1155-1160</pages><volume><style face="normal" font="default">66</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171113IS - 0021-4884 (Print)IS - 0021-4884 (Linking)LA - jpnPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29129885">PM:29129885</url></web-urls></urls><custom2><style face="normal" font="default">20171113, Kondo M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43261</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rangel,M.J.,Jr.</style></author><author><style face="normal" font="default"> Baldo,M.V.C.</style></author><author><style face="normal" font="default"> Canteras,N.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dept. Anatomy, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, SP 05508-000, Brazil</style></auth-address><titles><title><style face="normal" font="default">INFLUENCE OF THE ANTEROMEDIAL THALAMUS ON SOCIAL DEFEAT-ASSOCIATED CONTEXTUAL FEAR MEMORY</style></title><secondary-title><style face="normal" font="default">Behav Brain Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Behav Brain Res</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="2" Month="11" Year="2017">2017/11/2</year></dates><abstract><style face="normal" font="default">The ventral part of the anteromedial thalamic nucleus (AMv) is heavily targeted by the dorsal premammillary nucleus (PMd), which is the main hypothalamic site that is responsive to both predator and conspecific aggressor threats. This PMd-AMv pathway is likely involved in modulating memory processing, and previous findings from our group have shown that cytotoxic lesions or pharmacological inactivation of the AMv drastically reduced contextual fear responses to predator-associated environments. In the present study, we investigated the role of the AMv in both unconditioned (i.e., fear responses during social defeat) and contextual fear responses (i.e., during exposure to a social defeat-associated context). We addressed this question by placing N-methyl-D-aspartate (NMDA) lesions in the AMv and testing unconditioned fear responses during social defeat and contextual fear responses during exposure to a social defeat-associated context. Accordingly, bilateral AMv lesions did not change unconditioned responses, but decreased contextual conditioning related to social defeat. Notably, our bilateral AMv lesions also included, to a certain degree, the nucleus reuniens (RE), but single RE lesions did not affect innate or contextual fear responses. Overall, our results support the idea that the AMv works as a critical hub, receiving massive inputs from a hypothalamic site that is largely responsive to social threats and transferring social threat information to circuits involved in the processing of contextual fear memories</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 1872-7549 (Electronic)IS - 0166-4328 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1016/j.bbr.2017.10.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29103920">PM:29103920</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Behav Brain Res\20171207-RangelMJJr.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Behav Brain Res\20171207-RangelMJJr.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171207, Rangel MJ Jr</style></custom2><misc3><style face="normal" font="default">10.1016/j.bbr.2017.10.038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43262</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schanne,F.A.</style></author><author><style face="normal" font="default"> Long,G.J.</style></author><author><style face="normal" font="default"> Rosen,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10467, USA</style></auth-address><titles><title><style face="normal" font="default">Lead induced rise in intracellular free calcium is mediated through activation of protein kinase C in osteoblastic bone cells</style></title><secondary-title><style face="normal" font="default">Biochim Biophys Acta</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Biochim Biophys Acta</style></full-title></periodical><pages end="254" start="247">247-254</pages><volume><style face="normal" font="default">1360</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Animals</style></keyword><keyword><style face="normal" font="default"> Calcium</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Cell Line</style></keyword><keyword><style face="normal" font="default"> Egtazic Acid</style></keyword><keyword><style face="normal" font="default"> analogs &amp; derivatives</style></keyword><keyword><style face="normal" font="default"> Enzyme Activation</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> Lead</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> toxicity</style></keyword><keyword><style face="normal" font="default"> Magnetic Resonance Spectroscopy</style></keyword><keyword><style face="normal" font="default"> Protein Kinase C</style></keyword></keywords><dates><year Day="24" Month="5" Year="1997">1997/5/24</year></dates><abstract><style face="normal" font="default">Lead characteristically perturbs processes linked to the calcium messenger system. This study was undertaken to determine the role of PKC in the Pb2+ induced rise of [Ca2+]i. [Ca2+]i was measured using the divalent cation indicator, 1,2-bis(2-amino-5-fluorophenoxy) ethane N, N,N',N'-tetraacetic acid (5F-BAPTA) and 19F-NMR in the osteoblast cell line, ROS 17/2.8. Treatment of cells with Pb2+ at 1 and 5 microM produced a rise in [Ca2+]i from a basal level of 125 nM to 170 nM and 230 nM, respectively, while treatment with phorbol 12-myristate 13-acetate (PMA) (10 microM), an activator of PKC, produced a rise in [Ca2+]i to 210 nM. Pretreatment with calphostin C, a potent and highly selective inhibitor of PKC activation failed to produce a change in basal [Ca2+]i and prevented any rise in [Ca2+]i in response to Pb2+. To determine whether Pb2+ acts directly on PKC, we measured the Pb2(+)-dependent activation of phosphatidylserine/diolein-dependent incorporation of 32P from ATP into histone and endogenous TCA precipitable proteins in the 100,000 X g supernatant from homogenized ROS 17/2.8 cells. The free concentrations of Pb2+ and Ca2+ were set using 5F-BAPTA; and [Ca2+] and [Pb2+] in the PKC reaction mixtures were confirmed by 19F-NMR. We found that Pb2+ activates PKC in the range of 10(-11)-10(-7) M, with an activation constant of 1.1 X 10(-10) M, whereas Ca2+ activates PKC in the range from 10(-8) to 10(-3) M, with an activation constant of 3.6 X 10(-7) M. These data suggest that Pb2+ activates PKC in ROS 17/2.8 cells and that Pb2+ activation of PKC mediates the documented rise in [Ca2+]i and, perhaps, other toxic effects of Pb2+</style></abstract><notes><style face="normal" font="default">IS - 0006-3002 (Print)IS - 0006-3002 (Linking)LA - engPT - Journal ArticleRN - 2P299V784P (Lead)RN - 526U7A2651 (Egtazic Acid)RN - 85233-21-2 (5,5'-difluoro-1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid)RN - EC 2.7.11.13 (Protein Kinase C)RN - SY7Q814VUP (Calcium)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/S0925-4439(97)00006-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="9197467">PM:9197467</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biochim Biophys Acta\1997-1360-247-54.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biochim Biophys Acta\1997-1360-247-54.pdf</url></text-urls></urls><custom2><style face="normal" font="default">19971125, Schanne FA</style></custom2><misc3><style face="normal" font="default">10.1016/S0925-4439(97)00006-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43263</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,K.S.</style></author><author><style face="normal" font="default"> Chun,S.Y.</style></author><author><style face="normal" font="default"> Lee,M.G.</style></author><author><style face="normal" font="default"> Kim,S.</style></author><author><style face="normal" font="default"> Jang,T.J.</style></author><author><style face="normal" font="default"> Nam,K.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacology and Intractable Disease Research Center, School of Medicine, Dongguk University, Gyeongju, 38066, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">The prevention of TNF-alpha/IFN-gamma mixture-induced inflammation in human keratinocyte and atopic dermatitis-like skin lesions in Nc/Nga mice by mineral-balanced deep sea water</style></title><secondary-title><style face="normal" font="default">Biomed Pharmacother</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Biomed Pharmacother</style></full-title></periodical><pages end="1340" start="1331">1331-1340</pages><volume><style face="normal" font="default">97</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="11" Year="2017">2017/11/14</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a chronic inflammatory skin disease caused by environmental and chemical allergens. Despite the complexity of its pathogenesis, many investigations have shown that substances having anti-inflammatory activities alleviated the pathology of AD. Here, we evaluated the effects of mineral-balanced deep sea water (DSW) on AD-like skin damage in both in vitro and in vivo. The results showed that mineral-balanced DSW regressed inflammatory chemokines, such as macrophage-derived chemokine (MDC), thymus- and activation-regulated chemokine (TARC) and regulated on activation, normal T-cell expressed and secreted (RANTES), and cytokines, interleukin (IL)-6 and granulocyte-macrophage colony-stimulating factor (GM-CSF) mRNA expression in HaCaT immortal human keratinocyte treated with tumor necrosis factor (TNF)-alpha/ interferon (IFN)-gamma mixture. Furthermore, increased cyclooxygenase (COX)-2 protein expressions were also reversed, filaggrin gene expression was enhanced and decreased involucrin transcriptions was recovered by mineral-balanced DSW in TNF-alpha/IFN-gamma mixture-treated HaCaT human keratinocyte. Moreover, we revealed that the inhibitory effects of mineral-balanced DSW were mediated with the suppression of signal transducer and activator of transcription (STAT) 1 phosphorylation. In animal experiments, we showed that hardness 2000 of mineral-balanced DSW decreased the serum levels of IgE, IL-4, and histamine, and alleviated the severity score and numbers of scratching in dinitrochlorobezene (DNCB)-treated Nc/Nga mice. Furthermore, increased epidermal thickness and mast cell infiltration by DNCB treatment were reversed by the application of hardness 2000 mineral-balanced DSW. Taken together, the present investigation indicates that mineral-balanced DSW is a potent substance with anti-atopic dermatitis activity</style></abstract><notes><style face="normal" font="default">IS - 1950-6007 (Electronic)IS - 0753-3322 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.biopha.2017.11.056</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29156522">PM:29156522</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biomed Pharmacother\2017-97-1331-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biomed Pharmacother\2017-97-1331-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171206, Lee KS</style></custom2><misc3><style face="normal" font="default">10.1016/j.biopha.2017.11.056</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43264</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cabiaux,V.</style></author><author><style face="normal" font="default"> Oberg,K.A.</style></author><author><style face="normal" font="default"> Pancoska,P.</style></author><author><style face="normal" font="default"> Walz,T.</style></author><author><style face="normal" font="default"> Agre,P.</style></author><author><style face="normal" font="default"> Engel,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universite Libre de Bruxelles, Laboratoire de Chimie Physique des Macromolecules aux interfaces, Brussels, Belgium.</style></auth-address><titles><title><style face="normal" font="default">Secondary structures comparison of aquaporin-1 and bacteriorhodopsin: a Fourier transform infrared spectroscopy study of two-dimensional membrane crystals</style></title><secondary-title><style face="normal" font="default">Biophys J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Biophys J</style></abbr-1></periodical><pages end="417" start="406">406-417</pages><volume><style face="normal" font="default">73</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Aquaporin 1</style></keyword><keyword><style face="normal" font="default"> Aquaporins</style></keyword><keyword><style face="normal" font="default"> Bacteriorhodopsins</style></keyword><keyword><style face="normal" font="default"> chemistry</style></keyword><keyword><style face="normal" font="default"> isolation &amp; purification</style></keyword><keyword><style face="normal" font="default"> Blood Group Antigens</style></keyword><keyword><style face="normal" font="default"> Cluster Analysis</style></keyword><keyword><style face="normal" font="default"> Crystallization</style></keyword><keyword><style face="normal" font="default"> Enzymes</style></keyword><keyword><style face="normal" font="default"> Erythrocytes</style></keyword><keyword><style face="normal" font="default"> Halobacterium</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Ion Channels</style></keyword><keyword><style face="normal" font="default"> blood</style></keyword><keyword><style face="normal" font="default"> Least-Squares Analysis</style></keyword><keyword><style face="normal" font="default"> Protein Structure,Secondary</style></keyword><keyword><style face="normal" font="default"> Proteins</style></keyword><keyword><style face="normal" font="default"> Spectroscopy,Fourier Transform Infrared</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword></keywords><dates><year Day="0" Month="7" Year="1997">1997/7</year></dates><abstract><style face="normal" font="default">Aquaporins are integral membrane proteins found in diverse animal and plant tissues that mediate the permeability of plasma membranes to water molecules. Projection maps of two-dimensional crystals of aquaporin-1 (AQP1) reconstituted in lipid membranes suggested the presence of six to eight transmembrane helices in the protein. However, data from other sequence and spectroscopic analyses indicate that this protein may adopt a porin-like beta-barrel fold. In this paper, we use Fourier transform infrared spectroscopy to characterize the secondary structure of highly purified native and proteolyzed AQP1 reconstituted in membrane crystalline arrays and compare it to bacteriorhodopsin. For this analysis the fractional secondary structure contents have been determined by using several different algorithms. In addition, a neural network-based evaluation of the Fourier transform infrared spectra in terms of numbers of secondary structure segments and their interconnections [sij] has been performed. The following conclusions were reached: 1) AQP1 is a highly helical protein (42-48% alpha-helix) with little or no beta-sheet content. 2) The alpha-helices have a transmembrane orientation, but are more tilted (21 degrees or 27 degrees, depending on the considered refractive index) than the bacteriorhodopsin helices. 3) The helices in AQP1 undergo limited hydrogen/deuterium exchange and thus are not readily accessible to solvent. Our data support the AQP1 structural model derived from sequence prediction and epitope insertion experiments: AQP1 is a protein with at least six closely associated alpha-helices that span the lipid membrane</style></abstract><notes><style face="normal" font="default">IS - 0006-3495 (Print)IS - 0006-3495 (Linking)LA - engPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tPT - Research Support, U.S. Gov't, P.H.SRN - 0 (AQP1 protein, human)RN - 0 (Aquaporins)RN - 0 (Blood Group Antigens)RN - 0 (Enzymes)RN - 0 (Ion Channels)RN - 0 (Proteins)RN - 146410-94-8 (Aquaporin 1)RN - 53026-44-1 (Bacteriorhodopsins)SB - IMCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1016/S0006-3495(97)78080-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="9199804">PM:9199804</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biophys J\1997-73-406-17.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biophys J\1997-73-406-17.pdf</url></text-urls></urls><custom2><style face="normal" font="default">19970612, Cabiaux V</style></custom2><misc3><style face="normal" font="default">10.1016/S0006-3495(97)78080-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43265</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Curtis,B.S.</style></author><author><style face="normal" font="default"> Megan,E.B.</style></author><author><style face="normal" font="default"> Michael,R.G.</style></author><author><style face="normal" font="default"> Nilay,D.S.</style></author><author><style face="normal" font="default"> Matthew,A.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Mayo Clinic, Rochester, MN, USA</style></auth-address><titles><title><style face="normal" font="default">Prediction of individual outcomes for asthma sufferers</style></title><secondary-title><style face="normal" font="default">Biostatistics</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Biostatistics</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="11" Year="2017">2017/11/6</year></dates><abstract><style face="normal" font="default">We consider the problem of individual-specific medication level recommendation (initiation, removal, increase, or decrease) for asthma sufferers. Asthma is one of the most common chronic diseases in both adults and children, affecting 8% of the US population and costing $37-63 billion/year in the United States of America. Asthma is a complex disease, whose symptoms may wax and wane, making it difficult for clinicians to predict outcomes and prognosis. Improved ability to predict prognosis can inform decision making and may promote conversations between clinician and provider around optimizing medication therapy. Data from the US Medical Expenditure Panel Survey (MEPS) years 2000-2010 were used to fit a longitudinal model for a multivariate response of adverse events (Emergency Department or in-patient visits, excessive rescue inhaler use, and oral steroid use). To reduce bias in the estimation of medication effects, medication level was treated as a latent process which was restricted to be consistent with prescription refill data. This approach is demonstrated to be effective in the MEPS cohort via predictions on a validation hold out set and a synthetic data simulation study. This framework can be easily generalized to medication decisions for other conditions as well</style></abstract><notes><style face="normal" font="default">DA - 20171109IS - 1468-4357 (Electronic)IS - 1465-4644 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1093/biostatistics/kxx055</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29121247">PM:29121247</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biostatistics\20171109-CurtisBS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biostatistics\20171109-CurtisBS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171109, Curtis BS</style></custom2><misc3><style face="normal" font="default">10.1093/biostatistics/kxx055</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43266</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McCall,S.J.</style></author><author><style face="normal" font="default"> Bunch,K.J.</style></author><author><style face="normal" font="default"> Brocklehurst,P.</style></author><author><style face="normal" font="default"> D'Arcy,R.</style></author><author><style face="normal" font="default"> Hinshaw,K.</style></author><author><style face="normal" font="default"> Kurinczuk,J.J.</style></author><author><style face="normal" font="default"> Lucas,D.N.</style></author><author><style face="normal" font="default"> Stenson,B.</style></author><author><style face="normal" font="default"> Tuffnell,D.</style></author><author><style face="normal" font="default"> Knight,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Policy Research Unit in Maternal Health and Care, National Perinatal Epidemiology Unit (NPEU), Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, UK</style></auth-address><titles><title><style face="normal" font="default">The incidence, characteristics, managements and outcomes of anaphylaxis in pregnancy: a population-based descriptive study</style></title><secondary-title><style face="normal" font="default">BJOG</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BJOG</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="11" Year="2017">2017/11/29</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The aim of this study was to estimate the incidence of anaphylaxis in pregnancy and describe the management and outcomes in the UK. DESIGN: A population based descriptive study using the UK Obstetric Surveillance System(UKOSS). SETTING: All consultant-led maternity units in the UK. POPULATION: All pregnant women who had anaphylaxis between 1(st) October 2012 and 30(th) September 2015. Anaphylaxis was defined as a severe, life-threatening generalised or systemic hypersensitivity reaction. METHODS: Prospective case notification using UKOSS. RESULTS: There were 37 confirmed cases of anaphylaxis in pregnancy, giving an estimated incidence of 1.6(95%CI:1.1-2.2) per 100,000 maternities. Four cases of anaphylaxis were in women with known penicillin allergies: two received co-amoxiclav and two cephalosporins. Twelve women had anaphylaxis following prophylactic use of antibiotics at the time of a caesarean delivery. Prophylactic use of antibiotics for Group B Streptococcal infection accounted for anaphylaxis in one woman Two women died(5%), 14(38%) women were admitted to intensive care and seven women(19%) had one or more additional severe maternal morbidities, which included three haemorrhagic events, two cardiac arrests, one thrombotic event and one pneumonia. No infants died; however, in those infants whose mother had anaphylaxis before delivery(n=18) there were 7(41%) neonatal intensive care unit admissions, 3 preterm births and one baby was cooled for neonatal encephalopathy. CONCLUSIONS: Anaphylaxis is a rare severe complication of pregnancy and frequently the result of a reaction to antibiotic administration. This study highlights the seriousness of the outcomes of this condition for the mother. The low incidence is reassuring given the large proportion of the pregnant population that receive prophylactic antibiotics during delivery. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1471-0528 (Electronic)IS - 1470-0328 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/1471-0528.15041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29193647">PM:29193647</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BJOG\20171203-McCallSJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BJOG\20171203-McCallSJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171203, McCall SJ</style></custom2><misc3><style face="normal" font="default">10.1111/1471-0528.15041</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43267</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Amarin,J.Z.</style></author><author><style face="normal" font="default"> Naffa,R.G.</style></author><author><style face="normal" font="default"> Suradi,H.H.</style></author><author><style face="normal" font="default"> Alsaket,Y.M.</style></author><author><style face="normal" font="default"> Obeidat,N.M.</style></author><author><style face="normal" font="default"> Mahafza,T.M.</style></author><author><style face="normal" font="default"> Zihlif,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Medicine, The University of Jordan, Amman, Jordan</style></auth-address><titles><title><style face="normal" font="default">An intronic single-nucleotide polymorphism (rs13217795) in FOXO3 is associated with asthma and allergic rhinitis: a case-case-control study</style></title><secondary-title><style face="normal" font="default">BMC Med Genet</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Med Genet</style></abbr-1></periodical><pages end="" start="132">132-</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="15" Month="11" Year="2017">2017/11/15</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma and allergic rhinitis are respiratory diseases with a significant global burden. Forkhead box O3 (FOXO3) is a gene involved in the etiology of a number of respiratory diseases. The objective of this study is to assess the association of rs13217795, an intronic FOXO3 single-nucleotide polymorphism, with asthma and allergic rhinitis. METHODS: In this case-case-control genetic association study, genotyping was conducted using the PCR-RFLP method. Genotype-based associations were investigated under the general, recessive, and dominant models of disease penetrance using binomial logistic regression; and, allele-based associations were tested using Pearson's chi-squared test. RESULTS: The final study population consisted of 94 controls, 124 asthmatics, and 110 allergic rhinitis patients. The general and recessive models of disease penetrance were statistically significant for both case-control comparisons. Under the general model, the odds of the asthma phenotype were 1.46 (0.64 to 3.34) and 3.42 (1.37 to 8.57) times higher in heterozygotes and derived allele homozygotes, respectively, compared to ancestral allele homozygotes. The corresponding odds ratios for the allergic rhinitis phenotype were 1.05 (0.46 to 2.40) and 2.35 (0.96 to 5.73), respectively. The dominant model of disease penetrance was not statistically significant. The minor allele in all study groups was the ancestral allele, with a frequency of 0.49 in controls. There was no deviation from Hardy-Weinberg equilibrium in controls. Both case-control allele-based associations were statistically significant. CONCLUSIONS: Herein we present the first report of the association between rs13217795 and allergic rhinitis, and the first independent verification of the association between rs13217795 and asthma. Marker selection in future genetic association studies of asthma and allergic rhinitis should include functional polymorphisms in linkage disequilibrium with rs13217795</style></abstract><notes><style face="normal" font="default">DA - 20171116IS - 1471-2350 (Electronic)IS - 1471-2350 (Linking)LA - engPT - Journal ArticleCO - Jordan -</style></notes><work-type><style face="normal" font="default">10.1186/s12881-017-0494-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29141605">PM:29141605</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Med Genet\2017-18-132.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Med Genet\2017-18-132.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171116, Amarin JZ</style></custom2><misc3><style face="normal" font="default">10.1186/s12881-017-0494-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43268</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brooks,C.R.</style></author><author><style face="normal" font="default"> van Dalen,C.J.</style></author><author><style face="normal" font="default"> Harding,E.</style></author><author><style face="normal" font="default"> Hermans,I.F.</style></author><author><style face="normal" font="default"> Douwes,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Public Health Research, Massey University Wellington Campus, Private Box 756, Wellington, 6140, New Zealand.</style></auth-address><titles><title><style face="normal" font="default">Effects of treatment changes on asthma phenotype prevalence and airway neutrophil function</style></title><secondary-title><style face="normal" font="default">BMC Pulm Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Pulm Med</style></abbr-1></periodical><pages end="" start="169">169-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="12" Year="2017">2017/12/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma inflammatory phenotypes are often defined by relative cell counts of airway eosinophils/neutrophils. However, the importance of neutrophilia remains unclear, as does the effect of ICS treatment on asthma phenotypes and airway neutrophil function. The purpose of this study was to assess asthma phenotype prevalence/characteristics in a community setting, and, in a nested preliminary study, determine how treatment changes affect phenotype stability and inflammation, with particular focus on airway neutrophils. METHODS: Fifty adult asthmatics and 39 non-asthmatics were assessed using questionnaires, skin prick tests, spirometry, exhaled nitric oxide (FENO) measurement, and sputum induction. Twenty-one asthmatics underwent further assessment following treatment optimisation (n = 11) or sub-optimisation (n = 10). RESULTS: Forty percent (20/50) had eosinophilic asthma (EA) and 8% had neutrophilic asthma. EA was associated with increased FENO, bronchodilator reversibility (BDR) and reduced lung function (p &lt; 0.05). Following optimisation/sub-optimisation, the EA/NEA (non-eosinophilic asthma) phenotype changed in 11/21 (52%) asthmatics. In particular, fewer subjects had EA post treatment optimisation, but this was not statistically significant. However, a significant (p &lt; 0.05) reduction in FENO, ACQ7 score, and BDR was observed after treatment optimisation, as well as an increase in FEV1-% predicted (p &lt; 0.05). It was also associated with reduced eosinophils (p &lt; 0.05) and enhanced neutrophil phagocytosis (p &lt; 0.05) in EA only, and enhanced neutrophil oxidative burst in both EA and NEA (p &lt; 0.05). CONCLUSIONS: In this community based population, non-eosinophilic asthma was common, less severe than EA, and at baseline most asthmatics showed no evidence of inflammation. In the nested change in treatment study, treatment optimisation was associated with reduced sputum eosinophils, improved symptoms and lung function, and enhanced neutrophil function, but a significant reduction in EA could not be demonstrated. TRIAL REGISTRATION: The nested change in treatment component of this study is registered at the Australia and New Zealand Clinical Trial Registry ( www.ANZCTR.org.au ) ACTRN12617001356358 . Registration date 27/09/2017. Retrospectively registered</style></abstract><notes><style face="normal" font="default">IS - 1471-2466 (Electronic)IS - 1471-2466 (Linking)LA - engPT - Journal ArticleCO - New Zealand -</style></notes><work-type><style face="normal" font="default">10.1186/s12890-017-0511-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29202821">PM:29202821</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Pulm Med\2017-17-169.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Pulm Med\2017-17-169.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171203, Brooks CR</style></custom2><misc3><style face="normal" font="default">10.1186/s12890-017-0511-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43269</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wu,Y.F.</style></author><author><style face="normal" font="default"> Su,M.W.</style></author><author><style face="normal" font="default"> Chiang,B.L.</style></author><author><style face="normal" font="default"> Yang,Y.H.</style></author><author><style face="normal" font="default"> Tsai,C.H.</style></author><author><style face="normal" font="default"> Lee,Y.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Family Medicine, Taipei City Hospital, Renai Branch, Taipei, Taiwan</style></auth-address><titles><title><style face="normal" font="default">A simple prediction tool for inhaled corticosteroid response in asthmatic children</style></title><secondary-title><style face="normal" font="default">BMC Pulm Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Pulm Med</style></abbr-1></periodical><pages end="" start="176">176-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="12" Year="2017">2017/12/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Inhaled corticosteroids are recommended as the first-line controller medication for childhood asthma owing to their multiple clinical benefits. However, heterogeneity in the response towards these drugs remains a significant clinical problem. METHODS: Children aged 5 to 18 years with mild to moderate persistent asthma were recruited into the Taiwanese Consortium of Childhood Asthma Study. Their responses to inhaled corticosteroids were assessed based on their improvements in the asthma control test and peak expiratory flow. The predictors of responsiveness were demographic and clinical features that were available in primary care settings. We have developed a prediction model using logistic regression and have simplified it to formulate a practical tool. We assessed its predictive performance using the area under the receiver operating characteristic curve. RESULTS: Of the 73 asthmatic children with baseline and follow-up outcome measurements for inhaled corticosteroids treatment, 24 (33%) were defined as non-responders. The tool we have developed consisted of three predictors yielding a total score between 0 and 5, which are comprised of the following parameters: the age at physician-diagnosis of asthma, sex, and exhaled nitric oxide. Sensitivity and specificity of the tool for prediction of inhaled corticosteroids non-responsiveness, for a score of 3, were 0.75 and 0.69, respectively. The areas under the receiver operating characteristic curve for the prediction tool was 0.763. CONCLUSIONS: Our prediction tool represents a simple and low-cost method for predicting the response of inhaled corticosteroids treatment in asthmatic children</style></abstract><notes><style face="normal" font="default">IS - 1471-2466 (Electronic)IS - 1471-2466 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1186/s12890-017-0533-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29216859">PM:29216859</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Pulm Med\2017-17-176.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Pulm Med\2017-17-176.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171203, Wu YF</style></custom2><misc3><style face="normal" font="default">10.1186/s12890-017-0533-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43270</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yoshii,Y.</style></author><author><style face="normal" font="default"> Shimizu,K.</style></author><author><style face="normal" font="default"> Morozumi,M.</style></author><author><style face="normal" font="default"> Chiba,N.</style></author><author><style face="normal" font="default"> Ubukata,K.</style></author><author><style face="normal" font="default"> Uruga,H.</style></author><author><style face="normal" font="default"> Hanada,S.</style></author><author><style face="normal" font="default"> Wakui,H.</style></author><author><style face="normal" font="default"> Minagawa,S.</style></author><author><style face="normal" font="default"> Hara,H.</style></author><author><style face="normal" font="default"> Numata,T.</style></author><author><style face="normal" font="default"> Saito,K.</style></author><author><style face="normal" font="default"> Araya,J.</style></author><author><style face="normal" font="default"> Nakayama,K.</style></author><author><style face="normal" font="default"> Kishi,K.</style></author><author><style face="normal" font="default"> Kuwano,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Respiratory Diseases, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, 105-8461, Japan.</style></auth-address><titles><title><style face="normal" font="default">Detection of pathogens by real-time PCR in adult patients with acute exacerbation of bronchial asthma</style></title><secondary-title><style face="normal" font="default">BMC Pulm Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Pulm Med</style></abbr-1></periodical><pages end="" start="150">150-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="11" Year="2017">2017/11/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: Respiratory tract infection is a major cause of acute exacerbation of bronchial asthma (AEBA). Although recent findings suggest that common bacteria are causally associated with AEBA, a comprehensive epidemiologic analysis of infectious pathogens including common/atypical bacteria and viruses in AEBA has not been performed. Accordingly, we attempted to detect pathogens during AEBA by using real-time polymerase chain reaction (PCR) in comparison to conventional methods. METHODS: We prospectively enroled adult patients with AEBA from August 2012 to March 2014. Infectious pathogens collected in nasopharyngeal swab and sputum samples were examined in each patient by conventional methods and real-time PCR, which can detect 6 bacterial and 11 viral pathogens. The causal association of these pathogens with AEBA severity and their frequency of monthly distribution were also examined. RESULTS: Among the 64 enroled patients, infectious pathogens were detected in 49 patients (76.6%) using real-time PCR and in 14 patients (21.9%) using conventional methods (p &lt; 0.001). Real-time PCR detected bacteria in 29 patients (45.3%) and respiratory viruses in 28 patients (43.8%). Haemophilus influenzae was the most frequently detected microorganism (26.6%), followed by rhinovirus (15.6%). Influenza virus was the significant pathogen associated with severe AEBA. Moreover, AEBA occurred most frequently during November to January. CONCLUSIONS: Real-time PCR was more useful than conventional methods to detect infectious pathogens in patients with AEBA. Accurate detection of pathogens with real-time PCR may enable the selection of appropriate anti-bacterial/viral agents as a part of the treatment for AEBA</style></abstract><notes><style face="normal" font="default">IS - 1471-2466 (Electronic)IS - 1471-2466 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1186/s12890-017-0494-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29166936">PM:29166936</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Pulm Med\2017-17-150.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Pulm Med\2017-17-150.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171203, Yoshii Y</style></custom2><misc3><style face="normal" font="default">10.1186/s12890-017-0494-3</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43271</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,J.W.</style></author><author><style face="normal" font="default"> Kao,J.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109-5362, USA</style></auth-address><titles><title><style face="normal" font="default">Eosinophilic esophagitis: update on management and controversies</style></title><secondary-title><style face="normal" font="default">BMJ</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ</style></abbr-1></periodical><pages end="" start="j4482">j4482-</pages><volume><style face="normal" font="default">359</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="11" Year="2017">2017/11/13</year></dates><abstract><style face="normal" font="default">Eosinophilic esophagitis is a chronic allergen driven immune mediated disease that is increasingly recognized as a leading cause of dysphagia and foregut symptoms in children and adults. Much knowledge has been gained in recent years on the genetic and environmental risk factors for this disease, the associated inflammatory milieu, and the long term complications from esophageal remodeling. In this review we will highlight recent progress made in research into this disease, focusing on adults. We will discuss ongoing efforts to develop a minimally invasive technique that may obviate the need for repeated endoscopic assessment of disease activity. Moreover, we will review studies using novel tools such as mucosal impedance and functional lumen imaging as potential surrogate markers for mucosal integrity and esophageal remodeling. With regard to the treatment of eosinophilic inflammation, we will discuss the controversies surrounding responsiveness to proton pump inhibitors in some patients. Therapeutic trials continue to support the use of topical glucocorticoids and empiric food elimination diets as first line treatments. We will discuss ongoing efforts to optimize the elimination diet protocol to decrease the level and duration of food restrictions. Looking ahead, our growing knowledge on the pathogenesis of eosinophilic esophagitis has enabled further advancement of promising targeted biologic therapies</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 1756-1833 (Electronic)IS - 0959-535X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1136/bmj.j4482</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29133286">PM:29133286</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ\2017-359-j4482.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ\2017-359-j4482.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171114, Chen JW</style></custom2><misc3><style face="normal" font="default">10.1136/bmj.j4482</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43272</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Demarche,S.F.</style></author><author><style face="normal" font="default"> Schleich,F.N.</style></author><author><style face="normal" font="default"> Henket,M.A.</style></author><author><style face="normal" font="default"> Paulus,V.A.</style></author><author><style face="normal" font="default"> Van Hees,T.J.</style></author><author><style face="normal" font="default"> Louis,R.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, CHU Liege, GIGA I(3) Research Group, University of Liege, Liege, Belgium</style></auth-address><titles><title><style face="normal" font="default">Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre</style></title><secondary-title><style face="normal" font="default">BMJ Open</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Open</style></abbr-1></periodical><pages end="" start="e018186">e018186-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="28" Month="11" Year="2017">2017/11/28</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The impact of inhaled corticosteroids (ICS) on eosinophilic inflammation in asthma is well established, but their effect in a real-life setting has not been extensively studied. Our purpose was to investigate the effect of ICS on airway and systemic inflammation as well as on clinical outcomes in patients with asthma from clinical practice. DESIGN, SETTING AND PARTICIPANTS: We conducted a retrospective analysis on asthmatics from a secondary care centre in whom ICS were initiated/increased (n=101), stopped/decreased (n=60) or remained stable (n=63, used as a control group) between two visits with available sputum and blood cell counts. RESULTS: The median time between both visits ranged from 1 to 2 years. Initiating or increasing ICS (median variation (IQR): 800 (400-1200) microg beclomethasone equivalent dose per day) reduced sputum eosinophils and fractional exhaled nitric oxide (P&lt;0.0001) and to a lesser extent blood eosinophils (P&lt;0.0001), while withdrawing or decreasing ICS (median variation (IQR): 900 (500-1200) microg beclomethasone equivalentdose per day) resulted in increased sputum eosinophils (P=0.008). No change was found in patients with a stable dose. The effectiveness of ICS in improving asthma control, quality of life, forced expiratory volume in 1 s (FEV1), bronchial hyper-responsiveness and exacerbation rate was only observed in the eosinophilic phenotype (sputum eosinophils >/=3%, n=79). In non-eosinophilic asthmatics, stepping-down ICS resulted in an improvement in asthma control and quality of life, without any significant change in FEV1 (n=38). CONCLUSIONS: Our results confirm the effectiveness of ICS on eosinophilic inflammation in real life and demonstrate that their clinical benefit seems to be restricted to eosinophilic asthmatics. Our data also support a try for stepping-down ICS in non-eosinophilic asthmatics</style></abstract><notes><style face="normal" font="default">IS - 2044-6055 (Electronic)IS - 2044-6055 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1136/bmjopen-2017-018186</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29183929">PM:29183929</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Open\2017-7-e018186.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Open\2017-7-e018186.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Demarche SF</style></custom2><misc3><style face="normal" font="default">10.1136/bmjopen-2017-018186</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43273</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pols,D.H.J.</style></author><author><style face="normal" font="default"> Bohnen,A.M.</style></author><author><style face="normal" font="default"> Nielen,M.M.J.</style></author><author><style face="normal" font="default"> Korevaar,J.C.</style></author><author><style face="normal" font="default"> Bindels,P.J.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of General Practice, Erasmus MC, University Medical Center, Rotterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Risks for comorbidity in children with atopic disorders: an observational study in Dutch general practices</style></title><secondary-title><style face="normal" font="default">BMJ Open</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Open</style></abbr-1></periodical><pages end="" start="e018091">e018091-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="11" Year="2017">2017/11/12</year></dates><abstract><style face="normal" font="default">OBJECTIVE: This study aimed to investigate both atopic and non-atopic comorbid symptoms and diseases in children with physician-diagnosed atopic disorders (atopic eczema, asthma and allergic rhinitis). METHODS: All children aged 0-18 years listed in a nationwide primary care database (the Netherlands Institute for Health Services Research-Primary Care Database) with routinely collected healthcare data in 2014 were selected. Children with atopic disorders were matched on age and gender with non-atopic controls within the same general practice. A total of 404 International Classification of Primary Care codes were examined. Logistic regression analyses were performed to examine the associations between the presence of atopic disorders and (non-)atopic symptoms and diseases by calculating ORs. RESULTS: Having one of the atopic disorders significantly increased the risk of having other atopic-related symptoms, even if the child was not registered as having the related atopic disorder. Regarding non-atopic comorbidity, children with atopic eczema (n=15 530) were at significantly increased risk for (infectious) skin diseases (OR: 1.2-3.4). Airway symptoms or (infectious) diseases (OR: 2.1-10.3) were observed significantly more frequently in children with asthma (n=7887). Children with allergic rhinitis (n=6835) had a significantly distinctive risk of ear-nose-throat-related symptoms and diseases (OR: 1.5-3.9). Neither age nor gender explained these increased risks. CONCLUSION: General practitioners are not always fully aware of relevant atopic and non-atopic comorbidity. In children known to have at least one atopic disorder, specific attention is required to avoid possible insufficient treatment and unnecessary loss of quality of life</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 2044-6055 (Electronic)IS - 2044-6055 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1136/bmjopen-2017-018091</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29133326">PM:29133326</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Open\2017-7-e018091.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Open\2017-7-e018091.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171114, Pols DH</style></custom2><misc3><style face="normal" font="default">10.1136/bmjopen-2017-018091</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43274</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Johnson,A.</style></author><author><style face="normal" font="default"> Mason,T.</style></author><author><style face="normal" font="default"> Kirby,R.S.</style></author><author><style face="normal" font="default"> Ledford,D.</style></author><author><style face="normal" font="default"> Salihu,H.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Environmental and Occupational Health, University of South Florida, Tampa, Florida, USA</style></auth-address><titles><title><style face="normal" font="default">Examining the association between maternal atopy and birth outcomes using a retrospective cohort in the southeastern region of the USA</style></title><secondary-title><style face="normal" font="default">BMJ Open</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Open</style></abbr-1></periodical><pages end="" start="e017161">e017161-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="11" Year="2017">2017/11/12</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To assess birth outcomes in primiparous women with diagnosis of non-asthmatic atopy (NAA). Researchers hypothesised that women with NAA would have reduced the risk of adverse birth outcomes compared with women without NAA. NAA is defined as having allergic rhinitis and/or atopic dermatitis. SETTING: Women were mostly treated in primary care settings in South Carolina, USA. PARTICIPANTS: This is a retrospective cohort study in which participants were identified using a Medicaid database. Participants were primiparous women aged 19 to 25. Births occurring between 2004 and 2014 were identified using the South Carolina's Vital Statistics (VS) records of live births. Incomplete records (ie, information on plural birth, gestational age at birth or birth weight missing), plural births or infants born before completing 24 weeks of gestation were excluded. This provided 65 650 complete maternal-infant dyads, representing 97.6% of the maternal records and 96.9% of the VS records. Women previously diagnosed with NAA were frequency matched 1:4 to non-atopic controls for a total of 9965 maternal-infant dyads used in the statistical analysis. PRIMARY OUTCOME MEASURES: Low birth weight, small for gestational age and preterm birth. RESULTS: Linear tests for trend were statistically significant (p&lt;0.001), indicating that NAA was associated with improved birth weight and gestational age at birth. After controlling for potential confounders, mothers with NAA had equal risk for each outcome when compared with mothers with no diagnosis of NAA. CONCLUSION: A diagnosis of NAA among women living in the southeastern region of the USA does not reduce the risk of adverse birth outcomes nor does it elevate the risk of same. Additional studies with more rigorous designs are warranted to confirm the findings in this study</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 2044-6055 (Electronic)IS - 2044-6055 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1136/bmjopen-2017-017161</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29133318">PM:29133318</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Open\2017-7-e017161.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Open\2017-7-e017161.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171114, Johnson A</style></custom2><misc3><style face="normal" font="default">10.1136/bmjopen-2017-017161</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43275</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">AA.VV.</style></author></authors></contributors><titles><title><style face="normal" font="default">Mepolizumab -- Benefit Assessment According to §35a Social Code Book V [Internet].</style></title><secondary-title><style face="normal" font="default">Books</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Books</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="28" Month="4" Year="2016">2016/4/28</year></dates><abstract><style face="normal" font="default">Background In accordance with section sign 35a Social Code Book (SGB) V, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to assess the benefit of the drug mepolizumab. The assessment was based on a dossier compiled by the pharmaceutical company (hereinafter referred to as "the company"). The dossier was sent to IQWiG on 29 January 2016. Research question The aim of this report was to assess the added benefit of an add-on treatment with mepolizumab in comparison with the appropriate comparator therapy (ACT) in adult patients with severe refractory eosinophilic asthma. The G-BA specified the following ACT: Individually optimized treatment escalation: of moderate-to-high-dose inhaled corticosteroids (ICS) and of long-acting bronchodilators (LABAs), if applicable with oral corticosteroids (short-term) in their lowest effective dose; or with tiotropium; or, if applicable in immunoglobulin E (IgE)-mediated pathogenesis of the asthma, omalizumab in addition to high-dose ICS and LABAs and, if applicable, to oral corticosteroid treatment. The approvals of the drugs and the graded scheme of the Global Initiative for Asthma (GINA) were to be taken into account under the assumption that the therapeutic indication of mepolizumab is represented by the steps 4 to 5 (according to GINA). The G-BA additionally specified that placebo or unchanged continuation of inadequate treatment of severe asthma, if the option for treatment escalation is still available, does not comply with the ACT. The company concurred with the G-BA's specification. The present assessment was conducted in comparison with the G-BA's ACT. The assessment was conducted based on patient-relevant outcomes and on the data provided by the company in the dossier. A minimum study duration of 24 weeks was defined for the derivation of the added benefit</style></abstract><notes><style face="normal" font="default">DA - 20171117LA - engPT - ReviewPT - Book</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29144686">PM:29144686</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Books\Mepolizumab -- Benefit Assessment According to §35a Social Code Book V [Internet].pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Books\Mepolizumab -- Benefit Assessment According to §35a Social Code Book V [Internet].pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171117, AA.VV.</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43276</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ahmed,A.</style></author><author><style face="normal" font="default"> Solman,L.</style></author><author><style face="normal" font="default"> Williams,H.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Watford General Hospital, Watford, U.KDepartment of Paediatric Dermatology, Great Ormond Street Hospital for Children, London, WC1N 3JH, U.KCentre of Evidence Based Dermatology, University of Nottingham, Nottingham, U.K</style></auth-address><titles><title><style face="normal" font="default">Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="3" Month="12" Year="2017">2017/12/3</year></dates><abstract><style face="normal" font="default">AIM: To assess the efficacy and safety of crisaborole ointment, a phosphodiesterase 4 inhibitor, for the treatment of mild or moderate atopic dermatitis (AD) in two phase III studies (AD-301 and AD-302). DESIGN AND SETTING: Two identically designed multicentre, double-blind randomized controlled trials were conducted in the U.S.A. Participants were randomized 2 : 1 to receive crisaborole or vehicle treatment. In total 47 and 42 investigational centres were identified for AD-301 and AD-302, respectively. STUDY PARTICIPANTS: Inclusion criteria were identified as age >/= 2 years, clinical diagnosis of AD (as per the Hanifin and Rajka criteria), >/= 5% body surface area involvement, and baseline Investigator's Static Global Assessment (ISGA) mild or moderate. Exclusion criteria included previous use of biologics or systemic corticosteroids (within the last 28 days) or a topical calcineurin inhibitor/corticosteroid (within the last 14 days), and active skin infection. EXPOSURES: Participants were instructed to apply the study drug twice daily to all lesions identified at baseline, and all new lesions identified after day 1 (with weekly review of application instructions). Bland emollients were permitted to be used on skin not treated with the study drug. PRIMARY OUTCOME: The primary outcome was defined as ISGA clear or almost clear at day 29, with a 2-grade or more improvement from baseline. OUTCOMES: Secondary outcomes included the proportion of patients with an ISGA score of clear or almost clear at day 29, and time to success in ISGA score. Additional outcomes included pruritus severity and signs of AD (erythema, exudation, excoriation, induration/papulation and lichenification), and were measured on a 4-point scale (none, mild, moderate, severe). Adverse events were also recorded. RESULTS: More participants in the crisaborole-treated group achieved ISGA scores of clear or almost clear with >/= 2-grade improvement than in the vehicle-treated group (AD-301, 32.8% vs. 25.4%, P = 0.38; AD-302, 31.4% vs. 18.0%, P &lt; 0.001). Greater percentages of clear and almost clear scores were observed in the treatment groups (51.7% vs. 40.6%, P = 0.005; 48.5% vs. 29.7%; P &lt; 0.001), as well as earlier success in ISGA score and improvement in pruritus (P &lt;/= 0.001). No serious treatment-related adverse events were identified. CONCLUSIONS: Based on the study results, the authors suggest that crisaborole is a safe treatment that improves disease severity, pruritus and clinical signs associated with AD</style></abstract><notes><style face="normal" font="default">IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.16046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29205284">PM:29205284</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20171124-AhmedA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20171124-AhmedA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171124, Ahmed A</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.16046</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43277</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Thyssen,J.P.</style></author><author><style face="normal" font="default"> Halling-Overgaard,A.S.</style></author><author><style face="normal" font="default"> Andersen,Y.M.F.</style></author><author><style face="normal" font="default"> Gislason,G.</style></author><author><style face="normal" font="default"> Skov,L.</style></author><author><style face="normal" font="default"> Egeberg,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">The association between cardiovascular disease and type 2 diabetes in adults with atopic dermatitis: a systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="12" Year="2017">2017/12/6</year></dates><abstract><style face="normal" font="default">Recent studies examining the association between atopic dermatitis (AD) and cardiovascular disease (CVD) and type 2 diabetes have shown inconsistent results. We compared the risk of CVD and diabetes between adult patients with and without AD by searching the Pubmed, Embase, and Web of Science databases. Data extraction was done by two independent reviewers. We found a total of 2,855 citations, of which 53 were considered relevant based on title and abstract. Sixteen publications were included in the qualitative analysis, of which 13 were also included in a quantitative meta-analysis of crude data. No association was observed between AD and unspecified, but suspected type 2, diabetes (pooled odds ratio [OR] 1.11; 95% confidence interval [CI] 0.87-1.42), hypertension (pooled OR 1.16; 95% CI 0.98-1.37), stroke (pooled OR 1.15; 95% CI 0.95-1.39) or myocardial infarction (pooled OR 1.14; 95% CI 0.83-1.56), but a positive association was observed with angina pectoris (OR 1.73; 95% CI 1.27-2.37). Meta-analysis on adjusted data gave similar results. While adults with AD in some populations have increased prevalence of cardiovascular risk factors, such as obesity and smoking, it is unlikely that AD represents an independent and clinically relevant risk factor for cardiometabolic disease. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.16215</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29210061">PM:29210061</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20171124-ThyssenJP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20171124-ThyssenJP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171124, Thyssen JP</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.16215</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43278</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ruff,S.M.D.</style></author><author><style face="normal" font="default"> Engebretsen,K.A.</style></author><author><style face="normal" font="default"> Zachariae,C.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author><author><style face="normal" font="default"> Silverberg,J.I.</style></author><author><style face="normal" font="default"> Egeberg,A.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">The association between atopic dermatitis and hand eczema: a systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="24" Month="11" Year="2017">2017/11/24</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) and hand eczema (HE) are common chronic and relapsing inflammatory skin conditions that often co-occur. While several studies have addressed their relationship, the exact association estimate is unknown. We systematically reviewed published literature on the association between AD and HE in PubMed, Embase, and Web of Science using the following search terms; (atopic dermatitis OR atopic eczema) AND (hand dermatitis OR hand eczema). Meta-analyses were then performed to examine the association between AD and the point-, one-year- and lifetime prevalence of HE, respectively. We identified 35 relevant studies, of which 26 were included in the meta-analyses. AD was associated with an increased prevalence of HE with regards to point- (odds ratio (OR) 2.35; 95% CI: 1.47-3.76), one-year- (OR 4.29; 95% CI: 3.13-5.88), and lifetime prevalence (OR 4.06; 95% CI: 2.72-6.06). Furthermore, positive associations between AD and occupational HE were identified when assessing the one-year- 4.31 (95% CI: 2.08-8.91) and lifetime prevalence (OR 2.81; 95% CI: 2.08-3.79). Similar positive associations were found in the general population studies, i.e. OR 4.19 (95% CI: 3.46-5.08) and OR 5.69 (95% CI: 4.41-7.36). Important study limitations include the wide use of questionnaire studies, and lack of prospective studies as well as poor clinical phenotype descriptions. In conclusion, our systematic review and meta-analysis showed that patients with AD had a strongly increased prevalence of HE. Clinicians should continue to guide patients with AD away from occupations with high risk of HE. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Denmark -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.16147</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29172235">PM:29172235</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20171124-RuffSM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20171124-RuffSM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171124, Ruff SM</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.16147</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43279</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">de Bruin-Weller,M.</style></author><author><style face="normal" font="default"> Thaci,D.</style></author><author><style face="normal" font="default"> Smith,C.H.</style></author><author><style face="normal" font="default"> Reich,K.</style></author><author><style face="normal" font="default"> Cork,M.</style></author><author><style face="normal" font="default"> Radin,A.</style></author><author><style face="normal" font="default"> Zhang,Q.</style></author><author><style face="normal" font="default"> Akinlade,B.</style></author><author><style face="normal" font="default"> Gadkari,A.</style></author><author><style face="normal" font="default"> Eckert,L.</style></author><author><style face="normal" font="default"> Hultsch,T.</style></author><author><style face="normal" font="default"> Chen,Z.</style></author><author><style face="normal" font="default"> Pirozzi,G.</style></author><author><style face="normal" font="default"> Graham,N.M.H.</style></author><author><style face="normal" font="default"> Shumel,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">University Medical Center Utrecht, Utrecht, Netherlands</style></auth-address><titles><title><style face="normal" font="default">Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase 3 clinical trial (LIBERTY AD CAFE)</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="28" Month="11" Year="2017">2017/11/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease that may require systemic therapy. Ciclosporin A (CsA) is a widely-used, potent immunosuppressant for AD. CsA is not effective in all patients, and side effects limit its use. Dupilumab, a fully human anti-interleukin (IL)-4 receptor-alpha monoclonal antibody, inhibits signaling of IL-4 and IL-13, key drivers of type 2/Th2-mediated inflammation, and is approved in the U.S.A. and the E.U. for the treatment of adults with moderate-to-severe AD. OBJECTIVES: To evaluate efficacy and safety of dupilumab with concomitant topical corticosteroids (TCS) in adults with AD with inadequate response to/intolerance of CsA, or for whom CsA was medically inadvisable. METHODS: In this 16-week, double-blind, randomized, placebo-controlled, phase 3 trial, patients were randomized 1:1:1 to subcutaneous dupilumab 300 mg weekly (qw):every two weeks (q2w):placebo. All received concomitant medium-potency TCS from Week -2 through Week 16; dosage could be tapered if lesions cleared, or stopped for adverse reactions to TCS. RESULTS: 390 patients were screened; 325 were randomized and 318 completed the trial. Treatment groups had similar baseline characteristics. Significantly more patients on dupilumab qw+TCS/q2w+TCS achieved >/=75% improvement from baseline in Eczema Area and Severity Index at Week 16 vs placebo+TCS (primary endpoint) (59.1%/62.6% vs 29.6%; P&lt;0.0001 vs placebo+TCS, both doses). Dupilumab qw+TCS/q2w+TCS significantly improved other clinical outcomes and AD symptoms, including pruritus, pain, sleep disturbance, symptoms of anxiety and depression, and quality of life (QOL). Treatment groups had similar overall rates of adverse events (69.1%/72.0%/69.4%; qw+TCS/q2w+TCS/placebo+TCS) and serious adverse events (1.8%/1.9%/1.9%). Conjunctivitis was more frequent with dupilumab+TCS; skin infections were more frequent with placebo+TCS. CONCLUSIONS: Dupilumab+TCS significantly improved signs and symptoms of AD and QOL in adults with history of inadequate response to/intolerance of CsA, or for whom CsA treatment was medically inadvisable. No new safety signals were identified. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Germany -CO - United States -CO - United KIngdom -CO - France -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.16156</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29193016">PM:29193016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20171124-deBruinWellerM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20171124-deBruinWellerM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171124, de Bruin-Weller M</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.16156</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43280</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Danby,S.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Sheffield Dermatology Research, Department of Infection, Immunity &amp; Cardiovascular Disease, Faculty of Medicine, Dentistry and Health, The University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, U.K</style></auth-address><titles><title><style face="normal" font="default">Staphylococcus aureus in atopic dermatitis: a diverse problem?</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="1164">1164-</pages><volume><style face="normal" font="default">177</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.15942</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29192989">PM:29192989</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\2017-177-1164.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\2017-177-1164.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171203, Danby SG</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.15942</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43281</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Acat,M.</style></author><author><style face="normal" font="default"> Toru,Erbay U.</style></author><author><style face="normal" font="default"> Sahin,S.</style></author><author><style face="normal" font="default"> Arik,O.</style></author><author><style face="normal" font="default"> Ayada,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">High serum levels of IGF-I and IGFBP3 may increase comorbidity risk for asthmatic patients</style></title><secondary-title><style face="normal" font="default">Bratisl Lek Listy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Bratisl Lek Listy</style></abbr-1></periodical><pages end="694" start="691">691-694</pages><volume><style face="normal" font="default">118</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Asthma is known as a chronic inflammatory lung disease which has also systemic features. Insulin-like growth factor I (IGF-I) plays a role for asthma pathogenesis. Controversially, IGF-binding protein 3 (IGFBP3) blocks asthma development. That is why IGF-I and IGFBP3 are targeted for future therapeutic treatments of asthma. We aimed to investigate serum level of IGF-I and IGFBP3 in patients with asthma. This study was performed in 27 asthma and 23 healthy individuals. Serum levels of IGF-I and IGFBP3 were measured by human ELISA assay kits. Serum levels of IGF-I and IGFBP3 were significanlty higher in the asthma group than the control group. Significant negative correlation was found between IGF-I and asthma control test (ACT) puan, O2 saturation, Forced Expiratory Volume in 1 second/ Forced Vital Capacity (FEV1/FVC), Forced Expiratory Flow 25 second/75 second (FEF2575) (%). Significant positive correlation was found between IGFBP3 and IGF-I, systolic blood pressure. Significant negative correlation was found between IGF-I and FEV1 (ml). RESULTS: Our results indicate that the serum levels of IGF-I and IGFBP3 are significanlty elevated in the asthma group. We assume that current treatment strategies are not really good enough for asthma. We suppose further strategies which are seeking to balance IGF-I and IGFBP3 should be developed for more effective and curative treatment of asthma (Tab. 2, Fig. 2, Ref. 22)</style></abstract><notes><style face="normal" font="default">IS - 0006-9248 (Print)IS - 0006-9248 (Linking)LA - engPT - Journal ArticleCO - Slovakia -</style></notes><work-type><style face="normal" font="default">10.4149/BLL_2017_130</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29216726">PM:29216726</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Bratisl Lek Listy\2017-118-691-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Bratisl Lek Listy\2017-118-691-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171125, Acat M</style></custom2><misc3><style face="normal" font="default">10.4149/BLL_2017_130</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43282</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zaffanello,M.</style></author><author><style face="normal" font="default"> Gasperi,E.</style></author><author><style face="normal" font="default"> Tenero,L.</style></author><author><style face="normal" font="default"> Piazza,M.</style></author><author><style face="normal" font="default"> Pietrobelli,A.</style></author><author><style face="normal" font="default"> Sacchetto,L.</style></author><author><style face="normal" font="default"> Antoniazzi,F.</style></author><author><style face="normal" font="default"> Piacentini,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Surgery, Dentistry, Paediatrics and Gynaecology, Pediatric Division, University of Verona, Piazzale L.A. Scuro, 10, 37134 Verona, Italy.</style></auth-address><titles><title><style face="normal" font="default">Sleep-Disordered Breathing in Children with Recurrent Wheeze/Asthma: A Single Centre Study</style></title><secondary-title><style face="normal" font="default">Children (Basel)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Children (Basel)</style></abbr-1></periodical><pages end="" start=" E97"> E97-</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="11" Year="2017">2017/11/14</year></dates><abstract><style face="normal" font="default">The relationship between asthma and sleep-disordered breathing is bidirectional due to common risk factors that promote airway inflammation. Obstructive sleep-disordered breathing and recurrent wheeze/asthma are conditions that involve the upper and the lower respiratory system, respectively. The aim of the present study was to investigate the sleep disordered breathing in children with recurrent wheeze/asthma. This was a retrospective study concerning children older than 2 years who underwent-between January 2014 and November 2016-an in-laboratory overnight polygraphic study. We match the children between those who do or do not have recurrent wheeze/asthma disease. We examined the clinical records of 137 children. We excluded eight patients because of neurological and genetic conditions. Children with recurrent wheeze/asthma (N = 28) were younger (p = 0.002) and leaner (p = 0.013) compared to non-affected children (N = 98). Children with wheeze/asthma and unaffected ones had a similar obstructive apnea-hypopnea index (p = 0.733) and oxygen desaturation index (p = 0.535). The logistic regression analysis, in which the condition of wheeze/asthma (yes/no) was a dependent variable, while demographic (age, sex, body mass index (BMI) Z-score) and polygraphic results during sleep (obstructive apnea-hypopnea index, central apnea index, peripheral oxygen saturation (SpO(2)), and snoring) were covariates, showed that children with wheeze/asthma had higher central apnea index (Exp(B) = 2.212; Wald 6.845; p = 0.009). In conclusion, children with recurrent wheeze/asthma showed an increased number of central sleep apneas than unaffected children. This finding may suggest a dysfunction of the breathing control in the central nervous system during sleep. Systemic or central inflammation could be the cause</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 2227-9067 (Print)IS - 2227-9067 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.3390/children4110097</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29135910">PM:29135910</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Children (Basel)\2017-4-E97.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Children (Basel)\2017-4-E97.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171114, Zaffanello M</style></custom2><misc3><style face="normal" font="default">10.3390/children4110097</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43283</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arnold,J.D.</style></author><author><style face="normal" font="default"> Oldfield,R.K.</style></author><author><style face="normal" font="default"> Pollard,A.C.</style></author><author><style face="normal" font="default"> Davidson,G.P.</style></author></authors></contributors><titles><title><style face="normal" font="default">The magnesium content of duodenal mucosa in man</style></title><secondary-title><style face="normal" font="default">Clin Chim Acta</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Chim Acta</style></abbr-1></periodical><pages end="67" start="63">63-67</pages><volume><style face="normal" font="default">101</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adolescent</style></keyword><keyword><style face="normal" font="default"> Body Fluids</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Child</style></keyword><keyword><style face="normal" font="default"> Chronic Disease</style></keyword><keyword><style face="normal" font="default"> Diarrhea</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Diarrhea,Infantile</style></keyword><keyword><style face="normal" font="default"> Duodenum</style></keyword><keyword><style face="normal" font="default"> anatomy &amp; histology</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Infant</style></keyword><keyword><style face="normal" font="default"> Intestinal Mucosa</style></keyword><keyword><style face="normal" font="default"> Magnesium</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword></keywords><dates><year Day="14" Month="2" Year="1980">1980/2/14</year></dates><abstract><style face="normal" font="default">The magnesium content of duodenal mucosa was estimated in biopsy specimens from 50 patients, 43 of which had normal mucosal histopathology. There was no significant difference in the mean mucosal magnesium content of those speciments with normal and abnormal histopathology and overall the mean value was 30.9 mmol/kg dry weight of tissue, but there was a wide spread of values. The concentration of magnesium in plasma and duodenal fluid was also determined. There was no significant correlation between duodenal mucosal magnesium content and plasma magnesium concentration. However, there was a weak but statistically significant correlation between magnesium content in duodenal fluid and duodenal mucosa (r = 0.54, p less than 0.001)</style></abstract><notes><style face="normal" font="default">IS - 0009-8981 (Print)IS - 0009-8981 (Linking)LA - engPT - Comparative StudyPT - Journal ArticleRN - I38ZP9992A (Magnesium)SB - IMCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/0009-8981(80)90056-X</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="7357739">PM:7357739</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Chim Acta\1980-101-63-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Chim Acta\1980-101-63-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">198800412, Arnold JD</style></custom2><misc3><style face="normal" font="default">10.1016/0009-8981(80)90056-X</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43284</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gao,L.</style></author><author><style face="normal" font="default"> Millstein,J.</style></author><author><style face="normal" font="default"> Siegmund,K.D.</style></author><author><style face="normal" font="default"> Dubeau,L.</style></author><author><style face="normal" font="default"> Maguire,R.</style></author><author><style face="normal" font="default"> Gilliland,F.D.</style></author><author><style face="normal" font="default"> Murphy,S.K.</style></author><author><style face="normal" font="default"> Hoyo,C.</style></author><author><style face="normal" font="default"> Breton,C.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Preventive Medicine, USC Keck School of Medicine, 2001 N. Soto Street, Los Angeles, CA 90032 USA.</style></auth-address><titles><title><style face="normal" font="default">Epigenetic regulation of AXL and risk of childhood asthma symptoms</style></title><secondary-title><style face="normal" font="default">Clin Epigenetics</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Epigenetics</style></abbr-1></periodical><pages end="" start="121">121-</pages><volume><style face="normal" font="default">9</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: AXL is one of the TAM (TYRO3, AXL and MERTK) receptor tyrosine kinases and may affect numerous immune-related health conditions. However, the role for AXL in asthma, including its epigenetic regulation, has not been extensively studied. Methods: We investigated the association between AXL DNA methylation at birth and risk of childhood asthma symptoms at age 6 years. DNA methylation of multiple CpG loci across the regulatory regions of AXL was measured in newborn bloodspots using the Illumina HumanMethylation450 array on a subset of 246 children from the Children's Health Study (CHS). Logistic regression models were fitted to assess the association between asthma symptoms and DNA methylation. Findings were evaluated for replication in a separate population of 1038 CHS subjects using Pyrosequencing on newborn bloodspot samples. AXL genotypes were extracted from genome-wide data. Results: Higher average methylation of CpGs in the AXL gene at birth was associated with higher risk of parent-reported wheezing, and the association was stronger in girls than in boys. This relationship reflected the methylation status of the gene-body region near the 5' end, for which a 1% higher methylation level was significantly associated with a 72% increased risk of ever having wheezed by 6 years. The association of one CpG locus, cg00360107 was replicated using Pyrosequencing. Increased AXL methylation was also associated with lower mRNA expression level of this gene in lung tissue from the Cancer Genome Atlas (TCGA) dataset. Furthermore, AXL DNA methylation was strongly linked to underlying genetic polymorphisms. Conclusions: AXL DNA methylation at birth was associated with higher risk for asthma-related symptoms in early childhood</style></abstract><notes><style face="normal" font="default">IS - 1868-7083 (Electronic)IS - 1868-7075 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1186/s13148-017-0421-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29177020">PM:29177020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Epigenetics\2017-9-121.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Epigenetics\2017-9-121.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171011, Gao L</style></custom2><misc3><style face="normal" font="default">10.1186/s13148-017-0421-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43285</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Margaritte-Jeannin,P.</style></author><author><style face="normal" font="default"> Babron,M.C.</style></author><author><style face="normal" font="default"> Laprise,C.</style></author><author><style face="normal" font="default"> Lavielle,N.</style></author><author><style face="normal" font="default"> Sarnowski,C.</style></author><author><style face="normal" font="default"> Brossard,M.</style></author><author><style face="normal" font="default"> Moffatt,M.</style></author><author><style face="normal" font="default"> Gagne-Ouellet,V.</style></author><author><style face="normal" font="default"> Etcheto,A.</style></author><author><style face="normal" font="default"> Lathrop,M.</style></author><author><style face="normal" font="default"> Just,J.</style></author><author><style face="normal" font="default"> Cookson,W.O.</style></author><author><style face="normal" font="default"> Bouzigon,E.</style></author><author><style face="normal" font="default"> Demenais,F.</style></author><author><style face="normal" font="default"> Dizier,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Inserm, UMR-946, Genetic Variation and Human Diseases unit, F-75010, Paris, France</style></auth-address><titles><title><style face="normal" font="default">The COL5A3 and MMP9 genes interact in eczema susceptibility</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="11" Year="2017">2017/11/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: Genetic studies of eczema have identified many genes, which explain only 14% of the heritability. Missing heritability may be partly due to ignored Gene-Gene (G-G) interactions. OBJECTIVE: Our aim was to detect new interacting genes involved in eczema. METHODS: The search for G-G interaction in eczema was conducted using a two-step approach, which included as a first step, a biological selection of genes, which are involved either in the skin or epidermis development or in the collagen metabolism, and as a second-step, an interaction analysis of the selected genes. Analyses were carried out at both SNP and gene levels in three asthma-ascertained family samples: the discovery dataset of 388 EGEA (Epidemiological study on the Genetics and Environment of Asthma) families and the two replication datasets of 253 SLSJ (Saguenay-Lac-Saint-Jean) families and 207 MRCA (Medical Research Council) families. RESULTS: One pair of SNPs, rs2287807 in COL5A3 and rs17576 in MMP9, that were detected in EGEA at P &lt;/= 10(-5) showed significant interaction by meta-analysis of EGEA, SLSJ and MRCA samples (P=1.1x10(-8) under the significant threshold of 10(-7) ). Gene-based analysis confirmed strong interaction between COL5A3 and MMP9 (P=4x10(-8) under the significant threshold of 4x10(-6) ) by meta-analysis of the three datasets. When stratifying the data on asthma, this interaction remained in both groups of asthmatic and non-asthmatic subjects. CONCLUSION: This study identified significant interaction between two new genes, COL5A3 and MMP9, which may be accounted for by a degradation of COL5A3 by MMP9 influencing eczema susceptibility. Further confirmation of this interaction as well as functional studies are needed to better understand the role of these genes in eczema. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - France -CO - Canada -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13064</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29168291">PM:29168291</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20171113-MargaritteJeanninP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20171113-MargaritteJeanninP.pdf</url></text-urls><related-urls><url ppv-ref="no">xlsx in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20171113, Margaritte-Jeannin P</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13064</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43286</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jabbal,S.</style></author><author><style face="normal" font="default"> Lipworth,B.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Scottish Centre for Respiratory Research, Ninewells Hospital &amp; Medical School, Dundee, Scotland, DD1 9SYScottish Centre for Respiratory Research, Ninewells Hospital &amp; Medical School, Dundee, Scotland, DD1 9SY</style></auth-address><titles><title><style face="normal" font="default">Blood eosinophils: The forgotten man of inhaled steroid dose titration</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="11" Year="2017">2017/11/8</year></dates><abstract><style face="normal" font="default">Blood eosinophil counts which were once regarded as normal, have become of increasing interest in the era of Interluekin-5 (IL-5) asthma treatment. Blood eosinophils as low as 150 cells/muL have been suggested as treatment cut-offs for eosinophil depleting therapies such as mepolizumab [1], whilst a value of 300 cells/muL has been deemed a more pragmatic cut off by the National Institute for Health and Care Excellence (United Kingdom). In this era of eosinophil post-truths, inhaled corticosteroids (ICS), the eosinophil's oldest adversary, are very much the forgotten man. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171108IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13057</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29117628">PM:29117628</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20171108-JabbalS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20171108-JabbalS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171108, Jabbal S</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13057</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43287</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">den Dekker,H.T.</style></author><author><style face="normal" font="default"> Jaddoe,V.W.V.</style></author><author><style face="normal" font="default"> Reiss,I.K.</style></author><author><style face="normal" font="default"> de Jongste,J.C.</style></author><author><style face="normal" font="default"> Duijts,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Generation R Study GroupDepartment of Pediatrics, Division of Respiratory MedicineDepartment of EpidemiologyThe Generation R Study GroupDepartment of EpidemiologyDepartment of Pediatrics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The NetherlandsDepartment of Pediatrics, Division of NeonatologyDepartment of Pediatrics, Division of Respiratory MedicineDepartment of Pediatrics, Division of Respiratory MedicineDepartment of EpidemiologyDepartment of Pediatrics, Division of Neonatology</style></auth-address><titles><title><style face="normal" font="default">Maternal folic acid use during pregnancy, MTHFR polymorphism, and child's lung function and asthma</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="11" Year="2017">2017/11/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Folic acid supplement use during pregnancy might affect childhood respiratory health, potentially mediated by methylenetetrahydrofolate-reductase polymorphism C677T (MTHFR-C677T) carriership. OBJECTIVES: We examined the associations of maternal folic acid supplement use and folate, vitamin B12 and homocysteine concentrations during pregnancy with childhood lung function and asthma. METHODS: This study was embedded in a population-based prospective cohort study among 5,653 children. Folic acid supplement use was assessed by questionnaires. Folate, vitamin B12 and homocysteine plasma concentrations were measured in early pregnancy and at birth. At age 10 years, forced expiratory volume in 1 second (FEV1 ), forced vital capacity (FVC), FEV1 /FVC, forced expiratory flow between 25% and 75% (FEF25-75 ), at 75% of FVC (FEF75 ), and asthma were examined. RESULTS: Maternal folic acid supplement use during pregnancy was associated with higher childhood FEV1 and FVC and with a lower FEV1 /FVC, compared with no folic acid supplement use. Among mothers carrying MTHFR-C677T variants, preconceptional start of folic acid supplement use was associated with lower FEV1 /FVC (-0.17 (-0.32, -0.02)) and FEF25-75 (-0.24 (-0.40, -0.07)). Among children carrying MTHFR-C677T wildtype, a higher vitamin B12 level at birth was associated with a lower FEV1 (-0.07 (-0.12, -0.01)) and FVC (-0.09 (-0.15, -0.04). Folate and homocysteine concentrations were not consistently associated with lower childhood lung function or asthma. CONCLUSIONS: Preconceptional start of maternal folic acid supplement use and higher vitamin B12 concentrations at birth might adversely affect childhood lung function depending on MTHFR-C677T carriership. The clinical implications need to be evaluated. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171108IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13056</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29117460">PM:29117460</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20171108-denDekkerHT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20171108-denDekkerHT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171108, den Dekker HT</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13056</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43288</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fieten,K.</style></author><author><style face="normal" font="default"> Schappin,R.</style></author><author><style face="normal" font="default"> Zijlstra,W.</style></author><author><style face="normal" font="default"> Figee,L.</style></author><author><style face="normal" font="default"> Beutler,J.</style></author><author><style face="normal" font="default"> Raymakers,F.</style></author><author><style face="normal" font="default"> van Os-Medendorp,H.</style></author><author><style face="normal" font="default"> Stellato,R.</style></author><author><style face="normal" font="default"> Vandewall,M.</style></author><author><style face="normal" font="default"> Winkelhof,J.</style></author><author><style face="normal" font="default"> Uniken,V.M.</style></author><author><style face="normal" font="default"> Bruijnzeel-Koomen,C.</style></author><author><style face="normal" font="default"> Rijssenbeek-Nouwens,L.</style></author><author><style face="normal" font="default"> van der Ent,C.</style></author><author><style face="normal" font="default"> van Hoffen,E.</style></author><author><style face="normal" font="default"> Meijer,Y.</style></author><author><style face="normal" font="default"> Pasmans,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, the Netherlands</style></auth-address><titles><title><style face="normal" font="default">Effectiveness of alpine climate treatment for children with difficult to treat atopic dermatitis: results of a pragmatic randomized controlled trial (DAVOS trial)</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="11" Year="2017">2017/11/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Alpine climate treatment has historically been used in Europe to treat atopic dermatitis (AD), but no randomized trials have been conducted to provide evidence for its effectiveness. OBJECTIVE: To investigate the long-term effectiveness of alpine climate treatment for children with difficult to treat AD. MATERIALS &amp; METHODS: A pragmatic, open, randomized controlled trial was conducted. Children diagnosed with AD that was considered difficult to treat, aged between 8 and 18 years and willing to be treated in Switzerland were randomized to a six week personalized integrative multidisciplinary treatment period in a clinical setting in the alpine climate (Switzerland) or an outpatient setting in moderate maritime climate (Netherlands). Study assessments were conducted at the Wilhelmina Children's Hospital; an electronic portal was used for the collection of questionnaire data. Primary outcomes were disease activity (SAEASI), quality of life (CDLQI), and catastrophizing thoughts (JUCKKI/JU) six months after intervention. Other assessments were immediately and six weeks after intervention. Subgroup analyses concerned asthma-related outcomes. Children were randomly assigned to either the intervention or control group using a covariate adaptive randomization method, taking age and asthma diagnosis into account. Children, parents, and health care professionals involved in treatment were not blinded to group assignment. Data were analyzed according to intention-to-treat with linear mixed effects models for continuous outcomes. The trial is registered at Current Controlled Trials ISCRTN88136485. RESULTS: Between September 14th 2010 and September 30th 2014, 88 children were enrolled in the trial, 84 children were randomized (41 assigned to intervention, 43 to control) of whom 77 completed the intervention (38/41 (93%) intervention, 39/43 (91%) control) and 74 completed follow-up (38/41 (93%) intervention, 36/43 (84%) control). Six months after intervention there were no significant differences between the groups on disease activity (SAEASI mean difference -3.4 (95%CI -8.5 to 1.7)), quality of life (CDLQI mean difference -0.3 (95%CI -2.0 to 1.4)), and catastrophizing thoughts (JUCCKI/JU subscale mean difference -0.7 (95%CI -1.4 to -0.0)). Immediately and six weeks after intervention, disease activity and quality of life were significantly different in favor of alpine climate treatment. Mean differences on SAEASI were -10.1 (95%CI -14.5 to -5.8) and -8.4 (95%CI -12.2 to -4.6) and on CDLQI -1.9 (95%CI -3.3 to -0.5) and -1.5 (95%CI -2.8 to -0.3) immediately and six weeks after the intervention, respectively. There were no long-term differences on asthma related outcomes. Five serious adverse events occurred during the study period, which were not thought to be related to the treatment. CONCLUSIONS &amp; CLINICAL RELEVANCE: For children with difficult to treat AD, there was no additional long-term benefit of alpine climate treatment, in contrast to the short-term, compared to an outpatient treatment program in moderate maritime climate, using a personalized integrative multidisciplinary treatment approach. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171109IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13058</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29121432">PM:29121432</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20171109-FietenK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20171109-FietenK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171109, Fieten K</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13058</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43289</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chambers,E.S.</style></author><author><style face="normal" font="default"> Nanzer,A.M.</style></author><author><style face="normal" font="default"> Pfeffer,P.E.</style></author><author><style face="normal" font="default"> Richards,D.F.</style></author><author><style face="normal" font="default"> Martineau,A.R.</style></author><author><style face="normal" font="default"> Griffiths,C.J.</style></author><author><style face="normal" font="default"> Corrigan,C.J.</style></author><author><style face="normal" font="default"> Hawrylowicz,C.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">MRC and Asthma-UK Centre for Allergic Mechanisms in Asthma, King's College London, London, SE1 9RT</style></auth-address><titles><title><style face="normal" font="default">Dendritic cell phenotype in severe asthma reflects clinical responsiveness to glucocorticoids</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="11" Year="2017">2017/11/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Subsets of patients with severe asthma remain symptomatic despite prolonged, high dosage glucocorticoid therapy. We hypothesised that the clinical glucocorticoid sensitivity of these asthmatics is reflected in differences in peripheral blood dendritic cell subsets. OBJECTIVE: To compare peripheral blood leukocyte populations using flow cytometry at baseline and after 2 weeks of systemic glucocorticoid (steroid) treatment to identify immunological differences between steroid sensitive (SS) and steroid resistant (SR) asthmatics. METHODS: Adult severe asthmatics (SS n=12; SR n=23) were assessed for their response to two weeks of therapy with oral prednisolone. Peripheral blood was obtained before and after therapy and stained for lymphocyte (CD3, CD19, CD4, CD8 and Foxp3) and dendritic cell markers (Lineage negative [CD3, CD14, CD16, CD19, CD20, CD56], HLA-DR+, CD304, CD11c, ILT3 and CD86). RESULTS: A higher median frequency of myeloid DCs (mDCs) but not plasmacytoid DCs (pDCs) was observed in the blood of SR as compared to SS asthmatics (p=0.03). Glucocorticoid therapy significantly increased median B cell, but not T cell numbers in both cohorts, with a trend for increased numbers of Foxp3+ Tregs in SS (p=0.07), but not SR subjects. Oral prednisolone therapy significantly reduced the median numbers and frequencies of total DCs and pDCs in both SS and SR asthmatics. Interestingly the expression of HLA-DR and ILT3 was also reduced on pDCs in all patients. In contrast, therapy increased the median frequency of mDCs in SS, but reduced it in SR asthmatics. CONCLUSIONS: Myeloid DC frequency is elevated in SR compared with SS asthmatics, and mDC show a differential response to oral prednisolone therapy. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171113IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13061</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29130617">PM:29130617</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20171113-ChambersES.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20171113-ChambersES.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171113, Chambers ES</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13061</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43290</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gelardi,M.</style></author><author><style face="normal" font="default"> Landi,M.</style></author><author><style face="normal" font="default"> Ciprandi,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Italian Academy of RhinologyItalian Academy of Nasal CytologyItalian Academy of Nasal CytologyItalian Academy of Rhinology</style></auth-address><titles><title><style face="normal" font="default">Nasal Cytology: a Precision Medicine tool in clinical practice</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="11" Year="2017">2017/11/23</year></dates><abstract><style face="normal" font="default">The BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis represents a precise and accurate document in defining the different sub-groups of patients suffering from allergic rhinitis (AR) and non-allergic rhinitis (NAR). We would like to stimulate the debate about this matter, mainly concerning the definition and classification of NAR. In particular, we would convince the readers that there are different phenotypes/endotypes of NAR in addition to non-allergic rhinitis with eosinophils (NARES). This concept is clinically relevant as deserves an adequate work-up and constitutes the background for the Precision Medicine (PM) approach. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13065</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29168255">PM:29168255</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20171113-GelardiM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20171113-GelardiM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171113, Gelardi M</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13065</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43291</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Backman,K.</style></author><author><style face="normal" font="default"> Ollikainen,H.</style></author><author><style face="normal" font="default"> Piippo-Savolainen,E.</style></author><author><style face="normal" font="default"> Nuolivirta,K.</style></author><author><style face="normal" font="default"> Korppi,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland</style></auth-address><titles><title><style face="normal" font="default">Asthma and Lung Function in Adulthood after a Viral Wheezing Episode in Early Childhood</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="11" Year="2017">2017/11/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Viral etiology of infection has a significant role in the long-term outcome of early-childhood wheezing. OBJECTIVE: This study examines asthma and lung function in adulthood after early-childhood wheezing induced by respiratory syncytial virus (RSV) and rhinovirus (RV). METHODS: A total of 100 children were hospitalized for a wheezing episode at less than 24 months of age from 1992 to 1993 in Kuopio University Hospital (Finland). Adenovirus, influenza A and B virus, parainfluenza (1-3) virus, and RSV were tested on admission using antigen detection and antibody assays, and RSV and RV were tested by polymerase chain reaction (PCR). In 2010, 49 cases and 60 population controls attended a follow-up study, which included spirometry with bronchodilation test and fractionally exhaled nitric oxide (FENO ) measurements. RESULTS: Current asthma was present in 64% of the cases with RV-induced wheezing [OR 17.0 (95%CI 3.9-75.3) vs. controls], in 43% of the cases with RSV-induced wheezing episode [6.1 (1.5-24.9) vs. controls], and in 12% of the controls. The RV group showed significantly higher mean FENO values than the RSV group and controls. RV-positive cases had lower MEF50 before bronchodilation and higher MEF50, FEV1, and FEV1/FVC bronchodilation responses than controls. RSV-positive cases had lower FVC than controls before bronchodilation. CONCLUSION: Cases with RV- and RSV-induced early-childhood wheezing had increased risk for asthma in adulthood, and RV-positive cases had significantly higher FENO values than RSV-positive cases and controls. Compared to controls RV-positive cases showed more bronchial reactivity, and RSV-positive cases showed lower FVC before bronchodilation in lung function testing. CLINICAL RELEVANCE: Children with RV- or RSV-induced wheezing in early childhood have an increased risk for asthma and lung function abnormalities in adulthood. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171116IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13062</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29143374">PM:29143374</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20171116-BackmanK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20171116-BackmanK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171116, Backman K</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13062</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43292</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Laurence,M.</style></author><author><style face="normal" font="default"> Anne,H.</style></author><author><style face="normal" font="default"> Jean-Francois,N.</style></author><author><style face="normal" font="default"> Marie,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Saint-Luc University Hospital, Universite catholique de Louvain, Brussels, Belgium</style></auth-address><titles><title><style face="normal" font="default">Treatment of chronic spontaneous urticaria: Immunomodulatory approaches</style></title><secondary-title><style face="normal" font="default">Clin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="11" Year="2017">2017/11/9</year></dates><abstract><style face="normal" font="default">This paper summarizes and reviews the mechanisms of action and data concerning efficacy of recommended treatments as well as other treatments that have been tested, independently of the outcomes, in the management of chronic spontaneous urticaria. Due to the central role of mast cells and histamine in the pathophysiology of this disease, H1-antihistamines remain the first-line treatment. However, current knowledge about this complex disease, also recognizes an important role for T lymphocytes, B lymphocytes, and autoantibodies. Implications of these others mediators thus provide further targets for treatment. Indeed, agents previously used to treat other autoimmune and inflammatory diseases, have demonstrated efficacy in chronic spontaneous urticaria and are therefore potential therapeutic alternatives for antihistamine unresponsive patients</style></abstract><notes><style face="normal" font="default">DA - 20171113IS - 1521-7035 (Electronic)IS - 1521-6616 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Belgium -CO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.clim.2017.11.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29129806">PM:29129806</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Immunol\20171113-LaurenceM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Immunol\20171113-LaurenceM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171113, Laurence M</style></custom2><misc3><style face="normal" font="default">10.1016/j.clim.2017.11.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43293</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tannert,L.K.</style></author><author><style face="normal" font="default"> Falkencrone,S.</style></author><author><style face="normal" font="default"> Mortz,C.G.</style></author><author><style face="normal" font="default"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="default"> Skov,P.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis, Odense University Hospital, Klovervaenget 15, 5000 Odense C, Denmark.</style></auth-address><titles><title><style face="normal" font="default">Is a positive intracutaneous test induced by penicillin mediated by histamine? A cutaneous microdialysis study in penicillin-allergic patients</style></title><secondary-title><style face="normal" font="default">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Transl Allergy</style></full-title></periodical><pages end="" start="40">40-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Diagnostic workup of penicillin allergy comprises skin testing with penicillins, and patients are deemed allergic if skin test is positive. However, the literature suggests that skin test-positive patients may be challenge-negative, indicating that the skin test may be falsely positive. Objective: To investigate real-time histamine release from a positive intracutaneous test induced by penicillin in patients with positive and negative challenges to penicillin. Methods: Skin microdialysis was performed in 21 penicillin-allergic patients with positive skin test, 13 non-allergic volunteers serving as negative controls, and 7 grass pollen-allergic patients serving as positive controls. Histamine was measured by microdialysis after skin test with penicillin/grass/NaCl. Penicillin challenge was subsequently performed in 12 of the patients. Results: Only 10/21 patients (47.6%) were skin test positive at microdialysis. During microdialysis 13 single intracutaneous tests were positive and histamine was detected in 4/13 occurring in four challenge positive patients. Thirteen/21 patients (61.9%) were deemed allergic to penicillin; eight had positive skin test. Two patients with positive skin test were challenge negative. In grass pollen allergic patients, 7/7 had a positive intracutaneous test to grass and all released histamine in the wheals. All 13 negative controls had negative intracutaneous test to penicillin and no histamine release. Conclusion: Histamine was only detected in the minority of positive intracutaneous tests with penicillin in penicillin-allergic patients. Other mediators may be involved</style></abstract><notes><style face="normal" font="default">IS - 2045-7022 (Print)IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1186/s13601-017-0179-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29177030">PM:29177030</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Tannert LK</style></custom2><misc3><style face="normal" font="default">10.1186/s13601-017-0179-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43294</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brandstetter,S.</style></author><author><style face="normal" font="default"> Finger,T.</style></author><author><style face="normal" font="default"> Fischer,W.</style></author><author><style face="normal" font="default"> Brandl,M.</style></author><author><style face="normal" font="default"> Bohmer,M.</style></author><author><style face="normal" font="default"> Pfeifer,M.</style></author><author><style face="normal" font="default"> Apfelbacher,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical Sociology, Institute of Epidemiology and Preventive Medicine, University of Regensburg, Dr.-Gessler-Str. 17, 93051 Regensburg, Germany.</style></auth-address><titles><title><style face="normal" font="default">Differences in medication adherence are associated with beliefs about medicines in asthma and COPD</style></title><secondary-title><style face="normal" font="default">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Transl Allergy</style></full-title></periodical><pages end="" start="39">39-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Adherence to medication is crucial for achieving treatment control in chronic obstructive lung diseases. This study refers to the "necessity-concerns framework" and examines the associations between beliefs about medicines and self-reported medication adherence in people with chronic obstructive lung disease. 402 patients (196 with asthma, 206 with COPD) participated in the study and completed a questionnaire comprising the "Beliefs about Medicines-Questionnaire" (BMQ) and the "Medication Adherence Report Scale" (MARS). Multivariable logistic regression analyses with the BMQ-subscales as explanatory and the dichotomized MARS-score as dependent variable were computed for the asthma and the COPD sample, respectively, and adjusted for potentially confounding variables. 19% of asthma patients and 34% of COPD patients were completely adherent to their prescribed medication. While specific beliefs about the necessity of medicines were positively associated with medication adherence both in patients with asthma and with COPD, general beliefs about harm and overuse of medicines by doctors were negatively associated with medication adherence only among patients with asthma. The findings of this study suggest that patients' specific beliefs about the necessity of medicines represent an important modifiable target for improving patient-doctor consultations when prescribing medicines</style></abstract><notes><style face="normal" font="default">IS - 2045-7022 (Print)IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1186/s13601-017-0175-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29152167">PM:29152167</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-39.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Brandstetter S</style></custom2><misc3><style face="normal" font="default">10.1186/s13601-017-0175-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43295</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Roslita,R.</style></author><author><style face="normal" font="default"> Nurhaeni,N.</style></author><author><style face="normal" font="default"> Wanda,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Faculty of Nursing , Universitas Indonesia, Jalan Bahder Djohan Campus , Depok , Indonesia</style></auth-address><titles><title><style face="normal" font="default">The Effects of Music Therapy on the Physiological Response of Asthmatic Children Receiving Inhalation Therapy</style></title><secondary-title><style face="normal" font="default">Compr Child Adolesc Nurs</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Compr Child Adolesc Nurs</style></abbr-1></periodical><pages end="51" start="45">45-51</pages><volume><style face="normal" font="default">40</style></volume><number><style face="normal" font="default">sup1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The clinical manifestation of asthma in children can interfere with their daily activities. Music therapy may become one of the alternative approaches to making children feel comfortable during inhalation therapy. The aim of the study was to identify the effects of music therapy on the physiological response of asthmatic preschool and school-age children receiving inhalation therapy. This study used a quasi-experimental, nonequivalent control group with a pre-test-post-test design. The 44 respondents consisted of preschool and school-age children assigned to intervention and control groups. The results showed a significant difference in average oxygen saturation, heart rate, and respiratory rate between the control and intervention groups before and after intervention (p &lt; alpha; alpha = .05). Music therapy can be used as a nursing intervention to improve the physiological response of children with breathing problems</style></abstract><notes><style face="normal" font="default">IS - 2469-4207 (Electronic)LA - engPT - Journal ArticleCO - Indonesia -</style></notes><work-type><style face="normal" font="default">10.1080/24694193.2017.1386970</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29166194">PM:29166194</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Compr Child Adolesc Nurs\2017-40S1-45-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Compr Child Adolesc Nurs\2017-40S1-45-51.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171202, Roslita R</style></custom2><misc3><style face="normal" font="default">10.1080/24694193.2017.1386970</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43296</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sato,M.</style></author><author><style face="normal" font="default"> Inomata,N.</style></author><author><style face="normal" font="default"> Aihara,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Yokohama City University School of Medicine, Yokohama 236-0004, Japan</style></auth-address><titles><title><style face="normal" font="default">A case of contact dermatitis syndrome caused by Dermabond(R), followed by contact dermatitis caused by false eyelash glue and Aron Alpha(R) glue: possibility of cross-reactions among cyanoacrylates</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="415" start="414">414-415</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12823</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29164689">PM:29164689</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-414-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-414-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171202, Sato M</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12823</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43297</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">De Fre,C.</style></author><author><style face="normal" font="default"> Bergendorff,O.</style></author><author><style face="normal" font="default"> Raison-Peyron,N.</style></author><author><style face="normal" font="default"> van de Voorde,K.</style></author><author><style face="normal" font="default"> Romaen,E.</style></author><author><style face="normal" font="default"> Lambert,J.</style></author><author><style face="normal" font="default"> Persson,C.</style></author><author><style face="normal" font="default"> Aerts,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Hospital Antwerp (UZA) and University of Antwerp (UA), 2650 Antwerp, Belgium</style></auth-address><titles><title><style face="normal" font="default">Acetophenone azine: a new shoe allergen causing severe foot dermatitis</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="417" start="416">416-417</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Sweden -CO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12843</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29164697">PM:29164697</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-416-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-416-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171202, De Fre C</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12843</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43298</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kosumi,H.</style></author><author><style face="normal" font="default"> Yanagi,T.</style></author><author><style face="normal" font="default"> Izumi,K.</style></author><author><style face="normal" font="default"> Ito,T.</style></author><author><style face="normal" font="default"> Shimizu,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan</style></auth-address><titles><title><style face="normal" font="default">Hair colour shampoo dermatitis</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="421" start="419">419-421</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12851</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29164693">PM:29164693</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-419-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-419-21.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171202, Kosumi H</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12851</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43299</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sakuragi,Y.</style></author><author><style face="normal" font="default"> Sawada,Y.</style></author><author><style face="normal" font="default"> Nakamura,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan</style></auth-address><titles><title><style face="normal" font="default">Leukoderma following allergic contact dermatitis caused by the silicone component silprene-30A/B in swimming goggles</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="419" start="418">418-419</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12850</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29164696">PM:29164696</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-418-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-418-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171202, Sakuragi Y</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12850</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43300</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gether,L.</style></author><author><style face="normal" font="default"> Gyldenlove,M.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Herlev-Gentofte Hospital, University of Copenhagen, 2900 Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Christmas tree dermatitis caused by colophonium allergy</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="414" start="412">412-414</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12798</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29164686">PM:29164686</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-412-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-412-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171202, Hether L</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12798</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43301</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shiratori,T.</style></author><author><style face="normal" font="default"> Sowa-Osako,J.</style></author><author><style face="normal" font="default"> Fukai,K.</style></author><author><style face="normal" font="default"> Tsuruta,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan</style></auth-address><titles><title><style face="normal" font="default">Severe stomatitis with a deep buccal ulcer associated with an allergic reaction to methyl methacrylate used for dental treatment</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="407" start="406">406-407</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12742</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29164690">PM:29164690</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-406-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-406-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171202, Shiratori T</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12742</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43302</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wilkinson,M.</style></author><author><style face="normal" font="default"> Orton,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds LS7 4SA, UKDermatology, Hillingdon Hospital, Uxbridge UB8 3NN, UK</style></auth-address><titles><title><style face="normal" font="default">Acrylate allergy: time to intervene</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="355" start="353">353-355</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - EditorialCO - United KIngdom -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12923</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29164701">PM:29164701</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-353-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-353-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171202, Wilkinson M</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12923</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43303</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dittmar,D.</style></author><author><style face="normal" font="default"> Dahlin,J.</style></author><author><style face="normal" font="default"> Persson,C.</style></author><author><style face="normal" font="default"> Schuttelaar,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Groningen, University Medical Centre Groningen, 9713 GZ Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by acrylic acid used in transcutaneous electrical nervous stimulation</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="412" start="409">409-412</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12796</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29164695">PM:29164695</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-409-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-409-12.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171202, Dittmar D</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12796</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43304</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shah,V.</style></author><author><style face="normal" font="default"> Chaubal,T.V.</style></author><author><style face="normal" font="default"> Bapat,R.A.</style></author><author><style face="normal" font="default"> Shetty,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Maxillofacial surgeon, 400103, Mumbai, IndiaDepartment of Periodontology and Oral Implantology, D. Y. Patil School of Dentistry, 400706, Navi Mumbai, Maharashtra, India</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by polymethylmethacrylate following intradermal filler injection</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="408" start="407">407-408</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - India -CO - Malaysia -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12779</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29164691">PM:29164691</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-407-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-407-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171202, Shah V</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12779</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43305</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Malmberg,P.</style></author><author><style face="normal" font="default"> Guttenberg,T.</style></author><author><style face="normal" font="default"> Ericson,M.B.</style></author><author><style face="normal" font="default"> Hagvall,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Chemistry and Chemical Engineering, Centre for Imaging Mass Spectrometry, Chalmers University of Technology, 412 96, Gothenburg, Sweden</style></auth-address><titles><title><style face="normal" font="default">Imaging mass spectrometry for novel insights into contact allergy - a proof-of-concept study on nickel</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="11" Year="2017">2017/11/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: In spite of extensive regulation to limit exposure, nickel remains the main cause of contact allergy in the general population. More detailed knowledge on the skin uptake of haptens is required. So far, no method exists for the visualization of clinically relevant haptens and their distribution in the skin. OBJECTIVES: To show, in terms of a proof of concept, that imaging mass spectrometry [time of flight secondary ion mass spectrometry (ToF-SIMS)] can be applied for investigation of the penetration and distribution of nickel in human skin. METHOD: Full-thickness human skin obtained from breast reduction surgery was exposed to nickel sulfate (5% in deionized water) for 24 h in Franz-type diffusion cells. Biopsies were obtained from nickel-treated samples and control (deionized water). The tissue was sliced, and analysed with ToF-SIMS, generating high-resolution images of ion distribution in the epidermis and upper dermis. RESULTS: The skin layers could be discerned from the ToF-SIMS data, particularly on the basis of the collagen signal. Nickel ions were localized to the stratum corneum and upper epidermis. CONCLUSIONS: This is the first time that ToF-SIMS has been applied to trace the distribution of a hapten in human skin. Proof of principle was shown for nickel, and the technique can, in the future, be expanded for investigation of the skin distribution of clinically relevant sensitizers in general</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12911</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29168189">PM:29168189</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20171205-MalmbergP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20171205-MalmbergP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171205, Malmberg P</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12911</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43306</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Li,Z.</style></author><author><style face="normal" font="default"> Hu,L.</style></author><author><style face="normal" font="default"> Elias,P.M.</style></author><author><style face="normal" font="default"> Man,M.Q.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, China</style></auth-address><titles><title><style face="normal" font="default">Skin care products can aggravate epidermal function: studies in a murine model suggest a pathogenic role in sensitive skin</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="11" Year="2017">2017/11/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: Sensitive skin is defined as a spectrum of unpleasant sensations in response to a variety of stimuli. However, only some skin care products provoke cutaneous symptoms in individuals with sensitive skin. Hence, it would be useful to identify products that could provoke cutaneous symptoms in individuals with sensitive skin. OBJECTIVE: To assess whether vehicles, as well as certain branded skin care products, can alter epidermal function following topical applications to normal mouse skin. METHODS: Following topical applications of individual vehicle or skin care product to C57BL/6J mice twice daily for 4 days, transepidermal water loss (TEWL) rates, stratum corneum (SC) hydration and skin surface pH were measured on treated versus untreated mouse skin with an MPA5 device and pH 900 pH meter. RESULTS: Our results show that all tested products induced abnormalities in epidermal functions of varying severity, including elevations in TEWL and skin surface pH, and reduced SC hydration. CONCLUSIONS: Our results suggest that mice can serve as a predictive model that could be used to evaluate the potential safety of skin care products in humans with sensitive skin</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12909</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29152821">PM:29152821</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20171205-LiZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20171205-LiZ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171205, Li Z</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12909</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43307</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ko,L.N.</style></author><author><style face="normal" font="default"> Kroshinsky,D.</style></author><author><style face="normal" font="default"> Schalock,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Harvard Medical School, Boston, MA 02115, USA</style></auth-address><titles><title><style face="normal" font="default">Assessing the validity of self-reported history of rash caused by metal or jewellery</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="11" Year="2017">2017/11/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: The use of metal-containing bio-devices is becoming increasingly common. Self-reported history of dermatitis with metal exposure is not established as being predictive for metal allergy. OBJECTIVES: To assess the validity of two screening questions addressing metal allergy. METHODS: At Massachusetts General Hospital Contact Dermatitis Clinic, 2132 consecutive patients were asked either 'Do you get rashes when jewellery touches your skin' (Q1; N = 1816) or 'Do you get rashes when metal touches your skin?' (Q2; N = 316) before being patch tested. RESULTS: Testing showed that 20% of subjects had positive reactions to nickel, 7.4% had positive reactions to cobalt, and 5.8% had positive reactions to chromium. Q1 was 40% sensitive (95%CI: 35-45%). The positive predictive value (PPV) was 51%, and the negative predictive value (NPV) was 82%. Q2 was 77% sensitive (95%CI: 68-84%). The PPV was 71%, and the NPV was 84%. Q2 was 37% more sensitive than Q1 (p &lt; 0.0001), with a higher relative risk (RR) (4.75, p &lt; 0.001) than Q1 (RR = 3.01, p &lt; 0.001). CONCLUSIONS: Patient-reported metal allergy, although not perfect, is a reasonable method for metal allergy screening to help identify those needing further objective evaluation by patch testing</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12928</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29178264">PM:29178264</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20171205-KoLN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20171205-KoLN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171205, Ko LN</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12928</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43308</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Paulsen,E.</style></author><author><style face="normal" font="default"> Andersen,K.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy Centre, Odense University Hospital, University of Southern Denmark, 5000, Odense C, Denmark</style></auth-address><titles><title><style face="normal" font="default">Clinical patterns of Compositae dermatitis in Danish monosensitized patients</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="11" Year="2017">2017/11/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Compositae dermatitis was originally described as airborne contact dermatitis. More recent studies have reported a wider clinical spectrum, but often in polysensitized patients. OBJECTIVE: To evaluate the clinical features of patients sensitized to Compositae only. PATIENTS/METHODS: Consecutive Compositae-sensitive eczema patients, tested between 1990 and 2015, who, at the patch testing session diagnosing their Compositae allergy, were found to be sensitized only to the plant family, were included. RESULTS: Altogether, 529 of 13 139 patients tested (4.0%) were sensitized to Compositae, and 95 (18% of these) were monosensitized. The majority had hand eczema, and 39 (44%) had a vesicular volar pattern. Eighty-one patients were classified into one of three groups of similar size: localized eczema, eczema of exposed skin, and localized eczema turning into widespread eczema. CONCLUSIONS: The prevalence of Compositae sensitization is continuously high in consecutive eczema patients. Sensitization may occur at any age. Clinical features in monosensitized patients vary, but, with continuing exposure, the patients may develop more widespread dermatitis similar to classic Compositae dermatitis. Avoidance may clear the exogenous part, but not endogenous aetiological factors such as vesicular hand eczema or possible photosensitivity. Thorough clinical assessment and patient education are important in reducing the impact of Compositae contact allergy</style></abstract><notes><style face="normal" font="default">DA - 20171117IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12916</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29148057">PM:29148057</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20171205-PaulsenE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20171205-PaulsenE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171205, Paulsen E</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12916</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43309</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wilkinson,M.</style></author><author><style face="normal" font="default"> Gallo,R.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author><author><style face="normal" font="default"> Rustemeyer,T.</style></author><author><style face="normal" font="default"> Sanchez-Perez,J.</style></author><author><style face="normal" font="default"> Schuttelaar,M.L.</style></author><author><style face="normal" font="default"> Uter,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Leeds Teaching Hospitals NHS Trust, Leeds, LS7 4SA, UK</style></auth-address><titles><title><style face="normal" font="default">A proposal to create an extension to the European baseline series</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="12" Year="2017">2017/12/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: The current European baseline series consists of 30 allergens, and was last updated in 2015. OBJECTIVES: To use data from the European Surveillance System on Contact Allergies (ESSCA) to propose an extension to the European baseline series in response to changes in environmental exposures. METHODS: Data from departmental and national extensions to the baseline series, together with some temporary additions from departments contributing to the ESSCA, were collated during 2013-2014. RESULTS: In total, 31689 patients were patch tested in 46 European departments. Many departments and national groups already consider the current European baseline series to be a suboptimal screen, and use their own extensions to it. The haptens tested are heterogeneous, although there are some consistent themes. Potential haptens to include in an extension to the European baseline series include: sodium metabisulfite, formaldehyde-releasing preservatives, additional markers of fragrance allergy, propolis, Compositae mix, and 2-hydroxyethyl methacrylate. CONCLUSION: In combination with other published work from the ESSCA, changes to the current European baseline series are proposed for discussion. As well as addition of the allergens listed above, it is suggested that primin and clioquinol should be deleted from the series, owing to reduced environmental exposure</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Italy -CO - Belgium -CO - Denmark -CO - Netherlands -CO - Spain -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12918</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29194657">PM:29194657</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20171205-WIlkinsonM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20171205-WIlkinsonM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171205, Wilkinson M</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12918</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43310</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ozkaya,E.</style></author><author><style face="normal" font="default"> Kilic,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Venereology, Istanbul University, Istanbul Medical Faculty, 34093, Capa-Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="default">Polyethylene glycol as marker for nitrofurazone allergy: 20 years of experience from Turkey</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="28" Month="11" Year="2017">2017/11/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: Polyethylene glycols (PEGs) and propylene glycol (PG) are used as vehicles in various medicinal and cosmetic products. They are potential contact sensitizers, including low molecular weight PEGs in nitrofurazone preparations that are still widely used in Turkey. OBJECTIVES: To investigate the prevalence of allergic contact dermatitis caused by PEG and PG in a relatively large group of patients in Turkey. METHODS: In this retrospective, cross-sectional, single-centre study, 836 patients patch tested with PEG and PG between 1996 and 2015 were reviewed. RESULTS: Thirty-five patients (4.2%) showed positive patch test reactions to PEG, and 7 (0.8%) showed positive patch test reactions to PG, partly as late positive reactions with PEG. PEG sensitivity was almost exclusively related to nitrofurazone allergy. Patch test reactions to PG were currently relevant mainly with regard to the use of minoxidil, and antiherpetic or corticosteroid creams. Ten patients (25%) had concomitant contact allergies to various topical drugs containing mainly PEGs. CONCLUSIONS: PEG sensitivity seems to be a marker for contact allergy to topical nitrofurazone in Turkey. Nitrofurazone allergy appears to favour concomitant sensitization to PEG. We would suggest the inclusion of PEG in an extended baseline patch test series in Turkey. Late patch test readings are important to diagnose delayed positive reactions to PEG</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12931</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29193145">PM:29193145</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20171205-OzkayaE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20171205-OzkayaE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171205, Ozkaya E</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12931</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43311</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jaque,A.</style></author><author><style face="normal" font="default"> DeKoven,J.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Center, University of Toronto, Toronto M4N 3M5, CanadaDivision of Dermatology, Department of Medicine, Sunnybrook Health Sciences Center, University of Toronto, Toronto M4N 3M5, Canada</style></auth-address><titles><title><style face="normal" font="default">Polyhexamethylene biguanide and alkyl glucosides: unexpected allergens in an antimicrobial foam dressing</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="422" start="421">421-422</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12852</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29164688">PM:29164688</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-421-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-421-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171202, Jaque A</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12852</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43312</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Badaoui,A.</style></author><author><style face="normal" font="default"> Pecquet,C.</style></author><author><style face="normal" font="default"> Fargeas,C.</style></author><author><style face="normal" font="default"> Mahe,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Centre Hospitalier Victory Dupouy, 95100 Argenteuil, FranceDepartment of Dermatology and Allergology, Hopital Tenon, HUEP, APHP, 75020 Paris, FranceDepartment of Dermatology, Centre Hospitalier Victory Dupouy, 95100 Argenteuil, FranceDepartment of Dermatology, Centre Hospitalier Victory Dupouy, 95100 Argenteuil, France</style></auth-address><titles><title><style face="normal" font="default">Contact dermatitis caused by Geranium robertianum with erythema multiforme-like reaction</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="424" start="423">423-424</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12854</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29164698">PM:29164698</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-423-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-423-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171202, Badaoui A</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12854</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43313</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Peeters,C.</style></author><author><style face="normal" font="default"> Herman,A.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author><author><style face="normal" font="default"> Bruze,M.</style></author><author><style face="normal" font="default"> Mowitz,M.</style></author><author><style face="normal" font="default"> Baeck,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Cliniques Universitaires Saint-Luc &amp; Pole Pneumologie, ORL et Dermatologie Institut de Recherche Experimentale et Clinique (IREC), Universite Catholique de Louvain, 1200 Brussels, Belgium</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by 2-ethyl cyanoacrylate contained in glucose sensor sets in two diabetic adults</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="429" start="426">426-429</pages><volume><style face="normal" font="default">77</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12873</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29164694">PM:29164694</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-426-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\2017-77-426-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171202, Peeters C</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12873</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43314</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Elsner,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Hospital Jena, 07743, Jena, Germany</style></auth-address><titles><title><style face="normal" font="default">Classification of consumer products under the EU CLP Regulation: what to consider when caring for contact dermatitis patients</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="11" Year="2017">2017/11/17</year></dates><abstract><style face="normal" font="default">Possibly hazardous chemical substances and mixtures need to be clearly and correctly classified and labelled, in order for their hazards to be properly identified and communicated. As dermatologists may encounter cases of harm to patients induced by chemicals, such as chemical burns, and irritant and allergic contact dermatitis, it is essential for them to be aware of the EU CLP Regulation and its potential pitfalls. Manufacturers are required by CLP to classify their products according to the rules given in the CLP Regulation. The enforcement duty lies with the Member States and their competent authorities. Dangerous non-food consumer products have to be reported to the European Commission to be entered into the Rapid Alert System for Dangerous Non-food Products (RAPEX) notifications. The sheer complexity of the CLP Regulation and lack of awareness of its ramifications by companies, competent authorities, consumer associations and the public at large may prevent efficient enforcement actions. When dermatologists become aware of inappropriately labelled chemicals, they should inform the competent authorities</style></abstract><notes><style face="normal" font="default">DA - 20171117IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12915</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29148058">PM:29148058</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20171205-ElsnerP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20171205-ElsnerP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171205, Elsner P</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12915</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43315</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dittmar,D.</style></author><author><style face="normal" font="default"> Ofenloch,R.F.</style></author><author><style face="normal" font="default"> Schuttelaar,M.L.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Medical Centre Groningen, University of Groningen, 9700 RB, Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Persistence of contact allergy: a retrospective analysis</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="11" Year="2017">2017/11/27</year></dates><abstract><style face="normal" font="default">BACKGROUND: Studies have shown that not all positive patch test reactions are reproducible upon retesting, that is, persistent. Non-persistent reactions might represent initial false-positive reactions, meaning that patients might unnecessarily avoid allergens. OBJECTIVES: To investigate the occurrence of both persistent and non-persistent patch test reactions, to explore possible explanations, and to investigate whether allergen-specific differences exist. METHODS: A retrospective analysis was performed on patients who were patch tested at least twice between 1 January 1995 and 31 October 2016, with at least one positive patch test reaction to an allergen that had been retested. Both univariable and multivariable analyses were performed to investigate the influence of several factors on persistence. RESULTS: Of 274 retested positive reactions in 119 patients, 183 (66.8%) reactions remained positive. The strongest predictor for non-persistence in both univariable and multivariable analyses was strength of the first patch test, with weak positive reactions being significantly less persistent. Regarding allergen groups, metals and fragrances were less persistent than other allergens. CONCLUSION: Weak positive reactions have a low persistence rate, and the dermatologist should be conservative in advising the patient on avoidance of these allergens, especially if clinical relevance is uncertain</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12912</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29178341">PM:29178341</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20171205-DittmarD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20171205-DittmarD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171205, Dittmar D</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12912</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43316</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jeong,J.S.</style></author><author><style face="normal" font="default"> Kim,S.R.</style></author><author><style face="normal" font="default"> Cho,S.H.</style></author><author><style face="normal" font="default"> Lee,Y.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Research Center for Pulmonary Disorders, Chonbuk National University Medical School, san 2-20, Geumam-dong, Deokjin-gu, Jeonju, 561-180, South Korea</style></auth-address><titles><title><style face="normal" font="default">Endoplasmic Reticulum Stress and Allergic Diseases</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="82">82-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="11" Year="2017">2017/11/8</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: In this review, we will integrate recent knowledge on endoplasmic reticulum (ER) stress and allergy, thereby highlighting the therapeutic potential of ER stress in the context of precision medicine for allergic diseases. RECENT FINDINGS: Emerging evidence suggests that allergic diseases are very heterogeneous having numerous endotypes. This leads to the new era of modern medicine, which assumes that a particular endotype-driven therapy, called precision medicine, would be more efficacious in a specific group of patients rather than in all patients. Currently, a dichotomy involving type 2/non-type 2 immune response underlies most of the studies on inflammatory and immunologic mechanisms of allergic disorders. Whereas there are several approved or investigational endotype-driven therapeutic agents targeting type 2 immune responses, investigation of mechanisms and endotype-driven interventions regarding non-type 2 immune response lags far behind. Considering that non-type 2 immune response may represent a significant proportion of allergic disease, particularly corticosteroid-resistant severe disease, defining a novel concept of endotype-driven approach may be essential. Recently, stress responses originate from the endoplasmic reticulum (ER) and the associated inflammatory molecular platform has been suggested as a crucial player of immune and inflammatory responses. This implies that ER stress-related pathways may represent a new endotype-driven therapeutic strategy in the treatment of allergic diseases</style></abstract><notes><style face="normal" font="default">DA - 20171109IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - South Korea -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0751-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29119328">PM:29119328</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-82.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171109, Jeong JS</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0751-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43317</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bao,Y.</style></author><author><style face="normal" font="default"> Chen,Z.</style></author><author><style face="normal" font="default"> Liu,E.</style></author><author><style face="normal" font="default"> Xiang,L.</style></author><author><style face="normal" font="default"> Zhao,D.</style></author><author><style face="normal" font="default"> Hong,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Children's Medical Center, Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.</style></auth-address><titles><title><style face="normal" font="default">Risk Factors in Preschool Children for Predicting Asthma During the Preschool Age and the Early School Age: a Systematic Review and Meta-Analysis</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="85">85-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="11" Year="2017">2017/11/18</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: The aim of this study was to identify risk factors of asthma among children &lt; 6 years old (preschool age) for predicting asthma during the preschool age and early school age (&lt;/= 10 years of age). METHOD OF THE STUDY: MEDLINE, Cochrane, EMBASE, and Google Scholar databases were searched until June 30, 2017. Prospective or retrospective cohort and case-control studies were included. Studies had to have evaluated risk factors or a predictive model for developing asthma in children &lt;/= 6 years of age or persistent asthma in early school age. RECENT FINDINGS: A total of 17 studies were included in the analysis. Factors associated with developing asthma in children &lt;/= 10 years of age (both pre-school and early school age) included male gender (pooled OR = 1.70, P &lt; 0.001), atopic dermatitis (pooled OR = 2.02, P &lt; 0.001), a family history of asthma (pooled OR = 2.20, P &lt; 0.001), and serum IgE levels >/= 60 kU/l or having specific IgE (pooled OR = 2.36, P &lt; 0.001). A history of exposure to smoke or wheezing was also associated with persistent asthma in early school age (pooled OR = 1.51, P = 0.030 and pooled OR = 2.59, P &lt; 0.001, respectively). In general, asthma predictive models (e.g., API, PIAMA, PAPS) had relatively low sensitivity (range, 21% to 71.4%) but high specificity (range, 69% to 98%). The study found that male gender, exposure to smoke, atopic dermatitis, family history of asthma, history of wheezing, and serum IgE level >/= 60 kU/l or having specific IgE were significantly associated with developing asthma by either preschool or early school age. Asthma predictive models can be developed by those risk factors</style></abstract><notes><style face="normal" font="default">IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - China -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0753-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29151195">PM:29151195</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-85.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-85.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171207, Bao Y</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0753-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43318</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Esser,P.R.</style></author><author><style face="normal" font="default"> Martin,S.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Research Group, Department of Dermatology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Hauptstrasse 7, 79104, Freiburg im Breisgau, Germany.</style></auth-address><titles><title><style face="normal" font="default">Pathomechanisms of Contact Sensitization</style></title><secondary-title><style face="normal" font="default">Curr Allergy Asthma Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Asthma Rep</style></full-title></periodical><pages end="" start="83">83-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="11" Year="2017">2017/11/11</year></dates><abstract><style face="normal" font="default">Contact sensitization is the initial process involved in the development of an allergic reaction to xenobiotic environmental substances. Here, we briefly describe the differences between irritant and allergic contact dermatitis. Then, we highlight the essential steps involved in the development of an ACD reaction, i.e., the protein binding of haptens, genetic factors influencing the penetration of sensitizers into the skin, the different mechanisms driving the initial development of an inflammatory cytokine micromilieu enabling the full maturation of dendritic cells, the role of pre- and pro-haptens, antigen presentation and T cell activation via MHC and CD1 molecules, dendritic cell (DC) migration, and potential LC contribution as well as the different T cell subsets involved in ACD. In addition, we discuss the latest publications regarding factors that might influence the sensitizing potential such as repeated sensitizer application, penetration enhancers, humidity of the skin, microbiota, Tregs, and phthalates. Last but not least, we briefly touch upon novel targets for drug development that might serve as treatment options for ACD</style></abstract><notes><style face="normal" font="default">DA - 20171112IS - 1534-6315 (Electronic)IS - 1529-7322 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1007/s11882-017-0752-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29129023">PM:29129023</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Allergy Asthma Rep\2017-17-83.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171112, Esser PR</style></custom2><misc3><style face="normal" font="default">10.1007/s11882-017-0752-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43319</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Espinosa,E.</style></author><author><style face="normal" font="default"> Valitutti,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre de Physiopathologie de Toulouse Purpan (CPTP), Universite de Toulouse, CNRS, INSERM, UPS, France.</style></auth-address><titles><title><style face="normal" font="default">New roles and controls of mast cells</style></title><secondary-title><style face="normal" font="default">Curr Opin Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Opin Immunol</style></abbr-1></periodical><pages end="47" start="39">39-47</pages><volume><style face="normal" font="default">50</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="11" Year="2017">2017/11/13</year></dates><abstract><style face="normal" font="default">Mast cells are innate immune cells implicated in immune surveillance and defense. They are filled with secretory granules where a vast array of molecules endowed with multiple biological activities are stored. The process of granule secretion, named degranulation, is a tightly controlled biological phenomenon that allows mast cells to rapidly and efficiently release bioactive mediators in response to extracellular stimuli. MC degranulation allows fighting pathogens, limiting envenomation and contributes to tissue homeostasis. However, it is also a potentially harmful response that plays a key role in the development of allergy and inflammatory diseases. Recent findings revealed that MC degranulation is a complex modular process that can be controlled at multiple levels. First, mast cells can decode different activation stimuli into two main patterns of degranulation that differently impact inflammatory responses. Second, mast cells in contact with antibody-opsonized cells or parasites form antibody-dependent degranulatory synapse for dedicated secretion and defense. Third, IL-33 fine-tunes FcR-mediated degranulation at the single cell level. Together these recent findings show how mast cells adapt their degranulation responses to environmental cues and highlight the remarkable functional plasticity of these cells</style></abstract><notes><style face="normal" font="default">DA - 20171117IS - 1879-0372 (Electronic)IS - 0952-7915 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.coi.2017.10.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29144996">PM:29144996</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Opin Immunol\2017-50-39-47.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Opin Immunol\2017-50-39-47.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171117, Espinosa E</style></custom2><misc3><style face="normal" font="default">10.1016/j.coi.2017.10.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43320</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Licari,A.</style></author><author><style face="normal" font="default"> Castagnoli,R.</style></author><author><style face="normal" font="default"> Denicolo,C.</style></author><author><style face="normal" font="default"> Rossini,L.</style></author><author><style face="normal" font="default"> Seminara,M.</style></author><author><style face="normal" font="default"> Sacchi,L.</style></author><author><style face="normal" font="default"> Testa,G.</style></author><author><style face="normal" font="default"> De Amici,M.</style></author><author><style face="normal" font="default"> Marseglia,G.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy</style></auth-address><titles><title><style face="normal" font="default">Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience</style></title><secondary-title><style face="normal" font="default">Curr Respir Med Rev</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Respir Med Rev</style></abbr-1></periodical><pages end="42" start="36">36-42</pages><volume><style face="normal" font="default">13</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="3" Year="2017">2017/3</year></dates><abstract><style face="normal" font="default">Background: Anti-IgE treatment represents a major breakthrough in the therapeutic management of severe allergic asthma. To date, omalizumab is the only biological drug currently licensed as add-on therapy in children aged > 6 years with moderate-to-severe and severe allergic asthma uncontrolled after treatment with high dose of inhaled corticosteroids plus long-acting inhaled beta2-agonist. The clinical efficacy and safety of omalizumab treatment in the pediatric population has been extensively documented in specific trials and consistently expanded from real-life studies. Our aim is to describe the impact of omalizumab on asthma management, by reporting the results of the first Italian multicenter observational study conducted in children and adolescents with severe allergic asthma. Methods: The study was a 1-year real-life multicenter survey conducted in 13 pediatric allergy and pulmonology tertiary centers in Italy. All patients with confirmed severe allergic asthma from whom Omalizumab add-on treatment was initiated between 2007 and 2015 were included in the study. Results: Forty-seven patients with severe allergic asthma were included in the study. A significant reduction in the number of asthma exacerbations was observed during treatment with omalizumab, when compared with the previous year (1.03 vs 7.2 after 6 months (p&lt;0.001) and 0.8 after 12 months (p&lt;0.001), respectively). Hospital admissions were reduced by 96%. At 12 months, forced expiratory volume in 1 s improved and a corticosteroid sparing effect was observed.No serious adverse events were reported during the follow-up period of 12 months. Conclusion: The results of the first Italian multicenter observational study confirmed that omalizumab is an effective and safe add-on therapy in uncontrolled severe allergic asthma in children</style></abstract><notes><style face="normal" font="default">IS - 1573-398X (Print)IS - 1573-398X (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.2174/1573398X13666170426094536</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29213221">PM:29213221</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Curr Respir Med Rev\2017-13-36-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Curr Respir Med Rev\2017-13-36-42.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171129, Licari A</style></custom2><misc3><style face="normal" font="default">10.2174/1573398X13666170426094536</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43321</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ahsan,A.</style></author><author><style face="normal" font="default"> Ashley,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hypersensitivity to Dental Composites and Resin-Bonding Agents</style></title><secondary-title><style face="normal" font="default">Dent Update</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dent Update</style></full-title></periodical><pages end="842" start="836">836-842</pages><volume><style face="normal" font="default">43</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2016">2016/11</year></dates><abstract><style face="normal" font="default">Adverse reactions to dental materials are not an uncommon occurrence, although hypersensitivity has gained much renewed interest in light of public concerns over the safety of dental materials. Hypersensitivity can affect both patients and dental professionals and may manifest as either allergic contact dermatitis or stomatitis. Methacrylic monomers, such as MMA, EGDMA, TEGDMA and Bis-GMA, have been documented as causative allergens, however, little has been documented on the risk of such monomers in composites and bonding agents. The purpose of this article is to examine the current evidence and aspects of hypersensitivity to resin composites and bonding systems that are relevant within a dental setting. Clinical relevance: In the dental profession, dental materials have historically been documented as a cause of hypersensitivity. However, there remains little recent evidence on such reactions. The aims of this article are to highlight both the risk of hypersensitivity to dental composites and resin-bonding agents and the importance of reporting adverse reactions appropriately</style></abstract><notes><style face="normal" font="default">IS - 0305-5000 (Print)IS - 0305-5000 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29152954">PM:29152954</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dent Update\2016-43-836-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dent Update\2016-43-836-42.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20160821, Ahsan A</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43322</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Warshaw,E.M.</style></author><author><style face="normal" font="default"> Aschenbeck,K.A.</style></author><author><style face="normal" font="default"> DeKoven,J.G.</style></author><author><style face="normal" font="default"> Maibach,H.I.</style></author><author><style face="normal" font="default"> Taylor,J.S.</style></author><author><style face="normal" font="default"> Sasseville,D.</style></author><author><style face="normal" font="default"> Belsito,D.V.</style></author><author><style face="normal" font="default"> Fowler,J.F.,Jr.</style></author><author><style face="normal" font="default"> Zug,K.A.</style></author><author><style face="normal" font="default"> Zirwas,M.J.</style></author><author><style face="normal" font="default"> Fransway,A.F.</style></author><author><style face="normal" font="default"> Deleo,V.A.</style></author><author><style face="normal" font="default"> Marks,J.G.,Jr.</style></author><author><style face="normal" font="default"> Pratt,M.D.</style></author><author><style face="normal" font="default"> Mathias,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Department of Dermatology, Minneapolis Veterans Affairs Medical Center, MN</style></auth-address><titles><title><style face="normal" font="default">Piercing and Metal Sensitivity: Extended Analysis of the North American Contact Dermatitis Group Data, 2007-2014</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="341" start="333">333-341</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Body piercing provides a unique route of metal exposure. OBJECTIVE: The aim of this study was to update previous analyses using the North American Contact Dermatitis Group data comparing pierced and unpierced individuals. METHODS: This was a retrospective cross-sectional analysis of 17,912 patients patch tested by the North American Contact Dermatitis Group from 2007 to 2014 for demographics, positive reactions to metals (nickel, cobalt, chromium), and detailed analysis of nickel reactions by age, sex, and source of exposure. RESULTS: Piercing was significantly associated with female sex, being older than 18 years, and atopy (P &lt; 0.003). Nickel sensitivity was associated with 1 or more piercing for men and women combined (P &lt; 0.0001; relative risk [RR], 2.54; 95% confidence interval [CI], 2.35-2.75), although this association was stronger for men (RR, 2.21; 95% CI, 1.77-2.76) than women (RR, 1.47; 95% CI, 1.31-1.65). The frequency of positivity to nickel increased with number of piercings (14.3% for 1 piercing to 34.0% with >/=5 piercings). Piercing was not significantly associated with cobalt sensitivity alone (P = 0.8992) and was negatively associated with chromium sensitivity (P &lt; 0.0001). Jewelry was the most common source of allergic reactions to nickel irrespective of sex or pierced status. CONCLUSIONS: Nickel sensitivity was significantly associated with piercing in both men and women. Jewelry was the most common source</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000324</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29135681">PM:29135681</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-333-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-333-41.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171114, Warshaw EM</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000324</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43323</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yang,Y.W.</style></author><author><style face="normal" font="default"> Costello,C.M.</style></author><author><style face="normal" font="default"> Mangold,A.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Mayo Clinic, Scottsdale, AZ</style></auth-address><titles><title><style face="normal" font="default">Dermoscopic Findings of Irritant "Poral" Reactions to Cobalt During Patch Testing</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="" start="367">367-</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171023IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000322</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29059096">PM:29059096</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-367.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-367.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171023, Yang YW</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000322</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43324</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lampel,H.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Cary Dermatology Center, NC</style></auth-address><titles><title><style face="normal" font="default">Tan in a Can: Proceed With Patch Testing</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="" start="363">363-</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171023IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000313</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29059093">PM:29059093</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-363.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-363.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171023, Lampel HP</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000313</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43325</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">de Groot,A.</style></author><author><style face="normal" font="default"> Jagtman,B.A.</style></author><author><style face="normal" font="default"> Woutersen,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the *Acdegroot Publishing, Wapserveen; daggerVieCurie Medisch Centrum, Venlo; and double daggerNational Institute for Public Health and the Environment Centre for Safety of Substances and Products, Bilthoven, the Netherlands</style></auth-address><titles><title><style face="normal" font="default">Contact Allergy to Neem Oil</style></title><secondary-title><style face="normal" font="default">Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatitis</style></full-title></periodical><pages end="362" start="360">360-362</pages><volume><style face="normal" font="default">28</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">A case of allergic contact dermatitis from neem oil is presented. Neem oil (synonyms: Melia azadirachta seed oil [INCI name], nim oil, margosa oil) is a vegetable (fixed) oil obtained from the seed of the neem tree Azadirachta indica by cold pressing. Contact allergy to neem oil has been described previously in only 3 patients. The allergen(s) is/are unknown</style></abstract><notes><style face="normal" font="default">DA - 20171023IS - 2162-5220 (Electronic)IS - 1710-3568 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1097/DER.0000000000000309</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29059091">PM:29059091</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatitis\2017-28-360-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatitis\2017-28-360-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171023, de Groot A</style></custom2><misc3><style face="normal" font="default">10.1097/DER.0000000000000309</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43326</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chaturvedi,R.</style></author><author><style face="normal" font="default"> Kolhe,A.</style></author><author><style face="normal" font="default"> Pardeshi,K.</style></author><author><style face="normal" font="default"> Naik,L.</style></author><author><style face="normal" font="default"> Wanjare,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pathology, Seth G.S.M.C &amp; K.E.M.H, Mumbai, Maharashtra, IndiaDepartment of Pathology, Seth G.S.M.C &amp; K.E.M.H, Mumbai, Maharashtra, IndiaDepartment of Pathology, Seth G.S.M.C &amp; K.E.M.H, Mumbai, Maharashtra, IndiaDepartment of Pathology, Seth G.S.M.C &amp; K.E.M.H, Mumbai, Maharashtra, IndiaDepartment of Pathology, Seth G.S.M.C &amp; K.E.M.H, Mumbai, Maharashtra, India</style></auth-address><titles><title><style face="normal" font="default">Primary cutaneous aspergillosis, mimicking malignancy, a rare presentation in an immunocompetent patient</style></title><secondary-title><style face="normal" font="default">Diagn Cytopathol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Diagn Cytopathol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="11" Year="2017">2017/11/30</year></dates><abstract><style face="normal" font="default">Aspergillus species are ubiquitous opportunistic molds that cause both allergic and invasive syndromes. A 65-year-old female, farmer by occupation, presented with left upper limb and trunk swelling for one year, associated with pain, tightening of skin, and vesicles with watery discharge. Local examination showed a diffuse swelling extending from left arm to forearm and lateral chest wall associated with edema, induration, and raised temperature. The swelling was firm to hard with superficial skin ulcers and black eschar. Hematological investigations of the patient showed raised total WBC count and peripheral blood eosinophilia. Patient had no history suggesting immunosuppression. Clinico-radiological impression was left breast carcinoma with secondary skin involvement. fine-needle aspiration cytology (FNAC) from the swelling showed inflammatory cells, necrosis, epitheloid cell granulomas, and giant cells along with branching hyphae of variable thickness, confirmed on Gomori Methenamine Silver stain as fungal hyphae. Culture was advised which identified the species as Aspergillius fumigatus. Primary cutaneous infection by A. fumigatus in an immunocompetent patient is unheard of. FNAC has an important role in resolving diagnostic dilemma in primary cutaneous aspergillosis, which may mimic malignancy as in our case</style></abstract><notes><style face="normal" font="default">IS - 1097-0339 (Electronic)IS - 1097-0339 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.1002/dc.23869</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29193804">PM:29193804</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Diagn Cytopathol\20171021-ChaturvediR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Diagn Cytopathol\20171021-ChaturvediR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171021, Chaturvedi R</style></custom2><misc3><style face="normal" font="default">10.1002/dc.23869</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43327</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Siddique,M.I.</style></author><author><style face="normal" font="default"> Katas,H.</style></author><author><style face="normal" font="default"> Jamil,A.</style></author><author><style face="normal" font="default"> Mohd Amin,M.C.I.</style></author><author><style face="normal" font="default"> Ng,S.F.</style></author><author><style face="normal" font="default"> Zulfakar,M.H.</style></author><author><style face="normal" font="default"> Nadeem,S.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centre for Drug Delivery Research, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300, Kuala Lumpur, Malaysia</style></auth-address><titles><title><style face="normal" font="default">Potential treatment of atopic dermatitis: tolerability and safety of cream containing nanoparticles loaded with hydrocortisone and hydroxytyrosol in human subjects</style></title><secondary-title><style face="normal" font="default">Drug Deliv Transl Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Drug Deliv Transl Res</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="11" Year="2017">2017/11/20</year></dates><abstract><style face="normal" font="default">Hydrocortisone (HC), topical glucocorticoid along with hydroxytyrosol (HT), and anti-microbial- and anti-oxidant-loaded chitosan nanoparticles (CSNPs) were prepared in large scale and analyzed for their adverse effects on healthy human skin followed by repeated applications. Ten subjects were randomized to receive test (HC-HT CSNPs) and vehicle samples (aqueous (AQ) cream). They were applied on the arms for 28 days, and transepidermal water loss (TEWL), erythema intensity, and irritation score were measured. Blood samples were analyzed for blood hematology, blood biochemistry, and adrenal cortico-thyroid hormone (ACTH) levels. Skin biopsy was obtained to assess histopathological changes in the skin. HC-HT CSNP AQ cream was stored at 4, 25, and 45 degrees C for a period of 1 year, and its stability was assessed by monitoring their physical appearances, particle size, and pH. Spherical-shaped NPs were successfully upscaled using spinning-disc technology, with insignificant changes in particle size, zeta potential, and incorporation of drugs as compared to the well-established laboratory method. Particle size of HC-HT CSNPs was &lt; 250 nm, and HC-HT CSNPs AQ cream remained stable when stored at 25 degrees C. TEWL and erythema intensity for 28-day application did not indicate any signs of local irritation, redness, and toxicity, which were confirmed by normal Draize skin irritation scoring system and skin hematoxylin and eosin (H&amp;E) staining results. Comparative results of blood hematology, blood biochemistry, and adrenal cortico-thyroid hormone level at day 0 and day 28 were not significant, indicating non-systemic toxicity. In conclusion, HC-HT CSNP AQ cream is safe, well-tolerated, and non-toxic, which may be useful in treating atopic dermatitis</style></abstract><notes><style face="normal" font="default">IS - 2190-3948 (Electronic)IS - 2190-393X (Linking)LA - engPT - Journal ArticleCO - Malaysia -CO - Pakistan -</style></notes><work-type><style face="normal" font="default">10.1007/s13346-017-0439-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29159691">PM:29159691</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Drug Deliv Transl Res\20171106-SiddiqueMI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Drug Deliv Transl Res\20171106-SiddiqueMI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Siddique MI</style></custom2><misc3><style face="normal" font="default">10.1007/s13346-017-0439-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43328</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pelaia,C.</style></author><author><style face="normal" font="default"> Vatrella,A.</style></author><author><style face="normal" font="default"> Busceti,M.T.</style></author><author><style face="normal" font="default"> Gallelli,L.</style></author><author><style face="normal" font="default"> Terracciano,R.</style></author><author><style face="normal" font="default"> Savino,R.</style></author><author><style face="normal" font="default"> Pelaia,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University "Magna Graecia" of Catanzaro, Catanzaro</style></auth-address><titles><title><style face="normal" font="default">Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab</style></title><secondary-title><style face="normal" font="default">Drug Des Devel Ther</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Drug Des Devel Ther</style></full-title></periodical><pages end="3144" start="3137">3137-3144</pages><volume><style face="normal" font="default">11</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Mepolizumab is an anti-interleukin-5 (IL-5) humanized monoclonal antibody that has been recently approved as an add-on biological treatment for severe eosinophilic asthma, by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Moreover, mepolizumab is also currently included within the step 5 of the Global Initiative for Asthma guidelines, as an add-on therapy for severe uncontrolled asthma. The relevant therapeutic benefits detectable in patients with refractory eosinophilic asthma receiving mepolizumab depend on the pivotal pathogenic role played by IL-5 in these subjects. Indeed, IL-5 is the key cytokine responsible for maturation, activation, proliferation, and survival of eosinophils. Therefore, IL-5 represents a strategic molecular target for anti-eosinophilic treatments. By selectively inhibiting the biological actions of IL-5, mepolizumab provides a valuable therapeutic option for patients with severe eosinophilic asthma, refractory to standard treatments including inhaled and even systemic corticosteroids. In particular, the very important advantages linked to the use of mepolizumab in these difficult-to-treat asthmatic individuals have been well documented by several different trials performed worldwide</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 1177-8881 (Electronic)IS - 1177-8881 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="default">10.2147/DDDT.S150656</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29133975">PM:29133975</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Drug Des Devel Ther\2017-11-3137-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Drug Des Devel Ther\2017-11-3137-44.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171114, Pelaia C</style></custom2><misc3><style face="normal" font="default">10.2147/DDDT.S150656</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43329</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sugimoto,N.</style></author><author><style face="normal" font="default"> Kuribayashi,K.</style></author><author><style face="normal" font="default"> Yamamoto,Y.</style></author><author><style face="normal" font="default"> Nagayasu,S.</style></author><author><style face="normal" font="default"> Suga,O.</style></author><author><style face="normal" font="default"> Fujimoto,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pfizer Japan Inc., 3-22-7 Yoyogi, Shibuya-ku, Tokyo, 151-8589, Japan</style></auth-address><titles><title><style face="normal" font="default">Contact Dermatitis after Prescription of an Ophthalmic Ointment Containing Fradiomycin Sulfate: A Retrospective Database Study Using Japanese Health Insurance Claims Data</style></title><secondary-title><style face="normal" font="default">Drugs Real World Outcomes</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Drugs Real World Outcomes</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="11" Year="2017">2017/11/30</year></dates><abstract><style face="normal" font="default">BACKGROUND: Topical ointments containing fradiomycin sulfate, such as fradiomycin sulfate/methylprednisolone (F/M) and fradiomycin sulfate/betamethasone sodium phosphate (F/B), are known to cause allergic contact dermatitis (CD) in some patients, especially when used for the periocular region. F/M is commonly prescribed to patients for various conditions; however, there are no reports with respect to the incidence of CD caused by F/M in actual practice. OBJECTIVE: The aim was to investigate the incidence of CD using a data-based retrospective cohort study. METHODS: Using a Japanese health insurance claims database [MinaCare Co. Ltd. healthcare database (MinaCare HDB)], a comparative assessment was conducted of F/M and another combination drug (F/B) and two single-drug treatments (ophthalmic ointments with either an antibiotic or a steroid). The total data set consisted of 1,176,082 individuals in the MinaCare HDB, with 54,016 having received prescriptions for one of the four investigational drug regimens. RESULTS: Overall, the incidences of CD were similar in three of the four groups in this study (F/M 0.091; F/B 0.092; steroids 0.102), while being lower in the fourth group (antibiotics 0.060). Even after confirmation of a diagnosis of CD, prescriptions for the investigational drugs were repeatedly filled for some patients. CONCLUSION: This study demonstrated that there was no clear difference in the incidence of CD after filling prescriptions for F/M, F/B, and ophthalmic ointment containing a steroid, while the incidence with antibiotics was lower by 0.03-0.04 compared with the other groups. Considering the observation that the investigational drugs were repeatedly prescribed even after the diagnosis of CD, it is critical that the risk of CD with these prescribed topical ointments is better understood by primary care physicians in order to take appropriate countermeasures</style></abstract><notes><style face="normal" font="default">IS - 2199-1154 (Print)IS - 2198-9788 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1007/s40801-017-0127-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29188591">PM:29188591</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Drugs Real World Outcomes\20171118-SugimotoN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Drugs Real World Outcomes\20171118-SugimotoN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171118, Sugimoto N</style></custom2><misc3><style face="normal" font="default">10.1007/s40801-017-0127-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43330</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pal,I.</style></author><author><style face="normal" font="default"> Sinha Babu,A.</style></author><author><style face="normal" font="default"> Halder,I.</style></author><author><style face="normal" font="default"> Kumar,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology, College of Medicine and Jawaharlal Nehru Memorial Hospital, West Bengal University of Health Sciences, Kalyani, Nadia, West Bengal, India</style></auth-address><titles><title><style face="normal" font="default">Nasal smear eosinophils and allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Ear Nose Throat J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ear Nose Throat J</style></full-title></periodical><pages end="E22" start="E17">E17-E22</pages><volume><style face="normal" font="default">96</style></volume><number><style face="normal" font="default">10-11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Our aim was to find out the association between nasal smear eosinophil count and allergic rhinitis (AR) and to determine a cutoff value that is significant for a diagnosis of AR. We also wanted to determine whether this count is related to the predominant symptoms, duration, or type and severity of AR, or to the presence of coexisting asthma. We selected 100 patients with a clinical diagnosis of allergic rhinitis across all age groups and an equal number of age- and sex-matched controls for the study. Their nasal smear eosinophil counts were recorded in terms of the number of eosinophils per high-power field (HPF). All patients were then clinically assessed for asthma and underwent spirometry. The data were recorded and appropriate statistical analysis done. The difference in the mean eosinophil counts of patients with AR and controls was found to be statistically significant (p = 0.000). A nasal smear eosinophil count of >0.3 per HPF had a 100% specificity and a 100% positive predictive value for AR. Asthma was associated with allergic rhinitis in 40% of patients; an association was not found between nasal smear eosinophil count and the symptoms, duration, type, and severity of allergic rhinitis or coexistent asthma. We conclude that an eosinophil count of >0.3 per HPF in nasal smears is a highly specific criterion for the diagnosis of AR. However, nasal smear eosinophil counts are poor indicators of the degree, duration, or type of upper or associated lower airway inflammation due to allergy</style></abstract><notes><style face="normal" font="default">DA - 20171109IS - 1942-7522 (Electronic)IS - 0145-5613 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29121381">PM:29121381</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171109, Pal I</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43331</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,Y.</style></author><author><style face="normal" font="default"> Li,C.</style></author><author><style face="normal" font="default"> Luo,X.</style></author><author><style face="normal" font="default"> Xu,D.</style></author><author><style face="normal" font="default"> Xu,Y.</style></author><author><style face="normal" font="default"> Li,G.</style></author><author><style face="normal" font="default"> Liao,F.</style></author><author><style face="normal" font="default"> Tan,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Interleukin-33 promotes helper T cell type-2/17 inflammation in children with allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Eur Arch Otorhinolaryngol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Eur Arch Otorhinolaryngol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1434-4726</style></isbn><abstract><style face="normal" font="default">Interleukin-33 is a recently described cytokine which involved in helper T cell type-2 (Th2) mediated diseases. However, its regulatory effect in the pathogenesis of children allergic rhinitis (AR) needs to be further characterized. This study aims to evaluate the expression and role of IL-33 in children with AR</style></abstract><notes><style face="normal" font="default">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="default">10.1007/s00405-017-4807-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29150715">PM:29150715</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Arch Otorhinolaryngol\20171117-WangY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Arch Otorhinolaryngol\20171117-WangY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171117, Wang Y</style></custom2><misc3><style face="normal" font="default">10.1007/s00405-017-4807-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43332</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kallur,L.</style></author><author><style face="normal" font="default"> Gonzalez-Estrada,A.</style></author><author><style face="normal" font="default"> Eidelman,F.</style></author><author><style face="normal" font="default"> Dimov,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Internal Medicine Resident, Department of Internal Medicine , East Tennessee State University , Johnson City , TN , USAb Division of Pulmonary, Allergy, and Sleep Medicine, Department of Medicine , Mayo Clinic , Jacksonville , FL , USAc Department of Allergy and Clinical Immunology , Cleveland Clinic , Weston , FL , USAc Department of Allergy and Clinical Immunology , Cleveland Clinic , Weston , FL , USA</style></auth-address><titles><title><style face="normal" font="default">Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults</style></title><secondary-title><style face="normal" font="default">Expert Opin Drug Metab Toxicol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Expert Opin Drug Metab Toxicol</style></abbr-1></periodical><pages end="1280" start="1275">1275-1280</pages><volume><style face="normal" font="default">13</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Mepolizumab is a humanized monoclonal antibody that binds to and inactivates IL-5. It is available as a subcutaneous preparation. The practical application of mepolizumab is as an add-on therapy in the treatment of severe eosinophilic asthma. Areas covered: This article was created from a comprehensive literature search with information taken from meta-analyses, systematic reviews, and clinical trials of adults. The articles that have been selected evaluate the use of mepolizumab and its role in eosinophilic asthma. Expert opinion: Mepolizumab is significantly more effective than placebo in reducing exacerbations and need for systemic corticosteroids in severe eosinophilic asthma. There is a lack of head to head studies comparing mepolizumab to other monoclonal anti-IL-5 inhibitors in severe eosinophilic asthma. Post marketing surveillance revealed risk of anaphylaxis that is below 1%</style></abstract><notes><style face="normal" font="default">IS - 1744-7607 (Electronic)IS - 1742-5255 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/17425255.2017.1406919</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29157020">PM:29157020</url></web-urls></urls><custom2><style face="normal" font="default">20171111, Kallur L</style></custom2><misc3><style face="normal" font="default">10.1080/17425255.2017.1406919</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43333</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pretorius,R.</style></author><author><style face="normal" font="default"> Prescott,S.L.</style></author><author><style face="normal" font="default"> Palmer,D.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Medicine , University of Western Australia , Crawley , Australia</style></auth-address><titles><title><style face="normal" font="default">Taking a prebiotic approach to early immunomodulation for allergy prevention</style></title><secondary-title><style face="normal" font="default">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Expert Rev Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="12" Year="2017">2017/12/1</year></dates><abstract><style face="normal" font="default">INTRODUCTION: With increasing focus on nutritional strategies to counter the rising global burden of allergic disease, there has been a particular focus on prebiotic nutrients that are selectively utilized by host microorganisms to confer potential immunomodulatory benefits for disease prevention. Areas covered: In this review we examine maternal and infant dietary sources of prebiotics with a particular focus on non-digestible oligosaccharides, which undergo microbial fermentation by commensal gut bacteria to produce short chain fatty acids (SCFA). We summarize the major proposed health benefits of SCFA in early life immune development, together with the current evidence for maternal and/or infant prebiotic consumption in abrogating the risk of early childhood allergic diseases. Medline searches (to August 2017) for English language papers included prebiotics and SCFA search terms in combination with relevant allergic disease terms. Expert commentary: The potential beneficial effects of maternal and infant prebiotic consumption for allergy prevention are promising, but still require considerably further investigation through high-quality randomised controlled trials and detailed mechanistic studies. This should be coupled with more research on the biological effects of human milk oligosaccharides (HMO), including their influence on infant immune development, and the maternal nutritional factors that optimise HMO composition and infant outcomes</style></abstract><notes><style face="normal" font="default">IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/1744666X.2018.1411191</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29183179">PM:29183179</url></web-urls></urls><custom2><style face="normal" font="default">20171111, Pretorius R</style></custom2><misc3><style face="normal" font="default">10.1080/1744666X.2018.1411191</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43334</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vekaria,A.S.</style></author><author><style face="normal" font="default"> Brunner,P.M.</style></author><author><style face="normal" font="default"> Aleisa,A.I.</style></author><author><style face="normal" font="default"> Bonomo,L.</style></author><author><style face="normal" font="default"> Lebwohl,M.G.</style></author><author><style face="normal" font="default"> Israel,A.</style></author><author><style face="normal" font="default"> Guttman-Yassky,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA</style></auth-address><titles><title><style face="normal" font="default">Atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity</style></title><secondary-title><style face="normal" font="default">F1000Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">F1000Res</style></abbr-1></periodical><pages end="" start="1712">1712-</pages><volume><style face="normal" font="default">6</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Atopic dermatitis (AD), the most common chronic inflammatory skin disease, is evolving as a systemic disease, and associated systemic inflammation is possibly linked to increases in cardiovascular disease. Methods: We assessed levels of the inflammatory marker CRP in 59 patients with moderate-to-severe AD compared to matched healthy controls, and to determine correlation with skin disease severity. Clinical severity was measured using SCORing of Atopic Dermatitis (SCORAD) and body surface area (BSA). Control subjects (n=118), matched by age, gender, smoking status and ethnicity, were obtained from the National Health and Nutrition Survey (NHANES). Results: AD patients had significantly increased serum CRP levels compared to controls (0.7+/-1.0 vs. 0.4+/-0.7mg/dl; p=0.001). CRP levels were significantly correlated with both SCORAD (r=0.427, p=0.0008) and BSA (r=0.407, p=0.0015). IgE levels in AD were highly elevated (median 2903U/ml, IQR [234,10655]), but only weakly correlated with SCORAD (r=0.282, p=0.0427) and BSA (r=0.382, p=0.0052), but not with CRP levels. AD patients also showed increased LDH levels, but without significant correlations with disease severity (SCORAD, BSA) or CRP. Conclusions: Our study strongly supports CRP as a marker for disease severity in moderate-to-severe AD patients, further demonstrating its chronic systemic nature</style></abstract><notes><style face="normal" font="default">IS - 2046-1402 (Print)IS - 2046-1402 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Israel -</style></notes><work-type><style face="normal" font="default">10.12688/f1000research.12422.2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29188018">PM:29188018</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\F1000Res\2017-6-1712.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\F1000Res\2017-6-1712.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171112, Vekaria AS</style></custom2><misc3><style face="normal" font="default">10.12688/f1000research.12422.2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43335</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lila,M.A.</style></author><author><style face="normal" font="default"> Schneider,M.</style></author><author><style face="normal" font="default"> Devlin,A.</style></author><author><style face="normal" font="default"> Plundrich,N.</style></author><author><style face="normal" font="default"> Laster,S.</style></author><author><style face="normal" font="default"> Foegeding,E.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Plants for Human Health Institute, Food Bioprocessing &amp; Nutrition Sciences, North Carolina State University, North Carolina Research Campus, Kannapolis, NC, USA.</style></auth-address><titles><title><style face="normal" font="default">Polyphenol-enriched berry extracts naturally modulate reactive proteins in model foods</style></title><secondary-title><style face="normal" font="default">Food Funct</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Food Funct</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="12" Year="2017">2017/12/1</year></dates><abstract><style face="normal" font="default">Healthy foods like polyphenol-rich berries and high quality edible proteins are in demand in today's functional food marketplace, but it can be difficult to formulate convenient food products with physiologically-relevant amounts of these ingredients and still maintain product quality. In part, this is because proteins can interact with other food ingredients and precipitate destabilizing events, which can disrupt food structure and diminish shelf life. Proteins in foods can also interact with human receptors to provoke adverse consequences such as allergies. When proteins and polyphenols were pre-aggregated into stable colloidal particles prior to use as ingredients, highly palatable food formulations (with reduced astringency of polyphenols) could be prepared, and the overall structural properties of food formulations were significantly improved. All of the nutritive and phytoactive benefits of the proteins and concentrated polyphenols remained highly bioavailable, but the protein molecules in the particle matrix did not self-aggregate into networks or react with other food ingredients. Both the drainage half-life (a marker of structural stability) and the yield stress (resistance to flow) of model foams made with the protein-polyphenol particles were increased in a dose-dependent manner. Of high significance in this complexation process, the reactive allergenic epitopes of certain proteins were effectively blunted by binding with polyphenols, attenuating the allergenicity of the food proteins. Porcine macrophages produced TNF-alpha proinflammatory cytokine when provoked with whey protein, but, this response was blocked completely when the cells were stimulated with particles that complexed whey protein with cinnamon-derived polyphenols. Cytokine and chemokine production characteristic of allergic reactions were blocked by the polyphenols, allowing for the potential creation of hypoallergenic protein-berry polyphenol enriched foods</style></abstract><notes><style face="normal" font="default">IS - 2042-650X (Electronic)IS - 2042-6496 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1039/c7fo00883j</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29192707">PM:29192707</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Food Funct\20171115-LilaMA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Food Funct\20171115-LilaMA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171115, Lila MA</style></custom2><misc3><style face="normal" font="default">10.1039/c7fo00883j</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43336</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Coleman,S.L.</style></author><author><style face="normal" font="default"> Shaw,O.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Food and Wellness Group, The New Zealand Institute for Plant &amp; Food Research Ltd, Palmerston North 4442, New Zealand.</style></auth-address><titles><title><style face="normal" font="default">Progress in the understanding of the pathology of allergic asthma and the potential of fruit proanthocyanidins as modulators of airway inflammation</style></title><secondary-title><style face="normal" font="default">Food Funct</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Food Funct</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="15" Month="11" Year="2017">2017/11/15</year></dates><abstract><style face="normal" font="default">Allergic asthma is a chronic inflammatory lung disease characterized by sensitization of the airways, and the development of immunoglobulin E antibodies, to benign antigens. The established pathophysiology of asthma includes recurrent lung epithelial inflammation, excessive mucus production, bronchial smooth muscle hyperreactivity, and chronic lung tissue remodeling, resulting in reversible airflow restriction. Immune cells, including eosinophils and the recently characterized type 2 innate lymphoid cells, infiltrate into the lung tissue as part of the inflammatory response in allergic asthma. It is well established that a diet high in fruits and vegetables results in a reduction of the risk of developing inflammatory diseases. Secondary plant metabolites, such as proanthocyanidins which are found in apples, blackcurrants, boysenberries, cranberries, and grapes, have shown promising results in reducing or preventing allergic asthma airway inflammation. Recent evidence has also highlighted the importance of microbiome-mediated metabolism of plant polyphenols in modulating the immune system. In this review, we will discuss advances in our understanding of the pathophysiology of allergic asthma, including the role of the microbiome in lung immune function, and how proanthocyanidins modulate the airway inflammation. We will highlight the potential of dietary proanthocyanidins to impact on allergic asthma and the immune system</style></abstract><notes><style face="normal" font="default">DA - 20171115IS - 2042-650X (Electronic)IS - 2042-6496 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - New Zealand -</style></notes><work-type><style face="normal" font="default">10.1039/c7fo00789b</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29140397">PM:29140397</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Food Funct\20171115-ColemanSL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Food Funct\20171115-ColemanSL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171115, Coleman SL</style></custom2><misc3><style face="normal" font="default">10.1039/c7fo00789b</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43337</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Van der Leek,A.P.</style></author><author><style face="normal" font="default"> Yanishevsky,Y.</style></author><author><style face="normal" font="default"> Kozyrskyj,A.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, University of Alberta, Edmonton, AB, Canada</style></auth-address><titles><title><style face="normal" font="default">The Kynurenine Pathway As a Novel Link between Allergy and the Gut Microbiome</style></title><secondary-title><style face="normal" font="default">Front Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Immunol</style></abbr-1></periodical><pages end="" start="1374">1374-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">In the past few decades, the indoleamine 2,3 dioxygenase (IDO) subset of the kynurenine (KYN) pathway of tryptophan (TRP) metabolism has been the subject of much research in the area of immune tolerance. In this review, we aim to incorporate new findings on this pathway in relation to allergy and the gut microbiome, while providing a comprehensive overview of the pathway itself. Stimulated by interferon gamma, IDO acts as a tolerogenic, immunosuppressive enzyme to attenuate allergic responses by the induction of the KYN-IDO pathway, resultant depletion of TRP, and elevation in KYN metabolites. Acting through the aryl hydrocarbon receptor, KYN metabolites cause T-cell anergy and apoptosis, proliferation of Treg and Th17 cells, and deviation of the Th1/Th2 response, although the outcome is highly dependent on the microenvironment. Moreover, new evidence from germ-free mice and human infants shows that gut microbiota and breast milk are key in determining the functioning of the KYN-IDO pathway. As such, we recommend further research on how this pathway may be a critical link between the microbiome and development of allergy</style></abstract><notes><style face="normal" font="default">IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Canada -</style></notes><work-type><style face="normal" font="default">10.3389/fimmu.2017.01374</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29163472">PM:29163472</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Immunol\2017-8-1374.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Immunol\2017-8-1374.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Van der Leek AP</style></custom2><misc3><style face="normal" font="default">10.3389/fimmu.2017.01374</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43338</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kruzel,M.L.</style></author><author><style face="normal" font="default"> Zimecki,M.</style></author><author><style face="normal" font="default"> Actor,J.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">McGovern Medical School, University of Texas, Health Science Center, Houston, TX, United StatesPolish Academy of Sciences, Institute of Immunology and Experimental Therapy, Wroclaw, PolandMcGovern Medical School, University of Texas, Health Science Center, Houston, TX, United States</style></auth-address><titles><title><style face="normal" font="default">Lactoferrin in a Context of Inflammation-Induced Pathology</style></title><secondary-title><style face="normal" font="default">Front Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Immunol</style></abbr-1></periodical><pages end="" start="1438">1438-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Much progress has been achieved to elucidate the function of lactoferrin (LTF), an iron-binding glycoprotein, in the milieu of immune functionality. This review represents a unique examination of LTF toward its importance in physiologic homeostasis as related to development of disease-associated pathology. The immunomodulatory nature of this protein derives from its unique ability to "sense" the immune activation status of an organism and act accordingly. Underlying mechanisms are proposed whereby LTF controls disease states, thereby pinpointing regions of entry for LTF in maintenance of various physiological pathways to limit the magnitude of tissue damage. LTF is examined as a first line mediator in immune defense and response to pathogenic and non-pathogenic injury, as well as a molecule critical for control of oxidative cell function. Mechanisms of interaction of LTF with its receptors are examined, with a focus on protective effects via regulation of enzyme activities and reactive oxygen species production, immune deviation, and prevention of cell apoptosis. Indeed, LTF serves as a critical control point in physiologic homeostasis, functioning as a sensor of immunological performance related to pathology. Specific mediation of tissue pathophysiology is described for maintenance of intestinal integrity during endotoxemia, elicited airway inflammation due to allergens, and pulmonary damage during tuberculosis. Finally, the role of LTF to alter differentiation of adaptive immune function is examined, with specific recognition of its utility as a vaccine adjuvant to control subsequent lymphocytic reactivity. Overall, it is clear that while the ability of LTF to both sequester iron and to direct reactive oxygen intermediates is a major factor in lessening damage due to excessive inflammatory responses, further effects are apparent through direct control over development of higher order immune functions that regulate pathology due to insult and injury. This culminates in attenuation of pathological damage during inflammatory injury</style></abstract><notes><style face="normal" font="default">IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -CO - Poland -</style></notes><work-type><style face="normal" font="default">10.3389/fimmu.2017.01438</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29163511">PM:29163511</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Immunol\2017-8-1438.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Immunol\2017-8-1438.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Kruzel ML</style></custom2><misc3><style face="normal" font="default">10.3389/fimmu.2017.01438</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43339</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wu,Z.</style></author><author><style face="normal" font="default"> Wang,L.</style></author><author><style face="normal" font="default"> Tang,Y.</style></author><author><style face="normal" font="default"> Sun,X.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Parasitology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China</style></auth-address><titles><title><style face="normal" font="default">Parasite-Derived Proteins for the Treatment of Allergies and Autoimmune Diseases</style></title><secondary-title><style face="normal" font="default">Front Microbiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Microbiol</style></abbr-1></periodical><pages end="" start="2164">2164-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The morbidity associated with atopic diseases and immune dysregulation disorders such as asthma, food allergies, multiple sclerosis, atopic dermatitis, type 1 diabetes mellitus, and inflammatory bowel disease has been increasing all around the world over the past few decades. Although the roles of non-biological environmental factors and genetic factors in the etiopathology have been particularly emphasized, they do not fully explain the increase; for example, genetic factors in a population change very gradually. Epidemiological investigation has revealed that the increase also parallels a decrease in infectious diseases, especially parasitic infections. Thus, the reduced prevalence of parasitic infections may be another important reason for immune dysregulation. Parasites have co-evolved with the human immune system for a long time. Some parasite-derived immune-evasion molecules have been verified to reduce the incidence and harmfulness of atopic diseases in humans by modulating the immune response. More importantly, some parasite-derived products have been shown to inhibit the progression of inflammatory diseases and consequently alleviate their symptoms. Thus, parasites, and especially their products, may have potential applications in the treatment of autoimmune diseases. In this review, the potential of parasite-derived products and their analogs for use in the treatment of atopic diseases and immune dysregulation is summarized</style></abstract><notes><style face="normal" font="default">IS - 1664-302X (Print)IS - 1664-302X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - China -</style></notes><work-type><style face="normal" font="default">10.3389/fmicb.2017.02164</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29163443">PM:29163443</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Microbiol\2017-8-2164.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Microbiol\2017-8-2164.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171107, Wu Z</style></custom2><misc3><style face="normal" font="default">10.3389/fmicb.2017.02164</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43340</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tai,Y.H.</style></author><author><style face="normal" font="default"> Tai,Y.J.</style></author><author><style face="normal" font="default"> Hsu,H.C.</style></author><author><style face="normal" font="default"> Lee,S.P.</style></author><author><style face="normal" font="default"> Chen,Y.Y.</style></author><author><style face="normal" font="default"> Chiang,Y.C.</style></author><author><style face="normal" font="default"> Chen,Y.L.</style></author><author><style face="normal" font="default"> Chen,C.A.</style></author><author><style face="normal" font="default"> Cheng,W.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, Tainan, Taiwan</style></auth-address><titles><title><style face="normal" font="default">Risk Factors of Hypersensitivity to Carboplatin in Patients with Gynecologic Malignancies</style></title><secondary-title><style face="normal" font="default">Front Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Pharmacol</style></abbr-1></periodical><pages end="" start="800">800-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">We evaluated the prevalence of and risk factors for hypersensitivity reactions related to carboplatin, which is commonly used to treat gynecological malignancies. All women with pathologically documented ovarian, fallopian tube, or primary peritoneal cancer treated with carboplatin alone or a carboplatin-based combination chemotherapy regimen at a single hospital between January 2006 and December 2013 were retrospectively recruited. We analyzed the incidence, characteristics, risk factors, management, and outcomes of carboplatin-related hypersensitivity reactions among these patients. Among 735 eligible women, 75 (10.2%) experienced a total of 215 carboplatin-related hypersensitivity reaction events. The annual incidence of carboplatin-related hypersensitivity reactions gradually increased from 0.88% in 2006 to 5.42% in 2013. The incidence of carboplatin-related hypersensitivity was higher in patients with advanced stage disease (P &lt; 0.001, Kruskal-Wallis test), serous and mixed histological types (P = 0.003, Kruskal-Wallis test), malignant ascites (P = 0.009, chi-square test), and history of other drug allergy (P &lt; 0.001, chi-square test). Compared to women without hypersensitivity reactions, women who experienced hypersensitivity reactions had a significantly greater median cycle number (12 vs. 6, P &lt; 0.001, independent sample t-test) and dose (6,816 vs. 3,844 mg, P &lt; 0.001, independent sample t-test). The cumulative incidence of carboplatin-related hypersensitivity reactions dramatically increased with >8 cycles or dose >3,500 mg. Therefore, disease severity, histological type, malignant ascites, past drug allergies, and cumulative carboplatin dose are risk factors for carboplatin-related hypersensitivity reactions. Such reactions could potentially be reduced or prevented by slowing the infusion rate and using a desensitization protocol involving anti-allergy medications</style></abstract><notes><style face="normal" font="default">IS - 1663-9812 (Print)IS - 1663-9812 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.3389/fphar.2017.00800</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29163180">PM:29163180</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Pharmacol\2017-8-800.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Pharmacol\2017-8-800.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171128, Tai YH</style></custom2><misc3><style face="normal" font="default">10.3389/fphar.2017.00800</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43341</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Correa,M.F.</style></author><author><style face="normal" font="default"> Barbosa,A.J.R.</style></author><author><style face="normal" font="default"> Teixeira,L.B.</style></author><author><style face="normal" font="default"> Duarte,D.A.</style></author><author><style face="normal" font="default"> Simoes,S.C.</style></author><author><style face="normal" font="default"> Parreiras-E-Silva LT</style></author><author><style face="normal" font="default"> Balbino,A.M.</style></author><author><style face="normal" font="default"> Landgraf,R.G.</style></author><author><style face="normal" font="default"> Bouvier,M.</style></author><author><style face="normal" font="default"> Costa-Neto,C.M.</style></author><author><style face="normal" font="default"> Fernandes,J.P.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departamento de Ciencias Farmaceuticas, Universidade Federal de Sao Paulo, Diadema, Brazil</style></auth-address><titles><title><style face="normal" font="default">Pharmacological Characterization of 5-Substituted 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazines: Novel Antagonists for the Histamine H3 and H4 Receptors with Anti-inflammatory Potential</style></title><secondary-title><style face="normal" font="default">Front Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Pharmacol</style></abbr-1></periodical><pages end="" start="825">825-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The histamine receptors (HRs) are traditional G protein-coupled receptors of extensive therapeutic interest. Recently, H3R and H4R subtypes have been targeted in drug discovery projects for inflammation, asthma, pain, cancer, Parkinson's, and Alzheimer's diseases, which includes searches for dual acting H3R/H4R ligands. In the present work, nine 1-[(2,3-dihydro-1-benzofuran-2-yl)methyl]piperazine (LINS01 series) molecules were synthesized and evaluated as H3R and H4R ligands. Our data show that the N-allyl-substituted compound LINS01004 bears the highest affinity for H3R (pKi 6.40), while the chlorinated compound LINS01007 has moderate affinity for H4R (pKi 6.06). In addition, BRET assays to assess the functional activity of Gi1 coupling indicate that all compounds have no intrinsic activity and act as antagonists of these receptors. Drug-likeness assessment indicated these molecules are promising leads for further improvements. In vivo evaluation of compounds LINS01005 and LINS01007 in a mouse model of asthma showed a better anti-inflammatory activity of LINS01007 (3 g/kg) than the previously tested compound LINS01005. This is the first report with functional data of these compounds in HRs, and our results also show the potential of their applications as anti-inflammatory</style></abstract><notes><style face="normal" font="default">IS - 1663-9812 (Print)IS - 1663-9812 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - Canada -</style></notes><work-type><style face="normal" font="default">10.3389/fphar.2017.00825</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29184503">PM:29184503</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Pharmacol\2017-8-825.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Pharmacol\2017-8-825.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171128, Correa MF</style></custom2><misc3><style face="normal" font="default">10.3389/fphar.2017.00825</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43342</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sinniah,A.</style></author><author><style face="normal" font="default"> Yazid,S.</style></author><author><style face="normal" font="default"> Flower,R.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia</style></auth-address><titles><title><style face="normal" font="default">The Anti-allergic Cromones: Past, Present, and Future</style></title><secondary-title><style face="normal" font="default">Front Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Pharmacol</style></abbr-1></periodical><pages end="" start="827">827-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The anti-allergic cromones were originally synthesized in the 1960s by Fisons Plc, and the first drug to emerge from this program, disodium cromoglycate was subsequently marketed for the treatment of asthma and other allergic conditions. Whilst early studies demonstrated that the ability of the cromones to prevent allergic reactions was due to their 'mast cell stabilizing' properties, the exact pharmacological mechanism by which this occurred, remained a mystery. Here, we briefly review the history of these drugs, recount some aspects of their pharmacology, and discuss two new explanations for their unique actions. We further suggest how these findings could be used to predict further uses for the cromones</style></abstract><notes><style face="normal" font="default">IS - 1663-9812 (Print)IS - 1663-9812 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Malaysia -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.3389/fphar.2017.00827</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29184504">PM:29184504</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Pharmacol\2017-8-827.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Pharmacol\2017-8-827.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171128, Sinniah A</style></custom2><misc3><style face="normal" font="default">10.3389/fphar.2017.00827</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43343</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sacchelli,L.</style></author><author><style face="normal" font="default"> Banzola,N.</style></author><author><style face="normal" font="default"> Traniello Gradassi,A.</style></author><author><style face="normal" font="default"> Patrizi,A.</style></author><author><style face="normal" font="default"> D'Antuono,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Specialized, Clinical and Experimental Medicine, Division of Dermatology, University of Bologna, Bologna, Italy</style></auth-address><titles><title><style face="normal" font="default">Can a single drug administration elicit two different immunological pathways at the same time? A case report of Fixed Drug Eruption after anaphylaxis</style></title><secondary-title><style face="normal" font="default">G Ital Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">G Ital Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="11" Year="2017">2017/11/30</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1827-1820 (Electronic)IS - 0392-0488 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.23736/S0392-0488.17.05699-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29192468">PM:29192468</url></web-urls></urls><custom2><style face="normal" font="default">20171130, Sacchelli L</style></custom2><misc3><style face="normal" font="default">10.23736/S0392-0488.17.05699-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43344</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sue,S.</style></author><author><style face="normal" font="default"> Suzuki,N.</style></author><author><style face="normal" font="default"> Shibata,W.</style></author><author><style face="normal" font="default"> Sasaki,T.</style></author><author><style face="normal" font="default"> Yamada,H.</style></author><author><style face="normal" font="default"> Kaneko,H.</style></author><author><style face="normal" font="default"> Tamura,T.</style></author><author><style face="normal" font="default"> Ishii,T.</style></author><author><style face="normal" font="default"> Kondo,M.</style></author><author><style face="normal" font="default"> Maeda,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama, Japan</style></auth-address><titles><title><style face="normal" font="default">First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin</style></title><secondary-title><style face="normal" font="default">Gastroenterol Res Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Gastroenterol Res Pract</style></abbr-1></periodical><pages end="" start="2019802">2019802-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Aim: To assess the efficacy of 7-day first-line Helicobacter pylori eradication with vonoprazan (VPZ), clarithromycin (CAM), and metronidazole (MNZ) in patients with penicillin allergy. Methods: Patients with penicillin allergy, diagnosed with Helicobacter pylori infection and did not have history of Helicobacter pylori eradication, were eligible for the study. Twenty patients were prospectively treated with 20 mg VPZ twice daily, 200 or 400 mg CAM twice daily, and 250 mg MNZ twice daily for 7 days. We also collected the data from 30 patients retrospectively treated with proton pump inhibitor (PPI), CAM, and MNZ. Safety was evaluated in patients completing an adverse effect questionnaire. Results: Both the intention-to-treat and per-protocol effectiveness of VPZ-based eradication were 100% (95% CI: 86.1-100%; n = 20). The eradication rates of PPI-based regimen were 83.3% (95% CI: 65.3-94.4%) in the ITT and 82.7% (95% CI: 64.2-94.2%) in the PP analyses. Abdominal fullness was more frequent in VCM compared to PCM. However, all patients with VCM regimen had taken 100% of their course of medication. Conclusion: Triple therapy with VPZ, CAM, and MNZ is well tolerated and effective for eradicating Helicobacter pylori in patients allergic to penicillin. This study was registered in the UMIN Clinical Trials Registry as UMIN000016335</style></abstract><notes><style face="normal" font="default">IS - 1687-6121 (Print)IS - 1687-6121 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1155/2017/2019802</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29181022">PM:29181022</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Gastroenterol Res Pract\2017-2017-2019802.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Gastroenterol Res Pract\2017-2017-2019802.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171018, Sue S</style></custom2><misc3><style face="normal" font="default">10.1155/2017/2019802</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43345</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Weiss,S.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Harvard Medical School and Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, 02115, USA.</style></auth-address><titles><title><style face="normal" font="default">Emerging mechanisms and novel targets in allergic inflammation and asthma</style></title><secondary-title><style face="normal" font="default">Genome Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Genome Med</style></abbr-1></periodical><pages end="" start="107">107-</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="12" Year="2017">2017/12/4</year></dates><abstract><style face="normal" font="default">Airway inflammation is key to the severity and persistence of asthma. Recent studies have revealed novel immune mechanisms that target dendritic cells, T helper 2 cytokines, regulatory T cells, and type 2 innate lymphoid cells in allergic inflammation, as well as novel approaches that target airway smooth muscle in asthma. These advances inform the development of new targeted treatments for allergic inflammation and asthma with the potential to provide therapeutic benefit</style></abstract><notes><style face="normal" font="default">IS - 1756-994X (Electronic)IS - 1756-994X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1186/s13073-017-0501-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29202803">PM:29202803</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Genome Med\2017-9-107.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Genome Med\2017-9-107.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171211, Weiss ST</style></custom2><misc3><style face="normal" font="default">10.1186/s13073-017-0501-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43346</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vogel Ciernia,A.</style></author><author><style face="normal" font="default"> Careaga,M.</style></author><author><style face="normal" font="default"> LaSalle,J.M.</style></author><author><style face="normal" font="default"> Ashwood,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical Microbiology and Immunology, Genome Center, University of California, Davis, Davis, California, 95616</style></auth-address><titles><title><style face="normal" font="default">Microglia from offspring of dams with allergic asthma exhibit epigenomic alterations in genes dysregulated in autism</style></title><secondary-title><style face="normal" font="default">Glia</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Glia</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="11" Year="2017">2017/11/14</year></dates><abstract><style face="normal" font="default">Dysregulation in immune responses during pregnancy increases the risk of a having a child with an autism spectrum disorder (ASD). Asthma is one of the most common chronic diseases among pregnant women, and symptoms often worsen during pregnancy. We recently developed a mouse model of maternal allergic asthma (MAA) that induces changes in sociability, repetitive, and perseverative behaviors in the offspring. Since epigenetic changes help a static genome adapt to the maternal environment, activation of the immune system may epigenetically alter fetal microglia, the brain's resident immune cells. We therefore tested the hypothesis that epigenomic alterations to microglia may be involved in behavioral abnormalities observed in MAA offspring. We used the genome-wide approaches of whole genome bisulfite sequencing to examine DNA methylation and RNA sequencing to examine gene expression in microglia from juvenile MAA offspring. Differentially methylated regions were enriched for immune signaling pathways and important microglial developmental transcription factor binding motifs. Differential expression analysis identified genes involved in controlling microglial sensitivity to the environment and shaping neuronal connections in the developing brain. Differentially expressed genes significantly overlapped genes with altered expression in human ASD cortex, supporting a role for microglia in the pathogenesis of ASD</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 1098-1136 (Electronic)IS - 0894-1491 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1002/glia.23261</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29134693">PM:29134693</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Glia\20171114-VogelCierniaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Glia\20171114-VogelCierniaA.pdf</url></text-urls><related-urls><url ppv-ref="no">xlsx in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20171114, Vogel Ciernia A</style></custom2><misc3><style face="normal" font="default">10.1002/glia.23261</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43347</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pisi,G.</style></author><author><style face="normal" font="default"> Fainardi,V.</style></author><author><style face="normal" font="default"> Aiello,M.</style></author><author><style face="normal" font="default"> Bertorelli,G.</style></author><author><style face="normal" font="default"> Crisafulli,E.</style></author><author><style face="normal" font="default"> Chetta,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cystic Fibrotic Centre, University Hospital, Parma, Italy</style></auth-address><titles><title><style face="normal" font="default">The role of the microbiome in childhood asthma</style></title><secondary-title><style face="normal" font="default">Immunotherapy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immunotherapy</style></abbr-1></periodical><pages end="1304" start="1295">1295-1304</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">15</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">It is now well established that the healthy bronchial tree contains a microbiome distinct from that of the upper respiratory tract and that the lung microbiome may be dysregulated in individuals with a chronic respiratory disease, such as asthma. In addition, after birth, gut microbes interact with the host tissue, especially with the lymphatic tissue, thereby guaranteeing efficient immune activation. This review focuses on the available literature on the relationships between the gut microbiome, immune function and asthma in childhood, as well as the therapeutic strategies aimed at acting on the modulation of the microbiome</style></abstract><notes><style face="normal" font="default">DA - 20171113IS - 1750-7448 (Electronic)IS - 1750-743X (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.2217/imt-2017-0048</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29130800">PM:29130800</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171113, Pisi G</style></custom2><misc3><style face="normal" font="default">10.2217/imt-2017-0048</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43348</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mannan,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Future Science Group, Unitec House, 2 Albert Place, London, N3 1QB, UK</style></auth-address><titles><title><style face="normal" font="default">Allergen immunotherapy</style></title><secondary-title><style face="normal" font="default">Immunotherapy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Immunotherapy</style></abbr-1></periodical><pages end="1200" start="1199">1199-1200</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">15</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171113IS - 1750-7448 (Electronic)IS - 1750-743X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.2217/imt-2017-0157</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29130796">PM:29130796</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Immunotherapy\2017-9-1199-200.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Immunotherapy\2017-9-1199-200.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171113, Mannan S</style></custom2><misc3><style face="normal" font="default">10.2217/imt-2017-0157</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43349</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Altuntas,E.E.</style></author><author><style face="normal" font="default"> Turgut,N.H.</style></author><author><style face="normal" font="default"> Durmus,K.</style></author><author><style face="normal" font="default"> Dogan,O.T.</style></author><author><style face="normal" font="default"> Akyol,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey</style></auth-address><titles><title><style face="normal" font="default">Strontium chloride hexahydrate as a candidate molecule for long-term treatment of allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Indian J Med Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Indian J Med Res</style></abbr-1></periodical><pages end="125" start="121">121-125</pages><volume><style face="normal" font="default">146</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">BACKGROUND &amp; OBJECTIVES: Neurogenic inflammation plays a role in the pathophysiology of allergic rhinitis (AR). Strontium salts are highly effective in reducing the sensory irritation. This study was aimed to investigate the efficacy of strontium chloride (SC) on AR symptoms based on the duration of SC use before the symptoms begin. METHODS: Wistar albino rats (n=18) were randomly divided into three groups: Group 1, received 1mug mometasone furoate (MF); Group 2, three per cent SC; and Group 3 received five per cent SC (2 mul/site). Drugs were administered to the each nasal cavity for three weeks every morning. On the days 7, 14 and 21, histamine dihydrochloride (HD) 5 mumol (2 mul/site) was administered and the frequencies of nasal rubbing and sneezing were counted for 15 min. RESULTS: After 7, 14 and 21 day medication period, the groups were compared in terms of the frequency of sneezing and nasal rubbing following HD. There was a significant difference among the groups in terms of the frequency of sneezing on the day 7 (PPInterpretation &amp; conclusions: Our results showed that three and five per cent SC were less effective than MF for sneezing during the first week, but the efficiency was equal to that of MF after the first 14 days. Long-term use of SC was as effective as MF on nasal rubbing. SC can be as effective as MF on both sneezing and nasal rubbing on regular use over three weeks</style></abstract><notes><style face="normal" font="default">IS - 0971-5916 (Print)IS - 0971-5916 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.4103/ijmr.IJMR_894_15</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29168468">PM:29168468</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Med Res\2017-146-121-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Med Res\2017-146-121-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171111, Altuntas EE</style></custom2><misc3><style face="normal" font="default">10.4103/ijmr.IJMR_894_15</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43350</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mulholland,A.</style></author><author><style face="normal" font="default"> Ainsworth,A.</style></author><author><style face="normal" font="default"> Pillarisetti,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Respiratory Medicine, Starship Children's Hospital, Park Road, Grafton, Auckland, 1023, New Zealand</style></auth-address><titles><title><style face="normal" font="default">Tools in Asthma Evaluation and Management: When and How to Use Them?</style></title><secondary-title><style face="normal" font="default">Indian J Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Indian J Pediatr</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="15" Month="11" Year="2017">2017/11/15</year></dates><abstract><style face="normal" font="default">The goals of asthma management are accurate diagnosis, prompt initiation of treatment and monitoring of disease progression to limit potential morbidity and mortality. While the diagnosis and management is largely based on history taking and clinical examination, there are an increasing number of tools available that could be used to aid diagnosis, define phenotypes, monitor progress and assess response to treatment. Tools such as the Asthma Predictive Index could help in making predictions about the possibility of asthma in childhood based on certain clinical parameters in pre-schoolers. Lung function measurements such as peak expiratory flow, spirometry, bronchodilator responsiveness, and bronchial provocation tests help establish airway obstruction and variability over time. Tools such as asthma questionnaires, lung function measurements and markers of airway inflammation could be used in combination with clinical assessments to assess ongoing asthma control. Recent advances in digital technology, which open up new frontiers in asthma management, need to be evaluated and embraced if proven to be of value. This review summarises the role of currently available tools in asthma diagnosis and management. While many of the tools are readily available in resource rich settings, it becomes more challenging when working in resource poor settings. A rational approach to the use of these tools is recommended</style></abstract><notes><style face="normal" font="default">DA - 20171115IS - 0973-7693 (Electronic)IS - 0019-5456 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - New Zealand -</style></notes><work-type><style face="normal" font="default">10.1007/s12098-017-2462-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29139062">PM:29139062</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Pediatr\20171115-MulhollandA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Pediatr\20171115-MulhollandA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171115, Mulholland A</style></custom2><misc3><style face="normal" font="default">10.1007/s12098-017-2462-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43351</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gupta,S.</style></author><author><style face="normal" font="default"> Lodha,R.</style></author><author><style face="normal" font="default"> Kabra,S.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India</style></auth-address><titles><title><style face="normal" font="default">Asthma, GERD and Obesity: Triangle of Inflammation</style></title><secondary-title><style face="normal" font="default">Indian J Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Indian J Pediatr</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="11" Year="2017">2017/11/11</year></dates><abstract><style face="normal" font="default">There is increasing prevalence of both asthma and obesity in children globally in recent years. Various epidemiological studies link obesity as a risk factor for asthma and suggest a possible causal association. Obesity asthma phenotype is considered as distinct in view of greater severity and poor asthma control. Various mechanisms underlying this phenotype have been suggested including mechanical effects of obesity and systemic inflammation, but still the exact mechanism is unclear. Also, the comorbidities like gastroesophageal reflux disease (GERD) and sleep disordered breathing (SDB) lead to inflammation in airways and contribute to asthma obesity association. A better understanding of mechanisms by which obesity and GERD lead to inflammation in airways and increase the risk of asthma may provide insight towards targeted treatment approach of these patients</style></abstract><notes><style face="normal" font="default">DA - 20171111IS - 0973-7693 (Electronic)IS - 0019-5456 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - India -</style></notes><work-type><style face="normal" font="default">10.1007/s12098-017-2484-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29127618">PM:29127618</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Indian J Pediatr\20171111-GuptaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Indian J Pediatr\20171111-GuptaS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171111, Gupta S</style></custom2><misc3><style face="normal" font="default">10.1007/s12098-017-2484-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43352</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jeong,H.J.</style></author><author><style face="normal" font="default"> Kim,H.Y.</style></author><author><style face="normal" font="default"> Kim,H.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Food Science &amp; Technology, Hoseo University, 20, Hoseo-ro 79beon-gil, Baebang-eup, Asan, Chungcheongnam-do 31499, Republic of KoreaDepartment of Pharmacology, College of Korean Medicine, Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of KoreaDepartment of Pharmacology, College of Korean Medicine, Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea. Electronic address: hmkim@khu.ac.kr</style></auth-address><titles><title><style face="normal" font="default">Molecular mechanisms of anti-inflammatory effect of chrysophanol, an active component of AST2017-01 on atopic dermatitis in vitro models</style></title><secondary-title><style face="normal" font="default">Int Immunopharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int Immunopharmacol</style></full-title></periodical><pages end="244" start="238">238-244</pages><volume><style face="normal" font="default">54</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="11" Year="2017">2017/11/18</year></dates><abstract><style face="normal" font="default">AST2017-01 mainly consists of Rumex crispus and -Cordyceps militaris and has been widely consumed as an herbal medicine or functional food in Korea. Here we investigated the influences of AST2017-01 and its active component, chrysophanol on human mast cell (HMC-1 cell) and human keratinocyte (HaCaT cell)-mediated inflammatory reactions. Pretreatment with AST2017-01 or chrysophanol suppressed intracellular calcium levels and histamine release in phorbol 12-myristate 13-acetate and calcium ionophore A23187 (PMACI)-treated HMC-1 cells. Levels of phosphorylated-mitogen-activated protein kinase increased by PMACI stimulation were reduced by AST2017-01 or chrysophanol pretreatment. Protein levels of IkappaB kinasebeta and receptor-interacting protein 2 in PMACI-treated HMC-1 cells were decreased by AST2017-01 or chrysophanol pretreatment. Pretreatment with AST2017-01 or chrysophanol significantly blocked PMACI-induced activation of caspase-1 and nuclear factor-kappaB. In addition, pretreatment with AST2017-01 or chrysophanol significantly decreased the PMACI-induced levels of interleukin (IL)-1beta, IL-6, tumor necrosis factor-alpha, and thymic stromal lymphopoietin (TSLP) on HMC-1 cells. In activated HaCaT cells, pretreatment with AST2017-01 or chrysophanol significantly reduced production of TSLP and activation of caspase-1. In conclusion, these findings indicate that chrysophanol is an active component of AST2017-01 and AST2017-01 acts as a novel potent anti-inflammatory herbal medicine or functional food</style></abstract><notes><style face="normal" font="default">IS - 1878-1705 (Electronic)IS - 1567-5769 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.intimp.2017.11.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29161660">PM:29161660</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Immunopharmacol\2017-54-238-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Immunopharmacol\2017-54-238-44.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171112, Jeong HJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.intimp.2017.11.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43353</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Motoyama,K.</style></author><author><style face="normal" font="default"> Tanida,Y.</style></author><author><style face="normal" font="default"> Sakai,A.</style></author><author><style face="normal" font="default"> Higashi,T.</style></author><author><style face="normal" font="default"> Kaneko,S.</style></author><author><style face="normal" font="default"> Arima,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan</style></auth-address><titles><title><style face="normal" font="default">Anti-allergic effects of novel sulfated polysaccharide sacran on mouse model of 2,4-Dinitro-1-fluorobenzene-induced atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Int J Biol Macromol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Biol Macromol</style></full-title></periodical><pages end="118" start="112">112-118</pages><volume><style face="normal" font="default">108</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="11" Year="2017">2017/11/27</year></dates><abstract><style face="normal" font="default">In this study, in order to investigate the potential of the novel polysaccharide sacran from Aphanothece Sacrum for development of atopic dermatitis (AD), we evaluated the potential of pretreatment with topical sacran to prevent the development of hapten (dinitrofluorobenzene: DNFB)-induced AD-like disease in mice. In the AD model mice, sacran markedly ameliorated AD symptoms such as scratching behavior and edema in ear. In addition, sacran significantly increased water content of the stratum corneum which regulates the skin barrier function. Furthermore, sacran significantly inhibited inflammatory cytokine and chemokine mRNA levels in the dermatitis skin as well as the IgE antibody level in serum. Sacran inhibited inflammatory cytokines mRNA production from Jurkat cells derived from human leukemia T cells after stimulation with phorbol 12-myristate 13-acetate/ionomycin. Meanwhile, sacran did not inhibit the proliferation of primary B cells stimulated with lipopolysaccharide. These results suggest that sacran has good anti-allergic effect on AD model mice, probably due to the amelioration of skin barrier function and suppression of immune responses</style></abstract><notes><style face="normal" font="default">IS - 1879-0003 (Electronic)IS - 0141-8130 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.ijbiomac.2017.11.155</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29191418">PM:29191418</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Biol Macromol\2017-108-112-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Biol Macromol\2017-108-112-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171127, Motoyama K</style></custom2><misc3><style face="normal" font="default">10.1016/j.ijbiomac.2017.11.155</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43354</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oudin,A.</style></author><author><style face="normal" font="default"> Braback,L.</style></author><author><style face="normal" font="default"> Oudin,A.D.</style></author><author><style face="normal" font="default"> Forsberg,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Occupational and Environmental Medicine, Umea University, 90187 Umea, Sweden.</style></auth-address><titles><title><style face="normal" font="default">Air Pollution and Dispensed Medications for Asthma, and Possible Effect Modifiers Related to Mental Health and Socio-Economy: A Longitudinal Cohort Study of Swedish Children and Adolescents</style></title><secondary-title><style face="normal" font="default">Int J Environ Res Public Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Environ Res Public Health</style></abbr-1></periodical><pages end="" start="E1392">E1392-</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="11" Year="2017">2017/11/16</year></dates><abstract><style face="normal" font="default">It has been suggested that children that are exposed to a stressful environment at home have an increased susceptibility for air pollution-related asthma. The aim here was to investigate the association between air pollution exposure and asthma, and effect modification by mental health and by socio-economic status (as markers of a stressful environment). All individuals under 18 years of age in four Swedish counties during 2007 to 2010 (1.2 million people) were included. The outcome was defined as dispensing at least two asthma medications during follow up. We linked data on NO(2) from an empirical land use regression to data from national registers on outcome and potential confounders. Data was analyzed with logistic regression. There was an odds ratio (OR) of 1.02 (95% Confidence Interval (CI: 1.01-1.03) for asthma associated with a 10 microg.m-3 increase in NO(2). The association only seemed to be present in areas where NO(2) was higher than 15 microg.m-3 with an OR of 1.09 (95% CI: 1.07-1.12), and the association seemed stronger in children with parents with a high education, OR = 1.05 (95% CI: 1.02-1.09) and OR = 1.04 (95% CI: 1.01-1.07) in children to mothers and father with a high education, respectively. The association did not seem to depend on medication history of psychiatric disorders. There was weak evidence for the association between air pollution and asthma to be stronger in neighborhoods with higher education levels. In conclusion, air pollution was associated with dispensed asthma medications, especially in areas with comparatively higher levels of air pollution, and in children to parents with high education. We did not observe support for our hypothesis that stressors linked to socio-economy or mental health problems would increase susceptibility to the effects of air pollution on the development of asthma</style></abstract><notes><style face="normal" font="default">DA - 20171116IS - 1660-4601 (Electronic)IS - 1660-4601 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.3390/ijerph14111392</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29144419">PM:29144419</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Environ Res Public Health\2017-14-E1392.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Environ Res Public Health\2017-14-E1392.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171116, Oudin A</style></custom2><misc3><style face="normal" font="default">10.3390/ijerph14111392</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43355</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,H.N.</style></author><author><style face="normal" font="default"> Shin,S.A.</style></author><author><style face="normal" font="default"> Choo,G.S.</style></author><author><style face="normal" font="default"> Kim,H.J.</style></author><author><style face="normal" font="default"> Park,Y.S.</style></author><author><style face="normal" font="default"> Kim,B.S.</style></author><author><style face="normal" font="default"> Kim,S.K.</style></author><author><style face="normal" font="default"> Cho,S.D.</style></author><author><style face="normal" font="default"> Nam,J.S.</style></author><author><style face="normal" font="default"> Choi,C.S.</style></author><author><style face="normal" font="default"> Che,J.H.</style></author><author><style face="normal" font="default"> Park,B.K.</style></author><author><style face="normal" font="default"> Jung,J.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Companion and Laboratory Animal Science, Kongju National University, Yesan 340702, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Antiinflammatory effect of quercetin and galangin in LPSstimulated RAW264.7 macrophages and DNCBinduced atopic dermatitis animal models</style></title><secondary-title><style face="normal" font="default">Int J Mol Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Mol Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="11" Year="2017">2017/11/29</year></dates><abstract><style face="normal" font="default">Flavonols are compounds that have been shown to possess potent antiinflammatory effects in cellular and animal models of inflammation. In the present study, the antiinflammatory effects and mechanisms of two natural flavonols, quercetin and galangin, in lipopolysaccharide (LPS)stimulated RAW264.7 macrophages were investigated. It was identified that quercetin and galangin markedly reduced the production of nitric oxide (NO), inducible NO synthase and interleukin6, and the nuclear translocation of nuclear factorkappaB (NFkappaB). In addition, LPSinduced activation of extracellular signalregulated kinase 1/2 (Erk1/2) and cJun Nterminal kinase (JNK) was suppressed by quercetin and galangin. Taken together, these data implied that NFkappaB, Erk1/2 and JNK may be potential molecular targets of quercetin and galangin in an LPSinduced inflammatory response. Subsequently, the effects of oral administration of quercetin or galangin, either alone or in combination, in a 2,4dinitrochlorobenzeneinduced atopic dermatitis (AD) mouse model were investigated. As a result, measurements of ear thickness and the levels of serum immunoglobulin E, and histological analysis revealed that the two flavonols led to a decrease in inflammation, whereas, in combination, they were even more effective. These results suggested that quercetin and galangin may be promising therapeutic agents for AD. Additionally, their combination may be a novel therapeutic strategy for the prevention of AD</style></abstract><notes><style face="normal" font="default">IS - 1791-244X (Electronic)IS - 1107-3756 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.3892/ijmm.2017.3296</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29207037">PM:29207037</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171112, Lee HN</style></custom2><misc3><style face="normal" font="default">10.3892/ijmm.2017.3296</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43356</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zeinaly,I.</style></author><author><style face="normal" font="default"> Sadeghi-Shabestrai,M.</style></author><author><style face="normal" font="default"> Babaloo,Z.</style></author><author><style face="normal" font="default"> Razavi,A.</style></author><author><style face="normal" font="default"> Sajay-Asbaghi,M.</style></author><author><style face="normal" font="default"> Sadigh-Eteghad,S.</style></author><author><style face="normal" font="default"> Kazemi,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran</style></auth-address><titles><title><style face="normal" font="default">Investigating the Association of ADAM33 Single Nucleotide Polymorphisms (SNPs) with Susceptibility to Allergic Asthma in Azerbaijan Population of Iran: A Case-control Study</style></title><secondary-title><style face="normal" font="default">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Iran J Allergy Asthma Immunol</style></abbr-1></periodical><pages end="385" start="378">378-385</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Asthma, affecting a growing number of populations, is a clinical condition with complex cellular and genetic factors. Single nucleotide polymorphisms (SNPs) in gene coding for molecules, which play major roles in the immunopathogenesis of asthma have been considered recently as genetic predisposing factors this disease. Possible association between two SNPs in a disintegrin and metalloprotease 33 (ADAM33), which participates in airway remodeling, and susceptibility to asthma was studied in this study. 190 patients with asthma and 180 healthy controls were enrolled in this case-control study. Using conventional PCR method, specific bands were amplified and the frequency of genotypes of T1 (rs2280091) and V4 (rs2787094) ADAM33 SNPs were determined by digestion with NcoI and PstI, respectively. The results showed that the frequency of genotypes of T1 and V4 were not significantly different between patients and controls (p=0.54 and p=0.85, respectively). On the other hand, no significant differences were seen in allele frequency of both T1 and V4 SNPs (p=0.15 and p=0.47, respectively). In agreement with some other studies in different populations, our results showed no association between frequency of genotype or alleles of both T1 and V4 SNPs in ADAM33 gene and predisposition to asthma in Azerbaijan population of Iran. Genetic differences in different ethnic groups might be involved in such inconsistent results. More studies in populations with larger number of patients and healthy individuals are needed for concluding remarks for involvement of ADAM33 SNPs in asthma</style></abstract><notes><style face="normal" font="default">IS - 1735-1502 (Print)IS - 1735-1502 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29149777">PM:29149777</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2017-16-378-85.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Iran J Allergy Asthma Immunol\2017-16-378-85.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171123, Zeinaly I</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43357</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">van der Molen,T.</style></author><author><style face="normal" font="default"> Fletcher,M.</style></author><author><style face="normal" font="default"> Price,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Primary Care, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands.</style></auth-address><titles><title><style face="normal" font="default">Identifying Patient Attitudinal Clusters Associated With Asthma Control: The European REALISE Survey</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="11" Year="2017">2017/11/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is a highly heterogeneous disease that can be classified into different clinical phenotypes, and treatment may be tailored accordingly. However, factors beyond purely clinical traits, such as patient attitudes and behaviors, can also have a marked impact on treatment outcomes. OBJECTIVE: The objective of this study was to further analyze data from the REcognise Asthma and LInk to Symptoms and Experience (REALISE) Europe survey, to identify distinct patient groups sharing common attitudes toward asthma and its management. METHODS: Factor analysis of respondent data (N = 7,930) from the REALISE Europe survey consolidated the 34 attitudinal variables provided by the study population into a set of 8 summary factors. Cluster analyses were used to identify patient clusters that showed similar attitudes and behaviors toward each of the 8 summary factors. RESULTS: Five distinct patient clusters were identified and named according to the key characteristics comprising that cluster: "Confident and self-managing," "Confident and accepting of their asthma," "Confident but dependent on others," "Concerned but confident in their health care professional (HCP)," and "Not confident in themselves or their HCP." Clusters showed clear variability in attributes such as degree of confidence in managing their asthma, use of reliever and preventer medication, and level of asthma control. CONCLUSIONS: The 5 patient clusters identified in this analysis displayed distinctly different personal attitudes that would require different approaches in the consultation room certainly for asthma but probably also for other chronic diseases</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Netherlands -CO - United Kingdom -CO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.10.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29170004">PM:29170004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20171112-vanderMolenT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20171112-vanderMolenT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171112, van der Molen T</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.10.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43358</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schneider,T.R.</style></author><author><style face="normal" font="default"> Johns,C.B.</style></author><author><style face="normal" font="default"> Palumbo,M.L.</style></author><author><style face="normal" font="default"> Murphy,K.C.</style></author><author><style face="normal" font="default"> Cahill,K.N.</style></author><author><style face="normal" font="default"> Laidlaw,T.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, Mass</style></auth-address><titles><title><style face="normal" font="default">Dietary Fatty Acid Modification for the Treatment of Aspirin-Exacerbated Respiratory Disease: A Prospective Pilot Trial</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="11" Year="2017">2017/11/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: The high levels of eicosanoid production and the clinical efficacy of leukotriene-modifying pharmacotherapies for patients with aspirin-exacerbated respiratory disease (AERD) suggest that other interventions targeting arachidonic acid dysregulation may also improve disease control. OBJECTIVE: To assess the utility of a high omega-3/low omega-6 diet for the treatment of AERD. METHODS: Prospective, nonblinded dietary intervention in 10 adult patients with AERD at Brigham and Women's Hospital in Boston, MA. The primary objective was for subjects to reduce dietary omega-6 fatty acid consumption to less than 4 g/d and increase omega-3 intake to more than 3 g/d. The primary outcome was change in urinary leukotriene E4, with changes in other eicosanoids, platelet activation, lung function, and patient-reported questionnaires also assessed. RESULTS: Of the 10 subjects who screened for the study, all 10 completed the dietary intervention. Urinary leukotriene E4 decreased by 0.17 ng/mg (95% CI, -0.29 to -0.04; P = .02) and tetranor prostaglandin D-M decreased by 0.66 ng/mg creatinine (95% CI, -1.21 to -0.11; P = .02). There was a 15.1-point reduction in the 22-item Sino-Nasal Outcome Test score (95% CI, -24.3 to -6.0; P = .01), a 0.27-point reduction in the 7-item Asthma Control Questionnaire score (95% CI, -0.52 to -0.03; P = .03), and no change in FEV1 % predicted (P = .92) or forced vital capacity % predicted (P = .74). All patients lost some weight over the 2-week intervention period, and there were no diet-associated adverse events. CONCLUSIONS: A high omega-3/low omega-6 diet may be an appropriate adjunct treatment option for patients with AERD</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.10.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29133219">PM:29133219</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171110, Schneider TR</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.10.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43359</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cordova-Rivera,L.</style></author><author><style face="normal" font="default"> Gibson,P.G.</style></author><author><style face="normal" font="default"> Gardiner,P.A.</style></author><author><style face="normal" font="default"> Powell,H.</style></author><author><style face="normal" font="default"> McDonald,V.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Health and Medical Research Council Centre of Excellence in Severe Asthma, New Lambton Heights, New South Wales, Australia</style></auth-address><titles><title><style face="normal" font="default">Physical Activity and Exercise Capacity in Severe Asthma: Key Clinical Associations</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="11" Year="2017">2017/11/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Physical inactivity and sedentary time are distinct behaviors that may be more prevalent in severe asthma, contributing to poor disease outcomes. Physical activity and sedentary time in severe asthma however have not been extensively examined. OBJECTIVE: We aimed to objectively measure physical activity and sedentary time in people with severe asthma compared with age-matched control participants, describing the associations of these behaviors with clinical and biological outcomes. We hypothesized that people with severe asthma would be less active and more sedentary. In addition, more activity and less sedentary time would be associated with better clinical outcomes and markers of systemic and airway inflammation in people with severe asthma. METHODS: Adults with severe asthma (n = 61) and sex- and age-matched controls (n = 61) underwent measurement of lung function, exercise capacity, asthma control, health status, and airway and systemic inflammation. Physical activity and sedentary time were measured using an accelerometer. RESULTS: The severe asthma and control groups were matched in terms of age and sex (32 [53%] females in each group). Individuals with severe asthma accumulated less minutes per day in moderate and higher intensity activity, median (IQR) 21.9 (12.9-36.0) versus 41.7 (29.5-65.2) (P &lt; .0001) and accumulated 2,232 fewer steps per day (P = .0002). However, they engaged in more light-intensity physical activity. No differences were found for sedentary time. In a multivariate regression model, steps per day were strongly and independently associated with better exercise capacity in participants with severe asthma (coefficient, 0.0169; 95% CI, 0.008-0.025; P &lt; .001). CONCLUSIONS: People with severe asthma perform less moderate and vigorous activity than do controls. Higher levels of activity and lower levels of sedentary time are associated with better exercise capacity, asthma control, and lower levels of systemic inflammation</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.09.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29133222">PM:29133222</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171114, Cordova-Rivera L</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.09.022</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43360</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ange,N.</style></author><author><style face="normal" font="default"> Alley,S.</style></author><author><style face="normal" font="default"> Fernando,S.L.</style></author><author><style face="normal" font="default"> Coyle,L.</style></author><author><style face="normal" font="default"> Yun,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Allergy and Immunology, Royal North Shore Hospital, Sydney, Australia</style></auth-address><titles><title><style face="normal" font="default">Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome successfully treated with mepolizumab</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="11" Year="2017">2017/11/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">0.1016/j.jaip.2017.10.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29133221">PM:29133221</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171110, Ange N</style></custom2><misc3><style face="normal" font="default">0.1016/j.jaip.2017.10.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43361</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sundaresan,A.S.</style></author><author><style face="normal" font="default"> Hirsch,A.G.</style></author><author><style face="normal" font="default"> Young,A.J.</style></author><author><style face="normal" font="default"> Pollak,J.</style></author><author><style face="normal" font="default"> Tan,B.K.</style></author><author><style face="normal" font="default"> Schleimer,R.P.</style></author><author><style face="normal" font="default"> Kern,R.C.</style></author><author><style face="normal" font="default"> Kennedy,T.L.</style></author><author><style face="normal" font="default"> Greene,J.S.</style></author><author><style face="normal" font="default"> Stewart,W.F.</style></author><author><style face="normal" font="default"> Bandeen-Roche,K.</style></author><author><style face="normal" font="default"> Schwartz,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Epidemiology and Health Services Research, Geisinger Health System, Danville, Pa.</style></auth-address><titles><title><style face="normal" font="default">Longitudinal Evaluation of Chronic Rhinosinusitis Symptoms in a Population-based Sample</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="11" Year="2017">2017/11/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic rhinosinusitis (CRS) is a prevalent and disabling condition of the nose and sinuses. The natural history of CRS symptoms in a general population sample has not been previously studied. OBJECTIVE: In a general population-based sample from Pennsylvania, we used 2 questionnaires mailed 6 months apart to estimate the prevalence of, and identify predictors for, stability or change in symptoms over time. METHODS: We mailed the baseline and 6-month follow-up questionnaires to 23,700 primary care patients and 7,801 baseline responders, respectively. We categorized nasal and sinus symptoms using European Position Paper on Rhinosinusitis (EPOS) epidemiologic criteria. We defined 6 symptom groups over time on the basis of the presence of CRS symptoms at baseline and follow-up. We performed multivariable survey logistic regression controlling for confounding variables comparing persistent versus nonpersistent, recurrent versus stable past, and incident versus never. RESULTS: There were 4,966 responders at follow-up: 558 had persistent symptoms, 190 recurrent symptoms, and 83 new symptoms meeting EPOS criteria for CRS. The prevalence of persistent symptoms was 4.8% (95% CI, 3.8-5.8), whereas the annual cumulative incidence of new symptoms was 1.9% and of recurrent symptoms was 3.2%. More severe symptoms at baseline were associated with persistence, whereas minor symptoms, allergies, and multiple treatments were associated with the development of new symptoms. CONCLUSIONS: Less than half with nasal and sinus symptoms meeting CRS EPOS criteria in our general, regional population had symptom persistence over time, with symptom profiles at baseline and age of onset being strongly associated with stability of symptoms</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.10.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29133225">PM:29133225</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171114, Sundaresan AS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.10.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43362</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shalaby,K.H.</style></author><author><style face="normal" font="default"> Lyons-Cohen,M.R.</style></author><author><style face="normal" font="default"> Whitehead,G.S.</style></author><author><style face="normal" font="default"> Thomas,S.Y.</style></author><author><style face="normal" font="default"> Prinz,I.</style></author><author><style face="normal" font="default"> Nakano,H.</style></author><author><style face="normal" font="default"> Cook,D.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunogenetics Group, Immunity, Inflammation and Disease Laboratory, Division of Intramural Research, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina 27709, USA</style></auth-address><titles><title><style face="normal" font="default">Pathogenic Th17 inflammation is sustained in the lungs by conventional dendritic cells and TLR4 signaling</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="11" Year="2017">2017/11/14</year></dates><abstract><style face="normal" font="default">BACKGROUND: Mechanisms that elicit mucosal Th17 cell responses have been described, yet how these cells are sustained in chronically inflamed tissues remains unclear. OBJECTIVE: We sought to understand whether the maintenance of lung Th17 inflammation requires environmental agents in addition to antigen, and to identify the lung antigen-presenting cell types (APCs) that sustain the self-renewal of Th17 cells. METHODS: Animals were repeatedly exposed to aspiration of ovalbumin alone, or together with environmental adjuvants, including extracts of common house dust (HDE), to test their role in maintaining lung inflammation. Alternatively, antigen-specific effector/memory Th17 cells, generated in culture using CD4(+) T cells from Il17a fate-mapping mice, were adoptively transferred to assess their persistence in genetically modified animals lacking distinct lung APC subsets or cell-specific TLR4 signaling. Th17 cells were also co-cultured with lung APC subsets to determine which of these could revive their expansion and activation. RESULTS: Th17 cells and consequent neutrophilic inflammation were poorly sustained by inhaled antigen alone, but were augmented by inhalation of antigen together with HDE. This was associated with weight loss and changes in lung physiology consistent with interstitial lung disease. The effect of HDE required TLR4 signaling predominantly in lung hematopoietic cells, including CD11c(+) cells. CD103(+) and CD11b(+) conventional dendritic cells (cDCs) directly interacted with Th17 cells in situ and revived the clonal expansion of Th17 cells ex vivo and in vivo, whereas lung macrophages and B cells could not. CONCLUSION: Th17-dependent inflammation in the lungs can be sustained by persistent TLR4-mediated activation of lung cDCs</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Germany -</style></notes><work-type><style face="normal" font="default">    10.1016/j.jaci.2017.10.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29154958">PM:29154958</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171114-ShalabyKH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171114-ShalabyKH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171114, Shalaby KH</style></custom2><misc3><style face="normal" font="default">    10.1016/j.jaci.2017.10.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43363</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mummy,D.G.</style></author><author><style face="normal" font="default"> Kruger,S.J.</style></author><author><style face="normal" font="default"> Zha,W.</style></author><author><style face="normal" font="default"> Sorkness,R.L.</style></author><author><style face="normal" font="default"> Jarjour,N.N.</style></author><author><style face="normal" font="default"> Schiebler,M.L.</style></author><author><style face="normal" font="default"> Denlinger,L.C.</style></author><author><style face="normal" font="default"> Evans,M.D.</style></author><author><style face="normal" font="default"> Fain,S.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biomedical Engineering</style></auth-address><titles><title><style face="normal" font="default">Ventilation Defect Percent in Helium-3 MRI as a Biomarker of Severe Outcomes in Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="11" Year="2017">2017/11/9</year></dates><abstract><style face="normal" font="default">Ventilation defect percent (VDP) measured in asthmatics with hyperpolarized helium-3 MRI was more strongly associated with ED visits and hospitalizations due to asthma exacerbation than were conventional biomarkers of lung function and inflammation</style></abstract><notes><style face="normal" font="default">DA - 20171113IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.10.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29129582">PM:29129582</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171109-MummyDG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171109-MummyDG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171109, Mummy DG</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.10.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43364</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Silverberg,J.I.</style></author><author><style face="normal" font="default"> Vakharia,P.P.</style></author><author><style face="normal" font="default"> Chopra,R.</style></author><author><style face="normal" font="default"> Sacotte,R.</style></author><author><style face="normal" font="default"> Patel,N.</style></author><author><style face="normal" font="default"> Immaneni,S.</style></author><author><style face="normal" font="default"> White,T.</style></author><author><style face="normal" font="default"> Kantor,R.</style></author><author><style face="normal" font="default"> Hsu,D.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departments of Dermatology, Preventive Medicine and Medical Social Sciences, Feinberg School of Medicine at Northwestern University, Chicago</style></auth-address><titles><title><style face="normal" font="default">Phenotypical Differences of Childhood- and Adult-Onset Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="11" Year="2017">2017/11/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Little is known about adult-onset atopic dermatitis (AD). OBJECTIVE: To determine the associations and clinical characteristics of adult-onset AD. METHODS: A prospective study of 356 adults with AD (age >/=18 years) was performed using standardized questionnaires and examination. AD severity was assessed using the Patient-Oriented Eczema Measure, Eczema Area and Severity Index, Scoring Atopic Dermatitis, body surface area, and numeric rating scale for itch and sleeplessness. Latent class analysis was used to determine dominant clinical phenotypes. Multivariate logistic regression was used to determine the relationship between adult-onset AD and distinct phenotypes. RESULTS: One hundred forty-nine adults (41.9%) reported onset of AD during adulthood, with 87 (24.4%) after the age of 50 years. Adult- versus childhood-onset AD was associated with birthplace outside the United States (chi2, P = .0008), but not sex, race/ethnicity, current smoking status, or alcohol consumption (P >/= .11); and decreased personal history of asthma, hay fever, and food allergy and family history of asthma and food allergy (P &lt;/= .0001 for all). There was no significant difference in the Eczema Area and Severity Index, Scoring Atopic Dermatitis, body surface area, numeric rating scale for itch and sleeplessness, or Patient-Oriented Eczema Measure between adult- and childhood-onset AD (Mann-Whitney U test, P >/= .10). Latent class analysis identified 3 classes: (1) high probability of flexural dermatitis and xerosis with intermediate to high probabilities of head, neck, and hand dermatitis; (2) high probability of flexural dermatitis and xerosis, but low probabilities of head, neck, and hand dermatitis; and (3) lower probability of flexural dermatitis, but the highest probabilities of virtually all other signs and symptoms. Adult-onset AD was significantly associated with class 1 (multivariate logistic regression; adjusted odds ratio, 5.54; 95% CI, 1.59-19.28) and class 3 (adjusted odds ratio, 14.03; 95% CI, 2.33-85.50). CONCLUSIONS: Self-reported adult-onset AD is common and has distinct phenotypes with lesional predilection for the hands and/or head/neck</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.10.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29133223">PM:29133223</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171114, Silverberg JI</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.10.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43365</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schoos,A.M.</style></author><author><style face="normal" font="default"> Christiansen,C.F.</style></author><author><style face="normal" font="default"> Stokholm,J.</style></author><author><style face="normal" font="default"> Bonnelykke,K.</style></author><author><style face="normal" font="default"> Bisgaard,H.</style></author><author><style face="normal" font="default"> Chawes,B.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">COPSAC (Copenhagen Prospective Studies on Asthma in Childhood), Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default">FeNO and Exercise Testing in Children at Risk of Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="11" Year="2017">2017/11/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Exercise testing is the gold standard for diagnosing exercise-induced bronchoconstriction in children, but requires considerable cooperation and medical resources. Therefore, fraction of exhaled nitric oxide (FeNO) has been proposed as a tool to predict the need for exercise testing. OBJECTIVE: The objective of this study was to investigate the relationship between FeNO, exercise test results, and a history of respiratory symptoms during exercise in children at risk of asthma. METHODS: FeNO measurement, exercise testing, and interview about respiratory symptoms during exercise were completed in 224 seven-year-old children from the at-risk Copenhagen Prospective Studies on Asthma in Childhood2000 birth cohort. The associations between FeNO, exercise test results, and reported respiratory symptoms during exercise were analyzed adjusting for gender, respiratory infections, and inhaled corticosteroid treatment. The associations were also analyzed stratified by asthma and atopic status. RESULTS: Of the 224 children, 28 (13%) had an established asthma diagnosis and 58 (26%) had a positive exercise test (>/=15% drop in forced expiratory volume in 1 second [FEV1] from baseline). FeNO and bronchial obstruction after exercise were linearly associated with a doubling of FeNO corresponding to a 2.4% drop in FEV1 (95% confidence interval, 0.8-4.1; P &lt; .01). However, a receiver operating characteristic curve analysis showed that the best cutoff of FeNO for predicting exercise test outcome among children who reported respiratory symptoms during exercise was 17 ppb, which only had 74% negative predictive value. There was no association between FeNO and reported respiratory symptoms during exercise (odds ratio = 1.3 [0.8-1.9]; P = .29) or reported symptoms during exercise and exercise test results (odds ratio = 1.0 [1.0-1.1]; P = .12). CONCLUSIONS: A history of respiratory symptoms during exercise was not associated with either elevated FeNO or a positive exercise test in children at risk of asthma. FeNO and exercise test results were linearly associated traits, but FeNO could not reliably be used dichotomized to predict the need of exercise testing</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.10.014</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29133224">PM:29133224</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171114, Schoos AM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.10.014</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43366</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jiao,J.</style></author><author><style face="normal" font="default"> Wang,M.</style></author><author><style face="normal" font="default"> Duan,S.</style></author><author><style face="normal" font="default"> Meng,Y.</style></author><author><style face="normal" font="default"> Meng,N.</style></author><author><style face="normal" font="default"> Li,Y.</style></author><author><style face="normal" font="default"> Fan,E.</style></author><author><style face="normal" font="default"> Akdis,C.</style></author><author><style face="normal" font="default"> Zhang,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology, Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Beijing 100730, China; Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing 100005, China</style></auth-address><titles><title><style face="normal" font="default">Transforming growth factor-beta1 decreases epithelial tight junction integrity in chronic rhinosinusitis with nasal polyps</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="11" Year="2017">2017/11/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - China -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.08.045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29132958">PM:29132958</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171114-JiaoJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171114-JiaoJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171114, Jiao J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.08.045</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43367</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kulka,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Alberta T6G 2E1, Canada</style></auth-address><titles><title><style face="normal" font="default">Could Substance P be an antiviral mediator and potential therapeutic target in the nose?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="11" Year="2017">2017/11/13</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171117IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.11.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29146273">PM:29146273</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171113-KulkaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171113-KulkaM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171113, Kulka M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.11.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43368</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Weronica,E.E.</style></author><author><style face="normal" font="default"> Torgny,K.</style></author><author><style face="normal" font="default"> Carlos,A.H.</style></author><author><style face="normal" font="default"> Mathias,R.A.</style></author><author><style face="normal" font="default"> Asa,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.</style></auth-address><titles><title><style face="normal" font="default">Breastfeeding and risk of asthma, hay fever and eczema</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="11" Year="2017">2017/11/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.10.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29132959">PM:29132959</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171110-WeronicaEE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171110-WeronicaEE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171110, Weronica EE</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.10.022</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43369</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sorkness,R.L.</style></author><author><style face="normal" font="default"> Zoratti,E.M.</style></author><author><style face="normal" font="default"> Kattan,M.</style></author><author><style face="normal" font="default"> Gergen,P.J.</style></author><author><style face="normal" font="default"> Evans,M.D.</style></author><author><style face="normal" font="default"> Visness,C.M.</style></author><author><style face="normal" font="default"> Gill,M.</style></author><author><style face="normal" font="default"> Khurana Hershey,G.K.</style></author><author><style face="normal" font="default"> Kercsmar,C.M.</style></author><author><style face="normal" font="default"> Liu,A.H.</style></author><author><style face="normal" font="default"> O'Connor,G.T.</style></author><author><style face="normal" font="default"> Pongracic,J.A.</style></author><author><style face="normal" font="default"> Pillai,D.</style></author><author><style face="normal" font="default"> Sorkness,C.A.</style></author><author><style face="normal" font="default"> Togias,A.</style></author><author><style face="normal" font="default"> Wood,R.A.</style></author><author><style face="normal" font="default"> Busse,W.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Wisconsin-Madison, School of Pharmacy; Departments of Medicine; Departments of Pediatrics.Departments of Medicine</style></auth-address><titles><title><style face="normal" font="default">Obstruction phenotype as a predictor of asthma severity and instability in children</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="11" Year="2017">2017/11/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: Small airways instability, resulting in premature airway closure, has been recognized as a risk for asthma severity and poor control. Although spirometry has limited sensitivity for detecting small airway dysfunction, a focus on the air-trapping component of obstruction may identify a risk factor for asthma instability. OBJECTIVE: To use spirometric measurements to identify patterns of airway obstruction in children, and define obstruction phenotypes that relate to asthma instability. METHODS: Pre- and post-bronchodilation spirometry data were obtained from 560 children in the Asthma Phenotypes in the Inner City study. An air-trapping obstruction phenotype (A Trpg) was defined as forced vital capacity (FVC) Z-score &lt; -1.64, or an increase of FVC >/= 10% predicted with bronchodilation. The airflow limitation phenotype (A Limit) had forced expiratory volume in 1 s (FEV1)/FVC Z-score &lt; -1.64, but not A Trpg. The None phenotype had neither A Trpg nor A Limit. The 3 obstruction phenotypes were assessed as predictors of number of exacerbations, asthma severity, and airway lability. RESULTS: The A Trpg phenotype (14% of the cohort) had more exacerbations during the 12-month study, compared with the A Limit (P&lt;0.03) and the None (P&lt;0.001) phenotypes. The A Trpg phenotype also had the highest Composite Asthma Severity Index, the highest asthma treatment step, the greatest variability in FEV1 over time, and the greatest sensitivity to methacholine challenge. CONCLUSIONS: A Trpg and A Limit patterns of obstruction, defined with routine spirometric measurements, can identify obstruction phenotypes that are indicators of risk for asthma severity and instability</style></abstract><notes><style face="normal" font="default">DA - 20171117IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.09.047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29146272">PM:29146272</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171117-SorknessRL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171117-SorknessRL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171113, Sorkness RL</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.09.047</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43370</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sendin-Hernandez,M.P.</style></author><author><style face="normal" font="default"> Avila-Zarza,C.</style></author><author><style face="normal" font="default"> Sanz,C.</style></author><author><style face="normal" font="default"> Garcia-Sanchez,A.</style></author><author><style face="normal" font="default"> Marcos-Vadillo,E.</style></author><author><style face="normal" font="default"> Munoz-Bellido,F.J.</style></author><author><style face="normal" font="default"> Laffond,E.</style></author><author><style face="normal" font="default"> Domingo,C.</style></author><author><style face="normal" font="default"> Isidoro-Garcia,M.</style></author><author><style face="normal" font="default"> Davila,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Biochemistry, University Hospital of Salamanca, Salamanca, Spain</style></auth-address><titles><title><style face="normal" font="default">Cluster Analysis Identifies 3 Phenotypes within Allergic Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="11" Year="2017">2017/11/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is a heterogeneous chronic disease with different clinical expressions and responses to treatment. In recent years, several unbiased approaches based on clinical, physiological, and molecular features have described several phenotypes of asthma. Some phenotypes are allergic, but little is known about whether these phenotypes can be further subdivided. OBJECTIVE: We aimed to phenotype patients with allergic asthma using an unbiased approach based on multivariate classification techniques (unsupervised hierarchical cluster analysis). METHODS: From a total of 54 variables of 225 patients with well-characterized allergic asthma diagnosed following American Thoracic Society (ATS) recommendation, positive skin prick test to aeroallergens, and concordant symptoms, we finally selected 19 variables by multiple correspondence analyses. Then a cluster analysis was performed. RESULTS: Three groups were identified. Cluster 1 was constituted by patients with intermittent or mild persistent asthma, without family antecedents of atopy, asthma, or rhinitis. This group showed the lowest total IgE levels. Cluster 2 was constituted by patients with mild asthma with a family history of atopy, asthma, or rhinitis. Total IgE levels were intermediate. Cluster 3 included patients with moderate or severe persistent asthma that needed treatment with corticosteroids and long-acting beta-agonists. This group showed the highest total IgE levels. CONCLUSIONS: We identified 3 phenotypes of allergic asthma in our population. Furthermore, we described 2 phenotypes of mild atopic asthma mainly differentiated by a family history of allergy</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.10.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29133218">PM:29133218</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171114, Sendin-Hernandez MP</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.10.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43371</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pereira-Santos,M.</style></author><author><style face="normal" font="default"> Bispo Pereira,L.L.</style></author><author><style face="normal" font="default"> Santana de Oliveira,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center of Biological Sciences and Health, Universidade Federal do Oeste da Bahia, Barreiras-Ba, Brazil.</style></auth-address><titles><title><style face="normal" font="default">Obesity, asthma, and vitamin D deficiency in pregnancy: Cause or consequence?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="11" Year="2017">2017/11/21</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.08.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29169706">PM:29169706</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171121-PereiraSantosM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171121-PereiraSantosM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171121, Pereira-Santos M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.08.036</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43372</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vukmanovic-Stejic,M.</style></author><author><style face="normal" font="default"> Chambers,E.S.</style></author><author><style face="normal" font="default"> Farinas,M.S.</style></author><author><style face="normal" font="default"> Sandhu,D.</style></author><author><style face="normal" font="default"> Fuentes-Duculan,J.</style></author><author><style face="normal" font="default"> Patel,N.</style></author><author><style face="normal" font="default"> Agius,E.</style></author><author><style face="normal" font="default"> Lacy,K.E.</style></author><author><style face="normal" font="default"> Turner,C.T.</style></author><author><style face="normal" font="default"> Larbi,A.</style></author><author><style face="normal" font="default"> Birault,V.</style></author><author><style face="normal" font="default"> Noursadeghi,M.</style></author><author><style face="normal" font="default"> Mabbott,N.A.</style></author><author><style face="normal" font="default"> Rustin,M.H.A.</style></author><author><style face="normal" font="default"> Krueger,J.</style></author><author><style face="normal" font="default"> Akbar,A.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Infection and Immunity, University College London, London, WC1E 6EJ, England, UK.</style></auth-address><titles><title><style face="normal" font="default">Enhancement of cutaneous immunity during ageing by blocking p38 MAPkinase induced inflammation</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="11" Year="2017">2017/11/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Immunity declines with age that leads to re-activation of varicella zoster virus (VZV). In humans, age associated immune changes are usually measured in blood leukocytes however this may not reflect alterations in tissue-specific immunity. OBJECTIVES: We used a VZV antigen challenge system in the skin to investigate changes in tissue specific mechanisms involved in the decreased response to this virus during ageing. METHODS: We assessed cutaneous immunity by the extent of erythema and induration after intradermal VZV antigen injection. We also performed immune histology and transcriptomic analyses on skin biopsies taken from the site of challenge in young (&lt;40 yrs) and old (>65 yrs) subjects. RESULTS: Old humans exhibited decreased erythema and induration, CD4(+) and CD8(+) T cell infiltration and attenuated global gene activation at the site of cutaneous VZV antigen challenge compared to young subjects. This was associated with elevated sterile inflammation in the skin in the same subjects, related to p38 MAPK-related pro-inflammatory cytokine production (p &lt;0.0007). We inhibited systemic inflammation in old subjects by pre-treatment with an oral small molecule p38 MAP kinase inhibitor (Losmapimod), which reduced both serum C reactive protein (CRP) and peripheral blood monocyte secretion of IL-6 and TNF-alpha. In contrast, cutaneous responses to VZV antigen challenge was significantly increased in the same individuals (p &lt;0.0006). CONCLUSION: Excessive inflammation in the skin early after antigen challenge retards antigen-specific immunity. However this can be reversed by inhibition of inflammatory cytokine production that may be utilized to promote vaccine efficacy and the treatment of infections and malignancy during ageing</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - Singapore -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.10.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29155150">PM:29155150</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171117-VukmanovicStejicM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171117-VukmanovicStejicM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171117, Vukmanovic-Stejic M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.10.032</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43373</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zeiger,R.S.</style></author><author><style face="normal" font="default"> Tran,T.N.</style></author><author><style face="normal" font="default"> Butler,R.K.</style></author><author><style face="normal" font="default"> Schatz,M.</style></author><author><style face="normal" font="default"> Li,Q.</style></author><author><style face="normal" font="default"> Khatry,D.B.</style></author><author><style face="normal" font="default"> Martin,U.</style></author><author><style face="normal" font="default"> Kawatkar,A.A.</style></author><author><style face="normal" font="default"> Chen,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Kaiser Permanente Southern California, San Diego, Calif; Kaiser Permanente Southern California, Pasadena, Calif.</style></auth-address><titles><title><style face="normal" font="default">Relationship of Blood Eosinophil Count to Exacerbations in Chronic Obstructive Pulmonary Disease</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="15" Month="11" Year="2017">2017/11/15</year></dates><abstract><style face="normal" font="default">BACKGROUND: Eosinophilic airway inflammation characterizes a chronic obstructive pulmonary disease (COPD) phenotype that requires more study. OBJECTIVE: To investigate the relationship of blood eosinophil count to exacerbations in COPD. METHODS: Using administrative pharmacy and health care utilization data from 2009 to 2012, we retrospectively identified patients 40 years or older with a COPD diagnosis, postbronchodilator FEV1/forced vital capacity ratio of less than 0.7, and a blood eosinophil count (N = 7,245). COPD exacerbations were defined as hospitalizations or emergency department visits with a primary diagnosis of COPD, or outpatient visits with systemic corticosteroid dispensing within +/-14 days associated with an encounter code consistent with a COPD exacerbation. The relationship between the index blood eosinophil count and the rate of COPD exacerbations in the follow-up year was determined by multivariable analyses. RESULTS: Patients with COPD were predominantly male (57.1%), white (71.8%), often current or past smokers (75.4%), and had frequent comorbidities; 19.0% had eosinophil counts of greater than or equal to 300 cells/mm(3), 76.1% were classified as moderate to very severe by lung function, and the COPD exacerbation rate was 0.38 per year (95% CI, 0.37-0.40). After adjustment for potential confounders, COPD exacerbations during 1-year follow-up were significantly greater for patients with blood eosinophil counts of greater than or equal to 300 cells/mm(3) (rate ratio [RR], 1.25; 95% CI, 1.10-1.43), greater than or equal to 400 cells/mm(3) (RR, 1.48; 95% CI, 1.26-1.75), and greater than or equal to 500 cells/mm(3) (RR, 1.76; 95% CI, 1.45-2.14), respectively, compared with patients with eosinophils lower than the cutoffs. CONCLUSIONS: In this study, high blood eosinophil counts were an independent risk factor for future exacerbations in patients with COPD, a phenotype that might benefit from therapy directed at eosinophilic-driven disease and inflammation</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.10.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29153881">PM:29153881</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171115, Zeiger RS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.10.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43374</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Casale,T.B.</style></author><author><style face="normal" font="default"> Bateman,E.D.</style></author><author><style face="normal" font="default"> Vandewalker,M.</style></author><author><style face="normal" font="default"> Virchow,J.C.</style></author><author><style face="normal" font="default"> Schmidt,H.</style></author><author><style face="normal" font="default"> Engel,M.</style></author><author><style face="normal" font="default"> Moroni-Zentgraf,P.</style></author><author><style face="normal" font="default"> Kerstjens,H.A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Morsani College of Medicine, University of South Florida, Tampa, Fla.</style></auth-address><titles><title><style face="normal" font="default">Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="11" Year="2017">2017/11/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: Adding tiotropium to existing inhaled corticosteroid (ICS) maintenance therapy with or without a long-acting beta2-agonist (LABA) has been shown to be beneficial in patients with symptomatic asthma. OBJECTIVE: To assess whether responses to tiotropium Respimat add-on therapy were influenced by patients' T2 status. METHODS: In this exploratory study, data from 4 phase III trials were analyzed: once-daily tiotropium 5 mug or placebo as add-on to ICS + LABA (PrimoTinA-asthma; 2 replicate trials; NCT00772538/NCT00776984; n = 912); once-daily tiotropium 5 mug or 2.5 mug, twice-daily salmeterol 50 mug, or placebo as add-on to ICS (MezzoTinA-asthma; 2 replicate trials; NCT01172808/NCT01172821; n = 2100). The prespecified efficacy outcomes of these studies have been reported previously. Here, further exploratory subgroup analyses were performed to study whether these coprimary end points were influenced by serum IgE levels, blood eosinophil counts, and clinician judgment of allergic asthma. In addition, for the continuous parameters, namely, IgE and blood eosinophils, their influence on the treatment effect was modeled over the whole range of values. RESULTS: Tiotropium was efficacious in improving peak FEV1 within 3 hours postdose and trough FEV1, independent of T2 status. Tiotropium significantly reduced the risk of severe asthma exacerbations and asthma worsening, independent of T2 phenotype; Cox regression modeling supported a beneficial effect of tiotropium on exacerbations, independent of IgE levels or eosinophil counts. Numerical improvements in the 7-question Asthma Control Questionnaire (ACQ-7) responder rate with tiotropium versus placebo were observed in T2high and T2low patients; logistic regression modeling provided further evidence for improvement in ACQ-7 responder rates with tiotropium, independent of IgE levels or eosinophil counts. CONCLUSIONS: The results of our exploratory analyses suggest that the improvements seen with tiotropium Respimat as add-on to ICS +/- LABA in patients with symptomatic asthma on lung function, exacerbation risk, and symptom control are independent of T2 phenotype</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -CO - South Africa -CO - Germany -CO - Australia -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.037</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29174062">PM:29174062</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20171122-CasaleTB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol Pract\20171122-CasaleTB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171122, Casale TB</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.037</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43375</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Drucker,A.M.</style></author><author><style face="normal" font="default"> Qureshi,A.A.</style></author><author><style face="normal" font="default"> Amand,C.</style></author><author><style face="normal" font="default"> Villeneuve,S.</style></author><author><style face="normal" font="default"> Gadkari,A.</style></author><author><style face="normal" font="default"> Chao,J.</style></author><author><style face="normal" font="default"> Kuznik,A.</style></author><author><style face="normal" font="default"> Bego-Le-Bagousse,G.</style></author><author><style face="normal" font="default"> Eckert,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Warren Alpert Medical School, Brown University, Providence, RIRegeneron, Tarrytown, NYRegeneron, Tarrytown, NYRegeneron, Tarrytown, NYSanofi, Chilly-Mazarin, FranceSanofi, Chilly-Mazarin, France</style></auth-address><titles><title><style face="normal" font="default">Health Care Resource Utilization and Costs among Adults with Atopic Dermatitis in the United States: A Claims-Based Analysis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="11" Year="2017">2017/11/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: Data on health care resource utilization (HCRU) and costs for patients with atopic dermatitis (AD) are lacking. OBJECTIVE: The objective of this study was to determine HCRU and costs associated with AD in US adults. METHODS: This retrospective study identified patients with AD from the Truven Health Marketscan Commercial Claims and Encounters database during 2013 based on >/=2 claims with International Classification of Diseases, Ninth Revision code 691.8 (n = 10,533; first claim = index event); 1-year continuous enrollment before and after index was required. Patients were age- and gender-matched in a 1:3 ratio to controls without AD (n = 31,599). Patients with AD were further categorized into 2 groups, with treatment regimens as surrogates for increasing disease severity: claim for phototherapy or systemic immunomodulatory agents (more severe) or no claim for either (less severe). Incremental differences in resource use and costs were evaluated using multivariate analysis. RESULTS: AD was associated with higher utilization and costs across resource categories (all P &lt; .0001); adjusted total incremental annual costs were $3,302. Resource utilization and costs were higher in the more severe group, with adjusted total incremental annual costs of $4,463. CONCLUSION: AD is associated with significant incremental health care utilization and costs, which are higher in patients with more severe disease</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United states -CO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.10.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29174063">PM:29174063</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171121, Drucker AM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.10.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43376</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tonson la Tour,A.</style></author><author><style face="normal" font="default"> Michelet,M.</style></author><author><style face="normal" font="default"> Eigenmann,P.A.</style></author><author><style face="normal" font="default"> Caubet,J.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pediatric Emergency, University Hospital of Geneva, Geneva, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Natural History of Benign Nonimmediate Allergy to Beta-Lactams in Children: A Prospective Study in Retreated Patients After a Positive and a Negative Provocation Test</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="11" Year="2017">2017/11/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: The drug provocation test (DPT) is considered as the gold standard to diagnose drug allergy and is particularly important in the diagnosis of nonimmediate beta-lactam (BL) allergy in children. The natural history of BL allergy remains unknown. OBJECTIVE: Our main aim was to evaluate the natural history of nonimmediate BL hypersensitivity and the long-term tolerance acquisition, and our secondary objective was to determine the negative predictive value (NPV) of the DPT following a 2-day protocol. METHODS: Children developing a benign rash while treated by BL were prospectively recruited at the Emergency Department of the Geneva University Hospital from 2006 to 2011 and challenged with the incriminated BL (initial diagnostic drug provocation test [idDPT]) following a 2-day protocol. In case of a positive idDPT, the patients underwent a follow-up drug provocation test (fuDPT) 3 years later. In case of a negative idDPT, we sent a questionnaire to assess tolerance of a subsequent treatment with the incriminated BL. RESULTS: Among the 18 children with a positive idDPT, 16 children (89%) had a negative fuDPT and 2 children developed a benign exanthema. Among those 16 children, 11 tolerated a subsequent treatment with the incriminated BL without any reaction, suggesting natural antibiotic tolerance acquisition. From another point of view, we found that the NPV of the DPT following a 2-day protocol was excellent at 96.7%. CONCLUSIONS: Our data strongly suggest that a fuDPT is safe and useful to assess tolerance acquisition in children with a confirmed benign nonimmediate BL allergy. In addition, our results support the use of a short DPT protocol (2 days), which led to a high NPV of 96.7% in our population, with a favorable benefit-risk balance</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Switzerland -CO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.10.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29175371">PM:29175371</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171123, Tonson la Tour A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.10.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43377</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Agondi,R.C.</style></author><author><style face="normal" font="default"> Andrade,M.C.</style></author><author><style face="normal" font="default"> Takejima,P.</style></author><author><style face="normal" font="default"> Aun,M.V.</style></author><author><style face="normal" font="default"> Kalil,J.</style></author><author><style face="normal" font="default"> Giavina-Bianchi,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Immunology (LIM19), Heart Institute (InCor), School of Medicine, University of Sao Paulo, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="default">Atopy Is Associated with Age at Asthma Onset in Elderly Patients</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="11" Year="2017">2017/11/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma in the elderly population (60 years of age and older) is frequently underdiagnosed, as well as atopy. Atopy, although more prevalent in younger patients, can be a major cause of asthma in the elderly. Chronic obstructive pulmonary disease (COPD) and cardiovascular disease are common differential diagnoses, especially in elderly smokers. OBJECTIVE: The objective of this study was to assess atopy and comorbidities in elderly patients with asthma. METHODS: This was an observational and retrospective study involving elderly asthmatic patients followed up at a tertiary center. Patients were assessed for severity of asthma, frequency of atopy, and frequency of comorbidities concomitant with asthma. Then, they were classified according to their age at asthma onset and the groups compared with each other for atopy, spirometric parameters, and comorbidities. RESULTS: This study included 243 elderly asthmatic patients, 71.8% of them presenting severe disease and 82.3% forced expiratory volume in 1 second (FEV1) &lt; 80%. Gastroesophageal reflux disease, obesity, and asthma-COPD overlap syndrome were observed, respectively, in 64%, 37%, and 13% of these patients. Atopy was observed in 63%, mainly in those with early onset disease, and its frequency decreased as the age of asthma onset increased (P &lt; .05). Total serum IgE was higher for allergic patients and FEV1 values were lower for patients with long-term asthma. Aspirin-exacerbated respiratory disease was more frequent in patients with nonallergic asthma. CONCLUSIONS: Most elderly asthmatic patients followed up in our tertiary center were atopic and higher values of total serum IgE suggest atopy. Atopy was inversely correlated with age of asthma onset. The diagnosis of allergic asthma in the elderly population is essential to treat patients more properly, improving their quality of life and decreasing asthma morbidity and mortality</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.10.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29175370">PM:29175370</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171123, Agondi RC</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.10.028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43378</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Marcus,N.</style></author><author><style face="normal" font="default"> Smuel,K.</style></author><author><style face="normal" font="default"> Almog,M.</style></author><author><style face="normal" font="default"> Prais,D.</style></author><author><style face="normal" font="default"> Straussberg,R.</style></author><author><style face="normal" font="default"> Landau,D.</style></author><author><style face="normal" font="default"> Scheuerman,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics B, Schneider Children's Medical Center of Israel, Petach Tikva, Israel; Kipper Institute of Immunology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel</style></auth-address><titles><title><style face="normal" font="default">Successful Intravenous Immunoglobulin Treatment in Pediatric Severe DRESS Syndrome</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="11" Year="2017">2017/11/30</year></dates><abstract><style face="normal" font="default">BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare, potentially life-threatening delayed drug-induced hypersensitivity reaction. The most frequently reported drugs causing DRESS are aromatic antiepileptic agents. Prompt withdrawal of the offending drug and administering systemic corticosteroids is the most widely accepted and used treatment. The treatment of severe DRESS not responsive to systemic corticosteroids is uncertain. OBJECTIVE: The objective of this study was to describe a case series of pediatric patients with DRESS who were treated successfully with intravenous immunoglobulins (IVIGs). METHODS: A retrospective review of all children hospitalized in a tertiary care children's hospital with severe DRESS syndrome who received IVIG in addition to offending drug withdrawal and systemic corticosteroids during 1999-2017 is performed. RESULTS: Seven severe DRESS patients (4 males, age: 9.5 +/- 5.7 years) are described. The offending drugs were antiepileptics in all but one case. Clinical findings included fever, rash, lymphadenopathy, dyspnea, anasarca, and hepatic involvement. After IVIG treatment (total dosage: 1-2 g/kg), fever resolved within a median time of 1 (range, 0-5) day, rash disappeared after 6.3 +/- 1.6 days, and liver enzymes substantially improved after 3.8 +/- 1.6 days. Patients were discharged 6.1 +/- 2.7 days after IVIG commencement. There was no mortality. CONCLUSION: The addition of IVIG in DRESS syndrome resistant to regular drug withdrawal and systemic corticosteroid therapy may hasten disease recovery</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.10.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29198698">PM:29198698</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171130, Marcus N</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.10.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43379</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Andre-Gregoire,G.</style></author><author><style face="normal" font="default"> Dilasser,F.</style></author><author><style face="normal" font="default"> Chesne,J.</style></author><author><style face="normal" font="default"> Braza,F.</style></author><author><style face="normal" font="default"> Magnan,A.</style></author><author><style face="normal" font="default"> Loirand,G.</style></author><author><style face="normal" font="default"> Sauzeau,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">INSERM, CNRS, UNIV Nantes, l'institut du thorax, Nantes, France</style></auth-address><titles><title><style face="normal" font="default">Targeting of Rac1 prevents bronchoconstriction and airway hyperresponsiveness</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="15" Month="11" Year="2017">2017/11/15</year></dates><abstract><style face="normal" font="default">BACKGROUND: The molecular mechanisms responsible for airway smooth muscle cells (aSMC) contraction and proliferation in airway hyperresponsiveness (AHR) associated with asthma are still largely unknown. The small GTPases of the Rho family (RhoA, Rac1 and Cdc42) play a central role in SMC functions including migration, proliferation and contraction. OBJECTIVE: The objective of this study is to identify the role of Rac1 in aSMC contraction and to investigate its involvement in AHR associated with allergic asthma. METHODS: To define the role of Rac1 in aSMC, ex- and in vitro analyses of bronchial reactivity were performed on bronchi from smooth muscle (SM)-specific Rac1 knockout mice (SM-Rac1-KO) and human individuals. In addition, this murine model was exposed to allergens (ovalbumin or house dust mite extract) to decipher in vivo the implication of Rac1 in AHR. RESULTS: The specific SMC deletion or pharmacological inhibition of Rac1 in mice prevented the bronchoconstrictor response to methacholine. In human bronchi a similar role of Rac1 was observed during bronchoconstriction. We further demonstrated that Rac1 activation is responsible for bronchoconstrictor-induced increase in intracellular Ca(2+) concentration and contraction both in murine and human bronchial aSMC, through its association with phospholipase C beta2 and the stimulation of inositol 1,4,5-trisphosphate production. In vivo, Rac1 deletion in SMC or pharmacological Rac1 inhibition by nebulization of NSC23766 prevented AHR in murine models of allergic asthma. Moreover, nebulization of NSC23766 decreased eosinophil and neutrophil populations in bronchoalveolar lavages from asthmatic mice. CONCLUSION: Our data reveal an unexpected and essential role of Rac1 in the regulation of intracellular Ca(2+) and contraction of aSMC, and the development of AHR. Rac1 thus appears as an attractive therapeutic target in asthma, with a combined beneficial action on both bronchoconstriction and pulmonary inflammation</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.09.049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29155102">PM:29155102</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171115-AndreGregoireG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171115-AndreGregoireG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171115, Andre-Gregoire G</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.09.049</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43380</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Toennesen,L.L.</style></author><author><style face="normal" font="default"> Meteran,H.</style></author><author><style face="normal" font="default"> Hostrup,M.</style></author><author><style face="normal" font="default"> Wium Geiker,N.R.</style></author><author><style face="normal" font="default"> Jensen,C.B.</style></author><author><style face="normal" font="default"> Porsbjerg,C.</style></author><author><style face="normal" font="default"> Astrup,A.</style></author><author><style face="normal" font="default"> Bangsbo,J.</style></author><author><style face="normal" font="default"> Parker,D.</style></author><author><style face="normal" font="default"> Backer,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory Research Unit, Department of Respiratory Medicine, Bispebjerg University Hospital, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default">Effects of Exercise and Diet in Nonobese Asthma Patients-A Randomized Controlled Trial</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="11" Year="2017">2017/11/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Behavioral interventions focusing on exercise and healthy diet improve asthma control in obese patients with asthma, but whether these interventions can lead to improvements in nonobese patients remains unclear. OBJECTIVES: In a randomized, controlled parallel-group design, we studied the effects of an 8-week intervention of either exercise (high-intensity interval training), diet (high protein/low glycemic index), or a combination of the 2, on asthma control and clinical outcomes in nonobese patients with asthma. METHODS: Nonobese adult patients with asthma (n = 149) were randomized to 1 of 4 groups: an exercise group, a diet group, an exercise + diet group, or a control group. Outcomes included Asthma Control Questionnaire (ACQ) score, asthma-related quality-of-life (Asthma-Related Quality-of-Life Questionnaire [AQLQ]) score, inflammatory cell counts in induced sputum, FEV1, fractional exhaled nitric oxide, and airway hyperresponsiveness (AHR). RESULTS: A total of 125 patients completed the study and were included in the data analysis. Patients in the exercise + diet group improved the ACQ score from 1.9 +/- 0.7 to 1.0 +/- 0.7 and the AQLQ score from 5.2 +/- 0.8 to 6.2 +/- 0.7, which was statistically significant when compared with changes in the control group (P &lt; .05 and &lt;.01, respectively). The exercise group and the diet group did not improve either the ACQ score or the AQLQ score significantly compared with the control group and there were no significant changes in sputum cell counts, FEV1, fractional exhaled nitric oxide, or AHR within any groups following the intervention period. CONCLUSIONS: The combination of exercise and diet improves asthma control in nonobese patients, but does not affect AHR or airway inflammation</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.09.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29133220">PM:29133220</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171114, Toennesen LL</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.09.028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43381</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bender,B.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Behavioral Health, Department of Pediatrics, National Jewish Health, Denver, Colo.</style></auth-address><titles><title><style face="normal" font="default">Technology Interventions for Nonadherence: New Approaches to an Old Problem</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="11" Year="2017">2017/11/29</year></dates><abstract><style face="normal" font="default">Nonadherence to asthma medications is well recognized. Interventions to improve adherence, however, have been only moderately successful and are not often adopted because of limited provider time, training, or institutional support. The potential for mobile communication technology to improve adherence has gathered sharply growing interest. Technology-based adherence tracking devices have been in existence for almost 3 decades, but have only recently reached a level of reliability and utility to be considered in allergy practice. Adherence intervention technology includes smartphones, apps, and a growing number of potential new asthma uses such as inhaler technique assessment, portable fractional exhaled nitric oxide devices, and GPS activity trackers with environmental contaminant alerts. As technology has advanced, new capability has emerged including drawing information from electronic health records to tailor automated interventions, give real-time feedback to patients, leverage incentives, utilize predictive logarithms that identify patients at exacerbation risk, and initiate an intervention. Technology development moves faster than clinical trial tests of these new interventions, and gaps in evidence will need to be closed. As researchers establish cost effectiveness, sustainability, and patient and provider acceptance, technology-based adherence intervention systems are likely to be increasingly adopted into small and large practice settings</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.10.029</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29196085">PM:29196085</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171129, Bender BG</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.10.029</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43382</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Au,E.Y.L.</style></author><author><style face="normal" font="default"> Rosa Duque,J.S.</style></author><author><style face="normal" font="default"> Lau,C.S.</style></author><author><style face="normal" font="default"> Chan,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pathology, Queen Mary Hospital, Hong Kong; Department of Medicine, Queen Mary Hospital, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.</style></auth-address><titles><title><style face="normal" font="default">A patient with anaphylaxis to diphenhydramine without cross-reactivity to loratadine</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="11" Year="2017">2017/11/29</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Hong Kong -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.10.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29196087">PM:29196087</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171129, Au EY</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.10.032</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43383</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mirzakhani,H.</style></author><author><style face="normal" font="default"> Weiss,S.T.</style></author><author><style face="normal" font="default"> Litonjua,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass</style></auth-address><titles><title><style face="normal" font="default">Reply (Refers to: Obesity, asthma, and vitamin D deficiency in pregnancy: Cause or consequence?)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="11" Year="2017">2017/11/21</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.08.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29169707">PM:29169707</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171121-MirzakhaniH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171121-MirzakhaniH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171121, Mirzakhani H</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.08.035</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43384</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bartemes,K.</style></author><author><style face="normal" font="default"> Chen,C.C.</style></author><author><style face="normal" font="default"> Iijima,K.</style></author><author><style face="normal" font="default"> Drake,L.</style></author><author><style face="normal" font="default"> Kita,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergic Diseases, Department of Internal Medicine, Mayo Clinic</style></auth-address><titles><title><style face="normal" font="default">IL-33-Responsive Group 2 Innate Lymphoid Cells Are Regulated by Female Sex Hormones in the Uterus</style></title><secondary-title><style face="normal" font="default">J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="11" Year="2017">2017/11/13</year></dates><abstract><style face="normal" font="default">Group 2 innate lymphoid cells (ILC2s) reside in multiple organs in the body, where they play roles in immunity, tissue homeostasis, and metabolic regulation. However, little is known about the regulatory mechanisms of ILC2s in different organs. Here, we identified ILC2s in the mouse uterus and found that they express cell surface molecules, including the IL-33 receptor, ST2, that are roughly comparable to those expressed by lung ILC2s. Both in vivo and in vitro treatment with IL-33 induced type 2 cytokine production in uterine ILC2s, suggesting that they respond to IL-33 in a manner similar to ILC2s in other organs. Importantly, uterine ILC2s were nearly absent in ovariectomized mice and were increased in wild-type mice by estrogen administration, whereas lung ILC2s were unaffected by both ovariectomy and estrogen administration. Likewise, a marked reduction in uterine ILC2s was observed in mice deficient in estrogen receptor alpha or estrogen receptor beta. Furthermore, uterine ILC2s highly expressed estrogen receptor alpha, and in vitro culture of isolated uterine ILC2s with 17beta-estradiol modified expression of a number of genes. Finally, an increased prevalence in neonatal mortality was observed in litters from dams lacking the IL-33 receptor, ST2. Taken together, our findings indicate that unlike lung IL2Cs, uterine ILC2s are regulated by female sex hormones, which may specialize them for specific physiological functions</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.4049/jimmunol.1602085</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29133293">PM:29133293</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Immunol\20171114-BartemesK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Immunol\20171114-BartemesK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171114, Bartemes K</style></custom2><misc3><style face="normal" font="default">10.4049/jimmunol.1602085</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43385</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Irfan,O.</style></author><author><style face="normal" font="default"> Irfan,B.</style></author><author><style face="normal" font="default"> Khan,Z.A.</style></author><author><style face="normal" font="default"> Tahir,M.</style></author><author><style face="normal" font="default"> Sarwar Zubairi,A.B.</style></author><author><style face="normal" font="default"> Khan,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical College, Aga Khan University</style></auth-address><titles><title><style face="normal" font="default">Knowledge about asthma: A cross-sectional survey in 4 major hospitals of Karachi, Pakistan</style></title><secondary-title><style face="normal" font="default">J Pak Med Assoc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Pak Med Assoc</style></full-title></periodical><pages end="1790" start="1787">1787-1790</pages><volume><style face="normal" font="default">67</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To determine knowledge and misconceptions about asthma among the local population.. METHODS: This cross-sectional study was conducted at four tertiary care hospitals; Aga Khan University Hospital, Civil Hospital Karachi, Jinnah Postgraduate Medical Centre and Ojha Institute of Chest Diseases, Karachi, from October to November 2016, and comprised hospital attendants. The questionnaire used in the study comprised 26 questions answered with a true, false or not sure answer.SPSS 20 was used for data analysis. RESULTS: There were 400 participants. The overall mean age was 41.2+/-14.2 years, and 214(53.5%) of the participants were males. Moreover, 75(19%) participants thought that asthma was a psychological disorder while 181(45%) considered it an infectious disease. Nearly 174(43.5%) believed that inhaled medications had significant side effects. Besides, 264(66%) participants considered steam inhalation to be an effective treatment for asthma, 269(67%) thought that patients with asthma should avoid rice in their diet and 167(42%) considered milk as a common trigger. CONCLUSIONS: Participants' knowledge about asthma was poor and misconceptions were common about the condition</style></abstract><notes><style face="normal" font="default">IS - 0030-9982 (Print)IS - 0030-9982 (Linking)LA - engPT - Journal ArticleCO - Pakistan -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29171591">PM:29171591</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Pak Med Assoc\2017-67-1787-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Pak Med Assoc\2017-67-1787-90.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171123, Irfan O</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43386</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Obermeyer,R.J.</style></author><author><style face="normal" font="default"> Gaffar,S.</style></author><author><style face="normal" font="default"> Kelly,R.E.</style></author><author><style face="normal" font="default"> Ann Kuhn,M.</style></author><author><style face="normal" font="default"> Frantz,F.W.</style></author><author><style face="normal" font="default"> McGuire,M.M.</style></author><author><style face="normal" font="default"> Paulson,J.F.</style></author><author><style face="normal" font="default"> Kelly,C.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Selective Versus Routine Patch Metal Allergy Testing to Select Bar Material for the Nuss Procedure in 932 Patients Over 10Years</style></title><secondary-title><style face="normal" font="default">J Pediatr Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Pediatr Surg</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">pectus excavatum</style></keyword><keyword><style face="normal" font="default"> Metal allergy</style></keyword><keyword><style face="normal" font="default"> Nickel</style></keyword><keyword><style face="normal" font="default"> Titanium</style></keyword><keyword><style face="normal" font="default"> patch</style></keyword><keyword><style face="normal" font="default"> Dermatitis</style></keyword><keyword><style face="normal" font="default"> Nuss procedure</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0022-3468</style></isbn><abstract><style face="normal" font="default">Abstract The aim of the study was to determine the role of patch metal allergy testing to select bar material for the Nuss procedure. An IRB-approved (11</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô04-WC-0098) single institution retrospective, cohort study comparing selective versus routine patch metal allergy testing to select stainless steel or titanium bars for Nuss repair was performed. In Cohort A (9/2004</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô1/2011), selective patch testing was performed based on clinical risk factors. In Cohort B (2/2011</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô9/2014), all patients were patch tested. The cohorts were compared for incidence of bar allergy and resultant premature bar loss. Risk factors for stainless steel allergy or positive patch test were evaluated. Cohort A had 628 patients with 63 (10.0%) selected for patch testing, while all 304 patients in Cohort B were tested. Over 10years, 15 (1.8%) of the 842 stainless steel Nuss repairs resulted in a bar allergy, and 5 had a negative preoperative patch test. The incidence of stainless steel bar allergy (1.8% vs 1.7%, P=0.57) and resultant bar loss (0.5% vs 1.3%, P=0.23) was not statistically different between cohorts. An allergic reaction to a stainless steel bar or a positive patch test was more common in females (OR=2.3, p&lt;0.001) and patients with a personal (OR=24.8, P&lt;0.001) or family history (OR=3.1, P&lt;0.001) of metal sensitivity. Stainless steel bar allergies occur at a low incidence with either routine or selective patch metal allergy testing. If selective testing is performed, it is advisable in females and patients with a personal or family history of metal sensitivity. A negative preoperative patch metal allergy test does not preclude the possibility of a subsequent stainless steel bar allergy. Level III Treatment Study and Study of Diagnostic Test</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jpedsurg.2017.11.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29223667">PM:29223667</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Pediatr Surg\20171212-ObermeyerRJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Pediatr Surg\20171212-ObermeyerRJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171212, Obermeyer RJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jpedsurg.2017.11.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43387</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Papp,A.</style></author><author><style face="normal" font="default"> Gyorgyi,K.</style></author><author><style face="normal" font="default"> Nagymajtenyi,L.</style></author><author><style face="normal" font="default"> Desi,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dept. Public Health, Albert Szent-Gyorgyi Medical University, Dom ter, Hungary</style></auth-address><titles><title><style face="normal" font="default">Opposite short-term changes induced by an organophosphate in cortical and hippocampal evoked activity</style></title><secondary-title><style face="normal" font="default">Neurobiology (Bp)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Neurobiology (Bp)</style></abbr-1></periodical><pages end="440" start="431">431-440</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acetylcholinesterase</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Animals</style></keyword><keyword><style face="normal" font="default"> Cerebral Cortex</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> enzymology</style></keyword><keyword><style face="normal" font="default"> Dichlorvos</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Evoked Potentials,Somatosensory</style></keyword><keyword><style face="normal" font="default"> Hippocampus</style></keyword><keyword><style face="normal" font="default"> Insecticides</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Organ Specificity</style></keyword><keyword><style face="normal" font="default"> Rats</style></keyword><keyword><style face="normal" font="default"> Rats,Wistar</style></keyword></keywords><dates><year Day="0" Month="0" Year="1996">1996</year></dates><abstract><style face="normal" font="default">Organophosphates are the most widely used pesticides throughout the world. The considerable amount brought out to the environment poses a risk on the whole population. As organophosphates are neurotoxic substances and their residues can persist in the environment for several weeks, their influence on the nervous system of humans and animals is of principal interest. In the present study, we investigated the alterations induced by dichlorvos, a common pesticide substance, in parameters of somatosensory evoked potentials and hippocampal evoked population spikes of rats. The changes of the cortical vs. hippocampal evoked responses were opposite and only hippocampal effects could be directly explained through an increased cholinergic activity</style></abstract><notes><style face="normal" font="default">IS - 1216-8068 (Print)IS - 1216-8068 (Linking)LA - engPT - Comparative StudyPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Insecticides)RN - 7U370BPS14 (Dichlorvos)RN - EC 3.1.1.7 (Acetylcholinesterase)SB - IMCO - Hungary -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="9200134">PM:9200134</url></web-urls></urls><custom2><style face="normal" font="default">19969619, Papp A</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43388</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jancsik,V.</style></author><author><style face="normal" font="default"> Filliol,D.</style></author><author><style face="normal" font="default"> Rendon,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dept. of Anatomy and Histology, Univ. of Vet. Sci., Budapest, Hungary</style></auth-address><titles><title><style face="normal" font="default">Tau proteins bind to kinesin and modulate its activation by microtubules</style></title><secondary-title><style face="normal" font="default">Neurobiology (Bp)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Neurobiology (Bp)</style></abbr-1></periodical><pages end="429" start="417">417-429</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Animals</style></keyword><keyword><style face="normal" font="default"> Brain Chemistry</style></keyword><keyword><style face="normal" font="default"> Ca(2+) Mg(2+)-Atpase</style></keyword><keyword><style face="normal" font="default"> isolation &amp; purification</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Cattle</style></keyword><keyword><style face="normal" font="default"> Enzyme Activation</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Immunoblotting</style></keyword><keyword><style face="normal" font="default"> Kinesin</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Microtubule-Associated Proteins</style></keyword><keyword><style face="normal" font="default"> Microtubules</style></keyword><keyword><style face="normal" font="default"> enzymology</style></keyword><keyword><style face="normal" font="default"> Protein Binding</style></keyword><keyword><style face="normal" font="default"> tau Proteins</style></keyword></keywords><dates><year Day="0" Month="0" Year="1996">1996</year></dates><abstract><style face="normal" font="default">Microtubule-associated tau proteins are likely candidates to interfere with axonal transport of membranous organelles. We studied that tau proteins influenced the enzyme activity of kinesin, known to drive anterograd transport along microtubules. An in vitro reconstituted system was applied; microtubules were assembled from purified tubulin with or without tau proteins. Both types of reconstituted microtubules stimulated MgATPase activity of purified kinesin in a concentration dependent, saturable manner. The extent of maximal stimulation by tau-coated microtubules was lower than that of microtubules without tau proteins. Analysis of kinetic data, on the other hand, suggests that tau-coated microtubules apparently bind kinesin with higher affinity then microtubules not associated with tau proteins. Tau proteins, similarly to tubulin dimers, seem to bind to the heavy chain of kinesin. These data support the notion that tau proteins could act as regulators of kinesin-driven processes</style></abstract><notes><style face="normal" font="default">IS - 1216-8068 (Print)IS - 1216-8068 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tRN - 0 (Microtubule-Associated Proteins)RN - 0 (tau Proteins)RN - EC 3.6.1.- (Ca(2+) Mg(2+)-ATPase)RN - EC 3.6.4.4 (Kinesin)SB - IMCO - Hungary -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="9200133">PM:9200133</url></web-urls></urls><custom2><style face="normal" font="default">19960610, Jancsik V</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43389</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wosinski,M.</style></author><author><style face="normal" font="default"> Schleicher,A.</style></author><author><style face="normal" font="default"> Zilles,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute for Brain Research, Heinrich Heine University, Dusseldorf, GFR</style></auth-address><titles><title><style face="normal" font="default">Quantitative analysis of gyrification of cerebral cortex in dogs</style></title><secondary-title><style face="normal" font="default">Neurobiology (Bp)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Neurobiology (Bp)</style></abbr-1></periodical><pages end="468" start="441">441-468</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Animals</style></keyword><keyword><style face="normal" font="default"> Body Weight</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Cerebral Cortex</style></keyword><keyword><style face="normal" font="default"> anatomy &amp; histology</style></keyword><keyword><style face="normal" font="default"> Dogs</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Functional Laterality</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Organ Size</style></keyword><keyword><style face="normal" font="default"> Sex Characteristics</style></keyword><keyword><style face="normal" font="default"> Species Specificity</style></keyword></keywords><dates><year Day="0" Month="0" Year="1996">1996</year></dates><abstract><style face="normal" font="default">The degree of gyrification of the cerebral cortex was studied in a population of various breeds of dogs. The aim of the study was to demonstrate whether or not variations in brain weight, body size or body weight affect gyrification within a species. Results suggest that in spite of significant correlations between all these parameters the degree of gyrification is essentially determined by the size of the brain. This parameter shows neither sex-dependence nor asymmetry between the two hemispheres. The examination of frontal serial sections through dogs' brains has also revealed that in agreement with data on the primate brain the association cortical regions show an extraordinarily high gyrification. Accordingly, gyification is dependent from the overall growth of the brain in particular from that of the association areas growing most intensively in mammals. Measurement of the gyrification index is therefore, thought to be a suitable method to express in quantitative terms developmental trends of cortical organization</style></abstract><notes><style face="normal" font="default">IS - 1216-8068 (Print)IS - 1216-8068 (Linking)LA - engPT - Comparative StudyPT - Journal ArticleSB - IMCO - Germany -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="9200135">PM:9200135</url></web-urls></urls><custom2><style face="normal" font="default">19969619, Wosinki M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43390</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nam,S.Y.</style></author><author><style face="normal" font="default"> Kim,H.M.</style></author><author><style face="normal" font="default"> Jeong,H.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cysteine ameliorates allergic inflammatory reactions by suppressing thymic stromal lymphopoietin production in activated human mast cells</style></title><secondary-title><style face="normal" font="default">Nutr Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nutr Res</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">thymic stromal lymphopoietin</style></keyword><keyword><style face="normal" font="default"> Cysteine</style></keyword><keyword><style face="normal" font="default"> Human mast cell</style></keyword><keyword><style face="normal" font="default"> caspase-1</style></keyword><keyword><style face="normal" font="default"> Nuclear factor-+¦B</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0271-5317</style></isbn><abstract><style face="normal" font="default">Abstract Thymic stromal lymphopoietin (TSLP) derived by mast cells is recognized as a critical factor in many allergic inflammatory disorders. Cysteine is a well-known amino acid which exhibits anti-inflammatory activities. However, the effect and mechanism of cysteine on TSLP production have not been investigated. Thus, we hypothesized that cysteine may regulate TSLP production from mast cells. To test this hypothesis, the anti-inflammatory effects and signaling pathways of cysteine were investigated in phorbol 12-myristate 13-acetate4 and calcium ionophore A23187 (PMACI)-stimulated human mast cell line HMC-1. Cysteine dramatically attenuated the levels of TSLP of both mRNA and protein without cytotoxicity. Moreover, cysteine suppressed caspase-1 activation and nuclear factor (NF)-+¦B translocation. The phosphorylation of p38 and c-Jun N-terminal kinase (JNK) was down-regulated in all cases in PMACI-stimulated HMC-1 cells treated with cysteine. In addition, cysteine decreased PMACI-induced proinflammatory cytokines in terms of both protein and mRNA levels. In conclusion, cysteine regulates TSLP production by blocking caspase-1, NF-+¦B, p38, and JNK-dependent pathways in activated HMC-1 cells, suggesting its potential as a regulator of allergic inflammatory diseases</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.nutres.2017.11.005</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.nutres.2017.11.005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nutr Res\20171203-NamSY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nutr Res\20171203-NamSY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171203, Nam SY</style></custom2><misc3><style face="normal" font="default">10.1016/j.nutres.2017.11.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43391</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Solidoro,P.</style></author><author><style face="normal" font="default"> Bellocchia,M.</style></author><author><style face="normal" font="default"> Aredano,I.</style></author><author><style face="normal" font="default"> Mattei,A.</style></author><author><style face="normal" font="default"> Pivetta,E.</style></author><author><style face="normal" font="default"> Patrucco,F.</style></author><author><style face="normal" font="default"> Boita,M.</style></author><author><style face="normal" font="default"> de Blasio,F.</style></author><author><style face="normal" font="default"> Brussino,L.</style></author><author><style face="normal" font="default"> Rolla,G.</style></author><author><style face="normal" font="default"> Bucca,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Azienda Ospedaliero Universitaria Citta della Salute e della Scienza, S.C. Pneumologia U, 10126 Torino, Italy.</style></auth-address><titles><title><style face="normal" font="default">Asthmatic Patients with Vitamin D Deficiency have Decreased Exacerbations after Vitamin Replacement</style></title><secondary-title><style face="normal" font="default">Nutrients</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nutrients</style></abbr-1></periodical><pages end="" start="E1234">E1234-</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="11" Year="2017">2017/11/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Intervention studies with vitamin D in asthma are inconclusive for several reasons, such as inadequate dosing or duration of supplementation or uncontrolled baseline vitamin D status. Our aim was to evaluate the benefit of long term vitamin D add-on in asthmatic patients with actual vitamin D deficiency, that is a serum 25-hydroxy vitamin D (25-OHD ) below 20 ng/mL. METHODS: Serum 25-OHD, asthma exacerbations, spirometry and inhaled corticosteroids (CS) dose were evaluated in a cohort of 119 asthmatic patients. Patients with deficiency were evaluated again after one year vitamin supplementation. RESULTS: 25-OHD was low in 111 patients and was negatively related to exacerbations (p &lt; 0.001), inhaled CS dose (p = 0.008) and asthma severity (p = 0.001). Deficiency was found in 90 patients, 55 of whom took the supplement regularly for one year, while 24 discontinued the study and 11 were not adherent. Patients with vitamin D deficiency after 12 months supplementation showed significant decrease of exacerbations (from 2.6 +/- 1.2 to 1.6 +/- 1.1, p &lt; 0.001), circulating eosinophils (from 395 +/- 330 to 272 +/- 212 10(6)/L, p &lt; 0.001), and need of oral CS courses (from 35 to 20, p = 0.007) and improvement of airway obstruction. CONCLUSIONS: Asthma exacerbations are favored by vitamin D deficiency and decrease after long-term vitamin D replacement. Patients who are vitamin D deficient benefit from vitamin D supplementation</style></abstract><notes><style face="normal" font="default">DA - 20171115IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.3390/nu9111234</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29137124">PM:29137124</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nutrients\2017-9- E1234.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nutrients\2017-9- E1234.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171111, Solidoro P</style></custom2><misc3><style face="normal" font="default">10.3390/nu9111234</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43392</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jegal,J.</style></author><author><style face="normal" font="default"> Park,N.J.</style></author><author><style face="normal" font="default"> Bong,S.K.</style></author><author><style face="normal" font="default"> Jegal,H.</style></author><author><style face="normal" font="default"> Kim,S.N.</style></author><author><style face="normal" font="default"> Yang,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">College of Pharmacy, Pusan National University, Busan 46241, Korea.</style></auth-address><titles><title><style face="normal" font="default">Dioscorea quinqueloba Ameliorates Oxazolone- and 2,4-Dinitrochlorobenzene-induced Atopic Dermatitis Symptoms in Murine Models</style></title><secondary-title><style face="normal" font="default">Nutrients</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nutrients</style></abbr-1></periodical><pages end="" start="E1324">E1324-</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="12" Year="2017">2017/12/5</year></dates><abstract><style face="normal" font="default">Dioscorea quinqueloba has been used for food substances, as well as in herbal medicines for allergic diseases such as asthma. This study aimed to investigate the anti-atopic dermatitis (AD) effects of the total extract of D. quinqueloba rhizomes and active fractionson murine oxazolone- and 2,4-dinitrochlorobenzene-induced models of AD. Specific AD symptoms, such as erythema, ear swelling, and epidermis thickening, were significantly reduced in the oxazolone-mediated AD BALB/c mice upon topical application of D. quinqueloba rhizomes 95% EtOH extract (DQ). DQEA (D. quinqueloba rhizomes EtOAc fraction) was beneficial for protecting the skin barrier against AD in DNCB-sensitized SKH-1 hairless mice. Decreased total serum IgE and IL-4 levels could be observed in atopic dorsal skin samples of the DQEA-treated group. On the basis of the phytochemical analysis, DQEA was found to contain dioscin and gracillin as its main compounds. Therapeutic applications with D. quinqueloba might be useful in the treatment of AD and related inflammatory skin diseases</style></abstract><notes><style face="normal" font="default">IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.3390/nu9121324</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29206209">PM:29206209</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nutrients\2017-9-E1324.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nutrients\2017-9-E1324.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171205, Jegal J</style></custom2><misc3><style face="normal" font="default">10.3390/nu9121324</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43393</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Catassi,C.</style></author><author><style face="normal" font="default"> Alaedini,A.</style></author><author><style face="normal" font="default"> Bojarski,C.</style></author><author><style face="normal" font="default"> Bonaz,B.</style></author><author><style face="normal" font="default"> Bouma,G.</style></author><author><style face="normal" font="default"> Carroccio,A.</style></author><author><style face="normal" font="default"> Castillejo,G.</style></author><author><style face="normal" font="default"> De Magistris,L.</style></author><author><style face="normal" font="default"> Dieterich,W.</style></author><author><style face="normal" font="default"> Di Liberto,D.</style></author><author><style face="normal" font="default"> Elli,L.</style></author><author><style face="normal" font="default"> Fasano,A.</style></author><author><style face="normal" font="default"> Hadjivassiliou,M.</style></author><author><style face="normal" font="default"> Kurien,M.</style></author><author><style face="normal" font="default"> Lionetti,E.</style></author><author><style face="normal" font="default"> Mulder,C.J.</style></author><author><style face="normal" font="default"> Rostami,K.</style></author><author><style face="normal" font="default"> Sapone,A.</style></author><author><style face="normal" font="default"> Scherf,K.</style></author><author><style face="normal" font="default"> Schuppan,D.</style></author><author><style face="normal" font="default"> Trott,N.</style></author><author><style face="normal" font="default"> Volta,U.</style></author><author><style face="normal" font="default"> Zevallos,V.</style></author><author><style face="normal" font="default"> Zopf,Y.</style></author><author><style face="normal" font="default"> Sanders,D.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Marche Polytechnic University, 60121 Ancona, Italy.</style></auth-address><titles><title><style face="normal" font="default">The Overlapping Area of Non-Celiac Gluten Sensitivity (NCGS) and Wheat-Sensitive Irritable Bowel Syndrome (IBS): An Update</style></title><secondary-title><style face="normal" font="default">Nutrients</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nutrients</style></abbr-1></periodical><pages end="" start=" E1268"> E1268-</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="11" Year="2017">2017/11/21</year></dates><abstract><style face="normal" font="default">Gluten-related disorders have recently been reclassified with an emerging scientific literature supporting the concept of non-celiac gluten sensitivity (NCGS). New research has specifically addressed prevalence, immune mechanisms, the recognition of non-immunoglobulin E (non-IgE) wheat allergy and overlap of NCGS with irritable bowel syndrome (IBS)-type symptoms. This review article will provide clinicians with an update that directly impacts on the management of a subgroup of their IBS patients whose symptoms are triggered by wheat ingestion</style></abstract><notes><style face="normal" font="default">IS - 2072-6643 (Electronic)IS - 2072-6643 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -CO - United States -CO - Germany -CO - France -CO - Netherlands -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.3390/nu9111268</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29160841">PM:29160841</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nutrients\2017-9- E1268.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nutrients\2017-9- E1268.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171121, Catassi C</style></custom2><misc3><style face="normal" font="default">10.3390/nu9111268</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43394</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Suojalehto,H.</style></author><author><style face="normal" font="default"> Karvala,K.</style></author><author><style face="normal" font="default"> Ahonen,S.</style></author><author><style face="normal" font="default"> Ylinen,K.</style></author><author><style face="normal" font="default"> Airaksinen,L.</style></author><author><style face="normal" font="default"> Suuronen,K.</style></author><author><style face="normal" font="default"> Suomela,S.</style></author><author><style face="normal" font="default"> Lindstrom,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Occupational Medicine, Finnish Institute of Occupational Health, Helsinki, Finland</style></auth-address><titles><title><style face="normal" font="default">3-(Bromomethyl)-2-chloro-4-(methylsulfonyl)- benzoic acid: a new cause of sensitiser induced occupational asthma, rhinitis and urticaria</style></title><secondary-title><style face="normal" font="default">Occup Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Occup Environ Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="24" Month="11" Year="2017">2017/11/24</year></dates><abstract><style face="normal" font="default">OBJECTIVES: 3-(Bromomethyl)-2-chloro-4-(methylsulfonyl)-benzoic acid (BCMBA) has not previously been identified as a respiratory sensitiser. We detected two cases who presented respiratory and urticaria symptoms related to BCMBA and had positive skin prick tests to the agent. Subsequently, we conducted outbreak investigations at the BCMBA-producing factory and performed clinical examinations to confirm occupational diseases. METHODS: The outbreak investigations included observations of work processes, assessment of exposure, a medical survey with a questionnaire and skin prick tests with 0.5% BCMBA water solution on 85 exposed workers and 9 unexposed workers. We used specific inhalation or nasal challenge and open skin application test to investigate BCMBA-related occupational asthma, rhinitis and contact urticaria. RESULTS: We identified nine workers with respiratory and/or skin symptoms and positive skin prick tests to BCMBA in a chemical factory. A survey among chemical factory workers indicated a BCMBA-related sensitisation rate of 8% among all exposed workers; the rate was highest (25%) among production workers in the production hall. Sensitisation was detected only in workers with the estimated highest exposure levels. Six cases of occupational asthma, rhinitis and/or contact urticaria caused by BCMBA were confirmed with challenge tests. Asthma-provoking doses in specific inhalation challenges were very low (0.03% or 0.3% BCMBA in lactose). CONCLUSIONS: We identified a new low molecular weight agent causing occupational asthma, rhinitis and contact urticaria. A typical clinical picture of allergic diseases and positive skin prick tests suggest underlying IgE-mediated disease mechanisms. Stringent exposure control measures are needed in order to prevent BCMBA-related diseases</style></abstract><notes><style face="normal" font="default">IS - 1470-7926 (Electronic)IS - 1351-0711 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="default">10.1136/oemed-2017-104505</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29175989">PM:29175989</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Occup Environ Med\20171204-SuojalehtoH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Occup Environ Med\20171204-SuojalehtoH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Suojalehto H</style></custom2><misc3><style face="normal" font="default">10.1136/oemed-2017-104505</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43395</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ellis,P.R.</style></author><author><style face="normal" font="default"> Walters,G.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital, Birmingham B9 5SS, UKRegional NHS Occupational Lung Disease Service, Heart of England NHS Foundation Trust, Heartlands Hospital, Birmingham B9 5SS, UK</style></auth-address><titles><title><style face="normal" font="default">Missed opportunities to identify occupational asthma in acute secondary care</style></title><secondary-title><style face="normal" font="default">Occup Med (Lond)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Occup Med (Lond)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="11" Year="2017">2017/11/18</year></dates><abstract><style face="normal" font="default">Background: Occupational asthma (OA) accounts for one in six cases of new-onset adult asthma. Despite this it remains under-recognized in the UK. Delayed and missed diagnoses of OA lead to poor health outcomes for workers at significant cost to the UK economy. The burden of occupational aetiology on hospital admissions with asthma is not known. Aims: To measure how frequently medical professionals consider occupational aetiology in patients presenting to secondary care with acute asthma symptoms. Methods: We reviewed electronic records of working-age patients with asthma symptoms, presenting to three sites at a large West Midlands acute hospital NHS trust. We searched emergency department (ED) and acute medical unit (AMU) admission documents, looking specifically at documentation of employment status, job role and work effect on symptoms. We also examined the effect of using a prompt for enquiry about occupation contained within the clerking pro-forma. Results: We searched 100 ED and 100 AMU admission documents. Employment status was established in only 20-31% of patients and none were asked about the effect of their work on current asthma symptoms. The use of a clerking pro-forma, including a prompt for occupation, increased documentation to 63% from 10 to 14% where an enhanced pro-forma was not used. Conclusions: Enquiry into employment status and work effect in working-age patients with asthma symptoms presenting to the ED and the AMU is poor. These may be missed opportunities to identify OA. We propose medical education about high-risk exposures and the use of pro-formas including prompts about occupational exposures</style></abstract><notes><style face="normal" font="default">IS - 1471-8405 (Electronic)IS - 0962-7480 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1093/occmed/kqx167</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29165600">PM:29165600</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Occup Med (Lond)\20171205-EllisPR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Occup Med (Lond)\20171205-EllisPR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171205, Ellis PR</style></custom2><misc3><style face="normal" font="default">10.1093/occmed/kqx167</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43396</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Beyan,A.C.</style></author><author><style face="normal" font="default"> Alici,N.S.</style></author><author><style face="normal" font="default"> Cimrin,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Ayse Coskun Beyan, Dokuz Eylul University Faculty of Medicine, Occupational Medicine Department, Izmir, TurkeyNur Safak Alici, Dokuz Eylul University Faculty of Medicine, Occupational Medicine Department, Izmir, TurkeyArif Cimrin, Dokuz Eylul University Faculty of Medicine, Occupational Medicine Department, Izmir, Turkey</style></auth-address><titles><title><style face="normal" font="default">Assessment of work-related Asthma cases: Our three-year experience</style></title><secondary-title><style face="normal" font="default">Pak J Med Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pak J Med Sci</style></abbr-1></periodical><pages end="1235" start="1230">1230-1235</pages><volume><style face="normal" font="default">33</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Objective: Work-related asthma (WRA) is one of the most common occupational diseases. In this study, we aimed to review diagnosing procedures and the characteristics of patients who were diagnosed with WRA. Methods: Between November 2013 and June 2016; 214 patients were referred to our clinic with WRA suspicion by an occupational health specialist, personal visit, chest disease specialists [61 (28%), 51 (23%), and 102 (47%) respectively]. Occupational history, functional and radiological assessment, skin prick test, PEF monitoring were done. Results: Fifty-four patients (25%) were diagnosed with OA, and 24 (11%) with WEA, total 78 workers were diagnosed with WRA. Twenty-five (32.1%) had allergic rhinitis, 13 (16.7%) had allergic dermatitis, and 8 (10%) had both diseases. Conclusion: WRA can be seen in many areas. Complaints are the basic route for admission to physician, and the diagnosis can be delayed for a long time as one year. Lower rates of referral by occupational health physicians are the signs of limitations on management of cases. Non-specific BPT and skin prick test for selected cases would be sufficient besides occupational history and clinical examination for the diagnosis of WRA. PEF assessment, one of the most important tests for the diagnosis of WRA, must be performed</style></abstract><notes><style face="normal" font="default">DA - 20171116IS - 1682-024X (Print)IS - 1681-715X (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.12669/pjms.335.12923</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29142570">PM:29142570</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pak J Med Sci\2017-33-1230-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pak J Med Sci\2017-33-1230-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171116, Beyan AC</style></custom2><misc3><style face="normal" font="default">10.12669/pjms.335.12923</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43397</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Huang,C.C.</style></author><author><style face="normal" font="default"> Chiang,T.L.</style></author><author><style face="normal" font="default"> Chen,P.C.</style></author><author><style face="normal" font="default"> Lin,S.J.</style></author><author><style face="normal" font="default"> Wen,H.J.</style></author><author><style face="normal" font="default"> Guo,Y.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Environmental and Occupational Medicine, National Taiwan University and National Taiwan University Hospital, Taipei, Taiwan</style></auth-address><titles><title><style face="normal" font="default">Risk Factors for Asthma Occurrence in Children With Early-Onset Atopic Dermatitis: An 8-Year Follow-Up Study</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="11" Year="2017">2017/11/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: Children with early-onset atopic dermatitis (AD) are at substantial risk of developing asthma later in life, and identifying the critical window of detrimental exposure is advantageous for implementing preventive actions. The aim of this study was to evaluate the role of exposure to environmental modifiers during pregnancy and early childhood in asthma occurrence in an infantile AD cohort. METHODS: Eligible study participants were selected from the Taiwan Birth Cohort Study, which enrolled 24200 newborns in 2005. We enrolled those cases who had been diagnosed as having AD before 3 years of age and followed them up till age 8. We excluded those ever diagnosed with asthma before AD onset. The dependent variable was defined in terms of whether the participant was diagnosed as having asthma before 8 years of age. We applied logistic regression models to evaluate the risks of exposure to different determinants in asthma occurrence. RESULTS: A total of 1549 children with AD had completed the 8-year follow-up, and 334 (21.6%) of them had asthma. The results revealed that male sex, lower birth order, maternal asthma history, maternal obesity before pregnancy, and environmental tobacco smoke exposure before 3 years of age were significant risk factors for further development of asthma. Furthermore, food allergy during early life, lower respiratory tract infection, and longer durations of symptomatic AD influenced asthma development later in life. CONCLUSIONS: The findings confirmed the critical determinants for asthma occurrence in infantile AD, which may enable a more personalized approach to the prevention of asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12835</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29168282">PM:29168282</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171123-HuangCC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171123-HuangCC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171123, Huang CC</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12835</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43398</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guarnaccia,S.</style></author><author><style face="normal" font="default"> Quecchia,C.</style></author><author><style face="normal" font="default"> Festa,A.</style></author><author><style face="normal" font="default"> Magoni,M.</style></author><author><style face="normal" font="default"> Moneda,M.</style></author><author><style face="normal" font="default"> Gretter,V.</style></author><author><style face="normal" font="default"> Scarcella,C.</style></author><author><style face="normal" font="default"> Pluda,A.</style></author><author><style face="normal" font="default"> Gasparotti,C.</style></author><author><style face="normal" font="default"> Frassine,M.</style></author><author><style face="normal" font="default"> Vitale,L.</style></author><author><style face="normal" font="default"> D'Agata,E.</style></author><author><style face="normal" font="default"> Limina,R.M.</style></author><author><style face="normal" font="default"> Donato,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centro "Io e l'Asma", Ospedale dei Bambini, ASST Spedali Civili, Brescia, Italy</style></auth-address><titles><title><style face="normal" font="default">Evaluation of a diagnostic therapeutic educational pathway for asthma management in youth</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="11" Year="2017">2017/11/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: In spite of some evidence for positive effects of patient's education to asthma self-management by randomized clinical trials, there are few studies on the impact of patient' s educational programs in the real world. We aimed to assess the impact of a diagnostic therapeutic educational pathway (DTEP) on asthma control of children and adolescents by comparing frequency of outcomes indicative of asthma control before and after attending the pathway. METHODS: This is a retrospective cohort study including all patients aged 6-11 and 12-17 years who attended the DTEP in 2007-2014. The DTEP includes 3 specialist's evaluations at 8-12 week intervals and two follow-up visits. Patients and their parents receive an educational course concerning prevention measures, early recognition of symptoms and appropriate use of drugs and devices. The rates of hospitalizations, outpatient services, emergency room visits and drug prescriptions were considered as outcomes and computed as number of events divided by person-time. RESULTS: A total of 806 patients were enrolled. A statistically significant decrease of rates from before to after DTEP was observed for almost all outcomes, in both age groups, with relative risks ranging from 0.12 to 0.60. The rates of drug prescription showed a statistically significant decrease, from before to after DTEP, for each type of medicine for asthma, in both age groups, from percent difference of -66% to -24.3%. CONCLUSIONS: The positive impact of this program on the outcomes indicative of asthma control in both children and adolescents suggests that it may be valuable for asthma management. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12839</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29168239">PM:29168239</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171123-GuarnacciaS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171123-GuarnacciaS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171123, Guarnaccia S</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12839</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43399</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Leung,T.F.</style></author><author><style face="normal" font="default"> Tang,M.F.</style></author><author><style face="normal" font="default"> Leung,A.S.Y.</style></author><author><style face="normal" font="default"> Tam,W.W.S.</style></author><author><style face="normal" font="default"> Sy,H.Y.</style></author><author><style face="normal" font="default"> Wong,G.W.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Paediatrics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong</style></auth-address><titles><title><style face="normal" font="default">Trajectory of Spirometric and Exhaled Nitric Oxide Measurements in Chinese Schoolchildren with Asthma</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="11" Year="2017">2017/11/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: Lung function growth occurs in most asthmatic children. A subgroup has subnormal lung function trajectory, but such data is limited in children. This prospective study characterized longitudinal changes of spirometric indices and fractional exhaled nitric oxide level (FeNO) among asthmatic children and identified their genetic and environmental determinants. METHODS: Chinese asthmatic children recruited from paediatric clinics underwent 5-year follow-up for pre-bronchodilator spirometric indices and FeNO. Fourteen asthma-associated single-nucleotide polymorphisms (SNPs) were genotyped. Generalized estimating equation was used to analyze longitudinal changes of spirometric indices and FeNO. RESULTS: 193 asthmatic children, aged 9.7 (1.9) years, had significant annual decline of 1.3% for FVC and annual increase of 1.2% and 3.6% for FEV1 /FVC and FEF25-75 respectively. Patients who received inhaled corticosteroid (ICS) had 2.4% lower baseline FEV1 /FVC but 0.81% higher annual increase in FEV1 . Body mass index (BMI) was associated inversely with FEV1 /FVC but positively with FEV1 % and FVC% changes. Asthma exacerbation was associated with lower FEV1 % and FVC% but not their longitudinal changes. When classified by FEV1 curve, one-quarter of patients had reduced lung function growth which was associated with female gender and lower spirometric and higher FeNO values at baseline. IL33_rs1342326 was associated with spirometric indices and FeNO, whereas GSDMB_rs2305480 was significantly associated with FEV1 /FVC change. CONCLUSION: Asthmatic children have annual decline in FVC and increase in FEV1 /FVC and FEF25-75 . Their lung function trajectory is influenced by gender, ICS treatment, BMI and asthma exacerbations. IL33 and GSDMB may be candidate genes for their lung function growth. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Hong Kong -CO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12836</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29168228">PM:29168228</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171123-LeungTF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171123-LeungTF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171123, Leung TF</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12836</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43400</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Andrade,A.L.M.B.</style></author><author><style face="normal" font="default"> Riccetto,A.G.L.</style></author><author><style face="normal" font="default"> Vilela,M.M.D.S.</style></author><author><style face="normal" font="default"> de Oliveira,D.N.</style></author><author><style face="normal" font="default"> Catharino,R.R.</style></author><author><style face="normal" font="default"> Nolasco da Silva,M.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Medical Sciences, State University of Campinas, Campinas, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="default">Anaphylactic reaction to galactose-derived oligosaccharides residues from lactose used as a drug excipient</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="2" Month="12" Year="2017">2017/12/2</year></dates><abstract><style face="normal" font="default">Inhaled steroids are currently the most widely used and recommended medicines for the management of persistent asthma because of their high local and anti-inflammatory efficacy.(1) There are three main presentations of the drug: aerosol spray (hydrofluoroalkane -</style></abstract><notes><style face="normal" font="default">IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - LetterCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12840</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29197126">PM:29197126</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171202-AndradeAL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171202-AndradeAL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171202, Andrade AL</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12840</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43401</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Moles,J.P.</style></author><author><style face="normal" font="default"> Tuaillon,E.</style></author><author><style face="normal" font="default"> Kankasa,C.</style></author><author><style face="normal" font="default"> Bedin,A.S.</style></author><author><style face="normal" font="default"> Nagot,N.</style></author><author><style face="normal" font="default"> Marchant,A.</style></author><author><style face="normal" font="default"> McDermid,J.M.</style></author><author><style face="normal" font="default"> Van de Perre,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pathogenesis and Control of Chronic Infections, INSERM, EFS, Universite de Montpellier, Montpellier, France</style></auth-address><titles><title><style face="normal" font="default">Breast milk cells trafficking induces microchimerism-mediated immune system maturation in the infant</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="2" Month="12" Year="2017">2017/12/2</year></dates><abstract><style face="normal" font="default">Initiating breastfeeding within the first hour of life confers an important benefit in terms of child mortality and severe morbidity. Intestinal permeability to ingested macromolecules and immunoglobulins is limited to the first days of human life. These exchanges cease in the very early post-partum period but may increase beyond the neonatal period in response to local inflammation or introduction of a weaning food. From animal- and limited human-based observations, compelling evidence points out to breast milk cells also trafficking from mother to infant mucosal tissues and participating to the maternal microchimerism. The precise nature of breast milk cells that are involved is presently not known but likely includes progenitor/stem cells - representing up to 6% of breast milk cells - with possible contribution of mature immune cells. Stem cell microchimerism may induce tolerance to non-inherited maternal antigens (NIMAs), breastfeeding generating regulatory T cells (Treg ) that suppress anti-maternal immunity. Therefore, in complement to pregnancy-induced microchimerism, breastfeeding-induced microchimerism may be pivotal in infant immune development, intestinal tissue repair/growth and protection against infectious diseases. As a continuum of the gestational period, the neonatal gut may be considered as a temporary, but important developmental extension of the role played by the placenta during intrauterine life; breast milk playing the role of maternal blood by delivering maternal soluble factors (macromolecules, Ig, cytokines) and immunologically active milk cells. A better understanding of breastfeeding-induced maternal microchimerism would provide further evidence in support of public health messages that reinforce the importance of early initiation of breastfeeding. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - France -CO - Zambia -CO - United States -CO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12841</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29197124">PM:29197124</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171202-MolesJP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171202-MolesJP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171202, Moles JP</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12841</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43402</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Roy,A.</style></author><author><style face="normal" font="default"> Kocak,M.</style></author><author><style face="normal" font="default"> Hartman,T.J.</style></author><author><style face="normal" font="default"> Vereen,S.</style></author><author><style face="normal" font="default"> Adgent,M.</style></author><author><style face="normal" font="default"> Piyathilake,C.</style></author><author><style face="normal" font="default"> Tylavsky,F.A.</style></author><author><style face="normal" font="default"> Carroll,K.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA</style></auth-address><titles><title><style face="normal" font="default">Association of prenatal folate status with early childhood wheeze and atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="11" Year="2017">2017/11/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: Prenatal folic acid supplementation is recommended to prevent birth defects. Some foods are fortified in the U.S.to ensure sufficient intake among reproductive-aged women. However, high prenatal folate exposure may be a risk factor for childhood atopic diseases. We investigated associations between prenatal folate and early childhood wheeze and atopic dermatitis in a U.S. cohort. METHODS: We studied 858 mother-child dyads, enrolled prenatally. Folate was measured in 2(nd) and 3(rd) trimester maternal plasma. Parents reported current wheeze (previous 12 months) and healthcare provider diagnosis of atopic dermatitis at 3 years. We examined associations using logistic regression, modeling folate continuously and dichotomously (&lt; or >/=20 ng/ml), a level often considered supraphysiologic. RESULTS: Over half of women were African-American and on Medicaid. Median (interquartile range) folate levels were 22.6 (15.9-30.0) and 23.1 (16.1-30.0) ng/mL for 2(nd) and 3(rd) trimesters, respectively. Current wheeze and atopic dermatitis were reported for 20.4% and 26.8% of children, respectively. Second trimester folate as a continuous exposure was not significantly associated with outcomes. Decreased odds of current wheeze was observed in children born to mothers who had 2(nd) trimester folate >/= 20 ng/mL (adjusted odds ratios = 0.67, 95% confidence interval = 0.46, 0.97) compared to children with maternal levels &lt; 20 ng/mL. Third trimester folate was not associated with outcomes. CONCLUSIONS: High plasma folate in mid-pregnancy was associated with decreased odds of current wheeze at age 3. Our findings do not support harmful effects of high prenatal folate levels on childhood atopic diseases in this setting. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12834</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29168294">PM:29168294</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171123-RoyA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20171123-RoyA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171123, Roy A</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12834</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43403</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Christ,P.</style></author><author><style face="normal" font="default"> Hill,S.R.</style></author><author><style face="normal" font="default"> Schachtner,J.</style></author><author><style face="normal" font="default"> Hauser,F.</style></author><author><style face="normal" font="default"> Ignell,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Unit of Chemical Ecology, Department of Plant Protection Biology, Swedish University of Agricultural Sciences, Box 102, Sundsvagen 14, 230 53 Alnarp, Sweden.</style></auth-address><titles><title><style face="normal" font="default">Functional characterization of the dual allatostatin-A receptors in mosquitoes</style></title><secondary-title><style face="normal" font="default">Peptides</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Peptides</style></abbr-1></periodical><pages end="55" start="44">44-55</pages><volume><style face="normal" font="default">99</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="2" Month="11" Year="2017">2017/11/2</year></dates><abstract><style face="normal" font="default">The neuropeptide allatostatin-A (AstA) and its cognate receptors (AstARs) are involved in the modulation of feeding behavior, which in hematophagous insects includes the regulation of the disease vector-related behaviors, host seeking and blood feeding. In mosquitoes and other dipterans, there are two copies of AstAR, contrasting with the single copy found in other insects. In this study, we identified and cloned the dual AstAR system of two important disease vectors Aedes aegypti and Culex quinquefasciatus, and compared them with those previously described, including those in Anopheles coluzzii and Drosophila melanogaster. Phylogenetic analysis of the AstARs revealed that the mosquito AstAR1s has retained a similar amino acid sequence as the AstARs from non-dipteran insect species. Intron analysis revealed that the number of introns accumulated in the AstAR2s is similar to that in other insects, and that introns are conserved within the receptor types, but that only the final two introns are conserved across AstAR1s and 2s. We functionally characterized the dual AstARs in An. coluzzii, Ae. aegypti and Cx. quinquefasciatus by stably expressing the receptors in a Chinese hamster oocyte cell line (CHO) also stably expressing a promiscuous G-protein (G16), and challenged them with the endogenous isoforms of AstA from the three mosquito species. In the culicine mosquitoes, Ae. aegypti and Cx. quinquefasciatus, the AstARs demonstrated differential sensitivity to AstA, with the AstAR2s displaying a higher sensitivity than the AstAR1s, suggesting a divergence of functional roles for these AstARs. In contrast, both An. coluzzii AstARs demonstrated a similar sensitivity to the AstA ligands. We discuss our findings in the light of AstA acting as a regulator of blood feeding in mosquitoes. A better understanding of the regulation of host seeking and blood feeding in vector mosquitoes will lead to the rational development of novel approaches for vector control</style></abstract><notes><style face="normal" font="default">DA - 20171106IS - 1873-5169 (Electronic)IS - 0196-9781 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1016/j.peptides.2017.10.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29103918">PM:29103918</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Peptides\2017-99-44-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Peptides\2017-99-44-55.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171106, Christ P</style></custom2><misc3><style face="normal" font="default">10.1016/j.peptides.2017.10.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43404</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Luczak,E.</style></author><author><style face="normal" font="default"> Wieczfinska,J.</style></author><author><style face="normal" font="default"> Sokolowska,M.</style></author><author><style face="normal" font="default"> Pniewska,E.</style></author><author><style face="normal" font="default"> Luczynska,D.</style></author><author><style face="normal" font="default"> Pawliczak,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunopathology, Medical University of Lodz, Lodz, Poland</style></auth-address><titles><title><style face="normal" font="default">Troglitazone, a PPAR-gamma agonist, decreases LTC4 concentration in mononuclear cells in patients with asthma</style></title><secondary-title><style face="normal" font="default">Pharmacol Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pharmacol Rep</style></abbr-1></periodical><pages end="1321" start="1315">1315-1321</pages><volume><style face="normal" font="default">69</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="24" Month="5" Year="2017">2017/5/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is an inflammatory disorder with multiple mediators involved in the inflammatory response. Despite several attempts, no new anti-inflammatory drugs have been registered for asthma treatment for several years. However, thiazolidinediones, peroxisome proliferator-activated receptor agonists, have demonstrated some anti-inflammatory properties in various experimental settings. The aim of this study was to assess the influence of troglitazone on LTC4 and 15-HETE concentrations. It also evaluates TNF-induced eotaxin synthesis in peripheral blood mononuclear cells from 14 patients with mild asthma and 13 healthy controls. METHODS: PBMCs were isolated from the whole blood of the asthmatics and healthy subjects and pretreated with 0.1, 1 or 10muM of Troglitazone. The cells were then exposed to 10-6M calcium jonophore or 10ng/ml TNF. The production and release of LTC4, 15-HETE and eotaxin were then assessed. RESULTS: Troglitazone caused a dose-dependent inhibition in LTC4 synthesis in both asthmatics and healthy subjects. Troglitazone did not influence 15-HETE or eotaxin production in either asthmatic patients or in healthy individuals. CONCLUSION: Due to its inhibition of LTC4 synthesis, troglitazone therapy is an interesting potential therapeutic approach in asthma and other LTC4 related inflammatory disorders</style></abstract><notes><style face="normal" font="default">DA - 20171112IS - 1734-1140 (Print)IS - 1734-1140 (Linking)LA - engPT - Journal ArticleCO - POland -CO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1016/j.pharep.2017.05.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29128815">PM:29128815</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pharmacol Rep\2017-69-1315-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pharmacol Rep\2017-69-1315-21.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171112, Luczak E</style></custom2><misc3><style face="normal" font="default">10.1016/j.pharep.2017.05.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43405</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,B.</style></author><author><style face="normal" font="default"> Li,Q.</style></author><author><style face="normal" font="default"> Shi,C.</style></author><author><style face="normal" font="default"> Zhang,X.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacology, Institute of Materia Medica, Zhejiang Academy of Medical Sciences, Hangzhou, PR China</style></auth-address><titles><title><style face="normal" font="default">Drug-Induced Pseudoallergy: A Review of the Causes and Mechanisms</style></title><secondary-title><style face="normal" font="default">Pharmacology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pharmacology</style></full-title></periodical><pages end="110" start="104">104-110</pages><volume><style face="normal" font="default">101</style></volume><number><style face="normal" font="default">1-2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="15" Month="11" Year="2017">2017/11/15</year></dates><abstract><style face="normal" font="default">Adverse drug reactions occur frequently and can trigger pseudoallergy, which has become a serious threat to public health. Pseudoallergy is a typical non-immune anaphylactic reaction characterized by the independence of antigen-specific immune responses. In the clinic, pseudoallergy is often elicited by the first dose of medication, and here lies its unpredictability and occasional lethal outcome. However, the mechanisms of pseudoallergy are not well understood. This review focusses on the causes and mechanisms of pseudoallergy induced by drugs. Two categories of mechanisms will be considered, namely, (1) complement activation-related pseudoallergy and (2) mast cell activation-related pseudoallergy. The factors that induce pseudoallergy include opioid drugs, complement activation-related pseudoallergenic drugs, nonsteroidal anti-inflammatory drugs and traditional Chinese medicine injections</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 1423-0313 (Electronic)IS - 0031-7012 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1159/000479878</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29136631">PM:29136631</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pharmacology\2017-101-104-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pharmacology\2017-101-104-10.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171114, Zhang B</style></custom2><misc3><style face="normal" font="default">10.1159/000479878</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43406</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yugandhar,P.</style></author><author><style face="normal" font="default"> Rao,K.M.</style></author><author><style face="normal" font="default"> Sengupta,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonology, ASR Academy of Medical Sciences, Eluru, Andhra Pradesh, India</style></auth-address><titles><title><style face="normal" font="default">A novel herbal composition containing extracts of Boswellia serrata gum resin and Aegle marmelos fruit alleviates symptoms of asthma in a placebo controlled double-blind clinical study</style></title><secondary-title><style face="normal" font="default">Phytother Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Phytother Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="12" Year="2017">2017/12/6</year></dates><abstract><style face="normal" font="default">LI13109F is a novel herbal composition containing the extracts of Boswellia serrata gum resin and Aegle marmelos fruit. This composition dampens leukotriene dependent inflammatory reactions via inhibiting 5-lipoxygenase pathway. In a Sephadex LH-20 induced airway inflammation model of Sprague Dawley rats, LI13109F significantly reduced infiltrated granulocyte population in the bronco-alveolar lavage fluid and normalized Th1/Th2 cytokine balance. Further, a 56-day placebo-controlled and randomized double blind study (Clinical Trial Registration No. CTRI/2016/10/007393) on subjects with mild to moderate asthma has evaluated the clinical efficacy of LI13109F. The study subjects received either 200 mg/day of LI13109F (n = 18) or a similar dosage of placebo (n = 18). At the end of the trial period, LI13109F conferred significant improvements in the clinical parameters; the emotional function (p = .0305) and asthma symptoms scores (p = .0002) were improved even at 14 days, compared with the placebo. Further, 56 days supplementation of LI13109F resulted in significant increase in serum IFN-gamma (p = .0014) and reduction in IL-4 (p = .0497), compared with placebo. LI13109F supplementation did not yield any serious adverse events or any abnormal observations in routine laboratory examinations during the study. Together, these observations suggest that LI13109F (AlvioLife(R)) is tolerable and an effective intervention for management of mild to moderate asthma such as airway inflammation</style></abstract><notes><style face="normal" font="default">IS - 1099-1573 (Electronic)IS - 0951-418X (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.1002/ptr.5963</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29210124">PM:29210124</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Phytother Res\20171204-YugandharP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Phytother Res\20171204-YugandharP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Yugandhar P</style></custom2><misc3><style face="normal" font="default">10.1002/ptr.5963</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43407</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Choi,Y.H.</style></author><author><style face="normal" font="default"> Song,C.H.</style></author><author><style face="normal" font="default"> Mun,S.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anatomy, Medical School, Institute for Medical Sciences, Chonbuk National University, Jeonju, Jeonbuk, 561-180, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Proanthocyanidin-rich Pinus radiata bark extract inhibits mast cell-mediated anaphylaxis-like reactions</style></title><secondary-title><style face="normal" font="default">Phytother Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Phytother Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="12" Year="2017">2017/12/6</year></dates><abstract><style face="normal" font="default">Mast cells play a critical role in the effector phase of immediate hypersensitivity and allergic reactions. Pinus radiata bark extract exerts multiple biological effects and exhibits immunomodulatory and antioxidant properties. However, its role in mast cell-mediated anaphylactic reactions has not been thoroughly investigated. In this study, we examined the effects of proanthocyanidin-rich water extract (PAWE) isolated from P. radiata bark on compound 48/80-induced or antidinitrophenyl (DNP) immunoglobulin E (IgE)-mediated anaphylaxis-like reactions in vivo. In addition, we evaluated the mechanism underlying the inhibitory effect of PAWE on mast cell activation, with a specific focus on histamine release, using rat peritoneal mast cells. PAWE attenuated compound 48/80-induced or anti-DNP IgE-mediated passive cutaneous anaphylaxis-like reactions in mice, and it inhibited histamine release triggered by compound 48/80, ionophore A23187, or anti-DNP IgE in rat peritoneal mast cells in vitro. Moreover, PAWE suppressed compound 48/80-elicited calcium uptake in a concentration-dependent manner and promoted a transient increase in intracellular cyclic adenosine-3',5'-monophosphate levels. Together, these results suggest that proanthocyanidin-rich P. radiata bark extract effectively inhibits anaphylaxis-like reactions</style></abstract><notes><style face="normal" font="default">IS - 1099-1573 (Electronic)IS - 0951-418X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1002/ptr.5973</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29210121">PM:29210121</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Phytother Res\20171205-ChoiYH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Phytother Res\20171205-ChoiYH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171205, Choi YH</style></custom2><misc3><style face="normal" font="default">10.1002/ptr.5973</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43408</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Garcia-Garcia,M.L.</style></author><author><style face="normal" font="default"> Calvo,C.</style></author><author><style face="normal" font="default"> Ruiz,S.</style></author><author><style face="normal" font="default"> Pozo,F.</style></author><author><style face="normal" font="default"> del Pozo,V.</style></author><author><style face="normal" font="default"> Remedios,L.</style></author><author><style face="normal" font="default"> Exposito,N.</style></author><author><style face="normal" font="default"> Tellez,A.</style></author><author><style face="normal" font="default"> Casas,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatrics Department, Severo Ochoa Hospital, Leganes, Alfonso X El Sabio University, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Role of viral coinfections in asthma development</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0189083">e0189083-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Viral respiratory infections, especially acute bronchiolitis, play a key role in the development of asthma in childhood. However, most studies have focused on respiratory syncytial virus or rhinovirus infections and none of them have compared the long-term evolution of single versus double or multiple viral infections. OBJECTIVE: Our aim was to compare the frequency of asthma development at 6-8 years in children with previous admission for bronchiolitis associated with single versus double or multiple viral infection. PATIENTS &amp; METHODS: A cross-sectional study was performed in 244 children currently aged 6-8 years, previously admitted due to bronchiolitis between September 2008 and December 2011. A structured clinical interview and the ISAAC questionnaire for asthma symptoms for 6-7-year-old children, were answered by parents by telephone. Specimens of nasopharyngeal aspirate for virological study (polymerase chain reaction) and clinical data were prospectively taken during admission for bronchiolitis. RESULTS: Median current age at follow-up was 7.3 years (IQR: 6.7-8.1). The rate of recurrent wheezing was 82.7% in the coinfection group and 69.7% in the single-infection group, p = 0.06. The number of wheezing-related admissions was twice as high in coinfections than in single infections, p = 0.004. Regarding the ISAAC questionnaire, 30.8% of coinfections versus 15% of single infections, p = 0.01, presented "wheezing in the last 12 months", data that strongly correlate with current prevalence of asthma. "Dry cough at night" was also reported more frequently in coinfections than in single infections, p = 0.02. The strongest independent risk factors for asthma at 6-8 years of age were: age > 9 months at admission for bronchiolitis (OR: 3.484; CI95%: 1.459-8.317, p:0.005), allergic rhinitis (OR: 5.910; 95%CI: 2.622-13.318, p&lt;0.001), and viral coinfection-bronchiolitis (OR: 3.374; CI95%: 1.542-7.386, p:0.01). CONCLUSIONS: Asthma at 6-8 years is more frequent and severe in those children previously hospitalized with viral coinfection-bronchiolitis compared with those with single infection. Allergic rhinitis and older age at admission seem also to be strong independent risk factors for asthma development in children previously hospitalised because of bronchiolitis</style></abstract><notes><style face="normal" font="default">IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0189083</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29206851">PM:29206851</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0189083.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0189083.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171103, Garcia-Garcia ML</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0189083</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43409</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Janezic,A.</style></author><author><style face="normal" font="default"> Locatelli,I.</style></author><author><style face="normal" font="default"> Kos,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Chair of Social Pharmacy, Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia, EU</style></auth-address><titles><title><style face="normal" font="default">Criterion validity of 8-item Morisky Medication Adherence Scale in patients with asthma</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0187835">e0187835-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The 8-item Morisky Medication Adherence Scale (MMAS-8) is reliable and valid in patients with hypertension, but to our knowledge validity has not been established for patients with asthma. The aim of the study was to determine the criterion validity of the MMAS-8 in patients with asthma. In the cross-sectional study patients older than 12 year were recruited when dispensed asthma medications in community pharmacies. Criterion validity of the scale was assessed through associations with asthma control and quality of life. Asthma control was assessed by the Asthma Control Test (ACT) and quality of life was evaluated by the Saint George Respiratory Questionnaire (SGRQ). A total of 208 patients (mean age 56 years, 59% female) were included in the study. Almost all patients were prescribed inhaled corticosteroids (96%). Asthma was not controlled in 37% of the patients and 22% experienced at least one exacerbation requiring emergency room visit, hospitalization or treatment with oral corticosteroid therapy in the previous year. The 8-item MMAS was significantly associated with asthma control and quality of life. Patients who scored 8 points, &lt;8 to >6 points and &lt;/=6 points on the scale were considered to have high, medium and low adherence, respectively. High, medium and low adherence was found in 53%, 23% and 24% of the patients, respectively. As adherence improved from low to medium or from medium to high, the odds of asthma control increased by 1.7 times (OR 1.65, p = 0.027). Patients with high and medium adherence had SGRQ scores that were 6.1 and 5.3 points lower, respectively, compared with patients with low adherence. The MMAS-8 was found to be valid for assessing medication adherence and predicting health outcomes in patients with asthma</style></abstract><notes><style face="normal" font="default">IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Slovenia -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0187835</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29190693">PM:29190693</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\PLoS One\2017-12-e0187835.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\PLoS One\2017-12-e0187835.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171102, Janezic A</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0187835</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43410</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zastrzezynska,W.</style></author><author><style face="normal" font="default"> Gawlewicz-Mroczka,A.</style></author><author><style face="normal" font="default"> Soja,J.</style></author><author><style face="normal" font="default"> Sladek,K.</style></author><author><style face="normal" font="default"> Musial,J.</style></author><author><style face="normal" font="default"> Bazan-Socha,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Omalizumab is effective and available for treatment of patients with severe allergic asthma in Poland</style></title><secondary-title><style face="normal" font="default">Pol Arch Intern Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pol Arch Intern Med</style></abbr-1></periodical><pages end="717" start="715">715-717</pages><volume><style face="normal" font="default">127</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="10" Year="2017">2017/10/31</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1897-9483 (Electronic)IS - 0032-3772 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29162793">PM:29162793</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pol Arch Intern Med\2017-127-715-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pol Arch Intern Med\2017-127-715-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171116, Zastrzezynska W</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43411</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Inoue,H.</style></author><author><style face="normal" font="default"> Ito,I.</style></author><author><style face="normal" font="default"> Niimi,A.</style></author><author><style face="normal" font="default"> Matsumoto,H.</style></author><author><style face="normal" font="default"> Oguma,T.</style></author><author><style face="normal" font="default"> Tajiri,T.</style></author><author><style face="normal" font="default"> Iwata,T.</style></author><author><style face="normal" font="default"> Nagasaki,T.</style></author><author><style face="normal" font="default"> Kanemitsu,Y.</style></author><author><style face="normal" font="default"> Morishima,T.</style></author><author><style face="normal" font="default"> Hirota,T.</style></author><author><style face="normal" font="default"> Tamari,M.</style></author><author><style face="normal" font="default"> Wenzel,S.E.</style></author><author><style face="normal" font="default"> Mishima,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan</style></auth-address><titles><title><style face="normal" font="default">Association of interleukin 1 receptor-like 1 gene polymorphisms with eosinophilic phenotype in Japanese adults with asthma</style></title><secondary-title><style face="normal" font="default">Respir Investig</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Respir Investig</style></abbr-1></periodical><pages end="347" start="338">338-347</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: IL1RL1 (ST2) is involved in Th2 inflammation including eosinophil activation. Single nucleotide polymorphisms (SNPs) of the IL1RL1 gene are associated with asthma development and increased peripheral blood eosinophil counts. However, the association between IL1RL1 SNPs and eosinophilic phenotype among adults with asthma remains unexplored. METHODS: In a primary cohort of 110 adult Japanese patients with stable asthma, we examined the associations between IL1RL1 SNPs and clinical measurements including forced expiratory volume (FEV1), airway reversibility of FEV1, exhaled nitric oxide (FeNO), serum soluble-ST2 (sST2) levels, peripheral blood eosinophil differentials and serum total IgE level. The findings in the primary cohort were confirmed in a validation cohort of 126 adult Japanese patients with stable asthma. RESULTS: Patients with minor alleles in 3 SNPs (rs17026974, rs1420101, and rs1921622) had high FeNO, blood eosinophil differentials, and reversibility of FEV1, but low levels of serum sST2 and FEV1. Minor alleles of rs1041973 were associated with low serum sST2 levels alone. In the validation cohort, minor alleles of rs1420101 were associated with high FeNO and blood eosinophil differentials, whereas minor alleles of rs17026974 and rs1921622 were associated with high blood eosinophil differentials and FeNO, respectively. Multivariate analyses revealed that the minor allele of rs1420101 additively contributed to the FeNO, blood eosinophil differentials, and reversibility of FEV1. CONCLUSIONS: The minor alleles of IL1RL1 SNPs were associated with high FeNO and peripheral blood eosinophilia among adult Japanese patients with stable asthma. IL1RL1 SNPs may characterize the eosinophilic phenotype with greater eosinophilic inflammation in the Japanese asthma cohort</style></abstract><notes><style face="normal" font="default">IS - 2212-5353 (Electronic)IS - 2212-5345 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.resinv.2017.08.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29153414">PM:29153414</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respir Investig\2017-55-338-47.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respir Investig\2017-55-338-47.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Inoue H</style></custom2><misc3><style face="normal" font="default">10.1016/j.resinv.2017.08.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43412</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cox,C.A.</style></author><author><style face="normal" font="default"> Boudewijn,I.M.</style></author><author><style face="normal" font="default"> Vroegop,S.J.</style></author><author><style face="normal" font="default"> Schokker,S.</style></author><author><style face="normal" font="default"> Lexmond,A.J.</style></author><author><style face="normal" font="default"> Frijlink,H.W.</style></author><author><style face="normal" font="default"> Hagedoorn,P.</style></author><author><style face="normal" font="default"> Vonk,J.M.</style></author><author><style face="normal" font="default"> Farenhorst,M.P.</style></author><author><style face="normal" font="default"> Ten Hacken,N.H.T.</style></author><author><style face="normal" font="default"> Kerstjens,H.A.M.</style></author><author><style face="normal" font="default"> Postma,D.S.</style></author><author><style face="normal" font="default"> van den Berge,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Groningen, University Medical Centre Groningen, Department of Pulmonary Diseases, PO Box 30.0001, 9700 RB Groningen, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Extrafine compared to non-extrafine particle inhaled corticosteroids in smokers and ex-smokers with asthma</style></title><secondary-title><style face="normal" font="default">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respir Med</style></full-title></periodical><pages end="42" start="35">35-42</pages><volume><style face="normal" font="default">130</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Smoking is as prevalent in asthmatics as in the general population. Asthmatic smokers benefit less from inhaled corticosteroids (ICS) than non-smoking asthmatics, possibly due to more smoking-induced small airways disease. Thus targeting small airways may be important in treating asthmatic (ex-)smokers. We hypothesized that extrafine particle ICS improve small airways function more than non-extrafine particle ICS in asthmatic (ex-)smokers. METHODS: We performed an open-label, randomized, three-way cross-over study comparing extrafine beclomethasone (HFA-QVAR) to non-extrafine beclomethasone (HFA-Clenil) and fluticasone (HFA-Flixotide) in 22 smokers and 21 ex-smokers with asthma (?5 packyears). RESULTS: Improvement from baseline in PD20 adenosine after using QVAR, Clenil or Flixotide was 1.04 +/- 1.71, 1.09 +/- 2.12 and 0.94 +/- 1.97 doubling doses, mean +/- standard deviation (SD), respectively. The change from baseline in R5-R20 at PD20 adenosine after using QVAR, Clenil or Flixotide was ?0.02 +/- 0.27, 0.02 +/- 0.21, and ?0.02 +/- 0.31 kPa sL(?1), mean +/- SD, respectively. The change in PD20 adenosine and R5-R20 at PD20 adenosine were neither statistically significant different between QVAR and Clenil (p = 0.86 and p = 0.82) nor between QVAR and Flixotide (p = 0.50 and p = 0.96). CONCLUSION: Similar effectiveness in improving small airways function was found for extrafine and non-extrafine particle ICS treatment for asthmatic smokers and ex-smokers</style></abstract><notes><style face="normal" font="default">IS - 1532-3064 (Electronic)IS - 0954-6111 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.rmed.2017.07.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29206631">PM:29206631</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respir Med\2017-130-35-42.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respir Med\2017-130-35-42.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171120, Cox CA</style></custom2><misc3><style face="normal" font="default">10.1016/j.rmed.2017.07.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43413</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Maniscalco,M.</style></author><author><style face="normal" font="default"> Zamparelli,A.S.</style></author><author><style face="normal" font="default"> Vitale,D.F.</style></author><author><style face="normal" font="default"> Faraone,S.</style></author><author><style face="normal" font="default"> Molino,A.</style></author><author><style face="normal" font="default"> Zedda,A.</style></author><author><style face="normal" font="default"> Motta,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pulmonary Rehabilitation Unit, ICS Maugeri SpA SB, Institute of Telese Terme, Benevento, Italy.</style></auth-address><titles><title><style face="normal" font="default">Long-term effect of weight loss induced by bariatric surgery on asthma control and health related quality of life in asthmatic patients with severe obesity: A pilot study</style></title><secondary-title><style face="normal" font="default">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respir Med</style></full-title></periodical><pages end="74" start="69">69-74</pages><volume><style face="normal" font="default">130</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: The weight loss induced by bariatric surgery (BS) improves asthma clinical control evaluated usually after a short time. The long-term effects of weight loss attained by BS on asthma control and health related-quality of life (HRQoL) in patients affected by asthma and obesity are not known. OBJECTIVE: To investigate the five-year effect of weight reduction induced by BS on asthma control, quality of life and pulmonary functional parameters in severely obese intermittent or mild-to-moderate asthmatic patients. METHODS: Twenty-six consecutive severe obese subjects with previous diagnosis of asthma with indication for laparoscopic adjustable gastric banding (LAGB) were enrolled into the study. Fifteen of them agreed to undertake the surgery (treatment group, TG) while the remaining eleven non-operated patients represented the control group (CG). Body mass index (BMI), Asthma Control Test (ACT), Mini Asthma Quality of Life Questionnaire (mini-AQLQ) and spirometric parameters were evaluated at baseline and after one and five years from surgery. RESULTS: Mean BMI of TG significantly decreased at one and five years after the surgery, while it remained unchanged in CG. After surgery, both the overall ACT and the mini-AQLQ score significantly improved in TG after one year, persisting improved after 5-years (p &lt; 0.001), while these outcomes remained unchanged in CG. As compared with the pre-surgery values, the percentage of predicted FEV1 and FVC significantly increased at five-year follow-up from surgery in TG, while it remained unchanged in CG. CONCLUSIONS: In severe obese asthmatic patients, the significant improvement of asthma control test and HRQoL, observed one year after LAGB, persists five years after surgery</style></abstract><notes><style face="normal" font="default">IS - 1532-3064 (Electronic)IS - 0954-6111 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.rmed.2017.06.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29206636">PM:29206636</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respir Med\2017-130-69-74.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respir Med\2017-130-69-74.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171120, Maniscalco M</style></custom2><misc3><style face="normal" font="default">10.1016/j.rmed.2017.06.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43414</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tanno,L.K.</style></author><author><style face="normal" font="default"> Haahtela,T.</style></author><author><style face="normal" font="default"> Calderon,M.A.</style></author><author><style face="normal" font="default"> Cruz,A.</style></author><author><style face="normal" font="default"> Demoly,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hospital Sirio Libanes, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="default">Implementation gaps for asthma prevention and control</style></title><secondary-title><style face="normal" font="default">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respir Med</style></full-title></periodical><pages end="19" start="13">13-19</pages><volume><style face="normal" font="default">130</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Asthma and allergic diseases can start in childhood and persist throughout life, but could also be manifested later, at any time for still misunderstood reasons. They are major chronic multifactorial respiratory diseases, for which prevention, early diagnosis and treatment is recognized as a priority for the Europe's public health policy and the United Nations. Given that allergy triggers (including infections, rapid urbanization leading to loss in biodiversity, pollution and climate changes) are not expected to change in a foreseeable future, it is imperative that steps are taken to develop, strengthen and optimize preventive and treatment strategies. Currently there are good treatments for asthma, several risk factors are known (e.g., allergies, rhinitis, tobacco smoke) and tools to control the disease have been developed. However, we are still uncertain how to prevent patients from developing asthma and allergic diseases. In this paper, we list the positive and negative experiences in this field as well as analyze the missing links in the process. This critical analysis will be the basis of setting-up an effective program for prevention and making, a process labeled as "implementation gaps"</style></abstract><notes><style face="normal" font="default">IS - 1532-3064 (Electronic)IS - 0954-6111 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Brazil -CO - France -CO - Finland -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.rmed.2017.07.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29206628">PM:29206628</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respir Med\2017-130-13-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respir Med\2017-130-13-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171120, Tanno LK</style></custom2><misc3><style face="normal" font="default">10.1016/j.rmed.2017.07.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43415</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Di Bona,D.</style></author><author><style face="normal" font="default"> Fiorino,I.</style></author><author><style face="normal" font="default"> Taurino,M.</style></author><author><style face="normal" font="default"> Frisenda,F.</style></author><author><style face="normal" font="default"> Minenna,E.</style></author><author><style face="normal" font="default"> Pasculli,C.</style></author><author><style face="normal" font="default"> Kourtis,G.</style></author><author><style face="normal" font="default"> Rucco,A.S.</style></author><author><style face="normal" font="default"> Nico,A.</style></author><author><style face="normal" font="default"> Albanesi,M.</style></author><author><style face="normal" font="default"> Giliberti,L.</style></author><author><style face="normal" font="default"> D'Elia,L.</style></author><author><style face="normal" font="default"> Caiaffa,M.F.</style></author><author><style face="normal" font="default"> Macchia,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">School and Chair of Allergology and Clinical Immunology, Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Italy.</style></auth-address><titles><title><style face="normal" font="default">Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study</style></title><secondary-title><style face="normal" font="default">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respir Med</style></full-title></periodical><pages end="60" start="55">55-60</pages><volume><style face="normal" font="default">130</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Randomized Controlled Trials showed that omalizumab exhibited a good safety and tolerability profile in patients with moderate-to-severe asthma. However, safety data of long-term treatment with omalizumab are scarce. Our aim was to assess the safety of omalizumab in patients under long-term treatment in a real-life setting. METHODS: Difficult-to-control asthmatic patients treated with omalizumab up to 9 years were retrospectively evaluated. Mild to severe adverse events any and reasons for discontinuation were recorded. RESULTS: Ninety-one patients (26.4% males, mean age 49.9 +/- 14.9 years) were included: mean treatment length, 3.8 +/- 2.6 years; mean individual monthly dose, 514.5 +/- 345.7 mg (range, 150-1200 mg). A total of 10,472 single injections were given cumulatively to the 91 patients (115 single injections per patients, on average, over a treatment period up to 9 years). Fifty-nine patients (64.8%) were treated for a period of time from 3 to 9 years, 14 of whom from 6 to 9 years. A high proportion of patients who discontinued treatment dropped out within the first year (18, 39.1%), mainly for reasons unrelated to treatment. Six patients (6.6%) discontinued omalizumab for treatment-related adverse events: arthralgia/myalgia (3 patients); urticaria, angioedema (1 patients); metrorrhagia (1 patient); relapsing herpes labialis (1 patient). Four other patients complained of mild adverse events (rhinitis/conjunctivitis, injection site reaction, fatigue, thrombosis) but continued the treatment. Anaphylaxis was not reported. CONCLUSIONS: Long-term treatment with omalizumab appears remarkably safe and well tolerated in real-life setting. Prolonged omalizumab treatment for many consecutive years did not increase the risk of side effects, particularly anaphylaxis</style></abstract><notes><style face="normal" font="default">IS - 1532-3064 (Electronic)IS - 0954-6111 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.rmed.2017.07.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29206634">PM:29206634</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respir Med\2017-130-55-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respir Med\2017-130-55-60.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171120, Di Bona D</style></custom2><misc3><style face="normal" font="default">10.1016/j.rmed.2017.07.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43416</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Berghea,C.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hypersensitivity reactions to nonsteroidal antiinflamatory drugs</style></title><secondary-title><style face="normal" font="default">Alergologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Alergologia</style></full-title></periodical><pages end="38" start="34">34-38</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Drugs can induce several different types of immunological reactions that, together with nonallergic drug hypersensitivity reactions comprise 15% of all adverse drug reactions. Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most frequent triggers of drug hypersensitivity in adults, with NSAIDs-induced urticaria/angioedema being the most common phenotype, and the second most commonly involved drug group in pediatric population. The European Network on Drug Allergy (ENDA) report define five clinical entities according to clinical manifestation, the presence of concomitant disease, and cross-reactivity with other COX-1 inhibitors: Immunologically mediated (non-cross-reactive) reactions: IgE-mediated, immediate hypersensitivity reaction - NSAID-induced urticaria/angioedema/anaphylaxis;  T-cell-mediated single-NSAID-induced delayed hypersensitivity reactions.Nonimmunologically mediated  reactions, possibly caused by COX-1 enzyme inhibition (cross-reactive NSAID hypersensitivity): NSAID-exacerbated respiratory disease; NSAID-exacerbated cutaneous disease; NSAID-induced urticaria/angioedema.Proper classification of reactions support rational diagnostic procedures and adequate patient management. Detailed history, in vivo and in vitro tests not necessarily sensitive, specific, and reproducible enough to be recommended for routine practice and with particularities age-related, and drug provocation tests are all useful in identification of the culprit drug, of cross-reactivity and of therapeutical solution for the adult and pediatric pacients.</style></abstract><notes><style face="normal" font="default">LA - ROMCO - Romania -</style></notes><work-type><style face="normal" font="default">10.26416/Aler.1.1.2017.1243</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.26416/Aler.1.1.2017.1243</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Alergologia\2017-1-34-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Alergologia\2017-1-34-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171128, Berghea CE</style></custom2><misc3><style face="normal" font="default">10.26416/Aler.1.1.2017.1243</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43417</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bumbacea,R.S.</style></author><author><style face="normal" font="default"> Deaconu,C.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hypersensitivity reactions to chemotherapeutic agents: platinum salts and taxanes</style></title><secondary-title><style face="normal" font="default">Alergologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Alergologia</style></full-title></periodical><pages end="27" start="22">22-27</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Hypersensitivity reactions (HSRs) to chemotherapeutic agents have a steadily increasing incidence, with a major impact on oncological diseases outcome, inducing the discontinuity of an effective therapy. The most commonly involved agents are platinum salts and taxanes, which can cause HSRs with different degrees of severity. Given the risk of defining some adverse reactions as HSRs, it is recommended to use a well-structured allergy assessment protocol in which in vivo and in vitro specific tests have proven their utility. There is, however, a limitation of the skin tests, due to the risk of an irritant reaction even at low concentrations, despite the establishment of certain concentrations considered non-irritating for skin testing. The management of HSRs to chemotherapeutic agents provides two major options depending on the severity of the reaction and risk: resuming treatment with a modified protocol (perfusion rate, premedication, etc.) or replacement of the culprit agent. In the absence of a therapeutic alternative, the desensitisation procedure allows maintaining the therapy in safety, improving the oncological prognosis. Desensitization has been shown to be an effective therapeutic tool in chemotherapy hypersensitivity, with more and more studies presenting rapid desensitization protocols, by steps, on the basis of escalating low doses until the full therapeutic dose is reached in few hours.</style></abstract><notes><style face="normal" font="default">LA - ROMCO - Romania -</style></notes><work-type><style face="normal" font="default">10.26416/Aler.1.1.2017.1241</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.26416/Aler.1.1.2017.1241</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Alergologia\2017-1-22-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Alergologia\2017-1-22-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171128, Bumbacea RS</style></custom2><misc3><style face="normal" font="default">10.26416/Aler.1.1.2017.1241</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43418</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vlaicu,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Anticonvulsant hypersensitivity syndrome or drug rash with eosinophilia and systemic symptoms (DRESS) induced by anticonvulsants</style></title><secondary-title><style face="normal" font="default">Alergologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Alergologia</style></full-title></periodical><pages end="33" start="28">28-33</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Introduction. Anticonvulsant hypersensitivity syndrome (AHS)/DRESS induced by anticonvulsants (ACs) is a rare, but severe and potentially fatal adverse reaction that occurs in patients who are treated with classical aromatic anticonvulsants (AAs) (phenytoin, carbamazepine and phenobarbital) as well as with some of the new ACs. Covered fields. AHS is a disease often difficult to diagnose, with high variability in its clinical presentation. The usual presentation is rash associated with fever and internal organ dysfunction. Symptoms usually occur between 2 and 8 weeks after starting treatment. A type IV hypersensitivity mechanism has been proposed, but viral infections, particularly herpes virus 6, have been shown to play a role. Individuals with specific HLA haplotypes are predisposed to develop this syndrome when exposed to certain medications. In vivo (patch test) and in vitro tests (lymphocyte transformation test) may be useful for the etiologic diagnosis of AHS. Management of AHS consists in its recognition, discontinuation of the causative AC, and the use of systemic corticosteroids. A 40-80% incidence of cross-reactivity between different AAs has been reported. Non-aromatic ACs are considered safe in these patients, but sometimes choosing an alternative AC may be difficult. Conclusions. Given the high variability in the clinical presentation of AHS, physicians should have a high index of suspicion in AC-treated patients experiencing cutaneous manifestations and internal organ dysfunction. Early recognition of AHS and withdrawal of the causative AC therapy are essential for the treatment and for a successful outcome.</style></abstract><notes><style face="normal" font="default">LA - ROMCO - Romania -</style></notes><work-type><style face="normal" font="default">10.26416/Aler.1.1.2017.1242</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.26416/Aler.1.1.2017.1242</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Alergologia\2017-1-28-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Alergologia\2017-1-28-33.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171128, Vlaicu C</style></custom2><misc3><style face="normal" font="default">10.26416/Aler.1.1.2017.1242</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43419</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bocsan,C.</style></author><author><style face="normal" font="default"> Muntean,A.</style></author><author><style face="normal" font="default"> Buzoianu,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hypersensitivity reactions induced by antiretroviral agents</style></title><secondary-title><style face="normal" font="default">Alergologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Alergologia</style></full-title></periodical><pages end="18" start="12">12-18</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Drugs hypersensitivity reactions in HIV-infected patients are induced by both antiretroviral agents and antibiotic therapy for oportunistic infections. The most frequently involved agents are abacavir, nevirapine and co-trimoxazole as prophylactic treatment. The incidence of drug hypersensitivity reactions in HIV-infected patients is higher than in general population, the skin reaction being 100 more frequent in these cases. The most common manifestations of drug hypersensitivity reactions are cutaneous reactions and hepatotoxicity, both having an immune mechanism. The occurence of hypersensitivity reactions in HIV infected patients is related to  a complex association of factors: chronic treatment, drugs association, cytokine profile in HIV-infected patients, oxidative stress, drug metabolism alteration, genetic predisposition. The complex management of patients with hypersensitivity reactions requiers good knowledge of risk factors for such kind of reactions, metabolism and pharmacokinetic of recommended drugs, in order to prevent consequent hypersensitivity reactions. Genetic screening for abacavir hypersensitivity is an optimal method for diagnosis and prevention of hypersensitivity reactions in Caucasian population. Strict avoidance of culprit drug is mandatory in case of abacavir hypersensitivity and nevirapine hepatotoxicity; desensitization is possible in case of co-trimoxazole-induced reactions.</style></abstract><notes><style face="normal" font="default">LA - ROMCO - Romania -</style></notes><work-type><style face="normal" font="default">10.26416/Aler.1.1.2017.1239</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.26416/Aler.1.1.2017.1239</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Alergologia\2017-1-12-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Alergologia\2017-1-12-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171128, Bocsan C</style></custom2><misc3><style face="normal" font="default">10.26416/Aler.1.1.2017.1239</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43420</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Leru,P.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Reactions induced by angiotensin-converting enzyme inhibitors - etiopathogenic, clinical and therapeutic aspects</style></title><secondary-title><style face="normal" font="default">Alergologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Alergologia</style></full-title></periodical><pages end="21" start="19">19-21</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Angiotensin-converting enzyme inhibitors (ACEI) have been largely used in clinical practice for more than 30 years, mainly for treating arterial hypertension and heart failure. They have been proven to reduce cardiovascular risk, by reducing mortality and morbidity after miocardial infarction and stroke . Besides their well known positive effects, treatment with ACEI may induce some adverse reactions, such as chronic cough and angioedema. Intolerance to ACEI is due to increasing levels of bradikinin in plasma and lungs, secondary to blocking the conversion of angiotensin II to angiotensin I. Cough induced or agravated by ACEI is quite frequently encountered in clinical practice and generally underestimated. Angioedema associated with ACEI therapy has a low incidence, but because of the large number of patients treated with this class of medication, ACEI is the most common cause of angioedema in adults who presented to hospitals or emergency departments. Angioedema may occur  any time during the ACEI therapy, usually in the first year, but late onset is possible, leading to delayed or confused diagnosis. The reported  incidence is higher in women, African-Americans and patients with previous drug allergies. Diagnosis of ACEI induced angioedema may be difficult because of the late onset, clinical picture similar with histamine-induced angioedema and concomitant medication. Bradikinin- mediated angioedema does not respond to standard therapy with antihistamines, corticosteroids and adrenaline, usually used for treating allergic reactions. Recent studies support the usefulness of subcutaneous icatibant, a selective bradikin B2 receptor antagonist.</style></abstract><notes><style face="normal" font="default">LA - ROMCO - Romania -</style></notes><work-type><style face="normal" font="default">10.26416/Aler.1.1.2017.1240</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.26416/Aler.1.1.2017.1240</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Alergologia\2017-1-19-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Alergologia\2017-1-19-21.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171128, Leru PM</style></custom2><misc3><style face="normal" font="default">10.26416/Aler.1.1.2017.1240</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43421</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ureche,C.</style></author><author><style face="normal" font="default"> Danila,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Allergy to drug excipients</style></title><secondary-title><style face="normal" font="default">Alergologia</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Alergologia</style></full-title></periodical><pages end="41" start="40">40-41</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Lactose (C12H22O11) is a disaccharide composed of one molecule of galactose and one glucose. In the pharmaceutical industry, lactose is used to aid in tablet formation because it has excellent compressibility properties. It is also used to form a diluent powder for dry powder inhalations. Lactose may be present as anhydrous lactose, lactose monohydrate or spray-dried lactose. High-quality pharmaceutical lactose contains traces of milk protein (0.012-0.029% impurities, including cow's milk). These amounts may cause allergic reactions in people suffering from milk allergy if ingested or inhaled. We present the case of a 60-year-old patient who, since February 2017 reports the occurrence of chronic urticaria accompanied by sporadic palpebral angioedema and lips. The patient presents cardiovascular comorbidities (arterial hypertension under treatment), diabetes mellitus with ADO, chronic gastritis, hyperuricemia. As a result of the investigations carried out, a hypersensitivity to cow's milk proteins was identified despite the regimen of avoiding this type of diet, the patient continued to present the symptoms aforementioned. The conjugated and correctly administered antihypertensive treatment of the patient was altered without results, and afterwards it was attempted to administer all concomitant medication with preparations that did not contain lactose as an excipient. Clinical evolution was favorable, with remission of skin eruptions, with isolated recurrence (2 episodes/3 months) of unilateral palpebral edema. With this clinical case, we want to draw the attention to the importance of allergies/intolerances to drug excipients.</style></abstract><notes><style face="normal" font="default">LA - ROMCO - Romania -</style></notes><work-type><style face="normal" font="default">10.26416/Aler.1.1.2017.1244</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.26416/Aler.1.1.2017.1244</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Alergologia\2017-1-40-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Alergologia\2017-1-40-1.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171128, Ureche C</style></custom2><misc3><style face="normal" font="default">10.26416/Aler.1.1.2017.1244</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43422</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wedi,B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Current diagnostics in NSAID hypersensitivity</style></title><secondary-title><style face="normal" font="default">Allergo J Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergo J Int</style></abbr-1></periodical><pages end="211" start="204">204-211</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2197-0378</style></isbn><abstract><style face="normal" font="default">Non-steroidal anti-inflammatory drugs (NSAID) are the second most common trigger of drug hypersensitivity in adults and children and are considered the most common or second most common cause of drug-induced anaphylaxis. NSAID hypersensitivity reactions are classified according to the latency of symptoms in relation to ingestion and on the basis of symptoms, potential underlying disease (chronic urticaria, bronchial asthma/chronic rhinosinusitis/nasal polyps), cross-reactivity to other NSAID, and the suspected pathomechanism. The diagnosis and management of NSAID hypersensitivity depend on the confirmed or suspected type of reaction. The pathomechanism for the majority of hypersensitivity reactions to NSAID has not been elucidated in detail; preferential COX-1 inhibition, which causes a-áshift in arachidonic acid metabolism, is considered relevant to an extent in immediate-type reactions. Delayed reactions to NSAID are rarer, diverse, and considered to be T-ácell mediated. All NSAIDs are essentially able to trigger all types of reaction. Immediate-type reactions involving cutaneous (urticaria/angioedema) and/or respiratory symptoms (rhinitis, bronchial asthma), as well as anaphylactic reactions are the most common</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1007/s40629-017-0030-2</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40629-017-0030-2</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2017-26-204-11.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2017-26-204-11.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Wedi B</style></custom2><misc3><style face="normal" font="default">10.1007/s40629-017-0030-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43423</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Klimek,L.</style></author><author><style face="normal" font="default"> Aderhold,C.</style></author><author><style face="normal" font="default"> Sperl,A.</style></author><author><style face="normal" font="default"> Trautmann,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Allergic reactions to antibiotics </style><style face="normal" font="Symbol">-</style><style face="normal" font="default"> two sides of the same coin: clearly diagnose or reliably rule out</style></title><secondary-title><style face="normal" font="default">Allergo J Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Allergo J Int</style></abbr-1></periodical><pages end="218" start="212">212-218</pages><volume><style face="normal" font="default">26</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2197-0378</style></isbn><abstract><style face="normal" font="default">Antibiotics cause allergic reactions with a-ádisproportionate frequency compared with other drugs. Skin symptoms such as exanthema usually result but systemic anaphylactic responses may also occur</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1007/s40629-017-0025-z</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40629-017-0025-z</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergo J Int\2017-26-212-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergo J Int\2017-26-212-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Klimek L</style></custom2><misc3><style face="normal" font="default">10.1007/s40629-017-0025-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43424</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ohta,N.</style></author><author><style face="normal" font="default"> Ueki,S.</style></author><author><style face="normal" font="default"> Konno,Y.</style></author><author><style face="normal" font="default"> Hirokawa,M.</style></author><author><style face="normal" font="default"> Kubota,T.</style></author><author><style face="normal" font="default"> Tomioka-Matsutani,S.</style></author><author><style face="normal" font="default"> Suzuki,T.</style></author><author><style face="normal" font="default"> Ishida,Y.</style></author><author><style face="normal" font="default"> Kawano,T.</style></author><author><style face="normal" font="default"> Miyasaka,T.</style></author><author><style face="normal" font="default"> Takahashi,T.</style></author><author><style face="normal" font="default"> Suzuki,T.</style></author><author><style face="normal" font="default"> Ohno,I.</style></author><author><style face="normal" font="default"> Kakehata,S.</style></author><author><style face="normal" font="default"> Fujieda,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Otolaryngology, Tohoku Medical and Pharmaceutical University, Sendai, Japan; Yamagata City Hospital Saiseikan, Yamagata, Japan.</style></auth-address><titles><title><style face="normal" font="default">ETosis-derived DNA trap production in middle ear effusion is a common feature of eosinophilic otitis media</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="12" Year="2017">2017/12/11</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.11.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29242145">PM:29242145</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20171204-OhtaN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20171204-OhtaN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Ohta N</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.11.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43425</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kimura,H.</style></author><author><style face="normal" font="default"> Konno,S.</style></author><author><style face="normal" font="default"> Makita,H.</style></author><author><style face="normal" font="default"> Taniguchi,N.</style></author><author><style face="normal" font="default"> Kimura,H.</style></author><author><style face="normal" font="default"> Goudarzi,H.</style></author><author><style face="normal" font="default"> Shimizu,K.</style></author><author><style face="normal" font="default"> Suzuki,M.</style></author><author><style face="normal" font="default"> Shijubo,N.</style></author><author><style face="normal" font="default"> Shigehara,K.</style></author><author><style face="normal" font="default"> Ono,J.</style></author><author><style face="normal" font="default"> Izuhara,K.</style></author><author><style face="normal" font="default"> Ito,Y.M.</style></author><author><style face="normal" font="default"> Nishimura,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido, Japan</style></auth-address><titles><title><style face="normal" font="default">Serum periostin is associated with body mass index and allergic rhinitis in healthy and asthmatic subjects</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="12" Year="2017">2017/12/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Many studies have attempted to clarify the factors associated with serum periostin levels in asthmatic patients. However, these results were based on studies of subjects mainly characterized by high eosinophil counts, which may present as an obstacle for clarification in the identification of other factors associated with serum periostin levels. The aim of this study was to determine the factors associated with serum periostin levels in healthy subjects. We also assessed some factors in asthmatic subjects to confirm their extrapolation for management of asthma. METHODS: Serum periostin levels were measured in 230 healthy subjects. Clinical factors of interest included body mass index (BMI) and allergic rhinitis (AR). Additionally, we confirmed whether these factors were associated with serum periostin in 206 asthmatic subjects. We further evaluated several obesity-related parameters, such as abdominal fat distribution and adipocytokine levels. RESULTS: Smoking status, blood eosinophil count, total immunoglobulin E, and the presence of AR were associated with serum periostin in healthy subjects. There was a negative association between BMI and serum periostin in both healthy and asthmatic subjects, while there was a tendency of a positive association with AR in asthmatic subjects. There were no differential associations observed for subcutaneous and abdominal fat in relation to serum periostin in asthmatic subjects. Serum periostin was significantly associated with serum levels of adiponectin, but not with leptin. CONCLUSIONS: Our results provided clarity as to the factors associated with serum periostin levels, which could be helpful in the interpretation of serum periostin levels in clinical practice</style></abstract><notes><style face="normal" font="default">IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.11.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29223720">PM:29223720</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\20171204-KimuraH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\20171204-KimuraH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Kimura H</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.11.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43426</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">de Graauw,E.</style></author><author><style face="normal" font="default"> Sitaru,C.</style></author><author><style face="normal" font="default"> Horn,M.P.</style></author><author><style face="normal" font="default"> Borradori,L.</style></author><author><style face="normal" font="default"> Yousefi,S.</style></author><author><style face="normal" font="default"> Simon,D.</style></author><author><style face="normal" font="default"> Simon,H.U.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Pharmacology, University of Bern, Bern, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Monocytes enhance neutrophil-induced blister formation in an ex vivo model of bullous pemphigoid</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="12" Year="2017">2017/12/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Lesions of bullous pemphigoid (BP), an autoimmune subepidermal blistering disease characterized by the presence of tissue-bound and circulating autoantibodies to hemidesmosomal antigens, harbour a mixed inflammatory cellular infiltrate. In various models, neutrophils, eosinophils, mast cells, monocytes as well as B and T cells have been shown to be involved in the pathogenesis of BP. However, their interactions with and effective role in blister formation remains uncertain. This study was aimed at investigating the effect of monocyte/neutrophil interaction on blister formation in an ex vivo BP model. METHODS: Skin cryosections were incubated with purified human neutrophils and monocytes, in the presence or absence of BP autoantibodies. Production of reactive oxygen species (ROS), degranulation, mediator release (neutrophil elastase (NE), myeloperoxidase (MPO), matrix metalloproteinase-9 (MMP-9)), binding of Fcgamma receptor (CD16, CD32, CD64), and cell adhesion (CD18, ICAM-1) were investigated using appropriate inhibitors. Dermal-epidermal separation (DES) was assessed by light microscopy and quantified by Fiji software. RESULTS: Monocytes and neutrophils synergistically interact resulting in a significantly higher DES compared to either monocytes or neutrophils separately (P &lt; 0.0001). Monocyte/neutrophil-induced DES was associated with increased ROS production and was dependent on adhesion and FcgammaRIII binding. Upon stimulation by the granule-poor fraction of monocyte supernatants, neutrophils increased their release of MMP-9, thereby also DES at the dermal-epidermal junction of skin cryosections. CONCLUSION: Our observations suggest that the interaction of cells, as shown here for monocytes and neutrophils, enhances mediator release resulting in an increased subepidermal blister formation. Thus, blocking intercellular cross-talk promises a new therapeutic approach for blocking tissue damage in BP. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Switzerland -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/all.13376</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29222810">PM:29222810</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy\20171211-deGraauwE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy\20171211-deGraauwE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171211, de Graauw E</style></custom2><misc3><style face="normal" font="default">10.1111/all.13376</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43427</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ameratunga,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Immunology, Auckland Hospital, Park Rd, Grafton 1010, Auckland, New Zealand.0000 0000 9027 2851grid.414055.1</style></auth-address><titles><title><style face="normal" font="default">Initial intravenous immunoglobulin doses should be based on adjusted body weight in obese patients with primary immunodeficiency disorders</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Clin Immunol</style></full-title></periodical><pages end="" start="47">47-</pages><volume><style face="normal" font="default">13</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Immunoglobulin therapy plays a critical role in the treatment of immunodeficiency disorders as well as autoimmune and inflammatory conditions. In immunodeficient patients, there has been controversy whether initial loading doses of intravenous (IVIG) should be based on actual body weight or a calculated parameter such as adjusted body weight in obese patients. Case presentation: I describe a patient with Common Variable Immunodeficiency disorder (CVID) who underwent bariatric surgery for morbid obesity. Her weight decreased by 50% to below her calculated ideal body weight (IBW) while her immunoglobulin requirement fell by approximately 20%. Her steady state serum IgG increased from approximately 7 g/l to 11.7 g/l concomitant with weight loss. Conclusions: I present this observation as support for the recommendation that initial loading doses of SCIG/IVIG in immunodeficiency should be based on adjusted body weight (AjBW) and not actual body weight in obese patients. This has important fiscal implications for treating obese patients with immunodeficiency disorders</style></abstract><notes><style face="normal" font="default">IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - New Zealand -</style></notes><work-type><style face="normal" font="default">10.1186/s13223-017-0220-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29225631">PM:29225631</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-47.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-47.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171208, Ameratunga R</style></custom2><misc3><style face="normal" font="default">10.1186/s13223-017-0220-y</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43428</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Eindhoven,S.</style></author><author><style face="normal" font="default"> Levels,J.</style></author><author><style face="normal" font="default"> Huisman,M.</style></author><author><style face="normal" font="default"> de Winter,K.R.</style></author><author><style face="normal" font="default"> Dalm,V.</style></author><author><style face="normal" font="default"> Alwani,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, IJsselland Hospital, Capelle aan den IJssel, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default">MPO-ANCA associated vasculitis with mononeuritis multiplex following influenza vaccination</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Clin Immunol</style></full-title></periodical><pages end="" start="49">49-</pages><volume><style face="normal" font="default">13</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Although influenza vaccines are generally safe and effective, a variety of autoimmune phenomena have been reported after vaccination over the past years, such as Guillain-Barre syndrome, rheumatoid arthritis, pemphigus vulgaris, psoriasis, giant cell arteritis and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV). Case report: We describe the case of a 67-year old man who presented with a myeloperoxidase-ANCA associated vasculitis with renal involvement and mononeuritis multiplex after seasonal influenza vaccination. He was initially treated with intravenous cyclophosphamide and high-dose prednisolone followed by maintenance treatment consisting of azathioprine and prednisolone. Conclusion: We hypothesize that seasonal influenza vaccination triggered a systemic immune response in a susceptible patient to develop AAV with renal involvement and vasculitic neuropathy. In general, seasonal influenza vaccinations are considered to be safe, however, clinicians should be aware of this rare phenomenon</style></abstract><notes><style face="normal" font="default">IS - 1710-1484 (Print)IS - 1710-1484 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1186/s13223-017-0222-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29255476">PM:29255476</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-49.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2017-13-49.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171208, Eindhoven S</style></custom2><misc3><style face="normal" font="default">10.1186/s13223-017-0222-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43429</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Keet,C.A.</style></author><author><style face="normal" font="default"> Keller,J.P.</style></author><author><style face="normal" font="default"> Peng,R.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Johns Hopkins School of Medicine, Pediatric Allergy and Immunology, Baltimore, Maryland, United States</style></auth-address><titles><title><style face="normal" font="default">Long-term Coarse PM Exposure is Associated with Asthma Among Children in Medicaid</style></title><secondary-title><style face="normal" font="default">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Crit Care Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="15" Month="12" Year="2017">2017/12/15</year></dates><abstract><style face="normal" font="default">RATIONALE: Short and long-term fine particulate matter (PM2.5) pollution is associated with asthma development and morbidity, but there is little data on the effects of long-term exposure to coarse PM (PM10-2.5) on respiratory health. OBJECTIVES: To understand the relationship between long-term fine and coarse PM exposure and asthma prevalence and morbidity among children. METHODS: A semi-parametric regression model that incorporated PM2.5 and PM10 monitor data and geographic characteristics was developed to predict two-year average PM2.5 and PM10-2.5 exposure during the period 2009-2010 at the zip-code tabulation area level. Data from 7,810,025 children aged 5-20 years enrolled in Medicaid from 2009-2010 were used in a log-linear regression model with predicted PM levels to estimate the association between PM exposure and asthma prevalence and morbidity, adjusting for race/ethnicity, sex, age, area-level urbanicity, poverty, education, and unmeasured spatial confounding. MEASUREMENTS AND MAIN RESULTS: Exposure to coarse PM was associated with increased asthma diagnosis prevalence (RR for 1microg/m3 increase in coarse PM level: 1.006, 95%CI: 1.001-1.011), hospitalizations (RR: 1.023, 95%CI: 1.003-1.042), and emergency department (ED) visits (RR: 1.017, 95%CI: 1.001-1.033) when adjusting for fine PM. Fine PM exposure was more strongly associated with increased asthma prevalence and morbidity than coarse PM. The estimates remained elevated across different levels of spatial confounding adjustment. CONCLUSIONS: Among children enrolled in Medicaid, exposure to higher average coarse PM levels is associated with increased asthma prevalence and morbidity. These results suggest the need for direct monitoring of coarse PM and reconsideration of limits on long-term average coarse PM pollution levels</style></abstract><notes><style face="normal" font="default">IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1164/rccm.201706-1267OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29243937">PM:29243937</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171215, Keet CA</style></custom2><misc3><style face="normal" font="default">10.1164/rccm.201706-1267OC</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43430</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Polat,A.K.</style></author><author><style face="normal" font="default"> Belli,A.A.</style></author><author><style face="normal" font="default"> Karakus,V.</style></author><author><style face="normal" font="default"> Dere,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Istanbul Training and Research Hospital - Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="default">Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome</style></title><secondary-title><style face="normal" font="default">An Bras Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">An Bras Dermatol</style></full-title></periodical><pages end="61" start="59">59-61</pages><volume><style face="normal" font="default">92</style></volume><number><style face="normal" font="default">5 Suppl 1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Deferasirox is an iron chelator agent used in the treatment of diseases with iron overload, such as thalassemia and myelodysplastic syndrome. Although the majority of adverse reactions of deferasirox involve gastrointestinal symptoms and increase in serum creatinine and transaminases, skin rashes, such as maculopapular and urticarial eruptions, have also been reported. This study reports a case of myelodysplastic syndrome with urticarial vasculitis due to deferasirox therapy. Drug eruption was been confirmed by means of a challenge test, together with histopathological and clinical findings. To the best of our knowledge, we report the first case of deferasirox-induced urticarial vasculitis. Physicians should be aware of the possibility of urticarial vasculitis on deferasirox therapy and the fact that the discontinuation of the drug generally results in improvement</style></abstract><notes><style face="normal" font="default">IS - 1806-4841 (Electronic)IS - 0365-0596 (Linking)LA - engPT - Case ReportsCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1590/abd1806-4841.20176688</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29267448">PM:29267448</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\An Bras Dermatol\2017-92S1-59-61.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\An Bras Dermatol\2017-92S1-59-61.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171203, Polat AK</style></custom2><misc3><style face="normal" font="default">10.1590/abd1806-4841.20176688</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43431</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vakharia,P.P.</style></author><author><style face="normal" font="default"> Chopra,R.</style></author><author><style face="normal" font="default"> Sacotte,R.</style></author><author><style face="normal" font="default"> Patel,K.R.</style></author><author><style face="normal" font="default"> Singam,V.</style></author><author><style face="normal" font="default"> Patel,N.</style></author><author><style face="normal" font="default"> Immaneni,S.</style></author><author><style face="normal" font="default"> White,T.</style></author><author><style face="normal" font="default"> Kantor,R.</style></author><author><style face="normal" font="default"> Hsu,D.Y.</style></author><author><style face="normal" font="default"> Silverberg,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Feinberg School of Medicine at Northwestern University, Chicago, Illinois</style></auth-address><titles><title><style face="normal" font="default">Burden of skin pain in atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="552" start="548">548-552</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis (AD) is associated with itch, skin inflammation and barrier disruption, and scratching, all of which may be associated with skin pain. OBJECTIVE: To characterize the patient burden of skin pain in AD. METHODS: We performed a prospective dermatology practice-based study using questionnaires and evaluation by a dermatologist. RESULTS: Overall, 305 patients (age range, 13-97 years) were included in the study, with 564 encounters. The cohort included 195 females (63.9%) and 193 whites (63.7%). The mean (SD) age at enrollment was 42.3 (18.1) years, and the mean (SD) age of patient-reported AD onset was 29.6 (31.9) years. At baseline, 144 patients (42.7%) reported skin pain in the past week, with 42 (13.8%) reporting severe or very severe pain. Twenty-four (16.8%) thought the skin pain was part of their itch, 16 (11.2%) from scratching, and 77 (72.0%) from both. Patients with skin pain were more likely to describe their itch using terms that resembled neuropathic pain. Prevalence of skin pain was increased in patients with vs without excoriations (72.6% vs 57.6%; chi(2) test P = .02) but not other morphologic characteristics. Skin pain severity was most strongly correlated with the Patient-Oriented Eczema Measure (Spearman rho = 0.54), followed by ItchyQOL (rho = 0.52), 5-dimensions of itch scale (rho = 0.47), Dermatology Life Quality Index (rho = 0.45), numeric rating scale for itch (rho = 0.43) and sleep (rho = 0.36), Patient Health Questionnaire 9 (rho = 0.36), patient-reported global AD severity (rho = 0.34), Eczema Area and Severity Index (rho = 0.23), and objective Scoring AD index (rho = 0.20) (P &lt; .001 for all). Patients with both severe itch and pain vs those with only one or neither symptom being severe had significant increases in all these measures. CONCLUSION: Skin pain is a common and burdensome symptom in AD. Skin pain severity should be assessed with itch severity in AD patients and may be an important end point for monitoring treatment response</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.09.076</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29223299">PM:29223299</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-548-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-548-52.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171202, Vakharia PP</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.09.076</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43432</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Segundo,G.R.S.</style></author><author><style face="normal" font="default"> Takano,O.A.</style></author><author><style face="normal" font="default"> Moraes,L.S.L.</style></author><author><style face="normal" font="default"> Nadaf,M.I.S.V.</style></author><author><style face="normal" font="default"> Fernandes,S.J.</style></author><author><style face="normal" font="default"> Ochs,H.D.</style></author><author><style face="normal" font="default"> Torgerson,T.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, University of Washington, Seattle, Washington; Seattle Children's Hospital, Seattle, Washington</style></auth-address><titles><title><style face="normal" font="default">Paternal gonadal mosaicism as cause of a puzzling inheritance pattern of activated PI3-kinase delta syndrome</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="566" start="564">564-566</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.09.054</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29107464">PM:29107464</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-564-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-564-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171202, Segundo GR</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.09.054</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43433</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oppenheimer,J.</style></author><author><style face="normal" font="default"> Kelly,H.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">UMDNJ-Rutgers, Newark, New Jersey, Pulmonary and Allergy Associates, Summit, New Jersey.</style></auth-address><titles><title><style face="normal" font="default">Could calcium channel blockers treat 2 illnesses with 1 pill?</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="474" start="473">473-474</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.09.065</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29223295">PM:29223295</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-473-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-473-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171203, Oppenheimer J</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.09.065</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43434</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oppenheimer,J.J.</style></author><author><style face="normal" font="default"> Marshall,G.D.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy Immunology, Rutgers-UMDNJ and Pulmonary and Allergy Associates, Summit, New Jersey.</style></auth-address><titles><title><style face="normal" font="default">Increasing our knowledge base of asthma</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="479" start="476">476-479</pages><volume><style face="normal" font="default">119</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.10.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29223297">PM:29223297</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-476-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2017-119-476-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171202, Oppenheimer JJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.10.031</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43435</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Boguniewicz,M.</style></author><author><style face="normal" font="default"> Fonacier,L.</style></author><author><style face="normal" font="default"> Guttman-Yassky,E.</style></author><author><style face="normal" font="default"> Ong,P.Y.</style></author><author><style face="normal" font="default"> Silverberg,J.</style></author><author><style face="normal" font="default"> Farrar,J.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine, Denver, Colorado.</style></auth-address><titles><title><style face="normal" font="default">Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="22" start="10">10-22</pages><volume><style face="normal" font="default">120</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">The implementation of treatment guidelines for atopic dermatitis is challenging, in part because of different guidance documents being used by different groups of specialists and in part because the language of guidelines often reflects the evidence base rather than the practical "how to." The Atopic Dermatitis Yardstick is part of a series developed in response to the need to proactively address the loss of disease control for atopic illnesses at all levels of severity. It presents a comprehensive update on how to conduct a sustained step-up in therapy for the patient with inadequately controlled or poorly controlled atopic dermatitis. Patient profiles, based on current guidelines and the authors' combined clinical experience, provide a practical and clinically meaningful guide to aid physicians in helping their patients achieve the goal of clear to almost clear. The intent is not to replace guidelines but to complement their recommendations incorporating the latest research and therapies</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.10.039</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29273118">PM:29273118</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2018-120-10-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2018-120-10-22.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171222, Boguniewicz M</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.10.039</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43436</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Narla,S.</style></author><author><style face="normal" font="default"> Silverberg,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois</style></auth-address><titles><title><style face="normal" font="default">Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="72" start="66">66-72</pages><volume><style face="normal" font="default">120</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis (AD) is associated with barrier disruption, immune dysregulation, and immunosuppressing treatments that can increase the association with an unusual number of infections. OBJECTIVE: To determine whether adults with AD have an unusually large number of serious infections and related outcomes. METHODS: Data from the 2002 to 2012 National Inpatient Sample were analyzed, including an approximately 20% sample of all US hospitalizations (n = 72,108,077 adults). Prevalence of serious infections in hospitalized patients with vs without AD, length of stay, cost of care, and inpatient mortality secondary to serious infections were determined. RESULTS: The prevalence of serious infections expressed as a percentage (95% confidence interval) was higher in adults hospitalized with than in those without AD (42.1% [41.6-42.6] vs 25.4% [25.2-25.6]; P = .0002). In logistic regression models with multiple predictors (multivariable logistic regression models), AD was associated with 32 of 38 infections examined. Associated cutaneous infections included eczema herpeticum (odds ratio [95% confidence interval] adjusted for other predictors: 67.93 [47.93-96.28]), erysipelas (11.15 [9.47-13.1]), and cellulitis (4.53 [4.42-4.64]). Associated respiratory infections included aspergillosis (1.51 [1.21-1.88]) and tuberculosis (1.57 [1.41-1.76]). AD was associated with extracutaneous, multiorgan, and systemic infections, including infectious arthropathy (2.01 [1.84-2.20]), endocarditis (1.25 [1.12-1.39]), encephalitis (1.65 [1.40-1.96]), and methicillin-resistant Staphylococcus aureus infections (3.29 [3.17-3.42]). Patients with AD hospitalized with vs without any serious infection had an increased geometric mean cost of inpatient care ($8,273 [8,126-8,423] vs $7,179 [7,052-7,307]) and length of stay (5.3 days [5.2-5.3] vs 3.9 [3.9-4.0]; P = .0002), with $11 to $228 million excess annual costs from hospitalization with serious infections in adults with AD. CONCLUSION: Adults with AD had increased cutaneous, respiratory, multiorgan, and systemic infections, which were associated with a considerable cost burden</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.10.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29273131">PM:29273131</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2018-120-66-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2018-120-66-72.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171222, Narla S</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.10.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43437</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Greenhawt,M.</style></author><author><style face="normal" font="default"> Turner,P.J.</style></author><author><style face="normal" font="default"> Kelso,J.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Administration of influenza vaccines to egg allergic recipients: A practice parameter update 2017</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="52" start="49">49-52</pages><volume><style face="normal" font="default">120</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.10.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29273128">PM:29273128</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2018-120-49-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2018-120-49-52.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171222, Greenhawt M</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.10.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43438</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rosen,A.</style></author><author><style face="normal" font="default"> Del Paggio,J.C.</style></author><author><style face="normal" font="default"> Chan,B.</style></author><author><style face="normal" font="default"> Abu-Abed,S.</style></author><author><style face="normal" font="default"> Rawls,M.</style></author><author><style face="normal" font="default"> Ellis,A.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Queen's University, Kingston, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="default">Acute generalized exanthematous pustulosis with multisystem manifestations: Pinpoint pustules and purulent lakes</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="94" start="92">92-94</pages><volume><style face="normal" font="default">120</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.09.077</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29273137">PM:29273137</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2018-120-92-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2018-120-92-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171222, Rosen A</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.09.077</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43439</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dinakar,C.</style></author><author><style face="normal" font="default"> Fineman,S.M.</style></author><author><style face="normal" font="default"> Tilles,S.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">AllergyWatch, Stanford, California</style></auth-address><titles><title><style face="normal" font="default">Recent advances in atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="9" start="8">8-9</pages><volume><style face="normal" font="default">120</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.11.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29273133">PM:29273133</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2018-120-8-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2018-120-8-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171222, Dinakar C</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.11.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43440</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ong,P.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Clinical Immunology and Allergy, Children's Hospital Los Angeles, Los Angeles, California</style></auth-address><titles><title><style face="normal" font="default">Moving toward a more precise treatment of atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="4" start="3">3-4</pages><volume><style face="normal" font="default">120</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.10.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29273126">PM:29273126</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2018-120-3-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2018-120-3-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171222, Ong PY</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.10.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43441</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Izadi,N.</style></author><author><style face="normal" font="default"> Leung,D.Y.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, National Jewish Health, Denver, ColoradoDepartment of Pediatrics, National Jewish Health, Denver, Colorado; Depa</style></auth-address><titles><title><style face="normal" font="default">Clinical approach to the patient with refractory atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="33" start="23">23-33</pages><volume><style face="normal" font="default">120</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United states -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.09.061</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29273125">PM:29273125</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2018-120-23-33.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2018-120-23-33.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171222, Izadi N</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.09.061</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43442</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Abreo,A.</style></author><author><style face="normal" font="default"> Nickels,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee</style></auth-address><titles><title><style face="normal" font="default">Extended smoking cessation counseling service utilization in the Medicare population 2012-2014</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="106" start="105">105-106</pages><volume><style face="normal" font="default">120</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.10.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29273119">PM:29273119</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2018-120-105-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2018-120-105-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171222, Abreo A</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.10.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43443</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Klinnert,M.D.</style></author><author><style face="normal" font="default"> Booster,G.</style></author><author><style face="normal" font="default"> Copeland,M.</style></author><author><style face="normal" font="default"> Darr,J.M.</style></author><author><style face="normal" font="default"> Meltzer,L.J.</style></author><author><style face="normal" font="default"> Miller,M.</style></author><author><style face="normal" font="default"> Oland,A.</style></author><author><style face="normal" font="default"> Perry,S.</style></author><author><style face="normal" font="default"> Wise,B.K.</style></author><author><style face="normal" font="default"> Bender,B.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Jewish Health, Denver, Colorado</style></auth-address><titles><title><style face="normal" font="default">Role of behavioral health in management of pediatric atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="48" start="42">42-48</pages><volume><style face="normal" font="default">120</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To describe the behavioral components and complications in treating pediatric patients with atopic dermatitis (AD) and the critical role of behavioral health professionals in addressing disease impact and behavioral aspects of disease management for these patients and families. DATA SOURCES: Studies and review articles were selected from medical and psychology databases for relevance to pertinent topics. RESULTS: AD has significant negative effects in affected individuals and their families on quality of life, behavioral, emotional, and sleep disturbances, and family functioning. Effective treatment strategies for AD are available, but the challenges for children and parents in coping with disease-related concerns and in following through with the multiple aspects of treatment are considerable. A biopsychosocial model, which incorporates the interplay among biological, psychological, and social dimensions of medical care, can be implemented in various treatment settings to achieve an integrated medical and behavioral health care approach. By sharing a family orientation, using a stress and coping model, and taking into account children's developmental capabilities and concerns, medical and behavioral health care providers are equipped to bring an in-depth understanding and different evidence-based therapeutic tools to address emotional, behavioral, and interpersonal challenges imposed by moderate to severe AD in children and families. CONCLUSION: Behavioral health and medical providers working together to provide integrated care play a critical role in helping children and families cope with the burdens imposed by AD, successfully manage the disease, and achieve optimal quality of life for affected children and their families</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.10.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29273127">PM:29273127</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2018-120-42-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Allergy Asthma Immunol\2018-120-42-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171222, Klinnert MD</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.10.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43444</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Saad,K.</style></author><author><style face="normal" font="default"> Zahran,A.M.</style></author><author><style face="normal" font="default"> Elsayh,K.I.</style></author><author><style face="normal" font="default"> Abdelmoghny,A.</style></author><author><style face="normal" font="default"> Aboul-Khair,M.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Department, Faculty of Medicine, Assiut University, Assiut, Egypt</style></auth-address><titles><title><style face="normal" font="default">Variation of Regulatory T Lymphocytes in the Peripheral Blood of Children with Allergic Rhinitis</style></title><secondary-title><style face="normal" font="default">Arch Immunol Ther Exp (Warsz)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Arch Immunol Ther Exp (Warsz)</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="12" Year="2017">2017/12/18</year></dates><abstract><style face="normal" font="default">The studies of T-regulatory (Treg) cells in the pediatric allergic disorders, especially allergic rhinitis (AR), are very few and still far from being elucidated. The aim of this study is to assess the frequencies of CD4(+)CD25(+)Foxp3(+) (CD4(+)Tregs) and CD8(+)CD25(+high)Foxp3(+) (CD8(+)Tregs) regulatory T lymphocytes in the peripheral blood of children with AR. In fresh whole blood of 60 children with AR and 40 healthy controls, the frequencies of CD4(+)Tregs and CD8(+)Tregs were examined by flow cytometry. The total IgE concentration in the serum was measured. In AR children, the frequencies of CD4(+)Tregs and CD8(+)Tregs were significantly reduced when compared to control group (p = 0.041, p = 0.011, respectively). Moreover, the expressions of Foxp3(+) in CD4(+)CD25(+high) and CD8(+)CD25(+high) cells were significantly lower in patient group than controls. We found a significant negative correlation between the frequencies of CD4(+)Tregs and the total IgE concentration (p &lt; 0.01). In conclusion, the present study demonstrated that the percentages of CD8(+)Tregs and CD4(+)Tregs T cells were significantly decreased in children with AR. This suggests that decreased Treg cells might represent a defect in the compartment of T-cell population in children with AR. Further studies are warranted to fully appreciate the clinical relevance of Tregs in children with AR</style></abstract><notes><style face="normal" font="default">IS - 1661-4917 (Electronic)IS - 0004-069X (Linking)LA - engPT - Journal ArticleCO - Egypt -</style></notes><work-type><style face="normal" font="default">10.1007/s00005-017-0498-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29256093">PM:29256093</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Arch Immunol Ther Exp (Warsz)\20171218-SaadK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Arch Immunol Ther Exp (Warsz)\20171218-SaadK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171218, Saad K</style></custom2><misc3><style face="normal" font="default">10.1007/s00005-017-0498-y</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43445</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">van Tilburg,B.E.</style></author><author><style face="normal" font="default"> Arrieta,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Physiology and Pharmacology,; Department of Paediatrics, University of Calgary, Canada</style></auth-address><titles><title><style face="normal" font="default">Hygiene Hypothesis in Asthma Development: Is Hygiene to Blame?</style></title><secondary-title><style face="normal" font="default">Arch Med Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Arch Med Res</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="12" Year="2017">2017/12/7</year></dates><abstract><style face="normal" font="default">Industrialized countries have registered epidemic rates on allergic diseases, such as hay fever, asthma, eczema, and food allergies. The Hygiene Hypothesis was born from work made by Dr. David Strachan, who observed that younger siblings were less susceptible to eczema and asthma, and proposed that this was a result of increased transmission of infectious agents via unhygienic practices within a household. This initial hypothesis was then reframed as the old friends/microbiota hypothesis, implicating non-pathogenic commensal microorganisms as the source of immunomodulatory signals necessary to prevent immune-mediated chronic disorders. Although the hygiene hypothesis is supported by epidemiological research of allergic diseases in certain industrialized settings, it often fails to explain the incidence of asthma in less affluent regions of the world. In this review, we summarize up-to-date information on genetic and environmental factors associated with asthma in different human populations, and present evidence that calls for caution when associating hygiene with the pathogenesis of asthma and other allergic conditions</style></abstract><notes><style face="normal" font="default">IS - 1873-5487 (Electronic)IS - 0188-4409 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1016/j.arcmed.2017.11.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29224909">PM:29224909</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Arch Med Res\20171207-vanTilburgBE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Arch Med Res\20171207-vanTilburgBE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171207, van Tilburg BE</style></custom2><misc3><style face="normal" font="default">10.1016/j.arcmed.2017.11.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43446</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Usuba,A.</style></author><author><style face="normal" font="default"> Komase,Y.</style></author><author><style face="normal" font="default"> Oyama,B.</style></author><author><style face="normal" font="default"> Tsuburai,T.</style></author><author><style face="normal" font="default"> Hida,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine Yokohama City Seibu Hospital</style></auth-address><titles><title><style face="normal" font="default">[A CASE OF PERTUSSIS IN ADULT THAT COULD BE DIAGNOSED BY DETECTION OF BORDETELLA PERTUSSIS FROM SPUTUM]</style></title><secondary-title><style face="normal" font="default">Arerugi</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Arerugi</style></abbr-1></periodical><pages end="1235" start="1230">1230-1235</pages><volume><style face="normal" font="default">66</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Bordetella pertussis isolation by culture has low detection sensitivity for diagnosing pertussis; the diagnosis is confirmed by measuring serum anti-pertussis toxin (anti-PT) or anti-filamentous hemagglutinin antibody titers, and by genetic testing (polymerase chain reaction/loop-mediated isothermal amplification). Isolation of B. pertussis in adults is difficult, resulting in a delayed diagnosis, as a delayed cough may present >/=3 months after onset. Differentiation from bronchial asthma is also important. We encountered an adult patient in whom B. pertussis was isolated by culture who previously received rituximab for mucosa-associated lymphoid tissue (MALT) lymphoma and steroids for prolonged cough. No elevation of anti-PT antibody titers was observed in the patient</style></abstract><notes><style face="normal" font="default">IS - 0021-4884 (Print)IS - 0021-4884 (Linking)LA - jpnPT - English AbstractPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.15036/arerugi.66.1230</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29249756">PM:29249756</url></web-urls></urls><custom2><style face="normal" font="default">20171201, Usuba A</style></custom2><misc3><style face="normal" font="default">10.15036/arerugi.66.1230</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43447</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tamaoki,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">First Department of Medicine, Tokyo Women's Medical University</style></auth-address><titles><title><style face="normal" font="default">[AIRWAY MUCUS HYPERSECRETION AS A THERAPEUTIC TARGET OF ASTHMA]</style></title><secondary-title><style face="normal" font="default">Arerugi</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Arerugi</style></abbr-1></periodical><pages end="1223" start="1218">1218-1223</pages><volume><style face="normal" font="default">66</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 0021-4884 (Print)IS - 0021-4884 (Linking)LA - jpnPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.15036/arerugi.66.1218</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29249754">PM:29249754</url></web-urls></urls><custom2><style face="normal" font="default">20171201, Tamaoki J</style></custom2><misc3><style face="normal" font="default">10.15036/arerugi.66.1218</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43448</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arakawa,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Gunma University Graduate School of Medicine</style></auth-address><titles><title><style face="normal" font="default">[JAPANESE PEDIATRIC GUIDELINE FOR THE TREATMENT AND MANAGEMENT OF ASTHMA 2017 -WHAT'S NEW IN JPGL 2017]</style></title><secondary-title><style face="normal" font="default">Arerugi</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Arerugi</style></abbr-1></periodical><pages end="1217" start="1213">1213-1217</pages><volume><style face="normal" font="default">66</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 0021-4884 (Print)IS - 0021-4884 (Linking)LA - jpnPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.15036/arerugi.66.1213</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29249753">PM:29249753</url></web-urls></urls><custom2><style face="normal" font="default">20171201, Arakawa H</style></custom2><misc3><style face="normal" font="default">10.15036/arerugi.66.1213</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43449</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tan,R.</style></author><author><style face="normal" font="default"> Cvetkovski,B.</style></author><author><style face="normal" font="default"> Kritikos,V.</style></author><author><style face="normal" font="default"> Price,D.</style></author><author><style face="normal" font="default"> Yan,K.</style></author><author><style face="normal" font="default"> Smith,P.</style></author><author><style face="normal" font="default"> Bosnic-Anticevich,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Quality Use of Respiratory Medicines Group, Woolcock Institute, University of Sydney, Sydney, Australia</style></auth-address><titles><title><style face="normal" font="default">Identifying the hidden burden of allergic rhinitis (AR) in community pharmacy: a global phenomenon</style></title><secondary-title><style face="normal" font="default">Asthma Res Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asthma Res Pract</style></abbr-1></periodical><pages end="" start="8">8-</pages><volume><style face="normal" font="default">3</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Patients with allergic rhinitis often trivialise their condition, self-manage inappropriately, and would benefit from health care intervention. The primary point of health care contact for these self-managing allergic rhinitis patients is the community pharmacy. With the majority of allergic rhinitis treatments being available for purchase over the counter, without health care professional contact, we know little about how the patients self-manage. This study aims to identify the burden of allergic rhinitis in the community pharmacy and to identify key opportunity for intervention. Methods: Pharmacy customers, who purchased nasal treatment in a community pharmacy, were approached with a research-administered questionnaire that collected data on medical history, symptoms and products purchased for the treatment of nasal symptoms. Results: Of the 296 participants, 69.9% self-managed with over-the-counter medications; with 68% experiencing allergic rhinitis symptoms and only 44.3% of this subgroup had a doctor's diagnosis. Nasal congestion (73.6%) was most commonly experienced and oral antihistamines were most commonly purchased (44.3%), indicating a pattern of suboptimal management. A third of participants (36.5%) experienced moderate-severe symptoms, persistently, which impacted on their daily living. Medication selection was mainly based on pharmacy customers' perceptions of medication effectiveness (47.6%). Conclusion: A majority of participants that self-selected over-the-counter medications have symptoms consistent with allergic rhinitis, with almost half not having received a diagnosis. Medication purchasing patterns suggest that sub-optimal therapeutic decisions made by participants, even when they are experiencing significant symptoms. This study uncovers the hidden burden of allergic rhinitis in the community pharmacy and a missed opportunity to intervene and refer if necessary. Patients need to be guided through appropriate treatment as this study showed that many should be referred to a medical practitioner</style></abstract><notes><style face="normal" font="default">IS - 2054-7064 (Print)IS - 2054-7064 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1186/s40733-017-0036-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29201385">PM:29201385</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Res Pract\2017-3-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Res Pract\2017-3-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171221, Tan R</style></custom2><misc3><style face="normal" font="default">10.1186/s40733-017-0036-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43450</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,N.</style></author><author><style face="normal" font="default"> Che,D.</style></author><author><style face="normal" font="default"> Zhang,T.</style></author><author><style face="normal" font="default"> Liu,R.</style></author><author><style face="normal" font="default"> Cao,J.</style></author><author><style face="normal" font="default"> Wang,J.</style></author><author><style face="normal" font="default"> Zhao,T.</style></author><author><style face="normal" font="default"> Ma,P.</style></author><author><style face="normal" font="default"> Dong,X.</style></author><author><style face="normal" font="default"> He,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Pharmacy, Xi'an Jiaotong University, Xi'an 710061, China</style></auth-address><titles><title><style face="normal" font="default">Saikosaponin A inhibits compound 48/80-induced pseudo-allergy via the Mrgprx2 pathway in vitro and in vivo</style></title><secondary-title><style face="normal" font="default">Biochem Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Biochem Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="12" Year="2017">2017/12/20</year></dates><abstract><style face="normal" font="default">Pseudo-allergic reactions-adverse, non-immunologic, anaphylaxis-like sudden onsetreactions mediated through an IgE-independent pathway-are activated by various basic compounds and occur at least as frequently as IgE-mediated reactions to drugs. A large family of G protein coupled receptors (Mas-related genes; Mrgprs) is closely related to pseudo-allergies. However, few therapies can directly target pseudo-allergies and related Mrgprs. Saikosaponin A (SSA) is effective in the treatment of passive cutaneous anaphylaxis (PCA), adjuvant arthritis, and delayed hypersensitiveness. In this study, we investigated the anti-pseudo-allergy effect of SSA and its underlying mechanism. We examined the effect of SSA on both IgE-independent and IgE-dependent responses using PCA and active systemic anaphylaxis models, as well as in vitro-cultured mast cells. We also evaluated whether the anti-allergy effect is related to Mrgprs by using in vitro Mrgprx2-expressing HEK293 cells. SSA dose dependently suppressed compound 48/80 (C48/80)-induced PCA and mast cell degranulation in mice. When SSA and C48/80 were administered together through the vein, C48/80-induced systemic anaphylaxis did not occur, and C48/80-induced shock ratio decreased dose-dependently upon SSA treatment. However, SSA did not affect IgE-dependent allergy. When administered topically 24 hours before antigen challenge, Evans blue leakage and paw swelling were induced in the SSA-treated group and the vehicle group. Our in vitro studies revealed that SSA reduced C48/80-induced calcium flux and suppressed degranulation in LAD2 cells. SSA could also dose-dependently inhibit C48/80-induced Mrgprx2-expressing HEK293 cell activation. As a Conclusion, SSA could inhibits IgE-independent allergy, but not IgE-dependent allergy, and this effect involves the Mrgprx2 pathway. This study provided a new sight on Pseudo-allergy and its therapy</style></abstract><notes><style face="normal" font="default">IS - 1873-2968 (Electronic)IS - 0006-2952 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.bcp.2017.12.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29274317">PM:29274317</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biochem Pharmacol\20171221-WangN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biochem Pharmacol\20171221-WangN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171221, Wang N</style></custom2><misc3><style face="normal" font="default">10.1016/j.bcp.2017.12.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43451</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Higashio,H.</style></author><author><style face="normal" font="default"> Satoh,Y.I.</style></author><author><style face="normal" font="default"> Saino,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Chemistry, Center for Liberal Arts and Sciences, Iwate Medical University</style></auth-address><titles><title><style face="normal" font="default">Inhibitory role of Munc13-1 in antigen-induced mast cell degranulation</style></title><secondary-title><style face="normal" font="default">Biomed Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Biomed Res</style></abbr-1></periodical><pages end="329" start="321">321-329</pages><volume><style face="normal" font="default">38</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Secretory granules (SGs) of mast cells are lysosome-related organelles that contain various inflammatory molecules such as histamine, which are stored in the cytoplasm. Mast cell degranulation is the regulated exocytosis of SGs in response to external stimuli, such as the antigen-mediated cross-linking of the high-affinity IgE receptor, FcepsilonRI. Upon stimulation, SGs undergo priming to become fusion-competent prior to fusing with the plasma membrane, which is mediated by Munc13-4, one of the five members of the vesicle-priming Munc13 protein family. Although Munc13-4 is shown to be crucial for mast cell degranulation, the functional involvement of other Munc13 isoform(s) remains unknown. Herein, this was investigated using the RBL-2H3 mast cell line. We found that Munc13-1 and Munc13-4 are the only Munc13 isoforms that are expressed in the RBL-2H3 cells, and Munc13-1 is distributed in the cytoplasm, but highly concentrated on the late endosome and/or lysosome. Unexpectedly, antigen-induced degranulation was considerably increased by Munc13-1 knockdown, but decreased by its overexpression. Further, we found that the hypersecretion phenotype of the Munc13-1-knockdown cells was attenuated by simultaneous Munc13-4 knockdown. These results suggested that Munc13-1 has an inhibitory role in antigen-induced mast cell degranulation, which is performed in a Munc13-4-dependent manner</style></abstract><notes><style face="normal" font="default">IS - 1880-313X (Electronic)IS - 0388-6107 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.2220/biomedres.38.321</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29225210">PM:29225210</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biomed Res\2017-38-321-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biomed Res\2017-38-321-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171206, Higashio H</style></custom2><misc3><style face="normal" font="default">10.2220/biomedres.38.321</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43452</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Weinschenk,S.</style></author><author><style face="normal" font="default"> Mergenthaler,C.</style></author><author><style face="normal" font="default"> Armstrong,C.</style></author><author><style face="normal" font="default"> Gollner,R.</style></author><author><style face="normal" font="default"> Hollmann,M.W.</style></author><author><style face="normal" font="default"> Strowitzki,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Stefan Weinschenk,1,2,3 Caroline Mergenthaler,3,4 Christina Armstrong,3,4 Richard Göllner,5 Markus W. Hollmann,6 and Thomas Strowitzki1,3</style></auth-address><titles><title><style face="normal" font="default">Local Anesthetics, Procaine, Lidocaine, and Mepivacaine Show Vasodilatation but No Type 1 Allergy: A Double-Blind, Placebo-Controlled Study</style></title><secondary-title><style face="normal" font="default">Biomed Res Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Biomed Res Int</style></abbr-1></periodical><pages end="" start="9804693">9804693-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background. Therapy with local anesthetics (LAs), also known as neural therapy, is used in integrative medicine because of its anti-inflammatory properties. Ester-linked LAs are often avoided because of their alleged high allergenicity. Little data supports this assumption and hence the importance of our investigation on type-1 allergies against ester- and amide-linked LAs. We performed a prospective, double-blinded, placebo-controlled observational study. Methods. 177 patients received 340 intracutaneous injections with 1% procaine, 0.5% lidocaine, 1% mepivacaine, or saline solution. Every patient received two different tests on each forearm. Reactions were monitored for 15 minutes. Results. No type-1 allergy was observed. The mean erythema diameter of the wheals after 10 minutes was procaine 8.0</style><style face="normal" font="Symbol">±6.4 </style><style face="normal" font="default">mm, mepivacaine 7.6</style><style face="normal" font="Symbol">±6.3 </style><style face="normal" font="default">mm, lidocaine 4.4</style><style face="normal" font="Symbol">±4.8 </style><style face="normal" font="default">mm, and NaCl 3.7</style><style face="normal" font="Symbol">±3.2 </style><style face="normal" font="default">mm. The wheal diameter of all substances showed a crescendo-decrescendo phenomenon. The procaine and mepivacaine wheals were significantly larger than those of lidocaine and NaCl. No general signs of hypersensitivity were observed. Diameter and intensity were independent of the injection site, order of injection, age, gender, and body mass index. Conclusion. This study shows no higher type-1 allergenicity of the ester-linked LA procaine, compared to the amide-linked LAs lidocaine and mepivacaine, and supports its use in therapy and short-track surgery.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Germany -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1155/2017/9804693</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1155/2017/9804693</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Biomed Res Int\2017-2017-9804693.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Biomed Res Int\2017-2017-9804693.pdf</url></text-urls><image-urls><url ppv-ref="no">Stefan Weinschenk,1,2,3 Caroline Mergenthaler,3,4 Christina Armstrong,3,4 Richard Göllner,5 Markus W. Hollmann,6 and Thomas Strowitzki1,3</url></image-urls></urls><custom2><style face="normal" font="default">20171211, Weinschenk S</style></custom2><misc3><style face="normal" font="default">10.1155/2017/9804693</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43453</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yu,T.H.</style></author><author><style face="normal" font="default"> Fu,P.K.</style></author><author><style face="normal" font="default"> Tung,Y.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Health Care Management, National Taipei University of Nursing and Science, No.89, Nei-Chiang St, Taipei, Taiwan</style></auth-address><titles><title><style face="normal" font="default">Using medication utilization information to develop an asthma severity classification model</style></title><secondary-title><style face="normal" font="default">BMC Med Inform Decis Mak</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">BMC Med Inform Decis Mak</style></full-title></periodical><pages end="" start="177">177-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="12" Year="2017">2017/12/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: Claims data are currently widely used as source data in asthma studies. However, the insufficient information in claims data related to level of asthma severity may negatively impact study findings. The present study develops and validates an asthma severity classification model that uses medication utilization in Taiwan National Health Insurance claims data. METHODS: The National Health Insurance Research Database was used for the years 2006-2012 and included a total of 7221 patients newly diagnosed with asthma in 2007 for model development and in 2008 for model validation. The medication utilization of patients during the first year after the index date was used to classify level of severity, and the acute exacerbation of asthma during the second through fourth years after the index date was used as the outcome variable. Three models were developed, with subjects classified into four, three, and two groups, respectively. The area under the receiver operating characteristic curve (AUC) and the Kaplan-Meier survival curve were used to compare the performances of the classification models. RESULTS: In development data, the distribution of subjects and acute exacerbation rate among the stage 1 to stage 4 were: 62.71%, 5.54%, 22.79%, and 8.96%, and 8.17%, 9.55%, 11.97%, and 14.91%, respectively. The results also showed the higher severity groups to be more prone to being prescribed oral corticosteroids for asthma control, while lower severity groups were more likely to be prescribed short-acting medication and inhaled corticosteroid treatment. Furthermore, the results of survival analysis showed two-group classification was recommended and yield moderate performance (AUC = 0.671). In validation data, the distribution of subjects, acute exacerbation rates, and medication uses among stages were similar to those in development data, and the results of survival analysis were also the same. CONCLUSIONS: Understanding asthma severity is critical to conducting effective, scholarly research on asthma, which currently uses claims data as a primary data source. The model developed in the present study not only overcomes a gap in the current literature but also provides an opportunity to improve the validity and quality of claims-data-based asthma studies</style></abstract><notes><style face="normal" font="default">IS - 1472-6947 (Electronic)IS - 1472-6947 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1186/s12911-017-0571-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29262809">PM:29262809</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Med Inform Decis Mak\2017-17-177.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Med Inform Decis Mak\2017-17-177.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171210, Yu TH</style></custom2><misc3><style face="normal" font="default">10.1186/s12911-017-0571-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43454</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lefebvre,G.</style></author><author><style face="normal" font="default"> Samoilenko,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Mathematics, Universite du Quebec a Montreal, C.P. 8888, Succursale Centre-ville, Montreal, Quebec, H3C 3P8, Canada.</style></auth-address><titles><title><style face="normal" font="default">On the use of the outcome variable "small for gestational age" when gestational age is a potential mediator: a maternal asthma perspective</style></title><secondary-title><style face="normal" font="default">BMC Med Res Methodol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Med Res Methodol</style></abbr-1></periodical><pages end="" start="165">165-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="12" Year="2017">2017/12/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: The variable "small for gestational age," frequently defined as birth weight below the 10th percentile in a gestational age and sex-normalized population, is nowadays generally perceived as a more adequate measure than birth weight or low birth weight (birth weight &lt; 2500 g) to capture fetal growth. However, the use of small for gestational age rather than birth weight or low birth weight as an outcome (dependent) variable may have important impacts on the interpretation of analyses aimed at estimating the causal effect of an exposure of interest on infants. We hypothesized potential differences in both types of effects estimated (direct or total) and in ability to control for confounding bias. METHODS: We first examined the use of outcome variables birth weight and small for gestational age to get insights on modeling practices within the field of maternal asthma. Using directed acyclic graph simulations where gestational age was a potential mediator, we then compared estimated exposure effects in regression models for birth weight, low birth weight, and small for gestational age. Graphs with and without confounding were considered. RESULTS: Our simulations showed that the variable small for gestational age captures the direct effect of exposure on birth weight, but not the indirect effect of exposure on birth weight through gestational age. Interestingly, exposure effect estimates from small for gestational age models were found unbiased whenever exposure effect estimates from birth weight models were affected by collider bias due to conditioning on gestational age in the models. CONCLUSIONS: The sole consideration of the outcome small for gestational age in a study may lead to suboptimal understanding and quantification of the underlying effect of an exposure on birth weight-related measures. Instead, our results suggest that both outcome variables (low) birth weight and small for gestational age should minimally be considered in studies investigating perinatal outcomes</style></abstract><notes><style face="normal" font="default">IS - 1471-2288 (Electronic)IS - 1471-2288 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1186/s12874-017-0444-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29228913">PM:29228913</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Med Res Methodol\2017-17-165.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Med Res Methodol\2017-17-165.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171211, Lefebvre G</style></custom2><misc3><style face="normal" font="default">10.1186/s12874-017-0444-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43455</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chang,H.S.</style></author><author><style face="normal" font="default"> Park,J.S.</style></author><author><style face="normal" font="default"> Lee,H.S.</style></author><author><style face="normal" font="default"> Lyu,J.</style></author><author><style face="normal" font="default"> Son,J..</style></author><author><style face="normal" font="default"> Choi,I.S.</style></author><author><style face="normal" font="default"> Shin,H.D.</style></author><author><style face="normal" font="default"> Park,C.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Association analysis of ILVBL gene polymorphisms with aspirin-exacerbated respiratory disease in asthma</style></title><secondary-title><style face="normal" font="default">BMC Pulm Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Pulm Med</style></abbr-1></periodical><pages end="" start="210">210-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1471-2466</style></isbn><abstract><style face="normal" font="default">We previously reported that the ILVBL gene on chromosome 19p13.1 was associated with the risk for aspirin-exacerbated respiratory disease (AERD) and the percent decline of forced expired volume in one second (FEV1) after an oral aspirin challenge test. In this study, we confirmed the association between polymorphisms and haplotypes of the ILVBL gene and the risk for AERD and its phenotype</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1186/s12890-017-0556-6</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1186/s12890-017-0556-6</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Pulm Med\2017-17-210.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Pulm Med\2017-17-210.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Chang HS</style></custom2><misc3><style face="normal" font="default">10.1186/s12890-017-0556-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43456</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pascoe,C.D.</style></author><author><style face="normal" font="default"> Obeidat,M.</style></author><author><style face="normal" font="default"> Arsenault,B.A.</style></author><author><style face="normal" font="default"> Nie,Y.</style></author><author><style face="normal" font="default"> Warner,S.</style></author><author><style face="normal" font="default"> Stefanowicz,D.</style></author><author><style face="normal" font="default"> Wadsworth,S.J.</style></author><author><style face="normal" font="default"> Hirota,J.A.</style></author><author><style face="normal" font="default"> Jasemine,Y.S.</style></author><author><style face="normal" font="default"> Dorscheid,D.R.</style></author><author><style face="normal" font="default"> Carlsten,C.</style></author><author><style face="normal" font="default"> Hackett,T.L.</style></author><author><style face="normal" font="default"> Seow,C.Y.</style></author><author><style face="normal" font="default"> Pare,P.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">UBC Institute for Heart Lung Health, St. Paul's Hospital, 1081 Burrard St, Vancouver, BC, Canada.</style></auth-address><titles><title><style face="normal" font="default">Gene expression analysis in asthma using a targeted multiplex array</style></title><secondary-title><style face="normal" font="default">BMC Pulm Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Pulm Med</style></abbr-1></periodical><pages end="" start="189">189-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="12" Year="2017">2017/12/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Gene expression changes in the structural cells of the airways are thought to play a role in the development of asthma and airway hyperresponsiveness. This includes changes to smooth muscle contractile machinery and epithelial barrier integrity genes. We used a targeted gene expression arrays to identify changes in the expression and co-expression of genes important in asthma pathology. METHODS: RNA was isolated from the airways of donor lungs from 12 patients with asthma (8 fatal) and 12 non-asthmatics controls and analyzed using a multiplexed, hypothesis-directed platform to detect differences in gene expression. Genes were grouped according to their role in airway dysfunction: airway smooth muscle contraction, cytoskeleton structure and regulation, epithelial barrier function, innate and adaptive immunity, fibrosis and remodeling, and epigenetics. RESULTS: Differential gene expression and gene co-expression analyses were used to identify disease associated changes in the airways of asthmatics. There was significantly decreased abundance of integrin beta 6 and Ras-Related C3 Botulinum Toxin Substrate 1 (RAC1) in the airways of asthmatics, genes which are known to play an important role in barrier function. Significantly elevated levels of Collagen Type 1 Alpha 1 (COL1A1) and COL3A1 which have been shown to modulate cell proliferation and inflammation, were found in asthmatic airways. Additionally, we identified patterns of differentially co-expressed genes related to pathways involved in virus recognition and regulation of interferon production. 7 of 8 pairs of differentially co-expressed genes were found to contain CCCTC-binding factor (CTCF) motifs in their upstream promoters. CONCLUSIONS: Changes in the abundance of genes involved in cell-cell and cell-matrix interactions could play an important role in regulating inflammation and remodeling in asthma. Additionally, our results suggest that alterations to the binding site of the transcriptional regulator CTCF could drive changes in gene expression in asthmatic airways. Several asthma susceptibility loci are known to contain CTCF motifs and so understanding the role of this transcription factor may expand our understanding of asthma pathophysiology and therapeutic options</style></abstract><notes><style face="normal" font="default">IS - 1471-2466 (Electronic)IS - 1471-2466 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1186/s12890-017-0545-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29228930">PM:29228930</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Pulm Med\2017-17-189.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Pulm Med\2017-17-189.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171214, Pascoe CD</style></custom2><misc3><style face="normal" font="default">10.1186/s12890-017-0545-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43457</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rachid,M.</style></author><author><style face="normal" font="default"> Ahmad,K.</style></author><author><style face="normal" font="default"> Saunders-Kurban,M.</style></author><author><style face="normal" font="default"> Fatima,A.</style></author><author><style face="normal" font="default"> Shah,A.</style></author><author><style face="normal" font="default"> Nahhas,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Internal Medicine, Advocate Christ Medical Center, Oak Lawn, IL, USA</style></auth-address><titles><title><style face="normal" font="default">Daptomycin-Induced Acute Eosinophilic Pneumonia: Late Onset and Quick Recovery</style></title><secondary-title><style face="normal" font="default">Case Rep Pulmonol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Case Rep Pulmonol</style></abbr-1></periodical><pages end="" start="8525789">8525789-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Daptomycin is a cyclic lipopeptide antibiotic that provides great coverage for gram positive cocci. From the early years of daptomycin use, concerns were raised regarding the pulmonary side effects of daptomycin and potential development of acute eosinophilic pneumonia (AEP) secondary to daptomycin therapy. Discussion: AEP could be idiopathic or induced by drugs or toxins. It is a distinct entity from atopic diseases and autoimmune, parasitic, or fungal infections that can also cause pulmonary eosinophilia. Multiple medications are associated with acute eosinophilic pneumonia. Multiple cases of daptomycin-induced AEP have been reported in the literature. Diagnosis of AEP is based on clinical history, laboratory tests, and radiographic studies. Obtaining bronchoalveolar lavage or lung biopsy is needed to confirm the diagnosis. Timing of the drug use and clinical presentation is crucial in the diagnosis of drug-induced AEP. Discontinuation of the offending drug and systemic corticosteroids are the mainstay treatment with great outcomes and recovery. Conclusion: We present a case of AEP caused by daptomycin, with complete recovery after discontinuation of daptomycin and administration of steroids. The patient had AEP after almost 6 weeks of daptomycin therapy which has never been reported in literature and our patient achieved complete recovery with appropriate management</style></abstract><notes><style face="normal" font="default">IS - 2090-6846 (Print)IS - 2090-6854 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1155/2017/8525789</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29225987">PM:29225987</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Case Rep Pulmonol\2017-2017-8525789.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Case Rep Pulmonol\2017-2017-8525789.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171211, Rachid M</style></custom2><misc3><style face="normal" font="default">10.1155/2017/8525789</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43458</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chiesa,L.M.</style></author><author><style face="normal" font="default"> Ceriani,F.</style></author><author><style face="normal" font="default"> Caligara,M.</style></author><author><style face="normal" font="default"> Di Candia,D.</style></author><author><style face="normal" font="default"> Malandra,R.</style></author><author><style face="normal" font="default"> Panseri,S.</style></author><author><style face="normal" font="default"> Arioli,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Health, Animal Science and Food Safety, University of Milan, Via Celoria, 10, 20133 Milan, Italy</style></auth-address><titles><title><style face="normal" font="default">Mussels and clams from the italian fish market. is there a human exposition risk to metals and arsenic?</style></title><secondary-title><style face="normal" font="default">Chemosphere</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Chemosphere</style></abbr-1></periodical><pages end="649" start="644">644-649</pages><volume><style face="normal" font="default">194</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="12" Year="2017">2017/12/11</year></dates><abstract><style face="normal" font="default">Seafood is associated with many beneficial effects on human health. However, the overall level of contaminants in biota has increased over the last two centuries and seafood is one of the source of oral exposition to contaminants. Therefore, this work aimed to evaluate cadmium, lead, mercury, arsenic, chromium and nickel presence in mussels and clams, from the Italian market, and the associated risk. The samples were from five different FAO areas. Analyses were carried out using inductively-coupled plasms-mass spectrometry. The sample concentrations were below the maximum levels stated by Commission Regulation (EC) 1881/2006, except one mussel sample, which was non-compliant for cadmium (2.13 +/- 0.20 mg kg(-1)). For arsenic, nickel and chromium, maximum levels are not stated by the European Union. In this study, arsenic ranged from 1.29 to 13.35 mg kg(-1) and nickel ranged from &lt;LOQ-3.98 mg kg(-1), except one sample, whose nickel concentration was 21.70 mg kg(-1). Chromium was found only in 15 samples, with a maximum concentration of 2.81 +/- 0.27 mg kg(-1), in one clam sample. Our results indicate that the average Italian consumption of molluscs, does not pose a risk for consumers, except nickel, which can cause allergic dermatitis in nickel-sensitive individuals. However a particular concern is caused by the exposition to As of the 95th percentile consumers: the Hazard Index for skin lesions, was >1, and BMDL10 for lung bladder and skin cancer in all mussel samples was overcome, in the 100% and 25% of mussel and clam samples, respectively</style></abstract><notes><style face="normal" font="default">IS - 1879-1298 (Electronic)IS - 0045-6535 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.chemosphere.2017.12.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29241139">PM:29241139</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Chemosphere\2017-194-644-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Chemosphere\2017-194-644-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171205, Chiesa LM</style></custom2><misc3><style face="normal" font="default">10.1016/j.chemosphere.2017.12.041</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43459</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nissen,F.</style></author><author><style face="normal" font="default"> Quint,J.K.</style></author><author><style face="normal" font="default"> Wilkinson,S.</style></author><author><style face="normal" font="default"> Mullerova,H.</style></author><author><style face="normal" font="default"> Smeeth,L.</style></author><author><style face="normal" font="default"> Douglas,I.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK</style></auth-address><titles><title><style face="normal" font="default">Validation of asthma recording in electronic health records: a systematic review</style></title><secondary-title><style face="normal" font="default">Clin Epidemiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Epidemiol</style></abbr-1></periodical><pages end="656" start="643">643-656</pages><volume><style face="normal" font="default">9</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Objective: To describe the methods used to validate asthma diagnoses in electronic health records and summarize the results of the validation studies. Background: Electronic health records are increasingly being used for research on asthma to inform health services and health policy. Validation of the recording of asthma diagnoses in electronic health records is essential to use these databases for credible epidemiological asthma research. Methods: We searched EMBASE and MEDLINE databases for studies that validated asthma diagnoses detected in electronic health records up to October 2016. Two reviewers independently assessed the full text against the predetermined inclusion criteria. Key data including author, year, data source, case definitions, reference standard, and validation statistics (including sensitivity, specificity, positive predictive value [PPV], and negative predictive value [NPV]) were summarized in two tables. Results: Thirteen studies met the inclusion criteria. Most studies demonstrated a high validity using at least one case definition (PPV >80%). Ten studies used a manual validation as the reference standard; each had at least one case definition with a PPV of at least 63%, up to 100%. We also found two studies using a second independent database to validate asthma diagnoses. The PPVs of the best performing case definitions ranged from 46% to 58%. We found one study which used a questionnaire as the reference standard to validate a database case definition; the PPV of the case definition algorithm in this study was 89%. Conclusion: Attaining high PPVs (>80%) is possible using each of the discussed validation methods. Identifying asthma cases in electronic health records is possible with high sensitivity, specificity or PPV, by combining multiple data sources, or by focusing on specific test measures. Studies testing a range of case definitions show wide variation in the validity of each definition, suggesting this may be important for obtaining asthma definitions with optimal validity</style></abstract><notes><style face="normal" font="default">IS - 1179-1349 (Print)IS - 1179-1349 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.2147/CLEP.S143718</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29238227">PM:29238227</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Epidemiol\2017-9-643-56.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Epidemiol\2017-9-643-56.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171207, Nissen F</style></custom2><misc3><style face="normal" font="default">10.2147/CLEP.S143718</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43460</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bonini,M.</style></author><author><style face="normal" font="default"> Scichilone,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Airways Division, Airways Disease Section, National Heart and Lung Institute (NHLI), Royal Brompton Hospital &amp; Imperial College, Dovehouse Street, London, SW3 6LY UK.</style></auth-address><titles><title><style face="normal" font="default">Tiotropium in asthma: back to the future of anticholinergic treatment</style></title><secondary-title><style face="normal" font="default">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Mol Allergy</style></full-title></periodical><pages end="" start="20">20-</pages><volume><style face="normal" font="default">15</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Asthma is among the most common chronic diseases worldwide; however, despite progresses in the understanding of the patho-physiological mechanisms and advances in the development of new therapeutic options and strategies, the disease remains uncontrolled in a not trivial proportion of subjects. Thus, the need of new molecules to treat the underlying biological and functional abnormalities and to control symptoms is strongly advocated by clinicians. In this scenario, the most recent GINA guidelines have included the use of tiotropium bromide in the most severe and uncontrolled forms of the disease, in addition to treatment with inhaled corticosteroid plus long acting beta adrenergic agents. Indeed, a large body of evidence has accumulated to support the use of tiotropium bromide in asthma. The current review paper provides a state of the art systematic revision of findings on the efficacy and safety of tiotropium in the adult and paediatric asthma population. To this aim, electronic searches were undertaken in the most common scientific databases from the date of inception to March 2017. Robust and high quality evidence showed that tiotropium is effective and safe in both adults and children/adolescents. Predictive markers of response have been also suggested, as well as cost-benefit analyses reported. The tiotropium bronchodilator effect seems to be not solely related to the reduction of the smooth muscle tone. However, the observations on anti-inflammatory properties or reduction in mucus production, despite highly interesting, have been only demonstrated in in vitro studies and animal models, therefore advocating for further specifically designed investigations</style></abstract><notes><style face="normal" font="default">IS - 1476-7961 (Print)IS - 1476-7961 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -CO - Italy -</style></notes><work-type><style face="normal" font="default">10.1186/s12948-017-0076-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29213218">PM:29213218</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-20.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Mol Allergy\2017-15-20.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Bonini M</style></custom2><misc3><style face="normal" font="default">10.1186/s12948-017-0076-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43461</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Eskian,M.</style></author><author><style face="normal" font="default"> Khorasanizadeh,M.</style></author><author><style face="normal" font="default"> Assa'ad,A.H.</style></author><author><style face="normal" font="default"> Rezaei,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Molecular Immunology Research Center, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="default">Monoclonal Antibodies for Treatment of Eosinophilic Esophagitis</style></title><secondary-title><style face="normal" font="default">Clin Rev Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Rev Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="12" Year="2017">2017/12/12</year></dates><abstract><style face="normal" font="default">Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus affecting both children and adults, with debilitating and progressive symptoms. EoE has shown an explosive epidemiological rise in the past few decades. Many patients experience a poor level of disease control despite maximal use of available guideline-based therapies, which seriously hampers their quality of life. Diet restrictions and systemic and topical corticosteroids are the current mainstays of EoE therapy, but are associated with significant efficacy, treatment compliance, and safety issues such as oral or esophageal candidiasis, growth retardation, osteopenia, osteoporosis, glucose intolerance, and cataract formation. As EoE is a chronic inflammatory disease, immune cells and cytokines are responsible for the inflammatory response and symptoms. Monoclonal antibodies specifically targeting these pathophysiologic effectors offer more potent relief of histologic and clinical disease features while keeping off-target adverse effects to a minimum. Herein, we have reviewed the current evidence regarding efficacy and safety of monoclonal antibodies including mepolizumab (anti-IL-5), reslizumab (anti-IL-5), QAX576 (anti-IL-13), omalizumab (anti-immunoglobulin-E), and infliximab (anti-TNF-alpha) in treatment of EoE. Our review indicates that although the use of monoclonal antibodies for EoE treatment is safe with limited and reversible adverse events, however, it is not yet possible to reach a final verdict on the efficacy of mAbs in EoE. Future well-designed studies are needed to clarify the exact role of mAbs in EoE</style></abstract><notes><style face="normal" font="default">IS - 1559-0267 (Electronic)IS - 1080-0549 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Iran -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s12016-017-8659-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29234969">PM:29234969</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Rev Allergy Immunol\20171211-EskianM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Rev Allergy Immunol\20171211-EskianM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171211, Eskian M</style></custom2><misc3><style face="normal" font="default">10.1007/s12016-017-8659-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43462</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kliewer,K.L.</style></author><author><style face="normal" font="default"> Cassin,A.M.</style></author><author><style face="normal" font="default"> Venter,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, MLC 2010, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. kara.kliewer@cchmc.orgDivision of Nutrition Therapy, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USASection of Allergy and Immunology, University of Colorado Denver School of Medicine, Colorado Children's Hospital, Aurora, CO, USA</style></auth-address><titles><title><style face="normal" font="default">Dietary Therapy for Eosinophilic Esophagitis: Elimination and Reintroduction</style></title><secondary-title><style face="normal" font="default">Clin Rev Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Rev Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="12" Year="2017">2017/12/14</year></dates><abstract><style face="normal" font="default">Eosinophilic esophagitis (EoE) is a food antigen-mediated disorder of the esophagus characterized by eosinophil predominant inflammation and symptoms of esophageal dysfunction. Dietary antigen elimination induces clinical and histological remission in patients with EoE. The most restrictive of elimination diets (the elemental diet) removes all possible food antigens while empiric elimination diets remove all (or a subset) of food antigens most commonly reported to cause esophageal eosinophilia and food allergies (milk, egg, wheat, soy, peanuts, tree nuts, fish, or legumes). Elimination diets are effective treatments for EoE but pose psychosocial and financial challenges to patients and consequently may impair quality of life. Foods that are commonly eliminated, especially milk, are also nutrient-dense and therefore their elimination may result in inadequate nutrient intake or deficiencies without careful diet planning to include nutritionally comparable and safe food substitutes. After remission is achieved with elimination diets, foods can be reintroduced sequentially to identify specific food triggers, but this reintroduction is not standardized. Food elimination and food reintroductions should consider the patient's lifestyle, nutrition needs, and skills and ideally be managed by a team with knowledge of eosinophilic gastrointestinal disorders and nutrition</style></abstract><notes><style face="normal" font="default">IS - 1559-0267 (Electronic)IS - 1080-0549 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s12016-017-8660-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29238902">PM:29238902</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Rev Allergy Immunol\20171211-KliewerKL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Rev Allergy Immunol\20171211-KliewerKL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171211, Kliewer KL</style></custom2><misc3><style face="normal" font="default">10.1007/s12016-017-8660-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43463</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bousquet,J.</style></author><author><style face="normal" font="default"> Grattan,C.</style></author><author><style face="normal" font="default"> Bieber,T.</style></author><author><style face="normal" font="default"> Matricardi,P.</style></author><author><style face="normal" font="default"> Simon,H.U.</style></author><author><style face="normal" font="default"> Wahn,U.</style></author><author><style face="normal" font="default"> Muraro,A.</style></author><author><style face="normal" font="default"> Hellings,P.W.</style></author><author><style face="normal" font="default"> Agache,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">MACVIA-France, Contre les MAladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, FranceFaculty of Medicine, Transylvania University, Brasov, Romania</style></auth-address><titles><title><style face="normal" font="default">Prediction and prevention of allergy and asthma in EAACI journals (2016)</style></title><secondary-title><style face="normal" font="default">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Transl Allergy</style></full-title></periodical><pages end="" start="46">46-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The European Academy of Allergy and Clinical Immunology (EAACI) owns three journals: Allergy, Pediatric Allergy and Immunology and Clinical and Translational Allergy. One of the major goals of EAACI is to support health promotion in which prevention of allergy and asthma plays a critical role and to disseminate the knowledge of allergy to all stakeholders including the EAACI junior members</style></abstract><notes><style face="normal" font="default">IS - 2045-7022 (Print)IS - 2045-7022 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - France -CO - Belgium -CO - United Kingdom -CO - Switzerland -CO - Romania -</style></notes><work-type><style face="normal" font="default">10.1186/s13601-017-0185-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29214013">PM:29214013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-46.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-46.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171208, Bousquet J</style></custom2><misc3><style face="normal" font="default">10.1186/s13601-017-0185-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43464</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Versiani Nunes Pinheiro de Queiroz,M.</style></author><author><style face="normal" font="default"> Goncalves Alvim,C.</style></author><author><style face="normal" font="default"> Cruz,A.A.</style></author><author><style face="normal" font="default"> de Lima Belizario Facury Lasmar,L.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, School of Medicine, Federal University of Ouro Preto, Ouro Preto, Brazil.</style></auth-address><titles><title><style face="normal" font="default">Lung function in severe pediatric asthma: a longitudinal study in children and adolescents in Brazil</style></title><secondary-title><style face="normal" font="default">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Transl Allergy</style></full-title></periodical><pages end="" start="48">48-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: In severe asthma, high doses of inhaled corticosteroids (ICS) are used in order to achieve clinical and functional control. This study aimed to evaluate lung function in outpatients (children and adolescents) with severe asthma in Brazil, all of whom were treated with high doses of ICS. We evaluated all spirometry tests together and by ICS dose: 800 and > 800 microg/day. Methods: This was a 3-year longitudinal study in which we analyzed 384 spirometry tests in 65 severe asthma patients (6-18 years of age), divided into two groups by the dose of ICS (budesonide or equivalent): 800 and > 800 microg/day. Results: At baseline, the forced expiratory volume in one second (FEV1) and the FEV1/forced vital capacity (FVC) ratio were both &lt; 80% of the predicted values in 50.8% of the patients. The median age of the patients was 10.4 years (interquartile range 7.8-13.6 years). In the sample as a whole, there were significant increases in FEV1% and in the FEV1/FVC% ratio (p = 0.01 and p &lt; 0.001, respectively) over the course of the study. In the > 800 microg/day group, there were no statistical increases or decreases in FEV1, the FEV1/FVC ratio, or forced expiratory flow between 25 and 75% of the FVC (FEF25-75%), when calculated as percentages of the predicted values. However, the z-score for FEF25-75% showed a statistically significant reduction, in the sample as a whole and in the > 800 microg/day group. Also in the > 800 microg/day group, there was a significant reduction in the post-bronchodilator FEV1% (p = 0.004). Conclusions: The fact that the spirometric parameters (as percentages of the predicted values) remained constant in the > 800 microg/day group, whereas there was a gain in lung function in the sample as a whole, suggests an early plateau phase in the > 800 microg/day group. However, there was some loss of lung function in the > 800 microg/day group, as evidenced by a decrease in the z-score for FEF25-75%, suggesting irreversible small airway impairment, and by a reduction in the post-bronchodilator FEV1%, suggesting reduced reversibility of airway obstruction. Among children and adolescents with severe asthma, the use of ICS doses higher than those recommended for age does not appear to improve lung function</style></abstract><notes><style face="normal" font="default">IS - 2045-7022 (Print)IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1186/s13601-017-0183-6</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29259760">PM:29259760</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-48.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-48.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171208, Versiani Nunes Pinheiro de Queiroz M</style></custom2><misc3><style face="normal" font="default">10.1186/s13601-017-0183-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43465</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Alvarez-Perea,A.</style></author><author><style face="normal" font="default"> Tanno,L.K.</style></author><author><style face="normal" font="default"> Baeza,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Service, Hospital General Universitario Gregorio Maranon, Doctor Esquerdo, 46, 28007 Madrid, Spain.</style></auth-address><titles><title><style face="normal" font="default">How to manage anaphylaxis in primary care</style></title><secondary-title><style face="normal" font="default">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Transl Allergy</style></full-title></periodical><pages end="" start="45">45-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Anaphylaxis is defined as a severe life-threatening generalized or systemic hypersensitivity reaction characterized by rapidly developing airway and/or circulation problems. It presents with very different combinations of symptoms and apparently mild signs and can progress to fatal anaphylactic shock unpredictably. The difficulty in recognizing anaphylaxis is due, in part, to the variability of diagnostic criteria, which in turn leads to a delay in administration of appropriate treatment, thus increasing the risk of death. The use of validated clinical criteria can facilitate the diagnosis of anaphylaxis. Intramuscular epinephrine (adrenaline) is the medication of choice for the emergency treatment of anaphylaxis. Administration of corticosteroids and H1-antihistamines should not delay the administration of epinephrine, and the management of a patient with anaphylaxis should not end with the acute episode. Long-term management of anaphylaxis should include avoidance of triggers, following confirmation by an allergology study. Etiologic factors suspected in the emergency department often differ from the real causes of anaphylaxis. Evaluation of patients with a history of anaphylaxis should also include an assessment of personal data, such as age and comorbidities, which may increase the risk of severe reactions. Special attention should also be paid to co-factors, as these may easily confound the cause of the anaphylaxis. Patients experiencing anaphylaxis should administer epinephrine as soon as possible. Education (including the use of Internet and social media), written personalized emergency action plans, and self-injectable epinephrine have proven useful for the treatment of further anaphylaxis episodes</style></abstract><notes><style face="normal" font="default">IS - 2045-7022 (Print)IS - 2045-7022 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -CO - France -</style></notes><work-type><style face="normal" font="default">10.1186/s13601-017-0182-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29238519">PM:29238519</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-45.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171208, Alvarez-Perea A</style></custom2><misc3><style face="normal" font="default">10.1186/s13601-017-0182-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43466</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,X.</style></author><author><style face="normal" font="default"> Huang,H.</style></author><author><style face="normal" font="default"> Gao,H.</style></author><author><style face="normal" font="default"> Wu,X.</style></author><author><style face="normal" font="default"> Zhang,W.</style></author><author><style face="normal" font="default"> Yu,B.</style></author><author><style face="normal" font="default"> Dou,X.</style></author></authors></contributors><auth-address><style face="normal" font="default">Shenzhen Key Laboratory for Translational Medicine of Dermatology, Shenzhen Peking University - the Hong Kong University of Science and Technology Medical Centre, Shenzhen, 518036, China</style></auth-address><titles><title><style face="normal" font="default">Regulatory B cells induced by ultraviolet B through toll-like receptor 4 signalling contribute to the suppression of contact hypersensitivity responses in mice</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="12" Year="2017">2017/12/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Ultraviolet (UV) B irradiation is known to suppress contact hypersensitivity (CHS) responses in mouse models by suppressing immune responses. However, the cellular mechanisms responsible for UVB-induced systemic suppression remain unclear. Regulatory B cells have been reported to play an inhibitory role during CHS. It is presently unknown whether regulatory B cells contribute to the effect of UVB phototherapy. OBJECTIVE: To investigate the inductive effect of UVB on regulatory B cells and the underlying mechanisms by using a CHS mouse model. METHODS: CHS was induced with oxazolone, and evaluated by histopathology, flow cytometry, and quantitative real-time polymerase chain reaction. RESULT: We found that UVB irradiation induced regulatory B cell expansion and ameliorated CHS. UVB-induced regulatory B cells contribute to systemic immunosuppression by inhibiting the proliferation of T cells. Moreover, we determined that toll-like receptor (TLR) 4, the expression of which was upregulated in B cells after UVB exposure, played an essential role in the induction of regulatory B cells. CONCLUSION: Our data identified regulatory B cells as regulators of UVB-induced immunosuppression in CHS, and suggest the importance of the UVB-TLR4 axis in the generation of regulatory B cells</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12913</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29205369">PM:29205369</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20171211-LiuX.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20171211-LiuX.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171211, Liu X</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12913</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43467</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Aerts,O.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author><author><style face="normal" font="default"> Marguery,M.C.</style></author><author><style face="normal" font="default"> Castelain,M.</style></author><author><style face="normal" font="default"> Boursault,L.</style></author><author><style face="normal" font="default"> Giordano-Labadie,F.</style></author><author><style face="normal" font="default"> Lambert,J.</style></author><author><style face="normal" font="default"> Milpied,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Hospital Antwerp (UZA) and University of Antwerp (UA), 2650 Antwerp, Belgium</style></auth-address><titles><title><style face="normal" font="default">Photoaggravated allergic contact dermatitis and transient photosensitivity caused by methylisothiazolinone</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="12" Year="2017">2017/12/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Photoaggravated allergic contact dermatitis caused by methylchloroisothiazolinone (MCI)/methylisothiazolinone (MI) and MI has been reported. OBJECTIVES: To describe the clinical characteristics and results of (photo)patch tests and photo-tests of 10 patients in Belgium and France suffering from photoaggravated contact dermatitis caused by MI. PATIENTS AND METHODS: Five men and five women, with a median age of 49.5 years, were investigated between January 2012 and February 2017 because of suspected photoaggravated contact dermatitis. Patch tests, photopatch tests and/or photo-tests were performed. RESULTS: Seven patients had positive patch test reactions to both MCI/MI and MI, whereas 3 patients had positive patch test reactions only to MI. In most cases, MI was the (strong) primary sensitizer. Photopatch tests with MCI/MI and/or MI gave stronger reactions than patch tests with these derivatives, indicating photoaggravation. Sensitization probably took place from cosmetics and work-related biocides, whereas elicitation of dermatitis was remarkably often related to airborne exposure to MI present in paints or industrial biocides. Four patients suffered from transient photosensitivity. CONCLUSION: Photoaggravated allergic contact dermatitis and transient photosensitivity caused by MI is a peculiar clinical presentation of allergic contact dermatitis caused by this preservative, and should be considered in daily clinical practice</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Belgium -CO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12926</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29230841">PM:29230841</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20171211-AertsO.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20171211-AertsO.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171211, Aerts O</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12926</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43468</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gilissen,L.</style></author><author><style face="normal" font="default"> Huygens,S.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Hospitals KU Leuven, 3000, Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by topical herbal remedies: importance of patch testing with the patients' own products</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="12" Year="2017">2017/12/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Natural ingredients have variable compositions, so their allergenic potencies may differ. OBJECTIVES: To retrospectively analyse subjects reacting to herbal remedies over the past 27 years, with the aim of (i) evaluating demographic characteristics and lesion locations, (ii) describing the frequencies of positive patch test reactions, (iii) identifing sensitization sources, and (iv) studying concomitant sensitivity. PATIENTS AND METHODS: In total, 15980 patients were patch tested between 1990 and 2016 with the European baseline series and/or other series, product(s) used, and, whenever possible, the respective ingredients. RESULTS: Altogether, 8942 (56%) of 15 980 patients presented with at least one positive reaction. Reactions to topical herbal medicines, most often applied to treat an eczematous condition, leg ulcers, or other wounds, were seen in 125 (0.8%), that is, 1.4% of the contact-allergic subjects. Hands, legs and feet were the most frequently affected body sites. Twenty-one botanical allergens were identified, the commonest being Myroxylon pereirae (balsam of Peru), Compositae plants, and tincture of benzoin. Many patients presented with multiple positive test reactions, and some did not react to the commercial allergens but only to the products used. CONCLUSIONS: Topical herbal remedies should not be applied on damaged skin, as multiple sensitization may develop. Moreover, patch testing with the culprit products is important for the diagnosis</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12939</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29214642">PM:29214642</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20171211-GilissenL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20171211-GilissenL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171211, Gilissen L</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12939</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43469</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Thomsen,A.V.</style></author><author><style face="normal" font="default"> Schwensen,J.F.</style></author><author><style face="normal" font="default"> Bossi,R.</style></author><author><style face="normal" font="default"> Banerjee,P.</style></author><author><style face="normal" font="default"> Gimenez-Arnau,E.</style></author><author><style face="normal" font="default"> Lepoittevin,J.P.</style></author><author><style face="normal" font="default"> Liden,C.</style></author><author><style face="normal" font="default"> Uter,W.</style></author><author><style face="normal" font="default"> White,I.R.</style></author><author><style face="normal" font="default"> Johansen,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, National Allergy Research Centre, Copenhagen University Hospital Herlev and Gentofte, 2900, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Isothiazolinones are still widely used in paints purchased in five European countries: a follow-up study</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="12" Year="2017">2017/12/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: An increasing incidence of contact allergy to methylisothiazolinone (MI) has been seen, caused, in particular, by cosmetic products and paints. A study from 2015 showed that 93.0% of paints bought in five European countries contained MI. New regulations have been discussed for paints in the EU, which may have influenced this market. OBJECTIVES: To re-evaluate the use and concentrations of MI and four other isothiazolinones in water-based wall paints. METHODS: Water-based white wall paints (n = 60) were purchased in retail stores in five European countries: Denmark, France, Germany, Sweden, and the United Kingdom. The paints were analysed for isothiazolione content by the use of high-performance liquid chromatography coupled to ultraviolet detection, and the results were confirmed with high-performance liquid chromatography-tandem mass spectrometry. RESULTS: MI was identified in 55 (91.7%) of the paints, with concentrations ranging from 1.1 to 142.7 ppm. The other isothiazolinones were identified in 20.0% [methylchloroisothiazolinone (MCI)] to 88.3% [benzisothiazolinone (BIT)] of the paints. BIT concentrations varied significantly between countries, whereas MI and MCI concentrations did not. There were no statistically significant differences in MI, MCI and BIT concentrations between the current study and the 2015 study. CONCLUSIONS: MI and other isothiazolinones are widely used in paints available in Europe. Their use does not seem to be decreasing</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - United Kingdom -CO - France -CO - Sweden -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12937</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29265415">PM:29265415</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20171211-ThomsenAV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20171211-ThomsenAV.pdf</url></text-urls><related-urls><url ppv-ref="no">xlsx in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20171211, Thomsen AV</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12937</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43470</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Patel,A.</style></author><author><style face="normal" font="default"> Burns,E.</style></author><author><style face="normal" font="default"> Burkemper,N.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departments of Dermatology and Pathology, Saint Louis University, St Louis, MO, 63104, USADepartments of Dermatology and Pathology, Saint Louis University, St Louis, MO, 63104, USADepartments of Dermatology and Pathology, Saint Louis University, St Louis, MO, 63104, USA</style></auth-address><titles><title><style face="normal" font="default">Methotrexate use in allergic contact dermatitis: a retrospective study</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="12" Year="2017">2017/12/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Methotrexate, a folate antimetabolite, is used to treat atopic dermatitis and psoriasis. Although methotrexate's therapeutic efficacy has been noted in the literature, there are few data on the efficacy of methotrexate treatment for allergic contact dermatitis. OBJECTIVE: To evaluate the efficacy and tolerability of methotrexate in treating allergic contact dermatitis at a single institution, and also to assess methotrexate efficacy in patients with chronic, unavoidable allergen exposure. METHODS: We performed a retrospective chart review of 32 patients diagnosed with allergic contact dermatitis by positive patch test reactions, and who received treatment with methotrexate from November 2010 to November 2014. Demographic and treatment-associated data were collected from electronic medical records. Ten patients were identified as allergen non-avoiders secondary to their occupation, and were subgrouped as such. RESULTS: Seventy-eight per cent (25/32) of patients showed either a partial or a complete response. Methotrexate had a comparable efficacy rate in the allergen non-avoiders subset, at 10 of 10. Of the 32 patients, 23% (5/22) had complete clearance of their dermatitis, and 1/10 of allergen non-avoiders had complete clearance of their dermatitis. CONCLUSION: Methotrexate is a well-tolerated and effective treatment for allergic contact dermatitis, and shows comparable efficacy to immunomodulatory agents such as cyclosporine and azathioprine, with robust efficacy despite persistent allergen exposure in patients with allergic contact dermatitis</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12925</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29210087">PM:29210087</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20171211-PatelA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20171211-PatelA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171112, Patel A</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12925</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43471</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bakhshaee,M.</style></author><author><style face="normal" font="default"> Ashtiani,S.J.</style></author><author><style face="normal" font="default"> Hossainzadeh,M.</style></author><author><style face="normal" font="default"> Sehatbakhsh,S.</style></author><author><style face="normal" font="default"> Najafi,M.N.</style></author><author><style face="normal" font="default"> Salehi,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Sinus and Surgical Endoscopic Research Center, Mashhad University of Medical Sciences, Mashhad, Iran</style></auth-address><titles><title><style face="normal" font="default">Allergic rhinitis and dental caries in preschool children</style></title><secondary-title><style face="normal" font="default">Dent Res J (Isfahan)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Dent Res J (Isfahan)</style></abbr-1></periodical><pages end="381" start="376">376-381</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">Background: Allergic rhinitis (AR) may be overdocumented in cases of dental caries because of controversies in the literature This study was conducted to investigate the potential relationship between AR and dental caries in children. Materials and Methods: A total of 296 children were included in this cross-sectional study. Participants were evaluated using the decay-missing-filled (DMF) index, and their AR status was evaluated by physical examination and through a standard questionnaire. Baseline demographics and clinical characteristics were compared among groups using Student's t-test or the Mann-Whitney U-test, the Chi-square test, and/or Fisher's exact test as appropriate. A level of P &lt; 0.05 was regarded as statistically significant. Results: Evidence of AR was found in 77 (35.1%) participants. There was no significant difference in the rate of tooth decay or DMF between participants with or without AR (P = 0.07), but a significant difference was observed in the number of missing and filled teeth between those with and without AR (P &lt; 0.05). There were no significant differences in educational level, family income, milk intake, use of pacifier, use of a toothbrush, saliva secretion, or body mass index (P > 0.05 in all cases) between AR-positive and AR-negative patients. Fluoride therapy and oral breathing were identified as confounding factors and controlled using log-linear analysis. The mean rate of DMF in patients who also had AR was 20% greater than in the AR-negative group (odds ratio [OR] = 1.21, confidence interval [CI]: 1.05-1.35) and 15% greater in among children who breathed orally than those who did not (OR = 1.15 CI: 1.02-1.31). Conclusion: AR and oral breathing may have an effect on oral health and dental condition, leading to an increased rate of tooth loss, oral fillings, and development of dental caries</style></abstract><notes><style face="normal" font="default">IS - 1735-3327 (Print)IS - 1735-3327 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29238375">PM:29238375</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dent Res J (Isfahan)\2017-14-376-81.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dent Res J (Isfahan)\2017-14-376-81.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Bakhshaee M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43472</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rabinowitz,L.G.</style></author><author><style face="normal" font="default"> Zylberberg,H.M.</style></author><author><style face="normal" font="default"> Levinovitz,A.</style></author><author><style face="normal" font="default"> Stockwell,M.S.</style></author><author><style face="normal" font="default"> Green,P.H.R.</style></author><author><style face="normal" font="default"> Lebwohl,B.</style></author></authors></contributors><titles><title><style face="normal" font="default">Skepticism Regarding Vaccine and Gluten-Free Food Safety Among Patients with Celiac Disease and Non-celiac Gluten Sensitivity</style></title><secondary-title><style face="normal" font="default">Dig Dis Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Dig Dis Sci</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1573-2568</style></isbn><abstract><style face="normal" font="default">There has been a marked increase in the adoption of the gluten-free (GF) diet</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s10620-017-4879-1</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s10620-017-4879-1</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dig Dis Sci\20171209-RabinowitzLG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dig Dis Sci\20171209-RabinowitzLG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171209, Rabinowitz LG</style></custom2><misc3><style face="normal" font="default">10.1007/s10620-017-4879-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43473</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Eden,K.</style></author><author><style face="normal" font="default"> Rothschild,D.E.</style></author><author><style face="normal" font="default"> McDaniel,D.K.</style></author><author><style face="normal" font="default"> Heid,B.</style></author><author><style face="normal" font="default"> Allen,I.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biomedical Sciences and Pathobiology, Virginia Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24060, USA</style></auth-address><titles><title><style face="normal" font="default">Noncanonical NF-kappaB signaling and the essential kinase NIK modulate crucial features associated with eosinophilic esophagitis pathogenesis</style></title><secondary-title><style face="normal" font="default">Dis Model Mech</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Dis Model Mech</style></abbr-1></periodical><pages end="1527" start="1517">1517-1527</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="12" Year="2017">2017/12/19</year></dates><abstract><style face="normal" font="default">Eosinophilic esophagitis (EoE) is an allergic disease of the esophagus driven by T cell and eosinophil responses to dietary allergens, resulting in chronic mucosal inflammation. Few spontaneous animal models of esophageal eosinophilia exist, with most studies relying on artificial sensitization procedures. NF-kappaB-inducing kinase (NIK; MAP3K14) is a key signaling molecule of the noncanonical NF-kappaB (NFKB1) pathway, an alternative signaling cascade producing chemokines involved in lymphoid stroma development and leukocyte trafficking. Nik(-/-) mice have been shown to develop a hypereosinophilic syndrome in peripheral blood and major filtering organs; however, the gastrointestinal mucosa of these mice has not been well characterized. We show that Nik(-/-) mice develop significant, localized eosinophilic esophagitis that mimics human EoE, including features such as severe eosinophil accumulation, degranulation, mucosal thickening, fibrosis and basal cell hyperplasia. The remainder of the GI tract, including the caudal stomach, small intestine and colon, in mice with active EoE are unaffected, also similar to human patients. Gene expression patterns in esophageal tissue of Nik(-/-) mice mimics human EoE, with thymic stromal lymphopoetin (TSLP) in particular also elevated at the protein level. In gene expression data sets from human biopsy specimens, we further show that many genes associated with noncanonical NF-kappaB signaling are significantly dysregulated in EoE patients, most notably a paradoxical upregulation of NIK itself with concurrent upregulation of powerful protein-level destabilizers of NIK. These findings suggest that Nik(-/-) mice could be useful as a spontaneous model of specific features of EoE and highlight a novel role for noncanonical NF-kappaB signaling in human patients</style></abstract><notes><style face="normal" font="default">IS - 1754-8411 (Electronic)IS - 1754-8403 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1242/dmm.030767</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29259025">PM:29259025</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dis Model Mech\2017-10-1517-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dis Model Mech\2017-10-1517-27.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171208, Eden K</style></custom2><misc3><style face="normal" font="default">10.1242/dmm.030767</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43474</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ribeiro,M.L.K.K.</style></author><author><style face="normal" font="default"> Chong Neto,H.J.</style></author><author><style face="normal" font="default"> Rosario Filho,N.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universidade Federal do Parana, Curitiba, PR, Brazil</style></auth-address><titles><title><style face="normal" font="default">Diagnosis and treatment of anaphylaxis: there is an urgent needs to implement the use of guidelines</style></title><secondary-title><style face="normal" font="default">Einstein (Sao Paulo)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Einstein (Sao Paulo)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="12" Year="2017">2017/12/7</year></dates><abstract><style face="normal" font="default">Anaphylaxis is a severe, life-threatening generalized or systemic hypersensitivity reaction that requires rapid and adequate care. This study aimed to obtain an integrated view of the level of physicians' knowledge related with treatment of anaphylaxis in studies published within the last 5 years. Sixteen studies were found and four points were identified as of the great interest to the authors: (1) emergency pharmacological treatment, (2) epinephrine auto-injectors prescription, (3) knowledge of the main signs of anaphylaxis, and (4) admission of the patient to verify biphasic reactions. Concern about the use of intramuscular adrenaline as the first choice in relation with anaphylaxis was evident in most studies, rather than its use in the comparison dial, and especially low in a study that included data from Brazil, in which the frequency of its use was 23.8%. An adrenaline autoinjector is highly recommended among specialists for patients at risk of anaphylaxis, however, its use is still infrequent among non-specialists and in countries that this agent is not available. Intervention studies have shown improved medical knowledge of anaphylaxis following disclosure of the information contained in the international guidelines. The analysis of these studies reinforces the need to disseminate international guidelines for diagnosis and treatment of anaphylaxis, as well as providing an adrenaline autoinjector, to improve management and to prevent a fatal outcome</style></abstract><notes><style face="normal" font="default">IS - 2317-6385 (Electronic)IS - 1679-4508 (Linking)LA - engLA - porPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1590/s1679-45082017rw4089</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29236793">PM:29236793</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Einstein (Sao Paulo)\20171207-RibeiroML.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Einstein (Sao Paulo)\20171207-RibeiroML.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171207, Ribeiro ML</style></custom2><misc3><style face="normal" font="default">10.1590/s1679-45082017rw4089</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43475</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tischer,C.</style></author><author><style face="normal" font="default"> Dadvand,P.</style></author><author><style face="normal" font="default"> Basagana,X.</style></author><author><style face="normal" font="default"> Fuertes,E.</style></author><author><style face="normal" font="default"> Bergstrom,A.</style></author><author><style face="normal" font="default"> Gruzieva,O.</style></author><author><style face="normal" font="default"> Melen,E.</style></author><author><style face="normal" font="default"> Berdel,D.</style></author><author><style face="normal" font="default"> Heinrich,J.</style></author><author><style face="normal" font="default"> Koletzko,S.</style></author><author><style face="normal" font="default"> Markevych,I.</style></author><author><style face="normal" font="default"> Standl,M.</style></author><author><style face="normal" font="default"> Sugiri,D.</style></author><author><style face="normal" font="default"> Cirugeda,L.</style></author><author><style face="normal" font="default"> Estarlich,M.</style></author><author><style face="normal" font="default"> Fernandez-Somoano,A.</style></author><author><style face="normal" font="default"> Ferrero,A.</style></author><author><style face="normal" font="default"> Ibarlueza,J.</style></author><author><style face="normal" font="default"> Lertxundi,A.</style></author><author><style face="normal" font="default"> Tardon,A.</style></author><author><style face="normal" font="default"> Sunyer,J.</style></author><author><style face="normal" font="default"> Anto,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">ISGlobal, Barcelona Institute for Global Health - Campus MAR, Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default">Urban upbringing and childhood respiratory and allergic conditions: A multi-country holistic study</style></title><secondary-title><style face="normal" font="default">Environ Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Environ Res</style></abbr-1></periodical><pages end="283" start="276">276-283</pages><volume><style face="normal" font="default">161</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="11" Year="2017">2017/11/21</year></dates><abstract><style face="normal" font="default">OBJECTIVE: We integratively assessed the effect of different indoor and outdoor environmental exposures early in life on respiratory and allergic health conditions among children from (sub-) urban areas. METHODS: This study included children participating in four ongoing European birth cohorts located in three different geographical regions: INMA (Spain), LISAplus (Germany), GINIplus (Germany) and BAMSE (Sweden). Wheezing, bronchitis, asthma and allergic rhinitis throughout childhood were assessed using parental-completed questionnaires. We designed "environmental scores" corresponding to different indoor, green- and grey-related exposures (main analysis, a-priori-approach). Cohort-specific associations between these environmental scores and the respiratory health outcomes were assessed using random-effects meta-analyses. In addition, a factor analysis was performed based on the same exposure information used to develop the environmental scores (confirmatory analysis, data-driven-approach). RESULTS: A higher early exposure to the indoor environmental score increased the risk for wheezing and bronchitis within the first year of life (combined adjusted odds ratio: 1.20 [95% confidence interval: 1.13-1.27] and 1.28 [1.18-1.39], respectively). In contrast, there was an inverse association with allergic rhinitis between 6 and 8 years (0.85 [0.79-0.92]). There were no statistically significant associations for the outdoor related environmental scores in relation to any of the health outcomes tested. The factor analysis conducted confirmed these trends. CONCLUSION: Although a higher exposure to indoor related exposure through occupants was associated with an increased risk for wheezing and bronchitis within the 1st year, it might serve as a preventive mechanism against later childhood allergic respiratory outcomes in urbanized environments through enhanced shared contact with microbial agents</style></abstract><notes><style face="normal" font="default">IS - 1096-0953 (Electronic)IS - 0013-9351 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Sweden -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.envres.2017.11.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29172161">PM:29172161</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Environ Res\2017-161-276-83.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Environ Res\2017-161-276-83.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171226, Tischer C</style></custom2><misc3><style face="normal" font="default">10.1016/j.envres.2017.11.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43476</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Carrillo,G.</style></author><author><style face="normal" font="default"> Perez Patron,M.J.</style></author><author><style face="normal" font="default"> Johnson,N.</style></author><author><style face="normal" font="default"> Zhong,Y.</style></author><author><style face="normal" font="default"> Lucio,R.</style></author><author><style face="normal" font="default"> Xu,X.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Environmental and Occupational Health, School of Public Health. Texas A&amp;M University Health Science Center, TAMU 1266, 212 Adriance Lab Road, College Station, TX 77843, USA.</style></auth-address><titles><title><style face="normal" font="default">Asthma prevalence and school-related hazardous air pollutants in the US-Mexico border area</style></title><secondary-title><style face="normal" font="default">Environ Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Environ Res</style></abbr-1></periodical><pages end="48" start="41">41-48</pages><volume><style face="normal" font="default">162</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="12" Year="2017">2017/12/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is the most common chronic disease in children and has been linked to high levels of ambient air pollution and certain hazardous air pollutants (HAPs). Outdoor pollutants such as benzene, released by car emissions, and organic chemicals found in diesel exhaust, as well as particles and irritant gases, including nitrogen dioxide (NO2), sulfur dioxide (SO2), and ozone (O3), contribute to an increased prevalence of respiratory diseases such as asthma. OBJECTIVES: The objectives of this study were to: 1) conduct a screening survey to identify high risk for asthma among school-age children in Hidalgo County, and, 2) study the potential health impact of school-related exposure to HAPs pertaining to asthma risk. METHODS: We carried out a quantitative cross-sectional study combining a school-based asthma screening survey across 198 schools in Hidalgo County, Texas, with information on school neighborhood environments, including census tract-level information on hazardous air pollutants (HAPs) and socioeconomic status (SES) in the respective school neighborhoods. HAPs levels were assessed based on the EPA 2011 National-Scale Air Toxics Assessment (NATA) while SES information was assessed using data from the 2010-2014 American Community Survey. RESULTS: 2930 students completed the asthma screening survey and results showed an overall asthma prevalence of 9.4%, slightly higher than the national and state prevalence. Participants in the 14-18 years old age group showed a much higher asthma prevalence of 16.7%. When assessing school-neighborhood characteristics, our results revealed no significant differences in asthma prevalence across census tracts with different SES levels. For HAPs, in the single-pollutant model, chlorine levels showed a significant linear trend for prevalence of asthma (p=0.03) while hydrochloric acid had a marginally significant linear trend (p=0.08). The association with chlorine remained significant in the multi-pollutant model. CONCLUSIONS: Asthma prevalence among school-age children in Hidalgo County, Texas, is 9.4%, which is slightly higher than the state rate, especially among young adults, ages 14-18 years who had an asthma rate of 16.7%. Results support an association between exposures to school-neighborhood HAPs and risk for pediatric asthma, especially as related to chlorine. No significant effects of school-level SES on asthma risk were observed</style></abstract><notes><style face="normal" font="default">IS - 1096-0953 (Electronic)IS - 0013-9351 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.envres.2017.11.057</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29278810">PM:29278810</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Environ Res\2017-162-41-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Environ Res\2017-162-41-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171223, Carrillo G</style></custom2><misc3><style face="normal" font="default">10.1016/j.envres.2017.11.057</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43477</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Al-Ahmad,M.</style></author><author><style face="normal" font="default"> Rodriguez,B.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Microbiology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait</style></auth-address><titles><title><style face="normal" font="default">Pattern of inpatient referrals to a drug allergy unit in Kuwait</style></title><secondary-title><style face="normal" font="default">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="280" start="276">276-280</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">Summary: Introduction. There is no information regarding the pattern of inpatient referrals to drug allergy units in Kuwait. Objectives. The main goal of this study is to clarify the pattern of inpatient referrals to a drug allergy unit in terms of incidence, drugs implicated and allergy evaluation outcomes in comparison with studies in other countries. Patients and Methods. A retrospective chart review of inpatient drug allergy consultations at Al-Rashed Allergy Center over a 3-year period was performed. Results. A total of 51 patients were referred for drug allergy consultations, with an estimated incidence of reported drug allergy among inpatients of 0.008%. There is an increasing trend of referrals from public health centres located in proximity to Al-Rashed Allergy Center. Beta-lactams, contrast media, and general anaesthetics were the most common drugs leading to referrals. In total, 30% of patients were diagnosed with an allergy to the offending drug after a full allergy evaluation. Conclusion. Inpatient drug allergy referrals are highly underreported in Kuwait</style></abstract><notes><style face="normal" font="default">IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Kuwait -</style></notes><work-type><style face="normal" font="default">10.23822/EurAnnACI.1764-1489.18</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29249136">PM:29249136</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-276-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-276-80.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171213, Al-Ahmad M</style></custom2><misc3><style face="normal" font="default">10.23822/EurAnnACI.1764-1489.18</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43478</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dogru,M.</style></author><author><style face="normal" font="default"> Seren,L.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Zeynep Kamil Woman and Children' Diseases Training and Research Hospital, Department of Pediatrics, Burhanettin Ustunel Cad. 10 Uskudar, Istanbul, Turkey Phone: +90 505 270 35 14 Fax: +90 216 391 06 99 E-mail: mdmahmut@yahoo.comZeynep Kamil Woman and Children' Diseases Training and Research Hospital, Department of Pediatrics, Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="default">Serum 25-hydroxyvitamin D levels in children with recurrent wheezing and relation to the phenotypes and frequency of wheezing</style></title><secondary-title><style face="normal" font="default">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="262" start="257">257-262</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">Summary: Background. Recurrent wheezing may be related to various reasons. There is a lack of knowledge about the effect of vitamin D status in the children with recurrent wheezing. The aim of this study is to compare the level of vitamin D between recurrent wheezing children and healthy controls, and to investigate the relationship between vitamin D status and the clinical parameters of recurrent wheezing in preschool children. Methods. One hundred-ten children followed up in our hospital with recurrent wheezing were included in the study. The control group included fifty children without wheezing episodes. The serum 25-hydroxyvitamin D (25OHD) level was measured. The patients with recurrent wheezing were grouped according to their vitamin D status as "deficient group" and "non-deficient group (Vitamin D level is insufficient and normal)". We investigated the relationship between vitamin D status and the clinical and laboratory parameters of children with recurrent wheezing. Results. Mean 25OHD level was 21.66 +/- 8.13 ng/mL (5.6-53) in the study group and 25.36 +/- 10.17 ng/mL (6-59) in the control group. The difference was statistically significant (p = 0.015). When the patients with recurrent wheezing were compared according to their vitamin D status, number of hospitalizations, number of positive sensitivity, percentage of eosinophil, serum IgE levels, Asthma Predictive Index positivity and wheezing phenotypes were not found to be different between groups. However, the duration of wheezing, the number of wheezing episodes and systemic glucocorticoid need in the previous year, and the total number of wheezing episodes were significantly higher in the deficient group (p &lt; 0.05). The serum 25OHD level was negatively correlated with the duration of wheezing (r: -0.238; p: 0.012), total number of wheezing episodes (r: -0.436; p: 0.001), number of wheezing episodes in the previous year (r: -0.395; p: 0.001), and systemic glucocorticoid need in the previous year (r: -0.324; p: 0.001). Conclusions. Mean 25OHD levels were lower in patients with recurrent wheezing than in healthy controls. The duration of illness and number of wheezing episodes were correlated with vitamin D levels. An evaluation of the serum levels of vitamin D and supplementation if needed should be recommended in patients with recurrent wheezing, especially in those with long-term and frequent wheezing episodes</style></abstract><notes><style face="normal" font="default">IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.23822/EurAnnACI.1764-1489.14</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29249133">PM:29249133</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-257-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2017-49-257-62.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171213, Dogru M</style></custom2><misc3><style face="normal" font="default">10.23822/EurAnnACI.1764-1489.14</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43479</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bruno,F.</style></author><author><style face="normal" font="default"> Spaziano,G.</style></author><author><style face="normal" font="default"> Liparulo,A.</style></author><author><style face="normal" font="default"> Roviezzo,F.</style></author><author><style face="normal" font="default"> Nabavi,S.M.</style></author><author><style face="normal" font="default"> Sureda,A.</style></author><author><style face="normal" font="default"> Filosa,R.</style></author><author><style face="normal" font="default"> D'Agostino,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Via Costantinopoli, 16, 80138 Naples, Italy</style></auth-address><titles><title><style face="normal" font="default">Recent advances in the search for novel 5-lipoxygenase inhibitors for the treatment of asthma</style></title><secondary-title><style face="normal" font="default">Eur J Med Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Eur J Med Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="10" Year="2017">2017/10/10</year></dates><abstract><style face="normal" font="default">The products of 5-lipoxygenase are synthesized and released in the airway when an asthmatic reaction occurs. 5-lipoxygenase via arachidonic acid metabolism produces leukotrienes that mediate bronchoconstriction and inflammatory modifications essential in the pathophysiology of asthma. Until to now, only one approved 5-LO inhibitor, zileuton, can be found as a potential therapy for asthma. With the increasing number of indications for anti-leukotriene (anti-LT) drugs, the development of 5-LO inhibitor agents becomes increasingly important. The present MiniReview reports an update on 5-LO inhibitors currently under clinical investigation. In addition, the latest advances focused on the development of new 5-lipoxygenase inhibitors as asthma anti-inflammatory agents are also discussed</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 1768-3254 (Electronic)IS - 0223-5234 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.ejmech.2017.10.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29133059">PM:29133059</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur J Med Chem\20171114-BrunoF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur J Med Chem\20171114-BrunoF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171114, Bruno F</style></custom2><misc3><style face="normal" font="default">10.1016/j.ejmech.2017.10.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43480</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Xing,Y.</style></author><author><style face="normal" font="default"> Zhang,H.</style></author><author><style face="normal" font="default"> Sun,S.</style></author><author><style face="normal" font="default"> Ma,X.</style></author><author><style face="normal" font="default"> Pleasants,R.A.</style></author><author><style face="normal" font="default"> Tang,H.</style></author><author><style face="normal" font="default"> Zheng,H.</style></author><author><style face="normal" font="default"> Zhai,S.</style></author><author><style face="normal" font="default"> Wang,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Division of Pulmonology &amp; Allergy, Peking University Third Hospital, Beijing, China</style></auth-address><titles><title><style face="normal" font="default">Clinical features and treatment of pediatric patients with drug-induced anaphylaxis: a study based on pharmacovigilance data</style></title><secondary-title><style face="normal" font="default">Eur J Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Eur J Pediatr</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="11" Year="2017">2017/11/22</year></dates><abstract><style face="normal" font="default">We assessed the clinical features and treatment of pediatric patients with drug-induced anaphylaxis in clinical settings. Pediatric drug-induced anaphylaxis cases collected by the Beijing Pharmacovigilance Database from 2004 to 2014 were analyzed. A total of 91 cases were identified. Drug-induced anaphylaxis was primarily caused by antibiotics (53%). Children of 0-5 years were more likely to develop cyanosis symptoms than children of 13-17 years (OR = 5.14, 95%CI [1.74, 15.20], P = 0.002). Children of 13-17 years were more likely to develop hypotension than children of 6-12 years (OR = 11.79, 95%CI [2.28, 60.87], P = 0.002), and to manifest both neurological symptoms (OR = 3.56, 95%CI [1.26, 10.08], P = 0.015) and severe anaphylaxis than children of 0-5 years (OR = 15.46, 95%CI [1.85, 129.33], P = 0.002). Supratherapeutic doses of epinephrine were more likely with intravenous (IV) bolus (92%) in contrast to either intramuscular (IM) (36%, OR = 19.25, 95%CI [1.77, 209.55], P = 0.009) or subcutaneous (SC) injections (36%, OR = 19.80, 95% CI [1.94, 201.63], P = 0.005). Only 62 (68%) patients received epinephrine treatment as the first-line therapy. CONCLUSION: This study demonstrates that antibiotics were the most common cause of pediatric drug-induced anaphylaxis. Children may present with different anaphylactic signs/symptoms based on age groups. Epinephrine is under-utilized and provider education on the proper management of drug-induced anaphylaxis is warranted. What is Known: * The most common causes of anaphylaxis in children are allergies to foods. Drugs are the second most common cause of pediatric anaphylaxis. * IM epinephrine is the recommended initial treatment of anaphylaxis. What is New: * Drug-induced anaphylaxis in pediatric patients has age-related clinical features. * IV bolus epinephrine was overused and associated with supratherapeutic dosing</style></abstract><notes><style face="normal" font="default">IS - 1432-1076 (Electronic)IS - 0340-6199 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s00431-017-3048-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29168013">PM:29168013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur J Pediatr\20171122-XingY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur J Pediatr\20171122-XingY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171122, Xing Y</style></custom2><misc3><style face="normal" font="default">10.1007/s00431-017-3048-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43481</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Drummond,D.</style></author><author><style face="normal" font="default"> Truchot,J.</style></author><author><style face="normal" font="default"> Fabbro,E.</style></author><author><style face="normal" font="default"> Ceccaldi,P.F.</style></author><author><style face="normal" font="default"> Plaisance,P.</style></author><author><style face="normal" font="default"> Tesniere,A.</style></author><author><style face="normal" font="default"> Hadchouel,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Ilumens Simulation Department, Paris Descartes University, 45 rue des Saint Peres, 75006, Paris, France.</style></auth-address><titles><title><style face="normal" font="default">Fixed versus variable practice for teaching medical students the management of pediatric asthma exacerbations using simulation</style></title><secondary-title><style face="normal" font="default">Eur J Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Eur J Pediatr</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="12" Year="2017">2017/12/4</year></dates><abstract><style face="normal" font="default">Simulation-based trainings represent an interesting approach to teach medical students the management of pediatric asthma exacerbations (PAEs). In this study, we compared two pedagogical approaches, training students once on three different scenarios of PAEs versus training students three times on the same scenario of PAE. Eighty-five third-year medical students, novice learners for the management of PAEs, were randomized and trained. Students were assessed twice, 1 week and 4 months after the training, on a scenario of PAE new to both groups and on scenarios used during the training. The main outcome was the performance score on the new scenario of PAE at 1 week, assessed on a checklist custom-designed for the study. All students progressed rapidly and acquired excellent skills. One week after the training, there was no difference between the two groups on all the scenarios tested, including the new scenario of PAE (median performance score (IQR) of 8.3 (7.4-10.0) in the variation group versus 8.0 (6.0-10.0) in the repetition group (p = 0.16)). Four months later, the performance of the two groups remained similar. CONCLUSION: Varying practice with different scenarios was equivalent to repetitive practice on the same scenario for novice learners, with both methods leading to transfer and long-term retention of the skills acquired during the training. What is known: * Simulation-based trainings represent an interesting approach to teach medical students the management of pediatric asthma exacerbations. * It is unclear whether students would benefit more from repetitive practice on the same scenario of asthma exacerbation or from practice on different scenarios in terms of transfer of skills. What is new: * An individual 30-min training on the management of pediatric asthma exacerbations using simulation allows transfer and long-term retention of the skills acquired. * Varying practice with different scenarios is equivalent to repetitive practice on the same scenario in terms of transfer of skills</style></abstract><notes><style face="normal" font="default">IS - 1432-1076 (Electronic)IS - 0340-6199 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1007/s00431-017-3054-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29204851">PM:29204851</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur J Pediatr\20171204-DrummondD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur J Pediatr\20171204-DrummondD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Drummond D</style></custom2><misc3><style face="normal" font="default">10.1007/s00431-017-3054-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43482</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sebag,S.C.</style></author><author><style face="normal" font="default"> Koval,O.M.</style></author><author><style face="normal" font="default"> Paschke,J.D.</style></author><author><style face="normal" font="default"> Winters,C.J.</style></author><author><style face="normal" font="default"> Comellas,A.P.</style></author><author><style face="normal" font="default"> Grumbach,I.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA</style></auth-address><titles><title><style face="normal" font="default">Inhibition of the mitochondrial calcium uniporter prevents IL-13 and allergen-mediated airway epithelial apoptosis and loss of barrier function</style></title><secondary-title><style face="normal" font="default">Exp Cell Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Exp Cell Res</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="12" Year="2017">2017/12/7</year></dates><abstract><style face="normal" font="default">Mitochondria are increasingly recognized as key mediators of acute cellular stress responses in asthma. However, the distinct roles of regulators of mitochondrial physiology on allergic asthma phenotypes are currently unknown. The mitochondrial Ca(2+) uniporter (MCU) resides in the inner mitochondrial membrane and controls mitochondrial Ca(2+) uptake into the mitochondrial matrix. To understand the function of MCU in models of allergic asthma, in vitro and in vivo studies were performed using models of functional deficiency or knockout of MCU. In primary human respiratory epithelial cells, MCU inhibition abrogated mitochondrial Ca(2+) uptake and reactive oxygen species (ROS) production, preserved the mitochondrial membrane potential and protected from apoptosis in response to the pleiotropic Th2 cytokine IL-13. Consequently, epithelial barrier function was maintained with MCU inhibition. Similarly, the endothelial barrier was preserved in respiratory epithelium isolated from MCU-/- mice after exposure to IL-13. In the ovalbumin-model of allergic airway disease, MCU deficiency resulted in decreased apoptosis within the large airway epithelial cells. Concordantly, expression of the tight junction protein ZO-1 was preserved, indicative of maintenance of epithelial barrier function. These data implicate mitochondrial Ca(2+) uptake through MCU as a key controller of epithelial cell viability in acute allergic asthma</style></abstract><notes><style face="normal" font="default">IS - 1090-2422 (Electronic)IS - 0014-4827 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.yexcr.2017.12.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29225050">PM:29225050</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Exp Cell Res\20171208-SebagSC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Exp Cell Res\20171208-SebagSC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171208, Sebag SC</style></custom2><misc3><style face="normal" font="default">10.1016/j.yexcr.2017.12.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43483</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yu-Mo,D.</style></author><author><style face="normal" font="default"> Yong-Xun,Z.</style></author><author><style face="normal" font="default"> Rui,C.</style></author><author><style face="normal" font="default"> Lin,L.</style></author><author><style face="normal" font="default"> Ying,L.</style></author><author><style face="normal" font="default"> Jian-Guo,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, Guangdong, China</style></auth-address><titles><title><style face="normal" font="default">Mesenchymal stem cell exosomes promote immunosuppression of regulatory T cells in asthma</style></title><secondary-title><style face="normal" font="default">Exp Cell Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Exp Cell Res</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="12" Year="2017">2017/12/22</year></dates><abstract><style face="normal" font="default">Mesenchymal stem cells (MSCs) and regulatory T cells (Tregs) are both potent immune-modulators. The aberrant proliferation and function of Tregs plays an important role in the development of asthma. Our previous studies have demonstrated the role of MSCs in promoting proliferation and immune-modulating of Tregs, as well as alleviating airway inflammation of asthmatic mice. In the present study, we isolated exosomes secreted by MSCs and investigated their immunomodulation effect on peripheral blood mononuclear cells (PBMCs) of asthmatic patient. We found that MSC exosomes upregulated IL-10 and TGF-beta1 from PBMCs, thus promoting proliferation and immune-suppression capacity of Tregs. Furthermore, antigen presenting cells (APCs) but not CD4+ T cells-dependent pathway was shown to be possible mechanism involved in MSC exosome-mediated regulation. Our data elucidated the key role of exosomes in immune-modulation of MSCs, and suggested the therapeutic potential of MSC exosomes for asthma</style></abstract><notes><style face="normal" font="default">IS - 1090-2422 (Electronic)IS - 0014-4827 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.yexcr.2017.12.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29277503">PM:29277503</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Exp Cell Res\20171223-YuMoD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Exp Cell Res\20171223-YuMoD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171223, Yu-Mo D</style></custom2><misc3><style face="normal" font="default">10.1016/j.yexcr.2017.12.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43484</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pham,D.L.</style></author><author><style face="normal" font="default"> Trinh,T.H.</style></author><author><style face="normal" font="default"> Ban,G.Y.</style></author><author><style face="normal" font="default"> Kim,S.H.</style></author><author><style face="normal" font="default"> Park,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea</style></auth-address><titles><title><style face="normal" font="default">Epithelial folliculin is involved in airway inflammation in workers exposed to toluene diisocyanate</style></title><secondary-title><style face="normal" font="default">Exp Mol Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Exp Mol Med</style></abbr-1></periodical><pages end="" start="e395">e395-</pages><volume><style face="normal" font="default">49</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="11" Year="2017">2017/11/17</year></dates><abstract><style face="normal" font="default">Toluene diisocyanate (TDI) exposure can directly activate and damage airway epithelium. Folliculin (FLCN) is a protein expressed by human airway epithelial cells (HAECs) to maintain airway epithelial integrity and survival. This study investigated the involvement of FLCN in the pathogenesis of TDI-induced occupational asthma (OA). Enzyme-linked immunosorbent assay was used to measure serum levels of FLCN in TDI-exposed subjects (93 TDI-OA patients and 119 asymptomatic exposed controls (AEC)), 200 non-occupational asthma (NOA) patients and 71 unexposed healthy normal controls (NCs). Significantly more subjects in the TDI-OA and AEC groups had high serum levels of FLCN compared to those in the NOA group (P=0.002 and P=0.001, respectively), all of which were higher than the NC group (all P&lt;0.001). The serum level of FLCN was positively correlated with TDI exposure duration (r=0.251, P=0.027), but was negatively correlated with asthma duration of TDI-OA patients (r=-0.329, P=0.029). TDI-exposed subjects with high FLCN levels had higher serum levels of total IgE than those with lower levels. The effects of TDI exposure on FLCN production was investigated by treating HAECs (A549 cells) with TDI-human serum albumin conjugate, which showed increased expression and release of FLCN and interleukin-8 from HAECs. Co-culture with peripheral blood neutrophils also induced FLCN expression and release from HAECs. In conclusion, TDI exposure and TDI-induced neutrophil recruitment into the airways can activate and stimulate HAECs to produce FLCN, which could be involved in airway inflammation in workers exposed to TDI</style></abstract><notes><style face="normal" font="default">DA - 20171117IS - 2092-6413 (Electronic)IS - 1226-3613 (Linking)LA - engPT - Journal ArticleCO - South Korea -CO - Vietnam -</style></notes><work-type><style face="normal" font="default">10.1038/emm.2017.180</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29147010">PM:29147010</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Exp Mol Med\2017-49-e395.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Exp Mol Med\2017-49-e395.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171117, Pham DL</style></custom2><misc3><style face="normal" font="default">10.1038/emm.2017.180</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43485</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Xu,N.</style></author><author><style face="normal" font="default"> An,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Critical Care Medicine, Yulin Second Hospital, Yulin, Shaanxi 719000, P.R. ChinaDepartment of Respiration, 3201 Hospital, Hanzhong, Shaanxi 723000, P.R. China</style></auth-address><titles><title><style face="normal" font="default">Formononetin ameliorates mast cell-mediated allergic inflammation via inhibition of histamine release and production of pro-inflammatory cytokines</style></title><secondary-title><style face="normal" font="default">Exp Ther Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Exp Ther Med</style></abbr-1></periodical><pages end="6206" start="6201">6201-6206</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">Various allergic diseases cause allergic inflammation, which is mediated by mast cells. The current study investigated the anti-allergic inflammatory effects of formononetin and its mechanism of action in vitro using mast cells. Levels of histamine and pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta and IL-6, were measured to assess the effects of formononetin on allergic inflammation. The activation of intracellular calcium and nuclear factor (NF)-kappaB, as well as the activity of caspase-1, were assessed to determine the mechanism of action. It was determined that difference concentrations of formononetin (0.1, 1 and 10 microM) suppressed histamine release and secretion of TNF-alpha, IL-1beta and IL-6. Further investigations indicated that the effects of formononetin were associated with a reduction of intracellular calcium, suppression of NF-kappaB activation and upstream IkappaKalpha phosphorylation and inhibition of caspase-1 activity. Therefore, the results of the current study demonstrated that formononetin ameliorated mast cell-mediated allergic inflammation</style></abstract><notes><style face="normal" font="default">IS - 1792-0981 (Print)IS - 1792-0981 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.3892/etm.2017.5293</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29250144">PM:29250144</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Exp Ther Med\2017-14-6201-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Exp Ther Med\2017-14-6201-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171212, Xu N</style></custom2><misc3><style face="normal" font="default">10.3892/etm.2017.5293</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43486</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Matera,M.G.</style></author><author><style face="normal" font="default"> Rogliani,P.</style></author><author><style face="normal" font="default"> Calzetta,L.</style></author><author><style face="normal" font="default"> Cazzola,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Experimental Medicine , University of Campania Luigi Vanvitelli , Naples , Italy</style></auth-address><titles><title><style face="normal" font="default">Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma</style></title><secondary-title><style face="normal" font="default">Expert Opin Drug Metab Toxicol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Expert Opin Drug Metab Toxicol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="12" Year="2017">2017/12/21</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Allergic asthma is a Th2-driven inflammatory process characterized by the infiltration of eosinophils into the airways. IL-5 is a key trigger for eosinophil expansion and release from the bone marrow and plays a crucial role in the entire life span of eosinophils from differentiation to maturation and survival. IL-5 can be considered among the most obvious targets to selectively inhibit eosinophilic airway inflammation. Areas covered: The preclinical and clinical development of reslizumab, a humanized mAb against IL-5 that has been developed to block IL-5 bioactivity and reduce biologically available IL-5, are described with a particular focus on its pharmacodynamics (PK)/pharmacokinetic (PD) profile. Expert opinion: Although pivotal trials have documented that reslizumab can be recommended as add-on therapy for the treatment of patients with severe eosinophilic asthma, there is still important information that is lacking and certain PK and PD properties of reslizumab are still not fully understood</style></abstract><notes><style face="normal" font="default">IS - 1744-7607 (Electronic)IS - 1742-5255 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1080/17425255.2018.1421170</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29268638">PM:29268638</url></web-urls></urls><custom2><style face="normal" font="default">20171227, Matera MG</style></custom2><misc3><style face="normal" font="default">10.1080/17425255.2018.1421170</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43487</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lopatnikova,J.A.</style></author><author><style face="normal" font="default"> Alshevskaya,A.A.</style></author><author><style face="normal" font="default"> Krugleeva,O.L.</style></author><author><style face="normal" font="default"> Nepomnyschih,V.M.</style></author><author><style face="normal" font="default"> Gladkikh,V.S.</style></author><author><style face="normal" font="default"> Lukinov,V.L.</style></author><author><style face="normal" font="default"> Karaulov,A.V.</style></author><author><style face="normal" font="default"> Sennikov,S.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Federal State Budgetary Scientific Institution "Research Institute of Fundamental and Clinical Immunology," Novosibirsk, Russia</style></auth-address><titles><title><style face="normal" font="default">Expression of TNFalpha Receptors on Immunocompetent Cells Is Increased in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="160" start="151">151-160</pages><volume><style face="normal" font="default">174</style></volume><number><style face="normal" font="default">3-4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Expression levels of cytokine and growth factor receptors have been found to be important in the regulation of their action. Tumor necrosis factor-alpha (TNFalpha) is actively involved in inflammation processes in atopic dermatitis (AD), but the role of TNFalpha membrane receptors (TNFR) and their regulatory function in AD remains unclear. AIM: We aimed to determine the associations of parameters of TNFRalpha expression on immunocompetent cells with disease severity before and after therapy in AD patients. METHODS: TNFRalpha expression on T cells, B cells, and monocytes was evaluated by flow cytometry. To determine receptor numbers on the cells, Quantibrite PE beads were used. The content of soluble mediators was evaluated by ELISA. To reveal linear relationships between the index scoring AD (SCORAD) and the studied parameters, multiple linear regression model building was used. RESULTS: TNFR1 and TNFR2 expression in lymphocyte and monocyte populations of AD patients was higher than in healthy individuals (HI). At the same time an increased percentage of positive cells was not associated with high receptor density, and vice versa. Serum content of TNFalpha, both soluble receptors, the number of TNFR2/T cells, and the percentage of TNFR2+ monocytes were found to be strongly associated with the SCORAD index. CONCLUSION: AD patients had increased TNFR expression on immune cells. Changes in the parameters of TNFRalpha expression compared to HI were associated with the disease severity index SCORAD</style></abstract><notes><style face="normal" font="default">IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Russia -</style></notes><work-type><style face="normal" font="default">10.1159/000481135</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29212072">PM:29212072</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-174-151-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-174-151-60.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171206, Lopatnikova JA</style></custom2><misc3><style face="normal" font="default">10.1159/000481135</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43488</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Franzen,D.P.</style></author><author><style face="normal" font="default"> Lang,C.</style></author><author><style face="normal" font="default"> Agorastos,N.</style></author><author><style face="normal" font="default"> Freitag,L.</style></author><author><style face="normal" font="default"> Kohler,M.</style></author><author><style face="normal" font="default"> Schmid-Grendelmeier,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonology, University Hospital Zurich, Zurich, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Evaluation of Nickel Release from Endobronchial Valves as a Possible Cause of Hypersensitivity Pneumonitis in a Patient Treated with Bronchoscopic Lung Volume Reduction</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="150" start="144">144-150</pages><volume><style face="normal" font="default">174</style></volume><number><style face="normal" font="default">3-4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Endobronchial valve (EBV) placement is an established lung volume reduction procedure aiming to improve lung function and exercise capacity in patients with severe emphysema. As EBVs consist of silicone and nitinol (a metal alloy of nickel and titanium), there are concerns that nickel ions might be released and could have a clinical impact in patients with a contact allergy to nickel. Based on a case with hypersensitivity pneumonitis (HP) after treatment with EBVs, we aimed to evaluate the in vitro nickel release from EBVs using inductively coupled plasma mass spectrometry (ICP-MS) and scanning electron microscopy (SEM). METHODS: Six EBVs were immersed in artificial saliva for a period of 7 days. At 24-h intervals, the nickel ion concentration was measured using ICP-MS. RESULTS: There was evidence of a significant nickel release from EBV during the first 48 h, which is possibly due to an incomplete silicone layer detected by SEM. The concentration of released nickel was below the toxic limit. CONCLUSIONS: To the best of our knowledge, we report the first case of HP after EBV treatment. Our finding of in vitro release of nickel ions from EBVs may contribute to the current understanding on hypersensitivity reactions after nitinol implants in patients with nickel contact allergy. However, it did not confirm a causative relationship</style></abstract><notes><style face="normal" font="default">IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1159/000481986</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29136621">PM:29136621</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-174-144-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-174-144-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171206, Franzen DP</style></custom2><misc3><style face="normal" font="default">10.1159/000481986</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43489</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gianni,P.</style></author><author><style face="normal" font="default"> Loules,G.</style></author><author><style face="normal" font="default"> Zamanakou,M.</style></author><author><style face="normal" font="default"> Kompoti,M.</style></author><author><style face="normal" font="default"> Csuka,D.</style></author><author><style face="normal" font="default"> Psarros,F.</style></author><author><style face="normal" font="default"> Magerl,M.</style></author><author><style face="normal" font="default"> Moldovan,D.</style></author><author><style face="normal" font="default"> Maurer,M.</style></author><author><style face="normal" font="default"> Speletas,M.G.</style></author><author><style face="normal" font="default"> Farkas,H.</style></author><author><style face="normal" font="default"> Germenis,A.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology and Histocompatibility, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece</style></auth-address><titles><title><style face="normal" font="default">Genetic Determinants of C1 Inhibitor Deficiency Angioedema Age of Onset</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="204" start="200">200-204</pages><volume><style face="normal" font="default">174</style></volume><number><style face="normal" font="default">3-4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: In view of the large heterogeneity in the clinical presentation of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE), great efforts are being made towards detecting measurable biological determinants of disease severity that can help to improve the management of the disease. Considering the central role that plasma kallikrein plays in bradykinin production, we investigated the contribution of the functional polymorphism KLKB1-428G/A to the disease phenotype. METHODS: We studied 249 C1-INH-HAE patients from 114 European families, and we explored possible associations of C1-INH-HAE clinical features with carriage of KLKB1-428G/A, combined or not with that of the functional F12-46C/T polymorphism. RESULTS: Carriers of the G allele of the KLKB1-428G/A polymorphism exhibited a significantly delayed disease onset (i.e., by 4.1 years [p &lt; 0.001], depending on the zygocity status), while carriers of both the KLKB1-428G/A and the F12-46C/T polymorphism displayed an 8.8-year delay in disease onset (p &lt; 0.001) and a 64% lower probability of needing long-term prophylactic treatment (p = 0.019). CONCLUSIONS: These findings support our initial hypothesis that functional alterations in genes of proteins involved in bradykinin metabolism and function affect the clinical phenotype and possibly contribute to the pathogenesis of C1-INH-HAE. Given that an earlier onset of symptoms is inversely correlated with the subsequent course of the disease and, eventually, the need for long-term prophylaxis, these polymorphisms may be helpful prognostic biomarkers of disease severity</style></abstract><notes><style face="normal" font="default">IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Greece -CO - Hungary -CO - Germany -CO - Romania -</style></notes><work-type><style face="normal" font="default">10.1159/000481987</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29130992">PM:29130992</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-174-200-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-174-200-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171206, Gianni P</style></custom2><misc3><style face="normal" font="default">10.1159/000481987</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43490</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hussaarts,L.</style></author><author><style face="normal" font="default"> Kaisar,M.M.M.</style></author><author><style face="normal" font="default"> Guler,A.T.</style></author><author><style face="normal" font="default"> Dalebout,H.</style></author><author><style face="normal" font="default"> Everts,B.</style></author><author><style face="normal" font="default"> Deelder,A.M.</style></author><author><style face="normal" font="default"> Palmblad,M.</style></author><author><style face="normal" font="default"> Yazdanbakhsh,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Parasitology, Leiden University Medical Center (LUMC), Leiden, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Human Dendritic Cells with Th2-Polarizing Capacity: Analysis Using Label-Free Quantitative Proteomics</style></title><secondary-title><style face="normal" font="default">Int Arch Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int Arch Allergy Immunol</style></abbr-1></periodical><pages end="182" start="170">170-182</pages><volume><style face="normal" font="default">174</style></volume><number><style face="normal" font="default">3-4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Dendritic cells (DCs) are the sentinels of the immune system. Upon recognition of a pathogen, they mature and migrate to draining lymph nodes to prime and polarize T cell responses. Although it is known that helminths and helminth-derived molecules condition DCs to polarize T helper (Th) cells towards Th2, the underlying mechanisms remain incompletely understood. OBJECTIVES: The aim of this study was to conduct a proteome analysis of helminth antigen-stimulated DCs in order to gain more insight into the cellular processes associated with their ability to polarize immune responses. METHODS: We analyzed the maturation and polarization of monocyte-derived DCs from 9 donors at 2 different time points after stimulation with different Th1- and Th2-polarizing pathogen-derived molecules. The samples were measured using liquid chromatography-Fourier transform ion cyclotron resonance mass spectrometry for relative quantitation. RESULTS: Lipopolysaccharide-induced maturation promoted the expression of proteins related to metabolic, cellular, and immune system processes. Th1-polarizing DCs, conditioned by IFN-gamma during maturation, displayed accelerated maturation by differentially expressing cytoskeletal proteins and proteins involved in immune regulation. The stimulation of DCs with soluble egg antigens and omega-1 derived from Schistosoma mansoni, which are both Th2-inducing stimuli, increased 60S acidic ribosomal protein P2, and vesicle amine transferase 1 while decreasing the expression of proteins related to antigen processing and presentation. CONCLUSION: Our data indicate that not only proteins involved in the interaction between T cells and DCs at the level of the immunological synapse, but also those related to cellular metabolism and stress, may promote Th2 polarization</style></abstract><notes><style face="normal" font="default">IS - 1423-0097 (Electronic)IS - 1018-2438 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Indonesia -</style></notes><work-type><style face="normal" font="default">10.1159/000479512</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29130972">PM:29130972</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-174-170-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int Arch Allergy Immunol\2017-174-170-82.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171206, Hussaarts L</style></custom2><misc3><style face="normal" font="default">10.1159/000479512</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43491</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sheehan,W.J.</style></author><author><style face="normal" font="default"> Gaffin,J.M.</style></author><author><style face="normal" font="default"> Peden,D.B.</style></author><author><style face="normal" font="default"> Bush,R.K.</style></author><author><style face="normal" font="default"> Phipatanakul,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Boston Children's Hospital, Boston, Mass; Division of Harvard Medical School, Boston, Mass; Division of Allergy and Immunology, Children's National Health System, Washington, DC</style></auth-address><titles><title><style face="normal" font="default">Advances in environmental and occupational disorders in 2016</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="1692" start="1683">1683-1692</pages><volume><style face="normal" font="default">140</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">In this review we highlight recent studies that advance the knowledge and understanding of the effects of various environmental factors and associated immune responses in patients with allergic diseases. This review will focus on new literature regarding allergic and immune responses to a variety of environmental factors, including aeroallergens, stinging insects, fungi, pollutants, viral respiratory tract infections, climate change, and microbial exposures</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.09.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29080787">PM:29080787</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-140-1683-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-140-1683-92.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Sheehan WJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.09.032</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43492</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yancey,S.W.</style></author><author><style face="normal" font="default"> Keene,O.N.</style></author><author><style face="normal" font="default"> Albers,F.C.</style></author><author><style face="normal" font="default"> Ortega,H.</style></author><author><style face="normal" font="default"> Bates,S.</style></author><author><style face="normal" font="default"> Bleecker,E.R.</style></author><author><style face="normal" font="default"> Pavord,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory Therapeutic Area, GlaxoSmithKline, Research Triangle Park, NC.</style></auth-address><titles><title><style face="normal" font="default">Biomarkers for severe eosinophilic asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="1518" start="1509">1509-1518</pages><volume><style face="normal" font="default">140</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">The last decade has seen the approval of several new biologics for the treatment of severe asthma-targeting specific endotypes and phenotypes. This review will examine how evidence generated from the mepolizumab clinical development program showed that blood eosinophil counts, rather than sputum or tissue eosinophil counts, evolved as a pharmacodynamic and predictive biomarker for the efficacy of treatment with mepolizumab in patients with severe eosinophilic asthma. Based on the available evidence and combined with clinical judgement, a baseline blood eosinophil threshold of 150 cells/muL or greater or a historical blood eosinophil threshold of 300 cells/muL or greater will allow selection of patients with severe eosinophilic asthma who are most likely to achieve clinically significant reductions in the rate of exacerbations with mepolizumab treatment</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.10.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29221581">PM:29221581</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-140-1509-18.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\2017-140-1509-18.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Yancey SW</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.10.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43493</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cheon,I.S.</style></author><author><style face="normal" font="default"> Son,Y.M.</style></author><author><style face="normal" font="default"> Jiang,L.</style></author><author><style face="normal" font="default"> Goplen,N.P.</style></author><author><style face="normal" font="default"> Kaplan,M.H.</style></author><author><style face="normal" font="default"> Limper,A.H.</style></author><author><style face="normal" font="default"> Kita,H.</style></author><author><style face="normal" font="default"> Paczesny,S.</style></author><author><style face="normal" font="default"> Prakash,Y.S.</style></author><author><style face="normal" font="default"> Tepper,R.</style></author><author><style face="normal" font="default"> Ahlfeld,S.K.</style></author><author><style face="normal" font="default"> Sun,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Indiana University School of Medicine, Indianapolis</style></auth-address><titles><title><style face="normal" font="default">Neonatal hyperoxia promotes asthma-like features through IL-33-dependent ILC2 responses</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="15" Month="12" Year="2017">2017/12/15</year></dates><abstract><style face="normal" font="default">BACKGROUND: Premature infants often require oxygen supplementation and, therefore, are exposed to oxidative stress. Following oxygen exposure, preterm infants frequently develop chronic lung disease and have a significantly increased risk of asthma. OBJECTIVE: We sought to identify the underlying mechanisms by which neonatal hyperoxia promotes asthma development. METHODS: Mice were exposed to neonatal hyperoxia followed by a period room air recovery. A group of mice were also intranasally exposed to house dust mite antigen (HDM). Assessments were performed at various time points for evaluation of airway hyperresponsiveness (AHR), eosinophilia, mucus production, inflammatory gene expression, T helper (Th) and group 2 innate lymphoid cell (ILC2) responses. Sera from term- and preterm-born infants were also collected and the levels of IL-33 and type 2 cytokines were measured. RESULTS: Neonatal hyperoxia induced asthma-like features including AHR, mucus hyperplasia, airway eosinophilia, and type 2 pulmonary inflammation. In addition, neonatal hyperoxia promoted allergic Th responses to HDM exposure. Elevated IL-33 levels and ILC2 responses were observed in the lungs most likely due to oxidative stress caused by neonatal hyperoxia. IL-33 receptor signaling and ILC2s were vital for the induction of asthma-like features following neonatal hyperoxia. Serum IL-33 levels correlated significantly with serum levels of IL-5 and IL-13, but not IL-4 in preterm infants. CONCLUSION: These data demonstrate that an axis involving IL-33 and ILC2s is important for the development of asthma-like features following neonatal hyperoxia and suggest therapeutic potential for targeting IL-33, ILC2s, and oxidative stress to prevent and/or treat asthma development related to prematurity</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.11.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29253513">PM:29253513</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171215-CheonIS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171215-CheonIS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171215, Cheon IS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.11.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43494</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,H.</style></author><author><style face="normal" font="default"> Li,Z.Y.</style></author><author><style face="normal" font="default"> Jiang,W.X.</style></author><author><style face="normal" font="default"> Liao,B.</style></author><author><style face="normal" font="default"> Zhai,G.T.</style></author><author><style face="normal" font="default"> Wang,N.</style></author><author><style face="normal" font="default"> Zhen,Z.</style></author><author><style face="normal" font="default"> Ruan,J.W.</style></author><author><style face="normal" font="default"> Long,X.B.</style></author><author><style face="normal" font="default"> Wang,H.</style></author><author><style face="normal" font="default"> Liu,W.H.</style></author><author><style face="normal" font="default"> Liang,G.T.</style></author><author><style face="normal" font="default"> Xu,W.M.</style></author><author><style face="normal" font="default"> Kato,A.</style></author><author><style face="normal" font="default"> Liu,Z.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China</style></auth-address><titles><title><style face="normal" font="default">The activation and function of IL-36gamma in neutrophilic inflammation in chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="12" Year="2017">2017/12/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: Although increased accumulation of neutrophils has been noted in chronic rhinosinusitis (CRS), the function and regulation of neutrophils in CRS are largely unknown. IL-36 family cytokines may play an important role in neutrophilic inflammation. OBJECTIVE: To investigate the expression and function of IL-36 cytokines in CRS. METHODS: Quantitative RT-PCR, immunohistochemistry, immunofluorescence, and ELISA were used to investigate the expression of IL-36 cytokines and IL-36 receptor (IL-36R) in sinonasal mucosa. The expression of IL-36R on neutrophils in polyps and blood was measured by flow cytometry. Purified blood neutrophils were cultured to investigate the regulation of IL-36R expression. The cleavage of IL-36gamma was detected by Western blotting. Dispersed nasal polyp cells (DNPCs) were treated with IL-36gamma with or without elastase inhibitor and dexamethasone. RESULTS: Neutrophil infiltration and expression of IL-36 cytokines and IL-36R were up-regulated in both CRS with and without nasal polyps. IL-36gamma was the most abundant isoform and mainly expressed by epithelial cells in CRS. Neutrophils were the principal IL-36R(+) cell type in polyps. IL-36R expression was almost absent in blood neutrophils and up-regulated by IL-6, IL-1beta, and Dermatophagoides pteronyssinus group 1. Elastase activity was increased in polyps and degraded full-length IL-36gamma. Consistently, the levels of cleaved IL-36gamma were increased in polyps. Full-length IL-36gamma promoted the production of MMP-9, IL-17A, CXCL1, CXCL2 and CXCL8 from DNPCs, which was abolished by elastase inhibitor. The pro-inflammatory effect of IL-36gamma was not suppressed by dexamethasone. CONCLUSION: Increased production and activation of IL-36gamma may act on neutrophils and further exaggerate neutrophilic inflammation in CRS</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.12.972</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29274415">PM:29274415</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171209-WangH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171209-WangH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171209, WangH</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.12.972</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43495</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nyenhuis,S.M.</style></author><author><style face="normal" font="default"> Dixon,A.E.</style></author><author><style face="normal" font="default"> Ma,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine, University of Illinois at Chicago, Chicago, Ill.</style></auth-address><titles><title><style face="normal" font="default">Impact of Lifestyle Interventions Targeting Healthy Diet, Physical Activity, and Weight Loss on Asthma in Adults: What Is the evidence?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="12" Year="2017">2017/12/5</year></dates><abstract><style face="normal" font="default">Unhealthy lifestyle factors such as poor diet quality, sedentary lifestyle, and obesity are associated with negative health consequences in asthma including poor asthma control, impaired quality of life, and greater health care utilization. Lifestyle modification is the cornerstone of behavioral treatments and has been effective in chronic diseases such as atherothrombotic vascular disease and diabetes. There is a critical need for lifestyle interventions in asthma care that address obesity and its intimately linked risk behaviors in terms of poor diet and physical inactivity. We present in this commentary the promising lifestyle interventions emerging in asthma care that target poor diet, physical inactivity and weight loss, the proposed mechanisms of these lifestyle interventions, and the critical need for guideline-concordant lifestyle interventions in asthma care</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.10.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29221919">PM:29221919</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171205, Nyenhuis SM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.10.026</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43496</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arrieta,M.C.</style></author><author><style face="normal" font="default"> Arevalo,A.</style></author><author><style face="normal" font="default"> Stiemsma,L.</style></author><author><style face="normal" font="default"> Dimitriu,P.</style></author><author><style face="normal" font="default"> Chico,M.E.</style></author><author><style face="normal" font="default"> Loor,S.</style></author><author><style face="normal" font="default"> Vaca,M.</style></author><author><style face="normal" font="default"> Boutin,R.C.T.</style></author><author><style face="normal" font="default"> Morien,E.</style></author><author><style face="normal" font="default"> Jin,M.</style></author><author><style face="normal" font="default"> Turvey,S.E.</style></author><author><style face="normal" font="default"> Walter,J.</style></author><author><style face="normal" font="default"> Parfrey,L.W.</style></author><author><style face="normal" font="default"> Cooper,P.J.</style></author><author><style face="normal" font="default"> Finlay,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Michael Smith Laboratories and the Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia, Canada</style></auth-address><titles><title><style face="normal" font="default">Associations between infant fungal and bacterial dysbiosis and childhood atopic wheeze in a nonindustrialized setting</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="11" Year="2017">2017/11/30</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is the most prevalent chronic disease of childhood. Recently, we identified a critical window early in the life of both mice and Canadian infants during which gut microbial changes (dysbiosis) affect asthma development. Given geographic differences in human gut microbiota worldwide, we studied the effects of gut microbial dysbiosis on atopic wheeze in a population living in a distinct developing world environment. OBJECTIVE: We sought to determine whether microbial alterations in early infancy are associated with the development of atopic wheeze in a nonindustrialized setting. METHODS: We conducted a case-control study nested within a birth cohort from rural Ecuador in which we identified 27 children with atopic wheeze and 70 healthy control subjects at 5 years of age. We analyzed bacterial and eukaryotic gut microbiota in stool samples collected at 3 months of age using 16S and 18S sequencing. Bacterial metagenomes were predicted from 16S rRNA data by using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States and categorized by function with Kyoto Encyclopedia of Genes and Genomes ontology. Concentrations of fecal short-chain fatty acids were determined by using gas chromatography. RESULTS: As previously observed in Canadian infants, microbial dysbiosis at 3 months of age was associated with later development of atopic wheeze. However, the dysbiosis in Ecuadorian babies involved different bacterial taxa, was more pronounced, and also involved several fungal taxa. Predicted metagenomic analysis emphasized significant dysbiosis-associated differences in genes involved in carbohydrate and taurine metabolism. Levels of the fecal short-chain fatty acids acetate and caproate were reduced and increased, respectively, in the 3-month stool samples of children who went on to have atopic wheeze. CONCLUSIONS: Our findings support the importance of fungal and bacterial microbiota during the first 100 days of life on the development of atopic wheeze and provide additional support for considering modulation of the gut microbiome as a primary asthma prevention strategy</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Canada -CO - Ecuador -CO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.08.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29241587">PM:29241587</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171211-ArrietaMC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171211-ArrietaMC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171211, Arrieta MC</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.08.041</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43497</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cheung,D.S.</style></author><author><style face="normal" font="default"> Sigua,J.A.</style></author><author><style face="normal" font="default"> Simpson,P.M.</style></author><author><style face="normal" font="default"> Yan,K.</style></author><author><style face="normal" font="default"> Hussain,S.A.</style></author><author><style face="normal" font="default"> Santoro,J.L.</style></author><author><style face="normal" font="default"> Buell,E.J.</style></author><author><style face="normal" font="default"> Hunter,D.A.</style></author><author><style face="normal" font="default"> Rohlfing,M.</style></author><author><style face="normal" font="default"> Patadia,D.</style></author><author><style face="normal" font="default"> Grayson,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin</style></auth-address><titles><title><style face="normal" font="default">CysLTR1-expression identifies a subset of neutrophils during the antiviral response that contributes to post-viral atopic airway disease</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="12" Year="2017">2017/12/18</year></dates><abstract><style face="normal" font="default">BACKGROUND: Respiratory viral infections increase risk of development and exacerbation of atopic disease. We previously demonstrated the requirement for a neutrophil (PMN) subset expressing CD49d to drive development of post-viral atopic airway disease in mice. OBJECTIVE: To determine if human CD49d(+) PMN are present in the nasal mucosa during acute viral respiratory tract infections and further characterize this PMN subset in humans and mice. METHODS: Sixty subjects (5-50 years old) were enrolled within 4 days of acute onset of upper respiratory symptoms. Nasal lavage for flow cytometry and nasal swab for viral PCR were performed at enrollment and during convalescence. The Sendai virus mouse model was used to investigate the phenotype and functional relevance of CD49d(+) PMN. RESULTS: CD49d(+) PMN frequency was significantly higher in the nasal lavage during acute respiratory symptoms in all subjects (2.9% versus 1.0%, n=42, p&lt;0.001). In mice, CD49d(+) PMN represented a "pro-atopic" neutrophil subset that expressed CysLTR1 and produced TNF, CCL2, and CCL5. Inhibition of CysLTR1 signaling in only the first days of a viral respiratory infection was sufficient to reduce accumulation of CD49d(+) PMN in the lungs and development of post-viral atopic airway disease. Similar to the mouse, human CD49d(+) PMN isolated from nasal lavage during a respiratory viral infection expressed CysLTR1. CONCLUSION: CD49d and CysLTR1 co-expressing PMNs are present during symptoms of an acute respiratory viral infections in humans. Further study is needed to examine selective targeting of "pro-atopic" neutrophils as a potential therapeutic strategy to prevent development of post-viral atopic airway disease</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.11.026</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29269317">PM:29269317</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171209-CheungDS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171209-CheungDS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171209, Cheung DS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.11.026</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43498</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sallis,B.F.</style></author><author><style face="normal" font="default"> Erkert,L.</style></author><author><style face="normal" font="default"> Monino-Romero,S.</style></author><author><style face="normal" font="default"> Acar,U.</style></author><author><style face="normal" font="default"> Wu,R.</style></author><author><style face="normal" font="default"> Konnikova,L.</style></author><author><style face="normal" font="default"> Lexmond,W.S.</style></author><author><style face="normal" font="default"> Hamilton,M.J.</style></author><author><style face="normal" font="default"> Dunn,W.A.</style></author><author><style face="normal" font="default"> Szepfalusi,Z.</style></author><author><style face="normal" font="default"> Vanderhoof,J.A.</style></author><author><style face="normal" font="default"> Snapper,S.B.</style></author><author><style face="normal" font="default"> Turner,J.R.</style></author><author><style face="normal" font="default"> Goldsmith,J.D.</style></author><author><style face="normal" font="default"> Spencer,L.A.</style></author><author><style face="normal" font="default"> Nurko,S.</style></author><author><style face="normal" font="default"> Fiebiger,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, Massachusetts, USA</style></auth-address><titles><title><style face="normal" font="default">An algorithm for the classification of mRNA patters in eosinophilic esophagitis: integration of machine learning</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="12" Year="2017">2017/12/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: Diagnostic evaluation of eosinophilic esophagitis (EoE) remains difficult, particularly the assessment of the patient's allergic status. OBJECTIVE: Establish an automated medical algorithm to assist in the evaluation of EoE. METHODS: Machine learning techniques were used to establish a diagnostic probability score for EoE (pEoE) based on esophageal mRNA transcript patterns from biopsies of patients with EoE, gastroesophageal reflux disease, and controls. Dimensionality reduction in the training set established weighted factors, which were confirmed by immunohistochemistry. Following weighted factor analysis, p(EoE) was determined by Random Forest classification. Accuracy was tested in an external test set and predictive power was assessed with equivocal patients. Esophageal IgE production was quantified with epsilon germ line (IGHE) transcripts and correlated with serum IgE and the Th2-type mRNA profile to establish an IGHE-score for tissue allergy. RESULTS: In the primary analysis, a three-class statistical model generated a p(EoE) score based on common characteristics of the inflammatory EoE profile. A p(EoE) >/=25 successfully identified EoE with high accuracy (sensitivity 94.4%, specificity 92.9%, AUC 0.985) and improved diagnosis of equivocal cases by 84.6%. The p(EoE) changed in response to therapy. A secondary analysis loop in EoE patients defined an IGHE-score>/=37.5 for a patient subpopulation with increased esophageal allergic inflammation. CONCLUSION: The development of intelligent data analysis from a machine learning perspective provides exciting opportunities to improve diagnostic precision and improve patient care in EoE. The p(EoE) and the IGHE-score are steps towards the development of decision trees to define EoE subpopulations and, consequently, will facilitate individualized therapy</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Austria -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.11.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29273402">PM:29273402</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171209-SallisBF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171209-SallisBF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171209, Sallis BF</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.11.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43499</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Faitelson,Y.</style></author><author><style face="normal" font="default"> Boaz,M.</style></author><author><style face="normal" font="default"> Dalal,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy and Immunology Unit, Edit Wolfson Medical Center, Holon, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.</style></auth-address><titles><title><style face="normal" font="default">Asthma, Family History of Drug Allergy, and Age Predict Amoxicillin Allergy in Children</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="12" Year="2017">2017/12/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Suspected adverse reactions to amoxicillin are common, but there are no known factors that can predict amoxicillin allergy in children. In addition, methods used for the diagnosis of amoxicillin allergy are not standardized and their role in diagnosis is not clear. OBJECTIVE: To identify predictive factors and to assess the role of skin test in the diagnosis of amoxicillin allergy in children. METHODS: Children with a history of immediate (excluding anaphylaxis) or nonimmediate reactions to amoxicillin were tested by skin prick test, followed by oral graded challenge with amoxicillin. Clinical characteristics of the reaction before and after the challenge were recorded, and data of personal and relatives' drug allergies and atopy were collected for statistical analysis. RESULTS: Skin prick tests followed by an oral graded challenge with amoxicillin were performed on 133 children. The skin test result was not of clinical value because it was negative in all children. Three children (2%) had an immediate reaction and 7 children (5%) had a nonimmediate reaction. Asthma (odds ratio [OR], 0.12; 95% CI, 0.017-0.869; P = .03), family history of drug allergy (OR, 0.12; 95% CI, 0.026-0.613; P = .01), older age at reaction (OR, 0.837; 95% CI, 0.699-1; P = .05), and angioedema (OR, 0.22; 95% CI, 0.043-1.12; marginally significant at P = .069) were associated with reduced chance to pass the oral challenge. CONCLUSIONS: Skin prick test did not contribute to the diagnosis of amoxicillin allergy. The presence of asthma, family history of drug allergy, and older age at reaction can be used as predictive factors for true amoxicillin allergy in children</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.11.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29226807">PM:29226807</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171206, Faitelson Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.11.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43500</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Postolova,A.</style></author><author><style face="normal" font="default"> Bradley,J.T.</style></author><author><style face="normal" font="default"> Parris,D.</style></author><author><style face="normal" font="default"> Sherr,J.</style></author><author><style face="normal" font="default"> McGhee,S.A.</style></author><author><style face="normal" font="default"> Hernandez,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Immunology and Rheumatology, Department of Pediatrics, Stanford University, School of Medicine, Stanford, Calif.</style></auth-address><titles><title><style face="normal" font="default">Anaphylaxis to invasive chlorhexidine administration despite tolerance of topical chlorhexidine use</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="12" Year="2017">2017/12/6</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.11.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29226805">PM:29226805</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171206, Postolova A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.11.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43501</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tsurikisawa,N.</style></author><author><style face="normal" font="default"> Oshikata,C.</style></author><author><style face="normal" font="default"> Sato,T.</style></author><author><style face="normal" font="default"> Kimura,G.</style></author><author><style face="normal" font="default"> Mizuki,M.</style></author><author><style face="normal" font="default"> Tsuburai,T.</style></author><author><style face="normal" font="default"> Shoji,S.</style></author><author><style face="normal" font="default"> Saito,H.</style></author><author><style face="normal" font="default"> Shimoda,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respirology, National Hospital Organization Saitama National Hospital, Saitama, Japan</style></auth-address><titles><title><style face="normal" font="default">Low Variability in Peak Expiratory Flow Predicts Successful Inhaled Corticosteroid Step-Down in Adults with Asthma</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="12" Year="2017">2017/12/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: The prognosis for patients beyond 1 year after reduction of their inhaled corticosteroid (ICS) dose remains unknown. Predictive factors that can be evaluated before the initiation of asthma treatment or at ICS dose reduction are unknown. METHODS: We prospectively studied 223 patients in 6 hospitals in the National Hospital Organization of Japan during the 36 months after 50% reduction of their daily ICS dose. All patients recorded their morning and evening peak expiratory flows (PEFs) in their diaries. Lung function, bronchial hyperresponsiveness, fractional nitric oxide levels, number of eosinophils in sputum, and serum IgE levels were measured in most patients. Serum levels of IL-10, IL-33, and thymic stromal lymphopoietin before ICS dose reduction were measured in all patients. RESULTS: During the 36-month study period, asthma control was retained in 127 (59.6%) of the 213 enrolled patients who underwent ICS dose reduction. Multivariate logistic regression analysis revealed that, at the initiation of dose reduction, the factors most predictive of maintenance of asthma control after ICS dose reduction were a low serum IL-33 level (P &lt; .01), low PEF variability over 1 week (P = .014), childhood onset of asthma (at age &lt;10 years) (P = .03), and low serum IL-10 level (P = .035). CONCLUSIONS: We demonstrated that low PEF variability over 1 week, high serum IL-10 level, and low serum IL-33 concentration were useful factors for predicting that an adult's asthma will remain in control for months to years after a 50% reduction in the daily ICS dose</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.10.036</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29221918">PM:29221918</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171205, Tsurikisawa N</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.10.036</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43502</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Choi,G.E.</style></author><author><style face="normal" font="default"> Yoon,S.Y.</style></author><author><style face="normal" font="default"> Kim,J.Y.</style></author><author><style face="normal" font="default"> Kang,D.Y.</style></author><author><style face="normal" font="default"> Jang,Y.J.</style></author><author><style face="normal" font="default"> Kim,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biomedical Sciences, University of Ulsan College of Medicine, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Autophagy deficiency in myeloid cells exacerbates eosinophilic inflammation in chronic rhinosinusitis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="12" Year="2017">2017/12/7</year></dates><abstract><style face="normal" font="default">BACKGROUND: Eosinophilic inflammation is a major pathologic feature of chronic rhinosinusitis and is frequently associated with severe refractory disease. Prostaglandin D2 level is elevated in chronic rhinosinusitis and is an important contributing factor to eosinophilic inflammation. Autophagy has a pleiotropic effect on immune responses and disease pathogenesis. Recent studies suggest the potential involvement of autophagy in chronic rhinosinusitis and the prostaglandin pathway. OBJECTIVE: To investigate whether altered function of autophagy is associated with eosinophilic inflammation and dysregulated production of prostaglandin D2 in chronic rhinosinusitis. METHODS: We used myeloid cell-specific deletion of Atg7, which is vital for autophagy, and investigated the effects of impaired autophagy on eosinophilic inflammation in a murine model of eosinophilic chronic rhinosinusitis. The effect of autophagy on prostaglandin D2 production and gene expression profiles associated with allergy and the prostaglandin pathway were assessed. RESULTS: We found that impaired autophagy in myeloid cells aggravated eosinophilia, epithelial hyperplasia, and mucosal thickening in eosinophilic chronic rhinosinusitis mice. This aggravation was associated with gene expression profiles that favor eosinophilic inflammation, Th2 response, mast cell infiltration, and prostaglandin D2 dysregulation. Supporting this, prostaglandin D2 production was also significantly increased by impaired autophagy. Among other myeloid cells, macrophages were associated with autophagy deficiency, leading to elevated IL-1beta levels. Macrophage depletion or blockade of IL-1 receptor led to alleviation of eosinophilic inflammation and sinonasal anatomic abnormalities associated with autophagy deficiency. CONCLUSION: Our results suggest that impaired autophagy in myeloid cells, particularly macrophages, has a causal role in eosinophilic inflammation and eosinophilic chronic rhinosinusitis pathogenesis</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.10.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29225084">PM:29225084</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171207-ChoiGE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171207-ChoiGE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171207, Choi GE</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.10.038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43503</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lang,J.E.</style></author><author><style face="normal" font="default"> Fitzpatrick,A.M.</style></author><author><style face="normal" font="default"> Mauger,D.T.</style></author><author><style face="normal" font="default"> Guilbert,T.W.</style></author><author><style face="normal" font="default"> Jackson,D.J.</style></author><author><style face="normal" font="default"> Lemanske,R.F.,Jr.</style></author><author><style face="normal" font="default"> Martinez,F.D.</style></author><author><style face="normal" font="default"> Strunk,R.C.</style></author><author><style face="normal" font="default"> Zeiger,R.S.</style></author><author><style face="normal" font="default"> Phipatanakul,W.</style></author><author><style face="normal" font="default"> Bacharier,L.B.</style></author><author><style face="normal" font="default"> Pongracic,J.A.</style></author><author><style face="normal" font="default"> Holguin,F.</style></author><author><style face="normal" font="default"> Cabana,M.D.</style></author><author><style face="normal" font="default"> Covar,R.A.</style></author><author><style face="normal" font="default"> Raissy,H.H.</style></author><author><style face="normal" font="default"> Tang,M.</style></author><author><style face="normal" font="default"> Szefler,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Duke University School of Medicine, Durham, NC.</style></auth-address><titles><title><style face="normal" font="default">Overweight/obesity status in preschool children associates with worse asthma but robust improvement on inhaled corticosteroids</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="12" Year="2017">2017/12/8</year></dates><abstract><style face="normal" font="default">BACKGROUND: Overweight/obesity (OW) is linked to worse asthma and poorer inhaled corticosteroid (ICS) response in older children and adults. OBJECTIVE: We sought to describe the relationships between OW and asthma severity and response to ICS in preschool children. METHODS: This post hoc study of 3 large multicenter trials involving 2- to 5-year-old children compared annualized asthma symptom days and exacerbations among normal weight (NW) (body mass index: 10th-84th percentiles) versus OW (body mass index: >/=85th percentile) participants. Participants had been randomized to daily ICS, intermittent ICS, or daily placebo. Simple and multivariable linear regression was used to compare body mass index groups. RESULTS: Within the group not treated with a daily controller, OW children had more asthma symptom days (90.7 vs 53.2, P = .020) and exacerbations (1.4 vs 0.8, P = .009) thanNW children did. Within the ICS-treated groups, OW and NW children had similar asthma symptom days (daily ICS: 47.2 vs 44.0 days, P = .44; short-term ICS: 61.8 vs 52.9 days, P = .46; as-needed ICS: 53.3 vs 47.3 days, P = .53), and similar exacerbations (daily ICS: 0.6 vs 0.8, P = .10; short-term ICS: 1.1 vs 0.8 days, P = .25; as-needed ICS: 1.0 vs 1.1, P = .72). Compared with placebo, daily ICS in OW led to fewer annualized asthma symptom days (90.7 vs 41.2, P = .004) and exacerbations (1.4 vs 0.6, P = .006), while similar protective ICS effects were less apparent among NW. CONCLUSIONS: In preschool children off controller therapy, OW is associated with greater asthma impairment and exacerbations. However, unlike older asthmatic patients, OW preschool children do not demonstrate reduced responsiveness to ICS therapy</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.09.043.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29273557">PM:29273557</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171209-LangJE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171209-LangJE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171209, Lang JE</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.09.043.</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43504</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chinen,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Natural Disasters - Impact on Physicians and Researchers</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="12" Year="2017">2017/12/20</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.11.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29274409">PM:29274409</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171209-ChinenJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171209-ChinenJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171209, Chinen J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.11.033</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43505</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Saiganesh,A.</style></author><author><style face="normal" font="default"> Hales,B.J.</style></author><author><style face="normal" font="default"> Chen,S.</style></author><author><style face="normal" font="default"> Filipovska-Naumovska,E.</style></author><author><style face="normal" font="default"> Pereira,G.</style></author><author><style face="normal" font="default"> Garand,M.</style></author><author><style face="normal" font="default"> Kollmann,T.R.</style></author><author><style face="normal" font="default"> Currie,A.J.</style></author><author><style face="normal" font="default"> Souef,P.N.L.</style></author><author><style face="normal" font="default"> Zhang,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Paediatrics and Child Health, University of Western Australia, Subiaco, WA 6008 Australia; Telethon Kids Institute, University of Western Australia, Subiaco, WA 6008, Australia</style></auth-address><titles><title><style face="normal" font="default">The Western Environment Reduces Innate Immune Cytokine Production in Chinese Immigrants</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="12" Year="2017">2017/12/20</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.11.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29274412">PM:29274412</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171209-SaiganeshA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171209-SaiganeshA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171209, Saiganesh A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.11.031</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43506</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Qiao,Y.</style></author><author><style face="normal" font="default"> Yan,Y.</style></author><author><style face="normal" font="default"> Tan,K.S.</style></author><author><style face="normal" font="default"> Tan,S.S.</style></author><author><style face="normal" font="default"> Seet,J.E.</style></author><author><style face="normal" font="default"> Arumugam,T.V.</style></author><author><style face="normal" font="default"> Chow,V.T.</style></author><author><style face="normal" font="default"> Wang,Y.</style></author><author><style face="normal" font="default"> Tran,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore</style></auth-address><titles><title><style face="normal" font="default">CD151, A Novel Host Factor of Nuclear Export Signaling in Influenza Virus Infection</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="12" Year="2017">2017/12/20</year></dates><abstract><style face="normal" font="default">BACKGROUND: Despite advances in our understanding of the mechanisms of influenza A virus (IAV) infection, the crucial virus-host interactions during the viral replication cycle still remain incomplete. Tetraspanin CD151 is highly expressed in the human respiratory tract, but its pathological role in IAV infection is unknown. OBJECTIVES: To characterize the functional role and mechanisms of action of CD151 in IAV infection of the upper and lower respiratory tracts with H1N1 and H3N2 strains. METHODS: We used CD151-null mice in an in vivo model of IAV infection and clinical donor samples of in vitro-differentiated human nasal epithelial cells cultured at air-liquid interface. RESULTS: As compared with wild-type infected mice, CD151-null infected mice exhibited significant reduction in virus titer and improvement in survival that is associated with pronounced host anti-viral response and inflammasome activation together with accelerated lung repair. Interestingly, we show that CD151 complexes newly synthesized viral proteins with host nuclear export proteins and stabilizes microtubule complexes which are key processes necessary for the polarized trafficking of viral progeny to the host plasma membrane for assembly. CONCLUSIONS: Our results provide new mechanistic insights into our understanding of IAV infection. We show that CD151 is a critical novel host factor of nuclear export signaling whereby the IAV nuclear export utilizes it to complement its own nuclear export proteins (a site not targeted by current therapy), making this regulation unique and holds promise for the development of novel alternative/complementary strategies to reduce IAV severity</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Singapore -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.11.032</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29274410">PM:29274410</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171209-QiaoY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171209-QiaoY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171209, Qiao Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.11.032</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43507</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lopez-Gonzalez,P.</style></author><author><style face="normal" font="default"> Madrigal-Burgaleta,R.</style></author><author><style face="normal" font="default"> Carpio-Escalona,L.V.</style></author><author><style face="normal" font="default"> Bernal-Rubio,L.</style></author><author><style face="normal" font="default"> Guerra,E.</style></author><author><style face="normal" font="default"> Berges-Gimeno,M.P.</style></author><author><style face="normal" font="default"> Alvarez-Cuesta,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Division, Ramon y Cajal University Hospital, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Assessment of Antihistamines and Corticosteroids as Premedication in Rapid Drug Desensitization to Paclitaxel: Outcomes in 155 Procedures</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="12" Year="2017">2017/12/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: In early clinical trials, infusion reactions during the administration of taxanes were managed using systematic premedication with antihistamines and corticosteroids before standard infusions. Consequently, these premedications are also administered before rapid drug desensitization (RDD) with taxanes. However, their role in RDD has not been studied. OBJECTIVE: To assess the need for premedication with antihistamines and corticosteroids to prevent hypersensitivity reactions in RDD to paclitaxel. METHODS: Over a 4-year period, we selected patients with confirmed hypersensitivity to paclitaxel (positive skin testing and/or drug provocation testing results) who had received paclitaxel through RDD. These patients were assigned to 2 prospective noninception cohorts: one cohort premedicated with antihistamine and corticosteroids and another cohort that was not. RESULTS: We assessed 66 paclitaxel-reactive patients, of whom 22 met the inclusion criteria. A total of 155 RDDs to paclitaxel were performed. There were no significant differences in tolerance to RDD between the cohorts. CONCLUSIONS: Administering systematic premedication with corticosteroids and antihistamines had no significant effect on the effectiveness or safety of RDD in patients with confirmed hypersensitivity to paclitaxel in the study population. Moreover, these premedications can mask early signs of hypersensitivity and delay treatment. We believe that systematic premedication with these drugs for patients undergoing RDD should be carefully and individually assessed if their only purpose is to prevent breakthrough reactions during RDD</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.11.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29248386">PM:29248386</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171213, Lopez-Gonzalez P</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.11.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43508</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Capo,V.</style></author><author><style face="normal" font="default"> Castiello,M.C.</style></author><author><style face="normal" font="default"> Fontana,E.</style></author><author><style face="normal" font="default"> Penna,S.</style></author><author><style face="normal" font="default"> Bosticardo,M.</style></author><author><style face="normal" font="default"> Draghici,E.</style></author><author><style face="normal" font="default"> Poliani,L.P.</style></author><author><style face="normal" font="default"> Sergi,L.S.</style></author><author><style face="normal" font="default"> Rigoni,R.</style></author><author><style face="normal" font="default"> Cassani,B.</style></author><author><style face="normal" font="default"> Zanussi,M.</style></author><author><style face="normal" font="default"> Carrera,P.</style></author><author><style face="normal" font="default"> Uva,P.</style></author><author><style face="normal" font="default"> Dobbs,K.</style></author><author><style face="normal" font="default"> Sacchetti,N.</style></author><author><style face="normal" font="default"> Notarangelo,L.D.</style></author><author><style face="normal" font="default"> van Til,N.P.</style></author><author><style face="normal" font="default"> Wagemaker,G.</style></author><author><style face="normal" font="default"> Villa,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">San Raffaele Telethon Institute for Gene Therapy (TIGET), Division of Regenerative Medicine, Stem Cells and Gene Therapy, San Raffaele Scientific Institute, Milan, Italy</style></auth-address><titles><title><style face="normal" font="default">Efficacy of lentiviral mediated gene therapy in an Omenn syndrome Rag2 mouse model is not hindered by inflammation and immune dysregulation</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="12" Year="2017">2017/12/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Omenn syndrome (OS) is a rare severe combined immunodeficiency associated with autoimmunity, caused by defects of the lymphoid-specific V(D)J recombination. Most patients carry hypomorphic mutations in recombination activating genes (RAG) 1 or 2. Hematopoietic stem cell (HSC) transplantation is the standard treatment, however gene therapy (GT) may represent a valid alternative, especially for patients lacking a matched donor. OBJECTIVE: To determine the efficacy of lentiviral vector (LV) mediated GT in the murine model of OS (Rag2(R229Q/R229Q)) in correcting immunodeficiency and autoimmunity. METHODS: OS Lin(-) cells were transduced with a LV encoding the human RAG2 gene and injected into irradiated OS recipients. Control mice were transplanted with wild-type or OS untransduced Lin- cells. Immunophenotype, T-dependent and independent antigen challenges, immune spectratyping, autoantibodies detection and detailed tissue immunohistochemical analyses were performed. RESULTS: LV-mediated GT allowed immunological reconstitution, although suboptimal as compared to wild type bone marrow transplanted OS mice, in peripheral blood and hematopoietic organs, such as bone marrow, thymus and spleen. We observed in vivo variability in the efficacy of GT correlating with the levels of transduction achieved. Immunoglobulin levels and T cell repertoire normalized and gene corrected mice properly responded to challenges in vivo. Autoimmune manifestations, such as skin infiltration and autoantibodies, dramatically improved in GT mice with a vector copy number/genome higher than 1 in the bone marrow and 2 in the thymus. CONCLUSIONS: Our data show that LV-mediated GT for Omenn Syndrome significantly ameliorates the immunodeficiency even in an inflammatory environment</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Italy -CO - United States -CO - Netherlands -CO - Russia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.11.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29241731">PM:29241731</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171211-CapoV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171211-CapoV.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171211, Capo V</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.11.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43509</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Maric,J.</style></author><author><style face="normal" font="default"> Ravindran,A.</style></author><author><style face="normal" font="default"> Mazzurana,L.</style></author><author><style face="normal" font="default"> Bjorklund,A.K.</style></author><author><style face="normal" font="default"> Van Acker,A.</style></author><author><style face="normal" font="default"> Rao,A.</style></author><author><style face="normal" font="default"> Friberg,D.</style></author><author><style face="normal" font="default"> Dahlen,S.E.</style></author><author><style face="normal" font="default"> Heinemann,A.</style></author><author><style face="normal" font="default"> Konya,V.</style></author><author><style face="normal" font="default"> Mjosberg,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, SwedenCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden; Department of Clinical and Experimental Medicine, Linkoping University, Sweden. Electronic address: jenny.mjosberg@ki.se</style></auth-address><titles><title><style face="normal" font="default">PGE2 suppresses human group 2 innate lymphoid cell function</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="12" Year="2017">2017/12/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Group 2 innate lymphoid cells (ILC2) are involved in the initial phase of type 2 inflammation and can amplify allergic immune responses by orchestrating other type 2 immune cells. PGE2 is a bioactive lipid that plays protective roles in the lung, particularly during allergic inflammation. OBJECTIVE: We set out to investigate how PGE2 regulates human ILC2 function. METHODS: The effects of PGE2 on human ILC2 proliferation, intracellular cytokine and transcription factor expression were assessed by flow cytometry. Cytokine production was measured by ELISA and real-time quantitative PCR was performed to detect PGE2 receptor expression. RESULTS: PGE2 inhibited the expression of GATA3, as well as the production of type 2 cytokines, IL-5 and IL-13, from human tonsil and blood ILC2 in response to stimulation with a combination of IL-25, IL-33, TSLP and IL-2. Furthermore, PGE2 downregulated the expression of IL-2Ralpha (CD25). In line with that observation, PGE2 decreased ILC2 proliferation. These effects were mediated by the combined action of the EP2 and EP4 receptors, which were specifically expressed on ILC2. CONCLUSION: Our findings reveal that PGE2 limits ILC2 activation and propose that selective EP2 and EP4 receptor agonists might serve as promising therapeutic approach in treating allergic diseases by suppressing ILC2 function</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Austria -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.09.050</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29217133">PM:29217133</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171204-MaricJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171204-MaricJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Maric J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.09.050</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43510</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ramsey,A.</style></author><author><style face="normal" font="default"> Staicu,M.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Division of Allergy/Immunology/Rheumatology, Rochester Regional Health, Rochester, NY.</style></auth-address><titles><title><style face="normal" font="default">Use of a Penicillin Allergy Screening Algorithm and Penicillin Skin Testing for Transitioning Hospitalized Patients to First-Line Antibiotic Therapy</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="12" Year="2017">2017/12/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Penicillin allergy is the most commonly reported antibiotic allergy. Avoidance of beta-lactam antibiotics in hospitalized patients leads to the use of second-line therapies. OBJECTIVE: The utility of a penicillin allergy history algorithm (PAHA) and subsequent penicillin skin testing (PST) in transitioning hospitalized patients from second- to first-line antibiotic therapy is described. METHODS: Through an electronic medical record report, pharmacists identified adult inpatients with penicillin allergy receiving moxifloxacin, intravenous vancomycin, aztreonam, daptomycin, or linezolid, in which a beta-lactam antibiotic was preferred. The PAHA was administered to identify patients for PST. Skin-test negative patients were transitioned to first-line beta-lactam antibiotic therapy. RESULTS: Fifty patients consented to the study. Historical reactions included hives (16 patients, 32%), angioedema (15, 30%), anaphylaxis (6, 12%), unknown (6, 12%), rash (6, 12%), and dyspnea (1, 2%). Pre-PST antibiotic regimens included vancomycin (82%), aztreonam (22%), moxifloxacin (6%), daptomycin (4%), and/or linezolid (2%). Forty-seven patients (94%) were skin-test negative and were subsequently transitioned to a beta-lactam antibiotic. Two patients were skin-test positive and one was histamine nonreactive. No patients experienced an immediate adverse reaction when challenged with a penicillin-based antibiotic. A total of 982 days of second-line antibiotic therapy and at least 23 hospital days to administer the antibiotic were avoided. CONCLUSIONS: The use of the PAHA and subsequent PST is a safe, effective multidisciplinary intervention that facilitates the transition to beta-lactam antibiotics. Our approach is unique in that it prioritizes patients based on the use of second-line antibiotics, and then applies an algorithm to determine eligibility for PST</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.11.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29242142">PM:29242142</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171211, Ramsey A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.11.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43511</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Simons,L.</style></author><author><style face="normal" font="default"> Ma,K.</style></author><author><style face="normal" font="default"> de Chappedelaine,C.</style></author><author><style face="normal" font="default"> Moiranghtem,R.D.</style></author><author><style face="normal" font="default"> Elkaim,E.</style></author><author><style face="normal" font="default"> Olivre,J.</style></author><author><style face="normal" font="default"> Susini,S.</style></author><author><style face="normal" font="default"> Appourchaux,K.</style></author><author><style face="normal" font="default"> Reimann,C.</style></author><author><style face="normal" font="default"> Sadek,H.</style></author><author><style face="normal" font="default"> Pelle,O.</style></author><author><style face="normal" font="default"> Cagnard,N.</style></author><author><style face="normal" font="default"> Magrin,E.</style></author><author><style face="normal" font="default"> Lagresle-Peyrou,C.</style></author><author><style face="normal" font="default"> Taghon,T.</style></author><author><style face="normal" font="default"> Rausell,A.</style></author><author><style face="normal" font="default"> Cavazzana,M.</style></author><author><style face="normal" font="default"> Andre-Schmutz,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">the Human Lymphohaematopoiesis Laboratory, INSERM U1163, Paris, France; the University of Paris Descartes-Sorbonne Paris Cite, IMAGINE Institute, Paris, France</style></auth-address><titles><title><style face="normal" font="default">Generation of adult human T cell progenitors for immunotherapeutic applications</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="2" Month="12" Year="2017">2017/12/2</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - France -CO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.10.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29208547">PM:29208547</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171202-SimonsL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171202-SimonsL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171202, Simons L</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.10.034</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43512</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zirwas,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Ohio State University, 2359 E Main St, Columbus, OH, 43209.</style></auth-address><titles><title><style face="normal" font="default">The Future is Finally Here: Advances in the Treatment of Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="12" Year="2017">2017/12/14</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaad.2017.12.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29248517">PM:29248517</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am Acad Dermatol\20171214-ZirwasMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Am Acad Dermatol\20171214-ZirwasMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171214, Zirwas MJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaad.2017.12.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43513</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cotter,D.G.</style></author><author><style face="normal" font="default"> Schairer,D.</style></author><author><style face="normal" font="default"> Eichenfield,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departments of Dermatology and Pediatrics, University of California, San Diego and Rady Children's Hospital, San Diego</style></auth-address><titles><title><style face="normal" font="default">Emerging Therapies for Atopic Dermatitis: Jak Inhibitors</style></title><secondary-title><style face="normal" font="default">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="12" Year="2017">2017/12/14</year></dates><abstract><style face="normal" font="default">The Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) pathway is a conserved master regulator of immunity and myeloproliferation. Advanced understanding of this pathway has led to development of targeted inhibitors of Janus Kinases (Jakinibs). As a class, Jakinibs effectively treat a multitude of hematologic and inflammatory diseases. Given such success, use of Jakinibs for mitigation of atopic dermatitis is under active investigation. Herein, we review the evolving data on the safety and efficacy of Jakinibs in treatment of atopic dermatitis. While it is still early in the study of Jakinibs for atopic dermatitis, evidence identifies Jakinibs as effective alternatives to conventional therapies. Nonetheless, multiple large safety and efficacy trials are needed before widespread use of Jakinibs can be advocated for atopic dermatitis</style></abstract><notes><style face="normal" font="default">IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaad.2017.12.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29248518">PM:29248518</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am Acad Dermatol\20171214-CotterDG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Am Acad Dermatol\20171214-CotterDG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171214, Cotter DG</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaad.2017.12.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43514</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bonchak,J.G.</style></author><author><style face="normal" font="default"> Swerlick,R.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia.</style></auth-address><titles><title><style face="normal" font="default">Emerging Therapies for Atopic Dermatitis: TRPV1 Antagonists</style></title><secondary-title><style face="normal" font="default">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="12" Year="2017">2017/12/14</year></dates><abstract><style face="normal" font="default">Transient receptor potential (TRP) ion channels are important mediators of somatosensory signaling throughout the body. Our understanding of the contribution of TRPs to a multitude of cutaneous physiologic processes has grown substantially in the past decade. TRPV1, one of the better-understood members of this large family of ion channels, impacts multiple pathways involved in pruritus. Further, TRPV1 appears to play a role in maintaining skin barrier function. Together, these properties make TRPV1 a ripe target for new therapies in atopic dermatitis. Neurokinin antagonists may affect similar pathways and have been studied to this effect. Early trials data suggest these therapies are safe, but assessment of their efficacy in atopic dermatitis is pending as we await publication of phase II and III clinical trials data</style></abstract><notes><style face="normal" font="default">IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaad.2017.12.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29248524">PM:29248524</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am Acad Dermatol\20171214-BonchakJG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Am Acad Dermatol\20171214-BonchakJG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171214, Bonchak JG</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaad.2017.12.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43515</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nettis,E.</style></author><author><style face="normal" font="default"> Di Leo,E.</style></author><author><style face="normal" font="default"> Foti,C.</style></author><author><style face="normal" font="default"> Cegolon,L.</style></author><author><style face="normal" font="default"> Vacca,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biomedical Sciences and Human Oncology Unit of Internal Medicine "G. Baccelli""Aldo Moro" University of Bari Medical School, Policlinico, Bari, Italy</style></auth-address><titles><title><style face="normal" font="default">Efficacy and rapid activity of omalizumab retreatments in chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="12" Year="2017">2017/12/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaad.2017.11.047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29203434">PM:29203434</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am Acad Dermatol\20171214-NettisE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Am Acad Dermatol\20171214-NettisE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171214, Nettis E</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaad.2017.11.047</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43516</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hamann,C.R.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Monoclonal Antibodies Against IL-13 and IL-31RA in Development for Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="12" Year="2017">2017/12/14</year></dates><abstract><style face="normal" font="default">The IL-13 and IL-31 cytokines and inflammatory pathways have been identified as important for atopic dermatitis (AD) pathophysiology. Monoclonal antibodies against IL-13 have been studied for the treatment of asthma since 2011. More recently, two phase two trials have been completed with these antibodies in atopic dermatitis treatment. In both trials, significant reductions of Eczema Area and Severity Index (EASI) scores were seen. IL-31 is thought to play a role transmitting itch sensation to the central nervous system, and blocking IL-31 activity reduces itch in atopic dermatitis patients. One phase two trial has been completed for a humanized antibody against IL-31 receptor alpha, one subunit of the IL-31 receptor complex. This study showed significant dose-dependent reductions in pruritus, EASI scores, and markers of sleep quality. Initial clinical trials for monoclonal antibodies against IL-13 and IL-31 receptor A all show promise, although long term safety and efficacy data are lacking. Nevertheless, these medications will likely play a role in the treatment of moderate-to-severe atopic dermatitis</style></abstract><notes><style face="normal" font="default">IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaad.2017.12.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29248521">PM:29248521</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am Acad Dermatol\20171214-HamannCR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Am Acad Dermatol\20171214-HamannCR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171214, Hamann CR</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaad.2017.12.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43517</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yanes,D.A.</style></author><author><style face="normal" font="default"> Mosser-Goldfarb,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Dermatology, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH 43205, USA</style></auth-address><titles><title><style face="normal" font="default">Emerging Therapies for Atopic Dermatitis: The Prostaglandin/Leukotriene Pathway</style></title><secondary-title><style face="normal" font="default">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="12" Year="2017">2017/12/14</year></dates><abstract><style face="normal" font="default">The role of leukotrienes and prostaglandins in development of atopy has been prototypically established in studies of asthma pathogenesis. Likewise, both in vitro and in vivo studies of atopic dermatitis have demonstrated that these molecules maintain important pathophysiologic roles. Thus, it follows that targeted therapies against these molecules may be promising in management of atopic dermatitis. Montelukast has had questionable efficacy in patients with atopic dermatitis, while small pilots using zileuton did have some clinically significant improvement. There are several agents in development that target leukotrienes and/or prostaglandins as well, including OC000459, Q301, and ZPL-521. In atopic dermatitis, OC000459 did not demonstrate efficacy in clinical trials, and the efficacy of the other two agents remains to be seen. Should these medications prove promising, these topical agents may play a future role in chronic maintenance therapy and flare prophylaxis in atopic dermatitis, as anti-leukotriene therapy does in asthma</style></abstract><notes><style face="normal" font="default">IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaad.2017.12.021</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29248523">PM:29248523</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am Acad Dermatol\20171214-YanesDA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Am Acad Dermatol\20171214-YanesDA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171214, Yanes DA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaad.2017.12.021</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43518</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zebda,R.</style></author><author><style face="normal" font="default"> Paller,A.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois USA</style></auth-address><titles><title><style face="normal" font="default">Phosphodiesterase 4 (PDE4) Inhibitors</style></title><secondary-title><style face="normal" font="default">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="12" Year="2017">2017/12/14</year></dates><abstract><style face="normal" font="default">Historically, drugs available for treating atopic dermatitis (AD) have been limited to topical corticosteroids (TCS) and topical calcineurin inhibitors (TCI), with systemic immunosuppressants and phototherapy reserved for severe AD. Despite their efficacy, with long term use, these agents have associated safety concerns and limitations. More targeted options with fewer systemic and cutaneous side effects are needed for treating atopic dermatitis. Phosphodiesterase 4 is involved in the regulation of proinflammatory cytokines via the degradation of cAMP. Phosphodiesterase 4 (PDE4) activity is increased in the inflammatory cells of patients with AD, leading to increased production of proinflammatory cytokines and chemokines. Targeting PDE4 reduces the production of these proinflammatory mediators in AD. Both topical and oral PDE4 inhibitors have a favorable safety profile. Crisaborole 2% ointment, a topical PDE4, is now FDA-approved for children >2yrs of age and adults in the treatment of AD. Crisaborole 2% ointment shows early and sustained improvement in disease severity and pruritus/ other AD symptoms, with burning/stinging upon application as the only related adverse event. Other PDE4 inhibitors are currently in trials with promising efficacy and safety</style></abstract><notes><style face="normal" font="default">IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaad.2017.11.056</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29248522">PM:29248522</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am Acad Dermatol\20171214-ZebdaR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Am Acad Dermatol\20171214-ZebdaR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171214, Zebda R</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaad.2017.11.056</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43519</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tidwell,W.J.</style></author><author><style face="normal" font="default"> Fowler,J.F.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default">Scripps Clinic, Micrographic Surgery and Cutaneous Oncology, La Jolla, CA</style></auth-address><titles><title><style face="normal" font="default">T-Cell Inhibitors for Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="12" Year="2017">2017/12/14</year></dates><abstract><style face="normal" font="default">The management of atopic dermatitis is changing with the development of novel biological agents to target specific molecules in the inflammatory cascade. Dupilumab has proven its ability to act on the IL-4 receptor in treating atopic dermatitis. Thymic stromal lymphopoietin (TSLP) monoclonal antibody (AMG157/ MEDI9929) and OX40 blocking antibody (GBR 830) were developed by target the same pathway as dupilumab. The clinical data on the efficacy for these drugs is not yet known. There is some early evidence that AMG157/ MEDI9929 attenuates most measures of allergen-induced asthmatic responses. However, there is no public data on its ability to treat atopic dermatitis. In a Phase 2a study, GBR 830 showed at least a 50% reduction in patient's Eczema Area and Severity Index (EASI) scores in 17 out of 23 patients, but it was not powered enough for statistical differences between GBR 830 versus placebo. Although there is potential for these two drugs to greatly improve the management of severe atopic dermatitis, there is not yet any available phase 3 clinical trials which are needed to truly evaluate their efficacy in affecting T-cells</style></abstract><notes><style face="normal" font="default">IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaad.2017.12.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29248519">PM:29248519</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am Acad Dermatol\20171214-TidwellWJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Am Acad Dermatol\20171214-TidwellWJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171214, Tidwell WJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaad.2017.12.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43520</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vakharia,P.P.</style></author><author><style face="normal" font="default"> Silverberg,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA</style></auth-address><titles><title><style face="normal" font="default">New Therapies for Atopic Dermatitis: Additional Treatment Classes</style></title><secondary-title><style face="normal" font="default">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="12" Year="2017">2017/12/14</year></dates><abstract><style face="normal" font="default">BACKGROUND: A wide array of miscellaneous agents is being studied for the treatment of atopic dermatitis (AD), including targeted topical, oral systemic and biologic agents. OBJECTIVE: To review the known efficacy and safety to-date for such agents being studied for the treatment of AD. METHODS: A non-systematic review of the literature was performed. PubMed and ClinicalTrials.gov were searched for studies assessing agents not described in previous chapters for the treatment of AD. Randomized controlled trials (RCTs) were primarily sought, but other study types were also included if they contained pertinent data. Agents are presented by mechanism of action, with analysis of mechanism of action and data regarding efficacy and safety in AD patients. RESULTS: Data regarding the following agents are presented: omiganan (antimicrobial peptide), tapinarof (non-steroidal anti-inflammatory agent), PR022 (hypochlorous acid), asimadoline (kappa opioid agonist), DS107 (dihomo-gamma-linolenic acid), ZPL-389 (histamine H4 receptor antagonist), secukinumab (interleukin 17A inhibitor), fezakinumab (interleukin 22 inhibitor). LIMITATIONS: Limited clinical data exists for many of the described agents. CONCLUSIONS: As recent research has improved our understanding of AD pathogenesis, various agents with unique mechanisms of action have been studied for the treatment of AD. Many of these hold great therapeutic promise for AD, and continued research and development is warranted</style></abstract><notes><style face="normal" font="default">IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaad.2017.12.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29248520">PM:29248520</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am Acad Dermatol\20171214-VakhariaPP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Am Acad Dermatol\20171214-VakhariaPP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171214, Vakharia PP</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaad.2017.12.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43521</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Engelkes,M.</style></author><author><style face="normal" font="default"> van Blijderveen,J.C.</style></author><author><style face="normal" font="default"> Overbeek,J.A.</style></author><author><style face="normal" font="default"> Kuiper,J.</style></author><author><style face="normal" font="default"> Herings,R.C.M.</style></author><author><style face="normal" font="default"> Sturkenboom,M.C.J.M.</style></author><author><style face="normal" font="default"> de Jongste,J.C.</style></author><author><style face="normal" font="default"> Verhamme,K.M.C.</style></author><author><style face="normal" font="default"> Janssens,H.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Medical Informatics , Erasmus MC , Rotterdam , the Netherlands</style></auth-address><titles><title><style face="normal" font="default">Brand and generic use of inhalation medication and frequency of switching in children and adults: A population-based cohort study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="11" Year="2017">2017/11/29</year></dates><abstract><style face="normal" font="default">BACKGROUND: The expiration of patents of brand inhalation medications and the ongoing pressure on healthcare budgets resulted in a growing market for generics. AIM: To study the use of brand and generic inhalation medication and the frequency of switching between brand and generic and between devices. In addition, we investigated whether switching affected adherence. METHODS: From dispensing data from the Dutch PHARMO Database Network a cohort aged >/= 5 years, using >/= 1 year of inhalation medication between 2003 and 2012 was selected. Switching was defined as changing from brand to generic or vice versa. In addition, we studied change in aerosol delivery device type (e.g., DPI, pMDI, and nebulizers). Adherence was calculated using the medication possession ratio (MPR). RESULTS: The total cohort comprised 70,053 patients with 1,604,488 dispensations. Per calendar year, 5% switched between brand and generic inhalation medication and 5% switched between devices. Median MPRs over the first 12 months ranged between 33 and 55%. Median MPR over the total period was lower after switch from brand to generic and vice versa for formoterol (44.5 vs. 42.1 and 63.5 vs. 53.8) and beclomethasone (93.8 vs. 59.8 and 81.3 vs. 55.9). CONCLUSION: Per year, switching between brand and generic inhalation medication was limited to 5% of the patients, switching between device types was observed in 5% as well. Adherence to both generic and brand inhalation medication was low. Effect of switching on adherence was contradictory; depending on time period, medication and type, and direction of switching. Further research on reasons for switching and potential impact on clinical outcomes is warranted</style></abstract><notes><style face="normal" font="default">IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Netherlands -CO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1396468</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29185812">PM:29185812</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171204-EngelkesM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171204-EngelkesM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Engelkes M</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1396468</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43522</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Halwani,R.</style></author><author><style face="normal" font="default"> Vazquez-Tello,A.</style></author><author><style face="normal" font="default"> Kenana,R.</style></author><author><style face="normal" font="default"> Al-Otaibi,M.</style></author><author><style face="normal" font="default"> Alhasan,K.A.</style></author><author><style face="normal" font="default"> Shakoor,Z.</style></author><author><style face="normal" font="default"> Al-Muhsen,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Immunology Research Laboratory and Asthma Research Chair, College of Medicine , King Saud University , Riyadh , Saudi Arabia</style></auth-address><titles><title><style face="normal" font="default">Association of IL-13 rs20541 and rs1295686 variants with symptomatic asthma in a Saudi Arabian population</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="12" Year="2017">2017/12/6</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Interleukin 13 (IL-13) plays a critical pro-inflammatory role in asthma. Several single nucleotide polymorphisms (SNPs) are associated with asthma susceptibility in specific populations; however, further replicative studies in other ethnic groups are mandatory. METHODS: The association between IL-13 SNPs rs762534, rs20541, rs1295686, and rs1800925 (risk alleles A, A, T, and A, respectively) and asthma predisposition in a Saudi Arabian cohort was examined via a case-control cross-sectional study. RESULTS: The frequencies of alleles between asthmatics and control populations were significantly different for rs20541 and rs1295686 SNPs (p &lt; 0.001), whereas the frequencies of genotypes between asthmatics and controls were significantly different only for rs20541. The association of the risk (minor) alleles with asthma was examined using the dominant genetic model. Individuals with at least one copy of the risk alleles A (for rs20541) and T (for rs1295686) had significantly greater odds of being asthmatic (OR = 2.13, 95% CI = 1.39-3.26, p &lt; 0.0001; OR = 1.69, 95% CI = 1.12-2.54, p = 0.008) relative to their most common homozygous genotypes. On the other hand, the minor A alleles for rs762534 and rs1800925 were not significantly associated with asthma risk. Regarding haplotype association analysis, individuals with at least one copy of the minor "risk" allele for both rs20541 and rs1295686 (CATG and CATA, respectively) had greater odds of being asthmatic relative to CGCG haplotype; however, this trend was not statistically significant (p > 0.3). CONCLUSIONS: IL-13 minor T and A alleles for rs1295686 and rs20541, respectively, were associated with significantly higher risk of asthma in the Saudi Arabian population</style></abstract><notes><style face="normal" font="default">IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Saudi Arabia -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1400047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29211635">PM:29211635</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171204-HalwaniR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171204-HalwaniR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Halwani R</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1400047</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43523</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Heinrichs,K.</style></author><author><style face="normal" font="default"> Angerer,P.</style></author><author><style face="normal" font="default"> Loerbroks,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Institute of Occupational, Social, and Environmental Medicine, Centre for Health and Society, Faculty of Medicine , University of Dusseldorf , Dusseldorf , Germany</style></auth-address><titles><title><style face="normal" font="default">Psychosocial working conditions as determinants of asthma self-management at work: A systematic review</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="12" Year="2017">2017/12/4</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Asthma exerts a considerable impact on patients and their employers. While adequate self-management is able to improve patients' prognosis, its actual implementation in everyday life may depend on contextual factors. We aimed to review the literature on the potential determinants of asthma self-management at the workplace. DATA SOURCES: We systematically searched Medline and PsycINFO using terms related to the key concepts of interest (i.e., adult asthma, working conditions, and self-management). STUDY SELECTION: We included original studies published in peer-reviewed journals in English or German since 1992 addressing any type of asthma self-management behavior as the outcome and any type of working condition as the determinant. RESULTS: Upon implementation of a multi-stage selection process, seven articles were included. As those studies showed considerable methodological heterogeneity, a qualitative analysis was applied. A first study identified three different adaptation profiles among employees with asthma with implications for self-management behavior. Another study suggested that concerns about taking time off from work may be associated with the utilization of emergency ambulance services for asthma. Five studies among workers with various chronic illnesses addressed determinants of self-disclosure, coping with acute symptoms (e.g., medication use at work), and the potential effect of practical and emotional support from line managers or colleagues on self-management. CONCLUSION: Our review indicates that the evidence for a potential link of occupational factors with asthma self-management at work is relatively sparse. Future research should take a more comprehensive approach by considering multiple types of working conditions and asthma self-management behaviors simultaneously</style></abstract><notes><style face="normal" font="default">IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1396469</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29200315">PM:29200315</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171204-HeinrichsK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171204-HeinrichsK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Heinrichs K</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1396469</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43524</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bialek-Gosk,K.</style></author><author><style face="normal" font="default"> Maskey-Warzechowska,M.</style></author><author><style face="normal" font="default"> Krenke,R.</style></author><author><style face="normal" font="default"> Dabrowska,M.</style></author><author><style face="normal" font="default"> Paplinska-Goryca,M.</style></author><author><style face="normal" font="default"> Nejman-Gryz,P.</style></author><author><style face="normal" font="default"> Domagala-Kulawik,J.</style></author><author><style face="normal" font="default"> Przybylowski,T.</style></author><author><style face="normal" font="default"> Chazan,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Internal Medicine , Pulmonary Diseases and Allergy, Medical University of Warsaw , Warsaw , Poland</style></auth-address><titles><title><style face="normal" font="default">Menopausal asthma-much ado about nothing? An observational study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="12" Year="2017">2017/12/14</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Menopausal asthma is considered a distinct asthma phenotype. Our aim was to identify potential specific features of asthma in postmenopausal women in a cohort of Polish females. METHODS: Asthma severity and control, pulmonary function, exhaled nitric oxide (FENO), peripheral blood and induced sputum (IS) differential cell count were compared in three groups: women with premenopausal asthma (group 1), menopausal women with pre-existing asthma (group 2A) and menopausal women with asthma onset in the perimenopausal or menopausal period (group 2B). RESULTS: We enrolled 27 women to group 1, 13 to group 2A and 16 to group 2B. Asthma severity and control, blood eosinophil count and FENO did not differ among the groups. Menopausal women had a higher incidence of irreversible airway obstruction (84.6% in group 2A and 56.2% in group 2B vs. 22.2% in group 1, p &lt; 0.001 and p = 0.03, respectively). The proportion of patients with sputum eosinophilia was highest in menopausal women with pre-existing asthma, although the difference did not reach statistical significance (88.9% in group 2A vs. 66.7% in group 2B and 65.0% in group 1, respectively, p = 0.86). CONCLUSIONS: Menopausal women with asthma are characterized by an increased incidence of irreversible airway obstruction regardless of disease duration. This may indicate that age may contribute to pulmonary function impairment in asthmatic women independently of their hormonal status at the time of asthma diagnosis. Our results failed to confirm the presence of specific asthma features which would allow to distinguish the phenotype of menopausal asthma</style></abstract><notes><style face="normal" font="default">IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - POland -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1407336</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29240514">PM:29240514</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171204-BialekGoskK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171204-BialekGoskK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Bialek-Gosk K</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1407336</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43525</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Braithwaite,S.</style></author><author><style face="normal" font="default"> Coppel,J.</style></author><author><style face="normal" font="default"> Everson,L.</style></author><author><style face="normal" font="default"> Kearney,J.</style></author><author><style face="normal" font="default"> Gibson,L.</style></author><author><style face="normal" font="default"> Chodhari,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Asthma Innovation Research (AIR charity)</style></auth-address><titles><title><style face="normal" font="default">Letter re: Reducing emergency department visits utilizing a primary care asthma specialty clinic in a high risk patient population</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="10" Year="2017">2017/10/16</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1391284</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29035125">PM:29035125</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171204-BraithwaiteA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171204-BraithwaiteA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Braithwaite S</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1391284</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43526</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cordell,R.L.</style></author><author><style face="normal" font="default"> Valkenburg,T.S.E.</style></author><author><style face="normal" font="default"> Pandya,H.C.</style></author><author><style face="normal" font="default"> Hawcutt,D.B.</style></author><author><style face="normal" font="default"> Semple,M.G.</style></author><author><style face="normal" font="default"> Monks,P.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Chemistry , University of Leicester , Leicester , LE1 7RH , UK</style></auth-address><titles><title><style face="normal" font="default">Quantitation of salbutamol using micro-volume blood sampling - applications to exacerbations of pediatric asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="12" Year="2017">2017/12/6</year></dates><abstract><style face="normal" font="default">OBJECTIVES: A novel gas chromatography-mass spectrometry (GC-MS) method has been developed to quantify salbutamol in micro-volumes (10 microL) of blood. A potential application is paediatric therapeutic dose monitoring (TDM) in acute severe asthma. METHODS: At presentation, the children receive multiple doses of salbutamol (inhaled, nebulised and occasionally intravenous) but it is difficult to distinguish children who do not respond to treatment because of inadequate concentrations from those with toxicity, as symptoms are similar. A comparison was made between traditional dried blood spots (DBS) and the newly developed technique volumetric absorptive micro-sampling (VAMS), with specific investigation into the effect of drying time on analyte recovery. RESULTS: For both sampling techniques, the final assay demonstrated good precision and accuracy across the concentration range tested (3-100 ng/mL), including both the normal therapeutic and toxic range. The method was developed to comply with FDA guidelines with precision and accuracy &lt;/=15% for all concentrations, except the limit of quantification (5 ng/mL) where they were &lt;/=20%. VAMS offered advantages in sampling ease and reduced GC-MS interference. The assay was successfully applied to the quantification of blood salbutamol concentrations in three healthy volunteers dosed with 1 mg salbutamol by inhalation. CONCLUSIONS: This demonstrated its potential for use in paediatric TDM studies, where in the acute situation considerably higher doses of salbutamol will have been administered. This is the first time that a TDM method for salbutamol has been carried out using VAMS and offers all the advantages provided by DBS, whilst eliminating the inherent sampling volume inaccuracies of traditional DBS collection</style></abstract><notes><style face="normal" font="default">IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1402341</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29211599">PM:29211599</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171204-CordellRL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171204-CordellRL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Cordell RL</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1402341</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43527</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Parker-Lalomio,M.</style></author><author><style face="normal" font="default"> McCann,K.</style></author><author><style face="normal" font="default"> Piorkowski,J.</style></author><author><style face="normal" font="default"> Freels,S.</style></author><author><style face="normal" font="default"> Persky,V.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Division of Epidemiology and Biostatistics, School of Public Health , University of Illinois at Chicago , Chicago , IL , USA</style></auth-address><titles><title><style face="normal" font="default">Prenatal exposure to polychlorinated biphenyls and asthma, eczema/hay fever, and frequent ear infections</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="12" Year="2017">2017/12/6</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The effects of prenatal exposure to Polychlorinated biphenyls (PCBs) on the development of asthma, frequent ear infections, and eczema/hay fever are not well understood. We aim to investigate associations between prenatal PCB exposure and these health outcomes in the offspring of women who worked at the LaSalle Electrical Utilities Company (EUC). METHODS: A retrospective cohort with at least one live birth and known employment time at EUC was eligible for this analysis. Exposure was defined and categorized by the number of fiscal quarters worked during the PCB era (1952-1981). A total of 288 women with 800 live births were included. A Chi-Square test was used to compare maternal and child characteristics across exposure groups and repeated measures logistic regression, controlling for clustering among siblings, was used to assess the associations between prenatal PCB exposure and these outcomes. RESULTS: After adjustment for confounding and independent maternal predictors, 1-4 quarters of prenatal exposure to PCBs increased the odds for asthma (OR 3.24[1.30-8.09]), eczema/hay fever (OR 3.29[1.54-7.04]), and frequent ear infections (OR 2.24[1.19-4.22]) when compared with persons unexposed/exposed only to naphthalenes. The significance of the associations varied by exposure period and level of exposure, with the strongest associations in those employed exclusively after 1952 when PCBs were introduced. CONCLUSIONS: These results support previous findings of associations of prenatal exposure to PCBs with asthma, eczema/hay fever, and frequent ear infections. Additional prospective studies are needed to confirm these findings. Also required are more precise PCB exposures to separate them from other exposures in occupational settings</style></abstract><notes><style face="normal" font="default">IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1396470</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29211547">PM:29211547</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171204-ParkerLalomioM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171204-ParkerLalomioM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Parker-Lalomio M</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1396470</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43528</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tian,B.P.</style></author><author><style face="normal" font="default"> Zhang,G.S.</style></author><author><style face="normal" font="default"> Lou,J.</style></author><author><style face="normal" font="default"> Zhou,H.B.</style></author><author><style face="normal" font="default"> Cui,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Critical Care Medicine , Second Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou , Zhejiang , China</style></auth-address><titles><title><style face="normal" font="default">Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="12" Year="2017">2017/12/6</year></dates><abstract><style face="normal" font="default">CONTEXT: Benralizumab is a humanized monoclonal antibody that targets the alpha chain of the IL-5 receptor (IL-5Ralpha) and is currently being assessed in clinical trials for asthma control. OBJECTIVE: Our systematic review and meta-analysis intends to evaluate the therapeutic efficacy and safety of benralizumab in patients with eosinophilic asthma. DATA SOURCES AND EXTRACTION: Literature searches of PubMed, Embase, and the Cochrane Library were performed to identify randomized controlled trials of benralizumab and clinic outcomes in asthmatics. RESULTS: In total, 7 articles with 2,321 subjects met our inclusion criteria. From this pooled analysis, we found that benralizumab significantly reduces exacerbations (RR: 0.63, 95% CI: 0.52-0.76, p &lt; 0.00001; I(2) = 52%, p = 0.06) compared to placebo in eosinophilic asthma. There was no statistical trend for improvement in forced expiratory volume in 1 second or asthma control indices such as Quality of Life Assessment (AQLQ) and Asthma Control Questionnaire score in benralizumab-treated patients. In addition, safety data indicated that benralizumab administration resulted no increasing incidence of adverse events and was well tolerated (RR: 1.00, 95% CI: 0.95-1.05, p = 0.96; I(2) = 40%, p = 0.13). CONCLUSION: These results demonstrate the efficacy and safety of benralizumab for asthma patients with severe or uncontrolled symptoms and elevated eosinophils and provide support for benralizumab as an ideal option to treat asthma in this patient population</style></abstract><notes><style face="normal" font="default">IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1379534</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29211545">PM:29211545</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171204-TianBP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171204-TianBP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Tian BP</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1379534</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43529</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Trivedi,M.</style></author><author><style face="normal" font="default"> Patel,J.</style></author><author><style face="normal" font="default"> Lessard,D.</style></author><author><style face="normal" font="default"> Kremer,T.</style></author><author><style face="normal" font="default"> Byatt,N.</style></author><author><style face="normal" font="default"> Phipatanakul,W.</style></author><author><style face="normal" font="default"> Pbert,L.</style></author><author><style face="normal" font="default"> Goldberg,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Division of Pediatric Pulmonology, University of Massachusetts Medical School , Worcester , Massachusetts , USA</style></auth-address><titles><title><style face="normal" font="default">School nurse asthma program reduces healthcare utilization in children with persistent asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="12" Year="2017">2017/12/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: We examined the impact of a novel, school nurse-supervised asthma therapy program on healthcare utilization. METHODS: We retrospectively reviewed charts of 84 children enrolled in this program in central Massachusetts between 2012 and 2015. Physicians identified children with persistent asthma and poor medication adherence. These children were enrolled in the program to receive daily-inhaled corticosteroid at school, supervised by their school nurse, with ongoing communication between physician's office and school nurse through the school year. This program relied on established family, provider and school resources rather than research staff. The primary outcome was change in the number of emergency department (ED) visits in the year before and after enrollment. Secondary outcomes were hospital admissions, school absences, and rescue medication use. RESULTS: The study population was on average 10.5 years old, 63% male, 67% Hispanic, 19% black, 14% white with 95% using Medicaid insurance. Asthma-related ED visits over a 1-year period decreased 37.5%, from a pre-intervention mean of 0.8 visits to a post-intervention mean of 0.3 visits (p &lt; 0.001). Asthma-related hospital admissions decreased from a pre-intervention mean of 0.3 admissions to post-intervention mean of 0 admissions (p &lt; 0.001). Asthma rescue medication refills decreased by 46.3% from the pre- to post-intervention period (p = &lt;.001). There were also non-significant declines in school absences and oral steroid use for children enrolled. CONCLUSIONS: We demonstrate a significant reduction in healthcare utilization for children enrolled in this unique school nurse-supervised asthma program, which utilizes a clinical-school partnership to deliver preventative asthma medication to school-aged children under sustainable conditions</style></abstract><notes><style face="normal" font="default">IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1396473</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29206057">PM:29206057</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171204-TrivediM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171204-TrivediM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Trivedi M</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1396473</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43530</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hong,J.</style></author><author><style face="normal" font="default"> Bao,Y.</style></author><author><style face="normal" font="default"> Chen,A.</style></author><author><style face="normal" font="default"> Li,C.</style></author><author><style face="normal" font="default"> Xiang,L.</style></author><author><style face="normal" font="default"> Liu,C.</style></author><author><style face="normal" font="default"> Chen,Z.</style></author><author><style face="normal" font="default"> Zhao,D.</style></author><author><style face="normal" font="default"> Fu,Z.</style></author><author><style face="normal" font="default"> Shang,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatrics , Shanghai General Hospital, Shanghai Jiaotong University , Shanghai , China</style></auth-address><titles><title><style face="normal" font="default">Chinese guidelines for childhood asthma 2016: Major updates, recommendations and key regional data</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="12" Year="2017">2017/12/11</year></dates><abstract><style face="normal" font="default">OBJECTIVE: With increased industrialization and urbanization in China, pediatric asthma is becoming more prevalent. Despite a growing body of evidence, there remains a significant unmet need for adequate management of childhood asthma. The Subspecialty Group of Respiratory Diseases of the Society of Pediatrics, the Chinese Medical Association, and the editorial board of the Chinese Journal of Pediatrics have recently updated the "Guidelines for diagnosis and optimal management of asthma in children," first published in 2008. METHODS: This article reviews the major updates to the guidelines and covers the main recommendations for diagnosis, assessment, and treatment of pediatric asthma in China. Key regional data on epidemiology, clinical features, disease burden, knowledge among children and parents, and risk factors including pollution are provided to contextualize the recommendations. RESULTS: The major updates to the guidelines include: (1) A more practical definition of asthma; (2) assessment of asthma control that takes into account both current symptom control and future risk; (3) classification based on disease severity that corresponds with treatment step; (4) differentiation between difficult-to-treat and poorly controlled asthma; (5) an open-ended approach to pharmacological management; and (6) allergen immunotherapy (AIT) in mild- to moderate-persistent asthma. CONCLUSIONS: The updated "Guidelines for the diagnosis and optimal management of asthma in children (2016)" combine the latest national and international clinical evidence and experience to provide practical and reliable recommendations to Chinese clinicians</style></abstract><notes><style face="normal" font="default">IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1396474</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29227721">PM:29227721</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171204-HongJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171204-HongJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Hong J</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1396474</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43531</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mallol,J.</style></author><author><style face="normal" font="default"> Sole,D.</style></author><author><style face="normal" font="default"> Aguirre,V.</style></author><author><style face="normal" font="default"> Chong,H.</style></author><author><style face="normal" font="default"> Rosario,N.</style></author><author><style face="normal" font="default"> Garcia-Marcos,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatric Respiratory Medicine , Hospital El Pino, University of Santiago de Chile (USACH) , Santiago , Chile</style></auth-address><titles><title><style face="normal" font="default">Changes in the prevalence and severity of recurrent wheezing in infants: The results of two surveys administered 7 years apart</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="12" Year="2017">2017/12/12</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To identify changes in the prevalence and severity of recurrent wheezing (RW) in infants using data obtained from two surveys administered seven years apart. METHODS: A cross-sectional, international, population-based study in infants aged 12-15 months was conducted. Data were obtained from two surveys (S1 and S2, in 2005 and 2012, respectively) using the same methodology in three large Latin American cities: Curitiba (Brazil), Sao Paulo (Brazil), and Santiago (Chile). RESULTS: A decrease in the overall prevalence of RW was identified between S1 (23.3%) and S2 (20.4%), p = 0.004, but it was mainly driven by the reduction observed in Sao Paulo; in Curitiba and Santiago, this change was not significant. The mean prevalence of the following RW severity indicators remained high and stable: severe wheezing episodes (56.9% in S1 and 54.2% in S2, p = 0.32) and emergency department (ED) visits for wheezing (S1 = 68.1%, S2 70.9%, p = 0.21). A significant increase in admissions for wheezing (21.1% to 26.7%, p = 0.004) was observed. In Curitiba and Sao Paulo, there were significant increases in the prevalence of physician-diagnosed asthma and in the use of inhaled corticosteroids and oral antileukotrienes. CONCLUSIONS: The prevalence and severity of RW during the first year of life remained high over time, with remarkably high rates of ED visits, admissions for wheezing and use of asthma medications. This study suggests the need for considering early asthma diagnosis and to establish an appropriate treatment in infants with recurrent and severe asthma-like symptoms</style></abstract><notes><style face="normal" font="default">IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Chile -CO - Brazil -CO - Spain -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1403625</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29231772">PM:29231772</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171204-MallolJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171204-MallolJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Mallol J</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1403625</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43532</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Orellano,P.</style></author><author><style face="normal" font="default"> Quaranta,N.</style></author><author><style face="normal" font="default"> Reynoso,J.</style></author><author><style face="normal" font="default"> Balbi,B.</style></author><author><style face="normal" font="default"> Vasquez,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) , Buenos Aires , Argentina</style></auth-address><titles><title><style face="normal" font="default">Association of outdoor air pollution with the prevalence of asthma in children of Latin America and the Caribbean: A systematic review and meta-analysis</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="12" Year="2017">2017/12/6</year></dates><abstract><style face="normal" font="default">OBJECTIVE: This study aimed to evaluate the association between asthma prevalence and outdoor air pollution in children in Latin America and the Caribbean. DATA SOURCES: We searched studies in global and regional databases: PubMed, Scopus, LILACS and SciELO. STUDY SELECTION: Articles following a cross-sectional design, studying children from 0 to 18 years old, and comparing the prevalence of asthma in two or more areas of LAC countries with different air pollution levels were included. The exclusion criteria comprised air pollution not related to human activities. RESULTS: Database searches retrieved 384 records, while 20 studies were retained for qualitative and 16 for quantitative analysis, representing 48 442 children. We found a positive association, i.e. a higher prevalence of asthma in children living in a polluted environment, with pooled odds ratio (OR) of 1.34 (95% CI: 1.17-1.54). Heterogeneity between studies was moderate (I(2): 68.39%), while the risk of bias was intermediate or high in 14 studies. In all the subgroup and sensitivity analyses, the pooled ORs were significant and higher than those found in the general analysis Conclusions: Our results showed that living in a polluted environment is significantly associated with children having asthma in LAC. Limitations of this study include the low number of studies performed in LAC countries, differences in methodologies and the risk of bias in individual studies</style></abstract><notes><style face="normal" font="default">IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Argentina -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1402342</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29211546">PM:29211546</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171204-OrellanoP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171204-OrellanoP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Orellano P</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1402342</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43533</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arikoglu,T.</style></author><author><style face="normal" font="default"> Unlu,A.</style></author><author><style face="normal" font="default"> Yildirim,D.D.</style></author><author><style face="normal" font="default"> Kuyucu,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatric Allergy and Immunology, Faculty of Medicine , Mersin University , Mersin , Turkey</style></auth-address><titles><title><style face="normal" font="default">The airway hyperresponsiveness to methacholine may be predicted by impulse oscillometry and plethysmography in children with well-controlled asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="12" Year="2017">2017/12/12</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Airway hyperresponsiveness (AHR) is a hallmark of asthma. Methacholine challenge test which is mostly used to confirm AHR is not routinely available. The aim of this study was to investigate the predictive values of fractional exhaled nitric oxide (FeNO), impulse oscillometry (IOS), and plethysmography for the assessment of AHR in children with well-controlled asthma. METHODS: 60 children with controlled allergic asthma aged 6-18 years participated in the study. FeNO measurement, spirometry, IOS, and plethysmography were performed. Methacholine challenge test was done to assess AHR. PC20 and dose response slope (DRS) of methacholine was calculated. RESULTS: Mild to severe AHR with PC20 &lt; 4 mg/ml was confirmed in 31 (51.7%) patients. Baseline FeNO and total specific airway resistance (SRtot)%pred and residual volume (RV)%pred levels in plethysmography were significantly higher and FEV1%pred, FEV1/FVC%pred, MMEF%pred values were lower in the group with PC20 &lt; 4 mg/ml. FeNO, SRtot%pred, and RV%pred levels were found to be positively correlated with DRS methacholine. The higher baseline FeNO, frequency dependence of resistance (R5-R20) in IOS and SRtot%pred in plethysmography were found to be significantly related to DRS methacholine in linear regression analysis (beta: 1.35, p = 0.046, beta: 4.58, p = 0.002, and beta: 0.78, p = 0.035, respectively). The cut-off points for FeNO and SRtot% for differentiating asthmatic children with PC20 &lt; 4 mg/ml from those with PC20 >/= 4 mg/ml were 28 ppb (sensitivity: 67.7%, specificity: 72.4%, p &lt; 0.001) and 294.9% (sensitivity: 35.5%, specificity: 96.6%, p = 0.013), respectively. CONCLUSION: IOS and plethysmography may serve as reliable and practical tools for prediction of mild to severe methacholine induced AHR in otherwise "seemingly well-controlled'' asthma</style></abstract><notes><style face="normal" font="default">IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1407337</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29231775">PM:29231775</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171204-ArikogluT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171204-ArikogluT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Arikoglu T</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1407337</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43534</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Allen,E.D.</style></author><author><style face="normal" font="default"> Arcoleo,K.</style></author><author><style face="normal" font="default"> Rowe,C.</style></author><author><style face="normal" font="default"> Long,W.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Physician Lead, Asthma Quality Improvement, Nationwide Children's Hospital , Division of Pulmonary Medicine , Columbus , OH , USA</style></auth-address><titles><title><style face="normal" font="default">Implementation of a "real world" School-Based Asthma Therapy program targeting urban children with poorly controlled asthma</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="11" Year="2017">2017/11/30</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Describe implementation and clinical impact of a "real world" School-Based Asthma Therapy (SBAT) Program serving an urban, largely Medicaid population in a large midwestern city in the United States. METHODS: A retrospective, descriptive evaluation of SBAT was conducted. Students were referred by school nurses or providers, enrolled throughout the year, and could reenroll in subsequent years. A total of 286 students participated in the 2015-2016 school year. Kruskal-Wallis nonparametric testing compared Asthma Control Test (ACT) scores from enrollment (anytime between 2013 and 2015) to 2015-2016 for 198 students; and pre- and postenrollment asthma-related emergency department (ED), inpatient, and critical care (pediatric intensive care unit or PICU) utilization rates (events/student/year) for 98 students enrolled for a full year. RESULTS: SBAT participation grew from 17 to 131 schools and from 38 to 268 students between 2013-2014 and 2015-2016. Mean ACT scores increased from 16.2 (SD = 4.89) to 21.37 (SD = 3.41) (K-W chi(2) = 35.45, p = 0.008). Healthcare utilization rates from 1-year preenrollment to 1-year postenrollment decreased for ED (0.91-0.44; K-W chi(2) = 18.61, p = 0.0002) and Inpatient (0.38-0.10; K-W chi(2) = 7.68, p = 0.02). Reduction in PICU (0.27-0.02) was not statistically significant. CONCLUSIONS: SBAT, modeled after programs shown in controlled trials to improve asthma health markers ( 1-3 ), was successfully implemented in economically challenged, urban schools. Rapid growth and patient reenrollment reflect program acceptance by schools, providers, and caregivers. Improved ACT scores and healthcare utilization supported program efficacy. SBAT could be one solution to improved asthma control in underserved school-aged pediatric patients</style></abstract><notes><style face="normal" font="default">IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1396472</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29190172">PM:29190172</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma\20171204-AllenED.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma\20171204-AllenED.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Allen ED</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1396472</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43535</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brussino,L.</style></author><author><style face="normal" font="default"> Solidoro,P.</style></author><author><style face="normal" font="default"> Rolla,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy and Clinical Immunology, University of Torino and Mauriziano Hospital</style></auth-address><titles><title><style face="normal" font="default">Is it severe asthma or asthma with severe comorbidities?</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="305" start="303">303-305</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Severe asthma is defined as asthma that requires treatment with high-dose inhaled corticosteroids (ICSs) plus a second controller and/or systemic corticosteroids to prevent it from becoming uncontrolled or that remains uncontrolled despite this therapy. This definition has limitations: 1) it does not define any biological characteristic that distinguishes severe asthma from asthma in general and 2) it relies on the clinical interpretation of asthma symptoms that are not specific. Actually, wheezing, dyspnea, cough and chest tightness may be caused by the comorbidities (such as rhinosinusitis, obesity and vocal cord dysfunction [VCD]) which are associated with asthma. In clinical practice, clinicians are often prone to diagnose uncontrolled asthma and increase doses of ICSs without considering the comorbidities, resulting in poor control of symptoms. This commentary wishes the clinicians to focus on the comorbidities of asthma, particularly in patients with severe asthma, because the correct diagnosis of these comorbidities implies specific treatments that lead to a better asthma control</style></abstract><notes><style face="normal" font="default">IS - 1178-6965 (Print)IS - 1178-6965 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.2147/JAA.S150462</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29238208">PM:29238208</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-303-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2017-10-303-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171129, Brussino L</style></custom2><misc3><style face="normal" font="default">10.2147/JAA.S150462</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43536</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fernandes,S.S.C.</style></author><author><style face="normal" font="default"> Andrade,C.R.</style></author><author><style face="normal" font="default"> Alvim,C.G.</style></author><author><style face="normal" font="default"> Camargos,P.A.M.</style></author><author><style face="normal" font="default"> Ibiapina,C.D.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">. Departamento de Pediatria, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte (MG) Brasil</style></auth-address><titles><title><style face="normal" font="default">Epidemiological trends of allergic diseases in adolescents</style></title><secondary-title><style face="normal" font="default">J Bras Pneumol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Bras Pneumol</style></abbr-1></periodical><pages end="372" start="368">368-372</pages><volume><style face="normal" font="default">43</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To assess the prevalences of asthma, allergic rhinitis, and allergic rhinoconjunctivitis in adolescents in the city of Belo Horizonte, Brazil, in 2012 by administering the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire, as well as to compare the observed prevalences with those found in studies performed 10 years earlier and employing the same methodology used here. METHODS: This was a cross-sectional study conducted between May and December of 2012 and involving adolescents in the 13- to 14-year age bracket. Participants were randomly selected from among adolescents studying at public schools in Belo Horizonte and completed the ISAAC questionnaire. Proportions were calculated in order to assess the prevalences of asthma, allergic rhinitis, and allergic rhinoconjunctivitis in the sample as a whole, and the chi-square goodness-of-fit test was used in order to compare the prevalences observed in 2012 with those found in 2002. RESULTS: The prevalences of symptoms of asthma, allergic rhinitis, and allergic rhinoconjunctivitis in 2012 were 19.8%, 35.3%, and 16.3%, respectively, being significantly higher than those found in 2002 (asthma, p = 0.006; allergic rhinitis, p &lt; 0.01; and allergic rhinoconjunctivitis, p = 0.002). CONCLUSIONS: The prevalences of asthma, allergic rhinitis, and allergic rhinoconjunctivitis among adolescents in 2012 were found to be high, having increased in comparison with those found 10 years earlier, despite efforts in prevention, diagnosis, and treatment</style></abstract><notes><style face="normal" font="default">IS - 1806-3756 (Electronic)IS - 1806-3713 (Linking)LA - engLA - porPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1590/s1806-37562016000000255</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29160383">PM:29160383</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Bras Pneumol\2017-43-368-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Bras Pneumol\2017-43-368-72.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171130, Fernandes SS</style></custom2><misc3><style face="normal" font="default">10.1590/s1806-37562016000000255</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43537</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Choi,H.</style></author><author><style face="normal" font="default"> Kim,D.J.</style></author><author><style face="normal" font="default"> Nam,S.</style></author><author><style face="normal" font="default"> Lim,S.</style></author><author><style face="normal" font="default"> Hwang,J.S.</style></author><author><style face="normal" font="default"> Park,K.S.</style></author><author><style face="normal" font="default"> Hong,H.S.</style></author><author><style face="normal" font="default"> Won,Y.</style></author><author><style face="normal" font="default"> Shin,M.K.</style></author><author><style face="normal" font="default"> Chung,E.</style></author><author><style face="normal" font="default"> Son,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Genetic Engineering, College of Life Science and Graduate School of Biotechnology, Yong In 446-701, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Substance P restores normal skin architecture and reduces epidermal infiltration of sensory nerve fiber in TNCB-induced atopic dermatitis-like lesions in NC/Nga mice</style></title><secondary-title><style face="normal" font="default">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="12" Year="2017">2017/12/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by intense pruritus and eczematous lesion. Substance P (SP) is an 11-amino-acid endogenous neuropeptide that belongs to the tachykinin family and several reports recently have supported the anti-inflammatory and tissue repairing roles of SP. OBJECTIVE: In this study, we investigated whether SP can improve AD symptoms, especially the impaired skin barrier function, in 2, 4, 6-trinitrochlorobenzene (TNCB)-induced chronic dermatitis of NC/Nga mice or not. METHOD: AD-like dermatitis was induced in NC/Nga mice by repeated sensitization with TNCB for 5 weeks. The experimental group designations and topical treatments were as follows: vehicle group (AD-VE); SP group (AD-SP); and SP with NK1R antagonist CP99994 (AD-SP-A) group. Histological analysis was performed to evaluate epidermal differentiation, dermal integrity, and epidermal nerve innervation in AD-like lesions. The skin barrier functions and pruritus of NC/Nga mice were evaluated by measuring transepidermal water loss (TEWL) and scratching behavior, respectively. RESULT: Topical SP treatment resulted in significant down-regulation of Ki67 and the abnormal-type keratins (K) K6, K16, and K17, restoration of filaggrin and claudin-1, marked reduction of TEWL, and restoration of basement membrane and dermal collagen deposition, even under continuous sensitization of low dose TNCB. In addition, SP significantly reduced innervation of itch-evoking nerve fibers, gelatinase activity and nerve growth factor (NGF) expression in the epidermis but upregulated semaphorin-3A (Sema3A) expression in the epidermis, along with reduced scratching behavior in TNCB-treated NC/Nga mice. All of these effects were completely reversed by co-treatment with the NK1R antagonist CP99994. In cultured human keratinocytes, SP treatment reduced expression of TGF-alpha, but upregulated TGF-beta and Sema3A. CONCLUSION: Topically administered SP can restore normal skin barrier function, reduce epidermal infiltration of itch-evoking nerve fibers in the AD-like skin lesions, and alleviate scratching behavior. Thus, SP may be proposed as a potential medication for chronic dermatitis and AD</style></abstract><notes><style face="normal" font="default">IS - 1873-569X (Electronic)IS - 0923-1811 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.jdermsci.2017.11.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29269174">PM:29269174</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatol Sci\20171201-ChoiH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatol Sci\20171201-ChoiH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Choi H</style></custom2><misc3><style face="normal" font="default">10.1016/j.jdermsci.2017.11.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43538</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Huet,F.</style></author><author><style face="normal" font="default"> Severino-Freire,M.</style></author><author><style face="normal" font="default"> Cheret,J.</style></author><author><style face="normal" font="default"> Gouin,O.</style></author><author><style face="normal" font="default"> Praneuf,J.</style></author><author><style face="normal" font="default"> Pierre,O.</style></author><author><style face="normal" font="default"> Misery,L.</style></author><author><style face="normal" font="default"> Le Gall-Ianotto,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Western Brittany, Laboratory Interactions Neurons-Keratinocytes (LINK), Brest, France</style></auth-address><titles><title><style face="normal" font="default">Reconstructed human epidermis for in vitro studies on atopic dermatitis: A review</style></title><secondary-title><style face="normal" font="default">J Dermatol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="12" Year="2017">2017/12/1</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a chronic inflammatory skin disease causing a strong impact on quality of life. Its pathophysiology is the result of complex interactions involving immunological, genetic and environmental factors. Although there are several published in vitro three-dimensional models mimicking AD, none of them have taken all these pathophysiological features into account; thus, finding the right model may be complicated. This paper reviews the literature on the different reconstructed epidermis models of AD as well as their relevance. We focused our attention on both the defect of the epidermal barrier and the inflammation linked to the immune system</style></abstract><notes><style face="normal" font="default">IS - 1873-569X (Electronic)IS - 0923-1811 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jdermsci.2017.11.015</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29248403">PM:29248403</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatol Sci\20171201-HuetF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatol Sci\20171201-HuetF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Huet F</style></custom2><misc3><style face="normal" font="default">10.1016/j.jdermsci.2017.11.015</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43539</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vigano,S.</style></author><author><style face="normal" font="default"> Trabanelli,S.</style></author><author><style face="normal" font="default"> Indulsi,F.</style></author><author><style face="normal" font="default"> Salome,B.</style></author><author><style face="normal" font="default"> Harari,A.</style></author><author><style face="normal" font="default"> Romero,P.</style></author><author><style face="normal" font="default"> Helbling,A.</style></author><author><style face="normal" font="default"> Jandus,C.</style></author><author><style face="normal" font="default"> Jandus,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Experimental Therapeutics, Department of Oncology, Faculty of Biology and Medicine, University of Lausanne, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Dysregulated Innate Lymphocytes in Patients With Primary Antibody Deficiency Treated With Intravenous Immunoglobulin</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="396" start="394">394-396</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0200</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29199969">PM:29199969</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-378-96.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-378-96.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Vigano S</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0200</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43540</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Erfurt-Berge,C.</style></author><author><style face="normal" font="default"> Mahler,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University Hospital Erlangen, Erlangen, Germany</style></auth-address><titles><title><style face="normal" font="default">Contact Sensitization in Patients With Lower Leg Dermatitis, Chronic Venous Insufficiency, and/or Chronic Leg Ulcer: Assessment of the Clinical Relevance of Contact Allergens</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="380" start="378">378-380</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0188</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29199962">PM:29199962</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-378-96.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-378-96.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Erfurt-Berge C</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0188</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43541</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arribas,F.</style></author><author><style face="normal" font="default"> Falkencrone,S.</style></author><author><style face="normal" font="default"> Sola,J.</style></author><author><style face="normal" font="default"> Gomez-Serranillos,M.P.</style></author><author><style face="normal" font="default"> Laguna,J.J.</style></author><author><style face="normal" font="default"> Montanez,M.I.</style></author><author><style face="normal" font="default"> Fernandez,T.D.</style></author><author><style face="normal" font="default"> Rodriguez,D.</style></author><author><style face="normal" font="default"> Pineda,F.</style></author><author><style face="normal" font="default"> Skov,P.S.</style></author><author><style face="normal" font="default"> Mayorga,C.</style></author><author><style face="normal" font="default"> Torres,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Diater Laboratorios, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Basophil Histamine Release Induced by Amoxicilloyl-poly-L-lysine Compared With Amoxicillin in Patients With IgE-Mediated Allergic Reactions to Amoxicillin</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="362" start="356">356-362</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: Amoxicillin (AX) is the ss-lactam most often involved in IgE-mediated reactions. Diagnosis is based mainly on skin testing, although sensitivity is not optimal. We produced a new AX derivative, amoxicilloyl-poly-L-lysine (APL), and analyzed its recognition of IgE using the passive histamine release test (pHRT). METHODS: The study population comprised patients (n=19) with confirmed AX allergy and specific IgE to AX and controls (n=10) with good tolerance to AX. pHRT was performed using "IgE-stripped" blood from a single donor that was sensitized in vitro by patient sera and incubated with AX or APL. Histamine release was determined and expressed as nanograms of histamine released per milliliter of blood. RESULTS: The clinical symptoms were anaphylaxis (n=9), urticaria (n=7), erythema (n=2), and nondefined immediate reactions (n=1). The median (IQR) time interval between reaction and study was 90 (60-240) days and between drug intake and development of symptoms 24 (10-60) minutes. The median sIgE level was 3.37 (0.95-5.89) kUA/L. The sensitivity of pHRT to APL was 79% and the specificity 100%, which were higher than data obtained with pHRT to AX (63% sensitivity and 90% specificity). There was a positive correlation between maximal histamine release levels obtained with AX and APL (r=0.63). CONCLUSIONS: In patients with immediate hypersensitivity reactions to AX, APL showed higher sensitivity and specificity than the culprit drug, AX, when tested in vitro by pHRT. This indicates that APL can improve the in vitro diagnostic accuracy of allergic reactions to AX. Further assessment of skin testing is necessary</style></abstract><notes><style face="normal" font="default">IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0180</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28628008">PM:28628008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-356-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-356-62.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Arribas F</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0180</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43542</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jurado-Escobar,R.</style></author><author><style face="normal" font="default"> Perkins,J.R.</style></author><author><style face="normal" font="default"> Garcia-Martin,E.</style></author><author><style face="normal" font="default"> Isidoro-Garcia,M.</style></author><author><style face="normal" font="default"> Dona,I.</style></author><author><style face="normal" font="default"> Torres,M.J.</style></author><author><style face="normal" font="default"> Cornejo-Garcia,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Laboratory, IBIMA, Regional University Hospital of Malaga, UMA, Malaga, Spain</style></auth-address><titles><title><style face="normal" font="default">Update on the Genetic Basis of Drug Hypersensitivity Reactions</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="345" start="336">336-345</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Drug hypersensitivity reactions (DHRs) are unpredictable, complex responses to medicines in predisposed individuals. They represent a major health problem owing to the number of patients affected and the severity of the clinical conditions they can induce. In addition to environmental factors, the underlying mechanisms of DHRs are also influenced by genetic factors, although considerable gaps remain in our knowledge. Therefore, further study of the genetics of DHRs is necessary to shed light on their underlying mechanisms. In this manuscript, we provide an update on the genetic basis of the most frequent types of DHRs, including those mediated by immunological and nonimmunological mechanisms. For the first group, we will focus on immediate reactions to beta-lactam antibiotics, which are associated mainly with the IgE pathway (IL13, IL4R, LGALS3, and NOD2) and antigen presentation (HLA-DRA), and nonimmediate reactions to allopurinol, anticonvulsants, antibiotics, and antiretrovirals, which are often associated with polymorphisms in the HLA system. For the second group, we will focus on nonsteroidal anti-inflammatory drugs, which are mostly associated with genetic variants in enzymes and receptors from the arachidonic acid pathway (eg, ALOX5, ALOX5AP, PTGDR, and CYSLTR1). The information provided here will be of interest for medical practitioners from a range of disciplines who come across these reactions in their clinical practice, as well as for allergologists</style></abstract><notes><style face="normal" font="default">IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0199</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29199960">PM:29199960</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-336-45.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-336-45.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Jurado-Escobar R</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0199</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43543</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lopez-Rodriguez,J.C.</style></author><author><style face="normal" font="default"> Benede,S.</style></author><author><style face="normal" font="default"> Barderas,R.</style></author><author><style face="normal" font="default"> Villalba,M.</style></author><author><style face="normal" font="default"> Batanero,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departamento de Bioquimica y Biologia Molecular I, Facultad de Ciencias Quimicas, Universidad Complutense, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">Airway Epithelium Plays a Leading Role in the Complex Framework Underlying Respiratory Allergy</style></title><secondary-title><style face="normal" font="default">J Investig Allergol Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Investig Allergol Clin Immunol</style></full-title></periodical><pages end="355" start="346">346-355</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Airway epithelium is the cellular structure with the greatest surface exposed to a plethora of environmental airborne substances, including microorganisms, respiratory viruses, air pollutants, and allergens. In addition to being a protective physical barrier at the air-liquid interface, the airway epithelium acts as an effective chemical and immunological barrier that plays a crucial role in orchestrating the immune response in the lungs, by supporting the activation, recruitment, and mobilization of immune cells. Airway epithelium dysfunction has been clearly associated with various airway inflammatory diseases, such as allergic asthma. Although it is not fully understood why a person develops respiratory allergy, a growing body of evidence shows that the nature of the host's immune response is strongly determined by the state of the airway epithelium at the time of contact with the inhaled allergen. Our review highlights the physiological state of airway epithelium as a key element in the development of allergy and, particularly, in exacerbation of asthma. We review the role of physiological oxidants as signaling molecules in lung biology and allergic diseases and examine how high exposure to air pollutants (eg, cigarette smoke and diesel particles) can contribute to the increased incidence of respiratory allergy and exacerbation of the disease</style></abstract><notes><style face="normal" font="default">IS - 1018-9068 (Print)IS - 1018-9068 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Spain -</style></notes><work-type><style face="normal" font="default">10.18176/jiaci.0201</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29199961">PM:29199961</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-346-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Investig Allergol Clin Immunol\2017-27-346-55.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Lopez-Rodriguez JC</style></custom2><misc3><style face="normal" font="default">10.18176/jiaci.0201</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43544</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bedolla-Barajas,M.</style></author><author><style face="normal" font="default"> Machuca-Rincon,M.L.</style></author><author><style face="normal" font="default"> Morales-Romero,J.</style></author><author><style face="normal" font="default"> Mariz-Romero,N.</style></author><author><style face="normal" font="default"> Madrigal-Beas,I.M.</style></author><author><style face="normal" font="default"> Robles-Figueroa,M.</style></author><author><style face="normal" font="default"> Bedolla-Pulido,T.R.</style></author><author><style face="normal" font="default"> Gonzalez-Mendoza,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hospital Civil de Guadalajara "Dr. Juan I. Menchaca", Servicio de Alergia e Inmunologia Clinica, Guadalajara, Jalisco, Mexico.</style></auth-address><titles><title><style face="normal" font="default">[Self-reported prevalence of latex allergy and associated factors in healthcare workers]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="438" start="430">430-438</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: In our country, the prevalence of latex allergy in health personnel has rarely been studied. OBJECTIVE: To determine the prevalence and associated factors to self-reported latex allergy in health care workers. METHODS: A cross-sectional study was conducted among 1,292 health care workers of a second level hospital. All workers were included and they were required to answer a structured questionnaire aimed at identifying latex allergy, atopic personal and family history, exposure to latex gloves and surgical background. Odds ratio (OR) and 95 % confidence interval (95 % CI) were estimated using regression logistic to investigate factors associated to latex allergy. RESULTS: The female to male ratio was 2.4:1. The men age 38.4 +/- 11.6 years. The prevalence of latex allergy auto-reported was 9.7 %, with a confidence interval of 95 % (95 % CI) 8.1 %-11.3 %. There was no statistical difference by workplace (p = 0.508). Factors associated with latex allergy included female gender (OR = 1.68; 95 % CI: 1.03-2.73, p = 0.037), personal history of atopy (OR = 4.82; 95 % CI: 3.19-7.26, p &lt; 0.0001), family history of atopic dermatitis (OR = 4.33, 95 % CI: 1.20-4.41) and history of allergy to fruits (OR = 4.33; 95 % CI: 2.62-7.14, p &lt; 0.0001). CONCLUSIONS: Up to 10 out to 100 health workers may have latex allergy. The main factors associated with latex allergy in this study were: being a female, personal or familiar atopy and allergy to fruits</style></abstract><notes><style face="normal" font="default">IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="default">10.29262/ram.v64i4.289</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29249105">PM:29249105</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-430-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-430-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171208, Bedolla-Barajas M</style></custom2><misc3><style face="normal" font="default">10.29262/ram.v64i4.289</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43545</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cherrez-Ojeda,I.</style></author><author><style face="normal" font="default"> Plaza,K.</style></author><author><style face="normal" font="default"> Cano,J.A.</style></author><author><style face="normal" font="default"> Calderon,J.C.</style></author><author><style face="normal" font="default"> Cherrez,A.</style></author><author><style face="normal" font="default"> Baptist,A.</style></author><author><style face="normal" font="default"> Calero,E.</style></author><author><style face="normal" font="default"> Hoyos,R.</style></author><author><style face="normal" font="default"> Beltran,P.</style></author><author><style face="normal" font="default"> Cruz,V.</style></author><author><style face="normal" font="default"> Ramon,G.</style></author><author><style face="normal" font="default"> Simancas,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiralab, Research Group. Guayaquil, Ecuador.</style></auth-address><titles><title><style face="normal" font="default">[Does Ecuadorians with asthma has preferences in the use of information and communication technologies? Pilot study]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="414" start="403">403-414</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Inadequate communication between asthmatic patients and their physicians may interfere directly with asthma control. In the last years, the use of information and communication technologies (ICTs) it has increased in Latin-America. This technology seems to be a good tool to improve communication and management of the asthmatic patient. OBJECTIVE: We evaluated the frequency and preference patterns of communication and information technologies in Ecuadorian patients with bronchial asthma. METHODS: We conducted a pilot cross-sectional study to identify the frequency and preferences of ICT in patients with asthma. The Spanish version of the Michigan questionnaire was used. Age and educational level were categorized into 3 groups. We used logistic regression between these groups regarding the frequency of use, interest in seeking and receiving information related to their asthma for the age and educational level of the patients. RESULTS: A total of 222 patients participated in our study. The mean age was 45.6 years (SD 17.4), the most common sex was female with 89.25 %. Almost all patients had a cell phone (87.5 %) and internet access (62.7 %). The three ICTs most likely to be used to search for or receive information about their illness were WhatsApp, Facebook and email (p &lt;0.05). CONCLUSION: Information and communication technologies improve the care of asthmatic patients. In our pilot study email and text messages are the most preferred ICT among patients however WhatsApp and Facebook may be appropriate for certain ages especially young asthmatic. Knowledge of preferences can help the development of ICT in a personalized way and improve the outcomes in patients with asthma</style></abstract><notes><style face="normal" font="default">IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Ecuador -</style></notes><work-type><style face="normal" font="default">10.29262/ram.v64i4.277</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29249103">PM:29249103</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-403-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Alerg Mex\2017-64-403-14.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171208, Cherrez-Ojeda I</style></custom2><misc3><style face="normal" font="default">10.29262/ram.v64i4.277</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43546</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Park,Y.J.</style></author><author><style face="normal" font="default"> Dalal,P.G.</style></author><author><style face="normal" font="default"> Mostert,M.</style></author><author><style face="normal" font="default"> Fausnight,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Departments of Anesthesiology and Perioperative Medicine and Pediatrics, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania</style></auth-address><titles><title><style face="normal" font="default">Allergic Reaction Caused by a Lip Balm-Flavored Facemask Used During Inhalational Induction: A Case Report</style></title><secondary-title><style face="normal" font="default">A A Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">A A Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="12" Year="2017">2017/12/11</year></dates><abstract><style face="normal" font="default">Flavoring a facemask with a lip balm for inhalational induction in children is a common practice. However, most anesthesia providers are unaware of potential complications and the management of allergic reactions caused by lip balm. We describe the occurrence of allergic reaction to lip balm-flavored facemask in a child who underwent an inhalational anesthetic induction. The facial rash resolved completely without complications after administration of an antihistamine and steroid.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal</style></abstract><notes><style face="normal" font="default">IS - 2325-7237 (Electronic)IS - 2325-7237 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.1213/XAA.0000000000000686</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29240018">PM:29240018</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\A A Case Rep\20171211-ParkYJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\A A Case Rep\20171211-ParkYJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171211, Park YJ</style></custom2><misc3><style face="normal" font="default">10.1213/XAA.0000000000000686</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43547</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kornblit,A.</style></author><author><style face="normal" font="default"> Cain,A.</style></author><author><style face="normal" font="default"> Bauman,L.J.</style></author><author><style face="normal" font="default"> Brown,N.</style></author><author><style face="normal" font="default"> Reznik,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY, 10461, USA.</style></auth-address><titles><title><style face="normal" font="default">Barriers to Physical Activity in Urban School Children with Asthma: Parental Perspective</style></title><secondary-title><style face="normal" font="default">Acad Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Acad Pediatr</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="1" Year="2018">2018/1/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Physical activity (PA) levels are low in today's youth and may even be lower in those with asthma. Barriers to PA have not been well studied in inner-city, minority children with asthma. We conducted a qualitative study to characterize parental perceptions of barriers to PA and ways to improve PA levels in children with asthma. METHODS: We used the socio-ecological model (SEM) to inform development of our interview guide. Questions fell into two SEM domains: 1) interpersonal (parent, family) barriers and 2) community (neighborhood, school) barriers. Qualitative semi-structured interviews were conducted with 23 parents (21 mothers, 2 fathers) of inner-city children with asthma (ages 8-10 years) from 10 Bronx, New York (NY) elementary schools. Sampling continued until thematic saturation was reached. Interviews were recorded, transcribed, and independently coded for common themes. Emerging themes were discussed and agreed upon by investigators. RESULTS: Three themes surrounding interpersonal barriers to PA emerged: 1) parental fear of exercise-induced asthma due to lack of child symptom awareness; 2) non-adherence and refusal to take medications; and 3) challenges with asthma management. Four themes around community barriers to PA emerged: 1) lack of trust in school management of asthma; 2) lack of school PA facilities; 3) unsafe neighborhoods, and 4) financial burden of PA. CONCLUSIONS: Our results indicate a complex multi-level set of barriers to PA in children with asthma. Addressing these barriers by involving stakeholders at the family, school and community levels may improve PA levels in children with asthma</style></abstract><notes><style face="normal" font="default">IS - 1876-2867 (Electronic)IS - 1876-2859 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.acap.2017.12.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29309846">PM:29309846</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acad Pediatr\20180105-KornblitA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acad Pediatr\20180105-KornblitA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, Kornblit A</style></custom2><misc3><style face="normal" font="default">10.1016/j.acap.2017.12.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43548</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ennezat,P.V.</style></author><author><style face="normal" font="default"> Bruneval,P.</style></author><author><style face="normal" font="default"> Stephanov,O.</style></author><author><style face="normal" font="default"> Chavanon,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Cardiology , Centre Hospitalier Universitaire de Grenoble-Alpes , France</style></auth-address><titles><title><style face="normal" font="default">Exercise-induced asthma related to aortic regurgitation in ankylosing spondylitis</style></title><secondary-title><style face="normal" font="default">Acta Cardiol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Acta Cardiol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="3" Month="1" Year="2018">2018/1/3</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 0001-5385 (Print)IS - 0001-5385 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1080/00015385.2017.1421420</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29298640">PM:29298640</url></web-urls></urls><custom2><style face="normal" font="default">20180103, Ennezat PV</style></custom2><misc3><style face="normal" font="default">10.1080/00015385.2017.1421420</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43549</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Desager,K.</style></author><author><style face="normal" font="default"> Vermeulen,F.</style></author><author><style face="normal" font="default"> Bodart,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatrics , Hopital Erasme, Universite Libre de Bruxelles (ULB) , Brussels , Belgium</style></auth-address><titles><title><style face="normal" font="default">Adherence to asthma treatment in childhood and adolescence - a narrative literature review</style></title><secondary-title><style face="normal" font="default">Acta Clin Belg</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Acta Clin Belg</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="12" Year="2017">2017/12/11</year></dates><abstract><style face="normal" font="default">OBJECTIVES: We provide a narrative literature review on surveys used to assess the level of medication adherence in children and adolescents with asthma, the attitudes of these patients and their parents toward asthma therapy, and their expectations concerning asthma and available treatment. METHODS: A PubMed search and manual selection of the retrieved papers was conducted to identify studies using surveys or interviews that addressed one of the three topics of interest. RESULTS: Adherence to asthma medication varies across age groups and with the type of measurement used. Levels of 49-71% were observed in children and adolescents by objective measurements. Subjective measurements overestimate the level of adherence compared to objective measurements. A considerable percentage of parents expressed fear of side effects of inhaled corticosteroids, although the impact of these concerns on adherence is unclear. Many adolescents and parents adapt inhaled corticosteroids use according to the prevalence of asthma symptoms, by reducing or eliminating controller medication in the absence of symptoms. Pediatric asthma patients and their parents tend to overestimate the level of asthma control, either by underestimating asthma severity or by assuming that a better control is not possible. The knowledge of parents and adolescents concerning asthma management is suboptimal; moreover, insufficient knowledge about inhaled corticosteroids was linked to poor adherence. CONCLUSION: Medication adherence is crucial for a good control of asthma symptoms. Additional research concerning the triggers of non-adherence is still needed. Educating both the patients and their parents on proper asthma care might improve adherence</style></abstract><notes><style face="normal" font="default">IS - 2295-3337 (Electronic)IS - 1784-3286 (Linking)LA - engPT - Journal ArticleCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.1080/17843286.2017.1409684</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29228891">PM:29228891</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Clin Belg\20171211-DesagerK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Clin Belg\20171211-DesagerK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171211, Desager K</style></custom2><misc3><style face="normal" font="default">10.1080/17843286.2017.1409684</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43550</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wassef,C.</style></author><author><style face="normal" font="default"> Laureano,A.</style></author><author><style face="normal" font="default"> Schwartz,R.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Professor Robert A Schwartz MD, MPH, DSc (Hon), FRCP Edin Dermatology Rutgers New Jersey Medical School, 185 South Orange Avenue H-576, Newark, New Jersey 07103</style></auth-address><titles><title><style face="normal" font="default">Aquagenic Urticaria: A Perplexing Physical Phenomenon</style></title><secondary-title><style face="normal" font="default">Acta Dermatovenerol Croat</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Acta Dermatovenerol Croat</style></full-title></periodical><pages end="237" start="234">234-237</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Aquagenic urticaria (AQ) is a rare physical urticaria induced by contact with water. It may be distinctive clinically, evident as 1-2 mm folliculopapular urticaria, a pattern also characteristic of cholinergic urticaria. AQ has a truncal and upper extremity distribution within 20-30 minutes after contact with water, regardless of its temperature or source. AQ is usually symptomatic with mild to severe pruritus and a burning sensation. The mechanism by which water produces mast cell degranulation and histamine release remains unclear. We review its clinical presentation, diagnostic parameters, differential diagnosis, and treatment</style></abstract><notes><style face="normal" font="default">IS - 1847-6538 (Electronic)IS - 1330-027X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29252177">PM:29252177</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Dermatovenerol Croat\2017-25-234-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Dermatovenerol Croat\2017-25-234-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171223, Wassef C</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43551</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Horev,A.</style></author><author><style face="normal" font="default"> Freud,T.</style></author><author><style face="normal" font="default"> Manor,I.</style></author><author><style face="normal" font="default"> Cohen,A.D.</style></author><author><style face="normal" font="default"> Zvulunov,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Amir Horev, MD, Pediatric dermatology service, Soroka University Medical Center, PO Box 151, Beer-Sheva, Israel</style></auth-address><titles><title><style face="normal" font="default">Risk of Attention-Deficit/Hyperactivity Disorder in Children with Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">Acta Dermatovenerol Croat</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Acta Dermatovenerol Croat</style></full-title></periodical><pages end="214" start="210">210-214</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a common, chronic, inflammatory, pruritic skin disorder that affects up to 20% of the children in Western countries. Attention-Deficit/Hyperactivity disorder (ADHD) has been reported to be more frequent in children with AD. The purpose of this study was to explore the risk for ADHD in our population of patients with AD. A population-based case-control study, using the medical database of Clalit Health Services (CHS), the largest healthcare provider organization in Israel. The study included 840 patients with AD between the age of 0-18 years and 900 age and gender frequency-matched patients without AD. The proportion of ADHD in patients with AD was 7.1% as compared to 4.1% in controls. ADHD was more frequent in boys with AD (9.6% vs. 5.2%, odds ratio (OR) 1.9, 95% confidence interval (CI) 1.1-3.2) but not in girls with AD (4.6% vs. 2.9% OR 1.5). In multivariate analyses, AD was associated with ADHD (OR 2.1, 95% CI 1.3-3.4). The current study demonstrated an association between AD and ADHD. This report and earlier observations emphasize the need for detection and treatment of ADHD in atopic patients</style></abstract><notes><style face="normal" font="default">IS - 1847-6538 (Electronic)IS - 1330-027X (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29252173">PM:29252173</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Dermatovenerol Croat\2017-25-210-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Dermatovenerol Croat\2017-25-210-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171223, Horev A</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43552</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mancuso,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Giuseppe Mancuso, MD, Via Pescantini 33, 48022 Lugo Ravenna, Italy</style></auth-address><titles><title><style face="normal" font="default">Long Lasting Allergic Patch Test Reactions: A Literature Review</style></title><secondary-title><style face="normal" font="default">Acta Dermatovenerol Croat</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Acta Dermatovenerol Croat</style></full-title></periodical><pages end="244" start="238">238-244</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Long-lasting allergic patch test reactions (LLAPTR) are those in which the clinical features of palpable erythema are still present at the site of a positive allergic patch test reaction 14 or more days after application of the allergen. LLAPTR have been described for a wide range of contact allergens, many of these included in the baseline patch test series. LLAPTR are far from uncommon; they occur in consecutive patients with positive patch tests to baseline allergens with frequency up to 17.9% of the total reactions. Patch test reactions persisting for a very long time (up to several months after the test) have been described, the most frequent ones being those induced by gold salts. The pathomechanisms of LLAPTR have not been clarified, but may hypothetically involve a constant antigen stimulation and/or a defect in cell-mediated immunity down-regulation. Host-related factors significantly associated with LLAPTR are, according to some studies, a strong initial patch test response, older age, and atopy. No significant sex differences have been observed in the frequency of LLAPTR</style></abstract><notes><style face="normal" font="default">IS - 1847-6538 (Electronic)IS - 1330-027X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29252178">PM:29252178</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Dermatovenerol Croat\2017-25-238-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Dermatovenerol Croat\2017-25-238-44.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171223, Mancuso G</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43553</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fazlollahi,M.R.</style></author><author><style face="normal" font="default"> Souzanch,G.</style></author><author><style face="normal" font="default"> Nourizadeh,M.</style></author><author><style face="normal" font="default"> Sabetkish,N.</style></author><author><style face="normal" font="default"> Tazesh,B.</style></author><author><style face="normal" font="default"> Entezari,A.</style></author><author><style face="normal" font="default"> Pourpak,Z.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="default">The Prevalence of Allergic Rhinitis and It's Relationship With Second-Hand Tobacco Smoke Among Adults in Iran</style></title><secondary-title><style face="normal" font="default">Acta Med Iran</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Acta Med Iran</style></abbr-1></periodical><pages end="717" start="712">712-717</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">11</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">To determine the prevalence of allergic rhinitis (AR) among adult residents and investigate whether second-hand tobacco smoke (SHS) is correlated with AR as one of the global health problems and one of the most common respiratory disorders reducing the quality of life. A telephone interview survey was conducted by calling 16500 randomly selected telephone numbers from 22 regional telecommunications of Tehran (capital city of Iran) in 2010. A modified European Community Respiratory Health Survey (ECRHS) questionnaire was completed for adults aged between 20 to 44-year-old. Two questions about active smoking and being exposed to SHS were added to the questionnaire. five thousands five hundred cases (76.92%) responded to our calls among 7150 eligible telephone numbers. The gender of study population included 3412 female (62%) and 2088 male (38%) with the mean+/-SD age of 31.15+/-7.33. The prevalence of AR was 26.7%. There were no significant relationship between active smoking and AR; while a significant relationship was detected between SHS and AR among our participants (P=0.02). However, no significant difference was found between men and women. In addition, more than 50% of adults suffering from AR, showed significant symptoms of asthma (P&lt;0.001). The results of the current study revealed that the prevalence of AR was higher in Iran compared to other countries worldwide and SHS may be considered as a serious risk factor for AR</style></abstract><notes><style face="normal" font="default">IS - 1735-9694 (Electronic)IS - 0044-6025 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29307161">PM:29307161</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Acta Med Iran\2017-55-712-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Acta Med Iran\2017-55-712-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171203, Fazlollahi MR</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43554</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gonzalez-Villanueva,I.</style></author><author><style face="normal" font="default"> SIlvestre Salvador,J.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Servicio de Dermatologia, Hospital General Universitario de Alicante - ISABIAL, Alicante, Espana.</style></auth-address><titles><title><style face="normal" font="default">Diagnostic Tools to Use When We Suspect an Allergic Reaction to a Tattoo: A Proposal Based on Cases at Our Hospital</style></title><secondary-title><style face="normal" font="default">Actas Dermosifiliogr</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Actas Dermosifiliogr</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="11" Year="2017">2017/11/29</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Tattooing has become a popular practice in western countries, particularly among younger populations. Tattoos, however, can cause complications, such as infections, allergic or foreign-body reactions, and even systemic inflammatory responses. PATIENTS AND METHODS: We conducted a retrospective study of all patients seen for tattoo-related complications at our skin allergy unit between January 2002 and December 2016. RESULTS: We studied 23 patients. Nine of these experienced early complications, all related to infection. The other 14 patients developed late reactions. Ten were diagnosed with probable allergic contact dermatitis to ink, but the suspect allergen was identified in just 3 cases and confirmed in just 1 of these. There were 2 cases of cutaneous sarcoidosis, 1 case of foreign body granuloma, and 1 case of neuropathy. CONCLUSIONS: Complications resulting from tattoos are relatively common dermatology complaints. Drawing from our experience, we propose a diagnostic algorithm designed to guide dermatologists in evaluating different reactions to tattoos and prescribing appropriate treatment</style></abstract><notes><style face="normal" font="default">IS - 1578-2190 (Electronic)IS - 0001-7310 (Linking)LA - engLA - spaPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.ad.2017.10.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29197467">PM:29197467</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20173028, Gonzalez-Villanueva I</style></custom2><misc3><style face="normal" font="default">10.1016/j.ad.2017.10.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43555</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Larenas Linnemann,D.E.S.</style></author><author><style face="normal" font="default"> Del Rio Navarro,B.E.</style></author><author><style face="normal" font="default"> Luna Pech,J.A.</style></author><author><style face="normal" font="default"> Romero,L.J.</style></author><author><style face="normal" font="default"> Villaverde,R.J.</style></author><author><style face="normal" font="default"> Cano Salas,M.C.</style></author><author><style face="normal" font="default"> Fernandez,V.M.</style></author><author><style face="normal" font="default"> Ortega Martell,J.A.</style></author><author><style face="normal" font="default"> Lopez Estrada,E.C.</style></author><author><style face="normal" font="default"> Mayorga Butron,J.L.</style></author><author><style face="normal" font="default"> Salas,H.J.</style></author><author><style face="normal" font="default"> Vazquez Garcia,J.C.</style></author><author><style face="normal" font="default"> Ortiz,A.I</style></author><author><style face="normal" font="default"> Vargas Becerra,M.H.</style></author><author><style face="normal" font="default"> Bedolla,B.M.</style></author><author><style face="normal" font="default"> Rodriguez,P.N.</style></author><author><style face="normal" font="default"> Aguilar,A.A.</style></author><author><style face="normal" font="default"> Jimenez Gonzalez,C.A.</style></author><author><style face="normal" font="default"> Garcia,B.C.</style></author><author><style face="normal" font="default"> Garrido,G.C.</style></author><author><style face="normal" font="default"> Mendoza Hernandez,D.A.</style></author><author><style face="normal" font="default"> Mendoza,L.E.</style></author><author><style face="normal" font="default"> Lopez,P.G.</style></author><author><style face="normal" font="default"> Wakida Kuzonoki,G.H.</style></author><author><style face="normal" font="default"> Ruiz Gutierrez,H.H.</style></author><author><style face="normal" font="default"> Leon,M.H.</style></author><author><style face="normal" font="default"> Martinez de la Lanza,H.</style></author><author><style face="normal" font="default"> Stone,A.H.</style></author><author><style face="normal" font="default"> Gomez,V.J.</style></author><author><style face="normal" font="default"> Olvera,S.J.</style></author><author><style face="normal" font="default"> Oyoqui Flores,J.J.</style></author><author><style face="normal" font="default"> Galvez Romero,J.L.</style></author><author><style face="normal" font="default"> Lozano Saenz,J.S.</style></author><author><style face="normal" font="default"> Salgado Gama,J.I.</style></author><author><style face="normal" font="default"> Jimenez Chobillon,M.A.</style></author><author><style face="normal" font="default"> Garcia Aviles,M.A.</style></author><author><style face="normal" font="default"> Guinto Balanzar,M.P.</style></author><author><style face="normal" font="default"> Medina Avalos,M.A.</style></author><author><style face="normal" font="default"> Camargo,A.R.</style></author><author><style face="normal" font="default"> Garcia,T.R.</style></author><author><style face="normal" font="default"> Toral,F.S.</style></author><author><style face="normal" font="default"> Montes,N.G.</style></author><author><style face="normal" font="default"> Solorio,G.H.</style></author><author><style face="normal" font="default"> Rosas,P.J.</style></author><author><style face="normal" font="default"> Romero Tapia,S.J.</style></author><author><style face="normal" font="default"> Reyes,H.A.</style></author><author><style face="normal" font="default"> Cuevas,S.F.</style></author><author><style face="normal" font="default"> Esquer,F.J.</style></author><author><style face="normal" font="default"> Sacre Hazouri,J.A.</style></author><author><style face="normal" font="default"> Compean,M.L.</style></author><author><style face="normal" font="default"> Medina Sanchez,P.J.</style></author><author><style face="normal" font="default"> Garza,S.S.</style></author><author><style face="normal" font="default"> Baez,L.C.</style></author><author><style face="normal" font="default"> Romero,A.I.</style></author><author><style face="normal" font="default"> Miguel Reyes,J.L.</style></author><author><style face="normal" font="default"> Huerta Espinosa,L.E.</style></author><author><style face="normal" font="default"> Correa Flores,M.A.</style></author><author><style face="normal" font="default"> Castro,M.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Investigational Unit, Hospital Medica Sur, Mexico City, Mexico.</style></auth-address><titles><title><style face="normal" font="default">Recommendations for the prevention and diagnosis of asthma in children: Evidence from international guidelines adapted for Mexico</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="12" Year="2017">2017/12/26</year></dates><abstract><style face="normal" font="default">BACKGROUND: With the availability of high-quality asthma guidelines worldwide, one possible approach of developing a valid guideline, without re-working the evidence, already analysed by major guidelines, is the ADAPTE approach, as was used for the development of National Guidelines on asthma. METHODS: The guidelines development group (GDG) covered a broad range of experts from medical specialities, primary care physicians and methodologists. The core group of the GDG searched the literature for asthma guidelines 2005 onward, and analysed the 11 best guidelines with AGREE-II to select three mother guidelines. Key clinical questions were formulated covering each step of the asthma management. RESULTS: The selected mother guidelines are British Thoracic Society (BTS), GINA and GEMA 2015. Responses to the questions were formulated according to the evidence in the mother guidelines. Recommendations or suggestions were made for asthma treatment in Mexico by the core group, and adjusted during several rounds of a Delphi process, taking into account: 1. Evidence; 2. Safety; 3. Cost; 4. Patient preference - all these set against the background of the local reality. Here the detailed analysis of the evidence present in BTS/GINA/GEMA sections on prevention and diagnosis in paediatric asthma are presented for three age-groups: children with asthma &lt;/=5 years, 6-11 years and >/=12 years. CONCLUSIONS: For the prevention and diagnosis sections, applying the AGREE-II method is useful to develop a scientifically-sustained document, adjusted to the local reality per country, as is the Mexican Guideline on Asthma</style></abstract><notes><style face="normal" font="default">IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Mexico -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.05.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29288048">PM:29288048</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20171226-LarenasLinnemannDE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20171226-LarenasLinnemannDE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171226, Larenas Linnemann DE</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.05.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43556</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kang,Y.</style></author><author><style face="normal" font="default"> Cai,Y.</style></author><author><style face="normal" font="default"> Pan,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical School, Kunming University of Science and Technology, Kunming, Yunnan, China.</style></auth-address><titles><title><style face="normal" font="default">Change in gut microbiota for eczema: Implications for novel therapeutic strategies</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="12" Year="2017">2017/12/23</year></dates><abstract><style face="normal" font="default">Eczema is one of the most common inflammatory diseases, often constituting a lifelong burden for afflicted individuals. The complex interaction of host genetic and multiple environmental factors contribute to its pathogenesis. A relationship between maladjustment of gut microbiota and eczema has been brought into the light of day in most previous studies. In eczema preclinical models, specific intestinal microbial species have been demonstrated to prohibit or dwindle immune responsiveness, indicating that these strains among commensal gut bacteria may exert either a morbific or phylactic function in eczema progression. As such, oral probiotics can serve as a medicinal approach for eczema therapy. Given that relative scientific work is still at the early stage, only limited data are available in the field. New sequencing techniques have been fortunately performed to gain access to an extended research on the relationship between gut bacterial flora and human diseases. In the current review, we identified the role of intestinal microbiota in the development of eczema and how specific bacterial strains adjust the immune responsiveness in the midst of disease progression. Probiotics as an applicable treatment for eczema were evaluated in other threads as well</style></abstract><notes><style face="normal" font="default">IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.05.010</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29279259">PM:29279259</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20171224-KangY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20171224-KangY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171224, Kang Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.05.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43557</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Castro-Rodriguez,J.A.</style></author><author><style face="normal" font="default"> Atton,I.</style></author><author><style face="normal" font="default"> Villarroel,G.</style></author><author><style face="normal" font="default"> Serrano,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pediatrics, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile.</style></auth-address><titles><title><style face="normal" font="default">Serum periostin is not related to asthma predictive index</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="12" Year="2017">2017/12/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: In contrast to adult asthmatic patients, studies on the role of serum periostin levels in schoolchildren with asthma are still conflictive, and very few studies have been performed in pre-schoolers. The aim of this study was to compare serum periostin levels in recurrent wheezer pre-schoolers according to their asthma predictive index (API) condition. METHODS: We performed a case-control study enrolling pre-schoolers with recurrent wheezing episodes (>3 episodes confirmed by physician) presented at one paediatric clinic in Santiago, Chile. The population was divided according to stringent API criteria into positive or negative. RESULTS: In a one-year period, 60 pre-schoolers were enrolled. After excluding 12 (due to not fulfilment of inclusion criteria or refusal of blood sample extraction), 48 remaining pre-schoolers (27 males, age range from 24 to 71 months) completed the study; 34 were API positive and 14 were API negative. There were no significant differences in demographics between groups. The level of serum periostin levels for pre-schoolers with positive API and negative API were (median 46.7 [25.5-83.1] and 67.5 [20.5-131.8], p=0.9, respectively). The area under the curve for the serum periostin levels for predict positive API was 0.5, 95% CI [0.29-0.70], p=0.9. No significant correlation between serum periostin levels and peripheral blood eosinophils was found. CONCLUSION: Serum periostin levels were no significantly different between wheezer pre-schoolers with positive and negative API. More studies are needed to confirm this finding</style></abstract><notes><style face="normal" font="default">IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Chile -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.05.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29279258">PM:29279258</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20171224-CastroRodriguezJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Immunopathol (Madr)\20171224-CastroRodriguezJA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171224, Castro-Rodriguez JA</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.05.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43558</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gon,Y.</style></author><author><style face="normal" font="default"> Hashimoto,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan. Electronic address: gon.yasuhiro@nihon-u.ac.jpDivision of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">Role of airway epithelial barrier dysfunction in pathogenesis of asthma</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="17" start="12">12-17</pages><volume><style face="normal" font="default">67</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">Bronchial asthma is characterized by persistent cough, increased sputum, and repeated wheezing. The pathophysiology underlying these symptoms is the hyper-responsiveness of the airway along with chronic airway inflammation. Repeated injury, repair, and regeneration of the airway epithelium following exposure to environmental factors and inflammation results in histological changes and functional abnormalities in the airway mucosal epithelium; such changes are believed to have a significant association with the pathophysiology of asthma. Damage to the barrier functions of the airway epithelium enhances mucosal permeability of foreign substances in the airway epithelium of patients with asthma. Thus, epithelial barrier fragility is closely involved in releasing epithelial cytokines (e.g., TSLP, IL-25, and IL-33) because of the activation of airway epithelial cells, dendritic cells, and innate group 2 innate lymphoid cells (ILC2). Functional abnormalities of the airway epithelial cells along with the activation of dendritic cells, Th2 cells, and ILC2 form a single immunopathological unit that is considered to cause allergic airway inflammation. Here we use the latest published literature to discuss the potential pathological mechanisms regarding the onset and progressive severity of asthma with regard to the disruption of the airway epithelial function</style></abstract><notes><style face="normal" font="default">IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.08.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28941636">PM:28941636</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\2018-67-12-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\2018-67-12-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170921, Gon Y</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.08.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43559</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kabashima,K.</style></author><author><style face="normal" font="default"> Izuhara,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, JapanDivision of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan. Electronic address: kizuhara@cc.saga-u.ac.jp</style></auth-address><titles><title><style face="normal" font="default">Barrier dysfunction in allergy</style></title><secondary-title><style face="normal" font="default">Allergol Int</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Int</style></full-title></periodical><pages end="2" start="1">1-2</pages><volume><style face="normal" font="default">67</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1440-1592 (Electronic)IS - 1323-8930 (Linking)LA - engPT - EditorialCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.alit.2017.12.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29291812">PM:29291812</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergol Int\2018-67-1-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergol Int\2018-67-1-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171230, Kabashima K</style></custom2><misc3><style face="normal" font="default">10.1016/j.alit.2017.12.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43560</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tajti,G.</style></author><author><style face="normal" font="default"> Papp,C.</style></author><author><style face="normal" font="default"> Kardos,L.</style></author><author><style face="normal" font="default"> Keki,S.</style></author><author><style face="normal" font="default"> Pak,K.</style></author><author><style face="normal" font="default"> Szilasi,M.E.</style></author><author><style face="normal" font="default"> Gesztelyi,R.</style></author><author><style face="normal" font="default"> Mikaczo,A.</style></author><author><style face="normal" font="default"> Fodor,A.</style></author><author><style face="normal" font="default"> Szilasi,M.</style></author><author><style face="normal" font="default"> Zsuga,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Positive correlation of airway resistance and serum asymmetric dimethylarginine (ADMA) in bronchial asthma patients lacking evidence for systemic inflammation</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Clin Immunol</style></full-title></periodical><pages end="" start="2">2-</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><isbn><style face="normal" font="default">1710-1492</style></isbn><abstract><style face="normal" font="default">Contribution of nitric-oxide (NO) pathway to the pathogenesis of bronchial asthma (asthma) is ambiguous as NO may confer both protective and detrimental effects depending on the NO synthase (NOS) isoforms, tissue compartments and underlying pathological conditions (e.g. systemic inflammation). Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor and uncoupler of NOS with distinct selectivity for NOS isoforms. In a cross-sectional study, we assessed whether ADMA is an independent predictor of airway resistance (Raw) in therapy-controlled asthma</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Hungary -</style></notes><work-type><style face="normal" font="default">10.1186/s13223-017-0226-5</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1186/s13223-017-0226-5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2018-14-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Clin Immunol\2018-14-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180103, Tajti G</style></custom2><misc3><style face="normal" font="default">10.1186/s13223-017-0226-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43561</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stone,B.</style></author><author><style face="normal" font="default"> Davis,J.R.</style></author><author><style face="normal" font="default"> Trudo,F.</style></author><author><style face="normal" font="default"> Schiffman,B.</style></author><author><style face="normal" font="default"> Alzola,C.</style></author><author><style face="normal" font="default"> Brown,D.</style></author><author><style face="normal" font="default"> Fox,K.M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Characterizing patients with asthma who received Global Initiative for Asthma steps 4-5 therapy and managed in a specialty care setting</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="35" start="27">27-35</pages><volume><style face="normal" font="default">39</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="1" Year="2018">2018/1/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Severe asthma is recognized in the European Respiratory Society/American Thoracic Society guidelines as a major unmet need in the management of asthma. OBJECTIVE: The study objective was to describe the clinical burden of Global Initiative for Asthma (GINA) steps 4-5 asthma for patients treated by specialists in the U.S. community setting. METHODS: Patients, ages >/=12 years, with asthma who received GINA step 4 or 5 treatment and were treated at a large U.S. allergy practice network between January 1, 2010, and April 30, 2016, were retrospectively identified by using electronic health records. Clinical outcomes included lung function (forced expiratory volume in one second of expiration [FEV1] and FEV1% predicted), symptom control (Asthma Control Test [ACT]), the fractional exhaled nitric oxide (FeNO) value (FeNO >/=25 ppb indicates airway inflammation), and asthma medication use. The change in outcomes from baseline to 12 and 24 months after the index date was calculated. RESULTS: Of 120,116 patients with asthma, 12,922 (10.8%) had severe asthma, 68% (n = 8751) while on step 4 therapy. The mean baseline prebronchodilation FEV1% predicted was 79.7%, and the mean baseline ACT score was 17.0. With uncontrolled asthma defined as an ACT score of &lt;/=19 and/or an FEV1 value of &lt;80% predicted and/or oral corticosteroid use of >/=2 bursts, 52.5% and 57.7% of patients on step 4 and step 5 therapy, respectively, had uncontrolled asthma at baseline. Of a subset of patients, 40.9% had an eosinophil count of >/=300 cells/mm3 and 44% had an FeNO concentration of >/=25 ppb. Small increases in the FEV1 value were observed from baseline to 12 months (n = 4022) and 24 months (n = 2326) postindex (0.07 and 0.04 L, respectively). CONCLUSION: A considerable proportion of patients had uncontrolled asthma while on current GINA steps 4-5 treatment, which indicated that additional therapies may be required to reduce the clinical burden of severe asthma</style></abstract><notes><style face="normal" font="default">IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2018.39.4094</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29279057">PM:29279057</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2018-39-27-35.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2018-39-27-35.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180101, Stone B</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2018.39.4094</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43562</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bahna,S.L.</style></author><author><style face="normal" font="default"> Burkhardt,J.G.</style></author></authors></contributors><titles><title><style face="normal" font="default">The dilemma of allergy to food additives</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="8" start="3">3-8</pages><volume><style face="normal" font="default">39</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="1" Year="2018">2018/1/1</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To provide a brief summary on food additives and to outline a practical approach for evaluating subjects suspected of having reactions to food additives. DATA SOURCES: Information was derived from selected reviews and original articles published in peer-reviewed journals, supplemented by the clinical experience of the authors. STUDY SELECTION: Priority was given to studies that used blinded, placebo controlled, oral challenges to confirm adverse reactions to food additives. In addition, selected, appropriately evaluated case reports were included. RESULTS: A large number of food additives are widely used in the food industry. Allergic reactions to additives seem to be rare but are very likely underdiagnosed, primarily due to a low index of suspicion. A wide variety of symptoms to food additives have been reported, but a cause-and-effect relationship has not been well documented in the majority of cases. CONCLUSION: Reactions to food additives should be suspected in patients who report symptoms related to multiple foods or to a certain food when commercially prepared but not when home made. It is also prudent to investigate food additives in subjects considered to have "idiopathic" reactions. Except for a limited number of natural additives, there is a small role for skin tests or in vitro testing. Oral challenge, in stages, with commonly used additives is the definitive procedure for detecting the offending agent. Once the specific additive is identified, management is strict avoidance, which can be difficult</style></abstract><notes><style face="normal" font="default">IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2018.39.4092</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29279054">PM:29279054</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2018-39-3-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2018-39-3-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180101, Bahna SL</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2018.39.4092</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43563</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Marioni,G.</style></author><author><style face="normal" font="default"> Zanotti,C.</style></author><author><style face="normal" font="default"> Brescia,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Chronic rhinosinusitis with nasal polyps in the elderly: Assessing current evidence</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="13" start="9">9-13</pages><volume><style face="normal" font="default">39</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="1" Year="2018">2018/1/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: The recently reported prevalence of chronic rhinosinusitis (CRS) among people >60 years old was 4.7%, with CRS emerging as the sixth most common chronic condition in the elderly. There is still a dearth of studies that focused on older patients, however, regarding the characteristics of CRS with nasal polyps (CRSwNP). OBJECTIVE: The emerging role of CRSwNP endotyping to enable a tailored medical approach (for elderly patients also) was investigated. METHOD: The present review of data reported predominantly in the past 5 years aimed to critically discuss the pathophysiologic, clinical, and prognostic features of CRSwNP in elderly patients. RESULTS: Although the existing data were not final, they supported the notion that geriatric patients can be managed safely by adopting the same surgical algorithm as for younger adults, including endoscopic sinus surgery (ESS). As for medical therapies, prolonged systemic steroid treatment for CRSwNP should be given with caution to elderly patients because they risk significant adverse effects. There is increasing evidence of a lower CRSwNP recurrence rate after ESS in the elderly than in young adult patients. Contrary to findings in younger patients, recently, analysis of preliminary data showed that histologically eosinophilic CRSwNP or high blood eosinophil counts were not significantly associated with a higher recurrence rate in elderly patients. CONCLUSION: A great challenge in the field of geriatric CRSwNP is to investigate the different endotypes in large series (also by means of biomarker assay in blood and polyp tissue) to identify rational and tailored diagnostic, therapeutic (medical and/or surgical), and follow-up modalities</style></abstract><notes><style face="normal" font="default">IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2018.39.4101</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29279055">PM:29279055</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2018-39-9-13.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2018-39-9-13.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180101, Marioni G</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2018.39.4101</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43564</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jose,J.</style></author><author><style face="normal" font="default"> Lehman,E.B.</style></author><author><style face="normal" font="default"> Craig,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Evaluating satisfaction of patients with hereditary angioedema with their past and present treatments: Implications for future therapies</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="80" start="74">74-80</pages><volume><style face="normal" font="default">39</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="1" Year="2018">2018/1/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Ever-expanding armamentarium of treatments for hereditary angioedema (HAE) are associated with various adverse effects, issues with vascular access, or lack of self-administration. OBJECTIVE: To understand patients' impressions and confidence in their past and present treatments, and identifying adverse events while also directly asking patients to reveal their hope for the future of HAE management and treatments. METHODS: After institutional review board approval, all subjects with laboratory-confirmed HAE were mailed a survey that they completed and returned to the researchers, and data were collected and entered into a secure online web application for surveys. Medication confidence data were summarized and expressed as means, medians, standard deviations, and quartiles by using a 5-point Likert scale. Analyses were performed by using statistical software. RESULTS: Of 150 surveys, 38 (25.3%) were completed. Among 36 subjects, 27 (75.0%) were female subjects, and the mean age was 50.1 years. Cinryze and Berinert (both C1-esterase inhibitors) had the highest median scores (5.0) for patient confidence, followed by ecallantide (4.5), icatibant (4.0), and androgens (2.0). For Cinryze, 64.3% selected it as the most effective and 57.1% tolerated it best. For Berinert, 50% of the subjects found it to be most effective and 59.1% tolerated it best. Some subjects listed androgens as most effective (33.3%) or best tolerated (16.7%), and many reported that this class caused the most adverse effects (44.4%). Among those who answered, 50% preferred a noninvasive method of administration, such as oral (24%), subcutaneous (18%), or not intravenous (8%) routes. CONCLUSION: Determining patient predilections and the reasoning behind them can be valuable for determining specific therapies to achieve each individual's personal goals</style></abstract><notes><style face="normal" font="default">IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default"> 10.2500/aap.2018.39.4095</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29279063">PM:29279063</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2018-39-74-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2018-39-74-80.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180101, Jose J</style></custom2><misc3><style face="normal" font="default"> 10.2500/aap.2018.39.4095</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43565</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zhang,X.</style></author><author><style face="normal" font="default"> Zheng,J.</style></author><author><style face="normal" font="default"> Zhang,L.</style></author><author><style face="normal" font="default"> Liu,Y.</style></author><author><style face="normal" font="default"> Chen,G.P.</style></author><author><style face="normal" font="default"> Zhang,H.P.</style></author><author><style face="normal" font="default"> Wang,L.</style></author><author><style face="normal" font="default"> Kang,Y.</style></author><author><style face="normal" font="default"> Wood,L.G.</style></author><author><style face="normal" font="default"> Wang,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Systemic inflammation mediates the detrimental effects of obesity on asthma control</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="50" start="43">43-50</pages><volume><style face="normal" font="default">39</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="2" Month="1" Year="2018">2018/1/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Obesity negatively impacts asthma control, but the inflammatory mechanisms are poorly understood. OBJECTIVE: To explore which systemic inflammatory mediators mediate the effects of obesity on asthma control. METHODS: The subjects with stable asthma (n = 108) underwent assessment of clinical characteristics, which included using The Asthma Control Questionnaire (ACQ)-6. Obesity was defined as a body mass index (BMI) of >/=30 kg/m2, overweight was defined as BMI between 25 to 29.9 kg/m2, and lean weight was defined as BMI &lt; 25 kg/m2. Body composition, including fat mass (FM), visceral fat area (VFA), and percentage body fat (PBF) was analyzed by bioimpedance. Serum interleukin (IL) 4, IL-5, IL-8, IL-13, IL-17, chemokine (C-C motif) ligand (CCL) 17, CCL22, leptin, adiponectin, C-reactive protein (CRP), and interferon (IFN) gamma were measured by using ELISA. Linear regression models were fitted according to the Baron and Kenny procedures for mediation analysis. RESULTS: FM (12.73 +/- 3.95 versus 18.59 +/- 2.95 versus 27.82 +/- 5.17 kg; p &lt; 0.0001), VFA (65.99 +/- 23.17 versus 93.96 +/- 10.28 versus 123.10 +/- 18.34 cm2; p &lt; 0.0001), PBF (23.86 +/- 7.46 versus 30.74 +/- 5.08 versus 36.21 +/- 6.28 %; p = 0.0003) and ACQ-6 values (0.83 [0, 1.17]) versus 1.15 [0.50, 1.75] versus 1.33 [0.83, 1.83] score; p = 0.002) were different among lean (n = 52), overweight (n = 37), and obese (n = 19) subjects. Serum levels of leptin, IL-5, IL-13, IL-17, CCL17, CRP, and IFN-gamma in the obese group were significantly elevated compared with the subjects who were lean or overweight (all p &lt; 0.05). The mediation analyses found that the effect of obesity, assessed by BMI, on ACQ-6 was significantly mediated through IL-13 and CCL17. Furthermore, IL-13 and CCL17 mediated the effects of body composition (FM, VFA and PBF) on ACQ-6. The effects of obesity assessed by body composition, but not by using BMI, on ACQ-6 were mediated by leptin. CONCLUSION: Our mediation analysis confirmed that systemic inflammation biomarkers, such as leptin, CCL17, IL-4, and IL-13, mediated the effects of obesity on asthma control. This warrants prospective exploration in this distinct asthma phenotype in the future</style></abstract><notes><style face="normal" font="default">IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - China -CO - Australia -</style></notes><work-type><style face="normal" font="default"> 10.2500/aap.2018.39.4096</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29279059">PM:29279059</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2018-39-43-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2018-39-43-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180101, Zhang X</style></custom2><misc3><style face="normal" font="default"> 10.2500/aap.2018.39.4096</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43566</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Patel,B.</style></author><author><style face="normal" font="default"> Wi,C.I.</style></author><author><style face="normal" font="default"> Hasassri,M.E.</style></author><author><style face="normal" font="default"> Divekar,R.</style></author><author><style face="normal" font="default"> Absah,I.</style></author><author><style face="normal" font="default"> Almallouhi,E.</style></author><author><style face="normal" font="default"> Ryu,E.</style></author><author><style face="normal" font="default"> King,K.</style></author><author><style face="normal" font="default"> Juhn,Y.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Heterogeneity of asthma and the risk of celiac disease in children</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="58" start="51">51-58</pages><volume><style face="normal" font="default">39</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="1" Year="2018">2018/1/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Although human leukocyte antigen (HLA)-DR and HLA-DQ genes and gluten play crucial roles in developing celiac disease (CD), most patients with these risk factors still do not develop CD, which indicates additional unrecognized risk factors. OBJECTIVE: To determine the association between asthma and the risk of CD in children. METHODS: We conducted a population-based retrospective case-control study in children who resided in Olmsted County, Minnesota. We identified children with CD (cases) between January 1, 1997, and December 31, 2014, and compared these with children without CD (controls) (1:2 matching). Asthma status was ascertained by using the predetermined asthma criteria (PAC) and the asthma predictive index (API). Data analysis included conditional logistic regression models and an unsupervised network analysis by using an independent phenome-wide association scan (PheWAS) data set. RESULTS: Although asthma status as determined by using PAC was not associated with the risk of CD (odds ratio [OR] 1.4 [95% confidence interval {CI}, 0.8-2.5]; p = 0.2), asthma status by using the API was significantly associated (OR 2.8 [95% CI, 1.3-6.0]; p = 0.008). A subgroup analysis indicated that children with both asthma as determined by using PAC and a family history of asthma had an increased risk of CD compared with those without asthma (OR 2.28 [95% CI, 1.11-4.67]; p = 0.024). PheWAS data showed a cluster of asthma single nucleotide polymorphisms and patients with CD. CONCLUSION: A subgroup of children with asthma who also had a family history of asthma seemed to be at an increased risk of CD, and, thus, the third factor that underlies the risk of CD might be related to genetic factors for asthma. Heterogeneity of asthma plays a role in determining the risk of asthma-related comorbidity</style></abstract><notes><style face="normal" font="default">IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2018.39.4100</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29279060">PM:29279060</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2018-39-51-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2018-39-51-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180101, Patel B</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2018.39.4100</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43567</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Meltzer,E.O.</style></author><author><style face="normal" font="default"> Berger,W.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">A review of the efficacy and safety of once-daily tiotropium Respimat 2.5 micrograms in adults and adolescents with asthma</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="26" start="14">14-26</pages><volume><style face="normal" font="default">39</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="1" Year="2018">2018/1/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Despite current guidelines, many patients with asthma remain symptomatic, particularly those intolerant of, unresponsive to, or uncontrolled by long-acting beta 2-agonists (LABAs). Tiotropium bromide, delivered through the Respimat soft-mist inhaler in 2 puffs of 1.25 micrograms each, is approved for the long-term, maintenance treatment of asthma in patients aged >/=6 years. OBJECTIVE: An overview of the use of once-daily tiotropium Respimat 2.5 micrograms in adults and adolescents with varying degrees of asthma severity. The role of the parasympathetic nervous system in the pathophysiology of asthma, the development of tiotropium for respiratory disease, and the value of the Respimat inhaler are also discussed. METHODS: A literature search of all phase II and phase III trials of once-daily tiotropium Respimat 2.5 micrograms. RESULTS: Once-daily tiotropium Respimat 2.5 micrograms was studied in five phase III studies: three studies in adults and two in adolescents aged 12-17 years. Tiotropium Respimat 2.5 micrograms demonstrated efficacy in adults and adolescents with mild, moderate, or severe asthma, showing significant improvements in lung function and asthma control in patients with uncontrolled asthma despite inhaled corticosteroids (ICS) or ICS plus LABA use. The adverse event profile of tiotropium was very acceptable, with safety similar to placebo. CONCLUSION: Once-daily tiotropium Respimat 2.5 micrograms has positive attributes that include efficacy, a safety profile similar to placebo, once-daily dosing, administration by inhalation, and delivery in the easy-to-use and consistent-dosing Respimat device. However, more data are needed on the effects of tiotropium on clinical outcomes, patients' day-to-day lives, and real-world effectiveness</style></abstract><notes><style face="normal" font="default">IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2018.39.4103</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29279056">PM:29279056</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2018-39-14-26.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2018-39-14-26.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180101, Meltzer EO</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2018.39.4103</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43568</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bellanti,J.A.</style></author><author><style face="normal" font="default"> Settipane,R.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Unraveling the conundrum of asthma phenotypes and endotypes</style></title><secondary-title><style face="normal" font="default">Allergy Asthma Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy Asthma Proc</style></full-title></periodical><pages end="2" start="1">1-2</pages><volume><style face="normal" font="default">39</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="1" Year="2018">2018/1/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1539-6304 (Electronic)IS - 1088-5412 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/aap.2018.39.4112</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29279053">PM:29279053</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Allergy Asthma Proc\2018-39-1-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Allergy Asthma Proc\2018-39-1-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180101, Bellanti JA</style></custom2><misc3><style face="normal" font="default">10.2500/aap.2018.39.4112</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43569</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Owen,J.L.</style></author><author><style face="normal" font="default"> Vakharia,P.P.</style></author><author><style face="normal" font="default"> Silverberg,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA</style></auth-address><titles><title><style face="normal" font="default">The Role and Diagnosis of Allergic Contact Dermatitis in Patients with Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">Am J Clin Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Clin Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="1" Year="2018">2018/1/5</year></dates><abstract><style face="normal" font="default">Patients with atopic dermatitis (AD) have increased penetration of allergens, immune dysregulation (including shared cytokine pathways), and frequent use of emollients and topical medications, all of which may predispose toward developing allergic contact dermatitis (ACD). Recent systematic reviews have suggested that ACD is a significant clinical problem in both children and adults with AD. While this remains controversial, ACD remains an important comorbidity and potential exacerbant of AD in clinical practice. Common relevant allergens, include lanolin, neomycin, formaldehyde, sesquiterpene lactone mix, compositae mix, and fragrances that are commonly found in AD patients' personal care products. We herein review the clinical scenarios where patch testing is indicated in AD. In addition, we review the contraindications, preferred patch-testing series, pitfalls, and challenges determining the relevance of positive patch-test reactions in AD patients</style></abstract><notes><style face="normal" font="default">IS - 1179-1888 (Electronic)IS - 1175-0561 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s40257-017-0340-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29305764">PM:29305764</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Clin Dermatol\20180105-OwenJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Clin Dermatol\20180105-OwenJL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, Owen JL</style></custom2><misc3><style face="normal" font="default">10.1007/s40257-017-0340-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43570</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pavlis,J.</style></author><author><style face="normal" font="default"> Yosipovitch,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Itch Center, University of Miami Miller School of Medicine, Miami, FL, USA</style></auth-address><titles><title><style face="normal" font="default">Management of Itch in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">Am J Clin Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Clin Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is the most common itchy dermatosis that affects millions of children and adults worldwide. Chronic itch in this condition has significant impact on measures of quality of life, such as sleep. Treating itch in AD has been challenging for decades, but new drugs have emerged in the last year with significant anti-pruritic effect. The optimal treatment regimen for atopic itch addresses barrier dysfunction, inflammation, neural hypersensitivity, and the itch-scratch cycle. Topical moisturizers remain the foundation of treatment and should be used by all patients with AD-associated pruritus. Step-wise therapy, from topical anti-inflammatory creams to systemic monoclonal antibodies and immunosuppressants, is recommended. There are multiple adjuvant therapies that can be used, especially to target itch in the setting of minimal skin inflammation. Finally, patient education, sleep management, and stress relief are important components to optimize outcomes. This review assesses the latest advances and treatment recommendations for pruritus in AD. Finally, suggested therapeutic ladders and emerging treatments are discussed</style></abstract><notes><style face="normal" font="default">IS - 1179-1888 (Electronic)IS - 1175-0561 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s40257-017-0335-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29285724">PM:29285724</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Clin Dermatol\20171228-PavlisJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Clin Dermatol\20171228-PavlisJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171228, Pavlis J</style></custom2><misc3><style face="normal" font="default">10.1007/s40257-017-0335-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43571</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Magnus,M.C.</style></author><author><style face="normal" font="default"> Wright,R.J.</style></author><author><style face="normal" font="default"> Roysamb,E.</style></author><author><style face="normal" font="default"> Parr,C.L.</style></author><author><style face="normal" font="default"> Karlstad,O.</style></author><author><style face="normal" font="default"> Page,C.M.</style></author><author><style face="normal" font="default"> Nafstad,P.</style></author><author><style face="normal" font="default"> Haberg,S.E.</style></author><author><style face="normal" font="default"> London,S.J.</style></author><author><style face="normal" font="default"> Nystad,W.</style></author></authors></contributors><titles><title><style face="normal" font="default">Maternal Psychosocial Stress Associates With Increased Risk of Asthma Development in Offspring</style></title><secondary-title><style face="normal" font="default">Am J Epidemiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Am J Epidemiol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="12" Year="2017">2017/12/13</year></dates><abstract><style face="normal" font="default">Prenatal maternal psychosocial stress might influence childhood asthma development. Evaluating paternal psychosocial stress and conducting a sibling comparison could provide further insight into the role of unmeasured confounding. We examined the associations of parental psychosocial stress during and after pregnancy with asthma at 7 years in the Norwegian Mother and Child Cohort Study (n = 63,626). Measures of psychosocial stress included lifetime major depressive symptoms, current anxiety/depression symptoms, use of antidepressants, anxiolytics and/or hypnotics, life satisfaction, relationship satisfaction, work stress and social support. Childhood asthma was associated with maternal lifetime major depressive symptoms, adjusted relative risk (aRR) = 1.19 (95% CI: 1.09, 1.30), in addition to symptoms of anxiety/depression during pregnancy, aRR = 1.17 (95% CI: 1.06, 1.29), and 6 months after delivery, aRR = 1.17 (95% CI: 1.07, 1.28). Maternal negative life events during pregnancy, aRR = 1.10 (95% CI: 1.06, 1.13), and 6 months after delivery, aRR = 1.14 (95% CI: 1.11, 1.18), were also associated with asthma. These associations were not replicated when evaluated within sibling groups. There were no associations with paternal psychosocial stress. In conclusion, maternal anxiety/depression and negative life events was associated with offspring asthma, but this might be explained by unmeasured maternal background characteristics that remain stable across deliveries</style></abstract><notes><style face="normal" font="default">IS - 1476-6256 (Electronic)IS - 0002-9262 (Linking)LA - engPT - Journal ArticleCO - Norway -CO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1093/aje/kwx366</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29244063">PM:29244063</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Am J Epidemiol\20171213-MagnusMC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Am J Epidemiol\20171213-MagnusMC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171213, Magnus MC</style></custom2><misc3><style face="normal" font="default">10.1093/aje/kwx366</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43572</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ritchie,A.I.</style></author><author><style face="normal" font="default"> Singanayagam,A.</style></author><author><style face="normal" font="default"> Wiater,E.</style></author><author><style face="normal" font="default"> Edwards,M.R.</style></author><author><style face="normal" font="default"> Montminy,M.</style></author><author><style face="normal" font="default"> Johnston,S.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 National Heart and Lung Institute, Imperial College London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">beta2-Agonists Enhance Asthma-Relevant Inflammatory Mediators in Human Airway Epithelial Cells</style></title><secondary-title><style face="normal" font="default">Am J Respir Cell Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Cell Mol Biol</style></full-title></periodical><pages end="132" start="128">128-132</pages><volume><style face="normal" font="default">58</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1535-4989 (Electronic)IS - 1044-1549 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1165/rcmb.2017-0315LE</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29286858">PM:29286858</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20180101, Ritchie AI</style></custom2><misc3><style face="normal" font="default">10.1165/rcmb.2017-0315LE</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43573</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Karo-Atar,D.</style></author><author><style face="normal" font="default"> Munitz,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Biotherapeutics Cluster Augmanity Nano LTD Rehovot, Israel</style></auth-address><titles><title><style face="normal" font="default">Is Asthma Paying the Toll?</style></title><secondary-title><style face="normal" font="default">Am J Respir Cell Mol Biol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Cell Mol Biol</style></full-title></periodical><pages end="4" start="3">3-4</pages><volume><style face="normal" font="default">58</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1535-4989 (Electronic)IS - 1044-1549 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">10.1165/rcmb.2017-0288ED</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29286853">PM:29286853</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20180101, Karo-Atar D</style></custom2><misc3><style face="normal" font="default">10.1165/rcmb.2017-0288ED</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43574</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dunn,K.</style></author><author><style face="normal" font="default"> Pasternak,B.</style></author><author><style face="normal" font="default"> Kelsen,J.R.</style></author><author><style face="normal" font="default"> Sullivan,K.E.</style></author><author><style face="normal" font="default"> Dawany,N.</style></author><author><style face="normal" font="default"> Wright,B.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Phoenix Children's Hospital, Phoenix, Arizona</style></auth-address><titles><title><style face="normal" font="default">Mevalonate kinase deficiency presenting as recurrent rectal abscesses and perianal fistulae</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="28" Month="12" Year="2017">2017/12/28</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.11.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29290516">PM:29290516</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20171228-DunnK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20171228-DunnK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171228, Dunn K</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.11.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43575</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bennett,G.H.</style></author><author><style face="normal" font="default"> Carpenter,L.</style></author><author><style face="normal" font="default"> Hao,W.</style></author><author><style face="normal" font="default"> Song,P.</style></author><author><style face="normal" font="default"> Steinberg,J.</style></author><author><style face="normal" font="default"> Baptist,A.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Clinical Immunology, University of Michigan Health System, Ann Arbor, Michigan.</style></auth-address><titles><title><style face="normal" font="default">Risk factors and clinical outcomes associated with fixed airflow obstruction in older adults with asthma</style></title><secondary-title><style face="normal" font="default">Ann Allergy Asthma Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Ann Allergy Asthma Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="28" Month="12" Year="2017">2017/12/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma in older adults is associated with increased morbidity and mortality compared with asthma in younger patients. Fixed airflow obstruction (FAO) is associated with decreased survival in younger patients, but its significance remains unclear in older adults with asthma. OBJECTIVE: To identify risk factors and outcomes related to FAO in older adults with asthma. METHODS: Subjects older than 55 years with a physician diagnosis of persistent asthma were evaluated. Collected data included participant demographic information, medications, asthma exacerbations, Asthma Control Test (ACT) score, Asthma Quality of Life (AQLQ) score, comorbidities, spirometry, atopic status, and fractional exhaled nitric oxide. Clinical characteristics and outcomes associated with FAO (defined as post-bronchodilator ratio of forced expiratory volume in 1 second to forced vital capacity &lt;/=70%) were assessed. RESULTS: A total of 186 participants were analyzed (48 men and 138 women, mean age 66 years). FAO was demonstrated in 30% of participants. Using regression analysis, predictors of FAO included advanced age, African American race, male sex, and longer duration of asthma. In outcomes analysis, FAO was associated with worsened ACT and AQLQ scores; however, after controlling for confounding factors, logistic regression showed no association. No significant association was found between FAO and exacerbations, fractional exhaled nitric oxide, atopy, rhinitis, education level, depression, smoking, or body mass index. CONCLUSION: Risk factors associated with FAO in older adults with asthma include advanced age, African American race, increased asthma duration, and male sex. Unlike younger patients, FAO is not independently associated with worsened asthma control, quality of life, or exacerbations in older patients with asthma. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01979055</style></abstract><notes><style face="normal" font="default">IS - 1534-4436 (Electronic)IS - 1081-1206 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.anai.2017.10.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29290515">PM:29290515</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20171228-BennettGH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Allergy Asthma Immunol\20171228-BennettGH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171228, Bennett GH</style></custom2><misc3><style face="normal" font="default">10.1016/j.anai.2017.10.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43576</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fitzpatrick,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia</style></auth-address><titles><title><style face="normal" font="default">Out of One, Many: Moving beyond a Single Guideline toward Personalized Asthma Care for Obese Children</style></title><secondary-title><style face="normal" font="default">Ann Am Thorac Soc</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Am Thorac Soc</style></abbr-1></periodical><pages end="17" start="16">16-17</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 2325-6621 (Electronic)IS - 2325-6621 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1513/AnnalsATS.201710-836ED</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29286850">PM:29286850</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171220, Pitzpatrick AM</style></custom2><misc3><style face="normal" font="default">10.1513/AnnalsATS.201710-836ED</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43577</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cantrell,F.L.</style></author><author><style face="normal" font="default"> Cantrell,P.</style></author><author><style face="normal" font="default"> Wen,A.</style></author><author><style face="normal" font="default"> Gerona,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">From California Poison Control System, San Diego, California; Kaiser Permanente, San Diego, California; and University of California, San Francisco, San Francisco, California</style></auth-address><titles><title><style face="normal" font="default">Epinephrine Concentrations in EpiPens After the Expiration Date</style></title><secondary-title><style face="normal" font="default">Ann Intern Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Intern Med</style></abbr-1></periodical><pages end="919" start="918">918-919</pages><volume><style face="normal" font="default">166</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Anaphylaxis</style></keyword><keyword><style face="normal" font="default"> prevention &amp; control</style></keyword><keyword><style face="normal" font="default"> Drug Stability</style></keyword><keyword><style face="normal" font="default"> Epinephrine</style></keyword><keyword><style face="normal" font="default"> administration &amp; dosage</style></keyword><keyword><style face="normal" font="default"> analysis</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Injections</style></keyword><keyword><style face="normal" font="default"> instrumentation</style></keyword></keywords><dates><year Day="20" Month="6" Year="2017">2017/6/20</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1539-3704 (Electronic)IS - 0003-4819 (Linking)LA - engPT - LetterRN - YKH834O4BH (Epinephrine)SB - AIMSB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.7326/L16-0612</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28492859">PM:28492859</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Intern Med\2017-166-918-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Intern Med\2017-166-918-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170620, Cantrell FL</style></custom2><misc3><style face="normal" font="default">10.7326/L16-0612</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43578</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dominguez-Massa,C.</style></author><author><style face="normal" font="default"> Bel-Minguez,A.M.</style></author><author><style face="normal" font="default"> Perez-Guillen,M.</style></author><author><style face="normal" font="default"> Berbel-Bonillo,A.</style></author><author><style face="normal" font="default"> Hornero-Sos,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Cardiovascular Surgery. Hospital Universitario y Politecnico La Fe. Valencia. Spain.</style></auth-address><titles><title><style face="normal" font="default">Mitral Ring Extraction Due To Nickel Allergy</style></title><secondary-title><style face="normal" font="default">Ann Thorac Surg</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Thorac Surg</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="12" Year="2017">2017/12/20</year></dates><abstract><style face="normal" font="default">The incidence of allergic reactions due to mechanical prosthesis or rings is not well established. We report the case of a 56-year-old male patient who presented a persistent urticarial rash and anaphylactic shock after mitral valve repair surgery. Prick skin tests were positive for nickel. After removing the nucleus from the mitral annulus, the urticarial clinic disappeared</style></abstract><notes><style face="normal" font="default">IS - 1552-6259 (Electronic)IS - 0003-4975 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.athoracsur.2017.11.048</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29274313">PM:29274313</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Ann Thorac Surg\20171220-DominguezMassaC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Ann Thorac Surg\20171220-DominguezMassaC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171220, Dominguez-Massa C</style></custom2><misc3><style face="normal" font="default">10.1016/j.athoracsur.2017.11.048</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43579</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rudin,R.S.</style></author><author><style face="normal" font="default"> Fanta,C.H.</style></author><author><style face="normal" font="default"> Predmore,Z.</style></author><author><style face="normal" font="default"> Kron,K.</style></author><author><style face="normal" font="default"> Edelen,M.O.</style></author><author><style face="normal" font="default"> Landman,A.B.</style></author><author><style face="normal" font="default"> Zimlichman,E.</style></author><author><style face="normal" font="default"> Bates,D.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">RAND Corporation, Boston, Massachusetts, United States</style></auth-address><titles><title><style face="normal" font="default">Core Components for a Clinically Integrated mHealth App for Asthma Symptom Monitoring</style></title><secondary-title><style face="normal" font="default">Appl Clin Inform</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Appl Clin Inform</style></abbr-1></periodical><pages end="1043" start="1031">1031-1043</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1869-0327 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.4338/ACI-2017-06-RA-0096</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29241243">PM:29241243</url></web-urls></urls><custom2><style face="normal" font="default">20171203, Rudin RS</style></custom2><misc3><style face="normal" font="default">10.4338/ACI-2017-06-RA-0096</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43580</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Farzandipour,M.</style></author><author><style face="normal" font="default"> Nabovati,E.</style></author><author><style face="normal" font="default"> Sharif,R.</style></author><author><style face="normal" font="default"> Arani,M.H.</style></author><author><style face="normal" font="default"> Anvari,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Health Information Management Research Center, Kashan University of Medical Sciences, Kashan, Iran</style></auth-address><titles><title><style face="normal" font="default">Patient Self-Management of Asthma Using Mobile Health Applications: A Systematic Review of the Functionalities and Effects</style></title><secondary-title><style face="normal" font="default">Appl Clin Inform</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Appl Clin Inform</style></abbr-1></periodical><pages end="1081" start="1068">1068-1081</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1869-0327 (Electronic)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">10.4338/ACI-2017-07-R-0116</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29241254">PM:29241254</url></web-urls></urls><custom2><style face="normal" font="default">20171203, Farzandipour M</style></custom2><misc3><style face="normal" font="default">10.4338/ACI-2017-07-R-0116</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43581</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bouazza,N.</style></author><author><style face="normal" font="default"> Foissac,F.</style></author><author><style face="normal" font="default"> Urien,S.</style></author><author><style face="normal" font="default"> Guedj,R.</style></author><author><style face="normal" font="default"> Carbajal,R.</style></author><author><style face="normal" font="default"> Treluyer,J.M.</style></author><author><style face="normal" font="default"> Chappuy,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pharmacology and Clinical Research Departments, Paris Descartes Necker Cochin, Assistance Publique - Hopitaux de Paris, Paris, France</style></auth-address><titles><title><style face="normal" font="default">Fine particulate pollution and asthma exacerbations</style></title><secondary-title><style face="normal" font="default">Arch Dis Child</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arch Dis Child</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="12" Year="2017">2017/12/19</year></dates><abstract><style face="normal" font="default">OBJECTIVE: As the results from epidemiological studies about the impact of outdoor air pollution on asthma in children are heterogeneous, our objective was to investigate the association between asthma exacerbation in children and exposure to air pollutants. METHODS: A database of 1 264 585 paediatric visits during the 2010-2015 period to the emergency rooms from 20 emergency departments (EDs) of 'Assistance Publique Hopitaux de Paris (APHP)', the largest hospital group in Europe, was used. A total of 47 107 visits were classified as asthma exacerbations. Concentration of air pollutants (nitrogen dioxide, ozone, fine particulate matter (PM) with an aerodynamic diameter smaller than 10 microm (PM10) and 2.5 microm (PM2.5)), as well as meteorological data, evolution of respiratory syncytial virus infection and pollen exposition, were collected on an hourly or daily basis for the same period using institutional databases. To assess the association between air pollution and asthma, mixed-effects quasi-Poisson regression modelling was performed. RESULTS: The only compound independently associated with ED visits for asthma was PM2.5 (P&lt;10(-4)). The association between asthma exacerbation and PM2.5 was not linear, and a sigmoid function described the relationshipsatisfactorily. PM2.5 concentration, which gives half the maximum effect, was estimated at 13.5 microg/m(3). CONCLUSIONS: We found an association between daily asthma exacerbation in paediatric visits to the ED and fine particulate air pollutants</style></abstract><notes><style face="normal" font="default">IS - 1468-2044 (Electronic)IS - 0003-9888 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1136/archdischild-2017-312826</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29259031">PM:29259031</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Dis Child\20171219-BouazzaN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Dis Child\20171219-BouazzaN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171219, Bouazza N</style></custom2><misc3><style face="normal" font="default">10.1136/archdischild-2017-312826</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43582</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bush,A.</style></author><author><style face="normal" font="default"> Pavord,I.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, London, UK</style></auth-address><titles><title><style face="normal" font="default">'We can't diagnose asthma until &lt;insert arbitrary age>'</style></title><secondary-title><style face="normal" font="default">Arch Dis Child</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Arch Dis Child</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="1" Year="2018">2018/1/5</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1468-2044 (Electronic)IS - 0003-9888 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1136/archdischild-2017-314180</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29305357">PM:29305357</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Arch Dis Child\20180105-BushA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Arch Dis Child\20180105-BushA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, Bush A</style></custom2><misc3><style face="normal" font="default">10.1136/archdischild-2017-314180</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43583</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,J.Y.</style></author><author><style face="normal" font="default"> Yang,H.K.</style></author><author><style face="normal" font="default"> Kim,M.</style></author><author><style face="normal" font="default"> Kim,J.</style></author><author><style face="normal" font="default"> Ahn,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea</style></auth-address><titles><title><style face="normal" font="default">Is the prevalence of atopic dermatitis in Korean children decreasing? : National Database 2009-2014</style></title><secondary-title><style face="normal" font="default">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="149" start="144">144-149</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: The prevalence of atopic dermatitis (AD) in children is increasing in many developing countries. OBJECTIVE: This study aimed to explore trends in the prevalence of AD in Korean children. METHODS: We analyzed data from the Korean National Health Insurance Service (NHIS) from 2009 to 2014. Data for the estimated populations were collected from the Statistics Korea. The annual prevalence of AD was obtained by dividing the number of patients by the estimated population each year. We analyzed the prevalence of AD in 2014 and evaluated the change in the annual prevalence of AD from 2009 through 2014. RESULTS: The estimated population of children aged 18 years or younger was 9,992,581 in 2014, and the number of children with AD was 578,678 with the prevalence of 5.8%. The prevalence was 17.2% in infants aged 12-23 months, which decreased substantially to 7.3%, 3.2% and 2.4% at 5, 12 and 18 years of age, respectively. In the pediatric age group, the prevalence of AD slightly decreased from 6.5% to 5.8% from 2009 through 2014. Notably, in infants aged less than 24 months, the prevalence decreased from 20.8% to 15.4%. CONCLUSIONS: Based on the Korean NHIS database, the prevalence of AD in Korean children aged 18 years or younger appears to be decreasing, especially in infants. Although the reason is not clear, an increase in breast milk feeding, vaginal delivery or consumption of probiotics might be involved. Further studies are needed to confirm this trend and to explain the possible mechanisms</style></abstract><notes><style face="normal" font="default">IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.12932/AP0797</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996291">PM:27996291</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2017-35-144-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2017-35-144-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180104, Lee JY</style></custom2><misc3><style face="normal" font="default">10.12932/AP0797</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43584</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Siwarom,S.</style></author><author><style face="normal" font="default"> Puranitee,P.</style></author><author><style face="normal" font="default"> Plitponkarnpim,A.</style></author><author><style face="normal" font="default"> Manuyakorn,W.</style></author><author><style face="normal" font="default"> Sinitkul,R.</style></author><author><style face="normal" font="default"> Arj-Ong Vallipakorn,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand</style></auth-address><titles><title><style face="normal" font="default">Association of indoor air quality and preschool children's respiratory symptoms</style></title><secondary-title><style face="normal" font="default">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="126" start="119">119-126</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: This study aimed to assess the association between exposure to indoor air pollution in DCCs (Child Day Care Centers) and the respiratory symptoms of children under 6 years old. METHODS: Air quality data were collected three times regarding to seasonal variation. Pollutants measured in 11 DCCs included PM(1)(0), CO, NO(2), SO(2), O(3), benzene, bacteria, fungi, and dust mite. The frequencyof respiratory symptoms including coughing, rhinitis, and dyspnea were recorded via teacher and parent-report questionnaires. Fractional exhaled nitric oxide (FENO) levels were measured to assess airway inflammation. RESULTS: 436 children participated in the study. 83% completed data collection in all 3 seasons. The frequency of rhinitis correlated with PM(1)(0) (IRR=70.3, 95%CI=12.4-399.7, p&lt;0.001), CO (IRR=3.2, 95%CI=2.4-4.2, p&lt;0.001), benzene (IRR=2.3, 95%CI=1.8-3.2, p&lt;0.001) and D.Pteronyssinus level (IRR=2.1, 95%CI=1.7-2.7, p&lt;0.001). The frequency of coughingcorrelated with levels of PM10 (IRR=15.2, 95%CI=3.0-78.2, p&lt;0.001), CO (IRR=2.8, 95%CI=2.1-3.7, p&lt;0.001), benzene (IRR=1.4, 95%CI=1.1-1.9, p=0.02). The frequency of dyspnea correlated with D.Pteronyssinus level (IRR=3.9, 95%CI=1.7-9.1, p=0.001). FENO levels associated with high benzene levels (OR=5.9, 95%CI=1.5-22.9, p=0.01). The majority of DCCs had at least one PM(1)(0) measurement above the standard level, and these high levels were noted in all 3 seasons. Three DCCs had PM(1)(0) levels above the standard level in all seasons. 64% of the DCCs had indoor bacterial counts above the standard level in all seasons. CONCLUSIONS: PM(1)(0) and bacterial count is a significant problem in Bangkok metropolitan DCCs. The respiratory symptoms of children positively associated with PM(1)(0), CO, benzene and dust mite levels</style></abstract><notes><style face="normal" font="default">IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="default">10.12932/AP0838</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996287">PM:27996287</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2017-35-119-26.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2017-35-119-26.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180104, Siwarom S</style></custom2><misc3><style face="normal" font="default">10.12932/AP0838</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43585</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Somanunt,S.</style></author><author><style face="normal" font="default"> Chinratanapisit,S.</style></author><author><style face="normal" font="default"> Pacharn,P.</style></author><author><style face="normal" font="default"> Visitsunthorn,N.</style></author><author><style face="normal" font="default"> Jirapongsananuruk,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand</style></auth-address><titles><title><style face="normal" font="default">The natural history of atopic dermatitis and its association with Atopic March</style></title><secondary-title><style face="normal" font="default">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="143" start="137">137-143</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis (AD) is the first manifestation of Atopic March. The natural history of AD and predictive factors for Atopic March have not been widely studied in Asia. OBJECTIVE: To study the natural history and associated factors of disease remission and risk of respiratory allergy in Thai children with AD. METHODS: Medical records of AD patients attending Allergy clinic at Siriraj hospital from 2004-2014 were reviewed. Patients were further followed-up to obtain current symptoms and treatment. RESULTS: One hundred and two AD patients (60.8% female) were followed for 10.2+/-4.7 years. The median age at diagnosis was 1.5 (0.1-12.0) years. The most common allergen sensitization was Dermatophagoides pteronyssinus and Dermatophagoides farinae. Forty-four percent of patients had complete remission at the median age of 6.3 (2.0-15.0) years. Forty-seven percent of early AD patients (onset &lt; 2 years) had concomitant food allergy which egg and cow's milk were leading causes. The remission rate of AD was higher in early AD than later onset AD (p=0.02). Allergic rhinitis (AR) and asthma were diagnosed in 61.8% and 29.4% of the patients at the median age of 4.6 and 3.8 years, respectively. Early AD and food allergies were significantly associated with early asthma (onset &lt; 3years) (OR=10.80, p&lt; 0.01 and OR=8.70, p=0.01). CONCLUSION: Almost half of AD children had complete remission at school age with a better prognosis in early AD. At preschool age, two-thirds and one-third developed AR and asthma, respectively. Early AD and food allergy were risk factors of early asthma</style></abstract><notes><style face="normal" font="default">IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="default">10.12932/AP0825</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996288">PM:27996288</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2017-35-137-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2017-35-137-43.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180104, Somanunt S</style></custom2><misc3><style face="normal" font="default">10.12932/AP0825</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43586</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Choi,J.H.</style></author><author><style face="normal" font="default"> Nam,G.E.</style></author><author><style face="normal" font="default"> Kim,D.H.</style></author><author><style face="normal" font="default"> Lee,J.Y.</style></author><author><style face="normal" font="default"> Han,K.D.</style></author><author><style face="normal" font="default"> Cho,J.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology-Head and Neck Surgery, Soonchunhyang University College of Medicine, Bucheon Hospital, Bucheon, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Association between sleep duration and the prevalence of atopic dermatitis and asthma in young adults</style></title><secondary-title><style face="normal" font="default">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="155" start="150">150-155</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Sleep duration affects allergic diseases; however, this association requires further investigation. OBJECTIVE: To evaluate the association between sleep duration and the prevalence of atopic dermatitis and asthma in young Korean adults. METHOD: We analyzed data of 10,148 subjects (4,239 men; 5,909 women) aged 19-39 years from the Korean National Health and Nutrition Examination Survey 2008-2010. Self-reported sleep duration was categorized into five groups: &lt;/=5h, 6h, 7h, 8h, and >/=9h. The prevalence of atopic dermatitis and asthma was examined based on a questionnaire and compared between participants from five sleep duration groups after adjusting for potential confounding factors, including model 1 [age], model 2 [model 1 + BMI, current smoking, current alcohol use, regular physical activity, household income, and serum 25(OH)D level], and model 3 [model 2 + stress levels]. RESULTS: In female participants, a higher risk of atopic dermatitis was associated with sleep duration &lt;/=5 hours [odds ratio (OR): 1.665, 95% confidence interval (CI): 1.004-2.762; model 1], and >/=9 hours (OR, 1.746, 95% CI, 1.145-2.661; model 3), compared to a 7-hour sleep duration. Similarly, a higher risk of asthma was associated with sleep duration &lt;/=5 hours and >/=9 hours (OR, 1.553, 95% CI, 1.023-2.359 and OR, 1.569, 95% CI, 1.048-2.349, respectively; model 3). In male participants, there was no significant association between sleep duration and the prevalence of atopic dermatitis or asthma. CONCLUSIONS: Sleep duration &lt;/=5 and >/=9 hours may be a risk factor for atopic dermatitis and asthma in young female adults</style></abstract><notes><style face="normal" font="default">IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.12932/AP0772</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996279">PM:27996279</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2017-35-150-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2017-35-150-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180104, Choi JH</style></custom2><misc3><style face="normal" font="default">10.12932/AP0772</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43587</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Suksawat,Y.</style></author><author><style face="normal" font="default"> Pacharn,P.</style></author><author><style face="normal" font="default"> Jirapongsananuruk,O.</style></author><author><style face="normal" font="default"> Visitsunthorn,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand</style></auth-address><titles><title><style face="normal" font="default">Determination of fractional exhaled nitric oxide (FENO) reference values in healthy Thai population</style></title><secondary-title><style face="normal" font="default">Asian Pac J Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asian Pac J Allergy Immunol</style></abbr-1></periodical><pages end="131" start="127">127-131</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Fractional exhaled nitric oxide (FENO) level is directly correlated with airway inflammation in asthma patients. The objective of this study was to define normal FENO levels in healthy Thai volunteers. METHODS: This prospective cohort study was conducted in healthy Thai volunteers aged >/=5 years. Demographic and clinical data were recorded and pulmonary function test (PFT) was performed. FENO was measured using a chemiluminescence nitric oxide analyzer. RESULTS: Seventy-nine healthy Thai volunteers with normal lung function test were included. Mean age of participants was 13 (6-47) years and 58.2% were female. All subjects had no history of allergic respiratory diseases. Mean FENO level increased with age, and the differences between age groups were statistically significant (p=0.001). The highest mean FENO level was 13.6 ppb in the 11-15 year age group, and then the FENO level gradually declined with age. The highest mean FENO level was found in the 18-24.9 body mass index (BMI) group. Significant differences were observed for FENO levels between different height groups (p=0.005) but not between different BMI groups (p=0.46). Fair correlations between FENO levels and body weight, height, FEV1, and FVC were observed. A fair correlation between FENO level and age, FENO level and FEF25%-75% was found only in volunteers &lt;/=15 years of age. CONCLUSION: FENO level in healthy Thais increased with age until reaching maximum level (mean FENO 13.6 ppb) in the 11-15 year age group. Significant differences were observed for FENO levels between different age groups and different height groups</style></abstract><notes><style face="normal" font="default">IS - 0125-877X (Print)IS - 0125-877X (Linking)LA - engPT - Journal ArticleCO - Thailand -</style></notes><work-type><style face="normal" font="default">10.12932/AP0840</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="27996290">PM:27996290</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2017-35-127-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Asian Pac J Allergy Immunol\2017-35-127-31.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180104, Suksawat Y</style></custom2><misc3><style face="normal" font="default">10.12932/AP0840</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43588</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Xia,F.</style></author><author><style face="normal" font="default"> Deng,C.</style></author><author><style face="normal" font="default"> Jiang,Y.</style></author><author><style face="normal" font="default"> Qu,Y.</style></author><author><style face="normal" font="default"> Deng,J.</style></author><author><style face="normal" font="default"> Cai,Z.</style></author><author><style face="normal" font="default"> Ding,Y.</style></author><author><style face="normal" font="default"> Guo,Z.</style></author><author><style face="normal" font="default"> Wang,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Institute of Immunology , Zhejiang University School of Medicine , Hangzhou 310058 , China</style></auth-address><titles><title><style face="normal" font="default">IL4 (interleukin 4) induces autophagy in B cells leading to exacerbated asthma</style></title><secondary-title><style face="normal" font="default">Autophagy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Autophagy</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="3" Month="1" Year="2018">2018/1/3</year></dates><abstract><style face="normal" font="default">Allergic asthma is a common airway inflammatory disease in which B cells play important roles through IgE production and antigen presentation. SNP (single nucleotide polymorphism) analysis showed that Atg (autophagy-related) allele mutations are involved in asthma. It has been demonstrated that macroautophagy/autophagy is essential for B cell survival, plasma cell differentiation and immunological memory maintenance. However, whether B cell autophagy participates in asthma pathogenesis remains to be investigated. In this report, we found that autophagy was enhanced in pulmonary B cells from asthma-prone mice. Autophagy deficiency in B cells led to attenuated immunopathological symptoms in asthma-prone mice. Further investigation showed that IL4 (interleukin 4), a key effector Th2 cytokine in allergic asthma, was critical for autophagy induction in B cells both in vivo and in vitro, which further sustained B cell survival and enhanced antigen presentation by B cells. Moreover, IL4-induced autophagy depended on JAK signaling via an MTOR-independent, PtdIns3K-dependent pathway. Together, our data indicate that B cell autophagy aggravates experimental asthma through multiple mechanisms</style></abstract><notes><style face="normal" font="default">IS - 1554-8635 (Electronic)IS - 1554-8627 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1080/15548627.2017.142188</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29297752">PM:29297752</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Autophagy\20180103-XiaF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Autophagy\20180103-XiaF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180103, Xia F</style></custom2><misc3><style face="normal" font="default">10.1080/15548627.2017.142188</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43589</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McNeely,E.</style></author><author><style face="normal" font="default"> Staffa,S.J.</style></author><author><style face="normal" font="default"> Mordukhovich,I.</style></author><author><style face="normal" font="default"> Coull,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Environmental Health, Harvard T.H. Chan School of Public Health, Building 1, Room 1401, 655 Huntington Avenue, Boston, MA, 02115, USA.</style></auth-address><titles><title><style face="normal" font="default">Symptoms related to new flight attendant uniforms</style></title><secondary-title><style face="normal" font="default">BMC Public Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMC Public Health</style></abbr-1></periodical><pages end="" start="972">972-</pages><volume><style face="normal" font="default">17</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="3" Month="1" Year="2018">2018/1/3</year></dates><abstract><style face="normal" font="default">BACKGROUND: Flight attendants at Alaska Airlines reported health symptoms after the introduction of new uniforms in 2011. The airline replaced the uniforms in 2014 without acknowledging harm. To understand possible uniform-related health effects, we analyzed self-reported health symptoms in crew who participated in the Harvard Flight Attendant Health Study between 2007 and 2015, the period before, during, and after the introduction of new uniforms. METHODS: We calculated a standardized prevalence of respiratory, dermatological and allergic symptoms at baseline, as well as during and after uniform changes in 684 flight attendants with a varying number of surveys completed across each time point. We used Generalized Estimating Equations (GEE) to model the association between symptoms at baseline versus the exposure period after adjusting for age, gender and smoking status and weighting respondents for the likelihood of attrition over the course of the study period. RESULTS: We found the following symptom prevalence (per 100) increased after the introduction of new uniforms: multiple chemical sensitivity (10 vs 5), itchy/irritated skin (25 vs 13), rash/hives (23 vs 13), itchy eyes (24 vs 14), blurred vision (14 vs 6), sinus congestion (28 vs 24), ear pain (15 vs 12), sore throat (9 vs 5), cough (17 vs 7), hoarseness/loss of voice (12 vs 3), and shortness of breath (8 vs 3). The odds of several symptoms significantly increased compared to baseline after adjusting for potential confounders. CONCLUSION: This study found a relationship between health complaints and the introduction of new uniforms in this longitudinal occupational cohort</style></abstract><notes><style face="normal" font="default">IS - 1471-2458 (Electronic)IS - 1471-2458 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1186/s12889-017-4982-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29295715">PM:29295715</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMC Public Health\2018-17-972.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMC Public Health\2018-17-972.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180103, McNeely E</style></custom2><misc3><style face="normal" font="default">10.1186/s12889-017-4982-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43590</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bush,A.</style></author><author><style face="normal" font="default"> Griffiths,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Heart and Lung Institute, Royal Brompton Harefield NHS Foundation Trust, London, UK</style></auth-address><titles><title><style face="normal" font="default">Improving treatment of asthma attacks in children</style></title><secondary-title><style face="normal" font="default">BMJ</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ</style></abbr-1></periodical><pages end="" start="j5763">j5763-</pages><volume><style face="normal" font="default">359</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="12" Year="2017">2017/12/29</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1756-1833 (Electronic)IS - 0959-535X (Linking)LA - engPT - EditorialCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1136/bmj.j5763</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29288167">PM:29288167</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\BMJ\2017-359-j5763.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\BMJ\2017-359-j5763.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171229, Bush A</style></custom2><misc3><style face="normal" font="default">10.1136/bmj.j5763</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43591</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hayden,L.P.</style></author><author><style face="normal" font="default"> Hardin,M.E.</style></author><author><style face="normal" font="default"> Qiu,W.</style></author><author><style face="normal" font="default"> Lynch,D.A.</style></author><author><style face="normal" font="default"> Strand,M.J.</style></author><author><style face="normal" font="default"> van Beek,E.J.</style></author><author><style face="normal" font="default"> Crapo,J.D.</style></author><author><style face="normal" font="default"> Silverman,E.K.</style></author><author><style face="normal" font="default"> Hersh,C.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Respiratory Diseases, Boston Children's Hospital, Brigham and Women's Hospital, Boston</style></auth-address><titles><title><style face="normal" font="default">Asthma Is a Risk Factor for Respiratory Exacerbations Without Increased Rate of Lung Function Decline: Five-Year Follow-up in Adult Smokers From the COPDGene Study</style></title><secondary-title><style face="normal" font="default">Chest</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Chest</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="15" Month="12" Year="2017">2017/12/15</year></dates><abstract><style face="normal" font="default">BACKGROUND: Previous investigations in adult smokers from the COPDGene Study have shown that early-life respiratory disease is associated with reduced lung function, COPD, and airway thickening. Using 5-year follow-up data, we assessed disease progression in subjects who had experienced early-life respiratory disease. We hypothesized that there are alternative pathways to reaching reduced FEV1 and that subjects who had childhood pneumonia, childhood asthma, or asthma-COPD overlap (ACO) would have less lung function decline than subjects without these conditions. METHODS: Subjects returning for 5-year follow-up were assessed. Childhood pneumonia was defined by self-reported pneumonia at &lt; 16 years. Childhood asthma was defined as self-reported asthma diagnosed by a health professional at &lt; 16 years. ACO was defined as subjects with COPD who self-reported asthma diagnosed by a health-professional at &lt;/= 40 years. Smokers with and those without these early-life respiratory diseases were compared on measures of disease progression. RESULTS: Follow-up data from 4,915 subjects were examined, including 407 subjects who had childhood pneumonia, 323 subjects who had childhood asthma, and 242 subjects with ACO. History of childhood asthma or ACO was associated with an increased exacerbation frequency (childhood asthma, P &lt; .001; ACO, P = .006) and odds of severe exacerbations (childhood asthma, OR, 1.41; ACO, OR, 1.42). A history of childhood pneumonia was associated with increased exacerbations of COPD (absolute difference [beta], 0.17; P = .04). None of these early-life respiratory diseases were associated with an increased rate of lung function decline or progression on CT scans. CONCLUSIONS: Subjects who had early-life asthma are at increased risk of COPD developing and of having more active disease with more frequent and severe respiratory exacerbations without an increased rate of lung function decline over a 5-year period. TRIAL REGISTRY: ClinicalTrials.gov; No. NCT00608764; https://clinicaltrials.gov</style></abstract><notes><style face="normal" font="default">IS - 1931-3543 (Electronic)IS - 0012-3692 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.chest.2017.11.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29248621">PM:29248621</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Chest\20171215-HaydenLP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Chest\20171215-HaydenLP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171215, Hayden LP</style></custom2><misc3><style face="normal" font="default">10.1016/j.chest.2017.11.038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43592</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Garcia-Marcos,L.</style></author><author><style face="normal" font="default"> Edwards,J.</style></author><author><style face="normal" font="default"> Kennington,E.</style></author><author><style face="normal" font="default"> Aurora,P.</style></author><author><style face="normal" font="default"> Baraldi,E.</style></author><author><style face="normal" font="default"> Carraro,S.</style></author><author><style face="normal" font="default"> Gappa,M.</style></author><author><style face="normal" font="default"> Louis,R.</style></author><author><style face="normal" font="default"> Moreno-Galdo,A.</style></author><author><style face="normal" font="default"> Peroni,D.G.</style></author><author><style face="normal" font="default"> Pijnenburg,M.</style></author><author><style face="normal" font="default"> Priftis,K.N.</style></author><author><style face="normal" font="default"> Sanchez-Solis,M.</style></author><author><style face="normal" font="default"> Schuster,A.</style></author><author><style face="normal" font="default"> Walker,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory and Allergy units, Arrixaca University Children's hospital, University of Murcia &amp; IMIB Research Institute, Murcia, SpainDepartment of Paediatrics, University Hospital, Dusseldorf, GermanyAsthmaUK</style></auth-address><titles><title><style face="normal" font="default">Priorities for future research into asthma diagnostic tools: A PAN-EU Consensus exercise from the European asthma research innovation partnership (EARIP)</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="31" Month="12" Year="2017">2017/12/31</year></dates><abstract><style face="normal" font="default">The diagnosis of asthma is currently based on clinical history, physical examination and lung function; and to date there are no accurate objective tests either to confirm the diagnosis or to discriminate between different types of asthma. This consensus exercise reviews the state-of-the-art in asthma diagnosis to identify opportunities for future investment based on the likelihood of their successful development, potential for widespread adoption and their perceived impact on asthma patients. Using a two-stage e-Delphi process and a summarising workshop, a group of European asthma experts including health professionals, researchers, people with asthma and industry representatives ranked the potential impact of research investment in each technique or tool for asthma diagnosis and monitoring. After a systematic review of the literature, 21 statements were extracted and were subject of the two-stage Delphi process. Eleven statements were scored 3 or more and were further discussed and ranked in a face to face workshop. The three most important diagnostic/predictive tools ranked were: "New biological markers of asthma (e.g. genomics, proteomics and metabolomics) as a tool for diagnosis and/or monitoring", "Prediction of future asthma in preschool children with reasonable accuracy" and "Tools to measure volatile organic compounds (VOCs) in exhaled breath". This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - United Kingdom -CO - Italy -CO - Belgium -CO - Netherlands -CO - Greece -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13080</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29290104">PM:29290104</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20171231-GarciaMarcosL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20171231-GarciaMarcosL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171231, Garcia-Marcos L</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13080</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43593</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cabanas,R.</style></author><author><style face="normal" font="default"> Calderon,O.</style></author><author><style face="normal" font="default"> Ramirez,E.</style></author><author><style face="normal" font="default"> Fiandor,A.</style></author><author><style face="normal" font="default"> Caballero,T.</style></author><author><style face="normal" font="default"> Heredia,R.</style></author><author><style face="normal" font="default"> Herranz,P.</style></author><author><style face="normal" font="default"> Madero,R.</style></author><author><style face="normal" font="default"> Quirce,S.</style></author><author><style face="normal" font="default"> Bellon,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy, La Paz University Hospital Health Research Institute (IdiPAZ), Madrid, SpainPIELenRed Consortium</style></auth-address><titles><title><style face="normal" font="default">Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="12" Year="2017">2017/12/19</year></dates><abstract><style face="normal" font="default">BACKGROUND: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe delayed hypersensitivity reaction. The determination of drug causality is complex. The lymphocyte transformation test (LTT) has been reported positive in more than 50% of DRESS cases. Nevertheless, the sensitivity and specificity of LTT specifically in DRESS has not yet been established. Rechallenge with the culprit drug is contraindicated and cannot be used as gold standard for sensitivity and specificity determination. OBJECTIVE: To estimate the sensitivity and specificity of LTT in a clinically defined series of patients with DRESS. METHODS: Some 41 patients diagnosed with DRESS were included in the study. The results of the algorithm of the Spanish Pharmacovigilance System were used as the standard for a correct diagnosis of drug causality. A standard LTT was performed with involved drugs in acute or recovery samples. A stimulation index (SI) >/=2 in at least one concentration except for beta-lactams (SI >/=3), and contrast media (SI >/=4) was considered positive. Contingency tables and ROC curves were used for analysis. RESULTS: Sensitivity and specificity of LTT in the recovery phase of DRESS were 73% and 82%, respectively, whereas in the acute phase they were only 40% and 30%, respectively. Comparison of skin tests and LTT confirmed a higher sensitivity and specificity of LTT in DRESS. LTT showed high sensitivity (S) and specificity (Sp) for anticonvulsants (S 100%, Sp 100%; p=.008), anti-TB drugs (S 87.5%, Sp 100%; p=.004) and beta-lactams (S 73%, Sp 100%; p=.001). ROC curves revealed that the best criteria for LTT positivity for all drugs is SI >/=2 in at least one concentration, increasing overall sensitivity to 80%, and for beta-lactams from 73% to 92%. CONCLUSIONS AND CLINICAL RELEVANCE: LTT is a good diagnostic tool for drug causality in DRESS, mainly when performed in the recovery phase. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13076</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29265576">PM:29265576</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Allergy\20171219-CabanasR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Allergy\20171219-CabanasR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171219, Cabanas R</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13076</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43594</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lembo,C.</style></author><author><style face="normal" font="default"> Patruno,C.</style></author><author><style face="normal" font="default"> Balato,N.</style></author><author><style face="normal" font="default"> Ayala,F.</style></author><author><style face="normal" font="default"> Balato,A.</style></author><author><style face="normal" font="default"> Lembo,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Medicine and Surgery, Section of Dermatology and Venereology, University of Naples Federico II, Naples, Italy</style></auth-address><titles><title><style face="normal" font="default">Rational ideation and empiric validation of an innovative digital dermographic tester</style></title><secondary-title><style face="normal" font="default">Clin Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="12" Year="2017">2017/12/22</year></dates><abstract><style face="normal" font="default">BACKGROUND: Dermographism is a condition characterized by a weal response to a combination of pressure and traction on skin surface, and its diagnosis is based on medical history, clinical criteria and provocation test. The Dermographic Tester((R)) , a pen-sized tool containing a spring-loaded blunt tip, is the most widely used instrument for the provocation test, and it exerts increasing pressures on the skin surface according to an arbitrary units (AU) scale. Analysing the mechanism of function and trying to convert the AUs to SI units (g/mm(2) ), we found that this instrument had some defects and limits that would compromise a true and repeatable quantification of the weal response threshold. Consequently, we decided to develop a new instrument, the Digital Dermographic Tester (DDT), which is engineered with an inside force sensor to implement features lacking in the current tools, in the hope of enhancing the precision of the provocation test. AIM: To validate the effectiveness and accuracy of the DDT. METHODS: We tested the DDT on 213 participants purposely sampled to obtain three groups, each with a different pattern of reaction to mechanical stimuli. Based on anamnestic, diagnostic and symptomatic criteria, patients were divided into dermographic urticaria (DU), spontaneous urticaria (SU) and healthy control (HC) groups. The DDT was used to apply 12 levels of pressure to the skin surface, and a frequency distribution of positive reactions was displayed for each group. RESULTS: A force of 36-40 g/mm(2) appropriately differentiated physiological from pathological conditions with high sensitivity and specificity. CONCLUSIONS: The DDT was found to be capable of differentiating patients with DU patients from those with SU and from HCs, and was able to precisely identify the weal elicitation threshold</style></abstract><notes><style face="normal" font="default">IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/ced.13314</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29270994">PM:29270994</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Dermatol\20171222-LemboC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Dermatol\20171222-LemboC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171222, Lembo C</style></custom2><misc3><style face="normal" font="default">10.1111/ced.13314</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43595</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dittmer,M.</style></author><author><style face="normal" font="default"> Mutgi,K.A.J.</style></author><author><style face="normal" font="default"> Liu,V.</style></author><author><style face="normal" font="default"> Swick,B.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Carver College of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA</style></auth-address><titles><title><style face="normal" font="default">Localized, ovoid urticarial plaques with fine, nonfollicular pustules</style></title><secondary-title><style face="normal" font="default">Clin Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="12" Year="2017">2017/12/21</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/ced.13345</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29266388">PM:29266388</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Exp Dermatol\20171221-DittmerM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Exp Dermatol\20171221-DittmerM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171221, Dittmer M</style></custom2><misc3><style face="normal" font="default">10.1111/ced.13345</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43596</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Singh,D.</style></author><author><style face="normal" font="default"> Ravi,A.</style></author><author><style face="normal" font="default"> Southworth,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Infection, Immunity and Respiratory Medicine, The Medicines Evaluation Unit, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, The University of Manchester, Manchester, UKDivision of Infection, Immunity and Respiratory Medicine, The Medicines Evaluation Unit, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, The University of Manchester, Manchester, UKDivision of Infection, Immunity and Respiratory Medicine, The Medicines Evaluation Unit, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, The University of Manchester, Manchester, UK</style></auth-address><titles><title><style face="normal" font="default">CRTH2 antagonists in asthma: current perspectives</style></title><secondary-title><style face="normal" font="default">Clin Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Pharmacol</style></abbr-1></periodical><pages end="173" start="165">165-173</pages><volume><style face="normal" font="default">9</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) binds to prostaglandin D2. CRTH2 is expressed on various cell types including eosinophils, mast cells, and basophils. CRTH2 and prostaglandin D2 are involved in allergic inflammation and eosinophil activation. Orally administered CRTH2 antagonists are in clinical development for the treatment of asthma. The biology and clinical trial data indicate that CRTH2 antagonists should be targeted toward eosinophilic asthma. This article reviews the clinical evidence for CRTH2 involvement in asthma pathophysiology and clinical trials of CRTH2 antagonists in asthma. CRTH2 antagonists could provide a practical alternative to biological treatments for patients with severe asthma. Future perspectives for this class of drug are considered, including the selection of the subgroup of patients most likely to show a meaningful treatment response</style></abstract><notes><style face="normal" font="default">IS - 1179-1438 (Print)IS - 1179-1438 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.2147/CPAA.S119295</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29276415">PM:29276415</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Pharmacol\2017-9-165-73.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Pharmacol\2017-9-165-73.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171229, Singh D</style></custom2><misc3><style face="normal" font="default">10.2147/CPAA.S119295</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43597</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fazlollahi,M.R.</style></author><author><style face="normal" font="default"> Najmi,M.</style></author><author><style face="normal" font="default"> Fallahnezhad,M.</style></author><author><style face="normal" font="default"> Sabetkish,N.</style></author><author><style face="normal" font="default"> Kazemnejad,A.</style></author><author><style face="normal" font="default"> Bidad,K.</style></author><author><style face="normal" font="default"> Shokouhi,S.R.</style></author><author><style face="normal" font="default"> Mahloujirad,M.</style></author><author><style face="normal" font="default"> Pourpak,Z.</style></author><author><style face="normal" font="default"> Moin,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="default">The Prevalence of Asthma in Iranian Adults: The First National Survey and the Most Recent Updates</style></title><secondary-title><style face="normal" font="default">Clin Respir J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Respir J</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="12" Year="2017">2017/12/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: The worldwide increase in the prevalence of asthma has made it a major public-health concern. We aimed to identify the prevalence of asthma and asthma symptoms in adults living in urban and rural areas of Iran as a populated country with about 80 millions of residents. METHODS: This cross-sectional study was conducted to estimate the prevalence of asthma in adults between 20 to 44 years old in all provinces of Iran. Data were collected by personal interview via a standardized questionnaire (European Community Respiratory Health Survey (ECRHS)) between November 2015 and February 2016. RESULTS: A total of 24,344 individuals were enrolled. The prevalence of asthma was 8.9% (95% confidence interval [CI]: 8.5 - 9.3). The most common asthma symptoms were wheezing (14.2%, n=3465), nocturnal cough (13.3%, n=3234), and chest tightness (11.3%, n=2760). Additionally, the prevalence of current asthma (taking asthma medications or asthma attack) was estimated to be 4.7% (n=1155). Asthma was significantly more prevalent in males compared to females (p=0.002); while no significant relationship was detected between gender and asthma after adjusted analysis with other variables. The prevalence of asthma was significantly higher in older participants (p&lt;0.001), and individuals with low educational level (p&lt;0.001). Interestingly, there was no significant relationship between asthma and area of residency (p=0.8). CONCLUSIONS: The prevalence of asthma in Iran was similar to other Asian and European countries. However, repeated national surveys are required to determine the trend of asthma prevalence in Iran in comparison to other countries. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1752-699X (Electronic)IS - 1752-6981 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">10.1111/crj.12750</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29227026">PM:29227026</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Clin Respir J\20171211-FazlollahiMR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Clin Respir J\20171211-FazlollahiMR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171211, Fazlollahi MR</style></custom2><misc3><style face="normal" font="default">10.1111/crj.12750</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43598</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Uter,W.</style></author><author><style face="normal" font="default"> Wolter,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Informatics, Biometry and Epidemiology, University of Erlangen/Nurnberg, 91054 Erlangen, Germany</style></auth-address><titles><title><style face="normal" font="default">Nickel and cobalt release from earrings and piercing jewellery - analytical results of a German survey in 2014</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="28" Month="12" Year="2017">2017/12/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: Nickel and cobalt are important metal allergens, and more knowledge on the levels of exposure to these from everyday contacts is needed. OBJECTIVES: To report the results of a repeat routine surveillance scheme in the Federal Republic of Germany on the release of nickel and cobalt. METHODS: Fifteen laboratories assessed earrings and piercing jewellery items from 12 of the states in 2014, complying with EN 1811:2011 + AC:2012 and using atomic absorption spectrometry, inductively coupled plasma mass spectrometry and inductively coupled plasma optical emission spectrometry for quantification. Kaplan-Meier analysis for left-censored data was employed to account for measurements below the limit of quantification. RESULTS: Nickel release exceeded 0.35 microg/cm(2) per week in 26 of 160 piercing posts (16.2%), and 0.88 microg/cm(2) per week in 2.0-5.9% of other parts, that is, the current respective 'pass' thresholds, with no change from the previous 2008 survey. The level of cobalt release was lower than that of nickel release, and also significantly lower than in the previous survey. CONCLUSIONS: The finding of the highest level of nickel release from piercing posts, with their deliberately lower threshold of acceptability, is worrying, as is the largely unchanged overall level of nickel release. A regulation on cobalt release is currently lacking; risk assessment and management based on dose-elicitation data are needed</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12941</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29282733">PM:29282733</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Contact Dermatitis\20171228-UterW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Contact Dermatitis\20171228-UterW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171228, Uter W</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12941</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43599</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Goncalo,M.</style></author><author><style face="normal" font="default"> Pinho,A.</style></author><author><style face="normal" font="default"> Agner,T.</style></author><author><style face="normal" font="default"> Andersen,K.E.</style></author><author><style face="normal" font="default"> Bruze,M.</style></author><author><style face="normal" font="default"> Diepgen,T.</style></author><author><style face="normal" font="default"> Foti,C.</style></author><author><style face="normal" font="default"> Gimenez-Arnau,A.</style></author><author><style face="normal" font="default"> Goossens,A.</style></author><author><style face="normal" font="default"> Johanssen,J.D.</style></author><author><style face="normal" font="default"> Paulsen,E.</style></author><author><style face="normal" font="default"> Svedman,C.</style></author><author><style face="normal" font="default"> Wilkinson,M.</style></author><author><style face="normal" font="default"> Aalto-Korte,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Coimbra University Hospital, and Faculty of Medicine, University of Coimbra, 3000-075 Coimbra, Portugal</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by nail acrylates in Europe. An EECDRG study</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="12" Year="2017">2017/12/21</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic contact dermatitis (ACD) caused by nail acrylates, also including methacrylates and cyanoacrylates here, is being increasingly reported. METHODS: A retrospective study in 11 European Environmental Contact Dermatitis Research Group (EECDRG) clinics collected information on cases of ACD caused by nail acrylates diagnosed by aimed testing between 2013 and 2015. RESULTS: Among 18 228 studied patients, 136 had ACD caused by nail acrylates (0.75%; 95%CI: 0.60-0.90), representing 67.3% (95%CI: 60.4-73.7) of ACD cases caused by acrylates. There were 135 females and 1 male, with a mean age +/- standard deviation of 36.7 +/- 12.2 years; 59 (43.4%) were exposed as consumers, and 77 (56.6%) were occupationally exposed. Occupational cases were more frequent in southern Europe (83.7%), and were younger (mean age of 33.4 +/- 8.9 years); most developed ACD during the first year at work (65.0%), and at least 11.7% had to leave their jobs. Skin lesions involved the hands in 121 patients (88.9%) and the face in 50 (36.8%), with the face being the only affected site in 14 (10.3%). Most patients reacted to two or more acrylates on patch testing, mainly to 2-hydroxyethyl methacrylate (HEMA) (92.5%), 2-hydroxypropyl methacrylate (88.6%), ethylene glycol dimethacrylate (69.2%), and ethyl cyanoacrylate (9.9%). CONCLUSIONS: Nail cosmetics were responsible for the majority of ACD cases caused by acrylates, affecting nail beauticians and consumers, and therefore calling for stricter regulation and preventive measures. As HEMA detects most cases, and isolated facial lesions may be overlooked, inclusion of this allergen in the baseline series may be warranted</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Portugal -CO - Denmark -CO - Sweden -CO - Germany -CO - Italy -CO - Spain -CO - Belgium -CO - United Kingdom -CO - Finland -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12942</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29266254">PM:29266254</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Contact Dermatitis\20171221-GoncaloM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Contact Dermatitis\20171221-GoncaloM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171221, Gonclo M</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12942</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43600</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shibata,Y.</style></author><author><style face="normal" font="default"> Ohko,K.</style></author><author><style face="normal" font="default"> Sano,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Kochi Medical School, Kochi University, Kochi 783-8505, JapanDepartment of Dermatology, Kochi Medical School, Kochi University, Kochi 783-8505, JapanDepartment of Dermatology, Kochi Medical School, Kochi University, Kochi 783-8505, Japan</style></auth-address><titles><title><style face="normal" font="default">Can patch test sensitization with gold sodium thiosulfate be ruled out? - a case report</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="95" start="94">94-95</pages><volume><style face="normal" font="default">78</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12864</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29265450">PM:29265450</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Contact Dermatitis\2018-78-94-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Contact Dermatitis\2018-78-94-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171220, Shibata Y</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12864</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43601</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shutty,B.G.</style></author><author><style face="normal" font="default"> Scheinman,P.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Brigham and Women's Hospital, Contact Dermatitis and Occupational Dermatology Program, Harvard Medical School, Boston, MA, 02467, USA</style></auth-address><titles><title><style face="normal" font="default">Allergic contact mucositis caused by metal: a covertly located permanent dental retainer</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="90" start="88">88-90</pages><volume><style face="normal" font="default">78</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12848</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29265445">PM:29265445</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Contact Dermatitis\2018-78-88-90.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Contact Dermatitis\2018-78-88-90.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171220, Shutty BG</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12848</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43602</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Santos-Alarcon,S.</style></author><author><style face="normal" font="default"> Benavente-Villegas,F.C.</style></author><author><style face="normal" font="default"> Farzanegan-Minano,R.</style></author><author><style face="normal" font="default"> Perez-Frances,C.</style></author><author><style face="normal" font="default"> Sanchez-Motilla,J.M.</style></author><author><style face="normal" font="default"> Mateu-Puchades,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Hospital Universitario Doctor Peset, 46017 Valencia, Spain</style></auth-address><titles><title><style face="normal" font="default">Delayed hypersensitivity to topical and systemic corticosteroids</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="88" start="86">86-88</pages><volume><style face="normal" font="default">78</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12841</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29265451">PM:29265451</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Contact Dermatitis\2018-78-86-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Contact Dermatitis\2018-78-86-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171220, Santos-Alarcon S</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12841</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43603</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shono,M.</style></author><author><style face="normal" font="default"> Numata,M.</style></author><author><style face="normal" font="default"> Sasaki,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Shono Dermatology Clinic, Machida, #194-0012 Japan</style></auth-address><titles><title><style face="normal" font="default">Allergic contact dermatitis caused by Solvent Orange 60 in spectacle frames in Japan</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="84" start="83">83-84</pages><volume><style face="normal" font="default">78</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12752</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29265444">PM:29265444</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Contact Dermatitis\2018-78-83-94.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Contact Dermatitis\2018-78-83-94.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171220, Shono M</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12752</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43604</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Duhovic,C.</style></author><author><style face="normal" font="default"> Reckling,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology East Kent Hospitals University NHS Foundation Trust, Canterbury, CT1 3NG, UKDepartment of Dermatology East Kent Hospitals University NHS Foundation Trust, Canterbury, CT1 3NG, UK</style></auth-address><titles><title><style face="normal" font="default">Detecting photoallergic contact dermatitis with patch testing and daylight</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="86" start="85">85-86</pages><volume><style face="normal" font="default">78</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12759</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29265448">PM:29265448</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Contact Dermatitis\2018-78-85-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Contact Dermatitis\2018-78-85-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171220, Duhovic C</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12759</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43605</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tammaro,A.</style></author><author><style face="normal" font="default"> Palumbo,A.</style></author><author><style face="normal" font="default"> Bommarito,C.</style></author><author><style face="normal" font="default"> Pepe,G.</style></author><author><style face="normal" font="default"> Romano,I.</style></author><author><style face="normal" font="default"> Parisella,F.R.</style></author><author><style face="normal" font="default"> Persechino,S.</style></author><author><style face="normal" font="default"> Bartolazzi,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Unit, St Andrea University Hospital, Sapienza University, 00189 Rome, Italy</style></auth-address><titles><title><style face="normal" font="default">Case report: skin injury after contact with a red spine starfish, Protoreaster lincki</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="96" start="95">95-96</pages><volume><style face="normal" font="default">78</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12865</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29265447">PM:29265447</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Contact Dermatitis\2018-78-95-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Contact Dermatitis\2018-78-95-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171220, Tammaro A</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12865</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43606</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ozkaya,E.</style></author><author><style face="normal" font="default"> Yazganoglu,K.D.</style></author><author><style face="normal" font="default"> Kutlay,A.</style></author><author><style face="normal" font="default"> Mahmudov,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Venereology, Istanbul Medical Faculty, Istanbul University, 34093 Capa-Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="default">Varenicline-induced acute generalized exanthematous pustulosis confirmed by patch testing</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="99" start="97">97-99</pages><volume><style face="normal" font="default">78</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12867</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29265452">PM:29265452</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Contact Dermatitis\2018-78-97-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Contact Dermatitis\2018-78-97-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20172012, Ozkaya E</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12867</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43607</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Maurel,D.T.</style></author><author><style face="normal" font="default"> Durand-Moreau,Q.</style></author><author><style face="normal" font="default"> Pougnet,R.</style></author><author><style face="normal" font="default"> DeWitte,J.D.</style></author><author><style face="normal" font="default"> Roguedas-Contios,A.M.</style></author><author><style face="normal" font="default"> Bensefa-Colas,L.</style></author><author><style face="normal" font="default"> Lodde,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratoire ORPHY, Universite de Bretagne Occidentale, CS 93</style></auth-address><titles><title><style face="normal" font="default">Why is occupational photocontact allergic dermatitis caused by ketoprofen rarely reported in the literature?</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="94" start="92">92-94</pages><volume><style face="normal" font="default">78</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12861</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29265446">PM:29265446</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Contact Dermatitis\2018-78-92-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Contact Dermatitis\2018-78-92-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171220, Maurel DT</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12861</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43608</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Potter,P.C.</style></author><author><style face="normal" font="default"> Klein,M.</style></author><author><style face="normal" font="default"> Weinberg,E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hydration in severe acute asthma</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="227" start="224">224-227</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Twenty children were studied during severe attacks ofacute asthma to determine how dehydrated they wereon admission to hospital. Mean body weight on admissionwas 97.8% of their reference stable weight seven to tendays after the attack and in only three children was it lessthan 95% of the stable weight. Bedside assessment ofdehydration was unreliable. The mean packed cell volumewas significantly higher on admission than 7-10 days later(0.44 compared with 0.42, difference 0.02 SE 0.01). Serumsodium and potassium concentrations and osmolalityon admission were within normal ranges. The degree ofdehydration correlated best with a fall in blood pH. There was no association between the degree of dehydration andthe recovery of the peak expiratory flow rate during the first24 hours or thereafter. We conclude that mild dehydrationis common in severe acute childhood asthma. Fluid givenat a rate of 50 mL/kg/24 hours was safe and appropriatefor these children</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/Journal/December2017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-224-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-224-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171227, Potter PC</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43609</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Laher,A.E.</style></author><author><style face="normal" font="default"> Moolla,M.</style></author><author><style face="normal" font="default"> McDonald,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Successful desensitisation of non-immune type symptoms secondary to salicylate hypersensitivity/intolerance</style></title><secondary-title><style face="normal" font="default">Curr Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Allergy Clin Immunol</style></full-title></periodical><pages end="286" start="284">284-286</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Introduction: Salicylate allergy/intolerance is a well-described entity that may present with typicalhypersensitivity symptoms such as rhinitis, wheezing and urticaria or non-immune-type features such asheadache, migraine, fatigue and abdominal cramps. Whereas aspirin desensitisation has been associated withsuccess in patients presenting with Samter's triad of recurrent nasal polyps, asthma and aspirin sensitivity, theprocedure has not been described in patients presenting with atypical or non-hypersensitivity-type symptoms.Case report: A 48-year-old female presented with a two-year history of chronic headaches, migraines, fatigueand occasional upper-body myoclonic jerk-like movements upon exposure to a host of sodium salicylate-containing foods and beverages. The Flow-Cellular Antigen Stimulation Test (CAST) (Bühlmann LaboratoriesAG, Schönenbuch, Switzerland) for sodium salicylate was positive (stimulation index-3.9 [normal &lt;2],percentage basophils-6.4% [normal &lt;5%]). Aspirin desensitisation was successfully conducted in the ICU overa two-day period. At one month follow-up, she reported complete tolerance of salicylate-containing foods aswell as a much better quality of life (QoL).Discussion: Salicylate hypersensitivity/intolerance presenting with atypical or non-hypersensitivity-typesymptoms may be successfully treated with aspirin desensitisation, resulting in a significant improvement inQoL</style></abstract><notes><style face="normal" font="default">LA - ENGCO - South Africa -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">https://www.allergysa.co.za/Journal/December2017</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-284-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Allergy Clin Immunol\2017-30-284-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171227, Laher AE</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43610</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Plaza,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Institut d'Investigacio Biomedica Sant Pau (IIB Sant Pau), Universitat Autonoma de Barcelona, Barcelona, Spain</style></auth-address><titles><title><style face="normal" font="default">Update on questionnaires for assessing adherence to inhaler devices in respiratory patients</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="50" start="44">44-50</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="2" Year="2018">2018/2</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: It has been estimated that adherence to inhaled medications in patients with asthma and chronic obstructive pulmonary disease (COPD) is around 50%. This low adherence rate increases morbidity and mortality of these disorders. The objective of this review was to update information on main questionnaires used in daily for assessing adherence to inhalers of patients with chronic respiratory diseases. RECENT FINDINGS: The test of the adherence to inhalers (TAI) is a recently developed and validated 12-item questionnaire to assess adherence to inhalers of aerosolized drugs in patients with asthma or COPD. The instrument can easily identify nonadherence, classify the level of adherence into good, intermediate and poor, and establish three nonadherence behaviour patterns of erratic, deliberate, and unwitting, which are useful for tailoring corrective measures. SUMMARY: Adherence to inhaler devices may be underestimated with the use of validated self-report questionnaires as compared with other more sensitive methods. However, validated self-report questionnaires are more advantageous from a cost-effective perspective in clinical practice. The recently validated TAI is a reliable and homogeneous instrument to identify easily nonadherence and behavioural barriers to the use of inhalers in patients with asthma or COPD</style></abstract><notes><style face="normal" font="default">IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000410</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29135485">PM:29135485</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2018-18-44-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2018-18-44-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171229, Plaza V</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000410</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43611</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Canonica,G.W.</style></author><author><style face="normal" font="default"> Ferrando,M.</style></author><author><style face="normal" font="default"> Baiardini,I.</style></author><author><style face="normal" font="default"> Puggioni,F.</style></author><author><style face="normal" font="default"> Racca,F.</style></author><author><style face="normal" font="default"> Passalacqua,G.</style></author><author><style face="normal" font="default"> Heffler,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Biomedical Sciences, Humanitas UniversityPersonalized Medicine, Asthma and Allergy Clinic, Humanitas Research Hospital, Milano</style></auth-address><titles><title><style face="normal" font="default">Asthma: personalized and precision medicine</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="58" start="51">51-58</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="2" Year="2018">2018/2</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: In this review, we herein describe the progress in management of severe asthma, evolving from a 'blockbuster approach' to a more personalized approach targeted to the utilization of endotype-driven therapies. RECENT FINDINGS: Severe asthma characterization in phenotypes and endotypes, by means of specific biomarkers, have led to the dichotomization of the concepts of 'personalized medicine' and 'precision medicine', which are often used as synonyms, but actually have conceptual differences in meaning. The recent contribute of the omic sciences (i.e. proteomics, transcriptomics, metabolomics, genomics, ...) has brought this initially theoretic evolution into a more concrete level. SUMMARY: This step-by-step transition would bring to a better approach to severe asthmatic patients as the personalization of their therapeutic strategy would bring to a better patient selection, a more precise endotype-driven treatment, and hopefully to better results in terms of reduction of exacerbation rates, symptoms, pulmonary function and quality of life</style></abstract><notes><style face="normal" font="default">IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000416</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29189350">PM:29189350</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2018-18-51-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2018-18-51-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171229, Canonica GW</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000416</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43612</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zahiruddin,A.S.</style></author><author><style face="normal" font="default"> Grant,J.A.</style></author><author><style face="normal" font="default"> Sur,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA</style></auth-address><titles><title><style face="normal" font="default">Role of epigenetics and DNA-damage in asthma</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="37" start="32">32-37</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="2" Year="2018">2018/2</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Although asthma is a common disease worldwide, its pathogenesis remains to be fully elucidated. There is increasing evidence of the interaction between epigenetics, DNA-damage, and environmental allergens in the development of asthma. In this review, we will focus on the role of epigenetics and DNA-damage in asthma. RECENT FINDINGS: There is growing evidence of environmental allergens, particularly house dust mite, stimulating oxidative DNA damage in airway epithelial cells. The repair of this DNA damage has been implicated in the secretion of Th2 cytokines and the induction of allergic inflammation. SUMMARY: Studies of the role of epigenetics, DNA-damage, and environmental allergens have begun to reveal the their complex interactions and their roles in the development of asthma. Further study in these areas may lead to novel prevention and treatment approaches</style></abstract><notes><style face="normal" font="default">IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000415</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29189349">PM:29189349</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2018-18-32-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2018-18-32-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171229, Zahiruddin AS</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000415</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43613</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chambliss,J.M.</style></author><author><style face="normal" font="default"> Sur,S.</style></author><author><style face="normal" font="default"> Tripple,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Department of Internal Medicine, The University of Texas Medical Branch Galveston, Galveston, Texas, USA</style></auth-address><titles><title><style face="normal" font="default">Asthma versus chronic obstructive pulmonary disease, the Dutch versus British hypothesis, and role of interleukin-5</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="31" start="26">26-31</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="2" Year="2018">2018/2</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: Asthma and COPD represent heterogeneous disorders with broad ranging impact on patients and health systems. This review focuses on evidence for early attempts at understanding their pathogenesis by the British and Dutch hypotheses. It also addresses the role of eosinophils, IL-5, and biologics targeting these pathways in asthma and COPD. RECENT FINDINGS: Among asthma and COPD patients, clusters exist based on phenotypic and biologic markers allowing for further understanding of endotypes. Recent studies suggest the role of eosinophils and optimal therapies for each condition may be different. SUMMARY: Although patients with ACOS or overlap symptoms may be an exception, overall there appears to be more evidence supporting that asthma and COPD are distinct processes. Targeting eosinophils with anti-IL-5 therapy appears to be an exciting pathway in the properly selected patient with asthma and recent data also supports its use in COPD</style></abstract><notes><style face="normal" font="default">IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000409</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29257776">PM:29257776</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2018-18-26-31.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2018-18-26-31.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171229, Chambliss JM</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000409</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43614</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rodrigo,G.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departamento de Emergencia, Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay</style></auth-address><titles><title><style face="normal" font="default">Anticholinergics for asthma: a long history</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="43" start="38">38-43</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="2" Year="2018">2018/2</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: To provide a fast overview about the introduction and development of anticholinergic drugs in Western medicine to their current indications particularly in asthma. RECENT FINDINGS: Although short-acting muscarinic antagonists have been positioned in the last 15 years for the treatment of adults and children with moderate-to-severe acute asthma in the emergency setting (reducing the risk of hospital admissions and improving lung function), a growing body of evidence has recently emerged that positions the long-acting muscarinic anticholinergic tiotropium bromide as add-on therapy to at least inhaled corticosteroids (ICS) maintenance therapy in adults, adolescents, and children with symptomatic asthma. Thus, the addition of tiotropium bromide to ICS alone or ICS and another controller was associated with significant improvements in spirometric measures and asthma control, and a significantly decrease in the rate of asthma exacerbations. SUMMARY: Short-acting muscarinic antagonists and tiotropium bromide have a well established role in the treatment of different phases of asthma. Further data are needed to provide more evidence on other selective long-acting muscarinic antagonists in addition to tiotropium as potential treatment options</style></abstract><notes><style face="normal" font="default">IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Uruguay -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000408</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29040210">PM:29040210</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2018-18-38-43.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2018-18-38-43.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171229, Rodrigo GJ</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000408</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43615</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Giavina-Bianchi,P.</style></author><author><style face="normal" font="default"> Aun,M.V.</style></author><author><style face="normal" font="default"> Kalil,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Clinical Immunology and Allergy Division, Department of Medicine, University of Sao Paulo, Sao Paulo, Brazil</style></auth-address><titles><title><style face="normal" font="default">Drug-induced anaphylaxis: is it an epidemic?</style></title><secondary-title><style face="normal" font="default">Curr Opin Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Opin Allergy Clin Immunol</style></full-title></periodical><pages end="65" start="59">59-65</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="2" Year="2018">2018/2</year></dates><abstract><style face="normal" font="default">PURPOSE OF REVIEW: The present review addresses the epidemiology, analyzes the current data and promotes global awareness of drug-induced anaphylaxis. RECENT FINDINGS: Anaphylaxis is a medical emergency that may cause death! In the last decade, studies have shown an increasing incidence and prevalence of anaphylaxis. SUMMARY: Drug-induced anaphylaxis fatalities have increased, and this syndrome remains underdiagnosed and undertreated</style></abstract><notes><style face="normal" font="default">IS - 1473-6322 (Electronic)IS - 1473-6322 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1097/ACI.0000000000000411</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29135486">PM:29135486</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2018-18-59-65.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Opin Allergy Clin Immunol\2018-18-59-65.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171229, Giavina-Bianchi P</style></custom2><misc3><style face="normal" font="default">10.1097/ACI.0000000000000411</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43616</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Itoh,E.</style></author><author><style face="normal" font="default"> Furumura,M.</style></author><author><style face="normal" font="default"> Furue,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Histopathology of Urticaria</style></title><secondary-title><style face="normal" font="default">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Treat Options Allergy</style></full-title></periodical><pages end="457" start="450">450-457</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2196-3053</style></isbn><abstract><style face="normal" font="default">Urticaria is a common skin manifestation with many different causes. It is characterized by local or generalized edematous erythema with itching and increased blood flow and vascular permeability. Individual urticaria lesions typically last less than 24-áh (usually less than 12-áh), but new lesions may appear and resolve sporadically. Since the diagnosis is usually made based on the history and clinical appearance of the lesions, skin biopsy is not necessarily performed, but it is recommended for evaluating patients with refractory eruptions or suspicion of other diseases exhibiting urticaria-like lesions. The histopathological features of urticaria are dermal edema and perivascular and interstitial inflammatory cell infiltration, and there is only minimal change in the epidermis. Cellular infiltrates are composed of lymphocytes, neutrophils, and eosinophils</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1007/s40521-017-0144-2</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40521-017-0144-2</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-450-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-450-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171227, Itoh E</style></custom2><misc3><style face="normal" font="default">10.1007/s40521-017-0144-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43617</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lund,T.T.</style></author><author><style face="normal" font="default"> Agner,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hand Eczema: Treatment Options</style></title><secondary-title><style face="normal" font="default">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Treat Options Allergy</style></full-title></periodical><pages end="410" start="401">401-410</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2196-3053</style></isbn><abstract><style face="normal" font="default">Hand eczema is a common disease, it affects young people, is often work-related, and the burden of the disease is significant for the individual as well as for society. Factors to be considered when choosing a treatment strategy are, among others, whether the eczema is acute or chronic, the severity of the disease, and the specific sub-diagnosis of hand eczema, which relates to the etiology as well as the morphology of the disease. Optimal treatment is still a challenge. This review seeks to provide an overview of the most updated treatment of hand eczema</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1007/s40521-017-0148-y</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40521-017-0148-y</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-401-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-401-10.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171227, Lund TT</style></custom2><misc3><style face="normal" font="default">10.1007/s40521-017-0148-y</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43618</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fukunaga,A.</style></author><author><style face="normal" font="default"> Washio,K.</style></author><author><style face="normal" font="default"> Hatakeyama,M.</style></author><author><style face="normal" font="default"> Oda,Y.</style></author><author><style face="normal" font="default"> Ogura,K.</style></author><author><style face="normal" font="default"> Horikawa,T.</style></author><author><style face="normal" font="default"> Nishigori,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Management of Inducible Urticarias</style></title><secondary-title><style face="normal" font="default">Curr Treat Options Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Curr Treat Options Allergy</style></full-title></periodical><pages end="427" start="411">411-427</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2196-3053</style></isbn><abstract><style face="normal" font="default">Purpose of review This review aims to update the information and latest advances in chronic inducible urticarias</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1007/s40521-017-0149-x</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s40521-017-0149-x</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-411-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Curr Treat Options Allergy\2017-4-411-27.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171227, Fukunaga A</style></custom2><misc3><style face="normal" font="default">10.1007/s40521-017-0149-x</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43619</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">no authors</style></author></authors></contributors><titles><title><style face="normal" font="default">Process of testing for allergy to dental substances</style></title><secondary-title><style face="normal" font="default">Dental Abstracts</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Dental Abstracts</style></abbr-1></periodical><pages end="28" start="26">26-28</pages><volume><style face="normal" font="default">63</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><isbn><style face="normal" font="default">0011-8486</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENG</style></notes><work-type><style face="normal" font="default">10.1016/j.denabs.2017.09.020</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.denabs.2017.09.020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Dental Abstracts\2018-63-26-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Dental Abstracts\2018-63-26-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170103, no authors</style></custom2><misc3><style face="normal" font="default">10.1016/j.denabs.2017.09.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43620</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Labadie,J.G.</style></author><author><style face="normal" font="default"> Korta,D.Z.</style></author><author><style face="normal" font="default"> Barton,N.</style></author><author><style face="normal" font="default"> Mesinkovska,N.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of California Irvine School of Medicine, Irvine, California</style></auth-address><titles><title><style face="normal" font="default">Cutaneous Hypersensitivity-Like Reactions Associated With Breast Implants: A Review</style></title><secondary-title><style face="normal" font="default">Dermatol Surg</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatol Surg</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="28" Month="12" Year="2017">2017/12/28</year></dates><abstract><style face="normal" font="default">BACKGROUND: Breast implantation is an increasingly common procedure for both cosmesis and reconstruction. Risk of cutaneous reactions to breast implants is low and typically described in postsurgical settings. Adverse skin hypersensitivity-like reactions to implants have also been reported but are not well described. OBJECTIVE: To review the scientific literature on cutaneous hypersensitivity-like reactions to breast implants. METHODS: A systematic literature review was conducted using PubMed. Articles pertaining to breast implants and cutaneous hypersensitivity-like reactions in humans were included. RESULTS: In total, 10 studies on hypersensitivity-like reactions from breast implants were included in the review. Potential allergenic compounds in breast implants include silicone, polyurethane texturing, and acellular dermal matrix. Perivascular lymphocytic infiltrate was a common finding on histopathology. Patch testing and preoperative silicone cube implantation were used to determine sensitivity. Attempted treatments included topical and oral corticosteroids, montelukast and antibiotics. Most cases required implant removal for resolution of symptoms. CONCLUSION: Cutaneous hypersensitivity-like reactions to breast implants seem to be rare complications, sometimes necessitating implant removal. Future studies are needed to establish their incidence and etiology, and the diagnostic role of patch testing and preoperative screening</style></abstract><notes><style face="normal" font="default">IS - 1524-4725 (Electronic)IS - 1076-0512 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DSS.0000000000001448</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29293108">PM:29293108</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Dermatol Surg\20171228-LabadieJG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Dermatol Surg\20171228-LabadieJG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171228, Labadie JG</style></custom2><misc3><style face="normal" font="default">10.1097/DSS.0000000000001448</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43621</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Demir,S.</style></author><author><style face="normal" font="default"> Cetin,E.A.</style></author><author><style face="normal" font="default"> Unal,D.</style></author><author><style face="normal" font="default"> Coskun,R.</style></author><author><style face="normal" font="default"> Olgac,M.</style></author><author><style face="normal" font="default"> Gelincik,A.</style></author><author><style face="normal" font="default"> Colakoglu,B.</style></author><author><style face="normal" font="default"> Buyukozturk,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Millet Street, Capa, Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="default">Generalized Fixed Drug Eruption Induced by Fluconazole Without Cross-Reactivity to Itraconazole: Lymphocyte Transformation Test Confirms the Diagnosis</style></title><secondary-title><style face="normal" font="default">Drug Saf Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Drug Saf Case Rep</style></abbr-1></periodical><pages end="" start="2">2-</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="2" Month="1" Year="2018">2018/1/2</year></dates><abstract><style face="normal" font="default">We present a rare case of generalized fixed drug eruption caused by fluconazole. A 45-year-old female patient was referred to our outpatient clinic because of suspicious drug eruptions that occurred 5 months earlier and resolved within a month. The patient had sequela of hyperpigmentation on her arms, legs, back, and abdomen after oral administration of the fourth dose of 150 mg of fluconazole once daily because of vaginal candidiasis. Patch tests with the culprit drug applied both on unaffected skin areas and over one of the lesions were negative. A lymphocyte transformation test was performed and in response to fluconazole, CD4(+) T cells significantly proliferated. Because the patient needed a safe antifungal drug for her recurrent vaginal candidiasis symptoms, a single-blind placebo-controlled drug provocation test was performed with itraconazole and was negative. Accordingly, 200 mg of itraconazole once daily was given for 10 days safely</style></abstract><notes><style face="normal" font="default">IS - 2199-1162 (Print)IS - 2199-1162 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1007/s40800-017-0067-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29294202">PM:29294202</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Drug Saf Case Rep\2018-5-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Drug Saf Case Rep\2018-5-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171216, Demir S</style></custom2><misc3><style face="normal" font="default">10.1007/s40800-017-0067-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43622</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Paton,D.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Emeritus Professor of Pharmacology, University of Auckland, Auckland, New Zealand.</style></auth-address><titles><title><style face="normal" font="default">Dupilumab: human monoclonal antibody against IL-4Ralpha for moderate to severe atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Drugs Today (Barc)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Drugs Today (Barc)</style></abbr-1></periodical><pages end="487" start="477">477-487</pages><volume><style face="normal" font="default">53</style></volume><number><style face="normal" font="default">9</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is one of the most common skin disorders with a prevalence of about 20% in children and affecting adults in significant numbers. Moderate to severe AD significantly impairs a patient's quality of life with severe pruritus as a major issue that impairs sleep and contributes to major psychological disturbances. Detailed studies of its pathogenesis have revealed that immune mechanisms are involved including activation of T helper type 2 cells (Th2). Dupilumab is a fully human Ig4 monoclonal antibody directed against the interleukin-4 receptor subunit alpha (IL-4Ralpha) of IL-4 and IL-13 receptors. In clinical studies it has been demonstrated to significantly reduce the molecular signature in the skin of patients with AD and to significantly reduce the clinical manifestations of moderate to severe AD. It also very importantly significantly reduces the pruritus of moderate to severe AD thus improving the patients' quality of life. Dupilumab is administered by subcutaneous injection every other week. It was approved by the FDA in March 2017 for the treatment of moderate to severe AD</style></abstract><notes><style face="normal" font="default">IS - 1699-3993 (Print)IS - 1699-3993 (Linking)LA - engPT - Journal ArticleCO - New Zealand -</style></notes><work-type><style face="normal" font="default">10.1358/dot.2017.53.9.2693150</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29238761">PM:29238761</url></web-urls></urls><custom2><style face="normal" font="default">20171214, Paton DM</style></custom2><misc3><style face="normal" font="default">10.1358/dot.2017.53.9.2693150</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43623</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hossny,E.M.</style></author><author><style face="normal" font="default"> El-Owaidy,R.H.</style></author><author><style face="normal" font="default"> Mohamed,N.L.</style></author><author><style face="normal" font="default"> Hassanin,E.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Regulatory natural killer cell expression in atopic childhood asthma</style></title><secondary-title><style face="normal" font="default">Egypt J Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Egypt J Pediatr Allergy Immunol</style></full-title></periodical><pages end="62" start="57">57-62</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Introduction: Different subsets of natural killer (NK) cells were found to play a role in pathogenesis of allergy. We sought to investigate the expression of regulatory NK cells (CD56+CD16+CD158+) in atopic children with bronchial asthma in order to outline the value of these cells as biomarkers of disease severity and/or control. Methods: A cross sectional controlled study was carried out in the Pediatric Allergy and Immunology Unit, Ain Shams University. The study included 45 atopic children [mean age(SD)= (2.9) years] with bronchial asthma (BA) and/or allergic rhinitis (AR)as well as 40 healthy matched controls. Enrolled subjects underwent complete blood counting and flow cytometric measurement of NK cell (CD16+ CD56+) and regulatory NK cells (CD16+CD56+CD158+). Results: Patients had significantly higher regulatory NK cell percentages [mean (SD)= 41 (52) %] than controls [mean (SD)=15 (7.1)]; p=0.001. Regulatory NK cell counts and percentages did not vary with the concomitant presence of AR or the degree of asthma control. Regulatory NK cell counts tended to be higher in children with moderate/severe BA compared to those with mild asthma but the difference did not reach statistical significance (U= -1.8, p=0.06). NK cell counts [mean (SD)= 159 (164) cells/µl] and percentages [mean (SD)= 3.7 (3.2) %] were comparable among patients and controls and did not vary with the presence of AR (p= 0.51, 0.95) or with the degree of asthma control. NK cells absolute counts and percentages tended to be higher among patients with moderate/severe compared to mild asthma but the difference did not reach statistical significance. Conclusions: Regulatory NK cells seem to be increased in childhood asthma. We recommend wider scale prospective studies on steroid-naïve subjects involving measurement of cytokines that are secreted by different types of NK cells.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Egypt -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.jespai.org/ulogs/paperindex.php?paperID=260&amp;topicid=1&amp;issueid=30</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Egypt J Pediatr Allergy Immunol\2017-15-57-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Egypt J Pediatr Allergy Immunol\2017-15-57-62.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171211, Hossny EM</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43624</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kwon,W.J.</style></author><author><style face="normal" font="default"> Ko,J.Y.</style></author><author><style face="normal" font="default"> Ro,Y.S.</style></author><author><style face="normal" font="default"> Kim,M.H.</style></author><author><style face="normal" font="default"> Kim,B.S.</style></author><author><style face="normal" font="default"> Kim,H.O.</style></author><author><style face="normal" font="default"> Nam,J.H.</style></author><author><style face="normal" font="default"> Lee,G.Y.</style></author><author><style face="normal" font="default"> Park,M.Y.</style></author><author><style face="normal" font="default"> Son,S.W.</style></author><author><style face="normal" font="default"> Yang,J.M.</style></author><author><style face="normal" font="default"> Lee,D.H.</style></author><author><style face="normal" font="default"> Lee,A.Y.</style></author><author><style face="normal" font="default"> Lee,J.Y.</style></author><author><style face="normal" font="default"> Chang,S.E.</style></author><author><style face="normal" font="default"> Choi,H.Y.</style></author><author><style face="normal" font="default"> Park,E.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, Korea</style></auth-address><titles><title><style face="normal" font="default">Comparison of allergen responses based on the TRUE Test and IQ Chamber system in Korean patients</style></title><secondary-title><style face="normal" font="default">Eur J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur J Dermatol</style></full-title></periodical><pages end="578" start="573">573-578</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="11" Year="2017">2017/11/14</year></dates><abstract><style face="normal" font="default">A comparison between responses to allergens based on the TRUE Test(R)(TT) and IQ(R) Chamber (IQC) in Europeans has been previously reported, however, no such study has been performed in Asians. To compare allergen responses using the TT and IQC (using the Korean standard series) in order to gather more information regarding the positive response rates for each allergen and the clinical value of IQC. Suspected contact dermatitis patients were enrolled and tested with 18 allergens using the TT and IQC. The test was performed in 214 patients. Simultaneous positive results for both tests were recorded in 242 cases (positive concordance rate: 66.7%). IQC yielded more positive results. Allergens with a high positive concordance rate were nickel sulphate (82.1%), thimerosal (78.6%), and p-phenylenediamine (73.3%). IQC mostly showed similar or higher positive rates than TT, with high concordance. We recommend the IQC method as a screening test in patients with suspected contact dermatitis. To compensate for possible false positive results, careful history taking and a different patch test should be performed when appropriate</style></abstract><notes><style face="normal" font="default">DA - 20171115IS - 1952-4013 (Electronic)IS - 1167-1122 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1684/ejd.2017.3139</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29138124">PM:29138124</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171223, Kwon WJ</style></custom2><misc3><style face="normal" font="default">10.1684/ejd.2017.3139</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43625</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fotopoulou,M.</style></author><author><style face="normal" font="default"> Iordanidou,M.</style></author><author><style face="normal" font="default"> Vasileiou,E.</style></author><author><style face="normal" font="default"> Trypsianis,G.</style></author><author><style face="normal" font="default"> Chatzimichael,A.</style></author><author><style face="normal" font="default"> Paraskakis,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Paediatrics, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece</style></auth-address><titles><title><style face="normal" font="default">A short period of breast feeding in infancy, excessive house cleaning, absence of older sibling, and passive smoking are related to more severe atopic dermatitis in children</style></title><secondary-title><style face="normal" font="default">Eur J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="24" Month="11" Year="2017">2017/11/24</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis (AD) is one of the most common, chronic or chronically relapsing inflammatory skin diseases that affect children. Multiple genetic and environmental factors appear to regulate the pathogenesis of AD. OBJECTIVES: Our aim was to investigate the possible association between family, social, dieting, atopic and environmental factors and the severity of AD evaluated by SCORAD scores in children. MATERIALS &amp; METHODS: The study group included 100 children with AD who attended a paediatric dermatology outpatient clinic with a median age of 18.5 months. The diagnosis of AD was established on the basis of the clinical criteria according to the American Dermatology Society, while the SCORAD score was used to evaluate disease severity. RESULTS: Multivariate linear regression analysis disclosed that excessive cleanliness (p&lt;0.001), RAST level greater than 0.7 KU/l (p&lt;0.001), breastfeeding for less than two months (p = 0.001), and the absence of an older sibling (p = 0.049) were statistically significant independent determinants for high SCORAD scores. Multivariate logistic regression analysis showed that excessive cleanliness (p&lt;0.001) was the strongest independent risk factor for severe AD (SCORAD>36) (aOR: 59.4; 95% CI: 10.9-322.6). RAST level greater than 0.7 KU/l (aOR: 7.9; 95% CI: 1.5-41.0; p = 0.014) and severe passive smoking (aOR: 4.6; 95% CI: 1.0-22.1; p = 0.050) also showed a significant independent, but clearly weaker, association with severe AD. CONCLUSIONS: A short duration of breastfeeding, absence of older siblings, parental passive smoking, food allergens along with aeroallergens, and excessive cleanliness should be considered as negative prognostic factors, leading to a higher SCORAD score in children with AD</style></abstract><notes><style face="normal" font="default">IS - 1952-4013 (Electronic)IS - 1167-1122 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="default">10.1684/ejd.2017.3165</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29171402">PM:29171402</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171223, Fotopoulou M</style></custom2><misc3><style face="normal" font="default">10.1684/ejd.2017.3165</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43626</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McDonald,V.M.</style></author><author><style face="normal" font="default"> Yorke,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Priority Research Centre for Healthy Lungs and Centre of Excellence in Severe Asthma, Faculty of Health and Medicine, The University of Newcastle, Newcastle, Australia Vanessa.McDonald@newcastle.edu.auDept of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, AustraliaSchool of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UKManchester Academic Health Sciences Centre, University of Manchester, Manchester, UK</style></auth-address><titles><title><style face="normal" font="default">Adherence in severe asthma: time to get it right</style></title><secondary-title><style face="normal" font="default">Eur Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Respir J</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="default">50</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1399-3003 (Electronic)IS - 0903-1936 (Linking)LA - engPT - EditorialCO - Australia -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1183/13993003.02191-2017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29269587">PM:29269587</url></web-urls></urls><custom2><style face="normal" font="default">20171228, McDonald VM</style></custom2><misc3><style face="normal" font="default">10.1183/13993003.02191-2017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43627</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Koleva,P.T.</style></author><author><style face="normal" font="default"> Tun,H.M.</style></author><author><style face="normal" font="default"> Konya,T.</style></author><author><style face="normal" font="default"> Guttman,D.S.</style></author><author><style face="normal" font="default"> Becker,A.B.</style></author><author><style face="normal" font="default"> Mandhane,P.J.</style></author><author><style face="normal" font="default"> Turvey,S.E.</style></author><author><style face="normal" font="default"> Subbarao,P.</style></author><author><style face="normal" font="default"> Sears,M.R.</style></author><author><style face="normal" font="default"> Scott,J.A.</style></author><author><style face="normal" font="default"> Kozyrskyj,A.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dept of Pediatrics, University of Alberta, Edmonton, AB, Canada</style></auth-address><titles><title><style face="normal" font="default">Sex-specific impact of asthma during pregnancy on infant gut microbiota</style></title><secondary-title><style face="normal" font="default">Eur Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Respir J</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="default">50</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">Asthma during pregnancy is associated with retardation of fetal growth in a sex-specific manner. Lactobacilli microbes influence infant growth. This study aimed to determine whether lactobacilli and other microbes are reduced in the gut of infants born to an asthmatic mother, and whether this differs by the sex of the infant.Mother-infant pairs (N=1021) from the Canadian Healthy Infant Longitudinal Development full-term cohort were studied. The abundance of infant faecal microbiota at 3-4 months, profiled by gene sequencing, was compared between both women with and without asthma treatment during pregnancy. Infant sex, maternal ethnicity, pre-pregnancy overweight and atopy status, birth mode, breastfeeding status and intrapartum antibiotic treatment were tested as covariates.Independent of birth mode and other covariates, male, Caucasian infants born to women with prenatal asthma harboured fewer lactobacilli in the gut at 3-4 months of age. If asthmatic mothers had pre-pregnancy overweight, the abundance of Lactobacillus in males was further reduced in the infant gut, whereas the microbiota of female infants was enriched with Bacteroidaceae Similar differences in infant gut microbial composition according to maternal prenatal asthma status were also more evident among women with food or environmental allergies.Gut lactobacilli were less abundant in male infants, but Bacteroidaceae were more abundant in female infants at 3-4 months of age, following maternal asthma during pregnancy</style></abstract><notes><style face="normal" font="default">IS - 1399-3003 (Electronic)IS - 0903-1936 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1183/13993003.00280-2017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29167295">PM:29167295</url></web-urls></urls><custom2><style face="normal" font="default">20171228, Koleva PT</style></custom2><misc3><style face="normal" font="default">10.1183/13993003.00280-2017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43628</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Morjaria,J.B.</style></author><author><style face="normal" font="default"> Rigby,A.S.</style></author><author><style face="normal" font="default"> Morice,A.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Respiratory Medicine, Hull York Medical School, University of Hull, Castle Hill Hospital, Cottingham, UK</style></auth-address><titles><title><style face="normal" font="default">Asthma phenotypes: do cough and wheeze predict exacerbations in persistent asthma?</style></title><secondary-title><style face="normal" font="default">Eur Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Respir J</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="default">50</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">Little is known of the long-term symptom profile in uncontrolled asthma and whether symptoms can predict distinct phenotypes. The primary objective of these analyses was to assess diurnal profile of cough and wheeze in an uncontrolled asthma population. Secondary outcomes were to examine how these symptom profiles influence response to treatment.Twice-daily electronically recorded data from 1701 patients were examined in relation to the population demographics. Reliever treatment with salbutamol was then compared with extra-fine beclometasone/formoterol maintenance and reliever therapy (MART). Exacerbation frequency was then correlated with the symptom profile.Symptoms were commoner in older patients with an increased body mass index. In most patients, reported cough and wheeze were closely correlated (r=0.73). Two phenotypes of cough- and wheeze-predominant patients were identified; the former were overweight, older females and the latter older males. Diurnal symptoms of cough and wheeze were similarly attenuated by both therapies. MART reduced exacerbation frequency by a third compared with salbutamol, and this effect was greatest in patients with fewest reported symptoms.While cough and wheeze are highly correlated in uncontrolled asthma, some patients predominantly have cough whereas others wheeze. Symptoms and exacerbation frequency appear poorly associated, suggesting an alternative pathophysiology. MART may be the preferred option in those with fewest symptoms</style></abstract><notes><style face="normal" font="default">IS - 1399-3003 (Electronic)IS - 0903-1936 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1183/13993003.01366-2017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29217600">PM:29217600</url></web-urls></urls><custom2><style face="normal" font="default">20171228, Morjaria JB</style></custom2><misc3><style face="normal" font="default">10.1183/13993003.01366-2017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43629</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Song,Y.</style></author><author><style face="normal" font="default"> Khoo,S.K.</style></author><author><style face="normal" font="default"> Lee,K.H.</style></author><author><style face="normal" font="default"> Makela,M.</style></author><author><style face="normal" font="default"> Haahtela,T.</style></author><author><style face="normal" font="default"> LeSouef,P.</style></author><author><style face="normal" font="default"> Zhang,G.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">School of Public Health, Curtin University, Perth, Australia</style></auth-address><titles><title><style face="normal" font="default">Dual responses of CD14 methylation to distinct environments: a role in asthma and allergy</style></title><secondary-title><style face="normal" font="default">Eur Respir J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Respir J</style></full-title></periodical><pages end="" start="">-</pages><volume><style face="normal" font="default">50</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1399-3003 (Electronic)IS - 0903-1936 (Linking)LA - engPT - LetterCO - Australia -CO - Finland -</style></notes><work-type><style face="normal" font="default">10.1183/13993003.01228-2017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29242261">PM:29242261</url></web-urls></urls><custom2><style face="normal" font="default">20171228, Spng Y</style></custom2><misc3><style face="normal" font="default">10.1183/13993003.01228-2017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43630</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Qu,C.X.</style></author><author><style face="normal" font="default"> Zhang,Z.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Intensive Care Unit, Xuzhou Children's Hospital, Xuzhou, Jiangsu, P.R. China.</style></auth-address><titles><title><style face="normal" font="default">Current views of pediatric asthma</style></title><secondary-title><style face="normal" font="default">Eur Rev Med Pharmacol Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Eur Rev Med Pharmacol Sci</style></abbr-1></periodical><pages end="108" start="106">106-108</pages><volume><style face="normal" font="default">21</style></volume><number><style face="normal" font="default">4 Suppl</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Childhood asthma is influenced by multiple factors including genetic, socioeconomic, socio demographic and environmental factors. The symptoms of childhood asthma are observed to be variable. Some studies reported that asthma prevalence is disproportionately high among socially disadvantaged children. On the other hand, some reports found weak or no association between social disadvantage and childhood asthma. Recent literature showed that growth of health-related quality of life (HRQOL) instruments in the management of childhood asthma. The present review article would discuss the current views and the latest developments in the field of pediatric asthma</style></abstract><notes><style face="normal" font="default">IS - 2284-0729 (Electronic)IS - 1128-3602 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29165754">PM:29165754</url></web-urls></urls><custom2><style face="normal" font="default">20171229, Qu CX</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43631</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">MacBean,V.</style></author><author><style face="normal" font="default"> Pringle,C.L.</style></author><author><style face="normal" font="default"> Lunt,A.C.</style></author><author><style face="normal" font="default"> Sharp,K.D.</style></author><author><style face="normal" font="default"> Ali,A.</style></author><author><style face="normal" font="default"> Greenough,A.</style></author><author><style face="normal" font="default"> Moxham,J.</style></author><author><style face="normal" font="default"> Rafferty,G.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Asthma, Allergy and Lung Biology, King's College London, London, UK</style></auth-address><titles><title><style face="normal" font="default">Parasternal intercostal muscle activity during methacholine-induced bronchoconstriction</style></title><secondary-title><style face="normal" font="default">Exp Physiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Exp Physiol</style></abbr-1></periodical><pages end="484" start="475">475-484</pages><volume><style face="normal" font="default">102</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Adult</style></keyword><keyword><style face="normal" font="default"> Bronchial Provocation Tests</style></keyword><keyword><style face="normal" font="default"> methods</style></keyword><keyword><style face="normal" font="default"> Bronchoconstriction</style></keyword><keyword><style face="normal" font="default"> drug effects</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Forced Expiratory Volume</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Inspiratory Capacity</style></keyword><keyword><style face="normal" font="default"> Intercostal Muscles</style></keyword><keyword><style face="normal" font="default"> Lung</style></keyword><keyword><style face="normal" font="default"> Lung Volume Measurements</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Methacholine Chloride</style></keyword><keyword><style face="normal" font="default"> pharmacology</style></keyword><keyword><style face="normal" font="default"> Respiratory Muscles</style></keyword><keyword><style face="normal" font="default"> Tidal Volume</style></keyword><keyword><style face="normal" font="default"> Young Adult</style></keyword></keywords><dates><year Day="1" Month="4" Year="2017">2017/4/1</year></dates><abstract><style face="normal" font="default">NEW FINDINGS: What is the central question of this study? The parasternal intercostal electromyogram (EMGpara) is known to provide an accurate, non-invasive index of respiratory load-capacity balance. Although relationships between EMGpara and both airflow obstruction and hyperinflation have been shown, the independent contribution of each factor has not been examined. What is the main finding and its importance? Reductions in airway calibre and inspiratory capacity along with increases in EMGpara were induced via methacholine challenge. A strong inverse relationship was observed between EMGpara and airway obstruction, with no influence of inspiratory capacity. These data suggest that EMGpara is more strongly influenced by airway calibre than by changes in end-expiratory lung volume during airway challenge testing. Neural respiratory drive, measured via the parasternal intercostal electromyogram (EMGpara), provides a non-invasive index of the load-capacity balance of the respiratory muscle pump. Previous studies in patients with obstructive lung disease have shown strong relationships between EMGpara and the extent of both airflow obstruction and hyperinflation. The relative influence of the two factors has not, however, been described. Airflow obstruction was induced via methacholine challenge testing in 25 adult humans. Forced expiratory volume in 1 s (FEV1 ) and surface EMGpara during tidal breathing were measured after each dose, with 20 of the participants also undergoing measurements of inspiratory capacity (IC) at each stage. Linear mixed model analysis was used to assess dose-wise changes in FEV1 and EMGpara, and thereafter to determine the influence of changes in FEV1 and IC on change in EMGpara. Median (interquartile range) FEV1 decreased significantly [from 96.00 (80.00-122.30) to 67.80 (37.98-92.27)% predicted, P &lt; 0.0001] and EMGpara increased significantly [from 5.37 (2.25-8.92) to 6.27 (3.37-19.60) muV, P &lt; 0.0001] from baseline to end of test. Linear mixed model analysis showed a significant interaction between methacholine dose and induced change in EMGpara, with an increase in EMGpara of 0.24 (95% confidence interval 0.11-0.37) muV per methacholine dose(2) . Change in FEV1 further influenced this relationship [increase in slope of 0.002 (0.004-0.001) muV dose(-2) per % predicted fall in FEV1 , P = 0.011], but not with change in IC. These data suggest that bronchoconstriction exerts a more potent influence on levels of EMGpara than changes in end-expiratory lung volume during methacholine challenge</style></abstract><notes><style face="normal" font="default">IS - 1469-445X (Electronic)IS - 0958-0670 (Linking)LA - engPT - Journal ArticleRN - 0W5ETF9M2K (Methacholine Chloride)SB - IMCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1113/EP086120</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="28194830">PM:28194830</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Exp Physiol\2017-102-475-84.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Exp Physiol\2017-102-475-84.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170314, MacBean V</style></custom2><misc3><style face="normal" font="default">10.1113/EP086120</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43632</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fernandez,J.</style></author><author><style face="normal" font="default"> Dona,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Allergy Section , Alicante University Hospital, UMH-ISABIAL , Alicante , Spainb Allergy Service , Carlos Haya Hospital (Pavilion C) , Malaga , Spain</style></auth-address><titles><title><style face="normal" font="default">Diagnosing and managing patients with drug hypersensitivity</style></title><secondary-title><style face="normal" font="default">Expert Rev Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Expert Rev Clin Immunol</style></full-title></periodical><pages end="41" start="29">29-41</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Diagnosing and managing drug hypersensitivity is challenging because there are no clear limits between different types of drug reactions. Distinguishing between type A (predictable) and type B (hypersensitivity) reactions when a drug is introduced on the market is not easy. When many people use a drug, adverse reactions can occur, conditioned by diverse genetic profiles, viral infections or concomitant therapy. Occasionally the only tool clinicians have on which to base the diagnosis is the clinical history. Skins tests or in vitro tests sometimes have low sensitivity or are unavailable, and drug provocation tests may be dangerous or strictly forbidden in case of severe cutaneous reactions. Areas covered: This paper reviews the diagnosis and management of the two main types of immunological reactions: IgE-mediated immediate drug hypersensitivity reactions (IDHRs) and non-immediate drug hypersensitivity reactions (NIDHRs). Expert commentary: Although Europe and the United States use different diagnostic methods, patients with history of drug hypersensitivity must avoid the suspicious drug, and clinicians must assess tolerance to safe alternatives under medical surveillance. Sometimes desensitization may be required. There is a consensus about the need to perform genetic testing for specific drugs and give patients proper documentation to prevent future exposure to culprit drugs</style></abstract><notes><style face="normal" font="default">IS - 1744-8409 (Electronic)IS - 1744-666X (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1080/1744666X.2018.1410059</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29202594">PM:29202594</url></web-urls></urls><custom2><style face="normal" font="default">20171220, Fernandez J</style></custom2><misc3><style face="normal" font="default">10.1080/1744666X.2018.1410059</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43633</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,J.H.</style></author><author><style face="normal" font="default"> Jung,C.G.</style></author><author><style face="normal" font="default"> Park,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Allergy and Clinical Immunology , Ajou University School of Medicine , Suwon , South Koreab Division of Allergy and Clinical Immunology, Department of Internal Medicine , Keimyung University, Dongsan Medical Center , Daegu , South Koreaa Department of Allergy and Clinical Immunology , Ajou University School of Medicine , Suwon , South Korea</style></auth-address><titles><title><style face="normal" font="default">An update on the management of aspirin-exacerbated respiratory disease</style></title><secondary-title><style face="normal" font="default">Expert Rev Respir Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Expert Rev Respir Med</style></abbr-1></periodical><pages end="143" start="137">137-143</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Clinical features of aspirin-exacerbated respiratory disease (AERD) consist of moderate to severe asthma associated with chronic rhinosinusitis (CRS), which are derived from overproduction of cysteinyl leukotrienes along with chronic type 2 mediated inflammation in the upper and lower airway mucosa. Area covered: This review provides recent up-to-date information regarding phenotypes of AERD and encompasses comprehensive diagnostic methods and treatment options. To confirm the diagnosis of AERD, provocation testing via nasal, inhalation or the oral route of aspirin remains the gold standard; in vitro diagnostic methods are still not available. Essential management is to avoid cross-reacting cyclooxygenase 1 (COX-1) inhibitors along with use of highly selective COX-2 inhibitors and to maintain pharmacologic treatment depending on the severity of asthma and chronic rhinosinusitis. Recent biologics, including anti-IgE and anti-IL5 antibodies, are required in severe AERD patients with CRS. Aspirin desensitization can be recommended when indicated. Expert commentary: AERD is a heterogeneous disease in terms of severity and associated allergic disease. When performing diagnosis and treatment for AERD, such disease characteristics need to be kept in mind</style></abstract><notes><style face="normal" font="default">IS - 1747-6356 (Electronic)IS - 1747-6348 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1080/17476348.2018.1417843</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29249187">PM:29249187</url></web-urls></urls><custom2><style face="normal" font="default">20171211, Lee JH</style></custom2><misc3><style face="normal" font="default">10.1080/17476348.2018.1417843</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43634</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zanoni,T.B.</style></author><author><style face="normal" font="default"> Pedrosa,T.N.</style></author><author><style face="normal" font="default"> Catarino,C.M.</style></author><author><style face="normal" font="default"> Spiekstra,S.W.</style></author><author><style face="normal" font="default"> de Oliveira,D.P.</style></author><author><style face="normal" font="default"> Den Hartog,G.</style></author><author><style face="normal" font="default"> Bast,A.</style></author><author><style face="normal" font="default"> Hagemann,G.</style></author><author><style face="normal" font="default"> Gibbs,S.</style></author><author><style face="normal" font="default"> de Moraes Barros,S.B.</style></author><author><style face="normal" font="default"> Maria-Engler,S.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Skin Biology Group, Department of Clinical Chemistry &amp; Toxicology, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, (FCF/USP), Av. Lineu Prestes, 580, CEP 05508-900 Sao Paulo, Brazil.</style></auth-address><titles><title><style face="normal" font="default">Allergens of permanent hair dyes induces epidermal damage, skin barrier loss and IL-1 alpha increase in epidermal in vitro model</style></title><secondary-title><style face="normal" font="default">Food Chem Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Food Chem Toxicol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="12" Year="2017">2017/12/19</year></dates><abstract><style face="normal" font="default">Allergic and irritant skin reactions caused by topical exposure to permanent hair dyes are a common problem. For regulatory and ethnical purposes, it is required to perform chemical safety assessment following the replacement, reduction, and refinement of animal testing (3Rs). Permanent hair dyes are formed by a mixture of ingredients that vary from low to extreme skin sensitizing potency and that inter-react to form unknown by-products. Because of the complex reaction, this cytotoxic mechanism has not yet been elucidated and is the subject of this study. Here, we topically exposed p-phenylenediamine (PPD), Resorcinol (RES), H2O2 alone or as a mixture to RhE and evaluated parameters related to skin irritation such as epidermal viability, keratinocytes damage, barrier loss and IL-1 alpha. Our data indicates that ingredients tested alone did not lead to an increase of cytotoxic parameters related to skin irritation. However, when the mixture of PPD/H2O2/RES and PPD/H2O2 was applied to the RhE, some of the parameters such as morphological changes including the presence of apoptotic cells, barrier loss and increased IL- 1 alpha release were observed. The results indicate that the mixture of ingredients used in permanent hair dyes have an irritant effect in RhE while the ingredients alone not</style></abstract><notes><style face="normal" font="default">IS - 1873-6351 (Electronic)IS - 0278-6915 (Linking)LA - engPT - Journal ArticleCO - Brazil -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.fct.2017.12.033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29273420">PM:29273420</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem Toxicol\20171219-ZanoniTB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem Toxicol\20171219-ZanoniTB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171219,Zanoni TB</style></custom2><misc3><style face="normal" font="default">10.1016/j.fct.2017.12.033</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43635</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ezendam,J.</style></author><author><style face="normal" font="default"> Bokkers,B.G.H.</style></author><author><style face="normal" font="default"> Bil,W.</style></author><author><style face="normal" font="default"> Delmaar,J.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Skin sensitisation quantitative risk assessment (QRA) based on aggregate dermal exposure to methylisothiazolinone in personal care and household cleaning products</style></title><secondary-title><style face="normal" font="default">Food Chem Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Food Chem Toxicol</style></full-title></periodical><pages end="250" start="242">242-250</pages><volume><style face="normal" font="default">112</style></volume><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Quantitative risk assessment</style></keyword><keyword><style face="normal" font="default"> skin sensitization</style></keyword><keyword><style face="normal" font="default"> methylisothiazolinone</style></keyword><keyword><style face="normal" font="default"> Aggregate exposure assessment</style></keyword><keyword><style face="normal" font="default"> Cosmetic products</style></keyword><keyword><style face="normal" font="default"> Household cleaning products</style></keyword></keywords><dates><year Day="0" Month="0" Year="2018">2018</year></dates><isbn><style face="normal" font="default">0278-6915</style></isbn><abstract><style face="normal" font="default">Abstract Contact allergy to preservatives is an important public health problem. Ideally, new substances should be evaluated for the risk on skin sensitization before market entry, for example by using a quantitative risk assessment (QRA) as developed for fragrances. As a proof-of-concept, this QRA was applied to the preservative methylisothiazolinone (MI), a common cause of contact allergy. MI is used in different consumer products, including personal care products (PCPs) and household cleaning products (HCPs). Aggregate exposure to MI in PCPs and HCPs was therefore assessed with the Probabilistic Aggregated Consumer Exposure Model (PACEM). Two exposure scenarios were evaluated: scenario 1 calculated aggregate exposure on actual MI product concentrations before the restricted use in PCPs and scenario 2 calculated aggregate exposure using the restrictions for MI in PCPs. The QRA for MI showed that in scenarios 1 and 2, the proportion of the population at risk for skin sensitisation is 0.7% and 0.5%, respectively. The restricted use of MI in PCPs does not seem very effective in lowering the risk on skin sensitization. To conclude, it is important to consider aggregate exposure from the most important consumer products into consideration in the risk assessment</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.fct.2017.12.054</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.fct.2017.12.054</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Food Chem Toxicol\2018-112-242-50.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Food Chem Toxicol\2018-112-242-50.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171225, Ezendam J</style></custom2><misc3><style face="normal" font="default">10.1016/j.fct.2017.12.054</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43636</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Paivandy,A.</style></author><author><style face="normal" font="default"> Sandelin,M.</style></author><author><style face="normal" font="default"> Igelstrom,H.</style></author><author><style face="normal" font="default"> Landelius,P.</style></author><author><style face="normal" font="default"> Janson,C.</style></author><author><style face="normal" font="default"> Melo,F.R.</style></author><author><style face="normal" font="default"> Pejler,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden</style></auth-address><titles><title><style face="normal" font="default">Induction of Human Lung Mast Cell Apoptosis by Granule Permeabilization: A Novel Approach for Targeting Mast Cells</style></title><secondary-title><style face="normal" font="default">Front Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Immunol</style></abbr-1></periodical><pages end="" start="1645">1645-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Mast cells are implicated as detrimental players in inflammatory lung diseases, particularly asthma. Mast cells respond to activating stimuli by releasing a wide panel of pro-inflammatory compounds that can contribute profoundly to the pathology, and there is currently an unmet need for strategies that efficiently ameliorate harmful effects of mast cells under such conditions. Here, we sought to evaluate a novel concept for targeting human lung mast cells, by assessing the possibility of selectively depleting the lung mast cells by induction of apoptosis. For this purpose, we used lysosomotropic agents, i.e., compounds that are known to permeabilize the secretory granules of mast cells, thereby releasing the contents of the granules into the cytosol. Either intact human lung tissue, purified human lung mast cells or mixed populations of human lung cells were incubated with the lysosomotropic agents mefloquine or siramesine, followed by measurement of apoptosis, reactive oxygen species (ROS) production, and release of cytokines. We show that human lung mast cells were highly susceptible to apoptosis induced by this strategy, whereas other cell populations of the lung were largely refractory. Moreover, we demonstrate that apoptosis induced by this mode is dependent on the production of ROS and that the treatment of lung tissue with lysosomotropic agents causes a decrease in the release of pathogenic cytokines. We conclude that selective apoptosis of human lung mast cells can be accomplished by administration of lysosomotropic agents, thus introducing the possibility of using such drugs as novel therapeutics in the treatment of inflammatory lung disorders such as asthma</style></abstract><notes><style face="normal" font="default">IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.3389/fimmu.2017.01645</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29230220">PM:29230220</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Immunol\2017-8-1645.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Immunol\2017-8-1645.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171127, Paivandy A</style></custom2><misc3><style face="normal" font="default">10.3389/fimmu.2017.01645</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43637</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kahn,J.E.</style></author><author><style face="normal" font="default"> Groh,M.</style></author><author><style face="normal" font="default"> Lefevre,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Service de Medecine Interne, Centre de Reference des Syndromes Hypereosinophiliques-CEREO, Hopital Foch, Universite Versailles-Saint Quentin en Yvelines, Suresnes, FranceService de Medecine Interne, Hopital Saint Louis, Universite Paris-Diderot, Paris, FranceUniversite de Lille, INSERM, CHU Lille, U</style></auth-address><titles><title><style face="normal" font="default">(A Critical Appraisal of) Classification of Hypereosinophilic Disorders</style></title><secondary-title><style face="normal" font="default">Front Med (Lausanne)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Med (Lausanne)</style></abbr-1></periodical><pages end="" start="216">216-</pages><volume><style face="normal" font="default">4</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Hypereosinophilia (HE) is a heterogeneous condition that can be reported in various (namely inflammatory, allergic, infectious, or neoplastic) diseases with distinct pathophysiological pathways. In 1975, Chusid et al. published the first diagnostic criteria of hypereosinophilic syndromes (HES). Over the years, as both basic and clinical knowledge improved, several updates have been suggested, with a focus on better distinguishing isolated or asymptomatic eosinophilia from diseases with specific eosinophil-related organ damage. Moreover, underlying molecular and cellular mechanisms of eosinophilia gradually became the cornerstone of successive attempts to classify HE-related diseases. In 2011, the International Cooperative Working Group on Eosinophil Disorders criteria emerged from a multidisciplinary Working Conference on Eosinophil Disorders and Syndromes, and provided substantial contribution to the clarification of general concepts and definitions in the field of HE. Yet, owing to the low prevalence of HE/HES, to the numerous diseases encompassed in the spectrum of HE-related disorders (with sometimes overlapping phenotypes), many questions are left unanswered (e.g., the need to better standardize the use of modern molecular tools, or the clinical relevance of distinguishing different subtypes of idiopathic HES). Here, we review the current state of knowledge in the fields of classification and diagnosis criteria of HE-related diseases, with emphasis on the analysis of both strengths and weaknesses of present concepts and their usefulness in daily practice</style></abstract><notes><style face="normal" font="default">IS - 2296-858X (Print)IS - 2296-858X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - France -</style></notes><work-type><style face="normal" font="default">10.3389/fmed.2017.00216</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29259972">PM:29259972</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Front Med (Lausanne)\2017-4-216.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Front Med (Lausanne)\2017-4-216.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171205, Kahn JE</style></custom2><misc3><style face="normal" font="default">10.3389/fmed.2017.00216</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43638</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bergallo,M.</style></author><author><style face="normal" font="default"> Accorinti,M.</style></author><author><style face="normal" font="default"> Galliano,I.</style></author><author><style face="normal" font="default"> Coppo,P.</style></author><author><style face="normal" font="default"> Montanari,P.</style></author><author><style face="normal" font="default"> Quaglino,P.</style></author><author><style face="normal" font="default"> Savino,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Azienda Ospedaliera Universitaria Citta della Salute e della Scienza di Torino, Turin, Italy</style></auth-address><titles><title><style face="normal" font="default">Expression of miRNA 155, FOXP3 and ROR gamma, in children with moderate and severe atopic dermatitis</style></title><secondary-title><style face="normal" font="default">G Ital Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">G Ital Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="15" Month="12" Year="2017">2017/12/15</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis is a disease characterized by a chronic inflammatory process in the skin, but its link to miRNA 155 is less known. The aim of the study was to evaluate the expression of microRNA155, and T helper type 17 cells and Treg cells in children with atopic dermatitis. METHODS: The study population consisted of: children seen for atopic dermatitis at the outpatient ambulatory of Dermatology at the Children Hospital Regina Margherita, Torino, Italy,( n = 23); healthy control subjects ( n =23). Blood samples were taken during routine control analysis and the expression of miRNA 155 and the production of FOXP3 and ROR was determined using PCR real time. RESULTS: The analysis of miR-155 shows that the over-expression of miR-155 is statistically significant (p = 0.0040) in the group of patients with atopic dermatitis compared to the healthy control group. Analysis of mRNAs of FOXP3 and ROR shows a FOXP3 mRNA expression statistically higher in the group of patients (p = 0.0057). The Th17 / Treg ratio is significantly smaller in patients with atopic dermatitis (p = 0.0012). Also the ratio miR-155/Th17/Treg is larger in the group of patients with atopic dermatitis (p = 0.0002). CONCLUSIONS: Our results suggest that increased miR-155 and FOXP3 and ROR responses may provide a link to immune dysregulation associated with atopic dermatitis. Although a point-by-point correlation between miR-155 and the ratio Th17/Treg is not demonstrated, our findings shows that these two elements do not appear to be completely unrelated to each other</style></abstract><notes><style face="normal" font="default">IS - 1827-1820 (Electronic)IS - 0392-0488 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.23736/S0392-0488.17.05707-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29249119">PM:29249119</url></web-urls></urls><custom2><style face="normal" font="default">20171215, Bergallo M</style></custom2><misc3><style face="normal" font="default">10.23736/S0392-0488.17.05707-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43639</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pacholewska,A.</style></author><author><style face="normal" font="default"> Kraft,M.F.</style></author><author><style face="normal" font="default"> Gerber,V.</style></author><author><style face="normal" font="default"> Jagannathan,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Veterinary Medicine, Swiss Institute of Equine Medicine, Vetsuisse Faculty, University of Bern and Agroscope, Langgassstrasse 124, 3012 Bern, Switzerland.</style></auth-address><titles><title><style face="normal" font="default">Differential Expression of Serum MicroRNAs Supports CD4(+) T Cell Differentiation into Th2/Th17 Cells in Severe Equine Asthma</style></title><secondary-title><style face="normal" font="default">Genes (Basel)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Genes (Basel)</style></abbr-1></periodical><pages end="" start="">-</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="12" Year="2017">2017/12/12</year></dates><abstract><style face="normal" font="default">MicroRNAs (miRNAs) regulate post-transcriptional gene expression and may be exported from cells via exosomes or in partnership with RNA-binding proteins. MiRNAs in body fluids can act in a hormone-like manner and play important roles in disease initiation and progression. Hence, miRNAs are promising candidates as biomarkers. To identify serum miRNA biomarkers in the equine model of asthma we investigated small RNA derived from the serum of 34 control and 37 asthmatic horses. These samples were used for next generation sequencing, novel miRNA identification and differential miRNA expression analysis. We identified 11 significantly differentially expressed miRNAs between case and control horses: eca-miR-128, eca-miR-744, eca-miR-197, eca-miR-103, eca-miR-107a, eca-miR-30d, eca-miR-140-3p, eca-miR-7, eca-miR-361-3p, eca-miR-148b-3p and eca-miR-215. Pathway enrichment using experimentally validated target genes of the human homologous miRNAs showed a significant enrichment in the regulation of epithelial-to-mesenchymal transition (key player in airway remodeling in asthma) and the phosphatidylinositol (3,4,5)-triphosphate (PIP3) signaling pathway (modulator of CD4(+) T cell maturation and function). Downregulated miR-128 and miR-744 supports a Th2/Th17 type immune response in severe equine asthma</style></abstract><notes><style face="normal" font="default">IS - 2073-4425 (Print)IS - 2073-4425 (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.3390/genes8120383</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29231896">PM:29231896</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Genes (Basel)\2017-8-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Genes (Basel)\2017-8-12.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171212, Pacholewska A</style></custom2><misc3><style face="normal" font="default">10.3390/genes8120383</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43640</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ohkusu-Tsukada,K.</style></author><author><style face="normal" font="default"> Yamashita,T.</style></author><author><style face="normal" font="default"> Tsukada,T.</style></author><author><style face="normal" font="default"> Takahashi,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Veterinary Pathology, Nippon Veterinary and Life science University (NVLU), 1-7-1 Kyonan-cho, Musashino, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default">Low expression of a D(dm7)/L(dm7)-hybrid mutant (D/L(dm7)) in the novel haplotype H-2(nc) identified in atopic dermatitis model NC/Nga mice</style></title><secondary-title><style face="normal" font="default">Genes Immun</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Genes Immun</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="12" Year="2017">2017/12/22</year></dates><abstract><style face="normal" font="default">Environmental factors and the major histocompatibility complex (MHC) are involved in the pathogenesis of atopic dermatitis (AD). However, MHC type (H2 haplotype) of AD model mice NC/Nga is poorly understood. Alloreactive CD8(+) or CD4(+) T cells in NC/Nga strongly responded to each antigen-presenting cells (A/J: H-2(a), C57BL/6: H-2(b), BALB/c: H-2(d), or C3H/HeJ: H-2(k)), suggesting that NC/Nga has other H2 haplotype. Polymorphic microsatellite (CA)(n) repeats in TNF-alpha gene differ based on the H2 haplotype at present. NC/Nga's (CA)(n) repeats (n = 19) were different from other examined strains, A/J (n = 14), BALB/c (n = 14), C3H/HeJ (n = 16), and C57BL/6 (n = 20). Using flow cytometry and genotyping, we demonstrated the NC/Nga H2 haplotype had a unique phenotype (K(d), I-A(k), and I-E(k)) in which D(d) and L(d) lacked as protein despite sensitive mRNA detection. The loss of D(d) and L(d) was caused by forming a unique D(dm7)/L(dm7)-hybrid mutant (D/L(dm7)). We propose to call this novel H2 haplotype the "H-2(nc)," and provide the important information regarding the AD research using NC/Nga mice</style></abstract><notes><style face="normal" font="default">IS - 1476-5470 (Electronic)IS - 1466-4879 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1038/s41435-017-0003-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29282355">PM:29282355</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Genes Immun\20171227-OhkusuTsukadaK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Genes Immun\20171227-OhkusuTsukadaK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171227, Ohkusu-Tsukada K</style></custom2><misc3><style face="normal" font="default">10.1038/s41435-017-0003-y</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43641</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Klimek,L.</style></author><author><style face="normal" font="default"> Werfel,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Wichtige Informationen zur Leitlinie zur (allergen)spezifischen Immuntherapie (SIT)</style></title><secondary-title><style face="normal" font="default">Hautarzt</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Hautarzt</style></full-title></periodical><pages end="85" start="84">84-85</pages><volume><style face="normal" font="default">69</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><isbn><style face="normal" font="default">1432-1173</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - GERCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1007/s00105-017-4093-2</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s00105-017-4093-2</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hautarzt\2018-69-84-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hautarzt\2018-69-84-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171214, Klimek L</style></custom2><misc3><style face="normal" font="default">10.1007/s00105-017-4093-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43642</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rapp,K.I.</style></author><author><style face="normal" font="default"> Jack,L.,Jr.</style></author><author><style face="normal" font="default"> Wilson,C.</style></author><author><style face="normal" font="default"> Hayes,S.C.</style></author><author><style face="normal" font="default"> Post,R.</style></author><author><style face="normal" font="default"> McKnight,E.</style></author><author><style face="normal" font="default"> Malveaux,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Xavier University of Louisiana College of Pharmacy, New Orleans, LA, USA</style></auth-address><titles><title><style face="normal" font="default">Improving Asthma-Related Outcomes Among Children Participating in the Head-Off Environmental Asthma in Louisiana (HEAL), Phase II Study</style></title><secondary-title><style face="normal" font="default">Health Promot Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Health Promot Pract</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="default">PURPOSE: Pediatric asthma disproportionately affects low-income and minority children. The HEAL (Head-Off Environmental Asthma in Louisiana), Phase II Project was a collaborative effort with a primary focus to improve pediatric asthma management in New Orleans, Louisiana. The purpose of this article is to report clinical outcomes captured at baseline and 12-month follow-up. METHOD: HEAL (Head-off Environmental Asthma in Louisiana), Phase II was a pre-post intervention study that enrolled children ages 2 to 18 years of age with a diagnosis of asthma to receive asthma education within the clinic setting. Enrollees received an asthma education intervention, an environmental evaluation, and a 12-month follow-up session. Endpoints included symptom days, level of asthma control, asthma exacerbations, emergency room visits, hospitalizations, and missed school days. RESULTS: The majority of participants were aged 5 years and older, male, Black, and persistent asthmatics. Emergency room visits decreased from 41% to 20% ( p &lt; .001). Improvements in coughing (83% to 62%, p &lt; .001), wheezing (50% to 26%, p &lt; .001), and chest tightness (29% to 18%, p &lt; .001) were also seen. CONCLUSION: The novel intervention was associated with improved asthma outcomes among pediatric patients receiving care at the clinical sites in the Greater New Orleans area</style></abstract><notes><style face="normal" font="default">IS - 1524-8399 (Print)IS - 1524-8399 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/1524839917740126</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29166783">PM:29166783</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Health Promot Pract\20171122-RappKI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Health Promot Pract\20171122-RappKI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171122, Rapp KI</style></custom2><misc3><style face="normal" font="default">10.1177/1524839917740126</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43643</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shein,S.L.</style></author><author><style face="normal" font="default"> Farhan,O.</style></author><author><style face="normal" font="default"> Morris,N.</style></author><author><style face="normal" font="default"> Mahmood,N.</style></author><author><style face="normal" font="default"> Alter,S.J.</style></author><author><style face="normal" font="default"> Biagini Myers,J.M.</style></author><author><style face="normal" font="default"> Gunkelman,S.M.</style></author><author><style face="normal" font="default"> Kercsmar,C.M.</style></author><author><style face="normal" font="default"> Khurana Hershey,G.K.</style></author><author><style face="normal" font="default"> Martin,L.J.</style></author><author><style face="normal" font="default"> McCoy,K.S.</style></author><author><style face="normal" font="default"> Ruddy,J.R.</style></author><author><style face="normal" font="default"> Ross,K.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Divisions of Pediatric Critical Care Medicine</style></auth-address><titles><title><style face="normal" font="default">Adjunctive Pharmacotherapies in Children With Asthma Exacerbations Requiring Continuous Albuterol Therapy: Findings From The Ohio Pediatric Asthma Repository</style></title><secondary-title><style face="normal" font="default">Hosp Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Hosp Pediatr</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="1" Year="2018">2018/1/5</year></dates><abstract><style face="normal" font="default">OBJECTIVES: To identify associations between use of ipratropium and/or intravenous magnesium and outcomes of children hospitalized with acute asthma exacerbations and treated with continuous albuterol. METHODS: Secondary analysis of data from children prospectively enrolled in the multicenter Ohio Pediatric Asthma Repository restricted to only children who were treated with continuous albuterol in their initial inpatient location. Children were treated with adjunctive therapies per the clinical team. RESULTS: Among 242 children who received continuous albuterol, 94 (39%) received ipratropium only, 13 (5%) received magnesium alone, 42 (17%) received both, and 93 (38%) received neither. The median duration of continuous albuterol was 7.0 (interquartile range [IQR]: 2.8-12.0) hours. Ipratropium use was associated with a shorter duration of continuous albuterol (4.9 [IQR: 2.0-10.0] hours) compared with dual therapy (11.0 [IQR: 5.6-28.6] hours; P = .001), but magnesium use was not (7.5 [IQR: 2.5-16.0] hours; P = .542). In Cox proportional models (adjusted for hospital, demographics, treatment location, and respiratory failure), magnesium was associated with longer durations of continuous albuterol (hazard ratio, 0.54 [95% confidence interval: 0.37-0.77]; P &lt; .001) and hospitalization (hazard ratio, 0.41 [95% confidence interval: 0.28-0.60]; P &lt; .001), but ipratropium was not. CONCLUSIONS: Ipratropium and magnesium were both often used in children with severe asthma hospitalizations that required continuous albuterol therapy. Magnesium use was associated with unfavorable outcomes, possibly reflecting preferential treatment to patients with more severe cases and differing practices between centers. Given the high prevalence of asthma, wide variations in practice, and the potential to improve outcomes and costs, prospective trials of these adjunctive therapies are needed</style></abstract><notes><style face="normal" font="default">IS - 2154-1663 (Print)IS - 2154-1671 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1542/hpeds.2017-0088</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29305409">PM:29305409</url></web-urls><related-urls><url ppv-ref="no">presto - 1 anno</url></related-urls></urls><custom2><style face="normal" font="default">20180105, Shein SL</style></custom2><misc3><style face="normal" font="default">10.1542/hpeds.2017-0088</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43644</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mancano,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Temple University School of Pharmacy, Philadelphia, PA, USAInstitute for Safe Medication Practices, Horsham, PA, USA</style></auth-address><titles><title><style face="normal" font="default">ISMP Adverse Drug Reactions: Allergic Angina Caused by Fluconazole Rhabdomyolysis Caused by Risperidone High Incidence of Hyponatremia With High-Dose Trimethoprim-Sulfamethoxazole Lithium Carbonate-Induced Hypersalivation Persistent Hemorrhage After Idarucizumab Administration</style></title><secondary-title><style face="normal" font="default">Hosp Pharm</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Hosp Pharm</style></abbr-1></periodical><pages end="458" start="455">455-458</pages><volume><style face="normal" font="default">52</style></volume><number><style face="normal" font="default">7</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="7" Year="2017">2017/7</year></dates><abstract><style face="normal" font="default">The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA) MedWatch program (800-FDA-1088). If you have reported an interesting, preventable ADR to MedWatch, please consider sharing the account with our readers. Write to Dr. Mancano at ISMP, 200 Lakeside Drive, Suite 200, Horsham, PA 19044 (phone: 215-707-4936; e-mail: mmancano@temple.edu). Your report will be published anonymously unless otherwise requested. This feature is provided by the Institute for Safe Medication Practices (ISMP) in cooperation with the FDA's MedWatch program and Temple University School of Pharmacy. ISMP is an FDA MedWatch partner</style></abstract><notes><style face="normal" font="default">IS - 0018-5787 (Print)IS - 0018-5787 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/0018578717717621</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29276272">PM:29276272</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hosp Pharm\2017-52-455-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hosp Pharm\2017-52-455-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170911, Mancano MA</style></custom2><misc3><style face="normal" font="default">10.1177/0018578717717621</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43645</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Elkama,A.</style></author><author><style face="normal" font="default"> Ulker,O.C.</style></author><author><style face="normal" font="default"> Teker,E.</style></author><author><style face="normal" font="default"> Karakaya,A.</style></author><author><style face="normal" font="default"> Karakaya,A.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Department of Toxicology, Faculty of Pharmacy, Gazi University, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="default">Investigation of hypersensitivity potential of diacetyl by determining cytokine profiles</style></title><secondary-title><style face="normal" font="default">Hum Exp Toxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Hum Exp Toxicol</style></full-title></periodical><pages end="" start="960327117695636">960327117695636-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="default">Exposure to chemicals in workplace settings leads to significant occupational diseases related to hypersensitivity reactions. In recent years, diacetyl which is used as a food additive is thought to be as an important hazard due to its sensitization potency for worker's health. Therefore, in this study, we aimed to investigate the sensitization potency of diacetyl for the purpose of its hazard evaluation. Nonradioactive ex vivo local lymph node assay: BrdU-enzyme-linked immunosorbent assay (ELISA) method with short-term and long-term exposure protocols were conducted based on animal welfare principles. As end points, lymphocyte proliferation, cytokine releases, and total serum IgE levels were measured by ELISA method. After short-term dermal exposure to diacetyl, primary Th1 cytokine interleukin-2 (IL-2) and Th2 cytokines IL-4 and IL-13 levels were significantly increased relatively to vehicle control, whereas such significant increases were not observed in long-term exposure. According to our measurements of IgE levels after long-term dermal exposures to chemicals, diacetyl led to significant increase. In conclusion, the findings that showed significant increases in IL-13 and total serum IgE levels induced with diacetyl can be relevant to respiratory sensitizing hazard of this chemical</style></abstract><notes><style face="normal" font="default">IS - 1477-0903 (Electronic)IS - 0960-3271 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1177/0960327117695636</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29233007">PM:29233007</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Hum Exp Toxicol\20171201-ElkamaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Hum Exp Toxicol\20171201-ElkamaA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Elkama A</style></custom2><misc3><style face="normal" font="default">10.1177/0960327117695636</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43646</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Di Lorenzo,G.</style></author><author><style face="normal" font="default"> Di Bona,D.</style></author><author><style face="normal" font="default"> Belluzzo,F.</style></author><author><style face="normal" font="default"> Macchia,L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Immunological and non-immunological mechanisms of allergic diseases in the elderly: biological and clinical characteristics</style></title><secondary-title><style face="normal" font="default">Immun Ageing</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Immun Ageing</style></full-title></periodical><pages end="" start="23">23-</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1742-4933</style></isbn><abstract><style face="normal" font="default">A better hygiene, a Westernized diet, air pollution, climate changes, and other factors that influence host microbiota, a key player in the induction and maintenance of immunoregulatory circuits and tolerance, are thought to be responsible for the increase of allergic diseases observed in the last years. The increase of allergic diseases in elderly is related to the presence of other factors as several comorbidities that should interfere with the development and the type of allergic reactions. A central role is played by immunosenescence responsible for modifying response to microbiota and triggering inflamm-ageing. In addition, in elderly there is a shift from Th1 responses vs. Th2, hence favouring allergic responses. Better understanding of the mechanisms of immunosenescence and its effects on allergic inflammation will most certainly lead to improved therapy</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1186/s12979-017-0105-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29296117">PM:29296117</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Immun Ageing\2017-14-23.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Immun Ageing\2017-14-23.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171110, Di Lorenzo G</style></custom2><misc3><style face="normal" font="default">10.1186/s12979-017-0105-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43647</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Thakkar,S.</style></author><author><style face="normal" font="default"> Patel,T.K.</style></author><author><style face="normal" font="default"> Vahora,R.</style></author><author><style face="normal" font="default"> Bhabhor,P.</style></author><author><style face="normal" font="default"> Patel,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Skin and VD, GMERS Medical College, Gotri, Vadodara, Gujarat, India</style></auth-address><titles><title><style face="normal" font="default">Cutaneous Adverse Drug Reactions in a Tertiary Care Teaching Hospital in India: An Intensive Monitoring Study</style></title><secondary-title><style face="normal" font="default">Indian J Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Indian J Dermatol</style></abbr-1></periodical><pages end="625" start="618">618-625</pages><volume><style face="normal" font="default">62</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">Background: The epidemiological data based on intensive monitoring studies are limited for the cutaneous adverse drug reactions (CADRs) in terms of incidence. Most of earlier Indian studies focused only on types and causative drugs of CADRs. Aim: The aim of this study is to analyze the CADRs with reference to the incidence, its subgroup analysis, causative drugs, and other clinical characteristics in Indian population. Methodology: Intensive monitoring study was carried out over a period of 3 years in the dermatology outpatient and inpatient department. CADRs due to only systematically administered drugs were considered. The WHO definition for CADR, the WHO causality definitions, modified Schumock and Thornton's criteria for preventability, and International Conference on Harmonisation E2A guidelines for seriousness were considered. Incidence was expressed in percentage and its 95% confidence interval. The incidence was analyzed on basis of characteristics of study population and CADRs. Results: A total of 171 CADRs were observed from 37,623 patients. The CADR incidence was 0.45% (95% CI: 0.39-0.53). The incidence did not significantly differ in different age groups and gender. Commonly observed CADRs were maculopapular rash (23.98%), urticaria (21.64%), and fixed drug eruptions (FDEs) (18.13%). Antimicrobials (35.18%) and nonsteroidal anti-inflammatory drugs (NSAIDs) were suspected in all common CADRs. Anti-infective and NSAIDs were most commonly suspected drugs in overall CADRs, maculopapular rash, urticaria, FDEs, and erythema multiforme. The exact nature of drugs remained inaccessible in one-fourth cases due to use of the over-the-counter self-medications. The incidence of preventable and serious and fatal CADRs was 0.08% (95% CI: 0.05-0.11), 0.04% (95% CI: 0.02-0.06), and 0.003% (95% CI: 0.000-0.001), respectively. Conclusion: Ethnic characteristics should be considered while interpreting incidence from the international studies. The demographic characteristics of study population do not affect the incidence of CADRs. Indian patients should be sensitized about hazards of self-medications</style></abstract><notes><style face="normal" font="default">IS - 1998-3611 (Electronic)IS - 0019-5154 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.4103/ijd.IJD_703_16</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29263536">PM:29263536</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Dermatol\2017-62-618-25.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Dermatol\2017-62-618-25.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171216, Thakkar S</style></custom2><misc3><style face="normal" font="default">10.4103/ijd.IJD_703_16</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43648</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sankar,J.</style></author><author><style face="normal" font="default"> Ranjan Das,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Asthma </style><style face="normal" font="Symbol">-</style><style face="normal" font="default"> A Disease of How We Breathe: Role of Breathing Exercises and Pranayam</style></title><secondary-title><style face="normal" font="default">Indian J Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Indian J Pediatr</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">0973-7693</style></isbn><abstract><style face="normal" font="default">To describe the role of breathing exercises or yoga and/or pranayama in the management of childhood asthma. We conducted an updated literature search and retrieved relevant literature on the role of breathing exercises or yoga and/or pranayama in the management of childhood asthma. We found that the breathing exercises or yoga and/or pranayama are generally multi-component packaged interventions, and are described as follows: Papworth technique, Buteyko technique, Yoga and/or Pranayam. These techniques primarily modify the pattern of breathing to reduce hyperventilation resulting in normalisation of CO2 level, reduction of bronchospasm and resulting breathlessness. In addition they also change the behaviour, decrease anxiety, improve immunological parameters, and improve endurance of the respiratory muscles that may ultimately help asthmatic children. We found 10 clinical trials conducted in children with asthma of varying severity, and found to benefit children with chronic (mild and moderate) and uncontrolled asthma, but not acute severe asthma. Breathing exercises or yoga and/or pranayama may benefit children with chronic (mild and moderate) and uncontrolled asthma, but not acute severe asthma. Before these techniques can be incorporated into the standard care of asthmatic children, important outcomes like quality of life, medication use, and patient reported outcomes need to be evaluated in future clinical trials</style></abstract><notes><style face="normal" font="default">LA - ENGCO - India -</style></notes><work-type><style face="normal" font="default">10.1007/s12098-017-2519-6</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1007/s12098-017-2519-6</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Pediatr\20171216-SankarJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Pediatr\20171216-SankarJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171216, Sankar J</style></custom2><misc3><style face="normal" font="default">10.1007/s12098-017-2519-6</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43649</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kaur,S.</style></author><author><style face="normal" font="default"> Singh,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Vardhman Mahavir Medical College and Associated Safdarjung Hospital, New Delhi, IndiaDepartment of Pediatrics, Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital, New Delhi, India. 4vsingh@gmail.com</style></auth-address><titles><title><style face="normal" font="default">Asthma and Medicines - Long-Term Side-Effects, Monitoring and Dose Titration</style></title><secondary-title><style face="normal" font="default">Indian J Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Indian J Pediatr</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="1" Year="2018">2018/1/6</year></dates><abstract><style face="normal" font="default">Asthma is a major pediatric respiratory morbidity requiring long-term management. A thorough knowledge of long-term medication side-effects in children is, thus, essential for every physician dealing with childhood asthma. Establishing diagnosis and initiating treatment is just a beginning of the journey. Ongoing monitoring is an essential component of comprehensive asthma management programme. Monitoring includes not only assessment of asthma control but also checking for adherence to treatment, technique of inhaler device use, associated co-morbities, if any, and potential environmental exposure. Various tools - both subjective and objective - are available for assessment of asthma control. However, evidence for their optimum use in different settings and patient groups is lacking and monitoring has to be customized depending on available resources and individual patient characteristics. Patient education is an important component of long-term asthma therapy. The ultimate aim is to achieve optimum asthma control i.e., achieve and maintain control of clinical symptoms, decrease future risk to patients (risk of exacerbations, progressive loss of lung function and development of fixed airflow obstruction, adverse effects of medications) and enabling the child to lead a life without restrictions, at lowest possible dose of drugs. This article reviews the side-effects of medications used for long-term management of asthma and discusses current literature on asthma monitoring and dose titration in pediatric population to help the asthma therapist not only prescribe the drugs rationally but also help the family make right choices for treatment</style></abstract><notes><style face="normal" font="default">IS - 0973-7693 (Electronic)IS - 0019-5456 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - India -</style></notes><work-type><style face="normal" font="default">10.1007/s12098-017-2553-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29306991">PM:29306991</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Indian J Pediatr\20180106-KaurS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Indian J Pediatr\20180106-KaurS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180106, Kaur S</style></custom2><misc3><style face="normal" font="default">10.1007/s12098-017-2553-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43650</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Li,W.</style></author><author><style face="normal" font="default"> Liu,F.</style></author><author><style face="normal" font="default"> Wang,J.</style></author><author><style face="normal" font="default"> Long,M.</style></author><author><style face="normal" font="default"> Wang,Z.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Cardiology, Liyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, 430077, China</style></auth-address><titles><title><style face="normal" font="default">MicroRNA-21-Mediated Inhibition of Mast Cell Degranulation Involved in the Protective Effect of Berberine on 2,4-Dinitrofluorobenzene-Induced Allergic Contact Dermatitis in Rats via p38 Pathway</style></title><secondary-title><style face="normal" font="default">Inflammation</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Inflammation</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="12" Year="2017">2017/12/27</year></dates><abstract><style face="normal" font="default">The study aimed to investigate the effect of berberine on allergic contact dermatitis (ACD) in rats and explore its underlying mechanisms. Firstly, ACD model was established by sensitizing and challenging with 2,4-dinitrofluorobenzene (DNFB) topically, and the rats were treated with berberine. Ear swelling was assessed, and cytokine, IgE, and histamine productions were measured. The ear biopsies were obtained for histology analysis. Additionally, rat peritoneal mast cells (RPMCs) were isolated for detection of microRNA-21 (miR-21) expression, mitogen-activated protein kinase (MAPK) signaling, and MC degranulation. Lastly, RPMCs were transfected with miR-21 mimic or miR-21 inhibitor to investigate the relationship between miR-21 and p38 pathway in MC. Our results showed that berberine significantly attenuated ear swelling in DNFB-induced ACD (ACD vs high dose of berberine 0.48 +/- 0.03 vs. 0.33 +/- 0.03 mm, P &lt; 0.01), inhibited inflammatory cell infiltration (86 +/- 5.16 vs. 58 +/- 4.32 cells/mm(2), P &lt; 0.01), reduced MC recruitment (61 +/- 4.07 vs. 39 +/- 3.42 mast cells/mm(2), P &lt; 0.01), as well as decreased inflammatory cytokine, IgE, and histamine productions (all P &lt; 0.05). Berberine treatment inhibited miR-21 expression, suppressed beta-hexosaminidase and histamine release, and prevented p38 phosphorylation (all P &lt; 0.05), which was abrogated by pretreatment with miR-21 overexpression. These findings indicate that miR-21-mediated inhibition of MC degranulation is involved in the anti-ACD effect of berberine via inhibiting p38 pathway, which provide a new insight into the immunopharmacological role of berberine and suggest its potential application for the treatment of allergic inflammation, such as ACD</style></abstract><notes><style face="normal" font="default">IS - 1573-2576 (Electronic)IS - 0360-3997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1007/s10753-017-0723-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29282578">PM:29282578</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Inflammation\20171227-LiW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Inflammation\20171227-LiW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171227, Li W</style></custom2><misc3><style face="normal" font="default">10.1007/s10753-017-0723-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43651</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kutzora,S.</style></author><author><style face="normal" font="default"> Weber,A.</style></author><author><style face="normal" font="default"> Heinze,S.</style></author><author><style face="normal" font="default"> Hendrowarsito,L.</style></author><author><style face="normal" font="default"> Nennstiel-Ratzel,U.</style></author><author><style face="normal" font="default"> von Mutius,E.</style></author><author><style face="normal" font="default"> Fuchs,N.</style></author><author><style face="normal" font="default"> Herr,C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Asthmatic/wheezing phenotypes in preschool children: Influential factors, health care and urban-rural differences</style></title><secondary-title><style face="normal" font="default">Int J Hyg Environ Health</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Hyg Environ Health</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergy test</style></keyword><keyword><style face="normal" font="default"> asthma</style></keyword><keyword><style face="normal" font="default"> Children</style></keyword><keyword><style face="normal" font="default"> Health care</style></keyword><keyword><style face="normal" font="default"> Urban-rural differences</style></keyword><keyword><style face="normal" font="default"> Wheezing phenotypes</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1438-4639</style></isbn><abstract><style face="normal" font="default">AbstractBackground Different wheezing and asthmatic phenotypes turned out to indicate differences in etiology, risk factors and health care. We examined influential factors and urban-rural differences for different phenotypes. Methods Parents of 4732 children filled out a questionnaire concerning children</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖs health and environmental factors administered within the Health Monitoring Units (GME) in a cross-sectional study in Bavaria, Germany (2014/2015). To classify respiratory symptoms, five phenotype groups were built: episodic, unremitting and frequent wheeze, ISAAC (International Study of Asthma and Allergies in Children) </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô asthma and physician-diagnosed asthma (neither of the groups are mutually exclusive). For each phenotype, health care variables were presented and stratified for residence. Urban-rural differences were tested by Pearson</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖs chi-squared tests. Multivariable logistic regression was performed to analyze associations between influential factors and belonging to a phenotype group, and to compare groups with regard to health care variables as outcome. Results Risk factors for wheezing phenotypes were male gender (OR</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç»=</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç»2.02, 95%-CI</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç»=</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç»[1.65</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô2.48]), having older siblings (OR</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç»=</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç»1.24, 95%-CI</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç»=</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç»[1.02</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô1.51]), and preterm delivery (OR</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç»=</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç»1.61, 95%-CI</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç»=</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç»[1.13</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô2.29]) (ORs for unremitting wheeze). 57% of children with ISAAC asthma and 74% with physician-diagnosed asthma had performed allergy tests. Medication intake among all groups was more frequent in rural areas, and physician</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖs asthma diagnoses were more frequent in urban areas. Conclusions In accordance with previous research this study confirms that male gender, older siblings and preterm delivery are associated with several wheezing phenotypes. Overall, low numbers of allergy tests among children with physician</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖs diagnoses highlight a discrepancy between common practice and current knowledge and guidelines. Residential differences in health care might encourage further research and interventions strategies</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.ijheh.2017.12.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29330038">PM:29330038</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Hyg Environ Health\20171224-KutzoraS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Hyg Environ Health\20171224-KutzoraS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171224, Kutzora S</style></custom2><misc3><style face="normal" font="default">10.1016/j.ijheh.2017.12.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43652</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kasperska-Zajac,A.</style></author><author><style face="normal" font="default"> Damasiewicz-Bodzek,A.</style></author><author><style face="normal" font="default"> Bieniek,K.</style></author><author><style face="normal" font="default"> Skrzypulec-Frankel,A.</style></author><author><style face="normal" font="default"> Tyrpien-Golder,K.</style></author><author><style face="normal" font="default"> Grzanka,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Department of Internal Diseases, Dermatology and Allergology, School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland</style></auth-address><titles><title><style face="normal" font="default">Elevated circulating heat shock protein 70 and its antibody concentrations in chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default">Int J Immunopathol Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Immunopathol Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="12" Year="2017">2017/12/1</year></dates><abstract><style face="normal" font="default">Heat shock proteins (Hsp) play a complex role in cytoprotection, inflammation, and function of the immune system. They may be involved in pathogenesis of various diseases. Our aim was to determine circulating Hsp70 and anti-Hsp70 antibodies concentrations in patients with chronic spontaneous urticaria (CSU). Concentrations of Hsp70 in plasma and anti-Hsp70 antibodies in serum as well as serum C-reactive protein (CRP) were measured in CSU patients and in the controls. Plasma Hsp70 concentrations were significantly higher in CSU (all) and mild CSU patients as compared with the controls. Moderate-severe CSU patients tended to show higher Hsp70 concentration as compared with the controls, but not with mild activity of the disease. There were no significant differences in Hsp70 concentration between moderate-severe and mild CSU patients. Serum anti-Hsp70 antibodies concentrations were significantly higher in CSU (all) and mild CSU in comparison to the controls. Association was observed between anti-Hsp70 antibodies and increased CRP concentration; however, no correlation between anti-Hsp70 and Hsp70 concentrations was seen in the patients. It seems that up-regulation of Hsp70 in CSU may induce marked increase in anti-Hsp70 antibodies production, which are accompanied by parallel changes in CRP concentration. We suggest that Hsp may be released in CSU in response to stressful stimuli, such as inflammation</style></abstract><notes><style face="normal" font="default">IS - 2058-7384 (Electronic)IS - 0394-6320 (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1177/0394632017750440</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29268639">PM:29268639</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Int J Immunopathol Pharmacol\20171201-KasperskaZajacA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Int J Immunopathol Pharmacol\20171201-KasperskaZajacA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Kasperska-Zajac A</style></custom2><misc3><style face="normal" font="default">10.1177/0394632017750440</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43653</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Caruso,M.</style></author><author><style face="normal" font="default"> Morjaria,J.</style></author><author><style face="normal" font="default"> Emma,R.</style></author><author><style face="normal" font="default"> Amaradio,M.D.</style></author><author><style face="normal" font="default"> Polosa,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical and Experimental Medicine, A.O.U. Policlinico - Vittorio Emanuele, Universita degli Studi di Catania, Via S. Sofia, 78, 95123, Catania, Italy.</style></auth-address><titles><title><style face="normal" font="default">Biologic agents for severe asthma patients: clinical perspectives and implications</style></title><secondary-title><style face="normal" font="default">Intern Emerg Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Intern Emerg Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="12" Year="2017">2017/12/14</year></dates><abstract><style face="normal" font="default">Asthma is a chronic inflammatory multifactorial disorder of the airways characterized by the involvement of immune cells and mediators in its onset and maintenance. Traditional therapeutic strategies have been unsatisfactory in controlling the underlying pathology, especially in the more severe states. Hence in the last couple of decades, new biological approaches targeting molecular mediators have been developed. In this narrative review we examine biological agents currently available for the management of severe asthma, focusing our attention on their clinical application, pros and cons, and in particular on gaps regarding the use of these agents. The most well-known and used biologic agent in clinical practice is omalizumab, though there is emerging evidence for mepolizumab too. The future of these biological therapies is to broaden our knowledge of their practical use and ascertain predictive biomarkers, or define an algorithm, useful in the optimal application of these 'biological weapons'</style></abstract><notes><style face="normal" font="default">IS - 1970-9366 (Electronic)IS - 1828-0447 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1007/s11739-017-1773-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29238905">PM:29238905</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Intern Emerg Med\20171214-CarusoM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Intern Emerg Med\20171214-CarusoM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171214, Caruso M</style></custom2><misc3><style face="normal" font="default">10.1007/s11739-017-1773-y</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43654</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gunes,H.</style></author><author><style face="normal" font="default"> Turan Sonmez,F.</style></author><author><style face="normal" font="default"> Saritas,A.</style></author><author><style face="normal" font="default"> Koksal,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Kounis Syndrome Induced by Oral Intake of Diclofenac Potassium</style></title><secondary-title><style face="normal" font="default">Iran J Allergy Asthma Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Iran J Allergy Asthma Immunol</style></abbr-1></periodical><pages end="568" start="565">565-568</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Acute coronary syndrome,Anaphylaxis,Diclofenac potassium,Kounis syndrome</style></keyword></keywords><dates><year Day="23" Month="12" Year="2017">2017/12/23</year></dates><abstract><style face="normal" font="default">An acute coronary syndrome (ACS) occurring during the course of an allergic reaction is called Kounis syndrome (KS). The second case of KS induced by diclofenac potassium (DP) is presented in this report. A 67-year-old man was brought to our emergency department with the possible diagnosis of anaphylactic shock by the ambulance staff. It emerged that widespread erythema and pruritus developed after taking DP. Then, he lost consciousness. Diffuse urticarial lesions were detected on physical examination at the emergency department. He complained of chest pain during his observation, and progressive ST segment elevation was seen in the inferior leads on serial electrocardiograms. His coronary angiography showed 100% occlusion of the right coronary artery.-á Then, KS was diagnosed. The patient was discharged on the second day, and he was doing well on the control visit 2 weeks later. All allergic reactions may trigger an ACS so physicians should be aware of KS and always keep that unique clinical entity in mind to recognize it promptly and direct the therapy at suppressing the allergic reaction and improving the coronary circulation simultaneously when encountering a patient with symptoms suggesting an allergic reaction and a concomitant ACS</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Turkey -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://ijaai.tums.ac.ir/index.php/ijaai/article/view/1366</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-565-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Iran J Allergy Asthma Immunol\2017-16-565-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171208, Gunes H</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43655</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Smith,M.A.</style></author><author><style face="normal" font="default"> Schroer,B.C.</style></author></authors></contributors><titles><title><style face="normal" font="default">Could We Discontinue All Asthma Medications in a Third of Adult Asthmatics?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1472" start="1471">1471-1472</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2213-2198</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.04.023</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jaip.2017.04.023</url></web-urls></urls><custom2><style face="normal" font="default">20171228. Smith MA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.04.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43656</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nagatake,T.</style></author><author><style face="normal" font="default"> Shiogama,Y.</style></author><author><style face="normal" font="default"> Inoue,A.</style></author><author><style face="normal" font="default"> Kikuta,J.</style></author><author><style face="normal" font="default"> Honda,T.</style></author><author><style face="normal" font="default"> Tiwari,P.</style></author><author><style face="normal" font="default"> Kishi,T.</style></author><author><style face="normal" font="default"> Yanagisawa,A.</style></author><author><style face="normal" font="default"> Isobe,Y.</style></author><author><style face="normal" font="default"> Matsumoto,N.</style></author><author><style face="normal" font="default"> Shimojou,M.</style></author><author><style face="normal" font="default"> Morimoto,S.</style></author><author><style face="normal" font="default"> Suzuki,H.</style></author><author><style face="normal" font="default"> Hirata,S.</style></author><author><style face="normal" font="default"> Steneberg,P.</style></author><author><style face="normal" font="default"> Edlund,H.</style></author><author><style face="normal" font="default"> Aoki,J.</style></author><author><style face="normal" font="default"> Arita,M.</style></author><author><style face="normal" font="default"> Kiyono,H.</style></author><author><style face="normal" font="default"> Yasutomi,Y.</style></author><author><style face="normal" font="default"> Ishii,M.</style></author><author><style face="normal" font="default"> Kabashima,K.</style></author><author><style face="normal" font="default"> Kunisawa,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of Vaccine Materials and Laboratory of Gut Environmental System, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), 7-6-8 Asagi Saito, Ibaraki-city, Osaka 567-0085, Japan</style></auth-address><titles><title><style face="normal" font="default">17,18-EpETE-GPR40 axis ameliorates contact hypersensitivity by inhibiting neutrophil mobility in mice and cynomolgus macaques</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="12" Year="2017">2017/12/26</year></dates><abstract><style face="normal" font="default">BACKGROUND: Metabolites of eicosapentaenoic acid (EPA) exert various physiological actions. 17,18-epoxyeicosatetraenoic acid (17,18-EpETE) is a recently identified new class of anti-allergic and anti-inflammatory lipid metabolite of EPA, but its effects on skin inflammation and the underlying mechanisms remain to be investigated. OBJECTIVE: We evaluated the effectiveness of 17,18-EpETE for the control of contact hypersensitivity in mouse and cynomolgus macaques. We further sought to reveal underlying mechanisms by identifying the responsible receptor and cellular target of 17,18-EpETE. METHODS: Contact hypersensitivity was induced by topical application of 2,4-dinitrofluorobenzene. Skin inflammation and immune cell populations were analyzed by flow cytometric, immunohistologic and quantitative RT-PCR analyses. Neutrophil mobility was examined by imaging analysis in vivo and neutrophil culture in vitro. The receptor for 17,18-EpETE was identified by using the TGFalpha-shedding assay and receptor's involvement in the anti-inflammatory effects of 17,18-EpETE was examined by using KO mice and specific inhibitor treatment. RESULTS: We found that preventive or therapeutic treatment with 17,18-EpETE ameliorated contact hypersensitivity by inhibiting neutrophil mobility in mice and cynomolgus macaques. 17,18-EpETE was recognized by GPR40 (also known as free fatty acid receptor 1) and inhibited chemoattractant-induced Rac activation and pseudopod formation in neutrophils. Indeed, the anti-allergic inflammatory effect of 17,18-EpETE was abolished in the absence or inhibition of GPR40. CONCLUSION: 17,18-EpETE inhibits neutrophil mobility through the activation of GPR40, which is a potential therapeutic target to control allergic inflammatory diseases</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - Japan -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.09.053</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29288079">PM:29288079</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171226-NagatakeT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171226-NagatakeT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171226, Nagatake T</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.09.053</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43657</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bonilla,F.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Boston Children's Hospital, Division of Immunology, Harvard Medical School, Department of Pediatrics, 300 Longwood Avenue Boston, MA, 02115.</style></auth-address><titles><title><style face="normal" font="default">Update: Vaccines in Primary Immunodeficiency</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="12" Year="2017">2017/12/26</year></dates><abstract><style face="normal" font="default">Vaccines were originally developed in order to prevent or ameliorate infectious disease. As knowledge of immune function and the appreciation of immunodeficiency has developed, researchers have used vaccine responses as a tool to characterize the phenotypes of patients exhibiting various syndromes. Thus, it has become possible for a clinician to evaluate individual responses to vaccines in order to interrogate the immunocompetence of their patients. Although there have been many advances in these areas, we still have much to learn about the quantity and quality of humoral and cellular vaccine responses in normal and immunodeficient individuals and how that knowledge may then be extrapolated to diagnostic purposes. Adverse effects of vaccines have been recognized for many years, especially the occurrence of infections caused by viable vaccine organisms in immunodeficient hosts. Nevertheless, vaccines are essential for disease prevention in immunodeficient patients just as they are for healthy individuals. Clinicians must understand the appropriate and safe use of vaccines in patients with immunodeficiency. This review highlights some recent advances and ongoing challenges in application of vaccines for the diagnosis and treatment of immunodeficiencies</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.12.980</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29288077">PM:29288077</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171226-BonillaFA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Allergy Clin Immunol\20171226-BonillaFA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171226, Bonilla FA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.12.980</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43658</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lin,C.H.</style></author><author><style face="normal" font="default"> Lockey,R.F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prevention of Asthma: Fish or Fish Oil?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1800" start="1798">1798-1800</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2213-2198</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.023</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jaip.2017.08.023</url></web-urls></urls><custom2><style face="normal" font="default">20171228, Lin CH</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43659</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jose,J.</style></author><author><style face="normal" font="default"> Ishmael,F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Evaluating Safety and Adverse Events Associated with Long-Acting +¦-Agonist in Combination Asthma Therapy Versus Inhaled Corticosteroid Alone</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="1161" start="1158">1158-1161</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2213-2198</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.04.046</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jaip.2017.04.046</url></web-urls></urls><custom2><style face="normal" font="default">20171228, Jose J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.04.046</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43660</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Edslev,S.M.</style></author><author><style face="normal" font="default"> Clausen,M.L.</style></author><author><style face="normal" font="default"> Agner,T.</style></author><author><style face="normal" font="default"> Stegger,M.</style></author><author><style face="normal" font="default"> Andersen,P.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Bacteria, Parasites and Fungi, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default">Genomic analysis reveals different mechanisms of fusidic acid resistance in Staphylococcus aureus from Danish atopic dermatitis patients</style></title><secondary-title><style face="normal" font="default">J Antimicrob Chemother</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Antimicrob Chemother</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="12" Year="2017">2017/12/14</year></dates><abstract><style face="normal" font="default">Background: Staphylococcus aureus skin colonization is common in patients with atopic dermatitis (AD) and is associated with risk of skin infections. AD patients therefore often receive antibiotic treatments, including topical treatment with fusidic acid, which have been associated with resistance development. Objectives: To examine the prevalence of antibiotic resistance in S. aureus isolated from Danish AD patients, with a primary focus on fusidic acid resistance and the genetic mechanisms that underlie it. Methods: One hundred and thirty-eight S. aureus isolates collected from lesional skin (n = 54), non-lesional skin (n = 27) and anterior nares (n = 57) from 71 adult AD patients were included in the study. Isolates were tested for susceptibility to 17 selected antibiotics. S. aureus whole-genome sequences were used to examine the genetic determinants of fusidic acid resistance (fusA or fusE mutations or carriage of fusB or fusC genes). Results: One hundred and nine isolates (79%) were resistant to at least one of the tested antibiotics, with the most prevalent resistances being to penicillin (55%), fusidic acid (41%) and erythromycin (11%). The primary genetic mechanisms of fusidic acid resistance were carriage of fusC (57%) or mutations in fusA (38%). The most prevalent S. aureus lineage was ST1 (23%). All ST1 isolates carried fusC. Conclusions: S. aureus fusidic acid resistance, caused by either fusA mutations or fusC gene carriage, is a major concern among AD patients. Resistant S. aureus might spread from the patients to the community, indicating the need to reduce the use of fusidic acid in the treatment of AD</style></abstract><notes><style face="normal" font="default">IS - 1460-2091 (Electronic)IS - 0305-7453 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1093/jac/dkx481</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29253168">PM:29253168</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Antimicrob Chemother\20171214-EdslevSM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Antimicrob Chemother\20171214-EdslevSM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171214, Edslev SM</style></custom2><misc3><style face="normal" font="default">10.1093/jac/dkx481</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43661</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Carlos,K.S.</style></author><author><style face="normal" font="default"> de Jager,L.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Dr, HFS 706, College Park, MD 20740U.S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Dr, HFS 706, College Park, MD 20740</style></auth-address><titles><title><style face="normal" font="default">Determination of Sulfite in Food by Liquid Chromatography Tandem Mass Spectrometry: Collaborative Study</style></title><secondary-title><style face="normal" font="default">J AOAC Int</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J AOAC Int</style></abbr-1></periodical><pages end="1794" start="1785">1785-1794</pages><volume><style face="normal" font="default">100</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="11" Year="2017">2017/11/1</year></dates><abstract><style face="normal" font="default">Sulfites are added to a wide range of food and beverage products to prevent browning or oxidation. Although most of the population do not experience side effects from consuming sulfites, a small subset has been shown to experience an "allergic-like" response. For this reason, the U.S. Food and Drug Administration requires that sulfites be labeled on all products that contain more than 10 mg/kg (parts per million) sulfur dioxide. The current regulatory method, optimized Monier-Williams (OMW) Official Method 990.28, has been successful in quantifying sulfites in most matrixes, but is time-consuming and has a method detection limit at the regulatory-labeling threshold. Recently, an LC-tandem MS (MS/MS) method was published that was applicable to a wide range of sulfite-containing matrixes. This method converts free and reversibly bound sulfite to the formaldehyde adduct hydroxymethylsulfonate, which could then be separated from matrix constituents using a hydrophilic interaction LC analytical column and subsequently be detected with tandem MS (MS/MS). In this study, multilaboratory validation was conducted with 11 laboratories in the United States and Canada. Four matrixes were spiked at varying concentrations and three additional commercially sulfited matrixes were included. An abbreviated comparison study between the LC-MS/MS and OMW methods was conducted for select samples. Average recoveries for all matrixes ranged from 86 to 114% with RSDr and RSDR values of 4.5-17.5 and 8.6-22.5%, respectively. Further comparisons will be necessary to draw comparisons between the two methods. This method proved to be a faster and more sensitive way to determine sulfites in food and beverages, showing promise for the continuing improvement of enforcement of sulfite labeling requirements to protect individuals who have sulfite sensitivity</style></abstract><notes><style face="normal" font="default">DA - 20171115IS - 1060-3271 (Print)IS - 1060-3271 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.5740/jaoacint.17-0033</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29137699">PM:29137699</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J AOAC Int\2017-100-1785-94.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J AOAC Int\2017-100-1785-94.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171101, Carlos KS</style></custom2><misc3><style face="normal" font="default">10.5740/jaoacint.17-0033</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43662</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wasser,C.D.</style></author><author><style face="normal" font="default"> Grushevsky,A.</style></author><author><style face="normal" font="default"> Johnson,S.T.</style></author><author><style face="normal" font="default"> Smith,S.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Pediatrics , University of Connecticut School of Medicine, Connecticut Children's Medical Center , Hartford , CT , USA</style></auth-address><titles><title><style face="normal" font="default">Asthmonia: A clinical definition of a commonly used colloquial term</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="28" Month="12" Year="2017">2017/12/28</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To describe the clinical characteristics of pediatric asthmonia, a syndrome in which children have both an acute asthma exacerbation and a concomitant diagnosis of community acquired pneumonia. METHODS: A retrospective chart review was conducted on children admitted to Connecticut Children's Medical Center in the pediatric emergency department from January 1, 2012 to December 31, 2012. Children with asthma and pneumonia were identified using ICD-9 codes 493 (asthma) or 482 (pneumonia). In this study, we defined asthmonia, a third group, based on the following criteria: (1) history of asthma based on documentation in the past medical history section of the chart, (2) documented wheezing on presentation, (3) administration of bronchodilator(s), and (4) new focal infiltrate on chest radiograph during ED visit. The three nonoverlapping groups (asthma, pneumonia, and asthmonia) were described. RESULTS: Three hundred and sixty-eight children were identified for our study population. In the study population, 66.0% (N = 243) had asthma, 20.4% (N = 75) pneumonia, and 13.6% (N = 50) met our definition of asthmonia. We found that 84.0% (N = 42) of children who met asthmonia criteria in our study were treated with antibiotic therapies. Also, 28.0% (N = 14) of children who met asthmonia criteria had documented fever during admission or by parent report. CONCLUSIONS: This study defined clinical features of the coexistence of pneumonia in children with asthma. Overall, these children frequently presented with fever and were treated with antibiotics. More studies are needed to better elucidate this clinical entity and its ramifications</style></abstract><notes><style face="normal" font="default">IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1409235</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29283705">PM:29283705</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\20171228-WasserCD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\20171228-WasserCD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171228, Wasser CD</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1409235</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43663</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Backer,V.</style></author><author><style face="normal" font="default"> Stensen,L.</style></author><author><style face="normal" font="default"> Sverrild,A.</style></author><author><style face="normal" font="default"> Wedge,E.</style></author><author><style face="normal" font="default"> Porsbjerg,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Respiratory Medicine , Bispebjerg University hospital , Copenhagen , Denmark</style></auth-address><titles><title><style face="normal" font="default">Objective confirmation of asthma diagnosis improves medication adherence</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="12" Year="2017">2017/12/26</year></dates><abstract><style face="normal" font="default">OBJECTIVE: The impact of diagnostic work-up in asthma management on medication redemption and probably also drug adherence is largely unknown, but we hypothesized that a confirmed diagnosis of asthma in a hospital-based out-patient clinic increases the willingness to subsequent medication redemption in a real life setting. METHODS: In a retrospective register-based study, 300 medical records of patients referred with possible asthma during one year were examined, of whom 171 had asthma (57%). One-year data on dispensed medicine was collected using the Danish Registry of Medicinal Product Statistics. Patients who had a positive asthma (e.g. bronchial challenge) were classified as verified asthma, whereas unverified asthma refers to doctor's diagnosis of asthma with negative or no diagnostic tests performed. RESULTS: 111 (65%) had a verified diagnosis and patients with verified asthma were more frequently prescribed new therapy compared to those with unverified asthma (88.9% vs. 65.0%, respectively, p &lt; 0.001). No difference was found in first time redemption of prescriptions (72% vs. 64%, respectively, p = 0.3), whereas the second (52% vs. 27%, p = 0.001) and third or more asthma redeemed prescriptions (37% vs. 17%, p = 0.006) showed increased redemption of prescription and probably adherence in the verified compared with the unverified patients with asthma. Furthermore, the use of inhaled corticosteroid (ICS) was calculated as Percent Days Covered (PDC), which was higher in the verified group compared with the non-verified asthma group (88% vs. 30%, p = 0.004). CONCLUSION: Objective verification of a diagnosis of asthma using asthma tests was associated with an improved redemption of prescription</style></abstract><notes><style face="normal" font="default">IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1410830</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29278942">PM:29278942</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\20171226-BackerV.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\20171226-BackerV.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171226, Backer V</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1410830</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43664</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hunt,E.</style></author><author><style face="normal" font="default"> Flynn,D.</style></author><author><style face="normal" font="default"> MacHale,E.</style></author><author><style face="normal" font="default"> Costello,R.W.</style></author><author><style face="normal" font="default"> Murphy,D.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Respiratory Medicine , Cork University Hospital , Cork , Ireland</style></auth-address><titles><title><style face="normal" font="default">Reduction in exhaled nitric oxide tracks improved patient inhaler compliance in difficult asthma-a case study</style></title><secondary-title><style face="normal" font="default">J Asthma</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Asthma</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="26" Month="12" Year="2017">2017/12/26</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Exhaled nitric oxide is believed be a useful surrogate for airways inflammation while non-adherence with therapy is known to be associated with worsening of asthma control. CASE: We present the case of a 49-year-old female with steroid-dependent asthma and an exacerbation rate of >20/year. She was enrolled in a 3-month-long prospective study using a validated diagnostic inhaler device that provided objective evidence of inhaler compliance. Fractional exhaled nitric oxide (FeNO), peak expiratory flow rates, asthma control questionnaires were measured throughout the study period. Peripheral eosinophil count was obtained prior to the study, during the study, and immediately afterwards. RESULTS: Improvement in compliance at the end of the study led to significant improvements in lung function peak expiratory flow rate (PEFR), and objective scores of asthma. There was an observed improvement in PEFR after 4 weeks, with an associated decrease in FeNO from 92 to 9 ppb that plateaued over the remainder of the study. Her eosinophil count was 0.79 x 10(9)/litre prior to starting in the study, 0.37 x 10(9)/litre after 2 months, and 0.1 x 10(9)/litre at the end of the study. CONCLUSION: We believe that this is the first case study to objectively prove that improvements in compliance can lead to dramatic reductions in the overall inflammatory airway response and in particular that improvements in patient compliance are mirrored by marked reduction in FeNO levels. These changes occurred in tandem with an observed clinical improvement in our patient</style></abstract><notes><style face="normal" font="default">IS - 1532-4303 (Electronic)IS - 0277-0903 (Linking)LA - engPT - Journal ArticleCO - Ireland -</style></notes><work-type><style face="normal" font="default">10.1080/02770903.2017.1414237</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29278953">PM:29278953</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Asthma\20171226-HuntE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Asthma\20171226-HuntE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171226, Hunt E</style></custom2><misc3><style face="normal" font="default">10.1080/02770903.2017.1414237</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43665</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kasperska-Zajac,A.</style></author><author><style face="normal" font="default"> Grzanka,A.</style></author><author><style face="normal" font="default"> Damasiewicz-Bodzek,A.</style></author><author><style face="normal" font="default"> Bieniek,K.</style></author><author><style face="normal" font="default"> Skrzypulec-Frankel,A.</style></author><author><style face="normal" font="default"> Stencel-Gabriel,K.</style></author><author><style face="normal" font="default"> Sikora-Zydek,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Diseases, Dermatology and Allergology in Zabrze, SMDZ in Zabrze, Medical University of Silesia in Katowice, Poland</style></auth-address><titles><title><style face="normal" font="default">Elevated plasma il-8 concentration is related to severity of systemic inflammation in chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default">J Biol Regul Homeost Agents</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Biol Regul Homeost Agents</style></abbr-1></periodical><pages end="961" start="957">957-961</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Chronic spontaneous urticaria (CSU) is associated with activation of acute phase response. Questions arise regarding its association with other inflammatory mediators. To determine plasma IL-8 concentration in CSU patients and its association with C-reactive protein (CRP) concentration, a nonspecific inflammatory marker of the disease activity, concentrations of plasma IL-8 and serum CRP were measured in CSU patients and compared with healthy controls. IL-8 and CRP concentrations were significantly higher in CSU patients as compared with the healthy subjects. In addition, there were significant differences in IL-8 and CRP concentrations between CSU patients with moderate-severe symptoms and the healthy subjects. Plasma IL-8 and serum CRP concentrations showed a significant correlation with urticaria activity score (UAS). Additionally, a significant positive correlation was observed between IL-8 and CRP concentrations. Up-regulations of IL-8 and its association with the marker of clinical and inflammatory activity suggest a role of this cytokine in the pathogenesis of CSU</style></abstract><notes><style face="normal" font="default">IS - 0393-974X (Print)IS - 0393-974X (Linking)LA - engPT - Journal ArticleCO - Poland -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29254299">PM:29254299</url></web-urls><related-urls><url ppv-ref="no">presto - un mumero</url></related-urls></urls><custom2><style face="normal" font="default">20171012, Kasperska-Zajac A</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43666</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Robuffo,I.</style></author><author><style face="normal" font="default"> Toniato,E.</style></author><author><style face="normal" font="default"> Tettamanti,L.</style></author><author><style face="normal" font="default"> Mastrangelo,F.</style></author><author><style face="normal" font="default"> Ronconi,G.</style></author><author><style face="normal" font="default"> Frydas,I.</style></author><author><style face="normal" font="default"> Caraffa,A.</style></author><author><style face="normal" font="default"> Kritas,S.K.</style></author><author><style face="normal" font="default"> Conti,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Molecular Genetics, CNR, Sede di Chieti, Italy</style></auth-address><titles><title><style face="normal" font="default">Mast cell in innate immunity mediated by proinflammatory and antiinflammatory IL-1 family members</style></title><secondary-title><style face="normal" font="default">J Biol Regul Homeost Agents</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Biol Regul Homeost Agents</style></abbr-1></periodical><pages end="842" start="837">837-842</pages><volume><style face="normal" font="default">31</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Innate immunity consists of physical and chemical barriers which provide the early defense against infections. Innate immunity orchestrates the defense of the host with cellular and biochemical proteins. Mast cells (MCs) are involved in innate and adaptive immunity and are the first line of defense which generates multiple inflammatory cytokines/chemokines in response to numerous antigens. MC-activated antigen receptor Fc-RI provokes a number of important biochemical pathways with secretion of numerous vasoactive, chemoattractant and inflammatory compounds which participate in allergic and inflammatory diseases. MCs can also be activated by Th1 cytokines and generate pre-formed and de novo inflammatory mediators, including TNF. IL-37 is an anti-inflammatory cytokine which binds IL-18R-alpha chain and reduces the production of inflammatory IL-1 family members. IL-37 down-regulates innate immunity by inhibiting macrophage response and its accumulation and reduces the cytokines that mediate inflammatory diseases. Here, we discuss the relationship between MCs, innate immunity, and pro-inflammatory and anti-inflammatory cytokines</style></abstract><notes><style face="normal" font="default">IS - 0393-974X (Print)IS - 0393-974X (Linking)LA - engPT - Journal ArticleCO - Italy -CO - Greece -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29254286">PM:29254286</url></web-urls><related-urls><url ppv-ref="no">presto - un numero</url></related-urls></urls><custom2><style face="normal" font="default">20171012, Robuffo I</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43667</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Calciano,L.</style></author><author><style face="normal" font="default"> Portas,L.</style></author><author><style face="normal" font="default"> Corsico,A.G.</style></author><author><style face="normal" font="default"> Olivieri,M.</style></author><author><style face="normal" font="default"> Degan,P.</style></author><author><style face="normal" font="default"> Ferrari,M.</style></author><author><style face="normal" font="default"> Fois,A.</style></author><author><style face="normal" font="default"> Fratta Pasini,A.M.</style></author><author><style face="normal" font="default"> Pasini,A.</style></author><author><style face="normal" font="default"> Zanolin,M.E.</style></author><author><style face="normal" font="default"> de Marco,R.</style></author><author><style face="normal" font="default"> Accordini,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Unit of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, Verona, ITALY</style></auth-address><titles><title><style face="normal" font="default">Biomarkers related to respiratory symptoms and lung function in adults with asthma</style></title><secondary-title><style face="normal" font="default">J Breath Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Breath Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="11" Year="2017">2017/11/23</year></dates><abstract><style face="normal" font="default">BACKGROUND: There is a need for easily measurable biomarkers that are able to identify different levels of asthma severity.&amp;#13; Aim. To assess the association between peripheral blood cell counts, fractional nitric oxide in exhaled air (FeNO), urinary biomarkers of oxidative stress (8-hydroxy-2'-deoxyguanosine and 8-isoprostane), and asthma severity in adult patients from the general population.&amp;#13; Methods. In the Gene Environment Interactions in Respiratory Diseases study, 287 subjects with asthma (aged 20-64) were identified from the general population in Verona (Italy) (2008-2010). Self-reported asthma attacks, asthma-like symptoms and the use of hospital services in the past year were synthetised in a score of respiratory symptoms (SRS). The association of biomarkers with SRS and lung function measures (pre-bronchodilator FEV1% predicted and FEV1/FVC) was assessed using the quasi-Poisson and Gaussian regression models, respectively. &amp;#13; Results. Eosinophils (Ratio of Expected Scores: RES[95%CI]=1.19[1.09,1.30]), basophils (RES[95%CI]=1.24[1.10,1.40]), lymphocytes (RES[95%CI]=1.27[1.12,1.45]) and FeNO (RES[95%CI]=1.18[1.02,1.37]) were positively associated with SRS. However, only eosinophils (RES[95%CI]=1.15[1.02,1.30]) and lymphocytes (RES[95%CI]=1.25[1.06,1.47]) showed an independent association. Furthermore, eosinophils (Change in the Expected Outcome for 1-SD increase: CEO[95%CI]=-1.18[-2.09,-0.27]%), basophils (CEO[95%CI]=-1.24[-2.16,-0.33]%) and lymphocytes (CEO[95%CI]=-1.07[-1.99,-0.14]%) were individually, but not independently, associated with FEV1/FVC. Finally, neutrophils were negatively associated with FEV1% predicted (CEO[95%CI]=-2.22[-4.00,-0.44]%)</style></abstract><notes><style face="normal" font="default">IS - 1752-7163 (Electronic)IS - 1752-7155 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1088/1752-7163/aa9c86</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29167414">PM:29167414</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Breath Res\20171123-CalcianoL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Breath Res\20171123-CalcianoL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171123, Calciano L</style></custom2><misc3><style face="normal" font="default">10.1088/1752-7163/aa9c86</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43668</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Obara,S.</style></author><author><style face="normal" font="default"> Kurosawa,S.</style></author><author><style face="normal" font="default"> Honda,J.</style></author><author><style face="normal" font="default"> Oishi,R.</style></author><author><style face="normal" font="default"> Iseki,Y.</style></author><author><style face="normal" font="default"> Murakawa,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Surgical Operation Department, Fukushima Medical University Hospital, 1 Hikarigaoka, Fukushima, Fukushima 960-1295, Japan.</style></auth-address><titles><title><style face="normal" font="default">Cardiac arrest following anaphylaxis induced by sugammadex in a regional hospital</style></title><secondary-title><style face="normal" font="default">J Clin Anesth</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Clin Anesth</style></full-title></periodical><pages end="63" start="62">62-63</pages><volume><style face="normal" font="default">44</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="11" Year="2017">2017/11/13</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">DA - 20171117IS - 1873-4529 (Electronic)IS - 0952-8180 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jclinane.2017.11.003</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29145023">PM:29145023</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Anesth\2017-44-62-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Anesth\2017-44-62-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171114, Obara S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jclinane.2017.11.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43669</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Guadagnoli,E.</style></author><author><style face="normal" font="default"> Shapiro,C.</style></author><author><style face="normal" font="default"> Gurwitz,J.H.</style></author><author><style face="normal" font="default"> Silliman,R.A.</style></author><author><style face="normal" font="default"> Weeks,J.C.</style></author><author><style face="normal" font="default"> Borbas,C.</style></author><author><style face="normal" font="default"> Soumerai,S.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Health Care Policy, Department of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 02115, USA.</style></auth-address><titles><title><style face="normal" font="default">Age-related patterns of care: evidence against ageism in the treatment of early-stage breast cancer</style></title><secondary-title><style face="normal" font="default">J Clin Oncol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Clin Oncol</style></full-title></periodical><pages end="2344" start="2338">2338-2344</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Age Factors</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Axilla</style></keyword><keyword><style face="normal" font="default"> Breast Neoplasms</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> therapy</style></keyword><keyword><style face="normal" font="default"> Chemotherapy,Adjuvant</style></keyword><keyword><style face="normal" font="default"> utilization</style></keyword><keyword><style face="normal" font="default"> Cohort Studies</style></keyword><keyword><style face="normal" font="default"> Data Collection</style></keyword><keyword><style face="normal" font="default"> Diagnosis-Related Groups</style></keyword><keyword><style face="normal" font="default"> Female</style></keyword><keyword><style face="normal" font="default"> Hormones</style></keyword><keyword><style face="normal" font="default"> therapeutic use</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Lymph Nodes</style></keyword><keyword><style face="normal" font="default"> pathology</style></keyword><keyword><style face="normal" font="default"> Middle Aged</style></keyword><keyword><style face="normal" font="default"> Postmenopause</style></keyword><keyword><style face="normal" font="default"> Prejudice</style></keyword><keyword><style face="normal" font="default"> Retrospective Studies</style></keyword></keywords><dates><year Day="0" Month="6" Year="1997">1997/6</year></dates><abstract><style face="normal" font="default">PURPOSE: To assess whether the use of adjuvant systemic therapy in postmenopausal women with early-stage breast cancer is influenced by patient age. METHODS: A retrospective cohort study based on data collected from medical records and from patients and their surgeons was performed among 746 postmenopausal patients diagnosed with early-stage breast cancer at 30 hospitals located throughout Minnesota. The adjusted odds of receiving hormonal therapy, chemotherapy, and both hormonal therapy and chemotherapy as a function of age was determined. RESULTS: Among women with negative lymph nodes, 62% received some form of adjuvant drug therapy. For these women, the likelihood of receiving hormonal therapy or both hormonal therapy and chemotherapy did not vary with patient age and the likelihood of receiving chemotherapy declined with age. Among women with positive lymph nodes, 92% received some form of adjuvant therapy. For these women, the likelihood of receiving hormonal therapy increased with age and the likelihood of receiving chemotherapy declined with age, as did the likelihood of receiving both hormonal therapy and chemotherapy. CONCLUSION: The observed associations between age and the use of adjuvant systemic therapy appear to reflect, in general, available information about treatment efficacy and do not suggest underuse among elderly women with early-stage breast cancer. The use of adjuvant therapy depends on clinical factors that predict the increased risk of metastases or the increased likelihood of response to treatment, rather than other sociodemographic factors. Our results also suggest that younger postmenopausal women with positive lymph nodes compared with older women may be undertreated with respect to tamoxifen because of the substitution of chemotherapy for hormonal therapy</style></abstract><notes><style face="normal" font="default">IS - 0732-183X (Print)IS - 0732-183X (Linking)LA - engPT - Comparative StudyPT - Journal ArticlePT - Research Support, U.S. Gov't, P.H.SRN - 0 (Hormones)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.1200/JCO.1997.15.6.2338</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="9196148">PM:9196148</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Oncol\1997-15-2338-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Oncol\1997-15-2338-44.pdf</url></text-urls></urls><custom2><style face="normal" font="default">19979611, Guadagnoli E</style></custom2><misc3><style face="normal" font="default">10.1200/JCO.1997.15.6.2338</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43670</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Reid,E.F.</style></author><author><style face="normal" font="default"> Krishna,M.T.</style></author><author><style face="normal" font="default"> Bethune,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Peninsula Schools of Medicine and Dentistry, University of Plymouth, Plymouth, UK</style></auth-address><titles><title><style face="normal" font="default">Allergy teaching is suboptimal and heterogeneous in the undergraduate medical curriculum in the UK</style></title><secondary-title><style face="normal" font="default">J Clin Pathol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Clin Pathol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="1" Year="2018">2018/1/5</year></dates><abstract><style face="normal" font="default">AIM: To record the level of allergy teaching occurring in UK medical schools. The UK has experienced an 'allergy epidemic' during the last 3-4 decades. Previous government reviews have emphasised the importance of allergy education and training, treating common allergies in primary care with referral pathways to a specialist and the creation of regional networks. It is acknowledged that the delivery of allergy teaching in UK medical schools is variable, despite the well-recognised need. METHODS: All consultant members of the British Society for Allergy and Clinical Immunology involved in teaching medical students were invited to partake in qualitative research, employing an online questionnaire for data collection. Participants were asked to comment on the format of the allergy teaching delivered, the student participation and the clinical opportunities provided. Students were recruited to complete a similar survey as supporting evidence. RESULTS: 44 responses were collected, representing 64.7% of medical schools in the UK. Clinical allergy placements were compulsory in 31.8% of medical schools that responded. In 36.4%, it was reported that less than 10% of students had an opportunity to take an independent history from a patient with allergic disease, or practise using an epinephrine autoinjector. 90.9% responded that an allergy rotation was not offered to final year students. CONCLUSIONS: Allergy undergraduate teaching is suboptimal and heterogeneous in UK medical schools and there is a real need for standardisation as a means to enhance quality of care</style></abstract><notes><style face="normal" font="default">IS - 1472-4146 (Electronic)IS - 0021-9746 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1136/jclinpath-2017-204885</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29305517">PM:29305517</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Clin Pathol\20180105-ReidEF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Clin Pathol\20180105-ReidEF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, Reid EF</style></custom2><misc3><style face="normal" font="default">10.1136/jclinpath-2017-204885</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43671</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sgouros,D.</style></author><author><style face="normal" font="default"> Katoulis,A.</style></author><author><style face="normal" font="default"> Rigopoulos,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">2nd Department of Dermatology-Venereology, National Kapodistrian University of Athens Medical School, ATTIKON University Hospital, Athens, Greece</style></auth-address><titles><title><style face="normal" font="default">Novel topical agent containing superoxide dismutase 100 000 IU and 4% of plant extracts as a mono-therapy for atopic dermatitis</style></title><secondary-title><style face="normal" font="default">J Cosmet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Cosmet Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="11" Year="2017">2017/11/13</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Corticosteroids are the mainstay of treatment for the acute phase of atopic dermatitis (AD), whereas topical emollients are mainly used for maintenance of remission. A topical agent that combines emollient and anti-inflammatory properties would achieve control of all phases of AD, without the need for chronic corticosteroid use. AIM: To assess the efficacy of a novel topical agent containing superoxide dismutase (SOD) 100 000 IU and 4% of a combination of plant extracts (blackcurrant seed oil, sunflower oil concentrate, balloon vine extract). METHODS: Twenty patients (age range from 8 months to 72 years old) with mild-to-moderate atopic dermatitis were assessed. The product was used as mono-therapy, applied to the affected skin areas twice daily. Patients were evaluated before and after a 30-day course using the SCORAD and the Visual Analog Scale for assessment of pruritus intensity. Primary endpoint was improvement of AD according to SCORAD and clinical assessment. Secondary endpoint was patient satisfaction and improvement of pruritus. RESULTS: Mean SCORAD on day 0 was 32.61(range = 16.0-46.9) and decreased to 10.55 (range = 0-17.0) on day 30, reflecting a reduction of 67.6%. On day 30, all patients described significant improvement in pruritus and quality of sleep. CONCLUSION: The application of the study product cream resulted in significant improvement of AD, as reflected by the objective SCORAD measurement, and the subjective assessment of pruritus and quality of life. This novel anti-inflammatory emollient product may emerge as a safe and effective therapeutic tool for all phases of AD without the adverse effects of chronic use of corticosteroids</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 1473-2165 (Electronic)IS - 1473-2130 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="default">10.1111/jocd.12462</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29134748">PM:29134748</url></web-urls><related-urls><url ppv-ref="no">presto - link infetto</url></related-urls></urls><custom2><style face="normal" font="default">20171113, Sgouros D</style></custom2><misc3><style face="normal" font="default">10.1111/jocd.12462</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43672</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wu,L.</style></author><author><style face="normal" font="default"> Liu,X.</style></author><author><style face="normal" font="default"> Jian,X.</style></author><author><style face="normal" font="default"> Wu,X.</style></author><author><style face="normal" font="default"> Xu,N.</style></author><author><style face="normal" font="default"> Dou,X.</style></author><author><style face="normal" font="default"> Yu,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Peking University Shenzhen Hospital, Shenzhen, China</style></auth-address><titles><title><style face="normal" font="default">Delayed allergic hypersensitivity to hyaluronidase during the treatment of granulomatous hyaluronic acid reactions</style></title><secondary-title><style face="normal" font="default">J Cosmet Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Cosmet Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="11" Year="2017">2017/11/21</year></dates><abstract><style face="normal" font="default">Hyaluronic acid (HA) is now extensively employed for esthetic concerns. In the majority of cases, HA is considered to be safe, but mild-to-severe complications can occur in a few cases. Hyaluronidase is enzymes that degrade HA, also being suggested for the treatment of HA filler-induced complications. However, hyaluronidase has been reported to be a potential cause of allergic responses in some anesthetic and ophthalmic literature. However, there are few reports of allergic reactions to hyaluronidase in cosmetic medicine. We herein report on a 39-year-old Asian woman who developed a delayed allergic hypersensitivity to hyaluronidase in the treatment process of HA-related granulomatous reaction</style></abstract><notes><style face="normal" font="default">IS - 1473-2165 (Electronic)IS - 1473-2130 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1111/jocd.12461</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29159865">PM:29159865</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Cosmet Dermatol\20171121-WuL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Cosmet Dermatol\20171121-WuL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171121, Wu L</style></custom2><misc3><style face="normal" font="default">10.1111/jocd.12461</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43673</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pan,Y.</style></author><author><style face="normal" font="default"> Xu,L.</style></author><author><style face="normal" font="default"> Qiao,J.</style></author><author><style face="normal" font="default"> Fang,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Dermatology , The First Affiliated Hospital of Zhejiang University , Hangzhou , Zhejiang , 310000 , China</style></auth-address><titles><title><style face="normal" font="default">A systematic review of ustekinumab in the treatment of atopic dermatitis</style></title><secondary-title><style face="normal" font="default">J Dermatolog Treat</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatolog Treat</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="11" Year="2017">2017/11/22</year></dates><abstract><style face="normal" font="default">Ustekinumab is a human monoclonal IgG1 antibody targeting the p40 subunit shared by IL-12 and IL-23. We reviewed the published literature by searching from PubMed, EMBASE, Web of Science and ClinicalTrial.gov to evaluate the efficacy and safety of ustekinumab in the treatment of AD. Ten studies including eight cases and two RCT, comprising 107 patients, were included in the systematic review. Analysis all studies, a total of 58 patients (54.2%) gained an effective treatment with little adverse events. Ustekinumab is a well-tolerated and safe treatment with no significant difference in effect from placebo in patients with AD. Further larger randomized controlled trials need to be conducted to identify a suitable regimen for AD and provide more evidence for clinical application</style></abstract><notes><style face="normal" font="default">IS - 1471-1753 (Electronic)IS - 0954-6634 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1080/09546634.2017.1406894</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29164954">PM:29164954</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Dermatolog Treat\20171122-PanY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Dermatolog Treat\20171122-PanY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171122, Pan Y</style></custom2><misc3><style face="normal" font="default">10.1080/09546634.2017.1406894</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43674</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fowler,J.F.,Jr.</style></author><author><style face="normal" font="default"> Zirwas,J.</style></author><author><style face="normal" font="default"> Napolitano,L.</style></author><author><style face="normal" font="default"> Russell,M.</style></author><author><style face="normal" font="default"> Coope-Epstein,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">A Novel Multifactorial Approach to Developing Mild Laundry Detergents and Assessing Their Relative Mildnes</style></title><secondary-title><style face="normal" font="default">J Drugs Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Drugs Dermatol</style></full-title></periodical><pages end="1239" start="1235">1235-1239</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="12" Year="2017">2017/12/1</year></dates><abstract><style face="normal" font="default">&lt;p>INTRODUCTION: Dermatologists are becoming more aware of the irritant and allergic potential of laundry detergents that incorporate harsh surfactants and potentially sensitizing ingredients. It is difficult however for the physician to distinguish one laundry detergent from another because the only distinguishing feature advertised tends to be the lack of dyes and fragrances.&lt;/p> &lt;p>DESIGN: A new objective method was developed for measuring the harshness of laundry detergents using a three-pronged laboratory testing approach consisting of zein, corneosurfametry, and cytokine testing. Combing these methods, a Detergent Mildness Index was created which conveniently provides a single value by which products can be compared.&lt;/p> &lt;p>Results: A new mild laundry detergent was formulated with ingredients carefully selected by dermatologists who are experts in con-tact dermatitis. The irritancy potential of the formula was measured using the Detergent mildness index score. Compared to 11 other commercial laundry detergents marketed for sensitive skin, the new formula is measurably the mildest formula.&lt;/p> &lt;p>Discussion: The Detergent Mildness Index provides dermatologists with an objective method to compare commercial laundry deter-gents. Currently the only method available is patch testing, this new test is able to more finely differentiate between products and thus enables more informed recommendations on laundry detergent choices for their patients with sensitive skin.&lt;/p> &lt;p>&lt;em>J Drugs Dermatol. 2017;16(12):1235-1239.&lt;/em>&lt;/p></style></abstract><notes><style face="normal" font="default">IS - 1545-9616 (Print)IS - 1545-9616 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29240858">PM:29240858</url></web-urls></urls><custom2><style face="normal" font="default">20171201, Fowler JF Jr</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43675</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vikhe,S.</style></author><author><style face="normal" font="default"> Nirmal,S.</style></author><author><style face="normal" font="default"> Siddheshwar,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacognosy, Pravara Rural College of Pharmacy, Loni, (413736), Maharashtra, India.</style></auth-address><titles><title><style face="normal" font="default">Antiallergic and antihistaminic actions of Ceasalpinia bonducella seeds: Possible role in treatment of asthma</style></title><secondary-title><style face="normal" font="default">J Ethnopharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Ethnopharmacol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="12" Year="2017">2017/12/13</year></dates><abstract><style face="normal" font="default">ETHNOPHARMACOLOGICAL RELEVANCE: Seed kernel of the plant Ceasalpinia bonducella Linn (Caesalpiniacaeae) are used for the treatment of asthma in folk medicine and ancient books. AIM OF STUDY: To assess the pharmacological efficacy of the plant in asthma and to confine and describe the synthetic constituents from the seeds that are in charge of the action. MATERIAL AND METHODS: The viability of petroleum ether and ethanol extracts of C. bonducella seeds were screened for the treatment of asthma by various methods viz. effect of test drug on clonidine and haloperidol induced catalepsy, milk-induced leukocytosis and eosinophilia, mast cell stabilizing activity in mice and studies on smooth muscle preparation of guinea pig ileum (in-vitro). Column chromatography of active extract was done to pinpoint the active compound followed by structure elucidation by FTIR, GCMS and NMR spectroscopic methods. RESULTS: Ethanol extract of C. bonducella seeds exhibited antihistaminic activity at the dose of 50 and 100mg/kg, inhibited clonidine-induced catalepsy but not haloperidol-induced catalepsy. Ethanol extract significantly inhibited increased leukocyte and eosinophil count due to milk allergen and showed maximum protection against mast cell degranulation by clonidine. The results of guinea pig ileum indicated that the compound 2 methyl, 1 hexadecanol isolated from ethanol extract relaxed significantly the ileum muscle strips pre-contracted by which suggests the involvement of beta2-agonists on the relaxation of the tissue. All the results are dose dependent. Active ethanol extract showed presence of anti-asthmatic compound, 2-methyl, 1-hexadecanol. CONCLUSION: The ethanol extract of seeds of the plant C. bonducella can inhibit parameters linked to asthma disease</style></abstract><notes><style face="normal" font="default">IS - 1872-7573 (Electronic)IS - 0378-8741 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.1016/j.jep.2017.12.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29247697">PM:29247697</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ethnopharmacol\20171213-VikheS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ethnopharmacol\20171213-VikheS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171213, Vikhe S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jep.2017.12.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43676</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,S.</style></author><author><style face="normal" font="default"> Park,N.J.</style></author><author><style face="normal" font="default"> Bong,S.K.</style></author><author><style face="normal" font="default"> Jegal,J.</style></author><author><style face="normal" font="default"> Park,S.A.</style></author><author><style face="normal" font="default"> Kim,S.N.</style></author><author><style face="normal" font="default"> Yang,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Natural Products Research Institute, Korea Institute of Science and Technology, Gangneung 25451, Republic of Korea.</style></auth-address><titles><title><style face="normal" font="default">Ameliorative effects of Juniperus rigida fruit on oxazolone- and 2,4-dinitrochlorobenzene-induced atopic dermatitis in mice</style></title><secondary-title><style face="normal" font="default">J Ethnopharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Ethnopharmacol</style></abbr-1></periodical><pages end="167" start="160">160-167</pages><volume><style face="normal" font="default">214</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="12" Year="2017">2017/12/16</year></dates><abstract><style face="normal" font="default">ETHNOPHARMACOLOGICAL RELEVANCE: The fruits of Juniperus rigida have been used in Korean traditional medicine for the treatment of inflammatory diseases in humans such as rheumatoid arthritis. AIM OF THE STUDY: This study aimed to investigate the anti-atopic properties of J. rigida fruit in in vivo murine atopic dermatitis (AD) models. METHODS AND RESULTS: BALB/c mouse ears ad SKH-1 hairless mice stimulated with oxazolone (4 weeks) and DNCB (3 weeks), respectively, were treated with the 1% Juniperus rigida fruit EtOH extract (JFE). The JFE improved AD symptoms in both oxazolone- and DNCB-induced AD mice by accelerating skin barrier recovery function and suppressing the overproduction of serum immunoglobulin E (IgE) and interleukin 4 (IL-4). The JFE was found to contain isoscutellarein-7-O-beta-xylopyranoside, cupressuflavone, podocarpusflavone A, and hinokiflavone as major components based on phytochemical analysis. Eight flavonoids were isolated from JFE, and of those, cupressuflavone and isoscutellarein-7-O-beta-xylopyranoside strongly down-regulated IL-4 expression and beta-hexosaminidase release in RBL-2H3 cells. CONCLUSION: Therapeutic attempts with J. rigida fruit and its active components might be useful in treating AD and related skin inflammatory diseases</style></abstract><notes><style face="normal" font="default">IS - 1872-7573 (Electronic)IS - 0378-8741 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.jep.2017.12.022</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29258854">PM:29258854</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Ethnopharmacol\2017-214-160-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Ethnopharmacol\2017-214-160-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171216, Lee S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jep.2017.12.022</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43677</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Simonsen,A.B.</style></author><author><style face="normal" font="default"> Duus Johansen,J.</style></author><author><style face="normal" font="default"> Deleuran,M.</style></author><author><style face="normal" font="default"> Mortz,C.G.</style></author><author><style face="normal" font="default"> Skov,L.</style></author><author><style face="normal" font="default"> Sommerlund,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Venereology, Aarhus University Hospital</style></auth-address><titles><title><style face="normal" font="default">Children with atopic dermatitis may have unacknowledged contact allergies contributing to their skin symptoms</style></title><secondary-title><style face="normal" font="default">J Eur Acad Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Eur Acad Dermatol Venereol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="12" Year="2017">2017/12/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Whether children with atopic dermatitis have an altered risk of contact allergy than children without atopic dermatitis is frequently debated and studies have been conflicting. Theoretically, the impaired skin barrier in AD facilitates the penetration of potential allergens and several authors have highlighted the risk of underestimating and overlooking contact allergy in children with atopic dermatitis. OBJECTIVE: To determine the prevalence of contact allergy in Danish children with atopic dermatitis and explore the problem of unacknowledged allergies maintaining or aggravating the skin symptoms. METHODS: In a cross sectional study, 100 children and adolescents aged 5-17 years with a diagnosis of atopic dermatitis were patch tested with a pediatric series of 31 allergens. RESULTS: Thirty percent of the children had at least one positive patch test reaction and 17% had at least one contact allergy that was relevant to the current skin symptoms. The risk of contact allergy was significantly correlated to the severity of atopic dermatitis. Metals and components of topical skin care products were the most frequent sensitizers. CONCLUSION: Patch testing is relevant as a screening tool in the management of children with atopic dermatitis as they may have unacknowledged contact allergies contributing to or maintaining their skin symptoms. Children with atopic dermatitis seem to be at greater risk of sensitization to certain allergens including metals and components of skin care products. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1468-3083 (Electronic)IS - 0926-9959 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1111/jdv.14737</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29222945">PM:29222945</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20180103-SimonsenAB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Eur Acad Dermatol Venereol\20180103-SimonsenAB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180103, Simonsen AB</style></custom2><misc3><style face="normal" font="default">10.1111/jdv.14737</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43678</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Li,L.</style></author><author><style face="normal" font="default"> Spengler,J.D.</style></author><author><style face="normal" font="default"> Cao,S.J.</style></author><author><style face="normal" font="default"> Adamkiewicz,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA.</style></auth-address><titles><title><style face="normal" font="default">Prevalence of asthma and allergic symptoms in Suzhou, China: Trends by domestic migrant status</style></title><secondary-title><style face="normal" font="default">J Expo Sci Environ Epidemiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Expo Sci Environ Epidemiol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="12" Year="2017">2017/12/21</year></dates><abstract><style face="normal" font="default">Rapid urbanization in developing countries, with significant rural-to-urban and between-urban areas migration, presents a natural epidemiological model to better understand population-level trends in asthma and allergy prevalance without confounding by genetic factors. This cross-sectional study, conducted November 2014 to January 2015 in Suzhou, China, investigated differences in asthma and allergic symptoms between domestic migrant residents and long-term residents and their children. Using multivariate logistic regression, the odds ratios for children in migrant families compared to those in long-term resident families in Suzhou for doctor-diagnosed asthma, pneumonia, rhinitis, and eczema were 0.56 (95% CI: 0.42.0.73), 0.60 (95% CI: 0.49, 0.72), 0.63 (95% CI:0.52, 0.77), and 0.73 (95% CI: 0.60, 0.89), respectively. While there was a lower prevalence of asthma and allergic symptoms for domestic migrants (children and parents) compared to the local population in Suzhou, migrant children had a higher asthma rate than their parents. This follows the trend of increasing asthma rates for children in the urban local population, suggesting an environmental component. Parental migration plays a role in both parental and children's health but further investigations are needed to determine how these results may be shaped by early life exposures, lifestyle differences, and other environmental factors</style></abstract><notes><style face="normal" font="default">IS - 1559-064X (Electronic)IS - 1559-0631 (Linking)LA - engPT - Journal ArticleCO - United States -CO - China -</style></notes><work-type><style face="normal" font="default">10.1038/s41370-017-0007-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29269755">PM:29269755</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Expo Sci Environ Epidemiol\20171221-LiL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Expo Sci Environ Epidemiol\20171221-LiL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171221. Li L</style></custom2><misc3><style face="normal" font="default">10.1038/s41370-017-0007-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43679</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shimogori,K.</style></author><author><style face="normal" font="default"> Araki,M.</style></author><author><style face="normal" font="default"> Shibazaki,S.</style></author><author><style face="normal" font="default"> Tuda,K.</style></author><author><style face="normal" font="default"> Miura,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal MedicineSuwa Central HospitalChinoNaganoJapan</style></auth-address><titles><title><style face="normal" font="default">Nonimmediate allergic reactions induced by Mesna</style></title><secondary-title><style face="normal" font="default">J Gen Fam Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Gen Fam Med</style></abbr-1></periodical><pages end="287" start="285">285-287</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Mesna (2-mercaptoethane sulfonate Na), a drug that alleviates cyclophosphamide (CYC)-induced hemorrhagic cystitis, is frequently used to treat cancer and collagen diseases. A 33-year-old woman presented with high fever during CYC-based induction therapy for systemic lupus erythematosus. Her final diagnosis was mesna-induced drug hypersensitivity. Although mesna is widely used, allergic reactions are rare. This may be because of misdiagnosis as a primary disease flare-up, infection, or CYC-induced hypersensitivity reaction, which are commonly reported. Thus, accurate diagnosis is important for completion of the CYC-based regimen</style></abstract><notes><style face="normal" font="default">IS - 2189-6577 (Print)IS - 2189-7948 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1002/jgf2.79</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29264044">PM:29264044</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Gen Fam Med\2017-18-285-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Gen Fam Med\2017-18-285-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170622, Shigomori K</style></custom2><misc3><style face="normal" font="default">10.1002/jgf2.79</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43680</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schwarzschild,M.</style></author><author><style face="normal" font="default"> Rordorf,G.</style></author><author><style face="normal" font="default"> Bekken,K.</style></author><author><style face="normal" font="default"> Buonanno,F.</style></author><author><style face="normal" font="default"> Schmahmann,J.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Neurology, Massachusetts General Hospital, Boston 02114, USA</style></auth-address><titles><title><style face="normal" font="default">Normal-pressure hydrocephalus with misleading features of irreversible dementias: a case report</style></title><secondary-title><style face="normal" font="default">J Geriatr Psychiatry Neurol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Geriatr Psychiatry Neurol</style></abbr-1></periodical><pages end="54" start="51">51-54</pages><volume><style face="normal" font="default">10</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Activities of Daily Living</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Aged</style></keyword><keyword><style face="normal" font="default"> Aged,80 and over</style></keyword><keyword><style face="normal" font="default"> Alzheimer Disease</style></keyword><keyword><style face="normal" font="default"> diagnosis</style></keyword><keyword><style face="normal" font="default"> Creutzfeldt-Jakob Syndrome</style></keyword><keyword><style face="normal" font="default"> Dementia</style></keyword><keyword><style face="normal" font="default"> etiology</style></keyword><keyword><style face="normal" font="default"> surgery</style></keyword><keyword><style face="normal" font="default"> Diagnosis,Differential</style></keyword><keyword><style face="normal" font="default"> Electroencephalography</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Hydrocephalus,Normal Pressure</style></keyword><keyword><style face="normal" font="default"> complications</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Neurologic Examination</style></keyword><keyword><style face="normal" font="default"> Postoperative Complications</style></keyword><keyword><style face="normal" font="default"> Tomography,Emission-Computed</style></keyword><keyword><style face="normal" font="default"> Tomography,X-Ray Computed</style></keyword><keyword><style face="normal" font="default"> Ventriculoperitoneal Shunt</style></keyword></keywords><dates><year Day="0" Month="4" Year="1997">1997/4</year></dates><abstract><style face="normal" font="default">An 85-year-old man presented with the clinical triad (gait instability, dementia, and bladder and bowel incontinence), the ventriculomegaly, and the normal CSF pressure that characterize normal-pressure hydrocephalus (NPH). Diagnostic uncertainty was raised by an unusually rapid onset and a lack of initial response to CSF tap tests. Additionally, periodic sharp waves on EEG suggested the possibility of Creutzfeldt-Jakob disease, and positron emission tomography (PET) demonstrated a pattern of cerebral hypometabolism typical of Alzheimer's disease. Nevertheless, the diagnosis of NPH was supported by delayed improvement following CSF tap tests, and it was confirmed by a dramatic clinical recovery after CSF shunting, resolution of the EEG and PET abnormalities, and a normal brain biopsy. NPH remains one of the few reversible causes of dementia, and the presence of its core features, regardless of rate of onset or ancillary test results, warrants careful consideration of therapeutic intervention</style></abstract><notes><style face="normal" font="default">IS - 0891-9887 (Print)IS - 0891-9887 (Linking)LA - engPT - Case ReportsPT - Journal ArticleSB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/089198879701000202</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="9188018">PM:9188018</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Geriatr Psychiatry Neurol\1997-10-51-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Geriatr Psychiatry Neurol\1997-10-51-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">19970412, Schwarzschild M</style></custom2><misc3><style face="normal" font="default">10.1177/089198879701000202</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43681</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tungsukruthai,P.</style></author><author><style face="normal" font="default"> Nootim,P.</style></author><author><style face="normal" font="default"> Worakunphanich,W.</style></author><author><style face="normal" font="default"> Tabtong,N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Efficacy and safety of herbal steam bath in allergic rhinitis: a randomized controlled trial</style></title><secondary-title><style face="normal" font="default">J Integr Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Integr Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Herbal steam bath</style></keyword><keyword><style face="normal" font="default"> Steam Bath</style></keyword><keyword><style face="normal" font="default"> allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> randomized controlled trial</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2095-4964</style></isbn><abstract><style face="normal" font="default">AbstractBACKGROUND Allergic rhinitis is a nasal mucosa inflammatory disorder that is induced by exposure to an allergen which results in four major symptoms, including anterior or posterior rhinorrhoea, sneezing, nasal itching and nasal congestion. Allergic rhinitis may result in sleep disturbance, fatigue, depression of mood-cognitive function and quality of life impairment. OBJECTIVE This study examined the efficacy and safety of herbal steam bath used for the reduction of allergic rhinitis symptoms, and evaluated treatment satisfaction and improvements in quality of life among participating patients with allergic rhinitis. DESIGN, SETTING, PARTICIPANTS AND INTERVENTION: A single-blind randomized controlled trial was conducted at Thai Traditional and Alternative Medicine Hospital between June and December 2016, using 64 subjects, equally divided into two groups. The treatment group received herbal steam bath and the control group received steam bath without herbs for 30 min 3 times a week for 4 consecutive weeks. MAIN OUTCOME MEASURES: Allergic rhinitis symptoms, such as itchy nose, runny nose, sneezing, nasal congestion and watery eyes, were measured using the visual analog scale at weeks 0, 1, 2, 3 and 4. Quality of life was assessed at week 0 and week 4. RESULTS The characteristics (sex, age, marital status, education, allergic rhinitis symptoms and frequency of symptoms) at the baseline were not statistically different (P &amp;gt; 0.05) between the two test groups. Anterior or posterior rhinorrhea symptoms, including sneezing, nasal itching and nasal congestion, were statistically reduced over the course of the treatment, but reductions were not significantly different between the control and treatment groups. The treatment group, however, was shown to be significantly more satisfied with the treatment than the control group (P &amp;lt; 0.05). CONCLUSION Both treatments appear to be able to significantly reduce the symptoms of allergic rhinitis. However, there was no difference in the effectiveness of steam bath with herbs and steam bath without herbs. TRIAL REGISTRATION: This trial was registered in the Thai Clinical Trial Registry with the identifier TCTR20170712002</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Thailand -</style></notes><work-type><style face="normal" font="default">10.1016/j.joim.2017.12.010</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.joim.2017.12.010</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Integr Med\20171216-TungsukruthaiP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Integr Med\20171216-TungsukruthaiP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171216, Tungsukruthai P</style></custom2><misc3><style face="normal" font="default">10.1016/j.joim.2017.12.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43682</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oetjen,L.K.</style></author><author><style face="normal" font="default"> Trier,A.M.</style></author><author><style face="normal" font="default"> Kim,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA; Center for the Study of Itch, Washington University School of Medicine, St. Louis, Missouri 63110, USA</style></auth-address><titles><title><style face="normal" font="default">PXR: A New Player in Atopic Dermatitis</style></title><secondary-title><style face="normal" font="default">J Invest Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Invest Dermatol</style></full-title></periodical><pages end="10" start="8">8-10</pages><volume><style face="normal" font="default">138</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">Epidemiological evidence suggests that environmental pollutants contribute to atopic dermatitis, but mechanistic details are currently lacking. Elentner et al. show that PXR, a key transcription factor involved in pollutant metabolism, drives features of subclinical atopic dermatitis. These observations provide new insight into how environmental insults may predispose individuals to atopic dermatitis</style></abstract><notes><style face="normal" font="default">IS - 1523-1747 (Electronic)IS - 0022-202X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jid.2017.08.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29273149">PM:29273149</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Invest Dermatol\2018-138-8-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Invest Dermatol\2018-138-8-10.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171219, Oetjen LK</style></custom2><misc3><style face="normal" font="default">10.1016/j.jid.2017.08.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43683</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Jentzsch,N.S.</style></author><author><style face="normal" font="default"> Silva,G.C.G.</style></author><author><style face="normal" font="default"> Mendes,G.M.S.</style></author><author><style face="normal" font="default"> Brand,P.L.P.</style></author><author><style face="normal" font="default"> Camargos,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculdade de Ciencias Medicas de Minas Gerais, Hospital Universitario Ciencias Medicas, Belo Horizonte, MG, Brazil.</style></auth-address><titles><title><style face="normal" font="default">Treatment adherence and level of control in moderate persistent asthma in children and adolescents treated with fluticasone and salmeterol</style></title><secondary-title><style face="normal" font="default">J Pediatr (Rio J)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Pediatr (Rio J)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="12" Year="2017">2017/12/20</year></dates><abstract><style face="normal" font="default">OBJECTIVE: There is a scarcity of studies that assessed the association between adherence to combination therapy and asthma control in pediatric patients. The authors investigated the association between adherence to fluticasone propionate/salmeterol xinafoate combination-pMDI and the level of asthma control in children. METHODS: This was a prospective observational study of 84 patients aged 5-16 years with moderate persistent asthma, who remained uncontrolled despite the use of 1000mug/day of inhaled nonextrafine-HFA-beclomethasone dipropionate in the three months prior to study enrollment. Participants were prescribed two daily doses of FP (125mug)/salmeterol xinafoate (25mug) combination by pMDI/spacer for six months. Adherence rates were assessed using the device's dose counter after the 2nd, 4th, and 6th months of follow up. Asthma control was assessed using a simplified Global Initiative for Asthma 2014 Report classification. RESULTS: Mean adherence rates after the second, fourth, and sixth months were 87.8%, 74.9%, and 62.1% respectively, for controlled asthma, and 71.7%, 56.0%, and 47.6% respectively, for uncontrolled asthma (all p-values&lt;/=0.03). The proportion of children achieving asthma control increased to 42.9%, 67.9% and 89.3% after the 2nd, 4th and 6th months of follow-up, respectively (p&lt;/=0.001). CONCLUSION: Adherence rates between 87.8% in the 2nd month and 62.1% in the 6th month were strong determinants of asthma control</style></abstract><notes><style face="normal" font="default">IS - 1678-4782 (Electronic)IS - 0021-7557 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1016/j.jped.2017.10.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29274305">PM:29274305</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pediatr (Rio J)\20171120-JentzschNS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pediatr (Rio J)\20171120-JentzschNS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171220, Jentzsch NS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jped.2017.10.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43684</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Krey,S.C.</style></author><author><style face="normal" font="default"> Waise,J.</style></author><author><style face="normal" font="default"> Skrupky,L.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Department of Pharmacy, Aurora Medical Center-Grafton, Grafton, WI, USA</style></auth-address><titles><title><style face="normal" font="default">Confronting the Challenge of Beta-Lactam Allergies: A Quasi-Experimental Study Assessing Impact of Pharmacy-Led Interventions</style></title><secondary-title><style face="normal" font="default">J Pharm Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Pharm Pract</style></full-title></periodical><pages end="" start="897190017743154">897190017743154-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To improve allergy history documentation and increase the use of beta-lactams when appropriate in patients with a reported beta-lactam allergy. METHODS: This pre-post study was conducted at a 167-bed tertiary care community hospital and evaluated multidisciplinary interventions on allergy documentation and antibiotic selection. Interventions included education, creation of local practice guidelines, and modified practices for pharmacists and pharmacy technicians. Inpatients with a reported beta-lactam allergy receiving at least 1 antibiotic for >24 hours were included; first admissions were assessed. Primary outcomes were documentation of reaction type and percentage of patients receiving non-beta-lactam therapy. Secondary outcomes included documentation of previously tolerated beta-lactams, modification of non-beta-lactam therapy, discharge antibiotics, and adverse reactions. RESULTS: A total of 179 patients were included, 91 preintervention and 88 postintervention. No significant differences were observed between the before versus after groups in the percentage of patients with documentation of reaction type (90.1% vs 89.8%, P = .940) or the overall percentage of patients receiving non-beta-lactams (86.8% vs 84.1%, P = .605). However, significantly more patients in the after phase had documentation of previously tolerated beta-lactams (8.8% vs 28.4%, P = .001), and among patients receiving a non-beta-lactam, a greater percentage was subsequently switched to a beta-lactam (11.4% vs 25.7%, P = .022). One allergic reaction was documented during the study, which occurred in the before phase. CONCLUSION: Multidisciplinary education and local guideline implementation led by pharmacists may improve allergy documentation and antibiotic selection in patients with reported beta-lactam allergies</style></abstract><notes><style face="normal" font="default">IS - 1531-1937 (Electronic)IS - 0897-1900 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/0897190017743154</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29162022">PM:29162022</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pharm Pract\20171121-KreySC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pharm Pract\20171121-KreySC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171121, Krey SC</style></custom2><misc3><style face="normal" font="default">10.1177/0897190017743154</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43685</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Osada-Oka,M.</style></author><author><style face="normal" font="default"> Hirai,S.</style></author><author><style face="normal" font="default"> Izumi,Y.</style></author><author><style face="normal" font="default"> Misumi,K.</style></author><author><style face="normal" font="default"> Samukawa,K.</style></author><author><style face="normal" font="default"> Tomita,S.</style></author><author><style face="normal" font="default"> Miura,K.</style></author><author><style face="normal" font="default"> Minamiyama,Y.</style></author><author><style face="normal" font="default"> Iwao,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Food Hygiene and Environmental Health, Division of Applied Life Science, Graduate School of Life and Environmental Sciences, Kyoto Prefectural University, Kyoto, Japan.</style></auth-address><titles><title><style face="normal" font="default">Red ginseng extracts attenuate skin inflammation in atopic dermatitis through p70 ribosomal protein S6 kinase activation</style></title><secondary-title><style face="normal" font="default">J Pharmacol Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Pharmacol Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="11" Year="2017">2017/11/10</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease with increased immunoglobulin E (IgE) levels. Activation of the mammalian target of rapamycin (mTOR)/p70 ribosomal protein S6 kinase (p70S6K) signaling is known to occur in the inflammatory regions of AD skin. We previously demonstrated that red ginseng extract (RGE), as an anti-inflammatory agent, had potential for treating AD. However, it is still unclear whether RGE inhibits mTOR/p70S6K signaling. Thus, we examined the anti-inflammatory effects of RGE on IgE or interferon-gamma (IFN-gamma) induced signaling pathways. In KU812 human basophils, activation of Fcepsilon receptor type Ialpha (FCepsilonRI), also known as the high affinity IgE receptor, induced phosphorylation of both mTOR and p70S6K. Moreover, levels of phosphorylated p70S6K (p-p70S6K), but not p-mTOR, were decreased by RGE. RGE also decreased p-p70S6K levels in IFN-gamma-stimulated human keratinocytes, suppressing the IFN-gamma induced increase in levels of C-C chemokine ligand 2 mRNA. Interestingly, the increased p70S6K phosphorylation in skin lesions of AD model mice was attenuated by RGE treatment. In conclusion, RGE is a potential therapy against inflammatory responses involving the p70S6K signaling pathway</style></abstract><notes><style face="normal" font="default">IS - 1347-8648 (Electronic)IS - 1347-8613 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jphs.2017.11.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29274665">PM:29274665</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Pharmacol Sci\20171110-OsadaOkaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Pharmacol Sci\20171110-OsadaOkaM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171110, Osada-Oka M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jphs.2017.11.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43686</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hajiheydari,M.R.</style></author><author><style face="normal" font="default"> Yarmohammadi,M.E.</style></author><author><style face="normal" font="default"> Izadi,P.</style></author><author><style face="normal" font="default"> Jafari,F.</style></author><author><style face="normal" font="default"> Emadi,F.</style></author><author><style face="normal" font="default"> Emaratkar,E.</style></author><author><style face="normal" font="default"> Reza Abtahi,S.H.</style></author><author><style face="normal" font="default"> Zargaran,A.</style></author><author><style face="normal" font="default"> Naseri,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Traditional Iranian Medicine, Faculty of Medicine, Shahed University, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="default">Effect of Nepeta bracteata Benth. on allergic rhinitis symptoms: A randomized double-blind clinical trial</style></title><secondary-title><style face="normal" font="default">J Res Med Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Res Med Sci</style></abbr-1></periodical><pages end="" start="128">128-</pages><volume><style face="normal" font="default">22</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Allergic rhinitis (AR) is one of the health problems in the world. It is necessary to develop new treatment procedure for control of this disease. The aim of this study was to assess the effect of Zofa (Nepeta bracteata Benth) on AR patients. Materials and Methods: In this double-blind randomized clinical trial study, 71 patients (37 patients in treatment and 34 in placebo group) participated. In treatment group, N. bracteata syrup (NBS) was used for 4 weeks as three times a day. The efficacy of the drug regarding AR symptoms (rhinorrhea, sneezing, nasal obstruction, itchy nose, and ocular symptoms) were evaluated through a visual analog scale (VAS) by 0-10 before administration and at the end of the whole treatment period. The collected information was entered in the SPSS software (version 18) and was analyzed using the Fisher's exact test, Chi-square test, independent sample t-test, and paired sample test. Results: The improvement of AR symptoms in the group receiving NBS was significantly higher compared to control group (4.73 +/- 1.84 vs. 0.38 +/- 2.06; P &lt; 0.0001). Furthermore, the mean of total VAS before and after the treatment (in case group) was 7.10 +/- 1.92 and 2.37 +/- 1.76, respectively (P &lt; 0.001). Conclusion: The results of this study indicate that N. bracteata has significant effects on improving the symptoms of AR. Hence, it can be a good alternative to AR symptoms relief</style></abstract><notes><style face="normal" font="default">IS - 1735-1995 (Print)IS - 1735-1995 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">10.4103/jrms.JRMS_316_17</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29259639">PM:29259639</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Res Med Sci\2017-22-128.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Res Med Sci\2017-22-128.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171228, Hajiheydari MR</style></custom2><misc3><style face="normal" font="default">10.4103/jrms.JRMS_316_17</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43687</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,Z.</style></author><author><style face="normal" font="default"> Zhang,Q.</style></author><author><style face="normal" font="default"> Li,H.</style></author><author><style face="normal" font="default"> Lv,Q.</style></author><author><style face="normal" font="default"> Wang,W.</style></author><author><style face="normal" font="default"> Bai,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Industrial and Consumer Product Safety, Chinese Academy of Inspection and Quarantine, Beijing, China</style></auth-address><titles><title><style face="normal" font="default">Rapid and green determination of 58 fragrance allergens in plush toys</style></title><secondary-title><style face="normal" font="default">J Sep Sci</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Sep Sci</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="11" Year="2017">2017/11/17</year></dates><abstract><style face="normal" font="default">This paper presents a simple, rapid, and green method based on a static headspace gas chromatography with mass spectrometry for determining 58 fragrance allergens in plush toys. This study is the first to meet the requirement for simultaneously determining 66 fragrances, except for eight natural extracts restricted by the European Toy Safety Directive 2009/48/EC. A minimal amount of sample (20 mg) and acetone solvent (20 muL) were placed in a headspace vial. A gas-solid equilibration of fragrances between the headspace and the sample was achieved within 10 min under the vapor atmosphere of acetone at 200 degrees C, which allowed the fragrances in the sample to be measured by gas chromatography with mass spectrometry. Results showed that the interference caused by different sample matrices was negligible. The proposed method exhibited determination results that were highly similar to those of traditional ultrasonic extraction with sufficient sensitivity (limits of quantification: 0.02-10 mg/kg) for 58 fragrances, indicating its accuracy and reliability. The average recoveries ranged from 71.3 to 137.4%, and the relative standard deviation (n = 6) varied from 1.1 to 18.0%. Finally, the method was applied to monitor the fragrances in 20 commercial toys. This study provides a good reference for rapidly and greenly determining the semi-volatile analytes in toys, textiles, and other products. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">DA - 20171118IS - 1615-9314 (Electronic)IS - 1615-9306 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1002/jssc.201700556</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29150895">PM:29150895</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Sep Sci\20171108-WangZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Sep Sci\20171108-WangZ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171108, Wang Z</style></custom2><misc3><style face="normal" font="default">10.1002/jssc.201700556</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43688</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fernandes,V.</style></author><author><style face="normal" font="default"> Alfaro,T.M.</style></author><author><style face="normal" font="default"> Baptista,J.P.</style></author><author><style face="normal" font="default"> Regateiro,F.S.</style></author><author><style face="normal" font="default"> Fradinho,F.</style></author><author><style face="normal" font="default"> Cordeiro,C.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pneumology Unit A, Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal</style></auth-address><titles><title><style face="normal" font="default">Severe ketorolac-induced asthma diagnosed by chest computed tomography</style></title><secondary-title><style face="normal" font="default">J Thorac Dis</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Thorac Dis</style></abbr-1></periodical><pages end="S1569" start="S1567">S1567-S1569</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">Suppl 16</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">Aspirin-exacerbated respiratory disease (AERD) affects 15% of severe asthmatics and drug reactions cause 200,000 annual deaths in Europe. A 65-year-old lady presented to emergency for progressive abdominal pain. Her medical history included gallstones, asthma, rhinosinusitis and hypertension. She was regularly medicated with inhaled fluticasone, vilanterol and tiotropium, nasal budesonide, pantoprazole, oxazepam and perindopril. She reported partial asthma control and an exacerbation requiring admission to a respiratory ward 6 weeks before. On examination, there was right upper quadrant tenderness and no other changes. Blood tests were normal, and an ultrasound showed gallbladder stones with normal wall. Intravenous ketorolac led to prompt pain resolution. After 30 minutes she became severely dyspnoeic, with an O2 saturation of 85% on high flow O2. She had no breath sounds on the left lung, and there was no wheezing or prolonged expiration. A chest X-ray showed no pneumothorax and a computed tomography (CT) angiography was performed showing bilateral mucoid impaction and sub-segmental atelectasis. Continuous bronchodilation and systemic steroids led to gradual improving in the following 6 hours. After 9 days of admission on a respiratory ward she was discharged home with no symptoms and normal oxygenation. Importantly, she denied previous allergies to nonsteroidal anti-inflammatory drugs (NSAIDs) and had actually taken diclofenac and nimesulid before with no reactions. This report illustrates both an intravenous NSAID causing severe AERD, and how a chest CT may be instrumental for the diagnosis of life-threatening asthma</style></abstract><notes><style face="normal" font="default">IS - 2072-1439 (Print)IS - 2072-1439 (Linking)LA - engPT - Journal ArticleCO - Portugal -</style></notes><work-type><style face="normal" font="default">10.21037/jtd.2017.11.36</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29255644">PM:29255644</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\J Thorac Dis\2017-9S16-1567-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\J Thorac Dis\2017-9S16-1567-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171113, Fernandes V</style></custom2><misc3><style face="normal" font="default">10.21037/jtd.2017.11.36</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43689</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tate,C.</style></author><author><style face="normal" font="default"> Tang,F.</style></author><author><style face="normal" font="default"> Lane,S.W.</style></author><author><style face="normal" font="default"> Seymour,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pathology Queensland, Royal Brisbane and Women's Hospital, Herston, Australia</style></auth-address><titles><title><style face="normal" font="default">Clinical and molecular categorization of progressive, adult-onset cutaneous mastocytosis</style></title><secondary-title><style face="normal" font="default">JAAD Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JAAD Case Rep</style></abbr-1></periodical><pages end="32" start="30">30-32</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 2352-5126 (Print)IS - 2352-5126 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jdcr.2017.09.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29296647">PM:29296647</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAAD Case Rep\2018-4-30-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAAD Case Rep\2018-4-30-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171218, Tate C</style></custom2><misc3><style face="normal" font="default">10.1016/j.jdcr.2017.09.038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43690</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Reed,C.T.</style></author><author><style face="normal" font="default"> Mockbee,C.S.</style></author><author><style face="normal" font="default"> Brodell,R.T.</style></author><author><style face="normal" font="default"> Helms,S.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Is the hip prosthesis responsible for this rash?</style></title><secondary-title><style face="normal" font="default">JAAD Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JAAD Case Rep</style></abbr-1></periodical><pages end="3" start="1">1-3</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><isbn><style face="normal" font="default">2352-5126</style></isbn><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jdcr.2016.11.011</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.jdcr.2016.11.011</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\JAAD Case Rep\2018-4-1-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\JAAD Case Rep\2018-4-1-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171218, Reed CT</style></custom2><misc3><style face="normal" font="default">10.1016/j.jdcr.2016.11.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43691</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Carter,E.A.</style></author><author><style face="normal" font="default"> Tompkins,R.G.</style></author><author><style face="normal" font="default"> Hsu,H.</style></author><author><style face="normal" font="default"> Christian,B.</style></author><author><style face="normal" font="default"> Alpert,N.M.</style></author><author><style face="normal" font="default"> Weise,S.</style></author><author><style face="normal" font="default"> Fischman,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA</style></auth-address><titles><title><style face="normal" font="default">Metabolic alterations in muscle of thermally injured rabbits, measured by positron emission tomography</style></title><secondary-title><style face="normal" font="default">Life Sci</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Life Sci</style></abbr-1></periodical><pages end="44" start="39">39-44</pages><volume><style face="normal" font="default">61</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Animals</style></keyword><keyword><style face="normal" font="default"> Glucose</style></keyword><keyword><style face="normal" font="default"> metabolism</style></keyword><keyword><style face="normal" font="default"> Hindlimb</style></keyword><keyword><style face="normal" font="default"> Diagnostic Imaging</style></keyword><keyword><style face="normal" font="default"> injuries</style></keyword><keyword><style face="normal" font="default"> physiology</style></keyword><keyword><style face="normal" font="default"> Male</style></keyword><keyword><style face="normal" font="default"> Muscle,Skeletal</style></keyword><keyword><style face="normal" font="default"> Oxygen Consumption</style></keyword><keyword><style face="normal" font="default"> Rabbits</style></keyword><keyword><style face="normal" font="default"> Tomography,Emission-Computed</style></keyword></keywords><dates><year Day="0" Month="0" Year="1997">1997</year></dates><abstract><style face="normal" font="default">The hypermetabolic inflammatory state that occurs after major trauma has been extensively studied at the whole body level, however, there is only limited information on metabolic changes in individual tissues. In this study, the effect of thermal injury on metabolic function of uninjured hind limb muscle of rabbits was measured noninvasively by positron emission tomography (PET). Rabbits were subjected to full thickness burn on 25% of their body surface area. Two to three weeks after injury, PET and arterial blood sampling was performed during inhalation of 15O2, C15O2 and 11CO and after injection of 18FDG. The tissue and blood data were analyzed by standard kinetic models for blood flow, oxygen extraction fraction (OEF), oxygen utilization and glucose metabolism. A total of seven injured and five sham animals were studied. Total body oxygen consumption was measured by indirect calorimetry and plasma concentrations of glucose, insulin and IGF-1 were measured with standard assays. Compared to sham rabbits, blood flow to muscle of injured animals was unchanged. However, OEF, oxygen utilization and glucose metabolism were significantly reduced (p&lt;0.01) in uninjured muscle of burned rabbits. These data demonstrate that thermal injury is associated with alterations in muscle metabolism, which are not related to change in blood flow</style></abstract><notes><style face="normal" font="default">IS - 0024-3205 (Print)IS - 0024-3205 (Linking)LA - engPT - Journal ArticlePT - Research Support, Non-U.S. Gov'tPT - Research Support, U.S. Gov't, P.H.SRN - IY9XDZ35W2 (Glucose)SB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/S0024-3205(97)00355-X</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="9200667">PM:9200667</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Life Sci\1997-61-39-44.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Life Sci\1997-61-39-44.pdf</url></text-urls></urls><custom2><style face="normal" font="default">19971217, Carter EA</style></custom2><misc3><style face="normal" font="default">10.1016/S0024-3205(97)00355-X</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43692</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Boehm,I.</style></author><author><style face="normal" font="default"> Hungerbuhler,M.</style></author><author><style face="normal" font="default"> Heverhagen,J.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital, Bern University Hospital, University of Bern, Switzerland</style></auth-address><titles><title><style face="normal" font="default">Insight into the dynamic of gadolinium based contrast agent (GBCA) hypersensitivity: Acquisition, persistence and disappearance</style></title><secondary-title><style face="normal" font="default">Magn Reson Imaging</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Magn Reson Imaging</style></abbr-1></periodical><pages end="3" start="1">1-3</pages><volume><style face="normal" font="default">49</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="default">Anaphylaxis against gadolinium based contrast agents (GBCAs) has been reported in all severity grades but is less frequent than hypersensitivity/allergy against iodinated contrast materials. Once a patient acquires such an adverse reaction a life-long premedication is usually the consequence in concert with GBCA-enhanced MR-imaging procedures. The usefulness of this prophylaxis has been questioned, and discussed controversially during the past. The herein presented case may shed some light into the dynamic of contrast-medium-induced hypersensitivity reactions</style></abstract><notes><style face="normal" font="default">IS - 1873-5894 (Electronic)IS - 0730-725X (Linking)LA - engPT - Journal ArticleCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1016/j.mri.2017.12.013</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29247752">PM:29247752</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Magn Reson Imaging\2018-49-1-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Magn Reson Imaging\2018-49-1-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171213, Boehm I</style></custom2><misc3><style face="normal" font="default">10.1016/j.mri.2017.12.013</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43693</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kitulwatte,I.</style></author><author><style face="normal" font="default"> Gangahawatte,S.</style></author><author><style face="normal" font="default"> Perera,U.</style></author><author><style face="normal" font="default"> Edirisinghe,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Forensic Medicine, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka</style></auth-address><titles><title><style face="normal" font="default">Death following ceftazidime-induced Kounis syndrome</style></title><secondary-title><style face="normal" font="default">Med Leg J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Med Leg J</style></abbr-1></periodical><pages end="218" start="215">215-218</pages><volume><style face="normal" font="default">85</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">Kounis syndrome, also known as allergic myocardial infarction or allergic angina syndrome, coincides with chest pain and allergic reactions. It involves the activation of interrelated inflammatory cells following allergic, anaphylactic or anaphylactoid insults. We report a case of Kounis syndrome complicated by an injection of ceftazidime. A 52-year-old man developed shortness of breath and hypotension, leading to immediate unconsciousness, after a ceftazidime injection. Despite intensive care management, he showed no improvement and died approximately 19 h after ceftazidime administration. Autopsy showed massive laryngeal oedema, mucous plugging and collapsed lungs. An ImmunoCAP tryptase assay showed the tryptase level in an autopsy sample to be 118 microg/L (normal &lt; 11.4 microg/L). Microscopy of the myocardium showed cellular infiltration preceding myocardial necrosis. These findings support the pathophysiological theory of Kounis syndrome, with cellular infiltration proposed as the cause of myocardial injury rather than an effect related to the healing process</style></abstract><notes><style face="normal" font="default">IS - 2042-1834 (Electronic)IS - 0025-8172 (Linking)LA - engPT - Journal ArticleCO - Sri Lanka -</style></notes><work-type><style face="normal" font="default">10.1177/0025817217695904</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29210337">PM:29210337</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Med Leg J\2017-85-215-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Med Leg J\2017-85-215-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170227, Kitulwatte I</style></custom2><misc3><style face="normal" font="default">10.1177/0025817217695904</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43694</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Leal,V.N.C.</style></author><author><style face="normal" font="default"> Genov,I.R.</style></author><author><style face="normal" font="default"> Mallozi,M.C.</style></author><author><style face="normal" font="default"> Sole,D.</style></author><author><style face="normal" font="default"> Pontillo,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratorio de Imunogenetica, Departamento de Imunologia, Instituto de Ciencias Biomedicas/ICB, Universidade de Sao Paulo/USP, Sao Paulo, SP, Brazil</style></auth-address><titles><title><style face="normal" font="default">Polymorphisms in inflammasome genes and risk of asthma in Brazilian children</style></title><secondary-title><style face="normal" font="default">Mol Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Mol Immunol</style></full-title></periodical><pages end="67" start="64">64-67</pages><volume><style face="normal" font="default">93</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">Considering its role in inflammation and recently described "alternative" roles in epithelial homeostasis and Th1/Th2 balance, we hypothesize that inflammasome genetics could contribute to the development of asthma. Selected functional polymorphisms in inflammasome genes are evaluated in a cohort of asthmatic children and their families. Gain-of-function NLRP1 variants rs11651270, rs12150220 and rs2670660 resulted significantly associated to asthma in trios (TDT) analysis; and rs11651270 and rs2670660 also with asthma severity and total IgE level in asthmatic children. NLRP1 activators in humans are still unknown, however we hypothesized that individuals with gain-of-function SNPs in NLRP1 could be more prone in activating inflammasome in the presence of asthma-related cell stressors (i.e. ER stress or ROS), and this activation contribute to exacerbate inflammatory response and asthma development. Gain-of-function IL1A rs17561 resulted significantly associated with a reduced pulmonary capacity in asthmatic children. IL18 rs5744256 which lead to lower serum level of IL-18 appeared to be associated to a worse response to bronchodilators. Concluding, this work provides evidences about the contribution of inflammasome genetics in the development of paediatric asthma, both considering its inflammatory role in alveolar macrophages (i.e.: NLRP1) or its homeostatic role in lung epithelial cells (i.e.: IL1A, IL18)</style></abstract><notes><style face="normal" font="default">IS - 1872-9142 (Electronic)IS - 0161-5890 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1016/j.molimm.2017.11.006</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29154202">PM:29154202</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Mol Immunol\2018-93-64-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Mol Immunol\2018-93-64-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171115, Leal VN</style></custom2><misc3><style face="normal" font="default">10.1016/j.molimm.2017.11.006</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43695</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Miura,K.</style></author><author><style face="normal" font="default"> Morishita,Y.</style></author><author><style face="normal" font="default"> Matsuno,H.</style></author><author><style face="normal" font="default"> Aota,Y.</style></author><author><style face="normal" font="default"> Ito,H.</style></author><author><style face="normal" font="default"> Tai,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Life and Environmental Sciences, Prefectural University of Hiroshima, 5562 Nanatsuka-cho, Shobara, Hiroshima 727-0023, Japan.</style></auth-address><titles><title><style face="normal" font="default">Anti-Allergic Activity of Monoacylated Ascorbic Acid 2-Glucosides</style></title><secondary-title><style face="normal" font="default">Molecules</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Molecules</style></abbr-1></periodical><pages end="" start="2202">2202-</pages><volume><style face="normal" font="default">22</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="12" Year="2017">2017/12/12</year></dates><abstract><style face="normal" font="default">2-O-alpha-d-Glucopyranosyl-l-ascorbic acid (AA-2G) is one of the stable ascorbic acid (AA) derivatives known as provitamin C agents. We have previously synthesized two types of monoacylated derivatives of AA-2G, 6-O-acyl-2-O-alpha-d-glucopyranosyl-l-ascorbic acids having a straight-acyl chain of varying length from C(4) to C18 (6-sAcyl-AA-2G) and a branched-acyl chain of varying length from C(6) to C16 (6-bAcyl-AA-2G) in order to improve the bioavailability of AA-2G. In this study, 6-sAcyl-AA-2G and 6-bAcyl-AA-2G per se showed the inhibitory effects on hyaluronidase activity and degranulation. 6-sAcyl-AA-2G exhibited strong inhibitory effects on hyaluronidase activity and degranulation in a concentration-dependent manner, and the inhibitory effects tended to become stronger with increasing length of the acyl chain. 2-O-alpha-d-Glucopyranosyl-6-O-hexadecanoyl-l-ascorbic acid (6-sPalm-AA-2G), which has a straight C16 acyl chain, was the most potent effective for inhibition of hyaluronidase activity and for inhibition of degranulation among the 6-sAcyl-AA-2G derivatives and the two isomers of 6-sPalm-AA-2G. Furthermore, percutaneous administration of 6-sPalm-AA-2G significantly inhibited IgE-mediated passive cutaneous anaphylaxis reaction in mice. These findings suggest that 6-sPalm-AA-2G will be useful for treatment of allergies</style></abstract><notes><style face="normal" font="default">IS - 1420-3049 (Electronic)IS - 1420-3049 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.3390/molecules22122202</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29231858">PM:29231858</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Molecules\2017-22-2202.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Molecules\2017-22-2202.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171030, Miura K</style></custom2><misc3><style face="normal" font="default">10.3390/molecules22122202</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43696</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lodin,K.</style></author><author><style face="normal" font="default"> Lekander,M.</style></author><author><style face="normal" font="default"> Syk,J.</style></author><author><style face="normal" font="default"> Alving,K.</style></author><author><style face="normal" font="default"> Andreasson,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.</style></auth-address><titles><title><style face="normal" font="default">Associations between self-rated health, sickness behaviour and inflammatory markers in primary care patients with allergic asthma: a longitudinal study</style></title><secondary-title><style face="normal" font="default">NPJ Prim Care Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">NPJ Prim Care Respir Med</style></full-title></periodical><pages end="" start="67">67-</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="12" Year="2017">2017/12/18</year></dates><abstract><style face="normal" font="default">Allergic asthma is a chronic inflammatory disorder associated with elevated levels of immunoglobulin E (IgE), serum eosinophilic cationic protein (S-ECP), plasma eosinophil-derived neurotoxin (P-EDN) and fraction of exhaled nitric oxide (FENO). Poor self-rated health and sickness behaviour has repeatedly been associated with inflammatory markers, but the nature of this relationship in chronic inflammatory disease is not known. Likewise, such findings largely rely on cross-sectional investigations. Self-rated health (How would you rate your general state of health?), sickness behaviour (mean rating of satisfaction with energy, sleep, fitness, appetite and memory), IgE, S-ECP, P-EDN, and FENO were assessed in 181 non-smoking primary care patients with asthma in a 1-year longitudinal study. Associations between repeated measurements were calculated using mixed regression models and Spearman's correlations for change scores. Poor self-rated health was associated with high levels of seasonal IgE (p = 0.05) and food IgE (p = 0.04), but not total IgE or inflammatory markers. An increase over 1 year in perennial IgE was associated with a worsening of self-rated health (rho = 0.16, p = 0.04). Poor self-rated health was associated with more pronounced sickness behaviour (p &lt; 0.001), and a worsening in sickness behaviour was associated with a worsening of self-rated health over time (rho = 0.21, p = 0.007). The study corroborates the importance of sickness behaviour as a determinant of self-rated health by showing that these factors co-vary over a 1-year period in a group of patients with allergic asthma. The importance of specific IgE for perceived health in primary care patients with mild to moderate asthma needs further investigation</style></abstract><notes><style face="normal" font="default">IS - 2055-1010 (Electronic)IS - 2055-1010 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1038/s41533-017-0068-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29255205">PM:29255205</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\NPJ Prim Care Respir Med\2017-27-67.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\NPJ Prim Care Respir Med\2017-27-67.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171218, Lodin K</style></custom2><misc3><style face="normal" font="default">10.1038/s41533-017-0068-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43697</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chang,L.S.</style></author><author><style face="normal" font="default"> Lee,H.C.</style></author><author><style face="normal" font="default"> Tsai,Y.C.</style></author><author><style face="normal" font="default"> Shen,L.S.</style></author><author><style face="normal" font="default"> Li,C.L.</style></author><author><style face="normal" font="default"> Liu,S.F.</style></author><author><style face="normal" font="default"> Kuo,H.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital, Taiwan, China</style></auth-address><titles><title><style face="normal" font="default">Decreased incidence of glaucoma in children with asthma using inhaled corticosteroid: a cohort study</style></title><secondary-title><style face="normal" font="default">Oncotarget</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Oncotarget</style></abbr-1></periodical><pages end="105471" start="105463">105463-105471</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">62</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="12" Year="2017">2017/12/1</year></dates><abstract><style face="normal" font="default">Among the anti-inflammatory medications used for treating asthma, corticosteroids are the most effective. The effects of orally administered corticosteroids on intraocular pressure and lens opacity have been well defined, but the influence of inhaled corticosteroids (ICS) on children has yet to be clearly explained. Therefore, we used a nationwide cohort database to investigate glaucoma in childhood asthma patients using ICS. We analyzed a dataset of 1,000,000 randomly sampled individuals from Taiwan's 2000 National Health Insurance Research Database. The study cohort included 5,380 patients who were first diagnosed with asthma (ICD9: 493.X) diagnosis when they were six years old or younger. All subjects were followed through December 2011. We applied Cox's proportional hazard model to determine whether ICS use has a correlation with glaucoma. Of the 5,380 patients enrolled in this study, we identified 1,232 patients who had used ICS and 4,148 patients who had no history of ICS administration throughout the follow-up period. The prevalence of glaucoma was significantly lower in patients using ICS, with a 0.52-fold decreased risk of developing glaucoma in comparison to the control group [adjusted hazard ratio (HR) 0.52, 95% confidence interval (CI) 0.28 approximately 0.96]. Among the evaluated comorbidities, cataract was positively associated with glaucoma in asthma children (adjusted HR 8.22; 95% CI = 2.59 approximately 26.12). This study provides not only the first but also strong evidence that the glaucoma incidence in the ICS group is lower than that in the non-ICS group in children with asthma. Further consultation with an ophthalmologist regarding the high-risk group of asthma children with cataracts is necessary</style></abstract><notes><style face="normal" font="default">IS - 1949-2553 (Electronic)IS - 1949-2553 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.18632/oncotarget.22252</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29285264">PM:29285264</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Oncotarget\2017-8-105463-71.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Oncotarget\2017-8-105463-71.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Chang LS</style></custom2><misc3><style face="normal" font="default">10.18632/oncotarget.22252</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43698</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Grissinger,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">EPINEPHrine for Anaphylaxis: Autoinjector or 1-mg Vial or Ampoule?</style></title><secondary-title><style face="normal" font="default">P T</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">P T</style></abbr-1></periodical><pages end="725" start="724">724-725</pages><volume><style face="normal" font="default">42</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">Epinephrine for anaphylaxis: Autoinjector or 1-mg vial or ampoule?</style></abstract><notes><style face="normal" font="default">IS - 1052-1372 (Print)IS - 1052-1372 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29234208">PM:29234208</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\P T\2017-42-724-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\P T\2017-42-724-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171211, Grissinger M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43699</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nakahara,T.</style></author><author><style face="normal" font="default"> Morimoto,H.</style></author><author><style face="normal" font="default"> Murakami,N.</style></author><author><style face="normal" font="default"> Furue,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Division of Skin Surface Sensing, Department of Dermatology, Graduate School of Medical Sciences, Kyushu University</style></auth-address><titles><title><style face="normal" font="default">Mechanistic insights on topical tacrolimus for the treatment of atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="12" Year="2017">2017/12/4</year></dates><abstract><style face="normal" font="default">More than fifteen years have passed since the clinical launch of topical tacrolimus for the treatment of atopic dermatitis. Its efficacy and safety have been clearly demonstrated in many global and domestic short-term and long-term clinical trials. Although the prolonged external application of steroids causes many adverse reactions including cutaneous atrophy, no such reactions occur with the use of topical tacrolimus. Therefore, the therapeutic guidelines recommend a combined topical treatment with tacrolimus and steroids. Tacrolimus is a potent immunosuppressant. However, recent studies have revealed its diverse action on the cardinal pathomechanisms of atopic dermatitis. In this review, we summarize the mechanistic role of tacrolimus in various aspects of allergic inflammation including mast cell activation, innate allergic response, pruritus, sensory nerve activation and skin barrier dysfunction. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12842</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29205511">PM:29205511</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20180105-NakaharaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Allergy Immunol\20180105-NakaharaT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, Nakahara T</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12842</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43700</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zafrir,Y.</style></author><author><style face="normal" font="default"> Trattner,A.</style></author><author><style face="normal" font="default"> Hodak,E.</style></author><author><style face="normal" font="default"> Eldar,O.</style></author><author><style face="normal" font="default"> Lapidoth,M.</style></author><author><style face="normal" font="default"> Ben Amitai,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Sheba Medical Center, Tel Hashomer, Israel</style></auth-address><titles><title><style face="normal" font="default">Patch testing in Israeli children with suspected allergic contact dermatitis: A retrospective study and literature review</style></title><secondary-title><style face="normal" font="default">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="11" Year="2017">2017/11/16</year></dates><abstract><style face="normal" font="default">BACKGROUND/OBJECTIVES: Childhood allergic contact dermatitis is recognized as a significant clinical problem. The objective was to evaluate the rate of positive patch tests in Israeli children with clinically suspected allergic contact dermatitis, identify possible sex and age differences, compare results with those in Israeli adults, and review pediatric studies in the literature. METHODS: The study sample included 343 children and adolescents (197 female, 146 male; 1-18 years of age, mean age 11.8 years) with clinically suspected allergic contact dermatitis who underwent patch testing with a standard pediatric series of 23 allergens at a tertiary medical center from 1999 to 2012. Data on clinical characteristics and test results were collected retrospectively from the medical files. RESULTS: Ninety-eight subjects (28.6%) (75 girls [38.1%], 23 boys [15.8%]) had at least one positive reaction. The most frequent reactions were to nickel sulfate, followed by potassium dichromate and cobalt chloride. Nickel sulfate sensitivity was more common in girls, especially those younger than 3 years and older than 12 years. The prevalence of contact sensitization was similar in subjects with and without atopic dermatitis (50% and 51%, respectively). CONCLUSION: Nickel is the most common allergen in Israeli children, especially girls. Patch testing should be performed in children with clinically suspected allergic contact dermatitis regardless of atopic background</style></abstract><notes><style face="normal" font="default">DA - 20171116IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Journal ArticleCO - Israel -</style></notes><work-type><style face="normal" font="default">10.1111/pde.13333</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29143366">PM:29143366</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Dermatol\20171116-ZafrirY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Dermatol\20171116-ZafrirY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171116, Zafrir Y</style></custom2><misc3><style face="normal" font="default">10.1111/pde.13333</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43701</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liang,Y.</style></author><author><style face="normal" font="default"> Tian,J.</style></author><author><style face="normal" font="default"> Shen,C.P.</style></author><author><style face="normal" font="default"> Xu,F.</style></author><author><style face="normal" font="default"> Wang,H.</style></author><author><style face="normal" font="default"> Li,P.</style></author><author><style face="normal" font="default"> Guo,Y.P.</style></author><author><style face="normal" font="default"> Wei,F.L.</style></author><author><style face="normal" font="default"> Ma,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China</style></auth-address><titles><title><style face="normal" font="default">Therapeutic patient education in children with moderate to severe atopic dermatitis: A multicenter randomized controlled trial in China</style></title><secondary-title><style face="normal" font="default">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="15" Month="12" Year="2017">2017/12/15</year></dates><abstract><style face="normal" font="default">BACKGROUND: Therapeutic patient education is a continuous, systematic, patient-centered learning process to help patients and their families acquire and maintain the skills they need to manage their lives with a chronic disease. It has been proven effective in increasing treatment adherence and improving quality of life for patients with atopic dermatitis (AD) in Western countries. We introduce the first multicenter, randomized controlled clinical trial of therapeutic patient education in Chinese children with AD. OBJECTIVES: To evaluate the effects of therapeutic patient education on the severity of AD, quality of life, and understanding and successful use of emollients in Chinese children with eczema. METHODS: We recruited 580 children, ages 2-14 years, with moderate to severe AD from six hospitals in China. Participants were randomized (1:1) to an intervention (n = 293) or control (n = 249) group. In addition to the severity of AD, data on quality of life and a questionnaire on family and patient knowledge of emollients were evaluated at the 6-month follow-up. RESULTS: On study completion, we found that the intervention group showed a significantly greater reduction in mean SCORing Atopic Dermatitis (P &lt; .001) and Infant's Dermatology Life Quality Index (P = .030) scores than the control group. In addition, knowledge about the use of emollients improved significantly in the intervention group. There was no significant difference between groups in Children's Dermatology Life Quality Index scores. CONCLUSIONS: The first randomized controlled trial of a therapeutic patient education program in China had positive long-term effects on decreasing eczema severity and improvement of quality of life in children 2-4 years of age with AD, as well as in promoting greater understanding of the use of emollients</style></abstract><notes><style face="normal" font="default">IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1111/pde.13362</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29243849">PM:29243849</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Dermatol\20171215-LiangY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Dermatol\20171215-LiangY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171215, Liang Y</style></custom2><misc3><style face="normal" font="default">10.1111/pde.13362</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43702</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hortenhuber,T.</style></author><author><style face="normal" font="default"> Kiess,W.</style></author><author><style face="normal" font="default"> Frohlich-Reiterer,E.</style></author><author><style face="normal" font="default"> Raile,K.</style></author><author><style face="normal" font="default"> Stachow,R.</style></author><author><style face="normal" font="default"> Bollow,E.</style></author><author><style face="normal" font="default"> Rami-Merhar,B.</style></author><author><style face="normal" font="default"> Holl,R.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Medical University of Vienna, Vienna, Austria</style></auth-address><titles><title><style face="normal" font="default">Asthma in children and adolescents with type 1 diabetes in Germany and Austria: Frequency and metabolic control</style></title><secondary-title><style face="normal" font="default">Pediatr Diabetes</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pediatr Diabetes</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="12" Year="2017">2017/12/8</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To investigate the prevalence of asthma in young patients with type 1 diabetes mellitus (T1D) from Austria and Germany and its influence on their metabolic control. METHODS: This prospective, multicenter observational cohort study was based on the DPV-registry (German/Austrian DPV initiative) including 51 926 patients with T1D (&lt;20 years). All clinical data were documented prospectively. To identify patients with additional asthma, the entry of the diagnosis asthma as well as asthma medication was used for classification. RESULTS: 1755 patients (3.4%) of the cohort had the diagnosis asthma or received asthma-specific drugs. Patients with asthma needed higher insulin doses (0.88 +/- 0.3 vs 0.84 +/- 0.3 U/kg, P &lt; .01) and had decreased height-standard deviation score (SDS) (-0.002 +/- 1.04 vs 0.085 +/- 1.02, P &lt; .01); they were more often males (61% vs 52%, P &lt; .01), had an increased body mass index (BMI)-SDS (0.31 +/- 0.89 vs 0.28 +/- 0.89, P = .04) and experienced more severe hypoglycemia (4.5 [4.2; 4.8] vs 3.2 [3.2; 3.3] events/100 pts. years, P &lt; .01). Glycated hemoglobin A1c (HbA1c) did not differ between patients with and without asthma overall, only sub groups (corticosteroids vs leukotriene antagonist and corticosteroids vs sympatomimetics) revealed differences. No influence of asthma medication on metabolic control or BMI-SDS could be found. CONCLUSION: In our DPV-database, frequency of asthma and T1D seems similar to the prevalence of asthma in the healthy German background population. The concomitant diagnosis of asthma and T1D had minor influence on metabolic control and diabetes complication rate, although there was no difference in HbA1c overall. Patients with both diseases seem to be slightly growth restricted and require slightly higher insulin doses</style></abstract><notes><style face="normal" font="default">IS - 1399-5448 (Electronic)IS - 1399-543X (Linking)LA - engPT - Journal ArticleCO - Austria -CO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/pedi.12618</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29218837">PM:29218837</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pediatr Diabetes\20171208-HortenhuberT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pediatr Diabetes\20171208-HortenhuberT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171208, Hortenhuber T</style></custom2><misc3><style face="normal" font="default">10.1111/pedi.12618</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43703</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Grzeskowiak,L.E.</style></author><author><style face="normal" font="default"> Grieger,J.A.</style></author><author><style face="normal" font="default"> Clifton,V.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Adelaide Medical School, The Robinson Research Institute, The University of Adelaide, Australia</style></auth-address><titles><title><style face="normal" font="default">Strategies towards improving pharmacological management of asthma during pregnancy</style></title><secondary-title><style face="normal" font="default">Pharmacol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pharmacol Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="23" Month="12" Year="2017">2017/12/23</year></dates><abstract><style face="normal" font="default">Maternal asthma represents a significant burden to individuals and the healthcare system, affecting 1 in 10 pregnancies worldwide. Approximately 50% of asthmatic women experience a deterioration of asthma control at some stage during pregnancy, with a number requiring use of oral corticosteroids for the management of acute exacerbations. The presence of maternal asthma and exacerbations during pregnancy is a noted risk factor for a range of adverse perinatal outcomes including preterm birth, small-for-gestational age, pre-eclampsia, and gestational diabetes. These negative impacts highlight the need for evidence-based approaches for improving asthma management during pregnancy and subsequent perinatal outcomes. Despite this, relatively small progress has been made in enhancing the management of maternal asthma in the clinical setting. A major challenge in improving outcomes of asthmatic pregnancies is that there is no single simplified approach for improving outcomes, but rather the requirement to consider the dynamic relationship between a myriad of interrelated factors that ultimately determine an individual's ability to maintain adequate asthma control. Understanding how these factors are impacted by pregnancy and how they can be addressed through various interventions is therefore important in optimizing health outcomes. This review summarises key factors involved in influencing outcomes associated with maternal asthma. This includes an overview of the use of asthma medications in pregnancy, while also considering the impacts of interrelated aspects such as medication adherence, health-seeking behaviours, biological and lifestyle factors, co-morbidities, and asthma self-management strategies on asthma control. Addressing such factors through multidisciplinary approaches towards treatment have potential to improve the health of mothers and their offspring. Optimising asthma control should be a high priority within the antenatal setting, with women advised about the importance of good asthma control, managing asthma actively throughout pregnancy by utilising their asthma medications, and managing exacerbations in a timely and effective manner</style></abstract><notes><style face="normal" font="default">IS - 1096-1186 (Electronic)IS - 1043-6618 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/j.phrs.2017.12.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29278745">PM:29278745</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pharmacol Res\20171224-GrzeskowiakLE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pharmacol Res\20171224-GrzeskowiakLE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171224, Grzeskowiak LE</style></custom2><misc3><style face="normal" font="default">10.1016/j.phrs.2017.12.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43704</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,M.</style></author><author><style face="normal" font="default"> Yoo,J.</style></author><author><style face="normal" font="default"> Kim,J.</style></author><author><style face="normal" font="default"> Park,J.</style></author><author><style face="normal" font="default"> Han,E.</style></author><author><style face="normal" font="default"> Jang,W.</style></author><author><style face="normal" font="default"> Chae,H.</style></author><author><style face="normal" font="default"> Lee,J.H.</style></author><author><style face="normal" font="default"> Park,Y.M.</style></author><author><style face="normal" font="default"> Kim,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Association of FLG single nucleotide variations with clinical phenotypes of atopic dermatitis</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0190077">e0190077-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">BACKGROUND: FLG encodes a large protein called profilaggrin, which plays a key role in maintaining an effective skin barrier against the environment. In this study, we identified FLG single nucleotide variations (FLG-SNVs) and evaluated the association of FLG-SNVs with clinical phenotypes including atopic dermatitis (AD)-associated minor clinical features, presence of specific allergic sensitization, and serum parameters. METHODS: Eighty-one Korean patients with AD were enrolled. AD-associated minor clinical features as well as allergic rhinitis and asthma were diagnosed by specialists. FLG-SNVs were identified by Sanger sequencing of entire exons through long-range PCR. Allergic sensitization to a specific allergen was evaluated by multiple allergen simultaneous test. Serologic parameters such as serum eosinophil cationic protein (ECP) and eosinophil derived neurotoxin (EDN) were measured. RESULTS: A total of seventy-three SNVs and 4 LOF mutations were successfully genotyped. rs71626704 and rs76413899 were significantly associated with a history of asthma and cheilitis (P = 0.002 and P = 0.033, respectively), however, the associations were not found statistically significant after adjustment by multiple comparisons. In addition, we detected haplotype blocks which were correlated with non-specific hand or foot dermatitis and scalp scale. We identified FLG-SNVs which were associated with sensitization to environmental allergens; rs62623409 and rs71625199 (P = 0.038 and P = 0.008, respectively). Patients with FLG P478S TT and history of allergic rhinitis showed a higher EDN level, and among those patients, the ones with asthma showed a higher ECP level. CONCLUSION: This study revealed the association of FLG-SNVs with AD-associated minor clinical features. We firstly identified rs71625199 which was associated with higher environmental allergic sensitization. We also suggest that FLG P478S is a kind of disease modifier which affects serologic parameters such as EDN and ECP</style></abstract><notes><style face="normal" font="default">IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0190077</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29281699">PM:29281699</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0190077.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0190077.pdf</url></text-urls><related-urls><url ppv-ref="no">xlsx in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20171227, Kim M</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0190077</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43705</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yeh,J.J.</style></author><author><style face="normal" font="default"> Lin,C.L.</style></author><author><style face="normal" font="default"> Hsu,W.H.</style></author><author><style face="normal" font="default"> Kao,C.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan</style></auth-address><titles><title><style face="normal" font="default">The relationship of depression in asthma-chronic obstructive pulmonary disease overlap syndrome</style></title><secondary-title><style face="normal" font="default">PLoS One</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">PLoS One</style></abbr-1></periodical><pages end="" start="e0188017">e0188017-</pages><volume><style face="normal" font="default">12</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">PURPOSE: To clarify the relationship between asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) and depression. METHODS: We identified 10,911 patients who received an ACOS diagnosis and concurrent treatment between January 2000 and December 2009. Subjects without ACOS were included in the non-ACOS cohort (n = 10,911). Cox proportional hazard regression analysis was performed to compare the risk of depression between the ACOS and non-ACOS cohorts. RESULTS: The risk of depression was higher in the ACOS cohort than in the non-ACOS cohort (adjusted hazard ratios (aHRs) = 1.67, 95% confidence interval [CI] = 1.48-1.88). In the ACOS cohort, the aHRs for depression were [2.44 (95% CI = 1.45-4.11); 2.36 (95% CI = 1.58-3.52)] in patients [aged 20-39 years; without comorbidity]. In the ACOS cohort, the aHRs for depression were 1.70 (95% CI = 1.51-1.93) and 1.84 (95% CI = 1.55-2.19) in patients without inhaled corticosteroids (ICSs) and oral steroids (OSs) use, respectively. Moreover, the aHRs for the risk of depression were 1.16 (95% CI = 0.95-1.41) and 1.12 (95% CI = 0.96-1.29) in patients with ICSs and OSs use, respectively. CONCLUSION: The risk of depression is higher in ACOS patients, even in those without comorbidities or in young adults. The events of the depression were not significant difference in patients receiving the ICSs/OSs between the ACOS and the non-ACOS cohorts</style></abstract><notes><style face="normal" font="default">IS - 1932-6203 (Electronic)IS - 1932-6203 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1371/journal.pone.0188017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29232717">PM:29232717</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\PLoS One\2017-12-e0188017.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\PLoS One\2017-12-e0188017.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171212, Yeh JJ</style></custom2><misc3><style face="normal" font="default">10.1371/journal.pone.0188017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43706</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fuss,P.</style></author><author><style face="normal" font="default"> Bal-Gieranczyk,K.</style></author><author><style face="normal" font="default"> Jerzynska,J.</style></author><author><style face="normal" font="default"> Stelmach,I.</style></author></authors></contributors><titles><title><style face="normal" font="default">The effect of farming environment on asthma and allergy development in children</style></title><secondary-title><style face="normal" font="default">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pol J Allergol</style></full-title></periodical><pages end="108" start="103">103-108</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">+ørodowisko wiejskie</style></keyword><keyword><style face="normal" font="default"> zapobieganie astmie</style></keyword><keyword><style face="normal" font="default"> hipotezy</style></keyword><keyword><style face="normal" font="default"> Farming environment</style></keyword><keyword><style face="normal" font="default"> Asthma protection</style></keyword><keyword><style face="normal" font="default"> Hypotheses</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2353-3854</style></isbn><abstract><style face="normal" font="default">Abstract Children who grow up on dairy farms rarely develop asthma or allergies. Researchers suspect a key reason is that the kids breathe in air full of lipopolysaccharides, molecules from the cell wall of bacteria G-, known as endotoxins. Endotoxin-reduced epithelial cell cytokines activate dendritic cells (DCs), thus suppressing type 2 immunity to house dust mites and reducing the overall reactivity of the immune system and later protecting children from asthma. Schuijs et al showed that an enzyme involved in this defense, called A20, is made by the epithelial cells. Loss of the ubiquitin-modifying enzyme A20 abolished the protective effect. Thus, the farming environment protects from allergy by modifying the communication between barrier epithelial cells and DCs through A20 induction. Their study offers new support for the hygiene hypothesis, which posits that zeal for cleanliness and widespread use of antibiotics have purged the environment of microorganisms that once taught a child's developing immune system not to overreact to foreign substances. This paper is a summary of up-to-date information on hygiene hypothesis. The purpose is to review the important recent advances made in how innate immune cells, microbes, and the environment contribute to the expression of allergic disease, emphasizing the allergen-related signals that drive allergic responses</style></abstract><notes><style face="normal" font="default">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.alergo.2017.08.002</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.alergo.2017.08.002</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pol J Allergol\2017-4-103-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pol J Allergol\2017-4-103-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Fuss P</style></custom2><misc3><style face="normal" font="default">10.1016/j.alergo.2017.08.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43707</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ziaja,M.</style></author><author><style face="normal" font="default"> Pawliczak,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">miRNA - role and importance in bronchial asthma</style></title><secondary-title><style face="normal" font="default">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pol J Allergol</style></full-title></periodical><pages end="102" start="93">93-102</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">microRNA</style></keyword><keyword><style face="normal" font="default"> astma oskrzelowa</style></keyword><keyword><style face="normal" font="default"> kr-à++-àce miRNA</style></keyword><keyword><style face="normal" font="default"> bronchial asthma</style></keyword><keyword><style face="normal" font="default"> Circulating miRNAs</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2353-3854</style></isbn><abstract><style face="normal" font="default">Abstract Chronic inflammatory airway diseases, including asthma, are a significant health problem and previous treatment methods seem to be insufficient. There is a lack of effective therapies which are adjusted to treat all classes in terms of severity, and it is probably caused by insufficient understanding of molecular mechanisms involved in its occurrence. Small non-coding microRNA molecules in response to environmental factors lead to modulate gene expression. They regulate many processes associated with physiologic functions of the immune system. Researches showed crucial role of miRNA in pathogenesis of asthma and the other chronic inflammatory airway diseases. Despite the link of microRNA with pathogenesis of inflammatory airway diseases, the role of these molecules is still unclear. More detailed knowledge of the impact of miRNA molecules on the development of bronchial asthma would allow us to better understand the genesis process and might influence the effectiveness of the bronchial asthma treatment</style></abstract><notes><style face="normal" font="default">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.alergo.2017.07.001</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.alergo.2017.07.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pol J Allergol\2017-4-93-102.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pol J Allergol\2017-4-93-102.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Ziaja M</style></custom2><misc3><style face="normal" font="default">10.1016/j.alergo.2017.07.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43708</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sikorska,M.</style></author><author><style face="normal" font="default"> Nowicki,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Mycosis of smooth skin treated as contact allergy</style></title><secondary-title><style face="normal" font="default">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pol J Allergol</style></full-title></periodical><pages end="130" start="126">126-130</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">grzybica</style></keyword><keyword><style face="normal" font="default"> mikrosporioza</style></keyword><keyword><style face="normal" font="default"> kortykosteroidy</style></keyword><keyword><style face="normal" font="default"> Tinea incognito</style></keyword><keyword><style face="normal" font="default"> Dermatophytosis</style></keyword><keyword><style face="normal" font="default"> Corticosteroids</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2353-3854</style></isbn><abstract><style face="normal" font="default">Abstract Fungal skin infections are caused mainly by dermatophytes of the genus Trichophyton, Microsporum and Epidermophyton. Proper diagnosis based on clinical picture and mycological examination makes it possible to implement effective treatment </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô local, general or combination. Mycobacterial mycosis mostly develops on the skin of the scalp in the form of single or multiple lesions without inflammation. Zoophilic dermatophyte Microsporum canis is the most common causative pathogen, anthropophilic species such as Microsporum audouinii and Microsporum ferrugineum are observed occasionally. In case of zoonitic mycosis, a characteristic inflammation is formed on the periphery. Outside the scalp, skin of the face, neck, shoulders and the trunk can also be affected. Mycosis of smooth skin manifests in the form of oval or round erythematous patches or plaques with sharply defined borders, which spread circumferentially. The periphery of the lesion is inflamed with scaling and pustules, and centrally located resolution is observed. Pruritus in majority of the cases is a chief complaint. In most of the cases, a single lesion is observed, but over time, lesions tend to multiply and fuse together. Differential diagnosis of mycosis of the smooth skin includes seborrheic dermatitis, Gilbert's pink dandruff, mycosis fungoides, psoriasis and nummular dermatitis. The basis of treatment for microsporiasis is the use of topical preparations with antifungal agents. Local treatment is sufficient in most of the cases. General treatment (terbinafine, itraconazole, fluconazole or griseofulvin) is recommended if there is no improvement after topical treatment or in advanced disease stages. This article presents the case of a woman whose single facial fungal skin lesion was misdiagnosed as allergic contact dermatitis. Topical treatment with moderate-potent corticosteroids was used to achieve initial clinical improvement but discontinuation of therapy led to evolution of the lesion, which partially lost its original ring-shaped nature. The final diagnosis was based on mycological examination, and local and general antifungal treatment led to permanent cure. Not typical mycotic skin disease altered by immunosuppressive treatment is termed tinea incognito. Carelessly prescribing and using corticosteroids for infectious skin lesions results in complications as well as postponement of proper diagnosis and initiation of the treatment</style></abstract><notes><style face="normal" font="default">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.alergo.2017.08.003</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.alergo.2017.08.003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pol J Allergol\2017-4-126-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pol J Allergol\2017-4-126-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Sikorska M</style></custom2><misc3><style face="normal" font="default">10.1016/j.alergo.2017.08.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43709</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Czarnecka-Operacz,M.</style></author><author><style face="normal" font="default"> Sadowska-Przytocka,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Probiotics for the prevention of atopic dermatitis and other allergic diseases: What are the real facts?</style></title><secondary-title><style face="normal" font="default">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pol J Allergol</style></full-title></periodical><pages end="92" start="89">89-92</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Probiotics</style></keyword><keyword><style face="normal" font="default"> Synbiotics</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword><keyword><style face="normal" font="default"> Atopic dermatitis</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2353-3854</style></isbn><abstract><style face="normal" font="default">Abstract Atopic dermatitis (AD) is one of the most common inflammatory skin diseases diagnosed all over the world. The course of this complicated disease is chronic and relapsing and there have been many variants both endogenic and phenotypic already described and despite of our better understanding of AD we have no well </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç£structured</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇØ therapeutical approach to many of our patients. Mainly because we do not understand it in an adequate way and complexity of treatment must be highly individualized. Recent studies suggest prevention of AD can be achieved through early intervention to protect the disturbed skin barrier. While the skin lesions are developed AD requires appropriate control of local and systemic immune activation for optimal management which obviously may cause the whole variety of adverse events. Therefore it seems that early intervention might improve long-term outcomes of AD and reduce the risk of development of systemic sensitization that leads to associated allergic/atopic diseases within the gastrointestinal and respiratory tract. For some time probiotics have been suggested as an intervention to prevent allergic diseases such as AD. Therefore besides many publications, a systematic review of randomized trials assessing the effect of any probiotics administered to pregnant women breast-feeding mothers, and/or infants have been analyzed in this review paper in order to state what is the </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç£real truth</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇØ about this type of preventive approach</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.alergo.2017.08.001</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.alergo.2017.08.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Pol J Allergol\2017-4-89-92.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Pol J Allergol\2017-4-89-92.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170801, Czarnecka-Operacz M</style></custom2><misc3><style face="normal" font="default">10.1016/j.alergo.2017.08.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43710</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hensley,M.</style></author><author><style face="normal" font="default"> Singer,B.H.</style></author></authors></contributors><titles><title><style face="normal" font="default">Alternative topical anesthesia for bronchoscopy in a case of severe lidocaine allergy</style></title><secondary-title><style face="normal" font="default">Resp Med Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Resp Med Case Rep</style></full-title></periodical><pages end="92" start="90">90-92</pages><volume><style face="normal" font="default">23</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><isbn><style face="normal" font="default">2213-0071</style></isbn><abstract><style face="normal" font="default">Abstract Lidocaine allergy presents a unique difficulty for both patients and providers who undergo/perform bronchoscopy. We present a case of a 73 yo male with severe lidocaine allergy who successfully underwent bronchoscopy with chloroprocaine topical anesthesia and discuss alternative topical anesthetic agents that may be used in this special situation</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.rmcr.2017.12.010</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.rmcr.2017.12.010</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Resp Med Case Rep\2018-23-90-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Resp Med Case Rep\2018-23-90-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180103, Hensley M</style></custom2><misc3><style face="normal" font="default">10.1016/j.rmcr.2017.12.010</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43711</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mazenq,J.</style></author><author><style face="normal" font="default"> Dubus,J.C.</style></author><author><style face="normal" font="default"> Gaudart,J.</style></author><author><style face="normal" font="default"> Charpin,D.</style></author><author><style face="normal" font="default"> Viudes,G.</style></author><author><style face="normal" font="default"> Noel,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Pulmonology Department, Timone Children's Hospital, Aix-Marseille University, Marseille, France.</style></auth-address><titles><title><style face="normal" font="default">City housing atmospheric pollutant impact on emergency visit for asthma: A classification and regression tree approach</style></title><secondary-title><style face="normal" font="default">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respir Med</style></full-title></periodical><pages end="8" start="1">1-8</pages><volume><style face="normal" font="default">132</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Particulate matter, nitrogen dioxide (NO2) and ozone are recognized as the three pollutants that most significantly affect human health. Asthma is a multifactorial disease. However, the place of residence has rarely been investigated. We compared the impact of air pollution, measured near patients' homes, on emergency department (ED) visits for asthma or trauma (controls) within the Provence-Alpes-Cote-d'Azur region. METHODS: Variables were selected using classification and regression trees on asthmatic and control population, 3-99 years, visiting ED from January 1 to December 31, 2013. Then in a nested case control study, randomization was based on the day of ED visit and on defined age groups. Pollution, meteorological, pollens and viral data measured that day were linked to the patient's ZIP code. RESULTS: A total of 794,884 visits were reported including 6250 for asthma and 278,192 for trauma. Factors associated with an excess risk of emergency visit for asthma included short-term exposure to NO2, female gender, high viral load and a combination of low temperature and high humidity. CONCLUSION: Short-term exposures to high NO2 concentrations, as assessed close to the homes of the patients, were significantly associated with asthma-related ED visits in children and adults</style></abstract><notes><style face="normal" font="default">IS - 1532-3064 (Electronic)IS - 0954-6111 (Linking)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.rmed.2017.09.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29229079">PM:29229079</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Med\2017-132-1-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Med\2017-132-1-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170912, Mazenq J</style></custom2><misc3><style face="normal" font="default">10.1016/j.rmed.2017.09.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43712</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Peng,Y.H.</style></author><author><style face="normal" font="default"> Su,S.Y.</style></author><author><style face="normal" font="default"> Liao,W.C.</style></author><author><style face="normal" font="default"> Huang,C.W.</style></author><author><style face="normal" font="default"> Hsu,C.Y.</style></author><author><style face="normal" font="default"> Chen,H.J.</style></author><author><style face="normal" font="default"> Wu,T.N.</style></author><author><style face="normal" font="default"> Ho,W.C.</style></author><author><style face="normal" font="default"> Wu,C.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Public Health, China Medical University, Taichung, Taiwan; Department of Respiratory Therapy, Asia University Hospital, Asia University, Taichung, Taiwan</style></auth-address><titles><title><style face="normal" font="default">Asthma is associated with endometriosis: A retrospective population-based cohort study</style></title><secondary-title><style face="normal" font="default">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respir Med</style></full-title></periodical><pages end="116" start="112">112-116</pages><volume><style face="normal" font="default">132</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Evidence regarding the association between asthma and endometriosis is limited and inconsistent. The goal of the study was to investigate whether women diagnosed as having asthma were at a greater risk of endometriosis than age-matched unaffected women. METHODS: We conducted a nationwide population-based retrospective study by using data retrieved from the Taiwan National Health Insurance Research Database during the period of 2000-2005 with follow-up through 2013. The current analysis included 7337 women aged 12-50 years with newly diagnosed asthma and using asthma-related medications and 29,348 age-matched women without asthma. A Cox proportional hazards regression model was used to estimate the risks of endometriosis in women with asthma as compared with those without asthma. RESULTS: The overall risk of endometriosis in the asthma group was 1.50-fold higher (95% confidence interval = 1.33-1.70) than that in the nonasthma group. A stratified analysis by age further revealed that patients with asthma were associated with a higher risk of endometriosis in age groups of 21-50 years. CONCLUSION: Compared with women without asthma, women with asthma of reproductive age are at a higher risk of endometriosis. Additional studies are warranted to elucidate the mechanism(s) underlying the association between asthma and a higher risk of endometriosis</style></abstract><notes><style face="normal" font="default">IS - 1532-3064 (Electronic)IS - 0954-6111 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1016/j.rmed.2017.10.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29229082">PM:29229082</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Med\2017-132-112-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Med\2017-132-112-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170912, Peng YH</style></custom2><misc3><style face="normal" font="default">10.1016/j.rmed.2017.10.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43713</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Condreay,L.</style></author><author><style face="normal" font="default"> Chiano,M.</style></author><author><style face="normal" font="default"> Ortega,H.</style></author><author><style face="normal" font="default"> Buchan,N.</style></author><author><style face="normal" font="default"> Harris,E.</style></author><author><style face="normal" font="default"> Bleecker,E.R.</style></author><author><style face="normal" font="default"> Thompson,P.J.</style></author><author><style face="normal" font="default"> Humbert,M.</style></author><author><style face="normal" font="default"> Gibson,P.</style></author><author><style face="normal" font="default"> Yancey,S.</style></author><author><style face="normal" font="default"> Ghosh,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">GSK, Research Triangle Park, NC, USA.</style></auth-address><titles><title><style face="normal" font="default">No genetic association detected with mepolizumab efficacy in severe asthma</style></title><secondary-title><style face="normal" font="default">Respir Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respir Med</style></full-title></periodical><pages end="180" start="178">178-180</pages><volume><style face="normal" font="default">132</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><abstract><style face="normal" font="default">BACKGROUND AND OBJECTIVES: Treatment with mepolizumab, a humanized monoclonal antibody to interleukin-5, reduces the rate of asthma exacerbations and the requirement for systemic glucocorticoids while maintaining asthma control. Treatment decisions are guided by predictors of response, including blood eosinophil thresholds in patients with frequent exacerbations despite intensive anti-inflammatory and controller treatment. Identification of additional predictors of response could aid treatment decisions. We investigated genetic associations that may predict response to mepolizumab-treatment. METHODS: In this post hoc analysis of DREAM and MENSA, association of genetic markers was tested in patients with severe asthma treated with mepolizumab who provided consent for pharmacogenetic research. Association was tested in a tiered approach with alpha spend differing for candidate genetic markers selected for prior history of association with relevant traits or pathways and in a genome-wide analyses (p &lt; 4.7 x 10(-4) and p &lt; 5 x 10(-8), respectively). Efficacy endpoints included: clinically significant exacerbation rate (tested using a negative binomial model), time to first exacerbation (tested with a Cox proportional hazards model), change in exacerbation rate, change in eosinophil count, and change in IgE level (tested by linear regression). RESULTS: No genetic marker was significantly associated with the primary endpoint, clinically significant exacerbation rate. One genetic marker was associated with time to first clinically significant exacerbation, but this association was driven by the DREAM data and was not supported in additional sensitivity analyses by treatment regimen/dose. CONCLUSION: No genetic effect on mepolizumab-treatment response was identified in this population on intensive asthma treatment, with history of frequent exacerbations and pre-selected for airway eosinophilia</style></abstract><notes><style face="normal" font="default">IS - 1532-3064 (Electronic)IS - 0954-6111 (Linking)LA - engPT - Journal ArticleCO - United States -CO - United KIngdom -CO - Australia -CO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.rmed.2017.10.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29229094">PM:29229094</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Med\2017-132-170-80.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Med\2017-132-170-80.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170912, Condreay L</style></custom2><misc3><style face="normal" font="default">10.1016/j.rmed.2017.10.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43714</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vargas,A.</style></author><author><style face="normal" font="default"> Boivin,R.</style></author><author><style face="normal" font="default"> Cano,P.</style></author><author><style face="normal" font="default"> Murcia,Y.</style></author><author><style face="normal" font="default"> Bazin,I.</style></author><author><style face="normal" font="default"> Lavoie,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Sciences, Faculty of Veterinary Medicine, Universite de Montreal, 3200, rue Sicotte, Saint-Hyacinthe, Quebec, J2S 2M2, Canada</style></auth-address><titles><title><style face="normal" font="default">Neutrophil extracellular traps are downregulated by glucocorticosteroids in lungs in an equine model of asthma</style></title><secondary-title><style face="normal" font="default">Respir Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Respir Res</style></abbr-1></periodical><pages end="" start="207">207-</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="12" Year="2017">2017/12/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Severe neutrophilic asthma is poorly responsive to glucocorticosteroids (GC). Neutrophil extracellular traps (NETs) within the lungs have been associated with the severity of airway obstruction and inflammation in asthma, and were found to be unaffected by GC in vitro. As IL-17 is overexpressed in neutrophilic asthma and contributes to steroid insensitivity in different cell types, we hypothesized that NETs formation in asthmatic airways would be resistant to GC through an IL-17 mediated pathway. METHODS: Six neutrophilic severe asthmatic horses and six healthy controls were studied while being treated with dexamethasone. Lung function, bronchoalveolar lavage fluid (BALF) cytology and NETs formation, as well as the expression of CD11b and CD13 by blood and airway neutrophils were evaluated. The expression of IL-17 and its role in NETs formation were also studied. RESULTS: Airway neutrophils from asthmatic horses, as opposed to blood neutrophils, enhanced NETs formation, which was then decreased by GC. GC also tended to decrease the expression of CD11b in blood neutrophils, but not in airway neutrophils. IL-17 mRNA was increased in BALF cells of asthmatic horses and was unaffected by GC. However, both GC and IL-17 inhibited NETs formation in vitro. CONCLUSION: GC decreased NETs formation in vitro and also in vivo in the lungs of asthmatic horses. However, airway neutrophil activation during asthmatic inflammation was otherwise relatively insensitive to GC. The contribution of IL-17 to these responses requires further study</style></abstract><notes><style face="normal" font="default">IS - 1465-993X (Electronic)IS - 1465-9921 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1186/s12931-017-0689-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29233147">PM:29233147</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Respir Res\2017-18-207.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Respir Res\2017-18-207.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171212, Vargas A</style></custom2><misc3><style face="normal" font="default">10.1186/s12931-017-0689-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43715</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rodriguez-Gonzalez,M.</style></author><author><style face="normal" font="default"> Lugo-Reyes,S.O.</style></author><author><style face="normal" font="default"> Venegas-Montoya,E.</style></author><author><style face="normal" font="default"> Scheffler-Mendoza,S.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hospital Angeles Pedregal, Ciudad de Mexico, Mexico.</style></auth-address><titles><title><style face="normal" font="default">Fragments of immunological memory: An interview with Dr. Berron</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="512" start="509">509-512</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29249114">PM:29249114</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-509-12.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-509-12.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171226, Rodriguez-Gonzalez M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43716</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martinez-Ezquerro,J.D.</style></author><author><style face="normal" font="default"> Riojas-Garza,A.</style></author><author><style face="normal" font="default"> Rendon-Macias,M.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Instituto Mexicano del Seguro Social, Centro Medico Nacional Siglo XXI, Hospital de Pediatria, Unidad de Investigacion Medica en Genetica Humana, Ciudad de Mexico, Mexico.</style></auth-address><titles><title><style face="normal" font="default">[Clinical significance vs statistical significance. How to interpret the confidence interval at 95]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="486" start="477">477-486</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">The validity of a study depends on its proper planning, execution and analysis. If these are sufficiently correct, the decision to apply the recommendations issued depends on the expected clinical effect. This effect may have random variations, hence the need to use statistical inference. For years the p-value has been used to determine this statistical significance and the confidence intervals to measure the magnitude of the effect. In this review we present a proposal of how to interpret the 95 % confidence intervals (CI 95 %) as estimators of the expected effect variability based on considering the threshold or value of clinical significance and the null value of the difference or rejection of statistical significance. Thus, an association or effect where the CI 95 % includes the null value (no effect or difference) is interpreted as inconclusive; one between the null value and the clinical threshold (without including them) as possibly inconsequential; one that does not include the null value but the clinical threshold as yet not conclusive and one beyond the clinical threshold as conclusive</style></abstract><notes><style face="normal" font="default">IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29249109">PM:29249109</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-477-86.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-477-86.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171226, Martinez-Ezquerro JD</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43717</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mayorga,A.J.</style></author><author><style face="normal" font="default"> Ayestas-Moreno,G.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centro de Neumologia y Alergias, San Pedro Sula, Cortes, Honduras.</style></auth-address><titles><title><style face="normal" font="default">[Hereditary angioedema by C1 inhibitor-deficit: Diagnostic and therapeutic challenges. Case report]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="498" start="493">493-498</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hereditary angioedema is a disease which manifests itself with episodes of spontaneous edema on skin, mucosal and airway. Treatment includes acute and prophylactic approach to minimize the attacks and severity. In many parts of the world, androgen derivatives, antifibrinolytic and fresh frozen plasma are the therapies available for prophylaxis. CLINICAL REPORT: 16 years old teenager of without history of immune decease, has in the course of 1-year repetitive episodes of painless, non-pruritic angioedema, does not respond to antihistamine therapy, corticosteroids or adrenaline; fresh frozen plasma is applied in 1 occasion exacerbating episode with severity. The diagnosis is delayed because of the unavailability of the study in the country, so it is shipped abroad confirming the deficit of C1 Inhibitor (7.1 mug/mL). Initiating prophylactic therapy with Danazol, with subsequent episodes decreased. CONCLUSION: The delay diagnosis involves considerable risk in these patients; the importance of long-term prophylactic treatment is ratified in the use of androgens, being as an available option in developing countries</style></abstract><notes><style face="normal" font="default">IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Honduras -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29249111">PM:29249111</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-493-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-493-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171226, Mayorga AJ</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43718</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Monge-Ortega,O.P.</style></author><author><style face="normal" font="default"> Dominguez-Ortega,J.</style></author><author><style face="normal" font="default"> Gonzalez-Munoz,M.</style></author><author><style face="normal" font="default"> Cabanas,R.</style></author><author><style face="normal" font="default"> Lluch-Bernal,M.</style></author><author><style face="normal" font="default"> Fiandor,A.</style></author><author><style face="normal" font="default"> Bravo-Gallego,L.Y.</style></author><author><style face="normal" font="default"> Quirce,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hospital San Juan de Dios, Departamento de Alergia. San Jose, Costa Rica.</style></auth-address><titles><title><style face="normal" font="default">[Delayed allergic reaction to amlodipine with a positive lymphocyte transformation test]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="508" start="505">505-508</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Amlodipine is one of the third generation dihydropyridine calcium channel blockers used for hypertension. Mild, moderate and severe reactions have been reported with calcium channel blockers. Cross-reactivity among these drugs has not been established. CLINICAL REPORT: We have presented the case of a patient who developed a delayed pruritic, and erythematous maculopapular skin exanthema after the intake of amlodipine. A positive lymphocyte transformation test (LTT) confirmed the implication of amlodipine in the reaction and showed positivity to another calcium channel blocker, nifedipine, demonstrating cross reactivity. CONCLUSION: This is the first reported case of hypersensitivity to amlodipine in which the involvement of the drug is confirmed by a positive TTL. TTL could become a good diagnostic alternative for patients who experience late reactions to amlodipine and possibly cross-reactivity with nifedipine</style></abstract><notes><style face="normal" font="default">IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Costa Rica -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29249113">PM:29249113</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-505-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-505-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171226, Monge-Ortega OP</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43719</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martinez-Morales,M.C.</style></author><author><style face="normal" font="default"> Deswarte,C.</style></author><author><style face="normal" font="default"> Castaneda-Casimiro,J.</style></author><author><style face="normal" font="default"> Bustamante,J.</style></author><author><style face="normal" font="default"> Blancas-Galicia,L.</style></author><author><style face="normal" font="default"> Scheffler-Mendoza,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Secretaria de Salud, Instituto Nacional de Pediatria, Servicio de Inmunologia. Ciudad de Mexico, Mexico.</style></auth-address><titles><title><style face="normal" font="default">[Disseminated infection by M. tuberculosis complex in patient with IFN-gamma receptor 1 complete deficiency]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="504" start="499">499-504</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Several mutations have been described leading to impaired immunity in the IL-12/IFN-gamma axis and, they confer susceptibility to mycobacterial infections. One of the more serious clinical phenotypes is secondary to mutations at IFN-gamma receptor 1 gene, characterized by an early onset and more severe disease. CLINICAL REPORT: We present a 3-month-old female patient with systemic M. tuberculosis complex who has a homozygous mutation, it affects the splicing site at IFNGR1 c.201-1G> T. At time of this report, she is with antimycobacterial treatment in the protocol of pluripotent hematopoietic cell transplantation (TCHP). CONCLUSION: It has been reported that antiphimic treatment should be maintained until the immune system is restored by the TCHP. If patients receive THCP before the age of 1 year old, they have a better prognosis. Diminish the levels of IFN-gamma in plasma before the procedure is associated to better results</style></abstract><notes><style face="normal" font="default">IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29249112">PM:29249112</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-499-504.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-499-504.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171226, Martinez-Morales MC</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43720</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sugranes-Montalvan,A.</style></author><author><style face="normal" font="default"> Barreto-Suarez,E.</style></author><author><style face="normal" font="default"> Nicolau-Pestana,E.</style></author><author><style face="normal" font="default"> Quesada-Leyva,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Hospital Pediatrico "Dr. Eduardo Agramonte Pina", Camaguey, Cuba.</style></auth-address><titles><title><style face="normal" font="default">[Relation between Helicobacter pylori infection and chronic urticaria]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="402" start="396">396-402</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic spontaneous urticaria is a frequent disease that affects the quality of life of patients. Helicobacter pylori infection has increased in the world, linking current studies with a link between both entities. OBJECTIVE: To determine the relationship between chronic urticaria and Helicobacter pylori infection. METHODS: An observational cohort study was conducted with the objective of demonstrating the relationship between chronic urticaria and Helicobacter pylori infection in the allergology clinic of the Hospital Universitario "Manuel Ascunce Domenech" in the province of Camaguey, Cuba, in the period from January 2015 to December of 2016. A universe composed of 93 patients with spontaneous chronic urticaria and the sample by the 43 who met the criteria and formed the case and control group were the 35 apparently healthy patients who gave informed consent for the study. RESULTS: 76.6 % of the women had urticaria and the mean age was 36.10 years. The serological study was positive in 100 % of the cases. CONCLUSIONS: In the present study, the relationship between chronic urticaria and Helicobacter pylori infection was demonstrated. Apparently, the eradicating treatment for Helicobacter pylori was effective as the patients had no symptoms after treatment. Specific immunoglobulin G and urease test together constitute a suitable diagnostic module for the diagnosis of Helicobacter pylori conditions</style></abstract><notes><style face="normal" font="default">IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Cuba -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29249102">PM:29249102</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-396-402.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-396-402.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171226, Sugranes-Montalvan A</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43721</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Maravillas-Montero,J.L.</style></author><author><style face="normal" font="default"> Martinez-Cortes,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universidad Nacional Autonoma de Mexico/Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Red de Apoyo a la Investigacion, Ciudad de Mexico, Mexico.</style></auth-address><titles><title><style face="normal" font="default">[Regulation of immune responses by exosomes derived from antigen presenting cells]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="476" start="463">463-476</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Cells release several biomolecules to the extracellular environment using them as a communication alternative with neighbor cells. Besides these molecules, cells also release more complex elements, like vesicles; structures composed of a lipidic bilayer with transmembrane proteins that protect a hydrophilic content. Exosomes are a small subtype of vesicles (30-150 nm), produced by many cell types, such as tumor cells, neurons, epithelial cells and immune cells. Included in this last group, antigen presenting cells produce exosomes that contain different types of molecules depending on their activation and/or maturation state. In recent years there has been an exponential interest in exosomes due to the recent evidences that show the immunomodulatory properties of these vesicles and therefore, their great potential in diagnostic approaches and development of therapies for different inflammation-associated pathologies</style></abstract><notes><style face="normal" font="default">IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29249108">PM:29249108</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-463-76.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-463-76.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171226, Maravillas-Montero JL</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43722</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gonzalez-Diaz,S.N.</style></author><author><style face="normal" font="default"> Partida-Ortega,A.B.</style></author><author><style face="normal" font="default"> Macias-Weinmann,A.</style></author><author><style face="normal" font="default"> Arias-Cruz,A.</style></author><author><style face="normal" font="default"> Galindo-Rodriguez,G.</style></author><author><style face="normal" font="default"> Hernandez-Robles,M.</style></author><author><style face="normal" font="default"> Ibarra-Chavez,J.A.</style></author><author><style face="normal" font="default"> Monge-Ortega,O.P.</style></author><author><style face="normal" font="default"> Ramos-Valencia,L.</style></author><author><style face="normal" font="default"> Macouzet-Sanchez,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universidad Autonoma de Nuevo Leon, Centro Regional de Alergia e Inmunologia Clinica, Monterrey, Nuevo Leon, Mexico.</style></auth-address><titles><title><style face="normal" font="default">[Evaluation of functional capacity by 6-minute walk test in children with asthma]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="429" start="415">415-429</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma patients show lower exercise tolerance. OBJECTIVE: Assessment of functional capacity in children with asthma. METHODS: Girls and boys from 6 to 17 years old were included in two groups: asthmatic patients and healthy subjects. PSPQ was applied and vital signs, peak expiratory flow and Modi fi ed Borg Dyspnea Scale were measured at the beginning and the end of 6MWD. RESULTS: Participants included 58 subjects, including 32 asthmatic patients, and 55.2 % male subjects. Mean age: 10.6 years +/- 3.1. Asthmatic group: mean distance covered in meters 456.04 +/- 54.05, meters covered by gender 456.31 +/- 48.73 male and 455.74 +/- 61.29 female (p = 0.28). Control group: the mean was 468.28 +/- 54.52 meters, meters covered by gender 465.98 +/- 58.04 male, 471.44 +/- 51.95 female (p = 0.35). The difference between asthmatic group and control group was 12.24 meters in favor of control group (p = 0.378). There was no association between body mass index (BMI) and distance covered (p = 0.53), but a Pearson correlation p = -0.445. In the male gender, CF was positively associated with self-perception in CAF variables: physical condition, physical attractiveness, strength (p = 0.04) and physical self-concept in general (p = 0.02). CONCLUSIONS: There was no significant difference in the distance covered between the two groups. The main impact factor was the body mass index with an inverse relation to the distance. Males had better physical self-perception, which is positively associated with CF</style></abstract><notes><style face="normal" font="default">IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29249104">PM:29249104</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-415-29.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-415-29.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171226, Gonzalez-Diaz SN</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43723</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">O'Farrill-Romanillos,P.M.</style></author><author><style face="normal" font="default"> Herrera-Sanchez,D.A.</style></author><author><style face="normal" font="default"> Hernandez-Fernandez,C.</style></author><author><style face="normal" font="default"> Lopez-Rocha,E.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Instituto Mexicano del Seguro Social, Centro Medico Nacional Siglo XXI, Hospital de Especialidades, Servicio de Alergia e Inmunologia Clinica, Ciudad de Mexico, Mexico.</style></auth-address><titles><title><style face="normal" font="default">[Common immunodeficiency variable in adults]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="462" start="452">452-462</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Primary immunodeficiencies (PIDs) are low-incidence diseases caused by defects in genes involved in the development, maintenance, and regulation of the immune system. Common variable immunodeficiency (CVID) is the most common symptomatic immunodeficiency of adulthood. It has an approximate prevalence of 1 in 25 000-50 000 in the general population, with a delay in diagnosis between 6-7 years. The clinical manifestations of CVID constitute six main categories: infections, pulmonary complications, granulomatous or polyclonal lymphocytic disease, autoimmunity, gastrointestinal diseases and malignancy Most patients must have at least one of the following clinical manifestations (infection, autoimmunity, lymphoproliferation). However, the diagnosis of CVID can be conferred in asymptomatic patients, especially in familial cases. Secondary causes of hypogammaglobulinemia should be ruled out in any patient meeting the diagnostic criteria for CVID, as the treatment may be totally different from that required for CVID. Because CVID comprises a heterogeneous group of syndromes with poor primary antibody production, the potential number of entities within this group is unknown. Patients with CVID suffer from various complications that are considered prognostic. In the absence of clear guidelines for their search, it is recommended that lymphoproliferative disease, lung disease, liver disease and autoimmunity be investigated intentionally during the initial evaluation. The intervals in which they should be performed are not clear, but several evaluations may be required per year, according to the clinical evolution of the patient</style></abstract><notes><style face="normal" font="default">IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29249107">PM:29249107</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-452-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-452-62.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171226, O'Farrill-Romanillos PM</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43724</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gaviria,R.</style></author><author><style face="normal" font="default"> Ocampo,J.</style></author><author><style face="normal" font="default"> Londono,J.</style></author><author><style face="normal" font="default"> Calvo,V.</style></author><author><style face="normal" font="default"> Cardona,R.</style></author><author><style face="normal" font="default"> Sanchez,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universidad de Antioquia, Grupo de Alergologia Clinica y Experimental, Medellin, Colombia.</style></auth-address><titles><title><style face="normal" font="default">[IgE sensitization and sociodemographic conditions as determinant factors in asthma severity]</style></title><secondary-title><style face="normal" font="default">Rev Alerg Mex</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Alerg Mex</style></full-title></periodical><pages end="451" start="439">439-451</pages><volume><style face="normal" font="default">64</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: In Latin America there are few data about the factors that influence the control and severity of asthma. OBJECTIVE: To describe the association between IgE sensitization to intra-home allergens and housing conditions in the severity of asthma. METHODS: Sensitization to aero-allergens was evaluated by skin prick test and socio-demographic data by a questionnaire in a population between 6 and 14 years of age with diagnosis of asthma. Asthma control was measured according to spirometric results and to the application of the ACT (Asthma Control Test); the severity and symptom control was evaluated according to the GINA guideline. RESULTS: A total of 150 resident patients from the Aburra Valley (Colombia) were included. The median age of participants was 11 years, 95 (63.3 %) male. 92 % of the patients resided in the urban area. Mite sensitization was the most prevalent in controlled and uncontrolled patients. Sensitization to cockroach and some poverty conditions were risk factors for asthma severity. CONCLUSION: Poverty conditions appear to favor the development of severe asthma and in turn IgE sensitization to cockroaches. This sensitization could serve as a biomarker of severity</style></abstract><notes><style face="normal" font="default">IS - 0002-5151 (Print)IS - 0002-5151 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Colombia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29249106">PM:29249106</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-439-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Alerg Mex\2017-64-439-51.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171226, Gaviria R</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43725</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ponvert,C.</style></author><author><style face="normal" font="default"> Bourrier,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">"Allergic" reactions to anti-infective drugs in children (a review)</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergy/hypersensitivity</style></keyword><keyword><style face="normal" font="default"> Antibiotics</style></keyword><keyword><style face="normal" font="default"> beta-Lactams</style></keyword><keyword><style face="normal" font="default"> Skin Tests</style></keyword><keyword><style face="normal" font="default"> Challenge/provocation tests</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Seven to 15% of children report suspected allergic/hypersensitivity (HS) reactions to drugs, antibiotics especially, but studies based on clinical history, skin tests (ST) and drug challenge/provocation tests (DPT) have shown that only 10-15% of these children were truly allergic, except for the children reporting immediate and/or severe reactions. Diagnosis is usually based on a careful analysis of the clinical history, ST and DPT, but many authors currently recommend prolonged DPT with the suspected drugs as a first-line diagnostic test in non-immmediate and non-severe reactions because the diagnostic value of non-immediate-reading ST, the risk of a reaction during DPT, and, if such a reaction occurs, the risk of a severe reaction are low. Before the allergological work-up is performed, eviction of all drugs in the same and closely related classes (ie: penicillins and 1st generation cephalosporins in case of a reaction to amoxicillin) is recommended in children reporting immediate and/or anaphylactic reactions, because there is a high risk of cross-reactivity, except for macrolides. In mild to moderately severe non-immediate reactions, other drugs in the other classes of the same family can be prescribed safely because the risk of cross-reactivity is low. Most children reporting allergic-like reactions to several families or classes of antibiotics are not allergic to drugs. In those children, one may think to a possible allergic or non-allergic ("intolerance") HS to other drugs, often associated with antibiotics (non-opioid analgesics, antipyretics and non-steroidal anti-inflammatory drugs especially).</style></abstract><notes><style face="normal" font="default">LA - FRECO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.10.008</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.10.008</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Fr Allergol\20171206-PonvertC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Fr Allergol\20171206-PonvertC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171206, Ponvert C</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.10.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43726</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ortiz-Bautista,R.J.</style></author><author><style face="normal" font="default"> Garcia-Gonzalez,L.L.</style></author><author><style face="normal" font="default"> Ocadiz-Gonzalez,M.A.</style></author><author><style face="normal" font="default"> Flores-Tochihuitl,J.</style></author><author><style face="normal" font="default"> Garcia-Villasenor,A.</style></author><author><style face="normal" font="default"> Gonzalez-Hernandez,M.</style></author><author><style face="normal" font="default"> Munoz-Hernandez,L.</style></author><author><style face="normal" font="default"> Ortiz-Figuero,M.D.C.</style></author><author><style face="normal" font="default"> Ramirez-Anaya,M.</style></author><author><style face="normal" font="default"> Reyna-Tellez,S.</style></author><author><style face="normal" font="default"> Villanueva-Sanchez,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Departamento de Ciencias de la Salud, Escuela de Ciencias, Universidad de las Americas Puebla, Puebla, Mexico rj.ortizbautista@gmail.com</style></auth-address><titles><title><style face="normal" font="default">[Matricaria chamomilla (aqueous extract) improves atopic dermatitis-like lesions in a murine model]</style></title><secondary-title><style face="normal" font="default">Rev Med Inst Mex Seguro Soc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Med Inst Mex Seguro Soc</style></full-title></periodical><pages end="593" start="587">587-593</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="9" Year="2017">2017/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Matricaria Chamomilla L. (Mch), popularly known as chamomile, has been used for centuries as an herbolary remedy due to its broad clinical spectrum. The aim of this study was to evaluate the effect of Mch associated to a vehicle with emollient function in induced atopic dermatitis (AD)-like lesions in a murine model. METHODS: AD was induced with dinitrochlorobenzene on 12 male seven-week old BALB/c mice. Animals were divided in three groups (control, GC; control negative, GCN; and experimental, GE). Liquid petrolatum was applied to the GCN and liquid petrolatum with aqueous extract of Mch at 7% to the GE. Induction and evolution of the lesions were verified by biopsy at 2nd and 6th week. Evaluation of peripheral blood cells to correlate inflammatory cells was made as well at the same weeks. Lesions were clinically evaluated at 2nd, 4th and 6th week. Scratching was monitored according to the observation methodology of Kobayashi et al. RESULTS: Mch aqueous extract associated to a vehicle with emollient function improves atopic dermatitis-like lesions after two weeks</style></abstract><notes><style face="normal" font="default">IS - 2448-5667 (Electronic)IS - 0443-5117 (Linking)LA - spaPT - English AbstractPT - Journal ArticleCO - Mexico -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29193940">PM:29193940</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171213, Ortiz-Bautista RJ</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43727</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Couto,M.</style></author><author><style face="normal" font="default"> Silva,D.</style></author><author><style face="normal" font="default"> Marques,J.</style></author><author><style face="normal" font="default"> Paiva,M.</style></author><author><style face="normal" font="default"> Jacinto,T.</style></author><author><style face="normal" font="default"> Camara,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Allergic diseases in sports</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="275" start="259">259-275</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Exercise -induced hypersensitivity syndromes include several allergic diseases caused by exercise practice, namely exercise--induced asthma/bronchoconstriction, rhinitis associated with exercise, exercise -induced anaphylaxis or urticaria. These aresignificant problems for those practicing sports both in a recreational and in an elite level. An adequate management dependsupon its recognition, which allows a correct diagnosis and proper treatment. Allergic diseases associated with sports are a fre-quent cause of frustration both for patients, caregivers, coaches and physical education teachers. In this context, during the year2015/2016, the Interest Group of Asthma and Allergy in Sports of the Portuguese Society of Allergy and Clinical Immunologyorganized a course called "Allergic diseases in Sports", for teachers and coaches, aiming to spread the knowledge about thesepathologies. The present article includes the didactic material presented and also the feedback provided by the attendees.Key -words: Allergy, anaphylaxis, asthma, exercise, sports.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.spaic.pt/rpia/arquivos?ano_publicacao=2017&amp;volume_publicacao=25&amp;numero_publicacao=4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Port Imunoalergol\2017-25-259-75.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Port Imunoalergol\2017-25-259-75.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171221, Couto M</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43728</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sousa-Pinto,B.</style></author><author><style face="normal" font="default"> Pereira,A.M.</style></author><author><style face="normal" font="default"> Fonseca,J.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Impact of drug allergy diagnosis</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="258" start="249">249-258</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Drug allergy overdiagnosis is a frequently reported phenomenon for multiple drug classes. It might be, at least partially,due to difficulties in performing a diffferential diagnosis with other conditions with similar clinical presentations (such asinfectious exanthemas), and also due to a insufficiency in performing confirmatory tests. Nevertheless, labelling a patient as having a "drug allergy" is not innocuous - recent studies have shown that this label associates with worse clinical out-comes and with a negative economic impact on health systems. Therefore, this study aims to discuss the most relevantfindings regarding the clinical and economic impacts of "drug allergy" label, taking into account some of the most importantdrug classes.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.spaic.pt/rpia/arquivos?ano_publicacao=2017&amp;volume_publicacao=25&amp;numero_publicacao=4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Port Imunoalergol\2017-25-249-58.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Port Imunoalergol\2017-25-249-58.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171221, Sousa-Pinto B</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43729</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Costa,F.</style></author><author><style face="normal" font="default"> Vieira de Carvalho,R.</style></author><author><style face="normal" font="default"> Sokolova,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Cold-induced anaphylaxis</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="284" start="283">283-284</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.spaic.pt/rpia/arquivos?ano_publicacao=2017&amp;volume_publicacao=25&amp;numero_publicacao=4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Port Imunoalergol\2017-25-283-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Port Imunoalergol\2017-25-283-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171221, Costa F</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43730</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Moreira,A.S.</style></author><author><style face="normal" font="default"> Cadinha,S.</style></author><author><style face="normal" font="default"> Vieira,M.</style></author><author><style face="normal" font="default"> Moreira da Silva,J.P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Probable iodinated contrast media related DRESS syndrome</style></title><secondary-title><style face="normal" font="default">Rev Port Imunoalergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Port Imunoalergol</style></full-title></periodical><pages end="282" start="277">277-282</pages><volume><style face="normal" font="default">25</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The designation DRESS - Drug reaction with eosinophilia and systemic symptoms refers to a severe, potentially life -threateningdrug hypersensitivity reaction. We describe the case of a 70 years old male with pruritic and exfoliative exanthema, hand ede-ma, eosinophilia (1980/uL) and conjunctival hyperemia. The symptoms began 4 days after restart treatment with phenytoin and10 days after a computed tomography with contrast media administration. The patient was treated with corticosteroids andpresented gradual clinical improvement but, 2 months later, 24 hours after radiologic contrast media administration, there was a reappearance of a widespread exanthema, hand, face and feet edema, fever, eosinophilia and subsequently cervical lympha-denopathy. Skin prick test, intradermal and patch tests with contrast media were positive at 48 hours. Phenytoin patch testswere negative and the lymphocyte transformation test with phenytoin was doubtful. This case report describes a DRESS syn-drome probably related with iodinated contrast media administration.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Portugal -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url ppv-ref="no">http://www.spaic.pt/rpia/arquivos?ano_publicacao=2017&amp;volume_publicacao=25&amp;numero_publicacao=4</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Port Imunoalergol\2017-25-277-82.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Port Imunoalergol\2017-25-277-82.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171221, Moreira AS</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43731</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stamm,A.</style></author><author><style face="normal" font="default"> Kozlowski,P.</style></author><author><style face="normal" font="default"> Brandenberger,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Urology and Transplant Surgery, Virginia Mason Medical CenterSeattle, WADepartment of Urology and Transplant Surgery, Virginia Mason Medical CenterSeattle, WADepartment of Urology and Transplant Surgery, Virginia Mason Medical CenterSeattle, WA</style></auth-address><titles><title><style face="normal" font="default">Surgical solution to an intracorporeal nickel allergy</style></title><secondary-title><style face="normal" font="default">Rev Urol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Rev Urol</style></abbr-1></periodical><pages end="197" start="195">195-197</pages><volume><style face="normal" font="default">19</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">A previously healthy 30-year-old man with a symptomatic varicocele underwent gonadal vein embolization using nickel vascular plugs. He developed a painful hypersensitivity to his nickel plugs and elected to pursue laparoscopic excision and proximal gonadal vein ligation. In the operating room, the gonadal vein was isolated from the ureter, and ligated proximal to the cephalad plug and distal to the caudal coil. His pain is completely resolved 5 months after surgery. Metal allergies are well documented in orthopedics and cardiology implants, but there are a limited number of case reports of metal allergies after varicocele embolization. Interestingly, nickel is the most common type of metal hypersensitivity</style></abstract><notes><style face="normal" font="default">IS - 1523-6161 (Print)IS - 1523-6161 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.3909/riu0769</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29302245">PM:29302245</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Rev Urol\2017-19-195-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Rev Urol\2017-19-195-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171213, Stamm A</style></custom2><misc3><style face="normal" font="default">10.3909/riu0769</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43732</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kashif,M.</style></author><author><style face="normal" font="default"> Singh,T.</style></author><author><style face="normal" font="default"> Aslam,A.</style></author><author><style face="normal" font="default"> Khaja,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Icahn School of Medicine at Mount Sinai and Division of Pulmonary &amp; Critical Care Medicine, Bronx-Lebanon Hospital Center, Bronx, NY, USA</style></auth-address><titles><title><style face="normal" font="default">Asthma mimic: Case report and literature review of vocal cord nodule associated with wheezing</style></title><secondary-title><style face="normal" font="default">SAGE Open Med Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">SAGE Open Med Case Rep</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. Various clinical conditions can mimic asthma, such as foreign body aspiration, subglottic stenosis, congestive heart failure, diffuse panbronchiolitis, aortic arch anomalies, reactive airway dysfunction syndrome, chronic obstructive pulmonary disease, retrosternal goiter, vocal cord tumors, other airway tumors, and vocal cord dysfunction. Upper airway obstruction can be a life-threatening emergency. Here, we present the case of a 58-year-old female with recurrent hospital visits for wheezing and exacerbations of asthma, who was later found to have a vocal cord nodule confirmed to be squamous cell carcinoma, which was mimicking like asthma</style></abstract><notes><style face="normal" font="default">IS - 2050-313X (Print)IS - 2050-313X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/2050313X17744980</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29230286">PM:29230286</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\SAGE Open Med Case Rep\20171204-KashifM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\SAGE Open Med Case Rep\20171204-KashifM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Kashif M</style></custom2><misc3><style face="normal" font="default">10.1177/2050313X17744980</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43733</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pooli,A.</style></author><author><style face="normal" font="default"> Brush,T.</style></author><author><style face="normal" font="default"> Belle,J.D.</style></author><author><style face="normal" font="default"> LaGrange,C.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Urology, University of Nebraska Medical Center, Omaha, NE, USA</style></auth-address><titles><title><style face="normal" font="default">Delayed severe anaphylactoid reaction following retrograde pyelogram: A case report</style></title><secondary-title><style face="normal" font="default">SAGE Open Med Case Rep</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">SAGE Open Med Case Rep</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Retrograde pyelography is used to evaluate upper collecting system in patients with hematuria who have contrast allergy. Reported here is a patient who developed severe, late-onset anaphylactoid reaction after retrograde pyelography. Premedication is commonly used to reduce risk of allergic reaction but has limited evidence to support its efficacy. Caution should be used when evaluating microhematuria with retrograde pyelography in patients with prior anaphylactoid reaction to intravenous contrast</style></abstract><notes><style face="normal" font="default">IS - 2050-313X (Print)IS - 2050-313X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/2050313X17745212</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29230290">PM:29230290</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\SAGE Open Med Case Rep\20171204-PooliA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\SAGE Open Med Case Rep\20171204-PooliA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171204, Pooli A</style></custom2><misc3><style face="normal" font="default">10.1177/2050313X17745212</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43734</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Travers,J.</style></author><author><style face="normal" font="default"> Rochman,M.</style></author><author><style face="normal" font="default"> Caldwell,J.M.</style></author><author><style face="normal" font="default"> Besse,J.A.</style></author><author><style face="normal" font="default"> Miracle,C.E.</style></author><author><style face="normal" font="default"> Rothenberg,M.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229-3039, USA</style></auth-address><titles><title><style face="normal" font="default">IL-33 is induced in undifferentiated, non-dividing esophageal epithelial cells in eosinophilic esophagitis</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="17563">17563-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="12" Year="2017">2017/12/14</year></dates><abstract><style face="normal" font="default">The molecular and cellular etiology of eosinophilic esophagitis (EoE), an emerging tissue-specific allergic disease, involves dysregulated gene expression in esophageal epithelial cells. Herein, we assessed the esophageal expression of IL-33, an epithelium-derived alarmin cytokine, in patients with EoE. IL-33 protein was markedly overexpressed within the nuclei of a subpopulation of basal layer esophageal epithelial cells in patients with active EoE compared to control individuals. IL-33 exhibited dynamic expression as levels normalized upon EoE remission. IL-33-positive basal epithelial cells expressed E-cadherin and the undifferentiated epithelial cell markers keratin 5 and 14 but not the differentiation marker keratin 4. Moreover, the IL-33-positive epithelial cells expressed the epithelial progenitor markers p75 and p63 and lacked the proliferation markers Ki67 and phospho-histone H3. Additionally, the IL-33-positive cells had low expression of PCNA. IL-33 expression was detected in ex vivo-cultured primary esophageal epithelial cells in a subpopulation of cells lacking expression of proliferation markers. Collectively, we report that IL-33 expression is induced in an undifferentiated, non-dividing esophageal epithelial cell population in patients with active EoE</style></abstract><notes><style face="normal" font="default">IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1038/s41598-017-17541-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29242581">PM:29242581</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-17563.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-17563.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171214, Travers J</style></custom2><misc3><style face="normal" font="default">10.1038/s41598-017-17541-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43735</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Higgs,B.W.</style></author><author><style face="normal" font="default"> Liu,Y.</style></author><author><style face="normal" font="default"> Guo,J.</style></author><author><style face="normal" font="default"> Sebastian,Y.</style></author><author><style face="normal" font="default"> Morehouse,C.</style></author><author><style face="normal" font="default"> Zhu,W.</style></author><author><style face="normal" font="default"> Ren,L.</style></author><author><style face="normal" font="default"> Liu,M.</style></author><author><style face="normal" font="default"> Du,Y.</style></author><author><style face="normal" font="default"> Yu,G.</style></author><author><style face="normal" font="default"> Dong,L.</style></author><author><style face="normal" font="default"> Hua,H.</style></author><author><style face="normal" font="default"> Wei,P.</style></author><author><style face="normal" font="default"> Wang,Y.</style></author><author><style face="normal" font="default"> Wang,Z.</style></author><author><style face="normal" font="default"> Yao,Y.</style></author><author><style face="normal" font="default"> Li,Z.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">MedImmune, Gaithersburg, MD, 20878, USA</style></auth-address><titles><title><style face="normal" font="default">High-throughput RNA sequencing reveals distinct gene signatures in active IgG4-related disease</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="17567">17567-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="14" Month="12" Year="2017">2017/12/14</year></dates><abstract><style face="normal" font="default">We aimed to characterize the molecular differences and effects from prednisone treatment among IgG4-related disease with salivary gland lesions (RD-SG), without SG lesions (RD-nonSG), and IgG4-related retroperitoneal fibrosis (RF). RNA sequencing was conducted on blood from 25 RD-SG, 11 RD-nonSG, 3 RF and 10 control subjects. Among these, 8 RD-nonSG and 12 RD-SG patients were subjected to treatment with prednisone and/or glucocorticoid-sparing agents. Six RD patients had a longitudinal time point. The mRNA levels of IgG4 and IgE, genes specific for Th2 cells, eosinophils, and neutrophils were over-expressed in RD-SG and RD-nonSG. A B-cell signature was suppressed in patients group versus controls, while Th1, Th2, Treg, and eosinophil gene signatures were increased in patients without treatment. Interestingly, Tfh genes and B cell signature were decreased at flare disease state. Prednisone treatment led to increased neutrophil, but decreased Treg signatures. Serum IgG4 levels correlated with the eosinophil and neutrophil gene signatures in RD-SG patients, and with a B cell signature in only RD-nonSG patients. IgG4, IgE, and cell-specific signatures are regulated in patients, suggesting the imbalance of immune and inflammatory cells in IgG4-related disease. Prednisone treatment selectively modulates Treg, eosinophil, and neutrophil signatures</style></abstract><notes><style face="normal" font="default">IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - United States -CO - China -</style></notes><work-type><style face="normal" font="default">10.1038/s41598-017-17602-9</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29242501">PM:29242501</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-17567.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-17567.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171214, Higgs BW</style></custom2><misc3><style face="normal" font="default">10.1038/s41598-017-17602-9</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43736</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lin,W.</style></author><author><style face="normal" font="default"> Zhou,Q.</style></author><author><style face="normal" font="default"> Liu,C.</style></author><author><style face="normal" font="default"> Ying,M.</style></author><author><style face="normal" font="default"> Xu,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pharmacy, Affiliated Hospital of Ningbo University School of Medicine, Ningbo, 315020, China</style></auth-address><titles><title><style face="normal" font="default">Increased plasma IL-17, IL-31, and IL-33 levels in chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="17797">17797-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="12" Year="2017">2017/12/19</year></dates><abstract><style face="normal" font="default">Chronic spontaneous urticaria (CSU) is considered in a subset of patients to be an autoimmune disorder. Interleukin(IL)-17, IL-31, and IL-33 are involved in some immune response. The aim of this study was to quantify plasma IL-17, IL-31, and IL-33 levels in CSU patients and to examine their relationships with disease severity. Plasma IL-17, IL-31, and IL-33 concentration were measured in 51 CSU patients and 20 healthy subjects (HCs). Plasma IL-17 (P &lt; 0.001), IL-31 (P &lt; 0.001), and IL-33 (P &lt; 0.001) concentrations were significantly higher in CSU patients when compared with those of HCs. Concerning UAS7, severe group of CSU patients had significantly higher IL-17 levels than the moderate and mild groups (P = 0.028 and 0.007, respectively), and significantly higher IL-33 concentrations than the mild group (P = 0.026). Regarding only pruritus, severe group of patients had significantly higher IL-31 levels than the mild group (P = 0.003). The IL-33 levels in the total IgE positive group were significantly higher than that of negative group (P = 0.010). Our results showed higher plasma levels of IL-17, IL-31, and IL-33 among CSU patients which may highlight a functional role of these cytokines in the pathogenesis of CSU</style></abstract><notes><style face="normal" font="default">IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1038/s41598-017-18187-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29259273">PM:29259273</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Sci Rep\2017-7-17797.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Sci Rep\2017-7-17797.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171219, Lin W</style></custom2><misc3><style face="normal" font="default">10.1038/s41598-017-18187-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43737</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tuchinda,P.</style></author><author><style face="normal" font="default"> Erickson,C.</style></author><author><style face="normal" font="default"> Tammaro,A.</style></author><author><style face="normal" font="default"> Paterniti,M.O.</style></author><author><style face="normal" font="default"> Saini,S.S.</style></author><author><style face="normal" font="default"> Gaspari,A.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Maryland School of Medicine, Baltimore</style></auth-address><titles><title><style face="normal" font="default">Immunologic Studies of Progesterone-Induced Neutrophilic Urticaria</style></title><secondary-title><style face="normal" font="default">Skinmed</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Skinmed</style></full-title></periodical><pages end="472" start="471">471-472</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">A 33-year-old woman presented with recurring pruritic, erythematous papules around the mouth and on the hands, of 1.5 years' duration. These flares typically began several days before her menstrual cycle and persisted for approximately 1 week. Physical examination revealed urticarial plaques on the neck. Due to the nature of the eruption, which corresponded with her menstrual cycle, a diagnosis of autoimmune progesterone urticaria was considered and workup pursued</style></abstract><notes><style face="normal" font="default">IS - 1540-9740 (Print)IS - 1540-9740 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Thailand -CO - Italy -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29282190">PM:29282190</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171230, Tuchinda P</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43738</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sullenbarger,J.W.</style></author><author><style face="normal" font="default"> Hensley,B.</style></author><author><style face="normal" font="default"> Travers,J.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology</style></auth-address><titles><title><style face="normal" font="default">Kitty Litter Dermatitis from-Bromo-2-Nitropropane-1,3-Diol</style></title><secondary-title><style face="normal" font="default">Skinmed</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Skinmed</style></full-title></periodical><pages end="390" start="389">389-390</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">70-year-old white man presented with a 6-week history of an acute pruritic eruption in the axillary vaults, inguinal folds, and central lumbar area. Due to the severity of the pruritus, the patient was evaluated in the emergency department. He was treated with intramuscular triamcinolone, oral fluconazole, clobetasol cream, and miconazole powder, which provided only minimal relief. The patient had presented with brightly erythematous patches in the axillary vaults and inguinal folds with numerous erythematous, scaly, coalescing papules and plaques agminated on the lumbar region (Figure). Due to persistence, despite topical corticosteroids, an allergic contact dermatitis was suspected so patch-testing using the T.R.U.E. Test (SMARTPractice Denmark ApS, Hillerod, Denmark) epicutaneous system was conducted. Results were positive for 5-chloro-2-methyl-4-isothazolinone (panel 2.1, #17), budesonide (panel 3.1, #30), and 2-bromo-2-nitropropane-1,3-diol, also known as bronopol (panel 3.1, #36). The patient's topical medications were adjusted based on these results, and he was advised to avoid any products containing these contactants</style></abstract><notes><style face="normal" font="default">DA - 20171115IS - 1540-9740 (Print)IS - 1540-9740 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29139375">PM:29139375</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171230, Sullenbarger JW</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43739</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kramer,O.N.</style></author><author><style face="normal" font="default"> Barkoff,M.S.</style></author><author><style face="normal" font="default"> Hernandez,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Illinois at Chicago College of Medicine, Chicago, IL</style></auth-address><titles><title><style face="normal" font="default">Mast Cell Activation Syndrome</style></title><secondary-title><style face="normal" font="default">Skinmed</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Skinmed</style></full-title></periodical><pages end="479" start="477">477-479</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">A 51-year-old woman with a history of asthma and Hashimoto's thyroiditis presented to the dermatology service with a chief complaint of "itchy bumpy rashes" that persisted beyond 24 hours. She noted that, 3 days prior to the onset of urticaria, a pyrroloquinoline quinone supplement had been started. The urticaria was accompanied by variable episodes of transient facial swelling and difficulty breathing. The patient noted that exposure to fish, nuts, and nonsteroidal anti-inflammatory drugs triggered facial swelling. Other reported findings included a 5-year history of diarrhea, sense of memory deterioration, concentration difficulties, and clinical manifestations of anomic aphasia. Although her allergy testing was "negative," she had been given the diagnoses of lactose intolerance and gastroesophageal reflux disease. Laboratory studies on initial presentation were significant for a positive history of antithyroperoxidase antibodies and elevated total complement activity. Medications included budesonide/formoterol, fluticasone/salmeterol, levothyroxine, albuterol, and fexofenadine 180 mg twice daily. Although her "rash" had initially responded to fexofenadine, it soon became refractory to treatment. Her family history was significant only for thyroid disease</style></abstract><notes><style face="normal" font="default">IS - 1540-9740 (Print)IS - 1540-9740 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29282192">PM:29282192</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171230, Kramer ON</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43740</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tey,H.L.</style></author><author><style face="normal" font="default"> Tay,E.Y.</style></author><author><style face="normal" font="default"> Tan,W.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Skin Centre, Singapore</style></auth-address><titles><title><style face="normal" font="default">Safety and Antipruritic Efficacy of a Menthol-Containing Moisturizing Cream</style></title><secondary-title><style face="normal" font="default">Skinmed</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Skinmed</style></full-title></periodical><pages end="439" start="437">437-439</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Itch is frequently associated with dermatoses characterized by a defective skin barrier. We formulated an itch-relieving moisturizing cream containing 3% menthol and ceramides. Our aim was to evaluate the safety and antipruritic efficacy of application of this cream in volunteers with and without skin diseases. Volunteers were asked to apply the cream for 1 month on a minimum body surface area of 6%. Safety was assessed by the absence of contact dermatitis or other side effects, using a self-administered questionnaire completed at 5 minutes, 1 week, and 1 month after application. To determine efficacy, volunteers with pruritic dermatoses were asked to grade their average itch intensity at baseline, 1 week, and 1 month after application. Sixty volunteers were recruited, of whom 41 had no skin disease; no adverse events were reported in the latter. Of the 19 volunteers with dermatoses, 18 reportedly had atopic dermatitis. One of the 60 volunteers stopped application due to stinging sensations induced by menthol. Itch scores of volunteers with dermatitis improved from baseline at 1 week (P=.01) and 1 month (P&lt;.01) after application. Application of a 3% menthol-containing moisturizing cream was safe in healthy individuals and participants with dermatitis. In the latter, itch scores were significantly reduced during follow-up</style></abstract><notes><style face="normal" font="default">IS - 1540-9740 (Print)IS - 1540-9740 (Linking)LA - engPT - Journal ArticleCO - Singapore -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29282180">PM:29282180</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171230, Tey HL</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43741</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Darji,K.</style></author><author><style face="normal" font="default"> Tobin,C.</style></author><author><style face="normal" font="default"> Bryan,Z.T.</style></author><author><style face="normal" font="default"> Jansenn,M.</style></author><author><style face="normal" font="default"> Armbrecht,E.</style></author><author><style face="normal" font="default"> Siegfried,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">SSM Saint Louis University Hospital, St. Louis, MO</style></auth-address><titles><title><style face="normal" font="default">Vitamin D Deficiency and Atopic Dermatitis: Consider Disease, Race, and Body Mass</style></title><secondary-title><style face="normal" font="default">Skinmed</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Skinmed</style></full-title></periodical><pages end="420" start="415">415-420</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Vitamin D deficiency causes rickets, but has been associated with various diseases, including atopic dermatitis (AD). This study analyzes serum vitamin D in pediatric medical center patients with AD and potential confounding factors. At Cardinal Glennon Children's Hospital, charts of 665 children with serum 25-hydroxyvitamin D levels taken between 2009 and 2013 were retrospectively reviewed. Defining vitamin D deficiency as &lt;20 ng/mL, neither average 25-hydroxyvitamin D nor deficiency prevalence varied among disease groups, except for cystic fibrosis (CF), which demonstrated significantly higher average vitamin D and lower deficiency prevalence. Children with AD had the lowest prevalence of vitamin D sufficiency, without significant association with disease severity. No seasonal variation was detected. Strong correlations were observed between 25-hydroxyvitamin D levels, body mass index (BMI), and race. Our data showed no strong association between vitamin D levels and AD or AD severity. A strong association was noted between skin type and BMI. The lower prevalence of vitamin D deficiency among children with CF may be explained by lighter skin and lower BMI. A high prevalence of vitamin D insufficiency and deficiency as currently defined among children with dark skin and high BMI suggests a need to reevaluate normal vitamin D levels in these populations</style></abstract><notes><style face="normal" font="default">IS - 1540-9740 (Print)IS - 1540-9740 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29282177">PM:29282177</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20171230, Darji K</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43742</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Muneuchi,J.</style></author><author><style face="normal" font="default"> Okada,S.</style></author><author><style face="normal" font="default"> Nagatomo,Y.</style></author><author><style face="normal" font="default"> Iida,C.</style></author><author><style face="normal" font="default"> Matsuoka,R.</style></author><author><style face="normal" font="default"> Shirozu,M.</style></author><author><style face="normal" font="default"> Watanabe,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Intravascular Ultrasound-Guided Cardiac Intervention in a Fontan Patient with Allergy to Contrast Media</style></title><secondary-title><style face="normal" font="default">Tex Heart Inst J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Tex Heart Inst J</style></abbr-1></periodical><pages end="375" start="373">373-375</pages><volume><style face="normal" font="default">44</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="10" Year="2017">2017/10</year></dates><abstract><style face="normal" font="default">Allergy to contrast media is hazardous in patients who need multiple cardiac catheterizations. We describe the case of a 16-year-old boy who presented with fatigue and cyanosis. He had undergone a Fontan operation 14 years previously, after which he developed an allergy to iodinated contrast media. Contrast echocardiograms by manual injection of microbubbles suggested the presence of a venovenous collateral vessel from the brachiocephalic vein draining into the pulmonary vein. We used intravascular ultrasound as the sole imaging method to identify the target vessel and to guide deployment of an Amplatzer Vascular Plug II. The patient experienced immediate improvement in his systemic saturation. Our experience shows that intravascular ultrasound may be a feasible alternative to standard imaging methods in patients with congenital heart disease who need cardiac interventional procedures and are allergic to contrast media</style></abstract><notes><style face="normal" font="default">IS - 1526-6702 (Electronic)IS - 0730-2347 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.14503/THIJ-16-6096</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29259515">PM:29259515</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Tex Heart Inst J\2017-44-373-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Tex Heart Inst J\2017-44-373-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171001, Muneuchi J</style></custom2><misc3><style face="normal" font="default">10.14503/THIJ-16-6096</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43743</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mussotter,F.</style></author><author><style face="normal" font="default"> Potratz,S.</style></author><author><style face="normal" font="default"> Budczies,J.</style></author><author><style face="normal" font="default"> Luch,A.</style></author><author><style face="normal" font="default"> Haase,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">German Federal Institute for Risk Assessment (BfR), Department of Chemical and Product Safety, Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default">A multi-omics analysis reveals metabolic reprogramming in THP-1 cells upon treatment with the contact allergen DNCB</style></title><secondary-title><style face="normal" font="default">Toxicol Appl Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Toxicol Appl Pharmacol</style></abbr-1></periodical><pages end="29" start="21">21-29</pages><volume><style face="normal" font="default">340</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="default">Dendritic cell (DC) activation by contact allergens is one of the key steps in the development of allergic contact dermatitis (ACD). Recent evidence suggests that metabolic reprogramming is a prerequisite for the activation of DCs, macrophages and monocytes. Therefore, we used an integrated approach by combining proteomics and metabolomics to investigate the metabolism of human THP-1 cells in response to the strong contact allergen, 2,4-dinitrochlorobenzene (DNCB). Cells were treated with 5, 10 and 20muM DNCB for 4, 8, and 24h, respectively. Using a targeted metabolomics approach, we quantified levels of 188 endogenous metabolites, among them phospholipids, acylcarnitines, amino acids and hexoses. In addition, proteomic changes were analyzed using an untargeted quantitative approach based on stable isotope labeling with amino acids in cell culture (SILAC). We detected several alterations in the metabolome and consistently in the proteome indicating metabolic reprogramming of THP-1 cells by DNCB. In particular, we found an increase in phospholipids that was accompanied by an up-regulation of fatty acid synthase (FAS), a key enzyme in lipid synthesis</style></abstract><notes><style face="normal" font="default">IS - 1096-0333 (Electronic)IS - 0041-008X (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1016/j.taap.2017.12.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29289672">PM:29289672</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxicol Appl Pharmacol\2018-340-21-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxicol Appl Pharmacol\2018-340-21-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171228, Mussotter F</style></custom2><misc3><style face="normal" font="default">10.1016/j.taap.2017.12.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43744</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mai,W.</style></author><author><style face="normal" font="default"> Lu,D.</style></author><author><style face="normal" font="default"> Liu,X.</style></author><author><style face="normal" font="default"> Chen,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Department of Preventive Medicine, The Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China</style></auth-address><titles><title><style face="normal" font="default">MCP-1 produced by keratinocytes is associated with leucocyte recruitment during elicitation of nickel-induced occupational allergic contact dermatitis</style></title><secondary-title><style face="normal" font="default">Toxicol Ind Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Toxicol Ind Health</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="1" Year="2017">2017/1/1</year></dates><abstract><style face="normal" font="default">To investigate the expression profile of monocyte chemoattractant peptide-1 (MCP-1) by keratinocytes after nickel exposure and to identify its role for leucocyte migration during nickel-induced occupational allergic contact dermatitis (OACD), 26 workers diagnosed with nickel-induced OACD were enrolled. Skin biopsies from the positive nickel-challenged sites at different time points were assessed by immunohistochemistry (IHC) for MCP-1, CD68, CD45RO, and in situ hybridization (ISH) for MCP-1, using chronic periumbilical dermititis as controls. The expressions of MCP-1 in HaCaT cell culture after nickel treatment were quantified by enzyme-linked immunosorbent assay. The results showed that at positive nickel-challenged sites, strong expressions of MCP-1, both messenger RNA (mRNA) and protein, were detected in the basal keratinocytes during the early phase (24-48 h after nickel application), paralleled by the recruitment of CD68+ and CD45RO+ cells to the skin compartments. The expressions of MCP-1 declined gradually in the late phase (72-96 h after nickel application). Treatment with nickel sulfate at noncytotoxic concentrations (0.01-100 microM) induced a concentration-related elevation of MCP-1 expression by HaCaT cells compared to the untreated cells. The data indicated that a temporal expression pattern of MCP-1 produced by keratinocytes after nickel exposure was involved in the complex process of mononuclear cell infiltration during elicitation of nickel-induced OACD. Targeting MCP-1 might be a potential therapeutic strategy for OACD</style></abstract><notes><style face="normal" font="default">DA - 20171114IS - 1477-0393 (Electronic)IS - 0748-2337 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1177/0748233717738633</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29132256">PM:29132256</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Toxicol Ind Health\20171113-MaiW.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Toxicol Ind Health\20171113-MaiW.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171113, Mai W</style></custom2><misc3><style face="normal" font="default">10.1177/0748233717738633</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43745</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Geoghegan,J.A.</style></author><author><style face="normal" font="default"> Irvine,A.D.</style></author><author><style face="normal" font="default"> Foster,T.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Microbiology, Moyne Institute of Preventive Medicine, School of Genetics and Microbiology, Trinity College Dublin, Dublin 2, Ireland</style></auth-address><titles><title><style face="normal" font="default">Staphylococcus aureus and Atopic Dermatitis: A Complex and Evolving Relationship</style></title><secondary-title><style face="normal" font="default">Trends Microbiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Trends Microbiol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="12" Year="2017">2017/12/9</year></dates><abstract><style face="normal" font="default">Staphylococcus aureus is frequently isolated from the skin of atopic dermatitis (AD) patients during flares. The normal microbiota is disrupted and the diversity of the microorganisms on the skin is reduced. Many species that produce inhibitors of S. aureus growth decline. Strains from S. aureus clonal complex 1 are enriched among AD sufferers whereas the CC30 strains most frequently isolated from nasal carriers in the normal population are much rarer in AD. S. aureus expresses several molecules that contribute to the intensity of symptoms, including delta-toxin which stimulates mast cells, alpha-toxin which damages keratinocytes, phenol-soluble modulins which stimulate cytokine release by keratinocytes, protein A which triggers inflammatory responses from keratinocytes, superantigens which trigger B cell expansion and cytokine release, and proinflammatory lipoproteins. Proteases contribute to disruption of the epidermal barrier. S. aureus isolated from AD patients adheres to the deformed corneocytes from AD patients in a clumping factor B-dependent fashion. Novel targeted therapies for AD have recently been introduced to clinical practice with many more in development, including monoclonal antibodies that specifically target cytokines and their receptors, and a bacteriophage lysin that eliminates S. aureus from AD skin</style></abstract><notes><style face="normal" font="default">IS - 1878-4380 (Electronic)IS - 0966-842X (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Ireland -</style></notes><work-type><style face="normal" font="default">10.1016/j.tim.2017.11.008</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29233606">PM:29233606</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Trends Microbiol\20171217-GeogheganJA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Trends Microbiol\20171217-GeogheganJA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171217, Geoghegan JA</style></custom2><misc3><style face="normal" font="default">10.1016/j.tim.2017.11.008</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43746</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dreher,M.</style></author><author><style face="normal" font="default"> Muller,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pneumology, University Hospital RWTH Aachen, Aachen, Germany</style></auth-address><titles><title><style face="normal" font="default">Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid</style></title><secondary-title><style face="normal" font="default">Tuberc Respir Dis (Seoul)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Tuberc Respir Dis (Seoul)</style></abbr-1></periodical><pages end="" start="e18">e18-</pages><volume><style face="normal" font="default">80</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="12" Year="2017">2017/12/13</year></dates><abstract><style face="normal" font="default">Asthma, remains symptomatic despite ongoing treatment with high doses of inhaled corticosteroids (ICS) in conjunction with long-acting beta-agonists (LABA), is classified as "severe" asthma. In the course of caring for those patients diagnosed with severe asthma, stepping up from ICS/LABA to more aggressive therapeutic measures would be justified, though several aspects have to be checked in advance (including inhaler technique, adherence to therapy, and possible associated comorbidities). That accomplished, it would be advisable to step up care in accordance with the Global Initiative for Asthma (GINA) recommendations. Possible strategies include the addition of a leukotriene receptor antagonist or tiotropium (to the treatment regimen). The latter has been shown to be effective in the management of several subgroups of asthma. Oral corticosteroids have commonly been used for the treatment of patients with severe asthma in the past; however, the use of oral corticosteroids is commonly associated with corticosteroid-related adverse events and comorbidities. Therefore, according to GINA 2017 these patients should be referred to experts who specialize in the treatment of severe asthma to check further therapeutic options including biologics before starting treatment with oral corticosteroids</style></abstract><notes><style face="normal" font="default">IS - 1738-3536 (Print)IS - 1738-3536 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Germany -</style></notes><work-type><style face="normal" font="default">10.4046/trd.2017.0102</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29256220">PM:29256220</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Tuberc Respir Dis (Seoul)\2017-80-e18.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Tuberc Respir Dis (Seoul)\2017-80-e18.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171213, Dreher M</style></custom2><misc3><style face="normal" font="default">10.4046/trd.2017.0102</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43747</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shishkin,A.A.</style></author><author><style face="normal" font="default"> Karakulova,Y.V.</style></author><author><style face="normal" font="default"> Voronchikhina,N.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Academician E.A. Vagner Perm State Medical University, Perm, Russia, 614990</style></auth-address><titles><title><style face="normal" font="default">[The state of the serotonin system in the patients presenting with chronic polypous rhinosinusitis]</style></title><secondary-title><style face="normal" font="default">Vestn Otorinolaringol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Vestn Otorinolaringol</style></abbr-1></periodical><pages end="17" start="15">15-17</pages><volume><style face="normal" font="default">82</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">This article presents the results of the study designed to determine the concentration of the neuromediator serotonin in the blood serum and tissue homogenates prepared from the polypous tissue harvested in the patients presenting with chronic polypous rhinosinusitis (CPR). The study included 51 patients with this pathology while 11 patients with chronic maxillary rhinosinusitis (CMR) and deflection of the nasal septum (DNS) made up the group of comparison. The serum serotonin levels were measured and compared in the patients of the main and both control groups. The results obtained give evidence of the significant inverse correlation between serotonin levels in the sera and tissue homogenates on the one hand and the history of allergic diseases in individual patients on the other hand</style></abstract><notes><style face="normal" font="default">IS - 0042-4668 (Print)IS - 0042-4668 (Linking)LA - rusPT - English AbstractPT - Journal ArticleCO - Russia -</style></notes><work-type><style face="normal" font="default">10.17116/otorino201782615-17</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29260775">PM:29260775</url></web-urls></urls><custom2><style face="normal" font="default">20171216, Shishkin AA</style></custom2><misc3><style face="normal" font="default">10.17116/otorino201782615-17</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43748</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Smirnov,D.S.</style></author><author><style face="normal" font="default"> Kurbacheva,O.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">State Research Center 'Institute of Immunology', the Federal Medical-Biological Agency of Russia, Moscow, Russia, 115478State Research Center 'Institute of Immunology', the Federal Medical-Biological Agency of Russia, Moscow, Russia, 115478</style></auth-address><titles><title><style face="normal" font="default">[Possibilities of azelastine in the treatment of chronic rhinitis]</style></title><secondary-title><style face="normal" font="default">Vestn Otorinolaringol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Vestn Otorinolaringol</style></abbr-1></periodical><pages end="59" start="52">52-59</pages><volume><style face="normal" font="default">82</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">There is considered modern classification of rhinitis and the accents in diagnostic and therapeutic approaches to patients with this disease are indicated, as well as the possibilities of using topical intranasal antihistamines in the treatment of allergic, vasomotor and medicamentous rhinitis</style></abstract><notes><style face="normal" font="default">IS - 0042-4668 (Print)IS - 0042-4668 (Linking)LA - rusPT - English AbstractPT - Journal ArticleCO - Russia -</style></notes><work-type><style face="normal" font="default">10.17116/otorino201782652-59</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29260783">PM:29260783</url></web-urls></urls><custom2><style face="normal" font="default">20171214, Smirnov DS</style></custom2><misc3><style face="normal" font="default">10.17116/otorino201782652-59</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43749</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tataurshchikova,N.S.</style></author><author><style face="normal" font="default"> Sangidorzh,B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Russian University of Peoples' Friendship, Moscow, Russia, 117198Russian University of Peoples' Friendship, Moscow, Russia, 117198</style></auth-address><titles><title><style face="normal" font="default">[The role of local immunotherapy in the treatment of the patients presenting with virus-associated allergic rhinitis]</style></title><secondary-title><style face="normal" font="default">Vestn Otorinolaringol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Vestn Otorinolaringol</style></abbr-1></periodical><pages end="62" start="60">60-62</pages><volume><style face="normal" font="default">82</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The objective of the present study was to evaluate the clinical effectiveness of intranasal immunotherapy with the use of small es, Cyrillicycloferon in the patients presenting with seasonal virus-associated allergic rhinitis during the period of pollination. The results of the treatment of 50 patients with virus-associated allergic rhinitis (i.e. those allergic to the sagebrush pollen) were analyzed. The patients were divided into two groups depending on the therapeutic modality being used. Those comprising the main group (21 patients) received immunotherapy with small es, Cyrillicycloferon in addition to allergen-specific immunotherapy (by sublingual administration). A cycloferon solution in the physiological saline (2:1) at a concentration of 125 mg/ml was applied to the intranasal mucous membrane with the use of a nebulizer. The inhalation was performed every other day as a course of 10 procedures at a total cycloferon dose of 1250 mg. The control group was composed of 29 patients given sublingual allergen-specific immunotherapy alone. The study included the evaluation of the patients' quality of life in accordance with the adapted and modified RQLQ questionnaire. In addition, the demand for other relevant medications following the course of intranasal immunotherapy was determined by analyzing the data extracted from the self-monitoring diaries and questionnaires. The study has shown that the inclusion of small es, Cyrillicycloferon therapy in the scheme for the management of the patients presenting with virus-associated allergic rhinitis during the period of pollination enhanced the effectiveness of the treatment as assessed from the improvement of the patients' quality of life that correlated with the reduction in the severity of rhino-conjunctival manifestations of the disease (r= -0.4, p&lt;0.05). It is concluded that the intranasal administration of the immunomodulator small es, Cyrillicycloferon has resulted in a significant decrease of requirements for chromones (p&lt;0.001) and antihistamines (p&lt;0.05) among the patients suffering from allergic rhinitis</style></abstract><notes><style face="normal" font="default">IS - 0042-4668 (Print)IS - 0042-4668 (Linking)LA - rusPT - English AbstractPT - Journal ArticleCO - Russia -</style></notes><work-type><style face="normal" font="default">10.17116/otorino201782660-62</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29260784">PM:29260784</url></web-urls></urls><custom2><style face="normal" font="default">20171216, Tataurshchikova NS</style></custom2><misc3><style face="normal" font="default">10.17116/otorino201782660-62</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43750</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ivanova,O.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medical Institute of the M.K. Ammosov North-Eastern Federal University, Yakutsk, Russia, 677000</style></auth-address><titles><title><style face="normal" font="default">[Allergic rhinitis among the children of the Republic of Sakha (Yakutiya)]</style></title><secondary-title><style face="normal" font="default">Vestn Otorinolaringol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Vestn Otorinolaringol</style></abbr-1></periodical><pages end="65" start="63">63-65</pages><volume><style face="normal" font="default">82</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The objective of the present study was to elucidate dynamics of primary allergic rhinitis (AR) morbidity in the children population of the Republic of Sakha (Yakutiya) from the statistical materials of the Yakutian Republican Information and Analytical Centre available for the period from 2008 to 2014 in the combination with the results of allergological testing based at the National Centre of Medicine, Yakutsk, that involved 100 schoolchildren presenting with allergic rhinitis who resided in the northern regions of the Republic. The results of the study give evidence of the increasing primary allergic rhinitis morbidity rate among the population of the children and adolescents during the recent years. It is concluded that the regional programs for the prevention and early diagnostics of primary allergic rhinitis need to be elaborated and introduced in the practical work of healthcare facilities over the territory of the Republic</style></abstract><notes><style face="normal" font="default">IS - 0042-4668 (Print)IS - 0042-4668 (Linking)LA - rusPT - English AbstractPT - Journal ArticleCO - Russia -</style></notes><work-type><style face="normal" font="default">10.17116/otorino201782663-65</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29260785">PM:29260785</url></web-urls></urls><custom2><style face="normal" font="default">20171216, Ivanova ON</style></custom2><misc3><style face="normal" font="default">10.17116/otorino201782663-65</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43751</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shakhova,N.V.</style></author><author><style face="normal" font="default"> Kamaltynova,E.M.</style></author><author><style face="normal" font="default"> Lobanov,Y.F.</style></author><author><style face="normal" font="default"> Ardatova,T.S.</style></author><author><style face="normal" font="default"> Nikolaeva,K.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Altai State Medical University, Ministry of Health of the Russian Federation, Barnaul, Russia, 656038Siberian State Medical University, Ministry of Health of the Russian Federation, Tomsk, Russia, 634050Altai State Medical University, Ministry of Health of the Russian Federation, Barnaul, Russia, 656038Altai State Medical University, Ministry of Health of the Russian Federation, Barnaul, Russia, 656038Altai State Medical University, Ministry of Health of the Russian Federation, Barnaul, Russia, 656038</style></auth-address><titles><title><style face="normal" font="default">[The prevalence and risk factors of allergic rhinitis among the children of the preschool age]</style></title><secondary-title><style face="normal" font="default">Vestn Otorinolaringol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Vestn Otorinolaringol</style></abbr-1></periodical><pages end="51" start="47">47-51</pages><volume><style face="normal" font="default">82</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The objective of the present work was to estimate the prevalence and risk factors of the development of allergic rhinitis among the children at the age from 3 to 6 years. The cross-sectional study was carried out in five cities of the Altai region during the period from 2015 to 2016. The prevalence of allergic rhinitis was evaluated with the use of the Russian language version of the ISAAC questionnaire filled up by the parents of the children. A child whose parents answered in the affirmative to the question 'Did your child have the runny nose, nasal congestion, and/or sneezing in the absence of cold symptoms and acute viral infection during the last 12 months?' were considered to be suffering from active allergic rhinitis (AAR). The risk factors for the development of this condition were identified with the use of an additional questionnaire. A total of 3205 filled questionnaires were available for the analysis. Based on the data obtained, the prevalence of active allergic rhinitis among the study population was estimated at 18.0% (n=577). 243 (42.1%) of these children presented with the symptoms of conjunctivitis. Therefore, the prevalence of active allergic rhinoconjunctivitis (ARC appears to be 7.5% (n=243). In fact, the medically verified diagnosis of allergic rhinitis was established only in 6.4% (n=204) children of the 577 ones having AAR. The family history of allergic rhinitis was shown to increase the risk of development of AAR by 2.6 times (OR=2.63 , 95%; CI=2.16-3.19; p&lt;0.01) and that of ARC by 2.8 times (OR=2.85, 95%; CI=2.16-3.75; p&lt;0.01). Masculine gender was found to increase the risk of development of both AAR an ARC by 1.3 times (OR=1.35, 95%; CI=1.01-1.37; p&lt;0.05) and (OR=1.35, 95%; CI=1.03-1.76; p&lt;0.05) respectively. The actual prevalence of active allergic rhinitis was significantly higher than the frequency of the medically verified diagnoses of this condition. It is concluded that the family history of allergic diseases and the masculine gender considerably increase the risk of development of both AAR and AFC</style></abstract><notes><style face="normal" font="default">IS - 0042-4668 (Print)IS - 0042-4668 (Linking)LA - rusPT - English AbstractPT - Journal ArticleCO - Russia -</style></notes><work-type><style face="normal" font="default">10.17116/otorino201782647-51</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29260782">PM:29260782</url></web-urls></urls><custom2><style face="normal" font="default">20171216, Shakhova NV</style></custom2><misc3><style face="normal" font="default">10.17116/otorino201782647-51</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43752</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ferrari,C.R.</style></author><author><style face="normal" font="default"> Cooley,J.</style></author><author><style face="normal" font="default"> Mujahid,N.</style></author><author><style face="normal" font="default"> Costa,L.R.</style></author><author><style face="normal" font="default"> Wills,R.W.</style></author><author><style face="normal" font="default"> Johnson,M.E.</style></author><author><style face="normal" font="default"> Swiderski,C.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">1 Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, MS, USA</style></auth-address><titles><title><style face="normal" font="default">Horses With Pasture Asthma Have Airway Remodeling That Is Characteristic of Human Asthma</style></title><secondary-title><style face="normal" font="default">Vet Pathol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Vet Pathol</style></abbr-1></periodical><pages end="158" start="144">144-158</pages><volume><style face="normal" font="default">55</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">Severe equine asthma, formerly recurrent airway obstruction (RAO), is the horse counterpart of human asthma, affecting horses maintained indoors in continental climates. Equine pasture asthma, formerly summer pasture RAO, is clinically similar but affects grazing horses during hot, humid conditions in the southeastern United States and United Kingdom. To advance translational relevance of equine pasture asthma to human asthma, histologic features of airway remodeling in human asthma were scored in lung lobes from 15 pasture asthma-affected and 9 control horses of mixed breeds. All noncartilaginous airways were scored using a standardized grading rubric (0-3) in hematoxylin and eosin (HE) and Movat's pentachrome-stained sections; 15 airways were chosen randomly from each lobe for analysis. Logistic regression identified disease, age, and lobe effects on probability of histologic outcomes. Airway smooth muscle (odds ratio [OR] = 2.5, P &lt; .001), goblet cell hyperplasia/metaplasia (OR = 37.6, P &lt; .0001), peribronchiolar elastic system fibers (OR = 4.2, P &lt; .001), peribronchiolar fibrosis (OR = 3.8, P = .01), airway occlusion by mucus/inflammation (OR = 4.2, P = .04), and airway adventitial inflammation (OR = 3.0, P = .01) were significantly greater in diseased airways. A novel complex tissue disorganization, designated terminal bronchiolar remodeling, was overrepresented in diseased airways (OR = 3.7, P &lt; .0001). Distribution of terminal bronchiolar remodeling corresponded to putative sites of air trapping in human asthma, at secondary pulmonary lobules. Age (>15 years) was an independent risk factor for increased peribronchiolar fibrosis, elastic system fibers, and terminal bronchiolar remodeling. Remodeling differed significantly between lung lobes, congruent with nonhomogeneous remodeling in human asthma. Equine pasture asthma recapitulates airway remodeling in human asthma in a manner not achieved in induced animal asthma models, endorsing its translational relevance for human asthma investigation</style></abstract><notes><style face="normal" font="default">IS - 1544-2217 (Electronic)IS - 0300-9858 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1177/0300985817741729</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29254472">PM:29254472</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H HMW Papers\Vet Pathol\2018-55-144-58.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H HMW Papers\Vet Pathol\2018-55-144-58.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180103, Ferrari CR</style></custom2><misc3><style face="normal" font="default">10.1177/0300985817741729</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43753</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,X.</style></author><author><style face="normal" font="default"> Liu,B.</style></author><author><style face="normal" font="default"> Lu,B.</style></author><author><style face="normal" font="default"> Zhang,Y.</style></author><author><style face="normal" font="default"> Wang,L.</style></author><author><style face="normal" font="default"> Li,H.</style></author><author><style face="normal" font="default"> Han,X.</style></author><author><style face="normal" font="default"> Ding,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Zhengzhou Hospital of TCM, Zhengzhou 450007, Henan Province, China</style></auth-address><titles><title><style face="normal" font="default">[Micro-invasive embedding combined with montelukast sodium for children cough variant asthma:a randomized controlled trial]</style></title><secondary-title><style face="normal" font="default">Zhongguo Zhen Jiu</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Zhongguo Zhen Jiu</style></abbr-1></periodical><pages end="264" start="259">259-264</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="3" Year="2017">2017/3/12</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To observe the effects of micro-invasive embedding combined with montelukast sodium and simple montelukast sodium for children cough variant asthma (CVA). METHODS: A total of 240 patients were randomly assigned into an observation group and a control group, 120 cases in each one. Considering of cases dropping, 101 patients in the observation group and 105 cases in the control group were included. Montelukast sodium chewable tablets were applied before sleep for 3 months in the control group, 5 mg a time, once a day. Based on the treatment as the control group, micro-invasive embedding was used for 3 months in the observation group, twice in the first month and once in the other two months. The acupoints were Feishu (BL 13), Danzhong (CV 17), Dingchuan (EX-B 1), and Zusanli (ST 36). Follow-up was conducted 9 months after treatment in the two groups. The cough score, serum immunoglobulin (IgE, IgG, IgA), platelet activating factor (PAF) were observed before and after treatment. The indices were compared before and after treatment and at follow-up, including pulmonary function indices[peak expiratory flow rate (PEF), forced expiratory volume at the 1st second (FEV1)], and small airway function indices[forced expiratory flow rate with remaining 25% vital capacity (MEF25%), forced expiratory flow rate with remaining 50% vital capacity (MEF50%), forced expiratory flow rate with remaining 75% vital capacity (MEF75%) and mid expiratory flow rate (MEF25%-75%)]. Also, the total effects were evaluated. RESULTS: 1 in circleThe total effective rate in the observation group was 93.1% (94/101), which was better than 87.6% (92/105) in the control group (P&lt;0.05). The cough disappearance time of the cured children in the observation group was (10.38+/-2.64) d, and it was shorter than (10.72 +/-2.60) d of those in the control group (P&lt;0.05). After treatment, the cough score apparently decreased compared with those before treatment in the two groups (both P&lt;0.05), with better result in the observation group (P&lt;0.05). At follow-up, the recurrence frequency of the observation group was (1.43+/-1.20), and it was less than (1.91+/-1.71) in the control group (P&lt;0.05). 2 in circleThe levels of serum IgA and IgG after treatment in the two groups increased, and those of serum IgE and PAF decreased, compared with those before treatment. There was statistically significance except IgG in the control group before and after treatment (all P&lt;0.05), with better Results in the observation group after treatment (all P&lt;0.05). 3 in circle Compared with those before treatment, all the pulmonary function indices were improved obviously after treatment and at follow-up in the two groups (all P&lt;0.05), without statistically significance between the two groups (both P>0.05). 4 in circle There was no statistically significance before and after treatment on small airway function indices in the two groups (all P>0.05). The indices at follow-up increased compared with those before treatment in the two groups (all P&lt;0.05), with better Results in the observation group (all P&lt;0.05). CONCLUSIONS: Micro-invasive embedding combined with montelukast sodium achieved de-finite effect for children CVA, which can improve the body's immune and microcirculation. The effect is better than that of simple montelukast sodium on improving small airway function, etc</style></abstract><notes><style face="normal" font="default">IS - 0255-2930 (Print)IS - 0255-2930 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.13703/j.0255-2930.2017.03.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29231431">PM:29231431</url></web-urls></urls><custom2><style face="normal" font="default">20171219, Wang X</style></custom2><misc3><style face="normal" font="default">10.13703/j.0255-2930.2017.03.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43754</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shi,K.</style></author><author><style face="normal" font="default"> Wu,W.</style></author><author><style face="normal" font="default"> Liu,L.</style></author><author><style face="normal" font="default"> Wang,H.</style></author><author><style face="normal" font="default"> Chen,D.</style></author><author><style face="normal" font="default"> Liu,C.</style></author><author><style face="normal" font="default"> Zhang,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Second Clinical Medical School, Nanjing University of CM, Nanjing 210023, Jiangsu Province, ChinaAffiliated Hospital of Nanjing University of CM, Nanjing 210029, Jiangsu ProvinceAffiliated Hospital of Nanjing University of CM, Nanjing 210029, Jiangsu ProvinceAffiliated Hospital of Nanjing University of CM, Nanjing 210029, Jiangsu ProvinceAffiliated Hospital of Nanjing University of CM, Nanjing 210029, Jiangsu ProvinceAffiliated Hospital of Nanjing University of CM, Nanjing 210029, Jiangsu ProvinceAffiliated Hospital of Nanjing University of CM, Nanjing 210029, Jiangsu ProvinceAffiliated Hospital of Nanjing University of CM, Nanjing 210029, Jiangsu Province</style></auth-address><titles><title><style face="normal" font="default">[Optimization of acupoint application scheme in the treatment of bronchial asthma based on the orthogonal design method]</style></title><secondary-title><style face="normal" font="default">Zhongguo Zhen Jiu</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Zhongguo Zhen Jiu</style></abbr-1></periodical><pages end="575" start="571">571-575</pages><volume><style face="normal" font="default">37</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="6" Year="2017">2017/6/12</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To study the primary and secondary factors of the allergic history, the frequency of acupoint application and the time of acupoint application in the treatment of bronchial asthma and optimize its scheme. METHODS: Eighty patients of bronchial asthma were selected as the subjects in the orthogonal trial. The herbal medicines were the empirical formula of acupoint application (prepared at the ratio as 2:2:1:1:1:1:1:1:1 of semen brassicae, rhizome corydalis, unprocessed radix kansui, asarum sieboldii, ephedra, semen lepidii, syzygium aromaticum, cortex cinnamomi and fructus gleditsiae) and used on bilateral Feishu (BL 13), Xinshu (BL 15), Geshu (BL 17) and Shenshu (BL 23). Firstly, two groups were divided according to allergic history (40 cases with allergic history and 40 cases without allergic history), and then four subgroups were divided on the basis of the two main groups, 10 cases in each one. Through studying three factors and two levels, i.e. allergic history (Factor A:A:with allergic history; A:without allergic history), the frequency of acupoint application (Factor B:B:4 times; B:10 times, in which, in the group of 4-time applications, the application was given once every 10 days; in the group of 10-time applications, the application was given once every 4 days); and the time of application (Factor C:C:4 h; C:8 h), the optimal scheme was screened on the basis of the attack frequency before and after treatment and the score of the asthma quality life questionnaire (AQLQ) before treatment and 6 months after treatment in the patients of each group. RESULTS: 1 in circle The orthogonal trial indicated that the best optimal scheme was ABC, meaning the patients with allergic history were treated with acupoint application for 10 times, remained for 4 h. 2 in circleFactor B (frequency of acupoint application) and C (time of acpoint application) were the significant influential factors of AQLQ scores (both P&lt;0.05). 3 in circleThe comparison of the attack frequency and AQLQ score before and after treatment in all of the patients showed that the different combinations of factor levels induced the different impacts on the asthma attack frequency and AQLQ scores. Except in the group No.1 and the group No.5, the improvements were all significant in the rest groups, indicating the significant differences (P&lt;0.05, P&lt;0.01). CONCLUSIONS: Acupoint application reduces apparently the attack frequency of asthma in the patients and improves the living quality. The primary and secondary relationship among the allergic history, the frequency of acupoint application and the time of acupoint application for the impacts on the therapeutic effects are:the frequency of acupoint application > the time of acupoint application > the allergic history. The best optimal scheme is ABC, meaning the patients with allergic history are treated with acupoint application for 10 times, remained for 4h</style></abstract><notes><style face="normal" font="default">IS - 0255-2930 (Print)IS - 0255-2930 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.13703/j.0255-2930.2017.06.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29231494">PM:29231494</url></web-urls></urls><custom2><style face="normal" font="default">20171219, Shi K</style></custom2><misc3><style face="normal" font="default">10.13703/j.0255-2930.2017.06.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43755</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chen,X.Q.</style></author><author><style face="normal" font="default"> Ma,Q.</style></author><author><style face="normal" font="default"> Zhou,L.Y.</style></author><author><style face="normal" font="default"> Ma,H.A.</style></author><author><style face="normal" font="default"> Wu,J.Y.</style></author><author><style face="normal" font="default"> Zhao,J.J.</style></author><author><style face="normal" font="default"> Yan,D.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology, Affiliated Hospital of Nanjing University of TCM, Nanjing 210029, China</style></auth-address><titles><title><style face="normal" font="default">[Experimental study on the effect of Yiqi Wenyang Decoction on nasal mucosa infiltration of NK cells in mice with allergic rhinitis]</style></title><secondary-title><style face="normal" font="default">Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</style></abbr-1></periodical><pages end="926" start="921">921-926</pages><volume><style face="normal" font="default">52</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="7" Month="12" Year="2017">2017/12/7</year></dates><abstract><style face="normal" font="default">Objective: To observe the effect of Yiqi Wenyang Decoction on the infiltration and activation of NK cells in nasal mucosa of mouse model with allergic rhinitis (AR), and to explore the potential mechanism for effective intervention of AR with Yiqi Wenyang Decoction. Methods: Fourty-eight mice were randomly divided into blank group, model group, low, medium and high dose of Yiqi Wenyang Decoction group and Cetirizine group, with 8 rats in each group. After modeling of AR, the model group was filled with 0.9% sodium chloride solution. Yiqi Wenyang Decoction groups of each dose were given different concentrations of Yiqi Wenyang Decoction water extract, while the Cetirizine group was given aqueous solution of Cetirizine. The behavior, morphological changes of nasal mucosa and infiltration of NK cells in nasal mucosa were observed. The levels of IL-4 and INF-gamma in nasal lavage fluid were measured. Besides, the drug safety was observed by acute toxicity test. Results: In the respect of behavioral scoring, middle and high dose of Yiqi Wenyang Decoction group were superior to the model group (number of sneezing: q value was 7.189, 8.748, respectively; number of scratching nose: q value was 12.074, 14.560, respectively; all P&lt;0.05). In middle and high dose of Yiqi Wenyang Decoction group, the infiltration of NK cells and nasal lavage fluid IL-4 levels were lower than those in model group (IOD: q value was 10.073, 12.322, respectively; IOD/Area: q value was 10.954, 14.073, respectively; IL-4: q value was 4.705, 6.801, respectively; all P&lt;0.05). There was no significant difference in nasal lavage fluid of INF-gamma among each group (Fv=1.166, P>0.05). In acute toxicity test, no obvious poisoning symptoms and death occurred in mice. Conclusion: Yiqi Wenyang Decoction can control the nasal symptom, reduce the local NK cell infiltration of nasal mucosa and inhibit the expression of the 2-type cytokines released by NK cells, which may be related with the potential mechanism of effective intervention of AR with Yiqi Wenyang Decoction</style></abstract><notes><style face="normal" font="default">IS - 1673-0860 (Print)IS - 1673-0860 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.3760/cma.j.issn.1673-0860.2017.12.009</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29262451">PM:29262451</url></web-urls></urls><custom2><style face="normal" font="default">20171205, Chen XQ</style></custom2><misc3><style face="normal" font="default">10.3760/cma.j.issn.1673-0860.2017.12.009</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43756</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mai,W.H.</style></author><author><style face="normal" font="default"> Liu,X.W.</style></author><author><style face="normal" font="default"> Su,G.X.</style></author><author><style face="normal" font="default"> Wen,Z.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Preventive medicine, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai 519000, China</style></auth-address><titles><title><style face="normal" font="default">[Prediction of occupational allergic contact dermatitis induced by formaldehyde by IL17/IL22 secretion cell rest combined with patch test]</style></title><secondary-title><style face="normal" font="default">Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi</style></full-title></periodical><pages end="731" start="727">727-731</pages><volume><style face="normal" font="default">35</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="10" Year="2017">2017/10/20</year></dates><abstract><style face="normal" font="default">Objective: To investigate the possible role of IL17-and IL22-secreting cells combined with patch test for the prediction of formaldehyde-induced occupational allergic contact dermatitis(OACD). Methods: From October 2014 to October 2016, totally 131 formaldehyde-exposed workers(49 cases with inflammatory skin lesions,82 ones without inflammatory skin lesions)and 63 non-exposed health controls were recruited. Patch-test was performed in 49 cases of formaldehyde-exposed workers with inflammatory skin lesions. Circulating IL17+and IL22+Tcell subsets were assessed by flow cytometry(FCM). Results: Among 49 cases of formaldehyde-exposed workers with inflammatory skin lesions,32 cases were with positive patch-test while 17 cases with negative patch-test. The proportions of circulating CD3+CD8-IL17+ and CD3+CD8-IL22+ cells from patch-test(+) formaldehyde-exposed workers were significantly higher than that of patch-test(-)group, formaldehyde-exposed workers without skin lesions and non-exposed controls(P&lt;0.05). The proportions of circulating CD3+CD8-IL17+ and CD3+CD8-IL22+cells from patch-test(-)group and formaldehyde-exposed workers without skin lesions were also higher than that of non-exposed controls(P&lt;0.05). But there was no significant difference between patch-test(-)group and formaldehyde-exposed workers without skin lesions(P>0.05). Peripheral CD3+CD8+IL17+and CD3+CD8+IL22+cells were also detected in spite of small amounts. The percentages of CD3+CD8+IL17+and CD3+CD8+IL22+ cells inperipheral blood from patch-test(+)formaldehyde-exposed workers were enhanced significantly, compared to patch-test(-)group, formaldehyde-exposed workers without skin lesions and non-exposed controls(P&lt;0.05). The proportions of circulating CD3+CD8+IL17+ and CD3+CD8+IL22+ cells from patch-test(-)group and formaldehyde-exposed workers without skin lesions were significantly higher than that of non-exposed controls(P&lt;0.05). But there was no significant difference between patch-test(-) group and formaldehyde-exposed workers without skin lesions(P>0.05). Conclusion: The proportions of circulating IL17+ and IL22+T cells(both CD8-and CD8+)are enhanced in formaldehyde-exposed workers at proposed OEL, possibly involved in the development of formaldehyde-induced OACD.The detection of IL17-and IL22-secreting cells combined with formaldehyde patch test help to screen the workers with allergy property and prevent OACD</style></abstract><notes><style face="normal" font="default">IS - 1001-9391 (Print)IS - 1001-9391 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.3760/cma.j.issn.1001-9391.2017.10.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29294541">PM:29294541</url></web-urls></urls><custom2><style face="normal" font="default">20171205, Mai WH</style></custom2><misc3><style face="normal" font="default">10.3760/cma.j.issn.1001-9391.2017.10.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43757</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Weng,T.T.</style></author><author><style face="normal" font="default"> Yan,S.Q.</style></author><author><style face="normal" font="default"> Cao,H.</style></author><author><style face="normal" font="default"> Gu,C.L.</style></author><author><style face="normal" font="default"> Xu,Y.Q.</style></author><author><style face="normal" font="default"> Ni,L.L.</style></author><author><style face="normal" font="default"> Tao,H.H.</style></author><author><style face="normal" font="default"> Shao,T.</style></author><author><style face="normal" font="default"> Tao,F.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Child Health Care, Ma'anshan Maternity and Child Health Hospital, Ma'anshan 243011, China</style></auth-address><titles><title><style face="normal" font="default">[Epidemiological characteristics and relevant factors on the comorbidity of hyperactivity behavior and allergic diseases in preschool children]</style></title><secondary-title><style face="normal" font="default">Zhonghua Yu Fang Yi Xue Za Zhi</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Zhonghua Yu Fang Yi Xue Za Zhi</style></abbr-1></periodical><pages end="1064" start="1061">1061-1064</pages><volume><style face="normal" font="default">51</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="12" Year="2017">2017/12/6</year></dates><abstract><style face="normal" font="default">Objective: To understand the epidemiological characteristics and relevant factors on the comorbidity of hyperactivity behavior and allergic disease among preschool children in urban areas of Ma'anshan city. Methods: During April 2014 to April 2015, 91 kindergartens over 3 years old were investigated. In the investigation, 16 439 questionnaires were distributed to parents, and 15 291 valid questionnaires were collected. Conners abbreviated symptom questionnaire (brief symptom questionnaire) was filled out by parents to assess the children's hyperactive behaviors. Information of allergic disease history was reported by parents, including allergic dermatitis/eczema, food/drug allergy, allergic rhinitis and asthma. Multivariate unconditional logistic regression was used to analyze the relevant factors of comorbidity of hyperactivity behavior and allergy diseases. Results: The average age of the 15 291 children were (4.5+/-1.0) years old, among which 53.7% (8 218/15 291) were boys. The prevalence of hyperactive behaviors was 8.6%(1 317/15 291), and the comorbidity rate of hyperactivity and allergic deseases was 1.7% (258/15 291). After confounding factors including gender, age, delivery mode, father's age and pregnancy complications adjusted, poor sleep quality (OR=4.45, 95%CI: 2.85-6.94), long duration of watching TV at weekend (OR=1.39, 95%CI: 1.00-1.94) and poor eating behavior (OR=1.78, 95%CI: 1.07-2.98) were relevant factors of the comorbidity of hyperactivity and allergic diseases. Conclusion: The prevalence of comorbidity of hyperactivity behavior and allergic disease among preschool children in urban areas of Ma'anshan city was not high. Poor night sleep quality, long duration of watching TV and frequently picky eating were relevant factors of the comorbidity of hyperactive behaviors and allergic diseases</style></abstract><notes><style face="normal" font="default">IS - 0253-9624 (Print)IS - 0253-9624 (Linking)LA - chiPT - English AbstractPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.3760/cma.j.issn.0253-9624.2017.12.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29262484">PM:29262484</url></web-urls></urls><custom2><style face="normal" font="default">20171208, Weng TT</style></custom2><misc3><style face="normal" font="default">10.3760/cma.j.issn.0253-9624.2017.12.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43758</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mavroudi,A.</style></author><author><style face="normal" font="default"> Chrysochoou,E.A.</style></author><author><style face="normal" font="default"> Boyle,R.J.</style></author><author><style face="normal" font="default"> Trypsianis,G.</style></author><author><style face="normal" font="default"> Xinias,I.</style></author><author><style face="normal" font="default"> Cassimos,D.</style></author><author><style face="normal" font="default"> Imvrios,G.</style></author><author><style face="normal" font="default"> Katotomichelakis,M.</style></author><author><style face="normal" font="default"> Karagiannidou,A.</style></author><author><style face="normal" font="default"> Karantaglis,N.</style></author><author><style face="normal" font="default"> Kourentas,G.</style></author><author><style face="normal" font="default"> Warner,J.O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Unit of the 3rd Paediatric Department, Aristotle University of Thessaloniki, Greece.</style></auth-address><titles><title><style face="normal" font="default">Validation of the Children's Sleep Habits Questionnaire in a sample of Greek children with allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="1" Year="2018">2018/1/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Obstructive respiratory disorders, such as allergic rhinitis and asthma may impair sleep quality. The aim of this study is to validate the Children's Sleep Habits Questionnaire (CSHQ) for Greek children from 6 to 14 years of age. No validated tool has been developed so far to assess sleep disturbances in Greek school-aged children. METHODS: We examined the reliability and validity of the CSHQ in a sample of children with allergic rhinitis (AR) and a non-clinical population of parents of these children as a proxy measure of children's AR quality of life (QoL) as evaluated by the Pediatric Allergic Rhinitis Quality of Life (PedARQoL) questionnaire. RESULTS: The CSHQ questionnaire Child's Form (CF) had a moderate internal consistency with a Cronbach's alpha 0.671 and Guttman split-half coefficient of 0.563 when correlated with the PedARQoL (CF). There was also a moderate intraclass correlation of ICC=0.505 between the responses to both questionnaires in the two visits. The CSHQ Parent's Form (PF) had a very good internal consistency with a Cronbach's alpha of 0.928 and Guttman split-half coefficient of 0.798. There was a high intraclass correlation of 0.643 between the responses in the two visits. CONCLUSIONS: The Greek version of the CSHQ CF, but particularly the PF has proved to be a very reliable clinical instrument, which can be used in clinical trials for assessing sleep quality in school-aged children with sleep disturbances because of obstructive airway disorders, such as AR</style></abstract><notes><style face="normal" font="default">IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Greece -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.09.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29338964">PM:29338964</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20180113-MavroudiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20180113-MavroudiA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180113, Mavroudi A</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.09.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43759</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Arikoglu,T.</style></author><author><style face="normal" font="default"> Batmaz,S.B.</style></author><author><style face="normal" font="default"> Yildirim,D.D.</style></author><author><style face="normal" font="default"> Tezol,O.</style></author><author><style face="normal" font="default"> Bozlu,G.</style></author><author><style face="normal" font="default"> Kuyucu,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Mersin University, Faculty of Medicine, Department of Pediatric Allergy and Immunology, Mersin, Turkey.</style></auth-address><titles><title><style face="normal" font="default">Asthma predictive index in relation to respiratory mechanics by impulse oscillometry in recurrent wheezers</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="1" Year="2018">2018/1/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: The identification of children who will have persistent asthma has become a focus of recent research. The aim of this study was to assess whether impulse oscillometry (IOS) has a diagnostic value to predict modified API (asthma predictive index) in pre-schoolers with recurrent wheezing. METHODS: Pre-school children aged 3-6 years with recurrent wheezing were enrolled. The study population was divided into two groups based on mAPI criteria. Lung function was assessed by IOS. RESULTS: 115 children were assessed; 75 (65.2%) of them were male. The median age was 39 months (min: 36, max: 68 months). 64 (55.6%) of the children were mAPI positive. The R5-R20% levels of children with positive mAPI were significantly higher compared to negative mAPI. Also, R5-R20% levels of children with parental asthma and R20% pred and resonant frequency (Fres) levels of children with inhalant sensitization were higher than those without. No significant differences were found in IOS indices between groups based on the presence of atopic dermatitis, food sensitization, eosinophilia, inhaled corticosteroid usage or wheezing without colds. R5-R20% and total IgE values were found to be significantly related to positive mAPI (aOR: 1.40, p=0.022 and aOR: 1.02, p=0.001, respectively). In the ROC analysis, R5-R20% levels >14.4 had a sensitivity of 75% and specificity of 53% for predicting a positive mAPI (p=0.003). CONCLUSION: IOS may help clinicians to identify the pre-school wheezers with a high risk of asthma</style></abstract><notes><style face="normal" font="default">IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.09.028</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29331617">PM:29331617</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20180110-ArikogluT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20180110-ArikogluT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180110, Arikoglu T</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.09.028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43760</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gomez-Henao,C.M.</style></author><author><style face="normal" font="default"> Herrera-Morales,C.I.</style></author><author><style face="normal" font="default"> Ramirez-Giraldo,R.</style></author><author><style face="normal" font="default"> Cardona-Villa,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">GACE Group Research Associate, Universidad de Antioquia, Colombia; Clinical Allergist IPS Universitaria - Universidad de Antioquia, Colombia</style></auth-address><titles><title><style face="normal" font="default">Quality of life and clinical characterization of patients with vernal keratoconjunctivitis in a pediatric population in Colombia</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="1" Year="2018">2018/1/12</year></dates><abstract><style face="normal" font="default">Vernal keratoconjunctivitis is one of the most serious ocular allergies that have the potential to induce large ocular morbidity and significant visual changes affecting the quality of life of these individuals. METHODOLOGY: This study was conducted in two phases. The first phase consisted of the clinical characterization of 32 patients from the Clinical Allergology center of the I.P.S. Universitaria from July 2014 to February 2015. A retrospective analysis of medical records was performed. In the second phase, the evaluation of quality of life was conducted using the questionnaire KIDSCREEN 27, which was validated in our population and evaluated as recommended by the creators of this instrument. RESULTS: A total of 24 patients (75%) were men, mean age of 12.1 (SD 2.6) years. 100% of the patients had clinical evaluation and were monitored by Allergology and Ophthalmology, 12 patients (37.5%) were found in mild level, 5 patients (15.6%) were moderate and 14 patients (43.8%) were severe level. The most common symptoms were pruritus (75%), photophobia (50%), lacrimation (37.5%), and secretions (28.1%). 65.6% had a family history of atopy and 84.4% had an allergic comorbidity. Aeroallergen skin tests were found positive in 25 patients (78.1%). All patients had initiated ocular treatment by the time the survey of quality of life was conducted; but, they still had low quality of life scores in the 5 domains assessed. When the scores were evaluated by gender, the only statistically significant difference was found in the domain of family life and free time, which was lower for women. CONCLUSION: The vernal keratoconjunctivitis is a disease more prevalent in men. It apparently has an important atopic base in our environment, which due to its severe ocular involvement causes a marked decrease in the quality of life of the children who present it</style></abstract><notes><style face="normal" font="default">IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Colombia -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.12.002</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29338965">PM:29338965</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20180113-GomezHenaoCM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20180113-GomezHenaoCM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180113, Gomez-Henao CM</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.12.002</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43761</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Urrutia-Pereira,M.</style></author><author><style face="normal" font="default"> Mocellin,L.P.</style></author><author><style face="normal" font="default"> de Oliveira,R.B.</style></author><author><style face="normal" font="default"> Simon,L.</style></author><author><style face="normal" font="default"> Lessa,L.</style></author><author><style face="normal" font="default"> Sole,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Federal University of Pampa (Unipampa), Coordinator of Children's Asthma Prevention Program (PIPA), RS, Brazil</style></auth-address><titles><title><style face="normal" font="default">Knowledge on asthma, food allergies, and anaphylaxis: Assessment of elementary school teachers, parents/caregivers of asthmatic children, and university students in Uruguaiana, in the state of Rio Grande do Sul, Brazil</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="1" Year="2018">2018/1/12</year></dates><abstract><style face="normal" font="default">INTRODUCTION: Allergic diseases have become an increasingly common reality in the last years, extending beyond the family context. OBJECTIVE: Assessing the level of knowledge on asthma, food allergies and anaphylaxis of asthmatic children's parents/caregivers (PC), elementary school teachers (EST) and university students (US) in Uruguaiana, RS, Brazil. METHOD: 577 individuals (PC - N=111;</style></abstract><notes><style face="normal" font="default">IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.09.018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29338962">PM:29338962</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20180113-UrrutiaPereiraM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20180113-UrrutiaPereiraM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180113, Urrutia-Pereira M</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.09.018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43762</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Skylogianni,E.</style></author><author><style face="normal" font="default"> Triga,M.</style></author><author><style face="normal" font="default"> Douros,K.</style></author><author><style face="normal" font="default"> Bolis,K.</style></author><author><style face="normal" font="default"> Priftis,K.N.</style></author><author><style face="normal" font="default"> Fouzas,S.</style></author><author><style face="normal" font="default"> Anthracopoulos,M.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Pulmonology and Allergy Unit, Department of Pediatrics, University of Patras Medical School, Patras, Greece</style></auth-address><titles><title><style face="normal" font="default">Small-airway dysfunction precedes the development of asthma in children with allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="1" Year="2018">2018/1/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Epidemiological evidence suggests the existence of a direct link between allergic rhinitis (AR) and asthma. Several studies also support the presence of small-airway dysfunction (SAD) in non-asthmatic children with AR. However, it remains unknown whether SAD can predict the progression of AR to asthma. Our objective was to explore the existence of SAD in non-asthmatic children with AR and to assessed its ability to predict the development of asthma. METHODS: Seventy-three 6-year-old children with intermittent moderate-severe AR but without asthma symptoms/medication within the last two years, underwent spirometry and measurement of respiratory resistance (Rrs) and reactance (Xrs) before and after bronchodilation (BD) (300mcg salbutamol). Lung function measurements were performed in the absence of nasal symptoms and repeated at AR exacerbation. SAD was defined as >30% decrease in Rrs or >50% increase in Xrs at 6 or 8Hz post-BD. Participants were followed for five years. RESULTS: Twenty-three children (31.5%) developed asthma; this group presented significant post-BD changes in Rrs and Xrs, but only at AR exacerbation. The ability of these changes to predict the development of asthma was exceptional and superior to that of the spirometric parameters. SAD (22 children, 30.1%), emerged as the single most efficient predictor of asthma, independently of other risk factors such as parental asthma, personal history of eczema and type of allergic sensitisation. CONCLUSION: SAD precedes the development of asthma in children with AR. Changes in respiratory impedance at AR exacerbation may assist in identifying those at risk to progress to asthma</style></abstract><notes><style face="normal" font="default">IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.09.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29338960">PM:29338960</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20180113-SkylogianniE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20180113-SkylogianniE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180113, Skylogianni E</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.09.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43763</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Behniafard,N.</style></author><author><style face="normal" font="default"> Amirzargar,A.A.</style></author><author><style face="normal" font="default"> Gharagozlou,M.</style></author><author><style face="normal" font="default"> Delavari,F.</style></author><author><style face="normal" font="default"> Hosseinverdi,S.</style></author><author><style face="normal" font="default"> Sotoudeh,S.</style></author><author><style face="normal" font="default"> Farhadi,E.</style></author><author><style face="normal" font="default"> Mahmoudi,M.</style></author><author><style face="normal" font="default"> Khaledi,M.</style></author><author><style face="normal" font="default"> Moghaddam,Z.G.</style></author><author><style face="normal" font="default"> Aghamohammadi,A.</style></author><author><style face="normal" font="default"> Rezaei,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran</style></auth-address><titles><title><style face="normal" font="default">Single nucleotide polymorphisms of the genes encoding IL-10 and TGF-beta1 in Iranian children with atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Allergol Immunopathol (Madr)</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergol Immunopathol (Madr)</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="1" Year="2018">2018/1/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis is an inflammatory skin disease in which both genetic and environmental factors interact to determine the susceptibility and severity of the disease. OBJECTIVE: The aim of this study was to determine the association between atopic dermatitis and IL-10 and TGF-beta1 gene polymorphisms. METHODS: The allele and genotype frequencies of genes encoding for IL-10 and TGF-beta1 were investigated in 89 patients with atopic dermatitis in comparison with 138 in the control group using the PCR-SSP method. RESULTS: A significant increase was found in the frequency of the TGF-beta1 codon 10/C allele among patients (p&lt;0.001, OR=6.77), whereas a significant decrease was observed in the frequency of the T allele at the same position (p&lt;0.001, OR=0.14). The frequency of the TGF-beta1 codon 25/G allele in the control group was significantly higher than among patients (p&lt;0.001, OR=0.08). A significant positive correlation was seen between CC (p&lt;0.001, OR=15.10) and CG (p&lt;0.001) genotypes and AD at codons 10 and 25, respectively. The most frequent haplotypes among patients was TGF-beta1 CG which was significantly higher than in the control subjects (50% in patients vs. 39.9% in controls, p=0.042). A significant increase was found in the frequency of TGF-beta CC (36% in patients vs. 7.6% in controls, p&lt;0.001) and TC (14% in patients vs. 0% in controls, p&lt;0.001) haplotypes among patients compared to controls. By contrast, the TGF-beta1 TG haplotype was significantly lower in patients than controls (0% in patients vs. 52.5% in controls, p&lt;0.001). There were no significant differences in the frequency of alleles, genotypes and haplotypes of the IL-10 gene. CONCLUSIONS: We found a strong association between the polymorphisms of the TGF-beta1 gene at codon 10 and codon 25 positions and atopic dermatitis</style></abstract><notes><style face="normal" font="default">IS - 1578-1267 (Electronic)IS - 0301-0546 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">10.1016/j.aller.2017.05.007</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29310944">PM:29310944</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20180105-BehniafardN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergol Immunopathol (Madr)\20180105-BehniafardN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, Behniafard N</style></custom2><misc3><style face="normal" font="default">10.1016/j.aller.2017.05.007</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43764</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mehta,A.K.</style></author><author><style face="normal" font="default"> Doherty,T.</style></author><author><style face="normal" font="default"> Broide,D.</style></author><author><style face="normal" font="default"> Croft,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immune Regulation, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 92037</style></auth-address><titles><title><style face="normal" font="default">TNF Family Member LIGHT Acts with IL-1beta and TGF-beta to Promote Airway Remodeling During Rhinovirus Infection</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="1" Year="2018">2018/1/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Rhinovirus (RV) can exacerbate allergen-driven asthma. However, it has been suggested that serial infections with RV may also lead to asthma-like features in childhood without prior allergen exposure. AIM: We sought to test the effects of RV infection in the absence of allergen challenge on lung tissue remodeling and to understand if RV induced factors in common with allergen that promote remodeling. METHODS: We infected C57BL/6 mice multiple times with RV in the absence or presence of allergen to assess airway remodeling. We used knockout mice and blocking reagents to determine the participation of LIGHT (TNFSF14), as well as IL-1beta and TGF-beta, each previously shown to contribute to lung remodeling driven by allergen. RESULTS: Recurrent RV infection without allergen challenge induced an increase in peribronchial smooth muscle mass and subepithelial fibrosis. RV induced LIGHT expression in mouse lungs after infection, and alveolar epithelial cells and neutrophils were found to be potential sources of LIGHT. Accordingly, LIGHT-deficient mice, or mice where LIGHT was neutralized, displayed reduced smooth muscle mass and lung fibrosis. Recurrent RV infection also exacerbated the airway remodeling response to house dust mite allergen and this was significantly reduced in LIGHT deficient mice. Furthermore, neutralizing IL-1beta or TGF-beta also limited subepithelial fibrosis and/or smooth muscle thickness induced by RV. CONCLUSION: Rhinovirus can promote airway remodeling in the absence of allergen through upregulating common factors that also contribute to allergen-associated airway remodeling. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.1111/all.13390</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29315623">PM:29315623</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20180109-MehtaAK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20180109-MehtaAK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180109, Mehta AK</style></custom2><misc3><style face="normal" font="default">10.1111/all.13390</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43765</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hasegawa,K.</style></author><author><style face="normal" font="default"> Stewart,C.J.</style></author><author><style face="normal" font="default"> Celedon,J.C.</style></author><author><style face="normal" font="default"> Mansbach,J.M.</style></author><author><style face="normal" font="default"> Tierney,C.</style></author><author><style face="normal" font="default"> Camargo,C.A.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA</style></auth-address><titles><title><style face="normal" font="default">Circulating 25-hydroxyvitamin D, nasopharyngeal airway metabolome, and bronchiolitis severity</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="1" Year="2018">2018/1/9</year></dates><abstract><style face="normal" font="default">Low circulating 25-hydroxyvitamin D (25OHD) levels are a risk factor for acute respiratory infection (e.g., bronchiolitis) in children. However, little is known about the relation of circulating 25OHD with the many downstream functional molecules in target organs - such as the airway - and with clinical outcomes. In this prospective multicenter study of infants (age &lt;1 year) hospitalized with bronchiolitis, we measured serum 25OHD levels and profiled the metabolome of 144 nasopharyngeal airway samples. Among 254 metabolites identified, we defined a set of 20 metabolites that are related to lower serum 25OHD and higher vitamin D-binding protein levels. Of these metabolites, 9 metabolites were associated with a significantly higher risk of positive pressure ventilation use. These metabolites were glycerophosphocholines esterified with proinflammatory fatty acids (palmitate, arachidonate, linoleate, and stearate), sphingomyelins, alpha-hydroxyisovalerate, 2-hydroxybutyrate, and 3-(4-hydroxyphenyl)lactate (all FDR&lt;0.05). Based on the multicenter data, vitamin D-related airway metabolites were associated with risks of bronchiolitis severity. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.13379</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29315663">PM:29315663</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20180109-HasegawaK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20180109-HasegawaK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180109, Hasegawa K</style></custom2><misc3><style face="normal" font="default">10.1111/all.13379</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43766</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Maurer,M.</style></author><author><style face="normal" font="default"> Magerl,M.</style></author><author><style face="normal" font="default"> Ansotegui,I.</style></author><author><style face="normal" font="default"> Aygoren,P.E.</style></author><author><style face="normal" font="default"> Betschel,S.</style></author><author><style face="normal" font="default"> Bork,K.</style></author><author><style face="normal" font="default"> Bowen,T.</style></author><author><style face="normal" font="default"> Balle,Boysen H.</style></author><author><style face="normal" font="default"> Farkas,H.</style></author><author><style face="normal" font="default"> Grumach,A.</style></author><author><style face="normal" font="default"> Hide,M.</style></author><author><style face="normal" font="default"> Katelaris,C.</style></author><author><style face="normal" font="default"> Lockey,R.</style></author><author><style face="normal" font="default"> Longhurst,H.</style></author><author><style face="normal" font="default"> Lumry,W.</style></author><author><style face="normal" font="default"> Martinez-Saguer,I.</style></author><author><style face="normal" font="default"> Moldovan,D.</style></author><author><style face="normal" font="default"> Nast,A.</style></author><author><style face="normal" font="default"> Pawankar,R.</style></author><author><style face="normal" font="default"> Potter,P.</style></author><author><style face="normal" font="default"> Riedl,M.</style></author><author><style face="normal" font="default"> Ritchie,B.</style></author><author><style face="normal" font="default"> Rosenwasser,L.</style></author><author><style face="normal" font="default"> Sanchez-Borges,M.</style></author><author><style face="normal" font="default"> Zhi,Y.</style></author><author><style face="normal" font="default"> Zuraw,B.</style></author><author><style face="normal" font="default"> Craig,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Charite - Universitatsmedizin Berlin, Berlin, Germany</style></auth-address><titles><title><style face="normal" font="default">The international WAO/EAACI guideline for the management of hereditary angioedema - the 2017 revision and update</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="1" Year="2018">2018/1/10</year></dates><abstract><style face="normal" font="default">Hereditary angioedema (HAE) is a rare disease and a serious health problem, globally and for affected patients and their families. The pathophysiological background is primarily a vascular reaction to an overshooting local production of bradykinin. Evidence-based recommendations are needed to inform and guide clinical decision makers. This is the first revision and update of the global guideline for the diagnosis and management of HAE[5]. It was developed by the World Allergy Organization (WAO) in collaboration with the European Academy of Allergy and Clinical Immunology (EAACI). This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Spain -CO - Canada -CO - Switzerland -CO - Hungary -CO - Brazil -CO - Japan -CO - Australia -CO - United States -CO - United Kingdom -CO - Romania -CO - South Africa -CO - Venezuela -CO - China -</style></notes><work-type><style face="normal" font="default">10.1111/all.13384</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29318628">PM:29318628</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20180110-MaurerM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20180110-MaurerM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180110, Maurer M</style></custom2><misc3><style face="normal" font="default">10.1111/all.13384</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43767</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liao,B.</style></author><author><style face="normal" font="default"> Liu,J.X.</style></author><author><style face="normal" font="default"> Li,Z.Y.</style></author><author><style face="normal" font="default"> Zhen,Z.</style></author><author><style face="normal" font="default"> Cao,P.P.</style></author><author><style face="normal" font="default"> Yao,Y.</style></author><author><style face="normal" font="default"> Long,X.B.</style></author><author><style face="normal" font="default"> Wang,H.</style></author><author><style face="normal" font="default"> Wang,Y.</style></author><author><style face="normal" font="default"> Schleimer,R.</style></author><author><style face="normal" font="default"> Liu,Z.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China</style></auth-address><titles><title><style face="normal" font="default">Multidimensional endotypes of chronic rhinosinusitis and their association with treatment outcomes</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="1" Year="2018">2018/1/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: The expression of chronic rhinosinusitis (CRS) is multidimensional. Disease heterogeneity in patients with CRS remains poorly understood. This study aimed to identify endotypes of CRS using cluster analysis by integrating multidimensional characteristics and to explore their association with treatment outcomes. METHODS: A total of 28 clinical variables and 39 mucosal cellular and molecular variables were analyzed using principal component analysis. Cluster analysis was performed on 246 prospectively recruited Chinese CRS patients with at least one-year post-operative follow-up. Difficult-to-treat CRS was characterized in each generated cluster. RESULTS: Seven subject clusters were identified. Cluster 1 (13.01%) was comparable to the classic well-defined eosinophilic CRS with polyps, having severe disease and the highest proportion of difficult-to-treat CRS. Patients in cluster 2 (16.26%) and cluster 4 (13.82%) had relatively lower proportions of presence of polyps and presented mild inflammation with moderate proportions of difficult-to-treat cases. Subjects in cluster 2 were highly atopic. Cluster 3 (7.31%) and cluster 6 (21.14%) were characterized by severe or moderate neutrophilic inflammation, respectively, and with elevated levels of IL-8 and high proportions of difficult-to-treat CRS. Cluster 5 (4.07%) was a unique group characterized by the highest levels of IL-10 and lacked difficult-to-treat cases. Cluster 7 (24.39%) demonstrated the lowest symptom severity, a low proportion of difficult-to-treat CRS, and low inflammation load. Finally, we found that difficult-to-treat CRS was associated with distinct clinical features and biomarkers in the different clusters. CONCLUSIONS: Distinct clinicopathobiologic clusters of CRS display differences in clinical response to treatments and characteristics of difficult-to-treat CRS. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - China -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.1341</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29331025">PM:29331025</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20180113-LiaoB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20180113-LiaoB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180113, Liao B</style></custom2><misc3><style face="normal" font="default">10.1111/all.1341</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43768</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kuiper,J.R.</style></author><author><style face="normal" font="default"> Hirsch,A.G.</style></author><author><style face="normal" font="default"> Bandeen-Roche,K.</style></author><author><style face="normal" font="default"> Sundaresan,A.S.</style></author><author><style face="normal" font="default"> Tan,B.K.</style></author><author><style face="normal" font="default"> Schleimer,R.P.</style></author><author><style face="normal" font="default"> Kern,R.C.</style></author><author><style face="normal" font="default"> Stewart,W.F.</style></author><author><style face="normal" font="default"> Schwartz,B.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Environmental Health and Engineering, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MA, USA</style></auth-address><titles><title><style face="normal" font="default">Prevalence, severity, and risk factors for acute exacerbations of nasal and sinus symptoms by chronic rhinosinusitis status</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="1" Year="2018">2018/1/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: Nasal and sinus symptoms (NSS) are common to many health conditions, including chronic rhinosinusitis (CRS). Few studies have investigated the occurrence and severity of, and risk factors for, acute exacerbations of NSS (AENSS) by CRS status (current, past, or never met European Position Paper on Rhinosinusitis [EPOS] criteria for CRS). METHODS: Four seasonal questionnaires were mailed to a stratified random sample of Geisinger primary care patients. Logistic regression was used to identify individual characteristics associated with AENSS occurrence and severity by CRS status (current long-term, current recent, past, never) using EPOS subjective symptoms-only (EPOSS ) CRS criteria. We operationalized three AENSS definitions based on prescribed antibiotics or oral corticosteroids, symptoms, and symptoms with purulence. RESULTS: Baseline and at least one follow-up questionnaires were available from 4,736 subjects. Self-reported NSS severity with exacerbation was worst in the current long-term CRS group. AENSS was common in all subgroups examined and generally more common among those with current EPOSS CRS. Seasonal prevalence of AENSS differed by AENSS definition and CRS status. Associations of risk factors with AENSS differed by definition, but CRS status, body mass index, asthma, hay fever, sinus surgery history, and winter season consistently predicted AENSS. CONCLUSIONS: In this first longitudinal, population-based study of three AENSS definitions, NSS and AENSS were both common, sometimes severe, and differed by EPOSS CRS status. Contrasting associations of risk factors for AENSS by the different definitions suggest a need for a standardized approach to definition of AENSS. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.13409</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29331046">PM:29331046</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20180113-KuiperJR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20180113-KuiperJR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180113, Kuiper JR</style></custom2><misc3><style face="normal" font="default">10.1111/all.13409</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43769</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Campbell,A.P.</style></author><author><style face="normal" font="default"> Hoehle,L.P.</style></author><author><style face="normal" font="default"> Phillips,K.M.</style></author><author><style face="normal" font="default"> Caradonna,D.S.</style></author><author><style face="normal" font="default"> Gray,S.T.</style></author><author><style face="normal" font="default"> Sedaghat,A.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology, Harvard Medical School, Boston, MA</style></auth-address><titles><title><style face="normal" font="default">Depressed mood is associated with loss of productivity in allergic rhinitis</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="1" Year="2018">2018/1/10</year></dates><abstract><style face="normal" font="default">Allergic rhinitis (AR) is associated with significant decreases in quality of life and productivity losses. We hypothesized that symptoms of AR may differentially associate with lost productivity due to AR. We performed a cross-sectional cohort study of 105 prospectively recruited patients with persistent AR. AR control, severity of depressed mood and sinonasal symptoms were assessed with the Rhinitis Control Assessment Test (RCAT), Patient Health Questionnaire (PHQ-2), and the 22-item Sinonasal Outcome Test (SNOT-22) respectively. Lost productivity was assessed by asking the number of days of work/school missed due to AR in the last 3 months. Patients missed a mean of 1.5 days (SD:2.9) of work or school. Lost productivity was associated with PHQ-2 (adjusted linear regression coefficient [beta]=0.68, 95%CI: 0.20-1.15, p=0.007) analysis but not SNOT-22 or RCAT scores. Productivity losses due to AR are associated with severity of depressed mood rather than classic nasal or extra-nasal symptoms of AR. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/all.13387</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29319887">PM:29319887</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20180110-CampbellAP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20180110-CampbellAP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180110, Campbell AP</style></custom2><misc3><style face="normal" font="default">10.1111/all.13387</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43770</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mayado,A.</style></author><author><style face="normal" font="default"> Teodosio,C.</style></author><author><style face="normal" font="default"> Freire,N.D.</style></author><author><style face="normal" font="default"> Jara-Acevedo,M.</style></author><author><style face="normal" font="default"> Garcia-Montero,A.C.</style></author><author><style face="normal" font="default"> Alvarez-Twose,I.</style></author><author><style face="normal" font="default"> Sanchez-Munoz,L.</style></author><author><style face="normal" font="default"> Matito,A.</style></author><author><style face="normal" font="default"> Caldas,C.</style></author><author><style face="normal" font="default"> Munoz-Gonzalez,J.I.</style></author><author><style face="normal" font="default"> Henriques,A.</style></author><author><style face="normal" font="default"> Sanchez-Gallego,J.I.</style></author><author><style face="normal" font="default"> Escribano,L.</style></author><author><style face="normal" font="default"> Orfao,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Cancer Research Centre (IBMCC, USAL-CSIC), Cytometry Service (NUCLEUS), and Department of Medicine, University of Salamanca, Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain</style></auth-address><titles><title><style face="normal" font="default">Characterization of CD34(+) hematopoietic cells in systemic mastocytosis: potential role in disease dissemination</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="1" Year="2018">2018/1/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: Recent studies show that most systemic mastocytosis (SM) patients, including indolent SM (ISM) with (ISMs+) and without skin lesions (ISMs-), carry the KIT D816V mutation in PB leukocytes. We investigated the potential association between the degree of involvement of BM hematopoiesis by the KIT D816V mutation and the distribution of different maturation-associated compartments of bone marrow (BM) and peripheral blood (PB) CD34(+) hematopoietic precursors (HPC) in ISM, and identified the specific PB cell compartments that carry this mutation. METHODS: The distribution of different maturation-associated subsets of BM and PB CD34(+) HPC from 64 newly-diagnosed (KIT-mutated) ISM patients and 14 healthy controls was analyzed by flow cytometry. In 18 patients distinct FACS-purified PB cell compartments were also investigated for the KIT mutation. RESULTS: ISM patients showed higher percentages of both BM and PB MC-committed CD34(+) HPC vs. controls, particularly among ISM cases with MC-restricted KIT mutation (ISMMC ); this was associated with progressive blockade of maturation of CD34(+) HPC to the neutrophil lineage from ISMMC to multilineage KIT-mutated cases (ISMML ). Regarding the frequency of KIT-mutated cases and cell populations in PB, variable patterns were observed, the percentage of KIT-mutated PB CD34(+) HPC, eosinophils, neutrophils, monocytes and T-cells increasing from ISMs-MC and ISMs+MC to ISMML patients. CONCLUSION: The presence of the KIT D816V mutation in PB of ISM patients is associated with (early) involvement of circulating CD34(+) HPC and multiple myeloid cell subpopulations, KIT-mutated PB CD34(+) HPC potentially contributing to early dissemination of the disease. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/all.13413</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29331029">PM:29331029</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20180113-MayadoA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20180113-MayadoA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180113, Mayado A</style></custom2><misc3><style face="normal" font="default">10.1111/all.13413</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43771</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wi,C.I.</style></author><author><style face="normal" font="default"> Krusemark,E.A.</style></author><author><style face="normal" font="default"> Voge,G.</style></author><author><style face="normal" font="default"> Sohn,S.</style></author><author><style face="normal" font="default"> Liu,H.</style></author><author><style face="normal" font="default"> Ryu,E.</style></author><author><style face="normal" font="default"> Park,M.A.</style></author><author><style face="normal" font="default"> Castro-Rodriguez,J.A.</style></author><author><style face="normal" font="default"> Juhn,Y.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA</style></auth-address><titles><title><style face="normal" font="default">Usefulness of Asthma Predictive Index in Ascertaining Asthma Status of Children Using Medical Records: An Explorative Study</style></title><secondary-title><style face="normal" font="default">Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="1" Year="2018">2018/1/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: Frequent wheezing in original Asthma Predictive Index (API) was defined by parental report of recurrent wheezing within 1 year during the first 3 years of life. The nature of frequent wheezing in children, particularly aged over 3 years has not been studied. We aimed to assess the frequency and interval of wheezing to define frequent wheezing in ascertaining asthma for children using medical records. METHODS: Among children who participated in a previous study (n=427), all wheezing episodes documented in medical records were collected for children who had >/=2wheezing episodes PLUS met one major criteria or two minor criteria of API. We compared the distribution of known risk factors for asthma between subjects having two consecutive wheezing episodes with shorter interval (&lt;/=1year) compared to those with longer interval (1to3 years). RESULTS: 62 children met API at median age of 2.3 years. During follow-up period (median age: 11.3 years), a total of 198 wheezing episodes were observed. 81% of wheezing intervals were within 3 years from the earlier wheezing episode, including 60% within 1 year. Children who met API based on 1 year interval (n=40) vs. 1to3 year interval (n=13) appeared to be similar in regard to the known risk factors for asthma. CONCLUSIONS: Our exploratory study finding suggests that children who had frequent wheezing episodes with longer interval (&lt;3 years) need to be considered to be determined as asthma cases when API is applied to retrospective medical records. Prospective studies with a larger sample size need to replicate this finding. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1398-9995 (Electronic)IS - 0105-4538 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Chile -</style></notes><work-type><style face="normal" font="default">10.1111/all.13403</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29319899">PM:29319899</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Allergy\20180110-WiCI.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Allergy\20180110-WiCI.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180110, Wi CI</style></custom2><misc3><style face="normal" font="default">10.1111/all.13403</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43772</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Golisch,K.B.</style></author><author><style face="normal" font="default"> Gottesman,S.P.</style></author><author><style face="normal" font="default"> Ferrer,P.</style></author><author><style face="normal" font="default"> Culpepper,K.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">University of Arizona College of Medicine, Tucson, AZ</style></auth-address><titles><title><style face="normal" font="default">Cutis Laxa Acquisita After Urticarial Vasculitis in SLE Patients</style></title><secondary-title><style face="normal" font="default">Am J Dermapathol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Am J Dermapathol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="1" Year="2018">2018/1/11</year></dates><abstract><style face="normal" font="default">Cutis laxa is a rare connective tissue disease involving damage to dermal elastic fibers creating a clinical appearance of loose, sagging skin. The condition can be either acquired or genetic. Autoimmune diseases, neoplasms, infections, and medications have been proposed as the cause of, or in association with, the acquired form. In nearly 50% of cases, erythematous plaques present before the onset of cutis laxa. Separately, urticarial vasculitis and systemic lupus erythematosus have been linked to cutis laxa acquisita. Our case is the first in the literature documenting a coexistence of cutis laxa acquisita, hypocomplementemic urticarial vasculitis, and systemic lupus erythematosus</style></abstract><notes><style face="normal" font="default">IS - 1533-0311 (Electronic)IS - 0193-1091 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/DAD.0000000000001084</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29329127">PM:29329127</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Dermapathol\20180111-GolischKB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Dermapathol\20180111-GolischKB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180111, Golisch KB</style></custom2><misc3><style face="normal" font="default">10.1097/DAD.0000000000001084</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43773</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Svenningsen,S.</style></author><author><style face="normal" font="default"> Eddy,R.L.</style></author><author><style face="normal" font="default"> Lim,H.F.</style></author><author><style face="normal" font="default"> Cox,P.G.</style></author><author><style face="normal" font="default"> Nair,P.</style></author><author><style face="normal" font="default"> Parraga,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">McMaster University Department of Medicine, 152997, Hamilton, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="default">Sputum Eosinophilia and MRI Ventilation Heterogeneity in Severe Asthma</style></title><secondary-title><style face="normal" font="default">Am J Respir Crit Care Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Respir Crit Care Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="1" Year="2018">2018/1/9</year></dates><abstract><style face="normal" font="default">RATIONALE: Inflammation and smooth muscle dysfunction are integral components of severe asthma that contribute to luminal obstruction causing airflow limitation, ventilation heterogeneity and symptoms. This is important for guiding treatment decisions directed at inflammatory (eg. anti-Th2 monoclonal antibodies) and non-inflammatory, smooth muscle-mediated (eg. bronchial thermoplasty) components of severe asthma. OBJECTIVE: To investigate the contribution of eosinophilic-bronchitis and smooth muscle dysfunction to magnetic-resonance-imaging (MRI) ventilation heterogeneity in severe asthmatics. METHODS: We measured inhaled-hyperpolarized-gas MRI response to salbutamol as a marker of smooth muscle dysfunction, and sputum-eosinophils as a marker of airway inflammation, and their relative contributions to ventilation heterogeneity (quantified as ventilation-defect-percent (VDP)) in 27 severe asthmatics. Spirometry and forced oscillation airway resistance measurements were also acquired pre- and post-salbutamol. Patients were dichotomized based on sputum eosinophilia and pre- and post-salbutamol VDP and physiological measurements were evaluated. MEASUREMENTS AND MAIN RESULTS: MRI VDP improved with salbutamol inhalation in patients in whom sputum-eosinophilia was uncontrolled (>/=3%, n=16)(p=0.002) and in those in whom it was controlled (&lt;3%, n=11)(p=0.02), independent of improvements in FEV1, indicating smooth muscle response. In those patients in whom sputum-eosinophilia was uncontrolled, greater VDP persisted post-salbutamol (p=0.004). Post-salbutamol VDP correlated with sputum-eosinophils (r=0.63, p=0.005). CONCLUSIONS: In severe asthmatics, MRI regionally identifies the inflammatory and non-inflammatory components of airways disease. Ventilation heterogeneity persists post-salbutamol in patients with uncontrolled eosinophilic-bronchitis, which may be the functional consequence of airway inflammation</style></abstract><notes><style face="normal" font="default">IS - 1535-4970 (Electronic)IS - 1073-449X (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1164/rccm.201709-1948OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29313707">PM:29313707</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20180109, Svenningsen S</style></custom2><misc3><style face="normal" font="default">10.1164/rccm.201709-1948OC</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43774</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Patton,K.</style></author><author><style face="normal" font="default"> Borshoff,D.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anaesthesia, University Hospital Bristol, Bristol, UKDepartment of Anaesthesia and Pain Medicine, St. John of God Murdoch Hospital, Perth, Western Australia</style></auth-address><titles><title><style face="normal" font="default">Adverse drug reactions</style></title><secondary-title><style face="normal" font="default">Anaesthesia</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Anaesthesia</style></abbr-1></periodical><pages end="84" start="76">76-84</pages><volume><style face="normal" font="default">73 Suppl 1</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">Adverse drug reactions are a cause of significant morbidity and mortality to patients and a source of financial burden to the healthcare system. Of the wide spectrum of adverse drug reactions, the most concerning to the anaesthetist remain anaphylaxis and malignant hyperthermia. Although the incidence of anaphylaxis under anaesthesia is difficult to ascertain, it occurs commonly enough that most anaesthetists will manage at least one case in their career. The wide range of drugs given in the peri-operative period and the variable presentation in the anaesthetised patient can delay diagnosis and treatment, and adversely affect outcome. Furthermore, despite improvements in testing, causative drugs can still be difficult to identify, as adverse reactions may be mediated by mechanisms other than IgE activation. With an increase in the reporting of anaphylaxis to newer anaesthetic drugs such as sugammadex, combined with change over the recent decades in the most likely causative peri-operative agents, it is imperative anaesthetists remain up to date on recent developments. In addition, they should be vigilant to patient characteristics, including pharmacogenetic variations that may predispose to adverse drug reactions, in order to help minimise risks of a reaction. The severity of adverse drug reactions to peri-operative drugs means morbidity and mortality remain high</style></abstract><notes><style face="normal" font="default">IS - 1365-2044 (Electronic)IS - 0003-2409 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United Kingdom -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/anae.14143</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29313907">PM:29313907</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Anaesthesia\2018-73S1-76-84.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Anaesthesia\2018-73S1-76-84.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180112, Patton K</style></custom2><misc3><style face="normal" font="default">10.1111/anae.14143</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43775</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nurmagambetov,T.</style></author><author><style face="normal" font="default"> Kuwahara,R.</style></author><author><style face="normal" font="default"> Garbe,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Centers for Disease Control and Prevention, 1242, National Center for Environmental Health , 4770 Buford Hwy , MS F-60 , Atlanta, Georgia, United States</style></auth-address><titles><title><style face="normal" font="default">The Economic Burden of Asthma in the United States, 2</style></title><secondary-title><style face="normal" font="default">Ann Am Thorac Soc</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Ann Am Thorac Soc</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="1" Year="2018">2018/1/11</year></dates><abstract><style face="normal" font="default">RATIONALE: Asthma is a chronic disease that affects quality of life, productivity at work and school, healthcare use, and can result in death. Measuring the current economic burden of asthma provides important information on the impact of asthma on society. This information can be used to make informed decisions about allocation of limited public health resources. OBJECTIVES: In this paper, we provide a comprehensive approach to estimate current prevalence, medical costs, cost of absenteeism (missed work and schooldays) and mortality attributable to asthma from a national perspective. In addition, we estimate the association of incremental medical cost of asthma with several important factors, including race/ethnicity, education, poverty, and insurance status. METHODS: The primary source of data was the 2008-2013 household component of the Medical Expenditure Panel Survey. We defined treated asthma as the presence of at least one medical or pharmaceutical encounter or claim associated with asthma. For the main analysis, we applied two-part regression models to estimate asthma-related annual per-person incremental medical costs and negative binomial models to estimate absenteeism associated with asthma. RESULTS: Out of 213,994 people in the pooled sample, 10,237 persons had treated asthma (prevalence = 4.8%). The annual per-capita incremental medical cost of asthma was $3,266 (in 2015 US dollars): $1,830 was attributable to prescription medication, $640 to office visits, $529 to hospitalizations, $176 to hospital-based outpatient visits, and $105 to emergency room visits. For certain groups, the per-person incremental medical cost of asthma differed from that of the population average, namely, $2,145 for uninsured persons and $3.581 for those living below the poverty line. During 2008-2013, asthma was responsible for $3 billion in losses from missed work and school days, $29 billion from asthma-related mortality, and $50.3 billion in medical costs. All combined, the total cost of asthma in the U.S. based on the pooled sample amounted to $81.9 billion in 2013. CONCLUSION: Asthma places a significant economic burden on the United States with a total cost of asthma, including costs incurred by absenteeism and mortality, of $81.9 billion in 2013</style></abstract><notes><style face="normal" font="default">IS - 2325-6621 (Electronic)IS - 2325-6621 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1513/AnnalsATS.201703-259OC</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29323930">PM:29323930</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Ann Am Thorac Soc\20180111-NurmagambetovT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Ann Am Thorac Soc\20180111-NurmagambetovT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180111, Nurmagambetov T</style></custom2><misc3><style face="normal" font="default">10.1513/AnnalsATS.201703-259OC</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43776</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yilmaz,I.</style></author><author><style face="normal" font="default"> Tutar,N.</style></author><author><style face="normal" font="default"> Yenigun,S.</style></author><author><style face="normal" font="default"> Simsek,Z.O.</style></author><author><style face="normal" font="default"> Gulmez,I.</style></author></authors></contributors><titles><title><style face="normal" font="default">Tenoxicam-Induced Fixed Drug Eruption Confirmed by Skin Patch Test</style></title><secondary-title><style face="normal" font="default">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asthma Allergy Immunol</style></full-title></periodical><pages end="164" start="162">162-164</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Fixed drug eruption (FDE) with oxicams is very rare. FDE due to tenoxicam has been reported in several case reports. Skin patch test with the suspected or responsible drug is applied on sites of previous lesions developing with FDE. Recently, the test has been used quite often for diagnosis of FDE although results are variable. Our case was a 63-year-old woman who had developed itching and erythematous lesions 3-5 cm in size localized on her hands and elbows 3-4 hours after the intake of tenoxicam and ranitidine. The lesion became vesiculobullous a few days later. After two weeks, it resolved with hyperpigmentation. The diagnosis of tenoxicaminduced FDE was confirmed after applying patch and provocation tests. Here we described a case of bullous fixed drug eruption due to tenoxicam and we demonstrated the contribution of skin patch tests to the FDE diagnosis.</style></abstract><notes><style face="normal" font="default">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.21911/aai.76</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.21911/aai.76</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Allergy Immunol\2017-15-162-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Allergy Immunol\2017-15-162-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171102, Yilmaz I</style></custom2><misc3><style face="normal" font="default">10.21911/aai.76</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43777</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Akbas,P.E.</style></author><author><style face="normal" font="default"> Hokenek,N.B.</style></author><author><style face="normal" font="default"> Copur,M.</style></author><author><style face="normal" font="default"> Gungor,S.</style></author><author><style face="normal" font="default"> Karadag,D.T.</style></author><author><style face="normal" font="default"> Erguney,A.C.</style></author><author><style face="normal" font="default"> Kocaturk.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">A Rare Differential Diagnosis for Acute Urticarial Plaques: Adult Onset Still's Disease</style></title><secondary-title><style face="normal" font="default">Asthma Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Asthma Allergy Immunol</style></full-title></periodical><pages end="157" start="152">152-157</pages><volume><style face="normal" font="default">15</style></volume><number><style face="normal" font="default">3</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Adult-onset Still's disease (AOSD) was first described by Bywaters as a different clinical entity from Juvenile Rheumatoid Arthritis (Still's Disease). It is an uncommon, acute, systemic inflammatory disease of unknown etiology, which is characterized by a high spiking fever (=39°C), typical skin rash with an evanescent salmon-pink erythema, leukocytosis, arthritis/arthralgia, hepatosplenomegaly, lymphadenopathy, leukocytosis, sore throat and serositis. We report two patients in whom urticaria-like rash and angioedema were uncommon presenting features of AOSD where treatment was attempted with antihistamines and systemic steroids. AOSD should be kept in mind in persistent urticarial skin rash with accompanying spiking fever.</style></abstract><notes><style face="normal" font="default">LA - TURCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.21911/aai.5028</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.21911/aai.5028</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Allergy Immunol\2017-15-152-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Allergy Immunol\2017-15-152-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171102, Akbas PE</style></custom2><misc3><style face="normal" font="default">10.21911/aai.5028</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43778</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sokolowska,M.</style></author><author><style face="normal" font="default"> Frei,R.</style></author><author><style face="normal" font="default"> Lunjani,N.</style></author><author><style face="normal" font="default"> Akdis,C.A.</style></author><author><style face="normal" font="default"> O'Mahony,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Swiss Institute of Allergy and Asthma Research, University of Zurich, Obere Strasse 22, 7270 Davos, Switzerland.</style></auth-address><titles><title><style face="normal" font="default">Microbiome and asthma</style></title><secondary-title><style face="normal" font="default">Asthma Res Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Asthma Res Pract</style></abbr-1></periodical><pages end="" start="1">1-</pages><volume><style face="normal" font="default">4</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="default">The mucosal immune system is in constant communication with the vast diversity of microbes present on body surfaces. The discovery of novel molecular mechanisms, which mediate host-microbe communication, have highlighted the important roles played by microbes in influencing mucosal immune responses. Dendritic cells, epithelial cells, ILCs, T regulatory cells, effector lymphocytes, NKT cells and B cells can all be influenced by the microbiome. Many of the mechanisms being described are bacterial strain- or metabolite-specific. Microbial dysbiosis in the gut and the lung is increasingly being associated with the incidence and severity of asthma. More accurate endotyping of patients with asthma may be assisted by further analysis of the composition and metabolic activity of an individual's microbiome. In addition, the efficacy of specific therapeutics may be influenced by the microbiome and novel bacterial-based therapeutics should be considered in future clinical studies</style></abstract><notes><style face="normal" font="default">IS - 2054-7064 (Print)IS - 2054-7064 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Switzerland -</style></notes><work-type><style face="normal" font="default">10.1186/s40733-017-0037-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29318023">PM:29318023</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Asthma Res Pract\2018-4-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Asthma Res Pract\2018-4-1.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, Sokolowska,M.</style></custom2><misc3><style face="normal" font="default">10.1186/s40733-017-0037-y</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43779</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Erdei,A.</style></author><author><style face="normal" font="default"> Steiber,Z.</style></author><author><style face="normal" font="default"> Molnar,C.</style></author><author><style face="normal" font="default"> Berenyi,E.</style></author><author><style face="normal" font="default"> Nagy,E.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Endocrinology, Department of Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei krt 98, Debrecen, 4032, Hungary.</style></auth-address><titles><title><style face="normal" font="default">Exophthalmos in a young woman with no graves' disease - a case report of IgG4-related orbitopathy</style></title><secondary-title><style face="normal" font="default">BMC Ophthalmol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">BMC Ophthalmol</style></full-title></periodical><pages end="" start="5">5-</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="1" Year="2018">2018/1/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Immunoglobulin G4-related disease (IgG4-rd) is characterized by lymphoplasmacytic infiltration and tissue fibrosis. Orbital manifestations of IgG4-rd may include unilateral or bilateral proptosis, cicatricial extraocular muscle myopathy, orbital inflammation and pain which may mimic ophthalmic Graves' disease. CASE PRESENTATION: A 25-year-old woman has been referred to the endocrinology clinic, 4 months after delivery, with suspected Graves' orbitopathy. She has had bronchial asthma and recurrent skin rashes of unknown aetiology for the last 10 years and was treated for dacryoadenitis with steroid containing eye drops 5 years ago. During pregnancy she developed eyelid swelling. After delivery, eyelid redness and retrobulbar pain evolved. Proptosis was demonstrated by Hertel's exophthalmometry. Orbital magnetic resonance imaging showed enlarged lateral and superior rectus muscles in both orbits. Thyroid function tests were in the normal range and no thyroid stimulating hormone (TSH) receptor autoantibodies were present. The eye muscle involvement pattern raised suspicion, and the high IgG4 level with positive histology of the lacrimal gland confirmed the diagnosis of immunoglobulin G4-related orbitopathy. Rapid improvement was observed following oral methylprednisolone. CONCLUSIONS: IgG4-related orbitopathy may mimic Graves' orbitopathy. Euthyroid patients with no TSH receptor autoantibodies should be evaluated for immunoglobulin G4-related orbitopathy. Once IgG4-related orbitopathy is proven, other manifestations of IgG4-related disease have to be searched for; lifelong follow-up is warranted</style></abstract><notes><style face="normal" font="default">IS - 1471-2415 (Electronic)IS - 1471-2415 (Linking)LA - engPT - Journal ArticleCO - Hungary -</style></notes><work-type><style face="normal" font="default">10.1186/s12886-018-0672-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29329570">PM:29329570</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMC Ophthalmol\2018-18-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMC Ophthalmol\2018-18-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180112, Erdei A</style></custom2><misc3><style face="normal" font="default">10.1186/s12886-018-0672-y</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43780</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Iacobucci,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">The BMJ</style></auth-address><titles><title><style face="normal" font="default">"Conflicting" UK asthma guidelines should be streamlined, experts say</style></title><secondary-title><style face="normal" font="default">BMJ</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ</style></abbr-1></periodical><pages end="" start="k99">k99-</pages><volume><style face="normal" font="default">360</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="1" Year="2018">2018/1/9</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 1756-1833 (Electronic)IS - 0959-535X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1136/bmj.k99</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29317458">PM:29317458</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ\2018-360-k99.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ\2018-360-k99.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180111, Iacobucci G</style></custom2><misc3><style face="normal" font="default">10.1136/bmj.k99</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43781</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Keeley,D.</style></author><author><style face="normal" font="default"> Baxter,N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Primary Care Respiratory Society UK, Solihull, UK</style></auth-address><titles><title><style face="normal" font="default">Conflicting asthma guidelines cause confusion in primary care</style></title><secondary-title><style face="normal" font="default">BMJ</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ</style></abbr-1></periodical><pages end="" start="k29">k29-</pages><volume><style face="normal" font="default">360</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="1" Year="2018">2018/1/9</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 1756-1833 (Electronic)IS - 0959-535X (Linking)LA - engPT - EditorialCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1136/bmj.k29</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29317387">PM:29317387</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ\2018-360-k29.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ\2018-360-k29.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180111, Keeley D</style></custom2><misc3><style face="normal" font="default">10.1136/bmj.k29</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43782</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Azamgarhi,T.</style></author><author><style face="normal" font="default"> Shah,A.</style></author><author><style face="normal" font="default"> Warren,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pharmacy Department, Royal National Orthopaedic Hospital NHS Trust, Brockley Hill, Stanmore, HA7 4LPPharmacy Department, Royal National Orthopaedic Hospital NHS Trust, Brockley Hill, Stanmore, HA7 4LPBone Infection Unit, Royal National Orthopaedic Hospital NHS Trust, Brockley Hill, Stanmore, HA7 4LP</style></auth-address><titles><title><style face="normal" font="default">Teicoplanin Anaphylaxis Associated with Surgical Prophylaxis</style></title><secondary-title><style face="normal" font="default">Br J Clin Pharmacol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Clin Pharmacol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="1" Year="2018">2018/1/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: The rate of true anaphylaxis to teicoplanin is currently unknown. METHODS: A case-series including all suspected anaphylactic reactions attributed to teicoplanin anaphylaxis within a single institution over a 29-month period were categorised according to the probability of true IgE mediated anaphylaxis using previously published criteria. The number of patients who receive Teicoplanin was determined and used to calculate the rate of IgE mediated anaphylaxis. RESULTS: Approximately 18800-19600 patients received teicoplanin during the study period, during which, there were fourteen cases of suspected anaphylaxis attributed to the administration of teicoplanin: five were categorised as definite IgE mediated anaphylaxis, four as probable, two as uncertain and three were excluded. Of the excluded cases, two were found to have positive intradermal skin testing to alternative agents (rocuronium and chlorhexidine), and one did not meet the published clinical criteria. We therefore calculated the rate of IgE mediated anaphylaxis to be between 0.046% and 0.059% (equating to between 1:2088 and 1:1655). CONCLUSIONS: This is the first study to calculate a rate of IgE mediated anaphylaxis to teicoplanin in clinical practice. Our case series suggests that these life-threatening reactions occur less commonly than reported by the manufacturers. Mast Cell Tryptase is unreliable when used to predict the likelihood of IgE mediated anaphylaxis to teicoplanin</style></abstract><notes><style face="normal" font="default">IS - 1365-2125 (Electronic)IS - 0306-5251 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/bcp.13506</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29319891">PM:29319891</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Clin Pharmacol\20180110-AzamgarhiT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Clin Pharmacol\20180110-AzamgarhiT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180110, Azamgarhi T</style></custom2><misc3><style face="normal" font="default">10.1111/bcp.13506</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43783</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fityan,A.</style></author><author><style face="normal" font="default"> McGibbon,D.</style></author><author><style face="normal" font="default"> Fassihi,H.</style></author><author><style face="normal" font="default"> Sarkany,R.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Department, University Hospital, Southampton NHS Foundation TrustSt John's Institute of Dermatology, Guy's and St Thomas' NHS Trust, LondonSt John's Institute of Dermatology, Guy's and St Thomas' NHS Trust, LondonSt John's Institute of Dermatology, Guy's and St Thomas' NHS Trust, LondonSt John's Institute of Dermatology, Guy's and St Thomas' NHS Trust, London</style></auth-address><titles><title><style face="normal" font="default">Paediatric solar urticaria: A case series</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="1" Year="2018">2018/1/8</year></dates><abstract><style face="normal" font="default">Solar urticaria (SU) is a rare photodermatosis occurring in response to exposure to ultraviolet-A (UVA), ultraviolet-B (UVB), visible and rarely infrared light. The condition typically affects adults (median age of onset 35 years),(1) with only one report of SU occurring in a 2-year-old.(2) Here we present five cases of SU occurring in childhood. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - LetterCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.16325</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29315482">PM:29315482</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20180108-FityanA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20180108-FityanA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180108, Fityan A</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.16325</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43784</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Thomson,J.</style></author><author><style face="normal" font="default"> Wernham,A.G.H.</style></author><author><style face="normal" font="default"> Williams,H.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, The Royal London Hospital, Barts Health NHS Trust, London, U.KDepartment of Dermatology, University Hospitals Birmingham NHS Trust, Birmingham, U.KCentre of Evidence-Based Dermatology, King's Meadow Campus, University of Nottingham, Nottingham, U.K</style></auth-address><titles><title><style face="normal" font="default">Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="1" Year="2018">2018/1/6</year></dates><abstract><style face="normal" font="default">AIM: Blauvelt et al. (The Lancet 2017; 389: 2287-303) aimed to compare the long-term efficacy and safety of dupilumab with medium-potency topical corticosteroids (TCS) versus placebo with TCS in adults with moderate-to-severe atopic dermatitis (AD). SETTING AND DESIGN: This multicentre randomised, double-blinded, placebo-controlled trial was conducted in hospitals, clinics and academic institutions across 161 sites in 14 countries. STUDY EXPOSURE: Adults with moderate-to-severe AD were randomly assigned (3:1:3) to receive subcutaneous dupilumab 300mg once weekly (qw) plus TCS, dupilumab 300mg every 2 weeks (q2w) plus TCS, or placebo plus TCS until week-52. PRIMARY OUTCOME MEASURES: Co-primary efficacy endpoints were patients (%) achieving Investigator's Global Assessment (IGA) 0/1 and 2-points or higher improvement from baseline, and Eczema Area and Severity Index 75% improvement from baseline (EASI-75) at week-16. RESULTS: 740 patients were included in the trial: 319 were randomly assigned to dupilumab qw, 106 to dupilumab q2w and 315 to the placebo arm. At week-16, more patients in the dupilumab groups achieved the co-primary endpoints: IGA 0/1 (39% [125 patients] qw dosing, 39% [41 patients] q2w dosing vs 12% [39 patients] receiving placebo; p&lt;0.0001) and EASI-75 (64% [204] and 69% [73] vs 23% [73]; p&lt;0.0001). Whilst no new safety signals were identified, adverse effects (AEs) were noted in 261 (83%) in those receiving dupilumab qw plus TCS, 97 (88%) dupilumab q2w plus TCS and 266 (84%) for placebo plus TCS. Rates of conjunctivitis, injection site reactions and local herpes simplex infections were higher in the dupilumab groups compared with placebo. CONCLUSIONS: Blauvelt et al. concluded that dupilumab treatment added to TCS improved AD up to week-52 compared with TCS alone, and also demonstrated acceptable safety. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.16317</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29315479">PM:29315479</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20180106-ThomsonJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20180106-ThomsonJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180106, Thomson J</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.16317</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43785</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Castellano-Martinez,A.</style></author><author><style face="normal" font="default"> Rodriguez-Gonzalez,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">1Department of Pediatrics,Hospital Universitario Puerta del Mar,Cadiz,Spain2Department of Pediatric Cardiology,Hospital Universitario Puerta del Mar,Cadiz,Spain</style></auth-address><titles><title><style face="normal" font="default">Coronary artery spasm due to intravenous atropine infusion in a child: possible Kounis syndrome</style></title><secondary-title><style face="normal" font="default">Cardiol Young</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Cardiol Young</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="1" Year="2018">2018/1/10</year></dates><abstract><style face="normal" font="default">Coronary vasospasm can result from silent myocardial ischaemia to sudden death. There are many precipitant factors including different pharmacological agents. Kounis syndrome is defined by acute coronary syndromes associated with anaphylactic or anaphylactoid reactions. We report, to the best of our knowledge, the first paediatric case of Kounis syndrome due to intravenous atropine</style></abstract><notes><style face="normal" font="default">IS - 1467-1107 (Electronic)IS - 1047-9511 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1017/S1047951117002785</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29316984">PM:29316984</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cardiol Young\20180110-CastellanoMartinezA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cardiol Young\20180110-CastellanoMartinezA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180110, Castellano-Martinez A</style></custom2><misc3><style face="normal" font="default">10.1017/S1047951117002785</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43786</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Prunicki,M.</style></author><author><style face="normal" font="default"> Stell,L.</style></author><author><style face="normal" font="default"> Dinakarpandian,D.</style></author><author><style face="normal" font="default"> de Planell-Saguer,M.</style></author><author><style face="normal" font="default"> Lucas,R.W.</style></author><author><style face="normal" font="default"> Hammond,S.K.</style></author><author><style face="normal" font="default"> Balmes,J.R.</style></author><author><style face="normal" font="default"> Zhou,X.</style></author><author><style face="normal" font="default"> Paglino,T.</style></author><author><style face="normal" font="default"> Sabatti,C.</style></author><author><style face="normal" font="default"> Miller,R.L.</style></author><author><style face="normal" font="default"> Nadeau,K.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, CA 94305 USA.USA.0000000419368956grid.168010.e</style></auth-address><titles><title><style face="normal" font="default">Exposure to NO2, CO, and PM2.5 is linked to regional DNA methylation differences in asthma</style></title><secondary-title><style face="normal" font="default">Clin Epigenetics</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Epigenetics</style></abbr-1></periodical><pages end="" start="2">2-</pages><volume><style face="normal" font="default">10</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="default">Background: DNA methylation of CpG sites on genetic loci has been linked to increased risk of asthma in children exposed to elevated ambient air pollutants (AAPs). Further identification of specific CpG sites and the pollutants that are associated with methylation of these CpG sites in immune cells could impact our understanding of asthma pathophysiology. In this study, we sought to identify some CpG sites in specific genes that could be associated with asthma regulation (Foxp3 and IL10) and to identify the different AAPs for which exposure prior to the blood draw is linked to methylation levels at these sites. We recruited subjects from Fresno, California, an area known for high levels of AAPs. Blood samples and responses to questionnaires were obtained (n = 188), and in a subset of subjects (n = 33), repeat samples were collected 2 years later. Average measures of AAPs were obtained for 1, 15, 30, 90, 180, and 365 days prior to each blood draw to estimate the short-term vs. long-term effects of the AAP exposures. Results: Asthma was significantly associated with higher differentially methylated regions (DMRs) of the Foxp3 promoter region (p = 0.030) and the IL10 intronic region (p = 0.026). Additionally, at the 90-day time period (90 days prior to the blood draw), Foxp3 methylation was positively associated with NO2, CO, and PM2.5 exposures (p = 0.001, p = 0.001, and p = 0.012, respectively). In the subset of subjects retested 2 years later (n = 33), a positive association between AAP exposure and methylation was sustained. There was also a negative correlation between the average Foxp3 methylation of the promoter region and activated Treg levels (p = 0.039) and a positive correlation between the average IL10 methylation of region 3 of intron 4 and IL10 cytokine expression (p = 0.030). Conclusions: Short-term and long-term exposures to high levels of CO, NO2, and PM2.5 were associated with alterations in differentially methylated regions of Foxp3. IL10 methylation showed a similar trend. For any given individual, these changes tend to be sustained over time. In addition, asthma was associated with higher differentially methylated regions of Foxp3 and IL10</style></abstract><notes><style face="normal" font="default">IS - 1868-7083 (Electronic)IS - 1868-7075 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1186/s13148-017-0433-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29317916">PM:29317916</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Epigenetics\2018-10-2.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Epigenetics\2018-10-2.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, Prunicki M</style></custom2><misc3><style face="normal" font="default">10.1186/s13148-017-0433-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43787</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Turan,N.</style></author><author><style face="normal" font="default"> Edwards,M.J.</style></author><author><style face="normal" font="default"> Bates,S.</style></author><author><style face="normal" font="default"> Shaw,D.</style></author><author><style face="normal" font="default"> Chung,K.F.</style></author><author><style face="normal" font="default"> Loza,M.J.</style></author><author><style face="normal" font="default"> James,A.</style></author><author><style face="normal" font="default"> Van Oosterhout,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">GlaxoSmithKline Respiratory R&amp;D, Stevenage, UK</style></auth-address><titles><title><style face="normal" font="default">IL-6 pathway upregulation in subgroup of severe asthma is associated with neutrophilia and poor lung function</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="1" Year="2018">2018/1/6</year></dates><abstract><style face="normal" font="default">We have investigated the IL-6 pathway in the severe asthma phenotypes using U-BIOPRED database. A subset of severe asthma patients has increased IL6R mRNA levels and IL-6 protein levels in the sputum. This sub-population is highly neutrophilic and has poorer lung function. These neutrophilic patients have a high unmet medical need and they could potentially benefit from therapy targeting IL-6. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - LetterCO - United Kingdom -CO - United States -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13085</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29315928">PM:29315928</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20180106-TuranN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20180106-TuranN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180106, Turan N</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13085</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43788</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Karayama,M.</style></author><author><style face="normal" font="default"> Inui,N.</style></author><author><style face="normal" font="default"> Mori,K.</style></author><author><style face="normal" font="default"> Kono,M.</style></author><author><style face="normal" font="default"> Hozumi,H.</style></author><author><style face="normal" font="default"> Suzuki,Y.</style></author><author><style face="normal" font="default"> Furuhashi,K.</style></author><author><style face="normal" font="default"> Hashimoto,D.</style></author><author><style face="normal" font="default"> Enomoto,N.</style></author><author><style face="normal" font="default"> Fujisawa,T.</style></author><author><style face="normal" font="default"> Nakamura,Y.</style></author><author><style face="normal" font="default"> Watanabe,H.</style></author><author><style face="normal" font="default"> Suda,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan</style></auth-address><titles><title><style face="normal" font="default">Respiratory impedance is correlated with airway narrowing in asthma using three-dimensional computed tomography</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="1" Year="2018">2018/1/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Respiratory impedance comprises the resistance and reactance of the respiratory system, and can provide detailed information on respiratory function. However, details of the relationship between impedance and morphological airway changes in asthma are unknown. OBJECTIVE: We aimed to evaluate the correlation between imaging-based airway changes and respiratory impedance in patients with asthma. METHODS: Respiratory impedance and spirometric data were evaluated in 72 patients with asthma and 29 reference subjects. We measured the intraluminal area (Ai) and wall thickness (WT) of third- to sixth-generation bronchi using three-dimensional computed tomographic analyses, and values were adjusted by body surface area (BSA, Ai/BSA, and WT/the square root ( radical) of BSA). RESULTS: Asthma patients had significantly increased respiratory impedance, decreased Ai/BSA, and increased WT/ radicalBSA, as was the case in those without airflow limitation as assessed by spirometry. Ai/BSA was inversely correlated with respiratory resistance at 5 Hz (R5) and 20 Hz (R20). R20 had a stronger correlation with Ai/BSA than did R5. Ai/BSA was positively correlated with forced expiratory volume in 1 second/forced vital capacity ratio, percent predicted forced expiratory volume in 1 second, and percent predicted mid-expiratory flow. WT/ radicalBSA had no significant correlation with spirometry or respiratory impedance. CONCLUSIONS &amp; CLINICAL RELEVANCE: Respiratory resistance is associated with airway narrowing. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13083</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29315896">PM:29315896</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20180106-KarayamaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20180106-KarayamaM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180106, Karayama M</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13083</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43789</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Diver,S.</style></author><author><style face="normal" font="default"> Russell,R.J.</style></author><author><style face="normal" font="default"> Brightling,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute for Lung Health, Leicester NIHR Biomedical Research Centre, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK</style></auth-address><titles><title><style face="normal" font="default">New and emerging drug treatments for severe asthma</style></title><secondary-title><style face="normal" font="default">Clin Exp Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Allergy</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="1" Year="2018">2018/1/8</year></dates><abstract><style face="normal" font="default">Asthma is a common chronic inflammatory condition of the airways affecting over 300 million people worldwide. In 5-10% of cases it is severe, with disproportionate healthcare resource utilisation including costs associated with frequent exacerbations and the long-term health effects of systemic steroids. Characterisation of inflammatory pathways in severe asthma has led to development of targeted biological and small molecule therapies which aim to achieve disease control whilst minimising corticosteroid-associated morbidity. Herein we review currently licensed agents and those in development, and speculate how drug therapy for severe asthma might evolve and impact on clinical outcomes in the near future. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1365-2222 (Electronic)IS - 0954-7894 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/cea.13086</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29315966">PM:29315966</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Allergy\20180108-DiverS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Allergy\20180108-DiverS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180108, Diver S</style></custom2><misc3><style face="normal" font="default">10.1111/cea.13086</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43790</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Zbiciak-Nylec,M.</style></author><author><style face="normal" font="default"> Wcislo-Dziadecka,D.</style></author><author><style face="normal" font="default"> Kasprzyk,M.</style></author><author><style face="normal" font="default"> Kulig,A.</style></author><author><style face="normal" font="default"> Laszczak,J.</style></author><author><style face="normal" font="default"> Noworyta,M.</style></author><author><style face="normal" font="default"> Adamus,S.</style></author><author><style face="normal" font="default"> Brzezinska-Wcislo,L.</style></author><author><style face="normal" font="default"> Rogala,B.</style></author><author><style face="normal" font="default"> Brzoza,Z.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland</style></auth-address><titles><title><style face="normal" font="default">Overweight and obesity may play a role in the pathogenesis of chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default">Clin Exp Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Exp Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="1" Year="2018">2018/1/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic spontaneous urticaria (CSU) is one of the commonest diseases in allergological and dermatological practice. It constitutes an interdisciplinary problem, and its pathogenesis is not always easily determined. It has been suggested that metabolic syndrome and hyperlipidaemia are more frequent in patients with CSU, but the influence of overweight and obesity on the development of CSU has not been thoroughly investigated. AIM: To assess the association between body parameters and the development of CSU. METHODS: The study enrolled 85 patients with CSU, who were divided into three subgroups: patients whose only symptoms were weals, patients whose only symptom was angio-oedema, and patients with urticaria and accompanying angio-oedema. Mean weight, height, body mass index (BMI), body surface area, disease duration and age of disease onset were recorded RESULTS: There was a statistically significant association between CSU and heavier weight, higher BMI, greater affected body surface area and older age at disease onset. Subjects with higher BMI values had a tendency towards longer disease duration. There were no statistically significant differences between the three subgroups. CONCLUSIONS: Our results suggest that CSU, especially if of long duration, may be associated with overweight and obesity, while increased body mass can result in later onset of urticaria symptoms. Further analyses to confirm the presented results and possible association between obesity and CSU occurrence are needed</style></abstract><notes><style face="normal" font="default">IS - 1365-2230 (Electronic)IS - 0307-6938 (Linking)LA - engPT - Journal ArticleCO - POland -</style></notes><work-type><style face="normal" font="default">10.1111/ced.13368</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29327369">PM:29327369</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Dermatol\20180112-ZbiciakNylecM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Dermatol\20180112-ZbiciakNylecM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180112, Zbiciak-Nylec M</style></custom2><misc3><style face="normal" font="default">10.1111/ced.13368</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43791</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ariaee,N.</style></author><author><style face="normal" font="default"> Zarei,S.</style></author><author><style face="normal" font="default"> Mohamadi,M.</style></author><author><style face="normal" font="default"> Jabbari,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Research Center, Ghaem Hospital, Mashhad University of Medical Sciences, Shariati Square, Mashhad, Iran.</style></auth-address><titles><title><style face="normal" font="default">Amelioration of patients with chronic spontaneous urticaria in treatment with vitamin D supplement</style></title><secondary-title><style face="normal" font="default">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Mol Allergy</style></full-title></periodical><pages end="" start="22">22-</pages><volume><style face="normal" font="default">15</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Spontaneous urticaria is a common allergic skin condition affecting 0.5-1% of individuals and may burden on health care expenditure or may be associated with remarkable morbidity. Aim: In this study, we measured the effect of vitamin D supplementation in patients with a diagnosis of CSU. Furthermore, quality of life and cytokine changes were evaluated. Methods: The clinical trial was conducted on 20 patients with idiopathic chronic urticaria. Vitamin D was administered orally for 8 weeks and disease activity was measured pre- and post-treatment using USS and DLQI. On the other hand expressions of IL-17, IL-10, Foxp3, and TGF-beta by Real-time RT-PCR were assessed. Results: USS questionnaire showed that severity of idiopathic urticaria after the intervention, which compared with the first day reached a significant 55% reduction. The DLQI quality of life questionnaire 2 months after treatment showed 55% improvement. Along with the significant improvement of clinical symptoms, use of vitamin D increase FOXP3 gene expression and downregulation of IL-10, TGF-B, and FOXP3, IL-17, but these changes were not statistically significant. Limitation: These might happen due to lack of enrolled population in the investigation. Conclusion: Vitamin D can be used along with standard medical care and it's a safe and cost-effective method for the treatment of chronic urticaria with deficiency of vitamin D</style></abstract><notes><style face="normal" font="default">IS - 1476-7961 (Print)IS - 1476-7961 (Linking)LA - engPT - Journal ArticleCO - Iran -</style></notes><work-type><style face="normal" font="default">10.1186/s12948-017-0078-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29299028">PM:29299028</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Exp Dermatol\2017-15-22.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Exp Dermatol\2017-15-22.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171222, Ariaee N</style></custom2><misc3><style face="normal" font="default">10.1186/s12948-017-0078-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43792</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ferguson,A.E.</style></author><author><style face="normal" font="default"> Mukkada,V.A.</style></author><author><style face="normal" font="default"> Fulkerson,P.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 45229, USA</style></auth-address><titles><title><style face="normal" font="default">Pediatric Eosinophilic Esophagitis Endotypes: Are We Closer to Predicting Treatment Response?</style></title><secondary-title><style face="normal" font="default">Clin Rev Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Rev Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="21" Month="12" Year="2017">2017/12/21</year></dates><abstract><style face="normal" font="default">Eosinophilic esophagitis (EoE) is a chronic, food antigen-driven gastrointestinal disease that is characterized by esophageal eosinophilia. Currently, there are no Food and Drug Administration (FDA)-approved treatments for EoE, but the two most commonly prescribed therapies include topical corticosteroids and food elimination diets. Clinical trials have revealed a significant proportion of cases that are resistant to topical corticosteroids, and although we define EoE as a food antigen-driven disease, not all patients with EoE respond to elimination diets or even elemental diets. The varied response to treatments highlights the heterogeneity of EoE and the need for new treatment strategies. Despite the clinical differences in treatment response, predicting the outcome remains difficult since factors including age, histologic severity at diagnosis, atopic history, and anthropometrics are not predictive of treatment response. In our practice at an academic pediatric referral center, we observe distinct clinical EoE phenotypes, including cases with atopy, connective tissue disorders, or responsiveness to a proton pump inhibitor. Similar to the work in progress with asthma, stratification of patients with EoE by clinical phenotypes and/or molecular endotypes will likely assist with therapy selection and prediction of natural history. Molecular analysis with gene expression panels also shows promise in helping us classify patients based on molecular endotypes. In additional to the clinical and molecular classifications, more accurate histologic diagnostic criteria for EoE may help us tease out small differences between patient cohorts. Despite the leaps in knowledge over the past decade regarding EoE pathogenesis, it remains a challenge to predict the response to treatment. Future studies focused on molecular, genetic, and immunologic analyses of larger patient cohorts are needed to assist in identifying EoE phenotypes and endotypes as we attempt to improve patient outcomes in pediatric EoE</style></abstract><notes><style face="normal" font="default">IS - 1559-0267 (Electronic)IS - 1080-0549 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s12016-017-8658-8</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29270819">PM:29270819</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Rev Allergy Immunol\20171221-FergusonAE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Rev Allergy Immunol\20171221-FergusonAE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171221, Feruson AE</style></custom2><misc3><style face="normal" font="default">10.1007/s12016-017-8658-8</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43793</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Munoz-Mendoza,D.</style></author><author><style face="normal" font="default"> Chapa-Rodriguez,A.</style></author><author><style face="normal" font="default"> Bahna,S.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Allergy and Immunology Section, Louisiana State University Health Sciences Center in Shreveport, 1501 Kings Highway, Shreveport, LA, 71130-3932, USA</style></auth-address><titles><title><style face="normal" font="default">Eosinophilic Esophagitis Clinical Manifestations and Differential Diagnosis</style></title><secondary-title><style face="normal" font="default">Clin Rev Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Rev Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="30" Month="12" Year="2017">2017/12/30</year></dates><abstract><style face="normal" font="default">As a chronic inflammatory disease with eosinophilic infiltrate of the esophagus, eosinophilic esophagitis (EoE) causes a variety of gastrointestinal (GI) clinical manifestations. None of the symptoms, endoscopic features, or biopsy findings is pathognomonic of the disease, even with high degrees of esophageal eosinophilia. The pathogenesis has been explored by several studies, yet it still far from being completely understood. Evidence supports a role of allergen-driven Th2 lymphocyte mechanism, though not in every patient. This article addresses the disease's clinical manifestations, endoscopic findings, diagnosis, and differential diagnoses. In addition to the current diagnostic criteria, we summarize some recently emerging procedures that promise of enhancing more precise diagnosis and institution of early appropriate management, with consequent better quality of life and reduction of complications</style></abstract><notes><style face="normal" font="default">IS - 1559-0267 (Electronic)IS - 1080-0549 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s12016-017-8663-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29290036">PM:29290036</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Rev Allergy Immunol\20171230-MunozMendozaD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Rev Allergy Immunol\20171230-MunozMendozaD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171230, Munoz-Mendoza D</style></custom2><misc3><style face="normal" font="default">10.1007/s12016-017-8663-y</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43794</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ridolo,E.</style></author><author><style face="normal" font="default"> Incorvaia,C.</style></author><author><style face="normal" font="default"> Martignago,I.</style></author><author><style face="normal" font="default"> Caminati,M.</style></author><author><style face="normal" font="default"> Canonica,G.W.</style></author><author><style face="normal" font="default"> Senna,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Medicine and Surgery Department, University of Parma, Parma, Italy</style></auth-address><titles><title><style face="normal" font="default">Sex in Respiratory and Skin Allergies</style></title><secondary-title><style face="normal" font="default">Clin Rev Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Rev Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="1" Year="2018">2018/1/6</year></dates><abstract><style face="normal" font="default">A bulk of literature demonstrated that respiratory allergy, and especially asthma, is prevalent in males during childhood, while it becomes more frequent in females from adolescence, i.e., after menarche, to adulthood. The mechanisms underlying the difference between females and males are the effects on the immune response of female hormones and in particular the modulation of inflammatory response by estrogens, as well as the result of the activity of various cells, such as dendritic cells, innate lymphoid cells, Th1, Th2, T regulatory (Treg) and B regulatory (Bregs) cells, and a number of proteins and cytokines, which include interleukin (IL)-4, IL-5, IL-10, and IL-13. As far as sexual dimorphism is concerned, a gender difference in the expression profiles of histamine receptors and of mast cells was demonstrated in experimental studies. A critical phase of hormone production is the menstrual cycle, which often is associated with asthma deterioration, as assessed by worsening of clinical symptoms and increase of bronchial hyperresponsiveness. In asthmatic woman, there is a high risk to develop more severe asthma during menstruation. The higher prevalence of asthma in females is confirmed also in the post-menopause age, but the underlying mechanisms are not yet understood. In pregnancy, asthma may worsen but may also improve or remain unchanged, with no significant difference in frequency of these three outcomes. For allergic rhinitis, the available studies indicate, likewise asthma, a male predominance in prevalence in childhood that shifts to a female predominance in adolescence and adulthood, but further investigation is needed</style></abstract><notes><style face="normal" font="default">IS - 1559-0267 (Electronic)IS - 1080-0549 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1007/s12016-017-8661-0</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29306980">PM:29306980</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Rev Allergy Immunol\20180106-RidoloE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Rev Allergy Immunol\20180106-RidoloE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180106, Ridolo E</style></custom2><misc3><style face="normal" font="default">10.1007/s12016-017-8661-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43795</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Davis,B.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Division of Immunology, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA, 52246, USA.</style></auth-address><titles><title><style face="normal" font="default">Pathophysiology of Eosinophilic Esophagitis</style></title><secondary-title><style face="normal" font="default">Clin Rev Allergy Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Rev Allergy Immunol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="1" Year="2018">2018/1/13</year></dates><abstract><style face="normal" font="default">Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the esophagus associated with an atopic predisposition which appears to be increasing in prevalence over the last few decades. Symptoms stem from fibrosis, swelling, and smooth muscle dysfunction. In the past two decades, the etiology of EoE has been and is continuing to be revealed. This review provides an overview of the effects of genetics, environment, and immune function including discussions that touch on microbiome, the role of diet, food allergy, and aeroallergy. The review further concentrates on the pathophysiology of the disease with particular focus on the important concepts of the molecular etiology of EoE including barrier dysfunction and allergic hypersensitivity</style></abstract><notes><style face="normal" font="default">IS - 1559-0267 (Electronic)IS - 1080-0549 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1007/s12016-017-8665-9.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29332138">PM:29332138</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Rev Allergy Immunol\20180113-DavisBP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Rev Allergy Immunol\20180113-DavisBP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180113, Davis BP</style></custom2><misc3><style face="normal" font="default">10.1007/s12016-017-8665-9.</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43796</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hellings,P.W.</style></author><author><style face="normal" font="default"> Borrelli,D.</style></author><author><style face="normal" font="default"> Pietikainen,S.</style></author><author><style face="normal" font="default"> Agache,I.</style></author><author><style face="normal" font="default"> Akdis,C.</style></author><author><style face="normal" font="default"> Bachert,C.</style></author><author><style face="normal" font="default"> Bewick,M.</style></author><author><style face="normal" font="default"> Botjes,E.</style></author><author><style face="normal" font="default"> Constantinidis,J.</style></author><author><style face="normal" font="default"> Fokkens,W.</style></author><author><style face="normal" font="default"> Haahtela,T.</style></author><author><style face="normal" font="default"> Hopkins,C.</style></author><author><style face="normal" font="default"> Illario,M.</style></author><author><style face="normal" font="default"> Joos,G.</style></author><author><style face="normal" font="default"> Lund,V.</style></author><author><style face="normal" font="default"> Muraro,A.</style></author><author><style face="normal" font="default"> Pugin,B.</style></author><author><style face="normal" font="default"> Seys,S.</style></author><author><style face="normal" font="default"> Somekh,D.</style></author><author><style face="normal" font="default"> Stjarne,P.</style></author><author><style face="normal" font="default"> Valiulis,A.</style></author><author><style face="normal" font="default"> Valovirta,E.</style></author><author><style face="normal" font="default"> Bousquet,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otorhinolaryngology, University Hospitals Leuven, KU Leuven, Louvain, Belgium.EUFOREA aisbl, 132, Ave. Brand Whitlock, 1200 Brussels, Belgium</style></auth-address><titles><title><style face="normal" font="default">European Summit on the Prevention and Self-Management of Chronic Respiratory Diseases: report of the European Union Parliament Summit (29 March 2017)</style></title><secondary-title><style face="normal" font="default">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Transl Allergy</style></full-title></periodical><pages end="" start="49">49-</pages><volume><style face="normal" font="default">7</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">On March 29, 2017, a European Summit on the Prevention and Self-Management of Chronic Respiratory Diseases (CRD) was organized by the European Forum for Research and Education in Allergy and Airway Diseases. The event took place in the European Parliament of Brussels and was hosted by MEP David Borrelli and MEP Sirpa Pietikainen. The aim of the Summit was to correspond to the needs of the European Commission and of patients suffering from CRD to join forces in Europe for the prevention and self-management. Delegates of the European Rhinologic Society, European Respiratory Society, European Academy of Allergy and Clinical Immunology, European Academy of Paediatrics, and European Patients Organization EFA all lectured on their vision and action plan to join forces in achieving adequate prevention and self-management of CRD in the context of Precision Medicine. Recent data highlight the preventive capacity of education on optimal care pathways for CRD. Self-management and patient empowerment can be achieved by novel educational on-line materials and by novel mobile health tools enabling patients and doctors to monitor and optimally treat CRDs based on the level of control. This report summarizes the contributions of the representatives of different European academic stakeholders in the field of CRD</style></abstract><notes><style face="normal" font="default">IS - 2045-7022 (Print)IS - 2045-7022 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Belgium -CO - Netherlands -CO - Romania -CO - Switzerland -CO - United Kingdom -CO - Greece -CO - Finland -CO - Italy -CO - Finland -CO - Sweden -CO - Lithuania -CO - France -</style></notes><work-type><style face="normal" font="default">10.1186/s13601-017-0186-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29299230">PM:29299230</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-49.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Transl Allergy\2017-7-49.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171227, Hellings PW</style></custom2><misc3><style face="normal" font="default">10.1186/s13601-017-0186-3</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43797</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hofmann,M.A.</style></author><author><style face="normal" font="default"> Gimenez-Arnau,A.</style></author><author><style face="normal" font="default"> Aberer,W.</style></author><author><style face="normal" font="default"> Bindslev-Jensen,C.</style></author><author><style face="normal" font="default"> Zuberbier,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Charite-Universitatsmedizin Berlin, Chariteplatz 1, 10117 Berlin, Germany.</style></auth-address><titles><title><style face="normal" font="default">MI (2-methyl-4-isothiazolin-3-one) contained in detergents is not detectable in machine washed textiles</style></title><secondary-title><style face="normal" font="default">Clin Transl Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Transl Allergy</style></full-title></periodical><pages end="" start="1">1-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="default">Background: European legislation has banned the preservative methylisothiazolinone (MI) from inclusion in leave-on cosmetics. However, the risk for allergic reactions depends on exposure. The aim of this study was to determine the risk of MI in laundry detergents for household machine washing. Methods: Different formulations of laundry detergents with commercial MI levels, up to one thousand ppm were used and three different types of clothes were washed in a normal household machine setting one time and 10 times. The level of MI was measured by HPLC. Results: While MI could be retrieved in the positive control of clothes drenched with washing powder but not washed afterwards, MI could not be detected in any specimen of clothes washed under household conditions. The detection limit was 0.5 ppm. Conclusion: It is important to discuss the difference of risk and hazard. While MI clearly is a high hazard as a strong contact allergen, the risk depends on exposure. Regarding the risk of exposure levels for the consumer to MI in clothes it can be stated that the use of MI in laundry detergents is safe for the consumer if these products are used according to the instructions in the normal household setting machine wash</style></abstract><notes><style face="normal" font="default">IS - 2045-7022 (Print)IS - 2045-7022 (Linking)LA - engPT - Journal ArticleCO - Germany -CO - Denmark -CO - Spain -CO - Austria -</style></notes><work-type><style face="normal" font="default">10.1186/s13601-017-0187-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29312657">PM:29312657</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Transl Allergy\2018-8-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Transl Allergy\2018-8-1.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, Hofmann MA</style></custom2><misc3><style face="normal" font="default">10.1186/s13601-017-0187-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43798</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schubert,S.</style></author><author><style face="normal" font="default"> Lessmann,H.</style></author><author><style face="normal" font="default"> Schnuch,A.</style></author><author><style face="normal" font="default"> Uter,W.</style></author><author><style face="normal" font="default"> Geier,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Information Network of Departments of Dermatology (IVDK), University of Gottingen, 37075, Gottingen, Germany</style></auth-address><titles><title><style face="normal" font="default">Factors associated with p-phenylenediamine sensitization: data from the Information Network of Departments of Dermatology, 2008-2013</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="1" Year="2018">2018/1/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Risk factors for p-phenylenediamine (PPD) sensitization include the use of hair dyes, the application of temporary black henna tattoos, working as a hairdresser, and, possibly, exposure to hair dye pretests. OBJECTIVES: To quantify the impact of these (putative) risk factors on PPD sensitization. METHODS: Six items related to PPD exposure were added to the routine Information Network of Departments of Dermatology questionnaire from 2008 to 2013. A retrospective analysis of data from 4314 patients tested with PPD 1% pet. was conducted. RESULTS: Of the PPD-positive patients (n = 271), 80% had their hair dyed, and, of these, 57% subsequently developed scalp dermatitis, whereas only 11% had had a henna tattoo. The self-administrated pretest with hair dye was performed by only a few patients, precluding a more detailed analysis. Hair dyeing [odds ratio (OR) 6.0; 95% confidence interval (CI): 3.9-9.4], henna tattoos (OR 2.4; 95%CI: 1.5-3.7) and being a hairdresser (OR 2.1; 95%CI: 1.3-3.2) increased the risk of PPD sensitization. Neither dyeing of own hair nor application of a temporary henna tattoo seemed to affect PPD sensitization in hairdressers. p-Aminoaryl compounds more often gave positive reactions in patients with henna tattoo. CONCLUSIONS: Hair dyeing is the major risk factor for PPD sensitization in this clinical setting, and application of a temporary black henna tattoo may also lead to (strong) PPD sensitization</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12920</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29322532">PM:29322532</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20180111-SchubertS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20180111-SchubertS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180111, Schubert S</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12920</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43799</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">van der Heiden,J.</style></author><author><style face="normal" font="default"> Agner,T.</style></author><author><style face="normal" font="default"> Rustemeyer,T.</style></author><author><style face="normal" font="default"> Clemmensen,K.K.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Bispebjerg University Hospital, 2400, Copenhagen, Denmark</style></auth-address><titles><title><style face="normal" font="default">Hyperkeratotic hand eczema compared to other subgroups of hand eczema - a retrospective study with a follow-up questionnaire</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="1" Year="2018">2018/1/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Only a few clinical trials on hand eczema have included further classification into subtypes, and there is a need for studies evaluating the present classifications. OBJECTIVES: To examine differences in demographic factors, lifestyle factors and severity between subgroups of hand eczema patients, with a focus on hyperkeratotic hand eczema. METHODS: This was a retrospective study including hand eczema patients referred to the outpatient dermatological clinic, Bispebjerg Hospital, between January 2013 and July 2014. The study comprises information on subdiagnoses, treatment and foot eczema from patient files, as well as a follow-up questionnaire. RESULTS: A total of 120 patients were included, 10 of whom were diagnosed with hyperkeratotic hand eczema. A significantly higher proportion of the patients with hyperkeratotic hand eczema were male (p = 0.002) and received systemic or ultraviolet (UV) treatment (p = 0.026). The frequency of tobacco smoking was significantly higher in patients with hyperkeratotic hand eczema (p = 0.016), as well as in the other subgroups combined (p = 0.049), than in the background population. CONCLUSIONS: Studies evaluating the subdiagnoses of hand eczema are needed, to further validate the classification system, and to provide more detailed information about demographic factors, severity and possible risk factors for different subgroups of hand eczema</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12945</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29314088">PM:29314088</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20180104-vanderHeidenJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20180104-vanderHeidenJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180104, van der Heiden J</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12945</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43800</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Heratizadeh,A.</style></author><author><style face="normal" font="default"> Werfel,T.</style></author><author><style face="normal" font="default"> Schubert,S.</style></author><author><style face="normal" font="default"> Geier,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Immunodermatology and Allergy Research, Department of Dermatology and Allergy, Hannover Medical School, 30625 Hannover, Germany</style></auth-address><titles><title><style face="normal" font="default">Contact sensitization in dental technicians with occupational contact dermatitis. Data of the Information Network of Departments of Dermatology (IVDK) 2001-2015</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="1" Year="2018">2018/1/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Dental technicians (DTs) are at increased risk for allergic contact sensitization. OBJECTIVES: To assess the current spectrum of occupational sensitization in DTs with occupational contact dermatitis (OCD). METHODS: A retrospective analysis of Information Network of Departments of Dermatology patch test data from the years 2001-2015 concerning DTs with OCD was performed. RESULTS: Patients of the study group (226 DTs with OCD) were significantly more often diagnosed with allergic contact dermatitis (37.6% versus 18.5%; p = 0.0002) than patients of the control group (124 DTs without OCD). In the study group, positive reactions were most frequently observed to methacrylates and/or acrylates (n = 67). Of these, 61 patients showed positive reactions to at least one of the five most frequent allergens in this group, namely 2-hydroxyethyl methacrylate, 2-hydroxypropyl methacrylate, methyl methacrylate, ethyl methacrylate, and/or ethylene glycol dimethacrylate. In contrast, no positive reactions to diurethane dimethacrylate (DUDMA) occurred. Among allergens of the German Contact Dermatitis Research Group series 'dental metals', positive reactions were less frequent and were mainly to palladium chloride (n = 6). CONCLUSIONS: The present data analysis showed that the sensitization spectrum and spectrum of cross-reactivity are largely unchanged as compared with the 1990s. It can be concluded that test recommendations are still valid and useful, except for the methacrylate DUDMA, which could be omitted</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12943</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29327359">PM:29327359</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20180112-HeratizadehA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20180112-HeratizadehA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180112, Heratizadeh A</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12943</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43801</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hedberg,Y.S.</style></author><author><style face="normal" font="default"> Erfani,B.</style></author><author><style face="normal" font="default"> Matura,M.</style></author><author><style face="normal" font="default"> Liden,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Environmental Medicine, Karolinska Institute, 171 77, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default">Chromium(III) release from chromium-tanned leather elicits allergic contact dermatitis: a use test study</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="1" Year="2018">2018/1/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chromium (Cr) is a common skin sensitizer. The use of Cr(VI) in leather is restricted in the EU, but that of Cr(III) is not. OBJECTIVES: To assess whether prolonged exposure to Cr-tanned leather with mainly Cr(III) release may elicit allergic contact dermatitis in Cr-allergic individuals. METHOD: Ten Cr-allergic subjects and 22 controls were patch tested with serial dilutions of Cr(III) and Cr(VI), and with leather samples. They then conducted a use test with a Cr-tanned and a Cr-free leather bracelet over a period of 3 weeks, for 12 h per day. Cr deposited on the skin from the bracelets was measured in the controls, and the diphenylcarbazide test for Cr(VI) and extraction tests for Cr(III) and Cr(VI) were conducted for the different leathers. RESULTS: Four of 10 Cr-allergic subjects developed positive reactions to the Cr-tanned bracelet within 7-21 days, whereas only 1 of 10 had a positive patch test reaction to this leather. Cr released from the Cr-tanned leather was most probably entirely Cr(III), with a quantifiable amount being deposited on the skin. CONCLUSIONS: This study strongly suggests that prolonged and repeated exposure to Cr-tanned leather with mainly Cr(III) release is capable of eliciting allergic contact dermatitis in Cr-allergic individuals</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12946</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29322530">PM:29322530</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20180111-HedbergYS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20180111-HedbergYS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180111, Hedberg YS</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12946</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43802</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gatica-Ortega,M.E.</style></author><author><style face="normal" font="default"> Pastor-Nieto,M.A.</style></author><author><style face="normal" font="default"> Gil-Redondo,R.</style></author><author><style face="normal" font="default"> Martinez-Lorenzo,E.R.</style></author><author><style face="normal" font="default"> Schoendorff-Ortega,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Dermatology Department, Toledo Hospital Complex, 45071 Toledo, Spain</style></auth-address><titles><title><style face="normal" font="default">Non-occupational allergic contact dermatitis caused by long-lasting nail polish kits for home use: 'the tip of the iceberg'</style></title><secondary-title><style face="normal" font="default">Contact Dermatitis</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Contact Dermatitis</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="1" Year="2018">2018/1/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic contact dermatitis (ACD) from (meth)acrylates caused by long lasting nail polish (also known as "permanent", "semi-permanent" or "gel nail polish") has been described both in occupational and non-occupational settings. Inexpensive kits for home use have been available for purchase in many stores or through the Internet. OBJECTIVE: To report on several further cases of consumers sensitised to these nail products. METHODS: Patch test results and evaluation of ingredient labelling of products brought in by the patients. RESULTS: Four new cases are presented. Three of the patients reacted to 2-hydroxypropyl methacrylate, 2-hydroxyethyl methacrylate and ethyleneglycol dimethacrylate (EGDMA), and all 4 to 2-hydroxy ethylacrylate. CONCLUSIONS: Acrylates are present in a wide range of products including medical materials. Sensitization from (meth)acrylates caused by a merely aesthetic procedure might eventually significantly impact health by jeopardizing access to several types of medical interventions. Policies should be implemented restricting the use of long-lasting nail polishes to qualified professionals and banning the indiscriminate sale of kits for home use</style></abstract><notes><style face="normal" font="default">IS - 1600-0536 (Electronic)IS - 0105-1873 (Linking)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1111/cod.12948</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29327355">PM:29327355</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Contact Dermatitis\20180112-GaticaOrtegaME.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Contact Dermatitis\20180112-GaticaOrtegaME.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180112, Gatica-Ortega ME</style></custom2><misc3><style face="normal" font="default">10.1111/cod.12948</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43803</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Varricchi,G.</style></author><author><style face="normal" font="default"> Marone,G.</style></author><author><style face="normal" font="default"> Spadaro,G.</style></author><author><style face="normal" font="default"> Russo,M.</style></author><author><style face="normal" font="default"> Granata,F.</style></author><author><style face="normal" font="default"> Genovese,A.</style></author><author><style face="normal" font="default"> Marone,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Via S. Pansini 5, 80131 Naples. Italy</style></auth-address><titles><title><style face="normal" font="default">Novel Biological Therapies in Severe Asthma: Targeting the Right Trait</style></title><secondary-title><style face="normal" font="default">Curr Med Chem</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Curr Med Chem</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="1" Year="2018">2018/1/9</year></dates><abstract><style face="normal" font="default">Asthma is a heterogeneous disease characterized by chronic airway inflammation that results in a wide spectrum of clinical manifestations. Patients with severe asthma represent a substantial share of consumption of healthcare resources and hospitalization. Moreover, these patients are at risk of increased morbidity and mortality. Recently, several phenotypes and endotypes of asthma have been identified. The identification of specific subtypes of asthma is fundamental for optimizing the clinical benefit of novel treatments. Although in most patients the disease can be controlled by some combination of pharmacologic agents, in some 5-10% of patients the disease remains uncontrolled. Several monoclonal antibodies (mAbs) targeting pathogenetic molecules (e.g., IgE, IL-5, IL-5Ra, IL-4, IL-13, TSLP) are currently available or under development for the treatment of different forms of severe type 2 asthma. The identification of diagnostic and predictive biomarkers (e.g., IgE, blood eosinophil count, FeNO, periostin, etc.) has revolutioned the field of targeted therapy in severe asthma. Monoclonal antibodies targeting Th2-driven inflammation are generally safe in adult patients with moderate-to-severe asthma. The long-term safety of these biologics is a relevant issue that should be addressed. Unfortunately, little is known about non-type 2 asthma. Further studies are needed to identify biomarkers to guide targeted therapies of different forms of non-type 2 asthma</style></abstract><notes><style face="normal" font="default">IS - 1875-533X (Electronic)IS - 0929-8673 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.2174/0929867325666180110094542</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29318959">PM:29318959</url></web-urls></urls><custom2><style face="normal" font="default">20180109, Varricchi G</style></custom2><misc3><style face="normal" font="default">10.2174/0929867325666180110094542</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43804</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nygaard,U.</style></author><author><style face="normal" font="default"> Vestergaard,C.</style></author><author><style face="normal" font="default"> Deleuran,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Venereology, Aarhus University Hospital, Aarhus, Denmark</style></auth-address><titles><title><style face="normal" font="default">Emerging Treatment Options in Atopic Dermatitis: Systemic Therapies</style></title><secondary-title><style face="normal" font="default">Dermatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatology</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="1" Year="2018">2018/1/11</year></dates><abstract><style face="normal" font="default">The pathogenesis of atopic dermatitis (AD) is multifactorial and intricate, and the clinical presentation of the condition varies greatly. Symptoms and severity depend on individual trigger factors and stage of the disease. The majority of AD patients are sufficiently treated with emollients in combination with existing topical or systemic therapies. Yet treatment failure with existing drugs and treatment options can be a significant clinical problem. New treatments are under development, and the majority of these new drugs focus on targeting a skewed immune response in AD. Novel therapeutic approaches, which target the pathways involved in the pathogenesis of AD, may provide a potentially more effective and less harmful approach to systemic therapy. These pharmaceutical agents are designed to narrowly modify or directly block a specific cellular signal or pro-inflammatory pathway. We review systemic drugs in the pipeline for AD. To make the review as current and pertinent as possible, we selected to focus on AD-related therapies available in the clinicaltrials.gov database with a first received date after January 1, 2014, up until May 31, 2017. We excluded therapies that could be categorized as either traditional Chinese medicine, herbal medicine, probiotics, histamine/leukotriene blockers, immuno-adsorption, or immunostimulants</style></abstract><notes><style face="normal" font="default">IS - 1421-9832 (Electronic)IS - 1018-8665 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1159/000484406</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29320765">PM:29320765</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Dermatology\20180111-NygaardU.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Dermatology\20180111-NygaardU.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180111, Nygaard U</style></custom2><misc3><style face="normal" font="default">10.1159/000484406</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43805</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Szebeni,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Nanomedicine Research and Education Center, Department of Pathophysiology, Semmelweis University and SeroScience Ltd, Budapest, Hungary</style></auth-address><titles><title><style face="normal" font="default">Mechanism of nanoparticle-induced hypersensitivity in pigs: complement or not complement?</style></title><secondary-title><style face="normal" font="default">Drug Discov Today</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Drug Discov Today</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="1" Year="2018">2018/1/8</year></dates><abstract><style face="normal" font="default">A recent study on nanoparticle-induced hypersensitivity reactions in pigs showed robust pulmonary intravascular macrophage clearance of Polybead((R)) carboxylate microspheres in mediating the adverse cardiopulmonary distress, irrespective of the ability of these particles to activate the Complement (C) system in vitro. Focusing on this observation, this article highlights the controversies in projecting in vitro C assay data to in vivo conditions and applying data on polystyrene particles to therapeutic nanopharmaceuticals. Based on overwhelming evidence of a role of anaphylatoxins in hypersensitivity reactions, the need to further explore the role of C activation in the reported and other reactions is highlighted. C-activation-related and C-independent pseudoallergies (CARPA and CIPA) can proceed simultaneously, as outlined by the 'double-hit' hypothesis</style></abstract><notes><style face="normal" font="default">IS - 1878-5832 (Electronic)IS - 1359-6446 (Linking)LA - engPT - Journal ArticleCO - Hungary -</style></notes><work-type><style face="normal" font="default">10.1016/j.drudis.2018.01.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29326077">PM:29326077</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Drug Discov Today\20180108-SzebeniJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Drug Discov Today\20180108-SzebeniJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180108, Szebeni J</style></custom2><misc3><style face="normal" font="default">10.1016/j.drudis.2018.01.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43806</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Park,H.J.</style></author><author><style face="normal" font="default"> Choi,W.S.</style></author><author><style face="normal" font="default"> Lee,W.Y.</style></author><author><style face="normal" font="default"> Choi,Y.</style></author><author><style face="normal" font="default"> Park,C.</style></author><author><style face="normal" font="default"> Kim,J.H.</style></author><author><style face="normal" font="default"> Hong,K.H.</style></author><author><style face="normal" font="default"> Song,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Stem Cell and Regenerative Biology, Konkuk University, 120 Neungdongro, Gwangjin-gu, Seoul 05029, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">A novel mouse model of atopic dermatitis that is T helper 2 (Th2)-polarized by an epicutaneous allergen</style></title><secondary-title><style face="normal" font="default">Environ Toxicol Pharmacol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Environ Toxicol Pharmacol</style></abbr-1></periodical><pages end="130" start="122">122-130</pages><volume><style face="normal" font="default">58</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="29" Month="12" Year="2017">2017/12/29</year></dates><abstract><style face="normal" font="default">The pathogenesis of atopic dermatitis (AD) involves T helper 2 (Th2) cells, and effective therapies remain elusive due to the paucity of animal models. We aimed to develop a mouse model of an immune system aberration caused by allergen. Experiments were conducted in two phases. In experiment 1, BALB/c mice were sensitized with one of four chemical allergens - toluene diisocyanate (TDI), hexamethylene diisocyanate (HDI), trimellitic anhydride (TMA), or 2,4-dinitrochlorobenzene (DNCB) - for 3 weeks. Based on results of experiment 1, immunological features were compared between TMA-sensitized BALB/c mice and NC/Nga mice, after exposure to mite extracts, harmful chemicals and detergents in experiment 2. Sensitization by allergen caused a large number of pathological changes in the skin, and an increase in mast cell number. TMA-sensitized BALB/c mice models showed higher sensitivity to an environmental allergen than NC/Nga mice did. Overall, the initial sensitization with TMA leads to disturbances in Th2-mediated immunity</style></abstract><notes><style face="normal" font="default">IS - 1872-7077 (Electronic)IS - 1382-6689 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.etap.2017.12.025</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29329020">PM:29329020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Environ Toxicol Pharmacol\2017-58-122-30.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Environ Toxicol Pharmacol\2017-58-122-30.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171229, Park HJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.etap.2017.12.025</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43807</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bosmans,G.</style></author><author><style face="normal" font="default"> Shimizu Bassi,G.</style></author><author><style face="normal" font="default"> Florens,M.</style></author><author><style face="normal" font="default"> Gonzalez-Dominguez,E.</style></author><author><style face="normal" font="default"> Matteoli,G.</style></author><author><style face="normal" font="default"> Boeckxstaens,G.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium</style></auth-address><titles><title><style face="normal" font="default">Cholinergic Modulation of Type 2 Immune Responses</style></title><secondary-title><style face="normal" font="default">Front Immunol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Immunol</style></abbr-1></periodical><pages end="" start="1873">1873-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">In recent years, the bidirectional relationship between the nervous and immune system has become increasingly clear, and its role in both homeostasis and inflammation has been well documented over the years. Since the introduction of the cholinergic anti-inflammatory pathway, there has been an increased interest in parasympathetic regulation of both innate and adaptive immune responses, including T helper 2 responses. Increasing evidence has been emerging suggesting a role for the parasympathetic nervous system in the pathophysiology of allergic diseases, including allergic rhinitis, asthma, food allergy, and atopic dermatitis. In this review, we will highlight the role of cholinergic modulation by both nicotinic and muscarinic receptors in several key aspects of the allergic inflammatory response, including barrier function, innate and adaptive immune responses, and effector cells responses. A better understanding of these cholinergic processes mediating key aspects of type 2 immune disorders might lead to novel therapeutic approaches to treat allergic diseases</style></abstract><notes><style face="normal" font="default">IS - 1664-3224 (Print)IS - 1664-3224 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Belgium -</style></notes><work-type><style face="normal" font="default">10.3389/fimmu.2017.01873</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29312347">PM:29312347</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Immunol\2017-8-1873.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Immunol\2017-8-1873.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171219, Bosmans G</style></custom2><misc3><style face="normal" font="default">10.3389/fimmu.2017.01873</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43808</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Agbenyefia,P.</style></author><author><style face="normal" font="default"> Shilliam,L.A.</style></author><author><style face="normal" font="default"> Stoicea,N.</style></author><author><style face="normal" font="default"> Roth,A.</style></author><author><style face="normal" font="default"> Moran,K.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesiology, OSU Wexner Medical Center, Columbus, OH, United States</style></auth-address><titles><title><style face="normal" font="default">Perioperative Management of a Patient with Cold Urticaria</style></title><secondary-title><style face="normal" font="default">Front Med (Lausanne)</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Med (Lausanne)</style></abbr-1></periodical><pages end="" start="222">222-</pages><volume><style face="normal" font="default">4</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Cold urticaria consists of an allergic immune response to cold temperatures with symptoms ranging from pruritic wheals to life-threatening angioedema, bronchospasm, or anaphylactic shock. Adequate planning to maintain normothermia perioperatively is vital due to impaired hypothalamic thermoregulation and overall depression of sympathetic outflow during deep sedation and general anesthesia. This case report describes the successful perioperative management of a 45-year-old female with a history of cold urticaria undergoing a laparoscopic Nissen fundoplication for refractory gastroesophageal reflux disease and discusses how to appropriately optimize the care of these patients</style></abstract><notes><style face="normal" font="default">IS - 2296-858X (Print)IS - 2296-858X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.3389/fmed.2017.00222</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29326933">PM:29326933</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Med (Lausanne)\2017-4-222.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Med (Lausanne)\2017-4-222.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171218, Agbenyefia P</style></custom2><misc3><style face="normal" font="default">10.3389/fmed.2017.00222</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43809</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Miljkovic,D.</style></author><author><style face="normal" font="default"> Psaltis,A.J.</style></author><author><style face="normal" font="default"> Wormald,P.J.</style></author><author><style face="normal" font="default"> Vreugde,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Surgery-Otolaryngology Head and Neck Surgery, University of Adelaide, Adelaide, SA, Australia</style></auth-address><titles><title><style face="normal" font="default">Chronic Rhinosinusitis with Polyps Is Characterized by Increased Mucosal and Blood Th17 Effector Cytokine Producing Cells</style></title><secondary-title><style face="normal" font="default">Front Physiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Front Physiol</style></abbr-1></periodical><pages end="" start="898">898-</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Background: Recent studies have implied a role for Th17 cells in CRS with nasal polyps (CRSwNP) patients. However, the capacity of these cells to produce Th17 cytokines is still unknown. Here we sought to quantify IL-17A, IL-17F, IL-21, and IL-22 cytokines produced by Th17 cells in mucosal tissue and peripheral blood of CRSwNP, CRS without nasal polyps (CRSsNP) and control patients. Methods: Samples were prospectively collected from CRS patients and non-CRS controls. We used flow cytometry to characterize the Th17 cells and their cytokines in sinonasal tissue and peripheral blood. Results: A total of 36 patients were recruited to the study. CRSwNP patients had significantly more tissue IL-17A (9.53 +/- 2.71 vs. 1.11 +/- 0.43 vs. 0.77 +/- 0.07), IL-17F (4.96 +/- 1.48 vs. 0.88 +/- 0.31 vs. 0.56 +/- 0.04), IL-21 (5.55 +/- 2.01 vs. 1.60 +/- 0.71 vs. 1.53 +/- 0.55) and IL-22 (4.73 +/- 1.58 vs. 0.70 +/- 0.28 vs. 0.88 +/- 0.26) producing Th17 cells compared to CRSsNP and control mucosa per mg of tissue, respectively. Allergic CRSwNP patients had decreased numbers of IL-21 producing Th17 cells compared to non-Allergic CRSwNP. (1.69 +/- 0.57 vs. 9.41 +/- 3.23) per mg of tissue, respectively (Kruskal-Wallis p &lt; 0.05). Conclusion: In summary our study identified increased numbers of IL-17A, IL-17F, IL-21 and IL-22 positive Th17 cells in CRSwNP patient polyps and peripheral blood suggesting an altered activation state of those cells both locally and systemically. Atopic CRSwNP had decreased amounts of tissue Th17 cell derived IL-21 implying a potential protective role for IL-21 in CRSwNP allergic inflammation</style></abstract><notes><style face="normal" font="default">IS - 1664-042X (Print)IS - 1664-042X (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.3389/fphys.2017.00898</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29311948">PM:29311948</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Front Physiol\2017-8-898.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Front Physiol\2017-8-898.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171219, Miljkovic D</style></custom2><misc3><style face="normal" font="default">10.3389/fphys.2017.00898</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43810</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Panarese,F.</style></author><author><style face="normal" font="default"> Auriemma,M.</style></author><author><style face="normal" font="default"> Carbone,A.</style></author><author><style face="normal" font="default"> Amerio,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">CESI Institute, University of Chieti-Pescara, Chieti, Italy</style></auth-address><titles><title><style face="normal" font="default">Atopic dermatitis treatment: what's new on the horizon?</style></title><secondary-title><style face="normal" font="default">G Ital Dermatol Venereol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">G Ital Dermatol Venereol</style></full-title></periodical><pages end="101" start="95">95-101</pages><volume><style face="normal" font="default">153</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="2" Year="2018">2018/2</year></dates><abstract><style face="normal" font="default">Atopic dermatitis (AD) is an inflammatory disorder of the skin characterized by an impaired immune response and skin barrier function. It is very frequent in adult population being present in up to 10% of population. Quality of life is often reduced in AD patients due to disease burden and symptoms like itch. AD is also frequently associated with psychological diseases such as anxiety or depression. Due to its chronic nature and severity of presentation AD often may not respond to topical treatment and requires systemic treatments which can be associated with significant side effects. A Medline search of the last five years with the keywords "Atopic dermatitis" and "treatment" was performed. Moreover a search throughout the clinicaltrial.gov webpage was performed with the keyword AD. Several topical and systemic treatments are being studied in randomized controlled trials or in case series or in pivotal studies. The progression of the insight on AD pathogenesis have made possible to target single molecules responsible for key aspect of the development of this disease. We discuss the various molecules (small anti-inflammatory molecules, monoclonal antibodies against cytokines) that will be hopefully soon available for the treatment of this disease which still carries an important burden of unmet needs for its treatment</style></abstract><notes><style face="normal" font="default">IS - 1827-1820 (Electronic)IS - 0392-0488 (Linking)LA - engPT - Journal ArticleCO - Italy -</style></notes><work-type><style face="normal" font="default">10.23736/S0392-0488.17.05794-7</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29319277">PM:29319277</url></web-urls></urls><custom2><style face="normal" font="default">20180112, Panarese F</style></custom2><misc3><style face="normal" font="default">10.23736/S0392-0488.17.05794-7</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43811</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Makrantonaki,E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Derma Zentrum Wildeshausen, Westerstr. 46-48, 27793, Wildeshausen, Deutschland.</style></auth-address><titles><title><style face="normal" font="default">[Chronic spontaneous urticaria : A disease of civilization?]</style></title><secondary-title><style face="normal" font="default">Hautarzt</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Hautarzt</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="1" Year="2018">2018/1/10</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 1432-1173 (Electronic)IS - 0017-8470 (Linking)LA - gerPT - Journal ArticleCO - Germany -</style></notes><work-type><style face="normal" font="default">10.1007/s00105-017-4111-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29322224">PM:29322224</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Hautarzt\20180110-MakrantonakiE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Hautarzt\20180110-MakrantonakiE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180110, Makrantonaki E</style></custom2><misc3><style face="normal" font="default">10.1007/s00105-017-4111-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43812</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Al-Sheyab,N.A.</style></author><author><style face="normal" font="default"> Alomari,M.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Jordan University of Science and Technology, Faculty of Nursing, Midwifery and Health, PO BOX 3030, Irbid, 22110, Jordan</style></auth-address><titles><title><style face="normal" font="default">Prevalence, associated factors, and control level of asthma symptoms among adolescents in Northern Jordan</style></title><secondary-title><style face="normal" font="default">Int J Adolesc Med Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Adolesc Med Health</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="1" Year="2018">2018/1/13</year></dates><abstract><style face="normal" font="default">Objective To investigate the prevalence, associated factors, and control level of asthma in Jordanian high school students. Methods A descriptive, comparative, cross sectional design was used and a cluster sample of 2691 students (mean age = 14.5 years, 51.0% girls), drawn from eight randomly selected public high schools in Northern Jordan, participated in the study. Each student had the International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire completed in the classroom between February and May, 2015. Results The prevalence of recent wheezing in the last 12 months was 11.7% whereas the prevalence of diagnosed asthma was 6.2%. About 49% of students experienced cough all the time, and 33.5% experienced waking up at night due to wheezing some of the time. About 30.9% of students reported moderate to big exercise-induced asthma. The mean total Asthma Control Test (ACT) score was 5.85 (SD = 3.56) with all of students reporting uncontrolled asthma during the last month. Higher rates of asthma symptoms were reported by females, 10th graders, and students with negative family history. Importantly, students with diagnosed asthma or recent wheezing reported higher rates of ever smoking tobacco vs. non-asthmatics (p &lt; 0.000); dual (18.6% vs. 9.8%), cigarettes only (11.2% vs. 7.3%), and waterpipe only (18.0% vs. 14.7%). Conclusion Overall, students with asthma or wheezing had increased rates of tobacco smoking. Policies need to be set and enforced to provide a better environment for these youth, especially making all schools smoke-free zones. A multifaceted, comprehensive awareness and management program is required in schools to control and manage asthma symptoms</style></abstract><notes><style face="normal" font="default">IS - 2191-0278 (Electronic)IS - 0334-0139 (Linking)LA - engPT - Journal ArticleCO - Jordan -</style></notes><work-type><style face="normal" font="default">10.1515/ijamh-2017-0159</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29331100">PM:29331100</url></web-urls><related-urls><url ppv-ref="no">presto - 6 mesi</url></related-urls></urls><custom2><style face="normal" font="default">20180113, Al-Sheyab NA</style></custom2><misc3><style face="normal" font="default">10.1515/ijamh-2017-0159</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43813</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Otrofanowei,E.</style></author><author><style face="normal" font="default"> Ayanlowo,O.O.</style></author><author><style face="normal" font="default"> Akinkugbe,A.</style></author><author><style face="normal" font="default"> Oresanya,F.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medicine, Lagos University Teaching Hospital, Lagos, NigeriaKyutis Clinic, Ikoyi Lagos, Nigeria</style></auth-address><titles><title><style face="normal" font="default">Clinico-etiologic profile of hand dermatitis and patch response of patients at a tertiary hospital in Lagos, Nigeria: results of a prospective observational study</style></title><secondary-title><style face="normal" font="default">Int J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Int J Dermatol</style></full-title></periodical><pages end="155" start="149">149-155</pages><volume><style face="normal" font="default">57</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="2" Year="2018">2018/2</year></dates><abstract><style face="normal" font="default">BACKGROUND: Hand dermatitis is an acute or chronic inflammation of the skin of the hands from a multifactorial cause which may be endogenous, exogenous, or a combination of both. With a wide range in severity and recurrent periods of flares, it has significant impact on the quality of life of its sufferers. A history of atopy predisposes patients to hand dermatitis, but contact dermatitis, either allergic or irritant, is the more commonly implicated factor in the etiology of hand dermatitis. Patch testing is an important tool in identifying the allergen responsible for allergic hand dermatitis, and this knowledge will contribute to improved management. AIM AND OBJECTIVES: This study was undertaken to evaluate the clinical and etiologic profile and review the patch responses of patients who presented with hand dermatitis at a foremost tertiary skin clinic in the most populous state of the most populous country in Africa. METHODS: A prospective, observational study in which consecutive walk-in patients who fulfilled the inclusion criteria were enrolled. Ethical clearance was obtained. Study tools included self-administered questionnaires, physical examination, and patch tests (European Hermal series), amongst others. The patch tests were carried out. Results were documented, and treatment was individualized based on clinical and investigation findings. The results were collated and analyzed with SPSS((R)) 17.0 edition (SPSS II). RESULTS: Hand dermatitis was seen in 177 (13.3%) patients who presented during the study period. The mean age was 34.6 + 17.4 years. Almost two-thirds of patients (119; 67.2%) had chronic hand dermatitis, while 53 (32.8%) presented acutely. Patch responses were positive in 65 (36.7%) patients with paraphenylenediamine identified as the most frequent cause. Respondents had at least one (+) response to 20 of the 28 allergens, while there was no response to eight of the allergens in the European series. CONCLUSION: The study reveals that hand dermatitis is present in a younger age group and a variety of subtypes coexist. Locally sourced allergens are needed to improve the yield of patch responses</style></abstract><notes><style face="normal" font="default">IS - 1365-4632 (Electronic)IS - 0011-9059 (Linking)LA - engPT - Journal ArticleCO - Nigeria -</style></notes><work-type><style face="normal" font="default">10.1111/ijd.13845</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29318580">PM:29318580</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Dermatol\2018-57-149-55.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Dermatol\2018-57-149-55.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180110, Otrofanowei E</style></custom2><misc3><style face="normal" font="default">10.1111/ijd.13845</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43814</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Fernandez,D.</style></author><author><style face="normal" font="default"> Sram,R.J.</style></author><author><style face="normal" font="default"> Dostal,M.</style></author><author><style face="normal" font="default"> Pastorkova,A.</style></author><author><style face="normal" font="default"> Gmuender,H.</style></author><author><style face="normal" font="default"> Choi,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research and Development Unit, Parc Sanitari Sant Joan de Deu, Fundacio Sant Joan de Deu, CIBERSAM, Dr. Antoni Pujadas, 42, Sant Boi de Llobregat, 08830 Barcelona, Spain.</style></auth-address><titles><title><style face="normal" font="default">Modeling Unobserved Heterogeneity in Susceptibility to Ambient Benzo[a]pyrene Concentration among Children with Allergic Asthma Using an Unsupervised Learning Algorithm</style></title><secondary-title><style face="normal" font="default">Int J Environ Res Public Health</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Environ Res Public Health</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="1" Year="2018">2018/1/10</year></dates><abstract><style face="normal" font="default">Current studies of gene x air pollution interaction typically seek to identify unknown heritability of common complex illnesses arising from variability in the host's susceptibility to environmental pollutants of interest. Accordingly, a single component generalized linear models are often used to model the risk posed by an environmental exposure variable of interest in relation to a priori determined DNA variants. However, reducing the phenotypic heterogeneity may further optimize such approach, primarily represented by the modeled DNA variants. Here, we reduce phenotypic heterogeneity of asthma severity, and also identify single nucleotide polymorphisms (SNP) associated with phenotype subgroups. Specifically, we first apply an unsupervised learning algorithm method and a non-parametric regression to find a biclustering structure of children according to their allergy and asthma severity. We then identify a set of SNPs most closely correlated with each sub-group. We subsequently fit a logistic regression model for each group against the healthy controls using benzo[a]pyrene (B[a]P) as a representative airborne carcinogen. Application of such approach in a case-control data set shows that SNP clustering may help to partly explain heterogeneity in children's asthma susceptibility in relation to ambient B[a]P concentration with greater efficiency</style></abstract><notes><style face="normal" font="default">IS - 1660-4601 (Electronic)IS - 1660-4601 (Linking)LA - engPT - Journal ArticleCO - Spain -CO - New Zealand -CO - Czechia -CO - Switzerland -CO - United States -</style></notes><work-type><style face="normal" font="default">10.3390/ijerph15010106</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29320438">PM:29320438</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Environ Res Public Health\20180110-FernandezD.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Environ Res Public Health\20180110-FernandezD.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180110, Fernandez D</style></custom2><misc3><style face="normal" font="default">10.3390/ijerph15010106</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43815</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Tan,E.</style></author><author><style face="normal" font="default"> Thompson,G.</style></author><author><style face="normal" font="default"> Ekstrom,C.</style></author><author><style face="normal" font="default"> Lucas,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Clinical Immunology, Sir Charles Gairdner Hospital, QEII Medical Centre, Perth, Western Australia, Australia</style></auth-address><titles><title><style face="normal" font="default">Non-immediate heparin and heparinoid cutaneous allergic reactions: a role for fondaparinux</style></title><secondary-title><style face="normal" font="default">Intern Med J</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Intern Med J</style></full-title></periodical><pages end="77" start="73">73-77</pages><volume><style face="normal" font="default">48</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">Non-immediate allergic cutaneous reactions to heparins have been increasingly reported, typically manifesting as large, eczematous plaques at sites of subcutaneous injection. Patients may demonstrate cross-reactivity between unfractionated heparin, low molecular weight heparin and semi-synthetic heparinoids, making finding an alternative difficult. Fondaparinux has been identified as a useful alternative in such patients; here we present the first two documented cases in Australia and a literature review</style></abstract><notes><style face="normal" font="default">IS - 1445-5994 (Electronic)IS - 1444-0903 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/imj.13659</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29314514">PM:29314514</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Intern Med J\2018-48-73-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Intern Med J\2018-48-73-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180103, Tan E</style></custom2><misc3><style face="normal" font="default">10.1111/imj.13659</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43816</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mallia,P.</style></author><author><style face="normal" font="default"> Webber,J.</style></author><author><style face="normal" font="default"> Gill,S.K.</style></author><author><style face="normal" font="default"> Trujillo-Torralbo,M.B.</style></author><author><style face="normal" font="default"> Calderazzo,M.A.</style></author><author><style face="normal" font="default"> Finney,L.</style></author><author><style face="normal" font="default"> Bakhsoliani,E.</style></author><author><style face="normal" font="default"> Farne,H.</style></author><author><style face="normal" font="default"> Singanayagam,A.</style></author><author><style face="normal" font="default"> Footitt,J.</style></author><author><style face="normal" font="default"> Hewitt,R.</style></author><author><style face="normal" font="default"> Kebadze,T.</style></author><author><style face="normal" font="default"> Aniscenko,J.</style></author><author><style face="normal" font="default"> Padmanaban,V.</style></author><author><style face="normal" font="default"> Molyneaux,P.L.</style></author><author><style face="normal" font="default"> Adcock,I.M.</style></author><author><style face="normal" font="default"> Barnes,P.J.</style></author><author><style face="normal" font="default"> Ito,K.</style></author><author><style face="normal" font="default"> Elkin,S.L.</style></author><author><style face="normal" font="default"> Kon,O.M.</style></author><author><style face="normal" font="default"> Cookson,W.O.</style></author><author><style face="normal" font="default"> Moffat,M.F.</style></author><author><style face="normal" font="default"> Johnston,S.L.</style></author><author><style face="normal" font="default"> Tregoning,J.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Airway Disease Infection Section, National Heart and Lung Institute, Imperial College, London, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">Role of airway glucose in bacterial infections in patients with chronic obstructive pulmonary disease</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="13" Month="12" Year="2017">2017/12/13</year></dates><abstract><style face="normal" font="default">BACKGROUND: Patients with chronic obstructive pulmonary disease (COPD) have increased susceptibility to respiratory tract infection, which contributes to disease progression and mortality, but mechanisms of increased susceptibility to infection remain unclear. OBJECTIVES: The aim of this study was to determine whether glucose concentrations were increased in airway samples (nasal lavage fluid, sputum, and bronchoalveolar lavage fluid) from patients with stable COPD and to determine the effects of viral infection on sputum glucose concentrations and how airway glucose concentrations relate to bacterial infection. METHODS: We measured glucose concentrations in airway samples collected from patients with stable COPD and smokers and nonsmokers with normal lung function. Glucose concentrations were measured in patients with experimentally induced COPD exacerbations, and these results were validated in patients with naturally acquired COPD exacerbations. Relationships between sputum glucose concentrations, inflammatory markers, and bacterial load were examined. RESULTS: Sputum glucose concentrations were significantly higher in patients with stable COPD compared with those in control subjects without COPD. In both experimental virus-induced and naturally acquired COPD exacerbations, sputum and nasal lavage fluid glucose concentrations were increased over baseline values. There were significant correlations between sputum glucose concentrations and sputum inflammatory markers, viral load, and bacterial load. Airway samples with higher glucose concentrations supported more Pseudomonas aeruginosa growth in vitro. CONCLUSIONS: Airway glucose concentrations are increased in patients with stable COPD and further increased during COPD exacerbations. Increased airway glucose concentrations might contribute to bacterial infections in both patients with stable and those with exacerbated COPD. This has important implications for the development of nonantibiotic therapeutic strategies for the prevention or treatment of bacterial infection in patients with COPD</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.10.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29310905">PM:29310905</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171213-MalliaP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20171213-MalliaP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171213, Mallia P</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.10.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43817</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">White,K.D.</style></author><author><style face="normal" font="default"> Abe,R.</style></author><author><style face="normal" font="default"> rdern-Jones,M.</style></author><author><style face="normal" font="default"> Beachkofsky,T.</style></author><author><style face="normal" font="default"> Bouchard,C.</style></author><author><style face="normal" font="default"> Carleton,B.</style></author><author><style face="normal" font="default"> Chodosh,J.</style></author><author><style face="normal" font="default"> Cibotti,R.</style></author><author><style face="normal" font="default"> Davis,R.</style></author><author><style face="normal" font="default"> Denny,J.C.</style></author><author><style face="normal" font="default"> Dodiuk-Gad,R.P.</style></author><author><style face="normal" font="default"> Ergen,E.N.</style></author><author><style face="normal" font="default"> Goldman,J.L.</style></author><author><style face="normal" font="default"> Holmes,J.H.</style></author><author><style face="normal" font="default"> Hung,S.I.</style></author><author><style face="normal" font="default"> Lacouture,M.E.</style></author><author><style face="normal" font="default"> Lehloenya,R.J.</style></author><author><style face="normal" font="default"> Mallal,S.</style></author><author><style face="normal" font="default"> Manolio,T.A.</style></author><author><style face="normal" font="default"> Micheletti,R.G.</style></author><author><style face="normal" font="default"> Mitchell,C.M.</style></author><author><style face="normal" font="default"> Mockenhaupt,M.</style></author><author><style face="normal" font="default"> Ostrov,D.A.</style></author><author><style face="normal" font="default"> Pavlos,R.</style></author><author><style face="normal" font="default"> Pirmohamed,M.</style></author><author><style face="normal" font="default"> Pope,E.</style></author><author><style face="normal" font="default"> Redwood,A.</style></author><author><style face="normal" font="default"> Rosenbach,M.</style></author><author><style face="normal" font="default"> Rosenblum,M.D.</style></author><author><style face="normal" font="default"> Roujeau,J.C.</style></author><author><style face="normal" font="default"> Saavedra,A.P.</style></author><author><style face="normal" font="default"> Saeed,H.N.</style></author><author><style face="normal" font="default"> Struewing,J.P.</style></author><author><style face="normal" font="default"> Sueki,H.</style></author><author><style face="normal" font="default"> Sukasem,C.</style></author><author><style face="normal" font="default"> Sung,C.</style></author><author><style face="normal" font="default"> Trubiano,J.A.</style></author><author><style face="normal" font="default"> Weintraub,J.</style></author><author><style face="normal" font="default"> Wheatley,L.M.</style></author><author><style face="normal" font="default"> Williams,K.B.</style></author><author><style face="normal" font="default"> Worley,B.</style></author><author><style face="normal" font="default"> Chung,W.H.</style></author><author><style face="normal" font="default"> Shear,N.H.</style></author><author><style face="normal" font="default"> Phillips,E.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Vanderbilt University Medical Center, Nashville, Tenn</style></auth-address><titles><title><style face="normal" font="default">SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="69" start="38">38-69</pages><volume><style face="normal" font="default">6</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening, immunologically mediated, and usually drug-induced disease with a high burden to individuals, their families, and society with an annual incidence of 1 to 5 per 1,000,000. To effect significant reduction in short- and long-term morbidity and mortality, and advance clinical care and research, coordination of multiple medical, surgical, behavioral, and basic scientific disciplines is required. On March 2, 2017, an investigator-driven meeting was held immediately before the American Academy of Dermatology Annual meeting for the central purpose of assembling, for the first time in the United States, clinicians and scientists from multiple disciplines involved in SJS/TEN clinical care and basic science research. As a product of this meeting, this article summarizes the current state of knowledge and expert opinion related to SJS/TEN covering a broad spectrum of topics including epidemiology and pharmacogenomic networks; clinical management and complications; special populations such as pediatrics, the elderly, and pregnant women; regulatory issues and the electronic health record; new agents that cause SJS/TEN; pharmacogenomics and immunopathogenesis; and the patient perspective. Goals include the maintenance of a durable and productive multidisciplinary network that will significantly further scientific progress and translation into prevention, early diagnosis, and management of SJS/TEN</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticlePT - ReviewCO - United States -CO - Japan -CO - United Kingdom -CO - Canada -CO - Australia -CO - France -CO - Thailand -CO - Singapore -CO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.11.023</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29310768">PM:29310768</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20180105, White KD</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.11.023</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43818</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Prince,B.T.</style></author><author><style face="normal" font="default"> Routes,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio.</style></auth-address><titles><title><style face="normal" font="default">Abnormal T-Cell Receptor Excision Circle Newborn Screen: What Next?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="319" start="318">318-319</pages><volume><style face="normal" font="default">6</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.047</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29310763">PM:29310763</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20180105, Prince BT</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.047</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43819</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rutkowski,K.</style></author><author><style face="normal" font="default"> Li,P.H.</style></author><author><style face="normal" font="default"> Wagner,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.</style></auth-address><titles><title><style face="normal" font="default">The Paradox of Antihistamine Hypersensitivity</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="259" start="258">258-259</pages><volume><style face="normal" font="default">6</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.10.035</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29310760">PM:29310760</url></web-urls></urls><custom2><style face="normal" font="default">20180105, Rutkowski K</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.10.035</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43820</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kelly,B.T.</style></author><author><style face="normal" font="default"> Knutsen,A.P.</style></author><author><style face="normal" font="default"> Routes,J.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">St. Paul Allergy and Asthma, PA, St. Paul, Minn.</style></auth-address><titles><title><style face="normal" font="default">Bronchiectasis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="316" start="315">315-316</pages><volume><style face="normal" font="default">6</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.07.011</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29310762">PM:29310762</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20180105, Kelly BT</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.07.011</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43821</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Karim,A.F.</style></author><author><style face="normal" font="default"> Heeringa,J.J.</style></author><author><style face="normal" font="default"> van Laar,J.A.M.</style></author><author><style face="normal" font="default"> Verdijk,R.M.</style></author><author><style face="normal" font="default"> Dik,W.A.</style></author><author><style face="normal" font="default"> Paridaens,A.D.</style></author><author><style face="normal" font="default"> van Hagen,P.M.</style></author><author><style face="normal" font="default"> van Zelm,M.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands</style></auth-address><titles><title><style face="normal" font="default">Reply</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="1" Year="2018">2018/1/9</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.11.016</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29329899">PM:29329899</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180106-KarimAF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180106-KarimAF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20170106, Karim AF</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.11.016</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43822</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Castagna,J.</style></author><author><style face="normal" font="default"> Nosbaum,A.</style></author><author><style face="normal" font="default"> Vial,T.</style></author><author><style face="normal" font="default"> Rozieres,A.</style></author><author><style face="normal" font="default"> Hacard,F.</style></author><author><style face="normal" font="default"> Vocanson,M.</style></author><author><style face="normal" font="default"> Pralong,P.</style></author><author><style face="normal" font="default"> Chuniaud-Louche,C.</style></author><author><style face="normal" font="default"> Nicolas,J.F.</style></author><author><style face="normal" font="default"> Gouraud,A.</style></author><author><style face="normal" font="default"> Berard,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy and Clinical Immunology Department, Lyon Sud University Hospital, Pierre Benite, France</style></auth-address><titles><title><style face="normal" font="default">Drug-induced aseptic meningitis: A possible T-cell-mediated hypersensitivity</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="1" Year="2018">2018/1/5</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.11.034</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29310902">PM:29310902</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20180105, Castagna J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.11.034</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43823</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mathur,S.K.</style></author><author><style face="normal" font="default"> Bernstein,D.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wis. Electronic address: skmathur@wisc.eduDivision of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, Ohio</style></auth-address><titles><title><style face="normal" font="default">On the Road to Improving Asthma Outcomes in Older Adults: The Phenotyping of Asthma in Older Adults</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="251" start="250">250-251</pages><volume><style face="normal" font="default">6</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.08.038</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29310759">PM:29310759</url></web-urls></urls><custom2><style face="normal" font="default">20180105, Mathur SK</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.08.038</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43824</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lieberman,J.A.</style></author><author><style face="normal" font="default"> Lieberman,P.</style></author><author><style face="normal" font="default"> Wang,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy and Immunology, The University of Tennessee Health Science Center, Memphis, Tenn.</style></auth-address><titles><title><style face="normal" font="default">Allergists' opinions on anaphylaxis and epinephrine administration-a case-based survey</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="1" Year="2018">2018/1/4</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.11.031</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29306683">PM:29306683</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20180104, Lieberman JA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.11.031</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43825</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kuruvilla,M.</style></author><author><style face="normal" font="default"> Vanijcharoenkarn,K.</style></author><author><style face="normal" font="default"> Wan,J.</style></author><author><style face="normal" font="default"> Pereira,N.</style></author><author><style face="normal" font="default"> Chung,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Allergy/Immunology, Emory University, Atlanta, Ga.</style></auth-address><titles><title><style face="normal" font="default">Exogenous progesterone hypersensitivity associated with recurrent pregnancy loss</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="1" Year="2018">2018/1/12</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.11.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29339132">PM:29339132</url></web-urls></urls><custom2><style face="normal" font="default">20180112, Kuruvilla M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.11.041</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43826</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kulhas,C.I.</style></author><author><style face="normal" font="default"> Buyuktiryaki,B.</style></author><author><style face="normal" font="default"> Misirlioglu,E.D.</style></author><author><style face="normal" font="default"> Hasbek,E.</style></author><author><style face="normal" font="default"> Kocabas,C.N.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pediatric Allergy and Immunology, Ankara Child Health and Diseases Hematology Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey</style></auth-address><titles><title><style face="normal" font="default">Fixed Drug Eruption Related to Cefixime in an Adolescent Case</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="1" Year="2018">2018/1/12</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.12.004</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29339130">PM:29339130</url></web-urls></urls><custom2><style face="normal" font="default">20180112, Kulhas CI</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.12.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43827</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stein,M.M.</style></author><author><style face="normal" font="default"> Thompson,E.E.</style></author><author><style face="normal" font="default"> Schoettler,N.</style></author><author><style face="normal" font="default"> Helling,B.A.</style></author><author><style face="normal" font="default"> Magnaye,K.M.</style></author><author><style face="normal" font="default"> Stanhope,C.</style></author><author><style face="normal" font="default"> Igartua,C.</style></author><author><style face="normal" font="default"> Morin,A.</style></author><author><style face="normal" font="default"> Washington,C.,III</style></author><author><style face="normal" font="default"> Nicolae,D.</style></author><author><style face="normal" font="default"> Bonnelykke,K.</style></author><author><style face="normal" font="default"> Ober,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Human Genetics, University of Chicago, Chicago, IL 60637</style></auth-address><titles><title><style face="normal" font="default">A Decade of Research on the 17q12-21 Asthma Locus: Piecing Together the Puzzle</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="1" Year="2018">2018/1/4</year></dates><abstract><style face="normal" font="default">Chromosome 17q12-21 remains the most highly replicated and significant asthma locus. Genotypes in the core region defined by the first GWAS correlate with expression of two genes, ORMDL3 and GSDMB, making these prime candidate asthma genes, although recent studies have implicated GSDMA distal to and PGAP3 proximal to the core region as independent loci. We review here 10 years of studies on the 17q12-21 locus and suggest that genotype-specific risks for asthma at the proximal and distal loci are not specific to early onset asthma and mediated by PGAP3, ORMDL3, and/or GSDMA expression. We propose that the weak and inconsistent associations of 17q SNPs with asthma in African Americans is due to the high frequency of some 17q alleles, the breakdown of linkage disequilibrium on African-derived chromosomes, and possibly different early life asthma endotypes in these children. Finally, the inconsistent association between asthma and gene expression levels in blood or lung cells from older children and adults suggests that genotype effects may mediate asthma risk or protection during critical developmental windows and/or in response to relevant exposures in early life. Thus, studies of young children and ethnically diverse populations are required to fully understand the relationship between genotype and asthma phenotype and the gene regulatory architecture at this locus</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.12.974</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29307657">PM:29307657</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180106-SteinMM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180106-SteinMM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180106, Stein MM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.12.974</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43828</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Toki,S.</style></author><author><style face="normal" font="default"> Goleniewska,K.</style></author><author><style face="normal" font="default"> Reiss,S.</style></author><author><style face="normal" font="default"> Zhang,J.</style></author><author><style face="normal" font="default"> Bloodworth,M.H.</style></author><author><style face="normal" font="default"> Stier,M.T.</style></author><author><style face="normal" font="default"> Zhou,W.</style></author><author><style face="normal" font="default"> Newcomb,D.C.</style></author><author><style face="normal" font="default"> Ware,L.B.</style></author><author><style face="normal" font="default"> Stanwood,G.D.</style></author><author><style face="normal" font="default"> Galli,A.</style></author><author><style face="normal" font="default"> Boyd,K.L.</style></author><author><style face="normal" font="default"> Niswender,K.D.</style></author><author><style face="normal" font="default"> Peebles,R.S.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA</style></auth-address><titles><title><style face="normal" font="default">Glucagon-like peptide 1 signaling inhibits allergen-induced lung IL-33 release and reduces group 2 innate lymphoid cell (ILC2) cytokine production in vivo</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="1" Year="2018">2018/1/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: IL-33 is one of the most consistently associated gene candidates for asthma identified by GWAS. Studies in mice and in human cells have confirmed the importance of IL-33 in inducing type-2 cytokine production from both group 2 innate lymphoid cells (ILC2) and Th2 cells. However, there are no pharmacologic agents known to inhibit IL-33 release from airway cells. OBJECTIVE: To determine the effect of glucagon like peptide receptor-1 GLP-1R signaling on aeroallergen-induced airway IL-33 production and release and on innate type-2 airway inflammation. METHODS: BALB/c mice were challenged intranasally with Alternaria extract for 4 consecutive days. GLP-1R agonist or the vehicle was administered starting either 2 days before the first Alternaria extract-challenge or 1 day after the first Alternaria extract-challenge. RESULTS: GLP-1R agonist treatment starting 2 days before the first Alternaria extract-challenge decreased IL-33 release in the BAL fluid and DUOX1 mRNA expression 1 h after the first Alternaria extract-challenge, and IL-33 expression in lung epithelial cells 24 h after the last Alternaria extract-challenge. Further, GLP-1R agonist significantly decreased the number of ILC2 expressing IL-5 and IL-13, the lung protein expression of type-2 cytokines and chemokines, the number of perivascular eosinophils, mucus production, and airway responsiveness compared with vehicle treatment. GLP-1R agonist treatment starting one day after the first Alternaria extract-challenge also significantly decreased eosinophilia and type-2 cytokine and chemokine expression in the airway after 4 days of Alternaria extract-challenge. CONCLUSION: These results reveal that GLP-1R signaling may be a potential therapy to reduce IL-33 release and inhibit the ILC2 response to protease-containing aeroallergens, such as Alternaria</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.11.043</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29331643">PM:29331643</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180106-TokiS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180106-TokiS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180106, Toki S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.11.043</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43829</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dekhuijzen,R.</style></author><author><style face="normal" font="default"> Lavorini,F.</style></author><author><style face="normal" font="default"> Usmani,O.S.</style></author><author><style face="normal" font="default"> van Boven,J.F.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.</style></auth-address><titles><title><style face="normal" font="default">Addressing the Impact and Unmet Needs of Nonadherence in Asthma and Chronic Obstructive Pulmonary Disease: Where Do We Go From Here?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="1" Year="2018">2018/1/12</year></dates><abstract><style face="normal" font="default">Nonadherence to treatment, and its associated health and economic burden, is particularly problematic in asthma and chronic obstructive pulmonary disease management because of heterogeneous patient populations and the need for an inhaled route of drug administration. Symptom variability, comorbidities, and device switching further add to suboptimal adherence rates. As opposed to controlled clinical trials, real-life studies show consistently low inhaler adherence in daily practice, yet exact adherence rates have long been affected by disagreement on standardized definitions. The recently developed Ascertaining Barriers to Compliance taxonomy helps to address adherence research disparities by identifying 3 phases of adherence (initiation, implementation [including correct inhaler technique], and discontinuation). This review considers the reasons for and impact of suboptimal adherence, together with summaries of key studies that demonstrate how improving adherence can reduce exacerbations, inhaled corticosteroid use (in cases of better inhaler technique), hospitalizations, and treatment costs. Strategies to help ensure optimal adherence are discussed, including the choice of a patient-tailored inhaler, patient empowerment, education and training, and the potential of electronic monitoring and digital technology. It is concluded that a combined effort from payers, health care professionals, and manufacturers could make a real difference to asthma and chronic obstructive pulmonary disease control, as well as to health care budgets</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Netherlands -CO - Italy -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.11.027</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29339126">PM:29339126</url></web-urls></urls><custom2><style face="normal" font="default">20180112, Dekhuijzen R</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.11.027</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43830</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kulkarni,H.S.</style></author><author><style face="normal" font="default"> Liszewski,M.K.</style></author><author><style face="normal" font="default"> Brody,S.L.</style></author><author><style face="normal" font="default"> Atkinson,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pulmonary and Critical Care Medicine, Department of Medicine, Washington University in Saint Louis, Saint Louis, MO 63110, United States</style></auth-address><titles><title><style face="normal" font="default">The complement system in the airway epithelium - an overlooked host defense mechanism and therapeutic target?</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="1" Year="2018">2018/1/12</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - EditorialCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.11.046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29339260">PM:29339260</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180111-KulkarniHS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180111-KulkarniHS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180111, Kulkarni HS</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.11.046</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43831</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hong,H.</style></author><author><style face="normal" font="default"> Chen,F.</style></author><author><style face="normal" font="default"> Sun,Y.</style></author><author><style face="normal" font="default"> Yang,Q.</style></author><author><style face="normal" font="default"> Gao,W.</style></author><author><style face="normal" font="default"> Cao,Y.</style></author><author><style face="normal" font="default"> Fan,Y.</style></author><author><style face="normal" font="default"> Shi,J.</style></author><author><style face="normal" font="default"> Li,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Center, Otorhinolaryngology Hospital, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou</style></auth-address><titles><title><style face="normal" font="default">Nasal IL-25 predicts the response to oral-corticosteroid in chronic rhinosinusitis with nasal polyps (CRSwNP)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="1" Year="2018">2018/1/11</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.10.050</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29337030">PM:29337030</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180111-HongH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180111-HongH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180111, Hong H</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.10.050</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43832</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Beigelman,A.</style></author><author><style face="normal" font="default"> Rosas-Salazar,C.</style></author><author><style face="normal" font="default"> Hartert,T.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Pediatric Allergy, Immunology, and Pulmonary Medicine, Department of Pediatrics, Washington University School of Medicine, St Louis, Mo.</style></auth-address><titles><title><style face="normal" font="default">Childhood Asthma: Is It All About Bacteria and Not About Viruses? A Pro/Con Debate</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="1" Year="2018">2018/1/12</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.11.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29339131">PM:29339131</url></web-urls></urls><custom2><style face="normal" font="default">20180112, Beigelman A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.11.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43833</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,M.J.</style></author><author><style face="normal" font="default"> Kang,M.J.</style></author><author><style face="normal" font="default"> Lee,S.Y.</style></author><author><style face="normal" font="default"> Lee,E.</style></author><author><style face="normal" font="default"> Kim,K.</style></author><author><style face="normal" font="default"> Won,S.</style></author><author><style face="normal" font="default"> Suh,D.I.</style></author><author><style face="normal" font="default"> Kim,K.W.</style></author><author><style face="normal" font="default"> Sheen,Y.H.</style></author><author><style face="normal" font="default"> Ahn,K.</style></author><author><style face="normal" font="default"> Kim,B.S.</style></author><author><style face="normal" font="default"> Hong,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Life Science, Multidisciplinary Genome Institute, Hallym University, Chuncheon, Gangwon-do 24252, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Perturbations of the gut microbiome genes in infants with atopic dermatitis according to feeding type</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="1" Year="2018">2018/1/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Perturbations of the infant gut microbiota can shape the development of the immune system and link to the risk of allergic diseases. OBJECTIVE: To understand the role of the gut microbiome in atopic dermatitis, the metagenome of the infant gut microbiome was analyzed according to feeding types. METHODS: The composition of gut microbiota was analyzed in fecal samples from 129 infants (6-month-old) by pyrosequencing, including 66 healthy infants and 63 infants with atopic dermatitis. The functional profile of the gut microbiome was analyzed by whole metagenome sequencing (20 controls and 20 AD). In addition, the total number of bacteria in the feces was determined by real-time PCR. RESULTS: The gut microbiome of 6-month-old infants was different by feeding types, and two microbiota groups (Bifidobacterium dominated and Escherichia/Veillonella dominated group) were found in breast-fed and mixed-fed infants. The bacterial cell amounts in the feces were lower in infants with AD than in controls. Although no specific taxa directly correlated with AD in 16S rRNA gene results, whole metagenome analysis revealed differences in functional genes related to immune development. The reduction of genes for oxidative phosphorylation, PI3K-Akt signaling, estrogen signaling, NOD-like receptor signaling, and antigen processing and presentation induced by reduced colonization of mucin-degrading bacteria (Akkermansia muciniphila, Ruminocccus gnavus, and Lachnospiraceae bacterium 2_1_58FAA) was significantly associated with stunted immune development in the AD group compared to the control group (P &lt; .05). CONCLUSIONS: Alterations in the gut microbiome may be associated with atopic dermatitis due to different bacterial genes that can modulate host immune cell function</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.11.045</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29339259">PM:29339259</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180111-LeeMJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180111-LeeMJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180111, Lee MJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.11.045</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43834</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kennedy,J.L.</style></author><author><style face="normal" font="default"> Koziol-White,C.J.</style></author><author><style face="normal" font="default"> Jeffus,S.</style></author><author><style face="normal" font="default"> Rettiganti,M.R.</style></author><author><style face="normal" font="default"> Fisher,P.</style></author><author><style face="normal" font="default"> Kurten,M.</style></author><author><style face="normal" font="default"> Eze,A.</style></author><author><style face="normal" font="default"> House,S.</style></author><author><style face="normal" font="default"> Sikes,J.D.</style></author><author><style face="normal" font="default"> Askew,E.</style></author><author><style face="normal" font="default"> Putt,C.</style></author><author><style face="normal" font="default"> Panettieri,R.A.</style></author><author><style face="normal" font="default"> Jones,S.M.</style></author><author><style face="normal" font="default"> Kurten,R.C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Division of Allergy and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR; Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR; Arkansas Children's Research Institute, Little Rock, AR; Translational Research Institute, University of Arkansas for Medical Sciences, Little Rock, AR. Electronic address: kennedyjoshual@uams.eduDepartment of Medicine, Rutgers, the State University of New Jersey, New Brunswick, NJ</style></auth-address><titles><title><style face="normal" font="default">Effects of Rhinovirus (RV) 39 Infection on Airway Hyper-responsiveness (AHR) to Carbachol in Human Airways Precision Cut Lung Slices (PCLS)</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="1" Year="2018">2018/1/6</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.11.041</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29317243">PM:29317243</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180106-KennedyJL.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180106-KennedyJL.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180106, Kennedy JL</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.11.041</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43835</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Michaudel,C.</style></author><author><style face="normal" font="default"> Mackowiak,C.</style></author><author><style face="normal" font="default"> Maillet,I.</style></author><author><style face="normal" font="default"> Fauconnier,L.</style></author><author><style face="normal" font="default"> Akdis,C.</style></author><author><style face="normal" font="default"> Sokolowska,M.</style></author><author><style face="normal" font="default"> Dreher,A.</style></author><author><style face="normal" font="default"> Tan,H.T.</style></author><author><style face="normal" font="default"> Quesniaux,V.F.</style></author><author><style face="normal" font="default"> Ryffel,B.</style></author><author><style face="normal" font="default"> Togbe,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Laboratory of experimental and molecular immunology and neurogenetics (INEM), UMR 7355 CNRS-University of Orleans, F-45071 Orleans-Cedex2, France, University of Orleans</style></auth-address><titles><title><style face="normal" font="default">Ozone exposure induces respiratory barrier biphasic injury and inflammation controlled by Interleukin-33</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="1" Year="2018">2018/1/10</year></dates><abstract><style face="normal" font="default">BACKGROUND: IL-33 plays critical role in the regulation of tissue homeostasis, injury and repair. Whether IL-33 regulates neutrophil recruitment and function independently of airways hyperresponsiveness (AHR) in ozone induced lung injury and inflammation is unclear. OBJECTIVE: To examine the role of IL-33/ST2 axis in lung inflammation upon acute ozone exposure in mice. METHODS: ST2 and IL-33 deficient mice, IL-33-citrine reporter and C57BL/6 (WT) mice underwent a single ozone exposure (1 ppm for 1h) in all studies. Cell recruitment in lung and broncho-alveolar space, inflammatory parameters, epithelial barrier damage and airway hyperreactivity (AHR) were determined. RESULTS: We report that a single ozone exposure causes a rapid disruption of the epithelial barrier within 1h followed by second phase of respiratory barrier injury with increased neutrophil recruitment, ROS production, AHR and IL-33 expression in epithelial and myeloid cells in WT mice. In the absence of IL-33 or IL-33R/ST2, epithelial cell injury with protein leak and myeloid cell recruitment and inflammation are further increased, while tight junction proteins E-cadherin and ZO-1, ROS expression in neutrophils and AHR are diminished. ST2 neutralization recapitulated the enhanced ozone induced neutrophilic inflammation. However, myeloid cell depletion using GR1 antibody reduced ozone induced lung inflammation, epithelial cell injury and protein leak, while administration of rmIL-33 reduced neutrophil recruitment in IL-33 deficient mice. CONCLUSION: The data demonstrate that ozone causes an immediate barrier injury which precedes myeloid cell mediated inflammatory injury under the control of IL-33/ST2 axis. Thus, IL-33/ST2 signaling is critical for the maintenance of intact epithelial barrier and inflammation</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -CO - France -CO - Switzerland -CO - Malaysia -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.11.044</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29331644">PM:29331644</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180106-MichaudelC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180106-MichaudelC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180106, Michaudel C</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.11.044</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43836</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dyjack,N.</style></author><author><style face="normal" font="default"> Goleva,E.</style></author><author><style face="normal" font="default"> Rios,C.</style></author><author><style face="normal" font="default"> Kim,B.E.</style></author><author><style face="normal" font="default"> Bin,L.</style></author><author><style face="normal" font="default"> Taylor,P.</style></author><author><style face="normal" font="default"> Bronchick,C.</style></author><author><style face="normal" font="default"> Hall,C.F.</style></author><author><style face="normal" font="default"> Richers,B.N.</style></author><author><style face="normal" font="default"> Seibold,M.A.</style></author><author><style face="normal" font="default"> Leung,D.Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Genes, Environment, and Health, National Jewish Health, 1400 Jackson St. Denver, CO</style></auth-address><titles><title><style face="normal" font="default">Minimally invasive skin tape strip RNA-seq identifies novel characteristics of type 2-high atopic dermatitis disease endotype</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="1" Year="2018">2018/1/5</year></dates><abstract><style face="normal" font="default">BACKGROUND: Expression profiling of skin biopsies has established molecular features of the skin in atopic dermatitis (AD). Invasiveness of biopsies has prevented their use in defining individual level AD pathobiological mechanisms (endotypes) in large research studies. OBJECTIVE: To determine if minimally invasive skin tape strip transcriptome analysis identifies gene expression dysregulation in AD and molecular disease endotypes. METHODS: We sampled non-lesional and lesional skin tape strips and biopsies from adult Caucasian subjects AD patients (18 males, 12 females; age (Mean+/-SE) 36.3+/-2.2 yrs) and healthy controls (9 males, 16 females; age (Mean+/-SE) 34.8+/-2.2 yrs). Ampliseq whole transcriptome sequencing was performed on extracted RNA. Differential expression, clustering/pathway analyses, immunostaining of skin biopsies, and clinical trait correlations were performed. RESULTS: Skin tape expression profiles were distinct from skin biopsy profiles and better sampled epidermal differentiation complex genes. Skin tape expression of 29 immune and epidermis-related genes (FDR&lt;5%) separated AD from healthy subjects. Agnostic gene set analyses and clustering revealed 50% of AD subjects exhibited a type 2 inflammatory signature (type 2-high endotype) characterized by differential expression of 656 genes including overexpression of IL13, IL4R, CCL22, CCR4 (log2FC=5.5, 2.0, 4.0, and 4.1, respectively), and at a pathway level by T-helper 2/dendritic cell activation. Both expression and immunostaining of skin biopsies indicated this type 2-high group was enriched for inflammatory, type 2-skewed dendritic cells expressing the high affinity IgE receptor (FcepsilonRI). The type 2-high endotype group exhibited more severe disease by both EASI score and body surface area covered by lesions. CONCLUSION: Minimally invasive expression profiling of non-lesional skin reveals stratification in AD molecular pathology by type 2 inflammation that correlates with disease severity</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.10.046</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29309794">PM:29309794</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180106-DyjackN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180106-DyjackN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180106, Dyjack N</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.10.046</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43837</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Akiyama,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.</style></auth-address><titles><title><style face="normal" font="default">The call for considering follicular helper T cells in IgG4-related disease</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="1" Year="2018">2018/1/9</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.11.017</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29329900">PM:29329900</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180106-AkiyamaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180106-AkiyamaM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180106, Akiyama M</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.11.017</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43838</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Laguna,J.J.</style></author><author><style face="normal" font="default"> Bogas,G.</style></author><author><style face="normal" font="default"> Salas,M.</style></author><author><style face="normal" font="default"> Mayorga,C.</style></author><author><style face="normal" font="default"> Dionicio,J.</style></author><author><style face="normal" font="default"> Gonzalez-Mendiola,R.</style></author><author><style face="normal" font="default"> Ariza,A.</style></author><author><style face="normal" font="default"> Fernandez-Santamaria,R.</style></author><author><style face="normal" font="default"> Olazabal,I.</style></author><author><style face="normal" font="default"> Dona,I.</style></author><author><style face="normal" font="default"> Fernandez,T.D.</style></author><author><style face="normal" font="default"> Torres,M.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy Unit, Hospital de la Cruz Roja, Madrid, Spain; Immunology Department, Alfonso X el Sabio University, Madrid, Spain</style></auth-address><titles><title><style face="normal" font="default">The Basophil Activation Test Can Be of Value for Diagnosing Immediate Allergic Reactions to Omeprazole</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="1" Year="2018">2018/1/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Proton pump inhibitors (PPIs) are commonly used to treat gastrointestinal diseases. Incidence of hypersensitivity reactions to PPIs has risen, likely because of increased consumption. Their diagnosis is difficult, with skin tests (STs) presenting low sensitivity, making it necessary to perform drug provocation tests (DPTs). The value of in vitro tests for the diagnosis of immediate reaction to PPI is unclear. OBJECTIVE: To analyze the diagnostic value of the basophil activation test (BAT) in a group of patients diagnosed with immediate allergy to omeprazole. METHODS: The study included 42 patients with confirmed immediate allergic reactions to omeprazole confirmed by positive ST results or DPT results and 22 age- and sex-matched subjects tolerant to PPIs. BAT was performed with omeprazole, pantoprazole, and lansoprazole using CD63 and CD203c as activation markers. RESULTS: ST sensitivity was 66.7% with a specificity of 100%. BAT using CD63 with a stimulation index of more than 2 as positive revealed a sensitivity of 73.8%, a specificity of 100%, a positive predictive value of 100%, and a negative predictive value of 66.7%. BAT was positive in 57.1% of patients with negative ST result, and thus by combining ST and BAT we can correctly diagnose 85.7% of patients with immediate allergy to omeprazole. CONCLUSION: BAT represents a complementary tool for inclusion in the allergological workup for patients allergic to omeprazole. When combined with ST, it can be of value to guide the clinician as to whether to perform a DPT</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Spain -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.12.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29339127">PM:29339127</url></web-urls></urls><custom2><style face="normal" font="default">20180112, Laguna JJ</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.12.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43839</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rosas-Salazar,C.</style></author><author><style face="normal" font="default"> Shilts,M.H.</style></author><author><style face="normal" font="default"> Tovchigrechko,A.</style></author><author><style face="normal" font="default"> Schobel,S.</style></author><author><style face="normal" font="default"> Chappell,J.D.</style></author><author><style face="normal" font="default"> Larkin,E.K.</style></author><author><style face="normal" font="default"> Gebretsadik,T.</style></author><author><style face="normal" font="default"> Halpin,R.A.</style></author><author><style face="normal" font="default"> Nelson,K.E.</style></author><author><style face="normal" font="default"> Moore,M.L.</style></author><author><style face="normal" font="default"> Anderson,L.J.</style></author><author><style face="normal" font="default"> Peebles,R.S.,Jr.</style></author><author><style face="normal" font="default"> Das,S.R.</style></author><author><style face="normal" font="default"> Hartert,T.V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN; Center for Asthma Research, Vanderbilt University School of Medicine, Nashville, TN</style></auth-address><titles><title><style face="normal" font="default">Nasopharyngeal Lactobacillus is Associated with Childhood Wheezing Illnesses Following Acute Respiratory Syncytial Virus Infection in Infancy</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="1" Year="2018">2018/1/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Early-life acute respiratory infection (ARI) with respiratory syncytial virus (RSV) has been strongly associated with the development of childhood wheezing illnesses, but the pathways underlying this association are poorly understood. OBJECTIVE: To examine the role of the nasopharyngeal microbiome in the development of childhood wheezing illnesses following RSV ARI in infancy. METHODS: We conducted a nested cohort study of 118 previously healthy, term infants with confirmed RSV ARI by RT-PCR. We used next-generation sequencing of the V4 region of the 16S rRNA gene to characterize the nasopharyngeal microbiome during RSV ARI. Our main outcome of interest was 2-year subsequent wheeze. RESULTS: One hundred thirteen (95.8%) of the 118 infants had 2-year outcome data. Of these, 46 (40.7%) had parental report of subsequent wheeze. There was no association between the overall taxonomic composition, diversity, and richness of the nasopharyngeal microbiome during RSV ARI with the development of subsequent wheeze. However, the nasopharyngeal detection and abundance of Lactobacillus was consistently higher in infants who did not develop this outcome. Lactobacillus also ranked first among the different genera in a model distinguishing infants with and without subsequent wheeze. CONCLUSION: The nasopharyngeal detection and increased abundance of Lactobacillus during RSV ARI in infancy are associated with a reduced risk of childhood wheezing illnesses at age 2 years</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.10.049</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29330010">PM:29330010</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180106-RosasSalazarC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180106-RosasSalazarC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180106, Rosas-Salazar C</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.10.049</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43840</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Losappio,L.M.</style></author><author><style face="normal" font="default"> Cappai,A.</style></author><author><style face="normal" font="default"> Arcolaci,A.</style></author><author><style face="normal" font="default"> Badiu,I.</style></author><author><style face="normal" font="default"> Bonadonna,P.</style></author><author><style face="normal" font="default"> Boni,E.</style></author><author><style face="normal" font="default"> Bussolino,C.</style></author><author><style face="normal" font="default"> Caminati,M.</style></author><author><style face="normal" font="default"> Galati,P.</style></author><author><style face="normal" font="default"> Heffler,E.</style></author><author><style face="normal" font="default"> Intravaia,R.</style></author><author><style face="normal" font="default"> Mauro,M.</style></author><author><style face="normal" font="default"> Massaro,I.</style></author><author><style face="normal" font="default"> Romano,A.</style></author><author><style face="normal" font="default"> Rumi,G.</style></author><author><style face="normal" font="default"> Parolo,A.</style></author><author><style face="normal" font="default"> Pizzimenti,S.</style></author><author><style face="normal" font="default"> Nichelatti,M.</style></author><author><style face="normal" font="default"> Pastorello,E.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy and Immunology Unit, Niguarda Ca' Granda Hospital, Milano, Italy.</style></auth-address><titles><title><style face="normal" font="default">Anxiety and Depression Effects during Drug Provocation Test</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol Pract</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol Pract</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="1" Year="2018">2018/1/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Drug provocation test (DPT) represents the gold standard for the diagnosis of drug allergy. A DPT can be performed in a single-blind placebo-controlled manner. In anxiety and depressive disorders, patients need to be evaluated to understand the nature of placebo reactions. OBJECTIVE: The aim of this study was to evaluate the psychological profile of patients with reactions to placebo during a DPT. METHODS: We consecutively enrolled patients with suspected drug allergy undergoing a DPT preceded by the administration of the placebo. All patients underwent the Hospital Anxiety and Depression Scale (HADS), a questionnaire aimed to identify anxiety and depression, before the challenge test. RESULTS: A total of 196 patients were enrolled into this study: 8 (4%) patients resulted positive to the DPT, 60 (30.6%) demonstrated anxiety or depression based on the HADS, and 54 had at least 1 placebo reaction during drug provocation. There were statically significant correlations between the positivity of the HADS and the finding of a placebo reaction (Fisher's exact test: P &lt; .001), and between the latter and a history of severe reactions to drug (Fisher's exact test: P &lt; .001). CONCLUSIONS: There is a significant and strong correlation between the loss of psychic equilibrium and the development of a placebo reaction during a DPT. We suggest the use the HADS or other validated questionnaire in clinical practice before a DPT to evaluate the possible psychiatric components</style></abstract><notes><style face="normal" font="default">IS - 2213-2201 (Electronic)LA - engPT - Journal ArticleCO - Italy -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaip.2017.12.005</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29339128">PM:29339128</url></web-urls></urls><custom2><style face="normal" font="default">20180112, Losappio LM</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaip.2017.12.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43841</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Panganiban,R.A.</style></author><author><style face="normal" font="default"> Sun,M.</style></author><author><style face="normal" font="default"> Dahlin,A.</style></author><author><style face="normal" font="default"> Park,H.R.</style></author><author><style face="normal" font="default"> Kan,M.</style></author><author><style face="normal" font="default"> Himes,B.E.</style></author><author><style face="normal" font="default"> Mitchel,J.A.</style></author><author><style face="normal" font="default"> Iribarren,C.</style></author><author><style face="normal" font="default"> Jorgenson,E.</style></author><author><style face="normal" font="default"> Randell,S.H.</style></author><author><style face="normal" font="default"> Israel,E.</style></author><author><style face="normal" font="default"> Tantisira,K.</style></author><author><style face="normal" font="default"> Shore,S.</style></author><author><style face="normal" font="default"> Park,J.A.</style></author><author><style face="normal" font="default"> Weiss,S.T.</style></author><author><style face="normal" font="default"> Wu,A.C.</style></author><author><style face="normal" font="default"> Lu,Q.</style></author></authors></contributors><auth-address><style face="normal" font="default">Program in Molecular and Integrative Physiological Sciences, Departments of Environmental Health and Genetics &amp; Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts 02115</style></auth-address><titles><title><style face="normal" font="default">A functional splicing variant associated with decreased asthma risk abolishes the ability of gasdermin B (GSMDB) to induce epithelial cell pyroptosis</style></title><secondary-title><style face="normal" font="default">J Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Allergy Clin Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="9" Month="1" Year="2018">2018/1/9</year></dates><abstract><style face="normal" font="default">BACKGROUND: Genetic variants in the chromosomal region 17q21 are consistently associated with asthma. However, mechanistic studies have not yet linked any of the associated variants to a function that could influence asthma, and as a result, the identity of the asthma gene(s) remains elusive. OBJECTIVES: We sought to identify and characterize functional variants in the 17q21 locus. METHODS: We used the Exome Aggregation Consortium (ExAC) browser to identify coding (amino acid-changing) variants in the 17q21 locus. We obtained asthma association measures for these variants in both the GERA cohort (16,274 cases and 38,269 matched controls) and the EVE Consortium study (5,303 asthma cases and 12,560 individuals). Gene expression and protein localization were determined by quantitative RT-PCR and fluorescence immunostaining, respectively. Molecular and cellular studies were performed to determine the functional effects of coding variants. RESULTS: Two coding variants (rs2305480 and rs11078928) of the gasdermin B (GSDMB) gene in the 17q21 locus were associated with lower asthma risk in both GERA (OR = 0.92; P= 1.01 x 10(-6)) and EVE (OR= 0.85; Joint PEVE = 1.31 x10(-13)). In GERA, rs11078928 had a minor allele frequency (MAF) of 0.45 in unaffected (non-asthmatic) controls and 0.43 in asthma cases. For European Americans in EVE the MAF of rs2305480 was 0.45 for controls and 0.39 for cases; for all EVE subjects the MAF was 0.32 for controls and 0.27 for cases. GSDMB is highly expressed in differentiated airway epithelial cells, including the ciliated cells. We found that when the GSDMB protein is cleaved by inflammatory caspase-1 to release its N-terminal fragment, potent pyroptotic cell death was induced. The splicing variant rs11078928 deletes the entire exon 6, which encodes 13 amino acids in the critical N-terminus, and abolishes the pyroptotic activity of the GSDMB protein. CONCLUSIONS: Our study identified a functional asthma variant in the GSDMB gene of the 17q21 locus and implicates GSDMB-mediated epithelial cell pyroptosis in pathogenesis</style></abstract><notes><style face="normal" font="default">IS - 1097-6825 (Electronic)IS - 0091-6749 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaci.2017.11.040</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29330013">PM:29330013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180106-PanganibanRA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Allergy Clin Immunol\20180106-PanganibanRA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180106, Panganiban RA</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaci.2017.11.040</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43842</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">He,A.</style></author><author><style face="normal" font="default"> Feldman,S.R.</style></author><author><style face="normal" font="default"> Fleischer,A.B.,Jr.</style></author></authors></contributors><auth-address><style face="normal" font="default">Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina</style></auth-address><titles><title><style face="normal" font="default">An assessment of the use of antihistamines in the management of atopic dermatitis</style></title><secondary-title><style face="normal" font="default">J Am Acad Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Am Acad Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="6" Month="1" Year="2018">2018/1/6</year></dates><abstract><style face="normal" font="default">BACKGROUND: Antihistamines are often used to treat pruritus associated with atopic dermatitis (AD) despite lack of evidence for their efficacy. The American Academy of Dermatology does not recommend the general use of antihistamines in the management of AD, although the value of short-term sedating antihistamine use for insomnia secondary to itch is recognized. OBJECTIVE: To assess the use of sedating and non-sedating antihistamines for AD from 2003-2012. METHODS: The National Ambulatory Medical Care Survey (NAMCS) provided data on physician visits from 2003-2012. Sedating and non-sedating antihistamine use was identified at AD visits. RESULTS: There were 990,000 annual visits for AD. Antihistamines were prescribed for AD in a significant proportion of visits across physician specialties (16-44%). Dermatologists and pediatricians primarily used sedating antihistamines (58-70%), while the majority of family/general practitioners, internists, and other specialists prescribed non-sedating antihistamines for AD (55-100%) LIMITATIONS: We were limited by the accuracy of AD diagnosis and medication recording. CONCLUSIONS: Antihistamines are widely used for the treatment of AD. There is no high-level evidence to suggest that non-sedating antihistamines reduce itch in patients with AD, or that sedating antihistamines provide benefit in controlling AD symptoms (except perhaps sleep and AD co-morbidities, such as allergic rhinitis)</style></abstract><notes><style face="normal" font="default">IS - 1097-6787 (Electronic)IS - 0190-9622 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.jaad.2017.12.077</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29317281">PM:29317281</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Am Acad Dermatol\20180106-HeA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Am Acad Dermatol\20180106-HeA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180106, He A</style></custom2><misc3><style face="normal" font="default">10.1016/j.jaad.2017.12.077</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43843</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Schwantes,E.A.</style></author><author><style face="normal" font="default"> Evans,M.D.</style></author><author><style face="normal" font="default"> Cuskey,A.</style></author><author><style face="normal" font="default"> Burford,A.</style></author><author><style face="normal" font="default"> Smith,J.A.</style></author><author><style face="normal" font="default"> Lemanske,R.F.,Jr.</style></author><author><style face="normal" font="default"> Jarjour,N.N.</style></author><author><style face="normal" font="default"> Mathur,S.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergy, Pulmonary and Critical Care, Department of MedicineDivision of Allergy, Pulmonary and Critical Care, Department of Medicine</style></auth-address><titles><title><style face="normal" font="default">Elevated fractional exhaled nitric oxide and blood eosinophil counts are associated with a 17q21 asthma risk allele in adult subjects</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="9" start="1">1-9</pages><volume><style face="normal" font="default">11</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="default">Background and objectives: Genome-wide association studies identified single-nucleotide polymorphisms (SNPs) at the 17q21 locus conferring increased risk for childhood-onset asthma. Little is known about how these SNPs impact adult asthma patients. We sought to examine an adult population for associations between rs7216389 (17q21-associated SNP) and features of asthma including fractional exhaled nitric oxide (FeNO), eosinophil counts, and age of asthma onset. Methods: Subjects were genotyped at SNP rs7216389. The geometric mean of FeNO measurements and peripheral blood eosinophil counts from 2008 to 2015 were collected. Demographics and medical history were collected including self-reported allergy diagnoses and age of asthma onset. Eosinophils, monocytes, and peripheral blood mononuclear cells (PBMCs) were isolated for the examination of ORMDL3 expression. Results: FeNO levels from 157 genotyped subjects (31CC, 72CT, and 54TT) and peripheral eosinophil counts from 252 genotyped subjects (46CC, 122CT, and 84TT) were analyzed. In a sub-group analysis of asthma subjects, the number of attributable T alleles was associated with significantly lower age of asthma onset (P=0.03) and greater FeNO levels (geometric mean 30.0 ppb TT, 20.0 ppb CT, 20.0 ppb CC, P=0.02). In the total cohort of subjects, the T allele was associated with a higher percentage of individual eosinophil counts >200/mm(3) (45% TT, 26% CT, 24% CC, P=0.005). Eosinophils expressed ORMDL3 mRNA and protein. Conclusion: In adult subjects, the number of T alleles at SNP rs7216389 corresponds to significantly greater FeNO levels and peripheral eosinophil counts. The expression of ORMDL3 in eosinophils suggests that they may participate in mediating the asthma risk associated with the 17q21 locus</style></abstract><notes><style face="normal" font="default">IS - 1178-6965 (Print)IS - 1178-6965 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2147/JAA.S149183</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29296089">PM:29296089</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2018-11-1-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2018-11-1-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171219, Schwantes EA</style></custom2><misc3><style face="normal" font="default">10.2147/JAA.S149183</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43844</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Uwaezuoke,S.N.</style></author><author><style face="normal" font="default"> Ayuk,A.C.</style></author><author><style face="normal" font="default"> Eze,J.N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Severe bronchial asthma in children: a review of novel biomarkers used as predictors of the disease</style></title><secondary-title><style face="normal" font="default">J Asthma Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Asthma Allergy</style></abbr-1></periodical><pages end="18" start="11">11-18</pages><volume><style face="normal" font="default">11</style></volume><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="default">Severe asthma or therapy-resistant asthma in children is a heterogeneous disease that affects all age-groups. Given its heterogeneity, precision in diagnosis and treatment has become imperative, in order to achieve better outcomes. If one is thus able to identify specific patient phenotypes and endotypes using the appropriate biomarkers, it will assist in providing the patient with more personalized and appropriate treatment. However, there appears to be a huge diagnostic gap in severe asthma, as there is no single test yet that accurately determines disease phenotype. In this paper, we review the published literature on some of these biomarkers and their possible role in bridging this diagnostic gap. We also highlight the cellular and molecular mechanisms involved in severe asthma, in order to show the basis for the novel biomarkers. Some markers useful for monitoring therapy and assessing airway remodeling in the disease are also discussed. A review of the literature was conducted with PubMed to gather baseline data on the subject. The literature search extended to articles published within the last 40 years. Although biomarkers specific to different severe asthma phenotypes have been identified, progress in their utility remains slow, because of several disease mechanisms, the variation of biomarkers at different levels of inflammation, changes in relying on one test over time (eg, from sputum eosinophilia to blood eosinophilia), and the degree of invasive tests required to collect biomarkers, which limits their applicability in clinical settings. In conclusion, several biomarkers remain useful in recognizing various asthma phenotypes. However, due to disease heterogeneity, identification and utilization of ideal and defined biomarkers in severe asthma are still inconclusive. The development of novel serum/sputum-based biomarker panels with enhanced sensitivity and specificity may lead to prompt diagnosis of the disease in the future.</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Nigeria -</style></notes><work-type><style face="normal" font="default">10.2147/JAA.S149577</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.2147/JAA.S149577</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Asthma Allergy\2018-11-11-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Asthma Allergy\2018-11-11-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180110, Uwaezuoke SN</style></custom2><misc3><style face="normal" font="default">10.2147/JAA.S149577</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43845</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lee,Y.B.</style></author><author><style face="normal" font="default"> Lee,J.H.</style></author><author><style face="normal" font="default"> Kang,M.J.</style></author><author><style face="normal" font="default"> Choi,J.Y.</style></author><author><style face="normal" font="default"> Kim,J.W.</style></author><author><style face="normal" font="default"> Yu,D.S.</style></author><author><style face="normal" font="default"> Han,K.D.</style></author><author><style face="normal" font="default"> Park,Y.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, College of Medicine, The Catholic University of Korea, Uijeongbu St Mary's Hospital, Gyeonggi-do, Korea</style></auth-address><titles><title><style face="normal" font="default">Association between allergic diseases and ophthalmologic diseases, including cataracts and glaucoma, using the Korean National Health and Nutrition Examination Survey 2010-2012: A STROBE-compliant article</style></title><secondary-title><style face="normal" font="default">J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="1" Year="2018">2018/1/4</year></dates><abstract><style face="normal" font="default">This study investigated the association between allergic diseases and comorbid ophthalmologic diseases. We enrolled 14 776 participants who were at least 19 years of age. Multiple logistic regression analyses were used to evaluate the odds ratios for cataracts and glaucoma according to the presence of allergic diseases. Atopic dermatitis was not associated with the development of cataracts and glaucoma. However, asthma and allergic rhinitis were significantly associated with cataracts (hazard ratio [HR] = 1.511, 95% confidence interval [CI] = 1.120-2.039 and HR = 1.565, 95% CI = 1.192-2.054, respectively). This study examined a nationwide, population-based survey, and concluded that cataracts were significantly associated with asthma and allergic rhinitis but not with atopic dermatitis. Efforts should be made to reduce the risk of ophthalmologic complications when treating patients with allergic diseases</style></abstract><notes><style face="normal" font="default">IS - 1346-8138 (Electronic)IS - 0385-2407 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1111/1346-8138.14193</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29315741">PM:29315741</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatol\20180104-LeeYB.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatol\20180104-LeeYB.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180104, Lee YB</style></custom2><misc3><style face="normal" font="default">10.1111/1346-8138.14193</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43846</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Otobe,S.</style></author><author><style face="normal" font="default"> Sugaya,M.</style></author><author><style face="normal" font="default"> Nakajima,R.</style></author><author><style face="normal" font="default"> Oka,T.</style></author><author><style face="normal" font="default"> Takahashi,N.</style></author><author><style face="normal" font="default"> Kabasawa,M.</style></author><author><style face="normal" font="default"> Miyagaki,T.</style></author><author><style face="normal" font="default"> Asano,Y.</style></author><author><style face="normal" font="default"> Sato,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan</style></auth-address><titles><title><style face="normal" font="default">Increased interleukin-36gamma expression in skin and sera of patients with atopic dermatitis and mycosis fungoides/Sezary syndrome</style></title><secondary-title><style face="normal" font="default">J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="3" Month="1" Year="2018">2018/1/3</year></dates><abstract><style face="normal" font="default">Interleukin (IL)-36gamma is expressed by keratinocytes and functions as a key initiator of inflammation in the skin. IL-36gamma expression is enhanced by tumor necrosis factor-alpha and IL-17A, having a strong association with psoriasis. In this study, we examined the role of IL-36gamma in atopic dermatitis (AD) and mycosis fungoides (MF)/Sezary syndrome (SS). Serum levels of IL-36gamma in AD patients and MF/SS patients were elevated compared with those of healthy controls. Importantly, serum IL-36gamma levels in AD patients positively correlated with Eczema Area and Severity Index and those of MF/SS patients positively correlated with serum soluble IL-2 receptor levels. IL-36gamma mRNA levels in AD skin and MF/SS skin were significantly higher than those of normal skin. IL-36gamma mRNA levels in MF/SS skin positively correlated with IL-17A mRNA levels. Immunohistochemical staining revealed that IL-36gamma was highly expressed in keratinocytes in lesional skin of AD and MF/SS. Taken together, our study demonstrated that IL-36gamma expression was increased in sera and skin of patients with AD and MF/SS as was reported in psoriatic patients</style></abstract><notes><style face="normal" font="default">IS - 1346-8138 (Electronic)IS - 0385-2407 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1111/1346-8138.14198</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29314201">PM:29314201</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Dermatol\20180103-OtobeS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Dermatol\20180103-OtobeS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180103, Otobe S</style></custom2><misc3><style face="normal" font="default">10.1111/1346-8138.14198</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43847</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,T.</style></author><author><style face="normal" font="default"> Barrett,N.A.</style></author><author><style face="normal" font="default"> Kanaoka,Y.</style></author><author><style face="normal" font="default"> Yoshimoto,E.</style></author><author><style face="normal" font="default"> Garofalo,D.</style></author><author><style face="normal" font="default"> Cirka,H.</style></author><author><style face="normal" font="default"> Feng,C.</style></author><author><style face="normal" font="default"> Boyce,J.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA 02115</style></auth-address><titles><title><style face="normal" font="default">Type 2 Cysteinyl Leukotriene Receptors Drive IL-33-Dependent Type 2 Immunopathology and Aspirin Sensitivity</style></title><secondary-title><style face="normal" font="default">J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="27" Month="12" Year="2017">2017/12/27</year></dates><abstract><style face="normal" font="default">Cysteinyl leukotrienes (cysLTs) facilitate mucosal type 2 immunopathology by incompletely understood mechanisms. Aspirin-exacerbated respiratory disease, a severe asthma subtype, is characterized by exaggerated eosinophilic respiratory inflammation and reactions to aspirin, each involving the marked overproduction of cysLTs. Here we demonstrate that the type 2 cysLT receptor (CysLT2R), which is not targeted by available drugs, is required in two different models to amplify eosinophilic airway inflammation via induced expression of IL-33 by lung epithelial cells. Endogenously generated cysLTs induced eosinophilia and expanded group 2 innate lymphoid cells (ILC2s) in aspirin-exacerbated respiratory disease-like Ptges(-/-) mice. These responses were mitigated by deletions of either Cysltr2 or leukotriene C4 synthase (Ltc4s). Administrations of either LTC4 (the parent cysLT) or the selective CysLT2R agonist N-methyl LTC4 to allergen sensitized wild-type mice markedly boosted ILC2 expansion and IL-5/IL-13 generation in a CysLT2R-dependent manner. Expansion of ILC2s and IL-5/IL-13 generation reflected CysLT2R-dependent production of IL-33 by alveolar type 2 cells, which engaged in a bilateral feed-forward loop with ILC2s. Deletion of Cysltr1 blunted LTC4-induced ILC2 expansion and eosinophilia but did not alter IL-33 induction. Pharmacological blockade of CysLT2R prior to inhalation challenge of Ptges(-/-) mice with aspirin blocked IL-33-dependent mast cell activation, mediator release, and changes in lung function. Thus, CysLT2R signaling, IL-33-dependent ILC2 expansion, and IL-33-driven mast cell activation are necessary for induction of type 2 immunopathology and aspirin sensitivity. CysLT2R-targeted drugs may interrupt these processes</style></abstract><notes><style face="normal" font="default">IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.4049/jimmunol.1700603</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29282304">PM:29282304</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Immunol\20171227-LiuT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Immunol\20171227-LiuT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171227, Liu T</style></custom2><misc3><style face="normal" font="default">10.4049/jimmunol.1700603</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43848</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Deacon,K.</style></author><author><style face="normal" font="default"> Knox,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Respiratory Medicine, University of Nottingham, Nottingham NG5 1PB, United Kingdom</style></auth-address><titles><title><style face="normal" font="default">PINX1 and TERT Are Required for TNF-alpha-Induced Airway Smooth Muscle Chemokine Gene Expression</style></title><secondary-title><style face="normal" font="default">J Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="1" Year="2018">2018/1/5</year></dates><abstract><style face="normal" font="default">Airway smooth muscle (ASM) cells contribute to asthmatic lung pathology with chemokine hypersecretion and increased ASM cell mass. With little recent progress in the development of asthma therapies, a greater understanding of lung inflammation mechanisms has become a priority. Chemokine gene expression in ASM cells is dependent upon NF-kappaB transcription factor activity. The telomerase/shelterin complex maintains chromosomal telomere ends during cell division. Telomerase is a possible cofactor for NF-kappaB activity, but its role in NF-kappaB activity in airway tissue inflammation is not known. In this study, we sought to address two key questions: whether telomerase is involved in inflammation in ASM cells, and whether components of the shelterin complex are also required for an inflammatory response in ASM cells. Telomerase inhibitors and telomerase small interfering RNA (siRNA) reduced TNF-alpha-induced chemokine expression in ASM cells. Telomerase siRNA and inhibitors reduced NF-kappaB activity. An siRNA screen of shelterin components identified a requirement for PIN2/TERF1 interacting-telomerase inhibitor 1 (PINX1) in chemokine gene expression. High-level PINX1 overexpression reduced NF-kappaB reporter activity, but low-level expression amplified NF-kappaB activity. Coimmunoprecipitation studies showed association of PINX1 and p65. Overexpression of the N terminus (2-252 aa) of PINX1, but not the C-terminal telomerase-inhibitor domain (253-328 aa), amplified TNF-alpha-induced NF-kappaB activity. GST pull-downs demonstrated that the N terminus of PINX1 bound more p65 than the C-terminal telomerase-inhibitor domain; these observations were confirmed in whole cells with N-terminal and C-terminal PINX1 immunoprecipitation. We conclude that telomerase and PINX1 are required for chemokine expression in ASM cells and represent significant new targets for future anti-inflammatory therapies for lung diseases, such as asthma</style></abstract><notes><style face="normal" font="default">IS - 1550-6606 (Electronic)IS - 0022-1767 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.4049/jimmunol.1700414</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29305433">PM:29305433</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Immunol\20171227-DeaconK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Immunol\20171227-DeaconK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171227, Deacon K</style></custom2><misc3><style face="normal" font="default">10.4049/jimmunol.1700414</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43849</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Shane,H.L.</style></author><author><style face="normal" font="default"> Lukomska,E.</style></author><author><style face="normal" font="default"> Stefaniak,A.B.</style></author><author><style face="normal" font="default"> Anderson,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Health Effects Laboratory Division , National Institute for Occupational Safety and Health , Morgantown , WV , USA</style></auth-address><titles><title><style face="normal" font="default">Divergent hypersensitivity responses following topical application of the quaternary ammonium compound, didecyldimethylammonium bromide</style></title><secondary-title><style face="normal" font="default">J Immunotoxicol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Immunotoxicol</style></full-title></periodical><pages end="214" start="204">204-214</pages><volume><style face="normal" font="default">14</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">Didecyldimethylammonium bromide (DDAB) is a fourth generation dialkyl-quaternary ammonium compound (QAC) that is used in numerous products for its antimicrobial properties. While many QACs have been associated with allergic disease, the toxicity and sensitization of DDAB have not been thoroughly investigated. The purpose of these studies was to evaluate the irritancy and sensitization potential of DDAB following dermal application in a murine model. DDAB induced significant irritancy (0.0625-2%), evaluated by ear swelling in female BALB/c mice. Initial evaluation of the sensitization potential was conducted using the local lymph node assay (LLNA) at concentrations ranging from 0.0625% to 2%. A concentration-dependent increase in lymphocyte proliferation was observed with a calculated EC3 value of 0.057%. Immune cell phenotyping along with local and systemic IgE levels were evaluated following 4 and 14 days of dermal application. Phenotypic analyses revealed significant and dose-responsive increases in the absolute number of B-cells, CD4+ T-cells, CD8+ T-cells, and dendritic cells in the draining lymph nodes (DLNs) following 4 and 14 days of dermal exposure with significant increases in the number of activated B-cells and dendritic cells. However, increased activation of CD4+ T-cell and CD8+ T-cells was only observed following four days of DDAB exposure. Exposure to DDAB also induced increased production of IgE as evaluated by phenotypic analysis of DLN B-cells (IgE+ B-cells) and measurement of total serum IgE levels following 14 days but not four days of dermal application. Significant increases in gene expression were observed in the DLN (Il-4, Il-10, and ox40l) and ear (tslp) following 4 and 14 days of DDAB exposure. These results demonstrate the potential for development of irritation and hypersensitivity responses to DDAB following dermal exposure and raise concerns about the effects of exposure duration on hypersensitivity responses</style></abstract><notes><style face="normal" font="default">DA - 20171110IS - 1547-6901 (Electronic)IS - 1547-691X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/1547691X.2017.1397826</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29124973">PM:29124973</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Immunotoxicol\2017-14-204-14.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Immunotoxicol\2017-14-204-14.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171214, Shane HL</style></custom2><misc3><style face="normal" font="default">10.1080/1547691X.2017.1397826</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43850</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Baghlaf,H.</style></author><author><style face="normal" font="default"> Spence,A.R.</style></author><author><style face="normal" font="default"> Czuzoj-Shulman,N.</style></author><author><style face="normal" font="default"> Abenhaim,H.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Obstetrics and Gynecology , Jewish General Hospital, McGill University , Montreal , Canada</style></auth-address><titles><title><style face="normal" font="default">Pregnancy outcomes among women with asthma</style></title><secondary-title><style face="normal" font="default">J Matern Fetal Neonatal Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Matern Fetal Neonatal Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="22" Month="11" Year="2017">2017/11/22</year></dates><abstract><style face="normal" font="default">PURPOSE: The purpose of this study is to examine the association between maternal asthma and pregnancy, delivery and neonatal outcomes. MATERIALS AND METHODS: We carried out a retrospective cohort study using the Health Care Cost and Utilization Project-Nationwide Inpatient Sample (HCUP-NIS) database from 2003 to 2011. Among women who delivered during this time period, we compared pregnancy, delivery, and neonatal outcomes in asthmatics versus non-asthmatics. Multivariate logistic regression was used to estimate adjusted odds ratios and 95% confidence intervals. RESULTS: In a cohort of 7,772,999 pregnant women, 223,236 (2.9%) had asthma. The prevalence of asthma-complicated pregnancies rose over the study period from 1.9% in 2003 to 3.7% in 2011 (p &lt; .001). Pregnant asthmatics had more pre-existing health conditions, such as diabetes, chronic hypertension, obesity, and thyroid disease, and were more likely to smoke. Even after adjustment for these comorbidities, and other covariates, within statistical models, asthma was found to be associated with greater risk of several pregnancy complications: gestational hypertension, preeclampsia, gestational diabetes, placenta previa, preterm premature rupture of membranes, placental abruption, chorioamnionitis, preterm delivery, postpartum hemorrhage, venous thromboembolism, caesarean section delivery, and maternal mortality. Neonates born to asthmatics had greater risk of being small for gestational age and for having congenital anomalies, and lower risk of intrauterine fetal death. CONCLUSIONS: Asthma is associated with an increase in adverse pregnancy, labor, and neonatal outcomes. Close surveillance of asthmatic patients during the prenatal period is warranted and care in a tertiary hospital is advised</style></abstract><notes><style face="normal" font="default">IS - 1476-4954 (Electronic)IS - 1476-4954 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1080/14767058.2017.1404982</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29166819">PM:29166819</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Matern Fetal Neonatal Med\20171122-BaghlafH.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Matern Fetal Neonatal Med\20171122-BaghlafH.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171122, Baghlaf H</style></custom2><misc3><style face="normal" font="default">10.1080/14767058.2017.1404982</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43851</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Coudray,S.</style></author><author><style face="normal" font="default"> Fabre,C.</style></author><author><style face="normal" font="default"> Aichoun,I.</style></author><author><style face="normal" font="default"> Perez-Martin,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Anaphylactic shock with an ultrasound contrast agent</style></title><secondary-title><style face="normal" font="default">J Med Vasc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Med Vasc</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Allergic reaction</style></keyword><keyword><style face="normal" font="default"> Shock</style></keyword><keyword><style face="normal" font="default"> Ultrasound contrast agent</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2542-4513</style></isbn><abstract><style face="normal" font="default">Summary Echo contrast agents, such as SonoVue-«, (Bracco, Milan, Italy) are often used to enhance diagnosis. Although their use is safe, some rare side effects could be severe or even fatal. We are reporting a case of severe systemic allergic reaction after infusion of SonoVue-«. After a brief review of the literature, the aim of this paper is to draw attention to this risk and recall the safety instructions coming with the use of ultrasound contrast agents</style></abstract><notes><style face="normal" font="default">LA - ENGCO - France -</style></notes><work-type><style face="normal" font="default">10.1016/j.jdmv.2017.10.001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29203045">PM:29203045</url></web-urls></urls><custom2><style face="normal" font="default">20171103, Coudray S</style></custom2><misc3><style face="normal" font="default">10.1016/j.jdmv.2017.10.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43852</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pawel,J.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Sports Medicine &amp; Dietetics, University School of Physical Education, Wroclaw, Poland</style></auth-address><titles><title><style face="normal" font="default">A Change in Pregnancy Rate Due to Exercise Training in Men?</style></title><secondary-title><style face="normal" font="default">J Obstet Gynaecol Can</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Obstet Gynaecol Can</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="2" Month="11" Year="2017">2017/11/2</year></dates><notes><style face="normal" font="default">DA - 20171106IS - 1701-2163 (Print)IS - 1701-2163 (Linking)LA - engPT - LetterCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.jogc.2017.09.019</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29103919">PM:29103919</url></web-urls><related-urls><url ppv-ref="no">presto - 2 anni</url></related-urls></urls><custom2><style face="normal" font="default">20171102, Pawel J</style></custom2><misc3><style face="normal" font="default">10.1016/j.jogc.2017.09.019</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43853</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Harju,M.</style></author><author><style face="normal" font="default"> Pekkanen,J.</style></author><author><style face="normal" font="default"> Heinonen,S.</style></author><author><style face="normal" font="default"> Keski-Nisula,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Obstetrics and Gynecology, Kuopio University Hospital, Kuopio, Finland</style></auth-address><titles><title><style face="normal" font="default">Maternal anemia during pregnancy and slightly higher risk of asthma in male offspring</style></title><secondary-title><style face="normal" font="default">J Obstet Gynaecol Res</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Obstet Gynaecol Res</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="1" Year="2018">2018/1/4</year></dates><abstract><style face="normal" font="default">AIM: We aimed to determine whether maternal hemoglobin levels or anemia during pregnancy are associated with the development of asthma among offspring. METHODS: Data were retrieved from the birth register database of Kuopio University Hospital between 1989 and 2007 (n = 38 381). Hemoglobin levels were measured during three trimesters of pregnancy and anemia was defined according to the World Health Organization criteria. The prevalence of asthma was determined from the register of reimbursement for medication for asthma at the Finnish Social Security Institution. Cox proportional hazard regression analysis was performed to evaluate the possible associations between prenatal factors and development of asthma ever. RESULTS: A total of 8198 (21.4%) women had anemia at some stage of pregnancy. Mild maternal anemia during the first trimester was associated with an increased risk of asthma among male offspring (adjusted hazard ratio, 1.46; 95% confidence interval, 1.11-1.94) compared with those with normal maternal hemoglobin levels. This finding remained significant also after applying the Bonferroni correction. CONCLUSION: Male offspring with maternal anemia during the first trimester of pregnancy had significantly more asthma ever than the offspring of women with normal hemoglobin levels during pregnancy. These findings were not strong but suggest possible sex-specific effects of maternal health on prenatal programming and future risk of asthma</style></abstract><notes><style face="normal" font="default">IS - 1447-0756 (Electronic)IS - 1341-8076 (Linking)LA - engPT - Journal ArticleCO - Finland -</style></notes><work-type><style face="normal" font="default">10.1111/jog.13569</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29314471">PM:29314471</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Obstet Gynaecol Res\20180104-HarjuM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Obstet Gynaecol Res\20180104-HarjuM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180104, Harju M</style></custom2><misc3><style face="normal" font="default">10.1111/jog.13569</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43854</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Steinemann,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Adjunct Professor, College of Science and Engineering, James Cook University, Townsville Queensland 4811 Australia</style></auth-address><titles><title><style face="normal" font="default">National Prevalence and Effects of Multiple Chemical Sensitivities</style></title><secondary-title><style face="normal" font="default">J Occup Environ Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">J Occup Environ Med</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="1" Year="2018">2018/1/11</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To assess the prevalence of multiple chemical sensitivities (MCS), its co-occurrence with asthma and fragrance sensitivity, and effects from exposure to fragranced consumer products. METHODS: A nationally representative cross-sectional population-based sample of adult Americans (n = 1,137) was surveyed in June 2016. RESULTS: Among the population, 12.8% report medically diagnosed MCS and 25.9% report chemical sensitivity. Of those with MCS, 86.2% experience health problems, such as migraine headaches, when exposed to fragranced consumer products; 71.0% are asthmatic; 70.3% cannot access places that use fragranced products such as air fresheners; and 60.7% lost workdays or a job in the past year due to fragranced products in the workplace. CONCLUSIONS: Prevalence of diagnosed MCS has increased over 300%, and self-reported chemical sensitivity over 200%, in the past decade. Reducing exposure to fragranced products could help reduce adverse health and societal effects.This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0</style></abstract><notes><style face="normal" font="default">IS - 1536-5948 (Electronic)IS - 1076-2752 (Linking)LA - engPT - Journal ArticleCO - Australia -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/JOM.0000000000001272</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29329146">PM:29329146</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Occup Environ Med\20180111-SteinemannA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Occup Environ Med\20180111-SteinemannA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180111, Steinemann A</style></custom2><misc3><style face="normal" font="default">10.1097/JOM.0000000000001272</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43855</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Xu,S.</style></author><author><style face="normal" font="default"> Kwa,M.</style></author><author><style face="normal" font="default"> Silverberg,J.I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IllinoisDepartment of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IllinoisDepartment of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois</style></auth-address><titles><title><style face="normal" font="default">Allergen Concerns and Popular Skin Care Products-Reply</style></title><secondary-title><style face="normal" font="default">JAMA Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JAMA Dermatol</style></abbr-1></periodical><pages end="116" start="115">115-116</pages><volume><style face="normal" font="default">154</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 2168-6084 (Electronic)IS - 2168-6068 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1001/jamadermatol.2017.5000</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29188272">PM:29188272</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Dermatol\2018-57-115-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Dermatol\2018-57-115-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180101, Xu S</style></custom2><misc3><style face="normal" font="default">10.1001/jamadermatol.2017.5000</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43856</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Harview,C.L.</style></author><author><style face="normal" font="default"> Hsiao,J.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los AngelesDivision of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles</style></auth-address><titles><title><style face="normal" font="default">Allergen Concerns and Popular Skin Care Products</style></title><secondary-title><style face="normal" font="default">JAMA Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JAMA Dermatol</style></abbr-1></periodical><pages end="" start="114">114-</pages><volume><style face="normal" font="default">154</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 2168-6084 (Electronic)IS - 2168-6068 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1001/jamadermatol.2017.4999</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29188287">PM:29188287</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Dermatol\2018-57-114.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Dermatol\2018-57-114.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180101, Harview CL</style></custom2><misc3><style face="normal" font="default">10.1001/jamadermatol.2017.4999</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43857</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hamann,C.R.</style></author><author><style face="normal" font="default"> Thyssen,J.P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark</style></auth-address><titles><title><style face="normal" font="default">Allergen Concerns and Popular Skin Care Products</style></title><secondary-title><style face="normal" font="default">JAMA Dermatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JAMA Dermatol</style></abbr-1></periodical><pages end="115" start="114">114-115</pages><volume><style face="normal" font="default">154</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 2168-6084 (Electronic)IS - 2168-6068 (Linking)LA - engPT - Journal ArticleCO - Denmark -</style></notes><work-type><style face="normal" font="default">10.1001/jamadermatol.2017.5001</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29188288">PM:29188288</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Dermatol\2018-57-114-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Dermatol\2018-57-114-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180101, Hamann CR</style></custom2><misc3><style face="normal" font="default">10.1001/jamadermatol.2017.5001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43858</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Halterman,J.S.</style></author><author><style face="normal" font="default"> Fagnano,M.</style></author><author><style face="normal" font="default"> Tajon,R.S.</style></author><author><style face="normal" font="default"> Tremblay,P.</style></author><author><style face="normal" font="default"> Wang,H.</style></author><author><style face="normal" font="default"> Butz,A.</style></author><author><style face="normal" font="default"> Perry,T.T.</style></author><author><style face="normal" font="default"> McConnochie,K.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, University of Rochester, Rochester, New York</style></auth-address><titles><title><style face="normal" font="default">Effect of the School-Based Telemedicine Enhanced Asthma Management (SB-TEAM) Program on Asthma Morbidity: A Randomized Clinical Trial</style></title><secondary-title><style face="normal" font="default">JAMA Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JAMA Pediatr</style></abbr-1></periodical><pages end="" start="e174938">e174938-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="8" Month="1" Year="2018">2018/1/8</year></dates><abstract><style face="normal" font="default">Importance: Poor adherence to recommended preventive asthma medications is common, leading to preventable morbidity. We developed the School-Based Telemedicine Enhanced Asthma Management (SB-TEAM) program to build on school-based supervised therapy programs by incorporating telemedicine at school to overcome barriers to preventive asthma care. Objective: To evaluate the effect of the SB-TEAM program on asthma morbidity among urban children with persistent asthma. Design, Setting, and Participants: In this randomized clinical trial, children with persistent asthma aged 3 to 10 years in the Rochester City School District in Rochester, New York, were stratified by preventive medication use at baseline and randomly assigned to the SB-TEAM program or enhanced usual care for 1 school year. Participants were enrolled at the beginning of the school year (2012-2016), and outcomes were assessed through the end of the school year. Data were analyzed between May 2017 and November 2017 using multivariable modified intention-to-treat analyses. Interventions: Supervised administration of preventive asthma medication at school as well as 3 school-based telemedicine visits to ensure appropriate assessment, preventive medication prescription, and follow-up care. The school site component of the telemedicine visit was completed by telemedicine assistants, who obtained history and examination data. These data were stored in a secure virtual waiting room and then viewed by the primary care clinician, who completed the assessment and communicated with caregivers via videoconference or telephone. Preventive medication prescriptions were sent to pharmacies that deliver to schools for supervised daily administration. Main Outcomes and Measures: The primary outcome was the mean number of symptom-free days per 2 weeks, assessed by bimonthly blinded interviews. Results: Of the 400 enrolled children, 247 (61.8%) were male and 230 (57.5%) were African American, and the mean (SD) age was 7.8 (1.7) years. Demographic characteristics and asthma severity in the 2 groups were similar at baseline. Among children in the SB-TEAM group, 196 (98.0%) had 1 or more telemedicine visits, and 165 (82.5%) received supervised therapy through school. We found that children in the SB-TEAM group had more symptom-free days per 2 weeks postintervention compared with children in the enhanced usual care group (11.6 vs 10.97; difference, 0.69; 95% CI, 0.15-1.22; P = .01), with the largest difference observed at the final follow-up (difference, 0.85; 95% CI, 0.10-1.59). In addition, children in the SB-TEAM group were less likely to have an emergency department visit or hospitalization for asthma (7% vs 15%; odds ratio, 0.52; 95% CI, 0.32-0.84). Conclusions and Relevance: The SB-TEAM intervention significantly improved symptoms and reduced health care utilization among urban children with persistent asthma. This program could serve as a model for sustainable asthma care among school-aged children. Trial Registration: clinicaltrials.gov Identifier: NCT01650844</style></abstract><notes><style face="normal" font="default">IS - 2168-6211 (Electronic)IS - 2168-6203 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1001/jamapediatrics.2017.4938</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29309483">PM:29309483</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JAMA Pediatr\2018-e174938.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JAMA Pediatr\2018-e174938.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180108, Halterman JS</style></custom2><misc3><style face="normal" font="default">10.1001/jamapediatrics.2017.4938</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43859</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gray,N.</style></author><author><style face="normal" font="default"> Howard,A.</style></author><author><style face="normal" font="default"> Zhu,J.</style></author><author><style face="normal" font="default"> Feldman,L.Y.</style></author><author><style face="normal" font="default"> To,T.</style></author></authors></contributors><auth-address><style face="normal" font="default">The Hospital for Sick Children, Toronto, Ontario, Canada</style></auth-address><titles><title><style face="normal" font="default">Association Between Inhaled Corticosteroid Use and Bone Fracture in Children With Asthma</style></title><secondary-title><style face="normal" font="default">JAMA Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JAMA Pediatr</style></abbr-1></periodical><pages end="64" start="57">57-64</pages><volume><style face="normal" font="default">172</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="default">Importance: Daily use of inhaled corticosteroids is a widely recommended treatment for mild persistent asthma in children. There is concern that, similar to systemic corticosteroids, inhaled corticosteroids may have adverse effects on bone health. Objective: To determine whether there is an increased risk of bone fracture associated with inhaled corticosteroid use in children with asthma. Design, Setting, and Participants: In this population-based nested case-control study, we used health administrative databases to identify a cohort of children aged 2 to 18 years with a physician diagnosis of asthma between April 1, 2003, and March 31, 2014, who were eligible for public drug coverage through the Ontario Drug Benefit Program (Ontario, Canada). We matched cases of first fracture after asthma diagnosis to fracture-free controls (ratio of 1 to 4) based on date of birth (within 1 year), sex, and age at asthma diagnosis (within 2 years). We used a 1-year lookback period to ascertain history of inhaled corticosteroid use. Multivariable conditional logistic regression was used to obtain an odds ratio (OR) with 95% confidence interval for fracture, comparing no inhaled corticosteroid use vs current, recent, and past use. Exposures: Inhaled corticosteroid use during the child's 1-year lookback period, measured as current user if the prescription was filled less than 90 days prior to the index date, recent user (91-180 days), past user (181-365 days), or no use. Main Outcomes and Measures: First emergency department visit for fracture after asthma diagnosis, identified using International Statistical Classification of Diseases and Related Health Problems, 10th Revision codes. Results: This study included 19420 children (61.0% male; largest proportion of children, 31.5%, were aged 6-9 years at their index date). The multivariable regression results did not show a significant association between first fracture after asthma diagnosis and current use (OR, 1.07; 95% CI, 0.97-1.17), recent use (OR, 0.96; 95% CI, 0.86-1.07), or past use (OR, 1.00; 95% CI, 0.91-1.11) of inhaled corticosteroids, compared with no use, while adjusting for sociodemographic factors and other medication use. However, use of systemic corticosteroids in the 1-year lookback period resulted in greater odds of fracture (OR, 1.17; 95% CI, 1.04-1.33). Conclusions and Relevance: Systemic corticosteroids, but not inhaled corticosteroids, were significantly associated with increased odds of fracture in the pediatric asthma population</style></abstract><notes><style face="normal" font="default">DA - 20171113IS - 2168-6211 (Electronic)IS - 2168-6203 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1001/jamapediatrics.2017.3579</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29131874">PM:29131874</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JAMA Pediatr\2018-172-57-64.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JAMA Pediatr\2018-172-57-64.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171113, Gray N</style></custom2><misc3><style face="normal" font="default">10.1001/jamapediatrics.2017.3579</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43860</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kruckeberg,B.M.</style></author><author><style face="normal" font="default"> Ridley,T.J.</style></author><author><style face="normal" font="default"> Reichel,L.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">1University of Minnesota Medical School, Minneapolis, Minnesota2Dell Medical School, The University of Texas at Austin, Austin, Texas</style></auth-address><titles><title><style face="normal" font="default">Severe Metal Hypersensitivity Following Internal Fixation of an Ankle Fracture: A Case Report</style></title><secondary-title><style face="normal" font="default">JBJS Case Connect</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JBJS Case Connect</style></abbr-1></periodical><pages end="" start="e38">e38-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">CASE: A 67-year-old woman underwent internal fixation of an ankle fracture. Ten days postoperatively, the patient developed systemic hives, difficulty breathing, and oral swelling. At 8 weeks postoperatively, the hardware was removed because of a suspected metal hypersensitivity. Despite experiencing perioral edema and difficulty breathing after the hardware removal, she had complete resolution of the symptoms at the 2-week, 6-week, and 12-month follow-up appointments. CONCLUSION: Hypersensitivities to metal-based implants can develop and cause local and systemic reactions. Orthopaedic surgeons should inquire about a history of metal allergies, and possibly perform allergy testing for patients with a history suggestive of metal hypersensitivities. Consideration should be given for hospital admission following hardware removal for patient monitoring</style></abstract><notes><style face="normal" font="default">IS - 2160-3251 (Electronic)IS - 2160-3251 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2106/JBJS.CC.16.00202</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29244676">PM:29244676</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JBJS Case Connect\2017-7-e38.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JBJS Case Connect\2017-7-e38.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171229, Kruckeberg BM</style></custom2><misc3><style face="normal" font="default">10.2106/JBJS.CC.16.00202</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43861</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Chan,F.J.</style></author><author><style face="normal" font="default"> Richardson,K.</style></author><author><style face="normal" font="default"> Kim,S.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">1Department of Orthopaedic Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York</style></auth-address><titles><title><style face="normal" font="default">Allergic Dermatitis After Total Knee Arthroplasty Using the Prineo Wound-Closure Device: A Report of Three Cases</style></title><secondary-title><style face="normal" font="default">JBJS Case Connect</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">JBJS Case Connect</style></abbr-1></periodical><pages end="" start="e39">e39-</pages><volume><style face="normal" font="default">7</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="4" Year="2017">2017/4</year></dates><abstract><style face="normal" font="default">CASE: Three patients who underwent uncomplicated total knee arthroplasty with use of the Prineo (Ethicon) wound-closure system had development of allergic contact dermatitis. All patients were started on Keflex (cephalexin), and two were started on topical corticosteroid. In all patients, the reaction resolved within weeks. CONCLUSION: To our knowledge, the present report describes the first case series of patients in whom allergic contact dermatitis developed in association with the use of the Prineo wound-closure system during orthopaedic procedures. The presentation can range from blistering to erythematous papules and vesicles to crusted plaques that resolve with Keflex and topical corticosteroid cream</style></abstract><notes><style face="normal" font="default">IS - 2160-3251 (Electronic)IS - 2160-3251 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2106/JBJS.CC.17.00064</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29244677">PM:29244677</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\JBJS Case Connect\2017-7-e39.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\JBJS Case Connect\2017-7-e39.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171229, Chan FJ</style></custom2><misc3><style face="normal" font="default">10.2106/JBJS.CC.17.00064</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43862</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kim,M.Y.</style></author><author><style face="normal" font="default"> Park,C.S.</style></author><author><style face="normal" font="default"> Jeong,J.W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea</style></auth-address><titles><title><style face="normal" font="default">Management and educational status of adult anaphylaxis patients at emergency department</style></title><secondary-title><style face="normal" font="default">Korean J Intern Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Korean J Intern Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="28" Month="12" Year="2017">2017/12/28</year></dates><abstract><style face="normal" font="default">Background/Aims: We evaluated the management and educational status of adult anaphylaxis patients at emergency departments (EDs). Methods: Anaphylaxis patients who visited ED from 2011 to 2013 were enrolled from three hospitals. We analyzed clinical features, prior history of anaphylaxis, management and provided education for etiology and/or prevention. For analyzing associated factors with epinephrine injection, Pearson chi-square test was used by SPSS version 21 (IBM Co.). Results: A total of 194 anaphylaxis patients were enrolled. Ninety-nine patients (51%) visited ED by themselves. Time interval from symptom onset to ED visit was 62 +/- 70.5 minutes. Drug (56.2%) was the most frequent cause of anaphylaxis. Forty-seven patients (24.2%) had prior history of anaphylaxis and 33 patients had same suspicious cause with current anaphylaxis. Cutaneous (88.7%) and respiratory (72.7%) symptoms were frequent. Hypotension was presented in 114 patients (58.8%). Mean observation time in ED was 12 +/- 25.7 hours and epinephrine was injected in 114 patients (62%). In 68 patients, epinephrine was injected intramuscularly with mean dose of 0.3 +/- 0.10 mg. Associated factor with epinephrine injection was hypotension (p = 0.000). Twenty-three patients (13%) were educated about avoidance of suspicious agent. Epinephrine auto-injectors were prescribed only in five patients. Only 34 (19%) and 72 (40%) patients were consulted to allergist at ED and outpatient allergy department respectively. Conclusions: We suggested that management and education of anaphylaxis were not fully carried out in ED. An education and promotion program on anaphylaxis is needed for medical staff</style></abstract><notes><style face="normal" font="default">IS - 2005-6648 (Electronic)IS - 1226-3303 (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.3904/kjim.2016.024</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29277095">PM:29277095</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Korean J Intern Med\20171228-KimMY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Korean J Intern Med\20171228-KimMY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171228, Kim MY</style></custom2><misc3><style face="normal" font="default">10.3904/kjim.2016.024</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43863</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Papi,A.</style></author><author><style face="normal" font="default"> Brightling,C.</style></author><author><style face="normal" font="default"> Pedersen,S.E.</style></author><author><style face="normal" font="default"> Reddel,H.K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Research Centre on Asthma and COPD, Department of Medical Sciences, University of Ferrara, Ferrara, Italy. Electronic address: ppa@unife.itInstitute for Lung Health, Leicester National Institute for Health Research Biomedical Research Centre, Department of Infection, Immunity, and Inflammation, University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UKDepartment of Paediatrics, University of Southern Denmark, Kolding Hospital, Kolding, DenmarkClinical Management Group and NHMRC Centre of Research Excellence in Severe Asthma, Woolcock Institute of Medical Research, University of Sydney, NSW, Australia</style></auth-address><titles><title><style face="normal" font="default">Asthma</style></title><secondary-title><style face="normal" font="default">Lancet</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Lancet</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="12" Year="2017">2017/12/19</year></dates><abstract><style face="normal" font="default">Asthma-one of the most common chronic, non-communicable diseases in children and adults-is characterised by variable respiratory symptoms and variable airflow limitation. Asthma is a consequence of complex gene-environment interactions, with heterogeneity in clinical presentation and the type and intensity of airway inflammation and remodelling. The goal of asthma treatment is to achieve good asthma control-ie, to minimise symptom burden and risk of exacerbations. Anti-inflammatory and bronchodilator treatments are the mainstay of asthma therapy and are used in a stepwise approach. Pharmacological treatment is based on a cycle of assessment and re-evaluation of symptom control, risk factors, comorbidities, side-effects, and patient satisfaction by means of shared decisions. Asthma is classed as severe when requiring high-intensity treatment to keep it under control, or if it remains uncontrolled despite treatment. New biological therapies for treatment of severe asthma, together with developments in biomarkers, present opportunities for phenotype-specific interventions and realisation of more personalised treatment. In this Seminar, we provide a clinically focused overview of asthma, including epidemiology, pathophysiology, clinical diagnosis, asthma phenotypes, severe asthma, acute exacerbations, and clinical management of disease in adults and children older than 5 years. Emerging therapies, controversies, and uncertainties in asthma management are also discussed</style></abstract><notes><style face="normal" font="default">IS - 1474-547X (Electronic)IS - 0140-6736 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Italy -CO - United Kingdom -CO - Denmark -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1016/S0140-6736(17)33311-1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29273246">PM:29273246</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Lancet\20171219-PapiA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Lancet\20171219-PapiA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171219, Papi A</style></custom2><misc3><style face="normal" font="default">10.1016/S0140-6736(17)33311-1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43864</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Blakey,J.D.</style></author><author><style face="normal" font="default"> Abraham,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Health Services Research, University of Liverpool, Liverpool, UK; North West Severe Asthma Service, Royal Liverpool Hospital, Liverpool L7 8XP, UK.</style></auth-address><titles><title><style face="normal" font="default">Remote or in-person breathing retraining for uncontrolled asthma symptoms</style></title><secondary-title><style face="normal" font="default">Lancet Respir Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Lancet Respir Med</style></abbr-1></periodical><pages end="3" start="2">2-3</pages><volume><style face="normal" font="default">6</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 2213-2619 (Electronic)IS - 2213-2600 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/S2213-2600(17)30471-X</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29248432">PM:29248432</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Lancet Respir Med\2018-6-2-3.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Lancet Respir Med\2018-6-2-3.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171213, Blakey JD</style></custom2><misc3><style face="normal" font="default">10.1016/S2213-2600(17)30471-X</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43865</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bruton,A.</style></author><author><style face="normal" font="default"> Lee,A.</style></author><author><style face="normal" font="default"> Yardley,L.</style></author><author><style face="normal" font="default"> Raftery,J.</style></author><author><style face="normal" font="default"> Arden-Close,E.</style></author><author><style face="normal" font="default"> Kirby,S.</style></author><author><style face="normal" font="default"> Zhu,S.</style></author><author><style face="normal" font="default"> Thiruvothiyur,M.</style></author><author><style face="normal" font="default"> Webley,F.</style></author><author><style face="normal" font="default"> Taylor,L.</style></author><author><style face="normal" font="default"> Gibson,D.</style></author><author><style face="normal" font="default"> Yao,G.</style></author><author><style face="normal" font="default"> Stafford-Watson,M.</style></author><author><style face="normal" font="default"> Versnel,J.</style></author><author><style face="normal" font="default"> Moore,M.</style></author><author><style face="normal" font="default"> George,S.</style></author><author><style face="normal" font="default"> Little,P.</style></author><author><style face="normal" font="default"> Djukanovic,R.</style></author><author><style face="normal" font="default"> Price,D.</style></author><author><style face="normal" font="default"> Pavord,I.D.</style></author><author><style face="normal" font="default"> Holgate,S.T.</style></author><author><style face="normal" font="default"> Thomas,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Faculty of Health Sciences, University of Southampton, Southampton, UK; NIHR Southampton Biomedical Research Centre, Southampton, UK</style></auth-address><titles><title><style face="normal" font="default">Physiotherapy breathing retraining for asthma: a randomised controlled trial</style></title><secondary-title><style face="normal" font="default">Lancet Respir Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Lancet Respir Med</style></abbr-1></periodical><pages end="28" start="19">19-28</pages><volume><style face="normal" font="default">6</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="default">BACKGROUND: Despite effective pharmacotherapy, asthma continues to impair quality of life for most patients. Non-pharmacological approaches, including breathing retraining, are therefore of great interest to patients. However, clinicians rarely advocate breathing retraining and access to this intervention is restricted for most patients due to the limited availability of suitable physiotherapists and poor integration of breathing retraining into standard care. We aimed to assess the effectiveness of a digital self-guided breathing retraining intervention. METHODS: In this randomised controlled trial, we recruited patients from 34 general practices in the UK. Eligibility criteria for patients with asthma were broad, comprising a physician diagnosis of asthma, age of 16-70 years, receipt of at least one anti-asthma medication in the previous year, and impaired asthma-related quality of life (Asthma Quality of Life Questionnaire [AQLQ] score of &lt;5.5). We developed a self-guided intervention, which was delivered as a DVD plus a printed booklet (DVDB). Participants were randomly assigned to receive either the DVDB intervention, three face-to-face breathing retraining sessions, or standard care, in a 2:1:2 ratio, for 12 months. Randomisation was achieved using the Southampton Clinical Trials Unit telephone randomisation service by use of random number generators. The primary outcome was the AQLQ score in the intention-to-treat population at 12 months. The trial was powered to show equivalence between the two active intervention groups, and superiority of both intervention groups over usual care. Secondary outcomes included patient-reported and physiological measures of asthma control, patient acceptability, and health-care costs. This trial was registered with International Standard Randomised Controlled Trial Number registry, number ISRCTN88318003. FINDINGS: Between Nov 5, 2012 and Jan 28, 2014, invitations to participate in the study were sent to 15 203 patients with general practitioner-diagnosed asthma, of whom 655 were recruited into the study. AQLQ scores at 12 months were significantly higher in the DVDB group (mean 5.40, SD 1.14) than in the usual care group (5.12, SD 1.17; adjusted mean difference 0.28, 95% CI 0.11 to 0.44), and in the face-to-face group (5.33, SD 1.06) than in the usual care group (adjusted mean difference 0.24, 95% CI 0.04 to 0.44); AQLQ scores were similar between the DVDB group and the face-to-face group (0.04, 95% CI -0.16 to 0.24). There were no significant differences between the randomisation groups in FEV1 or fraction of exhaled nitric oxide. 744 adverse events occurred in 272 patients: 101 (39%) of 261 patients in the DVDB group, 55 (42%) of 132 patients in the face-to-face group, and 132 (50%) of 262 in the usual care group, with patients reporting one or more event. 11 (4%) patients in the DVDB group, four (3%) patients in the face-to-face group, and 20 (8%) patients in the usual care group had a serious adverse event. INTERPRETATION: Breathing retraining programmes improve quality of life in patients with incompletely controlled asthma despite having little effect on lung function or airway inflammation. Such programmes can be delivered conveniently and cost-effectively as a self-guided digital audiovisual programme, so might also reduce health-care costs. FUNDING: UK National Institute of Health Research</style></abstract><notes><style face="normal" font="default">IS - 2213-2619 (Electronic)IS - 2213-2600 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1016/S2213-2600(17)30474-5</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29248433">PM:29248433</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Lancet Respir Med\2018-6-19-28.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Lancet Respir Med\2018-6-19-28.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171217, Bruton A</style></custom2><misc3><style face="normal" font="default">10.1016/S2213-2600(17)30474-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43866</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wang,Z.</style></author><author><style face="normal" font="default"> Pianosi,P.T.</style></author><author><style face="normal" font="default"> Keogh,K.A.</style></author><author><style face="normal" font="default"> Zaiem,F.</style></author><author><style face="normal" font="default"> Alsawas,M.</style></author><author><style face="normal" font="default"> Alahdab,F.</style></author><author><style face="normal" font="default"> Almasri,J.</style></author><author><style face="normal" font="default"> Mohammed,K.</style></author><author><style face="normal" font="default"> Larrea-Mantilla,L.</style></author><author><style face="normal" font="default"> Farah,W.</style></author><author><style face="normal" font="default"> Daraz,L.</style></author><author><style face="normal" font="default"> Barrionuevo,P.</style></author><author><style face="normal" font="default"> Morrow,A.S.</style></author><author><style face="normal" font="default"> Prokop,L.J.</style></author><author><style face="normal" font="default"> Murad,M.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Mayo Clinic Evidence-based Practice Center, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN; Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN</style></auth-address><titles><title><style face="normal" font="default">The Diagnostic Accuracy of Fractional Exhaled Nitric Oxide Testing in Asthma: A Systematic Review and Meta-analyses</style></title><secondary-title><style face="normal" font="default">Mayo Clin Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Mayo Clin Proc</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="12" Year="2017">2017/12/16</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To evaluate the diagnostic accuracy of fractional exhaled nitric oxide (FeNO) measurement in individuals with suspected asthma. METHODS: We searched MEDLINE, EMBASE, PsycINFO, Cochrane databases, and SciVerse Scopus from the databases' inception through April 4, 2017, for studies that enrolled patients aged 5 years and older with suspected asthma and evaluated FeNO diagnostic accuracy. Independent reviewers selected studies and extracted data. We used the symmetric hierarchical summary receiver operating characteristic models to estimate test performance. RESULTS: We included 43 studies with a total of 13,747 patients. In adults, using FeNO cutoffs of less than 20, 20 to 29, 30 to 39, and 40 or more parts per billion, FeNO testing had sensitivities of 0.80, 0.69, 0.53, and 0.41, respectively, and specificities of 0.64, 0.78, 0.85, and 0.93, respectively. In children, using FeNO cutoffs of less than 20 and 20 to 29 parts per billion, FeNO testing had sensitivities of 0.78 and 0.61, respectively, and specificities of 0.79 and 0.89, respectively. Depending on the FeNO cutoff, the posttest odds of having asthma with a positive FeNO test result increased by 2.80- to 7.00-fold. Diagnostic accuracy was modestly better in corticosteroid-naive asthmatics, children, and nonsmokers than in the overall population. CONCLUSION: Fractional exhaled nitric oxide measurement has moderate accuracy to diagnose asthma in individuals aged 5 years and older. Test performance may be modestly better in corticosteroid-naive asthmatics, children, and nonsmokers than in the general population with suspected asthma. TRIAL REGISTRATION: International Prospective Register of Systematic Reviews (PROSPERO) Identifier: CRD42016047887</style></abstract><notes><style face="normal" font="default">IS - 1942-5546 (Electronic)IS - 0025-6196 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.mayocp.2017.11.012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29275031">PM:29275031</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mayo Clin Proc\20171216-WangZ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mayo Clin Proc\20171216-WangZ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171216, Wang Z</style></custom2><misc3><style face="normal" font="default">10.1016/j.mayocp.2017.11.012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43867</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pongdee,T.</style></author><author><style face="normal" font="default"> Li,J.T.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Allergic Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN.</style></auth-address><titles><title><style face="normal" font="default">Evaluation and Management of Penicillin Allergy</style></title><secondary-title><style face="normal" font="default">Mayo Clin Proc</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Mayo Clin Proc</style></full-title></periodical><pages end="107" start="101">101-107</pages><volume><style face="normal" font="default">93</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">Penicillin allergy is the most commonly reported drug allergy in the United States. Although penicillin allergy is widely reported, 80% to 90% of individuals with self-reported penicillin allergy are actually able to tolerate penicillins after undergoing evaluation for penicillin allergy. Because most patients with self-reported penicillin allergy will have subsequent negative allergy testing results and tolerate penicillins, they may be unnecessarily exposed to broader-spectrum antibiotics. Use of such antibiotics leads to increased risks of developing antibiotic-resistant microorganisms and incur higher health care utilization costs. In this article, we provide an overview of penicillin allergy and its clinical manifestations as well as an approach for the evaluation and management of penicillin allergy</style></abstract><notes><style face="normal" font="default">IS - 1942-5546 (Electronic)IS - 0025-6196 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.mayocp.2017.09.020</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29304914">PM:29304914</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mayo Clin Proc\2018-93-101-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mayo Clin Proc\2018-93-101-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180102, Pongdee T</style></custom2><misc3><style face="normal" font="default">10.1016/j.mayocp.2017.09.020</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43868</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mukand,J.</style></author><author><style face="normal" font="default"> Wortman,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Southern New England Rehabilitation Center, Providence, RI 02907, USA</style></auth-address><titles><title><style face="normal" font="default">Stroke rehabilitation</style></title><secondary-title><style face="normal" font="default">Med Health R I</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Med Health R I</style></abbr-1></periodical><pages end="192" start="188">188-192</pages><volume><style face="normal" font="default">80</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Cerebrovascular Disorders</style></keyword><keyword><style face="normal" font="default"> physiopathology</style></keyword><keyword><style face="normal" font="default"> rehabilitation</style></keyword><keyword><style face="normal" font="default"> Humans</style></keyword><keyword><style face="normal" font="default"> Prognosis</style></keyword></keywords><dates><year Day="0" Month="6" Year="1997">1997/6</year></dates><notes><style face="normal" font="default">IS - 1086-5462 (Print)IS - 1086-5462 (Linking)LA - engPT - Journal ArticlePT - ReviewSB - IMCO - United States -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="9200898">PM:9200898</url></web-urls></urls><custom2><style face="normal" font="default">19970620, Mukand J</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43869</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sutherland,M.F.</style></author><author><style face="normal" font="default"> Portelli,E.L.</style></author><author><style face="normal" font="default"> Collins,A.L.</style></author><author><style face="normal" font="default"> Rahman,M.A.</style></author><author><style face="normal" font="default"> McDonald,C.F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Austin Health, Melbourne, VIC Christine.</style></auth-address><titles><title><style face="normal" font="default">Patients with thunderstorm asthma or severe asthma in Melbourne: a comparison</style></title><secondary-title><style face="normal" font="default">Med J Aust</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Med J Aust</style></full-title></periodical><pages end="435" start="434">434-435</pages><volume><style face="normal" font="default">207</style></volume><number><style face="normal" font="default">10</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="20" Month="11" Year="2017">2017/11/20</year></dates><notes><style face="normal" font="default">DA - 20171113IS - 1326-5377 (Electronic)IS - 0025-729X (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29129175">PM:29129175</url></web-urls></urls><custom2><style face="normal" font="default">20171120, Sutherland MF</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43870</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Saeki,T.</style></author><author><style face="normal" font="default"> Kobayashi,D.</style></author><author><style face="normal" font="default"> Ito,T.</style></author><author><style face="normal" font="default"> Tamura,M.</style></author><author><style face="normal" font="default"> Yoshikawa,S.</style></author><author><style face="normal" font="default"> Yamazaki,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Internal Medicine , Nagaoka Red Cross Hospital , Nagaoka , Japan</style></auth-address><titles><title><style face="normal" font="default">Comparison of clinical and laboratory features of patients with and without allergic conditions in IgG4-related disease: a single-center experience in Japan</style></title><secondary-title><style face="normal" font="default">Mod Rheumatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Mod Rheumatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="12" Year="2017">2017/12/18</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To compare the clinical and laboratory features of Japanese patients with IgG4-related disease, with and without allergic conditions. METHODS: We retrospectively examined the clinical and laboratory features and clinical courses of 51 patients with definitively diagnosed IgG4-RD, collected from Nagaoka Red Cross Hospital between January 2004 and August 2017, with reference to the presence of allergic conditions. RESULTS: Among these patients, 43% had allergic conditions. In the allergy group, the proportion of females was significantly higher, the age at diagnosis was significantly lower, and upper body organ involvement was predominant in comparison with the non-allergy group. There was no significant inter-group difference in the absolute number of peripheral blood eosinophils, the levels of serum IgG4 and IgE, the response to steroid, or the proportion of patients who relapsed. CONCLUSIONS: The present findings suggest that there may be some differences in the clinical features of IgG4-RD patients according to the allergic conditions that are present, although eosinophilia and high serum levels of IgE and IgG4 are common features regardless of allergy</style></abstract><notes><style face="normal" font="default">IS - 1439-7609 (Electronic)IS - 1439-7595 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1080/14397595.2017.1416891</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29251026">PM:29251026</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mod Rheumatol\20180108-SaekiT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mod Rheumatol\20180108-SaekiT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180108, Saeki T</style></custom2><misc3><style face="normal" font="default">10.1080/14397595.2017.1416891</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43871</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Handa,T.</style></author><author><style face="normal" font="default"> Matsui,S.</style></author><author><style face="normal" font="default"> Yoshifuji,H.</style></author><author><style face="normal" font="default"> Kodama,Y.</style></author><author><style face="normal" font="default"> Yamamoto,H.</style></author><author><style face="normal" font="default"> Minamoto,S.</style></author><author><style face="normal" font="default"> Waseda,Y.</style></author><author><style face="normal" font="default"> Sato,Y.</style></author><author><style face="normal" font="default"> Kubo,K.</style></author><author><style face="normal" font="default"> Mimori,T.</style></author><author><style face="normal" font="default"> Chiba,T.</style></author><author><style face="normal" font="default"> Hirai,T.</style></author><author><style face="normal" font="default"> Mishima,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Department of Respiratory Medicine, Graduate School of Medicine , Kyoto University , Kyoto , Japan</style></auth-address><titles><title><style face="normal" font="default">Serum soluble interleukin-2 receptor as a biomarker in immunoglobulin G4-related disease</style></title><secondary-title><style face="normal" font="default">Mod Rheumatol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Mod Rheumatol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="12" Year="2017">2017/12/18</year></dates><abstract><style face="normal" font="default">OBJECTIVES: Serum soluble interleukin-2 (IL-2) receptor (sIL-2R) might reflect disease activity in immunoglobulin G4-related disease (IgG4-RD). We aimed to elucidate the clinical significance of blood markers, including sIL-2R, in patients with IgG4-RD. METHODS: We enrolled 59 patients with IgG4-RD and investigated the association between blood markers (white blood cells, C-reactive protein, sIL-2R, IgG, IgG4, IgE, total hemolytic complement) and clinical indices. RESULTS: At baseline, serum sIL-2R (Rs = 0.532, p &lt; 0.001) and IgG4 (Rs = 0.545, p &lt; 0.001) levels showed significant correlation to the number of organs involved. During follow-up period (median, 70 months; range, 7-195 months), 40 patients were treated with corticosteroids. Receiver operating characteristic (ROC) analysis showed that baseline sIL-2R levels most accurately predicted patients requiring glucocorticoid treatment (area under the ROC curve, 0.807). Among the 46 patients who improved, sIL-2R and IgG4 levels decreased in 42 and 41 patients, respectively. Among them, serum sIL-2R levels decreased to a normal range in 42 patients (91%), whereas IgG4 levels normalized in 19 (41%). CONCLUSIONS: The serum sIL-2R level is a potential biomarker for IgG4-RD that may reflect the number of involved organs and may predict patients requiring glucocorticoid treatment</style></abstract><notes><style face="normal" font="default">IS - 1439-7609 (Electronic)IS - 1439-7595 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1080/14397595.2017.1416739</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29251035">PM:29251035</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mod Rheumatol\20180108-HandaT.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mod Rheumatol\20180108-HandaT.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180108, Handa T</style></custom2><misc3><style face="normal" font="default">10.1080/14397595.2017.1416739</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43872</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lyu,Y.</style></author><author><style face="normal" font="default"> Zhao,H.</style></author><author><style face="normal" font="default"> Ye,Y.</style></author><author><style face="normal" font="default"> Liu,L.</style></author><author><style face="normal" font="default"> Zhu,S.</style></author><author><style face="normal" font="default"> Xia,Y.</style></author><author><style face="normal" font="default"> Zou,F.</style></author><author><style face="normal" font="default"> Cai,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China</style></auth-address><titles><title><style face="normal" font="default">Decreased soluble RAGE in neutrophilic asthma is correlated with disease severity and RAGE G82S variants</style></title><secondary-title><style face="normal" font="default">Mol Med Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Mol Med Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="12" Year="2017">2017/12/18</year></dates><abstract><style face="normal" font="default">The advanced glycosylation end product-specific receptor (RAGE) has been demonstrated to be an important mediator of asthma pathogenesis. The soluble isoform of RAGE (sRAGE) acts as a 'decoy' to sequester RAGE ligands, and thus prevents their binding to the receptor. A number of reports have linked deficiency of sRAGE to the severity and outcomes of various human diseases, and association with RAGE G82S variants. However, whether sRAGE levels are increased or decreased in asthmatic patients is unclear. The aim of the present study was to determine plasma sRAGE levels in different asthma phenotypes and associations of plasma sRAGE levels with RAGE G82S variants. A total of 85 neutrophilic and 109 nonneutrophilic newly diagnosed asthmatic patients, and 118 healthy controls, were recruited. Plasma sRAGE levels were measured by ELISA analysis. RAGE G82S genotypes were detected using the Sanger sequencing method. Plasma sRAGE levels were decreased in neutrophilic asthmatics (443.67+/-208.9 pg/ml) and increased in nonneutrophilic asthmatics (677.63+/-300.75 pg/ml) compared with healthy controls (550.02+/-300.83 pg/ml) (P&lt;0.001). Plasma sRAGE levels were positively correlated with FEV1% predicted (FEV1% Pre) (rp=0.258; P=0.023) in neutrophilic asthmatics. The frequency of G82S genotypes was significantly different between neutrophilic and nonneutrophilic asthmatics (P=0.009). Neutrophilic asthmatics with genotypes A/G or A/A (389.83+/-150.37 and 264.59+/-161.74 pg/ml, respectively) had significantly decreased sRAGE levels compared with the G/G genotype (498.64+/-235.37 pg/ml) (P=0.022). Those with the A/G and A/A genotype (60.14+/-22.36%) displayed a trend toward lower FEV1% Pre compared with those with the G/G genotype (64.51+/-27.37%). No significant difference in sRAGE levels or an association with FEV1% Pre was observed between the different genotypes in nonneutrophilic asthmatics. In conclusion, the results of the present study indicated that plasma sRAGE levels are altered in different asthma inflammatory phenotypes. Plasma sRAGE may be a biomarker of asthma severity and may be associated with G82S gene variants in neutrophilic asthmatics</style></abstract><notes><style face="normal" font="default">IS - 1791-3004 (Electronic)IS - 1791-2997 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.3892/mmr.2017.8302</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29257350">PM:29257350</url></web-urls><related-urls><url ppv-ref="no">presto - ProQuest</url></related-urls></urls><custom2><style face="normal" font="default">20171218, Lyu Y</style></custom2><misc3><style face="normal" font="default">10.3892/mmr.2017.8302</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43873</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Agarwal,R.</style></author><author><style face="normal" font="default"> Sehgal,I.S.</style></author><author><style face="normal" font="default"> Dhooria,S.</style></author><author><style face="normal" font="default"> Aggarwal,A.N.</style></author><author><style face="normal" font="default"> Sachdeva,N.</style></author><author><style face="normal" font="default"> Bhadada,S.K.</style></author><author><style face="normal" font="default"> Garg,M.</style></author><author><style face="normal" font="default"> Behera,D.</style></author><author><style face="normal" font="default"> Chakrabarti,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pulmonary Medicine Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India</style></auth-address><titles><title><style face="normal" font="default">Vitamin D levels in asthmatic patients with and without allergic bronchopulmonary aspergillosis</style></title><secondary-title><style face="normal" font="default">Mycoses</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Mycoses</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="1" Year="2018">2018/1/4</year></dates><abstract><style face="normal" font="default">Vitamin D deficiency is believed to a pathogenetic factor in patients with allergic bronchopulmonary aspergillosis (ABPA) and cystic fibrosis. Whether vitamin D deficiency is also prevalent in ABPA complicating asthma, remains unknown. Herein, we evaluate vitamin D levels in asthmatic patients with and without ABPA. In a prospective study, plasma vitamin D (25[OH]D) levels were measured in consecutive subjects with asthma (n=75), ABPA (n=158) and healthy volunteers (n=50). Vitamin D levels &lt;20 ng/mL were considered as vitamin D deficiency. There was no difference in mean (95% CI) vitamin D levels between healthy controls (15.3 [12.7-17.9]), asthmatics (19.2 [16.3-22.1]) and subjects with ABPA (18.9 [16.9-20.8]) (p=0.22). Vitamin D deficiency was encountered in 70%, 64% and 65% of the healthy controls, asthmatics and ABPA subjects, respectively, and was not different between the groups (p=0.79). There was no difference in the asthma control, pulmonary function, immunological findings and the severity of bronchiectasis, in patients with ABPA, with and without vitamin D deficiency. Vitamin D deficiency is equally prevalent in asthmatic patients with or without ABPA in the Indian subcontinent, and does not appear to play a major role in the pathogenesis of ABPA complicating asthma. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1439-0507 (Electronic)IS - 0933-7407 (Linking)LA - engPT - Journal ArticleCO - India -</style></notes><work-type><style face="normal" font="default">10.1111/myc.12744</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29314357">PM:29314357</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Mycoses\20180104-AgarwalR.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Mycoses\20180104-AgarwalR.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180104, Agarwal R</style></custom2><misc3><style face="normal" font="default">10.1111/myc.12744</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43874</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stokholm,J.</style></author><author><style face="normal" font="default"> Blaser,M.J.</style></author><author><style face="normal" font="default"> Thorsen,J.</style></author><author><style face="normal" font="default"> Rasmussen,M.A.</style></author><author><style face="normal" font="default"> Waage,J.</style></author><author><style face="normal" font="default"> Vinding,R.K.</style></author><author><style face="normal" font="default"> Schoos,A.M.</style></author><author><style face="normal" font="default"> Kunoe,A.</style></author><author><style face="normal" font="default"> Fink,N.R.</style></author><author><style face="normal" font="default"> Chawes,B.L.</style></author><author><style face="normal" font="default"> Bonnelykke,K.</style></author><author><style face="normal" font="default"> Brejnrod,A.D.</style></author><author><style face="normal" font="default"> Mortensen,M.S.</style></author><author><style face="normal" font="default"> Al-Soud,W.A.</style></author><author><style face="normal" font="default"> Sorensen,S.J.</style></author><author><style face="normal" font="default"> Bisgaard,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Ledreborg Alle 34, 2820, Gentofte, Denmark</style></auth-address><titles><title><style face="normal" font="default">Maturation of the gut microbiome and risk of asthma in childhood</style></title><secondary-title><style face="normal" font="default">Nat Commun</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nat Commun</style></abbr-1></periodical><pages end="" start="141">141-</pages><volume><style face="normal" font="default">9</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="10" Month="1" Year="2018">2018/1/10</year></dates><abstract><style face="normal" font="default">The composition of the human gut microbiome matures within the first years of life. It has been hypothesized that microbial compositions in this period can cause immune dysregulations and potentially cause asthma. Here we show, by associating gut microbial composition from 16S rRNA gene amplicon sequencing during the first year of life with subsequent risk of asthma in 690 participants, that 1-year-old children with an immature microbial composition have an increased risk of asthma at age 5 years. This association is only apparent among children born to asthmatic mothers, suggesting that lacking microbial stimulation during the first year of life can trigger their inherited asthma risk. Conversely, adequate maturation of the gut microbiome in this period may protect these pre-disposed children</style></abstract><notes><style face="normal" font="default">IS - 2041-1723 (Electronic)IS - 2041-1723 (Linking)LA - engPT - Journal ArticleCO - Denmark -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1038/s41467-017-02573-2</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29321519">PM:29321519</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nat Commun\2018-9-141.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nat Commun\2018-9-141.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180110, Stokholm J</style></custom2><misc3><style face="normal" font="default">10.1038/s41467-017-02573-2</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43875</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Stenberg,H.K.</style></author><author><style face="normal" font="default"> Niespodziana,K.</style></author><author><style face="normal" font="default"> Van Hage,M.</style></author><author><style face="normal" font="default"> Kere,J.</style></author><author><style face="normal" font="default"> Valenta,R.</style></author><author><style face="normal" font="default"> Hedlin,G.</style></author><author><style face="normal" font="default"> Soderhall,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default">Reduced CDHR3 expression in children wheezing with rhinovirus</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="1" Year="2018">2018/1/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Rhinovirus induced wheezing in young children has been associated with increased asthma risk at school age. Recently, the transmembrane protein cadherin related family member 3 (CDHR3) was identified as the RV-C receptor and the genetic variant rs6967330 (p.Cys529Tyr) was reported to be associated with enhanced RV-C binding and increased replication in vitro. The aim of this study was to examine rs6967330 genotypes and mRNA expression of CDHR3 in relation to presence of rhinovirus and clinical symptoms in children with acute wheezing and compare to a group of age-matched healthy children. METHODS: rs6967330;G>A was genotyped (n=216) and CDHR3 mRNA expression were measured in peripheral blood leukocytes (n=69) from a subgroup of children wheezing with RV infection acute and at a follow-up visit 2-3 months later, and in healthy controls. Standardized TaqMan assays were used. RESULTS: The risk allele rs6967330-A was overrepresented in the wheezing group (p&lt;0.001). Reduced mRNA levels of CDHR3 were found in children with acute wheezing as compared to the control group (p=0.001). Children with the rs6967330 genotypes AA/AG showed the largest differences in CDHR3 expression between acute and follow-up visit (p&lt;0.04). CONCLUSIONS: Preschool children with RV-induced wheezing were shown to have reduced CDHR3 mRNA levels, which might result in an increased permeability of the epithelial layers of the airways and thereby an increased vulnerability. Thus, measuring CDHR3 mRNA levels might help to identify a more severe phenotype of wheezing preschool children. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Sweden -CO - Austria -CO - Finland -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12858</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29314338">PM:29314338</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20180104-StenbergHK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20180104-StenbergHK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180104, Stenberg HK</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12858</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43876</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Laurence,C.</style></author><author><style face="normal" font="default"> van der Merwe,L.</style></author><author><style face="normal" font="default"> Zhang,G.</style></author><author><style face="normal" font="default"> LeSouef,P.</style></author><author><style face="normal" font="default"> Levin,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Paediatrics and Child Health, University of Cape Town and Red Cross War Memorial Children's Hospital, Cape Town, South Africa</style></auth-address><titles><title><style face="normal" font="default">Association Between Pro-Inflammatory Alleles and Allergic Phenotypes in Xhosa Adolescents</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="1" Year="2018">2018/1/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Significant differences exist in the prevalence, spectrum and severity of allergic diseases between developing and developed countries and between sub-populations within single countries. These discrepancies likely result from a complex interaction between genetic and environmental factors. However, the precise nature of the contribution of ethnicity to genetic differences in the predisposition to allergic disease is not yet fully understood. In particular, there is a paucity of literature regarding the genetic determinants of allergic disease in people of black African origin with little or no genetic admixture. OBJECTIVE: We aimed to analyse associations between 27 single nucleotide polymorphisms (SNPs) and allergy phenotypes in the local Xhosa population. METHODS: A convenience sample of 213 Xhosa teenagers was enrolled at a local high school. Phenotypic data was collected in the form of a symptom questionnaire, skin prick tests for common food and aeroallergens, total serum IgE and IgE to Ascaris lumbricoides. In addition, genotyping was performed to establish the prevalence of putative pro-inflammatory alleles. RESULTS: We demonstrated several significant associations between polymorphisms and allergy phenotypes. In particular, 2 polymorphisms in the IL-10 gene (IL10 -592A>C and IL10 -1082A>G) and 1 in the IL-4 gene (IL4 -589C>T) showed multiple associations with allergic sensitization and asthma phenotypes. Other polymorphisms, across a multitude of genes with discrepant functions, showed less consistent associations. CONCLUSION: This study represents an important first step in genotype/phenotype association in this population. Further research is required to confirm or refute our findings. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - South Africa -CO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12859</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29314322">PM:29314322</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20180104-LaurenceC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20180104-LaurenceC.pdf</url></text-urls><related-urls><url ppv-ref="no">xlsx in cartella</url></related-urls></urls><custom2><style face="normal" font="default">20180104, Laurence C</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12859</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43877</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Hu,J.M.</style></author><author><style face="normal" font="default"> Lin,C.S.</style></author><author><style face="normal" font="default"> Chen,S.J.</style></author><author><style face="normal" font="default"> Chen,C.Y.</style></author><author><style face="normal" font="default"> Lin,C.L.</style></author><author><style face="normal" font="default"> Kao,C.H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Colorectal Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan</style></auth-address><titles><title><style face="normal" font="default">Association of between Obstructive Sleep Apnea and Atopic Dermatitis in Children: A Nationwide, Population-Based Cohort Study</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="1" Year="2018">2018/1/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Atopic dermatitis (AD) is associated with systemic inflammation and may have a similar pathogenesis as obstructive sleep apnea (OSA). However, to date, studies on the association between AD and OSA is limited. OBJECTIVES: This study evaluated the association between OSA and AD in children in a large-scale, population-based cohort. METHODS: A total of approximately 120,736 children (&lt;18 years) with newly diagnosed AD and 120,736 age- and sex-matched patients without AD from 2000 to 2007 were identified from Taiwan's National Health Insurance Research Database from 2000 to 2007. The Kaplan-Meier test was used for measuring the cumulative incidence of OSA in each cohort. Cox proportional hazard regression models were used for evaluating the risk of OSA in patients with or without AD between the two cohorts. RESULTS: The Kaplan-Meier analysis revealed that the cumulative incidence curves of OSA were significantly higher in patients with AD than in those without AD (log-rank test, P &lt; 0.001). After adjusting for age, sex, urbanization level, and comorbidities, patients with AD had a higher risk of OSA than those without AD (adjusted hazard ratio = 1.86, 95% confidence interval = 1.43-2.42). Compared with patients without AD, patients with AD exhibited a higher risk of developing OSA, irrespective of underlying comorbidities. CONCLUSION: This nationwide, population-based cohort study revealed an increased risk of OSA in children with AD. Therefore, comprehensive evaluation and aggressive risk reduction for OSA are recommended in these patients. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Taiwan -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12853</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29314287">PM:29314287</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20180104-HuJM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20180104-HuJM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180104, Hu JM</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12853</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43878</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nilsson,S.</style></author><author><style face="normal" font="default"> Odling,M.</style></author><author><style face="normal" font="default"> Andersson,N.</style></author><author><style face="normal" font="default"> Bergstrom,A.</style></author><author><style face="normal" font="default"> Kull,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default">Does asthma affect school performance in adolescents? - Results from the Swedish population-based birth cohort BAMSE</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="1" Year="2018">2018/1/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Asthma is common among schoolchildren and may influence quality of life and school attendance. However, it is unclear if asthma affects school performance. The aim of this study was to examine if different phenotypes of asthma affect school performance during adolescence. METHODS: The study population consisted of 1,715 adolescents from a population-based birth cohort, followed to age 16 with questionnaires and clinical examinations. Asthma was defined as at least 4 wheeze episodes or at least 1 wheeze episode in combination with inhaled steroids in the last 12 months. School grades were obtained from Statistics Sweden and logistic regression analysis was performed to investigate the association between the final overall grade from elementary school and asthma phenotypes. RESULTS: Among the adolescents, 20.8% have had ever asthma; 24.2% early-transient, 47.2% school age onset and 24.2% persistent asthma. At 16 years, 7.8% had asthma; 71.7% multimorbidity and 73.9% allergic asthma. A statistically significant association for performing less well was seen for ever asthma (ORadj =1.43, CI=1.09-1.88). In analyses of asthma onset an association was seen for school age onset (ORadj =1.49, CI=1.02-2.16) and a tendency for persistent asthma (ORadj =1.61, CI=0.98-2.66), although with overlapping confidence intervals. Further, adolescents with uncontrolled asthma tended to perform less well (ORadj =2.60, CI=0.87-7.80) compared to adolescents with partly controlled (ORadj =1.12, CI=0.68-1.83) and fully controlled (ORadj =1.29, CI=0.55-3.01) asthma. CONCLUSIONS: Our results indicate that asthma impairs school performance in adolescence. Moreover, some evidence suggests the adolescents with asthma during school age and with poorer asthma control to be more likely to perform less well. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12855</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29314343">PM:29314343</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20180104-NilssonS.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20180104-NilssonS.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180104, Nilsson S</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12855</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43879</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oosterloo,B.C.</style></author><author><style face="normal" font="default"> Van Elburg,R.M.</style></author><author><style face="normal" font="default"> Rutten,N.B.</style></author><author><style face="normal" font="default"> Bunkers,C.M.</style></author><author><style face="normal" font="default"> Crijns,C.E.</style></author><author><style face="normal" font="default"> Meijssen,C.B.</style></author><author><style face="normal" font="default"> Oudshoorn,J.H.</style></author><author><style face="normal" font="default"> Rijkers,G.T.</style></author><author><style face="normal" font="default"> Van der Ent,C.K.</style></author><author><style face="normal" font="default"> Vlieger,A.M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Emma Children's Hospital, Academic Medical Center, Amsterdam, the Netherlands</style></auth-address><titles><title><style face="normal" font="default">Wheezing and infantile colic are associated with neonatal antibiotic treatment</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="1" Year="2018">2018/1/4</year></dates><abstract><style face="normal" font="default">BACKGROUND: Cohort studies have suggested that early life antibiotic treatment is associated with increased risk of atopy. We determined whether antibiotic treatment already in the first week of life increases the risk for atopic and non-atopic disorders. METHODS: The INCA study is a prospective observational birth cohort study of 436 term infants, with follow-up of one year. 151 neonates received broad-spectrum antibiotics for suspected neonatal infection (AB+), versus a healthy untreated control group (N=285) (AB-). In the first year, parents recorded daily (non-) allergic symptoms. At 1 year, doctors-diagnoses were registered and a blood sample was taken (n=205). RESULTS: Incidence of wheezing in the first year was higher in AB+ than AB- (41.0% vs. 30.5%, p=0.026; aOR 1.56 (95%CI 0.99-2.46, p=0.06). Infantile colics were more prevalent in AB+ compared to AB- (21.9% and 14.4% p=0.048), antibiotic treatment was an independent risk factor for infantile colics (aOR 1.66 (95%CI 1.00-2.77) p=0.05). Allergic sensitization (Phadiatop >0.70kUA/L) showed a trend towards a higher risk in AB+ (aOR 3.26 (95%CI 0.95-11.13) p=0.06). Incidence of eczema, infections, and GP visits in the first year were similar in AB+ and AB-. CONCLUSION: Antibiotic treatment in the first week of life is associated with an increased risk for wheezing and infantile colics. This study may provide a rationale for early cessation of antibiotics in neonates without proven or probable infection. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1399-3038 (Electronic)IS - 0905-6157 (Linking)LA - engPT - Journal ArticleCO - Netherlands -</style></notes><work-type><style face="normal" font="default">10.1111/pai.12857</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29314334">PM:29314334</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20180104-OosterlooBC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Allergy Immunol\20180104-OosterlooBC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180104, Oosterloo BC</style></custom2><misc3><style face="normal" font="default">10.1111/pai.12857</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43880</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Carroll,C.L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Connecticut Children's Medical Center, Hartford, CT</style></auth-address><titles><title><style face="normal" font="default">Is the ICU a Risk Factor for Future Asthma Readmissions?</style></title><secondary-title><style face="normal" font="default">Pediatr Crit Care Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pediatr Crit Care Med</style></abbr-1></periodical><pages end="1177" start="1176">1176-1177</pages><volume><style face="normal" font="default">18</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><notes><style face="normal" font="default">IS - 1529-7535 (Print)IS - 1529-7535 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/PCC.0000000000001365</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29206733">PM:29206733</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Crit Care Med\2017-18-1176-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Crit Care Med\2017-18-1176-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171228, Carroll CL</style></custom2><misc3><style face="normal" font="default">10.1097/PCC.0000000000001365</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43881</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gordon,S.C.</style></author><author><style face="normal" font="default"> Bartenstein,D.W.</style></author><author><style face="normal" font="default"> Tajmir,S.H.</style></author><author><style face="normal" font="default"> Song,J.S.</style></author><author><style face="normal" font="default"> Hawryluk,E.B.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA</style></auth-address><titles><title><style face="normal" font="default">Delayed-type hypersensitivity to vaccine aluminum adjuvant causing subcutaneous leg mass and urticaria in a child</style></title><secondary-title><style face="normal" font="default">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="1" Year="2018">2018/1/4</year></dates><abstract><style face="normal" font="default">A 3-year-old girl presented with a 7-month history of a waxing and waning left thigh mass associated with pruritus and erythema at the site of two previous DTaP-HepB-IPV vaccinations. Patch testing was positive to aluminum chloride, supporting a diagnosis of vaccine granuloma secondary to aluminum allergy; her symptoms had been well controlled with antihistamines and topical steroids. Injection site granulomas are a benign but potentially bothersome reaction to aluminum-containing immunizations that can be supportively managed, and we encourage strict adherence to the recommended vaccine schedule in this setting. Patch testing is a sensitive, noninvasive diagnostic tool for patients presenting with this clinical finding, and dermatologist awareness can prevent unnecessary medical examination and provide reassurance</style></abstract><notes><style face="normal" font="default">IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Case ReportsCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pde.13390</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29314223">PM:29314223</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Dermatol\20180104-GordonSC.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Dermatol\20180104-GordonSC.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180104, Gordon SC</style></custom2><misc3><style face="normal" font="default">10.1111/pde.13390</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43882</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ivey,L.A.</style></author><author><style face="normal" font="default"> Limone,B.A.</style></author><author><style face="normal" font="default"> Jacob,S.E.</style></author></authors></contributors><auth-address><style face="normal" font="default">Loma Linda University, Loma Linda, CA, USALoma Linda University, Loma Linda, CA, USADepartment of Dermatology, Loma Linda University, Loma Linda, CA, USA</style></auth-address><titles><title><style face="normal" font="default">Approach to the jewelry aficionado</style></title><secondary-title><style face="normal" font="default">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="1" Year="2018">2018/1/4</year></dates><abstract><style face="normal" font="default">Children's and teens' frequent use of inexpensive "costume" jewelry exposes them to a variety of contact allergens. Greater use heightens the risk of developing allergic contact dermatitis, especially in the setting of body piercings. Several clinical pearls, prevention strategies, and avoidance alternatives are provided in this article to guide clinicians and patients in the management of jewelry-related allergic contact dermatitis</style></abstract><notes><style face="normal" font="default">IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pde.13379</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29314260">PM:29314260</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Dermatol\20180104-IveyLA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Dermatol\20180104-IveyLA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180104, Ivey LA</style></custom2><misc3><style face="normal" font="default">10.1111/pde.13379</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43883</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lewis,D.J.</style></author><author><style face="normal" font="default"> Feldman,S.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX, USA</style></auth-address><titles><title><style face="normal" font="default">Rapid, successful treatment of atopic dermatitis recalcitrant to topical corticosteroids</style></title><secondary-title><style face="normal" font="default">Pediatr Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="4" Month="1" Year="2018">2018/1/4</year></dates><abstract><style face="normal" font="default">Atopic dermatitis is responsive to midpotency topical corticosteroids, which are the mainstay of treatment, yet many patients have disease that is "resistant" to triamcinolone prescribed for outpatient use. Such resistance is often due to poor adherence, but patients and caregivers may remain adamant that the steroid was ineffective and assure the physician that it was applied as recommended. We describe the case of a young girl with a 2-year history of atopic dermatitis resistant to triamcinolone whose condition rapidly improved with continued use of triamcinolone. Our case raises the ethical dilemma of whether physicians should base treatment plans on what patients report or what evidence on adherence suggests</style></abstract><notes><style face="normal" font="default">IS - 1525-1470 (Electronic)IS - 0736-8046 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/pde.13376</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29314244">PM:29314244</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Dermatol\20180104-LewisDJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Dermatol\20180104-LewisDJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180104, Lewis DJ</style></custom2><misc3><style face="normal" font="default">10.1111/pde.13376</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43884</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Abaya,R.</style></author><author><style face="normal" font="default"> Jones,L.</style></author><author><style face="normal" font="default"> Zorc,J.J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Dexamethasone Compared to Prednisone for the Treatment of Children With Acute Asthma Exacerbations</style></title><secondary-title><style face="normal" font="default">Pediatr Emerg Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Emerg Care</style></full-title></periodical><pages end="58" start="53">53-58</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">Systemic corticosteroids are recommended in clinical practice guidelines for the treatment of acute asthma exacerbation based on evidence demonstrating reduced hospitalizations and improved outcomes after administration in the emergency department. Although prednisone and related oral preparations have been recommended previously, researchers have assessed dexamethasone as an alternative based on its longer biologic half-life and improved palatability. Systematic reviews of multiple small trials and 2 larger trials have found no difference in revisits to the emergency department compared to prednisone for dexamethasone given either as an intramuscular injection or orally. Studies of oral administration have found reduced emesis for dexamethasone compared to prednisone both in the emergency department and for a second oral dose, typically given 24 to 48 hours later. Studies assessing a single dose of dexamethasone have found equivalent improvement at follow-up but with some evidence of increased symptoms and increased need for additional corticosteroids compared to multiple doses of prednisone. Future research could further assess dexamethasone dose, formulation, and frequency and measure other related adverse effects such as behavior change. Consideration of baseline differences within the heterogeneous population of children requiring acute care for asthma may also guide the design of an optimal dexamethasone regimen</style></abstract><notes><style face="normal" font="default">IS - 1535-1815 (Electronic)IS - 0749-5161 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/PEC.0000000000001371</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29293202">PM:29293202</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Emerg Care\2018-34-53-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Emerg Care\2018-34-53-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180111, Abaya R</style></custom2><misc3><style face="normal" font="default">10.1097/PEC.0000000000001371</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43885</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Liu,H.</style></author><author><style face="normal" font="default"> Turner,T.W.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Allergic Colitis With Pneumatosis Intestinalis in an Infant</style></title><secondary-title><style face="normal" font="default">Pediatr Emerg Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Emerg Care</style></full-title></periodical><pages end="e15" start="e14">e14-e15</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="default">Inflammatory causes of bloody diarrhea during infancy include necrotizing enterocolitis and allergic colitis, often due to cow's milk protein. We report this case of cow's milk protein allergy, managed successfully with elimination of dietary antigen, to highlight the unusual finding of pneumatosis intestinalis on abdominal x-ray, a radiographic hallmark associated with necrotizing enterocolitis. Detailed patient's history, clinical presentation, and physical examinations are discussed for cow's milk protein allergy and necrotizing enterocolitis</style></abstract><notes><style face="normal" font="default">IS - 1535-1815 (Electronic)IS - 0749-5161 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1097/PEC.0000000000001369</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29210890">PM:29210890</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Emerg Care\2018-34-e14-5.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Emerg Care\2018-34-e14-5.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180111, Liu H</style></custom2><misc3><style face="normal" font="default">10.1097/PEC.0000000000001369</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43886</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Akinbami,L.J.</style></author><author><style face="normal" font="default"> Rossen,L.M.</style></author><author><style face="normal" font="default"> Fakhouri,T.H.I.</style></author><author><style face="normal" font="default"> Fryar,C.D.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, MD, USA</style></auth-address><titles><title><style face="normal" font="default">Asthma prevalence trends by weight status among US children aged 2-19 years, 1988-2014</style></title><secondary-title><style face="normal" font="default">Pediatr Obes</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pediatr Obes</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="11" Year="2017">2017/11/12</year></dates><abstract><style face="normal" font="default">BACKGROUND: Obesity is a risk factor for asthma. However, it is unclear if increased obesity prevalence contributed to rising childhood asthma prevalence. OBJECTIVE: To assess if population-level changes in weight status impacted asthma prevalence over time. METHODS: Using nationally representative 1988-2014 National Health and Nutrition Examination Survey data for 40 644 children aged 2-19 years, we analyzed asthma trends by weight status (body mass index age-specific percentiles determined using measured weight and height). Logistic regression and population attributable fraction were used to assess the association between obesity and asthma prevalence. RESULTS: Although obesity was a risk factor for asthma throughout the period, asthma prevalence increased only among children with normal weight; there was no interaction between weight status and time. The population attributable fraction for overweight/obesity rose from 8.5% in 1988-1994 to 11.9% in 2011-2014, but this increase was not significant (P = 0.44). CONCLUSIONS: Together, these data do not support a contribution of obesity trends to asthma prevalence trends</style></abstract><notes><style face="normal" font="default">DA - 20171113IS - 2047-6310 (Electronic)IS - 2047-6302 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1111/ijpo.12246</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29130640">PM:29130640</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Obes\20171112-AkinbamiLJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Obes\20171112-AkinbamiLJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171112, Akinbami LJ</style></custom2><misc3><style face="normal" font="default">10.1111/ijpo.12246</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43887</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Korhonen,P.</style></author><author><style face="normal" font="default"> Haataja,P.</style></author><author><style face="normal" font="default"> Ojala,R.</style></author><author><style face="normal" font="default"> Hirvonen,M.</style></author><author><style face="normal" font="default"> Korppi,M.</style></author><author><style face="normal" font="default"> Paassilta,M.</style></author><author><style face="normal" font="default"> Uotila,J.</style></author><author><style face="normal" font="default"> Gissler,M.</style></author><author><style face="normal" font="default"> Luukkaala,T.</style></author><author><style face="normal" font="default"> Tammela,O.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics, Tampere University Hospital, Finland</style></auth-address><titles><title><style face="normal" font="default">Asthma and atopic dermatitis after early-, late-, and post-term birth</style></title><secondary-title><style face="normal" font="default">Pediatr Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Pulmonol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="1" Year="2018">2018/1/5</year></dates><abstract><style face="normal" font="default">OBJECTIVE: To assess the incidence and risk factors of asthma and atopic dermatitis by seven years of age after early-term (ET) (37(+0) -38(+6) weeks), full-term (FT) (39(+0) -40(+6) weeks), late-term (LT) (41(+0) -41(+6) weeks), and especially post-term (PT) (>/=42 weeks) birth. METHODS: Altogether, 965 203 infants born between 1991 and 2008 in Finland were investigated in ET, FT, LT, and PT groups. Data on asthma medication reimbursement and hospital visits for atopic dermatitis were retrieved from national health databases. RESULTS: The frequencies of asthma medication reimbursement in the ET, FT, LT, and PT groups were 4.5%, 3.7%, 3.3%, and 3.2%, respectively. Hospital visits due to atopic dermatitis were most common after PT birth. Compared with FT births, ET births were associated with an increased risk of asthma (adjusted odds ratio (aOR), 95% confidence interval (CI) 1.20, 1.17-1.23), while LT (aOR, 95%CI 0.91, 0.89-0.93) births and PT (aOR, 95%CI 0.87, 0.83-0.92) births decreased this risk. PT birth (aOR, 95%CI 1.06, 1.01-1.10) predicted atopic dermatitis. From a population point of view, the most relevant risk factors for asthma were male sex, ET birth, smoking during pregnancy and birth by elective cesarean section, and for atopic dermatitis male sex, first delivery, birth in a level II hospital and birth by cesarean section. CONCLUSIONS: Early-term birth was a predictor of asthma, and PT birth was associated with atopic dermatitis. Counseling against smoking and following strict indications for planned ET deliveries and cesarean sections may be means to reduce the risk of later asthma</style></abstract><notes><style face="normal" font="default">IS - 1099-0496 (Electronic)IS - 1099-0496 (Linking)LA - engPT - Journal ArticleCO - Finland -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1002/ppul.23942</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29316371">PM:29316371</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Pulmonol\20180105-KorhonenP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Pulmonol\20180105-KorhonenP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, Korhonen P</style></custom2><misc3><style face="normal" font="default">10.1002/ppul.23942</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43888</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Brew,B.K.</style></author><author><style face="normal" font="default"> Almqvist,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden</style></auth-address><titles><title><style face="normal" font="default">Acid Suppressant Use in Pregnancy and Asthma in Offspring: Should We Be Worried?</style></title><secondary-title><style face="normal" font="default">Pediatrics</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatrics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="1" Year="2018">2018/1/11</year></dates><notes><style face="normal" font="default">IS - 1098-4275 (Electronic)IS - 0031-4005 (Linking)LA - engPT - Journal ArticleCO - Sweden -</style></notes><work-type><style face="normal" font="default">10.1542/peds.2017-3741</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29326338">PM:29326338</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatrics\20180111-BrewBK.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatrics\20180111-BrewBK.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180111, Brew BK</style></custom2><misc3><style face="normal" font="default">10.1542/peds.2017-3741</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43889</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Okamoto-Uchida,Y.</style></author><author><style face="normal" font="default"> Nakamura,R.</style></author><author><style face="normal" font="default"> Matsunaga,K.</style></author><author><style face="normal" font="default"> Aihara,M.</style></author><author><style face="normal" font="default"> Saito,Y.</style></author></authors></contributors><auth-address><style face="normal" font="default">Division of Medicinal Safety Science, National Institute of Health Sciences, Tokyo</style></auth-address><titles><title><style face="normal" font="default">Specific association of the rs6500265 and rs9933632 single-nucleotide polymorphisms in Japanese patients with antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements</style></title><secondary-title><style face="normal" font="default">Pharmacogenet Genomics</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pharmacogenet Genomics</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="12" Month="12" Year="2017">2017/12/12</year></dates><abstract><style face="normal" font="default">A recent study using the microarray for single-nucleotide polymorphisms (SNPs) genotyping specifically designed for the Japanese population in combination with genome-wide imputation showed the association of several SNPs with cold medicine-related Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) with severe ocular complications. However, it remains to be determined whether these polymorphisms are associated with the onset of antipyretic analgesic (AA)-related SJS/TEN, the progression of severe ocular involvements (SOIs), or both AA-related SJS/TEN and SOI phenotypes. To gain a better understanding of the features of these genetic markers, we compared the allele and carrier frequencies of these SNPs among our original SJS/TEN patient groups: (a) AA-related SJS/TEN with SOIs, (b) AA-related SJS/TEN without SOIs, and (c) AA-unrelated SJS/TEN with SOIs. AA-related SJS/TEN with SOIs were found to be associated significantly with both rs6500265 [allele frequency: odds ratio (OR): 2.18; 95% confidence interval (CI): 1.30-3.65; P=0.0052; carrier frequency: OR: 2.52; 95% CI: 1.33-4.78; P=0.058] and rs9933632 (allele frequency: OR: 2.28: 95% CI: 1.37-3.79; P=0.0032; carrier frequency: OR: 2.76; 95% CI: 1.46-5.22; P=0.0031). In contrast, allele and carrier frequencies of these SNPs in patients with AA-related SJS/TEN without SOIs or with SOIs not treated with any AAs were comparable with those in healthy Japanese controls. Collectively, our findings indicate that the rs6500265 and rs9933632 SNPs could be specific markers for AA-related SJS/TEN with SOIs, suggesting that certain genetic backgrounds contribute toward the etiology of this complex syndrome</style></abstract><notes><style face="normal" font="default">IS - 1744-6880 (Electronic)IS - 1744-6872 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1097/FPC.0000000000000324</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29239905">PM:29239905</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pharmacogenet Genomics\20171212-OkamotoUchidaY.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pharmacogenet Genomics\20171212-OkamotoUchidaY.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171212, Okamoto-Uchida Y</style></custom2><misc3><style face="normal" font="default">10.1097/FPC.0000000000000324</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43890</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kaczmarczyk,M.</style></author><author><style face="normal" font="default"> Por-Öbski,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Drug hypersensitivity - recommendations set up for practice</style></title><secondary-title><style face="normal" font="default">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pol J Allergol</style></full-title></periodical><pages end="151" start="146">146-151</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Drug allergy</style></keyword><keyword><style face="normal" font="default"> Hypersensitivity to drugs</style></keyword><keyword><style face="normal" font="default"> Recommendations</style></keyword><keyword><style face="normal" font="default"> classification</style></keyword><keyword><style face="normal" font="default"> Pharmacogenetics</style></keyword><keyword><style face="normal" font="default"> prevention</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2353-3854</style></isbn><abstract><style face="normal" font="default">Abstract Drug hypersensitivity reactions (DHRs) are an important public health concern related to the safety of individuals and the costs incurred in consequence for the health care system. DHRs are functionally and clinically heterogeneous. They are classified according to the timing of symptom appearance (immediate and nonimmediate reactions) or the type of mechanism (nonallergic or allergic, when the immune mechanisms are involved). Several guidelines and literature regarding the general and specific drug classes that induce hypersensitivity reactions have been recently published to assist in the management of DHRs. In this article, we highlight the key messages of the current recommendations and discuss the advances in knowledge of the mechanisms for the diagnosis and prevention of drug hypersensitivity reactions</style></abstract><notes><style face="normal" font="default">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.alergo.2017.09.004</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.alergo.2017.09.004</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Pulmonol\2017-4-146-51.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Pulmonol\2017-4-146-51.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171107, Kaczmarczyk M</style></custom2><misc3><style face="normal" font="default">10.1016/j.alergo.2017.09.004</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43891</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Piwowarek,K.</style></author><author><style face="normal" font="default"> Kruszewski,J.</style></author></authors></contributors><titles><title><style face="normal" font="default">Biogenic amines intolerance syndromes. II. Tyramine, serotonin and others</style></title><secondary-title><style face="normal" font="default">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pol J Allergol</style></full-title></periodical><pages end="157" start="152">152-157</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Food allergy</style></keyword><keyword><style face="normal" font="default"> Biogenic Amines</style></keyword><keyword><style face="normal" font="default"> Histamine intolerance</style></keyword><keyword><style face="normal" font="default"> Putrescine</style></keyword><keyword><style face="normal" font="default"> Serotonin</style></keyword><keyword><style face="normal" font="default"> Tyramine</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2353-3854</style></isbn><abstract><style face="normal" font="default">Abstract Histamine intolerance is the most important biogenic amines intolerance syndrome, but not the only one. Clinically, significant reactions may be induced by tyramine, serotonin, putrescine, cadaverine, phenylethylamine and tryptamine. Substantial variation of these highly bioactive compounds determines multiplicity of potentially caused symptoms. In addition, the situation is complicated by frequent co-occurrence in food products. Therefore, the diagnostics of biogenic amines intolerance syndromes is difficult and depends heavily on meticulously collected information through an interview. The intention of the following literature review is to present the aforementioned subject</style></abstract><notes><style face="normal" font="default">LA - POLCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.alergo.2017.09.005</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.alergo.2017.09.005</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Pulmonol\2017-4-152-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Pulmonol\2017-4-152-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171107, Piwowarek K</style></custom2><misc3><style face="normal" font="default">10.1016/j.alergo.2017.09.005</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43892</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Szymczak-Pajor,I.</style></author><author><style face="normal" font="default"> Pawliczak,R.</style></author></authors></contributors><titles><title><style face="normal" font="default">Adipose tissue as a potential source of hormones and cytokines involved in asthma pathogenesis</style></title><secondary-title><style face="normal" font="default">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pol J Allergol</style></full-title></periodical><pages end="138" start="132">132-138</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> Obesity</style></keyword><keyword><style face="normal" font="default"> Adipokines</style></keyword><keyword><style face="normal" font="default"> Inflammation</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2353-3854</style></isbn><abstract><style face="normal" font="default">Abstract Asthma and obesity are chronic inflammatory diseases affecting millions of people worldwide. Numerous epidemiological data have revealed increased adiposity as a potential risk factor for severity and incidence of asthma. In addition, obesity is not only risk factor for asthma but is also related to its poor control. Despite the mechanism underlying obesity</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çôasthma relation is not fully understood, it has been proposed that the common inflammatory mechanism plays a crucial role in determination of this relation. Adipose tissue is referred as extremely active endocrine organ secreting numerous hormones and cytokines that regulate immune responses and metabolism. In the lean state, the high levels of anti-inflammatory adipokines such as adiponetctin as well as low levels of pro-inflammatory adipokines i.e. leptin, and pro-inflammatory cytokines such as TNF-+¦, IL-8, IL-6 are secreted by adipose tissue. On the other hand, in the obese state, hypertrophic adipocytes and activated macrophages produce decreased level of adiponectin and increased levels of pro-inflammatory adipokines and cytokines leading to </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç£metabolic inflammation</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇØ. It may be possible that these obesity-related pro-inflammatory adipokines may be associated with airway inflammation in obesity-related asthma. In the current review, we summarized the recent knowledge concerning possible molecular mechanisms mediating the relation between obesity and asthma</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="default">10.1016/j.alergo.2017.10.001</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.alergo.2017.10.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Pulmonol\2017-4-132-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Pulmonol\2017-4-132-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171107, Szymczak-Pajor I</style></custom2><misc3><style face="normal" font="default">10.1016/j.alergo.2017.10.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43893</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Eichenfield,L.F.</style></author><author><style face="normal" font="default"> Ahluwalia,J.</style></author><author><style face="normal" font="default"> Waldman,A.</style></author><author><style face="normal" font="default"> Borok,J.</style></author><author><style face="normal" font="default"> Udkoff,J.</style></author><author><style face="normal" font="default"> Boguniewicz,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Current guidelines for the evaluation and management of atopic dermatitis </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô A comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology Guidelines</style></title><secondary-title><style face="normal" font="default">Pol J Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pol J Allergol</style></full-title></periodical><pages end="168" start="158">158-168</pages><volume><style face="normal" font="default">4</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">Atopic dermatitis</style></keyword><keyword><style face="normal" font="default"> Eczema</style></keyword><keyword><style face="normal" font="default"> Guidelines</style></keyword><keyword><style face="normal" font="default"> Joint Task Force</style></keyword><keyword><style face="normal" font="default"> American Academy of Dermatology</style></keyword><keyword><style face="normal" font="default"> Topical and systemic treatments</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">2353-3854</style></isbn><abstract><style face="normal" font="default">Abstract Atopic dermatitis (AD) is a chronic, remitting-relapsing inflammatory dermatitis often managed by a multidisciplinary group of providers including allergists, dermatologists, and primary care practitioners. As the pathogenesis of AD is complex and multifactorial, there are numerous approaches to therapeutic management. Current AD management guidelines cover a broad range of interventions, from treating acute flares to environmental modifications. Allergists and dermatologists have both common and distinct approaches to AD management highlighted in their respective guidelines, providing multiple approaches to disease management. We compare and contrast the recent AAAAI/ACAAI JTF 2012 AD Practice Parameter and AAD 2014 guidelines, highlighting differing approaches to disease management</style></abstract><notes><style face="normal" font="default">LA - ENGCO - United States -</style></notes><work-type><style face="normal" font="default">10.1016/j.alergo.2017.11.001</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.alergo.2017.11.001</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pediatr Pulmonol\2017-4-158-68.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pediatr Pulmonol\2017-4-158-68.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171107, Eichenfield LF</style></custom2><misc3><style face="normal" font="default">10.1016/j.alergo.2017.11.001</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43894</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Blazewicz,I.</style></author><author><style face="normal" font="default"> Jaskiewicz,M.</style></author><author><style face="normal" font="default"> Bauer,M.</style></author><author><style face="normal" font="default"> Piechowicz,L.</style></author><author><style face="normal" font="default"> Nowicki,R.J.</style></author><author><style face="normal" font="default"> Kamysz,W.</style></author><author><style face="normal" font="default"> Baranska-Rybak,W.</style></author></authors></contributors><titles><title><style face="normal" font="default">Decolonization of &lt;i>Staphylococcus aureus&lt;/i> in patients with atopic dermatitis: a reason for increasing resistance to antibiotics?</style></title><secondary-title><style face="normal" font="default">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Postepy Dermatol Alergol</style></full-title></periodical><pages end="560" start="553">553-560</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1642-395X</style></isbn><abstract><style face="normal" font="default">Introduction : Exacerbation of atopic dermatitis can be associated with bacterial infection. The skin of patients is colonized with Staphylococcus aureus in 90% of cases. An attempt has been made to demonstrate that eradication significantly reduces the severity of the disease. Studies indicate the efficacy of topical antibiotics, topical corticosteroids and calcineurin inhibitors. Due to increasing resistance to drugs and the defective antimicrobial peptide profile, decolonization is virtually impossible. Aim : To determine the prevalence of S. aureus colonization among patients with atopic dermatitis and to assess antimicrobial susceptibility of isolated strains to antibiotics, especially fusidic acid and mupirocin. Material and methods : One hundred patients with atopic dermatitis and 50 healthy subjects were microbiologically assessed for the carriage of S. aureus . Antimicrobial susceptibility tests were performed using the broth-microdilution method for antibiotics: ampicillin, ciprofloxacin, daptomycin, erythromycin, fusidic acid, linezolid, lincomycin, mupirocin, tetracycline and vancomycin. Results : Staphylococcus aureus strains were isolated from the majority of our patients, either from the skin (71%) or the anterior nares (67%). In the present study, 10% of isolations represented methicillin-resistant S. aureus (MRSA). Antibiotics exhibited diverse activities against clinical isolates of S. aureus . Among those tested, the highest rates of resistance were shown for ampicillin </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô 58.5%, lincomycin </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô 37.5% and erythromycin </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Çô 31.0%. Enhanced resistance levels were expressed to mupirocin (17.5%) and fusidic acid (15.5%). Conclusions : According to the increasing rate of resistance and quick recolonization after discontinuation of the treatment, chronic use of topical antibiotics is not recommended and should be limited to exacerbation of atopic dermatitis with clinical signs of bacterial infection</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="default">10.5114/ada.2017.72461</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5114/ada.2017.72461</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-553-60.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-553-60.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171205, Blazewicz I</style></custom2><misc3><style face="normal" font="default">10.5114/ada.2017.72461</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43895</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Blazewicz,I.</style></author><author><style face="normal" font="default"> Jaskiewicz,M.</style></author><author><style face="normal" font="default"> Piechowicz,L.</style></author><author><style face="normal" font="default"> Neubauer,D.</style></author><author><style face="normal" font="default"> Nowicki,R.J.</style></author><author><style face="normal" font="default"> Kamysz,W.</style></author><author><style face="normal" font="default"> Baranska-Rybak,W.</style></author></authors></contributors><titles><title><style face="normal" font="default">Increasing rate of daptomycin non-susceptible strains of &lt;i>Staphylococcus aureus&lt;/i> in patients with atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Postepy Dermatol Alergol</style></full-title></periodical><pages end="552" start="547">547-552</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1642-395X</style></isbn><abstract><style face="normal" font="default">Introduction : Daptomycin is a cyclic lipopeptide that is bactericidal against Staphylococcus aureus , including methicillin-resistant S. aureus (MRSA), vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) strains. Daptomycin exerts its antimicrobial effect by a calcium-dependent interaction with the cytoplasmic membrane resulting in depolarization, ion loss and rapid cell death. Unfortunately, loss of daptomycin susceptibility in S. aureus in the clinical setting has been noted. Aim : To evaluate the susceptibility profile to daptomycin among S. aureus strains isloted from patients with atopic dermatitis (AD). Another point was to correlate the results obtained by broth microdilution method and Etest, which is commonly applied in clinical setting. Material and methods : One hundred patients with the diagnosis of atopic dermatitis were microbiologically assessed for the carriage of S. aureus . Antimicrobial susceptibility tests were performed using broth-microdilution (BMD) and Etests for daptomycin. Results : Staphylococcus aureus strains were isolated from the majority of our patients, either from the skin (73%) or the anterior nares (75%). Six of the 100 nasal swabs (6%) and 5 of the 100 skin swabs (5%) were positive for methicillin-resistant Staphylococcus aureus (MRSA). A total of 81 of 148 (54.7%) daptomycin non-susceptible isolates of S. aureus were identified by BMD. Only 19 of 81 were also classified as non-susceptible by Etest. Conclusions : Clinicians and microbiologists should be aware of the possibility of the emergence of daptomycin non-susceptibility (or increase in minimal inhibitory concentration) during prolonged therapy and closely monitor the susceptibility of persisting isolates that might be recovered during therapy</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="default">10.5114/ada.2017.72460</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5114/ada.2017.72460</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-547-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-547-52.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171206, Blazewicz I</style></custom2><misc3><style face="normal" font="default">10.5114/ada.2017.72460</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43896</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sztafinska,A.</style></author><author><style face="normal" font="default"> Jerzynska,J.</style></author><author><style face="normal" font="default"> Stelmach,W.</style></author><author><style face="normal" font="default"> Woicka-Kolejwa,K.</style></author><author><style face="normal" font="default"> Stelmach,I.</style></author></authors></contributors><titles><title><style face="normal" font="default">Quality of life in asthmatic children and their caregivers after two-year treatment with omalizumab, a real-life study</style></title><secondary-title><style face="normal" font="default">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Postepy Dermatol Alergol</style></full-title></periodical><pages end="447" start="439">439-447</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1642-395X</style></isbn><abstract><style face="normal" font="default">Introduction : Omalizumab, a monoclonal anti-immunoglobulin E antibody, has been successfully used as a supplementary therapy to improve asthma control in children aged </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ëÑ 6 years with severe persistent allergic asthma. Aim : To demonstrate the quality of life in children with severe asthma and their caregivers, and changes from baseline in forced expiratory volume in 1 s (FEV 1 ) and daily inhaled corticosteroids (ICS) dose after 2-year treatment with omalizumab. Material and methods : Participants were seen in the clinic at enrollment (visit 1), after 16 weeks (visit 2), after 52 weeks (visit 3) and after 104 weeks (visit 4) of treatment with omalizumab. We evaluated lung function, ICS use and the quality of life with the Pediatric Asthma Quality of Life Questionnaire (PAQLQ) and the Pediatric Asthma Caregiver</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇÖs Quality of Life Questionnaire (PACQLQ). Results : Nineteen children and caregivers were enrolled. Significant improvement was observed in PAQLQ and PACQLQ scores, both in all domains and in total scores. Significant differences were found between the first and the other visits. A positive correlation between PAQLQ and PACQLQ at the first and at the second visit was found, 63.3% of patients achieved reduction in ICS doses. We did not notice any significant improvement in FEV 1 . Conclusions : The improvement in quality of life in asthmatic children and adolescents observed after omalizumab correlates with the improvement of quality of life in caregivers, reduction in ICS use but not with FEV 1</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Poland -</style></notes><work-type><style face="normal" font="default">10.5114/ada.2017.71109</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5114/ada.2017.71109</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-439-47.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-439-47.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171005, Sztafinska A</style></custom2><misc3><style face="normal" font="default">10.5114/ada.2017.71109</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43897</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nettis,E.</style></author><author><style face="normal" font="default"> Distaso,M.</style></author><author><style face="normal" font="default"> Saitta,S.</style></author><author><style face="normal" font="default"> Casciaro,M.</style></author><author><style face="normal" font="default"> Cristani,M.</style></author><author><style face="normal" font="default"> Saija,A.</style></author><author><style face="normal" font="default"> Vacca,A.</style></author><author><style face="normal" font="default"> Gangemi,S.</style></author><author><style face="normal" font="default"> Minciullo,P.L.</style></author></authors></contributors><titles><title><style face="normal" font="default">Involvement of new oxidative stress markers in chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default">Postepy Dermatol Alergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Postepy Dermatol Alergol</style></full-title></periodical><pages end="452" start="448">448-452</pages><volume><style face="normal" font="default">34</style></volume><number><style face="normal" font="default">5</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1642-395X</style></isbn><abstract><style face="normal" font="default">Introduction : Oxidative stress is a result of an imbalance between endogenous production of free reactive oxygen species and reduced effectiveness of antioxidant defence mechanisms. Advanced glycation end products (AGEs) and advanced oxidation protein products (AOPPs) are compounds formed by transformation of macromolecules, including proteins which can serve as markers of oxidative stress and inflammation in several diseases. Aim : To investigate the role of AGEs and AOPPs as new markers of oxidative stress and inflammation in patients with chronic spontaneous urticaria (CSU). Material and methods : Advanced glycation end products and AOPP levels were determined in the sera of 85 patients with CSU and 64 healthy controls, using spectrofluorimetry and spectrophotometry, respectively. Results : Advanced oxidation protein products levels in patients were statistically higher than those in controls. These levels were not affected by the presence of positive autologous serum test results or autologous plasma test results. No statistically significant differences were found between AGE levels in patients and controls. Conclusions : Formation of AGEs and AOPPs may be accelerated in immunological and allergic disorders. Depending on the sites evaluated, the presence or absence of oxidative stress in chronic urticaria is controversial. To our knowledge, this is the first study showing the possible involvement of AOPPs in CSU. The different behaviour observed for these two biomarkers is very likely due to the activation of specific related biochemical pathways associated with the condition under study</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="default">10.5114/ada.2017.71110</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5114/ada.2017.71110</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-448-52.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Postepy Dermatol Alergol\2017-34-448-52.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171005, Nettis E</style></custom2><misc3><style face="normal" font="default">10.5114/ada.2017.71110</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43898</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Colice,G.</style></author><author><style face="normal" font="default"> Price,D.</style></author><author><style face="normal" font="default"> Gerhardsson de Verdier,M.</style></author><author><style face="normal" font="default"> Rabon-Stith,K.</style></author><author><style face="normal" font="default"> Ambrose,C.</style></author><author><style face="normal" font="default"> Cappell,K.</style></author><author><style face="normal" font="default"> Irwin,D.E.</style></author><author><style face="normal" font="default"> Juneau,P.</style></author><author><style face="normal" font="default"> Vlahiotis,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Global Medicines Development, AstraZeneca, Gaithersburg, MD, USA</style></auth-address><titles><title><style face="normal" font="default">The effect of DPP-4 inhibitors on asthma control: an administrative database study to evaluate a potential pathophysiological relationship</style></title><secondary-title><style face="normal" font="default">Pragmat Obs Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Pragmat Obs Res</style></abbr-1></periodical><pages end="240" start="231">231-240</pages><volume><style face="normal" font="default">8</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Rationale: DPP-4 may regulate immunological pathways implicated in asthma. Assessing whether DPP-4 inhibitor (DPP-4i) use might affect asthma control is clinically important because DPP-4i use in type 2 diabetes mellitus management (T2DM) is increasing. This study evaluated associations between DPP-4i use and asthma control. Methods: This was a retrospective, observational, matched cohort study using administrative claims in the MarketScan((R)) Commercial Claims and Encounters (Commercial) and Medicare Supplemental and Coordination of Benefits (Medicare Supplemental) databases. Adult asthma patients initiating an oral DPP-4i or a non-DPP-4i between November 1, 2006 and March 31, 2014 were included. Patients were followed for asthma-related outcomes for 12 months after initiation of the antidiabetes medication. Outcomes included risk-domain asthma control (RDAC), defined as no asthma hospitalizations, no lower respiratory tract infections, and no oral corticosteroid (OCS) prescriptions; overall asthma control (RDAC criteria plus limited short-acting beta agonist use); treatment stability (RDAC criteria plus no increase of >/=50% in inhaled corticosteroid dose or addition of other asthma therapy); and severe asthma exacerbation rates (asthma-related hospitalizations, emergency room visits, or acute treatments with OCS). Comparisons were made between two matched cohorts (DPP-4i vs. non-DPP-4i initiators) using multivariable logistic regression and generalized linear modeling. Covariates included baseline demographic and clinical characteristics related to asthma and T2DM. Results: The adjusted odds of achieving RDAC (odds ratio [OR]: 1.05; 95% CI: 0.964 to 1.147), overall asthma control (OR: 1.04; 95% CI: 0.956 to 1.135), and treatment stability (OR: 1.04; 95% CI: 0.949 to 1.115) did not differ between the DPP-4i and non-DPP-4i cohorts. A difference was not found between cohorts in severe asthma exacerbation rates during the 12 months following initiation of antidiabetes treatment (mean = 0.32 vs. 0.34 exacerbations per subject-year, respectively; p=0.064). Conclusion: Asthma control was similar between patients initiating DPP-4i and non-DPP-4i antidiabetes medications, suggesting no association between DPP-4i use and asthma control</style></abstract><notes><style face="normal" font="default">IS - 1179-7266 (Print)IS - 1179-7266 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Singapore -CO - United Kingdom -CO - Sweden -</style></notes><work-type><style face="normal" font="default">10.2147/POR.S144018</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29238240">PM:29238240</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Pragmat Obs Res\2017-8-231-40.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Pragmat Obs Res\2017-8-231-40.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171201, Colice G</style></custom2><misc3><style face="normal" font="default">10.2147/POR.S144018</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43899</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bevanda,D.G.</style></author><author><style face="normal" font="default"> Cacic,M.</style></author><author><style face="normal" font="default"> Mihaljevic,S.</style></author><author><style face="normal" font="default"> Bevanda,M.</style></author><author><style face="normal" font="default"> Bogut,A.</style></author><author><style face="normal" font="default"> Karin,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">University Clinical Hospital of Mostar, Department for Internal Medicine Kralja Tvrtka bb, 8000 Mostar, Bosnia and Herzegovina, ela.bevanda@gmail.com</style></auth-address><titles><title><style face="normal" font="default">Allergic reactions and anesthesia</style></title><secondary-title><style face="normal" font="default">Psychiatr Danub</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Psychiatr Danub</style></full-title></periodical><pages end="786" start="778">778-786</pages><volume><style face="normal" font="default">29</style></volume><number><style face="normal" font="default">Suppl 4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">The diagnosis of allergic reactions during anesthesia is difficult. For example, cardio-respiratory symptoms may be due to the accompanying pharmacological effects of anesthetics and poor interpretation of the reaction during anesthesia. It is important to distinguish whether a real allergic reaction has occurred. Accidents with anesthetics and muscle relaxants are observed more often than we expect. Proper anaphylaxis rarely occurs during anesthesia (1: 20000). Muscle relaxants are the most common causes, followed by latex, chlorhexidine, antibiotics and opioids. To confirm the diagnosis it is necessary to perform a larger number of blood and skin tests. Targeted diagnostic approach and therapy allow avoiding more difficult events. Anesthesia should be selected for those medications that have been tested. Additionally, patients should be premedicated with antihistaminics and systemic steroids, as the emergence of intolerance is not completely excluded by negative testing. There is no gold standard for testing, even if every method is precisely performed; there are always false positive and false negative results. When anaphylaxis appears, urgent approach is needed to provide the patient with appropriate treatment. It is necessary to act according to the established algorithms and treatment protocols. Many anesthesiologists will not ever see such a reaction, and very few will see more than one during their work life. Awareness of allergy in anesthesia is still insufficient</style></abstract><notes><style face="normal" font="default">IS - 0353-5053 (Print)IS - 0353-5053 (Linking)LA - engPT - Journal ArticleCO - Bosnia and Herzegovina -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29278624">PM:29278624</url></web-urls></urls><custom2><style face="normal" font="default">20171209, Vevanda DG</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43900</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nannini,L.J.</style></author><author><style face="normal" font="default"> Neumayer,N.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pulmonary Section, Hospital "E. Peron", Granadero Baigorria, Argentina</style></auth-address><titles><title><style face="normal" font="default">Treatment Step 1 for Asthma Should Not Be Left Blank, and SABA-Only Might Not Be a Treatment Step 1 Option for Asthma</style></title><secondary-title><style face="normal" font="default">Respiration</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Respiration</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><notes><style face="normal" font="default">IS - 1423-0356 (Electronic)IS - 0025-7931 (Linking)LA - engPT - Journal ArticleCO - Argentina -</style></notes><work-type><style face="normal" font="default">10.1159/000484568</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29241185">PM:29241185</url></web-urls><related-urls><url ppv-ref="no">presto - MedLine</url></related-urls></urls><custom2><style face="normal" font="default">20171214, Nannini LJ</style></custom2><misc3><style face="normal" font="default">10.1159/000484568</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43901</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">McDonald,V.M.</style></author><author><style face="normal" font="default"> Maltby,S.</style></author><author><style face="normal" font="default"> Gibson,P.G.</style></author></authors></contributors><auth-address><style face="normal" font="default">National Health and Medical Research Council Centre of Excellence in Severe Asthma, Newcastle, NSW, Australia</style></auth-address><titles><title><style face="normal" font="default">Severe asthma: We can fix it? We can try!</style></title><secondary-title><style face="normal" font="default">Respirology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Respirology</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="5" Month="1" Year="2018">2018/1/5</year></dates><abstract><style face="normal" font="default">No Abstrat Available</style></abstract><notes><style face="normal" font="default">IS - 1440-1843 (Electronic)IS - 1323-7799 (Linking)LA - engPT - EditorialCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/resp.13249.</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29314456">PM:29314456</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Respirology\20180105-McDonaldVM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Respirology\20180105-McDonaldVM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, McDonald VM</style></custom2><misc3><style face="normal" font="default">10.1111/resp.13249.</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43902</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cherif,J.</style></author><author><style face="normal" font="default"> Kacem,M.</style></author><author><style face="normal" font="default"> Mjid,M.</style></author><author><style face="normal" font="default"> Hedhli,A.</style></author><author><style face="normal" font="default"> Cheikhrouhou,S.</style></author><author><style face="normal" font="default"> Ouahchi,Y.</style></author><author><style face="normal" font="default"> Beji,M.</style></author><author><style face="normal" font="default"> Toujani,S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prevalence of active tobacco smoking and its impact on adult asthmatics</style></title><secondary-title><style face="normal" font="default">Rev Fr Allergol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Rev Fr Allergol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">asthma</style></keyword><keyword><style face="normal" font="default"> epidemiology</style></keyword><keyword><style face="normal" font="default"> Tobacco</style></keyword><keyword><style face="normal" font="default"> asthma control</style></keyword><keyword><style face="normal" font="default"> treatment</style></keyword></keywords><dates><year Day="0" Month="0" Year="2018">2018</year></dates><isbn><style face="normal" font="default">1877-0320</style></isbn><abstract><style face="normal" font="default">Some controversy continues to surround the role of active smoking and its impact on asthma. To determine the prevalence of smoking among asthma patients and to assess its impact on the disease. From a sample of 172-áasthmatic subjects, identified through an epidemiological survey of the Greater Tunis area, we analyzed the data of subjects who were active smokers (G1) vs. non-smoking asthmatics (G2). The data were collected using a </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç£face-to-face</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇØ questionnaire inspired by the international ISAAC and ECRHS studies. Smoking was assessed by self-declaration. Asthma control was assessed using the Asthma Control Test questionnaire. The mean subject age was 33.5-¦10-áyears, with female predominance (65.1%). Among our population, 32% were active smokers (G1) with an average consumption estimated at 17.3-áPA. The average age on starting smoking was 22-áyears. The prevalence of symptoms was comparable in the two groups, aside from awakening due to respiratory discomfort (72.7% of G1-ávs. 53.8% of G2). We noted that only 14.5% of asthmatics were currently taking their long-term treatment: 3.6% of G1-áand 19.7% of G2 (P=0.006). According to the ACT, 25.4% of subjects had controlled asthma: 50% of G1-áand 24.5% of G2 (P>0.05). Active smoking was high among our subjects, and this is consistent with several studies. However, we found no evidence that asthmatics who smoke either exhibit more symptoms or have more severe asthma. The impact of cigarette smoking on asthma remains controversial and the results are fairly contradictory</style></abstract><notes><style face="normal" font="default">LA - FRECO - Tunisia -</style></notes><work-type><style face="normal" font="default">10.1016/j.reval.2017.11.003</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/j.reval.2017.11.003</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Rev Fr Allergol\20180109-CherifJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Rev Fr Allergol\20180109-CherifJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180109, Cherif J</style></custom2><misc3><style face="normal" font="default">10.1016/j.reval.2017.11.003</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43903</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Mi,J.</style></author><author><style face="normal" font="default"> Chen,X.</style></author><author><style face="normal" font="default"> Lin,X.</style></author><author><style face="normal" font="default"> Guo,J.</style></author><author><style face="normal" font="default"> Chen,H.</style></author><author><style face="normal" font="default"> Wei,L.</style></author><author><style face="normal" font="default"> Hong,H.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Otolaryngology Head and Neck Surgery, the 5th Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, 519020, People's Republic of China</style></auth-address><titles><title><style face="normal" font="default">Treatment of persistent allergic rhinitis via acupuncture at the sphenopalatine acupoint: a randomized controlled trial</style></title><secondary-title><style face="normal" font="default">Trials</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Trials</style></abbr-1></periodical><pages end="" start="28">28-</pages><volume><style face="normal" font="default">19</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="11" Month="1" Year="2018">2018/1/11</year></dates><abstract><style face="normal" font="default">BACKGROUND: Allergic rhinitis is a common respiratory disease. Acupuncture is used to treat it in traditional Chinese medicine, and generally, the L120, ST2 and ST36 acupoints are selected in clinical practice. We report a new method of acupuncture at the sphenopalatine acupoint (SPA) for treatment of persistent allergic rhinitis (PAR). The effect of this treatment was investigated using two different needling depths. The efficacy of this treatment was associated with accurate stimulation of the sphenopalatine ganglion (SPG). METHODS/DESIGN: A total of 61 patients diagnosed with PAR were randomly allocated to either the acupuncture or the sham acupuncture group. The difference between the groups was the needle depth when acupuncture was administered, which was 50 mm and 20 mm. Alteration in total nasal symptom score (TNSS) was the primary outcome. Quality of life, medication dosages and adverse events were secondary outcomes, measured using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ). Confidence assessment was performed to evaluate data from the treatment and follow-up periods. RESULTS: Results were: (1) average TNSS in the treatment group was significantly lower than in the control group at week 4 (median and 25th and 75th percentiles were 5.00 (4.00, 7.00) and 8.00 (7.00, 10.00), respectively (P &lt; 0.001)). However, scores in the two groups were not significantly different at week 12; (2) quality of life (RQLQ) was significantly improved at week 2 in the treatment group compared to the control group (scores of 35.47 +/- 8.20 and 45.48 +/- 8.84; P &lt; 0.001); (3) during the follow-up period, the medication dosage in the treatment group was much lower than in the control group (3.64 +/- 1.45 and 6.14 +/- 2.34; P &lt; 0.05); and (4) no adverse events were observed in either group during treatment. CONCLUSIONS: This pilot study revealed a profound effect of acupuncture at the SPA on prevention of PAR development. The TNSS in the treatment group (needle depth 50 mm), was significantly lower than in the control group (needle depth of only 20 mm). Our result demonstrates that performing acupuncture directly at the SPA to stimulate the SPG is an effective method to treat PAR. TRIAL REGISTRATION: Acupuncture Clinical Trial Registry, AMCTR-OOR-16000014 and Chinese Clinical Trial Register, ChiCTR-IOR-16009211 . Registered on 1 September 1 2016</style></abstract><notes><style face="normal" font="default">IS - 1745-6215 (Electronic)IS - 1745-6215 (Linking)LA - engPT - Journal ArticleCO - China -</style></notes><work-type><style face="normal" font="default">10.1186/s13063-017-2339-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29325594">PM:29325594</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Trials\2018-19-28.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Trials\2018-19-28.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180111, Mi J</style></custom2><misc3><style face="normal" font="default">10.1186/s13063-017-2339-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43904</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Serpa,F.S.</style></author><author><style face="normal" font="default"> Cruz,A.A.</style></author><author><style face="normal" font="default"> Condino Neto,A.</style></author><author><style face="normal" font="default"> Costa Silva,E.F.</style></author><author><style face="normal" font="default"> Motta Franco,J.</style></author><author><style face="normal" font="default"> Lima Mello,J.M.</style></author><author><style face="normal" font="default"> Urrutia-Pereira,M.</style></author><author><style face="normal" font="default"> de Fatima Guidacci,M.</style></author><author><style face="normal" font="default"> Di Gesù,R.S.</style></author><author><style face="normal" font="default"> Rubini,N.</style></author><author><style face="normal" font="default"> Sole,D.</style></author></authors></contributors><titles><title><style face="normal" font="default">Caring for patients with immunoallergic diseases in Brazil: reflections and proposals for improvement - The Belo Horizonte Charter</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="34" start="327">327-34</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Despite the increase observed in the prevalence and severity ofimmunoallergic diseases, both in Brazil and worldwide, access tospecialized care and to complementary tests and therapies thatallow adequate disease control, especially in potentially fatal cases,is restricted to a few centers in Brazil. In addition, many of theseconditions and therapies are not included in the Brazilian Ministryof Health's Clinical Protocols and Therapeutic Guidelines. In thepresent study, we analyze the current situation and weaknessesin the care of patients with allergic diseases such as anaphylaxis,cow's milk allergy, asthma, atopic dermatitis, and chronic urticaria,as well as those with primary immunodeficiencies. Possible actionsthat could be undertaken by the Brazilian Association of Allergyand Immunology in partnership with the Brazilian Ministry of Healthare proposed, with the aim of reducing the medical, social, andfinancial impact associated with these diseases.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170049</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170049</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-327-34.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-327-34.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, Serpa FS</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170049</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43905</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Barata dos Santos Figueira,M.C.</style></author><author><style face="normal" font="default"> Cavalcanti Sarinho,E.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Use of corticosteroids and antihistamines in the prevention of anaphylaxis: a bibliometric review</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="341" start="335">335-341</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Despite the scarcity of evidence, prescribing corticosteroids andantihistamines to prevent anaphylaxis is a common practice. Theobjective of this study was to perform a bibliometric analysis of theuse of these drugs for anaphylaxis prevention. In the present study,articles published until October 2016 were actively searched in theScopus database using the terms "anaphylaxis and prevention andsteroid or antihistaminic" in the title, abstract, and keyword fields.Selected articles were fully read and searched for the specificvariable under investigation, i.e., the use of the corticosteroidand/or antihistamine to prevent anaphylaxis. A total of 292 articlespublished until October 2016 were initially identified in the Scopusdatabase. When searching for the 104 full-length eligible articles,only 49 made clear reference to the use of the drugs to potentiallyprevent anaphylaxis and were digitally available. None of the 49articles fully read addressed specifically the role of corticosteroidsand/or antihistamines in preventing anaphylaxis. At present, thereis no evidence in the literature that the use of corticosteroids andantihistamines is either beneficial or detrimental to the preventionof anaphylaxis.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170050</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170050</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-335-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-335-41.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, Barata dos Santos Figueira MC</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170050</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43906</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Faria,M.E.</style></author><author><style face="normal" font="default"> Orso,V.</style></author><author><style face="normal" font="default"> Lisciotto,I.</style></author><author><style face="normal" font="default"> Faria,C.</style></author><author><style face="normal" font="default"> Filho,M.</style></author><author><style face="normal" font="default"> Soares,B.</style></author><author><style face="normal" font="default"> de Siqueira,M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Biomarkers in atopic dermatitis</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="348" start="342">342-348</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The objective of this study is to describe the findings of recentlypublished articles on the diagnostic, prognostic and therapeuticadvances in the use of biomarkers in atopic dermatitis. Nineteenarticles published in the Journal of Allergy and Clinical Immunologyand in The New England Journal of Medicine were reviewed.Currently, more than 1 billion people have some type of allergicdisease; among such diseases, atopic dermatitis is highlyprevalent. Even though atopic dermatitis can be diagnosedclinically using the Hanifin and Rajka criteria, diagnosis isexaminer-dependent, leading to major variations in results.Likewise, IgE dosage is non-specific. Thus, these methods arenot accurate for diagnosis, highlighting the importance of findingnew, more reliable markers. Biomarkers are quantifiable biologicalcharacteristics that provide objective measures of health status ordisease. They have a potential for risk stratification, early detection,treatment identification, response monitoring and prevention ofprogression to the atopic march. Technological advances allowclinicians to determine a large number of biomarkers through bodyfluids, which will result in a better characterization and stratificationof patients with atopic dermatitis and lead to objective measuresof treatment response and better comparisons between currentand new therapies.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170051</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170051</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-342-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-342-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, Faria ME</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170051</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43907</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Pereira dos Reis,A.</style></author><author><style face="normal" font="default"> Nogueira Machado,J.A:</style></author></authors></contributors><titles><title><style face="normal" font="default">Precision medicine in asthma</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="356" start="349">349-356</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The objective of this study was to conduct an updated review ofthe role of personalized phenotype-endotype driven precisionmedicine in asthma. Sources of data included original articles,reviews and other publications indexed in PubMed, MEDLINE,LILACS, and SciELO and published online over the last 20 years.The results showed that asthma has been considered as a singledisease for years, and more recent studies have increasinglyfocused on its heterogeneity. This heterogeneity has promoted theconcept that asthma consists of multiple phenotypes or consistentgroupings of characteristics. An endotype is a subtype of acondition, defined by a distinct pathophysiological mechanism andlinked to a biomarker. Several immune response modifiers havebeen evaluated in T2-high asthma geared at blocking interleukinsIL-5, IL-13, immunoglobulin E, and other pathways. Thus, manyof the T2-high asthma therapies available have shown improvedeffectiveness when certain biomarkers are elevated, especiallyeosinophils. Conversely, T2-low asthma does not currently haveany readily available point-of-care biomarkers, and therefore isoften diagnosed based on the absence of T2-high biomarkers.These patients tend to present greater resistance to steroids, andthe development of therapies has lagged behind that observed forT2-high asthma. In conclusion, the availability of biotherapeuticagents specifically targeted at IgE, IL-5, and IL-13 is an excitingvindication of molecular medicine. However, these biotherapeuticagents are only effective when targeted at specific asthmaphenotypes.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170052</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170052</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-349-56.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-349-56.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, Pereira dos Reis A</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170052</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43908</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gois Goncalves,D.</style></author><author><style face="normal" font="default"> Kalil,J.</style></author><author><style face="normal" font="default"> Giavina-Bianchi,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Autoimmune progesterone dermatitis</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="362" start="357">357-362</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Autoimmune progesterone dermatitis (APD) is an autoimmunereaction to either endogenous or exogenous progesterone,characterized by diverse clinical manifestations andpathophysiological mechanisms. This complex disease isunderdiagnosed and associated with high rates of morbidity. Thediagnosis of APD is based on the association of cyclical symptomsor symptoms induced by exogenous progesterone, positive skintests and/or the progesterone challenge test, as well as on clinicalresponse to ovulation inhibition.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170053</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170053</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-357-62.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-357-62.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, Gois Goncalves D</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170053</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43909</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">da Silva Veiga,F.M.</style></author><author><style face="normal" font="default"> Moschione Castro,A.P.</style></author><author><style face="normal" font="default"> Nunes dos Santos,C.</style></author><author><style face="normal" font="default"> de Barros Dorna,M.</style></author><author><style face="normal" font="default"> Pastorino,A.</style></author></authors></contributors><titles><title><style face="normal" font="default">Eosinophilic esophagitis: an evolving concept?</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="372" start="363">363-372</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">The objective of this paper was to review literature on eosinophilicesophagitis (EoE) published over the last 10 years and to describecurrent disease concepts related to definition, pathophysiology,risk factors, clinical presentation, diagnosis and treatment. Wesearched the PubMed, Bireme/LILACS and SciELO databasesfor articles published in the last 10 years. The following inclusioncriteria were used to select articles: (a) publication in the last 10years; (b) original articles; (c) studies with humans only; (d) reviewarticles; (e) guidelines. Exclusion criteria were: (a) articles thatdid not have EoE as the main subject; (b) repeated articles; (c)case reports; (d) articles addressing a very specific treatment ordiagnostic technique. Abstracts were screened by two investigators,and articles meeting the criteria were selected for full-text reading.Any relevant studies addressing crucial aspects of the review wereadded to the sample, resulting in a total of 3 consensus articles,35 original articles, and 3 review articles. The review showed thatEoE is a chronic disease in which clinical aspects are essential fordiagnostic suspicion, but associated endoscopic and histologicalfindings are required to confirm diagnosis. Over the last 10 years,significant changes were observed in diagnostic criteria, and somenew treatment recommendations emerged, however still requiringlong-term follow-up.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170054</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170054</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-363-72.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-363-72.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, da Silva Veiga FM</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170054</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43910</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Regnier Galvao,V.</style></author><author><style face="normal" font="default"> Phillips,E.</style></author><author><style face="normal" font="default"> Castells,M.</style></author><author><style face="normal" font="default"> Giavina-Bianchi,P.</style></author></authors></contributors><titles><title><style face="normal" font="default">Increased incidence of a class II HLA haplotype in severe anaphylaxis secondary to carboplatin</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="378" start="373">373-378</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Objective: The role of biomarkers in hypersensitivity reactions(HSR) to platinum compounds has been studied, and thepresence of BRCA1/2 gene mutation is known to be a risk factorfor carboplatin HSR. Class I and II HLA genotyping helps identifypatients at risk for IgE-mediated and T lymphocyte-mediatedreactions associated with beta-lactams and abacavir, respectively.Associations between HLA alleles or haplotypes and carboplatinHSR are not known. The main objective of the present studywas to evaluate whether specific class II HLA alleles are moreprevalent in patients allergic to carboplatin who underwent rapiddrug desensitization (RDD). Methods: Class II HLA genotypingwas performed in 11 carboplatin-allergic patients with tubo-ovarianmalignancies who were submitted to RDD, and in 12 patients whotolerated carboplatin, for at least eight cycles. The prevalence ofthe BRCA1/2 mutation was also analyzed in both groups. Results:The HLA-DRB1*15:01 allele was more prevalent among allergicpatients (5/11; 45%) than in controls (1/12; 8.3%) (p = 0.06).Class II haplotype DQA1*01:02-DQB1*06:02-DRB1*15:01 andthe BRCA1/2 mutation were also more prevalent in the allergicgroup. Conclusions: The identification of patients at risk forcarboplatin HSR is of utmost importance, as the use of thismedication is increasing. HLA genotyping and screening for theBRCA1/2 mutation are promising tools that may increase safetyduring regular carboplatin infusion and RDD.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170055</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170055</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-373-8.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-373-8.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, Regnier Galvao V</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170055</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43911</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Oliveira e Silva,L.</style></author><author><style face="normal" font="default"> da Silva,P.L.</style></author><author><style face="normal" font="default"> Borges Silva,M.</style></author><author><style face="normal" font="default"> Cheik,N.</style></author></authors></contributors><titles><title><style face="normal" font="default">Assessment of risk factors associated with exercise-induced bronchospasm in children and adolescents without prior diagnosis of asthma</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="394" start="387">387-394</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Objective: To assess risk factors associated with exercise-inducedbronchospasm (EIB) in children and adolescents without priordiagnosis of asthma using spirometric parameters. Methods: 90volunteers above the 85th percentile for weight (overweight) and30 eutrophic participants were included in this study. EIB testingwas performed according to the protocol proposed in 2000 by DelRio-Navarro et al., using a treadmill. The EIB test was consideredpositive when there was a decrease of 10% or more in forcedexpiratory volume in one second (FEV 1 ) or a reduction of 26% ormore in forced expiratory flow between 25 and 75% of the forcedvital capacity (FEF 25-75% ). Results: There was an associationbetween EIB and excess body mass in children and adolescents,but not between EIB and level of physical activity. Furthermore,the diagnosis of EIB was associated with prolonged significantreductions in pulmonary function parameters FEV 1 and FEF 25-75% .Conclusion: Excess body weight may increase the frequency ofBIE in children and adolescents without prior diagnosis of asthmawhen compared with eutrophic subjects, based on differentspirometric parameters.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170057</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170057</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-387-94.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-387-94.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, Oliveira e Silva L</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170057</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43912</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rocha Felix,M.M.</style></author><author><style face="normal" font="default"> de Queiroz,G.</style></author><author><style face="normal" font="default"> Aranda,C.S.</style></author><author><style face="normal" font="default"> Vivolo Aun,M.</style></author><author><style face="normal" font="default"> Padua de Menezes,U.</style></author><author><style face="normal" font="default"> Teixeira Rodrigues,A.</style></author><author><style face="normal" font="default"> Camelo Nunes,I.C.</style></author><author><style face="normal" font="default"> Soares de Souza,M.</style></author><author><style face="normal" font="default"> Cavalcanti Sarinho,E.S.</style></author><author><style face="normal" font="default"> Malaman,M.F.</style></author></authors></contributors><titles><title><style face="normal" font="default">Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs in children: report of two cases and review of new classifications</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="416" start="410">410-416</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Non-steroidal anti-inflammatory drugs (NSAIDs) are widely usedto treat pain and fever in children. Currently, they are consideredthe main cause of drug hypersensitivity reaction (DHR) in adultsand children from several countries, including Brazil. There aretwo mechanisms involved in these reactions: non-immune (due toinhibition of cyclooxygenase enzyme) and immune mechanismsresponsible for allergic reactions (IgE or T-cell mediated). The mostcommon reactions in children and adolescents are those resultingfrom non-immunological mechanisms. Clinical manifestationsrange from urticaria/angioedema/anaphylaxis that occur withina few minutes to hours after NSAID administration up to latereactions that may occur several days after starting treatment.Detailed medical history is critical to diagnosis. In vitro tests arepoorly validated, but skin tests can be performed in cases ofsuspected selective DHR with a probable immune mechanism.Oral provocation test (OPT) is considered the "gold standard"for diagnosis and may help in choosing a safe alternative. This article reports two cases of hypersensitivity to NSAIDs in childrenthat illustrate different types of mechanisms (non-immunologicaland immunological) with distinct clinical manifestations: urticaria(immediate) and fixed drug eruption (non-immediate). There isdifficulty in classifying DHRs for NSAIDs, as occurred in one ofthe cases described. Therefore, there is a need for further studiesin this area in order to increase knowledge and improve theevaluation and follow-up of these children with DHR to NSAIDs.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170060</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-410-6.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-410-6.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, Rocha Felix MM</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170060</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43913</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Lopes Ferreira,M.</style></author><author><style face="normal" font="default"> de Freitas Silva,E.</style></author><author><style face="normal" font="default"> Porto,L.C.</style></author><author><style face="normal" font="default"> Scotelaro Alves,M.</style></author><author><style face="normal" font="default"> Arraes,A.C.</style></author><author><style face="normal" font="default"> Castro,A.</style></author><author><style face="normal" font="default"> Conte,S.</style></author><author><style face="normal" font="default"> Lacerda Pedrazzi,D.</style></author><author><style face="normal" font="default"> Coelho Dias,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">DRESS syndrome: case report with genetic testin</style></title><secondary-title><style face="normal" font="default">Braz J Allergy Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Braz J Allergy Immunol</style></full-title></periodical><pages end="421" start="417">417-421</pages><volume><style face="normal" font="default">1</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="in-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Drug reaction with eosinophilia and systemic symptoms (DRESSsyndrome) is a rare, potentially fatal adverse reaction to drugsthat may have long-term sequelae. Aromatic anticonvulsants areamong the drugs most commonly associated with DRESS. Wereport a case of DRESS associated with allele HLA-A*31:01,with emphasis on clinical and laboratory findings, the diagnosticapproach adopted, and outpatient follow-up of late sequelae. A69-year old Japanese male patient was admitted with a clinicalsuspicion of DRESS. He had started carbamazepine treatmentfor epilepsy 4 weeks before the rash. He presented skin biopsycompatible with pharmacodermia. The patient was treated withprednisolone for 4 months. HLA-A-B-DRB1 typing using the PCR-RSSO technique (ONE LAMBDA) and specific SSP allele revealedHLA related to hypersensitivity reactions to carbamazepine.The skin test performed with carbamazepine 10% on the firstday after the reaction resulted positive. Future restriction ofaromatic anticonvulsants was recommended. Eight months afterthe apparent clinical resolution of DRESS, the patient showedincreased levels of antithyroid antibodies and Hashimoto disease.Thirteen months after the onset of the reaction, increased FANresults were observed, with no clinical manifestations. This casereport describes clinical and laboratory aspects of DRESS relatedto clinical, laboratory, and histopathological diagnosis, as well asclinical evolution in the short and long terms. The pharmacogenetic approach and the skin test were important to confirm theimputability of carbamazepine in the etiology of DRESS.</style></abstract><notes><style face="normal" font="default">LA - PORCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.5935/2526-5393.20170061</style></work-type><urls><web-urls><url ppv-ref="no">http://dx.doi.org/10.5935/2526-5393.20170061</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-417-21.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Braz J Allergy Immunol\2017-1-417-21.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180105, Lopes Ferreira M</style></custom2><misc3><style face="normal" font="default">10.5935/2526-5393.20170061</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43914</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Paganelli,R.</style></author><author><style face="normal" font="default"> Petrarca,C.</style></author><author><style face="normal" font="default"> Di Gioacchino,M.</style></author></authors></contributors><titles><title><style face="normal" font="default">Biological clocks: their relevance to immune-allergic diseases</style></title><secondary-title><style face="normal" font="default">Clin Mol Allergy</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Clin Mol Allergy</style></full-title></periodical><pages end="" start="1">1-</pages><volume><style face="normal" font="default">16</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><isbn><style face="normal" font="default">1476-7961</style></isbn><abstract><style face="normal" font="default">The 2017 Nobel Prize for Physiology or Medicine, awarded for the discoveries made in the past 15-áyears on the genetic and molecular mechanisms regulating many physiological functions, has renewed the attention to the importance of circadian rhythms. These originate from a central pacemaker in the suprachiasmatic nucleus in the brain, photoentrained via direct connection with melanopsin containing, intrinsically light-sensitive retinal ganglion cells, and it projects to periphery, thus creating an inner circadian rhythm. This regulates several activities, including sleep, feeding times, energy metabolism, endocrine and immune functions. Disturbances of these rhythms, mainly of wake/sleep, hormonal secretion and feeding, cause decrease in quality of life, as well as being involved in development of obesity, metabolic syndrome and neuropsychiatric disorders. Most immunological functions, from leukocyte numbers, activity and cytokine secretion undergo circadian variations, which might affect susceptibility to infections. The intensity of symptoms and disease severity show a 24-áh pattern in many immunological and allergic diseases, including rheumatoid arthritis, bronchial asthma, atopic eczema and chronic urticaria. This is accompanied by altered sleep duration and quality, a major determinant of quality of life. Shift work and travel through time zones as well as artificial light pose new health threats by disrupting the circadian rhythms. Finally, the field of chronopharmacology uses these concepts for delivering drugs in synchrony with biological rhythms</style></abstract><notes><style face="normal" font="default">LA - ENGCO - Italy -</style></notes><work-type><style face="normal" font="default">10.1186/s12948-018-0080-0</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1186/s12948-018-0080-0</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Mol Allergy\2018-16-1.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Mol Allergy\2018-16-1.pdf</url></text-urls></urls><misc3><style face="normal" font="default">10.1186/s12948-018-0080-0</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43915</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Everhart,R.S.</style></author><author><style face="normal" font="default"> Heron,K.E.</style></author><author><style face="normal" font="default"> Leibach,G.G.</style></author><author><style face="normal" font="default"> Miadich,S.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Psychology, Virginia Commonwealth University, Richmond, Virginia</style></auth-address><titles><title><style face="normal" font="default">Developing a Mobile Health Intervention for Low-Income, Urban Caregivers of Children with Asthma: A Pilot Study</style></title><secondary-title><style face="normal" font="default">Pediatr Allergy Immunol Pulmonol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pediatr Allergy Immunol Pulmonol</style></full-title></periodical><pages end="256" start="252">252-256</pages><volume><style face="normal" font="default">30</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="12" Year="2017">2017/12/1</year></dates><abstract><style face="normal" font="default">Objective: This pilot study explored the initial feasibility and efficacy of providing feedback to low-income, urban caregivers of children with persistent asthma about their daily experiences reported via ecological momentary assessment (EMA) on caregiver emotional health (quality of life, perceived stress, and positive affect). Methods: Data were collected from 28 caregivers and their children (7-12 years). Caregivers completed a baseline session, 14 days of EMA surveys via smartphone, and were randomized to intervention or control groups. The intervention group received individualized EMA feedback regarding areas of daily life that may be making it harder to manage child asthma. The control group received information on general child health. Caregivers completed assessments 4 weeks and 4 months postintervention. Results: In the EMA group, caregivers experienced an increase in perceived stress from baseline to postintervention, but a decrease in perceived stress from postintervention to follow-up. There were no significant changes in outcome measures for the control group. Conclusion: Preliminary findings suggest that providing caregivers with feedback from daily assessments may reduce stress, which could be targeted in future mobile health interventions for low-income, urban families of children with asthma</style></abstract><notes><style face="normal" font="default">IS - 2151-321X (Print)IS - 2151-321X (Linking)LA - engPT - Journal ArticleCO - United states -</style></notes><work-type><style face="normal" font="default">10.1089/ped.2017.0794</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29279790">PM:29279790</url></web-urls></urls><custom2><style face="normal" font="default">20171201, Everhart RS</style></custom2><misc3><style face="normal" font="default">10.1089/ped.2017.0794</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43916</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Rajcani,J.</style></author><author><style face="normal" font="default"> Solarikova,P.</style></author><author><style face="normal" font="default"> Brezina,I.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Psychology, Faculty of Arts, Comenius University, Gondova 2, 81499 Bratislava, Slovakia</style></auth-address><titles><title><style face="normal" font="default">Allergy and high trait anxiety are related to increases in heart rate variability: results of naturalistic long-term design study</style></title><secondary-title><style face="normal" font="default">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="27" start="19">19-27</pages><volume><style face="normal" font="default">50</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">Summary: A number of studies report heart rate variability (HRV) changes in allergic as well as high trait anxious people, and associations between allergic inflammation and trait anxiety. This study investigated HRV of 20 low anxious allergic, 19 healthy high trait anxious and 18 healthy low anxious, in naturalistic setting. On arranged research days, subjects performed measurements using portable ECG device and subjective self-assessment of perceived stress. Five repeated measurements data from each subject have shown increases in overall HRV, as well as HRV on respiratory frequencies in both allergy and high trait anxiety. Subject's sex was an important factor, because HRV increases in allergy were only apparent in women. Data from self-assessment show no differences in experienced stress attributable to allergy, only to trait anxiety</style></abstract><notes><style face="normal" font="default">IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Slovakia -</style></notes><work-type><style face="normal" font="default">10.23822/EurAnnACI.1764-1489.33</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29350018">PM:29350018</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2018-50-19-27.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2018-50-19-27.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180114, Rajcani J</style></custom2><misc3><style face="normal" font="default">10.23822/EurAnnACI.1764-1489.33</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43917</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Sanchez-Borges,M.</style></author><author><style face="normal" font="default"> Capriles-Hulett,A.</style></author><author><style face="normal" font="default"> Caballero-Fonseca,F.</style></author><author><style face="normal" font="default"> Gonzalez-Aveledo,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Allergy and Clinical Immunology Department, Centro Medico Docente La Trinidad, Caracas, Venezuela.</style></auth-address><titles><title><style face="normal" font="default">Biomarkers of treatment efficacy in patients with chronic spontaneous urticaria</style></title><secondary-title><style face="normal" font="default">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="9" start="5">5-9</pages><volume><style face="normal" font="default">50</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">Summary: Background. Currently there are no biomarkers useful to predict the future evolution and the therapeutic response in patients with chronic spontaneous urticaria (CSU). Objective. To review the available information on biomarkers that might be applied for the follow up of the response to guideline recommended therapies for CSU. Methods. A review of the medical literature on CSU potential clinical and laboratory biomarkers in PubMed and MEDLINE including the terms urticaria, chronic urticaria, chronic idiopathic urticaria, chronic spontaneous urticaria, antihistamines (AHs), omalizumab (OMA), cyclosporine (CyA), and treatment. Results. Clinical manifestations that were associated to poor responses to AHs were atopy, asthma, rhinitis / rhinosinusitis, thyroid disease, hypertension, higher disease activity and duration. Laboratory markers of AH resistance that have been reported include Complement C5a fraction, Autologous Serum Skin Test (ASST), Basophil Activation Test (BAT), D-dimer and LCN2 adipokine. Basophil Histamine Release Assay (BHRA), ASST, and basophil CD203c-upregulating activity in the serum correlated with favorable response to OMA, whereas disease duration and severity, BAT, BHRA, and D-dimer levels were associated with better responses to CyA. Conclusion. Some promising biomarkers useful for patient management in CSU, have been identified in the literature. There is, however, an urgent need of new, easy-to-perform markers that can be made widely available for the optimal care of patients suffering CSU</style></abstract><notes><style face="normal" font="default">IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Venezuela -</style></notes><work-type><style face="normal" font="default">10.23822/EurAnnACI.1764-1489.24</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29350016">PM:29350016</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2018-50-5-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2018-50-5-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180114, Sanchez-Borges M</style></custom2><misc3><style face="normal" font="default">10.23822/EurAnnACI.1764-1489.24</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43918</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Buyukozturk,S.</style></author><author><style face="normal" font="default"> Kekik,C.</style></author><author><style face="normal" font="default"> Gokyigit,A.Z.</style></author><author><style face="normal" font="default"> Tezer Filik,F.I.</style></author><author><style face="normal" font="default"> Karakaya,G.</style></author><author><style face="normal" font="default"> Saygi,S.</style></author><author><style face="normal" font="default"> Dursun,A.B.</style></author><author><style face="normal" font="default"> Kirbas,S.</style></author><author><style face="normal" font="default"> Tufekci,A.</style></author><author><style face="normal" font="default"> Sin,A.Z.</style></author><author><style face="normal" font="default"> Aydogdu,I.</style></author><author><style face="normal" font="default"> Sorgun,M.H.</style></author><author><style face="normal" font="default"> Aydin,N.</style></author><author><style face="normal" font="default"> Gelincik,A.</style></author><author><style face="normal" font="default"> Colakoglu,B.</style></author><author><style face="normal" font="default"> Celik,G.</style></author><author><style face="normal" font="default"> Oguz,F.</style></author></authors></contributors><auth-address><style face="normal" font="default">Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Allergy and Clinical Immunology Unit, Istanbul, Turkey</style></auth-address><titles><title><style face="normal" font="default">Cutaneous drug reactions to antiepileptic drugs and relation with HLA alleles in the Turkish population</style></title><secondary-title><style face="normal" font="default">Eur Ann Allergy Clin Immunol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Eur Ann Allergy Clin Immunol</style></full-title></periodical><pages end="41" start="36">36-41</pages><volume><style face="normal" font="default">50</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="1" Year="2018">2018/1</year></dates><abstract><style face="normal" font="default">Summary: Background and objective. Many studies have shown associations between HLAB*15:02, HLA-A*31:01 and carbamazepine (CBZ)-induced delayed cutaneous hypersensitivity reactions. The aim of this study is to evaluate a possible association between delayed cutaneous reactions to antiepileptic drugs (AEDs) and certain HLA-A and HLA-B alleles in the Turkish population. Methods. The study consisted of 3 groups: Group I (reactive group) included the patients who had documented delayed cutaneous reactions to any antiepileptic drug. Group II (non-reactive group) included the patients who have been on antiepileptic treatment at least for three months without any adverse reactions. Group III consisted of healthy subjects. The HLA-A and B alleles were analyzed in all groups. Results. Forty patients (29 female) had experienced different hypersensitivity reactions due to AEDs: maculopapular exanthema (26 patients), Stevens-Johnson syndrome (6 patients), drug rash with eosinophilia and systemic symptoms (7 patients), toxic epidermal necrolysis (1 patient). Lamotrigine (11) and CBZ (10) were the most common culprit drugs involved in the reactions. The HLA-B*15:02 was not present in any of the study groups. However, HLA-B*35:02 was found in 4 patients from the reactive group, while it was not observed in non-reactive patients and was detected in only one healthy subject (p = 0.021). Conclusion. Although our preliminary results did not indicate a strong allele association with AED hypersensitivity, HLA-B*35:02 appears to be a candidate allele for MPE / DRESS / DIHSS induced by AED's in Turkish population. Further studies with a larger sample size may result in more comprehensive data about the genetic tendency for AED hypersensitivity in the Turkish population</style></abstract><notes><style face="normal" font="default">IS - 1764-1489 (Print)IS - 1764-1489 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.23822/EurAnnACI.1764-1489.23</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29350020">PM:29350020</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2018-50-36-41.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Eur Ann Allergy Clin Immunol\2018-50-36-41.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180114, Buyukozturk S</style></custom2><misc3><style face="normal" font="default">10.23822/EurAnnACI.1764-1489.23</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43919</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">White,A.A.</style></author><author><style face="normal" font="default"> Doherty,T.A.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Divison of Allergy, Asthma and Immunology, Scripps Clinic, La Jolla, California</style></auth-address><titles><title><style face="normal" font="default">Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis</style></title><secondary-title><style face="normal" font="default">Am J Rhinol Allergy</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Am J Rhinol Allergy</style></abbr-1></periodical><pages end="11" start="7">7-11</pages><volume><style face="normal" font="default">32</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="1" Year="2018">2018/1/1</year></dates><abstract><style face="normal" font="default">Aspirin-exacerbated respiratory disease (AERD) is characterized by chronic eosinophilic nasal polyps, asthma, and airway reactions upon cyclooxygenase (COX) 1 inhibition. AERD is present in up to 7% of adult patients with asthma and the underlying pathogenesis remains largely elusive but prostaglandin D2, cysteinyl leukotrienes, mast cells, and type 2 cytokines are thought to contribute. A wealth of studies have recently implicated group 2 innate lymphoid cells (ILC2), a novel lineage-negative lymphocyte population that produces type 2 cytokines, in human allergic disease pathogenesis. Importantly, our recent work identified that ILC2s are recruited to the nasal mucosa of patients on AERD after COX-1 inhibitor administration. Here, we review the potential impact of ILC2s in the development and propagation of type 2 inflammation in AERD</style></abstract><notes><style face="normal" font="default">IS - 1945-8932 (Electronic)IS - 1945-8932 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.2500/ajra.2018.32.4498</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29336282">PM:29336282</url></web-urls><related-urls><url ppv-ref="no">presto -</url></related-urls></urls><custom2><style face="normal" font="default">20180101, White AA</style></custom2><misc3><style face="normal" font="default">10.2500/ajra.2018.32.4498</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43920</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Szolnoky,G.</style></author><author><style face="normal" font="default"> Altmayer,A.</style></author><author><style face="normal" font="default"> Varga,J.</style></author><author><style face="normal" font="default"> Gavaller,H.</style></author><author><style face="normal" font="default"> Kemeny,L.</style></author><author><style face="normal" font="default"> Forster,T.</style></author><author><style face="normal" font="default"> Nemes,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.</style></auth-address><titles><title><style face="normal" font="default">Adult Atopic Dermatitis is Associated with Increased Aortic Stiffness</style></title><secondary-title><style face="normal" font="default">Am J Clin Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Am J Clin Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="1" Year="2018">2018/1/16</year></dates><notes><style face="normal" font="default">IS - 1179-1888 (Electronic)IS - 1175-0561 (Linking)LA - engPT - LetterCO - Hungary -</style></notes><work-type><style face="normal" font="default">10.1007/s40257-018-0344-y</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29340955">PM:29340955</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Am J Clin Dermatol\20180116-SzolnokyG.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Am J Clin Dermatol\20180116-SzolnokyG.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180116, Szolnoky G</style></custom2><misc3><style face="normal" font="default">10.1007/s40257-018-0344-y</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43921</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nacaroglu,H.T.</style></author><author><style face="normal" font="default"> Bahceci,E.S.</style></author><author><style face="normal" font="default"> Durgun,E.</style></author><author><style face="normal" font="default"> Karaman,S.</style></author><author><style face="normal" font="default"> Baris,E.C.</style></author><author><style face="normal" font="default"> Unsal Karkmer,C.S.</style></author><author><style face="normal" font="default"> Can,D.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Pediatrics Allergy, Istanbul Medipol University Faculty of Medicine, Istanbul, Turkey.</style></auth-address><titles><title><style face="normal" font="default">Markers of inflammation and tolerance development in allergic proctocolitis</style></title><secondary-title><style face="normal" font="default">Arch Argent Pediatr</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Arch Argent Pediatr</style></abbr-1></periodical><pages end="e7" start="e1">e1-e7</pages><volume><style face="normal" font="default">116</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="1" Month="2" Year="2018">2018/2/1</year></dates><abstract><style face="normal" font="default">BACKGROUND: Today, as a result of an increase in the frequency of food protein-induced allergic proctocolitis (FPIAP), there is a need for studies not only to enlighten the pathophysiology of the disease but also to determine simple, non-invasive markers in both diagnosis, and evaluation of the development of tolerance. No study has been found in the literature about the place of neutrophil/lymphocyte ratio (NLR) and mean platelet volume (MPV), which are easy to calculate and non-invasive markers. OBJECTIVES: The purpose is to determine the relation between NLR and MPV with the diagnosis and development of tolerance in children with FPIAP. METHODS: In this retrospective cross-sectional study, clinical, demographic symptoms and laboratory findings of patients, monitored with FPIAP diagnosis in allergy and gastroenterology clinics, were acquired from the patient record system. Hemogram values at the time of diagnosis were compared with the values of healthy children of the same age and gender. RESULTS: Among 59 patients diagnosed with FPIAP, males constitute 47.4% and females constitute 52.6%. MPV and platelet crit (PCT) values were significantly high when compared to the control group (n: 67) in FPIAP cases (p &lt; 0.001). Also, MPV and PCT values were significantly high in non-tolerance developing cases when compared to developing ones (p= 0.01). CONCLUSIONS: Contrary to NLR, MPV and PCT values have been considered to be good markers in predicting prognosis in cases with FPIAP since they are quick, cost effective and easy to calculate</style></abstract><notes><style face="normal" font="default">IS - 1668-3501 (Electronic)IS - 0325-0075 (Linking)LA - engLA - spaPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.5546/aap.2018.eng.e1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29333812">PM:29333812</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Arch Argent Pediatr\2018-116-e1-7.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Arch Argent Pediatr\2018-116-e1-7.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180107, Nacaroglu HT</style></custom2><misc3><style face="normal" font="default">10.5546/aap.2018.eng.e1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43922</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Martinez,E.</style></author><author><style face="normal" font="default"> Sahni,S.</style></author><author><style face="normal" font="default"> Cheema,M.A.</style></author><author><style face="normal" font="default"> Iftikhar,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Primary Care, Touro College of Osteopathic Medicine, New York, USA</style></auth-address><titles><title><style face="normal" font="default">Vancomycin-induced coronary artery spasm: a case of Kounis syndrome</style></title><secondary-title><style face="normal" font="default">BMJ Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="1" Year="2018">2018/1/17</year></dates><abstract><style face="normal" font="default">Kounis syndrome defined as the appearance of acute coronary syndrome in the context of an allergic reaction is a relatively rare phenomenon. There are three variants of this syndrome in which the patient presents with symptoms of an acute chest. Herein, we describe a case of an 83-year-old woman who demonstrated type I variant of Kounis syndrome in response to vancomycin administration. After initialisation of vancomycin, she became unresponsive and an ECG demonstrated ST changes consistent with inferior-lateral myocardial infarction. Once allergic stimulus was removed, ECG normalised. Differential diagnosis includes, myocardial infarctions, angina as well as intravascular stent thrombosis, which must all be ruled out. The patient was monitored and discharged soon thereafter</style></abstract><notes><style face="normal" font="default">IS - 1757-790X (Electronic)IS - 1757-790X (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1136/bcr-2017-222846</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29348285">PM:29348285</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Arch Argent Pediatr\20180117-MartinezE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Arch Argent Pediatr\20180117-MartinezE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180117, Martinez E</style></custom2><misc3><style face="normal" font="default">10.1136/bcr-2017-222846</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43923</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Peat,F.</style></author><author><style face="normal" font="default"> Coomber,R.</style></author><author><style face="normal" font="default"> Rana,A.</style></author><author><style face="normal" font="default"> Vince,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Trauma and Orthopaedics, Addenbrooke's Hospital, Cambridge, UK</style></auth-address><titles><title><style face="normal" font="default">Vanadium allergy following total knee arthroplasty</style></title><secondary-title><style face="normal" font="default">BMJ Case Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Case Rep</style></abbr-1></periodical><pages end="" start="">-</pages><volume><style face="normal" font="default">2018</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="1" Year="2018">2018/1/18</year></dates><abstract><style face="normal" font="default">Allergic reactions to metals following joint arthroplasty represent a rare and poorly understood phenomenon. Much is still unknown regarding the natural history of this complication, and how it can best be prevented and managed. We present a case of a 68-year-old woman who underwent a left total knee arthroplasty for treatment of osteoarthritis. After an initial uneventful postoperative course, she developed a troublesome erythematous rash both around the incision site and over her trunk. Blood testing revealed no evidence of infection and clinically her prosthesis was functioning well. Skin patch testing revealed positive results for vanadium (+) and palladium (+). Her cutaneous symptoms are currently being managed conservatively and have shown a partial response to topical steroids. Revision surgery remains a long-term treatment option should conservative therapy fail; however, it would require a custom-made prosthesis as no standard tibial component is free from vanadium</style></abstract><notes><style face="normal" font="default">IS - 1757-790X (Electronic)IS - 1757-790X (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1136/bcr-2017-222092</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29351933">PM:29351933</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Case Rep\20180118-PeatF.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Case Rep\20180118-PeatF.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180118, Peat F</style></custom2><misc3><style face="normal" font="default">10.1136/bcr-2017-222092</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43924</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Griffiths,L.J.</style></author><author><style face="normal" font="default"> Lyons,R.A.</style></author><author><style face="normal" font="default"> Bandyopadhyay,A.</style></author><author><style face="normal" font="default"> Tingay,K.S.</style></author><author><style face="normal" font="default"> Walton,S.</style></author><author><style face="normal" font="default"> Cortina-Borja,M.</style></author><author><style face="normal" font="default"> Akbari,A.</style></author><author><style face="normal" font="default"> Bedford,H.</style></author><author><style face="normal" font="default"> Dezateux,C.</style></author></authors></contributors><auth-address><style face="normal" font="default">Life Course Epidemiology and Biostatistics, UCL Great Ormond Street Institute of Child Health, London, UK</style></auth-address><titles><title><style face="normal" font="default">Childhood asthma prevalence: cross-sectional record linkage study comparing parent-reported wheeze with general practitioner-recorded asthma diagnoses from primary care electronic health records in Wales</style></title><secondary-title><style face="normal" font="default">BMJ Open Respir Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">BMJ Open Respir Res</style></abbr-1></periodical><pages end="" start="e000260">e000260-</pages><volume><style face="normal" font="default">5</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2018">2018</year></dates><abstract><style face="normal" font="default">Introduction: Electronic health records (EHRs) are increasingly used to estimate the prevalence of childhood asthma. The relation of these estimates to those obtained from parent-reported wheezing suggestive of asthma is unclear. We hypothesised that parent-reported wheezing would be more prevalent than general practitioner (GP)-recorded asthma diagnoses in preschool-aged children. Methods: 1529 of 1840 (83%) Millennium Cohort Study children registered with GPs in the Welsh Secure Anonymised Information Linkage databank were linked. Prevalences of parent-reported wheezing and GP-recorded asthma diagnoses in the previous 12 months were estimated, respectively, from parent report at ages 3, 5, 7 and 11 years, and from Read codes for asthma diagnoses and prescriptions based on GP EHRs over the same time period. Prevalences were weighted to account for clustered survey design and non-response. Cohen's kappa statistics were used to assess agreement. Results: Parent-reported wheezing was more prevalent than GP-recorded asthma diagnoses at 3 and 5 years. Both diminished with age: by age 11, prevalences of parent-reported wheezing and GP-recorded asthma diagnosis were 12.9% (95% CI 10.6 to 15.4) and 10.9% (8.8 to 13.3), respectively (difference: 2% (-0.5 to 4.5)). Other GP-recorded respiratory diagnoses accounted for 45.7% (95% CI 37.7 to 53.9) and 44.8% (33.9 to 56.2) of the excess in parent-reported wheezing at ages 3 and 5 years, respectively. Conclusion: Parent-reported wheezing is more prevalent than GP-recorded asthma diagnoses in the preschool years, and this difference diminishes in primary school-aged children. Further research is needed to evaluate the implications of these differences for the characterisation of longitudinal childhood asthma phenotypes from EHRs</style></abstract><notes><style face="normal" font="default">IS - 2052-4439 (Print)IS - 2052-4439 (Linking)LA - engPT - Journal ArticleCO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1136/bmjresp-2017-000260</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29333271">PM:29333271</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\BMJ Open Respir Res\2018-5-e000260.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\BMJ Open Respir Res\2018-5-e000260.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180106, Griffiths LJ</style></custom2><misc3><style face="normal" font="default">10.1136/bmjresp-2017-000260</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43925</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Dizon,M.P.</style></author><author><style face="normal" font="default"> Yu,A.M.</style></author><author><style face="normal" font="default"> Singh,R.K.</style></author><author><style face="normal" font="default"> Wan,J.</style></author><author><style face="normal" font="default"> Chren,M.M.</style></author><author><style face="normal" font="default"> Flohr,C.</style></author><author><style face="normal" font="default"> Silverberg,J.</style></author><author><style face="normal" font="default"> Margolis,D.J.</style></author><author><style face="normal" font="default"> Langan,S.M.</style></author><author><style face="normal" font="default"> Abuabara,K.</style></author></authors></contributors><auth-address><style face="normal" font="default">Program for Clinical Research, Department of Dermatology, University of California, San Francisco School of Medicine, San Francisco, CA, USA</style></auth-address><titles><title><style face="normal" font="default">Systematic review of atopic dermatitis disease definition in studies using routinely-collected health data</style></title><secondary-title><style face="normal" font="default">Br J Dermatol</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Br J Dermatol</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="1" Year="2018">2018/1/16</year></dates><abstract><style face="normal" font="default">BACKGROUND: Routinely collected electronic health data (RCD) obtained for administrative and clinical purposes are increasingly used to study atopic dermatitis (AD). Methods for identifying AD patients in RCD differ, and it is unknown how this might affect study results. OBJECTIVES: We sought to evaluate how AD patients have been identified in studies using RCD, to determine whether these methods were validated, and to estimate how the method for identifying AD patients affected variability in prevalence estimates. METHODS: We systematically searched PubMed, EMBASE, and Web of Science for studies utilizing RCD that reported on AD as a primary outcome. Studies of localized AD and other types of dermatitis were excluded. The protocol for this review was registered in PROSPERO (CRD42016037968). RESULTS: 59 studies met eligibility criteria. Medical diagnosis codes for inclusion and exclusion, number of occasions of a code, type of provider associated with a code, and prescription data were used to identify AD patients. Only two studies described validation of their methods and no study reported on disease severity. Prevalence estimates ranged from 0.18%-38.33% (median 4.91%) and up to 3-fold variation in prevalence was introduced by differences in the method for identifying AD patients. CONCLUSIONS: This systematic review highlights the need for clear reporting of methods for identifying AD patients in routinely collected electronic health data to allow for meaningful interpretation and comparison of results. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 1365-2133 (Electronic)IS - 0007-0963 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - United States -CO - Canada -CO - United Kingdom -</style></notes><work-type><style face="normal" font="default">10.1111/bjd.16340</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29336013">PM:29336013</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Br J Dermatol\20180116-DizonMP.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Br J Dermatol\20180116-DizonMP.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180116, Dizon MP</style></custom2><misc3><style face="normal" font="default">10.1111/bjd.16340</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43926</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vicente,C.T.</style></author><author><style face="normal" font="default"> Revez,J.A.</style></author><author><style face="normal" font="default"> Ferreira,M.A.R.</style></author></authors></contributors><auth-address><style face="normal" font="default">QIMR Berghofer Medical Research Institute, Brisbane, QLD, AustraliaQIMR Berghofer Medical Research Institute, Brisbane, QLD, AustraliaQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia</style></auth-address><titles><title><style face="normal" font="default">Lessons from ten years of genome-wide association studies of asthma</style></title><secondary-title><style face="normal" font="default">Clin Transl Immunology</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Clin Transl Immunology</style></abbr-1></periodical><pages end="" start="e165">e165-</pages><volume><style face="normal" font="default">6</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><abstract><style face="normal" font="default">Twenty-five genome-wide association studies (GWAS) of asthma were published between 2007 and 2016, the largest with a sample size of 157242 individuals. Across these studies, 39 genetic variants in low linkage disequilibrium (LD) with each other were reported to associate with disease risk at a significance threshold of P&lt;5 x 10(-8), including 31 in populations of European ancestry. Results from analyses of the UK Biobank data (n=380 503) indicate that at least 28 of the 31 associations reported in Europeans represent true-positive findings, collectively explaining 2.5% of the variation in disease liability (median of 0.06% per variant). We identified 49 transcripts as likely target genes of the published asthma risk variants, mostly based on LD with expression quantitative trait loci (eQTL). Of these genes, 16 were previously implicated in disease pathophysiology by functional studies, including TSLP, TNFSF4, ADORA1, CHIT1 and USF1. In contrast, at present, there is limited or no functional evidence directly implicating the remaining 33 likely target genes in asthma pathophysiology. Some of these genes have a known function that is relevant to allergic disease, including F11R, CD247, PGAP3, AAGAB, CAMK4 and PEX14, and so could be prioritized for functional follow-up. We conclude by highlighting three areas of research that are essential to help translate GWAS findings into clinical research or practice, namely validation of target gene predictions, understanding target gene function and their role in disease pathophysiology and genomics-guided prioritization of targets for drug development</style></abstract><notes><style face="normal" font="default">IS - 2050-0068 (Print)IS - 2050-0068 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1038/cti.2017.54</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29333270">PM:29333270</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Clin Transl Immunology\2017-6-e165.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Clin Transl Immunology\2017-6-e165.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171229, Vicente CT</style></custom2><misc3><style face="normal" font="default">10.1038/cti.2017.54</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43927</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ebrahimiadib,N.</style></author><author><style face="normal" font="default"> Hernandez,M.</style></author><author><style face="normal" font="default"> Modjtahedi,B.S.</style></author><author><style face="normal" font="default"> Roohipoor,C.R.</style></author><author><style face="normal" font="default"> Foster,C.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, MA</style></auth-address><titles><title><style face="normal" font="default">Atopy in Patients With Ocular Cicatricial Pemphigoid</style></title><secondary-title><style face="normal" font="default">Cornea</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Cornea</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="1" Year="2018">2018/1/16</year></dates><abstract><style face="normal" font="default">PURPOSE: To evaluate the presence of atopy in patients with ocular cicatricial pemphigoid (OCP). METHOD: Patient encounters between August 2005 and November 2016 at the Massachusetts Eye Research and Surgery Institute (MERSI) were searched to identify those with biopsy-proven OCP who had concurrent evidence of atopy. RESULTS: There were 230 patients with biopsy-proven OCP. Thirty-three of them were found to have clinical symptoms of atopy (asthma, hay fever, and eczema) and of these, 23 had evidence of atopy in their conjunctival biopsy specimens. All patients were administered immunomodulatory therapy for treatment of their OCP with 20 patients requiring additional antiallergy treatment to control residual atopic ocular symptoms. Among patients who used antiallergy medications, 80% showed improvement in residual symptoms. Rituximab and/or intravenous immunoglobulin is a preferred OCP medication for patients with OCP with some evidence of atopy. CONCLUSIONS: Clinicians should consider the coexistence of atopy in patients with OCP, especially in those with persistent symptoms after initiation of immunomodulatory therapy</style></abstract><notes><style face="normal" font="default">IS - 1536-4798 (Electronic)IS - 0277-3740 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/ICO.0000000000001477</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29341971">PM:29341971</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Cornea\20180116-EbrahimiadibN.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Cornea\20180116-EbrahimiadibN.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180116, Ebrahimiadib N</style></custom2><misc3><style face="normal" font="default">10.1097/ICO.0000000000001477</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43928</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Vas,K.</style></author><author><style face="normal" font="default"> Altmayer,A.</style></author><author><style face="normal" font="default"> Mihalyi,L.</style></author><author><style face="normal" font="default"> Garaczi,E.</style></author><author><style face="normal" font="default"> Kinyo,A.</style></author><author><style face="normal" font="default"> Jakobicz,E.</style></author><author><style face="normal" font="default"> Husz,S.</style></author><author><style face="normal" font="default"> Kemeny,L.</style></author><author><style face="normal" font="default"> Bata-Csorgo,Z.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary</style></auth-address><titles><title><style face="normal" font="default">Successful Treatment of Autoimmune Urticaria with Low-Dose Prednisolone Therapy Administered for a Few Months: A Case Series of 42 Patients</style></title><secondary-title><style face="normal" font="default">Dermatology</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Dermatology</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="1" Year="2018">2018/1/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Chronic spontaneous urticaria (CSU) is defined as symptoms of urticaria persisting for 6 weeks or more without obvious cause. Autologous serum skin test (ASST) positivity in patients with CSU is considered to be associated with autoimmune urticaria (AIU). METHODS: In this retrospective study we retrieved the medical records of 1,073 urticaria patients seen at the Department of Dermatology and Allergology of Szeged University between January 2005 and February 2014. Forty-two patients (36 female and 6 male) met the study criteria by having CSU and giving positive results in the ASST. Our aim was to assess the clinical efficacy and safety of low-dose oral prednisolone therapy administered to patients with antihistamine-refractory ASST-positive CSU for a few months. Patients were given an initial dose (40 mg/day) of prednisolone until the complete resolution of the symptoms, usually 7-10 days, and then the dose was gradually decreased, as in other autoimmune diseases. RESULTS: Prednisolone therapy lasted for an average of 3.6 months and a complete long-lasting response was achieved in 35 of 42 AIU patients (83.3%). The follow-up period was at least 36 months (3 years) for each AIU patient; the longest follow-up time was 139 months (11.5 years). None of the patients reported any considerable side effects. CONCLUSION: Based on our results, we suggest that the use of this treatment could be an alternative for the treatment of AIU. Our present results also highlight the need for other therapies in a small percentage of AIU patients. Our results suggest that AIU represents a transient autoimmunity that can be successfully treated with low-dose steroid therapy administered for a few months</style></abstract><notes><style face="normal" font="default">IS - 1421-9832 (Electronic)IS - 1018-8665 (Linking)LA - engPT - Journal ArticleCO - Hungary -</style></notes><work-type><style face="normal" font="default">10.1159/000484085</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29339636">PM:29339636</url></web-urls><related-urls><url ppv-ref="no">presto - MedLine</url></related-urls></urls><custom2><style face="normal" font="default">20180117, Vas K</style></custom2><misc3><style face="normal" font="default">10.1159/000484085</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43929</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bullone,M.</style></author><author><style face="normal" font="default"> Joubert,P.</style></author><author><style face="normal" font="default"> Gagne,A.</style></author><author><style face="normal" font="default"> Lavoie,J.P.</style></author><author><style face="normal" font="default"> Helie,P.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universite de Montreal, Faculty of Veterinary Medicine, Department of Clinical Sciences, 3200 rue Sicotte, St-Hyacinthe, J2S 6C7, Quebec, Canada</style></auth-address><titles><title><style face="normal" font="default">Bronchoalveolar lavage fluid neutrophilia is associated with the severity of pulmonary lesions during equine asthma exacerbations</style></title><secondary-title><style face="normal" font="default">Equine Vet J</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Equine Vet J</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="1" Year="2018">2018/1/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: The severe form of equine asthma is associated with pathological changes of the peripheral airways and pulmonary parenchyma that are only partly described. Also, the relationship between these structural alterations and the percentage of neutrophils found within the airway lumen, assessed by bronchoalveolar lavage fluid (BALF) cytology, remains ill-defined. OBJECTIVE: To examine the histological lesions associated with equine asthma during disease exacerbation and remission, and their relationship with lung function and BALF neutrophilia. STUDY DESIGN: Observational retrospective study. METHODS: Peripheral lung tissues, BALF cytology, and lung function data from 61 horses (22 controls, 24 asthma exacerbations, and 15 asthma remission) were obtained from an equine pulmonary tissue bank. Two pathologists semi-quantitatively assessed histological features, including airway wall inflammation, interstitial fibrosis, mucus cell hyperplasia, mucostasis, peribronchiolar metaplasia, presence of granuloma, and the overall severity of these lesions. RESULTS: Mucostasis, mucus cell hyperplasia, peribronchiolar metaplasia, and interstitial fibrosis were associated with the disease exacerbation (p&lt;/=0.05), and these changes were all attenuated during remission. Airway wall inflammation was greater in horses with asthma in exacerbation compared to horses with asthma remission and control horses (p&lt;/=0.05). Acute (neutrophilic) airway wall inflammation was more frequently detected in asthmatic cases compared to control horses (p&lt;0.0001) and was associated with BALF neutrophilia >5% in control horses (p = 0.002). The degree of bronchiolar inflammation was higher in asthmatic horses in remission stabled and treated pharmacologically compared to those kept on pasture (p = 0.04). MAIN LIMITATIONS: Samples obtained from a convenient cohort of horses was studied. CONCLUSIONS: Severely asthmatic horses present parenchymal and peribronchial/peribronchiolar lesions possibly contributing to the obstructive nature of the disease. This article is protected by copyright. All rights reserved</style></abstract><notes><style face="normal" font="default">IS - 2042-3306 (Electronic)IS - 0425-1644 (Linking)LA - engPT - Journal ArticleCO - Canada -</style></notes><work-type><style face="normal" font="default">10.1111/evj.12806</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29341228">PM:29341228</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Equine Vet J\20180117-BulloneM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Equine Vet J\20180117-BulloneM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180117, Bullone M</style></custom2><misc3><style face="normal" font="default">10.1111/evj.12806</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43930</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kang,S.Y.</style></author><author><style face="normal" font="default"> Jung,H.W.</style></author><author><style face="normal" font="default"> Nam,J.H.</style></author><author><style face="normal" font="default"> Kim,W.K.</style></author><author><style face="normal" font="default"> Kang,J.S.</style></author><author><style face="normal" font="default"> Kim,Y.H.</style></author><author><style face="normal" font="default"> Cho,C.W.</style></author><author><style face="normal" font="default"> Cho,C.W.</style></author><author><style face="normal" font="default"> Park,Y.K.</style></author><author><style face="normal" font="default"> Bae,H.S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Herbology, College of Korean Medicine, Dongguk University, 123 Dongdae-ro, Gyeongju 38066, Republic of Korea</style></auth-address><titles><title><style face="normal" font="default">Effects of the Fruit Extract of Tribulus terrestris on Skin Inflammation in Mice with Oxazolone-Induced Atopic Dermatitis through Regulation of Calcium Channels, Orai-1 and TRPV3, and Mast Cell Activation</style></title><secondary-title><style face="normal" font="default">Evid Based Complement Alternat Med</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Evid Based Complement Alternat Med</style></full-title></periodical><pages end="" start="8312946">8312946-</pages><volume><style face="normal" font="default">2017</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Ethnopharmacological Relevance: In this study, we investigated the effects of Tribulus terrestris fruit (Leguminosae, Tribuli Fructus, TF) extract on oxazolone-induced atopic dermatitis in mice. Materials and Methods: TF extract was prepared with 30% ethanol as solvent. The 1% TF extract with or without 0.1% HC was applied to the back skin daily for 24 days. Results: 1% TF extract with 0.1% HC improved AD symptoms and reduced TEWL and symptom scores in AD mice. 1% TF extract with 0.1% HC inhibited skin inflammation through decrease in inflammatory cells infiltration as well as inhibition of Orai-1 expression in skin tissues. TF extract inhibited Orai-1 activity in Orai-1-STIM1 cooverexpressing HEK293T cells but increased TRPV3 activity in TRPV3-overexpressing HEK293T cells. TF extract decreased beta-hexosaminidase release in RBL-2H3 cells. Conclusions: The present study demonstrates that the topical application of TF extract improves skin inflammation in AD mice, and the mechanism for this effect appears to be related to the modulation of calcium channels and mast cell activation. This outcome suggests that the combination of TF and steroids could be a more effective and safe approach for AD treatment</style></abstract><notes><style face="normal" font="default">IS - 1741-427X (Print)IS - 1741-427X (Linking)LA - engPT - Journal ArticleCO - South Korea -</style></notes><work-type><style face="normal" font="default">10.1155/2017/8312946</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29348776">PM:29348776</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Evid Based Complement Alternat Med\2017-2017-8312946.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Evid Based Complement Alternat Med\2017-2017-8312946.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171227, Kang SY</style></custom2><misc3><style face="normal" font="default">10.1155/2017/8312946</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43931</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Ntontsi,P.</style></author><author><style face="normal" font="default"> Papathanassiou,E.</style></author><author><style face="normal" font="default"> Loukides,S.</style></author><author><style face="normal" font="default"> Bakakos,P.</style></author><author><style face="normal" font="default"> Hillas,G.</style></author></authors></contributors><auth-address><style face="normal" font="default">a 2nd Respiratory Medicine Department , National and Kapodistrian University of Athens, Medical School, Attikon Hospital , Athens , Greece</style></auth-address><titles><title><style face="normal" font="default">Targeted anti-IL-13 therapies in asthma: current data and future perspectives</style></title><secondary-title><style face="normal" font="default">Expert Opin Investig Drugs</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Expert Opin Investig Drugs</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="1" Year="2018">2018/1/19</year></dates><abstract><style face="normal" font="default">INTRODUCTION: The identification of patients with severe asthma who will benefit from a personalized management approach remains an unmet need. Interleukin-13 (IL-13) is a cytokine possessing a significant role in asthma pathogenesis and progression of disease. Humanised monoclonal antibodies against IL-13 and IL-13 and IL-4 receptors are mainly proposed as add-on therapy in patients with TH2-high inflammation with uncontrolled asthma despite maximum therapy. Areas covered: The role of IL-13 in airway inflammation in severe asthma, the targeted anti-IL-13 therapies and biomarkers that predict response to anti-IL-13 treatment are discussed. Expert opinion: New effective individualized therapies in severe asthma are urgently needed to block specific inflammatory pathways using monoclonal antibodies. Studies on anti-IL-13 therapies showed that asthmatic patients could benefit from this novel targeted therapy as far as lung function and exacerbation rate are concerned. TH2-high and especially periostin-high groups of asthmatics with moderate-to-severe uncontrolled asthma seem to compose the group that could benefit from anti-IL-13 therapy. Targeting IL-13 alone may not be sufficient to achieve asthma control. Inhibition of IL-13 and IL-4 with mabs may be more encouraging and patients will probably have additional benefits from these therapeutic interventions because of IL-13/IL-4 overlapping actions in asthma pathophysiology</style></abstract><notes><style face="normal" font="default">IS - 1744-7658 (Electronic)IS - 1354-3784 (Linking)LA - engPT - Journal ArticleCO - Greece -</style></notes><work-type><style face="normal" font="default">10.1080/13543784.2018.1427729</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29334288">PM:29334288</url></web-urls></urls><custom2><style face="normal" font="default">20180119, Ntontsi P</style></custom2><misc3><style face="normal" font="default">10.1080/13543784.2018.1427729</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43932</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Gur,M.</style></author><author><style face="normal" font="default"> Hakim,F.</style></author><author><style face="normal" font="default"> Bentur,L.</style></author></authors></contributors><auth-address><style face="normal" font="default">Pediatric Pulmonary Institute and CF Center, Rappaport Children's Hospital, Rambam Health Care Campus, Haifa, Israel</style></auth-address><titles><title><style face="normal" font="default">Better understanding of childhood asthma, towards primary prevention - are we there yet? Consideration of pertinent literature</style></title><secondary-title><style face="normal" font="default">F1000Res</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">F1000Res</style></abbr-1></periodical><pages end="" start="2152">2152-</pages><volume><style face="normal" font="default">6</style></volume><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="0" Year="2017">2017</year></dates><abstract><style face="normal" font="default">Asthma is a chronic disease, characterized by reversible airway obstruction, airway inflammation and hyper-reactivity. The prevalence of asthma has risen dramatically over the past decade, affecting around 300,000,000 people. The etiology is multifactorial, with genetic, epigenetic, developmental and environmental factors playing a role. A complex interaction between the intrauterine environment, the developing immune system, the infant's microbiome and infectious organisms may lead to the development of allergic sensitization and asthma. Thus, a large number of studies have investigated the risk factors for childhood asthma, with a meticulous search of modifiable factors that could aid in primary prevention. We present a current literature review from 2014-2017, as well as older classic publications, on the pathogenesis and the potential modifiable factors for primary prevention of asthma. No ideal preventive measure has yet been found. Rather, creating favorable prenatal and postnatal environments, minimal exposure to hostile environmental factors, prevention of infections in early life, allergic desensitization and nutritional modifications could possibly reduce asthma inception. In the era of personalized medicine, identifying individual risk factors and tailoring specific preventive measures is warranted</style></abstract><notes><style face="normal" font="default">IS - 2046-1402 (Print)IS - 2046-1402 (Linking)LA - engPT - Journal ArticlePT - ReviewCO - Israel -</style></notes><work-type><style face="normal" font="default">10.12688/f1000research.11601.1</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29333254">PM:29333254</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\F1000Res\2017-6-2152.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\F1000Res\2017-6-2152.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171227, Gur M</style></custom2><misc3><style face="normal" font="default">10.12688/f1000research.11601.1</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43933</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Torda,A.</style></author><author><style face="normal" font="default"> Chan,V.</style></author></authors></contributors><auth-address><style face="normal" font="default">Prince of Wales Clinical School, University of New South Wales, Randwick, NSW, Australia</style></auth-address><titles><title><style face="normal" font="default">Antibiotic allergy labels-the impact of taking a clinical history</style></title><secondary-title><style face="normal" font="default">Int J Clin Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Int J Clin Pract</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="17" Month="1" Year="2018">2018/1/17</year></dates><abstract><style face="normal" font="default">BACKGROUND: Many patients admitted to hospital have an antibiotic allergy (AAL) documented in their medical record. In many of these, the reaction is not a hypersensitivity reaction or may no longer be relevant. Despite this, the label adversely affects patient care directly in terms of antibiotic selection, and indirectly in terms of patient costs and the development of antimicrobial resistance. AIMS: To estimate the prevalence of AALs in a cohort of hospitalised patients, to investigate the feasibility of de-labelling through re-challenge based solely upon clinical grounds. DESIGN: This is a cross-sectional study conducted over a 6-month period on adult inpatients. An allergy history was taken from each patient and compared with medical record data regarding allergy. Antibiotic selection data were collected (if relevant). It was then determined whether immediate de-labelling was appropriate, if direct provocation test (DPT) could be relatively safely performed, and if antibiotic selection was appropriate. RESULTS: Three thousand eight hundred and fifty five patients were screened, 553 (14.35%) had an AAL, and 352 were interviewed. There were 426 AALs; 276 (64.8%) towards a penicillin. After taking a detailed clinical history of the type of reaction, approximately 20% could be immediately de-labelled and educated (non-allergic, non-severe reactions) and another 38% with either a definite or vague history of mild cutaneous reaction would be suitable for an attempt at clinical de-labelling DPT. CONCLUSIONS: These simple measures to 'de-label' patients appropriately, would increase the quality of care of this group known to have higher costs, infection with more resistant bacteria and worse health outcomes that 'non-labelled' patients</style></abstract><notes><style face="normal" font="default">IS - 1742-1241 (Electronic)IS - 1368-5031 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1111/ijcp.13058</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29341373">PM:29341373</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Int J Clin Pract\20180117-TordaA.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Int J Clin Pract\20180117-TordaA.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180117, Torda A</style></custom2><misc3><style face="normal" font="default">10.1111/ijcp.13058</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43934</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Forbes-Amrhein,M.M.</style></author><author><style face="normal" font="default"> Dillman,J.R.</style></author><author><style face="normal" font="default"> Trout,A.T.</style></author><author><style face="normal" font="default"> Koch,B.L.</style></author><author><style face="normal" font="default"> Dickerson,J.M.</style></author><author><style face="normal" font="default"> Giordano,R.M.</style></author><author><style face="normal" font="default"> Towbin,A.J.</style></author></authors></contributors><auth-address><style face="normal" font="default">From the Cincinnati Children's Hospital Medical Center, Cincinnati, OH</style></auth-address><titles><title><style face="normal" font="default">Frequency and Severity of Acute Allergic-Like Reactions to Intravenously Administered Gadolinium-Based Contrast Media in Children</style></title><secondary-title><style face="normal" font="default">Invest Radiol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Invest Radiol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="15" Month="1" Year="2018">2018/1/15</year></dates><abstract><style face="normal" font="default">OBJECTIVES: The purpose of this study is to determine the frequency and severity of acute allergic-like reactions to gadolinium-based contrast media (GBCM) in children before, during, and after the transition from gadopentetate dimeglumine to gadoterate meglumine as our primary clinical GBCM. MATERIALS AND METHODS: Institutional review board approval was obtained for this Health Insurance Portability and Accountability Act-compliant retrospective investigation. Allergic-like reactions to GBCM in pediatric patients were retrospectively assessed from January 2009 to January 2017, which included a departmental change of GBCM from gadopentetate dimeglumine to gadoterate meglumine. Allergic-like reactions were identified from departmental and hospital databases. The number of doses of GBCM was obtained from billing data. Allergic-like reaction frequencies for each GBCM were calculated and compared using the chi-squared test. RESULTS: A total of 32,365 administrations of GBCM occurred during the study period (327 for gadofosveset trisodium; 672 for gadoxetate disodium; 12,012 for gadoterate meglumine; and 19,354 for gadopentetate dimeglumine). Allergic-like reactions occurred after 21 (0.06%) administrations. Reaction frequencies were not significantly different among the GBCM (0.3% gadofosveset trisodium; 0% gadoxetate disodium, 0.06% gadoterate meglumine, 0.08% gadopentetate dimeglumine; P > 0.05). Ten (47.6%) reactions were mild, 10 (47.6%) were moderate, and 1 (4.8%) was severe. The overall reaction frequency peaked during the 6-month transition period from gadopentetate dimeglumine to gadoterate meglumine (0.20%), compared with 0.07% pretransition (P = 0.048) and 0.04% posttransition (P = 0.0095). CONCLUSION: Allergic-like reactions to GBCM in children are rare. Gadoterate meglumine has a reaction frequency that does not significantly differ from other GBCMs. During the transition from gadopentetate dimeglumine to gadoterate meglumine, an increase in the frequency of reported allergic-like reactions was observed, likely reflective of the Weber effect</style></abstract><notes><style face="normal" font="default">IS - 1536-0210 (Electronic)IS - 0020-9996 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/RLI.0000000000000444</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29337841">PM:29337841</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Invest Radiol\20180115-ForbesAmrheinMM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Invest Radiol\20180115-ForbesAmrheinMM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180115, Forbes-Amrhein MM</style></custom2><misc3><style face="normal" font="default">10.1097/RLI.0000000000000444</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43935</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Orihara,M.</style></author><author><style face="normal" font="default"> Takazawa,T.</style></author><author><style face="normal" font="default"> Saito,S.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesiology, Gunma University Graduate School of Medicine, Maebashi, Gunma, 371-8511, Japan</style></auth-address><titles><title><style face="normal" font="default">Is sugammadex alone sufficient to cause anaphylaxis?</style></title><secondary-title><style face="normal" font="default">J Anesth</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Anesth</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="15" Month="1" Year="2018">2018/1/15</year></dates><notes><style face="normal" font="default">IS - 1438-8359 (Electronic)IS - 0913-8668 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1007/s00540-018-2453-4</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29335892">PM:29335892</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Anesth\20180115-OriharaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Anesth\20180115-OriharaM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180115, Orihara M</style></custom2><misc3><style face="normal" font="default">10.1007/s00540-018-2453-4</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43936</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Yamaoka,M.</style></author></authors></contributors><auth-address><style face="normal" font="default">Department of Anesthesiology, Japanese Red Cross Society Himeji Hospital, 1-12-1 Shimoteno, Himeji, Japan. mskz16@yahoo.co.jp</style></auth-address><titles><title><style face="normal" font="default">In reply: Is sugammadex alone enough to cause anaphylaxis?</style></title><secondary-title><style face="normal" font="default">J Anesth</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Anesth</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="1" Year="2018">2018/1/19</year></dates><abstract><style face="normal" font="default">No Abstract Available</style></abstract><notes><style face="normal" font="default">IS - 1438-8359 (Electronic)IS - 0913-8668 (Linking)LA - engPT - LetterCO - Japan -</style></notes><work-type><style face="normal" font="default">10.1007/s00540-018-2454-3</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29352376">PM:29352376</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Anesth\20180119-YamaokaM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Anesth\20180119-YamaokaM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180119, Yamaoka M</style></custom2><misc3><style face="normal" font="default">10.1007/s00540-018-2454-3</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43937</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Carvalho-Pinto,R.M.</style></author><author><style face="normal" font="default"> Agondi,R.C.</style></author><author><style face="normal" font="default"> Giavina-Bianchi,P.</style></author><author><style face="normal" font="default"> Cukier,A.</style></author><author><style face="normal" font="default"> Stelmach,R.</style></author></authors></contributors><auth-address><style face="normal" font="default">. Divisao de Pneumologia, Instituto do Coracao - InCor - Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo (SP) Brasil. Disciplina de Imunologia Clinica e Alergia, Departamento de Clinica Medica, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo (SP) Brasil. Disciplina de Imunologia Clinica e Alergia, Departamento de Clinica Medica, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo (SP) Brasil. Divisao de Pneumologia, Instituto do Coracao - InCor - Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo (SP) Brasil. Divisao de Pneumologia, Instituto do Coracao - InCor - Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo (SP) Brasil</style></auth-address><titles><title><style face="normal" font="default">Omalizumab in patients with severe uncontrolled asthma: well-defined eligibility criteria to promote asthma control</style></title><secondary-title><style face="normal" font="default">J Bras Pneumol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Bras Pneumol</style></abbr-1></periodical><pages end="489" start="487">487-489</pages><volume><style face="normal" font="default">43</style></volume><number><style face="normal" font="default">6</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="11" Year="2017">2017/11</year></dates><notes><style face="normal" font="default">IS - 1806-3756 (Electronic)IS - 1806-3713 (Linking)LA - engLA - porPT - LetterCO - Brazil -</style></notes><work-type><style face="normal" font="default">10.1590/s1806-37562017000000012</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29340498">PM:29340498</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\J Bras Pneumol\2017-43-487-9.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\J Bras Pneumol\2017-43-487-9.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20171213, Carvalho-Pinto RM</style></custom2><misc3><style face="normal" font="default">10.1590/s1806-37562017000000012</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43938</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Kogure,T.</style></author><author><style face="normal" font="default"> Ebata,T.</style></author></authors></contributors><titles><title><style face="normal" font="default">Activity During Sleep Measured by a Sheet-Shaped Body Vibrometer and the Severity of Atopic Dermatitis in Adults: A Comparison With Wrist Actigraphy</style></title><secondary-title><style face="normal" font="default">J Clin Sleep Med</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Clin Sleep Med</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="1" Year="2018">2018/1/16</year></dates><abstract><style face="normal" font="default">STUDY OBJECTIVES: To use a sheet-shaped body vibrometer (SBV) for measuring sleep in adult patients with atopic dermatitis (AD) of various severities and to compare the results with those measured by wrist actigraphy (WA). METHODS: Simultaneous measurements of activity during sleep by WA and the SBV were performed in 20 outpatients with AD for 5 to 10 days. The mean activity count per minute (ACT) and sleep efficiency (SE) were obtained using each device. The severity of AD was evaluated by the severity scoring of AD (SCORAD), serum thymus and activation-regulated chemokine (TARC) level, serum total immunoglobulin E level, and peripheral eosinophil count. RESULTS: The ACT measured by WA was correlated with SCORAD (Spearman correlation coefficient [rs] = .64, P = .002) and TARC (rs = .60, P = .005). The ACT obtained by the SBV was significantly correlated with TARC (rs = .58, P = .008) and ACT obtained by WA (rs = .63, P = .003). SE obtained by WA resulted in lower values compared with SE obtained by the SBV (69.7 +/- 9.4% versus 82.9 +/- 9.3%, P&lt; .001), although SE obtained by WA was highly correlated with SE obtained by the SBV (rs = .82, P&lt; .001). Bland-Altman plots revealed that SE measured by WA always had lower values in all the patients. CONCLUSIONS: Activity during sleep, presumably composed of scratching and other motions, is more vigorous in patients with severe adult AD. This was successfully demonstrated by the SBV and WA assessment. However, we consider that ACT measured by WA is more suited for the scratch evaluation and SE measured by the SBV is preferable for the sleep evaluation</style></abstract><notes><style face="normal" font="default">IS - 1550-9397 (Electronic)IS - 1550-9389 (Linking)LA - engPT - Journal ArticleCO - Japan -</style></notes><work-type><style face="normal" font="default">NO-DOI</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29351828">PM:29351828</url></web-urls><related-urls><url ppv-ref="no">presto - 1 anno</url></related-urls></urls><custom2><style face="normal" font="default">20180116, Kogure T</style></custom2><misc3><style face="normal" font="default">NO-DOI</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43939</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Bozo,O.</style></author><author><style face="normal" font="default"> Demirtepe-Saygili,D.</style></author><author><style face="normal" font="default"> Gunes,S.</style></author><author><style face="normal" font="default"> Cenesiz,G.Z.</style></author><author><style face="normal" font="default"> Baysan,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">a Orta Dogu Teknik Universitesi , Psychology , Ankara , Turkey</style></auth-address><titles><title><style face="normal" font="default">Does Problem Focused Coping Buffer the Effects of Trait Anxiety on Depressive Symptoms of Chronic Urticaria Patients?</style></title><secondary-title><style face="normal" font="default">J Gen Psychol</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">J Gen Psychol</style></abbr-1></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="18" Month="1" Year="2018">2018/1/18</year></dates><abstract><style face="normal" font="default">The present study examined the moderating role of problem-focused coping in trait anxiety-depressive symptoms' relationship in patients with chronic urticaria (CU). Eighty-eight CU patients, who applied to an outpatient clinic of Clinical Immunology and Allergic Diseases, filled out a questionnaire set including State-Trait Anxiety Inventory, Ways of Coping Inventory, and Beck Depression Inventory. The results suggested that CU patients high on trait anxiety reported more depressive symptoms, and the ones using more problem-focused coping (PFC) strategies reported less depressive symptoms. Also, PFC strategies moderated trait anxiety-depressive symptoms relation. Accordingly, PFC strategies did not lead to any significant difference in CU patients who were low on trait anxiety in terms of the level of depressive symptoms. However, CU patients with high trait anxiety experienced significantly less depressive symptoms if they used more PFC strategies. The findings were discussed in the light of the relevant literature</style></abstract><notes><style face="normal" font="default">IS - 1940-0888 (Electronic)IS - 0022-1309 (Linking)LA - engPT - Journal ArticleCO - Turkey -</style></notes><work-type><style face="normal" font="default">10.1080/00221309.2017.1420622</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29345527">PM:29345527</url></web-urls><related-urls><url ppv-ref="no">presto - 18 mesi</url></related-urls></urls><custom2><style face="normal" font="default">20180118, Bozo O</style></custom2><misc3><style face="normal" font="default">10.1080/00221309.2017.1420622</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43940</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Nyhoff,H.</style></author></authors></contributors><titles><title><style face="normal" font="default">A private case of allergic contact dermatitis</style></title><secondary-title><style face="normal" font="default">Nurse Pract</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Nurse Pract</style></abbr-1></periodical><pages end="10" start="9">9-10</pages><volume><style face="normal" font="default">43</style></volume><number><style face="normal" font="default">2</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="2" Year="2018">2018/2/16</year></dates><notes><style face="normal" font="default">IS - 1538-8662 (Electronic)IS - 0361-1817 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1097/01.NPR.0000529665.31694.ed</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29341989">PM:29341989</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Nurse Pract\2018-43-9-10.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Nurse Pract\2018-43-9-10.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180116, Nyhoff H</style></custom2><misc3><style face="normal" font="default">10.1097/01.NPR.0000529665.31694.ed</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43941</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Buhl,R.</style></author><author><style face="normal" font="default"> Bals,R.</style></author><author><style face="normal" font="default"> Baur,X.</style></author><author><style face="normal" font="default"> Berdel,D.</style></author><author><style face="normal" font="default"> Criee,C.P.</style></author><author><style face="normal" font="default"> Gappa,M.</style></author><author><style face="normal" font="default"> Gillissen,A.</style></author><author><style face="normal" font="default"> Greulich,T.</style></author><author><style face="normal" font="default"> Haidl,P.</style></author><author><style face="normal" font="default"> Hamelmann,E.</style></author><author><style face="normal" font="default"> Kardos,P.</style></author><author><style face="normal" font="default"> Kenn,K.</style></author><author><style face="normal" font="default"> Klimek,L.</style></author><author><style face="normal" font="default"> Korn,S.</style></author><author><style face="normal" font="default"> Lommatzsch,M.</style></author><author><style face="normal" font="default"> Magnussen,H.</style></author><author><style face="normal" font="default"> Nicolai,T.</style></author><author><style face="normal" font="default"> Nowak,D.</style></author><author><style face="normal" font="default"> Pfaar,O.</style></author><author><style face="normal" font="default"> Rabe,K.F.</style></author><author><style face="normal" font="default"> Riedler,J.</style></author><author><style face="normal" font="default"> Ritz,T.</style></author><author><style face="normal" font="default"> Schultz,K.</style></author><author><style face="normal" font="default"> Schuster,A.</style></author><author><style face="normal" font="default"> Spindler,T.</style></author><author><style face="normal" font="default"> Taube,C.</style></author><author><style face="normal" font="default"> Taube,K.</style></author><author><style face="normal" font="default"> Vogelmeier,C.</style></author><author><style face="normal" font="default"> von Leupold,A.</style></author><author><style face="normal" font="default"> Wantke,F.</style></author><author><style face="normal" font="default"> Weise,S.</style></author><author><style face="normal" font="default"> Wildhaber,J.</style></author><author><style face="normal" font="default"> Worth,H.</style></author><author><style face="normal" font="default"> Zacharasiewicz,A.</style></author></authors></contributors><auth-address><style face="normal" font="default">Universitatsmedizin der Johannes Gutenberg-Universitat Mainz, Schwerpunkt Pneumologie, III. Medizinische Klinik, Mainz</style></auth-address><titles><title><style face="normal" font="default">[Guideline for the Diagnosis and Treatment of Asthma - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology]</style></title><secondary-title><style face="normal" font="default">Pneumologie</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Pneumologie</style></full-title></periodical><pages end="" start="e2">e2-</pages><volume><style face="normal" font="default">71</style></volume><number><style face="normal" font="default">12</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="0" Month="12" Year="2017">2017/12</year></dates><notes><style face="normal" font="default">IS - 1438-8790 (Electronic)IS - 0934-8387 (Linking)LA - gerPT - Journal ArticleCO - Germany -CO - Austria -CO - United States -</style></notes><work-type><style face="normal" font="default">10.1055/s-0044-100881</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29334688">PM:29334688</url></web-urls></urls><custom2><style face="normal" font="default">20171211, Buhl R</style></custom2><misc3><style face="normal" font="default">10.1055/s-0044-100881</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43942</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Andrew,E.</style></author><author><style face="normal" font="default"> Nehme,Z.</style></author><author><style face="normal" font="default"> Bernard,S.</style></author><author><style face="normal" font="default"> Smith,K.</style></author></authors></contributors><titles><title><style face="normal" font="default">Pediatric Anaphylaxis in the Prehospital Setting: Incidence, Characteristics, and Management</style></title><secondary-title><style face="normal" font="default">Prehosp Emerg Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Prehosp Emerg Care</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="19" Month="1" Year="2018">2018/1/19</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Although hospital presentations for pediatric anaphylaxis have been described in the literature, a minimal amount is known regarding the incidence, characteristics, and management of pediatric anaphylaxis presenting to emergency medical services (EMS). METHODS: We performed a retrospective observational study of pediatrics (&lt;/=16 years) presenting to EMS in Victoria, Australia. Patients with suspected anaphylaxis were included if they were treated with epinephrine before or after EMS arrival. We used descriptive statistics to compare baseline characteristics and linear regression to assess trends in incidence over time. RESULTS: Between July 2008 and June 2016, we identified 2,137 pediatric anaphylaxis presentations. Overall, 59% were male and 70% had pre-existing anaphylaxis. The age-adjusted incidence increased over the study period, from 11.8 presentations per 100,000 person-years in 2008-09 to 38.7 in 2015-16 (p for trend &lt; 0.001). Common suspected allergens included nuts (52%) and dairy/milk formula (17%). In total, 1,333 (62%) patients received epinephrine via an autoinjector, and 51 (2%) from a doctor before EMS arrival. When compared to patients receiving epinephrine after EMS arrival, patients treated prior were more likely to present with vital signs within normal limits, including heart rate (66% vs. 84%, p &lt; 0.001), systolic blood pressure (77% vs. 93%, p &lt; 0.001) and respiratory rate (79% vs. 91%, p &lt; 0.001). The most common EMS interventions were intramuscular epinephrine (45%) and inhaled salbutamol (14%). Three out-of-hospital cardiac arrests were observed, two of whom received endotracheal intubation. CONCLUSION: The incidence of prehospital pediatric anaphylaxis is increasing significantly. Despite this, most patients are hemodynamically stable on presentation and few require emergency treatments beyond the administration of intramuscular epinephrine</style></abstract><notes><style face="normal" font="default">IS - 1545-0066 (Electronic)IS - 1090-3127 (Linking)LA - engPT - Journal ArticleCO - Australia -</style></notes><work-type><style face="normal" font="default">10.1080/10903127.2017.1402110</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29351501">PM:29351501</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Prehosp Emerg Care\20180119-AndrewE.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Prehosp Emerg Care\20180119-AndrewE.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180119, Andrew E</style></custom2><misc3><style face="normal" font="default">10.1080/10903127.2017.1402110</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43943</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Cristiano,L.M.</style></author><author><style face="normal" font="default"> Hiestand,B.</style></author><author><style face="normal" font="default"> Caldwell,J.W.</style></author><author><style face="normal" font="default"> Gower,W.A.</style></author><author><style face="normal" font="default"> Fernandez,A.R.</style></author><author><style face="normal" font="default"> Gilbert,K.</style></author><author><style face="normal" font="default"> Winslow,J.E.</style></author></authors></contributors><titles><title><style face="normal" font="default">Prehospital Administration of Epinephrine in Pediatric Anaphylaxis - A Statewide Perspective</style></title><secondary-title><style face="normal" font="default">Prehosp Emerg Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Prehosp Emerg Care</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="1" Year="2018">2018/1/16</year></dates><abstract><style face="normal" font="default">OBJECTIVE: Timely administration of epinephrine is critical in the treatment of anaphylaxis. This study sought to determine the frequency of administration of epinephrine by EMS providers caring for pediatric patients in the prehospital setting. METHODS: We examined data from the NC EMS database (PreMIS) from 2010-3 to determine frequency of epinephrine administration in pediatric patients with anaphylaxis. We studied patients &lt;18 years of age with an EMS provider impression of "allergic reaction." Anaphylaxis was present if there was hypotension (defined as SBP &lt; 90 or DBP &lt; 45 for patients age 11 and older, and SBP &lt; 70 + (2 x age) for patients ages 0-10), or impaired respirations (defined as description of labored or absent respirations, or RR &lt; 12 or > 30). We determined the overall frequency of epinephrine administration. A multivariate logistic regression was then constructed to examine the impact of the following variables on appropriate epinephrine administration: age &lt; 10, non-white race, rural county of case origin, duration of transportation from scene, and presence of a paramedic. RESULTS: A total of 504 patients met inclusion criteria, of which 471 demonstrated anaphylaxis as previously defined. A total of 153 patients with anaphylaxis received epinephrine (32.4%, 95% CI 28.3-36.9%). Age &lt; 10 was associated with increased odds of not receiving epinephrine appropriately (OR 2.90, 95% CI 1.85-4.54, p &lt; 0.001). Other variables did not have statistically significant impact on epinephrine administration. CONCLUSION: There are missed opportunities for prehospital administration of epinephrine in pediatric patients with anaphylaxis. Very young children (age &lt; 10) had increased odds for not receiving epinephrine</style></abstract><notes><style face="normal" font="default">IS - 1545-0066 (Electronic)IS - 1090-3127 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/10903127.2017.1399184</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29336638">PM:29336638</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Prehosp Emerg Care\20180116-CristianoLM.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Prehosp Emerg Care\20180116-CristianoLM.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180116, Cristiano LM</style></custom2><misc3><style face="normal" font="default">10.1080/10903127.2017.1399184</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43944</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Latimer,A.J.</style></author><author><style face="normal" font="default"> Husain,S.</style></author><author><style face="normal" font="default"> Nolan,J.</style></author><author><style face="normal" font="default"> Doreswamy,V.</style></author><author><style face="normal" font="default"> Rea,T.D.</style></author><author><style face="normal" font="default"> Sayre,M.R.</style></author><author><style face="normal" font="default"> Eisenberg,M.S.</style></author></authors></contributors><titles><title><style face="normal" font="default">Syringe Administration of Epinephrine by Emergency Medical Technicians for Anaphylaxis</style></title><secondary-title><style face="normal" font="default">Prehosp Emerg Care</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">Prehosp Emerg Care</style></full-title></periodical><pages end="" start="">-</pages><reprint-status status="no-file"/><keywords/><dates><year Day="15" Month="1" Year="2018">2018/1/15</year></dates><abstract><style face="normal" font="default">OBJECTIVE: In recent years, the costs of epinephrine autoinjectors (EAIs) in the United States have risen substantially. King County Emergency Medical Services implemented the "Check and Inject" program to replace EAIs by teaching emergency medical technicians (EMTs) to manually aspirate epinephrine from a single-use 1 mg/mL epinephrine vial using a needle and syringe followed by prehospital intramuscular administration of the correct adult or pediatric dose of epinephrine for anaphylaxis or serious allergic reaction. Treatment was guided by an EMT protocol that required a trigger and symptoms. We sought to determine if the "Check and Inject" program was safely implemented by EMTs treating presumed prehospital anaphylaxis or serious allergic reaction. METHODS: We conducted a prospective investigation of all cases treated as part of the "Check and Inject" program from July 2014 through December 2016 in suburban King County, Washington, and January 2016 through December 2016 within the city of Seattle. All cases were prospectively collected using a custom quality improvement data form completed by the first responding EMTs. Two physicians completed a structured review of each EMS medical record to determine if the EMTs followed the Check and Inject protocol and determine if epinephrine was clinically-indicated based on physician review. RESULTS: Of the 411 cases eligible for analysis, EMTs followed the protocol appropriately in 367 (89.3%) cases. In the remaining 44 (10.7%) cases, the EMS incident report form failed to document either a clear inciting allergic trigger or an appropriate symptom from the protocol list. Physician review determined that epinephrine was clinically indicated in 36 of the 44 cases. Among the remaining 8 cases (1.9%) that did not meet protocol criteria and were not clinically-indicated based on physician review, none had a documented adverse reaction to the epinephrine. CONCLUSION: We observed that EMTs successfully implemented the manual "Check and Inject" program for severe allergic reactions and anaphylaxis in a manner that typically agreed with physician review and without any overt identified safety issues</style></abstract><notes><style face="normal" font="default">IS - 1545-0066 (Electronic)IS - 1090-3127 (Linking)LA - engPT - Journal ArticleCO - United States -</style></notes><work-type><style face="normal" font="default">10.1080/10903127.2017.1392667</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29333893">PM:29333893</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Prehosp Emerg Care\20180119-LatimerAJ.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Prehosp Emerg Care\20180119-LatimerAJ.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180115, Latimer AJ</style></custom2><misc3><style face="normal" font="default">10.1080/10903127.2017.1392667</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43945</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Buttrick,T.S.</style></author><author><style face="normal" font="default"> Wang,W.</style></author><author><style face="normal" font="default"> Yung,C.</style></author><author><style face="normal" font="default"> Trieu,K.G.</style></author><author><style face="normal" font="default"> Patel,K.</style></author><author><style face="normal" font="default"> Khoury,S.J.</style></author><author><style face="normal" font="default"> Ai,X.</style></author><author><style face="normal" font="default"> Elyaman,W.</style></author></authors></contributors><auth-address><style face="normal" font="default">Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA</style></auth-address><titles><title><style face="normal" font="default">Foxo1 Promotes Th9 Cell Differentiation and Airway Allergy</style></title><secondary-title><style face="normal" font="default">Sci Rep</style></secondary-title></titles><periodical><abbr-1><style face="normal" font="System">Sci Rep</style></abbr-1></periodical><pages end="" start="818">818-</pages><volume><style face="normal" font="default">8</style></volume><number><style face="normal" font="default">1</style></number><reprint-status status="no-file"/><keywords/><dates><year Day="16" Month="1" Year="2018">2018/1/16</year></dates><abstract><style face="normal" font="default">T helper 9 (Th9) cells are effector CD4(+) T cells that are characterized by the production of interleukin-9 (IL-9) and have been associated with allergic responses. Here, we found that the expression of the transcription factor forkhead box O1 (Foxo1) was induced in Th9 and Foxo1 plays a crucial role in the differentiation of Th9 cells. Pharmacological inhibition of Foxo1 or genetic disruption of Foxo1 in CD4(+) T cells caused a reduction in IL-9 expression while upregulating IL-17A and IFNgamma production. Furthermore, chromatin immunoprecipitation (ChIP) followed by luciferase assays revealed direct binding of Foxo1 to both the Il9 and Irf4 promoters and induces their transactivation. Lastly, adoptive transfer of Th9 cells into lungs induced asthma-like symptoms that were ameliorated by Foxo1 inhibitor, AS1842856. Together, our findings demonstrate a novel regulator of Th9 cells with a direct implication in allergic inflammation</style></abstract><notes><style face="normal" font="default">IS - 2045-2322 (Electronic)IS - 2045-2322 (Linking)LA - engPT - Journal ArticleCO - United States -CO - Lebanon -</style></notes><work-type><style face="normal" font="default">10.1038/s41598-018-19315-z</style></work-type><urls><web-urls><url has-ut="yes" ppv-app="PM" ppv-ref="yes" ppv-ut="29339772">PM:29339772</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\Sci Rep\2018-8-818.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\Sci Rep\2018-8-818.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180116, Buttrick TS</style></custom2><misc3><style face="normal" font="default">10.1038/s41598-018-19315-z</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43946</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Wu,J.H.</style></author><author><style face="normal" font="default"> Fu,Y.</style></author></authors></contributors><titles><title><style face="normal" font="default">Allergic rhinitis treated with warming-needle moxibustion</style></title><secondary-title><style face="normal" font="default">World J Acupunct Moxibust</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">World J Acupunct Moxibust</style></full-title></periodical><pages end="78" start="73">73-78</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> warming-needle moxibustion</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1003-5257</style></isbn><abstract><style face="normal" font="default">Abstract A case of allergic rhinitis treated with warming-needle moxibustion was introduced. A 57-year old patient with allergic rhinitis for more than 10 years was treated. Y+¡ngxi-üng ( LI 20), Sh+ángy+¡ngxi-üng ( EX-HN8), Sh+ángx-½ng ( GV 23), Y+¼nt+íng ( EX-HN3), Cu+ínzh+¦ ( BL 2), F-ôngch+¡ ( GB 20), Ti-ünt+½ ( CV 22), W+áigu-ün ( TE 5), H+®g+¡ ( LI 4), Z+¦s-ünl-¥ ( ST 36), Sh+¿nsh+½ ( BL 23) and T+áix-½ ( KI 3) were punctured. After deqi, warming-needle moxibustion was performed at LI 20 and ST 36. After treatment for 2 courses, all the symptoms disappeared without relapse of urticaria or asthma during treatment. Another 1 course of treatment was conducted additionally for consolidating the curative effect. No relapse was found during the follow-up visit half a year after treatment</style></abstract><notes><style face="normal" font="default">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/S1003-5257(18)30017-5</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/S1003-5257(18)30017-5</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\World J Acupunct Moxibust\2017-27-73-8.pdf</url></pdf-urls></urls><custom2><style face="normal" font="default">20180109, Wu JH</style></custom2><misc3><style face="normal" font="default">10.1016/S1003-5257(18)30017-5</style></misc3></record><record><database name="LMW Allergens" path="D:\Bibliografia Generale\LMW Allergens">LMW Allergens</database><source-app name="Reference Manager 11.0" version="11.0.1.1709">Reference Manager 11.0</source-app><rec-number>43947</rec-number><ref-type name="Journal">17</ref-type><contributors><authors><author><style face="normal" font="default">Feng,G.</style></author></authors></contributors><titles><title><style face="normal" font="default">Treatment of "itching symptom" of allergic rhinitis from the perspective of "wind"</style></title><secondary-title><style face="normal" font="default">World J Acupunct Moxibust</style></secondary-title></titles><periodical><full-title><style face="normal" font="System">World J Acupunct Moxibust</style></full-title></periodical><pages end="64" start="60">60-64</pages><volume><style face="normal" font="default">27</style></volume><number><style face="normal" font="default">4</style></number><reprint-status status="no-file"/><keywords><keyword><style face="normal" font="default">allergic rhinitis</style></keyword><keyword><style face="normal" font="default"> itching symptom</style></keyword><keyword><style face="normal" font="default"> wind-evil</style></keyword><keyword><style face="normal" font="default"> serum IgE</style></keyword></keywords><dates><year Day="0" Month="0" Year="2017">2017</year></dates><isbn><style face="normal" font="default">1003-5257</style></isbn><abstract><style face="normal" font="default">Abstract To observe the clinical efficacy of </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç£itching symptom</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇØ of allergic rhinitis treated from the perspective of </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç£wind</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇØ. Forty patients were given acupuncture therapy, F-ôngch+¡ ( GB 20, bilaterally), D+ázhu-½ ( GV 14), F-ôngm+®n ( BL 12, bilaterally), F+¿ish+½ ( BL 13, bilaterally) and Sh+ángy+¡ngxi-üng ( EX-HN8, bilaterally) were selected. After needle withdrawal, a fire cup was applied between GV 14 and BL 13, and the cup was retained for 10 min. Treatment for 15 times was considered as 1 course of treatment. Three days were free from treatment between 2 courses, and 3 courses were needed. The curative effect was evaluated after treatment ends, and follow-up visit was performed one year after treatment. The scores of nasal symptom and itching symptom after treatment ends and one year after treatment significantly reduced when compared with that before treatment (all P&lt;0.05), the difference was not statistically significant when compared the scores of nasal symptom and itching symptom one year after treatment with that after treatment ends (both P>0.05). According to the follow-up visit performed one year after treatment, the markedly effective and effective cases reduced, ineffective cases increased, and the total effective rate declined slightly. The serum IgE levels, after treatment ends [(164.79-¦44.29) IU/mL] and one year after treatment [(180.71-¦52.81) IU/mL], both significantly reduced when compared with that before treatment [(380.12-¦61.45) IU/mL, both P&lt;0.05], the serum IgE level one year after treatment increased when compared with that after treatment ends, but the difference was not statistically significant (P>0.05). (1) Significant short-term and long-term curative effects have been obtained during the treatment of </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç£itching symptom</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇØ of allergic rhinitis from the perspective of </style><style face="normal" font="Symbol">G</style><style face="normal" font="default">Ç£wind</style><style face="normal" font="Symbol">G</style><style face="normal" font="default">ÇØ, (2) the mechanism of action may be related with the decrease of serum IgE level, (3) it is indicated that there are correlations between allergic rhinitis and atopic diseases such as atopic dermatitis and allergic conjunctivitis, etc</style></abstract><notes><style face="normal" font="default">LA - ENGCO - China -</style></notes><work-type><style face="normal" font="default">10.1016/S1003-5257(18)30014-X</style></work-type><urls><web-urls><url ppv-ref="no">https://doi.org/10.1016/S1003-5257(18)30014-X</url></web-urls><pdf-urls><url ppv-ref="no">C:\A&amp;H LMW Papers\World J Acupunct Moxibust\2017-27-60-4.pdf</url></pdf-urls><text-urls><url ppv-ref="no">F:\A&amp;H LMW Papers\World J Acupunct Moxibust\2017-27-60-4.pdf</url></text-urls></urls><custom2><style face="normal" font="default">20180109, Feng G</style></custom2><misc3><style face="normal" font="default">10.1016/S1003-5257(18)30014-X</style></misc3></record></records></xml>
